TAB-5103 167680344 Monoclonal Antibody for Specific Detection of the Transcription Factor Eos (Ikzf4) in Regulatory T Cells NIAID Application, Diagnostics, ResearchProducts, Therapeutics Application Diagnostics ResearchProducts Therapeutics Angela DeVico, Patricia Korty, Ethan Shevach <p>Regulatory T cells (Tregs) are immune cells that keep the immune system balanced and prevent autoimmunity. Tregs depend on a protein called Eos (Ikzf4) that helps turn genes on and off for their development and function, but until now, antibodies used to detect and study Eos were unreliable.<br /> Researchers at the National Institute of Allergy and Infectious Diseases (NIAID) have created monoclonal antibody 18H2 to accurately detect Eos in mouse and human Treg cells. To make 18H2, they immunized hamsters with a segment of the Eos protein and used advanced techniques to select the best antibody-producing cells. The resulting 18H2 antibody specifically detects Eos and does not react with cells lacking Eos.<br /> The 18H2 antibody stands out by reliably detecting both human and mouse Eos and performing better in laboratory tests, such as flow cytometry, used to analyze Treg cells. This technology offers a powerful new way to study Treg cell development and how Eos helps protect against autoimmune conditions.</p> <p>&nbsp;</p> <ul> <li> Eos-specific detection, confirmed by lack of reactivity in cells that lack Eos. </li> <li> Detection of both mouse and human Eos, enabling application to human research. </li> <li> Precise detection and measurement of Treg cells in diverse sample types. </li> </ul> <ul> <li> Development of tests that track Treg cell function and Eos protein levels in patients and monitor Eos levels in autoimmune diseases, cancer treatments, and organ transplants. </li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. Areas of specific interest include (a) application in pre-clinical models of autoimmunity, cancer, and transplantation, (b) development of diagnostic assays for immune monitoring and biomarker discovery, and (c) inclusion in high-throughput screening platforms for drug discovery targeting Treg pathways. For collaboration opportunities, please contact Yogikala Prabhu at 202-365-4785, or yogikala.prabhu@nih.gov. 2026-06-01 2026-06-02 2026-06-02 2026-06-02 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 167681122 Xie X, et al. Eos plays a critical role in Treg homeostasis and modulates the function of recirculating thymic Tregs in the control of Treg development. Cell Rep. 2026;45(1):116838. (doi:10.1016/j.celrep.2025.116838) Xie X, et al. Eos plays a critical role in Treg homeostasis and modulates the function of recirculating thymic Tregs in the control of Treg development. Cell Rep. 2026;45(1):116838. (doi:10.1016/j.celrep.2025.116838) 167680373 Shevach, Ethan NIAID - DIR NIAID Shevach, Ethan (NIAID) 1 167680411 DeVico, Angela NIAID - DIR NIAID DeVico, Angela (NIAID) 2 167680417 Korty, Patricia NIAID - DIR NIAID Korty, Patricia (NIAID) 3 167680373 Shevach, Ethan NIAID - DIR NIAID Shevach, Ethan (NIAID) 1 167680411 DeVico, Angela NIAID - DIR NIAID DeVico, Angela (NIAID) 2 167680417 Korty, Patricia NIAID - DIR NIAID Korty, Patricia (NIAID) 3 167680347 Anti-mouse Ikzf4 (Eos) Monoclonal Antibody E-104-2025-0 Research Material National Institute of Allergy and Infectious Diseases (NIAID/NIH), NIAID - DIR 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-5103] Monoclonal Antibody for Specific Detection of the Transcription Factor Eos (Ikzf4) in Regulatory T Cells&body=Please send me information about technology [TAB-5103] Monoclonal Antibody for Specific Detection of the Transcription Factor Eos (Ikzf4) in Regulatory T Cells. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-5103] Monoclonal Antibody for Specific Detection of the Transcription Factor Eos (Ikzf4) in Regulatory T Cells&body=Please send me information about technology [TAB-5103] Monoclonal Antibody for Specific Detection of the Transcription Factor Eos (Ikzf4) in Regulatory T Cells.">yogikala.prabhu@nih.gov</a><br> TAB-5101 167599021 Human-Bovine Reassortant Rotavirus Vaccine NIAID TherapeuticArea, Vaccines TherapeuticArea Vaccines Robert Chanock (Estate), Yasutaka Hoshino, Albert Kapikian (Estate Of) <p>Rotavirus is a major cause of severe diarrhea and dehydration in infants and young children. Vaccines that cover the most important rotavirus serotypes could help reduce serious illness worldwide.</p> <p>Researchers at NIAID&rsquo;s Laboratory of Infectious Diseases developed a multivalent human-bovine reassortant rotavirus vaccine using vaccine strains created by combining selected genes from human and bovine (cow) rotaviruses. This approach targets the most important rotavirus serotypes at once, including G1, G2, G3, and G4, with the potential to expand coverage to G5, G9, and G10.</p> <p>These multivalent vaccine candidates trigger immune responses against multiple rotavirus serotypes in a single formulation at lower doses than earlier human-bovine vaccine approaches. The multivalent formulation does not cause the low-grade, short-lived fever seen with prior candidates.</p> <p>&nbsp;</p> <ul> <li> Designed for lower-dose immunogenicity than earlier human-bovine reassortant approaches described in the literature. </li> <li> No low-grade, transient fever observed compared with prior candidates. </li> <li> Flexible reassortant design that may support addition of newly important rotavirus serotypes. </li> </ul> <ul> <li> Multivalent rotavirus vaccine that covers several clinically important rotavirus serotypes in a single product, including G1, G2, G3, and G4, with potential to expand coverage to the additional serotypes G5, G9, and G10. </li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. For collaboration opportunities, please contact Elizabeth Pitts at 240–669–5299, or elizabeth.pitts@nih.gov. 2026-05-27 2026-05-28 2026-05-28 2026-05-27 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 167599438 Kapikian (Estate Of), Albert National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Kapikian (Estate Of), Albert (NIAID) 1 167599455 Chanock (Estate), Robert National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Chanock (Estate), Robert (NIAID) 2 167599463 Hoshino, Yasutaka National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Hoshino, Yasutaka (NIAID) 3 167599438 Kapikian (Estate Of), Albert National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Kapikian (Estate Of), Albert (NIAID) 1 167599455 Chanock (Estate), Robert National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Chanock (Estate), Robert (NIAID) 2 167599463 Hoshino, Yasutaka National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Hoshino, Yasutaka (NIAID) 3 167599024 Multivalent Human-Bovine Rotavirus Vaccine E-015-1998-0 Filing authorized NIAID 91021353 Pitts, Elizabeth elizabeth.pitts@nih.gov
United States of America elizabeth.pitts@nih.gov?subject=Web Inquiry on [TAB-5101] Human-Bovine Reassortant Rotavirus Vaccine&body=Please send me information about technology [TAB-5101] Human-Bovine Reassortant Rotavirus Vaccine. Pitts, Elizabeth<br><a href="mailto:elizabeth.pitts@nih.gov?subject=Web Inquiry on [TAB-5101] Human-Bovine Reassortant Rotavirus Vaccine&body=Please send me information about technology [TAB-5101] Human-Bovine Reassortant Rotavirus Vaccine.">elizabeth.pitts@nih.gov</a><br> 167599028 E-015-1998-0 E-015-1998-0-US-01 Multivalent Human-Bovine Rotavirus Vaccine PRV US 60/094,425 Abandoned US <br />Provisional (PRV) 60/094,425<br />Filed on 1998-07-28<br />Status: Abandoned 167599029 E-015-1998-0 E-015-1998-0-PCT-02 Multivalent Human-Bovine Rotavirus Vaccine PCT Patent Cooperation Treaty PCT/US1999/017036 Expired Patent Cooperation Treaty <br />(PCT) PCT/US1999/017036<br />Filed on 1999-07-27<br />Status: Expired 167599030 E-015-1998-0 E-015-1998-0-US-10 Multivalent Human-Bovine Rotavirus Vaccine National Stage US 7,932,074 09/743,338 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7932074 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7932074">7,932,074</a><br />Filed on 2001-01-04<br />Status: Expired 167599031 E-015-1998-0 E-015-1998-0-AU-06 Multivalent Human-Bovine Rotavirus Vaccine National Stage Australia 759123 53221/99 Expired Australia <br />National Stage 53221/99<br />Filed on 1999-07-27<br />Status: Expired 167599032 E-015-1998-0 E-015-1998-0-BR-11 Multivalent Human-Bovine Rotavirus Vaccine National Stage Brazil PI9912485-8 PI9912485-8 Expired Brazil <br />National Stage PI9912485-8<br />Filed on 1999-07-27<br />Status: Expired 167599033 E-015-1998-0 E-015-1998-0-CA-07 Multivalent Human-Bovine Rotavirus Vaccine National Stage Canada 2336875 2336875 Expired Canada <br />National Stage 2336875<br />Filed on 1999-07-27<br />Status: Expired 167599034 E-015-1998-0 E-015-1998-0-CN-03 Multivalent Human-Bovine Rotavirus Vaccine National Stage China ZL99810311.X 99810311.X Expired China <br />National Stage 99810311.X<br />Filed on 1999-07-27<br />Status: Expired 167599035 E-015-1998-0 E-015-1998-0-EP-08 Multivalent Human-Bovine Rotavirus Vaccine National Stage European Patent 1100537 99938819.2 Expired European Patent <br />National Stage 99938819.2<br />Filed on 1999-07-27<br />Status: Expired 167599036 E-015-1998-0 E-015-1998-0-IN-04 Multivalent Human-Bovine Rotavirus Vaccine National Stage India 243453 IN/PCT/2001/0106/CHE Expired India <br />National Stage IN/PCT/2001/0106/CHE<br />Filed on 1999-07-27<br />Status: Expired 167599037 E-015-1998-0 E-015-1998-0-JP-09 Multivalent Human-Bovine Rotavirus Vaccine National Stage Japan 4414095 2000-562050 Expired Japan <br />National Stage 2000-562050<br />Filed on 1999-07-27<br />Status: Expired 167599038 E-015-1998-0 E-015-1998-0-KR-05 Multivalent Human-Bovine Rotavirus Vaccine National Stage South Korea 10-0688434 10-2001-7001236 Expired South Korea <br />National Stage 10-2001-7001236<br />Filed on 1999-07-27<br />Status: Expired 167599040 E-015-1998-0 E-015-1998-0-DE-12 Multivalent Human-Bovine Rotavirus Vaccine EP Germany 69929443.6 99938819.2 Expired Germany <br />European patent (EP) 99938819.2<br />Filed on 1999-07-27<br />Status: Expired 167599041 E-015-1998-0 E-015-1998-0-FR-13 Multivalent Human-Bovine Rotavirus Vaccine EP France 1100537 99938819.2 Expired France <br />European patent (EP) 99938819.2<br />Filed on 1999-07-27<br />Status: Expired 167599042 E-015-1998-0 E-015-1998-0-GB-14 Multivalent Human-Bovine Rotavirus Vaccine EP United Kingdom 1100537 99938819.2 Expired United Kingdom <br />European patent (EP) 99938819.2<br />Filed on 1999-07-27<br />Status: Expired 167599043 E-015-1998-0 E-015-1998-0-IE-15 Multivalent Human-Bovine Rotavirus Vaccine EP Ireland 1100537 99938819.2 Expired Ireland <br />European patent (EP) 99938819.2<br />Filed on 1999-07-27<br />Status: Expired 167599044 E-015-1998-0 E-015-1998-0-IT-16 Multivalent Human-Bovine Rotavirus Vaccine EP Italy 1100537 99938819.2 Expired Italy <br />European patent (EP) 99938819.2<br />Filed on 1999-07-27<br />Status: Expired 167599045 E-015-1998-0 E-015-1998-0-CN-17 Multivalent Human-Bovine Rotavirus Vaccine DIV China ZL200810090397.2 200810090397.2 Expired China <br />Divisional (DIV) 200810090397.2<br />Filed on 2008-04-11<br />Status: Expired 167599047 E-015-1998-0 E-015-1998-0-JP-19 Multivalent Human-Bovine Rotavirus Vaccine DIV Japan 2009-148918 Abandoned Japan <br />Divisional (DIV) 2009-148918<br />Filed on 2009-06-23<br />Status: Abandoned TAB-5100 167551551 Human antibodies with anti-lymphocyte specificities and lytic activity NIAID Antibodies, Application, TherapeuticArea Antibodies Application TherapeuticArea Ainhoa Perez-Diez, Irini Sereti <p>&nbsp; &nbsp; &nbsp; &nbsp;Antibody therapies that target human B cells are a promising way to treat diseases like B-cell cancers and autoimmune conditions like lupus and multiple sclerosis. Traditionally, these antibodies are made in animals and modified to resemble human antibodies to reduce immune rejection. Researchers in the Laboratory of Immunoregulation (LIR) at the National Institute of Allergy and Infectious Diseases (NIAID) have developed a new approach of using blood plasma from a patient with the rare immune disorder idiopathic CD4 lymphocytopenia (ICL) to find naturally occurring human antibodies.</p> <p>&nbsp; &nbsp; &nbsp; &nbsp;By using advanced genetic sequencing, the researchers discovered and reproduced several new antibodies that could effectively attack and kill B-cell tumors, normal B cells, and T cells, demonstrating potential for eliminating cancerous or disease-causing immune cells. One potent antibody, NIH58.9, killed B cells at low concentrations of 0.01 nanomolar. These new antibodies may be used as treatments, combined with other therapies, or engineered into special formats like bispecific antibodies or antibody-drug conjugates.</p> <ul> <li>First fully human IgM antibody that binds to and kills B cells</li> <li>Fully human monoclonal antibodies eliminating humanization steps associated with antibodies derived from animal models and lowering risk of anti-drug antibody response</li> <li>B-cell death observed at concentrations as low as 0.01Nm</li> <li>Versatile antibody that may be used directly, engineered as IgG1 antibody, and possibly developed into bispecifics or antibody-drug conjugates</li> </ul> <ul> <li>Development of monoclonal antibody therapies, bispecific antibodies, and antibody-targeted drugs for use in organ transplantation, B-cell lymphomas, and autoimmune conditions</li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. For collaboration opportunities, please contact Benjamin Hurley at 240-276-5489, or benjamin.hurley@nih.gov. 2026-05-21 2026-05-21 2026-05-21 2026-05-21 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 167551741 Perez-Diez, Ainhoa National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Perez-Diez, Ainhoa (NIAID) 1 167551745 Sereti, Irini NIAID - DIR NIAID Sereti, Irini (NIAID) 2 167551741 Perez-Diez, Ainhoa National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Perez-Diez, Ainhoa (NIAID) 1 167551745 Sereti, Irini NIAID - DIR NIAID Sereti, Irini (NIAID) 2 167551554 Human antibodies with anti-lymphocyte specificities and lytic activity linked to ICL. E-025-2025-0 Filing authorized National Institute of Allergy and Infectious Diseases (NIAID/NIH), NIAID - DIR 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-5100] Human antibodies with anti-lymphocyte specificities and lytic activity&body=Please send me information about technology [TAB-5100] Human antibodies with anti-lymphocyte specificities and lytic activity. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-5100] Human antibodies with anti-lymphocyte specificities and lytic activity&body=Please send me information about technology [TAB-5100] Human antibodies with anti-lymphocyte specificities and lytic activity.">benjamin.hurley@nih.gov</a><br> 167551560 E-025-2025-0 E-025-2025-0-US-01 MONOCLONAL ANTI-LYMPHOCYTE ANTIBODIES AND THEIR USE PRV US 63/787,190 Expired US <br />Provisional (PRV) 63/787,190<br />Filed on 2025-04-11<br />Status: Expired 167551561 E-025-2025-0 E-025-2025-0-PC-01 MONOCLONAL ANTI-LYMPHOCYTE ANTIBODIES AND THEIR USE PCT Patent Cooperation Treaty PCT/US2026/022767 Pending Patent Cooperation Treaty <br />(PCT) PCT/US2026/022767<br />Filed on 2026-04-08<br />Status: Pending TAB-3924 147157204 Chimeric Adaptor Proteins (CAPs) Containing a Linker for Activation of T Cells (LAT) and a Kinase Domain for Use in T Cell-Based Immunotherapy NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Lakshmi Balagopalan, Katherine McIntire, Lawrence Samelson, Chang Yi <p>T cell immunotherapy is used in the treatment of various pathologies – including cancers and infections. Current therapies employ chimeric antigen receptors (CARs) consisting of the intracellular fragment of CD3-zeta as the signaling domain with varied combinations of co-stimulatory, transmembrane, spacer/hinge, and extracellular targeting domains. While effective in treating hematological malignancies, CAR T cells need to be activated through T cell receptor (TCR) activation. Such activation is subject to various regulatory and inhibitory mechanisms that can limit their full therapeutic potential. Moreover, CAR T cells are less effective in the treatment of solid tumors due to exhaustion. There remains a need for effective immunotherapies to treat solid tumors as well as hematological malignancies. Researchers at the National Cancer Institute (NCI) have found that after T cell receptor (TCR) activation, the linker for activation of T cells (LAT) forms a distinct signaling complex and its formation is sufficient to cause full T-cell activation independent of the TCR complex. As activation of the TCR complex is highly regulated by a number of competing kinases and phosphatases, the downstream LAT molecule offers several advantages over CD3-zeta as the signaling domain in CARs.</p> <p>Researchers at the NCI have developed chimeric adaptor proteins (CAPs) consisting of an extracellular targeting domain, transmembrane domain, intracellular LAT domain, and the kinase domain of ZAP70. The inventors have observed that the formation of these complexes is sufficient to cause full T-cell activation independent of TCR activation. It is expected that the circumvention of the regulatory mechanisms targeting upstream TCR activation will increase the potency of T-cell signaling and the sensitivity of immunotherapy. Furthermore, T cells prepared with these recombinant molecules may be more resistant to exhaustion by molecules targeting TCR activation, and tunable, as the activity of the kinase domain can be altered with small molecules.</p> <p>The <a href="https://ccr.cancer.gov/Laboratory-of-Cellular-and-Molecular-Biology" rel="nofollow">Laboratory of Cellular and Molecular Biology</a>, is seeking statements of capability or interest from parties interested in licensing this invention and/or collaborative research to further develop, evaluate, or commercialize CAPs for the treatment of solid tumors and hematological malignancies.</p> <h2>Competitive Advantages:</h2> <ul><li>Potential for demonstrable efficacy against solid cancers previously refractory to cellular immunotherapy via: <ul><li>Signaling through LAT allows circumvention of regulatory and inhibitory mechanisms involved in TCR activation</li> <li>Directly triggering the downstream signaling cascade could cause more potent activation of T cells </li> <li>LAT-based CAP-expressing T cells may be more resistant to PD-1-mediated T-cell exhaustion </li> <li>Signaling from CAPs consisting of LAT and ZAP70 kinase domain may be tunable </li> </ul></li> </ul> <h2>Commercial Applications:</h2> <ul><li>Treatment of hematological malignancies and solid tumors</li> <li>Therapeutic use as a combination therapy with immune checkpoint inhibitors and/or chemotherapy</li> </ul> 2019-06-28 2025-04-22 2020-05-19 2026-05-19 2019-06-28 CAP, CAR, Chimeric Adaptor Protein, chimeric antigen receptor, Immunotherapy, LAT, Linker for Activation of T cells, Samelson, T cell False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-05-19 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-159-2009 147162087 Yi J, et al. TCR microclusters form spatially segregated domains and sequentially assemble in calcium-dependent kinetic steps https://www.ncbi.nlm.nih.gov/pubmed/30655520 <a href="https://www.ncbi.nlm.nih.gov/pubmed/30655520">Yi J, et al. TCR microclusters form spatially segregated domains and sequentially assemble in calcium-dependent kinetic steps</a> 147162165 Balagopalan L, et al. Plasma membrane LAT activation precedes vesicular recruitment defining two phases of early T-cell activation https://www.ncbi.nlm.nih.gov/pubmed/29789604 <a href="https://www.ncbi.nlm.nih.gov/pubmed/29789604">Balagopalan L, et al. Plasma membrane LAT activation precedes vesicular recruitment defining two phases of early T-cell activation</a> 167504673 Balagopalan L, et al. Generation of antitumor chimeric antigen receptors incorporating T cell signaling motifs (PMID: 39042728) https://pubmed.ncbi.nlm.nih.gov/39042728/ <a href="https://pubmed.ncbi.nlm.nih.gov/39042728/">Balagopalan L, et al. Generation of antitumor chimeric antigen receptors incorporating T cell signaling motifs (PMID: 39042728)</a> 147162882 Yi, Chang NIH - NCI Yi, Chang 1 147162881 Balagopalan, Lakshmi NIH - NCI NCI Balagopalan, Lakshmi (NCI) 2 147162883 McIntire, Katherine NIH - NCI NCI McIntire, Katherine (NCI) 3 147162880 Samelson, Lawrence NIH - NCI NCI Samelson, Lawrence (NCI) 4 147162882 Yi, Chang NIH - NCI Yi, Chang 1 147162881 Balagopalan, Lakshmi NIH - NCI NCI Balagopalan, Lakshmi (NCI) 2 147162883 McIntire, Katherine NIH - NCI NCI McIntire, Katherine (NCI) 3 147162880 Samelson, Lawrence NIH - NCI NCI Samelson, Lawrence (NCI) 4 147158213 Recombinant Molecule Containing LAT For Use In T Cell Immunotherapy E-210-2018-0 Filing authorized NCI 147162560 Chimeric Adaptor Proteins (CAPs) For Improved T-Cell Immunotherapy E-210-2018-1 Filing authorized NCI 83694133 Gulay French, Suna suna.gulay@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB suna.gulay@nih.gov?subject=Web Inquiry on [TAB-3924] Chimeric Adaptor Proteins (CAPs) Containing a Linker for Activation of T Cells (LAT) and a Kinase Domain for Use in T Cell-Based Immunotherapy&body=Please send me information about technology [TAB-3924] Chimeric Adaptor Proteins (CAPs) Containing a Linker for Activation of T Cells (LAT) and a Kinase Domain for Use in T Cell-Based Immunotherapy.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Gulay French, Suna<br><a href="mailto:suna.gulay@nih.gov?subject=Web Inquiry on [TAB-3924] Chimeric Adaptor Proteins (CAPs) Containing a Linker for Activation of T Cells (LAT) and a Kinase Domain for Use in T Cell-Based Immunotherapy&body=Please send me information about technology [TAB-3924] Chimeric Adaptor Proteins (CAPs) Containing a Linker for Activation of T Cells (LAT) and a Kinase Domain for Use in T Cell-Based Immunotherapy.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">suna.gulay@nih.gov</a><br> 147161195 E-210-2018-0 E-210-2018-0-PCT-02 CHIMERIC ADAPTOR AND KINASE SIGNALING PROTEINS AND THEIR USE IN IMMUNOTHERAPY PCT Patent Cooperation Treaty PCT/US2020/022752 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2020/022752<br />Filed on 2020-03-13<br />Status: Expired 147165286 E-210-2018-0 E-210-2018-0-US-01 RECOMBINANT MOLECULES CONTAINING LINKER FOR ACTIVATION OF T CELLS AND THEIR USE IN IMMUNOTHERAPY PRV US 62/819,386 Abandoned US <br />Provisional (PRV) 62/819,386<br />Filed on 2019-03-15<br />Status: Abandoned 147165287 E-210-2018-0 E-210-2018-0-EP-03 CHIMERIC ADAPTOR AND KINASE SIGNALING PROTEINS AND THEIR USE IN IMMUNOTHERAPY National Stage European Patent 20718061.3 Pending European Patent <br />National Stage 20718061.3<br />Filed on 2020-03-13<br />Status: Pending 147165288 E-210-2018-0 E-210-2018-0-CN-04 CHIMERIC ADAPTOR AND KINASE SIGNALING PROTEINS AND THEIR USE IN IMMUNOTHERAPY National Stage China 202080021582.5 Pending China <br />National Stage 202080021582.5<br />Filed on 2020-03-13<br />Status: Pending 147165289 E-210-2018-0 E-210-2018-0-HK-05 CHIMERIC ADAPTOR AND KINASE SIGNALING PROTEINS AND THEIR USE IN IMMUNOTHERAPY EP Hong Kong 62022051308.4 Pending Hong Kong <br />European patent (EP) 62022051308.4<br />Filed on 2020-03-13<br />Status: Pending 147165291 E-210-2018-1 E-210-2018-1-US-01 CHIMERIC ADAPTOR AND KINASE SIGNALING PROTEINS AND THEIR USE IN IMMUNOTHERAPY CIP US 17/475,810 Pending US <br />Continuation in Part (CIP) 17/475,810<br />Filed on 2021-09-15<br />Status: Pending 147165292 E-210-2018-1 E-210-2018-1-PCT-02 Chimeric adaptor and kinase signaling proteins and their use in immunotherapy PCT Patent Cooperation Treaty PCT/US2022/076358 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2022/076358<br />Filed on 2022-09-13<br />Status: Expired 147173698 CAP 147173699 CAR 147173701 Chimeric Adaptor Protein 147173702 chimeric antigen receptor 147173703 Immunotherapy 147173704 LAT 147173706 Linker for Activation of T cells 147173708 Samelson 147173709 T cell TAB-4435 147157730 Levonorgestrel Butanoate Formulation and Methods Relating Thereto NICHD Collaboration, Endocrinology, Licensing, Reproductive Health, Therapeutics Collaboration Endocrinology Licensing Reproductive Health Therapeutics Diana Blithe, Ken Chen, Jia-Hwa Fang, Min Lee, Eduardo Ruiz <h2>Summary:</h2> <p>The National Institute of Child Health and Human Development (NICHD) seeks licensees and/or research co-development partners for the development of an injectable contraceptive for women with a pharmaceutical formulation containing levonorgestrel butanoate (LB), a steroidal progestin.</p> <h2>Description of Technology:</h2> <p>This invention is a potential subcutaneous or intramuscular progestin-only, injectable contraceptive for women. Forty-five percent (45%) of pregnancies in the United States are unintended. In this group, one-third of reproductive age women are obese &ndash; increasing the risk of diabetes, hypertension and venous thromboembolism (VTE). All these are conditions for which most hormonal methods are contraindicated. Thus, additional safe and effective injectable contraceptive options are needed. A subcutaneous formulation may be self-injected without the need of a skilled care provider or medical office visit. Levonorgestrel butanoate (LB) serves as a pro-drug to deliver Levonorgestrel (LNG) to serum after hydrolysis of the ester. It addresses the demand for estrogen-free contraception with no increased risk of VTE. The lack of increased risk is a benefit for all women, especially those obese.&nbsp;</p> <p>Injectables have lower failure rates than combined hormonal birth control pills or patches or progestin-only pills (POP). Also, POPs require strict adherence to a daily administration schedule. Currently, the only injectable contraceptive on the U.S. market is depomedroxyprogesterone acetate (DMPA). While popular, DMPA contraceptive with certain risks. DMPA may cause weight gain, moodiness, and a decrease in bone mineral density leading to a higher risk of bone fracture.&nbsp;&nbsp;</p> <p>Levonorgestrel butanoate (LB) is a butyl prodrug of levonorgestrel, a widely-used steroidal progestin. It was in development as a long-acting injectable contraceptive since the 1980s by the World Health Organization (WHO) in collaboration with institutions around the world, including NICHD. However, conventional LB formulations, including the WHO formulation, exhibit undesirable stability issues reducing contraceptive activity and the ability to large-scale manufacture.&nbsp;&nbsp;</p> <p>NICHD developed an injectable pharmaceutical formulation of LB with a potential for self-administration. The formulation promotes increased stability through a longer lasting and more concentrated dosage than previous LB formulations. This invention also involves a unique manufacturing process requiring only one vendor for more efficient production. NICHD is testing this formulation in an ongoing Phase I subcutaneous study. Results so far indicate promise as a long-lasting, reversible, injectable female contraceptive. Further, there is a competitive advantage as patients in the Phase I study thus far did not report some side effects associated with other contraceptive agents such as DMPA; e.g., weight gain or mood swings.&nbsp;</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Injectable contraceptive use by humans</li> <li>Use in the treatment of progestin-related diseases</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Safer for women with high-risk conditions</li> <li>Self-subcutaneous and reversible injectable</li> <li>Long-lasting contraceptive effects</li> <li>Increased stability relative to previous formulations</li> <li>Amenable to large-scale manufacture relative to previous formulations</li> <li>Estrogen free contraceptive</li> <li>Progestin only self-injectable contraceptive</li> </ul> 2022-02-24 2026-04-30 2022-02-24 2026-05-18 2022-02-23 Blithe, CONTRACEPTIVE, INJECTABLE, LB, Lee, Levonorgestrel, Levonorgestrel Butanoate, LNG, National Institute of Child Health and Human Development, NICHD, Steroidal Progestin False True Clinical True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2022-02-24 72159138 Clinical Phase I 72159138 NCI 37470483 Website Abstract 147164730 Lee, Min NIH - NICHD NICHD Lee, Min (NICHD) 1 147164729 Blithe, Diana NIH - NICHD NICHD Blithe, Diana (NICHD) 2 147164731 Fang, Jia-Hwa SRI International Fang, Jia-Hwa 3 147164732 Ruiz, Eduardo SRI International Ruiz, Eduardo 4 147164733 Chen, Ken SRI International Chen, Ken 5 147164730 Lee, Min NIH - NICHD NICHD Lee, Min (NICHD) 1 147164729 Blithe, Diana NIH - NICHD NICHD Blithe, Diana (NICHD) 2 147164731 Fang, Jia-Hwa SRI International Fang, Jia-Hwa 3 147164732 Ruiz, Eduardo SRI International Ruiz, Eduardo 4 147164733 Chen, Ken SRI International Chen, Ken 5 147158168 Levonorgestrel Prodrug Formulation And Methods Relating Thereto E-184-2021-0 Filing authorized NICHD, SRI International 91788919 Gunas, Heather gunash@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America gunash@mail.nih.gov?subject=Web Inquiry on [TAB-4435] Levonorgestrel Butanoate Formulation and Methods Relating Thereto&body=Please send me information about technology [TAB-4435] Levonorgestrel Butanoate Formulation and Methods Relating Thereto.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Gunas, Heather<br><a href="mailto:gunash@mail.nih.gov?subject=Web Inquiry on [TAB-4435] Levonorgestrel Butanoate Formulation and Methods Relating Thereto&body=Please send me information about technology [TAB-4435] Levonorgestrel Butanoate Formulation and Methods Relating Thereto.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">gunash@mail.nih.gov</a><br> 147161163 E-184-2021-0 E-184-2021-0-US-01 LEVONORGESTREL BUTANOATE FORMULATION AND METHODS RELATING THERETO PRV US 63/289,965 Expired US <br />Provisional (PRV) 63/289,965<br />Filed on 2021-12-15<br />Status: Expired 147168900 E-184-2021-0 E-184-2021-0-PCT-02 LEVONORGESTREL BUTANOATE FORMULATION AND METHODS RELATING THERETO PCT Patent Cooperation Treaty PCT/US2022/052704 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2022/052704<br />Filed on 2022-12-13<br />Status: Expired 167305206 E-184-2021-0 E-184-2021-0-IN-01 LEVONORGESTREL BUTANOATE FORMULATION AND METHODS RELATING THERETO National Stage India 202417045561 Pending India <br />National Stage 202417045561<br />Filed on 2024-06-13<br />Status: Pending 147173251 Blithe 147173252 CONTRACEPTIVE 147173253 INJECTABLE 147173255 LB 147173256 Lee 147173257 Levonorgestrel 147173259 Levonorgestrel Butanoate 147173261 LNG 147173262 National Institute of Child Health and Human Development 147173263 NICHD 147173265 Steroidal Progestin TAB-5094 166511676 Novel malaria vaccine candidates comprising engineered nanoparticles NIAID Collaboration Sought, ResearchProducts, TherapeuticArea, Vaccines Collaboration Sought ResearchProducts TherapeuticArea Vaccines Thayne Dickey, Vu Nguyen, Dashuang Shi, Niraj Tolia <p>Using proteins derived from the malaria Plasmodium falciparum parasite, NIAID has developed three different nanoparticle platforms to serve as scaffolds for displaying multiple copies of malaria antigens in an organized, repetitive manner to enhance vaccine effectiveness. The first platform uses the pyridoxal 5&rsquo;-phosphate (PLP) synthase protein to form a nanoparticle displaying 48 copies of up to 4 different proteins. The second platform uses the chaperone 60 (Cpn60), which can display 28 copies of up to 2 different proteins. The third platform uses a caseinolytic protease (Clp) which can display 28 copies of up to two different proteins.</p> <p>This technology is available for licensing for commercial development in accordance with 35 U.S.C. &sect; 209 and 37 CFR Part 404, as well as for further development and evaluation under a research collaboration.</p> <ul> <li>Pre-clinical data indicates that nanoparticles displaying the malaria circumsporozoite protein (CSP) confer 100% sterilizing immunity in mice.</li> </ul> <ul> <li>Malaria vaccinology</li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. For collaboration opportunities, please contact Chris Kornak at 240-565-2632, or chris.kornak@nih.gov. 2026-03-19 2026-05-14 2026-05-14 2026-03-24 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 166527395 Shi D, et al. A Plasmodium-derived nanoparticle vaccine elicits sterile protection against malaria in mice. Nat Microbiol. 2026;11(1):67–80. (doi:10.1038/s41564-025-02209-y) https://pubmed.ncbi.nlm.nih.gov/41420060/ <a href="https://pubmed.ncbi.nlm.nih.gov/41420060/">Shi D, et al. A Plasmodium-derived nanoparticle vaccine elicits sterile protection against malaria in mice. Nat Microbiol. 2026;11(1):67–80. (doi:10.1038/s41564-025-02209-y)</a> 166511805 Tolia, Niraj National Institute of Allergy and Infectious Diseases (NIAID/NIH) Tolia, Niraj 1 166511821 Shi, Dashuang NIAID Shi, Dashuang (NIAID) 2 166511842 Nguyen, Vu National Institute of Allergy and Infectious Diseases (NIAID/NIH) Nguyen, Vu 3 166512001 Dickey, Thayne NIAID - DIR NIAID Dickey, Thayne (NIAID) 4 166511805 Tolia, Niraj National Institute of Allergy and Infectious Diseases (NIAID/NIH) Tolia, Niraj 1 166511821 Shi, Dashuang NIAID Shi, Dashuang (NIAID) 2 166511842 Nguyen, Vu National Institute of Allergy and Infectious Diseases (NIAID/NIH) Nguyen, Vu 3 166512001 Dickey, Thayne NIAID - DIR NIAID Dickey, Thayne (NIAID) 4 166511679 Novel malaria vaccine candidates comprising engineered nanoparticles E-182-2024-0 Filing authorized National Institute of Allergy and Infectious Diseases (NIAID/NIH), NIAID - DIR, NIH - NIAID 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-5094] Novel malaria vaccine candidates comprising engineered nanoparticles&body=Please send me information about technology [TAB-5094] Novel malaria vaccine candidates comprising engineered nanoparticles. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-5094] Novel malaria vaccine candidates comprising engineered nanoparticles&body=Please send me information about technology [TAB-5094] Novel malaria vaccine candidates comprising engineered nanoparticles.">benjamin.hurley@nih.gov</a><br> 166511684 E-182-2024-0 E-182-2024-0-US-01 MALARIA PROTEIN NANOPARTICLE VACCINES AND USES THEREOF PRV US 63/695,288 Expired US <br />Provisional (PRV) 63/695,288<br />Filed on 2024-09-16<br />Status: Expired 166511685 E-182-2024-0 E-182-2024-0-PC-01 MALARIA PROTEIN NANOPARTICLE VACCINES AND USES THEREOF PCT Patent Cooperation Treaty PCT/US2025/046419 Pending Patent Cooperation Treaty <br />(PCT) PCT/US2025/046419<br />Filed on 2025-09-15<br />Status: Pending TAB-5049 162271101 A Novel Strategy to Produce 6-cys Proteins Based on Pfs230D1 Domain Fusions NIAID Application, Collaboration, Collaboration Sought, Immunology, Infectious Disease, Licensing, Materials Available, Research Materials, Sequences, Therapeutics, Vaccines Application Collaboration Collaboration Sought Immunology Infectious Disease Licensing Materials Available Research Materials Sequences Therapeutics Vaccines Patrick Duffy, Jonathan Renn <p>The Plasmodium parasite has a complex lifecycle during human infection and in the mosquito vector. Most advanced malaria vaccine candidates can confer only partial, short-term protection in malaria-endemic areas. A means of breaking the transmission of malaria to subsequent individuals could prevent a significant amount of human disease.</p> <p>The primary embodiments of this technology are novel compositions of matter that produce enhanced transmission-blocking responses over current transmission blocking vaccines:</p> <ul> <li>The inventors designed fusion protein sequences incorporating Pfs230 domain1 (Pfs230D1) at the N-terminus with additional Plasmodium 6-cys domains downstream.</li> <li>The artificial immunogens retained structured transmission blocking epitopes.</li> </ul> <p>This technology is available for licensing for commercial development in accordance with 35 U.S.C. &sect; 209 and 37 CFR Part 404, as well as for further development and evaluation under a research collaboration.</p> <ul> <li>The immunogens were used in small animal vaccination studies where the Pfs230D1-Pfs48/45D3, Pfs230D1-Pfs230D9, Pfs230D1-3 fusions prompted greater functional serum activity compared to Pfs230D1 alone.</li> <li>Pfs230D1 or its ortholog Pvs230D1 enabled expression of other downstream domains of Pvs230 or Pv48/45D3 another malaria species that causes human disease.</li> </ul> <ul> <li>This technology could be used alone or in combination with existing malaria vaccines. </li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. For collaboration opportunities, please contact Chris Kornak 240-627-3705 or chris.kornak@nih.gov, and reference E-086-2023. 2025-05-08 2026-05-14 2026-05-14 2025-05-09 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 162271181 Duffy, Patrick NIAID - DIR NIAID Duffy, Patrick (NIAID) 1 162271185 Renn, Jonathan National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Renn, Jonathan (NIAID) 2 162271181 Duffy, Patrick NIAID - DIR NIAID Duffy, Patrick (NIAID) 1 162271185 Renn, Jonathan National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Renn, Jonathan (NIAID) 2 162271104 A Novel Strategy To Produce 6-cys Proteins Based On Pfs230D1 Domain Fusions E-086-2023-0 Filing authorized National Institute of Allergy and Infectious Diseases (NIAID/NIH) 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-5049] A Novel Strategy to Produce 6-cys Proteins Based on Pfs230D1 Domain Fusions&body=Please send me information about technology [TAB-5049] A Novel Strategy to Produce 6-cys Proteins Based on Pfs230D1 Domain Fusions. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-5049] A Novel Strategy to Produce 6-cys Proteins Based on Pfs230D1 Domain Fusions&body=Please send me information about technology [TAB-5049] A Novel Strategy to Produce 6-cys Proteins Based on Pfs230D1 Domain Fusions.">benjamin.hurley@nih.gov</a><br> 162271153 E-086-2023-0 E-086-2023-0-US-01 NOVEL COMPOSITIONS OF MATTER COMPRISING PROTEINS THAT INCORPORATE PFS230 DOMAIN 1 (PFS230D1) AT THE N-TERMINUS, MALARIA VACCINE ANTIGENS, AND THEIR USE PRV US 63/617,717 Expired US <br />Provisional (PRV) 63/617,717<br />Filed on 2024-01-04<br />Status: Expired 162271154 E-086-2023-0 E-086-2023-0-PC-01 NOVEL COMPOSITIONS OF MATTER COMPRISING PROTEINS THAT INCORPORATE PFS230 DOMAIN 1 (PFS230D1) AT THE N-TERMINUS, MALARIA VACCINE ANTIGENS, AND THEIR USE PCT Patent Cooperation Treaty PCT/US2025/010325 Pending Patent Cooperation Treaty <br />(PCT) PCT/US2025/010325<br />Filed on 2025-01-03<br />Status: Pending 166735919 E-086-2023-0 E-086-2023-0-IN-01 NOVEL COMPOSITIONS OF MATTER COMPRISING PROTEINS THAT INCORPORATE PFS230 DOMAIN 1 (PFS230D1) AT THE N-TERMINUS, MALARIA VACCINE ANTIGENS, AND THEIR USE National Stage India In Preparation India <br />National Stage None<br />Filed on None<br />Status: In Preparation 166735995 E-086-2023-0 E-086-2023-0-US-02 NOVEL COMPOSITIONS OF MATTER COMPRISING PROTEINS THAT INCORPORATE PFS230 DOMAIN 1 (PFS230D1) AT THE N-TERMINUS, MALARIA VACCINE ANTIGENS, AND THEIR USE National Stage US In Preparation US <br />National Stage None<br />Filed on None<br />Status: In Preparation 166736025 E-086-2023-0 E-086-2023-0-EP-01 NOVEL COMPOSITIONS OF MATTER COMPRISING PROTEINS THAT INCORPORATE PFS230 DOMAIN 1 (PFS230D1) AT THE N-TERMINUS, MALARIA VACCINE ANTIGENS, AND THEIR USE National Stage European Patent In Preparation European Patent <br />National Stage None<br />Filed on None<br />Status: In Preparation TAB-4981 155111852 Enhanced Single-Component AMA1-RON2 Vaccine Candidates: A Breakthrough in Malaria Immunization NIAID Infectious Disease, Vaccines Infectious Disease Vaccines Palak Patel, Niraj Tolia <p>This technology focuses on the creation of single-component AMA1-RON2 (Apical membrane antigen 1-rhoptry neck protein 2) vaccine candidates. These candidates are based on a novel composition of matter designed to elicit a more effective immune response against the malaria parasite Plasmodium falciparum. The standout aspect of this technology is the Structure-Based Design 1 (SBD1) immunogen, engineered through a structure-based design that significantly enhances its ability to produce potent, strain-transcending neutralizing antibodies. This approach not only surpasses the efficacy of traditional AMA1-RON2 complexes and other insertion fusion designs but also boasts higher thermal stability, indicating better preservation and longevity of the vaccine. The technology&rsquo;s increased stability and efficiency in production present an opportunity to lower vaccine manufacturing costs and simplify logistics, especially in regions where malaria is endemic. Additionally, the adaptability of these immunogens for integration with nanoparticle platforms could further amplify their immunogenicity, paving the way for more robust and lasting protection against malaria. This innovation can potentially transform malaria prevention and control, offering a more effective, stable, and cost-efficient solution to a disease that continues to impact millions worldwide.</p> <ul> <li>No blood-stage malaria vaccine has been approved. This technology offers a competitive edge over other vaccine candidates in development through its easily manufactured single-component AMA1-RON2 design that elicits a potent broadly neutralizing response that is better than competing candidates</li> </ul> <ul> <li>Stable single-component AMA1-RON2 immunogens hold promise for improving malaria prevention and control efforts in endemic regions around the world.</li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. For collaboration opportunities, please contact Chris Kornak at 240-627-3705 or chris.kornak@nih.gov. 2024-04-09 2026-05-14 2026-05-14 2024-11-12 Design, FALCIPARUM, Malaria, PLASMODIUM, Structure-based False False True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 155122907 Patel, P. N. et. al., Structure-based design of a strain transcending AMA1-RON2L malaria vaccine. Nat. Commun. 14, 5345, 2023 Patel, P. N. et. al., Structure-based design of a strain transcending AMA1-RON2L malaria vaccine. Nat. Commun. 14, 5345, 2023 155122699 Tolia, Niraj NIH - NIAID Tolia, Niraj 1 155122722 Patel, Palak NIH - NIAID NIAID Patel, Palak (NIAID) 2 155122699 Tolia, Niraj NIH - NIAID Tolia, Niraj 1 155122722 Patel, Palak NIH - NIAID NIAID Patel, Palak (NIAID) 2 155111855 Novel malaria vaccine candidates comprising a stabilized designs of AMA1 and RON2 antigens E-096-2023-0 Filing authorized National Institute of Allergy and Infectious Diseases (NIAID/NIH) 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-4981] Enhanced Single-Component AMA1-RON2 Vaccine Candidates: A Breakthrough in Malaria Immunization&body=Please send me information about technology [TAB-4981] Enhanced Single-Component AMA1-RON2 Vaccine Candidates: A Breakthrough in Malaria Immunization. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-4981] Enhanced Single-Component AMA1-RON2 Vaccine Candidates: A Breakthrough in Malaria Immunization&body=Please send me information about technology [TAB-4981] Enhanced Single-Component AMA1-RON2 Vaccine Candidates: A Breakthrough in Malaria Immunization.">benjamin.hurley@nih.gov</a><br> 155111948 E-096-2023-0 E-096-2023-0-US-01 NOVEL MALARIA VACCINE COMPRISING AMA1 AND RON2 ANTIGENS PRV US 63/524,522 Expired US <br />Provisional (PRV) 63/524,522<br />Filed on 2023-06-30<br />Status: Expired 156351084 E-096-2023-0 E-096-2023-0-PC-01 NOVEL MALARIA VACCINE COMPRISING AMA1 AND RON2 ANTIGENS PCT Patent Cooperation Treaty PCT/US2024/035244 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2024/035244<br />Filed on 2024-06-24<br />Status: Expired 155154090 Malaria 155154109 PLASMODIUM 155154113 FALCIPARUM 155154263 Structure-based 155154272 Design TAB-4980 155110980 Next-Generation MSP1-Targeted Malaria Immunotherapy: Enhanced Vaccine Candidates and Monoclonal Antibodies NIAID Collaboration, Infectious Disease, Vaccines Collaboration Infectious Disease Vaccines Thayne Dickey, Carole Long, Kazutoyo Miura, Palak Patel, Niraj Tolia <p>This technology encompasses the development of highly advanced malaria vaccine candidates and human monoclonal antibodies, both centered on targeting the Merozoite Surface Protein 1 (MSP1) of the Plasmodium falciparum malaria parasite. The innovation lies in utilizing a novel computational design and in vitro screening process, which has created MSP1 vaccine candidates that are significantly more immunogenic, stable, and cost-effective than existing alternatives. These vaccines focus on the 19 kDa carboxy-terminus fragment of MSP1. They contain engineered amino acid changes and are displayed on self-assembling nanoparticles to elicit a more potent immune response, potentially offering more robust and durable protection against malaria. Additionally, the technology includes the production of enhanced human monoclonal antibodies with improved affinity for the same fragment of MSP1, designed to overcome the parasite&#39;s immune evasion tactics. These advancements hold immense promise for significantly improving malaria prevention and treatment. They could lead to the development of more effective vaccines and therapeutic antibodies, providing a critical solution to a significant global health challenge.</p> <ul> <li>This technology offers highly immunogenic and stable MSP1-based vaccine candidates and monoclonal antibodies, with superior efficacy, cost-effectiveness, and ease of production compared to current alternatives.</li> </ul> <ul> <li>This MSP1-focused technology has the potential to transform malaria treatment and prevention worldwide, offering more effective vaccines and therapeutic antibodies for use in clinical settings, public health programs, and potentially in regions with high malaria prevalence.</li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. For collaboration opportunities, please contact Chris Kornak at 240-627-3705 or chris.kornak@nih.gov. 2024-04-09 2026-05-14 2026-05-14 2024-11-12 antibodies, ANTIGENS, Enhanced, Immunotherapy, Malaria, monoclonal, MSP1 False False Pre-clinical True 37470483 Website Abstract 155111531 Patel, Palak N et al. “Neutralizing and interfering human antibodies define the structural and mechanistic basis for antigenic diversion.” Nature communications vol. 13,1 5888. 6 Oct. 2022, doi:10.1038/s41467-022-33336-3 Patel, Palak N et al. “Neutralizing and interfering human antibodies define the structural and mechanistic basis for antigenic diversion.” Nature communications vol. 13,1 5888. 6 Oct. 2022, doi:10.1038/s41467-022-33336-3 155111249 Tolia, Niraj NIH - NIAID Tolia, Niraj 1 155111332 Dickey, Thayne NIH - NIAID NIAID Dickey, Thayne (NIAID) 2 155111348 Patel, Palak NIH - NIAID NIAID Patel, Palak (NIAID) 3 155111357 Miura, Kazutoyo NIH - NIAID NIAID Miura, Kazutoyo (NIAID) 4 155111372 Long, Carole NIH - NIAID NIAID Long, Carole (NIAID) 5 155111249 Tolia, Niraj NIH - NIAID Tolia, Niraj 1 155111332 Dickey, Thayne NIH - NIAID NIAID Dickey, Thayne (NIAID) 2 155111348 Patel, Palak NIH - NIAID NIAID Patel, Palak (NIAID) 3 155111357 Miura, Kazutoyo NIH - NIAID NIAID Miura, Kazutoyo (NIAID) 4 155111372 Long, Carole NIH - NIAID NIAID Long, Carole (NIAID) 5 155110983 Novel Compositions Of Matter Comprising Stabilized MSP1 Malaria Antigens And High Affinity Anti-MSP1 Human Monoclonal Antibodies And Their Use E-154-2022-0 Filing authorized NIAID 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-4980] Next-Generation MSP1-Targeted Malaria Immunotherapy: Enhanced Vaccine Candidates and Monoclonal Antibodies&body=Please send me information about technology [TAB-4980] Next-Generation MSP1-Targeted Malaria Immunotherapy: Enhanced Vaccine Candidates and Monoclonal Antibodies. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-4980] Next-Generation MSP1-Targeted Malaria Immunotherapy: Enhanced Vaccine Candidates and Monoclonal Antibodies&body=Please send me information about technology [TAB-4980] Next-Generation MSP1-Targeted Malaria Immunotherapy: Enhanced Vaccine Candidates and Monoclonal Antibodies.">benjamin.hurley@nih.gov</a><br> 155111222 E-154-2022-0 E-154-2022-0-US-01 METHOD OF IMMUNOFOCUSING AN IMMUNE RESPONSE PRV US 63/369,909 Expired US <br />Provisional (PRV) 63/369,909<br />Filed on 2022-07-29<br />Status: Expired 155111223 E-154-2022-0 E-154-2022-0-PC-01 METHOD OF IMMMUNOFOCUSING AN IMMUNE RESPONSE PCT Patent Cooperation Treaty PCT/US2023/070926 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2023/070926<br />Filed on 2023-07-25<br />Status: Expired 155111074 antibodies 155111081 ANTIGENS 155111085 MSP1 155111092 Malaria 155111112 monoclonal 155111140 Immunotherapy 155111176 Enhanced TAB-4978 155044855 Enhanced Stability and Efficacy of Pfs48/45 Domain III Protein Variants for Malaria Vaccine Development Using SPEEDesign Technology NIAID Antibodies, Collaboration, Infectious Disease, Vaccines Antibodies Collaboration Infectious Disease Vaccines Thayne Dickey, Niraj Tolia <p>The technology includes modifying the Plasmodium falciparum Pfs48/45 Domain III protein sequence to enhance its stability and efficacy to aid in malaria vaccine development. This approach successfully overcomes previous production challenges by increasing the thermostability of the antigen and eliminating the need for additional modifications that could impair vaccine effectiveness. Crucially, the technology maintains the essential neutralizing epitope of Pfs48/45, ensuring its effectiveness in preventing malaria transmission as a transmission-blocking vaccine. Developed using the SPEEDesign program, these novel protein variants show increased stability and a more robust transmission blocking response than wild-type proteins. The potential applications of this technology are providing a more stable and effective vaccine, potentially reducing the incidence of malaria and leading to improved health outcomes.</p> <ul> <li> The development of more effective and stable malaria vaccines offers improved prevention strategies in regions affected by this disease and significantly contributing to global health initiatives.</li> </ul> <ul> <li> This malaria vaccine technology offers competitive advantages by providing increased thermostability and enhanced immune response without the need for efficacy-reducing modifications, potentially revolutionizing malaria prevention with more effective and stable vaccine options.</li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. For collaboration opportunities, please contact Chris Kornak at 240-627-3705 or chris.kornak@nih.gov. 2024-04-04 2026-05-14 2026-05-14 2024-11-12 Malaria Vaccine, Pfs48/45, proteins, Stabilized False False Preclinical Research True 37470483 Website Abstract 155046595 Tolia, Niraj National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Tolia, Niraj (NIAID) 1 155046603 Dickey, Thayne National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Dickey, Thayne (NIAID) 2 155046595 Tolia, Niraj National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Tolia, Niraj (NIAID) 1 155046603 Dickey, Thayne National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Dickey, Thayne (NIAID) 2 155044858 Novel Compositions Of Matter Comprising Stabilized Pfs48/45 Proteins And Their Use E-030-2023-0 Filing authorized NIAID 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-4978] Enhanced Stability and Efficacy of Pfs48/45 Domain III Protein Variants for Malaria Vaccine Development Using SPEEDesign Technology&body=Please send me information about technology [TAB-4978] Enhanced Stability and Efficacy of Pfs48/45 Domain III Protein Variants for Malaria Vaccine Development Using SPEEDesign Technology. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-4978] Enhanced Stability and Efficacy of Pfs48/45 Domain III Protein Variants for Malaria Vaccine Development Using SPEEDesign Technology&body=Please send me information about technology [TAB-4978] Enhanced Stability and Efficacy of Pfs48/45 Domain III Protein Variants for Malaria Vaccine Development Using SPEEDesign Technology.">benjamin.hurley@nih.gov</a><br> 155050145 E-030-2023-0 E-030-2023-0-US-01 Novel Compositions Of Matter Comprising Stabilized Pfs48/45 Proteins And Their Use PRV US 63/476,897 Expired US <br />Provisional (PRV) 63/476,897<br />Filed on 2022-12-22<br />Status: Expired 155050149 E-030-2023-0 E-030-2023-0-PC-01 STABILIZED PFS48/45 PROTEINS AND USES THEREOF PCT Patent Cooperation Treaty PCT/US2023/085849 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2023/085849<br />Filed on 2023-12-22<br />Status: Expired 161727281 E-030-2023-0 E-030-2023-0-IN-01 STABILIZED PFS48/45 PROTEINS AND USES THEREOF National Stage India 202517060138 Pending India <br />National Stage 202517060138<br />Filed on 2025-06-24<br />Status: Pending 161727321 E-030-2023-0 E-030-2023-0-US-02 STABILIZED PFS48/45 PROTEINS AND USES THEREOF National Stage US 19/142,034 Pending US <br />National Stage 19/142,034<br />Filed on 2025-06-20<br />Status: Pending 161727556 E-030-2023-0 E-030-2023-0-EP-01 STABILIZED PFS48/45 PROTEINS AND USES THEREOF National Stage European Patent 23848442.2 Pending European Patent <br />National Stage 23848442.2<br />Filed on 2025-07-04<br />Status: Pending 155049175 Pfs48/45 155049189 proteins 155049198 Stabilized 155049276 Malaria Vaccine TAB-3522 114097382 Novel Compositions of Matter Comprising Stabilized Coronavirus Antigens and Their Use NIAID Collaboration Collaboration Thayne Dickey, Niraj Tolia Using a computational design methodology, SARS-CoV-2 spike proteins containing engineered amino acid changes to the receptor binding domain (RBD) were designed. These engineered spike proteins improved the immune response upon immunization of animals. An engineered RBD was also expressed at greater yield, had increased temperature stability, and improved the immune response upon immunization of animals. Specifically, the disclosed RBD designs can be produced approximately 7 times more efficiently than the native sequence, facilitating vaccine manufacturing on a global scale. The disclosed designs also have up to 10 °C higher thermal stability than the native sequence, suggesting enhanced stability during storage and when in the body. Finally, immunization of animals with the disclosed antigens produces up to 10-fold higher levels of blocking antibodies than the native sequence and 30-fold higher levels of pseudoviral neutralizing antibodies. An additional RBD protein has been engineered to eliminate the need for glycosylation, facilitating production and single-component nanoparticle display of the antigen. The engineered receptor binding domain (RBD) and spike protein antigens produce significant improvements in pre-clinical animal models and may be used to develop improved coronavirus vaccines.<br /><br /> This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR Part 404, as well as for further development and evaluation under a research collaboration. <ul> <li>Novel SARS-CoV-2 spike vaccine with improved breadth and duration of protection.</li> <li>Novel RBD monomer and nanoparticle designs that are more immunogenic and stable than the naturally occurring RBD sequence.</li> <li>Computational method of designing vaccine antigens.</li> </ul> <ul> <li>Novel SARS-CoV-2 vaccine.</li> <li>Improved SARS-CoV-2 diagnostics using stabilized antigens.</li> <li>Method of designing vaccine candidates or stabilized antigens by computational. optimization of amino acid identity, followed by additional sequence comparison and selection (Stabilizer for Protein Expression and Epitope Design (SPEEDesign)).</li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize the invention. For collaboration opportunities, please contact Peter Tung at 240-669-5483; <a href="mailto:peter.tung@nih.gov.">peter.tung@nih.gov</a>. 2022-03-30 2026-05-14 2026-05-14 2022-03-30 ANTIGENS, Compositions, COMPRISING, CORONAVIRUS, Matter, Novel, Stabilized, Their False True True NIHTT 37470483 Website Abstract 114172677 Dickey TH, et al. https://pubmed.ncbi.nlm.nih.gov/34013270/ <a href="https://pubmed.ncbi.nlm.nih.gov/34013270/">Dickey TH, et al.</a> 114110541 Dickey, Thayne NIAID - DIR NIAID Dickey, Thayne (NIAID) 0 114110542 Tolia, Niraj NIAID - VRC Tolia, Niraj 1 114110542 Tolia, Niraj NIAID - VRC Tolia, Niraj 1 114110541 Dickey, Thayne NIAID - DIR NIAID Dickey, Thayne (NIAID) 0 114102633 Novel Compositions Of Matter Comprising Stabilized Coronavirus Antigens And Their Use E-045-2021-0 Filing authorized NIAID 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-3522] Novel Compositions of Matter Comprising Stabilized Coronavirus Antigens and Their Use&body=Please send me information about technology [TAB-3522] Novel Compositions of Matter Comprising Stabilized Coronavirus Antigens and Their Use. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-3522] Novel Compositions of Matter Comprising Stabilized Coronavirus Antigens and Their Use&body=Please send me information about technology [TAB-3522] Novel Compositions of Matter Comprising Stabilized Coronavirus Antigens and Their Use.">benjamin.hurley@nih.gov</a><br> 114169303 E-045-2021-0 E-045-2021-0-PCT-02 COMPOSITIONS OF MATTER COMPRISING STABILIZED CORONAVIRUS ANTIGENS AND THEIR USE PCT Patent Cooperation Treaty PCT/US2022/070744 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2022/070744<br />Filed on 2022-02-18<br />Status: Expired 114169304 E-045-2021-0 E-045-2021-0-US-01 Novel Compositions Of Matter Comprising Stabilized Coronavirus Antigens And Their Use PRV US 63/200,194 Abandoned US <br />Provisional (PRV) 63/200,194<br />Filed on 2021-02-19<br />Status: Abandoned 114152824 Their 114152825 ANTIGENS 114152826 CORONAVIRUS 114152827 Stabilized 114152828 COMPRISING 114152829 Matter 114152830 Compositions 114152831 Novel TAB-3459 114097328 Novel VAR2CSA Immunogens and Methods of Use Thereof NIAID Collaboration Collaboration Rui Ma, Niraj Tolia The invention provides immunogen polypeptides comprising fragments of VAR2CSA protein expressed by P. falciparum as potential second-generation placental malaria vaccine candidates. VAR2CSA is the leading antigen target for a placental malaria vaccine, where associated antibody titers are correlated with protection. Aspects of the inventive immunogen polypeptides comprise all or portions of the chondroitin sulfate A (CSA) binding regions of VAR2CSA, as identified by a structural study of VAR2CSA conducted by the inventors, that possess great sequence conservation among P. falciparum strains when compared to competing clinical vaccine candidates PRIMVAC and PAMVAC. Also provided are methods of using the immunogen polypeptides for vaccination and treatment of disease. <ul><li>Strain-transcending immunogens for vaccination</li> <li>Improved immunogen production through expression of key protein regions</li></ul> The VAR2CSA immunogens bind to oncofetal CSA, a putative therapeutic target for multiple cancers, including NSCLC, breast, bladder and 40-50% of all pediatric solid tumors. Oncofetal CSA is only expressed solely in the placenta, except in several cancerous tissues, making it an ideal target for targeted therapeutics such as immunogens that are cross linked to cytotoxic agents. <br /><br /> <ul><li>Placental malaria vaccine</li> <li>CSA-binding proteins for cancer therapeutics</li></ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize the invention. For collaboration opportunities, please contact Peter Tung at 240-669-5483; <a hef="mailto:Peter.Tung@nih.gov">Peter Tung@nih.gov</a>. 2022-04-01 2026-05-14 2026-05-14 2022-01-13 Against, CANCER, COMPOSITION, COMPRISING, Diagnostics, IMMUNOGENS, Malaria, Matter, Placental, PROTECT, proteins, That, therapeutics, Used False True True NIHTT 37470483 Website Abstract 114110245 Ma, Rui NIAID - VRC NIAID Ma, Rui (NIAID) 0 114110246 Tolia, Niraj NIAID - VRC Tolia, Niraj 1 114110246 Tolia, Niraj NIAID - VRC Tolia, Niraj 1 114110245 Ma, Rui NIAID - VRC NIAID Ma, Rui (NIAID) 0 114102572 New Composition Of Matter Comprising Immunogens That Will Protect Against Placental Malaria, And Proteins That Can Be Used For Cancer Diagnostics And Therapeutics E-021-2021-0 Filing authorized NIAID 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-3459] Novel VAR2CSA Immunogens and Methods of Use Thereof&body=Please send me information about technology [TAB-3459] Novel VAR2CSA Immunogens and Methods of Use Thereof. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-3459] Novel VAR2CSA Immunogens and Methods of Use Thereof&body=Please send me information about technology [TAB-3459] Novel VAR2CSA Immunogens and Methods of Use Thereof.">benjamin.hurley@nih.gov</a><br> 114169183 E-021-2021-0 E-021-2021-0-US-01 NOVEL VAR2CSA IMMUNOGENS AND METHODS OF USE THEREOF PRV US 63/115,729 Abandoned US <br />Provisional (PRV) 63/115,729<br />Filed on 2020-11-19<br />Status: Abandoned 114169184 E-021-2021-0 E-021-2021-0-PCT-02 NOVEL VAR2CSA IMMUNOGENS AND METHODS OF USE THEREOF PCT Patent Cooperation Treaty PCT/US2021/059941 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/059941<br />Filed on 2021-11-18<br />Status: Expired 114152318 COMPOSITION 114152319 Matter 114152320 COMPRISING 114152321 IMMUNOGENS 114152322 That 114152323 PROTECT 114152324 Against 114152325 Placental 114152326 Malaria 114152327 proteins 114152328 Used 114152329 CANCER 114152330 Diagnostics 114152331 therapeutics TAB-5099 167270778 Drug-Regulatable, Inducible Expression of Membrane-Bound Interleukin 12 (DRIM-IL-12) for Use in Adoptive Cell Therapy NCI Collaboration, Immunology, Licensing, Oncology, Therapeutics Collaboration Immunology Licensing Oncology Therapeutics Sanghyun (Peter) Kim, Steven Rosenberg <div> <div> <div class="msocomtxt" id="_com_2"> <h2>Summary:&nbsp;</h2> <p>Scientists at the National Cancer Institute (NCI) have developed a novel tightly regulated drug-responsive, membrane-bound IL-12 cytokine platform, that enhances anti-tumor efficacy in adoptive cell therapy (ACT) with engineered T-cells (CAR, TCR, TILs) while improving safety. The NCI seeks research co-development partners and/or licensees to advance this technology toward clinical translation.&nbsp;</p> <h2>Description of Technology:&nbsp;</h2> <p>ACT offers hope for patients with refractory or metastatic cancers, but effectiveness is frequently undermined by the immunosuppressive tumor microenvironment and T-cell dysfunction. Interleukin-12 (IL-12), a powerful cytokine with strong anti-tumor properties, has long been recognized for its potential to invigorate T-cell responses within tumors. However, systemic administration of IL-12 results in severe toxicity. Further, prior gene therapy strategies failed to provide sufficient control over IL-12 expression. These two factors compromise safety and therapeutic performance.</p> <p>This invention introduces a Nuclear Factor of Activated T cells (NFAT)-inducible, drug-regulatable, membrane-bound IL-12 (DRIM-IL-12) system that delivers spatiotemporally controlled cytokine expression within the engineered T cell therapy product. This platform ensures IL-12 is expressed only upon T-cell activation. Concurrently, the degron (D) sequence confers lenalidomide-dependent proteasome-mediated degradation&ndash;serving as a drug-controlled safety switch to limit systemic toxicity. A transmembrane (TM) domain anchors IL-12 in the plasma membrane, preventing unintended secretion and promoting localized immune modulation. When paired with tumor-specific TCRs or CARs (e.g., anti-mutant p53 or KRAS TCRs, or CD19 CAR), this platform enhances tumor cell killing and long-term survival in preclinical models. In a mouse model, DRIM-IL-12 demonstrated substantially improved safety compared to the previous generation of NFAT-inducible IL-12. The inventors also demonstrate that DRIM-IL-12 expression can be dialed down or fine-tuned to prevent T-cell exhaustion or differentiation, which can occur with uncontrolled IL-12 expression.</p> <p>The NCI invites industry partners and translational researchers to collaborate or license this technology for the next generation of safer, more effective ACT-based immunotherapies.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Solid tumors expressing p53 or KRAS mutations</li> <li>Hematologic malignancies</li> <li>Melanoma</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Versatile platform for inducible cytokine regulation</li> <li>Superior survival in mouse models compared with TCR-only T-cells</li> <li>Enhanced tumor cell killing and long-term survival in murine models</li> <li>Decreased IL-12&ndash;associated toxicity</li> <li>Maintenance of higher IL-12 expression&nbsp;</li> <li>Improved sensitivity to lenalidomide-mediated degradation</li> </ul> </div> </div> </div> Researchers at the NCI seek licensing and/or co-development research collaborations for developing a novel tightly regulated drug-responsive, membrane-bound IL-12 cytokine platform, that enhances anti-tumor efficacy in adoptive cell therapy (ACT) with engineered T-cells (CAR, TCR, TILs). 2026-05-14 2026-05-14 2026-05-14 2026-05-14 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 72159138 Clinical Phase I 72159138 NCI 37470483 Website Abstract 167271215 Kim SP, et al. Drug-regulatable, inducible, and membrane-bound interleukin 12 (IL-12TM-D) for use in adoptive cell therapies against advanced cancers. https://doi.org/10.1136/jitc-2024-SITC2024.0344 Kim SP, et al. Drug-regulatable, inducible, and membrane-bound interleukin 12 (IL-12TM-D) for use in adoptive cell therapies against advanced cancers. https://doi.org/10.1136/jitc-2024-SITC2024.0344 167270829 Rosenberg, Steven National Cancer Institute (NCI) NCI Rosenberg, Steven (NCI) 1 167270833 Kim, Sanghyun (Peter) NCI - CCR NCI Kim, Sanghyun (Peter) (NCI) 2 167270829 Rosenberg, Steven National Cancer Institute (NCI) NCI Rosenberg, Steven (NCI) 1 167270833 Kim, Sanghyun (Peter) NCI - CCR NCI Kim, Sanghyun (Peter) (NCI) 2 167270784 Drug-regulatable, inducible expression of membrane-bound interleukin 12 for use in adoptive cell therapy. E-217-2023-0 Filing authorized National Cancer Institute (NCI), Surgery Branch 83709866 Burke, Andrew burkear@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC burkear@nih.gov?subject=Web Inquiry on [TAB-5099] Drug-Regulatable, Inducible Expression of Membrane-Bound Interleukin 12 (DRIM-IL-12) for Use in Adoptive Cell Therapy&body=Please send me information about technology [TAB-5099] Drug-Regulatable, Inducible Expression of Membrane-Bound Interleukin 12 (DRIM-IL-12) for Use in Adoptive Cell Therapy.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Burke, Andrew<br><a href="mailto:burkear@nih.gov?subject=Web Inquiry on [TAB-5099] Drug-Regulatable, Inducible Expression of Membrane-Bound Interleukin 12 (DRIM-IL-12) for Use in Adoptive Cell Therapy&body=Please send me information about technology [TAB-5099] Drug-Regulatable, Inducible Expression of Membrane-Bound Interleukin 12 (DRIM-IL-12) for Use in Adoptive Cell Therapy.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">burkear@nih.gov</a><br> 167270791 E-217-2023-0 E-217-2023-0-US-01 DRUG-REGULATABLE, INDUCIBLE CYTOKINE EXPRESSION PRV US 63/652,871 Expired US <br />Provisional (PRV) 63/652,871<br />Filed on 2024-05-29<br />Status: Expired 167270792 E-217-2023-0 E-217-2023-0-PC-01 DRUG-REGULATABLE, INDUCIBLE CYTOKINE EXPRESSION PCT Patent Cooperation Treaty PCT/US2025/031121 Pending Patent Cooperation Treaty <br />(PCT) PCT/US2025/031121<br />Filed on 2025-05-28<br />Status: Pending TAB-3391 114097279 Wipes and Methods for Removal of Lead and Other Metal Contamination from Surfaces CDC Cardiology, Collaboration, Consumer Products, Dental, Endocrinology, Infectious Disease, Licensing, Neurology, Occupational Safety and Health, Oncology, Ophthalmology Cardiology Collaboration Consumer Products Dental Endocrinology Infectious Disease Licensing Neurology Occupational Safety and Health Oncology Ophthalmology Kevin Ashley, Mark Boeniger, Eric Esswein Exposure to lead (Pb) has long posed serious health risks. Ingestion of lead from skin exposure can adversely impact every organ in the body; the kidneys, blood, nervous, and reproductive systems are most affected. Washing skin with soap and water is not sufficient to remove lead residues. To prevent adverse impacts from Pb exposure, exposed individuals need cleaning methods that will effectively remove Pb ions from the skin to less than the limit of identification (i.e., 10 µg or less). <br /><br /> Centers for Disease Control and Prevention (CDC), National Institute for Occupational Safety and Health (NIOSH) researchers developed a method to remove metals such as lead from surfaces, including skin. This method includes applying a cationic surfactant (ISML (isostearamidopropyl morpholine lactate), a compound that lowers surface tension) and a weak acid (such as citric acid) to a surface and wiping the surface with a three-dimensionally textured absorbent support. The cationic surfactant and weak acid are in liquid form or are dissolved in a suitable solvent, such as water. This wetting agent can be applied directly to the surface and wiped away or can be contained within the absorbent support. Research has shown that this method does not damage or irritate the skin. <br/<br /> This technology can be used in conjunction with another CDC NIOSH invention, a handwipe disclosing method (HHS Reference No. E-336-2013) which uses colorimetric chemistry (a color change occurs) to detect lead sampled from surfaces. Combined, these two technologies can “close the loop” by both detecting and decontaminating skin or other surfaces contaminated with lead. <br /><br /> <ul> <li>Safe for use on skin</li> <li>Quick and easy to use</li> <li>Portable and convenient to use wherever lead is present</li> <li>Effectively removes Pb ions from the skin to less than the limit of identification</li> <li>Can be used to complement other lead detection methods</li> <li>Uses physical (wiping) and chemical means to decontaminate surfaces from lead and other metals mentioned above</li> </ul> <ul> <li>Cleansing the hands of workers who have occupational exposure to lead (e.g., auto repairers, battery manufacturers, pipe fitters, recyclers of metal and batteries, etc.) prior to eating, smoking, or leaving their work for the day</li> <li>Cleansing the hands of police, other law enforcement officers (e.g., immigration, customs, or Secret Service) or recreational firearms users after using firearms</li> <li>Cleansing the hands of lead abatement workers or those renovating old homes with lead-based paint</li> <li>Removing lead from any contaminated surface other than skin such as floors, walls, windowsills, clothing, laundry, shoes, equipment surfaces, and furniture surfaces that may pose an exposure risk</li> <li>Kit for detecting and removing lead from surfaces (when combined with the handwipe disclosing method to detect the presence of lead sampled from surfaces (HHS Reference No. E-336-2013))<li> <li>May be used to solubilize and remove a variety of metals such as cadmium, tin, barium, arsenic, chromium, copper, mercury, silver, zinc, strontium, thallium, germanium, or zirconium, or a combination thereof </li> </ul> The CDC Technology Transfer Office (TTO) is seeking statements of capability or interest from parties interested in collaborating to further commercialize Wipes and Methods for Removal of Lead and Other Metal Contamination from Surfaces. For collaboration opportunities, please contact CDC TTO at <a href="mailto:tto@cdc.gov">tto@cdc.gov</a> or 1-404-639-1330. For collaboration opportunities, please contact CDC TTO at <a href="mailto:tto@cdc.gov">tto@cdc.gov</a> or 1-404-639-1330. 2022-03-27 2026-05-14 2026-05-14 2020-02-13 CDC Docket Import, CDC Docket Import CDC Prosecuting, contamination, Listed LPM Surabian as of 4/15/2015, MECHANICAL, METAL, Methods, NIOSH-DSHEFS, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, REMOVAL, SURFACES, VEXXXX, VPXXXX, WGXXXX, WIPES, WMXXXX, XIXXXX, YFXXXX False True True 52406769 Prototype 52406769 NIHTT 37470483 Website Abstract E-336-2013-0 114172557 Esswein E., Boeniger M. (2005). Preventing the Toxic Hand-Off. Occupational Hazards, 67(9) https://www.researchgate.net/publication/311667267_Preventing_the_Toxic_Hand_Off <a href="https://www.researchgate.net/publication/311667267_Preventing_the_Toxic_Hand_Off ">Esswein E., Boeniger M. (2005). Preventing the Toxic Hand-Off. Occupational Hazards, 67(9)</a> 114172558 Esswein EJ, et al. http://dx.doi.org/10.1520/JAI103527 <a href="http://dx.doi.org/10.1520/JAI103527 ">Esswein EJ, et al.</a> 114172559 NIOSH. (2015). Combatting the Dangers of Heavy Metal Contamination: the CDC Can Lead the Way https://archive.cdc.gov/#/detailsq=combatting%20the%20dangers%20of%20heavy%20metal%20contamination:%20CDC%20can%20lead%20the%20way!&start=0&rows=10&url=https://www.cdc.gov/od/science/technology/techtransfer/successstories/leadwipes.htm <a href="https://archive.cdc.gov/#/detailsq=combatting%20the%20dangers%20of%20heavy%20metal%20contamination:%20CDC%20can%20lead%20the%20way!&start=0&rows=10&url=https://www.cdc.gov/od/science/technology/techtransfer/successstories/leadwipes.htm">NIOSH. (2015). Combatting the Dangers of Heavy Metal Contamination: the CDC Can Lead the Way</a> 114172560 NIOSH. (2018). Workplace Safety and Health Topics https://www.cdc.gov/niosh/topics/lead/default.html <a href="https://www.cdc.gov/niosh/topics/lead/default.html">NIOSH. (2018). Workplace Safety and Health Topics</a> 114110055 Boeniger, Mark CDC - NIOSH CDC Boeniger, Mark (CDC) 0 114110056 Ashley, Kevin CDC - NIOSH CDC Ashley, Kevin (CDC) 0 114110054 Esswein, Eric CDC - NIOSH CDC Esswein, Eric (CDC) 1 114110054 Esswein, Eric CDC - NIOSH CDC Esswein, Eric (CDC) 1 114110055 Boeniger, Mark CDC - NIOSH CDC Boeniger, Mark (CDC) 0 114110056 Ashley, Kevin CDC - NIOSH CDC Ashley, Kevin (CDC) 0 114102523 WIPES AND METHODS FOR REMOVAL OF METAL CONTAMINATION FROM SURFACES E-221-2013-0 Filing authorized Centers for Disease Control and Prevention (CDC) 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-3391] Wipes and Methods for Removal of Lead and Other Metal Contamination from Surfaces&body=Please send me information about technology [TAB-3391] Wipes and Methods for Removal of Lead and Other Metal Contamination from Surfaces. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-3391] Wipes and Methods for Removal of Lead and Other Metal Contamination from Surfaces&body=Please send me information about technology [TAB-3391] Wipes and Methods for Removal of Lead and Other Metal Contamination from Surfaces.">yogikala.prabhu@nih.gov</a><br> 114168962 E-221-2013-0 E-221-2013-0-US-01 WIPES AND METHODS FOR REMOVAL OF METAL CONTAMINATION FROM SURFACES ORD US 7,604,997 11/039,178 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7604997 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7604997">7,604,997</a><br />Filed on 2005-01-18<br />Status: Issued 114168963 E-221-2013-0 E-221-2013-0-PCT-02 WIPES AND METHODS FOR REMOVAL OF METAL CONTAMINATION FROM SURFACES PCT Patent Cooperation Treaty PCT/US2006/001515 Abandoned Patent Cooperation Treaty <br />(PCT) PCT/US2006/001515<br />Filed on 2006-01-17<br />Status: Abandoned 114128288 YFXXXX 114128289 VEXXXX 114128290 VPXXXX 114128291 WGXXXX 114128292 WMXXXX 114128293 XIXXXX 114151725 WIPES 114151726 Methods 114151727 REMOVAL 114151728 METAL 114151729 contamination 114151730 SURFACES 114151731 CDC Docket Import 114151732 CDC Docket Import CDC Prosecuting 114151733 NIOSH-DSHEFS 114151734 Listed LPM Surabian as of 4/15/2015 114151735 Pre LPM working set 20150418 114151736 Post LPM Assignment Set 20150420 114151737 MECHANICAL TAB-3392 114097280 Handwipe Disclosing Method for Detecting the Presence of Lead CDC Cardiology, Collaboration, Dental, Endocrinology, Infectious Disease, Licensing, Neurology, Occupational Safety and Health, Oncology, Ophthalmology, Research Materials Cardiology Collaboration Dental Endocrinology Infectious Disease Licensing Neurology Occupational Safety and Health Oncology Ophthalmology Research Materials Kevin Ashley, Mark Boeniger, Eric Esswein Lead (Pb) exposure can cause serious health concerns including abdominal pain, headaches, loss of appetite, memory loss, weakness, and other symptoms. Lead residues on human skin, especially on the hands of workers can be a significant health risk since such residues may be ingested during normal activities (e.g. eating, drinking, and smoking). A key component to reducing lead exposure is being able to identify areas of lead contamination. <br /><br /> US Centers for Disease Control and Prevention (CDC), National Institute for Occupational Safety and Health (NIOSH) researchers developed a method to detect lead on surfaces, including skin, using a handwipe system and a chemical test to effect a color change if lead is present. A handwipe is used to collect any lead contamination on the surface. Then the lead is solubilized with an aqueous acid solution and treated with rhodizonate or sulfide anions. When lead is detected, the color changes from pink to red (when rhodizonate anions are used) or from brown to black (where sulfide anions are used). <br /><br /> This invention can be used to test surfaces including human skin, floors, walls, windowsills, etc. It can be used to inform employers and workers on potential lead contamination, as well as evaluate lead removal efforts. This technology can also be used in conjunction with another CDC NIOSH invention involving wipes and methods for removal of lead. Combined, these two technologies can “close the loop” by both detecting and decontaminating skin and other surfaces contaminated with lead. <br /><br /> <ul> <li>Safe for use on skin</li> <li>Quick and easy to use</li> -<li>Portable and can be used during field evaluations</li> <li>Can be used wherever lead is present</li> <li>Simple color change readout indicates the presence of lead on a surface</li> <li>Lead concentration can be inferred by degree of color shift</li> <li>Can be used to guide and evaluate lead removal methods</li> </ul> <ul> <li>Testing potentially contaminated surfaces such as skin, floors, walls, windowsills, etc., for lead</li> <li>Informing employers and workers on potential lead contamination and exposure</li> <li> Educating potentially exposed individuals about their lead exposure and effectiveness of lead removal methods</li> <li>Evaluating effectiveness of lead removal from surfaces in workplaces, homes, hospitals, and schools <li>Confirming hand/skin/shoe/clothing washing effectiveness of lead removal for military, law enforcement, and target range personnel</li> <li>Part of a kit for detecting and removing lead from a surface (when combined with CDC NIOSH’s wipes and methods for removing lead and other metal contamination from surfaces technology (HHS Reference Number E-221-2013-0))</li> </ul> The CDC Technology Transfer Office (TTO) is seeking statements of capability or interest from parties interested in collaborating to further commercialize the Handwipe Disclosing Method for Detecting the Presence of Lead. For collaboration opportunities, please contact CDC TTO at <a href="mailto:tto@cdc.gov">tto@cdc.gov</a> or 1-404-639-1330. 2022-03-27 2026-05-14 2026-05-14 2020-02-13 CDC Docket Import, CDC Docket Import CDC Prosecuting, Contaminant, Contaminated, contamination, DEFENSE, Detection, detection system, DEVICE, DISCLOSING, firearm, firearm safety, firearms, HANDWIPE, LEAD, lead test, Listed LPM Surabian as of 4/15/2015, MECHANICAL, Method, military, NIOSH, NIOSH-DSHEFS, Occupational health, OSHA, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, PRESENCE, SAFETY, VEXXXX, VPXXXX, WCXXXX, WGXXXX, WHXXXX, WIPE, WIPES, WORKER, WORKER safety, YDXXXX, YEXXXX, YFXXXX False True True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract E-221-2013-0 114172561 Ashley K. (2010) Field-Portable Methods for Monitoring Occupational Exposures to Metals. Journal of Chemical Health and Safety, 17(3), 22-28. https://www.sciencedirect.com/science/article/pii/S1871553209000796 <a href="https://www.sciencedirect.com/science/article/pii/S1871553209000796">Ashley K. (2010) Field-Portable Methods for Monitoring Occupational Exposures to Metals. Journal of Chemical Health and Safety, 17(3), 22-28.</a> 114172562 Ashley K, et al. (2011). Evaluation of a handwipe disclosing method for lead. Journal of ATSM International, 8(4). https://www.astm.org/DIGITAL_LIBRARY/JOURNALS/JAI/PAGES/JAI103390.htm <a href="https://www.astm.org/DIGITAL_LIBRARY/JOURNALS/JAI/PAGES/JAI103390.htm ">Ashley K, et al. (2011). Evaluation of a handwipe disclosing method for lead. Journal of ATSM International, 8(4).</a> 114172563 Esswein E., & Boeniger M. (2005). Preventing the Toxic Hand-Off. Occupational Hazards, 67(9). https://www.researchgate.net/publication/311667267_Preventing_the_Toxic_Hand_Of <a href="https://www.researchgate.net/publication/311667267_Preventing_the_Toxic_Hand_Of">Esswein E., & Boeniger M. (2005). Preventing the Toxic Hand-Off. Occupational Hazards, 67(9).</a> 114172564 Esswein, EJ et al. Handwipe method for removing lead from skin. Journal of ATSM International, 8(5). https://www.researchgate.net/publication/239522749_Handwipe_method_for_removing_lead_from_skin <a href="https://www.researchgate.net/publication/239522749_Handwipe_method_for_removing_lead_from_skin">Esswein, EJ et al. Handwipe method for removing lead from skin. Journal of ATSM International, 8(5).</a> 114172565 NIOSH. (2015). Combatting the Dangers of Heavy Metal Contamination: the CDC Can Lead the Way! https://archive.cdc.gov/#/detailsq=combatting%20the%20dangers%20of%20heavy%20metal%20contamination:%20CDC%20can%20lead%20the%20way!&start=0&rows=10&url=https://www.cdc.gov/od/science/technology/techtransfer/successstories/leadwipes.htm <a href="https://archive.cdc.gov/#/detailsq=combatting%20the%20dangers%20of%20heavy%20metal%20contamination:%20CDC%20can%20lead%20the%20way!&start=0&rows=10&url=https://www.cdc.gov/od/science/technology/techtransfer/successstories/leadwipes.htm">NIOSH. (2015). Combatting the Dangers of Heavy Metal Contamination: the CDC Can Lead the Way!</a> 114172566 NIOSH. (2018). Workplace Safety and Health Topics: Lead. https://www.cdc.gov/niosh/topics/lead/default.html <a href="https://www.cdc.gov/niosh/topics/lead/default.html">NIOSH. (2018). Workplace Safety and Health Topics: Lead.</a> 114172567 NIOSH Manual of Analytical Methods (NMAM), Fourth Edition. Method 9105, Issue 1 - Lead in Dust Wipes by Chemical Spot Test Method (Colorimetric Screening Method), 15 March 2003. U.S. National Institute for Occupational Safety and Health (NIOSH), Cincinnati, OH. https://www.cdc.gov/niosh/docs/2003-154/pdfs/9105.pdf <a href="https://www.cdc.gov/niosh/docs/2003-154/pdfs/9105.pdf">NIOSH Manual of Analytical Methods (NMAM), Fourth Edition. Method 9105, Issue 1 - Lead in Dust Wipes by Chemical Spot Test Method (Colorimetric Screening Method), 15 March 2003. U.S. National Institute for Occupational Safety and Health (NIOSH), Cincinnati, OH.</a> 114110058 Boeniger, Mark CDC - NIOSH CDC Boeniger, Mark (CDC) 0 114110059 Ashley, Kevin CDC - NIOSH CDC Ashley, Kevin (CDC) 0 114110057 Esswein, Eric CDC - NIOSH CDC Esswein, Eric (CDC) 1 114110057 Esswein, Eric CDC - NIOSH CDC Esswein, Eric (CDC) 1 114110058 Boeniger, Mark CDC - NIOSH CDC Boeniger, Mark (CDC) 0 114110059 Ashley, Kevin CDC - NIOSH CDC Ashley, Kevin (CDC) 0 114102524 HANDWIPE DISCLOSING METHOD FOR THE PRESENCE OF LEAD E-336-2013-0 Closed Centers for Disease Control and Prevention (CDC) 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-3392] Handwipe Disclosing Method for Detecting the Presence of Lead &body=Please send me information about technology [TAB-3392] Handwipe Disclosing Method for Detecting the Presence of Lead . Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-3392] Handwipe Disclosing Method for Detecting the Presence of Lead &body=Please send me information about technology [TAB-3392] Handwipe Disclosing Method for Detecting the Presence of Lead .">yogikala.prabhu@nih.gov</a><br> 114168964 E-336-2013-0 E-336-2013-0-US-01 HANDWIPE DISCLOSING METHOD FOR THE PRESENCE OF LEAD PRV US 60/049,352 Abandoned US <br />Provisional (PRV) 60/049,352<br />Filed on 1997-06-11<br />Status: Abandoned 114168965 E-336-2013-0 E-336-2013-0-PCT-02 HANDWIPE DISCLOSING METHOD FOR THE PRESENCE OF LEAD PCT Patent Cooperation Treaty PCT/US1998/011776 Expired Patent Cooperation Treaty <br />(PCT) PCT/US1998/011776<br />Filed on 1998-06-08<br />Status: Expired 114168966 E-336-2013-0 E-336-2013-0-US-06 HANDWIPE DISCLOSING METHOD FOR THE PRESENCE OF LEAD National Stage US 6,248,593 09/458,152 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6248593 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6248593">6,248,593</a><br />Filed on 1999-12-09<br />Status: Expired 114128308 YEXXXX 114128309 YFXXXX 114128310 VEXXXX 114128311 YDXXXX 114128312 VPXXXX 114128313 WCXXXX 114128314 WGXXXX 114128315 WHXXXX 114151738 HANDWIPE 114151739 DISCLOSING 114151740 Method 114151741 PRESENCE 114151742 LEAD 114151743 CDC Docket Import 114151744 CDC Docket Import CDC Prosecuting 114151745 NIOSH-DSHEFS 114151746 NIOSH 114151747 WIPE 114151748 WIPES 114151749 SAFETY 114151750 lead test 114151751 Detection 114151752 detection system 114151753 Contaminant 114151754 Contaminated 114151755 contamination 114151756 OSHA 114151757 WORKER 114151758 WORKER safety 114151759 Occupational health 114151760 firearm 114151761 firearms 114151762 firearm safety 114151763 DEFENSE 114151764 military 114151765 DEVICE 114151766 Listed LPM Surabian as of 4/15/2015 114151767 Pre LPM working set 20150418 114151768 Post LPM Assignment Set 20150420 114151769 MECHANICAL TAB-4924 153511466 Methods for near real-time aerosol chemical analysis for environmental and occupational monitoring CDC Diagnostics, Licensing, Occupational Safety and Health Diagnostics Licensing Occupational Safety and Health Pramod Kulkarni, Orthodoxia Zervaki <p>&shy;Exposures to hazardous airborne particles can pose a significant health risk to those routinely exposed in ambient air and industrial work environments. Measuring chemical composition and concentration of aerosol particles is important to preventing worker exposures and protecting health. Current, widely used methods to measure aerosol chemicals in the workplace involve particle collection on filters over several hours, followed by laboratory analysis which requires considerable time and resources, cannot capture transient exposures, and provide results several days after the exposure has occurred. </p> <p><br /> CDC National Institute for Occupational Safety and Health (NIOSH) researchers have developed new methods to collect and analyze aerosol particles from an air sample. These direct-reading methods allow aerosol chemical analysis with high selectivity in near real-time in a portable or hand-held instrument. The methods allow collection of aerosols at high flow rates, 5-15 times higher than those in current commercial instruments, and involves concentration of the aerosol as a spot sample, followed by chemical analysis using laser spectroscopy techniques such as reflectance, Raman, absorption, fluorescence, and also through pulsed spark emission spectroscopy. The methods can be extended to detection of bioaerosols. The technology allows development of wearable, portable, or handheld instruments for continuous automated quantification of particulate chemical concentrations and bioaerosol analysis for environmental and occupational air quality monitoring applications. </p> <ul> <li>Near real-time and continuous automatic measurement of aerosol and bioaerosol</li> <li> Tandem spectroscopy: allows simultaneous elemental (i.e., atomic emission spectroscopy) and molecular (e.g., Raman and near infrared spectroscopy) analysis of aerosol samples with high selectivity</li> <li> High sample throughput collection </li> <li>- Allows space-saving and miniature designs for easy integration into portable instruments</li> <li> Eliminates the need for carrying heavy equipment in the field or waiting for laboratory analysis results</li> </ul> <ul> <li> Collecting and analyzing aerosol particles for the prevention and testing of hazardous exposures</li> <li> Air pollution studies and particulate matter monitoring</li> <li> Environmental and occupational personal exposure monitoring</li> <li> Evaluation of engineering controls</li> <li> Occupational safety and health</li> <li>Monitoring/public health surveillance</li> </ul> The CDC Technology Transfer Office is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. For collaboration opportunities, please contact CDC Technology Transfer Office at tto@cdc.gov or 404-639-1330. 2024-03-04 2026-05-14 2026-05-14 2024-03-06 Biodefense, ENVIRONMENTAL, MINING, MONITORING, Occupational health, QUALITY CONTROL, RESEARCH TOOL False False Early-stage In situ data available True 52406769 Prototype 52406769 37470483 Website Abstract E-291-2016-0 E-205-2013-0 E-163-2013-0 E-026-2014-0 E-146-2013-0 153512476 Zheng, L. et al. (DOI 10.1080/02786826.2016.1224804) Zheng, L. et al. (DOI 10.1080/02786826.2016.1224804) 153512484 Zheng, L. et al. (DOI 10.1016/j.jaerosci.2016.11.007) Zheng, L. et al. (DOI 10.1016/j.jaerosci.2016.11.007) 153512732 Zheng, L. et al. (DOI 10.1021/acs.analchem.9b02178) Zheng, L. et al. (DOI 10.1021/acs.analchem.9b02178) 153512740 Zervaki, O., et al. (DOI 10.1016/j.jaerosci.2023.106235) Zervaki, O., et al. (DOI 10.1016/j.jaerosci.2023.106235) 153511651 Kulkarni, Pramod CDC - NIOSH CDC Kulkarni, Pramod (CDC) 1 153511674 Zervaki, Orthodoxia CDC - NIOSH CDC Zervaki, Orthodoxia (CDC) 2 153511651 Kulkarni, Pramod CDC - NIOSH CDC Kulkarni, Pramod (CDC) 1 153511674 Zervaki, Orthodoxia CDC - NIOSH CDC Zervaki, Orthodoxia (CDC) 2 153511469 Methods For High Sample Throughput Collection And Trace Chemical Analysis Of Aerosols Using Laser And Optical Spectroscopies E-173-2021-0 Filing authorized Centers for Disease Control and Prevention (CDC) 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-4924] Methods for near real-time aerosol chemical analysis for environmental and occupational monitoring&body=Please send me information about technology [TAB-4924] Methods for near real-time aerosol chemical analysis for environmental and occupational monitoring. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-4924] Methods for near real-time aerosol chemical analysis for environmental and occupational monitoring&body=Please send me information about technology [TAB-4924] Methods for near real-time aerosol chemical analysis for environmental and occupational monitoring.">yogikala.prabhu@nih.gov</a><br> 155749516 E-173-2021-0 E-173-2021-0-JP-01 METHODS AND DEVICES FOR COLLECTING AND ANALYZING AEROSOL PARTICLES National Stage Japan 2024-544936 Pending Japan <br />National Stage 2024-544936<br />Filed on 2024-07-29<br />Status: Pending 155749555 E-173-2021-0 E-173-2021-0-US-02 METHODS AND DEVICES FOR COLLECTING AND ANALYZING AEROSOL PARTICLES National Stage US 18/832,139 Pending US <br />National Stage 18/832,139<br />Filed on 2024-07-23<br />Status: Pending 153542682 Biodefense 153542729 ENVIRONMENTAL 153542755 MINING 153542805 MONITORING 153542866 Occupational health 153542900 QUALITY CONTROL 153542943 RESEARCH TOOL TAB-3151 114097101 Direct Reading Detection Kits for Surface Contamination by Anti-Neoplastic (Anti-Cancer) Drugs CDC Cardiology, Collaboration, Consumer Products, Dental, Endocrinology, Infectious Disease, Licensing, Occupational Safety and Health, Oncology, Ophthalmology, Research Equipment, Research Materials, Therapeutics Cardiology Collaboration Consumer Products Dental Endocrinology Infectious Disease Licensing Occupational Safety and Health Oncology Ophthalmology Research Equipment Research Materials Therapeutics Shirley Robertson, Deborah Sammons, Jerome Smith Anti-neoplastic drugs, also known as anti-cancer drugs or chemotherapy, are used in the treatment of many types of cancer. However, these drugs are harmful to healthy cells as well as the cancerous cells. Exposure of healthcare workers to anti-neoplastic drugs from contaminated surfaces and drug vials in hospitals and pharmacies is a continuing problem as the drugs can cause both acute and long-term effects. Although there are sensitive techniques to evaluate contamination, results from these tests take time and must be performed in a laboratory. CDC researchers developed a real-time detection kit that can be used in the workplace to test for anti-neoplastic drug contamination. The direct reading anti-neoplastic drug detector based on lateral flow immunoassay (LFIA) technology has been developed for the assessment of drug residues on surfaces. These detectors are incorporated into kits that allow workers to sample surfaces to assess drug contamination in near real-time. Detection kits for three anti-neoplastic drugs (5-Fluorouracil, Paclitaxel, and Doxorubicin) have been developed and kits for several other anti-neoplastic agents may be possible based on this technology. <ul> <li>Near real-time results</li> <li>Can be used in various locations, on surfaces, and on protective equipment</li> <li>Simple to use</li> <li>Final kit configuration to incorporate laboratory and field studies for maximum benefit to healthcare workers</li> </ul> <ul> <li>Environmental sampling / detection kit for surface contamination by anti-neoplastic (anti-cancer) drugs in hospitals and pharmacies</li> <li>Kits can be used to assess decontamination procedures</li> <li>Kits can be used to assess protective equipment and closed system drug-transfer devices</li> <li>Kits can aid in the development of work practices to lower healthcare worker exposure to anti-neoplastic drugs from contaminated surfaces</li> </ul> The CDC/NIOSH is seeking statements of capability or interest from parties interested in collaborative reasearch to further develop, evaluate, or commercialize Detection Kits for Surface Contamination by Anti-Neoplastic Drugs. For collaboration opportunities, please contact Kathleen Goedel at <a href="mailto:keg2@cdc.gov">keg2@cdc.gov</a> or 1-513-533-8686. Foreign counterpart patent applications in Europe and Japan. 2022-03-27 2026-05-14 2026-05-14 2017-08-24 AE1BXX, AE2XXX, AE3XXX, Anti-neoplastic, CANCER, CANCER CHEMOTHERAPY, CANCEROUS, CB5XXX, CDC Docket Import, CDC Docket Import CDC Prosecuting, CDXXXX, Contaminant, Contaminants, Contaminated, contamination, CXXXXX, Detection, detection system, Direct, DRUGS, Kits, Listed LPM Surabian as of 4/15/2015, NIOSH, NIOSH-DART, Occupational health, OSHA, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Reading, SAFE, SAFETY, Surface, TOXIC, Toxicity, TOXIGENIC, TOXINS, VCXXXX, VPXXXX, WCXXXX, WFXXXX, WGXXXX, WIXXXX, WMXXXX, WORKER, WORKER safety, XHXXXX, XIXXXX, YBXXXX, YEXXXX False True True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114171896 Smith JP http://www.ncbi.nlm.nih.gov/pubmed/25293722 <a href="http://www.ncbi.nlm.nih.gov/pubmed/25293722">Smith JP</a> 114172342 Smith JP http://www.ncbi.nlm.nih.gov/pubmed/25379615 <a href="http://www.ncbi.nlm.nih.gov/pubmed/25379615">Smith JP</a> 114172343 Smith JP http://www.ncbi.nlm.nih.gov/pubmed/25956418 <a href="http://www.ncbi.nlm.nih.gov/pubmed/25956418">Smith JP</a> 114109302 Sammons, Deborah CDC Sammons, Deborah (CDC) 0 114109304 Robertson, Shirley CDC Robertson, Shirley (CDC) 0 114109303 Smith, Jerome CDC - NIOSH CDC Smith, Jerome (CDC) 1 114109303 Smith, Jerome CDC - NIOSH CDC Smith, Jerome (CDC) 1 114109302 Sammons, Deborah CDC Sammons, Deborah (CDC) 0 114109304 Robertson, Shirley CDC Robertson, Shirley (CDC) 0 114102303 Direct Reading Detection Kits For Surface Contamination By Anti-Neoplastic Drugs E-162-2013-0 Filing authorized Centers for Disease Control and Prevention (CDC) 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-3151] Direct Reading Detection Kits for Surface Contamination by Anti-Neoplastic (Anti-Cancer) Drugs&body=Please send me information about technology [TAB-3151] Direct Reading Detection Kits for Surface Contamination by Anti-Neoplastic (Anti-Cancer) Drugs. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-3151] Direct Reading Detection Kits for Surface Contamination by Anti-Neoplastic (Anti-Cancer) Drugs&body=Please send me information about technology [TAB-3151] Direct Reading Detection Kits for Surface Contamination by Anti-Neoplastic (Anti-Cancer) Drugs.">yogikala.prabhu@nih.gov</a><br> 114168338 E-162-2013-0 E-162-2013-0-US-01 Direct Reading Detection Kits For Surface Contamination By Anti-Neoplastic Drugs PRV US 61/672,059 Abandoned US <br />Provisional (PRV) 61/672,059<br />Filed on 2012-07-16<br />Status: Abandoned 114168339 E-162-2013-0 E-162-2013-0-PCT-02 Direct Reading Detection Kits For Surface Contamination By Anti-Neoplastic Drugs PCT Patent Cooperation Treaty PCT/US2013/050688 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2013/050688<br />Filed on 2013-07-16<br />Status: Expired 114168340 E-162-2013-0 E-162-2013-0-US-03 Direct Reading Detection Kits For Surface Contamination By Anti-Neoplastic Drugs ORD US 10,782,308 13/943,430 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10782308 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10782308">10,782,308</a><br />Filed on 2013-07-16<br />Status: Issued 114127316 AE3XXX 114127317 CDXXXX 114127318 CXXXXX 114127319 AE1BXX 114127320 AE2XXX 114127321 CB5XXX 114127322 VCXXXX 114127323 VPXXXX 114127324 WCXXXX 114127325 WFXXXX 114127326 WGXXXX 114127327 WIXXXX 114127328 WMXXXX 114127329 XIXXXX 114127330 XHXXXX 114127331 YEXXXX 114127332 YBXXXX 114149251 Direct 114149252 Surface 114149253 Detection 114149254 Reading 114149255 Kits 114149256 contamination 114149257 Anti-neoplastic 114149258 DRUGS 114149259 CDC Docket Import 114149260 CDC Docket Import CDC Prosecuting 114149261 NIOSH-DART 114149262 CANCER 114149263 CANCER CHEMOTHERAPY 114149264 CANCEROUS 114149265 NIOSH 114149266 Contaminants 114149267 Contaminated 114149268 Contaminant 114149269 detection system 114149270 OSHA 114149271 TOXIC 114149272 Toxicity 114149273 TOXINS 114149274 TOXIGENIC 114149275 SAFETY 114149276 SAFE 114149277 Occupational health 114149278 WORKER 114149279 WORKER safety 114149280 Listed LPM Surabian as of 4/15/2015 114149281 Pre LPM working set 20150418 114149282 Post LPM Assignment Set 20150420 TAB-3250 114097184 Near Real-time, Low-cost, Hand-held Sensors for Measuring Elemental Concentration of Airborne Particles for Indoor or Outdoor Air Quality Monitoring CDC Cardiology, Collaboration, Consumer Products, Dental, Diagnostics, Endocrinology, Infectious Disease, Licensing, Occupational Safety and Health, Oncology, Ophthalmology, Research Materials, Therapeutics, Vaccines Cardiology Collaboration Consumer Products Dental Diagnostics Endocrinology Infectious Disease Licensing Occupational Safety and Health Oncology Ophthalmology Research Materials Therapeutics Vaccines Pramod Kulkarni, Lina Zheng Airborne particles can have great impact on air quality, weather, and human health. In particular, long-term inhalation of toxic particulate matter in workplaces could pose a significant health risk. NIOSH scientists have developed a new, low-cost approach based on application of atmospheric radio frequency glow discharge (rf-GD) optical emission spectroscopy for near real-time measurement of elemental concentration in aerosols. The method involves collection of aerosol particles on an electrode tip in a coaxial microelectrode system, followed by excitation of the particles using rf-GD. NIOSH scientists identified far less expensive excitation sources for the rf-GD than traditional spark and laser-based excitation sources. Additionally, these excitation sources are compact and can be miniaturized for development of sensors for personal air sampling. The scientists developed a laboratory instrument, calibrated it for various elements including carbon, cadmium, manganese, and sodium, and established analytical detection limits for these elements. They demonstrated that these limits are well below most occupational exposure limits, allowing sensitive near real-time detection. This technology provides an excellent resource for air quality monitoring and the development of low-cost, hand-held sensors for aerosol measurement. <ul> <li>Currently, there are no real-time hand-held instruments (commercial or otherwise) for measuring elemental concentration of airborne particles (metals and nonmetals) in environmental and occupational settings</li> <li>Enables elemental analysis of aerosols in near real-time</li> <li>Uses low-cost and miniature-sized (approximately 3 x 1 x .05 inch) excitation sources</li> </ul> <ul> <li>Air pollution studies and particulate matter monitoring</li> <li>Environmental and occupational personal exposure monitoring</li> <li> Evaluation of engineering controls</li> </ul> The CDC Technology Transfer Office (TTO) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize: Near Real-time, Low-cost, Hand-held Sensors for Measuring Elemental Concentration of Airborne Particles for Indoor or Outdoor Air Quality Monitoring. For collaboration opportunities, please contact CDC TTO at <a href="mailto: tto@cdc.gov">tto@cdc.gov</a>. 2022-03-27 2026-05-14 2026-05-14 2018-02-13 AEROSOLS, analysis, Atmospheric, DART, Discharge, Elemental, Emission, Glow, NIOSH-DART, SPECTROSCOPY, VBXXXX, VPXXXX, WAXXXX, WCXXXX, WEXXXX, WFXXXX, WGXXXX, XGXXXX, XIXXXX, YAXXXX, YFXXXX False True True 52406768 Discovery 52406768 NIHTT 37470483 Website Abstract E-205-2013-0 E-163-2013-0 114172457 Zheng L, et al. https://www.ncbi.nlm.nih.gov/pubmed/28513144 <a href="https://www.ncbi.nlm.nih.gov/pubmed/28513144">Zheng L, et al.</a> 114109633 Zheng, Lina CDC - NIOSH CDC Zheng, Lina (CDC) 0 114109632 Kulkarni, Pramod CDC - NIOSH CDC Kulkarni, Pramod (CDC) 1 114109632 Kulkarni, Pramod CDC - NIOSH CDC Kulkarni, Pramod (CDC) 1 114109633 Zheng, Lina CDC - NIOSH CDC Zheng, Lina (CDC) 0 114102410 Elemental Analysis Of Aerosols Using Atmospheric Glow Discharge Emission Spectroscopy E-291-2016-0 Closed Centers for Disease Control and Prevention (CDC) 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-3250] Near Real-time, Low-cost, Hand-held Sensors for Measuring Elemental Concentration of Airborne Particles for Indoor or Outdoor Air Quality Monitoring&body=Please send me information about technology [TAB-3250] Near Real-time, Low-cost, Hand-held Sensors for Measuring Elemental Concentration of Airborne Particles for Indoor or Outdoor Air Quality Monitoring. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-3250] Near Real-time, Low-cost, Hand-held Sensors for Measuring Elemental Concentration of Airborne Particles for Indoor or Outdoor Air Quality Monitoring&body=Please send me information about technology [TAB-3250] Near Real-time, Low-cost, Hand-held Sensors for Measuring Elemental Concentration of Airborne Particles for Indoor or Outdoor Air Quality Monitoring.">yogikala.prabhu@nih.gov</a><br> 114168555 E-291-2016-0 E-291-2016-0-US-01 Elemental Analysis of Aerosols Using Atmospheric Glow Discharge Emission Spectroscopy PRV US 62/484,300 Abandoned US <br />Provisional (PRV) 62/484,300<br />Filed on 2017-04-11<br />Status: Abandoned 114168599 E-291-2016-0 E-291-2016-0-PCT-02 SYSTEMS AND METHODS FOR RAPID ELEMENTAL ANALYSIS OF AIRBORNE PARTICLES USING ATMOSPHERIC GLOW DISCHARGE OPTICAL EMISSION SPECTROSCOPY PCT Patent Cooperation Treaty PCT/US2018/027105 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2018/027105<br />Filed on 2018-04-11<br />Status: Expired 114168923 E-291-2016-0 E-291-2016-0-US-05 SYSTEMS AND METHODS FOR RAPID ELEMENTAL ANALYSIS OF AIRBORNE PARTICLES USING ATMOSPHERIC GLOW DISCHARGE OPTICAL EMISSION SPECTROSCOPY National Stage US 16/500,925 Abandoned US <br />National Stage 16/500,925<br />Filed on 2019-10-04<br />Status: Abandoned 114127769 YAXXXX 114127770 YFXXXX 114127771 VBXXXX 114127772 VPXXXX 114127773 WAXXXX 114127774 WCXXXX 114127775 WEXXXX 114127776 WFXXXX 114127777 WGXXXX 114127778 XGXXXX 114127779 XIXXXX 114150447 Elemental 114150448 analysis 114150449 AEROSOLS 114150450 Atmospheric 114150451 Glow 114150452 Discharge 114150453 Emission 114150454 SPECTROSCOPY 114150455 DART 114150456 NIOSH-DART TAB-3272 114097205 Respirator Protection Devices and Methods to Detect and Remove Toxic Gases from the Air - Cobinamide Encapsulated Silica-based Materials for Respirator Canisters CDC Cardiology, Collaboration, Consumer Products, Dental, Diagnostics, Endocrinology, Infectious Disease, Licensing, Materials Available, Occupational Safety and Health, Oncology, Ophthalmology, Therapeutics, Vaccines Cardiology Collaboration Consumer Products Dental Diagnostics Endocrinology Infectious Disease Licensing Materials Available Occupational Safety and Health Oncology Ophthalmology Therapeutics Vaccines Gerry Boss, Nicole Fry, Lee Greenawald, Michael Sailor A respirator protects the wearer from inhaling dangerous substances, such as chemicals and infectious particles. CDC developed devices and methods to detect and remove chemicals such as hydrogen cyanide, cyanogen, hydrogen sulfide, nitrite, and nitric oxide from the air for those wearing respirators. Cobinamide (a Vitamin B12 analog with a high affinity to cyanide) molecules are immobilized within a silica matrix that allows for the infiltration and containment of gaseous chemicals. Since the chemical(s) bind to the cobinamide, such material is embedded into respirator canisters to help facilitate the removal of toxic molecules from the air.<br /><br /> The chemical(s) binding to the cobinamide also result in a color change that can be analyzed qualitatively or quantitatively. The cobinamide-loaded silica matrix can be incorporated into a respirator canister (such as a canister designed to protect workers against chemical, biological, radiological and nuclear weapons (CBRN)) to act as an end-of-service-life indicator (ESLI) alerting when to change equipment. Different absorbance of the cobinamide/silica composite within the respirator canister can be monitored, and the device can be configured to trigger a visual and/or audible alarm once a particular concentration of the chemical(s) meets a certain threshold, indicating that the canister needs to be replaced. Current ESLI technology only depends on the user to monitor a color change via a colorimetric indicator, viewed through a clear box on the outside of the gas mask canister. This is an issue for color-blind persons, those in low-light settings, and users if they are preoccupied and unable to continuously monitor the indicator. The CDC/NIOSH technology can be configured for both a visual and/or audible alarm. <ul> <li>Technology senses and removes particles</li> <li>Ability to monitor several ligands (molecules that bind with others) at once<li> <li>An "active" vs. "passive" ESLI that will alert user to thresholds of CBRN agents important for replacing respirator canisters</li> <li>To the inventor’s knowledge, there is no known commercially-available ESLI for hydrogen cyanide gas, a significant risk with fires and chemical explosions</li> <li> Not based on electrochemical technology</li> <li>Apparatus is added to gas canisters</li> <li>Light weight and inexpensive</li> <li> Uses a light source and mini spectrometer</li> <li>Uses color and/or audible detection</li> </ul> <ul> <li>Detection and removal of chemical, biological, radiological, and nuclear (CBRN) agents for military and emergency response workers such as police, EMTs and fire fighters</li> <li> Detection of nitric oxide for miners exposed from the use of explosives for blasting and diesel engine emissions</li> <li>Occupational safety for manufacturing, agriculture, chemicals/pesticides, construction, roofing, painting, etc.</li> </ul> The CDC Technology Transfer Office (TTO) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize: Respirator Protection Devices and Methods to Detect and Remove Toxic Gases from the Air - Cobinamide Encapsulated Silica- based Materials for Respirator Canisters. For collaboration opportunities, please contact CDC TTO at <a href="mailto:tto@cdc.gov">tto@cdc.gov</a>or 1-404-639-1330. 2022-03-27 2026-05-14 2026-05-14 2018-06-06 Based, Canisters, Cobinamide, ENCAPSULATED, GAS, Listed LPM Surabian as of 4/15/2015, MATERIALS, NIOSH-NPPTL, NPPTL, optical, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, REMOVAL, Respirator, Sensing, SILICA, TOXIC, VBXXXX, VPXXXX, WCXXXX, WEXXXX, WFXXXX, WGXXXX, WMXXXX, YBXXXX, YFXXXX False True True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114172490 Greenawald LA, et al. https://www.ncbi.nlm.nih.gov/pubmed/26213448. <a href="https://www.ncbi.nlm.nih.gov/pubmed/26213448.">Greenawald LA, et al.</a> 114109705 Boss, Gerry University of California, San Diego Boss, Gerry 0 114109706 Fry, Nicole University of California, San Diego Fry, Nicole 0 114109707 Sailor, Michael University of California, San Diego Sailor, Michael 0 114109704 Greenawald, Lee CDC - NIOSH CDC Greenawald, Lee (CDC) 1 114109704 Greenawald, Lee CDC - NIOSH CDC Greenawald, Lee (CDC) 1 114109705 Boss, Gerry University of California, San Diego Boss, Gerry 0 114109706 Fry, Nicole University of California, San Diego Fry, Nicole 0 114109707 Sailor, Michael University of California, San Diego Sailor, Michael 0 114102434 Cobinamide Encapsulated Silica Based Materials For Optical Sensing And Toxic Gas Removal In Respirator Canisters E-144-2015-0 Closed Centers for Disease Control and Prevention (CDC), University of California, San Diego 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-3272] Respirator Protection Devices and Methods to Detect and Remove Toxic Gases from the Air - Cobinamide Encapsulated Silica-based Materials for Respirator Canisters&body=Please send me information about technology [TAB-3272] Respirator Protection Devices and Methods to Detect and Remove Toxic Gases from the Air - Cobinamide Encapsulated Silica-based Materials for Respirator Canisters. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-3272] Respirator Protection Devices and Methods to Detect and Remove Toxic Gases from the Air - Cobinamide Encapsulated Silica-based Materials for Respirator Canisters&body=Please send me information about technology [TAB-3272] Respirator Protection Devices and Methods to Detect and Remove Toxic Gases from the Air - Cobinamide Encapsulated Silica-based Materials for Respirator Canisters.">yogikala.prabhu@nih.gov</a><br> 114168626 E-144-2015-0 E-144-2015-0-US-01 Cobinamide Encapsulated Silica Based Materials For Optical Sensing And Toxic Gas Removal In Respirator Canisters PRV US 62/016,565 Abandoned US <br />Provisional (PRV) 62/016,565<br />Filed on 2014-06-24<br />Status: Abandoned 114168627 E-144-2015-0 E-144-2015-0-US-02 Cobinamide-Based Materials For Optical Sensing And Gas Removal ORD US 14/748,163 Abandoned US <br />Ordinary Patent (ORD) 14/748,163<br />Filed on 2015-06-23<br />Status: Abandoned 114127898 YBXXXX 114127899 YFXXXX 114127900 VBXXXX 114127901 VPXXXX 114127902 WCXXXX 114127903 WEXXXX 114127904 WFXXXX 114127905 WGXXXX 114127906 WMXXXX 114150727 NIOSH-NPPTL 114150728 Cobinamide 114150729 ENCAPSULATED 114150730 SILICA 114150731 Based 114150732 MATERIALS 114150733 optical 114150734 Sensing 114150735 TOXIC 114150736 GAS 114150737 REMOVAL 114150738 Respirator 114150739 Canisters 114150740 NPPTL 114150741 Listed LPM Surabian as of 4/15/2015 114150742 Pre LPM working set 20150418 114150743 Post LPM Assignment Set 20150420 TAB-3304 114097228 Adjustable Barricade Safety Rail System and Roof Bracket Assembly to Prevent Worker Falls CDC Cardiology, Collaboration, Consumer Products, Dental, Endocrinology, Infectious Disease, Licensing, Occupational Safety and Health, Oncology, Ophthalmology Cardiology Collaboration Consumer Products Dental Endocrinology Infectious Disease Licensing Occupational Safety and Health Oncology Ophthalmology Thomas Bobick, Douglas Cantis, Herbert Edgell, Eugene McKenzie Falls are the leading cause of death in construction. In 2016, there were 370 fatal falls out of 991 construction fatalities (Bureau of Labor Statistics, Census of Fatal Occupational Injuries data). These deaths are preventable. According to the Occupational Safety and Health Administration, employers must set up the workplace to prevent employees from falling from overhead platforms, elevated work stations, or into holes in the floor and walls. For a roofing job, employers should consider all potential fall hazards, such as holes, skylights, and leading edges, then plan and select fall protection suitable for the proposed work. <br /><br /> CDC's National Institute for Occupational Safety and Health (NIOSH) inventors developed a protective barricade system to prevent workers from accidentally falling through holes in roofs/floors, from the edges of stairwells, balconies, or pitched roofs. The barricade system comprises several barricade brackets that are spaced apart and can be temporarily fastened to the underlying surface. Using the adjustable safety rail and roof bracket assembly creates a protective guardrail system that can be easily installed along roof edges and around openings or skylights on roofs with slopes ranging from 18 degrees (4:12) to 63 degrees (24:12). The durable construction of the assembly provides a secure walking/working surface for workers while working on steep roof surfaces. This design also includes an adjustable plank adapter, which permits the use of wider planks, resulting in an increase of up to 20% in the foot-bearing surface area, thus providing more worker stability. <ul> <li>A portable, easily-installed guardrail system to protect workers from falling into holes of roofs and floors during all construction</li> <li> Easily deployable around skylight fixtures to guard workers from inadvertently stepping onto or sitting down onto the skylight lens and falling through</li> <li>Roof bracket can provide worker support when moving up-slope while installing roofing shingles</li> <li>Safety rail and roof bracket assembly can be used together as edge guarding for both low- and steep-slope roofs to prevent workers from falling or sliding off</li> </ul> <ul> <li>May be used widely throughout the residential and commercial construction building industry</li> <li>May be used to safeguard roof workers</li> <li>May be useful to do-it-yourself (DIY) home improvers</li> </ul> The CDC National Institute for Occupational Safety and Health (NIOSH) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize: Adjustable Barricade Safety Rail System and Roof Bracket Assembly to Prevent Worker Falls. For collaboration opportunities, please contact CDC TTO at <a href="mailto:tto@cdc.gov">tto@cdc.gov</a> or 1-404-639-1330. 2022-03-27 2026-05-14 2026-05-14 2018-07-05 BARRICADE, BRACKET, CDC Docket Import, CDC Docket Import CDC Prosecuting, Constructing, Construction, Listed LPM Surabian as of 4/15/2015, NIOSH, NIOSH-DSR, Occupational health, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, SAFETY, System, THEREIN, VPXXXX, WGXXXX, WMXXXX, WORKER, WORKER safety, XIXXXX, YFXXXX False True True 52406769 Prototype 52406769 NIHTT 37470483 Website Abstract E-141-2013-0 114172509 Bobick-TG, et al. https://www2a.cdc.gov/nioshtic-2/BuildQyr.asp?s1=20030149&f1=%2A&Startyear=&Adv=0&terms=1&EndYear=&Limit=10000&sort=&D1=10&PageNo=1&RecNo=1&View=f& <a href="https://www2a.cdc.gov/nioshtic-2/BuildQyr.asp?s1=20030149&f1=%2A&Startyear=&Adv=0&terms=1&EndYear=&Limit=10000&sort=&D1=10&PageNo=1&RecNo=1&View=f&">Bobick-TG, et al.</a> 114172510 Bobick T, et al. https://www2a.cdc.gov/nioshtic-2/BuildQyr.asp?s1=20033870&f1=%2A&Startyear=&Adv=0&terms=1&D1=10&EndYear=&Limit=10000&sort=&PageNo=1&RecNo=1&View=f& <a href="https://www2a.cdc.gov/nioshtic-2/BuildQyr.asp?s1=20033870&f1=%2A&Startyear=&Adv=0&terms=1&D1=10&EndYear=&Limit=10000&sort=&PageNo=1&RecNo=1&View=f&">Bobick T, et al.</a> 114172511 Bobick-TG, et al. https://www2a.cdc.gov/nioshtic-2/BuildQyr.asp?s1=20039599&f1=%2A&Startyear=&Adv=0&terms=1&D1=10&EndYear=&Limit=10000&sort=&PageNo=1&RecNo=1&View=f& <a href="https://www2a.cdc.gov/nioshtic-2/BuildQyr.asp?s1=20039599&f1=%2A&Startyear=&Adv=0&terms=1&D1=10&EndYear=&Limit=10000&sort=&PageNo=1&RecNo=1&View=f&">Bobick-TG, et al.</a> 114172512 Bobick-TG, el al. https://www2a.cdc.gov/nioshtic-2/BuildQyr.asp?s1=20046510&f1=%2A&Startyear=&Adv=0&terms=1&D1=10&EndYear=&Limit=10000&sort=&PageNo=1&RecNo=1&View=f& <a href="https://www2a.cdc.gov/nioshtic-2/BuildQyr.asp?s1=20046510&f1=%2A&Startyear=&Adv=0&terms=1&D1=10&EndYear=&Limit=10000&sort=&PageNo=1&RecNo=1&View=f&">Bobick-TG, el al.</a> 114109785 McKenzie, Eugene CDC - NIOSH CDC McKenzie, Eugene (CDC) 0 114109786 Bobick, Thomas CDC - NIOSH CDC Bobick, Thomas (CDC) 0 114109787 Edgell, Herbert CDC - NIOSH CDC Edgell, Herbert (CDC) 0 114109784 Cantis, Douglas CDC - NIOSH CDC Cantis, Douglas (CDC) 1 114109784 Cantis, Douglas CDC - NIOSH CDC Cantis, Douglas (CDC) 1 114109785 McKenzie, Eugene CDC - NIOSH CDC McKenzie, Eugene (CDC) 0 114109786 Bobick, Thomas CDC - NIOSH CDC Bobick, Thomas (CDC) 0 114109787 Edgell, Herbert CDC - NIOSH CDC Edgell, Herbert (CDC) 0 114102464 BARRICADE SYSTEM AND BARRICADE BRACKET FOR USE THEREIN E-450-2013-0 Filing authorized Centers for Disease Control and Prevention (CDC) 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-3304] Adjustable Barricade Safety Rail System and Roof Bracket Assembly to Prevent Worker Falls&body=Please send me information about technology [TAB-3304] Adjustable Barricade Safety Rail System and Roof Bracket Assembly to Prevent Worker Falls. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-3304] Adjustable Barricade Safety Rail System and Roof Bracket Assembly to Prevent Worker Falls&body=Please send me information about technology [TAB-3304] Adjustable Barricade Safety Rail System and Roof Bracket Assembly to Prevent Worker Falls.">yogikala.prabhu@nih.gov</a><br> 114168679 E-450-2013-0 E-450-2013-0-US-01 BARRICADE SYSTEM AND BARRICADE BRACKET FOR USE THEREIN ORD US 7,509,702 11/257,472 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7509702 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7509702">7,509,702</a><br />Filed on 2005-10-24<br />Status: Issued 114128019 YFXXXX 114128020 VPXXXX 114128021 WGXXXX 114128022 WMXXXX 114128023 XIXXXX 114151125 BARRICADE 114151126 System 114151127 BRACKET 114151128 THEREIN 114151129 CDC Docket Import 114151130 CDC Docket Import CDC Prosecuting 114151131 NIOSH-DSR 114151132 NIOSH 114151133 SAFETY 114151134 WORKER 114151135 WORKER safety 114151136 Occupational health 114151137 Construction 114151138 Constructing 114151139 Listed LPM Surabian as of 4/15/2015 114151140 Pre LPM working set 20150418 114151141 Post LPM Assignment Set 20150420 TAB-2825 114097004 Hearing Safety Devices: System for Monitoring Exposure to Impulse Noise CDC Cardiology, Computational models/software, Consumer Products, Dental, Endocrinology, Infectious Disease, Licensing, Medical Devices, Non-Medical Devices, Occupational Safety and Health, Oncology, Ophthalmology, Research Materials, Software / Apps Cardiology Computational models/software Consumer Products Dental Endocrinology Infectious Disease Licensing Medical Devices Non-Medical Devices Occupational Safety and Health Oncology Ophthalmology Research Materials Software / Apps Chucri Kardous This CDC-developed technology entails a system for monitoring and assessing the risk of auditory damage from exposure to impulse noise, such as noise created by construction machinery and firearms. Noise dosimeters have been used extensively over the past two decades to document personal exposure to noise and assure workplaces comply with permissible noise exposure levels. However, due to older methods of calculating "noise dose," current noise dosimeters often inaccurately determine the risk of an impulse event. Further, current state-of-the-art noise dosimeters have a sound pressure level (SPL) dynamic measurement range of about 80-146 dB, which is adequate for some impact noise environments, but cannot accurately measure impulse noise levels above 146 dB. When a dosimeter is used to measure a noise level greater than its dynamic range, the dosimeter “clips” the noise level at the upper end of its measurement range, resulting in errant assessments of noise exposure.<br /><br /> The system described by this technology can be used to measure exposure to impulse noise and replace older, "clipped-range" dosimeters. Additionally, this new technology will improve the collection of empirical data for establishing association of noise levels with hearing loss. <ul> <li>This technology will accurately quantify noise dose and measure impulse noise and avoid "clipping" artifacts associated with currently available noise dosimeters.</li> </ul> <ul> <li>Assessment of potentially hazardous levels of impulse noise</li> <li>Use by law enforcement officers, DOD infantry, armor and artillery personnel, and workers in the construction trades</li> <li>Improving collection of empirical data to gauge risk and establish links to possible causes of hearing loss</li> </ul> 2022-03-27 2026-05-14 2026-05-14 2014-05-27 AA5XXX, AAXXXX, AC1XXX, AC2XXX, ADXXXX, AE1BXX, AE1XXX, AE2BXX, AE2XXX, AE3XXX, AEXXXX, AXXXXX, CDC Docket Import, CDC Docket Import CDC Prosecuting, Exposure, firearm, firearm safety, IMPULSE, MONITORING, NIOSH, NIOSH-DART, NOISE, Occupational health, SAFETY, Sampling, System, VPXXXX, WCXXXX, WFXXXX, WGXXXX, WIXXXX, WMXXXX, XDXXXX, XIXXXX, XJXXXX, YEXXXX False True In situ data available (on-site) True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114172150 Kardous CA, et al. http://www.ncbi.nlm.nih.gov/pubmed/12851012 <a href="http://www.ncbi.nlm.nih.gov/pubmed/12851012">Kardous CA, et al.</a> 114172151 Kardous CA, et al. http://www.ncbi.nlm.nih.gov/pubmed/15238316 <a href="http://www.ncbi.nlm.nih.gov/pubmed/15238316">Kardous CA, et al.</a> 114172152 Kardous, CA, "Development and validation testing of an impulse noise meter," U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, In-Depth Survey Report EPHB-349-11a, September 2013. http://www.cdc.gov/niosh/surveyreports/pdfs/349-11a.pdf <a href="http://www.cdc.gov/niosh/surveyreports/pdfs/349-11a.pdf">Kardous, CA, "Development and validation testing of an impulse noise meter," U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, In-Depth Survey Report EPHB-349-11a, September 2013.</a> 114172153 Kardous CA, et al. Noise dosimeter for monitoring exposure to impulse noise. Appl Acoust. 2005 Aug;66(8):974-85. http://dx.doi.org/10.1016/j.apacoust.2004.11.007 <a href="http://dx.doi.org/10.1016/j.apacoust.2004.11.007">Kardous CA, et al. Noise dosimeter for monitoring exposure to impulse noise. Appl Acoust. 2005 Aug;66(8):974-85.</a> 114108736 Kardous, Chucri CDC - NIOSH CDC Kardous, Chucri (CDC) 1 114108736 Kardous, Chucri CDC - NIOSH CDC Kardous, Chucri (CDC) 1 114102162 System For Monitoring Exposure To Impulse Noise E-225-2013-0 Closed Centers for Disease Control and Prevention (CDC) 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2825] Hearing Safety Devices: System for Monitoring Exposure to Impulse Noise&body=Please send me information about technology [TAB-2825] Hearing Safety Devices: System for Monitoring Exposure to Impulse Noise. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2825] Hearing Safety Devices: System for Monitoring Exposure to Impulse Noise&body=Please send me information about technology [TAB-2825] Hearing Safety Devices: System for Monitoring Exposure to Impulse Noise.">yogikala.prabhu@nih.gov</a><br> 114167812 E-225-2013-0 E-225-2013-0-US-01 System For Monitoring Exposure To Impulse Noise PRV US 60/487,449 Abandoned US <br />Provisional (PRV) 60/487,449<br />Filed on 2003-07-14<br />Status: Abandoned 114167813 E-225-2013-0 E-225-2013-0-PCT-02 System For Monitoring Exposure To Impulse Noise PCT Patent Cooperation Treaty PCT/US2004/022499 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2004/022499<br />Filed on 2004-07-13<br />Status: Expired 114167814 E-225-2013-0 E-225-2013-0-US-03 System For Monitoring Exposure To Impulse Noise National Stage US 7,401,519 10/564,860 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7401519 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7401519">7,401,519</a><br />Filed on 2006-01-11<br />Status: Expired 114126187 AXXXXX 114126188 AAXXXX 114126189 AA5XXX 114126190 AC2XXX 114126191 AC1XXX 114126192 ADXXXX 114126193 AEXXXX 114126194 AE1XXX 114126195 AE2XXX 114126196 AE3XXX 114126197 AE2BXX 114126198 AE1BXX 114126199 VPXXXX 114126200 WCXXXX 114126201 WFXXXX 114126202 WGXXXX 114126203 WIXXXX 114126204 WMXXXX 114126205 XDXXXX 114126206 XIXXXX 114126207 XJXXXX 114126208 YEXXXX 114147425 System 114147426 MONITORING 114147427 Exposure 114147428 IMPULSE 114147429 NOISE 114147430 CDC Docket Import 114147431 CDC Docket Import CDC Prosecuting 114147432 NIOSH-DART 114147433 NIOSH 114147434 Occupational health 114147435 SAFETY 114147436 Sampling 114147437 firearm 114147438 firearm safety TAB-2826 114097005 Occupational Safety: Portable Exposure Assessment System for Prevention of Musculoskeletal Injury CDC Cardiology, Computational models/software, Consumer Products, Dental, Diagnostics, Endocrinology, Infectious Disease, Licensing, Medical Devices, Neurology, Non-Medical Devices, Occupational Safety and Health, Oncology, Ophthalmology, Research Equipment, Research Materials, Software / Apps Cardiology Computational models/software Consumer Products Dental Diagnostics Endocrinology Infectious Disease Licensing Medical Devices Neurology Non-Medical Devices Occupational Safety and Health Oncology Ophthalmology Research Equipment Research Materials Software / Apps Christopher Pan, Bryan Wimer, Shengke Zeng CDC researchers have developed the Portable Exposure Assessment System (PEAS), a field-based, remotely deployed tool to monitor and provide early warning of working conditions that have a high likelihood of musculoskeletal injury. PEAS is a noninvasive, real-time, instrument-based system. Sensor technology simultaneously measures and collects data regarding the body loads and awkward postures imposed by package handling as well as driving-related, low-frequency vibrations. Wireless technology establishes communication links between the sensors and a data logger and between the data logger and a smart phone with positioning and text messaging capabilities. The data logger records the body weight, posture, and vibration data over time and transfers the data to a databank for archiving and further data analysis. During data recording, the data logger detects the data that either exceed the lifting index limit defined by the NIOSH Lifting Equation or the human whole-body vibration exposure limit defined by the ISO-2631-1 Human Exposure to Whole-Body Vibration standard. The data logger wirelessly transmits the data segment, which contains the marked out-of-limit data, to the smart phone in real-time. The smart phone then automatically dials a predefined number and sends an alert text message and alarm detailing the exposure/safety data, the GPS location of the occurrence, the date/time stamps, and a corresponding safety message. Additionally, the smart phone stores the sent text message for archiving and further data analysis. <ul> <li>No comparable technology currently exists in the marketplace</li> <li>Real-time notification, via alarm and smart-phone transmission, of injury-risk conditions that are likely to lead to musculoskeletal injury, as well as exposure to slip-, trip-, and fall-related traumatic injuries; both the worker and any monitoring station can be notified by the alarm</li> <li>Portable; approximately the size of a mobile phone and uses comparable technology</li> </ul> <ul> <li>Safety officers within the environmental, safety, and health departments of public and private entities</li> <li>Industrial sectors such as construction, package delivery, manufacturing, healthcare, and trucking</li> <li>Workers' well-being concern groups</li> <li>Insurers and workers' compensation operations</li> <li>Monitoring tasks associated with high rates of personal injury and workers' compensation payments linked to repeated or continual heavy lifting</li> </ul> 2022-03-27 2026-05-14 2026-05-14 2014-05-27 AA1XXX, AA4XXX, AAXXXX, AE1BXX, AE1CXX, AE1XXX, AE2AXX, AE2BXX, AE2XXX, AE3XXX, AE4XXX, AEXXXX, AFXXXX, AG3XXX, AGXXXX, apparatus, ASSESSING, AXXXXX, CDC Docket Import, CDC Docket Import CDC Prosecuting, Conditions, Injured, Injuries, INJURY, LEAD, Likely, lumbar, Method, MOBILE, MOBILES, MUSCLE, Muscles, MUSCULAR, musculoskeletal, NIOSH, NIOSH-DSR, Occupational health, PERSONAL, Personalized, Portable, SAFE, Safely, SAFETY, System, VMXXXX, VPXXXX, WBXXXX, WCXXXX, WFXXXX, WGXXXX, WIXXXX, WMXXXX, WORKER, WORKER safety, WORKERS, XDXXXX, XHXXXX, XIXXXX, XJXXXX, YAXXXX, YEXXXX, YFXXXX False True <ul> <li>Early-stage</li> <li>In situ data available (on-site)</li> <li>Prototype</li> </ul> True 52406768 Discovery 52406768 NIHTT 37470483 Website Abstract 114108738 Wimer, Bryan CDC - NIOSH CDC Wimer, Bryan (CDC) 0 114108739 Zeng, Shengke CDC - DIR CDC Zeng, Shengke (CDC) 0 114108737 Pan, Christopher CDC - NIOSH CDC Pan, Christopher (CDC) 1 114108737 Pan, Christopher CDC - NIOSH CDC Pan, Christopher (CDC) 1 114108738 Wimer, Bryan CDC - NIOSH CDC Wimer, Bryan (CDC) 0 114108739 Zeng, Shengke CDC - DIR CDC Zeng, Shengke (CDC) 0 114102163 Portable System And Method For Assessing Conditions Likely To Lead To Musculoskeletal Injuries E-168-2013-0 Filing authorized Centers for Disease Control and Prevention (CDC) 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2826] Occupational Safety: Portable Exposure Assessment System for Prevention of Musculoskeletal Injury&body=Please send me information about technology [TAB-2826] Occupational Safety: Portable Exposure Assessment System for Prevention of Musculoskeletal Injury. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2826] Occupational Safety: Portable Exposure Assessment System for Prevention of Musculoskeletal Injury&body=Please send me information about technology [TAB-2826] Occupational Safety: Portable Exposure Assessment System for Prevention of Musculoskeletal Injury.">yogikala.prabhu@nih.gov</a><br> 114167816 E-168-2013-0 E-168-2013-0-US-01 Portable System And Method For Assessing Conditions Likely To Lead To Musculoskeletal Injuries PRV US 61/599,525 Abandoned US <br />Provisional (PRV) 61/599,525<br />Filed on 2012-02-16<br />Status: Abandoned 114167817 E-168-2013-0 E-168-2013-0-US-02 SYSTEM AND METHOD TO PREDICT AND AVOID MUSCULOSKELETAL INJURIES ORD US 8,942,662 13/768,290 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8942662 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8942662">8,942,662</a><br />Filed on 2013-02-15<br />Status: Issued 114126209 AXXXXX 114126210 AAXXXX 114126211 AA1XXX 114126212 AA4XXX 114126213 AEXXXX 114126214 AE1XXX 114126215 AE1BXX 114126216 AE1CXX 114126217 AE2XXX 114126218 AE2AXX 114126219 AE2BXX 114126220 AE3XXX 114126221 AE4XXX 114126222 AFXXXX 114126223 AGXXXX 114126224 AG3XXX 114126225 VMXXXX 114126226 VPXXXX 114126227 WBXXXX 114126228 WCXXXX 114126229 WFXXXX 114126230 WGXXXX 114126231 WMXXXX 114126232 XDXXXX 114126233 XIXXXX 114126234 XHXXXX 114126235 YAXXXX 114126236 WIXXXX 114126237 XJXXXX 114126238 YEXXXX 114126239 YFXXXX 114147439 Portable 114147440 System 114147441 Method 114147442 ASSESSING 114147443 Conditions 114147444 Likely 114147445 LEAD 114147446 musculoskeletal 114147447 Injuries 114147448 CDC Docket Import 114147449 CDC Docket Import CDC Prosecuting 114147450 NIOSH-DSR 114147451 NIOSH 114147452 WORKER 114147453 WORKER safety 114147454 WORKERS 114147455 Occupational health 114147456 SAFE 114147457 SAFETY 114147458 Safely 114147459 MUSCLE 114147460 MUSCULAR 114147461 Muscles 114147462 Injured 114147463 INJURY 114147464 PERSONAL 114147465 Personalized 114147466 MOBILE 114147467 MOBILES 114147468 apparatus 114147469 lumbar TAB-2827 114097006 Occupational Health: Wearable Kneel-Sit Support Device for Manual Labor and Heavy Industry Applications CDC Cardiology, Consumer Products, Dental, Endocrinology, Geriatrics, Immunology, Infectious Disease, Licensing, Medical Devices, Neurology, Non-Medical Devices, Occupational Safety and Health, Oncology, Ophthalmology Cardiology Consumer Products Dental Endocrinology Geriatrics Immunology Infectious Disease Licensing Medical Devices Neurology Non-Medical Devices Occupational Safety and Health Oncology Ophthalmology Stephen Hudock, Ova Johnston, Steven Wurzelbacher This CDC-developed technology describes a novel ergonomic device that supports a portion of the worker's weight while kneeling, relieving the knee pressure and pain common to many manual labor occupations. Unfortunately, many of the devices that have been used in the past to relieve pressure on the knees are bulky, heavy, and of questionable durability.<br /><br /> This device relieves pressure from the knees while kneeling, is easily portable, is attachable to the body, and can be moved automatically by the user without the user having to pick up the device and manually move it to a new position. The device is nonflammable and durable, so that it can be used in heavy industry and on horizontally constrained and uneven surfaces, and is comfortable to use while kneeling, thereby improving worker productivity. <ul> <li>Comfortable; relieves pressure from the knees while kneeling, increasing on-the-job comfort and worker productivity</li> <li>Device is extremely portable</li> <li>Easily attaches to a user's lower leg; allows for unhindered movement and ambulation</li> <li>Device automatically moves with the user; no manual readjustments or manipulations are required</li> <li>Durable and nonflammable</li> <li>Ideal for heavy industry applications; can be used on horizontally constrained and uneven surfaces</li> </ul> <ul> <li>Knee pain, low-back pain alleviation and prevention</li> <li>Improved workplace ergonomics</li> <li>Osteoarthrosis concerns, geriatric medicine applications and for aging populations in the workforce</li> <li>Occupations such as shipbuilding, welding, mining, plumbing, carpet and floor installation, construction, repair services, and auto body repair in which people must spend a considerable amount of time kneeling or squatting</li> </ul> 2022-03-27 2026-05-14 2026-05-14 2014-05-29 AB1XXX, AB3GXX, AB3XXX, AE2BXX, AE2XXX, AE4XXX, AEXXXX, AFXXXX, ARTHRITIS, AXXXXX, CDC Docket Import, CDC Docket Import CDC Prosecuting, DEVICE, Knee, Kneel-sit, LABOR, MINING, NIOSH, NIOSH-DART, OSHA, OSTEOARTHRITIS, SAFETY, SUPPORT, VAXXXX, VMXXXX, VPXXXX, Wearable, WEXXXX, WGXXXX, WMXXXX, WORK, WORKER, WORKER safety, WORKERS, XDXXXX, XIXXXX, YEXXXX, YFXXXX False True <ul> <li>In situ data available (on-site)</li> <li>Prototype</li> </ul> True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114108741 Johnston, Ova CDC - DIR CDC Johnston, Ova (CDC) 0 114108742 Hudock, Stephen CDC - NIOSH CDC Hudock, Stephen (CDC) 0 114108740 Wurzelbacher, Steven CDC - NIOSH CDC Wurzelbacher, Steven (CDC) 1 114108740 Wurzelbacher, Steven CDC - NIOSH CDC Wurzelbacher, Steven (CDC) 1 114108741 Johnston, Ova CDC - DIR CDC Johnston, Ova (CDC) 0 114108742 Hudock, Stephen CDC - NIOSH CDC Hudock, Stephen (CDC) 0 114102164 Wearable Kneel-sit Support Device E-261-2013-0 Closed Centers for Disease Control and Prevention (CDC) 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2827] Occupational Health: Wearable Kneel-Sit Support Device for Manual Labor and Heavy Industry Applications&body=Please send me information about technology [TAB-2827] Occupational Health: Wearable Kneel-Sit Support Device for Manual Labor and Heavy Industry Applications. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2827] Occupational Health: Wearable Kneel-Sit Support Device for Manual Labor and Heavy Industry Applications&body=Please send me information about technology [TAB-2827] Occupational Health: Wearable Kneel-Sit Support Device for Manual Labor and Heavy Industry Applications.">yogikala.prabhu@nih.gov</a><br> 114167818 E-261-2013-0 E-261-2013-0-PCT-02 Wearable Kneel-sit Support Device PCT Patent Cooperation Treaty PCT/US2002/016790 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2002/016790<br />Filed on 2002-05-28<br />Status: Expired 114167819 E-261-2013-0 E-261-2013-0-US-01 Wearable Kneel-sit Support Device PRV US 60/300,315 Abandoned US <br />Provisional (PRV) 60/300,315<br />Filed on 2001-06-22<br />Status: Abandoned 114167820 E-261-2013-0 E-261-2013-0-US-03 Wearable Kneel-sit Support Device National Stage US 7,152,919 10/481,532 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7152919 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7152919">7,152,919</a><br />Filed on 2003-12-19<br />Status: Abandoned 114126240 AXXXXX 114126241 AB1XXX 114126242 AB3XXX 114126243 AB3GXX 114126244 AEXXXX 114126245 AE2XXX 114126246 AE2BXX 114126247 AE4XXX 114126248 AFXXXX 114126249 VAXXXX 114126250 VMXXXX 114126251 VPXXXX 114126252 WEXXXX 114126253 WGXXXX 114126254 WMXXXX 114126255 XIXXXX 114126256 XDXXXX 114126257 YFXXXX 114126258 YEXXXX 114147470 Wearable 114147471 Kneel-sit 114147472 SUPPORT 114147473 DEVICE 114147474 CDC Docket Import 114147475 CDC Docket Import CDC Prosecuting 114147476 NIOSH-DART 114147477 NIOSH 114147478 SAFETY 114147479 Knee 114147480 WORK 114147481 WORKER 114147482 WORKER safety 114147483 WORKERS 114147484 ARTHRITIS 114147485 OSTEOARTHRITIS 114147486 LABOR 114147487 OSHA 114147488 MINING TAB-2890 114097051 Mobile Instrumentation for the Detection and Sampling of Aerosol Particles CDC Diagnostics, Licensing, Medical Devices, Neurology, Non-Medical Devices, Occupational Safety and Health, Research Materials, Therapeutics, Vaccines Diagnostics Licensing Medical Devices Neurology Non-Medical Devices Occupational Safety and Health Research Materials Therapeutics Vaccines Gregory Deye, Pramod Kulkarni Hazardous airborne particles pose a risk for health and safety in a variety of environments and thus detection of these small particles is essential. Current particle magnification systems are bulky and require a lot of power for operation, making them unsuitable to easily detect and analyze small particles in mobile and personal settings.<br /><br /> CDC/NIOSH scientists have developed a space-saving miniature instrumentation and methods for the direct sampling and analysis of small particles (diameter < 300-400nm). The systems can effectively sample air at a rate of a few liters per minute and concentrate the particulate matter into microliter or milliliter liquid samples. The novel system uses proton exchange membranes to grow small particles for optical detection using standard methods. Further, these methods allow the system to separate condensation and aerosol flow to enhance user mobility. Moreover, the described methods use inexpensive materials and require low power for operation. <ul> <li>Cost-effective</li> <li>Offers overall reduction of measurement time</li> <li>Requires minimal power to operate</li> <li>Mobile, wearable</li> <li>Space-saving miniature systems as small as 1" x 1" x 3"</li> </ul> <ul> <li>Condensation particle detectors</li> <li>Particle size magnification systems</li> <li>Microfluidic devices for sampling, detection, and growth of hazardous particles</li> </ul> 2022-03-27 2026-05-14 2026-05-14 2014-11-14 AEROSOL, APPLICATIONS, EXCHANGE, Growth, MEMBRANES, NIOSH-DART, PARTICLE, PERSONAL, Proton, Sampling, SYSTEMS, VBXXXX, VEXXXX, WAXXXX, WCXXXX, WGXXXX, WIXXXX, XDXXXX, XIXXXX, YFXXXX False True Prototype True 52406769 Prototype 52406769 NIHTT 37470483 Website Abstract E-146-2013-0 114108911 Deye, Gregory CDC - NIOSH CDC Deye, Gregory (CDC) 0 114108912 Kulkarni, Pramod CDC - NIOSH CDC Kulkarni, Pramod (CDC) 1 114108912 Kulkarni, Pramod CDC - NIOSH CDC Kulkarni, Pramod (CDC) 1 114108911 Deye, Gregory CDC - NIOSH CDC Deye, Gregory (CDC) 0 114102221 Aerosol Particle Growth Systems For Personal Sampling Applications Using Proton Exchange Membranes E-026-2014-0 Filing authorized Centers for Disease Control and Prevention (CDC), Regents of the University of Minnesota 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2890] Mobile Instrumentation for the Detection and Sampling of Aerosol Particles&body=Please send me information about technology [TAB-2890] Mobile Instrumentation for the Detection and Sampling of Aerosol Particles. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2890] Mobile Instrumentation for the Detection and Sampling of Aerosol Particles&body=Please send me information about technology [TAB-2890] Mobile Instrumentation for the Detection and Sampling of Aerosol Particles.">yogikala.prabhu@nih.gov</a><br> 114161376 E-026-2014-0 E-026-2014-0-US-05 Aerosol Particle Growth Systems Using Polymer Electrolyte Membranes National Stage US 10,583,410 15/325,986 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10583410 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10583410">10,583,410</a><br />Filed on 2015-07-20<br />Status: Issued 114163079 E-026-2014-0 E-026-2014-0-PCT-02 Aerosol Particle Growth Systems Using Polymer Electrolyte Membranes PCT Patent Cooperation Treaty PCT/US2015/041142 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2015/041142<br />Filed on 2015-07-20<br />Status: Expired 114167996 E-026-2014-0 E-026-2014-0-US-01 AEROSOL PARTICLE GROWTH SYSTEMS FOR PERSONAL SAMPLING APPLICATIONS USING POLYMER ELECTROLYTE MEMBRANES PRV US 62/026,559 Abandoned US <br />Provisional (PRV) 62/026,559<br />Filed on 2014-07-18<br />Status: Abandoned 114126677 VBXXXX 114126678 VEXXXX 114126679 WAXXXX 114126680 WCXXXX 114126681 WGXXXX 114126682 WIXXXX 114126683 XDXXXX 114126684 XIXXXX 114126685 YFXXXX 114147921 AEROSOL 114147922 PARTICLE 114147923 Growth 114147924 SYSTEMS 114147925 PERSONAL 114147926 Sampling 114147927 APPLICATIONS 114147928 Proton 114147929 EXCHANGE 114147930 MEMBRANES 114147931 NIOSH-DART TAB-2939 114097090 Emergency Maritime Battery Charger CDC Cardiology, Dental, Endocrinology, Infectious Disease, Licensing, Medical Devices, Non-Medical Devices, Occupational Safety and Health, Oncology, Ophthalmology, Research Materials Cardiology Dental Endocrinology Infectious Disease Licensing Medical Devices Non-Medical Devices Occupational Safety and Health Oncology Ophthalmology Research Materials Chelsea Woodward Boats and other watercrafts have emergency lifesaving equipment like strobe lamps to help rescuers locate individuals overboard in the event of a disaster. The battery life of the equipment is limited, so the amount of time rescuers have to find the victims is also limited. An emergency battery charger that can power emergency equipment is needed to remove this limitation.<br /><br /> Investigators at NIOSH have developed a battery that is powered by wave action in the water. Using a derivation of Faraday's Law, the principles of Lentz's Law were used to induce a current in a wire coil and manipulated to charge emergency batteries. This technology offers a back-up charger for equipment on boats and watercrafts. <ul> <li>Charging system is configured to be powered by wave action.</li> <li>Powering mechanism allows the maritime battery charger to be used in boats, life rafts, and personal flotation devices.</li> <li>Maritime charger can be used to charge radios, lamps, and back up batteries for emergency systems.</li> </ul> <ul> <li>Battery charger that can be used on personal or commercial boats.</li> <li>Maritime battery charger that can be used for specialized rescue vessels.</li> </ul> Patent protection is not being pursued for this technology. 2022-03-27 2026-05-14 2026-05-14 2015-05-19 Battery, CDC Docket Import, CDC Docket Import CDC Prosecuting, CDCRM, Charger/maintainer, EMERGENCY, FISH, Listed LPM Surabian as of 4/15/2015, Maritime, NIOSH, Occupational health, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, SAFE, SAFETY, VPXXXX, WGXXXX, WIXXXX, WORK, WORKER safety, XDXXXX, XIXXXX, YAXXXX, YFXXXX False True <ul> <li>Early-stage</li> <li>Prototype</li> </ul> True 52406769 Prototype 52406769 NIHTT 37470483 Website Abstract 114109045 Woodward, Chelsea CDC - NIOSH CDC Woodward, Chelsea (CDC) 1 114109045 Woodward, Chelsea CDC - NIOSH CDC Woodward, Chelsea (CDC) 1 114102274 Emergency Maritime Battery Charger/maintainer E-567-2013-0 Research Material Centers for Disease Control and Prevention (CDC) 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2939] Emergency Maritime Battery Charger&body=Please send me information about technology [TAB-2939] Emergency Maritime Battery Charger. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2939] Emergency Maritime Battery Charger&body=Please send me information about technology [TAB-2939] Emergency Maritime Battery Charger.">yogikala.prabhu@nih.gov</a><br> 114127039 VPXXXX 114127040 WGXXXX 114127041 WIXXXX 114127042 XDXXXX 114127043 XIXXXX 114127044 YAXXXX 114127045 YFXXXX 114148362 EMERGENCY 114148363 Maritime 114148364 Battery 114148365 Charger/maintainer 114148366 CDC Docket Import 114148367 CDC Docket Import CDC Prosecuting 114148368 NIOSH 114148369 WORK 114148370 WORKER safety 114148371 SAFETY 114148372 SAFE 114148373 Occupational health 114148374 FISH 114148375 CDCRM 114148376 Listed LPM Surabian as of 4/15/2015 114148377 Pre LPM working set 20150418 114148378 Post LPM Assignment Set 20150420 TAB-2940 114097091 Swing-Away Winch Cathead Guard CDC Cardiology, Dental, Endocrinology, Infectious Disease, Licensing, Medical Devices, Non-Medical Devices, Occupational Safety and Health, Oncology, Ophthalmology, Research Materials Cardiology Dental Endocrinology Infectious Disease Licensing Medical Devices Non-Medical Devices Occupational Safety and Health Oncology Ophthalmology Research Materials Chelsea Woodward Shrimp boat operators use two trawl retrieval mechanisms mounted on the same winch frame. The main spools are used in the first operation; the shrimpers stand within inches of rotating cathead drums and guide incoming wire rope onto the main spools. Second, lazy lines are wrapped multiple times around each of the two spinning catheads (horizontal beams that raise and secure the anchor). Lastly, the guarding ends are pulled by the operators to cinch the rope to the rotating spool aiding trawl retrieval, but poses a hazard for operators to get entangled in the spinning cathead spools.<br /><br /> Researchers at NIOSH have developed guarding devices to protect shrimp boat winch operators from being entangled in the continuously spinning cathead spools. The mechanical guards feature a swinging functionality covering the catheads after the main trawl operations, allowing access to the normal operation of the catheads. <ul> <li>Swing-away mechanism of cathead guard protects operators from becoming entangled in spinning cathead spools.</li> <li>Designed specifically to address safety issues with industry winch protocols.</li> </ul> <ul> <li>Protective guards used to protect shrimp boat operators from being entangled in cathead spools.</li> <li>Cathead guards used to protect operators in the mining, oil, and gas industries where cathead winch spools are used.</li> <li>Guards can be used in boating industry to protect operators of anchor windlasses.</li> </ul> Patent protection is not being pursued for this technology. 2022-03-27 2026-05-14 2026-05-14 2015-05-19 Cathead, CDC Docket Import, CDC Docket Import CDC Prosecuting, CDCRM, Guard, Listed LPM Surabian as of 4/15/2015, Maritime, NIOSH, Occupational health, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Swing-Away, VPXXXX, WGXXXX, WINCH, WIXXXX, WORKER, WORKER safety, XDXXXX, XIXXXX, YAXXXX, YFXXXX False True <ul> <li>Early-stage</li> </li>Prototype</li> </ul> True 52406768 Discovery 52406768 NIHTT 37470483 Website Abstract 114109046 Woodward, Chelsea CDC - NIOSH CDC Woodward, Chelsea (CDC) 1 114109046 Woodward, Chelsea CDC - NIOSH CDC Woodward, Chelsea (CDC) 1 114102275 Swing-Away Winch Cathead Guard E-568-2013-0 Research Material Centers for Disease Control and Prevention (CDC) 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2940] Swing-Away Winch Cathead Guard&body=Please send me information about technology [TAB-2940] Swing-Away Winch Cathead Guard. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2940] Swing-Away Winch Cathead Guard&body=Please send me information about technology [TAB-2940] Swing-Away Winch Cathead Guard.">yogikala.prabhu@nih.gov</a><br> 114127046 VPXXXX 114127047 WGXXXX 114127048 WIXXXX 114127049 XDXXXX 114127050 XIXXXX 114127051 YAXXXX 114127052 YFXXXX 114148379 Swing-Away 114148380 WINCH 114148381 Cathead 114148382 Guard 114148383 CDC Docket Import 114148384 CDC Docket Import CDC Prosecuting 114148385 NIOSH 114148386 WORKER 114148387 WORKER safety 114148388 Occupational health 114148389 Maritime 114148390 CDCRM 114148391 Listed LPM Surabian as of 4/15/2015 114148392 Pre LPM working set 20150418 114148393 Post LPM Assignment Set 20150420 TAB-2816 114096995 Methods for Near Real-time Chemical Analysis of Aerosols using Microwave-induced Plasma Spectroscopy CDC Cardiology, Consumer Products, Dental, Diagnostics, Endocrinology, Infectious Disease, Licensing, Medical Devices, Non-Medical Devices, Occupational Safety and Health, Oncology, Ophthalmology, Research Equipment, Research Materials, Therapeutics, Vaccines Cardiology Consumer Products Dental Diagnostics Endocrinology Infectious Disease Licensing Medical Devices Non-Medical Devices Occupational Safety and Health Oncology Ophthalmology Research Equipment Research Materials Therapeutics Vaccines Philip Efthimion, Pramod Kulkarni This CDC developed technology entails a novel method of near real-time elemental analysis of aerosols by corona assisted microwave induced plasma spectroscopy (CAMPS).<br /><br /> Analysis of elemental composition of aerosol particles holds significant implications for environmental and workplace pollution monitoring. Various plasma based analytical techniques, including laser-induced breakdown spectroscopy (LIBS) and spark-induced breakdown spectroscopy (SIBS), have been successfully used for multi-elemental analyses in solids, liquids, and gases, including aerosols. However, the characterization of fine and ultrafine aerosols using these techniques is particularly challenging due to small plasma volume, miniscule sample mass, and inferior sampling statistics, often leading to poor detection limits and precision.<br /><br /> This technology utilizes a microwave plasma-based detection system for aerosol analysis that features increased microplasma lifetime, repeatability, and stability over currently-available pulsed microplasma-based methods. This system produces microplasma lifetimes in the range of 5 to 50 milliseconds, a duration that is orders of magnitude larger than lifetimes for laser-induced or spark plasmas, as well as larger plasma volumes, which together are expected to provide improved detection limits over currently-available techniques. <ul> <li>Makes it possible to conduct accurate, near-real-time measurement of the elemental composition of aerosols in industrial and ambient atmospheres</li> <li>Corona field stabilizes the microwave plasma and results in repeatable plasma formation</li> <li>Larger size of CAMPS plasma provides sufficient plasma volume which can lead to complete ablation of deposited aerosol in the tip of the electrode</li> <li>Longer duration of CAMPS plasma (~10-50 ms) allows longer integration time which results in signal enhancement</li> </ul> <ul> <li>Elemental quantification of aerosols in near real-time</li> <li>Air pollution studies, Particulate Matter monitoring</li> <li>Hazardous materials exposure determinations and identification</li> <li>Biodefense, chemical-defense, homeland-security applications</li> <li>Environmental and occupational epidemiology</li> <li>Evaluation of engineering controls</li> </ul> 2022-03-27 2026-05-14 2026-05-14 2014-05-15 CDC Docket Import, CDC Docket Import CDC Prosecuting, Microelectrode-Assisted, Microwave-Induced, NIOSH-DART, PLASMA, SPECTROSCOPY, VBXXXX, VJXXXX, VKXXXX, VLXXXX, VOXXXX, VPXXXX, WAXXXX, WBXXXX, WCXXXX, WEXXXX, WFXXXX, WGXXXX, WHXXXX, WIXXXX, WMXXXX, XDXXXX, XHXXXX, XIXXXX, YEXXXX, YFXXXX False True <ul> <li>In situ data available (on-site)</li> <li>Prototype</li> </ul> True 52406769 Prototype 52406769 NIHTT 37470483 Website Abstract E-205-2013-0 114108712 Efthimion, Philip Efthimion, Philip 0 114108711 Kulkarni, Pramod CDC - NIOSH CDC Kulkarni, Pramod (CDC) 1 114108711 Kulkarni, Pramod CDC - NIOSH CDC Kulkarni, Pramod (CDC) 1 114108712 Efthimion, Philip Efthimion, Philip 0 114102149 Microelectrode-Assisted Microwave-Induced Plasma Spectroscopy E-163-2013-0 Filing authorized Centers for Disease Control and Prevention (CDC), Envimetrics, LLC 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2816] Methods for Near Real-time Chemical Analysis of Aerosols using Microwave-induced Plasma Spectroscopy&body=Please send me information about technology [TAB-2816] Methods for Near Real-time Chemical Analysis of Aerosols using Microwave-induced Plasma Spectroscopy. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2816] Methods for Near Real-time Chemical Analysis of Aerosols using Microwave-induced Plasma Spectroscopy&body=Please send me information about technology [TAB-2816] Methods for Near Real-time Chemical Analysis of Aerosols using Microwave-induced Plasma Spectroscopy.">yogikala.prabhu@nih.gov</a><br> 114167783 E-163-2013-0 E-163-2013-0-US-01 Microelectrode-Assisted Microwave-Induced Plasma Spectroscopy PRV US 61/652,593 Abandoned US <br />Provisional (PRV) 61/652,593<br />Filed on 2012-05-02<br />Status: Abandoned 114167784 E-163-2013-0 E-163-2013-0-US-02 Electrode-Assisted Microwave-Induced Plasma Spectroscopy ORD US 9,091,597 13/804,512 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9091597 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9091597">9,091,597</a><br />Filed on 2013-03-14<br />Status: Issued 114126002 VBXXXX 114126003 VJXXXX 114126004 VKXXXX 114126005 VLXXXX 114126006 VOXXXX 114126007 VPXXXX 114126008 WAXXXX 114126009 WBXXXX 114126010 WCXXXX 114126011 WEXXXX 114126012 WFXXXX 114126013 WGXXXX 114126014 WHXXXX 114126015 WIXXXX 114126016 WMXXXX 114126017 XDXXXX 114126018 XHXXXX 114126019 XIXXXX 114126020 YEXXXX 114126021 YFXXXX 114147256 Microelectrode-Assisted 114147257 Microwave-Induced 114147258 PLASMA 114147259 SPECTROSCOPY 114147260 CDC Docket Import 114147261 CDC Docket Import CDC Prosecuting 114147262 NIOSH-DART TAB-2817 114096996 Local Positioning System for Position-Time-Condition Correlation, Data-logging and Analysis CDC Computational models/software, Consumer Products, Diagnostics, Licensing, Medical Devices, Non-Medical Devices, Occupational Safety and Health, Research Equipment, Research Materials, Software / Apps, Therapeutics, Vaccines Computational models/software Consumer Products Diagnostics Licensing Medical Devices Non-Medical Devices Occupational Safety and Health Research Equipment Research Materials Software / Apps Therapeutics Vaccines Michael Flemmer, Ramesh Gali, Jennifer Hornsby-Myers, Larry Lee, Sidney Soderholm This CDC-developed technology describes an automated system for monitoring worker hazard exposures by recording data about where and when hazards occur in a workplace or other environment. This allows the hazards to be avoided and harmful exposures and risks reduced. This field-tested technology consists of an integrated, hand-held electronics instrument and software system that will precisely correlate multiple exposure levels with position coordinates of the user and features real-time data acquisition.<br /><br /> Workers in many outdoor occupations move about frequently during a typical day of work. Certain workers, such as agricultural and construction workers, are particularly mobile. This exposure monitoring system combines geographical location with real-time sensors and outputs the information to a user-friendly interface. By linking worker location throughout the workday to exposure levels from real-time monitors, Local Positioning System (LPS) units (with integrated software processing of data) identify and document where to direct hazard exposure analysis and control efforts. Post-processing of LPS data enables researchers, regulatory inspectors, and industry safety and health personnel to map exposure intensity and location, reveal hot spots to identify sources, and provide exposure intensity distributions to increase workplace safety. <ul> <li>Correlates real-time position and real-time condition data for multiple commercial/industrial applications</li> <li>An add-on capability for any sensor(s) when measurement of a location is also useful</li> <li>System is highly customizable and can be easily adapted for additional monitoring of noise, dust, gases, and vapor, heat stress, etc. exposures</li> <li>Automated system provides greater efficiency and greater feedback than video monitoring systems</li> <li>An integrated alarm will alert users to potential hazards</li> </ul> <ul> <li>Collection, analysis and display of mutual, real-time conditional and 3-dimensional position data</li> <li>Outdoor occupational exposure assessment with various real-time sensors/monitors (e.g., HAZMAT crews, safety inspection, etc.)</li> <li>Solid state "bread crumbs" allowing a person or machine to retrace their path</li> <li>Tracking of objects, animals or people, including sensing of their internal condition or environmental conditions</li> <li>Environmental pollution source-point monitoring and investigation</li> </ul> 2022-03-27 2026-05-14 2026-05-14 2014-05-15 apparatus, ASSESSING, CDC Docket Import, CDC Docket Import CDC Prosecuting, Conditions, Method, System, VBXXXX, WAXXXX, WCXXXX, WEXXXX, WFXXXX, WGXXXX, WIXXXX, WMXXXX, XDXXXX, XHXXXX, XIXXXX, XJXXXX, YEXXXX, YFXXXX False True <ul> <li>In situ data available (on-site)</li> <li>Prototype</li> </ul> True 52406769 Prototype 52406769 NIHTT 37470483 Website Abstract 114172138 Lee LA, et al. http://www.ncbi.nlm.nih.gov/pubmed/15986055 <a href="http://www.ncbi.nlm.nih.gov/pubmed/15986055">Lee LA, et al.</a> 114108714 Soderholm, Sidney CDC - NIOSH CDC Soderholm, Sidney (CDC) 0 114108715 Flemmer, Michael CDC - NIOSH CDC Flemmer, Michael (CDC) 0 114108716 Hornsby-Myers, Jennifer CDC - NIOSH CDC Hornsby-Myers, Jennifer (CDC) 0 114108717 Gali, Ramesh CDC - NIOSH CDC Gali, Ramesh (CDC) 0 114108713 Lee, Larry CDC - NIOSH CDC Lee, Larry (CDC) 1 114108713 Lee, Larry CDC - NIOSH CDC Lee, Larry (CDC) 1 114108714 Soderholm, Sidney CDC - NIOSH CDC Soderholm, Sidney (CDC) 0 114108715 Flemmer, Michael CDC - NIOSH CDC Flemmer, Michael (CDC) 0 114108716 Hornsby-Myers, Jennifer CDC - NIOSH CDC Hornsby-Myers, Jennifer (CDC) 0 114108717 Gali, Ramesh CDC - NIOSH CDC Gali, Ramesh (CDC) 0 114102150 Method, Apparatus, And System For Assessing Conditions E-144-2013-0 Closed Centers for Disease Control and Prevention (CDC) 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2817] Local Positioning System for Position-Time-Condition Correlation, Data-logging and Analysis&body=Please send me information about technology [TAB-2817] Local Positioning System for Position-Time-Condition Correlation, Data-logging and Analysis. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2817] Local Positioning System for Position-Time-Condition Correlation, Data-logging and Analysis&body=Please send me information about technology [TAB-2817] Local Positioning System for Position-Time-Condition Correlation, Data-logging and Analysis.">yogikala.prabhu@nih.gov</a><br> 114167785 E-144-2013-0 E-144-2013-0-US-01 Method, Apparatus, And System For Assessing Conditions ORD US 7,191,097 10/815,111 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7191097 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7191097">7,191,097</a><br />Filed on 2004-03-31<br />Status: Abandoned 114126022 VBXXXX 114126023 WAXXXX 114126024 WCXXXX 114126025 WEXXXX 114126026 WFXXXX 114126027 WGXXXX 114126028 WIXXXX 114126029 WMXXXX 114126030 XDXXXX 114126031 XHXXXX 114126032 XIXXXX 114126033 XJXXXX 114126034 YEXXXX 114126035 YFXXXX 114147263 Method 114147264 apparatus 114147265 System 114147266 ASSESSING 114147267 Conditions 114147268 CDC Docket Import 114147269 CDC Docket Import CDC Prosecuting TAB-2823 114097002 Focused Electrostatic Collection of Aerosol Particles for Chemical Analysis by Spectroscopic Techniques CDC Cardiology, Consumer Products, Dental, Diagnostics, Endocrinology, Infectious Disease, Licensing, Medical Devices, Non-Medical Devices, Occupational Safety and Health, Oncology, Ophthalmology, Pulmonology, Research Equipment, Research Materials, Software / Apps, Therapeutics, Vaccines Cardiology Consumer Products Dental Diagnostics Endocrinology Infectious Disease Licensing Medical Devices Non-Medical Devices Occupational Safety and Health Oncology Ophthalmology Pulmonology Research Equipment Research Materials Software / Apps Therapeutics Vaccines Prasson Diwakar, Pramod Kulkarni This CDC-developed technology is an aerosol preconcentration unit (APU) designed for use with spectroscopic detection techniques, including emission, Raman, or infrared spectroscopies. Most existing pulsed microplasma techniques, such as laser-induced breakdown, for aerosols rely mainly on filter-based collection and suffer from poor accuracy, precision, and detection limits and require long sample collection times. The APU is designed to address these drawbacks by pre-concentrating the aerosol particles on a tip of a microelectrode (a few hundreds of micrometers in diameter) to allow near-real time measurements with superior accuracy and precision. The APU is designed to be small, low-pressure drop unit for its use in a battery-operated, hand-portable instrumentation.<br /><br /> The design significantly improves accuracy and precision of measurements relative to existing methods. The APU can be integrated with a microplasma source (such as a laser-induced plasma) and the optical spectrometer to obtain elemental composition of aerosol particles. The unique features of this invention allow: i) semi-continuous or near-real-time measurement of elemental composition of aerosol particles, ii) measurement with high accuracy, precision, and repeatability, iii) collection of particles using electrostatic principles, iv) higher flow rates with smaller pumps because of a very low pressure drop, v) reliable calibration of the system, vi) easy miniaturization for portable instruments, and vii) lower detection limits, as needed, by increasing the particle collection time and/or sampling flow rate. <ul> <li>This APU allows accurate, near-real-time measurement of the elemental composition of aerosol particles in industrial and ambient atmospheres</li> <li>Can be readily miniaturized and integrated into existing portable plasma, Raman, or IR spectroscopy instruments to allow on-site, semi-continuous measurement of aerosol particles</li> <li>Provides lower detection limits compared to earlier technology, as needed, by increasing the particle collection time and/or sampling flow rate</li> </ul> <ul> <li>Personal exposure measurements of metals</li> <li>Air pollution studies</li> <li>Elemental quantification in near real-time</li> <li>Hazardous materials exposure determinations and identification</li> <li>Biodefense, chemical-defense applications</li> <li>Environmental and occupational epidemiology</li> <li>Evaluation of engineering controls</li> </ul> 2022-03-27 2026-05-14 2026-05-14 2014-05-21 AA2XXX, AA3AXX, AA3B5X, AA3CXX, AA3XXX, AC1XXX, AC3XXX, AC4XXX, AC6XXX, ACXXXX, ADXXXX, AE2AXX, AE2XXX, AE3XXX, AE4XXX, AEROSOL, AEXXXX, AG1XXX, ANALYSER, ANALYSES, analysis, apparatus, AXXXXX, CDC Docket Import, CDC Docket Import CDC Prosecuting, DAXXXX, DEVICE, DXXXXX, IA5XXX, IDXXXX, Method, NIOSH, NIOSH-DART, OID-NCIRD-DVD, optical, PLASMA, SPECTROSCOPY, TECHNIQUE, VBXXXX, VJXXXX, VKXXXX, VLXXXX, VOXXXX, VPXXXX, WAXXXX, WBXXXX, WCXXXX, WEXXXX, WFXXXX, WGXXXX, WIXXXX, WMXXXX, XDXXXX, XFXXXX, XGXXXX, XHXXXX, XIXXXX, YEXXXX, YFXXXX False True <ul> <li>In situ data available (on-site)</li> <li>Prototype</li> </ul> True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract E-163-2013-0 114108733 Diwakar, Prasson CDC - NIOSH CDC Diwakar, Prasson (CDC) 0 114108732 Kulkarni, Pramod CDC - NIOSH CDC Kulkarni, Pramod (CDC) 1 114108732 Kulkarni, Pramod CDC - NIOSH CDC Kulkarni, Pramod (CDC) 1 114108733 Diwakar, Prasson CDC - NIOSH CDC Diwakar, Prasson (CDC) 0 114102157 Method And Apparatus For Aerosol Analysis Using Optical Spectroscopy E-205-2013-0 Filing authorized Centers for Disease Control and Prevention (CDC), TKC Global 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2823] Focused Electrostatic Collection of Aerosol Particles for Chemical Analysis by Spectroscopic Techniques&body=Please send me information about technology [TAB-2823] Focused Electrostatic Collection of Aerosol Particles for Chemical Analysis by Spectroscopic Techniques. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2823] Focused Electrostatic Collection of Aerosol Particles for Chemical Analysis by Spectroscopic Techniques&body=Please send me information about technology [TAB-2823] Focused Electrostatic Collection of Aerosol Particles for Chemical Analysis by Spectroscopic Techniques.">yogikala.prabhu@nih.gov</a><br> 114167801 E-205-2013-0 E-205-2013-0-US-01 Method And Apparatus For Aerosol Analysis Using Optical Spectroscopy ORD US 8,970,840 13/315,372 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8970840 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8970840">8,970,840</a><br />Filed on 2011-12-09<br />Status: Issued 114126103 AXXXXX 114126104 AA2XXX 114126105 AA3XXX 114126106 AA3AXX 114126107 AA3B5X 114126108 AA3CXX 114126109 ACXXXX 114126110 AC1XXX 114126111 AC3XXX 114126112 AC4XXX 114126113 AC6XXX 114126114 ADXXXX 114126115 AEXXXX 114126116 AE2XXX 114126117 AE2AXX 114126118 AE3XXX 114126119 AE4XXX 114126120 AG1XXX 114126121 DXXXXX 114126122 DAXXXX 114126123 IA5XXX 114126124 IDXXXX 114126125 VBXXXX 114126126 VJXXXX 114126127 VKXXXX 114126128 VLXXXX 114126129 VOXXXX 114126130 VPXXXX 114126131 WAXXXX 114126132 WBXXXX 114126133 WCXXXX 114126134 WEXXXX 114126135 WFXXXX 114126136 WGXXXX 114126137 WIXXXX 114126138 WMXXXX 114126139 XDXXXX 114126140 XFXXXX 114126141 XGXXXX 114126142 XHXXXX 114126143 XIXXXX 114126144 YEXXXX 114126145 YFXXXX 114147358 Method 114147359 apparatus 114147360 AEROSOL 114147361 analysis 114147362 optical 114147363 SPECTROSCOPY 114147364 CDC Docket Import 114147365 CDC Docket Import CDC Prosecuting 114147366 OID-NCIRD-DVD 114147367 NIOSH-DART 114147368 NIOSH 114147369 PLASMA 114147370 ANALYSES 114147371 ANALYSER 114147372 DEVICE 114147373 TECHNIQUE TAB-2824 114097003 Improved Acoustic Plethysmograph System for Noninvasive Measurement of Pulmonary Function CDC Cardiology, Computational models/software, Consumer Products, Dental, Diagnostics, Endocrinology, Immunology, Infectious Disease, Licensing, Medical Devices, Non-Medical Devices, Occupational Safety and Health, Oncology, Ophthalmology, Pulmonology, Research Equipment, Research Materials, Software / Apps, Therapeutics, Vaccines Cardiology Computational models/software Consumer Products Dental Diagnostics Endocrinology Immunology Infectious Disease Licensing Medical Devices Non-Medical Devices Occupational Safety and Health Oncology Ophthalmology Pulmonology Research Equipment Research Materials Software / Apps Therapeutics Vaccines David Frazer, Jeffrey Reynolds CDC researchers have developed a novel acoustic whole body plethysmograph (AWBP) that allows measurement of tidal volume in lab animals, independent of gas compression in the lung. This system provides particular advantages over the traditional whole body plethysmograph (WBP) when measuring model animals with increased gas compression due to increased airway resistance or increased acceleration in the breathing pattern.<br /><br /> Measurement of tidal volume in conscious, unrestrained mice has traditionally been performed using WBP. An animal is placed in a chamber where pressure changes due to respiration are observed, which are then related to tidal volume. Although the effects of gas compression on the WBP signal of normal mice may be negligible, gas compression in mice with altered breathing pattern and/or increased airway resistance can produce significant errors in the measurement of tidal volume. A major advantage of this novel AWBP technology is the ability to measure the tidal volume signal independent of gas compression. This is particularly useful when measuring mice that have been exposed to a respiratory irritant or toxin that increases airway resistance or the frequency content of the breathing pattern. Further, with slight hardware and software modifications the system may also be used to measure specific airway resistances. <ul> <li>System allows fast, efficient, noninvasive measurement of lab animal pulmonary function for numerous inhalation, toxicology research studies</li> <li>Measures tidal volume signal independent of gas compression, increasing accuracy when gathering data from animals with altered breathing patterns and/or elevated airway resistance</li> <li>System operates at a fixed frequency, and automatically tracks the change in sound amplitude as a function of time due to change in lung volume</li> </ul> <ul> <li>Measurement of tidal volume, respiratory rate, and other breath rate parameters of laboratory animals</li> <li>Research and animal modeling tool for in vivo pulmonary investigations of therapeutics efficacy and studying certain infectious diseases </li> <li>Particularly useful when measuring animals exposed to a respiratory irritant or toxin that increases either airway resistance or the frequency</li> <li>Noninvasive measurement of specific airway resistance and restrictions in an unrestrained animal</li> </ul> 2022-03-27 2026-05-14 2026-05-14 2014-05-27 AA2XXX, AA5XXX, AAXXXX, AC1XXX, AC2XXX, AC3XXX, AC6XXX, Acoustic, ACXXXX, ADXXXX, AE1BXX, AE1XXX, AE3XXX, AE4XXX, AEXXXX, ANIMAL, Animal Model, ANIMAL welfare, ASTHMA, Breath, BREATHING, CDC Docket Import, CDC Docket Import CDC Prosecuting, DDXXXX, DEVICE, DEXXXX, DXXXXX, FUNCTION, IA3XXX, IA5XXX, ICXXXX, IDXXXX, LUNG, lung cancer, Lung Disease, LUNGS, Lung-Targeted, Measuring, NIOSH, NIOSH-HELD, Plethysmograph, Pulmonary, Pulmonary edema, PULMONARY FIBROSIS, research, RESEARCH TOOL, RESPIRABLE, Respiration, respiratory, Respiratory Diseases, respiratory INFECTION, Tool, VBXXXX, VJXXXX, VKXXXX, VLXXXX, VOXXXX, VPXXXX, WAXXXX, WBXXXX, WCXXXX, WGXXXX, WIXXXX, WMXXXX, XDXXXX, XHXXXX, XIXXXX, XJXXXX, YCXXXX, YEXXXX, YFXXXX False True <ul> <li>In vivo data available (animal)</li> <li>In situ data available (on-site)</li> <li>Prototype</li> <ul> True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114172147 Reynolds JS, et al. http://www.ncbi.nlm.nih.gov/pubmed/16897419 <a href="http://www.ncbi.nlm.nih.gov/pubmed/16897419">Reynolds JS, et al.</a> 114172148 Reynolds JS, et al. http://www.ncbi.nlm.nih.gov/pubmed/18450981 <a href="http://www.ncbi.nlm.nih.gov/pubmed/18450981">Reynolds JS, et al.</a> 114172149 Daubenspeck JA , et al. http://www.ncbi.nlm.nih.gov/pubmed/17962574 <a href="http://www.ncbi.nlm.nih.gov/pubmed/17962574">Daubenspeck JA , et al.</a> 114108735 Frazer, David CDC - NIOSH CDC Frazer, David (CDC) 0 114108734 Reynolds, Jeffrey CDC - NIOSH CDC Reynolds, Jeffrey (CDC) 1 114108734 Reynolds, Jeffrey CDC - NIOSH CDC Reynolds, Jeffrey (CDC) 1 114108735 Frazer, David CDC - NIOSH CDC Frazer, David (CDC) 0 114102161 Acoustic Plethysmograph For Measuring Pulmonary Function E-290-2013-0 Closed Centers for Disease Control and Prevention (CDC) 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2824] Improved Acoustic Plethysmograph System for Noninvasive Measurement of Pulmonary Function&body=Please send me information about technology [TAB-2824] Improved Acoustic Plethysmograph System for Noninvasive Measurement of Pulmonary Function. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2824] Improved Acoustic Plethysmograph System for Noninvasive Measurement of Pulmonary Function&body=Please send me information about technology [TAB-2824] Improved Acoustic Plethysmograph System for Noninvasive Measurement of Pulmonary Function.">yogikala.prabhu@nih.gov</a><br> 114167810 E-290-2013-0 E-290-2013-0-US-01 Acoustic Plethysmograph For Measuring Pulmonary Function PRV US 60/958,537 Abandoned US <br />Provisional (PRV) 60/958,537<br />Filed on 2007-07-06<br />Status: Abandoned 114167811 E-290-2013-0 E-290-2013-0-US-02 Acoustic Plethysmograph For Measuring Pulmonary Function ORD US 8,328,729 12/168,829 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8328729 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8328729">8,328,729</a><br />Filed on 2009-01-08<br />Status: Abandoned 114126147 AA2XXX 114126148 AAXXXX 114126149 AA5XXX 114126150 ACXXXX 114126151 AC1XXX 114126152 AC2XXX 114126153 AC3XXX 114126154 AC6XXX 114126155 ADXXXX 114126156 AEXXXX 114126157 AE3XXX 114126158 AE1XXX 114126159 AE1BXX 114126160 AE4XXX 114126161 DXXXXX 114126162 DDXXXX 114126163 DEXXXX 114126164 IA3XXX 114126165 IA5XXX 114126166 ICXXXX 114126167 IDXXXX 114126168 VBXXXX 114126169 VJXXXX 114126170 VKXXXX 114126171 VLXXXX 114126172 VOXXXX 114126173 WAXXXX 114126174 WBXXXX 114126175 WCXXXX 114126176 WGXXXX 114126177 WIXXXX 114126178 XDXXXX 114126179 XHXXXX 114126180 XIXXXX 114126181 XJXXXX 114126182 YCXXXX 114126183 YEXXXX 114126184 YFXXXX 114126185 VPXXXX 114126186 WMXXXX 114147394 Acoustic 114147395 Plethysmograph 114147396 Measuring 114147397 Pulmonary 114147398 FUNCTION 114147399 CDC Docket Import 114147400 CDC Docket Import CDC Prosecuting 114147401 NIOSH-HELD 114147402 NIOSH 114147403 Tool 114147404 ANIMAL welfare 114147405 Animal Model 114147406 ANIMAL 114147407 research 114147408 RESEARCH TOOL 114147409 DEVICE 114147410 Breath 114147411 BREATHING 114147412 LUNG 114147413 lung cancer 114147414 Lung Disease 114147415 Lung-Targeted 114147416 LUNGS 114147417 ASTHMA 114147418 PULMONARY FIBROSIS 114147419 Pulmonary edema 114147420 RESPIRABLE 114147421 Respiration 114147422 respiratory 114147423 Respiratory Diseases 114147424 respiratory INFECTION TAB-2786 114096965 Cable-line Safety System: Electro/hydraulic Emergency Stop Device for a Winch, Drum or Capstan CDC Consumer Products, Licensing, Medical Devices, Non-Medical Devices, Occupational Safety and Health, Research Materials Consumer Products Licensing Medical Devices Non-Medical Devices Occupational Safety and Health Research Materials John Bevan, Curtis Clark, Wayne Howie, Jennifer Lincoln, Lewis Martin, Robert Mckibbin, Gregory Miller, Todd Ruff, Chelsea Woodward This CDC-developed invention entails a system of electrical and hydraulic circuits used to stop a rotating winch in an emergency. Amongst other locations, one stop switch can be positioned on a capstan winch horn. This location makes it available to a victim entangled in rope being retrieved on a gypsy drum. As designed, the stop circuit could be used with an electrically, hydraulically or pneumatically operated winch. A variant of this safety system has been successfully tested on a purse seining fishing vessel in Alaskan waters. <ul> <li>Complies with numerous international safety regulations requiring winches, drums and capstans to have a master on/off switch in easy reach for worker safety</li> <li>Can be packaged as a ‘retrofit kit’ for integration with current commercial winch/drum usage</li> </ul> <ul> <li>Retrofitting existing winches for additional safety and adherence to possible future regulations</li> <li>Specifically designed and tested for the marine/fishing industries</li> <li>Applications in mining, construction, forestry, and/or off-road automotive industries</li> <li>Workers' well-being concern groups</li> <li>Insurers of fishing vessels; also mining, construction and forestry operations</li> <li>Manufacturers of cable reel trailers and wire-drawing machinery</li> </ul> Research Tool – Patent protection is not being pursued for this technology. Research Tools – Patent protection is not being pursued for these technologies. 2022-03-27 2026-05-14 2026-05-14 2014-03-07 AE1CXX, AE1XXX, AE2BXX, AE2XXX, AE4XXX, AEXXXX, AFXXXX, AG3XXX, AGXXXX, AXXXXX, CABLE, CABLES, capstan, CDC Docket Import, CDC Docket Import CDC Prosecuting, CDCRM, DEVICE, ELECTRO/HYDRAULIC, EMERGENCY, FISH, Maritime, NIOSH, Occupational health, RXXXXX, SAFETY, Stop, SWITCH, Switches, SWITCHING, System, WEXXXX, WFXXXX, WGXXXX, WINCH, WMXXXX, XDXXXX, XIXXXX, YEXXXX, YFXXXX False True <ul> <li>In situ data available (on-site)</li> <li>Prototype</li> </ul> True 52406769 Prototype 52406769 NIHTT 37470483 Website Abstract E-504-2013-0 E-567-2013-0 E-568-2013-0 E-643-2013-0 114108596 Bevan, John CDC - NIOSH CDC Bevan, John (CDC) 0 114108597 Miller, Gregory CDC - NIOSH CDC Miller, Gregory (CDC) 0 114108598 Ruff, Todd CDC - NIOSH CDC Ruff, Todd (CDC) 0 114108599 Howie, Wayne CDC - NIOSH CDC Howie, Wayne (CDC) 0 114108600 Lincoln, Jennifer CDC - NIOSH CDC Lincoln, Jennifer (CDC) 0 114108602 Martin, Lewis CDC - NIOSH CDC Martin, Lewis (CDC) 0 114108603 Mckibbin, Robert CDC - NIOSH CDC Mckibbin, Robert (CDC) 0 114108604 Clark, Curtis CDC - NIOSH CDC Clark, Curtis (CDC) 0 114108601 Woodward, Chelsea CDC - NIOSH CDC Woodward, Chelsea (CDC) 1 114108601 Woodward, Chelsea CDC - NIOSH CDC Woodward, Chelsea (CDC) 1 114108596 Bevan, John CDC - NIOSH CDC Bevan, John (CDC) 0 114108597 Miller, Gregory CDC - NIOSH CDC Miller, Gregory (CDC) 0 114108598 Ruff, Todd CDC - NIOSH CDC Ruff, Todd (CDC) 0 114108599 Howie, Wayne CDC - NIOSH CDC Howie, Wayne (CDC) 0 114108600 Lincoln, Jennifer CDC - NIOSH CDC Lincoln, Jennifer (CDC) 0 114108602 Martin, Lewis CDC - NIOSH CDC Martin, Lewis (CDC) 0 114108603 Mckibbin, Robert CDC - NIOSH CDC Mckibbin, Robert (CDC) 0 114108604 Clark, Curtis CDC - NIOSH CDC Clark, Curtis (CDC) 0 114102111 ELECTRO/HYDRAULIC EMERGENCY STOP DEVICE FOR A WINCH E-355-2013-0 Research Material Centers for Disease Control and Prevention (CDC) 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2786] Cable-line Safety System: Electro/hydraulic Emergency Stop Device for a Winch, Drum or Capstan&body=Please send me information about technology [TAB-2786] Cable-line Safety System: Electro/hydraulic Emergency Stop Device for a Winch, Drum or Capstan. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2786] Cable-line Safety System: Electro/hydraulic Emergency Stop Device for a Winch, Drum or Capstan&body=Please send me information about technology [TAB-2786] Cable-line Safety System: Electro/hydraulic Emergency Stop Device for a Winch, Drum or Capstan.">yogikala.prabhu@nih.gov</a><br> 114125655 AXXXXX 114125656 AEXXXX 114125657 AE1XXX 114125658 AE2XXX 114125659 AE1CXX 114125660 AE2BXX 114125661 AE4XXX 114125662 AFXXXX 114125663 AGXXXX 114125664 AG3XXX 114125665 RXXXXX 114125666 WEXXXX 114125667 WFXXXX 114125668 WGXXXX 114125669 WMXXXX 114125670 XDXXXX 114125671 XIXXXX 114125672 YEXXXX 114125673 YFXXXX 114146805 ELECTRO/HYDRAULIC 114146806 EMERGENCY 114146807 Stop 114146808 DEVICE 114146809 WINCH 114146810 CDC Docket Import 114146811 CDC Docket Import CDC Prosecuting 114146812 NIOSH 114146813 SAFETY 114146814 Occupational health 114146815 Maritime 114146816 FISH 114146817 capstan 114146818 CABLE 114146819 CABLES 114146820 System 114146821 SWITCH 114146822 SWITCHING 114146823 Switches 114146824 CDCRM TAB-2788 114096967 Mining Safety: Personal Dust Monitor Filters for Accurate, Quantifiable Spectrometric Analysis and Assessment of Worker Exposure Levels CDC Cardiology, Consumer Products, Dental, Diagnostics, Endocrinology, Infectious Disease, Licensing, Medical Devices, Non-Medical Devices, Occupational Safety and Health, Oncology, Ophthalmology Cardiology Consumer Products Dental Diagnostics Endocrinology Infectious Disease Licensing Medical Devices Non-Medical Devices Occupational Safety and Health Oncology Ophthalmology Donald Tuchman This CDC-developed invention pertains to a novel dust monitor filter that is specially constructed of organic materials for spectrometric analysis, ultimately allowing for detection and accurate quantification of a particular chosen analyte (e.g., crystalline silica/quartz dust that may lead to silicosis).<br /><br /> For miners, the risk of lung disease increases with the extent of dust exposure, and coal worker's pneumoconiosis (aka, black lung disease) and silicosis are still dangers routinely faced by those in the industry. Expectedly, both the concentration and the composition of airborne particulate matter present in mining environments are points of regulatory concern. For some time, collecting airborne dust samples and subsequent determination of quartz content have been integral for assessing mine worker exposure and demonstrating compliance with US Federal regulations.<br /><br /> Unfortunately, highly accurate spectrometric detection and quantification of particulate exposure has not always been possible. Generally, the filters used in existing oscillating microbalances (such as the TEOM® monitor) have been specially designed to for hydrophobicity, in order to retain as little moisture as possible on the filter. These specialized hydrophobic filters (and/or their mounting components) contain inorganic compounds that cannot be readily subjected to thermal or chemical destruction - a necessary first step of many instrumental analytical methods, such as spectroscopy.<br /><br /> This CDC-developed filter consists of entirely ashable material, making it ideal for spectrometric analysis and rapid exposure assessment. As an example, this dust monitor filter can be made entirely of organic materials and designed for quick, easy ashing that will not produce interference with the spectroscopic characteristics of the chosen analyte(s). Further, filter ashing can be carried out by a variety of methods: thermal ashing, microwave ashing, low temperature ashing, or chemical destruction. <ul> <li>Novel dust-monitoring instrument capable of providing near rapid particulate exposure information to miners/users</li> <li>Improves upon older technology by allowing for accurate detection and quantification of chosen analyte(s) and, unlike other filters, does not produce overlap or interfere with spectroscopic analysis</li> <li>Filter can be easily ashed for analysis by thermal ashing, microwave ashing, low temperature ashing, or chemical destruction</li> </ul> <ul> <li>Personal dust monitors worn wherever dust exposure levels and the presence of potentially injurious materials is evaluated</li> <li>Occupationally-mandated pneumoconiosis, asbestosis and/or silicosis prevention and monitoring programs, for complying with safety regulations</li> <li>Miners' wellness concern groups and insurance companies</li> </ul> 2022-03-27 2026-05-14 2026-05-14 2014-03-07 AAXXXX, AC1XXX, AC3XXX, ACXXXX, AE1XXX, AE2XXX, AE3XXX, AE4XXX, AEXXXX, AIRBORNE, AXXXXX, CDC Docket Import, CDC Docket Import CDC Prosecuting, CHARACTERIZING, COAL, DUST, Dust collector, Methods, MINE, MINER, MINING, MONITOR, NIOSH, NIOSH-PRL, PARTICULATES, VPXXXX, WBXXXX, WCXXXX, WEXXXX, WFXXXX, WGXXXX, WMXXXX, XDXXXX, XIXXXX, YAXXXX, YBXXXX, YEXXXX, YFXXXX False True <ul> <li>Early-stage</li> <li>In vitro data available</li> </ul> True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114172100 Tuchman DP. http://www.ncbi.nlm.nih.gov/pubmed/18449405 <a href="http://www.ncbi.nlm.nih.gov/pubmed/18449405">Tuchman DP.</a> 114108607 Tuchman, Donald CDC - NIOSH CDC Tuchman, Donald (CDC) 1 114108607 Tuchman, Donald CDC - NIOSH CDC Tuchman, Donald (CDC) 1 114102113 MONITOR AND METHODS FOR CHARACTERIZING AIRBORNE PARTICULATES E-312-2013-0 Closed Centers for Disease Control and Prevention (CDC) 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2788] Mining Safety: Personal Dust Monitor Filters for Accurate, Quantifiable Spectrometric Analysis and Assessment of Worker Exposure Levels&body=Please send me information about technology [TAB-2788] Mining Safety: Personal Dust Monitor Filters for Accurate, Quantifiable Spectrometric Analysis and Assessment of Worker Exposure Levels. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2788] Mining Safety: Personal Dust Monitor Filters for Accurate, Quantifiable Spectrometric Analysis and Assessment of Worker Exposure Levels&body=Please send me information about technology [TAB-2788] Mining Safety: Personal Dust Monitor Filters for Accurate, Quantifiable Spectrometric Analysis and Assessment of Worker Exposure Levels.">yogikala.prabhu@nih.gov</a><br> 114167693 E-312-2013-0 E-312-2013-0-PCT-02 MONITOR AND METHODS FOR CHARACTERIZING AIRBORNE PARTICULATES PCT Patent Cooperation Treaty PCT/US2006/023166 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2006/023166<br />Filed on 2006-06-14<br />Status: Expired 114167694 E-312-2013-0 E-312-2013-0-US-01 MONITOR AND METHODS FOR CHARACTERIZING AIRBORNE PARTICULATES PRV US 60/691,564 Abandoned US <br />Provisional (PRV) 60/691,564<br />Filed on 2005-06-17<br />Status: Abandoned 114167695 E-312-2013-0 E-312-2013-0-US-03 MONITOR AND METHODS FOR CHARACTERIZING AIRBORNE PARTICULATES National Stage US 7,947,503 11/922,381 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7947503 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7947503">7,947,503</a><br />Filed on 2007-12-14<br />Status: Abandoned 114125693 AXXXXX 114125694 AAXXXX 114125695 ACXXXX 114125696 AC1XXX 114125697 AC3XXX 114125698 AEXXXX 114125699 AE1XXX 114125700 AE2XXX 114125701 AE3XXX 114125702 AE4XXX 114125703 WCXXXX 114125704 WEXXXX 114125705 WFXXXX 114125706 WGXXXX 114125707 WMXXXX 114125708 XDXXXX 114125709 XIXXXX 114125710 VPXXXX 114125711 WBXXXX 114125712 YAXXXX 114125713 YBXXXX 114125742 YEXXXX 114125743 YFXXXX 114146853 MONITOR 114146854 Methods 114146855 CHARACTERIZING 114146856 AIRBORNE 114146857 PARTICULATES 114146858 CDC Docket Import 114146859 CDC Docket Import CDC Prosecuting 114146860 NIOSH-PRL 114146861 NIOSH 114146862 MINE 114146863 MINER 114146864 MINING 114146865 COAL 114146866 DUST 114146867 Dust collector TAB-2789 114096968 Computer Controlled Aerosol Generator with Multi-Walled Carbon Nanotube Inhalation Testing Capabilities CDC Cardiology, Computational models/software, Consumer Products, Dental, Diagnostics, Endocrinology, Infectious Disease, Licensing, Medical Devices, Non-Medical Devices, Occupational Safety and Health, Oncology, Ophthalmology, Research Materials, Software / Apps, Therapeutics Cardiology Computational models/software Consumer Products Dental Diagnostics Endocrinology Infectious Disease Licensing Medical Devices Non-Medical Devices Occupational Safety and Health Oncology Ophthalmology Research Materials Software / Apps Therapeutics Bean Chen, David Frazer, Walter McKinney This invention pertains to a CDC developed sonic aerosol generator that provides a controllable, stable concentration of particulate aerosol over a long period of time for aerosol exposure studies. Specifically, <em>in situ</em> testing data indicate uniform aerosol stability can be maintainable for greater than 30 hours at concentrations of 15 mg/m<sup>3</sup> or more. Additionally, the technology was specifically developed for, and validated in, animal studies assessing exposure to airborne multi-walled carbon nanotubes (MWCNT). It has been suggested that workers may be at risk for exposure to nanosized particles during the manufacture, handling, and cleanup of engineered nanomaterials. Compared to other technologies, this CDC aerosol generator is particularly helpful when used for generating high testing concentrations of MWCNT aerosols that more accurately represent particulate levels that may be seen in a workplace environment. <ul> <li>Fully automated system with integrated feedback control for optimized stability in testing</li> <li>Maintains concentration of aerosols for >30 hours at concentrations of 15 mg/cubic meter or more</li> <li>Capable of generating high concentrations of aerosols that more accurately represent the levels seen in a workplace environment</li> <li>System insures that each run produces a constant particle concentration, air flow, pressure, temperature and humidity within a testing chamber</li> </ul> <ul> <li>Studying the size and shape of the aerosolized particles produced from simple vibrations of bulk material</li> <li>Toxicological investigations and risk assessment of aerosol exposures, especially those related to nanoparticle manufacturing</li> <li>Any aerosolization application where the aggregating “bird's nest” tendencies of airborne multi-walled carbon nanotubes must be overcome</li> </ul> 2022-03-27 2026-05-14 2026-05-14 2014-03-07 AC1DXX, AC1XXX, AC4XXX, ACXXXX, AE1BXX, AE1XXX, AE2BXX, AE3XXX, AEROSOL, AEXXXX, AG2XXX, AG3XXX, AGXXXX, AXXXXX, CDC Docket Import, CDC Docket Import CDC Prosecuting, DEVICE, ENVIRONMENTAL, environmental health, GENERATOR, nanotechnology, Nanotube, NIOSH, NIOSH-HELD, PARTICULATE, TOXICOLOGICAL, TOXICOLOGY, VPXXXX, WCXXXX, WFXXXX, WGXXXX, WHXXXX, WIXXXX, WMXXXX, WORK, WORKER safety, XDXXXX, XGXXXX, XIXXXX, XJXXXX, YBXXXX, YCXXXX, YEXXXX, YFXXXX False True <ul> <li>In vitro data available</li> <li>In vivo data available (animal)</li> <li>In situ data available (on-site)</li> <li>Prototype</li> </ul> True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114172101 McKinney W, et al. http://www.ncbi.nlm.nih.gov/pubmed/19555230 <a href="http://www.ncbi.nlm.nih.gov/pubmed/19555230">McKinney W, et al.</a> 114172102 Porter DW, et al. http://www.ncbi.nlm.nih.gov/pubmed/22881873 <a href="http://www.ncbi.nlm.nih.gov/pubmed/22881873">Porter DW, et al.</a> 114172103 Porter DW, et al. http://www.ncbi.nlm.nih.gov/pubmed/19857541 <a href="http://www.ncbi.nlm.nih.gov/pubmed/19857541">Porter DW, et al.</a> 114172104 Chen BT, et al. http://www.ncbi.nlm.nih.gov/pubmed/23033994 <a href="http://www.ncbi.nlm.nih.gov/pubmed/23033994">Chen BT, et al.</a> 114108609 Frazer, David CDC - NIOSH CDC Frazer, David (CDC) 0 114108610 Chen, Bean CDC - NIOSH CDC Chen, Bean (CDC) 0 114108608 McKinney, Walter CDC - NIOSH CDC McKinney, Walter (CDC) 1 114108608 McKinney, Walter CDC - NIOSH CDC McKinney, Walter (CDC) 1 114108609 Frazer, David CDC - NIOSH CDC Frazer, David (CDC) 0 114108610 Chen, Bean CDC - NIOSH CDC Chen, Bean (CDC) 0 114102114 Aerosol Generator E-156-2013-0 Closed Centers for Disease Control and Prevention (CDC) 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2789] Computer Controlled Aerosol Generator with Multi-Walled Carbon Nanotube Inhalation Testing Capabilities&body=Please send me information about technology [TAB-2789] Computer Controlled Aerosol Generator with Multi-Walled Carbon Nanotube Inhalation Testing Capabilities. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2789] Computer Controlled Aerosol Generator with Multi-Walled Carbon Nanotube Inhalation Testing Capabilities&body=Please send me information about technology [TAB-2789] Computer Controlled Aerosol Generator with Multi-Walled Carbon Nanotube Inhalation Testing Capabilities.">yogikala.prabhu@nih.gov</a><br> 114167696 E-156-2013-0 E-156-2013-0-US-01 Aerosol Generator PRV US 61/237,945 Abandoned US <br />Provisional (PRV) 61/237,945<br />Filed on 2009-08-28<br />Status: Abandoned 114167697 E-156-2013-0 E-156-2013-0-US-02 Aerosol Generator ORD US 8,875,702 12/871,453 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8875702 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8875702">8,875,702</a><br />Filed on 2010-08-30<br />Status: Abandoned 114167923 E-156-2013-0 E-156-2013-0-US-03 Aerosol Generator DIV US 14/473,324 Abandoned US <br />Divisional (DIV) 14/473,324<br />Filed on 2014-08-29<br />Status: Abandoned 114125714 AXXXXX 114125715 ACXXXX 114125716 AC4XXX 114125717 AC1XXX 114125718 AC1DXX 114125719 AEXXXX 114125720 AE1XXX 114125721 AE1BXX 114125722 AE3XXX 114125723 AE2BXX 114125724 AGXXXX 114125725 AG2XXX 114125726 AG3XXX 114125727 VPXXXX 114125728 WCXXXX 114125729 WFXXXX 114125730 WGXXXX 114125731 WHXXXX 114125732 WIXXXX 114125733 WMXXXX 114125734 XDXXXX 114125735 XGXXXX 114125736 XIXXXX 114125737 XJXXXX 114125738 YBXXXX 114125739 YCXXXX 114125740 YEXXXX 114125741 YFXXXX 114146868 AEROSOL 114146869 GENERATOR 114146870 CDC Docket Import 114146871 CDC Docket Import CDC Prosecuting 114146872 NIOSH-HELD 114146873 Nanotube 114146874 TOXICOLOGICAL 114146875 TOXICOLOGY 114146876 DEVICE 114146877 NIOSH 114146878 WORK 114146879 WORKER safety 114146880 ENVIRONMENTAL 114146881 environmental health 114146882 nanotechnology 114146883 PARTICULATE TAB-2793 114096972 Silica Exposure Safety: Mini-baghouse Systems and Methods for Controlling Particulate Release from Large Sand Transfer Equipment CDC Cardiology, Consumer Products, Dental, Endocrinology, Infectious Disease, Licensing, Medical Devices, Non-Medical Devices, Occupational Safety and Health, Oncology, Ophthalmology Cardiology Consumer Products Dental Endocrinology Infectious Disease Licensing Medical Devices Non-Medical Devices Occupational Safety and Health Oncology Ophthalmology Michael Breitenstein, John Snawder CDC/NIOSH scientists have developed an effective point-source control for silica-containing dusts that can be generated from machinery on sites where hydraulic fracturing is occurring. The CDC/NIOSH mini-baghouse retrofit assembly is a bolt-on control designed to contain silica-containing respirable dusts generated during refill operations of sand movers during hydraulic fracturing.<br /><br /> In the U.S., most new oil and gas wells are hydraulically fractured to enhance well production. Most hydraulic fracturing operations have 2-5 sand movers on-site that transfer thousands to millions of pounds of silica sand during each stage of fracturing. While a variety of passive and active controls are currently available (or have been proposed) to limit release of silica-containing dusts, the CDC/NIOSH mini-baghouse retrofit assembly was designed to fill a unique need for a control. The retrofit to equipment can be made in the field, uses existing energy inherent in the system and is relatively simple and effective. CDC/NIOSH field research has shown that risks for exposure to respirable silica arise from at least 8 points of dust generation and that a variety of controls (engineering, administrative and personal protective equipment) are needed to control exposures. Use of the mini-baghouse retrofit technology is intended to limit release of respirable silica from thief hatches on top of the sand movers, enhancing workplace health and safety. <ul> <li>Designed for in-field retrofitting “thief hatches” of existing machinery</li> <li>Uses energy inherent in the pneumatic transfer of sand</li> <li>Provides a passive sand-mover-mounted control for silica release at hydraulic fracturing operations</li> </ul> <ul> <li>Controlling occupational exposure to respirable crystalline silica, particularly during work involving transfer of sand into sand movers on hydraulic fracturing sites</li> <li>In-field retrofits of currently operating heavy equipment (e.g., sand movers)</li> <li>Limiting visible dust emissions from sand moving equipment</li> <li>Reducing respirable crystalline silica dust emissions to enhance compliance with OSHA PEL for silica</li> </ul> 2022-03-27 2026-05-14 2026-05-14 2015-10-14 3/25/2014 -- designated as "Remove" per BHurley/CDC TTO: abstract contains inaccuracies and will be replaced at a later date... --ecr 4/16/2014 -- received updated abstract; okay to post now... --ecr AE1XXX, AE2XXX, AE3XXX, AEXXXX, AGXXXX, apparatus, AXXXXX, Baghouse, CDC Docket Import, CDC Docket Import CDC Prosecuting, CONTROL, CONTROLING, Crystalline, DEVICE, DUST, Dust collector, ENVIRONMENT, ENVIRONMENTAL, environmental health, Equipment, Fracturing, HYDRAULIC, LARGE, Methods, MINE, MINER, Mini, MINING, Movers, MULTIPLE, NIOSH, NIOSH-DSHEFS, Occupational health, PARTICULATE, Release, RESPIRABLE, Respiration, Respirator, Retrofit, SAND, SILICA, SILICOSIS, SYSTEMS, VPXXXX, WCXXXX, WEXXXX, WFXXXX, WGXXXX, WMXXXX, XDXXXX, XIXXXX, YEXXXX, YFXXXX False True <ul> <li>In situ data available (on-site)</li> <li>Prototype</li> </ul> True 52406769 Prototype 52406769 NIHTT 37470483 Website Abstract 114172133 Esswein EJ, et al. http://www.ncbi.nlm.nih.gov/pubmed/23679563 <a href="http://www.ncbi.nlm.nih.gov/pubmed/23679563">Esswein EJ, et al.</a> 114108622 Breitenstein, Michael CDC - NIOSH CDC Breitenstein, Michael (CDC) 0 114108623 Snawder, John CDC - NIOSH CDC Snawder, John (CDC) 0 114108622 Breitenstein, Michael CDC - NIOSH CDC Breitenstein, Michael (CDC) 0 114108623 Snawder, John CDC - NIOSH CDC Snawder, John (CDC) 0 114102118 Multiple Mini Baghouse Retrofit For Control Of Respirable Crystalline Silica Release From Hydraulic Fracturing Sand Movers E-291-2013-0 Closed Centers for Disease Control and Prevention (CDC) 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2793] Silica Exposure Safety: Mini-baghouse Systems and Methods for Controlling Particulate Release from Large Sand Transfer Equipment&body=Please send me information about technology [TAB-2793] Silica Exposure Safety: Mini-baghouse Systems and Methods for Controlling Particulate Release from Large Sand Transfer Equipment. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2793] Silica Exposure Safety: Mini-baghouse Systems and Methods for Controlling Particulate Release from Large Sand Transfer Equipment&body=Please send me information about technology [TAB-2793] Silica Exposure Safety: Mini-baghouse Systems and Methods for Controlling Particulate Release from Large Sand Transfer Equipment.">yogikala.prabhu@nih.gov</a><br> 114162543 E-291-2013-0 E-291-2013-0-US-03 SYSTEMS AND METHODS FOR CONTROLLING PARTICULATE RELEASE FROM LARGE EQUIPMENT DIV US 9,669,345 14/992,963 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9669345 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9669345">9,669,345</a><br />Filed on 2016-01-11<br />Status: Abandoned 114167705 E-291-2013-0 E-291-2013-0-US-01 SYSTEMS AND METHODS FOR CONTROLING PARTICULATE RELEASE FROM LARGE EQUIPMENT PRV US 61/673,658 Abandoned US <br />Provisional (PRV) 61/673,658<br />Filed on 2012-07-19<br />Status: Abandoned 114167706 E-291-2013-0 E-291-2013-0-US-02 SYSTEMS AND METHODS FOR CONTROLING PARTICULATE RELEASE FROM LARGE EQUIPMENT ORD US 13/802,265 Abandoned US <br />Ordinary Patent (ORD) 13/802,265<br />Filed on 2013-03-13<br />Status: Abandoned 114125774 AXXXXX 114125775 AEXXXX 114125776 AE1XXX 114125777 AE2XXX 114125778 AE3XXX 114125779 AGXXXX 114125780 WCXXXX 114125781 WEXXXX 114125782 WFXXXX 114125783 WGXXXX 114125784 WMXXXX 114125785 XDXXXX 114125786 XIXXXX 114125787 YFXXXX 114125788 YEXXXX 114125939 VPXXXX 114146928 SYSTEMS 114146929 Methods 114146930 CONTROLING 114146931 PARTICULATE 114146932 Release 114146933 LARGE 114146934 Equipment 114146935 Retrofit 114146936 Baghouse 114146937 Mini 114146938 MULTIPLE 114146939 CONTROL 114146940 RESPIRABLE 114146941 Crystalline 114146942 SILICA 114146943 HYDRAULIC 114146944 Fracturing 114146945 SAND 114146946 Movers 114146947 CDC Docket Import 114146948 CDC Docket Import CDC Prosecuting 114146949 NIOSH-DSHEFS 114146950 NIOSH 114146951 MINING 114146952 MINE 114146953 MINER 114146954 DEVICE 114146955 apparatus 114146956 Occupational health 114146957 ENVIRONMENT 114146958 ENVIRONMENTAL 114146959 environmental health 114146960 DUST 114146961 SILICOSIS 114146962 Dust collector 114146963 Respiration 114146964 Respirator TAB-2761 114096940 Automated Microscopic Image Acquisition, Compositing and Display Software Developed for Applied Microscopy/Cytology Training and Analysis CDC Cardiology, Computational models/software, Consumer Products, Dental, Diagnostics, Endocrinology, Geriatrics, Immunology, Infectious Disease, Licensing, Medical Devices, Neurology, Non-Medical Devices, Oncology, Ophthalmology, Psychiatry/Mental Health, Research Equipment, Research Materials, Software / Apps, Therapeutics, Vaccines Cardiology Computational models/software Consumer Products Dental Diagnostics Endocrinology Geriatrics Immunology Infectious Disease Licensing Medical Devices Neurology Non-Medical Devices Oncology Ophthalmology Psychiatry/Mental Health Research Equipment Research Materials Software / Apps Therapeutics Vaccines Carlyn Collins, MariBeth Gagnon, James Lange, Tommy Lee, Roger Taylor Micro-Screen is a CDC developed software program designed to capture images and archive and display a compiled image(s) from a portion of a microscope slide in real time. This program allows for the re-creation of larger images that are constructed from individual microscopic fields captured in up to five focal planes and two magnifications. This program may be especially useful for the creation of data archives for diagnostic and teaching purposes and for tracking histological changes during disease progression. <ul> <li>Readily adaptable to other microscopic disciplines</li> <li>Automated imaging and display provides increased cost efficiency and improves objectivity of analysis and testing</li> <li>Can be used to develop a database of standards or reference images for a variety of pathologies and/or applied microscopy concerns</li> </ul> <ul> <li>Medical/cytology training, education and certification</li> <li>All aspects of applied microscopy/histology, microbial smears, hematology, parasitology, etc.</li> <li>Clinical diagnostics</li> <li>Basic and applied biology lab research</li> <li>Forensic analysis</li> </ul> 2022-03-27 2026-05-14 2026-05-14 2014-02-06 AA3AXX, AA3B6X, AA3CXX, AA3XXX, AC2XXX, AC3XXX, Acquisition, ACXXXX, AD2XXX, AD3XXX, ADXXXX, Automated, AXXXXX, CDC Docket Import, CDC Docket Import CDC Prosecuting, Compositing, DISPLAY, Image, MICROSCOPIC, OID-NCPDCID-DLS, VAXXXX, VBXXXX, VCXXXX, VDXXXX, VEXXXX, VFXXXX, VGXXXX, VHXXXX, VIXXXX, VJXXXX, VKXXXX, VLXXXX, VMXXXX, VNXXXX, VOXXXX, VPXXXX, WBXXXX, WIXXXX, WMXXXX, XDXXXX, XFXXXX, XHXXXX, XJXXXX, YBXXXX, YEXXXX False True <ul> <li>In vitro data available</li> <li>In situ data available (on-site)</li> </ul> True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114172053 Taylor RN, et al. http://www.ncbi.nlm.nih.gov/pubmed/10578977 <a href="http://www.ncbi.nlm.nih.gov/pubmed/10578977">Taylor RN, et al.</a> 114108510 Taylor, Roger CDC - DIR CDC Taylor, Roger (CDC) 0 114108511 Lange, James CDC - DIR CDC Lange, James (CDC) 0 114108512 Lee, Tommy CDC - DIR CDC Lee, Tommy (CDC) 0 114108513 Collins, Carlyn CDC - DIR CDC Collins, Carlyn (CDC) 0 114108509 Gagnon, MariBeth CDC - DIR CDC Gagnon, MariBeth (CDC) 1 114108509 Gagnon, MariBeth CDC - DIR CDC Gagnon, MariBeth (CDC) 1 114108510 Taylor, Roger CDC - DIR CDC Taylor, Roger (CDC) 0 114108511 Lange, James CDC - DIR CDC Lange, James (CDC) 0 114108512 Lee, Tommy CDC - DIR CDC Lee, Tommy (CDC) 0 114108513 Collins, Carlyn CDC - DIR CDC Collins, Carlyn (CDC) 0 114102081 Automated Microscopic Image Acquisition, Compositing, And Display E-228-2013-0 Closed Centers for Disease Control and Prevention (CDC) 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2761] Automated Microscopic Image Acquisition, Compositing and Display Software Developed for Applied Microscopy/Cytology Training and Analysis&body=Please send me information about technology [TAB-2761] Automated Microscopic Image Acquisition, Compositing and Display Software Developed for Applied Microscopy/Cytology Training and Analysis. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2761] Automated Microscopic Image Acquisition, Compositing and Display Software Developed for Applied Microscopy/Cytology Training and Analysis&body=Please send me information about technology [TAB-2761] Automated Microscopic Image Acquisition, Compositing and Display Software Developed for Applied Microscopy/Cytology Training and Analysis.">yogikala.prabhu@nih.gov</a><br> 114167617 E-228-2013-0 E-228-2013-0-US-01 Automated Microscopic Image Acquisition, Compositing, And Display PRV US 60/248,948 Abandoned US <br />Provisional (PRV) 60/248,948<br />Filed on 2000-11-14<br />Status: Abandoned 114167618 E-228-2013-0 E-228-2013-0-US-02 Automated Microscopic Image Acquisition, Compositing, And Display ORD US 7,027,628 10/001,268 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7027628 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7027628">7,027,628</a><br />Filed on 2001-11-13<br />Status: Expired 114167619 E-228-2013-0 E-228-2013-0-US-03 Automated Microscopic Image Acquisition, Compositing, And Display CON US 7,305,109 11/345,863 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7305109 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7305109">7,305,109</a><br />Filed on 2006-02-01<br />Status: Expired 114125183 AXXXXX 114125184 ACXXXX 114125185 AC2XXX 114125186 AC3XXX 114125187 ADXXXX 114125188 AD2XXX 114125189 AD3XXX 114125190 AA3XXX 114125191 AA3AXX 114125192 AA3CXX 114125193 AA3B6X 114125194 VAXXXX 114125195 VBXXXX 114125196 VCXXXX 114125197 VDXXXX 114125198 VEXXXX 114125199 VFXXXX 114125200 VGXXXX 114125201 VHXXXX 114125202 VIXXXX 114125203 VJXXXX 114125204 VKXXXX 114125205 VLXXXX 114125206 VMXXXX 114125207 VNXXXX 114125208 VOXXXX 114125209 VPXXXX 114125210 WBXXXX 114125211 WIXXXX 114125212 WMXXXX 114125213 XDXXXX 114125214 XFXXXX 114125215 XHXXXX 114125216 XJXXXX 114125217 YBXXXX 114125218 YEXXXX 114146447 Automated 114146448 MICROSCOPIC 114146449 Image 114146450 Acquisition 114146451 Compositing 114146452 DISPLAY 114146453 CDC Docket Import 114146454 CDC Docket Import CDC Prosecuting 114146455 OID-NCPDCID-DLS TAB-2762 114096941 Inexpensive, Personal Dust Detector Tube/Dosimeter Operating on a Gas Detector Tube Platform CDC Cardiology, Consumer Products, Dental, Endocrinology, Infectious Disease, Licensing, Medical Devices, Non-Medical Devices, Occupational Safety and Health, Oncology, Ophthalmology, Research Equipment Cardiology Consumer Products Dental Endocrinology Infectious Disease Licensing Medical Devices Non-Medical Devices Occupational Safety and Health Oncology Ophthalmology Research Equipment Harry Dobroski, Steven Page, Jon Volkwein This CDC developed dust detector tube is designed to provide inexpensive, short-term, time weighted average dust exposure data feedback directly to device users. This invention operates upon a conventional gas detector tube platform and can be used with any low volume pump that can electronically measure pump back pressure. The device consists of three sections: the first defines the size of the dust and removes moisture, the second uses a filter whose pressure differential corresponds with cumulative dust loading, and a final section employs a pressure transducer.<br /><br /> Current methods require expensive instantaneous and short-term monitors or gravimetric filters that must be carefully pre- and post-weighed to determine the average dust exposure of a user's work-shift. This novel dust dosimeter fills the need for an inexpensive short-term determination of personal dust exposure aiding in the assessment and preservation of worker respiratory health. <ul> <li>Provides inexpensive, short-term assessment of personal dust exposure</li> <li>Gas detector tube platform makes commercialization of this instrument quite simple and efficient for related manufacturers/distributors</li> <li>Standardizing detection platforms increases cost-efficiency (especially for smaller companies) as the same pump can be used to measure both dust and gas</li> </ul> <ul> <li>Dust, gas and particulate detector/dosimeter manufacturers</li> <li>Industry applications where worker-exposure to dust will be a concern, especially mining, construction and demolition fields</li> <li>Worker health and safety, related insurance agency concerns</li> </ul> 2022-03-27 2026-05-14 2026-05-14 2014-02-06 AE1XXX, AE2BXX, AE2XXX, AE3XXX, AEXXXX, AG3XXX, AGXXXX, AXXXXX, CDC Docket Import, CDC Docket Import CDC Prosecuting, DETECTOR, DEVICE, DUST, Enviromental, environmental health, MINING, MONITOR, NIOSH, NIOSH-PRL, Occupational health, OSHA, Protection, SAMPLER, Tube, VPXXXX, WCXXXX, WEXXXX, WFXXXX, WGXXXX, WORKER, WORKER safety, XDXXXX, XHXXXX, YEXXXX False True In situ data available (on-site) True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114172054 Volkwein JC, et al. http://www.ncbi.nlm.nih.gov/pubmed/10712071 <a href="http://www.ncbi.nlm.nih.gov/pubmed/10712071">Volkwein JC, et al.</a> 114108515 Dobroski, Harry CDC - NIOSH CDC Dobroski, Harry (CDC) 0 114108516 Page, Steven CDC - NIOSH CDC Page, Steven (CDC) 0 114108514 Volkwein, Jon CDC - NIOSH CDC Volkwein, Jon (CDC) 1 114108514 Volkwein, Jon CDC - NIOSH CDC Volkwein, Jon (CDC) 1 114108515 Dobroski, Harry CDC - NIOSH CDC Dobroski, Harry (CDC) 0 114108516 Page, Steven CDC - NIOSH CDC Page, Steven (CDC) 0 114102082 Dust Detector Tube E-238-2013-0 Closed Centers for Disease Control and Prevention (CDC) 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2762] Inexpensive, Personal Dust Detector Tube/Dosimeter Operating on a Gas Detector Tube Platform&body=Please send me information about technology [TAB-2762] Inexpensive, Personal Dust Detector Tube/Dosimeter Operating on a Gas Detector Tube Platform. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2762] Inexpensive, Personal Dust Detector Tube/Dosimeter Operating on a Gas Detector Tube Platform&body=Please send me information about technology [TAB-2762] Inexpensive, Personal Dust Detector Tube/Dosimeter Operating on a Gas Detector Tube Platform.">yogikala.prabhu@nih.gov</a><br> 114167620 E-238-2013-0 E-238-2013-0-PCT-02 Dust Detector Tube PCT Patent Cooperation Treaty PCT/US1998/013267 Expired Patent Cooperation Treaty <br />(PCT) PCT/US1998/013267<br />Filed on 1998-06-26<br />Status: Expired 114167621 E-238-2013-0 E-238-2013-0-US-01 Dust Detector Tube PRV US 60/052,719 Abandoned US <br />Provisional (PRV) 60/052,719<br />Filed on 1997-07-03<br />Status: Abandoned 114167622 E-238-2013-0 E-238-2013-0-US-03 Dust Detector Tube ORD US 6,401,520 09/467,934 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6401520 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6401520">6,401,520</a><br />Filed on 1999-12-21<br />Status: Expired 114125219 AXXXXX 114125220 AEXXXX 114125221 AE1XXX 114125222 AE2XXX 114125223 AE2BXX 114125224 AE3XXX 114125225 AGXXXX 114125226 AG3XXX 114125227 WCXXXX 114125228 WEXXXX 114125229 WFXXXX 114125230 WGXXXX 114125231 VPXXXX 114125232 XDXXXX 114125233 XHXXXX 114125234 YEXXXX 114146456 DUST 114146457 DETECTOR 114146458 Tube 114146459 CDC Docket Import 114146460 CDC Docket Import CDC Prosecuting 114146461 NIOSH-PRL 114146462 NIOSH 114146463 OSHA 114146464 MINING 114146465 WORKER 114146466 WORKER safety 114146467 Occupational health 114146468 DEVICE 114146469 MONITOR 114146470 Enviromental 114146471 environmental health 114146472 SAMPLER 114146473 Protection TAB-2774 114096953 Auscultatory Training System and Telemedicine Tool with Accurate Reproduction of Physiological Sounds CDC Cardiology, Computational models/software, Consumer Products, Dental, Diagnostics, Endocrinology, Infectious Disease, Licensing, Medical Devices, Non-Medical Devices, Occupational Safety and Health, Oncology, Ophthalmology, Pulmonology, Research Materials, Software / Apps, Therapeutics Cardiology Computational models/software Consumer Products Dental Diagnostics Endocrinology Infectious Disease Licensing Medical Devices Non-Medical Devices Occupational Safety and Health Oncology Ophthalmology Pulmonology Research Materials Software / Apps Therapeutics David Frazer, Kimberly Friend, William Goldsmith, Walter McKinney, Jeffrey Reynolds This CDC developed auscultatory training apparatus includes a database of prerecorded physiological sounds (e.g., lung, bowel, or heart sounds) stored on a computer for playback. Current teaching tools, which utilize previously recorded sounds, suffer from the disadvantage that playback environments cause considerable distortion and errors in sound reproduction. For example, to those trainees using such systems, the reproduced respiratory sounds do not “sound” as if they are being generated by a live patient. Moreover, the aforementioned playback distortions often make it difficult for the listener to hear and interpret the subtleties of a recorded respiratory maneuver.<br /><br /> This device includes a software program that allows a user to select prerecorded sounds for playback. The program will also generate an inverse model of the playback system in the form of a digital filter. The inverse model processes a selected sound to cancel the distortions of the playback system so the sound is accurately reproduced. The program also permits the extraction of a specific sound component from a prerecorded sound so only the extracted sound component is audible during playback. In addition to the obvious role of a teaching tool for medical professionals, this invention could have applications as a diagnostic screening and/or telemedicine tool. <ul> <li>Accurate, realistic reproduction of in situ physiological sounds</li> <li>Apparatus features noise-cancelling filter to eliminate ambient distortion artifacts during playback</li> <li>Device is extremely portable</li> <li>Allows for isolation and playback of specific elements of a recording</li> </ul> <ul> <li>Auscultatory training for health care professionals</li> <li>Telemedicine tool</li> <li>Diagnostic screening comparison and control</li> </ul> International patent application pending (Canada) 2022-03-27 2026-05-14 2026-05-14 2014-02-07 AA3B6X, AA3BXX, AA3XXX, AAXXXX, AB4XXX, ACXXXX, ADXXXX, AFXXXX, Auscultatory, AXXXXX, CDC Docket Import, CDC Docket Import CDC Prosecuting, IA1XXX, IA5XXX, IAXXXX, IB1FXX, IB4XXX, ICXXXX, IDXXXX, IXXXXX, NIOSH-HELD, System, TRAINING, VDXXXX, VOXXXX, VPXXXX, WBXXXX, WFXXXX, WHXXXX, WIXXXX, WMXXXX, XDXXXX, XFXXXX, XIXXXX, XJXXXX, YEXXXX, YFXXXX False True <ul> <li>In situ data available (on-site)</li> <li>Prototype</li> </ul> True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract E-245-2013-0 114172068 Goldsmith WT, et al. http://www.ncbi.nlm.nih.gov/pubmed/19876736 <a href="http://www.ncbi.nlm.nih.gov/pubmed/19876736">Goldsmith WT, et al.</a> 114172069 Abaza AA, et al. http://www.ncbi.nlm.nih.gov/pubmed/19930559 <a href="http://www.ncbi.nlm.nih.gov/pubmed/19930559">Abaza AA, et al.</a> 114108555 Reynolds, Jeffrey CDC - NIOSH CDC Reynolds, Jeffrey (CDC) 0 114108556 Friend, Kimberly CDC - NIOSH CDC Friend, Kimberly (CDC) 0 114108557 Goldsmith, William CDC - NIOSH CDC Goldsmith, William (CDC) 0 114108558 Frazer, David CDC - NIOSH CDC Frazer, David (CDC) 0 114108554 McKinney, Walter CDC - NIOSH CDC McKinney, Walter (CDC) 1 114108554 McKinney, Walter CDC - NIOSH CDC McKinney, Walter (CDC) 1 114108555 Reynolds, Jeffrey CDC - NIOSH CDC Reynolds, Jeffrey (CDC) 0 114108556 Friend, Kimberly CDC - NIOSH CDC Friend, Kimberly (CDC) 0 114108557 Goldsmith, William CDC - NIOSH CDC Goldsmith, William (CDC) 0 114108558 Frazer, David CDC - NIOSH CDC Frazer, David (CDC) 0 114102096 Auscultatory Training System E-283-2013-0 Closed Centers for Disease Control and Prevention (CDC) 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2774] Auscultatory Training System and Telemedicine Tool with Accurate Reproduction of Physiological Sounds&body=Please send me information about technology [TAB-2774] Auscultatory Training System and Telemedicine Tool with Accurate Reproduction of Physiological Sounds. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2774] Auscultatory Training System and Telemedicine Tool with Accurate Reproduction of Physiological Sounds&body=Please send me information about technology [TAB-2774] Auscultatory Training System and Telemedicine Tool with Accurate Reproduction of Physiological Sounds.">yogikala.prabhu@nih.gov</a><br> 114167653 E-283-2013-0 E-283-2013-0-US-01 Auscultatory Training System PRV US 60/287,941 Abandoned US <br />Provisional (PRV) 60/287,941<br />Filed on 2001-04-30<br />Status: Abandoned 114167654 E-283-2013-0 E-283-2013-0-US-02 Auscultatory Training System ORD US 7,209,796 10/135,964 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7209796 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7209796">7,209,796</a><br />Filed on 2002-04-29<br />Status: Expired 114125443 AXXXXX 114125444 AAXXXX 114125445 ACXXXX 114125446 ADXXXX 114125447 AB4XXX 114125448 AA3XXX 114125449 AA3BXX 114125450 AA3B6X 114125451 AFXXXX 114125452 IXXXXX 114125453 IAXXXX 114125454 IA1XXX 114125455 IA5XXX 114125456 ICXXXX 114125457 IDXXXX 114125458 IB1FXX 114125459 IB4XXX 114125460 VDXXXX 114125461 VOXXXX 114125462 VPXXXX 114125463 WBXXXX 114125464 WFXXXX 114125465 WHXXXX 114125466 WIXXXX 114125467 WMXXXX 114125468 XDXXXX 114125469 XFXXXX 114125470 XIXXXX 114125471 XJXXXX 114125472 YEXXXX 114125473 YFXXXX 114146610 Auscultatory 114146611 TRAINING 114146612 System 114146613 CDC Docket Import 114146614 CDC Docket Import CDC Prosecuting 114146615 NIOSH-HELD TAB-2781 114096960 Air Quality Assurance: A Monitor for Continuous, Simultaneous Analysis of Atmospheric or Aerosolized Particulate Mixtures CDC Consumer Products, Licensing, Medical Devices, Non-Medical Devices, Occupational Safety and Health Consumer Products Licensing Medical Devices Non-Medical Devices Occupational Safety and Health Charles Litton, William Schiffbauer, Jon Volkwein This technology pertains to monitors for measuring the mass concentration of ambient particulate matter in an atmosphere containing both larger/coarser (e.g., respirable dust) and smaller/finer (sub-micrometer particles such as diesel particulate matter - DPM) particulate mixtures. The monitoring device can be configured for operation with a controller unit adapted to ionization sensor and/or light-scattering modules. The controller translates the sensor output signal into a quantifiable value, determining mass concentration of particulate matter within the ionization chamber. For example, practical applications of this monitor/analysis technology would easily extend to use in mining operations (where both DPM and respirable dust exist in abundance), industrial manufacturing facilities, and anywhere that frequent or extended exposure to fuel-combustion exhaust or airborne pollution is a concern. Further, by virtue of its ability to distinguish “fire smoke” from other aerosols that may be present, the device also has significant potential for use in early-warning fire detection. <ul> <li>Inexpensive and simple to implement</li> <li>Device provides continuous, simultaneous, and independent measurement of both respirable dust and diesel particulate matter (DPM) mass concentrations</li> <li>Previous particulate counting technologies are both expensive and cannot provide accurate quantification of coarse/fine aerosol mixtures, concentrations</li> </ul> <ul> <li>Airborne particle monitor for mining and industrial manufacturing operations</li> <li>Addressing emissions control standards and regulations</li> <li>Early-warning fire detection in locations where traditional smoke-detector use is impractical</li> </ul> 2022-03-27 2026-05-14 2026-05-14 2014-02-28 AE1BXX, AE2BXX, AE2XXX, AE3XXX, AEXXXX, ANALYZING, apparatus, AXXXXX, CDC Docket Import, CDC Docket Import CDC Prosecuting, Ionization, Light-scattering, Methods, NIOSH-PRL, PARTICLES, SENSORS, WCXXXX, WEXXXX, WFXXXX, WGXXXX, WMXXXX, XDXXXX, XIXXXX, YEXXXX, YFXXXX False True <ul> <li>In situ data available (on-site)</li> <li>Prototype</li> </ul> True 52406769 Prototype 52406769 NIHTT 37470483 Website Abstract 114108580 Volkwein, Jon CDC - NIOSH CDC Volkwein, Jon (CDC) 0 114108581 Schiffbauer, William CDC - NIOSH CDC Schiffbauer, William (CDC) 0 114108579 Litton, Charles CDC - NIOSH CDC Litton, Charles (CDC) 1 114108579 Litton, Charles CDC - NIOSH CDC Litton, Charles (CDC) 1 114108580 Volkwein, Jon CDC - NIOSH CDC Volkwein, Jon (CDC) 0 114108581 Schiffbauer, William CDC - NIOSH CDC Schiffbauer, William (CDC) 0 114102106 Apparatus And Methods For Analyzing Particles Using Light-scattering Sensors And Ionization Sensors E-240-2013-0 Closed Centers for Disease Control and Prevention (CDC) 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2781] Air Quality Assurance: A Monitor for Continuous, Simultaneous Analysis of Atmospheric or Aerosolized Particulate Mixtures&body=Please send me information about technology [TAB-2781] Air Quality Assurance: A Monitor for Continuous, Simultaneous Analysis of Atmospheric or Aerosolized Particulate Mixtures. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2781] Air Quality Assurance: A Monitor for Continuous, Simultaneous Analysis of Atmospheric or Aerosolized Particulate Mixtures&body=Please send me information about technology [TAB-2781] Air Quality Assurance: A Monitor for Continuous, Simultaneous Analysis of Atmospheric or Aerosolized Particulate Mixtures.">yogikala.prabhu@nih.gov</a><br> 114167678 E-240-2013-0 E-240-2013-0-US-01 Apparatus And Methods For Analyzing Particles Using Light-scattering Sensors And Ionization Sensors PRV US 60/369,537 Abandoned US <br />Provisional (PRV) 60/369,537<br />Filed on 2002-04-01<br />Status: Abandoned 114167679 E-240-2013-0 E-240-2013-0-US-02 Apparatus And Methods For Analyzing Particles Using Light-scattering Sensors And Ionization Sensors ORD US 6,965,240 10/401,980 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6965240 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6965240">6,965,240</a><br />Filed on 2003-03-27<br />Status: Abandoned 114125587 AXXXXX 114125588 AEXXXX 114125589 AE2XXX 114125590 AE2BXX 114125591 AE1BXX 114125592 AE3XXX 114125593 WCXXXX 114125594 WEXXXX 114125595 WFXXXX 114125596 WGXXXX 114125597 WMXXXX 114125598 XDXXXX 114125599 XIXXXX 114125600 YEXXXX 114125601 YFXXXX 114146739 apparatus 114146740 Methods 114146741 ANALYZING 114146742 PARTICLES 114146743 Light-scattering 114146744 SENSORS 114146745 Ionization 114146746 CDC Docket Import 114146747 CDC Docket Import CDC Prosecuting 114146748 NIOSH-PRL TAB-2739 114096918 Device to Measure Muscle Contractile-Relaxant and Epithelial Bioelectric Responses of Perfused, Intact Tracheal Airways Tissue In Vitro CDC Cardiology, Collaboration, Consumer Products, Dental, Diagnostics, Endocrinology, Infectious Disease, Licensing, Medical Devices, Non-Medical Devices, Oncology, Ophthalmology, Research Equipment, Research Materials, Therapeutics Cardiology Collaboration Consumer Products Dental Diagnostics Endocrinology Infectious Disease Licensing Medical Devices Non-Medical Devices Oncology Ophthalmology Research Equipment Research Materials Therapeutics Jeffrey Fedan, Yi Jing, Michael Van Scott CDC and collaborative researchers have developed a device allowing for simultaneous measurement of smooth muscle contractile/relaxant activity and transepithelial potential difference (Vt) [or short circuit currents (Isc)] and resistance (Rt) within an intact airway <em>in vitro</em>. Investigation of the underlying mechanisms of lung diseases, such as asthma or cystic fibrosis, involves understanding the roles of airway smooth muscle and epithelium. Smooth muscle is involved in the control of the airway diameter; epithelium regulates the ionic composition of the liquid lining the airways through electrogenic ion transport and releases factors that regulate the ability of smooth muscle to contract.<br /><br /> This invention allows for the measurement and study of pulmonary diseases under conditions retaining normal spatial relationships between all the cell types and an unmanipulated/undistorted tracheal airway wall. Further, the device permits evaluation of epithelial functional integrity using pharmacological techniques. Agents can be separately added to the lumen, where they must first cross the epithelium to reach the smooth muscle, or to the outside of the airway, where there is no hindrance of said agents to the muscle. The invention also permits the effective <em>in vitro</em> screening of the effects of agents and drugs on airway epithelium and smooth muscle within the same preparation. <ul> <li>Allows simultaneous measurement of transepithelial potential difference, transepithelial resistance, smooth muscle activity and changes in tracheal diameter</li> <li>In vitro analysis of trachea or tracheal segments retaining native, in situ structure</li> <li>Pharmacological agents may be added separately to the lumen for screening purposes</li> <li>First and only such "single-preparation" device allowing for such broad array of data output</li> </ul> <ul> <li>Investigations into physiological mechanisms of airway diseases, such as cystic fibrosis and asthma</li> <li>Screening of drugs and therapeutic compounds directed to complex, multi-tissue type matrices</li> <li>Biomedical research exploring pharmacology-physiology integration</li> </ul> 2022-03-27 2026-05-14 2026-05-14 2014-01-27 AA2XXX, AAXXXX, AC4XXX, AC5XXX, ACXXXX, apparatus, AXXXXX, CDC Docket Import, CDC Docket Import CDC Prosecuting, CHARACTERISTICS, ICXXXX, IDXXXX, INTACT, IXXXXX, Measuring, Method, PHYSIOLOGICAL, Trachea, Vitro, VPXXXX, WBXXXX, WIXXXX, WMXXXX, XDXXXX, XHXXXX, YAXXXX, YBXXXX, YEXXXX, YFXXXX False True <ul> <li>Early-stage</li> <li>In vitro data available</li> <li>In situ data available (on-site)</li> <li>Prototype</li> </ul> True 52406768 Discovery 52406768 NIHTT 37470483 Website Abstract 114172021 JIng Y, et. al. http://www.ncbi.nlm.nih.gov/pubmed/18835555 <a href="http://www.ncbi.nlm.nih.gov/pubmed/18835555">JIng Y, et. al.</a> 114108448 Jing, Yi CDC - NIOSH CDC Jing, Yi (CDC) 0 114108449 Van Scott, Michael East Carolina University Van Scott, Michael 0 114108447 Fedan, Jeffrey CDC - NIOSH CDC Fedan, Jeffrey (CDC) 1 114108447 Fedan, Jeffrey CDC - NIOSH CDC Fedan, Jeffrey (CDC) 1 114108448 Jing, Yi CDC - NIOSH CDC Jing, Yi (CDC) 0 114108449 Van Scott, Michael East Carolina University Van Scott, Michael 0 114102057 Apparatus And Method For Measuring Physiological Characteristics Of An Intact Trachea In Vitro E-246-2013-0 Closed Centers for Disease Control and Prevention (CDC), East Carolina University 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2739] Device to Measure Muscle Contractile-Relaxant and Epithelial Bioelectric Responses of Perfused, Intact Tracheal Airways Tissue In Vitro&body=Please send me information about technology [TAB-2739] Device to Measure Muscle Contractile-Relaxant and Epithelial Bioelectric Responses of Perfused, Intact Tracheal Airways Tissue In Vitro. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2739] Device to Measure Muscle Contractile-Relaxant and Epithelial Bioelectric Responses of Perfused, Intact Tracheal Airways Tissue In Vitro&body=Please send me information about technology [TAB-2739] Device to Measure Muscle Contractile-Relaxant and Epithelial Bioelectric Responses of Perfused, Intact Tracheal Airways Tissue In Vitro.">yogikala.prabhu@nih.gov</a><br> 114167534 E-246-2013-0 E-246-2013-0-US-02 Apparatus And Method For Measuring Physiological Characteristics Of An Intact Trachea In Vitro ORD US 7,907,999 11/655,635 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7907999 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7907999">7,907,999</a><br />Filed on 2007-01-19<br />Status: Abandoned 114167538 E-246-2013-0 E-246-2013-0-US-01 Apparatus And Method For Measuring Physiological Characteristics Of An Intact Trachea In Vitro PRV US 60/762,465 Abandoned US <br />Provisional (PRV) 60/762,465<br />Filed on 2006-01-25<br />Status: Abandoned 114124780 AXXXXX 114124781 AAXXXX 114124782 AA2XXX 114124783 ACXXXX 114124784 AC4XXX 114124785 AC5XXX 114124786 IXXXXX 114124787 ICXXXX 114124788 IDXXXX 114124790 VPXXXX 114124791 WBXXXX 114124792 WIXXXX 114124793 WMXXXX 114124794 XDXXXX 114124795 XHXXXX 114124796 YAXXXX 114124797 YBXXXX 114124798 YEXXXX 114124799 YFXXXX 114146197 apparatus 114146198 Method 114146199 Measuring 114146200 PHYSIOLOGICAL 114146201 CHARACTERISTICS 114146202 INTACT 114146203 Trachea 114146204 Vitro 114146205 CDC Docket Import 114146206 CDC Docket Import CDC Prosecuting TAB-2758 114096933 Cylindrical Handle Dynamometer for Improved Grip-Strength Measurement CDC Cardiology, Dental, Diagnostics, Endocrinology, Geriatrics, Immunology, Infectious Disease, Licensing, Medical Devices, Neurology, Non-Medical Devices, Occupational Safety and Health, Oncology, Ophthalmology Cardiology Dental Diagnostics Endocrinology Geriatrics Immunology Infectious Disease Licensing Medical Devices Neurology Non-Medical Devices Occupational Safety and Health Oncology Ophthalmology Renguang Dong, Thomas McDowell, Christopher Warren, Daniel Welcome, Bryan Wimer CDC researchers have developed an improved dynamometer device and method for measuring maximum hand grip force or grip-strength. Human test subjects were used in conducting experiments to evaluate the handle and to assess the measurement method. In contrast to the currently used "Jamar handle" grip strength dynamometer devices, the cylindrical handle proved to be able to determine the overall grip strength for a subject, as well as show the grip force distribution around the circumference of the handle. The cylindrical dynamometer handle is accurate with less than 4% error, and it demonstrates that the measurement is independent of the loading position along the handle. For real-world applications, the device can be used to help diagnose the musculoskeletal disorders of the hand, monitor the recovery progress after hand surgery or injury, and collect grip strength data for tool and machine design. Compared to currently used "Jamar" grip test devices: <ul> <li>Cylindrical handle shape more comparable with real-world/workplace machinery</li> <li>Improved comfort</li> <li>Cylindrical meter assesses the total grip force, together with the friction force and torque</li> <li>Grip force distributed at the different parts of the hand can be measured with cylindrical meter - important information for the diagnosis of hand disorders</li> </ul> <ul> <li>Useful for engineering functional design and ergonomic considerations for developing new tools and machinery</li> <li>Monitoring post-operative, post-stroke rehabilitation</li> <li>Diagnosis of carpel tunnel syndrome, musculoskeletal disorders and hand-arm vibration syndrome</li> <li>Training feedback for grip-strength focused athletes - climbing, gymnastics, rugby, martial arts, etc.</li> </ul> 2022-03-27 2026-05-14 2026-05-14 2014-02-06 AA1XXX, AA2XXX, AA4BXX, AA4XXX, AAXXXX, AB1XXX, AFXXXX, ASSESSMENT, AXXXXX, CDC Docket Import, CDC Docket Import CDC Prosecuting, Configuration, Dynamometer, GRIP, HAND, Improved, NIOSH-HELD, Strength, VAXXXX, VEXXXX, VPXXXX, WBXXXX, WGXXXX, XDXXXX, XIXXXX, YEXXXX, YFXXXX False True <ul> <li>In situ data available (on-site)</li> <li>Prototype</li> </ul> True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114172051 Wimer B, et al. http://www.ncbi.nlm.nih.gov/pubmed/19250853 <a href="http://www.ncbi.nlm.nih.gov/pubmed/19250853">Wimer B, et al.</a> 114108501 Welcome, Daniel CDC - NIOSH CDC Welcome, Daniel (CDC) 0 114108502 Warren, Christopher CDC - NIOSH CDC Warren, Christopher (CDC) 0 114108503 McDowell, Thomas CDC - NIOSH CDC McDowell, Thomas (CDC) 0 114108504 Dong, Renguang CDC - NIOSH CDC Dong, Renguang (CDC) 0 114108500 Wimer, Bryan CDC - NIOSH CDC Wimer, Bryan (CDC) 1 114108500 Wimer, Bryan CDC - NIOSH CDC Wimer, Bryan (CDC) 1 114108501 Welcome, Daniel CDC - NIOSH CDC Welcome, Daniel (CDC) 0 114108502 Warren, Christopher CDC - NIOSH CDC Warren, Christopher (CDC) 0 114108503 McDowell, Thomas CDC - NIOSH CDC McDowell, Thomas (CDC) 0 114108504 Dong, Renguang CDC - NIOSH CDC Dong, Renguang (CDC) 0 114102078 HAND DYNAMOMETER WITH IMPROVED CONFIGURATION FOR GRIP STRENGTH ASSESSMENT E-143-2013-0 Closed Centers for Disease Control and Prevention (CDC) 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2758] Cylindrical Handle Dynamometer for Improved Grip-Strength Measurement&body=Please send me information about technology [TAB-2758] Cylindrical Handle Dynamometer for Improved Grip-Strength Measurement. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2758] Cylindrical Handle Dynamometer for Improved Grip-Strength Measurement&body=Please send me information about technology [TAB-2758] Cylindrical Handle Dynamometer for Improved Grip-Strength Measurement.">yogikala.prabhu@nih.gov</a><br> 114167611 E-143-2013-0 E-143-2013-0-US-01 HAND DYNAMOMETER WITH IMPROVED CONFIGURATION FOR GRIP STRENGTH ASSESSMENT PRV US 61/175,473 Abandoned US <br />Provisional (PRV) 61/175,473<br />Filed on 2009-05-05<br />Status: Abandoned 114167612 E-143-2013-0 E-143-2013-0-US-02 HAND DYNAMOMETER WITH IMPROVED CONFIGURATION FOR GRIP STRENGTH ASSESSMENT ORD US 8,240,202 12/773,420 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8240202 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8240202">8,240,202</a><br />Filed on 2010-05-04<br />Status: Abandoned 114125132 AXXXXX 114125133 AAXXXX 114125134 AA1XXX 114125135 AA4XXX 114125136 AA4BXX 114125137 AA2XXX 114125138 AB1XXX 114125139 AFXXXX 114125140 XDXXXX 114125141 WBXXXX 114125142 WGXXXX 114125143 XIXXXX 114125144 VAXXXX 114125145 VEXXXX 114125146 VPXXXX 114125147 YEXXXX 114125148 YFXXXX 114146407 HAND 114146408 Dynamometer 114146409 Improved 114146410 Configuration 114146411 GRIP 114146412 Strength 114146413 ASSESSMENT 114146414 CDC Docket Import 114146415 CDC Docket Import CDC Prosecuting 114146416 NIOSH-HELD TAB-2757 114096937 Extension-Ladder Safety: Multimodal-feedback Indicator for Improved Ladder Positioning Safety and Efficiency CDC Cardiology, Consumer Products, Dental, Endocrinology, Infectious Disease, Licensing, Medical Devices, Non-Medical Devices, Occupational Safety and Health, Oncology, Ophthalmology Cardiology Consumer Products Dental Endocrinology Infectious Disease Licensing Medical Devices Non-Medical Devices Occupational Safety and Health Oncology Ophthalmology Hongwei Hsiao, John Powers, Peter Simeonov Improper positioning of an extension ladder frequently results in "ladder slide-outs," which are the most common cause of ladder-fall scenarios. This invention relates to an extension ladder positioning indicator which is easily installed in a ladder rung; provides multiple cues (visual, sound, and vibration) for rapidly identifying and positioning correct ladder inclination.<br /><br /> CDC-NIOSH researchers found that this technology improved accuracy and efficiency of ladder positioning for both "experienced" and "novice" ladder users, as compared to the "no instruction" method and the standard anthropometric method, and that it was also significantly faster than the bubble indicator method. When properly implemented, this effective and easy to use ladder positioning indicator will reduce the risk of extension ladder slipping and tipping and, ultimately, will reduce the number of fall incidents and injuries – benefitting construction workers, employers, contractors and workplace insurers. <ul> <li>Direct, multimodal user feedback reduces the time for accurate, safe ladder positioning compared to bubble-level indicator, anthropometric and sight- based ladder-positioning methods</li> <li>Visual, auditory and tactile feedback provide increased efficient-setup and safety</li> <li>Technology can be incorporated as an attachable, device which may be affixed to a ladder or integrated as an app for a mobile/tablet device</li> <li>Automated feedback ensures ladders are angled to OSHA and ANSI safety specifications</li> </ul> <ul> <li>Retrofitting existing ladders to provide automated, multisensory feedback for improved compliance with OSHA and ANSI ladder-angle safety guidelines</li> <li>Ladder manufacturing companies</li> <li>Construction contractors, retailers and insurers</li> <li>Training tool to aid worker safety education and adherence</li> </ul> 2022-03-27 2026-05-14 2026-05-14 2014-02-06 advanced ladder technology, AE1XXX, AE2AXX, AE2BXX, AE2XXX, AEXXXX, AFXXXX, apparatus, AXXXXX, CDC Docket Import, CDC Docket Import CDC Prosecuting, DEVICE, INDICATOR, LADDER, MULTIMODAL, NIOSH, NIOSH-DSR, Positioning, SAFETY, VPXXXX, WGXXXX, WMXXXX, XDXXXX, XIXXXX, YEXXXX, YFXXXX False True <ul> <li>In situ data available (on-site)</li> <li>Prototype</li> </ul> True 52406769 Prototype 52406769 NIHTT 37470483 Website Abstract 114172050 Simeonov P, et al. http://www.ncbi.nlm.nih.gov/pubmed/23177178 <a href="http://www.ncbi.nlm.nih.gov/pubmed/23177178">Simeonov P, et al.</a> 114108498 Hsiao, Hongwei CDC - NIOSH CDC Hsiao, Hongwei (CDC) 0 114108499 Powers, John CDC - NIOSH CDC Powers, John (CDC) 0 114108497 Simeonov, Peter CDC - NIOSH CDC Simeonov, Peter (CDC) 1 114108497 Simeonov, Peter CDC - NIOSH CDC Simeonov, Peter (CDC) 1 114108498 Hsiao, Hongwei CDC - NIOSH CDC Hsiao, Hongwei (CDC) 0 114108499 Powers, John CDC - NIOSH CDC Powers, John (CDC) 0 114102077 Multimodal Indicator Safety Device For Ladder Positioning E-141-2013-0 Filing authorized Centers for Disease Control and Prevention (CDC) 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2757] Extension-Ladder Safety: Multimodal-feedback Indicator for Improved Ladder Positioning Safety and Efficiency&body=Please send me information about technology [TAB-2757] Extension-Ladder Safety: Multimodal-feedback Indicator for Improved Ladder Positioning Safety and Efficiency. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2757] Extension-Ladder Safety: Multimodal-feedback Indicator for Improved Ladder Positioning Safety and Efficiency&body=Please send me information about technology [TAB-2757] Extension-Ladder Safety: Multimodal-feedback Indicator for Improved Ladder Positioning Safety and Efficiency.">yogikala.prabhu@nih.gov</a><br> 114167610 E-141-2013-0 E-141-2013-0-US-01 Multimodal Indicator Safety Device For Ladder Positioning ORD US 8,167,087 12/400,233 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8167087 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8167087">8,167,087</a><br />Filed on 2009-03-09<br />Status: Issued 114125118 AXXXXX 114125119 AEXXXX 114125120 AE1XXX 114125121 AE2XXX 114125122 AE2BXX 114125123 AE2AXX 114125124 AFXXXX 114125125 VPXXXX 114125126 WGXXXX 114125127 WMXXXX 114125128 XDXXXX 114125129 XIXXXX 114125130 YEXXXX 114125131 YFXXXX 114146395 MULTIMODAL 114146396 INDICATOR 114146397 SAFETY 114146398 DEVICE 114146399 LADDER 114146400 Positioning 114146401 CDC Docket Import 114146402 CDC Docket Import CDC Prosecuting 114146403 NIOSH-DSR 114146404 advanced ladder technology 114146405 apparatus 114146406 NIOSH TAB-2759 114096938 Physiologic Sampling Pump Capable of Rapidly Adapting to User Breathing Rate CDC Cardiology, Consumer Products, Dental, Diagnostics, Endocrinology, Infectious Disease, Licensing, Medical Devices, Non-Medical Devices, Occupational Safety and Health, Oncology, Ophthalmology, Therapeutics, Vaccines Cardiology Consumer Products Dental Diagnostics Endocrinology Infectious Disease Licensing Medical Devices Non-Medical Devices Occupational Safety and Health Oncology Ophthalmology Therapeutics Vaccines Michael Flemmer, Larry Lee This CDC developed physiologic sampling pump (PSP) overcomes shortcomings of previous devices by the use of calibrated valves in conjunction with a constant speed pump. This novel approach obviates typical PSP inertia that inherently limits system response, functionality and accuracy. All prior PSP designs have attempted to follow a user's breathing pattern by changing pump speed, thereby altering sampling rate. In that approach, pump inertia will limit system response and function due to the time required to adjust speed. Additionally, variable pump speeds often produce size selective sampling errors at low flow rates.<br /><br /> Performance of this PSP is not degraded by pump inertia or low flow size selective sampling errors. This design maintains a consistent pump speed, controlling PSP sampling rate with calibrated valves that redirect air flow almost instantaneously. In situ device testing demonstrated that when this air-flow valve is properly integrated into a sampling head, response time of the PSP is essentially mutually exclusive of the magnitude of changes in the effective flow, facilitating consistently small error in sampling performance regardless of user-exertion scenario. <ul> <li>Allows for air sampling to be modulated to follow breathing rate</li> <li>Design obviates the sluggishness inherent in prior art physiologic sampling pumps (PSPs) caused by variable pump speed effect on sampling rate</li> <li>Improved accuracy compared to earlier PSPs, irrelevant of user-exertion scenarios</li> <li>Follows inhalation on a breath-by-breath basis</li> </ul> <ul> <li>Air sampling device manufacturers</li> <li>Assessing airborne hazard exposures for workplace safety</li> <li>Industrial hygiene programs</li> <li>Respiration monitoring device for patients</li> <li>Aerobic training system for athletes</li> </ul> 2022-03-27 2026-05-14 2026-05-14 2014-02-06 BREATHING, Capable, CDC Docket Import, CDC Docket Import CDC Prosecuting, NIOSH-HELD, PHYSIOLOGIC, PSP, PUMP, RAPID, RESPONSE, Sampling, UNIVERSAL, VBXXXX, VPXXXX, WAXXXX, WBXXXX, WCXXXX, WEXXXX, WFXXXX, WGXXXX, WMXXXX, XDXXXX, XIXXXX, YEXXXX, YFXXXX False True <ul> <li>In situ data available (on-site)</li> <li>Prototype</li> </ul> True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114172052 Lee L, et al. http://www.ncbi.nlm.nih.gov/pubmed/19436860 <a href="http://www.ncbi.nlm.nih.gov/pubmed/19436860">Lee L, et al.</a> 114108506 Flemmer, Michael CDC - NIOSH CDC Flemmer, Michael (CDC) 0 114108505 Lee, Larry CDC - NIOSH CDC Lee, Larry (CDC) 1 114108505 Lee, Larry CDC - NIOSH CDC Lee, Larry (CDC) 1 114108506 Flemmer, Michael CDC - NIOSH CDC Flemmer, Michael (CDC) 0 114102079 A Universal Physiologic Sampling Pump (PSP) Capable Of Rapid Response To Breathing E-169-2013-0 Filing authorized Centers for Disease Control and Prevention (CDC) 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2759] Physiologic Sampling Pump Capable of Rapidly Adapting to User Breathing Rate&body=Please send me information about technology [TAB-2759] Physiologic Sampling Pump Capable of Rapidly Adapting to User Breathing Rate. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2759] Physiologic Sampling Pump Capable of Rapidly Adapting to User Breathing Rate&body=Please send me information about technology [TAB-2759] Physiologic Sampling Pump Capable of Rapidly Adapting to User Breathing Rate.">yogikala.prabhu@nih.gov</a><br> 114167613 E-169-2013-0 E-169-2013-0-US-01 Universal Physiologic Sampling Pump (PSP) Capable Of Rapid Response To Breathing PRV US 61/145,777 Abandoned US <br />Provisional (PRV) 61/145,777<br />Filed on 2010-01-20<br />Status: Abandoned 114167614 E-169-2013-0 E-169-2013-0-US-02 Universal Physiologic Sampling Pump (PSP) Capable Of Rapid Response To Breathing ORD US 8,459,098 12/690,550 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8459098 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8459098">8,459,098</a><br />Filed on 2010-01-20<br />Status: Issued 114125149 VBXXXX 114125150 VPXXXX 114125151 WAXXXX 114125152 WBXXXX 114125153 WCXXXX 114125154 WEXXXX 114125155 WFXXXX 114125156 WGXXXX 114125157 WMXXXX 114125158 XDXXXX 114125159 XIXXXX 114125160 YEXXXX 114125161 YFXXXX 114146417 UNIVERSAL 114146418 PHYSIOLOGIC 114146419 Sampling 114146420 PUMP 114146421 PSP 114146422 Capable 114146423 RAPID 114146424 RESPONSE 114146425 BREATHING 114146426 CDC Docket Import 114146427 CDC Docket Import CDC Prosecuting 114146428 NIOSH-HELD TAB-2760 114096939 Ultrasonic in situ Respirator Seal-Leakage Detection with Real-time Feedback Capabilities CDC Cardiology, Consumer Products, Dental, Diagnostics, Endocrinology, Infectious Disease, Licensing, Medical Devices, Non-Medical Devices, Occupational Safety and Health, Oncology, Ophthalmology, Research Materials, Therapeutics, Vaccines Cardiology Consumer Products Dental Diagnostics Endocrinology Infectious Disease Licensing Medical Devices Non-Medical Devices Occupational Safety and Health Oncology Ophthalmology Research Materials Therapeutics Vaccines William King, Jonathan Szalajda This CDC invention entails methods and apparatuses for <em>in situ</em> testing seal integrity and improved operation of respiratory masks (respirators). A variety of external factors, such as individual face shape, user environment, mask age and material used to construct the respirator, can lead to device malfunction and failure to sufficiently protect a user. To address these limitations, this invention relies on ultrasonic wave detection to assess face seal quality and other potential leak paths, as needed. Airborne ultrasound travel through atmosphere and will travel through respirator leaks. Applying this phenomena to occupational health and safety, CDC researchers have developed novel ultrasonics technology to identify and quantify respirator seal leakage in real-time. Small, low power consuming, and inexpensive apparatuses and methods for generating and detecting ultrasound may be easily obtained and customized for a given respirator and/or application.<br /><br /> By correlating user activity to seal sensor data, a precise understanding and awareness of respirator integrity may be obtained. When coupled with a subject alarm, these integrated values can immediately alert a user when a threshold of environmental exposure has been reached. Such real-time feedback will be invaluable to users in dangerous occupational activities, such as firefighters, biodefense and chemical spill first responders, mining applications, etc. Additionally, this invention possesses immense value for respirator mask manufacturers and workplace training programs for employees engaged in mandatory respirator usage applications. <ul> <li>Small, low power consuming, and inexpensive apparatuses and methods may be employed</li> <li>Real-time monitoring and feedback greatly diminish risk of user exposure to environmental hazards</li> </ul> <ul> <li>Manufacturers of respirators, leakage assessment devices and applied ultrasonic technology</li> <li>Regulators of respiratory protection plans</li> <li>Biohazard, biodefense and hazardous chemical handling and disposal</li> <li>Surgery/hospital training and use</li> </ul> 2022-03-27 2026-05-14 2026-05-14 2014-02-06 AE2XXX, AE3XXX, AEROSOL, AEROSOLS, AEXXXX, AXXXXX, Biodefense, CDC Docket Import, CDC Docket Import CDC Prosecuting, DEVICE, Devices, MASK, NIOSH-NPPTL, Preventative, PROCESS, Protection, Respirator, respiratory, SAFETY, Situ, TESTING, ultrasonic, VBXXXX, VJXXXX, VKXXXX, VLXXXX, VOXXXX, VPXXXX, WAXXXX, WCXXXX, WEXXXX, WFXXXX, WGXXXX, WIXXXX, WMXXXX, XDXXXX, XIXXXX, YEXXXX, YFXXXX False True <ul> <li>In situ data available (on-site)</li> <li>Prototype</li> </ul> True 52406769 Prototype 52406769 NIHTT 37470483 Website Abstract 114108508 Szalajda, Jonathan CDC - NIOSH CDC Szalajda, Jonathan (CDC) 0 114108507 King, William CDC - NIOSH CDC King, William (CDC) 1 114108507 King, William CDC - NIOSH CDC King, William (CDC) 1 114108508 Szalajda, Jonathan CDC - NIOSH CDC Szalajda, Jonathan (CDC) 0 114102080 Ultrasonic In Situ Respiratory Mask Testing Process And Mask E-174-2013-0 Closed Centers for Disease Control and Prevention (CDC) 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2760] Ultrasonic in situ Respirator Seal-Leakage Detection with Real-time Feedback Capabilities&body=Please send me information about technology [TAB-2760] Ultrasonic in situ Respirator Seal-Leakage Detection with Real-time Feedback Capabilities. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2760] Ultrasonic in situ Respirator Seal-Leakage Detection with Real-time Feedback Capabilities&body=Please send me information about technology [TAB-2760] Ultrasonic in situ Respirator Seal-Leakage Detection with Real-time Feedback Capabilities.">yogikala.prabhu@nih.gov</a><br> 114167615 E-174-2013-0 E-174-2013-0-US-01 Ultrasonic In Situ Respiratory Mask Testing Process And Mask PRV US 61/329,846 Abandoned US <br />Provisional (PRV) 61/329,846<br />Filed on 2012-04-30<br />Status: Abandoned 114167616 E-174-2013-0 E-174-2013-0-US-02 Ultrasonic In Situ Respiratory Mask Testing Process And Mask ORD US 8,573,199 13/098,980 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8573199 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8573199">8,573,199</a><br />Filed on 2011-05-02<br />Status: Abandoned 114125162 AEXXXX 114125163 AXXXXX 114125164 AE2XXX 114125165 AE3XXX 114125166 VBXXXX 114125167 VJXXXX 114125168 VKXXXX 114125169 VLXXXX 114125170 VOXXXX 114125171 VPXXXX 114125172 WAXXXX 114125173 WCXXXX 114125174 WEXXXX 114125175 WFXXXX 114125176 WGXXXX 114125177 WIXXXX 114125178 WMXXXX 114125179 XDXXXX 114125180 XIXXXX 114125181 YEXXXX 114125182 YFXXXX 114146429 ultrasonic 114146430 Situ 114146431 respiratory 114146432 MASK 114146433 TESTING 114146434 PROCESS 114146435 CDC Docket Import 114146436 CDC Docket Import CDC Prosecuting 114146437 NIOSH-NPPTL 114146438 AEROSOLS 114146439 AEROSOL 114146440 Preventative 114146441 Protection 114146442 SAFETY 114146443 Devices 114146444 DEVICE 114146445 Biodefense 114146446 Respirator TAB-2698 114096879 Nucleic Acid Detection of the Fungal Pathogen Histoplasma capsulatum from Clinical and Environmental Samples CDC Cardiology, Consumer Products, Dental, Diagnostics, Endocrinology, Infectious Disease, Licensing, Occupational Safety and Health, Oncology, Ophthalmology, Research Equipment, Research Materials, Therapeutics Cardiology Consumer Products Dental Diagnostics Endocrinology Infectious Disease Licensing Occupational Safety and Health Oncology Ophthalmology Research Equipment Research Materials Therapeutics Thomas Reid, Millie Schafer This invention relates to detecting <em>Histoplasma capsulatum</em> by PCR using oligonucleotide probes specific for the fungus. Histoplasmosis is a mycotic infection of varying severity, usually localized in the lungs. Caused by <em>H. capsulatum</em>, infections are usually symptomatic but can develop into chronic disease, especially in immunocompromised individuals.<br /><br /> Test samples may originate from the environment (soil, for example), where <em>H. capsulatum</em> spores are found or from clinical samples obtained from patients. Furthermore, the invention also provides for methods that detect the presence of <em>H. capsulatum</em> in a sample using a nested, or two-stage, PCR assay. <ul> <li>Rapid and precise</li> <li>Cost-effective</li> <li>Easily adapted for H. capsulatum detection kits</li> <li>Can positively identify small sample sizes of as few as 10 spores</li> <li>High-throughput capable</li> </ul> <ul> <li>Directing antifungal drug therapy for improved patient outcomes</li> <li>Occupational health and safety screening for workers who may encounter bird or bat waste</li> <li>Screening biological or soil samples for the presence of fungal pathogens</li> <li>Environment testing for immunocompromised patients</li> </ul> 2022-03-27 2026-05-14 2026-05-14 2013-12-23 AA5XXX, AAXXXX, AIDS, assay, Avian, AXXXXX, CAPSULATUM, CDC, CDC Docket Import, CDC Docket Import CDC Prosecuting, DA1XXX, DAXXXX, DETECTING, Detection, diagnostic, DXXXXX, FUNGAL, FUNGI, fungus, HISTOPLASMA, Histoplasmosis, HIV, Method, NESTED, NIOSH-DART, Nucleic, nucleic acid, NUCLEIC ACID DETECTION, PATHOGEN, PATHOGENIC, PATHOGENS, PCR, PCR ASSAY, RAPID, SENSITIVE, VKXXXX, VOXXXX, VPXXXX, WBXXXX, WCXXXX, WFXXXX, WGXXXX, WIXXXX, WMXXXX, XCXXXX, XEXXXX, XHXXXX, XIXXXX, YBXXXX, Zoo, Zoonotic False True In vitro data available True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract E-293-2013-0 E-332-2013-0 E-232-2013-0 E-335-2013-0 114171964 Reid TM, Schafer MP. https://www.ncbi.nlm.nih.gov/pubmed/10441199 <a href="https://www.ncbi.nlm.nih.gov/pubmed/10441199">Reid TM, Schafer MP.</a> 114171965 CDC Fact Sheet: Histoplasmosis https://www.cdc.gov/niosh/docs/2005-109/pdfs/2005-109FS.pdf <a href="https://www.cdc.gov/niosh/docs/2005-109/pdfs/2005-109FS.pdf">CDC Fact Sheet: Histoplasmosis</a> 114108324 Reid, Thomas CDC - NIOSH CDC Reid, Thomas (CDC) 0 114108325 Schafer, Millie CDC - NIOSH CDC Schafer, Millie (CDC) 1 114108325 Schafer, Millie CDC - NIOSH CDC Schafer, Millie (CDC) 1 114108324 Reid, Thomas CDC - NIOSH CDC Reid, Thomas (CDC) 0 114102008 RAPID AND SENSITIVE METHOD FOR DETECTING HISTOPLASMA CAPSULATUM E-313-2013-0 Closed Centers for Disease Control and Prevention (CDC) 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2698] Nucleic Acid Detection of the Fungal Pathogen Histoplasma capsulatum from Clinical and Environmental Samples&body=Please send me information about technology [TAB-2698] Nucleic Acid Detection of the Fungal Pathogen Histoplasma capsulatum from Clinical and Environmental Samples. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2698] Nucleic Acid Detection of the Fungal Pathogen Histoplasma capsulatum from Clinical and Environmental Samples&body=Please send me information about technology [TAB-2698] Nucleic Acid Detection of the Fungal Pathogen Histoplasma capsulatum from Clinical and Environmental Samples.">yogikala.prabhu@nih.gov</a><br> 114167422 E-313-2013-0 E-313-2013-0-US-01 RAPID AND SENSITIVE METHOD FOR DETECTING HISTOPLASMA CAPSULATUM PRV US 60/082,477 Abandoned US <br />Provisional (PRV) 60/082,477<br />Filed on 1998-04-21<br />Status: Abandoned 114167423 E-313-2013-0 E-313-2013-0-PCT-02 RAPID AND SENSITIVE METHOD FOR DETECTING HISTOPLASMA CAPSULATUM PCT Patent Cooperation Treaty PCT/US1999/008731 Expired Patent Cooperation Treaty <br />(PCT) PCT/US1999/008731<br />Filed on 1999-04-20<br />Status: Expired 114167424 E-313-2013-0 E-313-2013-0-US-05 RAPID AND SENSITIVE METHOD FOR DETECTING HISTOPLASMA CAPSULATUM National Stage US 6,469,156 09/673,298 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6469156 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6469156">6,469,156</a><br />Filed on 2001-01-12<br />Status: Expired 114124145 AXXXXX 114124146 AAXXXX 114124147 AA5XXX 114124148 DXXXXX 114124149 DAXXXX 114124150 DA1XXX 114124151 VKXXXX 114124152 VOXXXX 114124153 VPXXXX 114124154 WBXXXX 114124155 WCXXXX 114124156 WFXXXX 114124157 WGXXXX 114124158 WIXXXX 114124159 WMXXXX 114124160 XCXXXX 114124161 XEXXXX 114124162 XHXXXX 114124163 XIXXXX 114124164 YBXXXX 114145731 RAPID 114145732 SENSITIVE 114145733 Method 114145734 DETECTING 114145735 HISTOPLASMA 114145736 CAPSULATUM 114145737 nucleic acid 114145738 Nucleic 114145739 fungus 114145740 FUNGI 114145741 FUNGAL 114145742 PATHOGENS 114145743 CDC Docket Import 114145744 CDC Docket Import CDC Prosecuting 114145745 NIOSH-DART 114145746 PATHOGENIC 114145747 PATHOGEN 114145748 AIDS 114145749 HIV 114145750 Detection 114145751 diagnostic 114145752 assay 114145753 PCR ASSAY 114145754 PCR 114145755 Avian 114145756 Zoonotic 114145757 Zoo 114145758 Histoplasmosis 114145759 CDC 114145760 NUCLEIC ACID DETECTION 114145761 NESTED TAB-2709 114096888 Diisocyanate Specific Monoclonal Antibodies for Occupational and Environmental Monitoring of Polyurethane Production Exposure-related Asthma and Allergy and Clinical Diagnosis CDC Antibodies, Cardiology, Consumer Products, Dental, Dermatology, Diagnostics, Endocrinology, Immunology, Infectious Disease, Licensing, Occupational Safety and Health, Oncology, Ophthalmology, Pulmonology, Research Materials, Therapeutics Antibodies Cardiology Consumer Products Dental Dermatology Diagnostics Endocrinology Immunology Infectious Disease Licensing Occupational Safety and Health Oncology Ophthalmology Pulmonology Research Materials Therapeutics Donald Beezhold, Victor Johnson, Tinashe Ruwona, Detlef Schmechel, Paul Siegel CDC researchers have developed monoclonal antibodies useful as diagnostics for diisocyanate (dNCO) exposure and for toxicity characterization of specific dNCOs. Currently, dNCOs are used in the production of all polyurethane products and are the most commonly reported cause of occupational-induced asthma and also linked to allergic contact dermatitis. Presumptive diagnosis of dNCO asthma is presently dependent on criteria such as work history, report of work-related asthma-like symptoms and nonspecific airway reactivity to methacholine challenge. <br /><br /> This invention is a cost-effective, objective alternative for clinical assessment of occupational/environmental dNCO exposure in patient samples. These antibodies may also provide for passive-immunization and prevention of allergic contact dermatitis and/or asthma that can result from extended dermal exposure to dNCO contaminated surfaces and vapors. Further, the present technology allows for high-throughput testing of workplace dNCO air, fabric and working-surface contamination. <ul> <li>Ready for use in high-throughput immuno-histochemistry biomarker detection assays and kits.</li> <li>Two sandwich ELISAs have been developed and validated using human samples.</li> <li>Monitoring is currently performed by elaborate analytical chemical assays; this technology is more rapid and cost effective for dNCO exposure/contamination assessment.</li> <ul> <li>Occupational/environmental safety biomonitoring of polyurethane-worker/user exposure to diisocyanates(dNCOs).</li> <li>Clinical diagnostic use.</li> <li>dNCO-induced allergy/asthma prevention by passive immunization</li> </ul> 2022-03-27 2026-05-14 2026-05-14 2014-01-08 AAXXXX, AC5XXX, ACXXXX, AE2AXX, AE2CXX, AE2XXX, AE3XXX, AEXXXX, CDC Docket Import, CDC Docket Import CDC Prosecuting, Compositions, CONJUGATES, IA2XXX, IA3XXX, IA5XXX, IAXXXX, IDXXXX, Isocyanate, IXXXXX, Methods, NIOSH-HELD, Relating, VPXXXX, WCXXXX, WFXXXX, WGXXXX, WIXXXX, WJXXXX, WMXXXX, XAXXXX, XCXXXX, XIXXXX, YAXXXX, YBXXXX False True <ul> <li>Early-stage</li> </li>In vitro data available</li> </ul> True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114171975 Lemons AR, et al. http://www.ncbi.nlm.nih.gov/pubmed/24012971 <a href="http://www.ncbi.nlm.nih.gov/pubmed/24012971">Lemons AR, et al.</a> 114171976 Ruwona TB, et al. http://www.ncbi.nlm.nih.gov/pubmed/20568997 <a href="http://www.ncbi.nlm.nih.gov/pubmed/20568997">Ruwona TB, et al.</a> 114171977 Ruwona TB, et al. http://www.ncbi.nlm.nih.gov/pubmed/21878336 <a href="http://www.ncbi.nlm.nih.gov/pubmed/21878336">Ruwona TB, et al.</a> 114108359 Beezhold, Donald CDC - NIOSH CDC Beezhold, Donald (CDC) 0 114108360 Ruwona, Tinashe CDC - NIOSH CDC Ruwona, Tinashe (CDC) 0 114108361 Schmechel, Detlef CDC - NIOSH CDC Schmechel, Detlef (CDC) 0 114108362 Johnson, Victor CDC - NIOSH CDC Johnson, Victor (CDC) 0 114108358 Siegel, Paul CDC - NIOSH CDC Siegel, Paul (CDC) 1 114108358 Siegel, Paul CDC - NIOSH CDC Siegel, Paul (CDC) 1 114108359 Beezhold, Donald CDC - NIOSH CDC Beezhold, Donald (CDC) 0 114108360 Ruwona, Tinashe CDC - NIOSH CDC Ruwona, Tinashe (CDC) 0 114108361 Schmechel, Detlef CDC - NIOSH CDC Schmechel, Detlef (CDC) 0 114108362 Johnson, Victor CDC - NIOSH CDC Johnson, Victor (CDC) 0 114102018 Methods And Compositions Relating To Isocyanate Conjugates E-189-2013-0 Filing authorized Centers for Disease Control and Prevention (CDC) 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2709] Diisocyanate Specific Monoclonal Antibodies for Occupational and Environmental Monitoring of Polyurethane Production Exposure-related Asthma and Allergy and Clinical Diagnosis&body=Please send me information about technology [TAB-2709] Diisocyanate Specific Monoclonal Antibodies for Occupational and Environmental Monitoring of Polyurethane Production Exposure-related Asthma and Allergy and Clinical Diagnosis. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2709] Diisocyanate Specific Monoclonal Antibodies for Occupational and Environmental Monitoring of Polyurethane Production Exposure-related Asthma and Allergy and Clinical Diagnosis&body=Please send me information about technology [TAB-2709] Diisocyanate Specific Monoclonal Antibodies for Occupational and Environmental Monitoring of Polyurethane Production Exposure-related Asthma and Allergy and Clinical Diagnosis.">yogikala.prabhu@nih.gov</a><br> 114167449 E-189-2013-0 E-189-2013-0-US-01 Methods And Compositions Relating To Isocyanate Conjugates PRV US 61/104,429 Abandoned US <br />Provisional (PRV) 61/104,429<br />Filed on 2008-10-10<br />Status: Abandoned 114167450 E-189-2013-0 E-189-2013-0-US-02 Methods And Compositions Relating To Isocyanate Conjugates ORD US 8,828,667 12/577,241 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8828667 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8828667">8,828,667</a><br />Filed on 2009-10-12<br />Status: Issued 114124262 IXXXXX 114124263 IAXXXX 114124264 IA2XXX 114124265 IA3XXX 114124266 IA5XXX 114124267 IDXXXX 114124268 AAXXXX 114124269 ACXXXX 114124270 AC5XXX 114124271 AEXXXX 114124272 AE2XXX 114124273 AE2CXX 114124274 AE2AXX 114124275 AE3XXX 114124276 VPXXXX 114124277 WCXXXX 114124278 WFXXXX 114124279 WGXXXX 114124280 WIXXXX 114124281 WJXXXX 114124282 WMXXXX 114124283 XAXXXX 114124284 XCXXXX 114124285 XIXXXX 114124286 YAXXXX 114124287 YBXXXX 114145861 Methods 114145862 Compositions 114145863 Relating 114145864 Isocyanate 114145865 CONJUGATES 114145866 CDC Docket Import 114145867 CDC Docket Import CDC Prosecuting 114145868 NIOSH-HELD TAB-2710 114096889 Warning System for Mobile Machinery Hazardous Zones CDC Cardiology, Consumer Products, Dental, Endocrinology, Infectious Disease, Licensing, Medical Devices, Non-Medical Devices, Occupational Safety and Health, Oncology, Ophthalmology Cardiology Consumer Products Dental Endocrinology Infectious Disease Licensing Medical Devices Non-Medical Devices Occupational Safety and Health Oncology Ophthalmology Carl Ganoe, William Schiffbauer This invention relates to a warning system designed to protect individuals working near hazardous machinery. The system consists of a proximity-warning transmitter mounted to hazardous machinery and a receiver, worn by a worker, capable of detecting the transmitter signal. This worker-safety system can incorporate visual alerts and audible alerts. It also allows automatic shutdown of machinery upon receiver activation and may be particularly useful in the mining industry. <ul> <li>Easy transmitter installation</li> <li>Signal can be adjusted for an audio or visual "warning zone alert" and a proximal "imminent danger zone alert"</li> </ul> <ul> <li>Auxiliary safety equipment for heavy machinery</li> <li>Occupational health and safety</li> <li>Mining worker safety</li> </ul> 2022-03-27 2026-05-14 2026-05-14 2014-01-08 AE1CXX, AE1XXX, AE2BXX, AE2XXX, AEXXXX, AXXXXX, CDC Docket Import, CDC Docket Import CDC Prosecuting, HAZARDOUS, Machine, MOBILE, NIOSH-PRL, VPXXXX, WARNING, WEXXXX, WFXXXX, WGXXXX, WMXXXX, Working, XDXXXX, XIXXXX, YEXXXX, YFXXXX, ZONE False True <ul> <li>In situ data available (on-site)</li> <li>Prototype</li> </ul> True 52406769 Prototype 52406769 NIHTT 37470483 Website Abstract 114171978 Schiffbauer WH. http://www.ncbi.nlm.nih.gov/pubmed/10519790 <a href="http://www.ncbi.nlm.nih.gov/pubmed/10519790">Schiffbauer WH.</a> 114108364 Ganoe, Carl CDC - NIOSH CDC Ganoe, Carl (CDC) 0 114108363 Schiffbauer, William CDC - NIOSH CDC Schiffbauer, William (CDC) 1 114108363 Schiffbauer, William CDC - NIOSH CDC Schiffbauer, William (CDC) 1 114108364 Ganoe, Carl CDC - NIOSH CDC Ganoe, Carl (CDC) 0 114102019 MOBILE MACHINE HAZARDOUS WORKING ZONE WARNING E-239-2013-0 Closed Centers for Disease Control and Prevention (CDC) 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2710] Warning System for Mobile Machinery Hazardous Zones&body=Please send me information about technology [TAB-2710] Warning System for Mobile Machinery Hazardous Zones. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2710] Warning System for Mobile Machinery Hazardous Zones&body=Please send me information about technology [TAB-2710] Warning System for Mobile Machinery Hazardous Zones.">yogikala.prabhu@nih.gov</a><br> 114167451 E-239-2013-0 E-239-2013-0-US-01 MOBILE MACHINE HAZARDOUS WORKING ZONE WARNING SYSTEM ORD US 5,939,986 08/733,846 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/5939986 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/5939986">5,939,986</a><br />Filed on 1996-10-18<br />Status: Expired 114167452 E-239-2013-0 E-239-2013-0-US-02 MOBILE MACHINE HAZARDOUS WORKING ZONE WARNING DIV US 09/575,475 Abandoned US <br />Divisional (DIV) 09/575,475<br />Filed on 2000-05-19<br />Status: Abandoned 114124288 AXXXXX 114124289 AEXXXX 114124290 AE1XXX 114124291 AE1CXX 114124292 AE2XXX 114124293 AE2BXX 114124295 VPXXXX 114124296 WEXXXX 114124297 WFXXXX 114124298 WGXXXX 114124299 WMXXXX 114124300 XDXXXX 114124301 XIXXXX 114124302 YEXXXX 114124303 YFXXXX 114145869 MOBILE 114145870 Machine 114145871 HAZARDOUS 114145872 Working 114145873 ZONE 114145874 WARNING 114145875 CDC Docket Import 114145876 CDC Docket Import CDC Prosecuting 114145877 NIOSH-PRL TAB-2711 114096890 Personal Air Sampler for Collecting Airborne Aerosol Particulates for Molecular Analysis by Size CDC Consumer Products, Diagnostics, Infectious Disease, Licensing, Medical Devices, Non-Medical Devices, Occupational Safety and Health, Research Equipment, Therapeutics, Vaccines Consumer Products Diagnostics Infectious Disease Licensing Medical Devices Non-Medical Devices Occupational Safety and Health Research Equipment Therapeutics Vaccines Teh-Hsun Chen, Herbert Edgell, Jyoti Keswani This invention consists of a sampling apparatus that utilizes one or more cyclone separators to collect airborne particles from the atmosphere. The apparatus not only separates out aerosols from the atmosphere, but also serves as a collection tube for aerosol particles. Through its unique design, this CDC-developed apparatus is able to use the centrifugal force of the air flow on aerosolized particles forcing them to separate by size. Since the sample is collected directly in a microcentrifuge tube, in situ analysis of the ambient particulates can be performed. Analysis may include, but is not limited to, PCR, immunoassay analysis, microscopic spore counting, and counting colony-forming units. The device should also have many additional uses for environmental surveillance and occupational health applications. <ul> <li>Rapid, on-site sampling and analysis.</li> <li>Alternative to surface-sampling and culturing for aerosolized biological agents.</li> <li>Superior extraction efficiency compared to filters, impingers, and impactors.</li> <li>Real-world testing demonstrated device's ability to collect airborne mold and mycotoxins, pollen and pollen fragments, airborne dust particulates, as well as airborne influenza virus in a hospital environment.</li> </ul> <ul> <li>Analysis of ambient air particulates</li> <li>Environmental surveillance</li> <li>Occupational safety monitoring</li> <li>Biodefense</li> <li>Long-term exposure assessment</li> </ul> 2022-03-27 2026-05-14 2026-05-14 2014-01-08 AA2XXX, AA4XXX, AAXXXX, AE1XXX, AE2XXX, AE3XXX, AE4XXX, AEXXXX, AFXXXX, AIR, AXXXXX, CDC Docket Import, CDC Docket Import CDC Prosecuting, DEVICE, Method, NIOSH-HELD, Sampling, VBXXXX, VJXXXX, VKXXXX, VLXXXX, VOXXXX, WAXXXX, WBXXXX, WCXXXX, WEXXXX, WFXXXX, WGXXXX, WMXXXX, XDXXXX, XHXXXX, XIXXXX, YEXXXX, YFXXXX False True <ul> <li>In situ data available (on-site)</li> <li>Prototype</li> </ul> True 52406769 Prototype 52406769 NIHTT 37470483 Website Abstract 114171265 Chen BT, et al. http://dx.doi.org/10.1080/027868290511218 <a href="http://dx.doi.org/10.1080/027868290511218">Chen BT, et al.</a> 114171266 Macher JM, et al. http://www.ncbi.nlm.nih.gov/pubmed/18720289 <a href="http://www.ncbi.nlm.nih.gov/pubmed/18720289">Macher JM, et al.</a> 114171267 Macher JM, et al. http://www.ncbi.nlm.nih.gov/pubmed/18780236 <a href="http://www.ncbi.nlm.nih.gov/pubmed/18780236">Macher JM, et al.</a> 114171268 Su WC, et al. http://www.ncbi.nlm.nih.gov/pubmed/22833144 <a href="http://www.ncbi.nlm.nih.gov/pubmed/22833144">Su WC, et al.</a> 114171269 Wang CH, et al. http://www.ncbi.nlm.nih.gov/pubmed/25799419 <a href="http://www.ncbi.nlm.nih.gov/pubmed/25799419">Wang CH, et al.</a> 114171979 Lindsley WG, et al. http://www.ncbi.nlm.nih.gov/pubmed/17075620 <a href="http://www.ncbi.nlm.nih.gov/pubmed/17075620">Lindsley WG, et al.</a> 114171980 Blachere FM, et al. http://www.ncbi.nlm.nih.gov/pubmed/19453416 <a href="http://www.ncbi.nlm.nih.gov/pubmed/19453416">Blachere FM, et al.</a> 114171981 Lindsley WG, et al. http://www.ncbi.nlm.nih.gov/pubmed/21152051 <a href="http://www.ncbi.nlm.nih.gov/pubmed/21152051">Lindsley WG, et al.</a> 114171982 Cao G, et al. http://www.ncbi.nlm.nih.gov/pubmed/21975583 <a href="http://www.ncbi.nlm.nih.gov/pubmed/21975583">Cao G, et al.</a> 114171983 CDC-NIOSH Cyclone Bioaerosol Sampler webpage http://www.cdc.gov/niosh/topics/aerosols/biosampler.html <a href="http://www.cdc.gov/niosh/topics/aerosols/biosampler.html">CDC-NIOSH Cyclone Bioaerosol Sampler webpage</a> 114172037 NIOSH Personal Bioaerosol Cyclone Sampler video http://youtu.be/YHC0hw-DQTc <a href="http://youtu.be/YHC0hw-DQTc">NIOSH Personal Bioaerosol Cyclone Sampler video</a> 114108366 Keswani, Jyoti CDC - NIOSH CDC Keswani, Jyoti (CDC) 0 114108367 Edgell, Herbert CDC - NIOSH CDC Edgell, Herbert (CDC) 0 114108365 Chen, Teh-Hsun CDC - NIOSH CDC Chen, Teh-Hsun (CDC) 1 114108365 Chen, Teh-Hsun CDC - NIOSH CDC Chen, Teh-Hsun (CDC) 1 114108366 Keswani, Jyoti CDC - NIOSH CDC Keswani, Jyoti (CDC) 0 114108367 Edgell, Herbert CDC - NIOSH CDC Edgell, Herbert (CDC) 0 114102020 AIR SAMPLING DEVICE AND METHOD OF USE E-244-2013-0 Closed Centers for Disease Control and Prevention (CDC) 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2711] Personal Air Sampler for Collecting Airborne Aerosol Particulates for Molecular Analysis by Size&body=Please send me information about technology [TAB-2711] Personal Air Sampler for Collecting Airborne Aerosol Particulates for Molecular Analysis by Size. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2711] Personal Air Sampler for Collecting Airborne Aerosol Particulates for Molecular Analysis by Size&body=Please send me information about technology [TAB-2711] Personal Air Sampler for Collecting Airborne Aerosol Particulates for Molecular Analysis by Size.">yogikala.prabhu@nih.gov</a><br> 114167453 E-244-2013-0 E-244-2013-0-PCT-02 AIR SAMPLING DEVICE AND METHOD OF USE PCT Patent Cooperation Treaty PCT/US2004/032378 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2004/032378<br />Filed on 2004-10-01<br />Status: Expired 114167454 E-244-2013-0 E-244-2013-0-US-01 AIR SAMPLING DEVICE AND METHOD OF USE PRV US 60/512,252 Abandoned US <br />Provisional (PRV) 60/512,252<br />Filed on 2003-10-17<br />Status: Abandoned 114167455 E-244-2013-0 E-244-2013-0-US-03 AIR SAMPLING DEVICE AND METHOD OF USE National Stage US 7,370,543 10/575,048 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7370543 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7370543">7,370,543</a><br />Filed on 2006-04-04<br />Status: Abandoned 114167456 E-244-2013-0 E-244-2013-0-US-04 AIR SAMPLING DEVICE AND METHOD OF USE DIV US 8,205,511 12/152,156 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8205511 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8205511">8,205,511</a><br />Filed on 2008-05-12<br />Status: Abandoned 114124294 AXXXXX 114124304 AEXXXX 114124305 AE1XXX 114124306 AE2XXX 114124307 AE3XXX 114124308 AE4XXX 114124309 AFXXXX 114124310 AAXXXX 114124311 AA2XXX 114124312 AA4XXX 114124315 VBXXXX 114124316 VJXXXX 114124317 VKXXXX 114124318 VLXXXX 114124319 VOXXXX 114124320 WAXXXX 114124321 WBXXXX 114124322 WCXXXX 114124323 WEXXXX 114124324 WFXXXX 114124325 WGXXXX 114124326 WMXXXX 114124327 XDXXXX 114124328 XHXXXX 114124329 XIXXXX 114124330 YEXXXX 114124331 YFXXXX 114145878 AIR 114145879 Sampling 114145880 DEVICE 114145881 Method 114145882 CDC Docket Import 114145883 CDC Docket Import CDC Prosecuting 114145884 NIOSH-HELD TAB-2728 114096908 Non-radioactive, Miniature Bipolar Aerosol Particle Charger for Personal, Portable Instrumentation CDC Cardiology, Consumer Products, Dental, Diagnostics, Endocrinology, Infectious Disease, Licensing, Medical Devices, Non-Medical Devices, Occupational Safety and Health, Oncology, Ophthalmology, Research Materials, Therapeutics, Vaccines Cardiology Consumer Products Dental Diagnostics Endocrinology Infectious Disease Licensing Medical Devices Non-Medical Devices Occupational Safety and Health Oncology Ophthalmology Research Materials Therapeutics Vaccines Pramod Kulkarni, Chaolong Qi This CDC developed invention is a novel device for a miniature, nonradioactive bipolar charger to electrically charge aerosol particles for use in personal and portable aerosol instrumentation. Such devices are an integral component of aerosol instruments employing electrical mobility-based techniques. Current, commercial state-of-the-art mobility instruments employ aerosol chargers using radioactivity to achieve bipolar particle charging and, therefore, are not suitable for field-portable instruments. Due to strict regulatory restrictions on use of radioactive materials, these radioactive chargers also tend to be too bulky for use in compact aerosolization instruments. <p>This invention circumvents these two critical drawbacks by eliminating radioactivity and miniaturizing overall unit size (1x0.75 x 0.5 inch). Other unique aspects of the invention entail elimination of the need for additional air flows (other than the aerosol sample flow), minimal power consumption, a low per-unit cost, and simplicity of operation. In all, excellent transmission efficiency, steady-state charging characteristics and the miniature size make this bipolar particle charger well-suited for integration with portable or personal aerosol instrumentation.</p> <ul> <li>Non-radioactive; no associated regulatory or transportation issues</li> <li>Low-cost and requires very little power to operate</li> <li>Additional air flows other than sample airflow are unnecessary</li> <li>Unit is small (1x0.75x0.5in;2.54x1.91x1.27cm) and highly portable</li> <li>Eliminates a major barrier for reliable aerosol sampling using "bipolar charger + differential mobility analyzer + condensation particle detector" scheme in a compact device</li> </ul> <ul> <li>Personal and portable aerosol instrumentation</li> <li>Component of field-use device for determining workplace/environmental exposure to ultrafine aerosols and airborne nanoparticles</li> <li>Tool for environmental/occupational health, toxicology, workplace control evaluations and hazard identification involving aerosol exposure</li> </ul> 2022-03-27 2026-05-14 2026-05-14 2014-01-20 AA2XXX, AA4BXX, AAXXXX, AE1XXX, AE2BXX, AE2XXX, AE3XXX, AEROSOL, AEXXXX, AFXXXX, AGXXXX, AXXXXX, BIPOLAR, CDC Docket Import, CDC Docket Import CDC Prosecuting, Charger, NIOSH-DART, NON-RADIOACTIVE, PARTICLES, VBXXXX, VJXXXX, VKXXXX, VLXXXX, VOXXXX, VPXXXX, WAXXXX, WBXXXX, WCXXXX, WFXXXX, WGXXXX, WIXXXX, WMXXXX, XDXXXX, XIXXXX, YEXXXX False True In situ data available (on-site) True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114108415 Qi, Chaolong CDC - NIOSH CDC Qi, Chaolong (CDC) 0 114108414 Kulkarni, Pramod CDC - NIOSH CDC Kulkarni, Pramod (CDC) 1 114108414 Kulkarni, Pramod CDC - NIOSH CDC Kulkarni, Pramod (CDC) 1 114108415 Qi, Chaolong CDC - NIOSH CDC Qi, Chaolong (CDC) 0 114102044 Non-Radioactive Bipolar Charger For Aerosol Particles E-146-2013-0 Filing authorized Centers for Disease Control and Prevention (CDC) 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2728] Non-radioactive, Miniature Bipolar Aerosol Particle Charger for Personal, Portable Instrumentation&body=Please send me information about technology [TAB-2728] Non-radioactive, Miniature Bipolar Aerosol Particle Charger for Personal, Portable Instrumentation. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2728] Non-radioactive, Miniature Bipolar Aerosol Particle Charger for Personal, Portable Instrumentation&body=Please send me information about technology [TAB-2728] Non-radioactive, Miniature Bipolar Aerosol Particle Charger for Personal, Portable Instrumentation.">yogikala.prabhu@nih.gov</a><br> 114167500 E-146-2013-0 E-146-2013-0-US-01 Non-Radioactive Bipolar Charger For Aerosol Particles ORD US 8,611,066 13/315,344 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8611066 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8611066">8,611,066</a><br />Filed on 2011-12-09<br />Status: Issued 114124558 AXXXXX 114124559 AAXXXX 114124560 AEXXXX 114124561 AFXXXX 114124562 AGXXXX 114124563 AE1XXX 114124564 AE2XXX 114124565 AE2BXX 114124566 AE3XXX 114124567 AA2XXX 114124568 AA4BXX 114124569 VBXXXX 114124570 VJXXXX 114124571 VKXXXX 114124572 VLXXXX 114124573 VOXXXX 114124574 VPXXXX 114124575 WAXXXX 114124576 WBXXXX 114124577 WCXXXX 114124578 WFXXXX 114124579 WGXXXX 114124580 WIXXXX 114124581 WMXXXX 114124582 XDXXXX 114124583 XIXXXX 114124584 YEXXXX 114146051 BIPOLAR 114146052 NON-RADIOACTIVE 114146053 Charger 114146054 AEROSOL 114146055 PARTICLES 114146056 CDC Docket Import 114146057 CDC Docket Import CDC Prosecuting 114146058 NIOSH-DART TAB-2614 114096808 Monoclonal Antibodies for Detection of Stachybotrys chartarum (a Fungus) CDC Antibodies, Consumer Products, Diagnostics, Immunology, Infectious Disease, Licensing, Occupational Safety and Health, Research Materials Antibodies Consumer Products Diagnostics Immunology Infectious Disease Licensing Occupational Safety and Health Research Materials Daniel Lewis, Detlef Schmechel <p>CDC NIOSH researchers have developed a simple and rapid detection technique for <em>Stachybotrys chartarum</em> (a type of mold that commonly grows on wet building materials) by producing monoclonal antibodies which reacts with proteins in <em>Stachybotrys chartarum</em>. These antibodies can be used in immunologic detection assays to detect and possibly quantify <em>Stachybotrys chartarum</em> in environmental samples, and to our knowledge, they do not cross react with other fungi. The presence of mold in indoor environments has been associated with adverse health effects such as infections (in immunocompromised people) or allergies. Individuals with asthma or those with weaker immune systems can be affected more by mold exposure. Accurate detection methods are needed to measure mold contamination. Traditional methods for monitoring of molds are based on sample cultivation and microscopic analysis which can be time and labor intensive, and require expert classification skills. Immunoassays can potentially overcome these limitations and have been successfully developed for numerous biological aerosols. For more information on <em>Stachybotrys chartarum</em> and other molds, visit CDC&rsquo;s fact page:<a href="http://www.cdc.gov/mold/stachy.htm" target="_blank">&nbsp;www.cdc.gov/mold/stachy.htm</a>.</p> <ul> <li>Simple, rapid, and specific detection of <em>Stachybotrys chartarum</em></li> <li>Easily adaptable for kit format</li> <li>Less labor-intensive than spore counting or culturing</li> <li>Adaptable for high sample volumes (or throughputs) being processed</li> <li>Potential use in proteomics chip for screening multiple pathogens simultaneously</li> </ul> <ul> <li>Detection of <em>Stachybotrys chartarum</em> antigens in contaminated building materials or field environments with a color-changing dipstick assay</li> <li>Occupational health and home safety</li> </ul> 2022-03-27 2026-05-14 2026-05-14 2016-06-16 5/19/2016 -- per email from Karen Surabian, CDC is requesting that abstract be temporarily removed from the OTT website... --ecr 6/15/2016 -- updated abstract received from Karen Surabian, designated as Add... --ecr AE2CXX, AE2XXX, AE3XXX, AEXXXX, Against, antibodies, DA1XXX, FUNGI, Methods, monoclonal, Their, VKXXXX, VOXXXX, WCXXXX, WFXXXX, WGXXXX, WMXXXX, XAXXXX, XCXXXX, XIXXXX, YBXXXX, YEXXXX False True True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114108064 Lewis, Daniel CDC - NIOSH CDC Lewis, Daniel (CDC) 0 114108063 Schmechel, Detlef CDC - DIR CDC Schmechel, Detlef (CDC) 1 114108063 Schmechel, Detlef CDC - DIR CDC Schmechel, Detlef (CDC) 1 114108064 Lewis, Daniel CDC - NIOSH CDC Lewis, Daniel (CDC) 0 114101932 MONOCLONAL ANTIBODIES AGAINST FUNGI AND METHODS FOR THEIR USE E-224-2013-0 Research Material Centers for Disease Control and Prevention (CDC) 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2614] Monoclonal Antibodies for Detection of Stachybotrys chartarum (a Fungus)&body=Please send me information about technology [TAB-2614] Monoclonal Antibodies for Detection of Stachybotrys chartarum (a Fungus). Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2614] Monoclonal Antibodies for Detection of Stachybotrys chartarum (a Fungus)&body=Please send me information about technology [TAB-2614] Monoclonal Antibodies for Detection of Stachybotrys chartarum (a Fungus).">yogikala.prabhu@nih.gov</a><br> 114167199 E-224-2013-0 E-224-2013-0-PCT-02 MONOCLONAL ANTIBODIES AGAINST FUNGI AND METHODS FOR THEIR USE PCT Patent Cooperation Treaty PCT/US2002/025493 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2002/025493<br />Filed on 2002-08-09<br />Status: Expired 114167200 E-224-2013-0 E-224-2013-0-US-01 MONOCLONAL ANTIBODIES AGAINST FUNGI AND METHODS FOR THEIR USE PRV US 60/311,458 Abandoned US <br />Provisional (PRV) 60/311,458<br />Filed on 2001-08-10<br />Status: Abandoned 114167201 E-224-2013-0 E-224-2013-0-US-03 ANTIBODIES AGAINST STACHYBOTRYS CHARTARUM AND METHODS FOR THEIR USE National Stage US 7,368,256 10/483,921 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7368256 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7368256">7,368,256</a><br />Filed on 2004-01-14<br />Status: Expired 114121876 DA1XXX 114121877 VKXXXX 114121878 VOXXXX 114121879 WCXXXX 114121880 WFXXXX 114121881 WGXXXX 114121905 WMXXXX 114121906 XAXXXX 114121907 XCXXXX 114121908 XIXXXX 114121909 YBXXXX 114121910 YEXXXX 114123580 AE3XXX 114123581 AEXXXX 114123582 AE2CXX 114123586 AE2XXX 114144856 monoclonal 114144857 antibodies 114144858 Against 114144859 FUNGI 114144860 Methods 114144861 Their TAB-2623 114096817 Generation of Artificial Mutation Controls for Diagnostic Testing CDC Cardiology, Computational models/software, Consumer Products, Dental, Dermatology, Diagnostics, Endocrinology, Immunology, Infectious Disease, Licensing, Neurology, Oncology, Ophthalmology, Pulmonology, Research Materials, Software / Apps, Therapeutics Cardiology Computational models/software Consumer Products Dental Dermatology Diagnostics Endocrinology Immunology Infectious Disease Licensing Neurology Oncology Ophthalmology Pulmonology Research Materials Software / Apps Therapeutics Laurina Williams This technology relates to a method of generating artificial compositions that can be used as positive controls in a genetic testing assay, such as a diagnostic assay for a particular genetic disease. Such controls can be used to confirm the presence or absence of a particular genetic mutation. The lack of easily accessible, validated mutant controls has proven to be a major obstacle to the advancement of clinical molecular genetic testing, validation, quality control (QC), quality assurance (QA), and required proficiency testing. This method provides a consistent and renewable source of positive control material, as well as an alternative to patient-derived mutation-positive samples. <ul> <li>Positive controls can be included in new kits or packaged with pre-existing assays</li> <li>Increased accuracy in diagnosis compared to current controls</li> <li>Consistent and renewable source for high-quality controls containing mutations of interest</li> </ul> <ul> <li>Generation of positive controls for molecular genetic tests, particularly for tests to detect cystic fibrosis</li> </ul> Various international patent applications pending or issued. 2022-10-19 2026-05-14 2026-05-14 2013-08-23 AA1XXX, AA5XXX, AA6XXX, AAXXXX, ARTIFICIAL, AXXXXX, CA1AXX, CA1CXX, CA1XXX, CAXXXX, controls, CXXXXX, diagnostic, GAXXXX, GCXXXX, GXXXXX, IA1BXX, IA2XXX, IA3XXX, IA5XXX, IAXXXX, IXXXXX, MUTATION, NA2XXX, OA2XXX, TESTING, VPXXXX, WBXXXX, WHXXXX, WIXXXX, WMXXXX, XBXXXX, XCXXXX, XEXXXX, YAXXXX, YBXXXX False True </ul> <li>Early-stage</li> <li>In vitro data available</li> </ul> True 52406768 Discovery 52406768 NIHTT 37470483 Website Abstract 114108095 Williams, Laurina CDC - DIR CDC Williams, Laurina (CDC) 0 114108095 Williams, Laurina CDC - DIR CDC Williams, Laurina (CDC) 0 114101941 Artificial Mutation Controls For Diagnostic Testing E-255-2013-0 Closed Centers for Disease Control and Prevention (CDC), University of California, Los Angeles (UCLA) 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2623] Generation of Artificial Mutation Controls for Diagnostic Testing&body=Please send me information about technology [TAB-2623] Generation of Artificial Mutation Controls for Diagnostic Testing. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2623] Generation of Artificial Mutation Controls for Diagnostic Testing&body=Please send me information about technology [TAB-2623] Generation of Artificial Mutation Controls for Diagnostic Testing.">yogikala.prabhu@nih.gov</a><br> 114167219 E-255-2013-0 E-255-2013-0-PCT-02 Artificial Mutation Controls For Diagnostic Testing PCT Patent Cooperation Treaty PCT/US2005/008108 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2005/008108<br />Filed on 2005-03-11<br />Status: Expired 114167220 E-255-2013-0 E-255-2013-0-US-01 Artificial Mutation Controls For Diagnostic Testing PRV US 60/552,979 Abandoned US <br />Provisional (PRV) 60/552,979<br />Filed on 2004-03-11<br />Status: Abandoned 114167221 E-255-2013-0 E-255-2013-0-US-08 Artificial Mutation Controls For Diagnostic Testing National Stage US 8,603,745 10/598,589 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8603745 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8603745">8,603,745</a><br />Filed on 2006-09-05<br />Status: Abandoned 114123649 AXXXXX 114123650 AAXXXX 114123651 AA1XXX 114123652 AA5XXX 114123653 AA6XXX 114123654 CXXXXX 114123655 CAXXXX 114123656 CA1XXX 114123657 CA1AXX 114123658 CA1CXX 114123659 GAXXXX 114123660 GXXXXX 114123661 GCXXXX 114123662 IXXXXX 114123663 IAXXXX 114123664 IA1BXX 114123665 IA3XXX 114123666 IA2XXX 114123667 IA5XXX 114123668 NA2XXX 114123669 OA2XXX 114125360 VPXXXX 114125361 WBXXXX 114125362 WHXXXX 114125363 WIXXXX 114125364 WMXXXX 114125365 XBXXXX 114125366 XCXXXX 114125367 XEXXXX 114125368 YAXXXX 114125369 YBXXXX 114144941 ARTIFICIAL 114144942 MUTATION 114144943 controls 114144944 diagnostic 114144945 TESTING TAB-5085 164394726 Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions NCI Collaboration, Diagnostics, Immunology, Infectious Disease, Licensing, Oncology, Therapeutics Collaboration Diagnostics Immunology Infectious Disease Licensing Oncology Therapeutics Swati Choksi, Zheng-gang Liu, Yeon-Ji Park, PeiXing Wan <h2>Summary:</h2> <p>Scientists at the National Cancer Institute (NCI) have discovered a novel therapeutic, diagnostic and prognostic target for thrombosis: Soluble Tissue Factor (sTF). NCI has generated first-in-class antibodies and platform selectively neutralizing pathological coagulation while preserving normal hemostasis. This platform technology can be used to prevent, diagnose and treat pathological thrombosis caused by a variety of clinical conditions-including cancer, sepsis, infectious diseases (e.g., COVID), autoimmune disorders, trauma, heart conditions and inflammatory conditions. It offers a much more sensitive and specific test of thrombosis than the current D-dimer test. It may be applicable to any clinical condition which induces necroptosis, pyroptosis and NETosis, such as cancer, neurodegenerative disease, ischemia-reperfusion and acute injuries, traumatic injuries, bacterial and viral infections, cardiovascular conditions, and atherosclerosis, inflammatory, autoimmune conditions,<span style="font-size:11.0pt"> and others.&nbsp;&nbsp;&nbsp; </span></p> <h2>Description of Technology:</h2> <p><span style="font-size:11.0pt">Investigators at the National Cancer Institute (NCI) have identified and therapeutically validated a distinctive, disease-restricted driver of thrombosis: soluble tissue factor (sTF). sTF is generated through proteolytic cleavage during inflammatory cell death.</span></p> <p><span style="font-size:11.0pt">Mechanistically, the researchers demonstrated that sTF generation is not limited to necroptosis but represents a conserved outcome of multiple inflammatory cell death pathways, including pyroptosis and NETtosis.</span></p> <p><span style="font-size:11.0pt">Pathological thrombosis remains a leading cause of morbidity and mortality in sepsis, cancer, autoimmune diseases, viral infections, and inflammatory disorders. Current anticoagulant and thrombosis treatments options such as Heparins and Warfarin are effective at reducing clot formation, but act indiscriminately on the coagulation cascade, disrupt normal hemostasis, and are associated with significant bleeding risk. Current thrombosis diagnostics, D-dimer, a fibrin degradation byproduct, is a late stage marker that lacks sensitivity. This invention provides an alternative for early detection based on sTF that is more sensitive and specific. </span></p> <p><span style="font-size:11.0pt">To selectively target this mechanism, the team developed novel humanized monoclonal antibodies (e.g., 58B3 and 56E5) that specifically recognize human soluble tissue factor (hsTF), but not full-length membrane-bound tissue factor (flTF). This selectivity preserves physiological hemostasis while inhibiting pathological coagulation.</span></p> <p><span style="font-size:11.0pt">In vivo validation using human samples of various clinical diseases demonstrated that administration of sTF-specific antibodies prevents fibrinogen depletion and reduces thrombin&ndash;antithrombin (TAT) complex elevation, effectively normalizing coagulation parameters. These results establish proof of concept that selective sTF neutralization can block pathological thrombosis without systemic anticoagulation.</span></p> <p><span style="font-size:11.0pt">By establishing sTF as a unifying mechanistic link between inflammatory cell death and thrombosis across sepsis, cancer, infection, autoimmune disease, cardiovascular disorders, and metabolic inflammation, this antibody platform represents a first-in-class strategy to selectively inhibit pathological coagulation while preserving normal hemostasis. The approach offers a safer, more precise therapeutic and diagnostic alternative to conventional anticoagulants.</span></p> <p><span style="font-size:11.0pt">The humanized monoclonal antibodies, as well as methods of using sTF as a target for diagnosis, treatment and prevention of thrombosis and associated diseases are available for licensing or collaborative development to advance clinical translation. Partnership opportunities include preclinical optimization, clinical development, and diagnostic assay co-development.</span></p> <h2>Potential Commercial Applications:</h2> <ul> <li><span style="tab-stops:list .5in"><span style="text-autospace:ideograph-numeric ideograph-other"><span style="font-size:11.0pt">Diagnostic tool for early detection and monitoring of sTF in plasma.</span></span></span><span style="tab-stops:list .5in"><span style="text-autospace:ideograph-numeric ideograph-other"><span style="font-size:11.0pt">Diagnostic tool for early detection and monitoring of thrombosis, </span>much more sensitive and specific test than the currently used D-dimer test<span style="font-size:11.0pt">.</span></span></span></li> <li><span style="tab-stops:list .5in"><span style="text-autospace:ideograph-numeric ideograph-other"><span style="font-size:11.0pt">Basis for diagnostic kits such as ELISA and point-of-care assays.</span></span></span></li> <li><span style="tab-stops:list .5in"><span style="text-autospace:ideograph-numeric ideograph-other"><span style="font-size:11.0pt">Diagnostic tool for early detection of DVT and PE with radiolabeled anti-sTF antibody in combination with ultrasound /CT scan </span></span></span></li> <li><span style="tab-stops:list .5in"><span style="text-autospace:ideograph-numeric ideograph-other"><span style="font-size:11.0pt">Therapeutic use </span><span style="font-size:11.0pt">for sepsis-associated thrombosis.</span></span></span></li> <li><span style="tab-stops:list .5in"><span style="text-autospace:ideograph-numeric ideograph-other"><span style="font-size:11.0pt">Therapeutic use for cancer-associated thrombosis.</span></span></span></li> <li><span style="tab-stops:list .5in"><span style="text-autospace:ideograph-numeric ideograph-other"><span style="font-size:11.0pt">Therapeutic use viral infection&ndash;associated thrombosis. </span></span></span></li> <li><span style="tab-stops:list .5in"><span style="text-autospace:ideograph-numeric ideograph-other"><span style="font-size:11.0pt">Therapeutic use autoimmune disorders.</span></span></span></li> <li><span style="tab-stops:list .5in"><span style="text-autospace:ideograph-numeric ideograph-other"><span style="font-size:11.0pt">Therapeutic use cardiovascular inflammatory diseases.</span></span></span></li> <li><span style="tab-stops:list .5in"><span style="text-autospace:ideograph-numeric ideograph-other"><span style="font-size:11.0pt">Therapeutic use </span><span style="font-size:11.0pt">for acute lung injury including <span style="background-color:white"><span style="color:#0a0a0a">Acute Respiratory Distress Syndrome ARD.</span></span></span></span></span></li> <li><span style="tab-stops:list .5in"><span style="text-autospace:ideograph-numeric ideograph-other"><span style="font-size:11.0pt">Therapeutic use for metabolic and vascular inflammatory diseases</span></span></span></li> <li><span style="tab-stops:list .5in"><span style="text-autospace:ideograph-numeric ideograph-other"><span style="font-size:11.0pt">Therapeutic use for high efficient inhibition of thrombosis with anti-sTF-based bispecific antibodies. </span></span></span></li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Selective targeting of pathological soluble tissue factor (sTF).</li> <li>Preservation of normal hemostasis.</li> <li>Potential for long-acting biologic prevention.</li> <li>Specific mechanism-based intervention tied to inflammatory cell death.</li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for developing diagnostic, prognostic, preventative and therapeutic development of sTF. NCI is seeking collaborators with Access to clinical samples of thrombosis, and with experience of in vivo detection of thrombosis (e.g. DVT) in patients with current tools. Also seeking collaborators with experience in developing bi-specific antibodies. 2025-09-29 2026-05-12 2026-05-07 2026-05-12 2025-09-29 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2026-05-07 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 164395085 Wan, P., Choksi, S., Park, YJ. et al. Soluble tissue factor generated by necroptosis-triggered shedding is responsible for thrombosis. Cell Res 35, 840–858 (2025). https://doi.org/10.1038/s41422-025-01167-8 Wan, P., Choksi, S., Park, YJ. et al. Soluble tissue factor generated by necroptosis-triggered shedding is responsible for thrombosis. Cell Res 35, 840–858 (2025). https://doi.org/10.1038/s41422-025-01167-8 167182477 Yan J, Wan P, Choksi S, Liu ZG. Necroptosis and tumor progression. Trends Cancer. 2022 Jan;8(1):21-27. doi: 10.1016/j.trecan.2021.09.003. Yan J, Wan P, Choksi S, Liu ZG. Necroptosis and tumor progression. Trends Cancer. 2022 Jan;8(1):21-27. doi: 10.1016/j.trecan.2021.09.003. 164394956 Liu, Zheng-gang NIH - NCI NCI Liu, Zheng-gang (NCI) 1 164394984 Choksi, Swati NIH - NCI NCI Choksi, Swati (NCI) 2 164395025 Wan, PeiXing NIH - NCI NCI Wan, PeiXing (NCI) 3 167182419 Park, Yeon-Ji NIH - NCI NCI Park, Yeon-Ji (NCI) 4 164394956 Liu, Zheng-gang NIH - NCI NCI Liu, Zheng-gang (NCI) 1 164394984 Choksi, Swati NIH - NCI NCI Choksi, Swati (NCI) 2 164395025 Wan, PeiXing NIH - NCI NCI Wan, PeiXing (NCI) 3 167182419 Park, Yeon-Ji NIH - NCI NCI Park, Yeon-Ji (NCI) 4 164394729 The soluble Tissue Factor generated by necroptosis-triggered shedding of the cell surface TF is responsible for septic shock and viral infection-induced thrombosis E-263-2023-0 Filing authorized National Institute on Alcohol Abuse and Alcoholism (NIAAA), NCI - CCR, NIH - NCI 83683663 Cremesti, Aida aida.cremesti@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB aida.cremesti@nih.gov?subject=Web Inquiry on [TAB-5085] Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions&body=Please send me information about technology [TAB-5085] Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Cremesti, Aida<br><a href="mailto:aida.cremesti@nih.gov?subject=Web Inquiry on [TAB-5085] Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions&body=Please send me information about technology [TAB-5085] Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">aida.cremesti@nih.gov</a><br> 164394734 E-263-2023-0 E-263-2023-0-US-01 HUMANIZED ANTIBODIES SPECIFIC AGAINST SOLUBLE TISSUE FACTOR PRV US 63/783,685 Expired US <br />Provisional (PRV) 63/783,685<br />Filed on 2025-04-04<br />Status: Expired 166015111 E-263-2023-0 E-263-2023-0-PC-01 SOLUBLE TISSUE FACTOR, A NOVEL TARGET, AND ANTIBODIES, FOR DIAGNOSIS, PREVENTION AND TREATMENT OF THROMBOSIS AND RELATED CONDTIONS PCT Patent Cooperation Treaty PCT/US2026/022285 Pending Patent Cooperation Treaty <br />(PCT) PCT/US2026/022285<br />Filed on 2026-04-03<br />Status: Pending TAB-3930 147157210 Novel Furoquinolinediones as Inhibitors of TDP2 and Their Potential Use to Treat Cancer NCI Licensing, Oncology, Therapeutics Licensing Oncology Therapeutics Lin-kun An, Christophe Marchand, Yves Pommier <h2>Summary:</h2> <p>The National Cancer Institute (NCI) seeks licensees for a family of novel furoquinolinedione derivatives that inhibit tyrosyl-DNA phosphodiesterase 2 (TDP2) as cancer therapeutics. &nbsp;&nbsp;</p> <h2>Description of Technology:</h2> <p>Tyrosyl-DNA phosphodiesterase 2 (TDP2) is an enzyme that plays a critical role in repairing nucleic acid lesions, namely by repairing trapped DNA cleavage complexes. TDP2 repairs topoisomerase (TOP2)-mediated DNA damage induced by chemotherapeutic agents and removes endogenous TOP2-DNA cleavage complexes. Further, TDP2 deficiency potentiates the antiproliferative activity of TOP2 inhibitors. This suggest that combination therapies consisting of TDP2 and TOP2 inhibitors have a synergistic effect on tumor tissues. Therefore, TDP2 represents a promising anti-cancer pharmacological target as a monotherapy or part of a combination therapy.</p> <p>The NCI investigators and their collaborators have discovered a series of novel furoquinolinedione derivatives as specific TDP2 inhibitors that could act as anti-cancer therapeutics alone and/or potentiate the pharmacological action of TOP2 inhibitors. Systematic structure-activity relationship studies were conducted and demonstrated that several furoquinolinedione derivatives had TDP2 inhibitory activity in the low micromolar or submicromolar range and act in a dose-dependent manner. Further, enzyme-based assays showed the furoquinolinedione derivatives are specific to TDP2 and showed no inhibitory activity against TDP1 and TOP1.</p> <p>NCI is seeking licensees to further develop this family of compounds as anti-cancer agents. &nbsp;</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Standalone cancer therapeutic</li> <li>Part of a combination cancer therapeutic with other drugs, such as TOP2 inhibitors</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Potential first-in-class drug (novel mechanism of action and novel composition of matter)</li> <li>Selective inhibition of TDP2</li> <li>Can be used alone or in combination with TOP2 inhibitors</li> <li>Synergistic effect to boost the efficacy of TOP2 inhibitors (decrease effective dosage, minimize side effects)</li> <li>Potential for use across many cancer types</li> </ul> Researchers at the NCI seek licensing for a family of novel furoquinolinedione derivatives that inhibit tyrosyl-DNA phosphodiesterase 2 (TDP2) as cancer therapeutics 2017-10-23 2026-05-11 2026-01-13 2026-05-11 2017-10-23 CANCER, Combination Therapies, Pommier, therapeutic, Topoisomerase 2 (TOP2), Tyrosyl-DNA Phosphodiesterase 2 (TDP) Inhibitors False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2026-01-13 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147162094 Yang, H., et al. The synthesis of furoquinolinedione and isoxazoloquinolinedione derivatives as selective Tyrosyl-DNA phosphodiesterase 2 (TDP2) inhibitors. (PMID 33839584) https://pubmed.ncbi.nlm.nih.gov/33839584/ <a href="https://pubmed.ncbi.nlm.nih.gov/33839584/">Yang, H., et al. The synthesis of furoquinolinedione and isoxazoloquinolinedione derivatives as selective Tyrosyl-DNA phosphodiesterase 2 (TDP2) inhibitors. (PMID 33839584)</a> 147162172 Yu, L.-M., et al. Synthesis and structure-activity relationship of furoquinolinediones as inhibitors of Tyrosyl-DNA phosphodiesterase 2 (TDP2). (PMID 29677635). https://pubmed.ncbi.nlm.nih.gov/29677635/ <a href="https://pubmed.ncbi.nlm.nih.gov/29677635/">Yu, L.-M., et al. Synthesis and structure-activity relationship of furoquinolinediones as inhibitors of Tyrosyl-DNA phosphodiesterase 2 (TDP2). (PMID 29677635).</a> 147162905 Marchand, Christophe NIH - NCI NCI Marchand, Christophe (NCI) 1 147162906 An, Lin-kun Lin-Kun An (SYSU) An, Lin-kun 2 147162904 Pommier, Yves NIH - NCI NCI Pommier, Yves (NCI) 3 147162905 Marchand, Christophe NIH - NCI NCI Marchand, Christophe (NCI) 1 147162906 An, Lin-kun Lin-Kun An (SYSU) An, Lin-kun 2 147162904 Pommier, Yves NIH - NCI NCI Pommier, Yves (NCI) 3 147158307 Furoquinolinedione Derivatives As Tyrosyl-DNA Phosphodiesterase 2 (TDP2) Inhibitors E-275-2014-0 Filing authorized NCI, Sun Yat-sen University 91826910 McCrary, Michaela michaela.mccrary@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America michaela.mccrary@nih.gov?subject=Web Inquiry on [TAB-3930] Novel Furoquinolinediones as Inhibitors of TDP2 and Their Potential Use to Treat Cancer&body=Please send me information about technology [TAB-3930] Novel Furoquinolinediones as Inhibitors of TDP2 and Their Potential Use to Treat Cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov McCrary, Michaela<br><a href="mailto:michaela.mccrary@nih.gov?subject=Web Inquiry on [TAB-3930] Novel Furoquinolinediones as Inhibitors of TDP2 and Their Potential Use to Treat Cancer&body=Please send me information about technology [TAB-3930] Novel Furoquinolinediones as Inhibitors of TDP2 and Their Potential Use to Treat Cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">michaela.mccrary@nih.gov</a><br> 147161252 E-275-2014-0 E-275-2014-0-CA-04 Furoquinolinedione As Inhibitors Of TDP2 National Stage Canada 2973484 2973484 Issued Canada <br />National Stage 2973484<br />Filed on 2016-01-08<br />Status: Issued 147165346 E-275-2014-0 E-275-2014-0-US-01 FUROQUINOLINEDIONES AS INHIBITORS OF TDP2 PRV US 62/100,968 Abandoned US <br />Provisional (PRV) 62/100,968<br />Filed on 2015-01-08<br />Status: Abandoned 147165347 E-275-2014-0 E-275-2014-0-PCT-02 Furoquinolinedione As Inhibitors Of TDP2 PCT Patent Cooperation Treaty PCT/US2016/012672 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2016/012672<br />Filed on 2016-01-08<br />Status: Expired 147165348 E-275-2014-0 E-275-2014-0-AU-03 Furoquinolinedione As Inhibitors Of TDP2 National Stage Australia 2016205137 2016205137 Issued Australia <br />National Stage 2016205137<br />Filed on 2016-01-08<br />Status: Issued 147165349 E-275-2014-0 E-275-2014-0-EP-05 Furoquinolinedione As Inhibitors Of TDP2 National Stage European Patent 3242881 16703001.4 Issued European Patent <br />National Stage 16703001.4<br />Filed on 2016-01-08<br />Status: Issued 147165350 E-275-2014-0 E-275-2014-0-US-06 FUROQUINOLINEDIONES AS INHIBITORS OF TDP2 National Stage US 10,906,914 15/542,560 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10906914 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10906914">10,906,914</a><br />Filed on 2017-07-10<br />Status: Issued 147165351 E-275-2014-0 E-275-2014-0-CN-07 Furoquinolinedione As Inhibitors Of TDP2 National Stage China ZL201680014742.7 201680014742.7 Issued China <br />National Stage 201680014742.7<br />Filed on 2016-01-08<br />Status: Issued 147165352 E-275-2014-0 E-275-2014-0-DE-08 Furoquinolinedione As Inhibitors Of TDP2 EP Germany 3242881 16703001.4 Issued Germany <br />European patent (EP) 16703001.4<br />Filed on 2016-01-08<br />Status: Issued 147165353 E-275-2014-0 E-275-2014-0-FR-09 Furoquinolinedione As Inhibitors Of TDP2 EP France 3242881 16703001.4 Issued France <br />European patent (EP) 16703001.4<br />Filed on 2016-01-08<br />Status: Issued 147165354 E-275-2014-0 E-275-2014-0-GB-10 Furoquinolinedione As Inhibitors Of TDP2 EP United Kingdom 3242881 16703001.4 Issued United Kingdom <br />European patent (EP) 16703001.4<br />Filed on 2016-01-08<br />Status: Issued 147165355 E-275-2014-0 E-275-2014-0-CN-11 Furoquinolinedione As Inhibitors Of TDP2 DIV China ZL202110013140.2 202110013140.2 Issued China <br />Divisional (DIV) 202110013140.2<br />Filed on 2016-01-08<br />Status: Issued 147165356 E-275-2014-0 E-275-2014-0-US-12 FUROQUINOLINEDIONES AS INHIBITORS OF TDP2 CON US 11,999,747 17/146,327 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11999747 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11999747">11,999,747</a><br />Filed on 2021-01-11<br />Status: Issued 147174535 CANCER 147174537 Combination Therapies 147174538 Pommier 147174539 therapeutic 147174541 Topoisomerase 2 (TOP2) 147174543 Tyrosyl-DNA Phosphodiesterase 2 (TDP) Inhibitors TAB-4990 157143819 Suppression Of Uveitis By A STAT3 Single Domain Antibody NEI Application, Collaboration, Ear, Nose, & Throat, Licensing, Neurology, Therapeutics Application Collaboration Ear Nose & Throat Licensing Neurology Therapeutics Charles Egwuagu, Sunanda Singh <h2>Summary:&nbsp;</h2> <p>The National Eye Institute seeks research co-development partners and/or licensees for a STAT3 antibody that can suppress uveitis.</p> <h2>Description of Technology:</h2> <p>&nbsp;Uveitis is caused by inflammation in the eye that causes pain and reduce vision in affected patients. Rates of uveitis in the United States occurs 1 in every 200 people with eye-related irritation. Permanent damage, such as vision loss, occurs if uveitis goes untreated. Prolonged use of drugs that help treat chronic uveitis, such as periocular or intravitreal corticosteroid injections, can cause serious side-effects such as glaucoma. Therefore, finding alternative treatments for uveitis is an imperative.&nbsp;</p> <p>Signal transducers and activators of transcription-3 (STAT3) regulates the differentiation of pathogenic Th17 lymphocyte cells implicated in several autoimmune diseases. Genetically modified mice incapable of inducing Th17 cells are resistant to developing uveitis. Therefore, targeting the STAT3 pathway required for the differentiation and expansion of Th17 cells has been proposed as a potential therapy for mitigating uveitis. However, the major impediment to therapeutically target intracellular proteins &ndash; such as STAT3 &ndash; is the inability to deliver inhibitors inside cells.&nbsp;</p> <p>Scientists at the NEI have discovered a novel STAT3-specific nanobody (SBT-100) that can cross the blood-retina-barrier (BRB), inhibit pathogenic Th17 lymphocytes and suppress experimental autoimmune uveitis (EAU). The antibody&rsquo;s small size, rapid clearance from the blood and sequence similarity with mammalian STAT3 render SBT-100 non-immunogenic. These factors provide important advantages for its therapeutic use not only for chronic uveitis, but also for inflammatory diseases like multiple sclerosis.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Therapeutic for uveitis</li> <li>Therapeutic for multiple sclerosis</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Non-immunogenic compared to current uveitis treatments</li> <li>Novel STAT3-specific nanobody</li> <li>Crosses the blood-retina-barrier (BRB)</li> <li>Rapid blood clearance</li> <li>Sequence similarity with mammalian STAT3</li> <li>Potential multi-use for central nervous system autoimmune diseases and other autoinflammatory diseases</li> </ul> Researchers at the NEI seek licensing and/or co-development research collaborations for a STAT3 antibody that can suppress uveitis. 2024-07-17 2026-04-16 2026-05-06 2024-07-18 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 157173612 Egwuagu, Charles National Eye Institute (NEI) NEI Egwuagu, Charles (NEI) 1 157173719 Singh, Sunanda Singh Biotechnology, LLC Singh, Sunanda 2 157173612 Egwuagu, Charles National Eye Institute (NEI) NEI Egwuagu, Charles (NEI) 1 157173719 Singh, Sunanda Singh Biotechnology, LLC Singh, Sunanda 2 157143822 STAT3-specific Single Domain Nanobody Inhibits Expansion Of Pathogenic Th17 Responses And Suppresses Uveitis In Mice E-164-2021-0 Filing authorized National Eye Institute (NEI), Singh Biotechnology LLC 83737255 Baxter, Merissa merissa.baxter@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB merissa.baxter@nih.gov?subject=Web Inquiry on [TAB-4990] Suppression Of Uveitis By A STAT3 Single Domain Antibody&body=Please send me information about technology [TAB-4990] Suppression Of Uveitis By A STAT3 Single Domain Antibody.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Baxter, Merissa<br><a href="mailto:merissa.baxter@nih.gov?subject=Web Inquiry on [TAB-4990] Suppression Of Uveitis By A STAT3 Single Domain Antibody&body=Please send me information about technology [TAB-4990] Suppression Of Uveitis By A STAT3 Single Domain Antibody.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">merissa.baxter@nih.gov</a><br> 157175301 E-164-2021-0 E-164-2021-0-US-01 SINGLE DOMAIN ANTIBODY INHIBITS EXPANSION OF PATHOGENIC TH17 RESPONSES AND SUPPRESSION OF UVEITIS PRV US 63/219,161 Abandoned US <br />Provisional (PRV) 63/219,161<br />Filed on 2021-07-07<br />Status: Abandoned 160175629 E-164-2021-0 E-164-2021-0-US-03 SUPPRESSION OF UVEITIS BY SINGLE DOMAIN ANTIBODY ORD US 17/859,861 Pending US <br />Ordinary Patent (ORD) 17/859,861<br />Filed on 2022-07-07<br />Status: Pending 160175634 E-164-2021-0 E-164-2021-0-JP-01 SUPPRESSION OF UVEITIS BY SINGLE DOMAIN ANTIBODY National Stage Japan 2024-525189 Pending Japan <br />National Stage 2024-525189<br />Filed on 2024-01-05<br />Status: Pending 160175639 E-164-2021-0 E-164-2021-0-MX-01 SUPPRESSION OF UVEITIS BY SINGLE DOMAIN ANTIBODY National Stage Mexico MX/a/2024/000309 Pending Mexico <br />National Stage MX/a/2024/000309<br />Filed on 2024-01-04<br />Status: Pending 160175644 E-164-2021-0 E-164-2021-0-EP-01 SUPPRESSION OF UVEITIS BY SINGLE DOMAIN ANTIBODY National Stage European Patent 22838435.0 Pending European Patent <br />National Stage 22838435.0<br />Filed on 2024-02-05<br />Status: Pending 163826768 E-164-2021-0 E-164-2021-0-PCT-02 SUPPRESSION OF UVEITIS BY SINGLE DOMAIN ANTIBODY PCT Patent Cooperation Treaty PCT/US2022/036420 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2022/036420<br />Filed on 2022-07-07<br />Status: Expired 167147419 E-164-2021-0 E-164-2021-0-US-04 SUPPRESSION OF UVEITIS BY SINGLE DOMAIN ANTIBODY CON US 19/662,470 Pending US <br />Continuation (CON) 19/662,470<br />Filed on 2026-04-29<br />Status: Pending TAB-1977 114096197 qPCR Assay for Detection of JC Virus NINDS Diagnostics, Infectious Disease, Licensing, Research Materials Diagnostics Infectious Disease Licensing Research Materials Eugene Major, Caroline Ryschkewitsch JC Virus causes a fatal disease in the brain called progressive multifocal leukoencephalopathy (PML) that occurs in many patients with immunocompromised conditions. For example, more than five percent (5%) of AIDS patients develop PML. Additionally, these conditions include, but are not limited to, cancers such as leukemias and lymphomas, organ transplants such as kidney, heart and autoimmune conditions with treatment that modulates the immune system such as Multiple Sclerosis (MS), rheumatoid arthritis, psoriasis, and systemic lupus erythematosus. The finding of JCV DNA in the patients with neurological symptoms of PML is a diagnostic criterion and is needed to confirm the diagnosis of PML to rule out other neurological conditions. <br><br> This technology describes a qPCR assay that utilizes viral DNA standards and testing samples to detect the presence of the JC viral genome in patients' cerebrospinal fluid and blood, blood products, and tissue samples from biopsy or autopsy. Assay is sensitive, reproducible and highly specific because the amount JCV DNA in cerebrospinal fluid or blood or blood product samples may be very small. Development of JC Virus (JCV) diagnostics, calibration of existing JCV assays. Research Material -- patent protection is not being pursued for this technology Available for licensing. 2022-03-08 2024-10-28 2026-05-01 2009-07-02 assay, DA4BXX, DA4XXX, DAXXXX, DDXXXX, Detection, DEXXXX, DNA, DXXXXX, JC, Proficiency, Progressive multifocal leukoencephalopathy, QPCR, Samples', STANDARDS, Systemic lupus erythematosus, test, virus False True Materials and assay have been developed and tested. True NIHTT 37470483 Website Abstract 114170863 ML Landry et al. False negative PCR despite high levels of JC virus DNA in spinal fluid: Implications for diagnostic testing. J Clin Virol. 2008 Oct;43(2):247-249. http://www.ncbi.nlm.nih.gov/pubmed/18701345?dopt <a href="http://www.ncbi.nlm.nih.gov/pubmed/18701345?dopt">ML Landry et al. False negative PCR despite high levels of JC virus DNA in spinal fluid: Implications for diagnostic testing. J Clin Virol. 2008 Oct;43(2):247-249.</a> 114170864 C Ryschkewitsch et al. Comparison of PCR-southern hybridization and quantitative real-time PCR for the detection of JC and BK viral nucleotide sequences in urine and cerebrospinal fluid. J Virol Methods. 2004 Nov;121(2):217-221. http://www.ncbi.nlm.nih.gov/pubmed/15381359?dopt <a href="http://www.ncbi.nlm.nih.gov/pubmed/15381359?dopt">C Ryschkewitsch et al. Comparison of PCR-southern hybridization and quantitative real-time PCR for the detection of JC and BK viral nucleotide sequences in urine and cerebrospinal fluid. J Virol Methods. 2004 Nov;121(2):217-221.</a> 114170865 T Yousry et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med. 2006 Mar 2;354(9):924-933. http://www.ncbi.nlm.nih.gov/pubmed/16510746?dopt <a href="http://www.ncbi.nlm.nih.gov/pubmed/16510746?dopt">T Yousry et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med. 2006 Mar 2;354(9):924-933.</a> 114106668 Ryschkewitsch, Caroline NINDS NINDS Ryschkewitsch, Caroline (NINDS) 0 114106667 Major, Eugene NINDS NINDS Major, Eugene (NINDS) 1 114106667 Major, Eugene NINDS NINDS Major, Eugene (NINDS) 1 114106668 Ryschkewitsch, Caroline NINDS NINDS Ryschkewitsch, Caroline (NINDS) 0 114099880 QPCR Assay For Detection Of JC Virus With DNA Standards And Test Proficiency Samples' E-152-2009-0 Research Material NINDS 83667829 Ano, Susan susan.ano@nih.gov
United States of America susan.ano@nih.gov?subject=Web Inquiry on [TAB-1977] qPCR Assay for Detection of JC Virus&body=Please send me information about technology [TAB-1977] qPCR Assay for Detection of JC Virus. Ano, Susan<br><a href="mailto:susan.ano@nih.gov?subject=Web Inquiry on [TAB-1977] qPCR Assay for Detection of JC Virus&body=Please send me information about technology [TAB-1977] qPCR Assay for Detection of JC Virus.">susan.ano@nih.gov</a><br> 114120364 DDXXXX 114120365 DAXXXX 114120366 DA4XXX 114120367 DA4BXX 114120368 DEXXXX 114120369 DXXXXX 114138091 QPCR 114138092 assay 114138093 Detection 114138094 JC 114138095 virus 114138096 DNA 114138097 STANDARDS 114138098 test 114138099 Proficiency 114138100 Samples' 114156827 Systemic lupus erythematosus 114156828 Progressive multifocal leukoencephalopathy TAB-5054 162400945 Angubindin-1 Peptide for Transient Blood-Brain Barrier Opening to Boost Chemotherapy in Malignant Glioma NINDS Licensing, Neurology, Oncology, Therapeutics Licensing Neurology Oncology Therapeutics Sadhana Jackson <p><span style="font-size:11pt"><span style="line-height:107%"><span style="font-family:Calibri,sans-serif">This technology includes a first-in-class synthetic peptide, angubindin-1, designed to temporarily relax the blood-brain barrier (BBB)&mdash;the tightly sealed network of brain blood vessel cells that normally blocks most drugs&mdash;from the inside. By binding the tricellular tight-junction protein angulin-1/LSR, the peptide creates a reversible &ldquo;molecular doorway&rdquo; that lets cancer medicines such as liposomal doxorubicin (Doxil&reg;) reach tumors in the central nervous system (CNS). In rodent models of malignant glioma, co-administration of angubindin-1 increased drug penetration into the brain, cut tumor volume, and significantly prolonged survival compared with chemotherapy alone. The opening of the BBB is short-lived and spatially restricted, minimizing exposure of healthy brain tissue and avoiding the hardware, ultrasound, or high-dose osmotic agents required by competing methods.</span></span></span></p> <ul> <li>Peptide-based, systemic administration—no invasive devices or focused ultrasound, lowering clinical complexity and cost.</li> <li>Transient, selective BBB permeability (< hours) preserves barrier integrity post-treatment and limits off-target toxicity.</li> <li>Validated in vivo efficacy with improved survival; platform readily pairs with small-molecule drugs, antibodies, or gene/cell therapies targeting CNS diseases.</li> </ul> <ul> <li>Adjunct to standard-of-care chemotherapy for glioblastoma and other high-grade gliomas.</li> <li>Enabling delivery of emerging biologics (e.g., CAR-T cells, antibody–drug conjugates, gene therapies) to the brain.</li> <li>Enhancing uptake of CNS imaging or diagnostic agents for more accurate tumor visualization and monitoring.</li> </ul> 2025-05-13 2025-06-13 2026-04-30 2025-06-13 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 162400962 Jackson, Sadhana NINDS NINDS Jackson, Sadhana (NINDS) 1 162400962 Jackson, Sadhana NINDS NINDS Jackson, Sadhana (NINDS) 1 162400948 Angubindin-1 treatment against malignant glioma E-018-2024-0 Filing authorized NIH - NINDS 83687767 Olufemi, Olufunmilola (Lola) olufunmilola.olufemi@nih.gov
United States of America olufunmilola.olufemi@nih.gov?subject=Web Inquiry on [TAB-5054] Angubindin-1 Peptide for Transient Blood-Brain Barrier Opening to Boost Chemotherapy in Malignant Glioma&body=Please send me information about technology [TAB-5054] Angubindin-1 Peptide for Transient Blood-Brain Barrier Opening to Boost Chemotherapy in Malignant Glioma. Olufemi, Olufunmilola (Lola)<br><a href="mailto:olufunmilola.olufemi@nih.gov?subject=Web Inquiry on [TAB-5054] Angubindin-1 Peptide for Transient Blood-Brain Barrier Opening to Boost Chemotherapy in Malignant Glioma&body=Please send me information about technology [TAB-5054] Angubindin-1 Peptide for Transient Blood-Brain Barrier Opening to Boost Chemotherapy in Malignant Glioma.">olufunmilola.olufemi@nih.gov</a><br> 162400953 E-018-2024-0 E-018-2024-0-PCT-01 ANGUBINDIN-1 TREATMENT AGAINST MALIGNANT GLIOMA PCT Patent Cooperation Treaty PCT/US2023/079547 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2023/079547<br />Filed on 2023-11-13<br />Status: Expired 166152782 E-018-2024-0 E-018-2024-0-US-01 ANGUBINDIN-1 TREATMENT AGAINST MALIGNANT GLIOMA National Stage US In Preparation US <br />National Stage None<br />Filed on None<br />Status: In Preparation 166152811 E-018-2024-0 E-018-2024-0-EP-01 ANGUBINDIN-1 TREATMENT AGAINST MALIGNANT GLIOMA National Stage European Patent In Preparation European Patent <br />National Stage None<br />Filed on None<br />Status: In Preparation TAB-3973 147157254 Synthetic Lethality-mediated Precision Oncology via the Tumor Transcriptome NCI Diagnostics, Licensing, Oncology Diagnostics Licensing Oncology Joo Lee, Eytan Ruppin <h2>Description of Technology:</h2> <p>The use of tumor transcriptomics for precision oncology has made significant advances, mainly by identifying cancer driver genes or actionable mutations for treatment with targeted therapies.&nbsp; However, this strategy misses out on broader genetic interactions that could reveal additional biologically testable biomarkers for therapy response prediction and inform the selection of more effective drugs for targeted treatment.</p> <p>Scientists at the National Cancer Institute (NCI) have developed SELECT, a computational, precision-oncology framework that uses the tumor&rsquo;s whole transcriptome to identify synthetic lethal and synthetic rescue genetic interactions.&nbsp; These genetic interactions provided actional information predicting therapeutic response in 28 of 35 published targeted and immunotherapy trials from 10 different cancer types. Also, it was predictive of patients&rsquo; response in 80 % of these clinical trials.&nbsp; SELECT, an excellent tool in developing new targeted therapies or enhancing patient stratification in transcriptomic multi-arm trials, is available for co-development or licensing opportunity.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Patient stratification in clinical trials&nbsp;</li> <li>Identifying new actionable drug targets and treatments&nbsp;</li> <li>Analysis of genetic interactions that can provide actionable information for selecting effective treatment options for cancer patient</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Predictive accuracy of patients&rsquo; response in many treatment options, including chemotherapy, targeted drugs and immunotherapy</li> <li>Predictive accuracy of patients&rsquo; response across cancer types</li> <li>Enhancing patient stratification for clinical trials and improved therapeutic strategies</li> <li>Increasing the number of patients that could benefit from precision-based treatments</li> </ul> 2021-11-19 2026-04-24 2021-11-19 2026-04-30 2021-11-19 Genetic Interactions, Patient Stratification, Precision Diagnostics, Precision Oncology, Ruppin, Synthetic Lethality, Transcriptome False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-11-19 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147162079 PUBLICATION: Lee JS, et al. Synthetic lethality-mediated precision oncology via the tumor transcriptome. (PMID 33857424) https://pubmed.ncbi.nlm.nih.gov/33857424/ <a href="https://pubmed.ncbi.nlm.nih.gov/33857424/">PUBLICATION: Lee JS, et al. Synthetic lethality-mediated precision oncology via the tumor transcriptome. (PMID 33857424)</a> 167039304 Sahu AD, et al. Genome-wide prediction of synthetic rescue mediators of resistance to targeted and immunotherapy. https://pubmed.ncbi.nlm.nih.gov/30858180/CAPTION: 30858180 Sahu AD, et al. Genome-wide prediction of synthetic rescue mediators of resistance to targeted and immunotherapy. https://pubmed.ncbi.nlm.nih.gov/30858180/CAPTION: 30858180 167072741 Lee JS, et al. Harnessing Synthetic Lethality to Predict the Response to Cancer Treatment. (PMID 29959327) https://pubmed.ncbi.nlm.nih.gov/29959327/ <a href="https://pubmed.ncbi.nlm.nih.gov/29959327/">Lee JS, et al. Harnessing Synthetic Lethality to Predict the Response to Cancer Treatment. (PMID 29959327)</a> 147163087 Ruppin, Eytan NIH - NCI NCI Ruppin, Eytan (NCI) 1 147163088 Lee, Joo NIH - NCI Lee, Joo 2 147163087 Ruppin, Eytan NIH - NCI NCI Ruppin, Eytan (NCI) 1 147163088 Lee, Joo NIH - NCI Lee, Joo 2 147158081 Synthetic Lethality-mediated Precision Oncology Via The Tumor Transcriptome E-150-2020-0 Filing authorized NCI 83691647 Chang, Kevin changke@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB changke@mail.nih.gov?subject=Web Inquiry on [TAB-3973] Synthetic Lethality-mediated Precision Oncology via the Tumor Transcriptome&body=Please send me information about technology [TAB-3973] Synthetic Lethality-mediated Precision Oncology via the Tumor Transcriptome.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Chang, Kevin<br><a href="mailto:changke@mail.nih.gov?subject=Web Inquiry on [TAB-3973] Synthetic Lethality-mediated Precision Oncology via the Tumor Transcriptome&body=Please send me information about technology [TAB-3973] Synthetic Lethality-mediated Precision Oncology via the Tumor Transcriptome.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">changke@mail.nih.gov</a><br> 147161108 E-150-2020-0 E-150-2020-0-US-01 Synthetic Lethality-mediated Precision Oncology Via The Tumor Transcriptome PRV US 63/107,737 Abandoned US <br />Provisional (PRV) 63/107,737<br />Filed on 2020-10-30<br />Status: Abandoned 147165637 E-150-2020-0 E-150-2020-0-PCT-02 Synthetic Lethality-Mediated Precision Oncology via the Tumor Transcriptome PCT Patent Cooperation Treaty PCT/US2021/057229 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/057229<br />Filed on 2021-10-29<br />Status: Expired 147165638 E-150-2020-0 E-150-2020-0-US-02 Synthetic Lethality-Mediated Precision Oncology via the Tumor Transcriptome National Stage US 18/250,816 Pending US <br />National Stage 18/250,816<br />Filed on 2023-04-27<br />Status: Pending 147172374 Genetic Interactions 147172375 Patient Stratification 147172377 Precision Diagnostics 147172378 Precision Oncology 147172379 Ruppin 147172381 Synthetic Lethality 147172382 Transcriptome TAB-3970 147157250 Multidimensional MRI Signature for Specific Detection of Traumatic Brain Injury In Vivo NICHD Collaboration, Diagnostics, Licensing, Neurology Collaboration Diagnostics Licensing Neurology Peter Basser, Dan Benjamini, Diego Iacono <h2>Summary:</h2> <p>The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) seeks research co-development partners and/or licensees for the development of multidimensional MRI-based methods.</p> <h2>Description of Technology:</h2> <p>Traumatic brain injury (TBI) represents a major medical, social and economic concern worldwide due to significant mortality &ndash; especially among younger populations &ndash; and long-term disabilities. Various pathological brain lesions (e.g., intracerebral bleedings, necrotic-ischemic lesions, tissue avulsion) are produced by impacting mechanical forces. Among these, diffuse axonal injury (DAI) is one of the most significant brain lesions typically associated with trauma. However, DAI is not necessarily linked with TBI exposure. Therefore, the term &ldquo;traumatic axonal injury (TAI)&rdquo; is commonly used. TAI is a specific form of DAI.</p> <p>Multidimensional MRI-based methods permit identification and categorization of brain specimens to identify sub-voxel tissue components specific to traumatic axon injury or other lesions. Lower dimensional MR spectral data is acquired and processed to provide multidimensional MR data of higher dimensions. One or more spectral ranges are selected that define signatures for brain injury. Evaluation of the multidimensional MR data in these ranges is used to locate voxels associated with brain injury. The invention pertains to noninvasive methods of assessing nervous system injury, particularly TBI &ndash; both mild and severe. A unique TAI multidimensional spectral signature can be measured and used to generate biomarker images closely following amyloid precursor protein (&ldquo;APP&rdquo;) histopathology: APP-positive areas scale with multidimensional TAI biomarker intensity and negative APP corresponds to reduced or absent MRI signal. This specificity of the multidimensional TAI biomarkers permit so-called &ldquo;noninvasive histology.&rdquo; One or more T1-T2-MD ranges can be identified and specifically linked to TAI microscopic tissue alterations. T1, T2 and diffusion dynamics can be different in fixed compared with living tissue. Therefore, different T1-T2-MD ranges can be selected for fixed and living tissues.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Diagnosis and assessment of patients with TBI</li> <li>Noninvasive histology</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Noninvasive diagnostic technique</li> <li>Provides substantially more discrete data than prior methodologies</li> <li>Produces measurements with high specificity</li> <li>Unique TAI multidimensional spectral signatures can be measured and used to generate biomarker images</li> </ul> 2022-01-05 2026-04-23 2022-01-05 2026-04-30 2022-01-05 Amyloid Precursor Protein, Be, DAI, Diffuse Axonal Injury, Eunice Kennedy Shriver National Institute of Child Health an, Magnetic Resonance Imaging, MRI, MULTIDIMENSIONAL, NICHD, TAI, TBI, Traumatic Axonal Injury, Traumatic Brain Injury False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2022-01-05 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147162279 Benjamini D, et al. Multidimensional MRI for Characterization of Subtle Axonal Injury Accelerated Using an Adaptive Nonlocal Multispectral Filter. (https://doi.org/10.3389/fphy.2021.73737 : Benjamini D, et al. Multidimensional MRI for Characterization of Subtle Axonal Injury Accelerated Using an Adaptive Nonlocal Multispectral Filter. (https://doi.org/10.3389/fphy.2021.737374 <a href=": Benjamini D, et al. Multidimensional MRI for Characterization of Subtle Axonal Injury Accelerated Using an Adaptive Nonlocal Multispectral Filter. (https://doi.org/10.3389/fphy.2021.737374">Benjamini D, et al. Multidimensional MRI for Characterization of Subtle Axonal Injury Accelerated Using an Adaptive Nonlocal Multispectral Filter. (https://doi.org/10.3389/fphy.2021.73737</a> 167039252 Benjamini D, et al. Diffuse axonal injury has a characteristic multidimensional MRI signature in the human brain. .PUBLICATIONS HREF: https://doi.org/10.3389/fphy.2021.737374CAPTION: PMID 25838374 https://doi.org/10.1093/brain/awaa447 <a href="https://doi.org/10.1093/brain/awaa447">Benjamini D, et al. Diffuse axonal injury has a characteristic multidimensional MRI signature in the human brain. .PUBLICATIONS HREF: https://doi.org/10.3389/fphy.2021.737374CAPTION: PMID 25838374</a> 147163078 Benjamini, Dan NICHD NIA Benjamini, Dan (NIA) 1 147163077 Basser, Peter NIH - NICHD NICHD Basser, Peter (NICHD) 2 147163079 Iacono, Diego NINDS NINDS Iacono, Diego (NINDS) 3 147163078 Benjamini, Dan NICHD NIA Benjamini, Dan (NIA) 1 147163077 Basser, Peter NIH - NICHD NICHD Basser, Peter (NICHD) 2 147163079 Iacono, Diego NINDS NINDS Iacono, Diego (NINDS) 3 147158172 Multidimensional MRI Signature For Specific Detection Of Traumatic Brain Injury In Vivo E-185-2020-0 Filing authorized Henry M. Jackson Foundation (HJF), NICHD 119617417 Ravilious, Geoffrey geoffrey.ravilious@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
geoffrey.ravilious@nih.gov?subject=Web Inquiry on [TAB-3970] Multidimensional MRI Signature for Specific Detection of Traumatic Brain Injury In Vivo&body=Please send me information about technology [TAB-3970] Multidimensional MRI Signature for Specific Detection of Traumatic Brain Injury In Vivo.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Ravilious, Geoffrey<br><a href="mailto:geoffrey.ravilious@nih.gov?subject=Web Inquiry on [TAB-3970] Multidimensional MRI Signature for Specific Detection of Traumatic Brain Injury In Vivo&body=Please send me information about technology [TAB-3970] Multidimensional MRI Signature for Specific Detection of Traumatic Brain Injury In Vivo.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">geoffrey.ravilious@nih.gov</a><br> 147161166 E-185-2020-0 E-185-2020-0-US-01 MULTIDIMENSIONAL MRI SIGNATURE FOR SPECIFIC DETECTION OF TRAUMATIC BRAIN INJURY IN VIVO PRV US 63/061,105 Abandoned US <br />Provisional (PRV) 63/061,105<br />Filed on 2020-08-04<br />Status: Abandoned 147165625 E-185-2020-0 E-185-2020-0-PCT-02 Multidimensional MRI Signature For Specific Detection Of Traumatic Brain Injury In Vivo PCT Patent Cooperation Treaty PCT/US2021/041663 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/041663<br />Filed on 2021-07-14<br />Status: Expired 147165626 E-185-2020-0 E-185-2020-0-US-03 Multidimensional MRI Signature For Specific Detection Of Traumatic Brain Injury In Vivo National Stage US 12,343,132 18/019,725 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12343132 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12343132">12,343,132</a><br />Filed on 2023-02-03<br />Status: Issued 147173292 Amyloid Precursor Protein 147173294 Be 147173296 DAI 147173298 Diffuse Axonal Injury 147173299 Eunice Kennedy Shriver National Institute of Child Health an 147173300 Magnetic Resonance Imaging 147173301 MRI 147173302 MULTIDIMENSIONAL 147173303 NICHD 147173305 TAI 147173306 TBI 147173308 Traumatic Axonal Injury 147173309 Traumatic Brain Injury TAB-4424 147157719 Coumarin Luciferins and Mutant Luciferases for Bioluminescence Imaging NCI Collaboration, Immunology, Infectious Disease, Licensing, Oncology, Therapeutics Collaboration Immunology Infectious Disease Licensing Oncology Therapeutics Donald Caldwell, Anna Love, Jennifer Prescher, Martin Schnermann, Zi Wei Yao <h2>Summary:</h2> <p>Researchers at UCI and NCI seek licensing to adopt new applications for a family of far-red to near-infrared emission coumarin-based luciferins (CouLuc) with complementary mutant enzymes.&nbsp;</p> <h2>Description of Technology:</h2> <p>Bioluminescence imaging with luciferin-luciferase pairs is a well-established technique for tracking cells and other biological features in animal models. Bioluminescent is a chemical process which does not require an external input for excitation. Bioluminescent imaging is often limited to monitoring single processes in vivo due to the lack of distinguishable probes. Additionally, existing probes typically operate with light in the visible range, which is highly scattered and exhibits poor tissue penetration.&nbsp;</p> <p>To address these issues, researchers at UCI and NCI synthesized a new family of coumarin-based luciferins (CouLuc) with complementary mutant enzymes that exhibit far-red to near-infrared emission. This novel shift in emission opens the possibility of pairing with commercial luciferin-luciferase probes to form multicomponent systems. Additionally, far-red to near-infrared emission enables imaging at greater depths in live animals. Based on commercial courmarin precursors, these CouLuc scaffolds can be prepared in a straightforward two-step sequence. The resulting CouLuc with luciferase mutants provides stable substrate-selective luciferases with robust light emission. Overall, these probes are poised to advance the scope of bioluminescence imaging to more complex biological problems.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Live animal imaging&nbsp;</li> <li>Multicomponent imaging when combined with commercial luciferin-luciferase pairs</li> <li>Enhanced bioluminescence imaging</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Distinct from existing luciferin-luciferase pair due to their emission of far-red to near-red light</li> <li>Superior tissue penetration&nbsp;</li> <li>Greater depth and resolution&nbsp;&nbsp;</li> <li>Enhancement of a variety of current bioluminescence imaging applications</li> <li>Ability to quickly produce significant quantities of the novel CouLucs probes</li> </ul> 2021-09-23 2026-04-24 2021-11-05 2026-04-30 2021-09-23 CouLuc, Luciferases, Luciferins, Near-infrared, NIR, Optical Imaging, Schnermann False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-11-05 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147161919 Yao Z, et al. Coumarin luciferins and mutant luciferases for robust multicomponent bioluminescence imaging. (PMID) Yao Z, et al. Coumarin luciferins and mutant luciferases for robust multicomponent bioluminescence imaging. (PMID) 147164697 Schnermann, Martin NIH - NCI NCI Schnermann, Martin (NCI) 1 147164698 Caldwell, Donald NCI - CCR NCI Caldwell, Donald (NCI) 2 147164699 Prescher, Jennifer University of California, Irvine Prescher, Jennifer 3 147164700 Yao, Zi Wei University of California, Irvine Yao, Zi Wei 4 147164701 Love, Anna University of California, Irvine Love, Anna 5 147164697 Schnermann, Martin NIH - NCI NCI Schnermann, Martin (NCI) 1 147164698 Caldwell, Donald NCI - CCR NCI Caldwell, Donald (NCI) 2 147164699 Prescher, Jennifer University of California, Irvine Prescher, Jennifer 3 147164700 Yao, Zi Wei University of California, Irvine Yao, Zi Wei 4 147164701 Love, Anna University of California, Irvine Love, Anna 5 147157997 Coumarin Luciferins And Mutant Luciferases For Bioluminescence Imaging E-105-2021-0 Filing authorized NCI, University of California, Irvine 83704821 Nguyen-Antczak, Lauren lauren.nguyen-antczak@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-4424] Coumarin Luciferins and Mutant Luciferases for Bioluminescence Imaging&body=Please send me information about technology [TAB-4424] Coumarin Luciferins and Mutant Luciferases for Bioluminescence Imaging.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Nguyen-Antczak, Lauren<br><a href="mailto:lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-4424] Coumarin Luciferins and Mutant Luciferases for Bioluminescence Imaging&body=Please send me information about technology [TAB-4424] Coumarin Luciferins and Mutant Luciferases for Bioluminescence Imaging.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">lauren.nguyen-antczak@nih.gov</a><br> 147161047 E-105-2021-0 E-105-2021-0-US-01 COUMARIN LUCIFERINS FOR BIOLUMINESCENCE IMAGING PRV US 63/184,432 Abandoned US <br />Provisional (PRV) 63/184,432<br />Filed on 2021-05-05<br />Status: Abandoned 147171520 CouLuc 147171521 Luciferases 147171522 Luciferins 147171523 Near-infrared 147171524 NIR 147171526 Optical Imaging 147171528 Schnermann TAB-4516 151706972 Cas9 Protein Delivery with Lentiviral Vector Particles as a Therapy for Sickle Cell Disease NHLBI Licensing, Plasmids/Vectors, Therapeutics Licensing Plasmids/Vectors Therapeutics Juan Haro Mora, John Tisdale, Naoya Uchida <p>This technology includes efficient lentiviral gene delivery system for both guide RNA and Cas9 endonuclease as a method to cure sickle cell disease. Gene correction is an ideal gene therapy strategy for hereditary disease, including sickle cell disease. To deliver both guide RNA and Cas9 endonuclease into target cells, we used HIV-l based lentiviral vector system, which allows for efficient gene delivery in various cells, including hematopoietic stem cells and ES/1PS cells in this system, transgene expression cassettes can be integrated into genomic DNA in target cells, which results in long‐ term transgene expression. Out data demonstrate that Cas9/CypA fusion proteins can be delivered with lentiviral particles, and the Cas9 fusion proteins have an endonuclease function to induce GFP DNA double strand break.</p> In this system, much smaller size of viral genome is packaged in lentiviral particles, which should allow for more efficient gene/protein delivery with lentiviral vectors. ln addition, site-specific DNA break can be induced for a short term only, which should allow for safer genome editing by reduction of DNA damage in target cells. Perform gene correction in the β-globin gene and/or BCL11lA gene knock-down in hematopoietic stem cells to induce fetal hemoglobin expression to cure sickle cell disease. We are seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. 2023-12-07 2024-08-12 2026-04-30 2024-03-20 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 151706979 Uchida, Naoya University of Tokyo Uchida, Naoya 1 151706983 Haro Mora, Juan National Heart, Lung, and Blood Institute (NHLBI) NHLBI Haro Mora, Juan (NHLBI) 2 151707087 Tisdale, John National Heart, Lung, and Blood Institute (NHLBI) NHLBI Tisdale, John (NHLBI) 3 151706979 Uchida, Naoya University of Tokyo Uchida, Naoya 1 151706983 Haro Mora, Juan National Heart, Lung, and Blood Institute (NHLBI) NHLBI Haro Mora, Juan (NHLBI) 2 151707087 Tisdale, John National Heart, Lung, and Blood Institute (NHLBI) NHLBI Tisdale, John (NHLBI) 3 151706975 Development Of Lentiviral Protein Delivery System For RNA-guided Genome Editing E-165-2015-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 89788013 Kolesnitchenko, Vincent vk5q@nih.gov
United States of America Office of Technology Transfer and Development vk5q@nih.gov?subject=Web Inquiry on [TAB-4516] Cas9 Protein Delivery with Lentiviral Vector Particles as a Therapy for Sickle Cell Disease&body=Please send me information about technology [TAB-4516] Cas9 Protein Delivery with Lentiviral Vector Particles as a Therapy for Sickle Cell Disease. Kolesnitchenko, Vincent<br><a href="mailto:vk5q@nih.gov?subject=Web Inquiry on [TAB-4516] Cas9 Protein Delivery with Lentiviral Vector Particles as a Therapy for Sickle Cell Disease&body=Please send me information about technology [TAB-4516] Cas9 Protein Delivery with Lentiviral Vector Particles as a Therapy for Sickle Cell Disease.">vk5q@nih.gov</a><br> 157755526 E-165-2015-0 E-165-2015-0-US-01 LENTIVIRAL PROTEIN DELIVERY SYSTEM FOR RNA-GUIDED GENOME EDITING PRV US 62/236,223 Abandoned US <br />Provisional (PRV) 62/236,223<br />Filed on 2015-10-02<br />Status: Abandoned TAB-4468 150736756 Directed Acetylation of Cytidine in Cellular mRNA through Engineered snoRNA Adapters for the Treatment of Haploinsufficiencies NCI Application, Cardiology, Collaboration, Licensing, Neurology, Oncology, Therapeutics Application Cardiology Collaboration Licensing Neurology Oncology Therapeutics Shalini Oberdoerffer, Sarah Schiffers <h2>Summary:&nbsp;</h2> <p>The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for engineered chimeric snoRNA guides that recruit NAT10 to a specific target and cause directed acetylation of the target. They could be used to treat haploinsufficiency-associated disorders or diseases.</p> <h2>Description of Technology:&nbsp;</h2> <p>Haploinsufficiency (HI) is the loss of one allele of a gene. The resultant loss in associated protein expression/function is insufficient for a normal phenotype and manifests in a myriad of diseases. Such diseases include: [1] congenital malformations (e.g., eye defects, cleft lip/palate, etc.), [2] neurodevelopmental disorders (e.g., autism spectrum disorders, epilepsy, schizophrenia, etc.) and [3] disorders of maintenance and self-renewal. This latter category includes cancer predisposition syndromes, obesity, maturity onset diabetes of the young, and autoimmune disorders. In total, over 300 known human haploinsufficiencies exist. However, no therapies exist which can target these HIs without unbalanced protein expression and deleterious side effects.</p> <p>Scientists at the NCI engineered chimeric small nucleolar (snoRNA) guides that recruit the enzyme NAT10 to a target transcript. The NAT10 enzyme acetylates specific cytidines in RNA, including at the ac4C site, through association with these snoRNA guides. In mRNA, ac4C modulates the level of protein produced per mRNA template, manifesting in moderate increases in net protein levels. For HI-related disorders or diseases, moderate increases in protein production alleviate disease phenotypes without the potential side effects of more substantial over-expression and protein production. The inventors developed a proof-of-principle snoRNA guide that recruits NAT10 to the target transcript GAPDH mRNA. The snoRNA was delivered into HeLa cells through incorporation into a minigene vector. Recovery of GAPDH transcripts and mass spectrometry confirmed successful targeted acetylation in these cells. This invention of directed acetylation through engineered snoRNA adapters would be useful for the treatment of haploinsufficiencies where moderate protein expression can lead to alleviation of disease phenotype.</p> <p>The NCI is looking for research co-development partners and/or licensees to help develop these engineered chimeric snoRNA guides into clinically relevant therapeutics for the treatment of a variety of haploinsufficiencies.</p> <h2>Potential Commercial Applications:&nbsp;</h2> <p>Patient-specific, RNA-targeting therapy for haploinsufficiencies such as:</p> <ul> <li>Congenital malformations</li> <li>Neurodevelopmental disorders&nbsp;</li> <li>Cancer</li> <li>Autoimmune Lymphoproliferative Syndrome (ALPS)</li> <li>Myelodysplastic Syndrome (MDS)</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Potentially fewer and less severe side-effects compared with current gene therapy technology</li> <li>More moderate changes of protein expression&nbsp;</li> <li>Promotion of endogenous protein biosynthesis<br /> &nbsp;</li> </ul> 2023-10-10 2026-04-30 2026-04-30 2023-10-11 False False Basic (Target ID) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 150757256 Oberdoerffer, Shalini Laboratory of Receptor Biology and Gene Expression NCI Oberdoerffer, Shalini (NCI) 1 150757272 Schiffers, Sarah National Cancer Institute (NCI) NCI Schiffers, Sarah (NCI) 2 150757256 Oberdoerffer, Shalini Laboratory of Receptor Biology and Gene Expression NCI Oberdoerffer, Shalini (NCI) 1 150757272 Schiffers, Sarah National Cancer Institute (NCI) NCI Schiffers, Sarah (NCI) 2 150736762 Directed Acetylation Of Cytidine In Cellular MRNA Through Engineered SnoRNA Adapters For The Treatment Of Haploinsufficiencies E-017-2023-0 Filing authorized Laboratory of Receptor Biology and Gene Expression, NCI 91826910 McCrary, Michaela michaela.mccrary@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America michaela.mccrary@nih.gov?subject=Web Inquiry on [TAB-4468] Directed Acetylation of Cytidine in Cellular mRNA through Engineered snoRNA Adapters for the Treatment of Haploinsufficiencies&body=Please send me information about technology [TAB-4468] Directed Acetylation of Cytidine in Cellular mRNA through Engineered snoRNA Adapters for the Treatment of Haploinsufficiencies.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov McCrary, Michaela<br><a href="mailto:michaela.mccrary@nih.gov?subject=Web Inquiry on [TAB-4468] Directed Acetylation of Cytidine in Cellular mRNA through Engineered snoRNA Adapters for the Treatment of Haploinsufficiencies&body=Please send me information about technology [TAB-4468] Directed Acetylation of Cytidine in Cellular mRNA through Engineered snoRNA Adapters for the Treatment of Haploinsufficiencies.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">michaela.mccrary@nih.gov</a><br> 150894306 E-017-2023-0 E-017-2023-0-US-01 Directed acetylation of mRNA through engineered snoRNA adapters PRV US 63/423,714 Expired US <br />Provisional (PRV) 63/423,714<br />Filed on 2022-11-08<br />Status: Expired TAB-4466 149818526 Systems and Methods to Automatically Detect Ellipsoid Zone Loss in SD-OCT Imaging NEI Collaboration, Ear, Nose, & Throat, Licensing, Software / Apps, TherapeuticArea Collaboration Ear Nose & Throat Licensing Software / Apps TherapeuticArea Catherine Cukras, Wathudurage De Silva <h2>Summary:</h2> <p>The National Eye Institute (NEI) seeks research co-development partners and/or licensees for an automatic deep learning-based algorithm to detect and quantitate ellipsoid zone (EZ) loss in Spectral Domain Optical Coherence Tomography (SD-OCT) images.</p> <h2>Description of Technology:</h2> <p>The present disclosure generally relates a method of automatically detecting ellipsoid zone (EZ) loss in spectral domain optical coherence tomography (SD-OCT) imaging. EZ band represents outer segments of photoreceptors in the retina, and its loss reflects a deterioration of the photoreceptors. EZ loss has been proposed to be evidence of progression of several retinal degenerative diseases including, but not limited to, retinitis pigmentosa and hydroxychloroquine (HCQ)-induced retinal toxicity. HCQ is a first-line drug used to treat autoimmune diseases such as systemic lupus erythematosus, Sj&ouml;gren&rsquo;s syndrome, and rheumatoid arthritis. One of the major side-effects that can occur in long-term users of HCQ, is EZ loss that can result in retinal toxicity and permanent damage to photoreceptors and retinal pigment epithelium (RPE), eventually leading to irreversible loss of central vision. The American Academy of Ophthalmology (AAO) recommends two main screening modalities including SD-OCT imaging and functional tests such as visual fields with the goal of recognizing early definitive signs of HCQ-induced retinal toxicity to prevent vision loss. Although this side-effect is estimated to occur in 7.5% of patients taking the drug for more than 10 years, we currently have no treatment for this serious side effect that tends to continue even after the cessation of the drug.</p> <p>Researchers at the NEI have developed a method that can automatically detect and quantitate EZ loss in SD-OCT images immediately after image acquisition. The method includes a deep learning framework with a two-step approach. In the first stage, the method detects and annotates EZ loss regions in individual OCT B-scans. A 2D map is constructed twice in a dual architecture to enhance robustness, where horizontal and vertical slices extracted from the 3D image are trained separately. The second stage of the model operates on these two 2D maps and estimates the final EZ loss map representing the 3D OCT volume. Compared to other screening methods, the algorithm demonstrated excellent performance in diagnosing toxicity even as a stand-alone test, with an F1 score, a measure of test accuracy, of 0.91. This indicates the utility of the tool in assisting with screening for toxicity in an automatic, accurate, time-effective, cost-effective, and objective manner. Addition of this methodology onto current SD-OCT screening could assist the clinician in making diagnostic and treatment decisions immediately after SD-OCT acquisitions.</p> <p>Protected claims for this invention include the method of detecting and outlining the region of EZ loss directly from acquired OCT images, associated algorithms, and the device containing these algorithms and capabilities. This technology is available for licensing.</p> <h2>Potential Commercial Applications:</h2> <ul> <li style="margin-left:8px">Methodology to integrate with SD-OCT imaging for screening applications for different retinal degeneration diseases</li> <li style="margin-left:8px">Implementation of this automatic algorithm also in screening outside of ophthalmology offices (OCTs become more ubiquitous in internal medicine settings)</li> <li style="margin-left:8px">Quantitative data produced from the algorithms could provide surrogate end points for use in clinical trials and interventional studies aimed at halting progression of degenerative changes</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li style="margin-left:8px">Accurate and robust method: Provides excellent performance in diagnosing toxicity as a stand-alone test and compared to qualitative inspection of SD-OCT images</li> <li style="margin-left:8px">Time-efficient (can evaluate SD-OCT volumes): Fully automatic and available within seconds after SD-OCT acquisition</li> <li style="margin-left:8px">Objective: Performs as well as human grading in eyes that demonstrate even small amounts of EZ loss</li> <li style="margin-left:8px">Does not require segmentation of intact layers, avoiding failures in cases of layer deterioration</li> <li style="margin-left:8px">Does not require a large number of training examples, useful for rare diseases</li> </ul> <p><img alt="" src="https://nih.technologypublisher.com/files/sites/image435.png" style="height:391px; width:1042px" /></p> <p><br /> &emsp;</p> 2023-09-20 2026-04-30 2026-04-30 2023-10-05 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 150109557 De Silva T, et al. Deep Learning-Based Automatic Detection of Ellipsoid Zone Loss in Spectral-Domain OCT for Hydroxychloroquine Retinal Toxicity Screening (PMID 36246938) https://pubmed.ncbi.nlm.nih.gov/36246938/ <a href="https://pubmed.ncbi.nlm.nih.gov/36246938/">De Silva T, et al. Deep Learning-Based Automatic Detection of Ellipsoid Zone Loss in Spectral-Domain OCT for Hydroxychloroquine Retinal Toxicity Screening (PMID 36246938)</a> 150044076 De Silva, Wathudurage National Eye Institute (NEI) De Silva, Wathudurage 3 150044080 Cukras, Catherine Division of Epidemiology and Clinical Application NEI Cukras, Catherine (NEI) 4 150044076 De Silva, Wathudurage National Eye Institute (NEI) De Silva, Wathudurage 3 150044080 Cukras, Catherine Division of Epidemiology and Clinical Application NEI Cukras, Catherine (NEI) 4 149818530 Systems and Methods to Automatically Detect Ellipsoid Zone Loss in SD-OCT Imaging E-194-2021 Filing authorized National Eye Institute (NEI) 83724826 Pollard, Ricquita ricquita.pollard@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4466] Systems and Methods to Automatically Detect Ellipsoid Zone Loss in SD-OCT Imaging&body=Please send me information about technology [TAB-4466] Systems and Methods to Automatically Detect Ellipsoid Zone Loss in SD-OCT Imaging.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollard, Ricquita<br><a href="mailto:ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4466] Systems and Methods to Automatically Detect Ellipsoid Zone Loss in SD-OCT Imaging&body=Please send me information about technology [TAB-4466] Systems and Methods to Automatically Detect Ellipsoid Zone Loss in SD-OCT Imaging.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">ricquita.pollard@nih.gov</a><br> 150655563 E-194-2021 E-194-2021-0-US-01 SYSTEMS AND METHODS TO AUTOMATICALLY DETECT HYDROXYCHLOROQUINE-INDUCED RETINAL TOXICITY IN SD-OCT IMAGING PRV US 63/241,823 Abandoned US <br />Provisional (PRV) 63/241,823<br />Filed on 2021-09-08<br />Status: Abandoned 150655571 E-194-2021 E-194-2021-0-PCT-02 Systems and Methods to Automatically Detect Ellipsoid Zone Loss in SD-OCT Imaging PCT Patent Cooperation Treaty PCT/US2022/076135 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2022/076135<br />Filed on 2022-09-08<br />Status: Expired 164119729 E-194-2021 E-194-2021-0-CA-03 Systems and Methods to Automatically Detect Ellipsoid Zone Loss in SD-OCT Imaging National Stage Canada 3230840 Pending Canada <br />National Stage 3230840<br />Filed on 2024-03-01<br />Status: Pending 164119730 E-194-2021 E-194-2021-0-AU-04 Systems and Methods to Automatically Detect Ellipsoid Zone Loss in SD-OCT Imaging National Stage Australia 2022344259 Pending Australia <br />National Stage 2022344259<br />Filed on 2024-02-22<br />Status: Pending 164119731 E-194-2021 E-194-2021-0-US-05 Systems and Methods to Automatically Detect Ellipsoid Zone Loss in SD-OCT Imaging National Stage US 18/690,130 Pending US <br />National Stage 18/690,130<br />Filed on 2024-03-07<br />Status: Pending 164119732 E-194-2021 E-194-2021-0-EP-06 Systems and Methods to Automatically Detect Ellipsoid Zone Loss in SD-OCT Imaging National Stage European Patent 22789416.9 Pending European Patent <br />National Stage 22789416.9<br />Filed on 2024-03-08<br />Status: Pending TAB-4448 147157743 National Cancer Institute Dosimetry System for Nuclear Medicine (NCINM) Computer Program NCI Cardiology, Licensing, Neurology, Oncology, Software / Apps Cardiology Licensing Neurology Oncology Software / Apps <h2>Summary:</h2> <p>The National Cancer Institute (NCI) seeks licensees for a novel computer program performing radiation dose calculations for diagnostic and therapeutic nuclear medicine.</p> <h2>Description of Technology:</h2> <p>Nuclear medicine is the second largest source of medical radiation exposure to the general population after computed tomography imaging. Imaging modalities utilizing nuclear medicine produce a more detailed view of internal structure and function and are most commonly used to diagnose diseases such as heart disease, Alzheimer&rsquo;s and brain disorders. They are used to visualize tumors, abscesses due to infection or abnormalities in abdominal organs. When using radionuclides for diagnosis or therapy in nuclear medicine, it is critical to accurately estimate unintended dose to organs at risk surrounding tumors or of therapeutic or imaging interest. It is impossible to experimentally measure organ dose. Traditionally, computational approaches were used for this purpose, requiring a series of computational human phantoms and an extensive amount of computer simulation. However, existing model-based organ dose estimation tools rely on simplified human anatomy models or commercial programs.</p> <p>To address these challenges, Dr. Choonsik Lee from the NCI created a radiation dose-calculation tool for nuclear medicine imaging modalities based on more sophisticated human anatomy models. A comprehensive library of photon and electron specific absorbed fractions (SAF) were first calculated for multiple combinations of source and target regions within a series of pediatric and adult computational human phantoms matching the International Commission on Radiological Protection (ICRP)&#39;s reference data. These were combined with a Monte Carlo radiation transport code. Then, a library of S values was derived from these SAFs and the nuclear decay data from ICRP Publication 107. Finally, a graphical user interface, named the National Cancer Institute Dosimetry System for Nuclear Medicine (NCINM), was created to facilitate the dosimetry process. Approximately 13 million S values were derived from 2 million SAFs computed. A comprehensive library of biokinetic data were extracted from multiple up-to-date international reports and implemented into NCINM.&nbsp;</p> <p>The NCI seeks licensees for this technology who are interested in using NCINM, including their implementation within existing commercial solutions for patient dose monitoring.&nbsp;Applications of the NCINM program include computation of absorbed doses for use in radiation epidemiologic studies and patient dose monitoring in nuclear medicine.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Patient radiation dose monitoring in nuclear medicine imaging modalities</li> <li>Radiation epidemiologic studies</li> <li>Components can be incorporated with NCIDose software into a commercial platform: NCINM program, computational human phantom series (human anatomy models, electronic files), organ dose factor library (tabulated numbers)</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Easy implementation within existing commercial solutions</li> <li>Most advanced pediatric and adult computational phantoms</li> <li>Intuitive user interface</li> <li>Software can run on Macintosh, Windows, and LINUX operating systems</li> </ul> Researchers at the NCI seek licensing for a novel computer program that performs radiation dose calculations for diagnostic and therapeutic nuclear medicine. 2023-05-14 2026-04-30 2023-05-14 2026-04-30 2023-05-14 • National Cancer Institute Dosimetry System for Nuclear Med, Dosimetry, Lee, NCINM, Nuclear Medicine, Radiation, Radiation Dosing, SAF, Specific Absorbed Fraction False True Clinical True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2023-05-14 72159138 Clinical Phase I 72159138 NCI 37470483 Website Abstract E-082-2016 E-127-2023 147162076 Villoing D, et al. NCINM: organ dose calculator for patients undergoing nuclear medicine procedures. https://pubmed.ncbi.nlm.nih.gov/33444241/ <a href="https://pubmed.ncbi.nlm.nih.gov/33444241/">Villoing D, et al. NCINM: organ dose calculator for patients undergoing nuclear medicine procedures.</a> 155750754 National Cancer Institute Dosimetry System For Nuclear Medicine (NCINM) Computer Program E-125-2019-0 Closed NCI 83691647 Chang, Kevin changke@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB changke@mail.nih.gov?subject=Web Inquiry on [TAB-4448] National Cancer Institute Dosimetry System for Nuclear Medicine (NCINM) Computer Program&body=Please send me information about technology [TAB-4448] National Cancer Institute Dosimetry System for Nuclear Medicine (NCINM) Computer Program.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Chang, Kevin<br><a href="mailto:changke@mail.nih.gov?subject=Web Inquiry on [TAB-4448] National Cancer Institute Dosimetry System for Nuclear Medicine (NCINM) Computer Program&body=Please send me information about technology [TAB-4448] National Cancer Institute Dosimetry System for Nuclear Medicine (NCINM) Computer Program.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">changke@mail.nih.gov</a><br> 147171904 • National Cancer Institute Dosimetry System for Nuclear Med 147171905 Dosimetry 147171906 Lee 147171907 NCINM 147171909 Nuclear Medicine 147171910 Radiation 147171911 Radiation Dosing 147171913 SAF 147171915 Specific Absorbed Fraction TAB-4419 147157714 Device for Simulating Explosive Blast and Imaging Biological Specimens NICHD Collaboration, Licensing, Medical Devices, Neurology, Non-Medical Devices Collaboration Licensing Medical Devices Neurology Non-Medical Devices Sergey Bezrukov, Paul Blank, Kim Lee Mcafee, Rea Ravin, Alex Steinkamp, Joshua Zimmerberg <h2>Summary:</h2> <p>Researchers at the National Institute of Child Health and Human Development (NICHD) developed a device simulating a blast shock wave of the type produced by explosive devices such as bombs. The invention allows for the real-time study of blast effects on in vitro cell models. NICHD researchers seek licensing opportunities to further develop this device.</p> <h2>Description of Technology:</h2> <p>Traumatic brain injury (TBI) is a major health problem.&nbsp; Between 3.2 and 5.3 million people live with long-term disabilities resulting from TBI, and thus, contribute to the need to develop therapies that treat TBI-induced cellular damage. Researchers at the National Institute of Child Health and Human Development (NICHD) have developed a device that simulates the pressure waves resulting from explosions. This invention can be used to study the in vitro effects of shock waves on cells in culture and could be used to determine the effects of potential treatments for TBI in an in vitro cellular model. The device consists of a source of compressed gas connected to a chamber containing cells. Cells can be derived from central nervous system (CNS) tissue, muscle, etc. The effects of the release of the compressed gas (blast) on the cells can be monitored in real time in a microscope or other imaging device.&nbsp;</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Investigate the cellular effects of pressure waves in an in vitro model</li> <li>Use to screen for potential agents to treat traumatic brain injury (TBI)</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Allows for the real-time study of a blast effect on in vitro cellular models</li> <li>Allows for testing of potential therapies of traumatic brain injury in an in vitro model.&nbsp;</li> </ul> 2018-09-05 2026-04-30 2021-01-26 2026-04-30 2018-09-05 Central Nervous System, CNS, explosive blast, National Institute of Child Health and Human Development, NICHD, SIMULATOR, TBI, Traumatic Brain Injury, Zimmerberg False True Prototype True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-01-26 52406769 Prototype 52406769 NCI 37470483 Website Abstract 147164680 Ravin, Rea NIH - NICHD NIBIB Ravin, Rea (NIBIB) 1 147164678 Blank, Paul NIH - NICHD NICHD Blank, Paul (NICHD) 2 147164681 Steinkamp, Alex NIH - NICHD NICHD Steinkamp, Alex (NICHD) 3 147164677 Zimmerberg, Joshua NIH - NICHD NICHD Zimmerberg, Joshua (NICHD) 4 147164679 Bezrukov, Sergey NIH - NICHD NICHD Bezrukov, Sergey (NICHD) 5 147164682 Mcafee, Kim Lee NIH - NICHD Mcafee, Kim Lee 6 147164680 Ravin, Rea NIH - NICHD NIBIB Ravin, Rea (NIBIB) 1 147164678 Blank, Paul NIH - NICHD NICHD Blank, Paul (NICHD) 2 147164681 Steinkamp, Alex NIH - NICHD NICHD Steinkamp, Alex (NICHD) 3 147164677 Zimmerberg, Joshua NIH - NICHD NICHD Zimmerberg, Joshua (NICHD) 4 147164679 Bezrukov, Sergey NIH - NICHD NICHD Bezrukov, Sergey (NICHD) 5 147164682 Mcafee, Kim Lee NIH - NICHD Mcafee, Kim Lee 6 147157918 A Device To Simulate Explosive Blast For Use In Real Time Imaging Of Cells And Tissue. E-068-2012-0 Filing authorized NICHD 83682895 Girards, Richard richard.girards@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB richard.girards@nih.gov?subject=Web Inquiry on [TAB-4419] Device for Simulating Explosive Blast and Imaging Biological Specimens&body=Please send me information about technology [TAB-4419] Device for Simulating Explosive Blast and Imaging Biological Specimens.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Girards, Richard<br><a href="mailto:richard.girards@nih.gov?subject=Web Inquiry on [TAB-4419] Device for Simulating Explosive Blast and Imaging Biological Specimens&body=Please send me information about technology [TAB-4419] Device for Simulating Explosive Blast and Imaging Biological Specimens.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">richard.girards@nih.gov</a><br> 147168806 E-068-2012-0 E-068-2012-0-US-01 Device for Simulating Explosive Blast And Imaging Biological Specimen PRV US 61/590,209 Abandoned US <br />Provisional (PRV) 61/590,209<br />Filed on 2012-01-24<br />Status: Abandoned 147168807 E-068-2012-0 E-068-2012-0-US-02 Device For Simulating Explosive Blast And Imaging Biological Specimen ORD US 9,217,698 13/748,410 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9217698 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9217698">9,217,698</a><br />Filed on 2013-01-23<br />Status: Issued 147170708 Central Nervous System 147170709 CNS 147170710 explosive blast 147170711 National Institute of Child Health and Human Development 147170712 NICHD 147170713 SIMULATOR 147170714 TBI 147170715 Traumatic Brain Injury 147170717 Zimmerberg TAB-4417 147157712 Methods of Predicting Patient Treatment Response and Resistance via Single-Cell Transcriptomics of Their Tumors NCI Collaboration, Licensing, Oncology, Software / Apps Collaboration Licensing Oncology Software / Apps Eytan Ruppin, Alejandro Schaffer, Sanju Sinha, Rahulsimham Vegesna <h2>Summary:</h2> <p>The NCI is currently seeking research co-development partners for this first-in-kind computational method that is predictive of therapeutic response based on clonal SC gene expression of tumors.</p> <h2>Description of Technology:</h2> <p>Tailoring the best treatments to cancer patients remains a highly important endeavor in the oncology field. However, personalized treatment courses are challenging to determine, and technologies or methods that can successfully be employed for precision oncology are lacking.</p> <p>Researchers at the NCI have built a new method for guiding cancer patient therapy based on single cell transcriptomics data of their tumors. This precision oncology data science and software framework is termed PERsonalized single-Cell Expression-based Planning for Treatments In ONcology (PERCEPTION). It capitalizes on recent, matched bulk and single-cell transcriptome profiles sourced from large-scale cell-line drug screenings and builds treatment response models from patient single-cell (SC) tumor transcriptomes. As a proof-of-concept, PERCEPTION has been shown to successfully predict response to monotherapy and combination therapy based on SC-expression profiles, in screenings of standard cancer cell lines and patient-tumor-derived cell lines. It has also successfully identified responders to a combination therapy based on tumor SC-expression data from recent multiple myeloma and breast cancer clinical trials. Further, it has discovered the development of treatment resistance to five standard tyrosine kinase inhibitors in a recent SC dataset obtained from lung cancer patients undergoing treatment. PERCEPTION is the first technology to demonstrate that SC gene expression can provide a framework to predict effective targeted therapies for individual cancer patients in a data-driven manner.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Tool for personalized identification of effective patient therapies (precision oncology) based on single cell transcriptomics data of their tumors</li> <li>Tool for discovery of new drug combinations for specific cancer types and sub-types</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>First software of its kind that aims to tailor the best treatments to cancer patients based on single cell transcriptomics data of their tumors&nbsp; &nbsp; &nbsp;</li> <li>Has proof-of-concept retrospective validations in patient clinical trial data where PERCEPTION performed better than published state-of-the-art single-cell-based and bulk-based predictors&nbsp; &nbsp; &nbsp;</li> <li>Useful for companies focused on single cell sequencing or interested in the single cell domain</li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for a new method for guiding cancer patient therapy based on single cell transcriptomics data of their tumors. 2023-06-06 2026-04-30 2023-06-06 2026-04-30 2023-06-06 Cancer Prognosis, Cancer Treatment Resistance, COMPUTATIONAL, Precision Oncology, Ruppin, Single Cell, Single Cell Screening, Single Cell Transcriptomics, Transcriptomics, Tumor Response False True Prototype True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2023-06-06 52406769 Prototype 52406769 NCI 37470483 Website Abstract 147161872 Sinha. S, et al. 2022. bioRxiv. Predicting patient treatment response and resistance via single-cell transcriptomics of their tumors. https://doi.org/10.1101/2022.01.11.475728 <a href="https://doi.org/10.1101/2022.01.11.475728">Sinha. S, et al. 2022. bioRxiv. Predicting patient treatment response and resistance via single-cell transcriptomics of their tumors.</a> 147164668 Ruppin, Eytan NIH - NCI NCI Ruppin, Eytan (NCI) 1 147164670 Sinha, Sanju NCI - CCR NCI Sinha, Sanju (NCI) 2 147164671 Vegesna, Rahulsimham NCI - CCR NCI Vegesna, Rahulsimham (NCI) 3 147164669 Schaffer, Alejandro NIH - NCI NCI Schaffer, Alejandro (NCI) 4 147164668 Ruppin, Eytan NIH - NCI NCI Ruppin, Eytan (NCI) 1 147164670 Sinha, Sanju NCI - CCR NCI Sinha, Sanju (NCI) 2 147164671 Vegesna, Rahulsimham NCI - CCR NCI Vegesna, Rahulsimham (NCI) 3 147164669 Schaffer, Alejandro NIH - NCI NCI Schaffer, Alejandro (NCI) 4 147157874 PERsonalized Single-Cell Expression-based Planning For Treatments In ONcology (PERCEPTION) Software E-051-2022-0 Filing authorized NCI 83691647 Chang, Kevin changke@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB changke@mail.nih.gov?subject=Web Inquiry on [TAB-4417] Methods of Predicting Patient Treatment Response and Resistance via Single-Cell Transcriptomics of Their Tumors&body=Please send me information about technology [TAB-4417] Methods of Predicting Patient Treatment Response and Resistance via Single-Cell Transcriptomics of Their Tumors.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Chang, Kevin<br><a href="mailto:changke@mail.nih.gov?subject=Web Inquiry on [TAB-4417] Methods of Predicting Patient Treatment Response and Resistance via Single-Cell Transcriptomics of Their Tumors&body=Please send me information about technology [TAB-4417] Methods of Predicting Patient Treatment Response and Resistance via Single-Cell Transcriptomics of Their Tumors.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">changke@mail.nih.gov</a><br> 147168799 E-051-2022-0 E-051-2022-0-US-01 PREDICTING PATIENT TREATMENT RESPONSE AND RESISTANCE VIA SINGLE CELL TRANSCRIPTOMICS OF THEIR TUMORS PRV US 63/298,045 Expired US <br />Provisional (PRV) 63/298,045<br />Filed on 2022-01-10<br />Status: Expired 147168800 E-051-2022-0 E-051-2022-0-PCT-02 Predicting Patient Treatment Response and Resistance via Single-Cell Transcriptomics of their Tumors PCT Patent Cooperation Treaty PCT/US2023/060416 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2023/060416<br />Filed on 2023-01-10<br />Status: Expired 147170332 Cancer Prognosis 147170334 Cancer Treatment Resistance 147170335 COMPUTATIONAL 147170337 Precision Oncology 147170338 Ruppin 147170340 Single Cell 147170342 Single Cell Screening 147170344 Single Cell Transcriptomics 147170346 Transcriptomics 147170348 Tumor Response TAB-4123 147157405 Combined RNA and DNA Vaccination Strategy for Improving the Vaccine Immune Response NCI Collaboration, Infectious Disease, Licensing, Oncology, Vaccines Collaboration Infectious Disease Licensing Oncology Vaccines Barbara Felber, George Pavlakis <h2>Description of Technology:</h2> <p>The development of an effective HIV vaccine has been ongoing. HIV sequence diversity and immunodominance are major obstacles in the design of an effective vaccine. Researchers at the National Cancer Institute (NCI) developed a novel vaccine strategy combining both DNA and mRNA vaccination to induce an effective immune response. This combination strategy could also be used to develop vaccines against cancer or other infectious diseases (ex. SARS-CoV-2).&nbsp;<br /> Previous studies by NCI determined that regions of the polypeptides Gag and Env are both essential to the core structure and envelope of the HIV-1 virus. Co-administration of DNA expressing Gag and Env elicits a protective immune response and reduces infection burden.&nbsp;&nbsp;This current technology relates to earlier technology from the same inventors describing the identification of the conserved elements (CE) within HIV-1 p24Gag. Specifically, the inventors demonstrated that priming with p24gag CE followed by vaccination with either a full-length p55gag DNA plasmid or p24gag CE DNA together with full-length p55gag DNA increased the CE responses compared to vaccination with p24CE DNA alone.&nbsp;&nbsp;</p> <p>The current invention expands upon the earlier technology, combining DNA and RNA vaccination strategies to induce an effective HIV immune response.&nbsp;&nbsp;The inventors demonstrated that administration of gag mRNA/LNP efficiently boosted both humoral and cellular responses in rhesus macaques previously immunized by a Gag DNA-based vaccine. Furthermore, the mRNA/LNP as booster vaccination induced more potent cytotoxic T cell responses than using mRNA as prime. Overall, this invention describes a heterologous prime/boost regimen including a DNA prime followed by mRNA boost vaccination with the same or similar immunogens &ndash; resulting in optimal levels of humoral and cellular immune response. The use of a mRNA booster to stimulate DNA primed immunity may be broadly applicable as a vaccination strategy for other infectious diseases and cancer.&nbsp;</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Prophylactic and therapeutic vaccines for HIV</li> <li>Prophylactic and therapeutic vaccines for&nbsp;infectious diseases</li> <li>Prophylactic and therapeutic vaccines for cancer</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Addresses key hurdle faced by current HIV vaccines: sequence diversity of HIV and immunodominance of specific epitopes</li> <li>Induces optimal cellular and humoral responses</li> <li>Reduces infectious burden</li> <li>Potential vaccine strategy applicable to other non-HIV diseases, such as cancer</li> <li>In vivo validation of vaccine strategy in non-human primates (rhesus macaques)</li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for development of a RNA/DNA combination vaccine against infectious diseases (ex: HIV, SARS-CoV-2) or cancer 2023-07-04 2026-04-24 2023-07-05 2026-04-29 2023-07-04 CANCER VACCINE, DNA vaccine, ENV, Felber, GAG, HIV, Infectious Disease, Nci, Pavlakis, RNA Vaccine, SARS-CoV-2, Vaccine False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2023-07-05 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-087-2015 E-132-2012 147162002 Valentin A, et al. 2022. Comparative immunogenicity of an mRNA/LNP and a DNA vaccine targeting HIV gag conserved elements in macaques. (PMID: 35935984) https://pubmed.ncbi.nlm.nih.gov/35935984/ <a href="https://pubmed.ncbi.nlm.nih.gov/35935984/">Valentin A, et al. 2022. Comparative immunogenicity of an mRNA/LNP and a DNA vaccine targeting HIV gag conserved elements in macaques. (PMID: 35935984)</a> 147163589 Felber, Barbara NIH - NCI NCI Felber, Barbara (NCI) 1 147163588 Pavlakis, George NIH - NCI NCI Pavlakis, George (NCI) 2 147163589 Felber, Barbara NIH - NCI NCI Felber, Barbara (NCI) 1 147163588 Pavlakis, George NIH - NCI NCI Pavlakis, George (NCI) 2 147158103 Immunogens And Methods To Improve Vaccine Immune Response E-158-2022-0 Filing authorized NCI 91814193 Freel, Rose rose.freel@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America rose.freel@nih.gov?subject=Web Inquiry on [TAB-4123] Combined RNA and DNA Vaccination Strategy for Improving the Vaccine Immune Response&body=Please send me information about technology [TAB-4123] Combined RNA and DNA Vaccination Strategy for Improving the Vaccine Immune Response.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Freel, Rose<br><a href="mailto:rose.freel@nih.gov?subject=Web Inquiry on [TAB-4123] Combined RNA and DNA Vaccination Strategy for Improving the Vaccine Immune Response&body=Please send me information about technology [TAB-4123] Combined RNA and DNA Vaccination Strategy for Improving the Vaccine Immune Response.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">rose.freel@nih.gov</a><br> 147161119 E-158-2022-0 E-158-2022-0-US-01 IMMUNOGENS AND METHODS FOR INDUCING AN IMMUNE RESPONSE PRV US 63/358,919 Expired US <br />Provisional (PRV) 63/358,919<br />Filed on 2022-07-07<br />Status: Expired 147166705 E-158-2022-0 E-158-2022-0-PC-01 IMMUNOGENS AND METHODS FOR INDUCING AN IMMUNE RESPONSE PCT Patent Cooperation Treaty PCT/US2023/069057 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2023/069057<br />Filed on 2023-06-26<br />Status: Expired 147172586 CANCER VACCINE 147172587 DNA vaccine 147172588 ENV 147172589 Felber 147172590 GAG 147172591 HIV 147172592 Infectious Disease 147172593 Nci 147172594 Pavlakis 147172596 RNA Vaccine 147172597 SARS-CoV-2 147172598 Vaccine TAB-4122 147157404 Development and Characterization of the SLC46A3 Knockout Mouse Line NCI Endocrinology, Licensing, Oncology, Research Materials Endocrinology Licensing Oncology Research Materials Frank Gonzalez, Jung-Hwan Kim, Sun Hee Yim <h2>Summary:</h2> <p>The NCI is seeking licensees for the SLC46A3 knockout mouse line.</p> <h2>Description of Technology:</h2> <p>Nonalcoholic fatty liver disease is caused by several factors including 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), an environmental contaminant. TCDD causes lipid accumulation in humans by inducing the Solute Carrier Family 46 Member 3 (SLC46A3) gene expression. To effectively study TCDD-mediated lipid accumulation, research tools such as SLC46A3 knockout cells and animal models are required.</p> <p>Researchers at the National Cancer Institute (NCI) have developed an SLC46A3 knockout mouse line and demonstrated that TCDD-induced hepatic triglyceride accumulation was significantly reduced in the knockout mice compared to the wild type mice. This reduction in triglyceride accumulation was more pronounced when the mice were fed a high fat diet. The SLC46A3 knockout mouse line is therefore an effective tool to study TCDD-induced lipid accumulation, liver toxicity and nonalcoholic fatty liver disease. As SLC46A3 gene and protein are also associated with other diseases such as breast cancer, prostate cancer, liver cancer, papilloma, glioma, obesity, and SARS, this knockout mouse line may have wide applicability.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Drug screening and development against various diseases such as nonalcoholic fatty liver disease, obesity, liver cancer, SARS, breast cancer, prostate cancer, papilloma, glioma</li> <li>Research tool to study SLC46A3&rsquo;s role in hepatic lipid accumulation or as a solute carrier of the Major Facilitator Superfamily (MFS)</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>The only known SLC46A knockout mouse line available</li> <li>Effective research tool to study TCDD-mediated liver toxicity leading to nonalcoholic fatty liver disease&nbsp;</li> </ul> 2021-07-14 2026-04-24 2021-07-14 2026-04-29 2021-07-14 2, 3, 7, 8-tetracholodibenzo-p-dioxin, Gonzalez, hepatocellular carcinoma, Knockout Mouse, Liver cancer, Major Facilitator Superfamily, MFS, Nonalcoholic fatty liver disease, OBESITY, SLC46A3, Solute Carrier Family, TCDD False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-07-14 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147162426 Kim JH, et al. Lysosomal SLC46A3 modulates hepatic cytosolic copper homeostasis. (PMID 33436590) https://pubmed.ncbi.nlm.nih.gov/33436590/ <a href="https://pubmed.ncbi.nlm.nih.gov/33436590/">Kim JH, et al. Lysosomal SLC46A3 modulates hepatic cytosolic copper homeostasis. (PMID 33436590)</a> 147163585 Gonzalez, Frank NIH - NCI NCI Gonzalez, Frank (NCI) 1 147163586 Yim, Sun Hee NIH - NCI Yim, Sun Hee 2 147163587 Kim, Jung-Hwan NIH - NCI Kim, Jung-Hwan 3 147163585 Gonzalez, Frank NIH - NCI NCI Gonzalez, Frank (NCI) 1 147163586 Yim, Sun Hee NIH - NCI Yim, Sun Hee 2 147163587 Kim, Jung-Hwan NIH - NCI Kim, Jung-Hwan 3 147158087 Development And Characterization Of Teh SLC46A3 Knockout Mouse Line E-152-2021-0 Research Material NCI 83740301 Dattaroy, Diptadip diptadip.dattaroy@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB diptadip.dattaroy@nih.gov?subject=Web Inquiry on [TAB-4122] Development and Characterization of the SLC46A3 Knockout Mouse Line&body=Please send me information about technology [TAB-4122] Development and Characterization of the SLC46A3 Knockout Mouse Line.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dattaroy, Diptadip<br><a href="mailto:diptadip.dattaroy@nih.gov?subject=Web Inquiry on [TAB-4122] Development and Characterization of the SLC46A3 Knockout Mouse Line&body=Please send me information about technology [TAB-4122] Development and Characterization of the SLC46A3 Knockout Mouse Line.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">diptadip.dattaroy@nih.gov</a><br> 147172441 2 147172442 3 147172443 7 147172445 8-tetracholodibenzo-p-dioxin 147172447 Gonzalez 147172448 hepatocellular carcinoma 147172450 Knockout Mouse 147172451 Liver cancer 147172453 Major Facilitator Superfamily 147172455 MFS 147172457 Nonalcoholic fatty liver disease 147172458 OBESITY 147172459 SLC46A3 147172461 Solute Carrier Family 147172463 TCDD TAB-3980 147157261 Polymer-Cast Inserts for Cell Histology and Microscopy NCI Collaboration, Dermatology, Immunology, Infectious Disease, Licensing, Research Materials Collaboration Dermatology Immunology Infectious Disease Licensing Research Materials Thu Nguyen, Ralph Parchment <h2>Summary:</h2> <p>The National Cancer Institute (NCI) seeks co-development partners and/or licensees for polymer-cast inserts for cell histology and microscopy; a system for high throughput three-dimensional (3D) cell culture and screening microscopy.</p> <h2>Description of Technology:</h2> <p>Three-dimensional (3D) cell cultures systems are important for studying cell biology because they provide <em>in vivo-</em>like microenvironments more physiologically relevant than two-dimensional (2D) culture systems. In 3D culture systems, cells are grown in culture matrixes and turn into spheroids and organoids later processed for downstream analysis by microscopy and histology techniques. The processing of 3D cultures for analysis by microscopy or histology is laborious and time-consuming due to incompatibility of the 3D culture vessels and the microscopy and pathology blocks. Therefore, it is not amenable to high-throughput analysis.</p> <p>NCI scientists developed polymer-cast inserts for cell histology and microscopy (PICHAM), made of soft biocompatible polymer compatible with immunofluorescence microscopy. The technology encompasses fixation for paraffin embedding and sectioning, into which an array of vertical wells were bored to harbor cells in culture in the form of spheroids, organoids or other tissue replicas. A PICHAM is cast as a rectangular cuboid designed and fabricated with dimensions to precisely fit into standard histology cassettes. It is envisioned to provide a one-piece system that allows a seamless transition from 3D culture to high-throughput histopathology and microscopy analysis of spheroids and organoids. Due to the compatibility of PICHAMs with both cell culture and histopathology processes, it will eliminate a major roadblock in high throughput processing of 3D cell cultures for microscopy and histopathology analyses.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Research tool for cell biology</li> <li>Growing 3D cell cultures for histology and microscopy analysis</li> <li>High-throughput processing of 3D cell cultures for microscopy and histopathology analysis&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Minimizes processing of 3D cell cultures for histopathology analysis</li> <li>Saves time by reducing processes and eliminating manual steps</li> <li>Enables high-throughput microscopy and histopathology analysis of 3D cultures</li> <li>Minimizes disruptions of 3D cell cultures during processing</li> <li>Compatibility with both 3D cell culture vessels and histopathology cassettes reduces supplies required</li> </ul> 2021-06-12 2026-04-24 2021-06-14 2026-04-29 2021-06-11 3D Cell Culture, high-throughput screening, Histology, Histopathology, MICROSCOPY, Organoids, Parchment, Polymer-cast, Spheroids False True Prototype True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-06-14 52406769 Prototype 52406769 NCI 37470483 Website Abstract 147162164 Huang H, et al. Peptide hydrogelation and cell encapsulation for 3D culture of MCF-7 breast cancer cells. (PMID 23527204) https://pubmed.ncbi.nlm.nih.gov/23527204/ <a href="https://pubmed.ncbi.nlm.nih.gov/23527204/">Huang H, et al. Peptide hydrogelation and cell encapsulation for 3D culture of MCF-7 breast cancer cells. (PMID 23527204)</a> 147163107 Parchment, Ralph NIH - NCI Leidos Parchment, Ralph (Leidos) 1 147163108 Nguyen, Thu NIH - NCI Nguyen, Thu 2 147163107 Parchment, Ralph NIH - NCI Leidos Parchment, Ralph (Leidos) 1 147163108 Nguyen, Thu NIH - NCI Nguyen, Thu 2 147158192 Polymer-cast Inserts For Cell Histology And Microscopy (PICHAMs) - A System For High Throughput 3D Cell Culture And Screening Micro_scopy E-196-2018-0 Filing authorized NCI 83704821 Nguyen-Antczak, Lauren lauren.nguyen-antczak@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-3980] Polymer-Cast Inserts for Cell Histology and Microscopy&body=Please send me information about technology [TAB-3980] Polymer-Cast Inserts for Cell Histology and Microscopy.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Nguyen-Antczak, Lauren<br><a href="mailto:lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-3980] Polymer-Cast Inserts for Cell Histology and Microscopy&body=Please send me information about technology [TAB-3980] Polymer-Cast Inserts for Cell Histology and Microscopy.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">lauren.nguyen-antczak@nih.gov</a><br> 147161181 E-196-2018-0 E-196-2018-0-US-01 INSERT FOR PREPARING CELL CULTURE CHAMBERS PRV US 63/058,794 Abandoned US <br />Provisional (PRV) 63/058,794<br />Filed on 2020-07-30<br />Status: Abandoned 147165678 E-196-2018-0 E-196-2018-0-PCT-02 INSERT FOR PREPARING CELL CULTURE CHAMBERS PCT Patent Cooperation Treaty PCT/US2021/043930 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/043930<br />Filed on 2021-07-30<br />Status: Expired 147165679 E-196-2018-0 E-196-2018-0-US-02 INSERT FOR PREPARING CELL CULTURE CHAMBERS National Stage US 18/018,762 Pending US <br />National Stage 18/018,762<br />Filed on 2023-01-30<br />Status: Pending 147173485 3D Cell Culture 147173486 high-throughput screening 147173487 Histology 147173488 Histopathology 147173489 MICROSCOPY 147173490 Organoids 147173492 Parchment 147173493 Polymer-cast 147173494 Spheroids TAB-5050 162271610 Broadly neutralizing influenza hemagglutinin stem-directed antibodies NIAID Antibodies, Application, Collaboration, Collaboration Sought, Immunology, Infectious Disease, Licensing, Materials Available, Therapeutics, Vaccines Antibodies Application Collaboration Collaboration Sought Immunology Infectious Disease Licensing Materials Available Therapeutics Vaccines Sarah Andrews, Ankita Chopde, Adrian Creanga, Rebecca Gillespie, Masaru Kanekiyo, Grace Mantus, Julie Raab <p>In 2023, the World Health Organization (WHO) reported roughly 3 to 5 million cases of severe influenza worldwide, resulting in approximately 290,000 to 650,000 deaths. Given the high disease burden, the needs for both prophylactic and therapeutic influenza strategies remain significant. However, current treatments for influenza are susceptible to resistance and are useful for only a limited post-infection period. &nbsp;&nbsp;&nbsp;</p> <p>The highly conserved epitopes in the stem region of the influenza hemagglutinin (HA) protein are ideal targets for new vaccines, as they elicit broadly neutralizing antibodies. In light of this, researchers at the National Institute of Allergy and Infectious Diseases (NIAID) cloned and expressed HA stem-specific monoclonal antibodies (mAbs) from B cells isolated from human participants in influenza vaccine clinical trials. Four mAbs exhibited particularly potent neutralizing profiles against H1N1 strains, three exhibited very strong neutralization profiles against H3N2 strains, and two exhibited a good neutralization profile across all subtypes tested. These mAbs may help to substantially reduce global influenza disease burden given their potential to become effective therapeutic and prophylactic agents against a broad range of H1N1 and H3N2 influenza strains.</p> <p>This technology is available for licensing for commercial development in accordance with 35 U.S.C. &sect; 209 and 37 CFR Part 404, as well as for further development and evaluation under a research collaboration.</p> <ul> <li>Greater neutralization potency against H1N1 and H3N2 strains than observed for other high-profile candidates tested in phase II clinical trials</li> </ul> <ul> <li>Prophylactic or therapeutic strategies against influenza infection</li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. For collaboration opportunities, please contact Wade Green at 301-761-7505, or wade.green@nih.gov, and reference E-026-2024. 2025-05-08 2025-05-08 2026-04-29 2025-05-09 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 162272045 Andrews SF, et al. An influenza H1 hemagglutinin stem-only immunogen elicits a broadly cross-reactive B cell response in humans. Sci. Transl. Med. 2023;15:eade4976. https://doi.org/10.1126/scitranslmed.ade4976 <a href="https://doi.org/10.1126/scitranslmed.ade4976">Andrews SF, et al. An influenza H1 hemagglutinin stem-only immunogen elicits a broadly cross-reactive B cell response in humans. Sci. Transl. Med. 2023;15:eade4976.</a> 162272059 Mantus GE, et al. Vaccination with different group 2 influenza subtypes alters epitope targeting and breadth of hemagglutinin stem–specific human B cells. Sci. Transl. Med. 2025;17:eadr8373. https://doi.org/10.1126/scitranslmed.adr8373 <a href="https://doi.org/10.1126/scitranslmed.adr8373">Mantus GE, et al. Vaccination with different group 2 influenza subtypes alters epitope targeting and breadth of hemagglutinin stem–specific human B cells. Sci. Transl. Med. 2025;17:eadr8373.</a> 162271755 Andrews, Sarah NIAID - VRC NIAID Andrews, Sarah (NIAID) 1 162271768 Mantus, Grace NIAID - VRC NIAID Mantus, Grace (NIAID) 2 162271782 Chopde, Ankita NIAID - VRC NIAID Chopde, Ankita (NIAID) 3 162271793 Creanga, Adrian NIAID - VRC NIAID Creanga, Adrian (NIAID) 4 162271809 Gillespie, Rebecca NIAID - VRC NIAID Gillespie, Rebecca (NIAID) 5 162271837 Kanekiyo, Masaru National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Kanekiyo, Masaru (NIAID) 6 162271842 Raab, Julie University of Colorado NIAID Raab, Julie (NIAID) 7 162271755 Andrews, Sarah NIAID - VRC NIAID Andrews, Sarah (NIAID) 1 162271768 Mantus, Grace NIAID - VRC NIAID Mantus, Grace (NIAID) 2 162271782 Chopde, Ankita NIAID - VRC NIAID Chopde, Ankita (NIAID) 3 162271793 Creanga, Adrian NIAID - VRC NIAID Creanga, Adrian (NIAID) 4 162271809 Gillespie, Rebecca NIAID - VRC NIAID Gillespie, Rebecca (NIAID) 5 162271837 Kanekiyo, Masaru National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Kanekiyo, Masaru (NIAID) 6 162271842 Raab, Julie University of Colorado NIAID Raab, Julie (NIAID) 7 162271613 Broadly neutralizing influenza hemagglutinin stem-directed antibodies E-026-2024-0 Filing authorized National Institute of Allergy and Infectious Diseases (NIAID/NIH), NIAID - VRC, NIAID - VRC 91026778 Green, Wade wade.green@nih.gov
United States of America TTIPO wade.green@nih.gov?subject=Web Inquiry on [TAB-5050] Broadly neutralizing influenza hemagglutinin stem-directed antibodies&body=Please send me information about technology [TAB-5050] Broadly neutralizing influenza hemagglutinin stem-directed antibodies. Green, Wade<br><a href="mailto:wade.green@nih.gov?subject=Web Inquiry on [TAB-5050] Broadly neutralizing influenza hemagglutinin stem-directed antibodies&body=Please send me information about technology [TAB-5050] Broadly neutralizing influenza hemagglutinin stem-directed antibodies.">wade.green@nih.gov</a><br> 162271618 E-026-2024-0 E-026-2024-0-US-01 Broadly neutralizing influenza hemagglutinin stem-directed antibodies PRV US 63/605,374 Expired US <br />Provisional (PRV) 63/605,374<br />Filed on 2023-12-01<br />Status: Expired 162271619 E-026-2024-0 E-026-2024-0-PC-01 BROADLY NEUTRALIZING INFLUENZA HEMAGGLUTININ STEM-DIRECTED ANTIBODIES PCT Patent Cooperation Treaty PCT/US2024/057131 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2024/057131<br />Filed on 2024-11-22<br />Status: Expired 167038722 E-026-2024-0 E-026-2024-0-US-02 BROADLY NEUTRALIZING INFLUENZA HEMAGGLUTININ STEM-DIRECTED ANTIBODIES National Stage US In Preparation US <br />National Stage None<br />Filed on None<br />Status: In Preparation 167038787 E-026-2024-0 E-026-2024-0-EP-01 BROADLY NEUTRALIZING INFLUENZA HEMAGGLUTININ STEM-DIRECTED ANTIBODIES National Stage European Patent In Preparation European Patent <br />National Stage None<br />Filed on None<br />Status: In Preparation TAB-3949 147157229 Cross Species Single Domain Antibodies Targeting PD-L1 for Treating Solid Tumors NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Chi-Ping Day, Hejiao English, Mitchell Ho, Dan Li, Glenn Merlino <h2>Description of Technology:</h2> <p>Programed Death-Ligand 1 (PD-L1, also known as B7-H1 or CD274) is a cell surface protein that binds to Programmed Cell Death Protein 1 (PD-1, also known as CD279). An imbalance in PD-1/PD-L1 activity contributes to cancer immune escape.&nbsp; PD-1 is expressed on the surface of antigen-stimulated T cells. The interaction between PD-L1 and PD-1 negatively regulates T cell-mediated immune responses. It has been suggested that disrupting the PD-L1/PD-1 signaling pathway can be used to treat cancers. The aberrant expression of PD-L1 on multiple tumor types supports this suggestion. As a result, PD-L1 represents a strong target for the development of new anti-cancer therapeutics.&nbsp;</p> <p>Researchers at the NCI&rsquo;s Laboratory of Molecular Biology have isolated three anti-PD-L1 single domain antibodies (also known as nanobodies), B2, A11, and F5 that target PD-L1. These nanobodies can be used either as independent agents or as the targeting domain in chimeric antigen receptors (CARs), antibody drug conjugates (ADCs), recombinant immunotoxins (RITs), and bispecific antibodies. Significantly, CARs using these antibodies has shown potent in vitro and in vivo killing against PD-L1 positive tumors, including liver and triple-negative breast cancer, strongly supporting that these candidates may be further developed as therapeutics.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Therapeutic applications include the unconjugated antibodies and their use as a targeting moiety for CARs, RITs, ADCs, and bispecific antibodies</li> <li>Therapeutics against PD-L1-expressing cancers, including liver, bladder, pancreatic, prostate, gastric and triple-negative breast cancer</li> <li>Diagnostic agent for detection and monitoring levels of PD-L1-expressing cancers</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>These anti-PD-L1 nanobodies have an advantage, due to their small size, to potentially bind to epitopes unavailable to more conventional antibodies</li> <li>Cross-species reactivity in mouse and human</li> <li>Combination of B2 and hYP7 CARs in T cells improves lysis of liver cancer cells in mice compared to either CAR alone</li> <li>CARs using the B2 single domain antibody are available for immediate testing</li> </ul> 2021-07-14 2026-04-29 2021-08-05 2026-04-29 2021-08-05 adoptive cell therapy, Chimeric Antigen Receptor T Cells, HO, ICI, Immune Checkpoint Inhibitor, Immunotherapy, NANOBODY, PD-L1, phage display, Programed Death-Ligand, Single Domain Antibody False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-08-05 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-136-2012 147162983 Ho, Mitchell NIH - NCI NCI Ho, Mitchell (NCI) 1 147162982 Merlino, Glenn NIH - NCI NCI Merlino, Glenn (NCI) 2 147162986 Li, Dan NCI - CCR NCI Li, Dan (NCI) 3 147162984 English, Hejiao NIH - NCI NCI English, Hejiao (NCI) 4 147162985 Day, Chi-Ping NIH - NCI NCI Day, Chi-Ping (NCI) 5 147162983 Ho, Mitchell NIH - NCI NCI Ho, Mitchell (NCI) 1 147162982 Merlino, Glenn NIH - NCI NCI Merlino, Glenn (NCI) 2 147162986 Li, Dan NCI - CCR NCI Li, Dan (NCI) 3 147162984 English, Hejiao NIH - NCI NCI English, Hejiao (NCI) 4 147162985 Day, Chi-Ping NIH - NCI NCI Day, Chi-Ping (NCI) 5 153379661 Cross Species Single Domain Antibodies Targeting PD-L1 For Treating Solid Tumors E-118-2021-0 Filing authorized NCI 83731987 Dhal, Abritee abritee.dhal@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-3949] Cross Species Single Domain Antibodies Targeting PD-L1 for Treating Solid Tumors&body=Please send me information about technology [TAB-3949] Cross Species Single Domain Antibodies Targeting PD-L1 for Treating Solid Tumors.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dhal, Abritee<br><a href="mailto:abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-3949] Cross Species Single Domain Antibodies Targeting PD-L1 for Treating Solid Tumors&body=Please send me information about technology [TAB-3949] Cross Species Single Domain Antibodies Targeting PD-L1 for Treating Solid Tumors.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">abritee.dhal@nih.gov</a><br> 147161068 E-118-2021-0 E-118-2021-0-US-01 CROSS SPECIES SINGLE DOMAIN ANTIBODIES TARGETING PD-L1 FOR TREATING SOLID TUMORS PRV US 63/208,755 Abandoned US <br />Provisional (PRV) 63/208,755<br />Filed on 2021-06-09<br />Status: Abandoned 147165506 E-118-2021-0 E-118-2021-0-PCT-02 Cross Species Single Domain Antibodies Targeting PD-L1 For Treating Solid Tumors PCT Patent Cooperation Treaty PCT/US2022/032378 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2022/032378<br />Filed on 2022-06-06<br />Status: Expired 153379665 E-118-2021-0 E-118-2021-0-CA-01 Cross Species Single Domain Antibodies Targeting PD-L1 For Treating Solid Tumors National Stage Canada 3216228 Pending Canada <br />National Stage 3216228<br />Filed on 2023-10-04<br />Status: Pending 153379666 E-118-2021-0 E-118-2021-0-AU-01 Cross Species Single Domain Antibodies Targeting PD-L1 For Treating Solid Tumors National Stage Australia 2022291120 Pending Australia <br />National Stage 2022291120<br />Filed on 2023-11-01<br />Status: Pending 153379667 E-118-2021-0 E-118-2021-0-CN-01 Cross Species Single Domain Antibodies Targeting PD-L1 For Treating Solid Tumors National Stage China 202280041531.8 Pending China <br />National Stage 202280041531.8<br />Filed on 2023-12-08<br />Status: Pending 153379668 E-118-2021-0 E-118-2021-0-US-02 Cross Species Single Domain Antibodies Targeting PD-L1 For Treating Solid Tumors National Stage US 18/567,990 Pending US <br />National Stage 18/567,990<br />Filed on 2023-12-07<br />Status: Pending 153379669 E-118-2021-0 E-118-2021-0-EP-01 Cross Species Single Domain Antibodies Targeting PD-L1 For Treating Solid Tumors National Stage European Patent 22738126.6 Pending European Patent <br />National Stage 22738126.6<br />Filed on 2023-10-18<br />Status: Pending 147171812 adoptive cell therapy 147171814 Chimeric Antigen Receptor T Cells 147171815 HO 147171816 ICI 147171818 Immune Checkpoint Inhibitor 147171819 Immunotherapy 147171820 NANOBODY 147171821 PD-L1 147171822 phage display 147171824 Programed Death-Ligand 147171825 Single Domain Antibody TAB-3004 114096419 Gene Therapy for Niemann-Pick Disease Type C NHGRI Collaboration, Endocrinology, Neurology, Therapeutics Collaboration Endocrinology Neurology Therapeutics Randy Chandler, William ("Bill") Pavan, Charles Venditti Investigators at the National Human Genome Research Institute (NHGRI) of the National Institutes of Health (NIH) are seeking collaborators to further develop gene therapy to treat Niemann-Pick Disease Type C (NPC). NPC is a rare, autosomal recessive, neurodegenerative disease. Approximately 95% of patients with NPC have mutations in NPC1, a gene implicated in intracellular cholesterol trafficking. Mutations of NPC1 cause intracellular accumulation of unesterified cholesterol in late endosomal/lysosomal structures and marked accumulation of glycosphingolipids, especially in neuronal tissue. Thus, NPC patients generally present with hepatosplenomegaly (enlargement of liver and spleen) and neurological degeneration.<br /><br /> NHGRI investigators have generated adeno-associated viral (AAV) constructs that are able to correct cellular defects of certain cholesterol storage disease or disorders, such as NPC, in vivo. <ul> <li>Optimized components of the vectors (e.g., specific promoters).</li> <li>Shown to work in animal (murine) models.</li> </ul> <ul> <li>Potential for successful gene therapy for patients with NPC.</li> <li>Can lead to similar approaches for treating other cholesterol storage disorders.</li> </ul> NHGRI is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize these gene therapy vectors. For collaboration opportunities please contact Anna Solowiej at the email address above. 2022-03-08 2026-04-28 2026-04-28 2016-04-18 Adeno-associated, C, Disease, Gene, Listed LPM Contreras as of 4/15/2015, NIEMANN-PICK, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, THERAPY, treatment, TYPE, VEXXXX, VHXXXX, viral, WJXXXX, XEXXXX False True True NIHTT 37470483 Website Abstract 114107080 Chandler, Randy National Human Genome Research Institute (NHGRI) NHGRI Chandler, Randy (NHGRI) 0 114107081 Pavan, William ("Bill") National Human Genome Research Institute (NHGRI) NHGRI Pavan, William ("Bill") (NHGRI) 0 114107079 Venditti, Charles National Human Genome Research Institute (NHGRI) NHGRI Venditti, Charles (NHGRI) 1 114107079 Venditti, Charles National Human Genome Research Institute (NHGRI) NHGRI Venditti, Charles (NHGRI) 1 114107080 Chandler, Randy National Human Genome Research Institute (NHGRI) NHGRI Chandler, Randy (NHGRI) 0 114107081 Pavan, William ("Bill") National Human Genome Research Institute (NHGRI) NHGRI Pavan, William ("Bill") (NHGRI) 0 114101516 Adeno-associated Viral Gene Therapy As A New Treatment For Niemann-Pick Disease Type C E-185-2014-0 Filing authorized National Human Genome Research Institute (NHGRI) 83703934 Solowiej, Anna anna.solowiej@nih.gov
United States of America anna.solowiej@nih.gov?subject=Web Inquiry on [TAB-3004] Gene Therapy for Niemann-Pick Disease Type C&body=Please send me information about technology [TAB-3004] Gene Therapy for Niemann-Pick Disease Type C. Solowiej, Anna<br><a href="mailto:anna.solowiej@nih.gov?subject=Web Inquiry on [TAB-3004] Gene Therapy for Niemann-Pick Disease Type C&body=Please send me information about technology [TAB-3004] Gene Therapy for Niemann-Pick Disease Type C.">anna.solowiej@nih.gov</a><br> 114164810 E-185-2014-0 E-185-2014-0-PCT-02 Viral Gene Therapy As Treatment For Cholesterol Storage Disease or Disorder PCT Patent Cooperation Treaty PCT/US2016/026524 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2016/026524<br />Filed on 2016-04-07<br />Status: Expired 114166393 E-185-2014-0 E-185-2014-0-US-01 VIRAL GENE THERAPY AS TREATMENT FOR CHOLESTEROL STORAGE DISEASE OR DISORDER PRV US 62/144,702 Abandoned US <br />Provisional (PRV) 62/144,702<br />Filed on 2015-04-08<br />Status: Abandoned 114168403 E-185-2014-0 E-185-2014-0-US-04 VIRAL GENE THERAPY AS TREATMENT FOR CHOLESTEROL STORAGE DISEASE OR DISORDER National Stage US 15/565,065 Abandoned US <br />National Stage 15/565,065<br />Filed on 2016-04-07<br />Status: Abandoned 114169057 E-185-2014-0 E-185-2014-0-US-12 VIRAL GENE THERAPY AS TREATMENT FOR CHOLESTEROL STORAGE DISEASE OR DISORDER DIV US 12,201,658 17/033,166 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12201658 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12201658">12,201,658</a><br />Filed on 2020-09-25<br />Status: Issued 166893950 E-185-2014-0 E-185-2014-0-EP-06 Viral Gene Therapy As Treatment For Cholesterol Storage Disease or Disorder National Stage European Patent 3280451 16717228.7 Issued European Patent <br />National Stage 16717228.7<br />Filed on 2016-04-07<br />Status: Issued 166893955 E-185-2014-0 E-185-2014-0-CA-05 Viral Gene Therapy As Treatment For Cholesterol Storage Disease or Disorder National Stage Canada 2982129 Pending Canada <br />National Stage 2982129<br />Filed on 2016-04-07<br />Status: Pending 166893960 E-185-2014-0 E-185-2014-0-DE-07 Viral Gene Therapy As Treatment For Cholesterol Storage Disease or Disorder EP Germany 3280451 16717228.7 Issued Germany <br />European patent (EP) 16717228.7<br />Filed on 2016-04-07<br />Status: Issued 166893965 E-185-2014-0 E-185-2014-0-ES-08 Viral Gene Therapy As Treatment For Cholesterol Storage Disease or Disorder EP Spain 3280451 16717228.7 Issued Spain <br />European patent (EP) 16717228.7<br />Filed on 2016-04-07<br />Status: Issued 166893970 E-185-2014-0 E-185-2014-0-FR-09 Viral Gene Therapy As Treatment For Cholesterol Storage Disease or Disorder EP France 3280451 16717228.7 Issued France <br />European patent (EP) 16717228.7<br />Filed on 2016-04-07<br />Status: Issued 166893975 E-185-2014-0 E-185-2014-0-GB-10 Viral Gene Therapy As Treatment For Cholesterol Storage Disease or Disorder EP United Kingdom 3280451 16717228.7 Issued United Kingdom <br />European patent (EP) 16717228.7<br />Filed on 2016-04-07<br />Status: Issued 166893980 E-185-2014-0 E-185-2014-0-IT-11 Viral Gene Therapy As Treatment For Cholesterol Storage Disease or Disorder EP Italy 3280451 16717228.7 Issued Italy <br />European patent (EP) 16717228.7<br />Filed on 2016-04-07<br />Status: Issued 166893987 E-185-2014-0 E-185-2014-0-US-02 VIRAL GENE THERAPY AS TREATMENT FOR CHOLESTEROL STORAGE DISEASE OR DISORDER CON US 18/976,790 Pending US <br />Continuation (CON) 18/976,790<br />Filed on 2024-12-11<br />Status: Pending 114121791 VEXXXX 114121792 VHXXXX 114121793 WJXXXX 114121794 XEXXXX 114137443 Listed LPM Contreras as of 4/15/2015 114137444 Pre LPM working set 20150418 114137445 Post LPM Assignment Set 20150420 114140967 Adeno-associated 114140968 viral 114140969 Gene 114140970 THERAPY 114140971 treatment 114140972 NIEMANN-PICK 114140973 Disease 114140974 TYPE 114140975 C TAB-3848 146937956 Treating Kidney Disorders and Diabetic Nephropathy with N-acetyl mannosamine (ManNAc) NHGRI Therapeutics Therapeutics William Gahl, Marjan Huizing, Enriko Klootwijk, Eirini (Irini) Manoli <p>N-acetylmannosamine (ManNAc) is a small uncharged physiological molecule that crosses membranes readily and is the natural precursor of intracellular sialic acid synthesis. NHGRI investigators discovered that ManNAc can be used for therapeutic purposes, including treating certain kidney diseases (e.g., those involving abnormal levels of protein in the urine and/or blood in the urine), resulting primarily or secondarily from hyposialylation (deficiency of sialic acid). Notably, ManNAc can also potentially be used to treat diabetic nephropathy.</p> <p>ManNAc therapy is given orally and shows long-term safety and biochemical efficacy, consistent with its mechanism of action in humans.</p> <p>Thus, the following fields of use are available for licensing: Treating <strong>kidney disorders</strong> due to hyposialylation of the glomerular basement membrane (GBM), including but not limited to minimal change disease glomerulopathy (MCD), focal segmental glomerulosclerosis (FSGS), membranous nephropathy (MN), and diabetic nephropathy in humans with oral formulations of N-acetyl mannosamine (ManNAc) or derivative.</p> <p><img alt="" src="https://nih.technologypublisher.com/files/sites/huizing_et_al_graphical_abstract__tto_21apr2026.jpg" style="height:720px; width:1280px" /></p> <ul> <li>ManNAc is easy to administer to patients (oral administration).</li> <li>Long-term ManNAc administration has been shown to be safe and well-tolerated in humans.</li> <li>This technology includes many issued patents in the U.S, Canada, Europe, Japan, and Israel for these indications.</li> <li>Extensive published and unpublished preclinical data for these kidney indications is available.</li> <li>A Phase I clinical trial of ManNAc in subjects with primary glomerular diseases has been completed with positive results.</li> <li> A Phase II study in subjects with primary focal segmental glomerulosclerosis is ongoing.</li> <li>A clinical study in diabetic nephropathy is in planning stages.</li> </ul> The National Human Genome Research Institute (NHGRI) is seeking statements of capability or interest from parties interested in collaborating on further developing and commercializing this technology for proteinuric kidney diseases, including diabetic nephropathy. For collaboration opportunities, please contact Anna Solowiej at the email address provided above. 2023-07-19 2026-04-28 2026-04-28 2023-07-27 2023-07-26 False True Phase I completed. True 72159140 Clinical Phase II 72159140 37470483 Website Abstract E-217-2007-0 146938360 Huizing et al., "Rationale and design for Phase 1 study of N-acetylmannosamine for primary glomerular diseases," Kidney International Reports (2019) 4, 1454-1452 https://pubmed.ncbi.nlm.nih.gov/31701055/ <a href="https://pubmed.ncbi.nlm.nih.gov/31701055/">Huizing et al., "Rationale and design for Phase 1 study of N-acetylmannosamine for primary glomerular diseases," Kidney International Reports (2019) 4, 1454-1452</a> 166979020 Huizing et al., “Phase 1 Study of Oral N-Acetylmannosamine in Primary Podocytopathies,” Kidney International Reports (2025) 11, 103758 https://pmc.ncbi.nlm.nih.gov/articles/PMC12861195/ <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12861195/">Huizing et al., “Phase 1 Study of Oral N-Acetylmannosamine in Primary Podocytopathies,” Kidney International Reports (2025) 11, 103758</a> 146938169 Huizing, Marjan National Human Genome Research Institute (NHGRI) NHGRI Huizing, Marjan (NHGRI) 1 146938174 Gahl, William National Human Genome Research Institute (NHGRI) NHGRI Gahl, William (NHGRI) 2 146938314 Manoli, Eirini (Irini) National Human Genome Research Institute (NHGRI) NHGRI Manoli, Eirini (Irini) (NHGRI) 3 146938332 Klootwijk, Enriko National Human Genome Research Institute (NHGRI) Klootwijk, Enriko 4 146938169 Huizing, Marjan National Human Genome Research Institute (NHGRI) NHGRI Huizing, Marjan (NHGRI) 1 146938174 Gahl, William National Human Genome Research Institute (NHGRI) NHGRI Gahl, William (NHGRI) 2 146938314 Manoli, Eirini (Irini) National Human Genome Research Institute (NHGRI) NHGRI Manoli, Eirini (Irini) (NHGRI) 3 146938332 Klootwijk, Enriko National Human Genome Research Institute (NHGRI) Klootwijk, Enriko 4 146937959 Provision Of The Neutral Sugar N-acetyl Nammosamine (ManNAc) For Increased Intracellular Production Of Sialic Acids E-217-2007-0 Filing authorized National Human Genome Research Institute (NHGRI) 83703934 Solowiej, Anna anna.solowiej@nih.gov
United States of America anna.solowiej@nih.gov?subject=Web Inquiry on [TAB-3848] Treating Kidney Disorders and Diabetic Nephropathy with N-acetyl mannosamine (ManNAc)&body=Please send me information about technology [TAB-3848] Treating Kidney Disorders and Diabetic Nephropathy with N-acetyl mannosamine (ManNAc). Solowiej, Anna<br><a href="mailto:anna.solowiej@nih.gov?subject=Web Inquiry on [TAB-3848] Treating Kidney Disorders and Diabetic Nephropathy with N-acetyl mannosamine (ManNAc)&body=Please send me information about technology [TAB-3848] Treating Kidney Disorders and Diabetic Nephropathy with N-acetyl mannosamine (ManNAc).">anna.solowiej@nih.gov</a><br> TAB-3429 114097303 Prefusion-Stabilized Fusion (F) Glycoprotein Vaccine Immunogens For Human Metapneumovirus NIAID Licensing Licensing Ursula Buchholz, Peter Collins, Jason Gorman, Wing-pui Kong, Peter Kwong, John Mascola, Li Ou, Guillaume Stewart-Jones, Yaroslav Tsybovsky, Baoshan Zhang, Tongqing Zhou Human metapneumovirus (hMPV) infections have been shown as a common cause of upper and lower respiratory diseases such as bronchiolitis and pneumonia in young children, the elderly, and other immunocompromised individuals. Studies show that infections by the non-segmented negative strand RNA virus begin with attachment and entry of viral glycoproteins that mediate fusion with host cellular membranes. Like for the human respiratory syncytial virus (hRSV), a viral entry is initiated by the fusion (F) protein. Given its role in hMPV entry, the F protein has thus been a target for eliciting neutralizing antibodies and development of novel protein-based therapeutic vaccines.<br /><br /> Researchers at the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID) developed improved recombinant human metapneumovirus (hMPV) F proteins stabilized in the prefusion conformation that can elicit potent neutralizing antibodies against infection. Double and triple stabilized candidates were designed with inter-and intraprotomer disulfide mutations that increase protein production and show improved antigenic recognition by prefusion-specific antibodies. These second-generation immunogens constitute an improvement over the first generation constructs and are characterized by additional stabilization that results in optimal neutralization responses.<br /><br /> The second-generation stabilized prefusion hMPV F immunogens may be an ideal vaccine immunogen to elicit broad potent neutralizing antibodies against metapneumovirus infection, particularly in children and immunocompromised adults.<br /><br /> This technology is available for licensing for commercial development in accordance with 35 U.S.C. § 209 and 37 CFR Part 404. ... <ul> <li>There are no approved vaccines or therapeutics against the second leading cause of pediatric viral lower respiratory tract infection in infants and young children</li> <li>Second-generation hMPV F immunogens induce higher titer neutralizing responses than first-generation versions in mice</li> </ul> <ul> <li>A promising vaccine immunogen to elicit broad potent neutralizing antibodies against metapneumovirus infection, particularly in children and immunocompromised adults</li> </ul> </li> <li>Second-generation hMPV F immunogens induce higher titer neutralizing responses than first-generation versions in mice</li> </ul> 2022-10-25 2026-04-27 2026-04-27 2021-01-26 F, Fusion, GLYCOPROTEIN, Human, IMMUNOGENS, Metapneumovirus, Prefusion-Stabilized, Vaccine False True True NIHTT 37470483 Website Abstract 114172594 Liu, P., et al https://pubmed.ncbi.nlm.nih.gov/23761661/ <a href="https://pubmed.ncbi.nlm.nih.gov/23761661/">Liu, P., et al</a> 114172595 Battles, M. B., et al https://pubmed.ncbi.nlm.nih.gov/29142300/ <a href="https://pubmed.ncbi.nlm.nih.gov/29142300/">Battles, M. B., et al</a> 114110156 Tsybovsky, Yaroslav NCI - FCRDC (Leidos) NIAID Tsybovsky, Yaroslav (NIAID) 0 114110157 Buchholz, Ursula NIAID - DIR NIAID Buchholz, Ursula (NIAID) 0 114110158 Collins, Peter NIAID - DIR NIAID Collins, Peter (NIAID) 0 114110159 Kong, Wing-pui NIAID - VRC NIAID Kong, Wing-pui (NIAID) 0 114110160 Mascola, John NIAID - VRC NIAID Mascola, John (NIAID) 0 114110161 Ou, Li NIAID - VRC NIAID Ou, Li (NIAID) 0 114110162 Gorman, Jason NIAID - VRC NIAID Gorman, Jason (NIAID) 0 114110163 Stewart-Jones, Guillaume NIAID - VRC NIAID Stewart-Jones, Guillaume (NIAID) 0 114110164 Zhou, Tongqing NIAID - VRC NIAID Zhou, Tongqing (NIAID) 0 114110165 Zhang, Baoshan NIAID - VRC NIAID Zhang, Baoshan (NIAID) 0 114110155 Kwong, Peter NIAID - VRC NIAID Kwong, Peter (NIAID) 1 114110155 Kwong, Peter NIAID - VRC NIAID Kwong, Peter (NIAID) 1 114110156 Tsybovsky, Yaroslav NCI - FCRDC (Leidos) NIAID Tsybovsky, Yaroslav (NIAID) 0 114110157 Buchholz, Ursula NIAID - DIR NIAID Buchholz, Ursula (NIAID) 0 114110158 Collins, Peter NIAID - DIR NIAID Collins, Peter (NIAID) 0 114110159 Kong, Wing-pui NIAID - VRC NIAID Kong, Wing-pui (NIAID) 0 114110160 Mascola, John NIAID - VRC NIAID Mascola, John (NIAID) 0 114110161 Ou, Li NIAID - VRC NIAID Ou, Li (NIAID) 0 114110162 Gorman, Jason NIAID - VRC NIAID Gorman, Jason (NIAID) 0 114110163 Stewart-Jones, Guillaume NIAID - VRC NIAID Stewart-Jones, Guillaume (NIAID) 0 114110164 Zhou, Tongqing NIAID - VRC NIAID Zhou, Tongqing (NIAID) 0 114110165 Zhang, Baoshan NIAID - VRC NIAID Zhang, Baoshan (NIAID) 0 114102552 Prefusion-Stabilized Fusion (F) Glycoprotein Vaccine Immunogens For Human Metapneumovirus E-131-2019-0 Filing authorized NIAID 91026778 Green, Wade wade.green@nih.gov
United States of America TTIPO wade.green@nih.gov?subject=Web Inquiry on [TAB-3429] Prefusion-Stabilized Fusion (F) Glycoprotein Vaccine Immunogens For Human Metapneumovirus&body=Please send me information about technology [TAB-3429] Prefusion-Stabilized Fusion (F) Glycoprotein Vaccine Immunogens For Human Metapneumovirus. Green, Wade<br><a href="mailto:wade.green@nih.gov?subject=Web Inquiry on [TAB-3429] Prefusion-Stabilized Fusion (F) Glycoprotein Vaccine Immunogens For Human Metapneumovirus&body=Please send me information about technology [TAB-3429] Prefusion-Stabilized Fusion (F) Glycoprotein Vaccine Immunogens For Human Metapneumovirus.">wade.green@nih.gov</a><br> 114168285 E-131-2019-0 E-131-2019-0-PCT-02 RECOMBINANT HUMAN METAPNEUMOVIRUS F PROTEINS AND THEIR USE PCT Patent Cooperation Treaty PCT/US2021/029988 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/029988<br />Filed on 2021-04-29<br />Status: Expired 114169092 E-131-2019-0 E-131-2019-0-US-01 RECOMBINANT HUMAN METAPNEUMOVIRUS F PROTEINS AND THEIR USE PRV US 63/017,581 Abandoned US <br />Provisional (PRV) 63/017,581<br />Filed on 2020-04-29<br />Status: Abandoned 114169666 E-131-2019-0 E-131-2019-0-US-06 RECOMBINANT HUMAN METAPNEUMOVIRUS F PROTEINS AND THEIR USE National Stage US 17/919,733 Pending US <br />National Stage 17/919,733<br />Filed on 2022-10-18<br />Status: Pending 114152011 Prefusion-Stabilized 114152012 Fusion 114152013 F 114152014 GLYCOPROTEIN 114152015 Vaccine 114152016 IMMUNOGENS 114152017 Human 114152018 Metapneumovirus TAB-3342 114097257 Fusion Glycoprotein Vaccine for Human Metapneumovirus NIAID Infectious Disease, Licensing, Vaccines Infectious Disease Licensing Vaccines Ursula Buchholz, Peter Collins, Davide Corti, Michael Joyce, Peter Kwong, Antonio Lanzavecchia, Guillaume Stewart-Jones, Yongping Yang, Baoshan Zhang Human metapneumovirus (hMPV), a negative, single-stranded RNA virus, accounts for approximately 5-15% of infant respiratory tract infections and poses a severe risk of disease and hospitalization in both the elderly and the immunocompromised. Investigators at the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID) have generated an hMPV fusion glycoprotein (“F protein”) stabilized in a prefusion conformation.<br /><br /> Stabilizing this prefusion conformation of the F protein reveals an immunodominant site which makes it an ideal vaccine immunogen. The prefusion stabilized F protein immunogen can be delivered as either an isolated homotrimer or trimers displayed on a nanoparticle. These immunogens elicit broad and potent hMPV-neutralizing antibodies.<br /><br /> This technology is available for licensing for commercial development in accordance with 35 U.S.C. § 209 and 37 CFR Part 404. <ul> <li>No human metapneumovirus vaccine is currently available</li> </ul> <ul> <li>Vaccine for prevention of human metapneumovirus infection</li> </ul> Vaccine for prevention of human metapneumovirus infection 2022-04-12 2026-04-27 2026-04-27 2018-10-29 DC5XXX, Fusion, GLYCOPROTEIN, HMPV, Metapneumovirus, Prefusion, respiratory, Respiratory Diseases, respiratory INFECTION, Respiratory Syncytial Virus, Structure-based, Vaccine False True True NIHTT 37470483 Website Abstract 114109955 Joyce, Michael NIAID - VRC NIAID Joyce, Michael (NIAID) 0 114109956 Collins, Peter NIAID - DIR NIAID Collins, Peter (NIAID) 0 114109957 Buchholz, Ursula NIAID - DIR NIAID Buchholz, Ursula (NIAID) 0 114109958 Stewart-Jones, Guillaume NIAID - VRC NIAID Stewart-Jones, Guillaume (NIAID) 0 114109959 Zhang, Baoshan NIAID - VRC NIAID Zhang, Baoshan (NIAID) 0 114109960 Yang, Yongping NIAID - VRC NIAID Yang, Yongping (NIAID) 0 114109961 Corti, Davide Institute for Research in Biomedicine (IRB) Corti, Davide 0 114109962 Lanzavecchia, Antonio Institute for Research in Biomedicine (IRB) Lanzavecchia, Antonio 0 114109954 Kwong, Peter NIAID - VRC NIAID Kwong, Peter (NIAID) 1 114109954 Kwong, Peter NIAID - VRC NIAID Kwong, Peter (NIAID) 1 114109955 Joyce, Michael NIAID - VRC NIAID Joyce, Michael (NIAID) 0 114109956 Collins, Peter NIAID - DIR NIAID Collins, Peter (NIAID) 0 114109957 Buchholz, Ursula NIAID - DIR NIAID Buchholz, Ursula (NIAID) 0 114109958 Stewart-Jones, Guillaume NIAID - VRC NIAID Stewart-Jones, Guillaume (NIAID) 0 114109959 Zhang, Baoshan NIAID - VRC NIAID Zhang, Baoshan (NIAID) 0 114109960 Yang, Yongping NIAID - VRC NIAID Yang, Yongping (NIAID) 0 114109961 Corti, Davide Institute for Research in Biomedicine (IRB) Corti, Davide 0 114109962 Lanzavecchia, Antonio Institute for Research in Biomedicine (IRB) Lanzavecchia, Antonio 0 114102500 Structure-based Design Of A Fusion Glycoprotein Vaccine For Metapneumovirus E-260-2014-0 Filing authorized INSTITUTE FOR RESEARCH IN BIOMEDICINE, NIAID 91026778 Green, Wade wade.green@nih.gov
United States of America TTIPO wade.green@nih.gov?subject=Web Inquiry on [TAB-3342] Fusion Glycoprotein Vaccine for Human Metapneumovirus&body=Please send me information about technology [TAB-3342] Fusion Glycoprotein Vaccine for Human Metapneumovirus. Green, Wade<br><a href="mailto:wade.green@nih.gov?subject=Web Inquiry on [TAB-3342] Fusion Glycoprotein Vaccine for Human Metapneumovirus&body=Please send me information about technology [TAB-3342] Fusion Glycoprotein Vaccine for Human Metapneumovirus.">wade.green@nih.gov</a><br> 114168779 E-260-2014-0 E-260-2014-0-US-01 Structure-based Design Of A Fusion Glycoprotein Vaccine For Metapneumovirus PRV US 62/096,744 Abandoned US <br />Provisional (PRV) 62/096,744<br />Filed on 2014-12-24<br />Status: Abandoned 114168780 E-260-2014-0 E-260-2014-0-PCT-02 Recombinant Metapneumovirus F Proteins and Their Use PCT Patent Cooperation Treaty PCT/IB2015/059991 Expired Patent Cooperation Treaty <br />(PCT) PCT/IB2015/059991<br />Filed on 2015-12-24<br />Status: Expired 114168781 E-260-2014-0 E-260-2014-0-US-04 RECOMBINANT METAPNEUMOVIRUS F PROTEINS AND THEIR USE National Stage US 10,420,834 15/539,640 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10420834 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10420834">10,420,834</a><br />Filed on 2017-06-23<br />Status: Issued 114168782 E-260-2014-0 E-260-2014-0-EP-03 Recombinant Metapneumovirus F Proteins and Their Use National Stage European Patent 15831073.0 Pending European Patent <br />National Stage 15831073.0<br />Filed on 2015-12-24<br />Status: Pending 114168920 E-260-2014-0 E-260-2014-0-US-05 RECOMBINANT METAPNEUMOVIRUS F PROTEINS AND THEIR USE DIV US 11,027,007 16/578,748 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11027007 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11027007">11,027,007</a><br />Filed on 2019-09-23<br />Status: Issued 114169126 E-260-2014-0 E-260-2014-0-US-06 RECOMBINANT METAPNEUMOVIRUS F PROTEINS AND THEIR USE DIV US 11,786,591 17/334,505 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11786591 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11786591">11,786,591</a><br />Filed on 2021-05-18<br />Status: Issued 114128216 DC5XXX 114151489 Metapneumovirus 114151490 Vaccine 114151491 GLYCOPROTEIN 114151492 Fusion 114151493 Structure-based 114151494 HMPV 114151495 Prefusion 114151496 Respiratory Diseases 114151497 respiratory INFECTION 114151498 respiratory 114151499 Respiratory Syncytial Virus TAB-3336 114097252 Substitutions-Modified Prefusion RSV F Proteins and Their Use NIAID Licensing Licensing Ulrich Baxa, Man Chen, Aliaksandr Druz, Ivelin Georgiev, Barney Graham, Michael Joyce, Wing-pui Kong, Peter Kwong, John Mascola, Li Ou, Marie Pancera, Emily Rundlet, Mallika Sastry, Cinque Soto, Guillaume Stewart-Jones, Paul Thomas, Yaroslav Tsybovsky, Joseph Van Galen, Yongping Yang, Baoshan Zhang The respiratory syncytial virus (RSV) fusion (F) glycoprotein is the primary target of neutralizing antibodies. The F glycoprotein exists in at least two conformations, a meta-stable prefusion state, and an extremely stable postfusion state. Both states share several epitopes targeted by neutralizing antibodies, but it has been demonstrated that the prefusion conformation of F contains at least one epitope not present in the postfusion conformation. Natural infection results in neutralizing antibodies that are primarily directed against the prefusion conformation of F, not its postfusion conformation. The instability of the prefusion form of F has hindered both its characterization and its use as a vaccine antigen.<br /><br /> Researchers at the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases have overcome technical obstacles to produce a homogeneous, soluble RSV F glycoprotein vaccine which is stabilized in the prefusion conformation and has improved stability and immunogenicity compared to the native protein. Additionally, several modifications were introduced to remove the requirement for furin during production, resulting in an increase in expression levels of the immunogen. Stability of the immunogen was increased 20-fold as compared to DS-CAV1 (a prefusion-stabilized RSV F glycoprotein vaccine candidate that is currently being assessed in clinical trials) upon incubation at 60 ºC. In mice, these immunogens elicited neutralization titers that were 2 to 5-fold higher than DS-CAV1.<br /><br /> This technology is available for licensing for commercial development in accordance with 35 U.S.C. § 209 and 37 CFR Part 404, as well as for further development and evaluation under a research collaboration. <ul> <li>Increased stability compared to the current leading RSV vaccine candidate (DS-Cav1).</li> <li>Elicits increased neutralization titers in mice.</li> </ul> <ul> <li>Vaccine: RSV vaccine for human use.</li> <li>Probe: B cell-sorting probe to isolate potent neutralizing monoclonal antibodies.</li> <li>Diagnostics: To assess the titer of prefusion-specific antibodies in sera.</li> </ul> 2022-04-12 2026-04-27 2026-04-27 2018-10-17 COVALENT, DS-Cav1, IMPROVEMENTS, LEADING, Neutralizing, Prefusion, proteins, protomer, RSV F, Stabilization, Thermostability, TITERS, Trimeric False True True NIHTT 37470483 Website Abstract E-081-2013-0 114172542 Joyce MG, et al. http://www.nature.com/articles/nsmb.3267 <a href="http://www.nature.com/articles/nsmb.3267">Joyce MG, et al.</a> 114109901 Tsybovsky, Yaroslav NCI - FCRDC (Leidos) NIAID Tsybovsky, Yaroslav (NIAID) 0 114109903 Joyce, Michael NIAID - VRC NIAID Joyce, Michael (NIAID) 0 114109904 Zhang, Baoshan NIAID - VRC NIAID Zhang, Baoshan (NIAID) 0 114109905 Chen, Man NIAID - VRC NIAID Chen, Man (NIAID) 0 114109906 Graham, Barney NIAID - VRC NIAID Graham, Barney (NIAID) 0 114109907 Mascola, John NIAID - VRC NIAID Mascola, John (NIAID) 0 114109908 Ou, Li NIAID - VRC NIAID Ou, Li (NIAID) 0 114109909 Druz, Aliaksandr NIAID - DIR NIAID Druz, Aliaksandr (NIAID) 0 114109910 Kong, Wing-pui NIAID - VRC NIAID Kong, Wing-pui (NIAID) 0 114109911 Georgiev, Ivelin NIAID - VRC NIAID Georgiev, Ivelin (NIAID) 0 114109912 Rundlet, Emily NIAID - DIR NIAID Rundlet, Emily (NIAID) 0 114109913 Thomas, Paul NIAID - VRC NIAID Thomas, Paul (NIAID) 0 114109914 Pancera, Marie NIAID - VRC NIAID Pancera, Marie (NIAID) 0 114109915 Sastry, Mallika NIAID - VRC NIAID Sastry, Mallika (NIAID) 0 114109916 Soto, Cinque NIAID - VRC Soto, Cinque 0 114109917 Van Galen, Joseph NIAID - DIR Van Galen, Joseph 0 114109918 Stewart-Jones, Guillaume NIAID - VRC NIAID Stewart-Jones, Guillaume (NIAID) 0 114109919 Yang, Yongping NIAID - VRC NIAID Yang, Yongping (NIAID) 0 114109920 Baxa, Ulrich NIAID - VRC NIDDK Baxa, Ulrich (NIDDK) 0 114109902 Kwong, Peter NIAID - VRC NIAID Kwong, Peter (NIAID) 1 114109902 Kwong, Peter NIAID - VRC NIAID Kwong, Peter (NIAID) 1 114109901 Tsybovsky, Yaroslav NCI - FCRDC (Leidos) NIAID Tsybovsky, Yaroslav (NIAID) 0 114109903 Joyce, Michael NIAID - VRC NIAID Joyce, Michael (NIAID) 0 114109904 Zhang, Baoshan NIAID - VRC NIAID Zhang, Baoshan (NIAID) 0 114109905 Chen, Man NIAID - VRC NIAID Chen, Man (NIAID) 0 114109906 Graham, Barney NIAID - VRC NIAID Graham, Barney (NIAID) 0 114109907 Mascola, John NIAID - VRC NIAID Mascola, John (NIAID) 0 114109908 Ou, Li NIAID - VRC NIAID Ou, Li (NIAID) 0 114109909 Druz, Aliaksandr NIAID - DIR NIAID Druz, Aliaksandr (NIAID) 0 114109910 Kong, Wing-pui NIAID - VRC NIAID Kong, Wing-pui (NIAID) 0 114109911 Georgiev, Ivelin NIAID - VRC NIAID Georgiev, Ivelin (NIAID) 0 114109912 Rundlet, Emily NIAID - DIR NIAID Rundlet, Emily (NIAID) 0 114109913 Thomas, Paul NIAID - VRC NIAID Thomas, Paul (NIAID) 0 114109914 Pancera, Marie NIAID - VRC NIAID Pancera, Marie (NIAID) 0 114109915 Sastry, Mallika NIAID - VRC NIAID Sastry, Mallika (NIAID) 0 114109916 Soto, Cinque NIAID - VRC Soto, Cinque 0 114109917 Van Galen, Joseph NIAID - DIR Van Galen, Joseph 0 114109918 Stewart-Jones, Guillaume NIAID - VRC NIAID Stewart-Jones, Guillaume (NIAID) 0 114109919 Yang, Yongping NIAID - VRC NIAID Yang, Yongping (NIAID) 0 114109920 Baxa, Ulrich NIAID - VRC NIDDK Baxa, Ulrich (NIDDK) 0 114102490 Single-chain Covalent Trimeric Prefusion RSV F Proteins That Elicit Neutralizing Titers In Mice Four To Five-fold Higher And Display Substantially Higher Thermostability Than The Current Leading Candidate DS-Cav1 E-064-2016-0 Filing authorized NIAID 114102491 Single-chain Covalent Trimeric Prefusion RSV F Proteins That Elicit Neutralizing Titers In Mice Four To Five-fold Higher And Display Substantially Higher Thermostability Than The Current Leading Candidate DS-Cav1 E-064-2016-1 Filing authorized NIAID 148673287 Hafiz, Sabrina sabrina.hafiz@nih.gov
United States of America sabrina.hafiz@nih.gov?subject=Web Inquiry on [TAB-3336] Substitutions-Modified Prefusion RSV F Proteins and Their Use&body=Please send me information about technology [TAB-3336] Substitutions-Modified Prefusion RSV F Proteins and Their Use. Hafiz, Sabrina<br><a href="mailto:sabrina.hafiz@nih.gov?subject=Web Inquiry on [TAB-3336] Substitutions-Modified Prefusion RSV F Proteins and Their Use&body=Please send me information about technology [TAB-3336] Substitutions-Modified Prefusion RSV F Proteins and Their Use.">sabrina.hafiz@nih.gov</a><br> 114168764 E-064-2016-0 E-064-2016-0-US-01 RSV F Immunogens and Their Use PRV US 62/314,946 Expired US <br />Provisional (PRV) 62/314,946<br />Filed on 2016-03-29<br />Status: Expired 114168765 E-064-2016-1 E-064-2016-1-PCT-01 RSV F IMMUNOGENS AND THEIR USE PCT COMB Patent Cooperation Treaty PCT/US2017/024714 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2017/024714<br />Filed on 2017-03-29<br />Status: Expired 114168766 E-064-2016-1 E-064-2016-1-US-07 SUBSTITUTIONS-MODIFIED PREFUSION RSV F PROTEINS AND THEIR USE National Stage US 11,174,292 16/089,993 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11174292 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11174292">11,174,292</a><br />Filed on 2018-09-28<br />Status: Issued 114169139 E-064-2016-1 E-064-2016-1-US-08 PREFUSION RSV F PROTEINS AND THEIR USE CON US 11,878,998 17/524,380 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11878998 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11878998">11,878,998</a><br />Filed on 2021-11-11<br />Status: Issued 114151403 COVALENT 114151404 Prefusion 114151405 proteins 114151406 Neutralizing 114151407 IMPROVEMENTS 114151408 Trimeric 114151409 TITERS 114151410 Thermostability 114151411 LEADING 114151412 DS-Cav1 114151413 RSV F 114151414 Stabilization 114151415 protomer TAB-2717 114096896 Recombinant Stabilized Prefusion Protein of Respiratory Syncytial Virus for Use as a Subunit Vaccine NIAID Infectious Disease, Licensing, Vaccines Infectious Disease Licensing Vaccines Jeffrey Boyington, Lei Chen, Man Chen, Gwo-Yu Chuang, Ivelin Georgiev, Jason Gorman, Barney Graham, Michael Joyce, Masaru Kanekiyo, Peter Kwong, Jason McLellan, Gilad Ofek, Marie Pancera, Mallika Sastry, Cinque Soto, Sanjay Srivatsan, Guillaume Stewart-Jones, Yongping Yang, Baoshan Zhang, Tongqing Zhou The invention, a stabilized recombinant prefusion F protein (pre F), is a candidate subunit vaccine for Respiratory Syncytial Virus (RSV). Pre-F is stabilized in the prefusion conformation and displays epitopes not present in postfusion F protein. Several potent RSV neutralizing antibodies bind pre F, but not postfusion F. Therefore, immunization with pre F may elicit an immune response superior to the response generated by postfusion F.<br /><br /> NIH researchers have engineered pre F to expose an antigenic site 0, which is targeted by extremely potent RSV neutralizing antibodies. Structure-based design yielded several stabilized variants of pre F that maintained exposure of antigenic site 0 when subjected to extremes of pH, osmolality and temperature.<br /><br /> Preclinical in vivo data on stabilized pre F is available. Immunization of mice and macaques with antigenic site 0 stabilized pre F variants elicited high levels of RSV specific neutralizing activity. <ul> <li>Vaccine stably exposes antigenic site in RSV F that permits generation of potent RSV neutralizing antibodies.</li> <li>There is currently no RSV vaccine on the market.</li> </ul> <ul> <li>Vaccine for Respiratory Syncytial Virus</li> </ul> 2022-04-12 2026-04-27 2026-04-27 2014-01-16 CONFORMATION, DC5BXX, DC5XXX, DCXXXX, DXXXXX, F, GLYCOPROTEIN, Listed LPM Thalhammer-Reyero as of 4/15/2015, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Prefusion, PrefusionConformation, RSV, Stabilization, Structure-based, Vaccine, VLXXXX, YCXXXX False True <ul> <li>Pre-clinical</li> </li>In vivo data available (animal)</li> </ul> True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114171986 McLellan JS, et al. http://www.ncbi.nlm.nih.gov/pubmed/23618766 <a href="http://www.ncbi.nlm.nih.gov/pubmed/23618766">McLellan JS, et al.</a> 114171987 McLellan JS, et al. http://www.ncbi.nlm.nih.gov/pubmed/24179220 <a href="http://www.ncbi.nlm.nih.gov/pubmed/24179220">McLellan JS, et al.</a> 114103548 Gorman, Jason NIAID - VRC NIAID Gorman, Jason (NIAID) 0 114103549 Ofek, Gilad NIAID - VRC NIAID Ofek, Gilad (NIAID) 0 114103550 Pancera, Marie NIAID - VRC NIAID Pancera, Marie (NIAID) 0 114103551 Sastry, Mallika NIAID - VRC NIAID Sastry, Mallika (NIAID) 0 114104949 Srivatsan, Sanjay NIAID - VRC NIAID Srivatsan, Sanjay (NIAID) 0 114105607 Yang, Yongping NIAID - VRC NIAID Yang, Yongping (NIAID) 0 114105761 Chen, Lei NIAID - VRC NIAID Chen, Lei (NIAID) 0 114106323 Soto, Cinque NIAID - VRC Soto, Cinque 0 114106377 Zhou, Tongqing NIAID - VRC NIAID Zhou, Tongqing (NIAID) 0 114108383 Graham, Barney NIAID - VRC NIAID Graham, Barney (NIAID) 0 114108384 Kwong, Peter NIAID - VRC NIAID Kwong, Peter (NIAID) 0 114108385 Kanekiyo, Masaru NIAID - VRC NIAID Kanekiyo, Masaru (NIAID) 0 114108386 Joyce, Michael NIAID - VRC NIAID Joyce, Michael (NIAID) 0 114108387 Zhang, Baoshan NIAID - VRC NIAID Zhang, Baoshan (NIAID) 0 114108628 Stewart-Jones, Guillaume NIAID - VRC NIAID Stewart-Jones, Guillaume (NIAID) 0 114108673 Boyington, Jeffrey NIAID - VRC NIAID Boyington, Jeffrey (NIAID) 0 114108674 Chen, Man NIAID - VRC NIAID Chen, Man (NIAID) 0 114108675 Chuang, Gwo-Yu NIAID - DIR NIAID Chuang, Gwo-Yu (NIAID) 0 114108676 Georgiev, Ivelin NIAID - VRC NIAID Georgiev, Ivelin (NIAID) 0 114108382 McLellan, Jason NIAID - VRC NIAID McLellan, Jason (NIAID) 1 114108382 McLellan, Jason NIAID - VRC NIAID McLellan, Jason (NIAID) 1 114103548 Gorman, Jason NIAID - VRC NIAID Gorman, Jason (NIAID) 0 114103549 Ofek, Gilad NIAID - VRC NIAID Ofek, Gilad (NIAID) 0 114103550 Pancera, Marie NIAID - VRC NIAID Pancera, Marie (NIAID) 0 114103551 Sastry, Mallika NIAID - VRC NIAID Sastry, Mallika (NIAID) 0 114104949 Srivatsan, Sanjay NIAID - VRC NIAID Srivatsan, Sanjay (NIAID) 0 114105607 Yang, Yongping NIAID - VRC NIAID Yang, Yongping (NIAID) 0 114105761 Chen, Lei NIAID - VRC NIAID Chen, Lei (NIAID) 0 114106323 Soto, Cinque NIAID - VRC Soto, Cinque 0 114106377 Zhou, Tongqing NIAID - VRC NIAID Zhou, Tongqing (NIAID) 0 114108383 Graham, Barney NIAID - VRC NIAID Graham, Barney (NIAID) 0 114108384 Kwong, Peter NIAID - VRC NIAID Kwong, Peter (NIAID) 0 114108385 Kanekiyo, Masaru NIAID - VRC NIAID Kanekiyo, Masaru (NIAID) 0 114108386 Joyce, Michael NIAID - VRC NIAID Joyce, Michael (NIAID) 0 114108387 Zhang, Baoshan NIAID - VRC NIAID Zhang, Baoshan (NIAID) 0 114108628 Stewart-Jones, Guillaume NIAID - VRC NIAID Stewart-Jones, Guillaume (NIAID) 0 114108673 Boyington, Jeffrey NIAID - VRC NIAID Boyington, Jeffrey (NIAID) 0 114108674 Chen, Man NIAID - VRC NIAID Chen, Man (NIAID) 0 114108675 Chuang, Gwo-Yu NIAID - DIR NIAID Chuang, Gwo-Yu (NIAID) 0 114108676 Georgiev, Ivelin NIAID - VRC NIAID Georgiev, Ivelin (NIAID) 0 114100250 Structure-based Stabilization Of The RSV F Glycoprotein In Its Prefusion Conformation E-081-2013-5 Filing authorized NIAID 114100654 Structure-based Stabilization Of The RSV F Glycoprotein In Its Prefusion Conformation E-081-2013-4 Filing authorized NIAID 114102027 Structure-based Stabilization Of The RSV F Glycoprotein In Its Prefusion Conformation E-081-2013-0 Filing authorized NIAID 114102028 Structure-based Stabilization Of The RSV F Glycoprotein In Its Prefusion Conformation E-081-2013-1 Filing authorized NIAID 114102029 Structure-based Stabilization Of The RSV F Glycoprotein In Its Prefusion Conformation E-081-2013-2 Filing authorized NIAID 114102030 Structure-based Stabilization Of The RSV F Glycoprotein In Its Prefusion Conformation E-081-2013-3 Filing authorized NIAID 91026778 Green, Wade wade.green@nih.gov
United States of America TTIPO wade.green@nih.gov?subject=Web Inquiry on [TAB-2717] Recombinant Stabilized Prefusion Protein of Respiratory Syncytial Virus for Use as a Subunit Vaccine&body=Please send me information about technology [TAB-2717] Recombinant Stabilized Prefusion Protein of Respiratory Syncytial Virus for Use as a Subunit Vaccine. Green, Wade<br><a href="mailto:wade.green@nih.gov?subject=Web Inquiry on [TAB-2717] Recombinant Stabilized Prefusion Protein of Respiratory Syncytial Virus for Use as a Subunit Vaccine&body=Please send me information about technology [TAB-2717] Recombinant Stabilized Prefusion Protein of Respiratory Syncytial Virus for Use as a Subunit Vaccine.">wade.green@nih.gov</a><br> 114161993 E-081-2013-5 E-081-2013-5-US-01 PREFUSION RSV F PROTEINS AND THEIR USE ORD US 9,738,689 14/207,372 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9738689 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9738689">9,738,689</a><br />Filed on 2014-03-12<br />Status: Issued 114165078 E-081-2013-4 E-081-2013-4-US-12 Prefusion RSV F Proteins and Their Use National Stage US 10,017,543 14/776,651 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10017543 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10017543">10,017,543</a><br />Filed on 2015-09-14<br />Status: Issued 114167467 E-081-2013-0 E-081-2013-0-US-01 Prefusion RSV F Proteins and Their Use PRV US 61/780,910 Expired US <br />Provisional (PRV) 61/780,910<br />Filed on 2013-03-13<br />Status: Expired 114167468 E-081-2013-1 E-081-2013-1-US-01 PREFUSION RSV F PROTEINS AND THEIR USE PRV US 61/798,389 Expired US <br />Provisional (PRV) 61/798,389<br />Filed on 2013-03-15<br />Status: Expired 114167469 E-081-2013-2 E-081-2013-2-US-01 Prefusion RSV F Proteins And Their Use PRV US 61/857,613 Expired US <br />Provisional (PRV) 61/857,613<br />Filed on 2013-07-23<br />Status: Expired 114167470 E-081-2013-3 E-081-2013-3-US-01 PREFUSION RSV F PROTEINS AND THEIR USE PRV US 61/863,909 Expired US <br />Provisional (PRV) 61/863,909<br />Filed on 2013-08-09<br />Status: Expired 114168005 E-081-2013-4 E-081-2013-4-PCT-01 Prefusion RSV F Proteins And Their Use PCT COMB Patent Cooperation Treaty PCT/US2014/026714 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2014/026714<br />Filed on 2014-03-13<br />Status: Expired 114168303 E-081-2013-5 E-081-2013-5-US-02 PREFUSION RSV F PROTEINS AND THEIR USE DIV US 10,858,400 15/633,578 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10858400 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10858400">10,858,400</a><br />Filed on 2017-06-26<br />Status: Issued 114168678 E-081-2013-4 E-081-2013-4-US-13 PREFUSION RSV F PROTEINS AND THEIR USE CON US 11,130,785 16/025,858 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11130785 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11130785">11,130,785</a><br />Filed on 2018-07-02<br />Status: Issued 114169164 E-081-2013-4 E-081-2013-4-US-19 PREFUSION RSV F PROTEINS AND THEIR USE CON US 17/478,533 Abandoned US <br />Continuation (CON) 17/478,533<br />Filed on 2021-09-17<br />Status: Abandoned 114124377 DC5BXX 114124378 DXXXXX 114124379 DCXXXX 114124380 DC5XXX 114124381 VLXXXX 114124382 YCXXXX 114145938 Vaccine 114145939 Stabilization 114145940 RSV 114145941 GLYCOPROTEIN 114145942 PrefusionConformation 114145943 Structure-based 114147144 F 114147145 Prefusion 114147146 CONFORMATION 114148542 Listed LPM Thalhammer-Reyero as of 4/15/2015 114148543 Pre LPM working set 20150418 114148544 Post LPM Assignment Set 20150420 TAB-3130 114095545 Human-derived Monoclonal Antibody for Treatment of Ebola Virus Infection NIAID Licensing Licensing Davide Corti, Barney Graham, Antonio Lanzavecchia, Julie Ledgerwood, Sabue Mulangu, Jean-Jacques Muyembe-Tamfun, Daphne Stanley, Nancy Sullivan, John Trefry Ebola virus infection can lead to severe hemorrhagic fever, known as Ebola virus disease (EVD), which is often fatal. The Zaire species of Ebola virus (EBOV) was responsible for the largest Ebola outbreak in history, which occurred in 2014. Scientists at the NIAID Vaccine Research Center have developed a human monoclonal neutralizing antibody, mAb114 for treatment and prevention of EBOV infection. Because there are very few treatments available to treat or prevent EBOV infection, there is a great need to develop effective pre- and post- exposure therapeutics before another outbreak occurs.<br /><br /> Preclinical efficacy studies demonstrate that monoclonal antibodies can effectively prevent EBOV infection or reverse EVD, in non-human primates. Strikingly, mAb114 protected infected monkeys when administered as late as 6 days after infection. mAb114 has a favorable pharmacokinetic profile, making it a promising potential therapeutic. Clinical trials to test the efficacy of mAb114 in humans are projected for 2018. It is anticipated that mAb114 can be used to prevent EBOV infection and EVD both pre- and post-exposure.<br /><br /> Development Stage<br /> First-in-human trials to start in 2018. <ul> <li>Single Antibody</li> <li>Single-shot option</li> <li>Delayed Treatment (>5 days)</li> <li>Good Half-life</li> <li>Highly Stable</li> <li>Easy to manufacture</li> </ul> <ul> <li>Therapeutic - to treat or prevent infection by EBOV</li> <li>Diagnostic - to detect EBOV infection</li> <li>Research reagent</li> </ul> 2022-03-08 2026-04-27 2026-04-27 2021-05-12 antibodies, Ebola, Ebolavirus, GLYCOPROTEIN, Listed LPM Thalhammer-Reyero as of 4/15/2015, monoclonal, Neutralize, Novel, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, That, THEREOF, USES, virus False True True NIHTT 37470483 Website Abstract 114172320 Corti D, et al. https://www.ncbi.nlm.nih.gov/pubmed/26917593 <a href="https://www.ncbi.nlm.nih.gov/pubmed/26917593">Corti D, et al.</a> 114172321 Misasi J, et al. https://www.ncbi.nlm.nih.gov/pubmed/26917592 <a href="https://www.ncbi.nlm.nih.gov/pubmed/26917592">Misasi J, et al.</a> 114110191 Mulangu, Sabue NIAID - VRC NIAID Mulangu, Sabue (NIAID) 0 114110200 Lanzavecchia, Antonio Institute for Research in Biomedicine (IRB) Lanzavecchia, Antonio 0 114110201 Corti, Davide Institute for Research in Biomedicine (IRB) Corti, Davide 0 114110202 Graham, Barney NIAID - VRC NIAID Graham, Barney (NIAID) 0 114110203 Ledgerwood, Julie NIAID - VRC NIAID Ledgerwood, Julie (NIAID) 0 114110204 Trefry, John USAMRIID/WR Trefry, John 0 114110205 Stanley, Daphne NIAID - VRC NIAID Stanley, Daphne (NIAID) 0 114110206 Muyembe-Tamfun, Jean-Jacques NIAID - VRC NIAID Muyembe-Tamfun, Jean-Jacques (NIAID) 0 114110192 Sullivan, Nancy NIAID - VRC NIAID Sullivan, Nancy (NIAID) 1 114110192 Sullivan, Nancy NIAID - VRC NIAID Sullivan, Nancy (NIAID) 1 114110191 Mulangu, Sabue NIAID - VRC NIAID Mulangu, Sabue (NIAID) 0 114110200 Lanzavecchia, Antonio Institute for Research in Biomedicine (IRB) Lanzavecchia, Antonio 0 114110201 Corti, Davide Institute for Research in Biomedicine (IRB) Corti, Davide 0 114110202 Graham, Barney NIAID - VRC NIAID Graham, Barney (NIAID) 0 114110203 Ledgerwood, Julie NIAID - VRC NIAID Ledgerwood, Julie (NIAID) 0 114110204 Trefry, John USAMRIID/WR Trefry, John 0 114110205 Stanley, Daphne NIAID - VRC NIAID Stanley, Daphne (NIAID) 0 114110206 Muyembe-Tamfun, Jean-Jacques NIAID - VRC NIAID Muyembe-Tamfun, Jean-Jacques (NIAID) 0 114102563 Novel Monoclonal Antibodies To Ebolavirus Glycoprotein E-045-2015-0 Filing authorized INSTITUTE FOR RESEARCH IN BIOMEDICINE, NIAID, USAMRIID/WR 91026778 Green, Wade wade.green@nih.gov
United States of America TTIPO wade.green@nih.gov?subject=Web Inquiry on [TAB-3130] Human-derived Monoclonal Antibody for Treatment of Ebola Virus Infection&body=Please send me information about technology [TAB-3130] Human-derived Monoclonal Antibody for Treatment of Ebola Virus Infection. Green, Wade<br><a href="mailto:wade.green@nih.gov?subject=Web Inquiry on [TAB-3130] Human-derived Monoclonal Antibody for Treatment of Ebola Virus Infection&body=Please send me information about technology [TAB-3130] Human-derived Monoclonal Antibody for Treatment of Ebola Virus Infection.">wade.green@nih.gov</a><br> 114169119 E-045-2015-0 E-045-2015-0-EP-06 Neutralizing Antibodies to Ebola Virus Glycoprotein and Their Use DIV European Patent 3875481 21158309.1 Abandoned European Patent <br />Divisional (DIV) 21158309.1<br />Filed on 2015-11-13<br />Status: Abandoned 114169120 E-045-2015-0 E-045-2015-0-EP-03 Neutralizing Antibodies to Ebola Virus Glycoprotein and Their Use National Stage European Patent 3218397 15797815.6 Issued European Patent <br />National Stage 15797815.6<br />Filed on 2015-11-13<br />Status: Issued 114169121 E-045-2015-0 E-045-2015-0-US-04 NEUTRALIZING ANTIBODIES TO EBOLA VIRUS GLYCOPROTEIN AND THEIR USE National Stage US 10,160,795 15/526,661 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10160795 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10160795">10,160,795</a><br />Filed on 2017-05-12<br />Status: Issued 114169122 E-045-2015-0 E-045-2015-0-US-05 NEUTRALIZING ANTIBODIES TO EBOLA VIRUS GLYCOPROTEIN AND THEIR USE CON US 10,273,288 16/190,676 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10273288 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10273288">10,273,288</a><br />Filed on 2018-11-14<br />Status: Issued 114149028 monoclonal 114149029 Novel 114149030 antibodies 114149031 Ebolavirus 114149032 GLYCOPROTEIN 114149033 Listed LPM Thalhammer-Reyero as of 4/15/2015 114149034 Pre LPM working set 20150418 114149035 Post LPM Assignment Set 20150420 114149036 That 114149037 Neutralize 114149038 Ebola 114149039 virus 114149040 USES 114149041 THEREOF TAB-3424 114097298 Identification of a New Human Monoclonal Antibody that More Potently Prevents Malaria Infection NIAID Licensing Licensing Joseph Francica, Robert Seder, Rachel Vistein, Lawrence Wang Malaria is a major disease caused by a parasite transmitted through the bite of infected female mosquitoes. Globally, an estimated 214 million cases of malaria and 438,000 deaths from malaria occur annually, with chidren in African and South Asian regions being most vulnerable. Approximately 1,500-2,000 cases of malaria are reported in the United States each year, mostly in returning travelers from malaria- endemic countries. Among the international travelers, military personnel, diplomats, pregnant women, children and older individuals with weakened immune systems are more likely to be at risk of malaria infection and mortality.<br /><br /> Currently, there is no licensed vaccine against Plasmodium falciparum, the deadliest species of malaria parasites. Antibodies can prevent malaria infection by binding to sporozoites, the infectious form of P. falciparum that is transmitted to humans by the bites of infected mosquitoes. The major target of anti-sporozoite antibodies is the P. falciparum circumsporozoite protein (PfCSP), an abundant surface protein on sporozoites that is essential for infecting liver cells, which is the critical step for initiating a productive infection. PfCSP is comprised of an N-terminal domain, a central region and the C-terminal region.<br /><br /> Researchers at the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID) have isolated a new neutralizing recombinant human monoclonal antibody, L9, from a protected volunteer immunized with whole Plasmodium falciparum sporozoites. L9 is notable for targeting PfCSP, the immunodominant immunogen that coats the surface of the sporozoite, specifically the Plasmodium infectious form injected into the human host by the mosquito. Also, in vivo studies in a mouse model of malaria infection demonstrated that L9 is more potent than CIS43, another antimalarial mAb, at preventing malaria infection.<br /><br /> This technology is available for licensing for commercial development in accordance with 35 U.S.C. § 209 and 37 CFR Part 404. <ul> <li>L9 may represent a more attractive passive vaccine candidate to advance through clinical testing and could yield a product superior to other vaccine candidates due to potency and preferential binding to unique epitopes on PfCSP.</li> <li>L9 may result in more durable protection than other vaccine candidates.</li> </ul> <ul> <li>A passive vaccine candidate to prevent and eradicate malaria.</li> </ul> 2022-03-08 2026-04-27 2026-04-27 2020-11-13 ANTIBODY, Human, Identification, Infection, Malaria, monoclonal, Potently, PREVENTS, That False True True NIHTT 37470483 Website Abstract 114172588 Wang, LT, et al. https://pubmed.ncbi.nlm.nih.gov/32946741/ <a href="https://pubmed.ncbi.nlm.nih.gov/32946741/">Wang, LT, et al.</a> 114110137 Wang, Lawrence NIAID - VRC NIAID Wang, Lawrence (NIAID) 0 114110138 Vistein, Rachel NIAID - VRC NIAID Vistein, Rachel (NIAID) 0 114110139 Francica, Joseph NIAID - VRC NIAID Francica, Joseph (NIAID) 0 114110136 Seder, Robert NIAID - VRC NIAID Seder, Robert (NIAID) 1 114110136 Seder, Robert NIAID - VRC NIAID Seder, Robert (NIAID) 1 114110137 Wang, Lawrence NIAID - VRC NIAID Wang, Lawrence (NIAID) 0 114110138 Vistein, Rachel NIAID - VRC NIAID Vistein, Rachel (NIAID) 0 114110139 Francica, Joseph NIAID - VRC NIAID Francica, Joseph (NIAID) 0 114102546 Identification of a new human monoclonal antibody that more potently prevents malaria infection E-087-2019-0 Filing authorized NIAID 83720410 Yang, David (Po-Lung) polung.yang@nih.gov
United States of America Technology Transfer and Intellectual Property Office polung.yang@nih.gov?subject=Web Inquiry on [TAB-3424] Identification of a New Human Monoclonal Antibody that More Potently Prevents Malaria Infection&body=Please send me information about technology [TAB-3424] Identification of a New Human Monoclonal Antibody that More Potently Prevents Malaria Infection. Yang, David (Po-Lung)<br><a href="mailto:polung.yang@nih.gov?subject=Web Inquiry on [TAB-3424] Identification of a New Human Monoclonal Antibody that More Potently Prevents Malaria Infection&body=Please send me information about technology [TAB-3424] Identification of a New Human Monoclonal Antibody that More Potently Prevents Malaria Infection.">polung.yang@nih.gov</a><br> 114169069 E-087-2019-0 E-087-2019-0-US-01 NEUTRALIZING ANTIBODIES TO PLASMODIUM FALCIPARUM CIRCUMSPOROZOITE PROTEIN AND THEIR USE PRV US 62/842,590 Abandoned US <br />Provisional (PRV) 62/842,590<br />Filed on 2019-05-03<br />Status: Abandoned 114169070 E-087-2019-0 E-087-2019-0-PCT-01 NEUTRALIZING ANTIBODIES TO PLASMODIUM FALCIPARUM CIRCUMSPOROZOITE PROTEIN AND THEIR USE PCT COMB Patent Cooperation Treaty PCT/US2020/031345 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2020/031345<br />Filed on 2020-05-04<br />Status: Expired 114169182 E-087-2019-0 E-087-2019-0-US-03 NEUTRALIZING ANTIBODIES TO PLASMODIUM FALCIPARUM CIRCUMSPOROZOITE PROTEIN AND THEIR USE National Stage US 12,269,872 17/608,381 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12269872 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12269872">12,269,872</a><br />Filed on 2021-11-02<br />Status: Issued 114151964 Identification 114151965 Human 114151966 monoclonal 114151967 ANTIBODY 114151968 That 114151969 Potently 114151970 PREVENTS 114151971 Malaria 114151972 Infection TAB-3382 114097272 Recombinant Nipah F Proteins and Their Use NIAID Licensing Licensing Barney Graham, Rebecca Loomis, John Mascola, Guillaume Stewart-Jones Nipah virus is an emerging pathogenic paramyxovirus responsible for sporadic and isolated outbreaks of severe respiratory and neurologic disease in Southern Asia. As a zoonotic virus, disease can manifest in both animals and human with indigenous fruit bats acting as natural reservoirs of the virus. The effects of viral infection vary from acute respiratory distress to fatal encephalitis. There are currently no approved therapeutics or vaccines against the virus, and growing concerns that this highly pathogenic infection has the potential to cause larger epidemics capable of inflicting significant mortality burden.<br /><br /> Like the RSV fusion (F) glycoprotein, the Nipah fusion glycoprotein is a target of neutralizing antibodies that mediate protection against infection. Previous studies of prefusion-stabilized F glycoproteins from pneumoviruses and other paramyxoviruses (e.g. RSV and PIVs) have shown they elicit higher titers of neutralizing antibodies in both animals and humans than post-fusion F proteins.<br /><br /> Researchers at the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID) designed disulfide, cavity-filling and other mutations that stabilize the Nipah F glycoprotein in the prefusion conformation and bind prefusion-specific antibodies. These mutations also increase protein expression yields up to 50-fold making the recombinant proteins easy to manufacture and amenable to the use of genetic immunization using nucleic acid or vector-based applications.<br /><br /> The stabilized prefusion state of the Nipah F glycoprotein may be an ideal vaccine immunogen to elicit broad potent Nipah neutralizing antibodies. First and second generation prefusion molecules have been designed and tested in small animals and results (immunogenicity and stability) appear promising.<br /><br /> This technology is available for licensing for commercial development in accordance with 35 U.S.C. § 209 and 37 CFR Part 404. Nipah prefusion F design has the following features compared to wild-type fusion glycoprotein:<br /><br /> <ul> <li>Robust stabilization</li> <li>Up to 50-fold increase in expression yields, making the recombinant proteins easy to manufacture</li> <li>Potential to link the recombinant glycoprotein to nanoparticles or oligomerization peptides</li> </ul> <ul> <li>Vaccine - to elicit potent neutralizing antibodies against the Nipah Env glycoprotein</li> </ul> 2022-04-12 2026-04-27 2026-04-27 2019-08-21 F, nipah, proteins, recombinant, Their False True True NIHTT 37470483 Website Abstract 114110035 Loomis, Rebecca NIAID - DIR Loomis, Rebecca 0 114110036 Stewart-Jones, Guillaume NIAID - VRC NIAID Stewart-Jones, Guillaume (NIAID) 0 114110037 Mascola, John NIAID - VRC NIAID Mascola, John (NIAID) 0 114110034 Graham, Barney NIAID - VRC NIAID Graham, Barney (NIAID) 1 114110034 Graham, Barney NIAID - VRC NIAID Graham, Barney (NIAID) 1 114110035 Loomis, Rebecca NIAID - DIR Loomis, Rebecca 0 114110036 Stewart-Jones, Guillaume NIAID - VRC NIAID Stewart-Jones, Guillaume (NIAID) 0 114110037 Mascola, John NIAID - VRC NIAID Mascola, John (NIAID) 0 114102517 Recombinant Nipah F Proteins And Their Use E-050-2018-0 Filing authorized NIAID, University of Texas 83682222 Bailey, Brian bbailey@mail.nih.gov
United States of America TTIPO bbailey@mail.nih.gov?subject=Web Inquiry on [TAB-3382] Recombinant Nipah F Proteins and Their Use&body=Please send me information about technology [TAB-3382] Recombinant Nipah F Proteins and Their Use. Bailey, Brian<br><a href="mailto:bbailey@mail.nih.gov?subject=Web Inquiry on [TAB-3382] Recombinant Nipah F Proteins and Their Use&body=Please send me information about technology [TAB-3382] Recombinant Nipah F Proteins and Their Use.">bbailey@mail.nih.gov</a><br> 114168905 E-050-2018-0 E-050-2018-0-US-01 NIPAH VIRUS IMMUNOGENS AND THEIR USE PRV US 62/714,230 Abandoned US <br />Provisional (PRV) 62/714,230<br />Filed on 2018-08-03<br />Status: Abandoned 114168906 E-050-2018-0 E-050-2018-0-PCT-02 Nipah Virus Immunogens And Their Use PCT Patent Cooperation Treaty PCT/US2019/045110 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2019/045110<br />Filed on 2019-08-05<br />Status: Expired 114169089 E-050-2018-0 E-050-2018-0-US-07 NIPAH VIRUS IMMUNOGENS AND THEIR USE National Stage US 11,890,339 17/261,828 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11890339 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11890339">11,890,339</a><br />Filed on 2021-01-20<br />Status: Issued 114151635 recombinant 114151636 nipah 114151637 F 114151638 proteins 114151639 Their TAB-4079 147157361 Oxynitidine Derivatives Useful as Inhibitors of Topoisomerase IB (TOP1) and Tyrosyl-DNA Phosphodiesterase 1 (TDP1) for Treating Cancer NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Keli Agama, Lin-kun An, Evgeny Kiselev, Yves Pommier, Azhar Ravji <h2>Summary:&nbsp;</h2> <p>The National Cancer Institute (NCI) is actively seeking potential licensees and/or co-development research collaboration partners interested in advancing oxynitidine derivatives as novel inhibitors of topoisomerase IB (TOP1) and tyrosyl-DNA phosphodiesterase 1 (TDP1) for cancer treatment. These TOPI and TDP1 inhibitors, when administered together, demonstrate enhanced anti-tumor efficacy.</p> <h2>Description of Technology:&nbsp;</h2> <p>Topoisomerase 1B (TOP1) is an enzyme that relieves DNA torsional strain through the formation of transient TOP1-DNA covalent cleavage complexes (TOP1ccs) and is an attractive target for anti-cancer therapeutics. TOP1 inhibitors &ndash; such as camptothecin (CPT) &ndash; stabilize TOP1ccs, which ultimately leads to cell death. TOP1 inhibitors have long been recognized as anti-cancer agents and are used clinically. However, existing TOP1 inhibitor CPT, is limited by toxicity, chemical instability, poor solubility, and potential drug resistance via efflux mechanisms. Moreover, CPT directly competes with tyrosyl-DNA phosphodiesterase 1 (TDP1), which is an enzyme that repairs TOP1cc-induced cell damage. As such, this complicates CPT&rsquo;s effectiveness. Overall, there is ongoing interest in finding non-CPT compounds targeting TOP1 and/or TDP1 for cancer therapy.&nbsp;</p> <p>Researchers at the National Cancer Institute (NCI) and their collaborators have identified a range of oxynitidine derivatives that inhibit TOP1 and/or TDP1. These compounds represent a promising alternative to CPT. These oxynitidine derivatives have demonstrated potent TOP1 inhibition at nanomolar concentrations and effectively induce DNA damage and apoptosis in cancer cell lines. Additionally, some derivatives showed synergistic effects when used in combination with CPT. In vivo studies using xenograft mouse models of colon and breast cancer cells indicated that these derivatives (1) were generally well-tolerated and safe and (2) caused dose-dependent reduction in tumor weight. Crucially, these derivatives exhibit a significantly lower likelihood of eliciting drug resistance due to reduced susceptibility to drug efflux mechanisms. Overall, this research highlights a new class of compounds with potential for enhanced therapeutic efficacy and improved tolerability compared to traditional CPT-based therapies.</p> <h2>Potential Commercial Applications:&nbsp;</h2> <ul> <li>TOP1 and TDP1 inhibitors for treating various cancers</li> <li>Combinatorial drug treatment options to boost anti-tumor potency</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Novel chemotype for TOP1 and TDP1 inhibitors</li> <li>Can potentially be used synergistically with existing therapeutics such as CPT</li> <li>Limited number of chemotypes reported as TDP1 inhibitors provides good commercial potential given finite competition</li> <li>These compounds may overcome the limitations of CPT, especially chemical instability and diarrhea</li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for the development of oxynitidine derivatives as new TOP1 and TDP1 inhibitors for treating cancer. 2020-11-30 2026-04-24 2024-09-13 2026-04-24 2020-11-30 Benzophenanthridine Derivatives, Benzophenanthridinone, Camptothecin, Dihydrobenzophenanthridine, IRINOTECAN, Oxynitidine, Pommier, Tdp1, TOP1, Topoisomerase 1B, Topotecan, Tyrosyl-DNA Phosphodiesterase 1 False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2024-09-13 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-199-2010 147162124 Zhang X-R, et al. Discovery, Synthesis, and Evaluation of Oxynitidine Derivatives as Dual Inhibitors of DNA Topoisomerase IB (TOP1) and Tyrosyl-DNA Phosphodiesterase 1 (TDP1), and Potential Antitumor Agents. https://pubmed.ncbi.nlm.nih.gov/30336023/ <a href="https://pubmed.ncbi.nlm.nih.gov/30336023/">Zhang X-R, et al. Discovery, Synthesis, and Evaluation of Oxynitidine Derivatives as Dual Inhibitors of DNA Topoisomerase IB (TOP1) and Tyrosyl-DNA Phosphodiesterase 1 (TDP1), and Potential Antitumor Agents.</a> 158187906 Zhang X-R, et al. Discovery, Synthesis, and Evaluation of Oxynitidine Derivatives as Dual Inhibitors of DNA Topoisomerase IB (TOP1) and Tyrosyl-DNA Phosphodiesterase 1 (TDP1), and Potential Antitumor Agents. (PMID: 30336023) Tang W-L, et al. Synthesis and biological evaluation of 5-aminoethyl benzophenanthridone derivatives as DNA topoisomerase IB inhibitors. (PMID: 31176097) https://pubmed.ncbi.nlm.nih.gov/30336023/ <a href="https://pubmed.ncbi.nlm.nih.gov/30336023/">Zhang X-R, et al. Discovery, Synthesis, and Evaluation of Oxynitidine Derivatives as Dual Inhibitors of DNA Topoisomerase IB (TOP1) and Tyrosyl-DNA Phosphodiesterase 1 (TDP1), and Potential Antitumor Agents. (PMID: 30336023) Tang W-L, et al. Synthesis and biological evaluation of 5-aminoethyl benzophenanthridone derivatives as DNA topoisomerase IB inhibitors. (PMID: 31176097)</a> 158268568 Pommier, Yves National Cancer Institute (NCI) NCI Pommier, Yves (NCI) 1 158268572 An, Lin-kun Sun Yat-sen University An, Lin-kun 2 158268597 Agama, Keli NCI - CCR NCI Agama, Keli (NCI) 3 158268726 Kiselev, Evgeny NCI - CCR NCI Kiselev, Evgeny (NCI) 4 158268738 Ravji, Azhar Developmental Therapeutics Branch Ravji, Azhar 5 158268568 Pommier, Yves National Cancer Institute (NCI) NCI Pommier, Yves (NCI) 1 158268572 An, Lin-kun Sun Yat-sen University An, Lin-kun 2 158268597 Agama, Keli NCI - CCR NCI Agama, Keli (NCI) 3 158268726 Kiselev, Evgeny NCI - CCR NCI Kiselev, Evgeny (NCI) 4 158268738 Ravji, Azhar Developmental Therapeutics Branch Ravji, Azhar 5 147158159 Discovery, Synthesis And Evaluation Of Oxynitidine Derivatives As Dual Inhibitors Of DNA Topoisomerase IB (TOP1) And Tyrosyl-DNA Phosphodiesterase 1 (TDP1), And Potential Antitumor Agents E-181-2018-0 Filing authorized NCI, Sun Yat-sen University 147162552 Discovery, Synthesis And Evaluation Of Oxynitidine Derivatives As Dual Inhibitors Of DNA Topoisomerase IB (TOP1) And Tyrosyl-DNA Phosphodiesterase 1 (TDP1), And Potential Antitumor Agents E-181-2018-1 Filing authorized NCI, Sun Yat-sen University 147162553 Discovery, Synthesis And Evaluation Of Oxynitidine Derivatives As Dual Inhibitors Of DNA Topoisomerase IB (TOP1) And Tyrosyl-DNA Phosphodiesterase 1 (TDP1), And Potential Antitumor Agents E-181-2018-2 Filing authorized NCI, Sun Yat-sen University 91826910 McCrary, Michaela michaela.mccrary@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America michaela.mccrary@nih.gov?subject=Web Inquiry on [TAB-4079] Oxynitidine Derivatives Useful as Inhibitors of Topoisomerase IB (TOP1) and Tyrosyl-DNA Phosphodiesterase 1 (TDP1) for Treating Cancer&body=Please send me information about technology [TAB-4079] Oxynitidine Derivatives Useful as Inhibitors of Topoisomerase IB (TOP1) and Tyrosyl-DNA Phosphodiesterase 1 (TDP1) for Treating Cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov McCrary, Michaela<br><a href="mailto:michaela.mccrary@nih.gov?subject=Web Inquiry on [TAB-4079] Oxynitidine Derivatives Useful as Inhibitors of Topoisomerase IB (TOP1) and Tyrosyl-DNA Phosphodiesterase 1 (TDP1) for Treating Cancer&body=Please send me information about technology [TAB-4079] Oxynitidine Derivatives Useful as Inhibitors of Topoisomerase IB (TOP1) and Tyrosyl-DNA Phosphodiesterase 1 (TDP1) for Treating Cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">michaela.mccrary@nih.gov</a><br> 147161157 E-181-2018-0 E-181-2018-0-CN-01 Discovery, Synthesis And Evaluation Of Oxynitidine Derivatives As Dual Inhibitors Of DNA Topoisomerase IB (TOP1) And Tyrosyl-DNA Phosphodiesterase 1 (TDP1), And Potential Antitumor Agents ORD China 201810827467.1 Abandoned China <br />Ordinary Patent (ORD) 201810827467.1<br />Filed on 2018-07-25<br />Status: Abandoned 147166374 E-181-2018-1 E-181-2018-1-US-01 OXYNITIDINE DERIVATIVES USEFUL AS INHIBITORS OF TOPOISOMERASE IB (Top1) AND TYROSYL-DNA PHOSPHODIESTERASE 1(Tdp1) PRV US 62/732,885 Abandoned US <br />Provisional (PRV) 62/732,885<br />Filed on 2018-09-18<br />Status: Abandoned 147166377 E-181-2018-2 E-181-2018-2-PCT-01 OXYNITIDINE DERIVATIVES USEFUL AS INHIBITORS OF TOPOISOMERASE IB (Top1) AND TYROSYL-DNA PHOSPHODIESTERASE 1(Tdp1) PCT COMB Patent Cooperation Treaty PCT/US2019/043357 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2019/043357<br />Filed on 2019-07-25<br />Status: Expired 147166378 E-181-2018-2 E-181-2018-2-CN-02 OXYNITIDINE DERIVATIVES USEFUL AS INHIBITORS OF TOPOISOMERASE IB (Top1) AND TYROSYL-DNA PHOSPHODIESTERASE 1(Tdp1) National Stage China ZL201980062917.5 201980062917.5 Issued China <br />National Stage 201980062917.5<br />Filed on 2019-07-25<br />Status: Issued 147166379 E-181-2018-2 E-181-2018-2-EP-03 OXYNITIDINE DERIVATIVES USEFUL AS INHIBITORS OF TOPOISOMERASE IB (Top1) AND TYROSYL-DNA PHOSPHODIESTERASE 1(Tdp1) National Stage European Patent 19750204.0 Pending European Patent <br />National Stage 19750204.0<br />Filed on 2019-07-25<br />Status: Pending 147166380 E-181-2018-2 E-181-2018-2-US-04 OXYNITIDINE DERIVATIVES USEFUL AS INHIBITORS OF TOPOISOMERASE IB (TOP1) AND TYROSYL-DNA PHOSPHODIESTERASE 1 (TDP1) National Stage US 17/262,379 Pending US <br />National Stage 17/262,379<br />Filed on 2021-01-22<br />Status: Pending 147166381 E-181-2018-2 E-181-2018-2-HK-05 OXYNITIDINE DERIVATIVES USEFUL AS INHIBITORS OF TOPOISOMERASE IB (Top1) AND TYROSYL-DNA PHOSPHODIESTERASE 1(Tdp1) EP Hong Kong 62021043492.9 Pending Hong Kong <br />European patent (EP) 62021043492.9<br />Filed on 2021-12-02<br />Status: Pending 147173124 Benzophenanthridine Derivatives 147173126 Benzophenanthridinone 147173127 Camptothecin 147173129 Dihydrobenzophenanthridine 147173130 IRINOTECAN 147173131 Oxynitidine 147173132 Pommier 147173133 Tdp1 147173134 TOP1 147173136 Topoisomerase 1B 147173138 Topotecan 147173140 Tyrosyl-DNA Phosphodiesterase 1 TAB-4075 147157357 RNASEH-Assisted Detection Assay for RNA NCI Collaboration, Diagnostics, Infectious Disease, Licensing Collaboration Diagnostics Infectious Disease Licensing Dipak Poria, G Esta Sterneck <h2>Summary:</h2> <p>The NCI seeks research co-development partners and/or licensees for the development and commercialization of a diagnostic assay that detects sequence-specific (viral) RNA.</p> <h2>Description of Technology:</h2> <p>Several viral epidemics &ndash; such as the epidemics caused by H1N1 influenza virus, human immunodeficiency virus (HIV), Ebola virus, Zika virus, severe acute respiratory syndrome (SARS) virus, Middle East respiratory syndrome (MERS) virus and SARS-CoV-2 &ndash; have profoundly impacted global human health. Early identification of infected and/or infectious persons and isolating them from the population are some of the most effective and evident measures to prevent human-to-human spreading. In addition, areas with low resources and infrastructure may benefit from this technique for the detection of any viral or non-viral pathogens.</p> <p>Researchers at the National Cancer Institute (NCI) have developed a technology that describes an RNase-H-assisted detection assay for RNA (RADAR) that is rapid, inexpensive and highly sequence-specific.&nbsp; The assay is capable of detecting any RNA of interest, including cellular or viral RNA in a sequence-specific manner. The assay uses a modified isothermal rolling circle amplification (RCA) method that utilizes RNase H and a labeled RNA reporter molecule for the specific detection of a target RNA. The technology can detect viral RNA in approximately 2.5 hours and does not require expensive thermocyclers. Furthermore, the technology circumvents potential supply bottlenecks associated with other techniques that require enzymes other than DNA ligase, DNA polymerase, and RNaseH. Mode of detection of the amplified product is flexible depending on the nature of the label on the RNA reporter.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Diagnostic test for viral infection or any specific pathogen-derived RNA</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Rapid readout from isolated RNA of less than three hours&nbsp;</li> <li>May have the potential for point-of-care application</li> <li>Employs only three enzymes, which are relatively thermostable&nbsp;</li> <li>Does not require expensive and sophisticated thermocyclers</li> <li>Reagents are all commercially available and relatively low-cost</li> </ul> 2020-11-30 2026-04-24 2020-11-30 2026-04-24 2020-11-30 COVID, COVID-19, INFLUENZA, Poria, RNA, RNASEH, SARS-CoV2, Sterneck, Viral RNA False True Prototype True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-11-30 52406769 Prototype 52406769 NCI 37470483 Website Abstract 147163427 Sterneck, G Esta NIH - NCI NCI Sterneck, G Esta (NCI) 1 147163428 Poria, Dipak NIH - NCI NCI Poria, Dipak (NCI) 2 147163427 Sterneck, G Esta NIH - NCI NCI Sterneck, G Esta (NCI) 1 147163428 Poria, Dipak NIH - NCI NCI Poria, Dipak (NCI) 2 147158186 RNaseH-assisted Detection Assay For RNA (RADAR) E-193-2020-0 Filing authorized NCI 83704821 Nguyen-Antczak, Lauren lauren.nguyen-antczak@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-4075] RNASEH-Assisted Detection Assay for RNA&body=Please send me information about technology [TAB-4075] RNASEH-Assisted Detection Assay for RNA.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Nguyen-Antczak, Lauren<br><a href="mailto:lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-4075] RNASEH-Assisted Detection Assay for RNA&body=Please send me information about technology [TAB-4075] RNASEH-Assisted Detection Assay for RNA.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">lauren.nguyen-antczak@nih.gov</a><br> 147161176 E-193-2020-0 E-193-2020-0-US-01 RNASEH-ASSISTED DETECTION ASSAY FOR RNA (RADAR) PRV US 63/077,123 Abandoned US <br />Provisional (PRV) 63/077,123<br />Filed on 2020-09-11<br />Status: Abandoned 147166349 E-193-2020-0 E-193-2020-0-PCT-02 RNASE H-ASSISTED DETECTION ASSAY FOR RNA PCT Patent Cooperation Treaty PCT/US2021/049588 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/049588<br />Filed on 2021-09-09<br />Status: Expired 147173424 COVID 147173425 COVID-19 147173426 INFLUENZA 147173428 Poria 147173429 RNA 147173431 RNASEH 147173432 SARS-CoV2 147173434 Sterneck 147173436 Viral RNA TAB-4338 147157629 Dopamine D3 Receptor Agonist Compounds, Methods of Preparation, Intermediates Thereof, and their Methods of Use NIDA Collaboration, Licensing, Neurology, Therapeutics Collaboration Licensing Neurology Therapeutics Francisco Battiti, Alessandro Bonifazi, Sophe Cemaj, Amy Newman <h2>Description of Technology:</h2> <p>Due to the large degree of homology among dopamine D2-like receptors, discovering ligands capable of discriminating between the D2, D3, and D4 receptor subtypes remains a significant challenge. The development of subtype-selective pharmaceutical small molecules to activate (agonists) signals regulated by D2-like receptors has been especially difficult.&nbsp;</p> <p>The inventors at the National Institute on Aging (NIDA) have recently synthesized a new generation of D3R selective agonists by applying a well-established bitopic molecular approach. Inventors were able to combine a primary pharmacophore (PP) with a secondary pharmacophore (SP) to generate compounds with high D3R subtype affinity and selectivity (e.g., compound 53). All newly synthesized compounds were tested in radioligand competition binding studies for D2-like receptor affinities (D2R, D3R, and D4R). Compound 53 and its eutomer, 53a were further evaluated for metabolic stability in rat liver microsomes and metabolite identification to confirm their applicability to future in vivo studies.&nbsp;</p> <p>The molecules could not only serve as a tools for studying D3R dopaminergic signaling but have the potential to become a pharmacological treatment of neurodegenerative disorders associated with dopaminergic dysregulation. The characterization of these D3R specific agonists including compound 53 and 53a is further described in the listed manuscript (PMID: 31257877) and claimed in the referenced patent application below. The inventors have future plans to develop these compounds as molecular tools which will be appealing to a large group of scientists working in molecular biology, pharmacology, and computational sciences directed toward dopamine D3R and their multi-therapeutic potential. The syntheses and in vitro characterization are completed. Potential application as therapeutics is also a collaboration interest of the inventors.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>New molecular tools for the discovery of, and research into, D3R physiology</li> <li>Therapeutic use for neurodegenerative disorders such as Parkinson&rsquo;s Disease and Restless Legs Syndrome</li> <li>Neurological and neuropsychiatric disorders associated with dopamine dysregulation</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>The agonists have unique high D3R affinity and selectivity over D2R</li> <li>Potentially fewer side effects due to high selectivity toward D3R</li> <li>Broad range of clinical applications for the treatment neurological and neuropsychiatric disorders associated with dopamine dysregulation</li> </ul> 2020-10-27 2026-04-24 2020-10-27 2026-04-24 2020-10-27 D3R agonists, Dopamine, Newman, Parkinson’s Disease, Restless Legs Syndrome, RLS, small molecule False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-10-27 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147162030 Battiti FO, et al. The significance of chirality in drug design and synthesis of bitopic ligands as d3 receptor (d3r) selective agonists https://pubmed.ncbi.nlm.nih.gov/31257877/ <a href="https://pubmed.ncbi.nlm.nih.gov/31257877/">Battiti FO, et al. The significance of chirality in drug design and synthesis of bitopic ligands as d3 receptor (d3r) selective agonists</a> 147164363 Newman, Amy NIH - NIDA NIDA Newman, Amy (NIDA) 1 147164366 Bonifazi, Alessandro NIH - NIDA NIDA Bonifazi, Alessandro (NIDA) 2 147164364 Battiti, Francisco NIH - NIDA NIDA Battiti, Francisco (NIDA) 3 147164365 Cemaj, Sophe NIH - NIDA Cemaj, Sophe 4 147164363 Newman, Amy NIH - NIDA NIDA Newman, Amy (NIDA) 1 147164366 Bonifazi, Alessandro NIH - NIDA NIDA Bonifazi, Alessandro (NIDA) 2 147164364 Battiti, Francisco NIH - NIDA NIDA Battiti, Francisco (NIDA) 3 147164365 Cemaj, Sophe NIH - NIDA Cemaj, Sophe 4 147157933 Novel Opotically Active Dopamine D3 Receptor Selective Agonists E-077-2019-0 Filing authorized National Institute on Drug Abuse (NIDA) 83737255 Baxter, Merissa merissa.baxter@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB merissa.baxter@nih.gov?subject=Web Inquiry on [TAB-4338] Dopamine D3 Receptor Agonist Compounds, Methods of Preparation, Intermediates Thereof, and their Methods of Use&body=Please send me information about technology [TAB-4338] Dopamine D3 Receptor Agonist Compounds, Methods of Preparation, Intermediates Thereof, and their Methods of Use.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Baxter, Merissa<br><a href="mailto:merissa.baxter@nih.gov?subject=Web Inquiry on [TAB-4338] Dopamine D3 Receptor Agonist Compounds, Methods of Preparation, Intermediates Thereof, and their Methods of Use&body=Please send me information about technology [TAB-4338] Dopamine D3 Receptor Agonist Compounds, Methods of Preparation, Intermediates Thereof, and their Methods of Use.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">merissa.baxter@nih.gov</a><br> 147161004 E-077-2019-0 E-077-2019-0-US-01 D3 RECEPTOR AGONIST COMPOUNDS; METHODS OF PREPARATION; INTERMEDIATES THEREOF; AND METHODS OF USE THEREOF PRV US 62/833,023 Abandoned US <br />Provisional (PRV) 62/833,023<br />Filed on 2019-04-12<br />Status: Abandoned 147168275 E-077-2019-0 E-077-2019-0-PCT-02 Novel Opotically Active Dopamine D3 Receptor Selective Agonists PCT Patent Cooperation Treaty PCT/US2020/027903 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2020/027903<br />Filed on 2020-04-13<br />Status: Expired 147168276 E-077-2019-0 E-077-2019-0-AU-03 D3 RECEPTOR AGONIST COMPOUNDS; METHODS OF PREPARATION; INTERMEDIATES THEREOF; AND METHODS OF USE THEREOF National Stage Australia 2020270992 2020270992 Issued Australia <br />National Stage 2020270992<br />Filed on 2020-04-13<br />Status: Issued 147168277 E-077-2019-0 E-077-2019-0-CA-04 D3 RECEPTOR AGONIST COMPOUNDS; METHODS OF PREPARATION; INTERMEDIATES THEREOF; AND METHODS OF USE THEREOF National Stage Canada 3136151 Pending Canada <br />National Stage 3136151<br />Filed on 2020-04-13<br />Status: Pending 147168278 E-077-2019-0 E-077-2019-0-EP-05 Novel Opotically Active Dopamine D3 Receptor Selective Agonists National Stage European Patent 20724970.7 Pending European Patent <br />National Stage 20724970.7<br />Filed on 2020-04-13<br />Status: Pending 147168279 E-077-2019-0 E-077-2019-0-US-06 D3 RECEPTOR AGONIST COMPOUNDS; METHODS OF PREPARATION; INTERMEDIATES THEREOF; AND METHODS OF USE THEREOF National Stage US 12,479,838 17/602,504 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12479838 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12479838">12,479,838</a><br />Filed on 2021-10-08<br />Status: Issued 147170855 D3R agonists 147170856 Dopamine 147170857 Newman 147170859 Parkinson’s Disease 147170861 Restless Legs Syndrome 147170863 RLS 147170864 small molecule TAB-4166 147157449 Composite Gels and Methods of their Use in Tissue Repair, Drug Delivery, and as Implants NICHD Collaboration, Dermatology, Licensing, Materials Available, Medical Devices, Non-Medical Devices Collaboration Dermatology Licensing Materials Available Medical Devices Non-Medical Devices Peter Basser, Ferenc Horkay <h2>Description of Technology:</h2> <p style="margin-left:5.45pt">Gel materials, particularly hydrogels, typically lose their mechanical strength and stiffness as they swell. This property &nbsp;limits their use in both biological (e.g., cartilage and ECM repair) and non-biological (e.g., sealant) applications. Innovative materials in both medical and non-medical application areas are sorely needed.</p> <p style="margin-left:5.45pt">Recent innovations in this space, from the <em>Eunice Kennedy Shriver</em> National Institute of Child Health and Human Development (NICHD), include self-reinforcing composite hydrogels. These composite materials comprise novel combinations of solvents, swellable crosslinked polymer particles, and crosslinked polymer networks or matrices, which confine them. Exemplary solvents include water&nbsp;and organic solvents, silicone fluids and oils and others known in the art. Exemplary swellable crosslinked microgel polymer particles could comprise hyaluronic acid (HA) or other proteoglycans, polyethylene glycol, dextran particles, a poly(acrylic acid), a poly(methacrylic acid), polystyrene sulfonate, polyvinylpyrrolidone (PVP), polyacrylamide, or combinations thereof. Exemplary confining polymer networks or matrices in which these microgel polymer particles are incorporated can include polyvinyl alcohol (PVA) and its copolymers (e.g., polyvinyl alcohol-polyvinyl acetate copolymer, polyvinyl alcohol &ndash; polyvinyl acetal copolymer, polyvinyl alcohol &ndash; polyvinyl butyral copolymer) and other matrices or networks such as cellulose derivatives (e.g., methyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose). Tests of the innovative gels developed by NICHD scientists demonstrate that these gels have properties similar to, e.g., human cartilage &ndash; including load-bearing ability and demonstrating high self-reinforcement. The special properties of these gels also render them suitable for drug release to the intestines and other organs.</p> <p style="margin-left:5.45pt">Researchers at NICHD welcome a wide variety of collaborative and licensing relationships. Possibilities include a cooperative research and development agreement (CRADA). The NICHD and NCI technology transfer center welcome non-exclusive or exclusive license agreements. They are eager to transfer rights in these technologies &nbsp;&nbsp;to responsible commercial partners who will diligently move therapeutics and other applications towards commercialization.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Cartilage repair Intervertebral disc repair</li> <li>Drug delivery vehicle</li> <li>Breast implants and tissue expanders</li> <li>Commercial or industrial sealants</li> <li>Underwater (naval) or commercial sealant technology</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Highly self-reinforcing as compared to traditional gel materials Wide variety of potential clinical and industrial applications</li> <li>Fracture resistant, like rip-stop nylon</li> </ul> 2020-10-27 2026-04-24 2021-12-01 2026-04-24 2020-10-27 Basser, Cartilage, Composite, Drug Delivery, Gel, Horkay, Hydrogels, IMPLANTS, MATRIX, polymer, sealants, Tissue, Tissue Repair False True Prototype True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-12-01 52406769 Prototype 52406769 NCI 37470483 Website Abstract 147161866 Horkay F, et al. Composite Hydrogel Model of Cartilage Predicts Its Load-Bearing Ability. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7228937/ <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7228937/">Horkay F, et al. Composite Hydrogel Model of Cartilage Predicts Its Load-Bearing Ability.</a> 147163751 Horkay, Ferenc NIH - NICHD NICHD Horkay, Ferenc (NICHD) 1 147163750 Basser, Peter NIH - NICHD NICHD Basser, Peter (NICHD) 2 147163751 Horkay, Ferenc NIH - NICHD NICHD Horkay, Ferenc (NICHD) 1 147163750 Basser, Peter NIH - NICHD NICHD Basser, Peter (NICHD) 2 147157792 Composite Cartilage-like Load Bearing Hydrogel Systems E-014-2019-0 Filing authorized NICHD 119617417 Ravilious, Geoffrey geoffrey.ravilious@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
geoffrey.ravilious@nih.gov?subject=Web Inquiry on [TAB-4166] Composite Gels and Methods of their Use in Tissue Repair, Drug Delivery, and as Implants&body=Please send me information about technology [TAB-4166] Composite Gels and Methods of their Use in Tissue Repair, Drug Delivery, and as Implants.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Ravilious, Geoffrey<br><a href="mailto:geoffrey.ravilious@nih.gov?subject=Web Inquiry on [TAB-4166] Composite Gels and Methods of their Use in Tissue Repair, Drug Delivery, and as Implants&body=Please send me information about technology [TAB-4166] Composite Gels and Methods of their Use in Tissue Repair, Drug Delivery, and as Implants.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">geoffrey.ravilious@nih.gov</a><br> 147160901 E-014-2019-0 E-014-2019-0-US-02 COMPOSITE GELS AND METHODS OF USE THEREOF ORD US 12,083,246 16/783,494 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12083246 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12083246">12,083,246</a><br />Filed on 2020-02-06<br />Status: Issued 147167050 E-014-2019-0 E-014-2019-0-US-01 COMPOSITE GELS AND METHODS OF USE THEREOF PRV US 62/802,885 Abandoned US <br />Provisional (PRV) 62/802,885<br />Filed on 2019-02-08<br />Status: Abandoned 147169510 Basser 147169511 Cartilage 147169512 Composite 147169513 Drug Delivery 147169514 Gel 147169516 Horkay 147169517 Hydrogels 147169518 IMPLANTS 147169519 MATRIX 147169520 polymer 147169522 sealants 147169523 Tissue 147169525 Tissue Repair TAB-4020 147157301 Use of Acetalax for Treatment of Triple Negative Breast Cancer NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Matthew Garnett, Augustin Luna, Yves Pommier, Vinodh Rajapakse, William Reinhold <h2>Summary:</h2> <p>NCI seeks research co-development and/or potential licensees for a potential novel treatment for triple-negative breast cancer (TNBC) with acetalax (oxyphenisatin acetate).</p> <h2>Description of Technology:</h2> <p>Triple negative (progesterone receptor (PR)-, estrogen receptor (ER)-, human epidermal growth receptor 2 (HER2)-) breast cancer (TNBC) is an aggressive subtype that affects 15-20% of the 1.7 million cases of breast cancer occurring annually.&nbsp; Currently, standard treatments of TNBC include cytotoxic chemotherapies, surgery, and radiation. However, TNBC readily becomes resistant to chemotherapy, and those with TNBC are more likely to have a recurrence or die within five years compared to those with other breast cancer types. Therefore, there is a need for safer and more effective TNBC treatments to improve patient outcomes.</p> <p>Investigators from the National Cancer Institute (NCI) and collaborating institutions have identified the compound acetalax (oxyphenisatin acetate) as a promising potential therapy for TNBC. Strikingly, acetalax&rsquo;s cytotoxic effect checked first against ~178 FDA-approved or clinical trial oncology drugs on the three TNBC against the NCI-60 panel of cancer cell lines &ndash; subsequently followed up using the 22 different TNBC cell lines checked against 15 oncology drugs &ndash; were significantly most cytotoxic.<br /> Acetalax&rsquo;s efficacy in vivo has been investigated using a TNBC patient-derived xenograft (PDX) mouse model. Untreated PDX mice exhibited a tumor volume doubling rate of approximately 7-8 days whereas acetalax-treated mice tumor volumes decreased to undetectable levels in approximately 13 days.&nbsp;</p> <h2>Potential Commercial Applications:</h2> <ul> <li>A therapeutic for Triple Negative Breast Cancer</li> <li>Potential therapeutic for recalcitrant or estrogen-dependent cancers</li> <li>Potential applicability to breast (non-Triple Negative), ovarian, pancreatic, sarcoma, and uterine cancers</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Repurposed, previously approved FDA drug for a novel use as a therapeutic for TNBC and other cancers</li> <li>Repurposed, previously approved drugs can have an expedited approval process due in part to pre-existing safety data</li> </ul> 2020-09-25 2026-04-24 2020-09-25 2026-04-24 2020-09-25 Acetalax, Oxyphenisatin Acetate, Pommier, TNBC, Triple Negative Breast Cancer, Uterine Cancer False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-09-25 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147162411 Rajapakse VN, et al. CellMinerCDB for Integrative Cross-Database Genomics and Pharmacogenomics Analyses of Cancer Cell Lines. https://pubmed.ncbi.nlm.nih.gov/30553813/ <a href="https://pubmed.ncbi.nlm.nih.gov/30553813/">Rajapakse VN, et al. CellMinerCDB for Integrative Cross-Database Genomics and Pharmacogenomics Analyses of Cancer Cell Lines.</a> 147163245 Reinhold, William NIH - NCI NCI Reinhold, William (NCI) 1 147163248 Garnett, Matthew The Wellcome Trust Sanger Institute Garnett, Matthew 2 147163246 Rajapakse, Vinodh NIH - NCI NCI Rajapakse, Vinodh (NCI) 3 147163244 Pommier, Yves NIH - NCI NCI Pommier, Yves (NCI) 4 147163247 Luna, Augustin Harvard Medical School Luna, Augustin 5 147163245 Reinhold, William NIH - NCI NCI Reinhold, William (NCI) 1 147163248 Garnett, Matthew The Wellcome Trust Sanger Institute Garnett, Matthew 2 147163246 Rajapakse, Vinodh NIH - NCI NCI Rajapakse, Vinodh (NCI) 3 147163244 Pommier, Yves NIH - NCI NCI Pommier, Yves (NCI) 4 147163247 Luna, Augustin Harvard Medical School Luna, Augustin 5 147157846 Use Of Acetalax For Treatment Of Triple Negative Breast Cancer. E-041-2018-0 Filing authorized Harvard Medical School, NCI, The Wellcome Trust Sanger Institute 91826910 McCrary, Michaela michaela.mccrary@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America michaela.mccrary@nih.gov?subject=Web Inquiry on [TAB-4020] Use of Acetalax for Treatment of Triple Negative Breast Cancer&body=Please send me information about technology [TAB-4020] Use of Acetalax for Treatment of Triple Negative Breast Cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov McCrary, Michaela<br><a href="mailto:michaela.mccrary@nih.gov?subject=Web Inquiry on [TAB-4020] Use of Acetalax for Treatment of Triple Negative Breast Cancer&body=Please send me information about technology [TAB-4020] Use of Acetalax for Treatment of Triple Negative Breast Cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">michaela.mccrary@nih.gov</a><br> 147160946 E-041-2018-0 E-041-2018-0-US-01 A METHOD OF TREATING TRIPLE-NEGATIVE BREAST CANCER PRV US 62/627,926 Abandoned US <br />Provisional (PRV) 62/627,926<br />Filed on 2018-02-08<br />Status: Abandoned 147166039 E-041-2018-0 E-041-2018-0-PCT-02 A METHOD OF TREATING TRIPLE-NEGATIVE BREAST CANCER PCT Patent Cooperation Treaty PCT/US2019/017239 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2019/017239<br />Filed on 2019-02-08<br />Status: Expired 147166040 E-041-2018-0 E-041-2018-0-EP-03 A METHOD OF TREATING TRIPLE-NEGATIVE BREAST CANCER National Stage European Patent 3749302 19707221.8 Issued European Patent <br />National Stage 19707221.8<br />Filed on 2019-02-08<br />Status: Issued 147166041 E-041-2018-0 E-041-2018-0-US-04 A METHOD OF TREATING TRIPLE-NEGATIVE BREAST CANCER National Stage US 16/967,472 Pending US <br />National Stage 16/967,472<br />Filed on 2020-08-05<br />Status: Pending 147170058 Acetalax 147170060 Oxyphenisatin Acetate 147170061 Pommier 147170063 TNBC 147170065 Triple Negative Breast Cancer 147170067 Uterine Cancer TAB-4326 147157617 Extremely Rapid Method to Isolate Neoantigen Reactive T Cell Receptors (TCRs) NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Kenichi Hanada, Sri Krishna, Frank Lowery, Paul Robbins, Steven Rosenberg, James Yang, Rami Yoseph <h2>Summary:</h2> <p>NCI seeks commercial partners to co-develop and/or license a&nbsp;novel method to identify neoantigen reactive T cells and TCRs.</p> <h2>Description of Technology:</h2> <p>Adoptive cell transfer (ACT) uses tumor infiltrating lymphocytes (TILs) that recognize unique antigens expressed by cancer cells (&ldquo;neoantigens&rdquo;). Neoantigen specific TIL administration in patients has resulted in long term regression of certain metastatic cancers. However, one of the challenges of ACT and engineered T cell receptor (TCR) therapies more broadly, is the identification and isolation of these mutation specific TILs and TCRs. Only a fraction of TILs in a given patient is known to be tumor reactive, while the majority are not useful for cell therapy. The current procedures for isolating neoantigen reactive TILs and TCRs are time consuming, labor-intensive, and lack sensitivity and specificity.&nbsp;</p> <p>Researchers at the National Cancer Institute (NCI) have developed a novel method to identify neoantigen reactive T cells and TCRs, isolated from fresh tumors of common epithelial cancers. This method does not require tumor cells to be grown or propagated in vitro. By using a single cell, transcriptome-based approach and barcoded antibodies (CITE-seq), neoantigen reactive T cells can be clustered within tSNE (t-Distributed Stochastic Neighbor Embedding) plots. Using genetic markers that are highly expressed in such clusters, a transcriptomic gene signature, called &ldquo;NeoTCR Signature&rdquo;, has been developed. This NeoTCR Signature can be used to identify a very high frequency of previously unknown T-cell clones and TCRs that recognize neoantigens from the autologous tumor. Critically, identification and isolation of the neoantigen-reactive TCR can now occur in a few days, in stark contrast to the 6-8 weeks required for current methods. This rapid determination of the neoantigen reactive TCR sequences can be useful for translating this information into TCR-engineered T-cell populations for immunotherapy. This technique can also identify T-cells with specificities for new neoantigens not presently identifiable by conventional screening methods.&nbsp;</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Personalized cell therapy to treat cancer patients</li> <li>Immune monitoring of other immunotherapies</li> <li>Developing treatment against chronic infections which are expected to have similar T-cell dysfunction signatures (e.g. HIV, HCV, TB, etc.)</li> <li>Research tool to identify mutation-specific TCRs</li> <li>Prognostic testing for presence of tumor-relevant TILs</li> <li>Prospective isolation of cell population ideal for introduction of stem-like factors for cell therapy</li> <li>Biomarkers in immunotherapy</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Widely applicable to treat different types of cancer</li> <li>Significantly reduces the expensive and time-consuming procedures of tumor cell culture, propagation, and screening in vitro</li> <li>High specificity and sensitivity eliminate off-target effects</li> <li>Patient-specificity to improve efficacy of ACT or TCR therapy</li> </ul> 2020-09-03 2026-04-24 2022-01-19 2026-04-24 2020-09-03 act, Adoptive Cell Transfer, Immunotherapy, Neoantigen, Rosenberg, T Cell Receptor, TCR, TIL, tumor, Tumor Infiltrating Lymphocyte False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2022-01-19 52406768 Discovery 52406768 NCI 37470483 Website Abstract E-067-2017 E-229-2014 E-233-2014 147164323 Krishna, Sri NIH - NCI NCI Krishna, Sri (NCI) 1 147164318 Robbins, Paul NIH - NCI NCI Robbins, Paul (NCI) 2 147164321 Yoseph, Rami NIH - NCI NCI Yoseph, Rami (NCI) 3 147164320 Yang, James NIH - NCI NCI Yang, James (NCI) 4 147164319 Hanada, Kenichi NIH - NCI NCI Hanada, Kenichi (NCI) 5 147164322 Lowery, Frank NIH - NCI NCI Lowery, Frank (NCI) 6 147164317 Rosenberg, Steven NIH - NCI NCI Rosenberg, Steven (NCI) 7 147164323 Krishna, Sri NIH - NCI NCI Krishna, Sri (NCI) 1 147164318 Robbins, Paul NIH - NCI NCI Robbins, Paul (NCI) 2 147164321 Yoseph, Rami NIH - NCI NCI Yoseph, Rami (NCI) 3 147164320 Yang, James NIH - NCI NCI Yang, James (NCI) 4 147164319 Hanada, Kenichi NIH - NCI NCI Hanada, Kenichi (NCI) 5 147164322 Lowery, Frank NIH - NCI NCI Lowery, Frank (NCI) 6 147164317 Rosenberg, Steven NIH - NCI NCI Rosenberg, Steven (NCI) 7 147157897 Method For Rapid Isolation Of Neoantigen-reactive T-cell Receptors In Human Cancers By Single-cell Analysis For Immunotherapy E-061-2020-0 Filing authorized NCI 83709866 Burke, Andrew burkear@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC burkear@nih.gov?subject=Web Inquiry on [TAB-4326] Extremely Rapid Method to Isolate Neoantigen Reactive T Cell Receptors (TCRs)&body=Please send me information about technology [TAB-4326] Extremely Rapid Method to Isolate Neoantigen Reactive T Cell Receptors (TCRs).&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Burke, Andrew<br><a href="mailto:burkear@nih.gov?subject=Web Inquiry on [TAB-4326] Extremely Rapid Method to Isolate Neoantigen Reactive T Cell Receptors (TCRs)&body=Please send me information about technology [TAB-4326] Extremely Rapid Method to Isolate Neoantigen Reactive T Cell Receptors (TCRs).&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">burkear@nih.gov</a><br> 147160978 E-061-2020-0 E-061-2020-0-US-01 METHODS OF ISOLATING T-CELLS AND T-CELL RECEPTORS FROM TUMOR BY SINGLE-CELL ANALYSIS FOR IMMUNOTHERAPY PRV US 62/992,701 Abandoned US <br />Provisional (PRV) 62/992,701<br />Filed on 2020-03-20<br />Status: Abandoned 147168179 E-061-2020-0 E-061-2020-0-PCT-02 METHODS OF ISOLATING T-CELLS AND T-CELL RECEPTORS FROM TUMOR BY SINGLE-CELL ANALYSIS FOR IMMUNOTHERAPY PCT Patent Cooperation Treaty PCT/US2021/023240 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/023240<br />Filed on 2021-03-19<br />Status: Expired 147168180 E-061-2020-0 E-061-2020-0-AU-03 METHODS OF ISOLATING T-CELLS AND T-CELL RECEPTORS FROM TUMOR BY SINGLE-CELL ANALYSIS FOR IMMUNOTHERAPY National Stage Australia 2021237717 Pending Australia <br />National Stage 2021237717<br />Filed on 2022-09-28<br />Status: Pending 147168181 E-061-2020-0 E-061-2020-0-CA-04 METHODS OF ISOLATING T-CELLS AND T-CELL RECEPTORS FROM TUMOR BY SINGLE-CELL ANALYSIS FOR IMMUNOTHERAPY National Stage Canada 3171559 Pending Canada <br />National Stage 3171559<br />Filed on 2022-09-13<br />Status: Pending 147168182 E-061-2020-0 E-061-2020-0-CN-05 METHODS OF ISOLATING T-CELLS AND T-CELL RECEPTORS FROM TUMOR BY SINGLE-CELL ANALYSIS FOR IMMUNOTHERAPY National Stage China 202180022592.5 Pending China <br />National Stage 202180022592.5<br />Filed on 2021-03-19<br />Status: Pending 147168183 E-061-2020-0 E-061-2020-0-EP-06 METHODS OF ISOLATING T-CELLS AND T-CELL RECEPTORS FROM TUMOR BY SINGLE-CELL ANALYSIS FOR IMMUNOTHERAPY National Stage European Patent 21718712.9 Pending European Patent <br />National Stage 21718712.9<br />Filed on 2022-10-11<br />Status: Pending 147168184 E-061-2020-0 E-061-2020-0-JP-07 METHODS OF ISOLATING T-CELLS AND T-CELL RECEPTORS FROM TUMOR BY SINGLE-CELL ANALYSIS FOR IMMUNOTHERAPY National Stage Japan 2022-556459 Abandoned Japan <br />National Stage 2022-556459<br />Filed on 2022-09-16<br />Status: Abandoned 147168185 E-061-2020-0 E-061-2020-0-KR-08 METHODS OF ISOLATING T-CELLS AND T-CELL RECEPTORS FROM TUMOR BY SINGLE-CELL ANALYSIS FOR IMMUNOTHERAPY National Stage South Korea 10-2022-7036214 Pending South Korea <br />National Stage 10-2022-7036214<br />Filed on 2022-10-18<br />Status: Pending 147168186 E-061-2020-0 E-061-2020-0-US-09 METHODS OF ISOLATING T-CELLS AND T-CELL RECEPTORS FROM TUMOR BY SINGLE-CELL ANALYSIS FOR IMMUNOTHERAPY National Stage US 17/912,315 Pending US <br />National Stage 17/912,315<br />Filed on 2022-09-16<br />Status: Pending 147168187 E-061-2020-0 E-061-2020-0-IL-10 METHODS OF ISOLATING T-CELLS AND T-CELL RECEPTORS FROM TUMOR BY SINGLE-CELL ANALYSIS FOR IMMUNOTHERAPY National Stage Israel 296629 Pending Israel <br />National Stage 296629<br />Filed on 2022-09-19<br />Status: Pending 147170537 act 147170538 Adoptive Cell Transfer 147170539 Immunotherapy 147170540 Neoantigen 147170541 Rosenberg 147170542 T Cell Receptor 147170543 TCR 147170544 TIL 147170545 tumor 147170547 Tumor Infiltrating Lymphocyte TAB-4145 147157428 Method of Neoantigen-Reactive T Cell Receptor (TCR) Isolation from Peripheral Blood of Cancer Patients NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Amy Copeland, Sri Krishna, Frank Lowery, Paul Robbins, Steven Rosenberg, Rami Yoseph <h2>Summary:</h2> <p>NCI seeks commercial partners to co-develop and/or license&nbsp;a novel method for isolation and construction of neoantigen-reactive T-cell receptors (TCRs) from peripheral blood lymphocytes (PBL).</p> <h2>Description of Technology:</h2> <p>Adoptive cell transfer (ACT) uses tumor infiltrating lymphocytes (TILs) that recognize antigens expressed by cancer cells (neoantigens). Neoantigen specific TIL administration in patients has resulted in long-term regression of certain metastatic cancers. However, current procedures for TIL therapy are highly invasive, labor-intensive, and time consuming. The success of these procedures is limited and differs between patients and histologies. Isolation of neoantigen reactive TCRs have historically been challenging due to very low precursor frequencies of these T-cells as well as lack of technical advances that can determine phenotypic markers of these cells from the blood.&nbsp;</p> <p>Researchers at the National Cancer Institute (NCI) have developed a novel method for isolation and construction of neoantigen-reactive T-cell receptors (TCRs) from peripheral blood lymphocytes (PBL) of cancer patients.&nbsp; This method allows direct isolation of T cells from the blood, based on a distinct T cell gene signature; thus, it does not require tumor cells to be gown or propagated in vitro. In this method, peptide-HLA tetramers (pHLA) are used to isolate neoantigen reactive T cells based on patient specific information on major histocompatibility complex and tumor specific mutations. By taking advantage of the unique genetic signatures of neoantigen specific T cells, this method not only generates accurate scoring of single T cells from tumors, but also facilitates identification and reconstruction of unknown TCRs for immunotherapy. Additionally, these gene signatures can be used to identify TCRs from chronic infections (such as HIV).</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Personalized cell therapy to treat cancer patients</li> <li>Testing for the presence of tumor-relevant T cells in the blood of cancer patients</li> <li>Isolation of cell populations ideal for introduction of stem-like factors for cell therapy</li> <li>Biomarkers for cancer immunotherapy</li> <li>Developing treatment against chronic infections which are expected to have similar T-cell dysfunction signatures (e.g. HIV, HCV, TB, etc.)</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Widely applicable to treat different types of cancer</li> <li>Eliminates the expensive and time-consuming procedures of tumor cell culture, propagation, and screening in vitro</li> <li>High specificity and sensitivity significantly reduce off-target effects</li> <li>Patient-specificity to improve efficacy of ACT or TCR therapy</li> <li>Rapid and scalable method of isolating neoantigen-specific TCRs</li> </ul> 2020-09-03 2026-04-24 2020-09-03 2026-04-24 2020-09-03 act, Adoptive Cell Transfer, Immunotherapy, Neoantigen, Rosenberg, T Cell Receptors, TCRs, TILS, Tumor Infiltrating Lymphocytes False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-09-03 52406768 Discovery 52406768 NCI 37470483 Website Abstract E-061-2020 E-067-2017 E-229-2014 E-233-2014 147163676 Yoseph, Rami NIH - NCI NCI Yoseph, Rami (NCI) 1 147163675 Robbins, Paul NIH - NCI NCI Robbins, Paul (NCI) 2 147163677 Lowery, Frank NIH - NCI NCI Lowery, Frank (NCI) 3 147163678 Krishna, Sri NIH - NCI NCI Krishna, Sri (NCI) 4 147163679 Copeland, Amy NIH - NCI NCI Copeland, Amy (NCI) 5 147163674 Rosenberg, Steven NIH - NCI NCI Rosenberg, Steven (NCI) 6 147163676 Yoseph, Rami NIH - NCI NCI Yoseph, Rami (NCI) 1 147163675 Robbins, Paul NIH - NCI NCI Robbins, Paul (NCI) 2 147163677 Lowery, Frank NIH - NCI NCI Lowery, Frank (NCI) 3 147163678 Krishna, Sri NIH - NCI NCI Krishna, Sri (NCI) 4 147163679 Copeland, Amy NIH - NCI NCI Copeland, Amy (NCI) 5 147163674 Rosenberg, Steven NIH - NCI NCI Rosenberg, Steven (NCI) 6 147157991 NeoBlood TCR: Prospective Isolation Of Neoantigen-reactive T-cell Receptors From Peripheral Blood By Single-cell Analysis For Immunotherapy Of Cancer Patients E-102-2020-0 Filing authorized NCI 83709866 Burke, Andrew burkear@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC burkear@nih.gov?subject=Web Inquiry on [TAB-4145] Method of Neoantigen-Reactive T Cell Receptor (TCR) Isolation from Peripheral Blood of Cancer Patients&body=Please send me information about technology [TAB-4145] Method of Neoantigen-Reactive T Cell Receptor (TCR) Isolation from Peripheral Blood of Cancer Patients.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Burke, Andrew<br><a href="mailto:burkear@nih.gov?subject=Web Inquiry on [TAB-4145] Method of Neoantigen-Reactive T Cell Receptor (TCR) Isolation from Peripheral Blood of Cancer Patients&body=Please send me information about technology [TAB-4145] Method of Neoantigen-Reactive T Cell Receptor (TCR) Isolation from Peripheral Blood of Cancer Patients.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">burkear@nih.gov</a><br> 147161041 E-102-2020-0 E-102-2020-0-US-01 METHODS OF ISOLATING T CELLS AND T-CELL RECEPTORS FROM PERIPHERAL BLOOD BY SINGLE-CELL ANALYSIS FOR IMMUNOTHERAPY PRV US 62/992,715 Abandoned US <br />Provisional (PRV) 62/992,715<br />Filed on 2020-03-20<br />Status: Abandoned 147166908 E-102-2020-0 E-102-2020-0-PCT-02 METHODS OF ISOLATING T CELLS AND T-CELL RECEPTORS FROM PERIPHERAL BLOOD BY SINGLE-CELL ANALYSIS FOR IMMUNOTHERAPY PCT Patent Cooperation Treaty PCT/US2021/023225 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/023225<br />Filed on 2021-03-19<br />Status: Expired 147166909 E-102-2020-0 E-102-2020-0-AU-03 METHODS OF ISOLATING T CELLS AND T-CELL RECEPTORS FROM PERIPHERAL BLOOD BY SINGLE-CELL ANALYSIS FOR IMMUNOTHERAPY National Stage Australia 2021239379 Pending Australia <br />National Stage 2021239379<br />Filed on 2022-09-23<br />Status: Pending 147166910 E-102-2020-0 E-102-2020-0-CA-04 METHODS OF ISOLATING T CELLS AND T-CELL RECEPTORS FROM PERIPHERAL BLOOD BY SINGLE-CELL ANALYSIS FOR IMMUNOTHERAPY National Stage Canada 3171583 Pending Canada <br />National Stage 3171583<br />Filed on 2022-09-13<br />Status: Pending 147166911 E-102-2020-0 E-102-2020-0-CN-05 METHODS OF ISOLATING T CELLS AND T-CELL RECEPTORS FROM PERIPHERAL BLOOD BY SINGLE-CELL ANALYSIS FOR IMMUNOTHERAPY National Stage China 202180030252.7 Pending China <br />National Stage 202180030252.7<br />Filed on 2021-03-19<br />Status: Pending 147166912 E-102-2020-0 E-102-2020-0-EP-06 METHODS OF ISOLATING T CELLS AND T-CELL RECEPTORS FROM PERIPHERAL BLOOD BY SINGLE-CELL ANALYSIS FOR IMMUNOTHERAPY National Stage European Patent 21718376.3 Pending European Patent <br />National Stage 21718376.3<br />Filed on 2022-10-19<br />Status: Pending 147166913 E-102-2020-0 E-102-2020-0-JP-07 METHODS OF ISOLATING T CELLS AND T-CELL RECEPTORS FROM PERIPHERAL BLOOD BY SINGLE-CELL ANALYSIS FOR IMMUNOTHERAPY National Stage Japan 2022-556460 Pending Japan <br />National Stage 2022-556460<br />Filed on 2022-09-16<br />Status: Pending 147166914 E-102-2020-0 E-102-2020-0-KR-08 METHODS OF ISOLATING T CELLS AND T-CELL RECEPTORS FROM PERIPHERAL BLOOD BY SINGLE-CELL ANALYSIS FOR IMMUNOTHERAPY National Stage South Korea 10-2022-7036226 Pending South Korea <br />National Stage 10-2022-7036226<br />Filed on 2022-10-18<br />Status: Pending 147166915 E-102-2020-0 E-102-2020-0-US-09 METHODS OF ISOLATING T CELLS AND T-CELL RECEPTORS FROM PERIPHERAL BLOOD BY SINGLE-CELL ANALYSIS FOR IMMUNOTHERAPY National Stage US 17/906,524 Pending US <br />National Stage 17/906,524<br />Filed on 2022-09-16<br />Status: Pending 147166916 E-102-2020-0 E-102-2020-0-IL-10 METHODS OF ISOLATING T CELLS AND T-CELL RECEPTORS FROM PERIPHERAL BLOOD BY SINGLE-CELL ANALYSIS FOR IMMUNOTHERAPY National Stage Israel 296608 Pending Israel <br />National Stage 296608<br />Filed on 2022-09-19<br />Status: Pending 147171462 act 147171463 Adoptive Cell Transfer 147171464 Immunotherapy 147171465 Neoantigen 147171466 Rosenberg 147171468 T Cell Receptors 147171469 TCRs 147171470 TILS 147171472 Tumor Infiltrating Lymphocytes TAB-3944 147157224 Margaric Acid Decreases PIEZO2 Mediated Pain NCCIH Collaboration, Dermatology, Licensing, Neurology, Therapeutics Collaboration Dermatology Licensing Neurology Therapeutics Alexander Chesler, Julio Cordero-Morales, Luis Romero, Valeria Vasquez <h2>Summary:</h2> <p>The National Center for Complimentary and Integrative Health (NCCIH) seeks licensees and/or commercial partners to develop topical formulations of margaric acid to treat allodynia, neuropathy, and pain caused by chronic inflammation.&nbsp;&nbsp;</p> <h2>Description of Technology:</h2> <p>Some existing therapies for treatment of pain are administered systematically and have significant side effects, such as addiction and drowsiness. Alternative therapy that does not impair normal touch function could be used to treat pain caused by mechanical injury or chronic inflammation. Administration of margaric acid was shown to ameliorate pain in mouse models of pain. In vitro data shows that margaric acid counteracts PIEZO2 (Piezo-type mechanosensitive ion channel component 2) potentiation evoked by bradykinin (i.e. a peptide that promotes inflammation) by reducing the mechanocurrents up to non-inflammatory levels. Margaric acid seems to be specific to target mechanical pain as it does not significantly alter the electric excitability of mice dorsal root ganglia neurons or human iPSC-derived neurons. It mainly decreases action potential firing evoked by mechanical stimulation.</p> <p>&nbsp;</p> <p><img alt="E-081-2020 - PIEZO2 channel under different physiological conditions" src="https://nih.technologypublisher.com/files/sites/e-081-2020_-_piezo2_channel_under_different_physiological_conditions2.png" style="float:left; height:467px; width:700px" /></p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <h2>&nbsp;</h2> <h2>&nbsp;</h2> <h2>Potential Commercial Applications:</h2> <ul> <li>Treatment of pain caused by mechanical injury</li> <li>Treatment of pain caused by chronic inflammation (e.g., rheumatoid arthritis)</li> <li>Treatment of allodynia</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Not addictive</li> <li>Topical application</li> <li>Fewer side effects</li> </ul> 2020-09-03 2026-04-24 2020-09-03 2026-04-24 2020-09-03 ALLODYNIA, Chesler, Chronic Inflammation, fatty acid, Margaric Acid, migraine, National Center for Complimentary and Integrative Health, NCCIH, Neuropathy, Pain, PIEZO2, Vásquez False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-09-03 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147162417 Romero LO, et al. A dietary fatty acid counteracts neuronal mechanical sensitization https://pubmed.ncbi.nlm.nih.gov/32561714/ <a href="https://pubmed.ncbi.nlm.nih.gov/32561714/">Romero LO, et al. A dietary fatty acid counteracts neuronal mechanical sensitization</a> 147162963 Chesler, Alexander NIH - NCCIH NICHD Chesler, Alexander (NICHD) 1 147162964 Vasquez, Valeria University of Tennessee Health Science Center Vasquez, Valeria 2 147162965 Cordero-Morales, Julio University of Tennessee Health Science Center Cordero-Morales, Julio 3 147162966 Romero, Luis University of Tennessee Health Science Center Romero, Luis 4 147162963 Chesler, Alexander NIH - NCCIH NICHD Chesler, Alexander (NICHD) 1 147162964 Vasquez, Valeria University of Tennessee Health Science Center Vasquez, Valeria 2 147162965 Cordero-Morales, Julio University of Tennessee Health Science Center Cordero-Morales, Julio 3 147162966 Romero, Luis University of Tennessee Health Science Center Romero, Luis 4 147157946 MARGARIC ACID DECREASES PIEZO2-MEDIATED MECHANICAL ALLODYNIA E-081-2020-0 Filing authorized National Center for Complementary and Integrative Health (NCCIH), University of Tennessee Health Science Center 91800717 Hubbs, Alan hubbsa@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America Technology Transfer Center hubbsa@mail.nih.gov?subject=Web Inquiry on [TAB-3944] Margaric Acid Decreases PIEZO2 Mediated Pain&body=Please send me information about technology [TAB-3944] Margaric Acid Decreases PIEZO2 Mediated Pain.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Hubbs, Alan<br><a href="mailto:hubbsa@mail.nih.gov?subject=Web Inquiry on [TAB-3944] Margaric Acid Decreases PIEZO2 Mediated Pain&body=Please send me information about technology [TAB-3944] Margaric Acid Decreases PIEZO2 Mediated Pain.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">hubbsa@mail.nih.gov</a><br> 147161010 E-081-2020-0 E-081-2020-0-US-01 MARGARIC ACID DECREASES PIEZO2-MEDIATED PAIN PRV US 62/976,014 Abandoned US <br />Provisional (PRV) 62/976,014<br />Filed on 2020-02-13<br />Status: Abandoned 147165468 E-081-2020-0 E-081-2020-0-PCT-02 MARGARIC ACID DECREASES PIEZO2-MEDIATED MEDIATED PAIN PCT Patent Cooperation Treaty PCT/US2021/017780 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/017780<br />Filed on 2021-02-12<br />Status: Expired 147165469 E-081-2020-0 E-081-2020-0-JP-01 MARGARIC ACID DECREASES PIEZO2-MEDIATED MEDIATED PAIN National Stage Japan 7729824 2022-548411 Issued Japan <br />National Stage 2022-548411<br />Filed on 2022-08-08<br />Status: Issued 147165470 E-081-2020-0 E-081-2020-0-CA-01 MARGARIC ACID DECREASES PIEZO2-MEDIATED PAIN National Stage Canada 3167629 Pending Canada <br />National Stage 3167629<br />Filed on 2022-08-10<br />Status: Pending 147165471 E-081-2020-0 E-081-2020-0-AU-01 MARGARIC ACID DECREASES PIEZO2-MEDIATED MEDIATED PAIN National Stage Australia 2021220883 Pending Australia <br />National Stage 2021220883<br />Filed on 2021-02-12<br />Status: Pending 147165472 E-081-2020-0 E-081-2020-0-CN-01 MARGARIC ACID DECREASES PIEZO2-MEDIATED MEDIATED PAIN National Stage China 202180015900.1 Pending China <br />National Stage 202180015900.1<br />Filed on 2021-02-12<br />Status: Pending 147165473 E-081-2020-0 E-081-2020-0-NZ-01 MARGARIC ACID DECREASES PIEZO2-MEDIATED PAIN National Stage New Zealand 790763 Pending New Zealand <br />National Stage 790763<br />Filed on 2022-07-28<br />Status: Pending 147165474 E-081-2020-0 E-081-2020-0-KR-01 MARGARIC ACID DECREASES PIEZO2-MEDIATED MEDIATED PAIN National Stage South Korea 10-2022-7031665 Pending South Korea <br />National Stage 10-2022-7031665<br />Filed on 2022-09-13<br />Status: Pending 147165475 E-081-2020-0 E-081-2020-0-MX-01 MARGARIC ACID DECREASES PIEZO2-MEDIATED MEDIATED PAIN National Stage Mexico 431664 MX/a/2022/009914 Issued Mexico <br />National Stage MX/a/2022/009914<br />Filed on 2021-02-12<br />Status: Issued 147165476 E-081-2020-0 E-081-2020-0-EP-01 MARGARIC ACID DECREASES PIEZO2-MEDIATED MEDIATED PAIN National Stage European Patent 21710729.1 Pending European Patent <br />National Stage 21710729.1<br />Filed on 2021-02-12<br />Status: Pending 147171000 ALLODYNIA 147171002 Chesler 147171004 Chronic Inflammation 147171005 fatty acid 147171007 Margaric Acid 147171008 migraine 147171010 National Center for Complimentary and Integrative Health 147171012 NCCIH 147171013 Neuropathy 147171014 Pain 147171016 PIEZO2 147171018 Vásquez TAB-4195 147157480 Novel Regulatory B cells for Treatment of Cancer and Autoimmune Disease NIA Collaboration, Licensing, Oncology, Vaccines Collaboration Licensing Oncology Vaccines Bira Arya, Ioana Bodogai, Purevdorj Olkhanud <h2>Description of Technology:</h2> <p>The manner by which cancers evade the immune response is not well-understood. What is known is that the manner is an active process that regulates immune responses employing at least two types of suppressive cells, myeloid-derived suppressive cells and regulatory T cells (Tregs), a key subset of CD4+ T cells that controls peripheral tolerance to self- and allo-antigens. Tregs are considered to play a key role in the escape of cancer cells from anti-tumor effector T cells.</p> <p>Cancer cells have been found to directly activate resting B cells to form suppressive regulatory B cells (tBregs) and utilize them to evade immune surveillance and mediate metastasis. tBregs directly inhibit CD4+ and CD8+ T cell activity in a cell contact-dependent manner, induce FoxP3+ T cell activity, and promote Treg-dependent metastasis.</p> <p>Researchers from the <a href="https://www.nia.nih.gov/" rel="nofollow" target="_blank">National Institute on Aging</a> (NIA), NIH, have developed methods for the generation of tBregs, and for using tBregs to produce Tregs, and methods that inactivate or deplete tBregs. These methods have significant therapeutic value in the combat with cancer immune escape and metastasis, and in the control of harmful autoimmune diseases.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Production of cellular cancer vaccines</li> <li>Treatments for immune-mediated disorders</li> <li>Treatments for cancer</li> <li>Treatments for chronic viral infections</li> </ul> 2016-02-16 2026-04-24 2020-08-13 2026-04-24 2020-08-30 IMMUNOTHERAPEUTIC, Immunotherapy, suppressive regulatory B cells, tBregs False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-08-13 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147163863 Arya, Bira NIH - NIA NIA Arya, Bira (NIA) 1 147163864 Olkhanud, Purevdorj NIH - NIA NCI Olkhanud, Purevdorj (NCI) 2 147163865 Bodogai, Ioana NIH - NIA NIA Bodogai, Ioana (NIA) 3 147163863 Arya, Bira NIH - NIA NIA Arya, Bira (NIA) 1 147163864 Olkhanud, Purevdorj NIH - NIA NCI Olkhanud, Purevdorj (NCI) 2 147163865 Bodogai, Ioana NIH - NIA NIA Bodogai, Ioana (NIA) 3 147157989 Cancer-induced Regulatory B Cells (tBregs) Are Efficient Suppressors Of Immune Cellular Responses E-101-2010-0 Filing authorized National Institute on Aging (NIH/NIA) 91789173 Guyton, Nicole darackn@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America darackn@mail.nih.gov?subject=Web Inquiry on [TAB-4195] Novel Regulatory B cells for Treatment of Cancer and Autoimmune Disease&body=Please send me information about technology [TAB-4195] Novel Regulatory B cells for Treatment of Cancer and Autoimmune Disease.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Guyton, Nicole<br><a href="mailto:darackn@mail.nih.gov?subject=Web Inquiry on [TAB-4195] Novel Regulatory B cells for Treatment of Cancer and Autoimmune Disease&body=Please send me information about technology [TAB-4195] Novel Regulatory B cells for Treatment of Cancer and Autoimmune Disease.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">darackn@mail.nih.gov</a><br> 147167278 E-101-2010-0 E-101-2010-0-US-01 REGULATORY B CELLS (tBREGS) AND THEIR USE PRV US 61/302,074 Abandoned US <br />Provisional (PRV) 61/302,074<br />Filed on 2010-02-05<br />Status: Abandoned 147167279 E-101-2010-0 E-101-2010-0-PCT-02 Regulatory B Cells (tBregs) And Their Use PCT Patent Cooperation Treaty PCT/US2011/023789 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2011/023789<br />Filed on 2011-02-04<br />Status: Expired 147167280 E-101-2010-0 E-101-2010-0-US-03 Regulatory B Cells (TBregs) And Their Use National Stage US 9,228,171 13/577,226 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9228171 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9228171">9,228,171</a><br />Filed on 2012-08-03<br />Status: Issued 147167281 E-101-2010-0 E-101-2010-0-US-04 Regulatory B Cells (tBregs) And Their Uses CON US 9,657,269 14/952,768 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9657269 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9657269">9,657,269</a><br />Filed on 2015-11-25<br />Status: Issued 147171451 IMMUNOTHERAPEUTIC 147171452 Immunotherapy 147171454 suppressive regulatory B cells 147171455 tBregs TAB-3857 147157136 Use of Cucurbitacins and Withanolides for the Treatment of Cancer NCI Licensing, Oncology, Therapeutics Licensing Oncology Therapeutics Nancy Booth, Alan Brooks, Karen Erickson, Kirk Gustafson, Curtis Henrich, Thomas Sayers <h2>Description of Technology:</h2> <p>Certain members of the cucurbitacin and Withanolide family have been identified that can sensitize some tumor cell lines to cell death (apoptosis) on subsequent exposure of the cells to pro-apoptotic receptor agonists (PARAS) of the TRAIL &quot;death receptors&quot;. These PARAS include TRAIL itself, and agonist antibodies to two of its receptors death receptor-4 (DR4 or TRAIL-R1) and death receptor 5 (DR5, TRAIL-R2).&nbsp;</p> <p>The protein TRAIL has a very interesting characteristic that it can preferentially cause death of cancer cells whereas normal non-transformed cells are unaffected.&nbsp; Thus use of TRAIL or agonist antibodies to its so-called &quot;death receptors&quot; has been a current focus in cancer therapy.&nbsp;</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Use of the compounds with known TRAIL or agonist antibodies such as Mapatumumab or in combination with immunotherapeutic approaches for the treatment of cancer.</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Cucurbitacins and withanolides can be successfully developed in combination with known TRAIL agonist have the potential of new cancer combination therapies without major toxicities.</li> </ul> 2016-02-16 2026-04-24 2020-08-13 2026-04-24 2020-08-29 cucurbitacin, Immunotherapy, mapatumamab, TRAIL, withanolide False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-08-13 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147162452 Nancy L. Booth et al. A cell-based high-throughput screen to identify synergistic TRAIL sensitizers. https://www.ncbi.nlm.nih.gov/pubmed/19089423 <a href="https://www.ncbi.nlm.nih.gov/pubmed/19089423">Nancy L. Booth et al. A cell-based high-throughput screen to identify synergistic TRAIL sensitizers.</a> 147162634 Sayers, Thomas NIH - NCI Leidos Sayers, Thomas (Leidos) 1 147162635 Gustafson, Kirk NIH - NCI NCI Gustafson, Kirk (NCI) 2 147162636 Erickson, Karen NIH - NCI Erickson, Karen 3 147162638 Brooks, Alan NIH - NCI Leidos Brooks, Alan (Leidos) 4 147162637 Henrich, Curtis NIH - NCI Henrich, Curtis 5 147162639 Booth, Nancy NIH - NCI Booth, Nancy 6 147162634 Sayers, Thomas NIH - NCI Leidos Sayers, Thomas (Leidos) 1 147162635 Gustafson, Kirk NIH - NCI NCI Gustafson, Kirk (NCI) 2 147162636 Erickson, Karen NIH - NCI Erickson, Karen 3 147162638 Brooks, Alan NIH - NCI Leidos Brooks, Alan (Leidos) 4 147162637 Henrich, Curtis NIH - NCI Henrich, Curtis 5 147162639 Booth, Nancy NIH - NCI Booth, Nancy 6 147157869 Use Of Cucurbitacins And Withanolides To Sensitize Cancer Cells To The Cytotoxic Effects Of Apo2L/TRAIL E-050-2010-0 Filing authorized NCI 91814193 Freel, Rose rose.freel@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America rose.freel@nih.gov?subject=Web Inquiry on [TAB-3857] Use of Cucurbitacins and Withanolides for the Treatment of Cancer&body=Please send me information about technology [TAB-3857] Use of Cucurbitacins and Withanolides for the Treatment of Cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Freel, Rose<br><a href="mailto:rose.freel@nih.gov?subject=Web Inquiry on [TAB-3857] Use of Cucurbitacins and Withanolides for the Treatment of Cancer&body=Please send me information about technology [TAB-3857] Use of Cucurbitacins and Withanolides for the Treatment of Cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">rose.freel@nih.gov</a><br> 147160966 E-050-2010-0 E-050-2010-0-US-01 Use Of Cucurbitacins And Withanolides To Sensitize Cancer Cells To The Cytotoxic Effects Of Apo2L/TRAIL PRV US 61/287,139 Abandoned US <br />Provisional (PRV) 61/287,139<br />Filed on 2009-12-16<br />Status: Abandoned 147164857 E-050-2010-0 E-050-2010-0-PCT-02 Method of Sensitizing Cancer Cells To The Cytotoxic Effects Of Death Receptor Ligands In Cancer Treatment PCT Patent Cooperation Treaty PCT/US2010/060821 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2010/060821<br />Filed on 2010-12-16<br />Status: Expired 147164858 E-050-2010-0 E-050-2010-0-US-03 METHOD OF SENSITIZING CANCER CELLS TO THE CYTOTOXIC EFFECTS OF DEATH RECEPTOR LIGANDS IN CANCER TREATMENT National Stage US 9,238,069 13/516,514 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9238069 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9238069">9,238,069</a><br />Filed on 2012-10-26<br />Status: Issued 147170305 cucurbitacin 147170306 Immunotherapy 147170308 mapatumamab 147170309 TRAIL 147170311 withanolide TAB-4181 147157466 Denoising of Dynamic Magnetic Resonance Spectroscopic Imaging Using Low Rank Approximations in the Kinetic Domain NCI Collaboration, Licensing, Oncology, Software / Apps Collaboration Licensing Oncology Software / Apps Jeffery Brender, Murali Cherukuri, Shun Kishimoto, Hellmut Merkle, James Mitchell, Jeeva Munasinghe, Kazutoshi Yamamoto <h2>Summary:</h2> <p>The scientists seek co-development parties and/or licensees for a method for measuring low-abundance metabolites in vivo.</p> <h2>Description of Technology:</h2> <p>Accurate measurement of low metabolite concentrations produced by medically important enzymes is commonly obscured by noise during magnetic resonance imaging (MRI). Measuring the turnover rate of low-level metabolites can directly quantify the activity of enzymes of interest, including possible drug targets in cancer and other diseases. Noise can cause the in vivo signal to fall below the limit of detection. A variety of denoising methods have been proposed to enhance spectroscopic peaks, but still fall short for the detection of low-intensity signals. Dynamic nuclear polarization (DNP) is one method that has been critical for boosting weak signals. DNP must be performed near zero absolute temperature, requiring high operating costs. Measurements are limited to imaging immediately after tracer injection, limiting the range of injectable tracers that can be used in vivo.&nbsp;</p> <p>To address these issues, scientists at the National Cancer Institute (NCI) and National Institute of Neurological Disorders and Stroke (NINDS) have invented a unique method for measuring low-abundance metabolites in vivo which does not rely on frequency or spatial domains &ndash; but instead works in the kinetic domain. Data processing structure is simpler. True weak spectroscopic peaks can be more easily distinguished from noise. This technology improves the signal-to-noise ratio by an order of magnitude or more and has already been tested in vivo. The denoising software enhances low-metabolic signal without the need for DNP, which was previously thought impossible. The method makes MRI more informative for determining the metabolic activity of key enzymes in serious pathologies, is more dynamic in the range of tracers that can be used, and is generally less expensive. This software is also highly adaptable as it can be added as a plug-in to already existing MRI processing software.&nbsp;</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Plug-in software adaptable for use with current MRI-processing software</li> <li>MRIs for clinical or research purposes</li> <li>Ancillary invention of X-nuclei leg coil which improves signal-to-noise ratio and is compatible with software</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Unique method for measuring low-abundance metabolites in vivo which does not rely on frequency or spatial domains</li> <li>Significant enhancement of raw signal and differentiation when detecting pyruvic acid metabolism to lactate</li> </ul> 2020-08-24 2026-04-24 2020-08-24 2026-04-24 2020-08-24 13C imaging, Brender, Denoising, DNP, Dynamic Nuclear Polarization, Glucose Metabolism, Low Metabolite Concentration, Magnetic Resonance Imaging, Metabolic Enzymes, MRI, Software Plugin, SPECTROSCOPIC False True Prototype True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-08-24 52406769 Prototype 52406769 NCI 37470483 Website Abstract 147161913 Brender JR, et al. Dynamic Imaging of Glucose and Lactate Metabolism by 13C-MRS without Hyperpolarization. https://doi.org/10.1038/s41598-019-38981-1 <a href="https://doi.org/10.1038/s41598-019-38981-1">Brender JR, et al. Dynamic Imaging of Glucose and Lactate Metabolism by 13C-MRS without Hyperpolarization.</a> 147161951 Kishimoto S, et al. Imaging of glucose metabolism by 13C-MRI distinguishes pancreatic cancer subtypes in mice https://pubmed.ncbi.nlm.nih.gov/31408004/ <a href="https://pubmed.ncbi.nlm.nih.gov/31408004/">Kishimoto S, et al. Imaging of glucose metabolism by 13C-MRI distinguishes pancreatic cancer subtypes in mice</a> 147162338 Brender J, et al. PET by MRI: Glucose Imaging by 13C-MRS without Dynamic Nuclear Polarization by Noise Suppression through Tensor Decomposition Rank Reduction. https://www.biorxiv.org/content/10.1101/265793v1.full <a href="https://www.biorxiv.org/content/10.1101/265793v1.full">Brender J, et al. PET by MRI: Glucose Imaging by 13C-MRS without Dynamic Nuclear Polarization by Noise Suppression through Tensor Decomposition Rank Reduction.</a> 147163802 Brender, Jeffery NIH - NCI NCI Brender, Jeffery (NCI) 1 147163803 Yamamoto, Kazutoshi NIH - NCI NCI Yamamoto, Kazutoshi (NCI) 2 147163804 Munasinghe, Jeeva NIH - NCI NINDS Munasinghe, Jeeva (NINDS) 3 147163805 Kishimoto, Shun NIH - NCI NCI Kishimoto, Shun (NCI) 4 147163801 Merkle, Hellmut NIH - NINDS NINDS Merkle, Hellmut (NINDS) 5 147163800 Cherukuri, Murali NIH - NCI NCI Cherukuri, Murali (NCI) 6 147163799 Mitchell, James NIH - NCI NCI Mitchell, James (NCI) 7 147163802 Brender, Jeffery NIH - NCI NCI Brender, Jeffery (NCI) 1 147163803 Yamamoto, Kazutoshi NIH - NCI NCI Yamamoto, Kazutoshi (NCI) 2 147163804 Munasinghe, Jeeva NIH - NCI NINDS Munasinghe, Jeeva (NINDS) 3 147163805 Kishimoto, Shun NIH - NCI NCI Kishimoto, Shun (NCI) 4 147163801 Merkle, Hellmut NIH - NINDS NINDS Merkle, Hellmut (NINDS) 5 147163800 Cherukuri, Murali NIH - NCI NCI Cherukuri, Murali (NCI) 6 147163799 Mitchell, James NIH - NCI NCI Mitchell, James (NCI) 7 147157904 Denoising Of Dynamic Magnetic Resonance Spectroscopic Imaging Using Low Rank Approximations In The Kinetic Domain E-063-2017-0 Filing authorized NCI, NINDS 83673032 Whitney, Laurie WhitneyL@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC WhitneyL@mail.nih.gov?subject=Web Inquiry on [TAB-4181] Denoising of Dynamic Magnetic Resonance Spectroscopic Imaging Using Low Rank Approximations in the Kinetic Domain&body=Please send me information about technology [TAB-4181] Denoising of Dynamic Magnetic Resonance Spectroscopic Imaging Using Low Rank Approximations in the Kinetic Domain.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Whitney, Laurie<br><a href="mailto:WhitneyL@mail.nih.gov?subject=Web Inquiry on [TAB-4181] Denoising of Dynamic Magnetic Resonance Spectroscopic Imaging Using Low Rank Approximations in the Kinetic Domain&body=Please send me information about technology [TAB-4181] Denoising of Dynamic Magnetic Resonance Spectroscopic Imaging Using Low Rank Approximations in the Kinetic Domain.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">WhitneyL@mail.nih.gov</a><br> 147167173 E-063-2017-0 E-063-2017-0-US-01 DENOISING OF DYNAMIC RESONANCE SPECTROSCOPIC IMAGING USING LOW RANK APPROXIMATIONS IN THE KINETIC DOMAIN PRV US 62/459,008 Abandoned US <br />Provisional (PRV) 62/459,008<br />Filed on 2017-02-14<br />Status: Abandoned 147167174 E-063-2017-0 E-063-2017-0-PCT-02 DENOISING OF DYNAMIC RESONANCE SPECTROSCOPIC IMAGING USING LOW RANK APPROXIMATIONS IN THE KINETIC DOMAIN PCT Patent Cooperation Treaty PCT/US2018/018217 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2018/018217<br />Filed on 2018-02-14<br />Status: Expired 147167175 E-063-2017-0 E-063-2017-0-JP-06 DENOISING OF DYNAMIC MAGNETIC RESONANCE SPECTROSCOPIC IMAGING USING LOW RANK APPROXIMATIONS IN THE KINETIC DOMAIN National Stage Japan 7142017 2019-543765 Issued Japan <br />National Stage 2019-543765<br />Filed on 2018-02-14<br />Status: Issued 147167176 E-063-2017-0 E-063-2017-0-AU-03 DENOISING OF DYNAMIC MAGNETIC RESONANCE SPECTROSCOPIC IMAGING USING LOW RANK APPROXIMATIONS IN THE KINETIC DOMAIN National Stage Australia 2018221015 2018221015 Issued Australia <br />National Stage 2018221015<br />Filed on 2019-08-13<br />Status: Issued 147167177 E-063-2017-0 E-063-2017-0-CA-04 DENOISING OF DYNAMIC RESONANCE SPECTROSCOPIC IMAGING USING LOW RANK APPROXIMATIONS IN THE KINETIC DOMAIN National Stage Canada 3053157 3053157 Issued Canada <br />National Stage 3053157<br />Filed on 2018-02-14<br />Status: Issued 147167178 E-063-2017-0 E-063-2017-0-EP-05 DENOISING OF DYNAMIC RESONANCE SPECTROSCOPIC IMAGING USING LOW RANK APPROXIMATIONS IN THE KINETIC DOMAIN National Stage European Patent 3583436 18707581.7 Issued European Patent <br />National Stage 18707581.7<br />Filed on 2018-02-14<br />Status: Issued 147167179 E-063-2017-0 E-063-2017-0-US-07 Denoising Of Dynamic Magnetic Resonance Spectroscopic Imaging Using Low Rank Approximations In The Kinetic Domain National Stage US 16/485,772 Pending US <br />National Stage 16/485,772<br />Filed on 2019-08-13<br />Status: Pending 147167180 E-063-2017-0 E-063-2017-0-US-08 DENOISING OF DYNAMIC RESONANCE SPECTROSCOPIC IMAGING USING LOW RANK APPROXIMATIONS IN THE KINETIC DOMAIN CON US 12,270,881 17/576,283 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12270881 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12270881">12,270,881</a><br />Filed on 2022-01-14<br />Status: Issued 147167181 E-063-2017-0 E-063-2017-0-DE-09 DENOISING OF DYNAMIC RESONANCE SPECTROSCOPIC IMAGING USING LOW RANK APPROXIMATIONS IN THE KINETIC DOMAIN EP Germany 3583436 18707581.7 Issued Germany <br />European patent (EP) 18707581.7<br />Filed on 2018-02-14<br />Status: Issued 147167182 E-063-2017-0 E-063-2017-0-FR-10 DENOISING OF DYNAMIC RESONANCE SPECTROSCOPIC IMAGING USING LOW RANK APPROXIMATIONS IN THE KINETIC DOMAIN EP France 3583436 18707581.7 Issued France <br />European patent (EP) 18707581.7<br />Filed on 2018-02-14<br />Status: Issued 147167183 E-063-2017-0 E-063-2017-0-GB-11 DENOISING OF DYNAMIC RESONANCE SPECTROSCOPIC IMAGING USING LOW RANK APPROXIMATIONS IN THE KINETIC DOMAIN EP United Kingdom 3583436 18707581.7 Issued United Kingdom <br />European patent (EP) 18707581.7<br />Filed on 2018-02-14<br />Status: Issued 147170598 13C imaging 147170600 Brender 147170601 Denoising 147170603 DNP 147170605 Dynamic Nuclear Polarization 147170607 Glucose Metabolism 147170609 Low Metabolite Concentration 147170610 Magnetic Resonance Imaging 147170612 Metabolic Enzymes 147170613 MRI 147170615 Software Plugin 147170616 SPECTROSCOPIC TAB-3990 147157271 T-cell Receptors Targeting CD20-Positive Lymphomas and Leukemias NCI Licensing, Oncology, Therapeutics Licensing Oncology Therapeutics Christian Hinrichs, Kazusa Ishii <h2>Summary:</h2> <p>NCI seeks parties interested in licensing&nbsp;to further develop&nbsp;a collection of novel anti-CD20 TCRs that can be used to treat CD20 positive lymphomas and leukemias.</p> <h2>Description of Technology:</h2> <p>CD20 is a protein expressed by wide ranges of lymphoid malignancies originating from B cells but not by indispensable normal tissues, making it an attractive target for therapies such as T-cell receptor (TCR) therapy. Current anti-CD20 therapeutics face a number of limitations. The most important limitation to current anti-CD20 therapies include cancer cells becoming resistant to the therapy. Resistance mechanisms to the existing CD20 therapies include loss of target antigen expression from the cell surface, loss of antibody epitope, or modulation of antibody epitope &ndash; all of which make the malignant cells &ldquo;invisible&rdquo; to antibodies. Importantly, these resistance mechanisms do not affect TCR-mediated target recognition. Epitopes for TCRs are short fragments of peptides that are processed intracellularly and presented in the context of major histocompatibility complex. Thus, TCRs can recognize and kill leukemia and lymphoma that are no longer &ldquo;visible&rdquo; to existing antibodies.&nbsp;</p> <p>Investigators at the National Cancer Institute (NCI) have developed a collection of novel anti-CD20 TCRs that can be used to treat CD20 positive lymphomas and leukemias. These novel TCRs can recognize and exert cell killing against CD20-derived epitopes even when the target protein escapes surface expression and remains in a sub-cellular compartment, such as endoplasmic reticulum or cytoplasm. These characteristics of the novel anti-CD20 TCRs allow them to overcome known resistance mechanisms associated with B-cell malignancies, making them an attractive therapy over other current CD20 therapeutics on the market.&nbsp;</p> <h2>Potential Commercial Applications:</h2> <ul> <li>The TCRs can be used as a therapeutic against B-cell malignancies such as non-Hodgkin&rsquo;s lymphoma, chronic lymphocytic leukemia and acute lymphoblastic leukemia</li> <li>The TCRs can be used for treatment in: <ul> <li>CD20-expressing malignancies, even if the CD20 antigen escapes the surface of the tumor cells and resides within intracellular compartments or is only partially expressed</li> <li>CD20-expressing malignancies, even if the diseases are resistant to existing anti-CD20 antibodies through resistance to antibody-specific cytotoxicity mechanisms (such as antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity)&nbsp;</li> </ul> </li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>The novel TCRs can recognize and exert cell killing against CD20-derived epitopes even when the target protein escapes surface expression and remains in a sub-cellular compartment, which are current limitations of CAR-T cell therapy and anti-CD20 monoclonal antibodies</li> <li>The novel anti-CD20 TCRs&nbsp;can specifically recognize and exert tumor-cell killing in a target-antigen-restricted manner, when CD20 expression is low, or when CD20 is expressed intracellularly</li> <li>In in vitro experiments, T cells engineered to express anti-CD20 TCR recognize and mediate cytotoxicity against cells lines that are both CD20+ and HLA-A2+ and exhibit high functional activity</li> <li>CD20 targeting TCRs are available for immediate clinical validation</li> </ul> 2020-08-19 2026-04-24 2021-03-23 2026-04-24 2020-08-19 Acute Lymphoblastic Leukemia, ALL, CD20, Chronic lymphocytic leukemia, CLL, Hinrichs, Ishii, NHL, Non-Hodgkin’s Lymphoma, Resistant B-lymphoid malignancies, T-Cell Receptor, TCR False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-03-23 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147163144 Ishii, Kazusa NIH - NCI NCI Ishii, Kazusa (NCI) 1 147163143 Hinrichs, Christian NIH - NCI Hinrichs, Christian 2 147163144 Ishii, Kazusa NIH - NCI NCI Ishii, Kazusa (NCI) 1 147163143 Hinrichs, Christian NIH - NCI Hinrichs, Christian 2 147158086 Discovery Of T Cell Receptors (TCR) Against HLA-A*02:01-restricted CD20 Epitope E-152-2020-0 Filing authorized NCI 83694133 Gulay French, Suna suna.gulay@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB suna.gulay@nih.gov?subject=Web Inquiry on [TAB-3990] T-cell Receptors Targeting CD20-Positive Lymphomas and Leukemias&body=Please send me information about technology [TAB-3990] T-cell Receptors Targeting CD20-Positive Lymphomas and Leukemias.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Gulay French, Suna<br><a href="mailto:suna.gulay@nih.gov?subject=Web Inquiry on [TAB-3990] T-cell Receptors Targeting CD20-Positive Lymphomas and Leukemias&body=Please send me information about technology [TAB-3990] T-cell Receptors Targeting CD20-Positive Lymphomas and Leukemias.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">suna.gulay@nih.gov</a><br> 147165752 E-152-2020-0 E-152-2020-0-US-01 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST CD20 PRV US 63/043,520 Abandoned US <br />Provisional (PRV) 63/043,520<br />Filed on 2020-06-24<br />Status: Abandoned 147165753 E-152-2020-0 E-152-2020-0-PCT-02 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST CD20 PCT Patent Cooperation Treaty PCT/US2021/038649 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/038649<br />Filed on 2021-06-23<br />Status: Expired 147165754 E-152-2020-0 E-152-2020-0-US-03 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST CD20 National Stage US 18/012,056 Pending US <br />National Stage 18/012,056<br />Filed on 2022-12-21<br />Status: Pending 147172428 Acute Lymphoblastic Leukemia 147172429 ALL 147172430 CD20 147172431 Chronic lymphocytic leukemia 147172432 CLL 147172433 Hinrichs 147172434 Ishii 147172435 NHL 147172436 Non-Hodgkin’s Lymphoma 147172438 Resistant B-lymphoid malignancies 147172439 T-Cell Receptor 147172440 TCR TAB-4411 147157706 Gene Therapy for Treatment of CRX-Autosomal Dominant Retinopathies NEI Collaboration, Ear, Nose, & Throat, Licensing, Ophthalmology, Therapeutics Collaboration Ear Nose & Throat Licensing Ophthalmology Therapeutics Suja Hiriyanna, Kamil Kruczek, Anand Swaroop, Zhijian Wu <h2>Description of Technology:</h2> <p>Mutations in the cone rod homeobox (CRX) transcription factor lead to distinct retinopathy phenotypes, including early-onset vision impairment in dominant Leber congenital amaurosis (LCA). Adeno-Associated virus (AAV) vector-mediated delivery of a CRX cDNA under the control of a CRX promoter region partially restored photoreceptor phenotype and expression of phototransduction genes in an in vitro model of CRX-LCA. Gene therapy using the CRX-AAV vector to retinal organoids derived from induced pluripotent stem cells (iPSCs) of a patient with the dominant CRX-I138fs mutation partially restored expression of visual opsins and other phototransduction genes as revealed by immunohistochemistry and single cell RNA-sequencing. Retinal organoids from iPSCs of a second dominant CRX-LCA patient carrying a K88N mutation also revealed loss of expression of opsins and phototransduction genes as a common phenotype, which could be alleviated by AAV-mediated overexpression of CRX.&nbsp;</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Early onset blindness, including Leber congenital amaurosis</li> <li>Gene therapy of CRX retinopathies; i.e., patients with a mutation in the CRX gene</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Promising commercial potential given that there are no current treatments for CRX-retinopathies&nbsp;</li> <li>Gene therapy by delivering CRX should restore photoreceptor structure and function</li> <li>Existing commercial interest and an established regulatory path for directly administered gene therapy targeting an ophthalmic disease caused by mutations in a specific gene: In 2017, Luxturna (voretigene neparvovec-rzyl) was FDA approved for an inherited form of vision loss (confirmed biallelic RPE65 mutation-associated retinal dystrophy) that may result in blindness</li> </ul> 2020-08-17 2026-04-24 2020-08-17 2026-04-24 2020-08-17 AAV, Adeno-associated Virus, Cone-rod Dystrophy, CRD, GENE THERAPY, LCA, Leber Congenital Amaurosis, Lentivirus, NEI, rare disease, Retinitis Pigmentosa, Retinopathies, RP, Swaroop False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-08-17 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147164644 Swaroop, Anand NIH - NEI NEI Swaroop, Anand (NEI) 1 147164647 Kruczek, Kamil NIH - NEI NEI Kruczek, Kamil (NEI) 2 147164645 Hiriyanna, Suja NIH - NEI NEI Hiriyanna, Suja (NEI) 3 147164646 Wu, Zhijian NIH - NEI NEI Wu, Zhijian (NEI) 4 147164644 Swaroop, Anand NIH - NEI NEI Swaroop, Anand (NEI) 1 147164647 Kruczek, Kamil NIH - NEI NEI Kruczek, Kamil (NEI) 2 147164645 Hiriyanna, Suja NIH - NEI NEI Hiriyanna, Suja (NEI) 3 147164646 Wu, Zhijian NIH - NEI NEI Wu, Zhijian (NEI) 4 147157778 Gene Therapy For Treatment Of CRX-associated Retinopathies E-008-2020-0 Filing authorized National Eye Institute (NEI) 83724826 Pollard, Ricquita ricquita.pollard@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4411] Gene Therapy for Treatment of CRX-Autosomal Dominant Retinopathies&body=Please send me information about technology [TAB-4411] Gene Therapy for Treatment of CRX-Autosomal Dominant Retinopathies.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollard, Ricquita<br><a href="mailto:ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4411] Gene Therapy for Treatment of CRX-Autosomal Dominant Retinopathies&body=Please send me information about technology [TAB-4411] Gene Therapy for Treatment of CRX-Autosomal Dominant Retinopathies.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">ricquita.pollard@nih.gov</a><br> 147160891 E-008-2020-0 E-008-2020-0-US-01 Gene Therapy For Treatment Of CRX-associated Retinopathies PRV US 62/962,732 Abandoned US <br />Provisional (PRV) 62/962,732<br />Filed on 2020-01-17<br />Status: Abandoned 147168764 E-008-2020-0 E-008-2020-0-PCT-02 GENE THERAPY FOR TREATMENT OF CRX-AUTOSOMAL DOMINANT RETINOPATHIES PCT Patent Cooperation Treaty PCT/US2021/013733 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/013733<br />Filed on 2021-01-15<br />Status: Expired 147168765 E-008-2020-0 E-008-2020-0-US-03 GENE THERAPY FOR TREATMENT OF CRX-AUTOSOMAL DOMINANT RETINOPATHIES National Stage US 17/789,729 Pending US <br />National Stage 17/789,729<br />Filed on 2022-06-28<br />Status: Pending 147168766 E-008-2020-0 E-008-2020-0-AU-04 GENE THERAPY FOR TREATMENT OF CRX-AUTOSOMAL DOMINANT RETINOPATHIES National Stage Australia 2021208631 Pending Australia <br />National Stage 2021208631<br />Filed on 2021-01-15<br />Status: Pending 147168767 E-008-2020-0 E-008-2020-0-CA-05 GENE THERAPY FOR TREATMENT OF CRX-AUTOSOMAL DOMINANT RETINOPATHIES National Stage Canada 3165922 Pending Canada <br />National Stage 3165922<br />Filed on 2021-01-15<br />Status: Pending 147168768 E-008-2020-0 E-008-2020-0-EP-06 GENE THERAPY FOR TREATMENT OF CRX-AUTOSOMAL DOMINANT RETINOPATHIES National Stage European Patent 21705324.8 Pending European Patent <br />National Stage 21705324.8<br />Filed on 2021-01-15<br />Status: Pending 147168769 E-008-2020-0 E-008-2020-0-JP-07 GENE THERAPY FOR TREATMENT OF CRX-AUTOSOMAL DOMINANT RETINOPATHIES National Stage Japan 7703543 2022-540642 Issued Japan <br />National Stage 2022-540642<br />Filed on 2021-01-15<br />Status: Issued 147169363 AAV 147169364 Adeno-associated Virus 147169366 Cone-rod Dystrophy 147169368 CRD 147169369 GENE THERAPY 147169370 LCA 147169372 Leber Congenital Amaurosis 147169373 Lentivirus 147169375 NEI 147169376 rare disease 147169378 Retinitis Pigmentosa 147169379 Retinopathies 147169381 RP 147169383 Swaroop TAB-4342 147157634 CD206 Small Molecule Modulators, Their Use and Methods for Preparation NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Bolormaa Baljinnyam, Raul Calvo, Xin Hu, Juan Marugan, Udo Rudloff, Noel Southall <h2>Summary:</h2> <p>The NCI is seeking licensing partners and/or collaborators to perform IND enabling studies to translate the anti-CD206 small molecule into a therapeutic for CD206 expressing cancers.</p> <h2>Description of Technology:</h2> <p>Pancreatic ductal adenocarcinoma (PDA) accounts for more than 90% of pancreatic cancer cases, and it is one of the most aggressive malignancies with a 5-year survival rate of 6%. The high mortality rate caused by PDA is primarily from the lack of early diagnosis &ndash; it is often asymptomatic in early stages &ndash; and a poor response to conventional chemotherapy and radiotherapy. One of the major immune cell types present in the PDA microenvironment is a subset of macrophages commonly termed tumor-associated macrophages (TAM). TAMs originate, in part, from circulating monocytes upon activation by CCL2, a chemotactic chemokine secreted and then recruited to the tumor microenvironment by cytokines expressed by PDA cells.</p> <p>TAMs consist primarily of polarized M2 macrophages which promote tumor growth by secreting immunosuppressive factors that block effector T-cell activation. TAMs express scavenger receptors such as CD206 which facilitate tumor angiogenesis and migration. CD206 is a member of the large C-type lectin receptor family and not found on other TAM population like undifferentiated M0 or M1-like macrophages. CD206high expression and infiltration with CD206high macrophages has been associated with poor clinical outcomes in pancreatic cancer and other solid organ cancers. Current anti-macrophage therapy generally inhibits activation or the recruitment of macrophages (CCL2/CCR2), which lacks specificity towards M2-like macrophages, agonism of M1 signaling via CD40 ligation, or blockade of the CD47-SIRP &lsquo;do-not-eat&rsquo; cancer phagocytosis checkpoint.</p> <p>Researchers at the National Cancer Institute (NCI) have discovered a small molecule that binds to CD206 and induces M2-to-M1 reprogramming, cancer cell phagocytosis and M2 cell death. The anti-CD206 small molecule was identified through structure-based pharmacophore modeling and in silico screening of the anti-cancer peptide, RP-182 (NIH Reference Number: E-242-2015.) The activity of this CD206 small molecule modulator was confirmed in vitro and in vivo across a number of different solid organ cancer models. In addition to its reprogramming function to a M1 mechanism, a selective reduced cell viability was observed in human CD206high M2-like macrophages derived from healthy volunteers compared with M1 control macrophages. This new small molecule immunomodulator will be the first-in-class that will have application in selectively targeting M2 macrophages &ndash; a pro-tumor immune cell population &ndash; and the reprogramming of M2 macrophages towards a M1 phenotype (anti-tumor cell population) for the treatment of pancreatic cancer. The small molecule candidate has high oral bioavailability, a large therapeutic window, favorable pharmacokinetics, and limited off-target effects.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Treatment of cancers associated with high expression of CD206 including pancreatic, head and neck, lung, gastric, triple negative breast, renal cell, colorectal cancer, and melanoma</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>First-in-class small molecule targeting CD206 for oncology indication</li> <li>Targeted therapy decreases non-specific killing of healthy, essential cells, resulting in fewer non-specific side-effects and healthier patients</li> <li>High unmet needs and commercial opportunity for pancreatic cancer</li> </ul> 2020-08-17 2026-04-24 2021-05-20 2026-04-24 2020-08-17 CD206, M1 Macrophage, M2 Macrophage, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, PDA, Rudloff, TAM, Tumor-Associated Macrophages False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-05-20 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-242-2015 147164385 Rudloff, Udo NIH - NCI NCI Rudloff, Udo (NCI) 1 147164384 Marugan, Juan NIH - NCATS NCATS Marugan, Juan (NCATS) 2 147164386 Hu, Xin NIH - NCATS NCATS Hu, Xin (NCATS) 3 147164387 Calvo, Raul NIH - NCATS NCATS Calvo, Raul (NCATS) 4 147164383 Southall, Noel NIH - NCATS NCATS Southall, Noel (NCATS) 5 147164382 Baljinnyam, Bolormaa NIH - NCATS NCATS Baljinnyam, Bolormaa (NCATS) 6 147164385 Rudloff, Udo NIH - NCI NCI Rudloff, Udo (NCI) 1 147164384 Marugan, Juan NIH - NCATS NCATS Marugan, Juan (NCATS) 2 147164386 Hu, Xin NIH - NCATS NCATS Hu, Xin (NCATS) 3 147164387 Calvo, Raul NIH - NCATS NCATS Calvo, Raul (NCATS) 4 147164383 Southall, Noel NIH - NCATS NCATS Southall, Noel (NCATS) 5 147164382 Baljinnyam, Bolormaa NIH - NCATS NCATS Baljinnyam, Bolormaa (NCATS) 6 147157996 Small Molecules With Selective Activity Against The M2 Phenotype Of Macrophages E-105-2019-0 Filing authorized NCATS - NCGC, NCATS - NCGC, NCI, NIH - NCATS, NIH - NCI 83736770 Cheng, Eric eric.cheng2@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB eric.cheng2@nih.gov?subject=Web Inquiry on [TAB-4342] CD206 Small Molecule Modulators, Their Use and Methods for Preparation&body=Please send me information about technology [TAB-4342] CD206 Small Molecule Modulators, Their Use and Methods for Preparation.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Cheng, Eric<br><a href="mailto:eric.cheng2@nih.gov?subject=Web Inquiry on [TAB-4342] CD206 Small Molecule Modulators, Their Use and Methods for Preparation&body=Please send me information about technology [TAB-4342] CD206 Small Molecule Modulators, Their Use and Methods for Preparation.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">eric.cheng2@nih.gov</a><br> 147161046 E-105-2019-0 E-105-2019-0-US-01 CD206 MODULATORS THEIR USE AND METHODS FOR PREPARATION PRV US 62/950,488 Abandoned US <br />Provisional (PRV) 62/950,488<br />Filed on 2019-12-19<br />Status: Abandoned 147168315 E-105-2019-0 E-105-2019-0-PCT-02 CD206 MODULATORS THEIR USE AND METHODS FOR PREPARATION PCT Patent Cooperation Treaty PCT/US2020/065238 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2020/065238<br />Filed on 2020-12-16<br />Status: Expired 147168316 E-105-2019-0 E-105-2019-0-CA-04 CD206 MODULATORS THEIR USE AND METHODS FOR PREPARATION National Stage Canada 3165339 Pending Canada <br />National Stage 3165339<br />Filed on 2020-12-16<br />Status: Pending 147168317 E-105-2019-0 E-105-2019-0-CN-05 CD206 MODULATORS THEIR USE AND METHODS FOR PREPARATION National Stage China ZL202080096478.2 202080096478.2 Issued China <br />National Stage 202080096478.2<br />Filed on 2022-08-30<br />Status: Issued 147168318 E-105-2019-0 E-105-2019-0-EP-06 CD206 MODULATORS THEIR USE AND METHODS FOR PREPARATION National Stage European Patent 20842083.6 Pending European Patent <br />National Stage 20842083.6<br />Filed on 2020-12-16<br />Status: Pending 147168319 E-105-2019-0 E-105-2019-0-JP-07 CD206 MODULATORS THEIR USE AND METHODS FOR PREPARATION National Stage Japan 7801223 2022-537672 Issued Japan <br />National Stage 2022-537672<br />Filed on 2020-12-16<br />Status: Issued 147168320 E-105-2019-0 E-105-2019-0-US-08 CD206 Modulators Their Use and Methods for Preparation National Stage US 17/787,313 Pending US <br />National Stage 17/787,313<br />Filed on 2022-06-18<br />Status: Pending 147168321 E-105-2019-0 E-105-2019-0-AU-03 CD206 MODULATORS THEIR USE AND METHODS FOR PREPARATION National Stage Australia 2020404978 Pending Australia <br />National Stage 2020404978<br />Filed on 2020-12-16<br />Status: Pending 147171505 CD206 147171507 M1 Macrophage 147171509 M2 Macrophage 147171510 Pancreatic Cancer 147171512 Pancreatic Ductal Adenocarcinoma 147171513 PDA 147171515 Rudloff 147171516 TAM 147171518 Tumor-Associated Macrophages TAB-4281 147157569 High Affinity Nanobodies Targeting B7-H3 (CD276) for Treating Solid Tumors NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Mitchell Ho, Dan Li, Brad St. Croix, Ruixue Wang <h2>Summary:</h2> <p>The NCI seeks licensing and/or co-development research collaborations for CD276-targeting camel nanobodies.&nbsp;</p> <h2>Description of Technology:</h2> <p>CD276 (also called B7-H3) is a pan-cancer antigen expressed in multiple solid tumors and an emerging cancer target. CD276 protein is overexpressed in pancreatic cancer, prostate cancer, breast cancer, colon cancer, lung cancer, and brain tumors (such as neuroblastoma) &ndash; making it an ideal target for cancer therapy.&nbsp;</p> <p>Investigators at the National Cancer Institute (NCI) have isolated a panel of anti-CD276 single domain antibodies (also known as nanobodies) from novel camel and rabbit single domain (VHH) libraries by phage display.&nbsp;</p> <p>Nanobodies are the smallest known antigen-binding fragments of antibodies. Due to their small size, high solubility, thermal stability, refolding capacity, and relatively easy tissue penetration, they have great potential as medical applications and research tools. These antibodies can be used as either independent agents or targeting domains in recombinant immunotoxins (RITs), antibody-drug conjugates (ADCs), and chimeric antigen receptors (CARs). The CARs using the RWB12, RWC4 and RWG8 antibodies have shown potent killing in various CD276-expressing tumor cell models, strongly supporting that these candidates may be further developed as therapeutics.&nbsp;</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Numerous solid tumors &ndash; including, but not limited to: pancreatic cancer, prostate cancer, breast cancer, colon cancer, lung cancer, and brain tumors (such as neuroblastoma)&nbsp;</li> <li>Therapeutic applications include the unconjugated antibodies and their use as a targeting moiety for CARs, RITs, ADCs, and bispecific antibodies</li> <li>Diagnostic agent for detection and monitoring levels of mesothelin expressing cancers</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Antibodies with high CD276 binding specificity should result in less non-specific cell killing (off-target toxicity) and lower potential side-effects</li> <li>Similarity of camel and human VH sequences suggests humanization of these antibodies is not necessary, and that the product is ready for immediate clinical testing</li> <li>Relative ease of Tissue Penetration for targeting Solid Tumors</li> <li>CARs using the A101 and G8 antibodies available for immediate testing</li> <li>B7-H3 antagonist</li> </ul> 2020-08-17 2026-04-24 2020-08-17 2026-04-24 2020-08-17 ADC, Antibody-drug Conjugate, B7-H3, BREAST CANCER, CAR, CD276, chimeric antigen receptor, COLON CANCER, Glioma, HO, lung cancer, Nanobodies, Neuroblastoma, OVARIAN CANCER, Pancreatic Cancer, solid tumors False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-08-17 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147164144 Ho, Mitchell NIH - NCI NCI Ho, Mitchell (NCI) 1 147164145 St. Croix, Brad NIH - NCI NCI St. Croix, Brad (NCI) 2 147164147 Wang, Ruixue NIH - NCI NCI Wang, Ruixue (NCI) 3 147164146 Li, Dan NCI - CCR NCI Li, Dan (NCI) 4 147164144 Ho, Mitchell NIH - NCI NCI Ho, Mitchell (NCI) 1 147164145 St. Croix, Brad NIH - NCI NCI St. Croix, Brad (NCI) 2 147164147 Wang, Ruixue NIH - NCI NCI Wang, Ruixue (NCI) 3 147164146 Li, Dan NCI - CCR NCI Li, Dan (NCI) 4 147158171 High Affinity Nanobodies Targeting B7-H3 (CD276) For Treating Multiple Solid Tumors E-185-2019-0 Filing authorized NCI 83731987 Dhal, Abritee abritee.dhal@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-4281] High Affinity Nanobodies Targeting B7-H3 (CD276) for Treating Solid Tumors&body=Please send me information about technology [TAB-4281] High Affinity Nanobodies Targeting B7-H3 (CD276) for Treating Solid Tumors.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dhal, Abritee<br><a href="mailto:abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-4281] High Affinity Nanobodies Targeting B7-H3 (CD276) for Treating Solid Tumors&body=Please send me information about technology [TAB-4281] High Affinity Nanobodies Targeting B7-H3 (CD276) for Treating Solid Tumors.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">abritee.dhal@nih.gov</a><br> 147161165 E-185-2019-0 E-185-2019-0-US-01 High Affinity Nanobodies Targeting B7-H3 (CD276) For Treating Multiple Solid Tumors PRV US 62/924,498 Abandoned US <br />Provisional (PRV) 62/924,498<br />Filed on 2019-10-22<br />Status: Abandoned 147167851 E-185-2019-0 E-185-2019-0-PCT-02 High Affinity Nanobodies Targeting B7-H3 (CD276) For Treating Multiple Solid Tumors PCT Patent Cooperation Treaty PCT/US2020/056601 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2020/056601<br />Filed on 2020-10-21<br />Status: Expired 147167852 E-185-2019-0 E-185-2019-0-AU-03 High Affinity Nanobodies Targeting B7-H3 (CD276) For Treating Multiple Solid Tumors National Stage Australia 2020370125 Pending Australia <br />National Stage 2020370125<br />Filed on 2020-10-21<br />Status: Pending 147167853 E-185-2019-0 E-185-2019-0-CA-04 High Affinity Nanobodies Targeting B7-H3 (CD276) For Treating Multiple Solid Tumors National Stage Canada 3156761 Pending Canada <br />National Stage 3156761<br />Filed on 2020-10-21<br />Status: Pending 147167854 E-185-2019-0 E-185-2019-0-CN-05 High Affinity Nanobodies Targeting B7-H3 (CD276) For Treating Multiple Solid Tumors National Stage China ZL202080074414.2 202080074414.2 Issued China <br />National Stage 202080074414.2<br />Filed on 2020-10-21<br />Status: Issued 147167855 E-185-2019-0 E-185-2019-0-EP-06 High Affinity Nanobodies Targeting B7-H3 (CD276) For Treating Multiple Solid Tumors National Stage European Patent 20804404.0 Pending European Patent <br />National Stage 20804404.0<br />Filed on 2020-10-21<br />Status: Pending 147167856 E-185-2019-0 E-185-2019-0-JP-07 High Affinity Nanobodies Targeting B7-H3 (CD276) For Treating Multiple Solid Tumors National Stage Japan 7690468 2022-523456 Issued Japan <br />National Stage 2022-523456<br />Filed on 2020-10-21<br />Status: Issued 147167857 E-185-2019-0 E-185-2019-0-US-08 High Affinity Nanobodies Targeting B7-H3 (CD276) For Treating Multiple Solid Tumors National Stage US 12,552,865 17/770,940 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12552865 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12552865">12,552,865</a><br />Filed on 2022-04-21<br />Status: Issued 147173275 ADC 147173276 Antibody-drug Conjugate 147173277 B7-H3 147173278 BREAST CANCER 147173279 CAR 147173280 CD276 147173281 chimeric antigen receptor 147173282 COLON CANCER 147173283 Glioma 147173284 HO 147173285 lung cancer 147173286 Nanobodies 147173287 Neuroblastoma 147173288 OVARIAN CANCER 147173289 Pancreatic Cancer 147173290 solid tumors TAB-3899 147157179 Humanized Mouse Model to Study Mesothelin (MSLN) -targeted Cancer Therapeutics: Bl6/TPO Mice NCI Licensing, Oncology, Research Materials Licensing Oncology Research Materials Christine Alewine, Norman Collins, Theresa Guerin, Serguei Kozlov, Theresa O'Sullivan, Jerome Schlomer, Xianyu Zhang <h2>Summary:</h2> <p>The NCI Laboratory of Molecular Biology is seeking parties interested in licensing&nbsp;a genetically engineered&nbsp;mouse model expressing hMSLN in the thyroid gland for commercialization in the field of cancer therapeutics and research targeting mesothelin-expressing tumors.</p> <h2>Description of Technology:</h2> <p>Mesothelin (MSLN) is an antigen highly expressed in several human cancers including mesotheliomas, ovarian cancers and pancreatic cancers. As such, human MSLN (hMSLN) is a target for many anti-cancer drugs. Most therapeutics targeting hMSLN do not recognize the mouse isoform of MSLN (mMSLN) and therefore cannot be tested in mouse cancer models.&nbsp;</p> <p>Investigators at the National Cancer Institute (NCI) have developed a mouse model wherein mice are genetically engineered to express hMSLN in the thyroid gland under the transcriptional control of a thyroid-specific (Tpo) gene promoter. Due to the tolerance to the hMSLN isoform, these mice are efficient recipients of cancer cell lines engineered to express hMSLN. These mice allow the testing of cancer therapeutics targeted against hMSLN in a fully immunocompetent animal background. In addition, these mice can be used to investigate on-target, off-tumor toxicity caused by hMSLN-directed therapeutics.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Research, diagnostics, or therapeutics involving the target, mesothelin, such as in human mesotheliomas, ovarian cancers, pancreatic cancers</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>The humanized mice have expression of human mesothelin (hMSLN) that is localized to the thyroid. The Bl6/TPO mice are efficient recipients of cancer cells lines that express hMSLN</li> <li>Endogenous expression of hMSLN in mice allows for the unique ability to test therapies that target human mesothelin, including studies off-target toxicity</li> </ul> 2020-08-17 2026-04-24 2020-08-17 2026-04-24 2020-08-17 Alewine, Bl6/TPO, Cancer Animal Model, hMSLN, Humanized Mice, MESOTHELIN, MSLN, Murine Model, THYROID False True Prototype True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-08-17 52406769 Prototype 52406769 NCI 37470483 Website Abstract 147162190 Zhang X, et al. Engineering of transgenic mice expressing human mesothelin for investigation of mesothelin-targeted therapeutics. https://cancerres.aacrjournals.org/content/79/13_Supplement/268 <a href="https://cancerres.aacrjournals.org/content/79/13_Supplement/268">Zhang X, et al. Engineering of transgenic mice expressing human mesothelin for investigation of mesothelin-targeted therapeutics.</a> 147162791 Alewine, Christine NIH - NCI NCI Alewine, Christine (NCI) 1 147162792 Kozlov, Serguei NIH - NCI Leidos Kozlov, Serguei (Leidos) 2 147162796 Zhang, Xianyu NIH - NCI NCI Zhang, Xianyu (NCI) 3 147162794 Guerin, Theresa NIH - NCI Leidos Guerin, Theresa (Leidos) 4 147162790 O'Sullivan, Theresa NIH - NCI NCI O'Sullivan, Theresa (NCI) 5 147162795 Collins, Norman NIH - NCI NCI Collins, Norman (NCI) 6 147162793 Schlomer, Jerome NIH - NCI Leidos Schlomer, Jerome (Leidos) 7 147162791 Alewine, Christine NIH - NCI NCI Alewine, Christine (NCI) 1 147162792 Kozlov, Serguei NIH - NCI Leidos Kozlov, Serguei (Leidos) 2 147162796 Zhang, Xianyu NIH - NCI NCI Zhang, Xianyu (NCI) 3 147162794 Guerin, Theresa NIH - NCI Leidos Guerin, Theresa (Leidos) 4 147162790 O'Sullivan, Theresa NIH - NCI NCI O'Sullivan, Theresa (NCI) 5 147162795 Collins, Norman NIH - NCI NCI Collins, Norman (NCI) 6 147162793 Schlomer, Jerome NIH - NCI Leidos Schlomer, Jerome (Leidos) 7 147157978 C57BI6 Mice With Thyroid Specific Expression Of Human Mesothelin E-096-2020-0 Research Material NCI 83731987 Dhal, Abritee abritee.dhal@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-3899] Humanized Mouse Model to Study Mesothelin (MSLN) -targeted Cancer Therapeutics: Bl6/TPO Mice&body=Please send me information about technology [TAB-3899] Humanized Mouse Model to Study Mesothelin (MSLN) -targeted Cancer Therapeutics: Bl6/TPO Mice.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dhal, Abritee<br><a href="mailto:abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-3899] Humanized Mouse Model to Study Mesothelin (MSLN) -targeted Cancer Therapeutics: Bl6/TPO Mice&body=Please send me information about technology [TAB-3899] Humanized Mouse Model to Study Mesothelin (MSLN) -targeted Cancer Therapeutics: Bl6/TPO Mice.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">abritee.dhal@nih.gov</a><br> 147171332 Alewine 147171334 Bl6/TPO 147171336 Cancer Animal Model 147171338 hMSLN 147171340 Humanized Mice 147171341 MESOTHELIN 147171342 MSLN 147171344 Murine Model 147171345 THYROID TAB-4256 147157543 Antisense Oligonucleotides against Cancer Cell Migration and Invasion NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Stavroula Mili <h2>Summary:</h2> <p>NCI is seeking parties interested in co-developing and/or licensing therapeutic antisense oligonucleotides that target cell migration and cancer metastasis.</p> <h2>Description of Technology:</h2> <p>Advanced stage cancers are typically marked by metastases of the primary cancer to secondary sites such as lungs, liver, and bones. Such metastatic cancers result in strikingly low 5-year survival rates, underscoring the need for novel therapeutics. For example, bone metastasis of primary breast cancer has a 5-year survival rate of 13%, lung cancer only 1%. There is a need for targeted therapy options specific to metastases. One approach to targeting metastases is to reduce cancer cell migration and invasion.</p> <p>Several mRNAs become localized to subcellular destinations during the metastatic process. These mRNAs may play roles in cell and organelle development &ndash; either through corresponding increases in encoded protein concentration or through dynamic interactions with the extracellular environment. Their activities may be modulated via antisense oligonucleotides. One example is the mRNA localization at the protrusions extended by mesenchymal migrating cells, partially under control of the adenomatous polyposis coli (APC) tumor suppressor. Regulation of the mRNAs localized to these protrusions may be usurped to target cancer cell migration and invasion and, ultimately, metastasis. RAB13 and NET1 are especially promising mRNA targets as they are overexpressed in multiple cancer types and contributory to cell motility in vitro.</p> <p>Researchers at the National Cancer Institute (NCI), Laboratory of Cellular and Molecular Biology, have shown that mRNA localization at protrusive regions of migrating cells depends on specific signals within the 3&rsquo;-untranslated regions of these mRNAs. These signals may be modulated by antisense oligonucleotides as a novel mechanism to target cancer metastasis. The inventors have designed chemically modified antisense oligonucleotides against RAB13 and NET1, delivered these into cancer cells, and observed inhibition of cell migration and invasion in two-dimensional and three-dimensional in vitro assays. These oligonucleotides specifically target RNAs at protrusions without broadly affecting expression of encoded proteins, so they are expected to have minimal effects on non-migrating cells. In vivo studies with xenograft tumor models are currently taking place to optimize delivery of the oligonucleotides.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Metastatic cancer therapeutic</li> <li>Targeted cancer therapeutic</li> <li>Cardiovascular and neurodegenerative diseases, as well as genetic disorders</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Regulatory approval pathway exists following FDA/EMA approval of the first antisense-based molecule (Tegsedi&trade;) in 2018&nbsp;</li> <li>Targeting cancer metastasis and inhibition of cell movement through antisense oligonucleotides is a novel approach</li> <li>Antisense oligonucleotides specifically target RNAs at cell protrusions without broadly affecting cellular protein expression</li> <li>Antisense oligonucleotides can be highly specific, permitting induction at advanced stages of cancer growth &ndash; as compared with chemotherapy</li> </ul> 2020-07-21 2026-04-24 2020-07-21 2026-04-24 2020-07-21 Antisense, APC, CANCER, Invasion, Metastasis, MIGRATION, Mili, Net1, OLIGO, oligonucleotide, Oncology, Rab13, RNA False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-07-21 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147162220 Moissoglu K, et al. Translational regulation of protrusion-localized RNAs involves silencing and clustering after transport. https://pubmed.ncbi.nlm.nih.gov/31290739/ <a href="https://pubmed.ncbi.nlm.nih.gov/31290739/">Moissoglu K, et al. Translational regulation of protrusion-localized RNAs involves silencing and clustering after transport.</a> 147162297 Moissoglu K, et al. Local RNA translation controls cell migration and Rab GTPase function. https://www.biorxiv.org/content/10.1101/2020.05.19.104463v1 <a href="https://www.biorxiv.org/content/10.1101/2020.05.19.104463v1">Moissoglu K, et al. Local RNA translation controls cell migration and Rab GTPase function.</a> 147162373 Mili S, et al. Genome-wide screen reveals APC-associated RNAs enriched in cell protrusions. https://pubmed.ncbi.nlm.nih.gov/18451862/ <a href="https://pubmed.ncbi.nlm.nih.gov/18451862/">Mili S, et al. Genome-wide screen reveals APC-associated RNAs enriched in cell protrusions.</a> 147164065 Mili, Stavroula NIH - NCI NCI Mili, Stavroula (NCI) 1 147164065 Mili, Stavroula NIH - NCI NCI Mili, Stavroula (NCI) 1 147157847 Antisense Oligos That Block Cancer Cell Migration And Invasion E-041-2020-0 Filing authorized NCI 83694133 Gulay French, Suna suna.gulay@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB suna.gulay@nih.gov?subject=Web Inquiry on [TAB-4256] Antisense Oligonucleotides against Cancer Cell Migration and Invasion&body=Please send me information about technology [TAB-4256] Antisense Oligonucleotides against Cancer Cell Migration and Invasion.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Gulay French, Suna<br><a href="mailto:suna.gulay@nih.gov?subject=Web Inquiry on [TAB-4256] Antisense Oligonucleotides against Cancer Cell Migration and Invasion&body=Please send me information about technology [TAB-4256] Antisense Oligonucleotides against Cancer Cell Migration and Invasion.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">suna.gulay@nih.gov</a><br> 147160947 E-041-2020-0 E-041-2020-0-US-01 RAB13 AND NET1 ANTISENSE OLIGONUCLEOTIDES TO TREAT METASTATIC CANCER PRV US 62/966,204 Abandoned US <br />Provisional (PRV) 62/966,204<br />Filed on 2020-01-27<br />Status: Abandoned 147167709 E-041-2020-0 E-041-2020-0-PCT-02 RAB13 AND NET1 ANTISENSE OLIGONUCLEOTIDES TO TREAT METASTATIC CANCER PCT Patent Cooperation Treaty PCT/US2021/015053 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/015053<br />Filed on 2021-01-26<br />Status: Expired 147167710 E-041-2020-0 E-041-2020-0-US-03 RAB13 AND NET1 ANTISENSE OLIGONUCLEOTIDES TO TREAT METASTATIC CANCER National Stage US 12,503,695 17/792,507 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12503695 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12503695">12,503,695</a><br />Filed on 2022-07-13<br />Status: Issued 147170068 Antisense 147170069 APC 147170070 CANCER 147170071 Invasion 147170072 Metastasis 147170073 MIGRATION 147170075 Mili 147170077 Net1 147170078 OLIGO 147170079 oligonucleotide 147170080 Oncology 147170082 Rab13 147170083 RNA TAB-4155 147157438 Aryl Hydantoin Heterocycle Compounds that Target the Androgen Receptor for Prostate Cancer Treatment NCI Collaboration, Endocrinology, Licensing, Oncology, Therapeutics Collaboration Endocrinology Licensing Oncology Therapeutics Nicholas Aboreden, William Figg, Berkley Gryder, Adegboyega Oyelere, Eric Raftery, Subhasish Tapadar <h2>Description of Technology:</h2> <p>Prostate cancer is the most prevalent form of cancer among all men in the United States (US). It is also the second leading cause of cancer-related deaths in the US among men, largely due to the progressively treatment resistant nature of the disease. Treatment options for early stage prostate cancer include watchful waiting, radical prostatectomy, radiation therapy, and importantly androgen-deprivation therapy (ADT). Prostate cancer is dependent on androgen hormones, such as testosterone, for sustaining and promoting growth. Androgen hormones bind to the Androgen receptor (AR), causing AR localization to the nucleus where a complex is formed that regulates the transcription of critical genes. ADT is accomplished through administering an antagonist to the AR that blocks androgen ligands, or by castration (physical or chemical) to reduce the amount of testosterone. However, the disease frequently advances to castration resistant prostate cancer (CRPC), becoming resistant to these therapies by overexpressing AR. Additional anti-androgens have been developed, though these have had limited improvements in patient outcomes and are not effective against the refractory forms of prostate cancer.&nbsp;</p> <p>Recently, antiandrogenic diaryl thiohydantoin compounds have been shown to be more promising prostate cancer therapeutics. These compounds have shown success in clinical trials, though still with only mild improvement of patient outcomes. Therefore, more potent forms of these compounds are needed for improved therapies. Researchers at the National Cancer Institute (NCI) have developed aryl hydantoin derived heterocyclic compounds with improved efficacy as shown by in vitro and in vivo studies. These compounds include, most importantly, Androgen Receptor Inverse Agonists (ARIA), but also agonists and antagonists of the AR.&nbsp; &nbsp;</p> <p>NCI seeks research co-development partners and/or licensees to develop these compounds as therapeutics for prostate cancer. As these compounds consist of both AR agonists and antagonists, they may also be effective therapeutics for androgen dysfunctional disorders, such as androgen deficiency disorders or hyperandrogenism.&nbsp;</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Therapeutic for: <ul> <li>Early and advanced stages of prostate cancer</li> <li>Androgen receptor-positive breast cancer and other androgen receptor-positive solid tumors</li> <li>Androgen deficiency disorders</li> <li>Hyperandrogenism</li> </ul> </li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Increased potency compared with current prostate cancer therapeutic compounds</li> <li>Potency in disease models that are non-responsive to current prostate cancer therapeutics</li> <li>Potential to treat both early stage and advance stage prostate cancer</li> <li>Potential to treat a range of androgen receptor-positive solid tumors</li> <li>Other clinical trials with similar approaches provides promising human safety data</li> </ul> 2020-07-07 2026-04-24 2020-07-07 2026-04-24 2020-07-07 Androgen Deficiency Disorders, Androgen dysfunctional Disorders, Androgen Receptor, Androgen Receptor Inverse Agonists, Anti-androgens, AR, ARIA, BREAST CANCER, Georgia Institute of Technology, GIT, Gryder, Hyperandrogenism, PROSTATE CANCER False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-07-07 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147163711 Gryder, Berkley NIH - NCI NCI Gryder, Berkley (NCI) 1 147163712 Oyelere, Adegboyega Georgia Institute of Technology Oyelere, Adegboyega 2 147163713 Raftery, Eric Georgia Institute of Technology Raftery, Eric 3 147163714 Tapadar, Subhasish Georgia Institute of Technology Tapadar, Subhasish 4 147163715 Aboreden, Nicholas NIH - NCI NCI Aboreden, Nicholas (NCI) 5 147163710 Figg, William NIH - NCI NCI Figg, William (NCI) 6 147163711 Gryder, Berkley NIH - NCI NCI Gryder, Berkley (NCI) 1 147163712 Oyelere, Adegboyega Georgia Institute of Technology Oyelere, Adegboyega 2 147163713 Raftery, Eric Georgia Institute of Technology Raftery, Eric 3 147163714 Tapadar, Subhasish Georgia Institute of Technology Tapadar, Subhasish 4 147163715 Aboreden, Nicholas NIH - NCI NCI Aboreden, Nicholas (NCI) 5 147163710 Figg, William NIH - NCI NCI Figg, William (NCI) 6 147158131 Aryl Hydantoin Heterocycles And Methods Of Making And Using Thereof E-169-2018-0 Filing authorized Georgia Institute of Technology, National Cancer Institute (NCI), NCI 121111111 Greene, Jaime greenejaime@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America greenejaime@mail.nih.gov?subject=Web Inquiry on [TAB-4155] Aryl Hydantoin Heterocycle Compounds that Target the Androgen Receptor for Prostate Cancer Treatment&body=Please send me information about technology [TAB-4155] Aryl Hydantoin Heterocycle Compounds that Target the Androgen Receptor for Prostate Cancer Treatment.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Greene, Jaime<br><a href="mailto:greenejaime@mail.nih.gov?subject=Web Inquiry on [TAB-4155] Aryl Hydantoin Heterocycle Compounds that Target the Androgen Receptor for Prostate Cancer Treatment&body=Please send me information about technology [TAB-4155] Aryl Hydantoin Heterocycle Compounds that Target the Androgen Receptor for Prostate Cancer Treatment.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">greenejaime@mail.nih.gov</a><br> 147161140 E-169-2018-0 E-169-2018-0-US-01 ARYL HYDANTOIN HETEROCYCLES AND METHODS OF USE PRV US 62/963,959 Abandoned US <br />Provisional (PRV) 62/963,959<br />Filed on 2020-01-21<br />Status: Abandoned 147166960 E-169-2018-0 E-169-2018-0-PCT-02 ARYL HYDANTOIN HETEROCYCLES AND METHODS OF USE PCT Patent Cooperation Treaty PCT/US2021/014176 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/014176<br />Filed on 2021-01-20<br />Status: Expired 147166961 E-169-2018-0 E-169-2018-0-AU-03 ARYL HYDANTOIN HETEROCYCLES AND METHODS OF USE National Stage Australia 2021209875 Pending Australia <br />National Stage 2021209875<br />Filed on 2022-07-14<br />Status: Pending 147166962 E-169-2018-0 E-169-2018-0-CA-04 ARYL HYDANTOIN HETEROCYCLES AND METHODS OF USE National Stage Canada 3165120 Pending Canada <br />National Stage 3165120<br />Filed on 2022-07-18<br />Status: Pending 147166963 E-169-2018-0 E-169-2018-0-EP-05 ARYL HYDANTOIN HETEROCYCLES AND METHODS OF USE National Stage European Patent 21705753.8 Pending European Patent <br />National Stage 21705753.8<br />Filed on 2022-08-16<br />Status: Pending 147166964 E-169-2018-0 E-169-2018-0-US-06 ARYL HYDANTOIN HETEROCYCLES AND METHODS OF USE National Stage US 17/794,212 Pending US <br />National Stage 17/794,212<br />Filed on 2022-07-20<br />Status: Pending 147172873 Androgen Deficiency Disorders 147172875 Androgen dysfunctional Disorders 147172877 Androgen Receptor 147172879 Androgen Receptor Inverse Agonists 147172881 Anti-androgens 147172882 AR 147172884 ARIA 147172885 BREAST CANCER 147172887 Georgia Institute of Technology 147172889 GIT 147172891 Gryder 147172893 Hyperandrogenism 147172894 PROSTATE CANCER TAB-4032 147157313 Reporter Assay for Detection and Quantitation of Replication-Competent Gammaretrovirus NCI Immunology, Licensing, Research Materials Immunology Licensing Research Materials Amanda (Declined Roy Aloia, Alan Rein <h2>Description of Technology:</h2> <p>Gammaretroviral vectors were the first viral gene-therapy vectors to enter clinical trials and remain in use. One potential hazard associated with the use of such vectors is the presence of replication-competent retroviruses (RCR) in the vector preparations &ndash; either as a result of: 1) recombination events between the plasmids used for vector production, 2) interactions between the plasmids and endogenous retroviral sequences in the packaging cell lines, or 3) as a result of contamination in the laboratory. RCRs are potentially pathogenic and shown to induce malignancy in mice and non-human primates. Therefore, it is critical that vector preparations be rigorously tested to exclude the presence of RCRs given that the Food and Drug Administration (FDA) requires all vector preparations be screened for RCRs.</p> <p>At present, the FDA recommends RCR testing by inoculating an aliquot of each vector preparation into a permissive cell line and passaging the cells for at least three weeks (i.e., amplification phase). Cell-free media from the amplification phase can then be analyzed by a variety of methods to demonstrate the presence or absence of RCRs.</p> <p>Scientists at the National Cancer Institute (NCI) have developed a new research method for the detection of RCRs in gammaretrovirus-based gene-therapy products and the cell lines used to make them. The assay uses one of a series of DERSE (Detector of Exogenous Retroviral Sequence Elements) plasmids, stably maintained in a cell line permissive for the retrovirus of interest. Utilizing the unique reverse-transcription step of the retroviral infection cycle, a functional reporter gene is formed in the DERSE cell culture only after infection with an RCR. The DERSE assay can be constructed, potentially, to detect any RCR and can use any reporter gene.</p> <p>This invention is available for licensing.</p> <p><img alt="E-125-2020 - Schematic of inGluc-MLV-DERSE assay" src="https://nih.technologypublisher.com/files/sites/e-125-2020_-_schematic_of_ingluc-mlv-derse_assay2.jpg" style="float:left; height:489px; width:450px" /></p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <p><strong>Figure: Schematic of inGluc-MLV-DERSE assay</strong></p> <p>&nbsp;</p> <p>&nbsp;</p> <p>The inG<em>luc</em>-MLV-DERSE plasmid consists of a Gaussia Luciferase (G<em>luc</em>) sequence oriented in a reverse direction with respect to flanking MLV non-coding sequences. Within the non-coding G<em>luc</em> sequence is an intron that is oriented in a forward direction relative to the viral non-coding regions (and can be spliced by the host cell). The plasmid is maintained in 293mCAT1 cells. In the absence of RCR, only minus-strand, spliced G<em>luc</em> sequences are present in the cell. An RCR that infects the DERSE cell can package the RNA containing the minus-strand G<em>luc</em> sequence. In the next round of infection reverse transcription of the encapsidated RNA produces a double-stranded DNA containing an uninterrupted G<em>luc</em> gene. This gene is an intact, coding G<em>luc</em> sequence that is subsequently integrated into the DNA of, and expressed by, the newly infected cell. Expression of G<em>luc</em> is under the control of the cytomegalovirus (CMV) promoter.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Laboratory tool to investigate molecular mechanisms of retroviral replication</li> <li>Research tool to screen gene therapy regimens</li> <li>Manufacturing tool to screen viral vector preparations</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Provides reliable results in roughly half the time of traditional methods for detecting replication-competent retrovirus (RCR)</li> <li>Overcomes the inhibitory effect of excess gene-therapy vector in the detection of RCRs</li> <li>Does not require the identification of foci</li> <li>Useful for screening both gene-therapy products and the packaging cell lines used for vector production</li> <li>Enhanced detection sensitivity as the indicating reporter is only formed in cells infected with replication-competent retrovirus&nbsp;</li> </ul> 2020-07-07 2026-04-24 2020-07-07 2026-04-24 2020-07-07 Cell line, Gammaretrovirus, Gaussia Luciferase, GENE THERAPY, PLASMID, RCR, Rein, Replication-Competent Retrovirus, Vector Preparation False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-07-07 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147162154 Aloia AL, et al. A reporter system for replication-competent gammaretroviruses: the inGluc-MLV-DERSE assay. https://pubmed.ncbi.nlm.nih.gov/22402321/ <a href="https://pubmed.ncbi.nlm.nih.gov/22402321/">Aloia AL, et al. A reporter system for replication-competent gammaretroviruses: the inGluc-MLV-DERSE assay.</a> 147163285 Rein, Alan NIH - NCI Leidos Rein, Alan (Leidos) 1 147163286 Aloia, Amanda (Declined Royalty) NIH - NCI Aloia, Amanda (Declined Royalty) 2 147163285 Rein, Alan NIH - NCI Leidos Rein, Alan (Leidos) 1 147163286 Aloia, Amanda (Declined Royalty) NIH - NCI Aloia, Amanda (Declined Royalty) 2 147158032 Reporter For Detection And Quantitation Of Replication-Competent Gammaretrovirus E-125-2020-0 Research Material NCI 83704821 Nguyen-Antczak, Lauren lauren.nguyen-antczak@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-4032] Reporter Assay for Detection and Quantitation of Replication-Competent Gammaretrovirus&body=Please send me information about technology [TAB-4032] Reporter Assay for Detection and Quantitation of Replication-Competent Gammaretrovirus.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Nguyen-Antczak, Lauren<br><a href="mailto:lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-4032] Reporter Assay for Detection and Quantitation of Replication-Competent Gammaretrovirus&body=Please send me information about technology [TAB-4032] Reporter Assay for Detection and Quantitation of Replication-Competent Gammaretrovirus.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">lauren.nguyen-antczak@nih.gov</a><br> 147171916 Cell line 147171917 Gammaretrovirus 147171919 Gaussia Luciferase 147171920 GENE THERAPY 147171921 PLASMID 147171923 RCR 147171925 Rein 147171927 Replication-Competent Retrovirus 147171929 Vector Preparation TAB-4323 147157614 Mouse Embryo Culture Chamber and Imaging System and Methods of Use NEI Collaboration, Ear, Nose, & Throat, Licensing, Medical Devices, Non-Medical Devices, Ophthalmology, Reproductive Health Collaboration Ear Nose & Throat Licensing Medical Devices Non-Medical Devices Ophthalmology Reproductive Health Vijay Kumar Kalaskar <h2>Description of Technology:</h2> <p>The culture of mouse embryos <em>ex utero</em> and continuous monitoring and imaging of embryos as they develop have applications in drug testing, genetic studies, and basic research on embryonic development. However, the embryo culture systems currently available for post-implantation embryos include rolling bottle culture systems, which do not permit imaging of the developing embryos and do not support the long-term survival and development of embryos <em>ex utero</em>. Current culture systems for pre-implantation stage embryos, including microfluidic culture systems, are suitable for short-term culture of very early stage embryos &ndash; such as fertilized zygotes. However, they are not suitable for the culture and survival of post-implantation stage embryos. Similarly, the cell culture systems currently available (e.g., slides, multi-well plates, and microfluidic chambers) may allow for imaging of single-dimensional structures such as cells, but cannot be used for culturing or imaging three-dimensional structures such as embryos. Therefore, there is a need for a system that provides long-term embryo culturing combined with imaging. Such a system could support long-term culture while allowing for continuous imaging of the developing embryos.</p> <p>Scientists at the National Eye Institute (NEI) have developed an embryo culture chamber, an embryo culturing and imaging system, and a method of culturing and imaging an embryo. The chamber allows for the continuous imaging of the embryo for the culture period. This invention is available for licensing and co-development.</p> <p><img alt="" src="https://nih.technologypublisher.com/files/sites/e-042-2020_mouse_embryo_culture_imaging_multi-chamber_system2.png" style="height:450px; width:800px" /></p> <p><strong>Figure: Mouse embryo culture imaging multi-chamber system</strong>. The multi-chamber mouse embryo culture imaging system consists of multiple embryo culture chambers connected to a common medium and gas (95% O<sub>2</sub>/5% CO<sub>2</sub>) source. Culture medium (and serum/blood) flows through the peristaltic pump into the culture chamber (blood/serum flows through internal sub-chamber) submerging the embryos and passes through the outlets to recirculate. Gas flow through the chambers can be monitored as it passes through the water trap and adjusted by a flow meter. The inlet shows enlarged view of the culture chamber with a microscope objective lens for imaging and a removable chamber lid. Mouse embryos are cultured on specialized platform with pores and elevations to provide minimal contact with the surface and allow free flow of medium in all directions. The serum/blood flowing through the internal sub-chamber baths the mouse placenta/yolk sac simulating placental blood supply.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Drug screening for teratogenic and developmental effects with temporal and spatial evaluation on different organ systems during embryonic growth</li> <li>Substituting cell-culture and organoid based culture systems as direct testing or studies on mammalian embryos (e.g., mouse embryos)</li> <li>Genetic screening for developmental defects with direct visualization of the embryonic development&nbsp;</li> <li>Drug development and evaluation of molecules regardless of whether they cross the placental barrier</li> <li>Visualization of the developing organ systems and tissues at the embryonic level</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>The internal sub-chamber simulates placental blood supply through which blood/serum can be supplied to developing embryos</li> <li>The unique design of the stage/platform on which the embryo rests enables maximum exposure of the body surface area to the circulating medium and oxygen permits appropriate development and survival of the embryos long-term</li> <li>The embryo culture chamber enables continuous imaging of developing embryos during culture</li> <li>Development of specific organ systems, such as eye, lungs, heart, liver, etc., can be monitored and imaged</li> <li>Temporal and spatial distribution of pharmacological molecules (e.g., molecules/proteins tagged with fluorescent markers) in different organ systems and their effect on a specific organ or whole-body development can be monitored and studied</li> <li>The blood/serum supply through the internal sub-chamber simulates placental blood supply and can be used to treat embryos with specific drugs/molecules while the litter mates serve as controls for studying the effect of specific molecules on organ system development</li> <li>Long-term or complete ex utero development of post-implantation stage embryos provides access to developing mammalian embryos for pharmacological manipulation and research studies</li> </ul> 2020-06-30 2026-04-24 2020-06-30 2026-04-24 2020-06-30 Culture Chamber, Embryo Development, Embryonic, FETAL, GENE THERAPY, IMAGING, In Vitro Drug Toxicology, Kalaskar, National Eye Institute, NEI, Organ System Therapy False True Prototype True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-06-30 52406769 Prototype 52406769 NCI 37470483 Website Abstract 147164308 Kalaskar, Vijay Kumar NIH - NEI NEI Kalaskar, Vijay Kumar (NEI) 1 147164308 Kalaskar, Vijay Kumar NIH - NEI NEI Kalaskar, Vijay Kumar (NEI) 1 147157849 Mouse Embryo Culture Imaging Chamber E-042-2020-0 Filing authorized National Eye Institute (NEI) 83724826 Pollard, Ricquita ricquita.pollard@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4323] Mouse Embryo Culture Chamber and Imaging System and Methods of Use&body=Please send me information about technology [TAB-4323] Mouse Embryo Culture Chamber and Imaging System and Methods of Use.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollard, Ricquita<br><a href="mailto:ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4323] Mouse Embryo Culture Chamber and Imaging System and Methods of Use&body=Please send me information about technology [TAB-4323] Mouse Embryo Culture Chamber and Imaging System and Methods of Use.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">ricquita.pollard@nih.gov</a><br> 147160949 E-042-2020-0 E-042-2020-0-US-01 MOUSE EMBRYO CULTURE IMAGING CHAMBER AND METHODS THEREOF PRV US 62/968,474 Abandoned US <br />Provisional (PRV) 62/968,474<br />Filed on 2020-01-31<br />Status: Abandoned 147170091 Culture Chamber 147170093 Embryo Development 147170094 Embryonic 147170095 FETAL 147170096 GENE THERAPY 147170097 IMAGING 147170099 In Vitro Drug Toxicology 147170101 Kalaskar 147170103 National Eye Institute 147170104 NEI 147170106 Organ System Therapy TAB-4352 147157645 Inhibition of T Cell Lactate Dehydrogenase (LDH) ex vivo Enhances the Anti-tumor Efficacy of Adoptive T Cell Therapy NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Luca Gattinoni, Dalton Hermans, Warren Leonard, Leonard Neckers <h2>Description of Technology:</h2> <p>Adoptive T cell therapy (ACT) with tumor infiltrating lymphocytes (TIL), T cell receptor (TCR) and Chimeric Antigen Receptor (CAR) engineered T cells, or hematopoietic stem cell transplantation, is a promising new approach to cancer treatment. ACT harnesses an individual&#39;s adaptive immune system to fight against cancer, with fewer side-effects and more specific anti-tumor activity. Despite their promise of ACT as curative, these therapies are often limited by the persistence and robustness of the responses of the T cells to the cancer cells. Altering metabolic pathways is one way to affect the actions of T cells, and different cellular subtypes vary in how they produce and expend energy. T cell metabolism can be altered by several factors, including cytokine stimulation and by inhibiting lactate dehydrogenase (LDH), which mediates the final step in glycolytic metabolic pathway.</p> <p>Researchers at the National Cancer Institute (NCI) and the National Heart Lung and Blood Institute (NHLBI) have discovered that preconditioning T cells with LDH inhibitors during in vitro culture with cytokines improves efficacy of these cells once adoptively transferred to a mouse model of melanoma. This was accomplished by investigating the role of metabolic programming in the developmental differences induced by interleukin-21 (IL-21), a cytokine with known antitumor activity. IL-21 alone promoted stem cell memory T cells (TSCM) expansion, and this was enhanced when combined with an LDH inhibitor. This resulted in a more profound antitumor responses and prolonged host survival. Studies revealed that inhibition of LDH activity prior to adoptive transfer of CD8+ T cells promoted maintainence of the cells in a more T stem-cell like state. Combining IL-21 with the LDH inhibitor also prevented the induction of several immune checkpoints/exhaustion molecules known to limit in vivo antitumor responses &ndash; including PD-1, TIM-3, LAG3 and 2B4. Results are similar for LDH inhibition of human and murine CD8+ T cells in vitro, underscoring the potential therapeutic benefits of preconditioning with LDH inhibition before ACTimmunotherapy.&nbsp;&nbsp;</p> <p>The NCI seeks research co-development partners and/or licensees for clinical evaluation of this invention.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>A strategy to improve ACT immunotherapies to treat and/or prevent the recurrence of a variety of human cancers</li> <li>Use of this preconditioning method in a variety of ACT therapies, including TIL, TCR, and CAR therapies</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Improved host survival in a murine model, suggesting treatment benefit in human trials&nbsp;</li> <li>A mechanism for enhancing robustness of adoptive T cells</li> </ul> 2020-06-25 2026-04-24 2020-06-25 2026-04-24 2020-06-25 act, Adoptive T Cell Therapy, CAR T Cells, CD8+ T Cells, Gattinoni, Interleukin-21, Lactate Dehydrogenase Inhibitor, LDH, Neckers, Preconditioning, TCR-engineered T Cells, TILS False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-06-25 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-190-2016 E-244-2014 147161882 Hermans A, et al. Lactate dehydrogenase inhibition synergizes with IL-21 to promote CD8+ T cell stemness and antitumor immunity. https://pubmed.ncbi.nlm.nih.gov/32123114/ <a href="https://pubmed.ncbi.nlm.nih.gov/32123114/">Hermans A, et al. Lactate dehydrogenase inhibition synergizes with IL-21 to promote CD8+ T cell stemness and antitumor immunity.</a> 147164420 Leonard, Warren NIH - NHLBI NHLBI Leonard, Warren (NHLBI) 1 147164421 Hermans, Dalton NIH - NHLBI NHLBI Hermans, Dalton (NHLBI) 2 147164422 Gattinoni, Luca NIH - NCI NCI Gattinoni, Luca (NCI) 3 147164419 Neckers, Leonard NIH - NCI NCI Neckers, Leonard (NCI) 4 147164420 Leonard, Warren NIH - NHLBI NHLBI Leonard, Warren (NHLBI) 1 147164421 Hermans, Dalton NIH - NHLBI NHLBI Hermans, Dalton (NHLBI) 2 147164422 Gattinoni, Luca NIH - NCI NCI Gattinoni, Luca (NCI) 3 147164419 Neckers, Leonard NIH - NCI NCI Neckers, Leonard (NCI) 4 147158034 Inhibition Of T Cell Lactate Dehydrogenase (LDH) Ex Vivo Promotes Enhanced Anti-tumor Efficacy In A Model Of Adoptive Cell Therapy E-126-2019-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI), NCI 83691647 Chang, Kevin changke@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB changke@mail.nih.gov?subject=Web Inquiry on [TAB-4352] Inhibition of T Cell Lactate Dehydrogenase (LDH) ex vivo Enhances the Anti-tumor Efficacy of Adoptive T Cell Therapy&body=Please send me information about technology [TAB-4352] Inhibition of T Cell Lactate Dehydrogenase (LDH) ex vivo Enhances the Anti-tumor Efficacy of Adoptive T Cell Therapy.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Chang, Kevin<br><a href="mailto:changke@mail.nih.gov?subject=Web Inquiry on [TAB-4352] Inhibition of T Cell Lactate Dehydrogenase (LDH) ex vivo Enhances the Anti-tumor Efficacy of Adoptive T Cell Therapy&body=Please send me information about technology [TAB-4352] Inhibition of T Cell Lactate Dehydrogenase (LDH) ex vivo Enhances the Anti-tumor Efficacy of Adoptive T Cell Therapy.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">changke@mail.nih.gov</a><br> 147161074 E-126-2019-0 E-126-2019-0-US-01 T CELLS HAVING ENHANCED ANTI-TUMOR ACTIVITY PRV US 62/883,927 Abandoned US <br />Provisional (PRV) 62/883,927<br />Filed on 2019-08-07<br />Status: Abandoned 147168390 E-126-2019-0 E-126-2019-0-PCT-02 T CELLS HAVING ENHANCED ANTI-TUMOR ACTIVITY PCT Patent Cooperation Treaty PCT/US2020/045100 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2020/045100<br />Filed on 2020-08-06<br />Status: Expired 147168391 E-126-2019-0 E-126-2019-0-US-03 T CELLS HAVING ENHANCED ANTI-TUMOR ACTIVITY National Stage US 12,558,424 17/633,414 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12558424 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12558424">12,558,424</a><br />Filed on 2022-02-07<br />Status: Issued 147171947 act 147171949 Adoptive T Cell Therapy 147171951 CAR T Cells 147171953 CD8+ T Cells 147171954 Gattinoni 147171955 Interleukin-21 147171957 Lactate Dehydrogenase Inhibitor 147171958 LDH 147171960 Neckers 147171962 Preconditioning 147171964 TCR-engineered T Cells 147171965 TILS TAB-4275 147157563 Development of Next Generation Antibody Drug Conjugates (ADCs) Against CD276 NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Yang Feng, Steven Seaman, Brad St. Croix <h2>Summary:</h2> <p>The National Cancer Institute (NCI) seeks research collaborations and/or licensees for the development of a CD276 antibody drug conjugate (ADC) for the treatment of solid tumors.</p> <h2>Description of Technology:</h2> <p>Angiogenesis is the formation of new blood vessels from pre-existing blood vessels. Angiogenesis occurs during normal growth and development (physiological angiogenesis) and during the growth of solid tumors (pathological angiogenesis). CD276, also known as B7-H3, is a cell surface tumor endothelial marker that is highly expressed in the tumor vessels of human lung, breast, colon, endometrial, renal, and ovarian cancer, but not in the angiogenic vessels of normal, healthy tissue. This differential expression makes CD276 an attractive target for cancer treatment due to the ability to selectively target pathological angiogenesis without impacting physiological angiogenesis. In fact, CD276-directed therapeutic antibodies may have a higher degree of specificity for tumor vessels than current antiangiogenic agents that cannot distinguish physiological and pathological angiogenesis. Moreover, CD276 protein is also frequently overexpressed on tumor cells. The ability to target the vasculature as well as tumor cells directly makes CD276 a potentially ideal dual-compartment therapeutic target.</p> <p>Researchers at the National Cancer Institute (NCI) have created a potent antibody-drug conjugate (ADC) with an improved therapeutic index that selectively reacts with a broad variety of tumor types.&nbsp; The lead ADC, m276-PBD-SL, targets CD276 for the treatment of cancer. The m276 antibody used to develop this ADC is fully-human and recognizes mouse, non-human primate, and human CD276 with similar affinity &ndash; unlike all other CD276 antibodies described to date. This ADC contains mutations to prevent inappropriate interaction of the ADC with endogenous immunoglobulin receptors present on cells of the immune system. These mutations prevent the potentially harmful killing of normal cells and minimize off-target toxicity. The ADC also contains a mutation which allows site-directed conjugation of the payload to the antibody. Payload attachment at this specific site prevents the premature release of the warhead from the antibody, increasing the stability of the ADC in the circulation and preventing non-specific toxicity. This ADC is the only one that combines all these critical features with a potent optimized warhead and an optimally targeted pan anti-cancer fully-human antibody against CD276. These advantages can be leveraged to facilitate preclinical ADC studies and may be a better reflection of what a human clinical response would be, may facilitate GMP scale-up, may facilitate preclinical testing in multiple species using the same clinical-grade product, and may facilitate earlier toxicity assessments due to the multiple cross-species reactivity of the fully-human CD276 antibody.&nbsp; &nbsp; &nbsp;</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Therapeutic for various solid cancer including, but not limited to, lung, breast, colon, endometrial, renal, and ovarian cancer</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Simultaneously targets both tumor cells and tumor vasculature</li> <li>Potentially superior adverse events mitigation over existing anti-angiogenic agents due to the differential expression of CD276 on tumor versus normal vasculature</li> <li>Fully human antibodies are less likely to be recognized and cleared by the immune system upon repeated administration&nbsp; &nbsp;</li> <li>Cross-reactive with mouse, rat, and monkey CD276 making preclinical studies easier and more informative</li> <li>Antibody mutations block inappropriate killing of Fc-receptor-bearing normal cells to minimize off-target toxicity</li> <li>The mutation in the Fc domain creates a superior site-directed conjugation attachment site for the drug payload to the warhead by increasing solubility of the ADC and preventing premature shedding of the drug in serum</li> </ul> 2020-06-17 2026-04-24 2021-06-10 2026-04-24 2020-06-17 ADC, antibody drug conjugate, B7-H3, CD276, Immunotherapy, Monoclonal Antibody, St. Croix False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-06-10 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-104-2013 E-250-2014 147164128 St. Croix, Brad NIH - NCI NCI St. Croix, Brad (NCI) 1 147164129 Feng, Yang NIH - NCI NCI Feng, Yang (NCI) 2 147164130 Seaman, Steven NIH - NCI NCI Seaman, Steven (NCI) 3 147164128 St. Croix, Brad NIH - NCI NCI St. Croix, Brad (NCI) 1 147164129 Feng, Yang NIH - NCI NCI Feng, Yang (NCI) 2 147164130 Seaman, Steven NIH - NCI NCI Seaman, Steven (NCI) 3 147158076 Development Of Next Generation ADCs Against CD276 E-145-2019-0 Filing authorized NCI 91814193 Freel, Rose rose.freel@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America rose.freel@nih.gov?subject=Web Inquiry on [TAB-4275] Development of Next Generation Antibody Drug Conjugates (ADCs) Against CD276&body=Please send me information about technology [TAB-4275] Development of Next Generation Antibody Drug Conjugates (ADCs) Against CD276.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Freel, Rose<br><a href="mailto:rose.freel@nih.gov?subject=Web Inquiry on [TAB-4275] Development of Next Generation Antibody Drug Conjugates (ADCs) Against CD276&body=Please send me information about technology [TAB-4275] Development of Next Generation Antibody Drug Conjugates (ADCs) Against CD276.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">rose.freel@nih.gov</a><br> 147161104 E-145-2019-0 E-145-2019-0-US-01 ANTIBODY-DRUG CONJUGATES SPECIFIC FOR CD276 AND USES THEREOF PRV US 62/947,135 Abandoned US <br />Provisional (PRV) 62/947,135<br />Filed on 2019-12-12<br />Status: Abandoned 147167816 E-145-2019-0 E-145-2019-0-PCT-02 ANTIBODY-DRUG CONJUGATES SPECIFIC FOR CD276 AND USES THEREOF PCT Patent Cooperation Treaty PCT/US2020/063732 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2020/063732<br />Filed on 2020-12-08<br />Status: Expired 147167817 E-145-2019-0 E-145-2019-0-AU-03 ANTIBODY-DRUG CONJUGATES SPECIFIC FOR CD276 AND USES THEREOF National Stage Australia 2020402752 Pending Australia <br />National Stage 2020402752<br />Filed on 2020-12-08<br />Status: Pending 147167818 E-145-2019-0 E-145-2019-0-CA-04 ANTIBODY-DRUG CONJUGATES SPECIFIC FOR CD276 AND USES THEREOF National Stage Canada 3161573 Pending Canada <br />National Stage 3161573<br />Filed on 2020-12-08<br />Status: Pending 147167819 E-145-2019-0 E-145-2019-0-EP-05 ANTIBODY-DRUG CONJUGATES SPECIFIC FOR CD276 AND USES THEREOF National Stage European Patent 20834060.4 Pending European Patent <br />National Stage 20834060.4<br />Filed on 2020-12-08<br />Status: Pending 147167820 E-145-2019-0 E-145-2019-0-JP-06 ANTIBODY-DRUG CONJUGATES SPECIFIC FOR CD276 AND USES THEREOF National Stage Japan 7679380 2022-535127 Issued Japan <br />National Stage 2022-535127<br />Filed on 2020-12-08<br />Status: Issued 147167821 E-145-2019-0 E-145-2019-0-US-07 ANTIBODY-DRUG CONJUGATES SPECIFIC FOR CD276 AND USES THEREOF National Stage US 17/783,171 Pending US <br />National Stage 17/783,171<br />Filed on 2022-06-07<br />Status: Pending 147172319 ADC 147172320 antibody drug conjugate 147172321 B7-H3 147172322 CD276 147172323 Immunotherapy 147172324 Monoclonal Antibody 147172325 St. Croix TAB-4186 147157471 Mitotic Figures Electronic Counting Application for Surgical Pathology NCI Collaboration, Licensing, Oncology, Software / Apps Collaboration Licensing Oncology Software / Apps Stephen Hewitt, Munish Puri, Robert Simpson <h2>Summary:</h2> <p>The National Cancer Institute (NCI) Laboratory of Cancer Biology and Genetics is seeking parties interested in licensing and /or co-development research collaboration of a software application for commercialization in quantitative and digital pathology fields.&nbsp;&nbsp;</p> <h2>Description of Technology:</h2> <p>Cancer diagnosis depends on the assessment of patient biopsies to determine tumor type, grading, and stage of malignancy. Pathologists visually review specimens and count mitotic figures (MF) in a variety of cancer types to help gauge aggressiveness, guide treatment, and inform patient prognosis. Current technology for recording MF counts in surgical pathology is lacking in objectivity, and enumeration of MF by microscopy can be error prone. In particular, a lack of systematic means for recording contributes to recognized variability. Cell counting instruments have been employed in the field as an attempt to address these issues. However, these instruments were not designed to assess the mitotic activity index for tumor grading, and they do not record MF microscopy field-of-view by field-of-view, do not function to sum the counts, and do not export data for inclusion in a pathology report.</p> <p>This discovery provides a software application for the electronic recording, summation, and transcription of clinical data obtained during surgical pathology examination of patient tissues. This invention will enable standardization across diagnostic centers which will permit harmonization of MF counting by electronic means. Through standardization enabled by the application, interobserver variance in MF counting can be reduced and transcription errors eliminated, enhancing the accuracy of mitotic index generation that will improve patient care.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Quantitative Pathology&nbsp;</li> <li>Digital Pathology</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Systematic recordings of observation</li> <li>Objective counts</li> <li>Standard protocol for recording mitotic counts</li> <li>Graphical User Interface in MATLAB</li> </ul> 2020-06-17 2026-04-24 2020-06-17 2026-04-24 2020-06-17 cell proliferation, COUNTING, ELECTRONIC, MATLAB, Matrix Laboratory, MF, MICROSCOPY, Mitotic Figures, PATHOLOGY, Simpson, SURGICAL False True Prototype True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-06-17 52406769 Prototype 52406769 NCI 37470483 Website Abstract E-038-2019 147162267 Wei BR, et al. Agreement in Histological Assessment of Mitotic Activity Between Microscopy and Digital Whole Slide Images Informs Conversion for Clinical Diagnosis. https://pubmed.ncbi.nlm.nih.gov/31321298/ <a href="https://pubmed.ncbi.nlm.nih.gov/31321298/">Wei BR, et al. Agreement in Histological Assessment of Mitotic Activity Between Microscopy and Digital Whole Slide Images Informs Conversion for Clinical Diagnosis.</a> 147163824 Simpson, Robert NIH - NCI NCI Simpson, Robert (NCI) 1 147163823 Puri, Munish NIH - NCI NCI Puri, Munish (NCI) 2 147163822 Hewitt, Stephen NIH - NCI NCI Hewitt, Stephen (NCI) 3 147163824 Simpson, Robert NIH - NCI NCI Simpson, Robert (NCI) 1 147163823 Puri, Munish NIH - NCI NCI Puri, Munish (NCI) 2 147163822 Hewitt, Stephen NIH - NCI NCI Hewitt, Stephen (NCI) 3 147157983 Electronic Counting Application For Surgical Pathology E-097-2019-0 Research Material NCI 121111111 Greene, Jaime greenejaime@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America greenejaime@mail.nih.gov?subject=Web Inquiry on [TAB-4186] Mitotic Figures Electronic Counting Application for Surgical Pathology&body=Please send me information about technology [TAB-4186] Mitotic Figures Electronic Counting Application for Surgical Pathology.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Greene, Jaime<br><a href="mailto:greenejaime@mail.nih.gov?subject=Web Inquiry on [TAB-4186] Mitotic Figures Electronic Counting Application for Surgical Pathology&body=Please send me information about technology [TAB-4186] Mitotic Figures Electronic Counting Application for Surgical Pathology.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">greenejaime@mail.nih.gov</a><br> 147171373 cell proliferation 147171374 COUNTING 147171375 ELECTRONIC 147171376 MATLAB 147171378 Matrix Laboratory 147171379 MF 147171380 MICROSCOPY 147171382 Mitotic Figures 147171383 PATHOLOGY 147171384 Simpson 147171385 SURGICAL TAB-4108 147157390 Automated Cancer Diagnostic Tool of Detecting, Quantifying and Mapping Mitotically-Active Proliferative Cells in Tumor Tissue Histopathology Whole-Slide Images NCI Collaboration, Licensing, Oncology, Software / Apps Collaboration Licensing Oncology Software / Apps Stephen Hewitt, Shelley Hoover, Munish Puri, Robert Simpson <h2>Summary:</h2> <p>The National Cancer Institute (NCI) <a href="https://ccr.cancer.gov/Laboratory-of-Pathology" rel="nofollow" target="_blank">Laboratories of Pathology</a> and <a href="https://ccr.cancer.gov/Laboratory-of-Cancer-Biology-and-Genetics" rel="nofollow" target="_blank">Cancer Biology and Genetics</a> are seeking parties interested in licensing and/or partnering in co-development research of a software tool for commercialization in the field of clinical immunohistochemistry quantification.</p> <h2>Description of Technology:</h2> <p>Cancer diagnosis is based on the assessment of patient biopsies to determine the tumor type, grade, and stage of malignancy. The proliferative potential of tumors correlates to their growth and metastasis. Visually identifying and quantifying mitotic figures (MF) in cancer biopsy tissue can be used as a surrogate for proliferative activity in tumors. The manual examination and quantification of stained tissue sections to determine tumor areas with the greatest number of MF, known as mitotic hotspots (HS), is subjective because the current method of assessment is based on the skill of the examining pathologist. In addition, the method used to determine HS is tedious, time-consuming, and error prone due to inter- and intra-observer variability. A newly developed technology addresses the issue of standardizing the assessment of tumor cell proliferation, yielding a diagnostic tool improves medical decision making and diagnostic precision.</p> <p>This software tool identifies all tumor cell proliferating areas, maps foci in relation to the tumor tissue, and quantifies the proliferating cells for grading purposes. It provides MF metrics as a surrogate for tumor proliferative activity while also providing topographic information on HS locations. This new technology is a major improvement over current methods that use visual inspection and counting, which can result in the inclusion of erroneous findings during cancer grading. The software uses a computational approach by processing digital whole slide images (WSI) to render image grid tiles to extract immunolabeled MF and map the HS&rsquo;s topographically to the tissue section of the WSI. This technology has demonstrated highly reproducibility unaffected by diagnostic skill level or work-fatigue. The automated approach represents a technology that requires minimal computational operations on image tile-based processing &ndash; while providing low complexity and enhancements in determining HS.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Clinical immunohistochemistry quantification for improved cancer diagnosis</li> <li>Analytic software for improved cancer diagnosis</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Computation approach to process whole slide images</li> <li>High reproducibility, unaffected by diagnostic skill level or fatigue</li> <li>Low complexity and enhancements in determining mitotic hotspots</li> </ul> 2020-06-17 2026-04-24 2020-06-17 2026-04-24 2020-06-17 Cancer Biopsy, diagnostic, Hewitt, HS, IHC, Immunohistochemistry, MF, Mitotic Figure, Mitotic Hotspots, Simpson, Tissue Histopathology False True Prototype True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-06-17 52406769 Prototype 52406769 NCI 37470483 Website Abstract E-097-2019 147161947 Puri M, et al. Automated Computational Detection, Quantitation, and Mapping of Mitosis in Whole-Slide Images for Clinically Actionable Surgical Pathology Decision Support. https://pubmed.ncbi.nlm.nih.gov/30915258/ <a href="https://pubmed.ncbi.nlm.nih.gov/30915258/">Puri M, et al. Automated Computational Detection, Quantitation, and Mapping of Mitosis in Whole-Slide Images for Clinically Actionable Surgical Pathology Decision Support.</a> 147163537 Simpson, Robert NIH - NCI NCI Simpson, Robert (NCI) 1 147163535 Hewitt, Stephen NIH - NCI NCI Hewitt, Stephen (NCI) 2 147163538 Hoover, Shelley NCI - CCR NCI Hoover, Shelley (NCI) 3 147163536 Puri, Munish NIH - NCI NCI Puri, Munish (NCI) 4 147163537 Simpson, Robert NIH - NCI NCI Simpson, Robert (NCI) 1 147163535 Hewitt, Stephen NIH - NCI NCI Hewitt, Stephen (NCI) 2 147163538 Hoover, Shelley NCI - CCR NCI Hoover, Shelley (NCI) 3 147163536 Puri, Munish NIH - NCI NCI Puri, Munish (NCI) 4 147157839 Automated Cancer Diagnostic Tool For Detecting, Quantifying And Mapping Mitotically-active Proliferative Cells In Tumor Tissue Histopathology Whole-slide Images E-038-2019-0 Research Material NCI 121111111 Greene, Jaime greenejaime@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America greenejaime@mail.nih.gov?subject=Web Inquiry on [TAB-4108] Automated Cancer Diagnostic Tool of Detecting, Quantifying and Mapping Mitotically-Active Proliferative Cells in Tumor Tissue Histopathology Whole-Slide Images&body=Please send me information about technology [TAB-4108] Automated Cancer Diagnostic Tool of Detecting, Quantifying and Mapping Mitotically-Active Proliferative Cells in Tumor Tissue Histopathology Whole-Slide Images.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Greene, Jaime<br><a href="mailto:greenejaime@mail.nih.gov?subject=Web Inquiry on [TAB-4108] Automated Cancer Diagnostic Tool of Detecting, Quantifying and Mapping Mitotically-Active Proliferative Cells in Tumor Tissue Histopathology Whole-Slide Images&body=Please send me information about technology [TAB-4108] Automated Cancer Diagnostic Tool of Detecting, Quantifying and Mapping Mitotically-Active Proliferative Cells in Tumor Tissue Histopathology Whole-Slide Images.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">greenejaime@mail.nih.gov</a><br> 147169983 Cancer Biopsy 147169984 diagnostic 147169986 Hewitt 147169988 HS 147169989 IHC 147169990 Immunohistochemistry 147169992 MF 147169994 Mitotic Figure 147169996 Mitotic Hotspots 147169998 Simpson 147170000 Tissue Histopathology TAB-4413 147157708 Small Molecule Inhibitors of Histone Demethylases for Treating Rhabdomyosarcoma (RMS) and Other Cancers NCI Collaboration, Licensing, Neurology, Oncology, Therapeutics Collaboration Licensing Neurology Oncology Therapeutics Robert Hawley, Javed Khan, Megan Peach, Girma Woldemichael <h2>Description of Technology:</h2> <p>Rhabdomyosarcoma (RMS) is the most common type of soft tissue sarcoma in children and makes up 3% of all childhood cancers. Aveloar Rhabdomyosarcoma is the most aggressive subtype and is primarily established through a chromosomal translocation resulting in the fusion protein PAX3-FOXO1. Despite aggressive therapy, the 5-year survival rate for patients with high risk or recurrent Fusion Positive RMS (FP-RMS) is low (~30% and ~17%, respectively). Therefore, new therapies targeting the PAX3-FOXO1 oncogenic driver are urgently needed.&nbsp;&nbsp;</p> <p>To identify inhibitors of PAX3-FOXO1, scientists at the National Cancer Institute (NCI) developed a novel cell-based reporter assay of PAX3-FOXO1 activity. Using this system NCI scientists screened a 62,643 small molecule chemical library and found compounds with unknown function that disrupt PAX3-FOXO1 activity. Further studies of these compounds showed that they were inhibitors of histone lysine demethylases (KDMs), with enhanced selectivity for KDM3B. Treatment of RMS cell lines with these compounds resulted in cytotoxicity and apoptosis, highlighting their potential as therapeutics for RMS. These compounds were also found to be cytotoxic to other sarcoma cell lines, such as Ewing&rsquo;s sarcoma and osteosarcoma. Screening of the NCI-60 cancer cell panel with one of these compounds resulted in growth inhibition of a range of cancer cell types, including leukemias, CNS cancers, melanoma, prostate cancer, colon cancer, ovarian cancers, breast cancers, and renal caners. In the case of renal cancer, treatment resulted in growth inhibition followed by cell death. Thus, these compounds may be effective therapeutics for a variety of cancers outside of RMS.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Therapeutic for Rhabdomyosarcoma and other cancers &ndash; including, but perhaps not limited to: <ul> <li>breast cancer</li> <li>melanoma</li> <li>leukemias</li> <li>prostate cancer</li> <li>colon cancer</li> <li>renal cancer</li> </ul> </li> <li>Therapeutic for diseases involving aberrant histone lysine methylation, such as neurodevelopmental disorders&nbsp;&nbsp;</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>First-in-class inhibitors of the histone lysine demethylase KDM3B</li> <li>The ability of the compounds to target multiple histone demethylases (KDMs) has two main advantages: 1) may upregulate myogenesis and apoptosis, while at the same time downregulating PAX3-FOXO1 oncogenic targets, and 2) may reduce the frequency of acquired drug resistance resulting from the acquisition of mutations in a single therapeutic KDM target&nbsp;&nbsp;</li> </ul> 2020-06-08 2026-04-24 2022-05-11 2026-04-24 2020-06-08 Histone Lysine Demethylases, KDM3B, KDM3B inhibitors, KDMs, Khan, Lysine Demethylase 3B, PAX3-FOXO1, Rhabdomyosarcoma, RMS False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2022-05-11 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147164652 Khan, Javed NIH - NCI NCI Khan, Javed (NCI) 1 147164653 Hawley, Robert NIH - NCI Hawley, Robert 2 147164654 Peach, Megan NIH - NCI Leidos Peach, Megan (Leidos) 3 147164655 Woldemichael, Girma NIH - NCI Leidos Woldemichael, Girma (Leidos) 4 147164652 Khan, Javed NIH - NCI NCI Khan, Javed (NCI) 1 147164653 Hawley, Robert NIH - NCI Hawley, Robert 2 147164654 Peach, Megan NIH - NCI Leidos Peach, Megan (Leidos) 3 147164655 Woldemichael, Girma NIH - NCI Leidos Woldemichael, Girma (Leidos) 4 147157810 Identification Of A Novel Inhibitor Of The Jumonji Family Of Histone Lysine Demethylases That Disrupts The PAX3-FOXO1 Oncogenic Circuitry In Alveolar Rhabdomyosarcoma E-023-2019-0 Filing authorized NCI 121111111 Greene, Jaime greenejaime@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America greenejaime@mail.nih.gov?subject=Web Inquiry on [TAB-4413] Small Molecule Inhibitors of Histone Demethylases for Treating Rhabdomyosarcoma (RMS) and Other Cancers&body=Please send me information about technology [TAB-4413] Small Molecule Inhibitors of Histone Demethylases for Treating Rhabdomyosarcoma (RMS) and Other Cancers.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Greene, Jaime<br><a href="mailto:greenejaime@mail.nih.gov?subject=Web Inquiry on [TAB-4413] Small Molecule Inhibitors of Histone Demethylases for Treating Rhabdomyosarcoma (RMS) and Other Cancers&body=Please send me information about technology [TAB-4413] Small Molecule Inhibitors of Histone Demethylases for Treating Rhabdomyosarcoma (RMS) and Other Cancers.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">greenejaime@mail.nih.gov</a><br> 147160918 E-023-2019-0 E-023-2019-0-US-01 INHIBITORS OF HISTONE DEMETHYLASES PRV US 62/936,722 Abandoned US <br />Provisional (PRV) 62/936,722<br />Filed on 2019-11-18<br />Status: Abandoned 147168776 E-023-2019-0 E-023-2019-0-PCT-02 INHIBITORS OF HISTONE DEMETHYLASES (PFI-63 AND PFI-90) FOR THE TREATMENT OF CANCER AND FOR THE INHIBITION OF HISTONE DEMETHYLASE IN CELLS PCT Patent Cooperation Treaty PCT/US2020/060955 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2020/060955<br />Filed on 2020-11-18<br />Status: Expired 147168777 E-023-2019-0 E-023-2019-0-CA-03 INHIBITORS OF HISTONE DEMETHYLASES (PFI-63 AND PFI-90) FOR THE TREATMENT OF CANCER AND FOR THE INHIBITION OF HISTONE DEMETHYLASE IN CELLS National Stage Canada 3158557 Pending Canada <br />National Stage 3158557<br />Filed on 2022-05-16<br />Status: Pending 147168778 E-023-2019-0 E-023-2019-0-EP-04 INHIBITORS OF HISTONE DEMETHYLASES (PFI-63 AND PFI-90) FOR THE TREATMENT OF CANCER AND FOR THE INHIBITION OF HISTONE DEMETHYLASE IN CELLS National Stage European Patent 4061366 20824760.1 Issued European Patent <br />National Stage 20824760.1<br />Filed on 2022-06-17<br />Status: Issued 147168779 E-023-2019-0 E-023-2019-0-US-05 INHIBITORS OF HISTONE DEMETHYLASES (PFI-63 AND PFI-90) FOR THE TREATMENT OF CANCER AND FOR THE INHIBITION OF HISTONE DEMETHYLASE IN CELLS National Stage US 17/777,552 Pending US <br />National Stage 17/777,552<br />Filed on 2022-05-17<br />Status: Pending 147169672 Histone Lysine Demethylases 147169674 KDM3B 147169676 KDM3B inhibitors 147169678 KDMs 147169680 Khan 147169682 Lysine Demethylase 3B 147169683 PAX3-FOXO1 147169684 Rhabdomyosarcoma 147169686 RMS TAB-4260 147157547 Inducible Activation Nucleic Acid Hybrid Switch for Conditional Generation of Oligonucleotides NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Bruce Shapiro, Paul Zakrevsky <h2>Summary:</h2> <p>The NCI is looking for innovative companies interested in co-developing and/or licensing a&nbsp;novel nucleic-based therapy based on the conditional activation strategy.</p> <h2>Description of Technology:</h2> <p>Gene therapy research has yielded FDA-approved treatments for an array of diseases. However, challenges facing nucleic-acid based therapeutics include non-specific delivery and degradation of the nanoparticles. NCI investigators have developed a solution to address these challenges in their novel nucleic-based therapy based on the conditional activation strategy.&nbsp;</p> <p>The inducible activation nucleic acid hybrid switch overcomes the drawbacks of current technologies through its unique design. The implementation of nucleic acid logic elements in these constructs circumvents off-target effects. The functional oligonucleotide constructs would only be generated and activated in environments denoted by the presence or absence of a specific cognate RNA trigger, ensuring context-sensitive function. The systems were also optimized to be resistant to nuclease degradation yet inexpensive for commercial production. Furthermore, this collection of logic-based systems can accommodate different trigger/target sequence pairs, enhancing its diversity of application, and serves as a novel paradigm for conditionally regulated therapeutics against cancer, genetic disorders, or infectious diseases.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Cancer</li> <li>Infectious diseases</li> <li>Genetic disorders&nbsp;</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Resistant to nuclease degradation</li> <li>Specificity of action based on environmental context, minimizing off-target effects</li> <li>Amenable to alterations to accommodate different trigger/target sequence pairs without the need for sequence overlap or similarities&nbsp;</li> <li>A set of context sensitive drugs that separate diagnosis (disease state &ndash; e.g. over or under expression of particular genes) from the therapeutic state (targeting specific genes &ndash; e.g. Dicer substrate RNAs that induce apoptosis)</li> </ul> 2020-05-01 2026-04-24 2021-04-06 2026-04-24 2020-05-01 Conditional Activation, Functional RNA, Gene silencing, In Silico Design, Nanoparticle, Nucleic Acid Therapeutic, RNA, RNA Logic, Shapiro False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-04-06 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-039-2012 E-059-2009 E-075-2018 E-078-2016 E-156-2014 E-277-2016 E-765-2013 147162029 Zakrevsky P, et al. A Suite of Therapeutically-Inspired Nucleic Acid Logic Systems for Conditional Generation of Single-Stranded and Double-Stranded Oligonucleotides. https://www.ncbi.nlm.nih.gov/pubmed/30991728 <a href="https://www.ncbi.nlm.nih.gov/pubmed/30991728">Zakrevsky P, et al. A Suite of Therapeutically-Inspired Nucleic Acid Logic Systems for Conditional Generation of Single-Stranded and Double-Stranded Oligonucleotides.</a> 147164086 Shapiro, Bruce NIH - NCI NCI Shapiro, Bruce (NCI) 1 147164087 Zakrevsky, Paul NIH - NCI NCI Zakrevsky, Paul (NCI) 2 147164086 Shapiro, Bruce NIH - NCI NCI Shapiro, Bruce (NCI) 1 147164087 Zakrevsky, Paul NIH - NCI NCI Zakrevsky, Paul (NCI) 2 147157911 Inducible Activation Nucleic Acid Hybrid Switch E-065-2019-0 Filing authorized NCI 83732917 Favila, Michelle michelle.favila@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC michelle.favila@nih.gov?subject=Web Inquiry on [TAB-4260] Inducible Activation Nucleic Acid Hybrid Switch for Conditional Generation of Oligonucleotides&body=Please send me information about technology [TAB-4260] Inducible Activation Nucleic Acid Hybrid Switch for Conditional Generation of Oligonucleotides.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Favila, Michelle<br><a href="mailto:michelle.favila@nih.gov?subject=Web Inquiry on [TAB-4260] Inducible Activation Nucleic Acid Hybrid Switch for Conditional Generation of Oligonucleotides&body=Please send me information about technology [TAB-4260] Inducible Activation Nucleic Acid Hybrid Switch for Conditional Generation of Oligonucleotides.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">michelle.favila@nih.gov</a><br> 147160986 E-065-2019-0 E-065-2019-0-US-01 HYBRID NUCLEIC ACID SWITCHES PRV US 62/832,171 Abandoned US <br />Provisional (PRV) 62/832,171<br />Filed on 2019-04-10<br />Status: Abandoned 147167725 E-065-2019-0 E-065-2019-0-PCT-02 HYBRID NUCLEIC ACID SWITCHES PCT Patent Cooperation Treaty PCT/US2020/027637 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2020/027637<br />Filed on 2020-04-10<br />Status: Expired 147167726 E-065-2019-0 E-065-2019-0-US-03 HYBRID NUCLEIC ACID SWITCHES National Stage US 17/602,204 Pending US <br />National Stage 17/602,204<br />Filed on 2021-10-07<br />Status: Pending 147170647 Conditional Activation 147170649 Functional RNA 147170650 Gene silencing 147170652 In Silico Design 147170653 Nanoparticle 147170655 Nucleic Acid Therapeutic 147170656 RNA 147170658 RNA Logic 147170660 Shapiro TAB-4349 147157642 Induced Pluripotent Stem Cells Derived from Patients with CEP290-associated Ciliopathies and Unaffected Family Members NEI Collaboration, Ear, Nose, & Throat, Licensing, Ophthalmology, Research Materials Collaboration Ear Nose & Throat Licensing Ophthalmology Research Materials Yu Holly Chen, Milton English, Hiroko Shimada-Ishii, Anand Swaroop <h2>Summary:</h2> <p>The National Eye Institute (NEI) seeks research collaborations and/or licensees for the use of iPS cells.</p> <h2>Description of Technology:</h2> <p>Approximately one-third of non-syndromic retinal dystrophies involve a defect in a ciliary protein. Non-syndromic retinal ciliopathies include retinitis pigmentosa, cone dystrophy, cone-rod dystrophy, macular dystrophy, and Leber-congenital amaurosis (LCA). Many CEP290-LCA patients also exhibit auditory and olfactory defects. Induced pluripotent stem cells (iPS) cells were derived from patients with LCA and unaffected relatives.&nbsp;</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Screening for agents to treat patients with CEP290-associated ciliopathies such as retinitis pigmentosa, cone dystrophy, cone-rod dystrophy, macular dystrophy, and Leber-congenital amaurosis&nbsp;</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Extensive characterization, including use in making 3-D retinal organoids and optic cup organoids</li> <li>Complement studies with model organisms and examine retinal dystrophies relevant to humans</li> </ul> 2020-04-30 2026-04-24 2020-04-30 2026-04-24 2020-04-30 Anosmia, Cell therapy, Ciliopathies, Congenital Blindness, Drug Development, GENE THERAPY, hearing loss, iPS, National Eye Institute, NEI, Pluripotent Stem Cells, Primary Cilia, Retina, Retinal degeneration, Swaroop, VISION False True Basic (Target Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-04-30 52406768 Discovery 52406768 NCI 37470483 Website Abstract E-164-2014 147162306 Shimada H, el al. In vitro modeling using ciliopathy patient-derived cells reveals distinct cilia dysfunctions caused by CEP290 mutations https://www.ncbi.nlm.nih.gov/pubmed/28700940 <a href="https://www.ncbi.nlm.nih.gov/pubmed/28700940">Shimada H, el al. In vitro modeling using ciliopathy patient-derived cells reveals distinct cilia dysfunctions caused by CEP290 mutations</a> 147164412 Swaroop, Anand NIH - NEI NEI Swaroop, Anand (NEI) 1 147164414 Shimada-Ishii, Hiroko NIH - NEI Shimada-Ishii, Hiroko 2 147164413 Chen, Yu Holly NIH - NEI NEI Chen, Yu Holly (NEI) 3 147164415 English, Milton NIH - NEI NHGRI English, Milton (NHGRI) 4 147164412 Swaroop, Anand NIH - NEI NEI Swaroop, Anand (NEI) 1 147164414 Shimada-Ishii, Hiroko NIH - NEI Shimada-Ishii, Hiroko 2 147164413 Chen, Yu Holly NIH - NEI NEI Chen, Yu Holly (NEI) 3 147164415 English, Milton NIH - NEI NHGRI English, Milton (NHGRI) 4 147157988 Induced Pluripotent Stem Cells Derived From Patients With CEP290-associated Ciliopathies For Disease Modeling And Development And Relatives Of The Patients E-100-2020-0 Closed National Eye Institute (NEI) 83724826 Pollard, Ricquita ricquita.pollard@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4349] Induced Pluripotent Stem Cells Derived from Patients with CEP290-associated Ciliopathies and Unaffected Family Members&body=Please send me information about technology [TAB-4349] Induced Pluripotent Stem Cells Derived from Patients with CEP290-associated Ciliopathies and Unaffected Family Members.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollard, Ricquita<br><a href="mailto:ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4349] Induced Pluripotent Stem Cells Derived from Patients with CEP290-associated Ciliopathies and Unaffected Family Members&body=Please send me information about technology [TAB-4349] Induced Pluripotent Stem Cells Derived from Patients with CEP290-associated Ciliopathies and Unaffected Family Members.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">ricquita.pollard@nih.gov</a><br> 147171432 Anosmia 147171433 Cell therapy 147171434 Ciliopathies 147171436 Congenital Blindness 147171437 Drug Development 147171438 GENE THERAPY 147171439 hearing loss 147171440 iPS 147171441 National Eye Institute 147171442 NEI 147171444 Pluripotent Stem Cells 147171446 Primary Cilia 147171447 Retina 147171448 Retinal degeneration 147171449 Swaroop 147171450 VISION TAB-5098 166964729 Neutralizing Monoclonal Antibodies Against West Nile Virus NIAID Antibodies, Application, Diagnostics, ResearchProducts, TherapeuticArea, Virus/Bacteria Antibodies Application Diagnostics ResearchProducts TherapeuticArea Virus/Bacteria Katherine Burgomaster, Ananda Chowdhury, Parker Dabbs, Daniel Douek, Kimberly Dowd, David Gordon, Dror Harats, Yaniv Lustig, Yael Ottolenghi, Theodore Pierson, Chaim Schramm, Leonid Serebryannyy, Sarah Smith (Kerscher), Laura Vanblargan, Lu Wang, Yuxiang Wang <p>&nbsp; &nbsp; &nbsp; &nbsp;West Nile virus (WNV) is a mosquito-borne flavivirus that can cause fever and, in some cases, severe neurologic disease. There is no approved human vaccine or specific antiviral treatment for WNV.</p> <p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Researchers at NIAID&#39;s Vaccine Research Center (VRC), working with collaborators at Sheba Medical Center under the PREMISE program, identified five new human monoclonal antibodies that potently neutralize WNV. These antibodies bind the viral envelope (E) protein, with data indicating recognition of E dimers or quaternary epitopes on the virion.</p> <p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The invention includes compositions comprising the antibodies alone or in combination, nucleic acids encoding them, vectors and host cells for production, and methods for preventing, treating, or detecting WNV infection. The antibodies may be formulated for therapeutic administration, including emergency-use settings, and may also support diagnostic and research applications.</p> <ul> <li> Shown to strongly neutralize WNV at low concentrations in laboratory cell-based studies </li> <li> Novel antibodies with distinct molecular features not previously reported in scientific literature </li> <li> Human monoclonal antibodies targeting E dimer or quaternary epitopes on the WNV virion </li> <li> Potential applications in WNV treatment, diagnostics, and surveillance </li> <li> Collaboration may help speed development to support WNV outbreak response </li> </ul> <ul> <li> Prevention or treatment antibodies for WNV, including use alone or in combination </li> <li> Antibodies that strongly target the WNV E protein </li> <li> Potential treatments for WNV outbreak response and prevention in high-risk populations </li> <li> Genetic and cell-engineering tools for antibody production and product development </li> <li> Antibodies for WNV detection, surveillance, and research tests </li> <li> Potential intravenous treatments for patients with WNV </li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. For collaboration opportunities, please contact Brian Bailey at 240-669-5128, or bbailey@mail.nih.gov. 2026-04-23 2026-04-24 2026-04-24 2026-04-24 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract E-021-2026-0 166964944 Douek, Daniel National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Douek, Daniel (NIAID) 1 166964948 Schramm, Chaim National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Schramm, Chaim (NIAID) 2 166964953 Chowdhury, Ananda NIAID - VRC Chowdhury, Ananda 3 166964965 Dabbs, Parker NIAID - VRC Dabbs, Parker 4 166965179 Wang, Lu NIAID - VRC Wang, Lu 5 166966485 Serebryannyy, Leonid National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Serebryannyy, Leonid (NIAID) 6 166966491 Pierson, Theodore NIAID - VRC NIAID Pierson, Theodore (NIAID) 7 166966503 Dowd, Kimberly NIAID - VRC NIAID Dowd, Kimberly (NIAID) 8 166966531 Vanblargan, Laura National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Vanblargan, Laura (NIAID) 9 166966539 Burgomaster, Katherine NIAID - VRC NIAID Burgomaster, Katherine (NIAID) 10 166966613 Gordon, David National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Gordon, David (NIAID) 11 166966628 Wang, Yuxiang NIAID - VRC Wang, Yuxiang 12 166966639 Lustig, Yaniv Israel Ministry of Health [IL] Lustig, Yaniv 13 166966661 Ottolenghi, Yael The Sheba Fund for Health Services & Research (Sheba Medical Center) [IL] Ottolenghi, Yael 14 166966666 Harats, Dror Sheba Medical Center Harats, Dror 15 166967476 Smith (Kerscher), Sarah NIAID - VRC NIAID Smith (Kerscher), Sarah (NIAID) 16 166964944 Douek, Daniel National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Douek, Daniel (NIAID) 1 166964948 Schramm, Chaim National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Schramm, Chaim (NIAID) 2 166964953 Chowdhury, Ananda NIAID - VRC Chowdhury, Ananda 3 166964965 Dabbs, Parker NIAID - VRC Dabbs, Parker 4 166965179 Wang, Lu NIAID - VRC Wang, Lu 5 166966485 Serebryannyy, Leonid National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Serebryannyy, Leonid (NIAID) 6 166966491 Pierson, Theodore NIAID - VRC NIAID Pierson, Theodore (NIAID) 7 166966503 Dowd, Kimberly NIAID - VRC NIAID Dowd, Kimberly (NIAID) 8 166966531 Vanblargan, Laura National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Vanblargan, Laura (NIAID) 9 166966539 Burgomaster, Katherine NIAID - VRC NIAID Burgomaster, Katherine (NIAID) 10 166966613 Gordon, David National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Gordon, David (NIAID) 11 166966628 Wang, Yuxiang NIAID - VRC Wang, Yuxiang 12 166966639 Lustig, Yaniv Israel Ministry of Health [IL] Lustig, Yaniv 13 166966661 Ottolenghi, Yael The Sheba Fund for Health Services & Research (Sheba Medical Center) [IL] Ottolenghi, Yael 14 166966666 Harats, Dror Sheba Medical Center Harats, Dror 15 166967476 Smith (Kerscher), Sarah NIAID - VRC NIAID Smith (Kerscher), Sarah (NIAID) 16 166964734 Neutralizing antibodies against West Nile Virus E-200-2024-0 Filing authorized National Institute of Allergy and Infectious Diseases (NIAID/NIH), NIAID - DIR, NIAID - VRC, NIAID - VRC, Sheba Medical Center, The Sheba Fund for Health Services & Research (Sheba Medical Center) [IL] 83682222 Bailey, Brian bbailey@mail.nih.gov
United States of America TTIPO bbailey@mail.nih.gov?subject=Web Inquiry on [TAB-5098] Neutralizing Monoclonal Antibodies Against West Nile Virus&body=Please send me information about technology [TAB-5098] Neutralizing Monoclonal Antibodies Against West Nile Virus. Bailey, Brian<br><a href="mailto:bbailey@mail.nih.gov?subject=Web Inquiry on [TAB-5098] Neutralizing Monoclonal Antibodies Against West Nile Virus&body=Please send me information about technology [TAB-5098] Neutralizing Monoclonal Antibodies Against West Nile Virus.">bbailey@mail.nih.gov</a><br> 166964739 E-200-2024-0 E-200-2024-0-US-01 WEST NILE VIRUS NEUTRALIZING MONOCLONAL ANTIBODIES PRV US 63/677,612 Expired US <br />Provisional (PRV) 63/677,612<br />Filed on 2024-07-31<br />Status: Expired 166964740 E-200-2024-0 E-200-2024-0-PC-01 WEST NILE VIRUS NEUTRALIZING MONOCLONAL ANTIBODIES PCT Patent Cooperation Treaty PCT/US2025/039922 Pending Patent Cooperation Treaty <br />(PCT) PCT/US2025/039922<br />Filed on 2025-07-30<br />Status: Pending TAB-3947 147157227 EGFRvIII Antibodies for the Treatment of Human Cancer NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Antonella Antignani, David Fitzgerald, Eric Ho, Robert Sarnovsky <h2>Summary:</h2> <p>The NCI seeks research co-development partners or licensees for monoclonal antibodies that specifically target cancer-expressed EGFR.</p> <h2>Description of Technology:</h2> <p>Epidermal growth factor receptor variant III (EGFRvIII) is a variant of EGFR that is an excellent target for immunotherapy because of its expression in cancer cells and not in normal cells.&nbsp;</p> <p>Inventors from the National Cancer Institute (NCI) have isolated seven mouse monoclonal antibodies that bind to the human EGFRvIII but not wildtype EGFR. These EGFRvIII antibodies can be used as either independent agents or targeting domains in recombinant immunotoxins (RITs), antibody-drug conjugates (ADCs), bispecific antibodies, and chimeric antigen receptors (CARs). Significantly, RITs using one of the antibodies (40H3) have shown potent killing in breast cancer cells and in epidermoid cancer cells, strongly supporting that the antibodies may be further developed as therapeutics. The 40H3 antibody is also able to bind to EGFR when overexpressed as seen in various cancers, and thus has broad therapeutic potential.&nbsp; &nbsp;&nbsp;</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Therapeutic applications include the unconjugated antibodies and their use as a targeting moiety in ADCs, RITs, and CARs</li> <li>Diagnostic agent for detection and monitoring levels of EGFRvIII expressing cancers</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>The EGFRvIII antibodies with high EGFRvIII binding specificity will result in less non-specific cell killing and lower potential side effects&nbsp;</li> <li>RITs using the 40H3 antibody are available for immediate testing&nbsp;</li> <li>40H3 can also bind EGFR when over-expressed from amplified EGFR, which is specific to various cancers&nbsp;&nbsp;</li> </ul> 2020-04-28 2026-04-24 2021-03-29 2026-04-24 2020-04-28 ADC, Antibody-drug Conjugate, CAR, chimeric antigen receptor, EGFR, EGFRvIII, Epidermal Growth Factor Receptor, Epidermal growth factor receptor variant III, FitzGerald, Recombinant Immunotoxins, RITs False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-03-29 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147162975 Fitzgerald, David NIH - NCI NCI Fitzgerald, David (NCI) 1 147162976 Antignani, Antonella NIH - NCI NCI Antignani, Antonella (NCI) 2 147162977 Ho, Eric NIH - NCI NCI Ho, Eric (NCI) 3 147162978 Sarnovsky, Robert NIH - NCI NCI Sarnovsky, Robert (NCI) 4 147162975 Fitzgerald, David NIH - NCI NCI Fitzgerald, David (NCI) 1 147162976 Antignani, Antonella NIH - NCI NCI Antignani, Antonella (NCI) 2 147162977 Ho, Eric NIH - NCI NCI Ho, Eric (NCI) 3 147162978 Sarnovsky, Robert NIH - NCI NCI Sarnovsky, Robert (NCI) 4 147157993 Monoclonal Antibodies To Cancer-expressed EGFR E-103-2019-0 Filing authorized NCI 83731987 Dhal, Abritee abritee.dhal@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-3947] EGFRvIII Antibodies for the Treatment of Human Cancer&body=Please send me information about technology [TAB-3947] EGFRvIII Antibodies for the Treatment of Human Cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dhal, Abritee<br><a href="mailto:abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-3947] EGFRvIII Antibodies for the Treatment of Human Cancer&body=Please send me information about technology [TAB-3947] EGFRvIII Antibodies for the Treatment of Human Cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">abritee.dhal@nih.gov</a><br> 147161043 E-103-2019-0 E-103-2019-0-US-01 MONOCLONAL ANTIBODIES THAT BIND EGFRVIII AND THEIR USE PRV US 62/869,956 Abandoned US <br />Provisional (PRV) 62/869,956<br />Filed on 2019-07-02<br />Status: Abandoned 147165483 E-103-2019-0 E-103-2019-0-PCT-02 MONOCLONAL ANTIBODIES THAT BIND EGFRVIII AND THEIR USE PCT Patent Cooperation Treaty PCT/US2020/040544 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2020/040544<br />Filed on 2020-07-01<br />Status: Expired 147165484 E-103-2019-0 E-103-2019-0-AU-03 MONOCLONAL ANTIBODIES THAT BIND EGFRVIII AND THEIR USE National Stage Australia 2020299382 Pending Australia <br />National Stage 2020299382<br />Filed on 2020-07-01<br />Status: Pending 147165485 E-103-2019-0 E-103-2019-0-CA-04 MONOCLONAL ANTIBODIES THAT BIND EGFRVIII AND THEIR USE National Stage Canada 3142833 Pending Canada <br />National Stage 3142833<br />Filed on 2020-07-01<br />Status: Pending 147165486 E-103-2019-0 E-103-2019-0-CN-05 MONOCLONAL ANTIBODIES THAT BIND EGFRVIII AND THEIR USE National Stage China ZL202080055447.2 202080055447.2 Issued China <br />National Stage 202080055447.2<br />Filed on 2020-07-01<br />Status: Issued 147165487 E-103-2019-0 E-103-2019-0-EP-06 MONOCLONAL ANTIBODIES THAT BIND EGFRVIII AND THEIR USE National Stage European Patent 20745396.0 Pending European Patent <br />National Stage 20745396.0<br />Filed on 2020-07-01<br />Status: Pending 147165488 E-103-2019-0 E-103-2019-0-US-07 MONOCLONAL ANTIBODIES THAT BIND EGFRVIII AND THEIR USE National Stage US 12,565,532 17/623,370 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12565532 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12565532">12,565,532</a><br />Filed on 2021-12-28<br />Status: Issued 147165489 E-103-2019-0 E-103-2019-0-IL-08 MONOCLONAL ANTIBODIES THAT BIND EGFRVIII AND THEIR USE National Stage Israel 289488 Abandoned Israel <br />National Stage 289488<br />Filed on 2020-07-01<br />Status: Abandoned 147165490 E-103-2019-0 E-103-2019-0-IN-09 MONOCLONAL ANTIBODIES THAT BIND EGFRVIII AND THEIR USE National Stage India 202217002368 Pending India <br />National Stage 202217002368<br />Filed on 2020-07-01<br />Status: Pending 147165491 E-103-2019-0 E-103-2019-0-JP-10 MONOCLONAL ANTIBODIES THAT BIND EGFRVIII AND THEIR USE National Stage Japan 7815099 2022-500090 Issued Japan <br />National Stage 2022-500090<br />Filed on 2020-07-01<br />Status: Issued 147165492 E-103-2019-0 E-103-2019-0-KR-11 MONOCLONAL ANTIBODIES THAT BIND EGFRVIII AND THEIR USE National Stage South Korea 10-2022-7003667 Abandoned South Korea <br />National Stage 10-2022-7003667<br />Filed on 2020-07-01<br />Status: Abandoned 147165493 E-103-2019-0 E-103-2019-0-MX-12 MONOCLONAL ANTIBODIES THAT BIND EGFRVIII AND THEIR USE National Stage Mexico MX/a/2022/000174 Pending Mexico <br />National Stage MX/a/2022/000174<br />Filed on 2020-07-01<br />Status: Pending 147165495 E-103-2019-0 E-103-2019-0-SG-14 MONOCLONAL ANTIBODIES THAT BIND EGFRVIII AND THEIR USE National Stage Singapore 11202114486Y Abandoned Singapore <br />National Stage 11202114486Y<br />Filed on 2020-07-01<br />Status: Abandoned 147165496 E-103-2019-0 E-103-2019-0-EA-15 MONOCLONAL ANTIBODIES THAT BIND EGFRVIII AND THEIR USE National Stage Eurasian Patent 202290208 Pending Eurasian Patent <br />National Stage 202290208<br />Filed on 2020-07-01<br />Status: Pending 147165497 E-103-2019-0 E-103-2019-0-HK-16 MONOCLONAL ANTIBODIES THAT BIND EGFRVIII AND THEIR USE CN Hong Kong 62022061195.3 Pending Hong Kong <br />China Patent (CN) 62022061195.3<br />Filed on 2022-09-26<br />Status: Pending 147171479 ADC 147171480 Antibody-drug Conjugate 147171481 CAR 147171482 chimeric antigen receptor 147171483 EGFR 147171484 EGFRvIII 147171485 Epidermal Growth Factor Receptor 147171487 Epidermal growth factor receptor variant III 147171489 FitzGerald 147171490 Recombinant Immunotoxins 147171491 RITs TAB-4375 147157669 Peptide Hydrogels for Rate-Controlled Delivery of Therapeutics NCI Collaboration, Immunology, Infectious Disease, Licensing, Oncology, Therapeutics Collaboration Immunology Infectious Disease Licensing Oncology Therapeutics Caroline Andrews, Julie Hixon, Wenqing Li, Stephen Miller, Joel Schneider, Steven Tau, Scott Walsh, Yuji Yamada <h2>Description of Technology:</h2> <p>Hydrogels represent an attractive controlled drug-delivery system that have been used in various clinical applications, such as: tissue engineering for wound healing, surgical procedures, pain management, cardiology, and oncology. High-water content of hydrogels confers tissue-like physical properties and the crosslinked fibrillar network enables encapsulation of labile small molecule drugs, peptides, proteins, nucleic acids, proteins, nanoparticles, or cells. The porosity of the mesh-like network contributes to enhanced protection and controlled release of therapeutics compared with the rapid clearance and degradation of some proteins observed using conventional drug-delivery methods. Although all hydrogel platforms provide spatial and temporal control over the release of therapeutics, the current standard requires designing a unique hydrogel for a select therapeutic agent for a specific application. This one therapeutic agent-one gel model adds significant research and regulatory burden.</p> <p>To address this, researchers at the National Cancer Institute (NCI) developed a novel syringe-injectable/sprayable hydrogel platform that can deliver a variety of different therapeutic agents. This hydrogel can be used to deliver small molecules, peptides, proteins, nucleic acids, nanoparticles, or cells.&nbsp; Further, this hydrogel has been engineered to be compatible with a protein delivery platform invented at the NCI. This tunable combination system enables the release of different kinds of proteins based on the electrostatic interaction between the fusion sequence engineered directly at the amino- or carboxy-terminus of proteins and the anionic fibrillar network of the hydrogel AcVES3. In a proof-of-concept study, NCI researchers have delivered a cytokine protein, IL-7, a therapeutic agent critical for improving T cell development for immunotherapy in cancer, sepsis, and HIV-infected patients. Administration of a single dose of IL-7 encapsulated within AcVES3 was shown to exhibit comparable development of T cell populations compared to soluble IL-7 added every 3 days in vitro and to daily subcutaneous IL-7 injections for greater than 30 days in vivo. Thus, this hydrogel platform can reduce the amount of protein needed to attain desired endpoints and potentially reduce patient burden for targeted therapies.</p> <p>Furthermore, the AcVES3 platform can be used to culture cells in 2D and 3D environments and deliver these cells as potential therapeutic agents. NCI researchers conducted murine studies to culture and deliver fluorescently labeled human dermal fibroblasts encapsulated in AcVES3-RGDV hydrogel at high cellular concentrations. Stem and cancer cells can be also be grown within the 3D AcVES3 hydrogel environment; instead of the commonly used murine-derived Matrigel reagent and subsequently these cells may be injected in vivo, even into larger scale animal models such as non-human primates. These proof-of-concept studies suggest that the AcVES3 platform can be used to encapsulate an appropriate number of cells of interest over time in vivo for therapeutic applications. Overall, the AcVES3 platform is a promising hydrogel system that is applicable for numerous non-clinical and clinical applications.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Cancer &ndash; especially those involving therapeutic whole cells &ndash; such as stem cells, T cells, CAR T cells for cancer therapy and/or fibroblasts</li> <li>Sepsis &ndash; especially when boosting T cell levels is effective</li> <li>HIV</li> <li>Autoimmune disorders &ndash; especially to modulate T cell populations</li> <li>Transplantation</li> <li>Delivering viruses for gene therapy or oncolytic viruses for cancer therapy</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Rate-controlled release of therapeutic drugs including small molecules, nucleic acids, peptides, proteins, or nanoparticles: therapeutic drugs encapsulated in the anionic hydrogel platform&nbsp;</li> <li>Rate-controlled release of therapeutic whole cells: such as stem cells, T cells, CAR T cells for cancer therapy and/or fibroblasts</li> <li>T cell enhancer for in vitro and in clinical setting: stimulating T cells in cultures, essential in adoptive T cell therapy, cancer and HIV-immunotherapy, boosting T cell levels in sepsis patients, and modulating T cell populations in autoimmune diseases</li> <li>Delivers locally or systemically a variety of different therapeutic drugs including small molecule, peptides, proteins, nucleic acids, nanoparticles, or cells</li> <li>Reduces the amount of drugs or cells needed to attain desirable clinical results&nbsp;</li> <li>Reduces the patient burden from multiple injections and travel time to the clinic</li> <li>Offers targeted syringe or catheter injectable delivery or sprayable delivery</li> <li>Is a tunable delivery platform that can attenuate peptide or protein release rate within hydrogel</li> </ul> 2020-04-20 2026-04-24 2020-04-20 2026-04-24 2020-04-20 DEVICE, IL-7, Nanoparticle, Peptide, Peptide-based Hydrogel, Protein, Schneider, small molecule, T Cell Enhancer, Whole Cell Delivery System False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-04-20 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147161969 Yamada Y, et al. Design of a peptide-based electronegative hydrogel for the direct encapsulation, 3D culturing, in vivo syringe-based delivery, and long-term tissue engraftment of cells. https://www.ncbi.nlm.nih.gov/pubmed/?term=31448901 <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31448901">Yamada Y, et al. Design of a peptide-based electronegative hydrogel for the direct encapsulation, 3D culturing, in vivo syringe-based delivery, and long-term tissue engraftment of cells.</a> 147162356 Miller SE, et al. Electrostatically driven guanidinium interaction domains that control hydrogel-mediated protein delivery in vivo. https://www.ncbi.nlm.nih.gov/pubmed/?term=31807676 <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=31807676">Miller SE, et al. Electrostatically driven guanidinium interaction domains that control hydrogel-mediated protein delivery in vivo.</a> 147164499 Schneider, Joel NIH - NCI NCI Schneider, Joel (NCI) 1 147164500 Miller, Stephen NIH - NCI NCI Miller, Stephen (NCI) 2 147164501 Yamada, Yuji NIH - NCI NCI Yamada, Yuji (NCI) 3 147164502 Tau, Steven NIH - NCI NCI Tau, Steven (NCI) 4 147164503 Hixon, Julie NIH - NCI NCI Hixon, Julie (NCI) 6 147164504 Li, Wenqing NIH - NCI NCI Li, Wenqing (NCI) 7 147164506 Andrews, Caroline NIH - NCI NCI Andrews, Caroline (NCI) 8 147164505 Walsh, Scott NIH - NCI NCI Walsh, Scott (NCI) 9 147164499 Schneider, Joel NIH - NCI NCI Schneider, Joel (NCI) 1 147164500 Miller, Stephen NIH - NCI NCI Miller, Stephen (NCI) 2 147164501 Yamada, Yuji NIH - NCI NCI Yamada, Yuji (NCI) 3 147164502 Tau, Steven NIH - NCI NCI Tau, Steven (NCI) 4 147164503 Hixon, Julie NIH - NCI NCI Hixon, Julie (NCI) 6 147164504 Li, Wenqing NIH - NCI NCI Li, Wenqing (NCI) 7 147164506 Andrews, Caroline NIH - NCI NCI Andrews, Caroline (NCI) 8 147164505 Walsh, Scott NIH - NCI NCI Walsh, Scott (NCI) 9 147158178 Controlling The Rate Of Protein Release From Peptide Hydrogels Using Engineered Electrostatic Interactions E-188-2017-0 Filing authorized NCI 147162556 Controlling The Rate Of Protein Release From Peptide Hydrogels Using Engineered Electrostatic Interactions E-188-2017-1 Filing authorized NCI 83704821 Nguyen-Antczak, Lauren lauren.nguyen-antczak@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-4375] Peptide Hydrogels for Rate-Controlled Delivery of Therapeutics&body=Please send me information about technology [TAB-4375] Peptide Hydrogels for Rate-Controlled Delivery of Therapeutics.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Nguyen-Antczak, Lauren<br><a href="mailto:lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-4375] Peptide Hydrogels for Rate-Controlled Delivery of Therapeutics&body=Please send me information about technology [TAB-4375] Peptide Hydrogels for Rate-Controlled Delivery of Therapeutics.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">lauren.nguyen-antczak@nih.gov</a><br> 147161170 E-188-2017-1 E-188-2017-1-PCT-01 PEPTIDE HYDROGELS AND USE THEREOF PCT Patent Cooperation Treaty PCT/US2017/066893 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2017/066893<br />Filed on 2017-12-17<br />Status: Expired 147168524 E-188-2017-1 E-188-2017-1-US-02 PEPTIDE HYDROGELS AND USE THEREOF National Stage US 11,661,439 16/954,492 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11661439 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11661439">11,661,439</a><br />Filed on 2020-06-16<br />Status: Issued 147173348 DEVICE 147173349 IL-7 147173350 Nanoparticle 147173351 Peptide 147173353 Peptide-based Hydrogel 147173354 Protein 147173355 Schneider 147173356 small molecule 147173358 T Cell Enhancer 147173360 Whole Cell Delivery System TAB-4350 147157643 A Novel Genetically Encoded Inhibitor of Hippo Signaling Pathway to Study YAP1/TAZ-TEAD Dependent Events in Cancer NCI Licensing, Oncology, Research Materials Licensing Oncology Research Materials Ramiro Iglesias-Bartolome, Yao Yuan <h2>Summary:</h2> <p>The NCI Laboratory of Cellular and Molecular Biology seeks statements of capability or interest from parties interested in licensing this novel inhibitor of the Hippo signaling pathway.</p> <h2>Description of Technology:</h2> <p>The Hippo signaling pathway regulates a multitude of biological processes including cell proliferation, apoptosis, differentiation, tissue homeostasis, and stem cell functions. This axis has been recently listed as one of the top 10 signaling pathways altered in human cancer. Its role in modulating cell growth and proliferation is mediated by the activation of Yes-associated protein 1 (YAP1) and transcriptional co-activator with PDZ-binding domain (TAZ). Under low cell density conditions, YAP1/TAZ translocate to the nucleus, bind to various transcription factors including TEA domain (TEAD) family of transcription factors, and drive the expression of genes associated with cell proliferation and differentiation. If hyperactivated due to disruptions in the Hippo pathway, this upregulation in gene transcription leads to uncontrolled cell growth, transformation, and cancer development.</p> <p>Research into the Hippo pathway is limited due to technical difficulties in the precise study of the transcriptional networks downstream of YAP1 and TAZ. For example, simultaneous downregulation of YAP1 and TAZ is needed to observe an effect on cancer progression. Furthermore, there are numerous effectors to the Hippo pathway, not limited to transcription factors. To overcome these difficulties, researchers at the National Cancer Institute (NCI) have developed a genetically encoded, fluorescently labeled peptide inhibitor of YAP1/TAZ which specifically targets its interactions with TEADs (named TEAD-inhibitor or TEADi). TEADi consists of various TEAD binding domains, including those of YAP1 and TAZ, modified for efficient inhibition. Using this inhibitor, NCI researchers have studied the functions of the Hippo pathway in the epidermis and in squamous cell carcinoma.&nbsp;NCI is continuing to develop this inhibitor to improve its stability and potency.</p> <p>Considering that the Hippo pathway constitutes one of the top signaling pathways altered in human cancer, disruption of YAP1/TAZ-TEAD complexes has become a main target to suppress oncogenic activity. TEADi can be used to dissect the TEAD-dependent and independent roles of YAP1/TAZ signaling and aid in the discovery of improved targeting strategies for this pathway. In conclusion, TEADi is a valuable research tool for studying YAP1/TAZ and the Hippo pathway in cancer and other pathologies, with improved advantages that include rapid and simple inhibition of TEAD transcription and specific blockage of nuclear events mediated by both YAP1 and TAZ without affecting structural or cytoplasmic functions of these proteins. NCI is continuing to develop this inhibitor to improve its stability and potency.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>TEADi DNA construct to study Hippo signaling pathway in different pathologies and cellular systems.</li> <li>TEADi DNA construct to selectively shut off Hippo signaling pathway for broader research purposes</li> <li>Delivery of TEADi DNA construct using lentivirus, adenovirus (AV), or adeno-associated virus (AAV) for broad research purposes</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Rapid and simple inhibition of specific effectors of a signaling pathway frequently disrupted in cancer</li> <li>Inhibition of both YAP1 and TAZ factors that regulate the Hippo pathway</li> <li>Inhibition of YAP/TAZ interaction with a specific family of transcription factors</li> <li>Green fluorescent protein (GFP) label for easy tracking</li> <li>Nuclear localization signal to target hyperactivated YAP/TAZ</li> </ul> 2020-04-02 2026-04-24 2021-03-10 2026-04-24 2020-04-02 Cancer Progression, Hippo Signaling Pathway, Iglesias-Bartolome, Peptide Inhibitor, TAZ, TEAD, YAP1, Yes-Associated Protein 1 False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-03-10 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147162268 Yuan Y, et al. YAP1/TAZ-TEAD transcriptional networks maintain skin homeostasis by regulating cell proliferation and limiting KLF4 activity. https://pubmed.ncbi.nlm.nih.gov/32193376/ <a href="https://pubmed.ncbi.nlm.nih.gov/32193376/">Yuan Y, et al. YAP1/TAZ-TEAD transcriptional networks maintain skin homeostasis by regulating cell proliferation and limiting KLF4 activity.</a> 147162421 Yuan Y, et al. YAP1-TAZ/TEAD transcriptional networks restrain differentiation downstream of oncogenic Hedgehog-SMO activity. https://www.biorxiv.org/content/10.1101/2020.12.28.424593v1 <a href="https://www.biorxiv.org/content/10.1101/2020.12.28.424593v1">Yuan Y, et al. YAP1-TAZ/TEAD transcriptional networks restrain differentiation downstream of oncogenic Hedgehog-SMO activity.</a> 147164417 Iglesias-Bartolome, Ramiro NIH - NCI NCI Iglesias-Bartolome, Ramiro (NCI) 1 147164416 Yuan, Yao NIH - NCI Yuan, Yao 2 147164417 Iglesias-Bartolome, Ramiro NIH - NCI NCI Iglesias-Bartolome, Ramiro (NCI) 1 147164416 Yuan, Yao NIH - NCI Yuan, Yao 2 147158004 Peptide Inhibitors Of YAP1/TAZ-TEAD E-108-2019-0 Closed NCI 90072936 Mistry, Pragnesh pragnesh.mistry@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
HNH6Z08 pragnesh.mistry@nih.gov?subject=Web Inquiry on [TAB-4350] A Novel Genetically Encoded Inhibitor of Hippo Signaling Pathway to Study YAP1/TAZ-TEAD Dependent Events in Cancer&body=Please send me information about technology [TAB-4350] A Novel Genetically Encoded Inhibitor of Hippo Signaling Pathway to Study YAP1/TAZ-TEAD Dependent Events in Cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Mistry, Pragnesh<br><a href="mailto:pragnesh.mistry@nih.gov?subject=Web Inquiry on [TAB-4350] A Novel Genetically Encoded Inhibitor of Hippo Signaling Pathway to Study YAP1/TAZ-TEAD Dependent Events in Cancer&body=Please send me information about technology [TAB-4350] A Novel Genetically Encoded Inhibitor of Hippo Signaling Pathway to Study YAP1/TAZ-TEAD Dependent Events in Cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">pragnesh.mistry@nih.gov</a><br> 147171585 Cancer Progression 147171587 Hippo Signaling Pathway 147171589 Iglesias-Bartolome 147171590 Peptide Inhibitor 147171592 TAZ 147171594 TEAD 147171596 YAP1 147171598 Yes-Associated Protein 1 TAB-4157 147157440 T-Cell Therapy Against Patient-Specific Cancer Mutations NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Yong-Chen Lu, Paul Robbins, Steven Rosenberg, Eric Tran <h2>Description of Technology:</h2> <p>Human cancers contain genetic mutations that are unique to each patient. Some of the mutated peptides are immunogenic, can be recognized by T cells, and therefore, may serve as therapeutic targets.</p> <p>Scientists at the <a href="https://ccr.cancer.gov/Surgery-Branch" rel="nofollow" target="_blank">National Cancer Institute&#39;s Surgery Branch</a> developed a method to identify T cells that specifically recognize immunogenic mutations expressed only by cancer cells. The scientists identified cancer-specific mutations from a patient with widely metastatic cholangiocarcinoma by sequencing tumor samples and comparing with normal cells. Using tandem minigene constructs encoding all of the mutations expressed by a patient&#39;s tumor, the inventors identified T cells that recognized the immunogenic mutations from the same patient. These mutation-reactive T cells have the potential to eliminate the cancer cells while sparing normal tissues since normal tissues do not express the mutations. The mutation-reactive T cells were expanded <em>in vitro</em>, and then infused as a highly pure population back into the same patient. The patient experienced tumor regression when treated with this approach.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Personalized immunotherapy with mutation-reactive T cells for mediating tumor regression in patients with immunogenic mutations;</li> <li>Mutation-reactive T cell therapy especially beneficial for cancer patients refractory to other therapies;</li> <li>A research tool to identify patient-specific immunogenic mutations in the tumor.</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>This patient-specific therapy has the potential application to most epithelial cancers, which account for about 90% of cancer deaths in the United States;</li> <li>Personalized mutation-specific T cells recognize mutations harboring tumor cells only and spare normal tissues. This therapy has no tissue toxicities comparing to traditional chemotherapy and radiotherapy;</li> <li>The infusion of a highly pure population of these mutation-specific T cells may maximize therapy and result in regression of all target lesions.</li> </ul> 2020-02-03 2026-04-24 2020-02-03 2026-04-24 2020-02-03 Cholangiocarcinoma, Immunogenic, Rosenberg, T-cell, Tran False True Clinical True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-02-03 72159138 Clinical Phase I 72159138 NCI 37470483 Website Abstract 147161972 Tran E, et al. http://www.ncbi.nlm.nih.gov/pubmed/25046408 <a href="http://www.ncbi.nlm.nih.gov/pubmed/25046408">Tran E, et al.</a> 147162359 Robbins P, et al. http://www.ncbi.nlm.nih.gov/pubmed/23644516 <a href="http://www.ncbi.nlm.nih.gov/pubmed/23644516">Robbins P, et al.</a> 147162397 Tran E, et al. http://www.ncbi.nlm.nih.gov/pubmed/24812403 <a href="http://www.ncbi.nlm.nih.gov/pubmed/24812403">Tran E, et al.</a> 162585338 Per discussions with A. Burke Per discussions with A. Burke 147163723 Tran, Eric NIH - NCI Tran, Eric 1 147163724 Lu, Yong-Chen NIH - NCI NCI Lu, Yong-Chen (NCI) 2 147163722 Robbins, Paul NIH - NCI NCI Robbins, Paul (NCI) 3 147163721 Rosenberg, Steven NIH - NCI NCI Rosenberg, Steven (NCI) 4 147163723 Tran, Eric NIH - NCI Tran, Eric 1 147163724 Lu, Yong-Chen NIH - NCI NCI Lu, Yong-Chen (NCI) 2 147163722 Robbins, Paul NIH - NCI NCI Robbins, Paul (NCI) 3 147163721 Rosenberg, Steven NIH - NCI NCI Rosenberg, Steven (NCI) 4 147158242 A Genomics-based Method For Developing Personalized Adoptive Cell Therapies For Cancer By Targeting Tumor-specific Mutations E-229-2014-0 Filing authorized NCI 83709866 Burke, Andrew burkear@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC burkear@nih.gov?subject=Web Inquiry on [TAB-4157] T-Cell Therapy Against Patient-Specific Cancer Mutations&body=Please send me information about technology [TAB-4157] T-Cell Therapy Against Patient-Specific Cancer Mutations.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Burke, Andrew<br><a href="mailto:burkear@nih.gov?subject=Web Inquiry on [TAB-4157] T-Cell Therapy Against Patient-Specific Cancer Mutations&body=Please send me information about technology [TAB-4157] T-Cell Therapy Against Patient-Specific Cancer Mutations.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">burkear@nih.gov</a><br> 147166976 E-229-2014-0 E-229-2014-0-PCT-01 Methods of Isolating T Cells Having Antigenic Specificity for a Cancer-Specific Mutation PCT Patent Cooperation Treaty PCT/US2014/058805 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2014/058805<br />Filed on 2014-10-02<br />Status: Expired 147166977 E-229-2014-0 E-229-2014-0-AU-02 Methods of Isolating T Cells Having Antigenic Specificity for a Cancer-Specific Mutation National Stage Australia 2014407540 2014407540 Issued Australia <br />National Stage 2014407540<br />Filed on 2014-10-02<br />Status: Issued 147166978 E-229-2014-0 E-229-2014-0-CA-03 Methods of Isolating T Cells Having Antigenic Specificity for a Cancer-Specific Mutation National Stage Canada 2963364 Pending Canada <br />National Stage 2963364<br />Filed on 2014-10-02<br />Status: Pending 147166979 E-229-2014-0 E-229-2014-0-CN-04 Methods of Isolating T Cells Having Antigenic Specificity for a Cancer-Specific Mutation National Stage China 201480082922.X Abandoned China <br />National Stage 201480082922.X<br />Filed on 2014-10-02<br />Status: Abandoned 147166980 E-229-2014-0 E-229-2014-0-EP-05 Methods of Isolating T Cells Having Antigenic Specificity for a Cancer-Specific Mutation National Stage European Patent 14790878.4 Abandoned European Patent <br />National Stage 14790878.4<br />Filed on 2014-10-02<br />Status: Abandoned 147166981 E-229-2014-0 E-229-2014-0-JP-06 Methods of Isolating T Cells Having Antigenic Specificity for a Cancer-Specific Mutation National Stage Japan 6599450 2017-517677 Issued Japan <br />National Stage 2017-517677<br />Filed on 2014-10-02<br />Status: Issued 147166982 E-229-2014-0 E-229-2014-0-US-07 METHODS OF ISOLATING T CELLS HAVING ANTIGENIC SPECIFICITY FOR A CANCER-SPECIFIC MUTATION National Stage US 10,973,894 15/515,055 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10973894 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10973894">10,973,894</a><br />Filed on 2014-10-02<br />Status: Issued 147166983 E-229-2014-0 E-229-2014-0-JP-08 METHODS FOR ISOLATING T CELLS HAVING ANTIGEN SPECIFICITY TO CANCER SPECIFIC MUTATIONS DIV Japan 6878544 2019-182421 Issued Japan <br />Divisional (DIV) 2019-182421<br />Filed on 2019-10-02<br />Status: Issued 147166984 E-229-2014-0 E-229-2014-0-EP-09 Methods of Isolating T Cells Having Antigenic Specificity for a Cancer-Specific Mutation DIV European Patent 20212578.7 Pending European Patent <br />Divisional (DIV) 20212578.7<br />Filed on 2020-12-08<br />Status: Pending 147166985 E-229-2014-0 E-229-2014-0-US-10 METHODS OF ISOLATING T CELLS HAVING ANTIGENIC SPECIFICITY FOR A CANCER-SPECIFIC MUTATION CON US 12,171,818 17/195,072 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12171818 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12171818">12,171,818</a><br />Filed on 2021-03-08<br />Status: Issued 147166986 E-229-2014-0 E-229-2014-0-AU-11 Methods of Isolating T Cells Having Antigenic Specificity for a Cancer-Specific Mutation DIV Australia 2021202223 2021202223 Issued Australia <br />Divisional (DIV) 2021202223<br />Filed on 2021-04-13<br />Status: Issued 147166987 E-229-2014-0 E-229-2014-0-JP-12 METHODS FOR ISOLATING T CELLS HAVING ANTIGENIC SPECIFICITY FOR CANCER SPECIFIC MUTATIONS DIV Japan 7096397 2021-076293 Issued Japan <br />Divisional (DIV) 2021-076293<br />Filed on 2021-04-28<br />Status: Issued 147166988 E-229-2014-0 E-229-2014-0-JP-13 METHODS FOR ISOLATING T CELLS HAVING ANTIGENIC SPECIFICITY FOR CANCER SPECIFIC MUTATIONS DIV Japan 7340144 2022-101099 Issued Japan <br />Divisional (DIV) 2022-101099<br />Filed on 2022-06-23<br />Status: Issued 147173986 Cholangiocarcinoma 147173987 Immunogenic 147173988 Rosenberg 147173989 T-cell 147173991 Tran TAB-4373 147157667 A Viral Exposure Signature to Define and Detect Early Onset Hepatocellular Carcinoma NCI Collaboration, Diagnostics, Licensing, Oncology Collaboration Diagnostics Licensing Oncology Jinping Liu, Wei Tang, Xin Wei Wang <h2>Summary:</h2> <p>NCI seeks proposals from parties interested in co-development and licensing opportunities to employ biomarker viral exposure signature in diagnostic assays of early onset HCC.</p> <h2>Description of Technology:</h2> <p>Early detection of liver cancer, such as hepatocellular carcinoma (HCC), is key to improve cancer-related mortality. More than 800,000 people are diagnosed with this cancer each year throughout the world. Liver cancer is also a leading cause of cancer deaths worldwide, accounting for more than 700,000 deaths each year. Currently, millions of Americans and possibly billions in the world are considered at risk for developing liver cancer. Individuals are considered at risk for developing liver cancer if they have underlying chronic liver diseases such as fibrosis and cirrhosis which in turn may be caused by viral infections and inflammation. However, this risk greatly varies among individuals and the current methods for early detection and surveillance are inadequate.</p> <p>Scientists at the National Cancer Institute&rsquo;s (NCI) Laboratory of Human Carcinogenesis established a biomarker signature of viral infection that can predict HCC among at-risk individuals up to 7 years prior to their clinical diagnosis. This viral exposure signature has been identified through serological profiling of individuals from a case-control study and validated in a cohort of at-risk individuals who were followed up to 20 years for the development of HCC. The specificity and sensitivity of this biomarker signature is superior to current available methods of diagnosis such as alpha-fetoprotein screening.&nbsp;</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Diagnostic assay for early detection and surveillance of HCC</li> <li>Companion diagnostics for HCC therapeutic development</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>The large market for hepatocellular carcinoma is in need of improved diagnostics</li> <li>Detection of cancer patients from at-risk individuals up to 7 years prior to clinical diagnosis</li> <li>Potential competitive cost, easy to implement</li> <li>Serological profiling allows easy access to patient samples</li> </ul> 2020-01-15 2026-04-24 2020-12-15 2026-04-24 2020-01-15 Biomarker, HCC, hepatocellular carcinoma, Liver cancer, viral infection, Wang False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-12-15 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-024-2009 E-101-2016 147164491 Wang, Xin Wei NIH - NCI NCI Wang, Xin Wei (NCI) 1 147164493 Liu, Jinping NIH - NCI NCI Liu, Jinping (NCI) 2 147164492 Tang, Wei NIH - NCI NCI Tang, Wei (NCI) 3 147164491 Wang, Xin Wei NIH - NCI NCI Wang, Xin Wei (NCI) 1 147164493 Liu, Jinping NIH - NCI NCI Liu, Jinping (NCI) 2 147164492 Tang, Wei NIH - NCI NCI Tang, Wei (NCI) 3 147158147 A Viral Exposure Defines Nature Defines Early Onset Hepatocellular Carcinoma E-174-2019-0 Filing authorized NCI 83691647 Chang, Kevin changke@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB changke@mail.nih.gov?subject=Web Inquiry on [TAB-4373] A Viral Exposure Signature to Define and Detect Early Onset Hepatocellular Carcinoma&body=Please send me information about technology [TAB-4373] A Viral Exposure Signature to Define and Detect Early Onset Hepatocellular Carcinoma.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Chang, Kevin<br><a href="mailto:changke@mail.nih.gov?subject=Web Inquiry on [TAB-4373] A Viral Exposure Signature to Define and Detect Early Onset Hepatocellular Carcinoma&body=Please send me information about technology [TAB-4373] A Viral Exposure Signature to Define and Detect Early Onset Hepatocellular Carcinoma.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">changke@mail.nih.gov</a><br> 147161150 E-174-2019-0 E-174-2019-0-PCT-02 A VIRAL EXPOSURE SIGNATURE FOR DETECTION OF EARLY STAGE HEPATOCELLULAR CARCINOMA PCT Patent Cooperation Treaty PCT/US2020/055077 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2020/055077<br />Filed on 2020-10-09<br />Status: Expired 147168515 E-174-2019-0 E-174-2019-0-US-01 A VIRAL EXPOSURE SIGNATURE FOR DETECTION OF EARLY STAGE HEPATOCELLULAR CARCINOMA PRV US 62/914,138 Abandoned US <br />Provisional (PRV) 62/914,138<br />Filed on 2019-10-11<br />Status: Abandoned 147168516 E-174-2019-0 E-174-2019-0-CN-03 A VIRAL EXPOSURE SIGNATURE FOR DETECTION OF EARLY STAGE HEPATOCELLULAR CARCINOMA National Stage China ZL202080071446.7 202080071446.7 Issued China <br />National Stage 202080071446.7<br />Filed on 2020-10-09<br />Status: Issued 147168517 E-174-2019-0 E-174-2019-0-US-04 A VIRAL EXPOSURE SIGNATURE FOR DETECTION OF EARLY STAGE HEPATOCELLULAR CARCINOMA National Stage US 12,571,796 17/766,015 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12571796 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12571796">12,571,796</a><br />Filed on 2022-04-01<br />Status: Issued 147173045 Biomarker 147173046 HCC 147173047 hepatocellular carcinoma 147173048 Liver cancer 147173049 viral infection 147173050 Wang TAB-4200 147157485 A Preclinical Orthotopic Model for Glioblastoma Multiforme that Represents Key Pathways Aberrant in Human Brain Cancer NCI Licensing, Neurology, Oncology, Research Materials Licensing Neurology Oncology Research Materials Rajaa El Meskini, Michelle Gumprecht, Alan Kulaga, Anthony Lacovelli, Zoe Ohler, Terry Van Dyke <h2>Description of Technology:</h2> <p>Current therapies for glioblastoma multiforme (GBM), the highest grade malignant brain tumor, are mostly ineffective, and better preclinical model systems are needed to increase the successful translation of drug discovery efforts into the clinic. Scientists at the National Cancer Institute (NCI) have developed and characterized an orthotopic genetically engineered mouse (GEM)-derived model of GBM that closely recapitulates various human GBM subtypes and is useful for preclinical evaluation of candidate therapeutics. The GEM-derived GBM model harbors perturbations in the receptor tyrosine kinase (RTK), phosphoinositide 3-kinase (PI3K) and retinoblastoma (RB) tumor suppressor networks and develops spontaneous p53 aberrations upon induction of the constitutively active mutant KRASG12D and deletion of phosphatase and tensin homolog (PTEN) alleles; the orthotopically implanted mice are referred to as &lsquo;TRP&rsquo; mice. The TRP mice develop high grade GBM that are histologically similar to human GBM within weeks allowing the creation of large preclinical cohorts that are tractable for therapeutic evaluation.&nbsp;</p> <p><strong>Figure:&nbsp;Orthotopic GBM model characterization&nbsp;</strong></p> <p><img alt="" src="https://nih.technologypublisher.com/files/sites/image_for_e-264-20141.png" style="height:551px; width:600px" /></p> <p>(A) Tumor cells were isolated from TRP grade IV astrocytoma and cultured for several passages prior to intracranial injection into syngeneic mouse brains, or cells were implanted directly. (B) Both methods resulted in grade IV astrocyomas. Orthotopic tumors have large numbers of variably sized irregular blood vessels (*). Enlarged images of areas labeled X and Y are shown in panel C. (C) Orthotopic GBMs feature necrotic foci (N in region labeled X) in central regions that are lined by pseudopalisading tumor cells (P). The invasive tumor cells often track along adjacent small blood vessels (arrows in region labeled Y), as well as diffusely invading through the recipient&rsquo;s neuropil. Two images are shown for each marker stain; in the second, invasion is indicated by &lsquo;I&rsquo; where orthotopic tumors contain foci of extensive invasion into the adjacent recipient normal brain. Tumor cells express variable levels of T121 with increased levels at the invasive edge highlighting individual invading tumor cells (T121 and T121/I). GFAP expression is heterogeneous with greater numbers of negative cells at the periphery (GFAP and GFAP/I). Nestin expression is also greater at the invasive front (Nestin and Nestin/I). Most tumor cells express Olig-2 (Olig-2 and Olig-2/I) and Sox-2 (Sox-2 and Sox-2/I).</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Tractable mouse model of human glioblastoma multiforme for preclinical evaluation of GBM therapies&nbsp;</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Rapid preclinical evaluation of therapeutics. Primary cells from the GEM-GBM injected orthotopically into immune competent syngeneic mice brains induce grade IV tumors within 2 to 3 weeks.</li> <li>The GEM-GBM model represents a range of GBM cell types, recapitulating the heterogeneous cell population found in human GBM.&nbsp;</li> <li>GBM tumors are distinct and measurable on MRI scans and DCE-MRI properties have been described</li> <li>Superior to human cell xenograft models: syngeneic immunocompetent model allows for the evaluation of checkpoint inhibitors and other immunotherapeutic drugs.</li> </ul> 2020-01-15 2026-04-24 2020-12-15 2026-04-24 2020-01-15 Brain Cancer, GBM, GEM, Genetically Engineered Mouse, Meskini, mouse model, Multiforme, Ohler Weaver, Orthotopic Glioblastoma False True Prototype True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-12-15 52406769 Prototype 52406769 NCI 37470483 Website Abstract 147162437 El Meskini R, et al. A preclinical orthotopic model for glioblastoma recapitulates key features of human tumors and demonstrates sensitivity to a combination of MEK and PI3K pathway inhibitors. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4283649/ <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4283649/">El Meskini R, et al. A preclinical orthotopic model for glioblastoma recapitulates key features of human tumors and demonstrates sensitivity to a combination of MEK and PI3K pathway inhibitors.</a> 147163886 Ohler, Zoe NIH - NCI Leidos Ohler, Zoe (Leidos) 1 147163887 El Meskini, Rajaa NIH - NCI Leidos El Meskini, Rajaa (Leidos) 2 147163888 Lacovelli, Anthony NIH - NCI Leidos Lacovelli, Anthony (Leidos) 3 147163889 Kulaga, Alan NIH - NCI Leidos Kulaga, Alan (Leidos) 4 147163890 Gumprecht, Michelle NIH - NCI Leidos Gumprecht, Michelle (Leidos) 5 147163885 Van Dyke, Terry NIH - NCI Van Dyke, Terry 6 147163886 Ohler, Zoe NIH - NCI Leidos Ohler, Zoe (Leidos) 1 147163887 El Meskini, Rajaa NIH - NCI Leidos El Meskini, Rajaa (Leidos) 2 147163888 Lacovelli, Anthony NIH - NCI Leidos Lacovelli, Anthony (Leidos) 3 147163889 Kulaga, Alan NIH - NCI Leidos Kulaga, Alan (Leidos) 4 147163890 Gumprecht, Michelle NIH - NCI Leidos Gumprecht, Michelle (Leidos) 5 147163885 Van Dyke, Terry NIH - NCI Van Dyke, Terry 6 147158266 A Preclinical Orthotopic Model For Glioblastoma Multiforme That Represents Key Pathways Aberrant In Human Brain Cancer E-246-2014-0 Research Material NCI 83732917 Favila, Michelle michelle.favila@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC michelle.favila@nih.gov?subject=Web Inquiry on [TAB-4200] A Preclinical Orthotopic Model for Glioblastoma Multiforme that Represents Key Pathways Aberrant in Human Brain Cancer&body=Please send me information about technology [TAB-4200] A Preclinical Orthotopic Model for Glioblastoma Multiforme that Represents Key Pathways Aberrant in Human Brain Cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Favila, Michelle<br><a href="mailto:michelle.favila@nih.gov?subject=Web Inquiry on [TAB-4200] A Preclinical Orthotopic Model for Glioblastoma Multiforme that Represents Key Pathways Aberrant in Human Brain Cancer&body=Please send me information about technology [TAB-4200] A Preclinical Orthotopic Model for Glioblastoma Multiforme that Represents Key Pathways Aberrant in Human Brain Cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">michelle.favila@nih.gov</a><br> 147174184 Brain Cancer 147174185 GBM 147174186 GEM 147174187 Genetically Engineered Mouse 147174189 Meskini 147174190 mouse model 147174191 Multiforme 147174192 Ohler Weaver 147174194 Orthotopic Glioblastoma TAB-4175 147157460 Parental A2780 Ovarian Cancer Cell Line and Derivative Cisplatin-resistant and Adriamycin-resistant A2780 Cell Lines NCI Licensing, Oncology, Research Materials Licensing Oncology Research Materials Stuart Aaronson, Nelson Ellmore (Estate) <h2>Description of Technology:</h2> <p>Ovarian cancer is one of the most common and lethal types of gynecological malignancies worldwide, accounting for approximately 295,000 new cases and 185,000 deaths annually. The high lethality rate is due to multiple reasons, including recurrence and the resistance of recurrent tumors to chemotherapy. Cell line models are crucial for preclinical cancer studies, to identify mechanisms of disease, to study drug resistance, and to screen for candidate therapeutics.&nbsp;</p> <p>Researchers at the National Cancer Institute (NCI), Laboratory of Cellular and Molecular Biology have derived a cell line, A2780, from a patient with metastatic ovarian adenocarcinoma who was not exposed to any anti-cancer agents before tumor extraction. This cell line forms tumors in nude mice and can be used to evaluate the effects of anti-cancer agents on ovarian cancer. Furthermore, cisplatin- (A2780CIS) and adriamycin- resistant (A2780ADR) derivatives have been developed by chronic exposure of the parental cell line to cisplatin and adriamycin, respectively. These lines show cross-resistance to other agents such as melphalan, vinblastine or irradiation, and can be used to study the molecular basis of drug resistance in ovarian cancer.&nbsp;</p> <p>NCI is seeking parties to non-exclusively license these ovarian cancer cell lines.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Research tool for drug screen and related preclinical studies of ovarian cancer therapeutics</li> <li>Research tool for mechanistic studies of ovarian cancer such as the basis of drug resistance</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Well-characterized ovarian cancer cell lines</li> <li>Parental A2780 may be used to generate other drug-resistant cell lines through exposure to low concentrations of other agents</li> </ul> 2020-01-15 2026-04-24 2020-12-15 2026-04-24 2020-01-15 A2780, Aaronson, adriamycin, CISPLATIN, drug resistance, IRRADIATION, Melphalan, OVARIAN CANCER, VINBLASTINE False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-12-15 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147161944 Westin EH, et al. Differential expression of the amv gene in human hematopoietic cells. https://www.ncbi.nlm.nih.gov/pubmed/6954533 <a href="https://www.ncbi.nlm.nih.gov/pubmed/6954533">Westin EH, et al. Differential expression of the amv gene in human hematopoietic cells.</a> 147162331 Beaufort CM, et al. Ovarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypes. https://www.ncbi.nlm.nih.gov/pubmed/25230021 <a href="https://www.ncbi.nlm.nih.gov/pubmed/25230021">Beaufort CM, et al. Ovarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypes.</a> 147162369 Eva A, et al. Cellular genes analogous to retroviral onc genes are transcribed in human tumour cells. https://www.ncbi.nlm.nih.gov/pubmed/6173755 <a href="https://www.ncbi.nlm.nih.gov/pubmed/6173755">Eva A, et al. Cellular genes analogous to retroviral onc genes are transcribed in human tumour cells.</a> 147163782 Aaronson, Stuart NIH - NCI Aaronson, Stuart 1 147163783 Ellmore (Estate), Nelson NIH - NCI NCI Ellmore (Estate), Nelson (NCI) 2 147163782 Aaronson, Stuart NIH - NCI Aaronson, Stuart 1 147163783 Ellmore (Estate), Nelson NIH - NCI NCI Ellmore (Estate), Nelson (NCI) 2 147157800 Parental A2780 Ovarian Cancer Cell Line And Derivative Cisplatin-resistant And Adriamycin-resistant A2780 Cell Lines E-018-2020-0 Research Material NCI 83694133 Gulay French, Suna suna.gulay@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB suna.gulay@nih.gov?subject=Web Inquiry on [TAB-4175] Parental A2780 Ovarian Cancer Cell Line and Derivative Cisplatin-resistant and Adriamycin-resistant A2780 Cell Lines&body=Please send me information about technology [TAB-4175] Parental A2780 Ovarian Cancer Cell Line and Derivative Cisplatin-resistant and Adriamycin-resistant A2780 Cell Lines.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Gulay French, Suna<br><a href="mailto:suna.gulay@nih.gov?subject=Web Inquiry on [TAB-4175] Parental A2780 Ovarian Cancer Cell Line and Derivative Cisplatin-resistant and Adriamycin-resistant A2780 Cell Lines&body=Please send me information about technology [TAB-4175] Parental A2780 Ovarian Cancer Cell Line and Derivative Cisplatin-resistant and Adriamycin-resistant A2780 Cell Lines.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">suna.gulay@nih.gov</a><br> 147169600 A2780 147169602 Aaronson 147169603 adriamycin 147169604 CISPLATIN 147169605 drug resistance 147169606 IRRADIATION 147169608 Melphalan 147169609 OVARIAN CANCER 147169610 VINBLASTINE TAB-4116 147157398 A Preclinical Model for Mutant Human EGFR-driven Lung Adenocarcinoma NCI Licensing, Oncology, Research Materials Licensing Oncology Research Materials Simone Difilippantonio, Lionel Feigenbaum, Deborah Householder, Philip Martin, Zoe Ohler, Terry Van Dyke <h2>Description of Technology:</h2> <p>Previously described epidermal growth factor receptor- (EGFR) driven tumor mouse models develop diffuse tumors, which are dissimilar to human lung tumor morphology and difficult to measure by CT and MRI scans. Scientists at the National Cancer Institute (NCI) have developed and characterized a genetically engineered mouse (GEM) model of human EGFR-driven tumor model (hEGFR-TL) that recapitulates the discrete lung tumor nodules similar to those found in human lung tumor morphology. Individual tumor nodules can be easily measured by live animal imaging and the nodules can be harvested and isolated from surrounding lung tissue post-treatment, making this a more tractable model for human non-small cell lung adenocarcinoma. The lungs express an EGFR transgene that harbors two mutations (&lsquo;L858R&rsquo; and &lsquo;T790M&rsquo;) which render the lung tumors resistant to first generation EGFR inhibitors and are useful for evaluating drugs targeting resistant tumors.</p> <p>&nbsp;</p> <p><img alt="" src="https://nih.technologypublisher.com/files/sites/image_for_e-041-20145.png" /></p> <h2>Potential Commercial Applications:</h2> <ul> <li>Preclinical in vivo screen of therapeutics targeting tumor kinase inhibitors such as EGFR-mediated lung tumors, and identification of new biomarkers in this pathway&nbsp;</li> <li>Evaluation of novel therapeutics in inducible models of EGFR-driven drug resistant lung adenocarcinoma</li> <li>Dermatology Research</li> <li>Immunology, Inflammation and Autoimmunity Research</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Lung tumor development and response to drugs can be monitored by MRI or CT scanning</li> <li>Contain a human EGFR transgene (either TRE-EGFR-L858R or TRE-EGFR-L858R-T790M models are available) and an activating transgene (CCSP-rtTA) to direct expression of mutant EGFR to the Clara cells</li> </ul> 2020-01-15 2026-04-24 2020-12-15 2026-04-24 2020-01-15 EGFR, Epidermal Growth Factor Receptor, GEM, Genetically Engineered Mouse, Lung adenocarcinoma, lung cancer, mouse model, Ohler Weaver, respiratory False True Prototype True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-12-15 52406769 Prototype 52406769 NCI 37470483 Website Abstract 147162258 Nakamura Y, et al., Near infrared photoimmunotherapy in a transgenic mouse model of spontaneous epidermal growth factor receptor (EGFR)-expressing lung cancer. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5335921/ <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5335921/">Nakamura Y, et al., Near infrared photoimmunotherapy in a transgenic mouse model of spontaneous epidermal growth factor receptor (EGFR)-expressing lung cancer.</a> 147163562 Difilippantonio, Simone NIH - NCI Leidos Difilippantonio, Simone (Leidos) 1 147163561 Feigenbaum, Lionel NIH - NCI Leidos Feigenbaum, Lionel (Leidos) 2 147163565 Householder, Deborah NIH - NCI NCI Householder, Deborah (NCI) 3 147163566 Martin, Philip NIH - NCI Martin, Philip 4 147163564 Ohler, Zoe NIH - NCI Leidos Ohler, Zoe (Leidos) 5 147163563 Van Dyke, Terry NIH - NCI Van Dyke, Terry 6 147163562 Difilippantonio, Simone NIH - NCI Leidos Difilippantonio, Simone (Leidos) 1 147163561 Feigenbaum, Lionel NIH - NCI Leidos Feigenbaum, Lionel (Leidos) 2 147163565 Householder, Deborah NIH - NCI NCI Householder, Deborah (NCI) 3 147163566 Martin, Philip NIH - NCI Martin, Philip 4 147163564 Ohler, Zoe NIH - NCI Leidos Ohler, Zoe (Leidos) 5 147163563 Van Dyke, Terry NIH - NCI Van Dyke, Terry 6 147157845 A New Model For Mutant EGFR-driven Lung Adenocarcinoma That Develops Nodular, Discrete Tumors Useful For Preclinical Evaluation And Biomarker Discovery E-041-2014-0 Research Material NCI 83704821 Nguyen-Antczak, Lauren lauren.nguyen-antczak@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-4116] A Preclinical Model for Mutant Human EGFR-driven Lung Adenocarcinoma&body=Please send me information about technology [TAB-4116] A Preclinical Model for Mutant Human EGFR-driven Lung Adenocarcinoma.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Nguyen-Antczak, Lauren<br><a href="mailto:lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-4116] A Preclinical Model for Mutant Human EGFR-driven Lung Adenocarcinoma&body=Please send me information about technology [TAB-4116] A Preclinical Model for Mutant Human EGFR-driven Lung Adenocarcinoma.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">lauren.nguyen-antczak@nih.gov</a><br> 147170045 EGFR 147170047 Epidermal Growth Factor Receptor 147170049 GEM 147170051 Genetically Engineered Mouse 147170052 Lung adenocarcinoma 147170053 lung cancer 147170054 mouse model 147170056 Ohler Weaver 147170057 respiratory TAB-3968 147157248 Molecular Classification of Primary Mediastinal Large B Cell Lymphoma Using Formalin-Fixed, Paraffin-Embedded Tissue Specimens NCI Collaboration, Diagnostics, Licensing, Oncology Collaboration Diagnostics Licensing Oncology Rita Braziel, Wing Chan, James Cook, Jan Delabie, Kai Fu, Randy Gascoyne, Timothy Greiner, Elias Guerri, Elias Guerri, Elias Guerri, Elaine Jaffe, Anja Mottok, German Ott, Lisa Rimsza, Andreas Rosenwald, David Scott, Erlend Smeland, Joo Song, Louis Staudt, Christian Steidl, Dennis Weisenburger, George Wright <h2>Description of Technology:</h2> <p>Primary mediastinal B-cell lymphoma (PMBCL) is an aggressive type of non-Hodgkin lymphoma that mostly occurs in people between the ages of 30-40. It accounts for 5-7% of all aggressive lymphomas. The diagnosis of PMBCL is challenging as the histological features of PMBCL overlap with diffuse large B-cell lymphoma (DLBCL), another most common type of non-Hodgkin lymphoma. Available evidence suggests that PMBCL responds much more favorably to the DA-EPOCH-R chemotherapy regimen than to the standard R-CHOP regimen used to treat DLBCL. The diagnostic uncertainty of PMBCL can result in delayed and/or inappropriate treatment, serious harm, and even death of the patient, so there is a need to more precisely diagnose PMBCL.&nbsp;&nbsp;</p> <p>Researchers at the National Cancer Institute (NCI) have developed a gene expression-based assay comprising a set of 58 nucleic acid probes that measure the abundance of selected mRNA species using the Nanostring platform. This assay can be used successfully to better distinguish PMBCL from DLBCL and applied to further classify DLBCL into well-established cell-of-origin subtypes. This test can be applied by clinicians to support the pathological diagnosis of PMBCL, and therefore identify a group of patients whose tumors are characterized by a distinct underlying biology.&nbsp;&nbsp;</p> <p>The NCI seeks licensees and/or co-development partners to develop this technology toward commercialization.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Diagnosis of PMBCL</li> <li>Distinguishing PMBCL from DLBCL</li> <li>The invention could be used: <ul> <li>in the near term as a clinical tool in the initial diagnostic evaluation of suspected PMBCL, which is required in the WHO guidelines for diagnosis of hematologic malignancies</li> <li>as an entry criterion for clinical trials in order to include those patients for which the efficacy of a given treatment likely depends on the molecular subtype of their disease&nbsp;</li> </ul> </li> <li>Targeted therapies appropriate for each DLBCL subtype</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Easy to integrate into current clinical practice of cancer diagnosis as the assay can be performed using routinely available formalin-fixed, paraffin-embedded (FFPE) biopsies</li> <li>Superior prognostic ability over traditional histopathological diagnosis</li> </ul> 2020-01-15 2026-04-24 2020-01-15 2026-04-24 2020-01-15 assay, Diffuse Large B Cell Lymphoma, DLBCL, FFPE, Formalin-fixed, GENE EXPRESSION, paraffin-embedded biopsies, PMBCL, Primary Mediastinal Large B Cell Lymphoma, Staudt False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-01-15 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147162044 Mottok A, et al. Molecular classification of primary mediastinal large B-cell lymphoma using routinely available tissue specimens. https://www.ncbi.nlm.nih.gov/pubmed/30257882 <a href="https://www.ncbi.nlm.nih.gov/pubmed/30257882">Mottok A, et al. Molecular classification of primary mediastinal large B-cell lymphoma using routinely available tissue specimens.</a> 147162200 Mottok A, et al. Integrative genomic analysis identifies key pathogenic mechanisms in primary mediastinal large B-cell lymphoma. https://www.ncbi.nlm.nih.gov/pubmed/31292115 <a href="https://www.ncbi.nlm.nih.gov/pubmed/31292115">Mottok A, et al. Integrative genomic analysis identifies key pathogenic mechanisms in primary mediastinal large B-cell lymphoma.</a> 147163052 Staudt, Louis NIH - NCI NCI Staudt, Louis (NCI) 1 147163055 Rimsza, Lisa Mayo Clinic, Arizona Rimsza, Lisa 2 147163056 Scott, David BC Cancer Scott, David 3 147163053 Wright, George NIH - NCI NCI Wright, George (NCI) 4 147163057 Mottok, Anja BC Cancer Mottok, Anja 5 147163058 Steidl, Christian BC Cancer Steidl, Christian 6 147163054 Jaffe, Elaine NIH - NCI NCI Jaffe, Elaine (NCI) 7 147163065 Gascoyne, Randy BC Cancer Gascoyne, Randy 8 147163073 Guerri, Elias Clinical Research Foundation Barcelona - August Pi i Sunyer Biomedical Research Institute (IDIBAPS) Guerri, Elias 9 147163072 Guerri, Elias Hospital Clinic of Barcelona [Hospital Clinico de Barcelona] Guerri, Elias 10 147163069 Guerri, Elias University of Barcelona [Universitat de Barcelona] Guerri, Elias 11 147163059 Rosenwald, Andreas University Of Wurzburg Rosenwald, Andreas 12 147163063 Fu, Kai University of Nebraska Medical Center Fu, Kai 13 147163061 Greiner, Timothy University of Nebraska Medical Center Greiner, Timothy 14 147163066 Smeland, Erlend Oslo University Hospital Smeland, Erlend 15 147163067 Delabie, Jan Oslo University Hospital Delabie, Jan 16 147163068 Braziel, Rita Oregon Health and Science University (OHSU) Braziel, Rita 17 147163060 Chan, Wing City of Hope National Medical Center Chan, Wing 18 147163071 Song, Joo City of Hope National Medical Center Song, Joo 19 147163062 Weisenburger, Dennis City of Hope National Medical Center Weisenburger, Dennis 20 147163064 Ott, German Robert Bosch Stiftung Ott, German 21 147163070 Cook, James Cleveland Clinic Foundation Cook, James 22 147163052 Staudt, Louis NIH - NCI NCI Staudt, Louis (NCI) 1 147163055 Rimsza, Lisa Mayo Clinic, Arizona Rimsza, Lisa 2 147163056 Scott, David BC Cancer Scott, David 3 147163053 Wright, George NIH - NCI NCI Wright, George (NCI) 4 147163057 Mottok, Anja BC Cancer Mottok, Anja 5 147163058 Steidl, Christian BC Cancer Steidl, Christian 6 147163054 Jaffe, Elaine NIH - NCI NCI Jaffe, Elaine (NCI) 7 147163065 Gascoyne, Randy BC Cancer Gascoyne, Randy 8 147163073 Guerri, Elias Clinical Research Foundation Barcelona - August Pi i Sunyer Biomedical Research Institute (IDIBAPS) Guerri, Elias 9 147163072 Guerri, Elias Hospital Clinic of Barcelona [Hospital Clinico de Barcelona] Guerri, Elias 10 147163069 Guerri, Elias University of Barcelona [Universitat de Barcelona] Guerri, Elias 11 147163059 Rosenwald, Andreas University Of Wurzburg Rosenwald, Andreas 12 147163063 Fu, Kai University of Nebraska Medical Center Fu, Kai 13 147163061 Greiner, Timothy University of Nebraska Medical Center Greiner, Timothy 14 147163066 Smeland, Erlend Oslo University Hospital Smeland, Erlend 15 147163067 Delabie, Jan Oslo University Hospital Delabie, Jan 16 147163068 Braziel, Rita Oregon Health and Science University (OHSU) Braziel, Rita 17 147163060 Chan, Wing City of Hope National Medical Center Chan, Wing 18 147163071 Song, Joo City of Hope National Medical Center Song, Joo 19 147163062 Weisenburger, Dennis City of Hope National Medical Center Weisenburger, Dennis 20 147163064 Ott, German Robert Bosch Stiftung Ott, German 21 147163070 Cook, James Cleveland Clinic Foundation Cook, James 22 147158141 Molecular Classification Of Primary Mediastinal Large B Cell Lymphoma Using Formalin-fixed, Paraffin-embedded Tissue Specimens E-172-2017-0 Filing authorized BC Cancer, Mayo Clinic, Arizona, NCI 147162546 Molecular Classification Of Primary Mediastinal Large B Cell Lymphoma Using Formalin-fixed, Paraffin-embedded Tissue Specimens E-172-2017-1 Filing authorized BC Cancer, City of Hope National Medical Center, Cleveland Clinic Foundation, Clinical Research Foundation Barcelona - August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Hospital Clinic of Barcelona [Hospital Clinico de Barcelona], Mayo Clinic, Arizona, NCI, Oregon Health and Science University (OHSU), Oslo University Hospital, Robert Bosch Stiftung, University of Barcelona [Universitat de Barcelona], University of Nebraska Medical Center, University Of Wurzburg 83707317 Bhattacharya, Ramona ramona.bhattacharya@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB ramona.bhattacharya@nih.gov?subject=Web Inquiry on [TAB-3968] Molecular Classification of Primary Mediastinal Large B Cell Lymphoma Using Formalin-Fixed, Paraffin-Embedded Tissue Specimens&body=Please send me information about technology [TAB-3968] Molecular Classification of Primary Mediastinal Large B Cell Lymphoma Using Formalin-Fixed, Paraffin-Embedded Tissue Specimens.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Bhattacharya, Ramona<br><a href="mailto:ramona.bhattacharya@nih.gov?subject=Web Inquiry on [TAB-3968] Molecular Classification of Primary Mediastinal Large B Cell Lymphoma Using Formalin-Fixed, Paraffin-Embedded Tissue Specimens&body=Please send me information about technology [TAB-3968] Molecular Classification of Primary Mediastinal Large B Cell Lymphoma Using Formalin-Fixed, Paraffin-Embedded Tissue Specimens.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">ramona.bhattacharya@nih.gov</a><br> 147161145 E-172-2017-0 E-172-2017-0-US-01 METHOD FOR DETERMINING LYMPHOMA TYPE PRV US 62/519,728 Abandoned US <br />Provisional (PRV) 62/519,728<br />Filed on 2017-06-14<br />Status: Abandoned 147165605 E-172-2017-1 E-172-2017-1-PCT-01 METHOD FOR DETERMINING LYMPHOMA TYPE PCT Patent Cooperation Treaty PCT/US2018/036084 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2018/036084<br />Filed on 2018-06-05<br />Status: Expired 147165606 E-172-2017-1 E-172-2017-1-EP-02 METHOD FOR DETERMINING LYMPHOMA TYPE National Stage European Patent 3638814 18733500.5 Issued European Patent <br />National Stage 18733500.5<br />Filed on 2020-01-14<br />Status: Issued 147165607 E-172-2017-1 E-172-2017-1-US-03 METHOD FOR DETERMINING LYMPHOMA TYPE CIP US 11,646,099 16/713,528 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11646099 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11646099">11,646,099</a><br />Filed on 2019-12-13<br />Status: Issued 147165609 E-172-2017-1 E-172-2017-1-FR-01 METHOD FOR DETERMINING LYMPHOMA TYPE EP France 3638814 18733500.5 Issued France <br />European patent (EP) 18733500.5<br />Filed on 2020-01-14<br />Status: Issued 147165610 E-172-2017-1 E-172-2017-1-DE-01 METHOD FOR DETERMINING LYMPHOMA TYPE EP Germany 3638814 18733500.5 Issued Germany <br />European patent (EP) 18733500.5<br />Filed on 2020-01-14<br />Status: Issued 147165611 E-172-2017-1 E-172-2017-1-GB-01 METHOD FOR DETERMINING LYMPHOMA TYPE EP United Kingdom 3638814 18733500.5 Issued United Kingdom <br />European patent (EP) 18733500.5<br />Filed on 2020-01-14<br />Status: Issued 147172976 assay 147172977 Diffuse Large B Cell Lymphoma 147172978 DLBCL 147172979 FFPE 147172980 Formalin-fixed 147172981 GENE EXPRESSION 147172983 paraffin-embedded biopsies 147172985 PMBCL 147172987 Primary Mediastinal Large B Cell Lymphoma 147172988 Staudt TAB-4242 147157529 Improved Gene Therapy Vectors for the Treatment of Glycogen Storage Disease Type Ia (GSD-1a) NICHD Collaboration, Endocrinology, Licensing, Nephrology, Therapeutics Collaboration Endocrinology Licensing Nephrology Therapeutics Barry Byrne, Janice Chou <h2>Summary:</h2> <p>NICHD is seeking licensees for development&nbsp;of&nbsp;an adeno-associated viral (AAV) vectors for the treatment of glycogen storage disease type Ia (GSD-Ia).</p> <h2>Description of Technology:</h2> <p>GSD-Ia is an inherited disorder of metabolism associated with life-threatening hypoglycemia, hepatic malignancy, and renal failure caused by the deficiency of glucose-6-phosphatase-alpha (G6Pase-alpha or G6PC). Current therapy, which primarily consists of dietary modification, fails to prevent long-term complications in many patients, including growth failure, gout, pulmonary hypertension, renal dysfunction, osteoporosis, and hepatocellular adenomas (HCA). Gene therapy-based techniques, which directly address the underlying genetic deficiency driving the disorder, offer the prospect of long-term remission in patients with GSD-Ia.</p> <p>Researchers at the NIH <a href="https://www.nichd.nih.gov/Pages/index.aspx" rel="nofollow" target="_blank">National Institute for Child Health and Human Development</a>&nbsp;developed adeno-associated viral (AAV) vectors for the treatment of glycogen storage disease type Ia (GSD-Ia).This technology describes new AAV vectors for the delivery of corrective genes that express modified human G6Pase-alpha proteins, directed by the tissue-specific human G6PC promoter/enhancer.</p> <p>The NICHD inventor is also interested in the mechanisms by which GSD-1a may lead to hepatic malignancy and a collaboration project may be considered.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Gene therapy vector for the delivery of a corrective gene to treat of GSD-Ia.</li> <li>Useful in development of a combined pharmaceutical plus gene therapy approach to treat adult GSD-1a patients at risk of hepatocellular carcinoma.</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Protein coding sequences are modified from the wildtype human sequence for enhanced enzymatic activity.</li> </ul> 2021-04-30 2026-04-24 2021-04-30 2026-04-24 2021-04-30 Chou, GSD-1a, hepatic malignancy, hyperlipidemia, hypoglycemia, National Institute of Child Health and Human Development, NICHD False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-04-30 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-039-2015 147161903 Lee YM et al. Prevention of hepatocellular adenoma and correction of metabolic abnormalities in murine glycogen storage disease type Ia by gene therapy. Hepatology 2012 Nov;56(5):1719-29. https://pubmed.ncbi.nlm.nih.gov/22422504/ <a href="https://pubmed.ncbi.nlm.nih.gov/22422504/">Lee YM et al. Prevention of hepatocellular adenoma and correction of metabolic abnormalities in murine glycogen storage disease type Ia by gene therapy. Hepatology 2012 Nov;56(5):1719-29.</a> 147162291 Lee YM, et al. The upstream enhancer elements of the G6PC promoter are critical for optimal G6PC expression in murine glycogen storage disease type Ia. Mol Genet Metab. 2013 Nov;110(3):275-80. https://pubmed.ncbi.nlm.nih.gov/23856420/ <a href="https://pubmed.ncbi.nlm.nih.gov/23856420/">Lee YM, et al. The upstream enhancer elements of the G6PC promoter are critical for optimal G6PC expression in murine glycogen storage disease type Ia. Mol Genet Metab. 2013 Nov;110(3):275-80.</a> 147164018 Chou, Janice NICHD NICHD Chou, Janice (NICHD) 1 147164019 Byrne, Barry University of Florida Byrne, Barry 2 147164018 Chou, Janice NICHD NICHD Chou, Janice (NICHD) 1 147164019 Byrne, Barry University of Florida Byrne, Barry 2 147158357 The Enhancer Elements Upstream Of The Human G6PC Minimal Promoter Are Necessary For Efficient Hepatic G6PC Expression E-552-2013-0 Filing authorized NICHD, University of Florida 91800717 Hubbs, Alan hubbsa@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America Technology Transfer Center hubbsa@mail.nih.gov?subject=Web Inquiry on [TAB-4242] Improved Gene Therapy Vectors for the Treatment of Glycogen Storage Disease Type Ia (GSD-1a)&body=Please send me information about technology [TAB-4242] Improved Gene Therapy Vectors for the Treatment of Glycogen Storage Disease Type Ia (GSD-1a).&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Hubbs, Alan<br><a href="mailto:hubbsa@mail.nih.gov?subject=Web Inquiry on [TAB-4242] Improved Gene Therapy Vectors for the Treatment of Glycogen Storage Disease Type Ia (GSD-1a)&body=Please send me information about technology [TAB-4242] Improved Gene Therapy Vectors for the Treatment of Glycogen Storage Disease Type Ia (GSD-1a).&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">hubbsa@mail.nih.gov</a><br> 147161278 E-552-2013-0 E-552-2013-0-US-13 ADENO-ASSOCIATED VIRUS VECTORS FOR TREATMENT OF GLYCOGEN STORAGE DISEASE CON US 10,113,183 15/493,622 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10113183 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10113183">10,113,183</a><br />Filed on 2017-04-21<br />Status: Issued 147167619 E-552-2013-0 E-552-2013-0-US-01 ADENO-ASSOCIATED VIRUS VECTORS FOR TREATMENT OF GLYCOGEN STORAGE DISEASE PRV US 61/908,861 Abandoned US <br />Provisional (PRV) 61/908,861<br />Filed on 2013-11-26<br />Status: Abandoned 147167620 E-552-2013-0 E-552-2013-0-PCT-02 ADENO-ASSOCIATED VIRUS VECTORS FOR TREATMENT OF GLYCOGEN STORAGE DISEASE PCT Patent Cooperation Treaty PCT/US2014/067415 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2014/067415<br />Filed on 2014-11-25<br />Status: Expired 147167621 E-552-2013-0 E-552-2013-0-AU-03 ADENO-ASSOCIATED VIRUS VECTORS FOR TREATMENT OF GLYCOGEN STORAGE DISEASE National Stage Australia 2014354839 2014354839 Issued Australia <br />National Stage 2014354839<br />Filed on 2014-11-25<br />Status: Issued 147167622 E-552-2013-0 E-552-2013-0-BR-04 ADENO-ASSOCIATED VIRUS VECTORS FOR TREATMENT OF GLYCOGEN STORAGE DISEASE National Stage Brazil BR112016011997-5 BR112016011997-5 Issued Brazil <br />National Stage BR112016011997-5<br />Filed on 2014-11-25<br />Status: Issued 147167623 E-552-2013-0 E-552-2013-0-CA-05 ADENO-ASSOCIATED VIRUS VECTORS FOR TREATMENT OF GLYCOGEN STORAGE DISEASE National Stage Canada 2930872 2930872 Issued Canada <br />National Stage 2930872<br />Filed on 2014-11-25<br />Status: Issued 147167624 E-552-2013-0 E-552-2013-0-CN-06 ADENO-ASSOCIATED VIRUS VECTORS FOR TREATMENT OF GLYCOGEN STORAGE DISEASE National Stage China ZL201480074046.6 201480074046.6 Issued China <br />National Stage 201480074046.6<br />Filed on 2014-11-25<br />Status: Issued 147167625 E-552-2013-0 E-552-2013-0-CO-07 ADENO-ASSOCIATED VIRUS VECTORS FOR TREATMENT OF GLYCOGEN STORAGE DISEASE National Stage Colombia 33396 16162610 Abandoned Colombia <br />National Stage 16162610<br />Filed on 2016-06-21<br />Status: Abandoned 147167626 E-552-2013-0 E-552-2013-0-EP-08 ADENO-ASSOCIATED VIRUS VECTORS FOR TREATMENT OF GLYCOGEN STORAGE DISEASE National Stage European Patent 3074510 14812375.5 Issued European Patent <br />National Stage 14812375.5<br />Filed on 2014-11-25<br />Status: Issued 147167627 E-552-2013-0 E-552-2013-0-IL-09 ADENO-ASSOCIATED VIRUS VECTORS FOR TREATMENT OF GLYCOGEN STORAGE DISEASE National Stage Israel 245659 245659 Issued Israel <br />National Stage 245659<br />Filed on 2016-05-16<br />Status: Issued 147167628 E-552-2013-0 E-552-2013-0-JP-10 ADENO-ASSOCIATED VIRUS VECTORS FOR TREATMENT OF GLYCOGEN STORAGE DISEASE National Stage Japan 6649265 2016-554828 Issued Japan <br />National Stage 2016-554828<br />Filed on 2014-11-25<br />Status: Issued 147167629 E-552-2013-0 E-552-2013-0-MX-11 ADENO-ASSOCIATED VIRUS VECTORS FOR TREATMENT OF GLYCOGEN STORAGE DISEASE National Stage Mexico 375360 MX/a/2016/006774 Issued Mexico <br />National Stage MX/a/2016/006774<br />Filed on 2014-11-25<br />Status: Issued 147167630 E-552-2013-0 E-552-2013-0-US-12 Adeno-Associated Virus Vectors for Treatment of Glycogen Storage Disease National Stage US 9,644,216 15/038,979 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9644216 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9644216">9,644,216</a><br />Filed on 2016-05-24<br />Status: Issued 147167631 E-552-2013-0 E-552-2013-0-EP-14 ADENO-ASSOCIATED VIRUS VECTORS FOR TREATMENT OF GLYCOGEN STORAGE DISEASE DIV European Patent 3415620 18186594.0 Issued European Patent <br />Divisional (DIV) 18186594.0<br />Filed on 2018-07-31<br />Status: Issued 147167632 E-552-2013-0 E-552-2013-0-BE-15 ADENO-ASSOCIATED VIRUS VECTORS FOR TREATMENT OF GLYCOGEN STORAGE DISEASE EP Belgium 3074510 14812375.5 Issued Belgium <br />European patent (EP) 14812375.5<br />Filed on 2014-11-25<br />Status: Issued 147167633 E-552-2013-0 E-552-2013-0-CH-16 ADENO-ASSOCIATED VIRUS VECTORS FOR TREATMENT OF GLYCOGEN STORAGE DISEASE EP Switzerland 3074510 14812375.5 Issued Switzerland <br />European patent (EP) 14812375.5<br />Filed on 2014-11-25<br />Status: Issued 147167634 E-552-2013-0 E-552-2013-0-DE-17 ADENO-ASSOCIATED VIRUS VECTORS FOR TREATMENT OF GLYCOGEN STORAGE DISEASE EP Germany 3074510 14812375.5 Issued Germany <br />European patent (EP) 14812375.5<br />Filed on 2014-11-25<br />Status: Issued 147167635 E-552-2013-0 E-552-2013-0-ES-18 ADENO-ASSOCIATED VIRUS VECTORS FOR TREATMENT OF GLYCOGEN STORAGE DISEASE EP Spain 3074510 14812375.5 Issued Spain <br />European patent (EP) 14812375.5<br />Filed on 2014-11-25<br />Status: Issued 147167636 E-552-2013-0 E-552-2013-0-FR-19 ADENO-ASSOCIATED VIRUS VECTORS FOR TREATMENT OF GLYCOGEN STORAGE DISEASE EP France 3074510 14812375.5 Issued France <br />European patent (EP) 14812375.5<br />Filed on 2014-11-25<br />Status: Issued 147167637 E-552-2013-0 E-552-2013-0-GB-20 ADENO-ASSOCIATED VIRUS VECTORS FOR TREATMENT OF GLYCOGEN STORAGE DISEASE EP United Kingdom 3074510 14812375.5 Issued United Kingdom <br />European patent (EP) 14812375.5<br />Filed on 2014-11-25<br />Status: Issued 147167638 E-552-2013-0 E-552-2013-0-IT-21 ADENO-ASSOCIATED VIRUS VECTORS FOR TREATMENT OF GLYCOGEN STORAGE DISEASE EP Italy 3074510 14812375.5 Issued Italy <br />European patent (EP) 14812375.5<br />Filed on 2014-11-25<br />Status: Issued 147167639 E-552-2013-0 E-552-2013-0-NL-22 ADENO-ASSOCIATED VIRUS VECTORS FOR TREATMENT OF GLYCOGEN STORAGE DISEASE EP The Netherlands 3074510 14812375.5 Issued The Netherlands <br />European patent (EP) 14812375.5<br />Filed on 2014-11-25<br />Status: Issued 147167640 E-552-2013-0 E-552-2013-0-SE-23 ADENO-ASSOCIATED VIRUS VECTORS FOR TREATMENT OF GLYCOGEN STORAGE DISEASE EP Sweden 3074510 14812375.5 Issued Sweden <br />European patent (EP) 14812375.5<br />Filed on 2014-11-25<br />Status: Issued 147167641 E-552-2013-0 E-552-2013-0-US-24 ADENO-ASSOCIATED VIRUS VECTORS FOR TREATMENT OF GLYCOGEN STORAGE DISEASE CON US 11,060,110 16/148,435 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11060110 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11060110">11,060,110</a><br />Filed on 2018-10-01<br />Status: Issued 147167642 E-552-2013-0 E-552-2013-0-DE-25 ADENO-ASSOCIATED VIRUS VECTORS FOR TREATMENT OF GLYCOGEN STORAGE DISEASE EP Germany 3415620 18186594.0 Issued Germany <br />European patent (EP) 18186594.0<br />Filed on 2018-07-31<br />Status: Issued 147167643 E-552-2013-0 E-552-2013-0-FR-26 ADENO-ASSOCIATED VIRUS VECTORS FOR TREATMENT OF GLYCOGEN STORAGE DISEASE EP France 3415620 18186594.0 Issued France <br />European patent (EP) 18186594.0<br />Filed on 2018-07-31<br />Status: Issued 147167644 E-552-2013-0 E-552-2013-0-GB-27 ADENO-ASSOCIATED VIRUS VECTORS FOR TREATMENT OF GLYCOGEN STORAGE DISEASE EP United Kingdom 3415620 18186594.0 Issued United Kingdom <br />European patent (EP) 18186594.0<br />Filed on 2018-07-31<br />Status: Issued 147174903 Chou 147174905 GSD-1a 147174906 hepatic malignancy 147174907 hyperlipidemia 147174908 hypoglycemia 147174909 National Institute of Child Health and Human Development 147174910 NICHD TAB-4224 147157509 Monomeric and Oligomeric Compounds as Contraceptives and Endocrine Therapeutics NICHD Collaboration, Endocrinology, Licensing, Reproductive Health, Therapeutics Collaboration Endocrinology Licensing Reproductive Health Therapeutics Diana Blithe, Pranab Gupta, Bashir Kaskar, Min Lee, Ming-Teh Lin <h2>Summary:</h2> <p>NICHD is seeking research co-development partners and/or licensees for development of this invention as a male contraceptive.</p> <h2>Description of Technology:</h2> <p>The options for male contraceptives are limited. Research is ongoing to develop a male contraceptive based on hormonal activity. Testosterone is one of the hormones necessary in producing sperm.&nbsp; Testosterone is absolutely required as a hormone for male fertility. Derivatives of testosterone for male contraceptives currently in clinical trials are associated with estrogenic deficiency. This deficiency can cause several issues including, but not limited to, bone density loss, risk of obesity, cardiovascular disease, and/or ineffective carbohydrate or lipid metabolism.&nbsp;</p> <p>Researchers at the <em>Eunice Kennedy Shriver </em>National Institute of Child Health and Human Development (NICHD) have developed a new chemical entity and related embodiments of the following formula:&nbsp;</p> <p><img alt=" This invention discloses embodiments of the above compound, or a pharmaceutically acceptable salt, a prodrug, a solvate, or a tautomer thereof" src="https://nih.technologypublisher.com/files/sites/formula_1_for_e-141-2019_compound1.png" style="border-style:solid; border-width:1px; float:left; height:213px; width:300px" /></p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <p><strong>Formula 1.</strong> This invention discloses embodiments of the above compound, or a pharmaceutically acceptable salt, a prodrug, a solvate, or a tautomer thereof.&nbsp;&nbsp;</p> <p>Disclosed monomeric compounds and embodiments exhibit androgenic activity. Disclosed oligomeric compounds can provide control of receptor activation or deactivation and/or treatment through the coupling of steroidal-based compounds to one another or with therapeutic agents. Depending on the type and length between the compounds that form the oligomer, the rate at which each component of the oligomer release can be controlled as in &lsquo;time release&rsquo;. The appropriate dosage would depend on a variety of factors defined during further development.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Contraceptive use by humans, particularly male, and animals</li> <li>Compounds used as endocrine therapy</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Significant, unmet medical need given few current options for male contraceptives&nbsp;</li> <li>Timed release of active ingredients</li> </ul> 2021-02-09 2026-04-24 2021-02-09 2026-04-24 2021-02-09 Blithe, CONTRACEPTIVE, Estrogenic Activity, Eunice Kennedy Shriver National Institute of Child Health an, Lee, Male Contraceptive, MONOMERIC, NCE, New Chemical Entity, NICHD, OLIGOMERIC False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-02-09 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147163965 Lee, Min NIH - NICHD NICHD Lee, Min (NICHD) 1 147163961 Blithe, Diana NIH - NICHD NICHD Blithe, Diana (NICHD) 2 147163963 Gupta, Pranab Ash Stevens, LLC Gupta, Pranab 3 147163962 Kaskar, Bashir Ash Stevens, LLC Kaskar, Bashir 4 147163964 Lin, Ming-Teh Ash Stevens, LLC Lin, Ming-Teh 5 147163965 Lee, Min NIH - NICHD NICHD Lee, Min (NICHD) 1 147163961 Blithe, Diana NIH - NICHD NICHD Blithe, Diana (NICHD) 2 147163963 Gupta, Pranab Ash Stevens, LLC Gupta, Pranab 3 147163962 Kaskar, Bashir Ash Stevens, LLC Kaskar, Bashir 4 147163964 Lin, Ming-Teh Ash Stevens, LLC Lin, Ming-Teh 5 147158072 Novel Substituted Steroid Hormones E-141-2019-0 Filing authorized Ash Stevens, LLC, NICHD 91788919 Gunas, Heather gunash@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America gunash@mail.nih.gov?subject=Web Inquiry on [TAB-4224] Monomeric and Oligomeric Compounds as Contraceptives and Endocrine Therapeutics&body=Please send me information about technology [TAB-4224] Monomeric and Oligomeric Compounds as Contraceptives and Endocrine Therapeutics.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Gunas, Heather<br><a href="mailto:gunash@mail.nih.gov?subject=Web Inquiry on [TAB-4224] Monomeric and Oligomeric Compounds as Contraceptives and Endocrine Therapeutics&body=Please send me information about technology [TAB-4224] Monomeric and Oligomeric Compounds as Contraceptives and Endocrine Therapeutics.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">gunash@mail.nih.gov</a><br> 147167510 E-141-2019-0 E-141-2019-0-US-01 MONOMERIC AND OLIGOMERIC COMPOUND EMBODIMENTS AS CONTRACEPTIVES AND THERAPIES AND METHODS OF MAKING AND USING THE SAME PRV US 63/037,952 Abandoned US <br />Provisional (PRV) 63/037,952<br />Filed on 2020-06-11<br />Status: Abandoned 147167511 E-141-2019-0 E-141-2019-0-PCT-02 MONOMERIC AND OLIGOMERIC COMPOUND EMBODIMENTS AS CONTRACEPTIVES AND THERAPIES AND METHODS OF MAKING AND USING THE SAME PCT Patent Cooperation Treaty PCT/US2021/036809 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/036809<br />Filed on 2021-06-10<br />Status: Expired 147167512 E-141-2019-0 E-141-2019-0-CA-03 MONOMERIC AND OLIGOMERIC COMPOUND EMBODIMENTS AS CONTRACEPTIVES AND THERAPIES AND METHODS OF MAKING AND USING THE SAME National Stage Canada 3184810 Pending Canada <br />National Stage 3184810<br />Filed on 2021-06-10<br />Status: Pending 147167516 E-141-2019-0 E-141-2019-0-US-07 MONOMERIC AND OLIGOMERIC COMPOUND EMBODIMENTS AS CONTRACEPTIVES AND THERAPIES AND METHODS OF MAKING AND USING THE SAME National Stage US 18/009,571 Pending US <br />National Stage 18/009,571<br />Filed on 2022-12-09<br />Status: Pending 147167517 E-141-2019-0 E-141-2019-0-EP-08 MONOMERIC AND OLIGOMERIC COMPOUND EMBODIMENTS AS CONTRACEPTIVES AND THERAPIES AND METHODS OF MAKING AND USING THE SAME National Stage European Patent 21745474.3 Pending European Patent <br />National Stage 21745474.3<br />Filed on 2021-06-10<br />Status: Pending 147172272 Blithe 147172273 CONTRACEPTIVE 147172275 Estrogenic Activity 147172276 Eunice Kennedy Shriver National Institute of Child Health an 147172277 Lee 147172279 Male Contraceptive 147172280 MONOMERIC 147172282 NCE 147172284 New Chemical Entity 147172285 NICHD 147172286 OLIGOMERIC TAB-3996 147157277 Use of Neurotrophic Factor-alpha1/Carboxypeptidase E (CPE) to Treat Alzheimer Disease NICHD Collaboration, Licensing, Neurology, Therapeutics Collaboration Licensing Neurology Therapeutics Yong Cheng, Yoke Peng Loh <h2>Summary:</h2> <p>The NICHD is seeking licensees&nbsp;for development&nbsp;of Carboxypeptidase E (CPE)&nbsp;as a therapy for MCI or AD.</p> <h2>Description of Technology:</h2> <p>There is no known cure for Alzheimer&rsquo;s disease, a brain disorder that severely affects memory, thinking, learning, and organizing skills. It eventually decreases a person&rsquo;s ability to carry out simple, daily activities. It is predicted that over 14 million Americans will develop Alzheimer&rsquo;s without effective treatment options. Mild cognitive impairment (MCI) is a stage prior to Alzheimer&rsquo;s when memory problems become noticeable. A patient&rsquo;s ability to function and live independently remain intact as the brain compensates for disease-related changes. Disease symptoms worsen over a period that may progress over 10 years. In some people, MCI can hold steady at this stage. However, people with MCI are at high risk for progressing to dementia. Alzheimer&rsquo;s disease is the most common form of dementia.</p> <p>MCI is associated with neurological cell death in the hippocampus. The technology from the <em>Eunice Kennedy Shriver</em> National Institute of Child Health and Human Development (NICHD), describes that direct administration of an adenovirus carrying the Carboxypeptidase E (CPE) gene to the hippocampus results in overexpression of the CPE protein in an experimental mouse model of AD. CPE protein overexpression averts neurological cell death in the hippocampus. Treated mice do not develop memory impairment. This technology was effective in mice with normal expression of brain-derived neurotrophic factor (BNDF). It may be applicable to a wider range of patients, including those with BNDF deficiency and no deficiency of BNDF expression. Further, this technology may provide for a combination therapy with CPE and BNDF to treat AD.</p> <p>This technology protects neurons prior to the appearance of cell damage due to accumulation of intracellular tau-containing neurofibrillary tangles and extracellular &beta;-amyloid (A&beta;) deposits in the brain.</p> <p>The use of CPE as an early intervention in the initial diagnosis of MCI may stabilize the neurological condition of patients and avoid progression of AD in a large population of aging patients.</p> <p>There is also opportunity for preclinical co-development of the technology with the NICHD laboratory of Dr. Peng Loh.&nbsp;</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Treatment of patients: <ul> <li>Diagnosed with mild cognitive impairment (MCI)</li> <li>Diagnosed with neurologic damage to the hippocampus</li> <li>With early signs of Alzheimer&rsquo;s Disease (AD)</li> </ul> </li> <li>Combination therapy with Brain-Derived Neurotrophic Factor (BDNF)</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Halt the progression from MCI to AD</li> <li>Combination therapy with CPE and BNDF</li> <li>Neuroprotective prior to the appearance of cell damage</li> </ul> Researchers at the NICHD seek licensing and/or co-development research collaborations for Carboxypeptidase E (CPE) to Treat Mild Cognitive Impairment and Alzheimer Disease 2021-12-21 2026-04-24 2021-12-21 2026-04-24 2021-12-21 “Cognitive impairment”, Ad, Alzheimer’s Disease, BNDF, brain, Brain-Derived Neurotrophic Factor, Carboxypeptidase E, CPE, Hippocampus, LOH, MCI, MEMORY, Mild Cognitive Impairment, NEURODEGENERATION, NEUROTROPHIC False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-12-21 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147161932 Xiao L, et.al. Neurotrophic factor-α1, a novel tropin is critical for the prevention of stress-induced hippocampal CA3 cell death and cognitive dysfunction in mice: comparison to BDNF. https://pubmed.ncbi.nlm.nih.gov/33414376/ <a href="https://pubmed.ncbi.nlm.nih.gov/33414376/">Xiao L, et.al. Neurotrophic factor-α1, a novel tropin is critical for the prevention of stress-induced hippocampal CA3 cell death and cognitive dysfunction in mice: comparison to BDNF.</a> 147163162 Loh, Yoke Peng NIH - NICHD NICHD Loh, Yoke Peng (NICHD) 1 147163163 Cheng, Yong Minzu University of China Cheng, Yong 2 147163162 Loh, Yoke Peng NIH - NICHD NICHD Loh, Yoke Peng (NICHD) 1 147163163 Cheng, Yong Minzu University of China Cheng, Yong 2 147158202 Use Of Neurotrophic Factor-alpha1/Carboxypeptidase E To Treat Alzheimer Disease E-200-2021-0 Filing authorized Minzu University of China, NICHD 91827321 Jinnah, Zarpheen zarpheen.jinnah@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
zarpheen.jinnah@nih.gov?subject=Web Inquiry on [TAB-3996] Use of Neurotrophic Factor-alpha1/Carboxypeptidase E (CPE) to Treat Alzheimer Disease&body=Please send me information about technology [TAB-3996] Use of Neurotrophic Factor-alpha1/Carboxypeptidase E (CPE) to Treat Alzheimer Disease.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Jinnah, Zarpheen<br><a href="mailto:zarpheen.jinnah@nih.gov?subject=Web Inquiry on [TAB-3996] Use of Neurotrophic Factor-alpha1/Carboxypeptidase E (CPE) to Treat Alzheimer Disease&body=Please send me information about technology [TAB-3996] Use of Neurotrophic Factor-alpha1/Carboxypeptidase E (CPE) to Treat Alzheimer Disease.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">zarpheen.jinnah@nih.gov</a><br> 147161187 E-200-2021-0 E-200-2021-0-US-01 Use of Carboxypeptidase E / Neurotrophic Factor-Alpha 1 to Treat Neurodegenerative Disease PRV US 63/273,312 Abandoned US <br />Provisional (PRV) 63/273,312<br />Filed on 2021-10-29<br />Status: Abandoned 147165788 E-200-2021-0 E-200-2021-0-PCT-02 USE OF CARBOXYPEPTIDASE E/NEUROTROPHIC FACTOR-ALPHA1 TO TREAT NEURODEGENERATIVE DISEASE PCT Patent Cooperation Treaty PCT/US2022/078713 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2022/078713<br />Filed on 2022-10-26<br />Status: Expired 147173562 “Cognitive impairment” 147173563 Ad 147173564 Alzheimer’s Disease 147173566 BNDF 147173567 brain 147173569 Brain-Derived Neurotrophic Factor 147173571 Carboxypeptidase E 147173573 CPE 147173575 Hippocampus 147173576 LOH 147173578 MCI 147173579 MEMORY 147173581 Mild Cognitive Impairment 147173582 NEURODEGENERATION 147173583 NEUROTROPHIC TAB-4418 147157713 Novel Human Insulin Cα-Peptide as an Antagonist for Islet and Brain Amyloidosis NIA Collaboration, Endocrinology, Licensing, Therapeutics Collaboration Endocrinology Licensing Therapeutics Josephine Earley, Luigi Ferrucci, Qing Rong Liu, Pingbo Zhang, Min Zhu <h2>Summary:</h2> <p>The NIA seeks co-development partners and/or licensees for the further development of C&alpha;-peptide as a therapeutic that inhibits islet amyloidosis.</p> <h2>Description of Technology:</h2> <p>Over 32 million Americans are living with Diabetes and newly diagnosed cases of type 1 and type 2 diabetes is increasing. A defining feature of type 2 diabetes mellitus (T2DM) is the accumulation of islet amyloid polypeptide (IAPP) fibrils in pancreatic islets. Such accumulations form amyloid plaques, referred to as islet amyloidosis. Mounting evidence suggests that islet amyloidosis plays a causative role in the development and progression of &szlig;-cell dysfunction in T2DM. Currently, approved therapies for T2DM modulate the production of or sensitivity to insulin, but do not specifically target islet amyloidosis. Thus, there is an unmet need to develop new diabetes treatments that inhibit islet amyloidosis. Additionally, any therapy preventing IAPP amyloidosis may prevent other potential amyloidogenic peptides from forming amyloid and amyloid plaques.</p> <p>Insulin C-peptide, co-secreted from secretory granules within pancreatic &beta;-cells alongside mature insulin and IAPP, plays a key role in keeping insulin and IAPP non-aggregated by charge-based interactions. Researchers at the NIA uncovered a novel variant of the C-peptide, named C&alpha;- peptide, having 19 amino acids and lacking -sheet and hairpin motifs present in the middle portion of the conventional 31 amino acid length C-peptide. The newly discovered C&alpha;-peptide derives from a novel proinsulin of 74 amino acids and inhibits IAPP amyloid fibrillation more efficiently than conventional C-peptide. There is an opportunity for C&alpha;-peptide derivatives to be developed as a therapeutic inhibiting islet amyloidosis. Researchers also identified decreased levels of processed C&alpha;-peptide in T2DM pancreatic islets compared with control islets. This finding reveals the potential for C&alpha;-peptide as a clinical diagnostic marker for islet dysfunction and, potentially, neurodegenerative diseases.&nbsp;</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Therapy for type 2 diabetes</li> <li>Therapy for preventing amyloidosis by mutated transthyretin, therapy for primary (AL) amyloidosis, therapy for Amyloid &szlig;40 and 42</li> <li>Therapy for amyloidogenic diseases, including Alzheimer&rsquo;s disease and Parkinson disease</li> <li>Clinical diagnostic marker for type 1 and type 2 diabetes</li> <li>Clinical diagnostic marker for neurodegenerative diseases</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Peptides inhibit islet amyloidosis</li> <li>Peptides lack the amyloidogenic domain</li> <li>Potential for synergistic use with existing diabetes treatments</li> <li>Potential market applications for neurodegenerative diseases</li> </ul> 2021-08-25 2026-04-24 2021-08-27 2026-04-24 2021-08-26 Alzheimer’s Disease, Amyloidosis, C-peptide, DIABETES, Egan, insulin, Islet Amyloid Polypeptide, Liu, National Institute on Aging, NIA False True Basic (Target Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-08-27 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147164673 Liu, Qing Rong NIH - NIA NIDA Liu, Qing Rong (NIDA) 1 147164675 Zhu, Min National Institute on Aging (NIH/NIA) NIA Zhu, Min (NIA) 2 147164676 Zhang, Pingbo Johns Hopkins University Zhang, Pingbo 3 147164672 Earley, Josephine NIH - NIA NIA Earley, Josephine (NIA) 4 147164674 Ferrucci, Luigi NIH - NIA NIA Ferrucci, Luigi (NIA) 5 147164673 Liu, Qing Rong NIH - NIA NIDA Liu, Qing Rong (NIDA) 1 147164675 Zhu, Min National Institute on Aging (NIH/NIA) NIA Zhu, Min (NIA) 2 147164676 Zhang, Pingbo Johns Hopkins University Zhang, Pingbo 3 147164672 Earley, Josephine NIH - NIA NIA Earley, Josephine (NIA) 4 147164674 Ferrucci, Luigi NIH - NIA NIA Ferrucci, Luigi (NIA) 5 147157902 Novel Human Insulin Ca-peptide As An Antagonist For Islet And Brain Amyloidosis E-062-2021-0 Filing authorized Johns Hopkins University, National Institute on Aging (NIH/NIA) 91827321 Jinnah, Zarpheen zarpheen.jinnah@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
zarpheen.jinnah@nih.gov?subject=Web Inquiry on [TAB-4418] Novel Human Insulin Cα-Peptide as an Antagonist for Islet and Brain Amyloidosis&body=Please send me information about technology [TAB-4418] Novel Human Insulin Cα-Peptide as an Antagonist for Islet and Brain Amyloidosis.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Jinnah, Zarpheen<br><a href="mailto:zarpheen.jinnah@nih.gov?subject=Web Inquiry on [TAB-4418] Novel Human Insulin Cα-Peptide as an Antagonist for Islet and Brain Amyloidosis&body=Please send me information about technology [TAB-4418] Novel Human Insulin Cα-Peptide as an Antagonist for Islet and Brain Amyloidosis.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">zarpheen.jinnah@nih.gov</a><br> 147160981 E-062-2021-0 E-062-2021-0-US-01 HUMAN INSULIN C-ALPHA-PEPTIDES AND METHODS OF USE PRV US 63/178,083 Abandoned US <br />Provisional (PRV) 63/178,083<br />Filed on 2021-04-22<br />Status: Abandoned 147168802 E-062-2021-0 E-062-2021-0-PCT-02 HUMAN INSULIN C-ALPHA-PEPTIDES AND METHODS OF USE PCT Patent Cooperation Treaty PCT/US2022/025764 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2022/025764<br />Filed on 2022-04-21<br />Status: Expired 147168803 E-062-2021-0 E-062-2021-0-US-02 HUMAN INSULIN C-ALPHA-PEPTIDES AND METHODS OF USE National Stage US 18/287,630 Pending US <br />National Stage 18/287,630<br />Filed on 2023-10-19<br />Status: Pending 147168804 E-062-2021-0 E-062-2021-0-EP-01 HUMAN INSULIN C-ALPHA-PEPTIDES AND METHODS OF USE National Stage European Patent 22722061.3 Pending European Patent <br />National Stage 22722061.3<br />Filed on 2023-11-10<br />Status: Pending 147170577 Alzheimer’s Disease 147170578 Amyloidosis 147170580 C-peptide 147170581 DIABETES 147170583 Egan 147170584 insulin 147170586 Islet Amyloid Polypeptide 147170588 Liu 147170589 National Institute on Aging 147170590 NIA TAB-4380 147157674 AT-3 Mouse Breast Tumor Cell Line NCI Licensing, Oncology, Research Materials Licensing Oncology Research Materials Scott Abrams, Jeffrey Schlom <h2>Summary:</h2> <p>NCI is seeking licensees for the AT-3 mouse breast tumor cell line.</p> <h2>Description of Technology:</h2> <p>Tumor cell lines are important tools for the study of cancer. However, most tumor cell lines available today do not mimic physiological tumor development, progression, and host immune responses. Autochthonous tumors include spontaneously occurring tumors and chemical, viral, or physical carcinogen-induced tumors. They are considered to model human tumors more closely than transplanted tumors. Autochthonous tumors can be generated de novo in a model organism of interest and are thought to resemble physiological human tumor conditions. There is therefore a need for development of cell lines from autochthonous tumor models that recapitulate physiological tumor conditions to provide relevant tools for studying tumor development and progression, and host immune responses to cancers.&nbsp;</p> <p>Researchers at the National Cancer Institute (NCI) have developed a mouse breast tumor cell line, AT-3, derived from cells of the primary mammary gland carcinoma of the MTAG model. The MTAG&nbsp; mouse model was developed using the mouse mammary tumor virus (MMTV) long terminal repeat (LTR) promoter to specifically target the polyomavirus middle T antigen (Ag) expression in the mammary gland tissue of B6 mice. This strategy resulted in the generation of transgenic mice with autochthonous mammary carcinomas, with eventual metastatic spread to the lungs that occurs over an approximate 6-month life span. The AT-3 cell line has further been used to study tumor-specific immune dysfunction in the B6 mouse background.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Breast cancer research</li> <li>Anti-breast cancer drug screening</li> <li>Development of other mouse models for breast cancer research</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Orthotopic growth</li> <li>Tumor histology devoid of transplantation introduced changes</li> <li>Metastasis via lymphatic and vascular vessels surrounding and within the primary tumor&nbsp;</li> <li>AT-3 cells were isolated from an autochthonous mouse mammary tumor from the MTAG mouse model</li> <li>Mammary tumor development and progression in MTAG mice closely mimic breast cancer development and progression in humans</li> <li>AT-3 cell line is a physiologically relevant tool for study of breast cancer in humans</li> </ul> 2021-09-23 2026-04-24 2021-09-23 2026-04-24 2021-09-23 AT-3, Autochthonous Tumor, Autologous Tumor Cell Line, BREAST CANCER, In Vitro Animal Model, Mouse, Murine, Schlom False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-09-23 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147162360 Stewart TJ &amp; Abrams SI. Altered immune function during long-term host-tumor interactions can be modulated to retard autochthonous neoplastic growth. https://pubmed.ncbi.nlm.nih.gov/17709499/ <a href="https://pubmed.ncbi.nlm.nih.gov/17709499/">Stewart TJ &amp; Abrams SI. Altered immune function during long-term host-tumor interactions can be modulated to retard autochthonous neoplastic growth.</a> 147164516 Schlom, Jeffrey NIH - NCI NCI Schlom, Jeffrey (NCI) 1 147164517 Abrams, Scott NIH - NCI NCI Abrams, Scott (NCI) 2 147164516 Schlom, Jeffrey NIH - NCI NCI Schlom, Jeffrey (NCI) 1 147164517 Abrams, Scott NIH - NCI NCI Abrams, Scott (NCI) 2 147158257 AT-3 Mouse Breast Tumor Cell Line E-240-2016-0 Research Material NCI 83687903 Pollack, Michael michael.pollack@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC michael.pollack@nih.gov?subject=Web Inquiry on [TAB-4380] AT-3 Mouse Breast Tumor Cell Line&body=Please send me information about technology [TAB-4380] AT-3 Mouse Breast Tumor Cell Line.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollack, Michael<br><a href="mailto:michael.pollack@nih.gov?subject=Web Inquiry on [TAB-4380] AT-3 Mouse Breast Tumor Cell Line&body=Please send me information about technology [TAB-4380] AT-3 Mouse Breast Tumor Cell Line.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">michael.pollack@nih.gov</a><br> 147174122 AT-3 147174124 Autochthonous Tumor 147174126 Autologous Tumor Cell Line 147174127 BREAST CANCER 147174129 In Vitro Animal Model 147174130 Mouse 147174131 Murine 147174132 Schlom TAB-4365 147157659 Adjuvanted Mucosal Subunit Vaccines for Preventing SARS-CoV-2 Transmission and Infection NCI Collaboration, Immunology, Infectious Disease, Licensing, Vaccines Collaboration Immunology Infectious Disease Licensing Vaccines Jay Berzofsky, Yongjun Sui <h2>Summary:</h2> <p>Inventors are seeking licensing and/or co-development research collaborations&nbsp; for a unique novel molecular Adjuvanted Mucosal Subunit Vaccine to prevent SARS-CoV-2 transmission and infection.</p> <h2>Description of Technology:</h2> <p>The Corona virus disease, 2019 (COVID-19) pandemic is a worldwide public health crisis with over 153 million confirmed cases and 3.2 million deaths as of April 2021. COVID-19 is caused by a novel coronavirus called SARS-CoV-2. SARS-COV-2 infects hosts via its spike (S) protein, which has two portions, S1 that binds the cell and S2 that is involved in viral entry via fusion with the cell membrane. There are several vaccines available for COVID-19 patients that directly target SARS-CoV-2 by systemic immunization.</p> <p>Investigators at NCI have designed a unique adjuvanted mucosal subunit vaccine to prevent SARS-CoV-2 transmission and infection. The mucosal vaccine is generated as a subunit vaccine with spike protein S1 used for an intramuscular (IM) primed vaccine followed by intranasal boosted mucosal vaccine in rhesus macaques. The mucosal vaccines are administered intranasally and adjuvanted with the combination of TLR agonists CpG and Poly I:C and cytokine IL-15 incorporated in PLGA or DOTAP nanoparticles. The IM-alum-only vaccine induced robust binding and neutralizing antibody and persistent cellular immunity systemically and mucosally, while IN boosting with nanoparticles including IL-15 and TLR agonists elicited weaker T-cell and antibody responses, but higher dimeric IgA and IFNa, enhancing the effect of systemic immunization. Studies conducted by the inventors showed that the mucosal vaccine induced robust humoral and cellular as well as trained innate immunity in the vaccinated macaques, and cleared virus from the nasal mucosa more effectively, which should reduce forward transmission.</p> <p>Overall, the results demonstrated that the mucosal vaccine could protect against respiratory SARS-CoV-2 exposure and may enhance systemic vaccines, and thus is a good candidate for a SARS-CoV-2 vaccine.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Adjuvanted mucosal subunit vaccines (as single agents)&nbsp;</li> <li>Vaccine composition (s)</li> <li>Co-administration to enhance the effect of systemic immunization</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Stimulates both systemic and mucosal immunity;&nbsp; induces&nbsp; both humoral and cellular immunity, as well as trained innate immunity</li> <li>Leads to more effective virus clearance from the upper respiratory tract from which it could spread.</li> <li>Stimulated sustained immune response</li> <li>Protects against SARS-CoV-2 variants</li> <li>Intranasal administration avoids painful injection&nbsp;</li> <li>Notable improvement for manufacturing yield and cost, ease of administration, and distribution as compared to current candidates.</li> </ul> 2021-11-04 2026-04-24 2022-02-09 2026-04-24 2021-11-09 False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2022-02-09 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147162454 Yongjun Sui et al., Protection against SARS-CoV-2 infection by mucosal vaccine in rhesus macaques. https://pubmed.ncbi.nlm.nih.gov/33908897/ <a href="https://pubmed.ncbi.nlm.nih.gov/33908897/">Yongjun Sui et al., Protection against SARS-CoV-2 infection by mucosal vaccine in rhesus macaques.</a> 147164454 Berzofsky, Jay NIH - NCI NCI Berzofsky, Jay (NCI) 1 147164455 Sui, Yongjun NCI - CCR Sui, Yongjun 2 147164454 Berzofsky, Jay NIH - NCI NCI Berzofsky, Jay (NCI) 1 147164455 Sui, Yongjun NCI - CCR Sui, Yongjun 2 147157906 Adjuvanted Mucosal Subunit Vaccines For Preventing SARS-CoC-2 Transmission And Infection E-064-2021-0 Filing authorized NCI 83740301 Dattaroy, Diptadip diptadip.dattaroy@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB diptadip.dattaroy@nih.gov?subject=Web Inquiry on [TAB-4365] Adjuvanted Mucosal Subunit Vaccines for Preventing SARS-CoV-2 Transmission and Infection&body=Please send me information about technology [TAB-4365] Adjuvanted Mucosal Subunit Vaccines for Preventing SARS-CoV-2 Transmission and Infection.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dattaroy, Diptadip<br><a href="mailto:diptadip.dattaroy@nih.gov?subject=Web Inquiry on [TAB-4365] Adjuvanted Mucosal Subunit Vaccines for Preventing SARS-CoV-2 Transmission and Infection&body=Please send me information about technology [TAB-4365] Adjuvanted Mucosal Subunit Vaccines for Preventing SARS-CoV-2 Transmission and Infection.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">diptadip.dattaroy@nih.gov</a><br> 147160984 E-064-2021-0 E-064-2021-0-US-01 Adjuvanted Mucosal Subunit Vaccines For Preventing SARS-CoC-2 Transmission And Infection PRV US 63/146,279 Abandoned US <br />Provisional (PRV) 63/146,279<br />Filed on 2021-02-05<br />Status: Abandoned 147168461 E-064-2021-0 E-064-2021-0-PCT-03 Adjuvanted Mucosal Subunit Vaccines For Preventing SARS-CoV-2 Transmission And Infection PCT Patent Cooperation Treaty PCT/US2022/015349 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2022/015349<br />Filed on 2022-02-04<br />Status: Expired 147168462 E-064-2021-0 E-064-2021-0-US-02 Adjuvanted Mucosal Subunit Vaccines For Preventing SARS-CoV-2 Transmission And Infection National Stage US 18/275,925 Pending US <br />National Stage 18/275,925<br />Filed on 2023-08-04<br />Status: Pending 147168463 E-064-2021-0 E-064-2021-0-EP-01 Adjuvanted Mucosal Subunit Vaccines For Preventing SARS-CoV-2 Transmission And Infection National Stage European Patent 22705675.1 Pending European Patent <br />National Stage 22705675.1<br />Filed on 2023-08-30<br />Status: Pending TAB-4346 147157639 Human and Improved Murine Monoclonal Antibodies Against CD22 NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Dimiter Dimitrov, Ira Pastan, Xiaodong Xiao <h2>Summary:</h2> <p>Researchers at the NCI seek research and co-development partners and/or licensing for the development of human monoclonal antibodies and antibody-based therapeutics against CD22.</p> <h2>Description of Technology:</h2> <p>CD22 is a common cell surface glycoprotein expressed in B-cells and present in B-cell lymphomas; e.g., hairy cell leukemia (HCL), non-Hodgkins lymphoma (NHL), chronic lymphoblastic leukemia (CLL), and other cancers. It is therefore a target for cancer immunotherapy. Conjugation of anti-CD22 monoclonal antibodies with toxins or drugs has shown promise in clinical trials. However, all monoclonal anti-CD22 antibodies used in clinical trials are of murine origin. This is problematic because they have the potential of causing immunogenic reactions when used repeatedly in patients to achieve higher efficacy.</p> <p>NCI scientists isolated two human monoclonal anti-CD22 Fab antibodies; m972 and m971 with 2nM and 20nM affinities respectively. These two human anti-CD22 monoclonal antibodies are better alternatives for cancer immunotherapy over current humanized murine antibodies as they overcome the problem of immune reactivity. They also developed a murine anti-CD22 monoclonal antibody M973 with better affinity and solubility than its parent antibody HA22 and could have improved efficacy in cancer immunotherapy than the murine monoclonal anti-CD22 antibodies currently in use.&nbsp; The m971 binder has also been incorporated into chimeric antigen receptors (CARs) with positive results which are covered under NIH Reference Number E-291-2012 and other related filings.&nbsp;&nbsp;</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Monoclonal antibody therapeutic against B-cell lymphomas and other CD22-positive cancers</li> <li>Diagnostic tool for detection of CD22-positive cancers</li> <li>Delivery of drugs, toxins and liposomes to CD22-positive cancers</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Fully human monoclonal antibodies overcome the problem of immune reactivity to murine antibodies</li> <li>Improved monoclonal antibodies have better affinity and solubility than current antibodies</li> </ul> 2021-06-04 2026-04-24 2021-06-04 2026-04-24 2021-06-04 antibodies, ANTIGEN, B-CELL, B-Cell Lymphoma, Bcl, CANCER, CD22, Chronic Lymphoblastic Leukemia, CLL, Dimitrov, Hairy cell leukemia, HCL, Human, monoclonal, NHL, non-Hodgkins lymphoma, Oncology False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-06-04 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-017-2017 E-106-2015 E-161-2018 E-291-2012 147162148 Xiao X, et al. Identification and characterization of fully human anti-CD22 monoclonal antibody. https://pubmed.ncbi.nlm.nih.gov/20065646/ <a href="https://pubmed.ncbi.nlm.nih.gov/20065646/">Xiao X, et al. Identification and characterization of fully human anti-CD22 monoclonal antibody.</a> 147164404 Dimitrov, Dimiter NIH - NCI NCI Dimitrov, Dimiter (NCI) 1 147164405 Xiao, Xiaodong NIH - NCI Xiao, Xiaodong 2 147164403 Pastan, Ira NIH - NCI NCI Pastan, Ira (NCI) 3 147164404 Dimitrov, Dimiter NIH - NCI NCI Dimitrov, Dimiter (NCI) 1 147164405 Xiao, Xiaodong NIH - NCI Xiao, Xiaodong 2 147164403 Pastan, Ira NIH - NCI NCI Pastan, Ira (NCI) 3 147157941 Human And Improved Murine Monoclonal Antibodies Against CD22 E-080-2008-0 Filing authorized NCI 91814193 Freel, Rose rose.freel@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America rose.freel@nih.gov?subject=Web Inquiry on [TAB-4346] Human and Improved Murine Monoclonal Antibodies Against CD22&body=Please send me information about technology [TAB-4346] Human and Improved Murine Monoclonal Antibodies Against CD22.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Freel, Rose<br><a href="mailto:rose.freel@nih.gov?subject=Web Inquiry on [TAB-4346] Human and Improved Murine Monoclonal Antibodies Against CD22&body=Please send me information about technology [TAB-4346] Human and Improved Murine Monoclonal Antibodies Against CD22.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">rose.freel@nih.gov</a><br> 147168358 E-080-2008-0 E-080-2008-0-US-01 Human Monoclonal Antibodies Specific For CD22 PRV US 61/042,329 Abandoned US <br />Provisional (PRV) 61/042,329<br />Filed on 2008-04-04<br />Status: Abandoned 147168359 E-080-2008-0 E-080-2008-0-PCT-02 Human And Improved Murine Monoclonal Antibodies Against CD22 PCT Patent Cooperation Treaty PCT/US2009/039080 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2009/039080<br />Filed on 2009-04-01<br />Status: Expired 147168360 E-080-2008-0 E-080-2008-0-US-03 Human Monoclonal Antibodies Sepcific for CD22 National Stage US 8,591,889 12/934,214 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8591889 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8591889">8,591,889</a><br />Filed on 2010-09-23<br />Status: Issued 147168361 E-080-2008-0 E-080-2008-0-US-04 Human Monoclonal Antibodies Specific For CD22 DIV US 9,279,019 13/959,061 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9279019 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9279019">9,279,019</a><br />Filed on 2013-08-05<br />Status: Issued 147168362 E-080-2008-0 E-080-2008-0-US-05 Human Monoclonal Antibodies Specific for CD22 DIV US 9,598,492 15/012,023 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9598492 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9598492">9,598,492</a><br />Filed on 2016-02-01<br />Status: Issued 147168363 E-080-2008-0 E-080-2008-0-US-06 Human Monoclonal Antibodies Specific for CD22 CON US 10,494,435 15/424,238 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10494435 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10494435">10,494,435</a><br />Filed on 2017-02-03<br />Status: Issued 147170938 antibodies 147170939 ANTIGEN 147170940 B-CELL 147170942 B-Cell Lymphoma 147170943 Bcl 147170944 CANCER 147170945 CD22 147170947 Chronic Lymphoblastic Leukemia 147170948 CLL 147170949 Dimitrov 147170950 Hairy cell leukemia 147170952 HCL 147170953 Human 147170954 monoclonal 147170955 NHL 147170957 non-Hodgkins lymphoma 147170958 Oncology TAB-4330 147157621 Anti-Viral Polypeptide Griffithsin: Compounds, Compositions, and Methods of Use NCI Collaboration, Infectious Disease, Licensing, Therapeutics Collaboration Infectious Disease Licensing Therapeutics James McMahon, Toshiyuki Mori, Barry O'Keefe <h2>Description of Technology:</h2> <p>This technology describes additional methods of using the griffithsin anti-viral polypeptides described in related NCI invention (reference number E-106-2003).&nbsp; Specifically, this invention describes the use of GRFT to inhibit viral infection of hepatitis C viral infection, a severe acute respiratory syndrome (SARS) viral infection, an H5N1 viral infection, or an Ebola viral infection.&nbsp;</p> <p>Issued patents: <a href="https://patents.google.com/patent/US8088729B2/en?oq=US+8%2c088%2c729" rel="nofollow" target="_blank">US 8,088,729</a>&nbsp;(Jan. 3, 2012) and foreign rights in&nbsp;France, Germany, Ireland, United Kingdom, Switzerland (all granted)</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Microbicide that can prevent viral transmission</li> <li>Therapeutic against enveloped virus-mediated diseases</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Highly Potent Broad-Spectrum Antiviral Lectin</li> <li>Superior in vitro and in vivo antiviral activity with minimum host toxicity against a variety of clinically relevant, enveloped viruses.</li> </ul> 2021-07-07 2026-04-24 2021-07-07 2026-04-24 2021-07-07 Anti-Viral, Corona virus, Ebola, Griffithsin, INFLUENZA, O’Keefe, SARS False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2021-07-07 52406768 Discovery 52406768 NCI 37470483 Website Abstract E-106-2003 147162255 Giomarelli B, et al. Recombinant production of anti-HIV protein, griffithsin, by auto-induction in a fermentor culture https://pubmed.ncbi.nlm.nih.gov/16300962/ <a href="https://pubmed.ncbi.nlm.nih.gov/16300962/">Giomarelli B, et al. Recombinant production of anti-HIV protein, griffithsin, by auto-induction in a fermentor culture</a> 147162408 Mori T. et al., Isolation and characterization of griffithsin, a novel HIV-inactivating protein, from the red alga Griffithsia sp. https://pubmed.ncbi.nlm.nih.gov/15613479/ <a href="https://pubmed.ncbi.nlm.nih.gov/15613479/">Mori T. et al., Isolation and characterization of griffithsin, a novel HIV-inactivating protein, from the red alga Griffithsia sp.</a> 147164332 O'Keefe, Barry NIH - NCI NCI O'Keefe, Barry (NCI) 1 147164331 McMahon, James NIH - NCI NCI McMahon, James (NCI) 2 147164333 Mori, Toshiyuki NIH - NCI Mori, Toshiyuki 3 147164332 O'Keefe, Barry NIH - NCI NCI O'Keefe, Barry (NCI) 1 147164331 McMahon, James NIH - NCI NCI McMahon, James (NCI) 2 147164333 Mori, Toshiyuki NIH - NCI Mori, Toshiyuki 3 147157812 Antiviral Activity Of Griffithsin Against SARS And HCV E-025-2006-0 Filing authorized NCI 83732213 Dick, Taryn taryn.dick@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB taryn.dick@nih.gov?subject=Web Inquiry on [TAB-4330] Anti-Viral Polypeptide Griffithsin: Compounds, Compositions, and Methods of Use&body=Please send me information about technology [TAB-4330] Anti-Viral Polypeptide Griffithsin: Compounds, Compositions, and Methods of Use.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dick, Taryn<br><a href="mailto:taryn.dick@nih.gov?subject=Web Inquiry on [TAB-4330] Anti-Viral Polypeptide Griffithsin: Compounds, Compositions, and Methods of Use&body=Please send me information about technology [TAB-4330] Anti-Viral Polypeptide Griffithsin: Compounds, Compositions, and Methods of Use.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">taryn.dick@nih.gov</a><br> 147168226 E-025-2006-0 E-025-2006-0-US-01 Antiviral Activity Of Griffithsin Against SARS And HCV PRV US 60/741,403 Abandoned US <br />Provisional (PRV) 60/741,403<br />Filed on 2005-12-01<br />Status: Abandoned 147168227 E-025-2006-0 E-025-2006-0-PCT-02 Anti-Viral Griffithsin Compounds, Compositions, and Methods of Use PCT Patent Cooperation Treaty PCT/US2006/045930 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2006/045930<br />Filed on 2006-12-01<br />Status: Expired 147168228 E-025-2006-0 E-025-2006-0-US-03 Anti-Viral Griffithsin Compounds, Compositions, and Methods of Use National Stage US 8,088,729 12/095,697 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8088729 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8088729">8,088,729</a><br />Filed on 2008-05-30<br />Status: Issued 147168229 E-025-2006-0 E-025-2006-0-EP-04 Anti-Viral Griffithsin Compounds, Compositions, and Methods of Use National Stage European Patent 1976596 06838737.2 Issued European Patent <br />National Stage 06838737.2<br />Filed on 2006-12-01<br />Status: Issued 147168230 E-025-2006-0 E-025-2006-0-EP-05 Anti-Viral Griffithsin Compounds, Compositions, and Methods of Use DIV European Patent 10014894.9 Abandoned European Patent <br />Divisional (DIV) 10014894.9<br />Filed on 2006-12-01<br />Status: Abandoned 147168231 E-025-2006-0 E-025-2006-0-EP-06 Anti-Viral Griffithsin Compounds, Compositions, and Methods DIV European Patent 2314349 10014895.6 Abandoned European Patent <br />Divisional (DIV) 10014895.6<br />Filed on 2006-12-01<br />Status: Abandoned 147168232 E-025-2006-0 E-025-2006-0-EP-07 Anti-Viral Griffithsin Compounds, Compositions, and Methods of Use DIV European Patent 10014893.1 Abandoned European Patent <br />Divisional (DIV) 10014893.1<br />Filed on 2006-12-01<br />Status: Abandoned 147168233 E-025-2006-0 E-025-2006-0-FR-08 Anti-Viral Griffithsin Compounds, Compositions, and Methods of Use EP France 1976596 06838737.2 Issued France <br />European patent (EP) 06838737.2<br />Filed on 2006-12-01<br />Status: Issued 147168234 E-025-2006-0 E-025-2006-0-DE-09 Anti-Viral Griffithsin Compounds, Compositions, and Methods of Use EP Germany 1976596 06838737.2 Issued Germany <br />European patent (EP) 06838737.2<br />Filed on 2006-12-01<br />Status: Issued 147168235 E-025-2006-0 E-025-2006-0-IE-10 Anti-Viral Griffithsin Compounds, Compositions, and Methods of Use EP Ireland 1976596 06838737.2 Issued Ireland <br />European patent (EP) 06838737.2<br />Filed on 2006-12-01<br />Status: Issued 147168236 E-025-2006-0 E-025-2006-0-GB-11 Anti-Viral Griffithsin Compounds, Compositions, and Methods of Use EP United Kingdom 1976596 06838737.2 Issued United Kingdom <br />European patent (EP) 06838737.2<br />Filed on 2006-12-01<br />Status: Issued 147168237 E-025-2006-0 E-025-2006-0-CH-12 Anti-Viral Griffithsin Compounds, Compositions, and Methods of Use EP Switzerland 1976596 06838737.2 Issued Switzerland <br />European patent (EP) 06838737.2<br />Filed on 2006-12-01<br />Status: Issued 147169695 Anti-Viral 147169697 Corona virus 147169698 Ebola 147169699 Griffithsin 147169700 INFLUENZA 147169702 O’Keefe 147169703 SARS TAB-4307 147157597 High-Throughput Generation of Induced Pluripotent Stem Cells Carrying Antigen-Specific T Cell Receptors from Tumor Infiltrated Lymphocytes NCI Immunology, Licensing, Oncology, Therapeutics Immunology Licensing Oncology Therapeutics S M Rafiqul Islam, Takuya Maeda, Nicholas Restifo, Raul Sakoda, Naritaka Tamaoki <h2>Summary:</h2> <p>NCI seeks proposals from parties interested in licensing an&nbsp;improved method for the identification of TCRs from bulk populations of TIL for the development of cancer immunotherapies.</p> <h2>Description of Technology:</h2> <p>One form of adoptive T cell therapy (ACT) consists of harvesting tumor infiltrating lymphocytes (TIL), screening and isolating TIL which display tumor antigen-specific T-cell receptors (TCR), expanding the isolated T cells in vitro, and reinfusing them into the patient for treatment. While highly active in the treatment of certain cancers (e.g., melanoma), current methods used to produce cancer-reactive T cells require significant time and may not adequately identify the desired TCRs which bind cancer targets.</p> <p>Researchers at the National Cancer Institute (NCI) Surgery Branch have developed a method which allows for the identification of TCRs from bulk populations of TIL. This method generates induced pluripotent stem cell (iPSC) lines inheriting tumor antigen-specific TCRs from minor populations of TIL, not routinely achievable by other conventional approaches. Additionally, the method can generate previously unidentified tumor antigen-specific iPSC lines without pre-generating tumor antigen-specific T cell lines. This novel method is an improvement in the generation of tumor antigen-specific TCR inherited iPSC lines.</p> <h2>&nbsp;Potential Commercial Applications:</h2> <ul> <li>Therapeutics for a wide range of liquid and solid cancers</li> <li>iPSC lines inheriting tumor antigen-specific TCRs from minor populations of TIL not routinely achievable by other conventional approaches</li> <li>Improved and expedited cell therapy manufacturing, including: <ul> <li>Identification and reprogramming of bulk, polyclonal TIL populations with a high frequency of inherited tumor antigen-specific TCRs</li> <li>Method to identify, clone, and transduce tumor and neoantigen-specific TCRs from a bulk, polyclonal TIL population by genomic DNA sequencing</li> <li>Identification of tumor-reactive TCRs without having to identify their TCR alpha and TCR beta recombination patterns by bioinformatics and algorithm predictions</li> </ul> </li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>iPSC lines inheriting tumor antigen-specific TCRs from minor populations of TIL not routinely achievable by other conventional approaches</li> <li>Production of several TIL-derived iPSC (TIL-iPSC) with multiple different and novel tumor antigen-specific TCRs</li> <li>iPSC can be expanded without restrictions, and TCR sequencing and identification can be achieved with minimal error by genomic DNA based TCR sequencing</li> <li>Improved generation of tumor antigen-specific TIL for T cell rejuvenation purposes and subsequent TIL-iPSC-derived immunotherapy</li> </ul> 2021-04-28 2026-04-24 2021-04-28 2026-04-24 2021-04-28 act, adoptive cell therapy, ANTIGEN-SPECIFIC, Cancer Targets, Immunotherapy, Induced Pluripotent Stem Cells, iPSC, Restifo, Rosenberg, T Cell Receptors, TCR, TIL, Tumor Infiltrated Lymphocytes False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-04-28 52406768 Discovery 52406768 NCI 37470483 Website Abstract E-091-2019 147162230 Minagawa A, et al. Enhancing T cell receptor stability in rejuvenated iPSC-derived T cells improves their use in cancer immunotherapy. https://pubmed.ncbi.nlm.nih.gov/30449714/ <a href="https://pubmed.ncbi.nlm.nih.gov/30449714/">Minagawa A, et al. Enhancing T cell receptor stability in rejuvenated iPSC-derived T cells improves their use in cancer immunotherapy.</a> 147162345 Vizcardo R, et al. Regeneration of human tumor antigen-specific T cells from iPSCs derived from mature CD8(+) T cells. https://pubmed.ncbi.nlm.nih.gov/23290135/ <a href="https://pubmed.ncbi.nlm.nih.gov/23290135/">Vizcardo R, et al. Regeneration of human tumor antigen-specific T cells from iPSCs derived from mature CD8(+) T cells.</a> 147162383 Maeda T, et al. Regeneration of CD8alphabeta T cells from T-cell-derived iPSC imparts potent tumor antigen-specific cytotoxicity. https://pubmed.ncbi.nlm.nih.gov/27872100/ <a href="https://pubmed.ncbi.nlm.nih.gov/27872100/">Maeda T, et al. Regeneration of CD8alphabeta T cells from T-cell-derived iPSC imparts potent tumor antigen-specific cytotoxicity.</a> 147164245 Sakoda, Raul NIH - NCI Sakoda, Raul 1 147164246 Islam, S M Rafiqul NIH - NCI NCI Islam, S M Rafiqul (NCI) 2 147164244 Tamaoki, Naritaka NIH - NCI NCI Tamaoki, Naritaka (NCI) 3 147164247 Maeda, Takuya NIH - NCI NCI Maeda, Takuya (NCI) 4 147164243 Restifo, Nicholas NIH - NCI NCI Restifo, Nicholas (NCI) 5 147164245 Sakoda, Raul NIH - NCI Sakoda, Raul 1 147164246 Islam, S M Rafiqul NIH - NCI NCI Islam, S M Rafiqul (NCI) 2 147164244 Tamaoki, Naritaka NIH - NCI NCI Tamaoki, Naritaka (NCI) 3 147164247 Maeda, Takuya NIH - NCI NCI Maeda, Takuya (NCI) 4 147164243 Restifo, Nicholas NIH - NCI NCI Restifo, Nicholas (NCI) 5 147158008 High-throughput Generation Of IPSC Carrying Antigen Specific TCRs From Tumor Infiltrated Lymphocytes E-109-2020-0 Filing authorized NCI 83709866 Burke, Andrew burkear@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC burkear@nih.gov?subject=Web Inquiry on [TAB-4307] High-Throughput Generation of Induced Pluripotent Stem Cells Carrying Antigen-Specific T Cell Receptors from Tumor Infiltrated Lymphocytes&body=Please send me information about technology [TAB-4307] High-Throughput Generation of Induced Pluripotent Stem Cells Carrying Antigen-Specific T Cell Receptors from Tumor Infiltrated Lymphocytes.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Burke, Andrew<br><a href="mailto:burkear@nih.gov?subject=Web Inquiry on [TAB-4307] High-Throughput Generation of Induced Pluripotent Stem Cells Carrying Antigen-Specific T Cell Receptors from Tumor Infiltrated Lymphocytes&body=Please send me information about technology [TAB-4307] High-Throughput Generation of Induced Pluripotent Stem Cells Carrying Antigen-Specific T Cell Receptors from Tumor Infiltrated Lymphocytes.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">burkear@nih.gov</a><br> 147161056 E-109-2020-0 E-109-2020-0-US-01 HIGH-THROUGHPUT GENERATION OF iPSC CARRYING ANTIGEN SPECIFIC TCRs FROM TUMOR INFILTRATING LYMPHOCYTES PRV US 63/068,458 Abandoned US <br />Provisional (PRV) 63/068,458<br />Filed on 2020-08-21<br />Status: Abandoned 147168060 E-109-2020-0 E-109-2020-0-PCT-02 PREFERENTIAL GENERATION OF iPSC CARRYING ANTIGEN SPECIFIC TCRs FROM TUMOR INFILTRATING LYMPHOCYTES PCT Patent Cooperation Treaty PCT/US2021/046969 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/046969<br />Filed on 2021-08-20<br />Status: Expired 147168061 E-109-2020-0 E-109-2020-0-JP-01 PREFERENTIAL GENERATION OF iPSC CARRYING ANTIGEN SPECIFIC TCRs FROM TUMOR INFILTRATING LYMPHOCYTES National Stage Japan 2023-512482 Pending Japan <br />National Stage 2023-512482<br />Filed on 2023-02-20<br />Status: Pending 147168062 E-109-2020-0 E-109-2020-0-US-02 PREFERENTIAL GENERATION OF iPSC CARRYING ANTIGEN SPECIFIC TCRs FROM TUMOR INFILTRATING LYMPHOCYTES National Stage US 18/020,823 Pending US <br />National Stage 18/020,823<br />Filed on 2023-02-10<br />Status: Pending 147168063 E-109-2020-0 E-109-2020-0-EP-01 PREFERENTIAL GENERATION OF iPSC CARRYING ANTIGEN SPECIFIC TCRs FROM TUMOR INFILTRATING LYMPHOCYTES National Stage European Patent 21769306.8 Pending European Patent <br />National Stage 21769306.8<br />Filed on 2023-03-08<br />Status: Pending 147171635 act 147171636 adoptive cell therapy 147171637 ANTIGEN-SPECIFIC 147171639 Cancer Targets 147171640 Immunotherapy 147171642 Induced Pluripotent Stem Cells 147171643 iPSC 147171644 Restifo 147171645 Rosenberg 147171646 T Cell Receptors 147171647 TCR 147171648 TIL 147171650 Tumor Infiltrated Lymphocytes TAB-4283 147157572 Enhanced Cancer Chemotherapy Using the Bioactive Peptide Recifin And Its Analogues NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Alan Bermingham, Kirk Gustafson, Lauren Krumpe, Christophe Marchand, Barry O'Keefe, Yves Pommier, Johan Rosengren, Ingrid Schroeder, Brice Wilson <h2>Summary:</h2> <p>NCI seeks research co-development partners and/or licensees for the development of recifin and its analogues as new chemosensitizing agents in adjunct therapies with topotecan, irinotecan and related chemotherapeutic agents.</p> <h2>Description of Technology:</h2> <p>Topoisomerase enzymes play an important role in cancer progression by controlling changes in DNA structure through catalyzing the breaking and rejoining of the phosphodiester backbone of DNA strands during the normal cell cycle. Therefore, topoisomerases are important targets for cancer chemotherapy. Many topoisomerase 1 (TOP1) inhibitors such as camptothecin, rinotecan, and topotecan are widely used anti-cancer agents that work by stabilizing the TOP1-DNA cleavage complex. Stabilization causes irreversible double-strand DNA breaks, eventually leading to the death of replicating cancer cells. Tyrosyl-DNA phosphodiesterase 1 (TDP1) is an enzyme that plays a role in allowing cells to escape from TOP1 inhibitor-induced cell death by catalyzing the clearance of TOP1-DNA complexes. This activity led researchers to consider TDP1 a molecular target for the sensitization of replicating cancer cells to camptothecin and related chemotherapeutic agents.</p> <p>Scientists at the National Cancer Institute (NCI) discovered recifin, a unique cysteine-rich cyclic peptide that inhibits the human protein tyrosyl-DNA phosphodiesterase 1 (TDP1). The peptide was isolated from a natural source, the sponge Axinella sp. The three-dimensional structure of recifin was determined by NMR and found to represent a completely new structural class unlike previously published cyclic peptides. Recifin inhibits TDP1 via an allosteric mechanism of inhibition and is the first identified allosteric inhibitor of this protein. TDP1 is important for cancer chemotherapy because its inhibition can restore cancer-cell sensitivity to clinically-used topoisomerase inhibitors.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Treatment for various solid cancers previously chemoresistant to some degree &ndash; such as small cell lung and ovarian cancer&nbsp;</li> <li>Development of new chemosensitizing agents: inhibition of tyrosyl-DNA phosphodiesterase 1 (TDP1), an important DNA repair enzyme in humans and a promising inhibition target&nbsp;</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Numerous commercialization and/or sub-licensing opportunities due to wide range of relevant cancers.</li> <li>First-in-class drug; Recifin is the first member of a new family of cyclic peptides that inhibits the enzyme tyrosyl-DNA phosphodiesterase 1 (TDP1)</li> <li>First-in-class with effective and safe chemosensitizer to TOP1 inhibitors&nbsp;</li> <li>Potential for improved clinical responses</li> <li>TDP1 inhibitors can sensitize cancer cells to chemotherapeutic agents &ndash; including topotecan and irinotecan</li> <li>Recifin is stable to protease digestion</li> <li>Scale-up manufacturing: recifin analogues could be created with simple, automated peptide synthesis&nbsp;</li> <li>Sensitizing cells to topoisomerase I (TOP1) inhibitors, including topotecan, irinotecan and related chemotherapeutic agents</li> </ul> 2021-11-04 2026-04-24 2021-11-05 2026-04-24 2021-11-04 CANCER, Chemosensitizing Agents, CHEMOTHERAPY, Cyclic Peptide, Irinotecan TOP1, O’Keefe, Recifin, Tdp1, Topoisomerase 1 inhibitors, Topotecan, Tyrosyl-DNA Phosphodiesterase 1 Inhibitors False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-11-05 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147162473 Bermingham A, et al. Identification of Natural Products That Inhibit the Catalytic Function of Human Tyrosyl-DNA Phosphodiesterase (TDP1) https://pubmed.ncbi.nlm.nih.gov/28697309/ <a href="https://pubmed.ncbi.nlm.nih.gov/28697309/">Bermingham A, et al. Identification of Natural Products That Inhibit the Catalytic Function of Human Tyrosyl-DNA Phosphodiesterase (TDP1)</a> 147164154 O'Keefe, Barry NIH - NCI NCI O'Keefe, Barry (NCI) 1 147164155 Krumpe, Lauren NCI - FCRDC (Leidos) NCI Krumpe, Lauren (NCI) 2 147164159 Rosengren, Johan The University of Queensland Rosengren, Johan 3 147164157 Schroeder, Ingrid NIH - NCI Leidos Schroeder, Ingrid (Leidos) 4 147164158 Bermingham, Alan Revolution Medicines, Inc. Bermingham, Alan 5 147164153 Marchand, Christophe NIH - NCI NCI Marchand, Christophe (NCI) 6 147164152 Gustafson, Kirk NIH - NCI NCI Gustafson, Kirk (NCI) 7 147164156 Wilson, Brice NIH - NCI NCI Wilson, Brice (NCI) 8 147164151 Pommier, Yves NIH - NCI NCI Pommier, Yves (NCI) 9 147164154 O'Keefe, Barry NIH - NCI NCI O'Keefe, Barry (NCI) 1 147164155 Krumpe, Lauren NCI - FCRDC (Leidos) NCI Krumpe, Lauren (NCI) 2 147164159 Rosengren, Johan The University of Queensland Rosengren, Johan 3 147164157 Schroeder, Ingrid NIH - NCI Leidos Schroeder, Ingrid (Leidos) 4 147164158 Bermingham, Alan Revolution Medicines, Inc. Bermingham, Alan 5 147164153 Marchand, Christophe NIH - NCI NCI Marchand, Christophe (NCI) 6 147164152 Gustafson, Kirk NIH - NCI NCI Gustafson, Kirk (NCI) 7 147164156 Wilson, Brice NIH - NCI NCI Wilson, Brice (NCI) 8 147164151 Pommier, Yves NIH - NCI NCI Pommier, Yves (NCI) 9 147158203 Recifin, The First Of A Novel Class Of Bioactive Peptides E-202-2020-0 Filing authorized NCI, Revolution Medicines, Inc., The University of Queensland 83732213 Dick, Taryn taryn.dick@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB taryn.dick@nih.gov?subject=Web Inquiry on [TAB-4283] Enhanced Cancer Chemotherapy Using the Bioactive Peptide Recifin And Its Analogues&body=Please send me information about technology [TAB-4283] Enhanced Cancer Chemotherapy Using the Bioactive Peptide Recifin And Its Analogues.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dick, Taryn<br><a href="mailto:taryn.dick@nih.gov?subject=Web Inquiry on [TAB-4283] Enhanced Cancer Chemotherapy Using the Bioactive Peptide Recifin And Its Analogues&body=Please send me information about technology [TAB-4283] Enhanced Cancer Chemotherapy Using the Bioactive Peptide Recifin And Its Analogues.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">taryn.dick@nih.gov</a><br> 147167870 E-202-2020-0 E-202-2020-0-US-01 TYROSYL-LOCK PEPTIDES PRV US 63/115,418 Abandoned US <br />Provisional (PRV) 63/115,418<br />Filed on 2020-11-18<br />Status: Abandoned 147167871 E-202-2020-0 E-202-2020-0-PCT-02 TYROSYL-LOCK PEPTIDES PCT Patent Cooperation Treaty PCT/US2021/059764 Administratively Closed Patent Cooperation Treaty <br />(PCT) PCT/US2021/059764<br />Filed on 2021-11-17<br />Status: Administratively Closed 147167872 E-202-2020-0 E-202-2020-0-CA-01 TYROSYL-LOCK PEPTIDES National Stage Canada 3199368 Pending Canada <br />National Stage 3199368<br />Filed on 2023-05-17<br />Status: Pending 147167873 E-202-2020-0 E-202-2020-0-AU-01 TYROSYL-LOCK PEPTIDES National Stage Australia 2021385049 Pending Australia <br />National Stage 2021385049<br />Filed on 2023-05-23<br />Status: Pending 147167874 E-202-2020-0 E-202-2020-0-US-02 TYROSYL-LOCK PEPTIDES National Stage US 18/037,379 Pending US <br />National Stage 18/037,379<br />Filed on 2023-05-17<br />Status: Pending 147167875 E-202-2020-0 E-202-2020-0-EP-01 TYROSYL-LOCK PEPTIDES National Stage European Patent 21840215.4 Pending European Patent <br />National Stage 21840215.4<br />Filed on 2023-06-16<br />Status: Pending 147173584 CANCER 147173586 Chemosensitizing Agents 147173587 CHEMOTHERAPY 147173588 Cyclic Peptide 147173590 Irinotecan TOP1 147173591 O’Keefe 147173592 Recifin 147173593 Tdp1 147173595 Topoisomerase 1 inhibitors 147173596 Topotecan 147173598 Tyrosyl-DNA Phosphodiesterase 1 Inhibitors TAB-4269 147157557 HIV-1 IN Mutant in a Single Round Vector NCI Infectious Disease, Licensing, Research Materials Infectious Disease Licensing Research Materials Stephen Hughes, Steven Smith <h2>Summary:</h2> <p>The Retroviral Replication Laboratory of the National Cancer Institute actively seeks parties interested in non-exclusive licensing a&nbsp;collection of single-round vectors containing mutations in HIV-1 IN or RT.</p> <h2>Description of Technology:</h2> <p>Antiretroviral therapy (ART) has changed the prognosis of HIV-1 infection to a chronic illness that, in most cases, can be managed or controlled. Integrase strand transfer inhibitors (INSTIs) and reverse transcription inhibitors are essential components of ART drug cocktails. In compliant individuals, ART has been found to block viral replication completely. Additionally, blocking viral replication can prevent the emergence of drug resistance.</p> <p>Researchers at the Retroviral Replication Laboratory of the National Cancer Institute have introduced mutations into the nucleotides encoding the integrase (IN) or reverse transcriptase (RT) of a replication-defective variant of the pNL4.3 HIV-1 vector. The result is a collection of single-round vectors containing mutations in HIV-1 IN or RT. These mutants can be used in single round-infection assays to evaluate potential anti-HIV drugs. The vector collection contains over 140 mutations or a combination of mutations and has been thoroughly tested and validated. This collection is a good research surrogate as the included vectors are safer versions of HIV-1 viruses when compared to those found in patients.</p> <p>Parties interested in licensing the technology should submit an application for licensing and seek detailed information from the Licensing and Patenting Manager indicated below.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Screening assays to test the efficacy of potential INSTIs or RT anti-HIV drugs</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Collections make from replication-defective variant of the pNL4.3 HIV-1 vector</li> <li>Over 140 mutation or combination of mutations in collection</li> </ul> 2021-11-04 2026-04-24 2021-11-04 2026-04-24 2021-11-04 Anti-HIV Drugs, HIV, Hughes, INSTIs, Integrase Strand Transfer Inhibitors, pNL4.3, Reverse Transcriptase, RT, Single-Round Vectors, Smith False True Basic (Target Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-11-04 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147162075 Smith SJ, et al. Integrase Strand Transfer Inhibitors Are Effective Anti-HIV Drugs. https://pubmed.ncbi.nlm.nih.gov/33572956/ <a href="https://pubmed.ncbi.nlm.nih.gov/33572956/">Smith SJ, et al. Integrase Strand Transfer Inhibitors Are Effective Anti-HIV Drugs.</a> 147164115 Smith, Steven NCI - CCR Smith, Steven 1 147164114 Hughes, Stephen NIH - NCI NCI Hughes, Stephen (NCI) 2 147164115 Smith, Steven NCI - CCR Smith, Steven 1 147164114 Hughes, Stephen NIH - NCI NCI Hughes, Stephen (NCI) 2 147158016 HIV-1 IN Mutants In A Single Round Vector E-114-2021-0 Research Material NCI 83704821 Nguyen-Antczak, Lauren lauren.nguyen-antczak@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-4269] HIV-1 IN Mutant in a Single Round Vector&body=Please send me information about technology [TAB-4269] HIV-1 IN Mutant in a Single Round Vector.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Nguyen-Antczak, Lauren<br><a href="mailto:lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-4269] HIV-1 IN Mutant in a Single Round Vector&body=Please send me information about technology [TAB-4269] HIV-1 IN Mutant in a Single Round Vector.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">lauren.nguyen-antczak@nih.gov</a><br> 147171717 Anti-HIV Drugs 147171718 HIV 147171720 Hughes 147171721 INSTIs 147171723 Integrase Strand Transfer Inhibitors 147171725 pNL4.3 147171727 Reverse Transcriptase 147171728 RT 147171730 Single-Round Vectors 147171732 Smith TAB-4223 147157508 Chimeric Antigen Receptors to CD22 for Treating Hematological Cancers NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Dimiter Dimitrov, Crystal Mackall, Rimas Orentas, Ira Pastan, Nirali Shah <h2>Description of Technology:</h2> <p>Chimeric antigen receptors (CARs) are hybrid proteins consisting of an antibody binding fragment fused to protein signaling domains that cause T-cells which express the CAR to become cytotoxic.&nbsp; Once activated, these cytotoxic T-cells can selectively eliminate the cells which they recognize via the antibody binding fragment of the CAR.&nbsp; Thus, by engineering a T-cell to express a CAR that is specific for a certain cell surface protein, it is possible to selectively target those cells for destruction.&nbsp; This promising new therapeutic approach is known as adoptive cell therapy.<br /> &nbsp;<br /> CD22 is a cell surface protein expressed on a large number of B-cell lineage hematological cancers, such as leukemia and lymphoma.&nbsp; Several promising therapies are being developed which target CD22, including therapeutic antibodies and immunotoxins.&nbsp; This technology concerns the use of a high affinity antibody binding fragment to CD22 (known as m971), as the targeting moiety of a CAR. The resulting CAR can be used in adoptive cell therapy treatment for cancer.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Treatment of diseases associated with increased or preferential expression of CD22</li> <li>Hematological cancers such as chronic lymphocytic leukemia (CLL), hairy cell leukemia (HCL) and pediatric acute lymphoblastic leukemia (ALL)</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>High affinity of the m971 antibody binding fragment increases the likelihood of successful targeting</li> <li>Targeted therapy decreases non-specific killing of healthy, essential cells, potentially resulting in fewer non-specific side-effects and healthier patients</li> <li>Hematological cancers are susceptible to cytotoxic T-cells for treating because they are present in the bloodstream&nbsp;</li> <li>Expression of CD22 only on mature cells avoids stem cell elimination during treatment</li> </ul> 2021-06-02 2026-04-24 2021-06-02 2026-04-24 2021-06-02 Acute Lymphoblastic Leukemia, adoptive cell therapy, ALL, B-CELL, CD22, Chimeric antigen receptors (CARs), Chronic lymphocytic leukemia, CLL, Dimitrov, Hairy cell leukemia, HCL, Immunotherapy, pediatric False True Clinical True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-06-02 72159138 Clinical Phase I 72159138 NCI 37470483 Website Abstract E-017-2017 E-080-2008 E-106-2015 E-161-2018 147161901 Shah NN et. al. CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial https://pubmed.ncbi.nlm.nih.gov/32286905/ <a href="https://pubmed.ncbi.nlm.nih.gov/32286905/">Shah NN et. al. CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial</a> 147163959 Orentas, Rimas NIH - NCI NCI Orentas, Rimas (NCI) 0 147163960 Shah, Nirali NIH - NCI NCI Shah, Nirali (NCI) 1 147163956 Pastan, Ira NIH - NCI NCI Pastan, Ira (NCI) 2 147163958 Mackall, Crystal NIH - NCI NCI Mackall, Crystal (NCI) 3 147163957 Dimitrov, Dimiter NIH - NCI NCI Dimitrov, Dimiter (NCI) 4 147163960 Shah, Nirali NIH - NCI NCI Shah, Nirali (NCI) 1 147163959 Orentas, Rimas NIH - NCI NCI Orentas, Rimas (NCI) 0 147163956 Pastan, Ira NIH - NCI NCI Pastan, Ira (NCI) 2 147163958 Mackall, Crystal NIH - NCI NCI Mackall, Crystal (NCI) 3 147163957 Dimitrov, Dimiter NIH - NCI NCI Dimitrov, Dimiter (NCI) 4 147158326 High Activity Chimeric Antigen Receptor For CD22 E-291-2012-0 Filing authorized NCI 147162599 M971 CAR Research Material E-291-2012-1 Research Material NCI 83673032 Whitney, Laurie WhitneyL@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC WhitneyL@mail.nih.gov?subject=Web Inquiry on [TAB-4223] Chimeric Antigen Receptors to CD22 for Treating Hematological Cancers&body=Please send me information about technology [TAB-4223] Chimeric Antigen Receptors to CD22 for Treating Hematological Cancers.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Whitney, Laurie<br><a href="mailto:WhitneyL@mail.nih.gov?subject=Web Inquiry on [TAB-4223] Chimeric Antigen Receptors to CD22 for Treating Hematological Cancers&body=Please send me information about technology [TAB-4223] Chimeric Antigen Receptors to CD22 for Treating Hematological Cancers.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">WhitneyL@mail.nih.gov</a><br> 147161263 E-291-2012-0 E-291-2012-0-US-01 M971 Chimeric Antigen Receptors PRV US 61/717,960 Abandoned US <br />Provisional (PRV) 61/717,960<br />Filed on 2012-10-24<br />Status: Abandoned 147167485 E-291-2012-0 E-291-2012-0-PCT-02 M971 Chimeric Antigen Receptors PCT Patent Cooperation Treaty PCT/US2013/060332 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2013/060332<br />Filed on 2013-09-18<br />Status: Expired 147167486 E-291-2012-0 E-291-2012-0-AU-03 M971 Chimeric Antigen Receptors National Stage Australia 2013335180 2013335180 Issued Australia <br />National Stage 2013335180<br />Filed on 2013-09-18<br />Status: Issued 147167487 E-291-2012-0 E-291-2012-0-BR-04 M971 Chimeric Antigen Receptors National Stage Brazil BR112015009003-6 BR112015009003-6 Issued Brazil <br />National Stage BR112015009003-6<br />Filed on 2015-04-22<br />Status: Issued 147167488 E-291-2012-0 E-291-2012-0-CA-05 M971 Chimeric Antigen Receptors National Stage Canada 2889055 2889055 Issued Canada <br />National Stage 2889055<br />Filed on 2013-09-18<br />Status: Issued 147167489 E-291-2012-0 E-291-2012-0-CN-06 M971 Chimeric Antigen Receptors National Stage China ZL201380061387.5 201380061387.5 Issued China <br />National Stage 201380061387.5<br />Filed on 2015-05-25<br />Status: Issued 147167490 E-291-2012-0 E-291-2012-0-EP-07 M971 Chimeric Antigen Receptors National Stage European Patent 2912061 13773468.7 Issued European Patent <br />National Stage 13773468.7<br />Filed on 2013-09-18<br />Status: Issued 147167491 E-291-2012-0 E-291-2012-0-IN-08 M971 Chimeric Antigen Receptors National Stage India 385803 2344/CHENP/2015 Issued India <br />National Stage 2344/CHENP/2015<br />Filed on 2013-09-18<br />Status: Issued 147167492 E-291-2012-0 E-291-2012-0-JP-09 M971 Chimeric Antigen Receptors National Stage Japan 6338252 2015-539602 Issued Japan <br />National Stage 2015-539602<br />Filed on 2013-09-18<br />Status: Issued 147167493 E-291-2012-0 E-291-2012-0-RU-10 M971 Chimeric Antigen Receptors National Stage Russia 2658485 2015117237 Issued Russia <br />National Stage 2015117237<br />Filed on 2015-05-07<br />Status: Issued 147167494 E-291-2012-0 E-291-2012-0-US-11 M971 Chimeric Antigen Receptors National Stage US 10,072,078 14/437,889 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10072078 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10072078">10,072,078</a><br />Filed on 2015-04-23<br />Status: Issued 147167495 E-291-2012-0 E-291-2012-0-HK-12 M971 Chimeric Antigen Receptors National Stage Hong Kong HK1213922B 16101891.0 Issued Hong Kong <br />National Stage 16101891.0<br />Filed on 2016-02-19<br />Status: Issued 147167496 E-291-2012-0 E-291-2012-0-RU-13 M971 Chimeric Antigen Receptors DIV Russia 2770411 2018116582 Issued Russia <br />Divisional (DIV) 2018116582<br />Filed on 2018-05-04<br />Status: Issued 147167497 E-291-2012-0 E-291-2012-0-JP-14 M971 Chimeric Antigen Receptors DIV Japan 6643394 2018-088908 Issued Japan <br />Divisional (DIV) 2018-088908<br />Filed on 2018-05-02<br />Status: Issued 147167499 E-291-2012-0 E-291-2012-0-AU-16 M971 Chimeric Antigen Receptors DIV Australia 2018204257 2018204257 Issued Australia <br />Divisional (DIV) 2018204257<br />Filed on 2018-06-14<br />Status: Issued 147167500 E-291-2012-0 E-291-2012-0-US-17 M971 CHIMERIC ANTIGEN RECEPTORS DIV US 10,703,816 16/107,271 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10703816 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10703816">10,703,816</a><br />Filed on 2018-08-21<br />Status: Issued 147167501 E-291-2012-0 E-291-2012-0-DE-18 M971 Chimeric Antigen Receptors EP Germany 2912061 13773468.7 Issued Germany <br />European patent (EP) 13773468.7<br />Filed on 2015-04-22<br />Status: Issued 147167502 E-291-2012-0 E-291-2012-0-ES-19 M971 Chimeric Antigen Receptors EP Spain 2912061 13773468.7 Issued Spain <br />European patent (EP) 13773468.7<br />Filed on 2015-04-22<br />Status: Issued 147167503 E-291-2012-0 E-291-2012-0-FR-20 M971 Chimeric Antigen Receptors EP France 2912061 13773468.7 Issued France <br />European patent (EP) 13773468.7<br />Filed on 2015-04-22<br />Status: Issued 147167504 E-291-2012-0 E-291-2012-0-GB-21 M971 Chimeric Antigen Receptors EP United Kingdom 2912061 13773468.7 Issued United Kingdom <br />European patent (EP) 13773468.7<br />Filed on 2015-04-22<br />Status: Issued 147167505 E-291-2012-0 E-291-2012-0-IT-22 M971 Chimeric Antigen Receptors EP Italy 2912061 13773468.7 Issued Italy <br />European patent (EP) 13773468.7<br />Filed on 2015-04-22<br />Status: Issued 147167506 E-291-2012-0 E-291-2012-0-CN-23 M971 Chimeric Antigen Receptors DIV China ZL201910500128.7 201910500128.7 Issued China <br />Divisional (DIV) 201910500128.7<br />Filed on 2019-06-11<br />Status: Issued 147167507 E-291-2012-0 E-291-2012-0-US-24 M971 CHIMERIC ANTIGEN RECEPTORS DIV US 11,807,682 16/869,792 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11807682 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11807682">11,807,682</a><br />Filed on 2020-05-08<br />Status: Issued 147174692 Acute Lymphoblastic Leukemia 147174693 adoptive cell therapy 147174694 ALL 147174695 B-CELL 147174696 CD22 147174697 Chimeric antigen receptors (CARs) 147174698 Chronic lymphocytic leukemia 147174699 CLL 147174700 Dimitrov 147174701 Hairy cell leukemia 147174702 HCL 147174703 Immunotherapy 147174704 pediatric TAB-4216 147157501 New Heterocyclic Scaffold-Based Inhibitors of the Polo-Box Domain of Polo-like Kinase 1 for the Treatment of Cancer NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Celeste Alverez, Kenneth Jacobson, Kyung Lee, Jung-Eun Park <h2>Summary:</h2> <p>The National Institutes of Health is seeking commercial partners to co-develop and/or license a&nbsp;heterocyclic scaffold for development of&nbsp;therapeutics against Plk1-dependent cancers.</p> <h2>Description of Technology:</h2> <p>Polo-like kinase 1 (Plk1), a member of the Polo-like kinase family, plays a critical role in regulating mitosis and cell cycle progression. Aberrant expression of Plk1 has been observed in a variety of human cancers, and it is known to be associated with tumorigenesis as well as poor prognosis in cancer patients. Unlike normal cells, some cancer cells are dependent on augmented Plk1 levels to remain viable and are killed when Plk1 function is attenuated. Although Plk1 has proven to be an attractive target in cancer treatment, currently available Plk1 inhibitors have shown limited efficacy with significant dose-limiting toxicity and non-specificity in various preclinical or clinical trials. Thus, there remains an unmet need to develop anti-cancer drugs that are highly specific against Plk1 and have better clinical outcomes.</p> <p>Scientists at the National Institutes of Health have identified a new heterocyclic scaffold with unique structural and chemical features that can be leveraged for anti-Plk1 drug discovery. This triazoloquinazolinone scaffold can be used to synthesize various S-methyl prodrugs that effectively inhibit the functionally essential, polo-box domain (PBD) of Plk1 without affecting its related Plk2 and Plk3 PBDs. These prodrugs effectively arrest mitotic progression and cell proliferation in cell-based assays. Low molecular weight and moderate hydrophobicity of these prodrugs increase their availability in intracellular compartments. Promising chemical features of these compounds could offer a new avenue for developing therapeutics against Plk1-dependent cancers.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Anticancer therapeutics</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Potentially superior toxicity profile while maintaining specificity</li> <li>Inhibition of Plk1-driven cellular proliferation</li> <li>PBD-directed inhibitors show selectivity advantages over classical inhibitors of Plk1</li> <li>Exhibit specific anti-Plk1 PBD activity in both in vitro biochemical and cell-based assays without affecting Plk2 and Plk3 PBDs</li> <li>Anticipated not to be chemically reactive unlike many of the current inhibitors of Plk1 PBD that contain electrophilic groups</li> <li>Exhibit &ge;10-fold higher inhibitory activity than the previously characterized Plk1 PBD-specific phosphopeptide, PLHSpT</li> <li>Low molecular weight and moderate hydrophobicity of these molecules increases their anti-cancer activity in intracellular compartments</li> </ul> 2021-05-05 2026-04-24 2021-05-05 2026-04-24 2021-05-05 CANCER, cell cycle, Heterocyclic Scaffold, Lee, mitosis, Oncology, PBD, plk1, Polo-Box Domain, Polo-Like Kinase 1, PRODRUGS, Triazoloquinazolinone False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-05-05 52406768 Discovery 52406768 NCI 37470483 Website Abstract E-094-2013 E-178-2017 E-179-2017 E-181-2009 E-186-2015 E-254-2016 147161893 Alverez CN, et al. Identification of a new heterocyclic scaffold for inhibitors of the polo-box domain of polo-like kinase 1. https://pubmed.ncbi.nlm.nih.gov/33175530/ <a href="https://pubmed.ncbi.nlm.nih.gov/33175530/">Alverez CN, et al. Identification of a new heterocyclic scaffold for inhibitors of the polo-box domain of polo-like kinase 1.</a> 147163939 Lee, Kyung NIH - NCI NCI Lee, Kyung (NCI) 1 147163938 Jacobson, Kenneth NIH - NIDDK NIDDK Jacobson, Kenneth (NIDDK) 2 147163941 Alverez, Celeste NIH - NCI NCI Alverez, Celeste (NCI) 3 147163940 Park, Jung-Eun NIH - NCI NCI Park, Jung-Eun (NCI) 4 147163939 Lee, Kyung NIH - NCI NCI Lee, Kyung (NCI) 1 147163938 Jacobson, Kenneth NIH - NIDDK NIDDK Jacobson, Kenneth (NIDDK) 2 147163941 Alverez, Celeste NIH - NCI NCI Alverez, Celeste (NCI) 3 147163940 Park, Jung-Eun NIH - NCI NCI Park, Jung-Eun (NCI) 4 147158216 Development Of New Heterocyclic Scaffold-based Prodrugs Against The Polo-box Domain Of Polo-like Kinase 1 E-211-2020-0 Filing authorized National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NCI 83724826 Pollard, Ricquita ricquita.pollard@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4216] New Heterocyclic Scaffold-Based Inhibitors of the Polo-Box Domain of Polo-like Kinase 1 for the Treatment of Cancer&body=Please send me information about technology [TAB-4216] New Heterocyclic Scaffold-Based Inhibitors of the Polo-Box Domain of Polo-like Kinase 1 for the Treatment of Cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollard, Ricquita<br><a href="mailto:ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4216] New Heterocyclic Scaffold-Based Inhibitors of the Polo-Box Domain of Polo-like Kinase 1 for the Treatment of Cancer&body=Please send me information about technology [TAB-4216] New Heterocyclic Scaffold-Based Inhibitors of the Polo-Box Domain of Polo-like Kinase 1 for the Treatment of Cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">ricquita.pollard@nih.gov</a><br> 147161197 E-211-2020-0 E-211-2020-0-US-01 PLK1 POLO BOX DOMAIN INHIBITOR AND METHOD OF TREATING CANCER PRV US 63/082,813 Abandoned US <br />Provisional (PRV) 63/082,813<br />Filed on 2020-09-24<br />Status: Abandoned 147167463 E-211-2020-0 E-211-2020-0-PCT-02 PLK1 POLO BOX DOMAIN INHIBITOR AND METHOD OF TREATING CANCER PCT Patent Cooperation Treaty PCT/US2021/052054 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/052054<br />Filed on 2021-09-24<br />Status: Expired 147167464 E-211-2020-0 E-211-2020-0-AU-01 PLK1 POLO BOX DOMAIN INHIBITORS AND METHOD OF TREATING CANCER National Stage Australia 2021350736 Pending Australia <br />National Stage 2021350736<br />Filed on 2023-04-18<br />Status: Pending 147167465 E-211-2020-0 E-211-2020-0-US-02 PLK1 POLO BOX DOMAIN INHIBITORS AND METHOD OF TREATING CANCER National Stage US 18/028,463 Pending US <br />National Stage 18/028,463<br />Filed on 2023-03-24<br />Status: Pending 147167466 E-211-2020-0 E-211-2020-0-CA-01 PLK1 POLO BOX DOMAIN INHIBITOR AND METHOD OF TREATING CANCER National Stage Canada 3193855 Pending Canada <br />National Stage 3193855<br />Filed on 2023-03-24<br />Status: Pending 147167467 E-211-2020-0 E-211-2020-0-EP-01 PLK1 POLO DOMAIN INHIBITORS AND METHOD OF TREATING CANCER National Stage European Patent 21795110.2 Pending European Patent <br />National Stage 21795110.2<br />Filed on 2023-04-19<br />Status: Pending 147173725 CANCER 147173726 cell cycle 147173728 Heterocyclic Scaffold 147173729 Lee 147173730 mitosis 147173731 Oncology 147173732 PBD 147173733 plk1 147173735 Polo-Box Domain 147173737 Polo-Like Kinase 1 147173738 PRODRUGS 147173740 Triazoloquinazolinone TAB-4184 147157469 Automated Digital Pathology Device for High-Throughput Demand NCI Infectious Disease, Licensing, Medical Devices, Neurology, Non-Medical Devices, Oncology Infectious Disease Licensing Medical Devices Neurology Non-Medical Devices Oncology Anthony Cappadona, Young-Wan Moon, Zhengping (Ping) Zhuang <h2>Summary:</h2> <p>The NCI is seeking licensees to develop an automated digital pathology device compatible with high-throughput data analysis.</p> <h2>Description of Technology:</h2> <p>Computer and imaging technologies led to the development of digital pathology and the capture and storage of pathological specimens as digitally formatted images. The use of artificial intelligence (AI) in digital pathology, such as in three-dimensional (3D) reconstruction, requires analyses of high volumes of data. This resulted in increased demands for processing and acquisition of digital images of pathology samples. Increased usage cannot be met by the time-consuming, manual, and laborious methods currently used. Therefore, there is a need for automation of the techniques used in processing of pathology samples and acquisition of digital images to make them amenable with high-throughput approaches like AI analysis.</p> <p>National Cancer Institute inventors are developing an automated device with integrated tissue sectioning, staining, scanning, and high-throughput capability. This device integrates pathology sample processing (e.g., sectioning, fixing, and staining) with optical scanning and digital image acquisition. This streamlines the entire process enabling high-throughput preparation of large volumes of samples and data for subsequent AI analysis. As a result of automation, the device saves time, minimizes errors, and reduces wasting reagents and supplies.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Biopsy sample processing in pathology labs, hospitals, research labs</li> <li>Applicable to diagnoses of various disease indications, including cancer and infectious diseases</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Facilitates processing and imaging of large volumes of pathology samples</li> <li>Automation saves time, increases reproducibility, and minimizes errors</li> <li>Compatible with high-throughput processes, e.g., AI analysis of digital pathology images and 3D reconstruction</li> </ul> 2021-09-23 2026-04-24 2021-09-23 2026-04-24 2021-09-23 AI, Artificial Intelligence, AUTOMATION, Digital Pathology, High-throughput, Histology, IMAGING, Zhuang False True Prototype True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-09-23 52406769 Prototype 52406769 NCI 37470483 Website Abstract 147163813 Zhuang, Zhengping (Ping) NIH - NCI NCI Zhuang, Zhengping (Ping) (NCI) 1 147163814 Moon, Young-Wan AIPATec, Inc. Moon, Young-Wan 2 147163815 Cappadona, Anthony NCI - CCR NCI Cappadona, Anthony (NCI) 3 147163813 Zhuang, Zhengping (Ping) NIH - NCI NCI Zhuang, Zhengping (Ping) (NCI) 1 147163814 Moon, Young-Wan AIPATec, Inc. Moon, Young-Wan 2 147163815 Cappadona, Anthony NCI - CCR NCI Cappadona, Anthony (NCI) 3 147157951 Automated Device With Integrated Histology Tissue Sectioning, Staining, And Scanning For High Throughput Demand E-084-2019-0 Filing authorized AIPATec, Inc., NCI 83687903 Pollack, Michael michael.pollack@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC michael.pollack@nih.gov?subject=Web Inquiry on [TAB-4184] Automated Digital Pathology Device for High-Throughput Demand&body=Please send me information about technology [TAB-4184] Automated Digital Pathology Device for High-Throughput Demand.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollack, Michael<br><a href="mailto:michael.pollack@nih.gov?subject=Web Inquiry on [TAB-4184] Automated Digital Pathology Device for High-Throughput Demand&body=Please send me information about technology [TAB-4184] Automated Digital Pathology Device for High-Throughput Demand.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">michael.pollack@nih.gov</a><br> 147167192 E-084-2019-0 E-084-2019-0-US-01 Automated Device With Integrated Histology Tissue Sectioning, Staining, And Scanning For High Throughput Demand PRV US 62/820,604 Abandoned US <br />Provisional (PRV) 62/820,604<br />Filed on 2019-03-19<br />Status: Abandoned 147167193 E-084-2019-0 E-084-2019-0-PCT-02 AUTOMATIC SYSTEM AND METHOD FOR TISSUE SECTIONING, STAINING, AND SCANNING PCT Patent Cooperation Treaty PCT/US2020/023644 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2020/023644<br />Filed on 2020-03-19<br />Status: Expired 147167194 E-084-2019-0 E-084-2019-0-EP-03 Automated Device With Integrated Histology Tissue Sectioning, Staining, And Scanning For High Throughput Demand National Stage European Patent 20772823.9 Pending European Patent <br />National Stage 20772823.9<br />Filed on 2020-03-19<br />Status: Pending 147167195 E-084-2019-0 E-084-2019-0-JP-04 AUTOMATIC SYSTEM AND METHOD FOR TISSUE SECTIONING, STAINING, AND SCANNING National Stage Japan 7680363 2021-555576 Issued Japan <br />National Stage 2021-555576<br />Filed on 2021-09-14<br />Status: Issued 147167196 E-084-2019-0 E-084-2019-0-US-05 AUTOMATIC SYSTEM AND METHOD FOR TISSUE SECTIONING, STAINING, AND SCANNING National Stage US 17/440,368 Pending US <br />National Stage 17/440,368<br />Filed on 2021-09-17<br />Status: Pending 147167197 E-084-2019-0 E-084-2019-0-CN-06 Automated Device With Integrated Histology Tissue Sectioning, Staining, And Scanning For High Throughput Demand National Stage China ZL202080023309.6 202080023309.6 Issued China <br />National Stage 202080023309.6<br />Filed on 2020-03-19<br />Status: Issued 147167198 E-084-2019-0 E-084-2019-0-KR-07 AUTOMATIC SYSTEM AND METHOD FOR TISSUE SECTIONING, STAINING, AND SCANNING National Stage South Korea 10-2021-7033539 Pending South Korea <br />National Stage 10-2021-7033539<br />Filed on 2021-10-18<br />Status: Pending 147171081 AI 147171082 Artificial Intelligence 147171083 AUTOMATION 147171084 Digital Pathology 147171085 High-throughput 147171086 Histology 147171087 IMAGING 147171088 Zhuang TAB-4183 147157468 Size-dependent brain distribution of macromolecular drug delivery platform NCI Collaboration, Licensing, Neurology, Oncology Collaboration Licensing Neurology Oncology Stephan Stern, David Stevens <h2>Summary:</h2> <p>The NCI seeks research co-development partners and/or licensees for&nbsp;a selective polylysine succinylated (PLS) drug delivery platform.</p> <h2>Description of Technology:</h2> <p>The blood brain barrier (BBB) is a specialized endothelium that prevents the uptake of substances from the systemic circulation into the central nervous system. This barrier, while protecting the sensitive physiological environment of the brain, is also a major impediment in administering therapeutics that need to pass through the BBB. A drug delivery platform that could deliver therapeutic agents directly to the brain is needed, and could have wide ranging significance in a variety of psychiatric, oncology, infectious, and neurodegenerative diseases. Currently, there are no approved formulations that can effectively increase drug exposure to the brain, and this remains an unmet clinical need.</p> <p>&nbsp;Investigators in the Nanotechnology Characterization Laboratory at the National Cancer Institute (NCI) have developed a selective polylysine succinylated (PLS) drug delivery platform, which can pass through the BBB by scavenger receptor A1 (SR-A1)- mediated transcytosis, and also target SR-A1 expressing cells, such as macrophages, monocytes, mast cells, and dendritic cells. This PLS polymer has an anionic backbone, containing pendant carboxylic acids that facilitate conjugation of therapeutic agent having a free alcohol moiety via hydrolysable ester bonds. Thus, the PLS platform has tremendous versatility in delivering a wide variety of therapeutic cargos to the brain. In addition to small molecules, other classes of therapeutic drugs that can be conjugated to the PLS polymer include nucleic acids and peptides. In addition to delivering therapeutic agents, this technology can also be used for imaging applications by conjugating imaging agents to the PLS polymer. This technology is a variant of the PLS drug delivery platform previously developed by the inventors (NIH Reference # E-097-2017).&nbsp;&nbsp;</p> <p>Through in vivo mice fluorescent studies, the inventors have shown greater brain distribution with 10k and 25k PLS polymers in comparison to a larger, 62.5k polymer. This polymer platform has tremendous potential to increase drug delivery to the brain and lymphatic system, as well as stabilize metabolically labile drugs. It offers a novel therapeutic strategy for treating brain cancers and other neurological disorders. It also brings a novel imaging approach for diagnostic purposes.&nbsp;</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Treatment of brain cancer</li> <li>Treatment of neurological disorders representing significant unmet medical needs; e.g., Alzheimer&rsquo;s disease, depression and epilepsy</li> <li>Treatment of infectious diseases</li> <li>Imaging of the central nervous system</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Currently no efficient, general drug delivery system to cross the blood-brain barrier; this invention would be the first-to-market</li> <li>Several go-to-market opportunities; this technology could be used to treat psychiatric, oncology, infectious disease and neurodegenerative-related diseases</li> <li>Would overcome the major factor limiting the future growth of neurotherapeutics</li> </ul> 2021-02-09 2026-04-24 2022-10-04 2026-04-24 2021-02-09 BBB, Blood-brain Barrier, Brain Cancer, Controlled Drug Release, Drug Delivery Platform, Neurological Disorders, Stern False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2022-10-04 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-097-2017 147161875 Frederick National Laboratory web article entitled &ldquo;Novel prodrug platform enables drug delivery to lymphatic system&rdquo; https://frederick.cancer.gov/news/novel-prodrug-platform-enables-drug-delivery-lymphatic-system <a href="https://frederick.cancer.gov/news/novel-prodrug-platform-enables-drug-delivery-lymphatic-system">Frederick National Laboratory web article entitled &ldquo;Novel prodrug platform enables drug delivery to lymphatic system&rdquo;</a> 147161991 Stephan T. Stern et al., &ldquo;Application of a Scavenger Receptor A1-Targeted Polymeric Prodrug Platform for Lymphatic Drug Delivery in HIV&rdquo;, corresponding to NIH Ref. E-097-20172. https://pubmed.ncbi.nlm.nih.gov/32841040/ <a href="https://pubmed.ncbi.nlm.nih.gov/32841040/">Stephan T. Stern et al., &ldquo;Application of a Scavenger Receptor A1-Targeted Polymeric Prodrug Platform for Lymphatic Drug Delivery in HIV&rdquo;, corresponding to NIH Ref. E-097-20172.</a> 147163811 Stern, Stephan NIH - NCI Leidos Stern, Stephan (Leidos) 1 147163812 Stevens, David NIH - NCI Stevens, David 2 147163811 Stern, Stephan NIH - NCI Leidos Stern, Stephan (Leidos) 1 147163812 Stevens, David NIH - NCI Stevens, David 2 147157936 Size-dependent Brain Distribution Of Macromolecular Drug Delivery Platform E-078-2020-0 Filing authorized NCI, NIH - NCI 83704821 Nguyen-Antczak, Lauren lauren.nguyen-antczak@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-4183] Size-dependent brain distribution of macromolecular drug delivery platform&body=Please send me information about technology [TAB-4183] Size-dependent brain distribution of macromolecular drug delivery platform.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Nguyen-Antczak, Lauren<br><a href="mailto:lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-4183] Size-dependent brain distribution of macromolecular drug delivery platform&body=Please send me information about technology [TAB-4183] Size-dependent brain distribution of macromolecular drug delivery platform.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">lauren.nguyen-antczak@nih.gov</a><br> 147161007 E-078-2020-0 E-078-2020-0-US-01 SIZE-DEPENDENT BRAIN AND LYMPHATIC DISTRIBUTION OF MACROMOLECULAR DRUG DELIVERY PLATFORM PRV US 63/037,058 Abandoned US <br />Provisional (PRV) 63/037,058<br />Filed on 2020-06-10<br />Status: Abandoned 147167186 E-078-2020-0 E-078-2020-0-PCT-02 SIZE-DEPENDENT BRAIN AND LYMPHATIC DISTRIBUTION OF MACROMOLECULAR DRUG DELIVERY PLATFORM PCT Patent Cooperation Treaty PCT/US2021/036548 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/036548<br />Filed on 2021-06-09<br />Status: Expired 147167187 E-078-2020-0 E-078-2020-0-AU-03 SIZE-DEPENDENT BRAIN AND LYMPHATIC DISTRIBUTION OF MACROMOLECULAR DRUG DELIVERY PLATFORM National Stage Australia 2021289443 Pending Australia <br />National Stage 2021289443<br />Filed on 2021-06-09<br />Status: Pending 147167188 E-078-2020-0 E-078-2020-0-CA-04 SIZE-DEPENDENT BRAIN AND LYMPHATIC DISTRIBUTION OF MACROMOLECULAR DRUG DELIVERY PLATFORM National Stage Canada 3186654 Pending Canada <br />National Stage 3186654<br />Filed on 2021-06-09<br />Status: Pending 147167189 E-078-2020-0 E-078-2020-0-EP-05 SIZE-DEPENDENT BRAIN AND LYMPHATIC DISTRIBUTION OF MACROMOLECULAR DRUG DELIVERY PLATFORM National Stage European Patent 21822452.5 Pending European Patent <br />National Stage 21822452.5<br />Filed on 2023-01-05<br />Status: Pending 147167190 E-078-2020-0 E-078-2020-0-US-06 SIZE-DEPENDENT BRAIN AND LYMPHATIC DISTRIBUTION OF MACROMOLECULAR DRUG DELIVERY PLATFORM National Stage US 18/009,710 Pending US <br />National Stage 18/009,710<br />Filed on 2022-12-09<br />Status: Pending 147170873 BBB 147170875 Blood-brain Barrier 147170877 Brain Cancer 147170879 Controlled Drug Release 147170881 Drug Delivery Platform 147170883 Neurological Disorders 147170884 Stern TAB-4136 147157418 IgG4 Hinge Containing Chimeric Antigen Receptors Targeting Glypican-1 For Treating Solid Tumors NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Mitchell Ho, Jessica Hong <h2>Description of Technology:</h2> <p>Pancreatic cancer is the fourth most common cause of cancer deaths in the U.S. The overall 5-year survival rate is 8.5%. Glypican-1 (GPC1) is a cell surface heparan sulfate proteoglycan protein overexpressed in pancreatic cancer. Due to preferential expression, GPC1 represents a potential candidate for targeted therapy for pancreatic cancer and other GPC1-expressing cancers, such as prostate.</p> <p>Researchers at National Cancer Institute (NCI) developed novel Chimeric Antigen Receptors (CARs) specific for GPC1 that include short Immunoglobulin subclass 4 (IgG4) hinge sequences between the extracellular antigen recognition domain and the transmembrane domain. Hinge changes in CAR design can achieve the threshold of antigen density required for optimal CAR-T cell activity. Significantly, the optimized GPC1-IgG4 hinge CARs have shown rapid and complete tumor regression in mouse models.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Immunotherapeutic applications for the treatment of pancreatic adenocarcinoma &ndash; a significant unmet medical need</li> <li>Immunotherapeutic applications for the treatment of several GPC1-positive malignancies &ndash; including uterine cervical cancer, colorectal cancer, liver cancer, glioma, lung cancer, head and neck cancer, thyroid cancer, endometrial cancer, breast cancer and ovarian cancer</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>GPC1-targeted CAR T cells demonstrated potent antitumor efficacy in a peritoneal dissemination xenograft mouse model.</li> <li>Recombinant receptors providing both antigen-binding and T-cell&ndash;activating functions&nbsp;</li> <li>Likely successful targeting and lower toxicity due to high affinity of the GPC1 nanobody fragment</li> <li>Incorporation of the IgG4 hinge sequence increases the potency of the nanobody based CARs against pancreatic cancer&nbsp;</li> <li>CARs using the IgG4 hinge domain are available for immediate testing</li> <li>Potential immunotherapy for several cancer types with few treatment options &ndash; including pancreatic adenocarcinoma and uterine cervical cancer&nbsp;</li> </ul> 2021-08-18 2026-04-24 2021-08-18 2026-04-24 2021-08-18 cancer therapeutic, CAR, chimeric antigen receptor, Glypican-1, GPC-1, Hinge, HO, IgG4, Immunoglobulin subclass 4, NANOBODY, Pancreatic Cancer, Single Domain Antibody False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-08-18 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-028-2019 147163647 Ho, Mitchell NIH - NCI NCI Ho, Mitchell (NCI) 1 147163648 Hong, Jessica NIH - NCI NCI Hong, Jessica (NCI) 2 147163647 Ho, Mitchell NIH - NCI NCI Ho, Mitchell (NCI) 1 147163648 Hong, Jessica NIH - NCI NCI Hong, Jessica (NCI) 2 147158003 IgG4 Hinge Containing Chimeric Antigen Receptors For Treating Solid Tumors E-107-2020-0 Filing authorized NCI 83731987 Dhal, Abritee abritee.dhal@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-4136] IgG4 Hinge Containing Chimeric Antigen Receptors Targeting Glypican-1 For Treating Solid Tumors&body=Please send me information about technology [TAB-4136] IgG4 Hinge Containing Chimeric Antigen Receptors Targeting Glypican-1 For Treating Solid Tumors.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dhal, Abritee<br><a href="mailto:abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-4136] IgG4 Hinge Containing Chimeric Antigen Receptors Targeting Glypican-1 For Treating Solid Tumors&body=Please send me information about technology [TAB-4136] IgG4 Hinge Containing Chimeric Antigen Receptors Targeting Glypican-1 For Treating Solid Tumors.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">abritee.dhal@nih.gov</a><br> 147161052 E-107-2020-0 E-107-2020-0-US-01 IGG4 HINGE-CONTAINING CHIMERIC ANTIGEN RECEPTORS TARGETING GLYPICAN-1 (GPC1) FOR TREATING SOLID TUMORS PRV US 63/065,388 Abandoned US <br />Provisional (PRV) 63/065,388<br />Filed on 2020-08-13<br />Status: Abandoned 147166868 E-107-2020-0 E-107-2020-0-PCT-02 IGG4 HINGE-CONTAINING CHIMERIC ANTIGEN RECEPTORS TARGETING GLYPICAN-1 (GPC1) FOR TREATING SOLID TUMORS PCT Patent Cooperation Treaty PCT/US2021/045305 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/045305<br />Filed on 2021-08-10<br />Status: Expired 147166869 E-107-2020-0 E-107-2020-0-CN-01 IGG4 HINGE-CONTAINING CHIMERIC ANTIGEN RECEPTORS TARGETING GLYPICAN-1 (GPC1) FOR TREATING SOLID TUMORS National Stage China 202180070402.7 Pending China <br />National Stage 202180070402.7<br />Filed on 2023-04-13<br />Status: Pending 147166870 E-107-2020-0 E-107-2020-0-US-02 IGG4 HINGE-CONTAINING CHIMERIC ANTIGEN RECEPTORS TARGETING GLYPICAN-1 (GPC1) FOR TREATING SOLID TUMORS National Stage US 18/020,191 Pending US <br />National Stage 18/020,191<br />Filed on 2023-02-07<br />Status: Pending 147166871 E-107-2020-0 E-107-2020-0-EP-01 IGG4 HINGE-CONTAINING CHIMERIC ANTIGEN RECEPTORS TARGETING GLYPICAN-1 (GPC1) FOR TREATING SOLID TUMORS National Stage European Patent 21762956.7 Pending European Patent <br />National Stage 21762956.7<br />Filed on 2023-02-08<br />Status: Pending 147171570 cancer therapeutic 147171571 CAR 147171572 chimeric antigen receptor 147171573 Glypican-1 147171575 GPC-1 147171576 Hinge 147171577 HO 147171578 IgG4 147171580 Immunoglobulin subclass 4 147171581 NANOBODY 147171582 Pancreatic Cancer 147171583 Single Domain Antibody TAB-4135 147157417 3-o-sulfo-galactosylceramide Analogs for Targeting Lung Metastases NCI Collaboration, Immunology, Licensing, Oncology, Therapeutics Collaboration Immunology Licensing Oncology Therapeutics Jay Berzofsky, Kaddy Camara, Amy Howell, Lise Pasquet, Masaki Terabe <h2>Summary:</h2> <p>The NCI seeks research co-development partners and/or licensees for the sulfatide analog, C24:2</p> <h2>Description of Technology:</h2> <p>Lung metastases represent a major clinical challenge in advanced cancer, with poor survival rates and no effective therapies to prevent their development. Researchers at the National Cancer Institute (NCI) have developed C24:2, a first-in-class synthetic 3-O-sulfo-galactosylceramide analog. After lysosomal processing by dendritic cells, C24:2 switches immune specificity to activate type I NKT cells, triggering a potent IFN-&gamma;&ndash;mediated Th1 response. This novel mechanism significantly reduces lung metastases in preclinical models and positions C24:2 as a promising candidate for next-generation cancer immunotherapy.</p> <p>The structure and synthesis procedure of C24:2 are described in Patent Cooperation Treaty PCT/US2019/023890 which corresponds to E-100-2018 and for which Dr. Jay Berzofsky is the lead inventor. .</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Therapeutic agent for lung metastases from different types of cancers</li> <li>Immunomodulator for type I NKT cell</li> <li>Combination therapy with checkpoint inhibitors or cancer vaccines</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Addresses a high unmet need: No effective therapies currently exist for lung metastases.</li> <li>First-in-class approach: Exploits a unique mechanism based on antigen processing and NKT cell subtype switching.</li> <li>Broad cancer applicability: Effective against metastases from diverse tumor types.</li> <li>Combination potential: May synergize with approved checkpoint inhibitors to boost patient outcomes</li> </ul> The NCI seeks research co-development partners and/or licensees for the sulfatide analog, C24:2. 2021-02-24 2026-04-24 2021-02-24 2026-04-24 2021-02-24 3-o-sulfo-galactosylceramide Analogs, Berzofsky, C24:2, Immunotherapy, lung cancer, Metastasis, Natural Killer cells, NKT cells, Sulfatide Analogs, T Cells False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-02-24 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-034-2010 164128544 Nishio et al. Lysosomal processing of sulfatide analogs alters target NKT cell specificity and immune responses in cancer. (PMID 38127463) https://pubmed.ncbi.nlm.nih.gov/38127463/ <a href="https://pubmed.ncbi.nlm.nih.gov/38127463/">Nishio et al. Lysosomal processing of sulfatide analogs alters target NKT cell specificity and immune responses in cancer. (PMID 38127463)</a> 147163644 Pasquet, Lise NIH - NCI Pasquet, Lise 1 147163642 Berzofsky, Jay NIH - NCI NCI Berzofsky, Jay (NCI) 2 147163645 Howell, Amy University of Connecticut Howell, Amy 3 147163643 Terabe, Masaki NIH - NCI NCI Terabe, Masaki (NCI) 4 147163646 Camara, Kaddy University of Connecticut Camara, Kaddy 5 147163644 Pasquet, Lise NIH - NCI Pasquet, Lise 1 147163642 Berzofsky, Jay NIH - NCI NCI Berzofsky, Jay (NCI) 2 147163645 Howell, Amy University of Connecticut Howell, Amy 3 147163643 Terabe, Masaki NIH - NCI NCI Terabe, Masaki (NCI) 4 147163646 Camara, Kaddy University of Connecticut Camara, Kaddy 5 147157987 C24:2 Activates The Regulatory Type II NKT Cells And Limits The Development Of Lung Metastasis E-100-2018-0 Filing authorized NCI, University of Connecticut 83740301 Dattaroy, Diptadip diptadip.dattaroy@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB diptadip.dattaroy@nih.gov?subject=Web Inquiry on [TAB-4135] 3-o-sulfo-galactosylceramide Analogs for Targeting Lung Metastases&body=Please send me information about technology [TAB-4135] 3-o-sulfo-galactosylceramide Analogs for Targeting Lung Metastases.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dattaroy, Diptadip<br><a href="mailto:diptadip.dattaroy@nih.gov?subject=Web Inquiry on [TAB-4135] 3-o-sulfo-galactosylceramide Analogs for Targeting Lung Metastases&body=Please send me information about technology [TAB-4135] 3-o-sulfo-galactosylceramide Analogs for Targeting Lung Metastases.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">diptadip.dattaroy@nih.gov</a><br> 147161038 E-100-2018-0 E-100-2018-0-US-01 ACTIVATORS OF TYPE II NKT CELLS AND METHODS OF USE THEREOF PRV US 62/648,167 Abandoned US <br />Provisional (PRV) 62/648,167<br />Filed on 2018-03-26<br />Status: Abandoned 147166864 E-100-2018-0 E-100-2018-0-PCT-02 ACTIVATORS OF TYPE II NKT CELLS AND METHODS OF USE THEREOF PCT Patent Cooperation Treaty PCT/US2019/023890 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2019/023890<br />Filed on 2019-03-25<br />Status: Expired 147166865 E-100-2018-0 E-100-2018-0-EP-03 3-O-SULFO-GALACTOSYLCERAMIDE ANALOGS AS ACTIVATORS OF TYPE II NKT CELLS AND USES THEREOF National Stage European Patent 19716658.0 Pending European Patent <br />National Stage 19716658.0<br />Filed on 2020-10-07<br />Status: Pending 147166866 E-100-2018-0 E-100-2018-0-US-04 3-O-SULFO-GALACTOSYLCERAMIDE ANALOGS AS ACTIVATORS OF TYPE II NKT CELLS AND USES THEREOF National Stage US 12,268,700 17/041,604 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12268700 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12268700">12,268,700</a><br />Filed on 2020-09-25<br />Status: Issued 147171417 3-o-sulfo-galactosylceramide Analogs 147171419 Berzofsky 147171420 C24:2 147171421 Immunotherapy 147171422 lung cancer 147171423 Metastasis 147171425 Natural Killer cells 147171427 NKT cells 147171429 Sulfatide Analogs 147171430 T Cells TAB-4133 147157415 CytoSig: A Software Platform for Predicting Cytokine Signaling Activities, Target Discovery, and Clinical Decision Support System (CDSS) from Transcriptomic Profiles NCI Collaboration, Immunology, Licensing, Oncology, Research Materials Collaboration Immunology Licensing Oncology Research Materials Peng Jiang <h2>Description of Technology:</h2> <p>Cytokines are a broad category of intercellular signaling proteins that are critical for intercellular communication in human health and disease. However, systematic profiling of cytokine signaling activities has remained challenging due to the short half-lives of cytokines, and the pleiotropic functions and redundancy of cytokine activities within specific cellular contexts. The redundancy and pleiotropy in cytokine activities are not fully captured by most immunological assays such as the enzyme-linked immunosorbent assay (ELISA) and Luminex xMAP, which only measures the cytokine release level that could be transient and do not reflect target signaling activities. On the other hand, existing databases of cytokine signaling targets cover only a small fraction of cytokines, leaving most cytokine-induced target changes unexplored.&nbsp;</p> <p>Researchers at National Cancer Institute (NCI) have developed the Cytokine Signaling Analyzer (CytoSig) that uses transcriptome data to model the cytokine signaling activity and regulatory cascade in human inflammatory processes. To build the CytoSig platform, the Framework for Data Curation (FDC) was created to couple large-scale automatic data processing with natural language processing functions to assist expert annotations of metadata to analyze RNA-sequencing (RNA-seq) and MicroArray big-data resources. CytoSig includes an initial set of 20,591 curated human cytokine, chemokine, and growth factor response experiments, and can reliably predict the activity of 43 cytokines in both tissues and single cells based on the transcriptional effect of cytokine target genes. CytoSig, an excellent tool for leveraging the big-data resource in public domains to predict clinical outcome of anticancer therapies that inhibit cytokine signaling, is available for co-development and/or licensing.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Predicting cytokine target activities from bulk transcriptomic data available from large-scale cohorts and single-cell RNA-seq data</li> <li>Identifying new immunological functions of cytokines and candidate therapeutic targets in inflammatory diseases</li> <li>Predicting the clinical outcome of therapies that inhibit cytokine signaling in human inflammatory diseases and cancer.</li> <li>Framework for Data Curation (FDC) can be used by data scientists to accelerate data curation projects</li> <li>Applicable to cancers, infectious diseases, and inflammation</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li style="margin-left:9pt">Integrative framework that leverages the big-data resource in public domains to identify candidate therapeutic targets</li> <li style="margin-left:9pt">Higher cytokine coverage compared to existing databases</li> <li style="margin-left:9pt">CytoSig predictions had better associations with the clinical outcome than other metrics, such as ligand or receptor expression and gene-set signatures</li> <li style="margin-left:9pt">Offers particular advantages in analyzing single-cell data because it is not affected by the absence of cytokine-producing cells or zero read counts for ligand or receptor genes</li> </ul> 2021-11-17 2026-04-24 2021-11-17 2026-04-24 2021-11-17 Big-data Integration, Cancer Immunotherapy, CDSS, Clinical Decision Support System, Cytokine Signaling, Infectious Disease, Inflammation, Jiang, Target Discovery, Transcriptomic Profiles False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2021-11-17 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147161877 Jiang P, et al. Systematic investigation of cytokine signaling activity at the tissue and single-cell levels. https://pubmed.ncbi.nlm.nih.gov/34594031/ <a href="https://pubmed.ncbi.nlm.nih.gov/34594031/">Jiang P, et al. Systematic investigation of cytokine signaling activity at the tissue and single-cell levels.</a> 147163639 Jiang, Peng NCI - DCTD NCI Jiang, Peng (NCI) 1 147163639 Jiang, Peng NCI - DCTD NCI Jiang, Peng (NCI) 1 147157955 CellSig: A Data-driven Predictive Model Of Cytokine Signaling And Regulatory Activity E-086-2021-0 Research Material NCI 83691647 Chang, Kevin changke@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB changke@mail.nih.gov?subject=Web Inquiry on [TAB-4133] CytoSig: A Software Platform for Predicting Cytokine Signaling Activities, Target Discovery, and Clinical Decision Support System (CDSS) from Transcriptomic Profiles&body=Please send me information about technology [TAB-4133] CytoSig: A Software Platform for Predicting Cytokine Signaling Activities, Target Discovery, and Clinical Decision Support System (CDSS) from Transcriptomic Profiles.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Chang, Kevin<br><a href="mailto:changke@mail.nih.gov?subject=Web Inquiry on [TAB-4133] CytoSig: A Software Platform for Predicting Cytokine Signaling Activities, Target Discovery, and Clinical Decision Support System (CDSS) from Transcriptomic Profiles&body=Please send me information about technology [TAB-4133] CytoSig: A Software Platform for Predicting Cytokine Signaling Activities, Target Discovery, and Clinical Decision Support System (CDSS) from Transcriptomic Profiles.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">changke@mail.nih.gov</a><br> 147171118 Big-data Integration 147171119 Cancer Immunotherapy 147171121 CDSS 147171123 Clinical Decision Support System 147171125 Cytokine Signaling 147171126 Infectious Disease 147171127 Inflammation 147171129 Jiang 147171131 Target Discovery 147171133 Transcriptomic Profiles TAB-4072 147157354 Synergistic Use of Exo VII Inhibitors And Quinolone Antibiotics For Treating Bacterial Infection NCI Collaboration, Infectious Disease, Licensing, Therapeutics Collaboration Infectious Disease Licensing Therapeutics Shar-yin Huang, Brianna Mitchell, Yves Pommier <h2>Summary:</h2> <p>The NCI seeks co-development partners or licensees to further develop the novel ExoVII inhibitor(s) as antibiotic adjuvants for enhancing the efficacy of quinolone antibiotics, particularly in quinolone-resistant bacterial strains.</p> <h2>Description of Technology:</h2> <p>Topoisomerase poisons, such as quinolone antibiotics, are widely used as anticancer drugs and antibiotics. Quinolone antibiotics act by trapping prokaryotic type IIA topoisomerases (DNA gyrase and TOPO IV), resulting in irreversible topoisomerase cleavage complexes. However, current U.S. Food and Drug Administration (FDA) guidance reserves the use of quinolones for the most serious bacterial infections due to their associated side effects and to limit the occurrence of drug-resistant bacterial strains. Resistance to available antibiotics in pathogenic bacteria is a global challenge as the number of drug-resistant strains increased dramatically each year.&nbsp;</p> <p>Combination of antibiotics with antibiotic adjuvants offers a productive strategy to address the widespread emergence of antibiotic-resistant strains. Exonuclease VII (ExoVII) repairs quinolone-induced DNA damage by excising the tyrosyl-DNA linkage between DNA and trapped DNA gyrase, an essential prokaryotic type II A topoisomerase. Consequently, inactivation of ExoVII results in hypersensitivity to quinolones. Researchers at the NCI have discovered ExoVII inhibitors that synergize with the antimicrobial activity of the quinolone antibiotic ciprofloxacin. These inhibitors present strong potential as antibiotic adjuvants increasing the potency of quinolones &ndash; particularly against quinolone-resistant bacterial strains. In addition, the combination of ExoVII inhibitors with quinolones may allow dose reduction &ndash; potentially decreasing side-effects.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Antibiotic adjuvant in combination with ciprofloxacin and other quinolone antibiotics&nbsp;</li> <li>Antibiotic adjuvant in combination with other topoisomerase poisons&nbsp;</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>ExoVII inhibitor increases the efficacy of quinolone antibiotics, allowing dose reduction for quinolones and potentially decrease side-effects and be well-tolerated</li> <li>Potentially overcome bacterial resistance to quinolones&nbsp;</li> <li>Lack of inhibitory activity against human tyrosyl-DNA phosphodiesterase (TDP) suggests that inhibitors targeting prokaryotic ExoVII might decrease side-effects and be well-tolerated</li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for the development of ExoVII inhibitors and quinolones as a novel treatment for bacterial infections. 2021-05-07 2026-04-24 2021-05-07 2026-04-24 2021-05-12 Antibacterial, Antibiotic Adjuvants, Antibiotic Resistance, DNA gyrase, Exonuclease VII, ExoVII, Infection, Pommier, Quinolone, TOPO IV, Topoisomerase Poisons False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-05-07 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147162122 Huang SN, et al. Exonuclease VII repairs quinolone-induced damage by resolving DNA gyrase cleavage complexes. https://advances.sciencemag.org/content/7/10/eabe0384 <a href="https://advances.sciencemag.org/content/7/10/eabe0384">Huang SN, et al. Exonuclease VII repairs quinolone-induced damage by resolving DNA gyrase cleavage complexes.</a> 147163421 Pommier, Yves NIH - NCI NCI Pommier, Yves (NCI) 1 147163422 Huang, Shar-yin NIH - NCI NCI Huang, Shar-yin (NCI) 2 147163423 Mitchell, Brianna NIH - NCI NCI Mitchell, Brianna (NCI) 3 147163421 Pommier, Yves NIH - NCI NCI Pommier, Yves (NCI) 1 147163422 Huang, Shar-yin NIH - NCI NCI Huang, Shar-yin (NCI) 2 147163423 Mitchell, Brianna NIH - NCI NCI Mitchell, Brianna (NCI) 3 147158139 Isoquinolinedione Derivatives Specifically Inhibit Exonuclease VII And Synergizes With Quinolones As Antimicrobials E-171-2020-0 Filing authorized NCI 91826910 McCrary, Michaela michaela.mccrary@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America michaela.mccrary@nih.gov?subject=Web Inquiry on [TAB-4072] Synergistic Use of Exo VII Inhibitors And Quinolone Antibiotics For Treating Bacterial Infection&body=Please send me information about technology [TAB-4072] Synergistic Use of Exo VII Inhibitors And Quinolone Antibiotics For Treating Bacterial Infection.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov McCrary, Michaela<br><a href="mailto:michaela.mccrary@nih.gov?subject=Web Inquiry on [TAB-4072] Synergistic Use of Exo VII Inhibitors And Quinolone Antibiotics For Treating Bacterial Infection&body=Please send me information about technology [TAB-4072] Synergistic Use of Exo VII Inhibitors And Quinolone Antibiotics For Treating Bacterial Infection.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">michaela.mccrary@nih.gov</a><br> 147166338 E-171-2020-0 E-171-2020-0-US-01 EXO VII INHIBITOR AND QUINOLONE ANTIBIOTIC COMBINATION USEFUL FOR TREATING BACTERIAL INFECTION PRV US 63/129,271 Abandoned US <br />Provisional (PRV) 63/129,271<br />Filed on 2020-12-22<br />Status: Abandoned 147166339 E-171-2020-0 E-171-2020-0-PCT-02 EXO VII Inhibitor and Quinolone Antibiotic Combination Useful for Treating Bacterial Infection PCT Patent Cooperation Treaty PCT/US2021/064996 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/064996<br />Filed on 2021-12-22<br />Status: Expired 147166340 E-171-2020-0 E-171-2020-0-CA-01 EXO VII Inhibitor and Quinolone Antibiotic Combination Useful for Treating Bacterial Infection National Stage Canada 3205044 Pending Canada <br />National Stage 3205044<br />Filed on 2023-06-12<br />Status: Pending 147166341 E-171-2020-0 E-171-2020-0-AU-01 EXO VII Inhibitor and Quinolone Antibiotic Combination Useful for Treating Bacterial Infection National Stage Australia 2021409956 Pending Australia <br />National Stage 2021409956<br />Filed on 2023-06-25<br />Status: Pending 147166342 E-171-2020-0 E-171-2020-0-CN-01 EXO VII Inhibitor and Quinolone Antibiotic Combination Useful for Treating Bacterial Infection National Stage China 202180086835.1 Pending China <br />National Stage 202180086835.1<br />Filed on 2023-06-21<br />Status: Pending 147166343 E-171-2020-0 E-171-2020-0-US-02 EXO VII Inhibitor and Quinolone Antibiotic Combination Useful for Treating Bacterial Infection National Stage US 18/268,603 Pending US <br />National Stage 18/268,603<br />Filed on 2023-06-20<br />Status: Pending 147166344 E-171-2020-0 E-171-2020-0-EP-01 EXO VII Inhibitor and Quinolone Antibiotic Combination Useful for Treating Bacterial Infection National Stage European Patent 21851911.4 Pending European Patent <br />National Stage 21851911.4<br />Filed on 2023-05-16<br />Status: Pending 147172955 Antibacterial 147172957 Antibiotic Adjuvants 147172959 Antibiotic Resistance 147172961 DNA gyrase 147172963 Exonuclease VII 147172965 ExoVII 147172966 Infection 147172967 Pommier 147172969 Quinolone 147172971 TOPO IV 147172973 Topoisomerase Poisons TAB-4070 147157352 Human Synovial Sarcoma Cell Line A2243 NCI Licensing, Oncology, Research Materials Licensing Oncology Research Materials Stuart Aaronson, Nelson Ellmore (Estate) <h2>Summary:</h2> <p>NCI is seeking parties to non-exclusively license the A2243 human synovial sarcoma cell line.</p> <h2>Description of Technology:</h2> <p>Synovial sarcoma is a cancer affecting mesenchymal cells in connective tissues. This rare cancer is typically linked to genetic abnormalities or exposure to radiation. Metastatic growth throughout the body can occur primarily through blood circulation. More than 90% of synovial sarcomas show a characteristic t(X;18)(p11;q11) translocation involving the SYT and SSX genes. The resulting SYT-SSX abnormal fusion protein causes misregulation of downstream gene expression, leading to tumor formation.</p> <p>Researchers at the National Cancer Institute (NCI), Laboratory of Cellular and Molecular Biology (LCMB), have derived a cell line, A2243, from a patient with human synovial sarcoma. This cell line forms tumors in nude mice. The A2243 cell line has been used to characterize the abnormal karyotype associated with synovial sarcoma. Additionally, the A2243 cell line has been used to discover the gene involved in recurrent chromosomal translocation.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Research tool for drug screening efforts</li> <li>Research tool for identifying general and specific chromosomal translocations in synovial sarcoma</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Well-characterized cell line for a rare human cancer: synovial sarcoma</li> </ul> Available for licensing 2021-05-19 2026-04-24 2021-05-25 2026-04-24 2021-05-25 A2243, Aaronson, Chromosomal Translocation, CONNECTIVE TISSUE, Drug Screening, Human Cell Line, Mesenchymal Cells, Rare Cancer, SSX, Synovial sarcoma, SYT, tumor formation False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-05-25 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147162236 Clark J, et al. Identification of novel genes, SYT and SSX, involved in the t(X;18)(p11.2;q11.2) translocation found in human synovial sarcoma. https://pubmed.ncbi.nlm.nih.gov/7951320/ <a href="https://pubmed.ncbi.nlm.nih.gov/7951320/">Clark J, et al. Identification of novel genes, SYT and SSX, involved in the t(X;18)(p11.2;q11.2) translocation found in human synovial sarcoma.</a> 147163413 Aaronson, Stuart NIH - NCI Aaronson, Stuart 1 147163414 Ellmore (Estate), Nelson NIH - NCI NCI Ellmore (Estate), Nelson (NCI) 2 147163413 Aaronson, Stuart NIH - NCI Aaronson, Stuart 1 147163414 Ellmore (Estate), Nelson NIH - NCI NCI Ellmore (Estate), Nelson (NCI) 2 147158107 Human Synovial Sarcoma Cell Line A2243 E-160-2005-0 Research Material NCI 83694133 Gulay French, Suna suna.gulay@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB suna.gulay@nih.gov?subject=Web Inquiry on [TAB-4070] Human Synovial Sarcoma Cell Line A2243&body=Please send me information about technology [TAB-4070] Human Synovial Sarcoma Cell Line A2243.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Gulay French, Suna<br><a href="mailto:suna.gulay@nih.gov?subject=Web Inquiry on [TAB-4070] Human Synovial Sarcoma Cell Line A2243&body=Please send me information about technology [TAB-4070] Human Synovial Sarcoma Cell Line A2243.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">suna.gulay@nih.gov</a><br> 147172626 A2243 147172627 Aaronson 147172629 Chromosomal Translocation 147172630 CONNECTIVE TISSUE 147172631 Drug Screening 147172633 Human Cell Line 147172635 Mesenchymal Cells 147172637 Rare Cancer 147172639 SSX 147172640 Synovial sarcoma 147172642 SYT 147172643 tumor formation TAB-4059 147157341 Small Molecule Ephrin (Eph) Tyrosine Kinase Inhibitors for the Treatment of Colorectal Cancer and Other Eph Growth-dependent Solid Tumors NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Michael Diprima, Nathalie Jores, Denis Kudlinzki, Harald Schwalbe, Giovanna Tosato, Alix Troster <h2>Description of Technology:</h2> <p>Advanced colorectal carcinoma is currently incurable, and new therapies are urgently needed. Ephrin (Eph) receptors are a clinically relevant class of receptor tyrosine kinases. Related signaling pathways are associated with oncogenesis of a number of cancers. NCI investigators found that phosphotyrosine-dependent Eph receptor signaling sustains colorectal carcinoma cell survival, thereby uncovering a survival pathway active in colorectal carcinoma cells. Furthermore, colorectal cancers express the EphrinB2 ligand and its Eph receptors at significantly higher levels than numerous other cancer types. Colorectal cancer patients with the highest levels of EphrinB2 expression in their tumor have a lower probability of survival than those with the lowest levels.</p> <p>The NCI investigators found that a small-molecule inhibitor of the Eph kinase, NVP-BHG712 and its regioisomer NVP-Iso, reduce human colorectal cancer cell growth <em>in vitro</em> and tumor growth in mice. Proof-of-concept data demonstrate inhibition of the Eph tyrosine kinase inhibits the growth of human colorectal carcinomas. Eph signaling sustains colorectal carcinoma cell survival and growth and that inhibition of the phosphotyrosine‐dependent Eph signaling is effective at blocking this prosurvival function. Several derivatives of these prototype compounds have been synthesized and tested for inhibition of the Eph tyrosine kinase activity. Two of these new derivatives have promising biochemical and functional profiles.&nbsp; These small molecule inhibitors have the potential to be developed as a therapeutic for colorectal cancers, other types of Eph-growth dependent tumors, and diseases where the Eph kinase plays a pathogenic role.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Therapeutics for colorectal cancer</li> <li>Therapeutics for other Eph growth-dependent cancers, including breast, lung, prostate, and brain</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Differs in targeting selectivity from many other tyrosine kinase inhibitors</li> <li>Distinct mechanism of action from Regorafenib, the only existing receptor tyrosine inhibitor approved to treat metastatic colorectal cancer; Regorafenib is a multi-targeted tyrosine kinase inhibitor developed to inhibit VEGF-dependent tumor angiogenesis</li> <li>Promising combination therapy when used with other tyrosine kinase inhibitors and antibodies &ndash; such as Cetuximab (approved for metastatic colorectal cancer)</li> <li>Overcome resistance to EGFR or BRAF treatment in various tumor types; attributed to EphA2 kinase activity</li> </ul> 2021-12-14 2026-04-24 2021-12-14 2026-04-24 2021-12-14 colorectal cancer, Eph Kinase Inhibitors, Eph-related cancers, Ephrin, NVP-BHG712, Regioisomer NVP-Iso, small molecule, solid tumors, Tosato, Tyrosine kinase inhibitors False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-12-14 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147162046 Diprima M, et al. Identification of Eph receptor signaling as a regulator of autophagy and a therapeutic target in colorectal carcinoma. https://pubmed.ncbi.nlm.nih.gov/31545551/ <a href="https://pubmed.ncbi.nlm.nih.gov/31545551/">Diprima M, et al. Identification of Eph receptor signaling as a regulator of autophagy and a therapeutic target in colorectal carcinoma.</a> 147163376 Tosato, Giovanna NIH - NCI NCI Tosato, Giovanna (NCI) 1 147163377 Diprima, Michael NIH - NCI NCI Diprima, Michael (NCI) 2 147163378 Schwalbe, Harald J.W. Goethe University, Frankfurt Schwalbe, Harald 3 147163379 Troster, Alix J.W. Goethe University, Frankfurt Troster, Alix 4 147163380 Jores, Nathalie J.W. Goethe University, Frankfurt Jores, Nathalie 5 147163381 Kudlinzki, Denis German Cancer Research Center [Deutsches Krebsforschungszentrum] Kudlinzki, Denis 6 147163376 Tosato, Giovanna NIH - NCI NCI Tosato, Giovanna (NCI) 1 147163377 Diprima, Michael NIH - NCI NCI Diprima, Michael (NCI) 2 147163378 Schwalbe, Harald J.W. Goethe University, Frankfurt Schwalbe, Harald 3 147163379 Troster, Alix J.W. Goethe University, Frankfurt Troster, Alix 4 147163380 Jores, Nathalie J.W. Goethe University, Frankfurt Jores, Nathalie 5 147163381 Kudlinzki, Denis German Cancer Research Center [Deutsches Krebsforschungszentrum] Kudlinzki, Denis 6 147158164 A Receptor Tyrosine Kinase Inhibitor Is Identified As An Effective Drug For Treatment Of Colorectal Carcinoma E-182-2019-0 Filing authorized NCI 147162554 A Receptor Tyrosine Kinase Inhibitor Is Identified As An Effective Drug For Treatment Of Colorectal Carcinoma E-182-2019-1 Filing authorized J.W. Goethe University, NCI 147162555 A Receptor Tyrosine Kinase Inhibitor Is Identified As An Effective Drug For Treatment Of Colorectal Carcinoma E-182-2019-2 Filing authorized German Cancer Research Center [Deutsches Krebsforschungszentrum], J.W. Goethe University, NCI 83691647 Chang, Kevin changke@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB changke@mail.nih.gov?subject=Web Inquiry on [TAB-4059] Small Molecule Ephrin (Eph) Tyrosine Kinase Inhibitors for the Treatment of Colorectal Cancer and Other Eph Growth-dependent Solid Tumors&body=Please send me information about technology [TAB-4059] Small Molecule Ephrin (Eph) Tyrosine Kinase Inhibitors for the Treatment of Colorectal Cancer and Other Eph Growth-dependent Solid Tumors.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Chang, Kevin<br><a href="mailto:changke@mail.nih.gov?subject=Web Inquiry on [TAB-4059] Small Molecule Ephrin (Eph) Tyrosine Kinase Inhibitors for the Treatment of Colorectal Cancer and Other Eph Growth-dependent Solid Tumors&body=Please send me information about technology [TAB-4059] Small Molecule Ephrin (Eph) Tyrosine Kinase Inhibitors for the Treatment of Colorectal Cancer and Other Eph Growth-dependent Solid Tumors.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">changke@mail.nih.gov</a><br> 147161160 E-182-2019-2 E-182-2019-2-PCT-01 RECEPTOR TYROSINE KINASE INHIBITORS FOR TREATMENT OF PROTEIN KINASE MODULATION-RESPONSIVE DISEASE OR DISORDER PCT COMB Patent Cooperation Treaty PCT/US2020/050439 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2020/050439<br />Filed on 2020-09-11<br />Status: Expired 147166252 E-182-2019-0 E-182-2019-0-US-01 RECEPTOR TYROSINE KINASE INHIBITORS FOR TREATMENT OF PROTEIN KINASE MODULATION-RESPONSIVE DISEASE OR DISORDER PRV US 62/900,240 Abandoned US <br />Provisional (PRV) 62/900,240<br />Filed on 2019-09-13<br />Status: Abandoned 147166254 E-182-2019-1 E-182-2019-1-US-01 RECEPTOR TYROSINE KINASE INHIBITORS FOR TREATMENT OF PROTEIN KINASE MODULATION-RESPONSIVE DISEASE OR DISORDER PRV US 63/070,739 Abandoned US <br />Provisional (PRV) 63/070,739<br />Filed on 2020-08-26<br />Status: Abandoned 147166257 E-182-2019-2 E-182-2019-2-CA-03 RECEPTOR TYROSINE KINASE INHIBITORS FOR TREATMENT OF PROTEIN KINASE MODULATION-RESPONSIVE DISEASE OR DISORDER National Stage Canada 3153096 Pending Canada <br />National Stage 3153096<br />Filed on 2020-09-11<br />Status: Pending 147166259 E-182-2019-2 E-182-2019-2-EP-05 RECEPTOR TYROSINE KINASE INHIBITORS FOR TREATMENT OF PROTEIN KINASE MODULATION-RESPONSIVE DISEASE OR DISORDER National Stage European Patent 20785624.6 Pending European Patent <br />National Stage 20785624.6<br />Filed on 2020-09-11<br />Status: Pending 147166261 E-182-2019-2 E-182-2019-2-US-07 RECEPTOR TYROSINE KINASE INHIBITORS FOR TREATMENT OF PROTEIN KINASE MODULATION-RESPONSIVE DISEASE OR DISORDER National Stage US 12,486,270 17/692,978 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12486270 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12486270">12,486,270</a><br />Filed on 2022-03-11<br />Status: Issued 147173183 colorectal cancer 147173185 Eph Kinase Inhibitors 147173187 Eph-related cancers 147173188 Ephrin 147173190 NVP-BHG712 147173192 Regioisomer NVP-Iso 147173193 small molecule 147173194 solid tumors 147173195 Tosato 147173197 Tyrosine kinase inhibitors TAB-4031 147157312 Adriamycin-Resistant Ovarian Tumor Cell Line, NCI/ADR-RES NCI Licensing, Oncology, Research Materials Licensing Oncology Research Materials Kenneth Cowan <h2>Summary:</h2> <p>NCI is seeking parties to non-exclusively license the ADR-RES cell line.</p> <h2>Description of Technology:</h2> <p>Cancer cells may acquire drug resistance after prolonged chemotherapy. In many cases, cancer cells develop resistance to several drugs with distinct structures and modes of action. This multi-drug resistance phenomenon increases the complexity of cancer treatment.</p> <p>Researchers at the National Cancer Institute (NCI) have derived an Adriamycin-resistant cell line, NCI/ADR-RES, from human ovarian cancer cells. The parental cell line is OVCAR-8, obtained from a high-grade ovarian serous adenocarcinoma. NCI/ADR-RES is resistant to Adriamycin and found to express high levels of the Multi-Drug Resistance 1 (MDR1) protein &ndash; also known as P-glycoprotein. The cell line was extensively characterized and proven useful in identifying compounds subject to multi-drug resistance. NCI/ADR-RES was deposited into the Division of Cancer Treatment and Diagnosis (DCTD) Developmental Therapeutics Program (DTP) Tumor Repository and added to the NCI-60 Human Tumor Cell Lines Screen, along with parental OVCAR-8. Molecular characterization data are publicly available on the DTP website.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Research tool to study the multi-drug resistance phenomenon in cancer</li> <li>Research tool to study Adriamycin resistance in ovarian cancer</li> <li>Research tool to study the overexpression of MDR1 (P-glycoprotein) in cancer</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Extensively characterized and documented human ovarian adenocarcinoma cell line</li> <li>Part of the NCI anti-cancer drug screen human cell line panel (NCI-60 Human Tumor Cell Lines Screen)</li> <li>Molecular characterization data are publicly available</li> </ul> 2021-06-04 2026-04-24 2021-06-04 2026-04-24 2021-06-04 ADENOCARCINOMA, Adriamycin-resistant, Cell line, Cowan, MCF-7/ADR-RES, MDR1, Multi-Drug Resistance, NCI/ADR-RES, OVARIAN CANCER, OVCAR-8, P-GLYCOPROTEIN False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-06-04 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147161881 Scudiero DA, et al. Cell line designation change: multidrug-resistant cell line in the NCI anti-cancer screen. https://pubmed.ncbi.nlm.nih.gov/9625176/ <a href="https://pubmed.ncbi.nlm.nih.gov/9625176/">Scudiero DA, et al. Cell line designation change: multidrug-resistant cell line in the NCI anti-cancer screen.</a> 147162269 Batist G, et al. Overexpression of a novel anionic glutathione transferase in multidrug-resistant human breast cancer cells. https://pubmed.ncbi.nlm.nih.gov/3782078/ <a href="https://pubmed.ncbi.nlm.nih.gov/3782078/">Batist G, et al. Overexpression of a novel anionic glutathione transferase in multidrug-resistant human breast cancer cells.</a> 147162422 Vert A, et al. Transcriptional profiling of NCI/ADR-RES cells unveils a complex network of signaling pathways and molecular mechanisms of drug resistance. https://pubmed.ncbi.nlm.nih.gov/29379303/ <a href="https://pubmed.ncbi.nlm.nih.gov/29379303/">Vert A, et al. Transcriptional profiling of NCI/ADR-RES cells unveils a complex network of signaling pathways and molecular mechanisms of drug resistance.</a> 147163284 Cowan, Kenneth NIH - NCI NCI Cowan, Kenneth (NCI) 1 147163284 Cowan, Kenneth NIH - NCI NCI Cowan, Kenneth (NCI) 1 147158018 ADR-RES (adriamycin-resistant Cell Line) Cell Line E-115-2021-0 Research Material NCI 83740301 Dattaroy, Diptadip diptadip.dattaroy@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB diptadip.dattaroy@nih.gov?subject=Web Inquiry on [TAB-4031] Adriamycin-Resistant Ovarian Tumor Cell Line, NCI/ADR-RES&body=Please send me information about technology [TAB-4031] Adriamycin-Resistant Ovarian Tumor Cell Line, NCI/ADR-RES.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dattaroy, Diptadip<br><a href="mailto:diptadip.dattaroy@nih.gov?subject=Web Inquiry on [TAB-4031] Adriamycin-Resistant Ovarian Tumor Cell Line, NCI/ADR-RES&body=Please send me information about technology [TAB-4031] Adriamycin-Resistant Ovarian Tumor Cell Line, NCI/ADR-RES.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">diptadip.dattaroy@nih.gov</a><br> 147171738 ADENOCARCINOMA 147171739 Adriamycin-resistant 147171740 Cell line 147171742 Cowan 147171744 MCF-7/ADR-RES 147171745 MDR1 147171747 Multi-Drug Resistance 147171749 NCI/ADR-RES 147171750 OVARIAN CANCER 147171752 OVCAR-8 147171753 P-GLYCOPROTEIN TAB-3966 147157246 Immunogens for Use in a High Efficacy HIV Vaccine NCI Collaboration, Infectious Disease, Licensing, Vaccines Collaboration Infectious Disease Licensing Vaccines Manuel Becerra-Flores, Massimiliano Bissa, Timothy Cardozo, Genoveffa Franchini, Giacomo Gorini, Isabela Silva De Castro <h2>Summary:</h2> <p>The Vaccine Branch is seeking statements of capability or interest from parties interested in licensing V1-deleted immunogens to further develop, evaluate, or commercialize an improved HIV vaccine.</p> <h2>Description of Technology:</h2> <p>Human immunodeficiency virus (HIV) infections remain a pandemic, most prevalent in Africa and the Americas. Anti-retroviral treatments have been effective in preventing spread of the virus and active outbreaks of acquired immune deficiency syndrome (AIDS). However, the development and deployment of an effective vaccine would provide long-lasting protection and alleviate the need to depend heavily on prevention methods that require continued access and adherence. Immunization with the genetically engineered versions of HIV surface glycoprotein gp120, along with env, gag, pol, has been a promising approach that needs improved efficacy (currently at ~30%).&nbsp;</p> <p>Researchers at NCI have previously shown the levels and avidity of antibodies against variable envelope region 2 (V2) of gp120 correlate with protection of young macaques against the closely related simian immunodeficiency virus (SIV), while antibodies against V1 have an opposing effect on immunity. To improve the current HIV vaccine efforts, they deleted the V1 region from gp120, while preserving the V2 folded conformation, in a collaboration with researchers at NYU. They demonstrated increased antigenicity of V2 upon V1 deletion, as well as increased binding to soluble CD4 receptors. They further observed higher V2 responses in macaques with V1-deleted gp120 immunogen. Using SIV as a model, they could increase vaccine efficacy to nearly 70%.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Human immunodeficiency virus (HIV) vaccine</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Superior vaccine efficacy up to 70% using the closely related SIV as a model</li> <li>Increased antibody recognition of V2 via V1-deleted gp120 immunogens, previously associated with protection from SIV</li> <li>Increased V2 responses (in macaques, elicited via V1-deleted gp120 immunogens)</li> </ul> 2021-05-25 2026-04-24 2021-06-16 2026-04-24 2021-06-16 AIDS, Franchini, GLYCOPROTEIN, gp120, HIV, Human Immunodeficiency Virus, V1, V2, Vaccine, Variable Envelope Region False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2021-06-16 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-062-2014 E-157-2000 147161964 Silva de Castro I, et al. Anti-V2 antibodies virus vulnerability revealed by envelope V1 deletion in HIV vaccine candidates. https://doi.org/10.1016/j.isci.2021.102047 <a href="https://doi.org/10.1016/j.isci.2021.102047">Silva de Castro I, et al. Anti-V2 antibodies virus vulnerability revealed by envelope V1 deletion in HIV vaccine candidates.</a> 147162351 Vaccari M, et al. Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition. https://www.ncbi.nlm.nih.gov/pubmed/27239761 <a href="https://www.ncbi.nlm.nih.gov/pubmed/27239761">Vaccari M, et al. Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition.</a> 147162389 Gordon SN, et al. Boosting of ALVAC-SIV vaccine-primed macaques with the CD4-SIVgp120 fusion protein elicits antibodies to V2 associated with a decreased risk of SIVmac251 acquisition. https://www.ncbi.nlm.nih.gov/pubmed/27591322 <a href="https://www.ncbi.nlm.nih.gov/pubmed/27591322">Gordon SN, et al. Boosting of ALVAC-SIV vaccine-primed macaques with the CD4-SIVgp120 fusion protein elicits antibodies to V2 associated with a decreased risk of SIVmac251 acquisition.</a> 147163043 Franchini, Genoveffa NIH - NCI NCI Franchini, Genoveffa (NCI) 1 147163045 Cardozo, Timothy New York University School of Medicine Cardozo, Timothy 2 147163046 Silva De Castro, Isabela NCI - CCR Silva De Castro, Isabela 3 147163047 Gorini, Giacomo NIH - NCI Gorini, Giacomo 4 147163044 Bissa, Massimiliano NIH - NCI NCI Bissa, Massimiliano (NCI) 5 147163048 Becerra-Flores, Manuel NIH - New York University School of Medicine Becerra-Flores, Manuel 6 147163043 Franchini, Genoveffa NIH - NCI NCI Franchini, Genoveffa (NCI) 1 147163045 Cardozo, Timothy New York University School of Medicine Cardozo, Timothy 2 147163046 Silva De Castro, Isabela NCI - CCR Silva De Castro, Isabela 3 147163047 Gorini, Giacomo NIH - NCI Gorini, Giacomo 4 147163044 Bissa, Massimiliano NIH - NCI NCI Bissa, Massimiliano (NCI) 5 147163048 Becerra-Flores, Manuel NIH - New York University School of Medicine Becerra-Flores, Manuel 6 147158109 Delta V1/V2a Gp120 Immunogens To Augment Protective V2 Responses E-160-2018-0 Filing authorized NCI, New York University School of Medicine 83740301 Dattaroy, Diptadip diptadip.dattaroy@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB diptadip.dattaroy@nih.gov?subject=Web Inquiry on [TAB-3966] Immunogens for Use in a High Efficacy HIV Vaccine&body=Please send me information about technology [TAB-3966] Immunogens for Use in a High Efficacy HIV Vaccine.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dattaroy, Diptadip<br><a href="mailto:diptadip.dattaroy@nih.gov?subject=Web Inquiry on [TAB-3966] Immunogens for Use in a High Efficacy HIV Vaccine&body=Please send me information about technology [TAB-3966] Immunogens for Use in a High Efficacy HIV Vaccine.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">diptadip.dattaroy@nih.gov</a><br> 147165586 E-160-2018-0 E-160-2018-0-US-01 RECOMBINANT GP120 PROTEIN WITH V1-LOOP DELETION PRV US 62/748,905 Abandoned US <br />Provisional (PRV) 62/748,905<br />Filed on 2018-10-22<br />Status: Abandoned 147165587 E-160-2018-0 E-160-2018-0-PCT-02 RECOMBINANT GP120 PROTEIN WITH V1-LOOP DELETION PCT Patent Cooperation Treaty PCT/US2019/057268 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2019/057268<br />Filed on 2019-10-21<br />Status: Expired 147165588 E-160-2018-0 E-160-2018-0-AU-03 RECOMBINANT GP120 PROTEIN WITH V1-LOOP DELETION National Stage Australia 2019368218 Pending Australia <br />National Stage 2019368218<br />Filed on 2019-10-21<br />Status: Pending 147165589 E-160-2018-0 E-160-2018-0-CA-04 RECOMBINANT GP120 PROTEIN WITH V1-LOOP DELETION National Stage Canada 3117390 Pending Canada <br />National Stage 3117390<br />Filed on 2019-10-21<br />Status: Pending 147165590 E-160-2018-0 E-160-2018-0-EP-05 RECOMBINANT GP120 PROTEIN WITH V1-LOOP DELETION National Stage European Patent 19804901.7 Pending European Patent <br />National Stage 19804901.7<br />Filed on 2019-10-21<br />Status: Pending 147165591 E-160-2018-0 E-160-2018-0-US-06 RECOMBINANT GP120 PROTEIN WITH V1-LOOP DELETION National Stage US 12,162,910 17/285,453 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12162910 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12162910">12,162,910</a><br />Filed on 2021-04-14<br />Status: Issued 147172646 AIDS 147172647 Franchini 147172648 GLYCOPROTEIN 147172649 gp120 147172650 HIV 147172651 Human Immunodeficiency Virus 147172652 V1 147172653 V2 147172654 Vaccine 147172656 Variable Envelope Region TAB-3963 147157243 SMAD3 Reporter Mouse for Assessing TGF-ß/Activin Pathway Activation NCI Cardiology, Endocrinology, Immunology, Licensing, Neurology, Oncology, Research Materials Cardiology Endocrinology Immunology Licensing Neurology Oncology Research Materials Caroline Hill, Sushil Rane, Lalage Wakefield, Yu-an Yang <h2>Description of Technology:</h2> <p>The Transforming Growth Factor Beta (TGF-&szlig;) ligands (i.e., TGF-&szlig;1, -&szlig;2, -&szlig;3) are key regulatory proteins in animal physiology. Disruption of normal TGF-&szlig; signaling is associated with many diseases from cancer to fibrosis. In mice and humans, TGF-&szlig; activates TGF-&szlig; receptors (e.g., TGFBR1), which activates SMAD proteins that alter gene expression and contribute to tumorigenesis.&nbsp; Reliable animal models are essential for the study of TGF-&szlig; signaling. A previously developed animal model for TGF-&szlig; signaling utilizes a luciferase expression system under the control of SMAD protein responsive promoter elements (Lin et al., 2005, J. Immunol). The luciferase-based reporter mouse requires administering luciferin for bioluminescence detection. Another previously developed model is a SMAD protein-responsive, green fluorescent protein (GFP)-based reporter mouse (Neptune et al., 2003, Nat. Genet.); however, the model is no longer available. Thus, there remains a need for novel reporter animal models to study TGF-&szlig; signaling.</p> <p>NCI investigators designed an enhanced GFP (eGFP)-based reporter construct that is more sensitive to SMAD3 activation than other existing reporter constructs. Expression of eGFP is driven by an artificial enhancer element consisting of six repeats of a strong SMAD3 binding element. This reporter was greater than ten times more sensitive in vitro than the CAGA12-based reporter, another commonly used construct to detect TGF-&szlig; signaling.&nbsp; Using CRISPR/Cas9 technology, the inventors knocked this reporter construct into the Rosa26 locus, a ubiquitously expressed gene in most cells of the mouse. This strategy allows identification of tissues and cells in which signaling of TGF-&beta;s are endogenously active during normal development, tissue homeostasis, and disease.</p> <p>The mouse model is currently undergoing further validation using genetic and pharmacological approaches. It is available for licensing.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Development of oncology therapeutics</li> <li>Developing of fibrosis therapeutics</li> <li>Pre-clinical in vivo model to study TGF-&beta; signaling and pathway antagonists</li> <li>Pre-clinical model for TGF-&beta;/SMAD3 disease states</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>No requirement for luciferin injections</li> <li>Higher sensitivity for SMAD3 activation than other reporters</li> </ul> 2021-12-14 2026-04-24 2021-12-14 2026-04-24 2021-12-14 Animal Model, CANCER, EGFP, Fibrosis, Wakefield, mothers against decapentaplegic homolog 3, Oncology, Reporter Mouse, SMAD3, TGF-ß, Transforming Growth Factor Beta False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-12-14 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147162000 Yang Y, et al. A new TGF-ß pathway reporter mouse for analysis of TGF-β signaling in normal homeostasis and cancer. https://cancerres.aacrjournals.org/content/80/16_Supplement/1645 <a href="https://cancerres.aacrjournals.org/content/80/16_Supplement/1645">Yang Y, et al. A new TGF-ß pathway reporter mouse for analysis of TGF-β signaling in normal homeostasis and cancer.</a> 147163033 Wakefield, Lalage NIH - NCI NCI Wakefield, Lalage (NCI) 1 147163034 Yang, Yu-an NIH - NCI NCI Yang, Yu-an (NCI) 2 147163035 Rane, Sushil NIH - NIDDK NIDDK Rane, Sushil (NIDDK) 3 147163036 Hill, Caroline The Francis Crick Institute Hill, Caroline 4 147163033 Wakefield, Lalage NIH - NCI NCI Wakefield, Lalage (NCI) 1 147163034 Yang, Yu-an NIH - NCI NCI Yang, Yu-an (NCI) 2 147163035 Rane, Sushil NIH - NIDDK NIDDK Rane, Sushil (NIDDK) 3 147163036 Hill, Caroline The Francis Crick Institute Hill, Caroline 4 147158061 Smad3 Reporter Mouse For Assessing TGF-ß/activin Pathway Activation E-136-2019-0 Research Material National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NCI, The Francis Crick Institute 121111111 Greene, Jaime greenejaime@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America greenejaime@mail.nih.gov?subject=Web Inquiry on [TAB-3963] SMAD3 Reporter Mouse for Assessing TGF-ß/Activin Pathway Activation&body=Please send me information about technology [TAB-3963] SMAD3 Reporter Mouse for Assessing TGF-ß/Activin Pathway Activation.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Greene, Jaime<br><a href="mailto:greenejaime@mail.nih.gov?subject=Web Inquiry on [TAB-3963] SMAD3 Reporter Mouse for Assessing TGF-ß/Activin Pathway Activation&body=Please send me information about technology [TAB-3963] SMAD3 Reporter Mouse for Assessing TGF-ß/Activin Pathway Activation.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">greenejaime@mail.nih.gov</a><br> 147172187 Animal Model 147172188 CANCER 147172189 EGFP 147172191 Fibrosis, Wakefield 147172193 mothers against decapentaplegic homolog 3 147172194 Oncology 147172196 Reporter Mouse 147172197 SMAD3 147172199 TGF-ß 147172201 Transforming Growth Factor Beta TAB-3940 147157220 CODEFACS and LIRICS: Computation Tools for Identifying Cell-Type Specific Gene Expression Levels in Tumors and Other Types of Samples NCI Collaboration, Immunology, Licensing, Research Materials Collaboration Immunology Licensing Research Materials Joo Lee, Sushant Patkar, Eytan Ruppin, Alejandro Schaffer, Kun Wang <h2>Description of Technology:</h2> <p>The tumor microenvironment (TME) is a complex mixture of cell types whose interactions affect tumor growth and clinical outcome. Recent studies using fluorescence-activated cell sorting (FACS) and single-cell RNA sequencing (RNAseq) to elucidate tissue composition and cell-cell interactions in the TME led to improved biomarkers of patient response and new treatment opportunities. However, the use of FACS is limited to simultaneously measuring the expression of a few protein markers, whereas the use of single-cell RNAseq has been limited due to cost and scarcity of fresh tumor biopsies. In contrast, bulk tumor gene expression from preserved biopsies accompanied by clinical outcome metadata is abundant. Several algorithms have shown promise in accurately reconstructing cell-type-specific gene expression profiles from bulk gene expression.&nbsp;&nbsp;</p> <p>Researchers at National Cancer Institute (NCI) have developed CODEFACS (COnfident DEconvolution For All Cell Subsets), a transcriptomics computation tool that can confidently estimate cell type abundance and deconvolve cell-type-specific gene expression profiles of individual cancer patients from bulk gene expression measurements. A complementary, second software tool LIRICS (LIgand-Receptor Interaction between Cell Subsets) prioritizes clinically relevant ligand-receptor interactions between cell types from the deconvolved data. These tools uncovered TME ligand-receptor interactions associated with improved patient survival and high sensitivity to immune checkpoint blockade therapy. These excellent tools for understanding the TME can inform diagnosis and treatment strategies. They are available for co-development or licensing opportunities.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Development of improved immune checkpoint blockade therapies against cancer</li> <li>Development of improved therapies against cancer involving the TME</li> <li>Improved determination and analysis of cell-type abundance and cell-type-specific gene expression from bulk gene expression&nbsp;</li> <li>Identifying cell-cell and ligand-receptor interactions within complex tissues, including the TME&nbsp;</li> <li>Identifying cell type specific biomarkers, drug targets and drug repurposing opportunities to improve diagnosis and clinical outcome</li> <li>Applicable non-cancerous disease, including preeclampsia, pregnancy-related complications, autoimmune disorders, ageing and neurodegenerative disorders.&nbsp; &nbsp;</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Higher gene coverage for all cell types than existing related technologies</li> <li>Improved predictive accuracy of patient response to therapy&nbsp;</li> <li>Built-in confidence ranking system to compare prediction accuracies</li> </ul> 2021-11-04 2026-04-24 2021-11-04 2026-04-24 2021-11-04 Cell-cell Interaction, CODEFACS, Deconvolution, GENE EXPRESSION, Immunotherapy, Ligand-Receptor Interaction, LIRICS, Ruppin, TME, Tumor Microenvironment False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-11-04 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147162939 Ruppin, Eytan NIH - NCI NCI Ruppin, Eytan (NCI) 1 147162940 Wang, Kun NIH - NCI NCI Wang, Kun (NCI) 2 147162941 Patkar, Sushant NIH - NCI NCI Patkar, Sushant (NCI) 3 147162942 Lee, Joo NIH - NCI Lee, Joo 4 147162943 Schaffer, Alejandro NIH - NCI NCI Schaffer, Alejandro (NCI) 5 147162939 Ruppin, Eytan NIH - NCI NCI Ruppin, Eytan (NCI) 1 147162940 Wang, Kun NIH - NCI NCI Wang, Kun (NCI) 2 147162941 Patkar, Sushant NIH - NCI NCI Patkar, Sushant (NCI) 3 147162942 Lee, Joo NIH - NCI Lee, Joo 4 147162943 Schaffer, Alejandro NIH - NCI NCI Schaffer, Alejandro (NCI) 5 147157857 The COOEFACS And LIRICS Pipelines For Bulk Expression Deconvolution E-044-2020-0 Filing authorized NCI 83691647 Chang, Kevin changke@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB changke@mail.nih.gov?subject=Web Inquiry on [TAB-3940] CODEFACS and LIRICS: Computation Tools for Identifying Cell-Type Specific Gene Expression Levels in Tumors and Other Types of Samples&body=Please send me information about technology [TAB-3940] CODEFACS and LIRICS: Computation Tools for Identifying Cell-Type Specific Gene Expression Levels in Tumors and Other Types of Samples.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Chang, Kevin<br><a href="mailto:changke@mail.nih.gov?subject=Web Inquiry on [TAB-3940] CODEFACS and LIRICS: Computation Tools for Identifying Cell-Type Specific Gene Expression Levels in Tumors and Other Types of Samples&body=Please send me information about technology [TAB-3940] CODEFACS and LIRICS: Computation Tools for Identifying Cell-Type Specific Gene Expression Levels in Tumors and Other Types of Samples.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">changke@mail.nih.gov</a><br> 147160956 E-044-2020-0 E-044-2020-0-PCT-02 METHODS OF IDENTIFYING CELL-TYPE-SPECIFIC GENE EXPRESSION LEVELS BY DECONVOLVING BULK GENE EXPRESSION PCT Patent Cooperation Treaty PCT/US2020/062238 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2020/062238<br />Filed on 2020-11-25<br />Status: Expired 147165449 E-044-2020-0 E-044-2020-0-US-01 CODEFACS AND LIRICS PIPELINES FOR BULK EXPRESSION DECONVOLUTION PRV US 62/940,755 Abandoned US <br />Provisional (PRV) 62/940,755<br />Filed on 2019-11-26<br />Status: Abandoned 147165450 E-044-2020-0 E-044-2020-0-US-03 METHODS OF IDENTIFYING CELL-TYPE-SPECIFIC GENE EXPRESSION LEVELS BY DE-CONVOLVING BULK GENE EXPRESSION National Stage US 17/780,356 Abandoned US <br />National Stage 17/780,356<br />Filed on 2022-05-26<br />Status: Abandoned 147170168 Cell-cell Interaction 147170170 CODEFACS 147170171 Deconvolution 147170172 GENE EXPRESSION 147170173 Immunotherapy 147170175 Ligand-Receptor Interaction 147170176 LIRICS 147170178 Ruppin 147170180 TME 147170182 Tumor Microenvironment TAB-3922 147157202 HLA-A*01:01 Restricted Human T Cell Receptor Recognizing the NRAS Q61K Hotspot Mutation NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Gabriel Ivey, Almin Latani, Paul Robbins, Steven Rosenberg <h2>Summary:</h2> <p>The NCI is seeking research co-development and/or licensees for the HLA-A*01:01 restricted human T-cell receptor recognizing the NRAS Q61K hotspot mutation.</p> <h2>Description of Technology:</h2> <p>Mutation of amino acid 61of the neuroblastoma rat sarcoma viral oncogene homologue (NRAS) is a known driver of oncogenesis in melanoma. Glutamine (Q) to lysine (K) mutation at this position of NRAS is prevalent in approximately 10% of all melanoma cases and associated with aggressive tumors and low patient survival. Therefore, Q61K mutated NRAS is an important candidate for targeted therapies, including cellular immunotherapy.&nbsp;</p> <p>National Cancer Institute scientists developed a T-cell receptor (TCR) specific for NRAS Q61K for use in adoptive cell transfer (ACT) T-cell immunotherapy against melanoma. T cells reactive to NRAS Q61K were screened and isolated from tumor infiltrating lymphocytes of a melanoma patient with this mutation and the human leukocyte antigen (HLA) phenotype of A*01:01. TCR alpha and beta chains from the isolated T cells were then cloned to construct the NRAS Q61K-specific TCR. This TCR can be used to develop T-cell therapies against melanoma. Due to the similarities between different RAS isoforms (NRAS, KRAS, HRAS), the TCR could also be used to target other cancers exhibiting RAS Q61K mutations, such as colorectal, prostate, pancreatic and thyroid cancers in patients with the HLA-A*01:01 phenotype.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Use in adoptive cell transfer T-cell therapy against melanoma and other cancers</li> <li>Solid tumors without target antigens as surface proteins</li> <li>Diagnostic tool for NRAS Q61K tumors</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Potential for lower toxicity as NRAS Q61K is not present in healthy individuals</li> <li>Highly expressed target antigen for melanoma indication</li> <li>HLA-A*01:01 occurs in high frequency in Caucasian populations, therefore the TCR may benefit many patients&nbsp;</li> <li>Intracellular proteins TCRs target can be tumor-specific</li> <li>Redirects the immune system against tumors</li> <li>TCRs potentially target more antigens than Chimeric Antigen Receptors (CARs) since both surface and intracellular proteins can be presented as peptides on MHC molecules</li> </ul> 2021-09-24 2026-04-24 2021-09-24 2026-04-24 2021-09-24 act, Adoptive Cell Transfer, HLA, Human Leukocyte Antigen, immuno-oncology, Immunotherapy, Neuroblastoma Rat Sarcoma Viral Oncogene, NRAS, Robbins, Rosenberg, T-Cell Receptor, TCR False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-09-24 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147162874 Robbins, Paul NIH - NCI NCI Robbins, Paul (NCI) 1 147162873 Rosenberg, Steven NIH - NCI NCI Rosenberg, Steven (NCI) 2 147162875 Ivey, Gabriel Georgetown University Ivey, Gabriel 3 147162876 Latani, Almin NCI - CCR NCI Latani, Almin (NCI) 4 147162874 Robbins, Paul NIH - NCI NCI Robbins, Paul (NCI) 1 147162873 Rosenberg, Steven NIH - NCI NCI Rosenberg, Steven (NCI) 2 147162875 Ivey, Gabriel Georgetown University Ivey, Gabriel 3 147162876 Latani, Almin NCI - CCR NCI Latani, Almin (NCI) 4 147158181 HLA-A*01:01 Restricted Human T Cell Receptor Recognizing The NRAS Q61K Hotspot Mutation E-191-2019-0 Filing authorized Georgetown University, NCI 83709866 Burke, Andrew burkear@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC burkear@nih.gov?subject=Web Inquiry on [TAB-3922] HLA-A*01:01 Restricted Human T Cell Receptor Recognizing the NRAS Q61K Hotspot Mutation&body=Please send me information about technology [TAB-3922] HLA-A*01:01 Restricted Human T Cell Receptor Recognizing the NRAS Q61K Hotspot Mutation.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Burke, Andrew<br><a href="mailto:burkear@nih.gov?subject=Web Inquiry on [TAB-3922] HLA-A*01:01 Restricted Human T Cell Receptor Recognizing the NRAS Q61K Hotspot Mutation&body=Please send me information about technology [TAB-3922] HLA-A*01:01 Restricted Human T Cell Receptor Recognizing the NRAS Q61K Hotspot Mutation.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">burkear@nih.gov</a><br> 147161172 E-191-2019-0 E-191-2019-0-US-01 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH Q61K MUTATION PRV US 63/177,570 Abandoned US <br />Provisional (PRV) 63/177,570<br />Filed on 2021-04-21<br />Status: Abandoned 147165283 E-191-2019-0 E-191-2019-0-PCT-02 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH Q61K MUTATION PCT Patent Cooperation Treaty PCT/US2022/025177 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2022/025177<br />Filed on 2022-04-18<br />Status: Expired 147173375 act 147173376 Adoptive Cell Transfer 147173377 HLA 147173378 Human Leukocyte Antigen 147173379 immuno-oncology 147173380 Immunotherapy 147173382 Neuroblastoma Rat Sarcoma Viral Oncogene 147173383 NRAS 147173385 Robbins 147173386 Rosenberg 147173387 T-Cell Receptor 147173388 TCR TAB-3893 147157173 T-cell Phenotypes Associated with Clinical Response to Adoptive Immunotherapy NCI Collaboration, Infectious Disease, Licensing, Oncology, Therapeutics Collaboration Infectious Disease Licensing Oncology Therapeutics Gregoire Altan-Bonnet, Sri Krishna, Frank Lowery, Paul Robbins, Steven Rosenberg <h2>Summary:</h2> <p>The NCI seeks applications from parties interested in co-developing and/or licensing a method to develop improved cancer immunotherapies.</p> <h2>Description of Technology:</h2> <p>Adoptive T-cell therapy (ACT) utilizes tumor-reactive T cells to induce disease remission. While ACT has been used effectively to treat metastatic melanoma and certain epithelial cancers, most patients do not respond to treatment. Although the mechanisms underlying this variable response to therapy are not fully elucidated, the phenotype of the adoptively transferred cell is known to be a key determinant of treatment efficacy.</p> <p>Researchers at National Cancer Institute&rsquo;s (NCI) Surgery Branch have now determined that the CD3<sup>+</sup>CD39<sup>-</sup>CD69<sup>-</sup> subpopulation of T cells are highly associated with complete disease response following ACT. Leveraging over 30 years of ACT clinical data and associated biological materials, NCI researchers immune-profiled archived infusion products and correlated cell phenotypes with therapeutic outcomes. Clustering of clinically significant markers helped in determining the candidate profile. Validation of the markers in other patients and other cancer settings is ongoing.</p> <p>The inventive method could be used to engineer relevant cell therapy products in multiple disease settings, including, but not limited to, cancer and acute and chronic infectious diseases. The method could further be used to develop gene expression signatures to either screen prospective patients or genetically engineer better therapies. In addition to its application in ACT, the &ldquo;response&rdquo; immunoprofile may be applicable to immunotherapy regimens more generally, including checkpoint blockade therapies, immune modulators, and T-cell receptor (TCR) or chimeric antigen receptor (CAR) therapies.</p> <p>Related technologies are available.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Companion diagnostic to support cell therapy and utility products in multiple disease settings, including, but not limited to, cancer and acute and chronic infectious diseases&nbsp;</li> <li>Generation of gene expression signatures to prospectively screen patients or to engineer better ACT and TCR-based treatments</li> <li>Immunoprofiling patients before and after ACT, checkpoint blockade, immunomodulator, and TCR/CAR therapies</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Method to screen adoptive T-cell therapy (ACT) patients to predetermine therapy efficiency</li> <li>Method to increase the efficacy of ACT therapies</li> </ul> 2021-05-25 2026-04-24 2021-07-13 2026-04-24 2021-07-13 act, Adoptive T Cell Therapy, Cancer Immunotherapies, CAR, CD-39 Receptor, CD3-Receptor, CD-69 Receptor, chimeric antigen receptor, Lowery, Rosenberg, T Cell Receptor, TCR, TILS, Tumor-Infiltrating T-Lymphocytes False True Basic (Target Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-07-13 52406768 Discovery 52406768 NCI 37470483 Website Abstract E-022-2017 147162043 Krishna S, et al. Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer. https://pubmed.ncbi.nlm.nih.gov/33303615/ <a href="https://pubmed.ncbi.nlm.nih.gov/33303615/">Krishna S, et al. Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer.</a> 147162770 Rosenberg, Steven NIH - NCI NCI Rosenberg, Steven (NCI) 1 147162773 Altan-Bonnet, Gregoire NIH - NCI NCI Altan-Bonnet, Gregoire (NCI) 2 147162774 Krishna, Sri NIH - NCI NCI Krishna, Sri (NCI) 3 147162771 Robbins, Paul NIH - NCI NCI Robbins, Paul (NCI) 4 147162772 Lowery, Frank NIH - NCI NCI Lowery, Frank (NCI) 5 147162770 Rosenberg, Steven NIH - NCI NCI Rosenberg, Steven (NCI) 1 147162773 Altan-Bonnet, Gregoire NIH - NCI NCI Altan-Bonnet, Gregoire (NCI) 2 147162774 Krishna, Sri NIH - NCI NCI Krishna, Sri (NCI) 3 147162771 Robbins, Paul NIH - NCI NCI Robbins, Paul (NCI) 4 147162772 Lowery, Frank NIH - NCI NCI Lowery, Frank (NCI) 5 147158126 T-cell Phenotypes Associated With Clinical Response To Adoptive Immunotherapy E-167-2019-0 Filing authorized NCI 83709866 Burke, Andrew burkear@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC burkear@nih.gov?subject=Web Inquiry on [TAB-3893] T-cell Phenotypes Associated with Clinical Response to Adoptive Immunotherapy&body=Please send me information about technology [TAB-3893] T-cell Phenotypes Associated with Clinical Response to Adoptive Immunotherapy.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Burke, Andrew<br><a href="mailto:burkear@nih.gov?subject=Web Inquiry on [TAB-3893] T-cell Phenotypes Associated with Clinical Response to Adoptive Immunotherapy&body=Please send me information about technology [TAB-3893] T-cell Phenotypes Associated with Clinical Response to Adoptive Immunotherapy.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">burkear@nih.gov</a><br> 147161136 E-167-2019-0 E-167-2019-0-US-01 T CELL PHENOTYPES ASSOCIATED WITH RESPONSE TO ADOPTIVE CELL THERAPY PRV US 63/075,536 Abandoned US <br />Provisional (PRV) 63/075,536<br />Filed on 2020-09-08<br />Status: Abandoned 147165093 E-167-2019-0 E-167-2019-0-PCT-02 T CELL PHENOTYPES ASSOCIATED WITH RESPONSE TO ADOPTIVE CELL THERAPY PCT Patent Cooperation Treaty PCT/US2021/049387 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/049387<br />Filed on 2021-09-08<br />Status: Expired 147165094 E-167-2019-0 E-167-2019-0-JP-01 T CELL PHENOTYPES ASSOCIATED WITH RESPONSE TO ADOPTIVE CELL THERAPY National Stage Japan 2023-515322 Pending Japan <br />National Stage 2023-515322<br />Filed on 2023-03-07<br />Status: Pending 147165095 E-167-2019-0 E-167-2019-0-CA-01 T CELL PHENOTYPES ASSOCIATED WITH RESPONSE TO ADOPTIVE CELL THERAPY National Stage Canada 3191211 Pending Canada <br />National Stage 3191211<br />Filed on 2023-02-28<br />Status: Pending 147165096 E-167-2019-0 E-167-2019-0-AU-01 T CELL PHENOTYPES ASSOCIATED WITH RESPONSE TO ADOPTIVE CELL THERAPY National Stage Australia 2021341969 Pending Australia <br />National Stage 2021341969<br />Filed on 2023-02-21<br />Status: Pending 147165097 E-167-2019-0 E-167-2019-0-CN-01 T CELL PHENOTYPES ASSOCIATED WITH RESPONSE TO ADOPTIVE CELL THERAPY National Stage China 202180074998.8 Pending China <br />National Stage 202180074998.8<br />Filed on 2023-05-05<br />Status: Pending 147165098 E-167-2019-0 E-167-2019-0-US-02 T CELL PHENOTYPES ASSOCIATED WITH RESPONSE TO ADOPTIVE CELL THERAPY National Stage US 18/024,430 Pending US <br />National Stage 18/024,430<br />Filed on 2023-03-02<br />Status: Pending 147165099 E-167-2019-0 E-167-2019-0-EP-01 T CELL PHENOTYPES ASSOCIATED WITH RESPONSE TO ADOPTIVE CELL THERAPY National Stage European Patent 4211228 21787116.9 Issued European Patent <br />National Stage 21787116.9<br />Filed on 2023-03-28<br />Status: Issued 147172814 act 147172815 Adoptive T Cell Therapy 147172817 Cancer Immunotherapies 147172818 CAR 147172820 CD-39 Receptor 147172822 CD3-Receptor 147172824 CD-69 Receptor 147172825 chimeric antigen receptor 147172827 Lowery 147172828 Rosenberg 147172829 T Cell Receptor 147172830 TCR 147172831 TILS 147172833 Tumor-Infiltrating T-Lymphocytes TAB-3882 147157162 Single Domain Antibodies (Nanobodies) Targeting SARS-CoV-2 for treating COVID-19 NCI Collaboration, Infectious Disease, Licensing, Therapeutics Collaboration Infectious Disease Licensing Therapeutics Mitchell Ho, Jessica Hong <h2>Summary:</h2> <p>The NCI seeks licensing and/or co-development research collaborations for SARS-CoV-2 targeting nanobodies.</p> <h2>Description of Technology:</h2> <p>The COVID-19 pandemic is a worldwide public health crisis with over 100 million confirmed cases and 2.4 million deaths as of February 2021. COVID-19 is caused by a novel coronavirus called SARS-CoV-2. SARS-COV-2 infects hosts via its spike (S) protein. The S protein contains the receptor binding domain (RBD) that binds to the angiotensin converting enzyme 2 (ACE2) receptor on human cells to facilitate viral entry and infection. There are few therapeutics available for COVID-19 patients that directly target SARS-CoV-2.</p> <p>Investigators at the National Cancer Institute (NCI) have isolated a panel of anti-RBD single domain antibodies (also called &lsquo;nanobodies&rsquo;) from camel single domain (VHH) phage display libraries. RBD is an ideal target as it is the key virus-host contact region required for viral entry and infection. There are 3 lead nanobodies, 7A3, 1B5, and 2F7, which were found to be the most potent RBD-ACE2 blockers. Interestingly, the 1B5 nanobody can cross react with the S protein of the previous 2002-2003 SARs-CoV coronavirus. This indicates that this nanobody targets a conserved region of the S protein and may be useful for treatments against other coronavirus variants that may emerge.&nbsp;</p> <p>Nanobodies are the smallest known antigen-binding fragments of antibodies and have several advantages. Due to their small size, high solubility, thermal stability, refolding capacity, and relatively easy tissue penetration, they have great potential as medical applications and research tools. These nanobodies can be used as either independent agents or targeting domains in recombinant immunotoxins (RITs), antibody-drug conjugates (ADCs), and chimeric antigen receptors (CARs). Due to their small size and high stability, the nanobodies may have the ability to be administered by an inhaler making them uniquely attractive therapeutics for respiratory infections such as COVID-19.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Neutralizing nanobodies</li> <li>Nanobody-Fc fusion proteins as standard antibody therapy</li> <li>Antibody-drug conjugates (ADCs)</li> <li>Immunotoxins</li> <li>Diagnostic reagents (in vivo virus imaging)</li> <li>CARs (CAR T, NK, and macrophage)</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>The nanobodies directly target the receptor binding domain (RBD) of the SARS-CoV-2 spike (S) protein, which blocks the virus-host contact region required for viral entry and infection</li> <li>Due to their small size and high stability, the nanobodies may be administered by an inhaler making them ideal for respiratory infections such as COVID-19</li> </ul> 2021-04-05 2026-04-24 2021-04-05 2026-04-24 2021-04-05 ANTIBODY, antigen-binding fragment, CORONAVIRUS, COVID-19, HO, NANOBODY, respiratory INFECTION, S Protein, SARS-CoV-2, spike protein False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-04-05 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147162716 Ho, Mitchell NIH - NCI NCI Ho, Mitchell (NCI) 1 147162717 Hong, Jessica NIH - NCI NCI Hong, Jessica (NCI) 2 147162716 Ho, Mitchell NIH - NCI NCI Ho, Mitchell (NCI) 1 147162717 Hong, Jessica NIH - NCI NCI Hong, Jessica (NCI) 2 147158277 Single Domain Antibodies Targeting SARS-SoV-2 E-253-2020-0 Filing authorized NCI 83731987 Dhal, Abritee abritee.dhal@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-3882] Single Domain Antibodies (Nanobodies) Targeting SARS-CoV-2 for treating COVID-19&body=Please send me information about technology [TAB-3882] Single Domain Antibodies (Nanobodies) Targeting SARS-CoV-2 for treating COVID-19.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dhal, Abritee<br><a href="mailto:abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-3882] Single Domain Antibodies (Nanobodies) Targeting SARS-CoV-2 for treating COVID-19&body=Please send me information about technology [TAB-3882] Single Domain Antibodies (Nanobodies) Targeting SARS-CoV-2 for treating COVID-19.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">abritee.dhal@nih.gov</a><br> 147161233 E-253-2020-0 E-253-2020-0-US-01 Single Domain Antibodies Targeting SARS-CoV-2 PRV US 63/105,769 Abandoned US <br />Provisional (PRV) 63/105,769<br />Filed on 2020-10-26<br />Status: Abandoned 147165031 E-253-2020-0 E-253-2020-0-PCT-02 SINGLE DOMAIN ANTIBODIES TARGETING SARS CORONAVIRUS SPIKE PROTEIN AND USES THEREOF PCT Patent Cooperation Treaty PCT/US2021/056548 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/056548<br />Filed on 2021-10-26<br />Status: Expired 147165032 E-253-2020-0 E-253-2020-0-US-02 SINGLE DOMAIN ANTIBODIES TARGETING SARS CORONAVIRUS SPIKE PROTEIN AND USES THEREOF National Stage US 18/033,656 Pending US <br />National Stage 18/033,656<br />Filed on 2023-04-25<br />Status: Pending 147174284 ANTIBODY 147174285 antigen-binding fragment 147174286 CORONAVIRUS 147174287 COVID-19 147174288 HO 147174289 NANOBODY 147174290 respiratory INFECTION 147174292 S Protein 147174293 SARS-CoV-2 147174294 spike protein TAB-3877 147157157 An Anti-Viral Polypeptide: Griffithsin NCI Collaboration, Infectious Disease, Licensing, Therapeutics Collaboration Infectious Disease Licensing Therapeutics Michael Boyd, Toshiyuki Mori, Barry O'Keefe <h2>Summary:</h2> <p>Researchers at the NCI seek licensing and/or co-development research collaborations for anti-viral Griffithsin (GRFT) proteins.</p> <h2>Description of Technology:</h2> <p>Virus entry into a susceptible host cell is the first step in the formation of all viral diseases. Controlling viral infections by disrupting viral entry is advantageous for antibody-mediated neutralization by the host&rsquo;s immune system and as a preventive and therapeutic antiviral strategy. Plant-derived carbohydrate-binding proteins (lectins) have emerged as a new class of antiviral biologics by taking advantage of a unique glycosylation pattern only found on the surface of viruses.</p> <p>This technology describes the lectin, Griffithsin (GRFT), isolated from red algae. GRFT shows significant broad-spectrum anti-viral activity making it a promising agent for use as a general microbicide that can prevent viral transmission and as a therapeutic against enveloped virus-mediated diseases.&nbsp; The patent rights for this technology cover the sequence of the GRFT polypeptide as well as several GRFT variants mutated to render them glycosylation-resistant. The patent rights also cover GRFT conjugates, compositions, nucleic acids, vectors, host cells, antibodies and methods of their production and methods of use.&nbsp; The broad spectrum anti-viral activity of GRFT has been attributed to its ability to inhibit viral binding, fusion and entry into the host cells by binding to viral envelope gp120.&nbsp; GRFT has potential as a therapeutic or prophylactic for retroviral infections including HIV-1 and HIV-2 as well as FIV, SIV, MLV, BLV, equine infectious virus, avian sarcoma viruses, and HTLV. In addition, Griffithsin could be used in combination with other anti-viral agents to treat patients who have drug-resistant virus.</p> <p>A related NCI invention, reference number <a href="https://techtransfer.cancer.gov/available-technologies?abstract=TAB-4330" target="_blank">E-025-2006</a>, further covers the use of Griffithsin against viral infection including Hepatitis C, Severe Acute Respiratory Syndrome (SARS), H5N1, or Ebola.</p> <p>Issued patents include&nbsp;<a href="https://patents.google.com/patent/US7884178B2/en?oq=11%2f569%2c813" rel="nofollow" target="_blank">US 7,884,178</a>,&nbsp;<a href="https://patents.google.com/patent/US8394764B2/en?oq=US+8%2c394%2c764+" rel="nofollow" target="_blank">US 8,394,764</a>, with foreign rights in Canada, Australia, Japan, Israel, New Zealand, South Africa, France, Germany, Ireland, Switzerland, United Kingdom (all granted).</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Microbicide that can prevent viral transmission</li> <li>Therapeutic against enveloped virus-mediated diseases</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Highly Potent Broad-Spectrum Antiviral Lectin</li> <li>Superior in vitro and in vivo antiviral activity with minimum host toxicity against a variety of clinically relevant, enveloped viruses</li> </ul> 2021-07-08 2026-04-24 2021-07-08 2026-04-24 2021-07-08 Griffithsin, O'Keefe, SARS, Severe acute respiratory syndrome False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2021-07-08 52406768 Discovery 52406768 NCI 37470483 Website Abstract E-025-2006 147162113 Mori T. et al., Isolation and characterization of griffithsin, a novel HIV-inactivating protein, from the red alga Griffithsia sp. https://pubmed.ncbi.nlm.nih.gov/15613479 <a href="https://pubmed.ncbi.nlm.nih.gov/15613479">Mori T. et al., Isolation and characterization of griffithsin, a novel HIV-inactivating protein, from the red alga Griffithsia sp.</a> 147162460 Giomarelli B, et al. Recombinant production of anti-HIV protein, griffithsin, by auto-induction in a fermentor culture https://pubmed.ncbi.nlm.nih.gov/16300962/ <a href="https://pubmed.ncbi.nlm.nih.gov/16300962/">Giomarelli B, et al. Recombinant production of anti-HIV protein, griffithsin, by auto-induction in a fermentor culture</a> 147162700 Boyd, Michael NIH - NCI Boyd, Michael 1 147162702 Mori, Toshiyuki NIH - NCI Mori, Toshiyuki 2 147162701 O'Keefe, Barry NIH - NCI NCI O'Keefe, Barry (NCI) 3 147162700 Boyd, Michael NIH - NCI Boyd, Michael 1 147162702 Mori, Toshiyuki NIH - NCI Mori, Toshiyuki 2 147162701 O'Keefe, Barry NIH - NCI NCI O'Keefe, Barry (NCI) 3 147157998 Griffithsin, Sertulavirin And Related Proteins, Peptides, Conjugates, Antibodies, Compositions, Nucleic Acids, Vectors, Host Cells, Methods Of Production And Methods Of Using E-106-2003-0 Filing authorized NCI 83732213 Dick, Taryn taryn.dick@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB taryn.dick@nih.gov?subject=Web Inquiry on [TAB-3877] An Anti-Viral Polypeptide: Griffithsin&body=Please send me information about technology [TAB-3877] An Anti-Viral Polypeptide: Griffithsin.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dick, Taryn<br><a href="mailto:taryn.dick@nih.gov?subject=Web Inquiry on [TAB-3877] An Anti-Viral Polypeptide: Griffithsin&body=Please send me information about technology [TAB-3877] An Anti-Viral Polypeptide: Griffithsin.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">taryn.dick@nih.gov</a><br> 147161048 E-106-2003-0 E-106-2003-0-US-03 Griffithsin, Glycosylation-Resistant Griffithsin, and Related Conjugates, Compositions, Nucleic Acids, Vectors, Host Cells, Methods of Production and Methods of Use National Stage US 7,884,178 11/569,813 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7884178 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7884178">7,884,178</a><br />Filed on 2006-11-30<br />Status: Issued 147164988 E-106-2003-0 E-106-2003-0-US-01 Griffithsins and Related conjucages, Fusion Proteins, Nucleic Acids, Vectors, Host Cells, Compositions, Antibodies and Methods of Using Griffithsins PRV US 60/576,056 Abandoned US <br />Provisional (PRV) 60/576,056<br />Filed on 2004-06-01<br />Status: Abandoned 147164990 E-106-2003-0 E-106-2003-0-PCT-02 Griffithsin, Glycosylation-Resistant Griffithsin, and Related Conjugates, Compositions, Nucleic Acids, Vectors, Host Cells, Methods of Production And Methods of Use PCT Patent Cooperation Treaty PCT/US2005/018778 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2005/018778<br />Filed on 2005-05-27<br />Status: Expired 147164991 E-106-2003-0 E-106-2003-0-CA-04 Griffithsin, Glycosylation-Resistant Griffithsin, and Related Conjugates, Compositions, Nucleic Acids, Vectors, Host Cells, Methods of Production And Methods of Use National Stage Canada 2567728 2567728 Expired Canada <br />National Stage 2567728<br />Filed on 2010-03-09<br />Status: Expired 147164992 E-106-2003-0 E-106-2003-0-AU-05 Griffithsin, Glycosylation-Resistant Griffithsin, and Related Conjugates, Compositions, Nucleic Acids, Vectors, Host Cells, Methods of Production And Methods of Use National Stage Australia 2005250429 2005250429 Expired Australia <br />National Stage 2005250429<br />Filed on 2005-05-27<br />Status: Expired 147164993 E-106-2003-0 E-106-2003-0-EP-06 Griffithsin, Glycosylation-Resistant Griffithsin, and Related Conjugates, Compositions, Nucleic Acids, Vectors, Host Cells, Methods of Production And Methods of Use National Stage European Patent 1740605 05804849.7 Expired European Patent <br />National Stage 05804849.7<br />Filed on 2005-05-27<br />Status: Expired 147164994 E-106-2003-0 E-106-2003-0-JP-07 Griffithsin, Glycosylation-Resistant Griffithsin, and Related Conjugates, Compositions, Nucleic Acids, Vectors, Host Cells, Methods of Production And Methods of Use National Stage Japan 4776620 2007-515398 Expired Japan <br />National Stage 2007-515398<br />Filed on 2005-05-27<br />Status: Expired 147164995 E-106-2003-0 E-106-2003-0-IL-08 GRIFFITHSIN AND GLYCOSYLATION-RESISTANT VARIANTS THEREOF HAVING ANTI-VIRAL ACTIVITY AND RELATED METHODS National Stage Israel 179236 179236 Expired Israel <br />National Stage 179236<br />Filed on 2006-11-13<br />Status: Expired 147164996 E-106-2003-0 E-106-2003-0-NZ-09 Griffithsin, Glycosylation-Resistant Griffithsin, and Related Conjugates, Compositions, Nucleic Acids, Vectors, Host Cells, Methods of Production And Methods of Use National Stage New Zealand 551375 551375 Expired New Zealand <br />National Stage 551375<br />Filed on 2006-11-17<br />Status: Expired 147164997 E-106-2003-0 E-106-2003-0-ZA-10 Griffithsin, Glycosylation-Resistant Griffithsin, and Related Conjugates, Compositions, Nucleic Acids, Vectors, Host Cells, Methods of Production And Methods of Use National Stage South Africa 2006/09573 2006/09573 Expired South Africa <br />National Stage 2006/09573<br />Filed on 2006-11-17<br />Status: Expired 147164998 E-106-2003-0 E-106-2003-0-EP-11 Griffithsin, Glycosylation-Resistant Griffithsin, and Related Conjugates, Compositions, Nucleic Acids, Vectors, Host Cells, Methods of Production And Methods of Use DIV European Patent 5804849.7 Administratively Closed European Patent <br />Divisional (DIV) 5804849.7<br />Filed on 2005-05-27<br />Status: Administratively Closed 147164999 E-106-2003-0 E-106-2003-0-US-12 Griffithsin, Glycosylation-Resistant Griffithsin, And Related Conjugates, Compositions, Nucleic Acids, Vectors, Host Cells, Methods Of Production And Methods Of Use DIV US 8,394,764 13/022,289 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8394764 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8394764">8,394,764</a><br />Filed on 2011-02-07<br />Status: Expired 147165000 E-106-2003-0 E-106-2003-0-FR-13 Griffithsin, Glycosylation-Resistant Griffithsin, and Related Conjugates, Compositions, Nucleic Acids, Vectors, Host Cells, Methods of Production And Methods of Use EP France 1740605 05804849.7 Expired France <br />European patent (EP) 05804849.7<br />Filed on 2006-11-23<br />Status: Expired 147165001 E-106-2003-0 E-106-2003-0-DE-14 Griffithsin, Glycosylation-Resistant Griffithsin, and Related Conjugates, Compositions, Nucleic Acids, Vectors, Host Cells, Methods of Production And Methods of Use EP Germany 1740605 05804849.7 Expired Germany <br />European patent (EP) 05804849.7<br />Filed on 2006-11-23<br />Status: Expired 147165002 E-106-2003-0 E-106-2003-0-IE-15 Griffithsin, Glycosylation-Resistant Griffithsin, and Related Conjugates, Compositions, Nucleic Acids, Vectors, Host Cells, Methods of Production And Methods of Use EP Ireland 1740605 05804849.7 Expired Ireland <br />European patent (EP) 05804849.7<br />Filed on 2006-11-23<br />Status: Expired 147165003 E-106-2003-0 E-106-2003-0-CH-16 Griffithsin, Glycosylation-Resistant Griffithsin, and Related Conjugates, Compositions, Nucleic Acids, Vectors, Host Cells, Methods of Production And Methods of Use EP Switzerland 1740605 05804849.7 Expired Switzerland <br />European patent (EP) 05804849.7<br />Filed on 2006-11-23<br />Status: Expired 147165004 E-106-2003-0 E-106-2003-0-GB-17 Griffithsin, Glycosylation-Resistant Griffithsin, and Related Conjugates, Compositions, Nucleic Acids, Vectors, Host Cells, Methods of Production And Methods of Use EP United Kingdom 1740605 05804849.7 Expired United Kingdom <br />European patent (EP) 05804849.7<br />Filed on 2006-11-23<br />Status: Expired 147165005 E-106-2003-0 E-106-2003-0-CH-18 Griffithsin, Glycosylation-Resistant Griffithsin, and Related Conjugates, Compositions, Nucleic Acids, Vectors, Host Cells, Methods of Production And Methods of Use EP Switzerland 1740605 05804849.7 Expired Switzerland <br />European patent (EP) 05804849.7<br />Filed on 2006-11-23<br />Status: Expired 147165006 E-106-2003-0 E-106-2003-0-DE-19 Griffithsin, Glycosylation-Resistant Griffithsin, and Related Conjugates, Compositions, Nucleic Acids, Vectors, Host Cells, Methods of Production And Methods of Use EP Germany 1740605 05804849.7 Expired Germany <br />European patent (EP) 05804849.7<br />Filed on 2006-11-23<br />Status: Expired 147165007 E-106-2003-0 E-106-2003-0-FR-20 Griffithsin, Glycosylation-Resistant Griffithsin, and Related Conjugates, Compositions, Nucleic Acids, Vectors, Host Cells, Methods of Production And Methods of Use EP France 1740605 05804849.7 Expired France <br />European patent (EP) 05804849.7<br />Filed on 2006-11-23<br />Status: Expired 147165008 E-106-2003-0 E-106-2003-0-GB-21 Griffithsin, Glycosylation-Resistant Griffithsin, and Related Conjugates, Compositions, Nucleic Acids, Vectors, Host Cells, Methods of Production And Methods of Use EP United Kingdom 1740605 05804849.7 Expired United Kingdom <br />European patent (EP) 05804849.7<br />Filed on 2006-11-23<br />Status: Expired 147165009 E-106-2003-0 E-106-2003-0-IE-22 Griffithsin, Glycosylation-Resistant Griffithsin, and Related Conjugates, Compositions, Nucleic Acids, Vectors, Host Cells, Methods of Production And Methods of Use EP Ireland 1740605 05804849.7 Expired Ireland <br />European patent (EP) 05804849.7<br />Filed on 2006-11-23<br />Status: Expired 147171529 Griffithsin 147171531 O'Keefe 147171532 SARS 147171533 Severe acute respiratory syndrome TAB-4897 152954990 T Cell Receptors Targeting EGFR L858R mutation on HLA-A*11:01+ Tumors for Use as Research Tools NCI Diagnostics, Licensing, Oncology, Research Materials Diagnostics Licensing Oncology Research Materials Catherine Ade, Matthew Sporn, Zhiya Yu <h2>Summary:</h2> <p>The Surgery Branch seeks licensees for research use of TCRs targeting EGFR L858R mutation.&nbsp;</p> <h2>Description of Technology:</h2> <p>Tumor-specific mutated proteins can create neoepitopes, mutation-derived antigens that distinguish tumor cells from healthy cells, which are attractive targets for adoptive cell therapies. However, the process of precisely identifying the neoepitopes to target is complex and challenging. One method to identify such neoepitopes is Mass Spectrometry (MS) when used in conjunction with elution of peptides bound to a specific Human Leukocyte Antigen (HLA) allele. Using MS in this context can demonstrate which oncogene derived neoepitopes are presented by common HLA alleles, and can provide the data necessary to rapidly develop TCRs against the desired antigens.&nbsp;</p> <p>Using the MS approach, inventors at the National Cancer Institute (NCI) have identified neoepitopes derived from a mutated isoform of Epithelial Growth Factor Receptor (EGFR) presented by HLA A*11:01 across multiple biological replicates. From this MS data, the inventors were able to successfully isolate murine TCRs that specifically recognize HLA A*11:01 restricted neoepitopes targeting EGFR L858R. According to various cancer genome databases, EGFR L858R is highly prevalent in lung adenocarcinoma, non-small cell lung carcinoma, and nonsquamous non-small cell lung carcinoma, making this driver mutation an excellent target to develop off-the-shelf cellular therapies. While the clinical potential of these TCRs has not been explored, they are valuable research materials to identify HLA-A*11:01 EGFR L858R reactive T cells in various sources including patients and animal models.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Research use</li> <li>In vitro diagnostic use</li> <li>The TCRs may be used as positive controls to identify HLA-A*11:01 EGFR L858R reactive T cells from different sources such as patients or animal models</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>TCRs recognize the common EGFR L858R driver mutation in the context of HLA-A*11:01&nbsp;</li> <li>EGFR mutations are highly prevalent in lung cancers, especially lung adenocarcinoma, non-small cell lung cancer and non-squamous non-small cell lung cancer</li> <li>The prevalence of EGFR L858R substitutions, relative to the overall EGFR mutation population, ranges from 27.7% to 41.1% in non-small cell lung cancer patients</li> <li>HLA-A*11:01 allele frequency is particularly high (up to 60%) in Asian and Oceanian populations</li> <li>This research has validated the effectiveness of using mass spectrometry to detect amino acid sequences on specific HLA complexes&nbsp;<br /> &nbsp;</li> </ul> The NCI seeks licensees for T Cell Receptors (TCRs) targeting Epidermal Growth Factor Receptor (EGFR) L858 mutation for use as research tools. 2024-02-16 2026-04-24 2026-04-24 2024-02-16 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-098-2018 152960967 Ade CM, et al. Identification of neoepitope reactive T-cell receptors guided by HLA A*03:01 and HLA A*11:01 immunopeptidomics. (PMID 37758652) https://pubmed.ncbi.nlm.nih.gov/37758652/ <a href="https://pubmed.ncbi.nlm.nih.gov/37758652/">Ade CM, et al. Identification of neoepitope reactive T-cell receptors guided by HLA A*03:01 and HLA A*11:01 immunopeptidomics. (PMID 37758652)</a> 152956517 Ade, Catherine NCI - CCR NCI Ade, Catherine (NCI) 1 152956539 Sporn, Matthew NCI - CCR NCI Sporn, Matthew (NCI) 2 152956564 Yu, Zhiya NCI - CCR NCI Yu, Zhiya (NCI) 3 152956517 Ade, Catherine NCI - CCR NCI Ade, Catherine (NCI) 1 152956539 Sporn, Matthew NCI - CCR NCI Sporn, Matthew (NCI) 2 152956564 Yu, Zhiya NCI - CCR NCI Yu, Zhiya (NCI) 3 152954993 Identification and cloning of EGFR L858R/A11_mTCR1, EGFR L858R/A11_mTCR4, and EGFR L858R/A11_mTCR9, three T cell receptors targeting EGFR L858R mutation on HLA-A1101+ tumor cells E-251-2023-0 Under Review NCI - CCR, NIH - NCI 83709866 Burke, Andrew burkear@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC burkear@nih.gov?subject=Web Inquiry on [TAB-4897] T Cell Receptors Targeting EGFR L858R mutation on HLA-A*11:01+ Tumors for Use as Research Tools&body=Please send me information about technology [TAB-4897] T Cell Receptors Targeting EGFR L858R mutation on HLA-A*11:01+ Tumors for Use as Research Tools.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Burke, Andrew<br><a href="mailto:burkear@nih.gov?subject=Web Inquiry on [TAB-4897] T Cell Receptors Targeting EGFR L858R mutation on HLA-A*11:01+ Tumors for Use as Research Tools&body=Please send me information about technology [TAB-4897] T Cell Receptors Targeting EGFR L858R mutation on HLA-A*11:01+ Tumors for Use as Research Tools.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">burkear@nih.gov</a><br> TAB-3960 147157240 Camel VHH Nanobodies Bind the S2 Subunit of SARS-CoV-2 and Broadly Neutralize Variants including Omicron NCI Collaboration, Immunology, Infectious Disease, Licensing, Therapeutics Collaboration Immunology Infectious Disease Licensing Therapeutics Jesse Buffington, Zhijian Duan, Mitchell Ho, Jessica Hong <h2>Summary:</h2> <p>The NCI seeks research co-development partners and/or licensees to further develop this nanobody as a possible treatment of COVID-19 infections.</p> <h2>Description of Technology:</h2> <p>Since its emergence in 2019, COVID-19 infected over 600 million people and over 6 million people have died from the disease. COVID-19 is an infectious disease caused by the SARS-CoV-2 virus. Neutralizing antibodies have been developed to bind to the receptor binding domain (RBD) on the spike (S) protein. Blocking the interaction of the RBD and the ACE2 receptor, is critical in neutralizing the virus. However, the S2 subunit, is also critical for viral infection and entry into human cells. The S2 subunit is highly conserved across many coronaviruses, however, there are currently no effective antibodies targeting this S2 subunit.</p> <p>The inventors isolated the J1B4 camel VHH nanobody, a potent S2 binder that can neutralize all the known variants of SARS-CoV-2, including omicron. The J1B4 VHH can be engineered with other COVID binders to create multi-specific drugs to treat current COVID-19 infections as well as future SARS-like viral infections. This technology presents a promising novel treatment for SARS-CoV-2 infection by using the anti-S2 nanobodies alone or in combination with anti-S1/RBD nanobodies.&nbsp;</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Treatment of SARS-CoV-2 infections</li> <li>Multi-specific antibody therapy</li> <li>Delivery of nanoparticles</li> <li>Diagnostic reagents for in vivo virus imaging</li> <li>Antiviral nanobody nasal spray</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>No currently available therapeutic antibodies targeting the S2 subunit of SARS-CoV-2</li> <li>Potential treatment for current and future SARS-CoV-2 infections</li> <li>Use of nanobodies suitable for developing non-invasive treatments, such as an intranasal spray</li> </ul> 2023-06-28 2026-04-24 2023-06-27 2026-04-24 2023-06-28 ANTIBODY, Camel Nanobody, CORONAVIRUS, COVID-19, HO, Infectious Diseases, Nanobodies, Pandemic, SARS-CoV-2, therapeutic, Vaccine False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2023-06-27 52406768 Discovery 52406768 NCI 37470483 Website Abstract E-204-2021 E-253-2020 147163025 Ho, Mitchell NIH - NCI NCI Ho, Mitchell (NCI) 1 147163024 Hong, Jessica NIH - NCI NCI Hong, Jessica (NCI) 2 147163023 Buffington, Jesse NIH - NCI NCI Buffington, Jesse (NCI) 3 147163022 Duan, Zhijian NIH - NCI NCI Duan, Zhijian (NCI) 4 147163025 Ho, Mitchell NIH - NCI NCI Ho, Mitchell (NCI) 1 147163024 Hong, Jessica NIH - NCI NCI Hong, Jessica (NCI) 2 147163023 Buffington, Jesse NIH - NCI NCI Buffington, Jesse (NCI) 3 147163022 Duan, Zhijian NIH - NCI NCI Duan, Zhijian (NCI) 4 147158041 Camel VHH nanobodies bind the S2 subunit of SARS-CoV-2 and broadly neutralize variants including omicron E-129-2023-0 Filing authorized Laboratory of Molecular Biology, NCI - CCR, NIH - NCI 83731987 Dhal, Abritee abritee.dhal@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-3960] Camel VHH Nanobodies Bind the S2 Subunit of SARS-CoV-2 and Broadly Neutralize Variants including Omicron&body=Please send me information about technology [TAB-3960] Camel VHH Nanobodies Bind the S2 Subunit of SARS-CoV-2 and Broadly Neutralize Variants including Omicron.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dhal, Abritee<br><a href="mailto:abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-3960] Camel VHH Nanobodies Bind the S2 Subunit of SARS-CoV-2 and Broadly Neutralize Variants including Omicron&body=Please send me information about technology [TAB-3960] Camel VHH Nanobodies Bind the S2 Subunit of SARS-CoV-2 and Broadly Neutralize Variants including Omicron.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">abritee.dhal@nih.gov</a><br> 147161078 E-129-2023-0 E-129-2023-0-US-01 SINGLE DOMAIN ANTIBODIES THAT SPECIFICALLY BIND THE S2 SUBUNIT OF SARS-COV-2 SPIKE PROTEIN AND COMPOSITIONS AND USES THEREOF PRV US 63/501,772 Expired US <br />Provisional (PRV) 63/501,772<br />Filed on 2023-05-12<br />Status: Expired 163804438 E-129-2023-0 E-129-2023-0-PC-01 SINGLE DOMAIN ANTIBODIES THAT SPECIFICALLY BIND THE S2 SUBUNIT OF SARS-COV-2 SPIKE PROTEIN AND COMPOSITIONS AND USES THEREOF PCT Patent Cooperation Treaty PCT/US2024/028832 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2024/028832<br />Filed on 2024-05-10<br />Status: Expired 164238034 E-129-2023-0 E-129-2023-0-US-02 SINGLE DOMAIN ANTIBODIES THAT SPECIFICALLY BIND THE S2 SUBUNIT OF SARS-COV-2 SPIKE PROTEIN AND COMPOSITIONS AND USES THEREOF National Stage US 19/482,967 Pending US <br />National Stage 19/482,967<br />Filed on 2025-11-10<br />Status: Pending 147172022 ANTIBODY 147172024 Camel Nanobody 147172025 CORONAVIRUS 147172026 COVID-19 147172027 HO 147172028 Infectious Diseases 147172029 Nanobodies 147172030 Pandemic 147172031 SARS-CoV-2 147172032 therapeutic 147172033 Vaccine TAB-3938 147157218 T Cell Receptor Targeting CD22 for the Treatment of Lymphomas and Leukemias NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Christian Hinrichs, Kazusa Ishii <h2>Description of Technology:</h2> <p>CD22 is a protein expressed by normal B cells and B-lymphoid malignancies. Its limited tissue expression pattern makes it a safe antigen for targeted therapies, such as T-cell Receptor (TCR)-T cell therapy. CD22-targeting therapies already on the market, mainly antibody-immunotoxin conjugates and chimeric antigen receptors (CAR)-T cells, have limitations such as resistance to treatment and/or side effects. Resistance mechanisms to the current CD22 therapies involve loss or modulation of target antigen on the cell surface. TCRs are expected to overcome these resistance mechanisms as they use distinct target recognition mechanism. TCRs instead recognize epitopes derived from proteins processed intracellularly and presented in the context of Human Leukocyte Antigens (HLA), enabling detection of broad antigens inaccessible to antibodies or CAR-T&rsquo;s &ndash; including neoantigens, cancer germline antigens, and intracellular viral oncoproteins.</p> <p>Investigators at the National Cancer Institute (NCI) developed a TCR recognizing a CD22-derived epitope presented in context of the highly prevalent HLA-A*02:01. The TCR was not cross-reactive against unintended target antigens. T cells expressing the TCR (CD22 TCR-T cells) show anti-tumor activity at clinically-relevant doses without causing systemic cytokine elevation in pre-clinical, in vivo models. The inventors are translating their findings into the clinic.</p> <p>NCI seeks parties interested in licensing and/or collaborations to further develop this technology.</p> <h2>Potential Commercial Applications:</h2> <p>Therapeutic against B-cell malignancies such as non-Hodgkin&rsquo;s lymphoma, chronic lymphocytic leukemia and acute lymphoblastic leukemia&nbsp;<br /> Therapeutic for:</p> <ul> <li>CD22-expressing malignancies, even if the CD22 antigen escapes the surface of the tumor cells and resides within intracellular compartments or is only partially expressed</li> <li>CD22-expressing malignancies, even if the diseases are resistant to existing anti CD22 antibodies through resistance to antibody-specific cytotoxicity mechanisms (such as antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity).</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Established market need and regulatory path &ndash; following Accelerated Approval of Inotuzumab ozogamicin in 2017.</li> <li>T cells expressing the CD22 TCR (CD22 TCR-T cells) mediate dose-dependent anti-tumor activity in leukemia and lymphoma models in vivo.</li> <li>CD22 TCR-T cells, but not T cells expressing a comparable CAR (CD22 CAR-T cells), clear leukemia at clinically-relevant doses and without causing systemic cytokine elevation.</li> <li>CD22 TCR-T cells are not cross-reactive against other human proteins.</li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for a T-cell receptor (TCR) that specifically targets an HLA-A*02:01-restricted CD22 Epitope 2023-04-04 2026-04-24 2023-04-04 2026-04-24 2023-04-04 Acute Lymphoblastic Leukemia, ALL, B cells, CD22, Cellular Immunotherapy, Chronic lymphocytic leukemia, CLL, Hinrichs, Ishii, NHL, Non-Hodgkin’s Lymphoma, Relapsed / refractory B-Lymphoid Malignancies, T-Cell Receptor, TCR False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2023-04-04 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-152-2020 147162937 Ishii, Kazusa NIH - NCI NCI Ishii, Kazusa (NCI) 1 147162936 Hinrichs, Christian NIH - NCI Hinrichs, Christian 2 147162937 Ishii, Kazusa NIH - NCI NCI Ishii, Kazusa (NCI) 1 147162936 Hinrichs, Christian NIH - NCI Hinrichs, Christian 2 147157825 Discovery Of T Cell Receptors (TCR) Against HLA-A*02:01-restricted CD22 Epitope E-029-2021-0 Filing authorized NCI 83694133 Gulay French, Suna suna.gulay@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB suna.gulay@nih.gov?subject=Web Inquiry on [TAB-3938] T Cell Receptor Targeting CD22 for the Treatment of Lymphomas and Leukemias&body=Please send me information about technology [TAB-3938] T Cell Receptor Targeting CD22 for the Treatment of Lymphomas and Leukemias.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Gulay French, Suna<br><a href="mailto:suna.gulay@nih.gov?subject=Web Inquiry on [TAB-3938] T Cell Receptor Targeting CD22 for the Treatment of Lymphomas and Leukemias&body=Please send me information about technology [TAB-3938] T Cell Receptor Targeting CD22 for the Treatment of Lymphomas and Leukemias.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">suna.gulay@nih.gov</a><br> 147160930 E-029-2021-0 E-029-2021-0-PCT-02 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST CD22 PCT Patent Cooperation Treaty PCT/US2022/016561 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2022/016561<br />Filed on 2022-02-16<br />Status: Expired 147165424 E-029-2021-0 E-029-2021-0-US-01 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST CD22 PRV US 63/149,795 Abandoned US <br />Provisional (PRV) 63/149,795<br />Filed on 2021-02-16<br />Status: Abandoned 147165425 E-029-2021-0 E-029-2021-0-CA-01 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST CD22 National Stage Canada 3207989 Pending Canada <br />National Stage 3207989<br />Filed on 2023-08-10<br />Status: Pending 147165426 E-029-2021-0 E-029-2021-0-US-02 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST CD22 National Stage US 18/277,521 Pending US <br />National Stage 18/277,521<br />Filed on 2023-08-16<br />Status: Pending 147165427 E-029-2021-0 E-029-2021-0-EP-01 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST CD22 National Stage European Patent 22709092.5 Pending European Patent <br />National Stage 22709092.5<br />Filed on 2023-09-13<br />Status: Pending 147169834 Acute Lymphoblastic Leukemia 147169835 ALL 147169836 B cells 147169837 CD22 147169839 Cellular Immunotherapy 147169840 Chronic lymphocytic leukemia 147169841 CLL 147169842 Hinrichs 147169844 Ishii 147169846 NHL 147169847 Non-Hodgkin’s Lymphoma 147169849 Relapsed / refractory B-Lymphoid Malignancies 147169851 T-Cell Receptor 147169852 TCR TAB-4319 147157609 Enhanced Antigen Reactivity of Immune Cells Expressing a Mutant Non-Signaling CD3 Zeta Chain NICHD Collaboration, Immunology, Infectious Disease, Licensing, Oncology, Therapeutics Collaboration Immunology Infectious Disease Licensing Oncology Therapeutics John Davies, Guillaume Gaud, Christian Hinrichs, Paul Love <h2>Summary:</h2> <p>Researchers at the Eunice Kennedy Shriver National Institute of Child Health and Human Development are highly motivated in seeking licensing and/or collaboration partners to develop therapeutic cell populations arising out of these technologies.&nbsp; An ideal partner would enter into both a Cooperative Research and Development Agreement (CRADA) and an exclusive license agreement towards commercialization of one or more therapies to treat various oncologies.&nbsp;</p> <h2>Description of Technology:</h2> <p>Immunotherapy is a cutting-edge new category of treatment that aims to harness and, in some cases, modify the patient&rsquo;s own immune cells to improve their ability to cure diseases. It can be an effective approach for a variety of conditions, ranging from cancer to inflammatory diseases.&nbsp; However, a number of obstacles to the overall success of immunotherapy still exist.&nbsp; For example, reactivity against a target antigen can be attenuated or the lifespan of the &ldquo;modified&rdquo; immune cells can be too short. In cancer, some tumor cells could express antigen with very low reactivity, thus remaining undetected by &ldquo;classical&rdquo; immune cells.&nbsp; &nbsp;Despite considerable research in the field of immunotherapy, there still exists a need for improved methods and products.</p> <p>This technology describes the method of enhancing an antigen-specific immune response in a subject. This is accomplished through the modification of a CD3 subunit chain or related non-CD3 subunit chain which functions to transduce signals through immune receptors &ndash; such as the T cell antigen receptor. The specific subunit chain modifications are comprised of one or more of: (a) at least one Immuno-receptor Tyrosine-based Activation Motif (ITAM) deletion; or (b) at least one exogenous intracellular hematopoietic cell signaling domain; and (c) at least one modified ITAM comprising an amino acid sequence of Formula I.&nbsp;</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Immunotherapy treatment for cancer</li> <li>Immunotherapy treatment for autoimmune diseases</li> <li>Immunotherapy treatment for infectious diseases</li> <li>Autologous cell therapy with pharmaceutical compositions comprising novel cell populations</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Highly enhanced target antigen reactivity</li> <li>Highly enhanced functional avidity&nbsp;</li> <li>Cutting-edge therapeutic platform applicable to the treatment of multiple classes of diseases</li> </ul> 2022-02-15 2026-04-23 2022-02-15 2026-04-23 2022-02-15 CD3, Davies, Eunice Kennedy Shriver National Institute of Child Health an, Gaud, Hinrichs, Immuno-receptor Tyrosine-based Activation Motif, Immunotherapy, ITAM, Love, National Cancer Institute, Nci, NICHD, T Cell Receptor, TCR, Zeta Chain False True Basic (Target Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2022-02-15 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147164287 Love, Paul NIH - NICHD NICHD Love, Paul (NICHD) 1 147164289 Gaud, Guillaume NIH - NICHD NICHD Gaud, Guillaume (NICHD) 2 147164288 Hinrichs, Christian NIH - NCI Hinrichs, Christian 3 147164290 Davies, John NIH - NCI NCI Davies, John (NCI) 4 147164287 Love, Paul NIH - NICHD NICHD Love, Paul (NICHD) 1 147164289 Gaud, Guillaume NIH - NICHD NICHD Gaud, Guillaume (NICHD) 2 147164288 Hinrichs, Christian NIH - NCI Hinrichs, Christian 3 147164290 Davies, John NIH - NCI NCI Davies, John (NCI) 4 147157785 Enhanced Tumor Reactivity Of T Cells Expressing T Cell Antigen Receptors Containing A Mutant Non-signaling CD3zeta Chain E-010-2021-0 Filing authorized NCI, NICHD 119617417 Ravilious, Geoffrey geoffrey.ravilious@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
geoffrey.ravilious@nih.gov?subject=Web Inquiry on [TAB-4319] Enhanced Antigen Reactivity of Immune Cells Expressing a Mutant Non-Signaling CD3 Zeta Chain&body=Please send me information about technology [TAB-4319] Enhanced Antigen Reactivity of Immune Cells Expressing a Mutant Non-Signaling CD3 Zeta Chain.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Ravilious, Geoffrey<br><a href="mailto:geoffrey.ravilious@nih.gov?subject=Web Inquiry on [TAB-4319] Enhanced Antigen Reactivity of Immune Cells Expressing a Mutant Non-Signaling CD3 Zeta Chain&body=Please send me information about technology [TAB-4319] Enhanced Antigen Reactivity of Immune Cells Expressing a Mutant Non-Signaling CD3 Zeta Chain.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">geoffrey.ravilious@nih.gov</a><br> 147160895 E-010-2021-0 E-010-2021-0-US-01 ENHANCED ANTIGEN REACTIVITY OF IMMUNE CELLS EXPRESSING A MUTANT NON-SIGNALING CD3 ZETA CHAIN PRV US 63/113,428 Abandoned US <br />Provisional (PRV) 63/113,428<br />Filed on 2020-11-13<br />Status: Abandoned 147168135 E-010-2021-0 E-010-2021-0-PCT-02 ENHANCED ANTIGEN REACTIVITY OF IMMUNE CELLS EXPRESSING A MUTANT NON-SIGNALING CD3 ZETA CHAIN PCT Patent Cooperation Treaty PCT/US2021/059109 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/059109<br />Filed on 2021-11-12<br />Status: Expired 147168136 E-010-2021-0 E-010-2021-0-US-02 ENHANCED ANTIGEN REACTIVITY OF IMMUNE CELLS EXPRESSING A MUTANT NON-SIGNALING CD3 ZETA CHAIN National Stage US 18/036,112 Pending US <br />National Stage 18/036,112<br />Filed on 2023-05-09<br />Status: Pending 147168137 E-010-2021-0 E-010-2021-0-EP-01 ENHANCED ANTIGEN REACTIVITY OF IMMUNE CELLS EXPRESSING A MUTANT NON-SIGNALING CD3 ZETA CHAIN National Stage European Patent 21824143.8 Pending European Patent <br />National Stage 21824143.8<br />Filed on 2023-03-30<br />Status: Pending 147169426 CD3 147169428 Davies 147169429 Eunice Kennedy Shriver National Institute of Child Health an 147169431 Gaud 147169433 Hinrichs 147169435 Immuno-receptor Tyrosine-based Activation Motif 147169436 Immunotherapy 147169438 ITAM 147169440 Love 147169442 National Cancer Institute 147169443 Nci 147169444 NICHD 147169446 T Cell Receptor 147169447 TCR 147169449 Zeta Chain TAB-4228 147157513 Time Efficient Multi-Pulsed Field Gradient (mPFG) MRI Without Concomitant Gradient Field Artifacts NICHD Collaboration, Diagnostics, Immunology, Licensing, Oncology Collaboration Diagnostics Immunology Licensing Oncology Peter Basser, Michal Komlosh, Magdoom Mohamed Kulam Najmudeen <h2>Summary:</h2> <p>The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) seeks research co-development partners and/or licensees for the development of diffusion tensor distribution MR imaging (DTD-MRI) in assessing disease (e.g., cancer), normal and abnormal developmental processes, degeneration and trauma in the brain and other soft tissues, or in other applications.</p> <h2>Description of Technology:</h2> <p>Measuring and mapping nervous tissue microstructure noninvasively is a long sought-after goal in neuroscience. Clinically, several neuropathologies such as cancer and stroke, are associated with changes in tissue microstructure. Diffusion tensor imaging (DTI), which models diffusion anisotropy, is an ideal imaging modality to elucidate these changes. However, DTI provides a mean diffusion tensor averaged over the entire MRI voxel. This has limitations when applied to heterogeneous neural tissue. Although some of these could be overcome by increased spatial resolution, this comes at the cost of reduced signal-to-noise ratio (SNR) and increased scan time. The SNR limitation makes it impractical to resolve individual neuronal soma and axons whose size range between 0.1-60 &micro;m. Multiple pulsed field gradient (mPFG) methods can resolve microscopic features several orders of magnitude smaller than the typical MRI voxel size &ndash; for example, plant cell size and pore diameters in phantoms &ndash; using lower gradient strengths compared to single PFG methods.</p> <p>This technology describes methods and apparatus to measure and map the diffusion tensor distribution (DTD) in neural tissue or other specimens. Efficient and translatable methods of performing mPFG MRI experiments in a single spin echo sequence to generate b-matrices of ranks one, two, or three, without concomitant gradient field artifacts are disclosed. The disclosed approaches and signal inversion framework captures features of heterogeneity and anisotropy in the spinal cord or other specimens. The disclosed stains may have utility in assessing disease (e.g., cancer), normal and abnormal developmental processes, degeneration and trauma in the brain and other soft tissues, and other applications.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Neuro or whole-body MRI suites for disease assessment in neural or other tissues.</li> <li>Detection of microscopic anisotropy and heterogeneity within neural tissue (including the spinal cord)</li> <li>Assessing disease (e.g., cancer), normal and abnormal developmental processes, degeneration and trauma in the brain and other soft tissues, and other applications</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Superior non-invasive measurement and mapping of nervous tissue microstructure</li> <li>Better time efficiency relative to other multiple pulsed field gradient (mPFG) techniques</li> <li>Well-defined diffusion timing parameters for q-space MRI analysis</li> <li>Reduction of concomitant gradient field artifacts</li> </ul> 2022-02-11 2026-04-23 2022-02-10 2026-04-23 2022-02-10 Basser, Diffusion Tensor Distribution MR Imaging, DTI, Eunice Kennedy Shriver National Institute of Child Health an, Komlosh, Magnetic Resonance Imaging, mPFG, MRI, Multi-Pulsed Field Gradient, Najmudeen, NICHD False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2022-02-10 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147163976 Basser, Peter NIH - NICHD NICHD Basser, Peter (NICHD) 1 147163977 Komlosh, Michal Henry M. Jackson Foundation (HJF) NICHD Komlosh, Michal (NICHD) 2 147163978 Kulam Najmudeen, Magdoom Mohamed NIH - NICHD NICHD Kulam Najmudeen, Magdoom Mohamed (NICHD) 3 147163976 Basser, Peter NIH - NICHD NICHD Basser, Peter (NICHD) 1 147163977 Komlosh, Michal Henry M. Jackson Foundation (HJF) NICHD Komlosh, Michal (NICHD) 2 147163978 Kulam Najmudeen, Magdoom Mohamed NIH - NICHD NICHD Kulam Najmudeen, Magdoom Mohamed (NICHD) 3 147158136 Time Efficient Multi-pulsed Field Gradient (mPFG) MRI Without Concomitant Gradient Field Artifacts E-170-2020-0 Filing authorized Henry M. Jackson Foundation (HJF), NICHD 119617417 Ravilious, Geoffrey geoffrey.ravilious@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
geoffrey.ravilious@nih.gov?subject=Web Inquiry on [TAB-4228] Time Efficient Multi-Pulsed Field Gradient (mPFG) MRI Without Concomitant Gradient Field Artifacts&body=Please send me information about technology [TAB-4228] Time Efficient Multi-Pulsed Field Gradient (mPFG) MRI Without Concomitant Gradient Field Artifacts.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Ravilious, Geoffrey<br><a href="mailto:geoffrey.ravilious@nih.gov?subject=Web Inquiry on [TAB-4228] Time Efficient Multi-Pulsed Field Gradient (mPFG) MRI Without Concomitant Gradient Field Artifacts&body=Please send me information about technology [TAB-4228] Time Efficient Multi-Pulsed Field Gradient (mPFG) MRI Without Concomitant Gradient Field Artifacts.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">geoffrey.ravilious@nih.gov</a><br> 147161143 E-170-2020-0 E-170-2020-0-US-01 TIME EFFICIENT MULTI-PULSED FIELD GRADIENT (MPFG) MRI WITHOUT CONCOMITANT GRADIENT FIELD ARTIFACTS PRV US 63/055,150 Abandoned US <br />Provisional (PRV) 63/055,150<br />Filed on 2020-07-22<br />Status: Abandoned 147167537 E-170-2020-0 E-170-2020-0-PCT-02 Time Efficient Multi-pulsed Field Gradient (mPFG) MRI Without Concomitant Gradient Field Artifacts PCT Patent Cooperation Treaty PCT/US2021/040929 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/040929<br />Filed on 2021-07-08<br />Status: Expired 147167538 E-170-2020-0 E-170-2020-0-US-03 TIME EFFICIENT MULTI-PULSED FIELD GRADIENT (MPFG) MRI WITHOUT CONCOMITANT GRADIENT FIELD ARTIFACTS National Stage US 12,493,092 18/017,150 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12493092 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12493092">12,493,092</a><br />Filed on 2023-01-20<br />Status: Issued 147172929 Basser 147172931 Diffusion Tensor Distribution MR Imaging 147172932 DTI 147172933 Eunice Kennedy Shriver National Institute of Child Health an 147172935 Komlosh 147172936 Magnetic Resonance Imaging 147172937 mPFG 147172938 MRI 147172940 Multi-Pulsed Field Gradient 147172941 Najmudeen 147172942 NICHD TAB-4168 147157452 Tamperless Tensor Elastography Imaging NICHD Collaboration, Diagnostics, Licensing, Neurology, Oncology Collaboration Diagnostics Licensing Neurology Oncology Peter Basser, Magdoom Mohamed Kulam Najmudeen <h2>Summary:</h2> <p>The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) seeks research co-development partners and/or licensees for the development of tamper-less tensor elastography imaging in assessing disease (e.g., cancer), normal and abnormal developmental processes, degeneration and trauma in the brain and other soft tissues, and other applications.</p> <h2>Description of Technology:</h2> <p>Measuring and mapping nervous tissue microstructure noninvasively is a long sought-after goal in neuroscience. Several neuropathologies &ndash; such as cancer and stroke &ndash; are associated with changes in tissue microstructure. Changes in material properties, such as stiffness, represent a sensitive measure of<br /> underlying changes in tissue architecture, organization, and microstructure. Elastography techniques used to map material stiffness typically involves measuring displacement resulting from shear waves of known frequency imposed on the material by an external actuator or tamper. Material stiffness is estimated from measured displacement by inverting a model relating the material&rsquo;s strain to its stress. A minimal description of a constitutive law relating the stress and strain in the anisotropic material requires a rank-4 anisotropic elasticity tensor (E-tensor). The E-tensor has a number of free parameters ranging from 2 to 21 depending on the degree of material symmetry &ndash; instead of the 1-parameter isotropic scalar shear modulus used in conventional methods. Reconstructing the full E-tensor from a single mechanical excitation is an ill-posed inverse problem since the number of unknowns typically exceeds the number of available equations.</p> <p>The disclosure describes elastography methods permitting measurement of small physiological tissue displacements using spin echo MRI, ultrasound, or other techniques. It allows reconstruction of a full rank-4 anisotropic elasticity tensor (E-tensor). It includes strategies that denoise the measured displacement field using physically motivated compatibility conditions. Also, it includes a family of new intrinsic, invariant stains or parameters to characterize different features of the measured E-tensor. The disclosed E-tensor estimation pipelines are evaluated using simulated 3D displacement data in the presence of noise which confirm the applicability of the disclosed approaches. With the selected E-tensor and associated stains, physiological disorders &ndash; such as Alzheimer&rsquo;s disease and traumatic brain injury (TBI) &ndash; is more readily detected versus conventional methods not utilizing the full E-tensor.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Neuro or whole-body MRI suites for disease assessment and diagnosis in neural and other tissues</li> <li>Assessing disease (e.g., cancer), normal and abnormal developmental processes, degeneration and trauma in the brain and other soft tissues, and other applications</li> <li>Brain tissue stiffness atlas to design head gear which minimizes impact</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Superior non-invasive measurement and mapping of nervous tissue microstructure</li> <li>Produces estimates of a full rank-4 elasticity tensors (E-tensors) using suitable constraints</li> <li>Incorporates intrinsic deformation of the tissue caused by physiological motion, such as from cardiac pulsation and/or respiratory motion, rather than reliance on external tampers</li> </ul> 2022-04-01 2026-04-23 2022-04-01 2026-04-23 2022-04-01 Alzheimer’s Disease, Anisotropy, Basse, brain, CANCER, Elasticity Tensor, Elastography, Eunice Kennedy Shriver National Institute of Child Health an, Magnetic Resonance Imaging, MRI, Najmudeen, NICHD, TBI, TRAUMA, Traumatic Brain Injury False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2022-04-01 52406768 Discovery 52406768 NCI 37470483 Website Abstract E-170-2020 147163754 Basser, Peter NIH - NICHD NICHD Basser, Peter (NICHD) 1 147163755 Kulam Najmudeen, Magdoom Mohamed NIH - NICHD NICHD Kulam Najmudeen, Magdoom Mohamed (NICHD) 2 147163754 Basser, Peter NIH - NICHD NICHD Basser, Peter (NICHD) 1 147163755 Kulam Najmudeen, Magdoom Mohamed NIH - NICHD NICHD Kulam Najmudeen, Magdoom Mohamed (NICHD) 2 147157824 MR Viscoelasticity Tensor MRI Of The Brain And Other Tissue E-028-2020-0 Filing authorized NICHD 119617417 Ravilious, Geoffrey geoffrey.ravilious@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
geoffrey.ravilious@nih.gov?subject=Web Inquiry on [TAB-4168] Tamperless Tensor Elastography Imaging&body=Please send me information about technology [TAB-4168] Tamperless Tensor Elastography Imaging.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Ravilious, Geoffrey<br><a href="mailto:geoffrey.ravilious@nih.gov?subject=Web Inquiry on [TAB-4168] Tamperless Tensor Elastography Imaging&body=Please send me information about technology [TAB-4168] Tamperless Tensor Elastography Imaging.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">geoffrey.ravilious@nih.gov</a><br> 147160929 E-028-2020-0 E-028-2020-0-US-01 TAMPERLESS TENSOR ELASTOGRAPHY IMAGING PRV US 63/192,920 Abandoned US <br />Provisional (PRV) 63/192,920<br />Filed on 2021-05-25<br />Status: Abandoned 147167062 E-028-2020-0 E-028-2020-0-PCT-02 TAMPERLESS TENSOR ELASTOGRAPHY IMAGING PCT Patent Cooperation Treaty PCT/US2022/030846 Administratively Closed Patent Cooperation Treaty <br />(PCT) PCT/US2022/030846<br />Filed on 2022-05-25<br />Status: Administratively Closed 147169816 Alzheimer’s Disease 147169817 Anisotropy 147169819 Basse 147169820 brain 147169821 CANCER 147169823 Elasticity Tensor 147169824 Elastography 147169825 Eunice Kennedy Shriver National Institute of Child Health an 147169826 Magnetic Resonance Imaging 147169827 MRI 147169829 Najmudeen 147169830 NICHD 147169831 TBI 147169832 TRAUMA 147169833 Traumatic Brain Injury TAB-4016 147157297 Therapeutics Against Pathogenic Coronaviruses NICHD Collaboration, Infectious Disease, Licensing, Therapeutics Collaboration Infectious Disease Licensing Therapeutics Arup Chakraborty, Melvin DePamphilis, Matthew Frieman <h2>Summary:</h2> <p>Researchers at the Eunice Kennedy Shriver National Institute of Child Health and Human Development are highly motivated in seeking research co-development partners and/or licensees to further develop and commercialize PIKfyve phosphatidyl linositol kinase inhibitors for the treatment of pathogenic coronaviruses. An ideal partner would enter into both a Cooperative Research and Development Agreement (CRADA) and an exclusive license agreement towards commercialization of this technology.</p> <h2>Description of Technology:</h2> <p>The COVID-19 pandemic is a worldwide public health crisis with over 440 million confirmed cases and 6.0 million deaths as of March 2022. COVID-19 is caused by a novel coronavirus called Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). While there are several vaccines available for COVID-19, there are few therapeutics available that specifically target SARS-CoV-2. Middle East respiratory syndrome coronavirus (MERS-CoV) is less understood than SARS-CoV-2. MERS-CoV patients have a 65% long-term survival rate, according the World Health Organization (WHO).</p> <p>Researchers at the Eunice Kennedy Shriver National Institute of Child Health and Human Development discovered that PIKfyve phosphatidyl linositol kinase inhibitors exhibit therapeutic potential in preventing infection of mammalian cells by pathogenic coronaviruses. It does so by disrupting membrane trafficking to treat coronavirus infection and replication. These compounds are effective at concentrations 100-1000X less than those toxic to uninfected cells. The technology is for use in treating coronavirus infections in humans, particularly infections caused by SARS-CoV-2, SARS-CoV or MER-CoV.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Treatment of SARS-CoV-2 or SARS-CoV</li> <li>Treatment of MER-CoV</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Effective against SARS-CoV-2, SARS-CoV, and MER-CoV</li> <li>Disrupts membrane trafficking to treat coronavirus infection and replication</li> <li>Promising safety profile</li> </ul> 2022-04-01 2026-04-23 2022-04-01 2026-04-23 2022-03-31 CORONAVIRUS, COVID-19, Depamphilis, Eunice Kennedy Shriver National Institute of Child Health an, Infectious Diseases, MER-CoV, NICHD, PIKfyve Phosphatidyl Linositol Kinase Inhibitors, SARS-CoV, SARS-CoV-2, virus False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2022-04-01 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147163227 DePamphilis, Melvin NIH - NICHD NICHD DePamphilis, Melvin (NICHD) 1 147163228 Frieman, Matthew University of Maryland, School of Medicine Frieman, Matthew 2 147163229 Chakraborty, Arup NIH - NICHD NICHD Chakraborty, Arup (NICHD) 3 147163227 DePamphilis, Melvin NIH - NICHD NICHD DePamphilis, Melvin (NICHD) 1 147163228 Frieman, Matthew University of Maryland, School of Medicine Frieman, Matthew 2 147163229 Chakraborty, Arup NIH - NICHD NICHD Chakraborty, Arup (NICHD) 3 147157782 Therapeutics Against Pathogenic Coronaviruses SARS-CoV-2, MERS-CoV And SARS-CoV E-009-2021-0 Filing authorized NICHD, University of Maryland 91788919 Gunas, Heather gunash@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America gunash@mail.nih.gov?subject=Web Inquiry on [TAB-4016] Therapeutics Against Pathogenic Coronaviruses&body=Please send me information about technology [TAB-4016] Therapeutics Against Pathogenic Coronaviruses.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Gunas, Heather<br><a href="mailto:gunash@mail.nih.gov?subject=Web Inquiry on [TAB-4016] Therapeutics Against Pathogenic Coronaviruses&body=Please send me information about technology [TAB-4016] Therapeutics Against Pathogenic Coronaviruses.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">gunash@mail.nih.gov</a><br> 147160892 E-009-2021-0 E-009-2021-0-US-01 THERAPEUTICS AGAINST PATHOGENIC CORONAVIRUSES PRV US 63/119,522 Abandoned US <br />Provisional (PRV) 63/119,522<br />Filed on 2020-11-30<br />Status: Abandoned 147166008 E-009-2021-0 E-009-2021-0-PCT-02 THERAPEUTICS AGAINST PATHOGENIC CORONAVIRUSES PCT Patent Cooperation Treaty PCT/US2021/060122 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/060122<br />Filed on 2021-11-19<br />Status: Expired 147166009 E-009-2021-0 E-009-2021-0-US-02 THERAPEUTICS AGAINST PATHOGENIC CORONAVIRUSES National Stage US 18/028,490 Abandoned US <br />National Stage 18/028,490<br />Filed on 2023-03-24<br />Status: Abandoned 147169405 CORONAVIRUS 147169406 COVID-19 147169407 Depamphilis 147169408 Eunice Kennedy Shriver National Institute of Child Health an 147169409 Infectious Diseases 147169411 MER-CoV 147169412 NICHD 147169414 PIKfyve Phosphatidyl Linositol Kinase Inhibitors 147169415 SARS-CoV 147169416 SARS-CoV-2 147169417 virus TAB-3969 147157249 Nandrolone 17 Beta-Carbonates NICHD Collaboration, Endocrinology, Licensing, Reproductive Health, Therapeutics Collaboration Endocrinology Licensing Reproductive Health Therapeutics Richard Blye, Hyun Kim, Min Lee <h2>Summary:</h2> <p>Researchers at the Eunice Kennedy Shriver National Institute of Child Health and Human Development are highly motivated in seeking licensing and/or collaboration partners for the development and use of androgenic compounds as contraceptives and/or hormonal therapeutics.</p> <h2>Description of Technology:</h2> <p><img alt="" src="/sites/ttc/files/pictures/e-181-2004-0-us-07_abstract_image.docx" />The available options for male contraceptives are limited. Androgens are administered as part of hormone-based male contraception and have also been used in the treatment of hypogonadism and hormone replacement therapy HRT. Many synthetic androgens require an oil-based delivery vehicle and have limited durations of action.</p> <div>This technology describes androgenic compounds and pharmaceutical compositions thereof for use in a number of diseases or conditions, most notably as a potential male contraceptive, and as an androgenic agent suppressing the release of hormones such as the luteinizing hormone. Additional potential therapeutic areas include hypogonadism, osteoporosis, and anemia.&nbsp;</div> <div>Since 2016, NICHD has been testing the following lead compound as a male contraceptive in Phase I clinical trials:</div> <div> <p>Safety and pharmacokinetics of oral single-dose, 28 day repeat-dose, and dose escalation study of 11-MNTDC in healthy men have been conducted.&nbsp; The drug was well tolerated without serious adverse events.&nbsp; Daily oral dose of 11&beta;-MNTDC for 28 days in healthy men showed markedly suppressed serum gonadotropins and T concentrations without serious adverse effects.&nbsp; NICHD is planning another Phase I trial to test 11&beta;-MNTDC via intramuscular injection.&nbsp;</p> <p>&nbsp;</p> <p><img alt="" src="https://nih.technologypublisher.com/files/sites/e-181-2004-0-us-07_abstract_image4.png" /></p> </div> <h2>Potential Commercial Applications:</h2> <ul> <li>Male contraceptive</li> <li>Treatment of hormonal diseases</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Significant market need for male contraceptive</li> <li>Clinical-stage asset</li> <li>No adverse events in a Phase I dose-escalation study</li> <li>Intramuscular (IM) injection</li> </ul> 2022-09-13 2026-04-23 2026-04-23 2022-09-13 19-nortestosterone, Androgenic Compounds, Blye, Male Contraceptive, Nandrolone, National Institute of Child Health and Human Development, NICHD False True Clinical True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 72159138 Clinical Phase I 72159138 NCI 37470483 Website Abstract 147162240 Nguyen, BT, et al. Acceptability of the oral hormonal male contraceptive prototype, 11β-methyl-19-nortestosterone dodecylcarbonate (11β-MNTDC), in a 28-day placebo-controlled trial https://pubmed.ncbi.nlm.nih.gov/34153318/ <a href="https://pubmed.ncbi.nlm.nih.gov/34153318/">Nguyen, BT, et al. Acceptability of the oral hormonal male contraceptive prototype, 11β-methyl-19-nortestosterone dodecylcarbonate (11β-MNTDC), in a 28-day placebo-controlled trial</a> 147162355 Wu, S, et al. Safety and Pharmacokinetics of Single-Dose Novel Oral Androgen 11β-Methyl-19-Nortestosterone-17β-Dodecylcarbonate in Men. https://pubmed.ncbi.nlm.nih.gov/30252057/ <a href="https://pubmed.ncbi.nlm.nih.gov/30252057/">Wu, S, et al. Safety and Pharmacokinetics of Single-Dose Novel Oral Androgen 11β-Methyl-19-Nortestosterone-17β-Dodecylcarbonate in Men.</a> 147162393 Yuen, F, et al. Daily Oral Administration of the Novel Androgen 11β-MNTDC Markedly Suppresses Serum Gonadotropins in Healthy Men. https://pubmed.ncbi.nlm.nih.gov/31976519/#:~:text=Conclusion%3A%20Daily%20oral%2011%CE%B2%2DMNTDC,a%20potential%20male%20oral%20contraceptive. <a href="https://pubmed.ncbi.nlm.nih.gov/31976519/#:~:text=Conclusion%3A%20Daily%20oral%2011%CE%B2%2DMNTDC,a%20potential%20male%20oral%20contraceptive.">Yuen, F, et al. Daily Oral Administration of the Novel Androgen 11β-MNTDC Markedly Suppresses Serum Gonadotropins in Healthy Men.</a> 147163075 Blye, Richard NIH - NICHD NICHD Blye, Richard (NICHD) 1 147163074 Kim, Hyun NIH - NICHD Kim, Hyun 2 147163076 Lee, Min NICHD NICHD Lee, Min (NICHD) 3 147163075 Blye, Richard NIH - NICHD NICHD Blye, Richard (NICHD) 1 147163074 Kim, Hyun NIH - NICHD Kim, Hyun 2 147163076 Lee, Min NICHD NICHD Lee, Min (NICHD) 3 147158157 Preparation And Use Of Androgenic Compounds E-181-2004-0 Filing authorized NICHD 91788919 Gunas, Heather gunash@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America gunash@mail.nih.gov?subject=Web Inquiry on [TAB-3969] Nandrolone 17 Beta-Carbonates&body=Please send me information about technology [TAB-3969] Nandrolone 17 Beta-Carbonates.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Gunas, Heather<br><a href="mailto:gunash@mail.nih.gov?subject=Web Inquiry on [TAB-3969] Nandrolone 17 Beta-Carbonates&body=Please send me information about technology [TAB-3969] Nandrolone 17 Beta-Carbonates.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">gunash@mail.nih.gov</a><br> 147165613 E-181-2004-0 E-181-2004-0-US-01 Preparation And Use Of Androgenic Compounds PRV US 60/650,376 Abandoned US <br />Provisional (PRV) 60/650,376<br />Filed on 2005-02-04<br />Status: Abandoned 147165614 E-181-2004-0 E-181-2004-0-PCT-02 NANDROLONE 17B-CARBONATES PCT Patent Cooperation Treaty PCT/US2006/02436 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2006/02436<br />Filed on 2006-01-24<br />Status: Expired 147165615 E-181-2004-0 E-181-2004-0-AU-03 NANDROLONE 17 BETA-CARBONATES National Stage Australia 2006211907 2006211907 Abandoned Australia <br />National Stage 2006211907<br />Filed on 2006-01-24<br />Status: Abandoned 147165616 E-181-2004-0 E-181-2004-0-CA-04 NANDROLONE 17 BETA-CARBONATES National Stage Canada 2596884 2596884 Abandoned Canada <br />National Stage 2596884<br />Filed on 2006-01-24<br />Status: Abandoned 147165617 E-181-2004-0 E-181-2004-0-EP-05 NANDROLONE 17 BETA-CARBONATES National Stage European Patent 1846434 06719336.7 Abandoned European Patent <br />National Stage 06719336.7<br />Filed on 2006-01-24<br />Status: Abandoned 147165618 E-181-2004-0 E-181-2004-0-JP-06 NANDROLONE 17 BETA-CARBONATES National Stage Japan 5227593 2007-554134 Abandoned Japan <br />National Stage 2007-554134<br />Filed on 2006-01-24<br />Status: Abandoned 147165619 E-181-2004-0 E-181-2004-0-US-07 NANDROLONE 17B-CARBONATES National Stage US 7,820,642 11/815,532 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7820642 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7820642">7,820,642</a><br />Filed on 2007-08-03<br />Status: Issued 147165620 E-181-2004-0 E-181-2004-0-DE-08 NANDROLONE 17 BETA-CARBONATES EP Germany 1846434 06719336.7 Abandoned Germany <br />European patent (EP) 06719336.7<br />Filed on 2006-01-24<br />Status: Abandoned 147165621 E-181-2004-0 E-181-2004-0-FR-09 NANDROLONE 17 BETA-CARBONATES EP France 1846434 06719336.7 Abandoned France <br />European patent (EP) 06719336.7<br />Filed on 2006-01-24<br />Status: Abandoned 147165622 E-181-2004-0 E-181-2004-0-GB-10 NANDROLONE 17 BETA-CARBONATES EP United Kingdom 1846434 06719336.7 Abandoned United Kingdom <br />European patent (EP) 06719336.7<br />Filed on 2006-01-24<br />Status: Abandoned 147173106 19-nortestosterone 147173108 Androgenic Compounds 147173110 Blye 147173111 Male Contraceptive 147173113 Nandrolone 147173114 National Institute of Child Health and Human Development 147173115 NICHD TAB-3870 147157149 La Protein as a Novel Regulator of Osteoclastogenesis NICHD Collaboration, Licensing, Therapeutics Collaboration Licensing Therapeutics Leonid Chernomordik, Evgenia Leikina, Jarred Whitlock <h2>Summary:</h2> <p>NICHD seeks co-development partners and/or licensees for the further development of methods to target the La protein for the regulation of osteoclast fusion and osteoclastogenesis.</p> <h2>Description of Technology:</h2> <p>Millions of patients in the United States are afflicted by a host of bone diseases caused by osteoclast (specialized calls arising from the macrophage/monocyte lineage) dysfunction. Diseases include Paget&rsquo;s disease, osteoporosis, fibrous dysplasia and osteolytic bone metastasis. The current standard of care for these diseases uses broad-spectrum therapies that either coat the skeletal system or inhibit osteoclast development in an effort to modulate osteoclastogenesis. New therapies are needed that specifically target osteoclast fusion &ndash; allowing patients to forgo the off-target side effects caused by existing, broad-spectrum therapies.</p> <p>Researchers at the National Institute of Child Health and Human Development (NICHD) discovered that the Lupus autoantigen (La) protein is a master regulator of osteoclast fusion and osteoclastogenesis., The resorptive capacity of osteoclasts and the ability of osteoclasts to remodel bone can be modulated by :(1) administering an effective amount of a La protein or (2) an agent that modulates La protein expression or activity. This specific approach to regulating osteoclast fusion and osteoclastogenesis should bypass the off-target side effects associated with current therapies. It represents a major opportunity to improve the lives of millions who suffer from numerous bone diseases.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Therapeutics targeting La protein to treat all the most common types of bone disease &ndash; including but not limited to: <ul> <li>Osteoporosis</li> <li>Paget&rsquo;s disease</li> <li>Fibrous dysplasia</li> <li>Osteolytic bone metastasis</li> </ul> </li> <li>Therapeutics targeting La protein for relieving symptoms associated with: <ul> <li>Rheumatoid arthritis</li> <li>Metastatic bone disease</li> </ul> </li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Technology addresses most major forms of &ndash; and therefore the largest addressable markets for &ndash; bone disease</li> <li>Enables precise modulation of osteoclast fusion and function</li> <li>Potential to prevent off-target side-effects associated with current therapies</li> </ul> 2022-07-07 2026-04-23 2022-07-06 2026-04-23 2022-07-07 Chernomordik, La Protein, Lupus Autoantigen Protein, National Institute of Child Health and Human Development, NICHD, Osteoclast Fusion, Osteoclastogenesis False True Basic (Target Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2022-07-06 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147162677 Chernomordik, Leonid NIH - NICHD NICHD Chernomordik, Leonid (NICHD) 1 147162676 Leikina, Evgenia NICHD Leikina, Evgenia (NICHD) 2 147162678 Whitlock, Jarred NICHD NICHD Whitlock, Jarred (NICHD) 3 147162677 Chernomordik, Leonid NIH - NICHD NICHD Chernomordik, Leonid (NICHD) 1 147162676 Leikina, Evgenia NICHD Leikina, Evgenia (NICHD) 2 147162678 Whitlock, Jarred NICHD NICHD Whitlock, Jarred (NICHD) 3 147157887 La Protein As A Novel Regulator Of Osteoclastogenesis E-058-2021-0 Filing authorized Division of Intramural Research, NICHD 91788919 Gunas, Heather gunash@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America gunash@mail.nih.gov?subject=Web Inquiry on [TAB-3870] La Protein as a Novel Regulator of Osteoclastogenesis&body=Please send me information about technology [TAB-3870] La Protein as a Novel Regulator of Osteoclastogenesis.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Gunas, Heather<br><a href="mailto:gunash@mail.nih.gov?subject=Web Inquiry on [TAB-3870] La Protein as a Novel Regulator of Osteoclastogenesis&body=Please send me information about technology [TAB-3870] La Protein as a Novel Regulator of Osteoclastogenesis.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">gunash@mail.nih.gov</a><br> 147164935 E-058-2021-0 E-058-2021-0-US-01 La Protein As A Novel Regulator Of Osteoclastogenesis PRV US 63/155,896 Abandoned US <br />Provisional (PRV) 63/155,896<br />Filed on 2021-03-03<br />Status: Abandoned 147164936 E-058-2021-0 E-058-2021-0-PCT-02 La Protein As A Novel Regulator Of Osteoclastogenesis PCT Patent Cooperation Treaty PCT/US2022/018639 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2022/018639<br />Filed on 2022-03-03<br />Status: Expired 147170454 Chernomordik 147170456 La Protein 147170458 Lupus Autoantigen Protein 147170460 National Institute of Child Health and Human Development 147170461 NICHD 147170463 Osteoclast Fusion 147170464 Osteoclastogenesis TAB-4377 147157671 Use of Repurposed Compounds for the Treatment of Alzheimer’s Disease NIA Collaboration, Licensing, Neurology, Therapeutics Collaboration Licensing Neurology Therapeutics Madhav Thambisetty <h2>Summary:</h2> <p>The NIA seeks co-development partners and/or licensees for the further pre-clinical and clinical development of TTI-101, hydroxychloroquine, and Dasatinib to treat Alzheimer&rsquo;s disease.</p> <h2>Description of Technology:</h2> <p>There are no effective treatments for Alzheimer&rsquo;s disease (AD), a progressive brain disease that slowly destroys a person&rsquo;s memory, cognitive skills and ability to carry out the simplest tasks. AD affects more than 5 million individuals in the United States and ranks as the sixth leading cause of death. The &epsilon;4 allele of the apolipoprotein-E (APOE) gene is the strongest genetic risk factor for sporadic or late-onset AD. Heterozygous carriers of the &epsilon;4 allele are at three-to-four times greater risk; homozygous carriers are at ten times greater risk. In fact, APOE &epsilon;4 carriers accumulate AD neuropathology early in adulthood with earlier age onset of AD compared with &epsilon;4 non-carriers.</p> <p>Researchers at the National Institute on Aging (NIA) identified a brain proteomic signature comprised of 25 proteins that may drive the risk for developing AD in young APOE &epsilon;4 carriers. NIA researchers further identified compounds that target proteins in this AD proteomic signature and rescue molecular abnormalities associated with AD. Specifically, the STAT3 inhibitors TTI-101 and hydroxychloroquine rescued three specific AD phenotypes in cell culture-based phenotypic screens: (1) lipopolysaccharide (LPS)-induced neuroinflammation; (2) tau phosphorylation; and (3) A&beta; secretion/A&beta; clearance. Dasatinib, a YES1/FYN inhibitor, lowered tau phosphorylation. These findings reveal that TT1-101, hydroxychloroquine and Dasatinib &ndash; among other approved and experimental drugs &ndash; may be repurposed to treat AD.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>A therapeutic for patients with Alzheimer&rsquo;s disease</li> <li>A therapeutic for APOE &epsilon;4 carriers with Alzheimer&rsquo;s disease&nbsp;</li> <li>A therapeutic for APOE &epsilon;4 carriers with early signs of Alzheimer&rsquo;s disease</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Prevent the development and progression of Alzheimer&rsquo;s disease in high-risk <em>APOE</em> &epsilon;4 carriers</li> <li>Expedited approval process due in part to pre-existing safety data for repurposed drugs</li> </ul> 2022-02-11 2026-04-23 2022-02-23 2026-04-23 2022-02-11 Alzheimer’s Disease, ApoE, Apolipoprotein-E, Aβ, FYN, National Institute on Aging, Neuroinflammation, NIA, STAT3, Tau Phosphorylation, Thambisetty, YES1 False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2022-02-23 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147162048 Roberts JA, et al. A brain proteomic signature of incipient Alzheimer&rsquo;s disease in young APOE ε4 carriers identifies novel drug targets. https://pubmed.ncbi.nlm.nih.gov/34757788/ <a href="https://pubmed.ncbi.nlm.nih.gov/34757788/">Roberts JA, et al. A brain proteomic signature of incipient Alzheimer&rsquo;s disease in young APOE ε4 carriers identifies novel drug targets.</a> 147164508 Thambisetty, Madhav National Institute on Aging (NIH/NIA) NIA Thambisetty, Madhav (NIA) 1 147164508 Thambisetty, Madhav National Institute on Aging (NIH/NIA) NIA Thambisetty, Madhav (NIA) 1 147158210 C188-9 (STAT3 Inhibitor) And Dasatinib (Scr Family Tyrosine Kinases YES1 And FYN Inhibitor) Are Novel Disease-modifying Treatments For Alzheimer's Disease E-207-2021-0 Filing authorized National Institute on Aging (NIH/NIA) 91789173 Guyton, Nicole darackn@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America darackn@mail.nih.gov?subject=Web Inquiry on [TAB-4377] Use of Repurposed Compounds for the Treatment of Alzheimer’s Disease&body=Please send me information about technology [TAB-4377] Use of Repurposed Compounds for the Treatment of Alzheimer’s Disease.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Guyton, Nicole<br><a href="mailto:darackn@mail.nih.gov?subject=Web Inquiry on [TAB-4377] Use of Repurposed Compounds for the Treatment of Alzheimer’s Disease&body=Please send me information about technology [TAB-4377] Use of Repurposed Compounds for the Treatment of Alzheimer’s Disease.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">darackn@mail.nih.gov</a><br> 147161194 E-207-2021-0 E-207-2021-0-US-01 COMPOUNDS AND MOLECULAR TARGETS FOR TREATING AND/OR PREVENTING ALZHEIMER'S DISEASE PRV US 63/253,992 Abandoned US <br />Provisional (PRV) 63/253,992<br />Filed on 2021-10-08<br />Status: Abandoned 147168527 E-207-2021-0 E-207-2021-0-PCT-02 COMPOUNDS AND MOLECULAR TARGETS FOR TREATING AND/OR PREVENTING ALZHEIMER'S DISEASE PCT Patent Cooperation Treaty PCT/US2022/046018 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2022/046018<br />Filed on 2022-10-07<br />Status: Expired 147173670 Alzheimer’s Disease 147173671 ApoE 147173673 Apolipoprotein-E 147173675 Aβ 147173676 FYN 147173677 National Institute on Aging 147173678 Neuroinflammation 147173679 NIA 147173680 STAT3 147173682 Tau Phosphorylation 147173684 Thambisetty 147173685 YES1 TAB-4042 147157323 Sensitive and Economic RNA Virus Detection Using a Novel RNA Preparation Method NEI Collaboration, Diagnostics, Infectious Disease, Licensing, Oncology Collaboration Diagnostics Infectious Disease Licensing Oncology Bin Guan, Robert Hufnagel <h2>Summary:</h2> <p>Inventors at the National Eye Institute are seeking&nbsp;research and co-development partners and/or licensees to: (1) advance the production and uses of the new RNA preparation method, (2) manufacture reagent kits for testing in patients with suspected COVID-19 and other DNA/RNA viruses, and (3) manufacture reagent kits for patient biomarker profiles and inherited disease diagnostics.</p> <h2>Description of Technology:</h2> <p>DNA or RNA-based diagnostic tests for infectious diseases are critical in modern medicine. The current gold standard for COVID-19 detection is testing SARS-CoV-2 viral RNA by quantitative reverse transcription Polymerase Chain Reaction (RT-qPCR). This method involves patient sample collection with a nasopharyngeal swab, storage of the swab in a universal transport medium during transport to testing site, RNA extraction, and analysis of the extracted RNA sample. Collected patient samples &ndash; in addition to the possible presence of SARS-CoV-2 &ndash; also contain inhibitors for downstream enzymatic reactions, RNA degrading enzymes (e.g., RNase), and magnesium and calcium ions required for RNase activity. Active RNase in the patient sample reduces the amount of SARS-CoV-2 RNA in the sample; so the RNA needs to be extracted for analysis.&nbsp;<br /> &nbsp;<br /> Researchers at the National Institutes of Health&rsquo;s National Eye Institute (NEI) developed a novel improved sample preparation method that eliminates the need for an RNA extraction step from the currently used method of detecting SARS-CoV-2. NEI researchers discovered that incorporation of a chelating agent into the RT-qPCR heating step ties up the magnesium and calcium ions needed for RNase activity &ndash; thereby increasing the amount of RNA produced for analysis. The new procedure also simultaneously removes potential inhibitors of RT-qPCR and inactivates SARS-CoV-2 infectivity. This removal improves workflow safety and eliminates the need for a BSL-2 testing facility. This is a versatile and safe method for RNA preparation for a variety of patient samples beyond SARS-CoV-2. It is suitable for standard clinical collection and testing on high throughput platforms for both DNA and RNA.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Improved COVID-19 diagnostic test</li> <li>Improved DNA or RNA-based diagnostic test for additional infectious diseases</li> <li>Safer preparation of patient samples</li> <li>Reagent kits for biomarker profiles and inherited diseases</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Improved workflow safety</li> <li>Removes potential inhibitors of RT-qPCR</li> <li>Inactivates SARS-CoV-2 infectivity</li> <li>Increased RNA production for analysis</li> <li>Eliminates the need for an RNA extraction step</li> </ul> 2022-01-21 2026-04-23 2022-01-26 2026-04-23 2022-01-20 Biomarker, Chelating Resin, Chelex Resin, COVID, COVID-19, DNA/RNA diagnostic test, Extraction-free Detection, Infectious Diseases, SARS-CoV-2, virus False True Clinical True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2022-01-26 72159138 Clinical Phase I 72159138 NCI 37470483 Website Abstract 147162086 Guan B, et al. Sensitive extraction-free SARS-CoV-2 RNA virus detection using a novel RNA 1 preparation method. https://pubmed.ncbi.nlm.nih.gov/33532808/ <a href="https://pubmed.ncbi.nlm.nih.gov/33532808/">Guan B, et al. Sensitive extraction-free SARS-CoV-2 RNA virus detection using a novel RNA 1 preparation method.</a> 147163310 Guan, Bin NIH - NEI NEI Guan, Bin (NEI) 1 147163311 Hufnagel, Robert NIH - NEI NEI Hufnagel, Robert (NEI) 2 147163310 Guan, Bin NIH - NEI NEI Guan, Bin (NEI) 1 147163311 Hufnagel, Robert NIH - NEI NEI Hufnagel, Robert (NEI) 2 147158191 Sensitive And Economic RNA Virus Detection Using A Novel RNA Preparation Method E-195-2020-0 Filing authorized National Eye Institute (NEI) 83724826 Pollard, Ricquita ricquita.pollard@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4042] Sensitive and Economic RNA Virus Detection Using a Novel RNA Preparation Method&body=Please send me information about technology [TAB-4042] Sensitive and Economic RNA Virus Detection Using a Novel RNA Preparation Method.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollard, Ricquita<br><a href="mailto:ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4042] Sensitive and Economic RNA Virus Detection Using a Novel RNA Preparation Method&body=Please send me information about technology [TAB-4042] Sensitive and Economic RNA Virus Detection Using a Novel RNA Preparation Method.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">ricquita.pollard@nih.gov</a><br> 147161180 E-195-2020-0 E-195-2020-0-US-01 Sensitive And Economic RNA Virus Detection Using A Novel RNA Preparation Method PRV US 63/065,931 Abandoned US <br />Provisional (PRV) 63/065,931<br />Filed on 2020-08-14<br />Status: Abandoned 147166165 E-195-2020-0 E-195-2020-0-PCT-03 Sensitive And Economic RNA Virus Detection Using A Novel RNA Preparation Method PCT Patent Cooperation Treaty PCT/US2021/045675 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/045675<br />Filed on 2021-08-12<br />Status: Expired 147166166 E-195-2020-0 E-195-2020-0-US-03 SAMPLE PREPARATION AND VIRAL DETECTION METHODS National Stage US 12,637,705 18/041,295 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12637705 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12637705">12,637,705</a><br />Filed on 2023-02-10<br />Status: Issued 147173470 Biomarker 147173472 Chelating Resin 147173474 Chelex Resin 147173475 COVID 147173476 COVID-19 147173478 DNA/RNA diagnostic test 147173480 Extraction-free Detection 147173481 Infectious Diseases 147173482 SARS-CoV-2 147173483 virus TAB-4406 147157701 High Efficacy Vaccine and Microbicide Combination For Use Against HIV NCI Collaboration, Immunology, Infectious Disease, Licensing, Vaccines Collaboration Immunology Infectious Disease Licensing Vaccines Daniel Appella, Ettore Appella, Massimiliano Bissa, Genoveffa Franchini, Sabrina Helmold Hait, Lisa Marie Jenkins, Mohammed Rahman, Marjorie Robert-Guroff, Isabela Silva De Castro <h2>Summary:</h2> <p>NCI is seeking research co-development partners and/or licensees to evaluate, further develop or commercialize this high efficacy vaccine and microbicide combination for use against HIV.&nbsp;</p> <h2>Description of Technology:</h2> <p>Human immunodeficiency virus (HIV) remains a major global health challenge despite the advancement made in development of effective antiretrovirals (ARVs). ARVs are effective at limiting replication and spread of the virus, and progression to acquired immuno-deficiency syndrome (AIDS). However, ARVs often lead to emergence of drug-resistant virus strains insensitive to treatment and with toxic effects following long-term usage. In addition, access to ARVs is limited in certain regions, particularly in sub-Saharan Africa &ndash; where the HIV epidemic continues unabated and disproportionately affects women and adolescent girls. There is a global health need for development of alternative approaches providing long-term protection from the virus, such as vaccines.</p> <p>Researchers at the National Cancer Institute (NCI) previously demonstrated the efficacy of envelope glycoprotein 120 (gp120) variable region 1 (V1)-deleted simian immunodeficiency virus (SIV) vaccines against the highly pathogenic SIVmac251, which recapitulates human AIDS in animals. These SIV envelope V1-deleted vaccines increased the antigenicity of the envelope glycoprotein variable region 2 (V2) and were 65% effective in preventing vaginal SIVmac251 infection in the macaque animal model. However, the vaccine regimen was ineffective in about one third of animals. Therefore, the inventors added the SAMT-247 microbicide that disrupts the folded structure of the viral nucleocapsid protein NCp7 by interfering with zinc coordination in the protein. This resulted in the production of immature viral particles. Following 14 weekly exposures to SIVmac251, 80% of macaques vaccinated and treated with SAMT-247 remained uninfected &ndash; reducing infection risk &gt;90%. SAMT-247 was administered 4 hours before each challenge exposure and dramatically augmented vaccine-induced protection via increased NK cytotoxicity, increased monocyte efferocytosis, and decreased T-cell activation (figure below).</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Development of next generation HIV vaccines</li> <li>Prevention of HIV infection and AIDS</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Increased vaccine efficacy of up to 80%&nbsp;</li> <li>Combination treatment &ndash; vaccine and SAMT-247 microbicide &ndash; significantly reducing risk of SIV infection</li> <li>SAMT-247 microbicide is not toxic to human cervical tissue</li> <li>SAMT-247 microbicide remains effective in cervical mucus</li> </ul> 2022-10-21 2026-04-23 2022-10-21 2026-04-23 2022-10-21 Acquired Immuno-Deficiency Syndrome, ADCC, AIDS, Antibody-dependent Cellular Cytotoxicity, Efferocytosis, Envelope Glycoprotein 120, Envelope Variable Region, Franchini, gp120, HIV, Human Immunodeficiency Virus, Microbicide, SAMT-247, V1, Vaccine False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2022-10-21 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-160-2018 E-329-2000 147162336 Halt SH et al. An SAMT-247 microbicide provides potent protection against intravaginal Simian Immunodeficiency virus infection of Rhesus Macaques, whereas an added vaccine component elicits mixed outcomes. https://pubmed.ncbi.nlm.nih.gov/32393514/ <a href="https://pubmed.ncbi.nlm.nih.gov/32393514/">Halt SH et al. An SAMT-247 microbicide provides potent protection against intravaginal Simian Immunodeficiency virus infection of Rhesus Macaques, whereas an added vaccine component elicits mixed outcomes.</a> 147162374 Silva de Castro I et al. Anti-V2 antibodies virus vulnerability revealed by envelope V1 deletion in HIV vaccine candidates. https://pubmed.ncbi.nlm.nih.gov/33554060/ <a href="https://pubmed.ncbi.nlm.nih.gov/33554060/">Silva de Castro I et al. Anti-V2 antibodies virus vulnerability revealed by envelope V1 deletion in HIV vaccine candidates.</a> 147164617 Franchini, Genoveffa NIH - NCI NCI Franchini, Genoveffa (NCI) 1 147164616 Robert-Guroff, Marjorie NIH - NCI Robert-Guroff, Marjorie 2 147164619 Appella, Daniel NIH - NIDDK NIDDK Appella, Daniel (NIDDK) 3 147164622 Helmold Hait, Sabrina NIH - NCI NCI Helmold Hait, Sabrina (NCI) 4 147164623 Rahman, Mohammed NIH - NCI NCI Rahman, Mohammed (NCI) 5 147164620 Bissa, Massimiliano NIH - NCI NCI Bissa, Massimiliano (NCI) 6 147164618 Appella, Ettore NIH - NCI NCI Appella, Ettore (NCI) 7 147164624 Jenkins, Lisa Marie NIH - NCI NCI Jenkins, Lisa Marie (NCI) 8 147164621 Silva De Castro, Isabela NIH - NCI Silva De Castro, Isabela 9 147164617 Franchini, Genoveffa NIH - NCI NCI Franchini, Genoveffa (NCI) 1 147164616 Robert-Guroff, Marjorie NIH - NCI Robert-Guroff, Marjorie 2 147164619 Appella, Daniel NIH - NIDDK NIDDK Appella, Daniel (NIDDK) 3 147164622 Helmold Hait, Sabrina NIH - NCI NCI Helmold Hait, Sabrina (NCI) 4 147164623 Rahman, Mohammed NIH - NCI NCI Rahman, Mohammed (NCI) 5 147164620 Bissa, Massimiliano NIH - NCI NCI Bissa, Massimiliano (NCI) 6 147164618 Appella, Ettore NIH - NCI NCI Appella, Ettore (NCI) 7 147164624 Jenkins, Lisa Marie NIH - NCI NCI Jenkins, Lisa Marie (NCI) 8 147164621 Silva De Castro, Isabela NIH - NCI Silva De Castro, Isabela 9 147157867 DNA/ALVAC-SIV/gp120?V1/Alum Vaccination And SAMT-247 Microbicide Synergize In Protecting Female Rhesus Macaques From SIV Acquisition E-048-2021-0 Filing authorized National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NCI 83740301 Dattaroy, Diptadip diptadip.dattaroy@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB diptadip.dattaroy@nih.gov?subject=Web Inquiry on [TAB-4406] High Efficacy Vaccine and Microbicide Combination For Use Against HIV&body=Please send me information about technology [TAB-4406] High Efficacy Vaccine and Microbicide Combination For Use Against HIV.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dattaroy, Diptadip<br><a href="mailto:diptadip.dattaroy@nih.gov?subject=Web Inquiry on [TAB-4406] High Efficacy Vaccine and Microbicide Combination For Use Against HIV&body=Please send me information about technology [TAB-4406] High Efficacy Vaccine and Microbicide Combination For Use Against HIV.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">diptadip.dattaroy@nih.gov</a><br> 147160964 E-048-2021-0 E-048-2021-0-US-01 HIV-1 VACCINATION AND SAMT-247 MICROBICIDE TO PREVENT HIV-1 INFECTION PRV US 63/228,707 Abandoned US <br />Provisional (PRV) 63/228,707<br />Filed on 2021-08-03<br />Status: Abandoned 147168752 E-048-2021-0 E-048-2021-0-PCT-02 HIV-1 VACCINATION AND SAMT-247 MICROBICIDE TO PREVENT HIV-1 INFECTION PCT Patent Cooperation Treaty PCT/US2022/074432 Administratively Closed Patent Cooperation Treaty <br />(PCT) PCT/US2022/074432<br />Filed on 2022-08-02<br />Status: Administratively Closed 147170277 Acquired Immuno-Deficiency Syndrome 147170278 ADCC 147170279 AIDS 147170281 Antibody-dependent Cellular Cytotoxicity 147170283 Efferocytosis 147170285 Envelope Glycoprotein 120 147170287 Envelope Variable Region 147170289 Franchini 147170290 gp120 147170291 HIV 147170292 Human Immunodeficiency Virus 147170293 Microbicide 147170294 SAMT-247 147170295 V1 147170296 Vaccine TAB-4389 147157683 T Cell Receptors Targeting CDKN2A Mutations for Cancer Immunotherapy NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Sri Krishna, Shoshana Levi, Frank Lowery, Shirley Nah, Paul Robbins, Steven Rosenberg, Rami Yoseph <h2>Summary:</h2> <p>The NCI seeks parties interested in research co-development and/or licensing this library of TCRs targeting CDKN2A mutations.</p> <h2>Description of Technology:</h2> <p>Cyclin-dependent kinase inhibitor 2A gene, also known as CDKN2A, is a tumor suppressor gene and is commonly inactivated through somatic mutations in many human cancers. For example, inactivation of CDKN2A is highly prevalent in melanoma, gastrointestinal and pancreatic cancers. Through germline mutations, CDKN2A is associated with predisposition for a variety of cancers, including melanoma and pancreatic cancers. Despite the high frequency of CDKN2A mutations in cancer, there have been no successful therapies targeting these mutations to date. Adoptive cell therapy, a promising form of immunotherapy, offers a potential form of targeted therapy for cancers with CDKN2A mutations.</p> <p>Researchers at the National Cancer Institute (NCI) have developed seven novel human T cell receptors (TCRs) targeting CDKN2A. These TCRs may be used in adoptive cell therapy to treat cancers driven by CDKN2A mutations by targeting neoantigens expressed only by cancer cells. More specifically, the TCRs target neoantigens driven by frameshifts and those driven by nonsynonymous mutations that result in a proline to leucine in position 114 in the CDKN2A gene. Together, these account for 53% of CDKN2A mutations. The TCRs are restricted by some of the most common HLA alleles including HLA A*03:01, HLA A*11:01 and HLA A*02:01, which have an approximate frequency of 8%, 7%, and 40% respectively within the United States population. Thus, these TCRs allow for engineering TCR-based therapies resulting in specific elimination of tumor cells with the indicated CDKN2A mutations present in a diverse group of cancer patients.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Autologous TCR-engineered T cell therapy for cancer patients with CDKN2A mutations</li> <li>Off-the-shelf, allogeneic TCR-engineered T cell therapy for cancer patients with CDKN2A mutations</li> <li>Combination immunotherapies using TCR-engineered T cells alongside other immunotherapies targeting common driver mutations or patient specific mutations</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>No approved therapies targeting CDKN2A</li> <li>Targeted therapy against CDKN2A mutations with therapeutic potential for a wide variety of cancers</li> <li>Targets neoantigens presented by common HLA alleles making the therapy potentially effective for a broad cancer patient population</li> <li>CDKN2A mutations not present in healthy cells</li> </ul> 2022-11-22 2026-04-23 2022-11-22 2026-04-23 2022-11-22 adoptive cell therapy, CDKN2A, cyclin dependent kinase inhibitor 2A, Immunotherapy, Krishna, MELANOMA, Neoantigen, Rosenberg, T Cell Receptor, TCR False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2022-11-22 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-175-2016 E-237-2017 147164554 Krishna, Sri NIH - NCI NCI Krishna, Sri (NCI) 1 147164555 Levi, Shoshana NCI - CCR NCI Levi, Shoshana (NCI) 2 147164551 Robbins, Paul NIH - NCI NCI Robbins, Paul (NCI) 3 147164550 Rosenberg, Steven NIH - NCI NCI Rosenberg, Steven (NCI) 4 147164556 Nah, Shirley NCI - CCR NCI Nah, Shirley (NCI) 5 147164552 Yoseph, Rami NIH - NCI NCI Yoseph, Rami (NCI) 6 147164553 Lowery, Frank NIH - NCI NCI Lowery, Frank (NCI) 7 147164554 Krishna, Sri NIH - NCI NCI Krishna, Sri (NCI) 1 147164555 Levi, Shoshana NCI - CCR NCI Levi, Shoshana (NCI) 2 147164551 Robbins, Paul NIH - NCI NCI Robbins, Paul (NCI) 3 147164550 Rosenberg, Steven NIH - NCI NCI Rosenberg, Steven (NCI) 4 147164556 Nah, Shirley NCI - CCR NCI Nah, Shirley (NCI) 5 147164552 Yoseph, Rami NIH - NCI NCI Yoseph, Rami (NCI) 6 147164553 Lowery, Frank NIH - NCI NCI Lowery, Frank (NCI) 7 147158209 T Cell Receptors Targeting Mutations In CDKN2A For Cancer Immunotherapy E-206-2022-0 Filing authorized NCI 83709866 Burke, Andrew burkear@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC burkear@nih.gov?subject=Web Inquiry on [TAB-4389] T Cell Receptors Targeting CDKN2A Mutations for Cancer Immunotherapy&body=Please send me information about technology [TAB-4389] T Cell Receptors Targeting CDKN2A Mutations for Cancer Immunotherapy.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Burke, Andrew<br><a href="mailto:burkear@nih.gov?subject=Web Inquiry on [TAB-4389] T Cell Receptors Targeting CDKN2A Mutations for Cancer Immunotherapy&body=Please send me information about technology [TAB-4389] T Cell Receptors Targeting CDKN2A Mutations for Cancer Immunotherapy.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">burkear@nih.gov</a><br> 147161193 E-206-2022-0 E-206-2022-0-US-01 T CELL RECEPTORS TARGETING MUTATED CDKN2A PRV US 63/381,591 Expired US <br />Provisional (PRV) 63/381,591<br />Filed on 2022-10-31<br />Status: Expired 159507026 E-206-2022-0 E-206-2022-0-PC-01 T CELL RECEPTORS TARGETING MUTATED CDKN2A PCT Patent Cooperation Treaty PCT/US2023/078190 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2023/078190<br />Filed on 2023-10-30<br />Status: Expired 147173659 adoptive cell therapy 147173660 CDKN2A 147173662 cyclin dependent kinase inhibitor 2A 147173663 Immunotherapy 147173664 Krishna 147173665 MELANOMA 147173666 Neoantigen 147173667 Rosenberg 147173668 T Cell Receptor 147173669 TCR TAB-4359 147157652 Mice, Organs, and Mouse Alleles Carrying Germline and Conditional Deletions of the Zbtb7b Gene NCI Immunology, Infectious Disease, Licensing, Oncology, Research Materials Immunology Infectious Disease Licensing Oncology Research Materials <h2>Summary:</h2> <p>The NCI seeks parties interested in licensing this mouse model, including the mice, organs, tissues, and other derivatives from mice carrying deletions of the Zbtb7b gene.&nbsp;</p> <h2>Description:</h2> <p>The Zbtb7b gene encodes the zinc finger transcription factor ThPOK (also known as cKrox) that promotes CD4 lineage differentiation in immature T cells. CD4+ T cells, also known as &ldquo;helper&rdquo; T cells, are critical for long-term immunity against pathogens as well as for promoting CD8+ &ldquo;effector&rdquo; T cell and effective B cell responses. ThPOK is needed for the development and functional fitness of CD4+ T cells as well as multiple aspects of the immune response to infection. As such, ThPOK offers a potential target for immune regulation. For example, increasing the activity of ThPOK may enhance the efficacy of immunization strategies against infections or cancer; diseases associated with CD4+ T cell deficiency. Alternatively, inhibitors of ThPOK could offer new ways to interfere with CD4+ T cell activity, offering therapeutic benefit in inflammatory or autoimmune diseases such as multiple sclerosis and rheumatoid arthritis.</p> <p>Researchers at the National Cancer Institute (NCI) developed mouse alleles carrying germline and conditional deletions of the Zbtb7b gene. These alleles were used to generate mice which demonstrate the Zbtb7b gene is essential for CD4+ T cell development and function. These mice can be used to study the function of ThPOK and the role of CD4+ T cells in the immune system. In addition to generating mice that are homozygous for the Zbtb7b gene deletion, the researchers generated mice that can be beneficial as experimental controls. One such mouse line is heterozygous for the Zbtb7b gene deletion; it carries one wild-type allele and one knockout allele. The other mouse line appears wild-type phenotypically but contains a &ldquo;floxed&rdquo; version of the Zbtb7b gene flanked by LoxP sites. It may be used to generate additional conditional deletions for the temporal and spatial regulation of gene expression. Given the importance of CD4+ T cells for the immune system, these mice are applicable to preclinical studies regarding a wide variety of human disorders.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Research tool to study the role of CD4+ T cells in immune response</li> <li>Drug screening and evaluation</li> <li>Develop ThPOK inhibitors which could be relevant for inflammatory or autoimmune diseases</li> <li>Develop ThPOK activators which could enhance the efficacy of immunization strategies</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Investigate the function of CD4+ T cells in vivo</li> <li>Investigate the role of the Zbtb7b gene and its protein product ThPOK in vivo</li> <li>Control the expression of the Zbtb7b gene through alleles carrying conditional deletions and/or the floxed allele</li> </ul> 2022-12-06 2026-04-23 2022-12-06 2026-04-23 2022-12-06 Autoimmunity, Bosselut, CANCER, CD4, cKrox, Helper T Cell, Infection, LYMPHOCYTE, Memory T Cell, Oncology, ThPOK, transgenic mice, Zbtb7b, Zinc Finger Transcription Factor False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2022-12-06 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147161894 Vacchio MS, et al. A ThPOK-LRF transcriptional node maintains the integrity and effector potential of post-thymic CD4+ T cells. https://pubmed.ncbi.nlm.nih.gov/25129370/ <a href="https://pubmed.ncbi.nlm.nih.gov/25129370/">Vacchio MS, et al. A ThPOK-LRF transcriptional node maintains the integrity and effector potential of post-thymic CD4+ T cells.</a> 147162010 Ciucci T, et al. The emergence and functional fitness of memory CD4+ T cells require the transcription factor Thpok. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6503975/ <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6503975/">Ciucci T, et al. The emergence and functional fitness of memory CD4+ T cells require the transcription factor Thpok.</a> 147162282 Vacchio MS, et al. A Thpok-directed transcriptional circuitry promotes Bcl6 and Maf expression to orchestrate T follicular helper differentiation. https://pubmed.ncbi.nlm.nih.gov/31422869/ <a href="https://pubmed.ncbi.nlm.nih.gov/31422869/">Vacchio MS, et al. A Thpok-directed transcriptional circuitry promotes Bcl6 and Maf expression to orchestrate T follicular helper differentiation.</a> 155750779 Mice, Organs And Mouse Alleles Carrying Germline And Conditional Deletions Of The Zbtb7b Gene E-226-2022-0 Research Material NCI 83687903 Pollack, Michael michael.pollack@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC michael.pollack@nih.gov?subject=Web Inquiry on [TAB-4359] Mice, Organs, and Mouse Alleles Carrying Germline and Conditional Deletions of the Zbtb7b Gene&body=Please send me information about technology [TAB-4359] Mice, Organs, and Mouse Alleles Carrying Germline and Conditional Deletions of the Zbtb7b Gene.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollack, Michael<br><a href="mailto:michael.pollack@nih.gov?subject=Web Inquiry on [TAB-4359] Mice, Organs, and Mouse Alleles Carrying Germline and Conditional Deletions of the Zbtb7b Gene&body=Please send me information about technology [TAB-4359] Mice, Organs, and Mouse Alleles Carrying Germline and Conditional Deletions of the Zbtb7b Gene.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">michael.pollack@nih.gov</a><br> 147173916 Autoimmunity 147173918 Bosselut 147173919 CANCER 147173920 CD4 147173922 cKrox 147173924 Helper T Cell 147173925 Infection 147173926 LYMPHOCYTE 147173928 Memory T Cell 147173929 Oncology 147173931 ThPOK 147173932 transgenic mice 147173933 Zbtb7b 147173935 Zinc Finger Transcription Factor TAB-4357 147157650 Single Domain Antibodies Targeting the S2 Subunit of SARS-CoV-2 Spike Protein NCI Collaboration, Immunology, Infectious Disease, Licensing, Therapeutics Collaboration Immunology Infectious Disease Licensing Therapeutics Jesse Buffington, Zhijian Duan, Mitchell Ho <h2>Description:</h2> <p>The COVID-19 pandemic is a worldwide public health crisis with over 100 million confirmed cases and 2.4 million deaths as of February 2021. COVID-19 is caused by a novel coronavirus called SARS-CoV-2. Almost all the neutralizing antibodies targeting SARS-CoV-2 that are in development recognize the receptor binding domain (RBD) on the spike (S) protein. Blocking the interaction of RBD and the ACE2 receptor on human cells is the first of the two critical steps for neutralization of the virus. However, the S2 subunit of the spike is also critical for viral infection and entry into human cells. It is highly conserved across many coronaviruses, including other SARS-CoV-2 like viruses. To date there are no antibodies targeting the S2 subunit.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Treatment of SARS-CoV-2 infections</li> <li>&nbsp;Standard antibody therapy</li> <li>&nbsp;Delivery of nanoparticles</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Currently, only one antibody treatment received FDA-issued emergency use authorization for COVID-19 treatment.</li> <li>Currently, no antibodies targeting the S2 subunit of SARS-CoV-2.</li> <li>Potential to treat current and future SARS-CoV-2 infections.</li> <li>Nanobodies are attractive candidates for intranasal spray therapy due to their small size, high affinity and high stability</li> <li>Nanobody characteristics which could be a more effective treatment for the respiratory disease</li> <li>Does not require intravenous administration</li> </ul> 2022-09-14 2026-04-23 2022-09-14 2026-04-23 2022-09-14 : COVID-19, ANTIBODY, Camel Nanobody, CORONAVIRUS, HO, Infectious Diseases, Nanobodies, Pandemic, SARS-CoV-2, Shark Nanobody, therapeutic, Vaccine False True Basic (Target Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2022-09-14 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147164435 Ho, Mitchell NIH - NCI NCI Ho, Mitchell (NCI) 1 147164436 Duan, Zhijian NCI - CCR NCI Duan, Zhijian (NCI) 2 147164437 Buffington, Jesse NCI - CCR NCI Buffington, Jesse (NCI) 3 147164435 Ho, Mitchell NIH - NCI NCI Ho, Mitchell (NCI) 1 147164436 Duan, Zhijian NCI - CCR NCI Duan, Zhijian (NCI) 2 147164437 Buffington, Jesse NCI - CCR NCI Buffington, Jesse (NCI) 3 147158204 Single Domain Antibodies Targeting The S2 Subunit Of SARS-CoV-2 Spike Protein E-204-2021-0 Filing authorized NCI 83731987 Dhal, Abritee abritee.dhal@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-4357] Single Domain Antibodies Targeting the S2 Subunit of SARS-CoV-2 Spike Protein&body=Please send me information about technology [TAB-4357] Single Domain Antibodies Targeting the S2 Subunit of SARS-CoV-2 Spike Protein.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dhal, Abritee<br><a href="mailto:abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-4357] Single Domain Antibodies Targeting the S2 Subunit of SARS-CoV-2 Spike Protein&body=Please send me information about technology [TAB-4357] Single Domain Antibodies Targeting the S2 Subunit of SARS-CoV-2 Spike Protein.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">abritee.dhal@nih.gov</a><br> 147161188 E-204-2021-0 E-204-2021-0-US-01 Single Domain Antibodies Targeting The S2 Subunit Of SARS-CoV-2 Spike Protein PRV US 63/271,854 Abandoned US <br />Provisional (PRV) 63/271,854<br />Filed on 2021-10-26<br />Status: Abandoned 147168408 E-204-2021-0 E-204-2021-0-PCT-02 SINGLE DOMAIN ANTIBODIES TARGETING THE S2 SUBUNIT OF SARS-COV-2 SPIKE PROTEIN PCT Patent Cooperation Treaty PCT/US2022/078632 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2022/078632<br />Filed on 2022-10-25<br />Status: Expired 147173600 : COVID-19 147173601 ANTIBODY 147173602 Camel Nanobody 147173603 CORONAVIRUS 147173604 HO 147173605 Infectious Diseases 147173606 Nanobodies 147173607 Pandemic 147173608 SARS-CoV-2 147173610 Shark Nanobody 147173611 therapeutic 147173612 Vaccine TAB-4322 147157613 Chimeric Antigen Receptors (CAR)-T Cells that Target the Non-Shed Portion of Mesothelin as a Therapeutic Agent NCI Licensing, Oncology, Therapeutics Licensing Oncology Therapeutics Tapan Bera, Mitchell Ho, Xiu Fen Liu, Masanori Onda, Ira Pastan <h2>Description of Technology:</h2> <p>Mesothelin (MSLN) is an excellent target for antibody-based therapies of cancer because of its high expression in many malignancies but lack of expression on essential normal tissues. Unfortunately, a large fragment of MSLN is shed from cancer cells, causing the currently available anti-MSLN antibodies (and immunoconjugates thereof) which bind to the shed portion of MSLN to quickly lose their therapeutic effectiveness over time. Indeed, the shed portion of MSLN can act as a decoy for these antibodies, further limiting them from reaching and destroying tumor cells.</p> <p>Scientists at NCI&nbsp;previously developed MAB15B6, an antibody that specifically binds&nbsp;to the unshed region of MSLN and blocks MSLN shedding. Building on this discovery, the inventors made specific modifications to CARs which utilize humanized MAB15B6.&nbsp; T cells expressing these enhanced CARs are very active in blocking tumor progression in xenograph models. As a result, these CAR-T cells represent an excellent therapeutic candidate for patients who have not responded to other MSLN-targeted therapeutics.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Treatment of MSLN-positive malignancies such as synovial sarcoma, mesothelioma, and ovarian, lung, esophageal, pancreatic and gastric cancers</li> <li>Therapeutic Use as a targeting moiety for CARs, antibody-drug conjugates (ADCs), immunotoxins (RITs), bispecific antibodies, etc.</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>The inventors have made specific improvements to immunoconjugates which utilize MAB15B6 that significantly enhance the ability of these immunoconjugates to exert a therapeutic effect</li> <li>Specific binding to the unshed portion of MSLN allow the antibodies and CAR-T cells to maintain contact with the cancer cells for a longer duration to exert a therapeutic effect</li> <li>More effective in blocking tumor progression compared to currently available anti-MSLN antibodies</li> </ul> 2022-01-25 2026-04-23 2022-02-24 2026-04-23 2022-01-25 ANTIBODY, Bispecific T-cell engager, BITE, CANCER, CAR, chimeric antigen receptor, diagnostic, Immunotherapy, MESOTHELIN, Mesothelioma, Pastan, therapeutic False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2022-02-24 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-106-2017 147162063 Awuah P, et al. Reduced shedding of surface mesothelin improves efficacy of mesothelin-targeting recombinant immunotoxins. https://pubmed.ncbi.nlm.nih.gov/27196771/ <a href="https://pubmed.ncbi.nlm.nih.gov/27196771/">Awuah P, et al. Reduced shedding of surface mesothelin improves efficacy of mesothelin-targeting recombinant immunotoxins.</a> 147164303 Pastan, Ira NIH - NCI NCI Pastan, Ira (NCI) 1 147164305 Liu, Xiu Fen NIH - NCI NCI Liu, Xiu Fen (NCI) 2 147164304 Bera, Tapan NIH - NCI NCI Bera, Tapan (NCI) 3 147164306 Onda, Masanori NIH - NCI NCI Onda, Masanori (NCI) 4 147164307 Ho, Mitchell NCI - CCR NCI Ho, Mitchell (NCI) 5 147164303 Pastan, Ira NIH - NCI NCI Pastan, Ira (NCI) 1 147164305 Liu, Xiu Fen NIH - NCI NCI Liu, Xiu Fen (NCI) 2 147164304 Bera, Tapan NIH - NCI NCI Bera, Tapan (NCI) 3 147164306 Onda, Masanori NIH - NCI NCI Onda, Masanori (NCI) 4 147164307 Ho, Mitchell NCI - CCR NCI Ho, Mitchell (NCI) 5 147157833 Mab 15B6 Blocks Mesothelin Shedding And Makes Very Active CAR-T Cell And BITE E-033-2022-0 Filing authorized NCI, NCI - CCR, NIH - NCI 83673032 Whitney, Laurie WhitneyL@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC WhitneyL@mail.nih.gov?subject=Web Inquiry on [TAB-4322] Chimeric Antigen Receptors (CAR)-T Cells that Target the Non-Shed Portion of Mesothelin as a Therapeutic Agent&body=Please send me information about technology [TAB-4322] Chimeric Antigen Receptors (CAR)-T Cells that Target the Non-Shed Portion of Mesothelin as a Therapeutic Agent.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Whitney, Laurie<br><a href="mailto:WhitneyL@mail.nih.gov?subject=Web Inquiry on [TAB-4322] Chimeric Antigen Receptors (CAR)-T Cells that Target the Non-Shed Portion of Mesothelin as a Therapeutic Agent&body=Please send me information about technology [TAB-4322] Chimeric Antigen Receptors (CAR)-T Cells that Target the Non-Shed Portion of Mesothelin as a Therapeutic Agent.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">WhitneyL@mail.nih.gov</a><br> 147160936 E-033-2022-0 E-033-2022-0-US-01 ANTI-MESOTHELIN POLYPEPTIDES, PROTEINS, AND CHIMERIC ANTIGEN RECEPTORS PRV US 63/290,761 Expired US <br />Provisional (PRV) 63/290,761<br />Filed on 2021-12-17<br />Status: Expired 147168153 E-033-2022-0 E-033-2022-0-PCT-02 ANTI-MESOTHELIN POLYPEPTIDES, PROTEINS, AND CHIMERIC ANTIGEN RECEPTORS PCT Patent Cooperation Treaty PCT/US2022/081766 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2022/081766<br />Filed on 2022-12-16<br />Status: Expired 163272656 E-033-2022-0 E-033-2022-0-CA-01 ANTI-MESOTHELIN POLYPEPTIDES, PROTEINS, AND CHIMERIC ANTIGEN RECEPTORS National Stage Canada 3240254 Pending Canada <br />National Stage 3240254<br />Filed on 2024-06-06<br />Status: Pending 163272692 E-033-2022-0 E-033-2022-0-AU-01 ANTI-MESOTHELIN POLYPEPTIDES, PROTEINS, AND CHIMERIC ANTIGEN RECEPTORS National Stage Australia 2022416639 Pending Australia <br />National Stage 2022416639<br />Filed on 2024-06-18<br />Status: Pending 163272697 E-033-2022-0 E-033-2022-0-EP-01 ANTI-MESOTHELIN POLYPEPTIDES, PROTEINS, AND CHIMERIC ANTIGEN RECEPTORS National Stage European Patent 22854336.9 Pending European Patent <br />National Stage 22854336.9<br />Filed on 2024-05-17<br />Status: Pending 163272702 E-033-2022-0 E-033-2022-0-US-02 ANTI-MESOTHELIN POLYPEPTIDES, PROTEINS, AND CHIMERIC ANTIGEN RECEPTORS National Stage US 18/710,726 Pending US <br />National Stage 18/710,726<br />Filed on 2024-05-16<br />Status: Pending 147169935 ANTIBODY 147169937 Bispecific T-cell engager 147169938 BITE 147169939 CANCER 147169940 CAR 147169941 chimeric antigen receptor 147169942 diagnostic 147169943 Immunotherapy 147169944 MESOTHELIN 147169945 Mesothelioma 147169947 Pastan 147169948 therapeutic TAB-4321 147157612 Anti-Glypican 2 Chimeric Antigen Receptor (CAR) Containing CD28 Hinge And Transmembrane Domains For Treating Neuroblastoma NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Mitchell Ho, Rosandra Kaplan, Nan Li, Rosa Nguyen, Carol Thiele Galetto <h2>Description of Technology:</h2> <p>Neuroblastomas are the most common extracranial solid tumors in pediatric patients, with 700-800 new cases annually in the United States. Metastatic neuroblastomas have a five-year survival rate of 50% and account for 15% of all pediatric cancer deaths. As such, more effective treatments against high-risk neuroblastomas are urgently needed. Glypican-2 (GPC2) is a cell surface protein that is highly expressed in neuroblastomas and other cancers, including medulloblastoma, retinoblastoma, small-cell lung cancers, uterine carcinosarcomas and high-grade gliomas, which makes GPC2 an attractive candidate for targeted therapy in solid tumors.&nbsp;</p> <p>Researchers at the National Cancer Institute&rsquo;s (NCI) Center for Cancer Research have developed a novel Chimeric Antigen Receptor (CAR) specific for GPC2 that includes a potent anti-GPC2 antibody CT3 and a CD28 hinge and transmembrane domains.&nbsp; CT3 has been shown to specifically target GPC2-expressing neuroblastoma, medulloblastoma, and retinoblastoma cell lines. CT3.28H.BB&zeta; CAR T cells were shown to be more potent against neuroblastoma cells than the previous anti-GPC2 CAR T cells in vitro and in vivo. These preclinical data suggest that CT3.28H.BB&zeta; CAR T cells may be further developed as therapeutics for patients with neuroblastoma and other GPC2-positive cancers. Incorporation of the CD28 hinge and transmembrane domains increases the potency of the CT3 CARs against neuroblastoma cells.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Immunotherapeutic treatments of GPC2-positive pediatric malignancies, including neuroblastoma, medulloblastoma, retinoblastoma, and a subset of acute lymphocytic leukemias</li> <li>Immunotherapeutic treatments of GPC2-positive adult cancers, including small-cell lung cancers, uterine carcinosarcomas and high-grade gliomas</li> <li>CT3.28H.BB&zeta; CAR available for immediate testing</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>CT3 antibody with high GPC2 binding specificity leading to&nbsp; successful targeting</li> <li>CT3 antibody with high GPC2 binding specificity leading to lower potential side-effects</li> <li>Increased potency against neuroblastoma&nbsp;</li> <li>Potential immunotherapy for several GPC2-positive cancer types with few treatment options&nbsp;</li> </ul> 2022-12-13 2026-04-23 2022-12-13 2026-04-23 2022-12-12 CAR, chimeric antigen receptor, Glypican 2, GPC2, HO, Immunotherapy, Medulloblastoma, Neuroblastoma, Retinoblastoma, Small-Cell Lung Cancers False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2022-12-13 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-198-2018 147164299 Ho, Mitchell NIH - NCI NCI Ho, Mitchell (NCI) 1 147164298 Thiele Galetto, Carol NIH - NCI NCI Thiele Galetto, Carol (NCI) 2 147164300 Li, Nan NIH - NCI NCI Li, Nan (NCI) 3 147164302 Nguyen, Rosa NCI - CCR NCI Nguyen, Rosa (NCI) 4 147164301 Kaplan, Rosandra NIH - NCI NCI Kaplan, Rosandra (NCI) 5 147164299 Ho, Mitchell NIH - NCI NCI Ho, Mitchell (NCI) 1 147164298 Thiele Galetto, Carol NIH - NCI NCI Thiele Galetto, Carol (NCI) 2 147164300 Li, Nan NIH - NCI NCI Li, Nan (NCI) 3 147164302 Nguyen, Rosa NCI - CCR NCI Nguyen, Rosa (NCI) 4 147164301 Kaplan, Rosandra NIH - NCI NCI Kaplan, Rosandra (NCI) 5 147157817 CD28 Hinge And Transmembrane Containing Chimeric Antigen Receptors Targeting GPC2 For Treating Neuroblastoma E-025-2022-0 Filing authorized NCI 83731987 Dhal, Abritee abritee.dhal@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-4321] Anti-Glypican 2 Chimeric Antigen Receptor (CAR) Containing CD28 Hinge And Transmembrane Domains For Treating Neuroblastoma&body=Please send me information about technology [TAB-4321] Anti-Glypican 2 Chimeric Antigen Receptor (CAR) Containing CD28 Hinge And Transmembrane Domains For Treating Neuroblastoma.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dhal, Abritee<br><a href="mailto:abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-4321] Anti-Glypican 2 Chimeric Antigen Receptor (CAR) Containing CD28 Hinge And Transmembrane Domains For Treating Neuroblastoma&body=Please send me information about technology [TAB-4321] Anti-Glypican 2 Chimeric Antigen Receptor (CAR) Containing CD28 Hinge And Transmembrane Domains For Treating Neuroblastoma.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">abritee.dhal@nih.gov</a><br> 147168150 E-025-2022-0 E-025-2022-0-US-01 CD28 HINGE AND TRANSMEMBRANE CONTAINING CHIMERIC ANTIGEN RECEPTORS TARGETING GPC2 AND USE THEREOF PRV US 63/310,456 Expired US <br />Provisional (PRV) 63/310,456<br />Filed on 2022-02-15<br />Status: Expired 147168151 E-025-2022-0 E-025-2022-0-PC-01 CD28 HINGE AND TRANSMEMBRANE CONTAINING CHIMERIC ANTIGEN RECEPTORS TARGETING GPC2 AND USE THEREOF PCT Patent Cooperation Treaty PCT/US2023/062525 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2023/062525<br />Filed on 2023-02-14<br />Status: Expired 159504791 E-025-2022-0 E-025-2022-0-EP-01 CD28 HINGE AND TRANSMEMBRANE CONTAINING CHIMERIC ANTIGEN RECEPTORS TARGETING GPC2 AND USE THEREOF National Stage European Patent 23710624.0 Pending European Patent <br />National Stage 23710624.0<br />Filed on 2024-08-13<br />Status: Pending 159504796 E-025-2022-0 E-025-2022-0-US-02 CD28 HINGE AND TRANSMEMBRANE CONTAINING CHIMERIC ANTIGEN RECEPTORS TARGETING GPC2 AND USE THEREOF National Stage US 18/837,367 Pending US <br />National Stage 18/837,367<br />Filed on 2024-08-09<br />Status: Pending 159504801 E-025-2022-0 E-025-2022-0-CN-01 CD28 HINGE AND TRANSMEMBRANE CONTAINING CHIMERIC ANTIGEN RECEPTORS TARGETING GPC2 AND USE THEREOF National Stage China 202380034151.6 Pending China <br />National Stage 202380034151.6<br />Filed on 2024-10-14<br />Status: Pending 159504806 E-025-2022-0 E-025-2022-0-AU-01 CD28 HINGE AND TRANSMEMBRANE CONTAINING CHIMERIC ANTIGEN RECEPTORS TARGETING GPC2 AND USE THEREOF National Stage Australia 2023221836 Pending Australia <br />National Stage 2023221836<br />Filed on 2024-07-23<br />Status: Pending 159504816 E-025-2022-0 E-025-2022-0-JP-01 CD28 HINGE AND TRANSMEMBRANE CONTAINING CHIMERIC ANTIGEN RECEPTORS TARGETING GPC2 AND USE THEREOF National Stage Japan 2024-547534 Pending Japan <br />National Stage 2024-547534<br />Filed on 2024-08-09<br />Status: Pending 147169735 CAR 147169736 chimeric antigen receptor 147169738 Glypican 2 147169739 GPC2 147169740 HO 147169741 Immunotherapy 147169742 Medulloblastoma 147169743 Neuroblastoma 147169744 Retinoblastoma 147169746 Small-Cell Lung Cancers TAB-4318 147157608 Automatic System and Method for Tissue Sectioning, Staining, and Scanning NCI Infectious Disease, Licensing, Medical Devices, Neurology, Non-Medical Devices, Oncology Infectious Disease Licensing Medical Devices Neurology Non-Medical Devices Oncology Young-Wan Moon, Zhengping (Ping) Zhuang <h2>Summary:</h2> <p>The NCI is seeking licensees to develop an automated digital pathology device compatible with high-throughput data analysis.</p> <h2>Description of Technology:</h2> <p>Computer and imaging technologies led to the development of digital pathology and the capture and storage of pathological specimens as digitally formatted images. The use of artificial intelligence (AI) in digital pathology, such as in three-dimensional (3D) reconstruction, requires analyses of high volumes of data. This results in increased demands for processing and acquisition of digital images of pathology samples. Increased usage cannot be met by the time-consuming, manual, and laborious methods currently used. Therefore, there is a need for automation of techniques used in processing of pathology samples and acquisition of digital images to make them amenable with high-throughput approaches such as AI analysis.</p> <p>National Cancer Institute inventors developed an automated device with integrated tissue sectioning, staining, scanning, and high-throughput capability. This device integrates pathology sample processing (e.g., sectioning, fixing, and staining) with optical scanning and digital image acquisition. This invention, related to another technology, E-084-2019, is updated to include a coated tape for holding and carrying sample sections as an alternative to a carrier film. The tape carries sequentially cut sample slices into a staining cassette where the slices are simultaneously stained directly on the tape. The tape carrying the stained samples are then fed into the imaging unit. This streamlines the entire process enabling high-throughput preparation of large volumes of samples and data for subsequent AI analysis. As a result of automation, the device saves time, minimizes errors, and reduces wasting reagents and supplies. Automation is expected to reduce sample processing time ten-fold.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Biopsy sample processing in hospitals, pathology labs, research labs</li> <li>Diagnostics for various disease indications, including cancer and infectious diseases</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Facilitates processing and imaging of large volumes of pathology samples</li> <li>Automation is expected to reduce sample processing time ten-fold</li> <li>Automation increases reproducibility and minimizes errors</li> <li>Compatible with high-throughput processes, e.g., AI analysis of digital pathology images and 3D reconstruction</li> <li>Mounting and processing all sections of a sample on the same tape allows for an easier, more streamlined staining/imaging process</li> <li>Staining cassette is customizable</li> </ul> 2022-09-12 2026-04-23 2026-04-23 2022-12-13 AI, Artificial Intelligence, AUTOMATION, Digital Pathology, High-throughput, Histology, IMAGING, Zhuang False True Prototype True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52406769 Prototype 52406769 NCI 37470483 Website Abstract 147164285 Zhuang, Zhengping (Ping) NIH - NCI NCI Zhuang, Zhengping (Ping) (NCI) 1 147164286 Moon, Young-Wan MicroVizual Inc. Moon, Young-Wan 2 147164285 Zhuang, Zhengping (Ping) NIH - NCI NCI Zhuang, Zhengping (Ping) (NCI) 1 147164286 Moon, Young-Wan MicroVizual Inc. Moon, Young-Wan 2 147157769 Automatic System And Method For Tissue Sectioning, Staining, And Scanning E-003-2022-0 Filing authorized MicroVizual Inc., NCI 83687903 Pollack, Michael michael.pollack@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC michael.pollack@nih.gov?subject=Web Inquiry on [TAB-4318] Automatic System and Method for Tissue Sectioning, Staining, and Scanning&body=Please send me information about technology [TAB-4318] Automatic System and Method for Tissue Sectioning, Staining, and Scanning.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollack, Michael<br><a href="mailto:michael.pollack@nih.gov?subject=Web Inquiry on [TAB-4318] Automatic System and Method for Tissue Sectioning, Staining, and Scanning&body=Please send me information about technology [TAB-4318] Automatic System and Method for Tissue Sectioning, Staining, and Scanning.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">michael.pollack@nih.gov</a><br> 147160883 E-003-2022-0 E-003-2022-0-US-01 Automatic System And Method For Tissue Sectioning, Staining, And Scanning PRV US 63/254,743 Abandoned US <br />Provisional (PRV) 63/254,743<br />Filed on 2021-10-12<br />Status: Abandoned 147168133 E-003-2022-0 E-003-2022-0-PCT-02 AUTOMATIC SYSTEM AND METHOD FOR TISSUE SECTIONING, STAINING, AND SCANNING PCT Patent Cooperation Treaty PCT/US2022/046406 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2022/046406<br />Filed on 2022-10-12<br />Status: Expired 147169270 AI 147169272 Artificial Intelligence 147169273 AUTOMATION 147169275 Digital Pathology 147169276 High-throughput 147169277 Histology 147169278 IMAGING 147169279 Zhuang TAB-4305 147157595 PIM-Targeted PROTACs NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics John Brognard, Dawid Mehlich, Venkatareddy Sabbasani, Rolf Swenson, Pedro Torres-Ayuso, Noel Warfel <h2>Description of Technology:</h2> <p>Proviral Integration for the Moloney murine leukemia virus (PIM) kinases are overexpressed in many solid cancers &ndash; including prostate, breast, colon, endometrial, gastric and pancreatic. High of PIM1 expression is predictive of poor survival in multiple cancer types. While several selective pan-PIM inhibitors were developed and tested in clinical trials, all ultimately increased PIM1-3 protein levels and developed intrinsic resistance.&nbsp;</p> <p>Researchers at the National Institutes of Health (NIH) developed multiple PIM kinase-targeting proteolysis-targeting chimeras (PROTACs) that lead to PIM1 degradation in a prostate cancer cell model and increased chemo-sensitization. The targeting of PIM kinases for degradation provides superior catalytic inhibition as these compounds target pro-tumorigenic functions of the PIM kinases, which are not linked to kinase activity. Additionally, these PROTACs prevent the onset of resistance due to increased expression of PIM kinases that occur from catalytic inhibition. They represent unique opportunities as novel anti-cancer therapies. This is a continuation of the PROTAC technologies being developed by the NIH team of Brognard and Swenson.</p> <p>The inventors welcome licensing and co-development interests to further develop and commercialize the technology.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>A novel anti-cancer therapy to target the PIM kinases</li> <li>A PIM targeting PROTACs for the treatments of prostate, breast, and colon cancers, among others</li> <li>A PIM targeting moiety for additional targeted therapeutics</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Compound target pro-tumorigenic functions of the PIM kinases that are not linked to kinase activity</li> <li>Prevention of the onset of resistance due to increased expression of PIM kinases that occurs from catalytic inhibition</li> <li>Increased chemo-sensitivity</li> <li>Compared to small molecule inhibitors, PROTACs: <ul> <li>show promise overcoming tumor resistance</li> <li>address and degrade undruggable targets</li> <li>offer novel, rapid and reversible chemical knockout capabilities</li> </ul> </li> </ul> 2022-07-07 2026-04-23 2023-01-09 2026-04-23 2022-07-07 anti-cancer, Brognard, Chemotherapy Resistance, Kinase, PIM, PIM kinase-targeting proteolysis-targeting chimeras, PROTACs, solid tumors, Swenson, THERAPY False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2023-01-09 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147164235 Brognard, John NIH - NCI NCI Brognard, John (NCI) 1 147164236 Swenson, Rolf NIH - NHLBI NHLBI Swenson, Rolf (NHLBI) 2 147164237 Torres-Ayuso, Pedro NIH - NCI NCI Torres-Ayuso, Pedro (NCI) 3 147164238 Sabbasani, Venkatareddy NIH - NHLBI NHLBI Sabbasani, Venkatareddy (NHLBI) 4 147164239 Mehlich, Dawid NIH - NCI NCI Mehlich, Dawid (NCI) 5 147164240 Warfel, Noel University of Arizona Warfel, Noel 6 147164235 Brognard, John NIH - NCI NCI Brognard, John (NCI) 1 147164236 Swenson, Rolf NIH - NHLBI NHLBI Swenson, Rolf (NHLBI) 2 147164237 Torres-Ayuso, Pedro NIH - NCI NCI Torres-Ayuso, Pedro (NCI) 3 147164238 Sabbasani, Venkatareddy NIH - NHLBI NHLBI Sabbasani, Venkatareddy (NHLBI) 4 147164239 Mehlich, Dawid NIH - NCI NCI Mehlich, Dawid (NCI) 5 147164240 Warfel, Noel University of Arizona Warfel, Noel 6 147157976 PIM Kinase Developed PROTACs Target PIM Kinases For Degradation And Promote Cancer Cell Death E-094-2022-0 Filing authorized NCI, NCI - CCR, Polish Academy of Sciences, University of Arizona 83704821 Nguyen-Antczak, Lauren lauren.nguyen-antczak@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-4305] PIM-Targeted PROTACs&body=Please send me information about technology [TAB-4305] PIM-Targeted PROTACs.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Nguyen-Antczak, Lauren<br><a href="mailto:lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-4305] PIM-Targeted PROTACs&body=Please send me information about technology [TAB-4305] PIM-Targeted PROTACs.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">lauren.nguyen-antczak@nih.gov</a><br> 147161032 E-094-2022-0 E-094-2022-0-US-01 PIM-TARGETED PROTACS AND METHODS OF USE PRV US 63/341,757 Expired US <br />Provisional (PRV) 63/341,757<br />Filed on 2022-05-13<br />Status: Expired 147168048 E-094-2022-0 E-094-2022-0-PC-01 PIM-TARGETED PROTACS WITH PIM-BINDING MOIETIES SGI-1776, AZD-1208 OR PIM-447, AND A E3 UBIQUITIN LIGASE BINDING MOIETY FOR THE TREATMENT OF CANCER PCT Patent Cooperation Treaty PCT/US2023/022017 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2023/022017<br />Filed on 2023-05-12<br />Status: Expired 147171302 anti-cancer 147171304 Brognard 147171306 Chemotherapy Resistance 147171307 Kinase 147171308 PIM 147171310 PIM kinase-targeting proteolysis-targeting chimeras 147171311 PROTACs 147171312 solid tumors 147171314 Swenson 147171315 THERAPY TAB-5088 165166556 DNA Methylation-Based Cancer Diagnostics for Accurate Tumor Classification NCI Collaboration, Diagnostics, Licensing, Oncology Collaboration Diagnostics Licensing Oncology Ziedulla Abdullaev, Kenneth Aldape, Elaine Jaffe, Antonios Papanicolau-Sengos, Stefania Pittaluga, Mark Raffeld, Omkar Singh, Rustamzhon Turakulov <h2>Summary:</h2> <p>The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a collection of T-cell receptors (TCRs) that specifically target the mutated KRAS antigen.</p> <p>This technology encompasses a DNA methylation&ndash;based diagnostic platform designed to improve the accuracy and consistency of cancer classification, with demonstrated utility for tumors of the central nervous system, kidney, and hematopoietic system. By identifying disease-specific methylation signatures, the approach reduces interobserver variability and enhances diagnostic confidence. The central nervous system (CNS) classifier is built from a curated reference set of 16,567 methylation profiles and organizes tumors into 22 families and 133 clinically relevant diagnostic classes, including 21 newly developed methylation classes not represented in other existing tools. Across multiple independent validation cohorts (n = 5,875), the classifier demonstrated robust performance, and in a clinical-impact analysis of 1,204 NIH validation cases, methylation profiling materially influenced final diagnosis in 74.4% of cases by refining, increasing precision, or reclassifying. The CNS classifier was deployed as a user-facing software tool, MethylScape Analysis, which streamlines methylation-based classification workflows for CNS tumors (https://methylscape.ccr.cancer.gov/). The development of multiple specialized classifiers supports a more granular understanding of tumor biology and&nbsp; informed clinical decision-making.</p> <h2>Description of Technology:</h2> <p>Accurate CNS tumor classification can be challenging when tumors show overlapping histology, limited tissue or atypical features. A meaningful fraction of cases remains unclassified or assigned with limited confidence with current molecular tools. These diagnostic ambiguities directly affect subtype and grade assignment which, in turn, influence treatment planning, prognosis, and clinical trial eligibility. Variability across observers and institutions can lead to additional testing, delays, and inconsistent diagnoses.</p> <p>The NCI/Bethesda classifier addresses this gap using DNA methylation patterns as a robust molecular fingerprint. It applies a stratified machine learning framework to extend diagnostic coverage and improve assignment confidence for CNS tumors. The classifier was developed from a rigorously curated reference set of over 16k methylation profiles, structured into 22 tumor families and 133 clinically relevant diagnostic classes and includes 21 recently developed methylation classes not represented in existing tools. The approach has been validated across multiple independent cohorts (n = 5,875) and supports deployment through MethylScape, a public web-based portal that streamlines classifier execution for broad accessibility. In an NIH validation cohort analysis of 1,204 high-confidence matches with pre-methylation diagnoses available, methylation profiling confirmed the initial diagnosis in 25.6% of cases while driving clinically meaningful diagnostic evolution in the remainder, including refined diagnosis (subtyping) in 14.6%, new diagnosis with increased precision in 54.7%, and substantial diagnostic reclassification in 5.0%&mdash;changes that are expected to affect patient management in the reclassification subset.</p> <p>Renal neoplasms present a parallel diagnostic challenge due to morphologic and molecular heterogeneity, overlapping microscopic features, and interobserver variability. As a result, a subset of cases are unclassifiable even after immunohistochemical, mutation and cytogenetic workups. To address this, the Kidney Classifier component of this platform leverages genome-wide DNA methylation profiling (feasible on formalin-fixed paraffin-embedded tissue using robust array-based methods). It was developed through examination of methylation signatures from over 2,000 renal neoplasms, identifying 23 coherent methylation groups that correlate with known tumor types and reveal clinically relevant novel subtypes. A machine learning classifier trained on 1,284 samples was externally tested on 287 renal neoplasms, demonstrating &gt;90% concordance between expected neoplasm type and high-score methylation-based classification, with discordant cases highlighting opportunities for diagnostic reclassification and improved precision in challenging renal tumor evaluations.</p> <p>Licensing and collaboration opportunities include commercial development of methylation-based diagnostic tests and/or software-enabled classification solutions for clinical laboratories, reference labs, and diagnostic companies. Partners may engage in external validation (retrospective and prospective), assay standardization, integration into pathology workflows and reporting systems, and extension of classifier coverage to additional tumor types and multi-institutional datasets. Consistent with consensus recommendations for complementary classifiers, the inventors are also interested in collaborations that: (1) operationalize multi-classifier strategies (concordant/complementary prediction to increase confidence; (2) leverage discordance to trigger orthogonal follow-up) and (3) accelerate clinical translation through scalable deployment models- including CLIA laboratory workflows and regulated diagnostic pathways.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Molecular classification and diagnosis of CNS and kidney tumors, including difficult-to-classify and low-confidence cases</li> <li>Diagnostic subtyping aligned to WHO-guided entities</li> <li>Reference-lab and hospital-lab deployment</li> <li>Clinical trial stratification and translational research cohort harmonization</li> <li>Multi-classifier diagnostic decision support</li> <li>Cancer treatment development</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Developed from a rigorously curated, large reference set of methylation profiles</li> <li>Clinically relevant CNS diagnostic</li> <li>CNS tumor methylation classes not represented in existing tools, expanding diagnostic coverage</li> <li>Clinical-impact analysis creating superior diagnostic precision</li> <li>Superior classifier for kidney cancer</li> <li>Superior classifiers for multiple solid, difficult-to-diagnose tumors</li> <li>Integrative into clinical workflows, improving diagnostic practices and enhancing patient care</li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations to further develop and possibly expand the classification capabilities of the software. 2025-12-12 2026-04-23 2026-04-23 2026-04-10 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov 52406769 Prototype 52406769 NCI 37470483 Website Abstract 166817637 Singh O., et.al. Robust DNA Methylation-Based Diagnosis and Classification for Central Nervous 1 System Tumors, submitted Singh O., et.al. Robust DNA Methylation-Based Diagnosis and Classification for Central Nervous 1 System Tumors, submitted 166817672 Aldape K., et.al. cIMPACT-NOW update 9: Recommendations on utilization of genome-wide DNA methylation profiling for central nervous system tumor diagnostics. Neurooncol Adv. 2025 Jan 3;7(1):vdae228. PMID: 39902391 https://pubmed.ncbi.nlm.nih.gov/39902391/ <a href="https://pubmed.ncbi.nlm.nih.gov/39902391/">Aldape K., et.al. cIMPACT-NOW update 9: Recommendations on utilization of genome-wide DNA methylation profiling for central nervous system tumor diagnostics. Neurooncol Adv. 2025 Jan 3;7(1):vdae228. PMID: 39902391</a> 166817702 Papanicolau-Sengos A., et.al., Mod Pathol. 2025 Nov;38(11):100884, PMID: 40939817 https://pubmed.ncbi.nlm.nih.gov/40939817/ <a href="https://pubmed.ncbi.nlm.nih.gov/40939817/">Papanicolau-Sengos A., et.al., Mod Pathol. 2025 Nov;38(11):100884, PMID: 40939817</a> 165166621 Aldape, Kenneth Laboratory of Pathology NCI Aldape, Kenneth (NCI) 1 165166625 Abdullaev, Ziedulla National Cancer Institute (NCI) NCI Abdullaev, Ziedulla (NCI) 2 165166629 Turakulov, Rustamzhon Laboratory of Pathology Turakulov, Rustamzhon 3 165166639 Pittaluga, Stefania National Cancer Institute (NCI) NCI Pittaluga, Stefania (NCI) 4 165166643 Raffeld, Mark National Cancer Institute (NCI) NCI Raffeld, Mark (NCI) 5 165166647 Jaffe, Elaine NCI - CCR NCI Jaffe, Elaine (NCI) 6 165166651 Singh, Omkar National Cancer Institute (NCI) NCI Singh, Omkar (NCI) 7 165166699 Papanicolau-Sengos, Antonios Laboratory of Pathology NCI Papanicolau-Sengos, Antonios (NCI) 8 165166621 Aldape, Kenneth Laboratory of Pathology NCI Aldape, Kenneth (NCI) 1 165166625 Abdullaev, Ziedulla National Cancer Institute (NCI) NCI Abdullaev, Ziedulla (NCI) 2 165166629 Turakulov, Rustamzhon Laboratory of Pathology Turakulov, Rustamzhon 3 165166639 Pittaluga, Stefania National Cancer Institute (NCI) NCI Pittaluga, Stefania (NCI) 4 165166643 Raffeld, Mark National Cancer Institute (NCI) NCI Raffeld, Mark (NCI) 5 165166647 Jaffe, Elaine NCI - CCR NCI Jaffe, Elaine (NCI) 6 165166651 Singh, Omkar National Cancer Institute (NCI) NCI Singh, Omkar (NCI) 7 165166699 Papanicolau-Sengos, Antonios Laboratory of Pathology NCI Papanicolau-Sengos, Antonios (NCI) 8 165166559 DNA methylation-based cancer diagnostics for tumors of the central nervous system, kidney and hematopoietic system E-105-2023-0 Filing authorized Laboratory of Pathology, National Cancer Institute (NCI), NCI - CCR 121111111 Greene, Jaime greenejaime@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America greenejaime@mail.nih.gov?subject=Web Inquiry on [TAB-5088] DNA Methylation-Based Cancer Diagnostics for Accurate Tumor Classification&body=Please send me information about technology [TAB-5088] DNA Methylation-Based Cancer Diagnostics for Accurate Tumor Classification.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Greene, Jaime<br><a href="mailto:greenejaime@mail.nih.gov?subject=Web Inquiry on [TAB-5088] DNA Methylation-Based Cancer Diagnostics for Accurate Tumor Classification&body=Please send me information about technology [TAB-5088] DNA Methylation-Based Cancer Diagnostics for Accurate Tumor Classification.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">greenejaime@mail.nih.gov</a><br> 165166607 E-105-2023-0 E-105-2023-0-US-01 DNA methylation-based cancer diagnostics ORD US 18/499,833 Pending US <br />Ordinary Patent (ORD) 18/499,833<br />Filed on 2023-11-01<br />Status: Pending TAB-4285 147157574 Molecular Nanotags for Detection of Single Molecules NCI Collaboration, Endocrinology, Infectious Disease, Licensing, Oncology, Research Materials Collaboration Endocrinology Infectious Disease Licensing Oncology Research Materials Jennifer Jones, William Telford <h2>Description of Technology:</h2> <p>Biological nanoparticles, like extracellular vesicles (EVs), possess unique biological characteristics making them attractive therapeutic agents, targets, or disease biomarkers. However, their use is hindered by the lack of tools available to accurately detect, sort, and analyze. Flow cytometers are used to sort and study individual cells. But, they are unable to detect and sort nanomaterials smaller than 200 nanometers with single epitope sensitivity.</p> <p>Researchers at the National Cancer Institute (NCI) developed a new class of nanoscale molecular tags (nanotags) allowing the detection and sorting of single biological nanoparticle using conventional flow cytometers. Otherwise, using standard methods such as fluorescently labeled antibodies, very few epitopes are detected. These nanotags are composed of materials with high refractive indices, high optical absorption, and remarkable spectral scattering properties. These properties allow both low epitope number determination and spectral phenotyping of biological nanoparticles &ndash; such as EVs, lipoproteins, RNA-protein complexes and other circulating submicron particles with significant biomedical applications.</p> <p>The NCI seeks commercial partners to co-develop and/or license this technology.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Research tool for studying structure and function of biological nanoparticles</li> <li>Diagnostic tool for detection of clinical biomarkers&nbsp;</li> <li>Tool for characterization of industrial and environmental nanoparticles</li> <li>Biodefense</li> <li>Industrial sectors</li> <li>Environmental applications</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Detect, sort and analyze nanomaterials &lt;200 nanometers with single epitope sensitivity&nbsp;</li> <li>Enumeration of the number of labeled molecules beyond the capabilities of current flow cytometric labels and instruments</li> <li>Improved detection above background noise</li> <li>Improved signal:noise ratio&nbsp;</li> </ul> 2022-01-21 2026-04-23 2022-01-21 2026-04-23 2022-01-20 Biological Nanoparticle, Biomarker, EVs, Extracellular Vesicles, flow cytometer, Jones, Nanoscale Molecular Tags, Nanotags False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2022-01-21 52406768 Discovery 52406768 NCI 37470483 Website Abstract E-008-2018 E-105-2018 147162245 Welsh JA, et al. Prospective Use of High-Refractive Index Materials for Single Molecule Detection in Flow Cytometry. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6111846/ <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6111846/">Welsh JA, et al. Prospective Use of High-Refractive Index Materials for Single Molecule Detection in Flow Cytometry.</a> 147164164 Jones, Jennifer NIH - NCI NCI Jones, Jennifer (NCI) 1 147164165 Telford, William NIH - NCI NCI Telford, William (NCI) 2 147164164 Jones, Jennifer NIH - NCI NCI Jones, Jennifer (NCI) 1 147164165 Telford, William NIH - NCI NCI Telford, William (NCI) 2 147158254 Single Molecule Detection With NanoFACS E-238-2015-0 Filing authorized NCI 83724826 Pollard, Ricquita ricquita.pollard@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4285] Molecular Nanotags for Detection of Single Molecules&body=Please send me information about technology [TAB-4285] Molecular Nanotags for Detection of Single Molecules.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollard, Ricquita<br><a href="mailto:ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4285] Molecular Nanotags for Detection of Single Molecules&body=Please send me information about technology [TAB-4285] Molecular Nanotags for Detection of Single Molecules.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">ricquita.pollard@nih.gov</a><br> 147161219 E-238-2015-0 E-238-2015-0-US-01 MOLECULAR NANOTAGS PRV US 62/411,324 Abandoned US <br />Provisional (PRV) 62/411,324<br />Filed on 2016-10-21<br />Status: Abandoned 147167884 E-238-2015-0 E-238-2015-0-PCT-02 MOLECULAR NANOTAGS PCT Patent Cooperation Treaty PCT/US2017/057928 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2017/057928<br />Filed on 2017-10-23<br />Status: Expired 147167885 E-238-2015-0 E-238-2015-0-AU-03 MOLECULAR NANOTAGS National Stage Australia 2017345814 2017345814 Issued Australia <br />National Stage 2017345814<br />Filed on 2017-10-23<br />Status: Issued 147167886 E-238-2015-0 E-238-2015-0-CA-04 MOLECULAR NANOTAGS National Stage Canada 3041059 3041059 Issued Canada <br />National Stage 3041059<br />Filed on 2017-10-23<br />Status: Issued 147167887 E-238-2015-0 E-238-2015-0-CN-05 MOLECULAR NANOTAGS National Stage China ZL201780079138.7 201780079138.7 Issued China <br />National Stage 201780079138.7<br />Filed on 2017-10-23<br />Status: Issued 147167888 E-238-2015-0 E-238-2015-0-EP-06 MOLECULAR NANOTAGS National Stage European Patent 3529205 17809073.4 Issued European Patent <br />National Stage 17809073.4<br />Filed on 2017-10-23<br />Status: Issued 147167889 E-238-2015-0 E-238-2015-0-JP-07 MOLECULAR NANOTAGS National Stage Japan 7492826 2019-521089 Issued Japan <br />National Stage 2019-521089<br />Filed on 2017-10-23<br />Status: Issued 147167890 E-238-2015-0 E-238-2015-0-US-08 MOLECULAR NANOTAGS National Stage US 11,536,719 16/342,345 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11536719 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11536719">11,536,719</a><br />Filed on 2019-04-16<br />Status: Issued 147167891 E-238-2015-0 E-238-2015-0-HK-09 MOLECULAR NANOTAGS CN Hong Kong HK40013934B 62020003242.8 Issued Hong Kong <br />China Patent (CN) 62020003242.8<br />Filed on 2020-02-24<br />Status: Issued 147167892 E-238-2015-0 E-238-2015-0-DE-10 MOLECULAR NANOTAGS EP Germany 3529205 17809073.4 Issued Germany <br />European patent (EP) 17809073.4<br />Filed on 2017-10-23<br />Status: Issued 147167893 E-238-2015-0 E-238-2015-0-FR-11 MOLECULAR NANOTAGS EP France 3529205 17809073.4 Issued France <br />European patent (EP) 17809073.4<br />Filed on 2017-10-23<br />Status: Issued 147167894 E-238-2015-0 E-238-2015-0-GB-12 MOLECULAR NANOTAGS EP United Kingdom 3529205 17809073.4 Issued United Kingdom <br />European patent (EP) 17809073.4<br />Filed on 2017-10-23<br />Status: Issued 147174079 Biological Nanoparticle 147174080 Biomarker 147174081 EVs 147174082 Extracellular Vesicles 147174083 flow cytometer 147174084 Jones 147174086 Nanoscale Molecular Tags 147174088 Nanotags TAB-4284 147157573 Exo-Clean Technology for Purifying Extracellular Vesicle Preparations from Contaminants NCI Cardiology, Collaboration, Endocrinology, Immunology, Licensing, Oncology, Research Materials Cardiology Collaboration Endocrinology Immunology Licensing Oncology Research Materials Jay Berzofsky, Jennifer Jones, Katherine McKinnon, Joshua Welsh <h2>Description of Technology:</h2> <p>Extracellular Vesicles (EVs), including exosomes and microvesicles, are nanometer-sized membranous vesicles that can carry different types of cargos, such as proteins, nucleic acids and metabolites. EVs are produced and released by most cell types. They act as biological mediators for intercellular communication via delivery of their cargos. This unique ability spurred translational research interest for targeted delivery of therapeutic molecules to treat a wide range of diseases. EVs also contain interesting information of their specific cellular origin. Thus, EVs can reveal nature, severity, and prognosis of a various pathophysiologic disease states. Such characteristics also make them a reliable and stable source of biomarkers, accessible in several body fluids. However, their small size makes it difficult to isolate EVs by using standard purification methods commonly used for isolating cells and platelets. Currently available techniques for EV isolation, are non-scalable, labor intensive, time consuming, and ineffective in removing contaminants.</p> <p>Researchers at the National Cancer Institute (NCI) developed a chromatographic EV purification technology using a custom-made &ldquo;mixed mode&rdquo; resin. The resin combines Capto Core-type resin with other affinity-based beads for depletion of unwanted contaminants smaller than 700 MDa &ndash; such as proteins, nucleic acids, or other molecules. This Exo-Clean technology is both broadly applicable for biofluid processing and scalable for high-throughput screening (i.e., compatible with robotic 96- or 384- well format). This technology is also suitable for large-scale GMP production of therapeutic exosome and other EV analogue-based therapeutics.&nbsp;</p> <p>Unique biophysical features of this technology could offer a new avenue for developing EV based clinical biomarkers, and therapeutics. The NCI seeks commercial partners to co-develop and/or license this technology.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Research tool for studying structure and function of EVs</li> <li>EV-based clinical biomarkers for detecting various pathological conditions</li> <li>Therapeutic exosome and other EV analogue-based therapeutics for targeted drug delivery</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Efficient in removing proteins and various labels from EV preparations</li> <li>Scalable for high-throughput screening</li> <li>Amenable to a wide range of preparation scales and formats</li> </ul> 2022-01-19 2026-04-23 2022-01-19 2026-04-23 2022-01-18 Affinity, Biomarkers, CHROMATOGRAPHIC, EVs, Exo-Clean, Exosomes, Extracellular Vesicles, High-throughput, Jones, Microvesicles, purification, Resin False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2022-01-19 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147162321 Welsh JA, et al. A simple, high-throughput method of protein and label removal from extracellular vesicle samples. https://pubmed.ncbi.nlm.nih.gov/33544111/ <a href="https://pubmed.ncbi.nlm.nih.gov/33544111/">Welsh JA, et al. A simple, high-throughput method of protein and label removal from extracellular vesicle samples.</a> 147164161 Jones, Jennifer NIH - NCI NCI Jones, Jennifer (NCI) 1 147164160 Berzofsky, Jay NIH - NCI NCI Berzofsky, Jay (NCI) 2 147164163 Welsh, Joshua NIH - NCI NCI Welsh, Joshua (NCI) 3 147164162 McKinnon, Katherine NIH - NCI NCI McKinnon, Katherine (NCI) 4 147164161 Jones, Jennifer NIH - NCI NCI Jones, Jennifer (NCI) 1 147164160 Berzofsky, Jay NIH - NCI NCI Berzofsky, Jay (NCI) 2 147164163 Welsh, Joshua NIH - NCI NCI Welsh, Joshua (NCI) 3 147164162 McKinnon, Katherine NIH - NCI NCI McKinnon, Katherine (NCI) 4 147158238 Exo-Clean Method For Removing Proteins And Various Labels From Extracellular Vesicle And Exosome Preparations E-227-2017-0 Filing authorized NCI 83724826 Pollard, Ricquita ricquita.pollard@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4284] Exo-Clean Technology for Purifying Extracellular Vesicle Preparations from Contaminants&body=Please send me information about technology [TAB-4284] Exo-Clean Technology for Purifying Extracellular Vesicle Preparations from Contaminants.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollard, Ricquita<br><a href="mailto:ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4284] Exo-Clean Technology for Purifying Extracellular Vesicle Preparations from Contaminants&body=Please send me information about technology [TAB-4284] Exo-Clean Technology for Purifying Extracellular Vesicle Preparations from Contaminants.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">ricquita.pollard@nih.gov</a><br> 147161208 E-227-2017-0 E-227-2017-0-US-01 EXO-CLEAN METHOD FOR REMOVING PROTEINS AND UNBOUND LABELS FROM EXTRACELLULAR VESICLE PREPARATIONS PRV US 62/612,040 Abandoned US <br />Provisional (PRV) 62/612,040<br />Filed on 2017-12-29<br />Status: Abandoned 147167877 E-227-2017-0 E-227-2017-0-PCT-02 METHOD FOR REMOVING PROTEINS AND UNBOUND LABELS FROM EXTRACELLULAR VESICLE PREPARATIONS PCT Patent Cooperation Treaty PCT/US2018/067913 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2018/067913<br />Filed on 2018-12-28<br />Status: Expired 147167878 E-227-2017-0 E-227-2017-0-EP-03 PURIFICATION AND LABELING OF EXTRACELLULAR VESICLES USING A MIXED MODE RESIN COMPOSITION National Stage European Patent 3731947 18847175.9 Issued European Patent <br />National Stage 18847175.9<br />Filed on 2020-07-27<br />Status: Issued 147167879 E-227-2017-0 E-227-2017-0-US-04 PURIFICATION AND LABELING OF EXTRACELLULAR VESICLES USING A MIXED MODE RESIN COMPOSITION National Stage US 12,083,448 16/959,071 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12083448 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12083448">12,083,448</a><br />Filed on 2020-06-29<br />Status: Issued 147167880 E-227-2017-0 E-227-2017-0-FR-01 PURIFICATION AND LABELING OF EXTRACELLULAR VESICLES USING A MIXED MODE RESIN COMPOSITION EP France 3731947 18847175.9 Issued France <br />European patent (EP) 18847175.9<br />Filed on 2020-07-27<br />Status: Issued 147167881 E-227-2017-0 E-227-2017-0-DE-01 PURIFICATION AND LABELING OF EXTRACELLULAR VESICLES USING A MIXED MODE RESIN COMPOSITION EP Germany 3731947 18847175.9 Issued Germany <br />European patent (EP) 18847175.9<br />Filed on 2020-07-27<br />Status: Issued 147167882 E-227-2017-0 E-227-2017-0-GB-01 PURIFICATION AND LABELING OF EXTRACELLULAR VESICLES USING A MIXED MODE RESIN COMPOSITION EP United Kingdom 3731947 18847175.9 Issued United Kingdom <br />European patent (EP) 18847175.9<br />Filed on 2020-07-27<br />Status: Issued 147173949 Affinity 147173950 Biomarkers 147173951 CHROMATOGRAPHIC 147173953 EVs 147173954 Exo-Clean 147173955 Exosomes 147173956 Extracellular Vesicles 147173957 High-throughput 147173958 Jones 147173959 Microvesicles 147173960 purification 147173961 Resin TAB-4271 147157559 Bacteriophage Based-Vaccine System NCI Collaboration, Infectious Disease, Licensing, Oncology, Vaccines Collaboration Infectious Disease Licensing Oncology Vaccines Sankar Adhya, Donald Court, Xintian Li, Manoj Rajaure <h2>Summary:</h2> <p>Researchers at NCI seek licensing and/or co-development research collaborations for further development of the Bacteriophage based-vaccine system.</p> <h2>Description of Technology:</h2> <p>Vaccines have become one of the most important tools in the fight against cancers and infectious diseases. However, some vaccines have shown limitations due to their high cost and low immune responses. To overcome these limitations, bacteriophages were proposed for the development of more cost-effective, immunogenic vaccines. Phages have shown a strong ability to activate induced&nbsp;and adaptive immune systems. The genome of these viral particles can be engineered, and their surface proteins can be exploited for antigen display.</p> <p>Researchers at National Cancer Institute (NCI) developed an engineered bacteriophage lambda () vector for displaying antigens as a vaccine in the treatment of cancer and infectious diseases. In this technology, a nucleic acid sequence encoding a fusion protein linked to a heterologous antigen is inserted into a native gene D locus adjacent to gene E in the bacteriophage lambda genome. The researchers have also constructed several phages in the &lambda; prophage vector system to display different fusion proteins as candidate vaccines representing several human diseases like human Chronic Lymphocyte Leukemia disease and malaria.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Vaccine in the treatment of cancer and other infectious diseases</li> <li>Method for rapid production of bioengineered bacteriophage lambda for vaccine development</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Novel way to generate multivalent vaccine antigens against various cancers and infectious diseases&nbsp;</li> <li>Inexpensive to produce compared with competing technologies</li> <li>Can stimulate induced&nbsp;immune and therefore potentially act as a natural adjuvant</li> <li>Can be stored and shipped at ambient temperatures</li> </ul> 2022-08-16 2026-04-23 2022-11-30 2026-04-23 2022-08-16 Adhya, Bacteriophage Engineering, Bacteriophage Genetics, CANCER VACCINE, Infectious Diseases, Lambda Vector, Phage Therapy, Recombineering, Vaccine False True Prototype True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2022-11-30 52406769 Prototype 52406769 NCI 37470483 Website Abstract 147164119 Adhya, Sankar NIH - NCI NCI Adhya, Sankar (NCI) 1 147164118 Court, Donald NIH - NCI NCI Court, Donald (NCI) 2 147164120 Li, Xintian NIH - NCI NCI Li, Xintian (NCI) 3 147164121 Rajaure, Manoj NIH - NCI NCI Rajaure, Manoj (NCI) 4 147164119 Adhya, Sankar NIH - NCI NCI Adhya, Sankar (NCI) 1 147164118 Court, Donald NIH - NCI NCI Court, Donald (NCI) 2 147164120 Li, Xintian NIH - NCI NCI Li, Xintian (NCI) 3 147164121 Rajaure, Manoj NIH - NCI NCI Rajaure, Manoj (NCI) 4 147158014 Bacteriophage Based-Vaccine System E-113-2021-0 Filing authorized NCI 83731987 Dhal, Abritee abritee.dhal@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-4271] Bacteriophage Based-Vaccine System&body=Please send me information about technology [TAB-4271] Bacteriophage Based-Vaccine System.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dhal, Abritee<br><a href="mailto:abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-4271] Bacteriophage Based-Vaccine System&body=Please send me information about technology [TAB-4271] Bacteriophage Based-Vaccine System.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">abritee.dhal@nih.gov</a><br> 147161061 E-113-2021-0 E-113-2021-0-US-01 BACTERIOPHAGE LAMBDA-VACCINE SYSTEM PRV US 63/289,018 Expired US <br />Provisional (PRV) 63/289,018<br />Filed on 2021-12-13<br />Status: Expired 147167807 E-113-2021-0 E-113-2021-0-PCT-02 vBacteriophage Based-Vaccine System PCT Patent Cooperation Treaty PCT/US2022/081383 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2022/081383<br />Filed on 2022-12-12<br />Status: Expired 147171697 Adhya 147171699 Bacteriophage Engineering 147171701 Bacteriophage Genetics 147171702 CANCER VACCINE 147171703 Infectious Diseases 147171705 Lambda Vector 147171707 Phage Therapy 147171708 Recombineering 147171709 Vaccine TAB-4257 147157544 Neoantigen T Cell Therapy with Neoantigen Vaccination as a Combination Immunotherapy Against Cancer NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Kenichi Hanada, Sri Krishna, Steven Rosenberg, Zhiya Yu <h2>Summary:</h2> <p>The NCI seeks parties interested in research co-development and/or licensing of this combination immunotherapy approach of neoantigen-specific T cells administered alongside a neoantigen-targeting vaccine to enhance ACT and treat cancer.</p> <h2>Description of Technology:</h2> <p>Adoptive cell therapy (ACT) is a breakthrough form of cancer immunotherapy that utilizes autologous, antitumor T cells to attack tumors through recognition of tumor-specific mutations, or neoantigens. A major hurdle in the development of ACT is the exhausted phenotype exhibited by many neoantigen-specific T cells, which limits their efficacy and prevents a sustained immune response.&nbsp;<br /> Researchers at the National Cancer Institute (NCI) have developed a combination immunotherapy to rescue the function of exhausted, neoantigen-specific T cells and, thus, enhance ACT. The method involves concurrent administration of neoantigen-specific T cells alongside a vaccine targeting the same neoantigens. The antitumor effect of this combination immunotherapy is superior to that mediated by the vaccine or by ACT alone, as measured in vivo by overall survival and tumor regression. Patient T cells genetically engineered with a neoantigen-specific T-cell receptor (TCR) can also be synergistically enhanced when used alongside a vaccine targeting the same antigen in this combination immunotherapy. This combined immunotherapy approach has broad therapeutic potential in a wide range of metastatic cancers, particularly those that are not responsive to traditional treatment methods.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>A variety of human cancers potentially amenable to the synergistic combination therapy of adoptive cell therapy (ACT) and tumor vaccine to treat&nbsp;</li> <li>Cell therapies for which the ACT component can employ isolated exhausted, neoantigen-specific T cells or T cells transduced with a neoantigen-specific TCR&nbsp;</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Synergistic, instead of additive, effect observed with this combination therapy based on available in vivo data</li> <li>Increased efficacy of exhausted, neoantigen-specific T cells</li> <li>Reduced toxicity compared to non-tumor specific immunotherapies&nbsp;</li> <li>T cells and vaccine can target either patient-specific somatic mutations or common driver mutations</li> <li>Broad clinical applications, including solid tumors (which traditional ACT methods have struggled to effectively treat)&nbsp;</li> </ul> 2022-08-17 2026-04-23 2022-08-17 2026-04-23 2022-08-17 act, Adoptive Cell Transfer, Immunotherapy, Krishna, Neoantigen, Rosenberg, T-Cell Receptor, TCR, Vaccine False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2022-08-17 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-059-2013 E-061-2020 E-067-2017 E-085-2013 E-102-2020 E-229-2014 E-233-2014 E-280-2016 147164069 Krishna, Sri NIH - NCI NCI Krishna, Sri (NCI) 1 147164068 Yu, Zhiya NIH - NCI NCI Yu, Zhiya (NCI) 2 147164067 Hanada, Kenichi NIH - NCI NCI Hanada, Kenichi (NCI) 3 147164066 Rosenberg, Steven NIH - NCI NCI Rosenberg, Steven (NCI) 4 147164069 Krishna, Sri NIH - NCI NCI Krishna, Sri (NCI) 1 147164068 Yu, Zhiya NIH - NCI NCI Yu, Zhiya (NCI) 2 147164067 Hanada, Kenichi NIH - NCI NCI Hanada, Kenichi (NCI) 3 147164066 Rosenberg, Steven NIH - NCI NCI Rosenberg, Steven (NCI) 4 147157863 Neoantigen T Cell Therapy With Neoantigen Vaccination As A Combination Immunotherapy Against Cancer E-046-2022-0 Filing authorized NCI 83709866 Burke, Andrew burkear@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC burkear@nih.gov?subject=Web Inquiry on [TAB-4257] Neoantigen T Cell Therapy with Neoantigen Vaccination as a Combination Immunotherapy Against Cancer&body=Please send me information about technology [TAB-4257] Neoantigen T Cell Therapy with Neoantigen Vaccination as a Combination Immunotherapy Against Cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Burke, Andrew<br><a href="mailto:burkear@nih.gov?subject=Web Inquiry on [TAB-4257] Neoantigen T Cell Therapy with Neoantigen Vaccination as a Combination Immunotherapy Against Cancer&body=Please send me information about technology [TAB-4257] Neoantigen T Cell Therapy with Neoantigen Vaccination as a Combination Immunotherapy Against Cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">burkear@nih.gov</a><br> 147160960 E-046-2022-0 E-046-2022-0-US-01 Neoantigen T Cell Therapy With Neoantigen Vaccination As A Combination Immunotherapy Against Cancer PRV US 63/295,762 Expired US <br />Provisional (PRV) 63/295,762<br />Filed on 2021-12-31<br />Status: Expired 147167712 E-046-2022-0 E-046-2022-0-PCT-02 T CELL THERAPY WITH VACCINATION AS A COMBINATION IMMUNOTHERAPY AGAINST CANCER PCT Patent Cooperation Treaty PCT/US2022/082579 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2022/082579<br />Filed on 2022-12-29<br />Status: Expired 147170250 act 147170251 Adoptive Cell Transfer 147170252 Immunotherapy 147170254 Krishna 147170255 Neoantigen 147170256 Rosenberg 147170257 T-Cell Receptor 147170258 TCR 147170259 Vaccine TAB-4213 147157498 Cell Lines that Constitutively Express High-Frequency KRAS and P53 Mutations and Human Leukocyte Antigens (HLAs) NCI Immunology, Infectious Disease, Licensing, Oncology, Research Materials Immunology Infectious Disease Licensing Oncology Research Materials <h2>Summary:</h2> <p>The NCI seeks parties interested in licensing this library of cell lines stably expressing tumor-specific antigens and HLAs.</p> <h2>Description of Technology:</h2> <p>Adoptive cell therapy (ACT) is a breakthrough form of cancer immunotherapy that utilizes tumor infiltrating lymphocytes (TILs) or genetically engineered T cells to attack tumor cells through recognition of tumor-specific antigens. A major hurdle in the development of ACT is the identification and isolation of T cells that recognize antigens that are expressed by tumor cells but not by healthy tissues. Current methods to identify such T cells involve extracting autologous antigen presenting cells (APCs) from patients in an expensive, laborious, and time-consuming process. In addition, the quantity and quality of extracted APCs varies significantly between patients, necessitating a novel, standardized approach.<br /> Researchers at the National Cancer Institute (NCI) developed a library of cell lines to identify T cells that specifically target tumor cells, thus eliminating the need for autologous APCs. These cell lines stably express tumor-specific antigens at a high level in the tandem minigene (TMG) format. The antigens expressed arise from mutations in the RAS or p53 genes. These mutations are also referred to as &ldquo;hotspot&rdquo; driver mutations because they are shared among many cancer patients and are the most commonly mutated genes in solid tumors. The cells also stably and highly express Class-I or Class-II human leukocyte antigens (HLAs) of interest, allowing for determination of HLA restriction. These cell lines offer a versatile, quick, and cost-effective method to identify, isolate, and expand tumor-reactive T cells.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Rapid identification, isolation, and expansion of mutated RAS or p53-reactive TILs or TCR-engineered T cells</li> <li>Validation of mutated RAS or p53-reactive TILs or TCR-engineered T cells&nbsp;</li> <li>Determination of HLA restriction of mutated RAS or p53-reactive TILs or TCR-engineered T cells</li> <li>Identification of T cell reactivities in infectious diseases (ex. Influenza, COVID-19)</li> <li>Identification of T cell reactivities in immunological disorders&nbsp;</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Universal APCs</li> <li>Replace the expensive, laborious, and time-consuming process of extracting/preparing autologous APCs</li> <li>Express tumor-specific antigens in the tandem minigene (TMG) format, allowing the cell lines to cover multiple different RAS or p53 mutations&nbsp;</li> <li>Express hotspot driver mutations, granting applicability to a broad range of cancer patients</li> </ul> 2022-10-14 2026-04-23 2022-10-13 2026-04-23 2022-10-13 act, adoptive cell therapy, Antigen Presenting Cells, APC, cell lines, HLA, Human Leukocyte Antigen, Immunotherapy, KRAS, Levin, p53, Rosenberg, T Cell Receptor, TCR, TIL, Tumor Infiltrating Lymphocytes, Tumor-Specific Antigen False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2022-10-13 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-175-2016 155750792 Cell Lines Constitutively Expressing Tandem Minigenes (TMGs) Of Hotspot Mutations And Human Leukocyte Antigens (HLA) E-182-2022-0 Research Material NCI 83709866 Burke, Andrew burkear@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC burkear@nih.gov?subject=Web Inquiry on [TAB-4213] Cell Lines that Constitutively Express High-Frequency KRAS and P53 Mutations and Human Leukocyte Antigens (HLAs)&body=Please send me information about technology [TAB-4213] Cell Lines that Constitutively Express High-Frequency KRAS and P53 Mutations and Human Leukocyte Antigens (HLAs).&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Burke, Andrew<br><a href="mailto:burkear@nih.gov?subject=Web Inquiry on [TAB-4213] Cell Lines that Constitutively Express High-Frequency KRAS and P53 Mutations and Human Leukocyte Antigens (HLAs)&body=Please send me information about technology [TAB-4213] Cell Lines that Constitutively Express High-Frequency KRAS and P53 Mutations and Human Leukocyte Antigens (HLAs).&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">burkear@nih.gov</a><br> 147173198 act 147173199 adoptive cell therapy 147173200 Antigen Presenting Cells 147173201 APC 147173202 cell lines 147173203 HLA 147173204 Human Leukocyte Antigen 147173205 Immunotherapy 147173206 KRAS 147173208 Levin 147173209 p53 147173210 Rosenberg 147173211 T Cell Receptor 147173212 TCR 147173213 TIL 147173214 Tumor Infiltrating Lymphocytes 147173216 Tumor-Specific Antigen TAB-4201 147157486 Novel Small Molecule Inhibitors of Tyrosyl-DNA Phosphodiesterase 1 (TDP1) for Treatment of Solid Tumors NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Terrence Burke, Evgeny Kiselev, George Lountos, Yves Pommier, David Waugh, Xue Zhao <h2>Summary:</h2> <p>The NCI seeks proposals from parties interested in licensing and/or co-development for commercializing the use of TDP1 inhibitors as part of a potent and selective anti-cancer combination therapy.</p> <h2>Description of Technology:</h2> <p>Topoisomerase 1 (TOP1) is an essential enzyme that plays a critical role in DNA transcription and replication. TOP1 inhibitors are a known class of anti-cancer agents that work to interrupt DNA replication in cancer cells, causing cell death. Since the discovery of the TOP1 inhibitor camptothecin (CPT) from plant extracts more than 60 years ago, two CPT analogs (irinotecan and topotecan) were approved by the FDA for cancer treatment. Tyrosyl-DNA phosphodiesterase 1 (TDP1) is an enzyme involved in DNA repair created when TOP1 is inhibited. As a result, targeting TDP1 is considered a potential therapeutic approach to enhance and possibly synergize the potency of TOP1 inhibitors. While TOP1 inhibitors are widely used to treat solid tumors &ndash; such as colon, lung, ovarian and certain pediatric cancers &ndash; there are currently no drugs targeting TDP1. Many TDP1 inhibitors may potentially have mechanisms of action that are promiscuous and non-specific. Researchers at the NCI developed a series of novel compounds selectively targeting the catalytic domain of TDP1. These small molecules show low micromolar potency against TDP1. X-ray structures of TDP1 bound to some of the small molecules elucidated their catalytic binding modes. The compounds developed at the NCI show selectivity for TDP1 over TDP2.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Combination therapy with TOP1 inhibitors for cancer treatment</li> <li>Incorporation into Proteolysis Targeting Chimeric or Antibody-Drug Conjugate therapeutics</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Irreversible inhibition of TDP1</li> <li>Selectivity for TDP1 over TDP2</li> <li>Small molecules capable of accessing and binding to the catalytic machinery to cause cancer cell death</li> <li>Currently, no FDA-approved TDP1 inhibitors</li> </ul> 2022-12-04 2026-04-23 2022-12-04 2026-04-23 2022-12-04 Burke, CANCER, solid tumor, Tdp1, TOP1, Topoisomerase 1, Tyrosyl-DNA Phosphodiesterase 1, Zhao False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2022-12-04 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147162324 Zhao, X.Z. et al. Small molecule microarray identifies inhibitors of tyrosyl-DNA phosphodiesterase 1 that simultaneously access the catalytic pocket and two substrate binding sites https://pubmed.ncbi.nlm.nih.gov/34163656/ <a href="https://pubmed.ncbi.nlm.nih.gov/34163656/">Zhao, X.Z. et al. Small molecule microarray identifies inhibitors of tyrosyl-DNA phosphodiesterase 1 that simultaneously access the catalytic pocket and two substrate binding sites</a> 147163894 Zhao, Xue NIH - NCI NCI Zhao, Xue (NCI) 1 147163895 Lountos, George NIH - NCI NCI Lountos, George (NCI) 2 147163896 Kiselev, Evgeny NIH - NCI NCI Kiselev, Evgeny (NCI) 3 147163892 Waugh, David NIH - NCI NCI Waugh, David (NCI) 4 147163891 Pommier, Yves NIH - NCI NCI Pommier, Yves (NCI) 5 147163893 Burke, Terrence NIH - NCI NCI Burke, Terrence (NCI) 6 147163894 Zhao, Xue NIH - NCI NCI Zhao, Xue (NCI) 1 147163895 Lountos, George NIH - NCI NCI Lountos, George (NCI) 2 147163896 Kiselev, Evgeny NIH - NCI NCI Kiselev, Evgeny (NCI) 3 147163892 Waugh, David NIH - NCI NCI Waugh, David (NCI) 4 147163891 Pommier, Yves NIH - NCI NCI Pommier, Yves (NCI) 5 147163893 Burke, Terrence NIH - NCI NCI Burke, Terrence (NCI) 6 147158282 Tyrosyl-DNA Phosphodiesterase 1 (Tdp1) Inhibitors Derived From A Small Molecule Microarray (SMM) Screen E-256-2020-0 Filing authorized NCI, NIH - NCI 91814193 Freel, Rose rose.freel@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America rose.freel@nih.gov?subject=Web Inquiry on [TAB-4201] Novel Small Molecule Inhibitors of Tyrosyl-DNA Phosphodiesterase 1 (TDP1) for Treatment of Solid Tumors&body=Please send me information about technology [TAB-4201] Novel Small Molecule Inhibitors of Tyrosyl-DNA Phosphodiesterase 1 (TDP1) for Treatment of Solid Tumors.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Freel, Rose<br><a href="mailto:rose.freel@nih.gov?subject=Web Inquiry on [TAB-4201] Novel Small Molecule Inhibitors of Tyrosyl-DNA Phosphodiesterase 1 (TDP1) for Treatment of Solid Tumors&body=Please send me information about technology [TAB-4201] Novel Small Molecule Inhibitors of Tyrosyl-DNA Phosphodiesterase 1 (TDP1) for Treatment of Solid Tumors.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">rose.freel@nih.gov</a><br> 147161235 E-256-2020-0 E-256-2020-0-US-01 IMIDAZO[1,2-a]PYRAZINE AND IMIDAZO[1,2-a]PYRIDINE BASED TYROSYL-DNA PHOSPHODIESTERASE I (TDP1) INHIBITORS PRV US 63/141,634 Abandoned US <br />Provisional (PRV) 63/141,634<br />Filed on 2021-01-26<br />Status: Abandoned 147167316 E-256-2020-0 E-256-2020-0-PCT-04 IMIDAZO[1,2-A]PYRAZINE AND IMIDAZO[1,2-A]PYRIDINE BASED TYROSYL-DNA PHOSPHODIESTERASE I (TDP1) INHIBITORS PCT Patent Cooperation Treaty PCT/US2022/013946 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2022/013946<br />Filed on 2022-01-26<br />Status: Expired 147167317 E-256-2020-0 E-256-2020-0-US-04 IMIDAZO[1,2-A]PYRAZINE AND IMIDAZO[1,2-A]PYRIDINE BASED TYROSYL-DNA PHOSPHODIESTERASE I (TDP1) INHIBITORS National Stage US 18/262,779 Pending US <br />National Stage 18/262,779<br />Filed on 2023-07-25<br />Status: Pending 147167318 E-256-2020-0 E-256-2020-0-EP-01 IMIDAZO[1,2-A]PYRAZINE AND IMIDAZO[1,2-A]PYRIDINE BASED TYROSYL-DNA PHOSPHODIESTERASE I (TDP1) INHIBITORS National Stage European Patent 22705222.2 Pending European Patent <br />National Stage 22705222.2<br />Filed on 2023-08-08<br />Status: Pending 147174325 Burke 147174326 CANCER 147174327 solid tumor 147174328 Tdp1 147174329 TOP1 147174331 Topoisomerase 1 147174332 Tyrosyl-DNA Phosphodiesterase 1 147174334 Zhao TAB-4197 147157482 T Cell Receptors Targeting BRAF V600E Mutation for Cancer Immunotherapy NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Catherine Ade, Kenichi Hanada, Matthew Sporn, James Yang, Zhiya Yu <h2>Summary:</h2> <p>The NCI seeks parties interested in research co-development and/or licensing of these HLA-A*0301 restricted TCRs that target the BRAF V600E mutation.</p> <h2>Description of Technology:</h2> <p>BRAF is an oncogene that encodinges a serine-threonine kinase (B-Raf kinase) important in regulating cell growth and differentiation. Spontaneous mutations in the BRAF gene allow cells to continuously divide, leading to the development of cancer. A substitution of glutamic acid for valine at amino acid number 600 (designated V600E) accounts for 90% of BRAF mutations and is a driver of many cancers. The V600E mutation is present in ~3% of all cancer cases, representing a patient population of 540,000 patients per year. Though While the V600E mutation is found in a wide variety of cancers, it ishas a particularly high prevalentce in metastatic melanoma, colorectal cancer, thyroid cancer, and lung cancer. Many of these cancers are aggressive and the V600E mutation is commonly recognized as a poor prognostic factor. Therapies for these cancers are often nonspecific or limited by acquired resistance, necessitating novel therapeutic approaches specifically targeting the BRAF V600E mutation.&nbsp;</p> <p>Researchers at the National Cancer Institute (NCI) have identified two T cell receptors (TCRs) that target the BRAF V600E mutation. These TCRs specifically recognize tumor cells expressing the BRAF V600E mutation when presented by HLA-A*0301 molecules. The TCRs were identified by first using mass spectrometric analysis to isolate a short peptide derived from the BRAF V600E mutated protein that binds to HLA-A*0301. Transgenic mice harboring the HLA-A*0301 allele were then immunized with the peptide to obtain T cells recognizing the BRAF V600E mutation. The two TCRs were isolated from these T cells and tested in vitro for efficacy. Genetically engineered human T cells transduced with the TCRs were specifically reactive against multiple human tumor cell lines harboring the BRAF V600E mutation. These encouraging preclinical results suggest the potential for the TCRs to be used in a therapeutic approach such as T-cell therapy against cancers with the BRAF V600E mutation. Given the broad distribution of the V600E mutation across cancers, the TCRs are also an attractive candidate for allogeneic T-cell therapy among cancer patients with the HLA-A*0301 allele.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Adoptive cell therapy for cancers expressing the BRAF V600E mutation</li> <li>&ldquo;Off-the-shelf&rdquo; allogenic cell therapy for BRAF V600E mutated cancers</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Potential for therapeutic efficacy against many cancers, given the high prevalence and broad distribution of the BRAF V600E mutation among cancer patients</li> <li>Therapies for BRAF V600E mutation-relevant cancers are often nonspecific or limited by acquired resistance</li> <li>T cells engineered with the TCRs are cytotoxic to tumor cells as the BRAF V600E mutation is not present in healthy tissues</li> <li>Efficacy against solid tumors</li> </ul> 2022-11-21 2026-04-23 2022-11-21 2026-04-23 2022-11-21 BRAF, B-Raf kinase, B-Raf Proto-Oncogene, HLA-A*0301 restriction, Immunotherapy, Rosenberg, serine-threonine kinase, T Cell Receptor, T cell therapy, TCR, V600E mutation, Yang, Yu False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2022-11-21 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-175-2016 E-237-2017 147163872 Yu, Zhiya NIH - NCI NCI Yu, Zhiya (NCI) 1 147163873 Ade, Catherine NCI - CCR NCI Ade, Catherine (NCI) 2 147163874 Sporn, Matthew NCI - CCR NCI Sporn, Matthew (NCI) 3 147163871 Yang, James NIH - NCI NCI Yang, James (NCI) 4 147163870 Hanada, Kenichi NIH - NCI NCI Hanada, Kenichi (NCI) 5 147163872 Yu, Zhiya NIH - NCI NCI Yu, Zhiya (NCI) 1 147163873 Ade, Catherine NCI - CCR NCI Ade, Catherine (NCI) 2 147163874 Sporn, Matthew NCI - CCR NCI Sporn, Matthew (NCI) 3 147163871 Yang, James NIH - NCI NCI Yang, James (NCI) 4 147163870 Hanada, Kenichi NIH - NCI NCI Hanada, Kenichi (NCI) 5 147158219 Murine T Cell Receptors Targeting Human BRAF V600E Mutation On HLA-A*0301+ Tumor Cells E-213-2022-0 Filing authorized NCI 83709866 Burke, Andrew burkear@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC burkear@nih.gov?subject=Web Inquiry on [TAB-4197] T Cell Receptors Targeting BRAF V600E Mutation for Cancer Immunotherapy&body=Please send me information about technology [TAB-4197] T Cell Receptors Targeting BRAF V600E Mutation for Cancer Immunotherapy.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Burke, Andrew<br><a href="mailto:burkear@nih.gov?subject=Web Inquiry on [TAB-4197] T Cell Receptors Targeting BRAF V600E Mutation for Cancer Immunotherapy&body=Please send me information about technology [TAB-4197] T Cell Receptors Targeting BRAF V600E Mutation for Cancer Immunotherapy.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">burkear@nih.gov</a><br> 147161199 E-213-2022-0 E-213-2022-0-US-01 HLA-A3-RESTRICTED T CELL RECEPTORS AGAINST BRAF WITH V600E MUTATION PRV US 63/381,587 Expired US <br />Provisional (PRV) 63/381,587<br />Filed on 2022-10-31<br />Status: Expired 159504232 E-213-2022-0 E-213-2022-0-PC-01 HLA-A3-RESTRICTED T CELL RECEPTORS AGAINST BRAF WITH V600E MUTATION PCT Patent Cooperation Treaty PCT/US2023/078156 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2023/078156<br />Filed on 2023-10-30<br />Status: Expired 147173777 BRAF 147173779 B-Raf kinase 147173781 B-Raf Proto-Oncogene 147173783 HLA-A*0301 restriction 147173784 Immunotherapy 147173785 Rosenberg 147173786 serine-threonine kinase 147173787 T Cell Receptor 147173788 T cell therapy 147173789 TCR 147173791 V600E mutation 147173793 Yang 147173795 Yu TAB-4140 147157423 Optimized Monospecific or Bicistronic Chimeric Antigen Receptor (CAR) Constructs Targeting CD19 and CD20 NCI Collaboration, Immunology, Licensing, Oncology, Therapeutics Collaboration Immunology Licensing Oncology Therapeutics James Kochenderfer, Norris Lam <h2>Description of Technology:</h2> <p>Patients with chemotherapy-refractory, diffuse large B-cell lymphoma (DLBCL) have poor prognoses. CD19 and CD20 are promising targets for the treatment of B-Cell malignancies. However, despite the initial promising results from anti-CD19 CAR therapy, only 30-35% of patients with DLBCL achieve remissions lasting longer than 2-3 years after anti-CD19 CAR T-cell therapy. Relapse and non-response are likely due to diminished CD19 expression after anti-CD19 therapy and low expression of CD19 in some lymphomas.&nbsp;</p> <p>To overcome the limitations of the CD19 CAR T therapy, inventors developed an improved CAR targeting both CD19 and CD20. CARs targeting both CD19 and CD20 showed greater efficacy than the CD19 targeting CAR by itself. The structure of the CD20 binder in some of these CAR constructs is optimized to reduce death of CAR-expressing T cells and to promote retention of CAR expression. Also, these constructs are optimized to reduce retroviral recombination events.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Treatment of CD19-positive malignancies such as diffuse large B-cell lymphoma, acute lymphoblastic leukemia, and chronic lymphocytic leukemia</li> <li>Treatment of CD20-positive malignancies such as diffuse large B-cell lymphoma, chronic lymphocytic leukemia, follicular lymphoma, and mantle cell lymphoma</li> <li>Treatment of autoimmune diseases via B cell depletion</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Constructs optimized to reduce retroviral recombination events</li> <li>Bicistronic expression vector allows for more efficient targeting of two antigens versus two separate vectors</li> <li>Bicistronic construct targeting both CD19 and CD20 increases the durability of response often&nbsp;limited by diminished expression of CD19 on tumor cell surfaces after anti-CD19 therapy</li> </ul> 2022-01-19 2026-04-23 2022-01-20 2026-04-23 2022-01-19 act, adoptive cell therapy, Autoimmune, B Cell Malignancies, BICISTRONIC, CAR, CD19, CD20, chimeric antigen receptor, Kochenderfer, Leukemia, lymphoma, Monospecific False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2022-01-20 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-205-2018 147163659 Kochenderfer, James NIH - NCI NCI Kochenderfer, James (NCI) 1 147163660 Lam, Norris NIH - NCI NCI Lam, Norris (NCI) 2 147163659 Kochenderfer, James NIH - NCI NCI Kochenderfer, James (NCI) 1 147163660 Lam, Norris NIH - NCI NCI Lam, Norris (NCI) 2 147157912 Nucleotide Optimized Fully-human CAR Constructs Targeting CD19-CD20 E-065-2021-0 Filing authorized NCI 83709866 Burke, Andrew burkear@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC burkear@nih.gov?subject=Web Inquiry on [TAB-4140] Optimized Monospecific or Bicistronic Chimeric Antigen Receptor (CAR) Constructs Targeting CD19 and CD20&body=Please send me information about technology [TAB-4140] Optimized Monospecific or Bicistronic Chimeric Antigen Receptor (CAR) Constructs Targeting CD19 and CD20.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Burke, Andrew<br><a href="mailto:burkear@nih.gov?subject=Web Inquiry on [TAB-4140] Optimized Monospecific or Bicistronic Chimeric Antigen Receptor (CAR) Constructs Targeting CD19 and CD20&body=Please send me information about technology [TAB-4140] Optimized Monospecific or Bicistronic Chimeric Antigen Receptor (CAR) Constructs Targeting CD19 and CD20.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">burkear@nih.gov</a><br> 147160987 E-065-2021-0 E-065-2021-0-US-01 BICISTRONIC CHIMERIC ANTIGEN RECEPTORS DESIGNED TO REDUCE RETROVIRAL RECOMBINATION AND USES THEREOF PRV US 63/165,195 Abandoned US <br />Provisional (PRV) 63/165,195<br />Filed on 2021-03-24<br />Status: Abandoned 147166882 E-065-2021-0 E-065-2021-0-PCT-02 BICISTRONIC CHIMERIC ANTIGEN RECEPTORS DESIGNED TO REDUCE RETROVIRAL RECOMBINATION AND USES THEREOF PCT Patent Cooperation Treaty PCT/US2022/021545 Administratively Closed Patent Cooperation Treaty <br />(PCT) PCT/US2022/021545<br />Filed on 2022-03-23<br />Status: Administratively Closed 147170661 act 147170662 adoptive cell therapy 147170663 Autoimmune 147170665 B Cell Malignancies 147170666 BICISTRONIC 147170667 CAR 147170668 CD19 147170669 CD20 147170670 chimeric antigen receptor 147170672 Kochenderfer 147170673 Leukemia 147170674 lymphoma 147170675 Monospecific TAB-4126 147157408 T-cell Receptor Targeting Human Papillomavirus-16 E7 Oncoprotein NCI Collaboration, Infectious Disease, Licensing, Oncology, Therapeutics Collaboration Infectious Disease Licensing Oncology Therapeutics Christian Hinrichs, Steven Rosenberg <h2>Summary:</h2> <p>The NCI Center for Immuno-Oncology is actively seeking co-development partners and/or licensees for this E7-targeting TCR with therapeutic potential for HPV-positive conditions.&nbsp;&nbsp;</p> <h2>Description of Technology:</h2> <p>Human papillomavirus (HPV) is a group of human viruses known to cause various malignancies. Of the group, HPV-16 is the most prevalent strain &ndash; an estimated 90% of adults have been exposed. HPV-16 is also the strain most commonly associated with malignancy, causing the vast majority of cervical, anal, vaginal, vulvar, and penile cancers. Currently, HPV-positive malignancies non-responsive to surgery or radiation are incurable and poorly palliated by existing systemic therapies. Thus, an alternative therapeutic approach for HPV-positive malignancies is needed.&nbsp;</p> <p>Researchers at the National Cancer Institute (NCI) developed a T cell receptor (TCR) that may be used in adoptive cell therapy to treat HPV-positive malignancies. The TCR confers high-avidity recognition of the HPV-specific E7 oncoprotein that drives malignant transformation in HPV-infected cells. Further, E7 is specific to and constitutively expressed by cancer cells, making it an ideal therapeutic target. The TCR targets human leukocyte antigen (HLA)-A*02-restricted epitope E711-19. The inventors successfully transduced T cells obtained from peripheral blood mononuclear cells (PBMCs) with this TCR. An ongoing Phase I/II clinical trial is investigating the efficacy of the E7-targeting TCR in treating HPV-positive malignancies.&nbsp;&nbsp;</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Adoptive cell therapy against HPV-positive cancers</li> <li>Treatment of HPV-related infections and premalignant conditions</li> <li>Prevention of HPV-related infections and premalignant conditions</li> <li>Detection of HPV-infected or transformed cells for diagnostic purposes</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>FDA approval of another first-in-class TCR therapeutic demonstrates treatment benefit of approach&nbsp;</li> <li>FDA approval of another first-in-class TCR therapeutic decreases regulatory risk</li> <li>High avidity for the HPV-specific E7 oncoprotein</li> <li>Specifically recognize HLA-A*02-positive HPV-16 cancer cells</li> <li>TCR can be used to transduce T cells isolated from PBMCs, an easily accessible source of human immune cells&nbsp;</li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for a TCR with high-avidity recognition of the E7 oncoprotein to treat HPV-positive malignancies. 2022-07-06 2026-04-23 2022-07-08 2026-04-23 2022-07-08 act, adoptive cell therapy, Cervical cancer, E7, HLA-A*02, HPV, Human Papillomavirus, Major Histocompatibility Complex, MALIGNANCY, MHC, ONCOPROTEIN, Rosenberg, T Cell Receptor, TCR False True Clinical True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2022-07-08 72159138 Clinical Phase I 72159138 NCI 37470483 Website Abstract E-495-2013 147161890 Hinrichs CS, et al. Exploiting the curative potential of adoptive T-cell therapy for cancer. https://pubmed.ncbi.nlm.nih.gov/24329789/ <a href="https://pubmed.ncbi.nlm.nih.gov/24329789/">Hinrichs CS, et al. Exploiting the curative potential of adoptive T-cell therapy for cancer.</a> 147162006 Nagarsheth NB, et al. TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers. https://pubmed.ncbi.nlm.nih.gov/33558725/ <a href="https://pubmed.ncbi.nlm.nih.gov/33558725/">Nagarsheth NB, et al. TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers.</a> 147163607 Hinrichs, Christian NIH - NCI Hinrichs, Christian 1 147163606 Rosenberg, Steven NIH - NCI NCI Rosenberg, Steven (NCI) 2 147163607 Hinrichs, Christian NIH - NCI Hinrichs, Christian 1 147163606 Rosenberg, Steven NIH - NCI NCI Rosenberg, Steven (NCI) 2 147158151 T-cell Receptor Targeting An HLA-A2-restricted Epitope Of Human Papillomavirus-16 E7 E-176-2014-0 Filing authorized NCI 83709866 Burke, Andrew burkear@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC burkear@nih.gov?subject=Web Inquiry on [TAB-4126] T-cell Receptor Targeting Human Papillomavirus-16 E7 Oncoprotein&body=Please send me information about technology [TAB-4126] T-cell Receptor Targeting Human Papillomavirus-16 E7 Oncoprotein.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Burke, Andrew<br><a href="mailto:burkear@nih.gov?subject=Web Inquiry on [TAB-4126] T-cell Receptor Targeting Human Papillomavirus-16 E7 Oncoprotein&body=Please send me information about technology [TAB-4126] T-cell Receptor Targeting Human Papillomavirus-16 E7 Oncoprotein.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">burkear@nih.gov</a><br> 147166721 E-176-2014-0 E-176-2014-0-US-01 Anti-Human Papillomavirus-16 E7 T Cell Receptors PRV US 62/004,335 Abandoned US <br />Provisional (PRV) 62/004,335<br />Filed on 2014-05-29<br />Status: Abandoned 147166722 E-176-2014-0 E-176-2014-0-PCT-02 Anti-Human Papillomavirus 16 E7 T Cell Receptors PCT Patent Cooperation Treaty PCT/US2015/033129 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2015/033129<br />Filed on 2015-05-29<br />Status: Expired 147166723 E-176-2014-0 E-176-2014-0-CA-05 Anti-Human Papillomavirus 16 E7 T Cell Receptors National Stage Canada 2950192 Pending Canada <br />National Stage 2950192<br />Filed on 2015-05-29<br />Status: Pending 147166724 E-176-2014-0 E-176-2014-0-AU-03 Anti-Human Papillomavirus 16 E7 T Cell Receptors National Stage Australia 2015266818 2015266818 Issued Australia <br />National Stage 2015266818<br />Filed on 2015-05-29<br />Status: Issued 147166725 E-176-2014-0 E-176-2014-0-BR-04 Anti-Human Papillomavirus 16 E7 T Cell Receptors National Stage Brazil BR112016027805-4 BR112016027805-4 Issued Brazil <br />National Stage BR112016027805-4<br />Filed on 2015-05-29<br />Status: Issued 147166726 E-176-2014-0 E-176-2014-0-CN-06 Anti-Human Papillomavirus 16 E7 T Cell Receptors National Stage China ZL201580031789.X 201580031789.X Issued China <br />National Stage 201580031789.X<br />Filed on 2015-05-29<br />Status: Issued 147166727 E-176-2014-0 E-176-2014-0-EP-07 Anti-Human Papillomavirus 16 E7 T Cell Receptors National Stage European Patent 3149031 15729004.0 Issued European Patent <br />National Stage 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166728 E-176-2014-0 E-176-2014-0-IL-08 Anti-Human Papillomavirus 16 E7 T Cell Receptors National Stage Israel 248797 248797 Issued Israel <br />National Stage 248797<br />Filed on 2016-11-07<br />Status: Issued 147166729 E-176-2014-0 E-176-2014-0-JP-09 Anti-Human Papillomavirus 16 E7 T Cell Receptors National Stage Japan 6742991 2017-515021 Issued Japan <br />National Stage 2017-515021<br />Filed on 2015-05-29<br />Status: Issued 147166730 E-176-2014-0 E-176-2014-0-KR-10 Anti-Human Papillomavirus 16 E7 T Cell Receptors National Stage South Korea 10-2445667 10-2016-7033189 Issued South Korea <br />National Stage 10-2016-7033189<br />Filed on 2016-11-28<br />Status: Issued 147166731 E-176-2014-0 E-176-2014-0-MX-11 Anti-Human Papillomavirus 16 E7 T Cell Receptors National Stage Mexico 375379 MX/a/2016/015383 Issued Mexico <br />National Stage MX/a/2016/015383<br />Filed on 2015-05-29<br />Status: Issued 147166732 E-176-2014-0 E-176-2014-0-SA-12 Anti-Human Papillomavirus 16 E7 T Cell Receptors National Stage Saudi Arabia 7456 516380394 Issued Saudi Arabia <br />National Stage 516380394<br />Filed on 2015-05-29<br />Status: Issued 147166733 E-176-2014-0 E-176-2014-0-US-13 ANTI-HUMAN PAPILLOMAVIRUS 16 E7 T CELL RECEPTORS National Stage US 10,174,098 15/313,673 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10174098 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10174098">10,174,098</a><br />Filed on 2016-11-23<br />Status: Issued 147166734 E-176-2014-0 E-176-2014-0-HK-14 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP Hong Kong HK1236203B 17109823.5 Issued Hong Kong <br />European patent (EP) 17109823.5<br />Filed on 2017-09-27<br />Status: Issued 147166735 E-176-2014-0 E-176-2014-0-US-15 ANTI-HUMAN PAPILLOMAVIRUS 16 E7 T CELL RECEPTORS DIV US 10,870,687 16/205,631 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10870687 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10870687">10,870,687</a><br />Filed on 2018-11-30<br />Status: Issued 147166736 E-176-2014-0 E-176-2014-0-EP-16 ANTI-HUMAN PAPILLOMAVIRUS 16 E7 T CELL RECEPTORS DIV European Patent 3689900 19217074.4 Issued European Patent <br />Divisional (DIV) 19217074.4<br />Filed on 2019-12-17<br />Status: Issued 147166737 E-176-2014-0 E-176-2014-0-AU-17 Anti-Human Papillomavirus 16 E7 T Cell Receptors DIV Australia 2019283892 2019283892 Issued Australia <br />Divisional (DIV) 2019283892<br />Filed on 2019-12-18<br />Status: Issued 147166738 E-176-2014-0 E-176-2014-0-AL-18 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP Albania 3149031 15729004.0 Issued Albania <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166739 E-176-2014-0 E-176-2014-0-AT-19 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP Austria 3149031 15729004.0 Issued Austria <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166740 E-176-2014-0 E-176-2014-0-BE-20 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP Belgium 3149031 15729004.0 Issued Belgium <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166741 E-176-2014-0 E-176-2014-0-BG-21 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP Bulgaria 3149031 15729004.0 Issued Bulgaria <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166742 E-176-2014-0 E-176-2014-0-CH-22 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP Switzerland 3149031 15729004.0 Issued Switzerland <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166743 E-176-2014-0 E-176-2014-0-CY-23 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP Cyprus 3149031 15729004.0 Issued Cyprus <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166744 E-176-2014-0 E-176-2014-0-CZ-24 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP Czech Republic 3149031 15729004.0 Issued Czech Republic <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166745 E-176-2014-0 E-176-2014-0-DE-25 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP Germany 3149031 15729004.0 Issued Germany <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166746 E-176-2014-0 E-176-2014-0-DK-26 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP Denmark 3149031 15729004.0 Issued Denmark <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166747 E-176-2014-0 E-176-2014-0-EE-27 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP Estonia 3149031 15729004.0 Issued Estonia <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166748 E-176-2014-0 E-176-2014-0-ES-28 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP Spain 3149031 15729004.0 Issued Spain <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166749 E-176-2014-0 E-176-2014-0-FI-29 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP Finland 3149031 15729004.0 Issued Finland <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166750 E-176-2014-0 E-176-2014-0-FR-30 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP France 3149031 15729004.0 Issued France <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166751 E-176-2014-0 E-176-2014-0-GB-31 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP United Kingdom 3149031 15729004.0 Issued United Kingdom <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166752 E-176-2014-0 E-176-2014-0-GR-32 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP Greece 3149031 15729004.0 Issued Greece <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166753 E-176-2014-0 E-176-2014-0-HR-33 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP Croatia 3149031 15729004.0 Issued Croatia <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166754 E-176-2014-0 E-176-2014-0-HU-34 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP Hungary 3149031 15729004.0 Issued Hungary <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166755 E-176-2014-0 E-176-2014-0-IE-35 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP Ireland 3149031 15729004.0 Issued Ireland <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166756 E-176-2014-0 E-176-2014-0-IS-36 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP Iceland 3149031 15729004.0 Issued Iceland <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166757 E-176-2014-0 E-176-2014-0-IT-37 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP Italy 3149031 15729004.0 Issued Italy <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166758 E-176-2014-0 E-176-2014-0-LT-38 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP Lithuania 3149031 15729004.0 Issued Lithuania <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166759 E-176-2014-0 E-176-2014-0-LU-39 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP Luxembourg 3149031 15729004.0 Issued Luxembourg <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166760 E-176-2014-0 E-176-2014-0-LV-40 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP Latvia 3149031 15729004.0 Issued Latvia <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166761 E-176-2014-0 E-176-2014-0-MK-41 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP North Macedonia 3149031 15729004.0 Issued North Macedonia <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166762 E-176-2014-0 E-176-2014-0-MT-42 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP Malta 3149031 15729004.0 Issued Malta <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166763 E-176-2014-0 E-176-2014-0-NL-43 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP The Netherlands 3149031 15729004.0 Issued The Netherlands <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166764 E-176-2014-0 E-176-2014-0-NO-44 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP Norway 3149031 15729004.0 Issued Norway <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166765 E-176-2014-0 E-176-2014-0-PL-45 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP Poland 3149031 15729004.0 Issued Poland <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166766 E-176-2014-0 E-176-2014-0-PT-46 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP Portugal 3149031 15729004.0 Issued Portugal <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166767 E-176-2014-0 E-176-2014-0-RO-47 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP Romania 3149031 15729004.0 Issued Romania <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166768 E-176-2014-0 E-176-2014-0-SE-48 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP Sweden 3149031 15729004.0 Issued Sweden <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166769 E-176-2014-0 E-176-2014-0-SI-49 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP Slovenia 3149031 15729004.0 Issued Slovenia <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166770 E-176-2014-0 E-176-2014-0-SK-50 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP Slovakia 3149031 15729004.0 Issued Slovakia <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166771 E-176-2014-0 E-176-2014-0-SM-51 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP San Marino 3149031 15729004.0 Issued San Marino <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166772 E-176-2014-0 E-176-2014-0-TR-52 Anti-Human Papillomavirus 16 E7 T Cell Receptors EP Turkey 3149031 15729004.0 Issued Turkey <br />European patent (EP) 15729004.0<br />Filed on 2015-05-29<br />Status: Issued 147166773 E-176-2014-0 E-176-2014-0-JP-53 ANTI-HUMAN PAPILLOMAVIRUS 16 E7 T-CELL RECEPTOR DIV Japan 6997267 2020-127833 Issued Japan <br />Divisional (DIV) 2020-127833<br />Filed on 2020-07-29<br />Status: Issued 147166774 E-176-2014-0 E-176-2014-0-SA-54 Anti-Human Papillomavirus 16 E7 T Cell Receptors DIV Saudi Arabia 520412601 Abandoned Saudi Arabia <br />Divisional (DIV) 520412601<br />Filed on 2020-08-06<br />Status: Abandoned 147166775 E-176-2014-0 E-176-2014-0-HK-55 ANTI-HUMAN PAPILLOMAVIRUS 16 E7 T CELL RECEPTORS EP Hong Kong HK40030123B 42020020661.3 Issued Hong Kong <br />European patent (EP) 42020020661.3<br />Filed on 2020-11-24<br />Status: Issued 147166776 E-176-2014-0 E-176-2014-0-MX-56 Anti-Human Papillomavirus 16 E7 T Cell Receptors DIV Mexico 432750 MX/a/2020/010035 Issued Mexico <br />Divisional (DIV) MX/a/2020/010035<br />Filed on 2020-09-24<br />Status: Issued 147166777 E-176-2014-0 E-176-2014-0-US-57 ANTI-HUMAN PAPILLOMAVIRUS 16 E7 T CELL RECEPTORS CON US 11,434,272 17/101,360 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11434272 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11434272">11,434,272</a><br />Filed on 2020-11-23<br />Status: Issued 147166778 E-176-2014-0 E-176-2014-0-AU-58 Anti-Human Papillomavirus 16 E7 T Cell Receptors DIV Australia 2021202227 2021202227 Issued Australia <br />Divisional (DIV) 2021202227<br />Filed on 2021-04-13<br />Status: Issued 147166779 E-176-2014-0 E-176-2014-0-CN-59 Anti-Human Papillomavirus 16 E7 T Cell Receptors DIV China ZL202110399056.9 202110399056.9 Issued China <br />Divisional (DIV) 202110399056.9<br />Filed on 2021-04-14<br />Status: Issued 147166780 E-176-2014-0 E-176-2014-0-IL-60 Anti-Human Papillomavirus 16 E7 T Cell Receptors DIV Israel 282518 282518 Issued Israel <br />Divisional (DIV) 282518<br />Filed on 2021-04-21<br />Status: Issued 147166782 E-176-2014-0 E-176-2014-0-HK-62 Anti-Human Papillomavirus 16 E7 T Cell Receptors CN Hong Kong HK40056926B 42022046605.6 Issued Hong Kong <br />China Patent (CN) 42022046605.6<br />Filed on 2022-01-19<br />Status: Issued 147166783 E-176-2014-0 E-176-2014-0-JP-63 ANTI-HUMAN PAPILLOMAVIRUS 16 E7 T CELL RECEPTORS DIV Japan 7291196 2021-203953 Issued Japan <br />Divisional (DIV) 2021-203953<br />Filed on 2021-12-16<br />Status: Issued 147166784 E-176-2014-0 E-176-2014-0-IL-64 Anti-Human Papillomavirus 16 E7 T Cell Receptors DIV Israel 290655 290655 Issued Israel <br />Divisional (DIV) 290655<br />Filed on 2022-02-16<br />Status: Issued 147166785 E-176-2014-0 E-176-2014-0-US-65 ANTI-HUMAN PAPILLOMAVIRUS 16 E7 T CELL RECEPTORS CON US 12,534,508 17/816,496 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12534508 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12534508">12,534,508</a><br />Filed on 2022-08-01<br />Status: Issued 147166786 E-176-2014-0 E-176-2014-0-KR-66 Anti-Human Papillomavirus 16 E7 T Cell Receptors DIV South Korea 10-2618267 10-2022-7032043 Issued South Korea <br />Divisional (DIV) 10-2022-7032043<br />Filed on 2022-09-15<br />Status: Issued 147166787 E-176-2014-0 E-176-2014-0-AU-01 Anti-Human Papillomavirus 16 E7 T Cell Receptors DIV Australia 2023200608 2023200608 Issued Australia <br />Divisional (DIV) 2023200608<br />Filed on 2023-02-06<br />Status: Issued 147166788 E-176-2014-0 E-176-2014-0-JP-01 ANTI-HUMAN PAPILLOMAVIRUS 16 E7 T CELL RECEPTORS DIV Japan 7535158 2023-091878 Issued Japan <br />Divisional (DIV) 2023-091878<br />Filed on 2023-06-02<br />Status: Issued 147173065 act 147173066 adoptive cell therapy 147173067 Cervical cancer 147173068 E7 147173070 HLA-A*02 147173071 HPV 147173072 Human Papillomavirus 147173074 Major Histocompatibility Complex 147173075 MALIGNANCY 147173076 MHC 147173077 ONCOPROTEIN 147173078 Rosenberg 147173079 T Cell Receptor 147173080 TCR TAB-4115 147157397 Mouse Lines with Fluorescently Labelled Membrane Proteins Regulating Cellular Motility and Membrane Trafficking NCI Licensing, Oncology, Research Materials Licensing Oncology Research Materials Seham Ebrahim, Weiye Wang, Roberto Weigert <h2>Summary:</h2> <p>NCI is seeking licensees for mouse lines with fluorescently labeled membrane proteins regulating cellular motility and cancer progression.</p> <h2>Description of Technology:</h2> <p>Cell motility and membrane trafficking play important roles in regulating cell division, cell migration, cell death and autophagy. Impairment of these processes can result in enhanced cell proliferation and survival and increased migration and invasion leading to cancer. Several proteins involved in cell motility and membrane trafficking have been shown to be dysregulated in various cancers. There is therefore a need for development of animal models for studying the roles of these proteins in cancer and their responses to drug treatment in vivo.</p> <p>Researchers at the National Cancer Institute (NCI) have developed mouse lines with fluorescently labelled membrane proteins regulating cellular motility and membrane trafficking. These transgenic mouse lines were created by insertion of fluorescent proteins to tag Myosin IIA, Septin 2, Septin 7, Septin 9 and Rab25. They facilitate the study of cell motility and membrane trafficking proteins and their activity during tumor progression in live animal models.&nbsp;</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Cancer research</li> <li>Live animal imaging cancer studies</li> <li>Live animal imaging cancer drug screening</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Use of neon-Green and pTag-RFP tagging provides a superior means of imaging in vivo over other fluorescent proteins</li> <li>These mouse lines facilitate live animal imaging studies of cell motility and membrane trafficking proteins</li> <li>The first available mouse lines for live animal imaging of Septin 2, Septin 7, Septin 9 and Rab25 in vivo</li> </ul> Researchers at the NCI seek licensing for mouse lines with fluorescently labelled membrane proteins regulating cellular motility and cancer progression 2022-02-03 2026-04-23 2022-02-03 2026-04-23 2022-02-03 Cellular Motility, Florescent Labels, Membrane Trafficking, Mouse Lines, Rab25, Septin 2, Septin 7, Septin 9, Weigert False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2022-02-03 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147163558 Weigert, Roberto NIH - NCI NCI Weigert, Roberto (NCI) 1 147163560 Wang, Weiye NCI - CCR NCI Wang, Weiye (NCI) 2 147163559 Ebrahim, Seham NCI - CCR NCI Ebrahim, Seham (NCI) 3 147163558 Weigert, Roberto NIH - NCI NCI Weigert, Roberto (NCI) 1 147163560 Wang, Weiye NCI - CCR NCI Wang, Weiye (NCI) 2 147163559 Ebrahim, Seham NCI - CCR NCI Ebrahim, Seham (NCI) 3 147157829 Mouse Lines With Fluorescently Labeled Membrane Proteins (Septins, Myosin IIA, Rab25) Regulating Cellular Motility And Membrane Trafficking E-031-2022-0 Research Material NCI 147188440 Watson, Shana shana.watson@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America shana.watson@nih.gov?subject=Web Inquiry on [TAB-4115] Mouse Lines with Fluorescently Labelled Membrane Proteins Regulating Cellular Motility and Membrane Trafficking&body=Please send me information about technology [TAB-4115] Mouse Lines with Fluorescently Labelled Membrane Proteins Regulating Cellular Motility and Membrane Trafficking.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Watson, Shana<br><a href="mailto:shana.watson@nih.gov?subject=Web Inquiry on [TAB-4115] Mouse Lines with Fluorescently Labelled Membrane Proteins Regulating Cellular Motility and Membrane Trafficking&body=Please send me information about technology [TAB-4115] Mouse Lines with Fluorescently Labelled Membrane Proteins Regulating Cellular Motility and Membrane Trafficking.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">shana.watson@nih.gov</a><br> 147169887 Cellular Motility 147169889 Florescent Labels 147169891 Membrane Trafficking 147169893 Mouse Lines 147169894 Rab25 147169896 Septin 2 147169898 Septin 7 147169900 Septin 9 147169902 Weigert TAB-4043 147157325 IgG4 Hinge Containing Nanobody-based CARs Targeting GPC3 for Treating Liver Cancer NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Mitchell Ho, Aarti Kolluri, Nan Li <h2>Summary:</h2> <p>Researchers at the NCI seek licensing and/or co-development research collaborations for developing new nanobody-based CAR and/or antibody-T-cell receptor therapies for treating liver cancer.</p> <h2>Description of Technology:</h2> <p>Hepatocellular carcinoma (HCC) is the most common type of liver cancer. Globally, HCC is the sixth most prevalent cancer and third leading cause of cancer-related morbidity. Standard treatment for HCC is not suitable for a large proportion of liver cancer patients. Part of this is because less than a quarter of HCC patients are surgical candidates for curative-intent treatment. As a result, alternative treatments are needed. Chimeric antigen receptor (CAR) T cell therapy is a promising alternative approach selectively targets targeting tumors via tumor-specific antigens. However, to date, no effective CAR T cell therapy exists for HCC.</p> <p>Researchers at National Cancer Institute (NCI) developed novel Chimeric Antigen Receptors (CARs) specific for glypican-3 (GPC3) that include short Immunoglobulin subclass 4 (IgG4) and CD28 based hinge domains and the HN3 human single-domain antibody (also called nanobody). The specific HN3 nanobody-IgG4H-CD28TM CAR included in this invention was much more potent both in in vitro cell models and in vivo mouse models.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Treatment of liver cancer, whose worldwide incidence is increasing in direct relation to the spread of hepatitis C virus infection.</li> <li>Chimeric antigen receptor (CAR) and/or antibody-T-cell receptor cancer therapies.&nbsp;</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Increased therapeutic effectiveness of CAR T therapies for the vast majority patients with HCC without impactful treatment options</li> <li>New nanobody-based CAR immunotherapy in preclinical in vivo studies has a greater decrease in tumor size compared with other CAR formats</li> <li>Nanobodies&rsquo; lack of a light chain, making them much smaller and more flexible than standard antibodies, allows: (1) binding in different modes than typical antibodies, (2) coverage of more chemical space and (3) binding to epitopes otherwise inaccessible.&nbsp;&nbsp;</li> <li>Nanobodies can be readily genetically engineered for additional functionality and, consequently, paths to market.&nbsp;&nbsp;</li> </ul> 2022-07-06 2026-04-23 2022-07-06 2026-04-23 2022-07-06 ANTIBODY, cancer therapeutic, Chimeric antigen receptors (CARs), Glypican-3 (GPC3), Hepatocellular Carcinoma (HCC), HO, IgG4, Liver cancer, Macrophage, NANOBODY, Natural Killer (NK) Cell, T cell, therapeutic False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2022-07-06 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-016-2018 E-130-2011 147162126 Dan Li, et al. Persistent Polyfunctional Chimeric Antigen Receptor T Cells That Target Glypican 3 Eliminate Orthotopic Hepatocellular Carcinomas in Mice. Gastroenterology vol. 158,8 (2020): 2250-2265.e20. doi:10.1053/j.gastro.2020.02.011 https://pubmed.ncbi.nlm.nih.gov/32060001/ <a href="https://pubmed.ncbi.nlm.nih.gov/32060001/">Dan Li, et al. Persistent Polyfunctional Chimeric Antigen Receptor T Cells That Target Glypican 3 Eliminate Orthotopic Hepatocellular Carcinomas in Mice. Gastroenterology vol. 158,8 (2020): 2250-2265.e20. doi:10.1053/j.gastro.2020.02.011</a> 147163312 Ho, Mitchell NIH - NCI NCI Ho, Mitchell (NCI) 1 147163314 Kolluri, Aarti NCI - CCR NCI Kolluri, Aarti (NCI) 2 147163313 Li, Nan NIH - NCI NCI Li, Nan (NCI) 3 147163312 Ho, Mitchell NIH - NCI NCI Ho, Mitchell (NCI) 1 147163314 Kolluri, Aarti NCI - CCR NCI Kolluri, Aarti (NCI) 2 147163313 Li, Nan NIH - NCI NCI Li, Nan (NCI) 3 147158207 IgG4 Hinge Containing Nanobody-based CARs Targeting GPC3 For Treating Liver Cancer E-205-2021-0 Filing authorized NCI 83731987 Dhal, Abritee abritee.dhal@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-4043] IgG4 Hinge Containing Nanobody-based CARs Targeting GPC3 for Treating Liver Cancer&body=Please send me information about technology [TAB-4043] IgG4 Hinge Containing Nanobody-based CARs Targeting GPC3 for Treating Liver Cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dhal, Abritee<br><a href="mailto:abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-4043] IgG4 Hinge Containing Nanobody-based CARs Targeting GPC3 for Treating Liver Cancer&body=Please send me information about technology [TAB-4043] IgG4 Hinge Containing Nanobody-based CARs Targeting GPC3 for Treating Liver Cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">abritee.dhal@nih.gov</a><br> 147161191 E-205-2021-0 E-205-2021-0-US-01 IGG4 HINGE-CONTAINING CHIMERIC ANTIGEN RECEPTORS TARGETING GLYPICAN-3 (GPC3) AND USE THEREOF PRV US 63/277,287 Abandoned US <br />Provisional (PRV) 63/277,287<br />Filed on 2021-11-09<br />Status: Abandoned 147166168 E-205-2021-0 E-205-2021-0-PCT-02 IGG4 HINGE-CONTAINING CHIMERIC ANTIGEN RECEPTORS TARGETING GLYPICAN-3 (GPC3) AND USE THEREOF PCT Patent Cooperation Treaty PCT/US2022/079554 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2022/079554<br />Filed on 2022-11-09<br />Status: Expired 147173628 ANTIBODY 147173629 cancer therapeutic 147173631 Chimeric antigen receptors (CARs) 147173633 Glypican-3 (GPC3) 147173635 Hepatocellular Carcinoma (HCC) 147173636 HO 147173637 IgG4 147173638 Liver cancer 147173639 Macrophage 147173640 NANOBODY 147173642 Natural Killer (NK) Cell 147173643 T cell 147173644 therapeutic TAB-3933 147157213 T-cell Receptor Targeting Human Papillomavirus-16 E6 Oncoprotein NCI Collaboration, Infectious Disease, Licensing, Oncology, Therapeutics Collaboration Infectious Disease Licensing Oncology Therapeutics Christian Hinrichs, Steven Rosenberg <h2>Summary:</h2> <p>The NCI Center for Immuno-Oncology is actively seeking co-development partners and/or licensees for this E6-targeting TCR with therapeutic potential for HPV-positive conditions.</p> <h2>Description of Technology:</h2> <p>Human papillomavirus (HPV) is a group of human viruses known to cause various malignancies. Of the group, HPV-16 is the most prevalent strain &ndash; an estimated 90% of adults have been exposed. HPV-16 is also the strain most commonly associated with malignancy, causing the vast majority of cervical, anal, vaginal, vulvar, and penile cancers. Currently, HPV-positive malignancies non-responsive to surgery or radiation are incurable and poorly palliated by existing systemic therapies. Thus, an alternative therapeutic approach for HPV-positive malignancies is needed.&nbsp;</p> <p>Researchers at the National Cancer Institute (NCI) developed a T cell receptor (TCR) that may be used in adoptive cell therapy to treat HPV-positive malignancies. The TCR confers high-avidity recognition of the HPV-specific E6 oncoprotein that drives malignant transformation in HPV-infected cells. Further, E6 is specific to and constitutively expressed by cancer cells, making it an ideal therapeutic target. The TCR targets human leukocyte antigen (HLA)-A*02-restricted epitope E629-38. The inventors successfully transduced T cells obtained from peripheral blood mononuclear cells (PBMCs) with this TCR.&nbsp;</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Adoptive cell therapy against HPV-positive cancers</li> <li>Treatment of HPV-related infections and premalignant conditions</li> <li>Prevention of HPV-related infections and premalignant conditions</li> <li>Detection of HPV-infected or transformed cells for diagnostic purposes</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>FDA approval of another first-in-class TCR therapeutic demonstrates treatment benefit of approach&nbsp;</li> <li>FDA approval of another first-in-class TCR therapeutic decreases regulatory risk</li> <li>High avidity for the HPV-specific E6 oncoprotein</li> <li>Specifically recognize HLA-A*02-positive HPV-16 cancer cells</li> <li>TCR can be used to transduce T cells isolated from PBMCs, an easily accessible source of human immune cells&nbsp;</li> </ul> 2022-07-08 2026-04-23 2022-09-29 2026-04-23 2022-07-08 act, adoptive cell therapy, Cervical cancer, E6, HLA-A*02, HPV, Human Papillomavirus, Major Histocompatibility Complex, MALIGNANCY, MHC, ONCOPROTEIN, Rosenberg, T Cell Receptor, TCR False True Clinical True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2022-09-29 72159138 Clinical Phase I 72159138 NCI 37470483 Website Abstract E-176-2014 147162097 Doran SL, et al. T-Cell Receptor Gene Therapy for Human Papillomavirus&ndash;Associated Epithelial Cancers: A First-in-Human, Phase I/II Study. https://pubmed.ncbi.nlm.nih.gov/?term=31408414 <a href="https://pubmed.ncbi.nlm.nih.gov/?term=31408414">Doran SL, et al. T-Cell Receptor Gene Therapy for Human Papillomavirus&ndash;Associated Epithelial Cancers: A First-in-Human, Phase I/II Study.</a> 147162175 Hinrichs CS, et al. Exploiting the curative potential of adoptive T-cell therapy for cancer. https://pubmed.ncbi.nlm.nih.gov/24329789/ <a href="https://pubmed.ncbi.nlm.nih.gov/24329789/">Hinrichs CS, et al. Exploiting the curative potential of adoptive T-cell therapy for cancer.</a> 147162920 Hinrichs, Christian NIH - NCI Hinrichs, Christian 1 147162919 Rosenberg, Steven NIH - NCI NCI Rosenberg, Steven (NCI) 2 147162920 Hinrichs, Christian NIH - NCI Hinrichs, Christian 1 147162919 Rosenberg, Steven NIH - NCI NCI Rosenberg, Steven (NCI) 2 147158355 T Cell Receptor Targeting An HLA-A2 Restricted Epitope Of Human Papillomavirus-16 E6 E-495-2013-0 Filing authorized NCI 83709866 Burke, Andrew burkear@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC burkear@nih.gov?subject=Web Inquiry on [TAB-3933] T-cell Receptor Targeting Human Papillomavirus-16 E6 Oncoprotein&body=Please send me information about technology [TAB-3933] T-cell Receptor Targeting Human Papillomavirus-16 E6 Oncoprotein.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Burke, Andrew<br><a href="mailto:burkear@nih.gov?subject=Web Inquiry on [TAB-3933] T-cell Receptor Targeting Human Papillomavirus-16 E6 Oncoprotein&body=Please send me information about technology [TAB-3933] T-cell Receptor Targeting Human Papillomavirus-16 E6 Oncoprotein.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">burkear@nih.gov</a><br> 147165363 E-495-2013-0 E-495-2013-0-US-01 Anti-Human Papillomavirus 16 E6 T Cell Receptors PRV US 61/846,167 Abandoned US <br />Provisional (PRV) 61/846,167<br />Filed on 2013-07-15<br />Status: Abandoned 147165364 E-495-2013-0 E-495-2013-0-PCT-02 Anti-Human Papillomavirus 16 E6 T Cell Receptors PCT Patent Cooperation Treaty PCT/US2014/046480 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2014/046480<br />Filed on 2014-07-14<br />Status: Expired 147165365 E-495-2013-0 E-495-2013-0-JP-07 Anti-Human Papillomavirus 16 E6 T Cell Receptors National Stage Japan 6628719 2016-527006 Issued Japan <br />National Stage 2016-527006<br />Filed on 2016-01-15<br />Status: Issued 147165366 E-495-2013-0 E-495-2013-0-AU-03 Anti-Human Papillomavirus 16 E6 T Cell Receptors National Stage Australia 2014290288 2014290288 Issued Australia <br />National Stage 2014290288<br />Filed on 2014-07-14<br />Status: Issued 147165367 E-495-2013-0 E-495-2013-0-CA-04 Anti-Human Papillomavirus 16 E6 T Cell Receptors National Stage Canada 2918216 2918216 Issued Canada <br />National Stage 2918216<br />Filed on 2014-07-14<br />Status: Issued 147165368 E-495-2013-0 E-495-2013-0-CN-05 Anti-Human Papillomavirus 16 E6 T Cell Receptors National Stage China ZL201480044286.1 201480044286.1 Issued China <br />National Stage 201480044286.1<br />Filed on 2016-02-04<br />Status: Issued 147165369 E-495-2013-0 E-495-2013-0-EP-06 Anti-Human Papillomavirus 16 E6 T Cell Receptors National Stage European Patent 3022223 14748353.1 Issued European Patent <br />National Stage 14748353.1<br />Filed on 2014-07-14<br />Status: Issued 147165370 E-495-2013-0 E-495-2013-0-US-08 Anti-Human Papillomavirus 16 E6 T Cell Receptors National Stage US 9,822,162 14/905,108 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9822162 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9822162">9,822,162</a><br />Filed on 2016-01-14<br />Status: Issued 147165371 E-495-2013-0 E-495-2013-0-US-09 ANTI-HUMAN PAPILLOMAVIRUS 16 E6 T CELL RECEPTORS CON US 10,329,339 15/786,966 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10329339 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10329339">10,329,339</a><br />Filed on 2017-10-18<br />Status: Issued 147165372 E-495-2013-0 E-495-2013-0-EP-10 Anti-Human Papillomavirus 16 E6 T Cell Receptors DIV European Patent 3572423 19180239.6 Issued European Patent <br />Divisional (DIV) 19180239.6<br />Filed on 2019-06-14<br />Status: Issued 147165373 E-495-2013-0 E-495-2013-0-US-11 ANTI-HUMAN PAPILLOMAVIRUS 16 E6 T CELL RECEPTORS CON US 10,913,785 16/408,939 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10913785 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10913785">10,913,785</a><br />Filed on 2019-05-10<br />Status: Issued 147165374 E-495-2013-0 E-495-2013-0-DE-12 Anti-Human Papillomavirus 16 E6 T Cell Receptors EP Germany 3022223 14748353.1 Issued Germany <br />European patent (EP) 14748353.1<br />Filed on 2014-07-14<br />Status: Issued 147165375 E-495-2013-0 E-495-2013-0-ES-13 Anti-Human Papillomavirus 16 E6 T Cell Receptors EP Spain 3022223 14748353.1 Issued Spain <br />European patent (EP) 14748353.1<br />Filed on 2014-07-14<br />Status: Issued 147165376 E-495-2013-0 E-495-2013-0-FR-14 Anti-Human Papillomavirus 16 E6 T Cell Receptors EP France 3022223 14748353.1 Issued France <br />European patent (EP) 14748353.1<br />Filed on 2014-07-14<br />Status: Issued 147165377 E-495-2013-0 E-495-2013-0-GB-15 Anti-Human Papillomavirus 16 E6 T Cell Receptors EP United Kingdom 3022223 14748353.1 Issued United Kingdom <br />European patent (EP) 14748353.1<br />Filed on 2014-07-14<br />Status: Issued 147165378 E-495-2013-0 E-495-2013-0-IE-16 Anti-Human Papillomavirus 16 E6 T Cell Receptors EP Ireland 3022223 14748353.1 Issued Ireland <br />European patent (EP) 14748353.1<br />Filed on 2014-07-14<br />Status: Issued 147165379 E-495-2013-0 E-495-2013-0-IT-17 Anti-Human Papillomavirus 16 E6 T Cell Receptors EP Italy 3022223 14748353.1 Issued Italy <br />European patent (EP) 14748353.1<br />Filed on 2014-07-14<br />Status: Issued 147165380 E-495-2013-0 E-495-2013-0-CN-18 ANTI-HUMAN PAPILLOMAVIRUS 16 E6 T CELL RECEPTORS DIV China ZL201910649441.7 201910649441.7 Issued China <br />Divisional (DIV) 201910649441.7<br />Filed on 2019-07-18<br />Status: Issued 147165381 E-495-2013-0 E-495-2013-0-JP-19 Anti-Human Papillomavirus 16 E6 T Cell Receptors DIV Japan 6959970 2019-219105 Issued Japan <br />Divisional (DIV) 2019-219105<br />Filed on 2019-12-03<br />Status: Issued 147165382 E-495-2013-0 E-495-2013-0-HK-20 Anti-Human Papillomavirus 16 E6 T Cell Receptors EP Hong Kong HK40018191B 42020008016.6 Issued Hong Kong <br />European patent (EP) 42020008016.6<br />Filed on 2020-05-25<br />Status: Issued 147165383 E-495-2013-0 E-495-2013-0-HK-21 Anti-Human Papillomavirus 16 E6 T Cell Receptors CN Hong Kong HK40016948B 42020007152.0 Issued Hong Kong <br />China Patent (CN) 42020007152.0<br />Filed on 2020-05-09<br />Status: Issued 147165384 E-495-2013-0 E-495-2013-0-US-22 ANTI-HUMAN PAPILLOMAVIRUS 16 E6 T CELL RECEPTORS CON US 11,697,676 17/142,486 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11697676 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11697676">11,697,676</a><br />Filed on 2021-01-06<br />Status: Issued 147165385 E-495-2013-0 E-495-2013-0-JP-23 Anti-Human Papillomavirus 16 E6 T Cell Receptors DIV Japan 7223822 2021-166407 Issued Japan <br />Divisional (DIV) 2021-166407<br />Filed on 2021-10-08<br />Status: Issued 147165386 E-495-2013-0 E-495-2013-0-JP-01 Anti-Human Papillomavirus 16 E6 T Cell Receptors DIV Japan Administratively Closed Japan <br />Divisional (DIV) None<br />Filed on None<br />Status: Administratively Closed 147165387 E-495-2013-0 E-495-2013-0-US-02 ANTI-HUMAN PAPILLOMAVIRUS 16 E6 T CELL RECEPTORS CON US 12,187,779 18/323,493 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12187779 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12187779">12,187,779</a><br />Filed on 2023-05-25<br />Status: Issued 147174883 act 147174884 adoptive cell therapy 147174885 Cervical cancer 147174886 E6 147174887 HLA-A*02 147174888 HPV 147174889 Human Papillomavirus 147174890 Major Histocompatibility Complex 147174891 MALIGNANCY 147174892 MHC 147174893 ONCOPROTEIN 147174894 Rosenberg 147174895 T Cell Receptor 147174896 TCR TAB-3935 147157215 Optical Configuration Methods for Spectral Scatter Flow Cytometry NCI Cardiology, Collaboration, Immunology, Infectious Disease, Licensing, Research Materials Cardiology Collaboration Immunology Infectious Disease Licensing Research Materials Jay Berzofsky, Jennifer Jones, Ariel ("Ari") Rosner, William Telford, Joshua Welsh <h2>Summary:</h2> <p>The inventors are constructing a prototype system and seek licensing or co-development opportunities from commercial flow cytometry platforms to optimize the invention for use in combination with their proprietary platforms.</p> <h2>Description of Technology:</h2> <p>Multi-parameter flow cytometry has been extensively used in multiple disciplines of biological discoveries, including immunology and cancer research. However, the disadvantage of traditional flow cytometry platforms using excitation lasers and fluorescence detectors is spectral overlap when using multiple dyes on the same biological sample. Metaethical compensation of spectral overlap could only be effective to a certain degree. Mass cytometry is advantageous compared to flow cytometry but is pricey and requires highly skilled operators.&nbsp;</p> <p>The inventors from the National Cancer Institute (NCI) developed a new flow cytometry protype using molecular NanoTags. NanoTags are nano-sized cytometric labels detectable individually or quantitatively enumerated based on their intrinsic light scattering or fluorescence properties. They are modularly designed to embody distinctive light scattering, fluorescence, and epitope specificity properties. Because NanoTags are modular, they can be comprised of different nanomaterials &ndash; each with identifiable and distinctive light scattering spectral properties across a wide range of wavelengths. Using the unique property of NanoTags, the inventors have tested three unique configurations. Configuration #1, &ldquo;Spectral Scatter Cytometer,&rdquo; is designed for full spectral scatter flow cytometry and would implement a supercontinuum white laser providing illumination at all UV-visible wavelengths. Configuration #2, &ldquo;Co-linear Laser Alignment,&rdquo; involves the co-linear alignment of at least two monochromatic lasers onto the core stream of standard flow cytometry.&nbsp; Configuration #3, &ldquo;Spatially Separated Lasers with Slit Apertures,&rdquo; involves a white-light laser, with its wavelengths spatially separated or part of standard, multi-monochromatic laser flow cytometry. Configuration #3 has the potential of being built to stand alone or add on to existing flow cytometers, providing high-throughput sample characterization with improved resolution.&nbsp;</p> <h2>Potential Commercial Applications:</h2> <ul> <li>High-throughput sample characterization with flow cytometry</li> <li>Adaptable for other cytometric and microfluidic systems for enhanced detection</li> <li>Next generation cytometers&rsquo; configuration</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Enables single molecule detection in flow cytometry</li> <li>Identifying, quantifying and separating different subsets of extracellular vesicles and viruses</li> <li>Enable enhanced development of biomarkers, diagnostic and imaging products</li> </ul> 2022-01-21 2026-04-23 2022-01-21 2026-04-23 2022-01-21 flow cytometry, High-throughput Characterization, Jones, Molecular NanoTag, Multispectral Detection, Optical Configuration False True Prototype True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2022-01-21 52406769 Prototype 52406769 NCI 37470483 Website Abstract E-238-2015 147162926 Jones, Jennifer NIH - NCI NCI Jones, Jennifer (NCI) 1 147162928 Welsh, Joshua NIH - NCI NCI Welsh, Joshua (NCI) 2 147162927 Telford, William NIH - NCI NCI Telford, William (NCI) 3 147162924 Berzofsky, Jay NIH - NCI NCI Berzofsky, Jay (NCI) 4 147162925 Rosner, Ariel ("Ari") NIH - NCI Rosner, Ariel ("Ari") 5 147162926 Jones, Jennifer NIH - NCI NCI Jones, Jennifer (NCI) 1 147162928 Welsh, Joshua NIH - NCI NCI Welsh, Joshua (NCI) 2 147162927 Telford, William NIH - NCI NCI Telford, William (NCI) 3 147162924 Berzofsky, Jay NIH - NCI NCI Berzofsky, Jay (NCI) 4 147162925 Rosner, Ariel ("Ari") NIH - NCI Rosner, Ariel ("Ari") 5 147157777 Optical Configuration Device And Methods For Spectral Scatter Cytometry E-008-2018-0 Filing authorized NCI 83724826 Pollard, Ricquita ricquita.pollard@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-3935] Optical Configuration Methods for Spectral Scatter Flow Cytometry&body=Please send me information about technology [TAB-3935] Optical Configuration Methods for Spectral Scatter Flow Cytometry.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollard, Ricquita<br><a href="mailto:ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-3935] Optical Configuration Methods for Spectral Scatter Flow Cytometry&body=Please send me information about technology [TAB-3935] Optical Configuration Methods for Spectral Scatter Flow Cytometry.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">ricquita.pollard@nih.gov</a><br> 147160890 E-008-2018-0 E-008-2018-0-US-07 OPTICAL CONFIGURATION METHODS FOR SPECTRAL SCATTER FLOW CYTOMETRY National Stage US 10,876,955 16/756,420 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10876955 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10876955">10,876,955</a><br />Filed on 2020-04-15<br />Status: Issued 147165396 E-008-2018-0 E-008-2018-0-US-01 OPTICAL CONFIGURATION METHODS FOR SPECTRAL SCATTER FLOW CYTOMETRY PRV US 62/575,988 Abandoned US <br />Provisional (PRV) 62/575,988<br />Filed on 2017-10-23<br />Status: Abandoned 147165397 E-008-2018-0 E-008-2018-0-PCT-02 OPTICAL CONFIGURATION METHODS FOR SPECTRAL SCATTER FLOW CYTOMETRY PCT Patent Cooperation Treaty PCT/US2018/057128 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2018/057128<br />Filed on 2018-10-23<br />Status: Expired 147165398 E-008-2018-0 E-008-2018-0-CN-03 OPTICAL CONFIGURATION METHODS FOR SPECTRAL SCATTER FLOW CYTOMETRY National Stage China ZL201880069066.2 201880069066.2 Issued China <br />National Stage 201880069066.2<br />Filed on 2018-10-23<br />Status: Issued 147165399 E-008-2018-0 E-008-2018-0-EP-04 OPTICAL CONFIGURATION METHODS FOR SPECTRAL SCATTER FLOW CYTOMETRY National Stage European Patent 3701246 18808559.1 Issued European Patent <br />National Stage 18808559.1<br />Filed on 2018-10-23<br />Status: Issued 147165400 E-008-2018-0 E-008-2018-0-JP-05 OPTICAL CONFIGURATION METHODS FOR SPECTRAL SCATTER FLOW CYTOMETRY National Stage Japan 6788148 2020-522670 Issued Japan <br />National Stage 2020-522670<br />Filed on 2020-04-21<br />Status: Issued 147165401 E-008-2018-0 E-008-2018-0-KR-06 OPTICAL CONFIGURATION METHODS FOR SPECTRAL SCATTER FLOW CYTOMETRY National Stage South Korea 10-2182575 10-2020-7011517 Issued South Korea <br />National Stage 10-2020-7011517<br />Filed on 2020-04-21<br />Status: Issued 147165402 E-008-2018-0 E-008-2018-0-DE-08 OPTICAL CONFIGURATION METHODS FOR SPECTRAL SCATTER FLOW CYTOMETRY EP Germany 3701246 18808559.1 Issued Germany <br />European patent (EP) 18808559.1<br />Filed on 2018-10-23<br />Status: Issued 147165403 E-008-2018-0 E-008-2018-0-FR-09 OPTICAL CONFIGURATION METHODS FOR SPECTRAL SCATTER FLOW CYTOMETRY EP France 3701246 18808559.1 Issued France <br />European patent (EP) 18808559.1<br />Filed on 2018-10-23<br />Status: Issued 147165404 E-008-2018-0 E-008-2018-0-GB-10 OPTICAL CONFIGURATION METHODS FOR SPECTRAL SCATTER FLOW CYTOMETRY EP United Kingdom 3701246 18808559.1 Issued United Kingdom <br />European patent (EP) 18808559.1<br />Filed on 2018-10-23<br />Status: Issued 147165405 E-008-2018-0 E-008-2018-0-NL-11 OPTICAL CONFIGURATION METHODS FOR SPECTRAL SCATTER FLOW CYTOMETRY EP The Netherlands 3701246 18808559.1 Issued The Netherlands <br />European patent (EP) 18808559.1<br />Filed on 2018-10-23<br />Status: Issued 147169352 flow cytometry 147169354 High-throughput Characterization 147169356 Jones 147169358 Molecular NanoTag 147169360 Multispectral Detection 147169362 Optical Configuration TAB-3957 147157237 Biomarker Analysis Software for High-Throughput Diagnostic Multiplex Data NCI Collaboration, Licensing, Oncology, Software / Apps Collaboration Licensing Oncology Software / Apps Jay Berzofsky, Jennifer Jones, Joshua Welsh <h2>Summary:</h2> <p>The NCI seeks research co-development partners and/or licensees for a biomarker analysis software for high-throughput diagnostic multiplex data.</p> <h2>Description of Technology:</h2> <p>Extracellular vesicles (EVs) are lipid bilayer-enclosed particles that are released from cells. EVs may contain proteins derived from their cells of origin with the potential as diagnostic biomarkers indicating the state of the cells when released. However, due to their small size (50-1000nm), the methods currently used to phenotype EVs have limited sensitivity and scale. A need exists for development of novel technologies improving EV detection and phenotyping.</p> <p>National Cancer Institute (NCI) scientists have developed a software package to perform high-throughput multi-dimensional analysis of EVs. The software utilizes a multiplex bead-based approach, coupled with secondary markers, clinical data, and -omics data. This technology provides a mechanism for high-throughput, semi-automated multidimensional data analysis for potential diagnostic and prognostic outcomes. The inventors used the software to identify and visualize a broad range of EV subsets, while also indirectly measuring specific EV populations. Exploratory studies confirmed strong correlations of liquid biopsy EV repertoires with tumor burden and responses to treatment. Furthermore, this software allows a scalable method of using EVs as biomarkers in a highly multiplexed fashion. When coupled with other clinical data, it is a useful means of diagnostic and/or prognostic outcomes.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Software package for high-throughput screening of extracellular vesicles as diagnostic and prognostic markers in personalized medicine.</li> <li>Can be utilized as software interface for other multiplex assays</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Allows for high-throughput, multiplexed and semi-automated analysis of extracellular vesicles and cargo protein.</li> <li>Utilizes secondary markers, clinical data and -omics data to provide diagnostic and/or prognostic determinations.</li> </ul> 2022-02-23 2026-04-23 2022-02-23 2026-04-23 2022-02-23 Berzofsky, Biomarker, EV, Extracellular Vesicles, High-throughput, Jones, Lipid Bilayer-Enclosed Particles, software False True Prototype True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2022-02-23 52406769 Prototype 52406769 NCI 37470483 Website Abstract 147161957 Welsh JA et al. MPAPASS software enables stitched multiplex, multidimensional EV repertoire analysis and a standard framework for reporting bead-based assays. https://doi.org/10.1016/j.crmeth.2021.100136 <a href="https://doi.org/10.1016/j.crmeth.2021.100136">Welsh JA et al. MPAPASS software enables stitched multiplex, multidimensional EV repertoire analysis and a standard framework for reporting bead-based assays.</a> 147163014 Welsh, Joshua NIH - NCI NCI Welsh, Joshua (NCI) 1 147163013 Jones, Jennifer NIH - NCI NCI Jones, Jennifer (NCI) 2 147163012 Berzofsky, Jay NIH - NCI NCI Berzofsky, Jay (NCI) 3 147163014 Welsh, Joshua NIH - NCI NCI Welsh, Joshua (NCI) 1 147163013 Jones, Jennifer NIH - NCI NCI Jones, Jennifer (NCI) 2 147163012 Berzofsky, Jay NIH - NCI NCI Berzofsky, Jay (NCI) 3 147157995 Biomarker Analysis Software For High-Throughput Diagnostic Multiplex Data E-105-2018-0 Filing authorized NCI 83724826 Pollard, Ricquita ricquita.pollard@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-3957] Biomarker Analysis Software for High-Throughput Diagnostic Multiplex Data&body=Please send me information about technology [TAB-3957] Biomarker Analysis Software for High-Throughput Diagnostic Multiplex Data.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollard, Ricquita<br><a href="mailto:ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-3957] Biomarker Analysis Software for High-Throughput Diagnostic Multiplex Data&body=Please send me information about technology [TAB-3957] Biomarker Analysis Software for High-Throughput Diagnostic Multiplex Data.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">ricquita.pollard@nih.gov</a><br> 147161045 E-105-2018-0 E-105-2018-0-US-01 Biomarker Analysis Software For High-Throughput Diagnostic Multiplex Data PRV US 62/650,162 Abandoned US <br />Provisional (PRV) 62/650,162<br />Filed on 2018-03-29<br />Status: Abandoned 147165544 E-105-2018-0 E-105-2018-0-PCT-02 Biomarker Analysis Software For High-Throughput Diagnostic Multiplex Data PCT Patent Cooperation Treaty PCT/US2019/024975 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2019/024975<br />Filed on 2019-03-29<br />Status: Expired 147165545 E-105-2018-0 E-105-2018-0-AU-03 BIOMARKER ANALYSIS FOR HIGH-THROUGHPUT DIAGNOSTIC MULTIPLEX DATA National Stage Australia 2019245402 Pending Australia <br />National Stage 2019245402<br />Filed on 2019-03-29<br />Status: Pending 147165546 E-105-2018-0 E-105-2018-0-CA-04 Biomarker Analysis Software For High-Throughput Diagnostic Multiplex Data National Stage Canada 3095485 3095485 Issued Canada <br />National Stage 3095485<br />Filed on 2020-09-28<br />Status: Issued 147165547 E-105-2018-0 E-105-2018-0-EP-05 Biomarker Analysis Software For High-Throughput Diagnostic Multiplex Data National Stage European Patent 3775897 19717657.1 Issued European Patent <br />National Stage 19717657.1<br />Filed on 2020-10-29<br />Status: Issued 147165548 E-105-2018-0 E-105-2018-0-US-06 Biomarker Analysis Software For High-Throughput Diagnostic Multiplex Data National Stage US 17/042,765 Abandoned US <br />National Stage 17/042,765<br />Filed on 2020-09-28<br />Status: Abandoned 159504200 E-105-2018-0 E-105-2018-0-ES-07 Biomarker Analysis Software For High-Throughput Diagnostic Multiplex Data EP Spain 3775897 19717657.1 Issued Spain <br />European patent (EP) 19717657.1<br />Filed on 2020-10-29<br />Status: Issued 159504634 E-105-2018-0 E-105-2018-0-FR-08 Biomarker Analysis Software For High-Throughput Diagnostic Multiplex Data EP France 3775897 19717657.1 Issued France <br />European patent (EP) 19717657.1<br />Filed on 2020-10-29<br />Status: Issued 159504645 E-105-2018-0 E-105-2018-0-DK-09 Biomarker Analysis Software For High-Throughput Diagnostic Multiplex Data EP Denmark 3775897 19717657.1 Issued Denmark <br />European patent (EP) 19717657.1<br />Filed on 2020-10-29<br />Status: Issued 159504650 E-105-2018-0 E-105-2018-0-IT-10 Biomarker Analysis Software For High-Throughput Diagnostic Multiplex Data EP Italy 3775897 19717657.1 Issued Italy <br />European patent (EP) 19717657.1<br />Filed on 2020-10-29<br />Status: Issued 159504661 E-105-2018-0 E-105-2018-0-DE-11 Biomarker Analysis Software For High-Throughput Diagnostic Multiplex Data EP Germany 3775897 19717657.1 Issued Germany <br />European patent (EP) 19717657.1<br />Filed on 2020-10-29<br />Status: Issued 159504666 E-105-2018-0 E-105-2018-0-NL-14 Biomarker Analysis Software For High-Throughput Diagnostic Multiplex Data EP The Netherlands 3775897 19717657.1 Issued The Netherlands <br />European patent (EP) 19717657.1<br />Filed on 2020-10-29<br />Status: Issued 159504671 E-105-2018-0 E-105-2018-0-CH-13 Biomarker Analysis Software For High-Throughput Diagnostic Multiplex Data EP Switzerland 3775897 19717657.1 Issued Switzerland <br />European patent (EP) 19717657.1<br />Filed on 2020-10-29<br />Status: Issued 159504683 E-105-2018-0 E-105-2018-0-GB-12 Biomarker Analysis Software For High-Throughput Diagnostic Multiplex Data EP United Kingdom 3775897 19717657.1 Issued United Kingdom <br />European patent (EP) 19717657.1<br />Filed on 2020-10-29<br />Status: Issued 147171496 Berzofsky 147171497 Biomarker 147171498 EV 147171499 Extracellular Vesicles 147171500 High-throughput 147171501 Jones 147171503 Lipid Bilayer-Enclosed Particles 147171504 software TAB-4029 147157310 Nanobodies Neutralizing Lassa Virus NCI Collaboration, Infectious Disease, Licensing, Therapeutics Collaboration Infectious Disease Licensing Therapeutics Sao "Crystal" Cheung, Zhijian Duan, Jason Gorman, Mitchell Ho, Peter Kwong, Yaping Sun <h2>Summary:</h2> <p>Researchers at the National Cancer Institute (NCI) seek parties interested in collaborative research and/or licensing to further develop neutralizing nanobodies targeting Lassa virus.</p> <h2>Description of Technology:</h2> <p>Lassa Hemorrhagic Fever (LHF) is a serious disease caused by infection with Lassa virus (LASV) &ndash; highly prevalent in West Africa and spreading globally. LASV is associated with high morbidity and mortality rates, annually infecting 100,000 to 300,000 individuals and causing 5,000 deaths. Developing prophylactics and treatment for LASV is difficult due to challenges in inducing neutralizing antibodies and producing their target, the LASV glycoprotein trimer (GPC). LASV poses a severe public health threat with infections expanding outside the traditional endemic areas and no LHF- specific vaccines or therapies.</p> <p>Researchers at NCI&rsquo;s Laboratory of Molecular Biology, in collaboration with the Vaccine Research Center at the National Institute of Allergy and Infectious Diseases, developed and isolated six nanobodies with high binding affinity for the LASV envelop protein. Nanobodies are the smallest known antigen-binding fragments of antibodies. They have great potential as research tools and in medical applications due to their (1) small size, (2) high solubility, (3) thermal stability, (4) refolding capacity, and (5) relatively easy tissue penetration,.&nbsp;</p> <p>The nanobodies D5 and C3 show the most potent neutralizing activities. These nanobodies neutralized LASV Josiah pseduotyped virus when prepared in a bivalent IgG2a format as human IgG Fc-fusion. Overall, it is evident that the nanobodies can be used and developed into therapeutics that that neutralize Lassa virus.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Therapeutics against Lassa virus infection</li> <li>Lassa virus diagnostics (in vivo virus imaging)</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>No LSV-specific vaccines or treatments</li> <li>First stabilized, soluble LASV glycoprotein trimer</li> <li>Nanobodies with high affinity for the LASV GPC trimer</li> <li>Nanobodies compete with 4 different groups of human neutralizing antibodies</li> <li>Nanobodies neutralize LASV when prepared in a human IgG Fc-fusion</li> </ul> 2022-04-12 2026-04-23 2022-04-12 2026-04-23 2022-04-12 antibodies, diagnostic, HO, LASSA, Lassa Hemorrhagic Fever, LHF, Nanobodies, Neutralizing, virus False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2022-04-12 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147163277 Ho, Mitchell NIH - NCI NCI Ho, Mitchell (NCI) 1 147163276 Kwong, Peter NIH - NIAID NIAID Kwong, Peter (NIAID) 2 147163280 Duan, Zhijian NCI - CCR NCI Duan, Zhijian (NCI) 3 147163281 Sun, Yaping NCI - CCR NCI Sun, Yaping (NCI) 4 147163279 Cheung, Sao "Crystal" NIH - NIAID NIAID Cheung, Sao "Crystal" (NIAID) 5 147163278 Gorman, Jason NIH - NIAID NIAID Gorman, Jason (NIAID) 6 147163277 Ho, Mitchell NIH - NCI NCI Ho, Mitchell (NCI) 1 147163276 Kwong, Peter NIH - NIAID NIAID Kwong, Peter (NIAID) 2 147163280 Duan, Zhijian NCI - CCR NCI Duan, Zhijian (NCI) 3 147163281 Sun, Yaping NCI - CCR NCI Sun, Yaping (NCI) 4 147163279 Cheung, Sao "Crystal" NIH - NIAID NIAID Cheung, Sao "Crystal" (NIAID) 5 147163278 Gorman, Jason NIH - NIAID NIAID Gorman, Jason (NIAID) 6 147157986 Nanobodies Neutralizing Lassa Virus E-099-2021-0 Filing authorized NCI, NIAID 83731987 Dhal, Abritee abritee.dhal@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-4029] Nanobodies Neutralizing Lassa Virus&body=Please send me information about technology [TAB-4029] Nanobodies Neutralizing Lassa Virus.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dhal, Abritee<br><a href="mailto:abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-4029] Nanobodies Neutralizing Lassa Virus&body=Please send me information about technology [TAB-4029] Nanobodies Neutralizing Lassa Virus.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">abritee.dhal@nih.gov</a><br> 147161037 E-099-2021-0 E-099-2021-0-US-01 LASSA VIRUS-SPECIFIC NANOBODIES AND METHODS OF THEIR USE PRV US 63/181,519 Abandoned US <br />Provisional (PRV) 63/181,519<br />Filed on 2021-04-29<br />Status: Abandoned 147166111 E-099-2021-0 E-099-2021-0-PCT-02 LASSA VIRUS-SPECIFIC NANOBODIES AND METHODS OF THEIR USE PCT Patent Cooperation Treaty PCT/US2022/027082 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2022/027082<br />Filed on 2022-04-29<br />Status: Expired 147171405 antibodies 147171406 diagnostic 147171407 HO 147171408 LASSA 147171410 Lassa Hemorrhagic Fever 147171412 LHF 147171413 Nanobodies 147171414 Neutralizing 147171415 virus TAB-3568 114097423 Potency Assay for Membrane Transporter Protein-based Drugs Acting on Antioxidant, Redox, and Apoptosis Response Pathways NCI Cardiology, Dental, Endocrinology, Infectious Disease, Oncology, Ophthalmology, Research Materials, Therapeutics Cardiology Dental Endocrinology Infectious Disease Oncology Ophthalmology Research Materials Therapeutics Trevor Broadt, Xiaoyi Yang <h2>Description of Technology:</h2> <p>This technology includes a method of analyzing the potency of membrane transporter protein-based drugs acting on intracellular antioxidant and redox response pathways (and associated apoptosis pathways), wherein the drug delivery and activity is lipid associated. The present invention is a cell-based bioassay for measuring the bioactivity of drug substance and formulated drug product by determining the drug&#39;s dose-dependent inhibitory effects on 4 hydroxynonenal (4-HNE)-induced antioxidant response element (ARE) activity. The present invention covers use of HEK293 ARE-Luc Stable cell line as the detection system, high-throughput 96-well format, drug dilution approach, enclosure of negative controls with non-relevant heterologous proteins, use of the stimulator 4-HNE, and the optimal measurement time points with the ARE luciferase reporter gene. This is also an effective method to make liposome-drug substance mixtures for assembly of drug substance proteins into cellular membranes by using premade empty liposomes as a drug delivery system.</p> This method standardizes the analysis of the potency of RLIP76-based drug substance and drug product in a dose-dependent manner during the manufacturing process, release, and stability monitoring of RLIP76 and similar molecules. Applications include potency analysis of drug substance and drug product of membrane transporter protein-based drugs, such as RLIP76, acting on antioxidant and redox response pathways during the process, release, and stability monitoring. 2022-08-01 2026-04-23 2026-04-23 2022-08-01 ACTING, ANTIOXIDANT, APOPTOSIS, assay, DRUGS, MEMBRANE, PATHWAYS, POTENCY, Protein-based, Redox, RESPONSE, TRANSPORTER, VPXXXX, WIXXXX, WKXXXX False True True NIHTT 37470483 Website Abstract 114110830 Broadt, Trevor NCI - FCRDC (Leidos) Leidos Broadt, Trevor (Leidos) 0 114110829 Yang, Xiaoyi NCI - CCR Leidos Yang, Xiaoyi (Leidos) 1 114110829 Yang, Xiaoyi NCI - CCR Leidos Yang, Xiaoyi (Leidos) 1 114110830 Broadt, Trevor NCI - FCRDC (Leidos) Leidos Broadt, Trevor (Leidos) 0 114102677 Potency Assay For Membrane Transporter Protein-based Drugs Acting On Antioxidant, Redox, And Apoptosis Response Pathways E-225-2018-0 Filing authorized NCI 83682485 Vepa, Suryanarayana sury.vepa@nih.gov
United States of America Office of Strategic Alliances (OSA) sury.vepa@nih.gov?subject=Web Inquiry on [TAB-3568] Potency Assay for Membrane Transporter Protein-based Drugs Acting on Antioxidant, Redox, and Apoptosis Response Pathways&body=Please send me information about technology [TAB-3568] Potency Assay for Membrane Transporter Protein-based Drugs Acting on Antioxidant, Redox, and Apoptosis Response Pathways. Vepa, Suryanarayana<br><a href="mailto:sury.vepa@nih.gov?subject=Web Inquiry on [TAB-3568] Potency Assay for Membrane Transporter Protein-based Drugs Acting on Antioxidant, Redox, and Apoptosis Response Pathways&body=Please send me information about technology [TAB-3568] Potency Assay for Membrane Transporter Protein-based Drugs Acting on Antioxidant, Redox, and Apoptosis Response Pathways.">sury.vepa@nih.gov</a><br> 114128772 VPXXXX 114128773 WIXXXX 114128774 WKXXXX 114153251 POTENCY 114153252 assay 114153253 MEMBRANE 114153254 TRANSPORTER 114153255 Protein-based 114153256 DRUGS 114153257 ACTING 114153258 ANTIOXIDANT 114153259 Redox 114153260 APOPTOSIS 114153261 RESPONSE 114153262 PATHWAYS TAB-3897 147157177 National Cancer Institute dosimetry system for Computed Tomography (NCICT) Computer Program NCI Infectious Disease, Licensing, Neurology, Oncology, Software / Apps Infectious Disease Licensing Neurology Oncology Software / Apps <h2>Description of Technology:</h2> <p>About half of the per capita dose of radiation due to medical exposures is provided by computed tomography (CT) examinations. Approximately 80 million CTs are performed annually in the United States. CT scans most commonly look for internal bleeding or clots, abscesses due to infection, tumors and internal structures. Although CT provides great patient benefit, concerns exist about potential associated risks from radiation doses &ndash; especially in pediatric patients more sensitive to radiation. Better understanding of the magnitude of radiation dose delivered during CT examinations is crucial to estimate risks and make an informed clinical decisions. However, calculating organ radiation doses to be delivered to patients is complicated.</p> <p>To address these challenges, Dr. Choonsik Lee from the NCI developed a novel computer program with a graphical user interface (GUI) to interactively estimate radiation dose to the organs of patients undergoing CT examinations. The computer program provides radiation dose to 30 different radiosensitive organs and tissues in the human body by using data entered by users. These data include patient characteristics (age and sex) and CT scan data (scanner model and technical parameters). The calculation algorithm in the program is based on multiple datasets with international standard, human anatomy, and dosimetry data. Potential users of this computer program would include radiologists, clinical/research medical physicists, physicians, epidemiologists and other medical professionals.</p> <p>The NCI dosimetry system for Computed Tomography (NCICT) successfully converts existing CT scanner output &ndash; very simple to obtain &ndash; into organ radiation doses. NCICT makes it possible for vendors to incorporate this software program into their patient dose-monitoring systems. The NCI seeks licensees interested in estimating radiation doses and potential risks to the organs of CT patients</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Radiation dose calculations for computed tomography examinations</li> <li>Components can be incorporated with NCIDose software into a commercial platform: NCICT program, computational human phantom series (human anatomy models, electronic files), CT scanner simulation model, and organ dose library (tabulated numbers)</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Easily implemented within the existing commercial solutions</li> <li>Estimates organ doses for pediatric and adult patients with various body sizes and pregnant women</li> <li>Runs on standard Windows, Macintosh, and LINUX operating systems</li> </ul> Researchers at the NCI seek licensing for a novel computer program that converts existing CT scan output into organ radiation doses. 2023-05-14 2026-04-23 2023-05-14 2026-04-23 2023-05-14 • Computed Tomography, CT, CT Examination, Dosimetry, Lee, NCI dosimetry system for Computed Tomography, NCICT, Radiation, Radiation Dosing False True Clinical True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2023-05-14 72159138 Clinical Phase I 72159138 NCI 37470483 Website Abstract E-125-2019 E-127-2023 147162303 Lee C, et al. NCICT: a computational solution to estimate organ doses for pediatric and adult patients undergoing CT scans https://pubmed.ncbi.nlm.nih.gov/26609995/ <a href="https://pubmed.ncbi.nlm.nih.gov/26609995/">Lee C, et al. NCICT: a computational solution to estimate organ doses for pediatric and adult patients undergoing CT scans</a> 155750673 National Cancer Institute Dosimetry System For Computed Tomography (NCICT) Computer Program E-082-2016-0 Research Material NCI, University of Florida 83691647 Chang, Kevin changke@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB changke@mail.nih.gov?subject=Web Inquiry on [TAB-3897] National Cancer Institute dosimetry system for Computed Tomography (NCICT) Computer Program&body=Please send me information about technology [TAB-3897] National Cancer Institute dosimetry system for Computed Tomography (NCICT) Computer Program.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Chang, Kevin<br><a href="mailto:changke@mail.nih.gov?subject=Web Inquiry on [TAB-3897] National Cancer Institute dosimetry system for Computed Tomography (NCICT) Computer Program&body=Please send me information about technology [TAB-3897] National Cancer Institute dosimetry system for Computed Tomography (NCICT) Computer Program.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">changke@mail.nih.gov</a><br> 147171020 • Computed Tomography 147171021 CT 147171023 CT Examination 147171024 Dosimetry 147171026 Lee 147171028 NCI dosimetry system for Computed Tomography 147171029 NCICT 147171030 Radiation 147171032 Radiation Dosing TAB-4471 151021571 A Wearable Device for Monitoring Pregnancy Health NICHD Application, Collaboration, Licensing, Medical Devices, Reproductive Health Application Collaboration Licensing Medical Devices Reproductive Health George Downey, Amir Gandjbakhche, Kosar Khaksari, Alireza Khaligh, Thien Nguyen, Soongho Park, Zeyu Zhang <h2>Summary:&nbsp;</h2> <p>The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) seeks research co-development partners and/or licensees for clinical validation and to further develop the technology.&nbsp;</p> <h2>Description of Technology:&nbsp;</h2> <p>Observing the placenta during pregnancy offers a look into the utero fetal environment. Monitoring placental oxygenation level and maternal physiological signals can be useful to assess mother and fetus well-being during pregnancy. Additionally, fetal movement has long served as a measure for well-being and nervous system development helping identify adverse pregnancy outcomes. Identification of complications during pregnancy can allow for earlier interventions, including medications to reduce risk of perinatal mortality and maternal gene therapy. Current non-invasive techniques on available are considered expensive, bulky, and do not offer continuous monitoring of fetal physiological signals and placental oxygenation. There is an unmet need for a convenient way for mothers to safely monitor their pregnancy remotely.&nbsp;</p> <p>Researchers created a wearable, wireless device and protocol for continuously monitoring the placental oxygenation levels, multiple physiological signals and movement activities of a fetus and mother. The device includes a compact control board, flexible near-infrared spectroscopy (NIRS) probe and multiple accelerator probes. A classification algorithm based on Monte-Carlo simulations of multiple layers model computes oxygen saturation of the placenta. There is one or more accelerator probes attached to different body parts of the mother to detect mother movement activities and to eliminate the effect of mother movement on fetal movement. The overall data acquisition rate of this device is 10 Hz or more. With this acquisition rate, the output of the device contains extra physiological signal such as maternal respiratory and cardiac functions, and fetal cardiac functions.&nbsp;</p> <p>The NICHD seeks research co-development partners and/or licensees for clinical validation and to further develop the technology.</p> <h2>Potential Commercial Applications:&nbsp;</h2> <ul> <li>Low cost and flexible method of continuously monitoring pregnancy health</li> <li>Early identification of adverse outcomes such as reduced uteroplacental perfusion and stillbirth</li> <li>Potential for device to be applied in general health monitoring or sleep monitoring&nbsp;</li> <li>Daily measurement results may be collected by a cellphone and uploaded to cloud for patient&rsquo;s healthcare provider to remotely review and provide health suggestions</li> </ul> <h2>Competitive Advantage:</h2> <ul> <li>Wearable and non-invasive placenta and fetal monitoring device</li> <li>Capable of 24/7 monitoring of mother and fetal well-being</li> <li>Low power consumption&nbsp;</li> <li>Monitors both maternal and fetal multiple physiological signals and movement activities</li> </ul> Researchers at the NICHD seek licensing and/or co-development research collaborations for clinical validation and to further develop the technology. 2023-10-25 2026-04-23 2026-04-23 2023-11-27 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 151545526 Gandjbakhche, Amir NICHD NICHD Gandjbakhche, Amir (NICHD) 1 151545616 Nguyen, Thien NICHD NICHD Nguyen, Thien (NICHD) 2 151021496 Zhang, Zeyu AmpX Technologies, Inc. Zhang, Zeyu 3 151021500 Park, Soongho NICHD NICHD Park, Soongho (NICHD) 4 151021646 Downey, George AmpX Technologies, Inc. Downey, George 5 151021650 Khaligh, Alireza AmpX Technologies, Inc. Khaligh, Alireza 6 151587921 Khaksari, Kosar NICHD Khaksari, Kosar 7 151545526 Gandjbakhche, Amir NICHD NICHD Gandjbakhche, Amir (NICHD) 1 151545616 Nguyen, Thien NICHD NICHD Nguyen, Thien (NICHD) 2 151021496 Zhang, Zeyu AmpX Technologies, Inc. Zhang, Zeyu 3 151021500 Park, Soongho NICHD NICHD Park, Soongho (NICHD) 4 151021646 Downey, George AmpX Technologies, Inc. Downey, George 5 151021650 Khaligh, Alireza AmpX Technologies, Inc. Khaligh, Alireza 6 151587921 Khaksari, Kosar NICHD Khaksari, Kosar 7 151021574 A System And Protocol For Monitoring Pregnancy Health E-198-2022-0 Filing authorized AmpX Technologies, Inc., NICHD 91827321 Jinnah, Zarpheen zarpheen.jinnah@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
zarpheen.jinnah@nih.gov?subject=Web Inquiry on [TAB-4471] A Wearable Device for Monitoring Pregnancy Health&body=Please send me information about technology [TAB-4471] A Wearable Device for Monitoring Pregnancy Health.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Jinnah, Zarpheen<br><a href="mailto:zarpheen.jinnah@nih.gov?subject=Web Inquiry on [TAB-4471] A Wearable Device for Monitoring Pregnancy Health&body=Please send me information about technology [TAB-4471] A Wearable Device for Monitoring Pregnancy Health.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">zarpheen.jinnah@nih.gov</a><br> 151390934 E-198-2022-0 E-198-2022-0-US-01 SYSTEM AND PROTOCOL FOR MONITORING PREGNANCY HEALTH PRV US 63/451,066 Expired US <br />Provisional (PRV) 63/451,066<br />Filed on 2023-03-09<br />Status: Expired 157405584 E-198-2022-0 E-198-2022-0-PC-01 SYSTEM AND PROTOCOL FOR MONITORING PREGNANCY HEALTH PCT Patent Cooperation Treaty PCT/US2024/019168 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2024/019168<br />Filed on 2024-03-08<br />Status: Expired TAB-4472 151021715 A Protocol to Enhance Therapeutic Effects of Transcranial Magnetic Stimulation and the Methods to Realize It NIDA Collaboration, Licensing, Neurology, Therapeutics Collaboration Licensing Neurology Therapeutics Hanbing Lu, Qinglei Meng, Hieu Nguyen, Yihong Yang <h2>Summary:&nbsp;</h2> <p>The National Institute on Drug Abuse (NIDA) seeks research co-development partners and/or licensees for a high-powered electronic device and coil that delivers Transcranial Magnetic Stimulation (TMS) pulses as well as the software that controls the device for treating treatment resistant depression, substance use disorders and other CNS disorders.</p> <h2>Description of Technology:&nbsp;</h2> <p>Transcranial Magnetic Stimulation (TMS) is a non-invasive neuromodulation technique recently cleared by the FDA as a therapy for treatment-resistant major depression, obsessive-compulsive disorder (OCD) and nicotine addiction. Stimulation is produced by passing a brief, strong electric current through a coil placed in close proximity to the patient&rsquo;s head. The coil generates an electric field inside the patient&rsquo;s brain, exciting or inhibiting a targeted region. Repetitive high-frequency TMS at 10 Hz (rTMS) was the first protocol cleared by FDA for depression treatment, while Intermittent Theta Burst Stimulation (iTBS) is a newer protocol recently cleared by the FDA. The rTMS protocol requires 37.5 min per treatment session compared with only 190 seconds for iTBS &ndash; making iTBS much more tolerable to a patient. The therapeutic efficacy between these two protocols is non-distinguishable. However, given the high voltages and currents required in iTBS (e.g., 50 Hz instead of 10 Hz), it is more challenging to implement. In addition, clinical efficacy of TMS treatment overall has been relatively modest, with only about one-third of the patients responding well to the treatment. Enhancing TMS treatment efficacy is of great medical value and broad interest.</p> <p>Researchers at NIDA developed a novel TMS paradigm to enhance the effects of TMS treatment and, in addition, the machine to realize this paradigm. The invention allows specifying a variable number of pulses in each burst (e.g., up to 6 pulses per burst) and having an inter-burst interval of 200 ms (e.g., 5 Hz). The paradigm is based on iTBS but deliveries 6 pulses fixed per burst instead of 3. Thus, the number of TMS pulses delivered is effectively doubled in the same amount of time. Data from in vivo experiments using an awake rat model suggest that, compared with conventional iTBS protocol, this novel TMS paradigm enhance TMS after-effects by up to 92% versus conventional methods. This technology has the potential to greatly improve clinical outcomes of TMS treatment of depression and other neurological and/or psychiatric disorders.</p> <p>The National Institute on Drug Abuse (NIDA) seeks research co-development partners and/or licensees to further develop and commercialize this technology.</p> <h2>Potential Commercial Applications:&nbsp;</h2> <ul> <li>Enhanced TMS therapeutic for treatment resistant depression (MDD)</li> <li>Enhanced TMS therapeutic for treatment resistant obsessive-compulsive disorder (OCD)</li> <li>Enhanced TMS therapeutic for treatment resistant nicotine addiction</li> </ul> <h2>Competitive Advantage:</h2> <ul> <li>Novel TMS paradigm that can improve the outcome of TMS treatment</li> <li>The machine to deliver this paradigm has already been developed</li> <li>This technology delivers the high frequency pulses needed for TMS operations which occur at high current and high voltage (3000 Amperes and 2000 volts), which requires special expertise and is highly valuable</li> <li>This technology provides a new coil design, cooling, and fabrication strategy, and there is a need for new TMS coil development</li> <li>Prototypes have been developed for the technology and successfully validated in a rat modelc</li> </ul> Researchers at the NIDA seek licensing and/or co-development research collaborations for a high-powered electronic device and coil that delivers TMS pulses as well as the software that controls the device for treating treatment resistant depression and other CNS disorders. 2023-10-25 2026-04-23 2026-04-23 2023-10-26 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 151037341 Meng Q, Nguyen H, Vrana A, Baldwin S, Li CQ, Giles A, Wang J, Yang Y, Lu H. A high-density theta burst paradigm enhances the aftereffects of transcranial magnetic stimulation: Evidence from focal stimulation of rat motor cortex. Brain Stimulation. 2022;15(3):833-842. doi: 10.1016/j.brs.2022.05.017. PMID: 35636708 https://pubmed.ncbi.nlm.nih.gov/35636708/ <a href="https://pubmed.ncbi.nlm.nih.gov/35636708/">Meng Q, Nguyen H, Vrana A, Baldwin S, Li CQ, Giles A, Wang J, Yang Y, Lu H. A high-density theta burst paradigm enhances the aftereffects of transcranial magnetic stimulation: Evidence from focal stimulation of rat motor cortex. Brain Stimulation. 2022;15(3):833-842. doi: 10.1016/j.brs.2022.05.017. PMID: 35636708</a> 151037155 Lu, Hanbing NIDA - Biomedical Research Center NIDA Lu, Hanbing (NIDA) 1 151037163 Meng, Qinglei NIDA - Biomedical Research Center Meng, Qinglei 2 151037318 Nguyen, Hieu NIDA - Biomedical Research Center Nguyen, Hieu 3 151037326 Yang, Yihong NIDA - Biomedical Research Center NIDA Yang, Yihong (NIDA) 4 151037155 Lu, Hanbing NIDA - Biomedical Research Center NIDA Lu, Hanbing (NIDA) 1 151037163 Meng, Qinglei NIDA - Biomedical Research Center Meng, Qinglei 2 151037318 Nguyen, Hieu NIDA - Biomedical Research Center Nguyen, Hieu 3 151037326 Yang, Yihong NIDA - Biomedical Research Center NIDA Yang, Yihong (NIDA) 4 151021718 A Protocol To Enhance Therapeutic Effects Of Transcranial Magnetic Stimulation And The Methods To Realize It E-183-2021-0 Filing authorized National Institute on Drug Abuse (NIDA) 91828357 Bernier, Nicholas nicholas.bernier@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America nicholas.bernier@nih.gov?subject=Web Inquiry on [TAB-4472] A Protocol to Enhance Therapeutic Effects of Transcranial Magnetic Stimulation and the Methods to Realize It&body=Please send me information about technology [TAB-4472] A Protocol to Enhance Therapeutic Effects of Transcranial Magnetic Stimulation and the Methods to Realize It.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Bernier, Nicholas<br><a href="mailto:nicholas.bernier@nih.gov?subject=Web Inquiry on [TAB-4472] A Protocol to Enhance Therapeutic Effects of Transcranial Magnetic Stimulation and the Methods to Realize It&body=Please send me information about technology [TAB-4472] A Protocol to Enhance Therapeutic Effects of Transcranial Magnetic Stimulation and the Methods to Realize It.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">nicholas.bernier@nih.gov</a><br> 151037347 E-183-2021-0 E-183-2021-0-US-01 PROTOCOL TO ENHANCE THERAPEUTIC EFFECTS OF TRANSCRANIAL MAGNETIC STIMULATION PRV US 63/286,229 Expired US <br />Provisional (PRV) 63/286,229<br />Filed on 2021-12-06<br />Status: Expired 151037354 E-183-2021-0 E-183-2021-0-US-02 PROTOCOL TO ENHANCE THERAPEUTIC EFFECTS OF TRANSCRANIAL MAGNETIC STIMULATION ORD US 18/076,071 Pending US <br />Ordinary Patent (ORD) 18/076,071<br />Filed on 2022-12-06<br />Status: Pending TAB-5010 158185969 Single Source-Detector Separation Approach to Calculate Tissue Oxygen Saturation NICHD Collaboration, Infectious Disease, Licensing, Medical Devices, Neurology, Respiratory Collaboration Infectious Disease Licensing Medical Devices Neurology Respiratory Amir Gandjbakhche, Brian Hill, Thien Nguyen, Soongho Park <h2>Summary:</h2> <p>The National Institute of Child Health and Human Development (NICHD) seeks partners and/or licensees to further develop and commercialize the miniaturized tissue oximeter for implementing the single source-detector separation algorithm in existing devices/systems to collect tissue oxygen saturation.</p> <h2>Description of Technology:&nbsp;</h2> <p>Tissue oxygen saturation (StO2) is an important parameter to assess oxygen delivery and uptake. Hypoxia, a term used to indicate inadequate StO2, is often seen in patients with cardiac problems, respiratory infections or pulmonary diseases. Prolonged hypoxia can damage vital organs such as the brain, lungs, and heart, and can be fatal. Currently available tissue oximeters to monitor StO2 are expensive and cumbersome.&nbsp;</p> <p>The National Institute of Child Health and Human Development (NICHD) has developed a novel method, which uses a single source-detector separation to calculate StO2. With this technique, a simple tissue oximeter can be made with just a LED and a photodetector, which enables the development of a miniaturized device. As a result, it can be used independently or implemented on existing technologies to measure StO2 without any hardware modifications. It can be applied in wearable devices, implantable medicines or endoscopies to measure tissue oxygenation in different tissues such as muscle, brain, spinal cord, internal organs, fetus and placenta.&nbsp;</p> <p>The NICHD seeks partners and/or licensees to further develop and commercialize the miniaturized tissue oximeter for implementing the single source-detector separation algorithm in existing devices/systems to collect tissue oxygen saturation.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Miniaturized tissue oximeter for implantation or endoscopy</li> <li>Measure tissue oxygen saturation</li> <li>Multilayer tissue oximeter</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Simpler and more compact as it only requires a single light source such as LED and a single photodetector such as a photodetector to build a tissue oximeter</li> <li>Multilayer measurement</li> <li>Implementation with existing technologies without any hardware modifications</li> </ul> Researchers at the NICHD seek licensing and/or co-development research collaborations for the miniaturized tissue oximeter for implementing the single source-detector separation algorithm in existing devices/systems to collect tissue oxygen saturation. 2024-09-13 2026-04-23 2026-04-23 2024-09-13 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 72159138 Clinical Phase I 72159138 NCI 37470483 Website Abstract 158186553 Nguyen, T., et al. Application of the Single Source—Detector Separation Algorithm in Wearable Neuroimaging Devices: A Step toward Miniaturized Biosensor for Hypoxia Detection. (PMID 38671806) https://pubmed.ncbi.nlm.nih.gov/38671806/ <a href="https://pubmed.ncbi.nlm.nih.gov/38671806/">Nguyen, T., et al. Application of the Single Source—Detector Separation Algorithm in Wearable Neuroimaging Devices: A Step toward Miniaturized Biosensor for Hypoxia Detection. (PMID 38671806)</a> 166884104 Nguyen, T., et al. Single Source-Detector Separation Approach to Calculate Tissue Oxygen Saturation Using Continuous Wave Near-infrared Spectroscopy. (DOI 10.1109/OJEMB.2023.3246929) Nguyen, T., et al. Single Source-Detector Separation Approach to Calculate Tissue Oxygen Saturation Using Continuous Wave Near-infrared Spectroscopy. (DOI 10.1109/OJEMB.2023.3246929) 158186011 Nguyen, Thien NICHD NICHD Nguyen, Thien (NICHD) 1 158186023 Gandjbakhche, Amir NICHD NICHD Gandjbakhche, Amir (NICHD) 2 158434152 Park, Soongho National Heart and Lung Institute (Imperial College London; ICKL) [GB] NICHD Park, Soongho (NICHD) 3 158186178 Hill, Brian NICHD NICHD Hill, Brian (NICHD) 4 158186011 Nguyen, Thien NICHD NICHD Nguyen, Thien (NICHD) 1 158186023 Gandjbakhche, Amir NICHD NICHD Gandjbakhche, Amir (NICHD) 2 158434152 Park, Soongho National Heart and Lung Institute (Imperial College London; ICKL) [GB] NICHD Park, Soongho (NICHD) 3 158186178 Hill, Brian NICHD NICHD Hill, Brian (NICHD) 4 158185972 Single Source-Detector Separation Approach to Calculate Tissue Oxygen Saturation E-037-2023-0 Filing authorized NICHD 91827321 Jinnah, Zarpheen zarpheen.jinnah@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
zarpheen.jinnah@nih.gov?subject=Web Inquiry on [TAB-5010] Single Source-Detector Separation Approach to Calculate Tissue Oxygen Saturation&body=Please send me information about technology [TAB-5010] Single Source-Detector Separation Approach to Calculate Tissue Oxygen Saturation.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Jinnah, Zarpheen<br><a href="mailto:zarpheen.jinnah@nih.gov?subject=Web Inquiry on [TAB-5010] Single Source-Detector Separation Approach to Calculate Tissue Oxygen Saturation&body=Please send me information about technology [TAB-5010] Single Source-Detector Separation Approach to Calculate Tissue Oxygen Saturation.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">zarpheen.jinnah@nih.gov</a><br> 162828523 E-037-2023-0 E-037-2023-0-US-01 Single Source-Detector Separation Approach to Calculate Tissue Oxygen Saturation PRV US 63/434,827 Expired US <br />Provisional (PRV) 63/434,827<br />Filed on 2022-12-22<br />Status: Expired 162828524 E-037-2023-0 E-037-2023-0-PC-01 Single Source-Detector Separation Approach to Calculate Tissue Oxygen Saturation PCT Patent Cooperation Treaty PCT/US2023/085725 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2023/085725<br />Filed on 2023-12-22<br />Status: Expired 162828525 E-037-2023-0 E-037-2023-0-US-02 SINGLE SOURCE-DETECTOR SEPARATION APPROACH TO CALCULATE TISSUE OXYGEN SATURATION National Stage US 19/140,070 Pending US <br />National Stage 19/140,070<br />Filed on 2025-06-17<br />Status: Pending TAB-5093 166506999 Neutralizing Antibodies Against West Nile Virus NIAID Application, Diagnostics, ResearchProducts, TherapeuticArea, Vaccines, Virus/Bacteria Application Diagnostics ResearchProducts TherapeuticArea Vaccines Virus/Bacteria Daniel Douek, Kimberly Dowd, Dror Harats, Yaniv Lustig, Yael Ottolenghi, Theodore Pierson, Gili Regev-Yochay <p>&nbsp; &nbsp; &nbsp; &nbsp;West Nile virus (WNV) is a mosquito-borne virus that can cause severe disease affecting the brain and nervous system, especially in older adults and people with weakened immune systems. There is no approved human vaccine or specific antiviral treatment for WNV.</p> <p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Researchers at NIAID&rsquo;s Vaccine Research Center (VRC), together with collaborators at Sheba Medical Center and the Israeli Ministry of Health, have identified and characterized seven new fully human monoclonal antibodies that bind to the WNV envelope (E) protein&mdash;the main surface protein the virus uses to enter cells. In laboratory studies, these antibodies (AIS-196, AIS-204, AIS-259, AIS-260, AIS-261, AIS-262, and AIS-265) strongly blocked WNV infection, and several also showed protective effects in a mouse model.</p> <p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The invention includes the antibody sequences and tools needed to produce them, supporting development of full-length antibody therapies or smaller antibody fragments. These antibodies could help prevent WNV disease in people at higher risk or treat infection early, either individually or in combination. Modified versions are also included that may extend how long the antibodies remain active in the body or adjust how they interact with the immune system. The antibodies may also be useful in laboratory tests for WNV diagnosis, surveillance, and research.</p> <p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p> <ul> <li> An antibody-based approach for WNV prevention or treatment, given the lack of an approved human vaccine, specific antiviral treatment, or licensed antibody therapy </li> <li> Strong virus-neutralizing activity </li> <li> Fully human antibodies, which are less likely to cause anti-drug immune responses than non-human or humanized antibodies </li> <li> Engineered versions that may last longer in the body and tune immune activity to improve safety and effectiveness </li> <li> High-quality antibodies that support WNV prevention or treatment and can also be used in diagnostic tests, public health surveillance, and research </li> </ul> <ul> <li> Prevention or treatment antibodies for WNV, especially for people at higher risk of severe disease or after a known exposure </li> <li> Fully human antibodies that strongly neutralize virus infection by targeting its key surface E protein </li> <li> Flexible formats for different uses, including full-length antibodies or antibody fragments, and the option to use a single antibody or a combination (“cocktail") </li> <li> Engineered versions designed to last longer in the body and tune immune functions for safety and performance </li> <li> High-quality antibodies for WNV testing and surveillance, supporting laboratory detection, public health monitoring, and research </li> <li> Neutralizing antibodies as components of delivery systems for prophylactic or therapeutic applications </li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. For collaboration opportunities, please contact Brian Bailey at 240-669-5128, or bbailey@mail.nih.gov. 2026-03-19 2026-04-23 2026-04-23 2026-04-22 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract E-200-2024-0 166507438 Pierson, Theodore NIAID - VRC NIAID Pierson, Theodore (NIAID) 1 166507460 Dowd, Kimberly NIAID - VRC NIAID Dowd, Kimberly (NIAID) 2 166507484 Douek, Daniel National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Douek, Daniel (NIAID) 3 166507488 Harats, Dror Sheba Medical Center Harats, Dror 4 166507496 Ottolenghi, Yael The Sheba Fund for Health Services & Research (Sheba Medical Center) [IL] Ottolenghi, Yael 5 166507500 Regev-Yochay, Gili The Sheba Fund for Health Services & Research (Sheba Medical Center) [IL] Regev-Yochay, Gili 6 166507516 Lustig, Yaniv Israel Ministry of Health [IL] Lustig, Yaniv 7 166507438 Pierson, Theodore NIAID - VRC NIAID Pierson, Theodore (NIAID) 1 166507460 Dowd, Kimberly NIAID - VRC NIAID Dowd, Kimberly (NIAID) 2 166507484 Douek, Daniel National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Douek, Daniel (NIAID) 3 166507488 Harats, Dror Sheba Medical Center Harats, Dror 4 166507496 Ottolenghi, Yael The Sheba Fund for Health Services & Research (Sheba Medical Center) [IL] Ottolenghi, Yael 5 166507500 Regev-Yochay, Gili The Sheba Fund for Health Services & Research (Sheba Medical Center) [IL] Regev-Yochay, Gili 6 166507516 Lustig, Yaniv Israel Ministry of Health [IL] Lustig, Yaniv 7 166507002 Neutralizing antibodies against West Nile virus E-021-2026-0 Filing authorized Israel Ministry of Health [IL], National Institute of Allergy and Infectious Diseases (NIAID/NIH), NIAID - VRC, Sheba Medical Center, The Sheba Fund for Health Services & Research (Sheba Medical Center) [IL] 83682222 Bailey, Brian bbailey@mail.nih.gov
United States of America TTIPO bbailey@mail.nih.gov?subject=Web Inquiry on [TAB-5093] Neutralizing Antibodies Against West Nile Virus&body=Please send me information about technology [TAB-5093] Neutralizing Antibodies Against West Nile Virus. Bailey, Brian<br><a href="mailto:bbailey@mail.nih.gov?subject=Web Inquiry on [TAB-5093] Neutralizing Antibodies Against West Nile Virus&body=Please send me information about technology [TAB-5093] Neutralizing Antibodies Against West Nile Virus.">bbailey@mail.nih.gov</a><br> 166507058 E-021-2026-0 E-021-2026-0-US-01 Neutralizing antibodies against West Nile Virus PRV US 63/991,485 Pending US <br />Provisional (PRV) 63/991,485<br />Filed on 2026-02-26<br />Status: Pending TAB-5071 163810508 Method of Detecting Circulating Cell-Free HPV 6 and 11 DNA in Patients Afflicted With Diseases Caused by Chronic HPV 6 or 11 Infection and Use Thereof NCI Collaboration, Diagnostics, Infectious Disease, Licensing, Oncology, Pulmonology Collaboration Diagnostics Infectious Disease Licensing Oncology Pulmonology Clint Allen, Scott Norberg, Xiaolin Wu <h2>Summary:</h2> <p>The National Cancer Institute (NCI) and Frederick National Laboratory for Cancer Research (FNLCR) seek research co-development partners and/or licensees for commercial development of a novel liquid biopsy diagnostic for non-invasive detection of cell-free HPV 6 and 11 DNA for recurrent respiratory papillomatosis (RRP).</p> <h2>Description of Technology:</h2> <p>Recurrent respiratory papillomatosis (RRP), caused by chronic infection with human papillomavirus (HPV) types 6 and 11, is a rare but potentially fatal disease characterized by the growth of papillomas throughout the respiratory tract. While HPV 6/11 infections are common, affecting approximately 40% of U.S. adults, a subset of patients can develop a range of conditions from benign papillomas to dysplasia and invasive cancers. Current treatment for RRP typically involves repetitive surgical intervention or laser ablation to alleviate symptoms, which carries significant procedural risks. A recent breakthrough with a therapeutic HPV vaccine demonstrated that 51% of patients avoided surgery for at least a year, with some experiencing durable remission. However, there remains no reliable diagnostic tool to confirm viral clearance or guide systemic therapy decisions.</p> <p>Researchers at the NCI and FNLCR have developed a novel hybridization-based next-generation sequencing (NGS) liquid biopsy method to detect circulating cell-free HPV 6 and 11 DNA in the plasma of patients with RRP. This innovative approach uses the established relevance of circulating viral DNA as a valuable biomarker for disease monitoring and therapeutic decision-making in other virally-associated conditions. The method is designed to target multiple regions across the entire HPV 6 and 11 genomes. It employs a pull-down DNA technology to enhance coverage &ndash; overcoming limitations of fixed-primer PCR for small cell-free DNA fragments. While low-risk HPV-associated diseases like RRP exhibit less tumor cell turnover compared to advanced cancers, the inherent high vascularity of papillomas may facilitate the release of viral DNA into peripheral blood. This method offers a non-invasive, sensitive and potentially prognostic tool to aid in (1) diagnosis, (2) monitoring progression and (3) guiding systemic therapies such as HPV vaccination or predicting severity &ndash; including pulmonary risk.</p> <p>Investigators at the NCI and FNLCR continue to evaluate circulating HPV 6 and 11 DNA in patients previously treated in clinical trials to further assess its prognostic and predictive capabilities. This technology presents a compelling opportunity for commercial development and seamless integration into existing diagnostic platforms. NCI and FNLCR offer licensing and collaborative development opportunities to advance this critical diagnostic and prognostic tool for RRP.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Liquid biopsy diagnostic for RRP confirmation</li> <li>Monitoring RRP disease progression</li> <li>Prognostic test for RRP severity, especially pulmonary disease</li> <li>Companion diagnostic to guide systemic RRP therapies</li> <li>HPV 6/11 detection assay for anogenital condyloma</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Non-invasive, sensitive and potentially prognostic and diagnostic tool</li> <li>Reduces the need for, and risk from, repeat surgical procedures</li> <li>Detects disease even with a Derkay score of 0 (minimal laryngeal involvement)</li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for commercial development of a novel liquid biopsy diagnostic for non-invasive detection of cell-free HPV 6 and 11 DNA for Recurrent Respiratory Papillomatosis (RRP). 2025-08-21 2025-08-21 2026-04-20 2025-08-21 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 163810747 Norberg SM, et al. PRGN-2012 gene therapy in adults with recurrent respiratory papillomatosis: a pivotal phase 1/2 clinical trial. (PMID 39855244) https://pubmed.ncbi.nlm.nih.gov/39855244/ <a href="https://pubmed.ncbi.nlm.nih.gov/39855244/">Norberg SM, et al. PRGN-2012 gene therapy in adults with recurrent respiratory papillomatosis: a pivotal phase 1/2 clinical trial. (PMID 39855244)</a> 163810649 Norberg, Scott NIH - NCI NCI Norberg, Scott (NCI) 1 163810679 Allen, Clint NIH - NCI NCI Allen, Clint (NCI) 2 163810697 Wu, Xiaolin NIH - NCI Leidos Wu, Xiaolin (Leidos) 3 163810649 Norberg, Scott NIH - NCI NCI Norberg, Scott (NCI) 1 163810679 Allen, Clint NIH - NCI NCI Allen, Clint (NCI) 2 163810697 Wu, Xiaolin NIH - NCI Leidos Wu, Xiaolin (Leidos) 3 163922749 Method of detecting circulating cell-free HPV 6 and 11 DNA in patients afflicted with disease caused by chronic HPV 6 or 11 infection and use thereof (LBR# 25-004) (LBR Greater Rights Requested) E-019-2025-0 Filing authorized NIH - NCI 83694133 Gulay French, Suna suna.gulay@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB suna.gulay@nih.gov?subject=Web Inquiry on [TAB-5071] Method of Detecting Circulating Cell-Free HPV 6 and 11 DNA in Patients Afflicted With Diseases Caused by Chronic HPV 6 or 11 Infection and Use Thereof&body=Please send me information about technology [TAB-5071] Method of Detecting Circulating Cell-Free HPV 6 and 11 DNA in Patients Afflicted With Diseases Caused by Chronic HPV 6 or 11 Infection and Use Thereof.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Gulay French, Suna<br><a href="mailto:suna.gulay@nih.gov?subject=Web Inquiry on [TAB-5071] Method of Detecting Circulating Cell-Free HPV 6 and 11 DNA in Patients Afflicted With Diseases Caused by Chronic HPV 6 or 11 Infection and Use Thereof&body=Please send me information about technology [TAB-5071] Method of Detecting Circulating Cell-Free HPV 6 and 11 DNA in Patients Afflicted With Diseases Caused by Chronic HPV 6 or 11 Infection and Use Thereof.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">suna.gulay@nih.gov</a><br> 163922754 E-019-2025-0 E-019-2025-0-US-01 METHODS OF DETECTING CIRCULATING CELL-FREE HPV 6 AND HPV 11 DNA IN LIQUID BIOPSIES PRV US 63/803,323 Expired US <br />Provisional (PRV) 63/803,323<br />Filed on 2025-05-09<br />Status: Expired 166910976 E-019-2025-0 E-019-2025-0-PC-01 METHODS OF DETECTING CIRCULATING CELL-FREE HPV 6 AND HPV 11 DNA IN LIQUID BIOPSIES PCT Patent Cooperation Treaty PCT/US2026/027273 Pending Patent Cooperation Treaty <br />(PCT) PCT/US2026/027273<br />Filed on 2026-05-08<br />Status: Pending TAB-5092 166395418 MODIFIED PIGMENT EPITHELIUM-DERIVED FACTOR PEPTIDES AND METHODS OF USE NEI Collaboration, Ear, Nose, & Throat, Licensing, Ophthalmology, Therapeutics Collaboration Ear Nose & Throat Licensing Ophthalmology Therapeutics S. Patricia Becerra, Alexandra Bernardo-Colon, Burchelle Blackman, Natarajan Raju, Rolf Swenson, Carolyn Woodroofe <h2>Summary:</h2> <p>The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of an eyedrop formulation to deliver a series of peptides as a gene-agnostic approach to treating inherited retinal diseases.</p> <h2>Description of Technology:</h2> <p>Retinitis pigmentosa (RP) is one of the most common inherited retinal diseases (IRDs) that is estimated to affect 1 in 4,000 people in the United States and worldwide. Over 100,000 people in the US, and 1.5 million people worldwide suffer from RP. RP leads to progressive photoreceptor cell degeneration and ultimately vision loss, with more than 90 genes implicated in molecular pathways towards photoreceptor cell death. Due to this high heterogeneity, therapeutic approaches targeting specific genes generally benefit few patients, while for most forms of RP few or no medical options are available.</p> <p>Peptide drug development has made great progress recently thanks to new production, modification, and analytical technologies. Solutions of chemically synthesized bioactive peptides have unique advantages over mixed formulations. They are free of inactive ingredients that cause secondary effects. Structural biology and recombinant biologics aid in peptide design to modify amino acids, enhancing target affinity, specificity, and regulating bioactivity, as well as improving the solubility and stability of peptide drugs. Peptides can diffuse better than biologics (proteins, antibodies) with better penetrability. Compared with biologics, therapeutic peptides have demonstrably less immunogenicity and lower production costs.</p> <p>This technology optimizes synthetic peptides that are soluble, stable, and protect the retina. A series of peptides derived from the neurotrophic region of PEDF 17-mer (human sequence 98-114 amino acids, N- and C-terminus uncapped) is designed and synthesized. They have a series of truncations from the amino and carboxy ends, and internal region, as well as isosteric amino acid replacements, and amino terminal additions such as capping (X) and amidation (Y) to prevent exopeptidases from degrading the peptide. The peptides are optimized to protect photoreceptors and other retinal cells against death and degeneration. They optimized for solubility, stability, efficacy, in protecting the retina at the structural, morphological and functional level. The peptides can be tested in vitro, ex vivo, in cells and in vivo using models of retinal degeneration. The peptides can be used as eyedrops in vivo.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Potential simple and effective treatment for inherited eye diseases contributing to Retinitis Pigmentosa (RP) and macular degenerations, such as AMD and geographic atrophy</li> <li>Prevent disease progression by protecting degenerating photoreceptors</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Chemically synthesized bioactive peptide solutions are free of inactive ingredients that cause secondary effects as compared to mixed formulations</li> <li>Enhanced target affinity, specificity, bioactivity, as well as in improved solubility, and stability</li> <li>Peptides can diffuse better than biologics (proteins, antibodies) with better penetrability</li> <li>Compared to biologics, therapeutic peptides have demonstrably less immunogenicity and lower production costs</li> <li>Eye drop formulation is accessible to more patients and provides an easy administration route</li> <li>PEDF formulation mimics the natural protective process lost in patients with inherited eye diseases, contributing to RP</li> </ul> The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of an eyedrop formulation to deliver a series of peptides as a gene-agnostic approach to treating inherited retinal diseases. 2026-03-11 2026-03-11 2026-04-17 2026-03-11 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-028-2023 166395672 Bernardo-Colon A, et al. H105A peptide eye drops promote photoreceptor survival in murine and human models of retinal degeneration. (PMID: 40118996) https://pubmed.ncbi.nlm.nih.gov/40118996/ <a href="https://pubmed.ncbi.nlm.nih.gov/40118996/">Bernardo-Colon A, et al. H105A peptide eye drops promote photoreceptor survival in murine and human models of retinal degeneration. (PMID: 40118996)</a> 166395675 Valiente-Soriano FJ, et al. Pigment Epithelium-Derived Factor (PEDF) Fragments Prevent Mouse Cone Photoreceptor Cell Loss Induced by Focal Phototoxicity In Vivo. (PMID: 33008127) https://pubmed.ncbi.nlm.nih.gov/33008127/ <a href="https://pubmed.ncbi.nlm.nih.gov/33008127/">Valiente-Soriano FJ, et al. Pigment Epithelium-Derived Factor (PEDF) Fragments Prevent Mouse Cone Photoreceptor Cell Loss Induced by Focal Phototoxicity In Vivo. (PMID: 33008127)</a> 166395678 Hernández-Pinto A, et al. PEDF peptides promote photoreceptor survival in rd10 retina models. (PMID: 30980815) https://pubmed.ncbi.nlm.nih.gov/30980815/ <a href="https://pubmed.ncbi.nlm.nih.gov/30980815/">Hernández-Pinto A, et al. PEDF peptides promote photoreceptor survival in rd10 retina models. (PMID: 30980815)</a> 166395684 Kenealey J, et al. Small Retinoprotective Peptides Reveal a Receptor-binding Region on Pigment Epithelium-derived Factor. (PMID: 26304116) https://pubmed.ncbi.nlm.nih.gov/26304116/ <a href="https://pubmed.ncbi.nlm.nih.gov/26304116/">Kenealey J, et al. Small Retinoprotective Peptides Reveal a Receptor-binding Region on Pigment Epithelium-derived Factor. (PMID: 26304116)</a> 166395566 Becerra, S. Patricia National Eye Institute (NEI) NEI Becerra, S. Patricia (NEI) 1 166395574 Swenson, Rolf National Heart, Lung, and Blood Institute (NHLBI) NHLBI Swenson, Rolf (NHLBI) 2 166395593 Raju, Natarajan National Heart, Lung, and Blood Institute (NHLBI) NHLBI Raju, Natarajan (NHLBI) 3 166395604 Bernardo-Colon, Alexandra National Eye Institute (NEI) Bernardo-Colon, Alexandra 4 166395611 Woodroofe, Carolyn National Heart, Lung, and Blood Institute (NHLBI) NHLBI Woodroofe, Carolyn (NHLBI) 5 166395635 Blackman, Burchelle National Heart, Lung, and Blood Institute (NHLBI) NHLBI Blackman, Burchelle (NHLBI) 6 166395566 Becerra, S. Patricia National Eye Institute (NEI) NEI Becerra, S. Patricia (NEI) 1 166395574 Swenson, Rolf National Heart, Lung, and Blood Institute (NHLBI) NHLBI Swenson, Rolf (NHLBI) 2 166395593 Raju, Natarajan National Heart, Lung, and Blood Institute (NHLBI) NHLBI Raju, Natarajan (NHLBI) 3 166395604 Bernardo-Colon, Alexandra National Eye Institute (NEI) Bernardo-Colon, Alexandra 4 166395611 Woodroofe, Carolyn National Heart, Lung, and Blood Institute (NHLBI) NHLBI Woodroofe, Carolyn (NHLBI) 5 166395635 Blackman, Burchelle National Heart, Lung, and Blood Institute (NHLBI) NHLBI Blackman, Burchelle (NHLBI) 6 166395421 Photoreceptor-protective Peptides based on truncated PEDF E-156-2023-0 Filing authorized National Eye Institute (NEI), National Heart, Lung, and Blood Institute (NHLBI), National Heart, Lung, and Blood Institute (NHLBI) 83724826 Pollard, Ricquita ricquita.pollard@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-5092] MODIFIED PIGMENT EPITHELIUM-DERIVED FACTOR PEPTIDES AND METHODS OF USE&body=Please send me information about technology [TAB-5092] MODIFIED PIGMENT EPITHELIUM-DERIVED FACTOR PEPTIDES AND METHODS OF USE.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollard, Ricquita<br><a href="mailto:ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-5092] MODIFIED PIGMENT EPITHELIUM-DERIVED FACTOR PEPTIDES AND METHODS OF USE&body=Please send me information about technology [TAB-5092] MODIFIED PIGMENT EPITHELIUM-DERIVED FACTOR PEPTIDES AND METHODS OF USE.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">ricquita.pollard@nih.gov</a><br> 166395426 E-156-2023-0 E-156-2023-0-US-01 MODIFIED PIGMENT EPITHELIUM-DERIVED FACTOR PEPTIDES AND METHODS OF USE PRV US 63/604,026 Expired US <br />Provisional (PRV) 63/604,026<br />Filed on 2023-11-29<br />Status: Expired 166395427 E-156-2023-0 E-156-2023-0-PC-01 MODIFIED PIGMENT EPITHELIUM-DERIVED FACTOR PEPTIDES AND METHODS OF USE PCT Patent Cooperation Treaty PCT/US2024/057784 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2024/057784<br />Filed on 2024-11-27<br />Status: Expired 166895073 E-156-2023-0 E-156-2023-0-JP-01 MODIFIED PIGMENT EPITHELIUM-DERIVED FACTOR PEPTIDES AND METHODS OF USE National Stage Japan 2026-531738 Pending Japan <br />National Stage 2026-531738<br />Filed on 2026-05-27<br />Status: Pending 166895169 E-156-2023-0 E-156-2023-0-CA-01 MODIFIED PIGMENT EPITHELIUM-DERIVED FACTOR PEPTIDES AND METHODS OF USE National Stage Canada 3313052 Pending Canada <br />National Stage 3313052<br />Filed on 2026-05-28<br />Status: Pending 166895224 E-156-2023-0 E-156-2023-0-AU-01 MODIFIED PIGMENT EPITHELIUM-DERIVED FACTOR PEPTIDES AND METHODS OF USE National Stage Australia In Preparation Australia <br />National Stage None<br />Filed on None<br />Status: In Preparation 166895361 E-156-2023-0 E-156-2023-0-US-02 MODIFIED PIGMENT EPITHELIUM-DERIVED FACTOR PEPTIDES AND METHODS OF USE National Stage US In Preparation US <br />National Stage None<br />Filed on None<br />Status: In Preparation 166895416 E-156-2023-0 E-156-2023-0-EP-01 MODIFIED PIGMENT EPITHELIUM-DERIVED FACTOR PEPTIDES AND METHODS OF USE National Stage European Patent In Preparation European Patent <br />National Stage None<br />Filed on None<br />Status: In Preparation TAB-5029 159051371 NeoExpansion – A Method to Identify and Selectively Expand Neoantigen-specific T Cells, Including T Cell Receptor-engineered T Cells and Tumor Infiltrating Lymphocytes NCI Collaboration, Immunology, Licensing, Oncology, ResearchProducts Collaboration Immunology Licensing Oncology ResearchProducts Sanghyun (Peter) Kim, Noam Levin, Lior Levy, Steven Rosenberg <h2>Summary:</h2> <p>&nbsp;The National Cancer Institute (NCI) seeks co-development partners and/or licensees for a method of identifying and selectively expanding neoantigen-specific T cells.</p> <h2>Description of Technology:&nbsp;</h2> <p>Somatic mutations are spontaneous changes in the DNA sequence of somatic cells which drive the development of most cancers. These somatic mutations may also create neoantigens, newly formed antigens that can be recognized by T cells. Adoptive cell transfer (ACT) and T cell receptor- (TCR-) engineered T cell therapies (TCR-T) can be used to target cells expressing these neoantigens and treat cancer patients. Traditionally, TCR-T or tumor infiltrating lymphocyte (TIL) cell therapy products utilize an in vitro expansion step in their manufacture called a rapid expansion protocol (REP). However, recent evidence suggests that conventional REPs reduce the frequency of neoantigen-reactive T cells in the final product, which may diminish treatment efficacy.</p> <p>Researchers at the National Cancer Institute (NCI) have developed a method to identify and selectively expand neoantigen-specific T cells, including TCR-T and TIL-based products. This method, termed &ldquo;NeoExpand,&rdquo; promotes the selective growth of neoantigen-reactive T cells and, additionally, enables the sensitive identification of novel neoantigen-reactive TCRs.</p> <p>The NCI seeks co-development partners and/or licensees. As &ldquo;NeoExpand&rdquo; provides a novel method of identify and selectively expanding neoantigen-specific T cells, this technology may be particularly appealing to companies developing cell therapies.</p> <h2>Potential Commercial Applications:&nbsp;</h2> <ul> <li>Manufacturing method for ACT products</li> <li>Manufacturing method for TCR-T products</li> <li>Discovery engine for the isolation of neoantigen-specific TCRs</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Increase the efficacy of immunotherapies treating cancer</li> <li>Identify neoantigen-specific T cells</li> <li>Selectively expand neoantigen-specific T cells</li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for a method to identify and selectively expand neoantigen-specific T cells. 2024-11-12 2026-04-16 2026-04-16 2024-11-12 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 159081648 Wölfl M, et al. Antigen-specific activation and cytokine-facilitated expansion of naive, human CD8+ T cells. (PMID 24675735) https://pubmed.ncbi.nlm.nih.gov/24675735/ <a href="https://pubmed.ncbi.nlm.nih.gov/24675735/">Wölfl M, et al. Antigen-specific activation and cytokine-facilitated expansion of naive, human CD8+ T cells. (PMID 24675735)</a> 159081651 Cafri G, et al. Memory T cells targeting oncogenic mutations detected in peripheral blood of epithelial cancer patients. (PMID 30683863) https://pubmed.ncbi.nlm.nih.gov/30683863/ <a href="https://pubmed.ncbi.nlm.nih.gov/30683863/">Cafri G, et al. Memory T cells targeting oncogenic mutations detected in peripheral blood of epithelial cancer patients. (PMID 30683863)</a> 159081940 Levin N, et al. Identification and Validation of T-cell Receptors Targeting RAS Hotspot Mutations in Human Cancers for Use in Cell-based Immunotherapy. (PMID 34168045) https://pubmed.ncbi.nlm.nih.gov/34168045/ <a href="https://pubmed.ncbi.nlm.nih.gov/34168045/">Levin N, et al. Identification and Validation of T-cell Receptors Targeting RAS Hotspot Mutations in Human Cancers for Use in Cell-based Immunotherapy. (PMID 34168045)</a> 159051713 Levin, Noam National Cancer Institute (NCI) NCI Levin, Noam (NCI) 1 159051753 Kim, Sanghyun (Peter) Surgery Branch NCI Kim, Sanghyun (Peter) (NCI) 2 159051764 Levy, Lior NCI Levy, Lior (NCI) 3 159051780 Rosenberg, Steven NCI Rosenberg, Steven (NCI) 4 159051713 Levin, Noam National Cancer Institute (NCI) NCI Levin, Noam (NCI) 1 159051753 Kim, Sanghyun (Peter) Surgery Branch NCI Kim, Sanghyun (Peter) (NCI) 2 159051764 Levy, Lior NCI Levy, Lior (NCI) 3 159051780 Rosenberg, Steven NCI Rosenberg, Steven (NCI) 4 159051374 NeoExpansion - Method to identify and selectively expand neoantigen-specific T cells, including T cell receptor-engineered T cells and tumor infiltrating lymphocytes. E-101-2024-0 Filing authorized NCI - CCR, NIH - NCI, Surgery Branch 83709866 Burke, Andrew burkear@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC burkear@nih.gov?subject=Web Inquiry on [TAB-5029] NeoExpansion – A Method to Identify and Selectively Expand Neoantigen-specific T Cells, Including T Cell Receptor-engineered T Cells and Tumor Infiltrating Lymphocytes&body=Please send me information about technology [TAB-5029] NeoExpansion – A Method to Identify and Selectively Expand Neoantigen-specific T Cells, Including T Cell Receptor-engineered T Cells and Tumor Infiltrating Lymphocytes.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Burke, Andrew<br><a href="mailto:burkear@nih.gov?subject=Web Inquiry on [TAB-5029] NeoExpansion – A Method to Identify and Selectively Expand Neoantigen-specific T Cells, Including T Cell Receptor-engineered T Cells and Tumor Infiltrating Lymphocytes&body=Please send me information about technology [TAB-5029] NeoExpansion – A Method to Identify and Selectively Expand Neoantigen-specific T Cells, Including T Cell Receptor-engineered T Cells and Tumor Infiltrating Lymphocytes.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">burkear@nih.gov</a><br> 159502980 E-101-2024-0 E-101-2024-0-US-01 METHODS TO IDENTIFY AND SELECTIVELY EXPAND TUMOR ANTIGEN-SPECIFIC T CELLS . PRV US 63/572,693 Expired US <br />Provisional (PRV) 63/572,693<br />Filed on 2024-04-01<br />Status: Expired 162827652 E-101-2024-0 E-101-2024-0-PC-01 METHODS TO IDENTIFY AND SELECTIVELY EXPAND TUMOR ANTIGEN-SPECIFIC T CELLS PCT Patent Cooperation Treaty PCT/US2025/022247 Pending Patent Cooperation Treaty <br />(PCT) PCT/US2025/022247<br />Filed on 2025-03-31<br />Status: Pending TAB-4995 157267387 Using Artificial Intelligence To Predict The Risk Of Age-Related Macular Degeneration NEI Collaboration, Diagnostics, Ear, Nose, & Throat, Licensing Collaboration Diagnostics Ear Nose & Throat Licensing Elvira Agron, Qingyu Chen, Emily Chew, Tiarnan Keenan, Zhiyong Lu, Wai Wong <h2>Summary:&nbsp;</h2> <p>The National Eye Institute seeks research co-development partners and/or licensees for a deep learning algorithm that can predict the probability of progression to late age-related macular degeneration.</p> <h2>Description of Technology:&nbsp;</h2> <p>In 2024, an estimated 200 million people worldwide suffer from age-related macular degeneration (AMD); projected to affect ~288 million people by 2040. AMD is the leading cause of blindness in all developed countries. Identifying eyes at high risk of progression to late AMD, the stage associated with blindness, is vital. This would allow timely medical treatments, lifestyle interventions, more tailored home monitoring and improved clinical trials for patients.</p> <p>Reticular pseudodrusen (RPD) is an AMD disease feature recently discovered to confer greatly increased risk of progression to late AMD. However, RPD is often very difficult to detect on clinical examination or on color fundus photography (CFP). Detection usually requires specialized imaging (especially fundus autofluorescence) and highly expert grading typically available at few specialized centers. For these reasons, RPD have not been incorporated into AMD risk classification systems.</p> <p>We used Artificial Intelligence (AI) to predict the risk of progression to late AMD using over 80,000 images from almost 3300 participants from the Age-Related Eye Disease Studies AREDS and AREDS2. Using independent test data, our deep learning algorithm produced 5% higher prognostic accuracy compared to existing clinical standards. The predictive accuracy of the new approach was 5% higher than that of the two traditional approaches ((i) AREDS Simplified Severity Scale, and (ii) the Casey AMD online calculator). Our approach can make predictions over a wide range of time intervals (1-12 years), and separately for the two subtypes of late AMD (geographic and neovascular AMD). In contrast, the AREDS Simplified Severity Scale can make predictions at one fixed interval only (5 years), and for late AMD only (not separately by subtype). By separating the deep learning extraction of retinal features from the survival analysis, the final predictions are more explainable and biologically plausible, and error analysis is possible. By contrast, end-to-end &lsquo;black-box&rsquo; deep learning approaches are less transparent and may be more susceptible to failure<br /> A fully automated device that contains this novel image processing method has also been developed.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Diagnostic tool predicting risk of AMD</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Widely available via device&nbsp;</li> <li>Fully automated analysis of the CFP and no requirement for human grading of the CFP, either by retinal specialists or by reading center experts</li> <li>More predictive, accurate approach compared using the same test set of AREDS and AREDS2 participants&nbsp;</li> <li>Predictive over a wide range of time intervals (1-12 years) and separately for the two subtypes of late AMD (geographic and neovascular AMD)&nbsp;</li> <li>Two-step method separates the deep learning extraction of retinal features from the survival analysis</li> <li>Two-step method produces final predictions that are more explainable and biologically plausible</li> <li>Error analysis&nbsp;</li> <li>Our approach has the advantage of not requiring genetic information to provide a high level of predictive accuracy<br /> &nbsp;</li> </ul> Researchers at the NEI seek licensing and/or co-development research collaborations for a deep learning algorithm that can predict the probability of progression to late age-related macular degeneration. 2024-07-23 2026-04-16 2026-04-16 2024-07-23 False True prototype True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 157267554 Keenan, et al. Deep Learning Automated Detection of Reticular Pseudodrusen from Fundus Autofluorescence Images or Color Fundus Photographs in AREDS2. (PMID 32447042) https://pubmed.ncbi.nlm.nih.gov/32447042/ <a href="https://pubmed.ncbi.nlm.nih.gov/32447042/">Keenan, et al. Deep Learning Automated Detection of Reticular Pseudodrusen from Fundus Autofluorescence Images or Color Fundus Photographs in AREDS2. (PMID 32447042)</a> 166884053 Peng, et al. Predicting risk of late age-related macular degeneration using deep learning. (PMID 32904246) https://pubmed.ncbi.nlm.nih.gov/32904246/ <a href="https://pubmed.ncbi.nlm.nih.gov/32904246/">Peng, et al. Predicting risk of late age-related macular degeneration using deep learning. (PMID 32904246)</a> 166884056 Chen, et al. Multimodal, multitask, multiattention (M3) deep learning detection of reticular pseudodrusen: Toward automated and accessible classification of age-related macular degeneration. (PMID 33792724) https://pubmed.ncbi.nlm.nih.gov/33792724/ <a href="https://pubmed.ncbi.nlm.nih.gov/33792724/">Chen, et al. Multimodal, multitask, multiattention (M3) deep learning detection of reticular pseudodrusen: Toward automated and accessible classification of age-related macular degeneration. (PMID 33792724)</a> 157267522 Chew, Emily National Eye Institute (NEI) NEI Chew, Emily (NEI) 1 157267526 Lu, Zhiyong NLM NLM Lu, Zhiyong (NLM) 2 157267530 Keenan, Tiarnan National Eye Institute (NEI) NEI Keenan, Tiarnan (NEI) 3 157267534 Wong, Wai National Eye Institute (NEI) NEI Wong, Wai (NEI) 4 157267542 Chen, Qingyu NLM NLM Chen, Qingyu (NLM) 5 157267546 Agron, Elvira National Eye Institute (NEI) NEI Agron, Elvira (NEI) 6 157267522 Chew, Emily National Eye Institute (NEI) NEI Chew, Emily (NEI) 1 157267526 Lu, Zhiyong NLM NLM Lu, Zhiyong (NLM) 2 157267530 Keenan, Tiarnan National Eye Institute (NEI) NEI Keenan, Tiarnan (NEI) 3 157267534 Wong, Wai National Eye Institute (NEI) NEI Wong, Wai (NEI) 4 157267542 Chen, Qingyu NLM NLM Chen, Qingyu (NLM) 5 157267546 Agron, Elvira National Eye Institute (NEI) NEI Agron, Elvira (NEI) 6 157267390 Method And System Of Building A Data-base And Models For Determining The Presence Of Reticular Pseudodrusen (RPD) Associated With Age-Related Macular Degeneration (AMD) Using Fundus Autofluorescence And/or Color Fundus Photos E-057-2020-0 Filing authorized National Eye Institute (NEI), NLM 83724826 Pollard, Ricquita ricquita.pollard@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4995] Using Artificial Intelligence To Predict The Risk Of Age-Related Macular Degeneration&body=Please send me information about technology [TAB-4995] Using Artificial Intelligence To Predict The Risk Of Age-Related Macular Degeneration.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollard, Ricquita<br><a href="mailto:ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4995] Using Artificial Intelligence To Predict The Risk Of Age-Related Macular Degeneration&body=Please send me information about technology [TAB-4995] Using Artificial Intelligence To Predict The Risk Of Age-Related Macular Degeneration.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">ricquita.pollard@nih.gov</a><br> 157267585 E-057-2020-0 E-057-2020-0-US-01 METHODS AND SYSTEMS FOR PREDICTING RATES OF PROGRESSION OF AGE-RELATED MACULAR DEGENERATION PRV US 62/978,070 Abandoned US <br />Provisional (PRV) 62/978,070<br />Filed on 2020-02-18<br />Status: Abandoned 164119882 E-057-2020-0 E-057-2020-0-PCT-02 METHODS AND SYSTEMS FOR PREDICTING RATES OF PROGRESSION OF AGE-RELATED MACULAR DEGENERATION PCT Patent Cooperation Treaty PCT/US2021/018589 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/018589<br />Filed on 2021-02-18<br />Status: Expired 164119883 E-057-2020-0 E-057-2020-0-AU-03 METHODS AND SYSTEMS FOR PREDICTING RATES OF PROGRESSION OF AGE-RELATED MACULAR DEGENERATION National Stage Australia 2021224660 Pending Australia <br />National Stage 2021224660<br />Filed on 2021-02-18<br />Status: Pending 164119884 E-057-2020-0 E-057-2020-0-CA-04 METHODS AND SYSTEMS FOR PREDICTING RATES OF PROGRESSION OF AGE-RELATED MACULAR DEGENERATION National Stage Canada 3177173 Pending Canada <br />National Stage 3177173<br />Filed on 2021-02-18<br />Status: Pending 164119885 E-057-2020-0 E-057-2020-0-EP-05 METHODS AND SYSTEMS FOR PREDICTING RATES OF PROGRESSION OF AGE-RELATED MACULAR DEGENERATION National Stage European Patent 21711144.2 Pending European Patent <br />National Stage 21711144.2<br />Filed on 2021-02-18<br />Status: Pending 164119886 E-057-2020-0 E-057-2020-0-US-06 Method and Systems for Predicting Rates of Progression of Age-Related Macular Degeneration National Stage US 17/904,573 Pending US <br />National Stage 17/904,573<br />Filed on 2022-08-18<br />Status: Pending TAB-4061 147157343 Novel Human Islet Amyloid Polypeptides as Alzheimer’s Disease Biomarkers and Inhibitors of Amyloid Formation NIA Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Josephine Earley, Qing Rong Liu, Min Zhu <h2>Description of Technology:</h2> <p>Over 34 million Americans are living with diabetes. An estimated 6.5 million Americans are living with Alzheimer&rsquo;s disease (AD) and type 2 diabetes mellites (T2DM). Amyloidosis due to aggregation of amyloid-&beta; is key pathogenic event in AD, whereas aggregation of mature islet amyloid polypeptide (IAPP37) in human islet leads to &beta;-cell dysfunction. A hallmark feature of T2DM is the accumulation of islet amyloid polypeptide fibrils in pancreatic islets. Such accumulations form amyloid plaques and cause apoptosis of -cells of islets.&nbsp;</p> <p>Researchers at NIA used a bioinformatic and molecular biological approaches to identify two novel islet amyloid polypeptide isoforms: IAPP&beta;, encoding an elongated propeptide of the conventional IAPP and a non-aggregating IAPP&gamma;, which is processed to an unrelated mature IAPP25 instead of IAPP37. They developed a quantitative selective reaction monitoring (SRM) proteomic assay that determined the isoform peptide levels in human clinical plasma and CSF from individuals with early AD were significantly reduced. Further, mature IAPP25 derived from IAPP&gamma; isoform inhibited fibrillation of IAPP37 and amyloid-&beta; efficiently in vitro.</p> <p>The novel IAPP&beta; and IAPP&gamma; isoforms could potentially be developed as peptidyl therapeutics to counteract with amyloid forming IAPP37 and amyloid-&beta; in treatments of diabetes and Alzheimer&rsquo;s disease. These isoforms could also serve as blood-based biomarkers for Alzheimer&rsquo;s disease. The NIA seeks co-development partners and/or licensees for the further development of these therapeutics and biomarkers.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Therapy for amyloid diseases, including type 2 diabetes mellitus, Alzheimer&rsquo;s disease and Parkinson&rsquo;s disease</li> <li>Potential to be developed as peptidyl therapeutics&nbsp;</li> <li>Clinical diagnostic blood-derived biomarkers for AD</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Peptide based anti-amyloid medicine</li> <li>Potential market applications for neurodegenerative diseases</li> </ul> The National Institute on Aging (NIA) seeks licensing and/or co-development research collaboration partners for the further development of islet amyloid polypeptide (IAPP) diagnostic biomarkers and peptidyl therapeutics for amyloid related diseases. 2023-04-27 2026-04-16 2023-04-27 2026-04-16 2023-04-27 Ad, Age-Associated Disease, Alzheimer’s Disease, Amyloidosis, Amyloids, Biomarkers, DIABETES, IAPP, Islet Amyloid Polypeptide Isoforms, Liu, National Institute on Aging, NIA, PEPTIDYL False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2023-04-27 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147162280 Liu, Q.-R., et al. Novel Hominid-Specific IAPP Isoforms: Potential Biomarkers of Early Alzheimer&rsquo;s Disease and Inhibitors of Amyloid Formation. https://pubmed.ncbi.nlm.nih.gov/36671553/ <a href="https://pubmed.ncbi.nlm.nih.gov/36671553/">Liu, Q.-R., et al. Novel Hominid-Specific IAPP Isoforms: Potential Biomarkers of Early Alzheimer&rsquo;s Disease and Inhibitors of Amyloid Formation.</a> 147163385 Liu, Qing Rong NIH - NIA NIDA Liu, Qing Rong (NIDA) 1 147163386 Zhu, Min National Institute on Aging (NIH/NIA) NIA Zhu, Min (NIA) 2 147163384 Earley, Josephine NIH - NIA NIA Earley, Josephine (NIA) 3 147163385 Liu, Qing Rong NIH - NIA NIDA Liu, Qing Rong (NIDA) 1 147163386 Zhu, Min National Institute on Aging (NIH/NIA) NIA Zhu, Min (NIA) 2 147163384 Earley, Josephine NIH - NIA NIA Earley, Josephine (NIA) 3 147158195 Novel Islet Amyloid Polypeptide (IAPP ) And Soluble IAPP Polypeptides, Inhibitor Of Amyloid And Biomarkers Of AD E-197-2022-0 Filing authorized National Institute on Aging (NIH/NIA) 91827321 Jinnah, Zarpheen zarpheen.jinnah@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
zarpheen.jinnah@nih.gov?subject=Web Inquiry on [TAB-4061] Novel Human Islet Amyloid Polypeptides as Alzheimer’s Disease Biomarkers and Inhibitors of Amyloid Formation&body=Please send me information about technology [TAB-4061] Novel Human Islet Amyloid Polypeptides as Alzheimer’s Disease Biomarkers and Inhibitors of Amyloid Formation.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Jinnah, Zarpheen<br><a href="mailto:zarpheen.jinnah@nih.gov?subject=Web Inquiry on [TAB-4061] Novel Human Islet Amyloid Polypeptides as Alzheimer’s Disease Biomarkers and Inhibitors of Amyloid Formation&body=Please send me information about technology [TAB-4061] Novel Human Islet Amyloid Polypeptides as Alzheimer’s Disease Biomarkers and Inhibitors of Amyloid Formation.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">zarpheen.jinnah@nih.gov</a><br> 147161183 E-197-2022-0 E-197-2022-0-US-01 ISLET AMYLOID POLYPEPTIDE ISOFORMS AND PEPTIDES AND METHODS OF USE PRV US 63/417,582 Expired US <br />Provisional (PRV) 63/417,582<br />Filed on 2022-10-19<br />Status: Expired 147166277 E-197-2022-0 E-197-2022-0-PC-01 ISLET AMYLOID POLYPEPTIDE ISOFORMS AND PEPTIDES AND METHODS OF USE PCT Patent Cooperation Treaty PCT/US2023/077173 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2023/077173<br />Filed on 2023-10-18<br />Status: Expired 147173506 Ad 147173508 Age-Associated Disease 147173509 Alzheimer’s Disease 147173510 Amyloidosis 147173512 Amyloids 147173513 Biomarkers 147173514 DIABETES 147173515 IAPP 147173517 Islet Amyloid Polypeptide Isoforms 147173518 Liu 147173519 National Institute on Aging 147173520 NIA 147173521 PEPTIDYL TAB-4403 147157698 Novel Chemoattractant-Based Toxins To Improve Vaccine Immune Responses for Cancer and Infectious Diseases NIA Immunology, Licensing, Oncology, Therapeutics Immunology Licensing Oncology Therapeutics Bira Arya, Dolgor Bataar, Kouji Matsushima <h2>Description of Technology:</h2> <p>Cancer is one of the leading causes of death in United States and it is estimated that there will be more than half a million deaths caused by cancer in 2009.&nbsp; A major drawback of the current chemotherapy-based therapeutics is the cytotoxic side-effects associated with them.&nbsp; Thus there is a dire need to develop new therapeutic strategies with fewer side-effects.&nbsp; Immunotherapy has taken a lead among the new therapeutic approaches.&nbsp; Enhancing the innate immune response of an individual has been a key approach for the treatment against different diseases such as cancer and infectious diseases.</p> <p>This technology involves the generation of novel chemoattractant toxins that deplete the T regulatory cells (Treg) or other immunosuppressive or hyperactivated cells locally.&nbsp; Treg controls activation of immune responses by suppressing the induction of adaptive immune responses, particularly T cell responses.&nbsp; Immunosuppressive cells such as tumor infiltrating macrophages, regulatory T cells, regulatory B cells, or NKT and other cells down regulate antitumor immune responses.&nbsp; The chemoattractant toxins consist of a toxin moiety fused with a chemokine receptor ligand, such as chemokines and various chemoattractants, that enables specific targeting and delivery to the regulatory cells. This technology is advantageous over the more harmful antibodies and chemicals that are currently used for the systemic depletion of regulatory cells.&nbsp; The current technology can be used therapeutically in a variety of ways.&nbsp; They can be used together with vaccines to increase efficacy of the vaccine for the treatment of cancer, and can be used to locally deplete Treg, Bregs, or other immuno suppressive cells to induce cytolytic cell responses at the tumor site or to eliminate chronic infectious diseases such as HIV and tuberculosis.</p> <p>Development Status:&nbsp;<br /> The technology is currently in the pre-clinical stage of development.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>New chemoattractant-based toxins targeted towards Treg cells.</li> <li>New chemoattractant-based toxins targeted towards immunosuppressive B cells, NKT and macrophages.</li> <li>New chemoattractant based toxins targeted towards local depletion of hyperactivated CD4 T cells to treat autoimmune diseases.</li> <li>Chemoattractant-based toxins depleting Treg cells or other immunosuppressive cells causing enhanced vaccine immune responses.</li> <li>Novel immunotherapy by increasing vaccine efficacy against cancer and infectious diseases.</li> </ul> 2016-02-16 2026-04-16 2017-11-20 2026-04-16 2023-04-06 2016-03-07 AIDS/HIV, Chemoattractant toxins, Immune Diseases, immunosuppressant, T regulatory (Treg) cells, TUBERCULOSIS False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2017-11-20 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147162023 R Schiavo et al. Chemokine receptor targeting efficiently directs antigens to MHC class I pathways and elicits antigen-specific CD8+ T-cell responses. Blood 2006 Jun 15; 107(12):4597-4605. http://www.ncbi.nlm.nih.gov/pubmed/16514063?dopt <a href="http://www.ncbi.nlm.nih.gov/pubmed/16514063?dopt">R Schiavo et al. Chemokine receptor targeting efficiently directs antigens to MHC class I pathways and elicits antigen-specific CD8+ T-cell responses. Blood 2006 Jun 15; 107(12):4597-4605.</a> 147162062 D Baatar, P Olkhanud, D Newton, K Sumitomo, A Biragyn. CCR4-expressing T cell tumors can be specifically controlled via delivery of toxins to chemokine receptors. J Immunol. 2007 Aug 1;179(3):1996-2004. http://www.ncbi.nlm.nih.gov/pubmed/17641067?dopt <a href="http://www.ncbi.nlm.nih.gov/pubmed/17641067?dopt">D Baatar, P Olkhanud, D Newton, K Sumitomo, A Biragyn. CCR4-expressing T cell tumors can be specifically controlled via delivery of toxins to chemokine receptors. J Immunol. 2007 Aug 1;179(3):1996-2004.</a> 147162140 M Coscia, A Biragyn. Cancer immunotherapy with chemoattractant peptides. Semin Cancer Biol. 2004 Jun; 14(3):209-218. http://www.ncbi.nlm.nih.gov/pubmed/15246057?dopt <a href="http://www.ncbi.nlm.nih.gov/pubmed/15246057?dopt">M Coscia, A Biragyn. Cancer immunotherapy with chemoattractant peptides. Semin Cancer Biol. 2004 Jun; 14(3):209-218.</a> 147162179 D Baatar, P Olkhanud, K Sumitomo, D Taub, R Gress, A Biragyn. Human peripheral blood T regulatory cells (Tregs), functionally primed CCR4+ Tregs and unprimed CCR4- Tregs, regulate effector T cells using FasL. J Immunol. 2007 Apr 15;178(8):4891-4900. http://www.ncbi.nlm.nih.gov/pubmed/17404270?dopt <a href="http://www.ncbi.nlm.nih.gov/pubmed/17404270?dopt">D Baatar, P Olkhanud, K Sumitomo, D Taub, R Gress, A Biragyn. Human peripheral blood T regulatory cells (Tregs), functionally primed CCR4+ Tregs and unprimed CCR4- Tregs, regulate effector T cells using FasL. J Immunol. 2007 Apr 15;178(8):4891-4900.</a> 147164607 Arya, Bira NIH - NIA NIA Arya, Bira (NIA) 1 147164606 Matsushima, Kouji University of Tokyo Matsushima, Kouji 2 147164608 Bataar, Dolgor NIH - NIA NIA Bataar, Dolgor (NIA) 3 147164607 Arya, Bira NIH - NIA NIA Arya, Bira (NIA) 1 147164606 Matsushima, Kouji University of Tokyo Matsushima, Kouji 2 147164608 Bataar, Dolgor NIH - NIA NIA Bataar, Dolgor (NIA) 3 147157819 Chemoattractant-based Toxins Which Deplete T Regulatory Cells To Improve Vaccine Immune Responses For Cancer And Other Clinically Relevant Diseases E-027-2005-0 Filing authorized National Institute on Aging (NIH/NIA), University of Tokyo 91789173 Guyton, Nicole darackn@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America darackn@mail.nih.gov?subject=Web Inquiry on [TAB-4403] Novel Chemoattractant-Based Toxins To Improve Vaccine Immune Responses for Cancer and Infectious Diseases&body=Please send me information about technology [TAB-4403] Novel Chemoattractant-Based Toxins To Improve Vaccine Immune Responses for Cancer and Infectious Diseases.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Guyton, Nicole<br><a href="mailto:darackn@mail.nih.gov?subject=Web Inquiry on [TAB-4403] Novel Chemoattractant-Based Toxins To Improve Vaccine Immune Responses for Cancer and Infectious Diseases&body=Please send me information about technology [TAB-4403] Novel Chemoattractant-Based Toxins To Improve Vaccine Immune Responses for Cancer and Infectious Diseases.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">darackn@mail.nih.gov</a><br> 147168726 E-027-2005-0 E-027-2005-0-US-01 METHODS AND COMPOSITIONS FOR MODULATING IMMUNE TOLERANCE PRV US 60/722,675 Abandoned US <br />Provisional (PRV) 60/722,675<br />Filed on 2005-09-30<br />Status: Abandoned 147168727 E-027-2005-0 E-027-2005-0-PCT-02 Chemoattractant-based Toxins Which Deplete T Regulatory Cells To Improve Vaccine Immune Responses For Cancer And Other Clinically Relevant Diseases PCT Patent Cooperation Treaty PCT/US2006/038195 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2006/038195<br />Filed on 2006-09-28<br />Status: Expired 147168728 E-027-2005-0 E-027-2005-0-AU-03 Chemoattractant-based Toxins Which Deplete T Regulatory Cells To Improve Vaccine Immune Responses For Cancer And Other Clinically Relevant Diseases National Stage Australia 2006297126 Abandoned Australia <br />National Stage 2006297126<br />Filed on 2006-09-28<br />Status: Abandoned 147168729 E-027-2005-0 E-027-2005-0-CA-04 Chemoattractant-based Toxins Which Deplete T Regulatory Cells To Improve Vaccine Immune Responses For Cancer And Other Clinically Relevant Diseases National Stage Canada 2624662 Abandoned Canada <br />National Stage 2624662<br />Filed on 2006-09-28<br />Status: Abandoned 147168730 E-027-2005-0 E-027-2005-0-EP-05 Chemoattractant-based Toxins Which Deplete T Regulatory Cells To Improve Vaccine Immune Responses For Cancer And Other Clinically Relevant Diseases National Stage European Patent 06825277.4 Abandoned European Patent <br />National Stage 06825277.4<br />Filed on 2006-09-28<br />Status: Abandoned 147168731 E-027-2005-0 E-027-2005-0-US-06 METHODS AND COMPOSITIONS FOR MODULATING IMMUNE TOLERANCE National Stage US 8,795,674 11/992,880 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8795674 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8795674">8,795,674</a><br />Filed on 2008-03-28<br />Status: Issued 147168732 E-027-2005-0 E-027-2005-0-EP-07 Chemoattractant-based Toxins Which Deplete T Regulatory Cells To Improve Vaccine Immune Responses For Cancer And Other Clinically Relevant Diseases DIV European Patent 6825277.4 Administratively Closed European Patent <br />Divisional (DIV) 6825277.4<br />Filed on 2006-09-28<br />Status: Administratively Closed 147168733 E-027-2005-0 E-027-2005-0-US-08 Methods and Compositions for Modulating Immune Tolerance DIV US 9,605,044 14/313,481 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9605044 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9605044">9,605,044</a><br />Filed on 2014-06-24<br />Status: Issued 147168734 E-027-2005-0 E-027-2005-0-US-09 Methods and Compositions for Modulating Immune Tolerance DIV US 10,300,115 15/404,189 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10300115 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10300115">10,300,115</a><br />Filed on 2017-01-11<br />Status: Issued 147169754 AIDS/HIV 147169756 Chemoattractant toxins 147169758 Immune Diseases 147169759 immunosuppressant 147169761 T regulatory (Treg) cells 147169762 TUBERCULOSIS TAB-4205 147157490 Novel Dopamine Receptor Ligands As Therapeutics For Central Nervous System Disorders NIDA Gastroenterology, Licensing, Research Materials Gastroenterology Licensing Research Materials Jianjing Cao, George Cyriac, Peter Grundt, Robert Luedtke, Amy Newman <h2>Summary:</h2> <p>The National Institute on Drug Abuse&#39;s Medications Discovery Research Branch is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize 4-phenylpiperazine derivatives as dopamine D3 selective ligands.</p> <h2>Description of Technology:</h2> <p>The dopamine D3 receptor subtype is a member of the dopamine D2 subclass of receptors.&nbsp; These receptors have been implicated in a number of CNS disorders, including psychostimulant abuse, psychosis and Parkinson&#39;s disease.&nbsp; Compounds that bind with high affinity and selectivity to D3 receptors can not only provide important tools with which to study the structure and function of this receptor subtype, but may also have therapeutic potential in the treatment of numerous psychiatric and neurologic disorders.&nbsp;</p> <p>The 4-phenylpiperazine derivatives are an important class of dopamine D3 selective ligands.&nbsp; However, due to their highly lipophilic nature, these compounds suffer from solubility problems in aqueous media and reduced bioavailability.&nbsp; To address this problem, a process was designed to introduce functionality into the carbon chain linker of these compounds.&nbsp; Compared to currently available dopamine D3 receptor ligands, the resulting compounds show improved pharmacological properties and D3 selectivities but due to their more hydrophilic nature, these derivatives are predicted to have improved water solubility and bioavailability.</p> <p>R&amp;D Status: Pre-clinical discovery</p> <p>Further R&amp;D Needed:</p> <ul> <li>Evaluate selected compounds in animal models of drug abuse, psychosis, obesity and Parkinson&#39;&#39;s disease</li> <li>Design and synthesize novel, functionalized analogs using both classical and computational drug design to improve D3 receptor affinity and selectivity</li> <li>Evaluate compounds for binding in D3 and D2 receptor expressing cell lines and in in vitro functional assays</li> <li>Correlate in vitro binding affinities with in vivo function in rats and monkeys and evaluate compounds in knockout mice models</li> <li>Pursue PET and SPECT imaging agents by radiolabel of D3 ligands and evaluation in rats and non-human primates.</li> </ul> <p>IP Status:&nbsp; PCT Application PCT/US2007/071412 filed 6/17/2007</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Therapeutics for a variety of psychiatric and neurologic disorders</li> <li>Research tools to study D3 receptor structure and function</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Improved pharmacological properties and selectivity over existing dopamine D3 receptor ligands.</li> <li>Hydrophilic nature likely to lead to improved water solubility and bioavailability</li> </ul> 2016-02-16 2026-04-16 2017-11-20 2026-04-16 2023-04-06 2019-09-26 False True Basic (Target Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2017-11-20 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147163907 Newman, Amy NIH - NIDA NIDA Newman, Amy (NIDA) 1 147163909 Grundt, Peter NIH - NIDA NIDA Grundt, Peter (NIDA) 2 147163910 Cao, Jianjing NIH - NIDA NIDA Cao, Jianjing (NIDA) 3 147163908 Luedtke, Robert University of North Texas Health Science Center Luedtke, Robert 4 147163911 Cyriac, George NIH - NIDA Cyriac, George 5 147163907 Newman, Amy NIH - NIDA NIDA Newman, Amy (NIDA) 1 147163909 Grundt, Peter NIH - NIDA NIDA Grundt, Peter (NIDA) 2 147163910 Cao, Jianjing NIH - NIDA NIDA Cao, Jianjing (NIDA) 3 147163908 Luedtke, Robert University of North Texas Health Science Center Luedtke, Robert 4 147163911 Cyriac, George NIH - NIDA Cyriac, George 5 147158037 4-Phenylpiperazine Derivatives With Functionalized Linkers As Dopamine D3 Receptor Selective Ligands With Drug Abuse Therapeutic Potential E-128-2006-0 Filing authorized National Institute on Drug Abuse (NIDA), University of North Texas Health Science Center 83737255 Baxter, Merissa merissa.baxter@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB merissa.baxter@nih.gov?subject=Web Inquiry on [TAB-4205] Novel Dopamine Receptor Ligands As Therapeutics For Central Nervous System Disorders&body=Please send me information about technology [TAB-4205] Novel Dopamine Receptor Ligands As Therapeutics For Central Nervous System Disorders.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Baxter, Merissa<br><a href="mailto:merissa.baxter@nih.gov?subject=Web Inquiry on [TAB-4205] Novel Dopamine Receptor Ligands As Therapeutics For Central Nervous System Disorders&body=Please send me information about technology [TAB-4205] Novel Dopamine Receptor Ligands As Therapeutics For Central Nervous System Disorders.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">merissa.baxter@nih.gov</a><br> 147167344 E-128-2006-0 E-128-2006-0-PCT-01 4-Phenylpiperazine Derivatives With Functionalized Linkers as Dopamine D3 Receptor Selective Ligands and Methods Of Use PCT Patent Cooperation Treaty PCT/US2007/071412 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2007/071412<br />Filed on 2007-06-15<br />Status: Expired 147167345 E-128-2006-0 E-128-2006-0-US-02 4-Phenylpiperazine Derivatives With Functionalized Linkers As Dopamine D3 Receptor Selective Ligands And Methods of Use National Stage US 8,748,608 12/664,668 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8748608 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8748608">8,748,608</a><br />Filed on 2010-06-25<br />Status: Issued 147167346 E-128-2006-0 E-128-2006-0-AU-03 4-Phenylpiperazine Derivatives With Functionalized Linkers as Dopamine D3 Receptor Selective Ligands and Methods Of Use National Stage Australia 2007354861 2007354861 Issued Australia <br />National Stage 2007354861<br />Filed on 2007-06-15<br />Status: Issued 147167347 E-128-2006-0 E-128-2006-0-CA-04 4-Phenylpiperazine Derivatives With Functionalized Linkers as Dopamine D3 Receptor Selective Ligands and Methods Of Use National Stage Canada 2690789 2690789 Issued Canada <br />National Stage 2690789<br />Filed on 2012-03-20<br />Status: Issued 147167348 E-128-2006-0 E-128-2006-0-US-05 4-Phenylpiperazine Derivatives With Functionalized Linkers As Dopamine D3 Receptor Selective Ligands And Methods of Use DIV US 14/266,076 Abandoned US <br />Divisional (DIV) 14/266,076<br />Filed on 2014-04-30<br />Status: Abandoned TAB-4211 147157496 Single Domain Antibodies targeting HPV E6/E7 Oncogenic Peptide/MHC complexes NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Zhijian Duan, Christian Hinrichs, Mitchell Ho <h2>Description of Technology:</h2> <p>Human papillomavirus (HPV) has been linked to many cancers including cervix, uterine, anus, vulva, vagina, and penis. Although HPV vaccines exist to prevent HPV-associated cancers, there are still more than 5,000 deaths caused by HPV-associated cancers each year in the US and cervical cancer continues to be the second leading cause of cancer death in women ages 20 to 39. Engineered T cell receptor (TCR) therapy has been effective in some patients with HPV16 E6 expressing cancers, however, there continues to be a need for more therapies targeting HPV16 E6, when current treatment options fail.&nbsp;</p> <p>NCI inventors have identified two nanobodies (F5 and G9) against MHC/E6 by phage display technologies from the lab&rsquo;s multiple dromedary camel VHH single domain libraries. F5 and G9 could recognize the MHC/E6 complex more specifically over the control nanobodies. CAR T cells using the F5 nanobody as the binding domain showed specific killing of the target tumor cells in mouse models. These nanobodies could potentially treat cancers associated with the expression of HPV16 E6.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Therapeutic applications include the unconjugated antibodies and their use as a targeting moiety for CARs, TCRs, RITs, ADCs, immunocytokines and bispecific antibodies</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>These anti- HPV E6/E7 nanobodies have an advantage, due to their small size, to potentially bind to epitopes unavailable to more conventional antibodies or TCRs</li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for Single Domain Antibodies targeting HPV E6/E7 Oncogenic Peptide/MHC complexes 2023-04-03 2026-04-16 2023-04-03 2026-04-16 2023-04-03 adoptive cell therapy, HO, HPV16, Immunotherapy, NANOBODY, T Cell Receptor False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2023-04-03 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147163925 Ho, Mitchell NIH - NCI NCI Ho, Mitchell (NCI) 1 147163927 Duan, Zhijian NCI - CCR NCI Duan, Zhijian (NCI) 2 147163926 Hinrichs, Christian NIH - Rutgers Cancer Institute of New Jersey Hinrichs, Christian 3 147163925 Ho, Mitchell NIH - NCI NCI Ho, Mitchell (NCI) 1 147163927 Duan, Zhijian NCI - CCR NCI Duan, Zhijian (NCI) 2 147163926 Hinrichs, Christian NIH - Rutgers Cancer Institute of New Jersey Hinrichs, Christian 3 147158133 Single Domain Antibodies Targeting HPV E6/E7 Oncogenic Peptide/MHC Complexes E-169-2022-0 Filing authorized NCI, Rutgers Cancer Institute of New Jersey 83731987 Dhal, Abritee abritee.dhal@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-4211] Single Domain Antibodies targeting HPV E6/E7 Oncogenic Peptide/MHC complexes&body=Please send me information about technology [TAB-4211] Single Domain Antibodies targeting HPV E6/E7 Oncogenic Peptide/MHC complexes.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dhal, Abritee<br><a href="mailto:abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-4211] Single Domain Antibodies targeting HPV E6/E7 Oncogenic Peptide/MHC complexes&body=Please send me information about technology [TAB-4211] Single Domain Antibodies targeting HPV E6/E7 Oncogenic Peptide/MHC complexes.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">abritee.dhal@nih.gov</a><br> 147167370 E-169-2022-0 E-169-2022-0-US-01 Single Domain Antibodies Targeting HPV E6/E7 Oncogenic Peptide/MHC Complexes PRV US 63/374,307 Expired US <br />Provisional (PRV) 63/374,307<br />Filed on 2022-09-01<br />Status: Expired 147167371 E-169-2022-0 E-169-2022-0-PC-01 Single Domain Antibodies Targeting HPV E6/E7 Oncogenic Peptide/MHC Complexes PCT Patent Cooperation Treaty PCT/US2023/073144 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2023/073144<br />Filed on 2023-08-30<br />Status: Expired 147172911 adoptive cell therapy 147172912 HO 147172913 HPV16 147172914 Immunotherapy 147172915 NANOBODY 147172916 T Cell Receptor TAB-4088 147157370 High-Throughput Assay for Detection and Monitoring of Endocrine Disrupting Chemicals in Water Sources NCI Collaboration, Diagnostics, Endocrinology, Licensing Collaboration Diagnostics Endocrinology Licensing <h2>Description of Technology:</h2> <p>There is growing awareness that a wide variety of synthetic and natural compounds that may be present in water sources, such as streams, wells, and ground water, may lead to adverse health effects, including increased cancer risk. Even low concentrations of these compounds are of concern, as they may have biological effects at concentrations of parts per billion or less. In particular, the presence of endocrine disrupting chemicals (EDCs) in the environment is under examination for potential adverse effects on human health, such as immune suppression, impaired fertility, and increased incidence of cancer, diabetes, and obesity. However, these compounds are often laborious and difficult to measure and thus are not commonly monitored. In addition, even if such compounds are detected, only the known compound itself is typically measured, neglecting its metabolites which are more likely to be found in water samples and retain endocrine disrupting activity.&nbsp;</p> <p>Inventors at the NCI&rsquo;s Laboratory of Receptor Biology and Gene Expression have developed a novel assay methodology for detecting EDCs in contaminated water. The assay utilizes fluorescently labeled nuclear steroid receptor constructs in a high-throughput, mammalian cell-based format. Detection and measurements are based on translocation of the fluorescent marker from the cytoplasm to the nucleus in the presence of a ligand that interacts with a specific steroid receptor. Overall, this assay has the capability to detect very low concentrations of EDCs in water or other liquid samples. The inventors have demonstrated proof of concept for this technology by testing for the presence of Glucocorticoid Receptor (GR), Androgen Receptor (AR), Estrogen Receptor (ER), Aryl hydrocarbon receptor (AhR), Progesterone Receptor (PR), and Thyroid Hormone Receptor (TR) activity in water samples. For example, NCI scientists screened water samples collected from 14 states in the US and found AR activity in 35% of samples, as well as previously unrecognized glucocorticoid (GC) activity in 27% of the samples. In particular, the compound androst-4-en-3,6-dione was identified in one of the samples. AR-dependent nuclear translocation and transcriptional activation was also confirmed for two AR-responsive genes, NKX3.1 and RHOU. Moreover, NKX3.1 is a homeobox gene frequently deleted in prostate cancers, and RHOU is implicated in epidermal growth factor receptor signaling and cell migration.&nbsp;</p> <p>A product or service based on this technology could fulfill an unmet need for a high-throughput, rapid method for screening multiple water samples for contaminants with potential endocrine-disrupting activity. The NCI is seeking co-development partners and/or licensees for this technology as a product or service for detecting and screening for endocrine disrupting chemicals in water samples.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Water source testing</li> <li>Wastewater testing</li> <li>Drug ligand screening for agonistic and antagonistic activity</li> <li>Research tool to detect known and orphan receptor activity</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>High-throughput and rapid testing&nbsp;</li> <li>High sensitivity and selectivity</li> <li>Readily adaptable for use with a variety of endocrine receptor targets</li> <li>Can detect many EDC variants modified in the environment or other compounds that may act and interfere like EDCs&nbsp;</li> <li>Does not require a priori knowledge of the ligand chemical structure&nbsp;</li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for a product or service for detecting and screening for endocrine disrupting chemicals (EDCs) in samples from water sources and/or wastewater. 2023-03-02 2026-04-16 2023-03-13 2026-04-16 2023-03-02 EDC detection, EDCs, Endocrine disrupting chemicals, Endocrine disruption screening, Endocrine receptor ligand screening, Hager, Hormone receptor activity, Stavreva, Wastewater, Water sources False True Prototype True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2023-03-13 52406769 Prototype 52406769 NCI 37470483 Website Abstract 147161899 Bruno NE, et al. Chemical systems biology reveals mechanisms of glucocorticoid receptor signaling. https://pubmed.ncbi.nlm.nih.gov/33510451/ <a href="https://pubmed.ncbi.nlm.nih.gov/33510451/">Bruno NE, et al. Chemical systems biology reveals mechanisms of glucocorticoid receptor signaling.</a> 147162015 Stavreva DA, et al. Novel cell-based assay for detection of thyroid receptor beta-interacting environmental contaminants. https://pubmed.ncbi.nlm.nih.gov/27528272/ <a href="https://pubmed.ncbi.nlm.nih.gov/27528272/">Stavreva DA, et al. Novel cell-based assay for detection of thyroid receptor beta-interacting environmental contaminants.</a> 147162054 Jones RR, et al. Pilot study of global endocrine disrupting activity in Iowa public drinking water utilities using cell-based assays. https://pubmed.ncbi.nlm.nih.gov/32018941/ <a href="https://pubmed.ncbi.nlm.nih.gov/32018941/">Jones RR, et al. Pilot study of global endocrine disrupting activity in Iowa public drinking water utilities using cell-based assays.</a> 147162093 Stavreva DA, et al. Prevalent contamination of U.S. water sources with biologically active steroids. https://pubmed.ncbi.nlm.nih.gov/23226835/ <a href="https://pubmed.ncbi.nlm.nih.gov/23226835/">Stavreva DA, et al. Prevalent contamination of U.S. water sources with biologically active steroids.</a> 147162171 Paul-Friedman K, et al. Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library. https://pubmed.ncbi.nlm.nih.gov/31566444/ <a href="https://pubmed.ncbi.nlm.nih.gov/31566444/">Paul-Friedman K, et al. Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library.</a> 147162249 Varticovski L, et al. Endocrine disruptors of sex hormone activities. https://pubmed.ncbi.nlm.nih.gov/34339825/ <a href="https://pubmed.ncbi.nlm.nih.gov/34339825/">Varticovski L, et al. Endocrine disruptors of sex hormone activities.</a> 147162287 Bradley PM, et al. Juxtaposition of intensive agriculture, vulnerable aquifers, and mixed chemical/microbial exposures in private-well tap water in northeast Iowa. https://pubmed.ncbi.nlm.nih.gov/36657670/ <a href="https://pubmed.ncbi.nlm.nih.gov/36657670/">Bradley PM, et al. Juxtaposition of intensive agriculture, vulnerable aquifers, and mixed chemical/microbial exposures in private-well tap water in northeast Iowa.</a> 147162326 Stavreva DA, et al. Mapping multiple endocrine disrupting activities in Virginia rivers using effect-based assays. https://pubmed.ncbi.nlm.nih.gov/33592464/ <a href="https://pubmed.ncbi.nlm.nih.gov/33592464/">Stavreva DA, et al. Mapping multiple endocrine disrupting activities in Virginia rivers using effect-based assays.</a> 147162440 Lynch C, et al. Identifying environmental chemicals as agonists of the androgen receptor by using a quantitative high-throughput screening platform. https://pubmed.ncbi.nlm.nih.gov/28478275/ <a href="https://pubmed.ncbi.nlm.nih.gov/28478275/">Lynch C, et al. Identifying environmental chemicals as agonists of the androgen receptor by using a quantitative high-throughput screening platform.</a> 155750804 A Living Cell Fluorescence Assay For Detection And Monitoring Of Endocrine Disrupting Chemicals In Water Sources E-269-2011-0 Filing authorized NCI 91826910 McCrary, Michaela michaela.mccrary@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America michaela.mccrary@nih.gov?subject=Web Inquiry on [TAB-4088] High-Throughput Assay for Detection and Monitoring of Endocrine Disrupting Chemicals in Water Sources&body=Please send me information about technology [TAB-4088] High-Throughput Assay for Detection and Monitoring of Endocrine Disrupting Chemicals in Water Sources.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov McCrary, Michaela<br><a href="mailto:michaela.mccrary@nih.gov?subject=Web Inquiry on [TAB-4088] High-Throughput Assay for Detection and Monitoring of Endocrine Disrupting Chemicals in Water Sources&body=Please send me information about technology [TAB-4088] High-Throughput Assay for Detection and Monitoring of Endocrine Disrupting Chemicals in Water Sources.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">michaela.mccrary@nih.gov</a><br> 155750809 E-269-2011-0 E-269-2011-0-US-01 Kits For Detecting And Monitoring Endocrine Disrupting Chemicals (EDCs) PRV US 61/656,473 Abandoned US <br />Provisional (PRV) 61/656,473<br />Filed on 2012-06-06<br />Status: Abandoned 155750810 E-269-2011-0 E-269-2011-0-PCT-02 KITS FOR DETECTING AND MONITORING ENDOCRINE DISRUPTING CHEMICALS (EDCS) PCT Patent Cooperation Treaty PCT/US2013/044569 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2013/044569<br />Filed on 2013-06-06<br />Status: Expired 155750811 E-269-2011-0 E-269-2011-0-US-03 KITS FOR DETECTING AND MONITORING ENDOCRINE DISRUPTING CHEMICALS (EDCS) ORD US 9,040,248 13/912,071 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9040248 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9040248">9,040,248</a><br />Filed on 2013-06-06<br />Status: Issued 155750812 E-269-2011-0 E-269-2011-0-EP-04 KITS FOR DETECTING AND MONITORING ENDOCRINE DISRUPTING CHEMICALS (EDCS) National Stage European Patent 13730754.2 Abandoned European Patent <br />National Stage 13730754.2<br />Filed on 2013-06-06<br />Status: Abandoned 155750813 E-269-2011-0 E-269-2011-0-JP-05 KITS FOR DETECTING AND MONITORING ENDOCRINE DISRUPTING CHEMICALS (EDCS) National Stage Japan 6388575 2015-516223 Issued Japan <br />National Stage 2015-516223<br />Filed on 2014-12-05<br />Status: Issued 155750814 E-269-2011-0 E-269-2011-0-US-06 KITS FOR DETECTING AND MONITORING ENDOCRINE DISRUPTING CHEMICALS (EDCS) National Stage US 14/405,696 Abandoned US <br />National Stage 14/405,696<br />Filed on 2014-12-04<br />Status: Abandoned 155750815 E-269-2011-0 E-269-2011-0-US-07 METHODS FOR DETECTING AND MONITORING ENDOCRINE DISRUPTING CHEMICALS (EDCS) CON US 9,921,211 14/693,511 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9921211 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9921211">9,921,211</a><br />Filed on 2015-04-22<br />Status: Issued 155750816 E-269-2011-0 E-269-2011-0-JP-08 KITS FOR DETECTING AND MONITORING ENDOCRINE DISRUPTING CHEMICALS (EDCS) DIV Japan 6546311 2018-057959 Issued Japan <br />Divisional (DIV) 2018-057959<br />Filed on 2018-03-26<br />Status: Issued 147174481 EDC detection 147174483 EDCs 147174485 Endocrine disrupting chemicals 147174487 Endocrine disruption screening 147174489 Endocrine receptor ligand screening 147174491 Hager 147174493 Hormone receptor activity 147174495 Stavreva 147174497 Wastewater 147174499 Water sources TAB-4117 147157399 Method for HLA LOH Detection in Liquid Biopsies NCI Collaboration, Diagnostics, Licensing, Oncology Collaboration Diagnostics Licensing Oncology James Gulley, Cem Sievers, Andrew Sinkoe <h2>Description of Technology:</h2> <p>Human leukocyte antigen (HLA) LOH (LOH) is a known resistance mechanism by which cancers evade T cell receptor-(TCR-)based immunotherapies. This class of therapies includes immune checkpoint inhibition (ICI, e.g., Pembrolizumab), engineered TCR (T cell receptor)-T cell adoptive transfer, tumor infiltrating lymphocytes (TIL), T-cell engagers, and other modalities. Dozens of therapies in this category were developed with many in clinical trials. The resistance mechanism noted here, HLA LOH, causes these therapies to fail. Therefore, it is beneficial to know before treating a patient whether their cancer&rsquo;s genome has undergone HLA LOH. There is currently no HLA LOH detection method with widespread use in the market and, furthermore, no non-invasive HLA LOH detection test available. Approximately 17% of all cancer patients undergo HLA LOH (Montesion et al., Cancer Discovery, 2021) and would therefore be less likely to respond to TCR-based immunotherapies, making a test for HLA LOH crucial for attaining better patient outcomes.</p> <p>The inventors at the National Cancer Institute (NCI) a developed a non-invasive test for HLA LOH detection in liquid biopsies from blood. As a companion diagnostic (CDx), this HLA LOH detection method allows for improved patient selection. It determines patients unlikely to benefit prior to immunotherapy and thus, can avoid the toxicity, costs, and prevent delay in effective therapy.&nbsp;</p> <p>This is an application of precision oncology. For HLA LOH detection, treatment decisions can be based in part on the HLA LOH status of the patient&rsquo;s cancer, and a patient&rsquo;s treatment course is tailored to give the patient rapid access to more effective therapy. Because the test is non-invasive, determining HLA LOH status does not require surgery. This dramatically increases patient comfort, improves their experience and decreases healthcare costs. An additional benefit is that the patient will not undergo unnecessary treatments that could cause toxicities.&nbsp;</p> <p>The Center for Immuno-Oncology at the NCI is primarily looking for collaborators to co-develop this technology with the inventor. As a companion diagnostic, it will be paired with immunotherapies, to select patients who are most likely to achieve treatment benefit. The inventors seek co-development partners who developed immunotherapies that function via TCR-based mechanisms. The goal is to conduct clinical trials for the diagnostic concomitantly with the drug. The end-result of the trial will be determination of how accurately the diagnostic predicts efficacy of the drug. A companion diagnostic can increase the market potential of therapeutics by allowing them to be used as a first-line treatment. The companion diagnostic can be co-developed and/or co-marketed with a drug at any stage of the drug&rsquo;s regulatory approval process, from Phase I to FDA-approved. The next step for the diagnostic is a Phase I clinical trial, with possible IDE exemption. The companion diagnostic may also be a candidate for College of American Pathologists (CAP) accreditation and, more stringently, Clinical Laboratory Improvement Amendments (CLIA) designation while the clinical trials are being conducted.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Companion diagnostic for TCR-based immunotherapies in experimental clinical trials</li> <li>Companion diagnostic for TCR-based immunotherapies FDA-approved clinical practice</li> <li>Research use in labs studying/developing new pre-clinical therapeutic candidates</li> <li>Research use in basic research labs studying immunotherapy resistance mechanisms, antigen processing and presentation and basic immunology</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Mean overall survival (mOS) in TMB-(tumor mutational burden-)low, HLA-intact patients is twice as high as in patients with TMB-low and HLA LOH, which creates an opportunity to benefit patients by treating them with Pembrolizumab despite their TMB-low status (Montesion et al., Cancer Discovery, 2021); therefore HLA LOH as a biomarker may complement TMB-low for improved patient selection</li> <li>Non-invasive test not requiring surgical removal of solid tumor tissue</li> <li>Allows patient-tailored treatment utilizing a wide range of TCR-based immunotherapies</li> <li>Potential improvement in patient survival</li> <li>Potential time and money savings for patients, insurance companies, oncologists, and immunotherapy manufacturers by facilitating the selection of a precision treatment course for each patient</li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for a companion diagnostic (CDx) that detects HLA LOH and other biomarkers to predict efficacy of TCR-T cell adoptive transfer, immune checkpoint inhibition (ICI), tumor infiltrating lymphocytes (TIL), and other TCR-mediated immunotherapies. 2023-03-01 2026-04-16 2026-04-16 2023-03-01 Companion Diagnostic, Gulley, HLA, Human Leukocyte Antigen, ICI, Immune Checkpoint Inhibition, Immunotherapy, LOH, Loss of Heterozygosity, Sinkoe, T cell therapy False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147163568 Sinkoe, Andrew NCI - CCR NCI Sinkoe, Andrew (NCI) 1 147163567 Gulley, James NIH - NCI NCI Gulley, James (NCI) 2 147163569 Sievers, Cem National Institute on Deafness and Other Communication Disorders (NIDCD) NCI Sievers, Cem (NCI) 3 147163568 Sinkoe, Andrew NCI - CCR NCI Sinkoe, Andrew (NCI) 1 147163567 Gulley, James NIH - NCI NCI Gulley, James (NCI) 2 147163569 Sievers, Cem National Institute on Deafness and Other Communication Disorders (NIDCD) NCI Sievers, Cem (NCI) 3 147157861 Method Of HLA LOH Detection In Liquid Biopsies E-045-2022-0 Filing authorized NIH - NCI 83694133 Gulay French, Suna suna.gulay@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB suna.gulay@nih.gov?subject=Web Inquiry on [TAB-4117] Method for HLA LOH Detection in Liquid Biopsies&body=Please send me information about technology [TAB-4117] Method for HLA LOH Detection in Liquid Biopsies.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Gulay French, Suna<br><a href="mailto:suna.gulay@nih.gov?subject=Web Inquiry on [TAB-4117] Method for HLA LOH Detection in Liquid Biopsies&body=Please send me information about technology [TAB-4117] Method for HLA LOH Detection in Liquid Biopsies.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">suna.gulay@nih.gov</a><br> 147160958 E-045-2022-0 E-045-2022-0-US-01 METHOD OF HLA LOH DETECTION IN LIQUID BIOPSIES PRV US 63/299,672 Expired US <br />Provisional (PRV) 63/299,672<br />Filed on 2022-01-14<br />Status: Expired 147166647 E-045-2022-0 E-045-2022-0-PCT-02 Method of HLA loss Heterozygosity Detection in Liquid Biopsies PCT Patent Cooperation Treaty PCT/US2023/060664 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2023/060664<br />Filed on 2023-01-13<br />Status: Expired 162755006 E-045-2022-0 E-045-2022-0-US-02 METHOD OF HUMAN LEUKOCYTE ANTIGEN LOSS OF HETEROZYGOSITY DETECTION IN LIQUID BIOPSIES National Stage US 18/729,138 Pending US <br />National Stage 18/729,138<br />Filed on 2024-07-15<br />Status: Pending 162755007 E-045-2022-0 E-045-2022-0-EP-01 Method of HLA loss Heterozygosity Detection in Liquid Biopsies National Stage European Patent 23705845.8 Pending European Patent <br />National Stage 23705845.8<br />Filed on 2024-08-08<br />Status: Pending 147170222 Companion Diagnostic 147170223 Gulley 147170224 HLA 147170225 Human Leukocyte Antigen 147170226 ICI 147170227 Immune Checkpoint Inhibition 147170228 Immunotherapy 147170229 LOH 147170230 Loss of Heterozygosity 147170231 Sinkoe 147170232 T cell therapy TAB-3896 147157176 A Human Monoclonal Antibody Against Deacetylated PNAG for Use as an Antimicrobial Agent NCI Collaboration, Infectious Disease, Licensing, Therapeutics Collaboration Infectious Disease Licensing Therapeutics Jeffrey Gildersleeve, Joel Temme <h2>Description of Technology:</h2> <p>Biofilms are complex microbial communities, surface attached and held together by self-produced polymer matrices.&nbsp; These matrices are mainly composed of polysaccharides, secreted proteins and nucleic acids.&nbsp; Poly-N-acetyl glucosamine (PNAG) is a highly conserved surface polysaccharide expressed by a range of bacterial, fungal and protozoan microorganisms. It is associated with microbial biofilm formation.&nbsp; Partial deacetylation of PNAG (dPNAG) is critical for the function of PNAG in biofilm formation and required for the structural development and integrity of biofilm.&nbsp; Antibodies to PNAG and/or dPNAG have significant potential as broad-spectrum therapeutics for a range of bacterial and fungal infections.&nbsp; Research suggests that dPNAG is a better target than PNAG for antibody-based therapeutics; however, identification of dPNAG antibodies has been challenging.&nbsp;&nbsp;</p> <p>Researchers at the National Cancer Institute (NCI) identified a human antibody, denoted TG10, that selectively binds to dPNAG with potential as a novel antimicrobial agent.&nbsp; F598, a human IgG1 monoclonal antibody (mAb) which binds to both PNAG and dPNAG, is in active development as a potential antimicrobial agent in clinical trials.&nbsp; The novel antibody TG10 binds to a different location on the biofilm and shows synergistic effects when administered in combination with F598.&nbsp; The TG10 antibody has been tested both in vitro and in vivo and shows good efficacy both alone and in combination with F598.&nbsp;&nbsp;</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Therapeutic use against multiple microbial pathogens, either alone or in combination with other anti-PNAG/dPNAG agents</li> <li>Prophylactic use to prevent high-risk infections&nbsp;&nbsp;</li> <li>Diagnostic imaging (using labeled form of TG10)</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Possible combinatorial or synergistic effect on existing dPNAG or PNAG antibodies.&nbsp;</li> <li>Binds to a different location on dPNAG than the known dPNAG antibody F598&nbsp;</li> <li>Suggestion that combination therapy with TG10 and F598 is superior to either as mono-therapy</li> <li>F598 already used in human clinical trials; existing safety data could facilitate regulatory process of a combination therapy</li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for the development of an anti-deacetylated poly-N-acetyl glucosamine (dPNAG) antibody for use as an antimicrobial agent. 2023-03-01 2026-04-16 2026-04-16 2023-03-01 ANTIMICROBIAL, Biofilm, Deacetyleated Poly-N-Acetyl Glucosamine, dPNAG, Gildersleeve, Mab, Monoclonal Antibody, TG10 False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147162108 Temme JS, et al. Microarray-guided evaluation of the frequency, B-cell origins, and selectivity of human glycan-binding antibodies reveals new insights and novel antibodies. https://pubmed.ncbi.nlm.nih.gov/29786478/ <a href="https://pubmed.ncbi.nlm.nih.gov/29786478/">Temme JS, et al. Microarray-guided evaluation of the frequency, B-cell origins, and selectivity of human glycan-binding antibodies reveals new insights and novel antibodies.</a> 147162783 Gildersleeve, Jeffrey NIH - NCI NCI Gildersleeve, Jeffrey (NCI) 1 147162784 Temme, Joel NCI - CCR NCI Temme, Joel (NCI) 2 147162783 Gildersleeve, Jeffrey NIH - NCI NCI Gildersleeve, Jeffrey (NCI) 1 147162784 Temme, Joel NCI - CCR NCI Temme, Joel (NCI) 2 147157931 Human Monoclonal Antibody To Pathogen Associated Carbohydrate, Deacetylated-PNAG E-075-2022-0 Filing authorized Michigan State University, NCI 91814193 Freel, Rose rose.freel@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America rose.freel@nih.gov?subject=Web Inquiry on [TAB-3896] A Human Monoclonal Antibody Against Deacetylated PNAG for Use as an Antimicrobial Agent&body=Please send me information about technology [TAB-3896] A Human Monoclonal Antibody Against Deacetylated PNAG for Use as an Antimicrobial Agent.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Freel, Rose<br><a href="mailto:rose.freel@nih.gov?subject=Web Inquiry on [TAB-3896] A Human Monoclonal Antibody Against Deacetylated PNAG for Use as an Antimicrobial Agent&body=Please send me information about technology [TAB-3896] A Human Monoclonal Antibody Against Deacetylated PNAG for Use as an Antimicrobial Agent.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">rose.freel@nih.gov</a><br> 147161002 E-075-2022-0 E-075-2022-0-US-01 ANTIBODY MATERIALS AND METHODS TARGETING MICROBIAL POLYSACCHARIDES PRV US 63/319,090 Expired US <br />Provisional (PRV) 63/319,090<br />Filed on 2022-03-11<br />Status: Expired 147165119 E-075-2022-0 E-075-2022-0-PC-01 ANTIBODY MATERIALS AND METHODS TARGETING MICROBIAL POLYSACCHARIDES PCT Patent Cooperation Treaty PCT/US2023/064047 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2023/064047<br />Filed on 2023-03-09<br />Status: Expired 147170833 ANTIMICROBIAL 147170834 Biofilm 147170836 Deacetyleated Poly-N-Acetyl Glucosamine 147170838 dPNAG 147170839 Gildersleeve 147170840 Mab 147170841 Monoclonal Antibody 147170843 TG10 TAB-4054 147157336 Methods of Determining Homeostatic Perturbations NICHD Collaboration, Diagnostics, Licensing, Neurology, Oncology Collaboration Diagnostics Licensing Neurology Oncology Peter Basser, Teddy Cai, Rea Ravin, Nathan Williamson <h2><strong>Description of Technology:</strong></h2> <p>Biological homeostasis is a state of steady internal, physical, and chemical conditions maintained by a living organism observed at the cellular level.&nbsp; Biological homeostasis can vary in order to alter the cellular physical and chemical conditions. Thus, it acts as a mechanism to define the physiological state of cellular activity; for instance resting states or active states (e.g., intensive physical or mental activity or intensive physical or mental stimulation).&nbsp; Deviations or perturbations from biological homeostasis, even at the cellular level, can be caused by pathological conditions such as diseases within the organism.&nbsp; Such deviations result in physical and chemical conditions that feedback to prolong pathological states as part of an injury or disease.&nbsp; In the extreme case, cell death can be characterized by a complete loss of homeostasis.&nbsp; In these ways, states of biological homeostasis are linked to physiological and pathological activities occurring at various levels of the organism (e.g., organelle, cell, tissue, organ).&nbsp; States of biological homeostasis can be difficult to detect using conventional analytical techniques.</p> <p>The disclosed technology consists of methods to determine a homeostatic steady-state of a biological entity.&nbsp; Also disclosed are methods to use Nuclear Magnetic Resonance (NMR) or Magnetic Resonance Imaging (MRI) to quantify a water exchange rate between at least two compartments in a biological system, to characterize physiological water transport, and methods for non-invasively measuring transmembrane exchange rates of endogenous water in a biological system under steady-state or non-steady-state conditions in near-real time.</p> <p>Researchers at the Eunice Kennedy Shriver National Institute of Child Health and Human Development are highly motivated in seeking licensing and/or collaboration partners further to develop methods and/or assays arising out of these technologies. An ideal partner would enter into both a Cooperative Research and Development Agreement (CRADA) and an exclusive license agreement towards commercialization of this diagnostic in the area of neurology or another suitable field.</p> <h2><strong>Potential Commercial Applications:</strong></h2> <ul> <li><span style="tab-stops:list .5in">Diagnosis of benign tumors capable of immune stimulation (&ldquo;hot&rdquo;)</span></li> <li><span style="tab-stops:list .5in">Diagnosis of abnormal central nervous system (CNS) states (ex: those caused by stroke, brain aneurysm, traumatic brain injury, migraine aura, and seizure)</span></li> <li><span style="tab-stops:list .5in">Determining the physiological or functional activity state of the central nervous system (CNS) (e.g. sleep, wake, intense stimulation)</span></li> <li><span style="tab-stops:list .5in">Evaluating CNS therapeutics and their mechanism of action</span></li> </ul> <h2><strong>Competitive Advantages:</strong></h2> <ul> <li><span style="tab-stops:list .5in">Absolute measurement&mdash;can directly detect the homeostatic state&mdash;does not require a relative reading.&nbsp;</span></li> <li><span style="tab-stops:list .5in">Uses endogenous water&mdash;does not require a tracer or contrast agent</span></li> <li><span style="tab-stops:list .5in">Less invasive than the current state of the art methods to measure spreading depolarization</span></li> </ul> Researchers at the NICHD seek licensing and/or co-development research collaborations for methods to determine homeostatic perturbations. 2023-01-21 2026-04-16 2023-01-22 2026-04-16 2023-01-23 Basser, Biomarkers, Central Nervous System, CNS, functional imaging, HOMEOSTASIS, Magnetic Resonance Imaging, MRI, NICHD, NMR, Nuclear Magnetic Resonance, r, Steady-state, The Eunice Kennedy Shriver National Institute of Child Healt False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2023-01-22 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147161885 Cai TX, et al. Disentangling the effects of restriction and exchange with diffusion exchange spectroscopy https://doi.org/10.3389/fphy.2022.805793 <a href="https://doi.org/10.3389/fphy.2022.805793">Cai TX, et al. Disentangling the effects of restriction and exchange with diffusion exchange spectroscopy</a> 147162001 Cai TX, et al. Rapid detection of the presence of diffusion exchange https://scholar.google.com/citations?view_op=view_citation&hl=en&user=xGKhQ3sAAAAJ&sortby=pubdate&citation_for_view=xGKhQ3sAAAAJ:_FxGoFyzp5QC <a href="https://scholar.google.com/citations?view_op=view_citation&hl=en&user=xGKhQ3sAAAAJ&sortby=pubdate&citation_for_view=xGKhQ3sAAAAJ:_FxGoFyzp5QC">Cai TX, et al. Rapid detection of the presence of diffusion exchange</a> 147162273 Williamson NH, Magnetic resonance measurements of cellular and sub-cellular membrane structures in live and fixed neural tissue https://pubmed.ncbi.nlm.nih.gov/31829935 <a href="https://pubmed.ncbi.nlm.nih.gov/31829935">Williamson NH, Magnetic resonance measurements of cellular and sub-cellular membrane structures in live and fixed neural tissue</a> 147163350 Ravin, Rea NIH - Celoptics, Inc. NIBIB Ravin, Rea (NIBIB) 1 147163351 Williamson, Nathan NIGMS NIGMS Williamson, Nathan (NIGMS) 2 147163352 Cai, Teddy NICHD NICHD Cai, Teddy (NICHD) 3 147163349 Basser, Peter NIH - NICHD NICHD Basser, Peter (NICHD) 4 147163350 Ravin, Rea NIH - Celoptics, Inc. NIBIB Ravin, Rea (NIBIB) 1 147163351 Williamson, Nathan NIGMS NIGMS Williamson, Nathan (NIGMS) 2 147163352 Cai, Teddy NICHD NICHD Cai, Teddy (NICHD) 3 147163349 Basser, Peter NIH - NICHD NICHD Basser, Peter (NICHD) 4 147158084 Magnetic Resonance Method Of Measuring Water Exchange For Identifying Brain Physiology And Pathology E-151-2021-0 Filing authorized Celoptics, Inc., NICHD, NIGMS 119617417 Ravilious, Geoffrey geoffrey.ravilious@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
geoffrey.ravilious@nih.gov?subject=Web Inquiry on [TAB-4054] Methods of Determining Homeostatic Perturbations&body=Please send me information about technology [TAB-4054] Methods of Determining Homeostatic Perturbations.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Ravilious, Geoffrey<br><a href="mailto:geoffrey.ravilious@nih.gov?subject=Web Inquiry on [TAB-4054] Methods of Determining Homeostatic Perturbations&body=Please send me information about technology [TAB-4054] Methods of Determining Homeostatic Perturbations.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">geoffrey.ravilious@nih.gov</a><br> 147166229 E-151-2021-0 E-151-2021-0-US-01 Magnetic Resonance Method Of Measuring Water Exchange For Identifying Brain Physiology And Pathology PRV US 63/277,881 Abandoned US <br />Provisional (PRV) 63/277,881<br />Filed on 2021-11-10<br />Status: Abandoned 147166230 E-151-2021-0 E-151-2021-0-PCT-02 NUCLEAR MAGNETIC RESONANCE METHODS OF DETERMINING HOMEOSTATIC PERTURBATIONS PCT Patent Cooperation Treaty PCT/US2022/049542 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2022/049542<br />Filed on 2022-11-10<br />Status: Expired 147172398 Basser 147172399 Biomarkers 147172400 Central Nervous System 147172401 CNS 147172403 functional imaging 147172404 HOMEOSTASIS 147172405 Magnetic Resonance Imaging 147172406 MRI 147172407 NICHD 147172408 NMR 147172410 Nuclear Magnetic Resonance 147172411 r 147172412 Steady-state 147172414 The Eunice Kennedy Shriver National Institute of Child Healt TAB-5024 158742599 Immunotherapy Delivery System to Improve Organ Transplantation Outcomes NCI Cardiology, Collaboration, Immunology, Nephrology, Therapeutics Cardiology Collaboration Immunology Nephrology Therapeutics Xiomara Calderon-Colon, Alexander Komin, Monessha Nambiar, Julia Patrone, Giorgio Raimondi, Joel Schneider, Olivia Tiburzi <h2>Summary:&nbsp;</h2> <p>The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a delivery system to improve transplant outcomes through inhibition of the JAK/STAT pathway.&nbsp;</p> <h2>Description of Technology:&nbsp;</h2> <p>Value Proposition</p> <ul> <li>Novel Therapy: &nbsp;Hydro(LNp), is a new therapeutic application to improve outcomes for organ transplant recipients</li> <li>Broad Scope: Potential to adapt for applications beyond transplantation, such as cancer, autoimmunity, and regenerative medicine</li> <li>Convenient Delivery: Hydro(LNp) is a two-phase delivery system to increase effectiveness in regulating transplant rejection</li> </ul> <p>Transplantation becomes the only therapeutic option after end-stage organ diseases and other devastating tissue loss. However, transplanted patients need to receive high doses of multi-drug immunosuppressive therapy for the rest of their life to prevent rejection. This current standard of care often entails dangerous side effects &ndash;including nephrotoxicity, cardiovascular disease, diabetes, and higher predisposition to infections and cancer. Therefore, there is an unmet need to identify a safer and effective treatment plan for transplant recipients.</p> <p>Researchers from the National Cancer Institute (NCI), Johns Hopkins University (JHU) and Johns Hopkins Applied Physics Laboratory (JH-APL) have identified that concomitant inhibition of the JAK/STAT pathway (via small molecule inhibitors) and of a key costimulatory pathway (via the biologic CTLA4-Ig) improves the control of the immune response to a transplant. As a combination therapy, they create &ldquo;Enhanced Costimulation Blockade,&rdquo; generating positive results without many rejection episodes or side effects. The multidisciplinary team of researchers engineered a dual component delivery system called Hydro(LNp), which delivers JAK inhibitors (JAKi) in a dual form: (1) microcrystalline drug deposits in the hydrogel and (2) lipid nanoparticles encapsulated drug. This product can be injected near the transplant site. The microcrystalline drug is released locally, while the lipid nanoparticle (LNp) carry it to the specific distal sites where the immune response against the transplant is initiated. The net result is a localized synergy with CTLA4-Ig effectively preventing graft rejection.&nbsp;</p> <p>This technology could positively impact transplantation-control of immune response to prevent transplant rejection. An autoimmunity-based therapeutic that inhibits JAK signaling could bring therapeutic benefit to autoimmune diseases such as rheumatoid arthritis, psoriasis, systemic lupus erythematosus and inflammatory bowel disease. Cancers with a dysregulated JAK/STAT pathway could also be treated with this technology.</p> <p>This technology is co-owned by JHU and The National Institutes of Health (NIH), and was co-developed by NCI, JHU and JH-APL. The summary of the technology was provided by Johns Hopkins Technology Ventures (JHTV) and <a href="https://profiles.hopkinsmedicine.org/provider/giorgio-raimondi/2777419" target="_blank">Dr. Giorgio Raimondi</a>. The technology is cross-listed on<a href="https://jhu.technologypublisher.com/technology/47435" target="_blank"> JHTV&rsquo;s website Tech Publisher</a>. The &nbsp;Hydro(LNp) is as a modification of an earlier NCI-JHU co-owned technology (NIH Ref. No.&nbsp; E-123-2018) which is cross-listed as <a href="https://jhu.technologypublisher.com/technology/47435" target="_blank">Case ID:15347 on Tech Publisher</a>.&nbsp;</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Prevent transplant rejection</li> <li>Autoimmunity diseases such as rheumatoid arthritis, psoriasis, systemic lupus erythematosus and inflammatory bowel disease</li> <li>Cancer therapeutic&nbsp;</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Drug delivery method that extends the half-life of tofacitinib</li> <li>Provide continuous, rate-controlled, localized and targeted release of tofacitinib</li> <li>Treat autoimmunity or prevent transplant rejection when combined with CTLA4-Ig, an immunosuppressive agent, for Enhanced Costimulation Blockade</li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for further development of this delivery system to improve transplant outcomes through inhibition of the JAK/STAT pathway. 2024-10-23 2026-04-16 2026-04-16 2024-11-13 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-123-2018 162763644 Majumder, et al. Multiphase assembly of small molecule microcrystalline peptide hydrogel allows immunomodulatory combination therapy for long-term heart transplant survival. PMID: 32812339 https://doi.org/10.1002/smll.202002791 <a href="https://doi.org/10.1002/smll.202002791">Majumder, et al. Multiphase assembly of small molecule microcrystalline peptide hydrogel allows immunomodulatory combination therapy for long-term heart transplant survival. PMID: 32812339</a> 158990771 Raimondi, Giorgio Johns Hopkins School of Medicine Raimondi, Giorgio 1 158990775 Schneider, Joel NCI Schneider, Joel (NCI) 2 158990779 Patrone, Julia Patrone, Julia 3 159081976 Komin, Alexander Johns Hopkins University Komin, Alexander 4 159081980 Nambiar, Monessha National Cancer Institute (NCI) NCI Nambiar, Monessha (NCI) 5 159081984 Calderon-Colon, Xiomara Calderon-Colon, Xiomara 6 159081988 Tiburzi, Olivia Tiburzi, Olivia 7 158990771 Raimondi, Giorgio Johns Hopkins School of Medicine Raimondi, Giorgio 1 158990775 Schneider, Joel NCI Schneider, Joel (NCI) 2 158990779 Patrone, Julia Patrone, Julia 3 159081976 Komin, Alexander Johns Hopkins University Komin, Alexander 4 159081980 Nambiar, Monessha National Cancer Institute (NCI) NCI Nambiar, Monessha (NCI) 5 159081984 Calderon-Colon, Xiomara Calderon-Colon, Xiomara 6 159081988 Tiburzi, Olivia Tiburzi, Olivia 7 158742602 Dual-component Therapeutic Platform For Localized And Inflammation Triggered Immune Targeted Delivery Of Immunotherapies E-121-2022-0 Filing authorized Johns Hopkins School of Medicine, Johns Hopkins University, Johns Hopkins University, NCI, NIH - NCI 83704821 Nguyen-Antczak, Lauren lauren.nguyen-antczak@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-5024] Immunotherapy Delivery System to Improve Organ Transplantation Outcomes&body=Please send me information about technology [TAB-5024] Immunotherapy Delivery System to Improve Organ Transplantation Outcomes.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Nguyen-Antczak, Lauren<br><a href="mailto:lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-5024] Immunotherapy Delivery System to Improve Organ Transplantation Outcomes&body=Please send me information about technology [TAB-5024] Immunotherapy Delivery System to Improve Organ Transplantation Outcomes.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">lauren.nguyen-antczak@nih.gov</a><br> 159502867 E-121-2022-0 E-121-2022-0-US-01 COMPOSITIONS, SYSTEMS, AND METHODS FOR DELIVERY OF THERAPEUTICS PRV US 63/350,315 Expired US <br />Provisional (PRV) 63/350,315<br />Filed on 2022-06-08<br />Status: Expired 159502872 E-121-2022-0 E-121-2022-0-PC-01 COMPOSITIONS, SYSTEMS, AND METHODS FOR DELIVERY OF THERAPEUTICS PCT Patent Cooperation Treaty PCT/US2023/068139 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2023/068139<br />Filed on 2023-06-08<br />Status: Expired 159502877 E-121-2022-0 E-121-2022-0-US-02 COMPOSITIONS, SYSTEMS, AND METHODS FOR DELIVERY OF THERAPEUTICS National Stage US 18/872,676 Pending US <br />National Stage 18/872,676<br />Filed on 2024-12-06<br />Status: Pending TAB-5028 158934494 HLA-class II-restricted T Cell Receptors for PIK3CA “Hotspot” Mutations, E545K and N345K NCI Collaboration, Immunology, Licensing, Oncology, TherapeuticArea, Therapeutics Collaboration Immunology Licensing Oncology TherapeuticArea Therapeutics S M Rafiqul Islam, Frank Lowery, Maria Parkhurst, Steven Rosenberg, Samantha Seitter, NIkolaos Zacharakis <h2>Summary:&nbsp;</h2> <p>The National Cancer Institute (NCI) seeks co-development partners and/or licensees for a collection of T cell receptors (TCRs) that specifically target PIK3CA mutations to treat patients with tumors expressing these mutations in the context of HLA-DPA1*01:03:01, HLA-DPB1*04:01:01 or HLA-DRB1*04:01.</p> <h2>Description of Technology:</h2> <p>Phosphatidylinositol-4,5-biphosphate 3-kinase catalytic subunit alpha gene, also known as PIK3CA, makes a subunit of the PIK3 enzyme with various cellular functions. Mutations in the PIK3CA can result in the growth of cells through overactivation of the PIK3 enzyme and are associated with the development of several forms of cancers. Indeed, PIK3CA mutation is the third most common mutation in epithelial cancers. Previous studies attempted to inhibit the activity of mutant PIK3CA using both small molecules and monoclonal antibodies. However, these studies showed limited in vivo efficacy in treating tumors with mutant PIK3CA.</p> <p>The National Cancer Institute (NCI) has developed novel, HLA-class II-restrcited T cell receptors (TCRs) to target two of the most common PIK3CA &ldquo;hotspot&rdquo; mutations: E545K and N345K. Two TCRs against N345K are restricted by the common HLA-DPA1*01:03:01 and HLA-DPB1*04:01:01, found in about 85% of the US Caucasian population. The TCR against E545K is rectricted by the common HLA-DRB1*04:01, found in about 17-20% of US Caucasian population. Given the frequency of PIK3CA mutations in various common cancers, these inventions have the potential to benefit a wide range of cancer patients. Targeted therapy against PIK3CA mutations represents therapeutic potential for various types of cancer. Further, as PIK3CA mutations are not present in healthy tissue, this approach could produce fewer off-target effects and a more promising safety profile.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>TCR-engineered cell therapy products for cancers expressing PIK3CA mutations &ndash; including, but not limited to: <ul> <li>breast&nbsp;</li> <li>endometrial</li> <li>bladder</li> <li>colorectal carcinoma</li> <li>head and neck squamous cell carcinoma</li> </ul> </li> <li>Soluble TCR-fusion proteins</li> <li>Combination immunotherapies using ACT alongside other immunotherapies targeting PIK3CA mutations</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Targeted therapy</li> <li>Potentially fewer and less severe off-target effects</li> <li>Potentially more promising safety profile</li> <li>Therapeutic potential for various types of cancer</li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for T cell receptors (TCRs) targeting PIK3CA mutations to treat patients with tumors expressing these mutations such as metastatic epithelial cancers. 2024-11-01 2026-04-16 2026-04-16 2024-11-06 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 72159138 Clinical Phase I 72159138 NCI 37470483 Website Abstract E-206-2022 158934581 Fusco N, et al. PIK3CA Mutations as a Molecular Target for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer. (PMID 33842357) https://pubmed.ncbi.nlm.nih.gov/33842357/ <a href="https://pubmed.ncbi.nlm.nih.gov/33842357/">Fusco N, et al. PIK3CA Mutations as a Molecular Target for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer. (PMID 33842357)</a> 158990386 Martínex-Sáez, et al. Frequency and spectrum of PIK3CA somatic mutations in breast cancer. (PMID 32404150) https://pubmed.ncbi.nlm.nih.gov/32404150/ <a href="https://pubmed.ncbi.nlm.nih.gov/32404150/">Martínex-Sáez, et al. Frequency and spectrum of PIK3CA somatic mutations in breast cancer. (PMID 32404150)</a> 158990393 Krop IE, et al. Phase II Study of Taselisib in PIK3CA-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I. (PMID 35138919) https://pubmed.ncbi.nlm.nih.gov/35138919/ <a href="https://pubmed.ncbi.nlm.nih.gov/35138919/">Krop IE, et al. Phase II Study of Taselisib in PIK3CA-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I. (PMID 35138919)</a> 158934542 Rosenberg, Steven National Cancer Institute (NCI) NCI Rosenberg, Steven (NCI) 1 158934546 Zacharakis, NIkolaos National Cancer Institute (NCI) NCI Zacharakis, NIkolaos (NCI) 2 158934550 Islam, S M Rafiqul NCI Islam, S M Rafiqul (NCI) 3 158934554 Seitter, Samantha Seitter, Samantha 4 158934558 Parkhurst, Maria NCI Parkhurst, Maria (NCI) 5 158934562 Lowery, Frank NCI Lowery, Frank (NCI) 6 158934542 Rosenberg, Steven National Cancer Institute (NCI) NCI Rosenberg, Steven (NCI) 1 158934546 Zacharakis, NIkolaos National Cancer Institute (NCI) NCI Zacharakis, NIkolaos (NCI) 2 158934550 Islam, S M Rafiqul NCI Islam, S M Rafiqul (NCI) 3 158934554 Seitter, Samantha Seitter, Samantha 4 158934558 Parkhurst, Maria NCI Parkhurst, Maria (NCI) 5 158934562 Lowery, Frank NCI Lowery, Frank (NCI) 6 158934497 HLA-class II-restricted T cell receptors for PIK3CA “hotspot” mutations, E545K and N345K. E-076-2024-0 Filing authorized Inova Health System, NIH - NCI 83709866 Burke, Andrew burkear@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC burkear@nih.gov?subject=Web Inquiry on [TAB-5028] HLA-class II-restricted T Cell Receptors for PIK3CA “Hotspot” Mutations, E545K and N345K&body=Please send me information about technology [TAB-5028] HLA-class II-restricted T Cell Receptors for PIK3CA “Hotspot” Mutations, E545K and N345K.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Burke, Andrew<br><a href="mailto:burkear@nih.gov?subject=Web Inquiry on [TAB-5028] HLA-class II-restricted T Cell Receptors for PIK3CA “Hotspot” Mutations, E545K and N345K&body=Please send me information about technology [TAB-5028] HLA-class II-restricted T Cell Receptors for PIK3CA “Hotspot” Mutations, E545K and N345K.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">burkear@nih.gov</a><br> 159503000 E-076-2024-0 E-076-2024-0-US-01 T CELL RECEPTORS TARGETING E545K OR N345K MUTATION IN PIK3CA PRV US 63/565,764 Expired US <br />Provisional (PRV) 63/565,764<br />Filed on 2024-03-15<br />Status: Expired TAB-5025 158743710 Peptide Hydrogels for Delivery of Immunosuppressive Drugs and Uses Thereof NCI Cardiology, Collaboration, Immunology, Licensing, Nephrology, Therapeutics Cardiology Collaboration Immunology Licensing Nephrology Therapeutics Poulami Majumder, Giorgio Raimondi, Joel Schneider <h2>Summary:&nbsp;</h2> <p>The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a hydrogel-based delivery system for the local administration of tofacitinib to improve transplant outcomes.</p> <h2>Description of Technology:&nbsp;</h2> <p>More than 1 million tissue transplantations are performed each year. Organ transplantation therapies are typically combined with immunosuppressive agents to reduce the risk of allograft rejection and enhance transplant survival. Currently, immunosuppressive drugs are administered systemically and have several dose-limiting side effects, including impairment of renal function, hypertension, and lymphatic malignancies. Therefore, there is an unmet need to identify a safer, more effective treatment plan for transplant recipients.<br /> &nbsp;<br /> A multidisciplinary team of researchers from the National Cancer Institute (NCI) and <a href="https://www.hopkinsmedicine.org/plastic-reconstructive-surgery/research/vca-lab" target="_blank">Johns Hopkins University (JHU)</a> developed a peptide hydrogel containing a crystalized form of an immunosuppressive small molecule.&nbsp;<br /> This novel formulation can be syringe-injected to the site of transplantation during surgery, allowing for localized, sustained delivery of immunosuppressive agents &ndash; improving transplant outcomes while reducing off-target toxicities. As proof of concept, a hydrogel containing a potent JAK inhibitor, tofacitinib, was injected directly to the grafting site using a mouse model of heterotopic heart transplantation. A single, local application of the tofacitinib hydrogel, combined with systemic administration of CTLA4-Ig, a common immunosuppressant, significantly prolonged graft survival of the transplanted heart. This technology could positively impact transplantation-control of immune response to prevent transplant rejection. An autoimmunity-based therapeutic that inhibits JAK signaling could bring therapeutic benefit to autoimmune diseases such as rheumatoid arthritis, psoriasis, systemic lupus erythematosus and inflammatory bowel disease. Cancers with a dysregulated JAK/STAT pathway could also be treated with this technology.</p> <p>This technology is co-owned and was co-developed by JHU and The National Institutes of Health (NIH). The summary of the technology was provided by Johns Hopkins Technology Ventures (JHTV) and is cross-listed on <a href="https://jhu.technologypublisher.com/technology/47435" target="_blank">JHTV&rsquo;s Tech Publisher website Case ID C15347</a>. There is a modified, related, co-owned technology (E-121-2022) which is cross listed on <a href="https://jhu.technologypublisher.com/technology/55093" target="_blank">JHTV&rsquo;s Tech Publisher website Case ID C17351</a>.</p> <h2>Potential Commercial Applications:&nbsp;</h2> <ul> <li>Prevent transplant rejection</li> <li>Autoimmunity diseases such as rheumatoid arthritis, psoriasis, systemic lupus erythematosus and inflammatory bowel disease</li> <li>Cancer therapeutic</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Drug delivery method that extends the half-life of tofacitinib</li> <li>Provide continuous, rate-controlled, localized and targeted release of tofacitinib</li> <li>Treat autoimmunity or prevent transplant rejection when combined with CTLA4-Ig, an immunosuppressive agent, for Enhanced Costimulation Blockade&nbsp;</li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for further development of this delivery system to improve transplant outcomes through inhibition of the JAK/STAT pathway. 2024-10-23 2026-04-16 2026-04-16 2024-11-06 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-121-2022 158990415 Majumder, et al. Multiphase assembly of small molecule microcrystalline peptide hydrogel allows immunomodulatory combination therapy for long-term heart transplant survival. (PMID: 32812339). https://pubmed.ncbi.nlm.nih.gov/32812339/ <a href="https://pubmed.ncbi.nlm.nih.gov/32812339/">Majumder, et al. Multiphase assembly of small molecule microcrystalline peptide hydrogel allows immunomodulatory combination therapy for long-term heart transplant survival. (PMID: 32812339).</a> 158990403 Raimondi, Giorgio Raimondi, Giorgio 1 158990407 Schneider, Joel National Cancer Institute (NCI) NCI Schneider, Joel (NCI) 2 158990411 Majumder, Poulami NCI Majumder, Poulami (NCI) 3 158990403 Raimondi, Giorgio Raimondi, Giorgio 1 158990407 Schneider, Joel National Cancer Institute (NCI) NCI Schneider, Joel (NCI) 2 158990411 Majumder, Poulami NCI Majumder, Poulami (NCI) 3 158743713 Hydrogel Delivery Platform To Deliver Immunosuppressive Drugs E-123-2018-0 Filing authorized Johns Hopkins School of Medicine, NCI 83704821 Nguyen-Antczak, Lauren lauren.nguyen-antczak@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-5025] Peptide Hydrogels for Delivery of Immunosuppressive Drugs and Uses Thereof&body=Please send me information about technology [TAB-5025] Peptide Hydrogels for Delivery of Immunosuppressive Drugs and Uses Thereof.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Nguyen-Antczak, Lauren<br><a href="mailto:lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-5025] Peptide Hydrogels for Delivery of Immunosuppressive Drugs and Uses Thereof&body=Please send me information about technology [TAB-5025] Peptide Hydrogels for Delivery of Immunosuppressive Drugs and Uses Thereof.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">lauren.nguyen-antczak@nih.gov</a><br> 159503047 E-123-2018-0 E-123-2018-0-US-01 PEPTIDE HYDROGELS FOR DELIVERY OF IMMUNOSUPPRESSIVE DRUGS AND USES THEREOF PRV US 62/666,471 Abandoned US <br />Provisional (PRV) 62/666,471<br />Filed on 2018-05-03<br />Status: Abandoned 159503058 E-123-2018-0 E-123-2018-0-PCT-02 PEPTIDE HYDROGELS FOR DELIVERY OF IMMUNOSUPPRESSIVE DRUGS AND USES THEREOF PCT Patent Cooperation Treaty PCT/US2019/030656 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2019/030656<br />Filed on 2019-05-03<br />Status: Expired 159503063 E-123-2018-0 E-123-2018-0-EP-03 PEPTIDE HYDROGELS FOR DELIVERY OF IMMUNOSUPPRESSIVE DRUGS AND USES THEREOF National Stage European Patent 3787664 19724994.9 Abandoned European Patent <br />National Stage 19724994.9<br />Filed on 2019-05-03<br />Status: Abandoned 159503068 E-123-2018-0 E-123-2018-0-US-04 PEPTIDE HYDROGELS FOR DELIVERY OF IMMUNOSUPPRESSIVE DRUGS AND USES THEREOF National Stage US 12,527,870 17/051,574 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12527870 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12527870">12,527,870</a><br />Filed on 2020-10-29<br />Status: Issued 159503073 E-123-2018-0 E-123-2018-0-FR-01 PEPTIDE HYDROGELS FOR DELIVERY OF IMMUNOSUPPRESSIVE DRUGS AND USES THEREOF EP France 3787664 19724994.9 Abandoned France <br />European patent (EP) 19724994.9<br />Filed on 2019-05-03<br />Status: Abandoned 159503078 E-123-2018-0 E-123-2018-0-DE-01 PEPTIDE HYDROGELS FOR DELIVERY OF IMMUNOSUPPRESSIVE DRUGS AND USES THEREOF EP Germany 3787664 19724994.9 Abandoned Germany <br />European patent (EP) 19724994.9<br />Filed on 2019-05-03<br />Status: Abandoned 159503083 E-123-2018-0 E-123-2018-0-GB-01 PEPTIDE HYDROGELS FOR DELIVERY OF IMMUNOSUPPRESSIVE DRUGS AND USES THEREOF EP United Kingdom 3787664 19724994.9 Abandoned United Kingdom <br />European patent (EP) 19724994.9<br />Filed on 2019-05-03<br />Status: Abandoned TAB-5023 158678127 Machine Learning Model for the Prioritization of Cancer Neoepitopes NCI Licensing, Oncology, Research Materials Licensing Oncology Research Materials Jared Gartner, Paul Robbins, Steven Rosenberg <h2>Summary:&nbsp;</h2> <p>The National Cancer Institute (NCI) seeks licensees for a machine learning algorithm that scores epitopes for likelihood of reactivity in order to create personalized effective immunotherapy.</p> <h2>Description of Technology:&nbsp;</h2> <p>Success in immunotherapy is often attributable to the reactivity of patient T-cells to specific mutated peptide(s) found in the patient&rsquo;s tumor known as neoepitopes. In the development of patient-specific immunotherapies, there is no consistent standard for prioritizing such neoepitopes. Current models arrive at a ranked list of potential candidates by removing epitopes based on pre-determined criteria which might lead to the elimination of known reactive neoepitopes.&nbsp;</p> <p>Identification, prioritization and targeting of patient neoepitopes are crucial for developing effective, personalized treatments. Ranking or prioritizing neoepitopes is especially important when trying to construct a cancer vaccine that will elicit a therapeutically beneficialn immune response. Accordingly, scientists at the National Cancer Institute (NCI) have created a novel approach to identify and prioritize patient neoantigens. This model uses a training dataset of known neoantigens from patient screening and determines features of importance to epitope recognition using both reactive and non-reactive epitopes. The machine learning algorithm scores epitopes for their likelihood of reactivity and provides a stable, reproducible method to prioritize epitopes that can be used anywhere in the world.&nbsp;<br /> &nbsp;<br /> The National Cancer Institute (NCI) seeks licensees for this machine learning algorithm that scores epitopes for likelihood of reactivity in order to create personalized effective immunotherapy.</p> <h2>Potential Commercial Applications:&nbsp;</h2> <ul> <li>Oncology</li> <li>Prioritization of neoantigens for the development of effective personalized therapies</li> <li>Cancer vaccines</li> <li>TIL and T-cell receptor therapies</li> <li>Research use</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Model is trained using a dataset of verified neoantigens from patient tumor data&nbsp;</li> <li>Model is unbiased because it does not use prior assumptions about what features a neoepitope should have</li> <li>Uses two models (MMP and NMER model) aswhich is a more reproducible approach than using a single model</li> <li>Particularly useful for prioritizing epitopes for patients with large numbers of mutations</li> </ul> The NCI seeks licensees for a machine learning algorithm that scores epitopes for likelihood of reactivity in order to create personalized effective immunotherapy. 2024-10-17 2026-04-16 2026-04-16 2024-10-17 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 158678146 Gartner JJ, et al. A machine learning model for ranking candidate HLA class I neoantigens based on known neoepitopes from multiple human tumor types. (PMID: 34927080) https://pubmed.ncbi.nlm.nih.gov/34927080/ <a href="https://pubmed.ncbi.nlm.nih.gov/34927080/">Gartner JJ, et al. A machine learning model for ranking candidate HLA class I neoantigens based on known neoepitopes from multiple human tumor types. (PMID: 34927080)</a> 158678134 Gartner, Jared NCI Gartner, Jared (NCI) 1 158678138 Robbins, Paul NCI Robbins, Paul (NCI) 2 158678142 Rosenberg, Steven NCI Rosenberg, Steven (NCI) 3 158678134 Gartner, Jared NCI Gartner, Jared (NCI) 1 158678138 Robbins, Paul NCI Robbins, Paul (NCI) 2 158678142 Rosenberg, Steven NCI Rosenberg, Steven (NCI) 3 158678130 Development of a model for ranking candidate HLA class I neoantigens based upon datasets of known neoepitopes E-022-2024-0 Closed NIH - NCI, Surgery Branch 83709866 Burke, Andrew burkear@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC burkear@nih.gov?subject=Web Inquiry on [TAB-5023] Machine Learning Model for the Prioritization of Cancer Neoepitopes&body=Please send me information about technology [TAB-5023] Machine Learning Model for the Prioritization of Cancer Neoepitopes.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Burke, Andrew<br><a href="mailto:burkear@nih.gov?subject=Web Inquiry on [TAB-5023] Machine Learning Model for the Prioritization of Cancer Neoepitopes&body=Please send me information about technology [TAB-5023] Machine Learning Model for the Prioritization of Cancer Neoepitopes.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">burkear@nih.gov</a><br> TAB-5022 158677893 Fully Human Chimeric Antigen Receptors Against CD276 for the Treatment of Solid Tumors NCI Collaboration, Immunology, Licensing, Oncology, Therapeutics Collaboration Immunology Licensing Oncology Therapeutics Pradip Bajgain, Yang Feng, Brad St. Croix <h2>Summary:</h2> <p>The National Cancer Institute (NCI) seeks research co-development partners and licensees for a panel of five fully human antibodies against CD276 for the treatment of solid tumors. The collection also includes human CARs incorporating the antibodies for immunotherapeutic use.</p> <h2>Description of Technology:</h2> <p>Chimeric antigen receptor (CAR)-T cell therapy has been successful in leukemia but its use for the treatment of solid tumors has been challenging. &nbsp;CD276, also known as B7-H3, is a surface tumor marker highly expressed in the vasculature and surface of solid tumors. This strong expression in both areas of solid tumors makes CD276 a promising target for cancer therapies such as CARs.</p> <p>This technology comprises of a panel of five fully human antibodies (Y868, Y422, Y111, Y117, and YE5) against CD276 that can be incorporated into immunotherapies. &nbsp;The CARs generated using these antibodies were evaluated and compared to other known CD276-targeting CARs in development. &nbsp;One of the CARs showed a more durable anti-tumor response superior to all others tested, including those known in the literature. &nbsp;CARs generated from this set are effective against Panc1 pancreatic tumor models. One CAR in particular showing high efficacy in the HPAC pancreatic tumor model which was resistant to all other CARs. &nbsp;In addition to CARs, the antibodies developed under this invention could potentially be used in other antibody-based therapeutics targeting CD276 including other cell therapies such as CAR NK-cell therapies. &nbsp;&nbsp;</p> <h2>Potential Commercial Applications:&nbsp;</h2> <ul> <li>CAR T-Cell therapy for treatment of pancreatic cancer</li> <li>CAR T-Cell or NK cell therapy for treatment of several solid tumors&nbsp;</li> <li>Antibody based therapeutics such as antibody drug conjugates (ADCs) for the treatment of solid tumors&nbsp;</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>High efficacy against tumors resistant to other CARs</li> <li>CD276 target is highly expressed on many solid tumor types</li> <li>Fully human antibody potentially less immunogenic than those derived from mouse</li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for the development of antibody-based therapeutics targeting CD276 for the treatment of solid tumors. 2024-10-17 2026-04-16 2026-04-16 2024-10-17 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 158678102 Feng et al. Engineering CD276/B7-H3-targeting antibody-drug conjugates with enhanced cancer-eradicating capability (PMID 38019654) Seaman et al. Eradication of tumors through simultaneous ablation of CD276/B7-H3-positive tumor cells and tumor vasculature. (PMID 28399408) https://pubmed.ncbi.nlm.nih.gov/38019654/ <a href="https://pubmed.ncbi.nlm.nih.gov/38019654/">Feng et al. Engineering CD276/B7-H3-targeting antibody-drug conjugates with enhanced cancer-eradicating capability (PMID 38019654) Seaman et al. Eradication of tumors through simultaneous ablation of CD276/B7-H3-positive tumor cells and tumor vasculature. (PMID 28399408)</a> 158677900 St. Croix, Brad NCI St. Croix, Brad (NCI) 1 158678094 Bajgain, Pradip National Cancer Institute (NCI) NCI Bajgain, Pradip (NCI) 2 158678098 Feng, Yang NCI Feng, Yang (NCI) 3 158677900 St. Croix, Brad NCI St. Croix, Brad (NCI) 1 158678094 Bajgain, Pradip National Cancer Institute (NCI) NCI Bajgain, Pradip (NCI) 2 158678098 Feng, Yang NCI Feng, Yang (NCI) 3 158677896 Fully Human Chimeric Antigen Receptors against CD276 for the treatment of solid tumors E-125-2023-0 Filing authorized Mouse Cancer Genetics Program 91814193 Freel, Rose rose.freel@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America rose.freel@nih.gov?subject=Web Inquiry on [TAB-5022] Fully Human Chimeric Antigen Receptors Against CD276 for the Treatment of Solid Tumors&body=Please send me information about technology [TAB-5022] Fully Human Chimeric Antigen Receptors Against CD276 for the Treatment of Solid Tumors.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Freel, Rose<br><a href="mailto:rose.freel@nih.gov?subject=Web Inquiry on [TAB-5022] Fully Human Chimeric Antigen Receptors Against CD276 for the Treatment of Solid Tumors&body=Please send me information about technology [TAB-5022] Fully Human Chimeric Antigen Receptors Against CD276 for the Treatment of Solid Tumors.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">rose.freel@nih.gov</a><br> 159502484 E-125-2023-0 E-125-2023-0-US-01 Fully Human Chimeric Antigen Receptors against CD276 for the treatment of solid tumors PRV US 63/514,596 Expired US <br />Provisional (PRV) 63/514,596<br />Filed on 2023-07-20<br />Status: Expired 159502489 E-125-2023-0 E-125-2023-0-PC-01 FULLY HUMAN MONOCLONAL ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS AGAINST CD276 FOR THE TREATMENT OF SOLID TUMORS PCT Patent Cooperation Treaty PCT/US2024/037349 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2024/037349<br />Filed on 2024-07-10<br />Status: Expired 165318378 E-125-2023-0 E-125-2023-0-CA-01 FULLY HUMAN MONOCLONAL ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS AGAINST CD276 FOR THE TREATMENT OF SOLID TUMORS National Stage Canada 3299104 Pending Canada <br />National Stage 3299104<br />Filed on 2026-01-19<br />Status: Pending 165318413 E-125-2023-0 E-125-2023-0-AU-01 FULLY HUMAN MONOCLONAL ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS AGAINST CD276 FOR THE TREATMENT OF SOLID TUMORS National Stage Australia 2024295016 Pending Australia <br />National Stage 2024295016<br />Filed on 2026-01-15<br />Status: Pending 165318575 E-125-2023-0 E-125-2023-0-US-02 FULLY HUMAN MONOCLONAL ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS AGAINST CD276 FOR THE TREATMENT OF SOLID TUMORS National Stage US 19/503,627 Pending US <br />National Stage 19/503,627<br />Filed on 2026-01-20<br />Status: Pending 165318610 E-125-2023-0 E-125-2023-0-EP-01 FULLY HUMAN MONOCLONAL ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS AGAINST CD276 FOR THE TREATMENT OF SOLID TUMORS National Stage European Patent 24749087.3 Pending European Patent <br />National Stage 24749087.3<br />Filed on 2026-02-04<br />Status: Pending TAB-5021 158677813 Novel Kinase Inhibitory Thiazines NCI Application, Collaboration, Infectious Disease, Licensing, Oncology, Rare/Neglected Diseases, Therapeutics Application Collaboration Infectious Disease Licensing Oncology Rare/Neglected Diseases Therapeutics Lin Du, Ning Li, Juliana Martinez Fiesco, William Moore, Barry O'Keefe, Dongdong Wang, Brice Wilson, Ping Zhang <h2>Summary:</h2> <p>The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a class of novel aplithianine-derived small molecule analogs that compete with ATP for binding on a range of clinically relevant kinases including:</p> <ul> <li>Oncogenic gene fusion DNAJB1-PRKACA (PKADJ)</li> <li>Wild type protein kinase A (PKA)&nbsp;</li> <li>Protein kinase G (PKG)</li> <li>Ccdc2-like kinases (CLK) 1 &amp; 2</li> <li>DYRK family of kinases</li> </ul> <h2>Description of Technology:</h2> <p>In 2022, the NCI Molecular Targets Program (MTP) completed a screen of ~150,000 pre-fractionated natural products from the NCI Program for Natural Product Discovery (NPNPD). From this screen, a class of active compounds, named Aplithianines A &amp; B (isolated from the marine organism Aplidium sp.), showed broad potential applicability to numerous kinases of importance including, but not limited to:</p> <ul> <li>Oncogenic gene fusion DNAJB1-PRKACA (PKADJ) <ul> <li>Implicated in an ultra-rare adolescent liver cancer</li> </ul> </li> <li>Wild type protein kinase A (PKA)&nbsp; <ul> <li>Implicated in Cushing&rsquo;s Disease</li> </ul> </li> <li>Protein kinase G (PKG)&nbsp; <ul> <li>Potential treatment of malaria</li> </ul> </li> <li>Ccdc2-like kinases (CLK) 1 &amp; 2 <ul> <li>Implicated in gastric cancer</li> </ul> </li> <li>DYRK family of kinases&nbsp; <ul> <li>Implicated in gastric or colon cancer as well as infections caused by a protozoa or parasites</li> </ul> </li> </ul> <p>The original cohort of compounds, including the pharmaceutical compositions of the natural products Aplithianine A and Aplithianine B, as well as a range of synthetic derivatives are described in NIH Technology Ref # E-044-2022.&nbsp;</p> <p>This technology (NIH Ref # E-202-2023) describes the Second Cohort of compounds that comprise the same chemical scaffold of the broadest generic formula in the Original Family but represent a patentably distinct, subgenus formula. This Second Cohort of compounds shares the same chemical scaffold as aplithianine but have been optimized through extensive medicinal chemistry efforts to increase binding affinity to the oncogenic fusion kinase called DNAJB1-PRKACA (PKADJ) and its wild-type counterpart protein kinase A (PKA). These new compounds, like the Original Family compounds, compete with ATP for binding on these kinases and other related kinases (namely, protein kinase G, cdc2-like kinases (CLK) 1 &amp; 2, and the DYRK family of kinases). However, the compounds described in this Second Cohort exhibit improved low nanomolar binding affinity and high activity in secondary assays.&nbsp;</p> <p>A Third Cohort of compounds, namely the Reverse Thiazine Kinase inhibitors, are described in NIH Ref # E-162-2024. They are also structurally related to, but patentably distinct from the compounds described in the patent filings for the Original Family and Second Cohort.&nbsp;</p> <p><img alt="Image of Molecular Diagrams" src="https://nih.technologypublisher.com/files/sites/monosnap_structural_representatives.jpg_2024-10-30_17-57-471.png" style="height:1676px; width:1218px" /></p> <p>The specificity of several of the compounds have been examined in kinase panels to demonstrate that while applicable to a range of kinases, they are not promiscuous kinase inhibitors. The subject kinase inhibitors have broad potential commercial applicability&rsquo;s for cancer, immune suppression, preventing organ rejection, treating diabetic neuropathic pain, malaria, or protozoa infection. To date there are no approved therapeutics targeting DNAJB1-PRKCA, an oncogenic gene fusion is ubiquitously and exclusively detected in the tumors of patients with ultra-rare fibrolamellar hepatocellular carcinoma FLHCC.</p> <p>The NCI seeks licensing and/or co-development research collaborations for the future development of Kinase Inhibitory Aplithianines targeting &nbsp;DNAJB1-PRKACA (PKADJ), PKA, PKG, CLK, and/or DYRK.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Gastric cancer</li> <li>Ultra-rare adolescent liver cancer</li> <li>Solid cancers susceptible to kinase inhibitors</li> <li>Cushing&rsquo;s Disease</li> <li>Transplantation</li> <li>Diabetic neuropathic pain</li> <li>Malaria</li> <li>Protozoa infection&nbsp;</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Applicability to numerous clinically relevant kinases, including: <ul> <li>Oncogenic gene fusion DNAJB1-PRKACA (PKADJ)</li> <li>Wild type protein kinase A (PKA)</li> <li>Protein kinase G (PKG)</li> <li>Ccdc2-like kinases (CLK) 1 &amp; 2</li> <li>DYRK family of kinases</li> </ul> </li> <li>Applicable to a range of kinases, but are not promiscuous inhibitors</li> <li>Broad potential commercial applicability for several blockbuster indications, including: cancer, immune suppression, transplantation, diabetic neuropathic pain, malaria, and protozoa infection</li> <li>No approved therapeutics targeting DNAJB1-PRKCA</li> </ul> <p>&nbsp;</p> Researchers at the NCI seek licensing and/or co-development research collaborations for a class of novel aplithianine-derived small molecule analogs that compete with ATP for binding on a range of clinically relevant kinases 2024-10-17 2026-04-16 2026-04-16 2024-10-17 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-044-2022 E-162-2024 158677854 O'Keefe BR, et al. Biochemical Discovery, Intracellular Evaluation, and Crystallographic Characterization of Synthetic and Natural Product Adenosine 3',5'-Cyclic Monophosphate-Dependent Protein Kinase A (PKA) Inhibitors. PMID: 37082750 https://pubmed.ncbi.nlm.nih.gov/37082750/ <a href="https://pubmed.ncbi.nlm.nih.gov/37082750/">O'Keefe BR, et al. Biochemical Discovery, Intracellular Evaluation, and Crystallographic Characterization of Synthetic and Natural Product Adenosine 3',5'-Cyclic Monophosphate-Dependent Protein Kinase A (PKA) Inhibitors. PMID: 37082750</a> 162874682 O'Keefe BR, et al. Discovery and Synthesis of a Naturally Derived Protein Kinase Inhibitor that Selectively Inhibits Distinct Classes of Serine/Threonine Kinases. PMID: 37843072 https://pubmed.ncbi.nlm.nih.gov/37843072/ <a href="https://pubmed.ncbi.nlm.nih.gov/37843072/">O'Keefe BR, et al. Discovery and Synthesis of a Naturally Derived Protein Kinase Inhibitor that Selectively Inhibits Distinct Classes of Serine/Threonine Kinases. PMID: 37843072</a> 158677820 O'Keefe, Barry National Cancer Institute (NCI) NCI O'Keefe, Barry (NCI) 1 158677824 Du, Lin NCI Du, Lin (NCI) 2 158677828 Wilson, Brice NCI Wilson, Brice (NCI) 3 158677832 Zhang, Ping NCI Zhang, Ping (NCI) 4 158677838 Moore, William NCI Moore, William (NCI) 5 158677842 Wang, Dongdong NCI Wang, Dongdong (NCI) 6 158677846 Martinez Fiesco, Juliana Martinez Fiesco, Juliana 7 158677850 Li, Ning Leidos Li, Ning (Leidos) 8 158677820 O'Keefe, Barry National Cancer Institute (NCI) NCI O'Keefe, Barry (NCI) 1 158677824 Du, Lin NCI Du, Lin (NCI) 2 158677828 Wilson, Brice NCI Wilson, Brice (NCI) 3 158677832 Zhang, Ping NCI Zhang, Ping (NCI) 4 158677838 Moore, William NCI Moore, William (NCI) 5 158677842 Wang, Dongdong NCI Wang, Dongdong (NCI) 6 158677846 Martinez Fiesco, Juliana Martinez Fiesco, Juliana 7 158677850 Li, Ning Leidos Li, Ning (Leidos) 8 158677816 Novel Kinase Inhibitory Thiazines E-202-2023-0 Filing authorized National Cancer Institute (NCI), NIH - NCI 83732213 Dick, Taryn taryn.dick@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB taryn.dick@nih.gov?subject=Web Inquiry on [TAB-5021] Novel Kinase Inhibitory Thiazines&body=Please send me information about technology [TAB-5021] Novel Kinase Inhibitory Thiazines.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dick, Taryn<br><a href="mailto:taryn.dick@nih.gov?subject=Web Inquiry on [TAB-5021] Novel Kinase Inhibitory Thiazines&body=Please send me information about technology [TAB-5021] Novel Kinase Inhibitory Thiazines.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">taryn.dick@nih.gov</a><br> 159503095 E-202-2023-0 E-202-2023-0-US-01 KINASE INHIBITORS PRV US 63/527,274 Expired US <br />Provisional (PRV) 63/527,274<br />Filed on 2023-07-17<br />Status: Expired 159503100 E-202-2023-0 E-202-2023-0-PC-01 KINASE INHIBITORS PCT Patent Cooperation Treaty PCT/US2024/038376 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2024/038376<br />Filed on 2024-07-17<br />Status: Expired TAB-5020 158677380 Reverse Thiazine Kinase Inhibitors NCI Collaboration, Infectious Disease, Licensing, Oncology, Rare/Neglected Diseases, Therapeutics Collaboration Infectious Disease Licensing Oncology Rare/Neglected Diseases Therapeutics Lin Du, Ning Li, Juliana Martinez Fiesco, William Moore, Barry O'Keefe, Dongdong Wang, Brice Wilson, Ping Zhang <h3>Summary:</h3> <p>The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a class of novel aplithianine-derived small molecule analogs that compete with ATP for binding on a range of clinically relevant kinases including:</p> <ul> <li>Oncogenic gene fusion DNAJB1-PRKACA (PKADJ)</li> <li>Wild type protein kinase A (PKA)&nbsp;</li> <li>Protein kinase G (PKG)</li> <li>Ccdc2-like kinases (CLK) 1 &amp; 2</li> <li>DYRK family of kinases</li> </ul> <h3>Description of Technology:</h3> <p>In 2022, the NCI Molecular Targets Program (MTP) completed a screen of ~150,000 pre-fractionated natural products from the NCI Program for Natural Product Discovery (NPNPD). From this screen, a class of active compounds, named Aplithianines A &amp; B (isolated from the marine organism Aplidium sp.) showed broad potential applicability to numerous kinases of importance including but not limited to:</p> <ul> <li>Oncogenic gene fusion DNAJB1-PRKACA (PKADJ) <ul> <li>Implicated in an ultra-rare adolescent liver cancer</li> </ul> </li> <li>Wild type protein kinase A (PKA)&nbsp; <ul> <li>Implicated in Cushing&rsquo;s Disease</li> </ul> </li> <li>Protein kinase G (PKG)&nbsp; <ul> <li>Potential treatment of malaria</li> </ul> </li> <li>Ccdc2-like kinases (CLK) 1 &amp; 2 <ul> <li>Implicated in gastric cancer</li> </ul> </li> <li>DYRK family of kinases&nbsp; <ul> <li>Implicated in gastric or colon cancer as well as infections caused by a protozoa or parasites</li> </ul> </li> </ul> <p>This Technology (NIH Ref # <strong>E-162-2024</strong>) describes a Third Cohort of compounds, namely the Reverse Thiazine Kinase inhibitors &ndash; structurally related to, but patentably distinct from &ndash; compounds described in the patent filings for the Original Family and Second Cohort. This Third Cohort of reverse thiazine compounds were created based on the initial activity determination and structural interactions for the aplithianine kinase inhibitors (described in the Original Family) and the DNAJ-PKA fusion protein. These Third Cohort compounds are a new structural class of Ser/Thr kinase (i.e. PKA) inhibitors related to the aplithianine class of kinase inhibitors but differ in both their chemical structures and mode of binding into the ATP binding pocket of kinases. They show potent and improved biochemical inhibition, reduction of the phosphorylation of the PKA substrate CREB, and the ability to reduce the viability of cancer cells. Computational modeling predicted enhanced binding affinity of these reverse thiazines with the DNAJ-PKA fusion protein. Consistent with this hypothesis-driven modeling effort, the reverse thiazines show improved potency and cellular activity over the compounds described in the Original Family and Second Cohort patent families</p> <p>Original Cohort of compounds, including the pharmaceutical compositions of the natural products Aplithianine A and Aplithianine B, as well as a range of synthetic derivatives are described in NIH Technology Ref # E-044-2022.&nbsp;</p> <p>The Second Cohort of compounds are covered in (NIH Ref # E-202-2023). This Second Cohort comprises the same chemical scaffold of the broadest generic formula in the Original Family but represents a patentably distinct, subgenus formula. This Second Cohort of compounds shares the same chemical scaffold as aplithianine but have been optimized through extensive medicinal chemistry efforts to increase binding affinity to the oncogenic fusion kinase called DNAJB1-PRKACA (PKADJ) and its wild-type counterpart protein kinase A (PKA).</p> <p><img alt="Image of Molecular Diagrams" src="https://nih.technologypublisher.com/files/sites/monosnap_structural_representatives.jpg_2024-10-30_17-57-471.png" style="height:1676px; width:1218px" /></p> <p>The specificity of several of the compounds have been examined in kinase panels to demonstrate that, while applicable to a range of kinases, they are not promiscuous kinase inhibitors. The subject kinase inhibitors have broad potential commercial applicability&rsquo;s for cancer, immune suppression, preventing organ rejection, treating diabetic neuropathic pain, malaria, or protozoa infection. To date, there are no approved therapeutics targeting DNAJB1-PRKCA, an oncogenic gene fusion is ubiquitously and exclusively detected in the tumors of patients with ultra-rare fibrolamellar hepatocellular carcinoma FLHCC.</p> <p>The NCI seeks licensing and/or co-development research collaborations for the future development of Kinase Inhibitory Aplithianines targeting&nbsp;&nbsp;DNAJB1-PRKACA (PKADJ), PKA, PKG, CLK, and/or DYRK.</p> <h3>Potential Commercial Applications:</h3> <ul> <li style="margin-left: 8px;"><span style="font-family:Times New Roman,serif">Gastric Cancer</span></li> <li style="margin-left: 8px;"><span style="font-size:12pt"><span style="font-family:&quot;Times New Roman&quot;,serif">Ultra-rare, adolescent liver cancer</span></span></li> <li style="margin-left: 8px;"><span style="font-size:12pt"><span style="font-family:&quot;Times New Roman&quot;,serif">Solid cancers susceptible to kinase inhibitors</span></span></li> <li style="margin-left: 8px;"><span style="font-size:12pt"><span style="font-family:&quot;Times New Roman&quot;,serif">Cushing&rsquo;s Disease</span></span></li> <li style="margin-left: 8px;"><span style="font-size:12pt"><span style="font-family:&quot;Times New Roman&quot;,serif">Transplantation</span></span></li> <li style="margin-left: 8px;"><span style="font-size:12pt"><span style="font-family:&quot;Times New Roman&quot;,serif">Diabetic neuropathic pain</span></span></li> <li style="margin-left: 8px;"><span style="font-size:12pt"><span style="font-family:&quot;Times New Roman&quot;,serif">Malaria</span></span></li> <li style="margin-left: 8px;"><span style="font-size:12pt"><span style="font-family:&quot;Times New Roman&quot;,serif">Protozoa infection </span></span></li> </ul> <h3 style="margin-left:8px">Competitive Advantages:</h3> <ul> <li style="margin-left: 8px;"><span style="font-size:12pt"><span style="font-family:&quot;Times New Roman&quot;,serif">Applicability to numerous clinically relevant kinases, including:</span></span> <ul> <li style="margin-left: 8px;"><span style="font-size:12pt"><span style="font-family:&quot;Times New Roman&quot;,serif">Oncogenic gene fusion DNAJB1-PRKACA (PKADJ)</span></span></li> <li style="margin-left: 8px;"><span style="font-size:12pt"><span style="font-family:&quot;Times New Roman&quot;,serif">Wild type protein kinase A (PKA)</span></span></li> <li style="margin-left: 8px;"><span style="font-size:12pt"><span style="font-family:&quot;Times New Roman&quot;,serif">Protein kinase G (PKG)</span></span></li> <li style="margin-left: 8px;"><span style="font-size:12pt"><span style="font-family:&quot;Times New Roman&quot;,serif">Ccdc2-like kinases (CLK) 1 &amp; 2</span></span></li> <li style="margin-left: 8px;"><span style="font-size:12pt"><span style="font-family:&quot;Times New Roman&quot;,serif">DYRK family of kinases</span></span></li> </ul> </li> <li style="margin-left: 8px;">Applicable to range of kinases, but are not promiscuous kinase inhibitors</li> <li style="margin-left: 8px;">Broad potential commercial applicability for several blockbuster indications, including: cancer, immune suppression, transplantation, diabetic neuropathic pain, malaria, and protozoa infection</li> <li style="margin-left: 8px;">No approved therapeutics targeting DNAJB1-PRKCA</li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for a class of novel aplithianine-derived small molecule analogs that compete with ATP for binding on a range of clinically relevant kinases 2024-10-17 2026-04-16 2026-04-16 2024-10-17 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-044-2022 E-202-2023 158677441 O'Keefe BR, et al. Biochemical Discovery, Intracellular Evaluation, and Crystallographic Characterization of Synthetic and Natural Product Adenosine 3',5'-Cyclic Monophosphate-Dependent Protein Kinase A (PKA) Inhibitors. PMID: 37082750 https://pubmed.ncbi.nlm.nih.gov/37082750/ <a href="https://pubmed.ncbi.nlm.nih.gov/37082750/">O'Keefe BR, et al. Biochemical Discovery, Intracellular Evaluation, and Crystallographic Characterization of Synthetic and Natural Product Adenosine 3',5'-Cyclic Monophosphate-Dependent Protein Kinase A (PKA) Inhibitors. PMID: 37082750</a> 166884134 O'Keefe BR, et al. Discovery and Synthesis of a Naturally Derived Protein Kinase Inhibitor that Selectively Inhibits Distinct Classes of Serine/Threonine Kinases. PMID: 37843072 https://pubmed.ncbi.nlm.nih.gov/37843072/ <a href="https://pubmed.ncbi.nlm.nih.gov/37843072/">O'Keefe BR, et al. Discovery and Synthesis of a Naturally Derived Protein Kinase Inhibitor that Selectively Inhibits Distinct Classes of Serine/Threonine Kinases. PMID: 37843072</a> 158677389 O'Keefe, Barry NCI O'Keefe, Barry (NCI) 1 158677393 Du, Lin NCI - CCR NCI Du, Lin (NCI) 2 158677397 Wilson, Brice NCI Wilson, Brice (NCI) 3 158677401 Zhang, Ping NCI Zhang, Ping (NCI) 4 158677405 Moore, William National Cancer Institute (NCI) NCI Moore, William (NCI) 5 158677413 Wang, Dongdong NCI Wang, Dongdong (NCI) 6 158677417 Martinez Fiesco, Juliana Martinez Fiesco, Juliana 7 158677421 Li, Ning Leidos Li, Ning (Leidos) 8 158677389 O'Keefe, Barry NCI O'Keefe, Barry (NCI) 1 158677393 Du, Lin NCI - CCR NCI Du, Lin (NCI) 2 158677397 Wilson, Brice NCI Wilson, Brice (NCI) 3 158677401 Zhang, Ping NCI Zhang, Ping (NCI) 4 158677405 Moore, William National Cancer Institute (NCI) NCI Moore, William (NCI) 5 158677413 Wang, Dongdong NCI Wang, Dongdong (NCI) 6 158677417 Martinez Fiesco, Juliana Martinez Fiesco, Juliana 7 158677421 Li, Ning Leidos Li, Ning (Leidos) 8 158677383 Reverse Thiazine Kinase Inhibitors E-162-2024-0 Filing authorized National Cancer Institute (NCI), NIH - NCI 83732213 Dick, Taryn taryn.dick@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB taryn.dick@nih.gov?subject=Web Inquiry on [TAB-5020] Reverse Thiazine Kinase Inhibitors&body=Please send me information about technology [TAB-5020] Reverse Thiazine Kinase Inhibitors.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dick, Taryn<br><a href="mailto:taryn.dick@nih.gov?subject=Web Inquiry on [TAB-5020] Reverse Thiazine Kinase Inhibitors&body=Please send me information about technology [TAB-5020] Reverse Thiazine Kinase Inhibitors.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">taryn.dick@nih.gov</a><br> 159503194 E-162-2024-0 E-162-2024-0-US-01 Reverse Thiazine Kinase Inhibitors PRV US 63/672,577 Expired US <br />Provisional (PRV) 63/672,577<br />Filed on 2024-07-17<br />Status: Expired TAB-5019 158672233 Novel Kinase Inhibitory Aplithianines NCI Collaboration, Infectious Disease, Licensing, Oncology, Rare/Neglected Diseases, Therapeutics Collaboration Infectious Disease Licensing Oncology Rare/Neglected Diseases Therapeutics Lin Du, Ning Li, Juliana Martinez Fiesco, William Moore, Barry O'Keefe, Dongdong Wang, Brice Wilson, Ping Zhang <h3>Summary:</h3> <p>The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a class of novel aplithianine-derived small molecule analogs that compete with ATP for binding on a range of clinically relevant kinases including:</p> <ul> <li>Oncogenic gene fusion DNAJB1-PRKACA (PKADJ)</li> <li>Wild type protein kinase A (PKA)&nbsp;</li> <li>Protein kinase G (PKG)</li> <li>Ccdc2-like kinases (CLK) 1 &amp; 2</li> <li>DYRK family of kinases</li> </ul> <h3>Description of Technology:</h3> <p>In 2022, the NCI Molecular Targets Program (MTP) completed a screen of ~150,000 pre-fractionated natural products from the NCI Program for Natural Product Discovery (NPNPD). From this screen, a class of active compounds, named Aplithianines A &amp; B (isolated from the marine organism Aplidium sp.), showed broad potential applicability to numerous kinases of importance including but not limited to:</p> <ul> <li>Oncogenic gene fusion DNAJB1-PRKACA (PKADJ) <ul> <li>Implicated in an ultra-rare adolescent liver cancer</li> </ul> </li> <li>Wild type protein kinase A (PKA)&nbsp; <ul> <li>Implicated in Cushing&rsquo;s Disease</li> </ul> </li> <li>Protein kinase G (PKG)&nbsp; <ul> <li>Potential treatment of malaria</li> </ul> </li> <li>Ccdc2-like kinases (CLK) 1 &amp; 2 <ul> <li>Implicated in gastric cancer</li> </ul> </li> <li>DYRK family of kinases&nbsp; <ul> <li>Implicated in gastric or colon cancer as well as infections caused by a protozoa or parasites</li> </ul> </li> </ul> <p>This Technology describes the Original Family of compounds filed. Subsequent to this filing, two additional cohorts of related, but patentably distinct Cohorts of compounds have been filed under NIH Ref # &nbsp;<strong>E-202-2023</strong> and <strong>E-164-2024</strong>. Both the Second and the Third Cohorts comprise the same chemical scaffold of the broadest generic formula of this Original Family but represent patentably distinct subgenus formulas.&nbsp;</p> <p><img alt="Image of Molecular Diagrams" src="https://nih.technologypublisher.com/files/sites/monosnap_structural_representatives.jpg_2024-10-30_17-57-47.png" /></p> <p>The specificity of several of the compounds have been examined in kinase panels to demonstrate that while applicable to a range of kinases, they are not promiscuous kinase inhibitors. The subject kinase inhibitors have broad potential commercial applicability&rsquo;s for cancer, immune suppression, preventing organ rejection, treating diabetic neuropathic pain, malaria, or protozoa infection. To date there are no approved therapeutics targeting DNAJB1-PRKCA, an oncogenic gene fusion is ubiquitously and exclusively detected in the tumors of patients with ultra-rare fibrolamellar hepatocellular carcinoma FLHCC.</p> <p>The NCI seeks licensing and/or co-development research collaborations for the future development of Kinase Inhibitory Aplithianines targeting &nbsp;DNAJB1-PRKACA (PKADJ), PKA, PKG, CLK, and/or DYRK.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Gastric cancer</li> <li>Ultra-rare adolescent liver cancer</li> <li>Solid cancers susceptible to kinase inhibitors</li> <li>Cushing&rsquo;s Disease</li> <li>Transplantation</li> <li>Diabetic neuropathic pain</li> <li>Malaria</li> <li>Protozoa infection&nbsp;</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Applicability to numerous clinically relevant kinases, including: <ul> <li>Oncogenic gene fusion DNAJB1-PRKACA (PKADJ)</li> <li>Wild type protein kinase A (PKA)</li> <li>Protein kinase G (PKG)</li> <li>Ccdc2-like kinases (CLK) 1 &amp; 2</li> <li>DYRK family of kinases</li> </ul> </li> <li>Applicable to a range of kinases, but are not promiscuous kinase inhibitors</li> <li>Broad potential commercial applicability for several blockbuster indications including: cancer, immune suppression, transplantation, diabetic neuropathic pain, malaria, and protozoa infection</li> <li>No approved therapeutics targeting DNAJB1-PRKCA</li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for a class of novel aplithianine-derived small molecule analogs that compete with ATP for binding on a range of clinically relevant kinases 2024-10-17 2026-04-16 2026-04-16 2024-10-17 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-202-2023 E-162-2024 158672505 O'Keefe BR, et al. Biochemical Discovery, Intracellular Evaluation, and Crystallographic Characterization of Synthetic and Natural Product Adenosine 3',5'-Cyclic Monophosphate-Dependent Protein Kinase A (PKA) Inhibitors. PMID: 3708275 : O'Keefe BR, et al. Biochemical Discovery, Intracellular Evaluation, and Crystallographic Characterization of Synthetic and Natural Product Adenosine 3',5'-Cyclic Monophosphate-Dependent Protein Kinase A (PKA) Inhibitors. PMID: 37082750 <a href=": O'Keefe BR, et al. Biochemical Discovery, Intracellular Evaluation, and Crystallographic Characterization of Synthetic and Natural Product Adenosine 3',5'-Cyclic Monophosphate-Dependent Protein Kinase A (PKA) Inhibitors. PMID: 37082750">O'Keefe BR, et al. Biochemical Discovery, Intracellular Evaluation, and Crystallographic Characterization of Synthetic and Natural Product Adenosine 3',5'-Cyclic Monophosphate-Dependent Protein Kinase A (PKA) Inhibitors. PMID: 3708275</a> 158849587 O'Keefe BR, et al. Discovery and Synthesis of a Naturally Derived Protein Kinase Inhibitor that Selectively Inhibits Distinct Classes of Serine/Threonine Kinases.PMID: 3784307 : O'Keefe BR, et al. Discovery and Synthesis of a Naturally Derived Protein Kinase Inhibitor that Selectively Inhibits Distinct Classes of Serine/Threonine Kinases.PMID: 37843072 <a href=": O'Keefe BR, et al. Discovery and Synthesis of a Naturally Derived Protein Kinase Inhibitor that Selectively Inhibits Distinct Classes of Serine/Threonine Kinases.PMID: 37843072">O'Keefe BR, et al. Discovery and Synthesis of a Naturally Derived Protein Kinase Inhibitor that Selectively Inhibits Distinct Classes of Serine/Threonine Kinases.PMID: 3784307</a> 158672259 O'Keefe, Barry National Cancer Institute (NCI) NCI O'Keefe, Barry (NCI) 1 158848379 Du, Lin Molecular Targets Program NCI Du, Lin (NCI) 2 158672267 Wilson, Brice NCI Wilson, Brice (NCI) 3 158672273 Zhang, Ping National Cancer Institute (NCI) NCI Zhang, Ping (NCI) 4 158672277 Moore, William National Cancer Institute (NCI) NCI Moore, William (NCI) 5 158672346 Wang, Dongdong National Cancer Institute (NCI) NCI Wang, Dongdong (NCI) 6 158672350 Martinez Fiesco, Juliana National Cancer Institute (NCI) Martinez Fiesco, Juliana 7 158672377 Li, Ning Leidos Li, Ning (Leidos) 8 158672259 O'Keefe, Barry National Cancer Institute (NCI) NCI O'Keefe, Barry (NCI) 1 158848379 Du, Lin Molecular Targets Program NCI Du, Lin (NCI) 2 158672267 Wilson, Brice NCI Wilson, Brice (NCI) 3 158672273 Zhang, Ping National Cancer Institute (NCI) NCI Zhang, Ping (NCI) 4 158672277 Moore, William National Cancer Institute (NCI) NCI Moore, William (NCI) 5 158672346 Wang, Dongdong National Cancer Institute (NCI) NCI Wang, Dongdong (NCI) 6 158672350 Martinez Fiesco, Juliana National Cancer Institute (NCI) Martinez Fiesco, Juliana 7 158672377 Li, Ning Leidos Li, Ning (Leidos) 8 158672236 Novel Kinase Inhibitory Aplithianines E-044-2022-0 Filing authorized NCI, NIH - NCI 83732213 Dick, Taryn taryn.dick@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB taryn.dick@nih.gov?subject=Web Inquiry on [TAB-5019] Novel Kinase Inhibitory Aplithianines&body=Please send me information about technology [TAB-5019] Novel Kinase Inhibitory Aplithianines.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dick, Taryn<br><a href="mailto:taryn.dick@nih.gov?subject=Web Inquiry on [TAB-5019] Novel Kinase Inhibitory Aplithianines&body=Please send me information about technology [TAB-5019] Novel Kinase Inhibitory Aplithianines.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">taryn.dick@nih.gov</a><br> 159503214 E-044-2022-0 E-044-2022-0-US-01 KINASE INHIBITORS PRV US 63/389,937 Expired US <br />Provisional (PRV) 63/389,937<br />Filed on 2022-07-17<br />Status: Expired 159503219 E-044-2022-0 E-044-2022-0-PCT-01 KINASE INHIBITORS PCT Patent Cooperation Treaty PCT/US2023/070304 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2023/070304<br />Filed on 2023-07-17<br />Status: Expired 159503239 E-044-2022-0 E-044-2022-0-IN-01 KINASE INHIBITORS National Stage India 202547012577 Pending India <br />National Stage 202547012577<br />Filed on 2025-02-14<br />Status: Pending 159503244 E-044-2022-0 E-044-2022-0-JP-01 KINASE INHIBITORS National Stage Japan 2025-502384 Pending Japan <br />National Stage 2025-502384<br />Filed on 2025-01-16<br />Status: Pending 159503249 E-044-2022-0 E-044-2022-0-CN-01 KINASE INHIBITORS National Stage China 202380062947.2 Pending China <br />National Stage 202380062947.2<br />Filed on 2025-02-28<br />Status: Pending 159503254 E-044-2022-0 E-044-2022-0-US-02 KINASE INHIBITORS National Stage US 18/995,318 Pending US <br />National Stage 18/995,318<br />Filed on 2025-01-16<br />Status: Pending 159503259 E-044-2022-0 E-044-2022-0-EP-01 KINASE INHIBITORS National Stage European Patent 23755549.5 Pending European Patent <br />National Stage 23755549.5<br />Filed on 2025-02-04<br />Status: Pending TAB-5007 158185662 Methods of Detecting Loss of Heterozygosity and Damaging Mutations in Immune-Related Genes Using Liquid Biopsies NCI Collaboration, Diagnostics, Immunology, Oncology Collaboration Diagnostics Immunology Oncology James Gulley, Scott Norberg, Andrew Sinkoe, Xiaolin Wu <h2>Summary:&nbsp;</h2> <p>The National Cancer Institute (NCI) seeks co-development partners and/or licensees for a liquid biopsy diagnostic assay capable of detecting loss of heterozygosity (LOH) and somatic mutations in genes important for antigen processing and presentation and interferon-&gamma; response pathways.</p> <h2>Description of Technology:&nbsp;</h2> <p>Immunotherapy is an effective cancer treatment utilizing T cells to recognize and eliminate cancer cells. Antigen processing and presentation machinery (APM) and interferon-&gamma; (IFN) response pathways play an important role for T cells to target cancer cells. To evade immunotherapy, cancer cells can develop somatic mutations in genes important for APM and IFN.&nbsp;<br /> Liquid biopsy is a non-invasive tool that can diagnose and monitor cancer by analyzing circulating tumor DNA (ctDNA). The ability to detect somatic mutations and predict response to immunotherapies using liquid biopsy would be critical to provide more personalized cancer treatment. However, currently marketed liquid biopsies cannot predict response to cellular immunotherapies. As a result, patients with relapsed or recurrent disease lose valuable time and resources on ineffective treatments.</p> <p>The inventors at the National Cancer Institute (NCI) developed a novel method to detect somatic mutations from liquid biopsy samples. Combined with NCI&rsquo;s method to detect loss of heterozygosity in HLA genes &ndash; another mechanism for immunotherapy evasion &ndash; this invention allows for improved patient selection and non-invasive prediction of response. This novel precision medicine method will allow patient-tailored treatment by targeting treatment based on genetic mutations and prediction of immunotherapy response. This invention could potentially deliver better patient satisfaction, lower healthcare costs and better outcomes.</p> <p>The Center for Immuno-Oncology at the NCI is looking for co-development partners and/or licensees. As a companion diagnostic for immunotherapies, this invention will be used to select optimal patients and monitor efficacy of treatments &ndash; such as TCR-T cell therapy. There are no liquid biopsy assays on the market designed as companion diagnostic for cellular immunotherapy &ndash; such as TCR-T cell therapy. Therefore, this technology may be particularly appealing to co-development partners who are developing proprietary cellular immunotherapies.</p> <h2>Potential Commercial Applications:&nbsp;</h2> <ul> <li>Companion diagnostic for cellular immunotherapies</li> <li>Companion diagnostic for monitoring the effectiveness of TCR-based immunotherapies</li> <li>Companion diagnostic for T cell-based immunotherapies, including certain immune checkpoint inhibitors&nbsp;</li> <li>Research use in labs studying/developing new pre-clinical therapeutic candidates</li> <li>Research use in basic research labs studying immunotherapy resistance mechanisms, antigen processing and presentation, interferon-&gamma; response pathways, mutations in cancer cells, basic immunology and basic oncology</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>First method to predict response to immunotherapies by detecting damaging mutations using liquid biopsy samples</li> <li>Non-invasive test not requiring surgery</li> <li>Easy to administer</li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for a liquid biopsy analysis method capable of detecting loss of heterozygosity (LOH) and somatic mutations in genes important for antigen processing and presentation and interferon-γ response pathways. 2024-09-13 2026-04-16 2026-04-16 2024-09-13 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-045-2022-0 158185678 Norberg, Scott Center for Immuno-Oncology NCI Norberg, Scott (NCI) 1 158185693 Sinkoe, Andrew Sesh Incorporated NCI Sinkoe, Andrew (NCI) 2 158185700 Wu, Xiaolin Genomics Laboratory Leidos Wu, Xiaolin (Leidos) 3 158185717 Gulley, James NCI - CCR NCI Gulley, James (NCI) 4 158185678 Norberg, Scott Center for Immuno-Oncology NCI Norberg, Scott (NCI) 1 158185693 Sinkoe, Andrew Sesh Incorporated NCI Sinkoe, Andrew (NCI) 2 158185700 Wu, Xiaolin Genomics Laboratory Leidos Wu, Xiaolin (Leidos) 3 158185717 Gulley, James NCI - CCR NCI Gulley, James (NCI) 4 158185670 Method of detecting damaging mutations in immune related genes by liquid biopsy Leidos EIR # 23-018 E-027-2024-0 Filing authorized National Cancer Institute (NCI), NCI - FCRDC (Leidos) 83694133 Gulay French, Suna suna.gulay@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB suna.gulay@nih.gov?subject=Web Inquiry on [TAB-5007] Methods of Detecting Loss of Heterozygosity and Damaging Mutations in Immune-Related Genes Using Liquid Biopsies&body=Please send me information about technology [TAB-5007] Methods of Detecting Loss of Heterozygosity and Damaging Mutations in Immune-Related Genes Using Liquid Biopsies.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Gulay French, Suna<br><a href="mailto:suna.gulay@nih.gov?subject=Web Inquiry on [TAB-5007] Methods of Detecting Loss of Heterozygosity and Damaging Mutations in Immune-Related Genes Using Liquid Biopsies&body=Please send me information about technology [TAB-5007] Methods of Detecting Loss of Heterozygosity and Damaging Mutations in Immune-Related Genes Using Liquid Biopsies.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">suna.gulay@nih.gov</a><br> 159502811 E-027-2024-0 E-027-2024-0-US-01 METHODS OF DETECTING LOSS OF HETEROZYGOSITY AND DAMAGING MUTATIONS IN IMMUNERELATED GENES IN LIQUID BIOPSIES PRV US 63/572,760 Expired US <br />Provisional (PRV) 63/572,760<br />Filed on 2024-04-01<br />Status: Expired TAB-4999 157682678 Methods To Regulate Metabolism For Treatment Of Neural Injuries and Neurodegeneration NEI Collaboration, Ear, Nose, & Throat, Licensing, Neurology, Therapeutics Collaboration Ear Nose & Throat Licensing Neurology Therapeutics Wei Li, Jingxing Ou, Tantai Zhao <h2>Description of Technology:</h2> <p>Axonal injury and subsequent neuronal death underpin the pathology of many neurological disorders from acute neural injuries (motor vehicle crashes, combat related injuries, traumatic brain injuries) to neurological diseases (multiple sclerosis, glaucoma). In the central nervous system (CNS), microglia help respond to CNS injuries by mediating the immune response and increasing inflammation at the site of injury.&nbsp;</p> <p>Scientists at the National Eye Institute (NEI) have discovered a novel method of reducing neuronal death by using Dimethyl Malonate (DMM), a compound that inhibits the activity of succinate dehydrogenase (SDH). Using DMM on an optic nerve crush model in ground squirrels, DMM helped reduce the pro-inflammatory response of microglia via decreasing succinate levels or reducing the SDH activity. In the same model, treatment also improved the retinal function compared to controls. Additionally, administering DMM after optic crush injury reduced the microglia response and promoted neural protection against axonal injury.&nbsp;</p> <p>This method of treats immune-mediated disorders using DMM by decreasing levels of succinate or reducing the activity of succinate dehydrogenase in patients. It inhibits activation of microglial cells by using DMM by decreasing levels of succinate or reducing the activity of succinate dehydrogenase in cells. It prevents the activation of astrocytes in a system comprising of microglial cells and astrocytes using DMM by decreasing levels of succinate or reducing the activity of succinate dehydrogenase. Overall, these results show the promise of DMM for protecting neurodegeneration due to neural injury and possibly other neurodegenerative disorders.</p> <h2>Potential Commercial Applications:&nbsp;</h2> <ul> <li>Ophthalmic diseases, such as glaucoma</li> <li>Neurodegenative diseases, such as multiple sclerosis</li> <li>Acute neural injuries</li> </ul> <h2><strong>Competitive Advantages:&nbsp;</strong></h2> <ul> <li>Dimethyl Malonate (DMM) is inexpensive and readily available &ndash; reducing manufacturing costs</li> <li>Address significant, unmet medical needs since few, if any, treatments exist for neural injuries and neurodegeneration</li> <li>Mutation independent method for treating neurodegeneration</li> </ul> Researchers at the NEI seek licensing and/or co-development research collaborations for a novel method of treating neural injury and neurodegeneration via immune-metabolic regulation. 2024-08-08 2026-04-16 2026-04-16 2024-08-23 False True Discovery (Lead ID) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 158013913 Li, Wei National Eye Institute (NEI) Li, Wei 1 158013991 Ou, Jingxing National Sun Yat-Sen University NEI Ou, Jingxing (NEI) 2 158014042 Zhao, Tantai Zhao, Tantai 3 158013913 Li, Wei National Eye Institute (NEI) Li, Wei 1 158013991 Ou, Jingxing National Sun Yat-Sen University NEI Ou, Jingxing (NEI) 2 158014042 Zhao, Tantai Zhao, Tantai 3 157682681 Metabolic Regulation Of Mitochondria To Inhibit Inflammatory Microglia In Treatment Of Axonal Injury And Neurodegenerations E-077-2018-0 Filing authorized National Eye Institute (NEI) 83724826 Pollard, Ricquita ricquita.pollard@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4999] Methods To Regulate Metabolism For Treatment Of Neural Injuries and Neurodegeneration&body=Please send me information about technology [TAB-4999] Methods To Regulate Metabolism For Treatment Of Neural Injuries and Neurodegeneration.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollard, Ricquita<br><a href="mailto:ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4999] Methods To Regulate Metabolism For Treatment Of Neural Injuries and Neurodegeneration&body=Please send me information about technology [TAB-4999] Methods To Regulate Metabolism For Treatment Of Neural Injuries and Neurodegeneration.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">ricquita.pollard@nih.gov</a><br> 157851175 E-077-2018-0 E-077-2018-0-CN-03 METHODS OF METABOLIC REGULATION OF MITOCHONDRIA FOR TREATING NEURAL INJURY AND NEUROLOGICAL DISORDERS National Stage China 201980061762.3 Pending China <br />National Stage 201980061762.3<br />Filed on 2019-08-21<br />Status: Pending 157915564 E-077-2018-0 E-077-2018-0-US-01 Metabolic Regulation Of Mitochondria To Inhibit Inflammatory Microglia In Treatment Of Axonal Injury And Neurodegenerations PRV US 62/720,612 Abandoned US <br />Provisional (PRV) 62/720,612<br />Filed on 2018-08-21<br />Status: Abandoned 157915565 E-077-2018-0 E-077-2018-0-PCT-02 METHODS OF METABOLIC REGULATION OF MITOCHONDRIA FOR TREATING NEURAL INJURY AND NEUROLOGICAL DISORDERS PCT Patent Cooperation Treaty PCT/US2019/047504 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2019/047504<br />Filed on 2019-08-21<br />Status: Expired 157915566 E-077-2018-0 E-077-2018-0-US-04 METHODS OF METABOLIC REGULATION OF MITOCHONDRIA FOR TREATING NEURAL INJURY AND NEUROLOGICAL DISORDERS National Stage US 12,011,426 17/268,203 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12011426 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12011426">12,011,426</a><br />Filed on 2021-02-12<br />Status: Issued 157915567 E-077-2018-0 E-077-2018-0-US-02 METHODS OF METABOLIC REGULATION OF MITOCHONDRIA FOR TREATING NEURAL INJURY AND NEUROLOGICAL DISORDERS CON US 18/664,615 Abandoned US <br />Continuation (CON) 18/664,615<br />Filed on 2024-05-15<br />Status: Abandoned TAB-4998 157594389 Using FDA-approved Small Molecule Drug Reserpine and related compounds (especially Halofantrine) To Protect Photoreceptors In Inherited Retinal Degenerations And Age-Related Macular Degeneration NEI Collaboration, Ear, Nose, & Throat, Licensing, Therapeutics Collaboration Ear Nose & Throat Licensing Therapeutics Yu Holly Chen, Wenwei Huang, Zhiji Luo, Anupam Mondal, Samantha Papal, Anand Swaroop, Manju Swaroop, Gregory Tawa, Wei Zheng <h2>Summary:&nbsp;</h2> <p>The National Eye Institute seeks research co-development partners and/or licensees for a therapy using an FDA-approved small molecule drug reserpine (and related compounds especially halofantrine) that prevents photoreceptor cell death in retinal degenerations.</p> <h2>Description of Technology:&nbsp;</h2> <p>Inherited Retinal Degenerations (IRD), such as Leber Congenital Amaurosis (LCA) and retinitis pigmentosa (RP), are characterized by a progressive loss of photo-sensitive cells in the retina. Most forms of IRD have no therapeutic options available due to their genetic heterogeneity and/or lack of mechanistic understanding. In particular, LCA represents roughly 5% of all retinal dystrophies and results in severe vision loss at an early age. There is an FDA-approved treatment for one form of LCA caused by mutations in the RPE 65 gene. This involves injection of an adenovirus vector containing the normal copy of the RPE65 gene. Long-term data for the gene therapy achieved only transient results: progressive reduction in visual acuity, sensitivity and function occurred following an initial gain seen 6-12 months post-treatment.&nbsp;</p> <p>RP is a collection of rare eye diseases that affect roughly 1 in 4000 people worldwide. Currently, as there are no treatments, a majority of affected individuals lose most of their sight.</p> <p>By 2040, age-related macular degeneration (AMD) will affect ~288 million people worldwide. AMD is the leading cause of blindness in all developed countries. Identifying eyes at high risk of progression to late AMD, the stage associated with blindness, is vital. This would allow timely medical treatments, lifestyle interventions, more tailored home monitoring and improved clinical trials for patients.</p> <p>Scientists at the National Eye Institute (NEI) have developed a mutation-independent method to treat LCA, RP, other IRDs, and AMD using the FDA-approved small molecule, Halofantrine (NCGC00016833-01). Halofantrine, which was previously approved to treat malaria, helped protect photoreceptors from cell death in three different IRD model systems in 1) retinal organoid model systems, 2) two different mouse models, and 3) rat models. Furthermore, packaging Halofantrine and other potential candidate compounds for conjunctival delivery into the eye via eye drops is under development.&nbsp;</p> <p>These small molecules act by targeting several cellular pathways which are also affected in diseases of other organs, suggesting that they may be useful in treating other, mutation independent ocular diseases.</p> <h2>Potential Commercial Applications:&nbsp;</h2> <ul> <li>Therapeutic to treat Leber congenital amaurosis</li> <li>Therapeutic to treat Inherited Retinal Disorders associated with photoreceptor degeneration</li> <li>Therapeutic to treat AMD</li> <li>Therapeutic to treat mutation-independent ocular diseases</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Less time-consuming, costly and labor intensive versus the development of individualized gene therapies</li> <li>Small molecules are scalable with cost-effective manufacturing</li> <li>Small molecules are highly penetrant with easy routes of administration</li> <li>Small molecules can be delivered via eye drops or as intra-vitreal injection</li> <li>Less intrusive and easy administration route</li> <li>Conjunctival delivery and eye drop formulation more accessible than retinal implant or injection<br /> &nbsp;</li> </ul> Researchers at the NEI seek licensing and/or co-development research collaborations for a therapy using an FDA-approved small molecule drug reserpine and related compounds (such as halofantrine) that prevents retinal degeneration. 2024-08-02 2026-04-16 2026-04-16 2024-08-05 False True Discovery (Lead ID) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 157619396 Chen, HY, et al. Reserpine maintains photoreceptor survival in retinal ciliopathy by resolving proteostasis imbalance and ciliogenesis defects. (PMID 36975211) https://pubmed.ncbi.nlm.nih.gov/36975211/ <a href="https://pubmed.ncbi.nlm.nih.gov/36975211/">Chen, HY, et al. Reserpine maintains photoreceptor survival in retinal ciliopathy by resolving proteostasis imbalance and ciliogenesis defects. (PMID 36975211)</a> 157594396 Swaroop, Anand National Eye Institute (NEI) NEI Swaroop, Anand (NEI) 1 157594400 Chen, Yu Holly National Eye Institute (NEI) NEI Chen, Yu Holly (NEI) 2 157594408 Papal, Samantha National Eye Institute (NEI) NEI Papal, Samantha (NEI) 3 157594416 Mondal, Anupam National Eye Institute (NEI) NEI Mondal, Anupam (NEI) 4 157594424 Swaroop, Manju NCATS - NCGC NCATS Swaroop, Manju (NCATS) 5 157594428 Zheng, Wei NCATS - TRND NCATS Zheng, Wei (NCATS) 6 157594432 Tawa, Gregory NCATS - TRND NCATS Tawa, Gregory (NCATS) 7 157594436 Huang, Wenwei NCATS - TRND NCATS Huang, Wenwei (NCATS) 8 157594443 Luo, Zhiji Zhiji, Luo Luo, Zhiji 9 157594396 Swaroop, Anand National Eye Institute (NEI) NEI Swaroop, Anand (NEI) 1 157594400 Chen, Yu Holly National Eye Institute (NEI) NEI Chen, Yu Holly (NEI) 2 157594408 Papal, Samantha National Eye Institute (NEI) NEI Papal, Samantha (NEI) 3 157594416 Mondal, Anupam National Eye Institute (NEI) NEI Mondal, Anupam (NEI) 4 157594424 Swaroop, Manju NCATS - NCGC NCATS Swaroop, Manju (NCATS) 5 157594428 Zheng, Wei NCATS - TRND NCATS Zheng, Wei (NCATS) 6 157594432 Tawa, Gregory NCATS - TRND NCATS Tawa, Gregory (NCATS) 7 157594436 Huang, Wenwei NCATS - TRND NCATS Huang, Wenwei (NCATS) 8 157594443 Luo, Zhiji Zhiji, Luo Luo, Zhiji 9 157594392 Small Molecule Drug Candidates And Disease-associated Signature Genes For Therapeutic Interventions In Retinal Degeneration E-071-2020-0 Filing authorized National Eye Institute (NEI), NCATS - NCGC 83724826 Pollard, Ricquita ricquita.pollard@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4998] Using FDA-approved Small Molecule Drug Reserpine and related compounds (especially Halofantrine) To Protect Photoreceptors In Inherited Retinal Degenerations And Age-Related Macular Degeneration&body=Please send me information about technology [TAB-4998] Using FDA-approved Small Molecule Drug Reserpine and related compounds (especially Halofantrine) To Protect Photoreceptors In Inherited Retinal Degenerations And Age-Related Macular Degeneration.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollard, Ricquita<br><a href="mailto:ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4998] Using FDA-approved Small Molecule Drug Reserpine and related compounds (especially Halofantrine) To Protect Photoreceptors In Inherited Retinal Degenerations And Age-Related Macular Degeneration&body=Please send me information about technology [TAB-4998] Using FDA-approved Small Molecule Drug Reserpine and related compounds (especially Halofantrine) To Protect Photoreceptors In Inherited Retinal Degenerations And Age-Related Macular Degeneration.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">ricquita.pollard@nih.gov</a><br> 157595034 E-071-2020-0 E-071-2020-0-US-01 COMPOUND EMBODIMENTS FOR TREATING RETINAL DEGENERATION AND METHOD EMBODIMENTS OF MAKING AND USING THE SAME PRV US 63/047,858 Abandoned US <br />Provisional (PRV) 63/047,858<br />Filed on 2020-07-02<br />Status: Abandoned 157595066 E-071-2020-0 E-071-2020-0-PCT-02 COMPOUND EMBODIMENTS FOR TREATING RETINAL DEGENERATION AND METHOD EMBODIMENTS OF MAKING AND USING THE SAME PCT Patent Cooperation Treaty PCT/US2021/040157 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/040157<br />Filed on 2021-07-01<br />Status: Expired 164119845 E-071-2020-0 E-071-2020-0-AU-04 CYCLIC COMPOUNDS FOR USE IN TREATING RETINAL DEGENERATION National Stage Australia 2021300425 Pending Australia <br />National Stage 2021300425<br />Filed on 2022-12-08<br />Status: Pending 164119846 E-071-2020-0 E-071-2020-0-CA-05 COMPOUND EMBODIMENTS FOR TREATING RETINAL DEGENERATION AND METHOD EMBODIMENTS OF MAKING AND USING THE SAME National Stage Canada 3186586 Pending Canada <br />National Stage 3186586<br />Filed on 2021-07-01<br />Status: Pending 164119847 E-071-2020-0 E-071-2020-0-EP-06 CYCLIC COMPOUNDS FOR USE IN TREATING RETINAL DEGENERATION National Stage European Patent 21751672.3 Pending European Patent <br />National Stage 21751672.3<br />Filed on 2021-07-01<br />Status: Pending 164119848 E-071-2020-0 E-071-2020-0-JP-07 COMPOUND EMBODIMENTS FOR TREATING RETINAL DEGENERATION AND METHOD EMBODIMENTS OF MAKING AND USING THE SAME National Stage Japan 2022-581456 Pending Japan <br />National Stage 2022-581456<br />Filed on 2022-12-28<br />Status: Pending 164119849 E-071-2020-0 E-071-2020-0-US-08 CYCLIC COMPOUNDS FOR USE IN TREATING RETINAL DEGENERATION National Stage US 18/014,045 Pending US <br />National Stage 18/014,045<br />Filed on 2022-12-30<br />Status: Pending 165783069 E-071-2020-0 E-071-2020-0-JP-01 COMPOUND EMBODIMENTS FOR TREATING RETINAL DEGENERATION AND METHOD EMBODIMENTS OF MAKING AND USING THE SAME DIV Japan 2026-019246 Pending Japan <br />Divisional (DIV) 2026-019246<br />Filed on 2026-02-09<br />Status: Pending TAB-4996 157267605 Interleukin-27 Producing B-Cell Population and Uses Thereof NEI Collaboration, Ear, Nose, & Throat, Immunology, Licensing, Neurology, Therapeutics Collaboration Ear Nose & Throat Immunology Licensing Neurology Therapeutics Jin Choi, Charles Egwuagu <h2>Summary:&nbsp;</h2> <p>The National Eye Institute (NEI) seeks research co-development partners and/or licensees to advance the production and uses of interleukin-27 (IL-27) producing B-regulatory cell (i27-Breg) therapy for immune related autoimmune disorders. These disorders include but are not limited, to age-related macular degeneration (AMD), graft-versus-host disease (GVHD), multiple sclerosis (MS) and transplant rejection.</p> <h2>Description of Technology:&nbsp;</h2> <p>Autoimmune diseases in which the immune system attacks the body&#39;s own tissues or organs include: graft-vs-host disease (GVHD), age-related macular degeneration (AMD), multiple sclerosis (MS), uveitis and encephalomyelitis. &nbsp;These diseases can result in blindness, paralysis, and significant morbidity impacting quality of life. &nbsp;In GVHD, the allogeneic transplant views the recipient&rsquo;s body as foreign, and the transplant attacks the body. &nbsp;Uveitis is comprised of a diverse group of potentially sight-threatening intraocular inflammatory diseases of infectious or autoimmune etiology. &nbsp;Similarly, autoimmune processes contribute significantly to the progression of retinal degeneration associated with AMD. &nbsp;MS is caused in part by immune cells that attack and/or destroy neurons, thereby interfering with normal neurological function. Steroids and monoclonal antibodies are temporarily effective therapies; serious adverse effects preclude their prolonged use. Therefore, an unmet need remains for safe, effective long-term therapies for autoimmune disorders.</p> <p>The invention consists of an isolated population of mammal cells comprising about 75 % or higher B-1a regulatory cells and methods of preparation of such cell populations. i27-Bregs have distinct advantages over &nbsp;systemic administration of interleukin-27 (IL-27) since the latter is costly to synthesize and rapidly degrades in the body. i27-Bregs provide several therapeutic advantages over current standard of care: &nbsp;(i) self-renewal after administration and thereby sustained IL-27 production in host tissues; (ii) reprograms recipient lymphocytes into Bregs and Tregs (regulatory T cells) (iii) effective suppression of the host&rsquo;s overreactive immune system; (iv) no requirement of prior activation, providing a potential therapeutic advantage over other disease-specific cell therapies. Immune system suppression by i27-Bregs administration can also be used in conjunction with solid organ or allogenic cell transplants to reduce potentially fatal transplant rejection.&nbsp;</p> <p>This technology is available for development under a license for the above-mentioned disorders. Inventors at the National Eye Institute are interested in participating under a CRADA collaboration to further develop the technology toward clinical applications or will assist to transfer the technological know-how for licensing. &nbsp;&nbsp;</p> <h2>Potential Commercial Applications:&nbsp;</h2> <ul> <li>Cell therapy for severe CNS autoimmune disease, GVHD, transplants, encephalomyelitis, or multiple sclerosis</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Can be co-administered with other currently approved therapies currently&nbsp;</li> <li>No FDA approved B cell therapy for the treatment of auto immune disease</li> <li>Self-renewing</li> <li>Excreted interleukins following administration provide a longer-lasting effect than currently approved monoclonal antibody therapies</li> <li>Potentially fewer side effects since IL-27 extended release avoids the systemic administration of monoclonal antibodies or immunosuppressive drugs</li> <li>Ex-vivo preparation can be further genetically modified to enhance efficacy</li> <li>Activation not required to inhibit autoimmunity</li> </ul> Researchers at the NEI seek licensing and/or co-development research collaborations to advance the production and uses of IL-27 producing B-regulatory cells (i27-Bregs) for autoimmune disorders, including but not limited to, graft-versus-host disease (GVHD), age-related macular degeneration (AMD); and transplant rejection. 2024-07-23 2026-04-16 2026-04-16 2024-07-23 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-036-2012 157267704 Choi JK, et al. IL-27-producing B-1a cells suppress neuroinflammation and CNS autoimmune diseases. (PMID 34782464) https://pubmed.ncbi.nlm.nih.gov/34782464/ <a href="https://pubmed.ncbi.nlm.nih.gov/34782464/">Choi JK, et al. IL-27-producing B-1a cells suppress neuroinflammation and CNS autoimmune diseases. (PMID 34782464)</a> 157267612 Egwuagu, Charles National Eye Institute (NEI) NEI Egwuagu, Charles (NEI) 1 157267616 Choi, Jin National Eye Institute (NEI) NEI Choi, Jin (NEI) 2 157267612 Egwuagu, Charles National Eye Institute (NEI) NEI Egwuagu, Charles (NEI) 1 157267616 Choi, Jin National Eye Institute (NEI) NEI Choi, Jin (NEI) 2 157267608 A Novel IL-27-producing Innate B-1a Cell Population Regulates Neuroinflammation And Confers Protection against Severe CNS Autoimmune Diseases E-070-2019-0 Filing authorized National Eye Institute (NEI) 83737255 Baxter, Merissa merissa.baxter@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB merissa.baxter@nih.gov?subject=Web Inquiry on [TAB-4996] Interleukin-27 Producing B-Cell Population and Uses Thereof&body=Please send me information about technology [TAB-4996] Interleukin-27 Producing B-Cell Population and Uses Thereof.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Baxter, Merissa<br><a href="mailto:merissa.baxter@nih.gov?subject=Web Inquiry on [TAB-4996] Interleukin-27 Producing B-Cell Population and Uses Thereof&body=Please send me information about technology [TAB-4996] Interleukin-27 Producing B-Cell Population and Uses Thereof.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">merissa.baxter@nih.gov</a><br> 157267711 E-070-2019-0 E-070-2019-0-US-01 INTERLEUKIN-27 PRODUCING B-CELL POPULATION AND USES THEREOF PRV US 62/863,054 Abandoned US <br />Provisional (PRV) 62/863,054<br />Filed on 2019-06-18<br />Status: Abandoned 157267716 E-070-2019-0 E-070-2019-0-PCT-02 INTERLEUKIN-27 PRODUCING B-CELLS AND USES THEREOF PCT Patent Cooperation Treaty PCT/US2020/038368 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2020/038368<br />Filed on 2020-06-18<br />Status: Expired 162862740 E-070-2019-0 E-070-2019-0-AU-03 INTERLEUKIN-27 PRODUCING B-CELL AND USES THEREOF National Stage Australia 2020295470 2020295470 Issued Australia <br />National Stage 2020295470<br />Filed on 2020-06-18<br />Status: Issued 162862741 E-070-2019-0 E-070-2019-0-CA-04 INTERLEUKIN-27 PRODUCING B-CELL POPULATION AND USES THEREOF National Stage Canada 3143998 Pending Canada <br />National Stage 3143998<br />Filed on 2020-06-18<br />Status: Pending 162862742 E-070-2019-0 E-070-2019-0-EP-05 INTERLEUKIN-27 PRODUCING B-CELL POPULATION AND USES THEREOF National Stage European Patent 20736554.5 Pending European Patent <br />National Stage 20736554.5<br />Filed on 2020-06-18<br />Status: Pending 162862743 E-070-2019-0 E-070-2019-0-JP-06 INTERLEUKIN-27 PRODUCING B-CELL POPULATION AND USES THEREOF National Stage Japan 7662543 2021-575486 Issued Japan <br />National Stage 2021-575486<br />Filed on 2021-12-17<br />Status: Issued 162862744 E-070-2019-0 E-070-2019-0-US-07 INTERLEUKIN-27 PRODUCING B-CELLS AND USES THEREOF National Stage US 17/620,248 Pending US <br />National Stage 17/620,248<br />Filed on 2021-12-17<br />Status: Pending 162862745 E-070-2019-0 E-070-2019-0-JP-08 INTERLEUKIN-27 PRODUCING B-CELL POPULATION AND USES THEREOF DIV Japan 2025-061994 Pending Japan <br />Divisional (DIV) 2025-061994<br />Filed on 2025-04-03<br />Status: Pending 165287369 E-070-2019-0 E-070-2019-0-CA-10 INTERLEUKIN-27 PRODUCING B-CELL POPULATION AND USES THEREOF DIV Canada In Preparation Canada <br />Divisional (DIV) None<br />Filed on None<br />Status: In Preparation 165287503 E-070-2019-0 E-070-2019-0-AU-09 INTERLEUKIN-27 PRODUCING B-CELL AND USES THEREOF DIV Australia 2026200686 Pending Australia <br />Divisional (DIV) 2026200686<br />Filed on 2026-01-30<br />Status: Pending TAB-4993 157247834 Improved Methods For Cryopreservation Of Cells, Tissues, And Organs NEI Application, Collaboration, Ear, Nose, & Throat, Licensing, Research Materials Application Collaboration Ear Nose & Throat Licensing Research Materials Lihao Ge, Guanghui Jin, Wei Li, Kiyoharu Miyagishima, Jingxing Ou <h2>Summary:&nbsp;</h2> <p>The National Eye Institute seeks research co-development partners and/or licensees for novel methods of cryopreserving cells, tissues, and organs via FOXO1 activation and other mechanisms.</p> <h2>Description of Technology:&nbsp;</h2> <p>The cornea is a critical part of the eye that helps prevent debris from entering and refracts light for proper vision. Corneal disorders such as keratoconus, Fuchs dystrophy, and infectious keratitis require corneal transplantation to restore vision. Approximately 185,000 corneal transplants are performed annually worldwide to treat corneal disorders. Corneas for those transplants are supplied by donor eyes that are stored at eye banks in select countries.&nbsp;</p> <p>Currently, Optisol-GS&trade; is the corneal preservation solution that is most widely used to store donated corneas at eye banks. Per National Eye Institute (NEI) guidelines, corneas preserved in Optisol-GS&trade; have a 12-day shelf life. With the high demand for corneal transplantations worldwide, a 12-day shelf life cannot meet the requirement for long term cryogenic storage of corneas at large eye banks.&nbsp;</p> <p>Scientists at the NEI have developed improved methods for cryopreservation of cells, tissues, and organs (with focus of corneal tissue/cells) that increases cold storage shelf life 2.5 times longer than current market products.</p> <h2>Potential Commercial Applications:&nbsp;</h2> <ul> <li>Corneal biobanks</li> <li>Transplantation to remedy a wide range of corneal disorders</li> <li>Improved method of cryopreserving corneal cells and other cell types</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Superior corneal shelf life: 16-day compared to 12-day maximum shelf-life of current market products&nbsp;</li> <li>Better meets requirement for larger eye bank cryopreservation</li> <li>95% endothelial cell survival after 4 weeks in cold storage</li> </ul> Researchers at the NEI seek licensing and/or co-development research collaborations for improved methods of cryopreservation of cells, tissues, and organs via FOXO1 activation. 2024-07-23 2026-04-16 2026-04-16 2024-07-23 False True discovery (LeadID) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-073-2018 157266800 Ou, Jingxing National Eye Institute (NEI) NEI Ou, Jingxing (NEI) 1 157266831 Miyagishima, Kiyoharu National Eye Institute (NEI) NEI Miyagishima, Kiyoharu (NEI) 2 157266888 Jin, Guanghui Sun Yat-sen University Jin, Guanghui 3 157266928 Li, Wei National Eye Institute (NEI) NEI Li, Wei (NEI) 4 157266932 Ge, Lihao NINDS NINDS Ge, Lihao (NINDS) 5 157266800 Ou, Jingxing National Eye Institute (NEI) NEI Ou, Jingxing (NEI) 1 157266831 Miyagishima, Kiyoharu National Eye Institute (NEI) NEI Miyagishima, Kiyoharu (NEI) 2 157266888 Jin, Guanghui Sun Yat-sen University Jin, Guanghui 3 157266928 Li, Wei National Eye Institute (NEI) NEI Li, Wei (NEI) 4 157266932 Ge, Lihao NINDS NINDS Ge, Lihao (NINDS) 5 157247837 Regulations Of FOXO1A Pathway Protect Cells, Tissues, And Organs Against Stresses And Insults E-013-2021-0 Filing authorized National Eye Institute (NEI), NINDS, Sun Yat-sen University 83724826 Pollard, Ricquita ricquita.pollard@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4993] Improved Methods For Cryopreservation Of Cells, Tissues, And Organs&body=Please send me information about technology [TAB-4993] Improved Methods For Cryopreservation Of Cells, Tissues, And Organs.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollard, Ricquita<br><a href="mailto:ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4993] Improved Methods For Cryopreservation Of Cells, Tissues, And Organs&body=Please send me information about technology [TAB-4993] Improved Methods For Cryopreservation Of Cells, Tissues, And Organs.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">ricquita.pollard@nih.gov</a><br> 157266992 E-013-2021-0 E-013-2021-0-US-02 COMPOSITION AND METHOD OF PRESERVING VIABILITY OF CELL IN A LOW TEMPERATURE National Stage US 18/258,125 Pending US <br />National Stage 18/258,125<br />Filed on 2023-06-16<br />Status: Pending 157267002 E-013-2021-0 E-013-2021-0-CA-01 COMPOSITION AND METHOD OF PRESERVING VIABILITY OF CELL IN A LOW TEMPERATURE National Stage Canada 3202729 Pending Canada <br />National Stage 3202729<br />Filed on 2023-06-19<br />Status: Pending 157267007 E-013-2021-0 E-013-2021-0-AU-01 COMPOSITION AND METHOD OF PRESERVING VIABILITY OF CELL IN A LOW TEMPERATURE ENVIRONMENT National Stage Australia 2021400321 Abandoned Australia <br />National Stage 2021400321<br />Filed on 2023-06-23<br />Status: Abandoned 157267018 E-013-2021-0 E-013-2021-0-CN-02 COMPOSITION AND METHOD OF PRESERVING VIABILITY OF CELL IN A LOW TEMPERATURE National Stage China 202180094031.6 Pending China <br />National Stage 202180094031.6<br />Filed on 2023-08-17<br />Status: Pending 157267084 E-013-2021-0 E-013-2021-0-EP-01 COMPOSITION AND METHOD OF PRESERVING VIABILITY OF CELL IN A LOW TEMPERATURE ENVIRONMENT National Stage European Patent 21844141.8 Pending European Patent <br />National Stage 21844141.8<br />Filed on 2023-07-17<br />Status: Pending 164119806 E-013-2021-0 E-013-2021-0-PCT-02 COMPOSITION AND METHOD OF PRESERVING VIABILITY OF CELL IN A LOW TEMPERATURE PCT Patent Cooperation Treaty PCT/US2021/064086 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/064086<br />Filed on 2021-12-17<br />Status: Expired 164119807 E-013-2021-0 E-013-2021-0-CN-01 PREPARATION METHOD AND APPLICATION OF CELL, TISSUE OR ORGAN COLD PRESERVATION LIQUID ORD China ZL202011500962.5 202011500962.5 Issued China <br />Ordinary Patent (ORD) 202011500962.5<br />Filed on 2020-12-17<br />Status: Issued TAB-4992 157246749 Using Artificial Intelligence To Diagnose Uveitis NEI Collaboration, Diagnostics, Ear, Nose, & Throat, Licensing Collaboration Diagnostics Ear Nose & Throat Licensing Jongwoo Kim, Shilpa Kodati, Nam Nguyen <h2>Summary:&nbsp;</h2> <p>The National Eye Institute seeks research co-development partners and/or licensees for a deep learning algorithm that can identify retinal vasculitis using color fundus images.</p> <h2>Description of Technology:&nbsp;</h2> <p>Uveitis is caused by inflammation in the eye that can cause pain and reduce vision. The rate of uveitis in the United States is 1 in every 200 people with eye-related irritation. Permanent symptoms such as vision loss can occur if untreated. Therefore, early detection is crucial.&nbsp;</p> <p>In certain uveitis cases, fluorescein angiography (FA) is essential for the diagnosis and management due to its ability to display retinal vascular leakage (RVL). Although proven to be critical in diagnosing and assessing severity, FA is invasive and side effects have been reported. Additionally, the procedure is time-consuming and imposes economic burdens to patients, physicians and payors.&nbsp;</p> <p>Scientists at the NEI have developed a deep learning tool to non-invasively detect RVL using ultrawide-field color fundus photos. This algorithm identifies fundus images with and without RVL with high accuracy (79%) and sensitivity (85%). Compared to the current gold standard of assessing RVL (clinician interpretation), this deep learning tool provides an improved method of detecting RVL for patients with uveitis.</p> <h2>Potential Commercial Applications:</h2> <p>&bull; Diagnostic tool to predict uveitis&nbsp;<br /> &bull; Add-on to current color fundus imaging modalities</p> <h2>Competitive Advantages:</h2> <p>&bull; Greater accuracy and sensitivity versus current gold standard to assess RVL (clinician assessment)<br /> &bull; Deep learning tool to assess RVL<br /> &bull; Deep learning to assess ultrawide-field color fundus images and assess RVL</p> Researchers at the NEI seek licensing and/or co-development research collaborations for a deep learning algorithm that can identify retinal vasculitis using color fundus images. 2024-07-22 2026-04-16 2026-04-16 2024-07-23 False True Prototype True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 157246892 Young LH, et al. Automated Detection of Vascular Leakage in Fluorescein Angiography - A Proof of Concept. (PMID 35877095). https://pubmed.ncbi.nlm.nih.gov/35877095/ <a href="https://pubmed.ncbi.nlm.nih.gov/35877095/">Young LH, et al. Automated Detection of Vascular Leakage in Fluorescein Angiography - A Proof of Concept. (PMID 35877095).</a> 157246764 Kodati, Shilpa University of Michigan NEI Kodati, Shilpa (NEI) 1 157246768 Kim, Jongwoo NLM Kim, Jongwoo 2 157246772 Nguyen, Nam National Eye Institute (NEI) Nguyen, Nam 3 157246764 Kodati, Shilpa University of Michigan NEI Kodati, Shilpa (NEI) 1 157246768 Kim, Jongwoo NLM Kim, Jongwoo 2 157246772 Nguyen, Nam National Eye Institute (NEI) Nguyen, Nam 3 157246752 Deep Learning To Detect Retinal Vasculitis On Ultrawide-Field Color Fundus Photos E-005-2023-0 Filing authorized National Eye Institute (NEI), NLM 83724826 Pollard, Ricquita ricquita.pollard@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4992] Using Artificial Intelligence To Diagnose Uveitis&body=Please send me information about technology [TAB-4992] Using Artificial Intelligence To Diagnose Uveitis.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollard, Ricquita<br><a href="mailto:ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4992] Using Artificial Intelligence To Diagnose Uveitis&body=Please send me information about technology [TAB-4992] Using Artificial Intelligence To Diagnose Uveitis.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">ricquita.pollard@nih.gov</a><br> 157246801 E-005-2023-0 E-005-2023-0-US-01 Deep Learning to Detect Retinal Vasculitis on Color Fundus Photos of Patients with Uveitis PRV US 63/482,676 Expired US <br />Provisional (PRV) 63/482,676<br />Filed on 2023-02-01<br />Status: Expired 159507671 E-005-2023-0 E-005-2023-0-PC-01 SYSTEMS AND METHODS FOR DEEP LEARNING TO DETECT RETINAL VASCULITIS ON COLOR FUNDUS PHOTOGRAPHS OF PATIENTS WITH UVEITIS PCT Patent Cooperation Treaty PCT/US2024/013833 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2024/013833<br />Filed on 2024-01-31<br />Status: Expired 164119786 E-005-2023-0 E-005-2023-0-US-02 SYSTEMS AND METHODS FOR DEEP LEARNING TO DETECT RETINAL VASCULITIS ON COLOR FUNDUS PHOTOGRAPHS OF PATIENTS WITH UVEITIS National Stage US 19/153,124 Pending US <br />National Stage 19/153,124<br />Filed on 2025-08-01<br />Status: Pending 164119787 E-005-2023-0 E-005-2023-0-EP-01 SYSTEMS AND METHODS FOR DEEP LEARNING TO DETECT RETINAL VASCULITIS ON COLOR FUNDUS PHOTOGRAPHS OF PATIENTS WITH UVEITIS National Stage European Patent 24710954.9 Pending European Patent <br />National Stage 24710954.9<br />Filed on 2025-08-12<br />Status: Pending TAB-4991 157206100 TYROSINASE Gene Therapy for Oculocutaneous Albinism type 1A NEI Application, Collaboration, Ear, Nose, & Throat, Licensing, Ophthalmology, Rare/Neglected Diseases, Therapeutics Application Collaboration Ear Nose & Throat Licensing Ophthalmology Rare/Neglected Diseases Therapeutics Brian Brooks, Aman George <h2>Summary:</h2> <p>The National Eye Institute seeks research co-development partners and/or licensees for an adeno-associated viral gene therapy for Oculocutaneous Albinism type 1A.&nbsp;&nbsp;</p> <h2>Description of Technology:</h2> <p>Oculocutaneous albinism (OCA) is a genetically heterogeneous congenital disorder characterized by decreased or absent pigmentation in the hair, skin and eyes. The absence of pigmentation is caused by insufficient melanin production &ndash; an important pigment providing normal black color to important eye tissues such as the iris and retinal pigment epithelium. Lack of melanin in the eye results in abnormal development and impaired vision. Individuals diagnosed with OCA1, the most common type if albinism worldwide (1:40,000 people), is caused by mutations in the TYROSINASE (TYR) gene. OCA1A patients suffer complete loss of melanin caused by inactivity of the TYROSINASE enzyme. Currently, there is no treatment.&nbsp;&nbsp;</p> <p>Scientist at the National Eye Institute (NEI) have developed a gene therapy method for inducing pigmentation in human subjects who have OCA1A by administering the normal copy of human Tyrosinase via an adeno-associated viral (AAV) vector. Experiments in albino rat eyes showed that the AAV-Tyr construct localized to the tissue of interest (retinal pigment epithelium or RPE) and increased melanin production. Introducing the AAV-Tyr construct in OCA1A patient derived RPE also showed increased pigment density, demonstrating the construct&rsquo;s therapeutic potential to increase melanin production in vivo and in affected patient cells.&nbsp;</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Gene therapy for OCA1A</li> <li>Therapy for other TYROSINASE enzyme deficient eye disease</li> <li>Platform for AAV gene therapy for retinal pigment epithelium cells</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Addresses medical need with no treatment options</li> <li>Low damage to eye</li> <li>Potential one-time injection</li> </ul> Researchers at the NEI seek licensing and/or co-development research collaborations for an adeno-associated viral gene therapy for Oculocutaneous Albinism type 1A. 2024-07-19 2026-04-16 2026-04-16 2024-07-19 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 157206257 Brooks, Brian National Eye Institute (NEI) NEI Brooks, Brian (NEI) 1 157206261 George, Aman Ophthalmic Genetics Visual Function Branch NEI George, Aman (NEI) 2 157206257 Brooks, Brian National Eye Institute (NEI) NEI Brooks, Brian (NEI) 1 157206261 George, Aman Ophthalmic Genetics Visual Function Branch NEI George, Aman (NEI) 2 157206103 TYROSINASE Gene Therapy for Oculocutaneous Albinism type 1A E-116-2023-0 Filing authorized National Eye Institute (NEI), Ophthalmic Genetics Visual Function Branch 83724826 Pollard, Ricquita ricquita.pollard@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4991] TYROSINASE Gene Therapy for Oculocutaneous Albinism type 1A&body=Please send me information about technology [TAB-4991] TYROSINASE Gene Therapy for Oculocutaneous Albinism type 1A.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollard, Ricquita<br><a href="mailto:ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4991] TYROSINASE Gene Therapy for Oculocutaneous Albinism type 1A&body=Please send me information about technology [TAB-4991] TYROSINASE Gene Therapy for Oculocutaneous Albinism type 1A.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">ricquita.pollard@nih.gov</a><br> 157206338 E-116-2023-0 E-116-2023-0-US-01 TYROSINASE GENE THERAPY FOR OCULOCUTANEOUS ALBINISM TYPE 1A PRV US 63/468,748 Expired US <br />Provisional (PRV) 63/468,748<br />Filed on 2023-05-24<br />Status: Expired 157206461 E-116-2023-0 E-116-2023-0-PC-01 TYROSINASE GENE THERAPY FOR OCULOCUTANEOUS ALBINISM TYPE 1A PCT Patent Cooperation Treaty PCT/US2024/031101 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2024/031101<br />Filed on 2024-05-24<br />Status: Expired 164119766 E-116-2023-0 E-116-2023-0-US-02 Method for inducing pigmentation in human subjects who have Oculocutaneous albinism type 1A (OCA1A) or other clinically-defined pigmentation related condition due to a loss-of-function mutation in the gene encoding the TYROSINASE enzyme, the method comprises of administering to the patients a nucleic acid of human TYROSINASE cDNA using an adeno-associated viral vector. PRV US Administratively Closed US <br />Provisional (PRV) None<br />Filed on None<br />Status: Administratively Closed 164725054 E-116-2023-0 E-116-2023-0-CA-01 TYROSINASE GENE THERAPY FOR OCULOCUTANEOUS ALBINISM TYPE 1A National Stage Canada 3293242 Pending Canada <br />National Stage 3293242<br />Filed on 2025-11-21<br />Status: Pending 164725184 E-116-2023-0 E-116-2023-0-US-03 TYROSINASE GENE THERAPY FOR OCULOCUTANEOUS ALBINISM TYPE 1A National Stage US 19/486,763 Pending US <br />National Stage 19/486,763<br />Filed on 2025-11-21<br />Status: Pending 164725219 E-116-2023-0 E-116-2023-0-EP-01 TYROSINASE GENE THERAPY FOR OCULOCUTANEOUS ALBINISM TYPE 1A National Stage European Patent 24734696.8 Pending European Patent <br />National Stage 24734696.8<br />Filed on 2025-12-16<br />Status: Pending TAB-4982 155467337 Fluorinated MU-Opioid Receptor Agonists NIDA Application, Collaboration, Immunology, Licensing, Neurology, Radiology, Therapeutics Application Collaboration Immunology Licensing Neurology Radiology Therapeutics Michael Baumann, Juan Gomez, Michael ("Mike") Michaelides, Kenner Rice, Agnieszka Sulima <h2>Summary:&nbsp;</h2> <p>Investigators at the National Institute on Drug Abuse seek co-development partners and/or licensees for collection of mu opioid receptor (MOR) agonists as alternatives for existing compounds.</p> <h2>Description of Technology:&nbsp;</h2> <p>Although existing opioids are excellent analgesics and useful as positron emission tomography (PET) radiotracers, they come with debilitating side effects. These include addiction, respiratory distress, hyperalgesia, and constipation. Therefore, there is a need for alternatives with lower adverse effects.</p> <p>Investigators at NIDA have identified a novel fluorinated mu-opioid receptor agonist, Fluornitrazene (FNZ), a derivative of Etonitazene, that shows potent antinociceptive effects with low adverse effects. This compound does not accumulate in the brain or cause hyperalgesia. It has higher potency than morphine and fentanyl, but with fewer adverse effects. These characteristics make it and any derivatives useful as potential pain medications or anesthetics, and as therapeutics for treating opioid addiction or opioid use disorder. Compared to fentanyl, FNZ has greater potency and efficacy for the G protein activation pathway of the MOR and a lower incidence of respiratory depression in rats. This suggests that FNZ may be a better alternative to fentanyl in clinical use.</p> <p>Investigators seek co-development opportunities through cooperative research and development agreement (CRADA) collaborations. This technology is also available for development under a license.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Pain prevention or pain management</li> <li>Anesthetic&nbsp;</li> <li>Opioid addiction or opioid use disorder</li> <li>PET agonist radiotracer</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Reduced time in brain</li> <li>High potency</li> <li>MOR Selective</li> <li>No known hyperalgesia or tolerance</li> <li>Reduced side effects &ndash; such as respiratory depression&nbsp;</li> </ul> Researchers at the NIDA seek licensing and/or co-development research collaborations for research collaboration. 2024-04-17 2026-04-16 2026-04-16 2024-04-17 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 155467354 Michaelides, Michael ("Mike") NIDA - Biomedical Research Center NIDA Michaelides, Michael ("Mike") (NIDA) 1 155467358 Gomez, Juan NIDA - Biomedical Research Center NIDA Gomez, Juan (NIDA) 2 155467362 Rice, Kenner National Institute on Drug Abuse (NIDA) Rice, Kenner 3 155467366 Sulima, Agnieszka NIDA - Biomedical Research Center NIDA Sulima, Agnieszka (NIDA) 4 155467370 Baumann, Michael NIDA - Biomedical Research Center NIDA Baumann, Michael (NIDA) 5 155467354 Michaelides, Michael ("Mike") NIDA - Biomedical Research Center NIDA Michaelides, Michael ("Mike") (NIDA) 1 155467358 Gomez, Juan NIDA - Biomedical Research Center NIDA Gomez, Juan (NIDA) 2 155467362 Rice, Kenner National Institute on Drug Abuse (NIDA) Rice, Kenner 3 155467366 Sulima, Agnieszka NIDA - Biomedical Research Center NIDA Sulima, Agnieszka (NIDA) 4 155467370 Baumann, Michael NIDA - Biomedical Research Center NIDA Baumann, Michael (NIDA) 5 155467340 Selective and potent biased mu opioid receptor agonist with low adverse effects E-053-2023-0 Filing authorized NIDA - Biomedical Research Center 91828357 Bernier, Nicholas nicholas.bernier@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America nicholas.bernier@nih.gov?subject=Web Inquiry on [TAB-4982] Fluorinated MU-Opioid Receptor Agonists&body=Please send me information about technology [TAB-4982] Fluorinated MU-Opioid Receptor Agonists.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Bernier, Nicholas<br><a href="mailto:nicholas.bernier@nih.gov?subject=Web Inquiry on [TAB-4982] Fluorinated MU-Opioid Receptor Agonists&body=Please send me information about technology [TAB-4982] Fluorinated MU-Opioid Receptor Agonists.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">nicholas.bernier@nih.gov</a><br> 155467380 E-053-2023-0 E-053-2023-0-US-01 FLUORINATED MU-OPIOID RECEPTOR AGONISTS PRV US 63/452,879 Expired US <br />Provisional (PRV) 63/452,879<br />Filed on 2023-03-17<br />Status: Expired 155467385 E-053-2023-0 E-053-2023-0-PCT-01 FLUORINATED MU-OPIOID RECEPTOR AGONISTS PCT Patent Cooperation Treaty PCT/US2023/082355 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2023/082355<br />Filed on 2023-12-04<br />Status: Expired TAB-4828 152146471 T Cell Receptors Targeting the KRAS G13D Mutation in the Context of HLA-A11:01 for Research Use NCI Application, Licensing, Research Materials, TherapeuticArea Application Licensing Research Materials TherapeuticArea Catherine Ade, Kenichi Hanada, Matthew Sporn, James Yang, Zhiya Yu <h2>Summary:</h2> <p>The National Cancer Institute (NCI) has identified HLA-A11:01-restricted T Cell Receptors (TCRs) targeting the KRAS G13D mutation. The NCI seeks licensees for the use of these TCRs in research.</p> <h2>Description of Technology:</h2> <p>Tumor-specific mutated proteins can create immunogenic, mutation-containing &ldquo;neoepitopes&rdquo; which are attractive targets for adoptive T-cell therapies. There has been major interest in the field in targeting common shared mutations in driver genes, such as KRAS, using off-the-shelf T-cell receptors (TCRs) engineered into autologous lymphocytes. However, identifying the neoepitopes to pursue as therapeutics is a complex and challenging process. One method to demonstrate whether an epitope is presented at the cell surface is to elute peptides bound to a specific human leukocyte antigen (HLA) allele and analyze them by mass spectrometry (MS). These MS data can then be prospectively applied to isolate TCRs specific to the neoepitope.</p> <p>Using this MS methodology, investigators at the Surgery Branch have identified TCRs that can recognize the G13D substitution mutation of KRAS in the context of HLA-A11:01. Importantly, the G13D mutation of KRAS is an attractive target for adoptive cell therapy as it is highly mutated in cancers (e.g., KRAS is found to be mutated in 45% of all colorectal carcinoma patients, and about 16% of these patients have the G13D mutation). Furthermore, approximately 15% of the US population has the HLA-A11:01 allele.</p> <p>This is the first known report of HLA-A11:01-restricted TCRs that can recognize KRAS G13D. The identified TCRs have high specificity and immunogenicity for the G13D mutation and can recognize processed and presented antigen on the surface of cells. While these TCRs are not effective as therapeutics, they would be useful for identification of other KRAS G13D reactive TCRs in patient and animal models.</p> <p>The National Cancer Institute (NCI) seeks licensees for T Cell Receptors (TCRs) targeting the KRAS G13D mutation for potential use in research.</p> <h2>Potential Commercial Applications&nbsp;</h2> <ul> <li>Research use</li> <li>Diagnostic use</li> <li>Use as positive controls to identify other HLA-A11:01 KRAS G13D reactive T cells from different patient and/or animal models</li> <li>Use as negative controls in other research applications</li> </ul> <h2>Competitive Advantages</h2> <ul> <li>The KRAS G13D TCRs are highly specific and immunogenic</li> <li>&nbsp;G13D is a common mutation of the KRAS driver gene in cancers, making it an attractive target for immunotherapy</li> <li>The HLA-A11:01 allele is present in about 15% of the US population and up to 60% of the Asian and Oceanian populations</li> <li>The results indicate that Mass Spectrometry is an effective and accurate way to detect antigens on specific HLA complexes</li> </ul> The NCI seeks licensees for T Cell Receptors (TCRs) targeting KRAS mutation G13D for use as a research tool. 2024-01-11 2026-04-16 2026-04-16 2024-01-16 False True Discovery (Lead ID) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 152204876 Publications: Ade CM, et al. Identification of neoepitope reactive T-cell receptors guided by HLA A*03:01 and HLA A*11:01 immunopeptidomics. (PMID 37758652) https://pubmed.ncbi.nlm.nih.gov/37758652/ <a href="https://pubmed.ncbi.nlm.nih.gov/37758652/">Publications: Ade CM, et al. Identification of neoepitope reactive T-cell receptors guided by HLA A*03:01 and HLA A*11:01 immunopeptidomics. (PMID 37758652)</a> 152199868 Ade, Catherine NCI - CCR NCI Ade, Catherine (NCI) 1 152199916 Yu, Zhiya NCI - CCR NCI Yu, Zhiya (NCI) 2 152200031 Sporn, Matthew NCI - CCR NCI Sporn, Matthew (NCI) 3 152200061 Yang, James NCI - CCR NCI Yang, James (NCI) 4 152200083 Hanada, Kenichi NCI - CCR NCI Hanada, Kenichi (NCI) 5 152199868 Ade, Catherine NCI - CCR NCI Ade, Catherine (NCI) 1 152199916 Yu, Zhiya NCI - CCR NCI Yu, Zhiya (NCI) 2 152200031 Sporn, Matthew NCI - CCR NCI Sporn, Matthew (NCI) 3 152200061 Yang, James NCI - CCR NCI Yang, James (NCI) 4 152200083 Hanada, Kenichi NCI - CCR NCI Hanada, Kenichi (NCI) 5 152146474 Identification and cloning of KRAS G13D/A11_mTCR3 and KRAS G13D/A11_mTCR7, two T cell receptors targeting the KRAS G13D mutation on HLA-A1101+ cells E-006-2024-0 Closed NIH - NCI 83709866 Burke, Andrew burkear@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC burkear@nih.gov?subject=Web Inquiry on [TAB-4828] T Cell Receptors Targeting the KRAS G13D Mutation in the Context of HLA-A11:01 for Research Use&body=Please send me information about technology [TAB-4828] T Cell Receptors Targeting the KRAS G13D Mutation in the Context of HLA-A11:01 for Research Use.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Burke, Andrew<br><a href="mailto:burkear@nih.gov?subject=Web Inquiry on [TAB-4828] T Cell Receptors Targeting the KRAS G13D Mutation in the Context of HLA-A11:01 for Research Use&body=Please send me information about technology [TAB-4828] T Cell Receptors Targeting the KRAS G13D Mutation in the Context of HLA-A11:01 for Research Use.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">burkear@nih.gov</a><br> TAB-5091 166130102 Pigment Epithelium-Derived Factor Peptides and Their Use for Treating Retinal Degeneration NEI Collaboration, Ear, Nose, & Throat, Licensing, Ophthalmology, Therapeutics Collaboration Ear Nose & Throat Licensing Ophthalmology Therapeutics S. Patricia Becerra, Alexandra Bernardo-Colon, Andrea Bighinati, Valeria Marigo <h2>Summary:&nbsp;&nbsp;</h2> <p>The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of an AAV2-based delivery system or an eyedrop formulation to deliver a Pigment Epithelium-Derived Factor (PEDF) peptide as a gene-agnostic approach to treating inherited retinal diseases.&nbsp;</p> <h2>Description of Technology:&nbsp;&nbsp;</h2> <p>Retinitis pigmentosa (RP) is one of the most common inherited retinal diseases (IRDs) &ndash; estimated to affect 1 in 4,000 people worldwide. Over 100,000 people in the US and 1.5 million people worldwide suffer from RP. This disease leads to progressive photoreceptor cell degeneration and, ultimately, vision loss. More than 90 genes are implicated in molecular pathways towards photoreceptor cell death. Due to this high heterogeneity, therapeutic approaches targeting specific genes generally benefit few patients. For most forms of RP, few or no medical options are available. Thus, there remains a need to identify new and more effective treatments for RP and other inherited retinal degenerations. Mutation-independent strategies to protect photoreceptors against continued damage and degradation are appealing approaches.&nbsp;&nbsp;</p> <p>To delay photoreceptor degeneration, we propose using neurotrophic molecules as a mutation-independent approach using pigment epithelium-derived factor (PEDF). PEDF is a multifunctional member of the serine proteinase inhibitor (serpin) family with neurotrophic and antiangiogenic properties in the retina. Researchers at the NEI developed a peptide of 17 amino acid residues (17-mer) from the receptor-binding domain of PEDF. It contains amino acid substitution at position 105 from a histidine to an alanine (PEDF 17-mer[H105A]). H105A exhibits a highly potent protective effect on photoreceptors using in vivo mouse models of RP.&nbsp;&nbsp;</p> <p>The technology encompasses two delivery approaches for this proprietary peptide: (1) an eyedrop formulation and/or (2) an Adeno-Associated Vector 2 (AAV2). A sustained delivery system delivers the 17-mer [H105A] to treat or prevent photoreceptor degradation and vision loss in patients with IRDs (e.g., retinitis pigmentosa, Leber congenital amaurosis, cone-rod dystrophy, Stargardt-like macular degeneration or maculopathy) or age-related macular degenerations (AMD). The technology is available for licensing and co-development.&nbsp;</p> <h2>Potential Commercial Applications:&nbsp;&nbsp;</h2> <ul> <li>Minimally invasive therapy to prevent photoreceptor degeneration in retinal disorders (IRDs and AMD)&nbsp;</li> <li>Retinitis Pigmentosa (RP), macular degeneration, and other related diseases&nbsp;</li> <li>AAV2 vectors for delivery of genes to retinal cells both preventative and therapeutic&nbsp;</li> <li>Prevent disease progression to late-stage RP&nbsp;</li> </ul> <h2>Competitive Advantages:&nbsp;</h2> <ul> <li>Favorable safety profile&nbsp;</li> <li>Large addressable market given applications to IRDs and AMD (USD 13.7 billion in 2023 and an estimated compound annual growth rate (CAGR) of 9.6% from 2024 to 2032&nbsp;</li> <li>Partially established regulatory path, as their AAV2 vector is identical to Luxturna, an FDA-approved therapy for retinal dystrophy&nbsp;</li> <li>Superior diffusion and penetrability than biologics&nbsp;</li> <li>Demonstrably less immunogenicity and lower production costs than biologics&nbsp;</li> <li>Eye drop formulation has larger addressable market&nbsp;</li> <li>Eye drop formulation provides easy administration route&nbsp;&nbsp;</li> <li>Broad-spectrum therapeutic approach:&nbsp;&nbsp; <ul> <li>PEDF mimics the natural protective process lost in patients with inherited eye diseases&nbsp;</li> <li>Protective effects on photoreceptors are independent of the gene mutations causing degeneration&nbsp;</li> </ul> </li> <li>Chemically synthesized bioactive peptide solutions are free of inactive ingredients, causing fewer secondary effects than mixed formulations&nbsp;</li> </ul> Researchers at the ​NEI​ seek ​licensing and/or co-development research collaborations ​ for the development of an AVV2-based delivery system or an eyedrop formulation to deliver a PEDF peptide as a gene-agnostic approach to treating inherited retinal diseases. 2026-02-23 2026-03-24 2026-04-14 2026-03-13 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-156-2023 166427821 Bernardo-Colón A, et al. H105A peptide eye drops promote photoreceptor survival in murine and human models of retinal degeneration. (PMID: 40118996) https://pubmed.ncbi.nlm.nih.gov/40118996/ <a href="https://pubmed.ncbi.nlm.nih.gov/40118996/">Bernardo-Colón A, et al. H105A peptide eye drops promote photoreceptor survival in murine and human models of retinal degeneration. (PMID: 40118996)</a> 166427825 Valiente-Soriano FJ, et al. Pigment Epithelium-Derived Factor (PEDF) Fragments Prevent Mouse Cone Photoreceptor Cell Loss Induced by Focal Phototoxicity In Vivo. (PMID: 33008127) https://pubmed.ncbi.nlm.nih.gov/33008127/ <a href="https://pubmed.ncbi.nlm.nih.gov/33008127/">Valiente-Soriano FJ, et al. Pigment Epithelium-Derived Factor (PEDF) Fragments Prevent Mouse Cone Photoreceptor Cell Loss Induced by Focal Phototoxicity In Vivo. (PMID: 33008127)</a> 166427828 Hernández-Pinto A, et al. PEDF peptides promote photoreceptor survival in rd10 retina models. (PMID: 30980815) https://pubmed.ncbi.nlm.nih.gov/30980815/ <a href="https://pubmed.ncbi.nlm.nih.gov/30980815/">Hernández-Pinto A, et al. PEDF peptides promote photoreceptor survival in rd10 retina models. (PMID: 30980815)</a> 166427831 Kenealey J, et al. Small Retinoprotective Peptides Reveal a Receptor-binding Region on Pigment Epithelium-derived Factor. (PMID: 26304116) https://pubmed.ncbi.nlm.nih.gov/26304116/ <a href="https://pubmed.ncbi.nlm.nih.gov/26304116/">Kenealey J, et al. Small Retinoprotective Peptides Reveal a Receptor-binding Region on Pigment Epithelium-derived Factor. (PMID: 26304116)</a> 166427764 Becerra, S. Patricia National Eye Institute (NEI) NEI Becerra, S. Patricia (NEI) 1 166427768 Bernardo-Colon, Alexandra National Eye Institute (NEI) Bernardo-Colon, Alexandra 2 166427772 Marigo, Valeria University of Modena and Reggio Emilia Marigo, Valeria 3 166427779 Bighinati, Andrea University of Modena and Reggio Emilia Bighinati, Andrea 4 166427764 Becerra, S. Patricia National Eye Institute (NEI) NEI Becerra, S. Patricia (NEI) 1 166427768 Bernardo-Colon, Alexandra National Eye Institute (NEI) Bernardo-Colon, Alexandra 2 166427772 Marigo, Valeria University of Modena and Reggio Emilia Marigo, Valeria 3 166427779 Bighinati, Andrea University of Modena and Reggio Emilia Bighinati, Andrea 4 166130105 In Vivo Assay For Drug Discovery And Detection Of Photoreceptor Survival Factors: Discovery Of The PEDF Peptide 17- mer[H105A] E-028-2023-0 Filing authorized National Eye Institute (NEI), University of Modena and Reggio Emilia, University of Modena and Reggio Emilia 83724826 Pollard, Ricquita ricquita.pollard@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-5091] Pigment Epithelium-Derived Factor Peptides and Their Use for Treating Retinal Degeneration&body=Please send me information about technology [TAB-5091] Pigment Epithelium-Derived Factor Peptides and Their Use for Treating Retinal Degeneration.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollard, Ricquita<br><a href="mailto:ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-5091] Pigment Epithelium-Derived Factor Peptides and Their Use for Treating Retinal Degeneration&body=Please send me information about technology [TAB-5091] Pigment Epithelium-Derived Factor Peptides and Their Use for Treating Retinal Degeneration.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">ricquita.pollard@nih.gov</a><br> 166130110 E-028-2023-0 E-028-2023-0-US-01 PIGMENT EPITHELIUM-DERIVED FACTOR PEPTIDES AND USE FOR TREATING RETINAL DEGENERATION PRV US 63/430,251 Expired US <br />Provisional (PRV) 63/430,251<br />Filed on 2022-12-05<br />Status: Expired 166130111 E-028-2023-0 E-028-2023-0-PC-01 PIGMENT EPITHELIUM-DERIVED FACTOR PEPTIDES AND USE FOR TREATING RETINAL DEGENERATION PCT Patent Cooperation Treaty PCT/US2023/064947 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2023/064947<br />Filed on 2023-03-24<br />Status: Expired 166130112 E-028-2023-0 E-028-2023-0-JP-01 PIGMENT EPITHELIUM-DERIVED FACTOR PEPTIDES AND USE FOR TREATING RETINAL DEGENERATION National Stage Japan 2025-555099 Pending Japan <br />National Stage 2025-555099<br />Filed on 2025-06-04<br />Status: Pending 166130113 E-028-2023-0 E-028-2023-0-CA-01 PIGMENT EPITHELIUM-DERIVED FACTOR PEPTIDES AND USE FOR TREATING RETINAL DEGENERATION National Stage Canada 3275801 Pending Canada <br />National Stage 3275801<br />Filed on 2025-06-03<br />Status: Pending 166130114 E-028-2023-0 E-028-2023-0-AU-01 PIGMENT EPITHELIUM-DERIVED FACTOR PEPTIDES AND USE FOR TREATING RETINAL DEGENERATION National Stage Australia 2023390868 Pending Australia <br />National Stage 2023390868<br />Filed on 2025-06-05<br />Status: Pending 166130115 E-028-2023-0 E-028-2023-0-US-02 PIGMENT EPITHELIUM-DERIVED FACTOR PEPTIDES AND USE FOR TREATING RETINAL DEGENERATION National Stage US 19/135,668 Pending US <br />National Stage 19/135,668<br />Filed on 2025-06-04<br />Status: Pending 166130116 E-028-2023-0 E-028-2023-0-EP-01 PIGMENT EPITHELIUM-DERIVED FACTOR PEPTIDES AND USE FOR TREATING RETINAL DEGENERATION National Stage European Patent 23720018.3 Pending European Patent <br />National Stage 23720018.3<br />Filed on 2025-07-01<br />Status: Pending 166849971 E-028-2023-0 E-028-2023-0-HK-01 PIGMENT EPITHELIUM-DERIVED FACTOR PEPTIDES AND USE FOR TREATING RETINAL DEGENERATION EP Hong Kong 62026121881.7 Pending Hong Kong <br />European patent (EP) 62026121881.7<br />Filed on 2026-04-15<br />Status: Pending TAB-5096 166779508 48-Position Custom Deep Well Plate For In Vitro Equilibrium Dialysis at a 1:1 Sample to Buffer Volume Ratio CDC Collaboration Sought, Diagnostics, Endocrinology, Geriatrics, Hematology, Obstetrics/Neo-Natal, Reproductive Health, Research Materials, TherapeuticArea, Urology Collaboration Sought Diagnostics Endocrinology Geriatrics Hematology Obstetrics/Neo-Natal Reproductive Health Research Materials TherapeuticArea Urology Ashley Ribera, Hubert Vesper, Hui Zhou <p>CDC scientists have developed a new design for a multi-well dialysis microplate for equilibrium dialysis. The unique design accommodates a 1:1 buffer to sample ratio and provides additional room at the base of the well to enable optimal cartridge immersion and analyte diffusion. The microplate is readily adaptable into existing automated analytical systems and meets the criteria of American National Standards Institute (ANSI). The microplate is designed for measuring blood or other biological fluid samples over a wide range of sample volumes and may be used in a high throughput manner. Use of the microplate has been shown to reduce errors, while increasing accuracy, precision, and sensitivity.</p> <p>&nbsp;Thus far, the microplate has been successfully used for free testosterone measurement. The microplate may also be used for measuring other analytes and has the potential to be used in both clinical and research settings.&nbsp;&nbsp;</p> <ul> <li> Diagnostics: Dialysis microplate for measuring free hormone analytes such as free testosterone, free thyroxine (FT4), triiodothyronine, as well as measuring unbound drugs such as dolutegravir in diagnostic or research settings. </li> <li> Public Health: Use of the dialysis microplate to provide dialysis testing services for customers. </li> </ul> <ul> <li> Diagnostics: Meets the criteria of American National Standards Institute (ANSI). </li> <li> Research Materials. </li> </ul> The CDC-NICHD is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize the multi-well dialysis microplate. For collaboration opportunities, please contact: Madhavi Sriram nxu2@cdc.gov; TTO@cdc.gov. 2026-04-08 2026-04-10 2026-04-10 2026-04-10 False True Clinical Assay Development Stage True 72159134 Analytical Assay Performance Stage 72159134 37470483 Website Abstract 166779738 Ribera, Ashley Battelle Memorial Institute CDC Ribera, Ashley (CDC) 1 166779783 Zhou, Hui CDC - DIR CDC Zhou, Hui (CDC) 2 166779790 Vesper, Hubert CDC - DIR CDC Vesper, Hubert (CDC) 3 166779738 Ribera, Ashley Battelle Memorial Institute CDC Ribera, Ashley (CDC) 1 166779783 Zhou, Hui CDC - DIR CDC Zhou, Hui (CDC) 2 166779790 Vesper, Hubert CDC - DIR CDC Vesper, Hubert (CDC) 3 166779511 48-Position Custom Deep Well Plate For In Vitro Equilibrium Dialysis at a 1:1 Sample to Buffer Volume Ratio E-101-2023-0 Filing authorized CDC - DIR 83738793 Taylor-Mulneix, Dawn dawn.taylor-mulneix@nih.gov
United States of America dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-5096] 48-Position Custom Deep Well Plate For In Vitro Equilibrium Dialysis at a 1:1 Sample to Buffer Volume Ratio&body=Please send me information about technology [TAB-5096] 48-Position Custom Deep Well Plate For In Vitro Equilibrium Dialysis at a 1:1 Sample to Buffer Volume Ratio. Taylor-Mulneix, Dawn<br><a href="mailto:dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-5096] 48-Position Custom Deep Well Plate For In Vitro Equilibrium Dialysis at a 1:1 Sample to Buffer Volume Ratio&body=Please send me information about technology [TAB-5096] 48-Position Custom Deep Well Plate For In Vitro Equilibrium Dialysis at a 1:1 Sample to Buffer Volume Ratio.">dawn.taylor-mulneix@nih.gov</a><br> 166779516 E-101-2023-0 E-101-2023-0-US-01 MULTI-WELL DIALYSIS MICROPLATE PRV US 63/551,965 Expired US <br />Provisional (PRV) 63/551,965<br />Filed on 2024-02-09<br />Status: Expired 166779517 E-101-2023-0 E-101-2023-0-PC-01 MULTI-WELL DIALYSIS MICROPLATE PCT Patent Cooperation Treaty PCT/US2025/014980 Pending Patent Cooperation Treaty <br />(PCT) PCT/US2025/014980<br />Filed on 2025-02-07<br />Status: Pending TAB-5097 166811027 Nucleophosmin 1 (NPM1) Mutation-Specific T Cell Receptors for Targeted Treatment of Acute Myeloid Leukemia NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Catherine Ade, Kenichi Hanada, Vid Leko, Aidan Pursley, James Yang, Zhiya Yu <h2>Summary:&nbsp;</h2> <p>The NCI seeks research co-development partners or licensees for Nucleophosmin 1 (NPM1) Mutation-Specific T Cell Receptors for Targeted Treatment of Acute Myeloid Leukemia.</p> <h2>Description of Technology:&nbsp;</h2> <p>Acute myeloid leukemia (AML) is a rare form of blood cancer affecting myeloid stem and progenitor cells, associated with a poor prognosis and a 5-year survival rate of ~33%. Current treatments, including intensive chemotherapy and stem cell transplantation, are not suitable for all patients and can cause significant toxicities, including low blood cell counts, infection and graft-versus-host disease. Therefore, there is a need for safer and more effective treatments.&nbsp;</p> <p>This specific invention concerns the isolation of two highly specific T cell receptors (TCRs), known as TCR6 and TCR7, recognizing a neoepitope, AVEEVSLRK. The neoepitope is derived from mutant Nucleophosmin 1 (NPM1) and presented in the context of HLA-A*11:01. Pre-clinical results for these TCRs revealed robust and specific cytotoxicity against a leukemia cell line and several patient-derived AML samples expressing the NPM1 mutation and HLA-A*11:01. Furthermore, they showed no cross-reactivity to normal peripheral blood mononuclear cells, structurally similar peptides or unrelated HLA alleles. These results suggest these novel TCRs represent a potential adoptive T cell therapy for the treatment of AML.</p> <h2>Potential Commercial Applications:&nbsp;</h2> <ul> <li>Acute myeloid leukemia patients expressing HLA-A*11:01.&nbsp;</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Highly specific targeting of mutant NPM1</li> <li>Minimed off-target effects with enhanced safety profile</li> <li>&bull;Significant unmet medical need for AML patients</li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for NPM1 Mutation-Specific T Cell Receptors for Targeted Treatment of Acute Myeloid Leukemia. 2026-04-10 2026-04-10 2026-04-10 2026-04-10 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 166811280 https://ashpublications.org/blood/article/146/Supplement%201/4132/555170/T-cell-receptors-targeting-mutant-NPM1-for https://ashpublications.org/blood/article/146/Supplement%201/4132/555170/T-cell-receptors-targeting-mutant-NPM1-for 166811062 Leko, Vid NIH - NCI NCI Leko, Vid (NCI) 1 166811066 Pursley, Aidan NIH - NCI NCI Pursley, Aidan (NCI) 2 166811070 Hanada, Kenichi NIH - NCI NCI Hanada, Kenichi (NCI) 3 166811074 Yu, Zhiya NIH - NCI NCI Yu, Zhiya (NCI) 4 166811086 Ade, Catherine NIH - NCI NCI Ade, Catherine (NCI) 5 166811092 Yang, James NIH - NCI NCI Yang, James (NCI) 6 166811062 Leko, Vid NIH - NCI NCI Leko, Vid (NCI) 1 166811066 Pursley, Aidan NIH - NCI NCI Pursley, Aidan (NCI) 2 166811070 Hanada, Kenichi NIH - NCI NCI Hanada, Kenichi (NCI) 3 166811074 Yu, Zhiya NIH - NCI NCI Yu, Zhiya (NCI) 4 166811086 Ade, Catherine NIH - NCI NCI Ade, Catherine (NCI) 5 166811092 Yang, James NIH - NCI NCI Yang, James (NCI) 6 166811031 NPM1 mutation-specific T cell receptors for treatment of HLA-A*11:01-positive acute myeloid leukemia E-200-2025-0 Filing authorized NIH - NCI 83731987 Dhal, Abritee abritee.dhal@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-5097] Nucleophosmin 1 (NPM1) Mutation-Specific T Cell Receptors for Targeted Treatment of Acute Myeloid Leukemia&body=Please send me information about technology [TAB-5097] Nucleophosmin 1 (NPM1) Mutation-Specific T Cell Receptors for Targeted Treatment of Acute Myeloid Leukemia.&bcc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dhal, Abritee<br><a href="mailto:abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-5097] Nucleophosmin 1 (NPM1) Mutation-Specific T Cell Receptors for Targeted Treatment of Acute Myeloid Leukemia&body=Please send me information about technology [TAB-5097] Nucleophosmin 1 (NPM1) Mutation-Specific T Cell Receptors for Targeted Treatment of Acute Myeloid Leukemia.&bcc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">abritee.dhal@nih.gov</a><br> 166811036 E-200-2025-0 E-200-2025-0-US-01 NUCLEOPHOSMIN 1 MUTATION-SPECIFIC T CELL RECEPTORS PRV US 63/908,266 Pending US <br />Provisional (PRV) 63/908,266<br />Filed on 2025-10-30<br />Status: Pending TAB-5073 163873358 Chimeric Antigen Receptors Targeting the Gamma Delta (γδ) T-Cell Receptor NCI Collaboration, Immunology, Licensing, Oncology, Therapeutics Collaboration Immunology Licensing Oncology Therapeutics Lauren Cutmore, James Kochenderfer <h2>Summary:</h2> <p>The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a set of Chimeric Antigen Receptors (CARs) that target the &gamma;&delta; T-Cell Receptor.</p> <h2>Description of Technology:</h2> <p>T cells express two main types of receptors based on the proteins that make up the T-cell receptor (TCR) heterodimers: ab (alpha beta) and gd (gamma delta). T cells expressing the gd TCR are detected at lower frequencies compared with T cells expressing the ab TCR. gd T cells make up 0.3-10% of peripheral blood T cells. The gd TCR is expressed on the cell surface of several aggressive cancers, including &ndash; but not limited to &ndash; hepatosplenic T-cell lymphoma, primary cutaneous gd T-cell lymphoma and T-cell acute lymphoblastic leukemia (T-ALL). These cancers carry poor prognosis as they are often resistant to chemotherapy. In addition, to their roles in cancer development, gd T cells may also play role in autoimmune diseases, including psoriasis, rheumatoid arthritis, multiple sclerosis and myositis. There is evidence that gd T cells are involved in initiation or persistence of these autoimmune diseases. To this end, new treatment options are needed for gd T-cell malignancies and autoimmune diseases.</p> <p>Researchers at the National Cancer Institute (NCI) have developed several CARs targeting the gd TCR. These CARs can specifically bind to and immunologically recognize human gd TCR. Binding of the CAR to the gd TCR elicits an immune response that allows for killing of cells expressing this TCR.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Treatment of &gamma;&delta; T cell cancers <ul> <li>hepatosplenic T-cell lymphoma</li> <li>primary cutaneous gd T-cell lymphoma</li> <li>T-ALL</li> </ul> </li> <li>Treatment of &gamma;&delta; T cell autoimmune diseases <ul> <li>psoriasis</li> <li>rheumatoid arthritis</li> <li>multiple sclerosis</li> <li>myositis</li> </ul> </li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Promising new treatment option for several major market opportunities, including gd T cell malignancies and autoimmune diseases</li> <li>Promising new treatment option for patients resistant to chemotherapy</li> <li>In vivo proof-of-concept studies completed</li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for a set of Chimeric Antigen Receptors (CARs) that target the γδ T-Cell Receptor, and if applicable, CARs that target the αβ T-Cell Receptor, too. 2025-08-25 2025-08-25 2026-04-08 2025-08-25 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 163873535 Kochenderfer JN, et al. Development of Novel Chimeric Antigen Receptors Targeting the Gamma-Delta (γδ) T-Cell Receptor. https://doi.org/10.1182/blood-2024-204126 <a href="https://doi.org/10.1182/blood-2024-204126">Kochenderfer JN, et al. Development of Novel Chimeric Antigen Receptors Targeting the Gamma-Delta (γδ) T-Cell Receptor.</a> 163873409 Kochenderfer, James NIH - NCI NCI Kochenderfer, James (NCI) 1 163873416 Cutmore, Lauren NIH - NCI NCI Cutmore, Lauren (NCI) 2 163873409 Kochenderfer, James NIH - NCI NCI Kochenderfer, James (NCI) 1 163873416 Cutmore, Lauren NIH - NCI NCI Cutmore, Lauren (NCI) 2 163873361 Development of chimeric antigen receptors targeting the gamma-delta T-cell receptor E-214-2024-0 Filing authorized NIH - NCI 83709866 Burke, Andrew burkear@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC burkear@nih.gov?subject=Web Inquiry on [TAB-5073] Chimeric Antigen Receptors Targeting the Gamma Delta (γδ) T-Cell Receptor&body=Please send me information about technology [TAB-5073] Chimeric Antigen Receptors Targeting the Gamma Delta (γδ) T-Cell Receptor.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Burke, Andrew<br><a href="mailto:burkear@nih.gov?subject=Web Inquiry on [TAB-5073] Chimeric Antigen Receptors Targeting the Gamma Delta (γδ) T-Cell Receptor&body=Please send me information about technology [TAB-5073] Chimeric Antigen Receptors Targeting the Gamma Delta (γδ) T-Cell Receptor.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">burkear@nih.gov</a><br> 163873366 E-214-2024-0 E-214-2024-0-US-01 CHIMERIC ANTIGEN RECEPTORS TARGETING THE GAMMA DELTA T CELL RECEPTOR PRV US 63/678,625 Expired US <br />Provisional (PRV) 63/678,625<br />Filed on 2024-08-02<br />Status: Expired 163873367 E-214-2024-0 E-214-2024-0-PC-01 CHIMERIC ANTIGEN RECEPTORS TARGETING THE GAMMA DELTA T CELL RECEPTOR PCT Patent Cooperation Treaty PCT/US2025/040252 Pending Patent Cooperation Treaty <br />(PCT) PCT/US2025/040252<br />Filed on 2025-08-01<br />Status: Pending TAB-5056 162401133 Oral Iron-Chelator Therapy for Treating Developmental Stuttering NINDS Licensing, Neurology, Psychiatry/Mental Health, Therapeutics Licensing Neurology Psychiatry/Mental Health Therapeutics Shahriar SheikhBahaei <p><span style="font-size:11pt"><span style="line-height:107%"><span style="font-family:Calibri,sans-serif">This technology discloses the use of small-molecule iron chelators&mdash;drugs that bind and remove excess iron&mdash;for the oral treatment of developmental stuttering in children and adults. Mouse models carrying human stuttering mutations show both elevated striatal iron and impaired vocalization; daily low-dose deferiprone reverses these speech-like deficits while normalizing brain-iron MRI signals. Because exemplary chelators deferiprone, deferasirox, and deferoxamine are already marketed for other indications, their safety, dosing, and manufacturing are well characterized, enabling a streamlined regulatory path. The approach offers the first disease-targeted pharmacologic option for a disorder currently managed only by speech therapy.</span></span></span></p> <ul> <li>First-in-class, mechanism-based therapy for stuttering, addressing a $3 B underserved global market with no approved drugs.</li> <li>Repurposes FDA-approved iron chelators, leveraging extensive safety data and oral formulations for rapid Phase II entry and lower development risk.</li> <li>Quantifiable biomarker (MRI R2* brain-iron signal) enables patient stratification and objective efficacy read-outs, enhancing trial efficiency and market differentiation.</li> </ul> <ul> <li>Stand-alone or adjunctive pharmacotherapy for persistent developmental stuttering in pediatric and adult populations.</li> <li>MRI-guided precision treatment platform for speech-motor disorders linked to basal-ganglia iron dysregulation.</li> <li>Expansion into related neurodevelopmental or movement disorders where excess neural iron contributes to pathophysiology.</li> </ul> 2025-05-13 2025-07-31 2026-04-08 2025-06-13 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 162401172 SheikhBahaei, Shahriar Stony Brook University SheikhBahaei, Shahriar 1 162401172 SheikhBahaei, Shahriar Stony Brook University SheikhBahaei, Shahriar 1 162401136 Iron Chelators as potential therapeutics for stuttering E-186-2023-0 Filing authorized NIH - NINDS 162927805 Iron Chelators as potential therapeutics for stuttering E-186-2023-1 Filing authorized NIH - NINDS 83667829 Ano, Susan susan.ano@nih.gov
United States of America susan.ano@nih.gov?subject=Web Inquiry on [TAB-5056] Oral Iron-Chelator Therapy for Treating Developmental Stuttering&body=Please send me information about technology [TAB-5056] Oral Iron-Chelator Therapy for Treating Developmental Stuttering. Ano, Susan<br><a href="mailto:susan.ano@nih.gov?subject=Web Inquiry on [TAB-5056] Oral Iron-Chelator Therapy for Treating Developmental Stuttering&body=Please send me information about technology [TAB-5056] Oral Iron-Chelator Therapy for Treating Developmental Stuttering.">susan.ano@nih.gov</a><br> 162401141 E-186-2023-0 E-186-2023-0-US-01 Use of Iron Chelators for Treating Stuttering PRV US 63/510,794 Expired US <br />Provisional (PRV) 63/510,794<br />Filed on 2023-06-28<br />Status: Expired 162401143 E-186-2023-1 E-186-2023-1-PC-01 Use of Iron Chelators for Treating Stuttering PCT Patent Cooperation Treaty PCT/US2024/036062 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2024/036062<br />Filed on 2024-06-28<br />Status: Expired 164857199 E-186-2023-1 E-186-2023-1-US-01 Uses of Iron Chelators for Treating Stuttering National Stage US 19/496,195 Pending US <br />National Stage 19/496,195<br />Filed on 2025-12-22<br />Status: Pending 164857219 E-186-2023-1 E-186-2023-1-EP-01 Uses of Iron Chelators for Treating Stuttering National Stage European Patent 24742436.9 Pending European Patent <br />National Stage 24742436.9<br />Filed on 2026-01-05<br />Status: Pending TAB-3363 114097266 Monoclonal Antibodies that Bind Zika Virus Envelope Protein for Zika Diagnostics and Research CDC Antibodies, Collaboration, Consumer Products, Diagnostics, Immunology, Infectious Disease, Licensing, Occupational Safety and Health, Research Materials Antibodies Collaboration Consumer Products Diagnostics Immunology Infectious Disease Licensing Occupational Safety and Health Research Materials Dennis Bagarozzi, Jason Goldstein, Madhavan Nallani Padmanabha Zika virus infection during pregnancy can cause microcephaly and other severe birth defects. The CDC Zika MAC-ELISA (IgM antibody capture enzyme-linked immunosorbent assay) currently used for diagnosis detects antibodies produced to fight a Zika virus infection. However, reactivity of flavivirus antibodies (from exposure to other mosquito-borne infections such as dengue or West Nile virus) can complicate the interpretation of these results. <br /><br /> CDC and partner researchers have developed six monoclonal antibodies (mAbs) from hybridoma technology with high sensitivity to the Zika virus (ZIKV) pre-membrane/envelope (ENV) protein and limited cross-reactivity to other flaviviruses, notably dengue virus. Multiple methods such as indirect ELISA, bio-layer interferometry (BLI), immunoblotting, immunofluorescence, and plaque reduction neutralization tests (PRNTs) were used to validate the data. Additionally, ZIKV pre-membrane/envelope protein is a candidate biomarker for diagnosis during active infection vs. serological tests (based on identification of IgM and/or IgG) after clearance of infection. The technology can be used for immunoassay development and immunodiagnostic reagents for clinical sample and tissue confirmation of ZIKV. The mAbs also offer improved differentiation between ZIKV and related flaviviruses. <ul> <li>May be used for diagnosis during active Zika virus infection vs. serological tests (based on identification of IgM and/or IgG) after clearance of infection</li> <li>Offers higher sensitivity than many commercial and academic mAbs available to detect ZIKV</li> <li>Limited cross-reactivity with other flaviviruses</li> <li>High affinity mAbs (bind more quickly to the antigen and with a stronger bond)</li> </ul> <ul> <li>Engineering of mAbs for commercial diagnostic applications</li> <li>Clinical diagnostic assay to detect active Zika virus infection</li> <li>Multiple platforms such as immunoassay, lateral flow diagnostics, and nanotechnology device capable of interfacing with smartphone/digital technology</li> <li>ENV protein target is a valid target for diagnostic development with the understanding that a sufficient viral load needs to be present</li> <li>These mAbs may serve in a competition serological assay for dengue (or other closely related flaviviruses) where clinical IgG/IgM that do not compete with these ZIKV-specific mAbs for r-Env or VLP, can exclude a previous ZIKV infection</li> <li>Immunodiagnostic reagents for confirmation of Zika virus in clinical samples (e.g., serum, saliva and/or urine) or tissue</li> <li>Differentiation between Zika and related flaviviruses such as dengue, yellow fever or West Nile viruses</li> <li>Can be useful in more generalized diagnostic assay development to detect all flaviviruses</li> <li>Research tool, monitoring and public health surveillance</li> <li>Antiviral efficacy testing in animal models</li> </ul> The CDC Technology Transfer Office (TTO) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize: Monoclonal Antibodies that Bind Zika Virus Envelope Protein for Zika Diagnostics and Research. For collaboration opportunities, please contact CDC TTO at <a href="mailto:tto@cdc.gov">tto@cdc.gov</a> or 1-404-639-1330. Research Tool - Patent protection is not being pursued for this technology. 2022-03-08 2025-04-24 2026-04-02 2019-02-22 antibodies, Development, Diagnostics, monoclonal, NCEZID, NCEZID-DSR, Novel, virus, VLXXXX, WBXXXX, WFXXXX, WIXXXX, XAXXXX, YBXXXX, Zika False True True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract E-286-2016-0 E-341-2013-0 E-341-2013-1 E-081-2017-0 E-107-2016-1 114110009 Bagarozzi, Dennis CDC - DIR CDC Bagarozzi, Dennis (CDC) 0 114110011 Nallani Padmanabha, Madhavan ACM Biolabs Private Limited Nallani Padmanabha, Madhavan 0 114110010 Goldstein, Jason CDC - DIR CDC Goldstein, Jason (CDC) 1 114110010 Goldstein, Jason CDC - DIR CDC Goldstein, Jason (CDC) 1 114110009 Bagarozzi, Dennis CDC - DIR CDC Bagarozzi, Dennis (CDC) 0 114110011 Nallani Padmanabha, Madhavan ACM Biolabs Private Limited Nallani Padmanabha, Madhavan 0 114102510 Development Of Zika Virus Monoclonal Antibodies For Research, Development And Novel Diagnostics E-030-2017-0 Research Material ACM Biolabs Private Limited, Centers for Disease Control and Prevention (CDC) 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-3363] Monoclonal Antibodies that Bind Zika Virus Envelope Protein for Zika Diagnostics and Research&body=Please send me information about technology [TAB-3363] Monoclonal Antibodies that Bind Zika Virus Envelope Protein for Zika Diagnostics and Research. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-3363] Monoclonal Antibodies that Bind Zika Virus Envelope Protein for Zika Diagnostics and Research&body=Please send me information about technology [TAB-3363] Monoclonal Antibodies that Bind Zika Virus Envelope Protein for Zika Diagnostics and Research.">benjamin.hurley@nih.gov</a><br> 114168845 E-030-2017-0 E-030-2017-0-US-01 COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF ZIKA VIRUS INFECTION PRV US 62/622,521 Abandoned US <br />Provisional (PRV) 62/622,521<br />Filed on 2018-01-26<br />Status: Abandoned 114128232 YBXXXX 114128233 VLXXXX 114128234 WBXXXX 114128235 WFXXXX 114128236 WIXXXX 114128237 XAXXXX 114151572 Development 114151573 Zika 114151574 virus 114151575 monoclonal 114151576 antibodies 114151577 Novel 114151578 Diagnostics 114151579 NCEZID 114151580 NCEZID-DSR TAB-5058 162672189 First in class Small Molecule Agonists of the mammalian Relaxin family receptor 1 (RXFP1) and use in treatment of cancer, fibrotic, and vascular disorders (HHS Ref No. E-145-2024-0-US-02) NCATS Cardiology, Dermatology, Geriatrics, Oncology, Pulmonology, Reproductive Health, Research Materials, Therapeutics Cardiology Dermatology Geriatrics Oncology Pulmonology Reproductive Health Research Materials Therapeutics Alexander Agoulnik, Irina Agoulnik, Ana Cabrera, Mark Henderson, Wenwei Huang, Joshua Hutcheson, Jiankang Jiang, Abhijeet Kapoor, Bing Li, Juan Marugan, Khalida Shamim, Noel Southall, Kenneth Wilson, Wenjuan Ye <p><span style="font-size:12pt"><span style="font-family:&quot;Times New Roman&quot;,serif">It is well documented in literature that activation of RXFP1 by relaxin induces: 1) up-regulation of the endothelin system which leads to vasodilation; 2) extracellular matrix remodeling through regulation of collagen deposition, cell invasiveness, proliferation, and overall tissue homeostasis; 3) a moderation of inflammation by reducing levels of inflammatory cytokines, such as TNF-a and TGF-b; and 4) angiogenesis by activating transcription of VEGF.</span></span></p> <p><span style="font-size:12pt"><span style="font-family:&quot;Times New Roman&quot;,serif">The present invention is directed to novel relaxin receptor (RFXP1 receptor) small molecule agonists useful for treating relaxin-related disorders including fibrosis, certain cancers, vascular calcifications, including atherosclerosis, and heart failure. The RFXP1 agonists of this disclosure possess a number of advantages not found in earlier RFXP1 agonists. These properties include, for example, improved bioavailability, low toxicity, and better activity in RXFP1-dependent biological functional assays.</span></span></p> <p><span style="font-size:12pt"><span style="font-family:&quot;Times New Roman&quot;,serif">NCATS in collaboration with Florida International University (FIU) and </span></span>University of South Florida<span style="font-size:12pt"><span style="font-family:&quot;Times New Roman&quot;,serif"> (USF) has identified low molecular weight, highly potent, and efficient full RXFP1 agonists with low cytotoxicity. The identification and characterization of these compounds may lead to the development of a new class of cost-effective drugs for the treatment of numerous <span style="color:black">cancers, fibrotic, and vascular disorders</span>.</span></span></p> <p><span style="font-size:12pt"><span style="font-family:&quot;Times New Roman&quot;,serif">NCATS is actively seeking licensing to develop therapeutic interventions for cancers, fibrotic and vascular disease including but not limited to breast <span style="color:black">cancer, solid tumors, atherosclerosis, and liver fibrosis</span>. </span></span></p> <ul><li>First and only small molecule agonists of RXFP1</li><li>Potent and highly selective</li><li>Bioavailable with excellent exposure</li><li>Easy to synthesize and scale-up</li></ul> <ul><li>Vascular health</li><li>Fibrotic diseases</li><li>Cancers</li><li>Human reproductive health</li></ul> Researchers at the National Center for Advancing Translational Sciences (NCATS) seek to license these molecules. Licensing Contact: Jasmine Kalsi, M.S. Email: jasmine.kalsi@nih.gov Telephone: 301.435.0129 2025-05-29 2025-05-30 2026-04-01 2025-05-29 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 162672380 Marugan, Juan NCATS - NCGC NCATS Marugan, Juan (NCATS) 1 162672384 Henderson, Mark NCATS - NCGC NCATS Henderson, Mark (NCATS) 2 162672393 Wilson, Kenneth National Center for Advancing Translational Sciences Wilson, Kenneth 3 162672397 Huang, Wenwei NCATS - TRND NCATS Huang, Wenwei (NCATS) 4 162672401 Ye, Wenjuan NCATS - NCGC NCATS Ye, Wenjuan (NCATS) 5 162672410 Southall, Noel NCATS - TRND NCATS Southall, Noel (NCATS) 6 162672414 Jiang, Jiankang NCATS - NCGC NCATS Jiang, Jiankang (NCATS) 7 162672418 Shamim, Khalida NCATS - TRND NCATS Shamim, Khalida (NCATS) 8 162672422 Li, Bing National Center for Advancing Translational Sciences Li, Bing 9 162672458 Agoulnik, Alexander Florida International University (FIU) Agoulnik, Alexander 10 162672621 Kapoor, Abhijeet Florida International University (FIU) Kapoor, Abhijeet 11 162672761 Hutcheson, Joshua Florida International University (FIU) Hutcheson, Joshua 12 162672791 Cabrera, Ana Florida International University (FIU) Cabrera, Ana 13 162672896 Agoulnik, Irina Florida International University (FIU) Agoulnik, Irina 14 162672380 Marugan, Juan NCATS - NCGC NCATS Marugan, Juan (NCATS) 1 162672384 Henderson, Mark NCATS - NCGC NCATS Henderson, Mark (NCATS) 2 162672393 Wilson, Kenneth National Center for Advancing Translational Sciences Wilson, Kenneth 3 162672397 Huang, Wenwei NCATS - TRND NCATS Huang, Wenwei (NCATS) 4 162672401 Ye, Wenjuan NCATS - NCGC NCATS Ye, Wenjuan (NCATS) 5 162672410 Southall, Noel NCATS - TRND NCATS Southall, Noel (NCATS) 6 162672414 Jiang, Jiankang NCATS - NCGC NCATS Jiang, Jiankang (NCATS) 7 162672418 Shamim, Khalida NCATS - TRND NCATS Shamim, Khalida (NCATS) 8 162672422 Li, Bing National Center for Advancing Translational Sciences Li, Bing 9 162672458 Agoulnik, Alexander Florida International University (FIU) Agoulnik, Alexander 10 162672621 Kapoor, Abhijeet Florida International University (FIU) Kapoor, Abhijeet 11 162672761 Hutcheson, Joshua Florida International University (FIU) Hutcheson, Joshua 12 162672791 Cabrera, Ana Florida International University (FIU) Cabrera, Ana 13 162672896 Agoulnik, Irina Florida International University (FIU) Agoulnik, Irina 14 162672192 NCGC00846044 is a novel functionally selective RXFP1 agonist with exceptional properties E-145-2024-0 Filing authorized Florida International University (FIU), National Center for Advancing Translational Sciences, National Center for Advancing Translational Sciences, National Center for Advancing Translational Sciences, NCATS - NCGC, NCATS - NCGC, NCATS - TRND 93911356 Kalsi, Jasmine jasmine.kalsi@nih.gov
United States of America jasmine.kalsi@nih.gov?subject=Web Inquiry on [TAB-5058] First in class Small Molecule Agonists of the mammalian Relaxin family receptor 1 (RXFP1) and use in treatment of cancer, fibrotic, and vascular disorders (HHS Ref No. E-145-2024-0-US-02)&body=Please send me information about technology [TAB-5058] First in class Small Molecule Agonists of the mammalian Relaxin family receptor 1 (RXFP1) and use in treatment of cancer, fibrotic, and vascular disorders (HHS Ref No. E-145-2024-0-US-02). Kalsi, Jasmine<br><a href="mailto:jasmine.kalsi@nih.gov?subject=Web Inquiry on [TAB-5058] First in class Small Molecule Agonists of the mammalian Relaxin family receptor 1 (RXFP1) and use in treatment of cancer, fibrotic, and vascular disorders (HHS Ref No. E-145-2024-0-US-02)&body=Please send me information about technology [TAB-5058] First in class Small Molecule Agonists of the mammalian Relaxin family receptor 1 (RXFP1) and use in treatment of cancer, fibrotic, and vascular disorders (HHS Ref No. E-145-2024-0-US-02).">jasmine.kalsi@nih.gov</a><br> 162672197 E-145-2024-0 E-145-2024-0-US-01 RFXP1 AGONISTS PRV US 63/757,235 Expired US <br />Provisional (PRV) 63/757,235<br />Filed on 2025-02-11<br />Status: Expired 162672198 E-145-2024-0 E-145-2024-0-US-02 RFXP1 AGONISTS PRV US 63/780,976 Expired US <br />Provisional (PRV) 63/780,976<br />Filed on 2025-03-31<br />Status: Expired 166692346 E-145-2024-0 E-145-2024-0-PC-01 RFXP1 AGONISTS PCT Patent Cooperation Treaty PCT/US2026/021648 Pending Patent Cooperation Treaty <br />(PCT) PCT/US2026/021648<br />Filed on 2026-03-31<br />Status: Pending TAB-4989 156774528 Human Monoclonal Antibodies That Target Plasmodium Falciparum Sporozoites NIAID Antibodies, Collaboration, Infectious Disease, Licensing, Research Materials Antibodies Collaboration Infectious Disease Licensing Research Materials Cherelle Dacon, Joshua Tan <p>Malaria is one of the worlds deadliest infectious diseases, causing an estimated 249 million cases and 608,000 deaths annually, with children in the regions of Africa and South Asia being most vulnerable. Approx 2,000 cases of malaria are reported in the United States each year, by travelers from malaria-risk countries. Malaria is a mosquito-borne parasitic disease transmitted through the bite of infected female mosquitoes, which introduces Plasmodium sporozoites into the bloodstream of the human host. There are five Plasmodium parasite species that cause malaria in humans, of which, the vast majority of life-threatening cases are caused by infection with Plasmodium falciparum parasites. Researchers at NIAID have developed 11 human monoclonal antibodies that bind to a unique site on the circumsporozoite protein (CSP) on Plasmodium falciparum sporozoites that is not targeted by any known monoclonal antibodies. These antibodies do not bind to recombinant forms of CSP and as such bind to a processed or post-translational form of the protein processed by the sporozoites. In vivo studies have shown several of these antibodies can substantially reduce liver parasite burden in a mouse model of malaria. These antibodies can work cooperatively with known antibodies that target the repeat region of CSP. Some of these novel antibodies have shown enhanced protection in an animal model when combined with known protective monoclonal antibodies against sporozoites, suggesting that together they may form an effective cocktail to prevent malaria.</p> <ul> <li>These antibodies bind to a unique site on the circumsporozoite protein (CSP) on Plasmodium falciparum sporozoites that is distinct from the targets of pre-existing mAbs.</li> <li>These monoclonal antibodies can be used alone or in combination with existing antibodies.</li> </ul> <ul> <li>Prophylactic and preventative treatment against malaria.</li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. Areas of specific interest include: (a) testing developability of these antibodies (e.g., biophysical characteristics, cross-reactivity, pharmacokinetics, toxicity), (b) pre-clinical model assessment, and (c) human clinical trials. For collaboration opportunities, please contact Dawn Taylor-Mulneix at 301-767-5189, or dawn.taylor-mulneix@nih.gov. 2024-06-26 2025-05-29 2026-03-30 2024-06-27 False False <ul> <li>Pre-Clinical</li> </ul> True 37470483 Website Abstract E-212-2022-0 156774781 Tan, Joshua National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Tan, Joshua (NIAID) 1 156774785 Dacon, Cherelle National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Dacon, Cherelle (NIAID) 2 156774781 Tan, Joshua National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Tan, Joshua (NIAID) 1 156774785 Dacon, Cherelle National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Dacon, Cherelle (NIAID) 2 156774531 Human Monoclonal Antibodies That Target Plasmodium Falciparum Sporozoites E-212-2022-0 Filing authorized NIAID 83738793 Taylor-Mulneix, Dawn dawn.taylor-mulneix@nih.gov
United States of America dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-4989] Human Monoclonal Antibodies That Target Plasmodium Falciparum Sporozoites&body=Please send me information about technology [TAB-4989] Human Monoclonal Antibodies That Target Plasmodium Falciparum Sporozoites. Taylor-Mulneix, Dawn<br><a href="mailto:dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-4989] Human Monoclonal Antibodies That Target Plasmodium Falciparum Sporozoites&body=Please send me information about technology [TAB-4989] Human Monoclonal Antibodies That Target Plasmodium Falciparum Sporozoites.">dawn.taylor-mulneix@nih.gov</a><br> TAB-4509 151706142 High Relaxivity Mulitivalent Gadolinium on a Peptide Scaffold for Targeted MRI Applications in Disease Diagnosis NHLBI Diagnostics, Licensing, Medical Devices, Research Materials Diagnostics Licensing Medical Devices Research Materials Alan Koretsky, Nikorn Pothayee, Deepak Sail, Rolf Swenson <p>This technology includes a peptide containing alternating Alanine and Lys(DOTA-Gd) residues can be used to increase the MRI relaxivity of a peptide. The low molecular weight construct can be appended to proteins, antibodies and peptides to increase MRI signals. This approach offers advantages over previous dendrimeric constructs. The increased MRI signal may allow effective neuronal tracing of peptides that when misfolded and transported from the gut to the brain may lead to inflammation and serious diseases including Alzheimer&rsquo;s (A-beta), Parkinson&rsquo;s Disease, Lewey Body Dementia, and Multiple Systems atrophy (alpha synuclein), Creutzfeld-Jakob disease, and Amyotrophic lateral sclerosis.</p> Multivalent chelated Gd can be efficiently constructed on a peptide scaffold, with substantial increase in relaxivity (i.e., higher MRI signal), with minimum molecular weight increase and can be efficiently added to proteins, antibodies, and proteins for targeted MRI applications in disease diagnosis. For use in diagnostic MRI applications. We are seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. 2023-12-07 2025-08-13 2026-03-26 2024-03-27 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 151706190 Swenson, Rolf National Heart, Lung, and Blood Institute (NHLBI) NHLBI Swenson, Rolf (NHLBI) 1 151706194 Koretsky, Alan NINDS NINDS Koretsky, Alan (NINDS) 2 151706198 Pothayee, Nikorn NINDS NINDS Pothayee, Nikorn (NINDS) 3 151706203 Sail, Deepak National Heart, Lung, and Blood Institute (NHLBI) NHLBI Sail, Deepak (NHLBI) 4 151706190 Swenson, Rolf National Heart, Lung, and Blood Institute (NHLBI) NHLBI Swenson, Rolf (NHLBI) 1 151706194 Koretsky, Alan NINDS NINDS Koretsky, Alan (NINDS) 2 151706198 Pothayee, Nikorn NINDS NINDS Pothayee, Nikorn (NINDS) 3 151706203 Sail, Deepak National Heart, Lung, and Blood Institute (NHLBI) NHLBI Sail, Deepak (NHLBI) 4 151706145 High Relaxivity Mulitivalent Gadolinium On A Peptide Scaffold E-146-2019-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI), NINDS 153929528 Ghosh, Malabika malabika.ghosh@nih.gov
United States of America malabika.ghosh@nih.gov?subject=Web Inquiry on [TAB-4509] High Relaxivity Mulitivalent Gadolinium on a Peptide Scaffold for Targeted MRI Applications in Disease Diagnosis&body=Please send me information about technology [TAB-4509] High Relaxivity Mulitivalent Gadolinium on a Peptide Scaffold for Targeted MRI Applications in Disease Diagnosis. Ghosh, Malabika<br><a href="mailto:malabika.ghosh@nih.gov?subject=Web Inquiry on [TAB-4509] High Relaxivity Mulitivalent Gadolinium on a Peptide Scaffold for Targeted MRI Applications in Disease Diagnosis&body=Please send me information about technology [TAB-4509] High Relaxivity Mulitivalent Gadolinium on a Peptide Scaffold for Targeted MRI Applications in Disease Diagnosis.">malabika.ghosh@nih.gov</a><br> 157755246 E-146-2019-0 E-146-2019-0-US-01 HIGH RELAXIVITY MULITIVALENT GADOLINIUM ON A PEPTIDE SCAFFOLD PRV US 62/873,272 Abandoned US <br />Provisional (PRV) 62/873,272<br />Filed on 2019-07-12<br />Status: Abandoned TAB-2905 114097066 LRRK2 Inhibitors: Novel Treatment for Intestinal Bowel Disorders NIAID Cardiology, Dental, Endocrinology, Immunology, Infectious Disease, Licensing, Oncology, Ophthalmology, Therapeutics Cardiology Dental Endocrinology Immunology Infectious Disease Licensing Oncology Ophthalmology Therapeutics Atsushi Kitani, Warren Strober, Tetsuya Takagawa Use of Leucine Rich Repeat Kinase 2 (LRRK2) inhibitors for the treatment of Intestinal Bowel Disorders (IBD) is disclosed. IBD is a broad term that describes conditions with chronic or recurring immune response and inflammation of the gastrointestinal tract. Crohn's disease and ulcerative colitis, two common forms of idiopathic IBD, are chronic, relapsing inflammatory disorders of the gastrointestinal tract.<br /><br /> LRRK2 is a kinase encoded by a gene that contains a non-coding polymorphism (SNP). LRRK2 has been associated with and is a risk factor for inflammatory bowel disease. NIH inventors have shown that human cells expressing this SNP have increased levels of LRRK2 and, correspondingly, mice with increased levels of LRRK2 exhibit more severe Dextran Sulfate colitis. In various studies of the role of LRRK2 in cell signaling, NIH inventors have shown that increased levels of LRRK2 lead to increased pro-inflammatory cytokine secretion. Also, an inhibitor of LRRK2 is shown to abrogate the pro-inflammatory activity of LRRK2 both <em>in vitro</em> and <em>in vivo</em>. <ul> <li>A LRRK2 inhibitor would be a unique form of anti-inflammatory therapy that will complement or compete with an array of cytokines in primary treatment for lBD.</li> <li>A LRRK2 inhibitor would provide a much needed alternate mode of therapy.</li> </ul> <ul> <li>Treatment for or prevention of Intestinal Bowel Disorders.</li> </ul> 2022-03-08 2026-03-26 2026-03-26 2015-01-26 COLITIS, Crohn's, Disease, IB3XXX, inhibitor, LRRK2, TREAT, Ulcerative, VPXXXX, WKXXXX, XEXXXX, YAXXXX, YBXXXX, YCXXXX False True <ul> <li>Early-stage</li> <li>In vitro data available</li> <li>In vivo data available (animal)</li> </ul> True 52406768 Discovery 52406768 NIHTT 37470483 Website Abstract 114108958 Takagawa, Tetsuya NIAID - DIR NIAID Takagawa, Tetsuya (NIAID) 0 114108959 Kitani, Atsushi NIAID - DIR NIAID Kitani, Atsushi (NIAID) 0 114108957 Strober, Warren NIAID - DIR NIAID Strober, Warren (NIAID) 1 114108957 Strober, Warren NIAID - DIR NIAID Strober, Warren (NIAID) 1 114108958 Takagawa, Tetsuya NIAID - DIR NIAID Takagawa, Tetsuya (NIAID) 0 114108959 Kitani, Atsushi NIAID - DIR NIAID Kitani, Atsushi (NIAID) 0 114102240 Use Of LRRK2 Inhibitor To Treat Ulcerative Colitis And Crohn's Disease E-070-2014-0 Filing authorized NIAID 83720410 Yang, David (Po-Lung) polung.yang@nih.gov
United States of America Technology Transfer and Intellectual Property Office polung.yang@nih.gov?subject=Web Inquiry on [TAB-2905] LRRK2 Inhibitors: Novel Treatment for Intestinal Bowel Disorders&body=Please send me information about technology [TAB-2905] LRRK2 Inhibitors: Novel Treatment for Intestinal Bowel Disorders. Yang, David (Po-Lung)<br><a href="mailto:polung.yang@nih.gov?subject=Web Inquiry on [TAB-2905] LRRK2 Inhibitors: Novel Treatment for Intestinal Bowel Disorders&body=Please send me information about technology [TAB-2905] LRRK2 Inhibitors: Novel Treatment for Intestinal Bowel Disorders.">polung.yang@nih.gov</a><br> 114161781 E-070-2014-0 E-070-2014-0-US-03 Treatment or Prevention of an Intestinal Disease or Disorder National Stage US 10,058,559 15/311,405 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10058559 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10058559">10,058,559</a><br />Filed on 2016-11-15<br />Status: Issued 114167061 E-070-2014-0 E-070-2014-0-PCT-02 Treatment or Prevention of an Intestinal Disease or Disorder PCT Patent Cooperation Treaty PCT/US2015/031200 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2015/031200<br />Filed on 2015-05-15<br />Status: Expired 114168055 E-070-2014-0 E-070-2014-0-US-01 TREATMENT OR PREVENTION OF AN INTESTINAL DISEASE OR DISORDER PRV US 61/993,637 Abandoned US <br />Provisional (PRV) 61/993,637<br />Filed on 2014-05-15<br />Status: Abandoned 114126812 IB3XXX 114126813 VPXXXX 114126814 WKXXXX 114126815 XEXXXX 114126816 YAXXXX 114126817 YBXXXX 114126818 YCXXXX 114148050 LRRK2 114148051 inhibitor 114148052 TREAT 114148053 Ulcerative 114148054 COLITIS 114148055 Disease 114148056 Crohn's TAB-1758 114095987 Muramyl Dipeptide as a Therapeutic Agent for Inflammation NIAID Collaboration, Diagnostics, Immunology, Licensing, Research Materials, Therapeutics Collaboration Diagnostics Immunology Licensing Research Materials Therapeutics Warren Strober The nucleotide-binding oligomerization domain 2 (NOD2) protein plays a key role in innate immunity as a sensor of muramyl dipeptide (MDP), a breakdown product of bacterial peptidoglycan. Bacterial peptidoglycan promotes the innate immune response through the activation of Toll-like receptor 2 (TLR2), which ultimately provokes inflammation. Activation of NOD2 by MDP negatively regulates the activity of TLR2, and thus reduces inflammation. <br><br> The inventors have demonstrated that administration of MDP prevents the development of experimental colitis in mice. They have also determined that MDP reduces pro-inflammatory cytokine production from multiple Toll-like receptors, and that this reduction arises from the induction of IFN regulatory factor 4 (IRF4). The technology includes methods of treating or preventing inflammation associated with an autoimmune disorder, particularly inflammatory bowel disease, via administration of muramyl peptide; also included are methods of reducing symptoms characteristic of inflammation via administration of muramyl peptide. This technology has potential as an anti-inflammatory therapy for autoimmune or other inflammation-associated diseases, particularly inflammatory bowel diseases such as Crohn's disease and ulcerative colitis. The NIAID Laboratory of Host Defenses, Mucosal Immunity Section, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. Please contact either Rosemary Walsh or Charles Rainwater at 301-496-2644 for more information. This technology is available for exclusive or non-exclusive licensing. 2022-03-08 2026-03-26 2026-03-26 2008-05-01 Autoimmune, AUTOIMMUNE DISEASE, Autoimmune disorder, Autoimmunity, BBXXXX, BCXXXX, BOWEL, Crohn disease; Inflammatory bowel disease 1, Crohn's disease, Dipeptide, IB3XXX, IBD, IBXXXX, IL-12, Inflammation, INFLAMMATORY, inflammatory bowel disease, Inflammatory bowel disease 1, inflammatory disease, INTERLEUKIN, INTERLEUKIN-12, IRF4, IXXXXX, MDP, Muramyl, NOD2, peptidoglycan, TLR, TLR2, Toll-like, Toll-like receptors, Ulcerative Colitis False True <i>In vivo</i> data are available in an experimental colitis mouse model, and <i>in vitro</i> data supporting mechanism of action also are available. <i>In vivo</i> data are available in an experimental colitis mouse model, and <i>in vitro</i> data supporting mechanism of action also are available. True 52398218 Pre-Clinical (in vivo) 52398218 NIHTT 37470483 Website Abstract 114170513 T Watanabe et al. Muramyl dipeptide activation of nucleotide-binding oligomerization domain 2 protects mice from experimental colitis. J Clin Invest. 2008 Feb;118(2):545-559. http://www.ncbi.nlm.nih.gov/pubmed/18188453?dopt <a href="http://www.ncbi.nlm.nih.gov/pubmed/18188453?dopt">T Watanabe et al. Muramyl dipeptide activation of nucleotide-binding oligomerization domain 2 protects mice from experimental colitis. J Clin Invest. 2008 Feb;118(2):545-559.</a> 114106058 Strober, Warren NIAID - DIR NIAID Strober, Warren (NIAID) 1 114106058 Strober, Warren NIAID - DIR NIAID Strober, Warren (NIAID) 1 114100985 Adminstration Of Muramyl Dipeptide (MDP) For The Treatment Of Inflammatory Bowel Disease (IBD) E-110-2006-0 Filing authorized NIAID 83720410 Yang, David (Po-Lung) polung.yang@nih.gov
United States of America Technology Transfer and Intellectual Property Office polung.yang@nih.gov?subject=Web Inquiry on [TAB-1758] Muramyl Dipeptide as a Therapeutic Agent for Inflammation&body=Please send me information about technology [TAB-1758] Muramyl Dipeptide as a Therapeutic Agent for Inflammation. Yang, David (Po-Lung)<br><a href="mailto:polung.yang@nih.gov?subject=Web Inquiry on [TAB-1758] Muramyl Dipeptide as a Therapeutic Agent for Inflammation&body=Please send me information about technology [TAB-1758] Muramyl Dipeptide as a Therapeutic Agent for Inflammation.">polung.yang@nih.gov</a><br> 114164239 E-110-2006-0 E-110-2006-0-PCT-02 USE OF MURAMYL DIPEPTIDE (MDP) FOR TREATING INFLAMMATION PCT Patent Cooperation Treaty PCT/US2007/086117 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2007/086117<br />Filed on 2007-11-30<br />Status: Expired 114164444 E-110-2006-0 E-110-2006-0-US-01 USES OF MURAMYL DIPEPTIDE COMPOSITIONS FOR TREATING AND PREVENTING INFLAMMATION PRV US 60/872,384 Abandoned US <br />Provisional (PRV) 60/872,384<br />Filed on 2006-12-01<br />Status: Abandoned 114165302 E-110-2006-0 E-110-2006-0-US-03 Use Of Muramyl Dipeptide (MDP) For Treating Inflammation National Stage US 8,603,978 12/516,633 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8603978 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8603978">8,603,978</a><br />Filed on 2009-05-28<br />Status: Issued 114118678 IB3XXX 114118679 IBXXXX 114118680 IXXXXX 114120845 BBXXXX 114121282 BCXXXX 114130858 Ulcerative Colitis 114130859 Muramyl 114130860 Dipeptide 114130861 MDP 114130862 Crohn's disease 114130863 inflammatory bowel disease 114130864 INFLAMMATORY 114130865 BOWEL 114130866 inflammatory disease 114130867 IBD 114130868 Autoimmune 114130869 AUTOIMMUNE DISEASE 114130870 Autoimmune disorder 114130871 Autoimmunity 114130872 peptidoglycan 114130873 NOD2 114130874 TLR 114130875 TLR2 114130876 Toll-like 114130877 Toll-like receptors 114130878 Inflammation 114130879 INTERLEUKIN-12 114130880 INTERLEUKIN 114130881 IL-12 114130882 IRF4 114156529 Inflammatory bowel disease 1 114158348 Crohn disease; Inflammatory bowel disease 1 TAB-1364 114095691 Treatment and Prevention of Inflammatory Bowel Disease (IBD) using Mutant and Chimeric IL-13 Molecules NIAID Diagnostics, Immunology, Licensing, Reproductive Health, Research Materials, Therapeutics, Vaccines Diagnostics Immunology Licensing Reproductive Health Research Materials Therapeutics Vaccines Stefan Fichtner-Feigl, Koji Kawakami, Atsushi Kitani, Peter Mannon, Jan Preiss, Raj Puri, Warren Strober Ulcerative colitis (UC) is a chronic inflammatory disease of the colorectum and affects approximately 400,000 people in the United States. The cause of UC is not known, although an abnormal immunological response to bacterial antigens in the gut microflora is thought to be involved. Present treatments for UC include anti-inflammatory therapy using aminosalicylates or corticosteroids, as well as immunomodulators and diet. However, 25-40% of ulcerative colitis patients must eventually have their colons removed due to massive bleeding, severe illness, rupture of the colon, risk of cancer or due to side effects of corticosteroids and novel treatments are still actively being sought. NIH scientists and their collaborators have used a mouse model of experimental colitis (oxazolone colitis, OC) to show that IL-13, a Th2 cytokine, is a significant pathologic factor in OC and that neutralizing IL-13 in these animals effectively prevents colitis.<br /><br /> OC is a colitis induced by intrarectal administration of a relatively low dose of the haptenating agent oxazolone subsequent to skin sensitization with oxazolone. A highly reproducible and chronic colonic inflammation is obtained that is histologically similar to human ulcerative colitis. Studies show that Natural Killer T (NKT) cells, rather than conventional CD4+T cells, mediate oxazolone colitis and are the source of IL-13 as well as being activated by CD1- expressing intestinal epithelial cells. Tissue removed from ulcerative colitis patients were also shown to contain increased numbers of nonclassical NKT cells that produce markedly increased amounts of IL-13 and that in keeping with epithelial damage being a key factor in UC, these NKT cells are cytotoxic for epithelial cells. Building on their previous work, scientists at NIAID and FDA have shown that an Il-13 chimeric fusion protein linked to an effector molecule was able to prevent colitis in a mouse model of ulcerative colitis.<br /><br /> Available for licensing are methods for treating or preventing the inflammatory response of IBD by inhibiting the binding of IL-13 to IL-13 receptors on NKT cells. Additionally, these mutant and chimeric Il-13 molecules are able to block the chronic inflammatory response that results in fibrosis as seen in Crohn's disease. Preventing the inflammatory response of colitis by either modulating or blocking IL-13 and NKT cell activity continues to be an effective therapeutic approach in animal models of colitis with implications for the treatment of human ulcerative colitis and for the treatment of fibrosis associated with Crohn's disease. 2022-03-08 2026-03-26 2026-03-26 2006-06-01 Crohn disease; Inflammatory bowel disease 1, IB3XXX, IB6XXX, IBXXXX, Inflammatory bowel disease 1, IXXXXX False True True NIHTT 37470483 Website Abstract E-131-2002-0 114171191 Heller F, et al. http://www.ncbi.nlm.nih.gov/pubmed/12433369 <a href="http://www.ncbi.nlm.nih.gov/pubmed/12433369">Heller F, et al.</a> 114171192 Fuss IJ, et al. http://www.ncbi.nlm.nih.gov/pubmed/15146247 <a href="http://www.ncbi.nlm.nih.gov/pubmed/15146247">Fuss IJ, et al.</a> 114105505 Strober, Warren NIAID Strober, Warren (NIAID) 0 114105506 Mannon, Peter NIAID Mannon, Peter (NIAID) 0 114105507 Preiss, Jan Preiss, Jan 0 114105508 Puri, Raj FDA Puri, Raj (FDA) 0 114105509 Kawakami, Koji FDA Kawakami, Koji (FDA) 0 114105510 Fichtner-Feigl, Stefan Fichtner-Feigl, Stefan 0 114105511 Kitani, Atsushi NIAID Kitani, Atsushi (NIAID) 0 114105505 Strober, Warren NIAID Strober, Warren (NIAID) 0 114105506 Mannon, Peter NIAID Mannon, Peter (NIAID) 0 114105507 Preiss, Jan Preiss, Jan 0 114105508 Puri, Raj FDA Puri, Raj (FDA) 0 114105509 Kawakami, Koji FDA Kawakami, Koji (FDA) 0 114105510 Fichtner-Feigl, Stefan Fichtner-Feigl, Stefan 0 114105511 Kitani, Atsushi NIAID Kitani, Atsushi (NIAID) 0 114100606 Treatment And Prevention Of Inflammatory Bowel Disease (IBD) Using Mutant And Chimeric IL-13 Molecules E-003-2005-0 Filing authorized FDA, NIAID 83720410 Yang, David (Po-Lung) polung.yang@nih.gov
United States of America Technology Transfer and Intellectual Property Office polung.yang@nih.gov?subject=Web Inquiry on [TAB-1364] Treatment and Prevention of Inflammatory Bowel Disease (IBD) using Mutant and Chimeric IL-13 Molecules&body=Please send me information about technology [TAB-1364] Treatment and Prevention of Inflammatory Bowel Disease (IBD) using Mutant and Chimeric IL-13 Molecules. Yang, David (Po-Lung)<br><a href="mailto:polung.yang@nih.gov?subject=Web Inquiry on [TAB-1364] Treatment and Prevention of Inflammatory Bowel Disease (IBD) using Mutant and Chimeric IL-13 Molecules&body=Please send me information about technology [TAB-1364] Treatment and Prevention of Inflammatory Bowel Disease (IBD) using Mutant and Chimeric IL-13 Molecules.">polung.yang@nih.gov</a><br> 114163448 E-003-2005-0 E-003-2005-0-US-01 Treatment and prevention of IBD using Mutant and Chimeric Il-13 Molecules PRV US 60/671,624 Abandoned US <br />Provisional (PRV) 60/671,624<br />Filed on 2005-04-15<br />Status: Abandoned 114163451 E-003-2005-0 E-003-2005-0-US-03 Methods of treating and preventing inflammatory bowel disease involving il-13 and nkt cells National Stage US 9,072,716 11/918,711 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9072716 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9072716">9,072,716</a><br />Filed on 2008-11-10<br />Status: Expired 114166207 E-003-2005-0 E-003-2005-0-PCT-02 Methods of Treating and Preventing Inflammatory Bowel Disease Involving IL-13 and NKT Cells PCT Patent Cooperation Treaty PCT/US2006/014393 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2006/014393<br />Filed on 2006-04-14<br />Status: Expired 114117242 IB3XXX 114117243 IB6XXX 114117244 IBXXXX 114117246 IXXXXX 114156177 Inflammatory bowel disease 1 114158182 Crohn disease; Inflammatory bowel disease 1 TAB-5095 166536297 Gene Editing for ALPK1 p.Thr237Met NIAID Application, Collaboration Sought, Rare/Neglected Diseases, ResearchProducts, TherapeuticArea Application Collaboration Sought Rare/Neglected Diseases ResearchProducts TherapeuticArea Uimook Choi, Christina Kozycki, Colin Sweeney <p>ROSAH syndrome is a rare genetic disease caused by a mutation in the human alpha kinase 1 (ALPK1) gene (p.Thr237Met), leading to vision loss, swollen optic nerves, dry mouth, enlarged spleen, and frequent headaches. Researchers in the Laboratory of Clinical Immunology and Microbiology (LCIM) at the National Institute of Allergy and Infectious Diseases (NIAID) have developed a new approach that can precisely fix the ALPK1 mutation without causing unwanted changes in the patient&rsquo;s DNA. This method uses a base editor combined with a guide RNA to safely and efficiently convert the pathogenic thymine of the mutation back to cytosine. In laboratory tests, this gene editing technology successfully repaired the mutation in patient-derived affected cells with high accuracy and no side effects.</p> <p>This therapy could be delivered directly to the eye or salivary glands, or patient cells could be corrected outside the body and then returned to the patient, offering hope for personalized treatment to restore vision and improve quality of life for people with ROSAH syndrome.</p> <ul> <li>Highly accurate tool that directly repairs the faulty gene that causes ROSAH syndrome, while avoiding unwanted changes elsewhere in DNA</li> <li>Corrects the mutation in most patient cells with few or no mistakes</li> <li>Can be delivered directly to affected areas (e.g., eye or salivary glands) or can treat patient cells outside the body</li> <li>Custom therapy for people with the ALPK1 mutation</li> <li>Effective in cells that don’t divide, unlike older gene editing methods</li> </ul> <ul> <li>Personalized therapy for individuals with disease secondary to the ALPK1 p.Thr237Met genetic variant</li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. Area of specific interest includes human clinical trials. For collaboration opportunities, please contact David Yang at 240-695-6406, or David.Yang@niaid.nih.gov. 2026-03-23 2026-03-26 2026-03-26 2026-03-24 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 166536410 Kozycki, Christina National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Kozycki, Christina (NIAID) 1 166536424 Sweeney, Colin National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Sweeney, Colin (NIAID) 2 166538687 Choi, Uimook National Institute of Allergy and Infectious Diseases (NIAID/NIH) Choi, Uimook 3 166536410 Kozycki, Christina National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Kozycki, Christina (NIAID) 1 166536424 Sweeney, Colin National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Sweeney, Colin (NIAID) 2 166538687 Choi, Uimook National Institute of Allergy and Infectious Diseases (NIAID/NIH) Choi, Uimook 3 166536300 Gene editing for ALPK1 p.Thr237Met E-044-2024-0 Filing authorized National Institute of Allergy and Infectious Diseases (NIAID/NIH), NIH - NIAID 83720410 Yang, David (Po-Lung) polung.yang@nih.gov
United States of America Technology Transfer and Intellectual Property Office polung.yang@nih.gov?subject=Web Inquiry on [TAB-5095] Gene Editing for ALPK1 p.Thr237Met&body=Please send me information about technology [TAB-5095] Gene Editing for ALPK1 p.Thr237Met. Yang, David (Po-Lung)<br><a href="mailto:polung.yang@nih.gov?subject=Web Inquiry on [TAB-5095] Gene Editing for ALPK1 p.Thr237Met&body=Please send me information about technology [TAB-5095] Gene Editing for ALPK1 p.Thr237Met.">polung.yang@nih.gov</a><br> 166536305 E-044-2024-0 E-044-2024-0-US-01 COMPOSITIONS AND METHODS FOR EDITING THE HUMAN ALPHA KINASE 1 (ALPK1) GENE AND TREATING ROSAH SYNDROME PRV US 63/733,836 Expired US <br />Provisional (PRV) 63/733,836<br />Filed on 2024-12-13<br />Status: Expired 166536306 E-044-2024-0 E-044-2024-0-PC-01 COMPOSITIONS AND METHODS FOR EDITING THE HUMAN ALPHA KINASE 1 (ALPK1) GENE AND TREATING ROSAH SYNDROME PCT Patent Cooperation Treaty PCT/US2025/059432 Pending Patent Cooperation Treaty <br />(PCT) PCT/US2025/059432<br />Filed on 2025-12-12<br />Status: Pending TAB-4568 151739556 Astrocyte Differentiation of Neural Stem Cells with StemPro Embryonic Stem Cell Serum Free Medium for Research and Potential Therapeutic Use NIAMS Human Cell Lines, Materials Available, Neurology, Research Materials Human Cell Lines Materials Available Neurology Research Materials Nasir Malik, Mahendra Rao, Xianmin Zeng <p>This technology includes an innovative method for differentiating astrocytes from neural stem cells (NSCs). The process involves using Life Technologies StemPro embryonic stem cell serum-free medium to initially guide NSCs towards a neuronal lineage. Over a period of 28-35 days, as the cells are continually passaged, neurons gradually die off, leading to the proliferation of astrocytes. By the end of this differentiation protocol, approximately 70% of the cells exhibit markers characteristic of mature astrocytes, specifically GFAP. Additionally, this method allows for the astrocytes to be frozen at early stages and later thawed to continue their differentiation into the astrocyte lineage. This technology stands out from previous methods by significantly enhancing the efficiency and speed of astrocyte derivation. The potential applications of this technology are extensive, including facilitating research into astrocyte development mechanisms and providing a scalable way to produce astrocytes for potential clinical applications in cellular replacement therapies for brain and spinal cord injuries.</p> This astrocyte differentiation technology offers a competitive advantage by enabling the efficient and rapid generation of mature astrocytes, surpassing previous methods in both speed and efficacy. The technology holds promise for advancing research in astrocyte development and could be pivotal in cellular replacement therapies for treating brain and spinal cord injuries. We are seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. 2023-12-11 2025-08-13 2026-03-25 2024-03-27 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 151739563 Malik, Nasir NINDS NINDS Malik, Nasir (NINDS) 1 151739567 Rao, Mahendra New York Stem Cell Foundation Rao, Mahendra 2 151739571 Zeng, Xianmin Buck Institute for Research on Aging [US] Zeng, Xianmin 3 151739563 Malik, Nasir NINDS NINDS Malik, Nasir (NINDS) 1 151739567 Rao, Mahendra New York Stem Cell Foundation Rao, Mahendra 2 151739571 Zeng, Xianmin Buck Institute for Research on Aging [US] Zeng, Xianmin 3 151739559 Astrocyte Differentiation Of Neural Stem Cells With StemPro Embryonic Stem Cell Serum Free Medium E-612-2013-0 Research Material Buck Institute for Research on Aging [US], NIAMS 83656052 Knezevic, Vladimir vlado.knezevic@nih.gov
United States of America Technology Advancement Office vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-4568] Astrocyte Differentiation of Neural Stem Cells with StemPro Embryonic Stem Cell Serum Free Medium for Research and Potential Therapeutic Use&body=Please send me information about technology [TAB-4568] Astrocyte Differentiation of Neural Stem Cells with StemPro Embryonic Stem Cell Serum Free Medium for Research and Potential Therapeutic Use. Knezevic, Vladimir<br><a href="mailto:vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-4568] Astrocyte Differentiation of Neural Stem Cells with StemPro Embryonic Stem Cell Serum Free Medium for Research and Potential Therapeutic Use&body=Please send me information about technology [TAB-4568] Astrocyte Differentiation of Neural Stem Cells with StemPro Embryonic Stem Cell Serum Free Medium for Research and Potential Therapeutic Use.">vlado.knezevic@nih.gov</a><br> TAB-5057 162516862 Synergistic Interactions for Improved Cancer Treatment NCI Collaboration, Immunology, Licensing, Oncology, Therapeutics Collaboration Immunology Licensing Oncology Therapeutics Barbara Felber, Sevasti Karaliota, George Pavlakis, Dimitrios Stellas <h2>Summary:</h2> <p>The National Cancer Institute (NCI) seeks research co-development partners and/or licensees to develop hetIL-15 in combination with other agents, such as PPARa agonists (Fenofibrate), FLT3 inhibitors (quizartinib), IL-12, or chemotherapy into a therapeutic for cancer.</p> <h2>Description of Technology:</h2> <p>Immunotherapy has emerged as a promising treatment strategy for many types of cancer. However, a major challenge is &ldquo;exhausted&rdquo; tumor-infiltrating immune cells, which lose their ability to effectively eliminate cancer cells. To address this issue, researchers are exploring ways to reverse immune exhaustion and improve treatment outcomes. One potential approach involves interleukin-15 (IL-15), a cytokine that promotes the growth and killing ability of tumor-specific CD8+ T cells and NK cells. IL-15, either alone or in combination with other agents, has shown some promise in clinical trials. However, its use is hindered by toxicity at effective doses. Therefore, there is a critical need for safer and more effective combinations to improve patient outcomes.</p> <p>Inventors at the National Cancer Institute previously developed heterodimeric IL-15 (hetIL-15), composed of IL-15 and IL-15 receptor alpha (NIH Reference # E-254-2005, E-257-2009, E-141-2008, E-054-2013, and E-070-2015). The inventors now demonstrate novel combinations of hetIL-15 with other active agents to enhance the metabolic fitness of intratumoral lymphocytes to provide therapeutic improvement. Specifically, the combination of hetIL-15 and Fenofibrate, a cholesterol-lowering drug, increased cytotoxic T cell activity and provided an almost complete eradication of triple negative breast cancer tumors, including metastatic lesions. &nbsp;Similar results occurred in a mouse pancreatic cancer model. Using a mouse orthotopic breast cancer model, hetIL-15 combined with quizartinib &ndash; a potent Fms-like tyrosine kinase 3 (Flt3) inhibitor &ndash; resulted in a significant tumor growth delay and complete eradication of tumors in 50% of mice after 16 days of treatment. Additionally, the inventors constructed a fusion protein of IL-15 and IL-12 that controls metastatic disease in a mouse melanoma model.&nbsp; These novel combinations would be particularly useful for the treatment of triple negative breast or pancreatic cancer.</p> <p>The National Cancer Institute seeks parties interested in collaborative research and/or licensees to further develop this technology.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Treatment for triple negative breast cancer</li> <li>Treatment for pancreatic cancer</li> <li>Treatment of solid tumors for which cellular immunotherapy outcomes are diminished due to T or NK cell exhaustion</li> <li>Treatment of solid tumors for which IL-15-based therapy is diminished due to toxicity at clinically relevant doses</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Novel combination showing improved therapeutic potential in several solid cancers, including breast cancer and melanoma</li> <li>Combination of hetIL-15 with agents already approved (Fenofibrate, Flt-3) decreases regulatory risk and thus expedites commercialization</li> <li>Overcoming IL-15 toxicity at clinically relevant doses</li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for translating hetIL-15 in combination with other agents, such as PPARa agonists (Fenofibrate), FLT3 inhibitors (quizartinib), IL-12, or chemotherapy, into a therapeutic for the treatment of cancer. 2025-05-19 2025-06-27 2026-03-19 2025-06-27 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-254-2005 E-257-2009 E-141-2008 E-054-2013 E-070-2015 162518109 Karaliota S, et al. "Tumor eradication by het IL-15 locoregional therapy correlates with an induced intratumoral CD103intCD11b+ dendritic cell population." (PMID: 37178117) https://pubmed.ncbi.nlm.nih.gov/37178117/ <a href="https://pubmed.ncbi.nlm.nih.gov/37178117/">Karaliota S, et al. "Tumor eradication by het IL-15 locoregional therapy correlates with an induced intratumoral CD103intCD11b+ dendritic cell population." (PMID: 37178117)</a> 162518219 Bergamaschi C, et al. Heterodimeric "IL-15 in cancer immunotherapy." (PMID: 33671252) https://pubmed.ncbi.nlm.nih.gov/33671252/ <a href="https://pubmed.ncbi.nlm.nih.gov/33671252/">Bergamaschi C, et al. Heterodimeric "IL-15 in cancer immunotherapy." (PMID: 33671252)</a> 162518307 Conlon K, et al. "Phase Ⅰ study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist in adult patients with metastatic or unresectable solid tumors." (PMID: 34799399 https://pubmed.ncbi.nlm.nih.gov/34799399/ <a href="https://pubmed.ncbi.nlm.nih.gov/34799399/">Conlon K, et al. "Phase Ⅰ study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist in adult patients with metastatic or unresectable solid tumors." (PMID: 34799399</a> 162516976 Felber, Barbara NIH - NCI NCI Felber, Barbara (NCI) 1 162517000 Pavlakis, George NIH - NCI NCI Pavlakis, George (NCI) 2 162517016 Karaliota, Sevasti NIH - Leidos Leidos Karaliota, Sevasti (Leidos) 3 162517106 Stellas, Dimitrios NIH - NCI NCI Stellas, Dimitrios (NCI) 4 162516976 Felber, Barbara NIH - NCI NCI Felber, Barbara (NCI) 1 162517000 Pavlakis, George NIH - NCI NCI Pavlakis, George (NCI) 2 162517016 Karaliota, Sevasti NIH - Leidos Leidos Karaliota, Sevasti (Leidos) 3 162517106 Stellas, Dimitrios NIH - NCI NCI Stellas, Dimitrios (NCI) 4 162516865 Synergistic Interactions For Improved Cancer Treatment E-174-2022-0 Filing authorized Leidos Biomedical Research, Inc, NCI 91814193 Freel, Rose rose.freel@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America rose.freel@nih.gov?subject=Web Inquiry on [TAB-5057] Synergistic Interactions for Improved Cancer Treatment&body=Please send me information about technology [TAB-5057] Synergistic Interactions for Improved Cancer Treatment.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Freel, Rose<br><a href="mailto:rose.freel@nih.gov?subject=Web Inquiry on [TAB-5057] Synergistic Interactions for Improved Cancer Treatment&body=Please send me information about technology [TAB-5057] Synergistic Interactions for Improved Cancer Treatment.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">rose.freel@nih.gov</a><br> 162516871 E-174-2022-0 E-174-2022-0-US-01 Synergistic Interactions For Improved Cancer Treatment PRV US 63/398,450 Expired US <br />Provisional (PRV) 63/398,450<br />Filed on 2022-08-16<br />Status: Expired 162516872 E-174-2022-0 E-174-2022-0-PC-01 Synergistic Interactions For Improved Cancer Treatment PCT Patent Cooperation Treaty PCT/US2023/072333 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2023/072333<br />Filed on 2023-08-16<br />Status: Expired 162516873 E-174-2022-0 E-174-2022-0-US-02 Synergistic Interactions For Improved Cancer Treatment National Stage US 19/101,938 Pending US <br />National Stage 19/101,938<br />Filed on 2025-02-07<br />Status: Pending 162516874 E-174-2022-0 E-174-2022-0-EP-01 Synergistic Interactions For Improved Cancer Treatment National Stage European Patent 23768747.0 Pending European Patent <br />National Stage 23768747.0<br />Filed on 2025-01-29<br />Status: Pending TAB-4445 147157740 Tissue Clamp for Repeated Opening and Closure of Incisions/Wounds NEI Collaboration, Ear, Nose, & Throat, Licensing, Medical Devices, Non-Medical Devices, Ophthalmology Collaboration Ear Nose & Throat Licensing Medical Devices Non-Medical Devices Ophthalmology Juan Amaral, Kapil Bharti, Steven Charles, Vladimir Khristov, Arvydas Maminishkis <p>Medical clamps currently available are not efficient nor are they sufficiently precise in closure and alignment of the edges of an incision or wound. Many available designs are difficult to use and handle, especially in situations where repeated opening and closure of an incision or wound is required. The functional short-comings of existing clamp designs may result in surgical complications, such as excess loss of fluids and pressure and hemostasis during some procedures. These functional deficiencies may increase the difficulty and expense of a surgery or altogether limit the ability to perform some procedures. </p> <p>This clamp design is functionally superior in its ease of use and capability to precisely keep in alignment incision or wound margins during repeated opening and closure.  As a result, a surgeon using this clamp is able to quickly open or close an incision or wound, as needed. This ability is a critical attribute where there is need to insert instruments, sometimes repeatedly, through an incision or wound. These superior functionalities reduce potential for fluid loss, which is especially critical in procedures such as intraocular surgeries where maintaining fluid balance avoids serious complications. Excessive loss of intraocular fluid balance during surgery can result in collapse of the eye, hemorrhage, and retinal detachment. This clamp design may improve outcomes of many surgeries and potentially enable new procedures presently too risky to undertake with current clamp devices. </p> <p>This invention is available for licensing and/or collaborative development partnerships.</p> <h2>Competitive Advantages:</h2> <ul><li>Maintains more precise alignment of the wound margins</li> <li>Permits easy reopening and entry into the incision or wound and repeated closure</li> <li>Reduces fluid loss from wound or incision, helps maintain hemostasis</li> <li>Guides and controls placement and depth of sutures</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Intraocular surgeries requiring incision in sclera</li> <li>Rapid closure of traumatic wounds</li> </ul> 2017-02-17 2025-04-22 2018-02-17 2026-03-18 2017-02-21 CLAMP, ocular surgery, sclera incision closure False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2018-02-17 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-251-2012 147164764 Khristov, Vladimir NIH - NEI Khristov, Vladimir 1 147164765 Charles, Steven NIH - NEI NEI Charles, Steven (NEI) 2 147164762 Amaral, Juan NIH - NEI NEI Amaral, Juan (NEI) 3 147164761 Maminishkis, Arvydas NIH - NEI NEI Maminishkis, Arvydas (NEI) 4 147164763 Bharti, Kapil NIH - NEI NEI Bharti, Kapil (NEI) 5 147164764 Khristov, Vladimir NIH - NEI Khristov, Vladimir 1 147164765 Charles, Steven NIH - NEI NEI Charles, Steven (NEI) 2 147164762 Amaral, Juan NIH - NEI NEI Amaral, Juan (NEI) 3 147164761 Maminishkis, Arvydas NIH - NEI NEI Maminishkis, Arvydas (NEI) 4 147164763 Bharti, Kapil NIH - NEI NEI Bharti, Kapil (NEI) 5 147158331 A Surgical Clamp To Gate Large Scleral Surgery Port And Suture Alignment Tool E-293-2016-0 Filing authorized National Eye Institute (NEI) 83703238 Fenn, Edward (Tedd) tedd.fenn@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-4445] Tissue Clamp for Repeated Opening and Closure of Incisions/Wounds&body=Please send me information about technology [TAB-4445] Tissue Clamp for Repeated Opening and Closure of Incisions/Wounds.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Fenn, Edward (Tedd)<br><a href="mailto:tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-4445] Tissue Clamp for Repeated Opening and Closure of Incisions/Wounds&body=Please send me information about technology [TAB-4445] Tissue Clamp for Repeated Opening and Closure of Incisions/Wounds.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">tedd.fenn@nih.gov</a><br> 147168964 E-293-2016-0 E-293-2016-0-US-01 Tissue Clamp and Implantation Method PRV US 62/419,804 Abandoned US <br />Provisional (PRV) 62/419,804<br />Filed on 2016-11-09<br />Status: Abandoned 147168965 E-293-2016-0 E-293-2016-0-PCT-02 TISSUE CLAMP AND IMPLANTATION METHOD PCT Patent Cooperation Treaty PCT/US2017/060672 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2017/060672<br />Filed on 2017-11-08<br />Status: Expired 147168966 E-293-2016-0 E-293-2016-0-US-03 TISSUE CLAMP AND IMPLANTATION METHOD National Stage US 11,717,298 16/348,855 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11717298 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11717298">11,717,298</a><br />Filed on 2019-05-09<br />Status: Issued 147168967 E-293-2016-0 E-293-2016-0-AU-04 TISSUE CLAMP AND IMPLANTATION METHOD National Stage Australia 2017359336 2017359336 Issued Australia <br />National Stage 2017359336<br />Filed on 2019-05-03<br />Status: Issued 147168968 E-293-2016-0 E-293-2016-0-CA-05 TISSUE CLAMP AND IMPLANTATION METHOD National Stage Canada 3043174 Pending Canada <br />National Stage 3043174<br />Filed on 2017-11-08<br />Status: Pending 147168969 E-293-2016-0 E-293-2016-0-EP-06 TISSUE CLAMP AND IMPLANTATION METHOD National Stage European Patent 17801272.0 Pending European Patent <br />National Stage 17801272.0<br />Filed on 2017-11-08<br />Status: Pending 147168970 E-293-2016-0 E-293-2016-0-JP-07 TISSUE CLAMP AND IMPLANTATION METHOD National Stage Japan 7069192 2019-545900 Issued Japan <br />National Stage 2019-545900<br />Filed on 2017-11-08<br />Status: Issued 147168971 E-293-2016-0 E-293-2016-0-JP-08 TISSUE CLAMP AND IMPLANTATION METHOD DIV Japan 7417655 2022-075904 Issued Japan <br />Divisional (DIV) 2022-075904<br />Filed on 2022-05-02<br />Status: Issued 147168972 E-293-2016-0 E-293-2016-0-US-02 TISSUE CLAMP AND IMPLANTATION METHOD DIV US 12,605,156 18/226,043 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12605156 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12605156">12,605,156</a><br />Filed on 2023-07-25<br />Status: Issued 147168973 E-293-2016-0 E-293-2016-0-AU-01 TISSUE CLAMP AND IMPLANTATION METHOD DIV Australia 2023203954 2023203954 Issued Australia <br />Divisional (DIV) 2023203954<br />Filed on 2023-06-22<br />Status: Issued 163972577 E-293-2016-0 E-293-2016-0-JP-09 TISSUE CLAMP AND IMPLANTATION METHOD DIV Japan 7642109 2024-000617 Issued Japan <br />Divisional (DIV) 2024-000617<br />Filed on 2024-01-05<br />Status: Issued 163972579 E-293-2016-0 E-293-2016-0-JP-01 TISSUE CLAMP AND IMPLANTATION METHOD DIV Japan Administratively Closed Japan <br />Divisional (DIV) None<br />Filed on None<br />Status: Administratively Closed 163972580 E-293-2016-0 E-293-2016-0-JP-10 TISSUE CLAMP AND IMPLANTATION METHOD DIV Japan 2025-027718 Pending Japan <br />Divisional (DIV) 2025-027718<br />Filed on 2025-02-25<br />Status: Pending 164039358 E-293-2016-0 E-293-2016-0-AU-02 TISSUE CLAMP AND IMPLANTATION METHOD DIV Australia 2025283670 Pending Australia <br />Divisional (DIV) 2025283670<br />Filed on 2025-12-22<br />Status: Pending 166474398 E-293-2016-0 E-293-2016-0-US-04 TISSUE CLAMP AND IMPLANTATION METHOD CON US 19/638,763 Pending US <br />Continuation (CON) 19/638,763<br />Filed on 2026-04-03<br />Status: Pending 147174735 CLAMP 147174737 ocular surgery 147174739 sclera incision closure TAB-5083 164393859 Identification and Characterization of HLA-A24 Agonist Epitopes of MUC1 Oncoprotein NCI Collaboration, Immunology, Licensing, Oncology, Therapeutics Collaboration Immunology Licensing Oncology Therapeutics Jeffrey Schlom, Kwong-Yok Tsang <h2>Summary:</h2> <p>The National Cancer Institute (NCI) seeks co-development partners and licensees for a human cytotoxic T lymphocyte agonist epitope from the C-terminal subunit of mucin 1 (MUC1-C), which can be used as a peptide, polypeptide (protein), in a cancer vaccine or T-cell targeted therapy to target many tumor types.</p> <h2>Description of Technology:</h2> <p>Many human carcinomas and hematologic malignancies overexpress mucin 1 (MUC1), a transmembrane glycoprotein composed of heterodimers formed by a large, N-terminal subunit (MUC1-N) and a smaller, C-terminal subunit (MUC1-C). In tumors, the MUC-1 heterodimer becomes abnormally hypoglycosylated &ndash; leading to the exposure of antigenic epitopes to the immune system. Aberrant MUC1 expression, and in particular its MUC1-C subunit, has been associated with poor prognosis and correlates with cancer metastasis &ndash; further establishing MUC1 as a target for cancer therapy.</p> <p>Inventors at the National Cancer Institute have identified epitopes of MUC1-C and enhancer agonist peptides that can activate cytotoxic T lymphocytes. These epitopes and enhancers may be suitable to develop into immunotherapies, such as cancer vaccines against various malignancies. In particular, the agonist peptides are expected to further enhance responses in patients when used in vaccines or T-cell therapy. The epitopes span the human leukocyte antigen HLA-A24 allele and facilitate recognition of MUC1-C in the context of HLA-A24.</p> <p>This technology is available for collaboration and licensing opportunities.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Treatment of MUC1-expressing cancers</li> <li>Cancer vaccine compositions</li> <li>MUC1-targeting epitopes and agonists</li> <li>Activation of cytotoxic T cell response as an enhanced cancer treatment</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Agonist epitopes can be incorporated into various vaccine platforms</li> <li>Agonist epitopes can be used for the ex vivo generation of human T cells</li> <li>Epitopes span the HLA-A24 allele and facilitate recognition and killing of human tumor cells in an MHC-restricted manner</li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for agonist epitopes of the MUC1-C oncoprotein. 2025-09-29 2025-09-29 2026-03-17 2025-09-29 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 72159138 Clinical Phase I 72159138 NCI 37470483 Website Abstract 164394007 Jochems C, et al. Identification and characterization of agonist epitopes of the MUC1-C oncoprotein. (PMID 24233342) https://pubmed.ncbi.nlm.nih.gov/24233342/ <a href="https://pubmed.ncbi.nlm.nih.gov/24233342/">Jochems C, et al. Identification and characterization of agonist epitopes of the MUC1-C oncoprotein. (PMID 24233342)</a> 164393890 Schlom, Jeffrey NIH - NCI NCI Schlom, Jeffrey (NCI) 1 164393911 Tsang, Kwong-Yok NIH - NCI NCI Tsang, Kwong-Yok (NCI) 2 164393890 Schlom, Jeffrey NIH - NCI NCI Schlom, Jeffrey (NCI) 1 164393911 Tsang, Kwong-Yok NIH - NCI NCI Tsang, Kwong-Yok (NCI) 2 164393862 Identification And Characterization Of HLA-A24 Agonist Epitopes Of MUC1-Oncoprotein E-520-2013-0 Filing authorized NCI 83687903 Pollack, Michael michael.pollack@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC michael.pollack@nih.gov?subject=Web Inquiry on [TAB-5083] Identification and Characterization of HLA-A24 Agonist Epitopes of MUC1 Oncoprotein&body=Please send me information about technology [TAB-5083] Identification and Characterization of HLA-A24 Agonist Epitopes of MUC1 Oncoprotein.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollack, Michael<br><a href="mailto:michael.pollack@nih.gov?subject=Web Inquiry on [TAB-5083] Identification and Characterization of HLA-A24 Agonist Epitopes of MUC1 Oncoprotein&body=Please send me information about technology [TAB-5083] Identification and Characterization of HLA-A24 Agonist Epitopes of MUC1 Oncoprotein.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">michael.pollack@nih.gov</a><br> 164411756 E-520-2013-0 E-520-2013-0-US-01 Identification And Characterization Of HLA-A24 Agonist Epitopes Of MUC1-Oncoprotein PRV US 61/894,482 Abandoned US <br />Provisional (PRV) 61/894,482<br />Filed on 2013-10-23<br />Status: Abandoned 164411761 E-520-2013-0 E-520-2013-0-PCT-02 HLA-A24 Agonist Epitopes Of MUC1-C Oncoprotein and Compositions and Methods of Use PCT Patent Cooperation Treaty PCT/US2014/061723 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2014/061723<br />Filed on 2014-10-22<br />Status: Expired 164412485 E-520-2013-0 E-520-2013-0-US-02 Identification And Characterization Of HLA-A24 Agonist Epitopes Of MUC1-Oncoprotein DIV US 11,732,017 17/240,260 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11732017 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11732017">11,732,017</a><br />Filed on 2021-04-26<br />Status: Issued 164412490 E-520-2013-0 E-520-2013-0-US-03 HLA-A24 AGONIST EPITOPES OF MUC1-C ONCOPROTEIN AND COMPOSITIONS AND METHODS OF USE CON US 12,325,731 18/344,242 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12325731 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12325731">12,325,731</a><br />Filed on 2023-06-29<br />Status: Issued 164412495 E-520-2013-0 E-520-2013-0-US-07 HLA-A24 Agonist Epitopes Of MUC1-Oncoprotein and Compositions and Methods of Use National Stage US 10,035,832 15/031,435 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10035832 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10035832">10,035,832</a><br />Filed on 2016-04-22<br />Status: Issued 164412622 E-520-2013-0 E-520-2013-0-US-18 Identification And Characterization Of HLA-A24 Agonist Epitopes Of MUC1-Oncoprotein DIV US 10,508,141 16/034,654 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10508141 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10508141">10,508,141</a><br />Filed on 2018-07-13<br />Status: Issued 164412777 E-520-2013-0 E-520-2013-0-US-19 Identification And Characterization Of HLA-A24 Agonist Epitopes Of MUC1-Oncoprotein DIV US 11,155,588 16/715,038 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11155588 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11155588">11,155,588</a><br />Filed on 2019-12-16<br />Status: Issued 166454591 E-520-2013-0 E-520-2013-0-CA-01 HLA-A24 Agonist Epitopes Of MUC1-C Oncoprotein and Compositions and Methods of Use DIV Canada 3205348 Pending Canada <br />Divisional (DIV) 3205348<br />Filed on 2023-06-30<br />Status: Pending TAB-3828 143328687 Antibodies With Potent and Broad Neutralizing Activity Against Antigenically Diverse and Highly Transmissible SARS-CoV-2 Variants NIAID Kevina Birungi-Huff, Sabrina Bush, Man Chen, Nicole Doria-Rose, Daniel Douek, Richard Koup, John Mascola, John Misasi, Maryam Musayev, Chaim Schramm, Wei Shi, Nancy Sullivan, Lingshu Wang, Eun Yang, Yi Zhang <p>&nbsp; &nbsp; &nbsp; &nbsp;Emergence of highly transmissible SARS-CoV-2 variants of concern that are resistant to current therapeutic antibodies highlights the need for continuing discovery of broadly reactive antibodies.<br /> &nbsp; &nbsp; &nbsp; &nbsp;Scientists at the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases have identified multiple antibodies that ultra-potently neutralize SARS-CoV-2, including the highly transmissible BA.4, BA.5, BQ.1.1 and XBB subvariants of Omicron, as shown in a pseudovirus neutralization assay. &nbsp;These antibodies target several epitopes in the receptor binding domain of the spike protein that are not impacted by spike mutations that knockout binding to other therapeutic antibodies, including, K417N, N439K, N440K, K444T, V445P, G446S, L452R, Y453F, N460K, S477N, E484A/K, F486S/V and Q498R. &nbsp;Several of the antibodies are able to simultaneously bind to the spike protein and are compatible for use in combination therapies.&nbsp;<br /> &nbsp; &nbsp; &nbsp; This technology is available for licensing for commercial development in accordance with 35 U.S.C. &sect; 209 and 37 CFR Part 404.<br /> &nbsp;</p> <ul> <li>Ultra-potent neutralization of currently identified SARS-CoV-2 variants including Omicron subvariants BQ.1.1 and XBB</li> <li>Mechanism of Action – Some antibodies directly bind to and block ACE2 receptor binding to the SARS CoV-2 spike protein </li> </ul> <ul> <li>Treatment of SARS-CoV-2 infection</li> </ul> 2023-01-31 2026-03-13 2026-03-13 2023-01-25 False False Preclinical Research True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 144856488 Misasi, John NIAID - VRC NIAID Misasi, John (NIAID) 1 144856504 Wang, Lingshu NIAID - VRC NIAID Wang, Lingshu (NIAID) 2 144856514 Mascola, John ModeX Therapeutics, Inc. NIAID Mascola, John (NIAID) 3 144856519 Douek, Daniel NIAID - DIR NIAID Douek, Daniel (NIAID) 4 144856550 Sullivan, Nancy NIAID - VRC NIAID Sullivan, Nancy (NIAID) 5 144856554 Koup, Richard NIAID - VRC NIAID Koup, Richard (NIAID) 6 144856562 Chen, Man NIAID - VRC NIAID Chen, Man (NIAID) 7 144856694 Shi, Wei NIAID - VRC NIAID Shi, Wei (NIAID) 8 144856761 Zhang, Yi NIAID - VRC NIAID Zhang, Yi (NIAID) 9 144856798 Yang, Eun NIAID - VRC NIAID Yang, Eun (NIAID) 10 144856823 Doria-Rose, Nicole NIAID - VRC NIAID Doria-Rose, Nicole (NIAID) 11 144856855 Schramm, Chaim NIAID - DIR NIAID Schramm, Chaim (NIAID) 12 144856968 Birungi-Huff, Kevina National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Birungi-Huff, Kevina (NIAID) 13 144857042 Bush, Sabrina NIAID - VRC NIAID Bush, Sabrina (NIAID) 14 144857200 Musayev, Maryam National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Musayev, Maryam (NIAID) 15 144856488 Misasi, John NIAID - VRC NIAID Misasi, John (NIAID) 1 144856504 Wang, Lingshu NIAID - VRC NIAID Wang, Lingshu (NIAID) 2 144856514 Mascola, John ModeX Therapeutics, Inc. NIAID Mascola, John (NIAID) 3 144856519 Douek, Daniel NIAID - DIR NIAID Douek, Daniel (NIAID) 4 144856550 Sullivan, Nancy NIAID - VRC NIAID Sullivan, Nancy (NIAID) 5 144856554 Koup, Richard NIAID - VRC NIAID Koup, Richard (NIAID) 6 144856562 Chen, Man NIAID - VRC NIAID Chen, Man (NIAID) 7 144856694 Shi, Wei NIAID - VRC NIAID Shi, Wei (NIAID) 8 144856761 Zhang, Yi NIAID - VRC NIAID Zhang, Yi (NIAID) 9 144856798 Yang, Eun NIAID - VRC NIAID Yang, Eun (NIAID) 10 144856823 Doria-Rose, Nicole NIAID - VRC NIAID Doria-Rose, Nicole (NIAID) 11 144856855 Schramm, Chaim NIAID - DIR NIAID Schramm, Chaim (NIAID) 12 144856968 Birungi-Huff, Kevina National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Birungi-Huff, Kevina (NIAID) 13 144857042 Bush, Sabrina NIAID - VRC NIAID Bush, Sabrina (NIAID) 14 144857200 Musayev, Maryam National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Musayev, Maryam (NIAID) 15 143328697 Broadly Neutralizing Antibodies Against SARS-CoV-2 Variants E-024-2023-0 Filing authorized National Institute of Allergy and Infectious Diseases (NIAID/NIH), National Institute of Allergy and Infectious Diseases (NIAID/NIH), NIAID, NIAID - VRC, NIH - NIAID 83682222 Bailey, Brian bbailey@mail.nih.gov
United States of America TTIPO bbailey@mail.nih.gov?subject=Web Inquiry on [TAB-3828] Antibodies With Potent and Broad Neutralizing Activity Against Antigenically Diverse and Highly Transmissible SARS-CoV-2 Variants&body=Please send me information about technology [TAB-3828] Antibodies With Potent and Broad Neutralizing Activity Against Antigenically Diverse and Highly Transmissible SARS-CoV-2 Variants. Bailey, Brian<br><a href="mailto:bbailey@mail.nih.gov?subject=Web Inquiry on [TAB-3828] Antibodies With Potent and Broad Neutralizing Activity Against Antigenically Diverse and Highly Transmissible SARS-CoV-2 Variants&body=Please send me information about technology [TAB-3828] Antibodies With Potent and Broad Neutralizing Activity Against Antigenically Diverse and Highly Transmissible SARS-CoV-2 Variants.">bbailey@mail.nih.gov</a><br> TAB-4148 147157431 Iodonium Analogs as Inhibitors of NADPH Oxidases and Other Flavin Dehydrogenases for the Treatment of Cancer and Inflammatory Conditions NCI Immunology, Licensing, Oncology, Therapeutics Immunology Licensing Oncology Therapeutics James Doroshow, Tafazzai Hossain, Jaimo Lu, Prabhakar Risbood, Krishnendu Roy <h2>Summary:</h2> <p>The National Cancer Institute (NCI) seeks licensees for the further development of a family of novel iodonium analogs as therapeutics for cancer and/or chronic inflammatory conditions.</p> <h2>Description of Technology:</h2> <p>Diverse human cancers like colorectal, pancreatic, ovarian, melanoma, and pre-cancers express NADPH oxidases (NOX) at high levels. Reactive oxygen species (ROS) produced from metabolic reactions catalyzed by NOX in tumors are essential to the tumor&rsquo;s growth and play a key role in inflammation-related conditions. Though drugs that inhibit ROS production by NOX could be effective against a variety of human cancers and chronic inflammation-related conditions, these types of drugs are not widely available.</p> <p>Investigators in NCI&rsquo;s Developmental Therapeutics Branch have discovered a family of novel analogs of diphenylene iodonium (DPI) and di-thienyl-iodonium (DTI) as inhibitors of NOX and other flavin dehydrogenases for the treatment and prevention of cancer and chronic inflammation-related conditions. Several of these inhibitors displayed in vitro potency that were superior to their parent molecules and were effective in inhibiting cell growth, ROS production, NOX1 mRNA expression, and NOX isoform activity in multiple cancer cell lines, including those representing acute lymphocytic leukemia, chronic myelogenous leukemia, myeloma, large cell immunoblastic lymphoma, non-small cell lung cancer, colon, melanoma, and renal cancer. In vivo validation of parent molecules DPI and DTI using human colon cancer xenografted mice yielded a statistically significant reduction in the average rate of tumor growth in mice administered either DPI or DTI compared to control mice.</p> <p>The National Cancer Institute (NCI) seeks licensees for the further development of these novel iodonium analogs as therapeutics for cancer and/or chronic inflammatory conditions.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Anti-cancer therapeutic for tumors that overexpress NOXs or depend on ROS to proliferate, such as colorectal, pancreatic, and ovarian cancers</li> <li>Therapeutic for chronic inflammatory conditions, such as diabetes, neuropathies, chronic pancreatitis, and inflammatory bowel disease</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Increased potency which may facilitate lower dosing concentrations needed</li> <li>Optimized specificity and selectivity which may lessen risk of off-target effects</li> <li>Potential to be first-in-class drug</li> </ul> Researchers at the NCI seek licensing for the further development a family of novel iodonium analogs as therapeutics for cancer and/or chronic inflammatory conditions. 2021-04-14 2026-02-23 2026-02-23 2026-03-09 2021-04-14 Diphenylene Iodonium, Di-thienyl-iodonium, Doroshow, DPI, DTI, Flavin Dehydrogenases, NADPH oxidases, NOX, Pre-cancerous Lesions, Reactive Oxygen Species, ROS False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2026-02-23 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147161921 Lu J, et al. Characterization of potent and selective iodonium-class inhibitors of NADPH oxidases. (PMID 28709950) https://pubmed.ncbi.nlm.nih.gov/28709950/ <a href="https://pubmed.ncbi.nlm.nih.gov/28709950/">Lu J, et al. Characterization of potent and selective iodonium-class inhibitors of NADPH oxidases. (PMID 28709950)</a> 147161959 Doroshow JH, et al. Effects of iodonium-class flavin dehydrogenase inhibitors on growth, reactive oxygen production, cell cycle progression, NADPH oxidase 1 levels, and gene expression in human colon cancer and xenografts. (PMID 23314043) https://pubmed.ncbi.nlm.nih.gov/23314043/ <a href="https://pubmed.ncbi.nlm.nih.gov/23314043/">Doroshow JH, et al. Effects of iodonium-class flavin dehydrogenase inhibitors on growth, reactive oxygen production, cell cycle progression, NADPH oxidase 1 levels, and gene expression in human colon cancer and xenografts. (PMID 23314043)</a> 147162346 Doroshow JH, et al. Antiproliferative mechanisms of action of the flavin dehydrogenase inhibitors diphenylene iodonium and di-2-thienyliodonium based on molecular profiling of the NCI-60 human tumor cell panel. (PMID 22305747) https://pubmed.ncbi.nlm.nih.gov/22305747/ <a href="https://pubmed.ncbi.nlm.nih.gov/22305747/">Doroshow JH, et al. Antiproliferative mechanisms of action of the flavin dehydrogenase inhibitors diphenylene iodonium and di-2-thienyliodonium based on molecular profiling of the NCI-60 human tumor cell panel. (PMID 22305747)</a> 147163689 Doroshow, James NIH - NCI NCI Doroshow, James (NCI) 1 147163688 Risbood, Prabhakar NIH - NCI NCI Risbood, Prabhakar (NCI) 2 147163691 Lu, Jaimo NIH - NCI NCI Lu, Jaimo (NCI) 3 147163690 Roy, Krishnendu NIH - NCI NCI Roy, Krishnendu (NCI) 4 147163692 Hossain, Tafazzai Starks Associates, Inc. Hossain, Tafazzai 5 147163689 Doroshow, James NIH - NCI NCI Doroshow, James (NCI) 1 147163688 Risbood, Prabhakar NIH - NCI NCI Risbood, Prabhakar (NCI) 2 147163691 Lu, Jaimo NIH - NCI NCI Lu, Jaimo (NCI) 3 147163690 Roy, Krishnendu NIH - NCI NCI Roy, Krishnendu (NCI) 4 147163692 Hossain, Tafazzai Starks Associates, Inc. Hossain, Tafazzai 5 147158021 Development Of Analogs Of Diphenylene Iodonium And Di-thienyl-iodonium As Inhibitors Of NADPH Oxidases And Other Flavin Dehydrogenases For The Treatment And Prevention Of Cancer And Inflammation-related Conditions E-116-2014-0 Filing authorized NCI, Starks Associates, Inc. 91826910 McCrary, Michaela michaela.mccrary@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America michaela.mccrary@nih.gov?subject=Web Inquiry on [TAB-4148] Iodonium Analogs as Inhibitors of NADPH Oxidases and Other Flavin Dehydrogenases for the Treatment of Cancer and Inflammatory Conditions&body=Please send me information about technology [TAB-4148] Iodonium Analogs as Inhibitors of NADPH Oxidases and Other Flavin Dehydrogenases for the Treatment of Cancer and Inflammatory Conditions.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov McCrary, Michaela<br><a href="mailto:michaela.mccrary@nih.gov?subject=Web Inquiry on [TAB-4148] Iodonium Analogs as Inhibitors of NADPH Oxidases and Other Flavin Dehydrogenases for the Treatment of Cancer and Inflammatory Conditions&body=Please send me information about technology [TAB-4148] Iodonium Analogs as Inhibitors of NADPH Oxidases and Other Flavin Dehydrogenases for the Treatment of Cancer and Inflammatory Conditions.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">michaela.mccrary@nih.gov</a><br> 147166923 E-116-2014-0 E-116-2014-0-US-01 Iodonium Analogs As Inhibitors Of NADPH Oxidases And Other Flavin Dehydrogenases; Formulations Thereof; And Uses Thereof PRV US 61/976,362 Abandoned US <br />Provisional (PRV) 61/976,362<br />Filed on 2014-04-07<br />Status: Abandoned 147166924 E-116-2014-0 E-116-2014-0-PCT-02 IODONIUM ANALOGS AS INHIBITORS OF NADPH OXIDASES AND OTHER FLAVIN DEHYDROGENASES; FORMULATIONS THEREOF; AND USES THEREOF PCT Patent Cooperation Treaty PCT/US2015/024445 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2015/024445<br />Filed on 2015-04-06<br />Status: Expired 147166925 E-116-2014-0 E-116-2014-0-EP-03 IODONIUM ANALOGS AS INHIBITORS OF NADPH OXIDASES AND OTHER FLAVIN DEHYDROGENASES; FORMULATIONS THEREOF; AND USES THEREOF National Stage European Patent 3129102 15717363.4 Issued European Patent <br />National Stage 15717363.4<br />Filed on 2015-04-06<br />Status: Issued 147166926 E-116-2014-0 E-116-2014-0-US-04 Iodonium Analogs as Inhibitors of NADPH Oxidases and Other Flavin Dehydrogenases; Formulations Thereof; and Uses Thereof National Stage US 10,131,659 15/302,566 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10131659 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10131659">10,131,659</a><br />Filed on 2016-10-07<br />Status: Issued 147166927 E-116-2014-0 E-116-2014-0-US-05 IODONIUM ANALOGS AS INHIBITORS OF NADPH OXIDASES AND OTHER FLAVIN DEHYDROGENASES; FORMULATIONS THEREOF; AND USES THEREOF CON US 10,738,047 16/160,599 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10738047 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10738047">10,738,047</a><br />Filed on 2018-10-15<br />Status: Issued 147171769 Diphenylene Iodonium 147171770 Di-thienyl-iodonium 147171772 Doroshow 147171774 DPI 147171776 DTI 147171778 Flavin Dehydrogenases 147171780 NADPH oxidases 147171782 NOX 147171784 Pre-cancerous Lesions 147171785 Reactive Oxygen Species 147171786 ROS TAB-3176 114097126 Human CC Chemokine Receptor CX3CR1 / CMKBRL1 cDNA NIAID Licensing, Research Materials Licensing Research Materials Philip Murphy A plasmid encodes human CC chemokine receptor CX3CR1/CMKBRL1 as described in DNA Cell Biol. 1995 Aug;14(8):673-80, and developed in the laboratory of Philip M. Murphy at the National Institute of Allergy and Infectious Diseases. <ul> <li>Speed up product development with NIH developed material that has already been tested and validated.</li> </ul> <ul> <li>A research material that can be used in the development of assays, validation of products or in quality control.</li> </ul> Research Material – Patent protection is not being pursued for this technology. (IC Reference No. 1948-257) 2022-03-08 2026-03-02 2026-03-02 2017-12-04 cc, CC-CMKBRL1, cDNA, Chemokine, Human, PLASMID, RECEPTOR, RM, WIXXXX False True True NIHTT 37470483 Website Abstract 114171740 Combadiere C, et al. https://www.ncbi.nlm.nih.gov/pubmed/7646814 <a href="https://www.ncbi.nlm.nih.gov/pubmed/7646814">Combadiere C, et al.</a> 114107759 Murphy, Philip NIAID - DIR NIAID Murphy, Philip (NIAID) 1 114107759 Murphy, Philip NIAID - DIR NIAID Murphy, Philip (NIAID) 1 114101477 Human CC Chemokine Receptor CC-CMKBRL1 cDNA B-037-1995-6 Research Material NIAID 83738793 Taylor-Mulneix, Dawn dawn.taylor-mulneix@nih.gov
United States of America dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-3176] Human CC Chemokine Receptor CX3CR1 / CMKBRL1 cDNA&body=Please send me information about technology [TAB-3176] Human CC Chemokine Receptor CX3CR1 / CMKBRL1 cDNA. Taylor-Mulneix, Dawn<br><a href="mailto:dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-3176] Human CC Chemokine Receptor CX3CR1 / CMKBRL1 cDNA&body=Please send me information about technology [TAB-3176] Human CC Chemokine Receptor CX3CR1 / CMKBRL1 cDNA.">dawn.taylor-mulneix@nih.gov</a><br> 114126810 WIXXXX 114149570 Human 114149571 cc 114149572 Chemokine 114149573 RECEPTOR 114149574 CC-CMKBRL1 114149575 cDNA 114149576 PLASMID 114149598 RM TAB-3177 114097119 CXCR1 - Human IL-8 Receptor cDNA NIAID Licensing, Oncology, Research Materials, Therapeutics Licensing Oncology Research Materials Therapeutics Sunil Ahuja, Philip Murphy A plasmid encodes human interleukin-8 (IL-8) receptor CXCR1. IL-8 is a chemo-attractant cytokine that attracts and activates neutrophils in inflammatory regions. <ul> <li>Speed up product development with NIH developed material that has already been tested and validated.</li> </ul> <ul> <li>A research material that can be used in the development of assays, validation of products or in quality control.</li> </ul> Research Material – Patent protection is not being pursued for this technology. (IC Reference No. 1948-006) 2022-03-08 2026-03-02 2026-03-02 2017-12-04 CB3AXX, CC1XXX, cDNA, CXCRI, Hu, Human, IL-8, IL-8A, Listed LPM Ano as of 4/15/2015, PLASMID, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, RECEPTOR, RM, Subtype, WIXXXX False True True NIHTT 37470483 Website Abstract 114107016 Ahuja, Sunil NIAID - DIR Ahuja, Sunil 0 114107758 Murphy, Philip NIAID - DIR NIAID Murphy, Philip (NIAID) 1 114107758 Murphy, Philip NIAID - DIR NIAID Murphy, Philip (NIAID) 1 114107016 Ahuja, Sunil NIAID - DIR Ahuja, Sunil 0 114102339 CXCRI (Hu IL-8A) - Human IL-8 (A Subtype) Receptor cDNA B-004-1995-0 Research Material NIAID 83738793 Taylor-Mulneix, Dawn dawn.taylor-mulneix@nih.gov
United States of America dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-3177] CXCR1 - Human IL-8 Receptor cDNA&body=Please send me information about technology [TAB-3177] CXCR1 - Human IL-8 Receptor cDNA. Taylor-Mulneix, Dawn<br><a href="mailto:dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-3177] CXCR1 - Human IL-8 Receptor cDNA&body=Please send me information about technology [TAB-3177] CXCR1 - Human IL-8 Receptor cDNA.">dawn.taylor-mulneix@nih.gov</a><br> 114127493 CB3AXX 114127494 CC1XXX 114127495 WIXXXX 114149577 CXCRI 114149578 Hu 114149579 IL-8A 114149580 Human 114149581 IL-8 114149582 Subtype 114149583 RECEPTOR 114149584 cDNA 114149585 Listed LPM Ano as of 4/15/2015 114149586 Pre LPM working set 20150418 114149587 Post LPM Assignment Set 20150420 114149588 PLASMID 114149599 RM TAB-3183 114097117 Human CCR3 cDNA NIAID Diagnostics, Infectious Disease, Licensing, Research Materials Diagnostics Infectious Disease Licensing Research Materials Sunil Ahuja, Christophe Combadiere, Philip Murphy, James Pease A plasmid encodes human C-C motif chemokine receptor 3 (CCR3). It may contribute to the accumulation and activation of eosinophil and other inflammatory cells in the allergic airway. <ul> <li>Speed up product development with NIH developed material that has already been tested and validated.</li> </ul> <ul> <li>A research material that can be used in the development of assays, validation of products or in quality control.</li> </ul> Research Material – Patent protection is not being pursued for this technology. (IC Reference No. 1948-196) 2022-03-08 2026-03-02 2026-03-02 2017-12-04 4, CCR3, CCR3;, cDNA, Cell, DA4AXX, DE4-CCR3, Expressing, Human, Line, Listed LPM Ano as of 4/15/2015, Murine, PLASMID, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, RM, VLXXXX, WIXXXX False True True NIHTT 37470483 Website Abstract 114109426 Ahuja, Sunil NIAID - DIR Ahuja, Sunil 0 114109427 Combadiere, Christophe NIAID - DIR Combadiere, Christophe 0 114109428 Pease, James NIAID - DIR Pease, James 0 114109425 Murphy, Philip NIAID - DIR NIAID Murphy, Philip (NIAID) 1 114109425 Murphy, Philip NIAID - DIR NIAID Murphy, Philip (NIAID) 1 114109426 Ahuja, Sunil NIAID - DIR Ahuja, Sunil 0 114109427 Combadiere, Christophe NIAID - DIR Combadiere, Christophe 0 114109428 Pease, James NIAID - DIR Pease, James 0 114102345 cDNA for human CCR3; cDNA for murine CCR3; and cell line expressing human CCR3 (4 DE4-CCR3 cell line) B-009-1998-0 Research Material NIAID 83738793 Taylor-Mulneix, Dawn dawn.taylor-mulneix@nih.gov
United States of America dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-3183] Human CCR3 cDNA&body=Please send me information about technology [TAB-3183] Human CCR3 cDNA. Taylor-Mulneix, Dawn<br><a href="mailto:dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-3183] Human CCR3 cDNA&body=Please send me information about technology [TAB-3183] Human CCR3 cDNA.">dawn.taylor-mulneix@nih.gov</a><br> 114127507 DA4AXX 114127508 VLXXXX 114127509 WIXXXX 114149652 cDNA 114149653 Human 114149654 CCR3; 114149655 Murine 114149656 Cell 114149657 Line 114149658 Expressing 114149659 CCR3 114149660 4 114149661 DE4-CCR3 114149662 Listed LPM Ano as of 4/15/2015 114149663 Pre LPM working set 20150418 114149664 Post LPM Assignment Set 20150420 114149665 PLASMID 114149666 RM TAB-3182 114097116 Human CCR2 cDNA NIAID Licensing, Research Materials Licensing Research Materials Sunil Ahuja, Christophe Combadiere, Philip Murphy, James Pease A plasmid encodes human C-C chemokine receptor type 2 (CCR2). CCR2 play important roles in the recruitment of monocytes/macrophages and T cells. <ul> <li>Speed up product development with NIH developed material that has already been tested and validated.</li> </ul> <ul> <li>A research material that can be used in the development of assays, validation of products or in quality control.</li> </ul> Research Material – Patent protection is not being pursued for this technology. (IC Reference No. 1948-195) 2022-03-08 2026-03-02 2026-03-02 2017-12-04 cc, CCR2, cDNA, Cell, Chemokine, Cloning, EOSINOPHIL, Expression, FUNCTIONAL, Human, Including, line., Listed LPM Ano as of 4/15/2015, PLASMID, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, RECEPTOR, RM, WIXXXX False True True NIHTT 37470483 Website Abstract 114109422 Ahuja, Sunil NIAID - DIR Ahuja, Sunil 0 114109423 Combadiere, Christophe NIAID - DIR Combadiere, Christophe 0 114109424 Pease, James NIAID - DIR Pease, James 0 114109421 Murphy, Philip NIAID - DIR NIAID Murphy, Philip (NIAID) 1 114109421 Murphy, Philip NIAID - DIR NIAID Murphy, Philip (NIAID) 1 114109422 Ahuja, Sunil NIAID - DIR Ahuja, Sunil 0 114109423 Combadiere, Christophe NIAID - DIR Combadiere, Christophe 0 114109424 Pease, James NIAID - DIR Pease, James 0 114102344 CCR2 Cloning and Functional Expression of a Human Eosinophil CC Chemokine Receptor, including cDNA and cell line. B-008-1998-0 Research Material NIAID 83738793 Taylor-Mulneix, Dawn dawn.taylor-mulneix@nih.gov
United States of America dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-3182] Human CCR2 cDNA&body=Please send me information about technology [TAB-3182] Human CCR2 cDNA. Taylor-Mulneix, Dawn<br><a href="mailto:dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-3182] Human CCR2 cDNA&body=Please send me information about technology [TAB-3182] Human CCR2 cDNA.">dawn.taylor-mulneix@nih.gov</a><br> 114127506 WIXXXX 114149634 CCR2 114149635 Cloning 114149636 FUNCTIONAL 114149637 Expression 114149638 Human 114149639 EOSINOPHIL 114149640 cc 114149641 Chemokine 114149642 RECEPTOR 114149643 Including 114149644 cDNA 114149645 Cell 114149646 line. 114149647 Listed LPM Ano as of 4/15/2015 114149648 Pre LPM working set 20150418 114149649 Post LPM Assignment Set 20150420 114149650 PLASMID 114149651 RM TAB-3180 114097113 Human FPRL1 / FPR2 cDNA NIAID Licensing, Neurology, Research Materials Licensing Neurology Research Materials Philip Murphy A plasmid encodes human formyl peptide receptor-like 1 (FPRL1/FPR2). <ul> <li>Speed up product development with NIH developed material that has already been tested and validated.</li> </ul> <ul> <li>A research material that can be used in the development of assays, validation of products or in quality control.</li> </ul> Research Material – Patent protection is not being pursued for this technology. (IC Reference No. 1948-017) 2022-03-08 2026-03-02 2026-03-02 2017-12-04 cDNA, FPRL1, Human, Listed LPM Ano as of 4/15/2015, NC3XXX, PLASMID, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, RECEPTOR, RM, VEXXXX, WIXXXX False True True NIHTT 37470483 Website Abstract 114109412 Murphy, Philip NIAID - DIR NIAID Murphy, Philip (NIAID) 1 114109412 Murphy, Philip NIAID - DIR NIAID Murphy, Philip (NIAID) 1 114102342 Human FPRL1 Receptor cDNA B-008-1995-0 Research Material NIAID 83738793 Taylor-Mulneix, Dawn dawn.taylor-mulneix@nih.gov
United States of America dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-3180] Human FPRL1 / FPR2 cDNA&body=Please send me information about technology [TAB-3180] Human FPRL1 / FPR2 cDNA. Taylor-Mulneix, Dawn<br><a href="mailto:dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-3180] Human FPRL1 / FPR2 cDNA&body=Please send me information about technology [TAB-3180] Human FPRL1 / FPR2 cDNA.">dawn.taylor-mulneix@nih.gov</a><br> 114127500 NC3XXX 114127501 WIXXXX 114127502 VEXXXX 114149609 Human 114149610 FPRL1 114149611 RECEPTOR 114149612 cDNA 114149613 Listed LPM Ano as of 4/15/2015 114149614 Pre LPM working set 20150418 114149615 Post LPM Assignment Set 20150420 114149616 PLASMID 114149617 RM TAB-3179 114097112 Human fMLP Receptor / FPR cDNA NIAID Licensing, Neurology, Research Materials Licensing Neurology Research Materials Philip Murphy A plasmid encodes human fMLP receptor. Formyl peptide receptor (FPR, fMLP receptor) is a G protein-coupled receptor and mediates anti-inflammatory reactions in human neutrophils and other tissues. <ul> <li>Speed up product development with NIH developed material that has already been tested and validated.</li> </ul> <ul> <li>A research material that can be used in the development of assays, validation of products or in quality control.</li> </ul> Research Material – Patent protection is not being pursued for this technology. (IC Reference No. 1948-013) 2022-03-08 2026-03-02 2026-03-02 2017-12-04 cDNA, FMLP, Human, Listed LPM Ano as of 4/15/2015, NC3XXX, PLASMID, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, RECEPTOR, RM, VEXXXX, WIXXXX False True True NIHTT 37470483 Website Abstract 114109411 Murphy, Philip NIAID - DIR NIAID Murphy, Philip (NIAID) 1 114109411 Murphy, Philip NIAID - DIR NIAID Murphy, Philip (NIAID) 1 114102341 Human FMLP Receptor cDNA B-007-1995-0 Research Material NIAID 83738793 Taylor-Mulneix, Dawn dawn.taylor-mulneix@nih.gov
United States of America dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-3179] Human fMLP Receptor / FPR cDNA&body=Please send me information about technology [TAB-3179] Human fMLP Receptor / FPR cDNA. Taylor-Mulneix, Dawn<br><a href="mailto:dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-3179] Human fMLP Receptor / FPR cDNA&body=Please send me information about technology [TAB-3179] Human fMLP Receptor / FPR cDNA.">dawn.taylor-mulneix@nih.gov</a><br> 114127497 NC3XXX 114127498 VEXXXX 114127499 WIXXXX 114149600 Human 114149601 FMLP 114149602 RECEPTOR 114149603 cDNA 114149604 Listed LPM Ano as of 4/15/2015 114149605 Pre LPM working set 20150418 114149606 Post LPM Assignment Set 20150420 114149607 PLASMID 114149608 RM TAB-2917 114097074 CXCR4 Reduction Leads to Enhancement of Engraftment of Hematopoietic Stem Cells NIAID Cardiology, Dental, Endocrinology, Infectious Disease, Licensing, Oncology, Ophthalmology, Therapeutics Cardiology Dental Endocrinology Infectious Disease Licensing Oncology Ophthalmology Therapeutics Ji-Liang Gao, Qian Liu, Harry Malech, David McDermott, Philip Murphy, Marie Siwiki Methods of enhancing engraftment of donor hematopoietic stem cells (HSCs) by reducing expression or activity of CXCR4 in HSCs is described. HSC are the only cells in the bone marrow that are both pluripotent and long lived. Bone marrow transplantation (BMT) using HSC is an increasingly common medical therapy for severe hematologic cancers and primary hematologic immunodeficiencies. However, for significant HSC engraftment to occur there must usually be pre-transplant conditioning with either irradiation or chemotherapy or both. The technology described herein shows that it is possible to replace HSC without the need for pre-transplant conditioning regimen. It is known that the chemokine receptor CXCR4 plays a critical role in HSC homing to the bone marrow and in HSC quiescence. The inventors have identified a patient in which one copy of CXCR4 had been deleted in a somatic mutation of an HSC and this cell had clonally repopulated the bone marrow. This led to experiments in mice where the inventors clearly demonstrated in a bone marrow transplantation model, that donor cells with a single copy of the Cxcr4 gene repopulate recipient mice much faster and last much longer than donor cells having two copies of the Cxcr4 gene. This technology which shows that HSCs with one copy of the CXCR4 gene have a durable selective advantage in bone marrow repopulation can solve the problem frequently encountered in gene therapy, i.e., the short-lived nature of gene-corrected cells, by utilizing recently discovered gene editing methods that can be used to delete one copy of CXCR4 gene in gene-corrected cells. <ul> <li>This technology potentially facilitates HSC transplantation without the need of radiation or chemotherapy conditioning.</li> <li>This technology may uniquely overcome a major hurdle limiting all gene therapy applications, namely the failure to correct the gene defect over a long time.</li> </ul> <ul> <li>Improvement of engraftment in gene therapy protocols and in HSC transplantation.</li> <li>Improved bone marrow transplantation, enhancing the efficiency and durability of donor cell repopulation.</li> </ul> 2022-03-08 2026-03-02 2026-03-02 2015-03-20 Cell, COPY, CXCR4, Durably, ENGRAFTMENT, Enhanced, hematopoietic, ONE, SILENCING, Stem, VCXXXX, VPXXXX, WJXXXX, XEXXXX, YAXXXX, YBXXXX, YCXXXX False True <ul> <li>Early-stage</li> <li>In vitro data available</li> <li>In vivo data available (animal)</li> </ul> True 52406768 Discovery 52406768 NIHTT 37470483 Website Abstract 114172239 McDermott DH, et al. http://www.ncbi.nlm.nih.gov/pubmed/25662009 <a href="http://www.ncbi.nlm.nih.gov/pubmed/25662009">McDermott DH, et al.</a> 114108986 Murphy, Philip NIAID - DIR NIAID Murphy, Philip (NIAID) 0 114108987 McDermott, David NIAID - DIR NIAID McDermott, David (NIAID) 0 114108988 Siwiki, Marie NIAID - DIR NIAID Siwiki, Marie (NIAID) 0 114108989 Malech, Harry NIAID - DIR NIAID Malech, Harry (NIAID) 0 114108990 Liu, Qian NIAID - DIR NIAID Liu, Qian (NIAID) 0 114108985 Gao, Ji-Liang NIAID - DIR NIAID Gao, Ji-Liang (NIAID) 1 114108985 Gao, Ji-Liang NIAID - DIR NIAID Gao, Ji-Liang (NIAID) 1 114108986 Murphy, Philip NIAID - DIR NIAID Murphy, Philip (NIAID) 0 114108987 McDermott, David NIAID - DIR NIAID McDermott, David (NIAID) 0 114108988 Siwiki, Marie NIAID - DIR NIAID Siwiki, Marie (NIAID) 0 114108989 Malech, Harry NIAID - DIR NIAID Malech, Harry (NIAID) 0 114108990 Liu, Qian NIAID - DIR NIAID Liu, Qian (NIAID) 0 114102255 Hematopoietic Stem Cell Engraftment Can Be Durably Enhanced By Silencing One Copy Of CXCR4 E-173-2014-0 Filing authorized NIAID 83738793 Taylor-Mulneix, Dawn dawn.taylor-mulneix@nih.gov
United States of America dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-2917] CXCR4 Reduction Leads to Enhancement of Engraftment of Hematopoietic Stem Cells&body=Please send me information about technology [TAB-2917] CXCR4 Reduction Leads to Enhancement of Engraftment of Hematopoietic Stem Cells. Taylor-Mulneix, Dawn<br><a href="mailto:dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-2917] CXCR4 Reduction Leads to Enhancement of Engraftment of Hematopoietic Stem Cells&body=Please send me information about technology [TAB-2917] CXCR4 Reduction Leads to Enhancement of Engraftment of Hematopoietic Stem Cells.">dawn.taylor-mulneix@nih.gov</a><br> 114162342 E-173-2014-0 E-173-2014-0-US-03 Reducing CXCR4 Expression and/or Function to Enchance Engraftment of Hematopoietic Stem Cells National Stage US 11,278,572 15/324,219 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11278572 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11278572">11,278,572</a><br />Filed on 2017-01-05<br />Status: Issued 114168101 E-173-2014-0 E-173-2014-0-US-01 REDUCING CXCR4 EXPRESSION AND/OR FUNCTION TO ENHANCE ENGRAFTMENT OF HEMATOPOIETIC STEM CELLS PRV US 62/026,138 Abandoned US <br />Provisional (PRV) 62/026,138<br />Filed on 2014-07-18<br />Status: Abandoned 114168173 E-173-2014-0 E-173-2014-0-PCT-02 REDUCING CXCR4 EXPRESSION AND/OR FUNCTION TO ENHANCE ENGRAFTMENT OF HEMATOPOIETIC STEM CELLS PCT Patent Cooperation Treaty PCT/US2015/040954 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2015/040954<br />Filed on 2015-07-17<br />Status: Expired 114126882 VCXXXX 114126883 VPXXXX 114126884 WJXXXX 114126885 XEXXXX 114126886 YAXXXX 114126887 YBXXXX 114126888 YCXXXX 114148130 hematopoietic 114148131 Stem 114148132 Cell 114148133 ENGRAFTMENT 114148134 Durably 114148135 Enhanced 114148136 SILENCING 114148137 ONE 114148138 COPY 114148139 CXCR4 TAB-2173 114096388 Mouse Anti-Mouse CXCL9 (Mig) Monoclonal Antibodies NIAID Diagnostics, Immunology, Licensing, Oncology, Research Materials, Therapeutics Diagnostics Immunology Licensing Oncology Research Materials Therapeutics Joshua Farber, Hongwei Zhang This technology describes monoclonal antibodies against mouse chemokine (C-X-C motif) ligand 9 (CXCL9), also known as Monokine induced by gamma interferon (Mig). CXCL9 is a secreted protein that functions to attract white cells and increased expression of CXCL9 has been linked to several diseases. The inventors at the NIH generated over 100 anti-mouse CXCL9 antibodies from a CLXL9/Mig knockout mouse and further characterized several antibodies to show neutralization of CXCL9. As such, these antibodies could be used to measure concentrations of mouse CLXL9 in laboratory samples and block the activity of CXCL9 in injected mice. These antibodies are suitable for ELISA and Western blot. The antibodies have not been tested in flow cytometry or immunohistochemistry, but may also be useful for these applications. Can be used in mice without eliciting endogenous antibodies reacting against the injected anti-CXCL9. <ul> <li>ELISA assays for detection and measurement of CXCL9.</li> <li>Neutralization of CXCL9 activity in mouse models and <i>in vitro</i> assays to study the role of CXCL9 in immune response and disease.</li> </ul> Research Tool -- Patent protection is not being pursued for this technology. Available for licensing. 2022-03-08 2026-03-02 2026-03-02 2010-10-12 antibodies, Anti-mouse, AXXXXX, CCXXXX, CXCL9, CXXXXX, IA3XXX, IAXXXX, IDXXXX, IXXXXX, MIG, monoclonal, Mouse False True The technology is currently in the pre-clinical stage of development. True NIHTT 37470483 Website Abstract 114107011 Zhang, Hongwei NIAID - DIR NIAID Zhang, Hongwei (NIAID) 0 114107010 Farber, Joshua NIAID - DIR NIAID Farber, Joshua (NIAID) 1 114107010 Farber, Joshua NIAID - DIR NIAID Farber, Joshua (NIAID) 1 114107011 Zhang, Hongwei NIAID - DIR NIAID Zhang, Hongwei (NIAID) 0 114101474 Mouse Anti-Mouse CXCL9 (Mig) Monoclonal Antibodies E-198-2009-0 Research Material NIAID 83738793 Taylor-Mulneix, Dawn dawn.taylor-mulneix@nih.gov
United States of America dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-2173] Mouse Anti-Mouse CXCL9 (Mig) Monoclonal Antibodies&body=Please send me information about technology [TAB-2173] Mouse Anti-Mouse CXCL9 (Mig) Monoclonal Antibodies. Taylor-Mulneix, Dawn<br><a href="mailto:dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-2173] Mouse Anti-Mouse CXCL9 (Mig) Monoclonal Antibodies&body=Please send me information about technology [TAB-2173] Mouse Anti-Mouse CXCL9 (Mig) Monoclonal Antibodies.">dawn.taylor-mulneix@nih.gov</a><br> 114121620 AXXXXX 114121621 CXXXXX 114121622 CCXXXX 114121623 IA3XXX 114121624 IDXXXX 114121625 IXXXXX 114121626 IAXXXX 114140577 CXCL9 114140578 Anti-mouse 114140579 Mouse 114140580 MIG 114140581 monoclonal 114140582 antibodies TAB-1973 114096193 A Novel System for Producing Infectious Hepatitis C Virus (HCV) Virions and Development of a Novel Reporter System for Studying HCV Entry NIAID Collaboration, Infectious Disease, Licensing, Therapeutics Collaboration Infectious Disease Licensing Therapeutics Edward Berger, Bertrand Saunier, Miriam Triyatni HCV has infected an estimated 3% of the world population in whom viral infection persists for more than two third of the cases, often resulting in life-threatening complications. The standard of care (pegylated interferon alpha-2 plus ribavirin) is efficient in only 50% of treated patients, costly and has numerous side effects. In addition, viral resistance to newly developed drugs -- targeting viral protease or RNA polymerase -- has been described, but no vaccine is yet available. The difficulty in developing HCV vaccines is largely due to the broad sequence-diversity displayed by HCV, the frequent occurrence of viral mutations within immunogenic epitopes in vivo, and the lack of proper standard/definition for viral neutralization. <br><br> One alternative strategy in HCV-vaccine or drug development comprises measuring viral entry, the first step in viral infection. Such measurements are limited by the available screening systems, in that, HCV pseudo-typed retroviral particles have a different envelope conformation and contain foreign components that are likely to interfere with the measured HCV entry. Moreover, HCV lab strain requires intensive replication for its in vitro production, resulting in numerous mutations that impede development of convenient screening tools. <br><br> The inventors have developed a system for generating infectious HCV particles and HCV-like particles (HCV-LP) suitable for a qualitative single-cycle entry assay, completely independent of HCV replication. To adapt this system as a single assay to study HCV-LP entry, HCV non-structural genes were replaced with a heterologous gene that upon viral-entry triggers firefly luciferase and EGFP expressions in target as well as non-permissive cells. The pretreatment of HCV-replication permissive HuH-7.5 cells with siRNA targeting HCV candidate receptors inhibited viral entry. These new systems enable production of authentic HCV infectious particles as well as HCV-LPs suitable for single-cycle entry assays adaptable to high throughput screening. <ul> <li>These systems do not use pseudo-typed HCV particles, i.e. no foreign proteins present in the virus particles.</li> <li>Particle production in the producing cells is independent of HCV RNA replication, hence avoids the occurrence of adaptive mutations that could be detrimental for virus particle's infectivity or could alter tags or nucleotide sequences incorporated in the viral genome.</li> <li>These systems are not specifically dedicated to HCV of a particular genotype, i.e. they can be used to generate HCV particles of various genotypes without requiring the use of chimeras.</li> </ul> <ul> <li>Screening a library expressed in non-permissive cells for identifying new HCV candidate receptor(s) or entry molecule(s).</li> <li>Testing drugs or compounds inhibiting HCV particle entry or viral genome uncoating, or neutralizing antibodies in target cells.</li> <li>Testing drugs or compounds that inhibit virus assembly, maturation and/or egress, or genome packaging, in producer cells.</li> <li>Incorporating a 'tag' in the genome of various HCV genotypes to more conveniently study virus spreading and dissemination in an organ, tissue and/or small animal model.</li> <li>Enhancing immune response in patients: one way to trigger high level anti-HCV immunity is by isolating antigen-presenting cells from patients and incubating them with HCV particles produced with this system using replication-defective viral genome (with or without an immunogenic tag and/or in combination with other viral epitopes) and eventually re-inject their primed cells to the patients.</li> </ul> The NIAID OTD is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize a novel system for producing infectious HCV virions and developing a reporter system for studying HCV entry. Please contact Michael Piziali at 301-496-2644 for more information. Available for licensing. 2022-03-08 2026-03-02 2026-03-02 2009-06-23 AC4XXX, ACXXXX, AXXXXX, BBXXXX, Biotechnology, C, DB4BXX, DB4XXX, DBXXXX, Development, DXXXXX, Entry., Flavivirus-based, HCV, HCV:, Hepatitis, Hepatitis A, Hepatitis D, Hepatitis E, INFECTIOUS, Novel, Patent Category - Biotechnology, production, REPORTER, STUDYING, System, Virion, VIRIONS, virus False True <ul> <li>Proof of concept.</li> <li>Preliminary tools and techniques for screening strategies.</li> </ul> True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114106656 Berger, Edward NIAID - DIR NIAID Berger, Edward (NIAID) 0 114106658 Triyatni, Miriam NIAID - DIR NIAID Triyatni, Miriam (NIAID) 0 114106657 Saunier, Bertrand NIAID - DIR NIAID Saunier, Bertrand (NIAID) 1 114106657 Saunier, Bertrand NIAID - DIR NIAID Saunier, Bertrand (NIAID) 1 114106656 Berger, Edward NIAID - DIR NIAID Berger, Edward (NIAID) 0 114106658 Triyatni, Miriam NIAID - DIR NIAID Triyatni, Miriam (NIAID) 0 114101244 A Novel Flavivirus-based System For Production Of Hepatitis C Virus (HCV): Production Of Infectious Virions And Development Of A Novel Reporter System For Studying HCV Virion Entry. E-005-2009-0 Filing authorized NIAID 114101356 A Novel Flavivirus-based System For Production Of Hepatitis C Virus (HCV): Production Of Infectious Virions And Development Of A Novel Reporter System For Studying HCV Virion Entry. E-005-2009-1 Filing authorized NIAID 83738793 Taylor-Mulneix, Dawn dawn.taylor-mulneix@nih.gov
United States of America dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-1973] A Novel System for Producing Infectious Hepatitis C Virus (HCV) Virions and Development of a Novel Reporter System for Studying HCV Entry&body=Please send me information about technology [TAB-1973] A Novel System for Producing Infectious Hepatitis C Virus (HCV) Virions and Development of a Novel Reporter System for Studying HCV Entry. Taylor-Mulneix, Dawn<br><a href="mailto:dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-1973] A Novel System for Producing Infectious Hepatitis C Virus (HCV) Virions and Development of a Novel Reporter System for Studying HCV Entry&body=Please send me information about technology [TAB-1973] A Novel System for Producing Infectious Hepatitis C Virus (HCV) Virions and Development of a Novel Reporter System for Studying HCV Entry.">dawn.taylor-mulneix@nih.gov</a><br> 114165297 E-005-2009-0 E-005-2009-0-US-01 Flavivirus-Based System for Production of Hepatitis C Virus (HCV) PRV US 61/195,088 Abandoned US <br />Provisional (PRV) 61/195,088<br />Filed on 2008-10-03<br />Status: Abandoned 114165746 E-005-2009-1 E-005-2009-1-PCT-01 Flavivirus-Based System For Production Of Hepatitis C Virus (HCV) PCT COMB Patent Cooperation Treaty PCT/US09/58598 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US09/58598<br />Filed on 2009-09-28<br />Status: Expired 114166394 E-005-2009-1 E-005-2009-1-US-02 Flavivirus-based System For Production Of Hepatitis C Virus (HCV) National Stage US 9,052,321 13/122,154 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9052321 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9052321">9,052,321</a><br />Filed on 2011-04-01<br />Status: Issued 114120343 DB4BXX 114120344 AC4XXX 114120345 DXXXXX 114120346 DBXXXX 114120347 DB4XXX 114120348 AXXXXX 114120349 ACXXXX 114121306 BBXXXX 114138031 Novel 114138032 Flavivirus-based 114138033 System 114138034 production 114138035 Hepatitis 114138036 C 114138037 virus 114138038 HCV: 114138039 INFECTIOUS 114138040 VIRIONS 114138041 Development 114138042 REPORTER 114138043 STUDYING 114138044 HCV 114138045 Virion 114138046 Entry. 114138047 Patent Category - Biotechnology 114138048 Biotechnology 114156816 Hepatitis D 114156817 Hepatitis A 114156818 Hepatitis E TAB-1574 114095842 Mice Genetically Deficient in the Chemoattractant Receptor FPR (formyl peptide receptor) NIAID Animal Models, Collaboration, Consumer Products, Diagnostics, Infectious Disease, Licensing, Materials Available, Research Materials, Therapeutics Animal Models Collaboration Consumer Products Diagnostics Infectious Disease Licensing Materials Available Research Materials Therapeutics Ji-Liang Gao, Philip Murphy The present research tool is a knockout mouse model (FPR<sup>-/-</sup>) that lacks the high affinity N-formylpeptide receptor (FPR), created by targeted gene disruption.<br /><br /> N-formylpeptides derive from bacterial and mitochondrial proteins, and bind to specific receptors on mammalian phagocytes. Since binding induces chemotaxis and activation of phagocytes in vitro, it has been postulated that N-formylpeptide receptor signaling in vivo may be important in antibacterial host defense, although direct proof has been lacking. The inventors have found that FPR<sup>-/-</sup> mice have no obvious developmental defects and do not develop spontaneous infection when derived in specific pathogen-free conditions. This suggests that, under these conditions, FPR is dispensable. However, when challenged with L. monocytogenes, FPR-deficient mice have accelerated mortality and increased bacterial burden in liver and spleen early after infection, which suggests a role for FPR in host defense, specifically through regulation of innate immunity. <ul> <li>FPR knock out mouse can be used as antibacterial host defense model and innate immunity studies.</li> </ul> The Laboratory of Molecular Immunology, NIAID, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize FPR knockout mice. Please contact Philip Murphy, M.D. at Tel: 301-496-8616 and/or <a href="mailto:pmm@nih.gov">pmm@nih.gov</a> for more information. Research Tool -- Patent protection is not being pursued for this technology. (IC Reference No. 2007-087) This technology is not patented. The mouse model will be transferred through a Biological Materials License. 2022-03-08 2026-03-02 2026-03-02 2007-07-01 BAXXXX, CHEMOATTRACTANT, DDXXXX, DEFICIENT, DEXXXX, DXXXXX, Formyl, FPR, GENETICALLY, knockout mice, Mice, MXXXXX, Peptide, RECEPTOR, RM, WIXXXX False True The technology is a research tool. The technology is a research tool. True NIHTT 37470483 Website Abstract 114170379 Gao JL, et al. https://www.ncbi.nlm.nih.gov/pubmed/9989980 <a href="https://www.ncbi.nlm.nih.gov/pubmed/9989980">Gao JL, et al.</a> 114105774 Gao, Ji-Liang NIAID - DIR NIAID Gao, Ji-Liang (NIAID) 0 114105775 Murphy, Philip NIAID - DIR NIAID Murphy, Philip (NIAID) 1 114105775 Murphy, Philip NIAID - DIR NIAID Murphy, Philip (NIAID) 1 114105774 Gao, Ji-Liang NIAID - DIR NIAID Gao, Ji-Liang (NIAID) 0 114100812 Mice Genetically Deficient In The Chemoattractant Receptor FPR (formyl Peptide Receptor E-258-2007-0 Research Material NIAID 83738793 Taylor-Mulneix, Dawn dawn.taylor-mulneix@nih.gov
United States of America dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-1574] Mice Genetically Deficient in the Chemoattractant Receptor FPR (formyl peptide receptor)&body=Please send me information about technology [TAB-1574] Mice Genetically Deficient in the Chemoattractant Receptor FPR (formyl peptide receptor). Taylor-Mulneix, Dawn<br><a href="mailto:dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-1574] Mice Genetically Deficient in the Chemoattractant Receptor FPR (formyl peptide receptor)&body=Please send me information about technology [TAB-1574] Mice Genetically Deficient in the Chemoattractant Receptor FPR (formyl peptide receptor).">dawn.taylor-mulneix@nih.gov</a><br> 114117961 DDXXXX 114117962 DEXXXX 114117963 DXXXXX 114117964 MXXXXX 114121200 BAXXXX 114127368 WIXXXX 114135649 Mice 114135650 GENETICALLY 114135651 DEFICIENT 114135652 CHEMOATTRACTANT 114135653 RECEPTOR 114135654 FPR 114135655 Formyl 114135656 Peptide 114149419 RM 114149420 knockout mice TAB-788 114095125 Mouse Lacking the Chemokine Receptor CX3CR1 NIAID Diagnostics, Licensing, Materials Available, Oncology, Research Materials Diagnostics Licensing Materials Available Oncology Research Materials Ji-Liang Gao, Philip Murphy This mouse has been generated by targeted gene disruption. The mouse provides a model to investigate the function of the chemokine receptor CX3CR1, which is a proinflammatory receptor for the leukocyte chemoattractant CX3CL1 (aka fractalkine). As an example, the mouse is in use in the study of atherosclerosis. Further, the mouse may serve as a model study the role of the immune system during infection with pathogens as well as other immunologically mediated diseases and responses to tumors. Research Tool -- patent protection is not being pursued for this technology Available for licensing under a biological materials license. 2022-03-08 2026-03-02 2026-03-02 2003-11-01 CA1AXX, CA1XXX, CAXXXX, CXXXXX, RXXXXX False True True NIHTT 37470483 Website Abstract 114169937 C Combadière et al. Decreased atheroscelerotic lesion formation in CX3R1/apolipoprotein E double knockout mice. http://www.ncbi.nlm.nih.gov/pubmed/12600915?dopt <a href="http://www.ncbi.nlm.nih.gov/pubmed/12600915?dopt">C Combadière et al. Decreased atheroscelerotic lesion formation in CX3R1/apolipoprotein E double knockout mice.</a> 114104506 Murphy, Philip NIAID Murphy, Philip (NIAID) 0 114104507 Gao, Ji-Liang NIAID Gao, Ji-Liang (NIAID) 0 114104506 Murphy, Philip NIAID Murphy, Philip (NIAID) 0 114104507 Gao, Ji-Liang NIAID Gao, Ji-Liang (NIAID) 0 114099957 Mouse Lacking The Chemokine Receptor CX3CR1, Due To Targeted Gene Disruption E-216-2003-0 Research Material NIAID 83738793 Taylor-Mulneix, Dawn dawn.taylor-mulneix@nih.gov
United States of America dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-788] Mouse Lacking the Chemokine Receptor CX3CR1&body=Please send me information about technology [TAB-788] Mouse Lacking the Chemokine Receptor CX3CR1. Taylor-Mulneix, Dawn<br><a href="mailto:dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-788] Mouse Lacking the Chemokine Receptor CX3CR1&body=Please send me information about technology [TAB-788] Mouse Lacking the Chemokine Receptor CX3CR1.">dawn.taylor-mulneix@nih.gov</a><br> 114114682 CA1AXX 114114683 CAXXXX 114114684 CXXXXX 114114685 RXXXXX 114120914 CA1XXX TAB-3184 114094368 Mouse CCR1 cDNA NIAID Licensing, Research Materials Licensing Research Materials Ji-Liang Gao, Philip Murphy A plasmid encodes mouse C-C motif chemokine receptor 1 (CCR1). CCR1 plays an important role in host protection from inflammatory response, and susceptibility to virus and parasite. <ul> <li>Speed up product development with NIH developed material that has already been tested and validated.</li> </ul> <ul> <li>A research material that can be used in the development of assays, validation of products or in quality control.</li> </ul> Research Material – Patent protection is not being pursued for this technology. (IC Reference No. 1948-025) 2022-03-08 2026-03-02 2026-03-02 2017-12-04 CCR1, cDNA, Encoding, Listed LPM Ano as of 4/15/2015, Mouse, PLASMID, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, RECEPTOR, RM, WIXXXX False True True NIHTT 37470483 Website Abstract 114109430 Gao, Ji-Liang NIAID - DIR NIAID Gao, Ji-Liang (NIAID) 0 114109429 Murphy, Philip NIAID - DIR NIAID Murphy, Philip (NIAID) 1 114109429 Murphy, Philip NIAID - DIR NIAID Murphy, Philip (NIAID) 1 114109430 Gao, Ji-Liang NIAID - DIR NIAID Gao, Ji-Liang (NIAID) 0 114102346 cDNA Encoding the Mouse CCR1 Receptor B-012-1998-0 Research Material NIAID 83738793 Taylor-Mulneix, Dawn dawn.taylor-mulneix@nih.gov
United States of America dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-3184] Mouse CCR1 cDNA&body=Please send me information about technology [TAB-3184] Mouse CCR1 cDNA. Taylor-Mulneix, Dawn<br><a href="mailto:dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-3184] Mouse CCR1 cDNA&body=Please send me information about technology [TAB-3184] Mouse CCR1 cDNA.">dawn.taylor-mulneix@nih.gov</a><br> 114127510 WIXXXX 114149667 cDNA 114149668 Encoding 114149669 Mouse 114149670 CCR1 114149671 RECEPTOR 114149672 Listed LPM Ano as of 4/15/2015 114149673 Pre LPM working set 20150418 114149674 Post LPM Assignment Set 20150420 114149675 PLASMID 114149676 RM TAB-3178 114094359 Human Monocyte Chemoattractant Protein-1 (MCP-1/CCL2) cDNA NIAID Licensing, Research Materials Licensing Research Materials Philip Murphy A plasmid encodes human monocyte chemoattractant protein-1 (MCP-1/CCL2). MCP-1/CCL2 is a chemokine that regulate migration and infiltration of monocytes/macrophages. <ul> <li>Speed up product development with NIH developed material that has already been tested and validated.</li> </ul> <ul> <li>A research material that can be used in the development of assays, validation of products or in quality control.</li> </ul> Research Material – Patent protection is not being pursued for this technology. (IC Reference No. 1948-007) 2022-03-08 2026-03-02 2026-03-02 2017-12-04 1, Human, Listed LPM Ano as of 4/15/2015, MCP, PLASMID, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, RM, Subtype, WIXXXX False True True NIHTT 37470483 Website Abstract 114107015 Murphy, Philip NIAID - DIR NIAID Murphy, Philip (NIAID) 1 114107015 Murphy, Philip NIAID - DIR NIAID Murphy, Philip (NIAID) 1 114102340 Human MCP 1 (A Subtype) B-005-1995-0 Research Material NIAID 83738793 Taylor-Mulneix, Dawn dawn.taylor-mulneix@nih.gov
United States of America dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-3178] Human Monocyte Chemoattractant Protein-1 (MCP-1/CCL2) cDNA&body=Please send me information about technology [TAB-3178] Human Monocyte Chemoattractant Protein-1 (MCP-1/CCL2) cDNA. Taylor-Mulneix, Dawn<br><a href="mailto:dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-3178] Human Monocyte Chemoattractant Protein-1 (MCP-1/CCL2) cDNA&body=Please send me information about technology [TAB-3178] Human Monocyte Chemoattractant Protein-1 (MCP-1/CCL2) cDNA.">dawn.taylor-mulneix@nih.gov</a><br> 114127496 WIXXXX 114149589 Human 114149590 MCP 114149591 1 114149592 Subtype 114149593 Listed LPM Ano as of 4/15/2015 114149594 Pre LPM working set 20150418 114149595 Post LPM Assignment Set 20150420 114149596 PLASMID 114149597 RM TAB-4239 147157524 ELISA-Based Biodosimeter for Measuring and Quantifying DNA Damage NCI Collaboration, Diagnostics, Licensing, Oncology Collaboration Diagnostics Licensing Oncology William Bonner, Jiuping ("Jay") Ji, Christophe Redon, Yiping Zhang <h2>Summary:</h2> <p>The National Cancer Institute (NCI) seeks co-development partners and/or licensees to further develop a novel ELISA-based biodosimeter.</p> <h2>Description of Technology:</h2> <p>Exposure to ionizing radiation or agents that induce DNA double-stranded breaks (DSBs) can result in severe damage to cell and/or tissues, including cell death.&nbsp;This can lead to illness (i.e., acute radiation syndrome, cancer, etc.) or even death.&nbsp; Identifying the amount of exposure to a DNA DSB-causing agent can be useful in monitoring, determining the need for further testing, and avoidance or modification of certain medical interventions and/or types of medical treatments. DNA damage caused by DSBs can be identified and quantified&nbsp;in situ&nbsp;by detecting phosphorylated histone protein &gamma;-H2AX (gamma-H2AX) foci which is formed at DSBs.&nbsp;However, existing methods of analyzing &gamma;-H2AX are laborious, low-throughput, and prone to variability.</p> <p>Investigators in NCI&rsquo;s Developmental Therapeutics Branch have developed a novel, high-throughput ELISA-based biodosimeter to measure DNA damage. This biodosimeter simultaneously quantifies the amount of &gamma;-H2AX and total H2AX and results in a percent &gamma;-H2AX, which is a normalized value representative of the amount of DNA damage. Overall, this biodosimeter provides users with flexibility of input sample type (ex. cells, tissues, blood) and high-throughput, less laborious option to precisely measure DNA damage. It provides reliable, dose-dependent measurement outputs that are independent of variability in cell number, cell viability, cell lysis efficiency, and laboratory operator. Additionally, the biodosimeter is both sensitive and specific, having a 100-fold quantitative range with sensitivity of 5 pM for &gamma;-H2AX and 50 pM for H2AX.</p> <p>NCI is seeking co-development partners and/or licensees to further develop this novel ELISA-based biodosimeter.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Assay for measuring DNA damage by a variety of causes (ex. ionizing radiation, environmental agents, chemotherapeutic agents, etc.)</li> <li>Biodosimeter to monitor cancer drug treatment course</li> <li>High-throughput screening of new drugs targeting DNA metabolism</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Quantitative</li> <li>High sensitivity and selectivity</li> <li>Can be used on varying sample types (ex. cells, blood, and or tissues)</li> <li>Has internal controls for reliable measurements</li> <li>High-throughput and less laborious than other methods for assaying &gamma;H2AX levels</li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for further development of a novel ELISA-based biodosimeter. 2016-02-16 2026-02-23 2026-02-23 2026-02-23 2016-09-12 and environmental agents, chemotherapeutic agents, DNA damage, ionizing radiation False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2026-02-23 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 166121280 Ji J, et al. Phosphorylated Fraction of H2AX as a Measurement for DNA Damage in Cancer Cells and Potential Applications of a Novel Assay. (PMID: 28158293) https://pubmed.ncbi.nlm.nih.gov/28158293/ <a href="https://pubmed.ncbi.nlm.nih.gov/28158293/">Ji J, et al. Phosphorylated Fraction of H2AX as a Measurement for DNA Damage in Cancer Cells and Potential Applications of a Novel Assay. (PMID: 28158293)</a> 147164009 Redon, Christophe NIH - NCI NCI Redon, Christophe (NCI) 1 147164010 Zhang, Yiping NIH - NCI Leidos Zhang, Yiping (Leidos) 2 147164008 Bonner, William NIH - NCI NCI Bonner, William (NCI) 3 147164011 Ji, Jiuping ("Jay") NIH - NCI Leidos Ji, Jiuping ("Jay") (Leidos) 4 147164009 Redon, Christophe NIH - NCI NCI Redon, Christophe (NCI) 1 147164010 Zhang, Yiping NIH - NCI Leidos Zhang, Yiping (Leidos) 2 147164008 Bonner, William NIH - NCI NCI Bonner, William (NCI) 3 147164011 Ji, Jiuping ("Jay") NIH - NCI Leidos Ji, Jiuping ("Jay") (Leidos) 4 147158309 ELISA Biodosimeter Based On Gamma-H2AX To H2AX Ratios E-276-2014-0 Filing authorized NCI 91826910 McCrary, Michaela michaela.mccrary@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America michaela.mccrary@nih.gov?subject=Web Inquiry on [TAB-4239] ELISA-Based Biodosimeter for Measuring and Quantifying DNA Damage&body=Please send me information about technology [TAB-4239] ELISA-Based Biodosimeter for Measuring and Quantifying DNA Damage.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov McCrary, Michaela<br><a href="mailto:michaela.mccrary@nih.gov?subject=Web Inquiry on [TAB-4239] ELISA-Based Biodosimeter for Measuring and Quantifying DNA Damage&body=Please send me information about technology [TAB-4239] ELISA-Based Biodosimeter for Measuring and Quantifying DNA Damage.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">michaela.mccrary@nih.gov</a><br> 147167592 E-276-2014-0 E-276-2014-0-US-01 Methods and Kits for Measuring and Quantifying DNA Double-Stranded Breaks Using Gamma-H2AX and H2AX PRV US 62/110,764 Abandoned US <br />Provisional (PRV) 62/110,764<br />Filed on 2015-02-02<br />Status: Abandoned 147167593 E-276-2014-0 E-276-2014-0-PCT-02 Methods and Kits For Measuring and Quantifying DNA Double-Stranded Breaks Using Gamma-H2AX and H2AX PCT Patent Cooperation Treaty PCT/US2016/016000 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2016/016000<br />Filed on 2016-02-01<br />Status: Expired 147167594 E-276-2014-0 E-276-2014-0-US-03 METHODS AND KITS FOR MEASURING AND QUANTIFYING DNA DOUBLE-STRANDED BREAKS USING GAMMA-H2AX AND H2AX National Stage US 10,809,268 15/545,402 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10809268 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10809268">10,809,268</a><br />Filed on 2017-07-21<br />Status: Issued 147174553 and environmental agents 147174555 chemotherapeutic agents 147174556 DNA damage 147174558 ionizing radiation TAB-4214 147157499 Surgical Tool for Sub-retinal Tissue Implantation NEI Ear, Nose, & Throat, Licensing, Medical Devices, Non-Medical Devices, Ophthalmology Ear Nose & Throat Licensing Medical Devices Non-Medical Devices Ophthalmology Arvydas Maminishkis <p>The accurate placement of transplanted tissue at a precise position in the retina is difficult but critical for a successful implementation of an ocular surgical intervention.&nbsp;</p> <p>Researchers at the <a href="https://www.nei.nih.gov/" rel="nofollow">National Eye Institute</a> (NEI) developed a surgical tool (see image below)&nbsp;designed to place tissue patches, such as sheets of tissue, onto the retina in a precise and controlled fashion. The tissue for transplantation remains enshrouded in an internal channel until it is accurately delivered to the site of transplant by fluid pressure from a hydrostatic pump.&nbsp; The curved design of the tool matches the curvature of the human eye, and the ease of operation minimizes surgical damage to the eye during placement of the tissue. The secure and precise operation of the tool and delivery of the tissue to the transplantation site maximizes the therapeutic effectiveness. The researchers demonstrated that this tool can be used, with or without modification, to deliver small implantable devices into the retina.&nbsp;</p> <p>This tool is manufactured as a disposable prototype. It is available for licensing and the NEI is open to discussion on potential additional uses of the tool. For example, it is currently being used for autologous iPSC tissue transplant, and can be licensed for this field of use.</p> <p><img alt=" A handheld surgical device/tool designed for intra-ocular delivery and placement of single layer transplant retina tissue to the retina or sub retina. The device is an improvement over similar device as its curved design that matches the curvature of the human eye, making it easier operate and minimizes damage to the eye during placement. " height="150" src="https://nih.technologypublisher.com/files/sites/e-192-2014_image_surgical_tool_for_sub-retinal_delivery_of_rpe_implants4.png" width="732" /></p> <h2>Competitive Advantages:</h2> <p>&bull; Precision of operation for surgeon (no extra moving parts)&nbsp;<br /> &bull; Tool consists of separate disposable parts&nbsp;<br /> &bull; Ease of operation, controlled delivery&nbsp;<br /> &bull; Minimized damage to the eye and transplanted tissue&nbsp;<br /> &bull; Only tool available that can deliver tissue into the sub-retinal space</p> <h2>Commercial Applications:</h2> <p>&bull; Ocular tissue transplantation;<br /> &bull; Delivery of small devices or extended release drug pellets into sub-retinal space</p> 2018-02-16 2025-04-22 2018-07-19 2026-02-18 2018-02-16 EYE, Intra-Ocular, Maminishkis, National Eye Institute, NEI, sub-retinal, surgical tool, tissue placement retina False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2018-07-19 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-293-2016 147163934 Maminishkis, Arvydas NIH - NEI NEI Maminishkis, Arvydas (NEI) 1 147163934 Maminishkis, Arvydas NIH - NEI NEI Maminishkis, Arvydas (NEI) 1 147158184 Surgical Tool For Soft Ocular Tissue Transplantation E-192-2014-0 Filing authorized National Eye Institute (NEI) 147162558 Surgical Tool For Soft Ocular Tissue Transplantation E-192-2014-1 Filing authorized National Eye Institute (NEI) 83703238 Fenn, Edward (Tedd) tedd.fenn@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-4214] Surgical Tool for Sub-retinal Tissue Implantation&body=Please send me information about technology [TAB-4214] Surgical Tool for Sub-retinal Tissue Implantation.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Fenn, Edward (Tedd)<br><a href="mailto:tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-4214] Surgical Tool for Sub-retinal Tissue Implantation&body=Please send me information about technology [TAB-4214] Surgical Tool for Sub-retinal Tissue Implantation.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">tedd.fenn@nih.gov</a><br> 147167432 E-192-2014-0 E-192-2014-0-US-01 Surgical Tool and Method for Ocular Tissue Transplantation PRV US 62/023,289 Abandoned US <br />Provisional (PRV) 62/023,289<br />Filed on 2014-07-11<br />Status: Abandoned 147167434 E-192-2014-1 E-192-2014-1-PCT-01 Surgical Tool and Method for Ocular Tissue Transplantation PCT COMB Patent Cooperation Treaty PCT/US2015/039932 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2015/039932<br />Filed on 2015-07-10<br />Status: Expired 147167435 E-192-2014-1 E-192-2014-1-US-02 Surgical Tool For Soft Ocular Tissue Transplantation National Stage US 10,729,579 15/325,584 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10729579 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10729579">10,729,579</a><br />Filed on 2017-01-11<br />Status: Issued 147167436 E-192-2014-1 E-192-2014-1-AU-03 Surgical Tool and Method for Ocular Tissue Transplantation National Stage Australia 2015287692 Abandoned Australia <br />National Stage 2015287692<br />Filed on 2015-07-10<br />Status: Abandoned 147167437 E-192-2014-1 E-192-2014-1-CA-04 Surgical Tool and Method for Ocular Tissue Transplantation National Stage Canada 2954762 2954762 Issued Canada <br />National Stage 2954762<br />Filed on 2015-07-10<br />Status: Issued 147167438 E-192-2014-1 E-192-2014-1-EP-05 Surgical Tool and Method for Ocular Tissue Transplantation National Stage European Patent 3166550 15741462.4 Issued European Patent <br />National Stage 15741462.4<br />Filed on 2017-02-07<br />Status: Issued 147167439 E-192-2014-1 E-192-2014-1-IN-06 Surgical Tool and Method for Ocular Tissue Transplantation National Stage India 478178 201717003244 Issued India <br />National Stage 201717003244<br />Filed on 2015-07-10<br />Status: Issued 147167440 E-192-2014-1 E-192-2014-1-JP-07 Surgical Tool and Method for Ocular Tissue Transplantation National Stage Japan 6794343 2017-501212 Issued Japan <br />National Stage 2017-501212<br />Filed on 2017-01-10<br />Status: Issued 147167441 E-192-2014-1 E-192-2014-1-US-08 Surgical Tool And Method For Soft Ocular Tissue Transplantation CON US 11,723,799 16/910,388 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11723799 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11723799">11,723,799</a><br />Filed on 2020-06-24<br />Status: Issued 147167442 E-192-2014-1 E-192-2014-1-AU-09 Surgical Tool and Method for Ocular Tissue Transplantation DIV Australia 2020202248 2020202248 Issued Australia <br />Divisional (DIV) 2020202248<br />Filed on 2020-03-30<br />Status: Issued 147167443 E-192-2014-1 E-192-2014-1-EP-10 Surgical Tool and Method for Ocular Tissue Transplantation DIV European Patent 23215832.9 Pending European Patent <br />Divisional (DIV) 23215832.9<br />Filed on 2023-12-12<br />Status: Pending 147167444 E-192-2014-1 E-192-2014-1-AU-11 Surgical Tool and Method for Ocular Tissue Transplantation DIV Australia 2022203098 2022203098 Issued Australia <br />Divisional (DIV) 2022203098<br />Filed on 2022-05-09<br />Status: Issued 147167445 E-192-2014-1 E-192-2014-1-CH-01 Surgical Tool and Method for Ocular Tissue Transplantation EP Switzerland 3166550 15741462.4 Issued Switzerland <br />European patent (EP) 15741462.4<br />Filed on 2015-07-10<br />Status: Issued 147167446 E-192-2014-1 E-192-2014-1-DE-01 Surgical Tool and Method for Ocular Tissue Transplantation EP Germany 3166550 15741462.4 Issued Germany <br />European patent (EP) 15741462.4<br />Filed on 2015-07-10<br />Status: Issued 147167447 E-192-2014-1 E-192-2014-1-ES-01 Surgical Tool and Method for Ocular Tissue Transplantation EP Spain 3166550 15741462.4 Issued Spain <br />European patent (EP) 15741462.4<br />Filed on 2015-07-10<br />Status: Issued 147167448 E-192-2014-1 E-192-2014-1-DK-01 Surgical Tool and Method for Ocular Tissue Transplantation EP Denmark 3166550 15741462.4 Issued Denmark <br />European patent (EP) 15741462.4<br />Filed on 2015-07-10<br />Status: Issued 147167449 E-192-2014-1 E-192-2014-1-GB-01 Surgical Tool and Method for Ocular Tissue Transplantation EP United Kingdom 3166550 15741462.4 Issued United Kingdom <br />European patent (EP) 15741462.4<br />Filed on 2015-07-10<br />Status: Issued 147167450 E-192-2014-1 E-192-2014-1-FR-01 Surgical Tool and Method for Ocular Tissue Transplantation EP France 3166550 15741462.4 Issued France <br />European patent (EP) 15741462.4<br />Filed on 2015-07-10<br />Status: Issued 147167451 E-192-2014-1 E-192-2014-1-IE-01 Surgical Tool and Method for Ocular Tissue Transplantation EP Ireland 3166550 15741462.4 Issued Ireland <br />European patent (EP) 15741462.4<br />Filed on 2015-07-10<br />Status: Issued 147167452 E-192-2014-1 E-192-2014-1-SE-01 Surgical Tool and Method for Ocular Tissue Transplantation EP Sweden 3166550 15741462.4 Issued Sweden <br />European patent (EP) 15741462.4<br />Filed on 2015-07-10<br />Status: Issued 147167453 E-192-2014-1 E-192-2014-1-NL-01 Surgical Tool and Method for Ocular Tissue Transplantation EP The Netherlands 3166550 15741462.4 Issued The Netherlands <br />European patent (EP) 15741462.4<br />Filed on 2015-07-10<br />Status: Issued 147167454 E-192-2014-1 E-192-2014-1-US-01 Surgical Tool And Method For Soft Ocular Tissue Transplantation CON US 18/233,654 Pending US <br />Continuation (CON) 18/233,654<br />Filed on 2023-08-14<br />Status: Pending 164119644 E-192-2014-1 E-192-2014-1-IT-01 Surgical Tool and Method for Ocular Tissue Transplantation EP Italy 3166550 15741462.4 Issued Italy <br />European patent (EP) 15741462.4<br />Filed on 2017-02-07<br />Status: Issued 164119645 E-192-2014-1 E-192-2014-1-AU-12 Surgical Tool and Method for Ocular Tissue Transplantation DIV Australia 2024259653 Pending Australia <br />Divisional (DIV) 2024259653<br />Filed on 2024-10-31<br />Status: Pending 166059827 E-192-2014-1 E-192-2014-1-US-03 SURGICAL TOOL AND METHOD FOR SOFT OCULAR TISSUE TRANSPLANTATION CON US 19/543.817 Pending US <br />Continuation (CON) 19/543.817<br />Filed on 2026-02-18<br />Status: Pending 147173406 EYE 147173407 Intra-Ocular 147173409 Maminishkis 147173410 National Eye Institute 147173411 NEI 147173413 sub-retinal 147173415 surgical tool 147173417 tissue placement retina TAB-5089 165621401 Real-time AI System for Echocardiography Analysis and Quantification NLM Cardiology, Collaboration, Diagnostics, Software / Apps Cardiology Collaboration Diagnostics Software / Apps Ghada Alzamzmi, Sameer Antani, Li-Yueh Hsu, Sivarama Krishnan Rajaraman, Vandana Sachdev <h2>Summary:</h2> <p>We are seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize this technology.</p> <h2>Description of Technology:</h2> <p>Scientists have developed an artificial intelligence (AI) system to automatically extract predictive biomarkers from echocardiography. This AI system takes an echocardiography study as input and produces predictive biomarkers as output in real-time. It performs several automated image analysis tasks including echocardiography quality (quality for the acquired echo clips) assessment, echocardiography view retrieval (e.g., 2D four chamber or parasternal long axis view, Doppler), echocardiography cardiac region segmentation (e.g. inferior vena cava) and cardiac biomarker quantification (e.g. right atrial pressure). This system is:</p> <ol> <li>efficient (in terms of time and space)</li> <li>robust (can handle missing data)</li> <li>interpretable (can provide human-understandable insights)</li> </ol> <p>Such features allow its use in embedded devices for real-world clinical practice and point of care testing. This technology can be used to assist the diagnosis of a wide range of common cardiac diseases as well as to evaluate cardiac function in minority populations such as sickle cell disease patients.&nbsp;</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Cardiologists in clinical practice, to: <ul> <li>streamline cross-functional workflows</li> <li>obtain temporal biomarkers of a full study in a single run</li> </ul> </li> <li>Cardiology researchers, to: <ul> <li>Enable systematic comparison across millions of echocardiograms</li> <li>rapidly analyze cardiac data across hospitals and research centers</li> <li>perform analysis and quantification for pattern detection, verification, and informed hypothesis testing</li> </ul> </li> <li>Perform diagnosis and assessment of wide range of cardiac diseases including coronary artery disease, heart failure, and cardiopulmonary complications in sickle cell disease patients</li> <li>Once converted into a software application, can be installed in bedside and handheld ultrasound devices to extract imaging biomarkers</li> <li>Can combine the extracted imaging biomarkers with non-imaging biomarkers (e.g., lab tests, age)</li> <li>Applicable to other clinical fields; e.g., endocrinology</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Real-time medical imaging <ul> <li>No comparable system in the market that performs a series of medical image tasks in real-time to extract predictive imaging biomarkers from different echo types and views including Doppler, M-model, and B-mode (A2C, A4C, PLAX, IVC, etc.)</li> </ul> </li> <li>Enhance efficiency and save time &ndash; hours to minutes or seconds</li> <li>Enable deeper analysis of a patient&rsquo;s condition</li> <li>Enables the streamlining of tedious clinical tasks (e.g., image analysis tasks and visual biomarkers observation), potentially saving hours of physicians&rsquo; time</li> <li>Reduced costs to payers and patients resulting from decreased physician time</li> <li>Reproducible and precise image analysis anywhere</li> <li>Enables unprecedented portability and standardized access to care &mdash; including visual analytics, predictive biomarker calculation, diagnosis, assessment, and prognosis</li> </ul> Researchers at the NLM are seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize this technology. 2026-01-14 2026-02-18 2026-02-18 2026-02-18 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52406769 Prototype 52406769 NCI 37470483 Website Abstract 165622365 Zamzmia G, et al. Evaluation of An Artificial Intelligence-Based System for Echocardiographic Estimation of Right Atrial Pressure, International Journal of Cardiovascular Imaging, DOI: 10.1007/s10554-023-02941-8, September 2023. Zamzmia G, et al. Evaluation of An Artificial Intelligence-Based System for Echocardiographic Estimation of Right Atrial Pressure, International Journal of Cardiovascular Imaging, DOI: 10.1007/s10554-023-02941-8, September 2023. 165622368 Zamzmi G, et al. Real-time echocardiography image analysis and quantification of cardiac indices. Medical image analysis, 80, 102438. (2022). https://doi.org/10.1016/j.media.2022.102438 Zamzmi G, et al. Real-time echocardiography image analysis and quantification of cardiac indices. Medical image analysis, 80, 102438. (2022). https://doi.org/10.1016/j.media.2022.102438 165622371 Zamzmi G, et al. Open-world active learning for echocardiography view classification. Medical Imaging 2022: Computer-Aided Diagnosis. Vol. 12033. SPIE, 2022. DOI: https://doi.org/10.1117/12.2612578 Zamzmi G, et al. Open-world active learning for echocardiography view classification. Medical Imaging 2022: Computer-Aided Diagnosis. Vol. 12033. SPIE, 2022. DOI: https://doi.org/10.1117/12.2612578 165622504 Zamzmi G, et al. Fully automated spectral envelope and peak velocity detection from Doppler echocardiography images. Medical Imaging 2020: Computer-Aided Diagnosis. Vol. 11314G. SPIE, 2020. DOI: https://doi.org/10.1117/12.2551183 Zamzmi G, et al. Fully automated spectral envelope and peak velocity detection from Doppler echocardiography images. Medical Imaging 2020: Computer-Aided Diagnosis. Vol. 11314G. SPIE, 2020. DOI: https://doi.org/10.1117/12.2551183 166059633 Zamzmi G, Hsu LY, Li W, Sachdev V, Antani S. Echo doppler flow classification and goodness assessment with convolutional neural networks. 2019 18th IEEE International Conference On Machine Learning And Applications (ICMLA), 2019. DOI: https://doi.org/10.1109/ICMLA.2019.00283 Zamzmi G, Hsu LY, Li W, Sachdev V, Antani S. Echo doppler flow classification and goodness assessment with convolutional neural networks. 2019 18th IEEE International Conference On Machine Learning And Applications (ICMLA), 2019. DOI: https://doi.org/10.1109/ICMLA.2019.00283 165621507 Alzamzmi, Ghada NIH - NLM Alzamzmi, Ghada 1 165621532 Antani, Sameer NIH - NLM NLM Antani, Sameer (NLM) 2 165621551 Hsu, Li-Yueh NIH - CC NHLBI Hsu, Li-Yueh (NHLBI) 3 165622134 Sachdev, Vandana NIH - NHLBI NHLBI Sachdev, Vandana (NHLBI) 4 165622149 Rajaraman, Sivarama Krishnan NIH - NLM NLM Rajaraman, Sivarama Krishnan (NLM) 5 165621507 Alzamzmi, Ghada NIH - NLM Alzamzmi, Ghada 1 165621532 Antani, Sameer NIH - NLM NLM Antani, Sameer (NLM) 2 165621551 Hsu, Li-Yueh NIH - CC NHLBI Hsu, Li-Yueh (NHLBI) 3 165622134 Sachdev, Vandana NIH - NHLBI NHLBI Sachdev, Vandana (NHLBI) 4 165622149 Rajaraman, Sivarama Krishnan NIH - NLM NLM Rajaraman, Sivarama Krishnan (NLM) 5 165621416 Real-time AI System For Echocardiography Analysis And Quantification E-111-2022-0 Filing authorized Clinical Center (CC), National Heart, Lung, and Blood Institute (NHLBI), NLM 166060406 Real-time AI System For Echocardiography Analysis And Quantification E-111-2022-1 Filing authorized Clinical Center (CC), National Heart, Lung, and Blood Institute (NHLBI), NIH - NLM, NLM 166060441 Real-time AI System For Echocardiography Analysis And Quantification E-111-2022-2 Filing authorized NIH - CC, NIH - NHLBI, NIH - NLM, NLM 83724826 Pollard, Ricquita ricquita.pollard@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-5089] Real-time AI System for Echocardiography Analysis and Quantification&body=Please send me information about technology [TAB-5089] Real-time AI System for Echocardiography Analysis and Quantification.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollard, Ricquita<br><a href="mailto:ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-5089] Real-time AI System for Echocardiography Analysis and Quantification&body=Please send me information about technology [TAB-5089] Real-time AI System for Echocardiography Analysis and Quantification.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">ricquita.pollard@nih.gov</a><br> 166060412 E-111-2022-1 E-111-2022-1-US-01 ECHOCARDIOGRAPHIC ESTIMATION OF RIGHT ATRIAL PRESSURE USING A LIGHTWEIGHT AND OPEN-WORLD ARTIFICIAL INTELLIGENCE SYSTEM PRV US 63/458,054 Expired US <br />Provisional (PRV) 63/458,054<br />Filed on 2023-04-07<br />Status: Expired 166060445 E-111-2022-2 E-111-2022-2-PC-01 ECHOCARDIOGRAPHIC ESTIMATION OF RIGHT ATRIAL PRESSURE USING A LIGHTWEIGHT AND OPEN-WORLD ARTIFICIAL INTELLIGENCE SYSTEM PCT COMB Patent Cooperation Treaty PCT/US2023/024902 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2023/024902<br />Filed on 2023-06-09<br />Status: Expired 166060446 E-111-2022-2 E-111-2022-2-JP-01 ECHOCARDIOGRAPHIC ESTIMATION OF RIGHT ATRIAL PRESSURE USING A LIGHTWEIGHT AND OPEN-WORLD ARTIFICIAL INTELLIGENCE SYSTEM National Stage Japan 2024-572228 Abandoned Japan <br />National Stage 2024-572228<br />Filed on 2024-12-06<br />Status: Abandoned 166060447 E-111-2022-2 E-111-2022-2-CA-01 ECHOCARDIOGRAPHIC ESTIMATION OF RIGHT ATRIAL PRESSURE USING A LIGHTWEIGHT AND OPEN-WORLD ARTIFICIAL INTELLIGENCE SYSTEM National Stage Canada 3258628 Abandoned Canada <br />National Stage 3258628<br />Filed on 2024-12-06<br />Status: Abandoned 166060448 E-111-2022-2 E-111-2022-2-IL-01 ECHOCARDIOGRAPHIC ESTIMATION OF RIGHT ATRIAL PRESSURE USING A LIGHTWEIGHT AND OPEN-WORLD ARTIFICIAL INTELLIGENCE SYSTEM National Stage Israel 317482 Abandoned Israel <br />National Stage 317482<br />Filed on 2024-12-05<br />Status: Abandoned 166060450 E-111-2022-2 E-111-2022-2-CN-01 ECHOCARDIOGRAPHIC ESTIMATION OF RIGHT ATRIAL PRESSURE USING A LIGHTWEIGHT AND OPEN-WORLD ARTIFICIAL INTELLIGENCE SYSTEM National Stage China 202380055216.5 Abandoned China <br />National Stage 202380055216.5<br />Filed on 2025-01-21<br />Status: Abandoned 166060455 E-111-2022-2 E-111-2022-2-KR-01 ECHOCARDIOGRAPHIC ESTIMATION OF RIGHT ATRIAL PRESSURE USING A LIGHTWEIGHT AND OPEN-WORLD ARTIFICIAL INTELLIGENCE SYSTEM National Stage South Korea 10-2025-7000599 Abandoned South Korea <br />National Stage 10-2025-7000599<br />Filed on 2025-01-08<br />Status: Abandoned 166060458 E-111-2022-2 E-111-2022-2-US-01 ECHOCARDIOGRAPHIC ESTIMATION OF RIGHT ATRIAL PRESSURE USING A LIGHTWEIGHT AND OPEN-WORLD ARTIFICIAL INTELLIGENCE SYSTEM National Stage US 18/872,402 Pending US <br />National Stage 18/872,402<br />Filed on 2024-12-06<br />Status: Pending 166060459 E-111-2022-2 E-111-2022-2-EP-01 ECHOCARDIOGRAPHIC ESTIMATION OF RIGHT ATRIAL PRESSURE USING A LIGHTWEIGHT AND OPEN-WORLD ARTIFICIAL INTELLIGENCE SYSTEM National Stage European Patent 23738969.7 Pending European Patent <br />National Stage 23738969.7<br />Filed on 2024-12-18<br />Status: Pending TAB-3446 114097317 Antibodies with Potent and Broad Neutralizing Activity against Antigenically Diverse and Highly Transmissible SARS-CoV-2 Variants NIAID Licensing Licensing Daniel Douek, Amy Henry, Peter Kwong, John Mascola, John Misasi, Amarendra ("Amar") Pegu, Mario Roederer, Wei Shi, Nancy Sullivan, Lingshu Wang, Eun Yang, Yi Zhang, Tongqing Zhou Emergence of highly transmissible SARS-CoV-2 variants of concern that are resistant to current therapeutic antibodies highlights the need for continuing discovery of broadly reactive antibodies.<br /><br /> Scientists at the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases discovered and characterized a group of human monoclonal antibodies that target unique epitopes on the receptor binding domain of SARS-CoV-2 spike protein. These antibodies ultra-potently neutralize >12 variants of SARS-CoV-2, including P1, B.1.429, B.1.1.7 and B.1.351, as shown in a pseudovirus neutralization assay. These antibodies target 3 distinct epitopes in the receptor binding domain of the spike protein and function by blocking ACE2 binding. These antibodies are not impacted by spike mutations that knockout binding to other therapeutic antibodies, including E484K, N439K, Y453F, L452R and K417N. Several antibodies are able to simultaneously bind to the spike protein and are compatible for use in combination therapies. In in vitro assays, these combinations were shown to decrease the appearance of escape mutants suggesting the potential to mitigate resistance development when used as combination therapy.<br /><br /> This technology is available for licensing for commercial development in accordance with 35 U.S.C. § 209 and 37 CFR Part 404. <ul> <li>Ultra-potent neutralization of currently identified SARS-CoV-2 variants</li> <li>Combinations show the potential to mitigate resistance</li> <li>Mechanism of Action – These antibodies bind to block ACE2 receptor binding to the SARS CoV-2 spike protein</li> </ul> <ul> <li>Treatment of SARS-CoV-2 infection</li> </ul> 2022-03-08 2025-08-13 2026-02-09 2021-05-27 antibodies, Coronaviruses, Protein, SARS-CoV-2, spike, Targeting False True True NIHTT 37470483 Website Abstract 114172608 Wang L, et al. https://pubmed.ncbi.nlm.nih.gov/33655252/ <a href="https://pubmed.ncbi.nlm.nih.gov/33655252/">Wang L, et al.</a> 114110215 Yang, Eun NIAID - VRC NIAID Yang, Eun (NIAID) 0 114110216 Wang, Lingshu NIAID - VRC NIAID Wang, Lingshu (NIAID) 0 114110218 Douek, Daniel NIAID - DIR NIAID Douek, Daniel (NIAID) 0 114110219 Zhou, Tongqing NIAID - VRC NIAID Zhou, Tongqing (NIAID) 0 114110220 Mascola, John NIAID - VRC NIAID Mascola, John (NIAID) 0 114110221 Kwong, Peter NIAID - VRC NIAID Kwong, Peter (NIAID) 0 114110222 Henry, Amy NIAID - DIR NIAID Henry, Amy (NIAID) 0 114110223 Sullivan, Nancy NIAID - VRC NIAID Sullivan, Nancy (NIAID) 0 114110224 Shi, Wei NIAID - VRC NIAID Shi, Wei (NIAID) 0 114110225 Roederer, Mario NIAID - VRC NIAID Roederer, Mario (NIAID) 0 114110226 Zhang, Yi NIAID - VRC NIAID Zhang, Yi (NIAID) 0 114110227 Pegu, Amarendra ("Amar") NIAID - VRC NIAID Pegu, Amarendra ("Amar") (NIAID) 0 114110214 Misasi, John NIAID - VRC NIAID Misasi, John (NIAID) 1 114110214 Misasi, John NIAID - VRC NIAID Misasi, John (NIAID) 1 114110215 Yang, Eun NIAID - VRC NIAID Yang, Eun (NIAID) 0 114110216 Wang, Lingshu NIAID - VRC NIAID Wang, Lingshu (NIAID) 0 114110218 Douek, Daniel NIAID - DIR NIAID Douek, Daniel (NIAID) 0 114110219 Zhou, Tongqing NIAID - VRC NIAID Zhou, Tongqing (NIAID) 0 114110220 Mascola, John NIAID - VRC NIAID Mascola, John (NIAID) 0 114110221 Kwong, Peter NIAID - VRC NIAID Kwong, Peter (NIAID) 0 114110222 Henry, Amy NIAID - DIR NIAID Henry, Amy (NIAID) 0 114110223 Sullivan, Nancy NIAID - VRC NIAID Sullivan, Nancy (NIAID) 0 114110224 Shi, Wei NIAID - VRC NIAID Shi, Wei (NIAID) 0 114110225 Roederer, Mario NIAID - VRC NIAID Roederer, Mario (NIAID) 0 114110226 Zhang, Yi NIAID - VRC NIAID Zhang, Yi (NIAID) 0 114110227 Pegu, Amarendra ("Amar") NIAID - VRC NIAID Pegu, Amarendra ("Amar") (NIAID) 0 114102568 Antibodies Targeting The Spike Protein Of Coronaviruses E-037-2021-0 Filing authorized NIAID 160390377 Antibodies Targeting The Spike Protein Of Coronaviruses E-037-2021-1 Filing authorized NIAID 83682222 Bailey, Brian bbailey@mail.nih.gov
United States of America TTIPO bbailey@mail.nih.gov?subject=Web Inquiry on [TAB-3446] Antibodies with Potent and Broad Neutralizing Activity against Antigenically Diverse and Highly Transmissible SARS-CoV-2 Variants&body=Please send me information about technology [TAB-3446] Antibodies with Potent and Broad Neutralizing Activity against Antigenically Diverse and Highly Transmissible SARS-CoV-2 Variants. Bailey, Brian<br><a href="mailto:bbailey@mail.nih.gov?subject=Web Inquiry on [TAB-3446] Antibodies with Potent and Broad Neutralizing Activity against Antigenically Diverse and Highly Transmissible SARS-CoV-2 Variants&body=Please send me information about technology [TAB-3446] Antibodies with Potent and Broad Neutralizing Activity against Antigenically Diverse and Highly Transmissible SARS-CoV-2 Variants.">bbailey@mail.nih.gov</a><br> 114169124 E-037-2021-0 E-037-2021-0-US-01 Antibodies Targeting The Spike Protein Of Coronaviruses PRV US 63/147,419 Abandoned US <br />Provisional (PRV) 63/147,419<br />Filed on 2021-02-09<br />Status: Abandoned 114169200 E-037-2021-1 E-037-2021-1-PCT-01 Antibodies Targeting The Spike Protein Of Coronaviruses PCT Patent Cooperation Treaty PCT/US2022/015341 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2022/015341<br />Filed on 2022-02-04<br />Status: Expired 160390382 E-037-2021-1 E-037-2021-1-IN-09 Antibodies Targeting The Spike Protein Of Coronaviruses National Stage India 202317048889 Pending India <br />National Stage 202317048889<br />Filed on 2023-07-20<br />Status: Pending 160390383 E-037-2021-1 E-037-2021-1-JP-10 Antibodies Targeting The Spike Protein Of Coronaviruses National Stage Japan 2023-547766 Pending Japan <br />National Stage 2023-547766<br />Filed on 2023-08-08<br />Status: Pending 160390384 E-037-2021-1 E-037-2021-1-CA-04 Antibodies Targeting The Spike Protein Of Coronaviruses National Stage Canada 3209136 Pending Canada <br />National Stage 3209136<br />Filed on 2023-07-21<br />Status: Pending 160390385 E-037-2021-1 E-037-2021-1-AU-02 Antibodies Targeting The Spike Protein Of Coronaviruses National Stage Australia 2022221297 Pending Australia <br />National Stage 2022221297<br />Filed on 2023-07-17<br />Status: Pending 160390386 E-037-2021-1 E-037-2021-1-IL-08 Antibodies Targeting The Spike Protein Of Coronaviruses National Stage Israel 304955 Pending Israel <br />National Stage 304955<br />Filed on 2023-08-03<br />Status: Pending 160390387 E-037-2021-1 E-037-2021-1-CN-06 Antibodies Targeting The Spike Protein Of Coronaviruses National Stage China 202280027556.2 Pending China <br />National Stage 202280027556.2<br />Filed on 2023-10-09<br />Status: Pending 160390388 E-037-2021-1 E-037-2021-1-CL-05 Antibodies Targeting The Spike Protein Of Coronaviruses National Stage Chile 202302326 Pending Chile <br />National Stage 202302326<br />Filed on 2022-02-04<br />Status: Pending 160390389 E-037-2021-1 E-037-2021-1-BR-03 Antibodies Targeting The Spike Protein Of Coronaviruses National Stage Brazil BR112023015424-3 Pending Brazil <br />National Stage BR112023015424-3<br />Filed on 2023-07-31<br />Status: Pending 160390390 E-037-2021-1 E-037-2021-1-KR-11 Antibodies Targeting The Spike Protein Of Coronaviruses National Stage South Korea 10-2023-7030836 Pending South Korea <br />National Stage 10-2023-7030836<br />Filed on 2023-09-08<br />Status: Pending 160390391 E-037-2021-1 E-037-2021-1-MX-12 Antibodies Targeting The Spike Protein Of Coronaviruses National Stage Mexico MX/a/2023/009244 Pending Mexico <br />National Stage MX/a/2023/009244<br />Filed on 2023-08-07<br />Status: Pending 160390392 E-037-2021-1 E-037-2021-1-US-01 Antibodies Targeting The Spike Protein Of Coronaviruses National Stage US 18/263,995 Pending US <br />National Stage 18/263,995<br />Filed on 2023-08-02<br />Status: Pending 160390393 E-037-2021-1 E-037-2021-1-EP-07 Antibodies Targeting The Spike Protein Of Coronaviruses National Stage European Patent 22705961.5 Pending European Patent <br />National Stage 22705961.5<br />Filed on 2023-08-22<br />Status: Pending 165573219 E-037-2021-1 E-037-2021-1-JP-13 Antibodies Targeting The Spike Protein Of Coronaviruses DIV Japan In Preparation Japan <br />Divisional (DIV) None<br />Filed on None<br />Status: In Preparation 165938906 E-037-2021-1 E-037-2021-1-CL-14 Antibodies Targeting The Spike Protein Of Coronaviruses DIV Chile In Preparation Chile <br />Divisional (DIV) None<br />Filed on None<br />Status: In Preparation 114152177 antibodies 114152178 Targeting 114152179 spike 114152180 Protein 114152181 Coronaviruses 114152182 SARS-CoV-2 TAB-3289 114097216 Polyclonal and Monoclonal Antibodies to Human Eosinophil Major Basic Protein, Eosinophil Peroxidase, Eosinophil Cationic Protein, and Eosinophil-Derived Neurotoxin NIAID Licensing, Research Materials Licensing Research Materials Richard Davey, Thomas Nutman Reagents particularly useful in configuring multiplex assays for simultaneous measurement and quantification of multiple eosinophil granule proteins and for immunohistochemistry. Ultimately these reagents may be used as diagnostics for many eosinophil-mediated disorders. <ul> <li>Speed up product development with NIH developed material that has already been tested and validated.</li> </ul> <ul> <li>A research material that can be used in the development of assays, validation of products or in quality control.</li> </ul> Research Material – Patent protection is not being pursued for this technology. (IC Reference No. 2014-034) 2022-03-08 2026-02-06 2026-02-06 2018-06-07 antibodies, BASIC, CATIONIC, EOSINOPHIL, Eosinophil-Derived, Eosionophil, Human, Listed LPM Fenn as of 4/15/2015, MAJOR, monoclonal, Neurotoxin, PEROXIDASE, polyclonal, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Protein, RM, WIXXXX False True True NIHTT 37470483 Website Abstract 114109741 Davey, Richard NIAID - DIR NIAID Davey, Richard (NIAID) 0 114109740 Nutman, Thomas NIAID - DIR NIAID Nutman, Thomas (NIAID) 1 114109740 Nutman, Thomas NIAID - DIR NIAID Nutman, Thomas (NIAID) 1 114109741 Davey, Richard NIAID - DIR NIAID Davey, Richard (NIAID) 0 114102450 Polyclonal And Monoclonal Antibodies To Human Eosinophil Major Basic Protein, Eosionophil Peroxidase, Eosinophil Cationic Protein, And Eosinophil-Derived Neurotoxin E-286-2014-0 Research Material NIAID 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-3289] Polyclonal and Monoclonal Antibodies to Human Eosinophil Major Basic Protein, Eosinophil Peroxidase, Eosinophil Cationic Protein, and Eosinophil-Derived Neurotoxin&body=Please send me information about technology [TAB-3289] Polyclonal and Monoclonal Antibodies to Human Eosinophil Major Basic Protein, Eosinophil Peroxidase, Eosinophil Cationic Protein, and Eosinophil-Derived Neurotoxin. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-3289] Polyclonal and Monoclonal Antibodies to Human Eosinophil Major Basic Protein, Eosinophil Peroxidase, Eosinophil Cationic Protein, and Eosinophil-Derived Neurotoxin&body=Please send me information about technology [TAB-3289] Polyclonal and Monoclonal Antibodies to Human Eosinophil Major Basic Protein, Eosinophil Peroxidase, Eosinophil Cationic Protein, and Eosinophil-Derived Neurotoxin.">jonathan.motley@nih.gov</a><br> 114127949 WIXXXX 114150931 polyclonal 114150932 monoclonal 114150933 antibodies 114150934 Human 114150935 EOSINOPHIL 114150936 MAJOR 114150937 BASIC 114150938 Protein 114150939 Eosionophil 114150940 PEROXIDASE 114150941 CATIONIC 114150942 Eosinophil-Derived 114150943 Neurotoxin 114150944 Listed LPM Fenn as of 4/15/2015 114150945 Pre LPM working set 20150418 114150946 Post LPM Assignment Set 20150420 114150969 RM TAB-3282 114094375 Antigens for Use in Loa Loa Microfilariae Quantitative Immunoassays NIAID Infectious Disease, Licensing, Materials Available, Research Materials Infectious Disease Licensing Materials Available Research Materials Sasi Bennuru, Papa Drame, Thomas Nutman Loa loa microfilarial-specific peptide sequences that could be used as a research material as well as for development of immunoassays for detection of Loa loa microfilaremia. <ul> <li>Speed up product development with NIH developed material that has already been tested and validated.</li> </ul> <ul> <li>A research material that can be used in the development of assays, validation of products or in quality control.</li> </ul> Research Material – Patent protection is not being pursued for this technology. (IC Reference No. 2014-012) 2022-03-08 2026-02-06 2026-02-06 2018-06-07 ANTIGENS, IMMUNOASSAYS, Listed LPM Fenn as of 4/15/2015, Loa, Microfilariae, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, QUANTITATIVE, RM, VQXXXX, WIXXXX False True True NIHTT 37470483 Website Abstract 114109728 Drame, Papa NIAID - DIR NIAID Drame, Papa (NIAID) 0 114109729 Bennuru, Sasi NIAID - DIR NIAID Bennuru, Sasi (NIAID) 0 114109727 Nutman, Thomas NIAID - DIR NIAID Nutman, Thomas (NIAID) 1 114109727 Nutman, Thomas NIAID - DIR NIAID Nutman, Thomas (NIAID) 1 114109728 Drame, Papa NIAID - DIR NIAID Drame, Papa (NIAID) 0 114109729 Bennuru, Sasi NIAID - DIR NIAID Bennuru, Sasi (NIAID) 0 114102444 Antigens For Use In Loa Loa Microfilariae Quantitative Immunoassays E-230-2014-0 Research Material NIAID 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-3282] Antigens for Use in Loa Loa Microfilariae Quantitative Immunoassays&body=Please send me information about technology [TAB-3282] Antigens for Use in Loa Loa Microfilariae Quantitative Immunoassays. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-3282] Antigens for Use in Loa Loa Microfilariae Quantitative Immunoassays&body=Please send me information about technology [TAB-3282] Antigens for Use in Loa Loa Microfilariae Quantitative Immunoassays.">jonathan.motley@nih.gov</a><br> 114127927 VQXXXX 114127928 WIXXXX 114150844 IMMUNOASSAYS 114150845 QUANTITATIVE 114150846 Microfilariae 114150847 Loa 114150848 ANTIGENS 114150849 Listed LPM Fenn as of 4/15/2015 114150850 Pre LPM working set 20150418 114150851 Post LPM Assignment Set 20150420 114150852 RM TAB-3273 114097197 Recombinant LL-SXP-1 and Plasmid Encoding LL-SXP-1 for the Immunodiagnosis of Loa Loa NIAID Infectious Disease, Licensing, Research Materials Infectious Disease Licensing Research Materials Amy Klion, Thomas Nutman A Loa loa specific antigen that can be used as the basis of an immunoassay for the diagnosis of Loa loa infection. <ul> <li>Speed up product development with NIH developed material that has already been tested and validated.</li> </ul> <ul> <li>A research material that can be used in the development of assays, validation of products or in quality control.</li> </ul> Research Material – Patent protection is not being pursued for this technology. (IC Reference No. 2015-035) 2022-03-08 2026-02-06 2026-02-06 2018-06-07 Immunodiagnosis, LL-SXP1, Loa, RM, VQXXXX, WIXXXX False True True NIHTT 37470483 Website Abstract 114108380 Klion, Amy NIAID - DIR NIAID Klion, Amy (NIAID) 0 114108381 Nutman, Thomas NIAID - DIR NIAID Nutman, Thomas (NIAID) 1 114108381 Nutman, Thomas NIAID - DIR NIAID Nutman, Thomas (NIAID) 1 114108380 Klion, Amy NIAID - DIR NIAID Klion, Amy (NIAID) 0 114102026 LL-SXP1 For The Immunodiagnosis Of Loa Loa E-003-2016-0 Research Material NIAID 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-3273] Recombinant LL-SXP-1 and Plasmid Encoding LL-SXP-1 for the Immunodiagnosis of Loa Loa&body=Please send me information about technology [TAB-3273] Recombinant LL-SXP-1 and Plasmid Encoding LL-SXP-1 for the Immunodiagnosis of Loa Loa. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-3273] Recombinant LL-SXP-1 and Plasmid Encoding LL-SXP-1 for the Immunodiagnosis of Loa Loa&body=Please send me information about technology [TAB-3273] Recombinant LL-SXP-1 and Plasmid Encoding LL-SXP-1 for the Immunodiagnosis of Loa Loa.">jonathan.motley@nih.gov</a><br> 114127910 VQXXXX 114127911 WIXXXX 114150747 LL-SXP1 114150748 Immunodiagnosis 114150749 Loa 114150750 RM TAB-3120 114095716 Compositions and Methods for Detecting Loa loa NIAID Collaboration Collaboration Sasi Bennuru, Papa Drame, Thomas Nutman <em>Loa loa</em> is a filarial nematode estimated to infect 3-13 million people in Central and Western Africa. In parts of Africa, mass administration of ivermectin is common for onchocerciasis and lymphatic filariasis control. However, some individuals infected with <em>Loa loa</em> microfilariae in high densities are known to experience post-ivermectin severe adverse events, such as encephalopathy, coma, or even death. Therefore, diagnostic tools that can accurately identify and differentiate <em>Loa loa</em> microfilariae from other filarial infections are needed. Microscopic evaluation of blood samples is the only current diagnostic method used to detect <em>Loa loa</em> microfilaremia in endemic areas, and is impractical for widespread screening. Molecular based assays are useful and are quantitative, but require the use of sophisticated instrumentation.<br /><br /> The inventors analyzed samples from <em>Loa loa</em> infected patients and uninfected controls, and have identified <em>Loa loa</em> microfilaria-specific antigens. The pending application claims a variety of means of detecting these antigens. <ul> <li>Highly specific to <em>Loa loa</em> microfilariae</li> <li>Highly sensitive</li> <li>Both diagnostic and quantitative</li> <li>Works with blood, urine, or saliva sample</li> </ul> <ul> <li>Diagnostics</li> <ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize the methods of treating human tuberculosis. For collaboration opportunities, please contact Theodoric A. Mattes, Ph.D. at <a href="mailto:theodoric.mattes@nih.gov">theodoric.mattes@nih.gov</a>or 1-240-627-3827. 2022-03-08 2026-02-06 2026-02-06 2021-10-29 2021-10-15 ANTIGENS, Diagnostics, Listed LPM Fenn as of 4/15/2015, Loa, Microfilariae, Post LPM Assignment Set 20150420, Pre LPM working set 20150418 False True True NIHTT 37470483 Website Abstract 114172305 Drame PM, et al. http://www.ncbi.nlm.nih.gov/pubmed/26884435 <a href="http://www.ncbi.nlm.nih.gov/pubmed/26884435">Drame PM, et al.</a> 114109197 Drame, Papa NIAID - DIR NIAID Drame, Papa (NIAID) 0 114109198 Bennuru, Sasi NIAID - DIR NIAID Bennuru, Sasi (NIAID) 0 114109199 Nutman, Thomas NIAID - DIR NIAID Nutman, Thomas (NIAID) 1 114109199 Nutman, Thomas NIAID - DIR NIAID Nutman, Thomas (NIAID) 1 114109197 Drame, Papa NIAID - DIR NIAID Drame, Papa (NIAID) 0 114109198 Bennuru, Sasi NIAID - DIR NIAID Bennuru, Sasi (NIAID) 0 114101814 Antigens For Use In Loa Loa Microfilariae Diagnostics E-140-2015-0 Filing authorized NIAID 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-3120] Compositions and Methods for Detecting Loa loa&body=Please send me information about technology [TAB-3120] Compositions and Methods for Detecting Loa loa. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-3120] Compositions and Methods for Detecting Loa loa&body=Please send me information about technology [TAB-3120] Compositions and Methods for Detecting Loa loa.">jonathan.motley@nih.gov</a><br> 114159997 E-140-2015-0 E-140-2015-0-PCT-02 COMPOSITIONS AND METHODS FOR DETECTING LOA LOA PCT Patent Cooperation Treaty PCT/US2016/029673 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2016/029673<br />Filed on 2016-04-28<br />Status: Expired 114164219 E-140-2015-0 E-140-2015-0-US-01 Compositions and Methods for Detecting Loa Loa PRV US 62/153,654 Abandoned US <br />Provisional (PRV) 62/153,654<br />Filed on 2015-04-28<br />Status: Abandoned 114168013 E-140-2015-0 E-140-2015-0-US-03 COMPOSITIONS AND METHODS FOR DETECTING LOA LOA National Stage US 10,598,655 15/569,507 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10598655 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10598655">10,598,655</a><br />Filed on 2017-10-26<br />Status: Issued 114148919 Post LPM Assignment Set 20150420 114148920 Pre LPM working set 20150418 114148921 Listed LPM Fenn as of 4/15/2015 114148922 Diagnostics 114148923 Microfilariae 114148924 Loa 114148925 ANTIGENS TAB-2669 114096853 Recombinant NIE Antigen from Strongyloides stercoralis NIAID Diagnostics, Infectious Disease, Licensing, Research Materials Diagnostics Infectious Disease Licensing Research Materials Franklin Neva, Thomas Nutman, Ravi Varatharajalu <em>Strongyloides stercoralis</em> is an intestinal nematode endemic that affects an estimated 30 to 100 million people worldwide. Many of these individuals may be asymptomatic for decades. The present invention discloses a NIE recombinant antigen that can be used in improved assays and diagnostics for <em>S. stercoralis</em> infection. The NIE antigen is the only one that is non-cross-reactive with sera from humans with other related filaria infections. The NIE antigen can be utilized as a skin test antigen for immediate hypersensitivity as well as for use in ELISA or other assays. <ul> <li>Only non-cross-reactive <em>Strongyloides antigen</em></li> <li>Use in a variety of formats</li> </ul> <ul> <li>Assays and diagnostics for <em>S. stercoralis</em> infection</li> </ul> Research Material – Patent protection is not being pursued for this technology. 2022-03-08 2026-02-06 2026-02-06 2013-11-13 ANTIGEN, DA2XXX, DAXXXX, DDXXXX, DXXXXX, recombinant, S., SS-NIE, Stercoralis False True <ul> <li>Prototype</li> <li>Pilot</li> <li>Pre-clinical</li> <li>In vitro data available</li> <li>In vivo data available (human)</li> </ul> True NIHTT 37470483 Website Abstract 114170606 Krolewiecki AJ, et al. http://www.ncbi.nlm.nih.gov/pubmed/20739501 <a href="http://www.ncbi.nlm.nih.gov/pubmed/20739501">Krolewiecki AJ, et al.</a> 114171927 Ramanathan R, et al. http://www.ncbi.nlm.nih.gov/pubmed/18558872 <a href="http://www.ncbi.nlm.nih.gov/pubmed/18558872">Ramanathan R, et al.</a> 114171928 Ravi V, et al. http://www.ncbi.nlm.nih.gov/pubmed/15891128 <a href="http://www.ncbi.nlm.nih.gov/pubmed/15891128">Ravi V, et al.</a> 114171929 Ravi V, et al. http://www.ncbi.nlm.nih.gov/pubmed/12467975 <a href="http://www.ncbi.nlm.nih.gov/pubmed/12467975">Ravi V, et al.</a> 114108215 Varatharajalu, Ravi George Washington University Varatharajalu, Ravi 0 114108216 Neva, Franklin NIAID - DIR Neva, Franklin 0 114108214 Nutman, Thomas NIAID - DIR NIAID Nutman, Thomas (NIAID) 1 114108214 Nutman, Thomas NIAID - DIR NIAID Nutman, Thomas (NIAID) 1 114108215 Varatharajalu, Ravi George Washington University Varatharajalu, Ravi 0 114108216 Neva, Franklin NIAID - DIR Neva, Franklin 0 114101980 SS-NIE, Recombinant Antigen From S. Stercoralis E-081-2012-0 Research Material NIAID 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2669] Recombinant NIE Antigen from Strongyloides stercoralis&body=Please send me information about technology [TAB-2669] Recombinant NIE Antigen from Strongyloides stercoralis. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2669] Recombinant NIE Antigen from Strongyloides stercoralis&body=Please send me information about technology [TAB-2669] Recombinant NIE Antigen from Strongyloides stercoralis.">jonathan.motley@nih.gov</a><br> 114123868 DA2XXX 114123869 DDXXXX 114123870 DXXXXX 114123871 DAXXXX 114145285 ANTIGEN 114145286 recombinant 114145287 SS-NIE 114145288 Stercoralis 114145289 S. TAB-2133 114096351 Novel Antigen for Use as Vaccine Against Nematode Infection NIAID Collaboration, Infectious Disease, Licensing, Therapeutics, Vaccines Collaboration Infectious Disease Licensing Therapeutics Vaccines David Abraham, Thomas Nutman This invention describes a new vaccine against <i>Strongyoides stercoralis</i>, which establishes a parasitic infection that affects an estimated 100-200 million people worldwide. The potential for fatal disease associated with <i>S. stercoralis</i> infection and the difficulty in treating hyperinfection underscores the need for prophylactic vaccines against the disease. This vaccine uses <i>S. stercoralis</i> immunoreactive antigen (SsIR); a novel antigen capable of providing 70-90 % protection for mice immunized with the antigen. In addition, sera from immunized mice have also been used to effectively protect naive mice from infection.<br><br> The invention may also have potential use in diminishing allergic responses, as <i>Strongyoides stercoralis</i> infection has been shown to reduce the murine response to allergens. Consequently, SsIR may be used to immunize individuals and reduce the allergic response. The antigen may also be used to identify homologous antigens from other parasitic nematodes that may be important for vaccine development. <ul> <li>Vaccines against <i>S. stercoralis</i> infection</li> <li>Discovery and use of other anti-parasitic antigens for vaccines</li> <li>Potential for allergy therapy</li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize the methods of treating human tuberculosis. For collaboration opportunities, please contact Theodoric A. Mattes, Ph.D. at <a href="mailto:theodoric.mattes@nih.gov">theodoric.mattes@nih.gov</a>or 1-240-627-3827. Available for licensing 2022-03-08 2026-02-06 2026-02-06 2021-10-29 2021-10-15 Against, ANTIGEN, DB2XXX, DBXXXX, DC2XXX, DCXXXX, DXXXXX, Immunorcaclive, Infection, Patent Category - Biotechnology, Protection, S., SslR, Stercaralis, Stercoralis, STRONGYLOIDES, Vaccine False True Early stage True NIHTT 37470483 Website Abstract 114106930 Abraham, David Thomas Jefferson University Abraham, David 0 114106929 Nutman, Thomas NIAID - DIR NIAID Nutman, Thomas (NIAID) 1 114106929 Nutman, Thomas NIAID - DIR NIAID Nutman, Thomas (NIAID) 1 114106930 Abraham, David Thomas Jefferson University Abraham, David 0 114101434 S. Stercoralis Immunoreactive Antigen (SslR) As A Vaccine For Protection Against Strongyloides Stercoralis Infection E-084-2010-0 Filing authorized NIAID, Thomas Jefferson University 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2133] Novel Antigen for Use as Vaccine Against Nematode Infection&body=Please send me information about technology [TAB-2133] Novel Antigen for Use as Vaccine Against Nematode Infection. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2133] Novel Antigen for Use as Vaccine Against Nematode Infection&body=Please send me information about technology [TAB-2133] Novel Antigen for Use as Vaccine Against Nematode Infection.">jonathan.motley@nih.gov</a><br> 114163890 E-084-2010-0 E-084-2010-0-US-03 Vaccine And Methods Of Use Against Strongyloides Stercoralis Infection National Stage US 9,056,068 13/575,987 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9056068 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9056068">9,056,068</a><br />Filed on 2012-08-15<br />Status: Issued 114166098 E-084-2010-0 E-084-2010-0-US-01 Human Monoclonal Antibodies That Bind Insulin-like Growth Factor (IGF) I and II PRV US 61/301,426 Abandoned US <br />Provisional (PRV) 61/301,426<br />Filed on 2010-02-04<br />Status: Abandoned 114166313 E-084-2010-0 E-084-2010-0-PCT-02 Vaccine And Methods of Use Against Strongyloides Stercoralis Infection PCT Patent Cooperation Treaty PCT/US2011/023320 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2011/023320<br />Filed on 2011-02-01<br />Status: Expired 114121411 DC2XXX 114121412 DB2XXX 114121413 DXXXXX 114121414 DCXXXX 114121415 DBXXXX 114140150 S. 114140151 Stercoralis 114140152 Immunorcaclive 114140153 ANTIGEN 114140154 SslR 114140155 Vaccine 114140156 Protection 114140157 Against 114140158 STRONGYLOIDES 114140159 Stercaralis 114140160 Infection 114140161 Patent Category - Biotechnology TAB-1996 114096216 Methods for Treating or Ameliorating Fibrosis by Inhibiting the Interaction between IL-21 Receptor (IL-21R) and IL-21 NIAID Immunology, Licensing, Oncology, Therapeutics Immunology Licensing Oncology Therapeutics Thomas Wynn This invention includes methods for treating or ameliorating fibrosis by inhibiting the interaction between IL-21 Receptor (IL-21R) and IL-21 using either anti-IL-21R monoclonal antibodies (or binding fragments of anti-IL-21R mAbs), anti-IL-21 monoclonal antibodies (or binding fragments of anti-IL-21 mAbs) or soluble IL-21R (or binding fragments of IL-21R). It is believed that the TH2 immune response, induced by IL-21, plays a major role in the in the pathogenesis of tissue fibrosis. Antagonism of IL-21R by anti-IL-21R monoclonal antibodies or the sequestration of IL-21 by soluble IL-21R or anti-IL-21 monoclonal antibodies has been demonstrated to reduce TH2 immune responses associated with fibrosis in animal models.<br /><br /> The causes of chronic tissue fibrosis are diverse and the market for a therapeutic that targets fibrosis is large. Fibrosis is associated with diverse causes which include: genetic diseases (such as cystic fibrosis); autoimmune diseases (such as scleroderma); chronic viral infections (such as hepatitis), parasitic infections (such as schistosomiasis); and occupational exposures to causative agents (such as asbestosis). Additionally, many cases of tissue fibrosis are idiopathic. <ul> <li>The treatment or amelioration of tissue fibrosis.</li> </ul> International rights available. Available for licensing. 2022-03-08 2026-02-06 2026-02-06 2009-07-29 Asbestosis, CB1AXX, CB1XXX, CB6XXX, CBXXXX, CXXXXX, Cystic fibrosis, DEFICIENCY, FIBROSIS, Hepatitis A, Hepatitis D, Hepatitis E, IL-21, Immunity, Inflammmation, Patent Category - Biotechnology, RECEPTOR, REDUCES, SCHISTOSOMIASIS, Schistosomiasis (Schistosoma sp.), Scleroderma, Scleroderma, systemic, Tissue, TYPE-2 False True True NIHTT 37470483 Website Abstract 114170892 Pesce J, et al. The IL-21 receptor augments Th2 effector function and alternative macrophage activation. https://www.ncbi.nlm.nih.gov/pubmed/16778988 <a href="https://www.ncbi.nlm.nih.gov/pubmed/16778988">Pesce J, et al. The IL-21 receptor augments Th2 effector function and alternative macrophage activation.</a> 114106709 Wynn, Thomas NIAID - DIR NIAID Wynn, Thomas (NIAID) 0 114106709 Wynn, Thomas NIAID - DIR NIAID Wynn, Thomas (NIAID) 0 114101279 IL-21 Receptor Deficiency Reduces Type-2 Immunity, Inflammmation And Tissue Fibrosis E-250-2005-0 Filing authorized Genetics Institute, Inc., NIAID, Wyeth 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-1996] Methods for Treating or Ameliorating Fibrosis by Inhibiting the Interaction between IL-21 Receptor (IL-21R) and IL-21&body=Please send me information about technology [TAB-1996] Methods for Treating or Ameliorating Fibrosis by Inhibiting the Interaction between IL-21 Receptor (IL-21R) and IL-21. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-1996] Methods for Treating or Ameliorating Fibrosis by Inhibiting the Interaction between IL-21 Receptor (IL-21R) and IL-21&body=Please send me information about technology [TAB-1996] Methods for Treating or Ameliorating Fibrosis by Inhibiting the Interaction between IL-21 Receptor (IL-21R) and IL-21.">jonathan.motley@nih.gov</a><br> 114162892 E-250-2005-0 E-250-2005-0-US-01 Methods and Compositions for treating and preventing fibrosis (Wyeth Ref.: AM101991L1) PRV US 60/671,374 Abandoned US <br />Provisional (PRV) 60/671,374<br />Filed on 2005-04-14<br />Status: Abandoned 114165410 E-250-2005-0 E-250-2005-0-US-02 METHODS FOR TREATING AND PREVENTING FIBROSIS ORD US 7,910,105 11/402,885 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7910105 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7910105">7,910,105</a><br />Filed on 2006-04-13<br />Status: Expired 114165411 E-250-2005-0 E-250-2005-0-PCT-03 METHODS FOR TREATING AND PREVENTING FIBROSIS BY IL-21/IL-21R ANTAGONISTS PCT Patent Cooperation Treaty PCT/US2006/013829 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2006/013829<br />Filed on 2006-04-13<br />Status: Expired 114166366 E-250-2005-0 E-250-2005-0-US-44 Methods For Treating And Preventing Fibrosis DIV US 13/030,840 Abandoned US <br />Divisional (DIV) 13/030,840<br />Filed on 2011-02-18<br />Status: Abandoned 114120508 CB6XXX 114120509 CB1AXX 114120510 CXXXXX 114120511 CBXXXX 114120512 CB1XXX 114138414 IL-21 114138415 RECEPTOR 114138416 DEFICIENCY 114138417 REDUCES 114138418 TYPE-2 114138419 Immunity 114138420 Inflammmation 114138421 Tissue 114138422 FIBROSIS 114138423 Patent Category - Biotechnology 114156859 Hepatitis D 114156860 Scleroderma, systemic 114156861 Hepatitis A 114156862 Asbestosis 114156863 Cystic fibrosis 114156864 Hepatitis E 114156865 SCHISTOSOMIASIS 114157883 Schistosomiasis (Schistosoma sp.) 114158517 Scleroderma TAB-5090 165796379 Humanized 40H3 Antibody NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Antonella Antignani, David Fitzgerald, Robert Sarnovsky <h2>Summary:</h2> <p>The NCI seeks research co-development partners or licensees for monoclonal antibodies that specifically target cancer-expressed EGFR.</p> <h2>Description of Technology:</h2> <p>Epidermal growth factor receptor (EGFR) is a well-known oncogenic driver in lung cancer, head and neck cancer, glioblastoma multiforme (GBM) and other cancers. NCI inventors have previously isolated a mouse monoclonal antibody that binds to the human EGFRvIII &ndash; but not wildtype EGFR known as the 40H3 antibody (NCI Ref: E-103-2019). To improve the 40H3 antibody&rsquo;s suitability for the clinic, the inventors humanized the antibody through the generation of multiple variants with distinct sequences. The inventors produced about 14 humanized candidates of the 40H3 antibody. Significantly, CAR Ts using one of the antibodies (A10) showed potent killing of cancer cells in various pre-clinical models overexpressing EGFR. The pre-clinical results obtained to date suggest that the A10 antibody is a promising candidate for development as various therapeutics for the treatment of EGFRvIII-expressing cancers.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Cancer therapeutic against numerous EGFRvIII-expressing tumor types &ndash; including, but not limited to, lung cancer, head and neck cancer and GBM.</li> <li>Therapeutic applications of the unconjugated antibodies</li> <li>Use of the unconjugated antibodies as a targeting moiety in antibody-drug conjugates (ADCs), radio-immunotherapies (RITs) and chimeric antigen receptors (CARs)</li> <li>Diagnostic agent for detection and monitoring levels of EGFRvIII-expressing cancers</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Less non-specific cell killing using humanized EGFRvIII antibodies with high EGFRvIII binding specificity will result in fewer and lower grade potential side effects</li> <li>Therapeutic development against various common and rare cancers represent many paths to market and out-licensing opportunities</li> <li><span style="font-size:12pt"><span style="tab-stops:list .5in"><span style="text-autospace:ideograph-numeric ideograph-other"><span style="font-family:&quot;Times New Roman&quot;,serif">CAR Ts using the A10 antibody are available for immediate testing</span></span></span></span></li> <li><span style="font-size:12pt"><span style="tab-stops:list .5in"><span style="text-autospace:ideograph-numeric ideograph-other"><span style="font-family:&quot;Times New Roman&quot;,serif">A10 binding EGFR when over-expressed from amplified EGFR is specific to various cancers&nbsp;&nbsp;</span></span></span></span></li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for monoclonal antibodies that specifically target cancer-expressed EGFR. 2026-01-28 2026-02-05 2026-02-05 2026-02-05 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-103-2019 165796614 Fitzgerald, David NIH - NCI NCI Fitzgerald, David (NCI) 1 165796640 Antignani, Antonella NIH - NCI NCI Antignani, Antonella (NCI) 2 165796655 Sarnovsky, Robert NIH - NCI NCI Sarnovsky, Robert (NCI) 3 165796614 Fitzgerald, David NIH - NCI NCI Fitzgerald, David (NCI) 1 165796640 Antignani, Antonella NIH - NCI NCI Antignani, Antonella (NCI) 2 165796655 Sarnovsky, Robert NIH - NCI NCI Sarnovsky, Robert (NCI) 3 165796382 Humanization of the monoclonal antibody, 40H3: generation of improved variants E-188-2023-0 Filing authorized Laboratory of Molecular Biology, National Cancer Institute (NCI), NIH - NCI 83731987 Dhal, Abritee abritee.dhal@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-5090] Humanized 40H3 Antibody&body=Please send me information about technology [TAB-5090] Humanized 40H3 Antibody.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dhal, Abritee<br><a href="mailto:abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-5090] Humanized 40H3 Antibody&body=Please send me information about technology [TAB-5090] Humanized 40H3 Antibody.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">abritee.dhal@nih.gov</a><br> 165796387 E-188-2023-0 E-188-2023-0-US-01 HUMANIZED 40H3 ANTIBODY PRV US 63/525,493 Expired US <br />Provisional (PRV) 63/525,493<br />Filed on 2023-07-07<br />Status: Expired 165796388 E-188-2023-0 E-188-2023-0-PC-01 HUMANIZED 40H3 ANTIBODY PCT Patent Cooperation Treaty PCT/US2024/037091 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2024/037091<br />Filed on 2024-07-08<br />Status: Expired 165796389 E-188-2023-0 E-188-2023-0-JP-01 HUMANIZED 40H3 ANTIBODY National Stage Japan 2026-500043 Pending Japan <br />National Stage 2026-500043<br />Filed on 2026-01-05<br />Status: Pending 165796390 E-188-2023-0 E-188-2023-0-CA-01 HUMANIZED 40H3 ANTIBODY National Stage Canada 3297257 Pending Canada <br />National Stage 3297257<br />Filed on 2025-12-30<br />Status: Pending 165796391 E-188-2023-0 E-188-2023-0-AU-01 HUMANIZED 40H3 ANTIBODY National Stage Australia 2024296940 Pending Australia <br />National Stage 2024296940<br />Filed on 2026-01-13<br />Status: Pending 165796392 E-188-2023-0 E-188-2023-0-CN-01 HUMANIZED 40H3 ANTIBODY National Stage China 202480057586.7 Pending China <br />National Stage 202480057586.7<br />Filed on 2026-04-01<br />Status: Pending 165796393 E-188-2023-0 E-188-2023-0-US-02 HUMANIZED 40H3 ANTIBODY National Stage US 19/497,173 Pending US <br />National Stage 19/497,173<br />Filed on 2025-12-24<br />Status: Pending 165796394 E-188-2023-0 E-188-2023-0-EP-01 HUMANIZED 40H3 ANTIBODY National Stage European Patent 24748511.3 Pending European Patent <br />National Stage 24748511.3<br />Filed on 2026-01-27<br />Status: Pending TAB-4590 151763295 Concurrent Use of Atorvastatin During Chemotherapy Reduces Cisplatin-induced Ototoxicity NIDCD Oncology, Research Materials, Therapeutics Oncology Research Materials Therapeutics Lisa Cunningham, Katharine Fernandez, Nicle Schmitt <p>This technology includes the use of atorvastatin, a medication to manage hypercholesterolemia, as a method to protect patients receiving cisplatin from hearing loss. Cisplatin chemotherapy is indicated in various cancer types in adults and children and is known to cause hearing loss. A patient on atorvastatin during chemotherapy is 46% less likely to acquire a significant cisplatin-induced hearing loss relative to a non-statin user. Atorvastatin is an FDA-approved medication routinely prescribed and well-tolerated clinically. The quality of life in cisplatin-treated cancer patients may be dramatically improved by using atorvastatin to protect their hearing during cisplatin-based chemotherapy.</p> Currently, there is no FDA-approved clinical treatment to prevent hearing loss in patients receiving cisplatin as part of their cancer chemotherapy. Atorvastatin has a good safety profile, oral administration is non-invasive; significant side effects are rare, and statins do not reduce survival rates in cisplatin-treated patients. Atorvastatin could be rapidly translated into clinical practice to protect the hearing of cancer patients undergoing cisplatin therapy. 2023-12-12 2024-08-12 2026-01-30 2024-03-27 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 151763348 Fernandez K, et al. https://pubmed.ncbi.nlm.nih.gov/33393488/ <a href="https://pubmed.ncbi.nlm.nih.gov/33393488/">Fernandez K, et al.</a> 151763310 Cunningham, Lisa National Institute on Deafness and Other Communication Disorders (NIDCD) NIDCD Cunningham, Lisa (NIDCD) 1 151763320 Schmitt, Nicle Schmitt, Nicle 2 151763336 Fernandez, Katharine National Institute on Deafness and Other Communication Disorders (NIDCD) NIDCD Fernandez, Katharine (NIDCD) 3 151763310 Cunningham, Lisa National Institute on Deafness and Other Communication Disorders (NIDCD) NIDCD Cunningham, Lisa (NIDCD) 1 151763320 Schmitt, Nicle Schmitt, Nicle 2 151763336 Fernandez, Katharine National Institute on Deafness and Other Communication Disorders (NIDCD) NIDCD Fernandez, Katharine (NIDCD) 3 151763301 Concurrent Use Of Atorvastatin During Chemotherapy Reduces Cisplatin-induced Ototoxicity E-029-2020-0 Filing authorized National Institute on Deafness and Other Communication Disorders (NIDCD) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-4590] Concurrent Use of Atorvastatin During Chemotherapy Reduces Cisplatin-induced Ototoxicity&body=Please send me information about technology [TAB-4590] Concurrent Use of Atorvastatin During Chemotherapy Reduces Cisplatin-induced Ototoxicity. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-4590] Concurrent Use of Atorvastatin During Chemotherapy Reduces Cisplatin-induced Ototoxicity&body=Please send me information about technology [TAB-4590] Concurrent Use of Atorvastatin During Chemotherapy Reduces Cisplatin-induced Ototoxicity.">shmilovm@nih.gov</a><br> 157762794 E-029-2020-0 E-029-2020-0-US-01 Use of Statins to Treat or Prevent Drug Induced Hearing Loss PRV US 62/966,794 Abandoned US <br />Provisional (PRV) 62/966,794<br />Filed on 2020-01-28<br />Status: Abandoned 157762799 E-029-2020-0 E-029-2020-0-PCT-02 USE OF STATINS TO TREAT OR PREVENT DRUG INDUCED HEARING LOSS PCT Patent Cooperation Treaty PCT/U2021/014918 Expired Patent Cooperation Treaty <br />(PCT) PCT/U2021/014918<br />Filed on 2021-01-25<br />Status: Expired 157762804 E-029-2020-0 E-029-2020-0-EP-03 USE OF STATINS TO TREAT OR PREVENT DRUG INDUCED HEARING LOSS National Stage European Patent 21705831.2 Abandoned European Patent <br />National Stage 21705831.2<br />Filed on 2021-01-25<br />Status: Abandoned 157762809 E-029-2020-0 E-029-2020-0-US-04 USE OF STATINS TO TREAT OR PREVENT DRUG-INDUCED HEARING LOSS National Stage US 17/791,239 Abandoned US <br />National Stage 17/791,239<br />Filed on 2022-07-07<br />Status: Abandoned TAB-5004 158054566 PET Imaging Agents for Fungal Infections NHLBI Collaboration, Diagnostics, Licensing Collaboration Diagnostics Licensing Falguni Bhattacharyya, Dima Hammoud, Swati Shah, Rolf Swenson, Peter Williamson, Xiang Zhang <p><span style="font-size:12.0pt"><span style="font-family:&quot;Times New Roman&quot;,serif">Available for licensing and commercial development are patent rights covering PET imaging agents, methods of their synthesis, and their uses in imaging specific fungal infections. &nbsp;Fungal infections remain a global health problem resulting in over 1.5 million annual deaths.&nbsp; Immunocompromised patients, especially those undergoing cancer treatments or transplantation, are particularly vulnerable and the fungus, <em>Aspergillus fumigatus, </em>is of particular concern.&nbsp; To date, no fungal-<em>specific</em> imaging agents are available&mdash;existing imaging agents cannot discern fungal pathogens from bacteria or viruses and generally cannot differentiate between infection and inflammation. One naturally-occurring disaccharide, cellobiose, is selectively hydrolyzed by <em>Aspergillus fumigatus</em> and not by bacteria or human cells. &nbsp;The fluorinated version of the disaccharide, <sup>18</sup>F-Fluorodeoxycellobiose ([18F]-FCB), has been synthesized and tested. [18F]-FCB is particularly useful as it is not metabolized by human enzymes and hydrolyzed only by fungal beta-glucosidases. &nbsp;Both in vitro and in vivo testing in animal models (see publications below) of different infections and inflammation confirmed radioactivity accumulation only in live pathogenic fungi.&nbsp; Imaging with [18F]-FCB in mice infected with Aspergillus, for example, &nbsp;showed that the imaging agent can detect whether there has been a response to antifungal therapy.&nbsp; One major advantage is that synthesis of [18F]-FCB is simple and efficient using readily commercially available reagents. &nbsp;&nbsp;The radiolabeled agent can then be administered intravenously, and imaging performed 90-120 minutes after injection.&nbsp; A radiosynthesis kit has also been developed and can be used at ambient temperature to produce [18F]-FCB from a commercially acquired kit in less than two hours without the need for a cyclotron.</span></span></p> <ul> <li>Imaging of live infections</li> </ul> 2024-09-04 2025-08-13 2026-01-29 2025-05-09 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 158056239 Hammoud, Dima Radiology and Imaging Sciences CC Hammoud, Dima (CC) 1 158056738 Shah, Swati Clinical Center (CC) Shah, Swati 2 158057071 Williamson, Peter NIAID - DIR NIAID Williamson, Peter (NIAID) 3 158057105 Swenson, Rolf National Heart, Lung, and Blood Institute (NHLBI) NHLBI Swenson, Rolf (NHLBI) 4 158057174 Zhang, Xiang National Heart, Lung, and Blood Institute (NHLBI) NHLBI Zhang, Xiang (NHLBI) 5 158057735 Bhattacharyya, Falguni National Heart, Lung, and Blood Institute (NHLBI) NHLBI Bhattacharyya, Falguni (NHLBI) 6 158056239 Hammoud, Dima Radiology and Imaging Sciences CC Hammoud, Dima (CC) 1 158056738 Shah, Swati Clinical Center (CC) Shah, Swati 2 158057071 Williamson, Peter NIAID - DIR NIAID Williamson, Peter (NIAID) 3 158057105 Swenson, Rolf National Heart, Lung, and Blood Institute (NHLBI) NHLBI Swenson, Rolf (NHLBI) 4 158057174 Zhang, Xiang National Heart, Lung, and Blood Institute (NHLBI) NHLBI Zhang, Xiang (NHLBI) 5 158057735 Bhattacharyya, Falguni National Heart, Lung, and Blood Institute (NHLBI) NHLBI Bhattacharyya, Falguni (NHLBI) 6 158054574 Radiolabeled Sugars For Imaging Of Fungal Infections E-163-2019-0 Filing authorized Clinical Center (CC), National Heart, Lung, and Blood Institute (NHLBI), NIAID 158054579 Enzymatic Radiosynthesis of 2-deoxy 2-{18F] fluorocellobiose E-080-2023-0 Filing authorized Clinical Center (CC), National Heart, Lung, and Blood Institute (NHLBI) 153929528 Ghosh, Malabika malabika.ghosh@nih.gov
United States of America malabika.ghosh@nih.gov?subject=Web Inquiry on [TAB-5004] PET Imaging Agents for Fungal Infections&body=Please send me information about technology [TAB-5004] PET Imaging Agents for Fungal Infections. Ghosh, Malabika<br><a href="mailto:malabika.ghosh@nih.gov?subject=Web Inquiry on [TAB-5004] PET Imaging Agents for Fungal Infections&body=Please send me information about technology [TAB-5004] PET Imaging Agents for Fungal Infections.">malabika.ghosh@nih.gov</a><br> 158054584 E-080-2023-0 E-080-2023-0-US-01 ENZYMATIC RADIOSYNTHESIS OF DEOXY-[18F] FLUOROCELLOBIOSE AND DEOXY-[18F] FLUOROCELLOTRIOSE PRV US 63/492,302 Expired US <br />Provisional (PRV) 63/492,302<br />Filed on 2023-03-27<br />Status: Expired 158054585 E-080-2023-0 E-080-2023-0-PC-01 ENZYMATIC RADIOSYNTHESIS OF DEOXY-[18F] FLUOROCELLOBIOSE AND DEOXY-[18F] FLUOROCELLOTRIOSE PCT Patent Cooperation Treaty PCT/US2024/021440 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2024/021440<br />Filed on 2024-03-26<br />Status: Expired 163509665 E-080-2023-0 E-080-2023-0-US-02 ENZYMATIC RADIOSYNTHESIS OF DEOXY-[18F] FLUOROCELLOBIOSE AND DEOXY-[18F] FLUOROCELLOTRIOSE National Stage US 19/167,752 Pending US <br />National Stage 19/167,752<br />Filed on 2025-09-22<br />Status: Pending 163509710 E-080-2023-0 E-080-2023-0-EP-01 ENZYMATIC RADIOSYNTHESIS OF DEOXY-[18F] FLUOROCELLOBIOSE AND DEOXY-[18F] FLUOROCELLOTRIOSE National Stage European Patent 24721311.9 Pending European Patent <br />National Stage 24721311.9<br />Filed on 2025-09-18<br />Status: Pending 165818912 E-080-2023-0 E-080-2023-0-HK-01 ENZYMATIC RADIOSYNTHESIS OF DEOXY-[18F] FLUOROCELLOBIOSE AND DEOXY-[18F] FLUOROCELLOTRIOSE National Stage Hong Kong In Preparation Hong Kong <br />National Stage None<br />Filed on None<br />Status: In Preparation TAB-3817 114097664 Lymphatic Filariasis Biomarkers for Detection and Surveillance NIAID Sasi Bennuru, Thomas Nutman Lymphatic filariasis (elephantiasis; LF) is a neglected tropical disease that affects over 120 million people throughout the tropics and sub­tropics of Asia, Africa, the Western Pacific, and parts of the Caribbean and South America. LF results from infection with the filarial parasites Wuchereria bancrofti or Brugia malayi. Current methods of confirming active infection by W. bancrofti or B. malayi include microscopy and immunoassays using serum/plasma extracted from the patient. However, the sensitivity of microscopy detection varies among patients, and immunoassays show cross-reactivity with antibodies directed towards other parasites, such as Onchocerca volvulus or Loa loa whose geographic distribution can overlap with the LF-causing filarial parasites. <br /><br /> This new technology addresses the limitations of cross-reactivity through the detection of a single antigen, Wb5B, selected due to a lack of homologs in other filarial parasites that infect humans. Preliminary data indicates that Wb5B is immunogenic, highly specific (>99%), and accurate (>90%) for the detection of W. bancrofti infection in sera from humans and other mammalian sources. The antigen can be isolated in soluble form for integration in a variety of diagnostic assay formats. <ul> <li>Increased specificity compared to available diagnostics</li> <li>Differentiation from other parasites with similar geographic footprints</li> </ul> <ul> <li>Diagnostics for W. bancrofti infection</li> <li>Surveillance for W. bancrofti prevalence</li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize this technology. For collaboration opportunities, please contact Theodoric Mattes at <a href="mailto: theodoric.mattes@nih.gov."> theodoric.mattes@nih.gov.</a>or 240-627-3827. 2022-09-28 2026-01-22 2026-01-22 2022-09-28 2IXXXX, 2XXXXX, Biomarkers, Detection, Filariasis, Lymphatic, Surveillance False False True NIHTT 37470483 Website Abstract E-281-2010-0 114111637 Bennuru, Sasi NIAID - DIR NIAID Bennuru, Sasi (NIAID) 0 114111638 Nutman, Thomas NIAID - DIR NIAID Nutman, Thomas (NIAID) 1 114111638 Nutman, Thomas NIAID - DIR NIAID Nutman, Thomas (NIAID) 1 114111637 Bennuru, Sasi NIAID - DIR NIAID Bennuru, Sasi (NIAID) 0 114102914 Lymphatic Filariasis Biomarkers For Detection And Surveillance E-093-2022-0 Filing authorized NIAID 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-3817] Lymphatic Filariasis Biomarkers for Detection and Surveillance&body=Please send me information about technology [TAB-3817] Lymphatic Filariasis Biomarkers for Detection and Surveillance. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-3817] Lymphatic Filariasis Biomarkers for Detection and Surveillance&body=Please send me information about technology [TAB-3817] Lymphatic Filariasis Biomarkers for Detection and Surveillance.">jonathan.motley@nih.gov</a><br> 114169653 E-093-2022-0 E-093-2022-0-US-01 COMPOSITIONS AND METHODS FOR DETECTING LYMPHATIC FILARIASIS PRV US 63/347,794 Expired US <br />Provisional (PRV) 63/347,794<br />Filed on 2022-06-01<br />Status: Expired 114129707 2IXXXX 114129710 2XXXXX 114155636 Filariasis 114155637 Lymphatic 114155638 Biomarkers 114155639 Detection 114155640 Surveillance TAB-3343 114097258 Methods for Diagnosing and Treating Mycobacterium tuberculosis (Mtb) Infection through Detection of CD153 Expression Level. NIAID Collaboration Collaboration Daniel Barber, Keith Kauffman, Michelle Sallin <em>Mycobacterium tuberculosis</em> (Mtb) infection continues to be the leading cause of death due to a single infectious agent and poses significant global health challenges. Past research has shown that CD4 T cells are essential for resistance to Mtb infection, and for decades it has been thought that IFN(?) production is the primary mechanism of CD4 T cell-mediated protection. <br /><br /> NIAID researchers have discovered that the expression of TNF superfamily molecule CD153 (TNSF8) is required for control of the pulmonary Mtb infection by CD4 T cells. The results have shown that, in Mtb infected mice, CD153 expression is highest on Ag-specific Th1 cells in the lung tissue parenchyma. On the contrary, CD153 deficient mice have developed high pulmonary bacterial loads and succumb early to Mtb infection. In Mtb infected non-human primates, CD153 expression is much higher on Ag-specific CD4 T cells in the airways compared to the blood, and the frequency of Mtb-specific CD153-expressing CD4 T cells inversely correlates with bacterial loads in granulomas. Further, in Mtb infected humans, CD153 defines a subset of highly polyfunctional Mtb-specific CD4 T cells that are much more abundant in individuals with controlled latent Mtb infection compared to those with active TB. Since the expression of CD153 by CD4 T cells is a major immune mechanism of host protection against Mtb infection, the discovery can be used to effectively diagnose and treat Mtb infections in the future. <ul> <li>Ability to be used as a target for Mtb diagnostics and therapeutics</li> </ul> <ul> <li><em>Mycobacterium tuberculosis</em> diagnostic that measures the production of CD153 as an indicator of the disease and its severity </li> <li>A companion diagnostic can be used to determine the effectiveness of a vaccine against a <em>Mycobacterium tuberculosis</em> infection in a subject</li> <li>Therapeutic use to treat <em>Mycobacterium tuberculosis</em> in a subject</li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize the methods of treating human tuberculosis. For collaboration opportunities, please contact Theodoric A. Mattes, Ph.D. at <a href="mailto:theodoric.mattes@nih.gov">theodoric.mattes@nih.gov</a>or 1-240-627-3827. 2022-03-08 2026-01-22 2026-01-22 2021-11-02 CD153/CD30, Diagnosis, PATHWAY, Targeting, treatment, TUBERCULOSIS False True True NIHTT 37470483 Website Abstract 114172546 Sallin, Michelle A., et al. https://www.ncbi.nlm.nih.gov/pubmed/30202016 <a href="https://www.ncbi.nlm.nih.gov/pubmed/30202016">Sallin, Michelle A., et al.</a> 114109964 Sallin, Michelle NIAID - DIR NIA Sallin, Michelle (NIA) 0 114109965 Kauffman, Keith NIAID - DIR NIAID Kauffman, Keith (NIAID) 0 114109963 Barber, Daniel NIAID - DIR NIAID Barber, Daniel (NIAID) 1 114109963 Barber, Daniel NIAID - DIR NIAID Barber, Daniel (NIAID) 1 114109964 Sallin, Michelle NIAID - DIR NIA Sallin, Michelle (NIA) 0 114109965 Kauffman, Keith NIAID - DIR NIAID Kauffman, Keith (NIAID) 0 114102501 Targeting The CD153/CD30 Pathway For The Treatment And Diagnosis Of Tuberculosis E-085-2018-0 Filing authorized NIAID 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-3343] Methods for Diagnosing and Treating Mycobacterium tuberculosis (Mtb) Infection through Detection of CD153 Expression Level.&body=Please send me information about technology [TAB-3343] Methods for Diagnosing and Treating Mycobacterium tuberculosis (Mtb) Infection through Detection of CD153 Expression Level.. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-3343] Methods for Diagnosing and Treating Mycobacterium tuberculosis (Mtb) Infection through Detection of CD153 Expression Level.&body=Please send me information about technology [TAB-3343] Methods for Diagnosing and Treating Mycobacterium tuberculosis (Mtb) Infection through Detection of CD153 Expression Level..">jonathan.motley@nih.gov</a><br> 114168784 E-085-2018-0 E-085-2018-0-US-01 CD153 AND MYCOBACTERIUM TUBERCULOSIS INFECTION PRV US 62/633,816 Abandoned US <br />Provisional (PRV) 62/633,816<br />Filed on 2018-02-22<br />Status: Abandoned 114168847 E-085-2018-0 E-085-2018-0-PCT-02 CD153 AND/OR CD30 IN INFECTION PCT Patent Cooperation Treaty PCT/US2019/019164 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2019/019164<br />Filed on 2019-02-22<br />Status: Expired 114169048 E-085-2018-0 E-085-2018-0-US-04 CD153 AND/OR CD30 IN INFECTION National Stage US 16/971,144 Abandoned US <br />National Stage 16/971,144<br />Filed on 2020-08-19<br />Status: Abandoned 114151500 CD153/CD30 114151501 PATHWAY 114151502 treatment 114151503 Diagnosis 114151504 TUBERCULOSIS 114151505 Targeting TAB-4830 152187485 Recombinant IgG Monoclonal Antibody-Based Detection of Taenia Antigen In Humans And Pigs NIAID Hector Garcia-Garcia, Siddhartha Mahanty, Theodore Nash, Thomas Nutman, Elise O'Connell <p>The pork tapeworm, Taenia solium, is endemic in most of Asia, Latin America, and Sub-Saharan Africa. The risk of infection is increased in regions where pigs are raised in closed proximity to humans, with migration from endemic regions being directly proportional to the prevalence of infection in high-income countries. Human infection by T. solium occurs following oral ingestion of eggs passed in human feces from an infected carrier. The larvae can travel anywhere in the human body. Neurocysticercosis (NCC) occurs when the larvae traverse the blood-brain barrier and penetrate the central nervous system. Diagnosis of NCC is typically made through radiological imaging studies (such as computed tomography or magnetic resonance imaging) to visualize the morphology, stage, and location of the cysts.</p> <p>Investigators at NIAID have developed the recombinant IgG monoclonal antibody known as TsG10, which can target T. solium circulating antigens. An expression vector to produce TsG10 is available for expression in mammalian cell lines. The resulting construct allows for a scalable, repeatable, and broadly accessible production of monoclonal antibodies for both human and veterinary use. The TsG10 monoclonal antibodies are adaptable for plate-based diagnostic assays like ELISAs, to support a diagnosis of NCC.</p> <ul> <li>Detection of active T. solium infection</li> <li>Scalable and repeatable production of a monoclonal antibody targeting T. solium</li> <li>Materials available for development or licensing</li> </ul> <ul> <li>Plate-based diagnostic immunoassays, both human and veterinary, for the detection of T. solium circulating antigen</li> <li>Production of TsG10 recombinant monoclonal antibodies</li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. For collaboration opportunities, please contact Theodoric Mattes at 240–627–3827, or theodoric.mattes@nih.gov. 2024-01-16 2026-01-22 2026-01-22 2023-12-11 FOOD, HEALTH, Livestock, Monoclonal Antibody, pork, SOLIUM, TAENIA, tapeworm False False Research material True 37470483 Website Abstract 152187658 Nutman, Thomas National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Nutman, Thomas (NIAID) 1 152187733 O'Connell, Elise National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID O'Connell, Elise (NIAID) 2 152187764 Nash, Theodore National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Nash, Theodore (NIAID) 3 152187788 Mahanty, Siddhartha National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Mahanty, Siddhartha (NIAID) 4 152187855 Garcia-Garcia, Hector MedStar Health Research Institute Inc Garcia-Garcia, Hector 5 152187658 Nutman, Thomas National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Nutman, Thomas (NIAID) 1 152187733 O'Connell, Elise National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID O'Connell, Elise (NIAID) 2 152187764 Nash, Theodore National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Nash, Theodore (NIAID) 3 152187788 Mahanty, Siddhartha National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Mahanty, Siddhartha (NIAID) 4 152187855 Garcia-Garcia, Hector MedStar Health Research Institute Inc Garcia-Garcia, Hector 5 152187567 Recombinant IgG Monoclonal Antibody-based Detection Of Taenia Antigen In Humans And Pigs E-043-2022-0 Research Material NIAID, University of Melbourne 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-4830] Recombinant IgG Monoclonal Antibody-Based Detection of Taenia Antigen In Humans And Pigs&body=Please send me information about technology [TAB-4830] Recombinant IgG Monoclonal Antibody-Based Detection of Taenia Antigen In Humans And Pigs. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-4830] Recombinant IgG Monoclonal Antibody-Based Detection of Taenia Antigen In Humans And Pigs&body=Please send me information about technology [TAB-4830] Recombinant IgG Monoclonal Antibody-Based Detection of Taenia Antigen In Humans And Pigs.">jonathan.motley@nih.gov</a><br> 152205568 TAENIA 152205572 SOLIUM 152205595 Monoclonal Antibody 152205691 pork 152205698 tapeworm 152205707 FOOD 152205718 Livestock 152205728 HEALTH TAB-4829 152173053 Vaccine for Cats to Block Toxoplasma Gondii Oocyst Shedding and Transmission NIAID J. P. Dubey, Michael Grigg, Lukes Julius, Viviana Pszenny, Aline Sardinha da Silva <p>Toxoplasma gondii is the zoonotic causative agent of toxoplasmosis, a disease of significant concern for pregnant persons and livestock. A member of the phylum Apicomplexa, Toxoplasma gondii can infect almost any cell type found in mammals and birds. There are multiple transmission pathways, including consumption of undercooked meat from infected animals, consumption of unwashed plants, contaminated water supplies, blood transfers, and congenital transfer. Felines are considered the definitive host of Toxoplasma gondii. Direct or indirect transmission can occur via contact with the stool of infected felines.</p> <p>Researchers at the National Institute of Allergy and Infectious Diseases (NIAID), the U.S. Department of Agriculture (USDA), and the University of South Bohemia (Česke; Budějovice, Czechia) have demonstrated that T. gondii strains lacking expression of either the intracellular transport protein IFT88 or the CYS-6-type surface antigen SRS15B prevent the formation of oocysts and have potential for broad immunity to T. gondii. The inventors propose that mass inoculation of felines, specifically wild or feral felines, with a live vaccine developed from these strains could result in a significant reduction in oocyst production and environment contamination, reducing further infection in a geographical area. It is also proposed that loss of IFT88 or SRS15B homologs in other Apicomplexa parasites, like Neospora, Sarcocystis, or Cryptosporidium could have a similar impact.</p> <ul> <li>100% blocked Toxoplasma gondii oocyst shedding in felines</li> <li>Detectable seroconversion protective against future Toxoplasma gondii infection</li> <li>Scalable production strain with predictable inactivation of IFT88 or SRS15B gene</li> <li>Materials available for development or licensing</li> </ul> <ul> <li>Live vaccine for felines against Toxoplasma gondii infection</li> <li>Reduction in environmental Toxoplasma gondii oocysts</li> </ul> This technology is available for licensing for commercial development in accordance with 35 U.S.C. § 209 and 37 CFR Part 404, as well as for further development and evaluation under a research collaboration. 2024-01-12 2026-01-22 2026-01-22 2023-12-11 FELINE, Live-Attenuated, TOXOPLASMA, Toxoplasmosis, Vaccine, VETERINARY False False Pre-Clinical True 37470483 Website Abstract E-118-2023-1 E-118-2023-2 152173134 Grigg, Michael National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Grigg, Michael (NIAID) 1 152173144 Sardinha da Silva, Aline National Institute of Allergy and Infectious Diseases (NIAID/NIH) Sardinha da Silva, Aline 2 152173153 Pszenny, Viviana National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Pszenny, Viviana (NIAID) 3 152173157 Dubey, J. P. US Department of Agriculture (USDA) Dubey, J. P. 4 152173172 Julius, Lukes University of South Bohemia in Ceské Budejovice Julius, Lukes 5 152173134 Grigg, Michael National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Grigg, Michael (NIAID) 1 152173144 Sardinha da Silva, Aline National Institute of Allergy and Infectious Diseases (NIAID/NIH) Sardinha da Silva, Aline 2 152173153 Pszenny, Viviana National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Pszenny, Viviana (NIAID) 3 152173157 Dubey, J. P. US Department of Agriculture (USDA) Dubey, J. P. 4 152173172 Julius, Lukes University of South Bohemia in Ceské Budejovice Julius, Lukes 5 152173064 IFT88-Based Vaccine for cats to block Toxoplasma gondii oocyst shedding and transmission E-118-2023-0 Filing authorized National Institute of Allergy and Infectious Diseases (NIAID/NIH), US Department of Agriculture (USDA) 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-4829] Vaccine for Cats to Block Toxoplasma Gondii Oocyst Shedding and Transmission&body=Please send me information about technology [TAB-4829] Vaccine for Cats to Block Toxoplasma Gondii Oocyst Shedding and Transmission. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-4829] Vaccine for Cats to Block Toxoplasma Gondii Oocyst Shedding and Transmission&body=Please send me information about technology [TAB-4829] Vaccine for Cats to Block Toxoplasma Gondii Oocyst Shedding and Transmission.">jonathan.motley@nih.gov</a><br> 152175187 TOXOPLASMA 152175273 Toxoplasmosis 152175309 FELINE 152175405 Vaccine 152175409 Live-Attenuated 152175423 VETERINARY TAB-4047 147157329 Devices for Improved Tissue Cryopreservation and Recovery NEI Collaboration, Dermatology, Ear, Nose, & Throat, Immunology, Licensing, Materials Available, Medical Devices, Non-Medical Devices, Oncology, Ophthalmology Collaboration Dermatology Ear Nose & Throat Immunology Licensing Materials Available Medical Devices Non-Medical Devices Oncology Ophthalmology Kapil Bharti, Vladimir Khristov, Arvydas Maminishkis <p><strong>Problem:</strong> Cryopreservation is a process where living biological materials like cells, tissues, and cell therapies (which are susceptible to damage caused by unregulated chemical kinetics) are preserved by cooling to very low temperatures in the presence of specific cryopreservation media that protects the biological material from damage. In order to be used, the biological material ideally should be thawed in a controlled manner that minimizes damage and desirably brings the material back to a viable state. While this is not a problem for single cell suspensions, cryopreservation and efficient revival of sheets or layers of tissues and three-dimensional tissue constructs, is inefficient. Layers of tissue and three-dimensional tissue constructs can suffer damage from tensional stresses experienced during expansion and contractions that occur during freezing and thawing. Several other problems exist with conventional cryopreservation: 1) Uneven physical changes within the tissue during cooling or warming can cause damage to the tissue, 2) Conventional cryopreservation media can be toxic to the tissues in a non-frozen state and can render the tissues not suitable for later recovery, culturing, and transplantation in engineered cell and other tissue therapies, and 3) The sterility of the tissue during the thawing process is usually compromised.</p> <p><strong>Technical Solution:</strong> The technology developed by researchers at the <a href="https://nei.nih.gov/" target="_blank" rel="nofollow">National Eye Institute</a> (NEI) is a closed recovery device consisting of three chambers that allow for the separation of media and frozen tissue until it is time to defrost the tissue. The top portion is a media chamber controlled by a valve/lumen. The middle chamber houses the frozen tissue and the bottom chamber is a waste receptacle. The recovery device can be placed in a regulator apparatus that facilitates thawing and warming of the frozen tissue/cryopreservation media inside the tissue container.</p> <p><strong>Collaboration Opportunity:</strong> The inventor is interested in building other versions of the prototype device and testing them for performance. A collaboration or license interest is sought.  </p> <h2>Competitive Advantages:</h2> <ul><li>Current cryopreservation containers are less successful with confluent cells and need a large volume of toxic cryopreservation media, which hampers subsequent cell recovery and culturing. A cryopreservation/defrost system that uses minimal volume of cryopreservation media and conducts automated cell thawing and recovery for cell monolayers and 3D tissues can be useful in many clinical applications, such as transplantation.</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Transport, Storage and Recovery of cells, tissues for <em>in vitro</em> culture</li> <li><em>In vivo</em> experiments including cell therapy transplantation</li> </ul> 2017-04-14 2025-04-22 2020-04-13 2026-01-21 2017-04-14 Cell recovery, Cell thawing, Cell therapy, Cryopreservation, Defrost, National Eye Institute, NEI, Tissue transplant False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-04-13 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147163328 Khristov, Vladimir NIH - NEI Khristov, Vladimir 1 147163326 Maminishkis, Arvydas NIH - NEI NEI Maminishkis, Arvydas (NEI) 2 147163327 Bharti, Kapil NIH - NEI NEI Bharti, Kapil (NEI) 3 147163328 Khristov, Vladimir NIH - NEI Khristov, Vladimir 1 147163326 Maminishkis, Arvydas NIH - NEI NEI Maminishkis, Arvydas (NEI) 2 147163327 Bharti, Kapil NIH - NEI NEI Bharti, Kapil (NEI) 3 147157974 A Self-contained Cryopreservation And Recovery Device For Tissue Storage, Shipping And Recovery E-094-2016-0 Filing authorized National Eye Institute (NEI) 83703238 Fenn, Edward (Tedd) tedd.fenn@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-4047] Devices for Improved Tissue Cryopreservation and Recovery&body=Please send me information about technology [TAB-4047] Devices for Improved Tissue Cryopreservation and Recovery.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Fenn, Edward (Tedd)<br><a href="mailto:tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-4047] Devices for Improved Tissue Cryopreservation and Recovery&body=Please send me information about technology [TAB-4047] Devices for Improved Tissue Cryopreservation and Recovery.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">tedd.fenn@nih.gov</a><br> 147161030 E-094-2016-0 E-094-2016-0-US-01 Devices for Tissue Cryopreservation and Recovery PRV US 62/453,148 Abandoned US <br />Provisional (PRV) 62/453,148<br />Filed on 2017-02-01<br />Status: Abandoned 147166192 E-094-2016-0 E-094-2016-0-PCT-02 DEVICES FOR TISSUE CRYOPRESERVATION AND RECOVERY PCT Patent Cooperation Treaty PCT/US2018/016101 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2018/016101<br />Filed on 2018-01-31<br />Status: Expired 147166193 E-094-2016-0 E-094-2016-0-US-03 DEVICES FOR TISSUE CRYOPRESERVATION AND RECOVERY National Stage US 11,819,020 16/478,093 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11819020 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11819020">11,819,020</a><br />Filed on 2019-07-15<br />Status: Issued 147166194 E-094-2016-0 E-094-2016-0-AU-04 DEVICES FOR TISSUE CRYOPRESERVATION AND RECOVERY National Stage Australia 2018214954 2018214954 Issued Australia <br />National Stage 2018214954<br />Filed on 2018-01-31<br />Status: Issued 147166195 E-094-2016-0 E-094-2016-0-CA-05 DEVICES FOR TISSUE CRYOPRESERVATION AND RECOVERY National Stage Canada 3048523 Pending Canada <br />National Stage 3048523<br />Filed on 2018-01-31<br />Status: Pending 147166196 E-094-2016-0 E-094-2016-0-EP-06 DEVICES FOR TISSUE CRYOPRESERVATION AND RECOVERY National Stage European Patent 3576527 18704773.3 Issued European Patent <br />National Stage 18704773.3<br />Filed on 2019-07-30<br />Status: Issued 147166197 E-094-2016-0 E-094-2016-0-JP-07 DEVICES FOR TISSUE CRYOPRESERVATION AND RECOVERY National Stage Japan 2019-538157 Abandoned Japan <br />National Stage 2019-538157<br />Filed on 2018-01-31<br />Status: Abandoned 147166198 E-094-2016-0 E-094-2016-0-JP-01 DEVICES FOR TISSUE CRYOPRESERVATION AND RECOVERY DIV Japan 7824913 2023-127909 Issued Japan <br />Divisional (DIV) 2023-127909<br />Filed on 2023-08-04<br />Status: Issued 164118969 E-094-2016-0 E-094-2016-0-JP-02 DEVICES FOR TISSUE CRYOPRESERVATION AND RECOVERY DIV Japan 7812356 2023-127908 Issued Japan <br />Divisional (DIV) 2023-127908<br />Filed on 2023-08-04<br />Status: Issued 165688005 E-094-2016-0 E-094-2016-0-JP-03 DEVICES FOR TISSUE CRYOPRESERVATION AND RECOVERY DIV Japan In Preparation Japan <br />Divisional (DIV) None<br />Filed on None<br />Status: In Preparation 147171282 Cell recovery 147171284 Cell thawing 147171285 Cell therapy 147171286 Cryopreservation 147171288 Defrost 147171289 National Eye Institute 147171290 NEI 147171292 Tissue transplant TAB-4498 151704860 A Method to Remove Fluid-motion Related Artifacts in Magnetic Resonance Thermometry Images Using Magnetic Field Gradients NHLBI Computational models/software, Licensing, Research Materials, Software / Apps Computational models/software Licensing Research Materials Software / Apps Himanshu Bhat, Adrienne Campbell-Washburn, Waqas Majeed, Sunil Patil <p>This technology includes the incorporation of a magnetic field gradient waveform (consisting of two or more pulses) between excitation and encoding to eliminate signal from moving fluid for imaging applications. Proton Resonance Frequency (PRF) thermometry is a widely used Magnetic Resonance Imaging (MRI) based technique to monitor changes in tissue temperature in response to thermal therapy. The use of PRF thermometry with thermal therapy procedures is indispensable to ensure delivery of desired thermal dose to the target tissue, and to minimize unintended damage to the normal tissue. Motion of this water due to ultrasound vibrations, convection, and circulation between sonications causes diffuse artifacts in images, which can compromise clinical outcomes. PRF thermometry is a high impact application of MRI and plays a critical role in guiding thermal therapy procedures.</p> The proposed solution: <ul> <li>does not require any additional hardware, materials, or changes in clinical setup</li> <li>can easily be incorporated into the existing product pulse sequences, and therefore adds no additional cost for implementation</li> <li>does not impact image acquisition time under most practical circumstances</li> </ul> Our approach solves a significant problem encountered in routine clinical application of PRF thermometry and can therefore be of significant commercial value. We are seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. 2023-12-07 2024-08-12 2026-01-16 2024-03-27 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 151704868 Patil, Sunil Siemens Medical USA Patil, Sunil 1 151704872 Campbell-Washburn, Adrienne National Heart, Lung, and Blood Institute (NHLBI) NHLBI Campbell-Washburn, Adrienne (NHLBI) 2 151704876 Majeed, Waqas Siemens Medical Solutions USA Inc. Majeed, Waqas 3 151704880 Bhat, Himanshu Siemens Medical Solutions USA Inc. Bhat, Himanshu 4 151704868 Patil, Sunil Siemens Medical USA Patil, Sunil 1 151704872 Campbell-Washburn, Adrienne National Heart, Lung, and Blood Institute (NHLBI) NHLBI Campbell-Washburn, Adrienne (NHLBI) 2 151704876 Majeed, Waqas Siemens Medical Solutions USA Inc. Majeed, Waqas 3 151704880 Bhat, Himanshu Siemens Medical Solutions USA Inc. Bhat, Himanshu 4 151704863 A Method To Remove Fluid-motion Related Artifacts In Magnetic Resonance Thermometry Images Using Magnetic Field Gradients E-113-2019-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI), Siemens Medical Solutions USA Inc., Siemens Medical Solutions USA, Inc. 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-4498] A Method to Remove Fluid-motion Related Artifacts in Magnetic Resonance Thermometry Images Using Magnetic Field Gradients&body=Please send me information about technology [TAB-4498] A Method to Remove Fluid-motion Related Artifacts in Magnetic Resonance Thermometry Images Using Magnetic Field Gradients. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-4498] A Method to Remove Fluid-motion Related Artifacts in Magnetic Resonance Thermometry Images Using Magnetic Field Gradients&body=Please send me information about technology [TAB-4498] A Method to Remove Fluid-motion Related Artifacts in Magnetic Resonance Thermometry Images Using Magnetic Field Gradients.">shmilovm@nih.gov</a><br> TAB-4496 151704475 A Principal Component Analysis Based Multi-baseline Phase Correction Method for PRF Thermometry NHLBI Computational models/software, Licensing, Software / Apps Computational models/software Licensing Software / Apps Himanshu Bhat, Adrienne Campbell-Washburn, Waqas Majeed, Rainer Schneider <p>This technology includes a novel Principal Component Analysis (PCA) based approach to correct motion related B0 changes in PRF thermometry. Proton Resonance Frequency (PRF) thermometry is a widely used Magnetic Resonance Imaging (MRI) based technique to monitor changes in tissue temperature in response to thermal therapy. The use of PRF thermometry with thermal therapy procedures is indispensable to ensure delivery of desired thermal dose to the target tissue, and to minimize unintended damage to the normal tissue. PRF thermometry relies on phase difference between the acquired images, and therefore motion related baseline changes in organs of interest and background adversely affect the accuracy of temperature difference estimates, even when registration-based motion correction is performed to correct for displacements.</p> PRF thermometry is a high impact application of MRI and plays a critical role in guiding thermal therapy procedures. Our approach solves a significant problem encountered in routine clinical application of PRF thermometry and can therefore be of significant commercial value. Used in MRI clinical imaging to provide substantial reduction in bias and variance due to motion related baseline changes. 2023-12-07 2024-08-12 2026-01-16 2024-03-27 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 151704566 Campbell-Washburn, Adrienne National Heart, Lung, and Blood Institute (NHLBI) NHLBI Campbell-Washburn, Adrienne (NHLBI) 1 151704570 Majeed, Waqas Siemens Medical Solutions USA Inc. Majeed, Waqas 2 151704583 Schneider, Rainer Siemens Healthineers AG Schneider, Rainer 3 151704587 Bhat, Himanshu Siemens Medical Solutions USA, Inc. Bhat, Himanshu 4 151704566 Campbell-Washburn, Adrienne National Heart, Lung, and Blood Institute (NHLBI) NHLBI Campbell-Washburn, Adrienne (NHLBI) 1 151704570 Majeed, Waqas Siemens Medical Solutions USA Inc. Majeed, Waqas 2 151704583 Schneider, Rainer Siemens Healthineers AG Schneider, Rainer 3 151704587 Bhat, Himanshu Siemens Medical Solutions USA, Inc. Bhat, Himanshu 4 151704478 A Principal Component Analysis Based Multi-baseline Phase Correction Method For PRF Thermometry E-112-2019-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI), Siemens Healthineers AG, Siemens Medical Solutions USA Inc. 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-4496] A Principal Component Analysis Based Multi-baseline Phase Correction Method for PRF Thermometry&body=Please send me information about technology [TAB-4496] A Principal Component Analysis Based Multi-baseline Phase Correction Method for PRF Thermometry. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-4496] A Principal Component Analysis Based Multi-baseline Phase Correction Method for PRF Thermometry&body=Please send me information about technology [TAB-4496] A Principal Component Analysis Based Multi-baseline Phase Correction Method for PRF Thermometry.">shmilovm@nih.gov</a><br> 157754912 E-112-2019-0 E-112-2019-0-US-01 A Principal Component Analysis Based Multi-baseline Phase Correction Method For PRF Thermometry PRV US 62/840,006 Abandoned US <br />Provisional (PRV) 62/840,006<br />Filed on 2019-04-29<br />Status: Abandoned 157754917 E-112-2019-0 E-112-2019-0-US-02 A Principal Component Analysis Based Multi-baseline Phase Correction Method For PRF Thermometry ORD US 11,301,997 16/849,313 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11301997 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11301997">11,301,997</a><br />Filed on 2020-04-15<br />Status: Issued TAB-4495 151704426 A Method to Guide Protocol Development for Magnetic Resonance Thermometry NHLBI Computational models/software, Licensing, Medical Devices, Research Equipment Computational models/software Licensing Medical Devices Research Equipment Himanshu Bhat, Adrienne Campbell-Washburn, Waqas Majeed, Rainer Schneider <p>This technology includes tools to guide optimization of thermometry imaging/post-processing protocols. Proton Resonance Frequency (PRF) thermometry is a widely used Magnetic Resonance Imaging (MRI) based technique to monitor changes in tissue temperature in response to thermal therapy. The use of PRF thermometry with thermal therapy procedures is indispensable to ensure delivery of desired thermal dose to the target tissue, and to minimize unintended damage to the normal tissue.</p> <ul> <li>The invention is based on well-established principles of MR physics and statistics, and therefore results in reliable predictions</li> <li>No competing solutions present in the literature</li> <li>Given the immense utility of the features proposed in this invention, this will become a must-have feature on commercial MR Thermometry related products</li> </ul> PRF thermometry is a high impact application of MRI and plays a critical role in guiding thermal therapy procedures. Our approach solves a significant problem encountered in routine clinical application of PRF thermometry and can therefore be of significant commercial value. We are seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. 2023-12-07 2024-08-12 2026-01-16 2024-03-20 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 151704433 Campbell-Washburn, Adrienne National Heart, Lung, and Blood Institute (NHLBI) NHLBI Campbell-Washburn, Adrienne (NHLBI) 1 151704437 Majeed, Waqas Siemens Medical Solutions USA Inc. Majeed, Waqas 2 151704441 Schneider, Rainer Siemens Healthineers AG Schneider, Rainer 3 151704450 Bhat, Himanshu Siemens Medical Solutions USA, Inc. Bhat, Himanshu 4 151704433 Campbell-Washburn, Adrienne National Heart, Lung, and Blood Institute (NHLBI) NHLBI Campbell-Washburn, Adrienne (NHLBI) 1 151704437 Majeed, Waqas Siemens Medical Solutions USA Inc. Majeed, Waqas 2 151704441 Schneider, Rainer Siemens Healthineers AG Schneider, Rainer 3 151704450 Bhat, Himanshu Siemens Medical Solutions USA, Inc. Bhat, Himanshu 4 151704429 A Method To Guide Protocol Development For Magnetic Resonance Thermometry E-111-2019-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI), Siemens Healthineers AG, Siemens Medical Solutions USA Inc. 90072936 Mistry, Pragnesh pragnesh.mistry@nih.gov
HNH6Z08 pragnesh.mistry@nih.gov?subject=Web Inquiry on [TAB-4495] A Method to Guide Protocol Development for Magnetic Resonance Thermometry&body=Please send me information about technology [TAB-4495] A Method to Guide Protocol Development for Magnetic Resonance Thermometry. Mistry, Pragnesh<br><a href="mailto:pragnesh.mistry@nih.gov?subject=Web Inquiry on [TAB-4495] A Method to Guide Protocol Development for Magnetic Resonance Thermometry&body=Please send me information about technology [TAB-4495] A Method to Guide Protocol Development for Magnetic Resonance Thermometry.">pragnesh.mistry@nih.gov</a><br> 157754893 E-111-2019-0 E-111-2019-0-US-01 A Method To Guide Protocol Development For Magnetic Resonance Thermometry ORD US 11,176,717 16/583,596 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11176717 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11176717">11,176,717</a><br />Filed on 2019-09-26<br />Status: Issued TAB-4152 147157435 Fatty Acid Derivatives and Their Use for the Treatment and Prevention of Autoimmune, Inflammatory, and Pain Disorders NIA Collaboration, Immunology, Licensing, Therapeutics Collaboration Immunology Licensing Therapeutics Gregory Keyes, Christopher Ramsden <p>The discovery and selection of suitable compounds for the treatment and prevention of autoimmune, inflammatory, and pain disorders is a significant challenge. Researchers at National Institute of Aging (NIA) mitigated this issue. They discovered and synthesized numerous novel fatty acid derivatives (novel small molecules) that may ameliorate these conditions and provide treatment options for these disorders. In a relevant rat model, the fatty acid derivatives developed by NIA demonstrated:</p> <ul><li>increased activity</li> <li>lower toxicity</li> <li>greater stability</li> <li>longer half-life</li> </ul><p>These beneficial results favorably compare to prior agents utilized for treating inflammation, autoimmune disorders, and/or pain. Certain of the disclosed fatty acid derivatives are capable of readily crossing the blood-brain barrier – providing an advantage specifically with respect to certain pain disorders.  </p> <p>NIA is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize fatty acid derivatives.  In addition, NIA is open to collaborative research relationships (such as under a CRADA) whereby resources such as intellectual property can be pooled and applied to the development of therapies with respect to a wide variety of autoimmune and inflammatory and pain-related conditions.  In addition, NIA is open to a wide variety of licensing arrangements with respect to these technologies.</p> <h2>Competitive Advantages:</h2> <ul><li>Ability to readily cross the blood-brain barrier</li> <li>Increased activity, lower toxicity, greater stability, and longer half-life in a relevant proof-of-concept rat model compared with drugs currently available for treating inflammation, autoimmune disorders, and/or pain</li> <li>Substantial intellectual property life cycle: e.g., patents if issued likely will expire no earlier than 2038</li> <li>Proof-of-concept in rat model</li> </ul> <h2>Commercial Applications:</h2> <p><strong>Therapies to treat:</strong></p> <ul><li>Autoimmune disorders</li> <li>Inflammation</li> <li>Pain-related disorders</li> <li>Itching and/or skin disorders</li> </ul> 2018-04-25 2026-01-14 2022-03-23 2026-01-14 2018-04-25 Autoimmune, Inflammation, National Institute on Aging (NIA), Pain, Ramsden False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2022-03-23 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147162157 Ramden et al. A systems approach for discovering linoleic acid derivatives that potentially mediate pain and itch. https://www.ncbi.nlm.nih.gov/pubmed/28831021 <a href="https://www.ncbi.nlm.nih.gov/pubmed/28831021">Ramden et al. A systems approach for discovering linoleic acid derivatives that potentially mediate pain and itch.</a> 147163703 Ramsden, Christopher NIH - NIA NIA Ramsden, Christopher (NIA) 1 147163704 Keyes, Gregory NIH - NIA NIA Keyes, Gregory (NIA) 2 147163703 Ramsden, Christopher NIH - NIA NIA Ramsden, Christopher (NIA) 1 147163704 Keyes, Gregory NIH - NIA NIA Keyes, Gregory (NIA) 2 147158083 Synthesis And Use Of Endogenous Lipid Mediators, Their Stable Analogs, And Small Molecule Pharmacophores Containing The Same Active Moieties As The Endogenous Compounds, To Regulate Inflammation, Neuronal Activation, Nociceptive And Pruriceptive Sens E-151-2017-0 Filing authorized National Institute on Aging (NIH/NIA) 91827321 Jinnah, Zarpheen zarpheen.jinnah@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
zarpheen.jinnah@nih.gov?subject=Web Inquiry on [TAB-4152] Fatty Acid Derivatives and Their Use for the Treatment and Prevention of Autoimmune, Inflammatory, and Pain Disorders&body=Please send me information about technology [TAB-4152] Fatty Acid Derivatives and Their Use for the Treatment and Prevention of Autoimmune, Inflammatory, and Pain Disorders.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Jinnah, Zarpheen<br><a href="mailto:zarpheen.jinnah@nih.gov?subject=Web Inquiry on [TAB-4152] Fatty Acid Derivatives and Their Use for the Treatment and Prevention of Autoimmune, Inflammatory, and Pain Disorders&body=Please send me information about technology [TAB-4152] Fatty Acid Derivatives and Their Use for the Treatment and Prevention of Autoimmune, Inflammatory, and Pain Disorders.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">zarpheen.jinnah@nih.gov</a><br> 147166939 E-151-2017-0 E-151-2017-0-US-01 FATTY ACID DERIVATIVES AND THEIR USE PRV US 62/529,846 Abandoned US <br />Provisional (PRV) 62/529,846<br />Filed on 2017-07-07<br />Status: Abandoned 147166940 E-151-2017-0 E-151-2017-0-PCT-02 FATTY ACID DERIVATIVES AND THEIR USE PCT Patent Cooperation Treaty PCT/US2018/041086 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2018/041086<br />Filed on 2018-07-06<br />Status: Expired 147166941 E-151-2017-0 E-151-2017-0-AU-03 FATTY ACID DERIVATIVES AND THEIR USE National Stage Australia 2018297192 2018297192 Issued Australia <br />National Stage 2018297192<br />Filed on 2018-07-06<br />Status: Issued 147166942 E-151-2017-0 E-151-2017-0-CA-04 FATTY ACID DERIVATIVES AND THEIR USE National Stage Canada 3064132 3064132 Issued Canada <br />National Stage 3064132<br />Filed on 2018-07-06<br />Status: Issued 147166943 E-151-2017-0 E-151-2017-0-CN-05 FATTY ACID DERIVATIVES AND THEIR USE National Stage China 201880045287.6 Abandoned China <br />National Stage 201880045287.6<br />Filed on 2018-07-06<br />Status: Abandoned 147166944 E-151-2017-0 E-151-2017-0-EP-06 FATTY ACID DERIVATIVES AND THEIR USE National Stage European Patent 3649115 18746415.1 Issued European Patent <br />National Stage 18746415.1<br />Filed on 2018-07-06<br />Status: Issued 147166945 E-151-2017-0 E-151-2017-0-JP-07 FATTY ACID DERIVATIVES AND THEIR USE National Stage Japan 7234151 2019-572570 Issued Japan <br />National Stage 2019-572570<br />Filed on 2018-07-06<br />Status: Issued 147166946 E-151-2017-0 E-151-2017-0-KR-08 FATTY ACID DERIVATIVES AND THEIR USE National Stage South Korea 10-2725883 10-2020-7003568 Issued South Korea <br />National Stage 10-2020-7003568<br />Filed on 2020-02-06<br />Status: Issued 147166947 E-151-2017-0 E-151-2017-0-MX-09 FATTY ACID DERIVATIVES AND THEIR USE National Stage Mexico 391168 MX/a/2019/015730 Issued Mexico <br />National Stage MX/a/2019/015730<br />Filed on 2018-07-06<br />Status: Issued 147166948 E-151-2017-0 E-151-2017-0-US-10 FATTY ACID DERIVATIVES AND THEIR USE National Stage US 11,555,021 16/622,697 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11555021 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11555021">11,555,021</a><br />Filed on 2019-12-30<br />Status: Issued 147166949 E-151-2017-0 E-151-2017-0-HK-11 FATTY ACID DERIVATIVES AND THEIR USE National Stage Hong Kong 62020007841.3 Pending Hong Kong <br />National Stage 62020007841.3<br />Filed on 2018-07-06<br />Status: Pending 147166950 E-151-2017-0 E-151-2017-0-US-12 FATTY ACID DERIVATIVES AND THEIR USE DIV US 12,479,812 17/718,965 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12479812 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12479812">12,479,812</a><br />Filed on 2022-04-12<br />Status: Issued 147172391 Autoimmune 147172392 Inflammation 147172394 National Institute on Aging (NIA) 147172395 Pain 147172397 Ramsden TAB-2215 114096425 A Computer Program to Predict Optimal Sites on Protein Sequences for Production of Peptide-Directed Antibodies (NHLBI AbDesigner) NHLBI Collaboration, Licensing Collaboration Licensing Mark Knepper <p style="font-size:16px">The invention offered for licensing is a computer program called &quot;NHLBI AbDesigner&quot; that allows the user to input a unique identifier for an individual mammalian protein to be analyzed in order to find out what short peptides in its amino sequence would most likely result in a strong immunogenic response when injected into a research animal. The software displays standard predictors of immunogenicity and antigenicity in easy-to-view heat maps and also allows users to choose peptides most likely to elicit antibodies that are specific to said protein. The computer code is written in Java and would be made available in the form of .jar files.<br /> <br /> For additional information please refer to:&nbsp;<a href="http://esbl.nhlbi.nih.gov/AbDesigner/" target="_blank">https://esbl.nhlbi.nih.gov/AbDesigner/</a>.&nbsp;</p> <ul> <li>This program allows the user to identify tradeoffs in the decision making process by aligning various types of information with the amino acid sequence, constituting an improvement over present ad hoc methods of accumulating and relating different type of information regarding immunogenicity, uniqueness of sequences, conservation of sequences, and presence of post-translational modifications.</li> </ul> <ul> <li>Design and production of antibodies for research or therapeutic purposes</li> <li>Bioinformatic analysis of protein structure and functions</li> <li>Analysis and interpretation of proteomic data</li> </ul> The NHLBI is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. Please contact Brian Bailey, Ph.D. at 301-594-4094 or <a href="mailto:bbailey@mail.nih.gov">bbailey@mail.nih.gov</a> for more information. Software -- Patent protection is not being pursued for this technology. Available for licensing. 2022-03-08 2026-01-14 2026-01-14 2011-01-20 AbDesigner, ACXXXX, Along, antibodies, AXXXXX, CALLED, computer, INDIVIDUAL, NHLBI, OPTIMAL, Peptide-directed, PREDICTS, Primary, production, Program, proteins, sequence, Sites, That False True Fully developed True NIHTT 37470483 Website Abstract 114172477 Pisitkun T, et al. https://www.ncbi.nlm.nih.gov/pubmed/21956165 <a href="https://www.ncbi.nlm.nih.gov/pubmed/21956165">Pisitkun T, et al.</a> 114107091 Knepper, Mark National Heart, Lung, and Blood Institute (NHLBI) NHLBI Knepper, Mark (NHLBI) 1 114107091 Knepper, Mark National Heart, Lung, and Blood Institute (NHLBI) NHLBI Knepper, Mark (NHLBI) 1 114101520 A Computer Program Called "NHLBI AbDesigner" That Predicts Optimal Sites Along The Primary Sequence Of Individual Proteins For Production Of Peptide-directed Antibodies E-251-2010-0 Research Material National Heart, Lung, and Blood Institute (NHLBI) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-2215] A Computer Program to Predict Optimal Sites on Protein Sequences for Production of Peptide-Directed Antibodies (NHLBI AbDesigner)&body=Please send me information about technology [TAB-2215] A Computer Program to Predict Optimal Sites on Protein Sequences for Production of Peptide-Directed Antibodies (NHLBI AbDesigner). Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-2215] A Computer Program to Predict Optimal Sites on Protein Sequences for Production of Peptide-Directed Antibodies (NHLBI AbDesigner)&body=Please send me information about technology [TAB-2215] A Computer Program to Predict Optimal Sites on Protein Sequences for Production of Peptide-Directed Antibodies (NHLBI AbDesigner).">shmilovm@nih.gov</a><br> 114121808 ACXXXX 114121809 AXXXXX 114141000 computer 114141001 Program 114141002 CALLED 114141003 NHLBI 114141004 AbDesigner 114141005 That 114141006 PREDICTS 114141007 OPTIMAL 114141008 Sites 114141009 Along 114141010 Primary 114141011 sequence 114141012 INDIVIDUAL 114141013 proteins 114141014 production 114141015 Peptide-directed 114141016 antibodies TAB-4443 147157738 Polypeptides for Stimulation of Immune Response (Adjuvants) NCI Collaboration, Immunology, Licensing, Oncology, Therapeutics Collaboration Immunology Licensing Oncology Therapeutics Michael Bustin, Joost Oppenheim, De Yang <p>HMGN polypeptides belong to the high mobility group (HMG) family of chromosomal binding peptides. HMGN polypeptides typically function inside the cell nucleus to bind to DNA and nucleosomes and regulate the transcription of various genes. HMGN polypeptides also can be released by peripheral blood mononuclear cells. However, the extracellular release of a HMGN polypeptide initiates activation of the immune system. Therefore, it has potential use as a biological therapeutic for stimulating an immune response. Therefore, HMGN has potential use as a clinically effective immunoadjuvant for use in vaccines against tumors and many intracellular pathogens.</p> <p>Researchers at the National Cancer Institute, Laboratory of Cancer Immunometabolism&nbsp;developed compositions and methods for using HMGN and its derivatives as immunoadjuvants with microbial or tumor antigens. HMGN can be fused to an antigen gene to produce recombinant fusion proteins or can be administered as a DNA vaccine. Alternatively, HMGN could be exploited as a drug target to treat parasitic infections, inflammatory or autoimmune diseases. The technoloogy has shown effectiveness and high potency in several different mouse xenograft models.</p> <h2>Competitive Advantages:</h2> <ul> <li>Expected to have diminished adverse effects compared to currently available technologies</li> <li>Enables dendritic cells to induce enduring cellular immunity</li> <li>More selective for Th-1 type immunity allowing for a more controlled immune response.</li> </ul> <h2>Commercial Applications:</h2> <ul> <li>Immunostimulatory adjuvant to increase efficacy of vaccinations against microbes or cancer</li> <li>Attractant or activator of dendritic cells</li> <li>HMGN antagonists to suppress inflammatory immune response</li> </ul> 2016-02-16 2026-01-14 2018-07-13 2026-01-14 2016-08-30 Autoimmune, HMGN, immune response, immunoadjuvant, POLYPEPTIDES, Vaccine Adjuvant False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2018-07-13 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-069-2016 147161891 Yang D, et al. High-mobility group nucleosome-binding protein 1 acts as an alarmin and is critical for lipopolysaccharide-induced immune responses. http://www.ncbi.nlm.nih.gov/pubmed/22184635 <a href="http://www.ncbi.nlm.nih.gov/pubmed/22184635">Yang D, et al. High-mobility group nucleosome-binding protein 1 acts as an alarmin and is critical for lipopolysaccharide-induced immune responses.</a> 147164757 Yang, De NIH - NCI Leidos Yang, De (Leidos) 1 147164756 Oppenheim, Joost NIH - NCI NCI Oppenheim, Joost (NCI) 2 147164758 Bustin, Michael NIH - NCI NCI Bustin, Michael (NCI) 3 147164757 Yang, De NIH - NCI Leidos Yang, De (Leidos) 1 147164756 Oppenheim, Joost NIH - NCI NCI Oppenheim, Joost (NCI) 2 147164758 Bustin, Michael NIH - NCI NCI Bustin, Michael (NCI) 3 147158169 High-Mobility Group N1 Protein (HMGN1) Is An Immune Enhancer E-185-2008-0 Filing authorized NCI 83732213 Dick, Taryn taryn.dick@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB taryn.dick@nih.gov?subject=Web Inquiry on [TAB-4443] Polypeptides for Stimulation of Immune Response (Adjuvants)&body=Please send me information about technology [TAB-4443] Polypeptides for Stimulation of Immune Response (Adjuvants).&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dick, Taryn<br><a href="mailto:taryn.dick@nih.gov?subject=Web Inquiry on [TAB-4443] Polypeptides for Stimulation of Immune Response (Adjuvants)&body=Please send me information about technology [TAB-4443] Polypeptides for Stimulation of Immune Response (Adjuvants).&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">taryn.dick@nih.gov</a><br> 147168952 E-185-2008-0 E-185-2008-0-US-01 HMGN POLYPEPTIDES AS IMMUNE ENHANCERS AND HMGN ANTAGONISTS AS IMMUNE SUPPRESSANTS PRV US 61/083,781 Abandoned US <br />Provisional (PRV) 61/083,781<br />Filed on 2008-07-25<br />Status: Abandoned 147168953 E-185-2008-0 E-185-2008-0-US-02 HMGN Polypeptides As Immune Enhancers And HMGN Antagonists As Immune Suppressants ORD US 8,227,417 12/509,088 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8227417 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8227417">8,227,417</a><br />Filed on 2009-07-24<br />Status: Issued 147168954 E-185-2008-0 E-185-2008-0-US-03 HMGN Polypeptides As Immune Enhancers And HMGN Antagonists As Immune Suppressants CON US 9,567,566 13/533,492 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9567566 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9567566">9,567,566</a><br />Filed on 2012-06-26<br />Status: Issued 147168955 E-185-2008-0 E-185-2008-0-US-04 HMGN Polypeptides as Immune Enhancers and HMGN Antagonists as Immune Suppressants DIV US 15/191,000 Abandoned US <br />Divisional (DIV) 15/191,000<br />Filed on 2016-06-23<br />Status: Abandoned 147173266 Autoimmune 147173267 HMGN 147173268 immune response 147173270 immunoadjuvant 147173271 POLYPEPTIDES 147173272 Vaccine Adjuvant TAB-3779 114097630 Monoclonal Antibody Against Human Alpha-5 Integrin that Does Not Disrupt Adhesive Function NIDCR Antibodies, Immunology, Research Materials Antibodies Immunology Research Materials Steven Akiyama, Kenneth Yamada, Susan Yamada <p>This technology includes a rat monoclonal antibody termed mAb11 was generated against the human alpha-5 integrin subunit and can provide immunological characterizations without disrupting integrin adhesive function. It permits characterization of its localization even if the receptor is bound to its fibronectin ligand. The&nbsp;antibody is commercially available from Millipore Sigma.</p> Because it is a rat monoclonal antibody, it permits co-staining using a mouse monoclonal antibody using indirect immunofluorescence. Antibody characterization of the alpha-5/beta-1 integrin receptor for fibronectin. Available for non-exclusive licensing 2022-11-30 2024-12-26 2026-01-12 2022-11-30 2022-08-01 Against, Alpha-5, ANTIBODY, DISRUPT, DOES, FUNCTION, Human, INTEGRIN, monoclonal, That, WIXXXX, XAXXXX False True True NIHTT 37470483 Website Abstract 114172949 Miyamoto S, Akiyama S, et al. https://pubmed.ncbi.nlm.nih.gov/7846531/ <a href="https://pubmed.ncbi.nlm.nih.gov/7846531/">Miyamoto S, Akiyama S, et al.</a> 114172950 Miyamoto S, Teramoto H, et al. https://pubmed.ncbi.nlm.nih.gov/7593197/ <a href="https://pubmed.ncbi.nlm.nih.gov/7593197/">Miyamoto S, Teramoto H, et al.</a> 114111543 Akiyama, Steven Akiyama, Steven 0 114111544 Yamada, Susan NIDCR NIDCR Yamada, Susan (NIDCR) 0 114111542 Yamada, Kenneth NIDCR NIDCR Yamada, Kenneth (NIDCR) 1 114111542 Yamada, Kenneth NIDCR NIDCR Yamada, Kenneth (NIDCR) 1 114111543 Akiyama, Steven Akiyama, Steven 0 114111544 Yamada, Susan NIDCR NIDCR Yamada, Susan (NIDCR) 0 114102882 Monoclonal Antibody Against Human Alpha-5 Integrin That Does Not Disrupt Function E-016-2017-0 Research Material NIDCR 83656052 Knezevic, Vladimir vlado.knezevic@nih.gov
United States of America Technology Advancement Office vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-3779] Monoclonal Antibody Against Human Alpha-5 Integrin that Does Not Disrupt Adhesive Function&body=Please send me information about technology [TAB-3779] Monoclonal Antibody Against Human Alpha-5 Integrin that Does Not Disrupt Adhesive Function. Knezevic, Vladimir<br><a href="mailto:vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-3779] Monoclonal Antibody Against Human Alpha-5 Integrin that Does Not Disrupt Adhesive Function&body=Please send me information about technology [TAB-3779] Monoclonal Antibody Against Human Alpha-5 Integrin that Does Not Disrupt Adhesive Function.">vlado.knezevic@nih.gov</a><br> 114129576 WIXXXX 114129577 XAXXXX 114155352 monoclonal 114155353 ANTIBODY 114155354 Against 114155355 Human 114155356 Alpha-5 114155357 INTEGRIN 114155358 That 114155359 DOES 114155360 DISRUPT 114155361 FUNCTION TAB-2113 114096330 Simple, Quantitative Sensitive High-throughput Antibody Detection for Lyme Disease NIDCR Diagnostics, Infectious Disease Diagnostics Infectious Disease Peter Burbelo, Michael Iadarola, Adriana Marques This technology is for compositions and methods for diagnosis of Lyme disease. Currently, Lyme disease is diagnosed by clinical exam and a history of exposure to endemic regions. Although, laboratory tests may aid diagnosis, the best tests currently available are slow and labor intensive and require understanding of the test, and infection stage. A two-step antibody based test process is currently the recommended laboratory test. The first step is either an enzyme immunoassay (EIA), or an indirect immunofluorescence assay (IFA). If the first step is positive, a “Western blot” test is then performed. Because early intervention is critical to prevent neurological, rheumatological and cardiac damage from advanced infection, more sensitive, specific, simpler, high-throughput format laboratory diagnostics are needed. This technology uses a novel synthetic gene (VOVO) in a highly sensitive, specific and high-throughput Luciferase Immunoprecipitation Systems (LIPS) format. LIPS screening using VOVO offers an efficient and qualitative approach for serological screening of antibodies in Lyme disease in human and veterinary applications. <ul> <li>Higher efficiencies, High-throughput Format Qualitative</li> </ul> <ul> <li>Diagnostic for Lyme disease in human and veterinary applications.</li> </ul> Technology is available for non-exclusive or exclusive licensing 2022-03-08 2024-12-31 2026-01-12 2010-05-21 ANTIBODY, Borreliosis, DAXXXX, Detection, Disease, DXXXXX, Highly, Listed LPM Fenn as of 4/15/2015, LYME, Lyme Disease, Patent Category - Biotechnology, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, QUANTITATIVE, SENSITIVE, SIMPLE, VJXXXX, WBXXXX False True <ul> <li>Early-stage</li> <li>Pre-clinical</li> </ul> True NIHTT 37470483 Website Abstract 114171078 Burbelo PD, et al. https://www.ncbi.nlm.nih.gov/pubmed/20392886 <a href="https://www.ncbi.nlm.nih.gov/pubmed/20392886">Burbelo PD, et al.</a> 114107710 Marques, Adriana NIAID - DIR NIAID Marques, Adriana (NIAID) 0 114107711 Iadarola, Michael NIDCR CC Iadarola, Michael (CC) 0 114107712 Burbelo, Peter NIDCR NIDCR Burbelo, Peter (NIDCR) 1 114107712 Burbelo, Peter NIDCR NIDCR Burbelo, Peter (NIDCR) 1 114107710 Marques, Adriana NIAID - DIR NIAID Marques, Adriana (NIAID) 0 114107711 Iadarola, Michael NIDCR CC Iadarola, Michael (CC) 0 114101809 Simple, Quantitative, And Highly Sensitive Antibody Detection For Lyme Disease E-036-2010-1 Filing authorized NIAID, NIDCR 83739611 Yonter, Ediz ediz.yonter@nih.gov
United States of America Technology Advancement Office ediz.yonter@nih.gov?subject=Web Inquiry on [TAB-2113] Simple, Quantitative Sensitive High-throughput Antibody Detection for Lyme Disease&body=Please send me information about technology [TAB-2113] Simple, Quantitative Sensitive High-throughput Antibody Detection for Lyme Disease. Yonter, Ediz<br><a href="mailto:ediz.yonter@nih.gov?subject=Web Inquiry on [TAB-2113] Simple, Quantitative Sensitive High-throughput Antibody Detection for Lyme Disease&body=Please send me information about technology [TAB-2113] Simple, Quantitative Sensitive High-throughput Antibody Detection for Lyme Disease.">ediz.yonter@nih.gov</a><br> 114166902 E-036-2010-1 E-036-2010-1-US-04 Compositions and Methods for Screening For Lyme Disease DIV US 9,310,367 14/562,068 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9310367 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9310367">9,310,367</a><br />Filed on 2014-12-05<br />Status: Issued 114166903 E-036-2010-1 E-036-2010-1-US-03 Compositions and Methods for Screening for Lyme Disease National Stage US 8,926,989 13/583,472 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8926989 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8926989">8,926,989</a><br />Filed on 2012-09-07<br />Status: Issued 114121095 DAXXXX 114121096 DXXXXX 114127839 VJXXXX 114127840 WBXXXX 114139885 SIMPLE 114139886 QUANTITATIVE 114139887 Highly 114139888 SENSITIVE 114139889 ANTIBODY 114139890 Detection 114139891 LYME 114139892 Disease 114139893 Patent Category - Biotechnology 114143466 Listed LPM Fenn as of 4/15/2015 114143467 Pre LPM working set 20150418 114143468 Post LPM Assignment Set 20150420 114157051 Borreliosis 114158619 Lyme Disease TAB-2003 114096223 Antigen Mixtures for Serological Detection of HHV-8 Infection NIDCR Diagnostics, Infectious Disease, Research Materials Diagnostics Infectious Disease Research Materials Peter Burbelo, Michael Iadarola, Joseph Kovacs This invention describes a highly specific and sensitive serological test for human herpesvirus 8 (HHV-8) infection that uses the Luciferase Immunoprecipitation System (LIPS). A mixture of four virus-specific antigens, including K8.1, v-cyclin, ORF65 and LANA, was shown to provide more robust detection of HHV-8 infection than traditional methods due its ability to detect very low viral loads. In addition, one of the antigens, v-cyclin, was identified as a new serological marker for HHV-8 infection, and its similarity to a known human oncogene, cyclin-D, raises the possibility of its use as a diagnostic tool for detecting cancer.<br /><br /> This test is more sensitive and amenable to a high-throughput format than other conventional tests for HHV-8 infection such as Immunofluorescent Assays, Western Blots, ELISAs and PCR based approaches. It simplifies data collection and analysis and allows for more rapid clinical output. Validation tests on patient sera samples using this 4-antigen mixture has shown 100% sensitivity and specificity compared to 94% for ELISAs.<br /><br /> The test can be incorporated into routine screening panels for rapid screening of HHV-8 infection, and may be potentially adapted for use as a diagnostic tool for detecting cancer. A successful embodiment of the test can be incorporated into routine blood screening panels, and may lead a reduced risk of transfusion-transmitted HHV-8 infection in patients. It may also be useful for detecting HHV-8 induced cancer in HIV infected patients. <ul> <li>Rapid and efficient serological screening of HHV-8 infection</li> <li>Cancer diagnostics</li> </ul> Technology is available for non-exclusive or exclusive licensing 2022-03-08 2024-12-31 2026-01-12 2009-08-14 ANTIGEN, DA4XXX, DAXXXX, DDXXXX, DXXXXX, HERPES, HERPESVIRUS-8, HHV-8, Infection, MIXTURES, Patent Category - Biotechnology, screening, SEROLOGICAL False True Early Stage True NIHTT 37470483 Website Abstract 114170907 Burbelo PD, et al. https://www.ncbi.nlm.nih.gov/pubmed/19261774 <a href="https://www.ncbi.nlm.nih.gov/pubmed/19261774">Burbelo PD, et al.</a> 114106720 Kovacs, Joseph Clinical Center (CC) CC Kovacs, Joseph (CC) 0 114106721 Iadarola, Michael NIDCR CC Iadarola, Michael (CC) 0 114105581 Burbelo, Peter NIDCR NIDCR Burbelo, Peter (NIDCR) 1 114105581 Burbelo, Peter NIDCR NIDCR Burbelo, Peter (NIDCR) 1 114106720 Kovacs, Joseph Clinical Center (CC) CC Kovacs, Joseph (CC) 0 114106721 Iadarola, Michael NIDCR CC Iadarola, Michael (CC) 0 114101286 Serological Screening For HHV-8 Infection Using Antigen Mixtures E-063-2009-0 Filing authorized Clinical Center (CC), NIDCR 83739611 Yonter, Ediz ediz.yonter@nih.gov
United States of America Technology Advancement Office ediz.yonter@nih.gov?subject=Web Inquiry on [TAB-2003] Antigen Mixtures for Serological Detection of HHV-8 Infection&body=Please send me information about technology [TAB-2003] Antigen Mixtures for Serological Detection of HHV-8 Infection. Yonter, Ediz<br><a href="mailto:ediz.yonter@nih.gov?subject=Web Inquiry on [TAB-2003] Antigen Mixtures for Serological Detection of HHV-8 Infection&body=Please send me information about technology [TAB-2003] Antigen Mixtures for Serological Detection of HHV-8 Infection.">ediz.yonter@nih.gov</a><br> 114166537 E-063-2009-0 E-063-2009-0-US-03 Serological Screening For HHV-8 Infection Using Antigen Mixtures National Stage US 8,951,723 13/201,317 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8951723 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8951723">8,951,723</a><br />Filed on 2011-08-12<br />Status: Issued 114120551 DA4XXX 114120552 DDXXXX 114120553 DXXXXX 114120554 DAXXXX 114138493 SEROLOGICAL 114138494 screening 114138495 HHV-8 114138496 Infection 114138497 ANTIGEN 114138498 MIXTURES 114138499 HERPES 114138500 HERPESVIRUS-8 114138501 Patent Category - Biotechnology TAB-1697 114095925 Micropatterning of Extracellular Matrix Proteins Using Microphoto-ablation Of Poly vinyl Alcohol (PVA) Monolayers NIDCR Research Equipment, Research Materials Research Equipment Research Materials Andrew Doyle, Kenneth Yamada Available for licensure and commercial development is a micro-photoablation (µPA) method used as a micro-patterning technique to attach ECM proteins or other biological molecules to specified locations. Advantages of this photolytic technique are that it: (a) is stampless, (b) allows for flexible pattern generation to the submicron level, (c) allows for live cell fluorescence imaging, retains cell viability, and (d) allows the use of multiple proteins. The technique has demonstrated experimentally that micropatterning with live cell fluorescence imaging can be used to precisely visualize studying distinct cell-ECM interactions. <br><br> Applications of microlithography techniques into the study of cell biology aid in resolving cellular function as regulated by the interaction of cells with the extracellular matrix. Currently many techniques have used micro-contact patterning (µCP) to apply ECM proteins in distinct localized patterns. These techniques require the fabrication of silicone-based stamps to either "ink" proteins directly or indirectly onto a gold coated surface, limiting the user to a specified stamp shape and size. To bypass the necessity of a physical stamp the current technique provides submicron sized spots using a tunable multiphoton laser coupled to a confocal microscope to photo ablate hydrophilic poly vinyl alcohol (PVA) macro-molecular thin films. Through controlled photo ablation, PVA layers are locally removed allowing deposition of ECM proteins into distinct patterns. The use of ROI's produces a "virtual mask" that can be created in any shape or pattern and are easily modified. Unlike µCP techniques, micro-photoablation (µPA) allows live cell imaging of multiple fluorophores and is possible even with total internal reflection fluorescence (TIRF) microscopy. Therefore, micro-photo ablation (µPA) allows kinetic quantification of ECM-cell interactions. This technique that uses a macro-molecular thin film together with localized photo ablation allows the versatility to create protein spots of any size or shape easily on the same cover slip. Furthermore, this process can be repeated multiple times to directly conjugate different proteins to the same local region allowing the investigation of how single cells probe their surroundings to discern different ECM proteins. <ul> <li>Cellular interactions</li> <li>Protein visualization</li> <li>Diagnostics</li> </ul> Available for licensing. 2022-03-08 2024-10-28 2026-01-12 2007-12-01 AA2XXX, AA3AXX, AA3XXX, AAXXXX, AC3XXX, ACXXXX, AXXXXX, CELL-BINDING, Cellular Interactions, Extracellular, INTERACTION, INTERACTIONS, Micropatterning, Microphoto-ablation, Polyvinyl, PVA False True True NIHTT 37470483 Website Abstract 114170452 CM Cheng, PR LeDuc. Micropatterning polyvinyl alcohol as a biomimetic material through soft lithography with cell culture. Mol Biosyst. 2006 Jun;2(6-7):299-303. http://www.ncbi.nlm.nih.gov/pubmed/16880948?dopt <a href="http://www.ncbi.nlm.nih.gov/pubmed/16880948?dopt">CM Cheng, PR LeDuc. Micropatterning polyvinyl alcohol as a biomimetic material through soft lithography with cell culture. Mol Biosyst. 2006 Jun;2(6-7):299-303.</a> 114170453 T Matsuda, T Sugawara. Development of surface photochemical modification method for micropatterning of cultured cells. J Biomed Mater Res. 1995 Jun;29(6):749-756. http://www.ncbi.nlm.nih.gov/pubmed/7593012?dopt <a href="http://www.ncbi.nlm.nih.gov/pubmed/7593012?dopt">T Matsuda, T Sugawara. Development of surface photochemical modification method for micropatterning of cultured cells. J Biomed Mater Res. 1995 Jun;29(6):749-756.</a> 114105943 Yamada, Kenneth NIDCR NIDCR Yamada, Kenneth (NIDCR) 0 114105944 Doyle, Andrew NIDCR NIDCR Doyle, Andrew (NIDCR) 1 114105944 Doyle, Andrew NIDCR NIDCR Doyle, Andrew (NIDCR) 1 114105943 Yamada, Kenneth NIDCR NIDCR Yamada, Kenneth (NIDCR) 0 114100915 Micropatterning Of Extracellular Matrix Proteins Using Microphoto-ablation Of Poly(vinyl Alcohol) (PVA) Monolayers E-001-2008-0 Filing authorized National Institute of Standards and Technology, NIDCR 83656052 Knezevic, Vladimir vlado.knezevic@nih.gov
United States of America Technology Advancement Office vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-1697] Micropatterning of Extracellular Matrix Proteins Using Microphoto-ablation Of Poly vinyl Alcohol (PVA) Monolayers&body=Please send me information about technology [TAB-1697] Micropatterning of Extracellular Matrix Proteins Using Microphoto-ablation Of Poly vinyl Alcohol (PVA) Monolayers. Knezevic, Vladimir<br><a href="mailto:vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-1697] Micropatterning of Extracellular Matrix Proteins Using Microphoto-ablation Of Poly vinyl Alcohol (PVA) Monolayers&body=Please send me information about technology [TAB-1697] Micropatterning of Extracellular Matrix Proteins Using Microphoto-ablation Of Poly vinyl Alcohol (PVA) Monolayers.">vlado.knezevic@nih.gov</a><br> 114162393 E-001-2008-0 E-001-2008-0-US-02 Micropatterning Of Biological Molecules Using Laser Ablation ORD US 8,048,641 12/249,824 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8048641 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8048641">8,048,641</a><br />Filed on 2008-10-10<br />Status: Issued 114118397 AA3AXX 114118398 AAXXXX 114118399 ACXXXX 114118400 AXXXXX 114118950 AA2XXX 114118951 AA3XXX 114118952 AC3XXX 114131732 Micropatterning 114131733 Extracellular 114131734 Cellular Interactions 114131735 INTERACTION 114131736 Microphoto-ablation 114131737 INTERACTIONS 114131738 CELL-BINDING 114131739 PVA 114131740 Polyvinyl TAB-2955 114096791 WNT1-Induced Secreted Protein-1 Knockout Mouse Model NIDCR Cardiology, Dental, Diagnostics, Endocrinology, Geriatrics, Immunology, Infectious Disease, Oncology, Ophthalmology, Research Materials, Therapeutics Cardiology Dental Diagnostics Endocrinology Geriatrics Immunology Infectious Disease Oncology Ophthalmology Research Materials Therapeutics Azusa Maeda, Mitsuaki Ono, Marian Young <p>WNT1-induced secreted protein-1 (WISP1) is expressed at high levels in osteoblasts and their precursors. WIPS1 plays an important role in various aspects of bone formation. Scientists at the NIH generated <em>Wisp1</em>-deficient (<em>Wisp1<sup>-/-</sup></em>) mice. Deletion of <em>Wisp1</em> resulted in a decrease in bone mineral density, total bone volume, bone thickness, and biomechanical strength. <em>Wisp1</em> knockout mouse model can be used to study the molecular mechanisms of bone turnover and patho/physiology of tissues that express WISP1.&nbsp;The animal is only available from MMRRC.</p> <ul> <li>To study the molecular mechanisms of bone formation and osteodifferentiation.</li> <li>To study the patho/physiology of tissues that express WISP1, including cartilage during osteoarthritis, healing skin, and other soft tissues including lung, pancreas, and heart.</li> </ul> Research Tool - Patent protection is not being pursued for this technology. Available for non-exclusive licensing 2022-03-08 2024-12-26 2026-01-12 2015-08-03 DEFICIENT, Generation, Mice, OSTEOGENESIS, VAXXXX, VPXXXX, WISP1, WIXXXX, XCXXXX, XEXXXX, YCXXXX False True In vivo data available (animal) True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114171853 Maeda A, et al. http://www.ncbi.nlm.nih.gov/pubmed/25864198 <a href="http://www.ncbi.nlm.nih.gov/pubmed/25864198">Maeda A, et al.</a> 114103327 Maeda, Azusa Okayama University Graduate School of Medicine Maeda, Azusa 0 114103431 Ono, Mitsuaki Okayama University Graduate School of Medicine Ono, Mitsuaki 0 114104352 Young, Marian NIDCR NIDCR Young, Marian (NIDCR) 1 114104352 Young, Marian NIDCR NIDCR Young, Marian (NIDCR) 1 114103327 Maeda, Azusa Okayama University Graduate School of Medicine Maeda, Azusa 0 114103431 Ono, Mitsuaki Okayama University Graduate School of Medicine Ono, Mitsuaki 0 114101914 Generation Of WISP1 Deficient Mice For The Study Of Osteogenesis E-234-2015-0 Research Material NIDCR 83656052 Knezevic, Vladimir vlado.knezevic@nih.gov
United States of America Technology Advancement Office vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-2955] WNT1-Induced Secreted Protein-1 Knockout Mouse Model&body=Please send me information about technology [TAB-2955] WNT1-Induced Secreted Protein-1 Knockout Mouse Model. Knezevic, Vladimir<br><a href="mailto:vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-2955] WNT1-Induced Secreted Protein-1 Knockout Mouse Model&body=Please send me information about technology [TAB-2955] WNT1-Induced Secreted Protein-1 Knockout Mouse Model.">vlado.knezevic@nih.gov</a><br> 114121483 VAXXXX 114121484 VPXXXX 114123343 WIXXXX 114123344 XCXXXX 114123345 XEXXXX 114123346 YCXXXX 114139045 Generation 114139046 WISP1 114139047 DEFICIENT 114139048 Mice 114139049 OSTEOGENESIS TAB-3794 114097644 In-vivo System to Interrogate the Functions of Mucous Membranes and Identify Mucin/Glycan Mimetics and JAK/STAT Inhibitors for the Treatment of Diseases of the Oral Cavity and Digestive Tract NIDCR Cardiology, Dental, Endocrinology, Infectious Disease, Oncology, Ophthalmology, Research Materials, Therapeutics Cardiology Dental Endocrinology Infectious Disease Oncology Ophthalmology Research Materials Therapeutics Kelly Ten Hagen, Liping Zhang This technology includes a Drosophila mutant strain that can be used as an in vivo model for diseases of the oral cavity and digestive tract (Sjogren's syndrome, colitis, colon cancer, inflammatory bowel disease), where the mucous membrane is disrupted or non-functional. This mutant lacks a mucous membrane and displays epithelial cell damage, uncontrolled cell proliferation and the up-regulation of conserved signaling pathways (JAK/STAT). Specifically, this mutant could be used to screen for compounds that either: 1) act to minimize damage to the epithelial cells in vivo; 2) stop uncontrolled cell proliferation in vivo; 3) rescue the abnormal up-regulation of conserved signaling pathways in vivo; and/or 4) act as a synthetic mucous membrane or mucin mimetic in vivo. Preliminary results suggest that this mutant can provide a great read-out for compounds that suffice in restoring the functional properties of the mucous membrane and therefore could be of potential use in treating patients that suffer from a compromised mucous lining. <ul><li>It is a complete in vivo system, with intact, functional organs comprised of all the appropriately differentiated cell types</li> <li>Drosophila larvae are inexpensive to grow and maintain</li> <li>Large numbers of larvae can be easily generated to perform screening of many compounds</li></ul> Screen for compounds to be used in the treatment of oral cavity and digestive tract disorders. 2022-11-30 2024-12-26 2026-01-12 2022-11-30 2022-08-03 FUNCTIONS, IDENTIFY, Inhibitors, Interrogate, Jak/STAT, MEMBRANES, MIMETICS, Mucin/glycan, Mucous, System, Vivo, VPXXXX, WIXXXX, XEXXXX False True True NIHTT 37470483 Website Abstract 114172954 Zhang L, Syed Z, et al. https://pubmed.ncbi.nlm.nih.gov/24799692/ <a href="https://pubmed.ncbi.nlm.nih.gov/24799692/">Zhang L, Syed Z, et al.</a> 114172955 Kuraishi T, Binggeli O, et al. https://pubmed.ncbi.nlm.nih.gov/21896728/ <a href="https://pubmed.ncbi.nlm.nih.gov/21896728/">Kuraishi T, Binggeli O, et al.</a> 114111588 Zhang, Liping NIDCR NIDCR Zhang, Liping (NIDCR) 0 114111589 Ten Hagen, Kelly NIDCR NIDCR Ten Hagen, Kelly (NIDCR) 1 114111589 Ten Hagen, Kelly NIDCR NIDCR Ten Hagen, Kelly (NIDCR) 1 114111588 Zhang, Liping NIDCR NIDCR Zhang, Liping (NIDCR) 0 114102896 In Vivo System To Interrogate The Functions Of Mucous Membranes And Identify Mucin/glycan Mimetics And JAK/STAT Inhibitors E-148-2016-0 Research Material NIDCR 83656052 Knezevic, Vladimir vlado.knezevic@nih.gov
United States of America Technology Advancement Office vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-3794] In-vivo System to Interrogate the Functions of Mucous Membranes and Identify Mucin/Glycan Mimetics and JAK/STAT Inhibitors for the Treatment of Diseases of the Oral Cavity and Digestive Tract&body=Please send me information about technology [TAB-3794] In-vivo System to Interrogate the Functions of Mucous Membranes and Identify Mucin/Glycan Mimetics and JAK/STAT Inhibitors for the Treatment of Diseases of the Oral Cavity and Digestive Tract. Knezevic, Vladimir<br><a href="mailto:vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-3794] In-vivo System to Interrogate the Functions of Mucous Membranes and Identify Mucin/Glycan Mimetics and JAK/STAT Inhibitors for the Treatment of Diseases of the Oral Cavity and Digestive Tract&body=Please send me information about technology [TAB-3794] In-vivo System to Interrogate the Functions of Mucous Membranes and Identify Mucin/Glycan Mimetics and JAK/STAT Inhibitors for the Treatment of Diseases of the Oral Cavity and Digestive Tract.">vlado.knezevic@nih.gov</a><br> 114129625 VPXXXX 114129626 WIXXXX 114129627 XEXXXX 114155478 Vivo 114155479 System 114155480 Interrogate 114155481 FUNCTIONS 114155482 Mucous 114155483 MEMBRANES 114155484 IDENTIFY 114155485 Mucin/glycan 114155486 MIMETICS 114155487 Jak/STAT 114155488 Inhibitors TAB-2966 114094544 Rabbit Antisera to Various Matrix, Matricellular, and Other Secreted Proteins NIDCR Antibodies, Cardiology, Diagnostics, Endocrinology, Geriatrics, Immunology, Oncology, Research Materials Antibodies Cardiology Diagnostics Endocrinology Geriatrics Immunology Oncology Research Materials Larry Fisher <p>The extracellular matrix (ECM) is composed of a group of proteins that regulate many cellular functions, such as cell shape, adhesion, migration, proliferation, and differentiation. Deregulation of ECM protein production or function contributes to many pathological conditions, including asthma, chronic obstructive pulmonary disease, arthrosclerosis, and cancer. Scientists at the NIH have developed antisera against various ECM components such as proteoglycan, sialoprotein, collagen, etc.. These antisera can be used as research tools to study the biology of extracellular matrix molecules. The resource is only available from KeraFAST and Millipore Sigma.</p> <ul> <li>Studying the biology of extracellular matrix molecules.</li> </ul> Research Tool – Patent protection is not being pursued for this technology. 2022-03-08 2025-08-13 2026-01-12 2015-08-10 ANIMAL, Antisera, Human, Listed LPM Maddox as of 4/15/2015, Matricellular, MATRIX, polyclonal, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, proteins, rabbit, RXXXXX, SECRETED, VARIOUS, VAXXXX, VCXXXX, VDXXXX, VGXXXX, VIXXXX, WIXXXX, XAXXXX, XCXXXX, YAXXXX False True Early-stage True 52406768 Discovery 52406768 NIHTT 37470483 Website Abstract 114109055 Fisher, Larry NIDCR NIDCR Fisher, Larry (NIDCR) 1 114109055 Fisher, Larry NIDCR NIDCR Fisher, Larry (NIDCR) 1 114101876 Rabbit Polyclonal Antisera To Human And Various Animal Matrix, Matricellular And Other Secreted Proteins E-135-2008-0 Research Material NIDCR 83656052 Knezevic, Vladimir vlado.knezevic@nih.gov
United States of America Technology Advancement Office vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-2966] Rabbit Antisera to Various Matrix, Matricellular, and Other Secreted Proteins&body=Please send me information about technology [TAB-2966] Rabbit Antisera to Various Matrix, Matricellular, and Other Secreted Proteins. Knezevic, Vladimir<br><a href="mailto:vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-2966] Rabbit Antisera to Various Matrix, Matricellular, and Other Secreted Proteins&body=Please send me information about technology [TAB-2966] Rabbit Antisera to Various Matrix, Matricellular, and Other Secreted Proteins.">vlado.knezevic@nih.gov</a><br> 114127088 RXXXXX 114127089 VAXXXX 114127090 VCXXXX 114127091 VDXXXX 114127092 VGXXXX 114127093 VIXXXX 114127094 WIXXXX 114127095 XAXXXX 114127096 XCXXXX 114127097 YAXXXX 114148430 rabbit 114148431 polyclonal 114148432 Antisera 114148433 Human 114148434 VARIOUS 114148435 ANIMAL 114148436 MATRIX 114148437 Matricellular 114148438 SECRETED 114148439 proteins 114148440 Listed LPM Maddox as of 4/15/2015 114148441 Pre LPM working set 20150418 114148442 Post LPM Assignment Set 20150420 TAB-736 114095072 Postnatal Stem Cells and Uses Thereof NIDCR Dental, Diagnostics, Licensing, Therapeutics Dental Diagnostics Licensing Therapeutics Pamela Robey, Songtao Shi Many individuals with ongoing and severe dental problems are faced with the prospect of permanent tooth loss. Examples of such dental problems include: dentinal degradation due to chronic dental disease (caries or periodontal); mouth injury; or through surgical removal, such as with tumors associated with the jaw. For many, a technology that offers a possible alternative to artificial dentures by designing and transplanting a set of living teeth fashioned from an individual's own pulp cells would greatly improve their quality of life.<br /><br /> The NIH announces a new technology wherein human postnatal deciduous dental pulp stem cells commonly known as "baby teeth", are used to create dentin and have been shown to differentiate into cells of specialized function such as neural cells, adipocytes, and odontoblasts. It is believed that these cells could be manipulated to repair damaged teeth, induce the regeneration of bone, and treat neural injury or disease. 2022-03-08 2024-10-28 2026-01-12 2005-07-01 TB2XXX, TBXXXX, TCXXXX, TXXXXX False True True NIHTT 37470483 Website Abstract 114169909 Miura M, et al. http://www.ncbi.nlm.nih.gov/pubmed/12716973 <a href="http://www.ncbi.nlm.nih.gov/pubmed/12716973">Miura M, et al.</a> 114104426 Shi, Songtao Shi, Songtao 0 114104427 Robey, Pamela NIDCR Robey, Pamela (NIDCR) 0 114104426 Shi, Songtao Shi, Songtao 0 114104427 Robey, Pamela NIDCR Robey, Pamela (NIDCR) 0 114099893 Isolation Of Multipotent Post-Natal Stem Cells From Exfoliated Human Primary (Baby) Teeth E-018-2003-0 Filing authorized NIDCR 83656052 Knezevic, Vladimir vlado.knezevic@nih.gov
United States of America Technology Advancement Office vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-736] Postnatal Stem Cells and Uses Thereof&body=Please send me information about technology [TAB-736] Postnatal Stem Cells and Uses Thereof. Knezevic, Vladimir<br><a href="mailto:vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-736] Postnatal Stem Cells and Uses Thereof&body=Please send me information about technology [TAB-736] Postnatal Stem Cells and Uses Thereof.">vlado.knezevic@nih.gov</a><br> 114161793 E-018-2003-0 E-018-2003-0-US-02 Postnatal Stem Cells And Uses Thereof National Stage US 9,175,264 10/553,633 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9175264 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9175264">9,175,264</a><br />Filed on 2006-11-07<br />Status: Issued 114114477 TB2XXX 114114478 TBXXXX 114114479 TCXXXX 114114480 TXXXXX TAB-2808 114096988 Use of Antihistamine Compounds for the Treatment of Hepatitis C Virus NIDDK Infectious Disease, Licensing, Therapeutics Infectious Disease Licensing Therapeutics Shanshan (Melissa) He, Zongyi Hu, Tsanyang (Jake) Liang, Wei Zheng The vast majority of people infected with Hepatitis C Virus (HCV) will have chronic infection. Over decades, this can lead to liver disease and liver cancer. In fact, HCV infection is the leading cause of liver transplants in the U.S. Several new drugs have recently come into the market that will likely change the HCV treatment paradigm. However, the effectiveness of these new drugs can vary depending on the HCV genotype. Thus, there is still the need for additional new therapeutics against HCV.<br /><br /> The subject technology are small molecule compounds identified using a novel cell-based high throughput assay of HCV infection. The compounds are antihistamines that show potent antiviral properties against HCV. One advantage of these compounds is that they are already on the market for the treatment of allergic reactions and, thus, have been used extensively in humans and have excellent safety profiles with known pharmaceutical properties. The subject technology can also potentially be used in combination with other HCV therapeutics. <ul> <li>These compounds are already on the market and, thus, have known safety profiles and pharmaceutical properties.</li> </ul> <ul> <li>Prevention or treatment of HCV infection.</li> <ul> 2022-03-08 2025-08-13 2026-01-12 2017-04-18 Analogs, C, Chlorcyclizine, DB4BXX, Hepatitis, RELATED, treatment, VLXXXX, WKXXXX, YAXXXX, YBXXXX False True <ul> <li>Early-stage</li> <li>In vitro data available</li> </ul> True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114108684 Zheng, Wei NCATS - TRND NCATS Zheng, Wei (NCATS) 0 114108685 He, Shanshan (Melissa) National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) He, Shanshan (Melissa) 0 114108686 Hu, Zongyi National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Hu, Zongyi (NIDDK) 0 114107484 Liang, Tsanyang (Jake) National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Liang, Tsanyang (Jake) (NIDDK) 1 114107484 Liang, Tsanyang (Jake) National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Liang, Tsanyang (Jake) (NIDDK) 1 114108684 Zheng, Wei NCATS - TRND NCATS Zheng, Wei (NCATS) 0 114108685 He, Shanshan (Melissa) National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) He, Shanshan (Melissa) 0 114108686 Hu, Zongyi National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Hu, Zongyi (NIDDK) 0 114101692 Use Of Chlorcyclizine And Its Related Analogs In Treatment Of Hepatitis C E-011-2014-0 Filing authorized National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NCATS - NCGC 83656052 Knezevic, Vladimir vlado.knezevic@nih.gov
United States of America Technology Advancement Office vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-2808] Use of Antihistamine Compounds for the Treatment of Hepatitis C Virus&body=Please send me information about technology [TAB-2808] Use of Antihistamine Compounds for the Treatment of Hepatitis C Virus. Knezevic, Vladimir<br><a href="mailto:vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-2808] Use of Antihistamine Compounds for the Treatment of Hepatitis C Virus&body=Please send me information about technology [TAB-2808] Use of Antihistamine Compounds for the Treatment of Hepatitis C Virus.">vlado.knezevic@nih.gov</a><br> 114161387 E-011-2014-0 E-011-2014-0-PCT-02 Heterocyclic Compounds and Methods of Use Thereof PCT Patent Cooperation Treaty PCT/US2014/066680 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2014/066680<br />Filed on 2014-11-20<br />Status: Expired 114166359 E-011-2014-0 E-011-2014-0-US-08 Piperidine and Piperazine Derivatives and Their Use in Treating Viral Infections and Cancer National Stage US 15/039,781 Abandoned US <br />National Stage 15/039,781<br />Filed on 2016-05-26<br />Status: Abandoned 114167748 E-011-2014-0 E-011-2014-0-US-01 Heterocyclic Compounds and Methods of Use Thereof PRV US 61/909,414 Abandoned US <br />Provisional (PRV) 61/909,414<br />Filed on 2013-11-27<br />Status: Abandoned 114125940 DB4BXX 114125941 VLXXXX 114125942 WKXXXX 114125943 YAXXXX 114125944 YBXXXX 114147147 Chlorcyclizine 114147148 RELATED 114147149 Analogs 114147150 treatment 114147151 Hepatitis 114147152 C TAB-2421 114096623 MUP-tTA Mouse Model for Liver Function Studies NIDDK Diagnostics, Licensing, Research Materials, Therapeutics Diagnostics Licensing Research Materials Therapeutics Tsanyang (Jake) Liang Tetracycline-responsive transcriptional activator driven by the liver-specific mouse major urinary protein promoter (MUP-tTA). <br /><br /> The E. Coli tetracycline operon regulatory system was used to generate a liver-specific transcription activation system that was inhibited by tetracycline. The transcription activator was a fused protein consisting of a tetracycline repressor gene (tetR) that was only active in the presence of tetracycline and a herpes simplex virus protein (VP-16) transcription activating domain (Tet-Off). Transcription was induced only in the absence of tetracycline (Tet-Off). A liver-specific promoter such as the mouse major urinary protein (MUP) promoter determined that the tetracycline-regulated transcriptional activator (tTA) would be expressed specifically in liver. To study the effect of the transcription activator on a target gene (for example, beta-galactosidase, LacZ) specifically in liver, MUP-tTA mice would be mated with transgenic mice in which the TAg Target gene was controlled by the E.Coli Tetracycline Operator (Tet-O). The Tet technology may require a separate license. Mouse model to study liver function. Research Tool — Patent protection is not being pursued for this technology. 2022-03-08 2025-08-13 2026-01-12 2017-04-17 IDXXXX, IXXXXX, Mouse, MUP-tTA False True Pre-clinical True NIHTT 37470483 Website Abstract 114171566 Manickan E, et al. http://www.ncbi.nlm.nih.gov/pubmed/11278564 <a href="http://www.ncbi.nlm.nih.gov/pubmed/11278564">Manickan E, et al.</a> 114107524 Liang, Tsanyang (Jake) National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Liang, Tsanyang (Jake) (NIDDK) 1 114107524 Liang, Tsanyang (Jake) National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Liang, Tsanyang (Jake) (NIDDK) 1 114101723 MUP-tTA Mouse E-126-2012-0 Research Material National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83656052 Knezevic, Vladimir vlado.knezevic@nih.gov
United States of America Technology Advancement Office vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-2421] MUP-tTA Mouse Model for Liver Function Studies&body=Please send me information about technology [TAB-2421] MUP-tTA Mouse Model for Liver Function Studies. Knezevic, Vladimir<br><a href="mailto:vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-2421] MUP-tTA Mouse Model for Liver Function Studies&body=Please send me information about technology [TAB-2421] MUP-tTA Mouse Model for Liver Function Studies.">vlado.knezevic@nih.gov</a><br> 114122723 IXXXXX 114122724 IDXXXX 114142906 MUP-tTA 114142907 Mouse TAB-2420 114096622 Alb-tTA (Tg(Alb1-tTA)3123Lng) Mouse Model for Liver Function Studies NIDDK Diagnostics, Licensing, Research Materials, Therapeutics Diagnostics Licensing Research Materials Therapeutics Tsanyang (Jake) Liang Tetracycline-responsive transcriptional activator driven by the liver-specific mouse albumin promoter (Alb-tTA). <br /><br /> The E. Coli tetracycline operon regulatory system was used to generate a liver-specific transcription activation system that was inhibited by tetracycline. The transcription activator was a fused protein consisting of a tetracycline repressor gene (tetR) that was only active in the presence of tetracycline and a herpes simplex virus protein (VP-16) transcription activating domain. Transcription was induced only in the absence of tetracycline (Tet-Off). A liver-specific promoter such as mouse albumin determined that the tetracycline-regulated transcriptional activator (tTA) would be expressed specifically in liver. To study the effect of the transcription activator on a target gene (for example, Simian Virus 40 (SV4) large tumor (T) antigen (TAg)) specifically in liver, Alb-tTA mice were mated with transgenic mice in which the Target gene (TAg) was controlled by the E.Coli Tetracycline Operator (Tet-O). In this example, TAg was expressed in hepatocytes in the absence of Tetracycline, leading to hepatoma formation. When the mice were treated with tetracycline, TAg was not expressed and hepatomas did not form. Mouse model to liver function. Research Tool — Patent protection is not being pursued for this technology. 2022-03-08 2025-08-13 2026-01-12 2017-04-18 Alb-tTA, IDXXXX, IXXXXX, Mouse, TgAlb1-tTa3123Lng False True Pre-clinical True NIHTT 37470483 Website Abstract 114171565 Manickan E, et al. http://www.ncbi.nlm.nih.gov/pubmed/11278564 <a href="http://www.ncbi.nlm.nih.gov/pubmed/11278564">Manickan E, et al.</a> 114107523 Liang, Tsanyang (Jake) National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Liang, Tsanyang (Jake) (NIDDK) 1 114107523 Liang, Tsanyang (Jake) National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Liang, Tsanyang (Jake) (NIDDK) 1 114101722 Alb-tTA (Tg(Alb1-tTa)3123Lng) Mouse E-125-2012-0 Research Material National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83656052 Knezevic, Vladimir vlado.knezevic@nih.gov
United States of America Technology Advancement Office vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-2420] Alb-tTA (Tg(Alb1-tTA)3123Lng) Mouse Model for Liver Function Studies&body=Please send me information about technology [TAB-2420] Alb-tTA (Tg(Alb1-tTA)3123Lng) Mouse Model for Liver Function Studies. Knezevic, Vladimir<br><a href="mailto:vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-2420] Alb-tTA (Tg(Alb1-tTA)3123Lng) Mouse Model for Liver Function Studies&body=Please send me information about technology [TAB-2420] Alb-tTA (Tg(Alb1-tTA)3123Lng) Mouse Model for Liver Function Studies.">vlado.knezevic@nih.gov</a><br> 114122721 IXXXXX 114122722 IDXXXX 114142903 Alb-tTA 114142904 TgAlb1-tTa3123Lng 114142905 Mouse TAB-3726 114097578 Development of an Efficient and Affordable Protein Purification System to Study Protein Functions and Structures NIDDK Medical Devices, Non-Medical Devices, Research Materials Medical Devices Non-Medical Devices Research Materials Poorni Adika, Mritunjay Pandey, William Simonds, Jianhua Zhang This technology includes a semi-automatic and affordable protein purification system that produces purified proteins with yields and purities comparable to an automatic protein purification system for less than 10% of its cost, which can be used for studying protein structure and function, as well as antibody purifications and drug screenings. Additionally, the new system is flexible and customizable for use with both custom-made and commercial pre-made resin columns with either gravity flow or low-pressure configurations. Using a prototype, we have successfully performed one-step purification of different twin-strep tagged protein complexes overexpressed in mammalian cells and obtained proteins with more than 90% purity. This easy-to-use and user-friendly system can facilitate the affinity purification of any protein in both large and small scales. Therefore, this new system shares the advantages of both automatic and manual systems at a fraction of the cost, and therefore could be a better alternative for the protein purification systems currently available. Compared to existing protein purification systems, this innovation has the following unique features: <ul> <li>Significantly reduces the hands-on time compared to the regular gravity flow method</li> <li>Very low cost compared to automatic method</li> <li>Simple to use</li> <li>Semi-automatic</li> <li>Compatible with both premade and custom-made columns</li> <li>Flexible in column size and capacity</li> <li>Controlled flow rate and more reproducible results as compared to regular gravity flow method</li> </ul> The novel protein purification system can be used: <ul> <li>For purification of polyclonal, monoclonal antibodies</li> <li>For purification of proteins</li> <li>For separation of other materials using gravity flow mechanisms</li> <li>For use with existing and commercially available columns and custom-made columns</li> </ul> 2022-11-30 2026-01-12 2026-01-12 2022-11-30 Affordable, Development, Efficient, Protein, purification, System, WIXXXX, XDXXXX False True True NIHTT 37470483 Website Abstract 114111403 Simonds, William National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Simonds, William (NIDDK) 0 114111404 Pandey, Mritunjay National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Pandey, Mritunjay 0 114111405 Adika, Poorni National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Adika, Poorni (NIDDK) 0 114111406 Zhang, Jianhua National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Zhang, Jianhua (NIDDK) 1 114111406 Zhang, Jianhua National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Zhang, Jianhua (NIDDK) 1 114111403 Simonds, William National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Simonds, William (NIDDK) 0 114111404 Pandey, Mritunjay National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Pandey, Mritunjay 0 114111405 Adika, Poorni National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Adika, Poorni (NIDDK) 0 114102830 Development Of An Efficient And Affordable Protein Purification System E-011-2018-0 Research Material National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83656052 Knezevic, Vladimir vlado.knezevic@nih.gov
United States of America Technology Advancement Office vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-3726] Development of an Efficient and Affordable Protein Purification System to Study Protein Functions and Structures &body=Please send me information about technology [TAB-3726] Development of an Efficient and Affordable Protein Purification System to Study Protein Functions and Structures . Knezevic, Vladimir<br><a href="mailto:vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-3726] Development of an Efficient and Affordable Protein Purification System to Study Protein Functions and Structures &body=Please send me information about technology [TAB-3726] Development of an Efficient and Affordable Protein Purification System to Study Protein Functions and Structures .">vlado.knezevic@nih.gov</a><br> 114129410 WIXXXX 114129411 XDXXXX 114154848 Development 114154849 Efficient 114154850 Affordable 114154851 Protein 114154852 purification 114154853 System TAB-5076 164222822 Innovative Antibody Conjugates for Targeted Therapeutics NIBIB Diagnostics, Immunology, Oncology, Therapeutics Diagnostics Immunology Oncology Therapeutics Devon Hartigan, Katharina Maisel, Kaitlyn Sadtler <p><span style="font-size:12pt"><span style="font-family:&quot;Times New Roman&quot;,serif">This cutting-edge technology leverages innovative conjugated antibodies to transform the way diseases are treated. By engineering antibodies to deliver therapeutic agents directly to specific cells, this approach offers a powerful combination of precision, potency, and safety.</span></span></p> <p><span style="font-size:12pt"><span style="font-family:&quot;Times New Roman&quot;,serif">Unlike traditional therapies that often impact healthy tissues and cause significant side effects, these conjugated antibodies provide highly targeted delivery, ensuring that treatment is concentrated where it is needed most. This next-generation strategy addresses the critical limitations of conventional treatments by improving both accuracy in targeting disease mechanisms and overall treatment outcomes.</span></span></p> <p><span style="font-size:12pt"><span style="font-family:&quot;Times New Roman&quot;,serif">The technology&rsquo;s versatility makes it especially impactful in oncology, where eliminating tumor cells without harming surrounding tissue is paramount, and in autoimmune disorders, where precise modulation of immune activity can dramatically improve patient quality of life. With its potential to reshape multiple therapeutic landscapes, this innovation represents a new frontier in targeted medicine.</span></span></p> <ul> <li>Enhanced targeting capabilities leading to improved therapeutic outcomes.</li> <li>Reduced side effects compared to conventional treatments due to localized drug delivery.</li> <li>Potential for broad applications across various therapeutic areas, including oncology and autoimmune diseases.</li> </ul> <ul> <li>Targeted cancer therapies using engineered antibodies.</li> <li>Autoimmune disease treatments with reduced systemic effects.</li> <li>Diagnostic imaging agents for precise disease localization.</li> </ul> 2025-09-22 2025-09-22 2026-01-02 2025-09-22 False True True 52406768 Discovery 52406768 37470483 Website Abstract 164222874 Sadtler, Kaitlyn NIH - NIBIB NIBIB Sadtler, Kaitlyn (NIBIB) 1 164222853 Hartigan, Devon Hartigan, Devon 2 164222849 Maisel, Katharina Maisel, Katharina 3 164222874 Sadtler, Kaitlyn NIH - NIBIB NIBIB Sadtler, Kaitlyn (NIBIB) 1 164222853 Hartigan, Devon Hartigan, Devon 2 164222849 Maisel, Katharina Maisel, Katharina 3 164222825 A thermo-sensitive hydrogel for in situ delivery of Amphotericin B to fungal infection sites E-078-2024-0 Filing authorized NIBIB, NIBIB, University of Maryland 83656052 Knezevic, Vladimir vlado.knezevic@nih.gov
United States of America Technology Advancement Office vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-5076] Innovative Antibody Conjugates for Targeted Therapeutics&body=Please send me information about technology [TAB-5076] Innovative Antibody Conjugates for Targeted Therapeutics. Knezevic, Vladimir<br><a href="mailto:vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-5076] Innovative Antibody Conjugates for Targeted Therapeutics&body=Please send me information about technology [TAB-5076] Innovative Antibody Conjugates for Targeted Therapeutics.">vlado.knezevic@nih.gov</a><br> 164222831 E-078-2024-0 E-078-2024-0-PC-01 THERMO-SENSITIVE ANTI-FUNGAL HYDROGEL COMPOSITIONS AND METHODS OF USE PCT Patent Cooperation Treaty PCT/US2025/017838 Pending Patent Cooperation Treaty <br />(PCT) PCT/US2025/017838<br />Filed on 2025-02-28<br />Status: Pending TAB-5077 164223314 Innovative Antibody Conjugates for Targeted Therapy NIBIB Diagnostics, Immunology, Oncology, Therapeutics Diagnostics Immunology Oncology Therapeutics Parinaz Fathi, Nicole Morgan, Paniz Rezvan Sangsari, Kaitlyn Sadtler <p><span style="font-size:12pt"><span style="font-family:&quot;Times New Roman&quot;,serif">This advanced technology introduces innovative antibody conjugates that redefine the possibilities of targeted therapy. By coupling therapeutic agents to engineered antibodies with highly specific binding sites, these conjugates deliver treatments directly to diseased cells while sparing healthy tissues. The result is a powerful increase in treatment efficacy, accompanied by a meaningful reduction in side effects.</span></span></p> <p><span style="font-size:12pt"><span style="font-family:&quot;Times New Roman&quot;,serif">Designed with cutting-edge engineering techniques, the platform offers exceptional versatility, enabling adaptation across a wide range of therapeutic areas. Its greatest potential lies in oncology, where precision targeting is critical for destroying tumor cells while preserving patient health, and in immunology, where carefully modulating immune responses can transform chronic disease management.</span></span></p> <p><span style="font-size:12pt"><span style="font-family:&quot;Times New Roman&quot;,serif">By uniting precision targeting, enhanced safety, and broad therapeutic applicability, this technology represents a major step forward in the evolution of targeted therapies, offering new hope for improved patient outcomes and more effective treatments.</span></span></p> <ul> <li>High specificity and reduced off-target effects, leading to improved patient safety.</li> <li>Versatile applications across multiple therapeutic areas, including oncology and immunology.</li> <li>Potential for rapid development and commercialization due to established engineering techniques.</li> </ul> <ul> <li>Targeted cancer therapies using engineered immune cells.</li> <li>Diagnostic imaging agents for precise disease detection.</li> <li>Therapeutic agents for autoimmune diseases.</li> </ul> 2025-09-22 2025-09-22 2026-01-02 2025-09-22 False True True 52406768 Discovery 52406768 37470483 Website Abstract 164223425 Morgan, Nicole NIH - NIBIB NIBIB Morgan, Nicole (NIBIB) 1 164223416 Rezvan Sangsari, Paniz NIH - NIBIB NIBIB Rezvan Sangsari, Paniz (NIBIB) 2 164223458 Fathi, Parinaz Fathi, Parinaz 3 164223504 Sadtler, Kaitlyn NIH - NIBIB NIBIB Sadtler, Kaitlyn (NIBIB) 4 164223425 Morgan, Nicole NIH - NIBIB NIBIB Morgan, Nicole (NIBIB) 1 164223416 Rezvan Sangsari, Paniz NIH - NIBIB NIBIB Rezvan Sangsari, Paniz (NIBIB) 2 164223458 Fathi, Parinaz Fathi, Parinaz 3 164223504 Sadtler, Kaitlyn NIH - NIBIB NIBIB Sadtler, Kaitlyn (NIBIB) 4 164223317 Microfluidic Devices For Evaluating Fibrosis In Material Implantation And Cancer E-118-2022-0 Filing authorized NIBIB 83656052 Knezevic, Vladimir vlado.knezevic@nih.gov
United States of America Technology Advancement Office vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-5077] Innovative Antibody Conjugates for Targeted Therapy&body=Please send me information about technology [TAB-5077] Innovative Antibody Conjugates for Targeted Therapy. Knezevic, Vladimir<br><a href="mailto:vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-5077] Innovative Antibody Conjugates for Targeted Therapy&body=Please send me information about technology [TAB-5077] Innovative Antibody Conjugates for Targeted Therapy.">vlado.knezevic@nih.gov</a><br> 164223328 E-118-2022-0 E-118-2022-0-US-02 MICROFLUIDIC DEVICES FOR EVALUATING FIBROSIS IN MATERIAL IMPLANTATION AND CANCER National Stage US 18/859,345 Pending US <br />National Stage 18/859,345<br />Filed on 2024-10-23<br />Status: Pending 164223329 E-118-2022-0 E-118-2022-0-EP-01 MICROFLUIDIC DEVICES FOR EVALUATING FIBROSIS IN MATERIAL IMPLANTATION AND CANCER National Stage European Patent 23726232.4 Pending European Patent <br />National Stage 23726232.4<br />Filed on 2024-10-25<br />Status: Pending TAB-5079 164223742 Advanced Biodegradable Polymers for Medical Devices NIBIB Human Cell Lines, Medical Devices, Therapeutics Human Cell Lines Medical Devices Therapeutics Ravi Lokwani, Kaitlyn Sadtler <p><span style="font-size:12pt"><span style="font-family:&quot;Times New Roman&quot;,serif">This breakthrough technology features advanced biodegradable polymers engineered specifically for medical device applications. Designed to safely degrade within the body, these polymers eliminate the need for surgical removal, significantly reducing the risk of long-term complications and enhancing overall patient safety.</span></span></p> <p><span style="font-size:12pt"><span style="font-family:&quot;Times New Roman&quot;,serif">The polymers&rsquo; controlled degradation rates provide unmatched versatility, allowing them to be tailored for a wide range of clinical uses&mdash;from temporary implants to drug-delivery systems. Beyond patient care, the technology also addresses a growing global need for sustainable healthcare solutions, reducing medical waste and lessening environmental impact.</span></span></p> <p><span style="font-size:12pt"><span style="font-family:&quot;Times New Roman&quot;,serif">By combining safety, precision, and sustainability, this innovation represents a major step forward in next-generation medical device design. It sets a new standard for solutions that improve patient outcomes while contributing to a more environmentally responsible future.</span></span></p> <ul> <li>Biodegradable materials reduce the need for invasive follow-up surgeries.</li> <li>Customizable degradation rates tailored to specific medical applications.</li> <li>Environmentally friendly, addressing growing concerns about medical waste.</li> </ul> <ul> <li>Implantable devices such as stents and orthopedic implants.</li> <li>Drug delivery systems that dissolve after releasing medication.</li> <li>Wound care products that promote healing while degrading safely in the body.</li> </ul> 2025-09-22 2025-09-22 2026-01-02 2025-09-22 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 164223794 Sadtler, Kaitlyn NIBIB Sadtler, Kaitlyn (NIBIB) 1 164223789 Lokwani, Ravi NIBIB NIBIB Lokwani, Ravi (NIBIB) 2 164223794 Sadtler, Kaitlyn NIBIB Sadtler, Kaitlyn (NIBIB) 1 164223789 Lokwani, Ravi NIBIB NIBIB Lokwani, Ravi (NIBIB) 2 164223745 Modulation Of Antigen Presentation In Immune Responses To Medical Devices And Regenerative Therapeutics E-139-2022-2 Filing authorized NIBIB, NIH - NIBIB 83656052 Knezevic, Vladimir vlado.knezevic@nih.gov
United States of America Technology Advancement Office vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-5079] Advanced Biodegradable Polymers for Medical Devices&body=Please send me information about technology [TAB-5079] Advanced Biodegradable Polymers for Medical Devices. Knezevic, Vladimir<br><a href="mailto:vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-5079] Advanced Biodegradable Polymers for Medical Devices&body=Please send me information about technology [TAB-5079] Advanced Biodegradable Polymers for Medical Devices.">vlado.knezevic@nih.gov</a><br> 164223753 E-139-2022-2 E-139-2022-2-US-01 METHODS AND COMPOSITIONS FOR IMPROVING WOUND HEALING National Stage US 18/992,393 Pending US <br />National Stage 18/992,393<br />Filed on 2025-01-08<br />Status: Pending 164223754 E-139-2022-2 E-139-2022-2-EP-01 METHODS AND COMPOSITIONS FOR IMPROVING WOUND HEALING National Stage European Patent 23750873.4 Pending European Patent <br />National Stage 23750873.4<br />Filed on 2025-01-08<br />Status: Pending TAB-4579 151757285 Evans Blue Modified Small Molecule-based Prostate-specific Membrane Antigen (PSMA) Radiotherapy and Nuclear Imaging NIBIB Antibodies, Licensing, Oncology, Therapeutics Antibodies Licensing Oncology Therapeutics Xiaoyuan (Shawn) Chen, Orit Jacobson weiss <p>This technology includes anti-PSMA antibody labeled with 177Lu, which has shown to be an effective treatment for prostate cancer. Several small molecules targeting PSMA were also evaluated in prostate cancer patients labeled with betta emitters such as 177Lu. The most common one is 177Lu-PSMA-617 which is under clinical evaluation in many countries. Usual treatment in patients in most clinical trials was composed of up to 3 cycles of 177Lu-PSMA-617. The limited data available suggest partial response rates of up to 70%&ndash;80% that was limited to as few as several weeks in some of the patients. Encouragingly, only stage 1 -2 hematologic toxicities and sporadically mild xerostomia and fatigue were reported as side effects.</p> Our modification of small molecule-based radiotherapy attaches an albumin binding domain based on the structure of Evans blue that results in significantly increased blood half-life, increased tumor uptake, and more effective anti-tumor radiotherapy. This may improve therapy of patients with PSMA-positive tumors and the general design may be applicable to other therapeutic small molecules. This product will be of use in nuclear imaging and radiotherapy of PSMA-positive tumors, and the EB derivative can be used for increasing the blood half-life of small molecules targeting PSMA. We are seeking statements of capability or interest from parties interested in collaborative research to further developr, evaluate, or commercialize this technology. 2023-12-12 2025-08-13 2026-01-02 2024-03-27 False True True 72159138 Clinical Phase I 72159138 37470483 Website Abstract 151757299 Chen, Xiaoyuan (Shawn) NIBIB NIBIB Chen, Xiaoyuan (Shawn) (NIBIB) 1 151757313 Jacobson weiss, Orit NIBIB NCI Jacobson weiss, Orit (NCI) 2 151757299 Chen, Xiaoyuan (Shawn) NIBIB NIBIB Chen, Xiaoyuan (Shawn) (NIBIB) 1 151757313 Jacobson weiss, Orit NIBIB NCI Jacobson weiss, Orit (NCI) 2 151757288 Evans Blue Modified Small Molecule Based Prostate-specific Membrane Antigen (PSMA) Radiotherapy E-054-2018-0 Filing authorized NIBIB 83709191 Carranza, Mario carranzam@mail.nih.gov
United States of America Office of Technology Transfer and Development carranzam@mail.nih.gov?subject=Web Inquiry on [TAB-4579] Evans Blue Modified Small Molecule-based Prostate-specific Membrane Antigen (PSMA) Radiotherapy and Nuclear Imaging&body=Please send me information about technology [TAB-4579] Evans Blue Modified Small Molecule-based Prostate-specific Membrane Antigen (PSMA) Radiotherapy and Nuclear Imaging. Carranza, Mario<br><a href="mailto:carranzam@mail.nih.gov?subject=Web Inquiry on [TAB-4579] Evans Blue Modified Small Molecule-based Prostate-specific Membrane Antigen (PSMA) Radiotherapy and Nuclear Imaging&body=Please send me information about technology [TAB-4579] Evans Blue Modified Small Molecule-based Prostate-specific Membrane Antigen (PSMA) Radiotherapy and Nuclear Imaging.">carranzam@mail.nih.gov</a><br> 157762470 E-054-2018-0 E-054-2018-0-CN-03 CHEMICAL CONJUGATES OF EVANS BLUE DERIVATIVES AND THEIR USE AS RADIOTHERAPY AND IMAGING AGENTS FOR TARGETING PROSTATE CANCER National Stage China ZL201980014834.9 201980014834.9 Issued China <br />National Stage 201980014834.9<br />Filed on 2019-02-22<br />Status: Issued 157762475 E-054-2018-0 E-054-2018-0-EP-04 CHEMICAL CONJUGATES OF EVANS BLUE DERIVATIVES AND THEIR USE AS RADIOTHERAPY AND IMAGING AGENTS FOR TARGETING PROSTATE CANCER National Stage European Patent 3755321 19756548.4 Issued European Patent <br />National Stage 19756548.4<br />Filed on 2019-02-22<br />Status: Issued 157762480 E-054-2018-0 E-054-2018-0-IL-05 CHEMICAL CONJUGATES OF EVANS BLUE DERIVATIVES AND THEIR USE AS RADIOTHERAPY AND IMAGING AGENTS FOR TARGETING PROSTATE CANCER National Stage Israel 276653 276653 Issued Israel <br />National Stage 276653<br />Filed on 2020-08-11<br />Status: Issued 157762485 E-054-2018-0 E-054-2018-0-US-06 CHEMICAL CONJUGATES OF EVANS BLUE DERIVATIVES AND THEIR USE AS RADIOTHERAPY AND IMAGING AGENTS FOR TARGETING National Stage US 12,161,733 16/969,673 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12161733 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12161733">12,161,733</a><br />Filed on 2020-08-13<br />Status: Issued 157762495 E-054-2018-0 E-054-2018-0-AU-08 CHEMICAL CONJUGATES OF EVANS BLUE DERIVATIVES AND THEIR USE AS RADIOTHERAPY AND IMAGING AGENTS FOR TARGETING PROSTATE CANCER National Stage Australia 2019225154 2019225154 Issued Australia <br />National Stage 2019225154<br />Filed on 2019-02-22<br />Status: Issued 157762500 E-054-2018-0 E-054-2018-0-CA-09 CHEMICAL CONJUGATES OF EVANS BLUE DERIVATIVES AND THEIR USE AS RADIOTHERAPY AND IMAGING AGENTS FOR TARGETING PROSTATE CANCER National Stage Canada 3090812 Pending Canada <br />National Stage 3090812<br />Filed on 2019-02-22<br />Status: Pending 157762505 E-054-2018-0 E-054-2018-0-JP-10 CHEMICAL CONJUGATES OF EVANS BLUE DERIVATIVES AND THEIR USE AS RADIOTHERAPY AND IMAGING AGENTS FOR TARGETING PROSTATE CANCER National Stage Japan 7449864 2020-543529 Issued Japan <br />National Stage 2020-543529<br />Filed on 2019-02-22<br />Status: Issued 157762510 E-054-2018-0 E-054-2018-0-KR-11 CHEMICAL CONJUGATES OF EVANS BLUE DERIVATIVES AND THEIR USE AS RADIOTHERAPY AND IMAGING AGENTS FOR TARGETING PROSTATE CANCER National Stage South Korea 10-2902487 10-2020-7027109 Issued South Korea <br />National Stage 10-2020-7027109<br />Filed on 2020-09-18<br />Status: Issued 157762515 E-054-2018-0 E-054-2018-0-HK-12 CHEMICAL CONJUGATES OF EVANS BLUE DERIVATIVES AND THEIR USE AS RADIOTHERAPY AND IMAGING AGENTS FOR TARGETING PROSTATE CANCER CN Hong Kong HK40029571B 62020019110.9 Issued Hong Kong <br />China Patent (CN) 62020019110.9<br />Filed on 2019-02-22<br />Status: Issued 157762520 E-054-2018-0 E-054-2018-0-CN-01 CHEMICAL CONJUGATES OF EVANS BLUE DERIVATIVES AND THEIR USE AS RADIOTHERAPY AND IMAGING AGENTS FOR TARGETING PROSTATE CANCER DIV China 202410872371.2 Pending China <br />Divisional (DIV) 202410872371.2<br />Filed on 2024-07-01<br />Status: Pending 157762525 E-054-2018-0 E-054-2018-0-MO-01 CHEMICAL CONJUGATES OF EVANS BLUE DERIVATIVES AND THEIR USE AS RADIOTHERAPY AND IMAGING AGENTS FOR TARGETING PROSTATE CANCER CN Macao J/008699 J/008699 Issued Macao <br />China Patent (CN) J/008699<br />Filed on 2024-09-27<br />Status: Issued TAB-4581 151758960 Fluorescence Scanning System for Improvement of Analytical Ultracentrifugation NIBIB Licensing, Medical Devices, Research Equipment Licensing Medical Devices Research Equipment John Kakareka, George Patterson, Thomas Pohida, Peter Schuck, Huaying Zhao <p>This technology includes improvements in the fluorescence scanner to increase efficiency. This method works by eliminating the need to radially slide the optical assembly during scanning, instead using a galvanometric mirror deflecting a laser beam to different positions in the sample. This allows the scanner to be incorporated into existing commercial analytical ultracentrifugation (AUC) systems with minimal modifications. A further improvement designed to increase detection efficiency is the use of plano-convex windows replacing planar windows in the sample cell assembly, which can help focus excitation and emitted fluorescence. Ensuing spatial inhomogeneities of beam angles and excitation intensities and detection efficiencies are accounted for in the mathematical analysis.</p> Invention improves detection limits for fluorescence. The fluorescence detectors could be manufactured to retrofit existing preparative ultracentrifuges or AUC instruments as well as be incorporated into the design of new instruments. We are seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. 2023-12-12 2026-01-02 2026-01-02 2024-03-27 False True True 52406769 Prototype 52406769 37470483 Website Abstract 151759125 Schuck, Peter NIBIB NIBIB Schuck, Peter (NIBIB) 1 151759288 Pohida, Thomas Center for Information Technology (CIT) CIT Pohida, Thomas (CIT) 2 151759355 Patterson, George NIBIB NIBIB Patterson, George (NIBIB) 3 151759403 Zhao, Huaying NIBIB NIBIB Zhao, Huaying (NIBIB) 4 151759420 Kakareka, John NIBIB NIBIB Kakareka, John (NIBIB) 5 151759125 Schuck, Peter NIBIB NIBIB Schuck, Peter (NIBIB) 1 151759288 Pohida, Thomas Center for Information Technology (CIT) CIT Pohida, Thomas (CIT) 2 151759355 Patterson, George NIBIB NIBIB Patterson, George (NIBIB) 3 151759403 Zhao, Huaying NIBIB NIBIB Zhao, Huaying (NIBIB) 4 151759420 Kakareka, John NIBIB NIBIB Kakareka, John (NIBIB) 5 151758963 Fluorescence Scanning System For Analytical Ultracentrifugation E-076-2020-0 Filing authorized CIT, NIBIB 83656052 Knezevic, Vladimir vlado.knezevic@nih.gov
United States of America Technology Advancement Office vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-4581] Fluorescence Scanning System for Improvement of Analytical Ultracentrifugation&body=Please send me information about technology [TAB-4581] Fluorescence Scanning System for Improvement of Analytical Ultracentrifugation. Knezevic, Vladimir<br><a href="mailto:vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-4581] Fluorescence Scanning System for Improvement of Analytical Ultracentrifugation&body=Please send me information about technology [TAB-4581] Fluorescence Scanning System for Improvement of Analytical Ultracentrifugation.">vlado.knezevic@nih.gov</a><br> TAB-5063 163191393 Vascularized Thyroid-on-a-Chip for Personalized Drug Screening and Disease Modeling NIBIB Collaboration, Diagnostics, Endocrinology, Human Cell Lines, Immunology, Licensing, Medical Devices, Metabolic Disease, Oncology, Research Equipment, Research Materials, Therapeutics Collaboration Diagnostics Endocrinology Human Cell Lines Immunology Licensing Medical Devices Metabolic Disease Oncology Research Equipment Research Materials Therapeutics Madison Daminato, Parinaz Fathi, Parnika Kant, Nicole Morgan, Anagha Rama Varma, Paniz Rezvan Sangsari, Kaitlyn Sadtler <p><span style="font-size:11pt"><span style="line-height:107%"><span style="font-family:Calibri,sans-serif">This technology includes a micro-engineered &ldquo;thyroid-on-a-chip&rdquo; that combines human thyroid organoids with integrated micro-vasculature to replicate the gland&rsquo;s native blood flow and 3-D architecture, enabling rapid, patient-specific drug screening. By permitting real-time perfusion of nutrients, hormones, and immune cells, the platform yields more physiologically relevant data than conventional static cultures or animal surrogates. Its modular design accommodates cells from individual patients, helping clinicians predict therapeutic response and tailor treatment for thyroid cancers and autoimmune disorders. In pharmaceutical R&amp;D, the chip shortens pre-clinical timelines by providing actionable efficacy and toxicity read-outs within days. Overall, the system offers a high-fidelity bridge between benchtop discovery and clinical decision-making, addressing an unmet need for robust human thyroid models.</span></span></span></p> <ul> <li>First thyroid model to incorporate functional micro-vasculature, closely mirroring in-vivo hemodynamics and hormone exchange.</li> <li>Allows insertion of primary patient cells, enabling personalized therapy selection and reducing costly late-stage clinical failures.</li> <li>Generates predictive efficacy and safety data in days, cutting pre-clinical study time and animal use.</li> </ul> <ul> <li>Patient-specific screening of small-molecule, biologic, or radiotherapeutic candidates for thyroid cancer and autoimmune thyroiditis.</li> <li>Investigating thyroid-immune interactions to identify new immunomodulatory drug targets.</li> <li>High-throughput endocrine toxicity testing for pipeline compounds and environmental chemicals.</li> </ul> 2025-07-03 2026-01-02 2026-01-02 2025-07-03 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 163191536 Rama Varma, Anagha NIH - NIBIB NIBIB Rama Varma, Anagha (NIBIB) 1 163191540 Kant, Parnika NIH - NIBIB NIBIB Kant, Parnika (NIBIB) 2 163191551 Sadtler, Kaitlyn NIH - NIBIB NIBIB Sadtler, Kaitlyn (NIBIB) 3 163191563 Fathi, Parinaz NIBIB Fathi, Parinaz 4 163191572 Morgan, Nicole NIH - NIBIB NIBIB Morgan, Nicole (NIBIB) 5 163191576 Rezvan Sangsari, Paniz NIH - NIBIB NIBIB Rezvan Sangsari, Paniz (NIBIB) 6 163191583 Daminato, Madison NIH - NIBIB NIBIB Daminato, Madison (NIBIB) 7 163191536 Rama Varma, Anagha NIH - NIBIB NIBIB Rama Varma, Anagha (NIBIB) 1 163191540 Kant, Parnika NIH - NIBIB NIBIB Kant, Parnika (NIBIB) 2 163191551 Sadtler, Kaitlyn NIH - NIBIB NIBIB Sadtler, Kaitlyn (NIBIB) 3 163191563 Fathi, Parinaz NIBIB Fathi, Parinaz 4 163191572 Morgan, Nicole NIH - NIBIB NIBIB Morgan, Nicole (NIBIB) 5 163191576 Rezvan Sangsari, Paniz NIH - NIBIB NIBIB Rezvan Sangsari, Paniz (NIBIB) 6 163191583 Daminato, Madison NIH - NIBIB NIBIB Daminato, Madison (NIBIB) 7 163191396 Vascularized Thyroid on-a-chip E-076-2025-0 Filing authorized NIBIB, NIH - NIBIB 83656052 Knezevic, Vladimir vlado.knezevic@nih.gov
United States of America Technology Advancement Office vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-5063] Vascularized Thyroid-on-a-Chip for Personalized Drug Screening and Disease Modeling&body=Please send me information about technology [TAB-5063] Vascularized Thyroid-on-a-Chip for Personalized Drug Screening and Disease Modeling. Knezevic, Vladimir<br><a href="mailto:vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-5063] Vascularized Thyroid-on-a-Chip for Personalized Drug Screening and Disease Modeling&body=Please send me information about technology [TAB-5063] Vascularized Thyroid-on-a-Chip for Personalized Drug Screening and Disease Modeling.">vlado.knezevic@nih.gov</a><br> 163191402 E-076-2025-0 E-076-2025-0-US-01 VASCULARIZED THYROID-ON-A-CHIP PRV US 63/802,302 Expired US <br />Provisional (PRV) 63/802,302<br />Filed on 2025-05-08<br />Status: Expired 163191403 E-076-2025-0 E-076-2025-0-US-02 VASCULARIZED THYROID-ON-A-CHIP ORD US 19/247,851 Pending US <br />Ordinary Patent (ORD) 19/247,851<br />Filed on 2025-06-24<br />Status: Pending TAB-4085 147157367 Bioluminescent Bladder Cancer Cell Line for Tracking Cancer Progression NCI Licensing, Oncology, Research Materials Licensing Oncology Research Materials John Greiner, Jeffrey Schlom <p>Bladder cancer is the fifth most common cancer in the United States and one of the costliest cancers to treat. Compared to other cancer types, bladder cancer has been understudied, and there is a need for informative mouse bladder cancer models that resemble the clinical situation and allow for evaluation of chemotherapeutic or immunotherapeutic agents. The orthotopic murine bladder cancer model MB49 resembles non-muscle invasive, nonmetastatic urothelial carcinomas and provides an opportunity to study the anti-tumor effects of immune cell checkpoint inhibitors. Moreover, successful tumor cell implantation of MB49 cells fails in ~25% of the animals due to low tumor- take rates. Thus, there is also a need for methods that assess tumor- take rates in orthotopic bladder tumor models.    </p> <p>Researchers at the National Cancer Institute (NCI) have developed a MB49-luciferase cell line that allows for intravital imaging to evaluate anti-cancer agents in bladder cancer. Furthermore, the MB49-luciferase cell line is helpful in assessing the tumor- take to select mice for treatments groups based on equivalent tumor burden. The inventors have demonstrated in vivo that MB49-luciferase bladder tumors are highly positive for the expression of programmed death-ligand 1 (PD-L1). </p> <p>The <a href="https://ccr.cancer.gov/Laboratory-of-Tumor-Immunology-and-Biology" rel="nofollow">National Cancer Institute, Laboratory of Tumor Immunology and Biology</a>, is seeking <br /> statements of capability or interest from parties interested in licensing this research material to evaluate anti-cancer agents in bladder cancer. </p> <h2>Competitive Advantages:</h2> <ul><li>Bioluminescence allows for assessment of tumor progression after treatment with anti-cancer agents </li> <li>Intravital imaging is helpful in assessing early tumor-take and the amount of radiance can be used to select mice accurately for treatment groups based on equivalent tumor burden</li> <li>Intravital imaging also allows for temporal assessment of tumor growth in real time</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Use in preclinical studies to evaluate anti-cancer agents in bladder cancer</li> </ul> 2018-11-08 2025-04-22 2018-11-08 2025-12-30 2018-11-08 Bioluminescence, Bladder cancer, LUCIFERASE, MB49, Schlom False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2018-11-08 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-132-2011 147162322 Vandeveer A, et al. Systemic immunotherapy of non-muscle invasive mouse bladder cancer with avelumab, an anti-PD-L1 immune checkpoint inhibitor https://www.ncbi.nlm.nih.gov/pubmed/26921031 <a href="https://www.ncbi.nlm.nih.gov/pubmed/26921031">Vandeveer A, et al. Systemic immunotherapy of non-muscle invasive mouse bladder cancer with avelumab, an anti-PD-L1 immune checkpoint inhibitor</a> 147163463 Schlom, Jeffrey NIH - NCI NCI Schlom, Jeffrey (NCI) 1 147163464 Greiner, John NIH - NCI NCI Greiner, John (NCI) 2 147163463 Schlom, Jeffrey NIH - NCI NCI Schlom, Jeffrey (NCI) 1 147163464 Greiner, John NIH - NCI NCI Greiner, John (NCI) 2 147158253 MB49-luciferase Cell Line E-237-2018-0 Research Material NCI 83687903 Pollack, Michael michael.pollack@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC michael.pollack@nih.gov?subject=Web Inquiry on [TAB-4085] Bioluminescent Bladder Cancer Cell Line for Tracking Cancer Progression&body=Please send me information about technology [TAB-4085] Bioluminescent Bladder Cancer Cell Line for Tracking Cancer Progression.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollack, Michael<br><a href="mailto:michael.pollack@nih.gov?subject=Web Inquiry on [TAB-4085] Bioluminescent Bladder Cancer Cell Line for Tracking Cancer Progression&body=Please send me information about technology [TAB-4085] Bioluminescent Bladder Cancer Cell Line for Tracking Cancer Progression.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">michael.pollack@nih.gov</a><br> 147174072 Bioluminescence 147174073 Bladder cancer 147174074 LUCIFERASE 147174076 MB49 147174077 Schlom TAB-4180 147157465 Brachyury-directed Vaccine for the Prevention or Treatment of Cancers NCI Collaboration, Immunology, Licensing, Oncology, Vaccines Collaboration Immunology Licensing Oncology Vaccines Claudia Palena, Jeffrey Schlom <p>Tumor invasion and metastasis are the primary drivers of cancer-related mortality. Therapies that have an ability to specifically target invasive and/or metastatic cells are anticipated to have a significant impact in the clinical management of advanced cancers.</p> <p>Researchers at the NCI have developed a vaccine technology that stimulates the immune system to selectively destroy metastasizing cells. Brachyury, a master transcription factor that governs the epithelial-mesenchymal transition, was shown to be significantly overexpressed in primary and metastasizing tumors relative to normal human tissues. Stimulation of T cells with the Brachyury peptide promoted a robust immune response and the targeted lysis of invasive tumor cells. Brachyury overexpression has been demonstrated in a range of human tumors (breast, lung, colon and prostate, among others) suggesting that a therapeutic vaccine derived from this technology would be broadly applicable for the treatment of cancer.</p> <h2>Competitive Advantages:</h2> <ul><li>Treatment targets invasive and metastatic tumor cells which are the primary cause of cancer-related mortality.</li> <li>Vaccine can eliminate cancer stem cells which are resistant to conventional therapies</li> <li>Compatible with the clinically-proven TRICOM cancer vaccine platform</li> <li>Available (Optimized) for use with non-pox, non-yeast vectors including: adenovirus, lentivirus, etc., and for use with protein- or peptide-based vaccines</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Preventative cancer vaccine for patients with precancerous lesions of the breast, colon or prostate.</li> <li>Therapeutic cancer vaccine for the treatment of disseminated and late-stage tumors.</li> <li>Vaccine component of a multi-modal cancer therapy</li> </ul> 2017-10-06 2025-04-22 2018-03-20 2025-12-30 2017-10-06 Brachyury, CANCER VACCINE, Immunotherapy, T-CELLS, Transcription factor False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2018-03-20 72159138 Clinical Phase I 72159138 NCI 37470483 Website Abstract 147162222 R.I. Fernando et al. https://www.ncbi.nlm.nih.gov/pubmed/20071775 <a href="https://www.ncbi.nlm.nih.gov/pubmed/20071775">R.I. Fernando et al.</a> 147162375 C. Palena et al. https://www.ncbi.nlm.nih.gov/pubmed/17438107 <a href="https://www.ncbi.nlm.nih.gov/pubmed/17438107">C. Palena et al.</a> 147163797 Schlom, Jeffrey NIH - NCI NCI Schlom, Jeffrey (NCI) 1 147163798 Palena, Claudia NIH - NCI NCI Palena, Claudia (NCI) 2 147163797 Schlom, Jeffrey NIH - NCI NCI Schlom, Jeffrey (NCI) 1 147163798 Palena, Claudia NIH - NCI NCI Palena, Claudia (NCI) 2 147157880 The Development And Use Of Vaccines (Non-Yeast, Non-Poxvirus Based) For The Prevention And/or Therapy Of Human Cancer E-055-2011-0 Filing authorized NCI 83687903 Pollack, Michael michael.pollack@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC michael.pollack@nih.gov?subject=Web Inquiry on [TAB-4180] Brachyury-directed Vaccine for the Prevention or Treatment of Cancers&body=Please send me information about technology [TAB-4180] Brachyury-directed Vaccine for the Prevention or Treatment of Cancers.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollack, Michael<br><a href="mailto:michael.pollack@nih.gov?subject=Web Inquiry on [TAB-4180] Brachyury-directed Vaccine for the Prevention or Treatment of Cancers&body=Please send me information about technology [TAB-4180] Brachyury-directed Vaccine for the Prevention or Treatment of Cancers.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">michael.pollack@nih.gov</a><br> 147167163 E-055-2011-0 E-055-2011-0-US-05 BRACHYURY PROTEIN, NON-POXVIRUS NON-YEAST VECTORS ENCODING BRACHYURY PROTEIN, AND THEIR USE DIV US 11,357,839 16/107,559 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11357839 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11357839">11,357,839</a><br />Filed on 2018-08-21<br />Status: Issued 147167171 E-055-2011-0 E-055-2011-0-US-13 BRACHYURY PROTEIN, NON-POXVIRUS NON-YEAST VECTORS ENCODING BRACHYURY PROTEIN, AND THEIR USE DIV US 17/833,383 Pending US <br />Divisional (DIV) 17/833,383<br />Filed on 2022-06-06<br />Status: Pending 147170396 Brachyury 147170397 CANCER VACCINE 147170398 Immunotherapy 147170399 T-CELLS 147170400 Transcription factor TAB-4384 147157678 Agonist Epitopes for the Development of a Human Papillomavirus (HPV) Therapeutic Vaccine NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Jeffrey Schlom, Kwong-Yok Tsang <p>Human papillomavirus (HPV) has been associated with the cause of several cancer types, including cervical, anal, and head and neck cancers. There has been great success in preventing HPV infections with the development of prophylactic HPV vaccines, Gardasil and Cervarix. However, these vaccines have only been shown to prevent HPV infection and not treat those already infected with HPV. These vaccines elicit antibody responses to late HPV genes, and thus would not be effective in treating established tumors. To date, no therapeutic HPV vaccine has been approved by the FDA, and there is an unmet need for therapeutic vaccines for the treatment of cervical, anal, and head and neck cancers. </p> <p>One approach in the development of HPV therapeutic vaccines is the use of agonist epitopes that would elicit enhanced cytotoxic T-lymphocyte (CTL) responses capable of lysing human tumor cells expressing native HPV epitopes. Researchers at the National Cancer Institute (NCI) have identified three agonist epitopes that target early HPV genes responsible for maintaining the malignant phenotype. Moreover, these agonist epitopes generate CTLs capable of lysing carcinoma cells expressing the native HPV epitope. </p> <p>The NCI, Center for Cancer Research, is seeking statements of capability or interest from parties interested in licensing and/or collaborative research to further develop, evaluate, or commercialize the HPV agonist epitopes for the development of a therapeutic vaccine.</p> <h2>Competitive Advantages:</h2> <ul><li>Gardasil and Cervarix are prophylactic HPV vaccines and are not used to treat HPV-infected individuals. This technology could be used to develop the first therapeutic vaccine for HPV </li> <li>HPV agonist epitopes target early HPV genes that are responsible for maintenance of the malignant phenotype. Gardasil and Cervarix target late genes and would not be effective in treating established tumors</li> <li>HPV agonist epitopes activate HPV-specific CTLs that lyse tumor cells and control tumor growth/rejection </li> </ul> <h2>Commercial Applications:</h2> <ul><li>Development of HPV therapeutic vaccines for the treatment of cervical, anal, and head and neck cancers </li> <li>For cancer immunotherapy targeting HPV-mediated cancers or use as a combination therapy with immune checkpoint inhibitors, other immune modulators and/or chemotherapy, radiation therapy, and other modes of therapy such as the use of small molecule-targeted therapeutics</li> </ul> 2018-10-12 2025-04-22 2018-10-12 2025-12-30 2018-10-12 Agonist Epitope, CTL, Cytotoxic T Lymphocytes, HPV, Human Papillomavirus, Schlom, Therapeutic Vaccine False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2018-10-12 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-001-2012 147161888 Tsang KY, et al. Identification and characterization of enhancer agonist human cytotoxic T-cell epitopes of the human papillomavirus type 16 (HPV16) E6/E7. https://www.ncbi.nlm.nih.gov/pubmed/28389098 <a href="https://www.ncbi.nlm.nih.gov/pubmed/28389098">Tsang KY, et al. Identification and characterization of enhancer agonist human cytotoxic T-cell epitopes of the human papillomavirus type 16 (HPV16) E6/E7.</a> 147164531 Schlom, Jeffrey NIH - NCI NCI Schlom, Jeffrey (NCI) 1 147164532 Tsang, Kwong-Yok NIH - NCI NCI Tsang, Kwong-Yok (NCI) 2 147164531 Schlom, Jeffrey NIH - NCI NCI Schlom, Jeffrey (NCI) 1 147164532 Tsang, Kwong-Yok NIH - NCI NCI Tsang, Kwong-Yok (NCI) 2 147158130 Development Of Agonist Epitopes Of The Human Papillomavirus ( HPV) E-169-2016-0 Filing authorized NCI 83687903 Pollack, Michael michael.pollack@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC michael.pollack@nih.gov?subject=Web Inquiry on [TAB-4384] Agonist Epitopes for the Development of a Human Papillomavirus (HPV) Therapeutic Vaccine&body=Please send me information about technology [TAB-4384] Agonist Epitopes for the Development of a Human Papillomavirus (HPV) Therapeutic Vaccine.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollack, Michael<br><a href="mailto:michael.pollack@nih.gov?subject=Web Inquiry on [TAB-4384] Agonist Epitopes for the Development of a Human Papillomavirus (HPV) Therapeutic Vaccine&body=Please send me information about technology [TAB-4384] Agonist Epitopes for the Development of a Human Papillomavirus (HPV) Therapeutic Vaccine.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">michael.pollack@nih.gov</a><br> 147161139 E-169-2016-0 E-169-2016-0-US-01 Development Of Agonist Epitopes Of The Human Papillomavirus PRV US 62/497,064 Abandoned US <br />Provisional (PRV) 62/497,064<br />Filed on 2016-11-07<br />Status: Abandoned 147168558 E-169-2016-0 E-169-2016-0-PCT-02 DEVELOPMENT OF AGONIST EPITOPES OF THE HUMAN PAPILLOMAVIRUS PCT Patent Cooperation Treaty PCT/US2017/060109 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2017/060109<br />Filed on 2017-11-06<br />Status: Expired 147168559 E-169-2016-0 E-169-2016-0-AU-03 DEVELOPMENT OF AGONIST EPITOPES OF THE HUMAN PAPILLOMAVIRUS National Stage Australia 2017355564 2017355564 Issued Australia <br />National Stage 2017355564<br />Filed on 2019-05-06<br />Status: Issued 147168560 E-169-2016-0 E-169-2016-0-CA-04 DEVELOPMENT OF AGONIST EPITOPES OF THE HUMAN PAPILLOMAVIRUS National Stage Canada 3042703 3042703 Issued Canada <br />National Stage 3042703<br />Filed on 2017-11-06<br />Status: Issued 147168561 E-169-2016-0 E-169-2016-0-EP-05 DEVELOPMENT OF AGONIST EPITOPES OF THE HUMAN PAPILLOMAVIRUS National Stage European Patent 3535284 17 808 241.8 Issued European Patent <br />National Stage 17 808 241.8<br />Filed on 2019-06-07<br />Status: Issued 147168562 E-169-2016-0 E-169-2016-0-US-06 DEVELOPMENT OF AGONIST EPITOPES OF THE HUMAN PAPILLOMAVIRUS National Stage US 11,311,613 16/347,764 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11311613 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11311613">11,311,613</a><br />Filed on 2019-05-06<br />Status: Issued 147168563 E-169-2016-0 E-169-2016-0-CH-07 DEVELOPMENT OF AGONIST EPITOPES OF THE HUMAN PAPILLOMAVIRUS EP Switzerland 3535284 17 808 241.8 Issued Switzerland <br />European patent (EP) 17 808 241.8<br />Filed on 2019-06-07<br />Status: Issued 147168564 E-169-2016-0 E-169-2016-0-DE-08 DEVELOPMENT OF AGONIST EPITOPES OF THE HUMAN PAPILLOMAVIRUS EP Germany 3535284 17 808 241.8 Issued Germany <br />European patent (EP) 17 808 241.8<br />Filed on 2019-06-07<br />Status: Issued 147168565 E-169-2016-0 E-169-2016-0-ES-09 DEVELOPMENT OF AGONIST EPITOPES OF THE HUMAN PAPILLOMAVIRUS EP Spain 3535284 17 808 241.8 Issued Spain <br />European patent (EP) 17 808 241.8<br />Filed on 2019-06-07<br />Status: Issued 147168566 E-169-2016-0 E-169-2016-0-FR-10 DEVELOPMENT OF AGONIST EPITOPES OF THE HUMAN PAPILLOMAVIRUS EP France 3535284 17 808 241.8 Issued France <br />European patent (EP) 17 808 241.8<br />Filed on 2019-06-07<br />Status: Issued 147168567 E-169-2016-0 E-169-2016-0-GB-11 DEVELOPMENT OF AGONIST EPITOPES OF THE HUMAN PAPILLOMAVIRUS EP United Kingdom 3535284 17 808 241.8 Issued United Kingdom <br />European patent (EP) 17 808 241.8<br />Filed on 2019-06-07<br />Status: Issued 147168568 E-169-2016-0 E-169-2016-0-IE-12 DEVELOPMENT OF AGONIST EPITOPES OF THE HUMAN PAPILLOMAVIRUS EP Ireland 3535284 17 808 241.8 Issued Ireland <br />European patent (EP) 17 808 241.8<br />Filed on 2019-06-07<br />Status: Issued 147168569 E-169-2016-0 E-169-2016-0-IT-13 DEVELOPMENT OF AGONIST EPITOPES OF THE HUMAN PAPILLOMAVIRUS EP Italy 3535284 17 808 241.8 Issued Italy <br />European patent (EP) 17 808 241.8<br />Filed on 2019-06-07<br />Status: Issued 147168570 E-169-2016-0 E-169-2016-0-NL-14 DEVELOPMENT OF AGONIST EPITOPES OF THE HUMAN PAPILLOMAVIRUS EP The Netherlands 3535284 17 808 241.8 Issued The Netherlands <br />European patent (EP) 17 808 241.8<br />Filed on 2019-06-07<br />Status: Issued 147172862 Agonist Epitope 147172863 CTL 147172865 Cytotoxic T Lymphocytes 147172866 HPV 147172868 Human Papillomavirus 147172869 Schlom 147172871 Therapeutic Vaccine TAB-4551 151737494 Treatment of Periodontal Disease via ENPPI Inhibition NIAMS Collaboration, Collaboration Sought, Dental, Therapeutics Collaboration Collaboration Sought Dental Therapeutics Demetrios Braddock, Emily Chu, Brian Foster, Francisco Nociti, Martha Somerman, Vivek Thumbigere-Math <p>This technology focuses on enhancing cementum production, a key component in treating periodontal regression. The method involves inhibiting ectonucleotide pyrophosphatase phosphodiesterases (ENPP1), enzymes that play a significant role in mineralization processes. Pyrophosphate (PPi) is known to impede the growth of hydroxyapatite crystals, essential for mineralization. ENPP1 catalyzes the hydrolysis of ATP, generating PPi, which then hinders mineralization. Research indicates that the balance between inorganic phosphate (Pi) and PPi (Pi/PPi ratio) significantly influences cementum formation, a crucial tissue for dental health. Notably, cementum production can be considerably enhanced, by over ten times, when PPi levels are reduced. This has been observed in both murine models and humans with impaired ENPP1 function. Since ENPP1 is the primary extracellular source of PPi, its inhibition creates a favorable environment for increased cementum production, offering a promising avenue for treating periodontal diseases.</p> Current therapies for treating periodontal disease, such as dental hygiene, antibiotics, and teeth replacement via surgery, do not have predictable outcomes and do not demonstrate reliable cementum regeneration. Use for periodontal regeneration and beyond for other disorders, conditions, trauma related to mineralized tissues. We are seeking statements of capability or interest from parties interested in collaborative research to further developer, evaluate, or commercialize this technology. Technology is also available for non-exclusive or exclusive licensing 2023-12-11 2024-12-31 2025-12-30 2024-03-20 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 151737504 Braddock, Demetrios Yale University Braddock, Demetrios 1 151737508 Somerman, Martha NIDCR NIDCR Somerman, Martha (NIDCR) 2 151737524 Chu, Emily NIAMS Chu, Emily 3 151737536 Thumbigere-Math, Vivek University of Maryland, Baltimore NIAMS Thumbigere-Math, Vivek (NIAMS) 4 151737540 Foster, Brian NIAMS Foster, Brian 5 151737545 Nociti, Francisco State University of Campinas Nociti, Francisco 6 151737504 Braddock, Demetrios Yale University Braddock, Demetrios 1 151737508 Somerman, Martha NIDCR NIDCR Somerman, Martha (NIDCR) 2 151737524 Chu, Emily NIAMS Chu, Emily 3 151737536 Thumbigere-Math, Vivek University of Maryland, Baltimore NIAMS Thumbigere-Math, Vivek (NIAMS) 4 151737540 Foster, Brian NIAMS Foster, Brian 5 151737545 Nociti, Francisco State University of Campinas Nociti, Francisco 6 151737497 Method Of Treating Periodontal Disease Via ENPPl Inhibition E-024-2018-0 Filing authorized NIAMS, Yale University 83739611 Yonter, Ediz ediz.yonter@nih.gov
United States of America Technology Advancement Office ediz.yonter@nih.gov?subject=Web Inquiry on [TAB-4551] Treatment of Periodontal Disease via ENPPI Inhibition&body=Please send me information about technology [TAB-4551] Treatment of Periodontal Disease via ENPPI Inhibition. Yonter, Ediz<br><a href="mailto:ediz.yonter@nih.gov?subject=Web Inquiry on [TAB-4551] Treatment of Periodontal Disease via ENPPI Inhibition&body=Please send me information about technology [TAB-4551] Treatment of Periodontal Disease via ENPPI Inhibition.">ediz.yonter@nih.gov</a><br> 157760390 E-024-2018-0 E-024-2018-0-EP-04 COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING AND/OR PREVENTING PERIODONTAL DISEASE National Stage European Patent 18816451.1 Pending European Patent <br />National Stage 18816451.1<br />Filed on 2018-11-27<br />Status: Pending TAB-5075 163996507 Automated Cell Radiolabeling Device Using Acoustophoresis Micro-Fluidic Technology NCI Collaboration, Licensing, Medical Devices, Oncology, Research Materials Collaboration Licensing Medical Devices Oncology Research Materials Stephen Adler, Peter Choyke, Noriko Sato <h2>Summary:</h2> <p>The National Cancer Institute (NCI) sees research co-development partners and/or licensees for an automated acoustophoresis device to radio-label and isolate cells.</p> <h2>Description of Technology:</h2> <p>This technology includes an automated cell radiolabeling device that utilizes acoustophoresis microfluidic technology. The device streamlines the radiolabeling process by integrating cell washing and concentrating steps, which enhances reproducibility and standardization. This innovation simplifies the GMP (Good Manufacturing Practice) compliance for radiolabeling cells intended for human use. It also addresses the limitations of current manual methods that rely on centrifugation. The result is a benchtop system designed for clinical radio-pharmacies, ensuring efficient and reliable cell preparation for diagnostic and therapeutic applications.</p> <p><a href="https://cbiit.webex.com/recordingservice/sites/cbiit/recording/f287687265fd103cbf9de650e0bf904c/playback" target="_blank">Automated Acoustophoresis Device to Radio-Label &amp; Isolate Cells for Immunotherapy and Isolated Cells for Immunotherapy Treatment</a></p> <h2>Potential Commercial Applications:</h2> <ul> <li>Clinical radio-pharmacies for radiolabeled cell diagnostics</li> <li>Research institutions focused on cellular therapies and diagnostics</li> <li>Pharmaceutical companies developing radiolabeled therapeutics</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Fully automated process reduces manual intervention, increasing efficiency and consistency</li> <li>Micron-scale acoustophoresis technology enhances reproducibility and standardization of cell radiolabeling</li> <li>Streamlined GMP compliance simplifies regulatory processes for clinical applications</li> <li>Benchtop system</li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for an automated acoustophoresis device to radio-label and isolate cells. 2025-09-04 2025-12-15 2025-12-15 2025-12-08 False False True michael.salgaller@nih.gov, tdiaz@mail.nih.gov 52406769 Prototype 52406769 NCI 37470483 Website Abstract 165083181 Adler, S, et al. Using Acoustophoresis Cell Washing In The Immune Cell Radiolabeling Procedure. https://jnm.snmjournals.org/content/63/supplement_2/2755 <a href="https://jnm.snmjournals.org/content/63/supplement_2/2755">Adler, S, et al. Using Acoustophoresis Cell Washing In The Immune Cell Radiolabeling Procedure.</a> 163996723 Adler, Stephen NCI - FCRDC (Leidos) Leidos Adler, Stephen (Leidos) 1 163996730 Sato, Noriko National Cancer Institute (NCI) NCI Sato, Noriko (NCI) 2 163996736 Choyke, Peter National Cancer Institute (NCI) NCI Choyke, Peter (NCI) 3 163996723 Adler, Stephen NCI - FCRDC (Leidos) Leidos Adler, Stephen (Leidos) 1 163996730 Sato, Noriko National Cancer Institute (NCI) NCI Sato, Noriko (NCI) 2 163996736 Choyke, Peter National Cancer Institute (NCI) NCI Choyke, Peter (NCI) 3 163996510 Novel Device For Cell Radiolabeling Using Acoustophoresis Micro-fluidic Technology E-096-2021-0 Filing authorized NCI 83736770 Cheng, Eric eric.cheng2@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB eric.cheng2@nih.gov?subject=Web Inquiry on [TAB-5075] Automated Cell Radiolabeling Device Using Acoustophoresis Micro-Fluidic Technology&body=Please send me information about technology [TAB-5075] Automated Cell Radiolabeling Device Using Acoustophoresis Micro-Fluidic Technology.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Cheng, Eric<br><a href="mailto:eric.cheng2@nih.gov?subject=Web Inquiry on [TAB-5075] Automated Cell Radiolabeling Device Using Acoustophoresis Micro-Fluidic Technology&body=Please send me information about technology [TAB-5075] Automated Cell Radiolabeling Device Using Acoustophoresis Micro-Fluidic Technology.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">eric.cheng2@nih.gov</a><br> 163996515 E-096-2021-0 E-096-2021-0-US-01 LABELING BIOLOGICAL PARTICLES USING ACOUSTOPHORESIS PRV US 63/191,103 Abandoned US <br />Provisional (PRV) 63/191,103<br />Filed on 2021-05-20<br />Status: Abandoned 163996516 E-096-2021-0 E-096-2021-0-PCT-02 LABELING BIOLOGICAL PARTICLES USING ACOUSTOPHORESIS PCT Patent Cooperation Treaty PCT/US2022/028819 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2022/028819<br />Filed on 2022-05-11<br />Status: Expired 163996517 E-096-2021-0 E-096-2021-0-US-02 LABELING BIOLOGICAL PARTICLES USING ACOUSTOPHORESIS National Stage US 18/290,442 Pending US <br />National Stage 18/290,442<br />Filed on 2023-11-13<br />Status: Pending TAB-5032 159360802 Degrader Molecules for hRpn13Pru, PCLAF, RRM2 and Other KEN Box-containing Proteins NHLBI Collaboration, Immunology, Licensing, Oncology, Therapeutics Collaboration Immunology Licensing Oncology Therapeutics Xiuxiu Lu, Kylie Walters <p>Summary:</p> <p>The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for three small molecules that target hRpn13, an overexpressed protein in certain cancers.</p> <p><br /> Description of Technology:</p> <p>Over 35,000 new cases of multiple myeloma are diagnosed each year in the US. Standard of care and experimental therapies include monoclonal antibodies, immunomodulatory drugs, proteasome inhibitors and corticosteroids. While these therapies can be effective, a majority of patients experience relapse within four years. New proteasome-targeting drugs are needed to improve current myeloma treatments.</p> <p>Proteasome inhibitors function by interfering with a cell&rsquo;s normal protein recycling process and induce apoptosis via multiple mechanisms. FDA-approved proteasome inhibitors exist with indications for the treatment of liquid cancers, specifically multiple myeloma and mantle-cell lymphoma. However, these drugs can induce dose-limiting toxicities. It is hypothesized that targeting ubiquitin receptors upstream of the 20S proteasome may lead to less toxic therapies, such as targeting the 19S proteasome regulatory region associated within ubiquitin receptor Rpn13.</p> <p>Inventors at the NCI have generated three small molecules, XL44, XL69, XL80 that target ubiquitin receptor hRpn13. hRpn13Pru is produced in certain cancer cell types. XL44, XL69, and XL80 deplete it reliably without fusion to a known ligand related to ubiquitination complexes, suggesting a glue-like mechanism of depletion. XL44 induces apoptosis in a hRpn13-dependent manner, but can restrict cell viability independently of hRpn13, specifically via depletion of KEN box proteins. Early in vivo studies show reduced tumor size in xenograft multiple myeloma models. The inventors have developed an oral formulation.</p> <h2>Potential Commercial Applications:</h2> <p>* Multiple Myeloma therapeutic</p> <p>* Mantle Cell therapeutic</p> <h2><br /> Competitive Advantages:</h2> <p>* Oral formulation</p> <p>* Lower toxicity than currently approved proteasome inhibitors</p> Researchers at the NCI seek licensing and/or co-development research collaborations for three small molecules that inhibit hRpn13 as a cancer therapeutic 2024-11-27 2025-12-11 2025-12-11 2024-11-27 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 159360845 Osei-Amponsa, V. et al “hRpn13 shapes the proteome and transcriptome through epigenetic factors HDAC8, PADI4 and transcription factor NF-kB p50” PMID: 38151017. https://pubmed.ncbi.nlm.nih.gov/38151017/ <a href="https://pubmed.ncbi.nlm.nih.gov/38151017/">Osei-Amponsa, V. et al “hRpn13 shapes the proteome and transcriptome through epigenetic factors HDAC8, PADI4 and transcription factor NF-kB p50” PMID: 38151017.</a> 159360959 Lu, X., Chandravanshi, et al. “A structure-based designed small molecule depletes hRpn13Pru and a select group of KEN box proteins” PMID 38509117 https://pubmed.ncbi.nlm.nih.gov/38509117/ <a href="https://pubmed.ncbi.nlm.nih.gov/38509117/">Lu, X., Chandravanshi, et al. “A structure-based designed small molecule depletes hRpn13Pru and a select group of KEN box proteins” PMID 38509117</a> 159360809 Walters, Kylie National Cancer Institute (NCI) NCI Walters, Kylie (NCI) 1 159360813 Lu, Xiuxiu NCI Lu, Xiuxiu (NCI) 2 159360809 Walters, Kylie National Cancer Institute (NCI) NCI Walters, Kylie (NCI) 1 159360813 Lu, Xiuxiu NCI Lu, Xiuxiu (NCI) 2 159360805 A degrader molecule for an hRpn13 naturally generated fragment that includes the Pru domain, PCLAF, RRM2 and other KEN box containing proteins E-138-2023-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI), NIH - NCI, NIH - NHLBI, Structural Biophysics Laboratory 153929528 Ghosh, Malabika malabika.ghosh@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America malabika.ghosh@nih.gov?subject=Web Inquiry on [TAB-5032] Degrader Molecules for hRpn13Pru, PCLAF, RRM2 and Other KEN Box-containing Proteins&body=Please send me information about technology [TAB-5032] Degrader Molecules for hRpn13Pru, PCLAF, RRM2 and Other KEN Box-containing Proteins.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Ghosh, Malabika<br><a href="mailto:malabika.ghosh@nih.gov?subject=Web Inquiry on [TAB-5032] Degrader Molecules for hRpn13Pru, PCLAF, RRM2 and Other KEN Box-containing Proteins&body=Please send me information about technology [TAB-5032] Degrader Molecules for hRpn13Pru, PCLAF, RRM2 and Other KEN Box-containing Proteins.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">malabika.ghosh@nih.gov</a><br> 159502829 E-138-2023-0 E-138-2023-0-US-01 A MOLECULAR SCAFFOLD FOR DEPLETING HRPN13 AND A SELECT GROUP OF KEN BOX PROTEINS PRV US 63/539,663 Expired US <br />Provisional (PRV) 63/539,663<br />Filed on 2023-09-21<br />Status: Expired 159502834 E-138-2023-0 E-138-2023-0-PC-01 A MOLECULAR SCAFFOLD FOR DEPLETING HRPN13 AND A SELECT GROUP OF KEN BOX PROTEINS PCT Patent Cooperation Treaty PCT/US2024/047709 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2024/047709<br />Filed on 2024-09-20<br />Status: Expired TAB-5067 163489281 A conserved viral peptide for use in cancer immunotherapy NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Man Hsin Hung, Lichun Ma, Xin Wei Wang <h2>Summary:</h2> <p>The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for viral peptide (CE1)-based therapeutics for HCC prevention and treatment.</p> <h2>Description of Technology:</h2> <p>Hepatocellular carcinoma (HCC) is a common and aggressive primary liver cancer. It develops mainly from at-risk individuals with underlying chronic liver diseases, such as hepatitis and cirrhosis. HCC is a leading cause of cancer-related death worldwide and its global incidence and mortality rate continues to rise. The current methods for early detection, surveillance and treatment are suboptimal due to complex etiologies and intricate tumor biology.</p> <p>Through serological profiling across three independent cohorts, researchers at the National Cancer Institute (NCI) have identified a common epitope (CE1) shared among protective viral antigens enriched in healthy individuals compared to HCC patients. A synthetic CE1 peptide was demonstrated to have utility in eliciting a T cell response to HCC cells and can be developed as an immunotherapy for HCC, such as a CE1-based HCC vaccine. Currently, as there are limited therapeutic options for HCC patients, novel treatments would offer tremendous commercial and public health benefits.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>HCC prevention and treatment</li> <li>Predictive biomarker for HCC risk <ul> <li>Serological response test</li> <li>Patient stratification for CE1-based therapy</li> <li>Monitoring the efficacy of the CE1-based vaccine</li> </ul> </li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>VirScan data support that this peptide correlates with better outcomes in HCC and breast cancer</li> <li>CE1 peptide shows an immunomodulatory effect; immunomodulators are a promising approach to cancer treatment</li> <li>CE1 peptide is biologically active in inducing T cell cytolytic activity</li> <li>HCC cell killing in an HLA-specific manner &nbsp;</li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for viral peptide (CE1)-based therapeutics for HCC prevention and treatment 2025-07-28 2025-08-21 2025-11-19 2025-07-28 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52406768 Discovery 52406768 NCI 37470483 Website Abstract E-171-2022 E-174-2019 163489749 Ma L, et al. Beneficial infections of the enterovirus genus in patients with liver cancer. (PMID: 40345802) https://pubmed.ncbi.nlm.nih.gov/40345802/ <a href="https://pubmed.ncbi.nlm.nih.gov/40345802/">Ma L, et al. Beneficial infections of the enterovirus genus in patients with liver cancer. (PMID: 40345802)</a> 163489378 Wang, Xin Wei NIH - NCI NCI Wang, Xin Wei (NCI) 1 163489408 Ma, Lichun NIH - NCI Ma, Lichun 2 163489418 Hung, Man Hsin NIH - NCI NCI Hung, Man Hsin (NCI) 3 163489378 Wang, Xin Wei NIH - NCI NCI Wang, Xin Wei (NCI) 1 163489408 Ma, Lichun NIH - NCI Ma, Lichun 2 163489418 Hung, Man Hsin NIH - NCI NCI Hung, Man Hsin (NCI) 3 163489284 A conserved viral peptide for use in cancer immunotherapy E-023-2024-0 Filing authorized NIH - NCI 83691647 Chang, Kevin changke@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB changke@mail.nih.gov?subject=Web Inquiry on [TAB-5067] A conserved viral peptide for use in cancer immunotherapy&body=Please send me information about technology [TAB-5067] A conserved viral peptide for use in cancer immunotherapy.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Chang, Kevin<br><a href="mailto:changke@mail.nih.gov?subject=Web Inquiry on [TAB-5067] A conserved viral peptide for use in cancer immunotherapy&body=Please send me information about technology [TAB-5067] A conserved viral peptide for use in cancer immunotherapy.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">changke@mail.nih.gov</a><br> 163489289 E-023-2024-0 E-023-2024-0-US-01 VIRUS ANTIGEN-DERIVED IMMUNOGENIC PEPTIDES AND THEIR USE FOR THE PREVENTION AND TREATMENT OF HEPATOCELLULAR CARCINOMA PRV US 63/735,040 Expired US <br />Provisional (PRV) 63/735,040<br />Filed on 2024-12-17<br />Status: Expired 164898215 E-023-2024-0 E-023-2024-0-PC-01 VIRUS ANTIGEN-DERIVED IMMUNOGENIC PEPTIDES AND THEIR USE FOR THE EARLY INTERVENTION AND TREATMENT OF LIVER CANCER PCT Patent Cooperation Treaty PCT/US2025/059785 Pending Patent Cooperation Treaty <br />(PCT) PCT/US2025/059785<br />Filed on 2025-12-16<br />Status: Pending TAB-4543 151736665 Endo-cameral Closure Device for Structural Heart Defects and Blood Vessel Repair NHLBI Cardiology, Licensing, Medical Devices, Research Equipment, Research Materials Cardiology Licensing Medical Devices Research Equipment Research Materials Ozgur Kocaturk, Robert Lederman, Toby Rogers, Merdim Sonmez <p>This technology includes a device to close a hole in the wall of a large blood vessel or cardiac chamber from the inside out, delivered over a guidewire and through a catheter or sheath. First, the proximal portion deploys within the vessel or chamber and is advanced over a guidewire to oppose the wall and seal the hole. Second, the distal portion self-assembles outside the vessel or chamber upon withdrawal of the guidewire. Deployment of the distal portion anchors the device securely in place.</p> There are currently no commercially available devices to close holes in the wall of large blood vessels or cardiac chambers, and has the potential to enable novel procedures that are not possible currently because of a lack of custom closure device. This device could become a critical tool to have available in every interventional catheterization laboratory. We are seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. 2023-12-11 2025-08-13 2025-11-19 2024-03-20 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 151736678 Rogers, Toby Medstar Washington Hospital Center Rogers, Toby 1 151736684 Kocaturk, Ozgur Bogazici University Kocaturk, Ozgur 2 151736690 Lederman, Robert National Heart, Lung, and Blood Institute (NHLBI) NHLBI Lederman, Robert (NHLBI) 3 151736743 Sonmez, Merdim National Heart, Lung, and Blood Institute (NHLBI) NHLBI Sonmez, Merdim (NHLBI) 4 151736678 Rogers, Toby Medstar Washington Hospital Center Rogers, Toby 1 151736684 Kocaturk, Ozgur Bogazici University Kocaturk, Ozgur 2 151736690 Lederman, Robert National Heart, Lung, and Blood Institute (NHLBI) NHLBI Lederman, Robert (NHLBI) 3 151736743 Sonmez, Merdim National Heart, Lung, and Blood Institute (NHLBI) NHLBI Sonmez, Merdim (NHLBI) 4 151736668 Endo-cameral Closure Device E-273-2015-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-4543] Endo-cameral Closure Device for Structural Heart Defects and Blood Vessel Repair&body=Please send me information about technology [TAB-4543] Endo-cameral Closure Device for Structural Heart Defects and Blood Vessel Repair. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-4543] Endo-cameral Closure Device for Structural Heart Defects and Blood Vessel Repair&body=Please send me information about technology [TAB-4543] Endo-cameral Closure Device for Structural Heart Defects and Blood Vessel Repair.">shmilovm@nih.gov</a><br> 157756297 E-273-2015-0 E-273-2015-0-US-01 Endo-cameral Closure Device PRV US 62/236,734 Abandoned US <br />Provisional (PRV) 62/236,734<br />Filed on 2015-10-02<br />Status: Abandoned 157756302 E-273-2015-0 E-273-2015-0-PCT-02 Endo-cameral Closure Device PCT Patent Cooperation Treaty PCT/US2016/054961 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2016/054961<br />Filed on 2016-09-30<br />Status: Expired 157756307 E-273-2015-0 E-273-2015-0-EP-03 Endo-cameral Closure Device National Stage European Patent 3355802 16852768.7 Issued European Patent <br />National Stage 16852768.7<br />Filed on 2018-04-03<br />Status: Issued 157756312 E-273-2015-0 E-273-2015-0-US-04 Endo-cameral Closure Device National Stage US 10,603,021 15/761,923 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10603021 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10603021">10,603,021</a><br />Filed on 2018-03-21<br />Status: Issued 157756317 E-273-2015-0 E-273-2015-0-CH-05 Endo-cameral Closure Device EP Switzerland 3355802 16852768.7 Issued Switzerland <br />European patent (EP) 16852768.7<br />Filed on 2018-04-03<br />Status: Issued 157756322 E-273-2015-0 E-273-2015-0-DE-06 Endo-cameral Closure Device EP Germany 3355802 16852768.7 Issued Germany <br />European patent (EP) 16852768.7<br />Filed on 2018-04-03<br />Status: Issued 157756327 E-273-2015-0 E-273-2015-0-FR-07 Endo-cameral Closure Device EP France 3355802 16852768.7 Issued France <br />European patent (EP) 16852768.7<br />Filed on 2018-04-03<br />Status: Issued 157756332 E-273-2015-0 E-273-2015-0-GB-08 Endo-cameral Closure Device EP United Kingdom 3355802 16852768.7 Issued United Kingdom <br />European patent (EP) 16852768.7<br />Filed on 2018-04-03<br />Status: Issued 157756337 E-273-2015-0 E-273-2015-0-IE-09 Endo-cameral Closure Device EP Ireland 3355802 16852768.7 Issued Ireland <br />European patent (EP) 16852768.7<br />Filed on 2018-04-03<br />Status: Issued TAB-4527 151719871 Annuloplasty Procedures, Related Devices and Methods NHLBI Cardiology, Licensing, Medical Devices, Research Equipment Cardiology Licensing Medical Devices Research Equipment Robert Lederman, Nasser Raffie, Toby Rogers <p>This technology includes design enhancements to transcatheter mitral cerclage annuloplasty. They include a device to convert from crossing guidewire to tension element, refinements to the tension element which incorporates a coronary artery protection device, a target/capture/snare device, a wishbone locking device, and a cutting device.</p> These refinements represent years of iterative technology development and reflect the near-final design of the device. Improved procedures for repairing heart valves. We are seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. 2023-12-08 2024-08-12 2025-11-19 2024-03-20 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 151719878 Raffie, Nasser Mehr Medical Raffie, Nasser 1 151719882 Lederman, Robert National Heart, Lung, and Blood Institute (NHLBI) NHLBI Lederman, Robert (NHLBI) 2 151719886 Rogers, Toby Medstar Washington Hospital Center Rogers, Toby 3 151719878 Raffie, Nasser Mehr Medical Raffie, Nasser 1 151719882 Lederman, Robert National Heart, Lung, and Blood Institute (NHLBI) NHLBI Lederman, Robert (NHLBI) 2 151719886 Rogers, Toby Medstar Washington Hospital Center Rogers, Toby 3 151719874 Annuloplasty Procedures, Related Devices And Methods E-201-2016-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI), Transmural Systems, LLC 90072936 Mistry, Pragnesh pragnesh.mistry@nih.gov
HNH6Z08 pragnesh.mistry@nih.gov?subject=Web Inquiry on [TAB-4527] Annuloplasty Procedures, Related Devices and Methods&body=Please send me information about technology [TAB-4527] Annuloplasty Procedures, Related Devices and Methods. Mistry, Pragnesh<br><a href="mailto:pragnesh.mistry@nih.gov?subject=Web Inquiry on [TAB-4527] Annuloplasty Procedures, Related Devices and Methods&body=Please send me information about technology [TAB-4527] Annuloplasty Procedures, Related Devices and Methods.">pragnesh.mistry@nih.gov</a><br> 157755883 E-201-2016-0 E-201-2016-0-US-01 Annuloplasty Procedures, Related Devices And Methods PRV US 62/332,754 Abandoned US <br />Provisional (PRV) 62/332,754<br />Filed on 2016-05-06<br />Status: Abandoned 157755888 E-201-2016-0 E-201-2016-0-PCT-02 Annuloplasty Procedures, Related Devices And Methods PCT Patent Cooperation Treaty PCT/US2017/031543 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2017/031543<br />Filed on 2017-05-08<br />Status: Expired 157755893 E-201-2016-0 E-201-2016-0-US-03 Annuloplasty Procedures, Related Devices And Methods CIP US 10,433,962 15/796,344 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10433962 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10433962">10,433,962</a><br />Filed on 2017-10-27<br />Status: Issued 157755898 E-201-2016-0 E-201-2016-0-EP-04 Annuloplasty Procedures, Related Devices And Methods National Stage European Patent 3451973 17793543.4 Issued European Patent <br />National Stage 17793543.4<br />Filed on 2018-11-26<br />Status: Issued 157755903 E-201-2016-0 E-201-2016-0-JP-05 Annuloplasty Procedures, Related Devices And Methods National Stage Japan 7097351 2019-510584 Issued Japan <br />National Stage 2019-510584<br />Filed on 2018-06-11<br />Status: Issued 157755908 E-201-2016-0 E-201-2016-0-KR-06 Annuloplasty Procedures, Related Devices And Methods National Stage South Korea 10-2416646 10-2018-7035352 Issued South Korea <br />National Stage 10-2018-7035352<br />Filed on 2018-12-05<br />Status: Issued TAB-4521 151719298 Novel Bicuspid Transcatheter Heart Valve Frame and Leaflets for Mitro Valve Implantation NHLBI Cardiology, Licensing, Medical Devices, Research Equipment Cardiology Licensing Medical Devices Research Equipment Robert Lederman, Toby Rogers <p>This technology includes a pair of subsystems for a novel transcatheter bicuspid valve (frame and leaflets) intended for implantation in the mitral position. It is simple, it overcomes key limitations to transcatheter bicuspid mitral valve implants, and it overcomes key limitations to transcatheter tricuspid mitral valve implants.</p> This is novel, useful, non-obvious, clinically attractive, and commercially attractive despite the large number of investigational transcatheter mitral valve implantation devices currently under commercial development. This can be developed into a novel transcatheter mitral valve implant. We are seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. 2023-12-08 2025-08-13 2025-11-19 2024-03-20 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 151719305 Lederman, Robert National Heart, Lung, and Blood Institute (NHLBI) NHLBI Lederman, Robert (NHLBI) 1 151719309 Rogers, Toby Medstar Washington Hospital Center Rogers, Toby 2 151719305 Lederman, Robert National Heart, Lung, and Blood Institute (NHLBI) NHLBI Lederman, Robert (NHLBI) 1 151719309 Rogers, Toby Medstar Washington Hospital Center Rogers, Toby 2 151719301 Novel Bicuspid Transcatheter Heart Valve Frame And Leaflets E-191-2020-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-4521] Novel Bicuspid Transcatheter Heart Valve Frame and Leaflets for Mitro Valve Implantation&body=Please send me information about technology [TAB-4521] Novel Bicuspid Transcatheter Heart Valve Frame and Leaflets for Mitro Valve Implantation. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-4521] Novel Bicuspid Transcatheter Heart Valve Frame and Leaflets for Mitro Valve Implantation&body=Please send me information about technology [TAB-4521] Novel Bicuspid Transcatheter Heart Valve Frame and Leaflets for Mitro Valve Implantation.">shmilovm@nih.gov</a><br> 157755587 E-191-2020-0 E-191-2020-0-US-01 SYSTEMS AND METHODS FOR MITRAL VALVE REPLACEMENT PRV US 63/054,623 Abandoned US <br />Provisional (PRV) 63/054,623<br />Filed on 2020-07-21<br />Status: Abandoned 157755592 E-191-2020-0 E-191-2020-0-PCT-02 SYSTEMS AND METHODS FOR MITRAL VALVE REPLACEMENT PCT Patent Cooperation Treaty PCT/US2021/042380 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/042380<br />Filed on 2021-07-20<br />Status: Expired 157755597 E-191-2020-0 E-191-2020-0-CN-03 SYSTEMS AND METHODS FOR MITRAL VALVE REPLACEMENT National Stage China 202180059611.1 Pending China <br />National Stage 202180059611.1<br />Filed on 2023-01-28<br />Status: Pending 157755602 E-191-2020-0 E-191-2020-0-EP-04 SYSTEMS AND METHODS FOR MITRAL VALVE REPLACEMENT National Stage European Patent 21845838.8 Pending European Patent <br />National Stage 21845838.8<br />Filed on 2023-01-17<br />Status: Pending 157755607 E-191-2020-0 E-191-2020-0-IL-05 SYSTEMS AND METHODS FOR MITRAL VALVE REPLACEMENT National Stage Israel 299776 Pending Israel <br />National Stage 299776<br />Filed on 2021-07-20<br />Status: Pending 157755632 E-191-2020-0 E-191-2020-0-US-06 SYSTEMS AND METHODS FOR MITRAL VALVE REPLACEMENT National Stage US 18/006,331 Pending US <br />National Stage 18/006,331<br />Filed on 2023-01-20<br />Status: Pending TAB-4502 151705244 Device for Closure of Transvascular or Transcameral Access Ports NHLBI Cardiology, Licensing, Medical Devices, Research Equipment Cardiology Licensing Medical Devices Research Equipment Robert Lederman, Nasser Raffie, Toby Rogers <p>This technology includes a novel method to access the arterial circulation to allow introduction of large devices, such as transcatheter aortic valve replacement, percutaneous left ventricular assist devices, and thoracic aortic endografts. It also can be used in most labeled and off-label applications of Amplatzer nitinol occluder devices to occlude intracardiac holes and to allow non-surgical direct access to the heart. This new disclosure adds additional design features that have been tested in vivo. These include a new compression member design that enhances wall apposition and hemostasis, a new delivery cable design, alternative endoluminal limb designs. The new design allows flexible deliver and recovery but is designed to avoid inadvertent pull-through. The disclosed invention has already been built and reduced to practice in an animal model.</p> The unique features of the device which are not available in commercial devices marketed for the occlusion of congenital heart and vascular defects include: <ul> <li>New compression member design that enforces flattening of the nitinol endoluminal disks</li> <li>Wing-shaped endoluminal disks to enhance disk stiffness</li> <li>Flexible delivery cable that still allows continuous central guidewire access</li> <li>Beveled marker sheath catheter design to accommodate oblique delivery angles</li> </ul> Method and device to access arterial circulation to allow introduction of devices in various cardiac procedures. We are seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. 2023-12-07 2025-08-13 2025-11-19 2024-03-20 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 151705251 Lederman, Robert National Heart, Lung, and Blood Institute (NHLBI) NHLBI Lederman, Robert (NHLBI) 1 151705255 Rogers, Toby Medstar Washington Hospital Center Rogers, Toby 2 151705259 Raffie, Nasser Mehr Medical Raffie, Nasser 3 151705251 Lederman, Robert National Heart, Lung, and Blood Institute (NHLBI) NHLBI Lederman, Robert (NHLBI) 1 151705255 Rogers, Toby Medstar Washington Hospital Center Rogers, Toby 2 151705259 Raffie, Nasser Mehr Medical Raffie, Nasser 3 151705247 Device For Closure Of Transvascular Or Transcameral Access Ports E-124-2014-0 Filing authorized Mehr Medical, National Heart, Lung, and Blood Institute (NHLBI) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-4502] Device for Closure of Transvascular or Transcameral Access Ports&body=Please send me information about technology [TAB-4502] Device for Closure of Transvascular or Transcameral Access Ports. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-4502] Device for Closure of Transvascular or Transcameral Access Ports&body=Please send me information about technology [TAB-4502] Device for Closure of Transvascular or Transcameral Access Ports.">shmilovm@nih.gov</a><br> 157755053 E-124-2014-0 E-124-2014-0-US-01 Device For Closure Of Transvascular Or Transcameral Access Ports PRV US 61/971,458 Abandoned US <br />Provisional (PRV) 61/971,458<br />Filed on 2014-03-27<br />Status: Abandoned TAB-4485 151645196 Device for Closure of Transvascular or Transcameral Access Ports NHLBI Cardiology, Licensing, Medical Devices, Research Equipment, Research Materials Cardiology Licensing Medical Devices Research Equipment Research Materials Ozgur Kocaturk, Robert Lederman, Nasser Raffie, Kanishka Ratnayaka, Toby Rogers <p>This technology includes part of transcatheter aortic valve replacement and to enable non-surgical thoracic aortic aneurysm endograft repair. The invention enables a completely new way to access the arterial circulation to allow introduction of large devices, such as transcatheter aortic valve replacement, percutaneous left ventricular assist devices, and thoracic aortic endografts. It also can be used in most labeled and off-label applications of Amplatzer (AGA Medical, St Jude) nitinol occluder devices to occlude intracardiac holes and to allow non-surgical direct access to the heart. This invention has been applied, using marketed devices off-label, in 15 patients.</p> The unique features of the device which are not available in commercial devices marketed for the occlusion of congenital heart and vascular defects include: <ul> <li>Multiple disks, especially the favored three-disc embodiment with intra-aortic, extra-aortic, and venous disks</li> <li>Billowed nitinol disk, especially in the preferred embodiment of the extra-aortic disk, occupies space to achieve hemostasis on the aortic rent</li> <li>Tether mechanism for independent control of multiple disks during deployment</li> </ul> Permanent medical implant for use as part of transcatheter aortic valve replacement and to enable non-surgical thoracic aortic aneurysm endograft repair. We are seeking statements of capability or interest from parties interested in collaborative research to further developer, evaluate, or commercialize this technology. 2023-12-06 2024-08-12 2025-11-19 2024-03-27 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 151645204 Lederman, Robert National Heart, Lung, and Blood Institute (NHLBI) NHLBI Lederman, Robert (NHLBI) 1 151645208 Kocaturk, Ozgur National Heart, Lung, and Blood Institute (NHLBI) NHLBI Kocaturk, Ozgur (NHLBI) 2 151645212 Rogers, Toby Medstar Washington Hospital Center Rogers, Toby 3 151645216 Ratnayaka, Kanishka Rady Children's Hospital, San Diego Ratnayaka, Kanishka 4 151645224 Raffie, Nasser Mehr Medical Raffie, Nasser 5 151645204 Lederman, Robert National Heart, Lung, and Blood Institute (NHLBI) NHLBI Lederman, Robert (NHLBI) 1 151645208 Kocaturk, Ozgur National Heart, Lung, and Blood Institute (NHLBI) NHLBI Kocaturk, Ozgur (NHLBI) 2 151645212 Rogers, Toby Medstar Washington Hospital Center Rogers, Toby 3 151645216 Ratnayaka, Kanishka Rady Children's Hospital, San Diego Ratnayaka, Kanishka 4 151645224 Raffie, Nasser Mehr Medical Raffie, Nasser 5 151645199 Device For Closure Of Transvascular Or Transcameral Access Ports E-068-2014-0 Filing authorized Mehr Medical, National Heart, Lung, and Blood Institute (NHLBI) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-4485] Device for Closure of Transvascular or Transcameral Access Ports&body=Please send me information about technology [TAB-4485] Device for Closure of Transvascular or Transcameral Access Ports. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-4485] Device for Closure of Transvascular or Transcameral Access Ports&body=Please send me information about technology [TAB-4485] Device for Closure of Transvascular or Transcameral Access Ports.">shmilovm@nih.gov</a><br> 157754290 E-068-2014-0 E-068-2014-0-US-01 Device For Closure Of Transvascular Or Transcameral Access Ports PRV US 61/910,346 Abandoned US <br />Provisional (PRV) 61/910,346<br />Filed on 2013-11-30<br />Status: Abandoned TAB-3520 114097380 Systemic CRISPR Therapy for the Treatment of Inherited Diseases NCATS Cardiology, Dental, Endocrinology, Infectious Disease, Oncology, Ophthalmology, Research Materials Cardiology Dental Endocrinology Infectious Disease Oncology Ophthalmology Research Materials Dongsheng Duan, Chady Hakim, Nalinda Wasala, Youngping Yue This technology includes novel systemic adeno-associated virus (AAV)-mediated CRISPR gene therapy technology. While some diseases (e.g., retinal diseases) can be treated through local gene transfer, many diseases such as Duchenne Muscular Dystrophy (DMD) require systemic therapy. The CRISPR technology has two components, the Cas9 endonuclease, and the gRNA. To explore systemic CRISPR therapy, we co-delivered the AAV.Cas9 and AAV.gRNA vector to mdx mice, a mouse DMD model. Direct delivery to muscle yielded efficient gene correction. Through detailed analysis of gene editing at the protein and transcript level and detailed profiling of the two AAV CRISPR vectors, we identified preferential loss of the gRNA vector as the barrier to systemic AAV CRISPR therapy. Increasing gRNA vector dose successfully overcome this hurdle and resulted in correction in both heart and skeletal muscle. Importantly, modified CRISPR therapy significantly enhanced skeletal muscle and cardiac function. The patent illustrates the development of this novel systemic AAV CRISPR gene therapy technology, which can be applied to treat many inherited diseases. The modified CRISPR gene therapy technology has achieved efficient body wide skeletal muscle and heart CRISPR editing and function improvement which opens the door to treat many inherited diseases by systemic AAV CRISPR therapy. Further clinical work using novel systemic adeno-associated virus (AAV)-mediated CRISPR could establish this invention as a treatment of inherited diseases, such as Duchenne Muscular Dystrophy. 2022-08-01 2025-08-13 2025-11-14 2022-08-01 2022-03-30 CRISPR, SYSTEMIC, THERAPY, VPXXXX, WIXXXX False True True NIHTT 37470483 Website Abstract 114110536 Hakim, Chady NCATS - NCGC NCATS Hakim, Chady (NCATS) 0 114110537 Wasala, Nalinda University of Missouri Wasala, Nalinda 0 114110538 Yue, Youngping University of Missouri Yue, Youngping 0 114110535 Duan, Dongsheng University of Missouri Duan, Dongsheng 1 114110535 Duan, Dongsheng University of Missouri Duan, Dongsheng 1 114110536 Hakim, Chady NCATS - NCGC NCATS Hakim, Chady (NCATS) 0 114110537 Wasala, Nalinda University of Missouri Wasala, Nalinda 0 114110538 Yue, Youngping University of Missouri Yue, Youngping 0 114102632 Systemic CRISPR Therapy E-193-2018-0 Filing authorized NCATS - NCGC, University of Missouri 83673536 Erwin-Cohen, Rebecca rebecca.erwin-cohen@nih.gov
NCGC rebecca.erwin-cohen@nih.gov?subject=Web Inquiry on [TAB-3520] Systemic CRISPR Therapy for the Treatment of Inherited Diseases&body=Please send me information about technology [TAB-3520] Systemic CRISPR Therapy for the Treatment of Inherited Diseases. Erwin-Cohen, Rebecca<br><a href="mailto:rebecca.erwin-cohen@nih.gov?subject=Web Inquiry on [TAB-3520] Systemic CRISPR Therapy for the Treatment of Inherited Diseases&body=Please send me information about technology [TAB-3520] Systemic CRISPR Therapy for the Treatment of Inherited Diseases.">rebecca.erwin-cohen@nih.gov</a><br> 114169301 E-193-2018-0 E-193-2018-0-US-01 Systemic CRISPR Therapy PRV US 62/661,391 Abandoned US <br />Provisional (PRV) 62/661,391<br />Filed on 2018-04-23<br />Status: Abandoned 114169302 E-193-2018-0 E-193-2018-0-PCT-02 Improved CRISPR Therapy PCT Patent Cooperation Treaty PCT/US2019/028635 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2019/028635<br />Filed on 2019-04-23<br />Status: Expired 114128663 VPXXXX 114128664 WIXXXX 114152806 SYSTEMIC 114152807 CRISPR 114152808 THERAPY TAB-4534 151721981 Enhanced S10-3 Cell Line for Advanced Hepatitis E Virus Research and Therapeutic Development NIAID Human Cell Lines, Infectious Disease, Research Materials, ResearchProducts Human Cell Lines Infectious Disease Research Materials ResearchProducts Suzanne Emerson, Hanh Nguyen, Udana Torian <p>The Huh-7 cell line underwent a detailed sub-cloning process to enhance its effectiveness for Hepatitis E Virus (HEV) infection studies. This involved diluting and culturing cells in 96-well plates until confluent monolayers formed, followed by selection and expansion of the most suitable cells. The sub-clone S10-3, derived from this process, was identified as the most efficient for transfection and infection by HEV. Prepared using standard cell culture methods, these S10-3 cells from the Huh-7 line demonstrated superior abilities in both transfectability and infectivity, making them highly valuable for virological research focused on Hepatitis E Virus.</p> The S10-3 cells, derived from the Huh-7 cell line, offer a significant competitive advantage in Hepatitis E Virus research due to their enhanced efficiency in transfection and infection processes. The S10-3 cell line, with its heightened transfection and infection capabilities, holds potential for groundbreaking advances in the study and development of treatments and vaccines for Hepatitis E Virus. 2023-12-10 2025-08-13 2025-11-14 2024-12-10 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 151722002 Emerson, S. https://pubmed.ncbi.nlm.nih.gov/16928762/ <a href="https://pubmed.ncbi.nlm.nih.gov/16928762/">Emerson, S.</a> 151721990 Emerson, Suzanne National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Emerson, Suzanne (NIAID) 1 151721994 Nguyen, Hanh National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Nguyen, Hanh (NIAID) 2 151721998 Torian, Udana NIAID Torian, Udana (NIAID) 3 151721990 Emerson, Suzanne National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Emerson, Suzanne (NIAID) 1 151721994 Nguyen, Hanh National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Nguyen, Hanh (NIAID) 2 151721998 Torian, Udana NIAID Torian, Udana (NIAID) 3 151721984 Huh-7 Cell Line Derived S10-3 Cells For Hepatitis E Virus Infection Studies E-218-2018-0 Research Material NIAID 91021353 Pitts, Elizabeth elizabeth.pitts@nih.gov
United States of America elizabeth.pitts@nih.gov?subject=Web Inquiry on [TAB-4534] Enhanced S10-3 Cell Line for Advanced Hepatitis E Virus Research and Therapeutic Development&body=Please send me information about technology [TAB-4534] Enhanced S10-3 Cell Line for Advanced Hepatitis E Virus Research and Therapeutic Development. Pitts, Elizabeth<br><a href="mailto:elizabeth.pitts@nih.gov?subject=Web Inquiry on [TAB-4534] Enhanced S10-3 Cell Line for Advanced Hepatitis E Virus Research and Therapeutic Development&body=Please send me information about technology [TAB-4534] Enhanced S10-3 Cell Line for Advanced Hepatitis E Virus Research and Therapeutic Development.">elizabeth.pitts@nih.gov</a><br> TAB-5061 162910291 Discovery of potent and selective D3 antagonist with alleviated hERG liability and optimized pharmacokinetic properties NCATS Licensing, Materials Available, Neurology, Psychiatry/Mental Health, Therapeutics Licensing Materials Available Neurology Psychiatry/Mental Health Therapeutics Catherine Chen, Xin Hu, Wenwei Huang, Xiuli Huang, Amy Newman, Elias Padilha, Philip Sanderson, Pranav Shah, Khalida Shamim, Xin Xu, Wei Zheng <p>One of the most challenging hurdles in creating safe and effective new medicines for many diseases is finding drugs that are effective without causing off-target cardiac issues, such as cardiac arrythmias. In collaboration with NIDA, scientists at NCATS have developed a series of novel and highly specific dopamine D3 receptor agonists and antagonists that have potential to target and treat Parkinson&rsquo;s disease, Schizophrenia, Depression, and substance-use disorders including opioid addiction. Important features of these novel chemical compounds are that they exhibit favorable drug-like properties that are likely to make them successful drug candidates, and have reduced human ether-&agrave;-gogo-related gene (hERG) liability and effect on potassium channels, which suggests that the compounds may perform better as Dopamine D3 receptor agonists due to a lower propensity to create cardiac arrythmias.<br /> The novel compounds comprise potent and highly selective Dopamine D3 receptor effectors, inclusive of antagonists and agonists, with alleviated hERG liability and desirable pharmacokinetic properties.<br /> &nbsp;</p> <ul> <li>Superior potency and affinity for Dopamine D3 receptors</li> <li>Limited off-target effects due to brain-specific expression of D3 receptors and superior selectivity of compounds for D3 over D2</li> <li>Lead compounds exhibit 50-100 times greater selectivity for Dopamine D3 over D2 receptors</li> <li>Reduced hERG liability</li> <li>High D3R occupancy</li> <li>Ability to cross the Blood Brain Barrier with excellent brain penetration and low P-Glycoprotein efflux</li> <li>Early-stage invention with IND-enabling data including toxicity study data, in vivo studies</li> </ul> <ul> <li>Parkinson’s disease</li> <li>Schizophrenia</li> <li>Depression</li> <li>Substance use disorders</li> </ul> 2025-06-12 2025-06-13 2025-11-14 2025-06-13 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract E-053-2016 E-042-2022 162910318 Shamim, Khalida NCATS - TRND NCATS Shamim, Khalida (NCATS) 1 162910322 Huang, Wenwei NCATS Huang, Wenwei (NCATS) 2 162910326 Zheng, Wei NCATS Zheng, Wei (NCATS) 3 162910332 Chen, Catherine NCATS - TRND Chen, Catherine 4 162910336 Huang, Xiuli NCATS - TRND NCATS Huang, Xiuli (NCATS) 5 162910340 Hu, Xin NCATS - NCGC NCATS Hu, Xin (NCATS) 6 162910344 Xu, Xin NCATS Xu, Xin (NCATS) 7 162910393 Shah, Pranav NCATS Shah, Pranav (NCATS) 8 162910397 Padilha, Elias NCATS Padilha, Elias (NCATS) 9 162910401 Sanderson, Philip National Center for Advancing Translational Sciences NCATS Sanderson, Philip (NCATS) 10 162910405 Newman, Amy National Institute on Drug Abuse (NIDA) NIDA Newman, Amy (NIDA) 11 162910318 Shamim, Khalida NCATS - TRND NCATS Shamim, Khalida (NCATS) 1 162910322 Huang, Wenwei NCATS Huang, Wenwei (NCATS) 2 162910326 Zheng, Wei NCATS Zheng, Wei (NCATS) 3 162910332 Chen, Catherine NCATS - TRND Chen, Catherine 4 162910336 Huang, Xiuli NCATS - TRND NCATS Huang, Xiuli (NCATS) 5 162910340 Hu, Xin NCATS - NCGC NCATS Hu, Xin (NCATS) 6 162910344 Xu, Xin NCATS Xu, Xin (NCATS) 7 162910393 Shah, Pranav NCATS Shah, Pranav (NCATS) 8 162910397 Padilha, Elias NCATS Padilha, Elias (NCATS) 9 162910401 Sanderson, Philip National Center for Advancing Translational Sciences NCATS Sanderson, Philip (NCATS) 10 162910405 Newman, Amy National Institute on Drug Abuse (NIDA) NIDA Newman, Amy (NIDA) 11 162910294 Discovery of potent and selective D3 antagonist with alleviated hERG liability and optimized pharmacokinetic properties E-097-2023-0 Filing authorized NIH - NCATS, NIH - NIDA 83673536 Erwin-Cohen, Rebecca rebecca.erwin-cohen@nih.gov
NCGC rebecca.erwin-cohen@nih.gov?subject=Web Inquiry on [TAB-5061] Discovery of potent and selective D3 antagonist with alleviated hERG liability and optimized pharmacokinetic properties&body=Please send me information about technology [TAB-5061] Discovery of potent and selective D3 antagonist with alleviated hERG liability and optimized pharmacokinetic properties. Erwin-Cohen, Rebecca<br><a href="mailto:rebecca.erwin-cohen@nih.gov?subject=Web Inquiry on [TAB-5061] Discovery of potent and selective D3 antagonist with alleviated hERG liability and optimized pharmacokinetic properties&body=Please send me information about technology [TAB-5061] Discovery of potent and selective D3 antagonist with alleviated hERG liability and optimized pharmacokinetic properties.">rebecca.erwin-cohen@nih.gov</a><br> 162910298 E-097-2023-0 E-097-2023-0-US-01 POTENT AND SELECTIVE D3 ANTAGONISTS PRV US 63/511,452 Expired US <br />Provisional (PRV) 63/511,452<br />Filed on 2023-06-30<br />Status: Expired 162910300 E-097-2023-0 E-097-2023-0-PC-01 POTENT AND SELECTIVE DOPAMINE D3 ANTAGONISTS PCT Patent Cooperation Treaty PCT/US2024/036149 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2024/036149<br />Filed on 2024-06-28<br />Status: Expired TAB-5069 163660392 Chimeric VLP vaccines to Prevent HTLV-1 Infection NCI Collaboration, Immunology, Infectious Disease, Licensing, Oncology, Therapeutics Collaboration Immunology Infectious Disease Licensing Oncology Therapeutics Massimiliano Bissa, Genoveffa Franchini, Cynthia Masison, Ramona Moles, Sarkis Sarkis <h2>Summary:</h2> <p>The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for Chimeric VLP Vaccines to Prevent HTLV-1 Infection.</p> <h2>Description of Technology:</h2> <p>There is currently no approved vaccine to prevent human T-cell leukemia virus type I (HTLV-1) infection, a highly oncogenic virus linked to serious diseases like adult T-cell leukemia/lymphoma (ATLL) and Tropical Spastic paraparesis /HTLV-1-Associated Myelopathy (HAM/TSP). Existing interventions are limited to behavioral prevention, leaving millions at risk, especially in underserved global regions. A safe and effective vaccine is urgently needed to fill this critical public health gap.</p> <p>This invention is a nucleic acid-based vaccine that generates virus-like particles (VLPs) in the body using HTLV-1 Env and gag proteins to trigger a protective immune response against HTLV-1 infection. With no approved vaccines available and millions at risk&mdash;particularly in underserved regions&mdash;this first-of-its-kind solution addresses a critical public health need. It offers broad protection across HTLV-1 subtypes and is currently being tested in non-human primates, with strong potential for future clinical development and commercial interest.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>HTLV-1 Infection</li> <li>Adult T-cell leukemia/lymphoma (ATLL)</li> <li>Tropical Spastic paraparesis /HTLV-1-Associated Myelopathy (HAM/TSP)</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>No approved HTLV-1 vaccines</li> <li>Preventative vaccine to reduce healthcare costs and economic burden of treating people developing related diseases</li> </ul> The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for development of a nucleic acid-based vaccine for use as a preventative to human T-lymphotrophic virus-1 (HTLV-1) infection. 2025-08-12 2025-08-12 2025-11-10 2025-08-12 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 163660868 Franchini G, et al. HTLV-1 and HTLV-2: Pathogenesis and role of viral proteins. Viruses. 2022;14(10):2084. https://doi.org/10.3390/v14102084 <a href="https://doi.org/10.3390/v14102084">Franchini G, et al. HTLV-1 and HTLV-2: Pathogenesis and role of viral proteins. Viruses. 2022;14(10):2084.</a> 163660611 Franchini, Genoveffa NIH - NCI NCI Franchini, Genoveffa (NCI) 1 163660616 Sarkis, Sarkis NIH - NCI Sarkis, Sarkis 2 163660620 Moles, Ramona NIH - NCI NCI Moles, Ramona (NCI) 3 163660649 Masison, Cynthia NIH - NCI NCI Masison, Cynthia (NCI) 4 163660654 Bissa, Massimiliano NIH - NCI NCI Bissa, Massimiliano (NCI) 5 163660611 Franchini, Genoveffa NIH - NCI NCI Franchini, Genoveffa (NCI) 1 163660616 Sarkis, Sarkis NIH - NCI Sarkis, Sarkis 2 163660620 Moles, Ramona NIH - NCI NCI Moles, Ramona (NCI) 3 163660649 Masison, Cynthia NIH - NCI NCI Masison, Cynthia (NCI) 4 163660654 Bissa, Massimiliano NIH - NCI NCI Bissa, Massimiliano (NCI) 5 163660395 Chimeric VLP Vaccines To Prevent HTLV-1 Infection E-126-2022-0 Filing authorized NCI 83740301 Dattaroy, Diptadip diptadip.dattaroy@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB diptadip.dattaroy@nih.gov?subject=Web Inquiry on [TAB-5069] Chimeric VLP vaccines to Prevent HTLV-1 Infection&body=Please send me information about technology [TAB-5069] Chimeric VLP vaccines to Prevent HTLV-1 Infection.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dattaroy, Diptadip<br><a href="mailto:diptadip.dattaroy@nih.gov?subject=Web Inquiry on [TAB-5069] Chimeric VLP vaccines to Prevent HTLV-1 Infection&body=Please send me information about technology [TAB-5069] Chimeric VLP vaccines to Prevent HTLV-1 Infection.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">diptadip.dattaroy@nih.gov</a><br> 163660555 E-126-2022-0 E-126-2022-0-US-01 VACCINE FOR HUMAN T-LYMPHOTROPIC VIRUS-1 PRV US 63/340,400 Expired US <br />Provisional (PRV) 63/340,400<br />Filed on 2022-05-10<br />Status: Expired 163660556 E-126-2022-0 E-126-2022-0-PC-01 VACCINE FOR HUMAN T-LYMPHOTROPIC VIRUS-1 PCT Patent Cooperation Treaty PCT/US2023/066839 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2023/066839<br />Filed on 2023-05-10<br />Status: Expired 163660557 E-126-2022-0 E-126-2022-0-AU-01 VACCINE FOR HUMAN T-LYMPHOTROPIC VIRUS-1 National Stage Australia 2023268543 Pending Australia <br />National Stage 2023268543<br />Filed on 2024-11-14<br />Status: Pending 163660558 E-126-2022-0 E-126-2022-0-IN-01 VACCINE FOR HUMAN T-LYMPHOTROPIC VIRUS-1 National Stage India 202417088469 Pending India <br />National Stage 202417088469<br />Filed on 2024-11-15<br />Status: Pending 163660559 E-126-2022-0 E-126-2022-0-US-02 VACCINE FOR HUMAN T-LYMPHOTROPIC VIRUS-1 National Stage US 18/864,213 Pending US <br />National Stage 18/864,213<br />Filed on 2024-11-08<br />Status: Pending TAB-4566 151739492 Neural Stem Cells from an iPSC Line Ubiquitously Expressing Green Fluorescent Protein for Basic Science Research and Cell Line Tracking NIAMS Human Cell Lines, Materials Available, Neurology, Research Materials Human Cell Lines Materials Available Neurology Research Materials Nasir Malik, Mahendra Rao <p>This technology involves neural stem cells (NSCs) derived from pluripotent stem cells (PSCs) that can differentiate into neurons and glia. The key feature of this technology is the CY2 EEF1A1 GFP iPSC line, which includes a green fluorescent protein (GFP) expressed under the EEF1A1 promoter, leading to its ubiquitous expression in cells. This characteristic makes the NSCs and the neural cells differentiated from this line exhibit green fluorescence. Such cells, when transplanted into animal models like mice and rats, can be easily tracked due to their fluorescence. This tracking is critical for assessing whether these cells have successfully integrated into the host&#39;s nervous system and are functioning properly. The primary advantage of this technology is that the GFP expression allows for easier tracking of the transplanted cells in comparison to most other NSC lines which lack such fluorescent reporters. This technology has potential applications in studying the integration and functionality of transplanted neurons and astrocytes in animal models, providing significant insights into neural cell behavior and treatment efficacy.</p> The competitive advantage of this technology lies in its unique ability to track transplanted neural stem cells easily in animal models, thanks to the ubiquitous expression of green fluorescent protein, a feature not commonly found in other NSC lines. This technology has potential applications in neurological research and therapy, particularly in studying the integration and functionality of transplanted neurons and astrocytes in animal models, enhancing our understanding of neural cell behavior and treatment possibilities. We are seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. 2023-12-11 2024-08-12 2025-11-10 2024-03-27 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 151739499 Malik, Nasir NIAMS NINDS Malik, Nasir (NINDS) 1 151739503 Rao, Mahendra New York Stem Cell Foundation Rao, Mahendra 2 151739499 Malik, Nasir NIAMS NINDS Malik, Nasir (NINDS) 1 151739503 Rao, Mahendra New York Stem Cell Foundation Rao, Mahendra 2 151739495 Neural Stem Cells From An IPSC Line Ubiquitously Expressing Green Fluorescent Protein E-610-2013-0 Research Material NIAMS 83656052 Knezevic, Vladimir vlado.knezevic@nih.gov
United States of America Technology Advancement Office vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-4566] Neural Stem Cells from an iPSC Line Ubiquitously Expressing Green Fluorescent Protein for Basic Science Research and Cell Line Tracking&body=Please send me information about technology [TAB-4566] Neural Stem Cells from an iPSC Line Ubiquitously Expressing Green Fluorescent Protein for Basic Science Research and Cell Line Tracking. Knezevic, Vladimir<br><a href="mailto:vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-4566] Neural Stem Cells from an iPSC Line Ubiquitously Expressing Green Fluorescent Protein for Basic Science Research and Cell Line Tracking&body=Please send me information about technology [TAB-4566] Neural Stem Cells from an iPSC Line Ubiquitously Expressing Green Fluorescent Protein for Basic Science Research and Cell Line Tracking.">vlado.knezevic@nih.gov</a><br> TAB-4565 151739338 A Neural Stem Line from a Niemann Pick C (NPC) Type 1 Patient for Therapy Development NIAMS Human Cell Lines, Materials Available, Metabolic Disease, Neurology, Research Materials Human Cell Lines Materials Available Metabolic Disease Neurology Research Materials Nasir Malik <p>This technology includes a neural stem cell (NSC) line derived from a Niemann Pick C (NPC) patient, aimed at advancing research and drug development for NPC, an inherited neurodegenerative disorder characterized by the accumulation of cholesterol in neurons. The NSCs, which serve as a crucial intermediate cell type, can be differentiated into any neuronal or glial cell of the brain or spinal cord under appropriate culture conditions. These cells originate from fibroblasts reprogrammed into induced pluripotent stem cells. Their ability to differentiate into various central nervous system cell types is vital for understanding NPC&#39;s underlying causes. Additionally, these NSCs are uniquely positioned for high-throughput drug screening, with the potential to identify novel compounds for treating NPC. This technology is particularly groundbreaking as it represents the first reported NSC line from an NPC patient, offering significant opportunities for novel discoveries in the disease&#39;s study.</p> This neural stem cell technology represents a unique and groundbreaking advancement, offering unprecedented opportunities for in-depth study of the disease and the potential discovery of novel treatments through high-throughput drug screening. The differentiated neural stem cells can be used to study the mechanisms underlying Niemann Pick C disease and employing these cells in high-throughput drug screening to identify novel treatment options for this neurodegenerative disorder. We are seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. 2023-12-11 2024-08-12 2025-11-10 2024-03-27 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 151739345 Malik, Nasir NIAMS NINDS Malik, Nasir (NINDS) 1 151739345 Malik, Nasir NIAMS NINDS Malik, Nasir (NINDS) 1 151739341 A Neural Stem Line (NSC) From A Neiman Pick (NPC) Type 1 Patient E-609-2013-0 Research Material NIAMS 83656052 Knezevic, Vladimir vlado.knezevic@nih.gov
United States of America Technology Advancement Office vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-4565] A Neural Stem Line from a Niemann Pick C (NPC) Type 1 Patient for Therapy Development&body=Please send me information about technology [TAB-4565] A Neural Stem Line from a Niemann Pick C (NPC) Type 1 Patient for Therapy Development. Knezevic, Vladimir<br><a href="mailto:vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-4565] A Neural Stem Line from a Niemann Pick C (NPC) Type 1 Patient for Therapy Development&body=Please send me information about technology [TAB-4565] A Neural Stem Line from a Niemann Pick C (NPC) Type 1 Patient for Therapy Development.">vlado.knezevic@nih.gov</a><br> TAB-4483 151644902 A New Molecular Scaffold for Targeting hRpn13 as a Treatment for Cancer NHLBI Licensing, Oncology, Therapeutics Licensing Oncology Therapeutics Xiuxiu Lu, Venkatareddy Sabbasani, Rolf Swenson, Nadya Tarasova, Kylie Walters <p>This technology includes a new chemical scaffold (with lead compound XL5) against hRpn13 that induces apoptosis, which may have clinical efficacy against cancer. The structure of XL5-conjugated hRpn13 guided the design of XL5-PROTAC degrader compounds that exhibit greater efficacy than previous hRpn13-targeting compounds, as evaluated by selectivity for hRpn13, induction of apoptosis, and loss of cell viability. In cells, XL5-PROTACs revealed the presence of a truncated hRpn13 product that binds to proteasomes and is selectively degraded by XL5-PROTACs. The presence of this truncated hRpn13 protein correlates with induction of apoptosis by XL5-PROTACs, providing a previously unknown mechanism of action for hRpn13 targeting.</p> A next generation of hRpn13-targeting molecules that include degraders has been generated with superior efficacy compared to all previous generation molecules. These reagents and the structure-function assays provide insights into further optimization possibilities and set the stage for clinical trials. Moreover, the mechanism of action for hRpn13 targeting has now been revealed by using these molecules and defined to be a previously unknown Rpn13 species. In the near term, this chemical scaffold against hRpn13 can be used to 1) interrogate hRpn13 function in cells and 2) further development of hRpn13-targeting molecules for clinical application. In the long-term, this chemical scaffold and derived PROTACs or AUTACs may be clinically effective. We are seeking statements of capability or interest from parties interested in collaborative research to further developer, evaluate, or commercialize this technology. 2023-12-06 2025-08-13 2025-10-29 2024-03-27 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 151645039 Sabbasani, Venkatareddy National Heart, Lung, and Blood Institute (NHLBI) NHLBI Sabbasani, Venkatareddy (NHLBI) 1 151645043 Walters, Kylie National Cancer Institute (NCI) NCI Walters, Kylie (NCI) 2 151645047 Lu, Xiuxiu Structural Biophysics Laboratory NCI Lu, Xiuxiu (NCI) 3 151645051 Tarasova, Nadya Cancer Innovation Laboratory NCI Tarasova, Nadya (NCI) 4 151645055 Swenson, Rolf National Heart, Lung, and Blood Institute (NHLBI) NHLBI Swenson, Rolf (NHLBI) 5 151645039 Sabbasani, Venkatareddy National Heart, Lung, and Blood Institute (NHLBI) NHLBI Sabbasani, Venkatareddy (NHLBI) 1 151645043 Walters, Kylie National Cancer Institute (NCI) NCI Walters, Kylie (NCI) 2 151645047 Lu, Xiuxiu Structural Biophysics Laboratory NCI Lu, Xiuxiu (NCI) 3 151645051 Tarasova, Nadya Cancer Innovation Laboratory NCI Tarasova, Nadya (NCI) 4 151645055 Swenson, Rolf National Heart, Lung, and Blood Institute (NHLBI) NHLBI Swenson, Rolf (NHLBI) 5 151644905 A New Molecular Scaffold For Targeting HRpn13 E-056-2021-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI), NCI 153929528 Ghosh, Malabika malabika.ghosh@nih.gov
United States of America malabika.ghosh@nih.gov?subject=Web Inquiry on [TAB-4483] A New Molecular Scaffold for Targeting hRpn13 as a Treatment for Cancer&body=Please send me information about technology [TAB-4483] A New Molecular Scaffold for Targeting hRpn13 as a Treatment for Cancer. Ghosh, Malabika<br><a href="mailto:malabika.ghosh@nih.gov?subject=Web Inquiry on [TAB-4483] A New Molecular Scaffold for Targeting hRpn13 as a Treatment for Cancer&body=Please send me information about technology [TAB-4483] A New Molecular Scaffold for Targeting hRpn13 as a Treatment for Cancer.">malabika.ghosh@nih.gov</a><br> 157754219 E-056-2021-0 E-056-2021-0-US-01 A New Molecular Scaffold For Targeting HRpn13 PRV US 63/143,398 Abandoned US <br />Provisional (PRV) 63/143,398<br />Filed on 2021-01-29<br />Status: Abandoned 157754225 E-056-2021-0 E-056-2021-0-PCT-02 A New Molecular Scaffold For Targeting HRpn13 PCT Patent Cooperation Treaty PCT/US2022/014199 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2022/014199<br />Filed on 2022-01-28<br />Status: Expired 157754233 E-056-2021-0 E-056-2021-0-CA-01 A New Molecular Scaffold For Targeting HRpn13 National Stage Canada 3209597 Abandoned Canada <br />National Stage 3209597<br />Filed on 2022-01-28<br />Status: Abandoned 157754241 E-056-2021-0 E-056-2021-0-AU-01 A New Molecular Scaffold For Targeting HRpn13 National Stage Australia 2022212029 Abandoned Australia <br />National Stage 2022212029<br />Filed on 2022-01-28<br />Status: Abandoned 157754246 E-056-2021-0 E-056-2021-0-CN-01 A New Molecular Scaffold For Targeting HRpn13 National Stage China 202280022424.0 Abandoned China <br />National Stage 202280022424.0<br />Filed on 2023-09-18<br />Status: Abandoned 157754251 E-056-2021-0 E-056-2021-0-US-02 A New Molecular Scaffold For Targeting HRpn13 National Stage US 18/262,941 Pending US <br />National Stage 18/262,941<br />Filed on 2023-07-26<br />Status: Pending 157754256 E-056-2021-0 E-056-2021-0-EP-01 A New Molecular Scaffold For Targeting HRpn13 National Stage European Patent 22704672.9 Pending European Patent <br />National Stage 22704672.9<br />Filed on 2022-01-28<br />Status: Pending 157754261 E-056-2021-0 E-056-2021-0-IL-01 A New Molecular Scaffold For Targeting HRpn13 National Stage Israel 304725 Abandoned Israel <br />National Stage 304725<br />Filed on 2023-07-25<br />Status: Abandoned TAB-5037 159557783 Immunotherapy for Treating HER2-Positive Breast Cancer NIAID Angela DeVico, Ethan Shevach <p><span style="font-size:11.0pt"><span style="line-height:107%"><span style="font-family:&quot;Calibri&quot;,sans-serif">This technology includes a novel immunotherapy approach designed to target HER2-positive breast cancer cells. It leverages a specific mechanism to enhance the immune system&#39;s ability to identify and destroy these cancer cells. The technology demonstrated significant potential in pre-clinical in vivo studies, suggesting it could improve treatment outcomes for patients with HER2-positive breast cancer</span></span></span></p> This immunotherapy offers a targeted approach that specifically addresses HER2-positive cancer cells, potentially reducing side effects compared to conventional treatments. Additionally, its mechanism enhances the immune response, which may lead to better efficacy in eliminating cancer cells. This technology could be applied in developing new treatment protocols for HER2-positive breast cancer, particularly for patients who have not responded well to existing therapies. It also holds potential as a combination therapy, enhancing the effectiveness of current treatment regimens. 2024-12-10 2024-12-10 2025-10-28 2024-12-10 False False True 37470483 Website Abstract 159557809 Shevach, Ethan National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Shevach, Ethan (NIAID) 1 159557821 DeVico, Angela National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID DeVico, Angela (NIAID) 2 159557809 Shevach, Ethan National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Shevach, Ethan (NIAID) 1 159557821 DeVico, Angela National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID DeVico, Angela (NIAID) 2 159557786 Generation Of Ikzf2 Floxed X Foxp3Cre Mice E-248-2017-0 Research Material NIAID 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-5037] Immunotherapy for Treating HER2-Positive Breast Cancer&body=Please send me information about technology [TAB-5037] Immunotherapy for Treating HER2-Positive Breast Cancer. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-5037] Immunotherapy for Treating HER2-Positive Breast Cancer&body=Please send me information about technology [TAB-5037] Immunotherapy for Treating HER2-Positive Breast Cancer.">yogikala.prabhu@nih.gov</a><br> TAB-5036 159553715 Targeted Gene Mutation Technology for Studying Specific Cell Functions in Mice NIAID Angela DeVico, Ethan Shevach <p><span style="font-size:11.0pt"><span style="line-height:107%"><span style="font-family:&quot;Calibri&quot;,sans-serif">This technology includes the development of transgenic mice with a targeted gene mutation that flanks exon 8 of the Ikzf2 (Helios) gene using loxP sites. These Ikzf2 fl/fl (floxed) mice allow researchers to selectively delete the Ikzf2 gene in specific tissues or cells by crossing them with mice that express Cre recombinase under tissue-specific promoters. This approach provides a powerful tool for studying the role of the Helios gene in specific cells, which can be particularly useful in immunological research</span></span></span></p> This technology allows for precise gene deletion in targeted tissues or cells, avoiding the complications of whole-organism gene knockout. It offers a significant advantage in studying cell-specific functions without systemic effects. The technology can be applied in the research of immunological functions, particularly in understanding the role of the Helios gene in immune cells. Additionally, it has potential applications in developing targeted therapies that require precise genetic modifications in specific cell types. 2024-12-10 2024-12-10 2025-10-28 2024-12-10 False False True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 159553849 Shevach, Ethan National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Shevach, Ethan (NIAID) 1 159553923 DeVico, Angela National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID DeVico, Angela (NIAID) 2 159553849 Shevach, Ethan National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Shevach, Ethan (NIAID) 1 159553923 DeVico, Angela National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID DeVico, Angela (NIAID) 2 159553718 Generation Of Ikzf2 Floxed Mice E-241-2017-0 Research Material NIAID 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-5036] Targeted Gene Mutation Technology for Studying Specific Cell Functions in Mice&body=Please send me information about technology [TAB-5036] Targeted Gene Mutation Technology for Studying Specific Cell Functions in Mice. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-5036] Targeted Gene Mutation Technology for Studying Specific Cell Functions in Mice&body=Please send me information about technology [TAB-5036] Targeted Gene Mutation Technology for Studying Specific Cell Functions in Mice.">yogikala.prabhu@nih.gov</a><br> TAB-4928 153551276 A Key Advancement for Human Norovirus Research and Reverse Genetics NIAID Collaboration, Human Cell Lines, Infectious Disease, Licensing, Rare/Neglected Diseases, Therapeutics, Vaccines Collaboration Human Cell Lines Infectious Disease Licensing Rare/Neglected Diseases Therapeutics Vaccines Carlos Sandoval-Jaime, Stanislav Sosnovtsev <p>The HEK293T/T7 cell line is a novel development in virology research, particularly for studying human noroviruses. This cell line expresses the T7 RNA polymerase, a key enzyme used in reverse genetics systems. Unlike existing technologies, the HEK293T/T7 cell line offers the unique advantage of being able to produce functional T7 RNA polymerase, which is essential for driving transcription from T7 promoters. This capability opens up new possibilities for studying human noroviruses, which cannot be propagated in cell culture, and may facilitate the development of a reverse genetics system for these viruses. Overall, the HEK293T/T7 cell line represents a significant advancement in virology research and offers a valuable tool for researchers studying virus-host interactions and developing therapeutics or vaccines.</p> The HEK293T/T7 cell line offers several competitive advantages over existing technologies. Firstly, it is the first stable HEK293T cell line expressing T7 polymerase, filling a gap in available tools for researchers. This novel cell line provides a platform for developing reverse genetics systems for viruses, such as human noroviruses, which cannot be propagated in conventional cell culture. Secondly, the expression of functional T7 RNA polymerase in HEK293T cells has been confirmed, demonstrating its utility in driving transcription from T7 promoters. This feature is crucial for studying virus-host interactions and developing therapeutics or vaccines against viruses. Lastly, the compatibility of HEK293T cells with existing methodologies for recombinant protein expression enhances the versatility and usability of the HEK293T/T7 cell line in various research applications. Overall, these competitive advantages position the HEK293T/T7 cell line as a valuable and innovative tool for virology research. The HEK293T/T7 cell line has a wide range of potential applications in virology research and beyond. One key application is in the study of human noroviruses, where the cell line can facilitate the development of reverse genetics systems. This could lead to a better understanding of norovirus-host interactions and the development of novel therapeutics or vaccines. Additionally, the HEK293T/T7 cell line could be used in other virus research, where the T7 polymerase-driven transcription system is beneficial, such as in studying other viruses that are difficult to propagate in cell culture. Beyond virology, the HEK293T/T7 cell line's compatibility with existing methodologies for recombinant protein expression opens up possibilities for use in protein production and other biotechnology applications. Overall, the HEK293T/T7 cell line has the potential to significantly advance research in virology and related fields. 2024-03-04 2024-12-10 2025-10-27 2024-12-10 False True True 52406768 Discovery 52406768 37470483 Website Abstract 153551392 Sandoval-Jaime, Carlos National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Sandoval-Jaime, Carlos (NIAID) 1 153551414 Sosnovtsev, Stanislav NIAID - DIR NIAID Sosnovtsev, Stanislav (NIAID) 2 153551392 Sandoval-Jaime, Carlos National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Sandoval-Jaime, Carlos (NIAID) 1 153551414 Sosnovtsev, Stanislav NIAID - DIR NIAID Sosnovtsev, Stanislav (NIAID) 2 153551279 Human Embryonic Kidney Cell Line (designated HEK293T/T7 Constitutively Expressing The Phage T7 RNA Polymerase E-122-2013-0 Research Material NIAID 83643855 Soukas, Peter peter.soukas@nih.gov
United States of America Technology Transfer and Intellectual Property Office peter.soukas@nih.gov?subject=Web Inquiry on [TAB-4928] A Key Advancement for Human Norovirus Research and Reverse Genetics&body=Please send me information about technology [TAB-4928] A Key Advancement for Human Norovirus Research and Reverse Genetics. Soukas, Peter<br><a href="mailto:peter.soukas@nih.gov?subject=Web Inquiry on [TAB-4928] A Key Advancement for Human Norovirus Research and Reverse Genetics&body=Please send me information about technology [TAB-4928] A Key Advancement for Human Norovirus Research and Reverse Genetics.">peter.soukas@nih.gov</a><br> TAB-4591 151763432 Functions and Targets of Therapeutic MicroRNAs to Treat and Diagnose Cancer NIDCD Oncology, Research Materials, Therapeutics Oncology Research Materials Therapeutics Zhong Chen, Hui Cheng, Anthony Saleh, Carter Van Waes <p>This technology includes a method to identify potentially therapeutic microRNAs in cancer, particularly squamous cell carcinoma of the head and neck (HNSCC). This approach first utilizes a large and publicly available expression dataset, which is then validated by a smaller independent dataset to determine deregulated microRNAs expression. These results are then intersected with in vitro functional anti-proliferative screening data to select for microRNAs that play a functional tumor suppressive role and likely serve as therapeutic targets. Utilizing the recently published data from 279 tumor specimens, this analysis strategy identified 9 potentially therapeutic microRNAs, four of which were members of the miR-30-5p family. To further validate its role in tumor suppression, several classical oncogenes centering on Receptor tyrosine kinase (RTK) signaling as novel targets of miR-30 and display regulation both in vitro and in vivo were identified. Finally, its validity as a therapeutic target is supported by showing strong tumor growth delay for a synthetic miR-30a-5p mimic in a xenograft tumor model of HNSCC.</p> The greatest advantage of such a therapeutic would be the ability to target and repress multiple driving oncogenic pathways simultaneously, reducing the chances of resistance. Agents to be used in the treatment of cancer, either alone or in combination with chemotherapy/radiation, in addition to a companion diagnostic test. 2023-12-12 2024-08-12 2025-10-22 2024-03-27 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 151763442 Van Waes, Carter National Institute on Deafness and Other Communication Disorders (NIDCD) NIDCD Van Waes, Carter (NIDCD) 1 151763449 Saleh, Anthony miRecule, Inc. NIDCD Saleh, Anthony (NIDCD) 2 151763453 Cheng, Hui National Institute on Deafness and Other Communication Disorders (NIDCD) NIDCD Cheng, Hui (NIDCD) 3 151763457 Chen, Zhong National Institute on Deafness and Other Communication Disorders (NIDCD) NIDCD Chen, Zhong (NIDCD) 4 151763442 Van Waes, Carter National Institute on Deafness and Other Communication Disorders (NIDCD) NIDCD Van Waes, Carter (NIDCD) 1 151763449 Saleh, Anthony miRecule, Inc. NIDCD Saleh, Anthony (NIDCD) 2 151763453 Cheng, Hui National Institute on Deafness and Other Communication Disorders (NIDCD) NIDCD Cheng, Hui (NIDCD) 3 151763457 Chen, Zhong National Institute on Deafness and Other Communication Disorders (NIDCD) NIDCD Chen, Zhong (NIDCD) 4 151763435 Functions And Targets Of Therapeutic MicroRNAs To Treat Cancer E-043-2016-0 Filing authorized National Institute on Deafness and Other Communication Disorders (NIDCD) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-4591] Functions and Targets of Therapeutic MicroRNAs to Treat and Diagnose Cancer&body=Please send me information about technology [TAB-4591] Functions and Targets of Therapeutic MicroRNAs to Treat and Diagnose Cancer. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-4591] Functions and Targets of Therapeutic MicroRNAs to Treat and Diagnose Cancer&body=Please send me information about technology [TAB-4591] Functions and Targets of Therapeutic MicroRNAs to Treat and Diagnose Cancer.">shmilovm@nih.gov</a><br> 157762820 E-043-2016-0 E-043-2016-0-US-01 MICRORNAS AND METHODS OF THEIR USE PRV US 62/304,844 Abandoned US <br />Provisional (PRV) 62/304,844<br />Filed on 2016-03-07<br />Status: Abandoned 157762825 E-043-2016-0 E-043-2016-0-PCT-02 MICRORNAS AND METHODS OF THEIR USE PCT Patent Cooperation Treaty PCT/US2017/021178 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2017/021178<br />Filed on 2017-03-07<br />Status: Expired 157762830 E-043-2016-0 E-043-2016-0-CN-03 MICRORNAS AND METHODS OF THEIR USE National Stage China ZL201780027750.X 201780027750.X Issued China <br />National Stage 201780027750.X<br />Filed on 2017-03-07<br />Status: Issued 157762835 E-043-2016-0 E-043-2016-0-EP-04 MICRORNAS AND METHODS OF THEIR USE National Stage European Patent 3426781 17712348.6 Issued European Patent <br />National Stage 17712348.6<br />Filed on 2018-10-05<br />Status: Issued 157762840 E-043-2016-0 E-043-2016-0-IN-05 MICRORNAS AND METHODS OF THEIR USE National Stage India 201817037296 Abandoned India <br />National Stage 201817037296<br />Filed on 2018-10-03<br />Status: Abandoned 157762845 E-043-2016-0 E-043-2016-0-JP-06 MICRORNAS AND METHODS OF THEIR USE National Stage Japan 2018-547943 Pending Japan <br />National Stage 2018-547943<br />Filed on 2017-03-07<br />Status: Pending 157762850 E-043-2016-0 E-043-2016-0-US-07 MICRORNAS AND METHODS OF THEIR USE National Stage US 11,655,469 16/082,852 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11655469 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11655469">11,655,469</a><br />Filed on 2018-09-06<br />Status: Issued 157762855 E-043-2016-0 E-043-2016-0-US-02 MICRORNAS AND METHODS OF THEIR USE DIV US 18/301,040 Abandoned US <br />Divisional (DIV) 18/301,040<br />Filed on 2023-04-14<br />Status: Abandoned 157762860 E-043-2016-0 E-043-2016-0-EP-01 MICRORNAS AND METHODS OF THEIR USE DIV European Patent Administratively Closed European Patent <br />Divisional (DIV) None<br />Filed on None<br />Status: Administratively Closed 157762865 E-043-2016-0 E-043-2016-0-CN-08 MICRORNAS AND METHODS OF THEIR USE DIV China 202410174429.6 Abandoned China <br />Divisional (DIV) 202410174429.6<br />Filed on 2024-02-07<br />Status: Abandoned 157762870 E-043-2016-0 E-043-2016-0-CN-09 MICRORNAS AND METHODS OF THEIR USE DIV China 202410174426.2 Abandoned China <br />Divisional (DIV) 202410174426.2<br />Filed on 2024-02-07<br />Status: Abandoned 157762875 E-043-2016-0 E-043-2016-0-ES-01 MICRORNAS AND METHODS OF THEIR USE EP Spain 3426781 17712348.6 Issued Spain <br />European patent (EP) 17712348.6<br />Filed on 2018-10-05<br />Status: Issued 157762880 E-043-2016-0 E-043-2016-0-FR-01 MICRORNAS AND METHODS OF THEIR USE EP France 3426781 17712348.6 Issued France <br />European patent (EP) 17712348.6<br />Filed on 2018-10-05<br />Status: Issued 157762885 E-043-2016-0 E-043-2016-0-IT-01 MICRORNAS AND METHODS OF THEIR USE EP Italy 3426781 17712348.6 Issued Italy <br />European patent (EP) 17712348.6<br />Filed on 2018-10-05<br />Status: Issued 157762890 E-043-2016-0 E-043-2016-0-DE-01 MICRORNAS AND METHODS OF THEIR USE EP Germany 3426781 17712348.6 Issued Germany <br />European patent (EP) 17712348.6<br />Filed on 2018-10-05<br />Status: Issued 157762895 E-043-2016-0 E-043-2016-0-DK-01 MICRORNAS AND METHODS OF THEIR USE EP Denmark 3426781 17712348.6 Issued Denmark <br />European patent (EP) 17712348.6<br />Filed on 2018-10-05<br />Status: Issued 157762900 E-043-2016-0 E-043-2016-0-BE-01 MICRORNAS AND METHODS OF THEIR USE EP Belgium 3426781 17712348.6 Issued Belgium <br />European patent (EP) 17712348.6<br />Filed on 2018-10-05<br />Status: Issued 157762905 E-043-2016-0 E-043-2016-0-GB-01 MICRORNAS AND METHODS OF THEIR USE EP United Kingdom 3426781 17712348.6 Issued United Kingdom <br />European patent (EP) 17712348.6<br />Filed on 2018-10-05<br />Status: Issued 157762910 E-043-2016-0 E-043-2016-0-IE-01 MICRORNAS AND METHODS OF THEIR USE EP Ireland 3426781 17712348.6 Issued Ireland <br />European patent (EP) 17712348.6<br />Filed on 2018-10-05<br />Status: Issued 157762915 E-043-2016-0 E-043-2016-0-SE-01 MICRORNAS AND METHODS OF THEIR USE EP Sweden 3426781 17712348.6 Issued Sweden <br />European patent (EP) 17712348.6<br />Filed on 2018-10-05<br />Status: Issued 157762920 E-043-2016-0 E-043-2016-0-NO-01 MICRORNAS AND METHODS OF THEIR USE EP Norway 3426781 17712348.6 Issued Norway <br />European patent (EP) 17712348.6<br />Filed on 2018-10-05<br />Status: Issued 157762925 E-043-2016-0 E-043-2016-0-NL-01 MICRORNAS AND METHODS OF THEIR USE EP The Netherlands 3426781 17712348.6 Issued The Netherlands <br />European patent (EP) 17712348.6<br />Filed on 2018-10-05<br />Status: Issued TAB-4548 151737163 Antibody Targeting of Cell Surface Deposited Complement Protein C3d as a Treatment for Cancer NHLBI Antibodies, Licensing, Oncology, Therapeutics Antibodies Licensing Oncology Therapeutics Margaret Lindorfer, Christoph Rader, Martin Skarzynski, Ronald Taylor, Berengere Vire, Adrian Wiestner <p>This technology includes monoclonal antibodies (mAb) that specifically and with high affinity bind the final complement components C3dg and C3d (subsequently referred to as C3d), which can be used to kill tumor cells that carry C3d on their cell surface. We show that tumor cells of patients treated with the therapeutic anti-CD20 mAb ofatumumab carry C3d on the cell surface and can bind and be killed by addition of anti-C3 mAbs. In contrast, further addition of more ofatumumab has only minimal effects. This invention is a novel therapeutic concept to enhance the efficacy of therapeutic antibodies and the specific mAbs to achieve this goal. In a &quot;one-two punch&quot; approach, administration of a first tumor antigen-specific mAb that kills some but not all tumor cells is followed by an anti-C3d mAb that targets the C3d deposited on the tumor cells.</p> Novel therapeutic method and approach, which can enhance mAb-dependent tumor cell kill in an additive or even synergistic way. Therapy for multiple forms of cancer. We are seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. 2023-12-11 2024-08-12 2025-10-20 2024-03-20 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 151737171 Skarzynski, Martin National Heart, Lung, and Blood Institute (NHLBI) NHLBI Skarzynski, Martin (NHLBI) 1 151737179 Wiestner, Adrian National Heart, Lung, and Blood Institute (NHLBI) NHLBI Wiestner, Adrian (NHLBI) 2 151737183 Lindorfer, Margaret University of Virginia School of Medicine Lindorfer, Margaret 3 151737191 Taylor, Ronald University of Colorado Taylor, Ronald 4 151737206 Rader, Christoph The Scripps Research Institute NCI Rader, Christoph (NCI) 5 151737210 Vire, Berengere National Heart, Lung, and Blood Institute (NHLBI) Vire, Berengere 6 151737171 Skarzynski, Martin National Heart, Lung, and Blood Institute (NHLBI) NHLBI Skarzynski, Martin (NHLBI) 1 151737179 Wiestner, Adrian National Heart, Lung, and Blood Institute (NHLBI) NHLBI Wiestner, Adrian (NHLBI) 2 151737183 Lindorfer, Margaret University of Virginia School of Medicine Lindorfer, Margaret 3 151737191 Taylor, Ronald University of Colorado Taylor, Ronald 4 151737206 Rader, Christoph The Scripps Research Institute NCI Rader, Christoph (NCI) 5 151737210 Vire, Berengere National Heart, Lung, and Blood Institute (NHLBI) Vire, Berengere 6 151737166 Antibody Targeting Of Cell Surface Deposited Complement Protein C3 E-758-2013-0 Filing authorized EraMiondi R&D, National Heart, Lung, and Blood Institute (NHLBI), NCI, University of Virginia School of Medicine 83739538 Choudhry, Vidita vidita.choudhry@nih.gov
United States of America Office of Technology Transfer and Development vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-4548] Antibody Targeting of Cell Surface Deposited Complement Protein C3d as a Treatment for Cancer&body=Please send me information about technology [TAB-4548] Antibody Targeting of Cell Surface Deposited Complement Protein C3d as a Treatment for Cancer. Choudhry, Vidita<br><a href="mailto:vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-4548] Antibody Targeting of Cell Surface Deposited Complement Protein C3d as a Treatment for Cancer&body=Please send me information about technology [TAB-4548] Antibody Targeting of Cell Surface Deposited Complement Protein C3d as a Treatment for Cancer.">vidita.choudhry@nih.gov</a><br> 157756613 E-758-2013-0 E-758-2013-0-US-01 Antibody Targeting Cell Surface Deposited Complement Protein C3d and Use Thereof PRV US 61/924,967 Abandoned US <br />Provisional (PRV) 61/924,967<br />Filed on 2014-01-08<br />Status: Abandoned TAB-4530 151720340 Enhancing Activity of Bispecific Antibodies in Combination with Ibrutinib for the Treatment of Cancer NHLBI Licensing, Oncology, Research Materials Licensing Oncology Research Materials Sivasubramanian Baskar, Christoph Rader, Adrian Wiestner <p>This technology includes the combination of a kinase inhibitor (specifically ibrutinib) with a bispecific antibody (specifically a CD19/CD3 bispecific antibody) to be used to treat cancer. CD19/CD3 bispecific antibodies (bsAbs) can be used to recruit endogenous T cells against CD19+ tumor cells via the formation of cytolytic synapses. lbrutinib, a BTK inhibitor, has been shown to normalize T cell dysfunction characteristic of CLL. We show that achieved significantly more killing of ibrutinib-treated CLL cells compared to treatment-naive CLL cells after 3 days of exposure (56.85% versus -3.29% mean specific-killing, p = 0.002), and after 7 days of exposure.</p> The invention describes a new form of immunotherapy: the combination of a kinase inhibitor (specifically ibrutinib) with a bispecific antibody (specifically a CD19/CD3 bispecific antibody) to recruit T cell attack on tumor cells. Our data provide evidence for a superior treatment response of the combined modality. Combination therapy of bispecific antibodies in malignancies in combination with kinase inhibitors. We are seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. 2023-12-08 2024-08-12 2025-10-20 2024-03-20 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 151720373 Wiestner, Adrian National Heart, Lung, and Blood Institute (NHLBI) NHLBI Wiestner, Adrian (NHLBI) 1 151720377 Baskar, Sivasubramanian National Heart, Lung, and Blood Institute (NHLBI) NHLBI Baskar, Sivasubramanian (NHLBI) 2 151720381 Rader, Christoph The Scripps Research Institute NCI Rader, Christoph (NCI) 3 151720373 Wiestner, Adrian National Heart, Lung, and Blood Institute (NHLBI) NHLBI Wiestner, Adrian (NHLBI) 1 151720377 Baskar, Sivasubramanian National Heart, Lung, and Blood Institute (NHLBI) NHLBI Baskar, Sivasubramanian (NHLBI) 2 151720381 Rader, Christoph The Scripps Research Institute NCI Rader, Christoph (NCI) 3 151720343 Enhancing Activity Of Bispecific Antibodies In Combination With Ibrutinib E-212-2017-0 Research Material National Heart, Lung, and Blood Institute (NHLBI), NCI, The Scripps Research Institute, Scripps Florida 83739538 Choudhry, Vidita vidita.choudhry@nih.gov
United States of America Office of Technology Transfer and Development vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-4530] Enhancing Activity of Bispecific Antibodies in Combination with Ibrutinib for the Treatment of Cancer&body=Please send me information about technology [TAB-4530] Enhancing Activity of Bispecific Antibodies in Combination with Ibrutinib for the Treatment of Cancer. Choudhry, Vidita<br><a href="mailto:vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-4530] Enhancing Activity of Bispecific Antibodies in Combination with Ibrutinib for the Treatment of Cancer&body=Please send me information about technology [TAB-4530] Enhancing Activity of Bispecific Antibodies in Combination with Ibrutinib for the Treatment of Cancer.">vidita.choudhry@nih.gov</a><br> TAB-4545 151736902 Transcatheter MRI-guided Implantable Cavopulmonary Bypass Endograft for the Treatment of Congenital Heart Disease NHLBI Cardiology, Licensing, Medical Devices, Research Equipment Cardiology Licensing Medical Devices Research Equipment Robert Lederman, Stuart MacDonald, Nasser Raffie, Kanishka Ratnayaka <p>This technology includes a catheter-delivered endograft designed to treat congenital heart disease without surgery. The specific surgical procedure averted is cavopulmonary bypass graft. The key innovations are features to effect distal end-to-side anastomosis and proximal end-to-end anastomosis without surgery. The system operates under X-ray and MRI guidance.</p> Transcatheter endografts have long been proposed and frequently have failed, however, this successful, simple transcatheter endograft anastomosis based on unique strut and flange design. This endograft is specifically designed for congenital heart disease and may have applications for other bypass graft alternatives such as portal, visceral, and peripheral vascular such as carotid-subclavian to support thoracic aortic endograft. We are seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. 2023-12-11 2025-08-13 2025-10-14 2024-03-20 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 151736909 MacDonald, Stuart Transmural Systems, LLC MacDonald, Stuart 1 151736914 Raffie, Nasser Mehr Medical Raffie, Nasser 2 151736918 Lederman, Robert National Heart, Lung, and Blood Institute (NHLBI) NHLBI Lederman, Robert (NHLBI) 3 151736922 Ratnayaka, Kanishka Rady Children's Hospital, San Diego Ratnayaka, Kanishka 4 151736909 MacDonald, Stuart Transmural Systems, LLC MacDonald, Stuart 1 151736914 Raffie, Nasser Mehr Medical Raffie, Nasser 2 151736918 Lederman, Robert National Heart, Lung, and Blood Institute (NHLBI) NHLBI Lederman, Robert (NHLBI) 3 151736922 Ratnayaka, Kanishka Rady Children's Hospital, San Diego Ratnayaka, Kanishka 4 151736905 Device, Prosthesis And Delivery Systems, Transcatheter MRI-guided Implantable Cavopulmonary Bypass Endograft E-287-2015-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI), Transmural Systems, LLC 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-4545] Transcatheter MRI-guided Implantable Cavopulmonary Bypass Endograft for the Treatment of Congenital Heart Disease&body=Please send me information about technology [TAB-4545] Transcatheter MRI-guided Implantable Cavopulmonary Bypass Endograft for the Treatment of Congenital Heart Disease. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-4545] Transcatheter MRI-guided Implantable Cavopulmonary Bypass Endograft for the Treatment of Congenital Heart Disease&body=Please send me information about technology [TAB-4545] Transcatheter MRI-guided Implantable Cavopulmonary Bypass Endograft for the Treatment of Congenital Heart Disease.">shmilovm@nih.gov</a><br> 157756522 E-287-2015-0 E-287-2015-0-US-01 Device, Prosthesis And Delivery Systems, Transcatheter MRI-guided Implantable Cavopulmonary Bypass Endograft PRV US 62/219,118 Abandoned US <br />Provisional (PRV) 62/219,118<br />Filed on 2015-09-15<br />Status: Abandoned 157756537 E-287-2015-0 E-287-2015-0-US-02 Devices And Methods For Effectuating Percutaneous Glenn And Fontan Procedures ORD US 10,426,482 15/267,075 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10426482 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10426482">10,426,482</a><br />Filed on 2016-09-15<br />Status: Issued 157756542 E-287-2015-0 E-287-2015-0-US-03 DEVICES AND METHODS FOR EFFECTUATING PERCUTANEOUS GLENN AND FONTAN PROCEDURES CON US 11,179,156 16/399,670 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11179156 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11179156">11,179,156</a><br />Filed on 2019-04-30<br />Status: Issued TAB-4489 151702933 Helical Guidewires and Related Systems for Transcatheter Heart Valve Procedures NHLBI Cardiology, Licensing, Medical Devices, Research Equipment Cardiology Licensing Medical Devices Research Equipment Robert Lederman, Nasser Raffie <p>This technology includes a guidewire purpose-built for delivery of bulky transcatheter heart valves (THV). Conventional THV guidewires are rigid and have a distal tip shaped like a pigtail to prevent apical ventricular perforation. This invention is a 3-dimensional helical or antihelical curve that can protect against apical perforation, possibly better, and that allows subtle 3-mensional deflection to aid the operator in achieving coaxiality or overcoming delivery obstacles such as calcific spicules.</p> This simple device modification can ease and speed delivery of transcatheter heart valves over conventional designs. Guidewire for use during transcatheter heart valve procedures. We are seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. 2023-12-07 2025-08-13 2025-10-14 2024-03-20 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 151702940 Raffie, Nasser Mehr Medical Raffie, Nasser 1 151702954 Lederman, Robert National Heart, Lung, and Blood Institute (NHLBI) NHLBI Lederman, Robert (NHLBI) 2 151702940 Raffie, Nasser Mehr Medical Raffie, Nasser 1 151702954 Lederman, Robert National Heart, Lung, and Blood Institute (NHLBI) NHLBI Lederman, Robert (NHLBI) 2 151702936 HELICAL GUIDEWIRES AND RELATED SYSTEMS E-078-2019-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI), Transmural Systems, LLC 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-4489] Helical Guidewires and Related Systems for Transcatheter Heart Valve Procedures&body=Please send me information about technology [TAB-4489] Helical Guidewires and Related Systems for Transcatheter Heart Valve Procedures. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-4489] Helical Guidewires and Related Systems for Transcatheter Heart Valve Procedures&body=Please send me information about technology [TAB-4489] Helical Guidewires and Related Systems for Transcatheter Heart Valve Procedures.">shmilovm@nih.gov</a><br> 157754455 E-078-2019-0 E-078-2019-0-US-01 HELICAL GUIDEWIRES AND RELATED SYSTEMS PRV US 62/651,692 Abandoned US <br />Provisional (PRV) 62/651,692<br />Filed on 2018-04-02<br />Status: Abandoned 157754460 E-078-2019-0 E-078-2019-0-PCT-02 HELICAL GUIDEWIRES AND RELATED SYSTEMS PCT Patent Cooperation Treaty PCT/US2019/025383 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2019/025383<br />Filed on 2019-04-02<br />Status: Expired 157754465 E-078-2019-0 E-078-2019-0-US-03 HELICAL GUIDEWIRES AND RELATED SYSTEMS ORD US 17/038,095 Abandoned US <br />Ordinary Patent (ORD) 17/038,095<br />Filed on 2020-09-30<br />Status: Abandoned TAB-5087 164409186 Acyloxyacyl Hydrolase (AOAH) and Methods of Use NCI Collaboration, Immunology, Licensing, Oncology, Therapeutics Collaboration Immunology Licensing Oncology Therapeutics Lanqi Gong, Peng Jiang <h2>Summary:</h2> <p>The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for the development of AOAH as a cancer immunotherapy.</p> <h2>Description of Technology:</h2> <p>Immune CheckPoint Inhibitors (ICIs) and T-cell based therapies are part of the emerging immunology-based therapies being used to treat cancers.&nbsp; However, the efficacy of ICI therapies can be limited and a substantial portion of patients develop resistance or tolerance to treatment.&nbsp; T-cell based cancer immunotherapies have only been approved for hematological cancers. They are suboptimal in solid tumor cancers due to physical barriers and the immuno-suppressive tumor microenvironment.&nbsp; Thus, additional therapies and strategies are needed to improve efficacy and expand the types of cancer amendable to treatment.</p> <p>Scientists at the National Cancer Institute have identified a secreted lipase, Acyloxyacyl Hydrolase (AOAH), produced by cells such as macrophages and dendritic cells that can potentiate immunotherapies in murine tumor models.&nbsp; The protein sensitizes T cell receptors to weak antigens and protects dendritic cells through depleting immunosuppressive arachidonyl phoshatidylcholines and oxidized derivatives.&nbsp; Thus, the protein can potentially enhance the efficacy and types of cancers treated by ICI based and T-cell based immunotherapies.</p> <p>The National Cancer Institute is seeking collaborators and/or licensees to develop this technology as a cancer immunotherapy.</p> <h2>Potential Commercial Applications:&nbsp; &nbsp;</h2> <ul> <li>Cancer immunotherapy</li> <li>Combination therapy with ICIs or T-cell based therapies</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Novel therapeutic entity</li> <li>Potentially improved efficacy</li> <li>Increased types of addressable cancers</li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for the development of AOAH as an immunotherapy for cancer treatment. 2025-09-30 2025-09-30 2025-09-30 2025-09-30 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 164409372 Gong L et al. Cancer Immunology Data Engine Reveals Secreted AOAH as a Potential Immunotherapy. (PMID 40730154) https://pubmed.ncbi.nlm.nih.gov/40730154/ <a href="https://pubmed.ncbi.nlm.nih.gov/40730154/">Gong L et al. Cancer Immunology Data Engine Reveals Secreted AOAH as a Potential Immunotherapy. (PMID 40730154)</a> 164409292 Jiang, Peng NIH - NCI NCI Jiang, Peng (NCI) 1 164409296 Gong, Lanqi NIH - NCI NCI Gong, Lanqi (NCI) 2 164409292 Jiang, Peng NIH - NCI NCI Jiang, Peng (NCI) 1 164409296 Gong, Lanqi NIH - NCI NCI Gong, Lanqi (NCI) 2 164409189 Big data-driven discovery and development of AOAH as new immunotherapy E-038-2024-0 Filing authorized NIH - NCI 83691647 Chang, Kevin changke@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB changke@mail.nih.gov?subject=Web Inquiry on [TAB-5087] Acyloxyacyl Hydrolase (AOAH) and Methods of Use&body=Please send me information about technology [TAB-5087] Acyloxyacyl Hydrolase (AOAH) and Methods of Use.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Chang, Kevin<br><a href="mailto:changke@mail.nih.gov?subject=Web Inquiry on [TAB-5087] Acyloxyacyl Hydrolase (AOAH) and Methods of Use&body=Please send me information about technology [TAB-5087] Acyloxyacyl Hydrolase (AOAH) and Methods of Use.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">changke@mail.nih.gov</a><br> 164409194 E-038-2024-0 E-038-2024-0-US-01 ACYLOXYACYL HYDROLASE AND METHODS OF USE PRV US 63/717,036 Expired US <br />Provisional (PRV) 63/717,036<br />Filed on 2024-11-06<br />Status: Expired 164409195 E-038-2024-0 E-038-2024-0-PC-01 ACYLOXYACYL HYDROLASE AND METHODS OF USE PCT Patent Cooperation Treaty PCT/US2025/053940 Pending Patent Cooperation Treaty <br />(PCT) PCT/US2025/053940<br />Filed on 2025-11-04<br />Status: Pending TAB-5086 164407714 Photoactivatable Dye Compounds For Conjugate Formation And Methods of Making And Using the Same NCI Licensing, Oncology, Therapeutics Licensing Oncology Therapeutics Peter Choyke, Daiki Hara, Hisataka Kobayashi, Hideo Takakura <h2>Summary:</h2> <p>The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a new series of photo-absorbing silicon-phthalocyanine derivatives (IR702HKT) for use in near-infrared photoimmunotherapy (NIR-PIT) in the treatment of cancer.</p> <h2>Description of Technology:</h2> <p>Near-infrared photoimmunotherapy (NIR-PIT) is a method of treating cancers that utilizes an antibody-photoabsorber conjugate (APC), which is activated by near-infrared light to kill cells. The antibody binds to the appropriate cell surface antigen and a photo-activatable compound induces lethal damage to the cell membrane after NIR-light exposure. NIR-light exposure induces highly selective, necrotic cancer cell death within minutes without damage to adjoining cells.</p> <p>Researchers at the National Cancer Institute (NCI) and Kansai Medical University (KMU) have developed the current invention which is a new series of photo-absorbing silicon-phthalocyanine derivatives (IR702HKT) as alternatives to the current IRDye700DX. This series of IR702HKTs have modified linkers that improve the efficacy of cellular cytotoxicity of IR702HKT bound to target cancer cells. Additionally, appropriate modifications improved in vivo stability of these new APCs and required less energetic therapeutic light exposure, which should improve clinical therapeutic efficacy and safety of NIR-PIT.</p> <p>The inventors are open to co-development partners and/or licensing opportunities.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Cancer treatment</li> <li>Cancer diagnosis</li> <li>Cancer imaging</li> <li>Treatment against viral, fungus, parasite, or bacterial infection</li> <li>Age-related macular degeneration and lymphangioma, via depletion of abnormal vessels</li> <li>Improved metabolic and physical function, via targeting of senile senescent cells</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Improved in vivo stability</li> <li>Improved cytotoxicity against APC-bound target cells by the same light exposure</li> <li>Reduced therapeutic light exposure clinical therapeutic efficacy and safety, compared to current photo-absorbing silicon-phthalocyanine derivatives</li> <li>Improved synthesis yields</li> </ul> Researchers at the NCI seek licensing for a new series of photo-absorbing silicon-phthalocyanine derivatives (IR702HKT) as alternatives to the current IRDye700DX. 2025-09-30 2025-09-30 2025-09-30 2025-09-30 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-137-2024-1 164407776 Choyke, Peter NIH - NCI NCI Choyke, Peter (NCI) 1 164407780 Kobayashi, Hisataka NIH - NCI NCI Kobayashi, Hisataka (NCI) 2 164407791 Takakura, Hideo Kansai Medical University Takakura, Hideo 3 164407795 Hara, Daiki Kansai Medical University Hara, Daiki 4 164407776 Choyke, Peter NIH - NCI NCI Choyke, Peter (NCI) 1 164407780 Kobayashi, Hisataka NIH - NCI NCI Kobayashi, Hisataka (NCI) 2 164407791 Takakura, Hideo Kansai Medical University Takakura, Hideo 3 164407795 Hara, Daiki Kansai Medical University Hara, Daiki 4 164407717 Photoabsorbing Dyes (IR702HKTs) for Near Infrared PhotoImmuno Therapy (NIR-PIT) E-137-2024-0 Filing authorized Kansai Medical University, Molecular Imaging Branch 83736770 Cheng, Eric eric.cheng2@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB eric.cheng2@nih.gov?subject=Web Inquiry on [TAB-5086] Photoactivatable Dye Compounds For Conjugate Formation And Methods of Making And Using the Same&body=Please send me information about technology [TAB-5086] Photoactivatable Dye Compounds For Conjugate Formation And Methods of Making And Using the Same.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Cheng, Eric<br><a href="mailto:eric.cheng2@nih.gov?subject=Web Inquiry on [TAB-5086] Photoactivatable Dye Compounds For Conjugate Formation And Methods of Making And Using the Same&body=Please send me information about technology [TAB-5086] Photoactivatable Dye Compounds For Conjugate Formation And Methods of Making And Using the Same.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">eric.cheng2@nih.gov</a><br> 164407722 E-137-2024-0 E-137-2024-0-US-01 PHOTOACTIVATABLE DYE COMPOUNDS FOR CONJUGATE FORMATION AND METHODS OF MAKING AND USING THE SAME PRV US 63/690,585 Expired US <br />Provisional (PRV) 63/690,585<br />Filed on 2024-09-04<br />Status: Expired 164407723 E-137-2024-0 E-137-2024-0-PC-01 PHOTOACTIVATABLE DYE COMPOUNDS FOR CONJUGATE FORMATION AND METHODS OF MAKING AND USING THE SAME PCT Patent Cooperation Treaty PCT/US2025/044361 Pending Patent Cooperation Treaty <br />(PCT) PCT/US2025/044361<br />Filed on 2025-09-03<br />Status: Pending TAB-5082 164393007 Novel Human Immunogenic Epitopes of the Human Endogenous Retrovirus ERVMER34-1 NCI Collaboration, Immunology, Licensing, Oncology, Vaccines Collaboration Immunology Licensing Oncology Vaccines Renee Donahue, Duane Hamilton, Claudia Palena, Jeffrey Schlom <h2>Summary:</h2> <p>The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for the clinical translation of novel peptide-based therapeutic cancer vaccines derived from ERVMER34-1, a human endogenous retrovirus (HERV) antigen, offering a unique opportunity to address a significant unmet need in the treatment of various carcinomas.</p> <h2>Description of Technology:</h2> <p>Human Endogenous Retroviruses (HERVs), remnants of ancient retroviral germline infections that comprise ~8% of the human genome, represent a promising yet underexplored frontier in targeted cancer therapy. Although typically epigenetically silenced in normal adult tissues, select HERV components, including RNAs and envelope proteins, are frequently overexpressed in various carcinomas due to epigenetic dysregulation &ndash; a hallmark of cancer. The challenge lies in identifying specific, highly immunogenic HERV targets that elicit potent anti-tumor immune responses without triggering autoimmunity. Addressing this need is critical to advancing broadly applicable cancer immunotherapies.</p> <p>Inventors at the NCI have developed and characterized a novel cancer immunotherapy platform targeting ERVMER34-1, a specific HERV envelope protein that is highly expressed across multiple human carcinomas while exhibiting minimal expression in normal tissues. Using transcriptomic and proteomic datasets, the team confirmed the tumor-selective expression profile of ERVMER34-1. To improve safety and specificity, they engineered an artificial antigen-presenting cell line to express the full-length ERVMER34-1 protein, HLA-A2 and CD80 to facilitate efficient priming and expansion of ERVMER34-1-reactive CD8+ T cells. To therapeutically target ERVMER34-1, they modified the ERVMER34-1 protein by removing the signal peptide, cleavage site, predicted immunosuppressive domain, transmembrane domain and a 170-amino acid region homologous to human proteins. These modifications prevent surface trafficking, antigen shedding, immune dampening, and off-target reactivity. This modified sequence was incorporated into a recombinant adenoviral vector as a therapeutic cancer vaccine. In preclinical murine models (e.g., MC38 colon cancer, EMT6 breast cancer), vaccination with this construct alone or in combination with immune checkpoint blockade or an IL-15 superagonist elicited robust, multifunctional CD4⁺ and CD8⁺ T cell responses. Those enhanced T cell responses induced tumor clearance, increased intratumoral lymphocyte infiltration, broadened neoantigen spreading and prolonged tumor control. ERVMER34-1-reactive T cells could be expanded from both healthy donor and cancer patient Peripheral Blood Mononuclear Cells (PBMCs) and demonstrated specific cytolytic activity against ERVMER34-1⁺ human carcinoma cell lines in vitro. To support peptide-based approaches, researchers developed an overlapping 15-mer peptide library spanning the modified ERVMER34-1 protein sequence. These peptides elicited strong, polyfunctional T cell responses in vitro &ndash; including both CD4⁺ and HLA-A2-restricted CD8⁺ T cell activation, enabling precise epitope mapping and facilitating future peptide vaccine design and adoptive T cell receptor (TCR)-based therapies.</p> <p>The NCI invites industry partners and translational researchers to collaborate on or license this pioneering HERV ERVMER34-1 protein targeted vaccine technology. With promising preclinical data, this technology addresses a critical gap in the cancer vaccine landscape. It offers a unique opportunity to advance a novel therapeutic targeting widespread carcinomas, opening a substantial market for cancer treatment.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Peptide-based therapeutic cancer vaccines</li> <li>Adenoviral vector-based therapeutic cancer vaccines</li> <li>Liposome- or nanoparticle-formulated therapeutic cancer vaccines</li> <li>Artificial Antigen-Presenting Cell platforms expressing ERVMER34-1 with HLA-A2 and CD80 to expand antigen-specific T cells for adoptive cell therapies</li> <li>Adoptive T cell therapies using ERVMER34-1-specific TCRs isolated from PBMCs or engineered T cells redirected against shared HERV antigens</li> <li>Combination immunotherapies pairing the ERVMER34-1 vaccine with checkpoint inhibitors and/or epigenetic modifiers to boost response breadth and tumor infiltration</li> <li>Cytokine or immuno-cytokine-enhanced combination regimens incorporating immune-oncology agents to amplify tumor-specific T cell activation</li> <li>Companion diagnostic tools to identify ERVMER34-1-expressing tumors for patient selection and treatment stratification</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Broad tumor coverage across ~62% of carcinomas</li> <li>Minimal expression in normal tissues reduces toxicity risk and expands market potential</li> <li>Engineered antigen design in vaccine eliminates immunosuppressive and off-target domains, improving safety and therapeutic precision</li> <li>Elicits potent, multifunctional T cell responses with cytokine production and broad epitope recognition, enhancing anti-tumor efficacy</li> <li>Selectively clears tumor cells based on ERVMER34-1 expression, enabling precise targeting across variable antigen levels</li> <li>Demonstrates remarkable synergistic efficacy with immune checkpoint inhibitors, achieving ~89% tumor clearance in established large tumors in mouse models</li> <li>Exhibits synergistic interaction with cytokine agonists such as N-803 (Anktiva), significantly enhancing neoepitope-reactive T cell responses and improving tumor control in combination therapies</li> <li>Potential for use in combination with epigenetic modulators to enhance expression of targeted antigen in human carcinomas</li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for the clinical translation of novel peptide-based therapeutic cancer vaccines derived from ERVMER34-1, a human endogenous retrovirus (HERV) antigen, offering a unique opportunity to address a significant unmet need in the treatment of various carcinomas. 2025-09-29 2025-09-29 2025-09-29 2025-09-29 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-056-2023 164393294 Maldonado MDM, et al. Combination of a therapeutic cancer vaccine targeting the endogenous retroviral envelope protein ERVMER34-1 with immune-oncology agents facilitates expansion of neoepitope-specific T cells and promotes tumor control (PMID: 40360436) https://pubmed.ncbi.nlm.nih.gov/40360436/ <a href="https://pubmed.ncbi.nlm.nih.gov/40360436/">Maldonado MDM, et al. Combination of a therapeutic cancer vaccine targeting the endogenous retroviral envelope protein ERVMER34-1 with immune-oncology agents facilitates expansion of neoepitope-specific T cells and promotes tumor control (PMID: 40360436)</a> 164393297 Gracia-Hernandez M, et al. Combination Therapy Approaches to Enhance the Efficacy of ERV-Targeting Vaccines in Cancer (PMID: 40387511) https://pubmed.ncbi.nlm.nih.gov/40387511/ <a href="https://pubmed.ncbi.nlm.nih.gov/40387511/">Gracia-Hernandez M, et al. Combination Therapy Approaches to Enhance the Efficacy of ERV-Targeting Vaccines in Cancer (PMID: 40387511)</a> 164393132 Schlom, Jeffrey NIH - NCI NCI Schlom, Jeffrey (NCI) 1 164393153 Hamilton, Duane NIH - NCI NCI Hamilton, Duane (NCI) 2 164393157 Palena, Claudia NIH - NCI NCI Palena, Claudia (NCI) 3 164393178 Donahue, Renee NIH - NCI NCI Donahue, Renee (NCI) 4 164393132 Schlom, Jeffrey NIH - NCI NCI Schlom, Jeffrey (NCI) 1 164393153 Hamilton, Duane NIH - NCI NCI Hamilton, Duane (NCI) 2 164393157 Palena, Claudia NIH - NCI NCI Palena, Claudia (NCI) 3 164393178 Donahue, Renee NIH - NCI NCI Donahue, Renee (NCI) 4 164393010 Identification Of Novel Human Immunogenic Epitopes Of HEMO And HHLA2 Human Endogenous Retroviruses (HERVs) E-159-2019-0 Filing authorized Chan Soon-Shiong Institute of Molecular Medicine at Windber, MDR Global Systems, LLC, NCI, NIH - NCI, Uniformed Services University of the Health Sciences 83687903 Pollack, Michael michael.pollack@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC michael.pollack@nih.gov?subject=Web Inquiry on [TAB-5082] Novel Human Immunogenic Epitopes of the Human Endogenous Retrovirus ERVMER34-1&body=Please send me information about technology [TAB-5082] Novel Human Immunogenic Epitopes of the Human Endogenous Retrovirus ERVMER34-1.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollack, Michael<br><a href="mailto:michael.pollack@nih.gov?subject=Web Inquiry on [TAB-5082] Novel Human Immunogenic Epitopes of the Human Endogenous Retrovirus ERVMER34-1&body=Please send me information about technology [TAB-5082] Novel Human Immunogenic Epitopes of the Human Endogenous Retrovirus ERVMER34-1.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">michael.pollack@nih.gov</a><br> 164393022 E-159-2019-0 E-159-2019-0-US-01 HUMAN IMMUNOGENIC EPITOPES OF HEMO AND HHLA2 HUMAN ENDOGENOUS RETROVIRUSES (HERVs) PRV US 62/963,872 Abandoned US <br />Provisional (PRV) 62/963,872<br />Filed on 2020-01-21<br />Status: Abandoned 164393023 E-159-2019-0 E-159-2019-0-PCT-02 HUMAN IMMUNOGENIC EPITOPES OF HEMO and HHLA2 HUMAN ENDOGENOUS RETROVIRUSES (HERVS) PCT Patent Cooperation Treaty PCT/US2021/014335 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/014335<br />Filed on 2021-01-21<br />Status: Expired 164393024 E-159-2019-0 E-159-2019-0-CA-03 HUMAN IMMUNOGENIC EPITOPES OF HEMO and HHLA2 HUMAN ENDOGENOUS RETROVIRUSES (HERVS) National Stage Canada 3165251 Pending Canada <br />National Stage 3165251<br />Filed on 2022-07-19<br />Status: Pending 164393025 E-159-2019-0 E-159-2019-0-AU-04 HUMAN IMMUNOGENIC EPITOPES OF HEMO and HHLA2 HUMAN ENDOGENOUS RETROVIRUSES (HERVS) National Stage Australia 2021210915 Pending Australia <br />National Stage 2021210915<br />Filed on 2022-08-18<br />Status: Pending 164393026 E-159-2019-0 E-159-2019-0-EP-05 HUMAN IMMUNOGENIC EPITOPES OF HEMO and HHLA2 HUMAN ENDOGENOUS RETROVIRUSES (HERVS) National Stage European Patent 21705769.4 Pending European Patent <br />National Stage 21705769.4<br />Filed on 2022-08-18<br />Status: Pending 164393027 E-159-2019-0 E-159-2019-0-US-06 HUMAN IMMUNOGENIC EPITOPES OF HEMO AND HHLA2 HUMAN ENDOGENOUS RETROVIRUSES (HERVS) National Stage US 17/793,753 Pending US <br />National Stage 17/793,753<br />Filed on 2022-07-19<br />Status: Pending 164393028 E-159-2019-0 E-159-2019-0-HK-07 HUMAN IMMUNOGENIC EPITOPES OF HEMO and HHLA2 HUMAN ENDOGENOUS RETROVIRUSES (HERVS) EP Hong Kong 62023070659.5 Pending Hong Kong <br />European patent (EP) 62023070659.5<br />Filed on 2023-03-27<br />Status: Pending TAB-5081 164388769 Generating Conditional and Reverse Conditional Loss-of-Function Alleles in Mouse Casq2 NICHD Licensing, Rare/Neglected Diseases, Research Materials Licensing Rare/Neglected Diseases Research Materials Bjorn Knollmann, Karl Pfeifer <h2>Summary:</h2> <p>&nbsp;The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) is seeking potential licensees interested in further developing or utilizing these Casq2 mouse strains. As a research tool, patent protection is not being pursued for this technology. More information to access these strains can be found here: https://www.jax.org/strain/036291 and https://www.jax.org/strain/036290.</p> <h2>Description of Technology:</h2> <p>Cardiac calsequestrin (Casq2) plays an essential role in maintaining cardiac Ca2+ homeostasis. Human CASQ2 mutations are associated with catecholaminergic polymorphic ventricular tachycardia (CPVT), a rare familial arrhythmogenic disorder within a group of diseases characterized as Sudden Arrhythmic Death.</p> <p>The inventors have generated Casq2Flox and Casq2RevFlox mouse strains that model CPVT. The two novel strains successfully phenocopy aspects of CPVT, including stress-induced arrhythmias and reduced basal heart rates. The strains allow investigators to determine the importance of Casq2 gene function in specific tissues and at specific developmental time points. They also allow investigators to determine the efficacy of gene therapy and to address key mechanism questions. The materials are validated and fully functional.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Study of Casq2 function</li> <li>Study of calcium storage in cardiac muscle and CPVT</li> <li>Determining the efficacy of gene therapy for CPVT</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Only available conditional and reverse conditional loss-of-function alleles in mouse Casq2</li> <li>Allows the study of Casq2 gene function in specific tissues and at specific developmental points</li> </ul> NICHD seeks licensing for further developing or utilizing these Casq2 mouse strains. 2025-09-29 2025-09-29 2025-09-29 2025-09-29 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52406768 Discovery 52406768 NCI 37470483 Website Abstract 164390469 Knollmann BC, et al. Casq2 deletion causes sarcoplasmic reticulum volume increase, premature Ca2+ release, and catecholaminergic polymorphic ventricular tachycardia. (PMID 16932808) https://pubmed.ncbi.nlm.nih.gov/16932808/ <a href="https://pubmed.ncbi.nlm.nih.gov/16932808/">Knollmann BC, et al. Casq2 deletion causes sarcoplasmic reticulum volume increase, premature Ca2+ release, and catecholaminergic polymorphic ventricular tachycardia. (PMID 16932808)</a> 164390478 Flores DJ, et al. Conditional ablation and conditional rescue models for Casq2 elucidate the role of development and of cell-type specific expression of Casq2 in the CPVT2 phenotype. (PMID 29452352) https://pubmed.ncbi.nlm.nih.gov/29452352/ <a href="https://pubmed.ncbi.nlm.nih.gov/29452352/">Flores DJ, et al. Conditional ablation and conditional rescue models for Casq2 elucidate the role of development and of cell-type specific expression of Casq2 in the CPVT2 phenotype. (PMID 29452352)</a> 164390525 Blackwell DJ, et al. The Purkinje–myocardial junction is the anatomic origin of ventricular arrhythmia in CPVT. (PMID 34990403) https://pubmed.ncbi.nlm.nih.gov/34990403/ <a href="https://pubmed.ncbi.nlm.nih.gov/34990403/">Blackwell DJ, et al. The Purkinje–myocardial junction is the anatomic origin of ventricular arrhythmia in CPVT. (PMID 34990403)</a> 164388829 Pfeifer, Karl NICHD NICHD Pfeifer, Karl (NICHD) 1 164388840 Knollmann, Bjorn Vanderbilt University Knollmann, Bjorn 2 164388829 Pfeifer, Karl NICHD NICHD Pfeifer, Karl (NICHD) 1 164388840 Knollmann, Bjorn Vanderbilt University Knollmann, Bjorn 2 164388772 Generating conditional and reverse conditional loss-of-function alleles in mouse Casq2 E-128-2024-0 Research Material NIH - NICHD, Vanderbilt University 83746064 Whitman, Nathan nathan.whitman@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC nathan.whitman@nih.gov?subject=Web Inquiry on [TAB-5081] Generating Conditional and Reverse Conditional Loss-of-Function Alleles in Mouse Casq2&body=Please send me information about technology [TAB-5081] Generating Conditional and Reverse Conditional Loss-of-Function Alleles in Mouse Casq2.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Whitman, Nathan<br><a href="mailto:nathan.whitman@nih.gov?subject=Web Inquiry on [TAB-5081] Generating Conditional and Reverse Conditional Loss-of-Function Alleles in Mouse Casq2&body=Please send me information about technology [TAB-5081] Generating Conditional and Reverse Conditional Loss-of-Function Alleles in Mouse Casq2.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">nathan.whitman@nih.gov</a><br> TAB-3345 114097260 Antibodies and Methods for the Diagnosis and Treatment of Epstein-Barr Virus Infection NIAID Collaboration Collaboration Wei Bu, Jeffrey Cohen, Michael Joyce, Masaru Kanekiyo According to the World Health Organization, over 90% of the worldwide population is infected with Epstein-Barr virus by adulthood. In most cases, the disease accompanying initial infection is subclinical though some individuals who are infected as adolescents or adults do experience infectious mononucleosis. However, once infected, individuals carry latent EBV for their remaining lifespan. In such individuals, immune suppression can result in reactivation of the EBV and consequently, EBV-associated lymphoproliferative disease. Currently, there is no prophylactic to prevent primary EBV infection and additional therapeutics would be useful to treat EBV-associated B-cell driven lymphoproliferative disease.<br /><br /> Scientists at the NIAID are developing neutralizing antibodies, originally isolated from humans or non-human primates, that could be useful in preventing primary infection or reactivation of EBV in immunocompromised individuals. These antibodies are 10-100 times more potent than the most potent EBV neutralizing antibody identified to date (72A1). The antibodies target epitopes on either the gp350 surface glycoprotein of EBV or the gH/gL heterodimer. In vitro experiments have demonstrated that the antibodies effectively inhibit EBV infection of B cells and epithelial cells as well as cell-to-cell fusion of cells expressing the viral proteins gH/gL. <ul> <li>No EBV therapeutics or prophylactics currently exist</li> </ul><< <ul> <li>Treatment of individuals with compromised immune systems to prevent EBV-associated lymphoproliferative diseases</li> <li>Prevention of primary EBV infection in individuals with compromised immune systems to prevent EBV-associated lymphoproliferative diseases</li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize Epstein-Barr monoclonal antibody technologies. For collaboration opportunities, please contact Peter Soukas, J.D., 301-594-8730; <ahref="mailto:peter.soukas@nih.gov">peter.soukas@nih.gov</a> 2022-03-08 2025-09-29 2025-09-29 2018-11-05 Against, antibodies, B, both, Cells, Epithelial, EPSTEIN-BARR, Fusion, Infection, INHIBIT, Neutralize, Neutralizing, POTENT, That, Their, virus False True True NIHTT 37470483 Website Abstract 114109972 Joyce, Michael NIAID - VRC NIAID Joyce, Michael (NIAID) 0 114109973 Bu, Wei NIAID - DIR NIAID Bu, Wei (NIAID) 0 114109974 Cohen, Jeffrey NIAID - DIR NIAID Cohen, Jeffrey (NIAID) 0 114109971 Kanekiyo, Masaru NIAID - VRC NIAID Kanekiyo, Masaru (NIAID) 1 114109971 Kanekiyo, Masaru NIAID - VRC NIAID Kanekiyo, Masaru (NIAID) 1 114109972 Joyce, Michael NIAID - VRC NIAID Joyce, Michael (NIAID) 0 114109973 Bu, Wei NIAID - DIR NIAID Bu, Wei (NIAID) 0 114109974 Cohen, Jeffrey NIAID - DIR NIAID Cohen, Jeffrey (NIAID) 0 114102503 Potent Neutralizing Antibodies Against Epstein-Barr Virus And Their Use E-001-2017-0 Filing authorized NIAID 114102504 Potent Neutralizing Antibodies Against Epstein-Barr Virus And Their Use E-001-2017-1 Filing authorized NIAID 114102505 Epstein-Barr Virus Antibodies That Neutralize Virus Infection In Both Epithelial Cells And B Cells And Inhibit Fusion E-079-2018-0 Filing authorized NIAID 91027763 Puglielli, Maryann maryann.puglielli@nih.gov
United States of America maryann.puglielli@nih.gov?subject=Web Inquiry on [TAB-3345] Antibodies and Methods for the Diagnosis and Treatment of Epstein-Barr Virus Infection&body=Please send me information about technology [TAB-3345] Antibodies and Methods for the Diagnosis and Treatment of Epstein-Barr Virus Infection. Puglielli, Maryann<br><a href="mailto:maryann.puglielli@nih.gov?subject=Web Inquiry on [TAB-3345] Antibodies and Methods for the Diagnosis and Treatment of Epstein-Barr Virus Infection&body=Please send me information about technology [TAB-3345] Antibodies and Methods for the Diagnosis and Treatment of Epstein-Barr Virus Infection.">maryann.puglielli@nih.gov</a><br> 114168791 E-001-2017-0 E-001-2017-0-US-01 Antibodies and Methods for the Diagnosis and Treatment of Epstein Barr Virus Infection PRV US 62/490,023 Abandoned US <br />Provisional (PRV) 62/490,023<br />Filed on 2017-04-25<br />Status: Abandoned 114168792 E-001-2017-1 E-001-2017-1-PCT-01 ANTIBODIES AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF EPSTEIN BARR VIRUS INFECTION PCT COMB Patent Cooperation Treaty PCT/US2018/029463 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2018/029463<br />Filed on 2018-04-25<br />Status: Expired 114168793 E-079-2018-0 E-079-2018-0-US-01 Antibodies and Methods for the Diagnosis, Prevention, and Treatment of Epstein Barr Virus Infection PRV US 62/665,977 Abandoned US <br />Provisional (PRV) 62/665,977<br />Filed on 2018-05-02<br />Status: Abandoned 114168876 E-079-2018-0 E-079-2018-0-PCT-01 ANTIBODIES AND METHODS FOR THE DIAGNOSIS, PREVENTION, AND TREATMENT OF EPSTEIN BARR VIRUS INFECTION PCT COMB Patent Cooperation Treaty PCT/US2019/030431 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2019/030431<br />Filed on 2019-05-02<br />Status: Expired 114168925 E-001-2017-1 E-001-2017-1-US-03 ANTIBODIES AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF EPSTEIN BARR VIRUS INFECTION National Stage US 11,236,151 16/608,386 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11236151 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11236151">11,236,151</a><br />Filed on 2019-10-25<br />Status: Issued 114169067 E-079-2018-0 E-079-2018-0-US-03 ANTIBODIES AND METHODS FOR THE DIAGNOSIS, PREVENTION, AND TREATMENT OF EPSTEIN BARR VIRUS INFECTION National Stage US 12,084,489 17/052,470 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12084489 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12084489">12,084,489</a><br />Filed on 2020-11-02<br />Status: Issued 114169178 E-001-2017-1 E-001-2017-1-US-04 ANTIBODIES AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF EPSTEIN BARR VIRUS INFECTION DIV US 11,926,656 17/553,139 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11926656 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11926656">11,926,656</a><br />Filed on 2021-12-16<br />Status: Issued 114151522 Against 114151523 antibodies 114151524 Neutralizing 114151525 POTENT 114151526 Their 114151527 EPSTEIN-BARR 114151528 virus 114151529 That 114151530 Neutralize 114151531 Infection 114151532 both 114151533 Epithelial 114151534 Cells 114151535 B 114151536 INHIBIT 114151537 Fusion TAB-2321 114096515 Diagnostic Assays and Methods of Use for Detection of Filarial Infection NIAID Collaboration, Diagnostics, Infectious Disease Collaboration Diagnostics Infectious Disease Peter Burbelo, Doran Fink, Joseph Kubofcik, Thomas Nutman The effort targeting the mosquito borne neglected tropical disease lymphatic filariasis for elimination through mass drug administration by 2020 will require accurate, cost effective methods for detecting early infections. The World Health Organization-recommended immunochromatographic test detects adult <em>Wuchereria bancrofti</em> (Wb) antigen in blood, but shows variable efficacy due to the complex life cycle of the parasites and cross reactivity with other organisms. This variability may hinder effective lymphatic filariasis elimination efforts. This new technology improves available detection methods through use of an isolated immunoreactive antigen, Wb123, from infective stage larvae (L3) Wb; which results in specific detection early in the infective cycle with reduced cross reactivity. This technology may see wide application in testing and surveillance of lymphatic filariasis as part of the effort to eliminate the disease worldwide. <ul> <li>Improved detection of early stage lymphatic filariasis</li> </ul> <ul> <li>Diagnostics testing</li> <li>Infectious disease monitoring</li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize the methods of treating human tuberculosis. For collaboration opportunities, please contact Theodoric A. Mattes, Ph.D. at <a href="mailto:theodoric.mattes@nih.gov">theodoric.mattes@nih.gov</a>or 1-240-627-3827. 2022-03-08 2025-09-29 2025-09-29 2021-10-29 2021-08-16 Bancrofitan, Bancrofti, CONTROL, DA2XXX, DAXXXX, DXXXXX, Filariasis, FOLLOWING, Immunodiagnosis, Lymphatic filariasis (Wuchereria bancrofti, Brugia malayi), MOLECULE, Programs, Specific, Successful, Surveillance, Wuchereria False True <ul> <li>Early-stage</li> <li>Pre-clinical</li> </ul> True NIHTT 37470483 Website Abstract E-084-2010-0 E-014-2011-0 114171412 Senbagavalli P, et al. https://www.ncbi.nlm.nih.gov/pubmed/21734131 <a href="https://www.ncbi.nlm.nih.gov/pubmed/21734131">Senbagavalli P, et al.</a> 114171413 Bennuru S, et al. https://www.ncbi.nlm.nih.gov/pubmed/21606368 <a href="https://www.ncbi.nlm.nih.gov/pubmed/21606368">Bennuru S, et al.</a> 114171414 Steel C, et al. https://www.ncbi.nlm.nih.gov/pubmed/21559422 <a href="https://www.ncbi.nlm.nih.gov/pubmed/21559422">Steel C, et al.</a> 114171415 Fink DL, et al. https://www.ncbi.nlm.nih.gov/pubmed/20980560 <a href="https://www.ncbi.nlm.nih.gov/pubmed/20980560">Fink DL, et al.</a> 114171416 Bennuru S, et al. https://www.ncbi.nlm.nih.gov/pubmed/20889885 <a href="https://www.ncbi.nlm.nih.gov/pubmed/20889885">Bennuru S, et al.</a> 114107309 Fink, Doran NIAID - DIR NIAID Fink, Doran (NIAID) 0 114107311 Kubofcik, Joseph NIAID - DIR NIAID Kubofcik, Joseph (NIAID) 0 114107312 Burbelo, Peter NIDCR Burbelo, Peter (NIDCR) 0 114107310 Nutman, Thomas NIAID - DIR NIAID Nutman, Thomas (NIAID) 1 114107310 Nutman, Thomas NIAID - DIR NIAID Nutman, Thomas (NIAID) 1 114107309 Fink, Doran NIAID - DIR NIAID Fink, Doran (NIAID) 0 114107311 Kubofcik, Joseph NIAID - DIR NIAID Kubofcik, Joseph (NIAID) 0 114107312 Burbelo, Peter NIDCR Burbelo, Peter (NIDCR) 0 114101629 Wuchereria Bancrofti Specific Molecule For The Immunodiagnosis Of Bancrofitan Filariasis And For Surveillance Following Successful Control Programs E-281-2010-0 Filing authorized NIAID, NIDCR 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2321] Diagnostic Assays and Methods of Use for Detection of Filarial Infection&body=Please send me information about technology [TAB-2321] Diagnostic Assays and Methods of Use for Detection of Filarial Infection. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2321] Diagnostic Assays and Methods of Use for Detection of Filarial Infection&body=Please send me information about technology [TAB-2321] Diagnostic Assays and Methods of Use for Detection of Filarial Infection.">jonathan.motley@nih.gov</a><br> 114163154 E-281-2010-0 E-281-2010-0-PCT-02 DIAGNOSTIC ASSAYS AND METHODS OF USE FOR DETECTION OF FILARIAL INFECTION PCT Patent Cooperation Treaty PCT/US2011/58561 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2011/58561<br />Filed on 2011-10-31<br />Status: Expired 114166523 E-281-2010-0 E-281-2010-0-US-01 Diagnostic Assays And Methods Of Use For Detection Of Filarial Infection PRV US 61/410,239 Abandoned US <br />Provisional (PRV) 61/410,239<br />Filed on 2010-11-04<br />Status: Abandoned 114167058 E-281-2010-0 E-281-2010-0-US-03 Diagnostic Assays and Methods of Use for Detection of Filarial Infection National Stage US 9,068,993 13/882,850 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9068993 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9068993">9,068,993</a><br />Filed on 2013-06-13<br />Status: Issued 114122301 DA2XXX 114122302 DXXXXX 114122303 DAXXXX 114141989 Wuchereria 114141990 Bancrofti 114141991 Specific 114141992 MOLECULE 114141993 Immunodiagnosis 114141994 Bancrofitan 114141995 Filariasis 114141996 Surveillance 114141997 FOLLOWING 114141998 Successful 114141999 CONTROL 114142000 Programs 114157965 Lymphatic filariasis (Wuchereria bancrofti, Brugia malayi) TAB-2813 114096991 Novel Dopamine D2 Receptor Antagonists and Methods of Their Use NINDS Collaboration, Neurology, Psychiatry/Mental Health, Research Materials, Therapeutics Collaboration Neurology Psychiatry/Mental Health Research Materials Therapeutics Marc Ferrer-Alegre, R Benjamin Free, Juan Marugan, David Sibley, Noel Southall, Jingbo Xiao Investigators at the NIH have identified a series of novel, small molecule antagonists of the dopamine D2 receptor. Among the dopamine receptor (DAR) subtypes, D2 DAR is arguably one of the most validated drug targets in neurology and psychiatry. For instance, all receptor-based anti-Parkinsonian drugs work via stimulating the D2 DAR, whereas all FDA approved antipsychotic agents are antagonists of this receptor. Unfortunately, most agents that act as antagonists of D2 DAR are problematic, either they are less efficacious than desired or cause multiple adverse effects. Thus, it is desirable to develop a class of novel therapeutic agents with high selectivity for the D2 DAR. This invention describes dihydrobenzo[b,f][1,4]thiazepine-8-carboxamide compounds, methods of making these compounds, methods of characterizing their in vitro activity, demonstration of in vivo activity in animals, as well as methods of using these compounds to treat central nervous system (CNS) related disorders. <ul> <li>Highly selective</li> </ul> <ul> <li>Antipsychotic agent</li> <li>Treatment for schizophrenia, Tourette's syndrome, depression</li> <li>Alternative therapy for disorders currently treated with non-selective D2 antagonists</li> </ul> The National Institute of Neurological Disorders and Stroke is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize Novel Dopamine D2 Receptor Antagonists and Methods of Their Use. For collaboration opportunities, please contact Susan Ano at <a href="mailto:susan.ano@nih.gov">susan.ano@nih.gov</a>. 2022-03-08 2024-10-28 2025-09-23 2015-04-09 Agents, ANTAGONISTS, ANTIPSYCHOTIC, D2, Dopamine, Human, NB2BXX, NB2XXX, Potential, RECEPTOR, SELECTIVE, VEXXXX, VNXXXX, WIXXXX, WKXXXX, YBXXXX, YCXXXX False True <ul> <li>In vitro data available</li> <li>In vivo data available (animal)</li> </ul> True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114170781 Xiao J, et al. https://www.ncbi.nlm.nih.gov/pubmed/24666157 <a href="https://www.ncbi.nlm.nih.gov/pubmed/24666157">Xiao J, et al.</a> 114172244 Xiao J, et al. https://www.ncbi.nlm.nih.gov/pubmed/24260782 <a href="https://www.ncbi.nlm.nih.gov/pubmed/24260782">Xiao J, et al.</a> 164235772 responded 23Sept with copy of issued US patent and a link to the license application. responded 23Sept with copy of issued US patent and a link to the license application. 114108698 Marugan, Juan NCATS - NCGC NCATS Marugan, Juan (NCATS) 0 114108699 Xiao, Jingbo NCATS - NCGC FDA Xiao, Jingbo (FDA) 0 114108700 Ferrer-Alegre, Marc NCATS - NCGC NCATS Ferrer-Alegre, Marc (NCATS) 0 114108701 Southall, Noel NCATS - TRND NCATS Southall, Noel (NCATS) 0 114108703 Free, R Benjamin NINDS NINDS Free, R Benjamin (NINDS) 0 114108702 Sibley, David NINDS NINDS Sibley, David (NINDS) 1 114108702 Sibley, David NINDS NINDS Sibley, David (NINDS) 1 114108698 Marugan, Juan NCATS - NCGC NCATS Marugan, Juan (NCATS) 0 114108699 Xiao, Jingbo NCATS - NCGC FDA Xiao, Jingbo (FDA) 0 114108700 Ferrer-Alegre, Marc NCATS - NCGC NCATS Ferrer-Alegre, Marc (NCATS) 0 114108701 Southall, Noel NCATS - TRND NCATS Southall, Noel (NCATS) 0 114108703 Free, R Benjamin NINDS NINDS Free, R Benjamin (NINDS) 0 114102146 Selective Human D2 Dopamine Receptor Antagonists As Potential Antipsychotic Agents E-030-2013-0 Filing authorized NCATS - NCGC, NINDS 83667829 Ano, Susan susan.ano@nih.gov
United States of America susan.ano@nih.gov?subject=Web Inquiry on [TAB-2813] Novel Dopamine D2 Receptor Antagonists and Methods of Their Use&body=Please send me information about technology [TAB-2813] Novel Dopamine D2 Receptor Antagonists and Methods of Their Use. Ano, Susan<br><a href="mailto:susan.ano@nih.gov?subject=Web Inquiry on [TAB-2813] Novel Dopamine D2 Receptor Antagonists and Methods of Their Use&body=Please send me information about technology [TAB-2813] Novel Dopamine D2 Receptor Antagonists and Methods of Their Use.">susan.ano@nih.gov</a><br> 114161129 E-030-2013-0 E-030-2013-0-US-04 11-OXO-10,11-Dihydrodibenzo[B,F][1,4]Thiazepine S-Oxide Derivatives And Their Use As Dopamine D2 Receptor Antagonists National Stage US 9,550,742 14/908,271 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9550742 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9550742">9,550,742</a><br />Filed on 2014-07-29<br />Status: Issued 114167778 E-030-2013-0 E-030-2013-0-US-01 Selective Dopamine D2 Receptor Antagonists And Methods Of Their Use PRV US 61/859,532 Abandoned US <br />Provisional (PRV) 61/859,532<br />Filed on 2013-07-29<br />Status: Abandoned 114167909 E-030-2013-0 E-030-2013-0-PCT-02 Selective Human D2 Dopamine Receptor Antagonists And Methods Of Their Use PCT Patent Cooperation Treaty PCT/US2014/048619 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2014/048619<br />Filed on 2014-07-29<br />Status: Expired 114125977 VEXXXX 114125978 VNXXXX 114125979 WIXXXX 114125980 WKXXXX 114125981 NB2XXX 114125982 NB2BXX 114125983 YBXXXX 114125984 YCXXXX 114147215 SELECTIVE 114147216 Human 114147217 D2 114147218 Dopamine 114147219 RECEPTOR 114147220 ANTAGONISTS 114147221 Potential 114147222 ANTIPSYCHOTIC 114147223 Agents TAB-4227 147157512 Strategies to Protect Mammalian Neural Tissue Against Cold and Potentially Other Metabolic Stresses and Physical Damages NEI Cardiology, Collaboration, Ear, Nose, & Throat, Licensing, Nephrology, Ophthalmology, Research Materials Cardiology Collaboration Ear Nose & Throat Licensing Nephrology Ophthalmology Research Materials Wei Li, Kiyoharu Miyagishima, Jingxing Ou <p>Researchers at the National Eye Institute (NEI) have discovered an invention describing a composition and method(s) of using such composition for preserving viability of cells, tissues, or organs at a low temperature (around 4&ordm;C). Current cold storage solutions or methods for cells, tissues, and organs are suboptimal due to irreversible damage to cold-sensitive tissue or organ transplants that need a longer term of storage for facilitating clinical practices. In addition to mitigating this damage, the new method may be potentially used in therapeutic hypothermia for protecting neural injury or trauma, or for enhancing neuronal survival from axonal damage and degeneration.&nbsp;</p> <p>The invented composition, which was inspired by the inventors&rsquo; hibernation mechanism studies using their ground squirrel induced pluripotent stem (iPSC) cells, contains a mitochondrial uncoupling agent that reduces mitochondrial oxidation and thus protects tissues or organs from cold stress. The invention can be either used alone or may supplement other types of preservation reagents. The new composition represents an improved one as compared with currently available commercial preservation products for certain tissue types, such as Optisol&trade;-GS corneal storage solution or CoStorSol&reg; cold storage solution that is the current standard for liver and kidney transplantation.</p> <p>The NEI inventors seek licensees and/or to collaborate with commercial partners to develop the new composition into preservation products that can be used in research or variable clinical practices such as therapeutic hypothermia, transplantation, and physical neural injuries.&nbsp;</p> <p>The&nbsp;figure below shows pretreatments with the invented storage solution preserved cellular morphology and functions of retinal ganglion cells following 4-h cold storage:</p> <p><img alt=" pretreatments with the invented storage solution preserved cellular morphology and functions of retinal ganglion cells following 4-h cold storage" height="504" src="https://nih.technologypublisher.com/files/sites/e-165-2017_image_1_03.jpg" width="344" /></p> <p>The&nbsp;figure below shows pretreatments with the mitochondrial inhibitor Bam15 and/or protease inhibitors (Pi) preserved microtubule morphology following 24-h cold storage and 2-h rewarming, and reduced cell apoptosis following 72-h cold storage:</p> <p><img alt=" This Figure shows pretreatments with the mitochondrial inhibitor Bam15 and/or protease inhibitors (Pi) preserved microtubule morphology following 24-h cold storage and 2-h rewarming, and reduced cell apoptosis following 72-h cold storage. " height="623" src="https://nih.technologypublisher.com/files/sites/e-165-2017_image_22.jpg" width="600" /></p> <p>&nbsp;</p> <h2>Competitive Advantages:</h2> <ul> <li>This invented cold storage solution employs newly discovered mechanism for preserving cell or tissue viability under cold stress, thus improving preservation efficacy&nbsp;</li> <li>This new cold storage solution represents a better choice owing to its innovative concept in preservation, compared with current commercially available products, for enhanced preservation efficacy and prolonged storage of cold-sensitive cells, tissues, or organs, which include primary neural tissues, hepatocytes, kidneys retinas, etc.</li> <li>This new solution can be used as supplements into other current research- or clinical-grade of reagents for a variety of applications that demand induced cold tolerance&nbsp;</li> </ul> <h2>Commercial Applications:</h2> <ul> <li>Preservation storage solutions for extended preservation of cold-sensitive tissues or organs for research or medical procedures</li> <li>Medical product(s) that can be used in therapeutic hypothermia for treating neural injury or trauma</li> <li>Medical product(s) that can be used for directly treating neural injury or trauma&nbsp;&nbsp;</li> </ul> 2018-10-12 2025-05-15 2018-10-12 2025-09-15 2018-10-12 Cold Storage, Cold-sensitive, Hypothermia, lysosome, Mitochondria, National Eye Institute, NEI, neural injury, Ou, Protein Degradation, TRANSPLANTATION False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2018-10-12 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-059-2017 147162390 Ou J, et al. iPSCs from a Hibernator Provide a Platform for Studying Cold Adaptation and Its Potential Medical Applications. https://www.ncbi.nlm.nih.gov/pubmed/29576452 <a href="https://www.ncbi.nlm.nih.gov/pubmed/29576452">Ou J, et al. iPSCs from a Hibernator Provide a Platform for Studying Cold Adaptation and Its Potential Medical Applications.</a> 147163974 Ou, Jingxing NIH - NEI NEI Ou, Jingxing (NEI) 1 147163973 Li, Wei NIH - NCI NCI Li, Wei (NCI) 2 147163975 Miyagishima, Kiyoharu NIH - NEI NEI Miyagishima, Kiyoharu (NEI) 3 147163974 Ou, Jingxing NIH - NEI NEI Ou, Jingxing (NEI) 1 147163973 Li, Wei NIH - NCI NCI Li, Wei (NCI) 2 147163975 Miyagishima, Kiyoharu NIH - NEI NEI Miyagishima, Kiyoharu (NEI) 3 147158120 Strategies To Protect Mammalian Neural Tissue Against Cold And Potentially Other Metabolic Stresses E-165-2017-0 Filing authorized National Eye Institute (NEI), NCI 83724826 Pollard, Ricquita ricquita.pollard@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4227] Strategies to Protect Mammalian Neural Tissue Against Cold and Potentially Other Metabolic Stresses and Physical Damages&body=Please send me information about technology [TAB-4227] Strategies to Protect Mammalian Neural Tissue Against Cold and Potentially Other Metabolic Stresses and Physical Damages.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollard, Ricquita<br><a href="mailto:ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4227] Strategies to Protect Mammalian Neural Tissue Against Cold and Potentially Other Metabolic Stresses and Physical Damages&body=Please send me information about technology [TAB-4227] Strategies to Protect Mammalian Neural Tissue Against Cold and Potentially Other Metabolic Stresses and Physical Damages.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">ricquita.pollard@nih.gov</a><br> 147161132 E-165-2017-0 E-165-2017-0-PCT-02 COMPOSITIONS AND METHODS TO PROTECT MAMMALIAN TISSUE AGAINST COLD AND OTHER METABOLIC STRESSES PCT Patent Cooperation Treaty PCT/US2018/047064 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2018/047064<br />Filed on 2018-08-20<br />Status: Expired 147167532 E-165-2017-0 E-165-2017-0-US-01 Compositions and Methods To Protect Mammalian Tissue Against Cold And Other Metabolic Stresses PRV US 62/547,945 Abandoned US <br />Provisional (PRV) 62/547,945<br />Filed on 2017-08-21<br />Status: Abandoned 147167533 E-165-2017-0 E-165-2017-0-CN-03 COMPOSITIONS AND METHODS TO PROTECT MAMMALIAN TISSUE AGAINST COLD AND OTHER METABOLIC STRESSES National Stage China ZL201880068155.5 201880068155.5 Issued China <br />National Stage 201880068155.5<br />Filed on 2018-08-20<br />Status: Issued 147167534 E-165-2017-0 E-165-2017-0-US-04 COMPOSITIONS AND METHODS TO PROTECT MAMMALIAN TISSUE AGAINST COLD AND OTHER METABOLIC STRESSES National Stage US 11,547,708 16/636,945 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11547708 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11547708">11,547,708</a><br />Filed on 2020-02-06<br />Status: Issued 147167535 E-165-2017-0 E-165-2017-0-US-05 COMPOSITIONS AND METHODS TO PROTECT MAMMALIAN TISSUE AGAINST COLD AND OTHER METABOLIC STRESSES DIV US 12,383,554 18/058,064 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12383554 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12383554">12,383,554</a><br />Filed on 2022-11-22<br />Status: Issued 147172753 Cold Storage 147172755 Cold-sensitive 147172757 Hypothermia 147172758 lysosome 147172759 Mitochondria 147172760 National Eye Institute 147172761 NEI 147172762 neural injury 147172764 Ou 147172766 Protein Degradation 147172767 TRANSPLANTATION TAB-4119 147157401 Establishment of Induced Pluripotent Stem Cells (iPSC) from the Thirteen-lined Ground Squirrel NEI Licensing, Neurology, Research Materials Licensing Neurology Research Materials Wei Li, Barbara Mallon, Jingxing Ou <p>The limited choice in cell types available for in vitro studies has become an obstacle in hibernation research.&nbsp;</p> <p>Researchers at the National Eye Institute for the first time have successfully established iPSC line(s) from a mammalian hibernator, which can be potentially used to generate various cell types and tissue models for in-depth mechanistic studies of hibernation and coldness tolerance in vitro.&nbsp;</p> <p>Hibernation-specific features make this line a unique platform and valuable tool for inspiring novel pharmacological strategies. For example, they can be used to bestow cold adaptability to target cells and organs derived from non-hibernating mammals, as well as translating cold-adaptive strategies into humans in clinical applications, such as neural injury or other diseases that involve cold intolerance.</p> <p><img alt="Compared with human iPSC-derived neurons, GS iPSC-derived neurons are not susceptible to cold stress treatment." height="707" src="https://nih.technologypublisher.com/files/sites/e-059-2017_image_for_lynne_huang4.png" style="float:right" width="500" /></p> <h2>Competitive Advantages:</h2> <ul> <li>The first iPSC line established from small hibernators like ground squirrel</li> <li>Potential in generating various cell types and tissue models for in-depth mechanistic studies of hibernation and coldness tolerance in vitro</li> <li>Unique benefits in studying hibernation mechanism and cold-adaptive strategies&nbsp;</li> </ul> <h2>Commercial Applications:</h2> <ul> <li>Research tool for studying hibernation and cold adaptability and disease modeling</li> <li>Drug screening platform for neuronal injuries or other diseases</li> </ul> 2018-06-20 2025-05-15 2021-01-26 2025-09-15 2018-06-20 cellular stress, coldness, hibernation, Induced Pluripotent Stem Cell (iPSC), Li, neural injury, Squirrel False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-01-26 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147162028 J. Ou et al. iPSCs from a Hibernator Provide a Platform for Studying Cold Adaptation and Its Potential Medical Applications https://www.ncbi.nlm.nih.gov/pubmed/29576452 <a href="https://www.ncbi.nlm.nih.gov/pubmed/29576452">J. Ou et al. iPSCs from a Hibernator Provide a Platform for Studying Cold Adaptation and Its Potential Medical Applications</a> 147163573 Ou, Jingxing NIH - NEI NEI Ou, Jingxing (NEI) 1 147163575 Mallon, Barbara NIH - NINDS NINDS Mallon, Barbara (NINDS) 2 147163574 Li, Wei NIH - NEI NEI Li, Wei (NEI) 3 147163573 Ou, Jingxing NIH - NEI NEI Ou, Jingxing (NEI) 1 147163575 Mallon, Barbara NIH - NINDS NINDS Mallon, Barbara (NINDS) 2 147163574 Li, Wei NIH - NEI NEI Li, Wei (NEI) 3 147157893 Establishment Of Induced Pluripotent Stem Cells From The Thirteen-lined Ground Squirrel E-059-2017-0 Research Material National Eye Institute (NEI), NINDS 83724826 Pollard, Ricquita ricquita.pollard@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4119] Establishment of Induced Pluripotent Stem Cells (iPSC) from the Thirteen-lined Ground Squirrel&body=Please send me information about technology [TAB-4119] Establishment of Induced Pluripotent Stem Cells (iPSC) from the Thirteen-lined Ground Squirrel.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollard, Ricquita<br><a href="mailto:ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4119] Establishment of Induced Pluripotent Stem Cells (iPSC) from the Thirteen-lined Ground Squirrel&body=Please send me information about technology [TAB-4119] Establishment of Induced Pluripotent Stem Cells (iPSC) from the Thirteen-lined Ground Squirrel.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">ricquita.pollard@nih.gov</a><br> 147170492 cellular stress 147170494 coldness 147170496 hibernation 147170498 Induced Pluripotent Stem Cell (iPSC) 147170500 Li 147170502 neural injury 147170503 Squirrel TAB-3959 147157239 Interleukin 24 (IL-24) to treat inflammatory diseases NEI Collaboration, Immunology, Licensing, Therapeutics Collaboration Immunology Licensing Therapeutics Rachel Caspi, Wai Po Chong, Mary Mattapallil, Reiko Yamane <p>Proinflammatory T-helper 17 cells (Th17) play important roles in host immune defense against infection, but uncontrolled activation of these cells, known as the Th17 response, may cause autoimmune and autoinflammatory diseases (uveitis, multiple sclerosis, rheumatoid arthritis, and Crohn&rsquo;s disease) through the effects of Th17 lineage cytokines (such as, IL-17F, IL-22 and GM-CSF). Importantly, IL-17A (a proinflammatory cytokine) represses other Th17 lineage cytokines by upregulating the regulatory cytokine IL-24. Loss of this regulatory pathway due to IL-17A neutralization, and consequent upregulation of the other Th17 cytokines, may result in reduced efficacy of anti-IL-17A therapy. The inventors suggest that targeting the Th17 lineage cytokines as a class, by augmenting IL-24 may be a better approach for controlling the Th17 response than targeting IL-17A alone, which is currently under development by pharmaceutical companies. For instance, the current strategy to suppress Th17 activity [use of Secukinumab (Cosentyx)] has had only limited success in treating some autoimmune diseases, possibly because reducing IL-17A permits upregulation of other Th17-related proinflammatory cytokines through an intermediate step involving reduced IL-24. Researchers at the National Eye Institute (NEI) have developed a new strategy of using IL-24 to target the whole Th17 lineage and thus achieve improved efficacy in therapy of Th17-relevant autoimmune diseases.&nbsp;</p> <p><img alt="IL-17A represses other Th17 lineage cytokines in an autocrine (and paracrine?) fashion via IL-24" height="291" src="https://nih.technologypublisher.com/files/sites/e-119-2017_il-17a_image1.png" width="389" /></p> <h2>Competitive Advantages:</h2> <ul> <li>Monotherapy of IL-17A targeting alone is insufficient in some diseases</li> <li>May avoid patients&rsquo; exposure to infections that are possible when targeting both IL-23 and IL-12 combination therapy or STAT3 blockade &ndash; as either can be broadly suppressive&nbsp;</li> <li>This approach is designed to bring other members of the Th17 pathway back to normal, rather than massively inhibiting them, while targeting its most proinflammatory member IL-17A; the approach augments the naturally produced regulatory cytokine, IL-24, which becomes deficient due to IL-17 neutralization <ul> <li>Side effects of IL-24 augmentation/normalization are likely to be minimal</li> </ul> </li> <li>Local treatment to augment IL-24 in the eye reduces inflammation and may reduce systemic side effects&nbsp;</li> </ul> <h2>Commercial Applications:</h2> <ul> <li>Potential therapeutic drugs for Th17-relevant inflammatory diseases such as uveitis, arthritis, and multiple sclerosis etc.</li> <li>Potential therapeutic drugs for regulating the Th-17 response in various inflammatory conditions&nbsp;</li> </ul> 2018-07-19 2025-04-22 2018-07-19 2025-09-15 2018-07-19 Caspi, Crohn’s disease, IL-24, inflammatory disease, interleukin 24, Multiple sclerosis, National Eye Institute, NEI, proinflammatory T-helper 17 cell, RHEUMATOID ARTHRITIS, Th17, uveitis False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2018-07-19 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147163018 Caspi, Rachel NIH - NEI NEI Caspi, Rachel (NEI) 1 147163020 Mattapallil, Mary NIH - NEI NEI Mattapallil, Mary (NEI) 2 147163019 Yamane, Reiko NIH - NEI NEI Yamane, Reiko (NEI) 3 147163021 Chong, Wai Po Sun Yat-sen University Chong, Wai Po 4 147163018 Caspi, Rachel NIH - NEI NEI Caspi, Rachel (NEI) 1 147163020 Mattapallil, Mary NIH - NEI NEI Mattapallil, Mary (NEI) 2 147163019 Yamane, Reiko NIH - NEI NEI Yamane, Reiko (NEI) 3 147163021 Chong, Wai Po Sun Yat-sen University Chong, Wai Po 4 147158027 Interleukin 24 Limits Expression Of Tissue Specific Autoimmune Disease By Controlling Th17 Lineage Cytokines E-119-2017-0 Filing authorized National Eye Institute (NEI), Sun Yat-sen University 83737255 Baxter, Merissa merissa.baxter@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB merissa.baxter@nih.gov?subject=Web Inquiry on [TAB-3959] Interleukin 24 (IL-24) to treat inflammatory diseases&body=Please send me information about technology [TAB-3959] Interleukin 24 (IL-24) to treat inflammatory diseases.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Baxter, Merissa<br><a href="mailto:merissa.baxter@nih.gov?subject=Web Inquiry on [TAB-3959] Interleukin 24 (IL-24) to treat inflammatory diseases&body=Please send me information about technology [TAB-3959] Interleukin 24 (IL-24) to treat inflammatory diseases.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">merissa.baxter@nih.gov</a><br> 147161069 E-119-2017-0 E-119-2017-0-US-03 IL-24 TO TREAT INFLAMMATORY DISEASES ORD US 10,512,671 15/957,019 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10512671 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10512671">10,512,671</a><br />Filed on 2018-04-19<br />Status: Issued 147165565 E-119-2017-0 E-119-2017-0-US-01 IL-24 TO TREAT INFLAMMATORY DISEASES PRV US 62/487,223 Abandoned US <br />Provisional (PRV) 62/487,223<br />Filed on 2017-04-19<br />Status: Abandoned 147171836 Caspi 147171838 Crohn’s disease 147171840 IL-24 147171841 inflammatory disease 147171843 interleukin 24 147171844 Multiple sclerosis 147171845 National Eye Institute 147171846 NEI 147171848 proinflammatory T-helper 17 cell 147171849 RHEUMATOID ARTHRITIS 147171850 Th17 147171851 uveitis TAB-3855 147157134 Ex-vivo Production of Regulatory B-Cells for Use in Auto-immune Diseases NEI Collaboration, Immunology, Licensing, Therapeutics Collaboration Immunology Licensing Therapeutics Charles Egwuagu, Ren-Wi Wang, Chengrong Yu <p>Regulatory B-cells (Breg) play an important role in reducing autoimmunity and reduced levels of these cells are implicated in etiology of several auto-inflammatory diseases. Despite their impact in many diseases, their physiological inducers are unknown.  Given that Bregs are a very rare B-cell, identifying factors that promote their development would allow in vivo modulation of Breg levels and ex-vivo production of large amounts of antigen-specific Bregs to use in immunotherapy for auto-inflammatory diseases.<br />  <br /> Researchers at NEI's <a href="https://www.nei.nih.gov/research/research-labs-and-branches/laboratory-retinal-cell-and-molecular-biology" rel="nofollow">Molecular Immunology Section</a> developed a method for the <em>ex-vivo</em> production of Breg. The method of production involves treating isolated primary B-cells or B-cell lines with IL-35 to induce their conversion into IL-10, producing Breg. Using this method, B-regulatory cells can be produced in large quantity and used in a Breg-based therapy against autoimmune diseases including, but not limited to, uveitis and sarcoidosis. <em>In vivo</em> animal data are available.</p> <h2>Competitive Advantages:</h2> <ul><li>There is no known biological or chemical agent that can induce Bregs <em>ex-vivo</em></li> <li>This method produces large quantities of Bregs and can therefore aid in Breg-based therapy</li> <li>Pre-clinical mouse model data available that uses the Bregs to treat experimental autoimmune uveitis (EAU)</li> </ul> <h2>Commercial Applications:</h2> <ul><li><em>In vivo</em> modulation of Breg levels</li> <li>Supplement the low population of Breg in a patient suffering from an autoimmune disease where it is known that B-regulatory cell populations are severely reduced (i.e. uveitis)</li> <li>Use in immunotherapy for the treatment of other autoimmune diseases such as multiple sclerosis, sarcoidosis, colitis, and arthritis.</li> </ul> 2016-02-16 2025-04-22 2020-04-13 2025-09-15 2016-08-29 ARTHRITIS, B-CELL, COLITIS, EYE, Multiple sclerosis, sarcoidosis False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-04-13 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147162296 Q. Ding et al. Regulatory B cells are identified by expression of TIM-1 and can be induced through TIM-1 ligation to promote tolerance in mice. http://www.ncbi.nlm.nih.gov/pubmed/21821911 <a href="http://www.ncbi.nlm.nih.gov/pubmed/21821911">Q. Ding et al. Regulatory B cells are identified by expression of TIM-1 and can be induced through TIM-1 ligation to promote tolerance in mice.</a> 147162410 N. Carter et al. Mice lacking endogenous IL-10-producing regulatory B cells develop exacerbated disease and present with an increased frequency of Th1/Th17 but a decrease in regulatory T cells. http://www.ncbi.nlm.nih.gov/pubmed/21464089 <a href="http://www.ncbi.nlm.nih.gov/pubmed/21464089">N. Carter et al. Mice lacking endogenous IL-10-producing regulatory B cells develop exacerbated disease and present with an increased frequency of Th1/Th17 but a decrease in regulatory T cells.</a> 147162627 Egwuagu, Charles NIH - NEI NEI Egwuagu, Charles (NEI) 1 147162629 Wang, Ren-Wi NIH - NEI Wang, Ren-Wi 2 147162628 Yu, Chengrong NIH - NEI NEI Yu, Chengrong (NEI) 3 147162627 Egwuagu, Charles NIH - NEI NEI Egwuagu, Charles (NEI) 1 147162629 Wang, Ren-Wi NIH - NEI Wang, Ren-Wi 2 147162628 Yu, Chengrong NIH - NEI NEI Yu, Chengrong (NEI) 3 147157837 Production Of Regulatory B (Breg) Cells By A Genetically Engineered Heterodimeric Interleukin-35 Cytokine:IL-35-induced Bregs As Immunotherapy For Autoimmune Diseases E-036-2012-0 Filing authorized National Eye Institute (NEI) 83737255 Baxter, Merissa merissa.baxter@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB merissa.baxter@nih.gov?subject=Web Inquiry on [TAB-3855] Ex-vivo Production of Regulatory B-Cells for Use in Auto-immune Diseases&body=Please send me information about technology [TAB-3855] Ex-vivo Production of Regulatory B-Cells for Use in Auto-immune Diseases.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Baxter, Merissa<br><a href="mailto:merissa.baxter@nih.gov?subject=Web Inquiry on [TAB-3855] Ex-vivo Production of Regulatory B-Cells for Use in Auto-immune Diseases&body=Please send me information about technology [TAB-3855] Ex-vivo Production of Regulatory B-Cells for Use in Auto-immune Diseases.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">merissa.baxter@nih.gov</a><br> 147160939 E-036-2012-0 E-036-2012-0-US-01 Methods of Producing And Using Regulatory B Cells PRV US 61/637,915 Abandoned US <br />Provisional (PRV) 61/637,915<br />Filed on 2012-04-25<br />Status: Abandoned 147164846 E-036-2012-0 E-036-2012-0-PCT-02 Methods of Producing and Using Regulatory B-Cells PCT Patent Cooperation Treaty PCT/US2013/036175 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2013/036175<br />Filed on 2013-04-11<br />Status: Expired 147164847 E-036-2012-0 E-036-2012-0-AU-03 Methods of Producing and Using Regulatory B-Cells National Stage Australia 2013252771 2013252771 Issued Australia <br />National Stage 2013252771<br />Filed on 2013-04-11<br />Status: Issued 147164848 E-036-2012-0 E-036-2012-0-CA-04 Methods of Producing and Using Regulatory B-Cells National Stage Canada 2871499 2871499 Issued Canada <br />National Stage 2871499<br />Filed on 2013-04-11<br />Status: Issued 147164849 E-036-2012-0 E-036-2012-0-EP-05 Methods of Producing and Using Regulatory B-Cells National Stage European Patent 2841562 13718448.7 Issued European Patent <br />National Stage 13718448.7<br />Filed on 2013-04-11<br />Status: Issued 147164850 E-036-2012-0 E-036-2012-0-JP-06 Methods of Producing and Using Regulatory B-Cells National Stage Japan 6258922 2015-509008 Issued Japan <br />National Stage 2015-509008<br />Filed on 2014-10-24<br />Status: Issued 147164851 E-036-2012-0 E-036-2012-0-US-07 Methods of Producing and Using Regulatory B-Cells National Stage US 9,629,897 14/396,475 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9629897 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9629897">9,629,897</a><br />Filed on 2014-10-23<br />Status: Issued 147164852 E-036-2012-0 E-036-2012-0-DE-08 Methods of Producing and Using Regulatory B-Cells EP Germany 2841562 13718448.7 Issued Germany <br />European patent (EP) 13718448.7<br />Filed on 2013-04-11<br />Status: Issued 147164853 E-036-2012-0 E-036-2012-0-FR-09 Methods of Producing and Using Regulatory B-Cells EP France 2841562 13718448.7 Issued France <br />European patent (EP) 13718448.7<br />Filed on 2013-04-11<br />Status: Issued 147164854 E-036-2012-0 E-036-2012-0-GB-10 Methods of Producing and Using Regulatory B-Cells EP United Kingdom 2841562 13718448.7 Issued United Kingdom <br />European patent (EP) 13718448.7<br />Filed on 2013-04-11<br />Status: Issued 147169970 ARTHRITIS 147169971 B-CELL 147169972 COLITIS 147169973 EYE 147169974 Multiple sclerosis 147169976 sarcoidosis TAB-3875 147157155 Use of Interleukin (IL)-34 to Treat Retinal Inflammation and Neurodegeneration NEI Collaboration, Ear, Nose, & Throat, Immunology, Licensing, Ophthalmology, Therapeutics Collaboration Ear Nose & Throat Immunology Licensing Ophthalmology Therapeutics Rachel Caspi, Mary Mattapallil, Zhijian Wu <p>Interleukin (IL)-34 is a homodimer that is produced mainly by keratinocytes, neuronal cells and regulatory T cells (Tregs). It is believed to play important roles in chronic inflammation and the homeostasis of microglia. Currently, there is no effective treatment for many types of retinal degeneration. An improved treatment of autoimmune uveitis is also needed, as current uveitis treatment primarily uses steroidal anti-inflammation medication, which may produce significant unwanted side effects in long-term use. The inventors at the National Eye Institute (NEI) found that various retinal degeneration and uveitis models in mice with congenital mutations affecting vision have varying degrees of IL-34 deficiency in their intraocular environment. This suggests that IL-34 may be essential in modulating autoimmune uveitis and retinal degeneration. Therefore, Adeno-associated Virus (AAV) AAV8-IL-34-mediated gene therapy or other extended delivery methods of IL-34 protein to the eyes of patients with uveitis or retinal degeneration is a promising strategy for reducing retinal damage caused by ocular inflammation or degeneration and counteracting vision loss. AAV8 is a promising delivery method, as it preferentially infects retinal cells.</p> <h2>Competitive Advantages:</h2> <ul><li>Abrogates the need for chronic steroid use in uveitis, diminishing the risk of side effects from long-term use </li> <li>AAV8 preferentially infects retinal cells; therefore, it could be a good choice for IL-34 gene therapy of uveitis for improved efficacy </li> <li>Potential platform approach to the more than 200 inherited retinal dystrophies (IRDs) associated with progressive retinal degeneration. </li> <li>A regulatory path to approval now exists: the first FDA-approved gene therapy, voretigene neparvovec (Luxturna; Spark Therapeutics) was already approved by FDA and the European Medicines Agency (EMA) in November 2018. </li> <li>IRDs are strong candidates for gene therapy when causative mutations have been identified and, to some degree, the eye is an immune-privileged space. </li> <li>In clinical trials, no significant immune reactivity or systemic adverse events have been associated with the AAV as gene delivery vehicle.</li> </ul> <h2>Commercial Applications:</h2> <ul><li>New therapeutic approach for uveitis and retinal degenerative diseases.</li> </ul> 2019-06-28 2025-04-22 2019-06-28 2025-09-15 2019-06-28 AAV Vector, Caspi, GENE THERAPY, IL-34, inflammatory disease, Inherited Retinal Dystrophies, Interleukin 34, National Eye Institute, NEI, NEURODEGENERATION, Photoreceptor Death, Retinal degeneration, Retinal Inflammation, uveitis False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2019-06-28 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 162585908 per emails with M. Baxter. per emails with M. Baxter. 147162695 Caspi, Rachel NIH - NEI NEI Caspi, Rachel (NEI) 1 147162696 Mattapallil, Mary NIH - NEI NEI Mattapallil, Mary (NEI) 2 147162697 Wu, Zhijian NIH - NEI NEI Wu, Zhijian (NEI) 3 147162695 Caspi, Rachel NIH - NEI NEI Caspi, Rachel (NEI) 1 147162696 Mattapallil, Mary NIH - NEI NEI Mattapallil, Mary (NEI) 2 147162697 Wu, Zhijian NIH - NEI NEI Wu, Zhijian (NEI) 3 147157966 AAV8 Mediated Intra-Ocular Delivery Of Interleukin-34 For Treating Inflammation Of Neural Retina E-091-2018-0 Filing authorized National Eye Institute (NEI) 83737255 Baxter, Merissa merissa.baxter@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB merissa.baxter@nih.gov?subject=Web Inquiry on [TAB-3875] Use of Interleukin (IL)-34 to Treat Retinal Inflammation and Neurodegeneration&body=Please send me information about technology [TAB-3875] Use of Interleukin (IL)-34 to Treat Retinal Inflammation and Neurodegeneration.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Baxter, Merissa<br><a href="mailto:merissa.baxter@nih.gov?subject=Web Inquiry on [TAB-3875] Use of Interleukin (IL)-34 to Treat Retinal Inflammation and Neurodegeneration&body=Please send me information about technology [TAB-3875] Use of Interleukin (IL)-34 to Treat Retinal Inflammation and Neurodegeneration.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">merissa.baxter@nih.gov</a><br> 147164963 E-091-2018-0 E-091-2018-0-US-01 USE OF IL-34 TO TREAT RETINAL INFLAMMATION AND NEURODEGENERATION PRV US 62/637,592 Abandoned US <br />Provisional (PRV) 62/637,592<br />Filed on 2018-03-02<br />Status: Abandoned 147164964 E-091-2018-0 E-091-2018-0-PCT-02 USE OF IL-34 TO TREAT RETINAL INFLAMMATION AND NEURODEGENERATION PCT Patent Cooperation Treaty PCT/US2019/020341 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2019/020341<br />Filed on 2019-03-01<br />Status: Expired 147164965 E-091-2018-0 E-091-2018-0-CA-03 USE OF IL-34 TO TREAT RETINAL INFLAMMATION AND NEURODEGENERATION National Stage Canada 3091810 Pending Canada <br />National Stage 3091810<br />Filed on 2019-03-01<br />Status: Pending 147164966 E-091-2018-0 E-091-2018-0-EP-04 USE OF IL-34 TO TREAT RETINAL INFLAMMATION AND NEURODEGENERATION National Stage European Patent 3758736 19711759.1 Issued European Patent <br />National Stage 19711759.1<br />Filed on 2019-03-01<br />Status: Issued 147164967 E-091-2018-0 E-091-2018-0-JP-05 USE OF IL-34 TO TREAT RETINAL INFLAMMATION AND NEURODEGENERATION National Stage Japan 7356994 2020-545170 Issued Japan <br />National Stage 2020-545170<br />Filed on 2019-03-01<br />Status: Issued 147164968 E-091-2018-0 E-091-2018-0-US-06 USE OF IL-34 TO TREAT RETINAL INFLAMMATION AND NEURODEGENERATION National Stage US 16/971,288 Pending US <br />National Stage 16/971,288<br />Filed on 2020-08-19<br />Status: Pending 164119432 E-091-2018-0 E-091-2018-0-FR-07 USE OF IL-34 TO TREAT RETINAL INFLAMMATION AND NEURODEGENERATION EP France 3758736 19711759.1 Issued France <br />European patent (EP) 19711759.1<br />Filed on 2019-03-01<br />Status: Issued 164119433 E-091-2018-0 E-091-2018-0-DE-08 USE OF IL-34 TO TREAT RETINAL INFLAMMATION AND NEURODEGENERATION EP Germany 3758736 19711759.1 Issued Germany <br />European patent (EP) 19711759.1<br />Filed on 2019-03-01<br />Status: Issued 164119434 E-091-2018-0 E-091-2018-0-GB-09 USE OF IL-34 TO TREAT RETINAL INFLAMMATION AND NEURODEGENERATION EP United Kingdom 3758736 19711759.1 Issued United Kingdom <br />European patent (EP) 19711759.1<br />Filed on 2019-03-01<br />Status: Issued 147171185 AAV Vector 147171187 Caspi 147171188 GENE THERAPY 147171190 IL-34 147171191 inflammatory disease 147171193 Inherited Retinal Dystrophies 147171195 Interleukin 34 147171196 National Eye Institute 147171197 NEI 147171198 NEURODEGENERATION 147171200 Photoreceptor Death 147171201 Retinal degeneration 147171203 Retinal Inflammation 147171204 uveitis TAB-3911 147157191 Novel Methods for Generating Retinal Pigment Epithelium Cells from Induced Pluripotent Stem Cells NEI Collaboration, Ear, Nose, & Throat, Licensing, Ophthalmology, Research Materials Collaboration Ear Nose & Throat Licensing Ophthalmology Research Materials Kapil Bharti, Kapil Bharti, Janine Davis, Marc Ferrer-Alegre, Arvydas Maminishkis, Sheldon Miller <p>The retinal pigment epithelial cells (RPE) make up a polarized monolayer in the vertebrate eye that separates the neural retina from the choroid, and performs a crucial role in retinal physiology by forming a blood-retinal barrier and closely interacting with photoreceptors to maintain visual function.  Many ophthalmic diseases, such as age-related macular degeneration, are associated with a degeneration or deterioration of the RPE. </p> <p>Researchers at NEI have developed high efficiency methods for producing retinal pigment epithelial cells (RPE) from induced pluripotent stem cells (iPSCs).  The iPSCs are produced from somatic cells, including retinal pigment epithelial cells, such as fetal RPE.  These methods involve producing embryoid bodies from human iPSCs, culturing the embryoid bodies using specific media to induce differentiation into RPE and growing the differentiated RPE cells in a defined media to generate human RPE cells.  The investigators also developed methods for detecting RPE cells and authenticating RPE cells; determining agents that can affect the production of RPE cells from an iPSC; and identifying an agent that can increase RPE survival in response to a proteo toxic insult or stress.  These novel methods and RPE cells can be useful for both pre-clinical and clinical studies involving RPE.</p> <h2>Competitive Advantages:</h2> <ul><li>These methods dramatically increase the efficiency of iPSC differentiation into RPE and produce superior quality RPE</li> <li>The RPE cells produced using these methods are fully authenticated</li> <li>These novel methods provide ways to perform high throughput screens with RPE cells</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Production of RPE cells for use in screening for novel ocular therapeutics and for identifying toxic side effects of drugs</li> <li>The RPE cells produced with these methods could be used in novel cell-based therapies</li> <li>In a research setting, these cells could be used to study the pathophysiology of RPE</li> </ul> 2016-02-16 2025-04-22 2018-07-19 2025-09-15 2016-08-31 Age-related Macular Degeneration, AMD, DIFFERENTIATION, retinal pigment epithelial cells, STEM CELLS False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2018-07-19 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147162832 Bharti, Kapil NIH - NINDS NEI Bharti, Kapil (NEI) 0 147162834 Bharti, Kapil NIH - NINDS NINDS Bharti, Kapil (NINDS) 1 147162831 Davis, Janine NIH - NEI NEI Davis, Janine (NEI) 2 147162829 Miller, Sheldon NIH - NEI NEI Miller, Sheldon (NEI) 3 147162830 Maminishkis, Arvydas NIH - NEI NEI Maminishkis, Arvydas (NEI) 4 147162833 Ferrer-Alegre, Marc NIH - NCATS NCATS Ferrer-Alegre, Marc (NCATS) 5 147162834 Bharti, Kapil NIH - NINDS NINDS Bharti, Kapil (NINDS) 1 147162832 Bharti, Kapil NIH - NINDS NEI Bharti, Kapil (NEI) 0 147162831 Davis, Janine NIH - NEI NEI Davis, Janine (NEI) 2 147162829 Miller, Sheldon NIH - NEI NEI Miller, Sheldon (NEI) 3 147162830 Maminishkis, Arvydas NIH - NEI NEI Maminishkis, Arvydas (NEI) 4 147162833 Ferrer-Alegre, Marc NIH - NCATS NCATS Ferrer-Alegre, Marc (NCATS) 5 147158275 Methods For Authenticating Fully-differentiated And Functional RPE Cells From IPS Cells E-251-2012-0 Filing authorized National Eye Institute (NEI), NCATS - NCGC, NCATS - NCGC, NINDS 147162579 Methods Of Performing High Throughput And Multiplex Screenings With IPS Cell Derived RPE E-251-2012-1 Filing authorized NCATS - NCGC, NINDS 147162580 Use Of Fetal Human RPE Derived IPS Cells For Generating Authentic RPE Cells With High Efficiency E-251-2012-2 Filing authorized National Eye Institute (NEI) 147162581 GENERATING RETINAL PIGMENT EPITHELIUM (RPE) CELLS FROM INDUCED PLURIPOTENT STEM CELLS (IPSCS) E-251-2012-3 Filing authorized National Eye Institute (NEI), NINDS 83703238 Fenn, Edward (Tedd) tedd.fenn@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-3911] Novel Methods for Generating Retinal Pigment Epithelium Cells from Induced Pluripotent Stem Cells&body=Please send me information about technology [TAB-3911] Novel Methods for Generating Retinal Pigment Epithelium Cells from Induced Pluripotent Stem Cells.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Fenn, Edward (Tedd)<br><a href="mailto:tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-3911] Novel Methods for Generating Retinal Pigment Epithelium Cells from Induced Pluripotent Stem Cells&body=Please send me information about technology [TAB-3911] Novel Methods for Generating Retinal Pigment Epithelium Cells from Induced Pluripotent Stem Cells.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">tedd.fenn@nih.gov</a><br> 147165192 E-251-2012-3 E-251-2012-3-US-01 METHOD FOR GENERATING RETINAL PIGMENT EPITHELIUM (RPE) CELLS FROM INDUCED PLURIPOTENT STEM (IPS) CELLS PRV US 61/759,988 Abandoned US <br />Provisional (PRV) 61/759,988<br />Filed on 2013-02-01<br />Status: Abandoned 147165193 E-251-2012-3 E-251-2012-3-PCT-02 Methods For Generating Retinal Pigment Epithelium (RPE) Cells From Induced Pluripotent Stem Cells (IPSCS) PCT Patent Cooperation Treaty PCT/US2014/014160 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2014/014160<br />Filed on 2014-01-31<br />Status: Expired 147165194 E-251-2012-3 E-251-2012-3-US-03 Methods For Generating Retinal Pigment Epithelium (RPE) Cells From Induced Pluripotent Stem Cells (IPSCS) National Stage US 14/764,959 Abandoned US <br />National Stage 14/764,959<br />Filed on 2015-07-30<br />Status: Abandoned 147165195 E-251-2012-3 E-251-2012-3-EP-04 Methods For Generating Retinal Pigment Epithelium (RPE) Cells From Induced Pluripotent Stem Cells (IPSCS) National Stage European Patent 2951290 14705645.1 Issued European Patent <br />National Stage 14705645.1<br />Filed on 2014-01-31<br />Status: Issued 147165196 E-251-2012-3 E-251-2012-3-CA-05 Methods For Generating Retinal Pigment Epithelium (RPE) Cells From Induced Pluripotent Stem Cells (IPSCS) National Stage Canada 2899865 2899865 Issued Canada <br />National Stage 2899865<br />Filed on 2014-01-31<br />Status: Issued 147165197 E-251-2012-3 E-251-2012-3-AU-06 Methods For Generating Retinal Pigment Epithelium (RPE) Cells From Induced Pluripotent Stem Cells (IPSCS) National Stage Australia 2014212230 2014212230 Issued Australia <br />National Stage 2014212230<br />Filed on 2014-01-31<br />Status: Issued 147165198 E-251-2012-3 E-251-2012-3-JP-07 Method For Generating Retinal Pigment Epithelium (RPE) Cells From Induced Pluripotent Stem Cells (IPSCS) National Stage Japan 6426110 2015-556170 Issued Japan <br />National Stage 2015-556170<br />Filed on 2014-01-31<br />Status: Issued 147165199 E-251-2012-3 E-251-2012-3-DK-08 Methods For Generating Retinal Pigment Epithelium (RPE) Cells From Induced Pluripotent Stem Cells (IPSCS) EP Denmark 2951290 14705645.1 Issued Denmark <br />European patent (EP) 14705645.1<br />Filed on 2014-01-31<br />Status: Issued 147165200 E-251-2012-3 E-251-2012-3-FI-09 Methods For Generating Retinal Pigment Epithelium (RPE) Cells From Induced Pluripotent Stem Cells (IPSCS) EP Finland 2951290 14705645.1 Issued Finland <br />European patent (EP) 14705645.1<br />Filed on 2014-01-31<br />Status: Issued 147165201 E-251-2012-3 E-251-2012-3-FR-10 Methods For Generating Retinal Pigment Epithelium (RPE) Cells From Induced Pluripotent Stem Cells (IPSCS) EP France 2951290 14705645.1 Issued France <br />European patent (EP) 14705645.1<br />Filed on 2014-01-31<br />Status: Issued 147165202 E-251-2012-3 E-251-2012-3-DE-11 Methods For Generating Retinal Pigment Epithelium (RPE) Cells From Induced Pluripotent Stem Cells (IPSCS) EP Germany 2951290 14705645.1 Issued Germany <br />European patent (EP) 14705645.1<br />Filed on 2014-01-31<br />Status: Issued 147165203 E-251-2012-3 E-251-2012-3-IE-12 Methods For Generating Retinal Pigment Epithelium (RPE) Cells From Induced Pluripotent Stem Cells (IPSCS) EP Ireland 2951290 14705645.1 Issued Ireland <br />European patent (EP) 14705645.1<br />Filed on 2014-01-31<br />Status: Issued 147165204 E-251-2012-3 E-251-2012-3-NL-13 Methods For Generating Retinal Pigment Epithelium (RPE) Cells From Induced Pluripotent Stem Cells (IPSCS) EP The Netherlands 2951290 14705645.1 Issued The Netherlands <br />European patent (EP) 14705645.1<br />Filed on 2014-01-31<br />Status: Issued 147165205 E-251-2012-3 E-251-2012-3-GB-14 Methods For Generating Retinal Pigment Epithelium (RPE) Cells From Induced Pluripotent Stem Cells (IPSCS) EP United Kingdom 2951290 14705645.1 Issued United Kingdom <br />European patent (EP) 14705645.1<br />Filed on 2014-01-31<br />Status: Issued 147165206 E-251-2012-3 E-251-2012-3-EP-15 Methods For Generating Retinal Pigment Epithelium (RPE) Cells From Induced Pluripotent Stem Cells (IPSCS) DIV European Patent 17197785.3 Abandoned European Patent <br />Divisional (DIV) 17197785.3<br />Filed on 2014-01-31<br />Status: Abandoned 147165207 E-251-2012-3 E-251-2012-3-US-16 METHOD FOR GENERATING RETINAL PIGMENT EPITHELIUM (RPE) CELLS FROM INDUCED PLURIPOTENT STEM CELLS (IPSCs) CON US 10,480,031 15/969,686 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10480031 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10480031">10,480,031</a><br />Filed on 2018-05-02<br />Status: Issued 147165208 E-251-2012-3 E-251-2012-3-JP-17 Method For Generating Retinal Pigment Epithelium (RPE) Cells From Induced Pluripotent Stem Cells (IPSCS) DIV Japan 2018-200003 Abandoned Japan <br />Divisional (DIV) 2018-200003<br />Filed on 2014-01-31<br />Status: Abandoned 147165209 E-251-2012-3 E-251-2012-3-US-18 METHOD FOR GENERATING RETINAL PIGMENT EPITHELIUM (RPE) CELLS FROM INDUCED PLURIPOTENT STEM CELLS (IPSCs) DIV US 11,441,184 16/586,656 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11441184 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11441184">11,441,184</a><br />Filed on 2019-09-27<br />Status: Issued 147165210 E-251-2012-3 E-251-2012-3-AU-19 Methods For Generating Retinal Pigment Epithelium (RPE) Cells From Induced Pluripotent Stem Cells (IPSCS) DIV Australia 2019236596 Abandoned Australia <br />Divisional (DIV) 2019236596<br />Filed on 2019-09-23<br />Status: Abandoned 147165211 E-251-2012-3 E-251-2012-3-US-20 METHOD FOR GENERATING RETINAL PIGMENT EPITHELIUM (RPE) CELLS FROM INDUCED PLURIPOTENT STEM CELLS (IPSCS) DIV US 17/812,915 Pending US <br />Divisional (DIV) 17/812,915<br />Filed on 2022-07-15<br />Status: Pending 147174272 Age-related Macular Degeneration 147174273 AMD 147174274 DIFFERENTIATION 147174276 retinal pigment epithelial cells 147174277 STEM CELLS TAB-3951 147157231 Selective estrogen-receptor modulators (SERMs) confer protection against photoreceptor degeneration NEI Collaboration, Ear, Nose, & Throat, Licensing, Ophthalmology, Therapeutics Collaboration Ear Nose & Throat Licensing Ophthalmology Therapeutics Wenxin Ma, Xu Wang, Wai Wong, Lian Zhao <p>Retinal degeneration is a deteriorative condition of the human retina caused by the progressive and eventual death of photoreceptor cells. To date, no effective treatment for genetically inherited or age-associated retinal degeneration, which includes a large patient population worldwide, is available. Researchers at the National Eye Institute (NEI) have discovered a novel therapeutic strategy of using one or more SERMs compounds, which may include the FDA-approved drug, Tamoxifen, for treating retinal degenerative diseases, like retinitis pigmentosa (RP) and age-related degeneration (AMD). SERMs exert their specific protection on photoreceptor degeneration likely by inhibiting microglial activation. Commercial entities who are interested in developing new drugs for ocular disorders are being actively sought for co-developing this technology as collaborative partners or licensing it for commercialization.</p> <h2>Competitive Advantages:</h2> <ul><li>There is currently no treatment for the “dry” form (geographic atrophy form) of AMD, in which the degeneration of photoreceptors results in vision loss <ul><li>Chemical drugs, with a well-characterized safety profile (like SERMs), that can neuroprotect photoreceptors, may be an effective therapy for those types of AMD</li> </ul></li> <li>There is currently no treatment for RP. Although gene therapy of RP is under active commercial development, this may not be broadly applicable to RP patients with diverse genetic causes for their condition <ul><li>Microglial contribution to degeneration is shared in multiple genetic causes of RP, and the inhibition of this contribution (likely by SERMs) may be suitable to a broad spectrum of affected patients</li> <li>Chemical compounds, like SERMs may be more advantageous than RP gene therapy in many aspects such as safety and administration</li> </ul></li> </ul> <h2>Commercial Applications:</h2> <ul><li>Potential therapeutic drug(s) for retinal degenerative diseases such as RP, AMD etc.</li> <li>Potential therapeutic drug(s) for treating retinal degenerative conditions featuring photoreceptor death</li> </ul> 2017-06-22 2025-05-15 2020-04-13 2025-09-15 2017-06-22 Age-Related Degeneration, AMD, Estrogen-receptor, Microglial Inhibition, National Eye Institute, NEI, Photoreceptor, Retinal degeneration, Retinitis Pigmentosa, RP False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-04-13 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147161961 Wang X, et al. Tamoxifen Provides Structural and Functional Rescue in Murine Models of Photoreceptor Degeneration. https://www.ncbi.nlm.nih.gov/pubmed/28235894 <a href="https://www.ncbi.nlm.nih.gov/pubmed/28235894">Wang X, et al. Tamoxifen Provides Structural and Functional Rescue in Murine Models of Photoreceptor Degeneration.</a> 147162348 Brookshire B. Researchers stumble onto a new role for breast cancer drug. https://www.sciencenews.org/article/researchers-stumble-new-role-breast-cancer-drug <a href="https://www.sciencenews.org/article/researchers-stumble-new-role-breast-cancer-drug">Brookshire B. Researchers stumble onto a new role for breast cancer drug.</a> 147162993 Wong, Wai NIH - NEI NEI Wong, Wai (NEI) 1 147162994 Zhao, Lian NIH - NEI NEI Zhao, Lian (NEI) 2 147162995 Wang, Xu NIH - NEI Wang, Xu 3 147162996 Ma, Wenxin NIH - NEI NEI Ma, Wenxin (NEI) 4 147162993 Wong, Wai NIH - NEI NEI Wong, Wai (NEI) 1 147162994 Zhao, Lian NIH - NEI NEI Zhao, Lian (NEI) 2 147162995 Wang, Xu NIH - NEI Wang, Xu 3 147162996 Ma, Wenxin NIH - NEI NEI Ma, Wenxin (NEI) 4 147158055 Selective Estrogen-receptor Modulators (SERMs) Confer Protection Against Photoreceptor Degeneration E-134-2016-0 Filing authorized National Eye Institute (NEI) 83724826 Pollard, Ricquita ricquita.pollard@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-3951] Selective estrogen-receptor modulators (SERMs) confer protection against photoreceptor degeneration&body=Please send me information about technology [TAB-3951] Selective estrogen-receptor modulators (SERMs) confer protection against photoreceptor degeneration.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollard, Ricquita<br><a href="mailto:ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-3951] Selective estrogen-receptor modulators (SERMs) confer protection against photoreceptor degeneration&body=Please send me information about technology [TAB-3951] Selective estrogen-receptor modulators (SERMs) confer protection against photoreceptor degeneration.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">ricquita.pollard@nih.gov</a><br> 147161089 E-134-2016-0 E-134-2016-0-US-01 Selective Estrogen-receptor Modulators (SERMs) Confer Protection Against Photoreceptor Degeneration PRV US 62/377,439 Abandoned US <br />Provisional (PRV) 62/377,439<br />Filed on 2016-08-19<br />Status: Abandoned 147165512 E-134-2016-0 E-134-2016-0-PCT-02 Selective Estrogen-receptor Modulators (SERMs) Confer Protection Against Photoreceptor Degeneration PCT Patent Cooperation Treaty PCT/US2017/046359 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2017/046359<br />Filed on 2017-08-10<br />Status: Expired 147165513 E-134-2016-0 E-134-2016-0-AU-03 Selective Estrogen-receptor Modulators (SERMs) Confer Protection Against Photoreceptor Degeneration National Stage Australia 2017312499 2017312499 Issued Australia <br />National Stage 2017312499<br />Filed on 2019-01-16<br />Status: Issued 147165514 E-134-2016-0 E-134-2016-0-CA-04 Selective Estrogen-receptor Modulators (SERMs) Confer Protection Against Photoreceptor Degeneration National Stage Canada 3032153 3032153 Issued Canada <br />National Stage 3032153<br />Filed on 2017-08-10<br />Status: Issued 147165515 E-134-2016-0 E-134-2016-0-EP-05 Selective Estrogen-receptor Modulators (SERMs) Confer Protection Against Photoreceptor Degeneration National Stage European Patent 3484463 17757972.9 Issued European Patent <br />National Stage 17757972.9<br />Filed on 2017-08-10<br />Status: Issued 147165516 E-134-2016-0 E-134-2016-0-JP-06 Selective Estrogen-receptor Modulators (SERMs) Confer Protection Against Photoreceptor Degeneration National Stage Japan 7100019 2019-508935 Issued Japan <br />National Stage 2019-508935<br />Filed on 2017-08-10<br />Status: Issued 147165517 E-134-2016-0 E-134-2016-0-US-07 SELECTIVE ESTROGEN-RECEPTOR MODULATORS (SERMS) CONFER PROTECTION AGAINST PHOTORECEPTOR DEGENERATION National Stage US 11,040,019 16/325,678 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11040019 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11040019">11,040,019</a><br />Filed on 2019-02-14<br />Status: Issued 147165518 E-134-2016-0 E-134-2016-0-CH-08 Selective Estrogen-receptor Modulators (SERMs) Confer Protection Against Photoreceptor Degeneration EP Switzerland 3484463 17757972.9 Issued Switzerland <br />European patent (EP) 17757972.9<br />Filed on 2017-08-10<br />Status: Issued 147165519 E-134-2016-0 E-134-2016-0-DE-09 Selective Estrogen-receptor Modulators (SERMs) Confer Protection Against Photoreceptor Degeneration EP Germany 3484463 17757972.9 Issued Germany <br />European patent (EP) 17757972.9<br />Filed on 2017-08-10<br />Status: Issued 147165520 E-134-2016-0 E-134-2016-0-FR-10 Selective Estrogen-receptor Modulators (SERMs) Confer Protection Against Photoreceptor Degeneration EP France 3484463 17757972.9 Issued France <br />European patent (EP) 17757972.9<br />Filed on 2017-08-10<br />Status: Issued 147165521 E-134-2016-0 E-134-2016-0-GB-11 Selective Estrogen-receptor Modulators (SERMs) Confer Protection Against Photoreceptor Degeneration EP United Kingdom 3484463 17757972.9 Issued United Kingdom <br />European patent (EP) 17757972.9<br />Filed on 2017-08-10<br />Status: Issued 147172137 Age-Related Degeneration 147172138 AMD 147172139 Estrogen-receptor 147172141 Microglial Inhibition 147172142 National Eye Institute 147172143 NEI 147172144 Photoreceptor 147172145 Retinal degeneration 147172146 Retinitis Pigmentosa 147172147 RP TAB-3958 147157238 Treatment of Oculocutaneous/Ocular Albinism and for Increasing Pigmentation NEI Collaboration, Ear, Nose, & Throat, Licensing, Ophthalmology, Therapeutics Collaboration Ear Nose & Throat Licensing Ophthalmology Therapeutics David Adams, Brian Brooks, William Gahl <p>Albinism (also called achromia, achromasia, or achromatosis) is a congenital disorder characterized by the complete or partial absence of pigment in the skin, hair and eyes due to absence or defect in any one of a number of proteins involved in the production of melanin.  Certain forms of albinism are known to be due to mutations in tyrosine metabolism.  In oculocutaneous albinism (OCA), pigment is lacking in the eyes, skin and hair.  In ocular albinism, only the eyes lack pigment.  Patients with albinism experience varying degrees of vision loss associated with foveal hypoplasia, nystagmus, photophobia and/or glare sensitivity, refractive errors, and abnormal decussation of ganglion cell axons at the optic chiasm.  Current treatment options for vision problems caused by albinism are limited to correction of refractive errors and amblyopia, low vision aids, and (in some cases) extraocular muscle surgery.</p> <p> Nitisinone (NTBC) is an FDA-approved drug used in the treatment of tyrosinemia, type 1.  The drug blocks the normal degradation pathway of tyrosine thus allowing greater circulating plasma levels of tyrosine.  NEI investigators identified administration of NTBC to subjects (e.g., mice or humans) with certain forms of albinism, can result in increased circulating tyrosine levels, an increase in tyrosinase activity, and, subsequently, increased pigmentation. Co-development research agreements with companies are sought to advance this treatment to humans.</p> <h2>Competitive Advantages:</h2> <ul><li>Nitisinone (NTBC) is an FDA-approved drug used in the treatment of tyrosinemia, type 1</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Nitisinone (NTBC) is an FDA-approved drug used in the treatment of tyrosinemia, type 1</li> </ul> 2016-02-16 2025-05-15 2021-06-08 2025-09-15 2017-08-30 achromasia, achromatosis, achromia, Albinism, Nitisinone, Ocular disorders, pigmentation False True Clinical True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-06-08 72159138 Clinical Phase I 72159138 NCI 37470483 Website Abstract 147162114 Adams DR et al. One-year pilot study on the effects of nitisinone on melanin in patients with OCA-1B. JCI Insight. 2019 Jan 24;4(2):e124387. doi: 10.1172/jci.insight.124387. Epub ahead of print. https://pubmed.ncbi.nlm.nih.gov/30674731/ <a href="https://pubmed.ncbi.nlm.nih.gov/30674731/">Adams DR et al. One-year pilot study on the effects of nitisinone on melanin in patients with OCA-1B. JCI Insight. 2019 Jan 24;4(2):e124387. doi: 10.1172/jci.insight.124387. Epub ahead of print.</a> 147162461 Brooks, B.P. Nitisinone for Type 1B Oculocutaneous Albinism. ClinicalTrials.gov Identifier: NCT01838655 Brooks, B.P. Nitisinone for Type 1B Oculocutaneous Albinism. ClinicalTrials.gov Identifier: NCT01838655 147163016 Brooks, Brian NIH - NEI NEI Brooks, Brian (NEI) 1 147163015 Gahl, William NIH - NHGRI NHGRI Gahl, William (NHGRI) 2 147163017 Adams, David NIH - NHGRI NHGRI Adams, David (NHGRI) 3 147163016 Brooks, Brian NIH - NEI NEI Brooks, Brian (NEI) 1 147163015 Gahl, William NIH - NHGRI NHGRI Gahl, William (NHGRI) 2 147163017 Adams, David NIH - NHGRI NHGRI Adams, David (NHGRI) 3 147158011 Nitisinone (NTBC) For Treatment Of Oculocutaneous/Ocular Albinism And For Cosmetic Tanning E-113-2010-0 Filing authorized National Eye Institute (NEI), National Human Genome Research Institute (NHGRI) 83724826 Pollard, Ricquita ricquita.pollard@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-3958] Treatment of Oculocutaneous/Ocular Albinism and for Increasing Pigmentation&body=Please send me information about technology [TAB-3958] Treatment of Oculocutaneous/Ocular Albinism and for Increasing Pigmentation.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollard, Ricquita<br><a href="mailto:ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-3958] Treatment of Oculocutaneous/Ocular Albinism and for Increasing Pigmentation&body=Please send me information about technology [TAB-3958] Treatment of Oculocutaneous/Ocular Albinism and for Increasing Pigmentation.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">ricquita.pollard@nih.gov</a><br> 147165550 E-113-2010-0 E-113-2010-0-US-01 Nitisinone (NTBC) For Treatment Of Oculocutaneous/Ocular Albinism And For Cosmetic Tanning PRV US 61/308,771 Abandoned US <br />Provisional (PRV) 61/308,771<br />Filed on 2010-02-26<br />Status: Abandoned 147165551 E-113-2010-0 E-113-2010-0-PCT-02 Nitisinone (NTBC) For Treatment Of Oculocutaneous/Ocular Albinism And For Increasing Pigmentation PCT Patent Cooperation Treaty PCT/US2011/026260 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2011/026260<br />Filed on 2011-02-25<br />Status: Expired 147165552 E-113-2010-0 E-113-2010-0-AU-03 Nitisinone (NTBC) For Treatment Of Oculocutaneous/Ocular Albinism And For Increasing Pigmentation National Stage Australia 2011220475 2011220475 Issued Australia <br />National Stage 2011220475<br />Filed on 2011-02-25<br />Status: Issued 147165553 E-113-2010-0 E-113-2010-0-CA-04 Nitisinone For Treatment Of Oculocutaneous/Ocular Albinism And For Increasing Pigmentation National Stage Canada 2791245 2791245 Issued Canada <br />National Stage 2791245<br />Filed on 2016-02-23<br />Status: Issued 147165554 E-113-2010-0 E-113-2010-0-EP-05 Nitisinone (NTBC) For Treatment Of Oculocutaneous/Ocular Albinism And For Increasing Pigmentation National Stage European Patent 2538936 11706137.4 Issued European Patent <br />National Stage 11706137.4<br />Filed on 2011-02-25<br />Status: Issued 147165555 E-113-2010-0 E-113-2010-0-US-06 Nitisinone For Treatment Of Oculocutaneious/Ocular Albinism And For Increasing Pigmentation National Stage US 8,822,540 13/580,452 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8822540 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8822540">8,822,540</a><br />Filed on 2012-09-06<br />Status: Issued 147165556 E-113-2010-0 E-113-2010-0-US-07 Nitisinone For Treatment Of Oculocutaneous/Ocular Albinism And For Increasing Pigmentation CON US 9,364,448 14/471,142 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9364448 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9364448">9,364,448</a><br />Filed on 2014-08-28<br />Status: Issued 147165557 E-113-2010-0 E-113-2010-0-CH-08 Nitisinone (NTBC) For Treatment Of Oculocutaneous/Ocular Albinism And For Increasing Pigmentation EP Switzerland 2538936 11706137.4 Issued Switzerland <br />European patent (EP) 11706137.4<br />Filed on 2012-08-27<br />Status: Issued 147165558 E-113-2010-0 E-113-2010-0-DE-09 Nitisinone (NTBC) For Treatment Of Oculocutaneous/Ocular Albinism And For Increasing Pigmentation EP Germany 2538936 11706137.4 Issued Germany <br />European patent (EP) 11706137.4<br />Filed on 2012-08-27<br />Status: Issued 147165559 E-113-2010-0 E-113-2010-0-ES-10 Nitisinone (NTBC) For Treatment Of Oculocutaneous/Ocular Albinism And For Increasing Pigmentation EP Spain 2538936 11706137.4 Issued Spain <br />European patent (EP) 11706137.4<br />Filed on 2012-08-27<br />Status: Issued 147165560 E-113-2010-0 E-113-2010-0-FR-11 Nitisinone (NTBC) For Treatment Of Oculocutaneous/Ocular Albinism And For Increasing Pigmentation EP France 2538936 11706137.4 Issued France <br />European patent (EP) 11706137.4<br />Filed on 2012-08-27<br />Status: Issued 147165561 E-113-2010-0 E-113-2010-0-GB-12 Nitisinone (NTBC) For Treatment Of Oculocutaneous/Ocular Albinism And For Increasing Pigmentation EP United Kingdom 2538936 11706137.4 Issued United Kingdom <br />European patent (EP) 11706137.4<br />Filed on 2012-08-27<br />Status: Issued 147165562 E-113-2010-0 E-113-2010-0-IT-13 Nitisinone (NTBC) For Treatment Of Oculocutaneous/Ocular Albinism And For Increasing Pigmentation EP Italy 2538936 11706137.4 Issued Italy <br />European patent (EP) 11706137.4<br />Filed on 2012-08-27<br />Status: Issued 147165563 E-113-2010-0 E-113-2010-0-SE-14 Nitisinone (NTBC) For Treatment Of Oculocutaneous/Ocular Albinism And For Increasing Pigmentation EP Sweden 2538936 11706137.4 Issued Sweden <br />European patent (EP) 11706137.4<br />Filed on 2012-08-27<br />Status: Issued 147171657 achromasia 147171659 achromatosis 147171661 achromia 147171662 Albinism 147171663 Nitisinone 147171665 Ocular disorders 147171666 pigmentation TAB-3983 147157264 Metformin for the Treatment of Age-related Retinal Degeneration NEI Collaboration, Ear, Nose, & Throat, Licensing, Ophthalmology, Therapeutics Collaboration Ear Nose & Throat Licensing Ophthalmology Therapeutics Karla Barbosa-Sabenero, Kapil Bharti, Justin Chang, Katharina Clore-Gronenborn, Balendu Jha, Kiyoharu Miyagishima, Fnu Ruchi <p>Retinal Degenerations (RD) are the leading cause of blindness in the United States. The degeneration of the Retinal Pigment Epithelium (RPE) is associated with various types of RD such as Stargardt’s disease, retinitis pigmentosa, choroideremia, Late-Onset Retinal Degeneration (L-ORD), and Age-related Macular Degeneration (AMD). The RPE as a layer of cells in the back of the eye. Therefore, it is essential to maintain the health and integrity of retinal photoreceptors. RPE dysfunction and degeneration leads to photoreceptor cell death and vision loss, a common factor among several forms of RD.</p> <p>To resolve these challenges, researchers at the National Eye Institute (NEI) generated iPS cells from two L-ORD patients with a dominant mutation in CTRP5 protein and two of their unaffected siblings. They then differentiated all iPS cells into authenticated RPE cells. A comparative analysis of RPE differentiated from these iPS cells showed sub-RPE deposits and increased VEGF secretion; two of the shared characteristics of different RDs including AMD. Interestingly, the baseline activity of AMP-protein Kinase (AMPK) – a nutrient and energy sensor that maintains energy homeostasis – was changed: in L-ORD patient-derived RPE cells, the lowered baseline intracellular calcium would likely affect lysosomal function. Thus, the reduced AMPK activity leads to lower autophagy in L-ORD patient RPE cells. Researchers at the NEI have shown that: (i) native CTRP5 activates AMPK; and (ii) Metformin, as an FDA-approved drug currently used for the treatment of diabetes, activates AMPK, reduce VEGF secretion, and corrects baseline calcium levels in patient RPE cells.</p> <p>The NEI seeks licensing and/or co-development research collaborations for Metformin as an FDA-approved drug to treat Age-related Retinal Degeneration. </p> <h2>Competitive Advantages:</h2> <ul><li>Metformin provides an upstream therapy that rescues metabolic dysfunction and decline associated with aging, thereby potentially delaying the onset of retinal disease</li> <li>L-ORD patient RPE cells demonstrate reduced AMPK activity (leading to lower autophagy), increased VEGF secretion, and unbalanced calcium levels. Metformin might be able to correct/prevent vision loss of L-ORD patients (and possibly others with retinal degenerations) through its activation of AMPK, reduction of VEGF secretion, and correction of baseline calcium levels (as demonstrated in L-ORD patient RPE cells) </li> </ul> <h2>Commercial Applications:</h2> <p>Treatment for retinal diseases:</p> <ul><li>Age-related Macular Degeneration (AMD)</li> <li>Late-onset retinal degeneration (L-ORD)</li> <li>Stargardt’s disease</li> <li>Retinitis pigmentosa</li> <li>Choroideremia</li> </ul> 2019-05-15 2025-04-22 2019-05-15 2025-09-15 2019-05-15 Age-related Macular Degeneration, AMD, Bharti, choroideremia, iPS cells, Late-Onset Retinal Degeneration, L-ORD, Metformin, RD, Retinal degeneration, Retinal Pigment Epithelium, Retinitis Pigmentosa, RPE, Stargardt’s disease False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2019-05-15 52406768 Discovery 52406768 NCI 37470483 Website Abstract E-094-2016 E-192-2014 E-212-2015 E-251-2012 E-293-2016 147163115 Bharti, Kapil NIH - NEI NEI Bharti, Kapil (NEI) 1 147163116 Miyagishima, Kiyoharu NIH - NEI NEI Miyagishima, Kiyoharu (NEI) 2 147163118 Ruchi, Fnu NIH - NEI NEI Ruchi, Fnu (NEI) 2 147163119 Chang, Justin NIH - NEI NEI Chang, Justin (NEI) 2 147163117 Clore-Gronenborn, Katharina NIH - NEI Clore-Gronenborn, Katharina 3 147163120 Jha, Balendu NIH - NEI NEI Jha, Balendu (NEI) 3 147163121 Barbosa-Sabenero, Karla NIH - NEI NEI Barbosa-Sabenero, Karla (NEI) 3 147163115 Bharti, Kapil NIH - NEI NEI Bharti, Kapil (NEI) 1 147163116 Miyagishima, Kiyoharu NIH - NEI NEI Miyagishima, Kiyoharu (NEI) 2 147163118 Ruchi, Fnu NIH - NEI NEI Ruchi, Fnu (NEI) 2 147163119 Chang, Justin NIH - NEI NEI Chang, Justin (NEI) 2 147163117 Clore-Gronenborn, Katharina NIH - NEI Clore-Gronenborn, Katharina 3 147163120 Jha, Balendu NIH - NEI NEI Jha, Balendu (NEI) 3 147163121 Barbosa-Sabenero, Karla NIH - NEI NEI Barbosa-Sabenero, Karla (NEI) 3 147158239 Metformin For The Treatment Of Age-related Retinal Degeneration E-227-2018-0 Filing authorized Clinical Center (CC), National Eye Institute (NEI), NIH - NEI 147162569 L-745,870, Riluzole, Acadesine (INN), And Aminocaproic Acid For The Treatment Of Agerelated, Inherited Retinal Degenerations, And Proliferative Vitreoretinopathy E-227-2018-1 Filing authorized National Eye Institute (NEI), NIH - NEI 147162570 Therapeutics To Maintain Retinal Pigment Epithelium (RPE) Healthy Phenotype In RPE-associated Disorders E-227-2018-2 Filing authorized National Eye Institute (NEI), NIH - NEI 147162571 NOX4 - A Druggable Target To Treat Retinal Degeneration And Metastatice Cancers E-227-2018-3 Filing authorized National Eye Institute (NEI), NIH - NEI 83703238 Fenn, Edward (Tedd) tedd.fenn@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-3983] Metformin for the Treatment of Age-related Retinal Degeneration&body=Please send me information about technology [TAB-3983] Metformin for the Treatment of Age-related Retinal Degeneration.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Fenn, Edward (Tedd)<br><a href="mailto:tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-3983] Metformin for the Treatment of Age-related Retinal Degeneration&body=Please send me information about technology [TAB-3983] Metformin for the Treatment of Age-related Retinal Degeneration.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">tedd.fenn@nih.gov</a><br> 147165707 E-227-2018-0 E-227-2018-0-US-01 Metformin For The Treatment Of Age-related Retinal Degeneration PRV US 62/899,899 Abandoned US <br />Provisional (PRV) 62/899,899<br />Filed on 2019-09-13<br />Status: Abandoned 147165708 E-227-2018-0 E-227-2018-0-PCT-02 DRUGGABLE TARGET TO TREAT RETINAL DEGENERATION PCT Patent Cooperation Treaty PCT/US2020/050540 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2020/050540<br />Filed on 2020-09-11<br />Status: Expired 147165709 E-227-2018-0 E-227-2018-0-AU-03 Druggable Target to Treat Retinal Degeneration National Stage Australia 2020346064 Pending Australia <br />National Stage 2020346064<br />Filed on 2022-03-24<br />Status: Pending 147165710 E-227-2018-0 E-227-2018-0-BR-04 Druggable Taraget to Treat Retinal Degeneration National Stage Brazil BR112022004515-8 Pending Brazil <br />National Stage BR112022004515-8<br />Filed on 2022-03-11<br />Status: Pending 147165711 E-227-2018-0 E-227-2018-0-CA-05 Druggable Taraget to Treat Retinal Degeneration National Stage Canada 3151011 Pending Canada <br />National Stage 3151011<br />Filed on 2022-03-11<br />Status: Pending 147165712 E-227-2018-0 E-227-2018-0-CN-06 Druggable Taraget to Treat Retinal Degeneration National Stage China 202080075532.5 Pending China <br />National Stage 202080075532.5<br />Filed on 2022-04-27<br />Status: Pending 147165713 E-227-2018-0 E-227-2018-0-EP-07 Druggable Taraget to Treat Retinal Degeneration National Stage European Patent 20780525.0 Pending European Patent <br />National Stage 20780525.0<br />Filed on 2022-03-31<br />Status: Pending 147165714 E-227-2018-0 E-227-2018-0-ID-08 Druggable Taraget to Treat Retinal Degeneration National Stage Indonesia P-00202204386 Pending Indonesia <br />National Stage P-00202204386<br />Filed on 2022-04-13<br />Status: Pending 147165715 E-227-2018-0 E-227-2018-0-IN-09 DRUGGABLE TARGET TO TREAT RETINAL DEGENERATION National Stage India 202247021119 Pending India <br />National Stage 202247021119<br />Filed on 2022-04-08<br />Status: Pending 147165716 E-227-2018-0 E-227-2018-0-JP-10 Druggable Taraget to Treat Retinal Degeneration National Stage Japan 2022-516237 Pending Japan <br />National Stage 2022-516237<br />Filed on 2022-03-11<br />Status: Pending 147165717 E-227-2018-0 E-227-2018-0-KR-11 Druggable Taraget to Treat Retinal Degeneration National Stage South Korea 10-2022-7012050 Pending South Korea <br />National Stage 10-2022-7012050<br />Filed on 2022-04-12<br />Status: Pending 147165718 E-227-2018-0 E-227-2018-0-MX-12 Druggable Taraget to Treat Retinal Degeneration National Stage Mexico MX/a/2022/003027 Pending Mexico <br />National Stage MX/a/2022/003027<br />Filed on 2022-03-11<br />Status: Pending 147165719 E-227-2018-0 E-227-2018-0-US-13 DRUGGABLE TARGET TO TREAT RETINAL DEGENERATION National Stage US 17/642,610 Pending US <br />National Stage 17/642,610<br />Filed on 2022-03-11<br />Status: Pending 147165720 E-227-2018-0 E-227-2018-0-ZA-14 Druggable Target to Treat Retinal Degeneration National Stage South Africa 2022/03100 Pending South Africa <br />National Stage 2022/03100<br />Filed on 2022-03-15<br />Status: Pending 147173963 Age-related Macular Degeneration 147173964 AMD 147173965 Bharti 147173967 choroideremia 147173968 iPS cells 147173970 Late-Onset Retinal Degeneration 147173972 L-ORD 147173973 Metformin 147173975 RD 147173976 Retinal degeneration 147173978 Retinal Pigment Epithelium 147173979 Retinitis Pigmentosa 147173980 RPE 147173982 Stargardt’s disease TAB-3997 147157278 Method for Reproducible Differentiation of Clinical Grade Retinal Pigment Epithelium Cells NEI Collaboration, Ear, Nose, & Throat, Licensing, Ophthalmology, Therapeutics Collaboration Ear Nose & Throat Licensing Ophthalmology Therapeutics Kapil Bharti <p>The retinal pigment epithelium (RPE) is a cell monolayer with specialized functions crucial to maintaining the metabolic environment and chemistry of the sub-retinal and choroidal layers in the eye. Damage or disease causing RPE cell loss leads to progressive photoreceptor damage and impaired vision. Loss of RPE is observed in many of the most prevalent cases of vision loss, including age related macular degeneration (AMD) and Best disease. Retinal degenerative diseases linked to loss of RPE result in a substantial economic, social, and healthcare burden for individuals and governments worldwide.</p> <p>Currently, no Food and Drug Administration (FDA) approved treatments exist for AMD. Importantly, AMD vision loss is linked to RPE cell atrophy; thus, transplant and replacement of the lost RPE with healthy and functional RPE cells might be a treatment for AMD and other retina diseases. Healthy functional RPE can be grown/differentiated from induced pluripotent stem cells. A graft of such RPE cells may potentially be implanted into the eye of AMD patients to restore vision or prevent vision loss.  However, methods for producing RPE cells for human therapy must be consistent, scalable and reliable. Generation and differentiation of clinical grade RPE under good laboratory practice (GLP) and good manufacturing practices (GMP) is critical for generating cells suitable for regulatory approval studies and for development of RPE cells for transplantation therapies. </p> <p>Researchers at the National Eye Institute (NEI),  and National Institute of Arthritis and Muscoskeletal and Skin Diseases (NIAMS) have developed a novel invention that includes a procedure/method to consistently produce clinical grade RPE cells from human induced pluripotent stem cells (iPSC). The RPE cells produced may be used for advancing transplantation therapy for AMD and other retinal degenerative diseases associated with the loss of RPE. </p> <h2>Competitive Advantages:</h2> <ul><li>Clinical-grade process </li> <li>RPE cells for therapeutics or modeling</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Producing RPE cells for commercial or research purposes</li> </ul> 2018-08-14 2025-04-22 2018-08-14 2025-09-15 2018-08-14 Age Related Macular Degeneration, AMD, Best Disease, Bharti, Human Induced Pluripotent Stem Cells, Human Retinal Pigment Epithelial Cells, IPSCS, National Eye Institute, National Institute of Arthritis and Muscoskeletal and Skin D, NEI, NIAMS, Photoreceptor, Retinal Degenerative Diseases, RPE, STEM CELLS, Vision Loss False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2018-08-14 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147162281 Miyagishimaa K, et al. In Pursuit of Authenticity: iPS Cell-derived RPE for Clinical Applications. https://www.ncbi.nlm.nih.gov/pubmed/27400791 <a href="https://www.ncbi.nlm.nih.gov/pubmed/27400791">Miyagishimaa K, et al. In Pursuit of Authenticity: iPS Cell-derived RPE for Clinical Applications.</a> 147162434 Miyagishimaa K, et al. A basis for comparison: sensitive authentication of stem cell derived RPE using physiological responses of intact RPE monolayers. https://www.ncbi.nlm.nih.gov/pubmed/28286868 <a href="https://www.ncbi.nlm.nih.gov/pubmed/28286868">Miyagishimaa K, et al. A basis for comparison: sensitive authentication of stem cell derived RPE using physiological responses of intact RPE monolayers.</a> 147163164 Bharti, Kapil NIH - NEI NEI Bharti, Kapil (NEI) 1 147163164 Bharti, Kapil NIH - NEI NEI Bharti, Kapil (NEI) 1 147158218 An Efficient, Reproducible, And GMP-compatible And Commercially Scalable Stem Cell To RPE Differentiation Protocol E-212-2015-0 Filing authorized FUJIFILM Cellular Dynamics, Inc., National Eye Institute (NEI) 83703238 Fenn, Edward (Tedd) tedd.fenn@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-3997] Method for Reproducible Differentiation of Clinical Grade Retinal Pigment Epithelium Cells&body=Please send me information about technology [TAB-3997] Method for Reproducible Differentiation of Clinical Grade Retinal Pigment Epithelium Cells.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Fenn, Edward (Tedd)<br><a href="mailto:tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-3997] Method for Reproducible Differentiation of Clinical Grade Retinal Pigment Epithelium Cells&body=Please send me information about technology [TAB-3997] Method for Reproducible Differentiation of Clinical Grade Retinal Pigment Epithelium Cells.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">tedd.fenn@nih.gov</a><br> 147161198 E-212-2015-0 E-212-2015-0-US-01 Method for Reproducible Differentiation of Clinical-Grade Retinal Pigment Epithelium Cells PRV US 62/215,579 Abandoned US <br />Provisional (PRV) 62/215,579<br />Filed on 2015-09-08<br />Status: Abandoned 147165790 E-212-2015-0 E-212-2015-0-PCT-02 METHOD FOR REPRODUCIBLE DIFFERENTIATION OF CLINICAL-GRADE RETINAL PIGMENT EPITHELIUM CELLS PCT Patent Cooperation Treaty PCT/US2016/050543 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2016/050543<br />Filed on 2016-09-07<br />Status: Expired 147165791 E-212-2015-0 E-212-2015-0-AU-03 METHOD FOR REPRODUCIBLE DIFFERENTIATION OF CLINICAL-GRADE RETINAL PIGMENT EPITHELIUM CELLS National Stage Australia 2016321170 2016321170 Issued Australia <br />National Stage 2016321170<br />Filed on 2018-03-21<br />Status: Issued 147165792 E-212-2015-0 E-212-2015-0-CA-04 METHOD FOR REPRODUCIBLE DIFFERENTIATION OF CLINICAL-GRADE RETINAL PIGMENT EPITHELIUM CELLS National Stage Canada 2997952 Pending Canada <br />National Stage 2997952<br />Filed on 2016-09-07<br />Status: Pending 147165793 E-212-2015-0 E-212-2015-0-EP-05 METHOD FOR REPRODUCIBLE DIFFERENTIATION OF CLINICAL-GRADE RETINAL PIGMENT EPITHELIUM CELLS National Stage European Patent 3347456 16766444.0 Issued European Patent <br />National Stage 16766444.0<br />Filed on 2016-09-07<br />Status: Issued 147165794 E-212-2015-0 E-212-2015-0-JP-06 METHOD FOR REPRODUCIBLE DIFFERENTIATION OF CLINICAL-GRADE RETINAL PIGMENT EPITHELIUM CELLS National Stage Japan 6983762 2018-512373 Issued Japan <br />National Stage 2018-512373<br />Filed on 2018-03-07<br />Status: Issued 147165795 E-212-2015-0 E-212-2015-0-US-07 METHOD FOR REPRODUCIBLE DIFFERENTIATION OF CLINICAL-GRADE RETINAL PIGMENT EPITHELIUM CELLS National Stage US 15/758,314 Abandoned US <br />National Stage 15/758,314<br />Filed on 2018-03-07<br />Status: Abandoned 147165796 E-212-2015-0 E-212-2015-0-US-08 METHOD FOR REPRODUCIBLE DIFFERENTIATION OF CLINICAL-GRADE RETINAL PIGMENT EPITHELIUM CELLS CON US 12,065,671 16/931,003 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12065671 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12065671">12,065,671</a><br />Filed on 2020-07-16<br />Status: Issued 147165797 E-212-2015-0 E-212-2015-0-JP-09 METHOD FOR REPRODUCIBLE DIFFERENTIATION OF CLINICAL-GRADE RETINAL PIGMENT EPITHELIUM CELLS DIV Japan 2021-128087 Pending Japan <br />Divisional (DIV) 2021-128087<br />Filed on 2021-08-04<br />Status: Pending 164119154 E-212-2015-0 E-212-2015-0-US-02 METHOD FOR REPRODUCIBLE DIFFERENTIATION OF CLINICAL-GRADE RETINAL PIGMENT EPITHELIUM CELLS CON US 18/769,320 Pending US <br />Continuation (CON) 18/769,320<br />Filed on 2024-07-10<br />Status: Pending 147173756 Age Related Macular Degeneration 147173757 AMD 147173759 Best Disease 147173760 Bharti 147173762 Human Induced Pluripotent Stem Cells 147173764 Human Retinal Pigment Epithelial Cells 147173765 IPSCS 147173766 National Eye Institute 147173768 National Institute of Arthritis and Muscoskeletal and Skin D 147173769 NEI 147173770 NIAMS 147173771 Photoreceptor 147173773 Retinal Degenerative Diseases 147173774 RPE 147173775 STEM CELLS 147173776 Vision Loss TAB-4014 147157295 Machine Learning and/or Neural Networks to Validate Stem Cells and Their Derivatives for Use in Cell Therapy, Drug Delivery, and Diagnostics NEI Cardiology, Collaboration, Dermatology, Licensing, Oncology, Software / Apps Cardiology Collaboration Dermatology Licensing Oncology Software / Apps Kapil Bharti, Nathan Hotaling, Nicholas Schaub, Carl Simon <p>Many biological and clinical procedures require functional validation of a desired cell type. Current techniques to validate rely on various assays and methods, such as staining with dyes, antibodies, and nucleic acid probes, to assess stem cell health, death, proliferation, and functionality. These techniques potentially destroy stem cells and risk contaminating cells and cultures by exposing them to the environment; they are low-throughput and difficult to scale-up. Therefore, there is a significant need for potentially less invasive, scalable, higher throughput methods of validation, while maintaining quality and accuracy.</p> <p>Trained biologists can often recognize cells and phenotypic cell function based on cell appearance under a microscope. Applying machine learning to perform similar visual analysis may have many advantages. Computer-automated, image-based validation of a cell’s function does not require exposing the cells to the environment, thus significantly reducing the chance of cell contamination or destruction. Furthermore, such technology could be more inexpensive to implement than other validation or quality controls. It even has potential for high throughput use, to be scaled up, for many applications in research, manufacturing, and cell therapeutics settings. </p> <p>Scientists at the National Cancer Institute (NCI) and National Institute of Standards and Technology (NIST) have developed an image-based machine learning system that is able to validate functional cell phenotypes. The system may be trained to automatically recognize image features that correlate to a desired cell-type or properties for research, diagnostic, and therapeutic purposes. Learned models based on multiple visual characteristics may be developed using this system. The system has been shown to accurately recognize retinal pigment epithelial (RPE), with validated physiological function. It may also be trained to recognize numerous other cells such as embryonic stem cells (ESC), induced pluripotent stem cells (IPSC), neural stem cells (NSC), mesenchymal stem cells (MSC), hematopoietic stem cells (HSC), and cancer stem cells (CSC). This novel technology may have applications for cell therapies &amp; transplants, (including those that are stem cell-derived), and for validation, quality control, and cell diagnostics in many areas. </p> <h2>Competitive Advantages:</h2> <ul><li>Least invasive means of identifying cell qualities</li> <li>Inexpensive means of performing cell diagnostics</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Stem cell therapies</li> <li>Validation</li> <li>Quality control</li> <li>Cell diagnostic </li> <li>Clinical diagnostic </li> </ul> 2018-08-14 2025-04-22 2018-08-14 2025-09-15 2018-08-14 Bharti, Cell therapy, Cell Validation, Less Invasive Diagnostics, Machine Learning, Neural Networks, QUALITY CONTROL, Stem Cell Diagnostics, Stem Cell Therapy False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2018-08-14 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147163218 Bharti, Kapil NIH - NEI NEI Bharti, Kapil (NEI) 1 147163220 Schaub, Nicholas National Institute of Standards and Technology Schaub, Nicholas 2 147163221 Simon, Carl National Institute of Standards and Technology Simon, Carl 3 147163219 Hotaling, Nathan NIH - NEI NEI Hotaling, Nathan (NEI) 4 147163218 Bharti, Kapil NIH - NEI NEI Bharti, Kapil (NEI) 1 147163220 Schaub, Nicholas National Institute of Standards and Technology Schaub, Nicholas 2 147163221 Simon, Carl National Institute of Standards and Technology Simon, Carl 3 147163219 Hotaling, Nathan NIH - NEI NEI Hotaling, Nathan (NEI) 4 147157886 Using Machine Learning And/or Neural Networks To Validate Stem Cells And Their Derivatives (2-D Cells And 3-D Tissues) Fro Use In Cell Therapy And Tissue Engineered Products E-058-2018-0 Filing authorized National Eye Institute (NEI), National Institute of Standards and Technology 83703238 Fenn, Edward (Tedd) tedd.fenn@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-4014] Machine Learning and/or Neural Networks to Validate Stem Cells and Their Derivatives for Use in Cell Therapy, Drug Delivery, and Diagnostics&body=Please send me information about technology [TAB-4014] Machine Learning and/or Neural Networks to Validate Stem Cells and Their Derivatives for Use in Cell Therapy, Drug Delivery, and Diagnostics.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Fenn, Edward (Tedd)<br><a href="mailto:tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-4014] Machine Learning and/or Neural Networks to Validate Stem Cells and Their Derivatives for Use in Cell Therapy, Drug Delivery, and Diagnostics&body=Please send me information about technology [TAB-4014] Machine Learning and/or Neural Networks to Validate Stem Cells and Their Derivatives for Use in Cell Therapy, Drug Delivery, and Diagnostics.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">tedd.fenn@nih.gov</a><br> 147160975 E-058-2018-0 E-058-2018-0-US-01 USING MACHINE LEARNING AND/OR NEURAL NETWORKS TO VALIDATE STEM CELLS AND THEIR DERIVATIVES FOR USE IN CELL THERAPY, DRUG DISCOVERY AND DIAGNOSTICS PRV US 62/644,175 Abandoned US <br />Provisional (PRV) 62/644,175<br />Filed on 2018-03-16<br />Status: Abandoned 147165984 E-058-2018-0 E-058-2018-0-PCT-02 USING MACHINE LEARNING AND/OR NEURAL NETWORKS TO VALIDATE STEM CELLS AND THEIR DERIVATIVES FOR USE IN CELL THERAPY, DRUG DISCOVERY, AND DIAGNOSTICS PCT Patent Cooperation Treaty PCT/US2019/022611 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2019/022611<br />Filed on 2019-03-15<br />Status: Expired 147165985 E-058-2018-0 E-058-2018-0-US-03 Using Machine Learning And/or Neural Networks To Validate Stem Cells And Their Derivatives (2-D Cells And 3-D Tissues) For Use In Cell Therapy And Tissue Engineered Products National Stage US 11,531,844 16/981,531 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11531844 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11531844">11,531,844</a><br />Filed on 2020-09-16<br />Status: Issued 147165986 E-058-2018-0 E-058-2018-0-AU-04 USING MACHINE LEARNING AND/OR NEURAL NETWORKS TO VALIDATE STEM CELLS AND THEIR DERIVATIVES FOR USE IN CELL THERAPY, DRUG DISCOVERY, AND DIAGNOSTICS National Stage Australia 2019236297 2019236297 Issued Australia <br />National Stage 2019236297<br />Filed on 2020-09-16<br />Status: Issued 147165987 E-058-2018-0 E-058-2018-0-CA-05 USING MACHINE LEARNING AND/OR NEURAL NETWORKS TO VALIDATE STEM CELLS AND THEIR DERIVATIVES FOR USE IN CELL THERAPY, DRUG DISCOVERY, AND DIAGNOSTICS National Stage Canada 3094078 3094078 Issued Canada <br />National Stage 3094078<br />Filed on 2019-03-15<br />Status: Issued 147165988 E-058-2018-0 E-058-2018-0-EP-06 USING MACHINE LEARNING AND/OR NEURAL NETWORKS TO VALIDATE STEM CELLS AND THEIR DERIVATIVES FOR USE IN CELL THERAPY, DRUG DISCOVERY, AND DIAGNOSTICS National Stage European Patent 19714930.5 Pending European Patent <br />National Stage 19714930.5<br />Filed on 2019-03-15<br />Status: Pending 147165989 E-058-2018-0 E-058-2018-0-JP-07 USING MACHINE LEARNING AND/OR NEURAL NETWORKS TO VALIDATE STEM CELLS AND THEIR DERIVATIVES FOR USE IN CELL THERAPY, DRUG DISCOVERY, AND DIAGNOSTICS National Stage Japan 7659394 2020-549687 Issued Japan <br />National Stage 2020-549687<br />Filed on 2020-09-15<br />Status: Issued 147165990 E-058-2018-0 E-058-2018-0-US-08 USING MACHINE LEARNING AND/OR NEURAL NETWORKS TO VALIDATE STEM CELLS AND THEIR DERIVATIVES (2-D CELLS AND 3-D TISSUES) FOR USE IN CELL THERAPY AND TISSUE ENGINEERED PRODUCTS CON US 12,020,494 17/983,963 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12020494 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12020494">12,020,494</a><br />Filed on 2022-11-09<br />Status: Issued 164118996 E-058-2018-0 E-058-2018-0-US-09 Using Machine Learning And/or Neural Networks To Validate Stem Cells And Their Derivatives (2-D Cells And 3-D Tissues) For Use In Cell Therapy And Tissue Engineered Products CON US 18/662,788 Pending US <br />Continuation (CON) 18/662,788<br />Filed on 2024-05-13<br />Status: Pending 164118997 E-058-2018-0 E-058-2018-0-AU-10 USING MACHINE LEARNING AND/OR NEURAL NETWORKS TO VALIDATE STEM CELLS AND THEIR DERIVATIVES FOR USE IN CELL THERAPY, DRUG DISCOVERY, AND DIAGNOSTICS DIV Australia 2024227758 Pending Australia <br />Divisional (DIV) 2024227758<br />Filed on 2024-10-30<br />Status: Pending 164118998 E-058-2018-0 E-058-2018-0-JP-01 USING MACHINE LEARNING AND/OR NEURAL NETWORKS TO VALIDATE STEM CELLS AND THEIR DERIVATIVES FOR USE IN CELL THERAPY, DRUG DISCOVERY, AND DIAGNOSTICS DIV Japan 2025-055757 Pending Japan <br />Divisional (DIV) 2025-055757<br />Filed on 2025-03-28<br />Status: Pending 164118999 E-058-2018-0 E-058-2018-0-CA-01 USING MACHINE LEARNING AND/OR NEURAL NETWORKS TO VALIDATE STEM CELLS AND THEIR DERIVATIVES FOR USE IN CELL THERAPY, DRUG DISCOVERY, AND DIAGNOSTICS DIV Canada 3279009 Pending Canada <br />Divisional (DIV) 3279009<br />Filed on 2025-07-03<br />Status: Pending 147170438 Bharti 147170439 Cell therapy 147170441 Cell Validation 147170443 Less Invasive Diagnostics 147170445 Machine Learning 147170447 Neural Networks 147170448 QUALITY CONTROL 147170450 Stem Cell Diagnostics 147170452 Stem Cell Therapy TAB-4093 147157375 3D Vascularized Human Ocular Tissue for Cell Therapy and Drug Discovery NEI Collaboration, Ear, Nose, & Throat, Licensing, Ophthalmology, Therapeutics Collaboration Ear Nose & Throat Licensing Ophthalmology Therapeutics Kapil Bharti, Russell Quinn, Min Jae Song <p>Degeneration of retinal tissues occurs in many ocular disorders resulting in the loss of vision. Dysfunction and/or loss of Retinal Pigment Epithelium Cells (RPE) and disruption of the associated blood retinal barrier (BRB) tissue structures are linked with many ocular diseases and conditions including: age-related macular degeneration (AMD), Best disease, and retinitis pigmentosa. Engineered tissue structures that are able to replicate the function of lost BRB structures may restore lost vision and provide insight into new treatments and mechanisms of the underlying conditions. </p> <p>Scientists at the National Eye Institute (NEI) have developed a technology for a 3D bioprinting process. Through the process, an artificial blood retinal barrier (BRB) is constructed that may be used as a graft to potentially replace BRB tissues that are lost or damaged in many ocular disorders. The layers of BRB structures are printed as “bio-ink” (a specified formulation of cells that may be mixed with other biomaterials). The formulation of the bio-inks in each layer can be controlled. For example, induced pluripotent stem cells can be differentiated into RPE cells and endothelial cells, fibroblasts and pericytes. These differentiated cells may be used to formulate the desired composition for each bio-ink. Each formulated bio-ink layer may then be printed in a precise, user-defined, spatial and temporally-controlled pattern to build a 3D tissue architecture. Through this process, a 3D printed tissue architecture, similar in structure and function to natural BRB tissues, may be created.  The printed tissue structures might be therapeutically useful for grafts or as model systems to test function and physiological responses to drugs or other variables introduced into the system. </p> <p>The NEI is seeking partners for commercial licensing &amp; development and for possible collaborative research related to the development of this technology. </p> <h2>Competitive Advantages:</h2> <ul><li>No current in vitro model of human BRB diseases</li> <li>No current effective therapy to restore BRB tissue lost in human BRB disorders</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Cell based therapy </li> <li>Develop a human model for disease &amp; drug target testing, and identification</li> </ul> 2018-08-16 2025-04-22 2020-04-13 2025-09-15 2018-08-16 3D bio-printing, Bharti, Blood Retinal Barrier Disorder, BRB, Cell therapy, in Vitro Human Blood Retinal Barrier Model, Ocular cell therapy scaffold, Retinal disorder, Retinal Pigment Epithelium Cells False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-04-13 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147163480 Bharti, Kapil NIH - NEI NEI Bharti, Kapil (NEI) 1 147163481 Song, Min Jae NIH - NEI NCATS Song, Min Jae (NCATS) 2 147163482 Quinn, Russell NIH - NEI NEI Quinn, Russell (NEI) 3 147163480 Bharti, Kapil NIH - NEI NEI Bharti, Kapil (NEI) 1 147163481 Song, Min Jae NIH - NEI NCATS Song, Min Jae (NCATS) 2 147163482 Quinn, Russell NIH - NEI NEI Quinn, Russell (NEI) 3 147157770 3D Vascularized Human Ocular Tissue For Cell Therapy And Drug Discovery And A Manufacturing Process To Develop A 3D Vascularized Human Ocular Tissue That Can Be Used For Cell Therapy, Drug Discovery, And Drug Testing E-004-2017-0 Filing authorized National Eye Institute (NEI) 83703238 Fenn, Edward (Tedd) tedd.fenn@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-4093] 3D Vascularized Human Ocular Tissue for Cell Therapy and Drug Discovery&body=Please send me information about technology [TAB-4093] 3D Vascularized Human Ocular Tissue for Cell Therapy and Drug Discovery.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Fenn, Edward (Tedd)<br><a href="mailto:tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-4093] 3D Vascularized Human Ocular Tissue for Cell Therapy and Drug Discovery&body=Please send me information about technology [TAB-4093] 3D Vascularized Human Ocular Tissue for Cell Therapy and Drug Discovery.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">tedd.fenn@nih.gov</a><br> 147160884 E-004-2017-0 E-004-2017-0-US-01 3D Vascularized Human Ocular Tissue For Cell Therapy And Drug Discovery PRV US 62/419,835 Abandoned US <br />Provisional (PRV) 62/419,835<br />Filed on 2016-11-09<br />Status: Abandoned 147166433 E-004-2017-0 E-004-2017-0-PCT-02 3D VASCULARIZED HUMAN OCULAR TISSUE FOR CELL THERAPY AND DRUG DISCOVERY PCT Patent Cooperation Treaty PCT/US2017/060666 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2017/060666<br />Filed on 2017-11-08<br />Status: Expired 147166434 E-004-2017-0 E-004-2017-0-US-03 3D VASCULARIZED HUMAN OCULAR TISSUE FOR CELL THERAPY AND DRUG DISCOVERY National Stage US 11,458,225 16/347,939 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11458225 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11458225">11,458,225</a><br />Filed on 2019-05-07<br />Status: Issued 147166435 E-004-2017-0 E-004-2017-0-AU-04 3D VASCULARIZED HUMAN OCULAR TISSUE FOR CELL THERAPY AND DRUG DISCOVERY National Stage Australia 2017359330 2017359330 Issued Australia <br />National Stage 2017359330<br />Filed on 2017-11-08<br />Status: Issued 147166436 E-004-2017-0 E-004-2017-0-CA-05 3D VASCULARIZED HUMAN OCULAR TISSUE FOR CELL THERAPY AND DRUG DISCOVERY National Stage Canada 3043194 3043194 Issued Canada <br />National Stage 3043194<br />Filed on 2017-11-08<br />Status: Issued 147166437 E-004-2017-0 E-004-2017-0-EP-06 3D VASCULARIZED HUMAN OCULAR TISSUE FOR CELL THERAPY AND DRUG DISCOVERY National Stage European Patent 3538168 17801270.4 Issued European Patent <br />National Stage 17801270.4<br />Filed on 2017-11-08<br />Status: Issued 147166438 E-004-2017-0 E-004-2017-0-JP-07 3D VASCULARIZED HUMAN OCULAR TISSUE FOR CELL THERAPY AND DRUG DISCOVERY National Stage Japan 7222900 2019-545899 Issued Japan <br />National Stage 2019-545899<br />Filed on 2017-11-08<br />Status: Issued 147166439 E-004-2017-0 E-004-2017-0-US-08 3D VASCULARIZED HUMAN OCULAR TISSUE FOR CELL THERAPY AND DRUG DISCOVERY DIV US 17/894,773 Pending US <br />Divisional (DIV) 17/894,773<br />Filed on 2022-08-24<br />Status: Pending 147166440 E-004-2017-0 E-004-2017-0-JP-01 3D VASCULARIZED HUMAN OCULAR TISSUE FOR CELL THERAPY AND DRUG DISCOVERY DIV Japan 7565022 2023-015034 Issued Japan <br />Divisional (DIV) 2023-015034<br />Filed on 2023-02-03<br />Status: Issued 164118816 E-004-2017-0 E-004-2017-0-FR-09 3D VASCULARIZED HUMAN OCULAR TISSUE FOR CELL THERAPY AND DRUG DISCOVERY EP France 3538168 17801270.4 Issued France <br />European patent (EP) 17801270.4<br />Filed on 2017-11-08<br />Status: Issued 164118817 E-004-2017-0 E-004-2017-0-DE-10 3D VASCULARIZED HUMAN OCULAR TISSUE FOR CELL THERAPY AND DRUG DISCOVERY EP Germany 3538168 17801270.4 Issued Germany <br />European patent (EP) 17801270.4<br />Filed on 2017-11-08<br />Status: Issued 164118818 E-004-2017-0 E-004-2017-0-GB-11 3D VASCULARIZED HUMAN OCULAR TISSUE FOR CELL THERAPY AND DRUG DISCOVERY EP United Kingdom 3538168 17801270.4 Issued United Kingdom <br />European patent (EP) 17801270.4<br />Filed on 2017-11-08<br />Status: Issued 147169281 3D bio-printing 147169283 Bharti 147169285 Blood Retinal Barrier Disorder 147169286 BRB 147169288 Cell therapy 147169290 in Vitro Human Blood Retinal Barrier Model 147169292 Ocular cell therapy scaffold 147169294 Retinal disorder 147169296 Retinal Pigment Epithelium Cells TAB-4110 147157392 RP2 and RPGR Vectors For Treating X-linked Retinitis Pigmentosa NEI Collaboration, Ear, Nose, & Throat, Licensing, Ophthalmology, Therapeutics Collaboration Ear Nose & Throat Licensing Ophthalmology Therapeutics Suja Hiriyanna, Tiansen Li, Suddhasil Mookherjee, Anand Swaroop, Zhijian Wu <p>X-linked forms of retinitis pigmentosa (XLRP) are relatively severe blinding disorders, resulting from progressive photoreceptor dysfunction primarily caused by mutations in RPGR or RP2 gene.</p> <p>This technology is poised to advance RPGR or RP2 gene therapy to clinical stage using AAV8 or AAV9 vector carrying human full-length RPGR or RP2-coding sequence.  The investigators have performed a wide dose range study over 18-months and found it to preserve rod and/or cone function as evidenced by ERG and/or OCT, optomotor tests. Morphologically, the treatment preserved rod and cone viability, and corrected mistrafficking of cone opsin and/or rhodopsin. The therapeutic effect was also achieved in advanced disease stage. The broad treatment window and long-lasting therapeutic effects make the RPGR and RP2 gene therapy attractive for clinical development.</p> <p>This technology is available for licensing, or the NEI research team will entertain potential collaborations that will advance this technology through the remaining preclinical stage toward IND development under a CRADA or a license combined with a CRADA project.</p> <blockquote><p><em>This patented treatment of albinism has not been approved by the U.S. Food and Drug Administration (FDA), and currently there is no active clinical trial to assess this albinism therapy benefit. However, if you are interested in participating in a future or upcoming NIH clinical trial on albinism, please contact NIH clinical coordinator, Ms. Ellaine Galindez-Balut (<a href="mailto:ellaine.galindez-balut@nih.gov">ellaine.galindez-balut@nih.gov</a>), for helpful information. Thank you.</em></p> </blockquote> <h2>Competitive Advantages:</h2> <ul><li>Pre-clinical dose efficacy study done </li> <li>RPGR and RP2 available in both AAV-8 and AAV-9 vectors. </li> <li>Preclinical data to show that treatment at advanced age also shows remarkable preservation of retinal structure and function.</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Use in gene therapy to prevent or cure XLRP</li> <li>Preserving cone and/or rod function, restoring ERG and protein in the retina, increasing photoreceptor numbers, decrease in retinal detachments </li> <li>Improving quality of life, visual acuity, ability to drive and independent living</li> </ul> 2018-06-01 2025-05-15 2018-06-01 2025-09-15 2018-06-01 GENE THERAPY, hereditary ocular disease, Pigmentosa, Retina, Wu False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2018-06-01 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-162-2016 E-164-2014 147162027 Wu Z, et al. A long-term efficacy study of gene replacement therapy for RPGR-associated retinal degeneration https://www.ncbi.nlm.nih.gov/pubmed/25877300 <a href="https://www.ncbi.nlm.nih.gov/pubmed/25877300">Wu Z, et al. A long-term efficacy study of gene replacement therapy for RPGR-associated retinal degeneration</a> 147162066 Zhang H, et al. Mistrafficking of prenylated proteins causes retinitis pigmentosa 2. https://www.ncbi.nlm.nih.gov/pubmed/25422369 <a href="https://www.ncbi.nlm.nih.gov/pubmed/25422369">Zhang H, et al. Mistrafficking of prenylated proteins causes retinitis pigmentosa 2.</a> 147162105 Li L, et al. Ablation of the X-linked retinitis pigmentosa 2 (Rp2) gene in mice results in opsin mislocalization and photoreceptor degeneration https://www.ncbi.nlm.nih.gov/pubmed/23745007 <a href="https://www.ncbi.nlm.nih.gov/pubmed/23745007">Li L, et al. Ablation of the X-linked retinitis pigmentosa 2 (Rp2) gene in mice results in opsin mislocalization and photoreceptor degeneration</a> 147162183 Mookherjee S, et al. Long-term rescue of cone photoreceptor degeneration in retinitis pigmentosa 2 (RP2)-knockout mice by gene replacement therapy https://www.ncbi.nlm.nih.gov/pubmed/26358772 <a href="https://www.ncbi.nlm.nih.gov/pubmed/26358772">Mookherjee S, et al. Long-term rescue of cone photoreceptor degeneration in retinitis pigmentosa 2 (RP2)-knockout mice by gene replacement therapy</a> 147163543 Wu, Zhijian NIH - NEI NEI Wu, Zhijian (NEI) 1 147163540 Swaroop, Anand NIH - NEI NEI Swaroop, Anand (NEI) 2 147163544 Mookherjee, Suddhasil National Eye Institute (NEI) NEI Mookherjee, Suddhasil (NEI) 3 147163542 Hiriyanna, Suja NIH - NEI NEI Hiriyanna, Suja (NEI) 4 147163541 Li, Tiansen NIH - NEI NEI Li, Tiansen (NEI) 5 147163543 Wu, Zhijian NIH - NEI NEI Wu, Zhijian (NEI) 1 147163540 Swaroop, Anand NIH - NEI NEI Swaroop, Anand (NEI) 2 147163544 Mookherjee, Suddhasil National Eye Institute (NEI) NEI Mookherjee, Suddhasil (NEI) 3 147163542 Hiriyanna, Suja NIH - NEI NEI Hiriyanna, Suja (NEI) 4 147163541 Li, Tiansen NIH - NEI NEI Li, Tiansen (NEI) 5 147157871 Novel Gene Therapy Vectors For Treating X-linked Retinitis Pigmentosa Caused Bymutations In RPGR And/or RP2 Genes E-050-2015-0 Filing authorized National Eye Institute (NEI) 83724826 Pollard, Ricquita ricquita.pollard@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4110] RP2 and RPGR Vectors For Treating X-linked Retinitis Pigmentosa&body=Please send me information about technology [TAB-4110] RP2 and RPGR Vectors For Treating X-linked Retinitis Pigmentosa.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollard, Ricquita<br><a href="mailto:ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4110] RP2 and RPGR Vectors For Treating X-linked Retinitis Pigmentosa&body=Please send me information about technology [TAB-4110] RP2 and RPGR Vectors For Treating X-linked Retinitis Pigmentosa.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">ricquita.pollard@nih.gov</a><br> 147166581 E-050-2015-0 E-050-2015-0-US-01 RP2 and RPGR Vectors For Treating X-linked Retinitis Pigmentosa PRV US 62/131,661 Abandoned US <br />Provisional (PRV) 62/131,661<br />Filed on 2015-03-11<br />Status: Abandoned 147166583 E-050-2015-0 E-050-2015-0-PCT-03 RP2 and RPGR Vectors for Treating X-Linked Retinitis Pigmentosa PCT Patent Cooperation Treaty PCT/US2016/022072 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2016/022072<br />Filed on 2016-03-11<br />Status: Expired 147166584 E-050-2015-0 E-050-2015-0-AU-04 RP2 and RPGR Vectors for Treating X-Linked Retinitis Pigmentosa National Stage Australia 2016228751 2016228751 Issued Australia <br />National Stage 2016228751<br />Filed on 2016-03-11<br />Status: Issued 147166585 E-050-2015-0 E-050-2015-0-CA-05 RP2 and RPGR Vectors for Treating X-Linked Retinitis Pigmentosa National Stage Canada 2979229 Pending Canada <br />National Stage 2979229<br />Filed on 2016-03-11<br />Status: Pending 147166586 E-050-2015-0 E-050-2015-0-EP-06 RP2 and RPGR Vectors for Treating X-Linked Retinitis Pigmentosa National Stage European Patent 3268481 16762623.3 Issued European Patent <br />National Stage 16762623.3<br />Filed on 2017-10-11<br />Status: Issued 147166587 E-050-2015-0 E-050-2015-0-JP-07 RP2 and RPGR Vectors for Treating X-Linked Retinitis Pigmentosa National Stage Japan 6935049 2017-547425 Issued Japan <br />National Stage 2017-547425<br />Filed on 2017-09-08<br />Status: Issued 147166588 E-050-2015-0 E-050-2015-0-US-08 RP2 AND RPGR VECTORS FOR TREATING X-LINKED RETINITIS PIGMENTOSA National Stage US 10,646,588 15/556,746 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10646588 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10646588">10,646,588</a><br />Filed on 2017-09-08<br />Status: Issued 147166589 E-050-2015-0 E-050-2015-0-US-09 RP2 AND RPGR VECTORS FOR TREATING X-LINKED RETINITIS PIGMENTOSA DIV US 11,617,801 16/854,605 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11617801 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11617801">11,617,801</a><br />Filed on 2020-04-21<br />Status: Issued 147166590 E-050-2015-0 E-050-2015-0-DE-10 RP2 and RPGR Vectors for Treating X-Linked Retinitis Pigmentosa EP Germany 3268481 16762623.3 Issued Germany <br />European patent (EP) 16762623.3<br />Filed on 2017-10-11<br />Status: Issued 147166591 E-050-2015-0 E-050-2015-0-FR-11 RP2 and RPGR Vectors for Treating X-Linked Retinitis Pigmentosa EP France 3268481 16762623.3 Issued France <br />European patent (EP) 16762623.3<br />Filed on 2017-10-11<br />Status: Issued 147166592 E-050-2015-0 E-050-2015-0-GB-12 RP2 and RPGR Vectors for Treating X-Linked Retinitis Pigmentosa EP United Kingdom 3268481 16762623.3 Issued United Kingdom <br />European patent (EP) 16762623.3<br />Filed on 2017-10-11<br />Status: Issued 147166593 E-050-2015-0 E-050-2015-0-EP-13 RP2 and RPGR Vectors for Treating X-Linked Retinitis Pigmentosa DIV European Patent 3719134 20176667.2 Issued European Patent <br />Divisional (DIV) 20176667.2<br />Filed on 2020-05-26<br />Status: Issued 147166594 E-050-2015-0 E-050-2015-0-JP-14 RP2 and RPGR Vectors for Treating X-Linked Retinitis Pigmentosa DIV Japan 2020-167984 Abandoned Japan <br />Divisional (DIV) 2020-167984<br />Filed on 2020-10-02<br />Status: Abandoned 164118779 E-050-2015-0 E-050-2015-0-FR-14 RP2 and RPGR Vectors for Treating X-Linked Retinitis Pigmentosa EP France 3719134 20176667.2 Issued France <br />European patent (EP) 20176667.2<br />Filed on 2020-05-26<br />Status: Issued 164118780 E-050-2015-0 E-050-2015-0-IT-15 RP2 and RPGR Vectors for Treating X-Linked Retinitis Pigmentosa EP Italy 3719134 20176667.2 Issued Italy <br />European patent (EP) 20176667.2<br />Filed on 2020-05-26<br />Status: Issued 164118781 E-050-2015-0 E-050-2015-0-DE-16 RP2 and RPGR Vectors for Treating X-Linked Retinitis Pigmentosa EP Germany 3719134 20176667.2 Issued Germany <br />European patent (EP) 20176667.2<br />Filed on 2020-05-26<br />Status: Issued 164118782 E-050-2015-0 E-050-2015-0-GB-17 RP2 and RPGR Vectors for Treating X-Linked Retinitis Pigmentosa EP United Kingdom 3719134 20176667.2 Issued United Kingdom <br />European patent (EP) 20176667.2<br />Filed on 2020-05-26<br />Status: Issued 147170314 GENE THERAPY 147170316 hereditary ocular disease 147170317 Pigmentosa 147170318 Retina 147170320 Wu TAB-4162 147157445 Methods and Compositions for Treating Genetically Linked Diseases of the Eye NEI Ear, Nose, & Throat, Licensing, Ophthalmology, Therapeutics Ear Nose & Throat Licensing Ophthalmology Therapeutics Ronald Bush, Peter Colosi, Paul Sieving, Yong Zeng <p>X-linked retinoschisis (XLRS) is an inherited, monogenetic ocular disease caused by mutations in the retinoschisin (RS1) gene, resulting in the development of cystic cavities throughout the retina and leading to juvenile macular degeneration. Approximately 1:15,000 males in the US are affected, classifying the condition as an orphan indication. </p> <p>The National Eye Institute (NEI) has developed a tissue-specific gene therapy approach based upon adeno-associated virus (AAV) mediated delivery of the full coding sequence for human retinoschisin to retinal cells under the control of a retinoschisin promoter.  Delivery and expression of AAV-RS1 is a novel invention for the restoration of RS1 expression in those suffering from XLRS, presenting a potential cure to an untreatable disease.  Restoration of both structure and function was demonstrated in a preclinical mouse model. A single site Phase I/IIa clinical trial of AAV-RS1 using GMP-grade material is in progress at the NIH/NEI.  </p> <p>This technology will be of interest and value to licensors or co-development partners capable of evaluating the clinical and regulatory path, apply its regulatory, manufacturing, and clinical expertise in gene therapy. The licensors/collaborator will identify an optimal course toward regulatory approval in the US and other countries. Ideally, the collaborator will participate in conducting aPhase II/III multicenter trial including U.S. and European trial sites – will the submission of a BLA or comparable application for marketing approval in the US as well as relevant global markets.</p> <h2>Competitive Advantages:</h2> <ul><li>Clinical-stage asset</li> <li>No FDA approved drug or therapy is available for XLRS</li> <li>The XLRS gene replacement strategy is applicable to all XLRS causative gene defects</li> <li>The use of a low-seroprevalence, non-pathogenic AAV8 vector favors efficacy in a high percentage of the patient population</li> <li>The use of a tissue specific promoter limits non-specific gene expression</li> <li>Demonstrated GMP manufacturing process</li> <li>Eligible for Orphan Drug Status</li> </ul> <h2>Commercial Applications:</h2> <p>Potentially curative therapy for XLRS regardless of genetic background or causative XLRS genetic defect.</p> 2018-07-27 2025-05-15 2020-08-13 2025-09-15 2018-07-27 Clinical, EYE, GENE THERAPY, ophthalmological, Orphan Indication, Sieving, XLRS False True Clinical True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-08-13 72159138 Clinical Phase I 72159138 NCI 37470483 Website Abstract 147162134 Bush RA, et al. Preclinical Dose Escalation Study of Intravitreal AAV-RS1 Gene Therapy in a Mouse Model of X-linked Retinoschisis: Dose-Dependent Expression and Improved Retinal Structure and Function. https://www.ncbi.nlm.nih.gov/pubmed/27036983 <a href="https://www.ncbi.nlm.nih.gov/pubmed/27036983">Bush RA, et al. Preclinical Dose Escalation Study of Intravitreal AAV-RS1 Gene Therapy in a Mouse Model of X-linked Retinoschisis: Dose-Dependent Expression and Improved Retinal Structure and Function.</a> 147162212 Zeng Y, et al. Retinal Structure and Gene Therapy Outcome in Retinoschisin-Deficient Mice Assessed by Spectral-Domain Optical Coherence Tomography. https://www.ncbi.nlm.nih.gov/pubmed/27409484 <a href="https://www.ncbi.nlm.nih.gov/pubmed/27409484">Zeng Y, et al. Retinal Structure and Gene Therapy Outcome in Retinoschisin-Deficient Mice Assessed by Spectral-Domain Optical Coherence Tomography.</a> 147162481 Marangoni D, et al. Ocular and systemic safety of a recombinant AAV8 vector for X-linked retinoschisis gene therapy: GLP studies in rabbits and Rs1-KO mice. https://www.ncbi.nlm.nih.gov/pubmed/27626041 <a href="https://www.ncbi.nlm.nih.gov/pubmed/27626041">Marangoni D, et al. Ocular and systemic safety of a recombinant AAV8 vector for X-linked retinoschisis gene therapy: GLP studies in rabbits and Rs1-KO mice.</a> 147163738 Sieving, Paul NIH - NIDCD Sieving, Paul 1 147163741 Bush, Ronald NIH - NIDCD NEI Bush, Ronald (NEI) 2 147163740 Zeng, Yong NIH - NIDCD NEI Zeng, Yong (NEI) 3 147163739 Colosi, Peter NIH - NEI NEI Colosi, Peter (NEI) 4 147163738 Sieving, Paul NIH - NIDCD Sieving, Paul 1 147163741 Bush, Ronald NIH - NIDCD NEI Bush, Ronald (NEI) 2 147163740 Zeng, Yong NIH - NIDCD NEI Zeng, Yong (NEI) 3 147163739 Colosi, Peter NIH - NEI NEI Colosi, Peter (NEI) 4 147158321 A Method For Treating X-linked Rentinosisis Lntravitreal Injection Of An AAV Retinoschismin Vector E-284-2012-0 Filing authorized National Eye Institute (NEI), National Institute on Deafness and Other Communication Disorders (NIDCD) 147162592 A Method For Treating X-linked Rentinosisis Lntravitreal Injection Of An AAV Retinoschismin Vector E-284-2012-1 Filing authorized National Eye Institute (NEI), National Institute on Deafness and Other Communication Disorders (NIDCD) 147162593 A Method For Treating X-linked Rentinosisis Lntravitreal Injection Of An AAV Retinoschismin Vector E-284-2012-2 Filing authorized National Eye Institute (NEI), National Institute on Deafness and Other Communication Disorders (NIDCD) 83724826 Pollard, Ricquita ricquita.pollard@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4162] Methods and Compositions for Treating Genetically Linked Diseases of the Eye&body=Please send me information about technology [TAB-4162] Methods and Compositions for Treating Genetically Linked Diseases of the Eye.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollard, Ricquita<br><a href="mailto:ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4162] Methods and Compositions for Treating Genetically Linked Diseases of the Eye&body=Please send me information about technology [TAB-4162] Methods and Compositions for Treating Genetically Linked Diseases of the Eye.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">ricquita.pollard@nih.gov</a><br> 147167015 E-284-2012-0 E-284-2012-0-US-01 Methods And Compositions For Treating Genetically Linked Diseases Of The Eye PRV US 61/765,654 Abandoned US <br />Provisional (PRV) 61/765,654<br />Filed on 2013-02-15<br />Status: Abandoned 147167017 E-284-2012-1 E-284-2012-1-US-01 Methods And Compositions For Treating Genetically Linked Diseases Of The Eye PRV US 61/815,636 Abandoned US <br />Provisional (PRV) 61/815,636<br />Filed on 2013-04-24<br />Status: Abandoned 147167019 E-284-2012-2 E-284-2012-2-PCT-01 METHODS AND COMPOSITIONS FOR TREATING GENETICALLY LINKED DISEASES OF THE EYE PCT COMB Patent Cooperation Treaty PCT/US2014/016389 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2014/016389<br />Filed on 2014-02-14<br />Status: Expired 147167020 E-284-2012-2 E-284-2012-2-AU-02 Methods and Compositions for Treating Genetically Linked Diseases of the Eye National Stage Australia 2014216160 2014216160 Issued Australia <br />National Stage 2014216160<br />Filed on 2014-02-14<br />Status: Issued 147167021 E-284-2012-2 E-284-2012-2-CA-03 METHODS AND COMPOSITIONS FOR TREATING GENETICALLY LINKED DISEASES OF THE EYE National Stage Canada 2900231 2900231 Issued Canada <br />National Stage 2900231<br />Filed on 2014-02-14<br />Status: Issued 147167022 E-284-2012-2 E-284-2012-2-JP-04 METHODS AND COMPOSITIONS FOR TREATING GENETICALLY LINKED DISEASES OF THE EYE National Stage Japan 6449175 2015-558144 Issued Japan <br />National Stage 2015-558144<br />Filed on 2015-08-13<br />Status: Issued 147167023 E-284-2012-2 E-284-2012-2-US-05 Methods and Compositions for Treating Genetically Linked Diseases of the Eye National Stage US 9,873,893 14/766,842 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9873893 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9873893">9,873,893</a><br />Filed on 2015-08-10<br />Status: Issued 147167024 E-284-2012-2 E-284-2012-2-EP-06 AAV8 RETINOSCHISIN EXPRESSION VECTOR FOR TREATING X-LINKED RETINOSCHISIS National Stage European Patent 2956174 14708176.4 Issued European Patent <br />National Stage 14708176.4<br />Filed on 2014-02-14<br />Status: Issued 147167025 E-284-2012-2 E-284-2012-2-US-07 METHODS AND COMPOSITIONS FOR TREATING GENETICALLY LINKED DISEASES OF THE EYE CON US 10,350,306 15/876,821 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10350306 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10350306">10,350,306</a><br />Filed on 2018-01-22<br />Status: Issued 147167026 E-284-2012-2 E-284-2012-2-PCT-08 METHODS AND COMPOSITIONS FOR TREATING GENETICALLY LINKED DISEASES OF THE EYE PCT Patent Cooperation Treaty PCT/US2019/014418 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2019/014418<br />Filed on 2019-01-21<br />Status: Expired 147167027 E-284-2012-2 E-284-2012-2-US-09 METHODS AND COMPOSITIONS FOR TREATING GENETICALLY LINKED DISEASES OF THE EYE National Stage US 16/956,976 Abandoned US <br />National Stage 16/956,976<br />Filed on 2020-06-22<br />Status: Abandoned 164118742 E-284-2012-2 E-284-2012-2-FR-01 AAV8 RETINOSCHISIN EXPRESSION VECTOR FOR TREATING X-LINKED RETINOSCHISIS EP France 2956174 14708176.4 Issued France <br />European patent (EP) 14708176.4<br />Filed on 2014-02-14<br />Status: Issued 164118743 E-284-2012-2 E-284-2012-2-DE-01 AAV8 RETINOSCHISIN EXPRESSION VECTOR FOR TREATING X-LINKED RETINOSCHISIS EP Germany 2956174 14708176.4 Issued Germany <br />European patent (EP) 14708176.4<br />Filed on 2014-02-14<br />Status: Issued 164118744 E-284-2012-2 E-284-2012-2-GB-01 AAV8 RETINOSCHISIN EXPRESSION VECTOR FOR TREATING X-LINKED RETINOSCHISIS EP United Kingdom 2956174 14708176.4 Issued United Kingdom <br />European patent (EP) 14708176.4<br />Filed on 2014-02-14<br />Status: Issued 147174656 Clinical 147174657 EYE 147174658 GENE THERAPY 147174660 ophthalmological 147174661 Orphan Indication 147174662 Sieving 147174663 XLRS TAB-4170 147157454 Bone Marrow Mesenchymal Stem Cell (BMSC)-Derived Exosomes for the Treatment of Glaucoma NEI Collaboration, Ear, Nose, & Throat, Licensing, Ophthalmology, Therapeutics Collaboration Ear Nose & Throat Licensing Ophthalmology Therapeutics Benjamin Mead, Stanislav Tomarev <p>Glaucoma is one of the world’s leading causes of irreversible blindness. There is no cure and vision lost from glaucoma cannot be restored. Glaucoma is associated with fluid build-up in the eye resulting in an increased intraocular pressure (IOP). The pressure may cause damage to the optic nerve and lead to progressive degeneration of retinal ganglion cells (RGC) and vision loss. Currently, available treatments for glaucoma delay progression by reducing IOP, but no therapies exist to directly protect RGC from degradation and loss. </p> <p>Scientists at the National Eye Institute (NEI) have developed a method to treat glaucoma using exosomes derived from bone marrow-derived mesenchymal stem cells (BMSC).  BMSC‐derived exosome administration for glaucoma may confer a significant neuroprotective effect for RGC and prevent vision loss. Isolated exosomes have several immediate advantages for clinical translation compared to potential whole-cell (stem cell) therapies for glaucoma. Isolation and purification of BMSC‐derived exosomes, or their therapeutically active components, is relatively simple via centrifugation. BMSC‐derived exosomes are stable, and once isolated, can be stored at 4C for months to years. Prior clinical trials of BMSC‐derived exosomes administered systemically have shown a positive safety profile. These exosomes are immunologically inert and, due to their small size and stability, are also easy to dose &amp; deliver and will also readily diffuse from the vitreous into the retinal cell layers.  Significant therapeutic- neuroprotective effects for isolated BMSC‐derived exosomes have been shown in in vitro and in vivo glaucoma models. BMSC‐derived exosomes are a promising potential cell‐free therapy for glaucoma and degenerative ocular diseases associated with loss of RGC.</p> <h2>Competitive Advantages:</h2> <ul><li>More inexpensive than bone marrow-derived mesenchymal stem cells (BMSC)</li> <li>Safer than BMSC</li> <li>BMSC and BMSC exomes represent the only known treatments for protecting RGC</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Therapeutic to treat glaucoma</li> <li>Therapeutic to treat degenerative ocular diseases associated with loss of retinal ganglion cells (RGC)</li> </ul> 2018-08-16 2025-04-22 2018-08-16 2025-09-15 2018-08-16 Degenerative Ocular Disease, Exosomes, GLAUCOMA, National Eye Institute, NEI, Neuroprotection, Retinal Ganglion Cell Loss, RGC, Tomarev, Vector Encoding miRNA, Vision Loss False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2018-08-16 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147162065 Mead B, et al. Bone Marrow-Derived Mesenchymal Stem Cells-Derived Exosomes Promote Survival of Retinal Ganglion Cells Through miRNA-Dependent Mechanisms. https://www.ncbi.nlm.nih.gov/pubmed/28198592 <a href="https://www.ncbi.nlm.nih.gov/pubmed/28198592">Mead B, et al. Bone Marrow-Derived Mesenchymal Stem Cells-Derived Exosomes Promote Survival of Retinal Ganglion Cells Through miRNA-Dependent Mechanisms.</a> 147163762 Tomarev, Stanislav NIH - NEI NEI Tomarev, Stanislav (NEI) 1 147163763 Mead, Benjamin NIH - NEI NEI Mead, Benjamin (NEI) 2 147163762 Tomarev, Stanislav NIH - NEI NEI Tomarev, Stanislav (NEI) 1 147163763 Mead, Benjamin NIH - NEI NEI Mead, Benjamin (NEI) 2 147157856 Bone Marrow Mesenchymal Stem Cell (BMSC)-derived Exosomes For The Treatment Of Glaucoma E-044-2018-0 Filing authorized National Eye Institute (NEI) 83703238 Fenn, Edward (Tedd) tedd.fenn@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-4170] Bone Marrow Mesenchymal Stem Cell (BMSC)-Derived Exosomes for the Treatment of Glaucoma&body=Please send me information about technology [TAB-4170] Bone Marrow Mesenchymal Stem Cell (BMSC)-Derived Exosomes for the Treatment of Glaucoma.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Fenn, Edward (Tedd)<br><a href="mailto:tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-4170] Bone Marrow Mesenchymal Stem Cell (BMSC)-Derived Exosomes for the Treatment of Glaucoma&body=Please send me information about technology [TAB-4170] Bone Marrow Mesenchymal Stem Cell (BMSC)-Derived Exosomes for the Treatment of Glaucoma.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">tedd.fenn@nih.gov</a><br> 147160955 E-044-2018-0 E-044-2018-0-US-01 BMSC DERIVED EXOSOMES AND MIRNA TO TREAT GLAUCOMA PRV US 62/622,032 Abandoned US <br />Provisional (PRV) 62/622,032<br />Filed on 2018-01-25<br />Status: Abandoned 147167075 E-044-2018-0 E-044-2018-0-US-02 EXOSOMES AND MIRNA TO TREAT GLAUCOMA ORD US 11,058,729 16/257,026 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11058729 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11058729">11,058,729</a><br />Filed on 2019-01-24<br />Status: Issued 147167076 E-044-2018-0 E-044-2018-0-US-03 EXOSOMES AND MIRNA TO TREAT GLAUCOMA DIV US 11,806,369 17/341,057 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11806369 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11806369">11,806,369</a><br />Filed on 2021-06-07<br />Status: Issued 147170151 Degenerative Ocular Disease 147170152 Exosomes 147170153 GLAUCOMA 147170154 National Eye Institute 147170155 NEI 147170156 Neuroprotection 147170158 Retinal Ganglion Cell Loss 147170160 RGC 147170162 Tomarev 147170164 Vector Encoding miRNA 147170166 Vision Loss TAB-4834 152366631 Soluble Antigen-Based ELISA for the Detection of B. malayi Infections NIAID Collaboration, Diagnostics, Licensing, Therapeutics Collaboration Diagnostics Licensing Therapeutics Thomas Nutman <p>The technology presented is a breakthrough in the diagnosis of lymphatic filariasis, specifically targeting the B. malayi pathogen. It encompasses a novel soluble antigen extract used in both IgG and IgG4-based ELISA tests, aimed at detecting the presence of the filarial infection. This innovation serves as a cornerstone for a CLIA-certified reference test, established and utilized in Dr. Nutman&#39;s laboratory since the late 1980s. It offers a significant advancement in the field, particularly beneficial for remote areas where traditional PCR methods are challenging to implement, thereby facilitating more accessible point-of-care diagnostics for B. malayi infection.</p> The ELISA test for B. malayi provides a fast, cost-effective, and highly accurate diagnosis of lymphatic filariasis, outperforming traditional methods with its ease of use in field conditions and proven reliability, streamlining disease management in resource-limited settings. The ELISA technology for B. malayi has vast potential applications including widespread field diagnostics in endemic regions, integration into routine health screenings, and use in epidemiological surveillance programs. It also holds promise for facilitating ongoing research in filarial diseases and could be adapted for mass drug administration monitoring, enhancing global efforts to control and eventually eliminate lymphatic filariasis. 2024-01-24 2025-09-05 2025-09-05 2024-12-10 False True True 72159134 Analytical Assay Performance Stage 72159134 37470483 Website Abstract 152366638 Nutman, Thomas NIAID - DIR NIAID Nutman, Thomas (NIAID) 1 152366638 Nutman, Thomas NIAID - DIR NIAID Nutman, Thomas (NIAID) 1 152366634 Soluble Brugia Malayi Adult Antigen For Use In Immunoassays E-009-2014-0 Research Material NIAID 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-4834] Soluble Antigen-Based ELISA for the Detection of B. malayi Infections&body=Please send me information about technology [TAB-4834] Soluble Antigen-Based ELISA for the Detection of B. malayi Infections. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-4834] Soluble Antigen-Based ELISA for the Detection of B. malayi Infections&body=Please send me information about technology [TAB-4834] Soluble Antigen-Based ELISA for the Detection of B. malayi Infections.">jonathan.motley@nih.gov</a><br> TAB-5072 163822312 Method of Manufacturing Papilloma Infiltrating Lymphocyte (PIL) Cell Therapy Products as a Treatment for Patients with Chronic Viral Infection(s) NCI Collaboration, Immunology, Infectious Disease, Licensing, Therapeutics Collaboration Immunology Infectious Disease Licensing Therapeutics Clint Allen, Ke Bai, Zulmarie Franco, Scott Norberg <h2>Summary:</h2> <p>The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for development of papilloma-infiltrating lymphocytes (PIL) as treatment for patients with chronic human papillomavirus (HPV) 6 or 11 infections.</p> <h2>Description of Technology:</h2> <p>Recurrent Respiratory Papillomatosis (RRP) and anogenital condyloma are caused by chronic infection with human papillomavirus (HPV) types 6 or 11. These conditions lead to the development of papillomatous growths in different regions of the body &ndash; RRP affects the upper aerodigestive tract, while condylomas involve the anogenital area. In RRP, growths in the aerodigestive tract can cause dysphonia, dyspnea, and, in severe cases, airway obstruction, which may lead to recurrent pneumonia or respiratory failure.</p> <p>Current treatment for RRP primarily involves repeated surgical debulking or laser ablation to manage symptoms. However, the virus often persists in a latent state, resulting in continual papilloma regrowth. The need for frequent procedures exposes patients to cumulative anesthetic and surgical risks, emotional distress, and significantly diminished quality of life. Despite progress in localized treatments such as surgery and laser ablation, there are no approved systemic therapies for chronic HPV 6 or 11-related conditions. This highlights a clear unmet need for effective, curative therapy options.</p> <p>Researchers at the National Cancer Institute (NCI) have developed a novel adoptive cell therapy approach to target conditions driven by HPV types 6 or 11. They have successfully identified and preferentially expanded HPV 6 and/or 11-specific T cells from papilloma tissue obtained from patients with RRP. These papilloma-infiltrating lymphocytes (PILs) have demonstrated the ability to eliminate papillomatous tissue. This T cell manufacturing method holds promise for developing cell-based therapies for chronic HPV 6/11-related conditions, including RRP and potentially anogenital condyloma. Notably, the ability to isolate and expand antigen-specific lymphocytes from non-cancerous growths represents an exciting advancement in the field of adoptive cell therapy &ndash; potentially paving the way for treating a broader range of non-malignant diseases.</p> <p>This technology is available for licensing and offers a compelling opportunity for companies developing next-generation immunotherapies. The Center for Immuno-Oncology and the Surgical Oncology Program of the NCI, Center for Cancer Research are actively seeking industry partners to support the clinical development and commercialization of this approach. It is particularly well-suited for biotech firms focused on T cell therapies or addressing HPV-related diseases. Strategic collaboration could accelerate market entry and unlock significant value in an area with high unmet medical need.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Immunotherapy for chronic HPV-related conditions such as recurrent respiratory papillomatosis (RRP) and anogenital condyloma.</li> <li>Development of personalized T cell therapies targeting HPV 6 or HPV 11 infections.</li> <li>Generation of T cell receptor (TCR) libraries for research and therapeutic purposes.</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Selective expansion of T cells with high specificity for HPV 6 or HPV 11 antigens.</li> <li>Potential to treat both non-cancerous and cancerous HPV-related conditions.</li> <li>Ability to produce oligoclonal T cell populations, increasing the efficacy of the therapy.</li> <li>Methodology applicable to both therapeutic and preventative treatments for chronic HPV infections.</li> <li>Drug development for RRP may qualify for regulatory incentives due to the rarity of the disease.</li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for papilloma-infiltrating lymphocytes (PIL) in treatment for chronic HPV6/11-associated diseases 2025-08-21 2025-08-21 2025-09-04 2025-08-21 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 163822392 Bai K, Norberg SM, Sievers C, Meyer T, et al. Durable response in a patient with recurrent respiratory papillomatosis treated with immune checkpoint blockade. Case Reports Head Neck. 2022 Oct;44(10):E31-E37. doi: 10.1002/hed.27144. Bai K, Norberg SM, Sievers C, Meyer T, et al. Durable response in a patient with recurrent respiratory papillomatosis treated with immune checkpoint blockade. Case Reports Head Neck. 2022 Oct;44(10):E31-E37. doi: 10.1002/hed.27144. 163822341 Norberg, Scott NIH - NCI NCI Norberg, Scott (NCI) 1 163822345 Allen, Clint NIH - NCI NCI Allen, Clint (NCI) 2 163822349 Franco, Zulmarie NIH - NCI NCI Franco, Zulmarie (NCI) 3 163822353 Bai, Ke NIH - NCI NCI Bai, Ke (NCI) 4 163822341 Norberg, Scott NIH - NCI NCI Norberg, Scott (NCI) 1 163822345 Allen, Clint NIH - NCI NCI Allen, Clint (NCI) 2 163822349 Franco, Zulmarie NIH - NCI NCI Franco, Zulmarie (NCI) 3 163822353 Bai, Ke NIH - NCI NCI Bai, Ke (NCI) 4 163822315 Method of Manufacturing Papilloma Infiltrating Lymphocyte Cell Therapy Products as a Treatment for Patients with Chronic Viral Infection(s) E-143-2024-0 Filing authorized NIH - NCI 83694133 Gulay French, Suna suna.gulay@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB suna.gulay@nih.gov?subject=Web Inquiry on [TAB-5072] Method of Manufacturing Papilloma Infiltrating Lymphocyte (PIL) Cell Therapy Products as a Treatment for Patients with Chronic Viral Infection(s)&body=Please send me information about technology [TAB-5072] Method of Manufacturing Papilloma Infiltrating Lymphocyte (PIL) Cell Therapy Products as a Treatment for Patients with Chronic Viral Infection(s).&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Gulay French, Suna<br><a href="mailto:suna.gulay@nih.gov?subject=Web Inquiry on [TAB-5072] Method of Manufacturing Papilloma Infiltrating Lymphocyte (PIL) Cell Therapy Products as a Treatment for Patients with Chronic Viral Infection(s)&body=Please send me information about technology [TAB-5072] Method of Manufacturing Papilloma Infiltrating Lymphocyte (PIL) Cell Therapy Products as a Treatment for Patients with Chronic Viral Infection(s).&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">suna.gulay@nih.gov</a><br> 163822320 E-143-2024-0 E-143-2024-0-US-01 METHODS OF PREPARING CELL THERAPY PRODUCTS FOR THE TREATMENT OF CONDITIONS CAUSED BY HUMAN PAPILLOMAVIRUS 6 OR 11 INFECTION PRV US 63/709,683 Expired US <br />Provisional (PRV) 63/709,683<br />Filed on 2024-10-21<br />Status: Expired 164010270 E-143-2024-0 E-143-2024-0-PC-01 METHODS OF PREPARING CELL THERAPY PRODUCTS FOR THE TREATMENT OF CONDITIONS CAUSED BY HUMAN PAPILLOMAVIRUS 6 OR 11 INFECTION PCT Patent Cooperation Treaty PCT/US2025/051640 Pending Patent Cooperation Treaty <br />(PCT) PCT/US2025/051640<br />Filed on 2025-10-20<br />Status: Pending TAB-5074 163873661 Selective Expansion of Engineered TCR-T Cells for Use in Adoptive Cell Immunotherapy NCI Immunology, Licensing, Oncology, Therapeutics Immunology Licensing Oncology Therapeutics Drew Deniger, Steven Feldman, Steven Rosenberg <h2>Summary:</h2> <p>The National Cancer Institute (NCI) seeks capable licensees interested in commercializing T cell receptor (TCR)-engineered T cells expressing murine/human hybrid receptors.</p> <h2>Description of Technology:</h2> <p>TCR-T therapies, particularly those targeting patient-specific neoantigens, remain a promising approach to the treatment metastatic cancers. Contemporary gene engineering techniques permit both the targeted integration of the exogenous receptor(s) and further genetic manipulation of the host cells to enhance persistence and performance following adoptive transfer (e.g., through disruption of immune checkpoints such as CISH or PD1). However, these techniques often suffer from low transduction efficiencies and may result in the generation of infusion products with sub-optimal percentages of targeted cells.</p> <p>NCI scientists designed a new method that enables the selective expansion of T lymphocytes, under GMP conditions, that have been engineered to stably express a murine-human hybrid TCR. These hybrid TCRs consist of human variable regions and murine constant regions. The inventive approach uses irradiated feeder cells and an anti-mouse TCR beta constant region antibody (e.g., H57) to provide stimulation, enabling the specific activation and expansion of T cells transduced with the hybrid TCRs. Critically, replacement of the OKT3 activating antibody from the standard rapid expansion protocol with one specific for the TCR murine constant region prevents the outgrowth of non-transduced cells. Consequently, the new method produces a cell population highly enriched for the desired engineered cells.</p> <p>NCI seeks to market this method, which is analogous to an antigen-specific stimulation of the T cell, to companies interested in developing personalized ACT.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Enables the GMP production of personalized T cell therapy products targeting tumor specific mutations with a high percentage of engineered cells</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Increased therapeutic benefit due to enhanced persistence and performance following adoptive T cell transfer</li> <li>Increased therapeutic benefit due to improved surface expression of the therapeutic TCR &alpha;&beta; <ul> <li>TCR alpha/beta chains substantially eliminate the risk of mis-pairing with the endogenous alpha/beta chain sequences expressed by the host cell</li> </ul> </li> <li>Improved manufacturing since the population is highly enriched for the desired engineered cells <ul> <li>Greatly increases the frequency of tumor-specific T cells following expansion, exceeding what is achieved using alternative methods to generate mutation- or tumor-specific T cells</li> </ul> </li> </ul> <p>&nbsp;</p> Researchers at the NCI seek licensing for TCR-engineered T cells that will facilitate the ACT process. 2025-08-25 2025-08-25 2025-08-25 2025-08-25 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 72159140 Clinical Phase II 72159140 NCI 37470483 Website Abstract 163873915 Parkhurst M, et al. Adoptive transfer of personalized neoantigen-reactive TCR-transduced T cells in metastatic colorectal cancer: phase 2 trial interim results. (PMID 38992) https://pubmed.ncbi.nlm.nih.gov/38992/ <a href="https://pubmed.ncbi.nlm.nih.gov/38992/">Parkhurst M, et al. Adoptive transfer of personalized neoantigen-reactive TCR-transduced T cells in metastatic colorectal cancer: phase 2 trial interim results. (PMID 38992)</a> 163873942 Kim SP, et al. Adoptive cellular therapy with autologous tumor-infiltrating lymphocytes and T-cell receptor-engineered T cells targeting common p53 neoantigens in human solid tumors. (PMID 35749374) https://pubmed.ncbi.nlm.nih.gov/35749374/ <a href="https://pubmed.ncbi.nlm.nih.gov/35749374/">Kim SP, et al. Adoptive cellular therapy with autologous tumor-infiltrating lymphocytes and T-cell receptor-engineered T cells targeting common p53 neoantigens in human solid tumors. (PMID 35749374)</a> 163873951 Lowery FL, et al. Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers. (PMID 35113651) https://pubmed.ncbi.nlm.nih.gov/35113651/ <a href="https://pubmed.ncbi.nlm.nih.gov/35113651/">Lowery FL, et al. Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers. (PMID 35113651)</a> 163873866 Feldman, Steven NIH - NCI Feldman, Steven 1 163873878 Rosenberg, Steven NIH - NCI NCI Rosenberg, Steven (NCI) 2 163873886 Deniger, Drew NIH - NCI Deniger, Drew 3 163873866 Feldman, Steven NIH - NCI Feldman, Steven 1 163873878 Rosenberg, Steven NIH - NCI NCI Rosenberg, Steven (NCI) 2 163873886 Deniger, Drew NIH - NCI Deniger, Drew 3 163873664 Sorting And/or Selective Expansion Of T Lymphocytes For Use In Adoptive Cell Immunotherapy. E-182-2017-0 Filing authorized NCI 83709866 Burke, Andrew burkear@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC burkear@nih.gov?subject=Web Inquiry on [TAB-5074] Selective Expansion of Engineered TCR-T Cells for Use in Adoptive Cell Immunotherapy&body=Please send me information about technology [TAB-5074] Selective Expansion of Engineered TCR-T Cells for Use in Adoptive Cell Immunotherapy.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Burke, Andrew<br><a href="mailto:burkear@nih.gov?subject=Web Inquiry on [TAB-5074] Selective Expansion of Engineered TCR-T Cells for Use in Adoptive Cell Immunotherapy&body=Please send me information about technology [TAB-5074] Selective Expansion of Engineered TCR-T Cells for Use in Adoptive Cell Immunotherapy.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">burkear@nih.gov</a><br> 163873669 E-182-2017-0 E-182-2017-0-US-01 METHODS FOR SELECTIVELY EXPANDING CELLS EXPRESSING A TCR WITH A MURINE CONSTANT REGION PRV US 62/568,339 Abandoned US <br />Provisional (PRV) 62/568,339<br />Filed on 2017-10-05<br />Status: Abandoned 163873670 E-182-2017-0 E-182-2017-0-PCT-02 METHODS FOR SELECTIVELY EXPANDING CELLS EXPRESSING A TCR WITH A MURINE CONSTANT REGION PCT Patent Cooperation Treaty PCT/US2018/052432 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2018/052432<br />Filed on 2018-09-24<br />Status: Expired 163873710 E-182-2017-0 E-182-2017-0-AU-03 METHODS FOR SELECTIVELY EXPANDING CELLS EXPRESSING A TCR WITH A MURINE CONSTANT REGION National Stage Australia 2018345400 2018345400 Issued Australia <br />National Stage 2018345400<br />Filed on 2018-09-24<br />Status: Issued 163873711 E-182-2017-0 E-182-2017-0-CA-04 METHODS FOR SELECTIVELY EXPANDING CELLS EXPRESSING A TCR WITH A MURINE CONSTANT REGION National Stage Canada 3077595 Pending Canada <br />National Stage 3077595<br />Filed on 2018-09-24<br />Status: Pending 163873712 E-182-2017-0 E-182-2017-0-CN-05 METHODS FOR SELECTIVELY EXPANDING CELLS EXPRESSING A TCR WITH A MURINE CONSTANT REGION National Stage China ZL201880076862.9 201880076862.9 Issued China <br />National Stage 201880076862.9<br />Filed on 2018-09-24<br />Status: Issued 163873713 E-182-2017-0 E-182-2017-0-EP-06 METHODS FOR SELECTIVELY EXPANDING CELLS EXPRESSING A TCR WITH A MURINE CONSTANT REGION National Stage European Patent 3692140 18786145.5 Issued European Patent <br />National Stage 18786145.5<br />Filed on 2020-05-05<br />Status: Issued 163873714 E-182-2017-0 E-182-2017-0-IL-07 METHODS FOR SELECTIVELY EXPANDING CELLS EXPRESSING A TCR WITH A MURINE CONSTANT REGION National Stage Israel 273698 273698 Issued Israel <br />National Stage 273698<br />Filed on 2020-03-30<br />Status: Issued 163873715 E-182-2017-0 E-182-2017-0-JP-08 METHODS FOR SELECTIVELY EXPANDING CELLS EXPRESSING A TCR WITH A MURINE CONSTANT REGION National Stage Japan 7867764 2020-519092 Issued Japan <br />National Stage 2020-519092<br />Filed on 2020-04-02<br />Status: Issued 163873716 E-182-2017-0 E-182-2017-0-KR-09 METHODS FOR SELECTIVELY EXPANDING CELLS EXPRESSING A TCR WITH A MURINE CONSTANT REGION National Stage South Korea 10-2757789 10-2020-7012314 Issued South Korea <br />National Stage 10-2020-7012314<br />Filed on 2020-04-28<br />Status: Issued 163873717 E-182-2017-0 E-182-2017-0-SG-10 METHODS FOR SELECTIVELY EXPANDING CELLS EXPRESSING A TCR WITH A MURINE CONSTANT REGION National Stage Singapore 11202003112Q Abandoned Singapore <br />National Stage 11202003112Q<br />Filed on 2018-09-24<br />Status: Abandoned 163873718 E-182-2017-0 E-182-2017-0-US-11 METHODS FOR SELECTIVELY EXPANDING CELLS EXPRESSING A TCR WITH A MURINE CONSTANT REGION National Stage US 12,227,554 16/652,948 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12227554 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12227554">12,227,554</a><br />Filed on 2020-04-01<br />Status: Issued 163873719 E-182-2017-0 E-182-2017-0-HK-12 METHODS FOR SELECTIVELY EXPANDING CELLS EXPRESSING A TCR WITH A MURINE CONSTANT REGION EP Hong Kong HK40031098B 62020020943.0 Issued Hong Kong <br />European patent (EP) 62020020943.0<br />Filed on 2020-11-26<br />Status: Issued 163873720 E-182-2017-0 E-182-2017-0-EP-01 METHODS FOR SELECTIVELY EXPANDING CELLS EXPRESSING A TCR WITH A MURINE CONSTANT REGION DIV European Patent 23185846.5 Pending European Patent <br />Divisional (DIV) 23185846.5<br />Filed on 2023-07-17<br />Status: Pending 163873721 E-182-2017-0 E-182-2017-0-ES-01 METHODS FOR SELECTIVELY EXPANDING CELLS EXPRESSING A TCR WITH A MURINE CONSTANT REGION EP Spain 3692140 18786145.5 Issued Spain <br />European patent (EP) 18786145.5<br />Filed on 2020-05-05<br />Status: Issued 163873722 E-182-2017-0 E-182-2017-0-FI-01 METHODS FOR SELECTIVELY EXPANDING CELLS EXPRESSING A TCR WITH A MURINE CONSTANT REGION EP Finland 3692140 18786145.5 Issued Finland <br />European patent (EP) 18786145.5<br />Filed on 2020-05-05<br />Status: Issued 163873723 E-182-2017-0 E-182-2017-0-FR-01 METHODS FOR SELECTIVELY EXPANDING CELLS EXPRESSING A TCR WITH A MURINE CONSTANT REGION EP France 3692140 18786145.5 Issued France <br />European patent (EP) 18786145.5<br />Filed on 2020-05-05<br />Status: Issued 163873724 E-182-2017-0 E-182-2017-0-IT-01 METHODS FOR SELECTIVELY EXPANDING CELLS EXPRESSING A TCR WITH A MURINE CONSTANT REGION EP Italy 3692140 18786145.5 Issued Italy <br />European patent (EP) 18786145.5<br />Filed on 2020-05-05<br />Status: Issued 163873725 E-182-2017-0 E-182-2017-0-DE-01 METHODS FOR SELECTIVELY EXPANDING CELLS EXPRESSING A TCR WITH A MURINE CONSTANT REGION EP Germany 3692140 18786145.5 Issued Germany <br />European patent (EP) 18786145.5<br />Filed on 2020-05-05<br />Status: Issued 163873726 E-182-2017-0 E-182-2017-0-GB-01 METHODS FOR SELECTIVELY EXPANDING CELLS EXPRESSING A TCR WITH A MURINE CONSTANT REGION EP United Kingdom 3692140 18786145.5 Issued United Kingdom <br />European patent (EP) 18786145.5<br />Filed on 2020-05-05<br />Status: Issued 163873727 E-182-2017-0 E-182-2017-0-CH-01 METHODS FOR SELECTIVELY EXPANDING CELLS EXPRESSING A TCR WITH A MURINE CONSTANT REGION EP Switzerland 3692140 18786145.5 Issued Switzerland <br />European patent (EP) 18786145.5<br />Filed on 2020-05-05<br />Status: Issued 163873728 E-182-2017-0 E-182-2017-0-NO-01 METHODS FOR SELECTIVELY EXPANDING CELLS EXPRESSING A TCR WITH A MURINE CONSTANT REGION EP Norway 3692140 18786145.5 Issued Norway <br />European patent (EP) 18786145.5<br />Filed on 2020-05-05<br />Status: Issued 163873729 E-182-2017-0 E-182-2017-0-SG-01 METHODS FOR SELECTIVELY EXPANDING CELLS EXPRESSING A TCR WITH A MURINE CONSTANT REGION DIV Singapore 10202302822Q Pending Singapore <br />Divisional (DIV) 10202302822Q<br />Filed on 2023-10-03<br />Status: Pending 163873730 E-182-2017-0 E-182-2017-0-JP-01 METHODS FOR SELECTIVELY EXPANDING CELLS EXPRESSING A TCR WITH A MURINE CONSTANT REGION DIV Japan 7747724 2023-220106 Issued Japan <br />Divisional (DIV) 2023-220106<br />Filed on 2023-12-26<br />Status: Issued TAB-5065 163297774 Enhanced Tumor Reactivity of T Cells Lacking SIT1, LAX1 or TRAT1 NICHD Immunology, Oncology, Therapeutics Immunology Oncology Therapeutics Avik Dutta, Paul Love <h2>Summary:</h2> <p>The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) is actively seeking potential licensees interested in further developing these inhibitory transmembrane adapter proteins as targets for T-cell immunotherapy for the treatment of cancer, infectious diseases, and autoimmune diseases.</p> <h2>Description of Technology:</h2> <p>Cellular immunotherapy holds much promise for the treatment of cancer. However, certain cellular therapies have limited success because of immunosuppression in the tumor microenvironment. Thus, there is an unmet need for improved methods of cellular immunotherapy.</p> <p>T cells constitutively express inhibitory molecules that limit the activation response to antigens by the T cell antigen receptor (TCR). Among these are the transmembrane adapter proteins SIT1, LAX 1 and TRA T1. These appear to tonically associate with the TCR and inhibit signal transduction. Researchers at the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) have identified SIT1, LAX 1 and TRA T1 as potential targets for T-cell immunotherapy. Mouse models have demonstrated that deletion of SIT1, LAX1 and TRA T1 &ndash; or expression of nonfunctional mutant versions of these proteins in mouse T cells &ndash; enhances TCR signaling and significantly increases T cell cytotoxicity against tumor cells. Experiments confirming these results in human T cells are currently underway. This discovery provides a new therapeutic approach to greatly improve clinical outcomes of T-cell immunotherapy in treating cancers. It also holds potential to treat infectious diseases or autoimmune diseases</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Treatment for cancer</li> <li>Treatment for infectious diseases</li> <li>Treatment for autoimmune diseases</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Potentially superior therapeutic benefit in cancer by: <ul> <li>Enhancing tumoricidal activity of T-cell immunotherapy</li> <li>Overcoming immunosuppression in the tumor microenvironment</li> </ul> </li> <li>Potentially superior therapeutic benefit in infectious diseases by enhancing immune responses to pathogens</li> <li>Potentially superior therapeutic benefit in autoimmune disease by enhancing the generation or function of antigen-specific regulator T cells (Tregs)</li> </ul> Researchers at the NICHD seek licensing for further developing these inhibitory transmembrane adapter proteins as targets for T-cell immunotherapy for the treatment of cancer, infectious diseases, and autoimmune diseases. 2025-07-14 2025-08-21 2025-08-21 2025-07-14 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 163298026 Love, Paul NICHD NICHD Love, Paul (NICHD) 1 163298037 Dutta, Avik NICHD NICHD Dutta, Avik (NICHD) 2 163298026 Love, Paul NICHD NICHD Love, Paul (NICHD) 1 163298037 Dutta, Avik NICHD NICHD Dutta, Avik (NICHD) 2 163297777 Enhanced tumor of T cells lacking SIT1, LAX1 or TRAT1 E-004-2024-0 Filing authorized NIH - NICHD 91789173 Guyton, Nicole darackn@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America darackn@mail.nih.gov?subject=Web Inquiry on [TAB-5065] Enhanced Tumor Reactivity of T Cells Lacking SIT1, LAX1 or TRAT1&body=Please send me information about technology [TAB-5065] Enhanced Tumor Reactivity of T Cells Lacking SIT1, LAX1 or TRAT1.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Guyton, Nicole<br><a href="mailto:darackn@mail.nih.gov?subject=Web Inquiry on [TAB-5065] Enhanced Tumor Reactivity of T Cells Lacking SIT1, LAX1 or TRAT1&body=Please send me information about technology [TAB-5065] Enhanced Tumor Reactivity of T Cells Lacking SIT1, LAX1 or TRAT1.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">darackn@mail.nih.gov</a><br> 163363211 E-004-2024-0 E-004-2024-0-US-01 Enhanced Tumor Reactivity of T cells lacking SIT1, LAX1 or TRAT1 PRV US 63/625,354 Expired US <br />Provisional (PRV) 63/625,354<br />Filed on 2024-01-26<br />Status: Expired 163363216 E-004-2024-0 E-004-2024-0-PC-01 Enhanced Tumor Reactivity of T cells lacking SIT1, LAX1 or TRAT1 PCT Patent Cooperation Treaty PCT/US2025/013054 Pending Patent Cooperation Treaty <br />(PCT) PCT/US2025/013054<br />Filed on 2025-01-24<br />Status: Pending TAB-5066 163312519 Compositions and Methods for Producing Dendritic Cell-based Vaccines with Enhanced Efficacy NCI Collaboration, Immunology, Licensing, Oncology, Therapeutics Collaboration Immunology Licensing Oncology Therapeutics Jay Berzofsky, Shweta Tiwary <h2>Summary:</h2> <p>The National Cancer Institute (NCI) is seeking research co-development partners and/or licensees for NCI&rsquo;s compositions and methods to enhance the efficacy of dendritic cell (DC)-based cancer vaccines.&nbsp;&nbsp;</p> <h2>Description of Technology:</h2> <p>Current dendritic cell (DC)-based cancer vaccines are limited by impaired DC function due to cancer-driven lipid imbalances and other immunosuppressive factors reducing vaccine effectiveness. To address this issue, NCI has generated dendritic cells in the presence of omega-3 fatty acids (docosahexaenoic acid [DHA] and eicosapentaenoic acid [EPA]) and their derivatives, or specialized pro-resolving lipid mediators, to restore and enhance the dendritic cells&rsquo; antigen-presenting function and anti-tumor efficacy. This approach could significantly improve the potency of DC-based cancer vaccines, offering a promising strategy to overcome a major limitation in current cancer immunotherapies. NCI is actively continuing development of this technology and seeks licensing and/or collaboration partners to support further preclinical validation and potential clinical translation.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Cancer immunotherapy</li> <li>Development of human DC vaccines</li> <li>Formulations involving omega-3 fatty acids or pro-resolving lipids</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Production of DCs with enhanced antigen-presenting function, anti-tumor efficacy and potency</li> <li>Significant tumor reduction and improved survival compared in animals compared with wild-type DCs</li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for the development of NCI’s compositions and methods to enhance the efficacy of dendritic cell (DC)-based cancer vaccines by using omega-3 fatty acids or pro-resolving lipid mediators. 2025-07-15 2025-08-21 2025-08-21 2025-07-15 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 163312808 Tiwary, S., "Endogenously high Omega-3 levels lead to a less suppressive tumor microenvironment." https://doi.org/10.4049/jimmunol.210.Supp.172.18 <a href="https://doi.org/10.4049/jimmunol.210.Supp.172.18">Tiwary, S., "Endogenously high Omega-3 levels lead to a less suppressive tumor microenvironment."</a> 163312813 Tiwary, S., K. Hsu, K. C. Goldfarbmuren, Z. Xia, and J. A. Berzofsky. High levels of endogenous omega-3 fatty acids prolong the lifespan, promote antigen presentation, and improve DC-based cancer vaccine efficacy in mice. 2025. Cancer Immunology Research, in press. Tiwary, S., K. Hsu, K. C. Goldfarbmuren, Z. Xia, and J. A. Berzofsky. High levels of endogenous omega-3 fatty acids prolong the lifespan, promote antigen presentation, and improve DC-based cancer vaccine efficacy in mice. 2025. Cancer Immunology Research, in press. 163312555 Berzofsky, Jay NIH - NCI NCI Berzofsky, Jay (NCI) 1 163312567 Tiwary, Shweta NIH - NCI Tiwary, Shweta 2 163312555 Berzofsky, Jay NIH - NCI NCI Berzofsky, Jay (NCI) 1 163312567 Tiwary, Shweta NIH - NCI Tiwary, Shweta 2 163312522 Improving the efficacy of dendric cell-based cancer vaccines by DHA treatment E-231-2023-0 Filing authorized NIH - NCI 83740301 Dattaroy, Diptadip diptadip.dattaroy@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB diptadip.dattaroy@nih.gov?subject=Web Inquiry on [TAB-5066] Compositions and Methods for Producing Dendritic Cell-based Vaccines with Enhanced Efficacy&body=Please send me information about technology [TAB-5066] Compositions and Methods for Producing Dendritic Cell-based Vaccines with Enhanced Efficacy.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dattaroy, Diptadip<br><a href="mailto:diptadip.dattaroy@nih.gov?subject=Web Inquiry on [TAB-5066] Compositions and Methods for Producing Dendritic Cell-based Vaccines with Enhanced Efficacy&body=Please send me information about technology [TAB-5066] Compositions and Methods for Producing Dendritic Cell-based Vaccines with Enhanced Efficacy.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">diptadip.dattaroy@nih.gov</a><br> 163312527 E-231-2023-0 E-231-2023-0-US-01 COMPOSITIONS AND METHODS FOR PRODUCING DENDRITIC CELL-BASED VACCINES WITH ENHANCED EFFICACY PRV US 63/586,629 Expired US <br />Provisional (PRV) 63/586,629<br />Filed on 2023-09-29<br />Status: Expired 163312528 E-231-2023-0 E-231-2023-0-PC-01 COMPOSITIONS AND METHODS FOR PRODUCING DENDRITIC CELL-BASED VACCINES WITH ENHANCED EFFICACY PCT Patent Cooperation Treaty PCT/US2024/049057 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2024/049057<br />Filed on 2024-09-27<br />Status: Expired TAB-5033 160688466 Oxynitidine Derivatives as Tyrosyl DNA Phosphodiesterase (TDP) Inhibitors and Radiosensitizers NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Lin-kun An, Yves Pommier <h2>Summary:&nbsp;</h2> <p>The National Cancer Institute (NCI) is actively seeking potential licensees and/or co-development research collaboration partners interested in further developing this family of oxynitidine derivatives as tyrosyl-DNA phosphodiesterase 1 (TDP1) inhibitors and radiosensitizers for the treatment of cancer.&nbsp;</p> <h2>Description of Technology:&nbsp;</h2> <p>Tyrosyl-DNA phosphodiesterase 1 (TDP1) is an enzyme that promotes the repair of DNA damage caused by common anti-cancer interventions, such as ionizing radiation (IR) and topoisomerase 1 (TOP1) chemotherapy. This enzyme plays a critical role in repairing the trapped DNA cleavage complexes induced by clinically used TOP1 chemotherapy (such as irinotecan and topotecan). TDP1 also plays a regulatory role in non-homologous end joining (NHEJ) in the repair of DNA double-strand breaks and damage caused by ionizing radiation. In both cases, this leads to a diminished therapeutic effect of the intervention and is a limitation of radiotherapy and the use of TOP1 chemotherapies. TDP1 deficiency can help overcome this limitation by preventing the TDP1 DNA repair activity. As such, TDP1 is a promising target for novel anti-cancer and radiosensitizing agents. Although there are reported TDP1 inhibitors to enhance chemotherapy agents, such as TOP1 inhibitors, there are no reported TDP1 inhibitors as radiosensitizers. Additionally, there are no FDA-approved TDP1 inhibitors for cancer treatment or as a radiosensitizing agent.&nbsp;</p> <p>Researchers at the National Cancer Institute (NCI) and their collaborators have identified a family of oxynitidine derivatives that inhibit TDP1 while enhancing the effects of ionizing radiation. In vitro, these compounds have been demonstrated to be potent TDP1 inhibitors that target, stabilize, and increase the formation of DNA cleavage complexes in various cancers &ndash; including colorectal cancer (CRC). Additionally, these compounds exhibited a strong radiosensitizing effect in vitro and in vivo in a dose-dependent-manner in CRC. The compounds, in combination with IR, reduced intracellular NHEJ, inhibited tumor growth and reduced tumor weight. These results underscore the potential use of this family of oxynitidine derivatives as therapeutic radiosensitizers and TDP1 inhibitors. &nbsp;</p> <p>The NCI is seeking co-development research opportunities and/or potential licensees to further advance these oxynitidine derivatives as novel inhibitors of TDP1 and radiosensitizers for the treatment of cancer.</p> <h2><br /> Potential Commercial Applications:&nbsp;</h2> <ul> <li>TDP1 inhibitors for treating various cancers</li> <li>Radiosensitizing agent&nbsp;</li> <li>Combination drug treatment to boost anti-tumor potency</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Can be used synergistically with TOP1 inhibitors to increase effectiveness</li> <li>Few reported clinical trials</li> <li>No FDA approved TDP1 inhibitors&nbsp;</li> <li>Potential for first-in-class therapeutic/radiosensitizer&nbsp;</li> <li>Can be used synergistically with ionizing radiation to increase effectiveness&nbsp;</li> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for the development of a family of oxynitidine derivatives as tyrosyl-DNA phosphodiesterase 1 (TDP1) inhibitors and radiosensitizers for the treatment of cancer. 2025-02-21 2025-08-21 2025-08-21 2025-03-14 False False True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 160722928 Pommier, Yves National Cancer Institute (NCI) NCI Pommier, Yves (NCI) 1 160722940 An, Lin-kun Sun Yat-sen University An, Lin-kun 2 160722928 Pommier, Yves National Cancer Institute (NCI) NCI Pommier, Yves (NCI) 1 160722940 An, Lin-kun Sun Yat-sen University An, Lin-kun 2 160688469 Oxynitidine derivatives as tyrosyl DNA phosphodiesterase inhibitors and radiosensitizers E-075-2024-0 Filing authorized NIH - NCI, Sun Yat-sen University 91826910 McCrary, Michaela michaela.mccrary@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America michaela.mccrary@nih.gov?subject=Web Inquiry on [TAB-5033] Oxynitidine Derivatives as Tyrosyl DNA Phosphodiesterase (TDP) Inhibitors and Radiosensitizers&body=Please send me information about technology [TAB-5033] Oxynitidine Derivatives as Tyrosyl DNA Phosphodiesterase (TDP) Inhibitors and Radiosensitizers.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov McCrary, Michaela<br><a href="mailto:michaela.mccrary@nih.gov?subject=Web Inquiry on [TAB-5033] Oxynitidine Derivatives as Tyrosyl DNA Phosphodiesterase (TDP) Inhibitors and Radiosensitizers&body=Please send me information about technology [TAB-5033] Oxynitidine Derivatives as Tyrosyl DNA Phosphodiesterase (TDP) Inhibitors and Radiosensitizers.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">michaela.mccrary@nih.gov</a><br> 162827534 E-075-2024-0 E-075-2024-0-US-01 OXYNITIDINE DERIVATIVES USEFUL AS TYROSYL-DNA PHOSPHODIESTERASE INHIBITORS AND RADIOSENSITIZERS PRV US 63/674,198 Expired US <br />Provisional (PRV) 63/674,198<br />Filed on 2024-07-22<br />Status: Expired 162827539 E-075-2024-0 E-075-2024-0-PC-01 OXYNITIDINE DERIVATIVES USEFUL AS TYROSYL-DNA PHOSPHODIESTERASE INHIBITORS AND RADIOSENSITIZERS PCT Patent Cooperation Treaty PCT/US2025/038739 Pending Patent Cooperation Treaty <br />(PCT) PCT/US2025/038739<br />Filed on 2025-07-22<br />Status: Pending TAB-5068 163496618 T Cell Receptor Targeting HPV6 E2 and a Panel of Cos7 Cells Expressing Different HLA Class I Proteins for Use in Validation and Potency Studies NCI Immunology, Infectious Disease, Licensing, Oncology, Research Materials Immunology Infectious Disease Licensing Oncology Research Materials Clint Allen, Scott Norberg <h2>Summary:</h2> <p>The National Cancer Institute (NCI) seeks licensees for this invention comprising (1) a novel T cell receptor (TCR) specific to the E2 protein of Human papillomavirus (HPV) type 6 &nbsp;in the context of the human leukocyte antigen, HLA-B55, and (2) a panel of Cos7 cells expressing different HLA proteins for validation of T cell responses in immunotherapies for low-risk HPV-related diseases such as recurrent respiratory papillomatosis and anogenital condyloma.</p> <h2>Description of Technology:</h2> <p>Chronic infections with low-risk HPV types 6 and 11 can lead to such diseases as recurrent respiratory papillomatosis and anogenital condyloma. Such diseases can lower quality of life considerably, expose patients to repeated invasive procedures (such as surgery) and are often recurrent and unresponsive to standard treatments. There are few targeted treatments in development against these diseases. Therefore, there may be a need for reliable research tools to test the potency of targeted treatments, particularly immunotherapies, prior to the product&rsquo;s release for patient use.</p> <p><br /> The researchers at the National Cancer Institute (NCI) identified a novel T cell receptor (TCR) specific for an antigen derived from HPV6 E2, restricted to HLA-B55. This TCR was reconstructed with a mouse constant region for tracking in donor T cells and may be used in potency testing and release assays of vaccines and other immunotherapies that target HPV6.</p> <p>The NCI seeks licensees for the research-use TCR and the panel of Cos7 cells. This invention offers a unique opportunity for developing new TCR-based therapies and validation tools for HPV-related diseases.</p> <h2>Potential Commercial Applications: &nbsp;</h2> <ul> <li>Research materials to support therapeutic or diagnostic development against HPV-related diseases</li> <li>Potency testing and other release assays of HPV 6-containing immunotherapy products</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Unique TCR and cell line panel to validate T cell responses in immunotherapies for low-risk HPV-related diseases such as recurrent respiratory papillomatosis and anogenital condyloma</li> <li>Superior tools &ndash; together or separately &ndash; in release assays for HPV 6-targeting immunotherapy products</li> <li>Unique tools for lot release assays for low- or high-risk HPV-targeting immunotherapy products</li> <li>Unique tools for lot release, stability and comparability studies</li> </ul> Researchers at the NCI seek licensing for this invention that comprises a novel T cell receptor (TCR) targeting HPV6 E2 in the context of HLA-B55 and a panel of Cos7 cells expressing different Class I human leukocyte antigen (HLA) proteins, that may be used in development of validation and potency assays for vaccines and other therapies designed to induce HPV6-specific T cell responses. 2025-07-28 2025-08-21 2025-08-21 2025-07-28 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 163496887 Bai K, Norberg SM, Sievers C, Meyer T, et al. Durable response in a patient with recurrent respiratory papillomatosis treated with immune checkpoint blockade. Case Reports Head Neck. 2022 Oct;44(10):E31-E37. doi: 10.1002/hed.27144. Bai K, Norberg SM, Sievers C, Meyer T, et al. Durable response in a patient with recurrent respiratory papillomatosis treated with immune checkpoint blockade. Case Reports Head Neck. 2022 Oct;44(10):E31-E37. doi: 10.1002/hed.27144. 163496740 Allen, Clint NIH - NCI NCI Allen, Clint (NCI) 1 163496774 Norberg, Scott NIH - NCI NCI Norberg, Scott (NCI) 2 163496740 Allen, Clint NIH - NCI NCI Allen, Clint (NCI) 1 163496774 Norberg, Scott NIH - NCI NCI Norberg, Scott (NCI) 2 163496621 Discovery of a T cell receptor targeting an antigen derived from HPV6 E2 and a panel of Cos7 cells expressing different HLA class I proteins E-010-2024-0 Research Material NIH - NCI 142435134 Sherwani, Zehra zehra.sherwani@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America zehra.sherwani@nih.gov?subject=Web Inquiry on [TAB-5068] T Cell Receptor Targeting HPV6 E2 and a Panel of Cos7 Cells Expressing Different HLA Class I Proteins for Use in Validation and Potency Studies&body=Please send me information about technology [TAB-5068] T Cell Receptor Targeting HPV6 E2 and a Panel of Cos7 Cells Expressing Different HLA Class I Proteins for Use in Validation and Potency Studies.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Sherwani, Zehra<br><a href="mailto:zehra.sherwani@nih.gov?subject=Web Inquiry on [TAB-5068] T Cell Receptor Targeting HPV6 E2 and a Panel of Cos7 Cells Expressing Different HLA Class I Proteins for Use in Validation and Potency Studies&body=Please send me information about technology [TAB-5068] T Cell Receptor Targeting HPV6 E2 and a Panel of Cos7 Cells Expressing Different HLA Class I Proteins for Use in Validation and Potency Studies.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">zehra.sherwani@nih.gov</a><br> TAB-5070 163753648 C8166-45 Cells NCI Infectious Disease, Licensing, Oncology, Research Materials Infectious Disease Licensing Oncology Research Materials Genoveffa Franchini, Robert Gallo, V Kalyanaraman, Phillip Markham, Syed Salahuddin, Flossie Wong-Staal <h2>Summary:</h2> <p>The National Cancer Institute (NCI) seeks licensees for a human T-cell line, C8166-45, transformed by HTLV-1. C8166-45, also known as C63/CRII-2, contains three transcriptionally active proviruses useful for testing biological activities involved in T-cell immortalization and growth.</p> <h2>Description of Technology: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</h2> <p>Human T-cell leukemia virus type 1 (HTLV-1) was the first human retrovirus reported and is recognized as an etiological agent of adult T-cell leukemia (ATL). However, only a small percentage of individuals develop symptomatic ATL which carries a poor prognosis. The latency period can last for decades and universal screening for HTLV-1 infection has ceased. Thus, the C8166-45 cell line is a necessary component for understanding the mechanisms of HTLV-1 infection and improving clinical outcomes.</p> <p>NCI researchers derived C8166-45 by cocultivation or fusion of umbilical cord blood lymphocyte with T-cells cultures from leukemia-lymphoma patients. It is highly permissive to HIV-1 infection and characterized for its suitability in replication-competent lentiviral (RCL) assays to assess its safety for gene therapy products, such as lentiviral vectors. This cell line is highly useful in studying viral protein interactions, immortalization of human T-cells, and HIV replication.</p> <p>NCI is seeking parties to non-exclusively license the C8166-45 cell line.</p> <h2>Potential Commercial: &nbsp;</h2> <ul> <li>Investigation of HTLV pathogenesis and replication</li> <li>Studies of virus-induced T-cell transformation</li> <li>Studies of HTLV expression regulation by human T-cells</li> <li>Studies of HIV replication</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Contains a low amount of viral proteins</li> <li>Does not release detectable virus particles</li> <li>Suitable for testing RCL assay sensitivity</li> </ul> The NCI seeks licensing for the C8166-45 cell line. 2025-08-19 2025-08-21 2025-08-21 2025-08-19 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 72159134 Analytical Assay Performance Stage 72159134 NCI 37470483 Website Abstract 163753705 DeBoer J, et al. Alterations in the nuclear proteome of HIV-1 infected T-cells. (PMID 25240327) https://pubmed.ncbi.nlm.nih.gov/25240327/ <a href="https://pubmed.ncbi.nlm.nih.gov/25240327/">DeBoer J, et al. Alterations in the nuclear proteome of HIV-1 infected T-cells. (PMID 25240327)</a> 163753890 Salahuddin SZ, et al. Restricted expression of human T-cell leukemia-lymphoma virus (HTLV) in transformed human umbilical cord blood lymphocytes. (PMID 6412453) https://pubmed.ncbi.nlm.nih.gov/6412453/ <a href="https://pubmed.ncbi.nlm.nih.gov/6412453/">Salahuddin SZ, et al. Restricted expression of human T-cell leukemia-lymphoma virus (HTLV) in transformed human umbilical cord blood lymphocytes. (PMID 6412453)</a> 163753898 Cornetta K, et al. Absence of replication-competent lentivirus in the clinic: analysis of infused T cell products. (PMID 28970045) https://pubmed.ncbi.nlm.nih.gov/28970045/ <a href="https://pubmed.ncbi.nlm.nih.gov/28970045/">Cornetta K, et al. Absence of replication-competent lentivirus in the clinic: analysis of infused T cell products. (PMID 28970045)</a> 163753789 Franchini, Genoveffa NCI - CCR NCI Franchini, Genoveffa (NCI) 1 163753806 Salahuddin, Syed NIH - NCI Salahuddin, Syed 2 163753818 Wong-Staal, Flossie NIH - NCI Wong-Staal, Flossie 3 163753838 Gallo, Robert NIH - NCI NCI Gallo, Robert (NCI) 4 163753857 Markham, Phillip NIH - NCI Markham, Phillip 5 163753861 Kalyanaraman, V NIH - NCI Kalyanaraman, V 6 163753789 Franchini, Genoveffa NCI - CCR NCI Franchini, Genoveffa (NCI) 1 163753806 Salahuddin, Syed NIH - NCI Salahuddin, Syed 2 163753818 Wong-Staal, Flossie NIH - NCI Wong-Staal, Flossie 3 163753838 Gallo, Robert NIH - NCI NCI Gallo, Robert (NCI) 4 163753857 Markham, Phillip NIH - NCI Markham, Phillip 5 163753861 Kalyanaraman, V NIH - NCI Kalyanaraman, V 6 163753654 C8166-45 Cell Line (NIH AIDS Reagent Repository Catalog No. 404) E-272-2007-0 Research Material NCI 83740301 Dattaroy, Diptadip diptadip.dattaroy@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB diptadip.dattaroy@nih.gov?subject=Web Inquiry on [TAB-5070] C8166-45 Cells&body=Please send me information about technology [TAB-5070] C8166-45 Cells.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dattaroy, Diptadip<br><a href="mailto:diptadip.dattaroy@nih.gov?subject=Web Inquiry on [TAB-5070] C8166-45 Cells&body=Please send me information about technology [TAB-5070] C8166-45 Cells.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">diptadip.dattaroy@nih.gov</a><br> TAB-3591 114097445 Identification and Use of a Novel Functionally Selective GHSR1a Ghrelin Receptor Inhibitor, including NCGC00538279, for the Treatment of Food and Chemical Addiction NCATS Endocrinology, Neurology, Research Materials, Therapeutics Endocrinology Neurology Research Materials Therapeutics Marc Ferrer-Alegre, Mark Henderson, Xin Hu, Daniel Jansen, David Kim, Juan Marugan, Noel Southall This technology includes a chemical series, including the NCGC00538279 compound, that selectively activates the GHSR1a G-protein pathway for calcium mobilization while only partially activating the beta-arrestin-2 translocation pathway. The resulting chemical series may be therapeutically valuable for addictive disorders. Activation of the GHSR1a G-protein pathway promotes production and secretion of multiple hormones, including insulin, growth hormone, and IGF1. Activation of the beta-arrestin-2 pathway stimulates dopamine production and may mediate addictive behaviors. Work with non-selective antagonists in models has indicated good in vivo efficacy results for treating addictive disorders. However, long term exposure to this type of antagonist triggers multiple undesirable side effects due to their capacity to inhibit production of numerous hormones. A select antagonist has the potential to have positive therapeutic effects without the side effects. This technology describes a novel selective GHSR1a Ghrelin receptor inhibitor. Further optimization work could be used to produce a molecule with the selective beta-arrestin activity and improved oral bioavailability, increase CNS exposure and half-life. 2022-08-01 2024-10-28 2025-08-19 2022-08-01 2022-05-06 ADDICTION, Chemical, FOOD, Funtionally, Ghrelin, LIGAND, NCG00538279, Novel, RECEPTOR, SELECTIVE, treatment, VEXXXX, VGXXXX, WIXXXX, WKXXXX, XEXXXX False True True NIHTT 37470483 Website Abstract 114110934 Southall, Noel NCATS - TRND NCATS Southall, Noel (NCATS) 0 114110935 Ferrer-Alegre, Marc NCATS - NCGC NCATS Ferrer-Alegre, Marc (NCATS) 0 114110936 Jansen, Daniel FDA Jansen, Daniel 0 114110937 Henderson, Mark NCATS - NCGC NCATS Henderson, Mark (NCATS) 0 114110938 Hu, Xin NCATS - NCGC NCATS Hu, Xin (NCATS) 0 114110939 Kim, David NCATS - NCGC NCATS Kim, David (NCATS) 0 114110933 Marugan, Juan NCATS - NCGC NCATS Marugan, Juan (NCATS) 1 114110933 Marugan, Juan NCATS - NCGC NCATS Marugan, Juan (NCATS) 1 114110934 Southall, Noel NCATS - TRND NCATS Southall, Noel (NCATS) 0 114110935 Ferrer-Alegre, Marc NCATS - NCGC NCATS Ferrer-Alegre, Marc (NCATS) 0 114110936 Jansen, Daniel FDA Jansen, Daniel 0 114110937 Henderson, Mark NCATS - NCGC NCATS Henderson, Mark (NCATS) 0 114110938 Hu, Xin NCATS - NCGC NCATS Hu, Xin (NCATS) 0 114110939 Kim, David NCATS - NCGC NCATS Kim, David (NCATS) 0 114102699 NCG00538279 Is A Novel Funtionally Selective Ghrelin Receptor Ligand For The Treatment Of Food And Chemical Addiction E-082-2021-0 Under Review FDA, NCATS - NCGC 83727060 Gadhia, Ami ami.gadhia@nih.gov
United States of America NCGC ami.gadhia@nih.gov?subject=Web Inquiry on [TAB-3591] Identification and Use of a Novel Functionally Selective GHSR1a Ghrelin Receptor Inhibitor, including NCGC00538279, for the Treatment of Food and Chemical Addiction&body=Please send me information about technology [TAB-3591] Identification and Use of a Novel Functionally Selective GHSR1a Ghrelin Receptor Inhibitor, including NCGC00538279, for the Treatment of Food and Chemical Addiction. Gadhia, Ami<br><a href="mailto:ami.gadhia@nih.gov?subject=Web Inquiry on [TAB-3591] Identification and Use of a Novel Functionally Selective GHSR1a Ghrelin Receptor Inhibitor, including NCGC00538279, for the Treatment of Food and Chemical Addiction&body=Please send me information about technology [TAB-3591] Identification and Use of a Novel Functionally Selective GHSR1a Ghrelin Receptor Inhibitor, including NCGC00538279, for the Treatment of Food and Chemical Addiction.">ami.gadhia@nih.gov</a><br> 114128856 VEXXXX 114128857 VGXXXX 114128858 WIXXXX 114128859 WKXXXX 114128860 XEXXXX 114153467 NCG00538279 114153468 Novel 114153469 Funtionally 114153470 SELECTIVE 114153471 Ghrelin 114153472 RECEPTOR 114153473 LIGAND 114153474 treatment 114153475 FOOD 114153476 Chemical 114153477 ADDICTION TAB-3945 147157225 New Cancer Research Model: Spontaneously Transformed Mouse Epithelial Cancer Cell Lines NCI Licensing, Oncology, Research Materials Licensing Oncology Research Materials Karen Hathcock, Nicole McNeil Ford, Hesed Padilla-Nash, Karl Ried <p>The National Cancer Institute Cancer Genetics Branch is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize mouse epithelial cancer cell lines.</p> <p> Investigators at the NIH have created a collection of 45 mouse epithelial cancer cell lines derived from six organs: bladder, cervix, colon, lung, kidney, and mammary glands.  These cells lines were obtained from spontaneously transformed primary cell cultures without genetic, viral or chemical manipulation so they can serve as mouse models for studying the natural process of oncogenesis. </p> <p> The cell lines were characterized cytogenetically during their transformation from normal to spontaneously immortalization and were found to recapitulate many of the changes observed in human cancer cells such as the deregulation of oncogenes (Myc, Mdm2) and tumor suppressor genes (Cdnk4a/Ink4a/p16, Rb).</p> <p> Carcinomas that arise from the epithelial cells lining organs lead to the most common cancers in humans.  However, research on cellular transformation has largely relied on fibroblast cells which are not of epithelial origin and therefore, may not reflect the changes that lead to epithelial oncogenesis.  The availability of these mouse epithelial cancer cell lines should allow for a more accurate analysis of this process.</p> <h2>Competitive Advantages:</h2> <ul><li>Cytogenetically defined epithelial cell lines from mouse that model human carcinomas</li> <li>Spontaneously transformed primary cell cultures were generated from isogenic mouse strain that has a low propensity for epithelial tumors in vivo therefore, not involving other mouse strains potentially influencing the genetic background.</li> <li>These cell lines were generated without viral, chemical or genetic manipulation and thus can serve as mouse models for studying the natural process of oncogenesis and as mouse models of human cancers.</li> <li>Genomically defined colon, bladder, and kidney cell lines showing oncogene deregulation (i.e. Mdm2 and Myc overexpression)</li> </ul> <h2>Commercial Applications:</h2> <ul><li>These cell lines serve as "ideal" murine tumor models as they show evidence of progression, permitting analysis of the genetic and biological changes observed in the equivalent human carcinomas and associated with tumor progression. Their tumor histology is comparable to human cancers.</li> <li>The cell lines have unique properties that make them suitable for study of the following:</li> <li>Unlimited replicative potential</li> <li>Exhibit tumorigenic potential and EMT (Epithelial Mesencymal Transition</li> <li>Exhibit high degree of chromosome instability (chromosome rearrangements, amplifications) in regions orthologous to those altered in human cancers</li> <li>Use in mapping mouse genes homologous to human cancer genes and for the study of the effects of deregulation of cancer associated genes, through silencing or overexpression.</li> <li>For use in gene expression studies of tumor progression, comparing profiles to human cancers involving the same tissue types</li> <li>Use as experimental controls in the analysis of oncogene signaling pathways</li> <li>Use in the studying telomerase pathway regulation (200-fold expression difference between cell lines)</li> <li>Use of mouse as model of epithelial carcinomas and specifically cancers of the bladder, cervix, colon, lung, mammarys and kidney cancers</li> <li>These mouse models serve as vehicles to test the efficacy of new therapies, targeting specific targets associated with the transformation of six different mouse epithelial tissues.</li> <li>Use for discovering drugs that alter the tumorigenic potential, invasiveness, and the Epithelial-Mesenchymal Transition state</li> </ul> 2016-02-16 2025-08-19 2018-03-09 2025-08-19 2016-07-25 Mouse Epithelial Cancer Cell Lines, Research Tools False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2018-03-09 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147162969 Padilla-Nash, Hesed NIH - NCI NCI Padilla-Nash, Hesed (NCI) 1 147162968 Ried, Karl NIH - NCI NCI Ried, Karl (NCI) 2 147162967 Hathcock, Karen NIH - NCI NCI Hathcock, Karen (NCI) 3 147162970 McNeil Ford, Nicole NIH - NCI NCI McNeil Ford, Nicole (NCI) 4 147162969 Padilla-Nash, Hesed NIH - NCI NCI Padilla-Nash, Hesed (NCI) 1 147162968 Ried, Karl NIH - NCI NCI Ried, Karl (NCI) 2 147162967 Hathcock, Karen NIH - NCI NCI Hathcock, Karen (NCI) 3 147162970 McNeil Ford, Nicole NIH - NCI NCI McNeil Ford, Nicole (NCI) 4 147157961 Collection Of 45 Transformed Murine Epithelial Cell Lines Derived From Six Organs: Bladder, Cervix, Colon, Lime, Kidney And Mammary Glands E-089-2010-0 Research Material NCI 83657698 Specialist (ALS), Admin. Licensing nihott@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
nihott@mail.nih.gov?subject=Web Inquiry on [TAB-3945] New Cancer Research Model: Spontaneously Transformed Mouse Epithelial Cancer Cell Lines&body=Please send me information about technology [TAB-3945] New Cancer Research Model: Spontaneously Transformed Mouse Epithelial Cancer Cell Lines.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Specialist (ALS), Admin. Licensing<br><a href="mailto:nihott@mail.nih.gov?subject=Web Inquiry on [TAB-3945] New Cancer Research Model: Spontaneously Transformed Mouse Epithelial Cancer Cell Lines&body=Please send me information about technology [TAB-3945] New Cancer Research Model: Spontaneously Transformed Mouse Epithelial Cancer Cell Lines.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">nihott@mail.nih.gov</a><br> 147171161 Mouse Epithelial Cancer Cell Lines 147171162 Research Tools TAB-3987 147157268 GATA-3 Reporter Plasmids for Revealing Underlying Mechanisms in Breast Cancer NCI Collaboration, Licensing, Oncology, Research Materials Collaboration Licensing Oncology Research Materials Jeffrey Green, Hosein Kouros-Mehr <p>GATA-3 is a transcription factor that is highly expressed in normal cells of the mammary luminal epithelium. GATA-3 plays a regulatory role in determining the fate of cells in the mammary gland. Disruption of GATA-3 expression leads to defects in the development of mammary cells, including an inability to differentiate properly into the correct cell type. GATA-3 function is also disrupted in various breast cancer models indicating that GATA-3 has tumor suppressive properties in normal cells. Mammary cell differentiation during a cell's development and lifespan helps determine the progression, severity, and clinical outcome of disease for a breast cancer patient. Low or limited mammary GATA-3 expression is correlated with larger tumors, an increased likelihood of tumor-positive lymph nodes, and therefore predicts an overall poorer clinical outcome compared to patients with higher GATA-3 expression. Researchers at the National Cancer Institute, Laboratory of Cancer Biology and Genetics believe that a better understanding of GATA-3 function and dysregulated during the onset and progression of breast cancer will lead to new strategies in diagnosing and treating the disease. They are seeking statements of capability or interest from parties interested in collaborative research to co- develop, evaluate, or commercialize a research tool for the diagnosis or treatment of breast cancer. </p> <h2>Competitive Advantages:</h2> <ul><li>Useful for in vitro and in vivo assays</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Possible identification of new targets for breast cancer therapy</li> </ul> 2016-02-16 2025-08-19 2020-04-07 2025-08-19 2016-08-11 BREAST CANCER, diagnostic, GATA-3 expression, prognostic False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2020-04-07 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147162347 H. Kouros-Mehr et al. GATA-3 and the regulation of the mammary luminal cell fate. http://www.ncbi.nlm.nih.gov/pubmed/18358709 <a href="http://www.ncbi.nlm.nih.gov/pubmed/18358709">H. Kouros-Mehr et al. GATA-3 and the regulation of the mammary luminal cell fate.</a> 147163134 Kouros-Mehr, Hosein NIH - NCI Kouros-Mehr, Hosein 1 147163133 Green, Jeffrey NIH - NCI NCI Green, Jeffrey (NCI) 2 147163134 Kouros-Mehr, Hosein NIH - NCI Kouros-Mehr, Hosein 1 147163133 Green, Jeffrey NIH - NCI NCI Green, Jeffrey (NCI) 2 147158038 GATA-3 Reporter Plasmid E-128-2009-0 Research Material NCI 83657698 Specialist (ALS), Admin. Licensing nihott@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
nihott@mail.nih.gov?subject=Web Inquiry on [TAB-3987] GATA-3 Reporter Plasmids for Revealing Underlying Mechanisms in Breast Cancer&body=Please send me information about technology [TAB-3987] GATA-3 Reporter Plasmids for Revealing Underlying Mechanisms in Breast Cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Specialist (ALS), Admin. Licensing<br><a href="mailto:nihott@mail.nih.gov?subject=Web Inquiry on [TAB-3987] GATA-3 Reporter Plasmids for Revealing Underlying Mechanisms in Breast Cancer&body=Please send me information about technology [TAB-3987] GATA-3 Reporter Plasmids for Revealing Underlying Mechanisms in Breast Cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">nihott@mail.nih.gov</a><br> 147171998 BREAST CANCER 147171999 diagnostic 147172001 GATA-3 expression 147172002 prognostic TAB-5034 159362020 Next generation MRI platform Signal Amplification by Reversible Exchange (SABRE) hyperpolarization NHLBI Murali Cherukuri, Jessica Ettedgui-Benjamini, Rolf Swenson <p>Hyperpolarized magnetic resonance imaging (MRI) is an emerging molecular imaging method for metabolic imaging for detecting cancer, cardiovascular disease, stroke, and traumatic brain injury and monitoring therapy with no Gadolinium or Iron. Available for licensing and commercial development is a patent estate covering a perfluorinated single amplification by reversible exchange (SABRE) catalyst for generating MRI agents that includes a d-block element and a perfluorinated ligand hyperpolarized substrate comprising a 1/2 spin nucleus or nuclei using the perfluorinated SABRE catalysts, and isolating the resulting hyperpolarized substrate for administration. The invention also provides methods for separating a hyperpolarized substrate from the SABRE catalyst and/or hyperpolarized SABRE catalyst complex containing a heavy metal. These changes can be observed in patients in real time with a specialized MRI approach called hyperpolarization. By transiently changing the nuclear spin of naturally occurring intermediates in cellular energy production, the metabolic fate can be observed with greater than 10,000-fold sensitivity. Current methods of hyperpolarization require expensive machines with limited throughput.</p> <ul> <li>High Sensitivity: Over 10,000-fold sensitivity improvement.</li> <li>Cost Efficiency: Avoids expensive hyperpolarization machines.</li> <li>Metal-Free Imaging: No gadolinium or iron required.</li> <li>Real-Time Monitoring: Enables immediate observation of metabolic changes.</li> </ul> <ul> <li>MRI imaging</li> <li>Hyperpolarization</li> <li>Infusion Device for imaging reagents</li> <li>Cancer diagnostics</li> <li>Cardiovascular disease diagnostics</li> </ul> 2024-11-27 2025-08-19 2025-08-19 2024-12-03 False False True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 159422126 Ettedgui J, 2024 https://pubmed.ncbi.nlm.nih.gov/38154120/ <a href="https://pubmed.ncbi.nlm.nih.gov/38154120/">Ettedgui J, 2024</a> 159422129 Hong D, 2023 https://pubmed.ncbi.nlm.nih.gov/38024238/ <a href="https://pubmed.ncbi.nlm.nih.gov/38024238/">Hong D, 2023</a> 159422144 Schmidt AB, 2022 https://pubmed.ncbi.nlm.nih.gov/36379005/ <a href="https://pubmed.ncbi.nlm.nih.gov/36379005/">Schmidt AB, 2022</a> 159422158 Adelabu I, 2022 https://pubmed.ncbi.nlm.nih.gov/36136056/ <a href="https://pubmed.ncbi.nlm.nih.gov/36136056/">Adelabu I, 2022</a> 159422206 Adelabu I, 2022 https://pubmed.ncbi.nlm.nih.gov/34813142/ <a href="https://pubmed.ncbi.nlm.nih.gov/34813142/">Adelabu I, 2022</a> 159422221 AbuSalim JE, 2021 https://pubmed.ncbi.nlm.nih.gov/34554724/ <a href="https://pubmed.ncbi.nlm.nih.gov/34554724/">AbuSalim JE, 2021</a> 159422229 Miura N, 2021 https://pubmed.ncbi.nlm.nih.gov/34263489/ <a href="https://pubmed.ncbi.nlm.nih.gov/34263489/">Miura N, 2021</a> 159422271 Chapman B, 2021 https://pubmed.ncbi.nlm.nih.gov/34102835/ <a href="https://pubmed.ncbi.nlm.nih.gov/34102835/">Chapman B, 2021</a> 159422274 Yamamoto K, 2021 https://pubmed.ncbi.nlm.nih.gov/34108512/ <a href="https://pubmed.ncbi.nlm.nih.gov/34108512/">Yamamoto K, 2021</a> 159422074 Ettedgui-Benjamini, Jessica National Heart, Lung, and Blood Institute (NHLBI) NHLBI Ettedgui-Benjamini, Jessica (NHLBI) 1 159422090 Swenson, Rolf NHLBI Swenson, Rolf (NHLBI) 2 159422096 Cherukuri, Murali NCI Cherukuri, Murali (NCI) 3 159422074 Ettedgui-Benjamini, Jessica National Heart, Lung, and Blood Institute (NHLBI) NHLBI Ettedgui-Benjamini, Jessica (NHLBI) 1 159422090 Swenson, Rolf NHLBI Swenson, Rolf (NHLBI) 2 159422096 Cherukuri, Murali NCI Cherukuri, Murali (NCI) 3 159362025 Synthesis Of Iridium SABRE Catalysts Containing Heavy Perfluorinated Carbon Chains For Its Facile Removal And Delivery Of Metal-free Hyperpolarized Contrast Agents Such As Pyruvate E-036-2022-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI), NCI 159362038 Preparation Of Deuterated 12C, 13C-ketoglutarate (1-13C-3-D2-4-D-512C Ketoglutarate) And Methods To Hyperpolarization Using SABRE-Signal Amplification By Reversible Exchange E-035-2022-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI), NCI 159362045 TEMPERATURE CYCLING METHOD FOR HYPERPOLARIZATION OF TARGET MOLECULES AND CONTRAST AGENTS USING PARAHYDROGEN E-039-2022-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 159362213 INFUSION DEVICE FOR THE USE OF HYPERPOLARIZED MRI PROBES PREPARED BY FLUOROUS CATALYZED SABRE E-052-2022-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI), NCI 159362336 Real-time Monitoring Of In Vivo Free Radical Scavengers Through Hyperpolarized [1-13C] N-acetyl Cysteine E-069-2020-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI), NCI 159362413 Isotopes Of Alpha Ketoglutarate And Related Compounds For Hyperpolarized MRI Imaging E-070-2020-0 Filing authorized National Cancer Institute (NCI), National Heart, Lung, and Blood Institute (NHLBI), National Heart, Lung, and Blood Institute (NHLBI), Radiation Biology Branch 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-5034] Next generation MRI platform Signal Amplification by Reversible Exchange (SABRE) hyperpolarization&body=Please send me information about technology [TAB-5034] Next generation MRI platform Signal Amplification by Reversible Exchange (SABRE) hyperpolarization. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-5034] Next generation MRI platform Signal Amplification by Reversible Exchange (SABRE) hyperpolarization&body=Please send me information about technology [TAB-5034] Next generation MRI platform Signal Amplification by Reversible Exchange (SABRE) hyperpolarization.">shmilovm@nih.gov</a><br> 159362050 E-039-2022-0 E-039-2022-0-US-01 TEMPERATURE CYCLING METHOD FOR HYPERPOLARIZATION OF TARGET MOLECULES AND CONTRAST AGENTS USING PARAHYDROGEN PRV US 63/203,591 Abandoned US <br />Provisional (PRV) 63/203,591<br />Filed on 2021-07-27<br />Status: Abandoned 159362051 E-039-2022-0 E-039-2022-0-PCT-02 TEMPERATURE CYCLING METHOD FOR HYPERPOLARIZATION OF TARGET MOLECULES AND CONTRAST AGENTS USING PARAHYDROGEN PCT Patent Cooperation Treaty PCT/US2022/074122 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2022/074122<br />Filed on 2022-07-26<br />Status: Expired 159362052 E-039-2022-0 E-039-2022-0-US-02 TEMPERATURE CYCLING METHOD FOR HYPERPOLARIZATION OF TARGET MOLECULES AND CONTRAST AGENTS USING PARAHYDROGEN National Stage US 12,566,228 18/291,681 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12566228 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12566228">12,566,228</a><br />Filed on 2024-01-24<br />Status: Issued 159362079 E-035-2022-0 E-035-2022-0-US-01 PREPARATION OF ISOTOPICALLY LABELED KETOGLUTARATES AND METHODS OF HYPERPOLARIZATION THROUGH SIGNAL AMPLIFICATION BY REVERSIBLE EXCHANGE (SABRE) PRV US 63/303,190 Expired US <br />Provisional (PRV) 63/303,190<br />Filed on 2022-01-26<br />Status: Expired 159362080 E-035-2022-0 E-035-2022-0-PCT-02 PREPARATION OF ISOTOPICALLY LABELED KETOGLUTARATES AND METHODS OF HYPERPOLARIZATION THROUGH SIGNAL AMPLIFICATION BY REVERSIBLE EXCHANGE (SABRE) PCT Patent Cooperation Treaty PCT/US2023/011640 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2023/011640<br />Filed on 2023-01-26<br />Status: Expired 159362081 E-035-2022-0 E-035-2022-0-JP-01 PREPARATION OF ISOTOPICALLY LABELED KETOGLUTARATES AND METHODS OF HYPERPOLARIZATION THROUGH SIGNAL AMPLIFICATION BY REVERSIBLE EXCHANGE (SABRE) National Stage Japan 2024-544466 Abandoned Japan <br />National Stage 2024-544466<br />Filed on 2024-07-25<br />Status: Abandoned 159362082 E-035-2022-0 E-035-2022-0-CA-01 PREPARATION OF ISOTOPICALLY LABELED KETOGLUTARATES AND METHODS OF HYPERPOLARIZATION THROUGH SIGNAL AMPLIFICATION BY REVERSIBLE EXCHANGE (SABRE) National Stage Canada 3243219 Pending Canada <br />National Stage 3243219<br />Filed on 2024-07-23<br />Status: Pending 159362083 E-035-2022-0 E-035-2022-0-IL-01 PREPARATION OF ISOTOPICALLY LABELED KETOGLUTARATES AND METHODS OF HYPERPOLARIZATION THROUGH SIGNAL AMPLIFICATION BY REVERSIBLE EXCHANGE (SABRE) National Stage Israel 314428 Pending Israel <br />National Stage 314428<br />Filed on 2024-07-22<br />Status: Pending 159362084 E-035-2022-0 E-035-2022-0-CN-01 PREPARATION OF ISOTOPICALLY LABELED KETOGLUTARATES AND METHODS OF HYPERPOLARIZATION THROUGH SIGNAL AMPLIFICATION BY REVERSIBLE EXCHANGE (SABRE) National Stage China 202380026889.8 Abandoned China <br />National Stage 202380026889.8<br />Filed on 2024-09-11<br />Status: Abandoned 159362085 E-035-2022-0 E-035-2022-0-US-02 PREPARATION OF ISOTOPICALLY LABELED KETOGLUTARATES AND METHODS OF HYPERPOLARIZATION THROUGH SIGNAL AMPLIFICATION BY REVERSIBLE EXCHANGE (SABRE) National Stage US 18/833,627 Pending US <br />National Stage 18/833,627<br />Filed on 2024-07-26<br />Status: Pending 159362086 E-035-2022-0 E-035-2022-0-EP-01 PREPARATION OF ISOTOPICALLY LABELED KETOGLUTARATES AND METHODS OF HYPERPOLARIZATION THROUGH SIGNAL AMPLIFICATION BY REVERSIBLE EXCHANGE (SABRE) National Stage European Patent 23707534.6 Pending European Patent <br />National Stage 23707534.6<br />Filed on 2024-07-23<br />Status: Pending 159362087 E-035-2022-0 E-035-2022-0-HK-01 PREPARATION OF ISOTOPICALLY LABELED KETOGLUTARATES AND METHODS OF HYPERPOLARIZATION THROUGH SIGNAL AMPLIFICATION BY REVERSIBLE EXCHANGE (SABRE) EP Hong Kong Administratively Closed Hong Kong <br />European patent (EP) None<br />Filed on None<br />Status: Administratively Closed 159362218 E-052-2022-0 E-052-2022-0-US-01 INFUSION DEVICE FOR THE PREPARATION AND DELIVERY OF MRI PROBES PRV US 63/328,556 Expired US <br />Provisional (PRV) 63/328,556<br />Filed on 2022-04-07<br />Status: Expired 159362219 E-052-2022-0 E-052-2022-0-PC-01 INFUSION DEVICE FOR THE PREPARATION AND DELIVERY OF MRI PROBES PCT Patent Cooperation Treaty PCT/US2023/017895 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2023/017895<br />Filed on 2023-04-07<br />Status: Expired 159362220 E-052-2022-0 E-052-2022-0-JP-01 INFUSION DEVICE FOR THE PREPARATION AND DELIVERY OF MRI PROBES National Stage Japan 2024-559257 Abandoned Japan <br />National Stage 2024-559257<br />Filed on 2024-10-04<br />Status: Abandoned 159362221 E-052-2022-0 E-052-2022-0-CA-01 INFUSION DEVICE FOR THE PREPARATION AND DELIVERY OF MRI PROBES National Stage Canada 3246953 Pending Canada <br />National Stage 3246953<br />Filed on 2024-09-26<br />Status: Pending 159362222 E-052-2022-0 E-052-2022-0-IL-01 INFUSION DEVICE FOR THE PREPARATION AND DELIVERY OF MRI PROBES National Stage Israel 315942 Pending Israel <br />National Stage 315942<br />Filed on 2024-09-26<br />Status: Pending 159362223 E-052-2022-0 E-052-2022-0-CN-01 INFUSION DEVICE FOR THE PREPARATION AND DELIVERY OF MRI PROBES National Stage China 202380040403.6 Abandoned China <br />National Stage 202380040403.6<br />Filed on 2024-11-14<br />Status: Abandoned 159362224 E-052-2022-0 E-052-2022-0-US-02 INFUSION DEVICE FOR THE PREPARATION AND DELIVERY OF MRI PROBES National Stage US 18/854,462 Pending US <br />National Stage 18/854,462<br />Filed on 2024-10-04<br />Status: Pending 159362225 E-052-2022-0 E-052-2022-0-EP-01 INFUSION DEVICE FOR THE PREPARATION AND DELIVERY OF MRI PROBES National Stage European Patent 23721501.7 Pending European Patent <br />National Stage 23721501.7<br />Filed on 2024-11-06<br />Status: Pending 159362341 E-069-2020-0 E-069-2020-0-US-01 REAL-TIME MONITORING OF IN VIVO FREE RADICAL SCAVENGERS THROUGH HYPERPOLARIZED N-ACETYL CYSTEINE ISOTOPES PRV US 62/961,855 Abandoned US <br />Provisional (PRV) 62/961,855<br />Filed on 2020-01-16<br />Status: Abandoned 159362342 E-069-2020-0 E-069-2020-0-PCT-02 REAL-TIME MONITORING OF IN VIVO FREE RADICAL SCAVENGERS THROUGH HYPERPOLARIZED N-ACETYL CYSTEINE ISOTOPES PCT Patent Cooperation Treaty PCT/US2021/013634 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/013634<br />Filed on 2021-01-15<br />Status: Expired 159362343 E-069-2020-0 E-069-2020-0-EP-03 REAL-TIME MONITORING OF IN VIVO FREE RADICAL SCAVENGERS THROUGH HYPERPOLARIZED N-ACETYL CYSTEINE ISOTOPES National Stage European Patent 21741034.9 Pending European Patent <br />National Stage 21741034.9<br />Filed on 2021-01-15<br />Status: Pending 159362344 E-069-2020-0 E-069-2020-0-IL-04 REAL-TIME MONITORING OF IN VIVO FREE RADICAL SCAVENGERS THROUGH HYPERPOLARIZED N-ACETYL CYSTEINE ISOTOPES National Stage Israel 294365 Pending Israel <br />National Stage 294365<br />Filed on 2022-06-28<br />Status: Pending 159362345 E-069-2020-0 E-069-2020-0-US-05 REAL-TIME MONITORING OF INVIVO FREE RADICAL SCAVENGERS THROUGH HYPERPOLARIZED N-ACETYL CYSTEINE ISOTOPES National Stage US 17/793,083 Pending US <br />National Stage 17/793,083<br />Filed on 2022-07-15<br />Status: Pending 159362418 E-070-2020-0 E-070-2020-0-US-01 Isotopes Of Alpha Ketoglutarate And Related Compounds For Hyperpolarized MRI Imaging PRV US 62/962,473 Abandoned US <br />Provisional (PRV) 62/962,473<br />Filed on 2020-01-17<br />Status: Abandoned 159362419 E-070-2020-0 E-070-2020-0-PCT-02 ISOTOPES OF ALPHA KETOGLUTARATE AND RELATED COMPOUNDS FOR HYPERPOLARIZED IMAGING PCT Patent Cooperation Treaty PCT/US2021/013658 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/013658<br />Filed on 2021-01-15<br />Status: Expired 159362420 E-070-2020-0 E-070-2020-0-EP-03 ISOTOPES OF ALPHA KETOGLUTARATE AND RELATED COMPOUNDS FOR HYPERPOLARIZED IMAGING National Stage European Patent 21741941.5 Pending European Patent <br />National Stage 21741941.5<br />Filed on 2021-01-15<br />Status: Pending 159362421 E-070-2020-0 E-070-2020-0-IL-04 ISOTOPES OF ALPHA KETOGLUTARATE AND RELATED COMPOUNDS AND THEIR USE IN HYPERPOLARIZED IMAGING National Stage Israel 294464 Pending Israel <br />National Stage 294464<br />Filed on 2022-07-03<br />Status: Pending 159362422 E-070-2020-0 E-070-2020-0-US-05 ISOTOPES OF ALPHA KETOGLUTARATE AND RELATED COMPOUNDS AND THEIR USE IN HYPERPOLARIZED IMAGING National Stage US 17/793,089 Pending US <br />National Stage 17/793,089<br />Filed on 2022-07-15<br />Status: Pending 160031297 E-052-2022-0 E-052-2022-0-HK-01 INFUSION DEVICE FOR THE PREPARATION AND DELIVERY OF MRI PROBES CN Hong Kong 62025104551.9 Abandoned Hong Kong <br />China Patent (CN) 62025104551.9<br />Filed on 2025-03-11<br />Status: Abandoned TAB-946 114095280 Haplotypes of Human Bitter Taste Receptor Genes NIDCD Diagnostics, Licensing, Research Materials, Therapeutics Diagnostics Licensing Research Materials Therapeutics Dennis Drayna, Un-kyung Kim Bitter taste has evolved in mammals as a crucial, important warning signal against ingestion of poisonous or toxic compounds. However, many beneficial compounds are also bitter, and taste masking of bitter tasting pharmaceutical compounds is a billion dollar industry. The diversity of compounds that elicit bitter-taste sensations is very large and more than two dozen members of the T2R bitter taste receptor family have been identified. Individuals are now known to be genetically predisposed to respond or not to respond to the bitter taste of a number of substances. For example, large individual differences in the perception of bitterness have been well documented in compounds as different as nicotine, thiocyanates such as those found in cruciferous vegetables, and many bitter beta-glucopyranosides. This may have broad implications for nutritional status and tobacco use and common allelic variants of a member of the T2R bitter taste receptor gene family have been shown to underlie variation in the ability to taste phenylthiocarbamide (PTC) [Science (2003) 299, 1221-1225; HHS Ref No: E-169-2001/0]. <br><br> Scientists at the NIDCD have extended these results to other bitter taste receptors and have sequenced 22 of the 24 known T2R genes in a series of populations worldwide, including Northern Europeans, Hungarians, Japanese, Cameroonians, Pygmies and South American Indians and the present invention includes these isolated sequences and their variants. This includes a total of 127 SNPs and 103 different protein coding haplotypes, including those defined for the PTC Receptor (T2R38) [E-169-2001/0]. The inventors showed that 77% of the SNPs identified caused an amino acid substitution in the encoded receptor protein, giving rise to a very high degree of receptor protein variation in the population (Kim et al. (2005) Human Mutation 26, 199-204). The frequencies of these different haplotypes have been shown to differ in different populations which will aid in population-specific studies, such as those targeting differences in taste perception between Europeans and Asians, for example. <br><br> The invention available for licensing includes these novel SNPs and haplotypes and methods of use, which can be used to better identify and characterize different groups of individuals within and between populations that vary in the their bitter taste abilities. This is important to the food and flavoring industry, for example, where these variants can be used to aid in the development of a variety of taste improvements in foods and orally administered medications. 2022-03-08 2025-08-13 2025-08-15 2006-02-01 AC4XXX, ACXXXX, AXXXXX, Bitter, bitter taste, Chromosome 22 ring, flavor evaluation, Haplotypes, Human, ICXXXX, IXXXXX, population genetics, R 22, RECEPTOR, SNPs, TASTE, taste masking, taste receptors, VARIANTS False True True NIHTT 37470483 Website Abstract E-099-2005-0 E-169-2001-0 114104798 Kim, Un-kyung National Institute on Deafness and Other Communication Disorders (NIDCD) Kim, Un-kyung 0 114104797 Drayna, Dennis National Institute on Deafness and Other Communication Disorders (NIDCD) NIDCD Drayna, Dennis (NIDCD) 1 114104797 Drayna, Dennis National Institute on Deafness and Other Communication Disorders (NIDCD) NIDCD Drayna, Dennis (NIDCD) 1 114104798 Kim, Un-kyung National Institute on Deafness and Other Communication Disorders (NIDCD) Kim, Un-kyung 0 114100142 Human Bitter Taste Receptor Variants E-222-2003-1 Filing authorized National Institute on Deafness and Other Communication Disorders (NIDCD) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-946] Haplotypes of Human Bitter Taste Receptor Genes&body=Please send me information about technology [TAB-946] Haplotypes of Human Bitter Taste Receptor Genes. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-946] Haplotypes of Human Bitter Taste Receptor Genes&body=Please send me information about technology [TAB-946] Haplotypes of Human Bitter Taste Receptor Genes.">shmilovm@nih.gov</a><br> 114162357 E-222-2003-1 E-222-2003-1-US-02 Variants of Human Taste Receptor Genes National Stage US 7,579,453 10/561,487 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7579453 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7579453">7,579,453</a><br />Filed on 2005-12-19<br />Status: Expired 114165430 E-222-2003-1 E-222-2003-1-US-06 Variants of Human Taste Receptor Genes CON US 8,309,701 12/534,505 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8309701 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8309701">8,309,701</a><br />Filed on 2009-08-03<br />Status: Expired 114166899 E-222-2003-1 E-222-2003-1-US-07 Variants Of Human Taste Receptor Genes DIV US 9,783,590 13/674,637 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9783590 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9783590">9,783,590</a><br />Filed on 2012-11-12<br />Status: Expired 114168038 E-222-2003-1 E-222-2003-1-PCT-01 Human Bitter Taste Receptor Variants PCT COMB Patent Cooperation Treaty PCT/US2004/019489 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2004/019489<br />Filed on 2004-06-18<br />Status: Expired 114114574 AXXXXX 114115079 AC4XXX 114115425 ICXXXX 114115426 IXXXXX 114115576 ACXXXX 114136339 Human 114136340 Bitter 114136341 TASTE 114136342 RECEPTOR 114136343 VARIANTS 114136344 bitter taste 114136345 flavor evaluation 114136346 Haplotypes 114136347 population genetics 114136348 taste masking 114136349 SNPs 114136350 taste receptors 114157837 Chromosome 22 ring 114159041 R 22 TAB-910 114095244 Construction of Recombinant Baculoviruses Carrying the Gene Encoding the Major Capsid Protein, VP1, From Calicivirus Strains (Including Norovirus Strains Toronto, Hawaii, Desert Shield, Snow Mountain, and MD145-12) NIAID Collaboration, Diagnostics, Infectious Disease, Licensing, Materials Available, Research Materials, Therapeutics, Vaccines Collaboration Diagnostics Infectious Disease Licensing Materials Available Research Materials Therapeutics Vaccines Lisbeth Kim Green, Stanislav Sosnovtsev The noroviruses (known as "Norwalk-like viruses") are associated with an estimated 23,000,000 cases of acute gastroenteritis in the United States each year. Norovirus illness often occurs in outbreaks, affecting large numbers of individuals, illustrated recently by well-publicized reports of gastroenteritis outbreaks on several recreational cruise ships and in settings such as hospitals and schools. Norovirus disease is clearly important in terms of medical costs and missed workdays, and accumulating data support its emerging recognition as important agents of diarrhea-related morbidity.<br /><br /> Because the noroviruses cannot be propagated by any means in the laboratory, an important strategy in their study is the development of molecular biology-based tools. This invention reports the development of recombinant baculoviruses carrying the capsid gene from several caliciviruses associated with human disease. Growth of these baculovirus recombinants in insect cells results in the expression of virus-like particles (VLPs) that are antigenically indistinguishable from the native calicivirus particle. These VLPs can be purified in large quantities for use as diagnostic reagents and potential vaccine candidates. The Laboratory of Infectious Diseases, NIAID, NIH, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize norovirus VLP antigens. Please contact Kim Y. Green at <a href="mailto:kgreen@niaid.nih.gov">kgreen@niaid.nih.gov</a> for more information. Research Material --Patent protection is not being pursued for this technology Research Material -- Patent protection is not being pursued for these technologies The materials embodied in this invention are available nonexclusively through a biological materials license. 2022-03-08 2025-08-13 2025-08-15 2008-06-01 Baculoviruses, CALICIVIRUS, CAPSID, Construction, DA4BXX, DA4XXX, DAXXXX, DB4BXX, DB4XXX, DBXXXX, DC5BXX, DC5XXX, DCXXXX, DDXXXX, DXXXXX, Hawaii, MD145-12, Mountain, Norovirus, SHIELD, Snow, STRAINS, TORONTO, VP1 False True True NIHTT 37470483 Website Abstract E-283-2003-0 E-214-2003-0 E-212-2003-0 114169964 Green KY, et al. A predominant role for Norwalk-like viruses as agents of epidemic gastroenteritis in Maryland nursing homes for the elderly. https://www.ncbi.nlm.nih.gov/pubmed/11807686 <a href="https://www.ncbi.nlm.nih.gov/pubmed/11807686">Green KY, et al. A predominant role for Norwalk-like viruses as agents of epidemic gastroenteritis in Maryland nursing homes for the elderly.</a> 114104726 Sosnovtsev, Stanislav NIAID - DIR NIAID Sosnovtsev, Stanislav (NIAID) 0 114104728 Green, Lisbeth Kim NIAID - DIR NIAID Green, Lisbeth Kim (NIAID) 1 114104728 Green, Lisbeth Kim NIAID - DIR NIAID Green, Lisbeth Kim (NIAID) 1 114104726 Sosnovtsev, Stanislav NIAID - DIR NIAID Sosnovtsev, Stanislav (NIAID) 0 114100102 Construction Of Recombinant Baculoviruses Carrying The Gene Encoding The Major Capsid Protein, VP1, From Calicivirus Strains (including, But Not Limited To, Norovirus Strains, Toronto, Hawaii, Desert Shield, Snow Mountain And MD145-12) E-198-2003-0 Research Material NIAID 91021353 Pitts, Elizabeth elizabeth.pitts@nih.gov
United States of America elizabeth.pitts@nih.gov?subject=Web Inquiry on [TAB-910] Construction of Recombinant Baculoviruses Carrying the Gene Encoding the Major Capsid Protein, VP1, From Calicivirus Strains (Including Norovirus Strains Toronto, Hawaii, Desert Shield, Snow Mountain, and MD145-12)&body=Please send me information about technology [TAB-910] Construction of Recombinant Baculoviruses Carrying the Gene Encoding the Major Capsid Protein, VP1, From Calicivirus Strains (Including Norovirus Strains Toronto, Hawaii, Desert Shield, Snow Mountain, and MD145-12). Pitts, Elizabeth<br><a href="mailto:elizabeth.pitts@nih.gov?subject=Web Inquiry on [TAB-910] Construction of Recombinant Baculoviruses Carrying the Gene Encoding the Major Capsid Protein, VP1, From Calicivirus Strains (Including Norovirus Strains Toronto, Hawaii, Desert Shield, Snow Mountain, and MD145-12)&body=Please send me information about technology [TAB-910] Construction of Recombinant Baculoviruses Carrying the Gene Encoding the Major Capsid Protein, VP1, From Calicivirus Strains (Including Norovirus Strains Toronto, Hawaii, Desert Shield, Snow Mountain, and MD145-12).">elizabeth.pitts@nih.gov</a><br> 114115252 DA4BXX 114115253 DB4BXX 114115254 DC5BXX 114115255 DDXXXX 114115256 DAXXXX 114115257 DBXXXX 114115258 DCXXXX 114115259 DXXXXX 114119609 DA4XXX 114119610 DB4XXX 114119611 DC5XXX 114130371 Construction 114130372 Baculoviruses 114130373 CAPSID 114130374 VP1 114130375 CALICIVIRUS 114130376 STRAINS 114130377 Norovirus 114130378 TORONTO 114130379 Hawaii 114130380 SHIELD 114130381 Snow 114130382 Mountain 114130383 MD145-12 TAB-878 114095212 Method and Apparatus for Bioweapon Decontamination ORS Licensing Licensing Deborah Wilson It is in the interest of the public health and national security that the Public Health Service find a licensee for the commercial development and rapid dissemination of the apparatus and method of this invention. <p>The apparatus enables the decontamination of articles contaminated with bioweapons, more particularly sporolated bioweapons of which anthrax (Bacillus anthracis) is of notable concern. The system includes enclosing the article to be decontaminated in a humidified environment thus enhancing the susceptibility of spores to decontamination gases such as chlorine dioxide. Vacuum sealing the chamber and exposing the contaminated article to decontamination gases kills 100% of the spores.</p> 2022-03-08 2025-08-13 2025-08-15 2004-03-01 AB3FXX, AB3XXX, ABXXXX, AE1XXX, AE2BXX, AE2XXX, AEXXXX, Anthrax, AXXXXX False True True NIHTT 37470483 Website Abstract 114104667 Wilson, Deborah ORS Wilson, Deborah (ORS) 0 114104667 Wilson, Deborah ORS Wilson, Deborah (ORS) 0 114100059 Deliberately Enhanced Bio-indicators: A Better Monitor For Decontamination Of Weaponized Bacteriologic Agents E-218-2003-0 Filing authorized CDG Research Corporation, ORS 83697013 Miller, Marguerite millermarg@mail.nih.gov
United States of America Technology Advancement Office millermarg@mail.nih.gov?subject=Web Inquiry on [TAB-878] Method and Apparatus for Bioweapon Decontamination&body=Please send me information about technology [TAB-878] Method and Apparatus for Bioweapon Decontamination. Miller, Marguerite<br><a href="mailto:millermarg@mail.nih.gov?subject=Web Inquiry on [TAB-878] Method and Apparatus for Bioweapon Decontamination&body=Please send me information about technology [TAB-878] Method and Apparatus for Bioweapon Decontamination.">millermarg@mail.nih.gov</a><br> 114159999 E-218-2003-0 E-218-2003-0-US-03 Method And Apparatus For Bioweapon Decontamination National Stage US 7,776,292 10/597,191 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7776292 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7776292">7,776,292</a><br />Filed on 2006-07-14<br />Status: Abandoned 114163269 E-218-2003-0 E-218-2003-0-US-01 Method and Apparatus for Bioweapon Decontamination PRV US 60/537,457 Abandoned US <br />Provisional (PRV) 60/537,457<br />Filed on 2004-01-16<br />Status: Abandoned 114167595 E-218-2003-0 E-218-2003-0-PCT-02 Method And Apparatus For Decontamination PCT Patent Cooperation Treaty PCT/US2005/00766 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2005/00766<br />Filed on 2005-01-13<br />Status: Expired 114114933 ABXXXX 114114936 AXXXXX 114122942 AB3XXX 114122943 AB3FXX 114122944 AEXXXX 114122945 AE1XXX 114122946 AE2XXX 114122947 AE2BXX 114157781 Anthrax TAB-823 114095158 Phenylthiocarbamide (PTC) Taste Receptor NIDCD Diagnostics, Licensing, Research Materials, Therapeutics Diagnostics Licensing Research Materials Therapeutics Dennis Drayna, Un-kyung Kim Bitter taste has evolved in mammals as a central warning signal against ingestion of poisonous or toxic compounds. However, many beneficial compounds are also bitter and taste masking of bitter tasting pharmaceutical compounds is a billion dollar industry. The diversity of compounds that elicit bitter-taste sensations is vast and more than two dozen members of the TAS2R bitter taste receptor gene family have been identified. How individuals are genetically predisposed to respond or not to respond to the bitter taste of substances like nicotine and certain foods like broccoli may have broad implications for nutritional status and tobacco use. Large individual differences in the taste perception of bitter compounds have been well documented, and phenylthiocarbamide (PTC), the subject of this invention by scientists at the NIH and the University of Utah, has been widely used for genetic and anthropological studies.<br /><br /> The PTC receptor encodes a novel member of the G protein-coupled TAS2R bitter taste receptor family. Three coding SNPs in this gene were identified as giving rise to five haplotypes which accounted for the bimodal distribution of PTC taste sensitivity worldwide. Distinct phenotypes are associated with distinct genotypes and SNPs such as these identifying variations in the PTC receptor would allow taste masking of bitter tasting compounds tailored to the population genetics profile of different groups and populations.<br /><br /> The invention available for licensing includes composition of matter claims for a bitter taste receptor for PTC, antibodies to the receptor and methods of detecting nucleic acid and amino acid sequences as well as modulators of such PTC taste receptors. The ability to taste PTC has been shown to be correlated with the ability to taste other bitter substances, many of which are toxic. Thus variation in PTC perception and knowledge of the genetic basis of these variants can be used to aid the development of a variety of taste improvements in foods and orally administered medications. 2022-03-08 2025-08-13 2025-08-15 2003-12-01 bitter taste, ICXXXX, IXXXXX, Phenylthiocarbamide, POLYMORPHISMS, PTC, RECEPTOR, SNPs, taste masking False True True NIHTT 37470483 Website Abstract E-222-2003-1 E-099-2005-0 114171648 Kim UK, et al. http://www.ncbi.nlm.nih.gov/pubmed/12595690 <a href="http://www.ncbi.nlm.nih.gov/pubmed/12595690">Kim UK, et al.</a> 114104570 Kim, Un-kyung National Institute on Deafness and Other Communication Disorders (NIDCD) Kim, Un-kyung 0 114104571 Drayna, Dennis National Institute on Deafness and Other Communication Disorders (NIDCD) NIDCD Drayna, Dennis (NIDCD) 1 114104571 Drayna, Dennis National Institute on Deafness and Other Communication Disorders (NIDCD) NIDCD Drayna, Dennis (NIDCD) 1 114104570 Kim, Un-kyung National Institute on Deafness and Other Communication Disorders (NIDCD) Kim, Un-kyung 0 114099994 Phenylthiocarbamide (PTC) Taste Receptor E-169-2001-0 Filing authorized EM, National Institute on Deafness and Other Communication Disorders (NIDCD) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-823] Phenylthiocarbamide (PTC) Taste Receptor&body=Please send me information about technology [TAB-823] Phenylthiocarbamide (PTC) Taste Receptor. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-823] Phenylthiocarbamide (PTC) Taste Receptor&body=Please send me information about technology [TAB-823] Phenylthiocarbamide (PTC) Taste Receptor.">shmilovm@nih.gov</a><br> 114161145 E-169-2001-0 E-169-2001-0-US-01 Phenylthiocarbamide (PTC) Taste Receptor PRV US 60/306,991 Abandoned US <br />Provisional (PRV) 60/306,991<br />Filed on 2001-07-20<br />Status: Abandoned 114162024 E-169-2001-0 E-169-2001-0-US-07 Phenylthiocarbamide (PTC) Taste Receptor DIV US 7,666,601 11/871,131 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7666601 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7666601">7,666,601</a><br />Filed on 2007-10-11<br />Status: Expired 114164484 E-169-2001-0 E-169-2001-0-US-03 Phenylthiocarbamide (PTC) Taste Receptor National Stage US 7,314,725 10/484,525 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7314725 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7314725">7,314,725</a><br />Filed on 2004-01-20<br />Status: Expired 114165733 E-169-2001-0 E-169-2001-0-US-08 Phenylthiocarbamide (PTC) Taste Receptor CON US 8,148,082 12/690,286 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8148082 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8148082">8,148,082</a><br />Filed on 2010-01-20<br />Status: Expired 114167584 E-169-2001-0 E-169-2001-0-PCT-02 Phenylthiocarbamide (PTC) Taste Receptor PCT Patent Cooperation Treaty PCT/US2002/023172 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2002/023172<br />Filed on 2002-07-19<br />Status: Expired 114114830 ICXXXX 114114831 IXXXXX 114136351 Phenylthiocarbamide 114136352 PTC 114136353 bitter taste 114136354 RECEPTOR 114136355 SNPs 114136356 POLYMORPHISMS 114136357 taste masking TAB-776 114095112 Peptide Mimotope Candidates for Otitis Media Vaccine NIDCD Collaboration, Infectious Disease, Licensing, Rare/Neglected Diseases, Vaccines Collaboration Infectious Disease Licensing Rare/Neglected Diseases Vaccines Xinxing Gu This technology describes peptide mimotopes of lipooligosaccharides (LOS) from nontypeable <i>Haemophilus influenzae</i> (NTHi) and <i>Moraxella catarrhalis</i> that are suitable for developing novel vaccines against the respective pathogens, for which there are currently no licensed vaccines. The mimotopes not only immunologically mimic LOSs from NTHi and <i>M. catarrhalis</i> but will also bind to antibodies specific for the respective LOS. NTHi and <i>M. catarrhalis</i> are common pathogens that cause otitis media in children and lower respiratory tract infections in adults. The effectiveness of a vaccine could be increased by substitution of a LOS epitope with a peptide mimic. Preliminary experiments have shown that some of the mimic peptides conjugated to a carrier were as effective as their respective LOS-based vaccine in stimulating a humoral immune response in rabbits. A single consensus amino acid sequence was identified for <i>M. catarrhalis</i>, while four such sequences were identified for NTHi. Thus, the identified peptides are promising candidates for developing novel vaccines for NTHi or <i>M. catarrhalis</i>. Otitis media vaccine The NIDCD Vaccine Research Section is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize Peptide vaccines derived from LOS of NTHi or M. catarrhalis. Please contact Marianne Lynch, a technology development specialist, at 301-594-4094 or <a href="mailto:lynchm2@mail.nih.gov">lynchm2@mail.nih.gov</a> for more information. Available for licensing. 2022-03-08 2025-08-13 2025-08-15 2007-07-01 BCXXXX, CANDIDATES, DC5BXX, DC5XXX, DCXXXX, Development, DXXXXX, H. Influenzae, HAEMOPHILUS, HAEMOPHILUS INFLUENZ, Haemophilus influenzae, INFLUENZA, Lipoligosaccharide, MIMICING AGENT, Minotopes, NONTYPEABLE, OTITIS MEDIA, Peptide, Peptides, UAXXXX, Vaccine False True In vivo data available In vivo data available True 52398218 Pre-Clinical (in vivo) 52398218 NIHTT 37470483 Website Abstract 114104487 Gu, Xinxing National Institute on Deafness and Other Communication Disorders (NIDCD) NIAID Gu, Xinxing (NIAID) 1 114104487 Gu, Xinxing National Institute on Deafness and Other Communication Disorders (NIDCD) NIAID Gu, Xinxing (NIAID) 1 114099943 Development of Peptide Minotopes of Lipoligosaccharide From Nontypeable Haemophilus Influenza As Vaccine Candidates E-344-2002-0 Filing authorized National Institute on Deafness and Other Communication Disorders (NIDCD) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-776] Peptide Mimotope Candidates for Otitis Media Vaccine&body=Please send me information about technology [TAB-776] Peptide Mimotope Candidates for Otitis Media Vaccine. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-776] Peptide Mimotope Candidates for Otitis Media Vaccine&body=Please send me information about technology [TAB-776] Peptide Mimotope Candidates for Otitis Media Vaccine.">shmilovm@nih.gov</a><br> 114161922 E-344-2002-0 E-344-2002-0-US-01 Peptide Minotopes of Lipoligosaccharide From Nontypeable Haemophilus Influenza As Vaccines PRV US 60/441,928 Abandoned US <br />Provisional (PRV) 60/441,928<br />Filed on 2003-01-22<br />Status: Abandoned 114162916 E-344-2002-0 E-344-2002-0-PCT-02 Peptide Mimotopes of Lipoligosaccharide From Nontypeable Haemophilus Influenza As Vaccines PCT Patent Cooperation Treaty PCT/US2004/001457 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2004/001457<br />Filed on 2004-01-21<br />Status: Expired 114164375 E-344-2002-0 E-344-2002-0-US-03 Peptide Mimotopes of Lipooligosaccharide from Nontypeable Haemophilus Influenzae as Vaccines National Stage US 7,514,529 11/187,419 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7514529 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7514529">7,514,529</a><br />Filed on 2005-07-22<br />Status: Expired 114114624 DC5BXX 114114625 DCXXXX 114114626 UAXXXX 114114627 DXXXXX 114119671 DC5XXX 114121248 BCXXXX 114135432 Vaccine 114135433 H. Influenzae 114135434 HAEMOPHILUS INFLUENZ 114135435 Peptides 114135436 MIMICING AGENT 114135437 OTITIS MEDIA 114135438 Development 114135439 Peptide 114135440 Minotopes 114135441 Lipoligosaccharide 114135442 NONTYPEABLE 114135443 HAEMOPHILUS 114135444 INFLUENZA 114135445 CANDIDATES 114157693 Haemophilus influenzae TAB-770 114095105 Variable Curve Catheter NHLBI Collaboration, Licensing Collaboration Licensing Parag Karmarkar, Robert Lederman The invention provides a deflectable tip guiding device, such as a catheter, that enables the operator to vary the radius of curvature of the tip of the catheter. This is a novel variation on the classic "fixed fulcrum" tip deflectors used in minimally invasive procedures in open surgical treatments. The described device permits a more comprehensive ability to navigate complex geometric pathways in patient's body and enables better access to target structures (e.g., to all endomyocardial walls from a transaortic approach). The guiding device can be made compatible with imaging methods like MRI. The described technology can be used as a platform for a variety of interventional devices for delivery of drugs, cells, energy, or sutures through complex trajectories of the body. The NHLBI Translational Medicine Branch Cardiovascular Intervention Program is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize technology for image-guided cardiovascular interventions. Please contact Peg Koelble at <a href="mailto:koelblep@nhlbi.nih.gov">koelblep@nhlbi.nih.gov</a> for more information. Available for licensing. 2022-03-08 2025-08-13 2025-08-15 2005-08-01 AA4XXX, AAXXXX, AXXXXX False True True NIHTT 37470483 Website Abstract 114104479 Lederman, Robert NHLBI Lederman, Robert (NHLBI) 0 114104480 Karmarkar, Parag NHLBI Karmarkar, Parag (NHLBI) 0 114104479 Lederman, Robert NHLBI Lederman, Robert (NHLBI) 0 114104480 Karmarkar, Parag NHLBI Karmarkar, Parag (NHLBI) 0 114099933 Moving Fulcrum Deflectable-tip Having A Variable Radius Of Curvature For Minimally-invasive Diagnostic And Therapeutic Procedures E-035-2003-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-770] Variable Curve Catheter&body=Please send me information about technology [TAB-770] Variable Curve Catheter. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-770] Variable Curve Catheter&body=Please send me information about technology [TAB-770] Variable Curve Catheter.">shmilovm@nih.gov</a><br> 114161898 E-035-2003-0 E-035-2003-0-PCT-02 Variable Curve Catheter PCT Patent Cooperation Treaty PCT/US2003/036210 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2003/036210<br />Filed on 2003-11-14<br />Status: Expired 114161899 E-035-2003-0 E-035-2003-0-US-03 Variable Curve Catheter National Stage US 7,918,819 10/534,362 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7918819 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7918819">7,918,819</a><br />Filed on 2005-11-07<br />Status: Issued 114161900 E-035-2003-0 E-035-2003-0-US-01 Variable Curve Catheter PRV US 60/426,542 Abandoned US <br />Provisional (PRV) 60/426,542<br />Filed on 2002-11-15<br />Status: Abandoned 114114592 AA4XXX 114114593 AAXXXX 114114594 AXXXXX TAB-743 114095079 Mouse Monoclonal Antibodies Against Human IKKgamma/NEMO Protein NIAID Diagnostics, Licensing, Research Materials, Therapeutics Diagnostics Licensing Research Materials Therapeutics Kuan-teh Jeang (Estate) NF-kB has been found to be important in immune responses, cell proliferation, apoptosis, and in organ development. Several years ago it was discovered that an IKKgamma/NEMO protein was essential as an adaptor molecule to mediate TNF-alpha, IL-1, and oncoprotein induced activation of NF-kB. Mutation in IKKgamma/NEMO also results in two human genetic diseases, Familial incontinentia pigmenti and hypohidrotic/anhidrotic ectodermal dysplasia. The NIH announces mouse monoclonal antibodies to IKKgamma/NEMO that are far superior to other immunological reagents. It is anticipated that the antibodies would have both research and diagnostic capabilities. 2022-03-08 2025-08-13 2025-08-15 2003-06-01 Ectodermal dysplasia, IAXXXX, IDXXXX, Incontinentia pigmenti, IXXXXX, Neurofibromatosis type 2, Neurofibromatosis type 3, NF 2, NF 3, RXXXXX False True True NIHTT 37470483 Website Abstract 114104437 Jeang (Estate), Kuan-teh NIAID Jeang (Estate), Kuan-teh (NIAID) 0 114104437 Jeang (Estate), Kuan-teh NIAID Jeang (Estate), Kuan-teh (NIAID) 0 114099900 Mouse Monoclonal Antibodies Against IKKgamma/NEMO Protein, A Factor Required For Proinflammatory Cytokines To Activate NF-kB E-118-2003-0 Research Material NIAID 83724572 Tung, Peter peter.tung@nih.gov
United States of America DIR peter.tung@nih.gov?subject=Web Inquiry on [TAB-743] Mouse Monoclonal Antibodies Against Human IKKgamma/NEMO Protein&body=Please send me information about technology [TAB-743] Mouse Monoclonal Antibodies Against Human IKKgamma/NEMO Protein. Tung, Peter<br><a href="mailto:peter.tung@nih.gov?subject=Web Inquiry on [TAB-743] Mouse Monoclonal Antibodies Against Human IKKgamma/NEMO Protein&body=Please send me information about technology [TAB-743] Mouse Monoclonal Antibodies Against Human IKKgamma/NEMO Protein.">peter.tung@nih.gov</a><br> 114114502 IAXXXX 114114503 IDXXXX 114114504 IXXXXX 114114505 RXXXXX 114157643 Incontinentia pigmenti 114157644 Neurofibromatosis type 2 114157645 Neurofibromatosis type 3 114157646 Ectodermal dysplasia 114158924 NF 2 114158925 NF 3 TAB-671 114095007 Dengue Tetravalent Vaccine Containing a Common 30 Nucleotide Deletion in the 3'-UTR of Dengue Types 1, 2, 3, and 4 NIAID Diagnostics, Infectious Disease, Licensing, Rare/Neglected Diseases, Therapeutics, Vaccines Diagnostics Infectious Disease Licensing Rare/Neglected Diseases Therapeutics Vaccines Joseph Blaney, Barry Falgout, Kathryn Hanley, Lewis Markoff, Brian Murphy, Stephen Whitehead The invention relates to a dengue virus tetravalent vaccine containing a common 30-nucleotide deletion (delta30) in the 3'-untranslated region (UTR) of the genome of dengue virus serotypes 1, 2, 3, and 4. The previously identified delta30 attenuating mutation, created in dengue virus type 4 (DEN4) by the removal of 30 nucleotides from the 3'-UTR, is also capable of attenuating a wild-type strain of dengue virus type 1 (DEN1). Removal of 30 nucleotides from the DEN1 3'-UTR in a highly conserved region homologous to the DEN4 region encompassing the delta30 mutation yielded a recombinant virus attenuated in rhesus monkeys to a level similar to recombinant virus DEN4delta30. This established the transportability of the delta30 mutation and its attenuation phenotype to a dengue virus type other than DEN4. The effective transferability of the delta30 mutation establishes the usefulness of the delta30 mutation to attenuate and improve the safety of commercializable dengue virus vaccines of any serotype.<br /><br /> A tetravalent dengue virus vaccine containing dengue virus types 1, 2, 3, and 4 each attenuated by the delta30 mutation is being developed. The presence of the delta30 attenuating mutation in each virus component precludes the reversion to a wild-type virus by intertypic recombination. In addition, because of the inherent genetic stability of deletion mutations, the delta30 mutation represents an excellent alternative for use as a common mutation shared among each component of a tetravalent vaccine. 2022-03-08 2025-08-13 2025-08-15 2008-10-01 3'-UTR, ANTIGENIC, chimeric, Chromosome 7, monosomy, DA4BXX, DA4XXX, DAXXXX, DB4BXX, DB4XXX, DBXXXX, DC5BXX, DC5XXX, DCXXXX, Deletion, Deletion 7, DENGUE, Dengue (Flaviviridae), DXXXXX, Nucleotide, Tetravalent, UAXXXX, UBXXXX, Vaccine, Viruses False True True NIHTT 37470483 Website Abstract 114104300 Murphy, Brian NIAID - DIR NIAID Murphy, Brian (NIAID) 0 114104301 Markoff, Lewis FDA - CDER FDA Markoff, Lewis (FDA) 0 114104302 Falgout, Barry FDA - CDER FDA Falgout, Barry (FDA) 0 114104303 Hanley, Kathryn NIAID - DIR Hanley, Kathryn 0 114104305 Blaney, Joseph NIAID Blaney, Joseph (NIAID) 0 114104304 Whitehead, Stephen NIAID - DIR NIAID Whitehead, Stephen (NIAID) 1 114104304 Whitehead, Stephen NIAID - DIR NIAID Whitehead, Stephen (NIAID) 1 114104300 Murphy, Brian NIAID - DIR NIAID Murphy, Brian (NIAID) 0 114104301 Markoff, Lewis FDA - CDER FDA Markoff, Lewis (FDA) 0 114104302 Falgout, Barry FDA - CDER FDA Falgout, Barry (FDA) 0 114104303 Hanley, Kathryn NIAID - DIR Hanley, Kathryn 0 114104305 Blaney, Joseph NIAID Blaney, Joseph (NIAID) 0 114099816 Dengue Tetravalent Vaccine Containing A Common 30 Nucleotide Deletion In The 3'-UTR Of Dengue Types 1,2,3, And 4, Or Antigenic Chimeric Dengue Viruses 1,2,3, And 4 E-089-2002-1 Filing authorized FDA, NIAID 91029846 Ganelina, Anna ganelinaa@niaid.nih.gov
United States of America ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-671] Dengue Tetravalent Vaccine Containing a Common 30 Nucleotide Deletion in the 3'-UTR of Dengue Types 1, 2, 3, and 4&body=Please send me information about technology [TAB-671] Dengue Tetravalent Vaccine Containing a Common 30 Nucleotide Deletion in the 3'-UTR of Dengue Types 1, 2, 3, and 4. Ganelina, Anna<br><a href="mailto:ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-671] Dengue Tetravalent Vaccine Containing a Common 30 Nucleotide Deletion in the 3'-UTR of Dengue Types 1, 2, 3, and 4&body=Please send me information about technology [TAB-671] Dengue Tetravalent Vaccine Containing a Common 30 Nucleotide Deletion in the 3'-UTR of Dengue Types 1, 2, 3, and 4.">ganelinaa@niaid.nih.gov</a><br> 114160994 E-089-2002-1 E-089-2002-1-US-09 Dengue Tetravalent Vaccine Containing A Common 30 Nucleotide Deletion In The 3'-UTR Of Dengue Types 1,2,3, And 4, Or Antigenic Chimeric Dengue Viruses 1,2,3, And 4 CON US 8,075,903 12/398,043 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8075903 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8075903">8,075,903</a><br />Filed on 2009-03-04<br />Status: Expired 114162528 E-089-2002-1 E-089-2002-1-PCT-01 Dengue Tetravalent Vaccine Containing a Common 30 Nucleotide Deletion in The 3'-UTR of Dengue Types 1,2,3, And 4, or Antigenic Chimeric Dengue Viruses 1,2,3, And 4 PCT COMB Patent Cooperation Treaty PCT/US2003/013279 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2003/013279<br />Filed on 2003-04-25<br />Status: Expired 114164270 E-089-2002-1 E-089-2002-1-US-02 Dengue Tetravalent Vaccine Containing A Common 30 Nucleotide Deletion In The 3'-UTR Of Dengue Types 1,2,3, And 4, Or Antigenic Chimeric Dengue Viruses 1,2,3, And 4 National Stage US 7,517,531 10/970,640 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7517531 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7517531">7,517,531</a><br />Filed on 2004-10-21<br />Status: Expired 114165277 E-089-2002-1 E-089-2002-1-US-45 Dengue Tetravalent Vaccine Containing A Common 30 Nucleotide Deletion In The 3'-UTR Of Dengue Types 1,2,3, And 4, Or Antigenic Chimeric Dengue Viruses 1,2,3, And 4 DIV US 9,783,787 13/305,639 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9783787 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9783787">9,783,787</a><br />Filed on 2011-11-28<br />Status: Expired 114167086 E-089-2002-1 E-089-2002-1-US-47 Dengue Tetravalent Vaccine Containing A Common 30 Nucleotide Deletion In The 3'-UTR Of Dengue Types 1,2,3, And 4, Or Antigenic Chimeric Dengue Viruses 1,2,3, And 4 REISSUE US RE46,631 13/896,384 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/RE46631 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/RE46631">RE46,631</a><br />Filed on 2013-05-17<br />Status: Expired 114167087 E-089-2002-1 E-089-2002-1-US-48 Dengue Tetravalent Vaccine Containing A Common 30 Nucleotide Deletion In The 3-UTR Of Dengue Types 1,2,3, And 4, Or Antigenic Chimeric Dengue Viruses 1,2,3, And 4 REISSUE US RE46641 13/896,388 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/RE46641 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/RE46641">RE46641</a><br />Filed on 2013-05-17<br />Status: Expired 114168376 E-089-2002-1 E-089-2002-1-US-51 Dengue Tetravalent Vaccine Containing A Common 30 Nucleotide Deletion In The 3'-UTR Of Dengue Types 1,2,3, And 4, Or Antigenic Chimeric Dengue Viruses 1,2,3, And 4 DIV US 10,837,003 15/710,672 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10837003 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10837003">10,837,003</a><br />Filed on 2017-09-20<br />Status: Expired 114169052 E-089-2002-1 E-089-2002-1-US-89 Dengue Tetravalent Vaccine Containing A Common 30 Nucleotide Deletion In The 3'-UTR Of Dengue Types 1,2,3, And 4, Or Antigenic Chimeric Dengue Viruses 1,2,3, And 4 DIV US 11,753,627 17/009,448 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11753627 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11753627">11,753,627</a><br />Filed on 2020-09-01<br />Status: Expired 114114250 UBXXXX 114114251 UAXXXX 114114252 DC5BXX 114114253 DC5XXX 114114254 DCXXXX 114114255 DB4BXX 114114256 DB4XXX 114114257 DBXXXX 114119292 DA4BXX 114119293 DA4XXX 114119294 DAXXXX 114119295 DXXXXX 114132880 DENGUE 114132881 Tetravalent 114132882 Vaccine 114132883 Nucleotide 114132884 Deletion 114132885 3'-UTR 114132886 ANTIGENIC 114132887 chimeric 114132888 Viruses 114157586 Chromosome 7, monosomy 114157907 Dengue (Flaviviridae) 114158893 Deletion 7 TAB-641 114094978 Stem Cell Factor-responsive FcepsilonRI Bearing Human Mast Cell Line LAD2 NIAID Diagnostics, Immunology, Licensing, Research Materials, Therapeutics Diagnostics Immunology Licensing Research Materials Therapeutics Cem Akin, Arnold Kirshenbaum, Dean Metcalfe A human mast cell line LAD2 that more closely resembles normal in vivo and in vitro human mast cells by expressing functional FcepsilonRI receptors and responding to stem cell factor (SCF) with proliferation, as described in Leuk Res. 2003 Aug;27(8):677-82 and developed by the laboratory of Dr. Dean Metcalfe at the National Institute of Allergy and Infectious Diseases.  This cell line also releases mediators by cross-linking FcgammaRI (CD64) receptors and express FcgammaRII (CD32). <ul> <li>Speed up product development with NIH developed material that has already been tested and validated.</li> </ul> <ul> <li>A research material that can be used in the development of assays, validation of products or in quality control.</li> </ul> Research Material - Patent protection is no longer being pursued for this technology. (IC Reference No. 2001-022) 2022-03-08 2025-08-13 2025-08-15 2021-01-07 Cell line, IA3XXX, IAXXXX, IDXXXX, IXXXXX, Mast cell disease, Mastocytosis, RM, WIXXXX False True True NIHTT 37470483 Website Abstract 114170517 Kirshenbaum AS, et al. https://www.ncbi.nlm.nih.gov/pubmed/12801524 <a href="https://www.ncbi.nlm.nih.gov/pubmed/12801524">Kirshenbaum AS, et al.</a> 114104232 Kirshenbaum, Arnold NIAID Kirshenbaum, Arnold (NIAID) 0 114104233 Akin, Cem NIAID Akin, Cem (NIAID) 0 114104234 Metcalfe, Dean NIAID Metcalfe, Dean (NIAID) 0 114104232 Kirshenbaum, Arnold NIAID Kirshenbaum, Arnold (NIAID) 0 114104233 Akin, Cem NIAID Akin, Cem (NIAID) 0 114104234 Metcalfe, Dean NIAID Metcalfe, Dean (NIAID) 0 114099780 Stem Cell Factor-Responsive FC&RI Bearing Human Mast Cell Line LAD2 E-279-2001-0 Research Material NIAID 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-641] Stem Cell Factor-responsive FcepsilonRI Bearing Human Mast Cell Line LAD2&body=Please send me information about technology [TAB-641] Stem Cell Factor-responsive FcepsilonRI Bearing Human Mast Cell Line LAD2. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-641] Stem Cell Factor-responsive FcepsilonRI Bearing Human Mast Cell Line LAD2&body=Please send me information about technology [TAB-641] Stem Cell Factor-responsive FcepsilonRI Bearing Human Mast Cell Line LAD2.">yogikala.prabhu@nih.gov</a><br> 114164234 E-279-2001-0 E-279-2001-0-US-01 Stem Cell Factor-Responsive FC&RI Bearing Human Mast Cell Line LAD2 PRV US 60/354,440 Abandoned US <br />Provisional (PRV) 60/354,440<br />Filed on 2002-02-04<br />Status: Abandoned 114164237 E-279-2001-0 E-279-2001-0-PCT-02 Stem Cell Factor-Responsive FC&RI Bearing Human Mast Cell Line LADI PCT Patent Cooperation Treaty PCT/US03/02790 Abandoned Patent Cooperation Treaty <br />(PCT) PCT/US03/02790<br />Filed on 2003-01-29<br />Status: Abandoned 114114152 IA3XXX 114114153 IAXXXX 114114154 IDXXXX 114114155 IXXXXX 114127369 WIXXXX 114149421 RM 114149422 Cell line 114157561 Mast cell disease 114158879 Mastocytosis TAB-602 114094939 Live Attenuated Vaccine to Prevent Disease Caused by West Nile Virus NIAID Consumer Products, Diagnostics, Infectious Disease, Licensing, Therapeutics, Vaccines Consumer Products Diagnostics Infectious Disease Licensing Therapeutics Vaccines Joseph Blaney, Robert Chanock (Estate), Brian Murphy, Alexander Pletnev, Joseph Putnak, Stephen Whitehead West Nile virus (WNV) has recently emerged in the U.S. and is considered a significant emerging disease that has embedded itself over a considerable region of the U.S. WNV infections have been recorded in humans as well as in different animals. From 1999-2014, WNV killed 1,765 people in the U.S. and caused severe disease in more than 41,762 others. This project is part of NIAID's comprehensive emerging infectious disease program.<br /><br /> The methods and compositions of this invention provide a means for prevention of WNV infection by immunization with attenuated, immunogenic viral vaccines against WNV. The invention involves a chimeric virus form comprising parts of WNV and Dengue virus. Construction of the hybrids and their properties are described in detail in multiple publications. The WNV chimeric vaccine does not target the central nervous system, which would be the case in an infection with wild type WNV. Importantly, two successful Phase I clinical trials were recently carried out with the vaccine. The live attenuated WNV vaccine is safe, well-tolerated, and immunogenic in healthy adult volunteers. Furthermore, the vaccine virus may also be considered for use as a safe reagent handled at bio-safety level 2 facilities for WNV diagnosis and surveillance. <ul> <li>Low cost of manufacture</li> <li>Proven chimeric vaccine technology</li> <li>Phase I clinical data available</li> </ul> <ul> <li>Human West Nile vaccine</li> <li>Veterinary West Nile vaccine</li> <li>West Nile Virus diagnostics</li> <li>West Nile Virus therapeutics</li> </ul> Various international patents/applications issued/pending. 2022-03-08 2025-08-13 2025-08-15 2008-10-01 Chimeras, DC5BXX, DC5XXX, DCXXXX, DENGUE, Dengue (Flaviviridae), DXXXXX, Live, Nile, Vaccine, virus, VLXXXX, VOXXXX, WAXXXX, WBXXXX, West, WEST NILE VIRUS, WMXXXX, WNXXXX, XKXXXX, YCXXXX, YDXXXX False True <ul> <li>In vivo data available (animal)</li> <li>In vivo data available (human)</li> </ul> True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114169736 Pletnev AG, et al. http://www.ncbi.nlm.nih.gov/pubmed/11880643 <a href="http://www.ncbi.nlm.nih.gov/pubmed/11880643">Pletnev AG, et al.</a> 114172265 Pletnev AG, et al. http://www.ncbi.nlm.nih.gov/pubmed/14517072 <a href="http://www.ncbi.nlm.nih.gov/pubmed/14517072">Pletnev AG, et al.</a> 114172266 Hanley KA, et al. http://www.ncbi.nlm.nih.gov/pubmed/15815144 <a href="http://www.ncbi.nlm.nih.gov/pubmed/15815144">Hanley KA, et al.</a> 114172267 Pletnev AG, et al. http://www.ncbi.nlm.nih.gov/pubmed/16831498 <a href="http://www.ncbi.nlm.nih.gov/pubmed/16831498">Pletnev AG, et al.</a> 114172268 Durbin AP, et al. http://www.ncbi.nlm.nih.gov/pubmed/23968769 <a href="http://www.ncbi.nlm.nih.gov/pubmed/23968769">Durbin AP, et al.</a> 114172269 Maximova OA, et al. http://www.ncbi.nlm.nih.gov/pubmed/24736001 <a href="http://www.ncbi.nlm.nih.gov/pubmed/24736001">Maximova OA, et al.</a> 114103328 Chanock (Estate), Robert NIAID - DIR NIAID Chanock (Estate), Robert (NIAID) 0 114103329 Putnak, Joseph NIAID - DIR Putnak, Joseph 0 114109066 Murphy, Brian NIAID - DIR NIAID Murphy, Brian (NIAID) 0 114109067 Blaney, Joseph NIAID - DIR NIAID Blaney, Joseph (NIAID) 0 114109068 Whitehead, Stephen NIAID - DIR NIAID Whitehead, Stephen (NIAID) 0 114104185 Pletnev, Alexander NIAID - DIR NIAID Pletnev, Alexander (NIAID) 1 114104185 Pletnev, Alexander NIAID - DIR NIAID Pletnev, Alexander (NIAID) 1 114103328 Chanock (Estate), Robert NIAID - DIR NIAID Chanock (Estate), Robert (NIAID) 0 114103329 Putnak, Joseph NIAID - DIR Putnak, Joseph 0 114109066 Murphy, Brian NIAID - DIR NIAID Murphy, Brian (NIAID) 0 114109067 Blaney, Joseph NIAID - DIR NIAID Blaney, Joseph (NIAID) 0 114109068 Whitehead, Stephen NIAID - DIR NIAID Whitehead, Stephen (NIAID) 0 114099739 West NIle Virus And Dengue Virus Chimeras For Use In A Live Virus Vaccine E-357-2001-1 Filing authorized NIAID, Walter Reed National Military Medical Center (WRNMMC) 91027763 Puglielli, Maryann maryann.puglielli@nih.gov
United States of America maryann.puglielli@nih.gov?subject=Web Inquiry on [TAB-602] Live Attenuated Vaccine to Prevent Disease Caused by West Nile Virus&body=Please send me information about technology [TAB-602] Live Attenuated Vaccine to Prevent Disease Caused by West Nile Virus. Puglielli, Maryann<br><a href="mailto:maryann.puglielli@nih.gov?subject=Web Inquiry on [TAB-602] Live Attenuated Vaccine to Prevent Disease Caused by West Nile Virus&body=Please send me information about technology [TAB-602] Live Attenuated Vaccine to Prevent Disease Caused by West Nile Virus.">maryann.puglielli@nih.gov</a><br> 114161425 E-357-2001-1 E-357-2001-1-US-02 Construction of West NIle Virus And Dengue Virus Chimeras For Use In A Live Virus Vaccine to Prevent Disease Caused by West Nile Virus National Stage US 8,778,671 10/871,775 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8778671 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8778671">8,778,671</a><br />Filed on 2004-06-18<br />Status: Expired 114162527 E-357-2001-1 E-357-2001-1-PCT-01 Construction of West NIle Virus And Dengue Virus Chimeras For Use In A Live Virus Vaccine To Prevent Disease Caused by West Nile Virus PCT COMB Patent Cooperation Treaty PCT/US2003/000594 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2003/000594<br />Filed on 2003-01-09<br />Status: Expired 114167920 E-357-2001-1 E-357-2001-1-US-15 Construction of West Nile Virus and Dengue Virus Chimeras for Use in a Live Virus Vaccine to Prevent Disease Caused by West Nile Virus DIV US 10,058,602 14/305,572 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10058602 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10058602">10,058,602</a><br />Filed on 2014-06-16<br />Status: Expired 114168684 E-357-2001-1 E-357-2001-1-US-29 West NIle Virus And Dengue Virus Chimeras For Use In A Live Virus Vaccine DIV US 10,456,461 16/025,624 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10456461 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10456461">10,456,461</a><br />Filed on 2018-07-02<br />Status: Expired 114168927 E-357-2001-1 E-357-2001-1-US-33 CONSTRUCTION OF WEST NILE VIRUS AND DENGUE VIRUS CHIMERAS FOR USE IN A LIVE VIRUS VACCINE TO PREVENT DISEASE CAUSED BY WEST NILE VIRUS DIV US 10,869,920 16/596,175 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10869920 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10869920">10,869,920</a><br />Filed on 2019-10-08<br />Status: Expired 114169076 E-357-2001-1 E-357-2001-1-US-34 CONSTRUCTION OF WEST NILE VIRUS AND DENGUE VIRUS CHIMERAS FOR USE IN A LIVE VIRUS VACCINE TO PREVENT DISEASE CAUSED BY WEST NILE VIRUS DIV US 11,400,150 16/952,864 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11400150 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11400150">11,400,150</a><br />Filed on 2020-11-19<br />Status: Expired 114113994 DC5BXX 114113995 DCXXXX 114113996 DXXXXX 114119299 DC5XXX 114123347 VLXXXX 114126642 VOXXXX 114127155 WAXXXX 114127157 WBXXXX 114127158 WNXXXX 114127159 WMXXXX 114127160 XKXXXX 114127161 YCXXXX 114127162 YDXXXX 114132955 West 114132956 Nile 114132957 virus 114132958 DENGUE 114132959 Chimeras 114132960 Live 114132961 Vaccine 114157547 WEST NILE VIRUS 114157906 Dengue (Flaviviridae) TAB-587 114094926 Method and Apparatus to Improve an MRI Image NHLBI Licensing Licensing Peter Kellman, Elliot Mcveigh The invention is a method for improving image quality in MR imaging methods using the SENSE (SENSitivity Encoding) method, which is known to have degraded image quality due to numerical ill-conditioning (so called g-factor loss). The invention improves the numerical conditioning by means of an adaptive regularization (matrix conditioning), thereby improving image quality for a given scan time. This is accomplished by adaptively adjusting the regularization parameter for each pixel position to achieve a target ghost artifact suppression. In this manner, a higher degree of matrix conditioning is used in regions which have less artifact, thus improving the SNR in these regions. 2022-03-08 2025-08-13 2025-08-15 2002-03-01 AA3B1X, AA3BXX, AA3XXX, AAXXXX, ADXXXX, AXXXXX False True True NIHTT 37470483 Website Abstract 114104146 Kellman, Peter NHLBI Kellman, Peter (NHLBI) 0 114104147 Mcveigh, Elliot Mcveigh, Elliot 0 114104146 Kellman, Peter NHLBI Kellman, Peter (NHLBI) 0 114104147 Mcveigh, Elliot Mcveigh, Elliot 0 114099724 A Method and Apparatus to improve an MRI Image E-361-2001-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 89788013 Kolesnitchenko, Vincent vk5q@nih.gov
United States of America Office of Technology Transfer and Development vk5q@nih.gov?subject=Web Inquiry on [TAB-587] Method and Apparatus to Improve an MRI Image&body=Please send me information about technology [TAB-587] Method and Apparatus to Improve an MRI Image. Kolesnitchenko, Vincent<br><a href="mailto:vk5q@nih.gov?subject=Web Inquiry on [TAB-587] Method and Apparatus to Improve an MRI Image&body=Please send me information about technology [TAB-587] Method and Apparatus to Improve an MRI Image.">vk5q@nih.gov</a><br> 114161383 E-361-2001-0 E-361-2001-0-US-10 A Method and Apparatus to improve an MRI Image National Stage US 7,154,268 10/492,897 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7154268 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7154268">7,154,268</a><br />Filed on 2004-04-15<br />Status: Abandoned 114165807 E-361-2001-0 E-361-2001-0-US-01 A Method and Apparatus to improve an MRI Image PRV US 60/348,005 Abandoned US <br />Provisional (PRV) 60/348,005<br />Filed on 2001-10-19<br />Status: Abandoned 114165824 E-361-2001-0 E-361-2001-0-PCT-02 A Method and Apparatus to Improve an MRI Image PCT Patent Cooperation Treaty PCT/US2002/033571 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2002/033571<br />Filed on 2002-10-17<br />Status: Expired 114113927 AA3B1X 114113928 AA3BXX 114113929 AA3XXX 114113930 AAXXXX 114113931 ADXXXX 114113932 AXXXXX TAB-562 114094900 Vaccination Strategies to Provide Protection Against the Ebola Virus NIAID Infectious Disease, Licensing, Vaccines Infectious Disease Licensing Vaccines Gary Nabel This invention describes a method for vaccination against Ebola virus. Outbreaks of hemorrhagic fever caused by the Ebola virus, particularly the Zaire subtype, are associated with high mortality rates. The virus is very contagious, and during an outbreak, presents a threat to anybody who comes into contact with an infected person. Because the virus progresses so rapidly and the mortality rate is so high, there is little opportunity to develop natural immunity, making vaccination a promising intervention. This invention relates to a vaccine strategy employing DNA and adenoviral vectors expressing proteins associated with the Ebola virus. This vaccine strategy, a DNA prime with an adenoviral boost, elicits a protective immune response in primates. A vaccine was designed to optimize expression by incorporating genes for two subtypes of the glycoprotein (Zaire and Sudan) and minimizes toxicity by eliminating the trans-membrane region. The specific genes identified may be used for gene-based or protein-based vaccines that will prevent Ebola infection. 2022-03-08 2025-08-13 2025-08-15 2002-02-01 DC5XXX, DCXXXX, DXXXXX, Hemorrhagic fever, Q fever False True True NIHTT 37470483 Website Abstract 114104096 Nabel, Gary NIAID Nabel, Gary (NIAID) 0 114104096 Nabel, Gary NIAID Nabel, Gary (NIAID) 0 114099701 Development of a Preventive Vaccine for Filovirus Infection in Primate E-241-2001-0 Filing authorized Centers for Disease Control and Prevention (CDC), NIAID 148673287 Hafiz, Sabrina sabrina.hafiz@nih.gov
United States of America sabrina.hafiz@nih.gov?subject=Web Inquiry on [TAB-562] Vaccination Strategies to Provide Protection Against the Ebola Virus&body=Please send me information about technology [TAB-562] Vaccination Strategies to Provide Protection Against the Ebola Virus. Hafiz, Sabrina<br><a href="mailto:sabrina.hafiz@nih.gov?subject=Web Inquiry on [TAB-562] Vaccination Strategies to Provide Protection Against the Ebola Virus&body=Please send me information about technology [TAB-562] Vaccination Strategies to Provide Protection Against the Ebola Virus.">sabrina.hafiz@nih.gov</a><br> 114161324 E-241-2001-0 E-241-2001-0-US-01 Development of a Preventive Vaccine for Filovirus Infection in Primates PRV US 60/326,476 Abandoned US <br />Provisional (PRV) 60/326,476<br />Filed on 2001-10-01<br />Status: Abandoned 114161326 E-241-2001-0 E-241-2001-0-PCT-02 Development of a Preventive Vaccine for Filovirus Infection in Primates PCT Patent Cooperation Treaty PCT/US2002/030251 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2002/030251<br />Filed on 2002-09-24<br />Status: Expired 114161327 E-241-2001-0 E-241-2001-0-US-07 Development of a Preventive Vaccine for Filovirus Infection in Primates National Stage US 7,635,688 10/491,121 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7635688 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7635688">7,635,688</a><br />Filed on 2004-08-23<br />Status: Expired 114165656 E-241-2001-0 E-241-2001-0-US-08 Development of a Preventive Vaccine for Filovirus Infection in Primate DIV US 8,106,026 12/612,579 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8106026 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8106026">8,106,026</a><br />Filed on 2009-11-04<br />Status: Expired 114165658 E-241-2001-0 E-241-2001-0-US-09 Development of a Preventive Vaccine for Filovirus Infection in Primates DIV US 8,106,027 12/612,621 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8106027 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8106027">8,106,027</a><br />Filed on 2009-11-04<br />Status: Expired 114165660 E-241-2001-0 E-241-2001-0-US-10 Development of a Preventive Vaccine for Filovirus Infection in Primates DIV US 8,124,592 12/612,625 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8124592 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8124592">8,124,592</a><br />Filed on 2009-11-04<br />Status: Expired 114113819 DC5XXX 114113820 DCXXXX 114113821 DXXXXX 114157519 Q fever 114157520 Hemorrhagic fever TAB-560 114094898 Four Chimpanzee Monoclonal Antibodies that Neutralize Hepatitis A Virus NIAID Infectious Disease, Licensing, Therapeutics, Vaccines Infectious Disease Licensing Therapeutics Vaccines Suzanne Emerson, Robert Purcell, Darren Schofield This invention claims antibodies and/or fragments thereof specific for hepatitis A virus (HAV) and the use of the antibodies in the diagnosis, prevention, and treatment of hepatitis A. Hepatitis A is the most common type of hepatitis reported in the United States, which reports an estimated 134,000 cases annually, and infects at least 1.4 million people worldwide each year. HAV is a positive sense RNA virus that is transmitted via the fecal-oral route, mainly through contaminated water supplies and food sources. HAV is thought to replicate in the oropharynx and epithelial lining of the intestines, where it initiates a transient viremia and subsequently infects the liver. Humoral immunity has been shown to provide an effective defense against Hepatitis A. Prior to the availability of the current inactivated virus vaccines, pooled human immune globulin preparations were routinely used to protect individuals traveling to areas of the world where HAV is endemic. Chimpanzees are susceptible to infection with HAV and can produce antibodies that neutralize the virus. Chimpanzee immunoglobulins are virtually identical to those of humans; thus, they have the same potential as human antibodies for clinical applications. The inventors have shown that the four chimpanzee monoclonal antibodies described in the patent application neutralized HAV strains HM-175, AGM-27, and the HM-175 VP3-070 mutant. Since only a single serotype of HAV has been identified, these antibodies are predicted to neutralize most, if not all, isolates of HAV. 2022-03-08 2025-08-13 2025-08-15 2020-07-06 DB4BXX, DBXXXX, DCXXXX, DXXXXX, Hepatitis A, Hepatitis D, Hepatitis E False True True NIHTT 37470483 Website Abstract 114104089 Schofield, Darren NIAID Schofield, Darren (NIAID) 0 114104090 Emerson, Suzanne NIAID Emerson, Suzanne (NIAID) 0 114104091 Purcell, Robert NIAID Purcell, Robert (NIAID) 0 114104089 Schofield, Darren NIAID Schofield, Darren (NIAID) 0 114104090 Emerson, Suzanne NIAID Emerson, Suzanne (NIAID) 0 114104091 Purcell, Robert NIAID Purcell, Robert (NIAID) 0 114099699 Anti-hepatitis A Virus Antibodies E-356-2001-0 Filing authorized NIAID 91027763 Puglielli, Maryann maryann.puglielli@nih.gov
United States of America maryann.puglielli@nih.gov?subject=Web Inquiry on [TAB-560] Four Chimpanzee Monoclonal Antibodies that Neutralize Hepatitis A Virus&body=Please send me information about technology [TAB-560] Four Chimpanzee Monoclonal Antibodies that Neutralize Hepatitis A Virus. Puglielli, Maryann<br><a href="mailto:maryann.puglielli@nih.gov?subject=Web Inquiry on [TAB-560] Four Chimpanzee Monoclonal Antibodies that Neutralize Hepatitis A Virus&body=Please send me information about technology [TAB-560] Four Chimpanzee Monoclonal Antibodies that Neutralize Hepatitis A Virus.">maryann.puglielli@nih.gov</a><br> 114161073 E-356-2001-0 E-356-2001-0-US-05 Anti-Hepatitis A Virus Antibodies DIV US 7,635,476 11/789,377 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7635476 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7635476">7,635,476</a><br />Filed on 2007-04-23<br />Status: Abandoned 114161318 E-356-2001-0 E-356-2001-0-US-01 Four Chimpanzee Monoclonal Antibodies That Neutralize Hepatitis A Virus PRV US 60/339,109 Abandoned US <br />Provisional (PRV) 60/339,109<br />Filed on 2001-11-07<br />Status: Abandoned 114161320 E-356-2001-0 E-356-2001-0-PCT-02 Anti-Hepatitis A Virus Antibodies PCT Patent Cooperation Treaty PCT/US2002/036077 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2002/036077<br />Filed on 2002-11-07<br />Status: Expired 114161321 E-356-2001-0 E-356-2001-0-US-03 Anti-Hepatitis A Virus Antibodies National Stage US 7,282,205 10/494,676 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7282205 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7282205">7,282,205</a><br />Filed on 2004-05-04<br />Status: Abandoned 114113811 DB4BXX 114113812 DBXXXX 114113813 DCXXXX 114113814 DXXXXX 114157516 Hepatitis D 114157517 Hepatitis A 114157518 Hepatitis E TAB-553 114094891 TMC1, a Deafness-Related Gene NIDCD Collaboration, Diagnostics, Licensing, Rare/Neglected Diseases, Reproductive Health, Research Materials, Therapeutics, Vaccines Collaboration Diagnostics Licensing Rare/Neglected Diseases Reproductive Health Research Materials Therapeutics Vaccines Andrew Griffith Hearing loss is a common communication disorder affecting nearly 1 in 1,000 children in the United States alone, and nearly 50% of adults by the age of eighty. Hearing loss can be caused by environmental and disease-related factors; however, hearing loss due to genetic factors accounts for approximately 50% of cases. <br><br> The NIH announces the isolation of two novel genes involved in hearing; TMC1, short for transmembrane channel-like gene 1. The inventors have discovered that dominant and recessive mutations in TMC1 underlie two forms of hereditary deafness, known as DFNA36 and DFNB7/11. TMC1 encodes a protein required for normal function of the mammalian hair cell, which plays a critical role within the hearing pathway that detects sound in the inner ear. <br><br> The invention discloses TMC1 nucleic acids, vectors, and cells. Also disclosed are methods of detecting hearing loss, or a predisposition to hearing loss, due to a mutation in TMC1, as well as methods for identifying agents that interact with the TMC1 gene in a cell. Nucleic acids and methods of use for TMC2, a gene closely related to TMC1, are also disclosed. <ul> <li>Development of a genetic diagnostic test for hearing loss</li> <li>Development of pharmaceuticals to treat hearing loss</li> </ul> The NIDCD Otolaryngology Branch is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology as well as collaborate on further pre-clinical and clinical studies with the TMC2 gene mutations. Please contact Ms. Marianne Lynch at 301-402-5579 or via email at <a href="mailto:lynchm@nhlbi.nih.gov">lynchm@nhlbi.nih.gov</a> for more information. Available for non-exclusive licensing. 2022-03-08 2025-08-13 2025-08-15 2007-05-01 Hereditary deafness, IA6XXX, IAXXXX, IB6XXX, IBXXXX, IXXXXX, UAXXXX False True Early stage Early stage True NIHTT 37470483 Website Abstract 114169821 K Kurima et al. Dominant and recessive deafness caused by mutations of a novel gene, TMC1, required for cochlear hair-cell function. Nat Genet. 2002 Mar;30(3):277-284. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=11850618&query_hl=5&itool=pubmed_docsum <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=11850618&query_hl=5&itool=pubmed_docsum">K Kurima et al. Dominant and recessive deafness caused by mutations of a novel gene, TMC1, required for cochlear hair-cell function. Nat Genet. 2002 Mar;30(3):277-284.</a> 114104073 Griffith, Andrew NIDCD Griffith, Andrew (NIDCD) 0 114104073 Griffith, Andrew NIDCD Griffith, Andrew (NIDCD) 0 114099690 Transduction-1 And Transductin-2 And Applications to Hereditary Deafness E-168-2001-0 National Institute on Deafness and Other Communication Disorders (NIDCD) 114099691 Transduction-1 And Transductin-2 And Applications To Hereditary Deafness E-168-2001-1 Filing authorized National Institute on Deafness and Other Communication Disorders (NIDCD) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-553] TMC1, a Deafness-Related Gene&body=Please send me information about technology [TAB-553] TMC1, a Deafness-Related Gene. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-553] TMC1, a Deafness-Related Gene&body=Please send me information about technology [TAB-553] TMC1, a Deafness-Related Gene.">shmilovm@nih.gov</a><br> 114161296 E-168-2001-0 E-168-2001-0-US-01 Transduction-1 And Transductin-2 And Applications to Hereditary Deafness PRV US 60/323,275 Abandoned US <br />Provisional (PRV) 60/323,275<br />Filed on 2001-09-19<br />Status: Abandoned 114161297 E-168-2001-0 E-168-2001-0-PCT-02 Transductin-1 And Transductin-2 And Applications to Hereditary Deafness PCT Patent Cooperation Treaty PCT/US02/29614 Expired Patent Cooperation Treaty <br />(PCT) PCT/US02/29614<br />Filed on 2002-09-19<br />Status: Expired 114161299 E-168-2001-0 E-168-2001-0-US-03 Transduction-1 And Transductin-2 And Applications to Hereditary Deafness National Stage US 7,192,705 10/487,887 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7192705 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7192705">7,192,705</a><br />Filed on 2004-02-26<br />Status: Abandoned 114161301 E-168-2001-0 E-168-2001-0-US-08 Transduction-1 And Transductin-2 And Applications to Hereditary Deafness DIV US 7,659,115 11/615,250 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7659115 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7659115">7,659,115</a><br />Filed on 2006-12-22<br />Status: Expired 114162982 E-168-2001-1 E-168-2001-1-US-01 Transductin-1 And Transductin-2 And Applications To Hereditary Deafness CIP US 7,166,433 10/792,307 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7166433 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7166433">7,166,433</a><br />Filed on 2004-03-03<br />Status: Abandoned 114113778 IB6XXX 114113779 IA6XXX 114113780 IBXXXX 114113781 IAXXXX 114113782 IXXXXX 114113783 UAXXXX 114157504 Hereditary deafness TAB-538 114094876 Major Neutralization Site of Hepatitis E Virus and Use of this Neutralization Site in Methods of Vaccination NIAID Collaboration, Infectious Disease, Licensing, Vaccines Collaboration Infectious Disease Licensing Vaccines Suzanne Emerson, Robert Purcell Hepatitis E is endemic in many countries throughout the developing world, in particular on the continents of Africa and Asia. The disease generally affects young adults and has a very high mortality rate, up to 20%, in pregnant women. This invention relates to the identification of a neutralization site of hepatitis E virus (HEV) and neutralizing antibodies that react with it. The neutralization site is located on a polypeptide from the ORF2 gene (capsid gene) of HEV. This neutralization site was identified using a panel of chimpanzee monoclonal antibodies that are virtually identical to human antibodies. Since this neutralization site is conserved among genetically divergent strains of HEV, the neutralizing monoclonal antibodies may be useful in the diagnosis, treatment and/or prevention of hepatitis E. Furthermore, immunogens that encompass this neutralization site may be used in vaccination to effectively prevent, and/or reduce the incidence of HEV infection. Polypeptides containing this neutralization site may be useful in evaluating vaccine candidates for the production of neutralizing antibodies to HEV. The NIAID Laboratory of Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize these antibodies or structures they interact with. For more information, please contact Robert H. Purcell, M.D., Co-chief, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 50 South Drive, Bldg. 50, Rm. 6523, Bethesda, MD 20892-8009; Phone (301) 496-5090; Fax (301) 402-0524. Available for licensing. 2022-03-08 2025-08-13 2025-08-15 2020-07-06 DC5BXX, DCXXXX, DXXXXX, Hepatitis A, Hepatitis D, Hepatitis E False True True NIHTT 37470483 Website Abstract 114169817 YH Zhou et al. A truncated ORF2 protein contains the most immunogenic site on ORF2: antibody responses to non-vaccine sequences following challenge of vaccinated and non-vaccinated macaques with HEV. Vaccine 2005 May 2;23(24):3157-3165. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=15837215&query_hl=3&itool=pubmed_DocSum <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=15837215&query_hl=3&itool=pubmed_DocSum">YH Zhou et al. A truncated ORF2 protein contains the most immunogenic site on ORF2: antibody responses to non-vaccine sequences following challenge of vaccinated and non-vaccinated macaques with HEV. Vaccine 2005 May 2;23(24):3157-3165.</a> 114169818 DJ Schofield et al. Monoclonal antibodies that neutralize HEV recognize an antigenic site at the carboxyterminus of an ORF2 protein vaccine. Vaccine 2003 Dec 12;22(2):257-267. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=14615154&query_hl=1&itool=pubmed_docsum <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=14615154&query_hl=1&itool=pubmed_docsum">DJ Schofield et al. Monoclonal antibodies that neutralize HEV recognize an antigenic site at the carboxyterminus of an ORF2 protein vaccine. Vaccine 2003 Dec 12;22(2):257-267.</a> 114169819 YH Zhou et al. An ELISA for putative neutralizing antibodies to hepatitis E virus detects antibodies to genotypes 1,2,3,and 4. Vaccine 2004 Jun 30;22(20):2578-2585. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=15193383&query_hl=3&itool=pubmed_DocSum <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=15193383&query_hl=3&itool=pubmed_DocSum">YH Zhou et al. An ELISA for putative neutralizing antibodies to hepatitis E virus detects antibodies to genotypes 1,2,3,and 4. Vaccine 2004 Jun 30;22(20):2578-2585.</a> 114104039 Emerson, Suzanne NIAID Emerson, Suzanne (NIAID) 0 114104040 Purcell, Robert NIAID Purcell, Robert (NIAID) 0 114104039 Emerson, Suzanne NIAID Emerson, Suzanne (NIAID) 0 114104040 Purcell, Robert NIAID Purcell, Robert (NIAID) 0 114099678 Major Neutralization Site Of Hepatitis E Virus And Use Of This Neutralization Site In Methods Of Vaccination And In Methods Of..... E-043-2000-0 Filing authorized NIAID 91027763 Puglielli, Maryann maryann.puglielli@nih.gov
United States of America maryann.puglielli@nih.gov?subject=Web Inquiry on [TAB-538] Major Neutralization Site of Hepatitis E Virus and Use of this Neutralization Site in Methods of Vaccination&body=Please send me information about technology [TAB-538] Major Neutralization Site of Hepatitis E Virus and Use of this Neutralization Site in Methods of Vaccination. Puglielli, Maryann<br><a href="mailto:maryann.puglielli@nih.gov?subject=Web Inquiry on [TAB-538] Major Neutralization Site of Hepatitis E Virus and Use of this Neutralization Site in Methods of Vaccination&body=Please send me information about technology [TAB-538] Major Neutralization Site of Hepatitis E Virus and Use of this Neutralization Site in Methods of Vaccination.">maryann.puglielli@nih.gov</a><br> 114161260 E-043-2000-0 E-043-2000-0-US-04 Major Neutralization Site Of Hepatitis E Virus And Use Of This Neutralization Site In Methods Of Vaccination And In Methods Of Screening for Neutralizing Antibodies to Hepatitis E Virus National Stage US 6,930,176 10/148,737 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6930176 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6930176">6,930,176</a><br />Filed on 2003-01-27<br />Status: Abandoned 114161261 E-043-2000-0 E-043-2000-0-EP-03 Major Neutralization Site of Hepatitis E Virus and Use of this Neutralization Site in Methods of Vaccination and in Methods of Screeening for Neutralizing Antibodies to Hepatitis E Virus National Stage European Patent 1235862 00982311.3 Abandoned European Patent <br />National Stage 00982311.3<br />Filed on 2000-11-30<br />Status: Abandoned 114161263 E-043-2000-0 E-043-2000-0-US-05 Major Neutralization Site Of Hepatitis E Virus And Use Of This Neutralization Site In Methods Of Vaccination And In Methods Of..... CON US 7,148,323 11/054,041 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7148323 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7148323">7,148,323</a><br />Filed on 2005-02-09<br />Status: Abandoned 114164339 E-043-2000-0 E-043-2000-0-US-01 Major Neutralization Site Of Hepatitis E Virus And Use Of This Neutralization Site In Methods Of Vaccination And In Methods Of..... PRV US 60/167,490 Abandoned US <br />Provisional (PRV) 60/167,490<br />Filed on 1999-12-01<br />Status: Abandoned 114165614 E-043-2000-0 E-043-2000-0-PCT-02 Major Neutralization Site of Hepatitis E Virus and Use of This Neutralization Site in Methods of Vaccination and in Methods of..... PCT Patent Cooperation Treaty PCT/US00/32614 Expired Patent Cooperation Treaty <br />(PCT) PCT/US00/32614<br />Filed on 2000-11-30<br />Status: Expired 114113717 DC5BXX 114113718 DCXXXX 114113719 DXXXXX 114157488 Hepatitis D 114157489 Hepatitis A 114157490 Hepatitis E TAB-535 114094873 Development of Mutations Useful for Attenuating Dengue Viruses and Chimeric Dengue Viruses NIAID Collaboration, Infectious Disease, Licensing, Rare/Neglected Diseases, Vaccines Collaboration Infectious Disease Licensing Rare/Neglected Diseases Vaccines Joseph Blaney, Kathryn Hanley, Brian Murphy, Stephen Whitehead Although flaviviruses cause a great deal of human suffering and economic loss, there is a shortage of effective vaccines. This invention relates to dengue virus mutations that may contribute to the development of improved dengue vaccines. Site directed and random mutagenesis techniques were used to introduce mutations into the dengue virus genome and to assemble a collection of useful mutations for incorporation in recombinant live attenuated dengue virus vaccines. The resulting mutant viruses were screened for several valuable phenotypes, including temperature sensitivity in Vero cells or human liver cells, host cell restriction in mosquito cells or human liver cells, host cell adaptation for improved replication in Vero cells, and attenuation in mice or in mosquitoes. The genetic basis for each observed phenotype was determined by direct sequence analysis of the genome of the mutant virus. Mutations identified through these sequencing efforts have been further evaluated by re-introduction of the identified mutations, singly, or in combination, into recombinant dengue virus and characterization of the resulting recombinant virus for phenotypes. In this manner, a menu of attenuating and growth promoting mutations was developed that is useful in fine-tuning the attenuation and growth characteristics of dengue virus vaccine candidates. The mutations promoting growth in Vero cells have usefulness for the production of live or inactivated dengue virus vaccines. The National Institute of Allergy and Infectious Diseases, Laboratory of Infectious Diseases, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize these vaccines. Please contact Dr. Brian Murphy at 301-594-1616 or <a href="mailto:bm25f@nih.gov">bm25f@nih.gov</a> for more information. Available for licensing. 2022-03-08 2025-08-13 2025-08-15 2008-10-01 ATTENUATING, chimeric, DC5BXX, DC5XXX, DCXXXX, DENGUE, Dengue (Flaviviridae), Dengue Vaccine, Development, DXXXXX, Mutations, UAXXXX, UBXXXX, USEFUL, Viruses False True True NIHTT 37470483 Website Abstract 114104033 Blaney, Joseph NIAID - DIR NIAID Blaney, Joseph (NIAID) 0 114104034 Hanley, Kathryn NIAID - DIR Hanley, Kathryn 0 114104035 Murphy, Brian NIAID - DIR NIAID Murphy, Brian (NIAID) 0 114104036 Whitehead, Stephen NIAID - DIR NIAID Whitehead, Stephen (NIAID) 1 114104036 Whitehead, Stephen NIAID - DIR NIAID Whitehead, Stephen (NIAID) 1 114104033 Blaney, Joseph NIAID - DIR NIAID Blaney, Joseph (NIAID) 0 114104034 Hanley, Kathryn NIAID - DIR Hanley, Kathryn 0 114104035 Murphy, Brian NIAID - DIR NIAID Murphy, Brian (NIAID) 0 114099674 DEVELOPMENT OF MUTATIONS USEFUL FOR ATTENUATING DENGUE VIRUSES AND CHIMERIC DENGUE VIRUSES E-120-2001-0 Filing authorized NIAID 91029846 Ganelina, Anna ganelinaa@niaid.nih.gov
United States of America ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-535] Development of Mutations Useful for Attenuating Dengue Viruses and Chimeric Dengue Viruses&body=Please send me information about technology [TAB-535] Development of Mutations Useful for Attenuating Dengue Viruses and Chimeric Dengue Viruses. Ganelina, Anna<br><a href="mailto:ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-535] Development of Mutations Useful for Attenuating Dengue Viruses and Chimeric Dengue Viruses&body=Please send me information about technology [TAB-535] Development of Mutations Useful for Attenuating Dengue Viruses and Chimeric Dengue Viruses.">ganelinaa@niaid.nih.gov</a><br> 114160995 E-120-2001-0 E-120-2001-0-US-13 DEVELOPMENT OF MUTATIONS USEFUL FOR ATTENUATING DENGUE VIRUSES AND CHIMERIC DENGUE VIRUSES CON US 8,039,003 12/396,376 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8039003 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8039003">8,039,003</a><br />Filed on 2009-03-02<br />Status: Expired 114161250 E-120-2001-0 E-120-2001-0-US-10 DEVELOPMENT OF MUTATIONS USEFUL FOR ATTENUATING DENGUE VIRUSES AND CHIMERIC DENGUE VIRUSES DIV US 7,560,118 11/446,050 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7560118 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7560118">7,560,118</a><br />Filed on 2006-06-02<br />Status: Expired 114162529 E-120-2001-0 E-120-2001-0-PCT-02 Development of Mutations Useful For Attenuating Dengue Viruses And Chimeric PCT Patent Cooperation Treaty PCT/US2002/016308 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2002/016308<br />Filed on 2002-05-22<br />Status: Expired 114164261 E-120-2001-0 E-120-2001-0-US-04 Development of Mutations Useful For Attenuating Dengue Viruses And Chimeric Dengue Viruses National Stage US 7,226,602 10/719,547 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7226602 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7226602">7,226,602</a><br />Filed on 2003-11-21<br />Status: Expired 114164393 E-120-2001-0 E-120-2001-0-US-01 DEVELOPMENT OF MUTATIONS USEFUL FOR ATTENUATING DENGUE VIRUSES AND CHIMERIC DENGUE VIRUSES PRV US 60/293,049 Abandoned US <br />Provisional (PRV) 60/293,049<br />Filed on 2001-05-22<br />Status: Abandoned 114166539 E-120-2001-0 E-120-2001-0-US-18 DEVELOPMENT OF MUTATIONS USEFUL FOR ATTENUATING DENGUE VIRUSES AND CHIMERIC DENGUE VIRUSES DIV US 8,632,782 13/240,849 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8632782 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8632782">8,632,782</a><br />Filed on 2011-09-22<br />Status: Expired 114167082 E-120-2001-0 E-120-2001-0-US-35 Attenuated Dengue Virus Comprising Mutations in the NS3 Gene REISSUE US RE045053 13/896,411 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/RE45053 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/RE45053">RE045053</a><br />Filed on 2013-05-17<br />Status: Expired 114167083 E-120-2001-0 E-120-2001-0-US-36 DEVELOPMENT OF MUTATIONS USEFUL FOR ATTENUATING DENGUE VIRUSES AND CHIMERIC DENGUE VIRUSES REISSUE US RE45016 13/896,396 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/RE45016 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/RE45016">RE45016</a><br />Filed on 2013-05-17<br />Status: Expired 114167084 E-120-2001-0 E-120-2001-0-US-37 Recombinant Attenuated Dengue Viruses Comprising A Deletion in the 3' Untranslated Region and Additional Attenuating Mutations Induced by Chemical Mutagenesis REISSUE US RE45,123 13/896,409 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/RE45123 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/RE45123">RE45,123</a><br />Filed on 2013-05-17<br />Status: Expired 114167714 E-120-2001-0 E-120-2001-0-US-38 DEVELOPMENT OF MUTATIONS USEFUL FOR ATTENUATING DENGUE VIRUSES AND CHIMERIC DENGUE VIRUSES DIV US 9,707,287 14/096,424 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9707287 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9707287">9,707,287</a><br />Filed on 2013-12-04<br />Status: Expired 114168334 E-120-2001-0 E-120-2001-0-US-90 DEVELOPMENT OF MUTATIONS USEFUL FOR ATTENUATING DENGUE VIRUSES AND CHIMERIC DENGUE VIRUSES DIV US 10,500,264 15/650,482 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10500264 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10500264">10,500,264</a><br />Filed on 2017-07-14<br />Status: Expired 114113706 DC5BXX 114113707 DCXXXX 114113708 UBXXXX 114113709 UAXXXX 114113710 DXXXXX 114119291 DC5XXX 114132872 Dengue Vaccine 114132873 Development 114132874 Mutations 114132875 USEFUL 114132876 ATTENUATING 114132877 DENGUE 114132878 Viruses 114132879 chimeric 114157905 Dengue (Flaviviridae) TAB-5045 162060508 Fluorophthalimides as Anti-inflammatory Agents for Systemic and Neurodegenerative Disorder NIA Collaboration, Licensing, Neurology, Oncology, Therapeutics Collaboration Licensing Neurology Oncology Therapeutics Nigel Greig, Shih Chang Hsueh, Daniela Lecca, Weiming Luo, Michael Scerba, David Tweedie <h2>Summary:</h2> <p>The National Institute on Aging (NIA) seeks research co-development partners and/or licensees for the pre-clinical and clinical development of the compounds as anti-inflammatory therapeutics for systemic and neurodegenerative disorders.</p> <h2>Description of Technology:</h2> <p>Numerous systemic, as well as neurological disorders, have a hallmark inflammatory element that can drive disease progression. However, the use of currently available anti-inflammatory agents have failed to demonstrate efficacy as potential treatment for systemic and neurological disorders in clinical trials.</p> <p>The immunomodulatory imide drug (IMiD) thalidomide exerts anti-inflammatory effects through inhibition of tumor necrosis factor-alpha (TNF-&alpha;), which is a master regulator of the inflammatory response.&nbsp; Researchers at the National Institute on Aging (NIA) have synthesized novel thalidomide analogs possessing potent anti-inflammatory actions but, importantly, hinder the cerebon binding that associated with the adverse teratogenic actions of classic IMiDs. This invention has potential to be developed as therapeutics for a variety of systemic and neurological disorders including inflammatory disorders, autoimmune disorders, viral infections, traumatic brain injury, neurodegenerative diseases and cancer.</p> <h2>Potential Commercial Applications:</h2> <p>Therapeutics for:</p> <ul> <li>neurodegenerative diseases</li> <li>inflammatory disorders</li> <li>autoimmune disorders</li> <li>viral infections</li> <li>cancer</li> </ul> <h2>Competitive Advantages over Clinically Available IMiDs:</h2> <ul> <li>More potent anti-inflammatory properties</li> <li>Potentially clinically safer than classic IMiDs by lower risk of fetal malformations</li> <li>Potential to treat a wide range of significant unmet medical needs</li> </ul> Researchers at the NIA seek licensing and/or co-development research collaborations for pre-clinical and clinical development of fluorophthalimides as anti-inflammatory therapeutics for systemic and neurodegenerative diseases 2025-04-25 2025-06-27 2025-08-15 2025-05-02 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-045-2012-0 E-208-2015-0 162062596 Lecca D, et al. Novel, thalidomidelike, noncereblon binding drug tetrafluorobornylphthalimide mitigates inflammation and brain injury. (PMID 36872339) https://pubmed.ncbi.nlm.nih.gov/36872339/ <a href="https://pubmed.ncbi.nlm.nih.gov/36872339/">Lecca D, et al. Novel, thalidomidelike, noncereblon binding drug tetrafluorobornylphthalimide mitigates inflammation and brain injury. (PMID 36872339)</a> 162061129 Greig, Nigel National Institute on Aging (NIH/NIA) NIA Greig, Nigel (NIA) 1 162061218 Luo, Weiming National Institute on Aging (NIH/NIA) NIA Luo, Weiming (NIA) 2 162061257 Tweedie, David National Institute on Aging (NIH/NIA) NIA Tweedie, David (NIA) 3 162061271 Scerba, Michael National Institute on Aging (NIH/NIA) NIA Scerba, Michael (NIA) 4 162061286 Lecca, Daniela National Institute on Aging (NIH/NIA) Lecca, Daniela 5 162061304 Hsueh, Shih Chang National Institute on Aging (NIH/NIA) Hsueh, Shih Chang 6 162061129 Greig, Nigel National Institute on Aging (NIH/NIA) NIA Greig, Nigel (NIA) 1 162061218 Luo, Weiming National Institute on Aging (NIH/NIA) NIA Luo, Weiming (NIA) 2 162061257 Tweedie, David National Institute on Aging (NIH/NIA) NIA Tweedie, David (NIA) 3 162061271 Scerba, Michael National Institute on Aging (NIH/NIA) NIA Scerba, Michael (NIA) 4 162061286 Lecca, Daniela National Institute on Aging (NIH/NIA) Lecca, Daniela 5 162061304 Hsueh, Shih Chang National Institute on Aging (NIH/NIA) Hsueh, Shih Chang 6 162060511 Flurorphthalimides As Anti-inflammatory Agents For Systemic And Neurodegenerative Disorders E-151-2022-0 Filing authorized National Institute on Aging (NIH/NIA) 119617417 Ravilious, Geoffrey geoffrey.ravilious@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
geoffrey.ravilious@nih.gov?subject=Web Inquiry on [TAB-5045] Fluorophthalimides as Anti-inflammatory Agents for Systemic and Neurodegenerative Disorder&body=Please send me information about technology [TAB-5045] Fluorophthalimides as Anti-inflammatory Agents for Systemic and Neurodegenerative Disorder.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Ravilious, Geoffrey<br><a href="mailto:geoffrey.ravilious@nih.gov?subject=Web Inquiry on [TAB-5045] Fluorophthalimides as Anti-inflammatory Agents for Systemic and Neurodegenerative Disorder&body=Please send me information about technology [TAB-5045] Fluorophthalimides as Anti-inflammatory Agents for Systemic and Neurodegenerative Disorder.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">geoffrey.ravilious@nih.gov</a><br> 162060598 E-151-2022-0 E-151-2022-0-US-01 HALOPHTHALIMIDE COMPOUNDS AND METHODS OF USE PRV US 63/397,235 Expired US <br />Provisional (PRV) 63/397,235<br />Filed on 2022-08-11<br />Status: Expired 162060599 E-151-2022-0 E-151-2022-0-PC-01 HALOPHTHALIMIDE COMPOUNDS AND METHODS OF USE PCT Patent Cooperation Treaty PCT/US2023/029602 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2023/029602<br />Filed on 2023-08-07<br />Status: Expired 162060600 E-151-2022-0 E-151-2022-0-US-02 HALOPHTHALIMIDE COMPOUNDS AND METHODS OF USE AGAINST TBI, INFLAMMATORY DISORDER, AUTOIMMUNE DISORDER, NEURODEGENERATIVE DISEASE OR VIRAL INFECTION National Stage US 19/102,830 Pending US <br />National Stage 19/102,830<br />Filed on 2025-02-10<br />Status: Pending 162060601 E-151-2022-0 E-151-2022-0-EP-01 HALOPHTHALIMIDE COMPOUNDS AND METHODS OF USE AGAINST TBI, INFLAMMATORY DISORDER, AUTOIMMUNE DISORDER, NEURODEGENERATIVE DISEASE OR VIRAL INFECTION National Stage European Patent 23762066.1 Pending European Patent <br />National Stage 23762066.1<br />Filed on 2025-02-28<br />Status: Pending TAB-5038 159567984 Novel Antibody Test for Mycoplasma Detection NIAID Robert Purcell <p><span style="font-size:11pt"><span style="line-height:107%"><span style="font-family:Calibri,sans-serif">The technology is a novel antibody test designed for the detection of Mycoplasma antibodies, representing a significant advancement in Mycoplasma detection methods. This test offers a rapid and reliable means of diagnosing Mycoplasma infections, which is particularly valuable in research and clinical settings. Unlike existing tests, this innovative approach provides specificity and sensitivity in detecting Mycoplasma antibodies, ensuring accurate and timely diagnosis. The technology&#39;s development stage is currently at the prototype phase, indicating that it is undergoing initial testing and refinement to optimize its performance. Once fully developed, this antibody test has the potential to revolutionize Mycoplasma detection, improving research outcomes and patient care.</span></span></span></p> This novel antibody test for Mycoplasma detection offers several competitive advantages over existing methods. Firstly, it is the first of its kind, providing a unique solution to a previously unmet need in the field. Its specificity and sensitivity in detecting Mycoplasma antibodies surpass current standards, ensuring accurate and reliable results. Additionally, the test is designed to be rapid and easy to use, saving time and resources compared to traditional methods. Its innovative approach has the potential to significantly improve research and clinical outcomes related to Mycoplasma infections. As the technology advances towards commercialization, these competitive advantages position it as a game-changer in the field of Mycoplasma detection and diagnosis. The novel antibody test for Mycoplasma detection has a wide range of potential applications across various fields. In research settings, it can be used to screen cell cultures for Mycoplasma contamination, ensuring the integrity of experiments and the reliability of research outcomes. In clinical settings, the test can aid in the diagnosis of Mycoplasma infections, enabling healthcare providers to administer appropriate treatments promptly. Additionally, the test may find applications in veterinary medicine, agriculture, and environmental monitoring, where Mycoplasma contamination can have significant impacts. The test's versatility and reliability make it a valuable tool for a diverse range of applications, highlighting its potential to address key challenges in multiple industries. 2024-12-10 2025-08-13 2025-08-15 2024-12-10 False False True 52406769 Prototype 52406769 37470483 Website Abstract 159567997 Purcell, Robert National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Purcell, Robert (NIAID) 1 159567997 Purcell, Robert National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Purcell, Robert (NIAID) 1 159567987 Ureaplasma Urealyticum Mycoplasma Test E-198-2020-0 Research Material NIAID 91021353 Pitts, Elizabeth elizabeth.pitts@nih.gov
United States of America elizabeth.pitts@nih.gov?subject=Web Inquiry on [TAB-5038] Novel Antibody Test for Mycoplasma Detection&body=Please send me information about technology [TAB-5038] Novel Antibody Test for Mycoplasma Detection. Pitts, Elizabeth<br><a href="mailto:elizabeth.pitts@nih.gov?subject=Web Inquiry on [TAB-5038] Novel Antibody Test for Mycoplasma Detection&body=Please send me information about technology [TAB-5038] Novel Antibody Test for Mycoplasma Detection.">elizabeth.pitts@nih.gov</a><br> TAB-497 114094835 Generalized MRI Artifact Reduction Using Array Processing Method NHLBI Licensing Licensing Peter Kellman, Elliot Mcveigh The invention is a phased array combining method for reducing artifacts in Magnetic Resonance (MR) imaging. The method uses a constrained optimization that optimizes signal-to-noise subject to the constraint of nulling ghost artifacts at known locations. The method is effective in reducing or canceling artifacts that arise in a wide variety of MR applications, including ghost artifacts from echo planar imaging and Gradient Recalled Echo with Echo Train (FGRE-ET) imaging used in cardiac or other rapid imaging applications. The strategy of using phase encode acquisition orders with distortion that results in ghosts, followed by applying this phased array ghost cancellation method has a number of benefits, including reduced blur and geometric distortion, reduced acquisition time (eliminating echo shifting), and reduced sensitivity to flow. 2022-03-08 2025-08-13 2025-08-15 2001-08-01 AAXXXX, ACXXXX, ADXXXX, AXXXXX False True True NIHTT 37470483 Website Abstract 114103962 Kellman, Peter NHLBI Kellman, Peter (NHLBI) 0 114103963 Mcveigh, Elliot Mcveigh, Elliot 0 114103962 Kellman, Peter NHLBI Kellman, Peter (NHLBI) 0 114103963 Mcveigh, Elliot Mcveigh, Elliot 0 114099637 Ghost Artifact Cancellation Using Phased Array Processing E-198-2000-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 89788013 Kolesnitchenko, Vincent vk5q@nih.gov
United States of America Office of Technology Transfer and Development vk5q@nih.gov?subject=Web Inquiry on [TAB-497] Generalized MRI Artifact Reduction Using Array Processing Method&body=Please send me information about technology [TAB-497] Generalized MRI Artifact Reduction Using Array Processing Method. Kolesnitchenko, Vincent<br><a href="mailto:vk5q@nih.gov?subject=Web Inquiry on [TAB-497] Generalized MRI Artifact Reduction Using Array Processing Method&body=Please send me information about technology [TAB-497] Generalized MRI Artifact Reduction Using Array Processing Method.">vk5q@nih.gov</a><br> 114161156 E-198-2000-0 E-198-2000-0-AU-03 Ghost Artifact Cancellation Using Phased Array Processing National Stage Australia 2002247451 Abandoned Australia <br />National Stage 2002247451<br />Filed on 2002-03-28<br />Status: Abandoned 114164648 E-198-2000-0 E-198-2000-0-US-01 Ghost Artifact Cancellation Using Phased Array Processing ORD US 6,771,067 09/825,617 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6771067 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6771067">6,771,067</a><br />Filed on 2001-04-03<br />Status: Expired 114165813 E-198-2000-0 E-198-2000-0-PCT-02 Ghost Artifact Cancellation Using Phased Array Processing PCT Patent Cooperation Treaty PCT/US2002/009939 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2002/009939<br />Filed on 2002-03-28<br />Status: Expired 114113551 AAXXXX 114113552 ACXXXX 114113553 ADXXXX 114113554 AXXXXX TAB-4963 153986016 A Fundamental Tool for Efficient Recovery of RNA Viruses through Reverse Genetics NIAID Collaboration, Immunology, Infectious Disease, Licensing, Research Equipment, Therapeutics, Vaccines Collaboration Immunology Infectious Disease Licensing Research Equipment Therapeutics Vaccines Ursula Buchholz <p><span style="font-size:11pt"><span style="line-height:107%"><span style="font-family:Calibri,sans-serif">BSR T7/5 cells represent a foundational advancement in virology, offering a robust platform for the recovery of RNA viruses via reverse genetics. Established over 20 years ago, these cells have proven instrumental in the recovery of a wide array of RNA viruses, particularly those belonging to the mononegavirales order. By enabling the insertion of antigenome sequences into cDNA plasmids under a T7 RNA polymerase promoter, BSR T7/5 cells facilitate the transcription of RNA antigenomes and mRNA encoding RNP elements, leading to the assembly of infectious viruses. Notably, this system does not require helper viruses, and the cell line&#39;s permissiveness, attributed to the absence of a functional type 1 interferon response, makes it especially valuable for viruses replicating in the cytoplasm.</span></span></span></p> BSR T7/5 cells offer distinct competitive advantages over traditional methods for RNA virus recovery. Their efficiency in recovering RNA viruses from cDNA plasmids via reverse genetics surpasses that of other cell lines, particularly for members of the mononegavirales order. Unlike many existing approaches, the use of BSR T7/5 cells does not necessitate the presence of helper viruses, streamlining the recovery process. Additionally, the cell line's high permissiveness to RNA viruses, attributed to its lack of a functional type 1 interferon response, enhances the range of viruses that can be studied and recovered. These advantages make BSR T7/5 cells a superior choice for researchers seeking a reliable, efficient, and versatile platform for RNA virus recovery and study. The applications of BSR T7/5 cells extend across various fields, offering immense potential in virology, vaccine development, and antiviral drug discovery. Their ability to efficiently recover RNA viruses through reverse genetics makes them invaluable for studying viral pathogenesis, host-virus interactions, and viral evolution. In vaccine development, these cells can be instrumental in generating attenuated or modified viruses for vaccine candidates, particularly for viruses that replicate in the cytoplasm. Furthermore, BSR T7/5 cells hold promise in antiviral drug screening, allowing researchers to evaluate the efficacy of antiviral compounds against a wide range of RNA viruses. Overall, the versatility and reliability of BSR T7/5 cells make them a key tool for advancing our understanding of RNA viruses and developing strategies to combat them. 2024-03-25 2025-08-13 2025-08-15 2024-12-10 False True True 52406768 Discovery 52406768 37470483 Website Abstract 153986027 Buchholz, Ursula NIAID - DIR NIAID Buchholz, Ursula (NIAID) 1 153986027 Buchholz, Ursula NIAID - DIR NIAID Buchholz, Ursula (NIAID) 1 153986019 BSR T7/5 Cells: Baby Hamster Kidney (BHK-21) Cells Stably Expressing Phage T7 RNA Polymerase E-166-2020-0 Research Material NIAID 91021353 Pitts, Elizabeth elizabeth.pitts@nih.gov
United States of America elizabeth.pitts@nih.gov?subject=Web Inquiry on [TAB-4963] A Fundamental Tool for Efficient Recovery of RNA Viruses through Reverse Genetics&body=Please send me information about technology [TAB-4963] A Fundamental Tool for Efficient Recovery of RNA Viruses through Reverse Genetics. Pitts, Elizabeth<br><a href="mailto:elizabeth.pitts@nih.gov?subject=Web Inquiry on [TAB-4963] A Fundamental Tool for Efficient Recovery of RNA Viruses through Reverse Genetics&body=Please send me information about technology [TAB-4963] A Fundamental Tool for Efficient Recovery of RNA Viruses through Reverse Genetics.">elizabeth.pitts@nih.gov</a><br> TAB-4912 153267820 DeePlexing – Extending Imaging Multiplexity Using Machine Learning NIAID Computational models/software, Dermatology, Immunology, Licensing, Radiology, Research Equipment, Software / Apps Computational models/software Dermatology Immunology Licensing Radiology Research Equipment Software / Apps Ronald Germain, Spencer Grant, Nishant Thakur, Abigail Wong-Rolle, Chen Zhao <p>Spatial proteomics and transcriptomics are fast-emerging fields with the potential to revolutionize various branches of biology. In the last five years, various multiplex immunofluorescence and immunohistochemistry imaging methods have been developed to stain 5-60 different protein markers in a given tissue. Nonetheless, most of these techniques are iterative and can image a maximum of 3-8 markers in a single cycle, resulting in processing time of several hours to days.</p> <p>Scientists at National Institute of Allergy and Infectious Diseases (NIAID) and National Cancer Institute (NCI) have developed a new method - DeePlexing - that uses a deep learning algorithm to dramatically enhance the number of markers stained in a single imaging cycle. This is accomplished with no changes or upgrades to the imaging platform itself. In the DeePlexing method, multiple antibodies/probes are conjugated to the same fluorophores and later deconvolved computationally to retrieve the multichannel signal with high accuracy. In digital spatial profiling, DeePlexing enables the user to detect seven different protein markers in a single cycle using only three fluorophores and even quadruple the number of markers in a single round without compromising the quality of RNA and protein in the sample. For multiplex protein profiling, DeePlexing can potentially stain for up to 255 different protein markets with eight fluorophores and deconvolve the signal for each of the 255 markers computationally.</p> <ul> <li>Enhances the number of markers stained in a single imaging cycle</li> <li>Achieves this marker detection increase without compromising RNA or protein quality when that is part of the analytical pipeline</li> <li>Reduces the required processing time for multiplex imaging platforms</li> <li>Inexpensive and replicable</li> </ul> <ul> <li>Imaging platforms in spatial transcriptomics</li> <li>Multiplex protein spatial imaging</li> </ul> To license this technology, please contact Daniel Lee at 301-761-6327 or at <a href="mailto:daniel.lee5@nih.gov"> daniel.lee5@nih.gov</a>, and reference E-202-2021-0. 2024-02-23 2025-08-13 2025-08-15 2024-02-26 IMAGING, IMMUNOFLUORESCENCE, Immunohistochemistry, Methods, Multiplex False False True 52406769 Prototype 52406769 37470483 Website Abstract 153267958 Germain, Ronald NIH - NIAID NIAID Germain, Ronald (NIAID) 1 153267962 Grant, Spencer NIH - NIAID NIAID Grant, Spencer (NIAID) 2 153267981 Thakur, Nishant NIH - NIAID NIAID Thakur, Nishant (NIAID) 3 153267991 Zhao, Chen NCI - CCR NCI Zhao, Chen (NCI) 4 153268007 Wong-Rolle, Abigail NCI - CCR NCI Wong-Rolle, Abigail (NCI) 5 153267958 Germain, Ronald NIH - NIAID NIAID Germain, Ronald (NIAID) 1 153267962 Grant, Spencer NIH - NIAID NIAID Grant, Spencer (NIAID) 2 153267981 Thakur, Nishant NIH - NIAID NIAID Thakur, Nishant (NIAID) 3 153267991 Zhao, Chen NCI - CCR NCI Zhao, Chen (NCI) 4 153268007 Wong-Rolle, Abigail NCI - CCR NCI Wong-Rolle, Abigail (NCI) 5 153267823 DeePlexing - Extending Imaging Multiplexity Using Machine Learning E-202-2021-0 Research Material NCI, NIAID 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-4912] DeePlexing – Extending Imaging Multiplexity Using Machine Learning&body=Please send me information about technology [TAB-4912] DeePlexing – Extending Imaging Multiplexity Using Machine Learning. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-4912] DeePlexing – Extending Imaging Multiplexity Using Machine Learning&body=Please send me information about technology [TAB-4912] DeePlexing – Extending Imaging Multiplexity Using Machine Learning.">yogikala.prabhu@nih.gov</a><br> 153303249 Multiplex 153303253 IMMUNOFLUORESCENCE 153303265 Immunohistochemistry 153303309 IMAGING 153303313 Methods TAB-4898 153000177 Characterization and Comparison of LAD2 and LADR Mast Cell Lines: Insights into Mastocytosis and HIV Infection NIAID Collaboration, Human Cell Lines, Immunology, Infectious Disease, Research Materials Collaboration Human Cell Lines Immunology Infectious Disease Research Materials Arnold Kirshenbaum, Dean Metcalfe <p>LAD2 and LADR cell lines are invaluable tools in mast cell research, offering insights into mastocytosis and immune responses. Derived from CD34+ cells, LAD2 cells have been extensively used for over 18 years, while LADR cells, a newer variant, exhibit enhanced characteristics such as larger size, increased granulation, and faster doubling time. Both cell lines release granular contents upon FceRI aggregation and can be infected with various strains of HIV. LADR cells, in particular, show greater expression of certain surface receptors and mRNA compared to LAD2 cells. Additionally, gene expression arrays highlight differences in signaling pathways and regulatory mechanisms between the two cell lines, providing a comprehensive platform for studying mast cell biology and related diseases.</p> <p>&nbsp;</p> The LAD2 and LADR cell lines offer several competitive advantages in mast cell research compared to other models. Firstly, their origin from a patient with aggressive mastocytosis provides a more clinically relevant model for studying mast cell biology and diseases. Secondly, the long-standing use and distribution of LAD2 cells worldwide demonstrate their reliability and reproducibility in experiments. The recent establishment of LADR cells further enhances this model by offering a variant with distinct characteristics, allowing for more diverse and comprehensive studies. Additionally, the ability of both cell lines to be infected with HIV strains provides a unique opportunity to study mast cell interactions with viral infections. Overall, the availability, reliability, and versatility of LAD2 and LADR cells make them highly competitive choices for researchers studying mast cells and related disorders. The LAD2 and LADR cell lines have a wide range of potential applications in mast cell research and beyond. Their ability to mimic mast cell behavior and responses makes them valuable tools for studying allergic reactions, inflammatory responses, and immune system modulation. These cell lines can be used to investigate the molecular mechanisms underlying mast cell activation, mediator release, and signaling pathways, leading to a better understanding of mast cell-related diseases such as mastocytosis, allergic disorders, and autoimmune conditions. Furthermore, their susceptibility to HIV infection opens up avenues for studying the interaction between mast cells and the virus, potentially uncovering new therapeutic targets for HIV treatment. The versatility and reliability of LAD2 and LADR cells make them promising candidates for various research applications in immunology, virology, and pharmacology. 2024-02-20 2025-08-13 2025-08-15 2024-12-10 False True True 52406768 Discovery 52406768 37470483 Website Abstract 153000418 Kirshenbaum, Arnold NIAID Kirshenbaum, Arnold (NIAID) 1 153000434 Metcalfe, Dean NIAID Metcalfe, Dean (NIAID) 2 153000418 Kirshenbaum, Arnold NIAID Kirshenbaum, Arnold (NIAID) 1 153000434 Metcalfe, Dean NIAID Metcalfe, Dean (NIAID) 2 153000180 LADR Human Mast Cell Line E-082-2020-0 Research Material NIAID 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-4898] Characterization and Comparison of LAD2 and LADR Mast Cell Lines: Insights into Mastocytosis and HIV Infection&body=Please send me information about technology [TAB-4898] Characterization and Comparison of LAD2 and LADR Mast Cell Lines: Insights into Mastocytosis and HIV Infection. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-4898] Characterization and Comparison of LAD2 and LADR Mast Cell Lines: Insights into Mastocytosis and HIV Infection&body=Please send me information about technology [TAB-4898] Characterization and Comparison of LAD2 and LADR Mast Cell Lines: Insights into Mastocytosis and HIV Infection.">yogikala.prabhu@nih.gov</a><br> TAB-4883 152844291 Advancements in Postexposure Prophylaxis: Evaluating High-Potency Rabies-Neutralizing Monoclonal Antibodies NIAID Antibodies, Collaboration, Diagnostics, Infectious Disease, Licensing, Research Equipment, Therapeutics, Vaccines Antibodies Collaboration Diagnostics Infectious Disease Licensing Research Equipment Therapeutics Vaccines Joseph Blaney, Zhaochun Chen, Robert Purcell <p>This technology represents a significant advancement in the field of rabies prevention, focusing on the development of highly potent rabies-neutralizing monoclonal antibodies (mAbs) for use in postexposure prophylaxis (PEP). With two mAbs, F2 and G5a, displaying exceptional neutralizing titers of 1154 and 3462 International Units (IUs) per milligram, respectively, these antibodies have the potential to offer enhanced protection against rabies when administered alongside rabies vaccines. The production of these mAbs involves genetic engineering of mammalian cell lines, enabling their consistent and efficient production. While the in vitro results are promising, rigorous in vivo animal protection assays are necessary to confirm their effectiveness in providing protection against rabies, ultimately offering a promising solution to a disease that remains almost invariably fatal once clinical symptoms develop.</p> <p>&nbsp;</p> This technology's competitive advantages stem from its development of highly potent monoclonal antibodies (mAbs) for rabies prevention. These mAbs, such as F2 and G5a, offer superior protection compared to existing options. Additionally, their production through genetically engineered cell lines ensures a reliable supply, potentially addressing the global shortage of rabies immunoglobulin (RIG). By enhancing postexposure prophylaxis (PEP) when combined with rabies vaccines, this technology improves effectiveness and accessibility in regions with a high rabies incidence, making it a competitive solution in the fight against this deadly disease. These highly potent rabies-neutralizing monoclonal antibodies (mAbs) have diverse potential applications. They can enhance postexposure prophylaxis (PEP), improving survival rates for rabies-exposed individuals. Their utility extends to research, aiding in the study of rabies and the development of new treatments. With scalability and production efficiency, they are accessible tools for rabies control in regions facing shortages or high incidence rates, offering versatile solutions in the fight against rabies. 2024-02-12 2025-08-13 2025-08-15 2024-12-10 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 152844341 Chen, Zhaochun NIAID - DIR NIAID Chen, Zhaochun (NIAID) 1 152844357 Purcell, Robert NIAID Purcell, Robert (NIAID) 2 152844466 Blaney, Joseph NIAID Blaney, Joseph (NIAID) 3 152844341 Chen, Zhaochun NIAID - DIR NIAID Chen, Zhaochun (NIAID) 1 152844357 Purcell, Robert NIAID Purcell, Robert (NIAID) 2 152844466 Blaney, Joseph NIAID Blaney, Joseph (NIAID) 3 152844294 Development Of Chimpanzee/Human Neutralizing Monoclonal Antibodies Against Rabies E-067-2014-0 Research Material NIAID 91021353 Pitts, Elizabeth elizabeth.pitts@nih.gov
United States of America elizabeth.pitts@nih.gov?subject=Web Inquiry on [TAB-4883] Advancements in Postexposure Prophylaxis: Evaluating High-Potency Rabies-Neutralizing Monoclonal Antibodies&body=Please send me information about technology [TAB-4883] Advancements in Postexposure Prophylaxis: Evaluating High-Potency Rabies-Neutralizing Monoclonal Antibodies. Pitts, Elizabeth<br><a href="mailto:elizabeth.pitts@nih.gov?subject=Web Inquiry on [TAB-4883] Advancements in Postexposure Prophylaxis: Evaluating High-Potency Rabies-Neutralizing Monoclonal Antibodies&body=Please send me information about technology [TAB-4883] Advancements in Postexposure Prophylaxis: Evaluating High-Potency Rabies-Neutralizing Monoclonal Antibodies.">elizabeth.pitts@nih.gov</a><br> TAB-4855 152461954 Advancing VZV Antibody Detection: A High-Throughput LIPS Assay for Varicella Vaccine Recipients NIAID Antibodies, Collaboration, Diagnostics, Infectious Disease, Licensing, Research Equipment Antibodies Collaboration Diagnostics Infectious Disease Licensing Research Equipment Mir Ali, Peter Burbelo, Jeffrey Cohen <p>The technology described is a sophisticated and high-throughput luciferase immunoprecipitation system (LIPS) assay designed to detect antibodies specific to Varicella-zoster virus (VZV) glycoprotein E (gE). By transfecting cells with VZV protein-Renilla luciferase fusion protein constructs and subsequently performing immunoprecipitations with protein A/G beads, this innovative assay enables the quantitative measurement of VZV gE antibody levels in blood serum samples. Notably, it demonstrates a sensitivity comparable to the established fluorescent antibody to membrane antigen test (FAMA), making it a promising tool for identifying anti-VZV antibodies in individuals who have received the VZV vaccine. However, potential patent challenges may arise due to similarities with assays used for related herpesviruses, and the market for this technology is relatively niche, primarily targeting populations at higher risk of VZV infection, such as pregnant women and healthcare workers.</p> The proposed high-throughput luciferase immunoprecipitation system (LIPS) assay for VZV antibody detection offers key competitive advantages. It provides quantitative results, enables efficient screening of numerous samples, and matches the sensitivity of the established FAMA test. While patent challenges may arise, this technology serves niche markets, like pregnant women and healthcare workers at higher risk of VZV exposure, making it a valuable tool for focused serological diagnosis and research. The high-throughput luciferase immunoprecipitation system (LIPS) assay for VZV antibody detection has versatile potential applications. It can be used for vaccine studies, epidemiological research, and clinical diagnostics, offering accurate results similar to the FAMA test. Despite potential patent challenges, it's well-suited for specialized purposes like assessing vaccine responses in pregnant women and screening high-risk healthcare workers. This makes it valuable in focused serological research and diagnostics. 2024-01-29 2025-08-13 2025-08-15 2024-12-10 False True True 72159134 Analytical Assay Performance Stage 72159134 37470483 Website Abstract 152461962 Cohen, Jeffrey NIAID - DIR NIAID Cohen, Jeffrey (NIAID) 1 152461980 Burbelo, Peter NIDCR NIDCR Burbelo, Peter (NIDCR) 2 152462067 Ali, Mir NIAID - DIR NIAID Ali, Mir (NIAID) 3 152461962 Cohen, Jeffrey NIAID - DIR NIAID Cohen, Jeffrey (NIAID) 1 152461980 Burbelo, Peter NIDCR NIDCR Burbelo, Peter (NIDCR) 2 152462067 Ali, Mir NIAID - DIR NIAID Ali, Mir (NIAID) 3 152461957 Luciferase Immunoprecipitation Systems Assay To Detect Antibody To Varicella-Zoster Virus In Varicella Vaccine Recipients E-037-2014-0 Research Material NIAID, NIDCR 91021353 Pitts, Elizabeth elizabeth.pitts@nih.gov
United States of America elizabeth.pitts@nih.gov?subject=Web Inquiry on [TAB-4855] Advancing VZV Antibody Detection: A High-Throughput LIPS Assay for Varicella Vaccine Recipients&body=Please send me information about technology [TAB-4855] Advancing VZV Antibody Detection: A High-Throughput LIPS Assay for Varicella Vaccine Recipients. Pitts, Elizabeth<br><a href="mailto:elizabeth.pitts@nih.gov?subject=Web Inquiry on [TAB-4855] Advancing VZV Antibody Detection: A High-Throughput LIPS Assay for Varicella Vaccine Recipients&body=Please send me information about technology [TAB-4855] Advancing VZV Antibody Detection: A High-Throughput LIPS Assay for Varicella Vaccine Recipients.">elizabeth.pitts@nih.gov</a><br> TAB-4852 152461108 Optimizing RSV Infection Monitoring and High-Throughput Screening Through GFP Expression in the First-Gene Position of Respiratory Syncytial Virus (RSV) Strain A2 NIAID Collaboration, Computational models/software, Diagnostics, Infectious Disease, Licensing, Research Equipment, Research Materials, Respiratory, Therapeutics Collaboration Computational models/software Diagnostics Infectious Disease Licensing Research Equipment Research Materials Respiratory Therapeutics Ursula Buchholz, Peter Collins, Cindy Luongo <p>In this technology, researchers have engineered a modified version of Respiratory Syncytial Virus (RSV) strain A2 using reverse genetics to incorporate green fluorescent protein (GFP) into the first-gene position. This genetic modification allows for the efficient monitoring of RSV infection and the screening of potential chemical inhibitors. The GFP expression can be easily detected through fluorescence microscopy in live or fixed cells, providing a sensitive tool for both research and drug discovery. Importantly, placing GFP in the first-gene position minimizes interference with the expression of key RSV interferon antagonist genes, maintaining the virus&#39;s functionality while enhancing the brightness and utility of the GFP marker. This technology offers valuable insights into RSV infection dynamics and facilitates high-throughput screening for potential therapeutic agents.</p> <p>&nbsp;</p> The incorporation of green fluorescent protein (GFP) into the first-gene position of Respiratory Syncytial Virus (RSV) strain A2 offers a competitive advantage by providing a highly sensitive and non-invasive method for monitoring RSV infection. This modification ensures a robust and bright signal for accurate tracking, while strategically minimizing interference with key RSV genes. Researchers can better study the virus and expedite drug discovery efforts with this enhanced technology. This technology has versatile potential applications. It aids in better understanding RSV infection, enabling high-throughput screening for antiviral compounds and vaccine development. Additionally, it has broader applications in respiratory virus research, offering insights into host interactions and potential treatments for various viral infections. 2024-01-29 2025-08-13 2025-08-15 2024-12-10 False True True 52406769 Prototype 52406769 37470483 Website Abstract 152461118 Collins, Peter NIAID - DIR NIAID Collins, Peter (NIAID) 1 152461125 Buchholz, Ursula NIAID - DIR NIAID Buchholz, Ursula (NIAID) 2 152461129 Luongo, Cindy NIAID - DIR NIAID Luongo, Cindy (NIAID) 3 152461118 Collins, Peter NIAID - DIR NIAID Collins, Peter (NIAID) 1 152461125 Buchholz, Ursula NIAID - DIR NIAID Buchholz, Ursula (NIAID) 2 152461129 Luongo, Cindy NIAID - DIR NIAID Luongo, Cindy (NIAID) 3 152461111 Respiratory Syncytial Virus (RSV) Expressing Green Fluorescent Protein (GFP) From An Added Gene In The Fifth-gene Position E-034-2014-0 Research Material NIAID 91021353 Pitts, Elizabeth elizabeth.pitts@nih.gov
United States of America elizabeth.pitts@nih.gov?subject=Web Inquiry on [TAB-4852] Optimizing RSV Infection Monitoring and High-Throughput Screening Through GFP Expression in the First-Gene Position of Respiratory Syncytial Virus (RSV) Strain A2&body=Please send me information about technology [TAB-4852] Optimizing RSV Infection Monitoring and High-Throughput Screening Through GFP Expression in the First-Gene Position of Respiratory Syncytial Virus (RSV) Strain A2. Pitts, Elizabeth<br><a href="mailto:elizabeth.pitts@nih.gov?subject=Web Inquiry on [TAB-4852] Optimizing RSV Infection Monitoring and High-Throughput Screening Through GFP Expression in the First-Gene Position of Respiratory Syncytial Virus (RSV) Strain A2&body=Please send me information about technology [TAB-4852] Optimizing RSV Infection Monitoring and High-Throughput Screening Through GFP Expression in the First-Gene Position of Respiratory Syncytial Virus (RSV) Strain A2.">elizabeth.pitts@nih.gov</a><br> TAB-4851 152460971 Enhanced GFP-Expressing Human Metapneumovirus (HMPV): A Versatile Tool for Virology Research and Antiviral Drug Screening NIAID Collaboration, Diagnostics, Infectious Disease, Licensing, Plasmids/Vectors, Research Equipment, Respiratory Collaboration Diagnostics Infectious Disease Licensing Plasmids/Vectors Research Equipment Respiratory Stephanie Biacchesi, Ursula Buchholz, Peter Collins <p>The technology involves genetically engineering Human Metapneumovirus (HMPV) to express enhanced green fluorescent protein (GFP), enabling the monitoring of virus infection and gene expression through GFP fluorescence. This system serves as a sensitive and versatile tool for virology research, antiviral drug screening, and diagnostic applications. Researchers can use it to study HMPV behavior in real-time, identify potential antiviral compounds, and quantify viral particles in samples, making it invaluable for advancing our understanding of HMPV infections and the development of antiviral interventions.</p> The incorporation of enhanced green fluorescent protein (GFP) into Human Metapneumovirus (HMPV) offers a competitive advantage by providing a precise and rapid method for monitoring virus infection. This technology enables real-time visualization, simplifies high-throughput screening for potential antiviral agents, and streamlines viral particle quantification through GFP-based assays. Its sensitivity and efficiency make it a valuable tool for advancing virology research and expediting antiviral drug discovery. Incorporating enhanced green fluorescent protein (GFP) into Human Metapneumovirus (HMPV) offers versatile applications, including virology research for infection mechanisms, high-throughput drug screening, sensitive diagnostics, and vaccine development. 2024-01-29 2025-08-13 2025-08-15 2024-12-10 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 152460992 Collins, Peter NIAID - DIR NIAID Collins, Peter (NIAID) 1 152461000 Buchholz, Ursula NIAID - DIR NIAID Buchholz, Ursula (NIAID) 2 152461011 Biacchesi, Stephanie Institut national de la recherche agronomique (INRA) NIAID Biacchesi, Stephanie (NIAID) 3 152460992 Collins, Peter NIAID - DIR NIAID Collins, Peter (NIAID) 1 152461000 Buchholz, Ursula NIAID - DIR NIAID Buchholz, Ursula (NIAID) 2 152461011 Biacchesi, Stephanie Institut national de la recherche agronomique (INRA) NIAID Biacchesi, Stephanie (NIAID) 3 152460974 Human Metapneumovirus (HMPV) Expressing Green Fluorescent Protein (GFP) At The First Position (HMPV-GFP1) From An Added Gene E-033-2014-0 Research Material NIAID 91021353 Pitts, Elizabeth elizabeth.pitts@nih.gov
United States of America elizabeth.pitts@nih.gov?subject=Web Inquiry on [TAB-4851] Enhanced GFP-Expressing Human Metapneumovirus (HMPV): A Versatile Tool for Virology Research and Antiviral Drug Screening&body=Please send me information about technology [TAB-4851] Enhanced GFP-Expressing Human Metapneumovirus (HMPV): A Versatile Tool for Virology Research and Antiviral Drug Screening. Pitts, Elizabeth<br><a href="mailto:elizabeth.pitts@nih.gov?subject=Web Inquiry on [TAB-4851] Enhanced GFP-Expressing Human Metapneumovirus (HMPV): A Versatile Tool for Virology Research and Antiviral Drug Screening&body=Please send me information about technology [TAB-4851] Enhanced GFP-Expressing Human Metapneumovirus (HMPV): A Versatile Tool for Virology Research and Antiviral Drug Screening.">elizabeth.pitts@nih.gov</a><br> TAB-4847 152411254 Development of a High-Throughput Screening Tool for RSV Inhibition Using Engineered RSV Expressing GFP and Luciferase Genes NIAID Collaboration, Diagnostics, Infectious Disease, Licensing, Research Equipment, Research Materials, Respiratory Collaboration Diagnostics Infectious Disease Licensing Research Equipment Research Materials Respiratory Peter Collins, Mark Peeples <p>The technology involves the genetic engineering of Respiratory Syncytial Virus (RSV) to express two additional genes, green fluorescent protein (GFP) and Renilla luciferase, from different positions within the viral genome. GFP serves as a visual marker for RSV infection, allowing researchers to monitor and track infected cells using fluorescence microscopy, while luciferase functions as a highly sensitive reporter gene that enables quantitative assessment of viral replication through enzymatic assays. The engineered RSV strain also contains a mutation in the RSV G protein, making it a valuable tool for high-throughput screening of potential antiviral compounds. This technology offers a sensitive and efficient method for studying RSV infection and screening for inhibitors, facilitating both basic research and drug development efforts related to RSV.</p> <p>&nbsp;</p> This technology offers a competitive edge by enabling real-time monitoring of RSV infection through the use of GFP and Renilla luciferase markers, allowing for precise and sensitive assessments of viral replication. The engineered RSV strain's safety features, such as a mutated RSV G protein, enhance laboratory safety. These advantages streamline RSV research and drug development efforts, making it a powerful tool for studying the virus and screening potential inhibitors. This technology has diverse potential applications in RSV research and antiviral drug development. It enables rapid screening of antiviral compounds, facilitates the study of RSV infection dynamics, and aids in evaluating vaccines and therapies. The GFP and luciferase markers offer real-time monitoring for investigating RSV replication and pathogenesis. Overall, this versatile technology enhances our understanding of RSV and accelerates efforts to combat this respiratory virus. 2024-01-25 2025-08-13 2025-08-15 2024-12-10 False True True 72159134 Analytical Assay Performance Stage 72159134 37470483 Website Abstract 152411274 Collins, Peter NIAID - DIR NIAID Collins, Peter (NIAID) 1 152411278 Peeples, Mark Nationwide Children's Hospital Peeples, Mark 2 152411274 Collins, Peter NIAID - DIR NIAID Collins, Peter (NIAID) 1 152411278 Peeples, Mark Nationwide Children's Hospital Peeples, Mark 2 152411257 Respiratory Syncytial Virus (RSV) Expressing Green Fluorescent Protein (GFP) And Luciferase From Added Genes E-032-2014-0 Research Material Nationwide Children's Hospital, NIAID 91021353 Pitts, Elizabeth elizabeth.pitts@nih.gov
United States of America elizabeth.pitts@nih.gov?subject=Web Inquiry on [TAB-4847] Development of a High-Throughput Screening Tool for RSV Inhibition Using Engineered RSV Expressing GFP and Luciferase Genes&body=Please send me information about technology [TAB-4847] Development of a High-Throughput Screening Tool for RSV Inhibition Using Engineered RSV Expressing GFP and Luciferase Genes. Pitts, Elizabeth<br><a href="mailto:elizabeth.pitts@nih.gov?subject=Web Inquiry on [TAB-4847] Development of a High-Throughput Screening Tool for RSV Inhibition Using Engineered RSV Expressing GFP and Luciferase Genes&body=Please send me information about technology [TAB-4847] Development of a High-Throughput Screening Tool for RSV Inhibition Using Engineered RSV Expressing GFP and Luciferase Genes.">elizabeth.pitts@nih.gov</a><br> TAB-4585 151762284 Radiotherapy and Imaging Agent-based on Peptide Conjugated to Novel Evans Blue Derivatives with Long Half-life and High Accumulation in Target Tissue NIBIB Diagnostics, Oncology, Research Equipment, Research Materials Diagnostics Oncology Research Equipment Research Materials Xiaoyuan (Shawn) Chen, Orit Jacobson weiss <p>This technology includes a newly designed, truncated Evans Blue (EB) form which allows labeling with metal isotopes for nuclear imaging and radiotherapy. Unlike previous designs, this new form of truncated EB confers site specific mono-labeling of desired molecules. The newly designed truncated EB form can be conjugated to various molecules including small molecules, peptides, proteins and aptamers to improve blood half-life and tumor uptake, and confer better imaging, therapy and radiotherapy. As a proof of concept, we chose to conjugate the new truncated EB to Arg-Gly-Asp (RGD) tripeptide, which binds to integrin avl33. lntegrin avl33 is a molecular marker for angiogenesis which is significantly upregulated in cancerous tissue and can be used as a target for therapy.</p> Compared to RGD alone, the EB-RGD has significantly higher half-life in the blood. Because RGD binding to avl33 induce peptide internalization into the cell, the higher half-life of EB-RGD in the blood result in about tenfold increase in peptide accumulation in target organ and low background. This product will be of use in nuclear imaging and radiotherapy of cancer as the EB derivative can be used for increasing the blood half-life of peptides and molecule. We are seeking statements of capability or interest from parties interested in collaborative research to further developer, evaluate, or commercialize this technology. 2023-12-12 2025-08-13 2025-08-15 2024-03-27 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 151762350 Chen, Xiaoyuan (Shawn) NIBIB NIBIB Chen, Xiaoyuan (Shawn) (NIBIB) 1 151762378 Jacobson weiss, Orit NIBIB NCI Jacobson weiss, Orit (NCI) 2 151762350 Chen, Xiaoyuan (Shawn) NIBIB NIBIB Chen, Xiaoyuan (Shawn) (NIBIB) 1 151762378 Jacobson weiss, Orit NIBIB NCI Jacobson weiss, Orit (NCI) 2 151762287 Radiotherapy And Imaging Agent Based On Peptide Conjugated To Novel Evans Blue Derivatives With Long Half-life And High Accumulation In Target Tissue E-150-2016-0 Filing authorized NIBIB 83656052 Knezevic, Vladimir vlado.knezevic@nih.gov
United States of America Technology Advancement Office vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-4585] Radiotherapy and Imaging Agent-based on Peptide Conjugated to Novel Evans Blue Derivatives with Long Half-life and High Accumulation in Target Tissue&body=Please send me information about technology [TAB-4585] Radiotherapy and Imaging Agent-based on Peptide Conjugated to Novel Evans Blue Derivatives with Long Half-life and High Accumulation in Target Tissue. Knezevic, Vladimir<br><a href="mailto:vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-4585] Radiotherapy and Imaging Agent-based on Peptide Conjugated to Novel Evans Blue Derivatives with Long Half-life and High Accumulation in Target Tissue&body=Please send me information about technology [TAB-4585] Radiotherapy and Imaging Agent-based on Peptide Conjugated to Novel Evans Blue Derivatives with Long Half-life and High Accumulation in Target Tissue.">vlado.knezevic@nih.gov</a><br> 157762644 E-150-2016-0 E-150-2016-0-CN-03 Chemical Conjugates of Evans Blue Derivatives and Their Use as Radiotherapy and Imaging Agents National Stage China ZL201780029003.X 201780029003.X Issued China <br />National Stage 201780029003.X<br />Filed on 2018-11-09<br />Status: Issued 157762649 E-150-2016-0 E-150-2016-0-EP-04 Chemical Conjugates of Evans Blue Derivatives and Their Use as Radiotherapy and Imaging Agents National Stage European Patent 3455206 17796666.0 Issued European Patent <br />National Stage 17796666.0<br />Filed on 2018-11-12<br />Status: Issued 157762654 E-150-2016-0 E-150-2016-0-JP-05 Chemical Conjugates of Evans Blue Derivatives and Their Use as Radiotherapy and Imaging Agents National Stage Japan 6946342 2018-558662 Issued Japan <br />National Stage 2018-558662<br />Filed on 2018-11-08<br />Status: Issued 157762659 E-150-2016-0 E-150-2016-0-US-06 CHEMICAL CONJUGATES OF EVANS BLUE DERIVATIVES AND THEIR USE AS RADIOTHERAPY AND IMAGING AGENTS National Stage US 10,696,631 16/099,488 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10696631 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10696631">10,696,631</a><br />Filed on 2018-11-07<br />Status: Issued 157762664 E-150-2016-0 E-150-2016-0-SG-07 Chemical Conjugates of Evans Blue Derivatives and Their Use as Radiotherapy and Imaging Agents National Stage Singapore 11201809982R 11201809982R Issued Singapore <br />National Stage 11201809982R<br />Filed on 2018-11-09<br />Status: Issued 157762669 E-150-2016-0 E-150-2016-0-CH-08 Chemical Conjugates of Evans Blue Derivatives and Their Use as Radiotherapy and Imaging Agents EP Switzerland 3455206 17796666.0 Issued Switzerland <br />European patent (EP) 17796666.0<br />Filed on 2018-11-12<br />Status: Issued 157762674 E-150-2016-0 E-150-2016-0-DE-09 Chemical Conjugates of Evans Blue Derivatives and Their Use as Radiotherapy and Imaging Agents EP Germany 3455206 17796666.0 Issued Germany <br />European patent (EP) 17796666.0<br />Filed on 2018-11-12<br />Status: Issued 157762679 E-150-2016-0 E-150-2016-0-FR-10 Chemical Conjugates of Evans Blue Derivatives and Their Use as Radiotherapy and Imaging Agents EP France 3455206 17796666.0 Issued France <br />European patent (EP) 17796666.0<br />Filed on 2018-11-12<br />Status: Issued 157762684 E-150-2016-0 E-150-2016-0-GB-11 Chemical Conjugates of Evans Blue Derivatives and Their Use as Radiotherapy and Imaging Agents EP United Kingdom 3455206 17796666.0 Issued United Kingdom <br />European patent (EP) 17796666.0<br />Filed on 2018-11-12<br />Status: Issued 157762689 E-150-2016-0 E-150-2016-0-IE-12 Chemical Conjugates of Evans Blue Derivatives and Their Use as Radiotherapy and Imaging Agents EP Ireland 3455206 17796666.0 Issued Ireland <br />European patent (EP) 17796666.0<br />Filed on 2018-11-12<br />Status: Issued 157762694 E-150-2016-0 E-150-2016-0-IT-13 Chemical Conjugates of Evans Blue Derivatives and Their Use as Radiotherapy and Imaging Agents EP Italy 3455206 17796666.0 Issued Italy <br />European patent (EP) 17796666.0<br />Filed on 2018-11-12<br />Status: Issued TAB-4544 151736796 Segmented, Braided MRI Catheter for Cardiovascular Procedures NHLBI Cardiology, Licensing, Medical Devices, Research Equipment Cardiology Licensing Medical Devices Research Equipment Ozgur Kocaturk, Robert Lederman <p>This technology includes a catheter design to be used for cardiovascular procedures. This catheter has intrinsic freedom from MRI heating by segmenting and insulating the braiding material, yet that retains most of the mechanical properties of a braided catheter aligning the segment interruptions out-of-phase with each other.</p> A catheter is a fundamental tool for cardiovascular procedures, and this braided device is intrinsically safe by design, almost as strong as conventional braided catheters, and inexpensive to manufacture. This can be a valuable component of a suite of inventions for passive design catheters and guidewires that could together serve the basis of a product line or vendor. We are seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. 2023-12-11 2025-08-13 2025-08-15 2024-03-20 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 151736803 Lederman, Robert National Heart, Lung, and Blood Institute (NHLBI) NHLBI Lederman, Robert (NHLBI) 1 151736813 Kocaturk, Ozgur Bogazici University Kocaturk, Ozgur 2 151736803 Lederman, Robert National Heart, Lung, and Blood Institute (NHLBI) NHLBI Lederman, Robert (NHLBI) 1 151736813 Kocaturk, Ozgur Bogazici University Kocaturk, Ozgur 2 151736799 Segmented Braided MRI Catheter E-284-2015-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-4544] Segmented, Braided MRI Catheter for Cardiovascular Procedures&body=Please send me information about technology [TAB-4544] Segmented, Braided MRI Catheter for Cardiovascular Procedures. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-4544] Segmented, Braided MRI Catheter for Cardiovascular Procedures&body=Please send me information about technology [TAB-4544] Segmented, Braided MRI Catheter for Cardiovascular Procedures.">shmilovm@nih.gov</a><br> 157756491 E-284-2015-0 E-284-2015-0-US-01 Segmented Braided MRI Catheter PRV US 62/219,472 Abandoned US <br />Provisional (PRV) 62/219,472<br />Filed on 2015-09-16<br />Status: Abandoned 157756496 E-284-2015-0 E-284-2015-0-PCT-02 SEGMENTED MRI CATHETERS AND OTHER INTERVENTIONAL DEVICES PCT Patent Cooperation Treaty PCT/US2016/051600 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2016/051600<br />Filed on 2016-09-14<br />Status: Expired 157756501 E-284-2015-0 E-284-2015-0-EP-03 SEGMENTED MRI CATHETERS AND OTHER INTERVENTIONAL DEVICES National Stage European Patent 16847168.8 Abandoned European Patent <br />National Stage 16847168.8<br />Filed on 2016-09-14<br />Status: Abandoned 157756506 E-284-2015-0 E-284-2015-0-US-04 SEGMENTED MRI CATHETERS AND OTHER INTERVENTIONAL DEVICES National Stage US 10,835,710 15/755,186 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10835710 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10835710">10,835,710</a><br />Filed on 2018-02-26<br />Status: Issued TAB-4541 151736144 Segmented Metallic MRI Guidewires Using Stiffness-matched Nonconductive Connectors for Catheterization Procedures NHLBI Cardiology, Licensing, Medical Devices, Research Equipment Cardiology Licensing Medical Devices Research Equipment Burcu Basar, Ozgur Kocaturk, Robert Lederman <p>This technology includes a metallic guidewire that is suitable for MRI catheterization, because it is mechanically long but electrically consists of short conductive segments that cannot resonate during MRI. The invention consists of stiffness-matched non-conductive connectors or connections that are used along with short metallic segments. The embodiment reduced to practice has torquability and flexibility comparable to marketed metallic guidewires, yet is free from MRI heating.</p> The solution is novel, useful, and non-obvious as it solves the problem of heating during radiofrequency excitation without the complexity of detuning and decoupling electronic circuitry, and is mechanically suitable as a guidewire, yet it is immune to heating under MRI at specified field strengths. A guidewire is a fundamental tool for catheter procedures; an MRI guidewire is a fundamentally enabling tool for MRI catheter procedures. We are seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. 2023-12-11 2025-08-13 2025-08-15 2024-03-20 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 151736156 Basar, Burcu National Heart, Lung, and Blood Institute (NHLBI) NHLBI Basar, Burcu (NHLBI) 1 151736169 Lederman, Robert National Heart, Lung, and Blood Institute (NHLBI) NHLBI Lederman, Robert (NHLBI) 2 151736185 Kocaturk, Ozgur Bogazici University Kocaturk, Ozgur 3 151736156 Basar, Burcu National Heart, Lung, and Blood Institute (NHLBI) NHLBI Basar, Burcu (NHLBI) 1 151736169 Lederman, Robert National Heart, Lung, and Blood Institute (NHLBI) NHLBI Lederman, Robert (NHLBI) 2 151736185 Kocaturk, Ozgur Bogazici University Kocaturk, Ozgur 3 151736147 Segmented Metallic MRI Guidewires Using Stiffness-matched Nonconductive Connectors E-253-2014-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-4541] Segmented Metallic MRI Guidewires Using Stiffness-matched Nonconductive Connectors for Catheterization Procedures&body=Please send me information about technology [TAB-4541] Segmented Metallic MRI Guidewires Using Stiffness-matched Nonconductive Connectors for Catheterization Procedures. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-4541] Segmented Metallic MRI Guidewires Using Stiffness-matched Nonconductive Connectors for Catheterization Procedures&body=Please send me information about technology [TAB-4541] Segmented Metallic MRI Guidewires Using Stiffness-matched Nonconductive Connectors for Catheterization Procedures.">shmilovm@nih.gov</a><br> 157756230 E-253-2014-0 E-253-2014-0-US-01 Segmented Metallic Guidewires PRV US 62/066,167 Abandoned US <br />Provisional (PRV) 62/066,167<br />Filed on 2014-10-20<br />Status: Abandoned 157756235 E-253-2014-0 E-253-2014-0-PCT-02 Segmented Metallic Guidewires PCT Patent Cooperation Treaty PCT/US2015/056266 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2015/056266<br />Filed on 2015-10-19<br />Status: Expired 157756240 E-253-2014-0 E-253-2014-0-EP-03 Segmented Metallic Guidewires National Stage European Patent 3209364 15787824.0 Issued European Patent <br />National Stage 15787824.0<br />Filed on 2015-10-19<br />Status: Issued 157756245 E-253-2014-0 E-253-2014-0-US-04 Segmented Metallic Guidewires National Stage US 10,695,540 15/514,744 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10695540 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10695540">10,695,540</a><br />Filed on 2017-03-27<br />Status: Issued 157756250 E-253-2014-0 E-253-2014-0-CH-05 Segmented Metallic Guidewires EP Switzerland 3209364 15787824.0 Issued Switzerland <br />European patent (EP) 15787824.0<br />Filed on 2015-10-19<br />Status: Issued 157756255 E-253-2014-0 E-253-2014-0-DE-06 Segmented Metallic Guidewires EP Germany 3209364 15787824.0 Issued Germany <br />European patent (EP) 15787824.0<br />Filed on 2015-10-19<br />Status: Issued 157756260 E-253-2014-0 E-253-2014-0-FR-07 Segmented Metallic Guidewires EP France 3209364 15787824.0 Issued France <br />European patent (EP) 15787824.0<br />Filed on 2015-10-19<br />Status: Issued 157756265 E-253-2014-0 E-253-2014-0-GB-08 Segmented Metallic Guidewires EP United Kingdom 3209364 15787824.0 Issued United Kingdom <br />European patent (EP) 15787824.0<br />Filed on 2015-10-19<br />Status: Issued 157756270 E-253-2014-0 E-253-2014-0-IE-09 Segmented Metallic Guidewires EP Ireland 3209364 15787824.0 Issued Ireland <br />European patent (EP) 15787824.0<br />Filed on 2015-10-19<br />Status: Issued TAB-4540 151735998 Expanded Claims for Transcatheter Coronary Sinus Mitral Valve Annuloplasty Procedure and Coronary Artery and Myocardial Protection NHLBI Cardiology, Licensing, Medical Devices Cardiology Licensing Medical Devices Robert Lederman <p>This technology includes a novel transcatheter repair for functional mitral valve regurgitation, called mitral cerclage annuloplasty. This includes coronary artery protection for mitral cerclage annuloplasty against inside-out compression from subsequent transcatheter valve-in-ring mitral valve implantation, wherein the ring is created by the cerclage annuloplasty. Cerclage annuloplasty is to create a semi-rigid ring at the level of the mitral annulus. The purpose of this ring is to create a &ldquo;landing zone&rdquo; for a percutaneous mitral valve implant, which guides positioning of the percutaneous transcatheter mitral valve and also allows the valve to use outward compression against the cerclage annuloplasty for fixation. The value in this invention is that the arch not only protects the artery against compression from the outer surface of the annuloplasty but it also protects against compression from the heart surface of the coronary artery &lsquo;inside-out&rdquo;, when a transcatheter aortic valve is implanted in relation to or in tandem with the cerclage annuloplasty.</p> At present there is heavy market interest in transcatheter mitral valve implantation. To be used to repair functional mitral valve regurgitation. We are seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. 2023-12-11 2025-08-13 2025-08-15 2024-03-20 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 151736083 Lederman, Robert National Heart, Lung, and Blood Institute (NHLBI) NHLBI Lederman, Robert (NHLBI) 1 151736083 Lederman, Robert National Heart, Lung, and Blood Institute (NHLBI) NHLBI Lederman, Robert (NHLBI) 1 151736001 Expanded Claims For Transcatheter Coronary Sinus Mitral Valve Annuloplasty Procedure And Coronary Artery And Myocardial Protection E-249-2006-3 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-4540] Expanded Claims for Transcatheter Coronary Sinus Mitral Valve Annuloplasty Procedure and Coronary Artery and Myocardial Protection&body=Please send me information about technology [TAB-4540] Expanded Claims for Transcatheter Coronary Sinus Mitral Valve Annuloplasty Procedure and Coronary Artery and Myocardial Protection. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-4540] Expanded Claims for Transcatheter Coronary Sinus Mitral Valve Annuloplasty Procedure and Coronary Artery and Myocardial Protection&body=Please send me information about technology [TAB-4540] Expanded Claims for Transcatheter Coronary Sinus Mitral Valve Annuloplasty Procedure and Coronary Artery and Myocardial Protection.">shmilovm@nih.gov</a><br> 157756204 E-249-2006-3 E-249-2006-3-US-01 Transcatheter Coronary Sinus Mitral Valve Annuloplasty Procedure and Coronary Artery and Myocardial Protection Device CIP US 9,943,409 15/056,599 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9943409 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9943409">9,943,409</a><br />Filed on 2016-02-29<br />Status: Abandoned 157756209 E-249-2006-3 E-249-2006-3-PCT-02 Transcatheter Coronary Sinus Mitral Valve Annuloplasty Procedure And Coronary Artery And Myocardial Protection Device PCT Patent Cooperation Treaty PCT/US2017/017367 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2017/017367<br />Filed on 2017-02-10<br />Status: Expired 157756214 E-249-2006-3 E-249-2006-3-US-09 Expanded Claims For Transcatheter Coronary Sinus Mitral Valve Annuloplasty Procedure And Coronary Artery And Myocardial Protection CON US 10,687,942 15/954,555 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10687942 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10687942">10,687,942</a><br />Filed on 2018-04-16<br />Status: Issued 157756219 E-249-2006-3 E-249-2006-3-US-10 Coronary Sinus Mitral Valve Annuloplasty Procedure And Coronary Artery And Myocardial Protection CON US 11,925,558 16/882,896 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11925558 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11925558">11,925,558</a><br />Filed on 2020-05-26<br />Status: Issued TAB-4535 151722135 Advanced Human Cell Line Technology for RSV Replication Complex Production and Antiviral Drug Discovery NIAID Human Cell Lines, Infectious Disease, Research Materials Human Cell Lines Infectious Disease Research Materials Ursula Buchholz, Peter Collins, Cyril Le Nouen, Joseph Marcotrigiano <p>This technology includes the NeurEx&reg; mobile application, a groundbreaking tool designed for neurologists to conduct and document neurological examinations efficiently. Deployed on iPads, it integrates with a secure, cloud-based database, automating the computation of four key disability scales used in neuroimmunology. The app&#39;s robust design enables precise mapping of neurological deficits, blending spatial distribution with quantitative assessments. Its effectiveness is underscored by a study involving 865 neurological exams, where the app&#39;s computed scales matched the accuracy of multiple sclerosis-trained clinicians. Crucially, NeurEx&reg; enhances the sensitivity and specificity in tracking disability progression, outperforming traditional scales like the EDSS. This makes it an invaluable asset not only in clinical settings but also in research and multicentric trials, offering a more economical and precise alternative to conventional documentation of neurological examinations.</p> This technology uniquely enables the high-yield production and purification of the RSV replication complex in human cells, paving the way for groundbreaking antiviral drug discovery and structural analysis of the virus. The technology holds promise for facilitating detailed structural studies of the RSV replication mechanism, advancing antiviral drug development, and potentially applying similar methods to other significant negative-sense RNA viruses like measles and ebola. 2023-12-10 2025-08-13 2025-08-15 2024-12-10 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 151722142 Le Nouen, Cyril NIAID - DIR NIAID Le Nouen, Cyril (NIAID) 1 151722146 Marcotrigiano, Joseph NIAID - DIR NIAID Marcotrigiano, Joseph (NIAID) 2 151722154 Buchholz, Ursula NIAID - DIR NIAID Buchholz, Ursula (NIAID) 3 151722159 Collins, Peter NIAID - DIR NIAID Collins, Peter (NIAID) 4 151722142 Le Nouen, Cyril NIAID - DIR NIAID Le Nouen, Cyril (NIAID) 1 151722146 Marcotrigiano, Joseph NIAID - DIR NIAID Marcotrigiano, Joseph (NIAID) 2 151722154 Buchholz, Ursula NIAID - DIR NIAID Buchholz, Ursula (NIAID) 3 151722159 Collins, Peter NIAID - DIR NIAID Collins, Peter (NIAID) 4 151722138 Generation Of A Human Cell Line That Constitutively Expresses Respiratory Syncytial Virus (RSV) Nucleocapsid (N), Phosphoprotein (P) And Polymerase (L) Proteins, And Purification Of The RSV Replication Complex E-235-2020-0 Research Material NIAID 91021353 Pitts, Elizabeth elizabeth.pitts@nih.gov
United States of America elizabeth.pitts@nih.gov?subject=Web Inquiry on [TAB-4535] Advanced Human Cell Line Technology for RSV Replication Complex Production and Antiviral Drug Discovery&body=Please send me information about technology [TAB-4535] Advanced Human Cell Line Technology for RSV Replication Complex Production and Antiviral Drug Discovery. Pitts, Elizabeth<br><a href="mailto:elizabeth.pitts@nih.gov?subject=Web Inquiry on [TAB-4535] Advanced Human Cell Line Technology for RSV Replication Complex Production and Antiviral Drug Discovery&body=Please send me information about technology [TAB-4535] Advanced Human Cell Line Technology for RSV Replication Complex Production and Antiviral Drug Discovery.">elizabeth.pitts@nih.gov</a><br> TAB-4528 151719911 Devices and Methods for Cerclage of Luminal Systems NHLBI Cardiology, Licensing, Medical Devices, Research Equipment Cardiology Licensing Medical Devices Research Equipment Christopher Bruce, Robert Lederman <p>This technology includes a family of transcatheter endovenous intramyocardial tether (MIRTH) procedures to impose myocardial constraint on the LV (MIRTH), LV and RV (SCIMITAR), and cardiac resynchronization procedures. Included is a set of advanced cardiac treatment technologies that focus on minimally invasive procedures for heart patients. The main technology is the transcatheter endovenous intramyocardial tether (MIRTH) procedure, which is designed to apply physical constraint to the left ventricle (LV) of the heart. This method aims to aid in the treatment of certain heart conditions by altering the mechanical environment of the heart muscle. Additionally, the technology encompasses cardiac resynchronization procedures, which are used to improve the timing of the heart&#39;s contractions, particularly beneficial for patients with heart failure. Overall, these technologies represent a significant advancement in cardiac care, emphasizing less invasive methods to manage and treat complex heart conditions.</p> This technology is a minimally invasive approach, offering targeted myocardial constraint and cardiac resynchronization, potentially reducing recovery times and complications compared to more invasive heart treatments. Used for treating a range of cardiac conditions, including heart failure and ventricular dysfunction, by improving cardiac efficiency and synchronization through less invasive methods. We are seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. 2023-12-08 2025-08-13 2025-08-15 2024-03-20 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 151719918 Lederman, Robert National Heart, Lung, and Blood Institute (NHLBI) NHLBI Lederman, Robert (NHLBI) 1 151720113 Bruce, Christopher National Heart, Lung, and Blood Institute (NHLBI) Bruce, Christopher 2 151719918 Lederman, Robert National Heart, Lung, and Blood Institute (NHLBI) NHLBI Lederman, Robert (NHLBI) 1 151720113 Bruce, Christopher National Heart, Lung, and Blood Institute (NHLBI) Bruce, Christopher 2 151719914 Devices And Methods For Cerclage Of Luminal Systems (MIRTH Tranmural) E-206-2020-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI), Transmural Systems, LLC 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-4528] Devices and Methods for Cerclage of Luminal Systems&body=Please send me information about technology [TAB-4528] Devices and Methods for Cerclage of Luminal Systems. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-4528] Devices and Methods for Cerclage of Luminal Systems&body=Please send me information about technology [TAB-4528] Devices and Methods for Cerclage of Luminal Systems.">shmilovm@nih.gov</a><br> 157755920 E-206-2020-0 E-206-2020-0-US-01 Devices And Methods For Cerclage Of Luminal Systems PRV US 63/050,270 Abandoned US <br />Provisional (PRV) 63/050,270<br />Filed on 2020-07-10<br />Status: Abandoned 157755931 E-206-2020-0 E-206-2020-0-PCT-02 Devices And Methods For Cerclage Of Luminal Systems PCT Patent Cooperation Treaty PCT/US2021/041310 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/041310<br />Filed on 2021-07-12<br />Status: Expired 157755936 E-206-2020-0 E-206-2020-0-JP-01 Devices And Methods For Cerclage Of Luminal Systems National Stage Japan 2023-500441 Pending Japan <br />National Stage 2023-500441<br />Filed on 2023-01-05<br />Status: Pending 157755946 E-206-2020-0 E-206-2020-0-CA-01 Devices And Methods For Cerclage Of Lumenal Systems National Stage Canada 3184823 Pending Canada <br />National Stage 3184823<br />Filed on 2023-01-03<br />Status: Pending 157755951 E-206-2020-0 E-206-2020-0-AU-01 Devices And Methods For Cerclage Of Luminal Systems National Stage Australia 2021304368 Pending Australia <br />National Stage 2021304368<br />Filed on 2021-07-12<br />Status: Pending 157755956 E-206-2020-0 E-206-2020-0-IL-01 Devices And Methods For Cerclage Of Luminal Systems National Stage Israel 299587 Pending Israel <br />National Stage 299587<br />Filed on 2022-12-29<br />Status: Pending 157755961 E-206-2020-0 E-206-2020-0-CN-01 Devices And Methods For Cerclage Of Luminal Systems National Stage China 202180049654.1 Pending China <br />National Stage 202180049654.1<br />Filed on 2023-01-06<br />Status: Pending 157755966 E-206-2020-0 E-206-2020-0-EP-01 Devices And Methods For Cerclage Of Luminal Systems National Stage European Patent 21837310.8 Pending European Patent <br />National Stage 21837310.8<br />Filed on 2021-07-12<br />Status: Pending 157755971 E-206-2020-0 E-206-2020-0-US-02 DEVICES AND METHODS FOR CERCLAGE OF LUMENAL SYSTEMS CON US 18/151,601 Pending US <br />Continuation (CON) 18/151,601<br />Filed on 2023-01-09<br />Status: Pending TAB-4524 151719490 LZK and DLK Inhibitors to Target LZK and Suppress MYC Expression, Inhibit AKT Activation, and Promote Cancer Cell Death and Tumor Regression NHLBI Licensing, Oncology, Research Materials, Therapeutics Licensing Oncology Research Materials Therapeutics John Brognard, Amy Funk, Carolyn Hitko, Katherine Nyswaner, Rolf Swenson <p>This technology includes the use of LZK and DLK inhibitors to be used for the treatment of head and neck squamous cell carcinoma (HNSCC) or lung squamous cell carcinoma (LSCC). Specifically, we demonstrate that inhibitors that can be repurposed to target LZK suppresses LZK kinase-dependent stabilization of MYC and activation of the PI3K/AKT pathway. In vivo preclinical cell line xenograft mouse model demonstrates that targeting LZK will suppress tumor growth. We also demonstrate that several additional compounds potently inhibit LZK and could serve as new therapeutic modalities.</p> We have discovered LZK as a novel therapeutic target in squamous cell carcinomas with amplified LZK; over 50% of HNSCC and LSCC patients have amplifications or gains in LZK. LZK inhibitors that serve as lead compounds could lead to new therapies for the treatment of LSCC and HNSCC and other cancers with amplified LZK that include prostate, ovarian and small cell lung cancer. We are seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. 2023-12-08 2024-08-12 2025-08-15 2024-03-20 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 151719498 Brognard, John National Cancer Institute (NCI) NCI Brognard, John (NCI) 1 151719620 Swenson, Rolf National Heart, Lung, and Blood Institute (NHLBI) NHLBI Swenson, Rolf (NHLBI) 2 151719624 Funk, Amy NCI - CCR NCI Funk, Amy (NCI) 3 151719628 Hitko, Carolyn National Heart, Lung, and Blood Institute (NHLBI) NHLBI Hitko, Carolyn (NHLBI) 4 151719632 Nyswaner, Katherine NCI - CCR NCI Nyswaner, Katherine (NCI) 5 151719498 Brognard, John National Cancer Institute (NCI) NCI Brognard, John (NCI) 1 151719620 Swenson, Rolf National Heart, Lung, and Blood Institute (NHLBI) NHLBI Swenson, Rolf (NHLBI) 2 151719624 Funk, Amy NCI - CCR NCI Funk, Amy (NCI) 3 151719628 Hitko, Carolyn National Heart, Lung, and Blood Institute (NHLBI) NHLBI Hitko, Carolyn (NHLBI) 4 151719632 Nyswaner, Katherine NCI - CCR NCI Nyswaner, Katherine (NCI) 5 151719493 DLK Inhibitors Can Be Repurposed To Target LZK And Suppress MYC Expression, Inhibit AKT Activation, And Promote Cancer Cell Death And Tumor Regression E-196-2020-0 Closed National Heart, Lung, and Blood Institute (NHLBI), NCI 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-4524] LZK and DLK Inhibitors to Target LZK and Suppress MYC Expression, Inhibit AKT Activation, and Promote Cancer Cell Death and Tumor Regression&body=Please send me information about technology [TAB-4524] LZK and DLK Inhibitors to Target LZK and Suppress MYC Expression, Inhibit AKT Activation, and Promote Cancer Cell Death and Tumor Regression. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-4524] LZK and DLK Inhibitors to Target LZK and Suppress MYC Expression, Inhibit AKT Activation, and Promote Cancer Cell Death and Tumor Regression&body=Please send me information about technology [TAB-4524] LZK and DLK Inhibitors to Target LZK and Suppress MYC Expression, Inhibit AKT Activation, and Promote Cancer Cell Death and Tumor Regression.">shmilovm@nih.gov</a><br> TAB-4503 151705287 Methods to Produce Very Long Chain Fatty Acids (VLCFA) for Use as Nutritional Formulas and as Therapeutics for Disease NHLBI Licensing, Therapeutics Licensing Therapeutics Alan Remaley, Zhen-Dan Shi, Rolf Swenson, Zhihong Yang <p>This technology includes a new method to prepare very long chain fatty acids (VLCFA), which does not use the previously reported toxic mercury amalgam, for use as nutritional supplements, and as therapeutics for various diseases. The key coupling step involves an organocopper mediated coupling of the Grignard regent derived from the bromo alkyl tetraene with a bromoalkyl containing a protected alcohol. After the coupling the alcohol Is deprotected and oxidized to prepare the very long fatty acid. The synthetic approach is flexible and can be used to prepare the other VLCFA compounds. Similar methods are used in the chemical industry for preparation of fine chemicals and should allow the synthesis of large quantities of material.</p> This robust synthetic approach that can be used to prepare these VLCPUFAs that doesn’t include toxic mercury and can be conducted at large scales. Our product with significantly high purity could be used as nutritional formulas and supplements, and as therapeutics for various diseases, disorders, and conditions. We are seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. 2023-12-07 2025-08-13 2025-08-15 2024-03-27 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 151705373 Swenson, Rolf National Heart, Lung, and Blood Institute (NHLBI) NHLBI Swenson, Rolf (NHLBI) 1 151705377 Shi, Zhen-Dan National Heart, Lung, and Blood Institute (NHLBI) NHLBI Shi, Zhen-Dan (NHLBI) 2 151705381 Yang, Zhihong National Heart, Lung, and Blood Institute (NHLBI) Yang, Zhihong 3 151705386 Remaley, Alan National Heart, Lung, and Blood Institute (NHLBI) NHLBI Remaley, Alan (NHLBI) 4 151705373 Swenson, Rolf National Heart, Lung, and Blood Institute (NHLBI) NHLBI Swenson, Rolf (NHLBI) 1 151705377 Shi, Zhen-Dan National Heart, Lung, and Blood Institute (NHLBI) NHLBI Shi, Zhen-Dan (NHLBI) 2 151705381 Yang, Zhihong National Heart, Lung, and Blood Institute (NHLBI) Yang, Zhihong 3 151705386 Remaley, Alan National Heart, Lung, and Blood Institute (NHLBI) NHLBI Remaley, Alan (NHLBI) 4 151705369 Methods To Produce Very Long Chain Fatty Acids (VLCFA) E-126-2020-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 153929528 Ghosh, Malabika malabika.ghosh@nih.gov
United States of America malabika.ghosh@nih.gov?subject=Web Inquiry on [TAB-4503] Methods to Produce Very Long Chain Fatty Acids (VLCFA) for Use as Nutritional Formulas and as Therapeutics for Disease&body=Please send me information about technology [TAB-4503] Methods to Produce Very Long Chain Fatty Acids (VLCFA) for Use as Nutritional Formulas and as Therapeutics for Disease. Ghosh, Malabika<br><a href="mailto:malabika.ghosh@nih.gov?subject=Web Inquiry on [TAB-4503] Methods to Produce Very Long Chain Fatty Acids (VLCFA) for Use as Nutritional Formulas and as Therapeutics for Disease&body=Please send me information about technology [TAB-4503] Methods to Produce Very Long Chain Fatty Acids (VLCFA) for Use as Nutritional Formulas and as Therapeutics for Disease.">malabika.ghosh@nih.gov</a><br> 157755067 E-126-2020-0 E-126-2020-0-US-01 Methods To Produce Very Long Chain Fatty Acids (VLCFA) PRV US 63/072,519 Abandoned US <br />Provisional (PRV) 63/072,519<br />Filed on 2020-08-31<br />Status: Abandoned 157755072 E-126-2020-0 E-126-2020-0-PCT-02 Methods To Produce Very Long Chain Fatty Acids (VLCFA) PCT Patent Cooperation Treaty PCT/US2021/048390 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/048390<br />Filed on 2021-08-31<br />Status: Expired 157755077 E-126-2020-0 E-126-2020-0-US-02 Methods To Produce Very Long Chain Fatty Acids (VLCFA) National Stage US 18/042,743 Pending US <br />National Stage 18/042,743<br />Filed on 2023-02-23<br />Status: Pending 157755082 E-126-2020-0 E-126-2020-0-IL-01 Methods To Produce Very Long Chain Fatty Acids (VLCFA) National Stage Israel 300768 Pending Israel <br />National Stage 300768<br />Filed on 2023-02-19<br />Status: Pending 157755087 E-126-2020-0 E-126-2020-0-EP-01 Methods To Produce Very Long Chain Fatty Acids (VLCFA) National Stage European Patent 21862955.8 Pending European Patent <br />National Stage 21862955.8<br />Filed on 2023-02-28<br />Status: Pending TAB-4488 151702582 Systems and Methods for Applying Pressure to the Heart for the Treatment of Tricuspid Valve Regurgitation NHLBI Cardiology, Licensing, Medical Devices, Research Equipment Cardiology Licensing Medical Devices Research Equipment Neal Fearnot, Shaun Gittard, William Havel, Jeremy Newkirk <p>This technology includes structures and methods for cinching a band around the heart for treating conditions including tricuspid valve regurgitation (TR). When positioned appropriately along the atrioventricular groove, the band is tightened around the heart which narrows the tricuspid annulus and relieves TR.</p> Method minimizes any risk of coronary compression (unintended compression of vessels to limit or prevent flow). To be used for the treatment of tricuspid valve regurgitation. We are seeking statements of capability or interest from parties interested in collaborative research to further developer, evaluate, or commercialize this technology. 2023-12-07 2025-08-13 2025-08-15 2024-03-20 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 151702589 Havel, William Cook Medical Technologies LLC Havel, William 1 151702594 Fearnot, Neal Muffin Incorporated Fearnot, Neal 2 151702600 Newkirk, Jeremy Cook Medical Technologies LLC Newkirk, Jeremy 3 151702877 Gittard, Shaun Cook Medical Technologies LLC Gittard, Shaun 4 151702589 Havel, William Cook Medical Technologies LLC Havel, William 1 151702594 Fearnot, Neal Muffin Incorporated Fearnot, Neal 2 151702600 Newkirk, Jeremy Cook Medical Technologies LLC Newkirk, Jeremy 3 151702877 Gittard, Shaun Cook Medical Technologies LLC Gittard, Shaun 4 151702585 Systems And Methods For Applying Pressure To A Bodily Organ E-076-2021-0 Filing authorized Cook Medical Technologies LLC 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-4488] Systems and Methods for Applying Pressure to the Heart for the Treatment of Tricuspid Valve Regurgitation&body=Please send me information about technology [TAB-4488] Systems and Methods for Applying Pressure to the Heart for the Treatment of Tricuspid Valve Regurgitation. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-4488] Systems and Methods for Applying Pressure to the Heart for the Treatment of Tricuspid Valve Regurgitation&body=Please send me information about technology [TAB-4488] Systems and Methods for Applying Pressure to the Heart for the Treatment of Tricuspid Valve Regurgitation.">shmilovm@nih.gov</a><br> 157754411 E-076-2021-0 E-076-2021-0-US-01 Systems And Methods For Applying Pressure To A Bodily Organ PRV US 62/906,399 Abandoned US <br />Provisional (PRV) 62/906,399<br />Filed on 2019-09-26<br />Status: Abandoned 157754416 E-076-2021-0 E-076-2021-0-PCT-02 Systems And Methods For Applying Pressure To A Bodily Organ PCT Patent Cooperation Treaty PCT/US2020/052690 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2020/052690<br />Filed on 2020-09-25<br />Status: Expired 157754421 E-076-2021-0 E-076-2021-0-US-03 Systems And Methods For Applying Pressure To A Bodily Organ ORD US 12,213,881 17/032,283 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12213881 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12213881">12,213,881</a><br />Filed on 2020-09-25<br />Status: Issued TAB-4487 151702511 Isotopes of Alpha Ketoglutarate and Related Compounds for Hyperpolarized MRI Imaging NHLBI Computational models/software, Diagnostics, Licensing, Oncology, Research Equipment, Software / Apps Computational models/software Diagnostics Licensing Oncology Research Equipment Software / Apps Deepak Sail, Rolf Swenson <p>This technology includes 1-13C-ketoglutarate which can be used for imaging the conversion to hydroxyglutarate (HG) or Gln in cancer cells with an IDH1 mutations by hyperpolarized MRI. The ability to detect the status of IDH1 mutations is clinically prognostic for multiple cancers. These exciting observations are limited by two factors, the major one being that the natural abundance of 13C at position C5 overlaps with 1-13C-2-hydroxyglutarate peak, which limits the sensitivity of analysis and prevents simultaneous observations of HG and Gln formation. The other issue is that the ketoglutarate is not cell permeable. This invention provides a solution and enhances the utility of this imaging approach.</p> An improved hyperpolarized MRI tracer for prognostic imaging of cancer. Diagnostic imaging agent with potential for validating cancer treatment options. We are seeking statements of capability or interest from parties interested in collaborative research to further developer, evaluate, or commercialize this technology. 2023-12-07 2025-08-13 2025-08-15 2024-03-27 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 151702518 Swenson, Rolf National Heart, Lung, and Blood Institute (NHLBI) NHLBI Swenson, Rolf (NHLBI) 1 151702522 Sail, Deepak National Heart, Lung, and Blood Institute (NHLBI) NHLBI Sail, Deepak (NHLBI) 2 151702518 Swenson, Rolf National Heart, Lung, and Blood Institute (NHLBI) NHLBI Swenson, Rolf (NHLBI) 1 151702522 Sail, Deepak National Heart, Lung, and Blood Institute (NHLBI) NHLBI Sail, Deepak (NHLBI) 2 151702514 Isotopes Of Alpha Ketoglutarate And Related Compounds For Hyperpolarized MRI Imaging E-070-2020-0 Filing authorized National Cancer Institute (NCI), National Heart, Lung, and Blood Institute (NHLBI), National Heart, Lung, and Blood Institute (NHLBI), Radiation Biology Branch 153929528 Ghosh, Malabika malabika.ghosh@nih.gov
United States of America malabika.ghosh@nih.gov?subject=Web Inquiry on [TAB-4487] Isotopes of Alpha Ketoglutarate and Related Compounds for Hyperpolarized MRI Imaging&body=Please send me information about technology [TAB-4487] Isotopes of Alpha Ketoglutarate and Related Compounds for Hyperpolarized MRI Imaging. Ghosh, Malabika<br><a href="mailto:malabika.ghosh@nih.gov?subject=Web Inquiry on [TAB-4487] Isotopes of Alpha Ketoglutarate and Related Compounds for Hyperpolarized MRI Imaging&body=Please send me information about technology [TAB-4487] Isotopes of Alpha Ketoglutarate and Related Compounds for Hyperpolarized MRI Imaging.">malabika.ghosh@nih.gov</a><br> 157754378 E-070-2020-0 E-070-2020-0-US-01 Isotopes Of Alpha Ketoglutarate And Related Compounds For Hyperpolarized MRI Imaging PRV US 62/962,473 Abandoned US <br />Provisional (PRV) 62/962,473<br />Filed on 2020-01-17<br />Status: Abandoned 157754383 E-070-2020-0 E-070-2020-0-PCT-02 ISOTOPES OF ALPHA KETOGLUTARATE AND RELATED COMPOUNDS FOR HYPERPOLARIZED IMAGING PCT Patent Cooperation Treaty PCT/US2021/013658 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/013658<br />Filed on 2021-01-15<br />Status: Expired 157754388 E-070-2020-0 E-070-2020-0-EP-03 ISOTOPES OF ALPHA KETOGLUTARATE AND RELATED COMPOUNDS FOR HYPERPOLARIZED IMAGING National Stage European Patent 21741941.5 Pending European Patent <br />National Stage 21741941.5<br />Filed on 2021-01-15<br />Status: Pending 157754393 E-070-2020-0 E-070-2020-0-IL-04 ISOTOPES OF ALPHA KETOGLUTARATE AND RELATED COMPOUNDS AND THEIR USE IN HYPERPOLARIZED IMAGING National Stage Israel 294464 Pending Israel <br />National Stage 294464<br />Filed on 2022-07-03<br />Status: Pending 157754398 E-070-2020-0 E-070-2020-0-US-05 ISOTOPES OF ALPHA KETOGLUTARATE AND RELATED COMPOUNDS AND THEIR USE IN HYPERPOLARIZED IMAGING National Stage US 17/793,089 Pending US <br />National Stage 17/793,089<br />Filed on 2022-07-15<br />Status: Pending TAB-4481 151644566 Compositions and Methods for Reducing Serum Triglycerides NHLBI Cardiology, Licensing, Research Materials, Therapeutics, Vaccines Cardiology Licensing Research Materials Therapeutics Vaccines Marcelo Amar, Bryce Chackerian, Alexandra Fowler, Alan Remaley <p>This technology includes a vaccine for lowering plasma triglycerides by inducing the formation of autoantibodies against either ANGPTL3 or ANGPTL4, which are inhibitors of Lipoprotein Lipase. This was done by conjugating synthetic peptides based on ANGPTL3 or ANGPTL4 to virus- like particles (VLPS). Injection of the vaccine in animal models was shown to induce the autoantibody against the target and to lower plasma triglycerides.</p> The vaccine strategy for lowering plasma triglycerides is novel and could represent a low-cost alternative to drug therapy. Development into a novel therapy for lowering plasma triglycerides. We are seeking statements of capability or interest from parties interested in collaborative research to further developer, evaluate, or commercialize this technology. 2023-12-06 2024-08-12 2025-08-15 2024-03-20 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 151644600 Fowler, Alexandra University of New Mexico Fowler, Alexandra 1 151644608 Remaley, Alan National Heart, Lung, and Blood Institute (NHLBI) NHLBI Remaley, Alan (NHLBI) 2 151644612 Amar, Marcelo National Heart, Lung, and Blood Institute (NHLBI) NHLBI Amar, Marcelo (NHLBI) 3 151644616 Chackerian, Bryce University of New Mexico Health Science Center [US] Chackerian, Bryce 4 151644600 Fowler, Alexandra University of New Mexico Fowler, Alexandra 1 151644608 Remaley, Alan National Heart, Lung, and Blood Institute (NHLBI) NHLBI Remaley, Alan (NHLBI) 2 151644612 Amar, Marcelo National Heart, Lung, and Blood Institute (NHLBI) NHLBI Amar, Marcelo (NHLBI) 3 151644616 Chackerian, Bryce University of New Mexico Health Science Center [US] Chackerian, Bryce 4 151644569 Compositions And Methods For Reducing Serum Triglycerides E-054-2019-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI), University of New Mexico 153929528 Ghosh, Malabika malabika.ghosh@nih.gov
United States of America malabika.ghosh@nih.gov?subject=Web Inquiry on [TAB-4481] Compositions and Methods for Reducing Serum Triglycerides&body=Please send me information about technology [TAB-4481] Compositions and Methods for Reducing Serum Triglycerides. Ghosh, Malabika<br><a href="mailto:malabika.ghosh@nih.gov?subject=Web Inquiry on [TAB-4481] Compositions and Methods for Reducing Serum Triglycerides&body=Please send me information about technology [TAB-4481] Compositions and Methods for Reducing Serum Triglycerides.">malabika.ghosh@nih.gov</a><br> TAB-4474 151147722 Base-Covered HIV-1 Envelope Ectodomains and Their Use NIAID Cheng Cheng, Peter Kwong, John Mascola, Adam Olia, Reda Rawi, Yongping Yang, Tongqing Zhou <p>Researchers at the Vaccine Research Center (&ldquo;VRC&rdquo;) of the National Institute of Allergy and Infectious Diseases (&ldquo;NAID&rdquo;) continue to pursue a safe and effective HIV-1 vaccine to combat the HIV-1/AIDS pandemic. </p> <p><strong style="font-weight:bold"> To this end, researchers have engineered the soluble HIV-1 ectodomain trimer so that it is stabilized in its prefusion conformation by artificial disulfides, helix-disrupting prolines, and other structure-based alterations. However, mice and non-human primates immunized with these engineered soluble HIV-1 trimers produced a significant (>90% in some cases) immune response to the exposed trimer base.</strong></p> <p><strong style="font-weight:bold"> VRC researchers further modified the engineered prefusion soluble HIV-1 trimers by adding N-linked glycans to specific sites on the protein&rsquo;s base to block this immunodominant surface. They found that these N-linked glycans did reduce production of non-neutralizing antibodies directed to the trimer base. These soluble, glycan-masked prefusion HIV-1 trimers are envisioned as being a part of a heterologous prime-boost vaccine regimen.</strong></p> <p> This technology is available for licensing for commercial development in accordance with 35 U.S.C. &sect; 209 and 37 CFR Part 404, as well as further development and evaluation under a research collaboration.</p> Currently, no licensed HIV vaccine exists <li>Vaccine for prevention of HIV-1 infection</li> <li>Therapeutic vaccine for treatment of HIV-1 infection</li> 2023-11-01 2025-08-13 2025-08-15 2023-11-07 False False Animal Studies True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 151148328 Publications: Olia, et al. (2023) Soluble prefusion-closed HIV-envelope trimers with glycan-covered bases. iScience 26, 107403, August 18, 2023. DOI: https://doi.org/10.1016/j.sci.2023.107403 Publications: Olia, et al. (2023) Soluble prefusion-closed HIV-envelope trimers with glycan-covered bases. iScience 26, 107403, August 18, 2023. DOI: https://doi.org/10.1016/j.sci.2023.107403 151147900 Kwong, Peter NIH - NIAID NIAID Kwong, Peter (NIAID) 1 151147916 Mascola, John NIH - NIAID NIAID Mascola, John (NIAID) 2 151147922 Zhou, Tongqing NIH - NIAID NIAID Zhou, Tongqing (NIAID) 3 151147932 Olia, Adam NIH - NIAID NIAID Olia, Adam (NIAID) 4 151147936 Rawi, Reda NIAID - VRC NIAID Rawi, Reda (NIAID) 5 151147940 Yang, Yongping NIH - NIAID NIAID Yang, Yongping (NIAID) 6 151147987 Cheng, Cheng NIH - NIAID NIAID Cheng, Cheng (NIAID) 7 151147900 Kwong, Peter NIH - NIAID NIAID Kwong, Peter (NIAID) 1 151147916 Mascola, John NIH - NIAID NIAID Mascola, John (NIAID) 2 151147922 Zhou, Tongqing NIH - NIAID NIAID Zhou, Tongqing (NIAID) 3 151147932 Olia, Adam NIH - NIAID NIAID Olia, Adam (NIAID) 4 151147936 Rawi, Reda NIAID - VRC NIAID Rawi, Reda (NIAID) 5 151147940 Yang, Yongping NIH - NIAID NIAID Yang, Yongping (NIAID) 6 151147987 Cheng, Cheng NIH - NIAID NIAID Cheng, Cheng (NIAID) 7 151147726 Base-Covered Soluble HIV-1 Envelope Trimers E-079-2022-0 Filing authorized NIAID 91025211 Rainwater, Charles crainwater@mail.nih.gov
United States of America crainwater@mail.nih.gov?subject=Web Inquiry on [TAB-4474] Base-Covered HIV-1 Envelope Ectodomains and Their Use&body=Please send me information about technology [TAB-4474] Base-Covered HIV-1 Envelope Ectodomains and Their Use. Rainwater, Charles<br><a href="mailto:crainwater@mail.nih.gov?subject=Web Inquiry on [TAB-4474] Base-Covered HIV-1 Envelope Ectodomains and Their Use&body=Please send me information about technology [TAB-4474] Base-Covered HIV-1 Envelope Ectodomains and Their Use.">crainwater@mail.nih.gov</a><br> TAB-4452 147157747 CNS Therapeutics That Target Neuronal Ceroid-Lipofuscinoses and Thioesterase Deficiency Disorders NICHD Collaboration, Licensing, Therapeutics Collaboration Licensing Therapeutics Anil Mukherjee, Chinmoy Sarkar, Gary Zhongjian Zhang <p>Clinically known as Neuronal Ceroid-Lipofuscinoses (NCL), Batten disease, is a rare neuron killing disease and one of the lysosomal storage disorders (LSDs).  It is associated with a mutation or lack of palmitoyl-protein thioesterase-1 (PPT1) gene. It manifests very early in a child's life causing absence of brain activity as early as 4 years of age.</p> <p><a href="http://irp.nih.gov/pi/anil-mukherjee" target="_blank" rel="nofollow">Dr. Mukherje of NICHD</a> has discovered and developed N-t-BuHA, a chemical derivative of hydroxylamine that mimics the action of PPT1 enzyme.  Compared to hydroxylamine, N-t-BuHA has been shown to be non-toxic in mice expressing batten disease.  In addition, NtBuHA exhibited potent antioxidant property and extended the life of the diseased mice. NtBuHA has shown promising therapeutic potential to treat NCL-LSDs. </p> <h2>Competitive Advantages:</h2> <ul><li>First of its kind to treat INCL and other LSD</li> <li>Non-toxic dertivative therapeutic against thioesterase deficiency disorders</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Small molecule therapeutic for neuronal ceroid-lipfuscinoese</li> <li>Small molecule to treat or prevent thioesterase deficiency disorders.</li> </ul> 2016-02-16 2025-04-22 2018-11-09 2025-08-15 2016-08-30 lysosomal storage disorders (LSD), lysosome, Neuronal Ceroid-Lipofuscinoses (NCL), Non-toxic derivative of hydroxylamine, Palmitoyl-protein thioesterase False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2018-11-09 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147161925 Sarkar, C., et al. http://www.ncbi.nlm.nih.gov/pubmed/24056696 <a href="http://www.ncbi.nlm.nih.gov/pubmed/24056696">Sarkar, C., et al.</a> 147164786 Mukherjee, Anil NIH - NICHD NICHD Mukherjee, Anil (NICHD) 1 147164788 Sarkar, Chinmoy NIH - NICHD NICHD Sarkar, Chinmoy (NICHD) 2 147164787 Zhang, Gary Zhongjian NIH - NICHD NICHD Zhang, Gary Zhongjian (NICHD) 3 147164786 Mukherjee, Anil NIH - NICHD NICHD Mukherjee, Anil (NICHD) 1 147164788 Sarkar, Chinmoy NIH - NICHD NICHD Sarkar, Chinmoy (NICHD) 2 147164787 Zhang, Gary Zhongjian NIH - NICHD NICHD Zhang, Gary Zhongjian (NICHD) 3 147158095 Small Molecules (Derivatives Of Hydroxylamine) As Therapeutic Agents For Disorders Caused By Thioesterase Deficiency E-157-2011-0 Filing authorized NICHD 83746064 Whitman, Nathan nathan.whitman@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC nathan.whitman@nih.gov?subject=Web Inquiry on [TAB-4452] CNS Therapeutics That Target Neuronal Ceroid-Lipofuscinoses and Thioesterase Deficiency Disorders&body=Please send me information about technology [TAB-4452] CNS Therapeutics That Target Neuronal Ceroid-Lipofuscinoses and Thioesterase Deficiency Disorders.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Whitman, Nathan<br><a href="mailto:nathan.whitman@nih.gov?subject=Web Inquiry on [TAB-4452] CNS Therapeutics That Target Neuronal Ceroid-Lipofuscinoses and Thioesterase Deficiency Disorders&body=Please send me information about technology [TAB-4452] CNS Therapeutics That Target Neuronal Ceroid-Lipofuscinoses and Thioesterase Deficiency Disorders.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">nathan.whitman@nih.gov</a><br> 147161112 E-157-2011-0 E-157-2011-0-US-04 Small Molecule Therapeutic Compounds Targeting Thioesterase Deficiency Disorders And Methods Of Using The Same National Stage US 9,629,816 14/110,393 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9629816 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9629816">9,629,816</a><br />Filed on 2013-10-07<br />Status: Issued 147168992 E-157-2011-0 E-157-2011-0-US-01 Small Molecule (Derivatives Of Hydroxylamine) Therapeutic Compounds Targeting Thioesterase Deficiency Disorders And Methods of Using The Same PRV US 61/473,692 Abandoned US <br />Provisional (PRV) 61/473,692<br />Filed on 2011-04-08<br />Status: Abandoned 147168993 E-157-2011-0 E-157-2011-0-PCT-02 Small Molecule Therapeutic Compounds Targeting Thioesterase Deficiency Disorders and Methods of Using the Same PCT Patent Cooperation Treaty PCT/US2012/32772 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2012/32772<br />Filed on 2012-04-09<br />Status: Expired 147168994 E-157-2011-0 E-157-2011-0-EP-03 Small Molecule Therapeutic Compounds Targeting Thioesterase Deficiency Disorders and Methods of Using the Same National Stage European Patent 2694047 12716889.6 Issued European Patent <br />National Stage 12716889.6<br />Filed on 2012-04-09<br />Status: Issued 147168995 E-157-2011-0 E-157-2011-0-US-05 SMALL MOLECULE THERAPEUTIC COMPOUNDS TARGETING THIOESTERASE DEFICIENCY DISORDERS AND METHODS OF USING THE SAME DIV US 15/458,234 Abandoned US <br />Divisional (DIV) 15/458,234<br />Filed on 2017-03-14<br />Status: Abandoned 147168996 E-157-2011-0 E-157-2011-0-US-06 SMALL MOLECULE THERAPEUTIC COMPOUNDS TARGETING THIOESTERASE DEFICIENCY DISORDERS AND METHODS OF USING THE SAME CON US 16/020,392 Abandoned US <br />Continuation (CON) 16/020,392<br />Filed on 2018-06-27<br />Status: Abandoned 147168997 E-157-2011-0 E-157-2011-0-DE-07 Small Molecule Therapeutic Compounds Targeting Thioesterase Deficiency Disorders and Methods of Using the Same EP Germany 2694047 12716889.6 Issued Germany <br />European patent (EP) 12716889.6<br />Filed on 2013-11-07<br />Status: Issued 147168998 E-157-2011-0 E-157-2011-0-DK-08 Small Molecule Therapeutic Compounds Targeting Thioesterase Deficiency Disorders and Methods of Using the Same EP Denmark 2694047 12716889.6 Issued Denmark <br />European patent (EP) 12716889.6<br />Filed on 2013-11-07<br />Status: Issued 147168999 E-157-2011-0 E-157-2011-0-FI-09 Small Molecule Therapeutic Compounds Targeting Thioesterase Deficiency Disorders and Methods of Using the Same EP Finland 2694047 12716889.6 Issued Finland <br />European patent (EP) 12716889.6<br />Filed on 2013-11-07<br />Status: Issued 147169000 E-157-2011-0 E-157-2011-0-GB-10 Small Molecule Therapeutic Compounds Targeting Thioesterase Deficiency Disorders and Methods of Using the Same EP United Kingdom 2694047 12716889.6 Issued United Kingdom <br />European patent (EP) 12716889.6<br />Filed on 2013-11-07<br />Status: Issued 147169001 E-157-2011-0 E-157-2011-0-SE-11 Small Molecule Therapeutic Compounds Targeting Thioesterase Deficiency Disorders and Methods of Using the Same EP Sweden 2694047 12716889.6 Issued Sweden <br />European patent (EP) 12716889.6<br />Filed on 2013-11-07<br />Status: Issued 147172515 lysosomal storage disorders (LSD) 147172517 lysosome 147172519 Neuronal Ceroid-Lipofuscinoses (NCL) 147172521 Non-toxic derivative of hydroxylamine 147172523 Palmitoyl-protein thioesterase TAB-4438 147157733 T-Cell Immunotherapy that Targets Aggressive Epithelial Tumors NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Christian Hinrichs, Sanja Stevanovic <p>Metastatic cancers cause up to 90% of cancer deaths, yet few treatment options exist for patients with metastatic disease. Adoptive transfer of T cells that express tumor-reactive T-cell receptors (TCRs) has been shown to mediate regression of metastatic cancers in some patients. Unfortunately, identification of antigens expressed solely by cancer cells and not normal tissues has been a major challenge for the development of T-cell based immunotherapies. Thus, it is essential to find novel target antigens differentially expressed in cancer versus normal tissues.</p> <p>Inventors at the National Cancer Institute (NCI) have developed a TCR that specifically targets the Kita-Kyushu Lung Cancer Antigen 1 (KK-LC-1) 52-60 epitope. KK-LC-1 antigen (encoded by the CT83 gene) is highly expressed by several common and aggressive epithelial tumor types. Importantly, KK-LC-1 is expressed at very low levels in normal tissues and not in those tissues vital for survival. This expression profile makes KK-LC-1</p> <p>an attractive target for T-cell based, anti-cancer therapies.</p> <p>This TCR may be used to genetically modify peripheral blood lymphocytes (T cells) from eligible patients. After expansion, these genetically modified T cells can be used to treat patients. It may also be possible to use portions of the KK-LC-1 TCR in chimeric proteins for cancer therapy and/or antigen detection assays. This technology is currently being evaluated in clinical trials at the NCI and at Rutgers Cancer Institute of New Jersey.</p> <p>NCI&rsquo;s Center for Immuno-Oncology seeks licensees and/or co-development partners for a T-cell immunotherapy that targets KK-LC-1 for use in the treatment of epithelial cancers.</p> <p>&nbsp;</p> <h2>Commercial Applications:</h2> <ul> <li>Therapeutic against several common and aggressive epithelial tumor types &ndash; such as ovarian cancer</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Differential expression profile of KK-LC-1 suggests that therapy with a specific KK-LC-1 TCR could be cancer-specific and would not damage normal tissues</li> <li>The repertoire of targetable epithelial antigens for TCR-T cell therapy is larger than for CAR-T cells</li> <li>Increased sensitivity may improve tumor cell detection and killing versus CAR-T cells, due to lower epitope density required for activation</li> <li>Higher avidity and lower affinity could result in each TCR-T cell destroying numerous antigen-presenting cancer cells</li> <li>Thousands of cancer patients each year with otherwise untreatable disease may be eligible for immunotherapy with this TCR</li> </ul> <h2>&nbsp;</h2> <ul> </ul> Researchers at the NCI seek licensing and/or co-development research collaborations for T-cell immunotherapy that targets KK-LC-1 for use in the treatment of epithelial cancers. 2017-03-02 2025-04-22 2024-02-09 2025-08-15 2017-03-02 CT83, Immunotherapy, Kita-Kyushu Lung Cancer Antigen, KK-LC-1, T-Cell Receptor, TCR, Testis False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2024-02-09 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147164742 Stevanovic, Sanja NIH - NCI NCI Stevanovic, Sanja (NCI) 1 147164741 Hinrichs, Christian NIH - NCI Hinrichs, Christian 2 147164742 Stevanovic, Sanja NIH - NCI NCI Stevanovic, Sanja (NCI) 1 147164741 Hinrichs, Christian NIH - NCI Hinrichs, Christian 2 147158090 T-cell Receptor Targeting The Cancer/testis Antigen KK-LC-1 E-153-2016-0 Filing authorized NCI 83694133 Gulay French, Suna suna.gulay@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB suna.gulay@nih.gov?subject=Web Inquiry on [TAB-4438] T-Cell Immunotherapy that Targets Aggressive Epithelial Tumors&body=Please send me information about technology [TAB-4438] T-Cell Immunotherapy that Targets Aggressive Epithelial Tumors.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Gulay French, Suna<br><a href="mailto:suna.gulay@nih.gov?subject=Web Inquiry on [TAB-4438] T-Cell Immunotherapy that Targets Aggressive Epithelial Tumors&body=Please send me information about technology [TAB-4438] T-Cell Immunotherapy that Targets Aggressive Epithelial Tumors.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">suna.gulay@nih.gov</a><br> 147161109 E-153-2016-0 E-153-2016-0-US-01 Anti-KK-LC-1 T Cell Receptors PRV US 62/327,529 Abandoned US <br />Provisional (PRV) 62/327,529<br />Filed on 2016-04-26<br />Status: Abandoned 147168912 E-153-2016-0 E-153-2016-0-PCT-02 ANTI-KK-LC-1 T CELL RECEPTORS PCT Patent Cooperation Treaty PCT/US2017/027865 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2017/027865<br />Filed on 2017-04-17<br />Status: Expired 147168913 E-153-2016-0 E-153-2016-0-AU-03 ANTI-KK-LC-1 T CELL RECEPTORS National Stage Australia 2017258745 2017258745 Issued Australia <br />National Stage 2017258745<br />Filed on 2018-10-19<br />Status: Issued 147168914 E-153-2016-0 E-153-2016-0-CA-04 ANTI-KK-LC-1 T CELL RECEPTORS National Stage Canada 3021898 3021898 Issued Canada <br />National Stage 3021898<br />Filed on 2017-04-17<br />Status: Issued 147168915 E-153-2016-0 E-153-2016-0-EP-05 ANTI-KK-LC-1 T CELL RECEPTORS National Stage European Patent 3448882 17733120.4 Issued European Patent <br />National Stage 17733120.4<br />Filed on 2018-10-19<br />Status: Issued 147168916 E-153-2016-0 E-153-2016-0-US-06 ANTI-KK-LC-1 T CELL RECEPTORS National Stage US 11,352,410 16/096,118 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11352410 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11352410">11,352,410</a><br />Filed on 2018-10-24<br />Status: Issued 147168917 E-153-2016-0 E-153-2016-0-CH-08 ANTI-KK-LC-1 T CELL RECEPTORS EP Switzerland 3448882 17733120.4 Issued Switzerland <br />European patent (EP) 17733120.4<br />Filed on 2018-10-19<br />Status: Issued 147168918 E-153-2016-0 E-153-2016-0-DE-09 ANTI-KK-LC-1 T CELL RECEPTORS EP Germany 3448882 17733120.4 Issued Germany <br />European patent (EP) 17733120.4<br />Filed on 2018-10-19<br />Status: Issued 147168919 E-153-2016-0 E-153-2016-0-BE-07 ANTI-KK-LC-1 T CELL RECEPTORS EP Belgium 3448882 17733120.4 Issued Belgium <br />European patent (EP) 17733120.4<br />Filed on 2018-10-19<br />Status: Issued 147168920 E-153-2016-0 E-153-2016-0-DK-10 ANTI-KK-LC-1 T CELL RECEPTORS EP Denmark 3448882 17733120.4 Issued Denmark <br />European patent (EP) 17733120.4<br />Filed on 2018-10-19<br />Status: Issued 147168921 E-153-2016-0 E-153-2016-0-ES-11 ANTI-KK-LC-1 T CELL RECEPTORS EP Spain 3448882 17733120.4 Issued Spain <br />European patent (EP) 17733120.4<br />Filed on 2018-10-19<br />Status: Issued 147168922 E-153-2016-0 E-153-2016-0-FI-12 ANTI-KK-LC-1 T CELL RECEPTORS EP Finland 3448882 17733120.4 Issued Finland <br />European patent (EP) 17733120.4<br />Filed on 2018-10-19<br />Status: Issued 147168923 E-153-2016-0 E-153-2016-0-FR-13 ANTI-KK-LC-1 T CELL RECEPTORS EP France 3448882 17733120.4 Issued France <br />European patent (EP) 17733120.4<br />Filed on 2018-10-19<br />Status: Issued 147168924 E-153-2016-0 E-153-2016-0-GB-14 ANTI-KK-LC-1 T CELL RECEPTORS EP United Kingdom 3448882 17733120.4 Issued United Kingdom <br />European patent (EP) 17733120.4<br />Filed on 2018-10-19<br />Status: Issued 147168925 E-153-2016-0 E-153-2016-0-IE-15 ANTI-KK-LC-1 T CELL RECEPTORS EP Ireland 3448882 17733120.4 Issued Ireland <br />European patent (EP) 17733120.4<br />Filed on 2018-10-19<br />Status: Issued 147168926 E-153-2016-0 E-153-2016-0-IT-16 ANTI-KK-LC-1 T CELL RECEPTORS EP Italy 3448882 17733120.4 Issued Italy <br />European patent (EP) 17733120.4<br />Filed on 2018-10-19<br />Status: Issued 147168927 E-153-2016-0 E-153-2016-0-NL-17 ANTI-KK-LC-1 T CELL RECEPTORS EP The Netherlands 3448882 17733120.4 Issued The Netherlands <br />European patent (EP) 17733120.4<br />Filed on 2018-10-19<br />Status: Issued 147168928 E-153-2016-0 E-153-2016-0-NO-18 ANTI-KK-LC-1 T CELL RECEPTORS EP Norway 3448882 17733120.4 Issued Norway <br />European patent (EP) 17733120.4<br />Filed on 2018-10-19<br />Status: Issued 147168929 E-153-2016-0 E-153-2016-0-SE-19 ANTI-KK-LC-1 T CELL RECEPTORS EP Sweden 3448882 17733120.4 Issued Sweden <br />European patent (EP) 17733120.4<br />Filed on 2018-10-19<br />Status: Issued 147172479 CT83 147172480 Immunotherapy 147172482 Kita-Kyushu Lung Cancer Antigen 147172483 KK-LC-1 147172484 T-Cell Receptor 147172485 TCR 147172486 Testis TAB-4408 147157703 Improved HIV Vaccines Through Ras Activation NCI Collaboration, Infectious Disease, Licensing, Therapeutics Collaboration Infectious Disease Licensing Therapeutics Mark Cameron, Melvin Doster, Slim Fourati, Genoveffa Franchini, Shari Gordon, Namal Liyanage, Rafick Sakaly, Luca Schifanella, Monica Vaccari <p>Researchers at the National Cancer Institute (NCI) have developed a new method of improving the efficacy of vaccines in patients with human immunodeficiency virus (HIV) by activating Ras. This method can be used to develop more efficacious vaccine compositions by activating Ras before, during, or after vaccination. Additionally, the researchers discovered that modulation of the Ras pathways could be a predictive biomarker of protection against HIV. This novel method has been shown to effectively stimulate the Ras pathway and to improve vaccine protection from Simian Immunodeficiency Virus (SIV), a HIV animal model, in chimpanzees.</p> <p>More than 30 million people are currently infected with HIV worldwide and it is estimated to increase by as much as 3 million new infections yearly. Although effective anti-retroviral therapies exist, millions still succumb to acquired immune deficiency syndrome (AIDS) every year, underscoring the need to develop new therapeutics to prevent the spread of this disease. Agents that have the potential to modulate immune response can improve the efficacy of vaccine candidates. Ras, a central regulatory molecule that can be easily activated, is a potential target because it affects both the innate and adaptive immune responses.</p> <p>The National Cancer Institute, Vaccine Branch, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize this method of improving HIV vaccine efficacy by activating the Ras pathway. </p> <h2>Competitive Advantages:</h2> <ul><li>Easy and affordable preparation</li> <li>Usable in combination with established vaccine compositions and treatments</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Treatment of HIV patients using vaccines in combination with Ras-activating agents</li> <li>Method to detect likelihood that an HIV vaccine composition will induce a protective immune response</li> </ul> 2018-08-01 2025-04-22 2018-08-01 2025-08-15 2018-08-01 Franchini, HIV, Human Immunodeficiency Virus, immune response, RAS, Ras Pathway Activation False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2018-08-01 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147162300 Van Rompay KK, et al. Attenuated poxvirus-based simian immunodeficiency virus (SIV) vaccines given in infancy partially protect infant and juvenile macaques against repeated oral challenge with virulent SIV. https://www.ncbi.nlm.nih.gov/pubmed/15671796 <a href="https://www.ncbi.nlm.nih.gov/pubmed/15671796">Van Rompay KK, et al. Attenuated poxvirus-based simian immunodeficiency virus (SIV) vaccines given in infancy partially protect infant and juvenile macaques against repeated oral challenge with virulent SIV.</a> 147162414 Pegu P, et al. Antibodies with high avidity to the gp120 envelope protein in protection from simian immunodeficiency virus SIV(mac251) acquisition in an immunization regimen that mimics the RV-144 Thai trial. https://www.ncbi.nlm.nih.gov/pubmed/23175374 <a href="https://www.ncbi.nlm.nih.gov/pubmed/23175374">Pegu P, et al. Antibodies with high avidity to the gp120 envelope protein in protection from simian immunodeficiency virus SIV(mac251) acquisition in an immunization regimen that mimics the RV-144 Thai trial.</a> 147164629 Franchini, Genoveffa NIH - NCI NCI Franchini, Genoveffa (NCI) 1 147164632 Sakaly, Rafick Vaccine & Gene Therapy Institute of Florida Sakaly, Rafick 2 147164633 Fourati, Slim Vaccine & Gene Therapy Institute of Florida Fourati, Slim 3 147164634 Cameron, Mark Vaccine & Gene Therapy Institute of Florida Cameron, Mark 4 147164631 Vaccari, Monica NIH - NCI NCI Vaccari, Monica (NCI) 5 147164635 Schifanella, Luca NCI - CCR NCI Schifanella, Luca (NCI) 6 147164630 Gordon, Shari NIH - NCI NCI Gordon, Shari (NCI) 7 147164636 Doster, Melvin NIH - NCI NCI Doster, Melvin (NCI) 8 147164637 Liyanage, Namal NIH - NCI Liyanage, Namal 9 147164629 Franchini, Genoveffa NIH - NCI NCI Franchini, Genoveffa (NCI) 1 147164632 Sakaly, Rafick Vaccine & Gene Therapy Institute of Florida Sakaly, Rafick 2 147164633 Fourati, Slim Vaccine & Gene Therapy Institute of Florida Fourati, Slim 3 147164634 Cameron, Mark Vaccine & Gene Therapy Institute of Florida Cameron, Mark 4 147164631 Vaccari, Monica NIH - NCI NCI Vaccari, Monica (NCI) 5 147164635 Schifanella, Luca NCI - CCR NCI Schifanella, Luca (NCI) 6 147164630 Gordon, Shari NIH - NCI NCI Gordon, Shari (NCI) 7 147164636 Doster, Melvin NIH - NCI NCI Doster, Melvin (NCI) 8 147164637 Liyanage, Namal NIH - NCI Liyanage, Namal 9 147157899 Modulation Of The RAS Pathways As A Biomarker Of Protection Against HIV And As A Means To Improve Vaccine Efficacy E-062-2014-0 Filing authorized NCI, Vaccine & Gene Therapy Institute of Florida 83740301 Dattaroy, Diptadip diptadip.dattaroy@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB diptadip.dattaroy@nih.gov?subject=Web Inquiry on [TAB-4408] Improved HIV Vaccines Through Ras Activation&body=Please send me information about technology [TAB-4408] Improved HIV Vaccines Through Ras Activation.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dattaroy, Diptadip<br><a href="mailto:diptadip.dattaroy@nih.gov?subject=Web Inquiry on [TAB-4408] Improved HIV Vaccines Through Ras Activation&body=Please send me information about technology [TAB-4408] Improved HIV Vaccines Through Ras Activation.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">diptadip.dattaroy@nih.gov</a><br> 147160979 E-062-2014-0 E-062-2014-0-US-01 RAS Pathways As Markers Of Protection Against HIV And Means To Improve Vaccine Efficacy PRV US 61/925,154 Abandoned US <br />Provisional (PRV) 61/925,154<br />Filed on 2014-01-08<br />Status: Abandoned 147168756 E-062-2014-0 E-062-2014-0-PCT-02 RAS Pathways As Markers Of Protection Against HIV And Means To Improve Vaccine Efficacy PCT Patent Cooperation Treaty PCT/US2015/010664 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2015/010664<br />Filed on 2015-01-08<br />Status: Expired 147168757 E-062-2014-0 E-062-2014-0-US-03 RAS PATHWAYS AS MARKERS OF PROTECTION AGAINST HIV AND METHODS TO IMPROVE VACCINE EFFICACY National Stage US 10,398,772 15/110,400 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10398772 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10398772">10,398,772</a><br />Filed on 2016-07-07<br />Status: Issued 147170557 Franchini 147170558 HIV 147170559 Human Immunodeficiency Virus 147170560 immune response 147170561 RAS 147170563 Ras Pathway Activation TAB-4340 147157631 Natural product-based anti-cancer agents: aza-Englerin analogues NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics John Beutler, William Chain, Daniel Fash, William Figg, Zhenwu Li, Cody Peer, Joe Ramos, Florian Suizmaier, Ian Talisman <p>Chemotherapy resistance in a wide array of cancers is often associated with enhanced glucose uptake and dysregulation of the insulin signaling pathway.  Therapeutics capable of inhibiting insulin signaling would be valuable as a stand-alone treatment and for sensitizing resistant tumors to standard chemotherapy regiments.  Researchers at NCI’s <a href="https://ccr.cancer.gov/Genitourinary-Malignancies-Branch" rel="nofollow">Genitourinary Malignancies Branch</a><a href="http://irp.nih.gov/pi/william-figg" rel="nofollow"> </a>have synthesized and developed a series of Englerin-A analogues with potent anti-tumor activity that is linked to inhibition of the insulin pathway.</p> <p>The researchers have previously shown that Englerin A has potent activity <em>in vivo </em>using a renal carcinoma xenograft mouse model.  A new lead compound with specific activity against renal cell carcinoma, which can be synthesized to scale for <em>in vivo</em> studies, and improved oral bioavailability, has been identified. The NCI seeks partners interested in collaborative research to co-develop this therapeutic with an initial goal of preclinical evaluation leading to clinical testing.</p> <h2>Competitive Advantages:</h2> <ul><li>Novel compounds with potent and selective inhibitory effect on select cancer cells </li> <li>Parent compounds are effective in <em>in vivo</em> cancer models.</li> <li>Demonstrated bioavailability after oral administration (mouse model)</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Chemotherapeutic for renal cell carcinoma, in addition to glucose dependent tumors. </li> <li>Treatment of diseases or conditions associated with insulin resistance</li> </ul> 2016-02-16 2025-08-13 2017-12-20 2025-08-15 2017-08-30 Ewing, Glycolytic, insulin, Resistance, Sarcoma False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2017-12-20 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-042-2012 E-064-2008 E-201-2012 147162033 Akee R, et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=22280462 <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=22280462">Akee R, et al.</a> 147162111 Ratnayake R, et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=19061394 <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=19061394">Ratnayake R, et al.</a> 147162189 Li Z, et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=21476574 <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=21476574">Li Z, et al.</a> 147162458 Sourbier C, et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=23352416 <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=23352416">Sourbier C, et al.</a> 147164373 Chain, William University of Hawaii at Manoa Chain, William 1 147164371 Beutler, John NIH - NCI NCI Beutler, John (NCI) 2 147164374 Ramos, Joe University of Hawaii at Manoa Ramos, Joe 3 147164378 Figg, William NIH - NCI NCI Figg, William (NCI) 3 147164375 Suizmaier, Florian University of Hawaii at Manoa Suizmaier, Florian 4 147164376 Li, Zhenwu Yale University Li, Zhenwu 5 147164377 Fash, Daniel University of Hawaii at Manoa Fash, Daniel 6 147164372 Talisman, Ian NIH - NCI Talisman, Ian 7 147164379 Peer, Cody NIH - NCI NCI Peer, Cody (NCI) 8 147164373 Chain, William University of Hawaii at Manoa Chain, William 1 147164371 Beutler, John NIH - NCI NCI Beutler, John (NCI) 2 147164374 Ramos, Joe University of Hawaii at Manoa Ramos, Joe 3 147164378 Figg, William NIH - NCI NCI Figg, William (NCI) 3 147164375 Suizmaier, Florian University of Hawaii at Manoa Suizmaier, Florian 4 147164376 Li, Zhenwu Yale University Li, Zhenwu 5 147164377 Fash, Daniel University of Hawaii at Manoa Fash, Daniel 6 147164372 Talisman, Ian NIH - NCI Talisman, Ian 7 147164379 Peer, Cody NIH - NCI NCI Peer, Cody (NCI) 8 147157964 Aza-englerin Analogues And Use In Cancer Therapy E-090-2014-0 Filing authorized NCI, University of Hawaii at Manoa, Yale University 147162521 Aza-englerin Analogues And Use In Cancer Therapy E-090-2014-1 Filing authorized NCI, University of Hawaii at Manoa, Yale University 147162522 Aza-englerin Analogues And Use In Cancer Therapy E-090-2014-2 Filing authorized NCI, University of Hawaii at Manoa, Yale University 83732213 Dick, Taryn taryn.dick@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB taryn.dick@nih.gov?subject=Web Inquiry on [TAB-4340] Natural product-based anti-cancer agents: aza-Englerin analogues&body=Please send me information about technology [TAB-4340] Natural product-based anti-cancer agents: aza-Englerin analogues.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dick, Taryn<br><a href="mailto:taryn.dick@nih.gov?subject=Web Inquiry on [TAB-4340] Natural product-based anti-cancer agents: aza-Englerin analogues&body=Please send me information about technology [TAB-4340] Natural product-based anti-cancer agents: aza-Englerin analogues.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">taryn.dick@nih.gov</a><br> 147161021 E-090-2014-0 E-090-2014-0-US-01 Novel natural-product-based nitrogen-containing anti-cancer agents PRV US 61/936,285 Abandoned US <br />Provisional (PRV) 61/936,285<br />Filed on 2014-02-05<br />Status: Abandoned 147168290 E-090-2014-1 E-090-2014-1-US-01 AZA-EPOXY-GUAIANE DERIVATIVES AND TREATMENT OF CANCER PRV US 62/018,381 Abandoned US <br />Provisional (PRV) 62/018,381<br />Filed on 2014-06-27<br />Status: Abandoned 147168293 E-090-2014-2 E-090-2014-2-PCT-01 Aza-Epoxy-Guaiane Derivatives And Treatment of Cancer PCT COMB Patent Cooperation Treaty PCT/US2015/014601 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2015/014601<br />Filed on 2015-02-05<br />Status: Expired 147168294 E-090-2014-2 E-090-2014-2-AU-02 Aza-Epoxy-Guaiane Derivatives And Treatment of Cancer National Stage Australia 2015214189 2015214189 Issued Australia <br />National Stage 2015214189<br />Filed on 2015-02-05<br />Status: Issued 147168295 E-090-2014-2 E-090-2014-2-CA-03 Aza-Epoxy-Guaiane Derivatives And Treatment of Cancer National Stage Canada 2938971 2938971 Issued Canada <br />National Stage 2938971<br />Filed on 2015-02-05<br />Status: Issued 147168296 E-090-2014-2 E-090-2014-2-EP-04 Aza-Epoxy-Guaiane Derivatives And Treatment of Cancer National Stage European Patent 3102581 15705869.4 Issued European Patent <br />National Stage 15705869.4<br />Filed on 2015-02-05<br />Status: Issued 147168297 E-090-2014-2 E-090-2014-2-US-05 Aza-Epoxy-Guaiane Derivatives and Treatment of Cancer National Stage US 9,676,788 15/116,887 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9676788 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9676788">9,676,788</a><br />Filed on 2015-02-05<br />Status: Issued 147168298 E-090-2014-2 E-090-2014-2-DE-06 Aza-Epoxy-Guaiane Derivatives And Treatment of Cancer EP Germany 3102581 15705869.4 Issued Germany <br />European patent (EP) 15705869.4<br />Filed on 2015-02-05<br />Status: Issued 147168299 E-090-2014-2 E-090-2014-2-ES-07 Aza-Epoxy-Guaiane Derivatives And Treatment of Cancer EP Spain 3102581 15705869.4 Issued Spain <br />European patent (EP) 15705869.4<br />Filed on 2015-02-05<br />Status: Issued 147168300 E-090-2014-2 E-090-2014-2-FR-08 Aza-Epoxy-Guaiane Derivatives And Treatment of Cancer EP France 3102581 15705869.4 Issued France <br />European patent (EP) 15705869.4<br />Filed on 2015-02-05<br />Status: Issued 147168301 E-090-2014-2 E-090-2014-2-GB-09 Aza-Epoxy-Guaiane Derivatives And Treatment of Cancer EP United Kingdom 3102581 15705869.4 Issued United Kingdom <br />European patent (EP) 15705869.4<br />Filed on 2015-02-05<br />Status: Issued 147168302 E-090-2014-2 E-090-2014-2-NO-10 Aza-Epoxy-Guaiane Derivatives And Treatment of Cancer EP Norway 3102581 15705869.4 Issued Norway <br />European patent (EP) 15705869.4<br />Filed on 2015-02-05<br />Status: Issued 147168303 E-090-2014-2 E-090-2014-2-SE-11 Aza-Epoxy-Guaiane Derivatives And Treatment of Cancer EP Sweden 3102581 15705869.4 Issued Sweden <br />European patent (EP) 15705869.4<br />Filed on 2015-02-05<br />Status: Issued 147171175 Ewing 147171176 Glycolytic 147171177 insulin 147171178 Resistance 147171179 Sarcoma TAB-427 114094765 Adaptive Sensitivity Encoding Incorporating Temporal Filtering (TSENSE) NHLBI Licensing Licensing Peter Kellman, Elliot Mcveigh The invention is an accelerated magnetic resonance imaging method developed to reduce the total imaging time for gated, segmented cine imaging or to increase the frame rate when imaging dynamic activity, such as heart motion or brain activity. The invention combines temporal filtering (e.g., the UNFOLD method) with a known spatial sensitivity encoding technique (SENSE or SMASH) to achieve a new technique that is the subject of the invention (TSENSE) having a higher degree of alias artifact rejection than could be obtained using either temporal or spatial filtering individually. The new technique tracks changing coil sensitivities over time, which may arise due to chest wall or other body motions, and provides time saving by eliminating a separate reference acquisition. The invention is thus a robust accelerated imaging method that tolerates body motion or change in scan plane without the need to reacquire additional reference images, and the method may be used to reconstruct the full field-of-view with a large temporal bandwidth. 2022-03-08 2025-08-13 2025-08-15 2001-02-01 AA3B1X, AA3BXX, AA3XXX, AAXXXX, AC2XXX, ACXXXX, AXXXXX False True True NIHTT 37470483 Website Abstract 114103803 Kellman, Peter NHLBI Kellman, Peter (NHLBI) 0 114103804 Mcveigh, Elliot Mcveigh, Elliot 0 114103803 Kellman, Peter NHLBI Kellman, Peter (NHLBI) 0 114103804 Mcveigh, Elliot Mcveigh, Elliot 0 114099569 Accelerated Magnetic Resonance Imaging E-200-2000-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 89788013 Kolesnitchenko, Vincent vk5q@nih.gov
United States of America Office of Technology Transfer and Development vk5q@nih.gov?subject=Web Inquiry on [TAB-427] Adaptive Sensitivity Encoding Incorporating Temporal Filtering (TSENSE)&body=Please send me information about technology [TAB-427] Adaptive Sensitivity Encoding Incorporating Temporal Filtering (TSENSE). Kolesnitchenko, Vincent<br><a href="mailto:vk5q@nih.gov?subject=Web Inquiry on [TAB-427] Adaptive Sensitivity Encoding Incorporating Temporal Filtering (TSENSE)&body=Please send me information about technology [TAB-427] Adaptive Sensitivity Encoding Incorporating Temporal Filtering (TSENSE).">vk5q@nih.gov</a><br> 114164649 E-200-2000-0 E-200-2000-0-US-01 Accelerated Magnetic Resonance Imaging Using a Parallel Spatial Filter ORD US 6,556,009 09/735,263 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6556009 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6556009">6,556,009</a><br />Filed on 2000-12-11<br />Status: Expired 114165808 E-200-2000-0 E-200-2000-0-PCT-02 Accelerated Magnetic Resonance Imaging PCT Patent Cooperation Treaty PCT/US2001/046949 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2001/046949<br />Filed on 2001-12-05<br />Status: Expired 114113273 AA3B1X 114113274 AA3BXX 114113275 AA3XXX 114113276 AC2XXX 114113277 AAXXXX 114113278 ACXXXX 114113279 AXXXXX TAB-4111 147157393 Cancer Vaccines against POTE for Treating Solid Tumors NCI Collaboration, Licensing, Oncology, Vaccines Collaboration Licensing Oncology Vaccines Jay Berzofsky, Yi-Hisang Huang, Ira Pastan, Masaki Terabe <p>POTE is a novel tumor antigen expressed in a variety of cancers including breast, prostate, colon, lung, ovary, and pancreas cancers.  POTE has limited expression in normal tissues and therefore a specific target for cancer treatments, including immunotherapy.  The researchers seek statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize immunogenic peptides. </p> <p>Antigen-specific cancer immunotherapy often relies on identification of epitopes expressed by cancer cells that can targeted by cytotoxic T cells (CTL).  However, the CTL repertoire against high-affinity cancer epitopes is often ineffective because cancer epitopes may share a similar structure to natural "self" antigens.  As a result, cancer cells are not recognized by CTLs and destroyed.  The enhanced POTE epitopes induce a stronger immune response than natural responses.  These modified epitopes are more effective at inducing CTL against POTE expressing cancer cells and have greater potential to serve as cancer vaccine targets.</p> <h2>Competitive Advantages:</h2> <h2>Commercial Applications:</h2> 2016-02-16 2025-04-22 2021-10-27 2025-08-15 2016-08-23 CANCER, immunogenic peptides, Immunotherapy, POTE, Vaccine False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2021-10-27 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147163546 Berzofsky, Jay NIH - NCI NCI Berzofsky, Jay (NCI) 1 147163548 Huang, Yi-Hisang NIH - NCI NCI Huang, Yi-Hisang (NCI) 2 147163547 Terabe, Masaki NIH - NCI NCI Terabe, Masaki (NCI) 3 147163545 Pastan, Ira NIH - NCI NCI Pastan, Ira (NCI) 4 147163546 Berzofsky, Jay NIH - NCI NCI Berzofsky, Jay (NCI) 1 147163548 Huang, Yi-Hisang NIH - NCI NCI Huang, Yi-Hisang (NCI) 2 147163547 Terabe, Masaki NIH - NCI NCI Terabe, Masaki (NCI) 3 147163545 Pastan, Ira NIH - NCI NCI Pastan, Ira (NCI) 4 147157765 Modified POTE Peptide Vaccine Against Cancer Of The Prostate, Colon, Lung, Breast, Ovary And Pancreas E-003-2010-0 Filing authorized NCI 83740301 Dattaroy, Diptadip diptadip.dattaroy@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB diptadip.dattaroy@nih.gov?subject=Web Inquiry on [TAB-4111] Cancer Vaccines against POTE for Treating Solid Tumors&body=Please send me information about technology [TAB-4111] Cancer Vaccines against POTE for Treating Solid Tumors.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dattaroy, Diptadip<br><a href="mailto:diptadip.dattaroy@nih.gov?subject=Web Inquiry on [TAB-4111] Cancer Vaccines against POTE for Treating Solid Tumors&body=Please send me information about technology [TAB-4111] Cancer Vaccines against POTE for Treating Solid Tumors.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">diptadip.dattaroy@nih.gov</a><br> 147160880 E-003-2010-0 E-003-2010-0-US-03 Immunogenic Pote Peptides And Methods Of Use National Stage US 8,871,902 13/610,421 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8871902 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8871902">8,871,902</a><br />Filed on 2012-09-11<br />Status: Issued 147166596 E-003-2010-0 E-003-2010-0-US-01 Modified POTE Peplide Vaccine Againsl Cancer Of The Prostate, Colon, Lung, Breast, Ovary And Pancreas PRV US 61/313,559 Abandoned US <br />Provisional (PRV) 61/313,559<br />Filed on 2010-03-12<br />Status: Abandoned 147166597 E-003-2010-0 E-003-2010-0-PCT-02 Immunogenic POTE Peptides And Methods of Use PCT Patent Cooperation Treaty PCT/US2011/027577 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2011/027577<br />Filed on 2011-03-08<br />Status: Expired 147166598 E-003-2010-0 E-003-2010-0-US-04 Immunogenic POTE Peptides And Methods Of Use DIV US 9,394,352 14/496,194 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9394352 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9394352">9,394,352</a><br />Filed on 2014-09-25<br />Status: Issued 147169216 CANCER 147169218 immunogenic peptides 147169219 Immunotherapy 147169220 POTE 147169221 Vaccine TAB-3936 147157216 Treatment of Prostate Cancer Using Anti-androgen Small Molecules NCI Licensing, Oncology, Therapeutics Licensing Oncology Therapeutics Yeong Kim, Vineet Kumar, Sunmin Lee, Sanjay Malhotra, Jane Trepel Neckers <p>Castrate-resistant prostate cancer (CRPC) is characterized by androgen-independent cancer cells that have adapted to the depletion of hormones and continue to grow. Abnormal androgen receptor signaling is known to drive advanced castrate-resistant prostate cancer. The small molecule compounds of this invention are antiandrogens that target androgen receptor signaling in both androgen-independent and androgen-sensitive androgen receptor activity, and androgen receptors that are resistant to the current antiandrogens available.  Unlike the currently available antiandrogens, the new small molecules induce androgen receptor degradation and cell death in prostate cancer cells. Further, these compounds and methods can also induce degradation of other steroid hormone receptors demonstrating the possibility of treating a wider range of cancers.</p> <h2>Competitive Advantages:</h2> <ul><li>First small molecule antiandrogen treatment</li> <li>Causes cell death, not just loss of function</li> <li>Potential to treat other cancers through degradation of other steroid hormone receptors</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Series of steroid receptor compounds that cause cancer cell death</li> <li>Method of using the compounds in cancer treatment</li> </ul> 2016-02-16 2025-04-22 2022-09-29 2025-08-15 2016-08-24 Antiandrogen, castrate resistant, CRPC, PROSTATE CANCER, small molecule, steroid hormone receptor. False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2022-09-29 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147162929 Trepel Neckers, Jane NIH - NCI NCI Trepel Neckers, Jane (NCI) 1 147162931 Kim, Yeong NIH - NCI Kim, Yeong 2 147162930 Lee, Sunmin NIH - NCI NCI Lee, Sunmin (NCI) 3 147162933 Kumar, Vineet NIH - NCI Leidos Kumar, Vineet (Leidos) 4 147162932 Malhotra, Sanjay NIH - NCI Leidos Malhotra, Sanjay (Leidos) 5 147162929 Trepel Neckers, Jane NIH - NCI NCI Trepel Neckers, Jane (NCI) 1 147162931 Kim, Yeong NIH - NCI Kim, Yeong 2 147162930 Lee, Sunmin NIH - NCI NCI Lee, Sunmin (NCI) 3 147162933 Kumar, Vineet NIH - NCI Leidos Kumar, Vineet (Leidos) 4 147162932 Malhotra, Sanjay NIH - NCI Leidos Malhotra, Sanjay (Leidos) 5 147157793 A New Chemical Class Of Antiandrogen For The Treatment Of Castrate-resistant Prostate Cancer E-015-2011-0 Filing authorized NCI 83691647 Chang, Kevin changke@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB changke@mail.nih.gov?subject=Web Inquiry on [TAB-3936] Treatment of Prostate Cancer Using Anti-androgen Small Molecules&body=Please send me information about technology [TAB-3936] Treatment of Prostate Cancer Using Anti-androgen Small Molecules.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Chang, Kevin<br><a href="mailto:changke@mail.nih.gov?subject=Web Inquiry on [TAB-3936] Treatment of Prostate Cancer Using Anti-androgen Small Molecules&body=Please send me information about technology [TAB-3936] Treatment of Prostate Cancer Using Anti-androgen Small Molecules.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">changke@mail.nih.gov</a><br> 147160902 E-015-2011-0 E-015-2011-0-US-01 A New Chemical Class Of Antiandrogen For The Treatment Of Castrate-resistant Prostate Cancer PRV US 61/497,129 Abandoned US <br />Provisional (PRV) 61/497,129<br />Filed on 2011-06-15<br />Status: Abandoned 147165407 E-015-2011-0 E-015-2011-0-PCT-02 Nuclear Receptor Modulators And Their Use For The Treatment And Prevention Of Cancer. PCT Patent Cooperation Treaty PCT/US12/42753 Expired Patent Cooperation Treaty <br />(PCT) PCT/US12/42753<br />Filed on 2012-06-15<br />Status: Expired 147165408 E-015-2011-0 E-015-2011-0-AU-03 Nuclear Receptor Modulators And Their Use For The Treatment And Prevention Of Cancer National Stage Australia 2012271403 2012271403 Abandoned Australia <br />National Stage 2012271403<br />Filed on 2012-06-15<br />Status: Abandoned 147165409 E-015-2011-0 E-015-2011-0-CA-04 Nuclear Receptor Modulators And Their Use For The Treatment And Prevention Of Cancer National Stage Canada 2839301 2839301 Abandoned Canada <br />National Stage 2839301<br />Filed on 2012-06-15<br />Status: Abandoned 147165410 E-015-2011-0 E-015-2011-0-EP-05 Nuclear Receptor Modulators And Their Use For The Treatment And Prevention Of Cancer National Stage European Patent 2721003 12800764.8 Abandoned European Patent <br />National Stage 12800764.8<br />Filed on 2012-06-15<br />Status: Abandoned 147165411 E-015-2011-0 E-015-2011-0-US-06 Nuclear Receptor Modulators and Their Use for the Treatment and Prevention of Cancer National Stage US 10,071,945 14/126,178 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10071945 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10071945">10,071,945</a><br />Filed on 2014-02-07<br />Status: Issued 147165412 E-015-2011-0 E-015-2011-0-AU-07 Nuclear Receptor Modulators And Their Use For The Treatment And Prevention Of Cancer DIV Australia 2017248517 2017248517 Abandoned Australia <br />Divisional (DIV) 2017248517<br />Filed on 2017-10-19<br />Status: Abandoned 147165413 E-015-2011-0 E-015-2011-0-EP-08 Nuclear Receptor Modulators And Their Use For The Treatment And Prevention Of Cancer DIV European Patent 17211083.5 Abandoned European Patent <br />Divisional (DIV) 17211083.5<br />Filed on 2012-06-15<br />Status: Abandoned 147165414 E-015-2011-0 E-015-2011-0-DE-09 Nuclear Receptor Modulators And Their Use For The Treatment And Prevention Of Cancer EP Germany 2721003 12800764.8 Abandoned Germany <br />European patent (EP) 12800764.8<br />Filed on 2012-06-15<br />Status: Abandoned 147165415 E-015-2011-0 E-015-2011-0-FR-10 Nuclear Receptor Modulators And Their Use For The Treatment And Prevention Of Cancer EP France 2721003 12800764.8 Abandoned France <br />European patent (EP) 12800764.8<br />Filed on 2012-06-15<br />Status: Abandoned 147165416 E-015-2011-0 E-015-2011-0-GB-11 Nuclear Receptor Modulators And Their Use For The Treatment And Prevention Of Cancer EP United Kingdom 2721003 12800764.8 Abandoned United Kingdom <br />European patent (EP) 12800764.8<br />Filed on 2012-06-15<br />Status: Abandoned 147165417 E-015-2011-0 E-015-2011-0-US-12 NUCLEAR RECEPTOR MODULATORS AND THEIR USE FOR THE TREATMENT AND PREVENTION OF CANCER DIV US 10,737,995 16/107,532 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10737995 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10737995">10,737,995</a><br />Filed on 2018-08-21<br />Status: Issued 147169526 Antiandrogen 147169528 castrate resistant 147169530 CRPC 147169531 PROSTATE CANCER 147169532 small molecule 147169534 steroid hormone receptor. TAB-3867 147157146 A Novel Carbohydrate Antibody to GalNac1-3Gal and Its Application for Cancer Diagnostic and Prognosis NCI Licensing, Oncology, Research Materials Licensing Oncology Research Materials Miriam Anver, Donna Butcher, Jeffrey Gildersleeve, Qian Li, Zhitao Li <p>Cervical cancer is one of the most common cancers among women worldwide. Currently, physical descriptors such as tumor size and depth are the primary factors used for deciding the course of treatment. Despite significant efforts to identify prognostic biochemical markers or therapeutic targets to improve diagnosis and treatment, none have achieved routine clinical use. An example of one previously identified biomarker is the Tn antigen, a carbohydrate moiety composed of a GalNAc residue linked to serine or threonine. Previous studies examining Tn antigen levels present in cervical cancer tumors have produced conflicting results. The inventors discovered that this phenomenon is a direct result of using antibodies that are cross reactive to carbohydrates terminating in GalNAcal-3Gal or GalNAca1-6Gal. To precisely determine which carbohydrate antigen correlates with cervical cancer formation, the investigators produced a series of antibodies with high degrees of specificity for structurally distinct variants of the Tn antigen. The results show that relative to other carbohydrate antigens examined, GalNAca1-3Gal is expressed at high levels in squamous carcinomas of the cervix.  Importantly, expression levels of GalNAcal-3Gal have a statistically significant correlation with 5-year survival rates. </p> <p> Researchers at NCI developed antibodies with high specificity for GalNAca1-3Gal, which can be used to both diagnose cervical cancer and as a prognostic tool. In addition to cervical cancer, elevated GalNAc1-3Gal is present in a variety of other human carcinomas, including squamous cell carcinoma, esophageal cancer, laryngeal cancer, and skin cancer. </p> <h2>Competitive Advantages:</h2> <ul><li>Only monoclonal antibody known to bind the GalNAca1-3Gal antigen but no other closely related structures, including blood group A, the Forssman antigen, and the Tn antigen. </li> <li>Binds various human tumor samples via immunohistochemistry</li> <li>The antibody is a rabbit IgG. </li> </ul> <h2>Commercial Applications:</h2> <ul><li>Cervical cancer diagnostics and prognosis </li> <li>Research tool</li> <li>Immunohistochemical staining of a variety of carcinomas including cervical, larynx, and skin squamous cell carcinomas</li> </ul> 2018-02-16 2025-04-22 2018-02-16 2025-08-15 2018-02-16 ANTIBODY, CERVICAL, GaLNAc1-3Gal, Gildersleeve, Immunohistochemical staining, Larynx, Prognostic marker, SKIN, Squamous Cell False True Basic (Target Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2018-02-16 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147162337 Qian Li, et al. GalNAcα1-3Gal, a New Prognostic Marker for Cervical Cancer. https://www.ncbi.nlm.nih.gov/pubmed/19585575 <a href="https://www.ncbi.nlm.nih.gov/pubmed/19585575">Qian Li, et al. GalNAcα1-3Gal, a New Prognostic Marker for Cervical Cancer.</a> 147162667 Gildersleeve, Jeffrey NIH - NCI NCI Gildersleeve, Jeffrey (NCI) 1 147162668 Li, Zhitao NIH - NCI Li, Zhitao 2 147162669 Li, Qian NIH - NCI Li, Qian 3 147162666 Anver, Miriam NIH - NCI Leidos Anver, Miriam (Leidos) 4 147162670 Butcher, Donna Butcher, Donna 5 147162667 Gildersleeve, Jeffrey NIH - NCI NCI Gildersleeve, Jeffrey (NCI) 1 147162668 Li, Zhitao NIH - NCI Li, Zhitao 2 147162669 Li, Qian NIH - NCI Li, Qian 3 147162666 Anver, Miriam NIH - NCI Leidos Anver, Miriam (Leidos) 4 147162670 Butcher, Donna Butcher, Donna 5 147157884 Generation And Application Of Antibodies That Bind GaLNAc1-3Gal E-058-2009-0 Filing authorized NCI 83704821 Nguyen-Antczak, Lauren lauren.nguyen-antczak@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-3867] A Novel Carbohydrate Antibody to GalNac1-3Gal and Its Application for Cancer Diagnostic and Prognosis&body=Please send me information about technology [TAB-3867] A Novel Carbohydrate Antibody to GalNac1-3Gal and Its Application for Cancer Diagnostic and Prognosis.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Nguyen-Antczak, Lauren<br><a href="mailto:lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-3867] A Novel Carbohydrate Antibody to GalNac1-3Gal and Its Application for Cancer Diagnostic and Prognosis&body=Please send me information about technology [TAB-3867] A Novel Carbohydrate Antibody to GalNac1-3Gal and Its Application for Cancer Diagnostic and Prognosis.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">lauren.nguyen-antczak@nih.gov</a><br> 147160974 E-058-2009-0 E-058-2009-0-US-02 Antibodies That Bind GaLNAc1-3Gal, Pharmaceutical Compositions and Methods Of Using Same ORD US 8,957,188 12/752,331 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8957188 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8957188">8,957,188</a><br />Filed on 2010-04-01<br />Status: Issued 147164890 E-058-2009-0 E-058-2009-0-US-01 Generation And Application Of Antibodies That Bind GaLNAc1-3Gal PRV US 61/165,675 Abandoned US <br />Provisional (PRV) 61/165,675<br />Filed on 2009-04-01<br />Status: Abandoned 147170419 ANTIBODY 147170420 CERVICAL 147170421 GaLNAc1-3Gal 147170423 Gildersleeve 147170425 Immunohistochemical staining 147170427 Larynx 147170429 Prognostic marker 147170430 SKIN 147170432 Squamous Cell TAB-3841 144873504 Method To Generate Chondrocytes from Human Induced Pluripotent Stem Cells (hIPSCs) and their use in Repairing Human Injury and Degenerative Diseases NIDCR Application, Human Cell Lines, Human iPSC Lines, Immunology, Licensing, Research Materials, Therapeutics Application Human Cell Lines Human iPSC Lines Immunology Licensing Research Materials Therapeutics Stephen Gadomski, Pamela Robey <p>This technology includes a method for differentiating human induced pluripotent stem cells (hiPSCs) into stable chondrocytes, capable of producing cartilage, and their use in cartilage repair in human injury and degenerative diseases. In suspension culture, hiPSC aggregates demonstrate gene and protein expression patterns similar to articular cartilage. Transplantation of cells from the aggregates into a mouse/rat femoral articular cartilage defect leads to the formation of stable, hyaline-like cartilage that persists for up to 5 months in immunocompromised mice and rats, demonstrating that hiPSC could potentially be used to regenerate cartilage in humans with similar defects. A potential application includes the treatment of osteoarthritis (OA), a disease characterized by the permanent loss of articular cartilage that lines joint surfaces.</p> This technology has the potential to be used to repair a variety of sources of cartilage damage, including damage caused by injury, overuse, and disease. In addition, the method described here produces chondrocytes that are stable when transplanted in vivo, which can potentially effect long-term and significant healing. In vivo long-term transplantation of hIPSC-derived chondrocytes can potentially be used to treat: <ul> <li>Injuries: This technology could be used to treat cartilage damage caused by injuries such as sports injuries, falls, and car accidents.</li> <li>Overuse: This technology could be used to treat cartilage damage caused by overuse, such as in athletes and people who have physically demanding jobs. </li> <li>Diseases: This technology could be used to treat cartilage damage caused by diseases such as osteoarthritis, rheumatoid arthritis, and avascular necrosis. </li> </ul> 2023-04-13 2025-08-13 2025-08-15 2023-04-13 False True True 52406768 Discovery 52406768 37470483 Website Abstract 145042411 Robey, Pamela NIDCR NIDCR Robey, Pamela (NIDCR) 1 145042424 Gadomski, Stephen Gadomski, Stephen 2 145042411 Robey, Pamela NIDCR NIDCR Robey, Pamela (NIDCR) 1 145042424 Gadomski, Stephen Gadomski, Stephen 2 144875507 Generation of hiPSC-derived chondrospheroids that produce stable cartilage in vivo E-094-2023-0 Filing authorized NIDCR, NIDCR 83739611 Yonter, Ediz ediz.yonter@nih.gov
United States of America Technology Advancement Office ediz.yonter@nih.gov?subject=Web Inquiry on [TAB-3841] Method To Generate Chondrocytes from Human Induced Pluripotent Stem Cells (hIPSCs) and their use in Repairing Human Injury and Degenerative Diseases&body=Please send me information about technology [TAB-3841] Method To Generate Chondrocytes from Human Induced Pluripotent Stem Cells (hIPSCs) and their use in Repairing Human Injury and Degenerative Diseases. Yonter, Ediz<br><a href="mailto:ediz.yonter@nih.gov?subject=Web Inquiry on [TAB-3841] Method To Generate Chondrocytes from Human Induced Pluripotent Stem Cells (hIPSCs) and their use in Repairing Human Injury and Degenerative Diseases&body=Please send me information about technology [TAB-3841] Method To Generate Chondrocytes from Human Induced Pluripotent Stem Cells (hIPSCs) and their use in Repairing Human Injury and Degenerative Diseases.">ediz.yonter@nih.gov</a><br> TAB-3839 144783752 Codon Deoptimized (CD) Poliovirus Seed Strains for Use in an Inactivated Poliovirus Vaccine CDC Collaboration, Infectious Disease, Research Equipment, Vaccines Collaboration Infectious Disease Research Equipment Vaccines Cara Burns, Raymond (Ray) Campagnoli, Olen Kew, Jing Shaw <p>Polio is a&nbsp;disabling&nbsp;and&nbsp;potentially&nbsp;fatal infectious disease.&nbsp;Sabin Oral Poliovirus Vaccine (OPV) and Salk Inactivated Poliovirus Vaccine (IPV) have been crucial in the global poliovirus eradication efforts and substantial decrease in&nbsp;disease&nbsp;incidence&nbsp;rates.&nbsp;However,&nbsp;recent findings showed&nbsp;that&nbsp;Sabin OPV strains, due to their genetic instability,&nbsp;may revert to virulence and spread among communities, resulting in circulating vaccine-derived poliovirus (cVDPV).&nbsp;Salk IPV,&nbsp;which is made by inactivating live poliovirus,&nbsp;poses&nbsp;a&nbsp;potential threat of viral&nbsp;containment&nbsp;breach&nbsp;(spill/exposure)&nbsp;during&nbsp;the&nbsp;manufacturing process.&nbsp;Salk IPV&nbsp;is also limited by its inability to confer intestinal immunity, a factor that is&nbsp;crucial to stop fecal-oral viral transmission, especially in developing countries&nbsp;with poor sanitation and limited&nbsp;clean drinking water. A safer, genetically stable&nbsp;vaccine candidate is&nbsp;highly essential&nbsp;for the containment of poliovirus breach,&nbsp;whether&nbsp;it would occur&nbsp;during&nbsp;the&nbsp;manufacturing&nbsp;process&nbsp;or due to&nbsp;cVDPV&nbsp;spread, and in achieving complete eradication of the disease.</p> <p>CDC inventors discovered that replacing&nbsp;one or more natural (or native) codons in a pathogen with synonymous un-preferred codons can decrease&nbsp;replicative fitness&nbsp;of the pathogen, thereby&nbsp;attenuating&nbsp;(decreasing the virulence of)&nbsp;the&nbsp;pathogen.&nbsp;Building on this, CDC researchers&nbsp;applied&nbsp;the&nbsp;previously patented codon deoptimization&nbsp;(CD)&nbsp;technology to the Sabin oral poliovirus vaccine (OPV) strains&nbsp;to develop attenuated poliovirus strains with enhanced genetic stability. These attenuated strains were&nbsp;then&nbsp;used as seed strains&nbsp;for&nbsp;a&nbsp;new Sabin&nbsp;inactivated poliovirus vaccine (sIPV)&nbsp;that&nbsp;is more stable and has less likelihood of reverting back to virulence.&nbsp;These modified&nbsp;sIPV&nbsp;candidates,&nbsp;while antigenically equivalent to the currently used Sabin OPV, offer safer methods for vaccine manufacture and viral breach containment.&nbsp;Researchers produced CD seed strains of all three poliovirus serotypes&nbsp;for Sabin OPV.&nbsp;As&nbsp;polio eradication&nbsp;progresses, more&nbsp;poliovirus&nbsp;containment requirements may&nbsp;be enacted.&nbsp;</p> <ul> <li>Enhanced genetic stability</li> <li>Less likely to revert to virulence</li> <li>Antigenically equivalent to the currently used Sabin OPV</li> <li>Genetically distinct from novel OPV that is currently being used and alleviates some critical safety issues associated with using live attenuated vaccines</li> </ul> <ul> <li>Vaccine design and development for Sabin inactivated poliovirus (IPV) or other enterovirus vaccines</li> <li>Functional improvements for poliovirus vaccines or other enterovirus vaccines</li> <li>PV seed stocks</li> <li>Quality control in vaccine development</li> <li>Research tools</li> </ul> Collaborative Research Opportunity The CDC Technology Transfer Office (TTO) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize: - Codon Deoptimized Poliovirus Seed Strains for Use in an Inactivated Poliovirus Vaccine For collaboration opportunities, please contact: CDC Technology Transfer Office tto@cdc.gov 2023-04-06 2025-08-13 2025-08-15 2023-04-06 False False Pre-Clinical (in vivo (animal)) True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract E-328-2013-0 144784092 Burns CC, et al. PMID 19605476 https://pubmed.ncbi.nlm.nih.gov/19605476/ <a href="https://pubmed.ncbi.nlm.nih.gov/19605476/">Burns CC, et al. PMID 19605476</a> 144784118 Burns CC, et al. PMID 16537593 https://pubmed.ncbi.nlm.nih.gov/16537593/ <a href="https://pubmed.ncbi.nlm.nih.gov/16537593/">Burns CC, et al. PMID 16537593</a> 144784135 Bigouette JP, et al. PMID 34437527 https://pubmed.ncbi.nlm.nih.gov/34437527/ <a href="https://pubmed.ncbi.nlm.nih.gov/34437527/">Bigouette JP, et al. PMID 34437527</a> 144783785 Burns, Cara CDC - DIR CDC Burns, Cara (CDC) 1 144783807 Campagnoli, Raymond (Ray) CDC - DIR CDC Campagnoli, Raymond (Ray) (CDC) 2 144783858 Shaw, Jing CDC - DIR CDC Shaw, Jing (CDC) 3 144783867 Kew, Olen CDC - DIR CDC Kew, Olen (CDC) 4 144783785 Burns, Cara CDC - DIR CDC Burns, Cara (CDC) 1 144783807 Campagnoli, Raymond (Ray) CDC - DIR CDC Campagnoli, Raymond (Ray) (CDC) 2 144783858 Shaw, Jing CDC - DIR CDC Shaw, Jing (CDC) 3 144783867 Kew, Olen CDC - DIR CDC Kew, Olen (CDC) 4 144783755 Codon Deoptimized Poliovirus Seed Strains For Use In An Inactivated Poliovirus Vaccine E-004-2020-0 Research Material Centers for Disease Control and Prevention (CDC) 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-3839] Codon Deoptimized (CD) Poliovirus Seed Strains for Use in an Inactivated Poliovirus Vaccine&body=Please send me information about technology [TAB-3839] Codon Deoptimized (CD) Poliovirus Seed Strains for Use in an Inactivated Poliovirus Vaccine. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-3839] Codon Deoptimized (CD) Poliovirus Seed Strains for Use in an Inactivated Poliovirus Vaccine&body=Please send me information about technology [TAB-3839] Codon Deoptimized (CD) Poliovirus Seed Strains for Use in an Inactivated Poliovirus Vaccine.">jonathan.motley@nih.gov</a><br> TAB-3838 144746539 Hybridomas Producing Antibodies to Neuraminidase for Influenza A (H3N2) Diagnostics, Vaccine, and Therapeutic Development CDC Collaboration, Diagnostics, Infectious Disease, Research Materials, Therapeutics, Vaccines Collaboration Diagnostics Infectious Disease Research Materials Therapeutics Vaccines Shane Gansebom, Jason Wilson, Ian York <p>Influenza A and B viruses can cause seasonal flu epidemics ― commonly known as the &ldquo;flu season&rdquo; ― and infect the nose, throat, eyes, and lungs in humans. Typically, flu seasons that are dominated by influenza A (H3N2) virus activity have higher associated hospitalizations and deaths in at-risk groups, such as people ages 65 and older and young children. Influenza A (H3N2) virus can also cause respiratory disease in animals, such as canines and swine. </p> <p>CDC discovered a series of 17 hybridomas (murine B cell fused with an immortal myeloma that produces a specific monoclonal antibody (mAb)) that recognize neuraminidase (N2) from influenza A (H3N2) viruses. Researchers identified the hybridomas of murine origin with mAbs that recognize N2 from influenza A/Hong Kong/4801/2014. The technology has potential utility in diagnostic assays, surveillance, prophylaxis, therapeutic treatments, and research reagents. Additional testing is planned to better understand the technology&rsquo;s activities and potential. </p> <ul> <li>The newly identified mAbs may bind to regions on viral NA antigens in a manner that currently available antibodies do not</li> <li>The technology may have altered affinities or a broader range of subtype and strain specificity than existing antibodies</li> </ul> <ul> <li>Development or refinement of diagnostic assays for influenza A (H3N2)</li> <li>Controls or a reference reagent source for diagnostic assay validation</li> <li>Quality control/quality assurance testing for influenza A (H3N2) vaccine or therapeutic development</li> <li>Monitoring and public health surveillance</li> <li>Research tools</li> </ul> The CDC Technology Transfer Office (TTO) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize: - Hybridomas Producing Antibodies to Neuraminidase for Influenza A (H3N2) Diagnostics, Vaccine, and Therapeutic Development For collaboration opportunities, please contact: CDC Technology Transfer Office tto@cdc.gov 2023-04-04 2025-08-13 2025-08-15 2023-04-05 False False Early-stage True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract E-200-2016-0 E-163-2018 E-095-2022 E-562-2013-0 E-563-2013-0 E-331-2013-0 E-274-2013-0 E-560-2013-0 E-129-2020-0 E-177-2022-0 E-144-2022-0 E-145-2022-0 E-026-2022-0 E-193-2021-0 144746990 Publications: Guo Z., et al. [PMID 30053389.] https://pubmed.ncbi.nlm.nih.gov/30053389/ <a href="https://pubmed.ncbi.nlm.nih.gov/30053389/">Publications: Guo Z., et al. [PMID 30053389.]</a> 144747104 Chen X., et al. [PMID 35255298.] https://pubmed.ncbi.nlm.nih.gov/35255298/ <a href="https://pubmed.ncbi.nlm.nih.gov/35255298/">Chen X., et al. [PMID 35255298.]</a> 144747109 Wilson J., et al. [PMID 28888111.] https://pubmed.ncbi.nlm.nih.gov/28888111/ <a href="https://pubmed.ncbi.nlm.nih.gov/28888111/">Wilson J., et al. [PMID 28888111.]</a> 144747114 Xuemin C., et al. [PMID 35255298.] https://pubmed.ncbi.nlm.nih.gov/35255298/ <a href="https://pubmed.ncbi.nlm.nih.gov/35255298/">Xuemin C., et al. [PMID 35255298.]</a> 144746621 Wilson, Jason CDC - DIR CDC Wilson, Jason (CDC) 1 144746642 York, Ian CDC - DIR CDC York, Ian (CDC) 2 144746727 Gansebom, Shane CDC - DIR CDC Gansebom, Shane (CDC) 3 144746621 Wilson, Jason CDC - DIR CDC Wilson, Jason (CDC) 1 144746642 York, Ian CDC - DIR CDC York, Ian (CDC) 2 144746727 Gansebom, Shane CDC - DIR CDC Gansebom, Shane (CDC) 3 144746542 Monoclonal Antibodies Recognizing Neuraminidase From Influenza A(H3N2) E-129-2020-0 Research Material Centers for Disease Control and Prevention (CDC) 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-3838] Hybridomas Producing Antibodies to Neuraminidase for Influenza A (H3N2) Diagnostics, Vaccine, and Therapeutic Development&body=Please send me information about technology [TAB-3838] Hybridomas Producing Antibodies to Neuraminidase for Influenza A (H3N2) Diagnostics, Vaccine, and Therapeutic Development. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-3838] Hybridomas Producing Antibodies to Neuraminidase for Influenza A (H3N2) Diagnostics, Vaccine, and Therapeutic Development&body=Please send me information about technology [TAB-3838] Hybridomas Producing Antibodies to Neuraminidase for Influenza A (H3N2) Diagnostics, Vaccine, and Therapeutic Development.">jonathan.motley@nih.gov</a><br> TAB-3837 144735510 Human Monoclonal Antibodies That Recognize Influenza A Viruses for Vaccine, Therapeutic, and Diagnostic Development CDC Collaboration, Diagnostics, Therapeutics, Vaccines Collaboration Diagnostics Therapeutics Vaccines Zhu Guo, Wen-Pin Tzeng, Jason Wilson, Ian York <p>Human influenza A is one of two influenza virus types that cause seasonal epidemics of disease (known as flu season) almost every winter in the United States. Influenza A viruses are the only influenza viruses known to cause flu pandemics (i.e., global epidemics of flu disease). (<a href="https://www.cdc.gov/flu/about/viruses/types.htm">Source</a>.)</p> <p>CDC has discovered a series of human monoclonal antibodies (mAbs) that target hemagglutinin (HA), one of two proteins found on the surface of influenza A viruses. The mAbs are influenza virus subtype specific, broadly binding within a subtype, and broadly cross-reactive across influenza subtypes (group 1 and 2). CDC has obtained normal donor peripheral blood mononuclear cells (PBMCs) and purified B cells from a commercial source and sorted these cells based on influenza HA binding activity. The V(D)J genes of HA reactive B cells were then single-cell sequenced and cloned to produce recombinant mAbs for further characterization. </p> <p>CDC has screened the mAbs produced from these studies by ELISA to confirm antigen specificity and approximate breadth of reactivity. Some mAbs were tested for antiviral activity in HA inhibition assays and a small number were screened by bio-layer interferometry to determine their epitope binding profile. CDC ha additional protection studies in mouse and/or ferret models underway to understand the technology&rsquo;s potential to act as a prophylactic, therapeutic, and diagnostic.</p> <ul> <li> Each of the recombinant mAbs produced in these studies have unique sequences and therefore bind to influenza viruses in unique ways.</li> -<li>These mAbs do not exist as a commercial source. </li> -<li>This technology can be provided as an antibody or plasmid.</li> </ul> <ul> <li>Prevention of influenza A infection with hemagglutinin (HA) proteins</li> <li>Treatment of influenza A (HA) infection</li> <li>Diagnostic assays for detection and characterization of influenza A (HA) viruses</li> <li>Public health monitoring and surveillance</li> <li>Quality assurance and quality control for vaccine, therapeutic, or diagnostic development</li> <li>Research tools and diagnostic reagents</li> </ul> The CDC Technology Transfer Office (TTO) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize: - Human Monoclonal Antibodies That Recognize Influenza A Viruses for Vaccine, Therapeutic, and Diagnostic Development For collaboration opportunities, please contact: CDC Technology Transfer Office tto@cdc.gov 2023-04-04 2025-08-13 2025-08-15 2023-04-05 False False Early-stage Prototype True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract E-200-2016-0 E-163-2018-0 E-129-2020-0 E-061-2016-0 E-177-2022-0 E-144-2022-0 E-145-2022-0 E-026-2022-0 E-193-2021-0 E-095-2022 E-562-2013-0 E-563-2013-0 E-331-2013-0 E-274-2013-0 E-560-2013-0 144736229 Wilson, Jason CDC - DIR CDC Wilson, Jason (CDC) 1 144736294 York, Ian CDC - DIR CDC York, Ian (CDC) 2 144736298 Tzeng, Wen-Pin CDC - DIR CDC Tzeng, Wen-Pin (CDC) 3 144736312 Guo, Zhu CDC - DIR CDC Guo, Zhu (CDC) 4 144736229 Wilson, Jason CDC - DIR CDC Wilson, Jason (CDC) 1 144736294 York, Ian CDC - DIR CDC York, Ian (CDC) 2 144736298 Tzeng, Wen-Pin CDC - DIR CDC Tzeng, Wen-Pin (CDC) 3 144736312 Guo, Zhu CDC - DIR CDC Guo, Zhu (CDC) 4 144735513 Human Monoclonal Antibodies That Recognize Influenza A Viruses E-095-2022-0 Research Material Centers for Disease Control and Prevention (CDC) 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-3837] Human Monoclonal Antibodies That Recognize Influenza A Viruses for Vaccine, Therapeutic, and Diagnostic Development&body=Please send me information about technology [TAB-3837] Human Monoclonal Antibodies That Recognize Influenza A Viruses for Vaccine, Therapeutic, and Diagnostic Development. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-3837] Human Monoclonal Antibodies That Recognize Influenza A Viruses for Vaccine, Therapeutic, and Diagnostic Development&body=Please send me information about technology [TAB-3837] Human Monoclonal Antibodies That Recognize Influenza A Viruses for Vaccine, Therapeutic, and Diagnostic Development.">jonathan.motley@nih.gov</a><br> TAB-3836 144525520 Vascular Anchoring Introducer Sheath for Interventional Cardiac Procedures NHLBI Cardiology, Medical Devices Cardiology Medical Devices <p>This technology includes a device and method for maintaining access to a location in the body while reducing or eliminating the potential for pulling an access device (i.e., catheter) back through an opening, such as a cardiac procedure. An introducer sheath includes a distal indented portion and a balloon, so that once placed in a desired location through tissue, the balloon can be inflated to anchor the sheath against retraction. </p> Currently available devices do not have an anchoring feature particularly suitable to the sensitive tissues of the heart; this device is safer by preventing inadvertent pullback. Device to be used for interventional cardiac procedures or other procedures to prevent pullback. 2023-03-21 2025-08-13 2025-08-15 2024-03-20 False True True 52406768 Discovery 52406768 37470483 Website Abstract 144525538 Vascular Anchoring Introducer Sheath E-045-2018-0 Filing authorized Cook Medical Technologies LLC, National Heart, Lung, and Blood Institute (NHLBI), Rady Children's Hospital 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-3836] Vascular Anchoring Introducer Sheath for Interventional Cardiac Procedures&body=Please send me information about technology [TAB-3836] Vascular Anchoring Introducer Sheath for Interventional Cardiac Procedures. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-3836] Vascular Anchoring Introducer Sheath for Interventional Cardiac Procedures&body=Please send me information about technology [TAB-3836] Vascular Anchoring Introducer Sheath for Interventional Cardiac Procedures.">shmilovm@nih.gov</a><br> 157753749 E-045-2018-0 E-045-2018-0-US-01 Vascular Anchoring Introducer Sheath PRV US 62/412,646 Abandoned US <br />Provisional (PRV) 62/412,646<br />Filed on 2016-10-25<br />Status: Abandoned 157753757 E-045-2018-0 E-045-2018-0-PCT-02 Vascular Anchoring Introducer Sheath PCT Patent Cooperation Treaty PCT/US2017/058245 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2017/058245<br />Filed on 2017-10-25<br />Status: Expired 157753762 E-045-2018-0 E-045-2018-0-CN-03 Vascular Anchoring Introducer Sheath National Stage China 201780080201.9 Pending China <br />National Stage 201780080201.9<br />Filed on 2017-10-25<br />Status: Pending 157753767 E-045-2018-0 E-045-2018-0-EP-04 Vascular Anchoring Introducer Sheath National Stage European Patent 3532146 17794615.9 Issued European Patent <br />National Stage 17794615.9<br />Filed on 2017-10-25<br />Status: Issued 157753772 E-045-2018-0 E-045-2018-0-JP-05 Vascular Anchoring Introducer Sheath National Stage Japan 7200447 2019-545881 Issued Japan <br />National Stage 2019-545881<br />Filed on 2019-04-25<br />Status: Issued 157753777 E-045-2018-0 E-045-2018-0-US-06 Vascular Anchoring Introducer Sheath National Stage US 11,071,535 16/394,182 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11071535 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11071535">11,071,535</a><br />Filed on 2019-04-25<br />Status: Issued 157753794 E-045-2018-0 E-045-2018-0-US-07 Vascular Anchoring Introducer Sheath DIV US 12,011,151 17/385,230 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12011151 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12011151">12,011,151</a><br />Filed on 2021-07-26<br />Status: Issued TAB-3833 144184928 Replicating RNA Vaccine For Crimean-Congo Hemorrhagic Fever Virus NIAID Antibodies, Collaboration, Infectious Disease, Licensing, Vaccines Antibodies Collaboration Infectious Disease Licensing Vaccines Jesse Erasmus, Heinrich (Heinz) Feldmann, David Hawman <p>Crimean-Congo hemorrhagic fever (CCHF) is a deadly hemorrhagic fever having a high mortality rate. The disease results from infection of an individual by Crimean-Congo hemorrhagic fever virus (CCHFV), which is a tick-borne bunyavirus endemic in Southern and Eastern Europe, Africa, the Middle East, and Asia. Geographically, case distribution is consistent with the range of Hyalomma genus ticks, the main reservoir of CCHFV, and is likely to expand due to climate change. Humans may be infected from tick bites, through contact with infected animals or animal tissue. Nosocomial human-to-human transmission has also been described primarily for healthcare workers. Initial symptoms of CCHF include acute onset of a non-specific febrile illness consisting of sudden fever, myalgia, diarrhea, nausea, and vomiting. The hemorrhagic phase is characterized by large areas of severe bruising and uncontrolled bleeding throughout the body; among hospitalized patients, case fatality rates have ranged from 9-50%. Currently, there is no approved specific antiviral or vaccine for CCHFV infection.</p> <p>Scientists at NIAID in collaboration with HDT Bio have developed a replicating RNA (repRNA) vaccine based on Venezuelan Equine Encephalitis Virus replicon RNA expressing either the nucleoprotein (repNP) or the glycoprotein precursor (repGPC) from CCHFV alone or in combination. &nbsp;In mice, the repNP vaccine primarily elicited a robust but non-neutralizing antibody response while repGPC elicited primarily cellular immunity against epitopes in the CCHFV NSm and Gc proteins. Vaccination with repNP or repNP + repGPC resulted in protection against challenge with a heterologous strain of CCHFV in mice.</p> <ul> <li>Uses a cell-free system to express antigens thereby increasing safety of the vaccine</li> <li>RepRNA as a platform can drive high-level protein expression and mimics viral replication in a single round of replication resulting in a more robust immune response in comparison to DNA and mRNA platforms</li> </ul> <ul> <li>Prophylactic usage against CCHFV infections in normal or high-risk populations</li> <li>Therapeutic treatment, alone or in combination, in patients with CCHFV infection</li> <li>Assay development for surveillance, diagnostic, and prevention measures</li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. For collaboration opportunities, please contact Dr. Maryann Puglielli at <a href=mailto:maryann.puglielli@nih.gov>maryann.puglielli@nih.gov</a> or 1-240-627-3723 2023-03-02 2025-08-13 2025-08-15 2023-03-29 False False Pre-clinical True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 144206046 Leventhal, S. et al., EBioMedicine 82:104188 (2022), “Replicating RNA Vaccination Elicits an Unexpected Immune Response that Efficiently Protects Mice Against Lethal Crimean-Congo Hemorrhagic Fever Virus Challenge” Leventhal, S. et al., EBioMedicine 82:104188 (2022), “Replicating RNA Vaccination Elicits an Unexpected Immune Response that Efficiently Protects Mice Against Lethal Crimean-Congo Hemorrhagic Fever Virus Challenge” 144186769 Feldmann, Heinrich (Heinz) NIAID - DIR NIAID Feldmann, Heinrich (Heinz) (NIAID) 1 144186838 Hawman, David NIAID - DIR NIAID Hawman, David (NIAID) 2 144186889 Erasmus, Jesse HDT Bio Corp. Erasmus, Jesse 3 144186769 Feldmann, Heinrich (Heinz) NIAID - DIR NIAID Feldmann, Heinrich (Heinz) (NIAID) 1 144186838 Hawman, David NIAID - DIR NIAID Hawman, David (NIAID) 2 144186889 Erasmus, Jesse HDT Bio Corp. Erasmus, Jesse 3 144184931 Replicating RNA Vaccine For Crimean-Congo Hemorrhagic Fever Virus E-103-2022-0 Filing authorized HDT Biocorp, NIAID, University of Washington 146046171 Joyce, Terrence terrence.joyce@nih.gov
United States of America terrence.joyce@nih.gov?subject=Web Inquiry on [TAB-3833] Replicating RNA Vaccine For Crimean-Congo Hemorrhagic Fever Virus&body=Please send me information about technology [TAB-3833] Replicating RNA Vaccine For Crimean-Congo Hemorrhagic Fever Virus. Joyce, Terrence<br><a href="mailto:terrence.joyce@nih.gov?subject=Web Inquiry on [TAB-3833] Replicating RNA Vaccine For Crimean-Congo Hemorrhagic Fever Virus&body=Please send me information about technology [TAB-3833] Replicating RNA Vaccine For Crimean-Congo Hemorrhagic Fever Virus.">terrence.joyce@nih.gov</a><br> 144186591 E-103-2022-0 E-103-2022-0-US-01 Replicating RNA Vaccine For Crimean-Congo Hemorrhagic Fever Virus PRV US 63/365,015 Expired US <br />Provisional (PRV) 63/365,015<br />Filed on 2022-05-19<br />Status: Expired 146131382 E-103-2022-0 E-103-2022-0-PC-01 Replicating RNA Vaccine For Crimean-Congo Hemorrhagic Fever Virus PCT Patent Cooperation Treaty PCT/US2023/067226 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2023/067226<br />Filed on 2023-05-19<br />Status: Expired TAB-3825 114097671 Single Scan Bright-blood and Dark-blood Phase Sensitive Inversion Recovery (PSIR) Late Gadolinium Enhancement (LGE) for Cardiovascular Magnetic Resonance (CMR) Imaging NHLBI Cardiology, Diagnostics, Medical Devices, Non-Medical Devices, Software / Apps Cardiology Diagnostics Medical Devices Non-Medical Devices Software / Apps Peter Kellman, Hui Xue This technology includes a technique to improves detection of myocardial scar compared with conventional bright-blood late gadolinium enhancement (LGE) techniques. Dark-blood late gadolinium enhancement (DB-LGE) improves tissue delineation with signal suppression of the blood pool based on T2-preparation pulse that is relatively independent from the blood flow velocities and improves scar detection in patients with known or suspected coronary artery disease. Improves the quality and speed of scanning by imaging multiple parameters in a single free-breathing scan. Improve CMR scanning of commercial CMR. 2022-11-06 2024-10-28 2025-08-15 2024-03-27 2022-11-06 Bright-blood, Cardiovascular, Dark-blood, Dark-bloodphase, ENHANCEMENT, Gadolinium, Imaging:, inversion, Late, LGE, Magnetic, PHASE, PSIR, RECOVERY, Resonance, SCAN, SENSITIVE, Single, VDXXXX, WBXXXX, XFXXXX False True True 52398218 Pre-Clinical (in vivo) 52398218 NIHTT 37470483 Website Abstract 114172981 Kellman P, et al. https://pubmed.ncbi.nlm.nih.gov/34743718/ <a href="https://pubmed.ncbi.nlm.nih.gov/34743718/">Kellman P, et al.</a> 114111668 Xue, Hui National Heart, Lung, and Blood Institute (NHLBI) NHLBI Xue, Hui (NHLBI) 0 114111667 Kellman, Peter National Heart, Lung, and Blood Institute (NHLBI) NHLBI Kellman, Peter (NHLBI) 1 114111667 Kellman, Peter National Heart, Lung, and Blood Institute (NHLBI) NHLBI Kellman, Peter (NHLBI) 1 114111668 Xue, Hui National Heart, Lung, and Blood Institute (NHLBI) NHLBI Xue, Hui (NHLBI) 0 114102923 Cardiovascular Magnetic Resonance Imaging: Single Scan Bright-blood And Dark-blood Phase Sensitive Inversion Recovery (PSIR) Late Gadolinium Enhancement (LGE) E-025-2021-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 89788013 Kolesnitchenko, Vincent vk5q@nih.gov
United States of America Office of Technology Transfer and Development vk5q@nih.gov?subject=Web Inquiry on [TAB-3825] Single Scan Bright-blood and Dark-blood Phase Sensitive Inversion Recovery (PSIR) Late Gadolinium Enhancement (LGE) for Cardiovascular Magnetic Resonance (CMR) Imaging &body=Please send me information about technology [TAB-3825] Single Scan Bright-blood and Dark-blood Phase Sensitive Inversion Recovery (PSIR) Late Gadolinium Enhancement (LGE) for Cardiovascular Magnetic Resonance (CMR) Imaging . Kolesnitchenko, Vincent<br><a href="mailto:vk5q@nih.gov?subject=Web Inquiry on [TAB-3825] Single Scan Bright-blood and Dark-blood Phase Sensitive Inversion Recovery (PSIR) Late Gadolinium Enhancement (LGE) for Cardiovascular Magnetic Resonance (CMR) Imaging &body=Please send me information about technology [TAB-3825] Single Scan Bright-blood and Dark-blood Phase Sensitive Inversion Recovery (PSIR) Late Gadolinium Enhancement (LGE) for Cardiovascular Magnetic Resonance (CMR) Imaging .">vk5q@nih.gov</a><br> 114169682 E-025-2021-0 E-025-2021-0-US-01 SYNTHETIC BRIGHT-BLOOD AND DARK-BLOOD PSIR LGE IMAGES ORD US 11,454,691 17/472,838 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11454691 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11454691">11,454,691</a><br />Filed on 2021-09-13<br />Status: Issued 114129747 VDXXXX 114129748 WBXXXX 114129749 XFXXXX 114155739 Cardiovascular 114155740 Magnetic 114155741 Resonance 114155742 Imaging: 114155743 Single 114155744 SCAN 114155745 Bright-blood 114155746 Dark-bloodphase 114155747 SENSITIVE 114155748 inversion 114155749 RECOVERY 114155750 PSIR 114155751 Late 114155752 Gadolinium 114155753 ENHANCEMENT 114155754 LGE 114155755 Dark-blood 114155756 PHASE TAB-3822 114097668 Trans-auricular Left Atrial Appendage Ligation to Prevent Thrombosis NHLBI Cardiology, Consumer Products, Medical Devices, Non-Medical Devices Cardiology Consumer Products Medical Devices Non-Medical Devices Ozgur Kocaturk, Robert Lederman, Kanishka Ratnayaka, Toby Rogers This technology includes an interventional device to occlude the left atrial appendage to prevent thrombus formation. Atrial fibrillation is the most common cardiac arrhythmia and is associated with formation of thrombus in the left atrial appendage. Standard preventative treatment involves anticoagulation, which is not tolerated by all patients. Existing devices necessitate improvement because they need trans-septal puncture and anticoagulation to prevent thrombus or are prone to life-threatening complications. All existing devices can cause left atrial appendage perforation leading to cardiac tamponade, requiring urgent intervention. This device is designed to ligate and exclude the left atrial appendage from the left atrial cavity within the pericardial space. The left atrial appendage is then grasped with one limb of the device. The second limb deploys a suture and, using counter-traction between the two limbs, the suture is delivered to the base or neck of the left atrial appendage where it is tightened and secured. The suture is then cut, and the right atrial appendage puncture is sealed. The unique features of the device are: <ul><li>Two coaxial limbs with different purposes</li> <li>Application via a trans-auricular route</li> <li>An atraumatic grasper for the left atrial appendage</li> <li>A coaxial suture delivery system resembling the TRAIPTA device recently disclosed</li> <li>Counter traction between the two limbs allows complete external encirclement of the left atrial appendage at its ostium without risking appendage perforation rupture or avulsion</li></ul> Cardiac device to prevent thrombus formation. 2022-11-06 2025-08-13 2025-08-15 2024-03-20 Appendage, Atrial, Left, LIGATION, Listed LPM Shmilovich as of 4/15/2015, MECHANICAL, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Trans-auricular, VDXXXX, WMXXXX, XDXXXX False True True NIHTT 37470483 Website Abstract 114172980 Bartus K, Han F, et al. https://pubmed.ncbi.nlm.nih.gov/23062528/ <a href="https://pubmed.ncbi.nlm.nih.gov/23062528/">Bartus K, Han F, et al.</a> 114111654 Ratnayaka, Kanishka National Heart, Lung, and Blood Institute (NHLBI) Ratnayaka, Kanishka 0 114111655 Lederman, Robert National Heart, Lung, and Blood Institute (NHLBI) NHLBI Lederman, Robert (NHLBI) 0 114111656 Rogers, Toby National Heart, Lung, and Blood Institute (NHLBI) Rogers, Toby 0 114111653 Kocaturk, Ozgur National Heart, Lung, and Blood Institute (NHLBI) NHLBI Kocaturk, Ozgur (NHLBI) 1 114111653 Kocaturk, Ozgur National Heart, Lung, and Blood Institute (NHLBI) NHLBI Kocaturk, Ozgur (NHLBI) 1 114111654 Ratnayaka, Kanishka National Heart, Lung, and Blood Institute (NHLBI) Ratnayaka, Kanishka 0 114111655 Lederman, Robert National Heart, Lung, and Blood Institute (NHLBI) NHLBI Lederman, Robert (NHLBI) 0 114111656 Rogers, Toby National Heart, Lung, and Blood Institute (NHLBI) Rogers, Toby 0 114102920 Trans-auricular Left Atrial Appendage Ligation E-018-2014-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-3822] Trans-auricular Left Atrial Appendage Ligation to Prevent Thrombosis &body=Please send me information about technology [TAB-3822] Trans-auricular Left Atrial Appendage Ligation to Prevent Thrombosis . Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-3822] Trans-auricular Left Atrial Appendage Ligation to Prevent Thrombosis &body=Please send me information about technology [TAB-3822] Trans-auricular Left Atrial Appendage Ligation to Prevent Thrombosis .">shmilovm@nih.gov</a><br> 114169676 E-018-2014-0 E-018-2014-0-US-01 Trans-Auricular Left Atrial Appendage Ligation PRV US 61/896,048 Abandoned US <br />Provisional (PRV) 61/896,048<br />Filed on 2013-10-26<br />Status: Abandoned 114169677 E-018-2014-0 E-018-2014-0-PCT-02 Atrial Appendage Ligation PCT Patent Cooperation Treaty PCT/US2014/062364 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2014/062364<br />Filed on 2014-10-27<br />Status: Expired 114169678 E-018-2014-0 E-018-2014-0-US-04 ATRIAL APPENDAGE LIGATION National Stage US 10,575,851 15/030,574 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10575851 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10575851">10,575,851</a><br />Filed on 2016-04-19<br />Status: Issued 114129734 VDXXXX 114129735 WMXXXX 114129736 XDXXXX 114155700 Trans-auricular 114155701 Left 114155702 Atrial 114155703 Appendage 114155704 LIGATION 114155705 Listed LPM Shmilovich as of 4/15/2015 114155706 Pre LPM working set 20150418 114155707 Post LPM Assignment Set 20150420 114155708 MECHANICAL TAB-3773 114097624 Plasmid for the Study of Bam Complex and Screening of Therapeutic Molecules NIDDK Therapeutics Therapeutics Harris Bernstein, Janine Peterson, Giselle Roman-Hernandez This technology includes a plasmid (designated pJH114) that encodes all five subunits of the E. coli Bam (barrel assembly machine) complex under the control of an inducible promoter to be used in the study of the Bam and screen for therapeutic small molecules. The Bam (barrel assembly machine) complex is a highly conserved heterooligomer that catalyzes the integration of membrane proteins that have a beta barrel structure into the outer membrane of Gram-negative bacteria. Research suggests that this complex is essential for the viability of most, if not all bacteria in this class. An octahistidine tag was added to one of the subunits (BamE) to facilitate purification. The plasmid can be used to direct the synthesis of large amounts of all of the subunits simultaneously in E. coli. We have found that the proteins produced by this plasmid assemble into highly active complexes that are easily purified. This plasmid simplifies the production of intact Bam complexes and appears to yield a higher quality product. In academic laboratories this product can be used to study the function of the Bam complex using biochemical, biophysical and structural approaches. This product might also be used by academic or commercial entities to screen for compounds that inhibit Bam complex function. 2022-11-30 2025-08-13 2025-08-15 2022-11-30 ac5AXX, BAM, BamABCDE, Barn, COLI, COMPLEX, COMPONENTS, designated, E., ENCODES, Expression, Listed LPM Ano as of 4/15/2015, PJH114, PLASMID, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, That, WKXXXX False True True NIHTT 37470483 Website Abstract 114172938 Voulhoux R, Bos M, et al. https://pubmed.ncbi.nlm.nih.gov/12522254/ <a href="https://pubmed.ncbi.nlm.nih.gov/12522254/">Voulhoux R, Bos M, et al.</a> 114172939 Wu T, Malinverni J, et al. https://pubmed.ncbi.nlm.nih.gov/15851030/ <a href="https://pubmed.ncbi.nlm.nih.gov/15851030/">Wu T, Malinverni J, et al.</a> 114172940 Hagan C, Kim S, et al. https://pubmed.ncbi.nlm.nih.gov/20378773/ <a href="https://pubmed.ncbi.nlm.nih.gov/20378773/">Hagan C, Kim S, et al.</a> 114111528 Roman-Hernandez, Giselle National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Roman-Hernandez, Giselle 0 114111529 Peterson, Janine National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Peterson, Janine (NIDDK) 0 114111527 Bernstein, Harris National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Bernstein, Harris (NIDDK) 1 114111527 Bernstein, Harris National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Bernstein, Harris (NIDDK) 1 114111528 Roman-Hernandez, Giselle National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Roman-Hernandez, Giselle 0 114111529 Peterson, Janine National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Peterson, Janine (NIDDK) 0 114102876 Expression Plasmid Designated PJH114 That Encodes All Components Of The E. Coli Bam Complex (BamABCDE) E-288-2014-0 Research Material National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 91025239 Walsh, Rosemary rosemary.walsh@nih.gov
rosemary.walsh@nih.gov?subject=Web Inquiry on [TAB-3773] Plasmid for the Study of Bam Complex and Screening of Therapeutic Molecules&body=Please send me information about technology [TAB-3773] Plasmid for the Study of Bam Complex and Screening of Therapeutic Molecules. Walsh, Rosemary<br><a href="mailto:rosemary.walsh@nih.gov?subject=Web Inquiry on [TAB-3773] Plasmid for the Study of Bam Complex and Screening of Therapeutic Molecules&body=Please send me information about technology [TAB-3773] Plasmid for the Study of Bam Complex and Screening of Therapeutic Molecules.">rosemary.walsh@nih.gov</a><br> 114129559 ac5AXX 114129560 WKXXXX 114155273 Expression 114155274 PLASMID 114155275 PJH114 114155276 COLI 114155277 Barn 114155278 COMPLEX 114155279 BamABCDE 114155280 Listed LPM Ano as of 4/15/2015 114155281 Pre LPM working set 20150418 114155282 Post LPM Assignment Set 20150420 114155283 designated 114155284 That 114155285 ENCODES 114155286 COMPONENTS 114155287 E. 114155288 BAM TAB-3753 114097604 MLL3 (KMT2C), MLL4, PA1, UTX And PTIP Antibodies for the Treatment of Development Diseases and Cancers NIDDK Antibodies, Immunology, Oncology, Research Materials, Therapeutics Antibodies Immunology Oncology Research Materials Therapeutics Kai Ge, Ji-Eun Lee This technology includes polyclonal antibodies against MLL3 (KMT2C), MLL4, PA1, UTX And PTIP for the development of treatments for development diseases and cancer. Enhancers play a central role in cell-type-specific gene expression and are marked by H3K4me1/2. Active enhancers are further marked by H3K27ac. However, the methyltransferases responsible for H3K4me1/2 on enhancers remain elusive. Furthermore, how these enzymes function on enhancers to regulate cell-type-specific gene expression is unclear. Our findings suggest that loss-of-function mutations in MLL3 and MLL4 would impair H3K4me1/2 on enhancers, which lead to defects in enhancer activation, cell-type-specific gene expression and cell differentiation. Such a mechanism may contribute to the pathogenesis of these developmental diseases and cancers. Using MLL3/4 KO human and mouse cells, we demonstrated that MLL3/4 are major mammalian H3K4me1/2 methyltransferases in vivo and partially redundant each other. Treatment of various developmental diseases and cancers. 2022-11-30 2025-08-13 2025-08-15 2022-11-30 2022-07-11 Activation, antibodies, DIFFERENTIATION, Di-methyltransferase, ENHANCER, H3K4, ID1XXX, KMT2C, Listed LPM Contreras as of 4/15/2015, MLL3, MLL4, Mono-, pa1, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, PTIP, Required, RESEARCH MATERIAL, UTX, VCXXXX, WIXXXX, WJXXXX, XAXXXX False True True NIHTT 37470483 Website Abstract 114172912 Lee J, Wang C, et al. https://pubmed.ncbi.nlm.nih.gov/24368734/ <a href="https://pubmed.ncbi.nlm.nih.gov/24368734/">Lee J, Wang C, et al.</a> 114111474 Lee, Ji-Eun National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Lee, Ji-Eun (NIDDK) 0 114111473 Ge, Kai National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Ge, Kai (NIDDK) 1 114111473 Ge, Kai National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Ge, Kai (NIDDK) 1 114111474 Lee, Ji-Eun National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Lee, Ji-Eun (NIDDK) 0 114102856 MLL3 (KMT2C), MLL4, PA1, UTX And PTIP Antibodies E-114-2014-0 Research Material National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83739550 Shastri, Mythreyi shastrim@mail.nih.gov
United States of America Technology Advancement Office shastrim@mail.nih.gov?subject=Web Inquiry on [TAB-3753] MLL3 (KMT2C), MLL4, PA1, UTX And PTIP Antibodies for the Treatment of Development Diseases and Cancers&body=Please send me information about technology [TAB-3753] MLL3 (KMT2C), MLL4, PA1, UTX And PTIP Antibodies for the Treatment of Development Diseases and Cancers. Shastri, Mythreyi<br><a href="mailto:shastrim@mail.nih.gov?subject=Web Inquiry on [TAB-3753] MLL3 (KMT2C), MLL4, PA1, UTX And PTIP Antibodies for the Treatment of Development Diseases and Cancers&body=Please send me information about technology [TAB-3753] MLL3 (KMT2C), MLL4, PA1, UTX And PTIP Antibodies for the Treatment of Development Diseases and Cancers.">shastrim@mail.nih.gov</a><br> 114129488 ID1XXX 114129489 VCXXXX 114129490 WIXXXX 114129491 WJXXXX 114129492 XAXXXX 114155042 antibodies 114155043 H3K4 114155044 Mono- 114155045 Di-methyltransferase 114155046 MLL4 114155047 Required 114155048 ENHANCER 114155049 Activation 114155050 DIFFERENTIATION 114155051 MLL3 114155052 pa1 114155053 UTX 114155054 PTIP 114155055 Listed LPM Contreras as of 4/15/2015 114155056 Pre LPM working set 20150418 114155057 Post LPM Assignment Set 20150420 114155058 RESEARCH MATERIAL 114155059 KMT2C TAB-3738 114097590 Method For Improving Insulin Sensitivity for the Treatment of Diabetes NIDDK Endocrinology, Therapeutics Endocrinology Therapeutics Arnold Newman, Lynnette Nieman, Andre Ulmann This technology includes the administration of the antiglucocorticoid mifepristone for the treatment of diabetes. Administration of mifepristone (50 mg orally every 6 hours) for one week improves hepatic and adipose insulin resistance in men and women with pre-diabetes or mild type 2 diabetes mellitus. This class of compounds has not been previously used for the treatment of insulin resistance, which is found in patients with prediabetes and diabetes type 2. Thus, it is a novel discovery that may have important therapeutic applications in the many patients with these disorders. Treatment of insulin resistance, type 2 diabetes. 2022-11-30 2025-08-13 2025-08-15 2022-11-30 2022-07-10 IMPROVING, insulin, Method, SENSITIVITY, VFXXXX, WKXXXX False True True NIHTT 37470483 Website Abstract 114111443 Ulmann, Andre CEMAG CARE Ulmann, Andre 0 114111444 Newman, Arnold Unit Cell Diamond Newman, Arnold 0 114111442 Nieman, Lynnette NICHD NICHD Nieman, Lynnette (NICHD) 1 114111442 Nieman, Lynnette NICHD NICHD Nieman, Lynnette (NICHD) 1 114111443 Ulmann, Andre CEMAG CARE Ulmann, Andre 0 114111444 Newman, Arnold Unit Cell Diamond Newman, Arnold 0 114102842 Method For Improving Insulin Sensitivity E-081-2019-0 Filing authorized Laboratorie HRA Pharma Corporation, NICHD, Unit Cell Diamond 83692066 Tong, Betty tongb@niddk.nih.gov
United States of America Senior Technology Advancement Office tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-3738] Method For Improving Insulin Sensitivity for the Treatment of Diabetes&body=Please send me information about technology [TAB-3738] Method For Improving Insulin Sensitivity for the Treatment of Diabetes. Tong, Betty<br><a href="mailto:tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-3738] Method For Improving Insulin Sensitivity for the Treatment of Diabetes&body=Please send me information about technology [TAB-3738] Method For Improving Insulin Sensitivity for the Treatment of Diabetes.">tongb@niddk.nih.gov</a><br> 114169575 E-081-2019-0 E-081-2019-0-US-01 Method For Improving Insulin Sensitivity PRV US 62/919,496 Abandoned US <br />Provisional (PRV) 62/919,496<br />Filed on 2019-03-18<br />Status: Abandoned 114129450 VFXXXX 114129451 WKXXXX 114154942 Method 114154943 IMPROVING 114154944 insulin 114154945 SENSITIVITY TAB-3643 114097496 Staphylococcus Epidermidis Isolates from Human Skin Samples for Use as Clinical Molecular Markers NHGRI Diagnostics, Infectious Disease, Research Materials Diagnostics Infectious Disease Research Materials Heidi Kong, Lilia Mijares, Julia ("Julie") Segre This technology includes a catalog of commensal and pathogenic staphylococci from human skin for utilization as clinical molecular markers of skin conditions and infections. The study of microbial diversity of human skin in both healthy and disease states is important to develop tools to track infections, outbreaks, and multi-drug resistant organisms, particularly in atopic dermatitis, eczema and other microbial-associated infections. Commensal skin S. epidermidis have an open pan-genome and show considerable diversity between isolates. Previously unrecognized group of S. epidermidis strains have been characterized, which has the potential to be used as clinical molecular markers. This representative catalog of commensal and pathogenic staphylococci from the skin will also enable quantitative assessments of changes in staphylococcal burden during disease exacerbation, such as chronic relapsing atopic dermatitis or Methicillin-resistant Staphylococcus aureus (MRSA) infection. 2022-09-26 2025-08-13 2025-08-15 2022-09-26 2022-05-18 Epidermidis, Human, ISOLATES, SAMPLES, SKIN, Staphylococcus, VJXXXX, WBXXXX, WIXXXX, XCXXXX False True True NIHTT 37470483 Website Abstract 114172798 Conlan S, Mijares L, et al. https://pubmed.ncbi.nlm.nih.gov/22830599/ <a href="https://pubmed.ncbi.nlm.nih.gov/22830599/">Conlan S, Mijares L, et al.</a> 114111131 Mijares, Lilia University of Maryland, School of Medicine Mijares, Lilia 0 114111132 Kong, Heidi NIAMS - IRP NIAMS Kong, Heidi (NIAMS) 0 114111130 Segre, Julia ("Julie") National Human Genome Research Institute (NHGRI) NHGRI Segre, Julia ("Julie") (NHGRI) 1 114111130 Segre, Julia ("Julie") National Human Genome Research Institute (NHGRI) NHGRI Segre, Julia ("Julie") (NHGRI) 1 114111131 Mijares, Lilia University of Maryland, School of Medicine Mijares, Lilia 0 114111132 Kong, Heidi NIAMS - IRP NIAMS Kong, Heidi (NIAMS) 0 114102748 Staphylococcus Epidermidis Isolates From Human Skin Samples E-245-2020-0 Research Material National Human Genome Research Institute (NHGRI), NIAMS 83725487 Raghavan, Sangeetha sangeetha.raghavan@nih.gov
United States of America Technology Transfer Office sangeetha.raghavan@nih.gov?subject=Web Inquiry on [TAB-3643] Staphylococcus Epidermidis Isolates from Human Skin Samples for Use as Clinical Molecular Markers&body=Please send me information about technology [TAB-3643] Staphylococcus Epidermidis Isolates from Human Skin Samples for Use as Clinical Molecular Markers. Raghavan, Sangeetha<br><a href="mailto:sangeetha.raghavan@nih.gov?subject=Web Inquiry on [TAB-3643] Staphylococcus Epidermidis Isolates from Human Skin Samples for Use as Clinical Molecular Markers&body=Please send me information about technology [TAB-3643] Staphylococcus Epidermidis Isolates from Human Skin Samples for Use as Clinical Molecular Markers.">sangeetha.raghavan@nih.gov</a><br> 114129046 VJXXXX 114129047 WBXXXX 114129048 WIXXXX 114129049 XCXXXX 114153997 Staphylococcus 114153998 Epidermidis 114153999 ISOLATES 114154000 Human 114154001 SKIN 114154002 SAMPLES TAB-3639 114097492 Monoclonal Antibodies for the Recognition of Oncogene Fusions and Alveolar Rhabdomyosarcoma (ARMS) Diagnosis NHGRI Antibodies, Diagnostics, Immunology, Oncology, Research Materials Antibodies Diagnostics Immunology Oncology Research Materials David Azorsa, Javed Khan, Paul Meltzer This technology includes monoclonal antibody (mAb) that binds to the junction region of the PAX3-FOXO1 and PAX7-FOXO1 fusion protein for the diagnosis of Alveolar Rhabdomyosarcoma (ARMS). Specifically, two monoclonal antibodies (PFM.1 and PFM.2) have been isolated that recognize the 92kDa bands found uniquely to the pediatric striated muscle tumors of the type Alveolar Rhabdomyosarcoma (ARMS) carrying the characteristic t(2;13)(q35;q14) or t(1;13)(p36;q14) chromosomal translocations. This in-frame fusion protein is unique to the most common type of ARMS and acts as a potent transcriptional activator as the result of a decreased regulatory (of PAX3/7) sensitivity of the C-terminal domain of FOXO1. The mAbs recognize the ARMS fusion protein PAX3/7 FKHR on western analysis and do not recognize PAX3/7 or FOXO1 alone. The antibodies work by Westerns, Co-Immunoprecipitation, Chromatin Immunoprecipitation Sequencing (CHipSeq), and immunohistochemistry. Currently there is no recognized antibody capable of detecting the PAX3/7-FOXO1 fusion protein as a unique translocation product. To be utilized by pathologists for the diagnosis of ARMS. 2022-09-26 2025-08-13 2025-08-15 2022-09-26 2022-05-12 antibodies, Fusion, monoclonal, Oncogene, PAX3-FOXO1, PAX7-FOXO1, RECOGNIZE, That, VCXXXX, WBXXXX, WIXXXX, XAXXXX False True True NIHTT 37470483 Website Abstract 114172796 Gryder B, Yohe M, et al. https://pubmed.ncbi.nlm.nih.gov/28446439/ <a href="https://pubmed.ncbi.nlm.nih.gov/28446439/">Gryder B, Yohe M, et al.</a> 114111119 Meltzer, Paul NCI - CCR NCI Meltzer, Paul (NCI) 0 114111120 Azorsa, David University of Arizona College of Medicine - Phoenix Azorsa, David 0 114111118 Khan, Javed NCI - CCR NCI Khan, Javed (NCI) 1 114111118 Khan, Javed NCI - CCR NCI Khan, Javed (NCI) 1 114111119 Meltzer, Paul NCI - CCR NCI Meltzer, Paul (NCI) 0 114111120 Azorsa, David University of Arizona College of Medicine - Phoenix Azorsa, David 0 114102744 Monoclonal Antibodies That Recognize The Fusion Oncogene PAX3-FOXO1 And PAX7-FOXO1 E-213-2017-0 Research Material National Human Genome Research Institute (NHGRI) 83725487 Raghavan, Sangeetha sangeetha.raghavan@nih.gov
United States of America Technology Transfer Office sangeetha.raghavan@nih.gov?subject=Web Inquiry on [TAB-3639] Monoclonal Antibodies for the Recognition of Oncogene Fusions and Alveolar Rhabdomyosarcoma (ARMS) Diagnosis&body=Please send me information about technology [TAB-3639] Monoclonal Antibodies for the Recognition of Oncogene Fusions and Alveolar Rhabdomyosarcoma (ARMS) Diagnosis. Raghavan, Sangeetha<br><a href="mailto:sangeetha.raghavan@nih.gov?subject=Web Inquiry on [TAB-3639] Monoclonal Antibodies for the Recognition of Oncogene Fusions and Alveolar Rhabdomyosarcoma (ARMS) Diagnosis&body=Please send me information about technology [TAB-3639] Monoclonal Antibodies for the Recognition of Oncogene Fusions and Alveolar Rhabdomyosarcoma (ARMS) Diagnosis.">sangeetha.raghavan@nih.gov</a><br> 114129031 VCXXXX 114129032 WBXXXX 114129033 WIXXXX 114129034 XAXXXX 114153951 monoclonal 114153952 antibodies 114153953 That 114153954 RECOGNIZE 114153955 Fusion 114153956 Oncogene 114153957 PAX3-FOXO1 114153958 PAX7-FOXO1 TAB-3635 114097488 Fibroblast Cell Lines (with L444P/RecNci1 Genotype) for the Screening of Small Molecules for Gaucher Disease Treatment NHGRI Cardiology, Dental, Endocrinology, Infectious Disease, Oncology, Ophthalmology, Research Equipment, Therapeutics Cardiology Dental Endocrinology Infectious Disease Oncology Ophthalmology Research Equipment Therapeutics Ellen Sidransky, Barbara Stubblefield This technology includes two human fibroblast cell lines to be used to study the defects in GBA1 gene and protein and to screen small molecules for involvement in Gaucher disease. Glucocerebrosidase (GBA1 or GCase or beta-glucosidase) is a lysosomal enzyme, responsible for breakdown of a fatty material called glucocerebroside (or glucosyl ceramide). Deficiency or malfunction of GBA1 leads to the accumulation of insoluble glucocerebrosides in tissues, which is a major symptom of Gaucher disease. Gaucher disease is a rare and heterogeneous disorder, caused by inherited genetic mutations in GBA1. Fibroblasts from various patients were collected, including those with genotype L444P/ recombinant allele (recNci1). Because this mutation is involved in neuronopathic Gaucher disease, it can be used for the study of neuronopathic forms of the disorder. These cell lines can be used to study the defects in GBA1 gene and protein and to screen small molecules for involvement in Gaucher disease. 2022-09-26 2025-08-13 2025-08-15 2022-09-26 2022-05-12 Cell, Fibroblast, Gaucher, Genotype, L44P/RecNci1, Lines, PATIENT, VPXXXX, WKXXXX, XHXXXX False True True NIHTT 37470483 Website Abstract 114172793 Weiss K, Gonzalez A, et al. https://pubmed.ncbi.nlm.nih.gov/25435509/ <a href="https://pubmed.ncbi.nlm.nih.gov/25435509/">Weiss K, Gonzalez A, et al.</a> 114111108 Stubblefield, Barbara National Human Genome Research Institute (NHGRI) NHGRI Stubblefield, Barbara (NHGRI) 0 114111107 Sidransky, Ellen National Human Genome Research Institute (NHGRI) NHGRI Sidransky, Ellen (NHGRI) 1 114111107 Sidransky, Ellen National Human Genome Research Institute (NHGRI) NHGRI Sidransky, Ellen (NHGRI) 1 114111108 Stubblefield, Barbara National Human Genome Research Institute (NHGRI) NHGRI Stubblefield, Barbara (NHGRI) 0 114102740 Fibroblast Cell Lines From A Patient With Gaucher Genotype L44P/RecNci1 E-062-2016-0 Research Material National Human Genome Research Institute (NHGRI) 83718085 Surabian, Karen karen.surabian@nih.gov
United States of America Technology Transfer Office (TTO) karen.surabian@nih.gov?subject=Web Inquiry on [TAB-3635] Fibroblast Cell Lines (with L444P/RecNci1 Genotype) for the Screening of Small Molecules for Gaucher Disease Treatment&body=Please send me information about technology [TAB-3635] Fibroblast Cell Lines (with L444P/RecNci1 Genotype) for the Screening of Small Molecules for Gaucher Disease Treatment. Surabian, Karen<br><a href="mailto:karen.surabian@nih.gov?subject=Web Inquiry on [TAB-3635] Fibroblast Cell Lines (with L444P/RecNci1 Genotype) for the Screening of Small Molecules for Gaucher Disease Treatment&body=Please send me information about technology [TAB-3635] Fibroblast Cell Lines (with L444P/RecNci1 Genotype) for the Screening of Small Molecules for Gaucher Disease Treatment.">karen.surabian@nih.gov</a><br> 114129017 VPXXXX 114129018 WKXXXX 114129019 XHXXXX 114153915 Fibroblast 114153916 Cell 114153917 Lines 114153918 PATIENT 114153919 Gaucher 114153920 Genotype 114153921 L44P/RecNci1 TAB-3608 114097461 Novel Codon-Optimized MUT Gene Therapeutic for Methylmalonic Acidemia (MMA) NHGRI Cardiology, Dental, Endocrinology, Infectious Disease, Oncology, Ophthalmology, Therapeutics Cardiology Dental Endocrinology Infectious Disease Oncology Ophthalmology Therapeutics Ciprian Crainiceanu, Arthur Goldsmith, Daniel Reich, Colin Shea, Russell Shinohara, Elizabeth Sweeney Methylmalonic Acidemia (MMA) is a metabolic disorder characterized by increased acidity in the blood and tissues due to toxic accumulation of protein and fat by-products resulting in seizures, strokes, and chronic kidney failure. A significant portion of MMA cases stem from a deficiency in a key mitochondrial enzyme, methylmalonyl-CoA mutase (MUT), required to break down amino acids and lipids. Currently, there are no treatments for MMA and the disease is managed primarily with dietary restriction of amino acid precursors and liver-kidney transplantation in severe cases. <br /><r /> The present invention describes a synthetic codon-optimized MUT gene (co-MUT) that improves expression of human methylmalonyl-CoA mutase. A series of novel gene therapy vectors containing co-MUT rescued MMA mice from lethality and lowered levels of methylmalonic acid in the blood. Results of pre-clinical efficacy studies demonstrate a promising therapy for MMA and other renal-associated disorders. The co-MUT transgene could be used through non-viral and viral gene delivery. <ul> <li>The co-MUT transgene could be used to treat MMA patients.</li> <li>In addition, it could be used to produce MUT in vitro for MMA enzyme replacement therapy.</li> </ul> 2022-09-26 2025-08-13 2025-08-15 2022-09-26 2022-05-11 Automatic, brain, Detection, IMAGING, Incidence, Lesion, Listed LPM Shmilovich as of 4/15/2015, Longitudinal, Magnetic, MULTIMODALITY, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Resonance, software, SuBLIME:, VPXXXX, WJXXXX, XEXXXX False True True NIHTT 37470483 Website Abstract 114111032 Shea, Colin NINDS NINDS Shea, Colin (NINDS) 0 114111033 Crainiceanu, Ciprian Johns Hopkins University Crainiceanu, Ciprian 0 114111034 Sweeney, Elizabeth Johns Hopkins University Sweeney, Elizabeth 0 114111035 Shinohara, Russell Johns Hopkins University Shinohara, Russell 0 114111036 Goldsmith, Arthur Johns Hopkins University Goldsmith, Arthur 0 114110560 Reich, Daniel NINDS NINDS Reich, Daniel (NINDS) 1 114110560 Reich, Daniel NINDS NINDS Reich, Daniel (NINDS) 1 114111032 Shea, Colin NINDS NINDS Shea, Colin (NINDS) 0 114111033 Crainiceanu, Ciprian Johns Hopkins University Crainiceanu, Ciprian 0 114111034 Sweeney, Elizabeth Johns Hopkins University Sweeney, Elizabeth 0 114111035 Shinohara, Russell Johns Hopkins University Shinohara, Russell 0 114111036 Goldsmith, Arthur Johns Hopkins University Goldsmith, Arthur 0 152358172 A Synthetic Methylmalonyl-CoA Mutase Transgene For The Treatment Of Mut Class Methylmalonic Acidemia (MMA) E-243-2012-1 Filing authorized National Human Genome Research Institute (NHGRI) 83716782 Campbell, Eggerton eggerton.campbell@nih.gov
United States of America eggerton.campbell@nih.gov?subject=Web Inquiry on [TAB-3608] Novel Codon-Optimized MUT Gene Therapeutic for Methylmalonic Acidemia (MMA)&body=Please send me information about technology [TAB-3608] Novel Codon-Optimized MUT Gene Therapeutic for Methylmalonic Acidemia (MMA). Campbell, Eggerton<br><a href="mailto:eggerton.campbell@nih.gov?subject=Web Inquiry on [TAB-3608] Novel Codon-Optimized MUT Gene Therapeutic for Methylmalonic Acidemia (MMA)&body=Please send me information about technology [TAB-3608] Novel Codon-Optimized MUT Gene Therapeutic for Methylmalonic Acidemia (MMA).">eggerton.campbell@nih.gov</a><br> 114169325 E-043-2012-0 E-043-2012-0-US-03 SuBLIME: Automatic Brain Lesion Incidence And Detection Using Multimodality Longitudinal Magnetic Resonance Imaging National Stage US 9,607,392 14/362,354 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9607392 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9607392">9,607,392</a><br />Filed on 2014-06-02<br />Status: Issued 114169326 E-043-2012-0 E-043-2012-0-PCT-02 SYSTEM AND METHOD OF AUTOMATICALLY DETECTING TISSUE ABNORMALITIES PCT Patent Cooperation Treaty PCT/US2012/067997 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2012/067997<br />Filed on 2012-12-05<br />Status: Expired 114169327 E-043-2012-0 E-043-2012-0-US-01 SuBLIME: Automatic Brain Lesion Incidence And Detection Using Multimodality Longitudinal Magnetic Resonance Imaging PRV US 61/630,101 Abandoned US <br />Provisional (PRV) 61/630,101<br />Filed on 2011-12-05<br />Status: Abandoned 152358237 E-243-2012-1 E-243-2012-1-US-01 Synthetic Methylmalonyl-CoA Mutase Transgene For The Treatment Of Mut Class Methylmalonic Acidemia (MMA) CIP US 9,944,918 15/070,787 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9944918 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9944918">9,944,918</a><br />Filed on 2016-03-15<br />Status: Issued 114128921 VPXXXX 114128922 WJXXXX 114128923 XEXXXX 114153600 SuBLIME: 114153601 Automatic 114153602 brain 114153603 Lesion 114153604 Incidence 114153605 Detection 114153606 MULTIMODALITY 114153607 Longitudinal 114153608 Magnetic 114153609 Resonance 114153610 IMAGING 114153611 Listed LPM Shmilovich as of 4/15/2015 114153612 Pre LPM working set 20150418 114153613 Post LPM Assignment Set 20150420 114153614 software TAB-3599 114097452 Repurposing CDK Inhibitors for the Treatment of Zika Virus Infection NCATS Infectious Disease, Neurology, Research Materials, Therapeutics Infectious Disease Neurology Research Materials Therapeutics Ruili Huang, Wenwei Huang, Emily Lee, Guo-Li Ming, Hongjun Song, Hengli Tang, Zhexing Wen, Miao Xu, Cheng YiChen, Wei Zheng, Yi Zhou This invention includes the discovery and use of a group of CDK inhibitors that were found during a drug repurposing screen designed to find compounds that inhibit Zika virus caused cell death. The identified CDK inhibitors have all previously been used in clinical trials for other diseases, potentially reducing the long time course needed for new drug discovery and development. Repurposing CDK inhibitors that have been used in clinical trials for other diseases for the treatment of Zika virus infection can reduce the long time course needed for new drug discovery and development. The group of identified CDK inhibitors could be used with an animal model to test for in vivo efficacy and to optimize the chemistry of the lead compounds. 2022-08-01 2025-08-13 2025-08-15 2022-08-01 2022-05-06 CDK, Infection, Inhibitors, Repurposing, treatment, VEXXXX, virus, VLXXXX, WIXXXX, WKXXXX, Zika False True True NIHTT 37470483 Website Abstract 114110983 Huang, Ruili NCATS - NCGC NCATS Huang, Ruili (NCATS) 0 114110984 Xu, Miao NCATS - NCGC NCATS Xu, Miao (NCATS) 0 114110985 Huang, Wenwei NCATS - TRND NCATS Huang, Wenwei (NCATS) 0 114110986 Tang, Hengli Florida State University Research Foundation, Inc. (FSURF) Tang, Hengli 0 114110987 Lee, Emily Florida State University Research Foundation, Inc. (FSURF) Lee, Emily 0 114110988 YiChen, Cheng Florida State University Research Foundation, Inc. (FSURF) YiChen, Cheng 0 114110989 Zhou, Yi Florida State University Research Foundation, Inc. (FSURF) Zhou, Yi 0 114110990 Song, Hongjun Johns Hopkins University Song, Hongjun 0 114110991 Ming, Guo-Li Johns Hopkins University Ming, Guo-Li 0 114110992 Wen, Zhexing Johns Hopkins University Wen, Zhexing 0 114110982 Zheng, Wei NCATS - TRND NCATS Zheng, Wei (NCATS) 1 114110982 Zheng, Wei NCATS - TRND NCATS Zheng, Wei (NCATS) 1 114110983 Huang, Ruili NCATS - NCGC NCATS Huang, Ruili (NCATS) 0 114110984 Xu, Miao NCATS - NCGC NCATS Xu, Miao (NCATS) 0 114110985 Huang, Wenwei NCATS - TRND NCATS Huang, Wenwei (NCATS) 0 114110986 Tang, Hengli Florida State University Research Foundation, Inc. (FSURF) Tang, Hengli 0 114110987 Lee, Emily Florida State University Research Foundation, Inc. (FSURF) Lee, Emily 0 114110988 YiChen, Cheng Florida State University Research Foundation, Inc. (FSURF) YiChen, Cheng 0 114110989 Zhou, Yi Florida State University Research Foundation, Inc. (FSURF) Zhou, Yi 0 114110990 Song, Hongjun Johns Hopkins University Song, Hongjun 0 114110991 Ming, Guo-Li Johns Hopkins University Ming, Guo-Li 0 114110992 Wen, Zhexing Johns Hopkins University Wen, Zhexing 0 114102706 Repurposing CDK Inhibitors For Treatment Of Zika Virus Infection E-202-2016-0 Filing authorized Florida State University Research Foundation, Inc. (FSURF), Johns Hopkins University, NCATS - NCGC 83673536 Erwin-Cohen, Rebecca rebecca.erwin-cohen@nih.gov
NCGC rebecca.erwin-cohen@nih.gov?subject=Web Inquiry on [TAB-3599] Repurposing CDK Inhibitors for the Treatment of Zika Virus Infection&body=Please send me information about technology [TAB-3599] Repurposing CDK Inhibitors for the Treatment of Zika Virus Infection. Erwin-Cohen, Rebecca<br><a href="mailto:rebecca.erwin-cohen@nih.gov?subject=Web Inquiry on [TAB-3599] Repurposing CDK Inhibitors for the Treatment of Zika Virus Infection&body=Please send me information about technology [TAB-3599] Repurposing CDK Inhibitors for the Treatment of Zika Virus Infection.">rebecca.erwin-cohen@nih.gov</a><br> 114169443 E-202-2016-0 E-202-2016-0-US-01 Compounds and Methods for Treatment and Prevention of Flavivirus Infection PRV US 62/363,238 Abandoned US <br />Provisional (PRV) 62/363,238<br />Filed on 2016-07-16<br />Status: Abandoned 114128885 VEXXXX 114128886 VLXXXX 114128887 WIXXXX 114128888 WKXXXX 114153519 Repurposing 114153520 CDK 114153521 Inhibitors 114153522 treatment 114153523 Zika 114153524 virus 114153525 Infection TAB-3598 114097451 Novel ACRV1/ALK2 Inhibitors and Methods for Inhibiting BMP Signaling for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP) NCATS Endocrinology, Research Materials, Therapeutics Endocrinology Research Materials Therapeutics Asaf Alimardanov, Junfeng Huang, Wenwei Huang, Xiuli Huang, Jiankang Jiang, Arthur Lee, Philip Sanderson, Khalida Shamim, Gregory Tawa, Wei Zheng This technology includes the identification and use of novel ACRV1/ALK2 inhibitors for the treatment of fibrodysplasia ossificans progressiva (FOP), an autosomal-dominant rare disease that affects one person in every 1-2 million. FOP is characterized by malformation of the great (big) toes during embryonic development and by progressive heterotopic endochondral ossification (HEO) postnatally, which leads to the formation of a second skeleton of heterotopic bone. Individuals with the classical features of FOP have the identical heterozygous activating mutation (R206H) in the gene encoding ACRV1 (also known as ALK2), a BMP type 1 receptor. There are no effective treatments for fibrodysplasia ossificans progressiva (FOP). Further clinical work could establish the novel ACRV1/ALK2 inhibitors for the treatment of fibrodysplasia ossificans progressiva (FOP). Potent ALK2 inhibitors could conceivably be used prophylactic, acute or chronic therapy for patients with FOP as well as disorders associated with altered BMP signaling. 2022-08-01 2025-08-13 2025-08-15 2022-08-01 2022-05-06 ALK2, BMP, INHIBITING, Inhibitors, Methods, Novel, SIGNALING, VGXXXX, WIXXXX, WKXXXX, XEXXXX False True True NIHTT 37470483 Website Abstract 114172770 Yu PB, Deng DY, et al. https://pubmed.ncbi.nlm.nih.gov/19029982/ <a href="https://pubmed.ncbi.nlm.nih.gov/19029982/">Yu PB, Deng DY, et al.</a> 114172771 Hao J, Ho JN, et al. https://pubmed.ncbi.nlm.nih.gov/20020776/ <a href="https://pubmed.ncbi.nlm.nih.gov/20020776/">Hao J, Ho JN, et al.</a> 114172772 Cuny GD, Yu PB, et al. https://pubmed.ncbi.nlm.nih.gov/18621530/ <a href="https://pubmed.ncbi.nlm.nih.gov/18621530/">Cuny GD, Yu PB, et al.</a> 114172773 Sanvitale CE, Kerr G, et al. https://pubmed.ncbi.nlm.nih.gov/23646137/ <a href="https://pubmed.ncbi.nlm.nih.gov/23646137/">Sanvitale CE, Kerr G, et al.</a> 114110973 Jiang, Jiankang NCATS - NCGC NCATS Jiang, Jiankang (NCATS) 0 114110974 Shamim, Khalida NCATS - TRND NCATS Shamim, Khalida (NCATS) 0 114110975 Sanderson, Philip NCATS - TRND NCATS Sanderson, Philip (NCATS) 0 114110976 Zheng, Wei NCATS - TRND NCATS Zheng, Wei (NCATS) 0 114110977 Huang, Xiuli NCATS - NCGC NCATS Huang, Xiuli (NCATS) 0 114110978 Tawa, Gregory NCATS - TRND NCATS Tawa, Gregory (NCATS) 0 114110979 Alimardanov, Asaf NCATS - NCGC NCATS Alimardanov, Asaf (NCATS) 0 114110980 Lee, Arthur NCATS - TRND Lee, Arthur 0 114110981 Huang, Junfeng NCATS - TRND NCATS Huang, Junfeng (NCATS) 0 114110972 Huang, Wenwei NCATS - TRND NCATS Huang, Wenwei (NCATS) 1 114110972 Huang, Wenwei NCATS - TRND NCATS Huang, Wenwei (NCATS) 1 114110973 Jiang, Jiankang NCATS - NCGC NCATS Jiang, Jiankang (NCATS) 0 114110974 Shamim, Khalida NCATS - TRND NCATS Shamim, Khalida (NCATS) 0 114110975 Sanderson, Philip NCATS - TRND NCATS Sanderson, Philip (NCATS) 0 114110976 Zheng, Wei NCATS - TRND NCATS Zheng, Wei (NCATS) 0 114110977 Huang, Xiuli NCATS - NCGC NCATS Huang, Xiuli (NCATS) 0 114110978 Tawa, Gregory NCATS - TRND NCATS Tawa, Gregory (NCATS) 0 114110979 Alimardanov, Asaf NCATS - NCGC NCATS Alimardanov, Asaf (NCATS) 0 114110980 Lee, Arthur NCATS - TRND Lee, Arthur 0 114110981 Huang, Junfeng NCATS - TRND NCATS Huang, Junfeng (NCATS) 0 114102705 Novel ALK2 Inhibitors And Methods For Inhibiting BMP Signaling E-198-2016-0 Filing authorized NCATS - NCGC 93911356 Kalsi, Jasmine jasmine.kalsi@nih.gov
United States of America jasmine.kalsi@nih.gov?subject=Web Inquiry on [TAB-3598] Novel ACRV1/ALK2 Inhibitors and Methods for Inhibiting BMP Signaling for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)&body=Please send me information about technology [TAB-3598] Novel ACRV1/ALK2 Inhibitors and Methods for Inhibiting BMP Signaling for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP). Kalsi, Jasmine<br><a href="mailto:jasmine.kalsi@nih.gov?subject=Web Inquiry on [TAB-3598] Novel ACRV1/ALK2 Inhibitors and Methods for Inhibiting BMP Signaling for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)&body=Please send me information about technology [TAB-3598] Novel ACRV1/ALK2 Inhibitors and Methods for Inhibiting BMP Signaling for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP).">jasmine.kalsi@nih.gov</a><br> 114169439 E-198-2016-0 E-198-2016-0-US-01 Novel ALK2 Inhibitors And Methods For Inhibiting BMP Signaling PRV US 62/490,772 Abandoned US <br />Provisional (PRV) 62/490,772<br />Filed on 2017-04-27<br />Status: Abandoned 114169440 E-198-2016-0 E-198-2016-0-PCT-02 Novel ALK2 Inhibitors And Methods For Inhibiting BMP Signaling PCT Patent Cooperation Treaty PCT/US2018/029626 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2018/029626<br />Filed on 2018-04-26<br />Status: Expired 114169441 E-198-2016-0 E-198-2016-0-US-04 Novel ALK2 Inhibitors And Methods For Inhibiting BMP Signaling National Stage US 11,026,947 16/608,489 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11026947 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11026947">11,026,947</a><br />Filed on 2019-10-25<br />Status: Issued 114169442 E-198-2016-0 E-198-2016-0-US-08 Novel ALK2 Inhibitors And Methods For Inhibiting BMP Signaling CON US 11,654,147 17/340,589 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11654147 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11654147">11,654,147</a><br />Filed on 2021-06-07<br />Status: Issued 114128881 VGXXXX 114128882 WIXXXX 114128883 WKXXXX 114128884 XEXXXX 114153512 Novel 114153513 ALK2 114153514 Inhibitors 114153515 Methods 114153516 INHIBITING 114153517 BMP 114153518 SIGNALING TAB-3595 114097448 Repurposed Use of the Alkaloids Emetine and Cephaeline to Treat Zika Virus Infection NCATS Infectious Disease, Research Materials, Therapeutics Infectious Disease Research Materials Therapeutics Ruili Huang, Wenwei Huang, Emily Lee, Hao Li, Khalida Shamim, Hengli Tang, Miao Xu, Shu Yang, Wei Zheng This technology includes the use of two related compounds, Emetine and Cephaeline, as a potent inhibitor of the Zika virus (ZIKV). Emetine and it's analog Cephaeline were identified in a high-throughput assay aimed at identifying anti-ZIKV compounds. Both Emetine and Cephaeline are potent inhibitors of ZIKV infection in cell culture, and Emeline is a potent inhibitor of ZIKV infection in a live mouse model. These compounds were previously identified in an ipecac root crude extract which was used as a treatment for amoebic dysentery in addition to being used as an emetic agent, depending on dosage. While there has been some cardiotoxicity reported with high dosage of emetine, the effective IC50 observed in cell culture and mice is well below the toxic dosage. This is the first report of Emetine or Cephaeline as antiviral compounds in ZIKV infection. There are currently no known antiviral treatments against ZIKV infection. Current treatments for ZIKV are only supportive and not curative. Both Emetine and Cephaeline are potent inhibitors of ZIKV infection in cell culture, and Emeline is a potent inhibitor of ZIKV infection in a live mouse model. Further clinical work may support the use of these compounds for therapeutic use. 2022-08-01 2025-08-13 2025-08-15 2022-08-01 2022-05-06 compounds, Emetine, Flavivirus, Infection, Prevention, treatment, VLXXXX, WIXXXX, WKXXXX False True True NIHTT 37470483 Website Abstract 114172768 Yang S, Xu M, et al. https://pubmed.ncbi.nlm.nih.gov/29872540/ <a href="https://pubmed.ncbi.nlm.nih.gov/29872540/">Yang S, Xu M, et al.</a> 114110955 Lee, Emily Florida State University Research Foundation, Inc. (FSURF) Lee, Emily 0 114110956 Zheng, Wei NCATS - TRND NCATS Zheng, Wei (NCATS) 0 114110957 Xu, Miao NCATS - NCGC NCATS Xu, Miao (NCATS) 0 114110958 Huang, Ruili NCATS - NCGC NCATS Huang, Ruili (NCATS) 0 114110959 Yang, Shu NCATS - TRND NCATS Yang, Shu (NCATS) 0 114110960 Huang, Wenwei NCATS - TRND NCATS Huang, Wenwei (NCATS) 0 114110961 Shamim, Khalida NCATS - TRND NCATS Shamim, Khalida (NCATS) 0 114110962 Li, Hao NCATS - TRND NCATS Li, Hao (NCATS) 0 114110954 Tang, Hengli Florida State University Research Foundation, Inc. (FSURF) Tang, Hengli 1 114110954 Tang, Hengli Florida State University Research Foundation, Inc. (FSURF) Tang, Hengli 1 114110955 Lee, Emily Florida State University Research Foundation, Inc. (FSURF) Lee, Emily 0 114110956 Zheng, Wei NCATS - TRND NCATS Zheng, Wei (NCATS) 0 114110957 Xu, Miao NCATS - NCGC NCATS Xu, Miao (NCATS) 0 114110958 Huang, Ruili NCATS - NCGC NCATS Huang, Ruili (NCATS) 0 114110959 Yang, Shu NCATS - TRND NCATS Yang, Shu (NCATS) 0 114110960 Huang, Wenwei NCATS - TRND NCATS Huang, Wenwei (NCATS) 0 114110961 Shamim, Khalida NCATS - TRND NCATS Shamim, Khalida (NCATS) 0 114110962 Li, Hao NCATS - TRND NCATS Li, Hao (NCATS) 0 114102702 EMETINE COMPOUNDS FOR TREATMENT AND PREVENTION OF FLAVIVIRUS INFECTION E-115-2018-0 Filing authorized Florida State University Research Foundation, Inc. (FSURF), NCATS - NCGC 83673536 Erwin-Cohen, Rebecca rebecca.erwin-cohen@nih.gov
NCGC rebecca.erwin-cohen@nih.gov?subject=Web Inquiry on [TAB-3595] Repurposed Use of the Alkaloids Emetine and Cephaeline to Treat Zika Virus Infection&body=Please send me information about technology [TAB-3595] Repurposed Use of the Alkaloids Emetine and Cephaeline to Treat Zika Virus Infection. Erwin-Cohen, Rebecca<br><a href="mailto:rebecca.erwin-cohen@nih.gov?subject=Web Inquiry on [TAB-3595] Repurposed Use of the Alkaloids Emetine and Cephaeline to Treat Zika Virus Infection&body=Please send me information about technology [TAB-3595] Repurposed Use of the Alkaloids Emetine and Cephaeline to Treat Zika Virus Infection.">rebecca.erwin-cohen@nih.gov</a><br> 114169437 E-115-2018-0 E-115-2018-0-US-01 EMETINE COMPOUNDS FOR TREATMENT AND PREVENTION OF FLAVIVIRUS INFECTION PRV US 62/570,553 Abandoned US <br />Provisional (PRV) 62/570,553<br />Filed on 2017-10-10<br />Status: Abandoned 114128869 VLXXXX 114128870 WIXXXX 114128871 WKXXXX 114153496 Emetine 114153497 compounds 114153498 treatment 114153499 Prevention 114153500 Flavivirus 114153501 Infection TAB-3590 114097444 A Group of Compounds that Activate AMP-activated protein kinase (AMPK) that may Treat Niemann-Pick Disease Type C (NPC) NCATS Neurology, Research Materials, Therapeutics Neurology Research Materials Therapeutics Zachary Caffall, Nicole Calakos, Joseph Rittiner This technology relates to the identification and use of a group of compounds that activate the AMP-activated protein kinase (AMPK) and also effectively reduce lysosomal cholesterol accumulation in patients with Niemann-Pick disease Type C (NPC). Clinical trials are currently underway to determine the efficacy of beta-cyclodextrin in treating patients with NPC. A potential mechanism has been proposed indicating that beta-cyclodextrin activated AMP-activated protein kinase, leading to restoration of autophagy in cells from NPC patients. A computer modeling was used to identify the group of compounds that bind and activate AMPK. Eight of the compounds were found to effectively reduce cholesterol accumulation in lysosomes of cells from NPC patients. The small molecule AMPK modulators can be optimized for better penetration of the blood-brain barrier. This is advantageous over beta-cyclodextrin, which is impermeable to the blood-brain barrier and needs to be directly injected into the central nervous system. In addition, the allosteric modulation of AMPK function by these compounds is more tolerable as a treatment because beta-cyclodextrin directly activates the AMPK alpha-subunit which can cause significant cytotoxicity. The group of compounds identified as AMPK activators can be further developed to improve potency and ability of blood-brain-barrier penetration as a new drug for the treatment of Niemann-Pick disease Type C. 2022-08-01 2025-08-13 2025-08-15 2022-08-01 2022-05-06 AMPK, C, Compositions, Disease, DISORDERS, Dystonia, Identifying, Methods, MODULATORS, Niemann, Pick, TREATING, treatment, TYPE, VEXXXX, WIXXXX, WKXXXX, XEXXXX False True True NIHTT 37470483 Website Abstract 114172766 Dai S, Dulcey AE, et al. https://pubmed.ncbi.nlm.nih.gov/28613987/ <a href="https://pubmed.ncbi.nlm.nih.gov/28613987/">Dai S, Dulcey AE, et al.</a> 114110931 Caffall, Zachary Duke University Caffall, Zachary 0 114110932 Rittiner, Joseph Duke University Rittiner, Joseph 0 114110930 Calakos, Nicole Duke University Calakos, Nicole 1 114110930 Calakos, Nicole Duke University Calakos, Nicole 1 114110931 Caffall, Zachary Duke University Caffall, Zachary 0 114110932 Rittiner, Joseph Duke University Rittiner, Joseph 0 114102698 Compositions And Methods For Identifying And Treating Dystonia Disorders E-060-2017-0 Filing authorized Duke University, NIH - NCATS 83673536 Erwin-Cohen, Rebecca rebecca.erwin-cohen@nih.gov
NCGC rebecca.erwin-cohen@nih.gov?subject=Web Inquiry on [TAB-3590] A Group of Compounds that Activate AMP-activated protein kinase (AMPK) that may Treat Niemann-Pick Disease Type C (NPC)&body=Please send me information about technology [TAB-3590] A Group of Compounds that Activate AMP-activated protein kinase (AMPK) that may Treat Niemann-Pick Disease Type C (NPC). Erwin-Cohen, Rebecca<br><a href="mailto:rebecca.erwin-cohen@nih.gov?subject=Web Inquiry on [TAB-3590] A Group of Compounds that Activate AMP-activated protein kinase (AMPK) that may Treat Niemann-Pick Disease Type C (NPC)&body=Please send me information about technology [TAB-3590] A Group of Compounds that Activate AMP-activated protein kinase (AMPK) that may Treat Niemann-Pick Disease Type C (NPC).">rebecca.erwin-cohen@nih.gov</a><br> 114169433 E-060-2017-0 E-060-2017-0-US-01 Compositions and Methods for Identifying and Treating Dystonia Disorders PRV US 62/234,127 Abandoned US <br />Provisional (PRV) 62/234,127<br />Filed on 2015-09-29<br />Status: Abandoned 114128852 VEXXXX 114128853 WIXXXX 114128854 WKXXXX 114128855 XEXXXX 114153453 AMPK 114153454 MODULATORS 114153455 treatment 114153456 Niemann 114153457 Pick 114153458 TYPE 114153459 C 114153460 Disease 114153461 Compositions 114153462 Methods 114153463 Identifying 114153464 TREATING 114153465 Dystonia 114153466 DISORDERS TAB-3587 114097442 Process for Practical, Scalable, Commercially-viable Method for the Synthesis of Enantio-enriched Aminoalcohols, Including the Novel Antifungal VT-1129 Used to Treat Cryptococcal Meningitis NCATS Consumer Products, Neurology Consumer Products Neurology Asaf Alimardanov, Mark Behnke, Scott David, Douglas (Doug) Fry, William Hoekstra, Christopher Yates This technology relates to the discovery and development of a practical, scalable, and commercially viable method for the synthesis of the novel antifungal VT-1129. Cryptococcal meningitis (CM) is a fungal infection that is particularly prevalent in immune-compromised patients and can be treated by VT-1129. CM has a current estimated patient population of 1-1.25 million, predominately in sub-Saharan Africa and the developing world. Several deficiencies and difficulties preclude large-scale preparation and manufacturing with previous processes, which include high cost and potential safety issues. The method described in this invention enables the practical and economical synthesis of VT-1129 at a large scale. This discovery has the following advantages over previous synthesis methods: 1) avoids using expensive chiral chromatography for separation and preparation of enantiomerically enriched aminoalcohols and derivatives 2) avoids using expensive chromatographic purification of intermediates 3) avoids using of cryogenic conditions in the process 4) avoids using unstable/explosive reagents 5) allows cost-efficient and scalable preparation applicable to commercial scale manufacturing The discovery described here can generally be used to prepare enantioenriched aminoalcohols that contain tertiary alcohol fragments, and their derivatives, including the novel antifungal VT-1129 used for treating cryptococcal meningitis. 2022-08-01 2025-08-13 2025-08-15 2022-08-01 2022-05-06 Acid, Alcohol, Aminoalcohols, Benzenesulfonic, BSA., Co-crystal, Containing, Derivatives, Enantioenriched, Fragment, Including, Listed LPM Nguyen-Antczak as of 4/15/2015, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, PROCESS, Synthesis, Tertiary, THOSE, VEXXXX, VT-1129, WMXXXX False True True NIHTT 37470483 Website Abstract 114172760 Kolb HC et al. https://doi.org/10.1021/cr00032a009 <a href="https://doi.org/10.1021/cr00032a009">Kolb HC et al.</a> 114172761 Kitagawa O et al. https://doi.org/10.1246/CL.1989.389 <a href="https://doi.org/10.1246/CL.1989.389">Kitagawa O et al.</a> 114172762 Kurono N et al. https://doi.org/10.1002/ejoc.200901501 <a href="https://doi.org/10.1002/ejoc.200901501 ">Kurono N et al.</a> 114172763 Taguchi T et al. https://doi.org/10.1016/S0040-4039%2800%2985409-X <a href="https://doi.org/10.1016/S0040-4039%2800%2985409-X">Taguchi T et al.</a> 114172764 Wang X et al. https://doi.org/10.1016/S0040-4039%2800%2900741-3 <a href="https://doi.org/10.1016/S0040-4039%2800%2900741-3">Wang X et al.</a> 114110923 Behnke, Mark NCATS - TRND NCATS Behnke, Mark (NCATS) 0 114110924 David, Scott Ricerca Biosciences, LLC David, Scott 0 114110925 Fry, Douglas (Doug) Ricerca Biosciences, LLC Fry, Douglas (Doug) 0 114110926 Hoekstra, William Mycovia Pharmaceuticals Inc. Hoekstra, William 0 114110927 Yates, Christopher Mycovia Pharmaceuticals Inc. Yates, Christopher 0 114110922 Alimardanov, Asaf NCATS - NCGC NCATS Alimardanov, Asaf (NCATS) 1 114110922 Alimardanov, Asaf NCATS - NCGC NCATS Alimardanov, Asaf (NCATS) 1 114110923 Behnke, Mark NCATS - TRND NCATS Behnke, Mark (NCATS) 0 114110924 David, Scott Ricerca Biosciences, LLC David, Scott 0 114110925 Fry, Douglas (Doug) Ricerca Biosciences, LLC Fry, Douglas (Doug) 0 114110926 Hoekstra, William Mycovia Pharmaceuticals Inc. Hoekstra, William 0 114110927 Yates, Christopher Mycovia Pharmaceuticals Inc. Yates, Christopher 0 114102696 Process For Synthesis Of Enantioenriched Aminoalcohols Containing A Tertiary Alcohol Fragment, And Derivatives Of Those Aminoalcohols Including The Co-crystal Of VT-1129 With Benzenesulfonic Acid (BSA). E-046-2013-0 Filing authorized NCATS - NCGC, Ricerca Biosciences, LLC, Viamet Pharmaceuticals Inc. 93911356 Kalsi, Jasmine jasmine.kalsi@nih.gov
United States of America jasmine.kalsi@nih.gov?subject=Web Inquiry on [TAB-3587] Process for Practical, Scalable, Commercially-viable Method for the Synthesis of Enantio-enriched Aminoalcohols, Including the Novel Antifungal VT-1129 Used to Treat Cryptococcal Meningitis&body=Please send me information about technology [TAB-3587] Process for Practical, Scalable, Commercially-viable Method for the Synthesis of Enantio-enriched Aminoalcohols, Including the Novel Antifungal VT-1129 Used to Treat Cryptococcal Meningitis. Kalsi, Jasmine<br><a href="mailto:jasmine.kalsi@nih.gov?subject=Web Inquiry on [TAB-3587] Process for Practical, Scalable, Commercially-viable Method for the Synthesis of Enantio-enriched Aminoalcohols, Including the Novel Antifungal VT-1129 Used to Treat Cryptococcal Meningitis&body=Please send me information about technology [TAB-3587] Process for Practical, Scalable, Commercially-viable Method for the Synthesis of Enantio-enriched Aminoalcohols, Including the Novel Antifungal VT-1129 Used to Treat Cryptococcal Meningitis.">jasmine.kalsi@nih.gov</a><br> 114169432 E-046-2013-0 E-046-2013-0-US-01 Process For Synthesis Of Enantioenriched Aminoalcohols Containing A Tertiary Alcohol Fragment, And Derivatives Of Those Aminoalcohols Including The Co-crystal Of VT-1129 With Benzenesulfonic Acid (BSA). PRV US 61/802,071 Abandoned US <br />Provisional (PRV) 61/802,071<br />Filed on 2013-03-15<br />Status: Abandoned 114128846 VEXXXX 114128847 WMXXXX 114153430 PROCESS 114153431 Synthesis 114153432 Enantioenriched 114153433 Aminoalcohols 114153434 Containing 114153435 Tertiary 114153436 Alcohol 114153437 Fragment 114153438 Derivatives 114153439 THOSE 114153440 Including 114153441 Co-crystal 114153442 VT-1129 114153443 Benzenesulfonic 114153444 Acid 114153445 BSA. 114153446 Listed LPM Nguyen-Antczak as of 4/15/2015 114153447 Pre LPM working set 20150418 114153448 Post LPM Assignment Set 20150420 TAB-3585 114097440 A Novel High-Throughput Assay for Identifying Zike Virus NS2B-NS3 Protease Inhibitors NCATS Infectious Disease, Research Equipment, Research Materials, Therapeutics Infectious Disease Research Equipment Research Materials Therapeutics Ruili Huang, Laura Kramer, Hongmin Li, Zhong Li, Menghang Xia This invention includes a novel high-throughput assay to identify orthosteric inhibitors blocking the Zika virus NS2B-NS3 protease. Pathogenic flaviviruses, including Zika, require the NS2B-NS3 protease for viral replication. There is currently an unmet need for specific antiviral therapeutics against the Zika virus. Preliminary screening using the NCGC Pharmaceutical Collection library identified a group of drugs including temoporfin, erythrosin B, niclosamide, and nitazoxanide that can significantly inhibit the interactions between NS2B and NS3. The described assay is the first high-throughput method to aid in the identification of a flavivirus NS2B-NS3 protease inhibitor. The assay included in this invention can be used to identify novel compounds that inhibit the NS2B-NS3 interaction. 2022-08-01 2025-08-13 2025-08-15 2022-08-01 2022-05-06 Activity, Antiflaviviral, Compositions, PHARMACEUTICAL, VLXXXX, WIXXXX, WKXXXX, XHXXXX False True True NIHTT 37470483 Website Abstract 114172757 Li Z, Brecher M, et al. https://pubmed.ncbi.nlm.nih.gov/28685770/ <a href="https://pubmed.ncbi.nlm.nih.gov/28685770/">Li Z, Brecher M, et al.</a> 114110911 Xia, Menghang NCATS - NCGC NCATS Xia, Menghang (NCATS) 0 114110912 Huang, Ruili NCATS - NCGC NCATS Huang, Ruili (NCATS) 0 114110914 Kramer, Laura Health Research Incorporated Kramer, Laura 0 114110915 Li, Zhong Health Research Incorporated Li, Zhong 0 114110913 Li, Hongmin Health Research Incorporated Li, Hongmin 1 114110913 Li, Hongmin Health Research Incorporated Li, Hongmin 1 114110911 Xia, Menghang NCATS - NCGC NCATS Xia, Menghang (NCATS) 0 114110912 Huang, Ruili NCATS - NCGC NCATS Huang, Ruili (NCATS) 0 114110914 Kramer, Laura Health Research Incorporated Kramer, Laura 0 114110915 Li, Zhong Health Research Incorporated Li, Zhong 0 114102694 Pharmaceutical Compositions With Antiflaviviral Activity E-043-2017-0 Filing authorized Health Research Incorporated, NCATS - NCGC 83673536 Erwin-Cohen, Rebecca rebecca.erwin-cohen@nih.gov
NCGC rebecca.erwin-cohen@nih.gov?subject=Web Inquiry on [TAB-3585] A Novel High-Throughput Assay for Identifying Zike Virus NS2B-NS3 Protease Inhibitors&body=Please send me information about technology [TAB-3585] A Novel High-Throughput Assay for Identifying Zike Virus NS2B-NS3 Protease Inhibitors. Erwin-Cohen, Rebecca<br><a href="mailto:rebecca.erwin-cohen@nih.gov?subject=Web Inquiry on [TAB-3585] A Novel High-Throughput Assay for Identifying Zike Virus NS2B-NS3 Protease Inhibitors&body=Please send me information about technology [TAB-3585] A Novel High-Throughput Assay for Identifying Zike Virus NS2B-NS3 Protease Inhibitors.">rebecca.erwin-cohen@nih.gov</a><br> 114169431 E-043-2017-0 E-043-2017-0-US-01 Pharmaceutical Compositions With Antiflaviviral Activity PRV US 62/353,887 Abandoned US <br />Provisional (PRV) 62/353,887<br />Filed on 2016-06-23<br />Status: Abandoned 114128839 VLXXXX 114128840 WIXXXX 114128841 WKXXXX 114128842 XHXXXX 114153421 PHARMACEUTICAL 114153422 Compositions 114153423 Antiflaviviral 114153424 Activity TAB-3582 114097437 Treatment of primary hyperoxalurias with small molecule lactate dehydrogenase inhibitors such as WO2018005807A1 NCATS Cardiology, Dental, Endocrinology, Infectious Disease, Oncology, Ophthalmology, Research Materials, Therapeutics Cardiology Dental Endocrinology Infectious Disease Oncology Ophthalmology Research Materials Therapeutics Matthew Hall, Ross Holmes, Leonard Neckers, Daniel Urban, David Wood This technology includes the use of novel lactate dehydrogenase (LDH) inhibitors, including WO2018005807A1, for the treatment of primary hyperoxalurias (PHs). PHs are rare autosomal recessive disorders caused by overproduction of oxalate, leading to recurrent calcium oxalate kidney stone disease, and in some cases end-stage renal disease. One potential strategy to treat PHs is to reduce the production of oxalate by diminishing the activity of LDH, the proposed key enzyme responsible for converting glyoxylate to oxalate. Biochemical and cell-based assays were used to identify and characterize novel potent inhibitors of LDH that prevent the conversion of glyoxylate to oxalate. RNAi therapies targeting LDHA and GO enzymes are currently in clinical trials. Oral delivery of small molecule inhibitors of LDH would be more convenient than repetitive intravenous injections for patients. Small molecule inhibitors also have the advantage of being significantly cheaper to manufacture, thereby being more cost-effective for patients as well. Further clinical work could establish the identified small molecules, including WO2018005807A1, as the active pharmaceutical ingredient (API) for treatments for primary hyperoxalurias. 2022-08-01 2025-08-13 2025-08-15 2022-08-01 2022-05-06 DEHYDROGENASE, Hyperoxalurias, Inhibitors, LACTATE, MOLECULE, Primary, Small, TREATING, VPXXXX, WIXXXX, WKXXXX, XEXXXX False True True NIHTT 37470483 Website Abstract 114110894 Urban, Daniel FDA Urban, Daniel (FDA) 0 114110895 Neckers, Leonard NCI - CCR NCI Neckers, Leonard (NCI) 0 114110896 Holmes, Ross University of Alabama Holmes, Ross 0 114110897 Wood, David University of Alabama Wood, David 0 114110893 Hall, Matthew NCATS - NCGC NCATS Hall, Matthew (NCATS) 1 114110893 Hall, Matthew NCATS - NCGC NCATS Hall, Matthew (NCATS) 1 114110894 Urban, Daniel FDA Urban, Daniel (FDA) 0 114110895 Neckers, Leonard NCI - CCR NCI Neckers, Leonard (NCI) 0 114110896 Holmes, Ross University of Alabama Holmes, Ross 0 114110897 Wood, David University of Alabama Wood, David 0 114102691 Treating Primary Hyperoxalurias With Small Molecule Lactate Dehydrogenase Inhibitors E-035-2020-0 Filing authorized NCATS - NCGC, NCI, University of Alabama 83673536 Erwin-Cohen, Rebecca rebecca.erwin-cohen@nih.gov
NCGC rebecca.erwin-cohen@nih.gov?subject=Web Inquiry on [TAB-3582] Treatment of primary hyperoxalurias with small molecule lactate dehydrogenase inhibitors such as WO2018005807A1&body=Please send me information about technology [TAB-3582] Treatment of primary hyperoxalurias with small molecule lactate dehydrogenase inhibitors such as WO2018005807A1. Erwin-Cohen, Rebecca<br><a href="mailto:rebecca.erwin-cohen@nih.gov?subject=Web Inquiry on [TAB-3582] Treatment of primary hyperoxalurias with small molecule lactate dehydrogenase inhibitors such as WO2018005807A1&body=Please send me information about technology [TAB-3582] Treatment of primary hyperoxalurias with small molecule lactate dehydrogenase inhibitors such as WO2018005807A1.">rebecca.erwin-cohen@nih.gov</a><br> 114169426 E-035-2020-0 E-035-2020-0-US-01 TREATING PRIMARY OR IDIOPATHIC HYPEROXALURIA WITH SMALL MOLECULE INHIBITORS OF LACTATE DEHYDROGENASE PRV US 62/849,564 Abandoned US <br />Provisional (PRV) 62/849,564<br />Filed on 2019-05-17<br />Status: Abandoned 114128827 VPXXXX 114128828 WIXXXX 114128829 WKXXXX 114128830 XEXXXX 114153402 TREATING 114153403 Primary 114153404 Hyperoxalurias 114153405 Small 114153406 MOLECULE 114153407 LACTATE 114153408 DEHYDROGENASE 114153409 Inhibitors TAB-3580 114097434 Creation and Use of Kinetin Derivatives for Treating RNA Missplicing Diseases Such as Familial Dysautonomia NCATS Neurology, Therapeutics Neurology Therapeutics Juan Marugan, Susan Slaugenhuapt This technology includes the creation and use of compounds, including kinetin derivatives, that improve mRNA splicing in a cell for the treatment of disorders associated with misspliced mRNA, including familial dysautonomia (FD). FD, the best-known and most common member of a group of congenital sensory and autonomic neuropathies, affects neuronal development and is associated with progressive neuronal degeneration. This disease is caused by mutations in the splicing of intron 20 of the IKMKAP gene that results in a unique pattern of tissue-specific exon skipping. There are no current treatments of familial dysautonomia (FD) and the kinetin derivatives described in this technology could be the first-in-class. Further clinical work with the mRNA splicing compounds may establish these therapeutics as definitive treatments for familial dysautonomia (FD). 2022-08-01 2025-08-13 2025-08-15 2022-08-01 2022-05-06 Derivatives, Kinetin, VEXXXX, WKXXXX, XEXXXX False True True NIHTT 37470483 Website Abstract 114110885 Marugan, Juan NCATS - NCGC NCATS Marugan, Juan (NCATS) 0 114110884 Slaugenhuapt, Susan Massachusetts General Hospital Slaugenhuapt, Susan 1 114110884 Slaugenhuapt, Susan Massachusetts General Hospital Slaugenhuapt, Susan 1 114110885 Marugan, Juan NCATS - NCGC NCATS Marugan, Juan (NCATS) 0 114102688 Kinetin Derivatives E-026-2016-0 Filing authorized Massachusetts General Hospital, NCATS - NCGC 93911356 Kalsi, Jasmine jasmine.kalsi@nih.gov
United States of America jasmine.kalsi@nih.gov?subject=Web Inquiry on [TAB-3580] Creation and Use of Kinetin Derivatives for Treating RNA Missplicing Diseases Such as Familial Dysautonomia&body=Please send me information about technology [TAB-3580] Creation and Use of Kinetin Derivatives for Treating RNA Missplicing Diseases Such as Familial Dysautonomia. Kalsi, Jasmine<br><a href="mailto:jasmine.kalsi@nih.gov?subject=Web Inquiry on [TAB-3580] Creation and Use of Kinetin Derivatives for Treating RNA Missplicing Diseases Such as Familial Dysautonomia&body=Please send me information about technology [TAB-3580] Creation and Use of Kinetin Derivatives for Treating RNA Missplicing Diseases Such as Familial Dysautonomia.">jasmine.kalsi@nih.gov</a><br> 114169420 E-026-2016-0 E-026-2016-0-US-01 Compounds for Improving mRNA Splicing PRV US 62/104,547 Abandoned US <br />Provisional (PRV) 62/104,547<br />Filed on 2015-01-16<br />Status: Abandoned 114169421 E-026-2016-0 E-026-2016-0-PCT-03 Compounds for Improving MRNA Splicing PCT Patent Cooperation Treaty PCT/US2016/013553 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2016/013553<br />Filed on 2016-01-15<br />Status: Expired 114169422 E-026-2016-0 E-026-2016-0-US-10 Compounds for Improving mRNA Splicing National Stage US 10,676,475 15/543,826 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10676475 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10676475">10,676,475</a><br />Filed on 2017-07-14<br />Status: Issued 114169423 E-026-2016-0 E-026-2016-0-US-19 Compounds for Improving mRNA Splicing CON US 11,702,417 16/877,254 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11702417 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11702417">11,702,417</a><br />Filed on 2020-05-18<br />Status: Issued 114128819 VEXXXX 114128820 WKXXXX 114128821 XEXXXX 114153382 Kinetin 114153383 Derivatives TAB-3577 114097432 Sensor for Real-time Detection of Plasma Metabolites Levels for the Diagnosis and Care of Metabolic Disorders NCATS Cardiology, Consumer Products, Dental, Diagnostics, Endocrinology, Infectious Disease, Medical Devices, Non-Medical Devices, Occupational Safety and Health, Oncology, Ophthalmology, Research Materials Cardiology Consumer Products Dental Diagnostics Endocrinology Infectious Disease Medical Devices Non-Medical Devices Occupational Safety and Health Oncology Ophthalmology Research Materials Omar Ayyub, Adam Behrens, Gary Cunningham, Peter Kofinas, Juan Luque-Cabrera, Juan Marugan, Anton Simeonov, Marshall Summar This technology includes the development of devices capable of real-time evaluation of metabolite levels for the treatment of numerous metabolic disorders, including hyperammonemia and aminoacidopathies. Currently, the monitoring of metabolite levels is done in a hospital setting with specialized mass spectrometry instrumentation. As a consequence, susceptible patients who are undergoing a crisis need to visit the hospital for testing to determine if there is a metabolite disturbance. The development of a device, including an electrode with immobilized enzymes, could transform the care of these metabolite disorders similar to insulin detection and diabetes. The are no current sensors able to measure the proposed metabolites in real-time. The device included in this technology will allow the real-time evaluation of specific metabolite levels in blood. The device can be used for diagnosis, or for facilitating management, treatment, and follow-up care. 2022-08-01 2025-08-13 2025-08-15 2022-08-01 2022-05-06 Detection, DEVICE, Listed LPM Tong as of 4/15/2015, MECHANICAL, METABOLITES, Metabolites., PLASMA, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, REAL, SENSOR, TIME, VPXXXX, WBXXXX, WFXXXX, WIXXXX, XCXXXX, XDXXXX False True True NIHTT 37470483 Website Abstract 114110874 Behrens, Adam Behrens, Adam 0 114110875 Kofinas, Peter University of Maryland, College Park Kofinas, Peter 0 114110876 Summar, Marshall Children's National Medical Center Summar, Marshall 0 114110877 Luque-Cabrera, Juan Luque-Cabrera, Juan 0 114110878 Cunningham, Gary Cunningham, Gary 0 114110879 Marugan, Juan NCATS - NCGC NCATS Marugan, Juan (NCATS) 0 114110880 Simeonov, Anton NCATS - NCGC NCATS Simeonov, Anton (NCATS) 0 114110873 Ayyub, Omar Ayyub, Omar 1 114110873 Ayyub, Omar Ayyub, Omar 1 114110874 Behrens, Adam Behrens, Adam 0 114110875 Kofinas, Peter University of Maryland, College Park Kofinas, Peter 0 114110876 Summar, Marshall Children's National Medical Center Summar, Marshall 0 114110877 Luque-Cabrera, Juan Luque-Cabrera, Juan 0 114110878 Cunningham, Gary Cunningham, Gary 0 114110879 Marugan, Juan NCATS - NCGC NCATS Marugan, Juan (NCATS) 0 114110880 Simeonov, Anton NCATS - NCGC NCATS Simeonov, Anton (NCATS) 0 114102686 Sensor And Device For Real Time Detection Of Plasma Metabolites E-010-2013-0 Filing authorized Children's National Medical Center, NCATS - NCGC, University of Maryland 83673536 Erwin-Cohen, Rebecca rebecca.erwin-cohen@nih.gov
NCGC rebecca.erwin-cohen@nih.gov?subject=Web Inquiry on [TAB-3577] Sensor for Real-time Detection of Plasma Metabolites Levels for the Diagnosis and Care of Metabolic Disorders&body=Please send me information about technology [TAB-3577] Sensor for Real-time Detection of Plasma Metabolites Levels for the Diagnosis and Care of Metabolic Disorders. Erwin-Cohen, Rebecca<br><a href="mailto:rebecca.erwin-cohen@nih.gov?subject=Web Inquiry on [TAB-3577] Sensor for Real-time Detection of Plasma Metabolites Levels for the Diagnosis and Care of Metabolic Disorders&body=Please send me information about technology [TAB-3577] Sensor for Real-time Detection of Plasma Metabolites Levels for the Diagnosis and Care of Metabolic Disorders.">rebecca.erwin-cohen@nih.gov</a><br> 114169417 E-010-2013-0 E-010-2013-0-US-01 Point of Care Detection of Hyperammonemia and Aminoacidopathies PRV US 61/714,870 Expired US <br />Provisional (PRV) 61/714,870<br />Filed on 2012-10-17<br />Status: Expired 114169418 E-010-2013-0 E-010-2013-0-PCT-02 Sensor And Device For Real Time Detection Of Plasma Metabolites PCT Patent Cooperation Treaty PCT/US2013/065548 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2013/065548<br />Filed on 2013-10-17<br />Status: Expired 114169419 E-010-2013-0 E-010-2013-0-US-06 Sensor And Device For Real Time Detection Of Plasma Metabolites National Stage US 10,392,646 14/436,844 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10392646 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10392646">10,392,646</a><br />Filed on 2015-04-17<br />Status: Issued 114128810 VPXXXX 114128811 WBXXXX 114128812 WFXXXX 114128813 WIXXXX 114128814 XCXXXX 114128815 XDXXXX 114153351 TIME 114153352 SENSOR 114153353 REAL 114153354 DEVICE 114153355 Detection 114153356 PLASMA 114153357 Metabolites. 114153358 METABOLITES 114153359 Listed LPM Tong as of 4/15/2015 114153360 Pre LPM working set 20150418 114153361 Post LPM Assignment Set 20150420 114153362 MECHANICAL TAB-3575 114097430 A Novel Chemical Series for Inhibiting Bromodomain-containing Protein 4 (BRD4) for Treating Cancer NCATS Oncology, Therapeutics Oncology Therapeutics Ajit Jadhav, David Maloney, Jeffrey Strovel, Daniel Urban, Shyh-Ming Yang, Makoto Yoshioka This technology includes the design, synthesis, and use of a novel chemical series for multiple treatments, including for treating cancer. A series of substituted bicyclic heteroaryl small molecules were found to be a potent inhibitor of bromodomain-containing protein 4 (BRD4) for multiple uses, including cancer. A BRD4 inhibitor is in a class of drugs known as BET inhibitors that are used broadly as anti-inflammatories and as anti-cancer agents. The chemical series exhibited less hepatocyte toxicity compared to existing treatments. For example, the series also identified N-methyl 2-pyridone 1s as a great replacement for dimethylisoxazole, an existing BET inhibitor. The compounds identified in this chemical series have a novel composition and better drug-like properties. BRD4 has been identified as an important target, particularly for cancer. The chemical series has the potential to be used for a variety of indications including but not limited to cancer, diabetes, inflammation, and acute heart failure, and has a large market potential. 2022-08-01 2025-08-13 2025-08-15 2022-08-01 2022-05-06 BICYCLIC, Brd4, Bromodomain-containing, Heteroaryl, Inhibitors, Protein, Substituted, VCXXXX, WKXXXX, XEXXXX False True True NIHTT 37470483 Website Abstract 114110860 Maloney, David NCATS - NCGC NCATS Maloney, David (NCATS) 0 114110861 Yang, Shyh-Ming NCATS - NCGC NCATS Yang, Shyh-Ming (NCATS) 0 114110862 Jadhav, Ajit NCATS - NCGC NCATS Jadhav, Ajit (NCATS) 0 114110863 Urban, Daniel NCATS - NCGC FDA Urban, Daniel (FDA) 0 114110865 Yoshioka, Makoto ConverGene, LLC Yoshioka, Makoto 0 114110864 Strovel, Jeffrey ConverGene, LLC Strovel, Jeffrey 1 114110864 Strovel, Jeffrey ConverGene, LLC Strovel, Jeffrey 1 114110860 Maloney, David NCATS - NCGC NCATS Maloney, David (NCATS) 0 114110861 Yang, Shyh-Ming NCATS - NCGC NCATS Yang, Shyh-Ming (NCATS) 0 114110862 Jadhav, Ajit NCATS - NCGC NCATS Jadhav, Ajit (NCATS) 0 114110863 Urban, Daniel NCATS - NCGC FDA Urban, Daniel (FDA) 0 114110865 Yoshioka, Makoto ConverGene, LLC Yoshioka, Makoto 0 114102684 Substituted Bicyclic Heteroaryl Inhibitors Of Bromodomain-containing Protein BRD4 E-004-2016-0 Filing authorized ConverGene, LLC, NCATS - NCGC 93911356 Kalsi, Jasmine jasmine.kalsi@nih.gov
United States of America jasmine.kalsi@nih.gov?subject=Web Inquiry on [TAB-3575] A Novel Chemical Series for Inhibiting Bromodomain-containing Protein 4 (BRD4) for Treating Cancer&body=Please send me information about technology [TAB-3575] A Novel Chemical Series for Inhibiting Bromodomain-containing Protein 4 (BRD4) for Treating Cancer. Kalsi, Jasmine<br><a href="mailto:jasmine.kalsi@nih.gov?subject=Web Inquiry on [TAB-3575] A Novel Chemical Series for Inhibiting Bromodomain-containing Protein 4 (BRD4) for Treating Cancer&body=Please send me information about technology [TAB-3575] A Novel Chemical Series for Inhibiting Bromodomain-containing Protein 4 (BRD4) for Treating Cancer.">jasmine.kalsi@nih.gov</a><br> 114169413 E-004-2016-0 E-004-2016-0-US-01 Substituted Bicyclic Heteroaryl Inhibitors Of Bromodomain-containing Protein BRD4 PRV US 62/259,894 Abandoned US <br />Provisional (PRV) 62/259,894<br />Filed on 2015-11-25<br />Status: Abandoned 114169414 E-004-2016-0 E-004-2016-0-PCT-02 BICYCLIC BET BROMODOMAIN INHIBITORS AND USES THEREOF PCT Patent Cooperation Treaty PCT/US2016/063485 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2016/063485<br />Filed on 2016-11-23<br />Status: Expired 114169415 E-004-2016-0 E-004-2016-0-US-08 BICYCLIC BET BROMODOMAIN INHIBITORS AND USES THEREOF National Stage US 10,508,106 15/779,353 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10508106 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10508106">10,508,106</a><br />Filed on 2018-05-25<br />Status: Issued 114128804 VCXXXX 114128805 WKXXXX 114128806 XEXXXX 114153340 Substituted 114153341 BICYCLIC 114153342 Heteroaryl 114153343 Inhibitors 114153344 Bromodomain-containing 114153345 Protein 114153346 Brd4 TAB-3564 114097419 Compounds for Niemann Pick C and Other Lysosomal Storage Disorders NCATS Cardiology, Dental, Endocrinology, Infectious Disease, Oncology, Ophthalmology, Therapeutics Cardiology Dental Endocrinology Infectious Disease Oncology Ophthalmology Therapeutics Raul Calvo, Frannie Chen, Seameen Dehdashti, Patricia Dranchak, Marc Ferrer-Alegre, Yiannis Ioannou, Juan Marugan, Samarjit Patnaik, Noel Southall, Mercedes Taylor, Wei Zheng This technology includes compounds that improve endoplasmic reticulum-lysosomal trafficking and normalizes the Niemann-Pick type C (NPC) phenotype in assays using NPC1 patient cells, which can be used for the treatment of NPC, other lysosomal storage disorders, and potentially other neurodegenerative disorders. NPC is a rare neurodegenerative lipidosis caused by mutations in NPC1 or NPC2 genes, and characterized by the accumulation of cholesterol and glycolipids in the late endosomes and lysosomes. Currently there is no FDA-approved treatment for this devastating neurodegenerative disease. Overexpression of such mutant NPC1 proteins has been shown to rescue the disease phenotype in vitro, suggesting that upregulation of endogenous NPC1 as a therapeutic strategy. The current treatment under study is administered directly into the brain, therefore the development of small molecules as a targeted and curative treatment with the ability to cross the blood brain barrier is of utmost importance. Small molecules can be used as tools in research and can be developed into drugs for Niemann Pick C disease, other lysosomal storage disorders, and potentially other neurodegenerative diseases, including Alzheimer's and Parkinson's. 2022-08-01 2025-08-13 2025-08-15 2022-08-01 2022-05-06 C, compounds, DISORDERS, Iysosomal, Listed LPM Vepa as of 4/15/2015, Niemann, Pick, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Storage, VPXXXX, WKXXXX False True True NIHTT 37470483 Website Abstract 114172728 Gelsthorpe M, Baumann N, et al. https://pubmed.ncbi.nlm.nih.gov/18216017/ <a href="https://pubmed.ncbi.nlm.nih.gov/18216017/">Gelsthorpe M, Baumann N, et al.</a> 114172729 Millard E, Srivastava K, et al. https://pubmed.ncbi.nlm.nih.gov/10964915/ <a href="https://pubmed.ncbi.nlm.nih.gov/10964915/">Millard E, Srivastava K, et al.</a> 114110804 Taylor, Mercedes NCATS - NCGC NCATS Taylor, Mercedes (NCATS) 0 114110805 Dranchak, Patricia NCATS - NCGC NCATS Dranchak, Patricia (NCATS) 0 114110806 Dehdashti, Seameen NCATS - NCGC NCATS Dehdashti, Seameen (NCATS) 0 114110807 Chen, Frannie Icahn School of Medicine at Mount Sinai Chen, Frannie 0 114110808 Ioannou, Yiannis Icahn School of Medicine at Mount Sinai Ioannou, Yiannis 0 114110809 Southall, Noel NCATS - TRND NCATS Southall, Noel (NCATS) 0 114110810 Calvo, Raul NCATS - NCGC NCATS Calvo, Raul (NCATS) 0 114110811 Zheng, Wei NCATS - TRND NCATS Zheng, Wei (NCATS) 0 114110812 Ferrer-Alegre, Marc NCATS - NCGC NCATS Ferrer-Alegre, Marc (NCATS) 0 114110813 Marugan, Juan NCATS - NCGC NCATS Marugan, Juan (NCATS) 0 114110814 Patnaik, Samarjit NCATS - NCGC NCATS Patnaik, Samarjit (NCATS) 1 114110814 Patnaik, Samarjit NCATS - NCGC NCATS Patnaik, Samarjit (NCATS) 1 114110804 Taylor, Mercedes NCATS - NCGC NCATS Taylor, Mercedes (NCATS) 0 114110805 Dranchak, Patricia NCATS - NCGC NCATS Dranchak, Patricia (NCATS) 0 114110806 Dehdashti, Seameen NCATS - NCGC NCATS Dehdashti, Seameen (NCATS) 0 114110807 Chen, Frannie Icahn School of Medicine at Mount Sinai Chen, Frannie 0 114110808 Ioannou, Yiannis Icahn School of Medicine at Mount Sinai Ioannou, Yiannis 0 114110809 Southall, Noel NCATS - TRND NCATS Southall, Noel (NCATS) 0 114110810 Calvo, Raul NCATS - NCGC NCATS Calvo, Raul (NCATS) 0 114110811 Zheng, Wei NCATS - TRND NCATS Zheng, Wei (NCATS) 0 114110812 Ferrer-Alegre, Marc NCATS - NCGC NCATS Ferrer-Alegre, Marc (NCATS) 0 114110813 Marugan, Juan NCATS - NCGC NCATS Marugan, Juan (NCATS) 0 114102673 Compounds For Niemann Pick C And Other Iysosomal Storage Disorders E-040-2015-0 Filing authorized Mount Sinai Medical Center, Mount Sinai Hospital, NCATS - NCGC 93911356 Kalsi, Jasmine jasmine.kalsi@nih.gov
United States of America jasmine.kalsi@nih.gov?subject=Web Inquiry on [TAB-3564] Compounds for Niemann Pick C and Other Lysosomal Storage Disorders&body=Please send me information about technology [TAB-3564] Compounds for Niemann Pick C and Other Lysosomal Storage Disorders. Kalsi, Jasmine<br><a href="mailto:jasmine.kalsi@nih.gov?subject=Web Inquiry on [TAB-3564] Compounds for Niemann Pick C and Other Lysosomal Storage Disorders&body=Please send me information about technology [TAB-3564] Compounds for Niemann Pick C and Other Lysosomal Storage Disorders.">jasmine.kalsi@nih.gov</a><br> 114169393 E-040-2015-0 E-040-2015-0-US-07 Compounds For Niemann Pick C And Other Iysosomal Storage Disorders CON US 16/362,179 Abandoned US <br />Continuation (CON) 16/362,179<br />Filed on 2019-03-22<br />Status: Abandoned 114169394 E-040-2015-0 E-040-2015-0-US-03 BENZENESULFONAMIDE UPREGULATORS OF NPC1 FOR NEIMANN-PICK DISEASE AND OTHER LYSOSOMAL STORAGE DISORDERS National Stage US 10,239,830 15/549,743 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10239830 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10239830">10,239,830</a><br />Filed on 2017-08-09<br />Status: Issued 114169395 E-040-2015-0 E-040-2015-0-PCT-02 BENZENESULFONAMIDE UPREGULATORS OF NPC1 FOR NEIMANN-PICK DISEASE AND OTHER LYSOSOMAL STORAGE DISORDERS PCT Patent Cooperation Treaty PCT/US2016/017504 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2016/017504<br />Filed on 2016-02-11<br />Status: Expired 114169396 E-040-2015-0 E-040-2015-0-US-01 BENZENESULFONAMIDE UPREGULATORS OF NPC1 FOR NEIMANN-PICK DISEASE AND OTHER LYSOSOMAL STORAGE DISORDERS PRV US 62/114,840 Abandoned US <br />Provisional (PRV) 62/114,840<br />Filed on 2015-02-11<br />Status: Abandoned 114128763 VPXXXX 114128764 WKXXXX 114153214 Post LPM Assignment Set 20150420 114153215 Pre LPM working set 20150418 114153216 Listed LPM Vepa as of 4/15/2015 114153217 DISORDERS 114153218 Storage 114153219 Iysosomal 114153220 C 114153221 Pick 114153222 Niemann 114153223 compounds TAB-3561 114097417 Sensor and Device for Real-Time Discovery of Metabolites in Blood for Disease Detection, Monitoring and Control NCATS Consumer Products, Medical Devices, Non-Medical Devices, Occupational Safety and Health, Research Materials Consumer Products Medical Devices Non-Medical Devices Occupational Safety and Health Research Materials Omar Ayyub, Adam Behrens, Juan Cabrera-Luque, Gary Cunningham, Peter Kofinas, Juan Marugan, Anton Simeonov, Marshall Summar This technology includes device and sensor selection for the detection of blood metabolites which can be used to diagnose and monitor diseases in real-time. Currently the monitoring of metabolite levels is performed with specialized mass spectrometry instrumentation, therefore patient quality-of-life and financial advantages exist to develop devices capable of detecting metabolites in real-time. Our invention deals with the reduction to practice of this concept, showing how to select the metabolite and immobilized enzymes, how to do the immobilization, how to attach the components to the electrode, how to make the measurement and develop a prototype. Further, our invention deals with selection of light source and light detection to quantitate the blue color produced, as well as specific design features of the portable meter to enable direct loading of small volume of whole blood, transport of the sample through the fluidic channels and chambers, and mixing of the reagents. Currently there are no sensors able to measure the proposed metabolites in real-time. This method and device will allow the real-time evaluation of the levels of a specific metabolite in blood, and it can be used as diagnostic tool, or for facilitating the management, treatment, and follow up of metabolic disorders. 2022-08-01 2025-08-13 2025-08-15 2022-08-01 2022-05-06 Blood, Detection, DEVICE, Listed LPM Shmilovich as of 4/15/2015, MECHANICAL, METABOLITES, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, REAL, SENSOR, TIME, WFXXXX, WIXXXX, XDXXXX False True True NIHTT 37470483 Website Abstract 114110788 Marugan, Juan NCATS - NCGC NCATS Marugan, Juan (NCATS) 0 114110789 Simeonov, Anton NCATS - NCGC NCATS Simeonov, Anton (NCATS) 0 114110790 Kofinas, Peter University of Maryland, College Park Kofinas, Peter 0 114110791 Summar, Marshall Children's National Medical Center Summar, Marshall 0 114110793 Behrens, Adam University of Maryland, College Park Behrens, Adam 0 114110794 Cabrera-Luque, Juan University of Maryland, College Park Cabrera-Luque, Juan 0 114110795 Cunningham, Gary Children's National Medical Center Cunningham, Gary 0 114110792 Ayyub, Omar University of Maryland, College Park Ayyub, Omar 1 114110792 Ayyub, Omar University of Maryland, College Park Ayyub, Omar 1 114110788 Marugan, Juan NCATS - NCGC NCATS Marugan, Juan (NCATS) 0 114110789 Simeonov, Anton NCATS - NCGC NCATS Simeonov, Anton (NCATS) 0 114110790 Kofinas, Peter University of Maryland, College Park Kofinas, Peter 0 114110791 Summar, Marshall Children's National Medical Center Summar, Marshall 0 114110793 Behrens, Adam University of Maryland, College Park Behrens, Adam 0 114110794 Cabrera-Luque, Juan University of Maryland, College Park Cabrera-Luque, Juan 0 114110795 Cunningham, Gary Children's National Medical Center Cunningham, Gary 0 114102671 Sensor And Device For Real Time Detection Of Metabolites In Blood E-072-2015-0 Filing authorized Children's National Medical Center, NCATS - NCGC, University of Maryland 83673536 Erwin-Cohen, Rebecca rebecca.erwin-cohen@nih.gov
NCGC rebecca.erwin-cohen@nih.gov?subject=Web Inquiry on [TAB-3561] Sensor and Device for Real-Time Discovery of Metabolites in Blood for Disease Detection, Monitoring and Control&body=Please send me information about technology [TAB-3561] Sensor and Device for Real-Time Discovery of Metabolites in Blood for Disease Detection, Monitoring and Control. Erwin-Cohen, Rebecca<br><a href="mailto:rebecca.erwin-cohen@nih.gov?subject=Web Inquiry on [TAB-3561] Sensor and Device for Real-Time Discovery of Metabolites in Blood for Disease Detection, Monitoring and Control&body=Please send me information about technology [TAB-3561] Sensor and Device for Real-Time Discovery of Metabolites in Blood for Disease Detection, Monitoring and Control.">rebecca.erwin-cohen@nih.gov</a><br> 114169386 E-072-2015-0 E-072-2015-0-US-01 Sensor And Device For Real Time Detection Of Metabolites In Blood PRV US 61/872,149 Abandoned US <br />Provisional (PRV) 61/872,149<br />Filed on 2013-08-30<br />Status: Abandoned 114169387 E-072-2015-0 E-072-2015-0-PCT-02 DEVICE AND METHODS OF USING DEVICE FOR DETECTION OF HYPERAMMONEMA PCT Patent Cooperation Treaty PCT/US2014/053756 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2014/053756<br />Filed on 2014-09-02<br />Status: Expired 114169388 E-072-2015-0 E-072-2015-0-US-15 DEVICE AND METHODS OF USING DEVICE FOR DETECTION OF HYPERAMMONEMIA National Stage US 9,952,199 14/915,602 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9952199 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9952199">9,952,199</a><br />Filed on 2016-02-29<br />Status: Issued 114169389 E-072-2015-0 E-072-2015-0-US-17 Sensor And Device For Real Time Detection Of Metabolites In Blood DIV US 10,620,187 15/933,834 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10620187 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10620187">10,620,187</a><br />Filed on 2018-03-23<br />Status: Issued 114128758 WFXXXX 114128759 WIXXXX 114128760 XDXXXX 114153198 SENSOR 114153199 DEVICE 114153200 REAL 114153201 TIME 114153202 Detection 114153203 METABOLITES 114153204 Blood 114153205 Listed LPM Shmilovich as of 4/15/2015 114153206 Pre LPM working set 20150418 114153207 Post LPM Assignment Set 20150420 114153208 MECHANICAL TAB-3557 114097413 Inhibitors of 3-phosphoglycerate Dehydrogenase as an Anticancer Therapy NCATS Oncology, Therapeutics Oncology Therapeutics Matthew Boxer, Kyle Brimacombe, Michael Pacold, Jason Rohde, David Sabatini, Min Shen This technology includes a family of inhibitors of 3-phosphoglycerate dehydrogenase (PHGDH) which could be utilized as a treatment for cancer. These compounds are based on a carbiothioamide core and represent the first chemotype capable of inhibiting this enzyme. The compounds have in vitro IC50s of 1-5 uM and exhibit selective cytotoxicity towards PHGDH-overexpressing cell lines of ~10 uM. They exhibit at least an order of magnitude lower toxicity towards cell lines that do not express PHGDH. These compounds block flux through the serine synthesis pathway in PHGDH-overexpressing cells, and preliminarily appear to do the same in mice. First chemotype capable of inhibiting 3-phosphoglycerate dehydrogenase. Utilization as an anticancer therapy. 2022-08-01 2025-08-13 2025-08-15 2022-08-01 2022-05-06 3-phosphoglycerate, Aerobic glycolysis, Alpha-Ketoglutarate, CB5CXX, CB5EXX, DEHYDROGENASE, Inhibitors, Listed LPM McCue as of 4/15/2015, phgdh, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, TCA cycle, VCXXXX, WKXXXX False True True NIHTT 37470483 Website Abstract 114172726 Possemato R, Marks K, et al. https://pubmed.ncbi.nlm.nih.gov/21760589/ <a href="https://pubmed.ncbi.nlm.nih.gov/21760589/">Possemato R, Marks K, et al.</a> 114110756 Rohde, Jason NCATS - NCGC NCATS Rohde, Jason (NCATS) 0 114110757 Brimacombe, Kyle NCATS - NCGC NCATS Brimacombe, Kyle (NCATS) 0 114110758 Shen, Min NCATS - NCGC NCATS Shen, Min (NCATS) 0 114110759 Sabatini, David Whitehead Institute for Biomedical Research Sabatini, David 0 114110760 Pacold, Michael Whitehead Institute for Biomedical Research Pacold, Michael 0 114110755 Boxer, Matthew NCATS - NCGC Boxer, Matthew 1 114110755 Boxer, Matthew NCATS - NCGC Boxer, Matthew 1 114110756 Rohde, Jason NCATS - NCGC NCATS Rohde, Jason (NCATS) 0 114110757 Brimacombe, Kyle NCATS - NCGC NCATS Brimacombe, Kyle (NCATS) 0 114110758 Shen, Min NCATS - NCGC NCATS Shen, Min (NCATS) 0 114110759 Sabatini, David Whitehead Institute for Biomedical Research Sabatini, David 0 114110760 Pacold, Michael Whitehead Institute for Biomedical Research Pacold, Michael 0 114102667 Inhibitors Of 3-phosphoglycerate Dehydrogenase E-282-2014-0 Filing authorized Dana-Farber Cancer Institute, NCATS - NCGC, Whitehead Institute for Biomedical Research 83673536 Erwin-Cohen, Rebecca rebecca.erwin-cohen@nih.gov
NCGC rebecca.erwin-cohen@nih.gov?subject=Web Inquiry on [TAB-3557] Inhibitors of 3-phosphoglycerate Dehydrogenase as an Anticancer Therapy&body=Please send me information about technology [TAB-3557] Inhibitors of 3-phosphoglycerate Dehydrogenase as an Anticancer Therapy. Erwin-Cohen, Rebecca<br><a href="mailto:rebecca.erwin-cohen@nih.gov?subject=Web Inquiry on [TAB-3557] Inhibitors of 3-phosphoglycerate Dehydrogenase as an Anticancer Therapy&body=Please send me information about technology [TAB-3557] Inhibitors of 3-phosphoglycerate Dehydrogenase as an Anticancer Therapy.">rebecca.erwin-cohen@nih.gov</a><br> 114169381 E-282-2014-0 E-282-2014-0-US-01 Inhibitors Of 3-phosphoglycerate Dehydrogenase PRV US 62/103,990 Abandoned US <br />Provisional (PRV) 62/103,990<br />Filed on 2015-01-15<br />Status: Abandoned 114169382 E-282-2014-0 E-282-2014-0-PCT-02 INHIBITORS OF PHOSPHOGLYCERATE DEHYDROGENASE (PHGDH) AND USES THEREOF PCT Patent Cooperation Treaty PCT/US2016/013602 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2016/013602<br />Filed on 2016-01-15<br />Status: Expired 114169383 E-282-2014-0 E-282-2014-0-US-03 INHIBITORS OF PHOSPHOGLYCERATE DEHYDROGENASE (PHGDH) AND USES THEREOF National Stage US 11,225,469 15/543,643 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11225469 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11225469">11,225,469</a><br />Filed on 2017-07-14<br />Status: Issued 114128744 CB5EXX 114128745 CB5CXX 114128746 VCXXXX 114128747 WKXXXX 114153160 Inhibitors 114153161 3-phosphoglycerate 114153162 DEHYDROGENASE 114153163 phgdh 114153164 Alpha-Ketoglutarate 114153165 TCA cycle 114153166 Aerobic glycolysis 114153167 Listed LPM McCue as of 4/15/2015 114153168 Pre LPM working set 20150418 114153169 Post LPM Assignment Set 20150420 TAB-3550 114097406 Small Molecule BET Bromodomain Inhibitors for the Treatment of Cancer and Inflammatory Diseases NCATS Oncology, Therapeutics Oncology Therapeutics Shyh-Ming Yang, Makoto Yoshioka This technology includes a new chemical series of substituted bicyclic heteroaryl small molecules as potent bromodomain-containing protein BRD4 inhibitors used for the treatment of cancer and inflammatory diseases. The optimization led to compounds with good potency in enzymatic assay (< 100 nM) and in MV4-11 cell-based assay (< 1000 nM) as well as excellent early ADME properties. We also identified N-methyl 2 pyridone and N-methyl pyrrolopyridone are great replacements of di-methylisoxazole. This chemical series also exhibited good ADME profiles, including PK. From recent data indicated that the selected analogs also potently inhibited bromodomain of CBP/p300. The selected analogs demonstrated in vivo efficacy in cancer xenograft models and in inflammatory disease models. These compounds have novel composition and better drug-like properties, and also have the potential to be used for a variety of indications. BRD4 has been identified as an important target for a number of potential indications, particularly cancer and inflammatory diseases, as well as diabetes and acute heart failure. 2022-08-01 2025-08-13 2025-08-15 2022-08-01 2022-05-04 Bet, Bromodomain, ConverGene, Inhibitors, MOLECULE, Small, THEREOF, THEREOFULE, USES, VCXXXX, WKXXXX False True True NIHTT 37470483 Website Abstract 114172719 Yang S, Yoshioka M, et al. https://pubmed.ncbi.nlm.nih.gov/30905542/ <a href="https://pubmed.ncbi.nlm.nih.gov/30905542/">Yang S, Yoshioka M, et al.</a> 114110695 Yang, Shyh-Ming NCATS - NCGC NCATS Yang, Shyh-Ming (NCATS) 0 114110694 Yoshioka, Makoto ConverGene, LLC Yoshioka, Makoto 1 114110694 Yoshioka, Makoto ConverGene, LLC Yoshioka, Makoto 1 114110695 Yang, Shyh-Ming NCATS - NCGC NCATS Yang, Shyh-Ming (NCATS) 0 114102660 SMALL MOLECULE BET BROMODOMAIN INHIBITORS AND USES THEREOF E-118-2019-0 Filing authorized ConverGene, LLC, NCATS - NCGC 93911356 Kalsi, Jasmine jasmine.kalsi@nih.gov
United States of America jasmine.kalsi@nih.gov?subject=Web Inquiry on [TAB-3550] Small Molecule BET Bromodomain Inhibitors for the Treatment of Cancer and Inflammatory Diseases&body=Please send me information about technology [TAB-3550] Small Molecule BET Bromodomain Inhibitors for the Treatment of Cancer and Inflammatory Diseases. Kalsi, Jasmine<br><a href="mailto:jasmine.kalsi@nih.gov?subject=Web Inquiry on [TAB-3550] Small Molecule BET Bromodomain Inhibitors for the Treatment of Cancer and Inflammatory Diseases&body=Please send me information about technology [TAB-3550] Small Molecule BET Bromodomain Inhibitors for the Treatment of Cancer and Inflammatory Diseases.">jasmine.kalsi@nih.gov</a><br> 114169364 E-118-2019-0 E-118-2019-0-US-01 SMALL MOLECULE BET BROMODOMAIN INHIBITORS AND USES THEREOF PRV US 62/838,083 Abandoned US <br />Provisional (PRV) 62/838,083<br />Filed on 2019-04-24<br />Status: Abandoned 114169365 E-118-2019-0 E-118-2019-0-PCT-02 SMALL MOLECULE BROMODOMAIN INHIBITORS AND USES THEREOF PCT Patent Cooperation Treaty PCT/US2020/022072 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2020/022072<br />Filed on 2020-03-11<br />Status: Expired 114128723 VCXXXX 114128724 WKXXXX 114153099 USES 114153100 Inhibitors 114153101 Bromodomain 114153102 Bet 114153103 MOLECULE 114153104 Small 114153105 ConverGene 114153106 THEREOF 114153107 THEREOFULE TAB-3542 114097400 Zika Virus NS-1 Inhibitors for the Treatment of Zika Virus Infection NCATS Infectious Disease, Therapeutics Infectious Disease Therapeutics Ruili Huang, Wenwei Huang, Emily Lee, Guo-Li Ming, Hongjun Song, Hengli Tang, Menghang Xia, Miao Xu, Wei Zheng This technology includes a new Zika virus NS-1 assay which was used for a compound screen. Because the NS-1 protein is synthesized only in the Zika virus replication stage, the inhibition of NS-1 protein level by compounds determined in this NS-1 assay indicates the inhibition of Zika virus replication in human cells. A total of 256 compounds have been identified as active compounds that inhibited NS-1 production in human cells that have the potential to be developed as new therapeutics for the treatment of infection with Zika virus. Repositioning CDK inhibitor to treat infection with Zika virus can move to clinical trials quickly. Treatment of Zika virus infection. 2022-08-01 2025-08-13 2025-08-15 2022-08-01 2022-05-04 Infection, Inhibitors, NS-1, treatment, virus, VLXXXX, WKXXXX, Zika False True True NIHTT 37470483 Website Abstract 114110644 Lee, Emily Florida State University Research Foundation, Inc. (FSURF) Lee, Emily 0 114110645 Zheng, Wei NCATS - TRND NCATS Zheng, Wei (NCATS) 0 114110646 Huang, Ruili NCATS - NCGC NCATS Huang, Ruili (NCATS) 0 114110647 Xu, Miao NCATS - NCGC NCATS Xu, Miao (NCATS) 0 114110648 Song, Hongjun Johns Hopkins University Song, Hongjun 0 114110649 Ming, Guo-Li Johns Hopkins University Ming, Guo-Li 0 114110650 Xia, Menghang NCATS - NCGC NCATS Xia, Menghang (NCATS) 0 114110651 Huang, Wenwei NCATS - TRND NCATS Huang, Wenwei (NCATS) 0 114110643 Tang, Hengli Florida State University Research Foundation, Inc. (FSURF) Tang, Hengli 1 114110643 Tang, Hengli Florida State University Research Foundation, Inc. (FSURF) Tang, Hengli 1 114110644 Lee, Emily Florida State University Research Foundation, Inc. (FSURF) Lee, Emily 0 114110645 Zheng, Wei NCATS - TRND NCATS Zheng, Wei (NCATS) 0 114110646 Huang, Ruili NCATS - NCGC NCATS Huang, Ruili (NCATS) 0 114110647 Xu, Miao NCATS - NCGC NCATS Xu, Miao (NCATS) 0 114110648 Song, Hongjun Johns Hopkins University Song, Hongjun 0 114110649 Ming, Guo-Li Johns Hopkins University Ming, Guo-Li 0 114110650 Xia, Menghang NCATS - NCGC NCATS Xia, Menghang (NCATS) 0 114110651 Huang, Wenwei NCATS - TRND NCATS Huang, Wenwei (NCATS) 0 114102653 Zika Virus NS-1 Inhibitors For Treatment Of Zika Virus Infection E-073-2017-0 Filing authorized Florida State University Research Foundation, Inc. (FSURF), Johns Hopkins University, NCATS - NCGC 83673536 Erwin-Cohen, Rebecca rebecca.erwin-cohen@nih.gov
NCGC rebecca.erwin-cohen@nih.gov?subject=Web Inquiry on [TAB-3542] Zika Virus NS-1 Inhibitors for the Treatment of Zika Virus Infection&body=Please send me information about technology [TAB-3542] Zika Virus NS-1 Inhibitors for the Treatment of Zika Virus Infection. Erwin-Cohen, Rebecca<br><a href="mailto:rebecca.erwin-cohen@nih.gov?subject=Web Inquiry on [TAB-3542] Zika Virus NS-1 Inhibitors for the Treatment of Zika Virus Infection&body=Please send me information about technology [TAB-3542] Zika Virus NS-1 Inhibitors for the Treatment of Zika Virus Infection.">rebecca.erwin-cohen@nih.gov</a><br> 114169354 E-073-2017-0 E-073-2017-0-US-01 Zika Virus NS-1 Inhibitors For Treatment Of Zika Virus Infection PRV US 62/430,107 Abandoned US <br />Provisional (PRV) 62/430,107<br />Filed on 2016-12-05<br />Status: Abandoned 114128707 VLXXXX 114128708 WKXXXX 114153026 Zika 114153027 virus 114153028 NS-1 114153029 Inhibitors 114153030 treatment 114153031 Infection TAB-3541 114097399 Preparation of Benzene-1,4-disulfonamide Derivatives Useful as Therapeutic TRPML1 Receptor Modulators for the Treatment of Lysosomal Dysfunction and Membrane Repair Disorders NCATS Cardiology, Dental, Endocrinology, Infectious Disease, Oncology, Ophthalmology, Therapeutics Cardiology Dental Endocrinology Infectious Disease Oncology Ophthalmology Therapeutics Raul Calvo, Marc Ferrer-Alegre, Xin Hu, Natalia Martinez, Juan Marugan, Noel Southall, Haoxing Xu, Lu Yu This technology includes a series of novel benzene-1,4-disulfonamides that activate TRPML1 receptor. The TRPML1 receptor is a lysosomal Ca2+ channel that has been shown to be involved in controlling lysosome functions, among then the maintenance of the integrity of the plasma membrane and the modulation of autophagosome-lysosome fusion. The improved ability of the receptor to deliver Ca2+ ions to the cytosol had been correlated with its capacity to modulate autophagy and lysosome exocytosis. Therapeutically, this activation alleviates many diseases involving lysosomal dysfunction, such as lysosomal storage disorders, and membrane repair, like in muscular dystrophies. First-in-class treatment for diseases with no cure and limited treatment options. Therapy for diseases involving lysosomal dysfunction (i.e., Gaucher’s Disease, Fabry Disease) and membrane repair (i.e., muscular dystrophies). 2022-08-01 2025-08-13 2025-08-15 2022-08-01 2022-05-04 4-disulfonamide, Benzene-1, Derivatives, MODULATORS, PREPARATION, RECEPTOR, therapeutic, TRPML1, USEFUL, VPXXXX, WKXXXX False True True NIHTT 37470483 Website Abstract 114110636 Yu, Lu University of Michigan Yu, Lu 0 114110637 Marugan, Juan NCATS - NCGC NCATS Marugan, Juan (NCATS) 0 114110638 Calvo, Raul NCATS - NCGC NCATS Calvo, Raul (NCATS) 0 114110639 Martinez, Natalia NCATS - NCGC NCATS Martinez, Natalia (NCATS) 0 114110640 Southall, Noel NCATS - TRND NCATS Southall, Noel (NCATS) 0 114110641 Hu, Xin NCATS - NCGC NCATS Hu, Xin (NCATS) 0 114110642 Ferrer-Alegre, Marc NCATS - NCGC NCATS Ferrer-Alegre, Marc (NCATS) 0 114110635 Xu, Haoxing University of Michigan Xu, Haoxing 1 114110635 Xu, Haoxing University of Michigan Xu, Haoxing 1 114110636 Yu, Lu University of Michigan Yu, Lu 0 114110637 Marugan, Juan NCATS - NCGC NCATS Marugan, Juan (NCATS) 0 114110638 Calvo, Raul NCATS - NCGC NCATS Calvo, Raul (NCATS) 0 114110639 Martinez, Natalia NCATS - NCGC NCATS Martinez, Natalia (NCATS) 0 114110640 Southall, Noel NCATS - TRND NCATS Southall, Noel (NCATS) 0 114110641 Hu, Xin NCATS - NCGC NCATS Hu, Xin (NCATS) 0 114110642 Ferrer-Alegre, Marc NCATS - NCGC NCATS Ferrer-Alegre, Marc (NCATS) 0 114102652 Preparation Of Benzene-1,4-disulfonamide Derivatives Useful As Therapeutic TRPML1 Receptor Modulators E-084-2020-0 Filing authorized NCATS - NCGC, University of Michigan 93911356 Kalsi, Jasmine jasmine.kalsi@nih.gov
United States of America jasmine.kalsi@nih.gov?subject=Web Inquiry on [TAB-3541] Preparation of Benzene-1,4-disulfonamide Derivatives Useful as Therapeutic TRPML1 Receptor Modulators for the Treatment of Lysosomal Dysfunction and Membrane Repair Disorders&body=Please send me information about technology [TAB-3541] Preparation of Benzene-1,4-disulfonamide Derivatives Useful as Therapeutic TRPML1 Receptor Modulators for the Treatment of Lysosomal Dysfunction and Membrane Repair Disorders. Kalsi, Jasmine<br><a href="mailto:jasmine.kalsi@nih.gov?subject=Web Inquiry on [TAB-3541] Preparation of Benzene-1,4-disulfonamide Derivatives Useful as Therapeutic TRPML1 Receptor Modulators for the Treatment of Lysosomal Dysfunction and Membrane Repair Disorders&body=Please send me information about technology [TAB-3541] Preparation of Benzene-1,4-disulfonamide Derivatives Useful as Therapeutic TRPML1 Receptor Modulators for the Treatment of Lysosomal Dysfunction and Membrane Repair Disorders.">jasmine.kalsi@nih.gov</a><br> 114169351 E-084-2020-0 E-084-2020-0-US-01 Preparation Of Benzene-1,4-disulfonamide Derivatives Useful As Therapeutic TRPML1 Receptor Modulators PRV US 62/894,289 Abandoned US <br />Provisional (PRV) 62/894,289<br />Filed on 2019-08-30<br />Status: Abandoned 114169352 E-084-2020-0 E-084-2020-0-PCT-02 Preparation Of Benzene-1,4-disulfonamide Derivatives Useful As Therapeutic TRPML1 Receptor Modulators PCT Patent Cooperation Treaty PCT/US2020/048482 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2020/048482<br />Filed on 2020-08-28<br />Status: Expired 114169353 E-084-2020-0 E-084-2020-0-US-03 SMALL MOLECULE AGONISTS OF MUCOLIPIN 1 AND USES THEREOF National Stage US 17/638,929 Abandoned US <br />National Stage 17/638,929<br />Filed on 2020-08-28<br />Status: Abandoned 114128705 VPXXXX 114128706 WKXXXX 114153017 PREPARATION 114153018 Benzene-1 114153019 4-disulfonamide 114153020 Derivatives 114153021 USEFUL 114153022 therapeutic 114153023 TRPML1 114153024 RECEPTOR 114153025 MODULATORS TAB-3540 114097398 Pyrazolo[1,5-a]pyrimidine Derivatives as Selective ALK Kinases Inhibitors for Inhibition of the Bone Morphogenetic Proteins Signaling Pathway for Treatment of Fibrodysplasia Ossificans Progressiva NCATS Therapeutics Therapeutics Asaf Alimardanov, Kenneth Bloch, Gregory Cuny, Gurmit Grewal, Arthur Lee, John McKew, Randall Peterson, Min Shen, Xin Xu, Paul Yu This technology includes compounds which are selective inhibitors of anaplastic lymphoma kinases (ALK1, ALK2, ALK3 and ALK6), which inhibit these ALKs with low nanomolar potency. These compounds could be developed as a treatment of Fibrodysplasia ossificans progressiva (FOP) and other BMP-related diseases. FOP is a rare congenital disease with no current treatment options. Since the disease is driven by constitutively active ALK2, inhibition of ALK2 would be like hitting the Achilles’ heel of the disease and would potentially be an efficacious therapy for FOP patients. It has also been shown that inhibition of these ALKs is efficacious in animal disease models of anemia of inflammation. Compounds of this invention inhibit ALK2, as well as ALK1, ALK3 and ALK6, with nanomolar potency, both in enzyme and cell assays. <ul> <li>There are currently no effective treatments available for FOP</li> <li>Current BMP inhibitor in development is metabolized by Cyp enzymes and aldehyde oxidase and has the potential of generating an aniline-metabolite which could be potentially toxic and difficult to predict a safe and efficacious dose</li> </ul> A treatment for FOP and anemia of inflammation, as well as BMP driven diseases (certain cancers, cardio-vascular disease, inflammation, hematological disease and bone disorders). 2022-08-01 2025-08-13 2025-08-15 2022-08-01 2022-05-04 5-a]pyrimidine, ALK, BMP, Bone, Derivatives, inhibition, Inhibitors, KINASES, Listed LPM Nguyen-Antczak as of 4/15/2015, MORPHOGENETIC, PATHWAY, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, proteins, Pyrazolo[1, SELECTIVE, SIGNALING, WKXXXX False True True NIHTT 37470483 Website Abstract 114172704 Yu P, Deng D, et al. https://pubmed.ncbi.nlm.nih.gov/19029982/ <a href="https://pubmed.ncbi.nlm.nih.gov/19029982/">Yu P, Deng D, et al.</a> 114172705 Hao J, Ho J, et al. https://pubmed.ncbi.nlm.nih.gov/20020776/ <a href="https://pubmed.ncbi.nlm.nih.gov/20020776/">Hao J, Ho J, et al.</a> 114172706 Cuny G, Yu P, et al. https://pubmed.ncbi.nlm.nih.gov/18621530/ <a href="https://pubmed.ncbi.nlm.nih.gov/18621530/">Cuny G, Yu P, et al.</a> 114110626 Lee, Arthur NCATS - TRND Lee, Arthur 0 114110627 Xu, Xin NCATS - TRND NCATS Xu, Xin (NCATS) 0 114110628 Shen, Min NCATS - NCGC NCATS Shen, Min (NCATS) 0 114110629 McKew, John NCATS - TRND McKew, John 0 114110630 Bloch, Kenneth Massachusetts General Hospital Bloch, Kenneth 0 114110631 Yu, Paul Massachusetts General Hospital Yu, Paul 0 114110632 Cuny, Gregory Massachusetts General Hospital Cuny, Gregory 0 114110633 Peterson, Randall Massachusetts General Hospital Peterson, Randall 0 114110634 Alimardanov, Asaf NCATS - NCGC NCATS Alimardanov, Asaf (NCATS) 0 114110625 Grewal, Gurmit NCATS - NCGC NCATS Grewal, Gurmit (NCATS) 1 114110625 Grewal, Gurmit NCATS - NCGC NCATS Grewal, Gurmit (NCATS) 1 114110626 Lee, Arthur NCATS - TRND Lee, Arthur 0 114110627 Xu, Xin NCATS - TRND NCATS Xu, Xin (NCATS) 0 114110628 Shen, Min NCATS - NCGC NCATS Shen, Min (NCATS) 0 114110629 McKew, John NCATS - TRND McKew, John 0 114110630 Bloch, Kenneth Massachusetts General Hospital Bloch, Kenneth 0 114110631 Yu, Paul Massachusetts General Hospital Yu, Paul 0 114110632 Cuny, Gregory Massachusetts General Hospital Cuny, Gregory 0 114110633 Peterson, Randall Massachusetts General Hospital Peterson, Randall 0 114110634 Alimardanov, Asaf NCATS - NCGC NCATS Alimardanov, Asaf (NCATS) 0 114102651 Pyrazolo[1,5-a]pyrimidine Derivatives As Selective Inhibitors Of ALK Kinases For Inhibition Of The Bone Morphogenetic Proteins (BMP) Signaling Pathway E-299-2012-0 Filing authorized Massachusetts General Hospital, NCATS - NCGC 93911356 Kalsi, Jasmine jasmine.kalsi@nih.gov
United States of America jasmine.kalsi@nih.gov?subject=Web Inquiry on [TAB-3540] Pyrazolo[1,5-a]pyrimidine Derivatives as Selective ALK Kinases Inhibitors for Inhibition of the Bone Morphogenetic Proteins Signaling Pathway for Treatment of Fibrodysplasia Ossificans Progressiva&body=Please send me information about technology [TAB-3540] Pyrazolo[1,5-a]pyrimidine Derivatives as Selective ALK Kinases Inhibitors for Inhibition of the Bone Morphogenetic Proteins Signaling Pathway for Treatment of Fibrodysplasia Ossificans Progressiva. Kalsi, Jasmine<br><a href="mailto:jasmine.kalsi@nih.gov?subject=Web Inquiry on [TAB-3540] Pyrazolo[1,5-a]pyrimidine Derivatives as Selective ALK Kinases Inhibitors for Inhibition of the Bone Morphogenetic Proteins Signaling Pathway for Treatment of Fibrodysplasia Ossificans Progressiva&body=Please send me information about technology [TAB-3540] Pyrazolo[1,5-a]pyrimidine Derivatives as Selective ALK Kinases Inhibitors for Inhibition of the Bone Morphogenetic Proteins Signaling Pathway for Treatment of Fibrodysplasia Ossificans Progressiva.">jasmine.kalsi@nih.gov</a><br> 114169346 E-299-2012-0 E-299-2012-0-US-01 Pyrazolo[1,5-a]pyrimidine Derivatives As Selective Inhibitors Of ALK Kinases For Inhibition Of The Bone Morphogenetic Proteins (BMP) Signaling Pathway PRV US 61/783,695 Abandoned US <br />Provisional (PRV) 61/783,695<br />Filed on 2013-03-14<br />Status: Abandoned 114169347 E-299-2012-0 E-299-2012-0-PCT-02 Pyrazolo[1,5-a]pyrimidine Derivatives As Selective Inhibitors Of ALK Kinases For Inhibition Of The Bone Morphogenetic Proteins (BMP) Signaling Pathway PCT Patent Cooperation Treaty PCT/US14/26042 Expired Patent Cooperation Treaty <br />(PCT) PCT/US14/26042<br />Filed on 2014-03-13<br />Status: Expired 114169348 E-299-2012-0 E-299-2012-0-US-05 BMP INHIBITORS AND METHODS OF USE THEREOF National Stage US 9,682,983 14/776,302 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9682983 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9682983">9,682,983</a><br />Filed on 2014-03-13<br />Status: Issued 114169349 E-299-2012-0 E-299-2012-0-US-06 BMP Inhibitors and Methods of Use Thereof CON US 10,017,516 15/598,540 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10017516 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10017516">10,017,516</a><br />Filed on 2017-05-18<br />Status: Issued 114169350 E-299-2012-0 E-299-2012-0-US-07 BMP Inhibitors and Methods of Use Thereof CON US 15/994,604 Abandoned US <br />Continuation (CON) 15/994,604<br />Filed on 2018-05-31<br />Status: Abandoned 114128704 WKXXXX 114153000 Pyrazolo[1 114153001 5-a]pyrimidine 114153002 Derivatives 114153003 SELECTIVE 114153004 Inhibitors 114153005 ALK 114153006 KINASES 114153007 inhibition 114153008 Bone 114153009 MORPHOGENETIC 114153010 proteins 114153011 BMP 114153012 SIGNALING 114153013 PATHWAY 114153014 Listed LPM Nguyen-Antczak as of 4/15/2015 114153015 Pre LPM working set 20150418 114153016 Post LPM Assignment Set 20150420 TAB-3536 114097394 Generation of Anti-TAT FXN Polyclonal and Monoclonal Antibodies to TAT Domain for Use in Quantitating or Detecting TATFrataxin (TAT-FXN) and Analogs NCATS Antibodies, Cardiology, Dental, Endocrinology, Immunology, Infectious Disease, Oncology, Ophthalmology, Therapeutics Antibodies Cardiology Dental Endocrinology Immunology Infectious Disease Oncology Ophthalmology Therapeutics Bonita Rup, Erik Wagner, Xin Xu This technology includes a strategy to generate antibodies of rabbit origin, both polyclonal and monoclonal, which have strong affinity to the TAT sequence and which enable specific immunocapture or immunodetection of TAT containing frataxin and analogs for quantitative or qualitative assays. In addition, antibodies that react with the FXN region have also been generated with this strategy. The HIV virus encoded a translational activator protein containing a 12 amino acid domain which permits transmembrane delivery of any therapeutic protein containing the sequence. Other anti-TAT antibodies are commercially available, but were found to be ineffective in immunocapturing TAT Frataxin, and are likely not to be directed to the same epitope as the 12 amino acid cell penetration sequence that we refer to as “TAT”. TAT-domain enhanced delivery of proteins or other biomolecules to the target sites has been used to enhance the efficacy of several therapeutics being currently developed. These biologics could involve antibodies, single chain variable regions (ScFv), or any derivative-sequence-containing-peptide, peptide mimetic, or protein containing the amino acid sequence which comprises the paratope of the TAT-binding monoclonal antibodies herein described could be the basis of a detection or quantitation mechanism for a TAT enhanced therapeutic. 2022-08-01 2025-08-13 2025-08-15 2022-08-01 2022-05-04 Analogs, antibodies, Anti-TAT, DETECTING, Domain, FXN, Generation, monoclonal, polyclonal, Protein, QUANTITATING, RELATED, Structurally, TAT, TATFrataxin, TAT-FXN, therapeutic, VPXXXX, WJXXXX, XAXXXX False True True NIHTT 37470483 Website Abstract 114110603 Rup, Bonita Bonnie Rup Consulting LLC Rup, Bonita 0 114110604 Xu, Xin NCATS - TRND NCATS Xu, Xin (NCATS) 0 114110602 Wagner, Erik NCATS - TRND NCATS Wagner, Erik (NCATS) 1 114110602 Wagner, Erik NCATS - TRND NCATS Wagner, Erik (NCATS) 1 114110603 Rup, Bonita Bonnie Rup Consulting LLC Rup, Bonita 0 114110604 Xu, Xin NCATS - TRND NCATS Xu, Xin (NCATS) 0 114102647 Generation Of Anti-TAT FXN Polyclonal And Monoclonal Antibodies To TAT Domain For Use In Quantitating Or Detecting TATFrataxin (TAT-FXN) And Its Structurally Related Therapeutic Protein Analogs E-176-2018-0 Filing authorized Bonnie Rup Consulting LLC, NCATS - NCGC 83673536 Erwin-Cohen, Rebecca rebecca.erwin-cohen@nih.gov
NCGC rebecca.erwin-cohen@nih.gov?subject=Web Inquiry on [TAB-3536] Generation of Anti-TAT FXN Polyclonal and Monoclonal Antibodies to TAT Domain for Use in Quantitating or Detecting TATFrataxin (TAT-FXN) and Analogs&body=Please send me information about technology [TAB-3536] Generation of Anti-TAT FXN Polyclonal and Monoclonal Antibodies to TAT Domain for Use in Quantitating or Detecting TATFrataxin (TAT-FXN) and Analogs. Erwin-Cohen, Rebecca<br><a href="mailto:rebecca.erwin-cohen@nih.gov?subject=Web Inquiry on [TAB-3536] Generation of Anti-TAT FXN Polyclonal and Monoclonal Antibodies to TAT Domain for Use in Quantitating or Detecting TATFrataxin (TAT-FXN) and Analogs&body=Please send me information about technology [TAB-3536] Generation of Anti-TAT FXN Polyclonal and Monoclonal Antibodies to TAT Domain for Use in Quantitating or Detecting TATFrataxin (TAT-FXN) and Analogs.">rebecca.erwin-cohen@nih.gov</a><br> 114169340 E-176-2018-0 E-176-2018-0-US-01 TAT PEPTIDE BINDING PROTEINS AND USES THEREOF PRV US 62/970,662 Abandoned US <br />Provisional (PRV) 62/970,662<br />Filed on 2020-02-05<br />Status: Abandoned 114169341 E-176-2018-0 E-176-2018-0-PCT-02 TAT PEPTIDE BINDING PROTEINS AND USES THEREOF PCT Patent Cooperation Treaty PCT/US2021/016959 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/016959<br />Filed on 2021-02-05<br />Status: Expired 114128695 VPXXXX 114128696 WJXXXX 114128697 XAXXXX 114152962 Generation 114152963 Anti-TAT 114152964 FXN 114152965 polyclonal 114152966 monoclonal 114152967 antibodies 114152968 TAT 114152969 Domain 114152970 QUANTITATING 114152971 DETECTING 114152972 TATFrataxin 114152973 TAT-FXN 114152974 Structurally 114152975 RELATED 114152976 therapeutic 114152977 Protein 114152978 Analogs TAB-3517 114097377 Small Molecule Inhibitors of LDHA for the Treatment of Glycolytic Cancers NCATS Oncology, Therapeutics Oncology Therapeutics Kyle Brimacombe, Plamen Christov, Chi Dang, Victor Darley-Usmar, Matthew Hall, Xin Hu, Ajit Jadhav, Somnath Jana, Kwangho Kim, David Maloney, William Moore, Bryan Mott, Leonard Neckers, Ganesha Rai Bantukallu, Anton Simeonov, Gary Sulikowski, Daniel Urban, Alex Waterson, Shyh-Ming Yang This technology includes LDHA inhibitors that have been synthesized and tested for the treatment of glycolytic cancers. These compounds may have improved activity over previous compounds. Currently there are no known high-quality inhibitors with demonstrated in vivo activity. These compounds are more potent than these prior art compound and have the potential for demonstrated in vivo activity as well. Further clinical work could establish these small molecule inhibitors of LDHA as a first-in-class/target therapy in oncology with a specific focus on glycolytic cancers. 2022-08-01 2025-08-13 2025-08-15 2022-08-01 2022-03-30 Inhibitors, LDHA, MOLECULE, Small, VCXXXX, WKXXXX False True True NIHTT 37470483 Website Abstract 114110496 Mott, Bryan NCATS - NCGC Mott, Bryan 0 114110497 Yang, Shyh-Ming NCATS - NCGC NCATS Yang, Shyh-Ming (NCATS) 0 114110498 Urban, Daniel NCATS - NCGC FDA Urban, Daniel (FDA) 0 114110499 Jadhav, Ajit NCATS - NCGC NCATS Jadhav, Ajit (NCATS) 0 114110500 Simeonov, Anton NCATS - NCGC NCATS Simeonov, Anton (NCATS) 0 114110501 Neckers, Leonard NCI - CCR NCI Neckers, Leonard (NCI) 0 114110502 Moore, William NCI - FCRDC (Leidos) NCI Moore, William (NCI) 0 114110503 Waterson, Alex Vanderbilt University Waterson, Alex 0 114110504 Rai Bantukallu, Ganesha NCATS - NCGC NCATS Rai Bantukallu, Ganesha (NCATS) 0 114110505 Brimacombe, Kyle NCATS - NCGC NCATS Brimacombe, Kyle (NCATS) 0 114110506 Christov, Plamen Vanderbilt University Christov, Plamen 0 114110507 Dang, Chi University of Pennsylvania Dang, Chi 0 114110508 Darley-Usmar, Victor University of Alabama Darley-Usmar, Victor 0 114110509 Hall, Matthew NCATS - NCGC NCATS Hall, Matthew (NCATS) 0 114110510 Hu, Xin NCATS - NCGC NCATS Hu, Xin (NCATS) 0 114110511 Jana, Somnath Vanderbilt University Jana, Somnath 0 114110512 Kim, Kwangho Vanderbilt University Kim, Kwangho 0 114110513 Sulikowski, Gary Vanderbilt University Sulikowski, Gary 0 114110495 Maloney, David NCATS - NCGC NCATS Maloney, David (NCATS) 1 114110495 Maloney, David NCATS - NCGC NCATS Maloney, David (NCATS) 1 114110496 Mott, Bryan NCATS - NCGC Mott, Bryan 0 114110497 Yang, Shyh-Ming NCATS - NCGC NCATS Yang, Shyh-Ming (NCATS) 0 114110498 Urban, Daniel NCATS - NCGC FDA Urban, Daniel (FDA) 0 114110499 Jadhav, Ajit NCATS - NCGC NCATS Jadhav, Ajit (NCATS) 0 114110500 Simeonov, Anton NCATS - NCGC NCATS Simeonov, Anton (NCATS) 0 114110501 Neckers, Leonard NCI - CCR NCI Neckers, Leonard (NCI) 0 114110502 Moore, William NCI - FCRDC (Leidos) NCI Moore, William (NCI) 0 114110503 Waterson, Alex Vanderbilt University Waterson, Alex 0 114110504 Rai Bantukallu, Ganesha NCATS - NCGC NCATS Rai Bantukallu, Ganesha (NCATS) 0 114110505 Brimacombe, Kyle NCATS - NCGC NCATS Brimacombe, Kyle (NCATS) 0 114110506 Christov, Plamen Vanderbilt University Christov, Plamen 0 114110507 Dang, Chi University of Pennsylvania Dang, Chi 0 114110508 Darley-Usmar, Victor University of Alabama Darley-Usmar, Victor 0 114110509 Hall, Matthew NCATS - NCGC NCATS Hall, Matthew (NCATS) 0 114110510 Hu, Xin NCATS - NCGC NCATS Hu, Xin (NCATS) 0 114110511 Jana, Somnath Vanderbilt University Jana, Somnath 0 114110512 Kim, Kwangho Vanderbilt University Kim, Kwangho 0 114110513 Sulikowski, Gary Vanderbilt University Sulikowski, Gary 0 114102629 Small Molecule Inhibitors Of LDHA E-190-2016-0 Filing authorized NCATS - NCGC, NCI, University of Alabama at Birmingham, University of Pennsylvania, Vanderbilt University 83673536 Erwin-Cohen, Rebecca rebecca.erwin-cohen@nih.gov
NCGC rebecca.erwin-cohen@nih.gov?subject=Web Inquiry on [TAB-3517] Small Molecule Inhibitors of LDHA for the Treatment of Glycolytic Cancers&body=Please send me information about technology [TAB-3517] Small Molecule Inhibitors of LDHA for the Treatment of Glycolytic Cancers. Erwin-Cohen, Rebecca<br><a href="mailto:rebecca.erwin-cohen@nih.gov?subject=Web Inquiry on [TAB-3517] Small Molecule Inhibitors of LDHA for the Treatment of Glycolytic Cancers&body=Please send me information about technology [TAB-3517] Small Molecule Inhibitors of LDHA for the Treatment of Glycolytic Cancers.">rebecca.erwin-cohen@nih.gov</a><br> 114169296 E-190-2016-0 E-190-2016-0-US-01 Small Molecule Inhibitors Of Lactate Dehydrogenase and Methods of Use Thereof PRV US 62/356,065 Abandoned US <br />Provisional (PRV) 62/356,065<br />Filed on 2016-06-29<br />Status: Abandoned 114169297 E-190-2016-0 E-190-2016-0-PCT-02 Small Molecule Inhibitors Of Lactate Dehydrogenase and Methods of Use Thereof PCT Patent Cooperation Treaty PCT/US2017/040021 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2017/040021<br />Filed on 2017-06-29<br />Status: Expired 114169298 E-190-2016-0 E-190-2016-0-US-08 1 H-PYRAZOL-1-YL-THIAZOLES AS INHIBITORS OF LACTATE DEHYDROGENASE AND METHODS OF USE THEREOF National Stage US 10,954,228 16/313,727 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10954228 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10954228">10,954,228</a><br />Filed on 2018-12-27<br />Status: Issued 114128655 VCXXXX 114128657 WKXXXX 114152785 Small 114152786 MOLECULE 114152787 Inhibitors 114152788 LDHA TAB-3508 114097371 Preparation of Substituted Diarylpropanamides as RORgt Antagonists for the Treatment of Th17-related Autoimmune Diseases NCATS Cardiology, Dental, Endocrinology, Geriatrics, Immunology, Infectious Disease, Oncology, Ophthalmology, Research Materials, Therapeutics Cardiology Dental Endocrinology Geriatrics Immunology Infectious Disease Oncology Ophthalmology Research Materials Therapeutics Jeffrey Baron, Youn Jee This technology includes a series of diphenylpropanamides as potent and selective RORgt inhibitors for the treatment of Th17-related autoimmune diseases. The retinoic acid-related orphan receptor RORgt plays an important role in the differentiation of thymocytes, lymphoid tissue inducer cells, and inflammatory T helper-expressing interleukin 17a (Th17) cells. Small molecule RORgt inhibitors may provide means to regulate Th17 mediated immune response. The novel molecules have potential to treat Th17-related autoimmune diseases. This invention may offer novel therapeutics for the treatment of Th17 autoimmune diseases. Potent and selective RORgt inhibitors can be used to developed novel treatments for Th17-related autoimmune diseases. 2022-08-01 2025-08-13 2025-08-15 2022-08-01 2022-03-16 assay, Benign, Biopsy, DISTINGUISH, dtx-ttcsite-08-2019, Fine, High-sensitivity, LEVELS, Listed LPM Campbell as of 4/15/2015, Malignant, MEASURE, Midkine, Needle, Nodules, Order, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, THYROID, Tissue, VAXXXX, VPXXXX, WIXXXX, WKXXXX False True True NIHTT 37470483 Website Abstract 114172671 Solt L, Kumar N, et al. https://pubmed.ncbi.nlm.nih.gov/21499262/ <a href="https://pubmed.ncbi.nlm.nih.gov/21499262/">Solt L, Kumar N, et al.</a> 114172672 Huh J, Leung M, et al. https://pubmed.ncbi.nlm.nih.gov/21441909/ <a href="https://pubmed.ncbi.nlm.nih.gov/21441909/">Huh J, Leung M, et al.</a> 114110464 Jee, Youn NICHD NICHD Jee, Youn (NICHD) 0 114110465 Baron, Jeffrey NICHD NICHD Baron, Jeffrey (NICHD) 1 114110465 Baron, Jeffrey NICHD NICHD Baron, Jeffrey (NICHD) 1 114110464 Jee, Youn NICHD NICHD Jee, Youn (NICHD) 0 152357510 Preparation Of Arylpropanamides As RORgt Antagonists E-106-2013-0 Filing authorized NCATS - NCGC, New York University Medical Center, New York University School of Medicine 83682485 Vepa, Suryanarayana sury.vepa@nih.gov
United States of America Office of Strategic Alliances (OSA) sury.vepa@nih.gov?subject=Web Inquiry on [TAB-3508] Preparation of Substituted Diarylpropanamides as RORgt Antagonists for the Treatment of Th17-related Autoimmune Diseases&body=Please send me information about technology [TAB-3508] Preparation of Substituted Diarylpropanamides as RORgt Antagonists for the Treatment of Th17-related Autoimmune Diseases. Vepa, Suryanarayana<br><a href="mailto:sury.vepa@nih.gov?subject=Web Inquiry on [TAB-3508] Preparation of Substituted Diarylpropanamides as RORgt Antagonists for the Treatment of Th17-related Autoimmune Diseases&body=Please send me information about technology [TAB-3508] Preparation of Substituted Diarylpropanamides as RORgt Antagonists for the Treatment of Th17-related Autoimmune Diseases.">sury.vepa@nih.gov</a><br> 114169277 E-016-2013-0 E-016-2013-0-US-01 Assay To Measure Midkine Or Pleiotrophin Level For Diagnosing A Growth PRV US 61/728,624 Abandoned US <br />Provisional (PRV) 61/728,624<br />Filed on 2012-11-20<br />Status: Abandoned 114128634 VAXXXX 114128635 VPXXXX 114128636 WIXXXX 114128637 WKXXXX 114152719 High-sensitivity 114152720 assay 114152721 MEASURE 114152722 Midkine 114152723 LEVELS 114152724 Tissue 114152725 Fine 114152726 Needle 114152727 Biopsy 114152728 Order 114152729 DISTINGUISH 114152730 Benign 114152731 Malignant 114152732 THYROID 114152733 Nodules 114152734 Listed LPM Campbell as of 4/15/2015 114152735 Pre LPM working set 20150418 114152736 Post LPM Assignment Set 20150420 114152737 dtx-ttcsite-08-2019 TAB-3491 114097355 Small Molecule Inhibitors of Lactate Dehydrogenase as an Anti-Cancer Therapy NCATS Oncology, Therapeutics Oncology Therapeutics Kyle Brimacombe, Plamen Christov, Chi Dang, Victor Darley-Usmar, Xin Hu, Ajit Jadhav, Somnath Jana, Kwangho Kim, Jennifer Kouznetsova, David Maloney, William Moore, Bryan Mott, Leonard Neckers, Ganesha Rai Bantukallu, Anton Simeonov, Gary Sulikowski, Daniel Urban, Alex Waterson, Shyh-Ming Yang This technology includes a novel pyrazole-based compound NCGC00274266 (MLS000714501) that inhibits LDH-A with an IC50 of approximately 20 µM with low efficacy that can be used as an anti-cancer therapeutic. Structure-activity relationship studies on this compound led to hydroxypryazole-based compounds and discovery that the hydroxypyrazole compound and related analogs demonstrated a strong metal-dependent activity. These efforts have ultimately led to derivatives of compounds of NCGC00345087 which have abrogated the Zn++ requirement for LDH-A inhibition and exhibit low nanomolar potency and favorable ADME properties. Agents that target enzymes involved in cancer cell metabolism are important because of their potential to preferentially target cancer tissues over normal tissues. The compounds described represent some of the most potent and drug-like inhibitors of LDHA reported to date. These compounds will be used as anti-cancer agents, both as a single agent therapy and in combination with existing agents. 2022-08-01 2025-08-13 2025-08-15 2022-08-01 2022-03-02 BIOCHEMISTRY, CB5EXX, Glycolysis, Inhibitors, LACTATE, Listed LPM Nguyen-Antczak as of 4/15/2015, Patent Category - Chemistry, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, VCXXXX, WKXXXX False True True NIHTT 37470483 Website Abstract 114110376 Jadhav, Ajit NCATS - NCGC NCATS Jadhav, Ajit (NCATS) 0 114110377 Yang, Shyh-Ming NCATS - NCGC NCATS Yang, Shyh-Ming (NCATS) 0 114110378 Hu, Xin NCATS - NCGC NCATS Hu, Xin (NCATS) 0 114110379 Brimacombe, Kyle NCATS - NCGC NCATS Brimacombe, Kyle (NCATS) 0 114110380 Kouznetsova, Jennifer NCATS - NCGC NCATS Kouznetsova, Jennifer (NCATS) 0 114110381 Rai Bantukallu, Ganesha NCATS - NCGC NCATS Rai Bantukallu, Ganesha (NCATS) 0 114110382 Mott, Bryan NCATS - NCGC Mott, Bryan 0 114110383 Simeonov, Anton NCATS - NCGC NCATS Simeonov, Anton (NCATS) 0 114110384 Urban, Daniel NCATS - NCGC FDA Urban, Daniel (FDA) 0 114110385 Neckers, Leonard NCI - CCR NCI Neckers, Leonard (NCI) 0 114110386 Moore, William NCI - FCRDC (Leidos) NCI Moore, William (NCI) 0 114110387 Waterson, Alex Vanderbilt University Waterson, Alex 0 114110388 Sulikowski, Gary Vanderbilt University Sulikowski, Gary 0 114110389 Kim, Kwangho Vanderbilt University Kim, Kwangho 0 114110390 Jana, Somnath Vanderbilt University Jana, Somnath 0 114110391 Christov, Plamen Vanderbilt University Christov, Plamen 0 114110392 Darley-Usmar, Victor University of Alabama Darley-Usmar, Victor 0 114110393 Dang, Chi University of Pennsylvania Dang, Chi 0 114110375 Maloney, David NCATS - NCGC NCATS Maloney, David (NCATS) 1 114110375 Maloney, David NCATS - NCGC NCATS Maloney, David (NCATS) 1 114110376 Jadhav, Ajit NCATS - NCGC NCATS Jadhav, Ajit (NCATS) 0 114110377 Yang, Shyh-Ming NCATS - NCGC NCATS Yang, Shyh-Ming (NCATS) 0 114110378 Hu, Xin NCATS - NCGC NCATS Hu, Xin (NCATS) 0 114110379 Brimacombe, Kyle NCATS - NCGC NCATS Brimacombe, Kyle (NCATS) 0 114110380 Kouznetsova, Jennifer NCATS - NCGC NCATS Kouznetsova, Jennifer (NCATS) 0 114110381 Rai Bantukallu, Ganesha NCATS - NCGC NCATS Rai Bantukallu, Ganesha (NCATS) 0 114110382 Mott, Bryan NCATS - NCGC Mott, Bryan 0 114110383 Simeonov, Anton NCATS - NCGC NCATS Simeonov, Anton (NCATS) 0 114110384 Urban, Daniel NCATS - NCGC FDA Urban, Daniel (FDA) 0 114110385 Neckers, Leonard NCI - CCR NCI Neckers, Leonard (NCI) 0 114110386 Moore, William NCI - FCRDC (Leidos) NCI Moore, William (NCI) 0 114110387 Waterson, Alex Vanderbilt University Waterson, Alex 0 114110388 Sulikowski, Gary Vanderbilt University Sulikowski, Gary 0 114110389 Kim, Kwangho Vanderbilt University Kim, Kwangho 0 114110390 Jana, Somnath Vanderbilt University Jana, Somnath 0 114110391 Christov, Plamen Vanderbilt University Christov, Plamen 0 114110392 Darley-Usmar, Victor University of Alabama Darley-Usmar, Victor 0 114110393 Dang, Chi University of Pennsylvania Dang, Chi 0 114102605 Small Molecule Inhibitors Of Lactate Dehydrogenase E-244-2014-0 Filing authorized NCATS - NCGC, NCI, University of Alabama at Birmingham, University of Pennsylvania, Vanderbilt University 83673536 Erwin-Cohen, Rebecca rebecca.erwin-cohen@nih.gov
NCGC rebecca.erwin-cohen@nih.gov?subject=Web Inquiry on [TAB-3491] Small Molecule Inhibitors of Lactate Dehydrogenase as an Anti-Cancer Therapy&body=Please send me information about technology [TAB-3491] Small Molecule Inhibitors of Lactate Dehydrogenase as an Anti-Cancer Therapy. Erwin-Cohen, Rebecca<br><a href="mailto:rebecca.erwin-cohen@nih.gov?subject=Web Inquiry on [TAB-3491] Small Molecule Inhibitors of Lactate Dehydrogenase as an Anti-Cancer Therapy&body=Please send me information about technology [TAB-3491] Small Molecule Inhibitors of Lactate Dehydrogenase as an Anti-Cancer Therapy.">rebecca.erwin-cohen@nih.gov</a><br> 114169242 E-244-2014-0 E-244-2014-0-US-01 Small Molecule Inhibitors Of Lactate Dehydrogenase and Methods of Use Thereof PRV US 62/097,226 Abandoned US <br />Provisional (PRV) 62/097,226<br />Filed on 2014-12-29<br />Status: Abandoned 114169243 E-244-2014-0 E-244-2014-0-PCT-02 Small Molecule Inhibitors Of Lactate Dehydrogenase and Methods of Use Thereof PCT Patent Cooperation Treaty PCT/US2015/067895 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2015/067895<br />Filed on 2015-12-29<br />Status: Expired 114169244 E-244-2014-0 E-244-2014-0-US-08 Small Molecule Inhibitors Of Lactate Dehydrogenase and Methods of Use Thereof National Stage US 10,351,532 15/540,893 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10351532 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10351532">10,351,532</a><br />Filed on 2017-06-29<br />Status: Issued 114169245 E-244-2014-0 E-244-2014-0-US-09 SMALL MOLECULE INHIBITORS OF LACTATE DEHYDROGENASE AND METHODS OF USE THEREOF DIV US 10,961,200 16/455,848 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10961200 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10961200">10,961,200</a><br />Filed on 2019-06-28<br />Status: Issued 114169246 E-244-2014-0 E-244-2014-0-US-11 Small Molecule Inhibitors Of Lactate Dehydrogenase CON US 11,247,971 17/160,868 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11247971 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11247971">11,247,971</a><br />Filed on 2021-01-28<br />Status: Issued 114169247 E-244-2014-0 E-244-2014-0-US-32 SMALL MOLECULE INHIBITORS OF LACTATE DEHYDROGENASE AND METHODS OF USE THEREOF CON US 11,897,845 17/572,359 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11897845 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11897845">11,897,845</a><br />Filed on 2022-01-10<br />Status: Issued 114128580 CB5EXX 114128581 VCXXXX 114128582 WKXXXX 114152604 Inhibitors 114152605 LACTATE 114152606 Patent Category - Chemistry 114152607 Glycolysis 114152608 BIOCHEMISTRY 114152609 Listed LPM Nguyen-Antczak as of 4/15/2015 114152610 Pre LPM working set 20150418 114152611 Post LPM Assignment Set 20150420 TAB-3490 114097354 Small Molecule Inhibitors of Alpha IIb Beta 3 Receptor for Potential Therapeutic Intervention within Myocardial Infarction and Stroke NCATS Cardiology, Dental, Endocrinology, Infectious Disease, Oncology, Ophthalmology, Research Materials, Therapeutics Cardiology Dental Endocrinology Infectious Disease Oncology Ophthalmology Research Materials Therapeutics Barry Coller, Wenwei Huang, Jiankang Jiang, Joshua McCoy, Min Shen, Craig Thomas This technology includes methods for screening compounds and compositions useful for inhibiting or reducing platelet deposition, adhesion, and/or aggregation. The present invention further relates to methods of treatment or prophylaxis of thrombotic disorders, including stroke, myocardial infarction, unstable angina, abrupt closure following angioplasty or stent placement, thrombosis induced by peripheral vascular surgery, peripheral vascular disease or thrombotic disorders resulting from atrial fibrillation or inflammation. Previous work with inhibitors of aIIbP3, particularly 2-ethyl-7-(piperazin-1-yl)-5H-[1,3,4]thiadiazolo[3,2-a]pyiimidin-5-one, has shown they are capable of inhibiting fibrinogen binding and platelet aggregation without inducing the binding of one or more integrin P3 LIBS-specific monoclonal antibodies (mAbs). Newly identified inhibitors of aIIbP3 are capable of inhibiting fibrinogen binding and platelet aggregation without inducing the binding of integrin P3 LIBS. Currently available agents are only available in parenteral form and cause adverse reactions (i.e., thrombocytopenia, hypotension). .This invention may offer a therapeutic option within IV bags, EpiPens and as therapy during surgery to avoid adverse clotting events. 2022-08-01 2025-08-13 2025-08-15 2022-08-01 2022-03-01 3, ALPHA, Beta, IIb, infarction, Inhibitors, INTERVENTION, Listed LPM Nguyen-Antczak as of 4/15/2015, MOLECULE, MYOCARDIAL, Post LPM Assignment Set 20150420, Potential, Pre LPM working set 20150418, RECEPTOR, Small, STROKE, therapeutic, VDXXXX, VPXXXX, WIXXXX, WKXXXX False True True NIHTT 37470483 Website Abstract 114172646 Luo B, Carman C, et al. https://pubmed.ncbi.nlm.nih.gov/17201681/ <a href="https://pubmed.ncbi.nlm.nih.gov/17201681/">Luo B, Carman C, et al.</a> 114172647 Coller B, Shattil S, et al. https://pubmed.ncbi.nlm.nih.gov/18840725/ <a href="https://pubmed.ncbi.nlm.nih.gov/18840725/">Coller B, Shattil S, et al.</a> 114172648 Gao C, Boylan B, et al. https://pubmed.ncbi.nlm.nih.gov/19197137/ <a href="https://pubmed.ncbi.nlm.nih.gov/19197137/">Gao C, Boylan B, et al.</a> 114172649 Blue R, Murcia M, et al. https://pubmed.ncbi.nlm.nih.gov/17978171/ <a href="https://pubmed.ncbi.nlm.nih.gov/17978171/">Blue R, Murcia M, et al.</a> 114172650 Blue R, Kowalska M, et al. https://pubmed.ncbi.nlm.nih.gov/19414864/ <a href="https://pubmed.ncbi.nlm.nih.gov/19414864/">Blue R, Kowalska M, et al.</a> 114172651 Zhu J, Zhu J, et al. https://pubmed.ncbi.nlm.nih.gov/20679525/ <a href="https://pubmed.ncbi.nlm.nih.gov/20679525/">Zhu J, Zhu J, et al.</a> 114110369 Thomas, Craig National Human Genome Research Institute (NHGRI) NCATS Thomas, Craig (NCATS) 0 114110370 Jiang, Jiankang National Human Genome Research Institute (NHGRI) NCATS Jiang, Jiankang (NCATS) 0 114110371 McCoy, Joshua Office of Research Services (ORS) McCoy, Joshua 0 114110372 Huang, Wenwei National Human Genome Research Institute (NHGRI) NCATS Huang, Wenwei (NCATS) 0 114110373 Shen, Min National Human Genome Research Institute (NHGRI) NCATS Shen, Min (NCATS) 0 114110374 Coller, Barry The Rockefeller University Coller, Barry 1 114110374 Coller, Barry The Rockefeller University Coller, Barry 1 114110369 Thomas, Craig National Human Genome Research Institute (NHGRI) NCATS Thomas, Craig (NCATS) 0 114110370 Jiang, Jiankang National Human Genome Research Institute (NHGRI) NCATS Jiang, Jiankang (NCATS) 0 114110371 McCoy, Joshua Office of Research Services (ORS) McCoy, Joshua 0 114110372 Huang, Wenwei National Human Genome Research Institute (NHGRI) NCATS Huang, Wenwei (NCATS) 0 114110373 Shen, Min National Human Genome Research Institute (NHGRI) NCATS Shen, Min (NCATS) 0 114102604 Small Molecule Inhibitors Of Alpha IIb Beta 3 Receptor For Potential Therapeutic Intervention Within Myocardial Infarction And Stroke E-074-2012-0 Filing authorized NCATS - NCGC, The Rockefeller University 83673536 Erwin-Cohen, Rebecca rebecca.erwin-cohen@nih.gov
NCGC rebecca.erwin-cohen@nih.gov?subject=Web Inquiry on [TAB-3490] Small Molecule Inhibitors of Alpha IIb Beta 3 Receptor for Potential Therapeutic Intervention within Myocardial Infarction and Stroke&body=Please send me information about technology [TAB-3490] Small Molecule Inhibitors of Alpha IIb Beta 3 Receptor for Potential Therapeutic Intervention within Myocardial Infarction and Stroke. Erwin-Cohen, Rebecca<br><a href="mailto:rebecca.erwin-cohen@nih.gov?subject=Web Inquiry on [TAB-3490] Small Molecule Inhibitors of Alpha IIb Beta 3 Receptor for Potential Therapeutic Intervention within Myocardial Infarction and Stroke&body=Please send me information about technology [TAB-3490] Small Molecule Inhibitors of Alpha IIb Beta 3 Receptor for Potential Therapeutic Intervention within Myocardial Infarction and Stroke.">rebecca.erwin-cohen@nih.gov</a><br> 114169239 E-074-2012-0 E-074-2012-0-US-01 Organic Compounds PRV US 61/587,030 Abandoned US <br />Provisional (PRV) 61/587,030<br />Filed on 2012-01-16<br />Status: Abandoned 114169240 E-074-2012-0 E-074-2012-0-PCT-02 Organic Compounds PCT Patent Cooperation Treaty PCT/US2013/021749 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2013/021749<br />Filed on 2013-01-16<br />Status: Expired 114169241 E-074-2012-0 E-074-2012-0-US-08 7-(PIPERAZIN-1-YL)-5H-[1,3,4]THIADIAZOLO[3,2-A]PYRIMIDIN-5-ONES FOR THE TREATMENT OF THROMBOTIC DISORDERS National Stage US 9,303,044 14/372,488 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9303044 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9303044">9,303,044</a><br />Filed on 2014-07-16<br />Status: Issued 114128576 VDXXXX 114128577 VPXXXX 114128578 WIXXXX 114128579 WKXXXX 114152587 Small 114152588 MOLECULE 114152589 Inhibitors 114152590 ALPHA 114152591 IIb 114152592 Beta 114152593 3 114152594 RECEPTOR 114152595 Potential 114152596 therapeutic 114152597 INTERVENTION 114152598 MYOCARDIAL 114152599 infarction 114152600 STROKE 114152601 Listed LPM Nguyen-Antczak as of 4/15/2015 114152602 Pre LPM working set 20150418 114152603 Post LPM Assignment Set 20150420 TAB-3486 114097351 Naphthalene-containing Selective Inhibitors of BMP type 1 Receptors for the Treatment of Fibrodysplasia Ossificans Progressiva NCATS Neurology, Oncology, Research Materials, Therapeutics Neurology Oncology Research Materials Therapeutics Xiuli Huang, Arthur Lee, John McKew, Paresma Patel, Philip Sanderson, Paul Yu, Wei Zheng This technology includes the use of a new class of molecules (nanomolar ALK2 inhibitor) to impede bone morphogenetic proteins (BMP) signaling for the treatment of Fibrodysplasia ossificans progressiva (FOP). FOP is a rare disease, characterized by malformation of the great (big) toes during embryonic development. Individuals with FOP have identical heterozygous activating mutation (R206H) in the gene encoding ACRV1 (also known as ALK2), a BMP type 1 receptor. This compound was created by replacing a quinoline moeity with a naphthalene moeity which gave rise to a class of molecules that are not susceptible to aldehyde oxidase (AO) metabolism, a major pathway for quinoline-containing molecules. Elimination of this metabolic pathway can have major benefits, such as increased systemic exposure, prevention of potential toxic effects of quinoline metabolites, and avoiding inter-subject variability based on AO polymorphism. This therapy is derived from a new, distinct class of compounds and would benefit those suffering from this disorder where there is currently no effective treatment available. A nanomolar ALK2 inhibitor could conceivably be used as prophylactic, acute, or chronic therapy for patients with FOP. 2022-08-01 2025-08-13 2025-08-15 2022-08-01 2022-02-23 1receptors, 5-a]pyrimidine, BMP, Derivatives, Inhibitors, Listed LPM Nguyen-Antczak as of 4/15/2015, Naphthalene-containing, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Pyrazolo[1, SELECTIVE, TYPE, VCXXXX, VEXXXX, WIXXXX, WKXXXX, XEXXXX, YAXXXX, YBXXXX False True True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114172643 Yu P, Deng D, et al. https://pubmed.ncbi.nlm.nih.gov/19029982/ [PMID 19029982] <a href="https://pubmed.ncbi.nlm.nih.gov/19029982/ [PMID 19029982]">Yu P, Deng D, et al.</a> 114172644 Hao J, Ho J, et al. https://pubmed.ncbi.nlm.nih.gov/20020776 <a href="https://pubmed.ncbi.nlm.nih.gov/20020776">Hao J, Ho J, et al.</a> 114172645 Cuny G, Yu P, et al. https://pubmed.ncbi.nlm.nih.gov/18621530 <a href="https://pubmed.ncbi.nlm.nih.gov/18621530">Cuny G, Yu P, et al.</a> 114110356 McKew, John NCATS - TRND McKew, John 0 114110357 Patel, Paresma NCATS - TRND FDA Patel, Paresma (FDA) 0 114110358 Yu, Paul Massachusetts General Hospital Yu, Paul 0 114110359 Sanderson, Philip NCATS - TRND NCATS Sanderson, Philip (NCATS) 0 114110360 Zheng, Wei NCATS - TRND NCATS Zheng, Wei (NCATS) 0 114110361 Huang, Xiuli NCATS - NCGC NCATS Huang, Xiuli (NCATS) 0 114110355 Lee, Arthur NCATS - TRND Lee, Arthur 1 114110355 Lee, Arthur NCATS - TRND Lee, Arthur 1 114110356 McKew, John NCATS - TRND McKew, John 0 114110357 Patel, Paresma NCATS - TRND FDA Patel, Paresma (FDA) 0 114110358 Yu, Paul Massachusetts General Hospital Yu, Paul 0 114110359 Sanderson, Philip NCATS - TRND NCATS Sanderson, Philip (NCATS) 0 114110360 Zheng, Wei NCATS - TRND NCATS Zheng, Wei (NCATS) 0 114110361 Huang, Xiuli NCATS - NCGC NCATS Huang, Xiuli (NCATS) 0 114102601 Naphthalene-containing Pyrazolo[1,5-a]pyrimidine Derivatives As Selective Inhibitors Of BMP Type 1receptors E-208-2014-0 Filing authorized Massachusetts General Hospital, NCATS - NCGC 93911356 Kalsi, Jasmine jasmine.kalsi@nih.gov
United States of America jasmine.kalsi@nih.gov?subject=Web Inquiry on [TAB-3486] Naphthalene-containing Selective Inhibitors of BMP type 1 Receptors for the Treatment of Fibrodysplasia Ossificans Progressiva&body=Please send me information about technology [TAB-3486] Naphthalene-containing Selective Inhibitors of BMP type 1 Receptors for the Treatment of Fibrodysplasia Ossificans Progressiva. Kalsi, Jasmine<br><a href="mailto:jasmine.kalsi@nih.gov?subject=Web Inquiry on [TAB-3486] Naphthalene-containing Selective Inhibitors of BMP type 1 Receptors for the Treatment of Fibrodysplasia Ossificans Progressiva&body=Please send me information about technology [TAB-3486] Naphthalene-containing Selective Inhibitors of BMP type 1 Receptors for the Treatment of Fibrodysplasia Ossificans Progressiva.">jasmine.kalsi@nih.gov</a><br> 114169232 E-208-2014-0 E-208-2014-0-US-01 Naphthalene-containing Pyrazolo[1,5-a]pyrimidine Derivatives As Selective Inhibitors Of BMP Type 1receptors PRV US 62/024,870 Abandoned US <br />Provisional (PRV) 62/024,870<br />Filed on 2014-07-15<br />Status: Abandoned 114169233 E-208-2014-0 E-208-2014-0-PCT-02 Compositions and Methods for Inhibiting BMP PCT Patent Cooperation Treaty PCT/US2015/040366 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2015/040366<br />Filed on 2015-07-14<br />Status: Expired 114169234 E-208-2014-0 E-208-2014-0-US-03 Compositions and Methods for Inhibiting BMP National Stage US 10,513,521 15/326,262 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10513521 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10513521">10,513,521</a><br />Filed on 2015-07-14<br />Status: Issued 114128568 WIXXXX 114128569 WKXXXX 114128570 YAXXXX 114128571 YBXXXX 114128889 VCXXXX 114128890 VEXXXX 114128891 XEXXXX 114152544 Naphthalene-containing 114152545 Pyrazolo[1 114152546 5-a]pyrimidine 114152547 Derivatives 114152548 SELECTIVE 114152549 Inhibitors 114152550 BMP 114152551 TYPE 114152552 1receptors 114152553 Listed LPM Nguyen-Antczak as of 4/15/2015 114152554 Pre LPM working set 20150418 114152555 Post LPM Assignment Set 20150420 TAB-3485 114097350 2-substituted Pyridines and Their Methods for Inhibiting BMP Signaling for the Treatment of Fibrodysplasia Ossificans Progressiva NCATS Cardiology, Dental, Endocrinology, Infectious Disease, Oncology, Ophthalmology, Research Materials, Therapeutics Cardiology Dental Endocrinology Infectious Disease Oncology Ophthalmology Research Materials Therapeutics Gregory Cuny, Arthur Lee, Agustin Mohedas, Paul Yu This technology includes the use of a new class of molecules (nanomolar ALK2 inhibitor) to impede bone morphogenetic proteins (BMP) signaling for the treatment of Fibrodysplasia ossificans progressiva (FOP). FOP is a rare disease, characterized by malformation of the great (big) toes during embryonic development. Individuals with FOP have an identical heterozygous activating mutation (R206H) in the gene encoding ACRV1 (also known as ALK2), a BMP type 1 receptor. This compound was created by replacing a quinoline moiety with a naphthalene moiety which gave rise to a class of molecules that are not susceptible to aldehyde oxidase (AO) metabolism, a major pathway for quinoline-containing molecules. Elimination of this metabolic pathway can have major benefits, such as increased systemic exposure, prevention of potential toxic effects of quinoline metabolites, and avoiding inter-subject variability based on AO polymorphism. This therapy is derived from a new, distinct class of compounds and would benefit those suffering from this disorder where there is currently no effective treatment available. A nanomolar ALK2 inhibitor to be used as a prophylactic, acute or chronic therapy for patients with FOP. 2022-08-01 2025-08-13 2025-08-15 2022-08-01 2022-02-22 2-SUBSTITUTED, BMP, INHIBITING, Listed LPM Nguyen-Antczak as of 4/15/2015, Methods, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, PYRIDINES, SIGNALING, Their, VPXXXX, WIXXXX, WKXXXX, XEXXXX False True True NIHTT 37470483 Website Abstract 114172639 Yu P, Deng D, et al. https://pubmed.ncbi.nlm.nih.gov/19029982/ <a href="https://pubmed.ncbi.nlm.nih.gov/19029982/">Yu P, Deng D, et al.</a> 114172640 Hao J, Ho J, et al. https://pubmed.ncbi.nlm.nih.gov/20020776 <a href="https://pubmed.ncbi.nlm.nih.gov/20020776">Hao J, Ho J, et al.</a> 114172641 Cuny G, Yu P, et al. https://pubmed.ncbi.nlm.nih.gov/18621530 <a href="https://pubmed.ncbi.nlm.nih.gov/18621530">Cuny G, Yu P, et al.</a> 114172642 Sanvitale C, Kerr G, et al. https://pubmed.ncbi.nlm.nih.gov/23646137 [PMID 23646137] <a href="https://pubmed.ncbi.nlm.nih.gov/23646137 [PMID 23646137]">Sanvitale C, Kerr G, et al.</a> 114110352 Yu, Paul Massachusetts General Hospital Yu, Paul 0 114110353 Cuny, Gregory Massachusetts General Hospital Cuny, Gregory 0 114110354 Mohedas, Agustin Massachusetts General Hospital Mohedas, Agustin 0 114110351 Lee, Arthur NCATS - TRND Lee, Arthur 1 114110351 Lee, Arthur NCATS - TRND Lee, Arthur 1 114110352 Yu, Paul Massachusetts General Hospital Yu, Paul 0 114110353 Cuny, Gregory Massachusetts General Hospital Cuny, Gregory 0 114110354 Mohedas, Agustin Massachusetts General Hospital Mohedas, Agustin 0 114102600 2-substituted Pyridines And Their Methods For Inhibiting BMP Signaling E-018-2015-0 Filing authorized Massachusetts General Hospital, NCATS - NCGC 93911356 Kalsi, Jasmine jasmine.kalsi@nih.gov
United States of America jasmine.kalsi@nih.gov?subject=Web Inquiry on [TAB-3485] 2-substituted Pyridines and Their Methods for Inhibiting BMP Signaling for the Treatment of Fibrodysplasia Ossificans Progressiva&body=Please send me information about technology [TAB-3485] 2-substituted Pyridines and Their Methods for Inhibiting BMP Signaling for the Treatment of Fibrodysplasia Ossificans Progressiva. Kalsi, Jasmine<br><a href="mailto:jasmine.kalsi@nih.gov?subject=Web Inquiry on [TAB-3485] 2-substituted Pyridines and Their Methods for Inhibiting BMP Signaling for the Treatment of Fibrodysplasia Ossificans Progressiva&body=Please send me information about technology [TAB-3485] 2-substituted Pyridines and Their Methods for Inhibiting BMP Signaling for the Treatment of Fibrodysplasia Ossificans Progressiva.">jasmine.kalsi@nih.gov</a><br> 114169228 E-018-2015-0 E-018-2015-0-US-01 2-substituted Pyridines And Their Methods For Inhibiting BMP Signaling PRV US 62/058,377 Abandoned US <br />Provisional (PRV) 62/058,377<br />Filed on 2014-10-01<br />Status: Abandoned 114169229 E-018-2015-0 E-018-2015-0-PCT-02 COMPOSITIONS AND METHODS FOR INHIBITING BMP PCT Patent Cooperation Treaty PCT/US2015/053545 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2015/053545<br />Filed on 2015-10-01<br />Status: Expired 114169230 E-018-2015-0 E-018-2015-0-US-05 Compositions and Methods for Inhibiting BMP National Stage US 15/516,273 Abandoned US <br />National Stage 15/516,273<br />Filed on 2017-03-31<br />Status: Abandoned 114128564 VPXXXX 114128565 WKXXXX 114128566 WIXXXX 114128567 XEXXXX 114152534 2-SUBSTITUTED 114152535 PYRIDINES 114152536 Their 114152537 Methods 114152538 INHIBITING 114152539 BMP 114152540 SIGNALING 114152541 Listed LPM Nguyen-Antczak as of 4/15/2015 114152542 Pre LPM working set 20150418 114152543 Post LPM Assignment Set 20150420 TAB-3482 114097347 Monoclonal Antibodies To Prevent or Treat SARS-CoV-2 Infection NIAID Collaboration Collaboration Zhaochun Chen, Patrizia Farci, Paolo Lusso, Kamille West, Peng Zhang The ongoing COVID-19 pandemic, caused by severe respiratory syndrome coronavirus 2 (SARS-CoV-2), has created an immense public health, social, and economic burden. Variants of concern continue to emerge that have increased transmissibility, pathogenicity, or both and that reduce the effectiveness of current therapeutics and vaccines. Thus, there is a great need for broadly protective therapeutics.<br /><br /> This technology relates to two monoclonal antibodies targeting the spike protein of SARS-CoV-2 that between the two have picomolar activity against wild-type SARS-CoV-2 and the Alpha, Beta, Delta, and Omicron variants of concern. Additionally, one of the antibodies recognizes a highly-conserved epitope of the spike protein. Treatment with either monoclonal antibody before or after challenge with SARS-CoV-2 reduced symptoms and viral load in nasal turbinate and lung tissue in the golden Syrian hamster model. This monoclonal antibody technology has great potential to treat SARS-CoV-2 infections and may provide protection against future variants of concern.<br /><br /> This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR part 404. <ul> <li>Broad and potent neutralization of several variants of concern, including Omicron</li> </ul> <ul> <li>Treatment for SARS-CoV-2 infection</li> <li>Prophylaxis treatment to prevent or reduce SARS-CoV-2 infection</li> <li>Diagnostic for SARS-CoV-2 infection</li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize this technology. For collaboration opportunities, please contact Elizabeth Pitts, Ph.D., 240-669-5299; <a href="mailto:elizabeth.pitts@nih.gov">elizabeth.pitts@nih.gov</a>. 2022-04-21 2025-08-13 2025-08-15 2022-04-21 2022-02-28 antibodies, Cure, Disease, monoclonal, Prevent, SARS-CoV-2 False True True NIHTT 37470483 Website Abstract 114110337 Farci, Patrizia NIAID - DIR NIAID Farci, Patrizia (NIAID) 0 114110338 West, Kamille Clinical Center (CC) CC West, Kamille (CC) 0 114110339 Zhang, Peng NIAID - DIR NIAID Zhang, Peng (NIAID) 0 114110340 Lusso, Paolo NIAID - DIR NIAID Lusso, Paolo (NIAID) 0 114110336 Chen, Zhaochun NIAID - DIR NIAID Chen, Zhaochun (NIAID) 1 114110336 Chen, Zhaochun NIAID - DIR NIAID Chen, Zhaochun (NIAID) 1 114110337 Farci, Patrizia NIAID - DIR NIAID Farci, Patrizia (NIAID) 0 114110338 West, Kamille Clinical Center (CC) CC West, Kamille (CC) 0 114110339 Zhang, Peng NIAID - DIR NIAID Zhang, Peng (NIAID) 0 114110340 Lusso, Paolo NIAID - DIR NIAID Lusso, Paolo (NIAID) 0 114102597 Monoclonal Antibodies Specific For SARS-CoV-2 Spike Protein And Uses Thereof E-132-2021-0 Filing authorized Centers for Disease Control and Prevention (CDC), Clinical Center (CC), NIAID 91027763 Puglielli, Maryann maryann.puglielli@nih.gov
United States of America maryann.puglielli@nih.gov?subject=Web Inquiry on [TAB-3482] Monoclonal Antibodies To Prevent or Treat SARS-CoV-2 Infection&body=Please send me information about technology [TAB-3482] Monoclonal Antibodies To Prevent or Treat SARS-CoV-2 Infection. Puglielli, Maryann<br><a href="mailto:maryann.puglielli@nih.gov?subject=Web Inquiry on [TAB-3482] Monoclonal Antibodies To Prevent or Treat SARS-CoV-2 Infection&body=Please send me information about technology [TAB-3482] Monoclonal Antibodies To Prevent or Treat SARS-CoV-2 Infection.">maryann.puglielli@nih.gov</a><br> 114169223 E-132-2021-0 E-132-2021-0-US-01_82723 Monoclonal Antibodies Specific for SARS-CoV-2 Spike Protein and Uses Thereof PRV US 63/296,380 Expired US <br />Provisional (PRV) 63/296,380<br />Filed on 2022-01-04<br />Status: Expired 114152517 antibodies 114152518 monoclonal 114152519 Prevent 114152520 Cure 114152521 SARS-CoV-2 114152522 Disease TAB-3479 114097345 A Device to Measure Force Continuously During Handgrip Contraction and Relaxation for Myotonic Dystrophies CC Cardiology, Dental, Diagnostics, Endocrinology, Infectious Disease, Licensing, Medical Devices, Neurology, Non-Medical Devices, Oncology, Ophthalmology, Research Materials Cardiology Dental Diagnostics Endocrinology Infectious Disease Licensing Medical Devices Neurology Non-Medical Devices Oncology Ophthalmology Research Materials Thomas Bulea, Diane Damiano, Andrew Gravunder, Ami Mankodi This invention relates to two devices that reliably, sensitively, and accurately measures force during handgrip contraction and subsequent relaxation. A delayed relaxation after a sustained and forceful handgrip is a cardinal symptom of myotonic dystrophies (DM). This delayed relaxation, handgrip myotonia, may be a therapeutic response biomarker in clinical trials. <br /><br /> The Hand Clasp Load Cell Device is an assembly of an upper piece to be held between the fingers and palm and a lower palmar piece embedded with force sensing transducers to measure grip strength and relaxation time. The accompanying software automates clinical assessment of hand strength and relaxation time, displays grip force in real-time and synchronizes data with verbal commands to also quantify reaction time. The Myotonia Relaxation Actuator consists of a servo-motor connected to a lever designed to track finger movements in addition to force measurements. Interactive software supports data collection, real-time synchronization, as well as a display of the force measurements and finger positions during handgrip and relaxation. <ul> <li>The combination of affordability, ease of use, and accuracy in measuring force during handgrip is unique in the market.</li> <li>The integrated software that automates clinical assessment of handgrip myotonia is also a unique feature.</li> <li>Portable set up is adaptable to any table surface and requires only a USB connection to any laptop and renders device attractive for a larger range of clinical settings.</li> </ul> The device can be used as a: <ul> <li>clinical assessment tool to quantify hand function biomarkers. The continuous force measurements may permit the assessment of other neurological disorders</li> <li>research device to affordably and accurately quantify grip force, thumb kinematics, and electromyography</li> </ul> <br /><br /> The real-time tracking of this device and associated software could be used in a virtual environment to be used in rehabilitation and non-medical fields. 2022-07-29 2025-08-13 2025-08-15 2022-02-08 Devices, Handgrip, MECHANICAL, Relaxometer, VEXXXX, VPXXXX, WBXXXX, WIXXXX, XCXXXX, XDXXXX False True True NIHTT 37470483 Website Abstract 114172635 Moxley, RT, Logigian EL, et al. https://pubmed.ncbi.nlm.nih.gov/17587223/ <a href="https://pubmed.ncbi.nlm.nih.gov/17587223/">Moxley, RT, Logigian EL, et al.</a> 114110323 Gravunder, Andrew Clinical Center (CC) Gravunder, Andrew 0 114110324 Bulea, Thomas Clinical Center (CC) CC Bulea, Thomas (CC) 0 114110325 Damiano, Diane Clinical Center (CC) CC Damiano, Diane (CC) 0 114110322 Mankodi, Ami NINDS NINDS Mankodi, Ami (NINDS) 1 114110322 Mankodi, Ami NINDS NINDS Mankodi, Ami (NINDS) 1 114110323 Gravunder, Andrew Clinical Center (CC) Gravunder, Andrew 0 114110324 Bulea, Thomas Clinical Center (CC) CC Bulea, Thomas (CC) 0 114110325 Damiano, Diane Clinical Center (CC) CC Damiano, Diane (CC) 0 114102590 Handgrip Relaxometer Devices E-001-2019-1 Filing authorized Clinical Center (CC), NINDS 91828331 Beka, Lidia lidia.beka@nih.gov
United States of America lidia.beka@nih.gov?subject=Web Inquiry on [TAB-3479] A Device to Measure Force Continuously During Handgrip Contraction and Relaxation for Myotonic Dystrophies&body=Please send me information about technology [TAB-3479] A Device to Measure Force Continuously During Handgrip Contraction and Relaxation for Myotonic Dystrophies. Beka, Lidia<br><a href="mailto:lidia.beka@nih.gov?subject=Web Inquiry on [TAB-3479] A Device to Measure Force Continuously During Handgrip Contraction and Relaxation for Myotonic Dystrophies&body=Please send me information about technology [TAB-3479] A Device to Measure Force Continuously During Handgrip Contraction and Relaxation for Myotonic Dystrophies.">lidia.beka@nih.gov</a><br> 114169213 E-001-2019-1 E-001-2019-1-PCT-01 HANDGRIP RELAXOMETER SYSTEM PCT COMB Patent Cooperation Treaty PCT/US2020/018273 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2020/018273<br />Filed on 2020-02-14<br />Status: Expired 114169608 E-001-2019-1 E-001-2019-1-US-02 HANDGRIP RELAXOMETER SYSTEM National Stage US 17/430,891 Pending US <br />National Stage 17/430,891<br />Filed on 2021-08-13<br />Status: Pending 114128545 VEXXXX 114128546 VPXXXX 114128547 WBXXXX 114128548 WIXXXX 114128549 XCXXXX 114128550 XDXXXX 114152486 Handgrip 114152487 Relaxometer 114152488 Devices 114152489 MECHANICAL TAB-3473 114097338 A Highly Efficient Astrocyte Differentiation Protocol for Human Pluripotent Stem Cells NCATS Neurology, Research Equipment, Research Materials Neurology Research Equipment Research Materials Vukasin Jovanovic, Anton Simeonov, Ilyas Singec This technology includes a robust and highly efficient protocol that differentiates induced pluripotent stem cells (iPSCs) exclusively into nociceptors (also called sensory neurons) under chemically defined conditions. The use of hPSCs, including hESCs and iPSCs, holds great promise for disease modeling, drug discovery, and cell therapy. However, efficient and highly reproducible protocols have not been developed for most cell types that are relevant and urgently needed for translational applications. Systematic testing of various cell culture conditions and simultaneous manipulation of specific cell signaling pathways has led to the ability to directly induce astrogliogenesis from iPSCs with over 95% efficiency in less than 30 days. These cells displayed astrocyte morphologies and expressed typical astrocyte markers such as GFAP, NF-IA, and S100-B. The protocol included in this technology is the most efficient and reproducible astrocyte differentiation protocol for human pluripotent stem cells. The protocol included in this invention will permit increased in vitro use of human astrocytes for basic research, drug discovery, disease modeling, and cell therapy. 2022-08-01 2025-08-13 2025-08-15 2022-08-01 2022-02-07 ASTROCYTE, Cells, DIFFERENTIATION, Efficient, Highly, Human, Pluripotent, PROTOCOL, Stem, VEXXXX, WIXXXX, XHXXXX False True True NIHTT 37470483 Website Abstract E-060-2019-0 E-022-2018-0 E-169-2019-0 114172631 Tristan CA, Ormanoglu P, et al. https://pubmed.ncbi.nlm.nih.gov/34861164/ <a href="https://pubmed.ncbi.nlm.nih.gov/34861164/">Tristan CA, Ormanoglu P, et al.</a> 114110301 Jovanovic, Vukasin NCATS - NCGC NCATS Jovanovic, Vukasin (NCATS) 0 114110302 Simeonov, Anton NCATS - NCGC NCATS Simeonov, Anton (NCATS) 0 114110300 Singec, Ilyas NCATS - NCGC NCATS Singec, Ilyas (NCATS) 1 114110300 Singec, Ilyas NCATS - NCGC NCATS Singec, Ilyas (NCATS) 1 114110301 Jovanovic, Vukasin NCATS - NCGC NCATS Jovanovic, Vukasin (NCATS) 0 114110302 Simeonov, Anton NCATS - NCGC NCATS Simeonov, Anton (NCATS) 0 114102588 A Highly Efficient Astrocyte Differentiation Protocol For Human Pluripotent Stem Cells E-168-2019-0 Filing authorized NCATS - NCGC 83727060 Gadhia, Ami ami.gadhia@nih.gov
United States of America NCGC ami.gadhia@nih.gov?subject=Web Inquiry on [TAB-3473] A Highly Efficient Astrocyte Differentiation Protocol for Human Pluripotent Stem Cells&body=Please send me information about technology [TAB-3473] A Highly Efficient Astrocyte Differentiation Protocol for Human Pluripotent Stem Cells. Gadhia, Ami<br><a href="mailto:ami.gadhia@nih.gov?subject=Web Inquiry on [TAB-3473] A Highly Efficient Astrocyte Differentiation Protocol for Human Pluripotent Stem Cells&body=Please send me information about technology [TAB-3473] A Highly Efficient Astrocyte Differentiation Protocol for Human Pluripotent Stem Cells.">ami.gadhia@nih.gov</a><br> 114169209 E-168-2019-0 E-168-2019-0-US-01 RADIAL GLIA AND ASTROCYTE DIFFERENTIATION FROM HUMAN PLURIPOTENT STEM CELLS PRV US 62/979,429 Abandoned US <br />Provisional (PRV) 62/979,429<br />Filed on 2020-02-21<br />Status: Abandoned 114169210 E-168-2019-0 E-168-2019-0-PCT-02 RADIAL GLIA AND ASTROCYTE DIFFERENTIATION FROM HUMAN PLURIPOTENT STEM CELLS PCT Patent Cooperation Treaty PCT/US2021/018659 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/018659<br />Filed on 2021-02-19<br />Status: Expired 114169609 E-168-2019-0 E-168-2019-0-US-07 RADIAL GLIA AND ASTROCYTE DIFFERENTIATION FROM HUMAN PLURIPOTENT STEM CELLS National Stage US 17/796,044 Pending US <br />National Stage 17/796,044<br />Filed on 2022-07-28<br />Status: Pending 114128521 VEXXXX 114128522 WIXXXX 114128523 XHXXXX 114152431 Highly 114152432 Efficient 114152433 ASTROCYTE 114152434 DIFFERENTIATION 114152435 PROTOCOL 114152436 Human 114152437 Pluripotent 114152438 Stem 114152439 Cells TAB-3472 114097337 A Highly Efficient Nociceptor Differentiation Protocol for Human Pluripotent Stem Cells NCATS Neurology, Research Equipment, Research Materials Neurology Research Equipment Research Materials Tao Deng, Anton Simeonov, Ilyas Singec This technology includes a robust and highly efficient protocol that differentiates human pluripotent stem cells (hPSCs) exclusively into nociceptors (also called sensory neurons) under chemically defined conditions. The use of hPSCs, including hESCs and iPSCs, holds great promise for drug screening, disease modeling, toxicology, and regenerative medicine. However, efficient and highly reproducible protocols have not been developed for most cell types that are relevant and urgently needed for translational applications. Systematic testing of various cell culture conditions and simultaneous manipulation of specific cell signaling pathways allows the scalable production of large numbers of nociceptors, including the use of automated cell culture systems. The protocol included in this technology is the most efficient and reproducible nociceptor differentiation protocol for human pluripotent stem cells. The protocol included in this invention will permit increased in vitro work with human nocireceptors in areas such as pain and addiction research. 2022-08-01 2025-08-13 2025-08-15 2022-08-01 2022-02-07 Cells, DIFFERENTIATION, Efficient, Highly, Human, Nociceptor, Pluripotent, PROTOCOL, Stem, VEXXXX, VMXXXX, WIXXXX, XHXXXX False True True NIHTT 37470483 Website Abstract E-022-2018-0 E-168-2019-0 E-169-2019-0 114172629 Jayakar S, Shim J, et al. https://pubmed.ncbi.nlm.nih.gov/34757806/ <a href="https://pubmed.ncbi.nlm.nih.gov/34757806/">Jayakar S, Shim J, et al.</a> 114172632 Tristan CA, Ormanoglu P, et al. https://pubmed.ncbi.nlm.nih.gov/34861164/ <a href="https://pubmed.ncbi.nlm.nih.gov/34861164/">Tristan CA, Ormanoglu P, et al.</a> 114110298 Deng, Tao NCATS - NCGC NCATS Deng, Tao (NCATS) 0 114110299 Simeonov, Anton NCATS - NCGC NCATS Simeonov, Anton (NCATS) 0 114110297 Singec, Ilyas NCATS - NCGC NCATS Singec, Ilyas (NCATS) 1 114110297 Singec, Ilyas NCATS - NCGC NCATS Singec, Ilyas (NCATS) 1 114110298 Deng, Tao NCATS - NCGC NCATS Deng, Tao (NCATS) 0 114110299 Simeonov, Anton NCATS - NCGC NCATS Simeonov, Anton (NCATS) 0 114102587 A Highly Efficient Nociceptor Differentiation Protocol For Human Pluripotent Stem Cells E-060-2019-0 Filing authorized NCATS - NCGC 83727060 Gadhia, Ami ami.gadhia@nih.gov
United States of America NCGC ami.gadhia@nih.gov?subject=Web Inquiry on [TAB-3472] A Highly Efficient Nociceptor Differentiation Protocol for Human Pluripotent Stem Cells&body=Please send me information about technology [TAB-3472] A Highly Efficient Nociceptor Differentiation Protocol for Human Pluripotent Stem Cells. Gadhia, Ami<br><a href="mailto:ami.gadhia@nih.gov?subject=Web Inquiry on [TAB-3472] A Highly Efficient Nociceptor Differentiation Protocol for Human Pluripotent Stem Cells&body=Please send me information about technology [TAB-3472] A Highly Efficient Nociceptor Differentiation Protocol for Human Pluripotent Stem Cells.">ami.gadhia@nih.gov</a><br> 114169207 E-060-2019-0 E-060-2019-0-US-01 ANOCICEPTOR DIFFERENTIATION FROM HUMAN PLURIPOTENT STEM CELLS PRV US 62/837,891 Abandoned US <br />Provisional (PRV) 62/837,891<br />Filed on 2019-04-24<br />Status: Abandoned 114169208 E-060-2019-0 E-060-2019-0-PCT-02 NOCICEPTOR DIFFERENTIATION FROM HUMAN PLURIPOTENT STEM CELLS PCT Patent Cooperation Treaty PCT/US2020/029721 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2020/029721<br />Filed on 2020-04-24<br />Status: Expired 114169547 E-060-2019-0 E-060-2019-0-US-03 NOCICEPTOR DIFFERENTIATION FROM HUMAN PLURIPOTENT STEM CELLS National Stage US 17/605,876 Pending US <br />National Stage 17/605,876<br />Filed on 2021-10-22<br />Status: Pending 114128517 VEXXXX 114128518 VMXXXX 114128519 WIXXXX 114128520 XHXXXX 114152422 Highly 114152423 Efficient 114152424 Nociceptor 114152425 DIFFERENTIATION 114152426 PROTOCOL 114152427 Human 114152428 Pluripotent 114152429 Stem 114152430 Cells TAB-3471 114097336 Improved Cell Survival and Differentiation of Human Pluripotent Stem Cells by Combining Small Molecules Chroman-1 and Emricasan NCATS Cardiology, Dental, Endocrinology, Infectious Disease, Oncology, Ophthalmology, Research Materials Cardiology Dental Endocrinology Infectious Disease Oncology Ophthalmology Research Materials Yu Chen, Anton Simeonov, Ilyas Singec This technology includes the use of the combination of the compounds Chroman-1 and Emricasan to achieve virtually 100% cell survival during human pluripotent stem cell passaging, cryopreservation/thawing, and differentiation in 2D and 3D cultures. Human pluripotent stem cells, including ESCs and iPSCs, are highly sensitive cells and undergo apoptosis during these routine procedures. A screening approach was used to identify the combination of the two compounds in this invention. The compounds allow dosing at a relatively low concentration, thus providing a cheaper iPSC growth media, stress-free environment, and minimization of off-target effects. The combination of the compounds Chroman-1 and Emricasan permit a higher cell survival rate for pluripotent and differentiating cells compared to commonly used procedures. This invention will significantly improve quality assurance, characterization, and application of pluripotent stem cells in both pre-clinical and clinical settings. 2022-08-01 2025-08-13 2025-08-15 2022-08-01 2022-02-07 Cell, Cells, Chroman-1, COMBINING, DIFFERENTIATION, Emricasan, Human, Improved, MOLECULES, Pluripotent, Small, Stem, SURVIVAL, VPXXXX, WIXXXX False True True NIHTT 37470483 Website Abstract E-060-2019-0 E-168-2019-0 E-169-2019-0 114172627 Watanabe K, Ueno M, et al. https://pubmed.ncbi.nlm.nih.gov/17529971/ <a href="https://pubmed.ncbi.nlm.nih.gov/17529971/">Watanabe K, Ueno M, et al.</a> 114172633 Tristan CA, Ormanoglu P, et al. https://pubmed.ncbi.nlm.nih.gov/34861164/ <a href="https://pubmed.ncbi.nlm.nih.gov/34861164/">Tristan CA, Ormanoglu P, et al.</a> 114110295 Chen, Yu NCATS - TRND NHGRI Chen, Yu (NHGRI) 0 114110296 Simeonov, Anton NCATS - NCGC NCATS Simeonov, Anton (NCATS) 0 114110294 Singec, Ilyas NCATS - NCGC NCATS Singec, Ilyas (NCATS) 1 114110294 Singec, Ilyas NCATS - NCGC NCATS Singec, Ilyas (NCATS) 1 114110295 Chen, Yu NCATS - TRND NHGRI Chen, Yu (NHGRI) 0 114110296 Simeonov, Anton NCATS - NCGC NCATS Simeonov, Anton (NCATS) 0 114102586 Improved Cell Survival And Differentiation Of Human Pluripotent Stem Cells By Combining Small Molecules Chroman-1 And Emricasan E-022-2018-0 Filing authorized NCATS - NCGC 83727060 Gadhia, Ami ami.gadhia@nih.gov
United States of America NCGC ami.gadhia@nih.gov?subject=Web Inquiry on [TAB-3471] Improved Cell Survival and Differentiation of Human Pluripotent Stem Cells by Combining Small Molecules Chroman-1 and Emricasan&body=Please send me information about technology [TAB-3471] Improved Cell Survival and Differentiation of Human Pluripotent Stem Cells by Combining Small Molecules Chroman-1 and Emricasan. Gadhia, Ami<br><a href="mailto:ami.gadhia@nih.gov?subject=Web Inquiry on [TAB-3471] Improved Cell Survival and Differentiation of Human Pluripotent Stem Cells by Combining Small Molecules Chroman-1 and Emricasan&body=Please send me information about technology [TAB-3471] Improved Cell Survival and Differentiation of Human Pluripotent Stem Cells by Combining Small Molecules Chroman-1 and Emricasan.">ami.gadhia@nih.gov</a><br> 114169204 E-022-2018-0 E-022-2018-0-US-01 Improved Cell Survival And Differentiation Of Human Pluripotent Stem Cells By Combining Small Molecules Chroman-1 And Emricasan PRV US 62/744,395 Abandoned US <br />Provisional (PRV) 62/744,395<br />Filed on 2018-10-11<br />Status: Abandoned 114169205 E-022-2018-0 E-022-2018-0-PCT-02 COMPOSITIONS AND METHODS FOR CELL CULTURE PCT Patent Cooperation Treaty PCT/US2019/055940 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2019/055940<br />Filed on 2019-10-11<br />Status: Expired 114169206 E-022-2018-0 E-022-2018-0-US-03 COMPOSITIONS AND METHODS FOR CELL CULTURE National Stage US 17/284,215 Pending US <br />National Stage 17/284,215<br />Filed on 2021-04-09<br />Status: Pending 114128515 VPXXXX 114128516 WIXXXX 114152409 Improved 114152410 Cell 114152411 SURVIVAL 114152412 DIFFERENTIATION 114152413 Human 114152414 Pluripotent 114152415 Stem 114152416 Cells 114152417 COMBINING 114152418 Small 114152419 MOLECULES 114152420 Chroman-1 114152421 Emricasan TAB-3469 114097334 Combination Therapy of Human Recombinant N-acetylgalactosamine-6-sulfate sulfatase (hrGALNS) and Chaperones for the Treatment of Mucopolysaccharidosis Type IVA NCATS Cardiology, Dental, Endocrinology, Infectious Disease, Oncology, Ophthalmology, Research Materials, Therapeutics Cardiology Dental Endocrinology Infectious Disease Oncology Ophthalmology Research Materials Therapeutics Wei Zheng This technology includes the identification and use of a combination therapy consisting of human recombinant N-acetylgalactosamine-6-sulfate sulfatase (hrGALNS) and the pharmacological chaperone compounds Ezetimibe and Pranlukast for the treatment of Mucopolysaccharidosis Type IVA (MPS IVA). MPS IVA is a rare disease caused by mutations in the gene encoding the lysosomal enzyme N-acetylgalactosamine-6-sulfate sulfatase (GALNS). Currently, hematopoietic stem cell transplantation (HSCT) and enzyme replacement therapy (ERT) are available for patients with MPS IVA. This technology includes the combinatorial use of hrGALNS and pharmacological chaperon compounds Ezetimibe and Pranlukast that have been found to have an additive/synergistic effect in reducing enlarged lysosomes in MPS IVA patient cells. The pharmacological chaperone compounds Ezetimibe and Pranlukast increase the activity of hrGALNS by a directly binding to it and stabilizing the protein structure. Therefore, these chaperone compounds can reduce the dose of hrGALNS needed for ERT when the two are used in a combination therapy. Further clinical work with the combination of hrGALNS and chaperones Ezetimibe and Pranlukast could establish these compounds as a treatment for Mucopolysaccharidosis Type IVA. 2022-08-01 2025-08-13 2025-08-15 2022-08-01 2022-02-07 CHAPERONES, Combination, hrGALNS, Human, IVA, Methods, Mucopolysaccharidosis, Nacetylgalactosamine6-sulfatase, PHARMACOLOGICAL, recombinant, THERAPY, treatment, TYPE, VPXXXX, WIXXXX, WJXXXX, WKXXXX False True True NIHTT 37470483 Website Abstract E-032-2021-0 114110287 Zheng, Wei NCATS - TRND NCATS Zheng, Wei (NCATS) 1 114110287 Zheng, Wei NCATS - TRND NCATS Zheng, Wei (NCATS) 1 114102584 Methods Of Combination Therapy For Treatment Of Mucopolysaccharidosis Type IVA Using Human Recombinant Nacetylgalactosamine 6-sulfatase (hrGALNS) And Pharmacological Chaperones E-229-2020-0 Filing authorized NCATS - NCGC 93911356 Kalsi, Jasmine jasmine.kalsi@nih.gov
United States of America jasmine.kalsi@nih.gov?subject=Web Inquiry on [TAB-3469] Combination Therapy of Human Recombinant N-acetylgalactosamine-6-sulfate sulfatase (hrGALNS) and Chaperones for the Treatment of Mucopolysaccharidosis Type IVA&body=Please send me information about technology [TAB-3469] Combination Therapy of Human Recombinant N-acetylgalactosamine-6-sulfate sulfatase (hrGALNS) and Chaperones for the Treatment of Mucopolysaccharidosis Type IVA. Kalsi, Jasmine<br><a href="mailto:jasmine.kalsi@nih.gov?subject=Web Inquiry on [TAB-3469] Combination Therapy of Human Recombinant N-acetylgalactosamine-6-sulfate sulfatase (hrGALNS) and Chaperones for the Treatment of Mucopolysaccharidosis Type IVA&body=Please send me information about technology [TAB-3469] Combination Therapy of Human Recombinant N-acetylgalactosamine-6-sulfate sulfatase (hrGALNS) and Chaperones for the Treatment of Mucopolysaccharidosis Type IVA.">jasmine.kalsi@nih.gov</a><br> 114169549 E-229-2020-0 E-229-2020-0-PCT-02 Methods Of Combination Therapy For Treatment Of Mucopolysaccharidosis Type IVA Using Human Recombinant Nacetylgalactosamine 6-sulfatase (hrGALNS) And Pharmacological Chaperones PCT Patent Cooperation Treaty PCT/IB2021/055134 Expired Patent Cooperation Treaty <br />(PCT) PCT/IB2021/055134<br />Filed on 2021-06-10<br />Status: Expired 114128508 VPXXXX 114128509 WIXXXX 114128510 WJXXXX 114128511 WKXXXX 114152392 Methods 114152393 Combination 114152394 THERAPY 114152395 treatment 114152396 Mucopolysaccharidosis 114152397 TYPE 114152398 IVA 114152399 Human 114152400 recombinant 114152401 Nacetylgalactosamine6-sulfatase 114152402 hrGALNS 114152403 PHARMACOLOGICAL 114152404 CHAPERONES TAB-3468 114097333 Identification and Use of Niclosamide Analogs as Inhibitors of SARS-CoV-2 Infection NCATS Infectious Disease, Licensing, Research Materials, Therapeutics Infectious Disease Licensing Research Materials Therapeutics Catherine Chen, Xin Hu, Wenwei Huang, Pranav Shah, Khalida Shamim, Amy Wang, Xin Xu, Wei Zheng This technology includes the identification and use of niclosamide analogs and prodrugs for the treatment of SARS-CoV-2 infection. In-vitro studies have found niclosamide, an old anthelminthic drug, to be potent and effective against Covid-19. But the broad antiviral effect of niclosamide is offset by the low solubility of the drug, leading to poor oral absorption. The niclosamide analogs and prodrugs included in this technology have better in vitro physicochemical properties. Also, these analogs were comparable to niclosamide in the in-vitro 3D models of SARS-CoV-2 infection. Pharmacokinetic studies of a prodrug conducted in mice and hamsters has shown better absorbtion of the active niclosamide, with higher concentrations of niclosamide in both plasma and lungs (the primary site of COVID-19 disease manifestation). The oral bio-availability of niclosamide is greatly enhanced with this prodrug. Despite poor solubility, niclosamide is showing promise for the treatment of COVID-19. The niclosamide analogs and prodrug included in this technology have increased solubility and oral absorption, making them suitable for further studies. Further clinical work could establish the niclosamide analogs and prodrug as new treatments for SARS-CoV-2 infection. 2022-03-08 2025-08-13 2025-08-15 2022-02-15 2022-02-04 Analogs, APPLICATION, INFECTIONS, Inhibitors, MOLECULE, Niclosamide, Pro-drugs, SARS-CoV-2, Small, VLXXXX, WIXXXX, WKXXXX False True True NIHTT 37470483 Website Abstract 114172628 Shamim K, Xu M, et al. https://pubmed.ncbi.nlm.nih.gov/33689873/ <a href="https://pubmed.ncbi.nlm.nih.gov/33689873/">Shamim K, Xu M, et al.</a> 114110280 Shamim, Khalida NCATS - TRND NCATS Shamim, Khalida (NCATS) 0 114110281 Zheng, Wei NCATS - TRND NCATS Zheng, Wei (NCATS) 0 114110282 Chen, Catherine NCATS - TRND Chen, Catherine 0 114110283 Xu, Xin NCATS - TRND NCATS Xu, Xin (NCATS) 0 114110284 Wang, Amy NCATS - TRND NCATS Wang, Amy (NCATS) 0 114110285 Hu, Xin NCATS - NCGC NCATS Hu, Xin (NCATS) 0 114110286 Shah, Pranav NCATS - TRND NCATS Shah, Pranav (NCATS) 0 114110279 Huang, Wenwei NCATS - TRND NCATS Huang, Wenwei (NCATS) 1 114110279 Huang, Wenwei NCATS - TRND NCATS Huang, Wenwei (NCATS) 1 114110280 Shamim, Khalida NCATS - TRND NCATS Shamim, Khalida (NCATS) 0 114110281 Zheng, Wei NCATS - TRND NCATS Zheng, Wei (NCATS) 0 114110282 Chen, Catherine NCATS - TRND Chen, Catherine 0 114110283 Xu, Xin NCATS - TRND NCATS Xu, Xin (NCATS) 0 114110284 Wang, Amy NCATS - TRND NCATS Wang, Amy (NCATS) 0 114110285 Hu, Xin NCATS - NCGC NCATS Hu, Xin (NCATS) 0 114110286 Shah, Pranav NCATS - TRND NCATS Shah, Pranav (NCATS) 0 114102583 Application Of Niclosamide Analogs And Pro-drugs As Small Molecule Inhibitors Of SARS-CoV-2 Infections E-234-2020-0 Filing authorized Florida State University, Florida State University College of Medicine, NCATS - NCGC 83673536 Erwin-Cohen, Rebecca rebecca.erwin-cohen@nih.gov
NCGC rebecca.erwin-cohen@nih.gov?subject=Web Inquiry on [TAB-3468] Identification and Use of Niclosamide Analogs as Inhibitors of SARS-CoV-2 Infection&body=Please send me information about technology [TAB-3468] Identification and Use of Niclosamide Analogs as Inhibitors of SARS-CoV-2 Infection. Erwin-Cohen, Rebecca<br><a href="mailto:rebecca.erwin-cohen@nih.gov?subject=Web Inquiry on [TAB-3468] Identification and Use of Niclosamide Analogs as Inhibitors of SARS-CoV-2 Infection&body=Please send me information about technology [TAB-3468] Identification and Use of Niclosamide Analogs as Inhibitors of SARS-CoV-2 Infection.">rebecca.erwin-cohen@nih.gov</a><br> 114169197 E-234-2020-0 E-234-2020-0-US-01 Small Molecule Inhibitors of SARS-CoV-2 PRV US 63/115,288 Abandoned US <br />Provisional (PRV) 63/115,288<br />Filed on 2020-11-18<br />Status: Abandoned 114169224 E-234-2020-0 E-234-2020-0-PCT-02 Small Molecule Inhibitors of Sars-Cov-2 Infections PCT Patent Cooperation Treaty PCT/US2021/059910 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/059910<br />Filed on 2021-11-18<br />Status: Expired 114128505 VLXXXX 114128506 WKXXXX 114128507 WIXXXX 114152368 APPLICATION 114152384 Niclosamide 114152385 Analogs 114152386 Pro-drugs 114152387 Small 114152388 MOLECULE 114152389 Inhibitors 114152390 SARS-CoV-2 114152391 INFECTIONS TAB-3454 114097324 Mononegavirales Vectors Expressing Chimeric Antigens NIAID Collaboration, Diagnostics, Infectious Disease, Research Materials, Vaccines Collaboration Diagnostics Infectious Disease Research Materials Vaccines Linda Brock, Ursula Buchholz, Peter Collins, Shirin Munir Human respiratory syncytial virus (RSV) continues to be the leading viral cause of severe acute lower respiratory tract disease in infants and children worldwide, and also is an important cause of morbidity and mortality in the elderly. A licensed vaccine or antiviral drug suitable for routine use remains unavailable. This invention relates to the use of murine pneumonia virus (MPV—previously known as pneumonia virus of mice, PVM—of family Pneumovirida e) as a vaccine vector expressing the RSV fusion protein F, the most important protective antigen of RSV. MPV is not a human pathogen and is not restricted by immunity to common human viruses. MPV replicates in the superficial epithelial cells of the respiratory mucosa and is expected to be attenuated in humans based on the strong host range restriction observed in non-human primates. To generate these MPV/RSV vector vaccine candidates, the RSV F ORF was codon optimized, placed under the control of MPV transcription signals, and inserted at the first (rMPV-F1), third (rMPV29 F3), or fourth (rMPV-F4) gene position of a version of the MPV genome that contained a codon-pair optimized L polymerase gene. The recovered viruses replicated in vitro as efficiently as the empty vector, with stable expression of RSV F protein. Replication and immunogenicity of rMPV-F1 and rMPV-F3 were evaluated in rhesus macaques following administration by the combined intranasal and intratracheal routes. Both viruses replicated at low levels in the upper and lower respiratory tract, maintained stable RSV F expression, and induced similarly high levels of RSV-neutralizing serum antibodies that reached peak titers by fourteen (14) days post-vaccination. Thus, rMPV provides a highly attenuated yet immunogenic vector for the expression of RSV F protein, with potential application in RSV-naïve and RSV-experienced populations. RSV F was expressed in the wild-type form, but can readily be engineered to be stabilized in the highly immunogenic prefusion form, as has been done with parainfluenza virus vectors.<br /><br /> The invention relates to live, chimeric non-human Mononegavirales vectors that allow a cell to express at least one protein from at least one human pathogen as well as compositions comprising the vectors, methods and kits for eliciting an immune response in a host, and methods of making the vectors.<br /><br /> This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as well as for further development and evaluation under a research collaboration. <ul> <li>Ease of manufacture</li> <li>Multivalent live attenuated vaccines</li> <li>B cell and T cell activation</li> <li>Low-cost vaccines</li> </ul> <ul> <li>Viral diagnostics</li> <li>Vaccine research</li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize for development of a vaccine for respiratory or other infections. For collaboration opportunities, please contact Peter Soukas, J.D., 301-496-2644; <a href="mailto:peter.soukas@nih.gov">peter.soukas@nih.gov</a>. 2022-03-08 2025-08-13 2025-08-15 2021-07-15 Added, Attenuated, DA4BXX, DA4XXX, DC5BXX, DC5XXX, DCXXXX, DD1XXX, DDXXXX, DEXXXX, DXXXXX, Expressing, F, Fusion, Gene, Highly, Human, Immunogenic, Macaques, MPV, Murine, PNEUMONIA, Protein, respiratory, RHESUS, RSV, Syncytial, virus False True True NIHTT 37470483 Website Abstract 114110255 Brock, Linda NIAID - DIR NIAID Brock, Linda (NIAID) 0 114110256 Buchholz, Ursula NIAID - DIR NIAID Buchholz, Ursula (NIAID) 0 114110257 Collins, Peter NIAID - DIR NIAID Collins, Peter (NIAID) 0 114110254 Munir, Shirin NIAID - DIR NIAID Munir, Shirin (NIAID) 1 114110254 Munir, Shirin NIAID - DIR NIAID Munir, Shirin (NIAID) 1 114110255 Brock, Linda NIAID - DIR NIAID Brock, Linda (NIAID) 0 114110256 Buchholz, Ursula NIAID - DIR NIAID Buchholz, Ursula (NIAID) 0 114110257 Collins, Peter NIAID - DIR NIAID Collins, Peter (NIAID) 0 114102574 Murine Pneumonia Virus (MPV) Expressing The Fusion F Protein Of Human Respiratory Syncytial Virus (RSV) From An Added Gene In Highly Attenuated And Immunogenic In Rhesus Macaques E-018-2018-0 Filing authorized NIAID 91029846 Ganelina, Anna ganelinaa@niaid.nih.gov
United States of America ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-3454] Mononegavirales Vectors Expressing Chimeric Antigens&body=Please send me information about technology [TAB-3454] Mononegavirales Vectors Expressing Chimeric Antigens. Ganelina, Anna<br><a href="mailto:ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-3454] Mononegavirales Vectors Expressing Chimeric Antigens&body=Please send me information about technology [TAB-3454] Mononegavirales Vectors Expressing Chimeric Antigens.">ganelinaa@niaid.nih.gov</a><br> 114169142 E-018-2018-0 E-018-2018-0-US-01 CHIMERIC VECTORS PRV US 62/661,320 Abandoned US <br />Provisional (PRV) 62/661,320<br />Filed on 2018-04-23<br />Status: Abandoned 114169143 E-018-2018-0 E-018-2018-0-PCT-02 CHIMERIC VECTORS PCT Patent Cooperation Treaty PCT/US2019/028771 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2019/028771<br />Filed on 2019-04-23<br />Status: Expired 114169144 E-018-2018-0 E-018-2018-0-US-12 CHIMERIC VECTORS National Stage US 12,071,632 17/049,916 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12071632 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12071632">12,071,632</a><br />Filed on 2020-10-22<br />Status: Issued 114128481 DXXXXX 114128482 DCXXXX 114128483 DC5XXX 114128484 DC5BXX 114128485 DDXXXX 114128486 DD1XXX 114128487 DA4XXX 114128488 DA4BXX 114128489 DEXXXX 114152258 Murine 114152259 PNEUMONIA 114152260 virus 114152261 MPV 114152262 Expressing 114152263 Fusion 114152264 F 114152265 Protein 114152266 Human 114152267 respiratory 114152268 Syncytial 114152269 RSV 114152270 Added 114152271 Gene 114152272 Highly 114152273 Attenuated 114152274 Immunogenic 114152275 RHESUS 114152276 Macaques TAB-3449 114097320 Recombinant Chimeric Bovine/Human Parainfluenza Virus 3 Expressing SARS-CoV-2 Spike Protein and Its Use NIAID Collaboration, Infectious Disease, Research Materials, Vaccines Collaboration Infectious Disease Research Materials Vaccines Ursula Buchholz, Peter Collins, Cyril Le Nouen, Xueqiao Liu, Cindy Luongo, Shirin Munir Vaccines for SARS-CoV-2 are increasingly available under emergency use authorizations; however, indications are currently limited to individuals twelve (12) years or older. They also involve intramuscular immunization, which does not directly stimulate local immunity in the respiratory tract, the primary site of SARS-CoV-2 infection, shedding and spread. While the major burden of COVID-19 disease is in adults, infection and disease also occur in infants and young children, contributing to viral transmission. Therefore, the development of safe and effective pediatric COVID-19 vaccines is important. Ideally, a vaccine should be effective as a single dose, should induce mucosal immunity with the ability to restrict SARS-CoV-2 infection and respiratory shedding, and should easily coordinate with vaccines for other illnesses, such as HPIV3.<br /><br /> The live-attenuated vaccine candidates are based on a recombinant chimeric bovine/human parainfluenza virus 3 (rB/HPIV3) vector expressing prefusion-stabilized versions of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Spike (S) protein. The B/HPIV3-SARS CoV-2 vaccine candidates are designed to be administered intranasally by drops or spray to infants and young children. The vaccines are expected to induce durable and broad systemic and respiratory mucosal immunity against SARS-CoV-2 and HPIV3. Immunogenicity and protective efficacy against SARS-CoV-2 challenge was confirmed in experimental animals including non-human primates. Based on experience with this B/HPIV3 platform and other live-attenuated PIV vaccine candidates in previous pediatric clinical studies, the present candidates are anticipated to be well-tolerated in humans, including infants and young children, and are available for clinical evaluation. The National Institute of Allergy and Infectious Diseases has extensive experience and capability in evaluating live-attenuated respiratory virus vaccine candidates in pediatric clinical studies, including PIV vaccine candidates, and opportunity for collaboration exists.<br /><br /> This technology is available for nonexclusive licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as well as for further development and evaluation under a research collaboration. <ul> <li>Ease of manufacture</li> <li>B cell and T cell activation</li> <li>Low-cost vaccines</li> <li>Intranasal administration/needle-free delivery</li> </ul> <ul> <li>Viral diagnostics</li> <li>Vaccine research</li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize for development of a vaccine for respiratory or other infections. For collaboration opportunities, please contact Peter Soukas, J.D., 301-496-2644; <a href="mailto:peter.soukas@nih.gov">peter.soukas@nih.gov</a>. 2022-05-09 2025-08-13 2025-08-15 2021-06-22 2, ACUTE, Attenuated, B/HPIV3, BOVINE/HUMAN, chimeric, CORONAVIRUS, DC5BXX, DC5XXX, DCXXXX, DDXXXX, DEXXXX, DXXXXX, Expression, GLYCOPROTEIN, PIV3, respiratory, S, SARS-CoV-2, SEVERE, spike, Syndrome False True True NIHTT 37470483 Website Abstract 114110233 Munir, Shirin NIAID - DIR NIAID Munir, Shirin (NIAID) 0 114110234 Luongo, Cindy NIAID - DIR NIAID Luongo, Cindy (NIAID) 0 114110235 Collins, Peter NIAID - DIR NIAID Collins, Peter (NIAID) 0 114110236 Le Nouen, Cyril NIAID - DIR NIAID Le Nouen, Cyril (NIAID) 0 114110237 Liu, Xueqiao NIAID - DIR NIAID Liu, Xueqiao (NIAID) 0 114110232 Buchholz, Ursula NIAID - DIR NIAID Buchholz, Ursula (NIAID) 1 114110232 Buchholz, Ursula NIAID - DIR NIAID Buchholz, Ursula (NIAID) 1 114110233 Munir, Shirin NIAID - DIR NIAID Munir, Shirin (NIAID) 0 114110234 Luongo, Cindy NIAID - DIR NIAID Luongo, Cindy (NIAID) 0 114110235 Collins, Peter NIAID - DIR NIAID Collins, Peter (NIAID) 0 114110236 Le Nouen, Cyril NIAID - DIR NIAID Le Nouen, Cyril (NIAID) 0 114110237 Liu, Xueqiao NIAID - DIR NIAID Liu, Xueqiao (NIAID) 0 114102570 Expression Of The Spike S Glycoprotein Of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) From An Attenuated Chimeric Bovine/human PIV3 (B/HPIV3) E-239-2020-0 Filing authorized NIAID 91029846 Ganelina, Anna ganelinaa@niaid.nih.gov
United States of America ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-3449] Recombinant Chimeric Bovine/Human Parainfluenza Virus 3 Expressing SARS-CoV-2 Spike Protein and Its Use&body=Please send me information about technology [TAB-3449] Recombinant Chimeric Bovine/Human Parainfluenza Virus 3 Expressing SARS-CoV-2 Spike Protein and Its Use. Ganelina, Anna<br><a href="mailto:ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-3449] Recombinant Chimeric Bovine/Human Parainfluenza Virus 3 Expressing SARS-CoV-2 Spike Protein and Its Use&body=Please send me information about technology [TAB-3449] Recombinant Chimeric Bovine/Human Parainfluenza Virus 3 Expressing SARS-CoV-2 Spike Protein and Its Use.">ganelinaa@niaid.nih.gov</a><br> 114169128 E-239-2020-0 E-239-2020-0-US-01 Recombinant Chimeric Bovine/Human Parainfluenza Virus 3 Expressing SARS-COV-2 Spike Protein and Its Use PRV US 63/180,534 Abandoned US <br />Provisional (PRV) 63/180,534<br />Filed on 2021-04-27<br />Status: Abandoned 114169451 E-239-2020-0 E-239-2020-0-PCT-02 RECOMBINANT CHIMERIC BOVINE/HUMAN PARAINFLUENZA VIRUS 3 EXPRESSING SARS-COV-2 SPIKE PROTEIN AND ITS USE PCT Patent Cooperation Treaty PCT/US2022/026576 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2022/026576<br />Filed on 2022-04-27<br />Status: Expired 114128475 DXXXXX 114128476 DCXXXX 114128477 DDXXXX 114128478 DC5XXX 114128479 DC5BXX 114128480 DEXXXX 114152188 Expression 114152189 spike 114152190 S 114152191 GLYCOPROTEIN 114152192 SEVERE 114152193 ACUTE 114152194 respiratory 114152195 Syndrome 114152196 CORONAVIRUS 114152197 2 114152198 SARS-CoV-2 114152199 Attenuated 114152200 chimeric 114152201 BOVINE/HUMAN 114152202 PIV3 114152203 B/HPIV3 TAB-3437 114097311 Improved Live-Attenuated Vaccine for Respiratory Syncytial Virus (RSV) Bearing Codon-Pair Deoptimized NS1, NS2, N, P, M and SH Genes and Additional Point Mutations in the P Gene NIAID Collaboration, Diagnostics, Infectious Disease, Research Materials, Vaccines Collaboration Diagnostics Infectious Disease Research Materials Vaccines Ursula Buchholz, Peter Collins, Cyril Le Nouen RSV is the most important viral agent of severe respiratory disease in infants and young children worldwide and also causes substantial morbidity and mortality in older adults. RSV is estimated to cause more than 33 million lower respiratory tract illnesses, three million hospitalizations, and nearly 200,000 childhood deaths worldwide annually, with many deaths occurring in developing countries. However, despite the prevalence of RSV and the dangers associated with infection, no RSV vaccine has been successfully developed to date. Accordingly, there is a public health need for RSV vaccines.<br /><br /> This vaccine candidate comprises live RSV that was attenuated by subjecting the protein-coding sequences of the viral NS1, NS2, N, P, M, and SH genes to codon-pair deoptimization, which resulted in many nucleotide substitutions that were silent at the amino acid level but conferred attenuation. In addition, specific amino acid substitutions were identified and introduced into the P protein that improved attenuation and genetic stability. Genetic stability was confirmed in vitro, and attenuation was confirmed in experimental animals.<br /><br /> This live-attenuated RSV vaccine is designed to be administered intranasally by drops or spray to infants and young children. Based on experience with other live-attenuated RSV vaccine candidates, the present candidates are anticipated to be well tolerated in humans and are available for clinical evaluation. The National Institute of Allergy and Infectious Diseases has extensive experience and capability in evaluating live-attenuated RSV vaccine candidates in pediatric clinical studies, and opportunity for collaboration exists.<br /><br /> This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as well as for further development and evaluation under a research collaboration.<br /><br /> <ul> <li>Ease of manufacture</li> <li>B cell and T cell activation</li> <li>Low-cost vaccines</li> <li>Intranasal administration/needle-free delivery</li> </ul> <ul> <li>Viral diagnostics</li> <li>Vaccine research</li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize for development of a vaccine for respiratory or other infections. For collaboration opportunities, please contact Peter Soukas, J.D., 301-594-8730; <a href="mailto:peter.soukas@nih.gov">peter.soukas@nih.gov</a>. 2022-03-08 2025-08-13 2025-08-15 2021-02-25 ADDITIONAL, BEARING, Codonpair, DA4BXX, DA4XXX, DAXXXX, DC5BXX, DC5XXX, DCXXXX, DDXXXX, Deoptimized, DXXXXX, GENES, Improved, Live-Attenuated, M, Mutations, N, NS1, NS2, P, Pgene, POINT, respiratory, RSV, SH, Syncytial, Vaccine, virus False True True NIHTT 37470483 Website Abstract 114110180 Le Nouen, Cyril NIAID - DIR NIAID Le Nouen, Cyril (NIAID) 0 114110181 Buchholz, Ursula NIAID - DIR NIAID Buchholz, Ursula (NIAID) 0 114110179 Collins, Peter NIAID - DIR NIAID Collins, Peter (NIAID) 1 114110179 Collins, Peter NIAID - DIR NIAID Collins, Peter (NIAID) 1 114110180 Le Nouen, Cyril NIAID - DIR NIAID Le Nouen, Cyril (NIAID) 0 114110181 Buchholz, Ursula NIAID - DIR NIAID Buchholz, Ursula (NIAID) 0 114102561 Improved Live-attenuated Vaccine For Respiratory Syncytial Virus (RSV) Bearing Codonpair Deoptimized NS1, NS2, N, P, M And SH Genes And Additional Point Mutations In The P gene E-104-2020-0 Filing authorized NIAID 91029846 Ganelina, Anna ganelinaa@niaid.nih.gov
United States of America ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-3437] Improved Live-Attenuated Vaccine for Respiratory Syncytial Virus (RSV) Bearing Codon-Pair Deoptimized NS1, NS2, N, P, M and SH Genes and Additional Point Mutations in the P Gene&body=Please send me information about technology [TAB-3437] Improved Live-Attenuated Vaccine for Respiratory Syncytial Virus (RSV) Bearing Codon-Pair Deoptimized NS1, NS2, N, P, M and SH Genes and Additional Point Mutations in the P Gene. Ganelina, Anna<br><a href="mailto:ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-3437] Improved Live-Attenuated Vaccine for Respiratory Syncytial Virus (RSV) Bearing Codon-Pair Deoptimized NS1, NS2, N, P, M and SH Genes and Additional Point Mutations in the P Gene&body=Please send me information about technology [TAB-3437] Improved Live-Attenuated Vaccine for Respiratory Syncytial Virus (RSV) Bearing Codon-Pair Deoptimized NS1, NS2, N, P, M and SH Genes and Additional Point Mutations in the P Gene.">ganelinaa@niaid.nih.gov</a><br> 114169106 E-104-2020-0 E-104-2020-0-US-01 RSV VACCINE BEARING ONE OR MORE P GENE MUTATIONS PRV US 63/023,949 Abandoned US <br />Provisional (PRV) 63/023,949<br />Filed on 2020-05-13<br />Status: Abandoned 114169123 E-104-2020-0 E-104-2020-0-PCT-02 RSV VACCINE BEARING ONE OF MORE P GENE MUTATIONS PCT Patent Cooperation Treaty PCT/US2021/032305 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/032305<br />Filed on 2021-05-13<br />Status: Expired 114128427 DXXXXX 114128428 DCXXXX 114128429 DC5XXX 114128430 DC5BXX 114128431 DAXXXX 114128432 DA4XXX 114128433 DA4BXX 114128434 DDXXXX 114152083 Improved 114152084 Live-Attenuated 114152085 Vaccine 114152086 respiratory 114152087 Syncytial 114152088 virus 114152089 RSV 114152090 BEARING 114152091 Codonpair 114152092 Deoptimized 114152093 NS1 114152094 NS2 114152095 N 114152096 P 114152097 M 114152098 SH 114152099 GENES 114152100 ADDITIONAL 114152101 POINT 114152102 Mutations 114152103 Pgene TAB-3431 114097306 Epstein-Barr Virus Antibody That Blocks Fusion And Neutralizes Virus Infection of B Cells NIAID Collaboration, Diagnostics, Infectious Disease, Research Materials, Therapeutics, Vaccines Collaboration Diagnostics Infectious Disease Research Materials Therapeutics Vaccines Nathan Board, Wei Bu, Jeffrey Cohen, Kennichl Dowdell Epstein-Barr virus (EBV) is the most common cause of infectious mononucleosis and is associated with nearly 200,000 cancers and 140,000 deaths each year. EBV-associated cancers include Hodgkin's lymphoma, non-Hodgkin's lymphoma, Burkitt B cell lymphoma, and EBV post-transplant lymphoproliferative disease. The latent reservoir for EBV in the body is the B lymphocyte. Thus, blocking B cell infection is important for reducing EBV-related disease.<br /><br /> EBV can infect both B cells and epithelial cells; however, the method of entry differs between these two cell types. To initiate B cell infection, EBV glycoprotein 350 (gp350) binds to compliment receptor 2 (CR2; also known as CD21), followed by binding of glycoprotein 42 (gp42) to HLA class II molecules, which triggers fusion of EBV with the B cell, allowing virus entry into the cell. Fusion also requires the EBV proteins gH/gL, which are found complexed with gp42 as a heterotrimer, and gB. Infection of epithelial cells is initiated by the binding of the EBV protein BMRF2 to cellular integrins, followed by binding of gH/gL to ephrin receptor A2 and integrins, which triggers fusion by EBV gB.<br /><br /> Monoclonal antibodies that specifically bind EBV gp42 are described by this invention. The gp42-specific antibodies are capable of neutralizing EBV infection and inhibiting fusion of EBV with B cells. The monoclonal antibodies can be used for the treatment or prophylaxis of EBV infection, prevention of EBV-associated disease or infection in immunocompromised subjects, diagnosis of EBV infection, and detection of EBV in a biological sample.<br /><br /> This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as well as for further development and evaluation under a research collaboration. <ul> <li>Ease of manufacture</li> <li>Strongly neutralizing antibodies</li> <li>Alternative to EBV vaccines</li> </ul> <ul> <li>Viral diagnostics</li> <li>Viral therapeutics</li> <li>Viral prophylaxis</li> <li>Vaccine research</li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize for development of a vaccine for respiratory or other infections. For collaboration opportunities, please contact Peter Soukas, J.D., 301-594-8730; <a href="mailto:peter.soukas@nih.gov">peter.soukas@nih.gov</a>.<br /><br /> Inventors: Jeffrey Cohen (NIAID), Wei Bu (NIAID), Nathan Board (NIAID), Kennichi Dowdell (NIAID).<br /><br /> Intellectual Property: HHS Reference No. E-020-2020-0—U.S. Provisional Application No. 62/979,070, filed February 20, 2020. 2022-08-19 2025-08-13 2025-08-15 2021-02-16 ANTIBODY, B, BLOCKS, Cells, DAXXXX, DB4BXX, DB4XXX, DB5XXX, DBXXXX, DC1XXX, DCXXXX, DDXXXX, DXXXXX, EPSTEIN-BARR, Fusion, Infection, Neutralizes, That, virus False True True NIHTT 37470483 Website Abstract 114110169 Bu, Wei NIAID - DIR NIAID Bu, Wei (NIAID) 0 114110170 Board, Nathan NIAID - DIR Board, Nathan 0 114110171 Dowdell, Kennichl NIAID - DIR NIAID Dowdell, Kennichl (NIAID) 0 114110166 Cohen, Jeffrey NIAID - DIR NIAID Cohen, Jeffrey (NIAID) 1 114110166 Cohen, Jeffrey NIAID - DIR NIAID Cohen, Jeffrey (NIAID) 1 114110169 Bu, Wei NIAID - DIR NIAID Bu, Wei (NIAID) 0 114110170 Board, Nathan NIAID - DIR Board, Nathan 0 114110171 Dowdell, Kennichl NIAID - DIR NIAID Dowdell, Kennichl (NIAID) 0 114102554 Epstein-Barr Virus Antibody That Blocks Fusion And Neutralizes Virus Infection Of B Cells E-020-2020-0 Filing authorized NIAID 91029846 Ganelina, Anna ganelinaa@niaid.nih.gov
United States of America ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-3431] Epstein-Barr Virus Antibody That Blocks Fusion And Neutralizes Virus Infection of B Cells&body=Please send me information about technology [TAB-3431] Epstein-Barr Virus Antibody That Blocks Fusion And Neutralizes Virus Infection of B Cells. Ganelina, Anna<br><a href="mailto:ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-3431] Epstein-Barr Virus Antibody That Blocks Fusion And Neutralizes Virus Infection of B Cells&body=Please send me information about technology [TAB-3431] Epstein-Barr Virus Antibody That Blocks Fusion And Neutralizes Virus Infection of B Cells.">ganelinaa@niaid.nih.gov</a><br> 114169098 E-020-2020-0 E-020-2020-0-US-01 EPSTEIN-BARR VIRUS MONOCLONAL ANTIBODIES AND USES THEREOF PRV US 62/979,070 Abandoned US <br />Provisional (PRV) 62/979,070<br />Filed on 2020-02-20<br />Status: Abandoned 114169101 E-020-2020-0 E-020-2020-0-PCT-02 EPSTEIN-BARR VIRUS MONOCLONAL ANTIBODIES AND USES THEREOF PCT Patent Cooperation Treaty PCT/US2021/018836 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/018836<br />Filed on 2021-02-19<br />Status: Expired 114169641 E-020-2020-0 E-020-2020-0-US-04 EPSTEIN-BARR VIRUS MONOCLONAL ANTIBODIES AND USES THEREOF National Stage US 17/800,706 Pending US <br />National Stage 17/800,706<br />Filed on 2022-08-18<br />Status: Pending 114128375 DXXXXX 114128376 DBXXXX 114128377 DB4XXX 114128378 DB4BXX 114128379 DAXXXX 114128380 DB5XXX 114128381 DDXXXX 114128382 DCXXXX 114128383 DC1XXX 114152034 EPSTEIN-BARR 114152035 virus 114152036 ANTIBODY 114152037 That 114152038 BLOCKS 114152039 Fusion 114152040 Neutralizes 114152041 Infection 114152042 B 114152043 Cells TAB-3430 114097304 A VSV-EBOV-Based Vaccine Against COVID-19 NIAID Licensing, Materials Available Licensing Materials Available Wakako Asada, Andrea Marzi Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of for coronavirus disease 2019 (COVID-19). COVID-19 is characterized by fever, cough, difficulty breathing, loss of taste and smell, nausea, and sore throat. As of the fourth quarter 2020, COVID-19 is responsible for over 1.17 million deaths worldwide. As the pandemic continues to surge, the importance of a safe, affordable, and efficacious vaccine is of urgent importance. The present technology utilizes the well characterized vesicular stomatitis virus (VSV) encoding the Ebola virus (VSV-EBOV) to express additionally a codon-optimized SARS-CoV-2 spike protein. A single intranasal or intramuscular administration of the vaccine showed protective efficacy against COVID-19 in hamsters after 4 weeks. A single intramuscular injection showed protective efficacy against COVID-19 pneumonia in rhesus macaques within 10 days. The vaccine is inexpensive to replicate, elicits a high antigen-specific antibody titer within Start Printed Page 8214the host, and provides protective efficacy after a single dose. <ul> <li>Utilizes the established and well characterized VSV-EBOV vector</li> <li>Expresses high antigen titers within host cells</li> <li>Single dose protective efficacy against COVID-19</li> <li>Inexpensive and replicable</li> </ul> <ul> <li>Single dose vaccine against COVID-19</li> </ul> This technology is available for licensing, as a biological material, for commercial development in accordance with 35 U.S.C. 209 and 37 CFR part 404. To license this technology, please contact Jeffrey Thruston at 301-594-5179 or <a href="mailto:Jeffrey.Thruston@nih.gov">Jeffrey.Thruston@nih.gov</a>, and reference E-258-2020-0. Research Material - Patent protection is not being pursued for this technology 2022-03-08 2025-08-13 2025-08-15 2021-02-05 Against, COVID-19, SARS-CoV-2, Vaccine, VSV-EBOV-based False True True NIHTT 37470483 Website Abstract 114110167 Asada, Wakako NIAID - DIR NIAID Asada, Wakako (NIAID) 0 114110168 Marzi, Andrea NIAID - DIR NIAID Marzi, Andrea (NIAID) 1 114110168 Marzi, Andrea NIAID - DIR NIAID Marzi, Andrea (NIAID) 1 114110167 Asada, Wakako NIAID - DIR NIAID Asada, Wakako (NIAID) 0 114102553 A VSV-EBOV-based Vaccine Against COVID-19 E-258-2020-0 Research Material NIAID 146046171 Joyce, Terrence terrence.joyce@nih.gov
United States of America terrence.joyce@nih.gov?subject=Web Inquiry on [TAB-3430] A VSV-EBOV-Based Vaccine Against COVID-19&body=Please send me information about technology [TAB-3430] A VSV-EBOV-Based Vaccine Against COVID-19. Joyce, Terrence<br><a href="mailto:terrence.joyce@nih.gov?subject=Web Inquiry on [TAB-3430] A VSV-EBOV-Based Vaccine Against COVID-19&body=Please send me information about technology [TAB-3430] A VSV-EBOV-Based Vaccine Against COVID-19.">terrence.joyce@nih.gov</a><br> 114152029 VSV-EBOV-based 114152030 Vaccine 114152031 Against 114152032 COVID-19 114152033 SARS-CoV-2 TAB-3420 114097295 Structure-Based Design of SARS-CoV-2 Spike Immunogens Stabilized in the RBD-All Down Conformation NIAID Licensing Licensing Peter Kwong, John Mascola, Adam Olia, Yaroslav Tsybovsky, Tongqing Zhou SARS-CoV-2 has emerged as a global pathogen, sparking urgent vaccine development efforts. The trimeric SARS-CoV-2 spike appears to be a leading vaccine antigen. However, the inability of antibodies such as CR3022, which binds tightly to a cryptic spike epitope, to neutralize SARS-CoV-2 suggests a spike-based means of neutralization escape.<br /><br /> Researchers at the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID) sought to understand how antibodies with high affinity fail to neutralize the SARS-CoV-2. To that end, the researchers characterized the SARS-CoV-2 spike protein conformational changes as a function of pH and observed that at endosomal pH the spike protein has a conformation in which all of the receptor binding domains (RBD) are in a down conformation which could explain the virus' ability to escape neutralization in the endosome.<br /><br /> Hypothesizing that SARS-CoV-2 escapes neutralization through pH-dependent conformational masking, the researchers designed spike proteins with mutations to stabilize the spike in the RBD-all down conformation. Such designs include cavity-filling mutations, disulfides, aspartic acid to asparagine mutations, proline mutations, and other sequence modifications to fix the spike protein in its RBD-all down conformation so that immunization at a physiological pH will elicit antibodies that can recognize the low pH-stabilized all RBD-down conformation of the spike protein and no longer be susceptible to pH-induced neutralization escape.<br /><br /> Immunogenicity studies are underway to determine which of the designs will yield a neutralizing immune response in mice. Pending results in mice, a lead candidate will be selected for studies in nonhuman primates.<br /><br /> This technology is available for licensing for commercial development in accordance with 35 U.S.C. § 209 and 37 CFR Part 404. <ul> <li>Stabilized SARS-CoV-2 spike variants with potential to elicit higher levels of neutralizing antibodies than current related vaccine development.</li> <li>Identification of a methodology to screen for improved spike variants (by assessing binding by neutralizing versus non-neutralizing antibodies).</li> </ul> <ul> <li>An improved stabilized spike immunogen for the development of protective SARS-CoV-2 vaccine.</li> </ul> 2022-03-08 2025-08-13 2025-08-15 2020-10-05 CONFORMATIONALLY-STABILIZED, Design, IMMUNOGENS, SARS-CoV-2, spike, Structure-based False True True NIHTT 37470483 Website Abstract 114172585 Zhou, T et al. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7337388/ <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7337388/">Zhou, T et al.</a> 114110123 Zhou, Tongqing NIAID - VRC NIAID Zhou, Tongqing (NIAID) 0 114110124 Tsybovsky, Yaroslav NCI - FCRDC (Leidos) NIAID Tsybovsky, Yaroslav (NIAID) 0 114110125 Olia, Adam NIAID - VRC NIAID Olia, Adam (NIAID) 0 114110126 Mascola, John NIAID - VRC NIAID Mascola, John (NIAID) 0 114110122 Kwong, Peter NIAID - VRC NIAID Kwong, Peter (NIAID) 1 114110122 Kwong, Peter NIAID - VRC NIAID Kwong, Peter (NIAID) 1 114110123 Zhou, Tongqing NIAID - VRC NIAID Zhou, Tongqing (NIAID) 0 114110124 Tsybovsky, Yaroslav NCI - FCRDC (Leidos) NIAID Tsybovsky, Yaroslav (NIAID) 0 114110125 Olia, Adam NIAID - VRC NIAID Olia, Adam (NIAID) 0 114110126 Mascola, John NIAID - VRC NIAID Mascola, John (NIAID) 0 114102543 Structure-Based Design Of Conformationally-Stabilized SARS-CoV-2 Spike Immunogens E-187-2020-0 Filing authorized NIAID 83682222 Bailey, Brian bbailey@mail.nih.gov
United States of America TTIPO bbailey@mail.nih.gov?subject=Web Inquiry on [TAB-3420] Structure-Based Design of SARS-CoV-2 Spike Immunogens Stabilized in the RBD-All Down Conformation&body=Please send me information about technology [TAB-3420] Structure-Based Design of SARS-CoV-2 Spike Immunogens Stabilized in the RBD-All Down Conformation. Bailey, Brian<br><a href="mailto:bbailey@mail.nih.gov?subject=Web Inquiry on [TAB-3420] Structure-Based Design of SARS-CoV-2 Spike Immunogens Stabilized in the RBD-All Down Conformation&body=Please send me information about technology [TAB-3420] Structure-Based Design of SARS-CoV-2 Spike Immunogens Stabilized in the RBD-All Down Conformation.">bbailey@mail.nih.gov</a><br> 114169060 E-187-2020-0 E-187-2020-0-US-01 SARS-CoV-2 VACCINE PRV US 63/046,603 Abandoned US <br />Provisional (PRV) 63/046,603<br />Filed on 2020-06-30<br />Status: Abandoned 114151942 Structure-based 114151943 Design 114151944 CONFORMATIONALLY-STABILIZED 114151945 SARS-CoV-2 114151946 spike 114151947 IMMUNOGENS TAB-3409 114097290 Recombinant Prefusion Measles and Mumps F and F–HN (H) Glycoproteins for Vaccine Development NIAID Licensing Licensing Barney Graham, Guillaume Stewart-Jones The Measles virus (MeV) and Mumps virus (MuV) are highly contagious paramyxoviruses that can be transmitted by respiratory droplets from or on direct contact with an infected person. The resulting diseases can lead to serious complications or death among children. The existing vaccines for MeV and MuV are live attenuated virus vaccines which are administered in two subcutaneous doses at 1 year of age and as early as one month later. Two doses of a combination measles, mumps and rubella vaccine are 97% effective against measles and 88% against mumps. A single dose of a combination measles, mumps, and rubella vaccine is 93% effective against measles and 78% effective against mumps.<br /><br /> Despite the effectiveness of the current licensed vaccines against MeV and MuV, incidences of both have increased in recent years. Contributing factors include reduced vaccination rates (especially in the U.S) due to vaccine hesitancy and circulation of divergent strains against which the licensed MMR vaccine offers limited protection. In the case of MuV, recent studies have shown that immunity wanes significantly after the second MMR vaccination which normally occurs in childhood. In response to recent recurring MuV disease outbreaks in the U.S and Europe, the Advisory Committee on Immunization Practices is advising a third MMR vaccination to boost protection. However, existing immunity neutralizes a third MMR vaccination limiting its effectiveness. Genotype G MuV is the main cause of recent outbreaks in the US and Europe, and a genotype-matched vaccine has been suggested as a solution for the recurring outbreaks.<br /><br /> Researchers at the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID) used structure-guided design to create immunogen constructs aimed at stabilizing the measles and mumps F glycoproteins in their prefusion conformations. This was achieved by following the discovery that the pre-fusion stabilized F glycoproteins from other members of the paramyxoviridae family induced high titer neutralizing responses.<br /><br /> The researchers developed recombinant immunogens based on: (a) the measles F glycoprotein trimer stabilized in its prefusion conformation (preF-MeV); (b) genotype G mumps F glycoprotein trimers stabilized in its prefusion conformation (preF-MuV); (c) a chimera in which a genotype G mumps F glycoprotein trimer stabilized in its prefusion conformation is fused with mumps HN protein (preF-HN); and (d) a chimera in which a genotype G mumps F glycoprotein trimer stabilized in its prefusion conformation is fused with measles H protein (preF-MuV/MeV H).<br /><br /> The prefusion stabilization of both the mumps and measles F glycoproteins relies on amino acid substitutions to allow the formation of intra-protomer disulfide bonds. Researchers found that the preF and preF-HN immunogens are stable for over a month at 37?C and hypothesize that lyophilized product would be stable at room temperature for months.<br /><br /> When mice are immunized in a prime-boost-boost regimen with the MuV immunogen constructs, the group receiving the preF-HN immunogens elicited similar antibody titers against genotype G MuV and Jeryl Lynn strain of MuV (genotype A) indicating that the preF-HN immunogens offer broad protection against divergent strains of MuV. Interestingly, mice immunized in a prime-boost regimen with the pre-F MuV/MeV H chimeric immunogen elicited antibody titers to both MuV and MeV that are above the determined protective thresholds.<br /><br /> This technology is available for licensing for commercial development in accordance with 35 U.S.C. § 209 and 37 CFR Part 404. <ul> <li>Currently, there is no licensed recombinant measles or mumps vaccine for use as boosters as a third vaccination.</li> <li>The preF-HN immunogens offer broad protection against divergent strains of mumps.</li> <li>The stabilized prefusion F molecules may be deliverable as mRNA vaccines, increasing yields of expressed antigen and presentation of the optimal conformation of target proteins.</li> <li>PreF and preF-HN immunogens are stable for over a month at 37?C, the lyophilized product may be stable at room temperature for months.</li> <li>Recombinant vaccine production is scalable, cost-effective vaccine production can be achieved.</li> </ul> <ul> <li>The products can be used as measles or mumps vaccines.</li> </ul> 2022-03-08 2025-08-13 2025-08-15 2020-11-05 F, F-HN, GLYCOPROTEINS, MEASLES, Mumps, Prefusion, recombinant, Their False True True NIHTT 37470483 Website Abstract 114110109 Stewart-Jones, Guillaume NIAID - VRC NIAID Stewart-Jones, Guillaume (NIAID) 0 114110108 Graham, Barney NIAID - VRC NIAID Graham, Barney (NIAID) 1 114110108 Graham, Barney NIAID - VRC NIAID Graham, Barney (NIAID) 1 114110109 Stewart-Jones, Guillaume NIAID - VRC NIAID Stewart-Jones, Guillaume (NIAID) 0 114102538 Recombinant Prefusion Measles And Mumps F And F-HN Glycoproteins And Their Use E-153-2019-0 Filing authorized NIAID 148673287 Hafiz, Sabrina sabrina.hafiz@nih.gov
United States of America sabrina.hafiz@nih.gov?subject=Web Inquiry on [TAB-3409] Recombinant Prefusion Measles and Mumps F and F–HN (H) Glycoproteins for Vaccine Development&body=Please send me information about technology [TAB-3409] Recombinant Prefusion Measles and Mumps F and F–HN (H) Glycoproteins for Vaccine Development. Hafiz, Sabrina<br><a href="mailto:sabrina.hafiz@nih.gov?subject=Web Inquiry on [TAB-3409] Recombinant Prefusion Measles and Mumps F and F–HN (H) Glycoproteins for Vaccine Development&body=Please send me information about technology [TAB-3409] Recombinant Prefusion Measles and Mumps F and F–HN (H) Glycoproteins for Vaccine Development.">sabrina.hafiz@nih.gov</a><br> 114169014 E-153-2019-0 E-153-2019-0-US-01 MUMPS AND MEASLES VIRUS IMMUNOGENS AND THEIR USE PRV US 62/946,902 Abandoned US <br />Provisional (PRV) 62/946,902<br />Filed on 2019-12-11<br />Status: Abandoned 114169080 E-153-2019-1 E-153-2019-1-PCT-01 MUMPS AND MEASLES VIRUS IMMUNOGENS AND THEIR USE PCT COMB Patent Cooperation Treaty PCT/US2020/064619 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2020/064619<br />Filed on 2020-12-11<br />Status: Expired 114151886 recombinant 114151887 Prefusion 114151888 MEASLES 114151889 Mumps 114151890 F 114151891 F-HN 114151892 GLYCOPROTEINS 114151893 Their TAB-3407 114097287 A Rapid Ultrasensitive Assay for Detecting Prions Based on the Seeded Polymerization of Recombinant Normal Prion Protein (rPrP-sen) NIAID Diagnostics, Infectious Disease, Licensing, Neurology Diagnostics Infectious Disease Licensing Neurology Ryuichiro Atarashi, Byron Caughey, Roger Moore, Suzette Priola Prion diseases are neurodegenerative diseases of great public concern as humans may either develop disease spontaneously or, more rarely, due to mutations in their prion protein gene or exposures to external sources of infection. Prion disease is caused by the accumulation in the nervous system of abnormal aggregates of prion protein. This technology enables rapid, economical, and ultrasensitive detection of disease-associated forms of prion protein. Specifically, prion aggregates (contained in a biological sample) seed the polymerization of recombinant, monomeric prion protein (rPrP-sen) and the polymerized product is detected as a highly amplified indicator of infectious prions in the sample. This assay differs from the protein-misfolding cyclic amplification assay (PMCA) because it enables the effective use of bacterially expressed rPrP-sen and does not require multiple amplification rounds. In its current embodiment, this assay can be used to detect prions in tissues or fluids from humans (Creutzfeldt-Jakob disease (CJD)), sheep (scrapie), cattle (bovine spongiform encephalopathy), and deer (chronic wasting disease (CWD)). For example, analyses of cerebrospinal fluid and/or nasal brushings from living sporadic CJD patients has allowed for nearly 100% accurate diagnosis.<br /><br/> This technology is available for licensing for commercial development in accordance with 35 U.S.C. § 209 and 37 CFR Part 404. <ul> <li>Uses a consistent, concentrated source of normal prion protein (rPrP-sen)</li> <li>Prions are detectable to low levels after a single amplification round</li> <li>Demonstrated to be effective at detecting prions from different species</li> <li>May be applicable to blood products, nasal brushings, skin, eye components and other accessible biospecimens</li> <li>Economical and rapid </ul> <ul> <li>A test/screen for infectious prions in live animals and food products</li> <li>Cervid CWD monitoring</li> <li>A human diagnostic for early detection of prion diseases</li> <li>Medical equipment screening</li> <li>A monitor for effectiveness of treatments or disease progression</li> <li>A high through-put screen for inhibitors of prion replication</li> </ul> To license this technology, please contact Jeffrey Thruston at 301-594-5179 or <a href="mailto:jeffrey.thruston@nih.gov">jeffrey.thruston@nih.gov</a>, and reference E-109-2007-0. 2022-10-08 2025-08-13 2025-08-15 2020-05-29 CONVERSION, DA5XXX, Detection, Highly, INFECTIOUS, Listed LPM Fenn as of 4/15/2015, NA1XXX, NA2XXX, Patent Category - Chemistry, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, prion, Protein, recombinant, Seeded, SENSITIVE False True True NIHTT 37470483 Website Abstract 114172579 Atarashi, Ryuichiro et al. “Simplified ultrasensitive prion detection by recombinant PrP conversion with shaking.” Nature Methods 5, pages 211–212 (2008). https://www.ncbi.nlm.nih.gov/pubmed/18309304 <a href="https://www.ncbi.nlm.nih.gov/pubmed/18309304">Atarashi, Ryuichiro et al. “Simplified ultrasensitive prion detection by recombinant PrP conversion with shaking.” Nature Methods 5, pages 211–212 (2008).</a> 114110092 Moore, Roger NIAID - DIR NIAID Moore, Roger (NIAID) 0 114110093 Caughey, Byron NIAID - DIR NIAID Caughey, Byron (NIAID) 0 114110094 Priola, Suzette NIAID - DIR NIAID Priola, Suzette (NIAID) 0 114110091 Atarashi, Ryuichiro NIAID - DIR NIAID Atarashi, Ryuichiro (NIAID) 1 114110091 Atarashi, Ryuichiro NIAID - DIR NIAID Atarashi, Ryuichiro (NIAID) 1 114110092 Moore, Roger NIAID - DIR NIAID Moore, Roger (NIAID) 0 114110093 Caughey, Byron NIAID - DIR NIAID Caughey, Byron (NIAID) 0 114110094 Priola, Suzette NIAID - DIR NIAID Priola, Suzette (NIAID) 0 114102535 Highly Sensitive Detection Of Infectious Prion Protein By Seeded Conversion Of Recombinant Prion Protein E-109-2007-0 Filing authorized NIAID 114102536 Highly Sensitive Detection Of Infectious Prion Protein By Seeded Conversion Of Recombinant Prion Protein E-109-2007-1 Filing authorized NIAID 146046171 Joyce, Terrence terrence.joyce@nih.gov
United States of America terrence.joyce@nih.gov?subject=Web Inquiry on [TAB-3407] A Rapid Ultrasensitive Assay for Detecting Prions Based on the Seeded Polymerization of Recombinant Normal Prion Protein (rPrP-sen)&body=Please send me information about technology [TAB-3407] A Rapid Ultrasensitive Assay for Detecting Prions Based on the Seeded Polymerization of Recombinant Normal Prion Protein (rPrP-sen). Joyce, Terrence<br><a href="mailto:terrence.joyce@nih.gov?subject=Web Inquiry on [TAB-3407] A Rapid Ultrasensitive Assay for Detecting Prions Based on the Seeded Polymerization of Recombinant Normal Prion Protein (rPrP-sen)&body=Please send me information about technology [TAB-3407] A Rapid Ultrasensitive Assay for Detecting Prions Based on the Seeded Polymerization of Recombinant Normal Prion Protein (rPrP-sen).">terrence.joyce@nih.gov</a><br> 114168997 E-109-2007-1 E-109-2007-1-US-15 DETECTION OF INFECTIOUS PRION PROTEIN BY SEEDED CONVERSION OF RECOMBINANT PRION PROTEIN CON US 15/665,323 Abandoned US <br />Continuation (CON) 15/665,323<br />Filed on 2017-07-31<br />Status: Abandoned 114168998 E-109-2007-1 E-109-2007-1-US-11 Detection Of Infectious Prion Protein By Seeded Conversion Of Recombinant Prion Protein CON US 14/263,703 Abandoned US <br />Continuation (CON) 14/263,703<br />Filed on 2014-04-28<br />Status: Abandoned 114168999 E-109-2007-1 E-109-2007-1-US-04 Detection Of Infectious Prion Protein By Seeded Conversion Of Recombinant Prion Protein CON US 13/489,321 Abandoned US <br />Continuation (CON) 13/489,321<br />Filed on 2012-06-05<br />Status: Abandoned 114169000 E-109-2007-1 E-109-2007-1-US-02 Detection Of Infectious Prion Protein By Seeded Conversion Of Recombinant Prion Protein ORD US 8,216,788 12/177,012 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8216788 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8216788">8,216,788</a><br />Filed on 2008-07-21<br />Status: Issued 114169001 E-109-2007-1 E-109-2007-1-PCT-01 Detection Of Infectious Prion Protein By Seeded Conversion Of Recombinant Prion Protein PCT COMB Patent Cooperation Treaty PCT/US2008/070656 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2008/070656<br />Filed on 2008-07-21<br />Status: Expired 114169002 E-109-2007-0 E-109-2007-0-US-01 Detection of Infectious Prion Protein by Seeded Conversion of Recombinant Prion Protein PRV US 60/961,364 Abandoned US <br />Provisional (PRV) 60/961,364<br />Filed on 2007-07-20<br />Status: Abandoned 114128323 DA5XXX 114128324 NA1XXX 114128325 NA2XXX 114151856 Highly 114151857 SENSITIVE 114151858 Detection 114151859 INFECTIOUS 114151860 prion 114151861 Protein 114151862 Seeded 114151863 CONVERSION 114151864 recombinant 114151865 Patent Category - Chemistry 114151866 Listed LPM Fenn as of 4/15/2015 114151867 Pre LPM working set 20150418 114151868 Post LPM Assignment Set 20150420 TAB-3406 114097286 Alpha-Synuclein RT-QuIC: An Ultrasensitive Assay for the Detection of Alpha-Synuclein Seeding Activity Associated with Synucleinopathies NIAID Licensing Licensing Byron Caughey, Bradley Groveman, Christina Groveman, Andrew Hughson, Lynne Raymond Synucleinopathies are a category of neurodegenerative diseases defined by the abnormal aggregation and accumulation of misfolded alpha-synuclein protein molecules within the brain. These aggregates are of particular concern to humans as they are a primary cause of Parkinson’s disease, dementia with Lewy bodies, and other neurological disorders. This technology enables rapid, economical and ultrasensitive detection of disease-associated forms of alpha-synuclein as biomarkers or indicators of synucleinopathy in a biological sample. Specifically, alpha-synuclein aggregates (contained in a biological sample) seed the polymerization of vast stoichiometric excesses of recombinant, normally folded alpha-synuclein into amyloid fibrils that are then detectable by an amyloid-sensitive fluorescent dye. This reaction can thereby amplify the seeds in a biospecimen by many orders of magnitude. For example, in its current embodiment, this assay has been used to detect alpha-synuclein seeds in cerebral spinal fluid from living patients with Parkinson’s disease and Lewy-body dementia, giving high diagnostic sensitivity and specificity with unprecedented speed. <br /><br /> This technology is available for licensing for commercial development in accordance with 35 U.S.C. § 209 and 37 CFR Part 404. <ul> <li>Uses a consistent, concentrated source of truncated alpha-synuclein protein substrate</li> <li>Capable of disease detection prior to onset of symptoms </li> <li>Rapid and economical </li> </ul> <ul> <li>Pre-mortem diagnosis of synucleinopathies, including Parkinson’s disease and Lewy-body dementia</li> <li>A monitor of the disease progression of dementia and synucleinopathies</li> <li>Clinical trial / drug development companion diagnostic</li> </ul> To license this technology, please contact Jeffrey Thruston at 301-594-5179 or <a href="mailto:jeffrey.thruston@nih.gov">jeffrey.thruston@nih.gov</a>, and reference E-233-2017-0. 2022-04-01 2025-08-13 2025-08-15 2020-05-29 Activity, Alpha-Synuclein, assay, Associated, Detection, RT-QuIC:, Seeding, Synucleinopathies, Ultrasensitive False True True NIHTT 37470483 Website Abstract 114172578 Groveman, Bradley R et al. “Rapid and ultra-sensitive quantitation of disease-associated a-synuclein seeds in brain and cerebrospinal fluid by aSyn RT-QuIC.” Acta Neuropathologica Communications vol. 6(1):7, 9 Feb. 2018. https://www.ncbi.nlm.nih.gov/pubmed/29422107 <a href="https://www.ncbi.nlm.nih.gov/pubmed/29422107">Groveman, Bradley R et al. “Rapid and ultra-sensitive quantitation of disease-associated a-synuclein seeds in brain and cerebrospinal fluid by aSyn RT-QuIC.” Acta Neuropathologica Communications vol. 6(1):7, 9 Feb. 2018.</a> 114110087 Groveman, Bradley NIAID - DIR NIAID Groveman, Bradley (NIAID) 0 114110088 Groveman, Christina NIAID - DIR NIAID Groveman, Christina (NIAID) 0 114110089 Raymond, Lynne NIAID - DIR NIAID Raymond, Lynne (NIAID) 0 114110090 Hughson, Andrew NIAID - DIR NIAID Hughson, Andrew (NIAID) 0 114110086 Caughey, Byron NIAID - DIR NIAID Caughey, Byron (NIAID) 1 114110086 Caughey, Byron NIAID - DIR NIAID Caughey, Byron (NIAID) 1 114110087 Groveman, Bradley NIAID - DIR NIAID Groveman, Bradley (NIAID) 0 114110088 Groveman, Christina NIAID - DIR NIAID Groveman, Christina (NIAID) 0 114110089 Raymond, Lynne NIAID - DIR NIAID Raymond, Lynne (NIAID) 0 114110090 Hughson, Andrew NIAID - DIR NIAID Hughson, Andrew (NIAID) 0 114102534 Alpha-Synuclein RT-QuIC: An Ultrasensitive Assay For The Detection Of Alpha-Synuclein Seeding Activity Associated With Synucleinopathies E-233-2017-0 Filing authorized NIAID 146046171 Joyce, Terrence terrence.joyce@nih.gov
United States of America terrence.joyce@nih.gov?subject=Web Inquiry on [TAB-3406] Alpha-Synuclein RT-QuIC: An Ultrasensitive Assay for the Detection of Alpha-Synuclein Seeding Activity Associated with Synucleinopathies &body=Please send me information about technology [TAB-3406] Alpha-Synuclein RT-QuIC: An Ultrasensitive Assay for the Detection of Alpha-Synuclein Seeding Activity Associated with Synucleinopathies . Joyce, Terrence<br><a href="mailto:terrence.joyce@nih.gov?subject=Web Inquiry on [TAB-3406] Alpha-Synuclein RT-QuIC: An Ultrasensitive Assay for the Detection of Alpha-Synuclein Seeding Activity Associated with Synucleinopathies &body=Please send me information about technology [TAB-3406] Alpha-Synuclein RT-QuIC: An Ultrasensitive Assay for the Detection of Alpha-Synuclein Seeding Activity Associated with Synucleinopathies .">terrence.joyce@nih.gov</a><br> 114169003 E-233-2017-0 E-233-2017-0-PCT-02 ASSAY FOR THE DETECTION OF ALPHA-SYNUCLEIN SEEDING ACTIVITY ASSOCIATED WITH SYNUCLEINOPATHIES PCT Patent Cooperation Treaty PCT/US2018/052968 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2018/052968<br />Filed on 2018-09-26<br />Status: Expired 114169004 E-233-2017-0 E-233-2017-0-US-01 ASSAY FOR THE DETECTION OF ALPHA-SYNUCLEIN SEEDING ACTIVITY ASSOCIATED WITH SYNUCLEINOPATHIES PRV US 62/567,079 Abandoned US <br />Provisional (PRV) 62/567,079<br />Filed on 2017-10-02<br />Status: Abandoned 114169009 E-233-2017-0 E-233-2017-0-US-05 ASSAY FOR THE DETECTION OF ALPHA-SYNUCLEIN SEEDING ACTIVITY ASSOCIATED WITH SYNUCLEINOPATHIES National Stage US 11,313,867 16/652,804 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11313867 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11313867">11,313,867</a><br />Filed on 2020-04-01<br />Status: Issued 114169307 E-233-2017-0 E-233-2017-0-US-06 ASSAY FOR THE DETECTION OF ALPHA-SYNUCLEIN SEEDING ACTIVITY ASSOCIATED WITH SYNUCLEINOPATHIES CON US 12,105,101 17/708,560 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12105101 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12105101">12,105,101</a><br />Filed on 2022-03-30<br />Status: Issued 114151847 Alpha-Synuclein 114151848 RT-QuIC: 114151849 Ultrasensitive 114151850 assay 114151851 Detection 114151852 Seeding 114151853 Activity 114151854 Associated 114151855 Synucleinopathies TAB-3404 114097284 Monoclonal Antibodies Against Bacillus Anthracis Antigens NIAID Collaboration, Diagnostics, Infectious Disease, Rare/Neglected Diseases, Research Materials, Therapeutics, Vaccines Collaboration Diagnostics Infectious Disease Rare/Neglected Diseases Research Materials Therapeutics Vaccines Zhaochun Chen, Lily Zhongdong Dai, Suzanne Emerson, Joanna Kubler-kielb, Stephen Leppla, Mahtab Moayeri, Robert Purcell, Rachel Schneerson Anthrax, whether resulting from natural or bioterrorist-associated exposure, is a constant threat to human health. Bacillus anthracis is the causative agent of anthrax. It is surrounded by a polypeptide capsule of poly-gamma-D-glutamic acid (gamma-D-PGA), which is essential for virulence, is poorly immunogenic and has anti-phagocytic properties. Antibodies to the capsule have been shown to enhance phagocytosis and killing of encapsulated bacilli. The lethality of anthrax is primarily the result of the effects of anthrax toxin, which has 3 components: a receptor-binding protein known as "protective antigen" (PA) and 2 catalytic proteins known as "lethal factor" (LF) and "edema factor" (EF). Although production of an efficient anthrax vaccine is an ultimate goal, the benefits of vaccination can be expected only if a large proportion of the population at risk is immunized. The low incidence of anthrax suggests that large-scale vaccination may not be the most efficient means of controlling this disease. In contrast, passive administration of neutralizing human or chimpanzee monoclonal antibody to a subject at risk for anthrax or exposed to anthrax could provide immediate efficacy for emergency prophylaxis against or treatment of anthrax.<br /><br /> Several monoclonal antibodies (mAbs) against gamma-D-PGA, PA, LF and EF of anthrax were isolated from a phage display library generated from immunized chimpanzees. Two anti-PA, and two anti-LF mAbs efficiently neutralized the cytotoxicity of lethal toxin in a macrophage lysis assay. One anti-EF mAb efficiently neutralized edema toxin in cell culture. All of these five neutralizing mAbs protected animals from anthrax toxin challenge. There are two anti-gamma-D-PGA mAbs that showed strong opsonophagocytic killing of bacilli in vitro assays. These two mAbs were also tested for protection of mice challenged with virulent anthrax spores and results showed that both mAbs provided full or nearly full protection. Since chimpanzee immunoglobulins are virtually identical to human immunoglobulins, these chimeric chimpanzee mAbs may have clinically useful applications. <br /><br /> <ul> <li>Strongly neutralizing antibodies</li> <li>Known regulatory pathway</li> <li>Potential for use as both a prophylaxis and therapy</li> </ul> <ul> <li>Prophylaxis, therapeutics or diagnostics against B. anthracis antigens</li> </ul> For collaboration opportunities, please contact Jenish Patel, PhD at <a href="mailto:jenish.patel@nih.gov">jenish.patel@nih.gov</a>or 1-240-669-2894. 2022-08-15 2025-08-13 2025-08-15 2020-07-06 Admin Lic Spec Review Mar-09 Active Determina, Anthracis, Anthrax, antibodies, ANTIBODY, ANTIGEN, Bacillus, Capsule, chimeric, Chimpaneze, Chimpanzee/Human, DA3XXX, DAXXXX, DB3XXX, DBXXXX, DC4XXX, DCXXXX, DD1XXX, DDXXXX, DXXXXX, Edema, FACTORS, KILL, Lethal, Listed LPM Soukas as of 4/15/2015, monoclonal, Neutralize, Neutralizes, Opsonophagocytosis, Opsonophagocytosis., ORGANISM, PA, Patent Category - Biotechnology, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Protective, REACT, That, toxin, UA1XXX, YCXXXX False True True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114172570 Z Chen et al. https://www.ncbi.nlm.nih.gov/pubmed/16453257 <a href="https://www.ncbi.nlm.nih.gov/pubmed/16453257">Z Chen et al.</a> 114172571 Z Chen et al. https://www.ncbi.nlm.nih.gov/pubmed/26041039 <a href="https://www.ncbi.nlm.nih.gov/pubmed/26041039">Z Chen et al.</a> 114110077 Leppla, Stephen NIAID - DIR NIAID Leppla, Stephen (NIAID) 0 114110078 Emerson, Suzanne NIAID - DIR NIAID Emerson, Suzanne (NIAID) 0 114110079 Purcell, Robert NIAID - DIR NIAID Purcell, Robert (NIAID) 0 114110080 Moayeri, Mahtab NIDCR NIAID Moayeri, Mahtab (NIAID) 0 114110081 Schneerson, Rachel NICHD NICHD Schneerson, Rachel (NICHD) 0 114110082 Kubler-kielb, Joanna NICHD NICHD Kubler-kielb, Joanna (NICHD) 0 114110083 Dai, Lily Zhongdong NICHD Dai, Lily Zhongdong 0 114110076 Chen, Zhaochun NIAID - DIR NIAID Chen, Zhaochun (NIAID) 1 114110076 Chen, Zhaochun NIAID - DIR NIAID Chen, Zhaochun (NIAID) 1 114110077 Leppla, Stephen NIAID - DIR NIAID Leppla, Stephen (NIAID) 0 114110078 Emerson, Suzanne NIAID - DIR NIAID Emerson, Suzanne (NIAID) 0 114110079 Purcell, Robert NIAID - DIR NIAID Purcell, Robert (NIAID) 0 114110080 Moayeri, Mahtab NIDCR NIAID Moayeri, Mahtab (NIAID) 0 114110081 Schneerson, Rachel NICHD NICHD Schneerson, Rachel (NICHD) 0 114110082 Kubler-kielb, Joanna NICHD NICHD Kubler-kielb, Joanna (NICHD) 0 114110083 Dai, Lily Zhongdong NICHD Dai, Lily Zhongdong 0 114102530 Chimpaneze Monoclonal Antibody That Neutralizes Anthrax Protective Antigen (PA) Toxin E-146-2004-0 Filing authorized NIAID 114102531 Chimpaneze Monoclonal Antibodies That Neutralize Lethal And Edema Factors Of Anthrax Toxin E-123-2007-0 Filing authorized NIAID, NIDCR 114102532 Chimpanzee/Human Chimeric Monoclonal Antibodies That React With The Capsule Of Bacillus Anthracis And Kill The Organism By Opsonophagocytosis. E-125-2008-0 Filing authorized NIAID, NICHD 91027763 Puglielli, Maryann maryann.puglielli@nih.gov
United States of America maryann.puglielli@nih.gov?subject=Web Inquiry on [TAB-3404] Monoclonal Antibodies Against Bacillus Anthracis Antigens&body=Please send me information about technology [TAB-3404] Monoclonal Antibodies Against Bacillus Anthracis Antigens. Puglielli, Maryann<br><a href="mailto:maryann.puglielli@nih.gov?subject=Web Inquiry on [TAB-3404] Monoclonal Antibodies Against Bacillus Anthracis Antigens&body=Please send me information about technology [TAB-3404] Monoclonal Antibodies Against Bacillus Anthracis Antigens.">maryann.puglielli@nih.gov</a><br> 114169050 E-146-2004-0 E-146-2004-0-US-03 Monoclonal Antibodies That Neutralize Anthrax Protective Antigen (PA) Toxin National Stage US 8,685,396 11/793,735 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8685396 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8685396">8,685,396</a><br />Filed on 2009-12-08<br />Status: Abandoned 114169051 E-146-2004-0 E-146-2004-0-US-04 Monoclonal Antibodies That Neutralize Anthrax Protective Antigen (PA) Toxin DIV US 10,227,395 14/181,099 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10227395 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10227395">10,227,395</a><br />Filed on 2014-02-14<br />Status: Abandoned 114169053 E-123-2007-0 E-123-2007-0-US-04 Chimpaneze Monoclonal Antibodies That Neutralize Lethal And Edema Factors Of Anthrax Toxin National Stage US 8,071,100 12/528,427 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8071100 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8071100">8,071,100</a><br />Filed on 2009-08-24<br />Status: Abandoned 114169054 E-125-2008-0 E-125-2008-0-US-03 Monoclonal Antibodies That React With The Capsule Of Bacillus Anthracis National Stage US 8,501,182 13/130,044 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8501182 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8501182">8,501,182</a><br />Filed on 2011-05-18<br />Status: Abandoned 114169068 E-123-2007-0 E-123-2007-0-US-33 Monoclonal Antibodies That Neutralize Anthrax Toxin DIV US 9,580,492 14/595,475 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9580492 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9580492">9,580,492</a><br />Filed on 2015-01-13<br />Status: Abandoned 114169138 E-123-2007-0 E-123-2007-0-US-05 Monoclonal Antibodies That Neutralize Anthrax Toxin DIV US 8,574,853 13/310,463 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8574853 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8574853">8,574,853</a><br />Filed on 2011-12-02<br />Status: Abandoned 114169153 E-125-2008-0 E-125-2008-0-US-05 MONOCLONAL ANTIBODIES THAT REACT WITH THE CAPSULE OF BACILLUS ANTHRACIS DIV US 9,845,350 15/003,719 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9845350 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9845350">9,845,350</a><br />Filed on 2016-01-21<br />Status: Abandoned 114169157 E-125-2008-0 E-125-2008-0-US-04 MONOCLONAL ANTIBODIES THAT REACT WITH THE CAPSULE OF BACILLUS ANTHRACIS CON US 9,273,124 13/935,956 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9273124 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9273124">9,273,124</a><br />Filed on 2013-07-05<br />Status: Abandoned 114169158 E-123-2007-0 E-123-2007-0-US-08 Monoclonal Antibodies That Neutralize Anthrax Toxin DIV US 8,961,975 14/031,508 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8961975 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8961975">8,961,975</a><br />Filed on 2013-09-19<br />Status: Abandoned 114169159 E-123-2007-0 E-123-2007-0-US-34 Monoclonal Antibodies That Neutralize Anthrax Toxins DIV US 10,053,503 15/411,065 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10053503 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10053503">10,053,503</a><br />Filed on 2017-01-20<br />Status: Abandoned 114169160 E-146-2004-0 E-146-2004-0-US-05 Monoclonal Antibodies that Neutralize Anthrax Protective Antigen (PA) Toxin DIV US 16/253,077 Abandoned US <br />Divisional (DIV) 16/253,077<br />Filed on 2019-01-21<br />Status: Abandoned 114169559 E-123-2007-0 E-123-2007-0-PCT-02 Chimpaneze Monoclonal Antibodies That Neutralize Lethal And Edema Factors Of Anthrax Toxin PCT Patent Cooperation Treaty PCT/US2008/054609 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2008/054609<br />Filed on 2008-02-21<br />Status: Expired 114169639 E-125-2008-0 E-125-2008-0-PCT-02 Monoclonal Antibodies That React With The Capsule Of Bacillus Anthracis PCT Patent Cooperation Treaty PCT/US2009/065198 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2009/065198<br />Filed on 2009-11-19<br />Status: Expired 114128294 DD1XXX 114128295 DC4XXX 114128296 DB3XXX 114128297 UA1XXX 114128316 DAXXXX 114128317 DCXXXX 114128318 DBXXXX 114128319 DA3XXX 114128320 DDXXXX 114128321 DXXXXX 114128322 YCXXXX 114151808 Chimpaneze 114151809 monoclonal 114151810 ANTIBODY 114151811 That 114151812 Neutralizes 114151813 Anthrax 114151814 Protective 114151815 ANTIGEN 114151816 PA 114151817 toxin 114151818 Patent Category - Biotechnology 114151819 Admin Lic Spec Review Mar-09 Active Determina 114151820 Listed LPM Soukas as of 4/15/2015 114151821 Pre LPM working set 20150418 114151822 Post LPM Assignment Set 20150420 114151823 antibodies 114151824 Neutralize 114151825 Lethal 114151826 Edema 114151827 FACTORS 114151828 Chimpanzee/Human 114151829 Opsonophagocytosis 114151830 REACT 114151831 Capsule 114151832 Bacillus 114151833 Anthracis 114151834 KILL 114151835 ORGANISM 114151836 chimeric 114151837 Opsonophagocytosis. TAB-3393 114097281 Ebola Virus Glycoprotein-Specific Monoclonal Antibodies and Uses Thereof NIAID Licensing Licensing Brandon Dekosky, Kendra Leigh, John Misasi, Nancy Sullivan Ebola virus is a large, negative-strand RNA virus composed of 7 genes encoding viral proteins, including a single glycoprotein (GP). The virus is responsible for causing Ebola virus disease (EVD), formerly known as Ebola hemorrhagic fever (EHF), in humans. In particular, Bundibugyo (BDBV), Zaire (EBOV), and Sudan (SUDV) species have been associated with large outbreaks of EVD in Africa and reported case fatality rates of up to 90%. Transmission of Ebola virus to humans is not yet fully understood but is likely due to incidental exposure to infected animals. EVD spreads through human-to-human transmission, with infection resulting from direct contact with blood, secretions, organs or other bodily fluids of infected people, and indirect contact with environments contaminated by such fluids.<br /><br /> EVD has an incubation period of 2 to 21 days (7 days on average, depending on the strain) followed by a rapid onset of non-specific symptoms such as fever, extreme fatigue, gastrointestinal complaints, abdominal pain, anorexia, headache, myalgias and/or arthralgias.<br /><br /> While prior outbreaks of EVD have been localized to regions of Africa, there is a potential threat of spread to other countries given the frequency of international travel. The 2014 outbreak in West Africa was first recognized in March 2014, and as of April 13, 2016, the number of cases far exceeded the largest prior EVD outbreak with a combined total (suspected, probable, and laboratory-confirmed) 28616 cases and 11310 deaths (case fatality rate = 39.5%). The largest previous outbreak occurred in Uganda in 2000-2001 with 425 cases and 224 deaths (case-fatality rate=53%).<br /><br /> Viruses in the Filoviridae family are also categorized as potential threats for use as biological weapons due to ease of dissemination and transmission, and high levels of mortality. Currently, no effective therapies or FDA-licensed vaccines exist for any member of Filoviridae family of viruses.<br /><br /> Researchers at the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID) developed eight high-affinity human monoclonal antibodies, specifically EboV.YD.01, EboV.YD.02, EboV.YD.03, and EboV.YD.04, EboV.YD.05, EboV.YD.06, EboV.YD.07 and EboV.YD.08 which bind with nanomolar affinity against Ebola virus glycoprotein. The human monoclonal antibodies have been assessed by functional assays, epitope mapping, affinity measurements and in vitro neutralization assays.<br /><br /> This technology is available for licensing for commercial development in accordance with 35 U.S.C. § 209 and 37 CFR Part 404. <ul> <li>High-affinity neutralizing antibodies (mAbs), targeting Ebola virus (EBOV) glycoprotein from a human Ebolavirus vaccine.</li> <li>Currently, there are no Food and Drug Administration (FDA)-approved vaccines or therapeutics available for prevention, post-exposure, or treatment for EBOV.</li> <li>The EboV.YD.01 - EboV.YD.08 antibodies can be combined with other biologicals and vaccines for prevention and therapy of Ebola Zaire infection/disease.</li> </ul> <ul> <li>Prevention of acquisition of Ebola Zaire virus.</li> <li>Antibody therapy for people exposed to Ebola Zaire virus.</li> <li>Diagnostics for Ebola Zaire virus.</li> </ul> 2022-03-08 2025-08-13 2025-08-15 2020-03-09 antibodies, Ebola, Human, Vaccinee False True True NIHTT 37470483 Website Abstract 114110064 Misasi, John NIAID - VRC NIAID Misasi, John (NIAID) 0 114110065 Leigh, Kendra NIAID - VRC NIAID Leigh, Kendra (NIAID) 0 114110066 Dekosky, Brandon NIAID - VRC Dekosky, Brandon 0 114110063 Sullivan, Nancy NIAID - VRC NIAID Sullivan, Nancy (NIAID) 1 114110063 Sullivan, Nancy NIAID - VRC NIAID Sullivan, Nancy (NIAID) 1 114110064 Misasi, John NIAID - VRC NIAID Misasi, John (NIAID) 0 114110065 Leigh, Kendra NIAID - VRC NIAID Leigh, Kendra (NIAID) 0 114110066 Dekosky, Brandon NIAID - VRC Dekosky, Brandon 0 114102526 Ebola Antibodies From Human Vaccinee E-061-2018-0 Filing authorized NIAID 148673287 Hafiz, Sabrina sabrina.hafiz@nih.gov
United States of America sabrina.hafiz@nih.gov?subject=Web Inquiry on [TAB-3393] Ebola Virus Glycoprotein-Specific Monoclonal Antibodies and Uses Thereof&body=Please send me information about technology [TAB-3393] Ebola Virus Glycoprotein-Specific Monoclonal Antibodies and Uses Thereof. Hafiz, Sabrina<br><a href="mailto:sabrina.hafiz@nih.gov?subject=Web Inquiry on [TAB-3393] Ebola Virus Glycoprotein-Specific Monoclonal Antibodies and Uses Thereof&body=Please send me information about technology [TAB-3393] Ebola Virus Glycoprotein-Specific Monoclonal Antibodies and Uses Thereof.">sabrina.hafiz@nih.gov</a><br> 114168970 E-061-2018-0 E-061-2018-0-US-01 EBOLA VIRUS GLYCOPROTEIN-SPECIFIC MONOCLONAL ANTIBODIES AND USES THEREOF PRV US 62/782,809 Abandoned US <br />Provisional (PRV) 62/782,809<br />Filed on 2018-12-20<br />Status: Abandoned 114168971 E-061-2018-0 E-061-2018-0-PCT-01 Ebola Virus Glycoprotein-Specific Monoclonal Antibodies and Uses Thereof PCT COMB Patent Cooperation Treaty PCT/US2019/067423 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2019/067423<br />Filed on 2019-12-19<br />Status: Expired 114169130 E-061-2018-0 E-061-2018-0-US-03 EBOLA VIRUS GLYCOPROTEIN-SPECIFIC MONOCLONAL ANTIBODIES AND USES THEREOF National Stage US 17/415,412 Abandoned US <br />National Stage 17/415,412<br />Filed on 2021-06-17<br />Status: Abandoned 114151770 Ebola 114151771 antibodies 114151772 Human 114151773 Vaccinee TAB-3387 114097276 A High-Yield Perfusion-Based Transient Gene Expression Bioprocess NIAID Licensing Licensing Daniel Blackstock, Jacob Demirji, Jinsung Hong, Joseph Horwitz Currently, fed-batch processes are the most commonly used bioprocesses in transient gene expression (TGE) vaccine manufacturing. However, because fed-batch processes keep all the cells and protein product in the vessel throughout the run, some limitations are intrinsic. First, waste products like cell debris or other unwanted small molecules accumulate in the vessel with a potential to disrupt the cell growth, protein production, and the stability of the generated protein of interest. Second, necessary buffer exchange and/or cell concentration steps must be performed outside of the culturing vessel. These steps are more involved and increase the risk of contamination. Lastly, even with the addition of daily supplementation in the fed-batch process, there are limitations in length of time that the transfected cells remain viable and productive.<br /><br /> Researchers at the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID) developed a new transient gene expression (TGE) bioprocess using a perfusion system that resolves the current fed-batch limitations for influenza vaccine production. The major components of this technology are two-fold: the optimization of conditions for polyethylenimine (PEI)-mediated gene transfection in the bioreactor without the interference of microbubbles; and the implementation of a perfusion-based alternating tangential flow (ATF) system for single-system, prolonged cell culture, combining the steps of cell concentration, waste clearance, culturing/media replenishment, and protein expression within a single vessel.<br /><br /> The development of the TGE bioprocess included optimization of conditions for HEK293 cell growth in the bioreactor, optimized transfection mediated by PEI, and protein expression for an extended period to achieve reproducibility and high protein yield.<br /><br /> Due to high improvement in cell growth and protein production without external handling, this bioprocess could lead to substantial cost saving and other benefits in vaccine and drug manufacturing of clinical grade materials.<br /><br /> This technology is available for licensing for commercial development in accordance with 35 U.S.C. § 209 and 37 CFR Part 404. The new transient gene expression (TGE) bioprocess for vaccine manufacturing has the following features compared to commonly used related processes such as fed-batch:<br /><br /> <ul> <li>Robust, prolonged cell growth</li> <li>High levels of protein production and reproducibility</li> <li>Cost efficiency</li> <li>Reduction in contamination risk</li> </ul> Development Stage: Final Product. <ul> <li>Bioprocess- A single-use protein production platform for transient gene expression (TGE) with potential applications in rapid protein expression as well as vaccine and drug manufacturing.</li> </ul> 2022-03-08 2025-04-23 2025-08-15 2019-12-02 Bioprocess, Development, Expression, Gene, High-yield, INFLUENZA, Perfusion-based, TGE, TRANSIENT, UNIVERSAL, Vaccine False True True NIHTT 37470483 Website Abstract 114110046 Demirji, Jacob NIAID - VRC NIAID Demirji, Jacob (NIAID) 0 114110047 Blackstock, Daniel NIAID - VRC NIAID Blackstock, Daniel (NIAID) 0 114110048 Horwitz, Joseph NIAID - VRC NIAID Horwitz, Joseph (NIAID) 0 114110045 Hong, Jinsung NIAID - VRC NIAID Hong, Jinsung (NIAID) 1 114110045 Hong, Jinsung NIAID - VRC NIAID Hong, Jinsung (NIAID) 1 114110046 Demirji, Jacob NIAID - VRC NIAID Demirji, Jacob (NIAID) 0 114110047 Blackstock, Daniel NIAID - VRC NIAID Blackstock, Daniel (NIAID) 0 114110048 Horwitz, Joseph NIAID - VRC NIAID Horwitz, Joseph (NIAID) 0 114102520 Development Of A High-yield Perfusion-based Transient Gene Expression (TGE) Bioprocess For Universal Influenza Vaccine E-187-2018-0 Filing authorized NIAID 91026778 Green, Wade wade.green@nih.gov
United States of America TTIPO wade.green@nih.gov?subject=Web Inquiry on [TAB-3387] A High-Yield Perfusion-Based Transient Gene Expression Bioprocess&body=Please send me information about technology [TAB-3387] A High-Yield Perfusion-Based Transient Gene Expression Bioprocess. Green, Wade<br><a href="mailto:wade.green@nih.gov?subject=Web Inquiry on [TAB-3387] A High-Yield Perfusion-Based Transient Gene Expression Bioprocess&body=Please send me information about technology [TAB-3387] A High-Yield Perfusion-Based Transient Gene Expression Bioprocess.">wade.green@nih.gov</a><br> 114168939 E-187-2018-0 E-187-2018-0-US-01 A HIGH-YIELD PERFUSION-BASED TRANSIENT GENE EXPRESSION BIOPROCESS PRV US 62/751,204 Abandoned US <br />Provisional (PRV) 62/751,204<br />Filed on 2018-10-26<br />Status: Abandoned 114168940 E-187-2018-0 E-187-2018-0-PCT-02 A HIGH-YIELD PERFUSION-BASED TRANSIENT GENE EXPRESSION BIOPROCESS PCT Patent Cooperation Treaty PCT/US2019/057038 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2019/057038<br />Filed on 2019-10-18<br />Status: Expired 114151692 Development 114151693 High-yield 114151694 UNIVERSAL 114151695 INFLUENZA 114151696 Vaccine 114151697 Perfusion-based 114151698 TRANSIENT 114151699 Gene 114151700 Expression 114151701 TGE 114151702 Bioprocess TAB-3364 114097267 Encapsulated Streptococcus Compositions and Methods for Pneumococcal Vaccine, Probiotic, and Diagnostic Assay Development CDC Collaboration, Consumer Products, Diagnostics, Infectious Disease, Licensing, Occupational Safety and Health, Research Materials, Therapeutics, Vaccines Collaboration Consumer Products Diagnostics Infectious Disease Licensing Occupational Safety and Health Research Materials Therapeutics Vaccines Bernard Beall, Maria Da Gloria Carvalho, Monica Farley, Fernanda Lessa, Jennifer Milucky, Fabiana Pimenta, Cynthia Whitney <em>Streptococcus pneumoniae (S. pneumoniae) </em>bacteria, or pneumococcus, can cause many types of illnesses. These range from ear and sinus infections to life-threatening conditions such as pneumonia, bloodstream infections, and meningitis. Pneumococci are surrounded by a polysaccharide capsule, which is thought to help it evade the immune system. Presently, over 90 known serotypes of <em>S. pneumoniae</em> have been identified, of which only a minority produce the majority of pneumococcal infections; a serotype is defined by a unique pneumococcal capsule structure. Currently available vaccines contain antigens made from capsular polysaccharides of 10, 13, or 23 common <em>S. pneumoniae</em> serotypes. <br /><br /> CDC has discovered encapsulated strains of commensal Streptococcus species,<em>S. mitis, S. oralis and S. infantis,</em> that have capsules that are identical to pneumococcal capsules. From this, researchers developed compositions and methods from the species’ biosynthetic capsular genes which show promise for protecting people against pneumococcal disease, either by using these strains as vaccines or probiotics or through development of diagnostic assays. Initial results show cross-protection against eight <em>S. pneumoniae</em> serotypes, including serotype 1, a leading cause of invasive pneumococcal disease globally outside of the US. The capsule components or a modified version of the commensal Streptococcus species could be used to develop a novel live, inactivated or a sub-unit vaccine for <em>S. pneumoniae</em>. Initial concept studies have been performed in animal models. <ul> <li>May be prepared in a variety of dosage forms such as solution, solid or powdered (e.g., lyophilized) form</li> <li>Easily adaptable to kit form</li> <li>Vaccine compositions may protect against multiple pneumococcal organisms or be tailored for specific serotypes affecting a particular population</li> <li>May address drawbacks of currently available <em>S. pneumoniae</em> vaccines where certain populations do not respond optimally to vaccine antigens</li> </ul> <ul> <li>Novel live vaccine or vaccine component to prevent against <em>Streptococcus pneumoniae</em></li> <li>Therapeutic, probiotic or preventive for other pneumococcal conditions (e.g., ear infections, meningitis, and bacteremia)</li> <li>Vaccine-related assays</li> <li>Diagnostic assays</li> </ul> The CDC Technology Transfer Office (TTO) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize: Encapsulated Streptococcus Compositions & Methods for Pneumococcal Vaccine, Probiotic and Diagnostic Assay Development. For collaboration opportunities, please contact CDC TTO at <a href="mailto:tto@cdc.gov">tto@cdc.gov</a> or 1-404-639-1330. 2022-03-27 2025-08-13 2025-08-15 2021-12-21 Against, Development, Disease, ENCAPSULATED, Mitis, Oralis, PNEUMOCOCCAL, POTENTIALLY, Streptococcus, Used, Vaccine, VJXXXX, WBXXXX, WFXXXX, Which, WIXXXX, WJXXXX, WNXXXX, XCXXXX, XKXXXX, YAXXXX, YBXXXX, YCXXXX False True True 52406768 Discovery 52406768 NIHTT 37470483 Website Abstract 114172550 Pimenta F. et al. https://www.ncbi.nlm.nih.gov/pubmed/30671034 <a href="https://www.ncbi.nlm.nih.gov/pubmed/30671034">Pimenta F. et al. </a> 114110012 Milucky, Jennifer CDC - DIR CDC Milucky, Jennifer (CDC) 0 114110013 Lessa, Fernanda CDC - DIR CDC Lessa, Fernanda (CDC) 0 114110014 Pimenta, Fabiana CDC - DIR CDC Pimenta, Fabiana (CDC) 0 114110015 Carvalho, Maria Da Gloria CDC - DIR CDC Carvalho, Maria Da Gloria (CDC) 0 114110017 Beall, Bernard CDC - DIR CDC Beall, Bernard (CDC) 0 114110018 Farley, Monica Emory University Farley, Monica 0 114110016 Whitney, Cynthia CDC - DIR CDC Whitney, Cynthia (CDC) 1 114110016 Whitney, Cynthia CDC - DIR CDC Whitney, Cynthia (CDC) 1 114110012 Milucky, Jennifer CDC - DIR CDC Milucky, Jennifer (CDC) 0 114110013 Lessa, Fernanda CDC - DIR CDC Lessa, Fernanda (CDC) 0 114110014 Pimenta, Fabiana CDC - DIR CDC Pimenta, Fabiana (CDC) 0 114110015 Carvalho, Maria Da Gloria CDC - DIR CDC Carvalho, Maria Da Gloria (CDC) 0 114110017 Beall, Bernard CDC - DIR CDC Beall, Bernard (CDC) 0 114110018 Farley, Monica Emory University Farley, Monica 0 114102511 Encapsulated Streptococcus Mitis And Oralis Which Can Be Potentially Be Used For Development Of Vaccine Against Pneumococcal Disease E-009-2018-0 Closed Centers for Disease Control and Prevention (CDC), Emory University 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-3364] Encapsulated Streptococcus Compositions and Methods for Pneumococcal Vaccine, Probiotic, and Diagnostic Assay Development&body=Please send me information about technology [TAB-3364] Encapsulated Streptococcus Compositions and Methods for Pneumococcal Vaccine, Probiotic, and Diagnostic Assay Development. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-3364] Encapsulated Streptococcus Compositions and Methods for Pneumococcal Vaccine, Probiotic, and Diagnostic Assay Development&body=Please send me information about technology [TAB-3364] Encapsulated Streptococcus Compositions and Methods for Pneumococcal Vaccine, Probiotic, and Diagnostic Assay Development.">jonathan.motley@nih.gov</a><br> 114128238 YAXXXX 114128239 YBXXXX 114128240 YCXXXX 114128241 VJXXXX 114128242 WBXXXX 114128243 WFXXXX 114128244 WIXXXX 114128245 WJXXXX 114128246 WNXXXX 114128247 XCXXXX 114128248 XKXXXX 114151581 Mitis 114151582 POTENTIALLY 114151583 Vaccine 114151584 ENCAPSULATED 114151585 Streptococcus 114151586 Oralis 114151587 Which 114151588 Used 114151589 Development 114151590 Against 114151591 PNEUMOCOCCAL 114151592 Disease TAB-3350 114097263 Recombinant HIV-1 Envelope Proteins and Their Use NIAID Licensing Licensing Jeffrey Boyington, Cheng Cheng, Gwo-Yu Chuang, Hui Geng, Peter Kwong, John Mascola, Yongping Yang An effective human immunodeficiency virus type 1 (HIV-1) vaccine has long been sought to contend with the Acquired Immunodeficiency Syndrome (AIDS) pandemic.<br /><br /> One approach researchers have taken to elicit broadly neutralizing antibodies against HIV-1 is to stabilize the structurally flexible HIV-1 envelope (Env) trimer. Researchers stabilized the Env trimer in a conformation that displays predominantly broadly neutralizing epitopes and few non-neutralizing epitopes. Currently, BG505 DS-SOSIP is a leading vaccine candidate with the desired conformation and antigenicity.<br /><br /> Ideally, to be useful as a vaccine, such a conformationally fixed Env immunogen should have high thermostability and should remain in the desired antigenic state, even in the presence of CD4, a glycoprotein found on the surface of immune cells.<br /><br /> Researchers at the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID) undertook efforts to improve the properties of BG505 DS-SOSIP for use as a vaccine. The VRC researchers introduced three additional mutations to further stabilize BG505 DS-SOSIP in the vaccine-preferred prefusion-closed conformation and refer to the engineered BG505 DS-SOSIP as BG505 DS-SOSIP.3mut. Experiments showed that these modifications conferred improved thermostability that will allow easier transport and storage of BG505 DS-SOSIP.3mut compared to BG505 DS-SOSIP. In addition, BG505 DS-SOSIP.3mut has lower antigenicity toward non/weak neutralizing antibodies compared to BG505 DS-SOSIP, which suggests that it could potentially elicit higher neutralization titer by targeting only broadly neutralizing antibodies. With improved antigenicity and stability, this version may have utility as an HIV-1 immunogen or in other antigen-specific contexts, such as for use with B-cell probes.<br /><br /> This technology is available for licensing for commercial development in accordance with 35 U.S.C. § 209 and 37 CFR Part 404, as well as for further development and evaluation under a research collaboration. Compared to previous engineered Env trimer versions: <ul> <li>300- fold reduction in CD4-binding affinity.</li> <li>Reduced binding affinity to ineffective HIV-1 antibodies.</li> <li>Increase in melting temperature (10 degrees over BG505 SOSIP).</li> </ul> <ul> <li>Vaccine - to elicit potent neutralizing antibodies against the HIV-1 Env glycoprotein.</li> <li>Probes - to identify broad and potent HIV-1-neutralizing antibodies.</li> </ul> 2022-10-11 2025-08-13 2025-08-15 2018-11-27 CONFORMATION, Design, HIV-1, IMMUNOGENS, MIMIC, Prefusion-closed, Soluble, spike, Structure-based, viral False True True NIHTT 37470483 Website Abstract E-178-2014-0 E-178-2014-1 E-178-2014-2 114110000 Mascola, John NIAID - VRC NIAID Mascola, John (NIAID) 0 114110001 Chuang, Gwo-Yu NIAID - DIR NIAID Chuang, Gwo-Yu (NIAID) 0 114110002 Geng, Hui NIAID - VRC NIAID Geng, Hui (NIAID) 0 114110003 Yang, Yongping NIAID - VRC NIAID Yang, Yongping (NIAID) 0 114110004 Cheng, Cheng NIAID - VRC NIAID Cheng, Cheng (NIAID) 0 114110005 Boyington, Jeffrey NIAID - VRC NIAID Boyington, Jeffrey (NIAID) 0 114109999 Kwong, Peter NIAID - VRC NIAID Kwong, Peter (NIAID) 1 114109999 Kwong, Peter NIAID - VRC NIAID Kwong, Peter (NIAID) 1 114110000 Mascola, John NIAID - VRC NIAID Mascola, John (NIAID) 0 114110001 Chuang, Gwo-Yu NIAID - DIR NIAID Chuang, Gwo-Yu (NIAID) 0 114110002 Geng, Hui NIAID - VRC NIAID Geng, Hui (NIAID) 0 114110003 Yang, Yongping NIAID - VRC NIAID Yang, Yongping (NIAID) 0 114110004 Cheng, Cheng NIAID - VRC NIAID Cheng, Cheng (NIAID) 0 114110005 Boyington, Jeffrey NIAID - VRC NIAID Boyington, Jeffrey (NIAID) 0 114102508 Structure-based Design Of Soluble Immunogens That Mimic The Prefusion-closed Conformation Of The HIV-1 Viral Spike E-240-2017-0 Filing authorized NIAID 91025211 Rainwater, Charles crainwater@mail.nih.gov
United States of America crainwater@mail.nih.gov?subject=Web Inquiry on [TAB-3350] Recombinant HIV-1 Envelope Proteins and Their Use&body=Please send me information about technology [TAB-3350] Recombinant HIV-1 Envelope Proteins and Their Use. Rainwater, Charles<br><a href="mailto:crainwater@mail.nih.gov?subject=Web Inquiry on [TAB-3350] Recombinant HIV-1 Envelope Proteins and Their Use&body=Please send me information about technology [TAB-3350] Recombinant HIV-1 Envelope Proteins and Their Use.">crainwater@mail.nih.gov</a><br> 114168811 E-240-2017-0 E-240-2017-0-US-01 RECOMBINANT HIV-1 ENVELOPE PROTEINS AND THEIR USE PRV US 62/572,973 Abandoned US <br />Provisional (PRV) 62/572,973<br />Filed on 2017-10-16<br />Status: Abandoned 114168812 E-240-2017-0 E-240-2017-0-PCT-03 RECOMBINANT HIV-1 ENVELOPE PROTEINS AND THEIR USE PCT Patent Cooperation Treaty PCT/US2018/056135 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2018/056135<br />Filed on 2018-10-16<br />Status: Expired 114169013 E-240-2017-0 E-240-2017-0-US-05 RECOMBINANT HIV-1 ENVELOPE PROTEINS AND THEIR USE National Stage US 11,136,356 16/756,777 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11136356 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11136356">11,136,356</a><br />Filed on 2020-04-16<br />Status: Issued 114151557 HIV-1 114151558 CONFORMATION 114151559 Prefusion-closed 114151560 MIMIC 114151561 IMMUNOGENS 114151562 Soluble 114151563 Design 114151564 Structure-based 114151565 viral 114151566 spike TAB-3347 114097262 Optimized Variants of the Broadly Neutralizing HIV-1 gp41 Antibody, 10E8 NIAID Licensing Licensing Mangaiarkarasi Asokan, Robert Bailer, Michael Bender, Kevin Carlton, Gwo-Yu Chuang, Mark Connors, Jonathan Cooper, Ivelin Georgiev, Tatyana Gindin, Lisa Kueltzo, Young Do Kwon, Peter Kwong, Mark Louder, John Mascola, Krisha McKee, Sijy O'Dell, Gilad Ofek, Amarendra ("Amar") Pegu, Richard Schwartz, Lawrence Shapiro, Baoshan Zhang Scientists at the National Institute of Allergy and Infectious Diseases (NIAID) recently discovered a human neutralizing antibody, 10E8, that binds to the GP41 protein of HIV-1 and prevents infection by HIV-1. 10E8 potently neutralizes up to 98% of genetically diverse HIV-1 strains.<br /><br /> By engineering the 10E8 antibody, NIAID scientists have improved the properties of 10E8 that affect manufacturability, such as solubility, while preserving its neutralizing breadth and potency.<br /><br /> 10E8 variants are useful for passive protection from infection, as therapeutics, and as a tool for vaccine development.<br /><br /> This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR Part 404. <ul> <li>Among the most potent and broadly neutralizing human antibodies isolated to date</li> <li>Broad reactivity and high affinity to most HIV-1 strains</li> <li>Improved manufacturability relative to the natural 10E8 antibody</li> </ul> <ul> <li>Passive protection to prevent HIV infection</li> <li>Passive protection to prevent mother-to-infant HIV transmission</li> <li>Gene-based vectors for anti-gp41 antibody expression</li> <li>Therapeutics for elimination of HIV infected cells that are actively producing virus</li> </ul> 2022-07-27 2025-08-13 2025-08-15 2018-11-19 1, 10e8, 4, 5, ANTIBODY, Listed LPM Thalhammer-Reyero as of 4/15/2015, OE8, OPTIMIZED, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Their, VARIANTS False True True NIHTT 37470483 Website Abstract E-253-2011-0 114172548 Kwon YD, et al. https://www.ncbi.nlm.nih.gov/pubmed/27053554 <a href="https://www.ncbi.nlm.nih.gov/pubmed/27053554">Kwon YD, et al.</a> 114109978 Georgiev, Ivelin NIAID - VRC NIAID Georgiev, Ivelin (NIAID) 0 114109979 Kwon, Young Do NIAID - VRC NIAID Kwon, Young Do (NIAID) 0 114109981 Ofek, Gilad NIAID - VRC NIAID Ofek, Gilad (NIAID) 0 114109982 Zhang, Baoshan NIAID - VRC NIAID Zhang, Baoshan (NIAID) 0 114109983 McKee, Krisha NIAID - VRC NIAID McKee, Krisha (NIAID) 0 114109984 Mascola, John NIAID - VRC NIAID Mascola, John (NIAID) 0 114109985 Chuang, Gwo-Yu NIAID - DIR NIAID Chuang, Gwo-Yu (NIAID) 0 114109986 O'Dell, Sijy NIAID - VRC NIAID O'Dell, Sijy (NIAID) 0 114109987 Bailer, Robert NIAID - VRC NIAID Bailer, Robert (NIAID) 0 114109988 Louder, Mark NIAID - DIR NIAID Louder, Mark (NIAID) 0 114109989 Asokan, Mangaiarkarasi NIAID - VRC Asokan, Mangaiarkarasi 0 114109990 Cooper, Jonathan NIAID - VRC Cooper, Jonathan 0 114109991 Carlton, Kevin NIAID - VRC NIAID Carlton, Kevin (NIAID) 0 114109992 Bender, Michael NIAID - VRC NIAID Bender, Michael (NIAID) 0 114109993 Connors, Mark NIAID - DIR NIAID Connors, Mark (NIAID) 0 114109994 Pegu, Amarendra ("Amar") NIAID - VRC NIAID Pegu, Amarendra ("Amar") (NIAID) 0 114109995 Kueltzo, Lisa NIAID - VRC NIAID Kueltzo, Lisa (NIAID) 0 114109996 Shapiro, Lawrence Columbia University Shapiro, Lawrence 0 114109997 Gindin, Tatyana Columbia University Gindin, Tatyana 0 114109998 Schwartz, Richard NIAID - VRC NIAID Schwartz, Richard (NIAID) 0 114109980 Kwong, Peter NIAID - VRC NIAID Kwong, Peter (NIAID) 1 114109980 Kwong, Peter NIAID - VRC NIAID Kwong, Peter (NIAID) 1 114109978 Georgiev, Ivelin NIAID - VRC NIAID Georgiev, Ivelin (NIAID) 0 114109979 Kwon, Young Do NIAID - VRC NIAID Kwon, Young Do (NIAID) 0 114109981 Ofek, Gilad NIAID - VRC NIAID Ofek, Gilad (NIAID) 0 114109982 Zhang, Baoshan NIAID - VRC NIAID Zhang, Baoshan (NIAID) 0 114109983 McKee, Krisha NIAID - VRC NIAID McKee, Krisha (NIAID) 0 114109984 Mascola, John NIAID - VRC NIAID Mascola, John (NIAID) 0 114109985 Chuang, Gwo-Yu NIAID - DIR NIAID Chuang, Gwo-Yu (NIAID) 0 114109986 O'Dell, Sijy NIAID - VRC NIAID O'Dell, Sijy (NIAID) 0 114109987 Bailer, Robert NIAID - VRC NIAID Bailer, Robert (NIAID) 0 114109988 Louder, Mark NIAID - DIR NIAID Louder, Mark (NIAID) 0 114109989 Asokan, Mangaiarkarasi NIAID - VRC Asokan, Mangaiarkarasi 0 114109990 Cooper, Jonathan NIAID - VRC Cooper, Jonathan 0 114109991 Carlton, Kevin NIAID - VRC NIAID Carlton, Kevin (NIAID) 0 114109992 Bender, Michael NIAID - VRC NIAID Bender, Michael (NIAID) 0 114109993 Connors, Mark NIAID - DIR NIAID Connors, Mark (NIAID) 0 114109994 Pegu, Amarendra ("Amar") NIAID - VRC NIAID Pegu, Amarendra ("Amar") (NIAID) 0 114109995 Kueltzo, Lisa NIAID - VRC NIAID Kueltzo, Lisa (NIAID) 0 114109996 Shapiro, Lawrence Columbia University Shapiro, Lawrence 0 114109997 Gindin, Tatyana Columbia University Gindin, Tatyana 0 114109998 Schwartz, Richard NIAID - VRC NIAID Schwartz, Richard (NIAID) 0 114102507 Optimized Variants Of Antibody 10E8 And Their Use (variants 1, 4, 5) E-133-2015-0 Filing authorized Columbia University, Columbia University, NIAID 91025211 Rainwater, Charles crainwater@mail.nih.gov
United States of America crainwater@mail.nih.gov?subject=Web Inquiry on [TAB-3347] Optimized Variants of the Broadly Neutralizing HIV-1 gp41 Antibody, 10E8&body=Please send me information about technology [TAB-3347] Optimized Variants of the Broadly Neutralizing HIV-1 gp41 Antibody, 10E8. Rainwater, Charles<br><a href="mailto:crainwater@mail.nih.gov?subject=Web Inquiry on [TAB-3347] Optimized Variants of the Broadly Neutralizing HIV-1 gp41 Antibody, 10E8&body=Please send me information about technology [TAB-3347] Optimized Variants of the Broadly Neutralizing HIV-1 gp41 Antibody, 10E8.">crainwater@mail.nih.gov</a><br> 114168799 E-133-2015-0 E-133-2015-0-US-01 Neutralizing Antibodies to HIV-1 GP41 and Thier Use PRV US 62/250,360 Abandoned US <br />Provisional (PRV) 62/250,360<br />Filed on 2015-11-03<br />Status: Abandoned 114168800 E-133-2015-0 E-133-2015-0-PCT-02 NEUTRALIZING ANTIBODIES TO HIV-1 GP41 AND THEIR USE PCT Patent Cooperation Treaty PCT/US2016/060390 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2016/060390<br />Filed on 2016-11-03<br />Status: Expired 114168801 E-133-2015-0 E-133-2015-0-US-07 NEUTRALIZING ANTIBODIES TO HIV-1 GP41 AND THEIR USE National Stage US 11,236,152 15/772,443 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11236152 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11236152">11,236,152</a><br />Filed on 2018-04-30<br />Status: Issued 114168802 E-133-2015-0 E-133-2015-0-CA-03 NEUTRALIZING ANTIBODIES TO HIV-1 GP41 AND THEIR USE National Stage Canada 3003878 Pending Canada <br />National Stage 3003878<br />Filed on 2016-11-03<br />Status: Pending 114168803 E-133-2015-0 E-133-2015-0-CN-04 NEUTRALIZING ANTIBODIES TO HIV-1 GP41 AND THEIR USE National Stage China ZL201680077520.X 201680077520.X Issued China <br />National Stage 201680077520.X<br />Filed on 2016-11-03<br />Status: Issued 114168804 E-133-2015-0 E-133-2015-0-EP-05 NEUTRALIZING ANTIBODIES TO HIV-1 GP41 AND THEIR USE National Stage European Patent 16801639.2 Abandoned European Patent <br />National Stage 16801639.2<br />Filed on 2016-11-03<br />Status: Abandoned 114168805 E-133-2015-0 E-133-2015-0-IN-06 NEUTRALIZING ANTIBODIES TO HIV 1 GP41 AND THEIR USE National Stage India 452881 201837016184 Issued India <br />National Stage 201837016184<br />Filed on 2018-04-30<br />Status: Issued 114168806 E-133-2015-0 E-133-2015-0-ZA-08 NEUTRALIZING ANTIBODIES TO HIV-1 GP41 AND THEIR USE National Stage South Africa 2018/02875 Pending South Africa <br />National Stage 2018/02875<br />Filed on 2016-11-03<br />Status: Pending 114168807 E-133-2015-0 E-133-2015-0-AU-09 NEUTRALIZING ANTIBODIES TO HIV-1 GP41 AND THEIR USE National Stage Australia 2016349392 2016349392 Issued Australia <br />National Stage 2016349392<br />Filed on 2016-11-03<br />Status: Issued 114169180 E-133-2015-0 E-133-2015-0-US-11 NEUTRALIZING ANTIBODIES TO HIV-1 GP41 AND THEIR USE CON US 12,043,660 17/551,066 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12043660 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12043660">12,043,660</a><br />Filed on 2021-12-14<br />Status: Issued 114151545 OPTIMIZED 114151546 VARIANTS 114151547 ANTIBODY 114151548 1 114151549 OE8 114151550 Their 114151551 4 114151552 5 114151553 10e8 114151554 Listed LPM Thalhammer-Reyero as of 4/15/2015 114151555 Pre LPM working set 20150418 114151556 Post LPM Assignment Set 20150420 TAB-3346 114097261 Universal Influenza Virus Probes for Enrichment of Influenza Viral Sequences NIAID Collaboration, Consumer Products, Diagnostics, Infectious Disease, Occupational Safety and Health, Research Materials, Therapeutics Collaboration Consumer Products Diagnostics Infectious Disease Occupational Safety and Health Research Materials Therapeutics Zong-Mei Sheng, Jeffery Taubenberger, Yongli Xiao This technology is a set of influenza virus enrichment probes developed to increase the sensitivity of sequence-based, universal detection of all influenza viruses. This universal influenza enrichment probe set contains a unique set of 46,953 biotin-labeled, RNA probes, each 120 base-pairs long, that can be used to enrich for any influenza sequences without prior knowledge of type or subtype. This probe set can capture and enrich influenza viral sequences selectively and effectively in a variety of samples, such as clinical samples with degraded nucleotides or samples containing very low amounts of influenza virus, thus making it a valuable tool for influenza virus diagnoses and surveillance.<br /><br /> This technology is available for licensing for commercial development in accordance with 35 U.S.C. § 209 and 37 CFR Part 404, as well as for further development and evaluation under a research collaboration. <ul> <li>Highly sensitive detection of influenza viruses</li> <li>Detection of any influenza viruses in a variety of samples</li> </ul> <ul> <li>Influenza diagnostics; influenza surveillance</li> </ul> The National Institute of Allergy and Infectious Diseases (NIAID) is also seeking statements of capability or interest from parties interested in collaborative research, such as from bio-analytic research groups to develop rapid influenza monitoring, diagnostic, and surveillance devices and biotechnology companies to formulate and test influenza next generation sequencing kits for challenging influenza infected samples, for example zoonotic infections of influenza A virus subtypes differing from currently circulating human influenza viruses or in mixed infections. NIAID will consider executing a Confidentiality Agreement with a prospective collaborator to facilitate receipt of a Capability Statement if requested. For collaboration opportunities, please contact Dr. Elizabeth Pitts at <a href="mailto: elizabeth.pitts@nih.gov">elizabeth.pitts@nih.gov</a> or 240-669-5299. 2022-03-08 2025-08-13 2025-08-15 2020-07-06 DA4BXX, ENRICHMENT, INFLUENZA, Probes, Sequences, UNIVERSAL, viral, virus, VLXXXX, WBXXXX, WCXXXX, WFXXXX, WIXXXX, XEXXXX, YBXXXX, YCXXXX False True True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114172547 Xiao Y, et al. https://www.ncbi.nlm.nih.gov/pubmed/30212665 <a href="https://www.ncbi.nlm.nih.gov/pubmed/30212665">Xiao Y, et al.</a> 114109976 Taubenberger, Jeffery NIAID - DIR NIAID Taubenberger, Jeffery (NIAID) 0 114109977 Sheng, Zong-Mei NIAID - DIR NIAID Sheng, Zong-Mei (NIAID) 0 114109975 Xiao, Yongli NIAID - DIR NIAID Xiao, Yongli (NIAID) 1 114109975 Xiao, Yongli NIAID - DIR NIAID Xiao, Yongli (NIAID) 1 114109976 Taubenberger, Jeffery NIAID - DIR NIAID Taubenberger, Jeffery (NIAID) 0 114109977 Sheng, Zong-Mei NIAID - DIR NIAID Sheng, Zong-Mei (NIAID) 0 114102506 Universal Influenza Virus Probes For Enrichment Of Influenza Viral Sequences E-032-2018-0 Filing authorized NIAID 91027763 Puglielli, Maryann maryann.puglielli@nih.gov
United States of America maryann.puglielli@nih.gov?subject=Web Inquiry on [TAB-3346] Universal Influenza Virus Probes for Enrichment of Influenza Viral Sequences&body=Please send me information about technology [TAB-3346] Universal Influenza Virus Probes for Enrichment of Influenza Viral Sequences. Puglielli, Maryann<br><a href="mailto:maryann.puglielli@nih.gov?subject=Web Inquiry on [TAB-3346] Universal Influenza Virus Probes for Enrichment of Influenza Viral Sequences&body=Please send me information about technology [TAB-3346] Universal Influenza Virus Probes for Enrichment of Influenza Viral Sequences.">maryann.puglielli@nih.gov</a><br> 114168797 E-032-2018-0 E-032-2018-0-US-01 UNIVERSAL INFLUENZA VIRUS PROBE SET FOR ENRICHMENT OF ANY INFLUENZA VIRUS NUCLEIC ACID PRV US 62/611,734 Abandoned US <br />Provisional (PRV) 62/611,734<br />Filed on 2017-12-29<br />Status: Abandoned 114168823 E-032-2018-0 E-032-2018-0-PCT-02 Universal Influenza Virus Probes For Enrichment Of Influenza Viral Sequences PCT Patent Cooperation Treaty PCT/US2018/067713 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2018/067713<br />Filed on 2018-12-27<br />Status: Expired 114128219 WIXXXX 114128220 WFXXXX 114128221 WCXXXX 114128222 WBXXXX 114128223 XEXXXX 114128224 YBXXXX 114128225 YCXXXX 114128226 VLXXXX 114128227 DA4BXX 114151538 UNIVERSAL 114151539 INFLUENZA 114151540 virus 114151541 Probes 114151542 ENRICHMENT 114151543 viral 114151544 Sequences TAB-3344 114097259 Middle East Respiratory Syndrome Coronavirus Antibodies NIAID Collaboration, Infectious Disease, Therapeutics, Vaccines Collaboration Infectious Disease Therapeutics Vaccines Barney Graham, Michael Joyce, Wing-pui Kong, Wei Shi, Lingshu Wang Middle East Respiratory Syndrome coronavirus (MERS-CoV) causes a highly lethal pulmonary infection with ~35% mortality. Currently there are no prophylactic measures or effective therapies. Inventors at the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases have identified and developed neutralizing monoclonal antibodies (nMAbs) against the MERS-CoV. This invention describes antibodies that target the Spike (S) glycoprotein on the coronavirus surface, which mediates viral entry into host cells. These novel antibodies target different regions of the S protein, and when administered in combination, reduce the possibility of viral escape. In preclinical testing, these nMAbs have demonstrated potent protective effects, preventing death, viral replication in the lower airways and severe disease in challenge studies with mice. In addition, these nMAbs have potential application for use in assays for detecting MERS-CoV S protein in infected patients or animals.<br /><br /> This technology is available for licensing for commercial development in accordance with 35 U.S.C. § 209 and 37 CFR Part 404, as well as for further development and evaluation under a research collaboration. <ul> <li>In vitro models, the combinations of antibodies have been demonstrated to be effective in reducing viral escape.</li> <li>In vivo data in animal models demonstrated a potent ability to control infection.</li> <li>Applicable in diagnostic assays</li> </ul> <ul> <li>Monoclonal antibodies developed against multiple regions of the coronavirus spike protein have potential application in the prevention and treatment of MERS-CoV. There is also potential application for their use as a diagnostic tool of infection.</li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize MERS-CoV monoclonal antibodies. For collaboration opportunities, please contact Amy Petrik, Ph.D., 240-627-3721; <a href="mailto:amy.petrik@nih.gov">amy.petrik@nih.gov</a>. 2022-03-08 2025-08-13 2025-08-15 2020-06-24 Against, antibodies, Candidate, CORONAVIRUS, DB4BXX, DC5BXX, East, Listed LPM Thalhammer-Reyero as of 4/15/2015, MERS-CoV, Middle, monoclonal, Novel, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, respiratory, Syndrome, Vaccine, vaccines False True True NIHTT 37470483 Website Abstract 114109967 Shi, Wei NIAID - VRC NIAID Shi, Wei (NIAID) 0 114109968 Kong, Wing-pui NIAID - VRC NIAID Kong, Wing-pui (NIAID) 0 114109969 Joyce, Michael NIAID - VRC NIAID Joyce, Michael (NIAID) 0 114109970 Wang, Lingshu NIAID - VRC NIAID Wang, Lingshu (NIAID) 0 114109966 Graham, Barney NIAID - VRC NIAID Graham, Barney (NIAID) 1 114109966 Graham, Barney NIAID - VRC NIAID Graham, Barney (NIAID) 1 114109967 Shi, Wei NIAID - VRC NIAID Shi, Wei (NIAID) 0 114109968 Kong, Wing-pui NIAID - VRC NIAID Kong, Wing-pui (NIAID) 0 114109969 Joyce, Michael NIAID - VRC NIAID Joyce, Michael (NIAID) 0 114109970 Wang, Lingshu NIAID - VRC NIAID Wang, Lingshu (NIAID) 0 114102502 Novel Vaccines And Monoclonal Antibodies Against Middle East Respiratory Syndrome Coronavirus (MERS-CoV) E-239-2014-0 Filing authorized NIAID 83682222 Bailey, Brian bbailey@mail.nih.gov
United States of America TTIPO bbailey@mail.nih.gov?subject=Web Inquiry on [TAB-3344] Middle East Respiratory Syndrome Coronavirus Antibodies&body=Please send me information about technology [TAB-3344] Middle East Respiratory Syndrome Coronavirus Antibodies. Bailey, Brian<br><a href="mailto:bbailey@mail.nih.gov?subject=Web Inquiry on [TAB-3344] Middle East Respiratory Syndrome Coronavirus Antibodies&body=Please send me information about technology [TAB-3344] Middle East Respiratory Syndrome Coronavirus Antibodies.">bbailey@mail.nih.gov</a><br> 114168785 E-239-2014-0 E-239-2014-0-US-01 MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS IMMUNOGENS, ANTIBODIES, AND THEIR USE PRV US 62/120,353 Abandoned US <br />Provisional (PRV) 62/120,353<br />Filed on 2015-02-24<br />Status: Abandoned 114168786 E-239-2014-0 E-239-2014-0-PCT-02 MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS IMMUNOGENS, ANTIBODIES, AND THEIR USE PCT Patent Cooperation Treaty PCT/US2016/019395 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2016/019395<br />Filed on 2016-02-24<br />Status: Expired 114168787 E-239-2014-0 E-239-2014-0-US-06 MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS IMMUNOGENS, ANTIBODIES, AND THEIR USE National Stage US 10,301,377 15/553,466 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10301377 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10301377">10,301,377</a><br />Filed on 2017-08-24<br />Status: Issued 114168788 E-239-2014-0 E-239-2014-0-EP-03 MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS IMMUNOGENS, ANTIBODIES, AND THEIR USE National Stage European Patent 16711059.2 Abandoned European Patent <br />National Stage 16711059.2<br />Filed on 2016-02-24<br />Status: Abandoned 114168789 E-239-2014-0 E-239-2014-0-KR-04 MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS IMMUNOGENS, ANTIBODIES, AND THEIR USE National Stage South Korea 10-2017-7027105 Abandoned South Korea <br />National Stage 10-2017-7027105<br />Filed on 2017-09-25<br />Status: Abandoned 114168790 E-239-2014-0 E-239-2014-0-SA-05 MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS IMMUNOGENS, ANTIBODIES, AND THEIR USE National Stage Saudi Arabia 517382168 Abandoned Saudi Arabia <br />National Stage 517382168<br />Filed on 2017-08-21<br />Status: Abandoned 114168878 E-239-2014-0 E-239-2014-0-US-07 MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS IMMUNOGENS, ANTIBODIES, AND THEIR USE DIV US 10,759,846 16/403,211 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10759846 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10759846">10,759,846</a><br />Filed on 2019-05-03<br />Status: Issued 114128217 DC5BXX 114128218 DB4BXX 114151506 MERS-CoV 114151507 Vaccine 114151508 Candidate 114151509 Novel 114151510 vaccines 114151511 monoclonal 114151512 antibodies 114151513 Against 114151514 Middle 114151515 East 114151516 respiratory 114151517 Syndrome 114151518 CORONAVIRUS 114151519 Listed LPM Thalhammer-Reyero as of 4/15/2015 114151520 Pre LPM working set 20150418 114151521 Post LPM Assignment Set 20150420 TAB-3341 114097256 Recombinant Respiratory Syncytial Virus Challenge Strain NIAID Collaboration, Diagnostics, Infectious Disease, Research Materials, Vaccines Collaboration Diagnostics Infectious Disease Research Materials Vaccines Ursula Buchholz, Peter Collins RSV is the most important viral agent of severe respiratory tract disease worldwide, especially in infants and young children, and it also causes severe disease in the elderly and in immunocompromised individuals. There are no licensed vaccines or antivirals suitable for routine use.<br /><br /> This invention relates to a reverse genetics system and cDNA-derived virus for a contemporary wild-type clinical isolate of RSV of antigenic subgroup A, termed RSV strain A/Maryland/001/11, that was isolated in 2011 from an adult with respiratory illness. The genomic sequence was determined. A reverse genetics system was created encoding a recombinant, replication competent RSV that contains a codon-optimized G ORF, which was done to stabilize the cDNA for replication in bacteria. Because this virus was generated by reverse genetics, it is a “clean” virus with a well-defined passage history. Clinical study material of this challenge virus has been manufactured and is available for use as an U.S. Food and Drug Administration (FDA) regulated Investigational New Drug (IND) in clinical studies in adult volunteers within and outside of the United States. Preliminary clinical data confirmed that this virus efficiently infects and replicates in 95% of study participants pre-selected for pre-existing RSV antibody titers in the bottom 50% of the range. The challenge virus causes mild upper respiratory illness in the majority of infected participants, typical for RSV illness in otherwise healthy adults. This provides a suitable challenge system for evaluating antivirals, as well as vaccines for older children and adults. This also could be used for developing live-attenuated RSV vaccine candidates based on this contemporary strain, using the stabilized point mutations, stabilized codon-deletions, and gene-deletions that were previously used in RSV strain A2.<br /><br /> This invention relates to a reverse genetics system and the encoded RSV vaccine challenge strain that infects and causes disease in RSV-experienced adults and is available for antiviral and vaccine research.<br /><br /> This technology is available for licensing for commercial development in accordance with 35 U.S.C. § 209 and 37 CFR Part 404, as well as for further development and evaluation under a research collaboration. <ul> <li>Ease of manufacture</li> <li>Clinical trial material</li> <li>Low-cost vaccines</li> <li>Intranasal administration/needle-free delivery</li> </ul> <ul> <li>Vaccine development</li> <li>Viral diagnostics</li> <li>Vaccine research</li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize for development of a vaccine for respiratory or other infections. For collaboration opportunities, please contact Peter Soukas, J.D., at <a href="mailto:Peter.Soukas@nih.gov">Peter.Soukas@nih.gov</a> or 301-594-8730. 2022-03-08 2025-08-13 2025-08-15 2018-10-25 A/Maryland/001/11, DA4BXX, DAXXXX, DC5BXX, DC5XXX, DC6XXX, DCXXXX, DD1XXX, DDXXXX, DXXXXX, recombinant, respiratory, RRSU, RRSV, Syncytial, virus, WILD-TYPE False True True NIHTT 37470483 Website Abstract 114109953 Collins, Peter NIAID - DIR NIAID Collins, Peter (NIAID) 0 114109952 Buchholz, Ursula NIAID - DIR NIAID Buchholz, Ursula (NIAID) 1 114109952 Buchholz, Ursula NIAID - DIR NIAID Buchholz, Ursula (NIAID) 1 114109953 Collins, Peter NIAID - DIR NIAID Collins, Peter (NIAID) 0 114102499 Recombinant Wild-type Respiratory Syncytial Virus RRSV A/Maryland/001/11 E-235-2018-0 Research Material NIAID 91021353 Pitts, Elizabeth elizabeth.pitts@nih.gov
United States of America elizabeth.pitts@nih.gov?subject=Web Inquiry on [TAB-3341] Recombinant Respiratory Syncytial Virus Challenge Strain&body=Please send me information about technology [TAB-3341] Recombinant Respiratory Syncytial Virus Challenge Strain. Pitts, Elizabeth<br><a href="mailto:elizabeth.pitts@nih.gov?subject=Web Inquiry on [TAB-3341] Recombinant Respiratory Syncytial Virus Challenge Strain&body=Please send me information about technology [TAB-3341] Recombinant Respiratory Syncytial Virus Challenge Strain.">elizabeth.pitts@nih.gov</a><br> 114128207 DXXXXX 114128208 DCXXXX 114128209 DC5XXX 114128210 DC6XXX 114128211 DC5BXX 114128212 DDXXXX 114128213 DD1XXX 114128214 DAXXXX 114128215 DA4BXX 114151481 recombinant 114151482 WILD-TYPE 114151483 respiratory 114151484 Syncytial 114151485 virus 114151486 RRSU 114151487 A/Maryland/001/11 114151488 RRSV TAB-3339 114097254 Hybridoma cell lines producing antibodies to RSV NS1 NIAID Collaboration, Diagnostics, Infectious Disease, Research Materials, Vaccines Collaboration Diagnostics Infectious Disease Research Materials Vaccines Peter Collins, Joseph Marcotrigiano, Thomas McCarty This technology provides a new set of hybridoma cell lines each expressing a single monoclonal antibody against human respiratory syncytial virus (RSV) nonstructural protein 1 (NS1). These antibodies have variously been shown to detect NS1 protein in an enzyme-linked immunosorbent assay (ELISA), Western blot assay, immunofluorescence microscopy of paraformaldehyde-fixed cells, and flow cytometry. The various antibodies can vary in their efficiency in each of these assays. This technology provides a unique set of qualified monoclonal antibodies against RSV NS1 protein which currently do not exist. These antibodies and cell lines may be of interest to any persons investigating RSV infection processes, particularly as it relates to the activity of NS1 in such an infection process.<br /><br /> This technology is available for licensing for commercial development in accordance with 35 U.S.C. § 209 and 37 CFR Part 404, as well as for further development and evaluation under a research collaboration. <ul> <li>Ease of manufacture</li> <li>Unique research tool</li> </ul> <ul> <li>Viral diagnostics</li> <li>Vaccine research</li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize for development of a vaccine for respiratory or other infections. For collaboration opportunities, please contact Peter Soukas, J.D., at <a href="mailto:Peter.Soukas@nih.gov">Peter.Soukas@nih.gov</a> or 301-594-8730. 2022-03-08 2025-08-13 2025-08-15 2021-01-25 Against, antibodies, Cell, DA4BXX, DA4XXX, DAXXXX, DCXXXX, DD1XXX, DDXXXX, DEXXXX, DXXXXX, Hybridoma, Imonoclonal, Lines, NS1, Producing, RSV False True True NIHTT 37470483 Website Abstract 114109947 Collins, Peter NIAID - DIR NIAID Collins, Peter (NIAID) 0 114109948 Marcotrigiano, Joseph NIAID - DIR NIAID Marcotrigiano, Joseph (NIAID) 0 114109946 McCarty, Thomas NIAID - DIR NIAID McCarty, Thomas (NIAID) 1 114109946 McCarty, Thomas NIAID - DIR NIAID McCarty, Thomas (NIAID) 1 114109947 Collins, Peter NIAID - DIR NIAID Collins, Peter (NIAID) 0 114109948 Marcotrigiano, Joseph NIAID - DIR NIAID Marcotrigiano, Joseph (NIAID) 0 114102497 Hybridoma Cell Lines Producing Antibodies To RSV NS1 And The Imonoclonal Antibodies Against RSV NS1 E-167-2018-0 Research Material NIAID 91021353 Pitts, Elizabeth elizabeth.pitts@nih.gov
United States of America elizabeth.pitts@nih.gov?subject=Web Inquiry on [TAB-3339] Hybridoma cell lines producing antibodies to RSV NS1&body=Please send me information about technology [TAB-3339] Hybridoma cell lines producing antibodies to RSV NS1. Pitts, Elizabeth<br><a href="mailto:elizabeth.pitts@nih.gov?subject=Web Inquiry on [TAB-3339] Hybridoma cell lines producing antibodies to RSV NS1&body=Please send me information about technology [TAB-3339] Hybridoma cell lines producing antibodies to RSV NS1.">elizabeth.pitts@nih.gov</a><br> 114128192 DXXXXX 114128193 DDXXXX 114128194 DD1XXX 114128195 DCXXXX 114128196 DEXXXX 114128197 DAXXXX 114128198 DA4XXX 114128199 DA4BXX 114151463 Hybridoma 114151464 Cell 114151465 Lines 114151466 Producing 114151467 antibodies 114151468 RSV 114151469 NS1 114151470 Imonoclonal 114151471 Against TAB-3338 114097253 Recombinant HIV-1 Envelope Protein for Vaccine Use NIAID Collaboration Collaboration Priyamvada Acharya, Ulrich Baxa, Rita Chen, Cheng Cheng, Gwo-Yu Chuang, Aliaksandr Druz, Ivelin Georgiev, Jason Gorman, Michael Joyce, Peter Kwong, Rebecca Lynch, John Mascola, Marie Pancera, Guillaume Stewart-Jones, Yongping Yang, Baoshan Zhang, Tongqing Zhou In pursuit of an effective vaccine to end the global HIV-1/AIDS pandemic, researchers at the Vaccine Research Center (“VRC”) continue to study the structure of HIV-1. Recently, these researchers have determined the three-dimensional structure of the HIV-1 Envelope trimeric ectodomain (“Env”), comprised of three gp120 and three gp41 subunits, in its prefusion, mature, closed conformation.<br /><br /> The researchers hypothesize that immunization with the prefusion, closed HIV-1 Env protein will elicit a neutralizing immune response. The VRC researchers engineered a portion of the HIV-1 Env trimer to stabilize it in this closed conformation for use as an immunogen.<br /><br /> This technology is available for licensing for commercial development in accordance with 35 U.S.C. § 209 and 37 CFR Part 404, as well as for further development and evaluation under a research collaboration. <ul> <li>Currently, no licensed HIV-1 vaccine exists.</li> </ul> </li> <ul> <li>Vaccine for prevention of HIV-1 infection.</li> <li>Therapeutic vaccine for treatment of HIV-1 infection.</li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize HIV-1 immunogens for treating or preventing HIV-1 infection. For collaboration opportunities, please contact Dr. Barry Buchbinder, 240-627-3674; <a href="mailto:barry.buchbinder@nih.gov">barry.buchbinder@nih.gov</a>. 2022-10-11 2025-08-13 2025-08-15 2018-10-18 ANTIGENS, Bi-component, chimeric, ChimericHfV-1, Closed, Co-assembled, CONFORMATION, Design, DISPLAY, DIVERSE, gp120, gp41, Ground, HfV-1, HIV-1, Immunociens, IMMUNOGENS, Listed LPM Thalhammer-Reyero as of 4/15/2015, MIMIC, Nanoparticles, Orefusion, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Prefusion, SELF-ASSEMBLING, Soluble, spike, Stabilized, STATE, Structure-based, That, Trimeric, viral False True True NIHTT 37470483 Website Abstract 114172545 Pancera M, et al. https://www.ncbi.nlm.nih.gov/pubmed/25296255 <a href="https://www.ncbi.nlm.nih.gov/pubmed/25296255">Pancera M, et al.</a> 114109930 Pancera, Marie NIAID - VRC NIAID Pancera, Marie (NIAID) 0 114109931 Zhou, Tongqing NIAID - VRC NIAID Zhou, Tongqing (NIAID) 0 114109932 Georgiev, Ivelin NIAID - VRC NIAID Georgiev, Ivelin (NIAID) 0 114109933 Joyce, Michael NIAID - VRC NIAID Joyce, Michael (NIAID) 0 114109934 Acharya, Priyamvada NIAID - DIR NIAID Acharya, Priyamvada (NIAID) 0 114109935 Gorman, Jason NIAID - VRC NIAID Gorman, Jason (NIAID) 0 114109936 Yang, Yongping NIAID - VRC NIAID Yang, Yongping (NIAID) 0 114109937 Druz, Aliaksandr NIAID - DIR NIAID Druz, Aliaksandr (NIAID) 0 114109938 Stewart-Jones, Guillaume NIAID - VRC NIAID Stewart-Jones, Guillaume (NIAID) 0 114109939 Chen, Rita NIAID - VRC Chen, Rita 0 114109940 Chuang, Gwo-Yu NIAID - DIR NIAID Chuang, Gwo-Yu (NIAID) 0 114109941 Baxa, Ulrich NIAID - VRC NIDDK Baxa, Ulrich (NIDDK) 0 114109942 Mascola, John NIAID - VRC NIAID Mascola, John (NIAID) 0 114109943 Lynch, Rebecca NIAID - VRC Lynch, Rebecca 0 114109944 Zhang, Baoshan NIAID - VRC NIAID Zhang, Baoshan (NIAID) 0 114109945 Cheng, Cheng NIAID - VRC NIAID Cheng, Cheng (NIAID) 0 114109929 Kwong, Peter NIAID - VRC NIAID Kwong, Peter (NIAID) 1 114109929 Kwong, Peter NIAID - VRC NIAID Kwong, Peter (NIAID) 1 114109930 Pancera, Marie NIAID - VRC NIAID Pancera, Marie (NIAID) 0 114109931 Zhou, Tongqing NIAID - VRC NIAID Zhou, Tongqing (NIAID) 0 114109932 Georgiev, Ivelin NIAID - VRC NIAID Georgiev, Ivelin (NIAID) 0 114109933 Joyce, Michael NIAID - VRC NIAID Joyce, Michael (NIAID) 0 114109934 Acharya, Priyamvada NIAID - DIR NIAID Acharya, Priyamvada (NIAID) 0 114109935 Gorman, Jason NIAID - VRC NIAID Gorman, Jason (NIAID) 0 114109936 Yang, Yongping NIAID - VRC NIAID Yang, Yongping (NIAID) 0 114109937 Druz, Aliaksandr NIAID - DIR NIAID Druz, Aliaksandr (NIAID) 0 114109938 Stewart-Jones, Guillaume NIAID - VRC NIAID Stewart-Jones, Guillaume (NIAID) 0 114109939 Chen, Rita NIAID - VRC Chen, Rita 0 114109940 Chuang, Gwo-Yu NIAID - DIR NIAID Chuang, Gwo-Yu (NIAID) 0 114109941 Baxa, Ulrich NIAID - VRC NIDDK Baxa, Ulrich (NIDDK) 0 114109942 Mascola, John NIAID - VRC NIAID Mascola, John (NIAID) 0 114109943 Lynch, Rebecca NIAID - VRC Lynch, Rebecca 0 114109944 Zhang, Baoshan NIAID - VRC NIAID Zhang, Baoshan (NIAID) 0 114109945 Cheng, Cheng NIAID - VRC NIAID Cheng, Cheng (NIAID) 0 114102494 Structure-based Design Of Soluble Immunogens That Mimic The Prefusion Ground State Of The HIV-1 Viral Spike E-178-2014-0 Filing authorized NIAID 114102495 Diverse Chimeric HIV-1 Immunogens Stabilized In The Closed Prefusion Conformation E-178-2014-1 Filing authorized NIAID 114102496 Self-Assembling Bi-component Nanoparticles For Display Of Co-assembled Trimeric Antigens E-178-2014-2 Filing authorized NIAID 91025211 Rainwater, Charles crainwater@mail.nih.gov
United States of America crainwater@mail.nih.gov?subject=Web Inquiry on [TAB-3338] Recombinant HIV-1 Envelope Protein for Vaccine Use&body=Please send me information about technology [TAB-3338] Recombinant HIV-1 Envelope Protein for Vaccine Use. Rainwater, Charles<br><a href="mailto:crainwater@mail.nih.gov?subject=Web Inquiry on [TAB-3338] Recombinant HIV-1 Envelope Protein for Vaccine Use&body=Please send me information about technology [TAB-3338] Recombinant HIV-1 Envelope Protein for Vaccine Use.">crainwater@mail.nih.gov</a><br> 114168769 E-178-2014-0 E-178-2014-0-US-01 RECOMBINANT HIV-1 ENVELOPE PROTEINS AND THEIR USE PRV US 62/046,059 Abandoned US <br />Provisional (PRV) 62/046,059<br />Filed on 2014-09-04<br />Status: Abandoned 114168770 E-178-2014-1 E-178-2014-1-US-01 RECOMBINANT HIV-1 ENVELOPE PROTEINS AND THEIR USE PRV US 62/136,480 Abandoned US <br />Provisional (PRV) 62/136,480<br />Filed on 2015-03-21<br />Status: Abandoned 114168771 E-178-2014-2 E-178-2014-2-PCT-01 RECOMBINANT HIV-1 ENVELOPE PROTEINS AND THEIR USE PCT COMB Patent Cooperation Treaty PCT/US2015/048729 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2015/048729<br />Filed on 2015-09-04<br />Status: Expired 114168772 E-178-2014-2 E-178-2014-2-US-02 RECOMBINANT HIV-1 ENVELOPE PROTEINS AND THEIR USE National Stage US 10,400,015 15/508,885 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10400015 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10400015">10,400,015</a><br />Filed on 2017-03-03<br />Status: Issued 114168910 E-178-2014-2 E-178-2014-2-US-04 Self-Assembling Bi-component Nanoparticles For Display Of Co-assembled Trimeric Antigens DIV US 11,459,360 16/557,894 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11459360 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11459360">11,459,360</a><br />Filed on 2019-08-30<br />Status: Issued 114169662 E-178-2014-2 E-178-2014-2-US-11 RECOMBINANT HIV-1 ENVELOPE PROTEINS AND THEIR USE CON US 12,145,968 17/937,719 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12145968 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12145968">12,145,968</a><br />Filed on 2022-10-03<br />Status: Issued 114151430 Structure-based 114151431 Design 114151432 Soluble 114151433 IMMUNOGENS 114151434 That 114151435 MIMIC 114151436 Prefusion 114151437 Ground 114151438 STATE 114151439 HIV-1 114151440 viral 114151441 spike 114151442 Listed LPM Thalhammer-Reyero as of 4/15/2015 114151443 Pre LPM working set 20150418 114151444 Post LPM Assignment Set 20150420 114151445 gp41 114151446 gp120 114151447 DIVERSE 114151448 ChimericHfV-1 114151449 Immunociens 114151450 Stabilized 114151451 Closed 114151452 Orefusion 114151453 CONFORMATION 114151454 chimeric 114151455 HfV-1 114151456 SELF-ASSEMBLING 114151457 Bi-component 114151458 Nanoparticles 114151459 DISPLAY 114151460 Co-assembled 114151461 Trimeric 114151462 ANTIGENS TAB-3332 114097248 HIV-1 Env Fusion Peptide Immunogens and Their Use NIAID Licensing Licensing Priyamvada Acharya, Cheng Cheng, Chang Choi, Gwo-Yu Chuang, Michael Joyce, Rui Kong, Wing-pui Kong, Peter Kwong, Kevin Liu, John Mascola, Li Ou, Kai Xu, Yongping Yang, Baoshan Zhang, Tongqing Zhou Millions of people are infected with HIV-1 worldwide, and 2.5 to 3 million new infections have been estimated to occur yearly. Although effective antiretroviral therapies are available, millions succumb to AIDS every year, especially in Sub-Saharan Africa, underscoring the need to develop measures to prevent the spread of this disease.<br /><br /> HIV-1 is an enveloped virus, which hides from humoral recognition behind a wide array of protective mechanisms. During infection, the major envelope protein of HIV-1 is cleaved by host cell proteases into two smaller versions (gp120 and gp41). Together gp120 and gp41 make up the HIV-1 Env spike, which is a target for neutralizing antibodies. It is believed that immunization with an effective immunogen based on the HIV-1 Env glycoprotein can elicit a neutralizing response, which may be protective against HIV-1 infection.<br /><br /> Researchers at the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases used knowledge from the crystal structure of an HIV-1 neutralizing antibody, VRC34.01, in complex with its epitope on the HIV-1 Env trimer, to develop novel immunogens. HIV-1 uses a fusion peptide, located at the N-terminus of the gp41 subunit, to fuse with a target cell to infect the cell. The crystal structure revealed the epitope recognized by VRC34.01 to be composed primarily of the exposed 8 residues of the fusion peptide at the N-terminus of the gp41 subunit. Researchers designed fusion peptide immunogens that were comprised of the exposed residues of the fusion peptide coupled to highly immunogenic carrier proteins to focus the immune response to this conserved site of vulnerability. The fusion peptide can be displayed on scaffold proteins and – when coupled to HIV-1 Env trimer boosts – has the potential to elicit antibodies capable of neutralizing diverse HIV-1 strains in mice, guinea pigs and rhesus macaques, and might therefore serve as the basis for an effective HIV vaccine.<br /><br /> This technology is available for licensing for commercial development in accordance with 35 U.S.C. § 209 and 37 CFR Part 404. <ul> <li>Potential to be a broadly neutralizing HIV-1 vaccine</li> </ul> <ul> <li>HIV-1 vaccine</li> </ul> <li> </ul> 2022-07-27 2025-08-13 2025-08-15 2018-10-17 Fusion, HIV-1, IMMUNOGENS, Peptide-based False True True NIHTT 37470483 Website Abstract 114172539 Kong R, et al. https://www.ncbi.nlm.nih.gov/pubmed/27174988 <a href="https://www.ncbi.nlm.nih.gov/pubmed/27174988">Kong R, et al.</a> 114172540 Xu K, et al. https://www.ncbi.nlm.nih.gov/pubmed/29867235 <a href="https://www.ncbi.nlm.nih.gov/pubmed/29867235">Xu K, et al.</a> 114109861 Zhang, Baoshan NIAID - VRC NIAID Zhang, Baoshan (NIAID) 0 114109862 Choi, Chang NIAID - VRC Choi, Chang 0 114109863 Kong, Rui NIAID - DIR NIAID Kong, Rui (NIAID) 0 114109864 Liu, Kevin NIAID - VRC NIAID Liu, Kevin (NIAID) 0 114109865 Mascola, John NIAID - VRC NIAID Mascola, John (NIAID) 0 114109866 Xu, Kai NIAID - DIR NIAID Xu, Kai (NIAID) 0 114109867 Zhou, Tongqing NIAID - VRC NIAID Zhou, Tongqing (NIAID) 0 114109868 Acharya, Priyamvada NIAID - DIR NIAID Acharya, Priyamvada (NIAID) 0 114109869 Chuang, Gwo-Yu NIAID - Technology Transfer and Intellectual Property Office Chuang, Gwo-Yu 0 114109870 Joyce, Michael NIAID - VRC NIAID Joyce, Michael (NIAID) 0 114109871 Cheng, Cheng NIAID - VRC NIAID Cheng, Cheng (NIAID) 0 114109872 Ou, Li NIAID - VRC NIAID Ou, Li (NIAID) 0 114109873 Kong, Wing-pui NIAID - VRC NIAID Kong, Wing-pui (NIAID) 0 114109874 Yang, Yongping NIAID - VRC NIAID Yang, Yongping (NIAID) 0 114109860 Kwong, Peter NIAID - VRC NIAID Kwong, Peter (NIAID) 1 114109860 Kwong, Peter NIAID - VRC NIAID Kwong, Peter (NIAID) 1 114109861 Zhang, Baoshan NIAID - VRC NIAID Zhang, Baoshan (NIAID) 0 114109862 Choi, Chang NIAID - VRC Choi, Chang 0 114109863 Kong, Rui NIAID - DIR NIAID Kong, Rui (NIAID) 0 114109864 Liu, Kevin NIAID - VRC NIAID Liu, Kevin (NIAID) 0 114109865 Mascola, John NIAID - VRC NIAID Mascola, John (NIAID) 0 114109866 Xu, Kai NIAID - DIR NIAID Xu, Kai (NIAID) 0 114109867 Zhou, Tongqing NIAID - VRC NIAID Zhou, Tongqing (NIAID) 0 114109868 Acharya, Priyamvada NIAID - DIR NIAID Acharya, Priyamvada (NIAID) 0 114109869 Chuang, Gwo-Yu NIAID - Technology Transfer and Intellectual Property Office Chuang, Gwo-Yu 0 114109870 Joyce, Michael NIAID - VRC NIAID Joyce, Michael (NIAID) 0 114109871 Cheng, Cheng NIAID - VRC NIAID Cheng, Cheng (NIAID) 0 114109872 Ou, Li NIAID - VRC NIAID Ou, Li (NIAID) 0 114109873 Kong, Wing-pui NIAID - VRC NIAID Kong, Wing-pui (NIAID) 0 114109874 Yang, Yongping NIAID - VRC NIAID Yang, Yongping (NIAID) 0 114102485 Fusion Peptide-Based HIV-1 Immunogens E-279-2016-0 Filing authorized NIAID 114102486 Fusion Peptide-Based HIV-1 Immunogens E-279-2016-1 Filing authorized NIAID 91025211 Rainwater, Charles crainwater@mail.nih.gov
United States of America crainwater@mail.nih.gov?subject=Web Inquiry on [TAB-3332] HIV-1 Env Fusion Peptide Immunogens and Their Use&body=Please send me information about technology [TAB-3332] HIV-1 Env Fusion Peptide Immunogens and Their Use. Rainwater, Charles<br><a href="mailto:crainwater@mail.nih.gov?subject=Web Inquiry on [TAB-3332] HIV-1 Env Fusion Peptide Immunogens and Their Use&body=Please send me information about technology [TAB-3332] HIV-1 Env Fusion Peptide Immunogens and Their Use.">crainwater@mail.nih.gov</a><br> 114168757 E-279-2016-0 E-279-2016-0-US-01 HIV-1 ENV FUSION PEPTIDE IMMUNOGENS AND THEIR USE PRV US 62/403,266 Abandoned US <br />Provisional (PRV) 62/403,266<br />Filed on 2016-10-03<br />Status: Abandoned 114168758 E-279-2016-1 E-279-2016-1-PCT-01 HIV-1 ENV FUSION PEPTIDE IMMUNOGENS AND THEIR USE PCT COMB Patent Cooperation Treaty PCT/US2017/054959 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2017/054959<br />Filed on 2017-10-03<br />Status: Expired 114168862 E-279-2016-1 E-279-2016-1-US-03 HIV-1 ENV FUSION PEPTIDE IMMUNOGENS AND THEIR USE National Stage US 11,602,559 16/338,964 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11602559 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11602559">11,602,559</a><br />Filed on 2019-04-02<br />Status: Issued 114151371 Fusion 114151372 Peptide-based 114151373 HIV-1 114151374 IMMUNOGENS TAB-3330 114097247 Recombinant RSV B1 expressing eGFP as a reporter gene NIAID Collaboration, Infectious Disease, Research Materials, Vaccines Collaboration Infectious Disease Research Materials Vaccines Ursula Buchholz, Peter Collins The inventors have created a reverse genetics system for RSV strain B1 of antigenic subgroup B encoding a replication-competent recombinant RSV that contains a codon-optimized G ORF and expresses enhanced green fluorescence protein (GFP). There are two antigenic subgroups of RSV, subgroups A and B, and most of the available information and reagents are for subgroup A. Immunity against either subgroup has reduced effectiveness in restricting the heterologous subgroup, suggesting that an effective RSV vaccine might need to contain both subgroups. The sequence of the wild type G gene was refractory to cloning into full-length antigenomic cDNA in E. coli, and so the inventors made and successfully used a codon optimized version. In addition, the inventors inserted an eGFP gene into the first gene position (promoter proximal). The resulting virus is replication-competent and efficiently expresses GFP in infected cells. This virus can be used as a tool to detect RSV-neutralizing antibodies to RSV subgroup B in a plaque-reduction assay. It also can be used to evaluate RSV infection in vitro and in vivo using GFP fluorescence to track infection. The antigenomic cDNA clone also provides the starting material for making live-attenuated subgroup B-specific RSV vaccine candidates containing defined mutations. These defined mutations can include ones that we previously developed for RSV subgroup A, and include stabilized point mutations, stabilized codon-deletions, and gene-deletions.<br /><br /> The present invention provides a reverse genetics system encoding strain B1 of RSV subgroup B containing a codon-optimized G ORF and encoding eGFP. This provides a tool for RSV subgroup B serology assays, for tracking RSV infection, and a starting point for making attenuated subgroup B strains for vaccine purposes.<br /><br /> This technology is available for licensing for commercial development in accordance with 35 U.S.C. § 209 and 37 CFR Part 404, as well as for further development and evaluation under a research collaboration. <ul> <li>Ease of manufacture</li> <li>Unique research tool</li> </ul> <ul> <li>Viral diagnostics</li> <li>Vaccine research</li> <li>Serology assays</li> <li>Vaccine manufacture</li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize for development of a vaccine for respiratory or other infections. For collaboration opportunities, please contact Peter Soukas, J.D., please contact Peter Soukas, J.D. at <a href="mailto:Peter.Soukas@nih.gov">Peter.Soukas@nih.gov</a> or 301-594-8730. 2022-03-08 2025-08-13 2025-08-15 2018-10-09 1, B, DC5BXX, DC5XXX, DCXXXX, DD1XXX, DDXXXX, DEXXXX, DXXXXX, E_x~ressing, EGFP, Expressing, Gene, R~V, recombinant, REPORTER False True True NIHTT 37470483 Website Abstract 114109857 Buchholz, Ursula NIAID - DIR NIAID Buchholz, Ursula (NIAID) 0 114109856 Collins, Peter NIAID - DIR NIAID Collins, Peter (NIAID) 1 114109856 Collins, Peter NIAID - DIR NIAID Collins, Peter (NIAID) 1 114109857 Buchholz, Ursula NIAID - DIR NIAID Buchholz, Ursula (NIAID) 0 114102484 Recombinant R~V B 1, Expressing EGFP As A Reporter Gene E-159-2018-0 Research Material NIAID 91021353 Pitts, Elizabeth elizabeth.pitts@nih.gov
United States of America elizabeth.pitts@nih.gov?subject=Web Inquiry on [TAB-3330] Recombinant RSV B1 expressing eGFP as a reporter gene&body=Please send me information about technology [TAB-3330] Recombinant RSV B1 expressing eGFP as a reporter gene. Pitts, Elizabeth<br><a href="mailto:elizabeth.pitts@nih.gov?subject=Web Inquiry on [TAB-3330] Recombinant RSV B1 expressing eGFP as a reporter gene&body=Please send me information about technology [TAB-3330] Recombinant RSV B1 expressing eGFP as a reporter gene.">elizabeth.pitts@nih.gov</a><br> 114128161 DXXXXX 114128162 DCXXXX 114128163 DC5XXX 114128164 DC5BXX 114128165 DDXXXX 114128166 DD1XXX 114128167 DEXXXX 114151362 recombinant 114151363 R~V 114151364 B 114151365 1 114151366 E_x~ressing 114151367 EGFP 114151368 REPORTER 114151369 Gene 114151370 Expressing TAB-3329 114097246 Attenuated Human Parainfluenza Virus Type 1 Expressing Ebola Virus Glycoprotein GP as an Intranasal Ebola Vaccine NIAID Collaboration, Diagnostics, Infectious Disease, Licensing, Research Materials, Vaccines Collaboration Diagnostics Infectious Disease Licensing Research Materials Vaccines Ursula Buchholz, Peter Collins, Matthias Lingemann, Shirin Munir Ebola virus (EBOV) hemorrhagic fever is one of the most lethal viral infections and lacks a licensed vaccine. EBOV is transmitted by contact with body fluids from infected individuals including droplets or aerosols. Aerosolized EBOV could also be exploited for intentional virus spread. Therefore, vaccines that protect against mucosal and systemic exposure are needed.<br /><br /> The NIH/NIAID has developed recombinant human parainfluenza virus type 1 (rHPIV1) bearing a stabilized attenuating mutation in the P/C gene to express the membrane-anchored form of EBOV glycoprotein GP as an intranasal (IN) EBOV vaccine. GP was codon optimized and expressed either as a full-length protein or a chimeric form in which its transmembrane and cytoplasmic tail (TMCT) domains were substituted with those of the HPIV1 F protein in an effort to increase packaging into the vector particle and enhance immunogenicity. GP was inserted either preceding the N gene (pre-N) or between the N and P genes (N-P) of rHPIV1. All vectors replicated to high titers in vitro and had stable GP expression. Viruses were attenuated and replicated at low titers in the respiratory tract of African green monkeys. Two doses of candidates expressing GP from the pre-N position elicited higher GP neutralizing serum antibody titers than the N-P viruses, and unmodified GP induced higher levels than its TMCT counterpart. Unmodified EBOV GP was packaged into the HPIV1 particle, and the TMCT modification did not increase packaging or immunogenicity. Overall, the candidate expressing full-length GP from the Pre-N position was the most immunogenic.<br /><br /> This invention relates to an attenuated and immunogenic IN vaccine candidate expected to be well tolerated in humans and is available for clinical evaluation.<br /><br /> This technology is available for licensing for commercial development in accordance with 35 U.S.C. § 209 and 37 CFR Part 404, as well as for further development and evaluation under a research collaboration. <ul> <li>Ease of manufacture</li> <li>Bivalent or Multivalent live attenuated vaccines</li> <li>B cell and T cell activation</li> <li>Low-cost vaccines</li> <li>Intranasal administration/needle-free delivery</li> </ul> <ul> <li>Viral diagnostics</li> <li>Vaccine research</li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize for development of a vaccine for respiratory or other infections. For collaboration opportunities, please contact Peter Soukas, J.D. at <a href="mailto:Peter.Soukas@nih.gov">Peter.Soukas@nih.gov</a> or 301-594-8730. 2022-03-08 2025-08-13 2025-08-15 2018-10-09 1, Attenuated, DA4BXX, DA4XXX, DAXXXX, DC5BXX, DC5XXX, DCXXXX, DDXXXX, DEXXXX, DXXXXX, Ebola, Expressing, GLYCOPROTEIN, GP, Human, Intranasal, Parainfluenza, TYPE, Vaccine, virus False True True NIHTT 37470483 Website Abstract 114172538 Lingemann M, et al. http://www.ncbi.nlm.nih.gov/pubmed/28250127 <a href="http://www.ncbi.nlm.nih.gov/pubmed/28250127">Lingemann M, et al.</a> 114109853 Lingemann, Matthias NIAID - DIADS NIAID Lingemann, Matthias (NIAID) 0 114109854 Munir, Shirin NIAID - DIR NIAID Munir, Shirin (NIAID) 0 114109855 Buchholz, Ursula NIAID - DIR NIAID Buchholz, Ursula (NIAID) 0 114109852 Collins, Peter NIAID - DIR NIAID Collins, Peter (NIAID) 1 114109852 Collins, Peter NIAID - DIR NIAID Collins, Peter (NIAID) 1 114109853 Lingemann, Matthias NIAID - DIADS NIAID Lingemann, Matthias (NIAID) 0 114109854 Munir, Shirin NIAID - DIR NIAID Munir, Shirin (NIAID) 0 114109855 Buchholz, Ursula NIAID - DIR NIAID Buchholz, Ursula (NIAID) 0 114102483 Attenuated Human Parainfluenza Virus Type 1 Expressing Ebola Virus Glycoprotein GP As An Intranasal Ebola Vaccine E-142-2018-0 Research Material NIAID 91021353 Pitts, Elizabeth elizabeth.pitts@nih.gov
United States of America elizabeth.pitts@nih.gov?subject=Web Inquiry on [TAB-3329] Attenuated Human Parainfluenza Virus Type 1 Expressing Ebola Virus Glycoprotein GP as an Intranasal Ebola Vaccine&body=Please send me information about technology [TAB-3329] Attenuated Human Parainfluenza Virus Type 1 Expressing Ebola Virus Glycoprotein GP as an Intranasal Ebola Vaccine. Pitts, Elizabeth<br><a href="mailto:elizabeth.pitts@nih.gov?subject=Web Inquiry on [TAB-3329] Attenuated Human Parainfluenza Virus Type 1 Expressing Ebola Virus Glycoprotein GP as an Intranasal Ebola Vaccine&body=Please send me information about technology [TAB-3329] Attenuated Human Parainfluenza Virus Type 1 Expressing Ebola Virus Glycoprotein GP as an Intranasal Ebola Vaccine.">elizabeth.pitts@nih.gov</a><br> 114128152 DXXXXX 114128153 DCXXXX 114128154 DC5XXX 114128155 DC5BXX 114128156 DDXXXX 114128157 DEXXXX 114128158 DAXXXX 114128159 DA4XXX 114128160 DA4BXX 114151350 Attenuated 114151351 Human 114151352 Parainfluenza 114151353 virus 114151354 TYPE 114151355 1 114151356 Expressing 114151357 Ebola 114151358 GLYCOPROTEIN 114151359 GP 114151360 Intranasal 114151361 Vaccine TAB-3323 114097243 Glycan-masked engineered outer domains of HIV-1 GP120 and Their Use NIAID Collaboration Collaboration Jeffrey Boyington, Xuejun Chen, Cheng Cheng, Hongying Duan, John Mascola The VRC01-class of potent, broadly neutralizing antibodies (bnAbs) targets the conserved CD4-binding site (CD4bs) of HIV-1 Env which has been a major target of HIV-vaccine design. The current best priming immunogen to engage the VRC01-class germline precursors is the eOD-GT8 60mer, which elicits VRC01-class precursors in multiple transgenic mouse models. However, a large proportion of the antibodies elicited by eOD-GT8 60mer are non-CD4bs or “off-target” antibodies, undermining its effectiveness in eliciting the VRC01-class bnAb precursors.<br /><br /> Researchers at the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases introduced multiple N-linked glycosylation sites to mask non-CD4bs regions of eOD-GT8 60mer to focus the antibody immune response to the CD4bs.<br /><br /> Several glycan-masked mutants showed significantly decreased antibody binding to non-CD4bs “off-target” epitopes while maintaining strong binding to CD4bs-specific bnAbs. Furthermore, in vivo studies showed that immunization with the best glycan-masked eOD-GT8 mutants resulted in significant increases in the elicitation of CD4bs-specific serum antibodies, CD4bs-specific B cells in the spleen, and VRC01-class precursors, compared to immunization with the parental eOD-GT8 immunogen. In conclusion, because of their improved antigenic and immunogenic profiles, glycan-masked eOD-GT8 60mer mutants may serve as improved priming immunogens to elicit VRC01-class bnAbs in humans. <ul> <li>Reduced off-target immunogenicity.</li> <li>Improved efficacy in eliciting precursors for broadly neutralizing CD4bs antibodies</li> <li>Facilitates the development of VRC01-class bnAbs in humans.</li> </ul> </li> </ul> <ul> <li>HIV-1 vaccine- the priming component in a prime-boost approach.</li> </ul> For collaboration opportunities, please contact Barry Buchbinder, PhD at <a href="mailto:barry.buchbinder@nih.gov">barry.buchbinder@nih.gov</a>or 1-240-627-3678. 2022-07-27 2025-08-13 2025-08-15 2018-10-12 60mer, antibodies, CD4bs-specificity, Elicited, EOD-GT8, Glycan~masking, IMPROVES False True True NIHTT 37470483 Website Abstract 114172535 Duan, H. et al. https://doi.org/10.1016/j.immuni.2018.07.005 <a href="https://doi.org/10.1016/j.immuni.2018.07.005">Duan, H. et al.</a> 114109843 Cheng, Cheng NIAID - VRC NIAID Cheng, Cheng (NIAID) 0 114109844 Boyington, Jeffrey NIAID - VRC NIAID Boyington, Jeffrey (NIAID) 0 114109845 Mascola, John NIAID - VRC NIAID Mascola, John (NIAID) 0 114109846 Duan, Hongying FDA - CBER FDA Duan, Hongying (FDA) 0 114109842 Chen, Xuejun NIAID - VRC NIAID Chen, Xuejun (NIAID) 1 114109842 Chen, Xuejun NIAID - VRC NIAID Chen, Xuejun (NIAID) 1 114109843 Cheng, Cheng NIAID - VRC NIAID Cheng, Cheng (NIAID) 0 114109844 Boyington, Jeffrey NIAID - VRC NIAID Boyington, Jeffrey (NIAID) 0 114109845 Mascola, John NIAID - VRC NIAID Mascola, John (NIAID) 0 114109846 Duan, Hongying FDA - CBER FDA Duan, Hongying (FDA) 0 114102478 Glycan~masking Improves The CD4bs-specificity Of Antibodies Elicited By EOD-GT8 60mer E-083-2017-0 Filing authorized FDA, NIAID 91025211 Rainwater, Charles crainwater@mail.nih.gov
United States of America crainwater@mail.nih.gov?subject=Web Inquiry on [TAB-3323] Glycan-masked engineered outer domains of HIV-1 GP120 and Their Use&body=Please send me information about technology [TAB-3323] Glycan-masked engineered outer domains of HIV-1 GP120 and Their Use. Rainwater, Charles<br><a href="mailto:crainwater@mail.nih.gov?subject=Web Inquiry on [TAB-3323] Glycan-masked engineered outer domains of HIV-1 GP120 and Their Use&body=Please send me information about technology [TAB-3323] Glycan-masked engineered outer domains of HIV-1 GP120 and Their Use.">crainwater@mail.nih.gov</a><br> 114168739 E-083-2017-0 E-083-2017-0-US-01 Glycan-Masked Engineered Outer Domains of HIV-1 GP120 and Their Use PRV US 62/476,397 Abandoned US <br />Provisional (PRV) 62/476,397<br />Filed on 2017-03-24<br />Status: Abandoned 114168740 E-083-2017-0 E-083-2017-0-PCT-02 GLYCAN-MASKED ENGINEERED OUTER DOMAINS OF HIV-1 GP120 AND THEIR USE PCT Patent Cooperation Treaty PCT/US2018/024330 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2018/024330<br />Filed on 2018-03-26<br />Status: Expired 114168917 E-083-2017-0 E-083-2017-0-US-03 GLYCAN-MASKED ENGINEERED OUTER DOMAINS OF HIV-1 GP120 AND THEIR USE National Stage US 11,235,056 16/496,912 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11235056 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11235056">11,235,056</a><br />Filed on 2019-09-23<br />Status: Issued 114169199 E-083-2017-0 E-083-2017-0-US-05 GLYCAN-MASKED ENGINEERED OUTER DOMAINS OF HIV-1 GP120 AND THEIR USE CON US 12,053,520 17/587,817 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12053520 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12053520">12,053,520</a><br />Filed on 2022-01-28<br />Status: Issued 114151321 Glycan~masking 114151322 IMPROVES 114151323 CD4bs-specificity 114151324 antibodies 114151325 Elicited 114151326 EOD-GT8 114151327 60mer TAB-3310 114097233 Prefusion HPIV F Immunogens and Their Use. NIAID Collaboration Collaboration Gwo-Yu Chuang, Davide Corti, Aliaksandr Druz, Wing-pui Kong, Peter Kwong, Antonio Lanzavecchia, John Mascola, Li Ou, Guillaume Stewart-Jones, Paul Thomas, Yaroslav Tsybovsky, Kai Xu, Yongping Yang, Baoshan Zhang, Tongqing Zhou Human parainfluenza virus (hPIV) is an RNA-based paramyxovirus that causes respiratory infections in children and adults. There are four serotypes that can result in a myriad of diseases of the respiratory tract including croup, bronchitis, and pneumonia (Mao et al., 2012). hPIV is a leading cause of respiratory tract infection and hospitalization among children under 5, only surpassed by the respiratory syncytial virus (RSV). Currently, there are limited treatment options and no approved vaccines. Recently, studies showed that a large proportion of neutralizing antibodies preferentially recognize exposed epitopes in the prefusion conformation of the RSV F protein, which together with other evidence suggests that creation of stabilized prefusion F protein immunogens might be a universal strategy to develop vaccine candidates for inducing protective immune responses in RSV and other related viruses, such as hPIV.<br /><br /> Researchers at the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases created immunogenic PIV fusion (F) glycoproteins for types 1,2,3 and 4 (hPIV1, hPIV2, hPIV3 and hPIV4) that have been modified to stabilize the prefusion conformation.<br /><br /> These stabilized prefusion F immunogens, especially hPIV3, induced high titer neutralizing responses in mice and rhesus macaques, and should thus serve as promising candidates for the prevention of PIV infection in humans.<br /><br /> This technology is available for licensing for commercial development in accordance with 35 U.S.C. § 209 and 37 CFR Part 404. <ul> <li>Use as a multivalent hPIV vaccine;</li> <li>Use in combination with influenza or RSV vaccine compositions;</li> <li>hPIV3 neutralizing titers induced in both mice and rhesus macaques were substantially higher than the highest PIV3 neutralizing titers observed in a cohort of over 100 humans.</li> </ul> <ul> <li>hPIV vaccines for people of all ages;</li> <li>Specific focus on the elderly and young children</li> </ul> NIAID is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize Prefusion HPIV F Immunogens and Their Use. For collaboration opportunities, please contact Vince Contreras, Ph.D., at <a href="mailto:Vince.Contreras@nih.gov">Vince.Contreras@nih.gov</a> or 240-669-2823. 2022-04-12 2025-08-13 2025-08-15 2018-08-31 ABXXXX, COVALENT, DS-Cav1, F, Fusion, HPIV, immunogen, IMPROVEMENTS, LEADING, Neutralizing, Parainfluenza, paramyxovirus, Prefusion, proteins, protomer, recombinant, respiratory, RSV F, Stabilization, Their, Thermostability, TITERS, Trimeric, Vaccine, virus False True True NIHTT 37470483 Website Abstract E-064-2016-0 114109802 Chuang, Gwo-Yu NIAID - DIR NIAID Chuang, Gwo-Yu (NIAID) 0 114109803 Xu, Kai NIAID - DIR NIAID Xu, Kai (NIAID) 0 114109804 Zhou, Tongqing NIAID - VRC NIAID Zhou, Tongqing (NIAID) 0 114109805 Tsybovsky, Yaroslav Leidos Biomedical Research, Inc NIAID Tsybovsky, Yaroslav (NIAID) 0 114109806 Druz, Aliaksandr NIAID - DIR NIAID Druz, Aliaksandr (NIAID) 0 114109807 Lanzavecchia, Antonio Institute for Research in Biomedicine (IRB) Lanzavecchia, Antonio 0 114109808 Corti, Davide Institute for Research in Biomedicine (IRB) Corti, Davide 0 114109809 Stewart-Jones, Guillaume NIAID - VRC NIAID Stewart-Jones, Guillaume (NIAID) 0 114109810 Zhang, Baoshan NIAID - VRC NIAID Zhang, Baoshan (NIAID) 0 114109811 Yang, Yongping NIAID - VRC NIAID Yang, Yongping (NIAID) 0 114109812 Thomas, Paul NIAID - VRC NIAID Thomas, Paul (NIAID) 0 114109813 Ou, Li NIAID - VRC NIAID Ou, Li (NIAID) 0 114109814 Kong, Wing-pui NIAID - VRC NIAID Kong, Wing-pui (NIAID) 0 114109815 Mascola, John NIAID - VRC NIAID Mascola, John (NIAID) 0 114109801 Kwong, Peter NIAID - VRC NIAID Kwong, Peter (NIAID) 1 114109801 Kwong, Peter NIAID - VRC NIAID Kwong, Peter (NIAID) 1 114109802 Chuang, Gwo-Yu NIAID - DIR NIAID Chuang, Gwo-Yu (NIAID) 0 114109803 Xu, Kai NIAID - DIR NIAID Xu, Kai (NIAID) 0 114109804 Zhou, Tongqing NIAID - VRC NIAID Zhou, Tongqing (NIAID) 0 114109805 Tsybovsky, Yaroslav Leidos Biomedical Research, Inc NIAID Tsybovsky, Yaroslav (NIAID) 0 114109806 Druz, Aliaksandr NIAID - DIR NIAID Druz, Aliaksandr (NIAID) 0 114109807 Lanzavecchia, Antonio Institute for Research in Biomedicine (IRB) Lanzavecchia, Antonio 0 114109808 Corti, Davide Institute for Research in Biomedicine (IRB) Corti, Davide 0 114109809 Stewart-Jones, Guillaume NIAID - VRC NIAID Stewart-Jones, Guillaume (NIAID) 0 114109810 Zhang, Baoshan NIAID - VRC NIAID Zhang, Baoshan (NIAID) 0 114109811 Yang, Yongping NIAID - VRC NIAID Yang, Yongping (NIAID) 0 114109812 Thomas, Paul NIAID - VRC NIAID Thomas, Paul (NIAID) 0 114109813 Ou, Li NIAID - VRC NIAID Ou, Li (NIAID) 0 114109814 Kong, Wing-pui NIAID - VRC NIAID Kong, Wing-pui (NIAID) 0 114109815 Mascola, John NIAID - VRC NIAID Mascola, John (NIAID) 0 114102469 Recombinant Parainfluenza Virus F Proteins And Their Use E-215-2016-0 Filing authorized INSTITUTE FOR RESEARCH IN BIOMEDICINE, NIAID 148673287 Hafiz, Sabrina sabrina.hafiz@nih.gov
United States of America sabrina.hafiz@nih.gov?subject=Web Inquiry on [TAB-3310] Prefusion HPIV F Immunogens and Their Use. &body=Please send me information about technology [TAB-3310] Prefusion HPIV F Immunogens and Their Use. . Hafiz, Sabrina<br><a href="mailto:sabrina.hafiz@nih.gov?subject=Web Inquiry on [TAB-3310] Prefusion HPIV F Immunogens and Their Use. &body=Please send me information about technology [TAB-3310] Prefusion HPIV F Immunogens and Their Use. .">sabrina.hafiz@nih.gov</a><br> 114167987 E-215-2016-0 E-215-2016-0-US-01 Prefusion HPIV F Immunogens and their use PRV US 62/412,699 Abandoned US <br />Provisional (PRV) 62/412,699<br />Filed on 2016-10-25<br />Status: Abandoned 114128068 ABXXXX 114151186 recombinant 114151187 Parainfluenza 114151188 virus 114151189 F 114151190 proteins 114151191 Their 114151192 COVALENT 114151193 Prefusion 114151194 Neutralizing 114151195 IMPROVEMENTS 114151196 Trimeric 114151197 TITERS 114151198 Thermostability 114151199 LEADING 114151200 DS-Cav1 114151201 RSV F 114151202 Stabilization 114151203 protomer 114151204 HPIV 114151205 paramyxovirus 114151206 respiratory 114151207 Fusion 114151208 immunogen 114151209 Vaccine TAB-3297 114097224 Simple and Rapid Loop-Mediated Isothermal Amplification (LAMP)-based Assay for <em>Mycoplasma pneumoniae</em> Detection CDC Collaboration, Consumer Products, Diagnostics, Infectious Disease, Licensing, Occupational Safety and Health, Research Materials, Therapeutics Collaboration Consumer Products Diagnostics Infectious Disease Licensing Occupational Safety and Health Research Materials Therapeutics Alexandra DeLaney, Maureen Diaz, Brianna Petrone, Jonas Winchell, Bernard Wolff <em>Mycoplasma pneumoniae (M. pneumonia)</em> can cause several different types of infection including chest colds and pneumonia. <em>M. pneumoniae</em> is a leading cause of community-acquired pneumonia. People of all ages are at risk for getting <em>M. pneumonia</em> infection, but it is most common among young adults and school-aged children. Current methods of detecting this agent are laborious and time consuming, so testing is not usually performed. However, knowing whether someone has <em>M. pneumoniae</em> infection is important for choosing the right antibiotic for treatment. Although real-time PCR assays exist for detecting this pathogen, they require sophisticated and expensive machinery as well as specialized technical expertise. CDC researchers have developed a simple loop-mediated isothermal amplification (LAMP)-based assay to detect this pathogen. This method only requires a simple heat block and is an easy-to-read colorimetric assay. The technology is simple to perform and can be a rapid point-of-care kit. It is ideal for use in resource-limited laboratories, hospitals, clinics, and community settings. <ul> <li>Rapid and simple diagnostic tool - Test development time is under 1 hour; newer reagents and enzymes may even improve time to results</li> <li>Similar sensitivity and specificity as compared to current commercially available kits for detecting <em>M. pneumoniae</em> in primary specimens</li> <li>Inexpensive and can be used in clinics or developing countries with little to no training</li> <li>Colorimetric assay is easy to read; no sophisticated instrumentation is required for performing or read-out</li> <li>Rapid and inexpensive diagnosis will facilitate proper use of antibiotics in pneumonia patients</li> <li>Can be used to improve currently available <em>M. pneumoniae</em> detection kits primarily used in hospitals and reference labs and approved for only throat swab testing - Works on many respiratory specimen types, can be performed directly on un-extracted specimens, is incredibly low cost at unde 50 cents per reaction, and can be performed and interpreted by technicians</li> <ul> <li>Detection of <em>Mycoplasma pneumoniae</em> from nucleic acid extracts and clinical specimens</li> <li>Rapid point-of-care testing (POCT) device or kit</li> <li>Research or clinical tool in fields of medicine, pharmacy, environmental hygiene, etc.</li> <li>Government or regional surveillance programs</li> <li>Quality control/quality assurance testing for <em> Mycoplasma</em> vaccine candidates</li> </ul> The CDC Technology Transfer Office (TTO) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize: Simple and Rapid Loop-Mediated Isothermal Amplification (LAMP)-based Assay for Mycoplasma pneumoniae Detection. For collaboration opportunities, please contact CDC TTO at <a href="mailto:tto@cdc.gov">tto@cdc.gov</a>or 1-404-639-1330. 2022-03-27 2025-08-13 2025-08-15 2018-06-20 Amplification/Detection, Isothermal, LAMP, Listed LPM Surabian as of 4/15/2015, mycoplasma, NCIRD, NCIRD-DBD, PNEUMONIAE, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, VJXXXX, WBXXXX, WFXXXX, WHXXXX, WIXXXX, XEXXXX, YBXXXX False True True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract E-108-1989-0 E-125-1992-0 E-300-2013-0 114172506 Petrone BL, et al. https://www.ncbi.nlm.nih.gov/pubmed/26179304 <a href="https://www.ncbi.nlm.nih.gov/pubmed/26179304">Petrone BL, et al. </a> 114109768 Petrone, Brianna CDC - DIR CDC Petrone, Brianna (CDC) 0 114109769 Diaz, Maureen CDC - DIR CDC Diaz, Maureen (CDC) 0 114109770 Wolff, Bernard CDC - DIR CDC Wolff, Bernard (CDC) 0 114109771 DeLaney, Alexandra CDC - DIR DeLaney, Alexandra 0 114109767 Winchell, Jonas CDC - DIR CDC Winchell, Jonas (CDC) 1 114109767 Winchell, Jonas CDC - DIR CDC Winchell, Jonas (CDC) 1 114109768 Petrone, Brianna CDC - DIR CDC Petrone, Brianna (CDC) 0 114109769 Diaz, Maureen CDC - DIR CDC Diaz, Maureen (CDC) 0 114109770 Wolff, Bernard CDC - DIR CDC Wolff, Bernard (CDC) 0 114109771 DeLaney, Alexandra CDC - DIR DeLaney, Alexandra 0 114102458 Isothermal Amplification/detection (LAMP) Of Mycoplasma Pneumoniae E-269-2014-0 Filing authorized Centers for Disease Control and Prevention (CDC) 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-3297] Simple and Rapid Loop-Mediated Isothermal Amplification (LAMP)-based Assay for <em>Mycoplasma pneumoniae</em> Detection&body=Please send me information about technology [TAB-3297] Simple and Rapid Loop-Mediated Isothermal Amplification (LAMP)-based Assay for <em>Mycoplasma pneumoniae</em> Detection. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-3297] Simple and Rapid Loop-Mediated Isothermal Amplification (LAMP)-based Assay for <em>Mycoplasma pneumoniae</em> Detection&body=Please send me information about technology [TAB-3297] Simple and Rapid Loop-Mediated Isothermal Amplification (LAMP)-based Assay for <em>Mycoplasma pneumoniae</em> Detection.">jonathan.motley@nih.gov</a><br> 114168665 E-269-2014-0 E-269-2014-0-US-01 METHODS AND COMPOSITIONS FOR ISOTHERMAL AMPLIFICATION AND DETECTION OF MYCOPLASMA PNEUMONIAE PRV US 62/116,166 Abandoned US <br />Provisional (PRV) 62/116,166<br />Filed on 2015-02-13<br />Status: Abandoned 114168666 E-269-2014-0 E-269-2014-0-US-02 METHODS AND COMPOSITIONS FOR ISOTHERMAL AMPLIFICATION AND DETECTION OF MYCOPLASMA PNEUMONIAE ORD US 10,233,504 15/043,194 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10233504 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10233504">10,233,504</a><br />Filed on 2016-02-12<br />Status: Issued 114127992 YBXXXX 114127993 VJXXXX 114127994 WBXXXX 114127995 WFXXXX 114127996 WHXXXX 114127997 WIXXXX 114127998 XEXXXX 114151053 NCIRD 114151054 Isothermal 114151055 Amplification/Detection 114151056 LAMP 114151057 mycoplasma 114151058 PNEUMONIAE 114151059 Listed LPM Surabian as of 4/15/2015 114151060 Pre LPM working set 20150418 114151061 Post LPM Assignment Set 20150420 114151062 NCIRD-DBD TAB-3294 114097221 Immunoassay for the Simultaneous Detection of Functional Antibodies against Multiple Serotypes of <em>Streptococcus pneumoniae</em> and Other Bacteria Types CDC Antibodies, Collaboration, Consumer Products, Diagnostics, Immunology, Infectious Disease, Licensing, Occupational Safety and Health, Research Materials Antibodies Collaboration Consumer Products Diagnostics Immunology Infectious Disease Licensing Occupational Safety and Health Research Materials George Carlone, Patricia Holder, GowriSankar Rajam, Sandra Steiner <em>Streptococcus pneumoniae</em>, or pneumococcus, is a type of bacteria that causes pneumococcal disease. Pneumococcal infections can range from ear and sinus infections to pneumonia and bloodstream infections. Children younger than 2 years old and adults 65 years or older are among those most at risk for disease.<br /><br /> CDC inventors have developed a simple, rapid flow, cytometric opsonophagocytic (mOPA) assay for the detection of functional antibodies against <em>Streptococcus pneumoniae (S. pneumoniae)<</em>. This in vitro assay measures functional antibody activity (of the phagocytes ingesting and eliminating pathogens) in samples from a subject vaccinated with a multivalent vaccine or after exposure to a bacterial pathogen. This assay can use a metabolic dye indicator that provides a colorimetric indicator of bacterial growth. As a result, neither growing bacteria into colonies, nor colony counting is needed, hence minimizing handling of viable bacteria. Alternately, the assay can also use fluorescently labelled beads conjugated with bacterial antigens, allowing rapid readout by flow cytometry. CDC’s technology demonstrates high reproducibility, detects up to 90 different <em>S. pneumoniae</em> serotypes, and can be adapted easily for automation.<br /><br /> Additionally, CDC’s technology will save time and resources versus the standard opsonophagocytic killing assay (OPK), a singleplex resource-intensive cell-based assay. At present time, OPK stands as the only in vitro correlate accepted by regulatory agencies for pneumococcal vaccine licensure. CDC’s mOPA addresses this major bottleneck in the pneumococcal vaccine evaluation by demonstrating efficacy of multivalent (i.e., 13-valent) vaccines. With more countries including pneumococcal vaccines in their immunization schedules, there is a strong need for this technique. <ul> <li> Multiple (up to 90 different) serotypes can be evaluated in a single multivalent assay versus the current singleplex standard assay</li> <li>Reduced assay time and reduced amount of serum</li> <li>Minimizes handling of viable bacteria</li> <li>High reproducibility</li> <li>Can be automated</li> </ul> <ul> <li>Medical diagnostic for detection of multiple (up to 90) Streptococcus pneumoniae serotypes</li> <li> Evaluate immune responses to vaccines or pathogens</li> <li> Large-scale immunogenicity studies</li> <li> Evaluation of existing or new pneumococcal vaccines for vaccine efficacy</li> <li> mOPA can be used with other types of bacteria, such as <em>Neisseria meningitidis</em> and <em>Hemophilus influenzae</em></li> <li> Monitoring and public health surveillance</li> </ul> The CDC Technology Transfer Office (TTO) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize: Immunoassay for the Simultaneous Detection of Functional Antibodies against Multiple Serotypes of Streptococcus pneumoniae and Other Bacteria Types. For collaboration opportunities, please contact CDC TTO at <a href="mailto:tto@cdc.gov">tto@cdc.gov</a>or 1-404-639-1330 National Patents Issued in Australia, Canada, and Europe 2022-03-27 2025-08-13 2025-08-15 2018-06-19 ARRAYS, assay, CDC Docket Import, CDC Docket Import CDC Prosecuting, Listed LPM Surabian as of 4/15/2015, Multiple-valent, OID-NCIRD-DBD, Opsonophagocytic, PANEL, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, SELECTION, THEREFOR, USES, VJXXXX, WBXXXX, WFXXXX, WHXXXX, WIXXXX, XAXXXX, XCXXXX, YBXXXX False True True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract E-329-2013-0 114172495 Martinez JE, et al. https://www.ncbi.nlm.nih.gov/pubmed/10391867 <a href="https://www.ncbi.nlm.nih.gov/pubmed/10391867">Martinez JE, et al. </a> 114172496 Romero-Steiner S., et al. https://www.ncbi.nlm.nih.gov/pubmed/14607861 <a href="https://www.ncbi.nlm.nih.gov/pubmed/14607861">Romero-Steiner S., et al. </a> 114172497 Bieging KT, et al. https://www.ncbi.nlm.nih.gov/pubmed/16210490 <a href="https://www.ncbi.nlm.nih.gov/pubmed/16210490">Bieging KT, et al. </a> 114172498 Martinez J, et al. https://www.ncbi.nlm.nih.gov/pubmed/11874898 <a href="https://www.ncbi.nlm.nih.gov/pubmed/11874898">Martinez J, et al.</a> 114172499 Martinez JE, et al. https://www.ncbi.nlm.nih.gov/pubmed/16603613 <a href="https://www.ncbi.nlm.nih.gov/pubmed/16603613">Martinez JE, et al.</a> 114172500 Romero-Steiner S., et al. https://www.ncbi.nlm.nih.gov/pubmed/9220157 <a href="https://www.ncbi.nlm.nih.gov/pubmed/9220157">Romero-Steiner S., et al.</a> 114172501 Romero-Steiner S., et al. https://www.ncbi.nlm.nih.gov/pubmed/16467321 <a href="https://www.ncbi.nlm.nih.gov/pubmed/16467321">Romero-Steiner S., et al.</a> 114109754 Holder, Patricia CDC - DIR CDC Holder, Patricia (CDC) 0 114109755 Carlone, George CDC - DIR CDC Carlone, George (CDC) 0 114109756 Rajam, GowriSankar CDC - DIR CDC Rajam, GowriSankar (CDC) 0 114109753 Steiner, Sandra CDC - DIR CDC Steiner, Sandra (CDC) 1 114109753 Steiner, Sandra CDC - DIR CDC Steiner, Sandra (CDC) 1 114109754 Holder, Patricia CDC - DIR CDC Holder, Patricia (CDC) 0 114109755 Carlone, George CDC - DIR CDC Carlone, George (CDC) 0 114109756 Rajam, GowriSankar CDC - DIR CDC Rajam, GowriSankar (CDC) 0 114102455 Multiple-valent Opsonophagocytic Assay Selection Panel Arrays And Uses Therefor E-227-2013-0 Closed Centers for Disease Control and Prevention (CDC) 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-3294] Immunoassay for the Simultaneous Detection of Functional Antibodies against Multiple Serotypes of <em>Streptococcus pneumoniae</em> and Other Bacteria Types&body=Please send me information about technology [TAB-3294] Immunoassay for the Simultaneous Detection of Functional Antibodies against Multiple Serotypes of <em>Streptococcus pneumoniae</em> and Other Bacteria Types. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-3294] Immunoassay for the Simultaneous Detection of Functional Antibodies against Multiple Serotypes of <em>Streptococcus pneumoniae</em> and Other Bacteria Types&body=Please send me information about technology [TAB-3294] Immunoassay for the Simultaneous Detection of Functional Antibodies against Multiple Serotypes of <em>Streptococcus pneumoniae</em> and Other Bacteria Types.">jonathan.motley@nih.gov</a><br> 114168658 E-227-2013-0 E-227-2013-0-US-01 Multiple-valent Opsonophagocytic Assay Selection Panel Arrays And Uses Therefor PRV US 60/674,197 Abandoned US <br />Provisional (PRV) 60/674,197<br />Filed on 2005-04-22<br />Status: Abandoned 114168659 E-227-2013-0 E-227-2013-0-PCT-02 Multiple-valent Opsonophagocytic Assay Selection Panel Arrays And Uses Therefor PCT Patent Cooperation Treaty PCT/US2006/015499 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2006/015499<br />Filed on 2006-04-21<br />Status: Expired 114168660 E-227-2013-0 E-227-2013-0-US-06 Multiple-valent Opsonophagocytic Assay Selection Panel Arrays And Uses Therefor National Stage US 7,642,068 11/910,517 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7642068 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7642068">7,642,068</a><br />Filed on 2007-10-02<br />Status: Abandoned 114168706 E-227-2013-0 E-227-2013-0-US-07 Multiple-valent Opsonophagocytic Assay Selection Panel Arrays And Uses Therefor DIV US 12/620,772 Abandoned US <br />Divisional (DIV) 12/620,772<br />Filed on 2009-11-18<br />Status: Abandoned 114127960 WFXXXX 114127961 WBXXXX 114127962 VJXXXX 114127963 YBXXXX 114127974 WHXXXX 114127975 WIXXXX 114127976 XAXXXX 114127977 XCXXXX 114151008 Multiple-valent 114151009 Opsonophagocytic 114151010 assay 114151011 SELECTION 114151012 PANEL 114151013 ARRAYS 114151014 USES 114151015 THEREFOR 114151016 CDC Docket Import 114151017 CDC Docket Import CDC Prosecuting 114151018 OID-NCIRD-DBD 114151019 Listed LPM Surabian as of 4/15/2015 114151020 Pre LPM working set 20150418 114151021 Post LPM Assignment Set 20150420 TAB-3283 114097210 Resurfaced Stabilized Core 3 (RSC3) Protein, Derived Proteins, and DNA Encoding These Proteins: RSC3, RSC3 delta371I, RSC3 delta371I/P363N, RSC3 G367R NIAID Licensing, Materials Available, Research Materials Licensing Materials Available Research Materials Peter Kwong, Gary Nabel, Ling Xu, Zhi-yong Yang, Tongqing Zhou Details for these materials may be found in the NIH AIDS Reagent Program Catalog – <ul> <li>RSC3 (Catalog# 12042): <a href="https://www.aidsreagent.org/reagentdetail.cfm?t=proteins&id=214" target="_blank" title="Catalog entry">https://www.aidsreagent.org/reagentdetail.cfm?t=proteins&id=214</a></li> <li>RSC3 delta371I (Catalog# 12043): <a href="https://www.aidsreagent.org/reagentdetail.cfm?t=proteins&id=146" target="_blank" title="Catalog entry">https://www.aidsreagent.org/reagentdetail.cfm?t=proteins&id=146</a></li> <li>RSC3 delta371I/P363N (Catalog# 12362): <a href="https://www.aidsreagent.org/reagentdetail.cfm?t=proteins&id=145" target="_blank" title="Catalog entry">https://www.aidsreagent.org/reagentdetail.cfm?t=proteins&id=145</a></li> <li>RSC3 G367R (Catalog# 12363): <a href="https://www.aidsreagent.org/reagentdetail.cfm?t=proteins&id=148" target="_blank" title="Catalog entry">https://www.aidsreagent.org/reagentdetail.cfm?t=proteins&id=148</a></li> </ul> <ul> <li>Speed up product development with NIH developed material that has already been tested and validated.</li> </ul> <ul> <li>A research material that can be used in the development of assays, validation of products or in quality control.</li> </ul> Research Material – Patent protection is not being pursued for this technology. (IC Reference No. 2016-019) 2022-07-27 2025-08-13 2025-08-15 2018-06-07 3, Core, DERIVED, DNA, Encoding, Protein, proteins, Resurfaced, RM, RSC3, Stabilized, THESE, WIXXXX False True True NIHTT 37470483 Website Abstract 114109731 Zhou, Tongqing NIAID - VRC NIAID Zhou, Tongqing (NIAID) 0 114109732 Nabel, Gary Sanofi Pasteur Biologics Co NIAID Nabel, Gary (NIAID) 0 114109733 Yang, Zhi-yong Sanofi R&D NIAID Yang, Zhi-yong (NIAID) 0 114109734 Xu, Ling Sanofi R&D Xu, Ling 0 114109730 Kwong, Peter NIAID - VRC NIAID Kwong, Peter (NIAID) 1 114109730 Kwong, Peter NIAID - VRC NIAID Kwong, Peter (NIAID) 1 114109731 Zhou, Tongqing NIAID - VRC NIAID Zhou, Tongqing (NIAID) 0 114109732 Nabel, Gary Sanofi Pasteur Biologics Co NIAID Nabel, Gary (NIAID) 0 114109733 Yang, Zhi-yong Sanofi R&D NIAID Yang, Zhi-yong (NIAID) 0 114109734 Xu, Ling Sanofi R&D Xu, Ling 0 114102445 Resurfaced Stabilized Core 3 (RSC3) Protein, Derived Proteins, And DNA Encoding These Proteins E-236-2016-0 Research Material NIAID 91025211 Rainwater, Charles crainwater@mail.nih.gov
United States of America crainwater@mail.nih.gov?subject=Web Inquiry on [TAB-3283] Resurfaced Stabilized Core 3 (RSC3) Protein, Derived Proteins, and DNA Encoding These Proteins: RSC3, RSC3 delta371I, RSC3 delta371I/P363N, RSC3 G367R&body=Please send me information about technology [TAB-3283] Resurfaced Stabilized Core 3 (RSC3) Protein, Derived Proteins, and DNA Encoding These Proteins: RSC3, RSC3 delta371I, RSC3 delta371I/P363N, RSC3 G367R. Rainwater, Charles<br><a href="mailto:crainwater@mail.nih.gov?subject=Web Inquiry on [TAB-3283] Resurfaced Stabilized Core 3 (RSC3) Protein, Derived Proteins, and DNA Encoding These Proteins: RSC3, RSC3 delta371I, RSC3 delta371I/P363N, RSC3 G367R&body=Please send me information about technology [TAB-3283] Resurfaced Stabilized Core 3 (RSC3) Protein, Derived Proteins, and DNA Encoding These Proteins: RSC3, RSC3 delta371I, RSC3 delta371I/P363N, RSC3 G367R.">crainwater@mail.nih.gov</a><br> 114127929 WIXXXX 114150853 Resurfaced 114150854 Stabilized 114150855 Core 114150856 3 114150857 RSC3 114150858 Protein 114150859 DERIVED 114150860 proteins 114150861 DNA 114150862 Encoding 114150863 THESE 114150964 RM TAB-3277 114097191 HIV-1 Clone Bal.01 NIAID Licensing, Materials Available, Research Materials, Therapeutics Licensing Materials Available Research Materials Therapeutics Yuxing Li, John Mascola, Krisha McKee, Richard Wyatt Details for this material are provided in the NIH AIDS Reagent Program Catalog (Catalog# 11445): <a href="https://www.aidsreagent.org/reagentdetail.cfm?t=expression_vectors&id=210" target="_blank" title="Catalog entry">https://www.aidsreagent.org/reagentdetail.cfm?t=expression_vectors&id=210</a>. <ul> <li>Speed up product development with NIH developed material that has already been tested and validated.</li> </ul> <ul> <li>A research material that can be used in the development of assays, validation of products or in quality control.</li> </ul> Research Material – Patent protection is not being pursued for this technology. (IC Reference No. 2013-052) 2022-07-27 2025-08-13 2025-08-15 2018-06-07 11445, AIDS Research & Reference Reagent Program, Bal.01, CLONE, GCXXXX, HIV-1, Listed LPM Ano as of 4/15/2015, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, RM, WIXXXX False True True NIHTT 37470483 Website Abstract 114109717 McKee, Krisha NIAID - VRC NIAID McKee, Krisha (NIAID) 0 114109718 Li, Yuxing NIAID - VRC Li, Yuxing 0 114109719 Wyatt, Richard The Scripps Research Institute NIAID Wyatt, Richard (NIAID) 0 114109716 Mascola, John NIAID - VRC NIAID Mascola, John (NIAID) 1 114109716 Mascola, John NIAID - VRC NIAID Mascola, John (NIAID) 1 114109717 McKee, Krisha NIAID - VRC NIAID McKee, Krisha (NIAID) 0 114109718 Li, Yuxing NIAID - VRC Li, Yuxing 0 114109719 Wyatt, Richard The Scripps Research Institute NIAID Wyatt, Richard (NIAID) 0 114102439 HIV-1 Clone Bal.01 E-040-2014-0 Research Material NIAID 91025211 Rainwater, Charles crainwater@mail.nih.gov
United States of America crainwater@mail.nih.gov?subject=Web Inquiry on [TAB-3277] HIV-1 Clone Bal.01&body=Please send me information about technology [TAB-3277] HIV-1 Clone Bal.01. Rainwater, Charles<br><a href="mailto:crainwater@mail.nih.gov?subject=Web Inquiry on [TAB-3277] HIV-1 Clone Bal.01&body=Please send me information about technology [TAB-3277] HIV-1 Clone Bal.01.">crainwater@mail.nih.gov</a><br> 114127919 GCXXXX 114127920 WIXXXX 114150792 Bal.01 114150793 CLONE 114150794 HIV-1 114150795 11445 114150796 AIDS Research & Reference Reagent Program 114150797 Listed LPM Ano as of 4/15/2015 114150798 Pre LPM working set 20150418 114150799 Post LPM Assignment Set 20150420 114150800 RM TAB-3275 114097147 Pneumonia Virus of Mice Expression Vector PSynK-PVMJ3666 NIAID Infectious Disease, Licensing, Research Materials Infectious Disease Licensing Research Materials Kimberly Dyer, Martin Moore, Helene Rosenberg Pneumonia virus of mice expression vector PSynK-PVMJ3666. <ul> <li>Speed up product development with NIH developed material that has already been tested and validated.</li> </ul> <ul> <li>A research material that can be used in the development of assays, validation of products or in quality control.</li> </ul> Research Material – Patent protection is not being pursued for this technology. (IC Reference No. 2014-036) 2022-03-08 2025-08-13 2025-08-15 2018-06-07 Expression, Listed LPM Ano as of 4/15/2015, Mice, PNEUMONIA, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, PSynK-PVMJ3666, RM, Vector, virus, VLXXXX, WIXXXX False True True NIHTT 37470483 Website Abstract 114109712 Dyer, Kimberly NIAID - DIR NIAID Dyer, Kimberly (NIAID) 0 114109713 Moore, Martin Emory University Moore, Martin 0 114109711 Rosenberg, Helene NIAID - DIR NIAID Rosenberg, Helene (NIAID) 1 114109711 Rosenberg, Helene NIAID - DIR NIAID Rosenberg, Helene (NIAID) 1 114109712 Dyer, Kimberly NIAID - DIR NIAID Dyer, Kimberly (NIAID) 0 114109713 Moore, Martin Emory University Moore, Martin 0 114102437 Pneumonia Virus Of Mice Expression Vector PSynK-PVMJ3666 E-016-2015-0 Research Material Emory University, NIAID 91026778 Green, Wade wade.green@nih.gov
United States of America TTIPO wade.green@nih.gov?subject=Web Inquiry on [TAB-3275] Pneumonia Virus of Mice Expression Vector PSynK-PVMJ3666&body=Please send me information about technology [TAB-3275] Pneumonia Virus of Mice Expression Vector PSynK-PVMJ3666. Green, Wade<br><a href="mailto:wade.green@nih.gov?subject=Web Inquiry on [TAB-3275] Pneumonia Virus of Mice Expression Vector PSynK-PVMJ3666&body=Please send me information about technology [TAB-3275] Pneumonia Virus of Mice Expression Vector PSynK-PVMJ3666.">wade.green@nih.gov</a><br> 114127915 VLXXXX 114127916 WIXXXX 114150769 PNEUMONIA 114150770 virus 114150771 Mice 114150772 Expression 114150773 Vector 114150774 PSynK-PVMJ3666 114150775 Listed LPM Ano as of 4/15/2015 114150776 Pre LPM working set 20150418 114150777 Post LPM Assignment Set 20150420 114150778 RM TAB-3274 114097198 Non-invasive Method for Ebola Virus Infection Detection in Great Apes and Other Wildlife Hosts NIAID Infectious Disease, Licensing, Research Materials Infectious Disease Licensing Research Materials Nancy Sullivan Ebola virus surveillance in wildlife vectors of infection transmission to humans. <ul> <li>Speed up product development with NIH developed material that has already been tested and validated.</li> </ul> <ul> <li>A research material that can be used in the development of assays, validation of products or in quality control.</li> </ul> Research Material – Patent protection is not being pursued for this technology. (IC Reference No. 2014-029) 2022-03-08 2025-08-13 2025-08-15 2018-06-07 ACXXXX, Apes, Detection, Ebola, HOSTS, HostsNon-invasive, Humans, Infection, Method, NON-INVASIVE, Nucleoprotien, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, primate, RM, Surveillance, TRANSMISSION, vectors, virus, VLXXXX, WIXXXX False True True NIHTT 37470483 Website Abstract 114109710 Sullivan, Nancy NIAID - VRC NIAID Sullivan, Nancy (NIAID) 1 114109710 Sullivan, Nancy NIAID - VRC NIAID Sullivan, Nancy (NIAID) 1 114102436 Non-invasive Method For Ebola Virus Infection Detection In Great Apes And Other Wildlife Hosts Non-invasive Method For Ebola Virus Detection In Great Apes And Other Wildlife Hosts. Ebola Virus Surveillance In Wildlife Vectors Of Infection Transmiss E-006-2015-0 Research Material NIAID 148673287 Hafiz, Sabrina sabrina.hafiz@nih.gov
United States of America sabrina.hafiz@nih.gov?subject=Web Inquiry on [TAB-3274] Non-invasive Method for Ebola Virus Infection Detection in Great Apes and Other Wildlife Hosts&body=Please send me information about technology [TAB-3274] Non-invasive Method for Ebola Virus Infection Detection in Great Apes and Other Wildlife Hosts. Hafiz, Sabrina<br><a href="mailto:sabrina.hafiz@nih.gov?subject=Web Inquiry on [TAB-3274] Non-invasive Method for Ebola Virus Infection Detection in Great Apes and Other Wildlife Hosts&body=Please send me information about technology [TAB-3274] Non-invasive Method for Ebola Virus Infection Detection in Great Apes and Other Wildlife Hosts.">sabrina.hafiz@nih.gov</a><br> 114127912 ACXXXX 114127913 VLXXXX 114127914 WIXXXX 114150751 HostsNon-invasive 114150752 Apes 114150753 Detection 114150754 Infection 114150755 virus 114150756 Ebola 114150757 Method 114150758 NON-INVASIVE 114150759 Surveillance 114150760 vectors 114150761 TRANSMISSION 114150762 Humans 114150763 HOSTS 114150764 Pre LPM working set 20150418 114150765 Post LPM Assignment Set 20150420 114150766 Nucleoprotien 114150767 primate 114150768 RM TAB-3268 114097203 Real-time RT-PCR Assay for Rapid, Highly Sensitive and Specific Detection of Human Enterovirus D68 (EV-D68) CDC Collaboration, Consumer Products, Diagnostics, Infectious Disease, Licensing, Occupational Safety and Health, Research Materials, Therapeutics Collaboration Consumer Products Diagnostics Infectious Disease Licensing Occupational Safety and Health Research Materials Therapeutics William Nix, Mark Oberste Human Enterovirus D68 (EV-D68) is a non-polio enterovirus that can cause mild to severe respiratory illness, especially in infants and children with asthma. Since its identification, every year EV-D68 has been detected sporadically throughout the world. The US experienced a nationwide outbreak of EV-D68 associated with a particularly severe respiratory illness from mid-August to early November 2014, with 1,153 confirmed cases in 49 states and the District of Columbia. Although various established detection methods are available for EV-D68, enteroviruses evolve rapidly. New methods are needed for specific testing to determine which types of enteroviruses are circulating.<br /><br /> CDC investigators have developed a real-time RT-PCR (reverse transcriptase – polymerase chain reaction) Taqman assay using primers and probes specific for EV-D68 viral protein 1 nucleic acid. This assay provides a more specific identification of EV-D68 strains allowing better diagnosis. The assay is simple, validated, and allows rapid testing and detection of EV-D68 in respiratory samples. This assay can be used in a kit or an array format for high-throughput (large scale) screening of samples, which is useful for public health facilities and surveillance programs. This assay was approved under an Emergency Use Authorization (EUA) by the FDA (US Food and Drug Administration) in May, 2015. <ul> <li>Detection of currently circulating, newly evolved human EV- D68 strains</li> <li> Simple and rapid as compared to previous methods, making the diagnosis easier</li> <li>High sensitivity and specificity</li> <li>Validated and easily implementable as a kit or array for high-throughput sample screening</li> <li>Faster screening than culturing and serological identification methods</li> <li>This assay was approved under an Emergency Use Authorization (EUA) by the FDA in May, 2015</li> </ul> <ul> <li>Rapid, simple and specific detection of new human EV-D68 strains</li> <li>Assay for research or clinical settings to diagnose respiratory infections directly attributable to EV-D68 versus other causative agents – for adults, children or neonates</li> <li> Government and regional Enterovirus surveillance programs</li> <li>Quality control/quality assurance testing for Enterovirus isolates</li> </ul> The CDC Technology Transfer Office (TTO) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize: Real-time RT-PCR Assay for Rapid, Sensitive and Specific Detection of Human Enterovirus D68 (EV-D68). For collaboration opportunities, please contact CDC TTO at <a href="mailto:tto@cdc.gov">tto@cdc.gov</a>or 1-404-639-1330. 2022-03-27 2025-08-13 2025-08-15 2018-06-05 assay, D68, Detection, Enterovirus, Genomic, ISOLATES, Listed LPM Surabian as of 4/15/2015, NCIRD-DVD, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, REAL-TIME, RT-PCR, Sequences, Specific, Taqman, virus, VLXXXX, WBXXXX, WFXXXX, WHXXXX, WIXXXX, XEXXXX, YAXXXX, YBXXXX False True True 52406768 Discovery 52406768 NIHTT 37470483 Website Abstract E-257-2013-0 E-157-2015-0 E-011-2015-1 114172482 Brown BA, et al. https://www.ncbi.nlm.nih.gov/pubmed/25414503 <a href="https://www.ncbi.nlm.nih.gov/pubmed/25414503 ">Brown BA, et al.</a> 114172483 Rhoden E, et al. https://www.ncbi.nlm.nih.gov/pubmed/26149998 <a href="https://www.ncbi.nlm.nih.gov/pubmed/26149998">Rhoden E, et al.</a> 114172484 Midgley CM, et al. https://www.ncbi.nlm.nih.gov/pubmed/26482320 <a href="https://www.ncbi.nlm.nih.gov/pubmed/26482320">Midgley CM, et al.</a> 114172485 Messacar K, et al. https://www.ncbi.nlm.nih.gov/pubmed/25638662 <a href="https://www.ncbi.nlm.nih.gov/pubmed/25638662">Messacar K, et al.</a> 114172486 Aliabadi N, et al. https://www.ncbi.nlm.nih.gov/pubmed/27434186 <a href="https://www.ncbi.nlm.nih.gov/pubmed/27434186">Aliabadi N, et al.</a> 114172487 Midgley CM, et al. https://www.ncbi.nlm.nih.gov/pubmed/25211545 <a href="https://www.ncbi.nlm.nih.gov/pubmed/25211545">Midgley CM, et al.</a> 114172488 Medical Devices - Emergency Use Authorizations https://www.fda.gov/MedicalDevices/Safety/EmergencySituations/ucm161496.htm <a href="https://www.fda.gov/MedicalDevices/Safety/EmergencySituations/ucm161496.htm">Medical Devices - Emergency Use Authorizations</a> 114109698 Oberste, Mark CDC - DIR CDC Oberste, Mark (CDC) 0 114109699 Nix, William CDC - DIR CDC Nix, William (CDC) 1 114109699 Nix, William CDC - DIR CDC Nix, William (CDC) 1 114109698 Oberste, Mark CDC - DIR CDC Oberste, Mark (CDC) 0 114102432 Enterovirus D68 Virus Isolates, Genomic Sequences, And A Real-time RT-PCR (Taqman) Assay For Specific Detection E-011-2015-0 Filing authorized Centers for Disease Control and Prevention (CDC) 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-3268] Real-time RT-PCR Assay for Rapid, Highly Sensitive and Specific Detection of Human Enterovirus D68 (EV-D68)&body=Please send me information about technology [TAB-3268] Real-time RT-PCR Assay for Rapid, Highly Sensitive and Specific Detection of Human Enterovirus D68 (EV-D68). Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-3268] Real-time RT-PCR Assay for Rapid, Highly Sensitive and Specific Detection of Human Enterovirus D68 (EV-D68)&body=Please send me information about technology [TAB-3268] Real-time RT-PCR Assay for Rapid, Highly Sensitive and Specific Detection of Human Enterovirus D68 (EV-D68).">jonathan.motley@nih.gov</a><br> 114168622 E-011-2015-0 E-011-2015-0-US-01 Compositions and Methods for Detecting Enterovirus D68 PRV US 62/171,657 Abandoned US <br />Provisional (PRV) 62/171,657<br />Filed on 2015-06-05<br />Status: Abandoned 114168623 E-011-2015-0 E-011-2015-0-US-02 COMPOSITIONS AND METHODS FOR DETECTING ENTEROVIRUS D68 ORD US 9,938,588 15/173,450 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9938588 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9938588">9,938,588</a><br />Filed on 2016-06-03<br />Status: Issued 114127881 YAXXXX 114127882 YBXXXX 114127883 VLXXXX 114127884 WBXXXX 114127885 WFXXXX 114127886 WHXXXX 114127887 WIXXXX 114127888 XEXXXX 114150696 Enterovirus 114150697 D68 114150698 virus 114150699 ISOLATES 114150700 Genomic 114150701 Sequences 114150702 REAL-TIME 114150703 RT-PCR 114150704 Taqman 114150705 assay 114150706 Specific 114150707 Detection 114150708 NCIRD-DVD 114150709 Listed LPM Surabian as of 4/15/2015 114150710 Pre LPM working set 20150418 114150711 Post LPM Assignment Set 20150420 TAB-3264 114097199 Inner Curvature Charge Concentration Device for Tissue Laceration NHLBI Cardiology, Collaboration, Medical Devices, Non-Medical Devices Cardiology Collaboration Medical Devices Non-Medical Devices Jaffar Khan, Robert Lederman, Toby Rogers Left ventricular outflow tract obstruction is a life-threatening complication of transcatheter mitral valve replacement caused by septal displacement of the anterior mitral leaflet (AML). The AML is a mobile structure that physically separates inflow and outflow zones of the left ventricle. Preserving the AML during surgical mitral valve replacement can cause left ventricular outflow tract obstruction, either when the prosthesis struts protrude into the left ventricular outflow tract or when along redundant anterior leaflet prolapses into the left ventrical outflow tract. The invention relates to devices having monopolar or bipolar tissue lacerators for efficiently and safely cutting AMLs percutaneously by vaporizing target tissue with electrical energy. Exemplary devices include a wire partially covered by electrical insulation, where the wire is kinked and where the wire is exposed through the insulation at one or more exposed regions along or near the inner curvature of the kink. The wire is configured to conduct electrical energy through the exposed region(s) and through a tissue target positioned adjacent the inner curvature to lacerate the tissue target via the electrical energy. The tissue target can be a native or prosthetic heart valve leaflet in a patient's heart. An optional feature of the device also includes an irrigation catheter to displace blood from the electrode, concentrating current at the tissue and reducing char and coagulum formation. <ul> <li>Prevention of iatrogenic left ventricular outflow tract obstruction following transcatheter mitral valve replacement</li> <li>Bioprosthetic aortic scallop intentional laceration</li> </ul> The National Institute of Environmental Health Sciences seeks statements of capability or interest from parties interested in collaborative research to further develop and evaluate this technology. Please contact Peg Koelble, Technology Development Specialist, Office of Technology Transfer, National Heart, Lung, and Blood Institute, Phone: 301.594.4095; <a href="mailto:koelblep@nhlbi.nih.gov">koelblep@nhlbi.nih.gov</a>. 2022-03-08 2025-08-13 2025-08-15 2018-05-21 AB2XXX, AB3GXX, BASILICA, Curvature, Laceration, Leaflet, LEAFLETS, Trans-auricular, VDXXXX, XDXXXX False True True NIHTT 37470483 Website Abstract 114109685 Khan, Jaffar National Heart, Lung, and Blood Institute (NHLBI) NHLBI Khan, Jaffar (NHLBI) 0 114109686 Rogers, Toby National Heart, Lung, and Blood Institute (NHLBI) Rogers, Toby 0 114109684 Lederman, Robert National Heart, Lung, and Blood Institute (NHLBI) NHLBI Lederman, Robert (NHLBI) 1 114109684 Lederman, Robert National Heart, Lung, and Blood Institute (NHLBI) NHLBI Lederman, Robert (NHLBI) 1 114109685 Khan, Jaffar National Heart, Lung, and Blood Institute (NHLBI) NHLBI Khan, Jaffar (NHLBI) 0 114109686 Rogers, Toby National Heart, Lung, and Blood Institute (NHLBI) Rogers, Toby 0 114102427 Inner Curvature Charge Concentration Device For Tissue Laceration E-064-2018-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-3264] Inner Curvature Charge Concentration Device for Tissue Laceration&body=Please send me information about technology [TAB-3264] Inner Curvature Charge Concentration Device for Tissue Laceration. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-3264] Inner Curvature Charge Concentration Device for Tissue Laceration&body=Please send me information about technology [TAB-3264] Inner Curvature Charge Concentration Device for Tissue Laceration.">shmilovm@nih.gov</a><br> 114161708 E-064-2018-0 E-064-2018-0-US-01 Inner Curvature Charge Concentration Device For Tissue Laceration PRV US 62/633,791 Abandoned US <br />Provisional (PRV) 62/633,791<br />Filed on 2018-02-22<br />Status: Abandoned 114168855 E-064-2018-0 E-064-2018-0-PCT-02 Inner Curvature Charge Concentration Device For Tissue Laceration PCT Patent Cooperation Treaty PCT/US2019/018503 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2019/018503<br />Filed on 2019-02-19<br />Status: Expired 114169034 E-064-2018-0 E-064-2018-0-US-05 Inner Curvature Charge Concentration Device For Tissue Laceration National Stage US 12,349,957 16/954,710 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12349957 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12349957">12,349,957</a><br />Filed on 2020-06-17<br />Status: Issued 114127848 AB2XXX 114127849 AB3GXX 114127850 VDXXXX 114127851 XDXXXX 114150653 Curvature 114150654 Laceration 114150655 BASILICA 114150656 Leaflet 114150657 LEAFLETS 114150658 Trans-auricular TAB-3259 114097194 Mononegavirales Vectors expressing Chimeric Antigens NIAID Collaboration, Diagnostics, Infectious Disease, Research Materials, Vaccines Collaboration Diagnostics Infectious Disease Research Materials Vaccines Linda Brock, Ursula Buchholz, Peter Collins, Shirin Munir Human respiratory syncytial virus (RSV) continues to be the leading viral cause of severe acute lower respiratory tract disease in infants and children worldwide. A licensed vaccine or antiviral drug suitable for routine use remains unavailable. This invention relates to the use of murine pneumonia virus (MPV), a virus to which humans normally are not exposed to and that is not cross-protected with RSV, as a vector to express the RSV fusion (F) glycoprotein as an RSV vaccine candidate. The RSV F ORF was codon optimized. The RSV F ORF was placed under the control of MPV transcription signals and inserted at the first (rMPV-F1), third (rMPV29 F3), or fourth (rMPV-F4) gene position of a version of the MPV genome that contained a codon pair optimized L polymerase gene. The recovered viruses replicated in vitro as efficiently as the empty vector, with stable expression of RSV F protein. Replication and immunogenicity of rMPV-F1 and rMPV-F3 were evaluated in rhesus macaques following administration by the combined intranasal and intratracheal routes. Both viruses replicated at low levels in the upper and lower respiratory tract, maintained stable RSV F expression, and induced similar high levels of RSV-neutralizing serum antibodies that reached peak titers by fourteen (14) days post-vaccination. rMPV provides a highly attenuated yet immunogenic vector for the expression of RSV F protein, with potential application in RSV-naïve and RSV experienced populations.<br /><br /> The invention relates to live, chimeric non-human Mononegavirales vectors that allow a cell to express at least one protein from at least one human pathogen as well as compositions comprising the vectors, methods and kits for eliciting an immune response in a host, and methods of making the vectors.<br /><br /> This technology is available for licensing for commercial development in accordance with 35 U.S.C. § 209 and 37 CFR Part 404, as well as for further development and evaluation under a research collaboration. <ul> <li>Ease of manufacture</li> <li>Multivalent live attenuated vaccines</li> <li>B cell and T cell activation</li> <li>Low-cost vaccines</li> </ul> <ul> <li>Viral diagnostics</li> <li>Vaccine research</li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize for development of a vaccine for respiratory or other infections. For collaboration opportunities, please contact Peter Soukas, J.D., at <a href="mailto:Peter.Soukas@nih.gov">Peter.Soukas@nih.gov</a> or 301-594-8730. 2022-03-08 2025-08-13 2025-08-15 2018-05-07 Added, Attenuated, DA4BXX, DA4XXX, DC5BXX, DC5XXX, DCXXXX, DD1XXX, DDXXXX, DEXXXX, DXXXXX, Expressing, F, Fusion, Gene, Highly, Human, Immunogenic, Macaques, MPV, Murine, PNEUMONIA, Protein, respiratory, RHESUS, RSV, Syncytial, virus False True True NIHTT 37470483 Website Abstract 114103675 Collins, Peter NIAID - DIR NIAID Collins, Peter (NIAID) 0 114103676 Buchholz, Ursula NIAID - DIR NIAID Buchholz, Ursula (NIAID) 0 114103677 Brock, Linda NIAID - DIR NIAID Brock, Linda (NIAID) 0 114103678 Munir, Shirin NIAID - DIR NIAID Munir, Shirin (NIAID) 1 114103678 Munir, Shirin NIAID - DIR NIAID Munir, Shirin (NIAID) 1 114103675 Collins, Peter NIAID - DIR NIAID Collins, Peter (NIAID) 0 114103676 Buchholz, Ursula NIAID - DIR NIAID Buchholz, Ursula (NIAID) 0 114103677 Brock, Linda NIAID - DIR NIAID Brock, Linda (NIAID) 0 114099509 Murine Pneumonia Virus (MPV) Expressing The Fusion F Protein Of Human Respiratory Syncytial Virus (RSV) From An Added Gene In Highly Attenuated And Immunogenic In Rhesus Macaques E-018-2018-0 Filing authorized NIAID 91029846 Ganelina, Anna ganelinaa@niaid.nih.gov
United States of America ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-3259] Mononegavirales Vectors expressing Chimeric Antigens&body=Please send me information about technology [TAB-3259] Mononegavirales Vectors expressing Chimeric Antigens. Ganelina, Anna<br><a href="mailto:ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-3259] Mononegavirales Vectors expressing Chimeric Antigens&body=Please send me information about technology [TAB-3259] Mononegavirales Vectors expressing Chimeric Antigens.">ganelinaa@niaid.nih.gov</a><br> 114160850 E-018-2018-0 E-018-2018-0-US-01 CHIMERIC VECTORS PRV US 62/661,320 Abandoned US <br />Provisional (PRV) 62/661,320<br />Filed on 2018-04-23<br />Status: Abandoned 114168760 E-018-2018-0 E-018-2018-0-US-12 CHIMERIC VECTORS National Stage US 12,071,632 17/049,916 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12071632 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12071632">12,071,632</a><br />Filed on 2020-10-22<br />Status: Issued 114168868 E-018-2018-0 E-018-2018-0-PCT-02 CHIMERIC VECTORS PCT Patent Cooperation Treaty PCT/US2019/028771 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2019/028771<br />Filed on 2019-04-23<br />Status: Expired 114127827 DXXXXX 114127828 DCXXXX 114127829 DC5XXX 114127830 DC5BXX 114127831 DDXXXX 114127832 DD1XXX 114127833 DA4XXX 114127834 DA4BXX 114127835 DEXXXX 114150535 Murine 114150536 PNEUMONIA 114150537 virus 114150538 MPV 114150539 Expressing 114150540 Fusion 114150541 F 114150542 Protein 114150543 Human 114150544 respiratory 114150545 Syncytial 114150546 RSV 114150547 Added 114150548 Gene 114150549 Highly 114150550 Attenuated 114150551 Immunogenic 114150552 RHESUS 114150553 Macaques TAB-3241 114097175 Enhanced Tissue Clearing Solution, Clearing-Enhanced 3D (Ce3D), Compatible with Advanced Fluorescence Microscopy Imaging NIAID Collaboration Collaboration Ronald Germain, Michael Gerner, Weizhe Li NIH immunologists have created a solution, Clearing-enhanced 3D (Ce3D), that can be used to make entire organs extremely transparent (top right panel). This allows the tissue to be imaged using advanced fluorescence microscopy techniques (bottom panel). Unlike current tissue clearing solutions, the Ce3D tissue clearing solution is robustly compatible with a variety of staining methods, and preserves tissue morphology and reporter fluorescence. Ce3D enabled microscopy provides unprecedented insight into the spatial organization of cells within intact organs. Further, when Ce3D enabled microscopy is coupled with multiplexed staining and a newly developed analysis pipeline, investigators are able to extensively characterize densely packed cells in situ, providing advantages to phenotyping cells with flow cytometric techniques.<br /><br /> This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as well as for further development and evaluation under a research collaboration. <ul> <li>Simple, quick and inexpensive procedure that has been extensively validated</li> <li>Generates excellent tissue transparency, resulting in high quality images</li> <li>Compatible with highly multiplexed staining/labeling techniques</li> <li>Fluorescence is maintained in diverse fluorescent proteins and fluorophores</li> <li>Enables quantitative analysis of tissue composition and cellular distribution in whole organs, and has advantages over flow cytometric techniques</li> </ul> <ul> <li>Research reagent – can be applied to a variety of biological disciplines</li> <li>Diagnostic medical imaging reagent – characterization of disease state/condition</li> </ul> National Institute of Allergy and Infectious Diseases, Laboratory of Parasitic Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize tissue-clearing technologies. For collaboration opportunities, please contact: Natalie Greco, Ph.D. at <a href="mailto:natalie.greco@nih.gov">Natalie.Greco@nih.gov</a> or 301-761-7898 2022-03-08 2025-08-13 2025-08-15 2018-01-19 3D, AA3AXX, Ce3D:, Cellular, Clearing, Epitope, Fluorescence, histo-cytometry, IMAGING, imaging agent, Method, MICROSCOPY, REPORTER, Tissue False True True NIHTT 37470483 Website Abstract 114172444 Li W, et al. http://www.ncbi.nlm.nih.gov/pubmed/28808033 <a href="http://www.ncbi.nlm.nih.gov/pubmed/28808033">Li W, et al.</a> 114109608 Gerner, Michael NIAID - DIR Gerner, Michael 0 114109609 Li, Weizhe NIAID - DIR NIAID Li, Weizhe (NIAID) 0 114109607 Germain, Ronald NIAID - DIR NIAID Germain, Ronald (NIAID) 1 114109607 Germain, Ronald NIAID - DIR NIAID Germain, Ronald (NIAID) 1 114109608 Gerner, Michael NIAID - DIR Gerner, Michael 0 114109609 Li, Weizhe NIAID - DIR NIAID Li, Weizhe (NIAID) 0 114102401 Clearing-enhanced 3D (Ce3D): A Novel Tissue Clearing Method Preserving Cellular Morphology, Reporter Fluorescence, Epitope E-168-2016-0 Filing authorized NIAID 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-3241] Enhanced Tissue Clearing Solution, Clearing-Enhanced 3D (Ce3D), Compatible with Advanced Fluorescence Microscopy Imaging&body=Please send me information about technology [TAB-3241] Enhanced Tissue Clearing Solution, Clearing-Enhanced 3D (Ce3D), Compatible with Advanced Fluorescence Microscopy Imaging. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-3241] Enhanced Tissue Clearing Solution, Clearing-Enhanced 3D (Ce3D), Compatible with Advanced Fluorescence Microscopy Imaging&body=Please send me information about technology [TAB-3241] Enhanced Tissue Clearing Solution, Clearing-Enhanced 3D (Ce3D), Compatible with Advanced Fluorescence Microscopy Imaging.">yogikala.prabhu@nih.gov</a><br> 114168536 E-168-2016-0 E-168-2016-0-US-01 TISSUE CLEARING METHOD PRV US 62/380,593 Abandoned US <br />Provisional (PRV) 62/380,593<br />Filed on 2016-08-29<br />Status: Abandoned 114168537 E-168-2016-0 E-168-2016-0-PCT-02 METHOD AND COMPOSITION FOR OPTICAL CLEARING OF TISSUES PCT Patent Cooperation Treaty PCT/US2017/049133 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2017/049133<br />Filed on 2017-08-29<br />Status: Expired 114168848 E-168-2016-0 E-168-2016-0-US-03 METHOD AND COMPOSITION FOR OPTICAL CLEARING OF TISSUES National Stage US 11,480,502 16/328,553 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11480502 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11480502">11,480,502</a><br />Filed on 2019-02-26<br />Status: Issued 114127739 AA3AXX 114150344 3D 114150345 Ce3D: 114150346 Tissue 114150347 Clearing 114150348 Method 114150349 Cellular 114150350 REPORTER 114150351 Fluorescence 114150352 Epitope 114150353 IMAGING 114150354 imaging agent 114150355 MICROSCOPY 114150356 histo-cytometry TAB-3202 114097142 Regulator of G Protein Signaling (RGS13) Knock-Out Mouse NIAID Licensing, Research Materials Licensing Research Materials Kirk Druey, Zhi Hui (Sherry) Xie RGS13, an intracellular protein in mast cells, was shown to suppress IgE-mediated anaphylactic response in mice. The RGS13-/- mouse may be used to screen compounds that inhibit mast cell degranulation. Research Material – Patent protection is not being pursued for this technology. (IC Reference No. 2001-097) 2022-03-08 2025-08-13 2025-08-15 2017-12-04 Anaphylactic, Cells, IGE-MEDIATED, Intracellutar, Knockout, Listed LPM Maddox as of 4/15/2015, MAST, Mice, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Protein, RESPONSE, RGS13, RM, RXXXXX, Suppresses, That, WIXXXX False True True NIHTT 37470483 Website Abstract 114109463 Xie, Zhi Hui (Sherry) NIAID - DIR NIAID Xie, Zhi Hui (Sherry) (NIAID) 0 114109462 Druey, Kirk NIAID - DIR NIAID Druey, Kirk (NIAID) 1 114109462 Druey, Kirk NIAID - DIR NIAID Druey, Kirk (NIAID) 1 114109463 Xie, Zhi Hui (Sherry) NIAID - DIR NIAID Xie, Zhi Hui (Sherry) (NIAID) 0 114102364 RGS13, An Intracellutar Protein In Mast Cells That Suppresses IgE-Mediated Anaphylactic Response In Mice E-181-2008-0 Research Material NIAID 91026778 Green, Wade wade.green@nih.gov
United States of America TTIPO wade.green@nih.gov?subject=Web Inquiry on [TAB-3202] Regulator of G Protein Signaling (RGS13) Knock-Out Mouse&body=Please send me information about technology [TAB-3202] Regulator of G Protein Signaling (RGS13) Knock-Out Mouse. Green, Wade<br><a href="mailto:wade.green@nih.gov?subject=Web Inquiry on [TAB-3202] Regulator of G Protein Signaling (RGS13) Knock-Out Mouse&body=Please send me information about technology [TAB-3202] Regulator of G Protein Signaling (RGS13) Knock-Out Mouse.">wade.green@nih.gov</a><br> 114127543 RXXXXX 114127544 WIXXXX 114149912 RGS13 114149913 Intracellutar 114149914 Protein 114149915 MAST 114149916 Cells 114149917 That 114149918 Suppresses 114149919 IGE-MEDIATED 114149920 Anaphylactic 114149921 RESPONSE 114149922 Mice 114149923 Listed LPM Maddox as of 4/15/2015 114149924 Pre LPM working set 20150418 114149925 Post LPM Assignment Set 20150420 114149926 Knockout 114149927 RM TAB-3201 114097141 Conformation Dependent Anti-major Outer Membrane Protein (MOMP) Monoclonal Antibody BD5 NIAID Licensing, Research Materials Licensing Research Materials Harlan Caldwell A murine hybridoma expressing mAb BD3 was found to react with a conformationally dependent epitope on the chlamydial Major Outer Membrane Protein (MOMP), a primary target of neutralizing antibodies and vaccine development. The BD3 neutralized the in vitro infectivity of C. trachomatis serovars B, Ba, D, E, L2. It is useful for verifying the correct conformation of MOMP in vaccines against chlamydia trachomatis, Serovars B, BA, D, E, AND L2. <ul> <li>Speed up product development with NIH developed material that has already been tested and validated.</li> </ul> <ul> <li>A research material that can be used in the development of assays, validation of products or in quality control.</li> </ul> Research Material – Patent protection is not being pursued for this technology. (IC Reference No. 2007-121) 2022-03-08 2025-08-13 2025-08-15 2017-12-04 Against, ANTIBODY, Anti-major, B, ba, BD5, Chlamydia, CONFORMATION, Correct, D, Dependent, e, Hybridoma, L2, Listed LPM Thalhammer-Reyero as of 4/15/2015, Mab, MEMBRANE, MOMP, monoclonal, OUTER, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Protein, RM, SEROVARS, TRACHOMATIS, USEFUL, vaccines, Verifying, WIXXXX False True True NIHTT 37470483 Website Abstract 114109461 Caldwell, Harlan NIAID - DIR NIAID Caldwell, Harlan (NIAID) 1 114109461 Caldwell, Harlan NIAID - DIR NIAID Caldwell, Harlan (NIAID) 1 114102363 Conformation Dependent Anti-major Outer Membrane Protein (MOMP) Monoclonal Antibody (BD3) Useful For Verifying The Correct Conformation Of MOMP In Vaccines Against Chlamydia Trachomatis, Serovars B, Ba, D, E, And L2 E-296-2007-0 Research Material NIAID 91026778 Green, Wade wade.green@nih.gov
United States of America TTIPO wade.green@nih.gov?subject=Web Inquiry on [TAB-3201] Conformation Dependent Anti-major Outer Membrane Protein (MOMP) Monoclonal Antibody BD5&body=Please send me information about technology [TAB-3201] Conformation Dependent Anti-major Outer Membrane Protein (MOMP) Monoclonal Antibody BD5. Green, Wade<br><a href="mailto:wade.green@nih.gov?subject=Web Inquiry on [TAB-3201] Conformation Dependent Anti-major Outer Membrane Protein (MOMP) Monoclonal Antibody BD5&body=Please send me information about technology [TAB-3201] Conformation Dependent Anti-major Outer Membrane Protein (MOMP) Monoclonal Antibody BD5.">wade.green@nih.gov</a><br> 114127542 WIXXXX 114149883 CONFORMATION 114149884 Dependent 114149885 Anti-major 114149886 OUTER 114149887 MEMBRANE 114149888 Protein 114149889 MOMP 114149890 monoclonal 114149891 ANTIBODY 114149892 BD5 114149893 USEFUL 114149894 Verifying 114149895 Correct 114149896 vaccines 114149897 Against 114149898 Chlamydia 114149899 TRACHOMATIS 114149900 SEROVARS 114149901 B 114149902 ba 114149903 D 114149904 e 114149905 L2 114149906 Listed LPM Thalhammer-Reyero as of 4/15/2015 114149907 Pre LPM working set 20150418 114149908 Post LPM Assignment Set 20150420 114149909 Hybridoma 114149910 Mab 114149911 RM TAB-3200 114097140 Hybridoma Cell Line D8H21, Monoclonal Antibody to the Specific Peptide-MHC Class II Complex NIAID Licensing, Research Materials Licensing Research Materials Ronald Germain Hybridoma Cell Line D8H21, as described in Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13856-61 and developed in the laboratory of Dr. Ronald Germain. <ul> <li>Speed up product development with NIH developed material that has already been tested and validated.</li> </ul> <ul> <li>A research material that can be used in the development of assays, validation of products or in quality control.</li> </ul> Research Material – Patent protection is not being pursued for this technology. (IC Reference No. 1948-039) 2022-03-08 2025-08-13 2025-08-15 2017-12-04 Cell, D8H21, Hybridoma, Line, Listed LPM Hastings as of 4/15/2015, Mab, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, RM, WIXXXX False True True NIHTT 37470483 Website Abstract 114172382 Zhong G, et al. https://www.ncbi.nlm.nih.gov/pubmed/9391117 <a href="https://www.ncbi.nlm.nih.gov/pubmed/9391117">Zhong G, et al.</a> 114109460 Germain, Ronald NIAID - DIR NIAID Germain, Ronald (NIAID) 1 114109460 Germain, Ronald NIAID - DIR NIAID Germain, Ronald (NIAID) 1 114102362 Hybridoma Cell Line D8H21 B-021-1999-0 Research Material NIAID 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-3200] Hybridoma Cell Line D8H21, Monoclonal Antibody to the Specific Peptide-MHC Class II Complex&body=Please send me information about technology [TAB-3200] Hybridoma Cell Line D8H21, Monoclonal Antibody to the Specific Peptide-MHC Class II Complex. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-3200] Hybridoma Cell Line D8H21, Monoclonal Antibody to the Specific Peptide-MHC Class II Complex&body=Please send me information about technology [TAB-3200] Hybridoma Cell Line D8H21, Monoclonal Antibody to the Specific Peptide-MHC Class II Complex.">yogikala.prabhu@nih.gov</a><br> 114127541 WIXXXX 114149874 Hybridoma 114149875 Cell 114149876 Line 114149877 D8H21 114149878 Listed LPM Hastings as of 4/15/2015 114149879 Pre LPM working set 20150418 114149880 Post LPM Assignment Set 20150420 114149881 Mab 114149882 RM TAB-3199 114097139 Hybridoma Cell Line B6GE1, Monoclonal Antibody to the Specific Peptide-MHC Class II Complex NIAID Licensing, Research Materials Licensing Research Materials Ronald Germain Hybridoma Cell Line B6GE1 as described in Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13856-61 and developed in the laboratory of Dr. Ronald Germain. <ul> <li>Speed up product development with NIH developed material that has already been tested and validated.</li> </ul> <ul> <li>A research material that can be used in the development of assays, validation of products or in quality control.</li> </ul> Research Material – Patent protection is not being pursued for this technology. (IC Reference No. 1999-006) 2022-03-08 2025-08-13 2025-08-15 2017-12-04 B6GE1, Cell, Hybridoma, Line, Mab, RM, WIXXXX False True True NIHTT 37470483 Website Abstract 114172381 Zhong G, et al. https://www.ncbi.nlm.nih.gov/pubmed/9391117 <a href="https://www.ncbi.nlm.nih.gov/pubmed/9391117">Zhong G, et al.</a> 114109459 Germain, Ronald NIAID - DIR NIAID Germain, Ronald (NIAID) 1 114109459 Germain, Ronald NIAID - DIR NIAID Germain, Ronald (NIAID) 1 114102361 Hybridoma Cell Line B6GE1 B-020-1999-0 Research Material NIAID 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-3199] Hybridoma Cell Line B6GE1, Monoclonal Antibody to the Specific Peptide-MHC Class II Complex&body=Please send me information about technology [TAB-3199] Hybridoma Cell Line B6GE1, Monoclonal Antibody to the Specific Peptide-MHC Class II Complex. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-3199] Hybridoma Cell Line B6GE1, Monoclonal Antibody to the Specific Peptide-MHC Class II Complex&body=Please send me information about technology [TAB-3199] Hybridoma Cell Line B6GE1, Monoclonal Antibody to the Specific Peptide-MHC Class II Complex.">yogikala.prabhu@nih.gov</a><br> 114127540 WIXXXX 114149868 Hybridoma 114149869 Cell 114149870 Line 114149871 B6GE1 114149872 Mab 114149873 RM TAB-3198 114097138 Hybridoma Cell Line 25-D1.16 Producing Monoclonal Anti-H-2Kb/SIINFEKL Complex Antibody NIAID Licensing, Research Materials Licensing Research Materials Ronald Germain, Angel Porgador An H-2Kb/OVA hybridoma cell line producing a monoclonal antibody specific for the H-2Kb/SIINFEKL complex (clone 25-D1.16) as described in Immunity 1997 Jun;6(6):715-26 and developed in the laboratory of Dr. Ronald Germain at the National Institute of Allergy and Infectious Diseases. <ul> <li>Speed up product development with NIH developed material that has already been tested and validated.</li> </ul> <ul> <li>A research material that can be used in the development of assays, validation of products or in quality control.</li> </ul> Research Material – Patent protection is not being pursued for this technology. (IC Reference No. 1948-011) 2022-03-08 2025-08-13 2025-08-15 2017-12-04 25-D1.16, Cell, Hybridoma, Line, Listed LPM Ano as of 4/15/2015, Mab, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, RM, WIXXXX False True True NIHTT 37470483 Website Abstract 114172380 Porgador A, et al. https://www.ncbi.nlm.nih.gov/pubmed/9208844 <a href="https://www.ncbi.nlm.nih.gov/pubmed/9208844">Porgador A, et al.</a> 114109458 Porgador, Angel Porgador, Angel 0 114109457 Germain, Ronald NIAID - DIR NIAID Germain, Ronald (NIAID) 1 114109457 Germain, Ronald NIAID - DIR NIAID Germain, Ronald (NIAID) 1 114109458 Porgador, Angel Porgador, Angel 0 114102360 Hybridoma Cell Line 25-D1.16 B-006-1999-0 Research Material NIAID 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-3198] Hybridoma Cell Line 25-D1.16 Producing Monoclonal Anti-H-2Kb/SIINFEKL Complex Antibody&body=Please send me information about technology [TAB-3198] Hybridoma Cell Line 25-D1.16 Producing Monoclonal Anti-H-2Kb/SIINFEKL Complex Antibody. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-3198] Hybridoma Cell Line 25-D1.16 Producing Monoclonal Anti-H-2Kb/SIINFEKL Complex Antibody&body=Please send me information about technology [TAB-3198] Hybridoma Cell Line 25-D1.16 Producing Monoclonal Anti-H-2Kb/SIINFEKL Complex Antibody.">yogikala.prabhu@nih.gov</a><br> 114127539 WIXXXX 114149859 Hybridoma 114149860 Cell 114149861 Line 114149862 25-D1.16 114149863 Listed LPM Ano as of 4/15/2015 114149864 Pre LPM working set 20150418 114149865 Post LPM Assignment Set 20150420 114149866 Mab 114149867 RM TAB-3197 114097137 Hybridoma Cell Line 715 Producing Monoclonal Antibody Specific for Murine Leukemia Virus gp70 NIAID Infectious Disease, Licensing, Research Materials Infectious Disease Licensing Research Materials Bruce Chesebro <p>Hybridoma cell line 715 expresses monoclonal antibody specific for Moloney murine leukemia virus (MuLV) gp70. Details may be found under NIH AIDS Reagent Program Catalog Number 1278: <a href="http://www.beiresources.org/Catalog/BEICellLinesUninfected/ARP-1278.aspx" target="_blank">https://www.beiresources.org/Catalog/BEICellLinesUninfected/ARP-1278.aspx&nbsp;</a>.&nbsp;</p> <ul> <li>Speed up product development with NIH developed material that has already been tested and validated.</li> </ul> <ul> <li>A research material that can be used in the development of assays, validation of products or in quality control.</li> </ul> Research Material – Patent protection is not being pursued for this technology. (IC Reference No. 1948-230) 2022-03-08 2025-08-13 2025-08-15 2017-12-04 715, Cell, DDXXXX, Detect, Hybridoma, Leukemia, Line, Listed LPM Ano as of 4/15/2015, Mab, moloney, Murine, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, RM, virus, VLXXXX, WIXXXX False True True NIHTT 37470483 Website Abstract 114109456 Chesebro, Bruce NIAID - DIR NIAID Chesebro, Bruce (NIAID) 1 114109456 Chesebro, Bruce NIAID - DIR NIAID Chesebro, Bruce (NIAID) 1 114102359 cell line 715 to detect moloney murine leukemia virus B-059-1994-2 Research Material NIAID 146046171 Joyce, Terrence terrence.joyce@nih.gov
United States of America terrence.joyce@nih.gov?subject=Web Inquiry on [TAB-3197] Hybridoma Cell Line 715 Producing Monoclonal Antibody Specific for Murine Leukemia Virus gp70&body=Please send me information about technology [TAB-3197] Hybridoma Cell Line 715 Producing Monoclonal Antibody Specific for Murine Leukemia Virus gp70. Joyce, Terrence<br><a href="mailto:terrence.joyce@nih.gov?subject=Web Inquiry on [TAB-3197] Hybridoma Cell Line 715 Producing Monoclonal Antibody Specific for Murine Leukemia Virus gp70&body=Please send me information about technology [TAB-3197] Hybridoma Cell Line 715 Producing Monoclonal Antibody Specific for Murine Leukemia Virus gp70.">terrence.joyce@nih.gov</a><br> 114127536 DDXXXX 114127537 VLXXXX 114127538 WIXXXX 114149845 Cell 114149846 Line 114149847 715 114149848 Detect 114149849 moloney 114149850 Murine 114149851 Leukemia 114149852 virus 114149853 Listed LPM Ano as of 4/15/2015 114149854 Pre LPM working set 20150418 114149855 Post LPM Assignment Set 20150420 114149856 Hybridoma 114149857 Mab 114149858 RM TAB-3196 114097136 Hybridoma Cell Line 500 Producing Monoclonal Antibody Specific for Murine Leukemia Virus gp80 NIAID Infectious Disease, Licensing, Research Materials Infectious Disease Licensing Research Materials Bruce Chesebro <p>Hybridoma cell line 500 expresses monoclonal antibody specific for Moloney murine leukemia virus (MuLV) gp80. Details may be found under NIH AIDS Reagent Program Catalog Number 1277: <a href="http://www.beiresources.org/Catalog/BEICellLinesUninfected/ARP-1277.aspx" target="_blank">https://www.beiresources.org/Catalog/BEICellLinesUninfected/ARP-1277.aspx&nbsp;</a>&nbsp;.</p> <ul> <li>Speed up product development with NIH developed material that has already been tested and validated.</li> </ul> <ul> <li>A research material that can be used in the development of assays, validation of products or in quality control.</li> </ul> Research Material – Patent protection is not being pursued for this technology. (IC Reference No. 1948-230) 2022-03-08 2025-08-13 2025-08-15 2017-12-04 500, Cell, DDXXXX, Detect, Hybridoma, Leukemia, Line, Listed LPM Ano as of 4/15/2015, Mab, moloney, Murine, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, RM, virus, VLXXXX, WIXXXX False True True NIHTT 37470483 Website Abstract 114109455 Chesebro, Bruce NIAID - DIR NIAID Chesebro, Bruce (NIAID) 1 114109455 Chesebro, Bruce NIAID - DIR NIAID Chesebro, Bruce (NIAID) 1 114102358 cell line 500 to detect moloney murine leukemia virus B-059-1994-1 Research Material NIAID 146046171 Joyce, Terrence terrence.joyce@nih.gov
United States of America terrence.joyce@nih.gov?subject=Web Inquiry on [TAB-3196] Hybridoma Cell Line 500 Producing Monoclonal Antibody Specific for Murine Leukemia Virus gp80&body=Please send me information about technology [TAB-3196] Hybridoma Cell Line 500 Producing Monoclonal Antibody Specific for Murine Leukemia Virus gp80. Joyce, Terrence<br><a href="mailto:terrence.joyce@nih.gov?subject=Web Inquiry on [TAB-3196] Hybridoma Cell Line 500 Producing Monoclonal Antibody Specific for Murine Leukemia Virus gp80&body=Please send me information about technology [TAB-3196] Hybridoma Cell Line 500 Producing Monoclonal Antibody Specific for Murine Leukemia Virus gp80.">terrence.joyce@nih.gov</a><br> 114127533 DDXXXX 114127534 WIXXXX 114127535 VLXXXX 114149831 Cell 114149832 Line 114149833 500 114149834 Detect 114149835 moloney 114149836 Murine 114149837 Leukemia 114149838 virus 114149839 Listed LPM Ano as of 4/15/2015 114149840 Pre LPM working set 20150418 114149841 Post LPM Assignment Set 20150420 114149842 Hybridoma 114149843 Mab 114149844 RM TAB-3195 114097135 Hybridoma Cell Line 273 Producing Monoclonal Antibody Specific for Murine Leukemia Virus gp70 NIAID Infectious Disease, Licensing, Research Materials Infectious Disease Licensing Research Materials Bruce Chesebro <p>Hybridoma cell line 273 expresses monoclonal antibody specific for murine leukemia virus (MuLV) gp70. Details may be found under NIH AIDS Reagent Program Catalog Number 1279: <a href="http://www.beiresources.org/Catalog/BEICellLinesUninfected/ARP-1279.aspx" target="_blank">https://www.beiresources.org/Catalog/BEICellLinesUninfected/ARP-1279.aspx&nbsp;</a>&nbsp;.</p> <ul> <li>Speed up product development with NIH developed material that has already been tested and validated.</li> </ul> <ul> <li>A research material that can be used in the development of assays, validation of products or in quality control.</li> </ul> Research Material – Patent protection is not being pursued for this technology. (IC Reference No. 1948-230) 2022-03-08 2025-08-13 2025-08-15 2017-12-04 273, Cell, DDXXXX, Detect, Hybridoma, Leukemia, Line, Listed LPM Ano as of 4/15/2015, Mab, moloney, Murine, NIH ARP, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, RM, virus, VLXXXX, WIXXXX False True True NIHTT 37470483 Website Abstract 114109454 Chesebro, Bruce NIAID - DIR NIAID Chesebro, Bruce (NIAID) 1 114109454 Chesebro, Bruce NIAID - DIR NIAID Chesebro, Bruce (NIAID) 1 114102357 cell line 273 to detect moloney murine leukemia virus B-059-1994-0 Research Material NIAID 146046171 Joyce, Terrence terrence.joyce@nih.gov
United States of America terrence.joyce@nih.gov?subject=Web Inquiry on [TAB-3195] Hybridoma Cell Line 273 Producing Monoclonal Antibody Specific for Murine Leukemia Virus gp70&body=Please send me information about technology [TAB-3195] Hybridoma Cell Line 273 Producing Monoclonal Antibody Specific for Murine Leukemia Virus gp70. Joyce, Terrence<br><a href="mailto:terrence.joyce@nih.gov?subject=Web Inquiry on [TAB-3195] Hybridoma Cell Line 273 Producing Monoclonal Antibody Specific for Murine Leukemia Virus gp70&body=Please send me information about technology [TAB-3195] Hybridoma Cell Line 273 Producing Monoclonal Antibody Specific for Murine Leukemia Virus gp70.">terrence.joyce@nih.gov</a><br> 114127530 DDXXXX 114127531 VLXXXX 114127532 WIXXXX 114149816 Cell 114149817 Line 114149818 273 114149819 Detect 114149820 moloney 114149821 Murine 114149822 Leukemia 114149823 virus 114149824 Listed LPM Ano as of 4/15/2015 114149825 Pre LPM working set 20150418 114149826 Post LPM Assignment Set 20150420 114149827 NIH ARP 114149828 Hybridoma 114149829 Mab 114149830 RM TAB-3188 114097129 Chlamydial Vaccine Technologies NIAID Diagnostics, Infectious Disease, Licensing, Rare/Neglected Diseases, Research Materials, Vaccines Diagnostics Infectious Disease Licensing Rare/Neglected Diseases Research Materials Vaccines Harlan Caldwell, Deborah Crane, Laszlo Kari The National Institute of Allergy and Infectious Diseases has invented three chlamydial vaccine technologies, which have shown promising preclinical efficacy. Chlamydia trachomatis infection is the most common sexually transmitted bacterial infection. If left untreated, chlamydia infection can lead to pelvic inflammatory disease and infertility. Chlamydia is also the leading cause of preventable blindness in the world. Despite increased surveillance, prevalence continues to increase, and the need to develop an effective chlamydial vaccine remains.<br /><br /> Technologies: <br /> 1. A plasmid-deficient Chlamydia trachomatis strain which was shown to be a safe, immunogenic, and protective live attenuated vaccine in a nonhuman primate model.<br /> 2. A Chlamydia trachomatis polymorphic membrane protein D (PmpD) based subunit vaccine.<br /> 3. A live-attenuated Chlamydia trachomatis plasmid vector deficient in virulence genes, pgp3 and pgp4, which can be used to vaccinate against chlamydia as well as other against other bacterial and viral mucosal pathogens. <ul> <li>Coverage against multiple serovars.</li> <li>Promising preclinical data.</li> </ul> <ul> <li>Chlamydia trachomatis vaccine or therapeutic.</li> <li>Vaccine platform technology for mucosal viral and bacterial pathogens.</li> </ul> Research Material – Patent protection is not being pursued for this technology. (IC Reference No. 2011-028) 2022-03-08 2025-08-13 2025-08-15 2018-03-28 Against, Attenuated, -Attenuated, Bacterial strains, Blinding, Chlamydia, DA3XXX, DC4XXX, DCXXXX, DD1XXX, DDXXXX, DISEASES, Human, Immunogenic, Listed LPM Stansberry as of 4/15/2015, Live, Model, MULTIPLE, NON, Patent Category - Biotechnology, Plasmid-deficient, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, primate, Protective, RM, SAFE, Sexually, Strain, Trachoma, TRACHOMATIS, Transmitted, UBXXXX, Vaccine, VJXXXX, WIXXXX, WNXXXX False True True NIHTT 37470483 Website Abstract 114170478 Olivares-Zavaleta N, et al. https://www.ncbi.nlm.nih.gov/pubmed/24711617 <a href="https://www.ncbi.nlm.nih.gov/pubmed/24711617">Olivares-Zavaleta N, et al.</a> 114172462 Kari L, et al. https://www.ncbi.nlm.nih.gov/pubmed/21987657 <a href="https://www.ncbi.nlm.nih.gov/pubmed/21987657">Kari L, et al.</a> 114172463 Song L, et al. https://www.ncbi.nlm.nih.gov/pubmed/23319558 <a href="https://www.ncbi.nlm.nih.gov/pubmed/23319558">Song L, et al.</a> 114172464 Carlson JH, et al. https://www.ncbi.nlm.nih.gov/pubmed/15557630 <a href="https://www.ncbi.nlm.nih.gov/pubmed/15557630">Carlson JH, et al.</a> 114172465 Caldwell HD, et al. https://www.ncbi.nlm.nih.gov/pubmed/12782678 <a href="https://www.ncbi.nlm.nih.gov/pubmed/12782678">Caldwell HD, et al.</a> 114172466 Swanson KA, et al. https://www.ncbi.nlm.nih.gov/pubmed/19001072 <a href="https://www.ncbi.nlm.nih.gov/pubmed/19001072">Swanson KA, et al.</a> 114172467 Crane DD, et al. https://www.ncbi.nlm.nih.gov/pubmed/16446444 <a href="https://www.ncbi.nlm.nih.gov/pubmed/16446444">Crane DD, et al.</a> 114109447 Kari, Laszlo NIAID - DIR NIAID Kari, Laszlo (NIAID) 0 114109658 Crane, Deborah NIAID - DIR NIAID Crane, Deborah (NIAID) 0 114109446 Caldwell, Harlan NIAID - DIR NIAID Caldwell, Harlan (NIAID) 1 114109446 Caldwell, Harlan NIAID - DIR NIAID Caldwell, Harlan (NIAID) 1 114109447 Kari, Laszlo NIAID - DIR NIAID Kari, Laszlo (NIAID) 0 114109658 Crane, Deborah NIAID - DIR NIAID Crane, Deborah (NIAID) 0 114102350 Plasmid-deficient Chlamydia Trachomatis Strain As Safe, Immunogenic, And Protective Live Attenuated Vaccine For Blinding Trachoma In A Non Human Primate Model E-028-2012-0 Research Material NIAID 114102418 Vaccine Against Chlamydia Trachomatis Sexually Transmitted Diseases And Blinding Trachoma E-031-2006-0 Filing authorized NIAID 114102419 Live -Attenuated Vaccine Against Multiple Sexually Transmitted Diseases E-133-2012-0 Filing authorized NIAID 91026778 Green, Wade wade.green@nih.gov
United States of America TTIPO wade.green@nih.gov?subject=Web Inquiry on [TAB-3188] Chlamydial Vaccine Technologies&body=Please send me information about technology [TAB-3188] Chlamydial Vaccine Technologies. Green, Wade<br><a href="mailto:wade.green@nih.gov?subject=Web Inquiry on [TAB-3188] Chlamydial Vaccine Technologies&body=Please send me information about technology [TAB-3188] Chlamydial Vaccine Technologies.">wade.green@nih.gov</a><br> 114168585 E-031-2006-0 E-031-2006-0-US-01 Chlamydia Vaccine PRV US 60/760,970 Abandoned US <br />Provisional (PRV) 60/760,970<br />Filed on 2006-01-19<br />Status: Abandoned 114168586 E-031-2006-0 E-031-2006-0-PCT-02 Chlamydia Vaccine PCT Patent Cooperation Treaty PCT/US2007/001213 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2007/001213<br />Filed on 2007-01-16<br />Status: Expired 114168587 E-031-2006-0 E-031-2006-0-US-03 Chlamydia Vaccine National Stage US 9,259,463 12/087,952 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9259463 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9259463">9,259,463</a><br />Filed on 2010-10-01<br />Status: Issued 114168588 E-031-2006-0 E-031-2006-0-US-05 Chlamydia Vaccine DIV US 10,420,829 15/043,975 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10420829 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10420829">10,420,829</a><br />Filed on 2016-02-15<br />Status: Issued 114168589 E-133-2012-0 E-133-2012-0-US-01 Novel Attenuated Vaccine PRV US 61/753,320 Abandoned US <br />Provisional (PRV) 61/753,320<br />Filed on 2013-01-16<br />Status: Abandoned 114168590 E-133-2012-0 E-133-2012-0-PCT-02 Attenuated Chlamydia Vaccine PCT Patent Cooperation Treaty PCT/US2014/011799 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2014/011799<br />Filed on 2014-01-16<br />Status: Expired 114168591 E-133-2012-0 E-133-2012-0-US-03 Attenuated Chlamydia Vaccine National Stage US 10,258,682 14/761,520 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10258682 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10258682">10,258,682</a><br />Filed on 2015-07-16<br />Status: Issued 114127515 WIXXXX 114127516 WNXXXX 114127517 VJXXXX 114127821 DCXXXX 114127822 DC4XXX 114127823 DDXXXX 114127824 DD1XXX 114127825 DA3XXX 114127826 UBXXXX 114149711 Plasmid-deficient 114149712 Chlamydia 114149713 TRACHOMATIS 114149714 Strain 114149715 SAFE 114149716 Immunogenic 114149717 Protective 114149718 Live 114149719 Attenuated 114149720 Vaccine 114149721 Blinding 114149722 Trachoma 114149723 NON 114149724 Human 114149725 primate 114149726 Model 114149727 Listed LPM Stansberry as of 4/15/2015 114149728 Pre LPM working set 20150418 114149729 Post LPM Assignment Set 20150420 114149730 Bacterial strains 114149731 RM 114150518 Against 114150519 Sexually 114150520 Transmitted 114150521 DISEASES 114150522 Patent Category - Biotechnology 114150523 MULTIPLE 114150524 -Attenuated TAB-3185 114097103 Regulators of G Protein Signalling (RGS) 1,3,4,5 & 13 cDNAs NIAID Licensing, Research Materials Licensing Research Materials Kendall Blumer, Kirk Druey, Eric Johnson, Veronica Kang, John Kehrl Plasmids encode regulators of G protein signalling (RGS). <ul> <li>Speed up product development with NIH developed material that has already been tested and validated.</li> </ul> <ul> <li>A research material that can be used in the development of assays, validation of products or in quality control.</li> </ul> Research Material – Patent protection is not being pursued for this technology. (IC Reference No. 2001-009) 2022-03-08 2025-08-13 2025-08-15 2017-12-04 &, 1, 13, 3, 4, 5, Listed LPM Maddox as of 4/15/2015, PLASMID, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, RGS, RM, RXXXXX, WIXXXX False True True NIHTT 37470483 Website Abstract 114109432 Johnson, Eric NIAID - DIR Johnson, Eric 0 114109433 Blumer, Kendall Blumer, Kendall 0 114109434 Kehrl, John NIAID - DIR NIAID Kehrl, John (NIAID) 0 114109435 Kang, Veronica NIAID - DIR Kang, Veronica 0 114109431 Druey, Kirk NIAID - DIR NIAID Druey, Kirk (NIAID) 1 114109431 Druey, Kirk NIAID - DIR NIAID Druey, Kirk (NIAID) 1 114109432 Johnson, Eric NIAID - DIR Johnson, Eric 0 114109433 Blumer, Kendall Blumer, Kendall 0 114109434 Kehrl, John NIAID - DIR NIAID Kehrl, John (NIAID) 0 114109435 Kang, Veronica NIAID - DIR Kang, Veronica 0 114102347 RGS 1,3,4,5, & 13 E-283-2001-0 Research Material EM, NIAID 91026778 Green, Wade wade.green@nih.gov
United States of America TTIPO wade.green@nih.gov?subject=Web Inquiry on [TAB-3185] Regulators of G Protein Signalling (RGS) 1,3,4,5 & 13 cDNAs&body=Please send me information about technology [TAB-3185] Regulators of G Protein Signalling (RGS) 1,3,4,5 & 13 cDNAs. Green, Wade<br><a href="mailto:wade.green@nih.gov?subject=Web Inquiry on [TAB-3185] Regulators of G Protein Signalling (RGS) 1,3,4,5 & 13 cDNAs&body=Please send me information about technology [TAB-3185] Regulators of G Protein Signalling (RGS) 1,3,4,5 & 13 cDNAs.">wade.green@nih.gov</a><br> 114127511 RXXXXX 114127512 WIXXXX 114149677 RGS 114149678 1 114149679 3 114149680 4 114149681 5 114149682 & 114149683 13 114149684 Listed LPM Maddox as of 4/15/2015 114149685 Pre LPM working set 20150418 114149686 Post LPM Assignment Set 20150420 114149687 PLASMID 114149688 RM TAB-3169 114097121 Broadly Neutralizing Antibodies Against HIV-1 Directed to the CD4 Binding Site of HIV Envelope Protein NIAID Diagnostics, Infectious Disease, Licensing, Research Materials, Therapeutics, Vaccines Diagnostics Infectious Disease Licensing Research Materials Therapeutics Vaccines Gwo-yu Chauang, Gwo-Yu Chuang, Mark Connors, Ivelin Georgiev, Carl-Magnus Hogerkorp, Young Do Kwon, Peter Kwong, Yuxing Li, John Mascola, Gary Nabel, Gilad Ofek, Mario Roederer, Rebecca Rudicell, William Schief, Lawrence Shapiro, Wei Shi, Xueling Wu, Richard Wyatt, Yongping Yang, Zhi-yong Yang, Baoshan Zhang, Tongqing Zhou, Jiang Zhu Inhibiting the ability of HIV-1, the virus that causes AIDS, to infect cells is one approach to both prevention and treatment of HIV. Scientists at the NIAID Vaccine Research Center have isolated and characterized neutralizing antibodies (VRC01, 02, 03, and 07) that bind to the CD4 binding site of HIV-1 envelope glycoprotein gp120. These human monoclonal antibodies can potentially be used as a therapeutic to: (1) treat an HIV infection, (2) decrease and prevent HIV-transmission from mother to infant, and (3) be effectively combined with anti-retroviral drug therapy. Additionally, the antibodies can be used for detection of HIV-1 infection in biological samples, including body fluids; and tissues from biopsies, autopsies, and pathology specimens.<br /><br /> VRC01 has been tested in several phase I clinical trials for safety and pharmacokinetics in infants, adults, and HIV-positive adults. VRC01 is currently being evaluated in a phase II clinical trial for prevention of HIV-1 acquisition. <ul> <li>Monoclonal neutralizing antibodies prevent viral entry into cells</li> <li>Monoclonal neutralizing antibodies can be used for vaccine design and to develop diagnostics for HIV-1</li> </ul> <ul> <li>Monoclonal antibodies to treat and/or diagnose HIV and/or AIDS</li> <li>Immunoassays and kits</li> </ul> Various international patent applications may also be available. 2022-07-27 2025-08-13 2025-08-15 2017-10-10 Against, antibodies, Antibodies., ANTIBODY, Antibody-based, B-Cells, Broadly, Chain, Constructs, CREATION, DA4AXX, DB4AXX, DC5AXX, DD2XXX, Epitope-Specific, Expressing, FUNCTION, Further, GENERAL, GLYCOPROTEIN, gp120, HIV, HIV-1, Identity, Immunoadesion, Immunoadhesin, Isolation, Listed LPM Thalhammer-Reyero as of 4/15/2015, MODE, Modifications, monoclonal, Monoco, Neutizing, Neutralization, Neutralizing, Novel, Patent Category - Biotechnology, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Probes, Single, Specific, VRC03, VRC03Isolation False True True NIHTT 37470483 Website Abstract 114172373 Nabel G, et al. https://www.ncbi.nlm.nih.gov/pubmed/26041300 <a href="https://www.ncbi.nlm.nih.gov/pubmed/26041300">Nabel G, et al.</a> 114172374 Nabel G, et al. https://www.ncbi.nlm.nih.gov/pubmed/25142607 <a href="https://www.ncbi.nlm.nih.gov/pubmed/25142607">Nabel G, et al.</a> 114172375 Wu X, et al. https://www.ncbi.nlm.nih.gov/pubmed/21325411 <a href="https://www.ncbi.nlm.nih.gov/pubmed/21325411">Wu X, et al.</a> 114172376 Zhou T, et al. https://www.ncbi.nlm.nih.gov/pubmed/20616231 <a href="https://www.ncbi.nlm.nih.gov/pubmed/20616231">Zhou T, et al.</a> 114109360 Wyatt, Richard NIAID - VRC NIAID Wyatt, Richard (NIAID) 0 114109361 Wu, Xueling NIAID - VRC NIAID Wu, Xueling (NIAID) 0 114109362 Li, Yuxing NIAID - VRC Li, Yuxing 0 114109363 Hogerkorp, Carl-Magnus NIAID - VRC Hogerkorp, Carl-Magnus 0 114109364 Roederer, Mario NIAID - DIR NIAID Roederer, Mario (NIAID) 0 114109365 Yang, Zhi-yong NIAID - DIR NIAID Yang, Zhi-yong (NIAID) 0 114109366 Nabel, Gary NIAID - VRC NIAID Nabel, Gary (NIAID) 0 114109367 Kwong, Peter NIAID - VRC NIAID Kwong, Peter (NIAID) 0 114109368 Zhou, Tongqing NIAID - VRC NIAID Zhou, Tongqing (NIAID) 0 114109369 Connors, Mark NIAID - DIR NIAID Connors, Mark (NIAID) 0 114109370 Ofek, Gilad NIAID - VRC NIAID Ofek, Gilad (NIAID) 0 114109371 Yang, Yongping NIAID - VRC NIAID Yang, Yongping (NIAID) 0 114109372 Zhu, Jiang NIAID - VRC NIAID Zhu, Jiang (NIAID) 0 114109373 Shapiro, Lawrence NIAID - VRC NIAID Shapiro, Lawrence (NIAID) 0 114109374 Schief, William University of Washington Schief, William 0 114109375 Rudicell, Rebecca NIAID - VRC NIAID Rudicell, Rebecca (NIAID) 0 114109376 Georgiev, Ivelin NIAID - VRC NIAID Georgiev, Ivelin (NIAID) 0 114109377 Kwon, Young Do NIAID - DIR NIAID Kwon, Young Do (NIAID) 0 114109378 Zhang, Baoshan NIAID Zhang, Baoshan (NIAID) 0 114109379 Chauang, Gwo-yu NIAID - VRC Chauang, Gwo-yu 0 114109380 Shi, Wei NIAID - VRC NIAID Shi, Wei (NIAID) 0 114109381 Chuang, Gwo-Yu NIAID - DIR NIAID Chuang, Gwo-Yu (NIAID) 0 114109359 Mascola, John NIAID - VRC NIAID Mascola, John (NIAID) 1 114109359 Mascola, John NIAID - VRC NIAID Mascola, John (NIAID) 1 114109360 Wyatt, Richard NIAID - VRC NIAID Wyatt, Richard (NIAID) 0 114109361 Wu, Xueling NIAID - VRC NIAID Wu, Xueling (NIAID) 0 114109362 Li, Yuxing NIAID - VRC Li, Yuxing 0 114109363 Hogerkorp, Carl-Magnus NIAID - VRC Hogerkorp, Carl-Magnus 0 114109364 Roederer, Mario NIAID - DIR NIAID Roederer, Mario (NIAID) 0 114109365 Yang, Zhi-yong NIAID - DIR NIAID Yang, Zhi-yong (NIAID) 0 114109366 Nabel, Gary NIAID - VRC NIAID Nabel, Gary (NIAID) 0 114109367 Kwong, Peter NIAID - VRC NIAID Kwong, Peter (NIAID) 0 114109368 Zhou, Tongqing NIAID - VRC NIAID Zhou, Tongqing (NIAID) 0 114109369 Connors, Mark NIAID - DIR NIAID Connors, Mark (NIAID) 0 114109370 Ofek, Gilad NIAID - VRC NIAID Ofek, Gilad (NIAID) 0 114109371 Yang, Yongping NIAID - VRC NIAID Yang, Yongping (NIAID) 0 114109372 Zhu, Jiang NIAID - VRC NIAID Zhu, Jiang (NIAID) 0 114109373 Shapiro, Lawrence NIAID - VRC NIAID Shapiro, Lawrence (NIAID) 0 114109374 Schief, William University of Washington Schief, William 0 114109375 Rudicell, Rebecca NIAID - VRC NIAID Rudicell, Rebecca (NIAID) 0 114109376 Georgiev, Ivelin NIAID - VRC NIAID Georgiev, Ivelin (NIAID) 0 114109377 Kwon, Young Do NIAID - DIR NIAID Kwon, Young Do (NIAID) 0 114109378 Zhang, Baoshan NIAID Zhang, Baoshan (NIAID) 0 114109379 Chauang, Gwo-yu NIAID - VRC Chauang, Gwo-yu 0 114109380 Shi, Wei NIAID - VRC NIAID Shi, Wei (NIAID) 0 114109381 Chuang, Gwo-Yu NIAID - DIR NIAID Chuang, Gwo-Yu (NIAID) 0 114102320 Isolation Of Novel Broadly Neutralizing Monoclonal Antibodies Against HIV-1 Using Epitope-Specific Glycoprotein Probes To Identify HIV-1 Specific B-Cells E-300-2009-0 Filing authorized NIAID, University of Washington 114102321 Isolation Of Novel Broadly Neutralizing Monoclonal Antibodies Against HIV-1 Using Epitope-specific Glycoprotein Probes To Identify HIV-1 Specific B-cells E-300-2009-1 Filing authorized NIAID, Sanofi Pasteur Biologics Co, Sanofi R&D, University of Maryland, University of Washington 114102322 Isolation Of Novel Broadly Neutralizing Monoclonal Antibodies Against HIV-1 Using Epitope-Specific Glycoprotein Probes To Identity HIV-1 Specific B-Cells (VRC03) E-300-2009-2 Filing authorized NIAID, University of Maryland, University of Washington 114102323 Creation Of Single Chain Antibody And Immunoadhesin Constructs Expressing Neutralizing Monoclonal Antibodies. E-300-2009-3 Filing authorized NIAID, University of Washington 114102324 A General Mode Of Antibody-based Neutralization Of HIV-1 Gp120 E-300-2009-4 Filing authorized NIAID, University of Washington 114102325 Isolation Of Novel Broadly Neutralizing Monoclonal Antibodies Against HIV-1 Using Epitope-Specific Glycoprotein Probes To Identity HIV-1 Specific B-Cells (VRC03) Isolation Of Novel Broadly Neutralizing Monoclonal Antibodies Against HIV-l Using Epitop E-300-2009-5 Filing authorized NIAID, University of Washington 114102326 Isolation Of Novel Broadly Neutralizing Monoclonal Antibodies Against HIV-1 Using Epitope-Specific Glycoprotein Probes To Identity HIV-1 Specific B-Cells (VRC03) Isolation Of Novel Broadly Neutralizing Monoclonal Antibodies Against HIV-l Using Epitop E-300-2009-6 Filing authorized NIAID, University of Washington 114102327 Isolation Of Novel Broadly Neutralizing Monoclonal Antibodies Against HIV-1 Using Epitope-Specific Glycoprotein Probes To Identity HIV-1 Specific B-Cells (VRC03) Isolation Of Novel Broadly Neutralizing Monoclonal Antibodies Against HIV-l Using Epitop E-300-2009-7 Filing authorized NIAID, University of Washington 114102328 HIV Neutralizing Antibodies E-051-2012-0 Filing authorized NIAID 114102329 Modifications To HIV Neutralizing Antibodies To Improve Function E-051-2012-1 Filing authorized NIAID 114102330 Further Modifications To HIV Neutralizing Antibodies To Improve Function E-051-2012-2 Filing authorized NIAID 114102331 Further Modifications To HIV Neutralizing Antibodies To Improve Function E-051-2012-3 Filing authorized NIAID 91025211 Rainwater, Charles crainwater@mail.nih.gov
United States of America crainwater@mail.nih.gov?subject=Web Inquiry on [TAB-3169] Broadly Neutralizing Antibodies Against HIV-1 Directed to the CD4 Binding Site of HIV Envelope Protein&body=Please send me information about technology [TAB-3169] Broadly Neutralizing Antibodies Against HIV-1 Directed to the CD4 Binding Site of HIV Envelope Protein. Rainwater, Charles<br><a href="mailto:crainwater@mail.nih.gov?subject=Web Inquiry on [TAB-3169] Broadly Neutralizing Antibodies Against HIV-1 Directed to the CD4 Binding Site of HIV Envelope Protein&body=Please send me information about technology [TAB-3169] Broadly Neutralizing Antibodies Against HIV-1 Directed to the CD4 Binding Site of HIV Envelope Protein.">crainwater@mail.nih.gov</a><br> 114160703 E-300-2009-1 E-300-2009-1-US-01 Neutralizing Antibodies Against HIV-1 And Their Use PRV US 61/252,613 Abandoned US <br />Provisional (PRV) 61/252,613<br />Filed on 2009-10-16<br />Status: Abandoned 114160704 E-300-2009-0 E-300-2009-0-US-01 Neutralizing Antibodies to HIV-1 and Their Use PRV US 61/246,039 Abandoned US <br />Provisional (PRV) 61/246,039<br />Filed on 2009-09-25<br />Status: Abandoned 114168386 E-300-2009-2 E-300-2009-2-US-01 Neutralizing Antibodies Against HIV-1 And Their Use PRV US 61/290,135 Abandoned US <br />Provisional (PRV) 61/290,135<br />Filed on 2009-12-24<br />Status: Abandoned 114168387 E-300-2009-3 E-300-2009-3-US-01 Neutralizing Antibodies to HIV-1 and their Use PRV US 61/346,808 Abandoned US <br />Provisional (PRV) 61/346,808<br />Filed on 2010-05-20<br />Status: Abandoned 114168388 E-300-2009-4 E-300-2009-4-US-01 Neutralizing Antibodies to HIV-1 And Their Use PRV US 61/402,314 Abandoned US <br />Provisional (PRV) 61/402,314<br />Filed on 2010-08-27<br />Status: Abandoned 114168389 E-300-2009-5 E-300-2009-5-PCT-01 Neutralizing Monoclonal Antibodies To HIV-1 And Their Use PCT COMB Patent Cooperation Treaty PCT/US2010/050295 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2010/050295<br />Filed on 2010-09-24<br />Status: Expired 114168390 E-300-2009-5 E-300-2009-5-US-07 NEUTRALIZING ANTIBODIES TO HIV-1 AND THEIR USE National Stage US 9,175,070 13/498,125 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9175070 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9175070">9,175,070</a><br />Filed on 2012-03-23<br />Status: Issued 114168391 E-300-2009-5 E-300-2009-5-US-09 NEUTRALIZING ANTIBODIES TO HIV-1 AND THEIR USE ORD US 8,637,036 13/429,286 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8637036 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8637036">8,637,036</a><br />Filed on 2012-03-23<br />Status: Issued 114168392 E-300-2009-5 E-300-2009-5-US-10 Neutralizing Antibodies to HIV-1 and Their Use DIV US 9,738,703 14/864,705 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9738703 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9738703">9,738,703</a><br />Filed on 2015-09-24<br />Status: Issued 114168393 E-300-2009-5 E-300-2009-5-US-11 NEUTRALIZING ANTIBODIES TO HIV-1 AND THEIR USE DIV US 10,035,845 15/661,867 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10035845 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10035845">10,035,845</a><br />Filed on 2017-07-27<br />Status: Issued 114168394 E-300-2009-6 E-300-2009-6-US-01 Neutralizing Antibodies To HIV-1 And Their Use PRV US 61/385,531 Abandoned US <br />Provisional (PRV) 61/385,531<br />Filed on 2010-09-22<br />Status: Abandoned 114168395 E-300-2009-7 E-300-2009-7-US-01 NEUTRALIZING ANTIBODIES TO HIV-1 AND THEIR USE CIP US 13/429,279 Abandoned US <br />Continuation in Part (CIP) 13/429,279<br />Filed on 2012-03-23<br />Status: Abandoned 114168396 E-051-2012-0 E-051-2012-0-US-01 Neutralizing Antibodies To HIV-1 And Their Use PRV US 61/568,520 Abandoned US <br />Provisional (PRV) 61/568,520<br />Filed on 2011-12-08<br />Status: Abandoned 114168397 E-051-2012-1 E-051-2012-1-US-01 NEUTRALIZING ANTIBODIES TO HIV-1 AND THEIR USE PRV US 61/613,431 Abandoned US <br />Provisional (PRV) 61/613,431<br />Filed on 2012-03-20<br />Status: Abandoned 114168398 E-051-2012-2 E-051-2012-2-US-01 NEUTRALIZING ANTIBODIES TO HIV-1 AND THEIR USE PRV US 61/698,452 Abandoned US <br />Provisional (PRV) 61/698,452<br />Filed on 2012-09-07<br />Status: Abandoned 114168399 E-051-2012-3 E-051-2012-3-PCT-01 Neutralizing Antibodies To HIV-1 and Their Use PCT Patent Cooperation Treaty PCT/US2012/068827 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2012/068827<br />Filed on 2012-12-10<br />Status: Expired 114168400 E-051-2012-3 E-051-2012-3-US-06 Broadly Neutralizing HIV-1 VRC07 Antibodies that Bind to the CD4-Binding Site of the Envelope Protein National Stage US 9,695,230 14/363,740 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9695230 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9695230">9,695,230</a><br />Filed on 2014-06-06<br />Status: Issued 114168401 E-051-2012-3 E-051-2012-3-US-09 NEUTRALIZING ANTIBODIES TO HIV-1 AND THEIR USE DIV US 10,035,844 15/612,846 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10035844 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10035844">10,035,844</a><br />Filed on 2017-06-02<br />Status: Issued 114168697 E-051-2012-3 E-051-2012-3-US-11 BROADLY NEUTRALIZING HIV-1 ANTIBODIES THAT BIND TO THE CD4-BINDING SITE OF THE ENVELOPE PROTEIN DIV US 10,815,295 16/044,083 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10815295 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10815295">10,815,295</a><br />Filed on 2018-07-24<br />Status: Issued 114127390 DA4AXX 114127391 DB4AXX 114127392 DC5AXX 114127393 DD2XXX 114149461 Neutralizing 114149462 monoclonal 114149463 antibodies 114149464 HIV-1 114149465 Epitope-Specific 114149466 Listed LPM Thalhammer-Reyero as of 4/15/2015 114149467 Pre LPM working set 20150418 114149468 Post LPM Assignment Set 20150420 114149469 VRC03 114149470 Patent Category - Biotechnology 114149471 Isolation 114149472 Novel 114149473 Broadly 114149474 Against 114149475 GLYCOPROTEIN 114149476 Probes 114149477 Identity 114149478 Specific 114149479 B-Cells 114149480 Single 114149481 CREATION 114149482 Chain 114149483 ANTIBODY 114149484 Immunoadhesin 114149485 Constructs 114149486 Expressing 114149487 Antibodies. 114149488 Immunoadesion 114149489 Neutizing 114149490 Monoco 114149491 VRC03Isolation 114149492 GENERAL 114149493 MODE 114149494 Antibody-based 114149495 Neutralization 114149496 gp120 114149497 HIV 114149498 FUNCTION 114149499 Modifications 114149500 Further TAB-3157 114097106 Hybrid Computer Tomography Scanning System NHLBI Collaboration, Diagnostics, Medical Devices, Non-Medical Devices, Software / Apps Collaboration Diagnostics Medical Devices Non-Medical Devices Software / Apps Han Wen The invention relates to a combination hybrid computer tomography (CT) system that is particularly suited for elucidating stages in pulmonary diseases, notably cystic fibrosis and lung cancer. Improved visualization of lung parenchyma and the margins of lung cysts (non-invasive “virtual biopsy”) may provide sufficient detail to distinguish the types of cystic lesions such that the typical lung tissue pathologic biopsy would not be needed to make a diagnosis. The system includes placing one or more x-ray detector panels near the patient’s body initially outside the view of a CT scanner and then moved into place for a secondary scan. An initial low dose scan, CT scan or X-ray, can be performed and if a high-resolution CT scan is then necessary a flat panel detector is positioned near the area of interest. It is preferable that the flat panel detector be transparent to high-energy x-ray photons. The plurality of acquired images are then reconstructed into a low and high-resolution image. <ul> <li>Non-invasive lung biopsies</li> </ul> The National Heart, Lung, and Blood Institute seeks statements of capability or interest from parties interested in collaborative research to further develop and evaluate this technology. Please contact Cecilia Pazman, PhD, Technology Development Specialist, Office of Technology Transfer, National Heart, Lung, and Blood Institute; Phone: (301) 594-4273; Email: <a href="mailto:pazmance@nhlbi.nih.gov">pazmance@nhlbi.nih.gov</a>. 2022-03-08 2025-08-13 2025-08-15 2017-08-23 AA3B6X, AA3CXX, CT, HYBRID, lung cancer, Lung Disease, Lung-Targeted, Pulmonary, PULMONARY FIBROSIS, WBXXXX, XFXXXX, X-RAY, YAXXXX False True True 52406768 Discovery 52406768 NIHTT 37470483 Website Abstract 114109320 Wen, Han National Heart, Lung, and Blood Institute (NHLBI) NHLBI Wen, Han (NHLBI) 1 114109320 Wen, Han National Heart, Lung, and Blood Institute (NHLBI) NHLBI Wen, Han (NHLBI) 1 114102307 Hybrid CT System With Additional Detectors In Close Proximity To The Body E-175-2017-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 83739538 Choudhry, Vidita vidita.choudhry@nih.gov
United States of America Office of Technology Transfer and Development vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-3157] Hybrid Computer Tomography Scanning System&body=Please send me information about technology [TAB-3157] Hybrid Computer Tomography Scanning System. Choudhry, Vidita<br><a href="mailto:vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-3157] Hybrid Computer Tomography Scanning System&body=Please send me information about technology [TAB-3157] Hybrid Computer Tomography Scanning System.">vidita.choudhry@nih.gov</a><br> 114168348 E-175-2017-0 E-175-2017-0-US-01 Hybrid CT System With Additional Detectors In Close Proximity To The Body PRV US 62/546,639 Abandoned US <br />Provisional (PRV) 62/546,639<br />Filed on 2017-08-17<br />Status: Abandoned 114168707 E-175-2017-0 E-175-2017-0-PCT-02 Hybrid CT System With Additional Detectors In Close Proximity To The Body PCT Patent Cooperation Treaty PCT/US2018/046666 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2018/046666<br />Filed on 2018-08-14<br />Status: Expired 114168990 E-175-2017-0 E-175-2017-0-US-03 Hybrid CT System With Additional Detectors In Close Proximity To The Body National Stage US 11,241,207 16/639,469 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11241207 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11241207">11,241,207</a><br />Filed on 2020-02-14<br />Status: Issued 114127342 AA3B6X 114127343 AA3CXX 114127344 WBXXXX 114127345 XFXXXX 114127346 YAXXXX 114149308 HYBRID 114149309 CT 114149310 Lung Disease 114149311 lung cancer 114149312 X-RAY 114149313 Lung-Targeted 114149314 PULMONARY FIBROSIS 114149315 Pulmonary TAB-3152 114097102 Real-Time RT-PCR Assay for Influenza B Lineage Characterization CDC Collaboration, Licensing Collaboration Licensing LaShondra Berman, Shannon Emery, Stephen Lindstrom, Christine Warnes, Kai-Hui Wu Influenza B causes significant morbidity and mortality yearly around the world. There are two genetically and antigenically distinct lineages of influenza B that are known to co-circulate within the same influenza season. Currently, the trivalent influenza vaccine only has one influenza B lineage component. CDC researchers developed technology that detects and distinguishes the two major co-circulating antigenic lineages of influenza B viruses (B/Yamagata/16/88 (YAM) and B/Victoria/2/87 (VIC)) and provides accurate and timely surveillance data that are less prone to contamination than current methods. This technology relies on real-time RT-PCR and provides reproducible, high-throughput screening results for accurate and timely collection of surveillance and diagnostic information. The real-time RT-PCR assay takes just over an hour to cycle and can detect the presence of influenza viral RNA in respiratory specimens. The primers and probes used in the assays target hemagglutinin (HA) protein 1 RNA of currently circulating VIC-like and YAM-like influenza viruses. The assays can be adapted by public health facilities and laboratories. <ul> <li>Highly specific and more sensitive than other influenza tests (e.g., rapid influenza diagnostic tests and immunofluorescence)</li> <li> Distinguishes between two lineages of Influenza B that co-circulate during the flu season</li> <li>Can yield results in just over an hour</li> <li> Relies on RT-PCR technology that has become more common in public health facilities and laboratories worldwide</li> <il>Reproducible and adaptable for high-throughput</li> </ul> <ul> <li>Influenza B diagnostic assay</li> <li>Surveillance studies to distinguish between circulating influenza B subtypes</li> </ul> The CDC Technology Transfer Office (TTO) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize the Influenza B Characterization rRT-PCR assay. For collaboration opportunities, please contact CDC Technology Transfer Office (TTO) at <a href="mailto:tto@cdc.gov">tto@cdc.gov</a> or404-639-1330. 2022-03-27 2025-08-13 2025-08-15 2017-08-28 ASSAYS, B, CHARACTERIZATION, INFLUENZA, LINEAGE, NCIRD, NCIRD-ID, REAL-TIME, RT-PCR False True True NIHTT 37470483 Website Abstract E-560-2013-0 114109307 Lindstrom, Stephen CDC - DIR CDC Lindstrom, Stephen (CDC) 0 114109308 Wu, Kai-Hui CDC - DIR CDC Wu, Kai-Hui (CDC) 0 114109309 Berman, LaShondra CDC - DIR CDC Berman, LaShondra (CDC) 0 114109310 Warnes, Christine CDC - DIR CDC Warnes, Christine (CDC) 0 114109306 Emery, Shannon CDC - DIR CDC Emery, Shannon (CDC) 1 114109306 Emery, Shannon CDC - DIR CDC Emery, Shannon (CDC) 1 114109307 Lindstrom, Stephen CDC - DIR CDC Lindstrom, Stephen (CDC) 0 114109308 Wu, Kai-Hui CDC - DIR CDC Wu, Kai-Hui (CDC) 0 114109309 Berman, LaShondra CDC - DIR CDC Berman, LaShondra (CDC) 0 114109310 Warnes, Christine CDC - DIR CDC Warnes, Christine (CDC) 0 114102304 Influenza B Lineage Characterization Real-Time RT-PCR Assays E-060-2016-0 Closed Centers for Disease Control and Prevention (CDC) 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-3152] Real-Time RT-PCR Assay for Influenza B Lineage Characterization&body=Please send me information about technology [TAB-3152] Real-Time RT-PCR Assay for Influenza B Lineage Characterization. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-3152] Real-Time RT-PCR Assay for Influenza B Lineage Characterization&body=Please send me information about technology [TAB-3152] Real-Time RT-PCR Assay for Influenza B Lineage Characterization.">jonathan.motley@nih.gov</a><br> 114167204 E-060-2016-0 E-060-2016-0-US-02 DETECTION OF INFLUENZA B VIRUSES ORD US 15/712,861 Abandoned US <br />Ordinary Patent (ORD) 15/712,861<br />Filed on 2017-09-22<br />Status: Abandoned 114168341 E-060-2016-0 E-060-2016-0-US-01 DETECTION OF INFLUENZA B VIRUSES PRV US 62/398,204 Abandoned US <br />Provisional (PRV) 62/398,204<br />Filed on 2016-09-22<br />Status: Abandoned 114149283 INFLUENZA 114149284 NCIRD 114149285 B 114149286 LINEAGE 114149287 CHARACTERIZATION 114149288 REAL-TIME 114149289 RT-PCR 114149290 ASSAYS 114149291 NCIRD-ID TAB-3125 114094928 Live Attenuated Zika Virus Vaccine NIAID Collaboration, Diagnostics, Infectious Disease, Research Materials, Vaccines Collaboration Diagnostics Infectious Disease Research Materials Vaccines Anna Durbin, Alexander Pletnev, Konstantin Tsetsarkin, Stephen Whitehead, Sara Woodson This application claims live attenuated Zika viruses and vaccines, attenuated chimeric Zika viruses and vaccines, and multivalent immunogenic compositions comprising Zika vaccines and vaccines for other flaviviruses. The chimeric Zika viruses claimed include a first nucleotide sequence encoding at least one structural protein from a Zika virus (ZIKV), a second nucleotide sequence encoding at least one nonstructural protein from a first flavivirus, and a third nucleotide sequence of a 3' untranslated region from a second flavivirus. The multivalent immunogenic compositions claimed comprise an attenuated ZIKV vaccine or an attenuated chimeric ZIKV vaccine (or their combination) together with one or more of a first attenuated virus that is immunogenic against dengue serotype 1, a second attenuated virus that is immunogenic against dengue serotype 2, a third attenuated virus that is immunogenic against dengue serotype 3, and a fourth attenuated virus that is immunogenic against dengue serotype 4. The present disclosure also claims methods of inducing immune responses, as well as preventing ZIKV and another flavivirus, <em>e.g.</em>, dengue virus.<br /><br /> Such a chimeric vaccine candidate may induce a humoral (antibody) and T-cell response to ZIKV, while the nonstructural proteins of dengue virus will likely induce a T-cell response. The dengue platform also contains a deletion in the TL2 stem-loop structure of the 3' untranslated region (UTR), called Delta30 and Delta30/31 attenuating mutations. The Delta30 deletion has proven to be one of the defining characteristics of the successful one dose dengue vaccine, which is currently in a large scale (17,000 patient) clinical trial in Brazil. <ul> <li>One-dose vaccine</li> <li>Ease of manufacture</li> <li>Can be included in multivalent flavivirus vaccines</li> </ul> <ul> <li>Diagnostics</li> <li>Vaccines</li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize this technology. For collaboration opportunities, please contact Peter Soukas, J.D., at <a href="mailto:peter.soukas@nih.gov">peter.soukas@nih.gov</a> or 301-594-8730. 2022-03-08 2025-08-13 2025-08-15 2018-08-16 2018-06-13 6/13/2018 -- designated as Remove at request of IC: "prospective grant" FR notice published... --ecr Attenuated, CANDIDATES, DA4BXX, DA4XXX, DAXXXX, DC5BXX, DC5XXX, DCXXXX, DDXXXX, DXXXXX, Live, Vaccine, virus, Zika False True True NIHTT 37470483 Website Abstract 114109214 Woodson, Sara NIAID - DIR NIAID Woodson, Sara (NIAID) 0 114109215 Durbin, Anna Johns Hopkins University NIAID Durbin, Anna (NIAID) 0 114109216 Pletnev, Alexander NIAID - DIR NIAID Pletnev, Alexander (NIAID) 0 114109217 Tsetsarkin, Konstantin NIAID - DIR NIAID Tsetsarkin, Konstantin (NIAID) 0 114109213 Whitehead, Stephen NIAID - DIR NIAID Whitehead, Stephen (NIAID) 1 114109213 Whitehead, Stephen NIAID - DIR NIAID Whitehead, Stephen (NIAID) 1 114109214 Woodson, Sara NIAID - DIR NIAID Woodson, Sara (NIAID) 0 114109215 Durbin, Anna Johns Hopkins University NIAID Durbin, Anna (NIAID) 0 114109216 Pletnev, Alexander NIAID - DIR NIAID Pletnev, Alexander (NIAID) 0 114109217 Tsetsarkin, Konstantin NIAID - DIR NIAID Tsetsarkin, Konstantin (NIAID) 0 114101301 Live Attenuated Zika Virus Vaccine Candidates E-118-2016-0 Filing authorized Johns Hopkins University, NIAID 91029846 Ganelina, Anna ganelinaa@niaid.nih.gov
United States of America ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-3125] Live Attenuated Zika Virus Vaccine&body=Please send me information about technology [TAB-3125] Live Attenuated Zika Virus Vaccine. Ganelina, Anna<br><a href="mailto:ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-3125] Live Attenuated Zika Virus Vaccine&body=Please send me information about technology [TAB-3125] Live Attenuated Zika Virus Vaccine.">ganelinaa@niaid.nih.gov</a><br> 114168256 E-118-2016-0 E-118-2016-0-US-01 Live Attenuated Zika Virus Vaccine PRV US 62/307,170 Abandoned US <br />Provisional (PRV) 62/307,170<br />Filed on 2016-03-11<br />Status: Abandoned 114168257 E-118-2016-0 E-118-2016-0-PCT-02 Live Attenuated Zika Virus Vaccine PCT Patent Cooperation Treaty PCT/US2017/021989 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2017/021989<br />Filed on 2017-03-11<br />Status: Expired 114168738 E-118-2016-0 E-118-2016-0-US-14 LIVE ATTENUATED ZIKA VIRUS VACCINE National Stage US 16/083,652 Abandoned US <br />National Stage 16/083,652<br />Filed on 2018-09-10<br />Status: Abandoned 114120113 DDXXXX 114120114 DAXXXX 114120115 DA4XXX 114121594 DXXXXX 114121595 DCXXXX 114121596 DC5XXX 114121597 DC5BXX 114127237 DA4BXX 114148970 Live 114148971 Attenuated 114148972 Zika 114148973 virus 114148974 Vaccine 114148975 CANDIDATES TAB-3116 114096000 A Full-Length Infectious cDNA Clone of Zika Virus from the 2015 Epidemic in Brazil as a Genetic Platform for Studies of Virus-Host Interactions and Vaccine Development NIAID Collaboration, Diagnostics, Infectious Disease, Research Materials, Therapeutics, Vaccines Collaboration Diagnostics Infectious Disease Research Materials Therapeutics Vaccines Alexander Pletnev, Konstantin Tsetsarkin An arthropod-borne virus, Zika virus (ZIKV), has recently emerged as a major human pathogen. Associated with complications during perinatal development and Guillain-Barré syndrome in adults, ZIKV raises new challenges for understanding the molecular determinants of flavivirus pathogenesis. This underscores the necessity for the development of a reverse genetic system based on an epidemic ZIKV strain. This technology relates to the generation and characterization in cell cultures of an infectious cDNA clone of ZIKV isolated from the 2015 epidemic in Brazil. The cDNA-derived ZIKV replicated efficiently in a variety of cell lines, including those of both neuronal and placental origin. It was observed that the growth of cDNA-derived virus was attenuated compared to the growth of the parental isolate in most cell lines, which correlates with substantial differences in sequence heterogeneity between these viruses that were determined by deep-sequencing analysis. Moreover, these results indicate that caution should be exercised when interpreting the results of reverse-genetics experiments in attempts to accurately predict the biology of natural viruses. Finally, a Vero cell-adapted cDNA clone of ZIKV was generated that can be used as a convenient platform for studies aimed at the development of ZIKV vaccines (live attenuated and inactivated) and therapeutics. <ul> <li>Use in development of flavivirus vaccines</li> <li>Virus growth in various cell lines</li> <li>Developing and developed world research tool</li> </ul> <ul> <li>Diagnostics</li> <li>Vaccines</li> <li>Development of therapeutics</li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize vaccine(s) or diagnostics for prophylaxis against flavivirus infections. For collaboration opportunities, please contact Peter Soukas, J.D. at <a href="mailto:peter.soukas@nih.gov">peter.soukas@nih.gov</a> or 301-594-8730. Research Materials 2022-03-08 2025-08-13 2025-08-15 2017-04-10 2015, Brazil, cDNA, CLONE, DAXXXX, DBXXXX, DC5BXX, DC5XXX, DC6XXX, DCXXXX, DD1XXX, DDXXXX, Development, DXXXXX, Epidemic, FULL-LENGTH, Genetic, INFECTIOUS, INTERACTIONS, PLATFORM, STUDIES, Vaccine, virus, Virus-Host, Zika False True True NIHTT 37470483 Website Abstract 114172304 Tsetsarkin KA, et al. http://www.ncbi.nlm.nih.gov/pubmed/27555311 <a href="http://www.ncbi.nlm.nih.gov/pubmed/27555311">Tsetsarkin KA, et al.</a> 114109196 Tsetsarkin, Konstantin NIAID - DIR NIAID Tsetsarkin, Konstantin (NIAID) 0 114105832 Pletnev, Alexander NIAID - DIR NIAID Pletnev, Alexander (NIAID) 1 114105832 Pletnev, Alexander NIAID - DIR NIAID Pletnev, Alexander (NIAID) 1 114109196 Tsetsarkin, Konstantin NIAID - DIR NIAID Tsetsarkin, Konstantin (NIAID) 0 114100892 Full-length Infectious CDNA Clone Of Zika Virus From The 2015 Epidemic In Brazil As A Genetic Platform For Studies Of Virus-Host Interactions And Vaccine Development E-114-2017-0 Research Material NIAID 91021353 Pitts, Elizabeth elizabeth.pitts@nih.gov
United States of America elizabeth.pitts@nih.gov?subject=Web Inquiry on [TAB-3116] A Full-Length Infectious cDNA Clone of Zika Virus from the 2015 Epidemic in Brazil as a Genetic Platform for Studies of Virus-Host Interactions and Vaccine Development&body=Please send me information about technology [TAB-3116] A Full-Length Infectious cDNA Clone of Zika Virus from the 2015 Epidemic in Brazil as a Genetic Platform for Studies of Virus-Host Interactions and Vaccine Development. Pitts, Elizabeth<br><a href="mailto:elizabeth.pitts@nih.gov?subject=Web Inquiry on [TAB-3116] A Full-Length Infectious cDNA Clone of Zika Virus from the 2015 Epidemic in Brazil as a Genetic Platform for Studies of Virus-Host Interactions and Vaccine Development&body=Please send me information about technology [TAB-3116] A Full-Length Infectious cDNA Clone of Zika Virus from the 2015 Epidemic in Brazil as a Genetic Platform for Studies of Virus-Host Interactions and Vaccine Development.">elizabeth.pitts@nih.gov</a><br> 114113944 DXXXXX 114113945 DCXXXX 114113946 DDXXXX 114113947 DD1XXX 114113948 DC5XXX 114116532 DC5BXX 114116533 DC6XXX 114116534 DAXXXX 114116535 DBXXXX 114148898 FULL-LENGTH 114148899 INFECTIOUS 114148900 cDNA 114148901 CLONE 114148902 Zika 114148903 virus 114148904 2015 114148905 Epidemic 114148906 Brazil 114148907 Genetic 114148908 PLATFORM 114148909 STUDIES 114148910 Virus-Host 114148911 INTERACTIONS 114148912 Vaccine 114148913 Development TAB-3108 114095363 Synergistic Internal Ribosomal Entry Site (IRES)—MicroRNA-Based Approach for Attenuation of Flaviviruses and Live Vaccine Development NIAID Collaboration, Infectious Disease, Research Materials, Vaccines Collaboration Infectious Disease Research Materials Vaccines Alexander Pletnev, Konstantin Tsetsarkin Many members of the <em>Flaviviridae</em> family are emerging and reemerging human pathogens that have caused outbreaks of devastating and often fatal diseases and represent a serious public health problem on a global scale. There is no single attenuation strategy that exists which is sufficient to prepare a safe, efficacious and immunogenic live attenuated virus vaccine that will work universally for <em>Flaviviridae</em>. This patent application claims live attenuated flavivirus vaccines, live attenuated multivalent flavivirus vaccines, and methods of preventing flavivirus infections as well as methods of making the vaccines claimed in the application. More specifically, this patent application claims methods for attenuating a flavivirus or chimeric flavivirus using a synergistic dual strategy involving inserting miRNA-targeting sequences to restrict virus replication in target hosts, cells and/or tissues and placing one or more flavivirus genes under translational control of an internal ribosomal entry site (IRES). <ul> <li>Potential one-dose flavivirus vaccine</li> <li>Ease of manufacture in Vero cells</li> <li>Low-cost potential vaccine</li> <li>Developing and developed world potential vaccines</li> </ul> <ul> <li>Diagnostics</li> <li>Vaccines</li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize vaccine(s) for prophylaxis against flavivirus infections. For collaboration opportunities, please contact Peter Soukas, J.D. at <a href="mailto:peter.soukas@nih.gov">peter.soukas@nih.gov</a> or 301-594-8730. 2022-03-08 2025-08-13 2025-08-15 2017-03-01 Approach, ATTENUATION, DC1XXX, DC5BXX, DC5XXX, DC6XXX, DCXXXX, DD1XXX, DDXXXX, Development, DEXXXX, DXXXXX, ENTRY, FLAVIVIRUSES, INTERNAL, Live, Pnd, RIBOSOME, Site/microRNA-based, Synergistic, Vaccine, Zika False True True NIHTT 37470483 Website Abstract 114109164 Tsetsarkin, Konstantin NIAID - DIR NIAID Tsetsarkin, Konstantin (NIAID) 0 114109163 Pletnev, Alexander NIAID - DIR NIAID Pletnev, Alexander (NIAID) 1 114109163 Pletnev, Alexander NIAID - DIR NIAID Pletnev, Alexander (NIAID) 1 114109164 Tsetsarkin, Konstantin NIAID - DIR NIAID Tsetsarkin, Konstantin (NIAID) 0 114102025 Synergistic Internal Ribosome Entry Site/microRNA-based Approach For Attenuation Of Flaviviruses Pnd Live Vaccine Development E-006-2017-0 Filing authorized NIAID 91027763 Puglielli, Maryann maryann.puglielli@nih.gov
United States of America maryann.puglielli@nih.gov?subject=Web Inquiry on [TAB-3108] Synergistic Internal Ribosomal Entry Site (IRES)—MicroRNA-Based Approach for Attenuation of Flaviviruses and Live Vaccine Development&body=Please send me information about technology [TAB-3108] Synergistic Internal Ribosomal Entry Site (IRES)—MicroRNA-Based Approach for Attenuation of Flaviviruses and Live Vaccine Development. Puglielli, Maryann<br><a href="mailto:maryann.puglielli@nih.gov?subject=Web Inquiry on [TAB-3108] Synergistic Internal Ribosomal Entry Site (IRES)—MicroRNA-Based Approach for Attenuation of Flaviviruses and Live Vaccine Development&body=Please send me information about technology [TAB-3108] Synergistic Internal Ribosomal Entry Site (IRES)—MicroRNA-Based Approach for Attenuation of Flaviviruses and Live Vaccine Development.">maryann.puglielli@nih.gov</a><br> 114168213 E-006-2017-0 E-006-2017-0-US-01 Synergistic Internal Ribosome Entry Site/microRNA-based Approach For Attenuation Of Flaviviruses And Live Vaccine Development PRV US 62/443,214 Abandoned US <br />Provisional (PRV) 62/443,214<br />Filed on 2017-01-06<br />Status: Abandoned 114168525 E-006-2017-0 E-006-2017-0-PCT-02 LIVE ATTENUATED FLAVIRUS VACCINES AND METHODS OF USING AND MAKING SAME PCT Patent Cooperation Treaty PCT/US2018/012346 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2018/012346<br />Filed on 2018-01-04<br />Status: Expired 114117902 DCXXXX 114117903 DC5XXX 114117904 DC5BXX 114118012 DDXXXX 114119433 DXXXXX 114120864 DD1XXX 114125803 DEXXXX 114125804 DC6XXX 114125805 DC1XXX 114148769 Site/microRNA-based 114148770 ATTENUATION 114148771 FLAVIVIRUSES 114148772 Approach 114148773 RIBOSOME 114148774 Live 114148775 Synergistic 114148776 Development 114148777 ENTRY 114148778 Pnd 114148779 INTERNAL 114148780 Vaccine 114148781 Zika TAB-3105 114096788 Zika Virus Vaccines NIAID Infectious Disease, Licensing, Vaccines Infectious Disease Licensing Vaccines Leda Castilho, Adrian Creanga, Christina Demaso, Kimberly Dowd, Barney Graham, Wing-pui Kong, Julie Ledgerwood, John Mascola, Rebecca Pelc, Theodore Pierson, Sebastian Ramesch, Wei Shi, Lingshu Wang, Eun Yang Zika virus (ZIKV) is a flavivirus transmitted by mosquitos that is strongly linked to neurological complications including Guillain-Barré syndrome, meningoencephalitis, and microcephaly. The association between active ZIKV infection during pregnancy and microcephaly and intrauterine growth retardation in the fetus has been confirmed in murine models of ZIKV infection.<br /><br /> Scientists at NIAID have developed nucleic acid-based vaccine candidates to prevent ZIKV infection in humans. The current lead candidate vaccine is a plasmid DNA vaccine demonstrated to accord protection in preclinical models and is undergoing clinical trial evaluation. Nucleic acid-based vaccines have been developed previously for West Nile virus, another flavivirus similar to Zika (J.E. Ledgerwood, et al. J. Infect. Dis. (2011) 203 (10): 1396-1404). Immunization with the nucleic acid ZIKV vaccine candidate results in production of noninfectious virus like particles (VLPs) made of ZIKV proteins. These ZIKV VLPs elicit an immune response which includes neutralizing antibodies to ZIKV.<br /><br /> Other preclinical ZIKV vaccine candidates include mRNA, protein, and noninfectious VLPs.<br /><br /> NIAID is continuing development of these vaccine candidates. The DNA-based ZIKV vaccine candidate is currently in clinical trials. Consequently, for some fields of use, NIAID will evaluate a license applicant’s capabilities and experience in advancing similar technologies through the regulatory process. <ul> <li>There is currently no licensed Zika virus vaccine</li> </ul> <ul> <li>Prevention of Zika virus infection</li> </ul> 2022-03-08 2025-08-13 2025-08-15 2017-02-28 Chimera, DC5BXX, GENE-BASED, JAPANESE ENCEPHALITIS VIRUS, vaccines, virus-like particles, VLP, Zika False True True NIHTT 37470483 Website Abstract 114172295 Dowd KA, et al. http://www.ncbi.nlm.nih.gov/pubmed/27708058 <a href="http://www.ncbi.nlm.nih.gov/pubmed/27708058">Dowd KA, et al.</a> 114109140 Mascola, John NIAID - VRC NIAID Mascola, John (NIAID) 0 114109141 Kong, Wing-pui NIAID - VRC NIAID Kong, Wing-pui (NIAID) 0 114109142 Yang, Eun NIAID - VRC NIAID Yang, Eun (NIAID) 0 114109143 Shi, Wei NIAID - VRC NIAID Shi, Wei (NIAID) 0 114109144 Pierson, Theodore NIAID - DIR NIAID Pierson, Theodore (NIAID) 0 114109145 Castilho, Leda Federal University of Rio de Janeiro Castilho, Leda 0 114109146 Dowd, Kimberly NIAID - VRC NIAID Dowd, Kimberly (NIAID) 0 114109147 Wang, Lingshu NIAID - VRC NIAID Wang, Lingshu (NIAID) 0 114109148 Demaso, Christina NIAID - DIR NIAID Demaso, Christina (NIAID) 0 114109149 Pelc, Rebecca NIAID - DIR Pelc, Rebecca 0 114109150 Creanga, Adrian NIAID - DIR NIAID Creanga, Adrian (NIAID) 0 114109151 Ledgerwood, Julie NIAID - VRC NIAID Ledgerwood, Julie (NIAID) 0 114109152 Ramesch, Sebastian The Scripps Research Institute Ramesch, Sebastian 0 114109139 Graham, Barney NIAID - VRC NIAID Graham, Barney (NIAID) 1 114109139 Graham, Barney NIAID - VRC NIAID Graham, Barney (NIAID) 1 114109140 Mascola, John NIAID - VRC NIAID Mascola, John (NIAID) 0 114109141 Kong, Wing-pui NIAID - VRC NIAID Kong, Wing-pui (NIAID) 0 114109142 Yang, Eun NIAID - VRC NIAID Yang, Eun (NIAID) 0 114109143 Shi, Wei NIAID - VRC NIAID Shi, Wei (NIAID) 0 114109144 Pierson, Theodore NIAID - DIR NIAID Pierson, Theodore (NIAID) 0 114109145 Castilho, Leda Federal University of Rio de Janeiro Castilho, Leda 0 114109146 Dowd, Kimberly NIAID - VRC NIAID Dowd, Kimberly (NIAID) 0 114109147 Wang, Lingshu NIAID - VRC NIAID Wang, Lingshu (NIAID) 0 114109148 Demaso, Christina NIAID - DIR NIAID Demaso, Christina (NIAID) 0 114109149 Pelc, Rebecca NIAID - DIR Pelc, Rebecca 0 114109150 Creanga, Adrian NIAID - DIR NIAID Creanga, Adrian (NIAID) 0 114109151 Ledgerwood, Julie NIAID - VRC NIAID Ledgerwood, Julie (NIAID) 0 114109152 Ramesch, Sebastian The Scripps Research Institute Ramesch, Sebastian 0 114101668 Development Of Gene-based And Viral Like Particle (VLP) Zika Virus(ZIKV) Vaccines E-181-2016-0 Filing authorized NIAID 91026778 Green, Wade wade.green@nih.gov
United States of America TTIPO wade.green@nih.gov?subject=Web Inquiry on [TAB-3105] Zika Virus Vaccines&body=Please send me information about technology [TAB-3105] Zika Virus Vaccines. Green, Wade<br><a href="mailto:wade.green@nih.gov?subject=Web Inquiry on [TAB-3105] Zika Virus Vaccines&body=Please send me information about technology [TAB-3105] Zika Virus Vaccines.">wade.green@nih.gov</a><br> 114161951 E-181-2016-0 E-181-2016-0-US-01 ZIKA VIRUS VACCINES PRV US 62/396,613 Abandoned US <br />Provisional (PRV) 62/396,613<br />Filed on 2016-09-19<br />Status: Abandoned 114168539 E-181-2016-0 E-181-2016-0-PCT-02 Zika Virus Vaccines PCT Patent Cooperation Treaty PCT/US2017/044468 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2017/044468<br />Filed on 2017-07-28<br />Status: Expired 114168859 E-181-2016-0 E-181-2016-0-US-03 ZIKA VIRUS VACCINES National Stage US 10,898,566 16/334,099 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10898566 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10898566">10,898,566</a><br />Filed on 2019-08-27<br />Status: Issued 114112857 DC5BXX 114148747 JAPANESE ENCEPHALITIS VIRUS 114148748 VLP 114148749 Zika 114148750 Chimera 114148751 vaccines 114148752 virus-like particles 114148753 GENE-BASED TAB-3100 114096785 A Human Progenitor Mast Cell Line for Allergic and Fibrotic Research and Therapeutic Screening NIAID Collaboration Collaboration Arnold Kirshenbaum, Dean Metcalfe Hermansky-Pudlak Syndrome type-1 (HPS-1) is a rare genetic disorder that affects around 1 in 500,000 people worldwide and 1 in 1,800 Puerto Ricans. Patients with HPS-1 display oculocutaneous albinism, bleeding due to platelet abnormality, and pulmonary fibrosis. Those that develop pulmonary fibrosis often succumb and live no more than a decade after early onset of breathing problems.<br /><br /> Scientists at the National Institute of Allergy and Infectious Diseases (NIAID) have developed the HPS-1 proMastocyte (HPM) cell line, containing an HPS-1 mutation. This cell line resembles a progenitor mast cell with reduced granule formation, significant chemotactic ability, and is the first mast cell line shown to constitutively release cytokines, chemokines, and most importantly fibrotic proteins. This cell line serves as a model to study granule formation, early mast cell development, chemotaxis and mechanisms controlling synthesis of molecules contributing to fibrosis.<br /><br /> Cell line available as live cells approximately 3-4 million cells per sample in a T25 Flask. <ul> <li>First progenitor mast cell line known to produce fibrotic elements</li> <li>Progenitor mast cell line with rapid growth, no cytokine stimulation needed. Cell doubling time of 2–3 days</li> </ul> <ul> <li>A tool to further understand fibrosis</li> <li>A tool to study granule formation, early mast cell development, degranulation and chemotaxis</li> <li>Screening tool to identify target compounds for the treatment of pulmonary fibrosis</li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize this invention. For collaboration opportunities, please contact Dr. Dianca Finch at <a href="mailto:dianca.finch@nih.gov">dianca.finch@nih.gov</a> or 240-669-5503. Available as Biological Material 2022-03-08 2025-08-13 2025-08-15 2017-02-28 16bp, c.1470-1486dup16, Cell, Cells, Cloning, Defect, DUPLICATION, EXPANSION, Expressing, FceRI, Hermansky, HPM, HPS1, Human, Immature, KNOWN, Line, Promastocyte, Pudlak, RECEPTORS, Syndrome-1 False True True NIHTT 37470483 Website Abstract 114172294 Kirshenbaum AS, et al. http://www.ncbi.nlm.nih.gov/pubmed/27459687 <a href="http://www.ncbi.nlm.nih.gov/pubmed/27459687">Kirshenbaum AS, et al.</a> 114109138 Metcalfe, Dean NIAID - DIR NIAID Metcalfe, Dean (NIAID) 0 114109137 Kirshenbaum, Arnold NIAID - DIR NIAID Kirshenbaum, Arnold (NIAID) 1 114109137 Kirshenbaum, Arnold NIAID - DIR NIAID Kirshenbaum, Arnold (NIAID) 1 114109138 Metcalfe, Dean NIAID - DIR NIAID Metcalfe, Dean (NIAID) 0 114101911 Cloning And Expansion Of An Immature Human Promastocyte Cell Line, Known As HPM Cells, Expressing FCeRI Receptors And The HPS1 16bp Duplication (c.1470-1486dup16, Hermansky Pudlak Syndrome-1) Defect E-270-2016-0 Research Material NIAID 91027763 Puglielli, Maryann maryann.puglielli@nih.gov
United States of America maryann.puglielli@nih.gov?subject=Web Inquiry on [TAB-3100] A Human Progenitor Mast Cell Line for Allergic and Fibrotic Research and Therapeutic Screening&body=Please send me information about technology [TAB-3100] A Human Progenitor Mast Cell Line for Allergic and Fibrotic Research and Therapeutic Screening. Puglielli, Maryann<br><a href="mailto:maryann.puglielli@nih.gov?subject=Web Inquiry on [TAB-3100] A Human Progenitor Mast Cell Line for Allergic and Fibrotic Research and Therapeutic Screening&body=Please send me information about technology [TAB-3100] A Human Progenitor Mast Cell Line for Allergic and Fibrotic Research and Therapeutic Screening.">maryann.puglielli@nih.gov</a><br> 114148726 Cloning 114148727 EXPANSION 114148728 Immature 114148729 Human 114148730 Promastocyte 114148731 Cell 114148732 Line 114148733 KNOWN 114148734 HPM 114148735 Cells 114148736 Expressing 114148737 FceRI 114148738 RECEPTORS 114148739 HPS1 114148740 16bp 114148741 DUPLICATION 114148742 c.1470-1486dup16 114148743 Hermansky 114148744 Pudlak 114148745 Syndrome-1 114148746 Defect TAB-3084 114095778 Non-invasive Pan-Cancer Detection Method NHGRI Collaboration, Computational models/software, Diagnostics, Oncology, Research Materials, Software / Apps, Therapeutics Collaboration Computational models/software Diagnostics Oncology Research Materials Software / Apps Therapeutics Laura Elnitski, Gennady Margolin, Hanna Petrykowska One of four deaths in the United States is due to cancer despite an emphasis on prevention, early detection, and treatment that has lowered cancer death rates by 20% in the past two decades. Further improvements in survival rates are likely to come from improving the limits of detection sensitivity at earlier stages of cancer. New approaches that rely heavily on genomic information, however, may change future testing strategies.<br /><br /> This invention is a method for detecting the presence of cancer in an individual by detecting the methylation state of a region in the promoter of the <em>ZNF154</em> gene. A distinct advantage of this assay is that it is minimally invasive unlike currently available methods for diagnosing cancer which typically require a tissue biopsy. This method requires only blood samples and can detect many different types of cancers. Bioinformatics methods are provided to analyze the methylation state of the <em>ZNF154</em> promoter and relate the methylation state to the likelihood of cancer in the individual from circulating tumor DNA. <ul> <li>Less invasive</li> <li>Less time consuming</li> </ul> <ul> <li>Diagnostic assay to detect cancer</li> <li>Monitoring tool to track patient response to cancer therapy</li> </ul> The National Human Genome Research Institute is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize Pan-Cancer Locus Blood-Based Diagnostic Development. For collaboration opportunities, please contact Eggerton Campbell at <a href="mailto:eggerton.campbell@nih.gov?subject=Web Inquiry Regarding E-177-2015">eggerton.campbell@nih.gov</a>. 2022-03-08 2025-08-13 2025-08-15 2016-11-08 CAXXXX, Detection, Listed LPM Campbell as of 4/17/2015, Methods, Pan-Cancer, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, VCXXXX, WBXXXX, XBXXXX, XCXXXX, XEXXXX, YAXXXX, YBXXXX, YGXXXX False True True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114171528 Margolin G, et al. https://www.ncbi.nlm.nih.gov/pubmed/26857064 <a href="https://www.ncbi.nlm.nih.gov/pubmed/26857064">Margolin G, et al.</a> 114171620 Sanchez-Vega F, et al. https://www.ncbi.nlm.nih.gov/pubmed/24149212 <a href="https://www.ncbi.nlm.nih.gov/pubmed/24149212">Sanchez-Vega F, et al.</a> 114107676 Margolin, Gennady National Human Genome Research Institute (NHGRI) NICHD Margolin, Gennady (NICHD) 0 114107677 Petrykowska, Hanna National Human Genome Research Institute (NHGRI) NHGRI Petrykowska, Hanna (NHGRI) 0 114107662 Elnitski, Laura National Human Genome Research Institute (NHGRI) NHGRI Elnitski, Laura (NHGRI) 1 114107662 Elnitski, Laura National Human Genome Research Institute (NHGRI) NHGRI Elnitski, Laura (NHGRI) 1 114107676 Margolin, Gennady National Human Genome Research Institute (NHGRI) NICHD Margolin, Gennady (NICHD) 0 114107677 Petrykowska, Hanna National Human Genome Research Institute (NHGRI) NHGRI Petrykowska, Hanna (NHGRI) 0 114101537 New Pan-Cancer Detection Methods E-177-2015-0 Closed National Human Genome Research Institute (NHGRI) 83718085 Surabian, Karen karen.surabian@nih.gov
United States of America Technology Transfer Office (TTO) karen.surabian@nih.gov?subject=Web Inquiry on [TAB-3084] Non-invasive Pan-Cancer Detection Method&body=Please send me information about technology [TAB-3084] Non-invasive Pan-Cancer Detection Method. Surabian, Karen<br><a href="mailto:karen.surabian@nih.gov?subject=Web Inquiry on [TAB-3084] Non-invasive Pan-Cancer Detection Method&body=Please send me information about technology [TAB-3084] Non-invasive Pan-Cancer Detection Method.">karen.surabian@nih.gov</a><br> 114165479 E-177-2015-0 E-177-2015-0-US-01 New Pan-Cancer Detection Methods PRV US 62/220,041 Abandoned US <br />Provisional (PRV) 62/220,041<br />Filed on 2015-09-17<br />Status: Abandoned 114165480 E-177-2015-0 E-177-2015-0-PCT-02 CANCER DETECTION METHODS PCT Patent Cooperation Treaty PCT/US2016/051905 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2016/051905<br />Filed on 2016-09-15<br />Status: Expired 114168572 E-177-2015-0 E-177-2015-0-US-04 CANCER DETECTION METHODS National Stage US 10,961,590 15/759,452 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10961590 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10961590">10,961,590</a><br />Filed on 2018-03-12<br />Status: Issued 114169107 E-177-2015-0 E-177-2015-0-US-05 CANCER DETECTION METHODS DIV US 17/179,298 Pending US <br />Divisional (DIV) 17/179,298<br />Filed on 2021-02-18<br />Status: Pending 114122740 CAXXXX 114122741 VCXXXX 114122742 WBXXXX 114122743 XBXXXX 114122744 XCXXXX 114122779 XEXXXX 114122780 YAXXXX 114122781 YBXXXX 114122782 YGXXXX 114143583 Pan-Cancer 114143584 Detection 114143585 Methods 114143586 Listed LPM Campbell as of 4/17/2015 114143587 Pre LPM working set 20150418 114143588 Post LPM Assignment Set 20150420 TAB-3072 114096596 Enhanced Functionalization of Carbon Nanoparticles for Biomedical Applications NHLBI Consumer Products, Diagnostics, Licensing, Research Materials, Therapeutics Consumer Products Diagnostics Licensing Research Materials Therapeutics Chandrasekhar Mushti, Keir Neuman, Ganesh Shenoy, Rolf Swenson The invention pertains to methods of increasing the density of carboxylic acids on the surface of a carbon nanoparticle that can be functionalized with biologically relevant molecules, such as antibodies or peptides, for biomedical applications. Advantageously, the method could increase functionalization of a nanoparticle by at least about 1x107 functional groups/g of nanoparticle. The method includes contacting an oxygen-containing functional group on a surface of a carbon nanoparticle with a reducing agent to provide a hydroxyl group; reacting the hydroxyl group with a diazoacetate ester in the presence of a transition metal catalyst to provide an ester and then cleaving the ester to provide a carboxylic acid group. The carboxylic acid can further be secondarily functionalized to an acyl chloride, an amide, pegylated, a biotinylate, a folate, a thiol, a maleimide, an active ester, an amine, a chelated gadolinium, an azide, an alkyne, a protein tag, or a dendrimer. Examples of notable nanoparticles that can be derivatized using this method include carbon nanoparticles such as carbon nanotubes, fullerenes, graphenes, graphene oxides, and nanodiamonds; with or without fluorescent properties. Fluorescent nanoparticles are of particular interest for functionalization as they are applicable to both research and diagnostic applications and can be visualized through microscopy. <ul> <li>Higher degree of functionalization for carbon nanoparticles</li> </ul> <ul> <li>Imaging</li> <li>Therapeutics</li> </ul> 2022-03-08 2025-08-13 2025-08-15 2016-10-12 AG1XXX, CARBOXYLIC, fluorescent, MXXXXX, Nanodiamonds, nanotechnology, PXXXXX, WMXXXX, XGXXXX, YAXXXX False True True 52406768 Discovery 52406768 NIHTT 37470483 Website Abstract 114171379 Mochalin VN, et al. https://www.ncbi.nlm.nih.gov/pubmed/22179567 <a href="https://www.ncbi.nlm.nih.gov/pubmed/22179567">Mochalin VN, et al.</a> 114171380 Aller E, et al. http://dx.doi.org/10.1021/jo00119a023 <a href="http://dx.doi.org/10.1021/jo00119a023">Aller E, et al.</a> 114171417 Huang J, et al. https://www.ncbi.nlm.nih.gov/pubmed/22222582 <a href="https://www.ncbi.nlm.nih.gov/pubmed/22222582">Huang J, et al.</a> 114171418 Nystrom RF, Brown WG. http://dx.doi.org/10.1021/ja01197a060 <a href="http://dx.doi.org/10.1021/ja01197a060">Nystrom RF, Brown WG.</a> 114171419 Nystrom RF, Brown WG. http://dx.doi.org/10.1021/ja01202a082 <a href="http://dx.doi.org/10.1021/ja01202a082">Nystrom RF, Brown WG.</a> 114171458 Hoehnel S, Lutolf MP. https://www.ncbi.nlm.nih.gov/pubmed/26079967 <a href="https://www.ncbi.nlm.nih.gov/pubmed/26079967">Hoehnel S, Lutolf MP.</a> 114171475 Chang BM, et al. http://dx.doi.org/10.1002/adfm.201301075 <a href="http://dx.doi.org/10.1002/adfm.201301075">Chang BM, et al.</a> 114171478 Moon WK, et al. https://www.ncbi.nlm.nih.gov/pubmed/12757377 <a href="https://www.ncbi.nlm.nih.gov/pubmed/12757377">Moon WK, et al.</a> 114171479 Fu CC, et al. https://www.ncbi.nlm.nih.gov/pubmed/17213326 <a href="https://www.ncbi.nlm.nih.gov/pubmed/17213326">Fu CC, et al.</a> 114104392 Mushti, Chandrasekhar National Heart, Lung, and Blood Institute (NHLBI) NHLBI Mushti, Chandrasekhar (NHLBI) 0 114107496 Shenoy, Ganesh National Heart, Lung, and Blood Institute (NHLBI) NHLBI Shenoy, Ganesh (NHLBI) 0 114107498 Swenson, Rolf National Heart, Lung, and Blood Institute (NHLBI) NHLBI Swenson, Rolf (NHLBI) 0 114106104 Neuman, Keir National Heart, Lung, and Blood Institute (NHLBI) NHLBI Neuman, Keir (NHLBI) 1 114106104 Neuman, Keir National Heart, Lung, and Blood Institute (NHLBI) NHLBI Neuman, Keir (NHLBI) 1 114104392 Mushti, Chandrasekhar National Heart, Lung, and Blood Institute (NHLBI) NHLBI Mushti, Chandrasekhar (NHLBI) 0 114107496 Shenoy, Ganesh National Heart, Lung, and Blood Institute (NHLBI) NHLBI Shenoy, Ganesh (NHLBI) 0 114107498 Swenson, Rolf National Heart, Lung, and Blood Institute (NHLBI) NHLBI Swenson, Rolf (NHLBI) 0 114101700 Method To Increase Carboxylic Acid Content On Fluorescent Nanodiamonds E-207-2016-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 83685986 Crooks, Denise crooksd@mail.nih.gov
United States of America Office of Technology Transfer and Development crooksd@mail.nih.gov?subject=Web Inquiry on [TAB-3072] Enhanced Functionalization of Carbon Nanoparticles for Biomedical Applications&body=Please send me information about technology [TAB-3072] Enhanced Functionalization of Carbon Nanoparticles for Biomedical Applications. Crooks, Denise<br><a href="mailto:crooksd@mail.nih.gov?subject=Web Inquiry on [TAB-3072] Enhanced Functionalization of Carbon Nanoparticles for Biomedical Applications&body=Please send me information about technology [TAB-3072] Enhanced Functionalization of Carbon Nanoparticles for Biomedical Applications.">crooksd@mail.nih.gov</a><br> 114159946 E-207-2016-0 E-207-2016-0-US-01 Method to Increase Carboxylic Acid Content on Fluorescent Nanodiamonds PRV US 62/402,339 Abandoned US <br />Provisional (PRV) 62/402,339<br />Filed on 2016-09-30<br />Status: Abandoned 114168402 E-207-2016-0 E-207-2016-0-PCT-02 METHOD FOR FUNCTIONALIZING CARBON NANOPARTICLES AND COMPOSITIONS PCT Patent Cooperation Treaty PCT/US2017/054351 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2017/054351<br />Filed on 2017-09-29<br />Status: Expired 114168866 E-207-2016-0 E-207-2016-0-US-03 Method To Increase Carboxylic Acid Content On Fluorescent Nanodiamonds National Stage US 10,995,004 16/336,709 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10995004 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10995004">10,995,004</a><br />Filed on 2019-03-26<br />Status: Issued 114120701 XGXXXX 114120702 YAXXXX 114122561 MXXXXX 114122562 PXXXXX 114122563 AG1XXX 114122564 WMXXXX 114142937 CARBOXYLIC 114142938 fluorescent 114142939 Nanodiamonds 114142940 nanotechnology TAB-2972 114096262 Three-Dimensional Curved Catheter for Right Atrial Appendage Traversal NHLBI Cardiology, Collaboration, Consumer Products, Licensing, Medical Devices, Non-Medical Devices Cardiology Collaboration Consumer Products Licensing Medical Devices Non-Medical Devices Adam Greenbaum, Robert Lederman, William O'Neill, Nasser Rafiee, Toby Rogers Available for licensing and commercial development is a three-dimensionally configured curved catheter for safe traversal of the right atrial appendage (RAA). The device is configured to optimize one-way access of the pericardial space through the right atrium and into the RAA reducing the risk of coronary lacerations. Specifically the curved catheter is best described in three segments: a proximal segment, a transitional segment and a distal segment; the transition segment having a clockwise spiral shaped curvature. When inserted into a patient, the proximal segment is positioned within the inferior vena cava, the transition segment extends across the caval-atrial junction and curves rightward, forward, and upward such that the catheter abuts a right lateral wall of the right atrium, and the distal segment curves leftward, forward, and upward from the transition segment through the right atrium such that the catheter abuts an anterior wall of the right atrium adjacent to the RAA. The catheter is configured to guide a coaxial puncturing device to through the superior left sulcal wall of the RAA. <ul> <li>Reduced risk of coronary or myocardial laceration</li> </ul> <ul> <li>Left atrial appendage ligation</li> <li>Circumferential tricuspid annuloplasty</li> <li>Epicardial ablation</li> </ul> The National Heart, Lung and Blood Institute is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize devices for pericardial interventional procedures. For collaboration opportunities, please contact Peg Koelble at 301-594-4095 or <a href="mailto:koelblep@nhlbi.nih.gov">koelblep@nhlbi.nih.gov</a>. 2022-03-08 2025-08-13 2025-08-15 2015-08-31 AB3CXX, AB3EXX, AB3FXX, AB3GXX, AB3XXX, Cardiovascular, catheter, Listed LPM Shmilovich as of 4/15/2015, Pericardial, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, VDXXXX, WMXXXX, XDXXXX, YAXXXX, YFXXXX False True <ul> <li>Early-stage</li> <li>Prototype</li> </ul> True 52406769 Prototype 52406769 NIHTT 37470483 Website Abstract E-027-2013-0 E-115-2013-0 E-018-2014-0 E-068-2014-0 E-124-2014-0 E-124-2014-1 E-124-2014-2 114109070 Rogers, Toby National Heart, Lung, and Blood Institute (NHLBI) Rogers, Toby 0 114109071 Rafiee, Nasser Mehr Medical Rafiee, Nasser 0 114109072 Greenbaum, Adam Henry Ford Hospital Greenbaum, Adam 0 114109073 O'Neill, William Henry Ford Hospital O'Neill, William 0 114109069 Lederman, Robert National Heart, Lung, and Blood Institute (NHLBI) NHLBI Lederman, Robert (NHLBI) 1 114109069 Lederman, Robert National Heart, Lung, and Blood Institute (NHLBI) NHLBI Lederman, Robert (NHLBI) 1 114109070 Rogers, Toby National Heart, Lung, and Blood Institute (NHLBI) Rogers, Toby 0 114109071 Rafiee, Nasser Mehr Medical Rafiee, Nasser 0 114109072 Greenbaum, Adam Henry Ford Hospital Greenbaum, Adam 0 114109073 O'Neill, William Henry Ford Hospital O'Neill, William 0 114100736 3D Right Atrial Appendage (3DRAA) Curve Catheter E-078-2015-0 Filing authorized Henry Ford Hospital, National Heart, Lung, and Blood Institute (NHLBI) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-2972] Three-Dimensional Curved Catheter for Right Atrial Appendage Traversal&body=Please send me information about technology [TAB-2972] Three-Dimensional Curved Catheter for Right Atrial Appendage Traversal. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-2972] Three-Dimensional Curved Catheter for Right Atrial Appendage Traversal&body=Please send me information about technology [TAB-2972] Three-Dimensional Curved Catheter for Right Atrial Appendage Traversal.">shmilovm@nih.gov</a><br> 114160129 E-078-2015-0 E-078-2015-0-US-01 THREE-DIMENSIONAL RIGHT ATRIAL APPENDAGE CURVE CATHETER PRV US 62/162,453 Abandoned US <br />Provisional (PRV) 62/162,453<br />Filed on 2015-05-15<br />Status: Abandoned 114164770 E-078-2015-0 E-078-2015-0-PCT-02 Three-Dimensional Right Atrial Appendage Curve Catheter PCT Patent Cooperation Treaty PCT/US2016/031461 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2016/031461<br />Filed on 2016-05-09<br />Status: Expired 114168441 E-078-2015-0 E-078-2015-0-US-04 THREE-DIMENSIONAL RIGHT ATRIAL APPENDAGE CURVE CATHETER National Stage US 11,173,278 15/571,342 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11173278 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11173278">11,173,278</a><br />Filed on 2017-11-02<br />Status: Issued 114127163 AB3CXX 114127164 AB3EXX 114127165 AB3FXX 114127166 AB3GXX 114127167 AB3XXX 114127168 VDXXXX 114127169 WMXXXX 114127170 XDXXXX 114127171 YAXXXX 114127172 YFXXXX 114129771 catheter 114129772 Listed LPM Shmilovich as of 4/15/2015 114129773 Pre LPM working set 20150418 114129774 Post LPM Assignment Set 20150420 114129775 Pericardial 114129776 Cardiovascular TAB-2847 114097026 Novel Epstein-Barr Virus Vaccines NIAID Infectious Disease, Licensing, Oncology, Vaccines Infectious Disease Licensing Oncology Vaccines Wei Bu, Jeffrey Cohen, Masaru Kanekiyo, Gary Nabel Epstein-Barr Virus (EBV) is the causative agent of infectious mononucleosis and is associated with certain types of cancers, such as Hodgkin's lymphoma, Burkitt's lymphoma, gastric carcinoma, and nasopharyngeal carcinoma. There are currently no vaccines against EBV on the market and there is only supportive treatment available for EBV infection.<br /><br /> The subject technologies are novel vaccine candidates against EBV that employ fusion proteins consisting of immunogenic portions of the EBV envelope glycoproteins (i.e. gp350, gH/gL, etc.) that are found on the surface of the virus fused with a self-assembling protein such as ferritin. The fusion proteins multimerize and the resulting nanoparticles serve as the antigens in the vaccine. In mice, these vaccine candidates were able to elicit neutralizing antibodies that were significantly higher than vaccination with only soluble forms of the EBV envelope glycoproteins lacking the self-assembly domains. In some cases, the fusion protein vaccine candidates were able to elicit neutralizing antibodies while vaccination with the corresponding soluble versions elicited primarily non-neutralizing antibodies. These neutralizing antibody titers in immunized mice were substantially higher than those seen in humans naturally infected with EBV. <ul> <li>The subject technologies are novel vaccine candidates against EBV that were able to elicit significantly higher levels of neutralizing antibodies than vaccines based solely on soluble forms of the EBV envelope glycoproteins lacking self-assembly domains.</li> </ul> <ul> <li>Vaccines against EBV</li> </ul> 2022-03-08 2025-08-13 2025-08-15 2014-08-06 D, DC5BXX, Development, EPSTEIN-BARR, Evelopment, Listed LPM Chang as of 4/15/2015, Nanoparticle-Based, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, vaccines, VCXXXX, virus, VLXXXX, YAXXXX, YBXXXX, YCXXXX False True <ul> <li>Early-stage</li> <li>In vitro data available</li> <li>In vivo data available (animal)</li> </ul> True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114107403 Bu, Wei NIAID - DIR NIAID Bu, Wei (NIAID) 0 114108815 Nabel, Gary NIAID - VRC NIAID Nabel, Gary (NIAID) 0 114108816 Cohen, Jeffrey NIAID - DIR NIAID Cohen, Jeffrey (NIAID) 0 114108814 Kanekiyo, Masaru NIAID - VRC NIAID Kanekiyo, Masaru (NIAID) 1 114108814 Kanekiyo, Masaru NIAID - VRC NIAID Kanekiyo, Masaru (NIAID) 1 114107403 Bu, Wei NIAID - DIR NIAID Bu, Wei (NIAID) 0 114108815 Nabel, Gary NIAID - VRC NIAID Nabel, Gary (NIAID) 0 114108816 Cohen, Jeffrey NIAID - DIR NIAID Cohen, Jeffrey (NIAID) 0 114101297 Development Of Nanoparticle-based Epstein-Barr Virus Vaccines E-531-2013-2 Filing authorized NIAID 114102191 Development Of Nanoparticle-based Epstein-Barr Virus Vaccines E-531-2013-0 Filing authorized NIAID 114102192 Development Of Nanoparticle-based Epstein-Barr Virus Vaccines E-531-2013-1 Filing authorized NIAID 91029846 Ganelina, Anna ganelinaa@niaid.nih.gov
United States of America ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-2847] Novel Epstein-Barr Virus Vaccines&body=Please send me information about technology [TAB-2847] Novel Epstein-Barr Virus Vaccines. Ganelina, Anna<br><a href="mailto:ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-2847] Novel Epstein-Barr Virus Vaccines&body=Please send me information about technology [TAB-2847] Novel Epstein-Barr Virus Vaccines.">ganelinaa@niaid.nih.gov</a><br> 114165186 E-531-2013-2 E-531-2013-2-US-06 Epstein-Barr Virus Vaccines National Stage US 10,744,199 15/028,655 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10744199 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10744199">10,744,199</a><br />Filed on 2016-04-11<br />Status: Issued 114165481 E-531-2013-2 E-531-2013-2-PCT-01 Novel Epstein-Barr Virus Vaccines PCT Patent Cooperation Treaty PCT/US2014/060142 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2014/060142<br />Filed on 2014-10-10<br />Status: Expired 114167902 E-531-2013-0 E-531-2013-0-US-01 NOVEL EPSTEIN-BARR VIRUS VACCINES PRV US 61/889,840 Abandoned US <br />Provisional (PRV) 61/889,840<br />Filed on 2013-10-11<br />Status: Abandoned 114167903 E-531-2013-1 E-531-2013-1-US-01 NOVEL EPSTEIN-BARR VIRUS VACCINES PRV US 61/921,284 Abandoned US <br />Provisional (PRV) 61/921,284<br />Filed on 2013-12-27<br />Status: Abandoned 114169040 E-531-2013-2 E-531-2013-2-US-07 EPSTEIN-BARR VIRUS VACCINES DIV US 12,005,115 16/922,322 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12005115 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12005115">12,005,115</a><br />Filed on 2020-07-07<br />Status: Issued 114126440 DC5BXX 114126441 VCXXXX 114126442 VLXXXX 114126443 YAXXXX 114126444 YBXXXX 114126445 YCXXXX 114133966 Post LPM Assignment Set 20150420 114134256 Listed LPM Chang as of 4/15/2015 114134257 Pre LPM working set 20150418 114147727 D 114147728 Evelopment 114147729 Nanoparticle-Based 114147730 EPSTEIN-BARR 114147731 virus 114147732 vaccines 114147733 Development TAB-2811 114096990 Real Time Medical Image Processing Using Cloud Computing NHLBI Collaboration, Computational models/software, Diagnostics, Medical Devices, Non-Medical Devices, Software / Apps Collaboration Computational models/software Diagnostics Medical Devices Non-Medical Devices Software / Apps Michael Hansen, Peter Kellman, Hui Xue The invention pertains to a system for reconstructing images acquired from MR and CT scanners in a robust Gadgetron based cloud computing system. A hardware interface connects clinical imaging instruments (e.g., MR or CT scanners) with a cloud computing environment that includes image data reconstruction and processing software not limited by the computational constraints typical of static hardware with finite processor power. Raw imaging data acquired from an MR or CT instrument is evaluated and categorized based on a pre-prioritized dimensionality parameter (e.g., spatial dimension parameter; three- or two-dimensionality, a time parameter, a flow/velocity parameter, an experiment timing dimension parameter, a diffusion encoding parameter, a functional/physiological testing dimension parameter, or a physiologic gating index parameter) and transmitted to a corresponding cloud computing environment for processing and reconstruction. The final processed image is retransmitted to a user interface that can be read by a radiologist or technician. <ul> <li>Eliminates the need for purchasing expensive data processing equipment that becomes obsolete</li> <li>Less equipment leads to lowers costs and space efficiency</li> <li>Exponentially more robust computer power, data acquisition and image reconstruction</li> </ul> <ul> <li>MRI imaging</li> <li>CT imaging</li> <li>Image processing</li> <li>Diagnostic radiology</li> </ul> The National Heart Lung & Blood Institute is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize Gadgetron mediated clinical image processing. For collaboration opportunities, please contact Denise Crooks, Ph.D. at 301-435-0103 or <a href="mailto:crooksd@nhlbi.nih.gov">crooksd@nhlbi.nih.gov</a>. 2022-03-08 2025-08-13 2025-08-15 2014-05-15 AD1XXX, AD2XXX, AD3XXX, Cloud, Computing, CT, DATA, Gadgetron, IMAGING, Listed LPM Shmilovich as of 4/15/2015, Magnetic Resonance, MEDICAL, MRI, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Processing, Raw, REAL-TIME, XFXXXX, XJXXXX False True <ul> <li>Early-stage</li> <li>In vitro data available</li> <li>In vivo data available (animal)</li> <li>In vivo data available (human)</li> <li>In situ data available (on-site)</li> <li>Prototype</li> </ul> True NIHTT 37470483 Website Abstract 114108691 Xue, Hui National Heart, Lung, and Blood Institute (NHLBI) NHLBI Xue, Hui (NHLBI) 0 114108692 Kellman, Peter National Heart, Lung, and Blood Institute (NHLBI) NHLBI Kellman, Peter (NHLBI) 0 114108693 Hansen, Michael National Heart, Lung, and Blood Institute (NHLBI) NHLBI Hansen, Michael (NHLBI) 1 114108693 Hansen, Michael National Heart, Lung, and Blood Institute (NHLBI) NHLBI Hansen, Michael (NHLBI) 1 114108691 Xue, Hui National Heart, Lung, and Blood Institute (NHLBI) NHLBI Xue, Hui (NHLBI) 0 114108692 Kellman, Peter National Heart, Lung, and Blood Institute (NHLBI) NHLBI Kellman, Peter (NHLBI) 0 114099458 Real-Time Processing Of Medical Imaging Raw Data Using Cloud Computing E-074-2014-2 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 114102142 Real-Time Processing Of Medical Imaging Raw Data Using Cloud Computing E-074-2014-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 114102144 Real-Time Processing Of Medical Imaging Raw Data Using Cloud Computing E-074-2014-1 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 89788013 Kolesnitchenko, Vincent vk5q@nih.gov
United States of America Office of Technology Transfer and Development vk5q@nih.gov?subject=Web Inquiry on [TAB-2811] Real Time Medical Image Processing Using Cloud Computing&body=Please send me information about technology [TAB-2811] Real Time Medical Image Processing Using Cloud Computing. Kolesnitchenko, Vincent<br><a href="mailto:vk5q@nih.gov?subject=Web Inquiry on [TAB-2811] Real Time Medical Image Processing Using Cloud Computing&body=Please send me information about technology [TAB-2811] Real Time Medical Image Processing Using Cloud Computing.">vk5q@nih.gov</a><br> 114160719 E-074-2014-2 E-074-2014-2-PCT-01 Real-Time Processing Of Medical Imaging Raw Data Using Cloud Computer PCT COMB Patent Cooperation Treaty PCT/US2015/014252 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2015/014252<br />Filed on 2015-02-03<br />Status: Expired 114162505 E-074-2014-2 E-074-2014-2-US-02 System and Apparatus for Real-Time Processing Of Medical Imaging Raw Data Using Cloud Computing National Stage US 10,068,331 15/115,839 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10068331 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10068331">10,068,331</a><br />Filed on 2016-08-01<br />Status: Issued 114167775 E-074-2014-0 E-074-2014-0-US-01 Real-Time Processing Of Medical Imaging Raw Data Using Cloud Computing PRV US 61/934,987 Abandoned US <br />Provisional (PRV) 61/934,987<br />Filed on 2014-02-03<br />Status: Abandoned 114167776 E-074-2014-1 E-074-2014-1-US-01 Real-Time Processing Of Medical Imaging Raw Data Using Cloud Computing PRV US 61/953,017 Abandoned US <br />Provisional (PRV) 61/953,017<br />Filed on 2014-03-14<br />Status: Abandoned 114125964 AD1XXX 114125965 AD2XXX 114125966 AD3XXX 114125967 XFXXXX 114125968 XJXXXX 114142917 Listed LPM Shmilovich as of 4/15/2015 114142918 Pre LPM working set 20150418 114142919 Post LPM Assignment Set 20150420 114147181 REAL-TIME 114147182 Processing 114147183 Magnetic Resonance 114147184 IMAGING 114147185 Raw 114147186 MRI 114147187 Cloud 114147188 Computing 114147189 Gadgetron 114147190 CT 114147191 MEDICAL 114147192 DATA TAB-2809 114096989 Viral Like Particles Based Chikungunya Vaccines NIAID Diagnostics, Infectious Disease, Licensing, Research Equipment, Therapeutics, Vaccines Diagnostics Infectious Disease Licensing Research Equipment Therapeutics Vaccines Wataru Akahata, Gary Nabel, Srinivas Rao Chikungunya virus (CHIKV) is mosquito-borne alphavirus endemic in Africa, India, and Southeast Asia. In 2013 CHIKV infection has also emerged in the Caribbean and a pandemic of CHIKV has re-emerged in the Philippines following Typhoon Haiyan. Currently, there is no vaccine available for the prevention of CHIKV infection and no specific therapy exists to treat the illness. Researchers at the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID) have developed a CHIKV Viral Like Particle (CHIKV VLP) vaccine based on plasmid expression vectors encoding structural proteins of the CHIKV virus, which gave rise to CHIKV VLPs in transfected cells. The CHIKV VLPs consist of the core, E1 and E2 proteins and are similar in buoyant density and morphology to replication-competent CHIKV virus. Immunization with CHIKV VLPs elicited neutralizing antibodies against envelope proteins from different CHIKV strains in mouse and nonhuman primate (NHP) models. Monkeys immunized with CHIKV VLPs produced high titer neutralizing antibodies that protected against viremia after high dose challenge. The selected CHIKV VLP vaccine candidate, VRC-CHKVLP059-00-VP, composed of the E1, E2, and capsid proteins from the CHIKV strain 37997, was recently evaluated by the VRC at the NIH Clinical Center for safety, tolerability and immunogenicity in the clinical protocol VRC 311 (ClinicalTrials.gov # NCT01489358), a Phase I, open-label, dose escalation clinical trial. The VRC-CHKVLP059-00-VP vaccine was highly immunogenic, safe, and well-tolerated. VRC researchers have also developed the transient transfection manufacturing process for CHIKV and other alphaviruses, such as Western, Eastern and Venezuelan Equine Encephalitis (WEVEE) viruses. Pre-clinical in vivo mouse and NHP data, Phase 1 clinical trial data and manufacturing data are available.<br /><br /> NIH will evaluate a license applicant's capabilities and experience in advancing similar technologies through the regulatory process. This technology is not eligible for the NIH's start-up license program. <ul> <li>There is currently no CHIKV vaccine on the market.</li> <li>VRC-CHKVLP059-00-VP vaccine candidate is highly immunogenic, safe, and well-tolerated.</li> <li>Minimal containment requirements for CHIKV VLP manufacturing because live virus production is not required.</li> </ul> <ul> <li>Chikungunya vaccines based on viral like particles.</li> </ul> and corresponding international filings 2022-07-08 2025-08-13 2025-08-15 2015-12-17 2014-05-12 5/12/2014 -- per e-mail from LPM, abstract to be removed from the website until further notice (a development/licensing blurb needs to be added)... --ecr 8/05/2014 -- received revised, IC-approved abstract from LPM, so TAB record reactivated. Against, ALPHA, ALPHAVIRUS, CAPSID, Chikungunya, CHIKV, DC5BXX, Development, DNA vaccine, E1, E1-E2, E2, Envelope, Generation, Method, MODIFICATION, Modifications, PARTICLES, Patent Category - Biotechnology, PLASMID, PREVENTIVE, production, Protein, proteins, Vaccine, VBXXXX, viral, virus, VIRUS-LIKE, VLPs, VLXXXX, XHXXXX False True <ul> <li>In vitro data available</li> <li>In vivo data available (animal)</li> <li>In vivo data available (human)</li> </ul> True NIHTT 37470483 Website Abstract 114172134 Akahata W, et al. http://www.ncbi.nlm.nih.gov/pubmed/20111039 <a href="http://www.ncbi.nlm.nih.gov/pubmed/20111039">Akahata W, et al.</a> 114172135 Akahata W, Nabel GJ. http://www.ncbi.nlm.nih.gov/pubmed/22647698 <a href="http://www.ncbi.nlm.nih.gov/pubmed/22647698">Akahata W, Nabel GJ.</a> 114172136 Chang LJ, et al. http://www.ncbi.nlm.nih.gov/pubmed/25132507 <a href="http://www.ncbi.nlm.nih.gov/pubmed/25132507">Chang LJ, et al.</a> 114108688 Akahata, Wataru NIAID - VRC NIAID Akahata, Wataru (NIAID) 0 114108689 Rao, Srinivas NIAID - VRC Rao, Srinivas 0 114108687 Nabel, Gary NIAID - VRC NIAID Nabel, Gary (NIAID) 1 114108687 Nabel, Gary NIAID - VRC NIAID Nabel, Gary (NIAID) 1 114108688 Akahata, Wataru NIAID - VRC NIAID Akahata, Wataru (NIAID) 0 114108689 Rao, Srinivas NIAID - VRC Rao, Srinivas 0 114102136 Use Of Viral Like Particles (VLPs) In The Development Of A Preventive Vaccine Against Chikungunya E-004-2009-0 Filing authorized NIAID 114102137 Use Of Viral Like Particles (VLPs) In The Development Of A Preventive Vaccine Against Chikungunya E-004-2009-1 Filing authorized NIAID 114102138 Use Of Viral Like Particles (VLPs) In The Development Of A Preventive Vaccine Against Chikungunya E-004-2009-2 Filing authorized NIAID 114102139 Modification Of Alpha Virus Envelope Proteins To Improve Production Of Virus Like Particles (VLPs) E-057-2011-0 Filing authorized NIAID 114102140 Generation Of Modifications To The Capsid Of Alpha Virus Envelope Proteins To Improve Production Of Virus-like Particles E-057-2011-1 Filing authorized NIAID 114102141 Virus Like Particles (VLPs) And Method Of Use E-057-2011-2 Filing authorized NIAID 91026778 Green, Wade wade.green@nih.gov
United States of America TTIPO wade.green@nih.gov?subject=Web Inquiry on [TAB-2809] Viral Like Particles Based Chikungunya Vaccines&body=Please send me information about technology [TAB-2809] Viral Like Particles Based Chikungunya Vaccines. Green, Wade<br><a href="mailto:wade.green@nih.gov?subject=Web Inquiry on [TAB-2809] Viral Like Particles Based Chikungunya Vaccines&body=Please send me information about technology [TAB-2809] Viral Like Particles Based Chikungunya Vaccines.">wade.green@nih.gov</a><br> 114160858 E-057-2011-2 E-057-2011-2-US-04 Virus Like Particles (VLPs) And Method Of Use DIV US 10,138,277 15/279,592 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10138277 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10138277">10,138,277</a><br />Filed on 2016-09-29<br />Status: Issued 114165732 E-004-2009-2 E-004-2009-2-US-15 METHODS FOR THE INDUCTION OF IMMUNE RESPONSES IN A SUBJECT COMPRISING ADMINISTERING VIRUS-LIKE PARTICLES (VLPS) PREPARED FROM CHIKUNGUNYA VIRUS STRUCTURAL PROTEINS DIV US 10,369,208 15/145,483 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10369208 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10369208">10,369,208</a><br />Filed on 2016-05-03<br />Status: Issued 114167749 E-004-2009-0 E-004-2009-0-US-01 Use Of Viral Like Particles (VLPs) In The Development Of A Preventive Vaccine Against Chikungunya PRV US 61/118,206 Abandoned US <br />Provisional (PRV) 61/118,206<br />Filed on 2008-11-26<br />Status: Abandoned 114167750 E-004-2009-1 E-004-2009-1-US-01 Use Of Viral Like Particles (VLPs) In The Development Of A Preventive Vaccine Against Chikungunya PRV US 61/201,118 Abandoned US <br />Provisional (PRV) 61/201,118<br />Filed on 2008-12-05<br />Status: Abandoned 114167751 E-004-2009-2 E-004-2009-2-PCT-01 Viral Like Particle Compositions and Methods of Use PCT COMB Patent Cooperation Treaty PCT/US2009/006294 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2009/006294<br />Filed on 2009-11-24<br />Status: Expired 114167752 E-004-2009-2 E-004-2009-2-US-05 Virus-Like Particles (VLPS) Prepared from Chikungunya Virus Structural Proteins National Stage US 9,353,353 13/131,287 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9353353 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9353353">9,353,353</a><br />Filed on 2011-09-19<br />Status: Issued 114167753 E-057-2011-0 E-057-2011-0-US-01 Virus-Like Particles (VLPs) And Methods of Use PRV US 61/438,236 Abandoned US <br />Provisional (PRV) 61/438,236<br />Filed on 2011-01-31<br />Status: Abandoned 114167754 E-057-2011-1 E-057-2011-1-US-01 VIRUS-LIKE PARTICLES AND METHODS OF USE PRV US 61/501,012 Abandoned US <br />Provisional (PRV) 61/501,012<br />Filed on 2011-06-24<br />Status: Abandoned 114167755 E-057-2011-2 E-057-2011-2-PCT-01 Virus Like Particles (VLPs) And Method Of Use PCT COMB Patent Cooperation Treaty PCT/US2012/023361 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2012/023361<br />Filed on 2012-01-31<br />Status: Expired 114167756 E-057-2011-2 E-057-2011-2-US-02 Virus-Like Particles And Methods Of Use National Stage US 9,487,563 13/982,986 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9487563 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9487563">9,487,563</a><br />Filed on 2013-07-31<br />Status: Issued 114168813 E-057-2011-2 E-057-2011-2-US-05 VIRUS-LIKE PARTICLES AND METHODS OF USE DIV US 11,098,084 16/199,671 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11098084 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11098084">11,098,084</a><br />Filed on 2018-11-26<br />Status: Issued 114168899 E-004-2009-2 E-004-2009-2-US-17 Virus Like Particle Compositions and Methods of Use DIV US 11,369,674 16/520,113 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11369674 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11369674">11,369,674</a><br />Filed on 2019-07-23<br />Status: Issued 114169155 E-057-2011-2 E-057-2011-2-US-06 VIRUS-LIKE PARTICLES AND METHODS OF USE CON US 11,718,647 17/410,182 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11718647 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11718647">11,718,647</a><br />Filed on 2021-08-24<br />Status: Issued 114169564 E-004-2009-2 E-004-2009-2-US-28 VIRUS LIKE PARTICLE COMPOSITIONS AND METHODS OF USE DIV US 11,992,523 17/850,706 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11992523 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11992523">11,992,523</a><br />Filed on 2022-06-27<br />Status: Issued 114125945 DC5BXX 114125946 VBXXXX 114125947 VLXXXX 114125948 XHXXXX 114147153 viral 114147154 E1 114147155 VLPs 114147156 DNA vaccine 114147157 PLASMID 114147158 Vaccine 114147159 ALPHAVIRUS 114147160 Chikungunya 114147161 CHIKV 114147162 Patent Category - Biotechnology 114147163 E1-E2 114147164 E2 114147165 Protein 114147166 PARTICLES 114147167 Development 114147168 PREVENTIVE 114147169 Against 114147170 MODIFICATION 114147171 ALPHA 114147172 virus 114147173 Envelope 114147174 proteins 114147175 production 114147176 Modifications 114147177 Generation 114147178 CAPSID 114147179 VIRUS-LIKE 114147180 Method TAB-2796 114096975 Human iPSC-Derived Mesodermal Precursor Cells and Differentiated Cells NHLBI Cardiology, Collaboration, Consumer Products, Dental, Diagnostics, Endocrinology, Geriatrics, Immunology, Infectious Disease, Neurology, Occupational Safety and Health, Oncology, Ophthalmology, Reproductive Health, Research Materials, Therapeutics, Vaccines Cardiology Collaboration Consumer Products Dental Diagnostics Endocrinology Geriatrics Immunology Infectious Disease Neurology Occupational Safety and Health Oncology Ophthalmology Reproductive Health Research Materials Therapeutics Vaccines Manfred Boehm, Guibin Chen, Andre Larochelle, Mahendra Rao Cells, cell culture methods, and cell culture media compositions useful for producing and maintaining iPSC-derived cell lines that are of higher purity and maintain cell type integrity better than current iPSC-derived cell lines are disclosed. Human induced pluripotent stem cells (hiPSCs) can be generated by reprogramming somatic cells by the expression of four transcription factors. The hiPSCs exhibit similar properties to human embryonic stem cells, including the ability to self-renew and differentiate into all three embryonic germ layers: ectoderm, endoderm, or mesoderm. Human iPSCs can be induced into any cell type and, since they can be maintained over many passages, they can serve as an almost unlimited source to generate cells from any given person. These properties make iPSC-derived cells a valuable product for cell therapies and toxicology or pharmaceutical high throughput screens. NIH investigators disclose an iPSC-derived mesodermal precursor cell line, positive for CD34 and CD31 expression, that may be used to produce at least four different cell types. When cultured under appropriate conditions, these mesodermal precursor cells can be used to produce hematopoietic stem cells, mesenchymal stem cells, smooth muscle cells, or unlimited functional endothelial cells. <ul> <li>The mesodermal precursor cells have the ability to maintain their phenotype for extended periods without differentiating, when maintained under appropriate conditions.</li> </ul> <ul> <li>The iPSC-derived mesodermal precursor cell (MPC) line described here can be used to produce hematopoietic stem cells, mesenchymal stem cells , smooth muscle cells, or unlimited functional endothelial cells.</li> <li>The differentiated cells produced using the disclosed methods and MPC can be used for screening, as well as therapeutic applications.</li> </ul> The National Heart, Lung, and Blood Institute is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize this technology. For collaboration opportunities, please contact Denise Crooks at <a href="mailto:crooksd@nhlbi.nih.gov">crooksd@nhlbi.nih.gov</a>. 2022-04-08 2025-08-13 2025-08-15 2014-03-18 Cells, Hematopoetic, Human, IB6XXX, IDXXXX, IPSC-derived, Screenings, THERAPIES, Toxicology/drug, Vascular-related, VAXXXX, VBXXXX, VCXXXX, VDXXXX, VEXXXX, VFXXXX, VGXXXX, VHXXXX, VIXXXX, VJXXXX, VKXXXX, VLXXXX, VPXXXX, WAXXXX, WBXXXX, WCXXXX, WGXXXX, WHXXXX, WIXXXX, WJXXXX, WKXXXX, WMXXXX, YAXXXX, YBXXXX, YCXXXX False True <ul> <li>Early-stage</li> <li>In vitro data available</li> <li>In vivo data available (animal)</li> </ul> True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract E-762-2013-0 E-763-2013-0 114108631 Chen, Guibin National Heart, Lung, and Blood Institute (NHLBI) NHLBI Chen, Guibin (NHLBI) 0 114108632 Rao, Mahendra National Institute on Aging (NIH/NIA) NIAMS Rao, Mahendra (NIAMS) 0 114108633 Larochelle, Andre National Heart, Lung, and Blood Institute (NHLBI) NHLBI Larochelle, Andre (NHLBI) 0 114108630 Boehm, Manfred National Heart, Lung, and Blood Institute (NHLBI) NHLBI Boehm, Manfred (NHLBI) 1 114108630 Boehm, Manfred National Heart, Lung, and Blood Institute (NHLBI) NHLBI Boehm, Manfred (NHLBI) 1 114108631 Chen, Guibin National Heart, Lung, and Blood Institute (NHLBI) NHLBI Chen, Guibin (NHLBI) 0 114108632 Rao, Mahendra National Institute on Aging (NIH/NIA) NIAMS Rao, Mahendra (NIAMS) 0 114108633 Larochelle, Andre National Heart, Lung, and Blood Institute (NHLBI) NHLBI Larochelle, Andre (NHLBI) 0 114102121 Human iPSC-derived Vascular-related And Hematopoetic Cells For Therapies And Toxicology/drug Screenings E-342-2013-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI), NIAMS 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-2796] Human iPSC-Derived Mesodermal Precursor Cells and Differentiated Cells&body=Please send me information about technology [TAB-2796] Human iPSC-Derived Mesodermal Precursor Cells and Differentiated Cells. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-2796] Human iPSC-Derived Mesodermal Precursor Cells and Differentiated Cells&body=Please send me information about technology [TAB-2796] Human iPSC-Derived Mesodermal Precursor Cells and Differentiated Cells.">shmilovm@nih.gov</a><br> 114167238 E-342-2013-0 E-342-2013-0-US-03 Human IPSC-Derived Vascular-Related And Hematopoetic Cells For Therapies And Toxicology/Drug Screenings National Stage US 10,385,313 15/026,313 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10385313 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10385313">10,385,313</a><br />Filed on 2016-03-31<br />Status: Issued 114167710 E-342-2013-0 E-342-2013-0-US-01 Human IPSC-derived Vascular-related And Hematopoetic Cells For Therapies And Toxicology/drug Screenings PRV US 61/885,209 Abandoned US <br />Provisional (PRV) 61/885,209<br />Filed on 2013-10-01<br />Status: Abandoned 114167986 E-342-2013-0 E-342-2013-0-PCT-02 Human IPSC-derived Vascular-Related And Hematopoetic Cells For Therapies And Toxicology/Drug Screenings PCT Patent Cooperation Treaty PCT/US2014/058583 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2014/058583<br />Filed on 2014-10-01<br />Status: Expired 114168908 E-342-2013-0 E-342-2013-0-US-06 Human IPSC-derived Vascular-related And Hematopoetic Cells For Therapies And Toxicology/drug Screenings DIV US 11,072,778 16/544,381 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11072778 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11072778">11,072,778</a><br />Filed on 2019-08-19<br />Status: Issued 114169125 E-342-2013-0 E-342-2013-0-US-07 Human IPSC-derived Vascular-related And Hematopoetic Cells For Therapies And Toxicology/drug Screenings CON US 12,071,634 17/337,978 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12071634 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12071634">12,071,634</a><br />Filed on 2021-06-03<br />Status: Issued 114125811 IB6XXX 114125812 IDXXXX 114125813 VAXXXX 114125814 VBXXXX 114125815 VCXXXX 114125816 VDXXXX 114125817 VEXXXX 114125818 VFXXXX 114125819 VGXXXX 114125820 VHXXXX 114125821 VIXXXX 114125822 VJXXXX 114125823 VKXXXX 114125824 VLXXXX 114125825 VPXXXX 114125826 WAXXXX 114125827 WBXXXX 114125828 WCXXXX 114125829 WGXXXX 114125830 WHXXXX 114125831 WIXXXX 114125832 WJXXXX 114125833 WKXXXX 114125834 WMXXXX 114125835 YAXXXX 114125836 YBXXXX 114125837 YCXXXX 114146995 Screenings 114146996 Toxicology/drug 114146997 THERAPIES 114146998 Cells 114146999 Hematopoetic 114147000 Vascular-related 114147001 IPSC-derived 114147002 Human TAB-2792 114096971 Human Influenza Virus Real-time RT-PCR: Detection and Discrimination of Influenza A (H3N2) Variant from Seasonal Influenza A (H3N2) Viruses, Including H3v and Seasonal H3 Assays CDC Consumer Products, Diagnostics, Infectious Disease, Licensing, Occupational Safety and Health, Research Materials, Therapeutics Consumer Products Diagnostics Infectious Disease Licensing Occupational Safety and Health Research Materials Therapeutics LaShondra Berman, Stephen Lindstrom, Bo Shu, Kai-Hui Wu This invention relates to methods of rapidly detecting influenza, including differentiating between type and subtype. CDC researchers have developed a rapid, accurate, real-time RT-PCR assay that has several advantages over culture and serological tests, which require 5 to 14 days for completion; this assay can also be easily implemented in kit form. To date, hundreds of human cases of infection with the H3N2 variant virus have been confirmed. The increased numbers of human infection of H3N2 variant virus has led to a need for a highly sensitive and specific assay for the diagnosis and confirmation of the H3N2 variant virus. <ul> <li>Especially useful for H3N2 screening</li> <li>Sensitive detection</li> <li>Specific discrimination of influenza subtypes</li> <li>Easily formatted as kit or array</li> <li>Faster than culturing and serological identification methods</li> <li>Less laborious and more objective than immunoassays</li> </ul> <ul> <li>Influenza diagnostic using clinical specimens</li> <li>High-throughput sample screening</li> <li>Government, regional influenza surveillance programs</li> </ul> 2022-03-27 2025-08-13 2025-08-15 2014-03-18 assay, ASSAYS, CDC Docket Import, CDC Docket Import CDC Prosecuting, CIRCULATING, DA4BXX, DA4XXX, DAXXXX, Detection, diagnostic, Diagnostic assay, diagnostic in vitro, discrimination, DXXXXX, Flu, H3, H3N2, H3v, Including, INFLUENZA, ivd, Pandemic, REAL-TIME, RT-PCR, Seasonal, VARIANT, virus, Viruses, VLXXXX, VOXXXX, WBXXXX, WFXXXX, WIXXXX, WMXXXX, XCXXXX, XEXXXX, YBXXXX False True In vitro data available True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract E-274-2013-0 E-331-2013-0 114172111 Lindstrom S, et al. http://www.ncbi.nlm.nih.gov/pubmed/22516540 <a href="http://www.ncbi.nlm.nih.gov/pubmed/22516540">Lindstrom S, et al.</a> 114172112 Cox CM, et al. http://www.ncbi.nlm.nih.gov/pubmed/21749798 <a href="http://www.ncbi.nlm.nih.gov/pubmed/21749798">Cox CM, et al.</a> 114172113 Jhung MA, et al. http://www.ncbi.nlm.nih.gov/pubmed/24065322 <a href="http://www.ncbi.nlm.nih.gov/pubmed/24065322">Jhung MA, et al.</a> 114108619 Lindstrom, Stephen CDC - DIR CDC Lindstrom, Stephen (CDC) 0 114108620 Wu, Kai-Hui CDC - DIR CDC Wu, Kai-Hui (CDC) 0 114108621 Berman, LaShondra CDC - DIR CDC Berman, LaShondra (CDC) 0 114108618 Shu, Bo CDC - DIR CDC Shu, Bo (CDC) 1 114108618 Shu, Bo CDC - DIR CDC Shu, Bo (CDC) 1 114108619 Lindstrom, Stephen CDC - DIR CDC Lindstrom, Stephen (CDC) 0 114108620 Wu, Kai-Hui CDC - DIR CDC Wu, Kai-Hui (CDC) 0 114108621 Berman, LaShondra CDC - DIR CDC Berman, LaShondra (CDC) 0 114102117 The Real-Time RT-PCR Assay For Detection And Discrimination Of Influenza A (H3N2) Variant Virus From Circulating Seasonal Influenza A (H3N2) Viruses, Including H3v And Seasonal H3 Assays E-562-2013-0 Closed Centers for Disease Control and Prevention (CDC) 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2792] Human Influenza Virus Real-time RT-PCR: Detection and Discrimination of Influenza A (H3N2) Variant from Seasonal Influenza A (H3N2) Viruses, Including H3v and Seasonal H3 Assays&body=Please send me information about technology [TAB-2792] Human Influenza Virus Real-time RT-PCR: Detection and Discrimination of Influenza A (H3N2) Variant from Seasonal Influenza A (H3N2) Viruses, Including H3v and Seasonal H3 Assays. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2792] Human Influenza Virus Real-time RT-PCR: Detection and Discrimination of Influenza A (H3N2) Variant from Seasonal Influenza A (H3N2) Viruses, Including H3v and Seasonal H3 Assays&body=Please send me information about technology [TAB-2792] Human Influenza Virus Real-time RT-PCR: Detection and Discrimination of Influenza A (H3N2) Variant from Seasonal Influenza A (H3N2) Viruses, Including H3v and Seasonal H3 Assays.">jonathan.motley@nih.gov</a><br> 114166597 E-562-2013-0 E-562-2013-0-US-04 Compositions and Methods for Detection And Discrimination Of Influenza Viruses National Stage US 10,006,097 15/030,843 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10006097 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10006097">10,006,097</a><br />Filed on 2016-04-20<br />Status: Abandoned 114167704 E-562-2013-0 E-562-2013-0-US-01 COMPOSITIONS AND METHODS FOR DETECTION AND DISCRIMINATION OF INFLUENZA VIRUSES PRV US 61/894,291 Abandoned US <br />Provisional (PRV) 61/894,291<br />Filed on 2013-10-22<br />Status: Abandoned 114167981 E-562-2013-0 E-562-2013-0-PCT-02 COMPOSITIONS AND METHODS FOR DETECTION AND DISCRIMINATION OF INFLUENZA VIRUSES PCT Patent Cooperation Treaty PCT/US2014/061802 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2014/061802<br />Filed on 2014-10-22<br />Status: Expired 114168616 E-562-2013-0 E-562-2013-0-US-05 Compositions and Methods for Detection and Discrimination of Influenza Viruses DIV US 15/989,924 Abandoned US <br />Divisional (DIV) 15/989,924<br />Filed on 2018-05-25<br />Status: Abandoned 114125761 DXXXXX 114125762 DAXXXX 114125763 DA4XXX 114125764 DA4BXX 114125765 VLXXXX 114125766 VOXXXX 114125767 WBXXXX 114125768 WFXXXX 114125769 WIXXXX 114125770 XCXXXX 114125771 YBXXXX 114125772 WMXXXX 114125773 XEXXXX 114146904 REAL-TIME 114146905 RT-PCR 114146906 assay 114146907 Detection 114146908 discrimination 114146909 INFLUENZA 114146910 H3N2 114146911 VARIANT 114146912 virus 114146913 CIRCULATING 114146914 Seasonal 114146915 Viruses 114146916 Including 114146917 H3v 114146918 H3 114146919 ASSAYS 114146920 CDC Docket Import 114146921 CDC Docket Import CDC Prosecuting 114146922 Flu 114146923 ivd 114146924 diagnostic 114146925 diagnostic in vitro 114146926 Diagnostic assay 114146927 Pandemic TAB-2776 114096955 Methods for Amelioration and Treatment of Pathogen-associated Inflammatory Response CDC Antibodies, Cardiology, Consumer Products, Dental, Diagnostics, Endocrinology, Geriatrics, Immunology, Infectious Disease, Licensing, Neurology, Oncology, Ophthalmology, Research Materials, Therapeutics, Vaccines Antibodies Cardiology Consumer Products Dental Diagnostics Endocrinology Geriatrics Immunology Infectious Disease Licensing Neurology Oncology Ophthalmology Research Materials Therapeutics Vaccines Larry Anderson, Deborah Moore, Ralph Tripp This CDC invention provides methods for preventing or treating inflammatory response-linked, infection induced pathologies, which are mediated by endogenous substance P. Substance P is a naturally-occurring and major pro-inflammatory neuromediator or neuromodulator, and elevated levels of substance P have been implicated in numerous inflammation-associated diseases. More specifically, this technology entails administration of anti-substance P antibodies or anti-substance P antibody fragments to a subject in need, thereby inhibiting the activity of endogenous substance P.<br /><br /> Small molecule anti-inflammatory agents currently employed to treat inflammation frequently cause adverse side effects, such as gastrointestinal discomfort and decreased blood clotting efficiency. Use of steroid-based anti-inflammatory drugs may result in reduced adrenal gland function and generalized immune system inhibition. This technology specifically targets and alleviates substance P-induced hyper-inflammatory diseases, potentially avoiding the complications associated with other anti-inflammatory compounds. Blocking the activity of endogenous substance P potentially can be employed to prevent or treat a wide variety of diseases or syndromes caused in whole or part by an inflammatory response mediated by substance P. These include, but are not limited to, virus-mediated bronchiolitis including that mediated by respiratory syncytial virus, bacterial colitis, inflammation associated with chlamydial diseases, lung injury associated with staphylococcal enterotoxin B, inflammation due to cytomegalovirus or hepatitis B virus, sepsis, allergic diseases such as asthma, autoimmune diseases such as rheumatoid arthritis, pancreatitis, inflammatory bowel disease, inflammation associated with multiple sclerosis, and rejection of allografts and other transplanted tissues or organs. <ul> <li>Useful for management of numerous inflammatory-related viral and/or bacterial infections</li> <li>May reduce or circumvent adverse side effects associated with other small-molecule and/or steroid-based anti-inflammatory treatments</li> </ul> <ul> <li>Treatment of pathogen induced inflammation, especially bronchiolitis</li> <li>Prevention or lessening of adverse effects associated with other anti-inflammatory agents</li> </ul> Various international patent applications pending or issued 2022-03-27 2025-08-13 2025-08-15 2014-02-19 bronchoilitis, CAUSED, CDC Docket Import, CDC Docket Import CDC Prosecuting, DB3XXX, DB4XXX, DBXXXX, DISEASES, DXXXXX, IB3XXX, Infection, Inflammation, INFLAMMATORY, Methods, nitric oxide, OID-NCIRD-DVD, P, Pain, pain control, Prevention, Pulmonary, RESPONSE, RSV, RSV virus, SUBSTANCE, SUBSTANCE p, treatment, treatment methods, vasodilation, VASODILATOR, VAXXXX, VBXXXX, VDXXXX, VEXXXX, VJXXXX, VKXXXX, VLXXXX, VMXXXX, VOXXXX, VPXXXX, WAXXXX, WIXXXX, WJXXXX, WKXXXX, WMXXXX, XAXXXX, XCXXXX, YBXXXX, YCXXXX False True <ul> <li>In vitro data available</li> <li>In vivo data available (animal)</li> </ul> True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114172081 Tripp RA, et al. http://www.ncbi.nlm.nih.gov/pubmed/10644330 <a href="http://www.ncbi.nlm.nih.gov/pubmed/10644330">Tripp RA, et al.</a> 114108566 Anderson, Larry CDC - DIR CDC Anderson, Larry (CDC) 0 114108567 Moore, Deborah CDC - DIR CDC Moore, Deborah (CDC) 0 114108565 Tripp, Ralph CDC - DIR Tripp, Ralph 1 114108565 Tripp, Ralph CDC - DIR Tripp, Ralph 1 114108566 Anderson, Larry CDC - DIR CDC Anderson, Larry (CDC) 0 114108567 Moore, Deborah CDC - DIR CDC Moore, Deborah (CDC) 0 114102101 METHODS FOR THE PREVENTION AND TREATMENT OF DISEASES CAUSED BY AN INFLAMMATORY RESPONSE E-236-2013-0 Closed Centers for Disease Control and Prevention (CDC) 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2776] Methods for Amelioration and Treatment of Pathogen-associated Inflammatory Response&body=Please send me information about technology [TAB-2776] Methods for Amelioration and Treatment of Pathogen-associated Inflammatory Response. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2776] Methods for Amelioration and Treatment of Pathogen-associated Inflammatory Response&body=Please send me information about technology [TAB-2776] Methods for Amelioration and Treatment of Pathogen-associated Inflammatory Response.">jonathan.motley@nih.gov</a><br> 114167663 E-236-2013-0 E-236-2013-0-US-01 METHODS FOR THE PREVENTION AND TREATMENT OF DISEASES CAUSED BY AN INFLAMMATORY RESPONSE PRV US 60/116,835 Abandoned US <br />Provisional (PRV) 60/116,835<br />Filed on 1999-01-22<br />Status: Abandoned 114167664 E-236-2013-0 E-236-2013-0-PCT-02 METHODS FOR THE PREVENTION AND TREATMENT OF DISEASES CAUSED BY AN INFLAMMATORY RESPONSE PCT Patent Cooperation Treaty PCT/US2000/001032 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2000/001032<br />Filed on 2000-01-14<br />Status: Expired 114167665 E-236-2013-0 E-236-2013-0-US-06 METHODS FOR THE PREVENTION AND TREATMENT OF DISEASES CAUSED BY AN INFLAMMATORY RESPONSE National Stage US 7,101,547 09/889,317 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7101547 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7101547">7,101,547</a><br />Filed on 2001-07-13<br />Status: Expired 114125500 DXXXXX 114125501 DBXXXX 114125502 DB3XXX 114125503 DB4XXX 114125504 IB3XXX 114125505 VAXXXX 114125506 VBXXXX 114125507 VDXXXX 114125508 VEXXXX 114125509 VJXXXX 114125510 VKXXXX 114125511 VLXXXX 114125512 VMXXXX 114125513 VOXXXX 114125514 VPXXXX 114125515 WAXXXX 114125516 WIXXXX 114125517 WJXXXX 114125518 WKXXXX 114125519 WMXXXX 114125520 XAXXXX 114125521 XCXXXX 114125522 YBXXXX 114125523 YCXXXX 114146655 Methods 114146656 Prevention 114146657 treatment 114146658 DISEASES 114146659 CAUSED 114146660 INFLAMMATORY 114146661 RESPONSE 114146662 CDC Docket Import 114146663 CDC Docket Import CDC Prosecuting 114146664 OID-NCIRD-DVD 114146665 RSV 114146666 RSV virus 114146667 treatment methods 114146668 Infection 114146669 Pulmonary 114146670 Inflammation 114146671 SUBSTANCE 114146672 SUBSTANCE p 114146673 bronchoilitis 114146674 Pain 114146675 pain control 114146676 nitric oxide 114146677 VASODILATOR 114146678 vasodilation 114146679 P TAB-2770 114096949 Peptide Sequences for Chlamydophila pneumoniae Vaccine and Serological Diagnosis CDC Antibodies, Consumer Products, Diagnostics, Immunology, Infectious Disease, Licensing, Occupational Safety and Health, Research Materials, Therapeutics, Vaccines Antibodies Consumer Products Diagnostics Immunology Infectious Disease Licensing Occupational Safety and Health Research Materials Therapeutics Vaccines Edwin Ades, George Carlone, Eric Marston, Jacquelyn Sampson CDC researchers have isolated select <em>Chlamydophila pneumoniae</em> peptide epitopes for development of vaccines and diagnostic assays. Currently, <em>C. pneumoniae</em> infection of humans has been linked to a wide variety of acute and chronic diseases, such as asthma, endocarditis, atherosclerotic vascular disease, chronic obstructive pulmonary disease, sarcoidosis, reactive arthritis and multiple sclerosis. There is presently no available peptide vaccine for the pathogen and reliable and accurate diagnostic methods are limited.<br /><br /> This technology encompasses polypeptide sequences that are specifically recognized by anti-<em>C. pneumoniae</em> antibodies. These antigens may be useful for improving diagnostic methods by reducing the variability and high backgrounds found with methods that rely on whole organisms for detection. Further, this technology may also be useful for production of peptide or DNA-based vaccines directed against <em>C. pneumoniae</em>. <ul> <li>No peptide vaccine for <em>C. pneumoniae</em> is presently available</li> <li>Present assays for the diagnosis of <em>C. pneumoniae</em> infections are laborious and limited in efficacy</li> </ul> <ul> <li><em>C. pneumoniae</em> vaccine and/or therapeutic developments</li> <li>Public health surveillance programs</li> <li>Clinical serological diagnostics development</li> </ul> 2022-03-27 2025-08-13 2025-08-15 2014-02-07 CDC Docket Import, CDC Docket Import CDC Prosecuting, Chlamydophila, DA3XXX, DAXXXX, DC1XXX, DC4XXX, Diagnosis, DXXXXX, OID-NCIRD-DBD, Peptides, PNEUMONIAE, Serologic, SEROLOGICAL, Vaccine, VJXXXX, WBXXXX, WFXXXX, WJXXXX, XAXXXX, XCXXXX, XEXXXX, YBXXXX False True In vitro data available True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114172062 Marston EL, et al. http://www.ncbi.nlm.nih.gov/pubmed/11874892 <a href="http://www.ncbi.nlm.nih.gov/pubmed/11874892">Marston EL, et al.</a> 114108535 Sampson, Jacquelyn CDC - DIR CDC Sampson, Jacquelyn (CDC) 0 114108536 Carlone, George CDC - DIR CDC Carlone, George (CDC) 0 114108537 Ades, Edwin CDC - DIR CDC Ades, Edwin (CDC) 0 114108534 Marston, Eric CDC - DIR CDC Marston, Eric (CDC) 1 114108534 Marston, Eric CDC - DIR CDC Marston, Eric (CDC) 1 114108535 Sampson, Jacquelyn CDC - DIR CDC Sampson, Jacquelyn (CDC) 0 114108536 Carlone, George CDC - DIR CDC Carlone, George (CDC) 0 114108537 Ades, Edwin CDC - DIR CDC Ades, Edwin (CDC) 0 114102090 Peptides For Chlamydophila Pneumoniae Vaccine And Diagnosis E-235-2013-0 Closed Centers for Disease Control and Prevention (CDC) 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2770] Peptide Sequences for Chlamydophila pneumoniae Vaccine and Serological Diagnosis&body=Please send me information about technology [TAB-2770] Peptide Sequences for Chlamydophila pneumoniae Vaccine and Serological Diagnosis. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2770] Peptide Sequences for Chlamydophila pneumoniae Vaccine and Serological Diagnosis&body=Please send me information about technology [TAB-2770] Peptide Sequences for Chlamydophila pneumoniae Vaccine and Serological Diagnosis.">jonathan.motley@nih.gov</a><br> 114167641 E-235-2013-0 E-235-2013-0-PCT-02 Peptides For Chlamydophila Pneumoniae Vaccine And Diagnosis PCT Patent Cooperation Treaty PCT/US2002/017278 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2002/017278<br />Filed on 2002-05-31<br />Status: Expired 114167642 E-235-2013-0 E-235-2013-0-US-01 Peptides For Chlamydophila Pneumoniae Vaccine And Diagnosis PRV US 60/296,496 Abandoned US <br />Provisional (PRV) 60/296,496<br />Filed on 2001-06-05<br />Status: Abandoned 114167643 E-235-2013-0 E-235-2013-0-US-07 Peptides For Chlamydophila Pneumoniae Vaccine And Diagnosis National Stage US 7,223,836 10/479,503 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7223836 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7223836">7,223,836</a><br />Filed on 2003-12-02<br />Status: Abandoned 114125370 DXXXXX 114125371 DAXXXX 114125372 DA3XXX 114125373 DC4XXX 114125374 DC1XXX 114125398 VJXXXX 114125399 WBXXXX 114125400 WFXXXX 114125401 WJXXXX 114125402 XAXXXX 114125403 XCXXXX 114125404 XEXXXX 114125405 YBXXXX 114146566 Peptides 114146567 Chlamydophila 114146568 PNEUMONIAE 114146569 Vaccine 114146570 Diagnosis 114146571 CDC Docket Import 114146572 CDC Docket Import CDC Prosecuting 114146573 OID-NCIRD-DBD 114146574 SEROLOGICAL 114146575 Serologic TAB-2767 114096946 Methods for the Simultaneous Detection of Multiple Analytes CDC Antibodies, Consumer Products, Diagnostics, Immunology, Infectious Disease, Licensing, Occupational Safety and Health, Oncology, Research Equipment, Research Materials, Therapeutics, Vaccines Antibodies Consumer Products Diagnostics Immunology Infectious Disease Licensing Occupational Safety and Health Oncology Research Equipment Research Materials Therapeutics Vaccines George Carlone, Joseph Martinez CDC researchers have developed a method of simultaneously detecting and distinguishing multiple antigens within a biological sample. Epidemiological and vaccine studies require species serotype identification. Current methods of serotyping are labor intensive and can easily give subjective, errant results. This technology utilizes serotype specific antibodies bound to fluorescent beads, allowing for simultaneous single tube capture and detection of multiple antigens in one rapid, high-throughput flow cytometry assay. Such technology has an extremely wide range of useful applications, including but not limited to complex serotyping investigations for vaccine development and formulation, as a tool for rapid clinical prognosis or diagnosis, and the assay can be formatted as a kit for any number of laboratory research uses. <ul> <li>Rapid flow cytometry assay</li> <li>Simultaneous detection of multiple different antigens and antibodies</li> <li>Excellent for high-throughput usage</li> <li>Provides a reliable, reproducible measurements of serotype-specific antigens within a sample</li> <li>Technology particularly well-developed for addressing <em>S. pneumoniae</em> serotyping concerns</li> </ul> <ul> <li>Complex serotyping and/or multi-antigen composition investigations</li> <li>Tool for clinical diagnosis or prognosis of a disease or infection</li> <li>Tool for basic research</li> </ul> 2022-03-27 2025-08-13 2025-08-15 2014-02-06 AA5XXX, AAXXXX, ANALYTES, AXXXXX, Bead, Beads, CA1BXX, CDC Docket Import, CDC Docket Import CDC Prosecuting, Compositions, DA1XXX, DA2XXX, DA3XXX, DA4AXX, DA4BXX, DA4XXX, DA5XXX, DAXXXX, Detection, flow cytometer, flow cytometry, IAXXXX, IMMUNOASSAY, Methods, MULTIPLE, SIMULTANEOUS, VBXXXX, VJXXXX, VKXXXX, VLXXXX, VOXXXX, WAXXXX, WBXXXX, WCXXXX, WFXXXX, WIXXXX, WMXXXX, XAXXXX, XCXXXX, XHXXXX, YBXXXX False True In vitro data available True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114108526 Carlone, George CDC - DIR CDC Carlone, George (CDC) 0 114108525 Martinez, Joseph CDC - DIR CDC Martinez, Joseph (CDC) 1 114108525 Martinez, Joseph CDC - DIR CDC Martinez, Joseph (CDC) 1 114108526 Carlone, George CDC - DIR CDC Carlone, George (CDC) 0 114102087 Methods And Compositions For The Simultaneous Detection Of Multiple Analytes E-142-2013-0 Closed Centers for Disease Control and Prevention (CDC) 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2767] Methods for the Simultaneous Detection of Multiple Analytes&body=Please send me information about technology [TAB-2767] Methods for the Simultaneous Detection of Multiple Analytes. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2767] Methods for the Simultaneous Detection of Multiple Analytes&body=Please send me information about technology [TAB-2767] Methods for the Simultaneous Detection of Multiple Analytes.">jonathan.motley@nih.gov</a><br> 114167630 E-142-2013-0 E-142-2013-0-PCT-02 Methods And Compositions For The Simultaneous Detection Of Multiple Analytes PCT Patent Cooperation Treaty PCT/US2001/009576 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2001/009576<br />Filed on 2001-03-26<br />Status: Expired 114167631 E-142-2013-0 E-142-2013-0-US-01 Methods And Compositions For The Simultaneous Detection Of Multiple Analytes PRV US 60/192,712 Abandoned US <br />Provisional (PRV) 60/192,712<br />Filed on 2000-03-28<br />Status: Abandoned 114167632 E-142-2013-0 E-142-2013-0-US-03 Methods And Compositions For The Simultaneous Detection Of Multiple Analytes National Stage US 7,659,085 10/259,907 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7659085 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7659085">7,659,085</a><br />Filed on 2002-09-27<br />Status: Expired 114125304 AXXXXX 114125305 AAXXXX 114125306 AA5XXX 114125307 DAXXXX 114125308 IAXXXX 114125309 CA1BXX 114125310 DA1XXX 114125311 DA2XXX 114125312 DA3XXX 114125313 DA4XXX 114125314 DA5XXX 114125315 DA4AXX 114125316 DA4BXX 114125317 VBXXXX 114125318 VJXXXX 114125319 VKXXXX 114125320 VLXXXX 114125321 VOXXXX 114125322 WAXXXX 114125323 WBXXXX 114125324 WCXXXX 114125325 WFXXXX 114125326 WIXXXX 114125327 WMXXXX 114125328 XAXXXX 114125329 XCXXXX 114125330 XHXXXX 114125331 YBXXXX 114146523 ANALYTES 114146524 MULTIPLE 114146525 Detection 114146526 SIMULTANEOUS 114146527 Compositions 114146528 Methods 114146529 CDC Docket Import 114146530 CDC Docket Import CDC Prosecuting 114146531 flow cytometer 114146532 flow cytometry 114146533 Bead 114146534 Beads 114146535 IMMUNOASSAY TAB-2764 114096943 Enterovirus Molecular Diagnostic Test Kit CDC Consumer Products, Diagnostics, Infectious Disease, Licensing, Occupational Safety and Health, Research Materials, Therapeutics Consumer Products Diagnostics Infectious Disease Licensing Occupational Safety and Health Research Materials Therapeutics William Nix, Mark Oberste CDC researchers have developed a reverse transcription/semi-nested polymerase chain reaction (RT-snPCR) assay for diagnosis of enterovirus infections within clinical specimens. Clinical laboratories currently identify enteroviruses by virus isolation and subsequent virus neutralization tests, or serological assays. In addition to being time consuming, these approaches are labor, cost and material intensive.<br /><br /> The enterovirus molecular diagnostic test is prepared in a kit form, consisting of three reagent preparations (three separate test steps), to which a technician adds enzymes and RNA extracted from a clinical specimen. This format is amenable to commercial manufacturing processes. The assay primers were designed for broad specificity and amplify all recognized enterovirus serotypes. In the course of assay development, PCR products have been successfully amplified and sequenced from cerebrospinal fluid, nasopharyngeal swabs, eye swabs, rectal swabs and stool suspensions, allowing for unambiguous identification of the infecting virus in all cases. This assay will be useful for the diagnosis of numerous common illnesses, such as foot-and-mouth disease, respiratory illness, conjunctivitis, neonatal illness, and myocarditis, among several others. <ul> <li>Ready for commercialization</li> <li>Easily adaptable to kit form</li> <li>Rapid, cost-efficient serotype identification</li> <li>High specificity and precision</li> <li>Assay covers all known human enterovirus serotypes</li> </ul> <ul> <li>Detection and identification of enterovirus infections, such as foot-and-mouth disease</li> <li>Diagnostic evaluations of respiratory or neonatal illnesses</li> <li>Enterovirus surveillance programs for humans and animals/livestock</li> </ul> Various international patents issued or pending 2022-03-27 2025-08-13 2025-08-15 2014-02-06 Acid, CDC Docket Import, CDC Docket Import CDC Prosecuting, DA4BXX, DA4XXX, DAXXXX, DETECTING, DXXXXX, Enteroviruses, Identifying, Including, Kits, MOLECULES, Nucleic, OID-NCIRD-DVD, USEFUL, VLXXXX, VOXXXX, VP1, VP3, WBXXXX, WFXXXX, WIXXXX, WMXXXX, XCXXXX, XEXXXX, YBXXXX False True In vitro data available True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114172056 Nix WA, et al. http://www.ncbi.nlm.nih.gov/pubmed/16891480 <a href="http://www.ncbi.nlm.nih.gov/pubmed/16891480">Nix WA, et al.</a> 114172057 Nix WA, et al. http://www.ncbi.nlm.nih.gov/pubmed/18596147 <a href="http://www.ncbi.nlm.nih.gov/pubmed/18596147">Nix WA, et al.</a> 114108520 Oberste, Mark CDC - DIR CDC Oberste, Mark (CDC) 0 114108519 Nix, William CDC - DIR CDC Nix, William (CDC) 1 114108519 Nix, William CDC - DIR CDC Nix, William (CDC) 1 114108520 Oberste, Mark CDC - DIR CDC Oberste, Mark (CDC) 0 114102084 Nucleic Acid Molecules And Kits Including VP1 And VP3 Nucleic Acid Molecules, Useful For Detecting And Identifying Enteroviruses E-257-2013-0 Closed Centers for Disease Control and Prevention (CDC) 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2764] Enterovirus Molecular Diagnostic Test Kit&body=Please send me information about technology [TAB-2764] Enterovirus Molecular Diagnostic Test Kit. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2764] Enterovirus Molecular Diagnostic Test Kit&body=Please send me information about technology [TAB-2764] Enterovirus Molecular Diagnostic Test Kit.">jonathan.motley@nih.gov</a><br> 114167625 E-257-2013-0 E-257-2013-0-US-01 Detection and identification of enteroviruses by semi-nested amplification of the enterovirus VP1 protein ORD US 7,247,457 11/115,860 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7247457 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7247457">7,247,457</a><br />Filed on 2005-04-26<br />Status: Abandoned 114167626 E-257-2013-0 E-257-2013-0-US-02 Nucleic Acid Molecules And Kits Including VP1 And VP3 Nucleic Acid Molecules, Useful For Detecting And Identifying Enteroviruses DIV US 7,714,122 11/777,916 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7714122 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7714122">7,714,122</a><br />Filed on 2007-07-13<br />Status: Abandoned 114125286 DXXXXX 114125287 DAXXXX 114125288 DA4XXX 114125289 DA4BXX 114125290 VLXXXX 114125291 VOXXXX 114125292 WBXXXX 114125293 WFXXXX 114125294 WIXXXX 114125295 WMXXXX 114125296 XCXXXX 114125297 XEXXXX 114125298 YBXXXX 114146484 Nucleic 114146485 Acid 114146486 MOLECULES 114146487 Kits 114146488 Including 114146489 VP1 114146490 VP3 114146491 USEFUL 114146492 DETECTING 114146493 Identifying 114146494 Enteroviruses 114146495 CDC Docket Import 114146496 CDC Docket Import CDC Prosecuting 114146497 OID-NCIRD-DVD TAB-2740 114096919 Multi-Antigenic Peptide(s) Vaccine and Immunogen for Conferring Streptococcus pneumoniae Immunity CDC Antibodies, Cardiology, Consumer Products, Dental, Diagnostics, Endocrinology, Immunology, Infectious Disease, Licensing, Occupational Safety and Health, Oncology, Ophthalmology, Research Materials, Therapeutics, Vaccines Antibodies Cardiology Consumer Products Dental Diagnostics Endocrinology Immunology Infectious Disease Licensing Occupational Safety and Health Oncology Ophthalmology Research Materials Therapeutics Vaccines Edwin Ades, George Carlone, Scott Johnson, Danny Jue, Jacquelyn Sampson Disease caused by <em>Streptococcus pneumoniae</em> (pneumococcus) is an important cause of morbidity and mortality in the United States and developing countries. Pneumococcal disease is prevalent among the very young, the elderly and immunocompromised individuals. This invention is an improved, immunogenic peptide construct consisting of a combination of antigenic epitopes of the PsaA (37-kDa) protein from <em>S. pneumoniae</em>. In addition, the peptides of the invention have the capability of serving as specific immunogens in a subject, effectively eliciting the production of antibodies and conferring protective immunity against <em>S. pneumoniae</em> infection following immunognen administration. <ul> <li>May provide better immune protection than current, single-epitope based vaccines</li> <li>Broader spectrum of <em>S. pneumoniae</em> serotypes addressed</li> <li>Immunization with these peptides was shown to reduce carriage in murine studies</li> </ul> <ul> <li>Development or improvement of <em>S. pneumoniae</em> vaccines</li> <li>Public health vaccination programs</li> <li>Clinical serodiagnostic development</li> </ul> Various international patent applications pending or issued 2022-03-27 2025-08-13 2025-08-15 2014-01-27 Against, ANTIGENIC, CDC Docket Import, CDC Docket Import CDC Prosecuting, DA3XXX, DAXXXX, DC4XXX, DCXXXX, DXXXXX, Epitope, Immunogenic, MULTIPLE, OID-NCIRD-DBD, Peptides, PNEUMONIA, PNEUMONIAE, Streptococcus, VJXXXX, VPXXXX, WBXXXX, WFXXXX, WIXXXX, WJXXXX, XAXXXX, XCXXXX, YBXXXX, YCXXXX False True <ul> <li>In vitro data available</li> <li>In vivo data available (animal)</li> </ul> True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114108450 Carlone, George CDC - DIR CDC Carlone, George (CDC) 0 114108452 Sampson, Jacquelyn CDC - DIR CDC Sampson, Jacquelyn (CDC) 0 114108453 Johnson, Scott CDC - DIR CDC Johnson, Scott (CDC) 0 114108454 Jue, Danny CDC - DIR CDC Jue, Danny (CDC) 0 114108451 Ades, Edwin CDC - DIR CDC Ades, Edwin (CDC) 1 114108451 Ades, Edwin CDC - DIR CDC Ades, Edwin (CDC) 1 114108450 Carlone, George CDC - DIR CDC Carlone, George (CDC) 0 114108452 Sampson, Jacquelyn CDC - DIR CDC Sampson, Jacquelyn (CDC) 0 114108453 Johnson, Scott CDC - DIR CDC Johnson, Scott (CDC) 0 114108454 Jue, Danny CDC - DIR CDC Jue, Danny (CDC) 0 114102058 MULTIPLE ANTIGENIC PEPTIDES IMMUNOGENIC AGAINST STREPTOCOCCUS PNEUMONIA E-248-2013-1 Closed Centers for Disease Control and Prevention (CDC) 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2740] Multi-Antigenic Peptide(s) Vaccine and Immunogen for Conferring Streptococcus pneumoniae Immunity&body=Please send me information about technology [TAB-2740] Multi-Antigenic Peptide(s) Vaccine and Immunogen for Conferring Streptococcus pneumoniae Immunity. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2740] Multi-Antigenic Peptide(s) Vaccine and Immunogen for Conferring Streptococcus pneumoniae Immunity&body=Please send me information about technology [TAB-2740] Multi-Antigenic Peptide(s) Vaccine and Immunogen for Conferring Streptococcus pneumoniae Immunity.">jonathan.motley@nih.gov</a><br> 114167533 E-248-2013-1 E-248-2013-1-US-01 MULTIPLE ANTIGENIC PEPTIDES IMMUNOGENIC AGAINST STREPTOCOCCUS PNEUMONIA CIP US 6,903,184 09/613,092 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6903184 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6903184">6,903,184</a><br />Filed on 2000-07-10<br />Status: Abandoned 114167535 E-248-2013-1 E-248-2013-1-PCT-02 MULTIPLE ANTIGENIC PEPTIDES IMMUNOGENIC AGAINST STREPTOCOCCUS PNEUMONIA PCT Patent Cooperation Treaty PCT/US2001/021626 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2001/021626<br />Filed on 2001-07-10<br />Status: Expired 114167536 E-248-2013-1 E-248-2013-1-US-07 MULTIPLE ANTIGENIC PEPTIDES IMMUNOGENIC AGAINST STREPTOCOCCUS PNEUMONIA National Stage US 7,501,132 11/145,814 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7501132 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7501132">7,501,132</a><br />Filed on 2005-06-06<br />Status: Abandoned 114167537 E-248-2013-1 E-248-2013-1-US-09 MULTIPLE ANTIGENIC PEPTIDES IMMUNOGENIC AGAINST STREPTOCOCCUS PNEUMONIA CON US 8,642,048 12/360,382 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8642048 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8642048">8,642,048</a><br />Filed on 2009-01-27<br />Status: Abandoned 114124789 DXXXXX 114124800 DAXXXX 114124801 DA3XXX 114124802 DCXXXX 114124803 DC4XXX 114124804 VJXXXX 114124805 VPXXXX 114124806 WBXXXX 114124807 WFXXXX 114124808 WIXXXX 114124809 WJXXXX 114124810 XAXXXX 114124811 XCXXXX 114124812 YBXXXX 114124813 YCXXXX 114146207 Immunogenic 114146208 Peptides 114146209 Epitope 114146210 Against 114146211 Streptococcus 114146212 PNEUMONIAE 114146213 MULTIPLE 114146214 ANTIGENIC 114146215 PNEUMONIA 114146216 CDC Docket Import 114146217 CDC Docket Import CDC Prosecuting 114146218 OID-NCIRD-DBD TAB-2730 114096907 Antigen, Encoding Gene, Related Monoclonal Antibody and Hybridoma Clones for Streptococcus pneumoniae Serological Diagnostics CDC Antibodies, Consumer Products, Diagnostics, Immunology, Infectious Disease, Licensing, Occupational Safety and Health, Research Materials, Therapeutics, Vaccines Antibodies Consumer Products Diagnostics Immunology Infectious Disease Licensing Occupational Safety and Health Research Materials Therapeutics Vaccines Steven O'connor, Harold Russell, Jacquelyn Sampson This CDC developed invention pertains to <em>Streptococcus pneumoniae</em> protein "pneumococcal fimbrial protein A (PfpA)," as well as the encoding <em>pfpA</em> gene. <em>S. pneumoniae</em> linked pneumococcal disease is prevalent among the very young, the elderly and also immunocompromised individuals. This invention covers the breadth of directly PfpA-related technology that might be employed for development of diagnostic tests for <em>S. pneumoniae</em> and/or vaccines directed against the pathogen. In addition to the the intellectual property protected amino acid sequence and encoding plasmid, monoclonal antibodies and corresponding hybridomas are also available. <ul> <li>Easily adapted to a high-throughput assay for mass screening purposes</li> <li>Can be formatted as an on-site, lateral-flow diagnostic; both PfpA antigen and anti-PfpA mAb are available</li> </ul> <ul> <li>Screening diagnostic young, elderly and immunocompromised patients for possible <em>S. pneumoniae</em> infection</li> <li>Pneumococcal disease vaccine development or refinement</li> </ul> 2022-03-27 2025-08-13 2025-08-15 2014-01-20 CDC Docket Import, CDC Docket Import CDC Prosecuting, DC4XXX, DCXXXX, FIMBRIAL, OID-NCIRD-DBD, PNEUMOCOCCAL, Protein, VJXXXX, WBXXXX, WFXXXX, WIXXXX, XAXXXX, XCXXXX, XEXXXX, YBXXXX False True In vitro data available True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract E-030-2010-0 E-250-2013-0 E-325-2013-0 114172003 Russell H, et al. http://www.ncbi.nlm.nih.gov/pubmed/2229341 <a href="http://www.ncbi.nlm.nih.gov/pubmed/2229341">Russell H, et al.</a> 114172004 Sampson JS, et al. http://www.ncbi.nlm.nih.gov/pubmed/7505262 <a href="http://www.ncbi.nlm.nih.gov/pubmed/7505262">Sampson JS, et al.</a> 114108420 Sampson, Jacquelyn CDC Sampson, Jacquelyn (CDC) 0 114108421 O'connor, Steven CDC O'connor, Steven (CDC) 0 114108419 Russell, Harold CDC Russell, Harold (CDC) 1 114108419 Russell, Harold CDC Russell, Harold (CDC) 1 114108420 Sampson, Jacquelyn CDC Sampson, Jacquelyn (CDC) 0 114108421 O'connor, Steven CDC O'connor, Steven (CDC) 0 114102046 PNEUMOCOCCAL FIMBRIAL PROTEIN A E-157-1991-0 Research Material Centers for Disease Control and Prevention (CDC) 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2730] Antigen, Encoding Gene, Related Monoclonal Antibody and Hybridoma Clones for Streptococcus pneumoniae Serological Diagnostics&body=Please send me information about technology [TAB-2730] Antigen, Encoding Gene, Related Monoclonal Antibody and Hybridoma Clones for Streptococcus pneumoniae Serological Diagnostics. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2730] Antigen, Encoding Gene, Related Monoclonal Antibody and Hybridoma Clones for Streptococcus pneumoniae Serological Diagnostics&body=Please send me information about technology [TAB-2730] Antigen, Encoding Gene, Related Monoclonal Antibody and Hybridoma Clones for Streptococcus pneumoniae Serological Diagnostics.">jonathan.motley@nih.gov</a><br> 114167505 E-157-1991-0 E-157-1991-0-US-02 PNEUMOCOCCAL FIMBRIAL PROTEIN A DIV US 6,312,944 08/356,106 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6312944 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6312944">6,312,944</a><br />Filed on 1994-12-15<br />Status: Expired 114167602 E-157-1991-0 E-157-1991-0-US-01 PNEUMOCOCCAL FIMBRIAL PROTEIN A ORD US 5,422,427 07/791,377 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/5422427 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/5422427">5,422,427</a><br />Filed on 1991-09-17<br />Status: Expired 114124606 DC4XXX 114124607 DCXXXX 114124608 VJXXXX 114124609 WBXXXX 114124610 WFXXXX 114124611 WIXXXX 114124612 XAXXXX 114124613 XCXXXX 114124614 XEXXXX 114124615 YBXXXX 114146066 PNEUMOCOCCAL 114146067 FIMBRIAL 114146068 Protein 114146069 CDC Docket Import 114146070 CDC Docket Import CDC Prosecuting 114146071 OID-NCIRD-DBD TAB-2724 114096903 Method for Finding Usable Portion of Sigmoid Curve (the Taylor Method), Improved Assay Readouts, and Enhanced Quality Control/Assurance CDC Cardiology, Computational models/software, Consumer Products, Dental, Diagnostics, Endocrinology, Infectious Disease, Licensing, Oncology, Ophthalmology, Research Equipment, Research Materials, Software / Apps, Therapeutics, Vaccines Cardiology Computational models/software Consumer Products Dental Diagnostics Endocrinology Infectious Disease Licensing Oncology Ophthalmology Research Equipment Research Materials Software / Apps Therapeutics Vaccines Thomas Taylor CDC researchers have developed algorithmic methods for determining sigmoid curve optimums and calculating component concentrations. Sigmoid curves are commonly generated in bioassays and used to calculate results. Various techniques have been used to define the curve, analyze the observations, and calculate a concentration. This technology is an algorithmic approach to identifying the usable portion of a sigmoid curve. This approach is more objective than other methods, reducing the variability introduced by individuals and/or by repetition and allows substantially higher throughput in a situation where a lot of samples are being analyzed using the same assay. <ul> <li>Less output-data subjectivity than alternate methods</li> <li>Rapid, accurate and simple to implement</li> <li>Quality control and assurance for a number of assays such as PCR, ELISA, toxin neutralization assays (TNA), flow cytometry, cell death assays, titrations, etc.</li> <li>Reduces data variability due to errant input</li> <li>Easily adapted to high-throughput analyses</li> <li>Demonstrated efficacy quantifying anthrax lethal toxin neutralization activity</li> </ul> <ul> <li>Observation and data analysis</li> <li>Determining concentrations</li> <li>Improving calculations and estimations</li> <li>Enhancing consistency and reproducibility of outcomes for bio and chem assays</li> </ul> Various international patent applications pending or issued 2022-03-27 2025-08-13 2025-08-15 2014-01-16 AA2XXX, AA5XXX, AA6XXX, AAXXXX, AB4XXX, AC2XXX, AC4XXX, AC6XXX, ACXXXX, AD3XXX, ADXXXX, AXXXXX, CDC Docket Import, CDC Docket Import CDC Prosecuting, CURVE, Finding, OID-NCIRD-DBD, Portion, Sigmoid, USABLE, VBXXXX, VPXXXX, WAXXXX, WHXXXX, WIXXXX, WMXXXX, XHXXXX, XJXXXX, YBXXXX False True In vitro data available True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114171996 Li H, et al. http://www.ncbi.nlm.nih.gov/pubmed/18304568 <a href="http://www.ncbi.nlm.nih.gov/pubmed/18304568">Li H, et al.</a> 114108400 Taylor, Thomas CDC - DIR CDC Taylor, Thomas (CDC) 1 114108400 Taylor, Thomas CDC - DIR CDC Taylor, Thomas (CDC) 1 114102038 Finding Usable Portion Of Sigmoid Curve E-270-2013-0 Closed Centers for Disease Control and Prevention (CDC) 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2724] Method for Finding Usable Portion of Sigmoid Curve (the Taylor Method), Improved Assay Readouts, and Enhanced Quality Control/Assurance&body=Please send me information about technology [TAB-2724] Method for Finding Usable Portion of Sigmoid Curve (the Taylor Method), Improved Assay Readouts, and Enhanced Quality Control/Assurance. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2724] Method for Finding Usable Portion of Sigmoid Curve (the Taylor Method), Improved Assay Readouts, and Enhanced Quality Control/Assurance&body=Please send me information about technology [TAB-2724] Method for Finding Usable Portion of Sigmoid Curve (the Taylor Method), Improved Assay Readouts, and Enhanced Quality Control/Assurance.">jonathan.motley@nih.gov</a><br> 114167484 E-270-2013-0 E-270-2013-0-US-01 Finding Usable Portion Of Sigmoid Curve PRV US 60/456,613 Abandoned US <br />Provisional (PRV) 60/456,613<br />Filed on 2003-03-21<br />Status: Abandoned 114167485 E-270-2013-0 E-270-2013-0-PCT-02 Finding Usable Portion Of Sigmoid Curve PCT Patent Cooperation Treaty PCT/US2004/008566 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2004/008566<br />Filed on 2004-03-19<br />Status: Expired 114167486 E-270-2013-0 E-270-2013-0-US-06 Finding Usable Portion Of Sigmoid Curve National Stage US 7,469,186 10/550,377 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7469186 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7469186">7,469,186</a><br />Filed on 2005-09-20<br />Status: Abandoned 114124486 AXXXXX 114124487 AAXXXX 114124488 AA5XXX 114124489 AA6XXX 114124490 AA2XXX 114124491 AB4XXX 114124492 ACXXXX 114124493 AC2XXX 114124494 AC4XXX 114124495 AC6XXX 114124496 ADXXXX 114124497 AD3XXX 114124498 VBXXXX 114124499 VPXXXX 114124500 WAXXXX 114124501 WHXXXX 114124502 WIXXXX 114124503 WMXXXX 114124504 XHXXXX 114124505 XJXXXX 114124506 YBXXXX 114146018 Finding 114146019 USABLE 114146020 Portion 114146021 Sigmoid 114146022 CURVE 114146023 CDC Docket Import 114146024 CDC Docket Import CDC Prosecuting 114146025 OID-NCIRD-DBD TAB-2723 114096902 Real-time PCR and High Resolution Melt Analysis for Genotyping of Chlamydophila psittaci CDC Consumer Products, Diagnostics, Infectious Disease, Licensing, Occupational Safety and Health, Research Materials, Therapeutics Consumer Products Diagnostics Infectious Disease Licensing Occupational Safety and Health Research Materials Therapeutics Stephanie Mitchell, Jonas Winchell This nucleic acid assay employs Light Upon Extension (LUX) chemistry and High Resolution Melt (HRM) analysis to detect and distinguish the different genotypes of <em>Chlamydophila psittaci</em>. <em>C. psittaci</em> is an atypical pathogen which may result in severe pneumonia upon infection of birds, mammals and humans (depending on inter-relationships between host and pathogen genotypes). Presently, <em>C. psittaci</em> clinical identification is achieved by a cumbersome and time-intensive mix of <em>ompA</em> gene sequencing, microarray analysis, RFLP and/or serological testing. Accurate and timely molecular <em>C. psittaci</em> diagnosis techniques are not generally available in most clinical facilities, leading to improper treatment of patients. <br /><br /> To that end, this robust CDC developed assay should be useful for epidemiological studies and may provide valuable information for best implementing public health measures in the event of outbreaks. This tool may also offer greater insight into the heterogeneity and dissemination of <em>C. psittaci</em> genotypes. Additionally, the assay can serve as a veterinary diagnostic and/or pre-screening tool for companion birds. Such applications would provide further benefit by resulting in reduced transmission of the disease to humans. <ul> <li>Rapid and simple</li> <li>Simultaneous detection and discrimination of C. psittaci genotypes</li> <li>Improved efficiency in time and cost</li> <li>Easily adapted for use in kits</li> </ul> <ul> <li>Validation studies, proficiency testing</li> <li>Public health and veterinary/zoonotic disease monitoring programs</li> <li>Diagnostic testing, especially within the poultry industry</li> <li>Disease screening of companion birds</li> </ul> 2022-03-27 2025-08-13 2025-08-15 2014-01-16 Acids, CDC Docket Import, CDC Docket Import CDC Prosecuting, Chlamydophila, DA3XXX, DAXXXX, Detection, discrimination, DXXXXX, GENOTYPES, Nucleic, OID-NCIRD-DBD, PSITTACI, VJXXXX, VOXXXX, WBXXXX, WCXXXX, WFXXXX, WHXXXX, WMXXXX, XCXXXX, XEXXXX, YBXXXX False True In vitro data available True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114171995 Mitchell SL, et al. http://www.ncbi.nlm.nih.gov/pubmed/19005152 <a href="http://www.ncbi.nlm.nih.gov/pubmed/19005152">Mitchell SL, et al.</a> 114108399 Winchell, Jonas CDC - DIR CDC Winchell, Jonas (CDC) 0 114108398 Mitchell, Stephanie CDC - DIR CDC Mitchell, Stephanie (CDC) 1 114108398 Mitchell, Stephanie CDC - DIR CDC Mitchell, Stephanie (CDC) 1 114108399 Winchell, Jonas CDC - DIR CDC Winchell, Jonas (CDC) 0 114102037 NUCLEIC ACIDS FOR DETECTION AND DISCRIMINATION OF GENOTYPES OF CHLAMYDOPHILA PSITTACI E-266-2013-0 Filing authorized Centers for Disease Control and Prevention (CDC) 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2723] Real-time PCR and High Resolution Melt Analysis for Genotyping of Chlamydophila psittaci&body=Please send me information about technology [TAB-2723] Real-time PCR and High Resolution Melt Analysis for Genotyping of Chlamydophila psittaci. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2723] Real-time PCR and High Resolution Melt Analysis for Genotyping of Chlamydophila psittaci&body=Please send me information about technology [TAB-2723] Real-time PCR and High Resolution Melt Analysis for Genotyping of Chlamydophila psittaci.">jonathan.motley@nih.gov</a><br> 114167481 E-266-2013-0 E-266-2013-0-US-01 NUCLEIC ACIDS FOR DETECTION AND DISCRIMINATION OF GENOTYPES OF CHLAMYDOPHILA PSITTACI PRV US 61/182,628 Abandoned US <br />Provisional (PRV) 61/182,628<br />Filed on 2009-05-29<br />Status: Abandoned 114167482 E-266-2013-0 E-266-2013-0-PCT-02 NUCLEIC ACIDS FOR DETECTION AND DISCRIMINATION OF GENOTYPES OF CHLAMYDOPHILA PSITTACI PCT Patent Cooperation Treaty PCT/US2010/036742 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2010/036742<br />Filed on 2010-05-28<br />Status: Expired 114167483 E-266-2013-0 E-266-2013-0-US-03 NUCLEIC ACIDS FOR DETECTION AND DISCRIMINATION OF GENOTYPES OF CHLAMYDOPHILA PSITTACI National Stage US 8,835,117 13/322,787 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8835117 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8835117">8,835,117</a><br />Filed on 2011-11-28<br />Status: Issued 114124473 DXXXXX 114124474 DAXXXX 114124475 DA3XXX 114124476 VJXXXX 114124477 VOXXXX 114124478 WBXXXX 114124479 WCXXXX 114124480 WFXXXX 114124481 WHXXXX 114124482 WMXXXX 114124483 XCXXXX 114124484 XEXXXX 114124485 YBXXXX 114146008 Nucleic 114146009 Acids 114146010 Detection 114146011 discrimination 114146012 GENOTYPES 114146013 Chlamydophila 114146014 PSITTACI 114146015 CDC Docket Import 114146016 CDC Docket Import CDC Prosecuting 114146017 OID-NCIRD-DBD TAB-2673 114096858 Intranasal Nebulizer with Disposable Drug Cartridge for Improved Delivery of Vaccines and Therapeutics CDC Cardiology, Consumer Products, Dental, Diagnostics, Endocrinology, Infectious Disease, Licensing, Medical Devices, Non-Medical Devices, Occupational Safety and Health, Oncology, Ophthalmology, Therapeutics, Vaccines Cardiology Consumer Products Dental Diagnostics Endocrinology Infectious Disease Licensing Medical Devices Non-Medical Devices Occupational Safety and Health Oncology Ophthalmology Therapeutics Vaccines Mark Bagley, James Barry, Nabil Elkouh, Eric Friets, Darin Knaus, James Norris, Mark Papania, Robert Trabka Intranasal delivery is a simple, inexpensive and needle-free route for administration of vaccines and therapeutics. This intranasal delivery technology, developed with Creare LLC., includes low-cost, disposable drug cartridges (DDCs) that mate with a durable hand-held device. The rechargeable-battery-powered device transmits ultrasonic energy to the DDC to aerosolize the drug and is capable of performing for eight hours at 120 vaccinations per hour. Potential applications for this platform technology include intranasal vaccination (e.g. seasonal or pandemic influenza vaccines) and intranasal delivery of locally active (e.g. antihistamines, steroids) or systemically active (e.g. pain medications, sedatives) pharmaceuticals.<br /><br /> The DDCs themselves offer two unique benefits. First, all components that contact the active agent or the patient may be easily disposed of, which reduces the risk of patient cross-contamination and minimizes cleaning and maintenance requirements of the hand-held device. Second, DDCs provide a low-cost and simple method to package and distribute individual doses.<br /><br /> This technology also allows for significant dose-sparing. Preliminary studies have shown robust immune responses when this technology is used to delivery significantly reduced doses of Live Attenuated Influenza Vaccine in animal models. The intranasal nebulizer produces droplets sized for optimum depositioning in the nasal airway. The small nebulizer droplets essentially “spray paint” the internal nasal airway, resulting in an increased tissue surface coverage that may enable a significant dose reduction. In contrast, currently available nasal delivery devices, such as nasal sprays and droppers, do not provide efficient intranasal delivery in humans because the large droplets they generate fail to coat a significant portion of the nasal airway. Large droplets also tend to drip out of the nose or down the throat, which can be unpleasant for the patient in addition to wasting a sizable portion of the active agent. <ul> <li>Safe, needle-less delivery</li> <li>No patient-to-patient contamination</li> <li>Long-life, rechargeable battery</li> <li>Consistent delivery and dose-sparing</li> <li>Nasal delivery of live-attenuated vaccines may be more effective than traditional injected vaccines</li> <li>Cost-effective</li> <li>Reduces biohazard waste</li> <li>May be administered by personnel with minimal medical training</li> <li>Easy means of delivery to children with fear of needles</li> </ul> <ul> <li>Intranasal delivery of vaccines and therapeutics</li> <li>Childhood vaccination programs, mass immunization campaigns, or response to epidemics</li> </ul> Various international issued and pending patents 2022-03-27 2025-08-13 2025-08-15 2013-11-19 AB1XXX, AB3FXX, AB3GXX, AB3XXX, AB4XXX, Able, ABXXXX, AC1XXX, ACXXXX, AEROSOL, AEROSOL-GENERATING, AEROSOLIZATION, Aerosolized, AEROSOLS, AXXXXX, BACTERIA, Bacterial, BACTERIAL VACCINES, CARTRIDGE, CDC, CDC Docket Import, CDC Docket Import CDC Prosecuting, Chamber, COOLING, DB1XXX, DB2XXX, DB3XXX, DB4XXX, DB5XXX, DBXXXX, DC1XXX, DC2XXX, DC3XXX, DC4XXX, DC5BXX, DC5XXX, DC6XXX, DCXXXX, Delivery, DEVICE, Devices, Disposable, DRUG, Drug Delivery, DXXXXX, FUNGAL, HAND, Having, INSERT, Intranasal, Methods, NASAL, NEBULIZER, NIOSH-PRL, OID-NCIRD-DVD, PLATFORM, Platforms, Pulmonary, respiratory, Respiratory Diseases, respiratory INFECTION, System, SYSTEMS, therapeutic, therapeutic delivery, Vaccine, VACCINE DELIVERY, Vaccine Design, VACCINE DEVELOPMENT, VBXXXX, viral, viral vaccine, VJXXXX, VKXXXX, VLXXXX, VOXXXX, VPXXXX, WAXXXX, WFXXXX, WJXXXX, WKXXXX, WMXXXX, XDXXXX, YBXXXX, YCXXXX, YFXXXX False True <ul> <li>Prototype</li> <li>In vitro data available</li> <li>In vivo data available (animal)</li> </ul> True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114171937 Smith JH, et al. https://www.ncbi.nlm.nih.gov/pubmed/22075083 <a href="https://www.ncbi.nlm.nih.gov/pubmed/22075083">Smith JH, et al.</a> 114108233 Barry, James Barry, James 0 114108234 Elkouh, Nabil Elkouh, Nabil 0 114108235 Bagley, Mark CDC - DIR CDC Bagley, Mark (CDC) 0 114108236 Knaus, Darin Knaus, Darin 0 114108237 Trabka, Robert Trabka, Robert 0 114108238 Friets, Eric Friets, Eric 0 114108660 Norris, James Norris, James 0 114108232 Papania, Mark CDC - DIR CDC Papania, Mark (CDC) 1 114108232 Papania, Mark CDC - DIR CDC Papania, Mark (CDC) 1 114108233 Barry, James Barry, James 0 114108234 Elkouh, Nabil Elkouh, Nabil 0 114108235 Bagley, Mark CDC - DIR CDC Bagley, Mark (CDC) 0 114108236 Knaus, Darin Knaus, Darin 0 114108237 Trabka, Robert Trabka, Robert 0 114108238 Friets, Eric Friets, Eric 0 114108660 Norris, James Norris, James 0 114101868 INSERT ABLE INTRANASAL NEBULIZER WITH DISPOSABLE AEROSOL-GENERATING DRUG CARTRIDGE E-564-2013-0 Closed Centers for Disease Control and Prevention (CDC), Creare LLC 114101984 NEBULIZER HAVING COOLING CHAMBER E-323-2013-0 Filing authorized Centers for Disease Control and Prevention (CDC), Creare LLC 114101985 Aerosol Delivery Systems And Methods E-324-2013-0 Closed Centers for Disease Control and Prevention (CDC), Creare LLC 114101986 NASAL AEROSOL DELIVERY SYSTEM E-308-2013-0 Closed Centers for Disease Control and Prevention (CDC), Creare LLC 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2673] Intranasal Nebulizer with Disposable Drug Cartridge for Improved Delivery of Vaccines and Therapeutics&body=Please send me information about technology [TAB-2673] Intranasal Nebulizer with Disposable Drug Cartridge for Improved Delivery of Vaccines and Therapeutics. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2673] Intranasal Nebulizer with Disposable Drug Cartridge for Improved Delivery of Vaccines and Therapeutics&body=Please send me information about technology [TAB-2673] Intranasal Nebulizer with Disposable Drug Cartridge for Improved Delivery of Vaccines and Therapeutics.">jonathan.motley@nih.gov</a><br> 114160198 E-564-2013-0 E-564-2013-0-US-01 INSERTABLE INTRANASAL NEBULIZER WITH DISPOSABLE AEROSOL-GENERATING DRUG CARTRIDGE PRV US 61/808,547 Abandoned US <br />Provisional (PRV) 61/808,547<br />Filed on 2013-04-04<br />Status: Abandoned 114161379 E-564-2013-0 E-564-2013-0-US-06 Nasal Aerosol Delivery System National Stage US 10,596,334 14/781,547 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10596334 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10596334">10,596,334</a><br />Filed on 2015-09-30<br />Status: Abandoned 114165249 E-308-2013-0 E-308-2013-0-US-09 NASAL AEROSOL DELIVERY SYSTEM DIV US 15/288,979 Abandoned US <br />Divisional (DIV) 15/288,979<br />Filed on 2016-10-07<br />Status: Abandoned 114167371 E-323-2013-0 E-323-2013-0-US-01 Systems and methods for aerosol delivery of agents PRV US 60/276,539 Abandoned US <br />Provisional (PRV) 60/276,539<br />Filed on 2001-03-15<br />Status: Abandoned 114167372 E-323-2013-0 E-323-2013-0-PCT-02 NEBULIZER HAVING COOLING CHAMBER PCT Patent Cooperation Treaty PCT/US2002/007973 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2002/007973<br />Filed on 2002-03-13<br />Status: Expired 114167373 E-323-2013-0 E-323-2013-0-US-07 SYSTEMS AND METHODS FOR AEROSOL DELIVERY OF AGENTS National Stage US 7,225,807 10/471,620 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7225807 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7225807">7,225,807</a><br />Filed on 2004-02-23<br />Status: Expired 114167374 E-323-2013-0 E-323-2013-0-US-08 SYSTEMS AND METHODS FOR AEROSOL DELIVERY OF AGENTS CON US 8,544,462 11/796,313 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8544462 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8544462">8,544,462</a><br />Filed on 2007-04-27<br />Status: Abandoned 114167375 E-324-2013-0 E-324-2013-0-US-01 Aerosol Delivery Systems And Methods PRV US 60/559,318 Abandoned US <br />Provisional (PRV) 60/559,318<br />Filed on 2004-04-02<br />Status: Abandoned 114167376 E-324-2013-0 E-324-2013-0-PCT-02 Aerosol Delivery Systems And Methods PCT Patent Cooperation Treaty PCT/US2005/011086 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2005/011086<br />Filed on 2005-04-01<br />Status: Expired 114167377 E-324-2013-0 E-324-2013-0-US-11 Aerosol Delivery Systems And Methods National Stage US 7,954,486 10/587,814 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7954486 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7954486">7,954,486</a><br />Filed on 2006-07-28<br />Status: Abandoned 114167378 E-324-2013-0 E-324-2013-0-US-18 Aerosol Delivery Systems And Methods DIV US 8,656,908 13/099,261 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8656908 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8656908">8,656,908</a><br />Filed on 2011-05-02<br />Status: Abandoned 114167379 E-308-2013-0 E-308-2013-0-US-01 NASAL AEROSOL DELIVERY SYSTEM PRV US 61/351,745 Abandoned US <br />Provisional (PRV) 61/351,745<br />Filed on 2010-06-04<br />Status: Abandoned 114167380 E-308-2013-0 E-308-2013-0-PCT-02 NASAL AEROSOL DELIVERY SYSTEM PCT Patent Cooperation Treaty PCT/US2011/039020 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2011/039020<br />Filed on 2011-06-03<br />Status: Expired 114167381 E-308-2013-0 E-308-2013-0-US-08 NASAL AEROSOL DELIVERY SYSTEM National Stage US 9,492,068 13/701,992 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9492068 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9492068">9,492,068</a><br />Filed on 2012-12-04<br />Status: Abandoned 114167760 E-564-2013-0 E-564-2013-0-PCT-02 NASAL AEROSOL DELIVERY SYSTEM PCT Patent Cooperation Treaty PCT/US2014/032863 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2014/032863<br />Filed on 2014-04-03<br />Status: Expired 114169008 E-564-2013-0 E-564-2013-0-US-07 NASAL AEROSOL DELIVERY SYSTEM DIV US 16/798,127 Abandoned US <br />Divisional (DIV) 16/798,127<br />Filed on 2020-02-21<br />Status: Abandoned 114123916 AXXXXX 114123917 ABXXXX 114123918 AB3XXX 114123919 AB3FXX 114123920 AB3GXX 114123921 DXXXXX 114123922 DBXXXX 114123923 DB1XXX 114123924 DB2XXX 114123925 DB3XXX 114123926 DB4XXX 114123927 DB5XXX 114123928 DCXXXX 114123929 DC1XXX 114123930 DC2XXX 114123931 DC3XXX 114123932 DC4XXX 114123933 DC5XXX 114123934 DC6XXX 114123935 AB4XXX 114125628 VBXXXX 114125630 VJXXXX 114125631 VKXXXX 114125632 VLXXXX 114125633 VOXXXX 114125634 VPXXXX 114125635 WAXXXX 114125637 WFXXXX 114125639 WJXXXX 114125640 WKXXXX 114125641 WMXXXX 114125642 XDXXXX 114125643 YBXXXX 114125644 YCXXXX 114125645 YFXXXX 114125887 AB1XXX 114125888 ACXXXX 114125889 AC1XXX 114125890 DC5BXX 114145409 NEBULIZER 114145410 Having 114145411 COOLING 114145412 Chamber 114145413 CDC Docket Import 114145414 CDC Docket Import CDC Prosecuting 114145415 NIOSH-PRL 114145416 OID-NCIRD-DVD 114145417 DEVICE 114145418 Devices 114145419 CDC 114145420 AEROSOL 114145421 AEROSOL-GENERATING 114145422 AEROSOLIZATION 114145423 Aerosolized 114145424 AEROSOLS 114145425 Vaccine 114145426 VACCINE DELIVERY 114145427 Vaccine Design 114145428 VACCINE DEVELOPMENT 114145429 PLATFORM 114145430 Platforms 114145431 therapeutic 114145432 therapeutic delivery 114145433 viral 114145434 viral vaccine 114145435 BACTERIA 114145436 Bacterial 114145437 BACTERIAL VACCINES 114145438 FUNGAL 114145439 Intranasal 114145440 respiratory 114145441 Respiratory Diseases 114145442 respiratory INFECTION 114145443 Pulmonary 114145444 HAND 114145445 Drug Delivery 114145446 Delivery 114145447 SYSTEMS 114145448 Methods 114145449 NASAL 114145450 System 114147096 INSERT 114147097 Able 114147098 Disposable 114147099 DRUG 114147100 CARTRIDGE TAB-2670 114096854 Intranasal Dry Powder Inhaler for Improved Delivery of Vaccines and Therapeutics CDC Consumer Products, Diagnostics, Infectious Disease, Licensing, Medical Devices, Non-Medical Devices, Therapeutics, Vaccines Consumer Products Diagnostics Infectious Disease Licensing Medical Devices Non-Medical Devices Therapeutics Vaccines Mark Bagley, James Barry, Eric Friets, Darin Knaus, Edward Moynihan, Mark Papania This Intranasal Dry Powder Inhaler (DPI), developed with Creare, Inc., allows low-cost delivery of powder vaccines. Nasal delivery has numerous advantages compared to traditional injected vaccines, including: 1) safe, needle-less administration by minimally-trained staff or patient; 2) better protection due to mucosal and cross-protection; and 3) decreased biohazard waste. Further, dry powder aerosol vaccine delivery is superior to liquid aerosol delivery in a number of ways, including: 1) no dose reconstitution required; 2) highly thermostable and may not need cold chain storage; 3) costs less to store and transport; 4) improved efficacy through elimination of liquid spray nasal-dripping. This CDC-Creare invention is unique in that it is inexpensive and suitable for single-use applications, such as vaccination. It prevents the dose being deposited within the lower respiratory tract, improving safety. This delivery system has a broad range of potential applications including, but not limited to, childhood vaccination programs, self-administered therapeutics, and emergency biodefense. <ul> <li>Safe, needle-less delivery</li> <li>Allows self-administration</li> <li>Improved protection via intranasal immunization</li> <li>Decreased biohazard waste</li> <li>Dose reconstitution is not required</li> <li>Highly thermostable and may not need cold chain storage</li> <li>Cost-effective</li> <li>Primate study with a thermostable measles vaccine expected in the next year</li> </ul> <ul> <li>Intranasal delivery of vaccines and therapeutics</li> <li>Childhood vaccination programs, mass immunization campaigns, or response to epidemics</li> </ul> 2022-03-27 2025-08-13 2025-08-15 2013-11-19 AB1XXX, AB3FXX, AB3GXX, ABXXXX, Agents, AXXXXX, BACTERIA, Bacterial, BACTERIAL VACCINES, Biodefense, biosecurity, bioterrorism, Bioterrorist, CDC Docket Import, CDC Docket Import CDC Prosecuting, Child safety device, CHILDHOOD, Children, DB1XXX, DB2XXX, DB3XXX, DB4AXX, DB4BXX, DB4XXX, DB5XXX, DBXXXX, DC1XXX, DC2XXX, DC3XXX, DC4XXX, DC5XXX, DC6XXX, DCXXXX, Delivery, delivery system, DEVELOPED, DEVELOPING, DEVICE, Devices, Disposable, DISPOSAL, Dry, DXXXXX, Field, Field-usable, FUNGAL, Intranasal, MEASLES, NASAL, Needle, OID-NCIRD-DVD, Portable, POWDER, Prevention, respiratory, SAFETY, SELF-ADMINISTRATION, Single-use, System, therapeutic delivery, treatment, VACCINATION, Vaccinations, VACCINE DELIVERY, vaccines, VBXXXX, viral vaccine, VJXXXX, VKXXXX, VLXXXX, VOXXXX, WAXXXX, WKXXXX, WMXXXX, XDXXXX, YBXXXX, YFXXXX False True <ul> <li>In vitro data available</li> <li>Prototype</li> </ul> True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114108218 Barry, James CDC - DIR Barry, James 0 114108219 Knaus, Darin CDC - DIR Knaus, Darin 0 114108220 Moynihan, Edward CDC - DIR CDC Moynihan, Edward (CDC) 0 114108221 Friets, Eric CDC - DIR Friets, Eric 0 114108222 Bagley, Mark CDC - DIR CDC Bagley, Mark (CDC) 0 114108217 Papania, Mark CDC - DIR CDC Papania, Mark (CDC) 1 114108217 Papania, Mark CDC - DIR CDC Papania, Mark (CDC) 1 114108218 Barry, James CDC - DIR Barry, James 0 114108219 Knaus, Darin CDC - DIR Knaus, Darin 0 114108220 Moynihan, Edward CDC - DIR CDC Moynihan, Edward (CDC) 0 114108221 Friets, Eric CDC - DIR Friets, Eric 0 114108222 Bagley, Mark CDC - DIR CDC Bagley, Mark (CDC) 0 114101981 NASAL DRY POWDER DELIVERY SYSTEM FOR VACCINES AND OTHER TREATMENT AGENTS E-258-2013-0 Closed Centers for Disease Control and Prevention (CDC), Creare LLC 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2670] Intranasal Dry Powder Inhaler for Improved Delivery of Vaccines and Therapeutics&body=Please send me information about technology [TAB-2670] Intranasal Dry Powder Inhaler for Improved Delivery of Vaccines and Therapeutics. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2670] Intranasal Dry Powder Inhaler for Improved Delivery of Vaccines and Therapeutics&body=Please send me information about technology [TAB-2670] Intranasal Dry Powder Inhaler for Improved Delivery of Vaccines and Therapeutics.">jonathan.motley@nih.gov</a><br> 114167362 E-258-2013-0 E-258-2013-0-US-01 NASAL DRY POWDER DELIVERY SYSTEM FOR VACCINES AND OTHER TREATMENT AGENTS PRV US 61/665,778 Abandoned US <br />Provisional (PRV) 61/665,778<br />Filed on 2012-06-28<br />Status: Abandoned 114167363 E-258-2013-0 E-258-2013-0-PCT-02 NASAL DRY POWDER DELIVERY SYSTEM FOR VACCINES AND OTHER TREATMENT AGENTS PCT Patent Cooperation Treaty PCT/US2013/047399 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2013/047399<br />Filed on 2013-06-24<br />Status: Expired 114168044 E-258-2013-0 E-258-2013-0-US-06 NASAL DRY POWDER DELIVERY SYSTEM FOR VACCINES AND OTHER TREATMENT AGENTS National Stage US 10,099,024 14/409,379 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10099024 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10099024">10,099,024</a><br />Filed on 2013-06-24<br />Status: Abandoned 114168773 E-258-2013-0 E-258-2013-0-US-11 NASAL DRY POWDER DELIVERY SYSTEM FOR VACCINES AND OTHER TREATMENT AGENTS DIV US 16/125,478 Abandoned US <br />Divisional (DIV) 16/125,478<br />Filed on 2018-09-07<br />Status: Abandoned 114123872 AXXXXX 114123873 ABXXXX 114123874 AB1XXX 114123875 AB3FXX 114123876 AB3GXX 114123877 DXXXXX 114123878 DBXXXX 114123879 DB1XXX 114123880 DB2XXX 114123881 DB3XXX 114123882 DB4XXX 114123883 DB4AXX 114123884 DB4BXX 114123885 DB5XXX 114123886 DCXXXX 114123887 DC1XXX 114123888 DC2XXX 114123889 DC3XXX 114123890 DC4XXX 114123891 DC5XXX 114123892 DC6XXX 114124016 VBXXXX 114124017 VJXXXX 114124018 VKXXXX 114124019 VLXXXX 114124020 VOXXXX 114124021 WAXXXX 114124022 WKXXXX 114124023 WMXXXX 114124024 XDXXXX 114124044 YBXXXX 114124045 YFXXXX 114145290 NASAL 114145291 Dry 114145292 POWDER 114145293 Delivery 114145294 System 114145295 vaccines 114145296 treatment 114145297 Agents 114145298 CDC Docket Import 114145299 CDC Docket Import CDC Prosecuting 114145300 OID-NCIRD-DVD 114145301 Intranasal 114145302 delivery system 114145303 Portable 114145304 DEVELOPING 114145305 DEVELOPED 114145306 VACCINE DELIVERY 114145307 therapeutic delivery 114145308 VACCINATION 114145309 Vaccinations 114145310 Biodefense 114145311 biosecurity 114145312 bioterrorism 114145313 Bioterrorist 114145314 MEASLES 114145315 SAFETY 114145316 CHILDHOOD 114145317 Children 114145318 Child safety device 114145319 Needle 114145320 SELF-ADMINISTRATION 114145321 respiratory 114145322 Prevention 114145323 Field 114145324 Field-usable 114145325 BACTERIA 114145326 Bacterial 114145327 BACTERIAL VACCINES 114145328 viral vaccine 114145329 FUNGAL 114145330 DEVICE 114145331 Devices 114145332 Disposable 114145333 DISPOSAL 114145334 Single-use TAB-2665 114096849 Peptide Vaccines Against Group A Streptococci CDC Diagnostics, Infectious Disease, Licensing, Therapeutics, Vaccines Diagnostics Infectious Disease Licensing Therapeutics Vaccines Edwin Ades, Bernard Beall, George Carlone, Jacquelyn Sampson This invention relates to synthetic immunoreactive peptides, which are portions of the M proteins of the most prevalent Group A Streptococcus (GAS) serotypes in the United States. These peptides may be useful in development of a flexible, multivalent GAS vaccine. They can be recognized by M type-specific antibodies and are capable of eliciting functional opsonic antibodies. Additionally, the peptides or isolated antibodies raised in response to the peptides may be useful for GAS diagnostics. <ul> <li>Easily adaptable to kit form</li> <li>Multivalent vaccine that can be tailored for protection against specific GAS serotypes affecting a particular population</li> </ul> <ul> <li>Group A streptococci (GAS) vaccine</li> <li>GAS therapeutics and diagnostics</li> <li>Lab tools for exploring GAS</li> </ul> Various international patent applications pending or issued 2022-03-27 2025-08-13 2025-08-15 2013-10-23 Against, CDC Docket Import, CDC Docket Import CDC Prosecuting, DA3XXX, DAXXXX, DB3XXX, DBXXXX, DC4XXX, DCXXXX, GROUP, OID-NCIRD-DBD, Peptide, Streptococci, vaccines False True <ul> <li>Pre-clinical</li> <li>In vitro data available</li> <li>In vivo data available (animal)</li> </ul> True NIHTT 37470483 Website Abstract 114171925 Bruner M, et al. http://www.ncbi.nlm.nih.gov/pubmed/12798606 <a href="http://www.ncbi.nlm.nih.gov/pubmed/12798606">Bruner M, et al.</a> 114108206 Carlone, George CDC - DIR CDC Carlone, George (CDC) 0 114108207 Sampson, Jacquelyn CDC - DIR CDC Sampson, Jacquelyn (CDC) 0 114108208 Ades, Edwin CDC - DIR CDC Ades, Edwin (CDC) 0 114108205 Beall, Bernard CDC - DIR CDC Beall, Bernard (CDC) 1 114108205 Beall, Bernard CDC - DIR CDC Beall, Bernard (CDC) 1 114108206 Carlone, George CDC - DIR CDC Carlone, George (CDC) 0 114108207 Sampson, Jacquelyn CDC - DIR CDC Sampson, Jacquelyn (CDC) 0 114108208 Ades, Edwin CDC - DIR CDC Ades, Edwin (CDC) 0 114101976 Peptide Vaccines Against Group A Streptococci E-330-2013-0 Closed Centers for Disease Control and Prevention (CDC) 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2665] Peptide Vaccines Against Group A Streptococci&body=Please send me information about technology [TAB-2665] Peptide Vaccines Against Group A Streptococci. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2665] Peptide Vaccines Against Group A Streptococci&body=Please send me information about technology [TAB-2665] Peptide Vaccines Against Group A Streptococci.">jonathan.motley@nih.gov</a><br> 114167336 E-330-2013-0 E-330-2013-0-US-08 Peptide Vaccines Against Group A Streptococci DIV US 12/973,247 Abandoned US <br />Divisional (DIV) 12/973,247<br />Filed on 2010-12-20<br />Status: Abandoned 114167337 E-330-2013-0 E-330-2013-0-PCT-02 Peptide Vaccines Against Group A Streptococci PCT Patent Cooperation Treaty PCT/US2002/015909 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2002/015909<br />Filed on 2002-05-20<br />Status: Expired 114167338 E-330-2013-0 E-330-2013-0-US-06 Peptide Vaccines Against Group A Streptococci National Stage US 7,407,664 10/477,955 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7407664 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7407664">7,407,664</a><br />Filed on 2004-03-15<br />Status: Abandoned 114167339 E-330-2013-0 E-330-2013-0-US-07 Peptide Vaccines Against Group A Streptococci CON US 7,883,710 12/144,461 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7883710 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7883710">7,883,710</a><br />Filed on 2008-06-23<br />Status: Abandoned 114167340 E-330-2013-0 E-330-2013-0-US-01 Peptide Vaccines Against Group A Streptococci PRV US 60/291,835 Abandoned US <br />Provisional (PRV) 60/291,835<br />Filed on 2001-05-18<br />Status: Abandoned 114167341 E-330-2013-0 E-330-2013-0-US-09 Peptide Vaccines Against Group A Streptococci DIV US 8,420,107 13/427,477 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8420107 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8420107">8,420,107</a><br />Filed on 2010-03-22<br />Status: Abandoned 114167342 E-330-2013-0 E-330-2013-0-US-10 Peptide Vaccines Against Group A Streptococci DIV US 8,637,050 13/846,166 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8637050 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8637050">8,637,050</a><br />Filed on 2013-03-18<br />Status: Abandoned 114123844 DAXXXX 114123845 DBXXXX 114123846 DCXXXX 114123847 DC4XXX 114123848 DA3XXX 114123849 DB3XXX 114145245 Peptide 114145246 vaccines 114145247 Against 114145248 GROUP 114145249 Streptococci 114145250 CDC Docket Import 114145251 CDC Docket Import CDC Prosecuting 114145252 OID-NCIRD-DBD TAB-2636 114096824 Monoclonal Antibodies that Neutralize Norovirus NIAID Antibodies, Collaboration, Immunology, Infectious Disease, Therapeutics, Vaccines Antibodies Collaboration Immunology Infectious Disease Therapeutics Vaccines Karin Bok, Zhaochun Chen, Lisbeth Kim Green, Robert Purcell, Stanislav Sosnovtsev Vaccines and therapies to prevent and treat Norovirus infections do not exist, despite the worldwide prevalence of Norovirus infections. Outbreaks of human gastroenteritis attributable to Norovirus commonly occur in group setting, such as hospitals, nursing homes, schools, dormitories, cruise ships and military barracks.<br /><br /> This technology relates to chimpanzee-human chimeric monoclonal antibodies, which specifically bind to Norovirus and have therapeutic potential. The antibodies that were tested in a primate model of infection have shown protection against Norovirus. These Norovirus antibodies may have application as immunoprophylaxis to protect individuals from infections or as a possible treatment for infected individuals, or can be used to develop a diagnostic for detection of norovirus infections. <ul> <li>There are currently no vaccines or therapeutics available against Norovirus infections</li> </ul> <ul> <li>Therapeutics</li> <li>Diagnostics</li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize for development of a therapeutic or a diagnostic for Norovirus infections. For collaboration opportunities, please contact Dr. Jenish Patel at <a href="mailto:Jenish.Patel@nih.gov">Jenish.Patel@nih.gov</a> or 240-669-2894. European patent application is also available. 2022-03-08 2025-08-13 2025-08-15 2020-07-06 antibodies, chimeric, Chimpanzee/Human, DB4BXX, DB4XXX, DBXXXX, DC5XXX, DCXXXX, DXXXXX, Listed LPM Fenn as of 4/15/2015, monoclonal, Neutralize, NORWALK, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, That, virus, VLXXXX, WJXXXX, WNXXXX, XAXXXX, XKXXXX, YCXXXX False True <ul> <li>Early-stage</li> <li>In vivo data available (animal)</li> </ul> True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114171898 Chen Z, et al. http://www.ncbi.nlm.nih.gov/pubmed/23785216 <a href="http://www.ncbi.nlm.nih.gov/pubmed/23785216">Chen Z, et al.</a> 114104155 Bok, Karin NIAID - DIR NIAID Bok, Karin (NIAID) 0 114104216 Sosnovtsev, Stanislav NIAID - DIR NIAID Sosnovtsev, Stanislav (NIAID) 0 114104245 Green, Lisbeth Kim NIAID - DIR NIAID Green, Lisbeth Kim (NIAID) 0 114105292 Purcell, Robert NIAID - DIR NIAID Purcell, Robert (NIAID) 0 114106374 Chen, Zhaochun NIAID - DIR NIAID Chen, Zhaochun (NIAID) 1 114106374 Chen, Zhaochun NIAID - DIR NIAID Chen, Zhaochun (NIAID) 1 114104155 Bok, Karin NIAID - DIR NIAID Bok, Karin (NIAID) 0 114104216 Sosnovtsev, Stanislav NIAID - DIR NIAID Sosnovtsev, Stanislav (NIAID) 0 114104245 Green, Lisbeth Kim NIAID - DIR NIAID Green, Lisbeth Kim (NIAID) 0 114105292 Purcell, Robert NIAID - DIR NIAID Purcell, Robert (NIAID) 0 114099790 Chimpanzee/Human Chimeric Monoclonal Antibodies That Neutralize Norwalk Virus E-226-2011-0 Filing authorized NIAID 91027763 Puglielli, Maryann maryann.puglielli@nih.gov
United States of America maryann.puglielli@nih.gov?subject=Web Inquiry on [TAB-2636] Monoclonal Antibodies that Neutralize Norovirus&body=Please send me information about technology [TAB-2636] Monoclonal Antibodies that Neutralize Norovirus. Puglielli, Maryann<br><a href="mailto:maryann.puglielli@nih.gov?subject=Web Inquiry on [TAB-2636] Monoclonal Antibodies that Neutralize Norovirus&body=Please send me information about technology [TAB-2636] Monoclonal Antibodies that Neutralize Norovirus.">maryann.puglielli@nih.gov</a><br> 114162099 E-226-2011-0 E-226-2011-0-US-01 Monoclonal Antibodies That Neutralize A Norovirus PRV US 61/763,879 Abandoned US <br />Provisional (PRV) 61/763,879<br />Filed on 2013-02-12<br />Status: Abandoned 114162100 E-226-2011-0 E-226-2011-0-PCT-02 MONOCLONAL ANTIBODIES THAT NEUTRALIZE A NOROVIRUS PCT Patent Cooperation Treaty PCT/US2014/015809 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2014/015809<br />Filed on 2014-02-11<br />Status: Expired 114162101 E-226-2011-0 E-226-2011-0-US-04 Monoclonal Antibodies that Neutralize a Norovirus National Stage US 9,534,041 14/767,274 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9534041 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9534041">9,534,041</a><br />Filed on 2015-08-11<br />Status: Issued 114162102 E-226-2011-0 E-226-2011-0-US-05 MONOCLONAL ANTIBODIES THAT NEUTRALIZE A NOROVIRUS DIV US 9,815,887 15/359,438 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9815887 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9815887">9,815,887</a><br />Filed on 2016-11-22<br />Status: Issued 114115068 DB4BXX 114115069 YCXXXX 114122948 VLXXXX 114122949 WJXXXX 114122950 WNXXXX 114122951 XAXXXX 114122965 XKXXXX 114123700 DXXXXX 114123701 DBXXXX 114123702 DCXXXX 114123703 DB4XXX 114123704 DC5XXX 114133255 Post LPM Assignment Set 20150420 114133256 Pre LPM working set 20150418 114134343 Listed LPM Fenn as of 4/15/2015 114145023 Chimpanzee/Human 114145024 chimeric 114145025 monoclonal 114145026 antibodies 114145027 That 114145028 Neutralize 114145029 NORWALK 114145030 virus TAB-2621 114096815 Linear Epitopes of Anthrax Toxin Protective Antigen for Development of a Peptide Vaccine CDC Infectious Disease, Licensing, Vaccines Infectious Disease Licensing Vaccines Shannon Dalton, Jan Pohl, Conrad Quinn, Jarad Schiffer, Vera Semenova, Stephen Soroka, Pavel Svoboda <em>Bacillus anthracis</em> is a gram-positive, spore-forming bacteria that causes anthrax infection in humans. CDC inventors have identified epitope sequences of <em>B. anthracis</em> protective antigen (PA) that may be useful for development of peptide-based anthrax vaccines. This invention also relates to methods for determining whether post-vaccination protection is achieved. Specifically, this invention relates to a screening method for determining protection against <em>B. anthracis</em> infection that involves testing a biological sample for the presence of antibodies to one or more predefined regions of <em>B. anthracis</em> PA. This technology may be important to any bioterrorism defense strategy. <ul> <li>May require fewer vaccination follow-ups, while present anthrax vaccines require numerous rounds of injections and boosters for full-effectiveness.</li> <li>Identified peptide sequences, representing regions of PA, elicit an immune response in primate and human sera studies.</li> </ul> <ul> <li>Novel anthrax vaccines</li> <li>Post-vaccination screening to determine if anthrax protection is achieved</li> <li>Biodefense</li> </ul> 2022-03-27 2025-08-13 2025-08-15 2013-08-23 Anthrax, ANTIGEN, Bacillus, biosecurity, Bioterrism, Bio-terrorism, Bioterrorist, BioWarfare, CDC Docket Import, CDC Docket Import CDC Prosecuting, DC1XXX, DC4XXX, DCXXXX, Development, DXXXXX, Epitopes, LINEAR, OID-NCIRD-DBD, PA, Peptide, Protection, Protective, toxin, Vaccine False True <ul> <li>Pre-clinical</li> <li>In vitro data available</li> </ul> True NIHTT 37470483 Website Abstract 114108087 Quinn, Conrad CDC - DIR CDC Quinn, Conrad (CDC) 0 114108088 Pohl, Jan CDC - DIR CDC Pohl, Jan (CDC) 0 114108089 Svoboda, Pavel CDC - DIR CDC Svoboda, Pavel (CDC) 0 114108657 Dalton, Shannon CDC - DIR CDC Dalton, Shannon (CDC) 0 114108658 Schiffer, Jarad CDC - DIR CDC Schiffer, Jarad (CDC) 0 114108659 Soroka, Stephen CDC - DIR CDC Soroka, Stephen (CDC) 0 114108086 Semenova, Vera CDC - DIR CDC Semenova, Vera (CDC) 1 114108086 Semenova, Vera CDC - DIR CDC Semenova, Vera (CDC) 1 114108087 Quinn, Conrad CDC - DIR CDC Quinn, Conrad (CDC) 0 114108088 Pohl, Jan CDC - DIR CDC Pohl, Jan (CDC) 0 114108089 Svoboda, Pavel CDC - DIR CDC Svoboda, Pavel (CDC) 0 114108657 Dalton, Shannon CDC - DIR CDC Dalton, Shannon (CDC) 0 114108658 Schiffer, Jarad CDC - DIR CDC Schiffer, Jarad (CDC) 0 114108659 Soroka, Stephen CDC - DIR CDC Soroka, Stephen (CDC) 0 114101939 Linear Epitopes Of Anthrax Toxin Protection Antigen (PA) For Development Of Peptide Vaccine E-158-2013-2 Closed Centers for Disease Control and Prevention (CDC) 114102128 Linear Epitopes Of Anthrax Toxin Protection Antigen (PA) For Development Of Peptide Vaccine E-158-2013-3 Closed Centers for Disease Control and Prevention (CDC) 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2621] Linear Epitopes of Anthrax Toxin Protective Antigen for Development of a Peptide Vaccine&body=Please send me information about technology [TAB-2621] Linear Epitopes of Anthrax Toxin Protective Antigen for Development of a Peptide Vaccine. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2621] Linear Epitopes of Anthrax Toxin Protective Antigen for Development of a Peptide Vaccine&body=Please send me information about technology [TAB-2621] Linear Epitopes of Anthrax Toxin Protective Antigen for Development of a Peptide Vaccine.">jonathan.motley@nih.gov</a><br> 114167214 E-158-2013-2 E-158-2013-2-PCT-01 Serologic Correlates Of Protection Against Bacillis Anthracis Infection PCT COMB Patent Cooperation Treaty PCT/US2011/024317 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2011/024317<br />Filed on 2011-02-10<br />Status: Expired 114167215 E-158-2013-2 E-158-2013-2-US-03 Serologic Correlates Of Protection Against Bacillis Anthracis Infection National Stage US 9,046,520 13/577,878 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9046520 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9046520">9,046,520</a><br />Filed on 2012-08-08<br />Status: Abandoned 114167736 E-158-2013-3 E-158-2013-3-US-01 SEROLOGIC CORRELATES OF PROTECTION AGAINST BACILLIS ANTHRACIS INFECTION CIP US 9,102,742 14/010,668 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9102742 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9102742">9,102,742</a><br />Filed on 2013-08-27<br />Status: Abandoned 114167919 E-158-2013-3 E-158-2013-3-PCT-02 SEROLOGIC CORRELATES OF PROTECTION AGAINST BACILLUS ANTHRACIS INFECTION PCT Patent Cooperation Treaty PCT/US2014/052895 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2014/052895<br />Filed on 2014-08-27<br />Status: Expired 114168105 E-158-2013-2 E-158-2013-2-US-04 SEROLOGIC CORRELATES OF PROTECTION AGAINST BACILLUS ANTHRACIS INFECTION DIV US 9,610,338 14/669,580 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9610338 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9610338">9,610,338</a><br />Filed on 2015-03-26<br />Status: Abandoned 114168217 E-158-2013-2 E-158-2013-2-US-05 SEROLOGIC CORRELATES OF PROTECTION AGAINST BACILLUS ANTHRACIS INFECTION DIV US 9,782,465 15/438,152 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9782465 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9782465">9,782,465</a><br />Filed on 2017-02-21<br />Status: Abandoned 114123633 DXXXXX 114123634 DCXXXX 114123635 DC4XXX 114123636 DC1XXX 114144922 LINEAR 114144923 Epitopes 114144924 Anthrax 114144925 toxin 114144926 Protection 114144927 ANTIGEN 114144928 PA 114144929 Development 114144930 Peptide 114144931 Vaccine 114147086 CDC Docket Import 114147087 CDC Docket Import CDC Prosecuting 114147088 OID-NCIRD-DBD 114147089 Protective 114147090 Bacillus 114147091 Bio-terrorism 114147092 Bioterrism 114147093 Bioterrorist 114147094 BioWarfare 114147095 biosecurity TAB-2616 114096810 Monoclonal Antibodies That Recognize the Human Type I Interferon Receptor and Block Interferon Signaling NIAID Collaboration, Infectious Disease, Research Materials Collaboration Infectious Disease Research Materials Sonja Best, Kirk Lubick, Shelly Robertson Type I interferons play a critical role in both innate and adaptive immunity through the stimulation of the IFNAR1 which initiates interferon signaling in response to viral and bacterial infections. However, abnormal interferon signaling is associated with human diseases, such as lupus. The present invention discloses six hybridomas that produce mouse monoclonal antibodies specific for the extracellular domain of human IFNAR1. Two of the monoclonal antibodies are able to bind IFNAR1 and reduce interferon signaling. As such, they can be utilized as a research tool for studying the expression of IFNAR1 and the inhibition of IFNAR1 function in humans or possibly as therapeutic reagents for human diseases. <ul> <li>Specific for the extracellular domain of human IFNAR1. Can therefore specifically recognize receptor expressed on the cell surface.</li> <li>Bind IFNAR1 and reduce interferon signaling</li> </ul> <ul> <li>Research reagents for studying the expression and signaling of IFNAR1.</li> <li>A potential therapeutic reagent.</li> </ul> The National Institute of Allergy and Infectious Diseases (NIAID) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize human type I interferon receptor antibodies. For collaboration opportunities, please contact Alicia Evangelista at <a href="mailto:alicia.evangelista@nih.gov">alicia.evangelista@nih.gov</a> or 301-594-1673. Research Material – Patent protection is not being pursued for this technology. 2022-03-08 2025-08-13 2025-08-15 2013-08-22 antibodies, ANTI-HUMAN, DDXXXX, DXXXXX, IFNAR1, monoclonal, RXXXXX False True <ul> <li>Pilot</li> <li>In vitro data available</li> </ul> True NIHTT 37470483 Website Abstract 114171880 Goldman LA, et al. http://www.ncbi.nlm.nih.gov/pubmed/10048764 <a href="http://www.ncbi.nlm.nih.gov/pubmed/10048764">Goldman LA, et al.</a> 114171881 Benoit P, et al. http://www.ncbi.nlm.nih.gov/pubmed/8423335 <a href="http://www.ncbi.nlm.nih.gov/pubmed/8423335">Benoit P, et al.</a> 114108069 Lubick, Kirk NIAID - DIR Lubick, Kirk 0 114108070 Robertson, Shelly NIAID - DIR NIAID Robertson, Shelly (NIAID) 0 114107446 Best, Sonja NIAID - DIR NIAID Best, Sonja (NIAID) 1 114107446 Best, Sonja NIAID - DIR NIAID Best, Sonja (NIAID) 1 114108069 Lubick, Kirk NIAID - DIR Lubick, Kirk 0 114108070 Robertson, Shelly NIAID - DIR NIAID Robertson, Shelly (NIAID) 0 114101934 Anti-human IFNAR1 Monoclonal Antibodies E-527-2013-0 Research Material NIAID 146046171 Joyce, Terrence terrence.joyce@nih.gov
United States of America terrence.joyce@nih.gov?subject=Web Inquiry on [TAB-2616] Monoclonal Antibodies That Recognize the Human Type I Interferon Receptor and Block Interferon Signaling&body=Please send me information about technology [TAB-2616] Monoclonal Antibodies That Recognize the Human Type I Interferon Receptor and Block Interferon Signaling. Joyce, Terrence<br><a href="mailto:terrence.joyce@nih.gov?subject=Web Inquiry on [TAB-2616] Monoclonal Antibodies That Recognize the Human Type I Interferon Receptor and Block Interferon Signaling&body=Please send me information about technology [TAB-2616] Monoclonal Antibodies That Recognize the Human Type I Interferon Receptor and Block Interferon Signaling.">terrence.joyce@nih.gov</a><br> 114123602 DDXXXX 114123603 RXXXXX 114123604 DXXXXX 114144873 ANTI-HUMAN 114144874 IFNAR1 114144875 monoclonal 114144876 antibodies TAB-2600 114096794 Real-Time RT-PCR Assay for Detection of Noroviruses CDC Diagnostics, Infectious Disease, Licensing Diagnostics Infectious Disease Licensing Leslie Barclay, Preeti Chhabra, Nicole Gregoricus, David Lee, Hannah Shirley, Jan Vinje A specific and sensitive TaqMan-based real-time (rt) RT-PCR assay has been developed by CDC scientists for detection of noroviruses in clinical and environmental specimens. This assay can be implemented to rapidly detect and distinguish norovirus strains from genogroups I and II, which are responsible for the majority of human infections. Additionally, the assay is multiplexed with an internal extraction control virus (coliphage MS2) to validate the results of the assay. Since the virus cannot be grown in cell culture and enzyme immunoassays lack the necessary sensitivity, this technology is particularly useful. <ul> <li>This is an internally controlled, multiplexed assay capable of rapid, accurate identification of norovirus genogroups responsible for human illness</li> <li>Superior sensitivity compared with immunoassay detection methods</li> </ul> <ul> <li>Development of norovirus diagnostics</li> <li>Specific rtRT-PCR assay for detecting and distinguishing of the major pathogenic norovirus genogroups (I and II) within clinical and environmental samples</li> </ul> 2022-03-27 2025-08-13 2025-08-15 2013-08-02 DA4BXX, DA4XXX, DAXXXX, Detection, DXXXXX, Norovirus, SELECTIVE False True <ul> <li>Pre-clinical</li> <li>In vitro data available</li> </ul> True NIHTT 37470483 Website Abstract 114171855 Vega E, et al. http://www.ncbi.nlm.nih.gov/pubmed/21801614 <a href="http://www.ncbi.nlm.nih.gov/pubmed/21801614">Vega E, et al.</a> 114171856 Schultz AC, et al. http://www.ncbi.nlm.nih.gov/pubmed/21195660 <a href="http://www.ncbi.nlm.nih.gov/pubmed/21195660">Schultz AC, et al.</a> 114108029 Gregoricus, Nicole CDC - DIR CDC Gregoricus, Nicole (CDC) 0 114108030 Chhabra, Preeti CDC - DIR CDC Chhabra, Preeti (CDC) 0 114108031 Barclay, Leslie CDC - DIR CDC Barclay, Leslie (CDC) 0 114108032 Shirley, Hannah CDC - DIR CDC Shirley, Hannah (CDC) 0 114108033 Lee, David CDC - DIR CDC Lee, David (CDC) 0 114108028 Vinje, Jan CDC - DIR CDC Vinje, Jan (CDC) 1 114108028 Vinje, Jan CDC - DIR CDC Vinje, Jan (CDC) 1 114108029 Gregoricus, Nicole CDC - DIR CDC Gregoricus, Nicole (CDC) 0 114108030 Chhabra, Preeti CDC - DIR CDC Chhabra, Preeti (CDC) 0 114108031 Barclay, Leslie CDC - DIR CDC Barclay, Leslie (CDC) 0 114108032 Shirley, Hannah CDC - DIR CDC Shirley, Hannah (CDC) 0 114108033 Lee, David CDC - DIR CDC Lee, David (CDC) 0 114101918 Selective Detection Of Norovirus E-145-2013-0 Filing authorized Centers for Disease Control and Prevention (CDC) 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2600] Real-Time RT-PCR Assay for Detection of Noroviruses&body=Please send me information about technology [TAB-2600] Real-Time RT-PCR Assay for Detection of Noroviruses. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2600] Real-Time RT-PCR Assay for Detection of Noroviruses&body=Please send me information about technology [TAB-2600] Real-Time RT-PCR Assay for Detection of Noroviruses.">jonathan.motley@nih.gov</a><br> 114167170 E-145-2013-0 E-145-2013-0-US-01 Selective Detection Of Norovirus PRV US 61/560,077 Abandoned US <br />Provisional (PRV) 61/560,077<br />Filed on 2011-11-15<br />Status: Abandoned 114167171 E-145-2013-0 E-145-2013-0-PCT-02 Selective Detection Of Norovirus PCT Patent Cooperation Treaty PCT/US2012/065269 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2012/065269<br />Filed on 2012-11-15<br />Status: Expired 114167806 E-145-2013-0 E-145-2013-0-US-05 Selective Detection Of Norovirus National Stage US 14/358,493 Abandoned US <br />National Stage 14/358,493<br />Filed on 2014-05-15<br />Status: Abandoned 114169175 E-145-2013-0 E-145-2013-0-US-10 Selective Detection Of Norovirus DIV US 17/456,323 Pending US <br />Divisional (DIV) 17/456,323<br />Filed on 2021-11-23<br />Status: Pending 114123513 DA4BXX 114123514 DXXXXX 114123515 DAXXXX 114123516 DA4XXX 114144755 Detection 114144756 SELECTIVE 114144757 Norovirus TAB-2598 114096792 Device for Non-Surgical Tricuspid Valve Annuloplasty NHLBI Collaboration Collaboration Robert Lederman, Kanishka Ratnayaka, Toby Rogers This is a non-surgical tricuspid annuloplasty to treat functional tricuspid valve regurgitation, meaning regurgitation with intact valve leaflets. The device is delivered using novel catheter techniques into the pericardial space and positioned along the atrioventricular groove. A compression member is positioned along the tricuspid annular free wall and tension applied through a variably-applied tension element. In the best embodiment, the compression member has an M shaped portion with at least two inflection points between the segments of difference curvatures. <ul> <li>Non-surgical catheter treatment of valve disease</li> <li>Tricuspid valve</li> </ul> <ul> <li>Valvular heart disease</li> <li>Tricuspid valve annuloplasty</li> </ul> The NHLBI is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize technologies for functional tricuspid valve regurgitation. For collaboration opportunities, please contact Peg Koelble at <a href="mailto:koelblep@nhlbi.nih.gov">koelblep@nhlbi.nih.gov</a>. 2022-03-08 2025-08-13 2025-08-15 2013-07-30 AB2XXX, AB3CXX, AB3EXX, AB3FXX, AB3GXX, AB3XXX, ABXXXX, Annuloplasty, AXXXXX, Cardiology, Cardiovascular, Intrapericardial, Regurgitation, Transauricular, Tricuspid, Valve False True <ul> <li>Prototype</li> <li>Pre-clinical</li> <li>In vitro data available</li> <li>In vivo data available (animal)</li> </ul> True NIHTT 37470483 Website Abstract E-108-2010-0 E-249-2006-2 114108023 Rogers, Toby National Heart, Lung, and Blood Institute (NHLBI) Rogers, Toby 0 114108025 Ratnayaka, Kanishka National Heart, Lung, and Blood Institute (NHLBI) Ratnayaka, Kanishka 0 114108024 Lederman, Robert National Heart, Lung, and Blood Institute (NHLBI) NHLBI Lederman, Robert (NHLBI) 1 114108024 Lederman, Robert National Heart, Lung, and Blood Institute (NHLBI) NHLBI Lederman, Robert (NHLBI) 1 114108023 Rogers, Toby National Heart, Lung, and Blood Institute (NHLBI) Rogers, Toby 0 114108025 Ratnayaka, Kanishka National Heart, Lung, and Blood Institute (NHLBI) Ratnayaka, Kanishka 0 114101915 Transauricular Intrapericardial Tricuspid Annuloplasty (TRAIPTA). A Method And Devices For Non-surgical Treatment For Functional Triscupid Valve Regurgitation E-027-2013-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-2598] Device for Non-Surgical Tricuspid Valve Annuloplasty&body=Please send me information about technology [TAB-2598] Device for Non-Surgical Tricuspid Valve Annuloplasty. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-2598] Device for Non-Surgical Tricuspid Valve Annuloplasty&body=Please send me information about technology [TAB-2598] Device for Non-Surgical Tricuspid Valve Annuloplasty.">shmilovm@nih.gov</a><br> 114163026 E-027-2013-0 E-027-2013-0-US-04 Devices and Methods for Treating Functional Tricuspid Valve Regurgitation National Stage US 9,987,135 14/776,488 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9987135 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9987135">9,987,135</a><br />Filed on 2015-09-14<br />Status: Issued 114167164 E-027-2013-0 E-027-2013-0-US-01 Devices And Methods for Treating Functional Triscupid Valve Regurgitation PRV US 61/785,652 Abandoned US <br />Provisional (PRV) 61/785,652<br />Filed on 2013-03-14<br />Status: Abandoned 114167701 E-027-2013-0 E-027-2013-0-PCT-02 Devices and Methods For Treating Functional Tricuspid Valve Reguritation PCT Patent Cooperation Treaty PCT/US2014/025300 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2014/025300<br />Filed on 2014-03-13<br />Status: Expired 114123502 AB3EXX 114123503 AB3CXX 114123504 AB2XXX 114123505 AB3FXX 114123506 AB3GXX 114123507 AB3XXX 114123508 AXXXXX 114123509 ABXXXX 114144743 Cardiology 114144744 Cardiovascular 114144745 Transauricular 114144746 Intrapericardial 114144747 Tricuspid 114144748 Valve 114144749 Regurgitation 114144750 Annuloplasty TAB-2589 114096786 Encircling Suture Delivery System NHLBI Licensing Licensing Dominigue Franson, Ozgur Kocaturk, Robert Lederman, Toby Rogers, Merdim Sonmez The invention provides a novel delivery system for delivering an encircling suture which includes two separate hollow limbs held together at an articulation by the suture to be delivered. The suture can extend through the hollow limbs, which slide along the suture. The distal ends of the limbs can be compressed into a desired delivery shape that allows the limbs to be advanced through the lumen of a delivery catheter (e.g., a transcutaneous, transvascular or intraluminal catheter) into any body cavity. As the distal portions of the limbs move out of the delivery catheter, the limbs cooperatively assume a loop shape complementary to the shape of the target around the encircling suture to leave only the suture in the desired delivery position while maintaining desired suture tension and position. The delivery device can be placed around a variety of anatomical structures (e.g., heart, arterial appendage, cecal appendix, gall bladder, neoplasm, uterus, hemorrhoid, uvula, aneurysm, transected blood vessel, folded or looped lumen, intraocular crystalline lens or implated intraocular lens or haptic, urinary bladder, kidney, prostate, intestine, or liver, etc.). <ul> <li>Formable suturing</li> <li>Circumferential suturing</li> <li>Flexible</li> <li>Easy to use</li> </ul> <ul> <li>Surgery</li> <li>Suturing</li> <li>Catheterization</li> <li>Cardiac valve repair</li> </ul> 2022-03-08 2025-08-13 2025-08-15 2013-07-16 AB3CXX, AB3FXX, AB3XXX, ABXXXX, AXXXXX, Circumferencial, Encircling, Suture, System False True Prototype True NIHTT 37470483 Website Abstract E-027-2013-0 E-108-2010-0 114107981 Sonmez, Merdim National Heart, Lung, and Blood Institute (NHLBI) NHLBI Sonmez, Merdim (NHLBI) 0 114107982 Franson, Dominigue National Heart, Lung, and Blood Institute (NHLBI) Franson, Dominigue 0 114107983 Lederman, Robert National Heart, Lung, and Blood Institute (NHLBI) NHLBI Lederman, Robert (NHLBI) 0 114107984 Kocaturk, Ozgur National Heart, Lung, and Blood Institute (NHLBI) NHLBI Kocaturk, Ozgur (NHLBI) 0 114107980 Rogers, Toby National Heart, Lung, and Blood Institute (NHLBI) Rogers, Toby 1 114107980 Rogers, Toby National Heart, Lung, and Blood Institute (NHLBI) Rogers, Toby 1 114107981 Sonmez, Merdim National Heart, Lung, and Blood Institute (NHLBI) NHLBI Sonmez, Merdim (NHLBI) 0 114107982 Franson, Dominigue National Heart, Lung, and Blood Institute (NHLBI) Franson, Dominigue 0 114107983 Lederman, Robert National Heart, Lung, and Blood Institute (NHLBI) NHLBI Lederman, Robert (NHLBI) 0 114107984 Kocaturk, Ozgur National Heart, Lung, and Blood Institute (NHLBI) NHLBI Kocaturk, Ozgur (NHLBI) 0 114101906 Encircling Suture Delivery System E-115-2013-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-2589] Encircling Suture Delivery System&body=Please send me information about technology [TAB-2589] Encircling Suture Delivery System. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-2589] Encircling Suture Delivery System&body=Please send me information about technology [TAB-2589] Encircling Suture Delivery System.">shmilovm@nih.gov</a><br> 114165486 E-115-2013-0 E-115-2013-0-US-04 Encircling Implant Delivery Systems and Methods National Stage US 10,463,495 14/898,020 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10463495 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10463495">10,463,495</a><br />Filed on 2015-12-11<br />Status: Issued 114167150 E-115-2013-0 E-115-2013-0-US-01 Encircling Suture Delivery System For Flexible Circumferential Suture PRV US 61/834,357 Abandoned US <br />Provisional (PRV) 61/834,357<br />Filed on 2013-06-12<br />Status: Abandoned 114167834 E-115-2013-0 E-115-2013-0-PCT-02 Encircling Implant Delivery System And Methods PCT Patent Cooperation Treaty PCT/US2014/040716 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2014/040716<br />Filed on 2014-06-03<br />Status: Expired 114123463 AB3XXX 114123464 AB3CXX 114123465 AB3FXX 114123466 AXXXXX 114123467 ABXXXX 114144664 Encircling 114144665 Suture 114144666 System 114144667 Circumferencial TAB-2583 114096782 Safer Attenuated Virus Vaccines with Missing or Diminished Latency of Infection NIAID Infectious Disease, Licensing, Rare/Neglected Diseases, Vaccines Infectious Disease Licensing Rare/Neglected Diseases Vaccines Jeffrey Cohen, Edward Cox, Lesley Pesnicak This technology describes recombinant viruses that have weakened ability to establish and/or maintain latency and their use as live vaccines. The viruses have one or more genetic mutations that allow for continued replication but that inhibit latency. The vaccine materials and methods for their construction are exemplified with the virus that causes chickenpox and whose latent infection results in shingles, a condition that affects up to an estimated 1 million people per year in the United States alone. Additionally, there are veterinary applications of this technology. Specific examples of gene deletions, modifications, and/or insertions are described. Furthermore, replacement of these deleted genes with other desirable viral antigen encoding sequence(s) and/or cytokine genes in order to enhance a desired immunological response is also described. Aspects of this technology are relevant to other live virus vaccines, thus increasing the safety of such vaccines. 2022-03-08 2025-08-13 2025-08-15 2013-07-09 BUT, chickenpox, DC5BXX, DC5XXX, DCXXXX, DXXXXX, Impaired, Latency, MUTANT, Patent Category - Biotechnology, REPLICATION, UAXXXX, Vaccine, VARICELLA-ZOSTER False True True NIHTT 37470483 Website Abstract 114107972 Pesnicak, Lesley NIAID - DIR Pesnicak, Lesley 0 114107973 Cox, Edward FDA Cox, Edward (FDA) 0 114107971 Cohen, Jeffrey NIAID - DIR NIAID Cohen, Jeffrey (NIAID) 1 114107971 Cohen, Jeffrey NIAID - DIR NIAID Cohen, Jeffrey (NIAID) 1 114107972 Pesnicak, Lesley NIAID - DIR Pesnicak, Lesley 0 114107973 Cox, Edward FDA Cox, Edward (FDA) 0 114101900 A Varicella-Zoster Vaccine Mutant Impaired For Latency But Not For Replication E-217-2004-0 Filing authorized NIAID 91029846 Ganelina, Anna ganelinaa@niaid.nih.gov
United States of America ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-2583] Safer Attenuated Virus Vaccines with Missing or Diminished Latency of Infection&body=Please send me information about technology [TAB-2583] Safer Attenuated Virus Vaccines with Missing or Diminished Latency of Infection. Ganelina, Anna<br><a href="mailto:ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-2583] Safer Attenuated Virus Vaccines with Missing or Diminished Latency of Infection&body=Please send me information about technology [TAB-2583] Safer Attenuated Virus Vaccines with Missing or Diminished Latency of Infection.">ganelinaa@niaid.nih.gov</a><br> 114167136 E-217-2004-0 E-217-2004-0-PCT-02 Safer Attenuated Virus Vaccines with Missing or Diminished Latency of Infection PCT Patent Cooperation Treaty PCT/US2005/021788 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2005/021788<br />Filed on 2005-06-22<br />Status: Expired 114167137 E-217-2004-0 E-217-2004-0-US-01 Safer Attenuated Virus Vaccines With Missing or Diminished Latency of Infection PRV US 60/583,399 Abandoned US <br />Provisional (PRV) 60/583,399<br />Filed on 2004-06-29<br />Status: Abandoned 114167138 E-217-2004-0 E-217-2004-0-US-05 SAFER ATTENUATED VARICELLA-ZOSTER VIRUS VACCINES WITH MISSING OR DIMINISHED LATENCY OF INFECTION National Stage US 8,916,175 11/630,147 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8916175 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8916175">8,916,175</a><br />Filed on 2008-01-03<br />Status: Issued 114123447 DC5BXX 114123448 UAXXXX 114123449 DXXXXX 114123450 DCXXXX 114123451 DC5XXX 114144608 VARICELLA-ZOSTER 114144609 Vaccine 114144610 MUTANT 114144611 Impaired 114144612 Latency 114144613 BUT 114144614 REPLICATION 114144615 chickenpox 114144616 Patent Category - Biotechnology TAB-2554 114096750 Novel Tocopherol and Tocopheryl Quinone Derivatives as Therapeutics for Lysosomal Storage Disorders NCATS Collaboration, Diagnostics, Reproductive Health, Research Materials, Therapeutics, Vaccines Collaboration Diagnostics Reproductive Health Research Materials Therapeutics Vaccines Juan Marugan, John McKew, Jingbo Xiao, Wei Zheng Novel tocopherol derivatives and tocopheryl quinone derivatives useful in the decrease of lysosomal substrate accumulation, the restoration of normal lysosomal size, and the treatment of lysosomal storage disorders (LSDs) are provided. The inventors have discovered that tocopherol and tocopheryl quinone derivatives with side chain modifications (such as terminal tri-halogenated methyl groups) exhibit improved pharmacokinetics, modulation of mitochondrial potential and restoration of some LSDs phenotypes. These molecules by themselves or in combination with Cyclodextrins (CDs) increase intracellular Ca2+ and enhance exocytosis. Also, the treatment with these compounds reduced the pathological changes in the ultrastructure of LSD cells as observed using electron microscopy analysis. The inventors also found that there is a synergy between CDs and the new tocopherol analogues when tested on the NPC cells and cells from six other lysosomal storage diseases including Wolman, Niemann Pick Type A, Farber, TaySachs, MSIIIB and CLN2 (Batten) diseases. These new tocopherol analogues are as good or better than natural occurring tocopherols and tocotrienols in reducing cholesterol accumulation in several LSDs. <ul> <li>The main advantage of the compounds disclosed here is their improved pharmacokinetics.</li> <li>The combination of CD and the novel tocopherol analogues may reduce the dosage of each drug and thereby reduce the potential side effects.</li> </ul> <ul> <li>To develop new therapeutics to treat LSDs.</li> </ul> The National Center for Advancing Translational Sciences (NCATS) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize Novel Tocopherol and Tocopheryl Quinone Derivatives as Therapeutics for Lysosomal Storage Disorders. For collaboration opportunities, please contact the NCATS Technology Development Coordinator at <a href="mailto:NCATSPartnerships@mail.nih.gov">NCATSPartnerships@mail.nih.gov</a>. 2022-03-08 2025-08-13 2025-08-15 2013-04-23 ANALOGUES, Correctors, DISORDERS, IB6XXX, IBXXXX, IXXXXX, Lysosomal, Storage, Tocopherol False True <ul> <li>Prototype</li> <li>Early-stage</li> <li>Pre-clinical</li> <li>In vitro data available</li> </ul> True NIHTT 37470483 Website Abstract E-294-2009-0 E-050-2012-0 114107875 Xiao, Jingbo NCATS - NCGC FDA Xiao, Jingbo (FDA) 0 114107876 Zheng, Wei NCATS - TRND NCATS Zheng, Wei (NCATS) 0 114107877 McKew, John NCATS - TRND McKew, John 0 114107874 Marugan, Juan NCATS - NCGC NCATS Marugan, Juan (NCATS) 1 114107874 Marugan, Juan NCATS - NCGC NCATS Marugan, Juan (NCATS) 1 114107875 Xiao, Jingbo NCATS - NCGC FDA Xiao, Jingbo (FDA) 0 114107876 Zheng, Wei NCATS - TRND NCATS Zheng, Wei (NCATS) 0 114107877 McKew, John NCATS - TRND McKew, John 0 114101864 Tocopherol Analogues As Correctors Of Lysosomal Storage Disorders E-148-2012-0 Filing authorized NCATS - NCGC 93911356 Kalsi, Jasmine jasmine.kalsi@nih.gov
United States of America jasmine.kalsi@nih.gov?subject=Web Inquiry on [TAB-2554] Novel Tocopherol and Tocopheryl Quinone Derivatives as Therapeutics for Lysosomal Storage Disorders&body=Please send me information about technology [TAB-2554] Novel Tocopherol and Tocopheryl Quinone Derivatives as Therapeutics for Lysosomal Storage Disorders. Kalsi, Jasmine<br><a href="mailto:jasmine.kalsi@nih.gov?subject=Web Inquiry on [TAB-2554] Novel Tocopherol and Tocopheryl Quinone Derivatives as Therapeutics for Lysosomal Storage Disorders&body=Please send me information about technology [TAB-2554] Novel Tocopherol and Tocopheryl Quinone Derivatives as Therapeutics for Lysosomal Storage Disorders.">jasmine.kalsi@nih.gov</a><br> 114164702 E-148-2012-0 E-148-2012-0-US-01 Tocopherol Analogues As Correctors Of Lysosomal Storage Disorders PRV US 61/727,296 Abandoned US <br />Provisional (PRV) 61/727,296<br />Filed on 2012-11-16<br />Status: Abandoned 114167385 E-148-2012-0 E-148-2012-0-PCT-02 TOCOPHEROL AND TOCOPHERYL QUINONE DERIVATIVES AS CORRECTORS OF LYSOSOMAL STORAGE DISORDERS PCT Patent Cooperation Treaty PCT/US2013/070156 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2013/070156<br />Filed on 2013-11-14<br />Status: Expired 114168165 E-148-2012-0 E-148-2012-0-US-08 TOCOPHEROL AND TOCOPHERYL QUINONE DERIVATIVES AS CORRECTORS OF LYSOSOMAL STORAGE DISORDERS National Stage US 9,663,485 14/442,637 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9663485 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9663485">9,663,485</a><br />Filed on 2015-05-13<br />Status: Issued 114168291 E-148-2012-0 E-148-2012-0-US-09 TOCOPHEROL AND TOCOPHERYL QUINONE DERIVATIVES AS CORRECTORS OF LYSOSOMAL STORAGE DISORDERS CON US 10,370,348 15/608,753 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10370348 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10370348">10,370,348</a><br />Filed on 2017-05-30<br />Status: Issued 114123298 IB6XXX 114123299 IXXXXX 114123300 IBXXXX 114144277 Tocopherol 114144278 ANALOGUES 114144279 Correctors 114144280 Lysosomal 114144281 Storage 114144282 DISORDERS TAB-2536 114096731 Novel Vaccine for Prevention and Treatment of Chlamydia Infection NIAID Collaboration, Infectious Disease, Vaccines Collaboration Infectious Disease Vaccines Harlan Caldwell The invention provides novel vectors, attenuated pathogens, compositions, methods and kits for preventing and/or treating chlamydia infections.<br /><br /> <em>Chlamydia trachomatis</em> is an obligate intracellular human pathogen with a unique biphasic developmental growth cycle. It's the etiological agent of trachoma, the world's leading cause of preventable blindness and the most common cause of bacterial sexually transmitted disease. <em>C. trachomatis</em> isolates maintain a highly conserved plasmid and naturally occurring plasmidless clinical isolates are rare, implicating its importance in chlamydial pathogenesis. Understanding the plasmid's role in chlamydial pathogenesis at a molecular level is an important objective for the future control of chlamydial infections. The NIAID inventor had studied chlamydia strains in both non-human primate and murine infectious models providing evidence that plasmids play an important role in chlamydial pathogenesis. In addition, the study results of macaque model of trachoma supports the use of plasmid-deficient organisms as novel live-attenuated chlamydial vaccines. <ul> <li>Virulence attenuated vectors that can be used as vaccines against chlamydia.</li> <li>Combination of vector with attenuated pathogenic agent improves the stability and replicative capacity of the pathogen.</li> <li>Features nucleic acids, attenuated pathogens, compositions, methods and kits to treat and prevent chlamydia infections.</li> </ul> <ul> <li>Novel live-attenuated chlamydial vaccines.</li> </ul> The National Institute of Allergy and Infectious Diseases, Laboratory of Clinical Infectious Diseases, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize chlamydia vaccine. For collaboration opportunities, please contact Harlan D. Caldwell, Ph.D. at <a href="mailto:hcaldwell@niaid.nih.gov">hcaldwell@niaid.nih.gov</a>. 2022-03-08 2025-08-13 2025-08-15 2013-02-21 Against, Attenuated, DCXXXX, DISEASES, DXXXXX, Live, MULTIPLE, Sexually, Transmitted, Vaccine, VJXXXX, WNXXXX, XKXXXX, YBXXXX, YCXXXX, YDXXXX, YFXXXX False True <ul> </li>In vitro data available</li> </li>In vivo data available (animal)</li> </li>In vivo data available (human)</li> <li>Prototype</li> </ul> True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114171763 Song L, et al. http://www.ncbi.nlm.nih.gov/pubmed/23319558 <a href="http://www.ncbi.nlm.nih.gov/pubmed/23319558">Song L, et al.</a> 114171764 Kari L, et al. http://www.ncbi.nlm.nih.gov/pubmed/21987657 <a href="http://www.ncbi.nlm.nih.gov/pubmed/21987657">Kari L, et al.</a> 114107813 Caldwell, Harlan NIAID - DIR NIAID Caldwell, Harlan (NIAID) 1 114107813 Caldwell, Harlan NIAID - DIR NIAID Caldwell, Harlan (NIAID) 1 114101849 Live -Attenuated Vaccine Against Multiple Sexually Transmitted Diseases E-133-2012-0 Filing authorized NIAID 91026778 Green, Wade wade.green@nih.gov
United States of America TTIPO wade.green@nih.gov?subject=Web Inquiry on [TAB-2536] Novel Vaccine for Prevention and Treatment of Chlamydia Infection&body=Please send me information about technology [TAB-2536] Novel Vaccine for Prevention and Treatment of Chlamydia Infection. Green, Wade<br><a href="mailto:wade.green@nih.gov?subject=Web Inquiry on [TAB-2536] Novel Vaccine for Prevention and Treatment of Chlamydia Infection&body=Please send me information about technology [TAB-2536] Novel Vaccine for Prevention and Treatment of Chlamydia Infection.">wade.green@nih.gov</a><br> 114167006 E-133-2012-0 E-133-2012-0-US-01 Novel Attenuated Vaccine PRV US 61/753,320 Abandoned US <br />Provisional (PRV) 61/753,320<br />Filed on 2013-01-16<br />Status: Abandoned 114167606 E-133-2012-0 E-133-2012-0-PCT-02 Attenuated Chlamydia Vaccine PCT Patent Cooperation Treaty PCT/US2014/011799 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2014/011799<br />Filed on 2014-01-16<br />Status: Expired 114168176 E-133-2012-0 E-133-2012-0-US-03 Attenuated Chlamydia Vaccine National Stage US 10,258,682 14/761,520 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10258682 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10258682">10,258,682</a><br />Filed on 2015-07-16<br />Status: Issued 114123211 DCXXXX 114123212 DXXXXX 114127103 VJXXXX 114127104 WNXXXX 114127105 XKXXXX 114127106 YBXXXX 114127107 YCXXXX 114127108 YDXXXX 114127109 YFXXXX 114144092 Attenuated 114144093 Vaccine 114144094 Against 114144095 MULTIPLE 114144096 Sexually 114144097 Transmitted 114144098 DISEASES 114144099 Live TAB-2494 114096690 Cyclodextrins as Therapeutics for Lysosomal Storage Disorders NCATS Collaboration, Diagnostics, Neurology, Rare/Neglected Diseases, Reproductive Health, Research Materials, Therapeutics, Vaccines Collaboration Diagnostics Neurology Rare/Neglected Diseases Reproductive Health Research Materials Therapeutics Vaccines Juan Marugan, John McKew, Manju Swaroop, Miao Xu, Wei Zheng Cyclodextrins (CD), alone or in combination with other agents (e.g., vitamin E), as therapeutics for the treatment of lysosomal storage disorders (LSDs) caused by the accumulation of non-cholesterol lipids.<br /><br /> CDs are sugar molecules in a ring form. The alpha-CD (6 sugars), beta-CD (7 sugars) and gamma-CD (8 sugars) are commonly used cyclodextrins. The hydroxypropyl-beta cyclodextrin (HPbCD) has been approved for pharmaceutical use. Recent reports show that beta-cyclodextrin including HPbCD and beta-methyl-cyclodextrin reduced cholesterol accumulation and neuronal cell loss in the mouse model of NPC1 disease.<br /><br /> NCATS investigators found that CD (alpha-, beta- and gamma-CDs) increased intracellular Ca2+ and lysosomal exocytosis in both wild type cells and cells with Wolman disease, and reduced the size of enlarged lysosomes in six patient cell lines with LSDs. Further, CD in combination with tocopherol synergistically/additively reduced cholesterol accumulation in cells of NPC and Wolman diseases. Based on these results, they propose treatment of LSDs with cyclodextrins (such as alpha and gamma forms) alone or in combination with Vitamin E and its analogues for better efficacy and less side effects. <ul> <li>use of cyclodextrins in combination with vitamin-E (e.g., delta-tocopherol) provides additive therapeutic effect</li> <li>less side effects than cyclodextrin only or vitamin E only for LSDs because of reduced doses for both compounds in combination</li> </ul> <ul> <li>treatment of lysosomal storage diseases</li> <li>treatment of disorders caused by accumulation of non-cholesterol lipids</li> </ul> The National Center for Advancing Translational Sciences is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize this technology. For collaboration opportunities, please contact Dr. Juan Marugan at <a href="mailto:maruganj@mail.nih.gov">maruganj@mail.nih.gov</a>. 2022-03-08 2025-08-13 2025-08-15 2012-11-06 Combination, CYCLODEXTRIN, DISEASES, e, IB6XXX, IBXXXX, IXXXXX, Lysosomal, NB1JXX, NB1XXX, NBXXXX, NXXXXX, Storage, treatment, UA1XXX, USES, Vitamin False True <ul> <li>Early-stage</li> <li>Pre-clinical</li> <li>In vitro data available</li> </ul> True NIHTT 37470483 Website Abstract 114170202 Swaroop M, et al. http://www.ncbi.nlm.nih.gov/pubmed/22923786 <a href="http://www.ncbi.nlm.nih.gov/pubmed/22923786">Swaroop M, et al.</a> 114171172 Xu M, et al. http://www.ncbi.nlm.nih.gov/pubmed/23035117 <a href="http://www.ncbi.nlm.nih.gov/pubmed/23035117">Xu M, et al.</a> 114107690 Zheng, Wei National Human Genome Research Institute (NHGRI) NCATS Zheng, Wei (NCATS) 0 114107692 Xu, Miao National Human Genome Research Institute (NHGRI) NCATS Xu, Miao (NCATS) 0 114107693 Swaroop, Manju National Human Genome Research Institute (NHGRI) NCATS Swaroop, Manju (NCATS) 0 114107694 Marugan, Juan National Human Genome Research Institute (NHGRI) NCATS Marugan, Juan (NCATS) 0 114107691 McKew, John National Human Genome Research Institute (NHGRI) McKew, John 1 114107691 McKew, John National Human Genome Research Institute (NHGRI) McKew, John 1 114107690 Zheng, Wei National Human Genome Research Institute (NHGRI) NCATS Zheng, Wei (NCATS) 0 114107692 Xu, Miao National Human Genome Research Institute (NHGRI) NCATS Xu, Miao (NCATS) 0 114107693 Swaroop, Manju National Human Genome Research Institute (NHGRI) NCATS Swaroop, Manju (NCATS) 0 114107694 Marugan, Juan National Human Genome Research Institute (NHGRI) NCATS Marugan, Juan (NCATS) 0 114101803 Uses Of Cyclodextrin And Cyclodextrin In Combination With Vitamin E For The Treatment Of All Lysosomal Storage Diseases E-050-2012-0 Filing authorized NCATS - NCGC 93911356 Kalsi, Jasmine jasmine.kalsi@nih.gov
United States of America jasmine.kalsi@nih.gov?subject=Web Inquiry on [TAB-2494] Cyclodextrins as Therapeutics for Lysosomal Storage Disorders&body=Please send me information about technology [TAB-2494] Cyclodextrins as Therapeutics for Lysosomal Storage Disorders. Kalsi, Jasmine<br><a href="mailto:jasmine.kalsi@nih.gov?subject=Web Inquiry on [TAB-2494] Cyclodextrins as Therapeutics for Lysosomal Storage Disorders&body=Please send me information about technology [TAB-2494] Cyclodextrins as Therapeutics for Lysosomal Storage Disorders.">jasmine.kalsi@nih.gov</a><br> 114163663 E-050-2012-0 E-050-2012-0-US-08 Cyclodextrin For The Treatment Of All Lysosomal Storage Diseases National Stage US 14/419,471 Abandoned US <br />National Stage 14/419,471<br />Filed on 2015-02-03<br />Status: Abandoned 114166893 E-050-2012-0 E-050-2012-0-US-01 Cyclodextrin For the Treatment of Lysosomal Storage Diseases PRV US 61/679,668 Abandoned US <br />Provisional (PRV) 61/679,668<br />Filed on 2012-08-03<br />Status: Abandoned 114167203 E-050-2012-0 E-050-2012-0-PCT-02 Cyclodextrin For The Treatment Of Lysosomal Storage Diseases PCT Patent Cooperation Treaty PCT/US2013/053527 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2013/053527<br />Filed on 2013-08-03<br />Status: Expired 114168580 E-050-2012-0 E-050-2012-0-US-11 Uses Of Cyclodextrin And Cyclodextrin In Combination With Vitamin E For The Treatment Of All Lysosomal Storage Diseases CON US 11,020,422 15/620,753 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11020422 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11020422">11,020,422</a><br />Filed on 2017-06-12<br />Status: Issued 114122979 UA1XXX 114122980 IB6XXX 114122981 NB1JXX 114122986 IXXXXX 114122987 IBXXXX 114122988 NXXXXX 114122989 NBXXXX 114122990 NB1XXX 114143620 USES 114143621 CYCLODEXTRIN 114143622 Combination 114143623 Vitamin 114143624 e 114143625 treatment 114143626 Lysosomal 114143627 Storage 114143628 DISEASES TAB-2464 114096664 Salen-Manganese Compounds for Therapy of Viral Infections NIAID Collaboration, Infectious Disease, Therapeutics Collaboration Infectious Disease Therapeutics Susan Doctrow, John Kash, Rodney Levine, Jeffery Taubenberger Salen-manganese compounds are synthetic, stable, low toxicity, low cost agents that may provide protection from immune reaction-related oxidative cell damage associated with many illnesses. In particular, oxidative cell damage has been associated with many viral infections including influenza. This invention demonstrates that treating mice with salen-manganese compounds, after lethal pandemic influenza virus infection, significantly enhances survival. Salen-manganese treatment also reduces lung pathology and also improved cellular recovery and repair. Because oxidative damage is observed in many viral infections, administration of salen-manganese compounds may have therapeutic relevance to a wide range of viral infections, in addition influenza. Existing viral therapeutics merely target the infectious viral agent and not the damage caused by the immune system reaction related to infection. Because, salen-manganese treatments target the untapped therapeutic space of infection-induced, immune system-related pathology and have favorable safety and cost profiles, such therapies are ideal candidates for development. <ul> <li>Synthetic, stable, low toxicity, low cost, untapped therapeutic target space.</li> </ul> <ul> <li>Viral therapeutics.</li> </ul> The NIAID Laboratory of Infectious Diseases, Viral Pathogenesis and Evolution Section, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize this technology. For collaboration opportunities, please contact Maryann Puglielli at 240-627-3723. 2022-03-08 2025-08-13 2025-08-15 2012-07-20 Catalase/Superoxide, DB4BXX, DB4XXX, DBXXXX, DISMUTASE, DXXXXX, INFECTIONS, MIMETICS, Synthetic, viral False True <ul> <li>Early-stage</li> <li>Pre-clinical</li> <li>In vivo data available (animal)</li> </ul> True NIHTT 37470483 Website Abstract 114171629 Doctrow SR, et al. Salen Manganese Complexes: Multifunctional Catalytic Antioxidants Protective in Models for Neurodegenerative Diseases of Aging. In: Medicinal Inorganic Chemistry, ACS Symposium Series, Vol. 903, Chapter 18, pp 319-347; August 25, 2005. http://dx.doi.org/10.1021/bk-2005-0903.ch018 <a href="http://dx.doi.org/10.1021/bk-2005-0903.ch018">Doctrow SR, et al. Salen Manganese Complexes: Multifunctional Catalytic Antioxidants Protective in Models for Neurodegenerative Diseases of Aging. In: Medicinal Inorganic Chemistry, ACS Symposium Series, Vol. 903, Chapter 18, pp 319-347; August 25, 2005.</a> 114171630 Schwarz KB. http://www.ncbi.nlm.nih.gov/pubmed/8891667 <a href="http://www.ncbi.nlm.nih.gov/pubmed/8891667">Schwarz KB.</a> 114107623 Taubenberger, Jeffery NIAID - DIR NIAID Taubenberger, Jeffery (NIAID) 0 114107624 Levine, Rodney National Heart, Lung, and Blood Institute (NHLBI) NHLBI Levine, Rodney (NHLBI) 0 114107625 Doctrow, Susan Boston University, School of Medicine Doctrow, Susan 0 114107622 Kash, John NIAID - DIR NIAID Kash, John (NIAID) 1 114107622 Kash, John NIAID - DIR NIAID Kash, John (NIAID) 1 114107623 Taubenberger, Jeffery NIAID - DIR NIAID Taubenberger, Jeffery (NIAID) 0 114107624 Levine, Rodney National Heart, Lung, and Blood Institute (NHLBI) NHLBI Levine, Rodney (NHLBI) 0 114107625 Doctrow, Susan Boston University, School of Medicine Doctrow, Susan 0 114101769 Synthetic Catalase/Superoxide Dismutase Mimetics For Viral Infections E-281-2011-0 Filing authorized Boston University, National Heart, Lung, and Blood Institute (NHLBI), NIAID 91027763 Puglielli, Maryann maryann.puglielli@nih.gov
United States of America maryann.puglielli@nih.gov?subject=Web Inquiry on [TAB-2464] Salen-Manganese Compounds for Therapy of Viral Infections&body=Please send me information about technology [TAB-2464] Salen-Manganese Compounds for Therapy of Viral Infections. Puglielli, Maryann<br><a href="mailto:maryann.puglielli@nih.gov?subject=Web Inquiry on [TAB-2464] Salen-Manganese Compounds for Therapy of Viral Infections&body=Please send me information about technology [TAB-2464] Salen-Manganese Compounds for Therapy of Viral Infections.">maryann.puglielli@nih.gov</a><br> 114165408 E-281-2011-0 E-281-2011-0-PCT-02 Synthetic Catalase/Superoxide Dismutase Mimetics For Viral Infections PCT Patent Cooperation Treaty PCT/US2012/064383 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2012/064383<br />Filed on 2012-11-09<br />Status: Expired 114166822 E-281-2011-0 E-281-2011-0-US-01 Synthetic Catalase/Superoxide Dismutase Mimetics and Methods For Treating Viral Infections PRV US 61/558,137 Abandoned US <br />Provisional (PRV) 61/558,137<br />Filed on 2011-11-10<br />Status: Abandoned 114167832 E-281-2011-0 E-281-2011-0-US-03 SYNTHETIC CATALASE/SUPEROXIDE DISMUTASE MIMETICS AND METHODS FOR TREATING VIRAL INFECTIONS National Stage US 10,683,316 14/357,556 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10683316 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10683316">10,683,316</a><br />Filed on 2014-05-09<br />Status: Issued 114122919 DB4BXX 114122920 DXXXXX 114122921 DBXXXX 114122922 DB4XXX 114143350 Synthetic 114143351 Catalase/Superoxide 114143352 DISMUTASE 114143353 MIMETICS 114143354 viral 114143355 INFECTIONS TAB-243 114094582 Automated Core Biopsy Instrument NIDCD Licensing Licensing Erik Kass The invention is an automated core biopsy instrument that may be operated with one hand. The instrument has a single activation element that causes a stylet to advance into the tissue of interest as a cutting cannula disposed around the stylet is fired to shear off the tissue into specimen notches disposed in the stylet. The invention is constructed so that the stylet and cutting cannula may be separately driven and biased. The cocking mechanism of the automated core biopsy instrument is used to cock both the stylet assembly and cutting cannula assemblies against separate biasing springs. Manipulation of the cocking mechanism permits the exposure of tissue in the specimen notches when desired. The instrument has a locking mechanism that is used to prevent inadvertent firing of the automated core biopsy instrument. 2022-03-08 2025-08-13 2025-08-15 2000-11-01 Do not post -- note in Patent module indicates that rights have been waived to inventor. 6/26/2008 ECR AA2XXX, AAXXXX, AXXXXX False True True NIHTT 37470483 Website Abstract 114103400 Kass, Erik Kass, Erik 0 114103400 Kass, Erik Kass, Erik 0 114099373 Automated Core Biopsy Instrument E-269-2000-0 National Institute on Deafness and Other Communication Disorders (NIDCD) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-243] Automated Core Biopsy Instrument&body=Please send me information about technology [TAB-243] Automated Core Biopsy Instrument. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-243] Automated Core Biopsy Instrument&body=Please send me information about technology [TAB-243] Automated Core Biopsy Instrument.">shmilovm@nih.gov</a><br> 114165792 E-269-2000-0 E-269-2000-0-US-01 Automated Core Biopsy Instrument PRV US 60/233,916 Abandoned US <br />Provisional (PRV) 60/233,916<br />Filed on 2000-09-20<br />Status: Abandoned 114165806 E-269-2000-0 E-269-2000-0-PCT-02 Automated Core Biopsy Instrument And Methods PCT Patent Cooperation Treaty PCT/US2001/042240 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2001/042240<br />Filed on 2001-09-20<br />Status: Expired 114165815 E-269-2000-0 E-269-2000-0-PCT-03 Tissue-Sampling Instrument and Methods of Use PCT Patent Cooperation Treaty PCT/US02/07782 Expired Patent Cooperation Treaty <br />(PCT) PCT/US02/07782<br />Filed on 2002-03-14<br />Status: Expired 114112560 AA2XXX 114112561 AAXXXX 114112562 AXXXXX TAB-2306 114096510 Monoclonal Antibodies Against Poliovirus NIAID Diagnostics, Infectious Disease, Licensing, Research Materials, Therapeutics Diagnostics Infectious Disease Licensing Research Materials Therapeutics Zhaochun Chen, Konstantin Chumakov, Robert Purcell Early work by Hammond at al. showed gamma globulin to be effective for the prevention of poliomyelitis. Therefore, passive immunotherapy could be another way to treat chronic excretors. Even though prior attempts to use intravenous immunoglobulin (IVIG) and breast milk were unsuccessful, there is reason to think that higher doses of antipoliovirus antibodies could result in complete clearance of poliovirus from chronically infected individuals. Six poliovirus-neutralizing MAbs were recovered from a combinatorial Fab phage display library constructed from bone marrow-derived lymphocytes of immunized chimpanzees. The six MAbs neutralized vaccine strains and virulent strains of poliovirus. Five MAbs were serotype specific, while one MAb cross-neutralized serotypes 1 and 2. Both serotype 2-specific antibodies recognized antigenic site 1. No escape mutants to serotype 3-specific MAbs could be generated. The administration of a serotype 1-specific MAb to transgenic mice susceptible to poliovirus at a dose of 5 µg/mouse completely protected them from paralysis after challenge with a lethal dose of wild-type poliovirus. Moreover, MAb injection 6 or 12 h after virus infection provided significant protection. This application claims the antibodies described above and methods for their use. <ul> <li>No humanization required.</li> <li>Highly potent neutralizing antibodies.</li> <li>Biological materials available.</li> </ul> <ul> <li>Prophylaxis/therapeutic for poliovirus.</li> <li>Post-exposure emergency prophylaxis of poliovirus.</li> </ul> Available as Research Tool only - Patent prosecution is no longer being pursued for this technology. 2022-03-08 2025-08-13 2025-08-15 2011-08-12 antibodies, chimeric, Chimpanzee/Human, DA4BXX, DA4XXX, DAXXXX, DB4BXX, DB4XXX, DBXXXX, DDXXXX, DEXXXX, DXXXXX, monoclonal, Neutralize, POLIOVIRUS, Serotypes, That, THREE False True <ul> <li>Pre-clinical</li> <li>In vitro data available</li> <li>In vivo data available (animal)</li> </ul> True NIHTT 37470483 Website Abstract 114171390 Chen Z, et al. http://www.ncbi.nlm.nih.gov/pubmed/21345966 <a href="http://www.ncbi.nlm.nih.gov/pubmed/21345966">Chen Z, et al.</a> 114107268 Chumakov, Konstantin FDA - CBER FDA Chumakov, Konstantin (FDA) 0 114107269 Purcell, Robert NIAID - DIR NIAID Purcell, Robert (NIAID) 0 114107271 Chen, Zhaochun NIAID - DIR NIAID Chen, Zhaochun (NIAID) 1 114107271 Chen, Zhaochun NIAID - DIR NIAID Chen, Zhaochun (NIAID) 1 114107268 Chumakov, Konstantin FDA - CBER FDA Chumakov, Konstantin (FDA) 0 114107269 Purcell, Robert NIAID - DIR NIAID Purcell, Robert (NIAID) 0 114101614 Chimpanzee/human Chimeric Monoclonal Antibodies That Neutralize Three Serotypes Of Poliovirus E-076-2011-0 Filing authorized FDA, NIAID 91027763 Puglielli, Maryann maryann.puglielli@nih.gov
United States of America maryann.puglielli@nih.gov?subject=Web Inquiry on [TAB-2306] Monoclonal Antibodies Against Poliovirus&body=Please send me information about technology [TAB-2306] Monoclonal Antibodies Against Poliovirus. Puglielli, Maryann<br><a href="mailto:maryann.puglielli@nih.gov?subject=Web Inquiry on [TAB-2306] Monoclonal Antibodies Against Poliovirus&body=Please send me information about technology [TAB-2306] Monoclonal Antibodies Against Poliovirus.">maryann.puglielli@nih.gov</a><br> 114166494 E-076-2011-0 E-076-2011-0-US-01 Compositions and Methods for treating Poliovirus PRV US 61/443,915 Abandoned US <br />Provisional (PRV) 61/443,915<br />Filed on 2011-02-17<br />Status: Abandoned 114166659 E-076-2011-0 E-076-2011-0-PCT-02 COMPOSITIONS AND METHODS FOR TREATING POLIOVIRUS PCT Patent Cooperation Treaty PCT/US2012/25571 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2012/25571<br />Filed on 2012-02-17<br />Status: Expired 114122223 DXXXXX 114122224 DBXXXX 114122225 DB4XXX 114122226 DB4BXX 114122227 DAXXXX 114122228 DA4XXX 114122229 DA4BXX 114122230 DDXXXX 114122231 DEXXXX 114141823 Chimpanzee/Human 114141824 chimeric 114141825 monoclonal 114141826 antibodies 114141827 That 114141828 Neutralize 114141829 THREE 114141830 Serotypes 114141831 POLIOVIRUS TAB-2259 114096468 Methods and Devices for Transcatheter Cerclage Annuloplasty NHLBI Collaboration, Licensing Collaboration Licensing Robert Lederman The invention relates to techniques and devices for cardiovascular valve repair, particularly annuloplasty techniques and devices in which tensioning elements are positioned to treat regurgitation of the mitral valve or tricuspid valve. More specifically, the technology pertains to a new device for myocardial septal traversal ("cerclage reentry") that also serves to capture (ensnare) and externalize the traversing guidewire. The focus of the invention is to avoid a phenomenon in cardiac surgery known as "trabecular entrapment." The device features an expandable and collapsible mesh deployed in the right ventricle to simplify capture of a reentering guidewire during transcatheter cerclage annuloplasty. The wire mesh exerts pressure against trabecular-papillary elements of the tricuspid valve to displace them against the right ventricular septal wall. By abutting the right ventricular reentry site of the cercalge guidewire, trabecular entrapment is avoided. The device comprises a shaft having a distal loop which provides a target in the interventrical myocardial septum through which a catheter-delivered tensioning system is guided. The loop ensnares the catheter-delivered tensioning system as it reenters the right ventricle or right atrium. The expandable and collapsible mesh is disposed within the right ventricle such that the catheter-delivered tensioning system is directed from the ventricular septum into the right ventricular cavity through only a suitable opening in the mesh and such that the catheter delivered tensioning system is captured or ensnared within the mesh opening. <ul> <li>The device avoids trabecular entrapment of the cerclage guidewire during septal-perforator-to-right-ventricular myocardial guidewire traversal.</li> <li>The device allows ensnarement of reentering guidewire.</li> <li>The device provides an X-ray target for guidewire reentry from the septal perforator veins.</li> <li>Collapsible transcatheter device that can be introduced from a cephalad (typically transjugular or transaxillary) or caudad (typically transfemoral) approach. </li> <li>The device is intended to allow straightforward removal from the same vascular sheath as the cerclage retrograde traversal guidewire, to allow both free ends of the guidewire to be externalized through the same sheath.</li> </ul> Cardiovascular valve repair surgeries. The National Heart, Lung, and Blood Institute is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. Please contact Peg Koelble at <a href="mailto:koelblep@nhlbi.nih.gov">koelblep@nhlbi.nih.gov</a> for more information. Available for licensing. 2022-03-08 2025-08-13 2025-08-15 2011-05-25 AB3FXX, ABXXXX, Annuloplasty, AXXXXX, CAPTURE, Cerclage, DEVICE, Expandable, Mesh, Patent Category - Mech/Elect/Soft, TARGET, Transcatheter False True <ul> <li>Practical usefulness of the technology has been demonstrated.</li> <li>Preclinical testing of extant prototype is planned.</li> <li>Clinical development is planned.</li> </ul> True NIHTT 37470483 Website Abstract 114171325 Kim JH, et al. Mitral cerelage annuloplasty, a novel transcatheter treatment for secondary mitral valve regurgitation: initial results in swine. J Am Coll Cardiol. 2009 Aug 11;54(7):638-651. http://www.ncbi.nlm.nih.gov/pubmed/19660696 <a href="http://www.ncbi.nlm.nih.gov/pubmed/19660696">Kim JH, et al. Mitral cerelage annuloplasty, a novel transcatheter treatment for secondary mitral valve regurgitation: initial results in swine. J Am Coll Cardiol. 2009 Aug 11;54(7):638-651.</a> 114107178 Lederman, Robert National Heart, Lung, and Blood Institute (NHLBI) NHLBI Lederman, Robert (NHLBI) 1 114107178 Lederman, Robert National Heart, Lung, and Blood Institute (NHLBI) NHLBI Lederman, Robert (NHLBI) 1 114101571 An Expandable Mesh Target And Capture Device For Transcatheter Cerclage Annuloplasty E-108-2010-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-2259] Methods and Devices for Transcatheter Cerclage Annuloplasty&body=Please send me information about technology [TAB-2259] Methods and Devices for Transcatheter Cerclage Annuloplasty. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-2259] Methods and Devices for Transcatheter Cerclage Annuloplasty&body=Please send me information about technology [TAB-2259] Methods and Devices for Transcatheter Cerclage Annuloplasty.">shmilovm@nih.gov</a><br> 114166085 E-108-2010-0 E-108-2010-0-PCT-02 Devices For Transcatheter Cerclage Annuloplasty PCT Patent Cooperation Treaty PCT/US2011/51748 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2011/51748<br />Filed on 2011-09-15<br />Status: Expired 114166431 E-108-2010-0 E-108-2010-0-US-01 Methods and Devices For Transcatheter Cerclage Annuloplasty PRV US 61/383,061 Abandoned US <br />Provisional (PRV) 61/383,061<br />Filed on 2010-09-15<br />Status: Abandoned 114167027 E-108-2010-0 E-108-2010-0-US-04 Methods and Devices for Transcatheter Cerclage Annuloplasty National Stage US 9,579,200 13/824,198 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9579200 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9579200">9,579,200</a><br />Filed on 2013-03-15<br />Status: Issued 114168228 E-108-2010-0 E-108-2010-0-US-05 Methods and Devices for Transcatheter Cerclage Annuloplasty DIV US 10,751,179 15/442,636 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10751179 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10751179">10,751,179</a><br />Filed on 2017-02-25<br />Status: Issued 114122011 AB3FXX 114122012 AXXXXX 114122013 ABXXXX 114141437 Expandable 114141438 Mesh 114141439 TARGET 114141440 CAPTURE 114141441 DEVICE 114141442 Transcatheter 114141443 Cerclage 114141444 Annuloplasty 114141445 Patent Category - Mech/Elect/Soft TAB-2251 114096461 Improved Standard for Immune System Recovery Assay NIAID Diagnostics, Infectious Disease, Licensing, Research Materials Diagnostics Infectious Disease Licensing Research Materials Daniel Douek, Brenna Hill, Richard Koup Monitoring an immune system that has been depleted by infection (e.g., HIV), chemotherapy, or progenitor cell transplantation is vital to assessing individual’s recovery status. This technology provides a new plasmid standard to be used as part of the existing TREC assay. This new plasmid has a shorter insert than the commercially available one, which means it now matches the PCR product generated in the qPCR reaction in the TREC assay. Additionally, the new plasmid is easier to grow up than the existing standard. <ul> <li>The insert of standard plasmid is shorter and directly matches the PCR product generated in the qPCR reaction</li> <li>The standard plasmid is easy to grow up</li> </ul> <ul> <li>TREC assay for T cell concentration measurements</li> </ul> Research Material (TREC DNA in carrier plasmid) — Patent protection is not being pursued for this technology. (IC Reference No. 2010-037) 2022-03-08 2025-08-13 2025-08-15 2011-04-29 Cell, Circles, DAXXXX, DDXXXX, DXXXXX, EXCISION, Humans, MEASURE, OUTPUT, PLASMID, QUANTIFICATION, rearrangement, RECEPTOR, RM, T, THYMIC, TREC, WIXXXX False True Fully developed True NIHTT 37470483 Website Abstract 114171310 Douek DC, et al. http://www.ncbi.nlm.nih.gov/pubmed/9872319 <a href="http://www.ncbi.nlm.nih.gov/pubmed/9872319">Douek DC, et al.</a> 114171311 Douek DC, et al. http://www.ncbi.nlm.nih.gov/pubmed/10866444 <a href="http://www.ncbi.nlm.nih.gov/pubmed/10866444">Douek DC, et al.</a> 114107154 Koup, Richard NIAID - DIR NIAID Koup, Richard (NIAID) 0 114107155 Hill, Brenna NIAID - VRC NCI Hill, Brenna (NCI) 0 114107153 Douek, Daniel NIAID - DIR NIAID Douek, Daniel (NIAID) 1 114107153 Douek, Daniel NIAID - DIR NIAID Douek, Daniel (NIAID) 1 114107154 Koup, Richard NIAID - DIR NIAID Koup, Richard (NIAID) 0 114107155 Hill, Brenna NIAID - VRC NCI Hill, Brenna (NCI) 0 114101563 Quantification Of T Cell Receptor Rearrangement Excision Circles To Measure Thymic Output In Humans E-067-2011-0 Research Material NIAID 148673287 Hafiz, Sabrina sabrina.hafiz@nih.gov
United States of America sabrina.hafiz@nih.gov?subject=Web Inquiry on [TAB-2251] Improved Standard for Immune System Recovery Assay&body=Please send me information about technology [TAB-2251] Improved Standard for Immune System Recovery Assay. Hafiz, Sabrina<br><a href="mailto:sabrina.hafiz@nih.gov?subject=Web Inquiry on [TAB-2251] Improved Standard for Immune System Recovery Assay&body=Please send me information about technology [TAB-2251] Improved Standard for Immune System Recovery Assay.">sabrina.hafiz@nih.gov</a><br> 114121981 DXXXXX 114121982 DAXXXX 114121983 DDXXXX 114127370 WIXXXX 114141373 QUANTIFICATION 114141374 T 114141375 Cell 114141376 RECEPTOR 114141377 rearrangement 114141378 EXCISION 114141379 Circles 114141380 MEASURE 114141381 THYMIC 114141382 OUTPUT 114141383 Humans 114149423 PLASMID 114149424 RM 114149425 TREC TAB-2202 114096417 Pyruvate Kinase M2 Activators for the Treatment of Cancer NCATS Collaboration, Oncology, Therapeutics Collaboration Oncology Therapeutics Douglas Auld, Matthew Boxer, Min Shen, Craig Thomas NIH investigators have discovered a series of small compounds with the potential to treat a variety of cancers as well as hemolytic anemia. Contrary to most cancer medications, these molecules can be non-toxic to normal cells because they target a protein specific to the metabolic pathways in tumors, thus representing a significant clinical advantage over less-specific chemotherapeutics.<br /><br /> The invention described here is a series of small molecules that activate pyruvate kinase (PK) isoform M2. PK-M2 is a critical metabolic enzyme that is affected in all forms of cancer. Inactivation of PK-M2 leads to a buildup of metabolic intermediates inside the cell. Tumor cells require a buildup of metabolic intermediates in order to undergo rapid cell growth and proliferation. Hence, activation of PK-M2 in tumor cells may prevent the buildup of metabolic intermediates and thereby stall tumor cell proliferation or destroy the tumor cells. Further, while in normal post-embryonic cells only PK isoforms R, L, or M1 are active, in all tumors only PK-M2 is active. So, PK-M2 activation would affect only tumor cells, and small-molecule PK-M2 activators may not be toxic to healthy cells.<br /><br /> This invention discloses the use of two new small molecule pharmacophores that can activate PKM2 through the allosteric site: 3-oxo-3,4-dihydro-2H-benzo [b] [1,4] oxazine-7-sulfonamides, and 2-oxo-1,2,3,4-tetrahydroquinoline-6-sulfonamides. <ul> <li>Small molecule (series of analogs can be derived in search of improved performance)</li> <li>Target a select group of cells (Cancerous cells)</li> </ul> <ul> <li>Therapeutic developments for various cancers</li> <li>Diagnostic assays for various cancers</li> <li>Regulation of embryonic stem cell proliferation</li> </ul> The National Center for Advancing Translational Sciences is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize these pyruvate kinase M2 activators. Please contact Dr. Matthew Boxer at <a href="mailto:boxerm@mail.nih.gov">boxerm@mail.nih.gov</a> for more information. 2022-03-08 2025-08-13 2025-08-15 2010-12-08 [1, [b], 2, 2-oxo-1, 3, 3-oxo-3, 4], 4-dihydroquinoline-2H-benzo, 4-tetrahydroquinoline-6-sulfonamides, ACTIVATORS, CB3CXX, CB3XXX, CBXXXX, CXXXXX, Human, Kinase, MOLECULE, Oxazine-7-sulfonamides, Patent Category - Chemistry, PYRUVATE, Small, Substituted False True <ul> <li>Early-stage</li> <li>In vitro data available</li> </ul> True NIHTT 37470483 Website Abstract 114171229 Jiang JK, et al. http://www.ncbi.nlm.nih.gov/pubmed/20451379 <a href="http://www.ncbi.nlm.nih.gov/pubmed/20451379">Jiang JK, et al.</a> 114171230 Boxer MB, et al. http://www.ncbi.nlm.nih.gov/pubmed/20017496 <a href="http://www.ncbi.nlm.nih.gov/pubmed/20017496">Boxer MB, et al.</a> 114107073 Shen, Min National Human Genome Research Institute (NHGRI) NCATS Shen, Min (NCATS) 0 114107074 Thomas, Craig National Human Genome Research Institute (NHGRI) NCATS Thomas, Craig (NCATS) 0 114107075 Auld, Douglas National Human Genome Research Institute (NHGRI) NHGRI Auld, Douglas (NHGRI) 0 114107076 Boxer, Matthew National Human Genome Research Institute (NHGRI) Boxer, Matthew 1 114107076 Boxer, Matthew National Human Genome Research Institute (NHGRI) Boxer, Matthew 1 114107073 Shen, Min National Human Genome Research Institute (NHGRI) NCATS Shen, Min (NCATS) 0 114107074 Thomas, Craig National Human Genome Research Institute (NHGRI) NCATS Thomas, Craig (NCATS) 0 114107075 Auld, Douglas National Human Genome Research Institute (NHGRI) NHGRI Auld, Douglas (NHGRI) 0 114101514 Substituted 3-oxo-3,4-dihydroquinoline-2H-benzo [b] [1,4] Oxazine-7-sulfonamides And 2-oxo-1,2,3,4-tetrahydroquinoline-6-sulfonamides Small Molecule Activators Of Human Pyruvate Kinase E-120-2010-0 Filing authorized NCATS - NCGC 83673536 Erwin-Cohen, Rebecca rebecca.erwin-cohen@nih.gov
NCGC rebecca.erwin-cohen@nih.gov?subject=Web Inquiry on [TAB-2202] Pyruvate Kinase M2 Activators for the Treatment of Cancer&body=Please send me information about technology [TAB-2202] Pyruvate Kinase M2 Activators for the Treatment of Cancer. Erwin-Cohen, Rebecca<br><a href="mailto:rebecca.erwin-cohen@nih.gov?subject=Web Inquiry on [TAB-2202] Pyruvate Kinase M2 Activators for the Treatment of Cancer&body=Please send me information about technology [TAB-2202] Pyruvate Kinase M2 Activators for the Treatment of Cancer.">rebecca.erwin-cohen@nih.gov</a><br> 114162345 E-120-2010-0 E-120-2010-0-PCT-02 Activators Of Human Pyruvate Kinase PCT Patent Cooperation Treaty PCT/US2011/033852 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2011/033852<br />Filed on 2011-04-26<br />Status: Expired 114164120 E-120-2010-0 E-120-2010-0-US-07 Activators Of Human Pyruvate Kinase National Stage US 13/643,594 Abandoned US <br />National Stage 13/643,594<br />Filed on 2012-10-26<br />Status: Abandoned 114166265 E-120-2010-0 E-120-2010-0-US-01 Activators Of Human Pyruvate Kinase PRV US 61/329,158 Abandoned US <br />Provisional (PRV) 61/329,158<br />Filed on 2010-04-29<br />Status: Abandoned 114168095 E-120-2010-0 E-120-2010-0-US-09 Activators Of Human Pyruvate Kinase CON US 9,708,267 14/643,107 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9708267 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9708267">9,708,267</a><br />Filed on 2015-03-10<br />Status: Issued 114121772 CB3CXX 114121773 CXXXXX 114121774 CBXXXX 114121775 CB3XXX 114140938 4-dihydroquinoline-2H-benzo 114140939 3-oxo-3 114140940 Substituted 114140941 [b] 114140942 [1 114140943 4] 114140944 Oxazine-7-sulfonamides 114140945 2-oxo-1 114140946 2 114140947 3 114140948 4-tetrahydroquinoline-6-sulfonamides 114140949 Small 114140950 MOLECULE 114140951 ACTIVATORS 114140952 Human 114140953 PYRUVATE 114140954 Kinase 114140955 Patent Category - Chemistry TAB-2190 114096405 Myosin-Based Protein-Protein Interaction Assay NIDCD Licensing, Materials Available Licensing Materials Available Inna Belyantseva, Erich Boger, Thomas Friedman Investigators at the National Institute on Deafness and Other Communication Disorders (NIDCD) have developed an assay for the detection of protein-protein interactions in living cells. This assay uses readily-available reagents and straightforward techniques that avoid the difficulty of purifying proteins or generating antibodies required for other binding studies. Proof-of-concept for this assay has been demonstrated, and a manuscript is in preparation for publication.<br /><br /> This technology utilizes a molecular motor, myosin X, which migrates along actin filaments within cells. A protein fused to a fragment of myosin X will carry its binding partners to the cell periphery. Since the myosin fusion protein and its partner are labeled with different fluorescent tags, an unambiguous fluorescence overlap will be visible as discrete points along the periphery of the cell. The inventors have designed a number of cDNAs for the construction of fusion proteins appropriate for such an assay.<br /><br /> Available for licensing are a variety of cDNAs which may be used for generating fluorescently-tagged myosin X fusion proteins, for use in the assay described above. Also available are a number of constructs incorporating other fluorescently-tagged myosins, kinesins, myosin and kinesin binding partners and a variety of PDZ scaffold proteins. Further details of the available cDNAs are available upon request. <ul> <li>Assay avoids the need to purify proteins or generate antibodies for binding studies</li> <li>Protein-protein interactions can be unambiguously identified</li> </ul> <ul> <li>Identification of protein-protein binding interactions in living cells</li> <li>DNA-based tools for study of myosins, trafficking, signaling complexes and other research focusing on molecular motors</li> </ul> Research Tool -- patent protection is not being sought for this invention. Available for licensing under a Biological Materials License Agreement. 2022-03-08 2025-08-13 2025-08-15 2010-11-09 [DC-023], [DC-024], [DC-025], [DC-026], [DC-027], [DC-028], [DC-029], 10, AC4XXX, AC5XXX, ACXXXX, assay, AXXXXX, cDNA, cDNAS, chimeric, Cloning, DsRed-tagged, ELEVEN, Flourescent, fluorescent, Fluorescent probe, Fourteen, Fusion, GFP, GFP-Myo, GFP-Myo10, GFP-MyolO, GFP-myosin, GFp-whirlin, GREEN, HEAVY, HMM, INTERACTION, KINESIN, Meromyosin, Mouse, MYOSIN, ONE, Patent Category - Biotechnology, Plasmic, PLASMID, Protein, PROTEIN-PROTEIN, PROTEIN-PROTEIN interactions, SIX, Sixteen, TAGGED, Twenty, Twenty-two, whirlin, X, XVa False True Proof of concept has been demonstrated. True NIHTT 37470483 Website Abstract 114171212 Belyantseva IA et al. Myosin-XVa is required for tip localization of whirlin and differential elongation of hair-cell stereocilia. Nat Cell Biol. 2005 Feb;7(2):148-156. http://www.ncbi.nlm.nih.gov/pubmed/15654330 <a href="http://www.ncbi.nlm.nih.gov/pubmed/15654330">Belyantseva IA et al. Myosin-XVa is required for tip localization of whirlin and differential elongation of hair-cell stereocilia. Nat Cell Biol. 2005 Feb;7(2):148-156.</a> 114107050 Friedman, Thomas National Institute on Deafness and Other Communication Disorders (NIDCD) NIDCD Friedman, Thomas (NIDCD) 0 114107051 Belyantseva, Inna National Institute on Deafness and Other Communication Disorders (NIDCD) NIDCD Belyantseva, Inna (NIDCD) 0 114107047 Boger, Erich National Institute on Deafness and Other Communication Disorders (NIDCD) NIDCD Boger, Erich (NIDCD) 1 114107047 Boger, Erich National Institute on Deafness and Other Communication Disorders (NIDCD) NIDCD Boger, Erich (NIDCD) 1 114107050 Friedman, Thomas National Institute on Deafness and Other Communication Disorders (NIDCD) NIDCD Friedman, Thomas (NIDCD) 0 114107051 Belyantseva, Inna National Institute on Deafness and Other Communication Disorders (NIDCD) NIDCD Belyantseva, Inna (NIDCD) 0 114101494 A Myosin-based Protein Interaction Assay [DC-022] E-069-2009-0 Research Material National Institute on Deafness and Other Communication Disorders (NIDCD) 114101495 Green Fluorescent Protein Tagged Myosin X Heavy Meromyosin (GFP-Myo10 HMM) Cloning Plasmid [DC-023] E-069-2009-1 Research Material National Institute on Deafness and Other Communication Disorders (NIDCD) 114101496 Eleven Chimeric GFP-MyolO HMM Fusion CDNAs [DC-024] E-069-2009-2 Research Material National Institute on Deafness and Other Communication Disorders (NIDCD) 114101497 Fourteen Chimeric GFP-myosin Fusion CDNAs [DC-025] E-069-2009-3 Research Material National Institute on Deafness and Other Communication Disorders (NIDCD) 114101498 Twenty One Green Fluorescent Protein (GFP) Tagged Mouse Myosin And Kinesin CDNAs [DC-026] E-069-2009-4 Research Material National Institute on Deafness and Other Communication Disorders (NIDCD) 114101499 Sixteen DsRed-tagged Mouse CDNAs [DC-027] E-069-2009-5 Research Material National Institute on Deafness and Other Communication Disorders (NIDCD) 114101500 Twenty-two GFP-myosin XVa CDNAs [DC-028] E-069-2009-6 Research Material National Institute on Deafness and Other Communication Disorders (NIDCD) 114101501 Six GFP-whirlin CDNAs [DC-029] E-069-2009-7 Research Material National Institute on Deafness and Other Communication Disorders (NIDCD) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-2190] Myosin-Based Protein-Protein Interaction Assay&body=Please send me information about technology [TAB-2190] Myosin-Based Protein-Protein Interaction Assay. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-2190] Myosin-Based Protein-Protein Interaction Assay&body=Please send me information about technology [TAB-2190] Myosin-Based Protein-Protein Interaction Assay.">shmilovm@nih.gov</a><br> 114121721 ACXXXX 114121722 AC5XXX 114121723 AC4XXX 114121724 AXXXXX 114140759 fluorescent 114140760 KINESIN 114140761 whirlin 114140762 MYOSIN 114140763 cDNA 114140764 PROTEIN-PROTEIN interactions 114140765 Protein 114140766 INTERACTION 114140767 assay 114140768 PROTEIN-PROTEIN 114140769 Patent Category - Biotechnology 114140770 Fluorescent probe 114140771 GREEN 114140772 TAGGED 114140773 X 114140774 HEAVY 114140775 Meromyosin 114140776 GFP-Myo10 114140777 HMM 114140778 Cloning 114140779 PLASMID 114140780 [DC-023] 114140781 Plasmic 114140782 GFP-Myo 114140783 10 114140784 ELEVEN 114140785 chimeric 114140786 GFP-MyolO 114140787 Fusion 114140788 cDNAS 114140789 [DC-024] 114140790 GFP-myosin 114140791 Fourteen 114140792 [DC-025] 114140793 Twenty 114140794 ONE 114140795 Flourescent 114140796 GFP 114140797 Mouse 114140798 [DC-026] 114140799 Sixteen 114140800 DsRed-tagged 114140801 [DC-027] 114140802 Twenty-two 114140803 XVa 114140804 [DC-028] 114140805 SIX 114140806 GFp-whirlin 114140807 [DC-029] TAB-2079 114096296 Caspase Inhibitors Useful for the Study of Autoimmune or Inflammatory Diseases NCATS Collaboration, Diagnostics, Immunology, Licensing, Research Materials, Therapeutics Collaboration Diagnostics Immunology Licensing Research Materials Therapeutics Matthew Boxer, Craig Thomas Novel and potent caspase 1 inhibitors are available for licensing. In particular, this technology discloses potent and selective caspase 1 inhibitors that target the active site of the enzyme. Caspase 1 is known to play a pro-inflammatory role in numerous autoimmune and inflammatory diseases and therefore represents an excellent target for treatment of a broad range of diseases, including but not limited to Huntington's, amyotrophic lateral sclerosis, ischemia, rheumatoid arthritis, osteoarthritis, inflammatory bowel disease, and sepsis. Not surprisingly this enormous potential has resulted in at least three caspase 1 inhibitors entering clinical trials (VX-740, IDN-6556, and VX-765) in recent years. <ul> <li>Potential therapeutic for a broad range of autoimmune diseases</li> <li>Potential therapeutic for a broad range of inflammatory diseases</li> </ul> The NIH Chemical Genomics Center is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize appropriate lead compounds described in U.S. Provisional Application No. 61/299,790. Please contact Dr. Craig J. Thomas via e-mail (<a href="mailto:craigt@nhgri.nih.gov">craigt@nhgri.nih.gov</a>) for more information. Available for licensing. 2022-03-08 2025-08-13 2025-08-15 2010-03-11 1, Amyotrophic lateral sclerosis, Amyotrophic lateral sclerosis 1; Amyotrophic lateral scleros, Amyotrophic lateral sclerosis 6, Caspase, IB3XXX, IBXXXX, Inflammatory bowel disease 1, inhibitor, IXXXXX, Lou Gehrig's disease, Patent Category - Chemistry False True Early stage True NIHTT 37470483 Website Abstract 114171026 Boxer MB, Quinn AM, Shen M, Jadhav A, Leister W, Simeonov A, Auld DS, Thomas CJ. A highly potent and selective caspase 1 inhibitor that utilizes a key 3-cyanopropanoic acid moiety. Chem Med Chem., accepted. Boxer MB, Quinn AM, Shen M, Jadhav A, Leister W, Simeonov A, Auld DS, Thomas CJ. A highly potent and selective caspase 1 inhibitor that utilizes a key 3-cyanopropanoic acid moiety. Chem Med Chem., accepted. 114106836 Boxer, Matthew National Human Genome Research Institute (NHGRI) Boxer, Matthew 0 114106835 Thomas, Craig National Human Genome Research Institute (NHGRI) NCATS Thomas, Craig (NCATS) 1 114106835 Thomas, Craig National Human Genome Research Institute (NHGRI) NCATS Thomas, Craig (NCATS) 1 114106836 Boxer, Matthew National Human Genome Research Institute (NHGRI) Boxer, Matthew 0 114101369 Caspase 1 Inhibitor E-308-2009-0 Filing authorized NCATS - NCGC 93911356 Kalsi, Jasmine jasmine.kalsi@nih.gov
United States of America jasmine.kalsi@nih.gov?subject=Web Inquiry on [TAB-2079] Caspase Inhibitors Useful for the Study of Autoimmune or Inflammatory Diseases&body=Please send me information about technology [TAB-2079] Caspase Inhibitors Useful for the Study of Autoimmune or Inflammatory Diseases. Kalsi, Jasmine<br><a href="mailto:jasmine.kalsi@nih.gov?subject=Web Inquiry on [TAB-2079] Caspase Inhibitors Useful for the Study of Autoimmune or Inflammatory Diseases&body=Please send me information about technology [TAB-2079] Caspase Inhibitors Useful for the Study of Autoimmune or Inflammatory Diseases.">jasmine.kalsi@nih.gov</a><br> 114161877 E-308-2009-0 E-308-2009-0-US-03 Caspase Inhibitors National Stage US 9,365,612 13/575,273 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9365612 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9365612">9,365,612</a><br />Filed on 2012-07-25<br />Status: Issued 114165962 E-308-2009-0 E-308-2009-0-US-01 Caspase 1 Inhibitor PRV US 61/299,790 Abandoned US <br />Provisional (PRV) 61/299,790<br />Filed on 2010-01-29<br />Status: Abandoned 114166304 E-308-2009-0 E-308-2009-0-PCT-02 Caspase Inhibitors PCT Patent Cooperation Treaty PCT/US2011/022744 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2011/022744<br />Filed on 2011-01-27<br />Status: Expired 114120946 IB3XXX 114120947 IXXXXX 114120948 IBXXXX 114139458 Patent Category - Chemistry 114139459 Caspase 114139460 1 114139461 inhibitor 114157015 Amyotrophic lateral sclerosis 6 114157016 Lou Gehrig's disease 114157017 Inflammatory bowel disease 1 114157018 Amyotrophic lateral sclerosis 114158604 Amyotrophic lateral sclerosis 1; Amyotrophic lateral scleros TAB-2053 114096272 Non-Contact Total Emission Detection Methods for Multiphoton Microscopy: Improved Image Fidelity and Biological Sample Analysis NHLBI Collaboration, Consumer Products, Diagnostics, Licensing, Medical Devices, Non-Medical Devices, Research Materials, Software / Apps Collaboration Consumer Products Diagnostics Licensing Medical Devices Non-Medical Devices Research Materials Software / Apps Jay Knutson The technology offered for licensing and for further development is in the field of multiphoton microscopy (MPM). More specifically, the invention pertains to optical designs that can enhance and extend the capabilities of MPM in spectral imaging of biological samples. The unique design of the light collection and the detection optics maximizes the collection of emitted light, thus increasing the signal and hence the signal-to-noise ratio (SNR). Improvement in image fidelity will result in improved analysis of biological samples and thus will favorably impact medical research and possibly clinical diagnosis. The present technology is a further improvement on the TED (Total Emission Detection) technology, first disclosed by Dr. Robert Balaban et al. at the NIH in 2006 and claimed in US Patent 7,667,210 (issued February 23, 2010). The earlier NIH TED technology proposed an optical design based on enveloping the entirety of a small sample in a parabolic mirror/condenser combination so light emanated by a sample in all directions is redirected to the detector. The present technology further expands the capabilities of TED as its unique design employing parabolic, toric and conic mirrors ensures maximum light collection from large samples in cases where there is only access to one side of the tissues (e.g., in vivo or ex vivo). This is accomplished by the redirection of all attainable light (i.e., light escaping the tissue or a whole animal in the epi and sideway directions) to the detector. <ul> <li>Increased signal-to-noise ratio</li> <li>Enhanced image resolution due to SNR</li> <li>Improved analytical capabilities</li> <li>Non-contact</li> <li>May readily be adaptable to commercial microscopes</li> </ul> <ul> <li>Tissue and cell analysis in biomedical research</li> <li>Potential applications in clinical diagnostics</li> </ul> The NHLBI Laboratory of Molecular Biophysics is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize an enhanced method of multiphoton microscopy that is suitable for the spectral imaging of biological samples. Please contact Brian W. Bailey, Ph.D. at <a href="mailto:bbailey@mail.nih.gov">bbailey@mail.nih.gov</a> for more information. 2022-03-08 2025-08-13 2025-08-15 2009-12-28 AC3XXX, ACXXXX, AXXXXX, Detection, Emission, Methods, MICROSCOPY, Multiphoton, NON-CONTACT, Patent Category - Mech/Elect/Soft, TOTAL, WBXXXX, WIXXXX, WMXXXX, XDXXXX, XFXXXX, YBXXXX, YFXXXX False True <ul> <li>In vitro data available</li> <li>Prototype</li> </ul> True 52406769 Prototype 52406769 NIHTT 37470483 Website Abstract E-257-2005-0 114170990 Combs CA, et al. http://www.ncbi.nlm.nih.gov/pubmed/18045327 <a href="http://www.ncbi.nlm.nih.gov/pubmed/18045327">Combs CA, et al.</a> 114170991 Combs CA, et al. http://www.ncbi.nlm.nih.gov/pubmed/24251437 <a href="http://www.ncbi.nlm.nih.gov/pubmed/24251437">Combs CA, et al.</a> 114170992 Combs CA, et al. http://www.ncbi.nlm.nih.gov/pubmed/21118209 <a href="http://www.ncbi.nlm.nih.gov/pubmed/21118209">Combs CA, et al.</a> 114106811 Knutson, Jay National Heart, Lung, and Blood Institute (NHLBI) NHLBI Knutson, Jay (NHLBI) 1 114106811 Knutson, Jay National Heart, Lung, and Blood Institute (NHLBI) NHLBI Knutson, Jay (NHLBI) 1 114101342 Non-contact Total Emission Detection Methods For Multiphoton Microscopy E-236-2009-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 83685986 Crooks, Denise crooksd@mail.nih.gov
United States of America Office of Technology Transfer and Development crooksd@mail.nih.gov?subject=Web Inquiry on [TAB-2053] Non-Contact Total Emission Detection Methods for Multiphoton Microscopy: Improved Image Fidelity and Biological Sample Analysis&body=Please send me information about technology [TAB-2053] Non-Contact Total Emission Detection Methods for Multiphoton Microscopy: Improved Image Fidelity and Biological Sample Analysis. Crooks, Denise<br><a href="mailto:crooksd@mail.nih.gov?subject=Web Inquiry on [TAB-2053] Non-Contact Total Emission Detection Methods for Multiphoton Microscopy: Improved Image Fidelity and Biological Sample Analysis&body=Please send me information about technology [TAB-2053] Non-Contact Total Emission Detection Methods for Multiphoton Microscopy: Improved Image Fidelity and Biological Sample Analysis.">crooksd@mail.nih.gov</a><br> 114161313 E-236-2009-0 E-236-2009-0-PCT-02 Emission Detection Methods For Multiphoton Microscopy PCT Patent Cooperation Treaty PCT/US2010/041723 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2010/041723<br />Filed on 2010-07-12<br />Status: Expired 114161622 E-236-2009-0 E-236-2009-0-US-01 Non-contact Total Emission Detection Methods For Multiphoton Microscopy PRV US 61/224,772 Abandoned US <br />Provisional (PRV) 61/224,772<br />Filed on 2009-07-10<br />Status: Abandoned 114166615 E-236-2009-0 E-236-2009-0-US-03 Non-contact Total Emission Detection Methods and System For Multi-photon Microscopy National Stage US 8,759,792 13/383,248 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8759792 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8759792">8,759,792</a><br />Filed on 2010-07-12<br />Status: Issued 114120795 AC3XXX 114120796 AXXXXX 114120797 ACXXXX 114122985 WBXXXX 114126317 WIXXXX 114126318 WMXXXX 114126319 XDXXXX 114126320 XFXXXX 114126321 YBXXXX 114126322 YFXXXX 114139152 NON-CONTACT 114139153 TOTAL 114139154 Emission 114139155 Detection 114139156 Methods 114139157 Multiphoton 114139158 MICROSCOPY 114139159 Patent Category - Mech/Elect/Soft TAB-2006 114096226 Monoclonal Antibodies That React With the Capsule of <i>Bacillus anthracis</i> NIAID Collaboration, Diagnostics, Infectious Disease, Licensing, Research Materials, Therapeutics, Vaccines Collaboration Diagnostics Infectious Disease Licensing Research Materials Therapeutics Vaccines Zhaochun Chen, Lily Zhongdong Dai, Joanna Kubler-kielb, Robert Purcell, Rachel Schneerson <i>Bacillus anthracis</i> is the causative agent of anthrax and is surrounded by a polypeptide capsule of poly-gamma-D-glutamic acid (gammaDPGA). gammaDPGA is poorly immunogenic and has antiphagocytic properties. The bacterial capsule is essential for virulence. Antibodies to the capsule have been shown to enhance phagocytosis and killing of encapsulated bacilli. These antibodies in combination with antibodies that neutralize the toxins of <i>B. anthracis</i> could provide enhanced protection by their dual antibacterial and antitoxic activities. Such antibodies would be especially useful for antibiotic-resistant strains.<br><br> In order to obtain therapeutically useful anti-gamma DPGA monoclonal antibodies (MAbs), the inventors immunized chimpanzees with conjugates of 15-mer glutamic acid polymers to immunogenic protein carriers (recombinant protective antigen (PA) of <i>B. anthracis</i>). After several immunizations, chimpanzees developed strong immune responses to gammaDPGA. A combinatorial Fab library of mRNA derived from the chimpanzee's bone marrow was prepared and eight (8) distinct Fabs reactive with native gammaDPGA were recovered. Two (2) of the Fabs were converted into full-length IgG with human gamma1 heavy chain constant regions. These two (2) MAbs showed strong opsonophagocytic killing of bacilli in an <i>in vitro</i> assay. These two (2) MAbs were also tested for protection of mice challenged with virulent anthrax spores and results showed that both MAbs provided full or nearly full protection at a dose of 0.3 mg, the lowest dose tested, which is much more potent than previously reported murine anti-PGA MAbs. Since chimpanzee immunoglobulins are virtually identical to human immunoglobulins, these chimpanzee anticapsule MAbs may have clinically useful applications.<br><br> This application claims the antibody compositions described above. Also claimed are methods of treating or preventing <i>B. anthracis</i> infection in a mammalian host and isolated polynucleotides comprising a nucleotide sequence encoding the antibodies of the technology. Strongly neutralizing antibodies, known regulatory pathway, potential for use as both a prophylaxis and therapy. Development of anthrax vaccines, therapeutics and diagnostics. The NIAID is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize MAbs neutralizing anthrax toxins and capsule for comprehensive protection against anthrax. Please contact Bill Ronnenberg, NIAID Office of Technology Development, at 301-451-3522 for more information. Available for licensing. 2022-03-08 2025-08-13 2025-08-15 2009-08-31 Anthracis, Anthrax, antibodies, Autoimmune polyendocrinopathy syndrome, type 1, Bacillus, Capsule, chimeric, Chimpanzee/Human, DA3XXX, DAXXXX, DB3XXX, DBXXXX, DC4XXX, DCXXXX, DDXXXX, DXXXXX, KILL, monoclonal, Opsonophagocytosis, ORGANISM, Patent Category - Biotechnology, PGA 1, PGA 2, REACT, Schmidt syndrome, That False True Preclinical studies have been performed utilizing the monoclonal antibodies of this technology. True NIHTT 37470483 Website Abstract 114106728 Purcell, Robert NIAID - DIR NIAID Purcell, Robert (NIAID) 0 114106729 Schneerson, Rachel NICHD NICHD Schneerson, Rachel (NICHD) 0 114106730 Kubler-kielb, Joanna NICHD NICHD Kubler-kielb, Joanna (NICHD) 0 114106731 Dai, Lily Zhongdong NICHD Dai, Lily Zhongdong 0 114106727 Chen, Zhaochun NIAID - DIR NIAID Chen, Zhaochun (NIAID) 1 114106727 Chen, Zhaochun NIAID - DIR NIAID Chen, Zhaochun (NIAID) 1 114106728 Purcell, Robert NIAID - DIR NIAID Purcell, Robert (NIAID) 0 114106729 Schneerson, Rachel NICHD NICHD Schneerson, Rachel (NICHD) 0 114106730 Kubler-kielb, Joanna NICHD NICHD Kubler-kielb, Joanna (NICHD) 0 114106731 Dai, Lily Zhongdong NICHD Dai, Lily Zhongdong 0 114101290 Chimpanzee/Human Chimeric Monoclonal Antibodies That React With The Capsule Of Bacillus Anthracis And Kill The Organism By Opsonophagocytosis. E-125-2008-0 Filing authorized NIAID, NICHD 91027763 Puglielli, Maryann maryann.puglielli@nih.gov
United States of America maryann.puglielli@nih.gov?subject=Web Inquiry on [TAB-2006] Monoclonal Antibodies That React With the Capsule of <i>Bacillus anthracis</i>&body=Please send me information about technology [TAB-2006] Monoclonal Antibodies That React With the Capsule of <i>Bacillus anthracis</i>. Puglielli, Maryann<br><a href="mailto:maryann.puglielli@nih.gov?subject=Web Inquiry on [TAB-2006] Monoclonal Antibodies That React With the Capsule of <i>Bacillus anthracis</i>&body=Please send me information about technology [TAB-2006] Monoclonal Antibodies That React With the Capsule of <i>Bacillus anthracis</i>.">maryann.puglielli@nih.gov</a><br> 114162647 E-125-2008-0 E-125-2008-0-US-05 MONOCLONAL ANTIBODIES THAT REACT WITH THE CAPSULE OF BACILLUS ANTHRACIS DIV US 9,845,350 15/003,719 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9845350 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9845350">9,845,350</a><br />Filed on 2016-01-21<br />Status: Abandoned 114165457 E-125-2008-0 E-125-2008-0-US-01 MONOCLONAL ANTIBODIES THAT REACT WITH THE CAPSULE OF BACILLUS ANTHRACIS PRV US 61/116,222 Abandoned US <br />Provisional (PRV) 61/116,222<br />Filed on 2008-11-19<br />Status: Abandoned 114165675 E-125-2008-0 E-125-2008-0-PCT-02 Monoclonal Antibodies That React With The Capsule Of Bacillus Anthracis PCT Patent Cooperation Treaty PCT/US2009/065198 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2009/065198<br />Filed on 2009-11-19<br />Status: Expired 114166429 E-125-2008-0 E-125-2008-0-US-03 Monoclonal Antibodies That React With The Capsule Of Bacillus Anthracis National Stage US 8,501,182 13/130,044 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8501182 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8501182">8,501,182</a><br />Filed on 2011-05-18<br />Status: Abandoned 114167157 E-125-2008-0 E-125-2008-0-US-04 MONOCLONAL ANTIBODIES THAT REACT WITH THE CAPSULE OF BACILLUS ANTHRACIS CON US 9,273,124 13/935,956 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9273124 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9273124">9,273,124</a><br />Filed on 2013-07-05<br />Status: Abandoned 114120565 DXXXXX 114120566 DB3XXX 114120567 DBXXXX 114120568 DA3XXX 114120569 DCXXXX 114120570 DC4XXX 114120571 DDXXXX 114120572 DAXXXX 114138546 Chimpanzee/Human 114138547 Opsonophagocytosis 114138548 monoclonal 114138549 antibodies 114138550 That 114138551 REACT 114138552 Capsule 114138553 Bacillus 114138554 Anthracis 114138555 KILL 114138556 ORGANISM 114138557 chimeric 114138558 Patent Category - Biotechnology 114156876 Autoimmune polyendocrinopathy syndrome, type 1 114156877 Anthrax 114156878 Schmidt syndrome 114158524 PGA 1 114158525 PGA 2 TAB-2005 114096225 Antigenic Chimeric Tick-Borne Encephalitis Virus/Dengue Virus Type 4 Recombinant Viruses NIAID Collaboration, Diagnostics, Infectious Disease, Research Materials, Vaccines Collaboration Diagnostics Infectious Disease Research Materials Vaccines Amber Engel, Brian Murphy, Alexander Pletnev The tick-borne encephalitis virus (TBEV) complex is a group of viruses that can cause severe neutrotropic disease and up to thirty percent (30%) mortality. While these viruses can be found in many parts of the world, the largest impact of the disease occurs in Europe and Russia, where approximately fourteen thousand (14,000) hospitalized TBEV cases occur annually. TBEV is in the family Flaviviridae, genus flavivirus and is composed of a positive-sense single stranded RNA genome that contains 5' and 3' non-coding regions and a single open reading frame encoding ten (10) proteins. At present, a vaccine or FDA approved antiviral therapy is not available.<br /><br /> The inventors have previously developed a WNV/Dengue4Delta30 antigenic chimeric virus as a live attenuated virus vaccine candidate that contains the WNV premembrane and envelope (prM and E) proteins on a dengue virus type 4 (DEN4) genetic background with a thirty nucleotide deletion (Delta30) in the DEN4 3'-UTR. Using a similar strategy, the inventors have generated an antigenic chimeric virus, TBEV/DEN4Delta30. This chimeric virus also contains attenuating mutations within the E and nonstructural NS5 proteins. Preclinical testing results with the derived virus indicate that chimerization of TBEV with DEN4Delta30 and introduction of the attenuating mutations decreased neuroinvasiveness and neurovirulence in mice. The TBEV/DEN4delta30 vaccine candidate was safe, immunogenic, and provided protection in monkeys against challenge with TBE viruses.<br /><br /> This application claims live attenuated chimeric TBEV/DEN4Delta30 vaccine compositions. Also claimed are methods of treating or preventing TBEV infection in a mammalian host, methods of producing a subunit vaccine composition, isolated polynucleotides comprising a nucleotide sequence encoding a TBEV immunogen, methods for detecting TBEV infection in a biological sample and infectious chimeric TBEV. Live attenuated chimeric vaccine, known regulatory pathway, potential for lasting immunity with fewer doses. Development of Tick-Borne Encephalitis Virus vaccines, therapeutics and diagnostics. The NIAID is seeking statements of capability or interest from parties interested in collaborative research in preclinical study of the long-term immunity induced by the TBEV/DEN4 vaccine candidate against highly virulent TBE viruses and in the clinical trials of this vaccine in humans. Please contact Maryann Puglielli, NIAID Office of Technology Development, at 301-496-2644 for more information. 2022-03-08 2025-08-13 2025-08-15 2009-08-31 4, ANTIGENIC, CANDIDATES, CAUSED, chimeric, Chromosome 7, monosomy, DA4BXX, DA4XXX, DAXXXX, DC5BXX, DC5XXX, DCXXXX, DDXXXX, Deletion 7, Dengue (Flaviviridae), Development, Disease, DXXXXX, ENCEPHALITIS, Patent Category - Biotechnology, Prevention, recombinant, TBEV, TBEV/DEN4, TICK-BORNE, Tick-borne encephalitis, TYPE, Vaccine, virus, Virus/dengue, Viruses False True Vaccine candidates have been synthesized and preclinical studies have been performed. True NIHTT 37470483 Website Abstract 114106725 Murphy, Brian NIAID - DIR NIAID Murphy, Brian (NIAID) 0 114106726 Engel, Amber NIAID - DIR NIAID Engel, Amber (NIAID) 0 114106724 Pletnev, Alexander NIAID - DIR NIAID Pletnev, Alexander (NIAID) 1 114106724 Pletnev, Alexander NIAID - DIR NIAID Pletnev, Alexander (NIAID) 1 114106725 Murphy, Brian NIAID - DIR NIAID Murphy, Brian (NIAID) 0 114106726 Engel, Amber NIAID - DIR NIAID Engel, Amber (NIAID) 0 114101289 Development Of Antigenic Chimeric Tick-borne Encephalitis Virus/dengue Virus Type 4 Recombinant Viruses (TBEV/DEN4) As Vaccine Candidates For The Prevention Of Disease Caused By TBEV E-078-2009-0 Filing authorized NIAID 91027763 Puglielli, Maryann maryann.puglielli@nih.gov
United States of America maryann.puglielli@nih.gov?subject=Web Inquiry on [TAB-2005] Antigenic Chimeric Tick-Borne Encephalitis Virus/Dengue Virus Type 4 Recombinant Viruses&body=Please send me information about technology [TAB-2005] Antigenic Chimeric Tick-Borne Encephalitis Virus/Dengue Virus Type 4 Recombinant Viruses. Puglielli, Maryann<br><a href="mailto:maryann.puglielli@nih.gov?subject=Web Inquiry on [TAB-2005] Antigenic Chimeric Tick-Borne Encephalitis Virus/Dengue Virus Type 4 Recombinant Viruses&body=Please send me information about technology [TAB-2005] Antigenic Chimeric Tick-Borne Encephalitis Virus/Dengue Virus Type 4 Recombinant Viruses.">maryann.puglielli@nih.gov</a><br> 114161787 E-078-2009-0 E-078-2009-0-US-04 Antigenic Chimeric Tick-Borne Encephalitis Virus/Dengue Virus Type 4 Recombinant Viruses National Stage US 8,568,739 13/322,317 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8568739 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8568739">8,568,739</a><br />Filed on 2011-11-23<br />Status: Abandoned 114165456 E-078-2009-0 E-078-2009-0-PCT-02 Antigenic Chimeric Tick-borne Encephalitis Virus/dengue Virus Type 4 Recombinant Viruses (TBEV/DEN4) PCT Patent Cooperation Treaty PCT/US2010/036678 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2010/036678<br />Filed on 2010-05-28<br />Status: Expired 114166070 E-078-2009-0 E-078-2009-0-US-01 Development Of Antigenic Chimeric Tick-borne Encephalitis Virus/dengue Virus Type 4 Recombinant Viruses (TBEV/DEN4) As Vaccine Candidates For The Prevention Of Disease Caused By TBEV PRV US 61/181,982 Abandoned US <br />Provisional (PRV) 61/181,982<br />Filed on 2009-05-28<br />Status: Abandoned 114167234 E-078-2009-0 E-078-2009-0-US-05 ANTIGENIC CHIMERIC TICK-BORNE ENCEPHALITIS VIRUS/DENGUE VIRUS TYPE 4 RECOMBINANT VIRUSES DIV US 9,238,799 14/014,920 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9238799 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9238799">9,238,799</a><br />Filed on 2013-08-30<br />Status: Abandoned 114120557 DXXXXX 114120558 DCXXXX 114120559 DC5XXX 114120560 DC5BXX 114120561 DDXXXX 114120562 DAXXXX 114120563 DA4XXX 114120564 DA4BXX 114138527 Development 114138528 ANTIGENIC 114138529 chimeric 114138530 TICK-BORNE 114138531 ENCEPHALITIS 114138532 Virus/dengue 114138533 virus 114138534 TYPE 114138535 4 114138536 recombinant 114138537 Viruses 114138538 TBEV/DEN4 114138539 Vaccine 114138540 CANDIDATES 114138541 Prevention 114138542 Disease 114138543 CAUSED 114138544 TBEV 114138545 Patent Category - Biotechnology 114156874 Chromosome 7, monosomy 114156875 Tick-borne encephalitis 114157917 Dengue (Flaviviridae) 114158523 Deletion 7 TAB-1978 114096198 A Locking Device for Permanently Securing Surgical Suture Loops NHLBI Collaboration, Licensing Collaboration Licensing Ozgur Kocaturk This technology relates to a device that can be used to non-invasively secure surgical suture loops when combined with a percutaneous delivery system. It has been shown to be effective in correcting mitral valve regurgitation (MVR) in an animal model. During the procedure, a guidewire is percutaneously conveyed to the atrium of the heart and is used to secure the "cerclage" suture encircling the mitral valve annulus, which is delivered using a delivery catheter. The locking device is advanced over the suture by the delivery catheter and it permanently secures the suture and maintains the tension on the annulus once the delivery system is removed. This locking device, in combination with the percutaneous procedure, allows for more complete coaptation of the valve leaflets and correction of MVR without the need for open heart surgery and its associated risks. The locking device is also adjustable, allowing the user to vary the tension on the suture if further tightening or loosening is required. It is also MRI compatible and all follow-up studies can be performed under MRI. <br><br> This invention has demonstrated its ability to correct MVR in animals where the locking device was observed to maintain the correct position and tension after implantation. This device has the potential to replace the traditional loop and knot method used for surgical correction of MVR, and may also be useful for other conditions that require permanently secured suture loops. <ul> <li>Technology amenable to a non-invasive technique</li> </li>Control of tension on surgical sutures</li> </ul> <ul> <li>Non-invasive and effective correction of MVR and other conditions</li> <li>Tensioning device for securing suture loops</li> </ul> The National Heart Lung and Blood Institute Cardiac Catheterization Lab is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize the tension fixation device. Please contact Peg Koelble at 301-594-4095 or <a href="mailto:koelblep@nhlbi.nih.gov">koelblep@nhlbi.nih.gov</a> for more information. Available for licensing. 2022-03-08 2025-08-13 2025-08-15 2009-07-02 AB3XXX, ABXXXX, AXXXXX, Cerclage, Delivery, DEVICE, Locking, Patent Category - Mech/Elect/Soft, System False True Early stage True NIHTT 37470483 Website Abstract 114106669 Kocaturk, Ozgur National Heart, Lung, and Blood Institute (NHLBI) NHLBI Kocaturk, Ozgur (NHLBI) 1 114106669 Kocaturk, Ozgur National Heart, Lung, and Blood Institute (NHLBI) NHLBI Kocaturk, Ozgur (NHLBI) 1 114101248 Cerclage Locking Device And Delivery System E-048-2009-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-1978] A Locking Device for Permanently Securing Surgical Suture Loops&body=Please send me information about technology [TAB-1978] A Locking Device for Permanently Securing Surgical Suture Loops. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-1978] A Locking Device for Permanently Securing Surgical Suture Loops&body=Please send me information about technology [TAB-1978] A Locking Device for Permanently Securing Surgical Suture Loops.">shmilovm@nih.gov</a><br> 114161465 E-048-2009-0 E-048-2009-0-US-01 Cerclage Locking Device And Delivery System PRV US 61/157,267 Abandoned US <br />Provisional (PRV) 61/157,267<br />Filed on 2009-03-04<br />Status: Abandoned 114165471 E-048-2009-0 E-048-2009-0-US-04 Tensioning Device and Methods for Use DIV US 10,285,813 14/956,238 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10285813 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10285813">10,285,813</a><br />Filed on 2015-12-01<br />Status: Issued 114165961 E-048-2009-0 E-048-2009-0-PCT-02 Cerclage Locking Device And Delivery System PCT Patent Cooperation Treaty PCT/US2010/026245 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2010/026245<br />Filed on 2010-03-04<br />Status: Expired 114166090 E-048-2009-0 E-048-2009-0-US-03 Tensioning Device And Methods For Use National Stage US 13/254,160 Abandoned US <br />National Stage 13/254,160<br />Filed on 2011-08-31<br />Status: Abandoned 114120370 AXXXXX 114120371 AB3XXX 114120372 ABXXXX 114138101 Cerclage 114138102 Locking 114138103 DEVICE 114138104 Delivery 114138105 System 114138106 Patent Category - Mech/Elect/Soft TAB-1935 114096156 Genetic Mutations Associated with Stuttering NIDCD Diagnostics, Licensing, Reproductive Health, Research Materials, Therapeutics, Vaccines Diagnostics Licensing Reproductive Health Research Materials Therapeutics Vaccines Dennis Drayna, Changsoo Kang NIH investigators, for the first time, identified specific mutations associated with stuttering. These mutations are located within the genes encoding three enzymes, Glc-NAc phosphotransferase catalytic subunit [GNPTAB], Glc-NAc phosphotransferase recognition subunit [GNPTG], and N-acetylglucosamine-1-phosphodiester alpha-N-acetylglucosaminidase [NAGPA]. Together these constitute the pathway that targets lysosomal enzymes to their proper location. This pathway is associated with lysosomal storage disorders, and thereby this discovery provides potential novel therapeutic targets for amelioration of stuttering. This discovery has the potential to facilitate DNA-based (micro-array) testing among individuals who stutter, as well as enzyme-replacement therapy and small-molecule chaperone therapy for treatment of stuttering. The mutations described in this invention may account for up to 5-10% of this disorder in individuals who stutter, estimated to represent 60,000-120,000 individuals in the United States. <ul> <li>Genetic diagnosis of stuttering disorder</li> <li>Therapeutics for stuttering disorder</li> </ul> Available for licensing. 2022-03-08 2025-08-13 2025-08-15 2009-05-05 diagnostic, GNPTAB, GNPTG, IAXXXX, IB6XXX, IBXXXX, IXXXXX, NAGPA, Patent Category - Biotechnology, Stuttering, therapeutic, USES False True Early stage True NIHTT 37470483 Website Abstract 114106592 Kang, Changsoo National Institute on Deafness and Other Communication Disorders (NIDCD) Kang, Changsoo 0 114106591 Drayna, Dennis National Institute on Deafness and Other Communication Disorders (NIDCD) NIDCD Drayna, Dennis (NIDCD) 1 114106591 Drayna, Dennis National Institute on Deafness and Other Communication Disorders (NIDCD) NIDCD Drayna, Dennis (NIDCD) 1 114106592 Kang, Changsoo National Institute on Deafness and Other Communication Disorders (NIDCD) Kang, Changsoo 0 114101208 Diagnostic And Therapeutic Uses Of GNPTAB, GNPTG, And NAGPA In Stuttering E-084-2009-0 Filing authorized National Institute on Deafness and Other Communication Disorders (NIDCD), University of Punjab 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-1935] Genetic Mutations Associated with Stuttering&body=Please send me information about technology [TAB-1935] Genetic Mutations Associated with Stuttering. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-1935] Genetic Mutations Associated with Stuttering&body=Please send me information about technology [TAB-1935] Genetic Mutations Associated with Stuttering.">shmilovm@nih.gov</a><br> 114165158 E-084-2009-0 E-084-2009-0-US-01 Diagnostic And Therapeutic Uses Of GNPTAB, GNPTG, And NAGPA In Stuttering PRV US 61/150,954 Abandoned US <br />Provisional (PRV) 61/150,954<br />Filed on 2009-02-09<br />Status: Abandoned 114165747 E-084-2009-0 E-084-2009-0-PCT-02 Diagnostic And Therapeutic Uses Of GNPTAB, GNPTG, And NAGPA In Stuttering PCT Patent Cooperation Treaty PCT/US10/23437 Expired Patent Cooperation Treaty <br />(PCT) PCT/US10/23437<br />Filed on 2010-02-08<br />Status: Expired 114166497 E-084-2009-0 E-084-2009-0-US-03 Diagnostic And Therapeutic Uses Of GNPTAB, GNPTG, And NAGPA In Stuttering National Stage US 8,530,167 13/148,340 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8530167 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8530167">8,530,167</a><br />Filed on 2011-08-31<br />Status: Issued 114120148 IB6XXX 114120149 IAXXXX 114120150 IXXXXX 114120151 IBXXXX 114137612 diagnostic 114137613 therapeutic 114137614 USES 114137615 GNPTAB 114137616 GNPTG 114137617 NAGPA 114137618 Stuttering 114137619 Patent Category - Biotechnology TAB-1930 114096151 Small Molecule Activators of Human Pyruvate Kinase for Treatment of Cancer and Enzyme-Deficient Hemolytic Anemia NCATS Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Craig Thomas NIH investigators have discovered a series of small compounds with the potential to treat a variety of cancers as well as hemolytic anemia. Contrary to most cancer medications, these molecules can be non-toxic to normal cells because they target a protein specific to the metabolic pathways in tumors, thus representing a significant clinical advantage over less-specific chemotherapeutics. <br><br> The invention described here is a series of small molecules that activate pyruvate kinase (PK) isoform M2. PK-M2 is a critical metabolic enzyme that is affected in all forms of cancer. Inactivation of PK-M2 leads to a buildup of metabolic intermediates inside the cell. Tumor cells require a buildup of metabolic intermediates in order to undergo rapid cell growth and proliferation. Hence, activation of PK-M2 in tumor cells may prevent the buildup of metabolic intermediates and thereby stall tumor cell proliferation or destroy the tumor cells. Further, while in normal adult cells only PK isoforms R, L, or M1 are active, in all tumors only PK-M2 is active. Therefore, PK-M2 activation would affect only tumor cells, and small-molecule PK-M2 activators are not expected to be toxic to healthy cells. <br><br> In addition, in patients with PK-R deficiency the buildup of metabolic intermediates in red blood cells ultimately leads to the loss of water from the cells and cell death. Small-molecule induced activation of PK-R in PK-deficient red blood cells may enhance vitality of these cells and decrease or eliminate enzyme-deficient hemolytic anemia in a patient. <ul> <li>Therapeutic for cancer</li> <li>Therapeutic for enzyme-deficient hemolytic anemia</li> </ul> The NIH Chemical Genomics Center is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize appropriate lead compounds described in U.S. Provisional Application No. 61/199,763. Please contact Dr. Craig J. Thomas via e-mail (<a href="mailto:craigt@nhgri.nih.gov">craigt@nhgri.nih.gov</a>) for more information. Available for licensing. 2022-03-08 2025-08-13 2025-08-15 2009-05-05 3-@hydroxyacyl-coa dehydrogenase deficiency, ACTIVATORS, CB3CXX, CB3XXX, CBXXXX, CXXXXX, HAD deficiency, HIS deficiency, Histidinemia, Human, Kinase, MOLECULE, Patent Category - Chemistry, PYRUVATE, Small False True Early stage True NIHTT 37470483 Website Abstract 114170807 In preparation In preparation 114106578 Thomas, Craig National Human Genome Research Institute (NHGRI) NCATS Thomas, Craig (NCATS) 1 114106578 Thomas, Craig National Human Genome Research Institute (NHGRI) NCATS Thomas, Craig (NCATS) 1 114101203 Small Molecule Activators Of Human Pyruvate Kinase E-326-2008-0 Filing authorized NCATS - NCGC 83673536 Erwin-Cohen, Rebecca rebecca.erwin-cohen@nih.gov
NCGC rebecca.erwin-cohen@nih.gov?subject=Web Inquiry on [TAB-1930] Small Molecule Activators of Human Pyruvate Kinase for Treatment of Cancer and Enzyme-Deficient Hemolytic Anemia&body=Please send me information about technology [TAB-1930] Small Molecule Activators of Human Pyruvate Kinase for Treatment of Cancer and Enzyme-Deficient Hemolytic Anemia. Erwin-Cohen, Rebecca<br><a href="mailto:rebecca.erwin-cohen@nih.gov?subject=Web Inquiry on [TAB-1930] Small Molecule Activators of Human Pyruvate Kinase for Treatment of Cancer and Enzyme-Deficient Hemolytic Anemia&body=Please send me information about technology [TAB-1930] Small Molecule Activators of Human Pyruvate Kinase for Treatment of Cancer and Enzyme-Deficient Hemolytic Anemia.">rebecca.erwin-cohen@nih.gov</a><br> 114165153 E-326-2008-0 E-326-2008-0-US-01 Activators of Human Pyruvate Kinase PRV US 61/104,091 Abandoned US <br />Provisional (PRV) 61/104,091<br />Filed on 2008-10-09<br />Status: Abandoned 114165624 E-326-2008-0 E-326-2008-0-PCT-02 Activators Of Human Pyruvate Kinase PCT Patent Cooperation Treaty PCT/US2009/060237 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2009/060237<br />Filed on 2009-10-09<br />Status: Expired 114166388 E-326-2008-0 E-326-2008-0-US-07 Activators Of Human Pyruvate Kinase M2 Receptor CON US 8,841,305 13/123,297 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8841305 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8841305">8,841,305</a><br />Filed on 2011-04-25<br />Status: Issued 114166695 E-326-2008-0 E-326-2008-0-US-08 Activators Of Human Pyruvate Kinase CON US 8,937,067 13/433,656 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8937067 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8937067">8,937,067</a><br />Filed on 2012-03-29<br />Status: Issued 114167103 E-326-2008-0 E-326-2008-0-US-11 Activators Of Human Pyruvate Kinase CON US 9,707,230 15/076,258 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9707230 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9707230">9,707,230</a><br />Filed on 2016-03-21<br />Status: Issued 114168036 E-326-2008-0 E-326-2008-0-US-10 Activators Of Human Pyruvate Kinase DIV US 9,290,512 14/576,333 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9290512 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9290512">9,290,512</a><br />Filed on 2014-12-19<br />Status: Issued 114120140 CB3CXX 114120141 CXXXXX 114120142 CBXXXX 114120143 CB3XXX 114137595 Small 114137596 MOLECULE 114137597 ACTIVATORS 114137598 Human 114137599 PYRUVATE 114137600 Kinase 114137601 Patent Category - Chemistry 114156780 3-@hydroxyacyl-coa dehydrogenase deficiency 114156781 Histidinemia 114158487 HAD deficiency 114158488 HIS deficiency TAB-1887 114096108 Humanized Monoclonal Antibodies that Specifically Bind Japanese Encephalitis Virus (JEV) and Their Use NIAID Collaboration, Diagnostics, Infectious Disease, Licensing, Research Materials, Therapeutics, Vaccines Collaboration Diagnostics Infectious Disease Licensing Research Materials Therapeutics Vaccines Ana Goncalvez, Ching-juh Lai, Robert Purcell Japanese encephalitis virus (JEV) is the prototype virus of the Japanese encephalitis (JE) group belonging to the Flavivirus genus of the Flaviviridae family. Other members of the group include Kunjin virus, St. Louis encephalitis virus, and West Nile encephalitis virus (WNV). JEV is widely distributed in South Asia, Southeast Asia, and the Asian Pacific Rim. In recent years, JE epidemics have spread to previously unaffected areas, such as northern Australia, Pakistan, India and Indonesia. The JE outbreak in India during July to November of 2005 was the longest and most severe in recent years, affecting more than 5,000 persons and causing more than 1,000 deaths. It is estimated that JEV causes 35,000 to 50,000 cases of encephalitis, including 10,000 deaths and as many neurologic sequelae, each year. The wide geographical distribution and the existence of multiple strains, coupled with the high rate of mortality and residual neurological complications in survivors, make JEV infection an important public health problem. Until a JEV vaccine becomes generally available, passive immunization with potently neutralizing anti-JEV antibodies remains an attractive strategy for short-term prevention of and therapeutic intervention in encephalitic JEV infections. <br><br> From a panel of 11 Fabs recovered by different panning strategies, three highly potent neutralizing antibodies, termed Fabs A3, B2, and E3, which recognized spatially separated regions on the JEV virion were identified. These antibodies reacted with epitopes in different domains: the major determinant for Fab A3 was Lys179 (domain I), that for Fab B2 was Ile126 (domain II), and that for Fab E3 was Gly302 (domain III) in the envelope protein, suggesting that these antibodies neutralize the virus by different mechanisms. These three Fabs and derived humanized monoclonal antibodies (MAbs) exhibited high neutralizing activities against a broad spectrum of JEV genotype strains. In preclinical testing, the monoclonal antibodies of the technology significantly prolonged the average survival time compared to the control group, suggesting a therapeutic potential for use of MAb B2 in humans. <br><br> This application claims the antibodies described above, methods of preventing and/or treating JEV with the antibodies, and diagnostics using the antibodies of the technology. Development of Japanese Encephalitis Virus (JEV) vaccines, therapeutics and diagnostics. The NIAID Office of Technology Development is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize "Humanized Monoclonal Antibodies that Specifically Bind Japanese Encephalitis Virus (JEV) and Their Use". Please contact Percy Pan at 301-451-3523 for more information. Available for licensing. 2022-03-08 2025-08-13 2025-08-15 2009-02-02 Against, antibodies, BBXXXX, Chimpanezee, DA4BXX, DA4XXX, DAXXXX, DB4XXX, DBXXXX, DC5XXX, DCXXXX, DDXXXX, DERIVED, DXXXXX, Efficient, Fabs, HUMANIZED, Infection, JAPANESE, Japanese encephalitis, JEV, Mice, monoclonal, Neutralization, Patent Category - Biotechnology, Protection, virus, Vitro False True Monoclonal antibodies have been synthesized and preclinical studies have been performed. True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114170721 AP Goncalvez et al. Humanized monoclonal antibodies derived from chimpanzee Fabs protect against Japanese encephalitis virus in vitro and in vivo. J Virol. 2008 Jul;82(14):7009-7021. http://www.ncbi.nlm.nih.gov/pubmed/18480437?dopt <a href="http://www.ncbi.nlm.nih.gov/pubmed/18480437?dopt">AP Goncalvez et al. Humanized monoclonal antibodies derived from chimpanzee Fabs protect against Japanese encephalitis virus in vitro and in vivo. J Virol. 2008 Jul;82(14):7009-7021.</a> 114106500 Purcell, Robert NIAID - DIR NIAID Purcell, Robert (NIAID) 0 114106501 Lai, Ching-juh NIAID - DIR NIAID Lai, Ching-juh (NIAID) 0 114106499 Goncalvez, Ana NIAID - DIR NIAID Goncalvez, Ana (NIAID) 1 114106499 Goncalvez, Ana NIAID - DIR NIAID Goncalvez, Ana (NIAID) 1 114106500 Purcell, Robert NIAID - DIR NIAID Purcell, Robert (NIAID) 0 114106501 Lai, Ching-juh NIAID - DIR NIAID Lai, Ching-juh (NIAID) 0 114101151 Humanized Monoclonal Antibodies Derived From Chimpanezee Fabs Efficient For Neutralization Of Japanese Virus (JEV) In Vitro And Protection Against JEV Infection In Mice E-142-2008-0 Filing authorized NIAID 91027763 Puglielli, Maryann maryann.puglielli@nih.gov
United States of America maryann.puglielli@nih.gov?subject=Web Inquiry on [TAB-1887] Humanized Monoclonal Antibodies that Specifically Bind Japanese Encephalitis Virus (JEV) and Their Use&body=Please send me information about technology [TAB-1887] Humanized Monoclonal Antibodies that Specifically Bind Japanese Encephalitis Virus (JEV) and Their Use. Puglielli, Maryann<br><a href="mailto:maryann.puglielli@nih.gov?subject=Web Inquiry on [TAB-1887] Humanized Monoclonal Antibodies that Specifically Bind Japanese Encephalitis Virus (JEV) and Their Use&body=Please send me information about technology [TAB-1887] Humanized Monoclonal Antibodies that Specifically Bind Japanese Encephalitis Virus (JEV) and Their Use.">maryann.puglielli@nih.gov</a><br> 114162649 E-142-2008-0 E-142-2008-0-US-05 HUMANIZED MONOCLONAL ANTIBODIES THAT SPECIFICALLY BIND AND/OR NEUTRALIZE JAPANESE ENCEPHALITIS VIRUS (JEV) AND THEIR USE DIV US 9,783,596 15/004,795 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9783596 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9783596">9,783,596</a><br />Filed on 2016-01-22<br />Status: Abandoned 114163691 E-142-2008-0 E-142-2008-0-US-01 Humanized Monoclonal Antibodies That Specifically BInd Japanese Encephalitis Virus (JEV) And Their Use PRV US 61/123,905 Abandoned US <br />Provisional (PRV) 61/123,905<br />Filed on 2008-04-10<br />Status: Abandoned 114165037 E-142-2008-0 E-142-2008-0-PCT-02 Humanized Monoclonal Antibodies Derived From Chimpanezee Fabs Efficient For Neutralization Of Japanese Virus (JEV) In Vitro And Protection Against JEV Infection In Mice PCT Patent Cooperation Treaty PCT/US2009/040227 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2009/040227<br />Filed on 2009-04-10<br />Status: Expired 114166200 E-142-2008-0 E-142-2008-0-US-03 Humanized Monoclonal Antibodies That Specifically Bind And/Or Neutralize Japanese Encephalitis Virus (JEV) And Their Use National Stage US 8,506,961 12/937,227 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8506961 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8506961">8,506,961</a><br />Filed on 2010-10-08<br />Status: Abandoned 114167166 E-142-2008-0 E-142-2008-0-US-04 Humanized Monoclonal Antibodies That Specifically Bind and/or Neutralize Japanese Encephalitis Virus (JEV) and Their Use CON US 9,273,121 13/941,283 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9273121 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9273121">9,273,121</a><br />Filed on 2013-07-12<br />Status: Abandoned 114119881 DXXXXX 114119882 DAXXXX 114119883 DBXXXX 114119884 DCXXXX 114119885 DDXXXX 114119886 DA4XXX 114119887 DA4BXX 114119888 DB4XXX 114119889 DC5XXX 114121154 BBXXXX 114136678 HUMANIZED 114136679 monoclonal 114136680 antibodies 114136681 DERIVED 114136682 Chimpanezee 114136683 Fabs 114136684 Efficient 114136685 Neutralization 114136686 JAPANESE 114136687 virus 114136688 JEV 114136689 Vitro 114136690 Protection 114136691 Against 114136692 Infection 114136693 Mice 114136694 Patent Category - Biotechnology 114156710 Japanese encephalitis TAB-1884 114096103 Mouse Monoclonal Antibodies to MAD1, a Human Spindle Assembly Checkpoint Protein for Maintaining Chromosomal Segregation NIAID Collaboration, Diagnostics, Oncology, Research Materials Collaboration Diagnostics Oncology Research Materials Kuan-teh Jeang (Estate) Scientists at the National Institutes of Health have developed mouse monoclonal antibodies against the human spindle assembly checkpoint protein, MAD1. The spindle assembly checkpoint in mitotic cell division regulates the fidelity of chromosome segregation during cell division. MAD1 is an important component of this checkpoint control, which if compromised, can lead to the initiation of cancer cell growth. These monoclonal antibodies are the first available antibodies against MAD1 and can be used in laboratory research and diagnostics. <ul> <li>Research tool in various laboratory procedures to identify and detect MAD1</li> <li>Diagnostic tool for aneuploidy, the condition of having an abnormal number of chromosomes, which results in birth and dev delopmental defects, such as Down syndrome</li> </ul> The NIAID NIAID Technology Transfer & Intellectual Property Office is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize reagents for studying cell cycle checkpoint factors. Research Tool -- Patent protection is not being pursued for this technology 2022-03-08 2025-08-13 2025-08-15 2009-02-02 (4)r syndrome, Against, ANEUPLOIDY, antibodies, ASSEMBLY, C syndrome, CAXXXX, CC2XXX, CCXXXX, CHECKPOINT, Chromosome 4 ring syndrome, Chromosome 6 ring syndrome, Chromosome 7 ring syndrome, CXXXXX, G syndrome, Human, Hypertelorism with esophageal abnormality and hypospadias, MAD1, monoclonal, Mouse, N syndrome, Protein, R(6) syndrome, R(7) syndrome, spindle, Syndrome X, W syndrome, W syndrome; Syndrome W False True True NIHTT 37470483 Website Abstract 114170719 Haller K, et al. http://www.ncbi.nlm.nih.gov/pubmed/16288203 <a href="http://www.ncbi.nlm.nih.gov/pubmed/16288203">Haller K, et al.</a> 114106483 Jeang (Estate), Kuan-teh NIAID - DIR NIAID Jeang (Estate), Kuan-teh (NIAID) 1 114106483 Jeang (Estate), Kuan-teh NIAID - DIR NIAID Jeang (Estate), Kuan-teh (NIAID) 1 114101148 Mouse Monoclonal Antibodies Against The Human Spindle Assembly Checkpoint Protein, MAD1 E-119-2003-0 Research Material NIAID 83724572 Tung, Peter peter.tung@nih.gov
United States of America DIR peter.tung@nih.gov?subject=Web Inquiry on [TAB-1884] Mouse Monoclonal Antibodies to MAD1, a Human Spindle Assembly Checkpoint Protein for Maintaining Chromosomal Segregation&body=Please send me information about technology [TAB-1884] Mouse Monoclonal Antibodies to MAD1, a Human Spindle Assembly Checkpoint Protein for Maintaining Chromosomal Segregation. Tung, Peter<br><a href="mailto:peter.tung@nih.gov?subject=Web Inquiry on [TAB-1884] Mouse Monoclonal Antibodies to MAD1, a Human Spindle Assembly Checkpoint Protein for Maintaining Chromosomal Segregation&body=Please send me information about technology [TAB-1884] Mouse Monoclonal Antibodies to MAD1, a Human Spindle Assembly Checkpoint Protein for Maintaining Chromosomal Segregation.">peter.tung@nih.gov</a><br> 114119866 CC2XXX 114119867 CAXXXX 114119868 CXXXXX 114119869 CCXXXX 114136651 Mouse 114136652 monoclonal 114136653 antibodies 114136654 Against 114136655 Human 114136656 spindle 114136657 ASSEMBLY 114136658 CHECKPOINT 114136659 Protein 114136660 MAD1 114156697 Syndrome X 114156698 C syndrome 114156699 Chromosome 7 ring syndrome 114156700 W syndrome 114156701 Hypertelorism with esophageal abnormality and hypospadias 114156702 ANEUPLOIDY 114156703 N syndrome 114156704 Chromosome 6 ring syndrome 114156705 Chromosome 4 ring syndrome 114158443 R(7) syndrome 114158444 W syndrome; Syndrome W 114158445 G syndrome 114158446 R(6) syndrome 114158447 (4)r syndrome TAB-1870 114096093 AFMAnalyze: Software Automation and Analysis of Atomic Force Microscopy (AFM) Data NIDCD Licensing Licensing Brett Shoelson AFMAnalyze is a software package that is designed to significantly enhance the analysis and application of Atomic Force Microscopy (AFM) data. This software automates AFM data collection and analysis, and is equipped with a Graphical User Interface (GUI)-intensive computational tool that is capable of replacing the manual or algorithmic methods for reconstructing, analyzing and interpreting large AFM data sets. AFMAnalyze provides a more robust, objective, and automated method for collecting and interpreting AFM results. A user, for example, can compute the Young’s modulus of a sample at the press of a button located on the software interface. <br><br> The software also enables “reverse fitting” of the data in order to calibrate AFM cantilevers using materials (such as reference gels) with known properties. This ability can significantly enhance the sensitivity, interpretation, and use of AFM measurements which depend on accurate determinations of cantilever properties. In a demonstration of the capabilities of AFMAnalyze, the software was successfully used to map the elasticity of the tectoral membrane (TM) by incorporating the analysis of over 500 force-distance curves. Generating such a map without automation would be prohibitively expensive and time consuming. <br><br> AFMAnalyze is also flexibly designed for expansion, and incorporates modular programs for additional data analysis. Further modifications to the software could enable the analysis of force-volume data. This type of data has been, so far, difficult to analyze, but has significant use as a tool for distinguishing the different mechanical properties of materials including metals, polymers, semiconductors, ceramics, and biological specimens on the sub-nanometer scale. <ul> <li>Automated, objective, and efficient AFM measurements of the nano-scale properties of materials</li> <li>Efficient AFM cantilever calibration</li> <li>Potential for AFM force-volume measurements</li> </ul> Available for licensing. 2022-03-08 2025-08-13 2025-08-15 2009-01-01 AC2XXX, ACXXXX, AD3XXX, ADXXXX, AFM, AFMAnalyze:, analysis, ATOMIC, Automating, AXXXXX, DATA, FORCE, MICROSCOPY, PACKAGE, software False True Late stage True NIHTT 37470483 Website Abstract 114170699 B Shoelson, EK Dimitriadis, H Cai, B Kachar, RS Chadwick. Evidence and implications of inhomogeneity in tectorial membrane elasticity. Biophys J. 2004 Oct;87(4):2768-2777. http://www.ncbi.nlm.nih.gov/pubmed/15454468?dopt <a href="http://www.ncbi.nlm.nih.gov/pubmed/15454468?dopt">B Shoelson, EK Dimitriadis, H Cai, B Kachar, RS Chadwick. Evidence and implications of inhomogeneity in tectorial membrane elasticity. Biophys J. 2004 Oct;87(4):2768-2777.</a> 114106467 Shoelson, Brett National Institute on Deafness and Other Communication Disorders (NIDCD) NIDCD Shoelson, Brett (NIDCD) 1 114106467 Shoelson, Brett National Institute on Deafness and Other Communication Disorders (NIDCD) NIDCD Shoelson, Brett (NIDCD) 1 114101136 AFMAnalyze: Software Package Automating The Analysis Of Atomic Force Microscopy (AFM) Data E-003-2004-0 National Institute on Deafness and Other Communication Disorders (NIDCD) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-1870] AFMAnalyze: Software Automation and Analysis of Atomic Force Microscopy (AFM) Data&body=Please send me information about technology [TAB-1870] AFMAnalyze: Software Automation and Analysis of Atomic Force Microscopy (AFM) Data. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-1870] AFMAnalyze: Software Automation and Analysis of Atomic Force Microscopy (AFM) Data&body=Please send me information about technology [TAB-1870] AFMAnalyze: Software Automation and Analysis of Atomic Force Microscopy (AFM) Data.">shmilovm@nih.gov</a><br> 114161372 E-003-2004-0 E-003-2004-0-US-01 AFMAnalyze: Software Package Automating The Analysis Of Atomic Force Microscopy (AFM) Data ORD US 6,993,959 10/686,738 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6993959 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6993959">6,993,959</a><br />Filed on 2003-10-17<br />Status: Expired 114119783 AD3XXX 114119784 AC2XXX 114119785 AXXXXX 114119786 ACXXXX 114119787 ADXXXX 114136264 analysis 114136265 Automating 114136266 PACKAGE 114136267 DATA 114136268 AFM 114136269 MICROSCOPY 114136270 FORCE 114136271 ATOMIC 114136272 software 114136273 AFMAnalyze: TAB-1825 114096048 Respiratory Syncytial Virus (RSV) Vaccines Based on Promoter-Proximate Attenuation NIAID Collaboration, Infectious Disease, Licensing, Vaccines Collaboration Infectious Disease Licensing Vaccines Ursula Buchholz, Peter Collins, Christine Krempl, Brian Murphy, Stephen Whitehead Available for licensing and commercial development is a patent estate and related biological materials for producing therapeutic or prophylactic vaccines against Respiratory Syncytial Virus (RSV). The claimed vaccine strategy relates to the engineering and creation of live-attenuated RSV vaccine candidates by shifting the position of one or more viral genes relative to the viral promoter (aka promoter-proximal attenuation). The gene shifts can be constructed by insertion, deletion or rearrangement of genes or genome segments within the recombinant genome or antigenome. Viral replication can increase or decrease depending on the position of expressed viral gene and depending on the nature and degree of the positional shift. Viral gene rearrangements are selected to maintain sufficient non-infectious replication of RSV while eliciting host anti-RSV immune responses. Viral genes targeted for such rearrangement include any of the NS1, NS2, N, P, M, SH, M2(ORF1), M2(ORF2), L, F or G genes or genome segment. <br><br> One modification of particular interest is the placement of the G and F protective antigen genes in a promoter-proximal position for increased expression. The gene position-shifted RSV can be further manipulated by the addition of specific nucleotide and amino acid point mutations or host range restriction determinants to yield desired phenotypic and structural effects. <ul> <li>Infectious Disease - Respiratory Syncytial Virus</li> <li>Vaccines</li> <li>Therapeutics</li> <li>Prophylactics</li> <li>Childhood Vaccines</li> </ul> The NIAID Office of Technology Development is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize live attenuated vaccines. Please contact Michael Piziali at 301-451-3527 for more information. Available for licensing. 2022-03-08 2025-08-13 2025-08-15 2008-09-01 ATTENUATE, Attenuated, ATTENUATING, ATTENUATION, Chromosome 7, monosomy, DC5BXX, DC5XXX, DCXXXX, Deletion 7, DXXXXX, GENES, Noonan syndrome, NS1, Promoter-proximal, RSV, RSV virus, RSV/PIV, Syncytial, Vaccine, Vaccine Design, VACCINE DEVELOPMENT, VACCINE VECTORS, vaccines, virus False True True NIHTT 37470483 Website Abstract 114170624 C Krempl et al. Recombinant respiratory syncytial virus with the G and F genes shifted to the promoter-proximal positions. J Virol. 2002 Dec;76(23):11931-11942. http://www.ncbi.nlm.nih.gov/pubmed/12414935?dopt <a href="http://www.ncbi.nlm.nih.gov/pubmed/12414935?dopt">C Krempl et al. Recombinant respiratory syncytial virus with the G and F genes shifted to the promoter-proximal positions. J Virol. 2002 Dec;76(23):11931-11942.</a> 114170625 Y Aloni, N Hay. Attenuation may regulate gene expression in animal viruses and cells. CRC Crit Rev Biochem. 1985;18(4):327-383. http://www.ncbi.nlm.nih.gov/pubmed/2996833?dopt <a href="http://www.ncbi.nlm.nih.gov/pubmed/2996833?dopt">Y Aloni, N Hay. Attenuation may regulate gene expression in animal viruses and cells. CRC Crit Rev Biochem. 1985;18(4):327-383.</a> 114106279 Collins, Peter NIAID - DIR NIAID Collins, Peter (NIAID) 0 114106280 Murphy, Brian NIAID - DIR NIAID Murphy, Brian (NIAID) 0 114106281 Buchholz, Ursula NIAID Buchholz, Ursula (NIAID) 0 114106282 Whitehead, Stephen NIAID Whitehead, Stephen (NIAID) 0 114106278 Krempl, Christine NIAID - DIR Krempl, Christine 1 114106278 Krempl, Christine NIAID - DIR Krempl, Christine 1 114106279 Collins, Peter NIAID - DIR NIAID Collins, Peter (NIAID) 0 114106280 Murphy, Brian NIAID - DIR NIAID Murphy, Brian (NIAID) 0 114106281 Buchholz, Ursula NIAID Buchholz, Ursula (NIAID) 0 114106282 Whitehead, Stephen NIAID Whitehead, Stephen (NIAID) 0 114101070 Respiratory Syncytial Virus Vaccines Expressing Protective Antigens From Promoter-proximal Genes E-225-2000-0 Filing authorized EM, NIAID 91027763 Puglielli, Maryann maryann.puglielli@nih.gov
United States of America maryann.puglielli@nih.gov?subject=Web Inquiry on [TAB-1825] Respiratory Syncytial Virus (RSV) Vaccines Based on Promoter-Proximate Attenuation&body=Please send me information about technology [TAB-1825] Respiratory Syncytial Virus (RSV) Vaccines Based on Promoter-Proximate Attenuation. Puglielli, Maryann<br><a href="mailto:maryann.puglielli@nih.gov?subject=Web Inquiry on [TAB-1825] Respiratory Syncytial Virus (RSV) Vaccines Based on Promoter-Proximate Attenuation&body=Please send me information about technology [TAB-1825] Respiratory Syncytial Virus (RSV) Vaccines Based on Promoter-Proximate Attenuation.">maryann.puglielli@nih.gov</a><br> 114164715 E-225-2000-0 E-225-2000-0-US-02 Respiratory Syncytial Virus Vaccines Expressing Protective Antigens From Promoter-Proximal Genes ORD US 6,923,971 09/887,469 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6923971 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6923971">6,923,971</a><br />Filed on 2001-06-22<br />Status: Expired 114164716 E-225-2000-0 E-225-2000-0-PCT-03 Respiratory Syncytial Virus Vaccines Expressing Protective Antigens From Promoter-Proximal Genes PCT Patent Cooperation Treaty PCT/US2001/020107 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2001/020107<br />Filed on 2001-06-22<br />Status: Expired 114164717 E-225-2000-0 E-225-2000-0-US-14 Respiratory Syncytial Virus Vaccines Expressing Protective Antigens From Promoter-Proximal Genes CON US 7,662,397 11/054,343 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7662397 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7662397">7,662,397</a><br />Filed on 2005-02-08<br />Status: Expired 114164718 E-225-2000-0 E-225-2000-0-US-15 Respiratory Syncytial Virus Vaccines Expressing Protective Antigens From Promoter-Proximal Genes CON US 7,744,902 11/033,055 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7744902 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7744902">7,744,902</a><br />Filed on 2005-01-10<br />Status: Expired 114164730 E-225-2000-0 E-225-2000-0-AU-04 Respiratory Syncytial Virus Vaccines Expressing Protective Antigens From Promotor-Proximal Genes National Stage Australia 2001268709 2001268709 Abandoned Australia <br />National Stage 2001268709<br />Filed on 2001-06-22<br />Status: Abandoned 114164731 E-225-2000-0 E-225-2000-0-BR-05 Respiratory Syncytial Virus Vaccines Expressing Protective Antigens From Promotor-Proximal Genes National Stage Brazil PI0112276-2 PI0112276-2 Expired Brazil <br />National Stage PI0112276-2<br />Filed on 2001-06-22<br />Status: Expired 114164732 E-225-2000-0 E-225-2000-0-CA-06 Respiratory Syncytial Virus Vaccines Expressing Protective Antigens From Promotor-Proximal Genes National Stage Canada 2413786 Abandoned Canada <br />National Stage 2413786<br />Filed on 2001-06-22<br />Status: Abandoned 114164733 E-225-2000-0 E-225-2000-0-CN-07 Respiratory Syncytial Virus Vaccines Expressing Protective Antigens From Promotor-Proximal Genes National Stage China 01814362.8 Abandoned China <br />National Stage 01814362.8<br />Filed on 2003-02-19<br />Status: Abandoned 114164734 E-225-2000-0 E-225-2000-0-EP-08 Respiratory Syncytial Virus Vaccines Expressing Protective Antigens From Promoter-Proximal Genes National Stage European Patent 1294858 01946696.0 Expired European Patent <br />National Stage 01946696.0<br />Filed on 2001-06-22<br />Status: Expired 114164735 E-225-2000-0 E-225-2000-0-IL-09 Respiratory Syncytial Virus Vaccines Expressing Protective Antigens From Promotor-Proximal Genes National Stage Israel 153530 153530 Abandoned Israel <br />National Stage 153530<br />Filed on 2001-06-22<br />Status: Abandoned 114164736 E-225-2000-0 E-225-2000-0-JP-10 Respiratory Syncytial Virus Vaccines Expressing Protective Antigens From Promoter-Proximal Genes National Stage Japan 2002-505815 Abandoned Japan <br />National Stage 2002-505815<br />Filed on 2001-06-22<br />Status: Abandoned 114164737 E-225-2000-0 E-225-2000-0-KR-11 Respiratory Syncytial Virus Vaccines Expressing Protective Antigens From Aomotor-Proximal Genes National Stage South Korea 10-0899030 10-2002-7017577 Abandoned South Korea <br />National Stage 10-2002-7017577<br />Filed on 2001-06-22<br />Status: Abandoned 114164738 E-225-2000-0 E-225-2000-0-MX-12 Respiratory Syncytial Virus Vaccines Expressing Protective Antigens from Promoter-Proximal Genes National Stage Mexico 266418 2002-012818 Abandoned Mexico <br />National Stage 2002-012818<br />Filed on 2001-06-22<br />Status: Abandoned 114164739 E-225-2000-0 E-225-2000-0-US-01 Respiratory Syncytial Virus Vaccines Expressing Protective Antigens from Promoter-Proximal Genes PRV US 60/213,708 Abandoned US <br />Provisional (PRV) 60/213,708<br />Filed on 2000-06-23<br />Status: Abandoned 114164740 E-225-2000-0 E-225-2000-0-US-13 Respiratory Syncytial Virus Vaccines Expressing Protective Antigens From Promoter-proximal Genes National Stage US 10/312,191 Abandoned US <br />National Stage 10/312,191<br />Filed on 2002-12-20<br />Status: Abandoned 114119201 DCXXXX 114119202 DC5XXX 114119203 DC5BXX 114119204 DXXXXX 114132415 RSV 114132416 Syncytial 114132417 virus 114132418 vaccines 114132419 ATTENUATION 114132420 ATTENUATING 114132421 Attenuated 114132422 Promoter-proximal 114132423 GENES 114132424 ATTENUATE 114132425 RSV virus 114132426 RSV/PIV 114132427 Vaccine 114132428 Vaccine Design 114132429 VACCINE DEVELOPMENT 114132430 VACCINE VECTORS 114156638 Chromosome 7, monosomy 114156639 Noonan syndrome 114158407 Deletion 7 114158408 NS1 TAB-1717 114095946 PSM Peptides as Vaccine Targets Against Methicillin-Resistant Staphylococcus aureus NIAID Collaboration, Infectious Disease, Licensing, Therapeutics, Vaccines Collaboration Infectious Disease Licensing Therapeutics Vaccines Michael Otto, Rong Wang Available for licensing and commercial development are compositions and methods for the treatment and inhibition of Methicillin-resistant <em>Staphylococcus aureus</em> (MRSA), a dangerous human pathogen. The invention concerns immunogenic peptides that can be used to induce protective immunity against MRSA, including phenol-soluble modulin (PSM) peptides.<br /><br /> In addition to the MRSA infections that occur in immunocompromised patients in hospitals, new MRSA strains have recently emerged that can cause severe infections (such as necrotizing fasciitis) or death in otherwise healthy adults. These strains are increasingly involved in community-associated (CA)-MRSA infections, and can be contracted outside of the health care settings. The incidence of CA-MRSA infections is increasing and the majority of infections in patients reporting to emergency departments in the US is now due to CA-MRSA.<br /><br /> The invention describes a class of secreted staphylococcal peptides with an extraordinary ability to recruit, activate, and subsequently lyse human neutrophils, thus eliminating the main cellular defense against <em>S. aureus</em> infection. The peptides are encoded by the PSM gene cluster and include PSMalpha1, PSMalpha2, PSMalpha3, and PSMalpha4, all of which activate and subsequently lyse neutrophils. These peptides are produced at especially high levels in CA-MRSA and to a large extent determine their aggressive behavior and ability to cause disease in animal models of infection. Thus, the peptides represent a set of virulence factors of <em>S. aureus</em> that account for the enhanced virulence of CA-MRSA. The identification of these peptides enables the production of vaccines and other preventative and/or therapeutic agents for use in subjects infected with MRSA. <ul> <li>Development of new classes of antibiotics and vaccines against Methicillin-resistant <em>Staphylococcus aureus</em> infections.</li> </ul> The NIAID Laboratory of Human Bacterial Pathogenesis is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. Please contact Jeffrey Thruston at 301-594-5179 or <a href="mailto:jeffrey.thruston@nih.gov">jeffrey.thruston@nih.gov</a> for more information. 2022-03-08 2025-08-13 2025-08-15 2008-03-01 Against, ANTIBIOTIC, AUREUS, CA-MRSA, DB3XXX, DBXXXX, DC4XXX, DCXXXX, DXXXXX, fasciitis, Gene, GenePeptides, Immunity, Immunogenic, Methicillin-resistant, MRSA, necrotizing, necrotizing fasciitis, Peptides, PMS, PSM, Staphloccus, STAPHYLOCOCCAL, Staphylococcus, Targets, Vaccine False True Early stage Early-stage True NIHTT 37470483 Website Abstract 114170461 Wang R, et al. https://www.ncbi.nlm.nih.gov/pubmed/17994102 <a href="https://www.ncbi.nlm.nih.gov/pubmed/17994102">Wang R, et al.</a> 114105978 Wang, Rong NIAID - DIR Wang, Rong 0 114105979 Otto, Michael NIAID - DIR NIAID Otto, Michael (NIAID) 1 114105979 Otto, Michael NIAID - DIR NIAID Otto, Michael (NIAID) 1 114105978 Wang, Rong NIAID - DIR Wang, Rong 0 114101625 PMS GenePeptides As Vaccine Targets Against Methicillin-Resistant Staphloccus Aureus E-239-2007-3 Filing authorized NIAID 146046171 Joyce, Terrence terrence.joyce@nih.gov
United States of America terrence.joyce@nih.gov?subject=Web Inquiry on [TAB-1717] PSM Peptides as Vaccine Targets Against Methicillin-Resistant Staphylococcus aureus&body=Please send me information about technology [TAB-1717] PSM Peptides as Vaccine Targets Against Methicillin-Resistant Staphylococcus aureus. Joyce, Terrence<br><a href="mailto:terrence.joyce@nih.gov?subject=Web Inquiry on [TAB-1717] PSM Peptides as Vaccine Targets Against Methicillin-Resistant Staphylococcus aureus&body=Please send me information about technology [TAB-1717] PSM Peptides as Vaccine Targets Against Methicillin-Resistant Staphylococcus aureus.">terrence.joyce@nih.gov</a><br> 114166513 E-239-2007-3 E-239-2007-3-US-01 PSM Peptides As Vaccine Targets Against Methicillin-Resistant Staphylococcus CIP US 8,211,445 12/631,253 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8211445 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8211445">8,211,445</a><br />Filed on 2009-12-04<br />Status: Issued 114118489 DB3XXX 114118490 DC4XXX 114118491 DBXXXX 114118492 DCXXXX 114118493 DXXXXX 114131444 PMS 114131445 Gene 114131446 Peptides 114131447 Vaccine 114131448 Targets 114131449 Against 114131450 Methicillin-resistant 114131451 Staphylococcus 114131452 AUREUS 114131453 PSM 114131454 ANTIBIOTIC 114131455 CA-MRSA 114131456 MRSA 114131457 fasciitis 114131458 necrotizing 114131459 STAPHYLOCOCCAL 114131460 Immunogenic 114131461 Immunity 114141938 GenePeptides 114141939 Staphloccus 114156436 necrotizing fasciitis TAB-1694 114095922 Aquaporin 2 Polyclonal Antibodies NHLBI Diagnostics, Licensing, Materials Available, Rare/Neglected Diseases, Research Materials, Therapeutics Diagnostics Licensing Materials Available Rare/Neglected Diseases Research Materials Therapeutics Mark Knepper Aquaporins, also known as water channels, form pores in cell membranes and selectively transport water in and out of the cell. Aquaporins are involved in regulation of water balance and blood pressure, and thirteen different isoforms have been found in mammals. Aquaporin 2 (AQP2) is located in the collecting duct of the kidney, and is regulated by the peptide hormone vasopressin. AQP2 expression is increased in conditions where there is water retention, such as pregnancy and congestive heart failure, and mutations of AQP2 are associated with nephrogenic diabetes insipidus. Also, lithium treatment, often administered for bipolar disorder, can cause acquired diabetes insipidus by decreasing AQP2 expression. <br><br> The inventors have developed rabbit polyclonal antibodies directed against a peptide sequence in the C-terminal region of AQP2 (LKGLEPDTDWEEREVRRRQ). The sequence is upstream of phosphorylation sites in this region, and consequently the antibodies recognize both unphosphorylated and phosphorylated AQP2. The sequence is identical in human, rat, mouse, cow, and sheep. Western blotting, immunohistochemistry, and immunoprecipitation. Research Tool -- Patent prosecution is not being pursued for this technology This technology is available as a research tool under a Biological Materials License. 2022-03-08 2025-08-13 2025-08-15 2007-12-01 Anti-Aquaporin, antibodies, ANTIBODY, AQUAPORIN, DIABETES, diabetes insipidus, IDXXXX, IXXXXX, KIDNEY, Nephrogenic diabetes insipidus, polyclonal, polyclonal antibodies, UAXXXX, WATER, water channel False True True NIHTT 37470483 Website Abstract 114170450 SR DiGiovanni, S Nielsen, EI Christensen, MA Knepper. Regulation of collecting duct water channel expression by vasopressin in Brattleboro rat. Proc Natl Acad Sci U S A. 1994 Sep 13;91(19):8984-8988. http://www.ncbi.nlm.nih.gov/pubmed/7522327?dopt <a href="http://www.ncbi.nlm.nih.gov/pubmed/7522327?dopt">SR DiGiovanni, S Nielsen, EI Christensen, MA Knepper. Regulation of collecting duct water channel expression by vasopressin in Brattleboro rat. Proc Natl Acad Sci U S A. 1994 Sep 13;91(19):8984-8988.</a> 114105939 Knepper, Mark National Heart, Lung, and Blood Institute (NHLBI) NHLBI Knepper, Mark (NHLBI) 1 114105939 Knepper, Mark National Heart, Lung, and Blood Institute (NHLBI) NHLBI Knepper, Mark (NHLBI) 1 114100912 Anti-Aquaporin 2 Antibody E-045-2008-0 Research Material National Heart, Lung, and Blood Institute (NHLBI) 89788013 Kolesnitchenko, Vincent vk5q@nih.gov
United States of America Office of Technology Transfer and Development vk5q@nih.gov?subject=Web Inquiry on [TAB-1694] Aquaporin 2 Polyclonal Antibodies&body=Please send me information about technology [TAB-1694] Aquaporin 2 Polyclonal Antibodies. Kolesnitchenko, Vincent<br><a href="mailto:vk5q@nih.gov?subject=Web Inquiry on [TAB-1694] Aquaporin 2 Polyclonal Antibodies&body=Please send me information about technology [TAB-1694] Aquaporin 2 Polyclonal Antibodies.">vk5q@nih.gov</a><br> 114118383 IDXXXX 114118384 IXXXXX 114118953 UAXXXX 114131775 Anti-Aquaporin 114131776 AQUAPORIN 114131777 ANTIBODY 114131778 DIABETES 114131779 diabetes insipidus 114131780 WATER 114131781 water channel 114131782 KIDNEY 114131783 polyclonal antibodies 114131784 polyclonal 114131785 antibodies 114156406 Nephrogenic diabetes insipidus TAB-1685 114095913 Hybridoma C4H3, Monoclonal Antibody to a Specific Peptide-MHC Class II Complex NIAID Antibodies, Collaboration, Diagnostics, Immunology, Oncology, Research Materials Antibodies Collaboration Diagnostics Immunology Oncology Research Materials Ronald Germain T lymphocytes play an important role in the immune system by recognizing foreign protein motifs on cells. T lymphocytes are stimulated to recognize these motifs through their interactions with peptide-MHC complexes (pMHC). Thus, studying pMHC is an important aspect of understanding how the immune system works, particularly with regard to the development of vaccines. Unfortunately, the detection of pMHC is largely dependent on indirect assays, due to the difficulty of producing antibodies for specific pMHC.<br /><br /> This invention regards the development of hybridomas (C4H3) for the production of antibodies that are highly specific for a particular pMHC complex consisting of hen egg lysozyme peptide 46-61 (HEL) and the I-A<sup>k</sup> MHC class II molecule. These antibodies can be used for a myriad of purposes which include studying how cells form pMHC. <ul> <li>High specificity for the pMHC complex of HEL-I-A<sup>k</sup> MHC class II molecule.</li> <li>HEL-I-A<sup>k</sup> is widely used in experimental immunological research systems, giving the hybridoma and antibodies great applicability.</li> </ul> <ul> <li>Discovery of methods for antigen delivery in the development of vaccines.</li> <li>Quantitation and distribution of pMHC complexes on cells.</li> <li>Study antigen processing in experimental immunological research systems.</li> </ul> The NIAID Lymphocyte Biology Section, Laboratory of Immunology is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize monoclonal antibody C4H3, specific for HEL (46-61) bound to the MHC class II molecule I-A<sup>k</sup>. Please contact Ronald N. Germain, M.D., Ph.D. at <a href="mailto:rgermain@nih.gov">rgermain@nih.gov</a> for more information. Research Material - Patent protection is not being pursued for this technology. (IC Reference # 2007-090) 2022-03-08 2025-08-13 2025-08-15 2007-11-01 ANTIBODY, CA1BXX, CA1XXX, CA2AXX, CA2XXX, CAXXXX, Class, COMPLEX, CXXXXX, Hybridoma, Mab, monoclonal, Peptide-MHC, RM, Specific, WIXXXX, XAXXXX False True True NIHTT 37470483 Website Abstract 114170443 Zhong G, et al. http://www.ncbi.nlm.nih.gov/pubmed/9391117 <a href="http://www.ncbi.nlm.nih.gov/pubmed/9391117">Zhong G, et al.</a> 114170444 Porgador A, et al. http://www.ncbi.nlm.nih.gov/pubmed/9208844 <a href="http://www.ncbi.nlm.nih.gov/pubmed/9208844">Porgador A, et al.</a> 114105927 Germain, Ronald NIAID - DIR NIAID Germain, Ronald (NIAID) 1 114105927 Germain, Ronald NIAID - DIR NIAID Germain, Ronald (NIAID) 1 114100900 Monoclonal Antibody To A Specific Peptide-MHC Class II Complex E-021-2008-0 Research Material NIAID 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-1685] Hybridoma C4H3, Monoclonal Antibody to a Specific Peptide-MHC Class II Complex&body=Please send me information about technology [TAB-1685] Hybridoma C4H3, Monoclonal Antibody to a Specific Peptide-MHC Class II Complex. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-1685] Hybridoma C4H3, Monoclonal Antibody to a Specific Peptide-MHC Class II Complex&body=Please send me information about technology [TAB-1685] Hybridoma C4H3, Monoclonal Antibody to a Specific Peptide-MHC Class II Complex.">yogikala.prabhu@nih.gov</a><br> 114118336 CA1BXX 114118337 CA2AXX 114118338 CAXXXX 114118339 CXXXXX 114119214 CA1XXX 114119215 CA2XXX 114127359 WIXXXX 114127360 XAXXXX 114132535 monoclonal 114132536 ANTIBODY 114132537 Specific 114132538 Peptide-MHC 114132539 Class 114132540 COMPLEX 114149405 RM 114149406 Mab 114149407 Hybridoma TAB-1610 114095878 Chlamydia Vaccine NIAID Collaboration, Diagnostics, Infectious Disease, Rare/Neglected Diseases, Research Materials, Vaccines Collaboration Diagnostics Infectious Disease Rare/Neglected Diseases Research Materials Vaccines Harlan Caldwell, Deborah Crane <em>Chlamydia trachomatis</em> is an obligate intracellular bacterial pathogen that colonizes and infects oculogenital mucosal surfaces. The organism exists as multiple serovariants that infect millions of people worldwide. Ocular infections cause trachoma, a chronic follicular conjunctivitis that results in scarring and blindness. The World Health Organization estimates that 300–500 million people are afflicted by trachoma, making it the most prevalent form of infectious preventable blindness. Urogenital infections are the leading cause of bacterial sexually transmitted disease in both industrialized and developing nations. Moreover, sexually transmitted diseases are risk factors for infertility, the transmission of HIV, and human papilloma virus-induced cervical neoplasia. Control of <em>C. trachomatis</em> infections is an important public health goal. Unexpectedly, however, aggressive infection control measures based on early detection and antibiotic treatment have resulted in an increase in infection rates, most likely by interfering with natural immunity, a concept suggested by studies performed in experimental infection models. Effective management of chlamydial disease will likely require the development of an efficacious vaccine.<br /><br /> This technology claims vaccine compositions that comprise an immunologically effective amount of PmpD protein from <em>C. trachomatis</em>. Also claimed in the application are methods of immunizing individuals against <em>C. trachomatis</em>. PmpD is an antigenically stable pan-neutralizing target that, in theory, would provide protection against all human strains, thus allowing the development of a univalent vaccine that is efficacious against both blinding trachoma and sexually transmitted disease. Prophylactics against <em>C. trachomatis</em>. The National Institute of Allergy and Infectious Diseases, Laboratory of Clinical Infectious Diseases, Chlamydial Diseases Section, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize PmpD vaccine development. Please contact Harlan D. Caldwell, at <a href="mailto:hcaldwell@niaid.nih.gov">hcaldwell@niaid.nih.gov</a> or 406-363-9333 for more information. 2022-03-08 2025-08-13 2025-08-15 2008-02-01 Against, Blinding, Chlamydia, DA3XXX, DAXXXX, DC4XXX, DCXXXX, DDXXXX, DISEASES, DXXXXX, Sexually, Trachoma, Trachoma (Chlamydia trachomatis), TRACHOMATIS, Transmitted, UBXXXX, Vaccine False True Preclinical studies have been performed. Preclinical studies have been performed. True NIHTT 37470483 Website Abstract 114170409 Crane DD, et al. http://www.ncbi.nlm.nih.gov/pubmed/16446444 <a href="http://www.ncbi.nlm.nih.gov/pubmed/16446444">Crane DD, et al.</a> 114105864 Crane, Deborah NIAID - DIR NIAID Crane, Deborah (NIAID) 0 114105865 Caldwell, Harlan NIAID - DIR NIAID Caldwell, Harlan (NIAID) 1 114105865 Caldwell, Harlan NIAID - DIR NIAID Caldwell, Harlan (NIAID) 1 114105864 Crane, Deborah NIAID - DIR NIAID Crane, Deborah (NIAID) 0 114100862 Vaccine Against Chlamydia Trachomatis Sexually Transmitted Diseases And Blinding Trachoma E-031-2006-0 Filing authorized NIAID 91026778 Green, Wade wade.green@nih.gov
United States of America TTIPO wade.green@nih.gov?subject=Web Inquiry on [TAB-1610] Chlamydia Vaccine&body=Please send me information about technology [TAB-1610] Chlamydia Vaccine. Green, Wade<br><a href="mailto:wade.green@nih.gov?subject=Web Inquiry on [TAB-1610] Chlamydia Vaccine&body=Please send me information about technology [TAB-1610] Chlamydia Vaccine.">wade.green@nih.gov</a><br> 114164018 E-031-2006-0 E-031-2006-0-US-03 Chlamydia Vaccine National Stage US 9,259,463 12/087,952 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9259463 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9259463">9,259,463</a><br />Filed on 2010-10-01<br />Status: Issued 114164019 E-031-2006-0 E-031-2006-0-PCT-02 Chlamydia Vaccine PCT Patent Cooperation Treaty PCT/US2007/001213 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2007/001213<br />Filed on 2007-01-16<br />Status: Expired 114164353 E-031-2006-0 E-031-2006-0-US-01 Chlamydia Vaccine PRV US 60/760,970 Abandoned US <br />Provisional (PRV) 60/760,970<br />Filed on 2006-01-19<br />Status: Abandoned 114167093 E-031-2006-0 E-031-2006-0-US-05 Chlamydia Vaccine DIV US 10,420,829 15/043,975 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10420829 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10420829">10,420,829</a><br />Filed on 2016-02-15<br />Status: Issued 114118148 DA3XXX 114118149 DC4XXX 114118150 DDXXXX 114118151 DAXXXX 114118152 DCXXXX 114118153 UBXXXX 114118154 DXXXXX 114135423 Vaccine 114135424 Against 114135425 Chlamydia 114135426 TRACHOMATIS 114135427 Sexually 114135428 Transmitted 114135429 DISEASES 114135430 Blinding 114135431 Trachoma 114157924 Trachoma (Chlamydia trachomatis) TAB-1608 114095876 Monoclonal Antibodies Against Dengue and Other Viruses With Deletion in Fc Region NIAID Infectious Disease, Licensing, Rare/Neglected Diseases, Research Materials, Therapeutics, Vaccines Infectious Disease Licensing Rare/Neglected Diseases Research Materials Therapeutics Vaccines Ana Goncalvez, Ching-juh Lai, Robert Purcell The four dengue virus (DENV) serotypes (DENV-1 to DENV-4) are the most important arthropod-borne flaviviruses in terms of morbidity and geographic distribution. Up to 100 million DENV infections occur every year, mostly in tropical and subtropical areas where vector mosquitoes are abundant. Infection with any of the DENV serotypes may be asymptomatic or may lead to classic dengue fever or more severe dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS), which are increasingly common in the dengue endemic areas. Immunity to the same virus serotype (homotypic immunity) is life-long, whereas immunity to different serotypes (heterotypic immunity) lasts 2–3 months so that infection with a different serotype virus is possible. DHF/DSS often occurs in patients with second, heterotypic DENV infections or in infants with maternally transferred dengue immunity. Severe dengue is a major cause of hospitalization, and fatality rates vary from <1% to 5% in children. <br><br> Antibody-dependent enhancement (ADE) has been proposed as an underlying pathogenic mechanism of DHF/DSS. ADE occurs because preexisting subneutralizing antibodies and the infecting DENV form complexes that bind to Fc receptor-bearing cells, leading to increased virus uptake and replication. ADE has been repeatedly demonstrated <i>in vitro</i> using dengue immune sera or monoclonal antibodies and cells of monocytic and recently, B lymphocytic lineages bearing Fc receptors. ADE of DENV-2 infection has also been demonstrated in monkeys infused with a human dengue immune serum. <br><br> We have identified chimpanzee–human chimeric IgG1 mAbs capable of neutralizing or binding to one or more DENV serotypes. Cross-reactive IgG 1A5 neutralizes DENV-1 and DENV-2 more efficiently than DENV-3 and DENV-4, and type-specific IgG 5H2 neutralizes DENV-4 at a high titer. Analysis of antigenic variants has localized the IgG 1A5 binding site to the conserved fusion peptide in E. Thus, IgG 1A5 shares many characteristics with the cross-reactive antibodies detected in flavivirus infections. <br><br> This application claims a variant of an antibody comprising a polypeptide in the Fc region, which binds an Fc gamma receptor (FcgammaR) with lower affinity than the parent antibody. The variant polypeptide comprises a deletion of nine amino acids at the N-terminus of the C<sub>H</sub>2 domain in the Fc region. Introduction of the Fc variant abrogates the antibody-mediated dengue virus replication enhancing activity. This invention has important implications for the antibody-mediated prevention of dengue virus infection. Immunization against Dengue and/or flaviviruses. Available for licensing. 2022-03-08 2025-08-13 2025-08-15 2008-10-01 (4)r syndrome, Against, antibodies, C syndrome, Chromosome 4 ring syndrome, Chromosome 6 ring syndrome, Chromosome 7 ring syndrome, Chromosome 7, monosomy, DB4XXX, DBXXXX, DC5XXX, DCXXXX, DDXXXX, Deletion, Deletion 7, DENGUE, Dengue (Flaviviridae), DENGUE FEVER, DXXXXX, FC, G syndrome, Hemorrhagic fever, Hypertelorism with esophageal abnormality and hypospadias, monoclonal, N syndrome, Q fever, R(6) syndrome, R(7) syndrome, Region, Syndrome X, UAXXXX, UBXXXX, Viruses, W syndrome, W syndrome; Syndrome W False True Antibody candidates have been synthesized and preclinical studies have been performed. Antibody candidates have been synthesized and preclinical studies have been performed. True NIHTT 37470483 Website Abstract 114170407 AP Goncalvez et al. Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention. Proc Natl Acad Sci USA. 2007 May 29;104(22):9422-9427. http://www.ncbi.nlm.nih.gov/pubmed/17517625?dopt <a href="http://www.ncbi.nlm.nih.gov/pubmed/17517625?dopt">AP Goncalvez et al. Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention. Proc Natl Acad Sci USA. 2007 May 29;104(22):9422-9427.</a> 114105858 Purcell, Robert NIAID - DIR NIAID Purcell, Robert (NIAID) 0 114105859 Lai, Ching-juh NIAID - DIR NIAID Lai, Ching-juh (NIAID) 0 114105860 Goncalvez, Ana NIAID - DIR NIAID Goncalvez, Ana (NIAID) 1 114105860 Goncalvez, Ana NIAID - DIR NIAID Goncalvez, Ana (NIAID) 1 114105858 Purcell, Robert NIAID - DIR NIAID Purcell, Robert (NIAID) 0 114105859 Lai, Ching-juh NIAID - DIR NIAID Lai, Ching-juh (NIAID) 0 114100858 Monoclonal Antibodies Against Dengue And Other Viruses With Deletion Of Fc Region E-159-2007-3 Filing authorized NIAID 91027763 Puglielli, Maryann maryann.puglielli@nih.gov
United States of America maryann.puglielli@nih.gov?subject=Web Inquiry on [TAB-1608] Monoclonal Antibodies Against Dengue and Other Viruses With Deletion in Fc Region&body=Please send me information about technology [TAB-1608] Monoclonal Antibodies Against Dengue and Other Viruses With Deletion in Fc Region. Puglielli, Maryann<br><a href="mailto:maryann.puglielli@nih.gov?subject=Web Inquiry on [TAB-1608] Monoclonal Antibodies Against Dengue and Other Viruses With Deletion in Fc Region&body=Please send me information about technology [TAB-1608] Monoclonal Antibodies Against Dengue and Other Viruses With Deletion in Fc Region.">maryann.puglielli@nih.gov</a><br> 114164009 E-159-2007-3 E-159-2007-3-PCT-01 Monoclonal Antibodies Against Dengue And Other Viruses With Deletion Of Fc Region PCT COMB Patent Cooperation Treaty PCT/US2008/059313 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2008/059313<br />Filed on 2008-04-03<br />Status: Expired 114165622 E-159-2007-3 E-159-2007-3-US-03 Monoclonal Antibodies Against Dengue And Other Viruses With Deletion Of Fc Region National Stage US 8,337,854 12/594,756 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8337854 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8337854">8,337,854</a><br />Filed on 2009-10-05<br />Status: Abandoned 114166946 E-159-2007-3 E-159-2007-3-US-04 Monoclonal Antibodies Against Dengue And Other Viruses With Deletion IN FC Region DIV US 13/722,275 Abandoned US <br />Divisional (DIV) 13/722,275<br />Filed on 2012-12-20<br />Status: Abandoned 114118136 DB4XXX 114118137 DC5XXX 114118138 DDXXXX 114118139 DBXXXX 114118140 DCXXXX 114118141 UBXXXX 114118142 UAXXXX 114118143 DXXXXX 114133607 monoclonal 114133608 antibodies 114133609 Against 114133610 DENGUE 114133611 Viruses 114133612 Deletion 114133613 FC 114133614 Region 114156363 Q fever 114156364 Syndrome X 114156365 Chromosome 7, monosomy 114156366 C syndrome 114156367 DENGUE FEVER 114156368 Chromosome 7 ring syndrome 114156369 W syndrome 114156370 Hypertelorism with esophageal abnormality and hypospadias 114156371 N syndrome 114156372 Chromosome 6 ring syndrome 114156373 Hemorrhagic fever 114156374 Chromosome 4 ring syndrome 114157912 Dengue (Flaviviridae) 114158282 Deletion 7 114158283 R(7) syndrome 114158284 W syndrome; Syndrome W 114158285 G syndrome 114158286 R(6) syndrome 114158287 (4)r syndrome TAB-1601 114095869 Monoclonal Antibodies Against Orthopoxviruses NIAID Collaboration, Diagnostics, Infectious Disease, Licensing, Research Materials, Therapeutics, Vaccines Collaboration Diagnostics Infectious Disease Licensing Research Materials Therapeutics Vaccines Zhaochun Chen, Patricia Earl, Suzanne Emerson, Bernard Moss, Robert Purcell Concerns that variola (smallpox) virus might be used as a biological weapon have led to the recommendation of widespread vaccination with vaccinia virus. While vaccination is generally safe and effective for prevention of smallpox, it is well documented that various adverse reactions in individuals have been caused by vaccination with existing licensed vaccines. Vaccinia immune globulin (VIG) prepared from vaccinated humans has historically been used to treat adverse reactions arising from vaccinia immunization. However, VIG lots may have different potencies and carry the potential to transmit other viral agents. <br><br> Chimpanzee Fabs against the B5 and A33 outer extracellular membrane proteins of vaccinia virus were isolated and converted into complete mAbs with human gamma1 heavy chain constant regions. The two mAbs displayed high binding affinities to B5 and A33. The mAbs inhibited the spread of vaccinia virus as well as variola virus (the causative agent of smallpox) <i>in vitro</i>, protected mice from subsequent intranasal challenge with virulent vaccinia virus, protected mice when administered 2 days after challenge, and provided significantly greater protection than that afforded by VIG. Prophylactics or therapeutics against orthopoxviruses. The National Institute of Allergy and Infectious Diseases, Laboratory of Infectious Diseases, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize Chimpanzee/human neutralizing monoclonal antibodies against orthopoxviruses. Please contact Dr. Robert Purcell at 301-496 5090 for more information. Available for licensing. 2022-03-08 2025-08-13 2025-08-15 2020-07-06 Against, antibodies, DAXXXX, DB4BXX, DB4XXX, DBXXXX, DC5BXX, DC5XXX, DCXXXX, DDXXXX, DXXXXX, monoclonal, ORTHOPOXVIRUSES False True Preclinical studies have been performed. Preclinical studies have been performed. True NIHTT 37470483 Website Abstract 114170397 Z Chen et al. Chimpanzee/human mAbs to vaccinia virus B5 protein neutralize vaccinia and smallpox viruses and protect mice against vaccinia virus. Proc Natl Acad Sci USA. 2006 Feb 7;103(6):1882-1887. http://www.ncbi.nlm.nih.gov/pubmed/16436502?dopt <a href="http://www.ncbi.nlm.nih.gov/pubmed/16436502?dopt">Z Chen et al. Chimpanzee/human mAbs to vaccinia virus B5 protein neutralize vaccinia and smallpox viruses and protect mice against vaccinia virus. Proc Natl Acad Sci USA. 2006 Feb 7;103(6):1882-1887.</a> 114170398 Z Chen et al. Characterization of chimpanzee/human monoclonal antibodies to vaccinia virus A33 glycoprotein and its variola virus homolog in vitro and in a vaccinia virus mouse protection model. J Virol. 2007 Sep;81(17):8989-8995. http://www.ncbi.nlm.nih.gov/pubmed/17581986?dopt <a href="http://www.ncbi.nlm.nih.gov/pubmed/17581986?dopt">Z Chen et al. Characterization of chimpanzee/human monoclonal antibodies to vaccinia virus A33 glycoprotein and its variola virus homolog in vitro and in a vaccinia virus mouse protection model. J Virol. 2007 Sep;81(17):8989-8995.</a> 114105835 Moss, Bernard NIAID - DIR NIAID Moss, Bernard (NIAID) 0 114105836 Emerson, Suzanne NIAID - DIR NIAID Emerson, Suzanne (NIAID) 0 114105837 Purcell, Robert NIAID - DIR NIAID Purcell, Robert (NIAID) 0 114105838 Earl, Patricia NIAID Earl, Patricia (NIAID) 0 114105839 Chen, Zhaochun NIAID - DIR NIAID Chen, Zhaochun (NIAID) 1 114105839 Chen, Zhaochun NIAID - DIR NIAID Chen, Zhaochun (NIAID) 1 114105835 Moss, Bernard NIAID - DIR NIAID Moss, Bernard (NIAID) 0 114105836 Emerson, Suzanne NIAID - DIR NIAID Emerson, Suzanne (NIAID) 0 114105837 Purcell, Robert NIAID - DIR NIAID Purcell, Robert (NIAID) 0 114105838 Earl, Patricia NIAID Earl, Patricia (NIAID) 0 114100849 Monoclonal Antibodies Against Orthopoxviruses E-145-2004-3 Filing authorized NIAID 91027763 Puglielli, Maryann maryann.puglielli@nih.gov
United States of America maryann.puglielli@nih.gov?subject=Web Inquiry on [TAB-1601] Monoclonal Antibodies Against Orthopoxviruses&body=Please send me information about technology [TAB-1601] Monoclonal Antibodies Against Orthopoxviruses. Puglielli, Maryann<br><a href="mailto:maryann.puglielli@nih.gov?subject=Web Inquiry on [TAB-1601] Monoclonal Antibodies Against Orthopoxviruses&body=Please send me information about technology [TAB-1601] Monoclonal Antibodies Against Orthopoxviruses.">maryann.puglielli@nih.gov</a><br> 114163991 E-145-2004-3 E-145-2004-3-US-02 Monoclonal Antibodies Against Orthopoxviruses National Stage US 7,914,788 12/142,594 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7914788 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7914788">7,914,788</a><br />Filed on 2008-06-19<br />Status: Issued 114164008 E-145-2004-3 E-145-2004-3-PCT-01 Monoclonal Antibodies Against Orthopoxviruses PCT COMB Patent Cooperation Treaty PCT/US2006/048832 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2006/048832<br />Filed on 2006-12-22<br />Status: Expired 114164050 E-145-2004-3 E-145-2004-3-US-04 Monoclonal Antibodies Against Orthopoxviruses DIV US 8,999,336 13/742,480 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8999336 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8999336">8,999,336</a><br />Filed on 2013-01-16<br />Status: Issued 114166355 E-145-2004-3 E-145-2004-3-US-03 Monoclonal Antibodies Against Orthopoxviruses DIV US 8,404,818 13/038,613 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8404818 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8404818">8,404,818</a><br />Filed on 2011-03-02<br />Status: Issued 114168114 E-145-2004-3 E-145-2004-3-US-05 Monoclonal Antibodies Against Orthopoxviruses DIV US 9,708,392 14/663,168 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9708392 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9708392">9,708,392</a><br />Filed on 2015-03-19<br />Status: Issued 114168330 E-145-2004-3 E-145-2004-3-US-06 Monoclonal Antibodies Against Orthopoxviruses DIV US 15/650,103 Abandoned US <br />Divisional (DIV) 15/650,103<br />Filed on 2017-07-14<br />Status: Abandoned 114118100 DB4BXX 114118101 DC5BXX 114118102 DDXXXX 114118103 DAXXXX 114118104 DBXXXX 114118105 DCXXXX 114118106 DXXXXX 114119351 DC5XXX 114119352 DB4XXX 114133631 monoclonal 114133632 antibodies 114133633 Against 114133634 ORTHOPOXVIRUSES TAB-1591 114095859 Targeting Poly-Gamma-Glutamic Acid to Treat Staphylococcus Epidermidis and Related Infections NIAID Collaboration, Diagnostics, Infectious Disease, Licensing, Research Materials, Vaccines Collaboration Diagnostics Infectious Disease Licensing Research Materials Vaccines Frank DeLeo, Stanislava Kocianova, Michael Otto, Jovanka Voyich, Cuong Vuong, Yufeng Yao Over the past decade, <i>Staphylococcus epidermidis</i> has become the most prevalent pathogen involved in nosocomial infections. Usually an innocuous commensal microorganism on human skin, this member of the coagulase-negative group of staphylococci can cause severe infection after penetration of the epidermal protective barriers of the human body. In the U.S. alone, <i>S. epidermidis</i> infections on in-dwelling medical devices, which represent the main type of infection with <i>S. epidermidis</i>, cost the public health system approximately $1 billion per year. Importantly, <i>S. epidermidis</i> is frequently resistant to common antibiotics. <br><br> Immunogenic compositions and methods for eliciting an immune response against <i>S. epidermidis</i> and other related staphylococci are claimed. The immunogenic compositions can include immunogenic conjugates of poly-gamma-glutamic acid (such as gammaDLPGA) polypeptides of <i>S. epidermidis</i>, or related staphylococci that express a gammaPGA polypeptide. The gammaPGA conjugates elicit an effective immune response against <i>S. epidermidis</i>, or other staphylococci, in subjects to which the conjugates are administered. A method of treating an infection caused by a <i>Staphylococcus</i> organism that expresses <i>cap</i> genes is also disclosed. The method can include selecting a subject who is at risk of or has been diagnosed with the infection by the <i>Staphylococcus</i> organism which expresses gammaPGA from the <i>cap</i> genes. Further, the expression of a gammaPGA polypeptide by the organism can then be altered. <ul> <li>Prophylactics against <i>S. epidermidis</i>.</li> </ul> The National Institute of Allergy and Infectious Diseases, Laboratory of Human Bacterial Pathogenesis, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize the use of poly-gamma-glutamic acid of staphylococci. Please contact Dr. Michael Otto at <a href="mailto:motto@niaid.nih.gov">motto@niaid.nih.gov</a> for more information. Available for licensing. 2022-03-08 2025-08-13 2025-08-15 2007-10-01 Capsule, DA3XXX, DAXXXX, DC4XXX, DCXXXX, DDXXXX, DXXXXX, Edidermis, Poly-gamma-DL-glutamate, Staphylococcus False True Preclinical studies have been performed. Preclinical studies have been performed. True NIHTT 37470483 Website Abstract 114170390 Kocianova S, et al. https://www.ncbi.nlm.nih.gov/pubmed/15696197 <a href="https://www.ncbi.nlm.nih.gov/pubmed/15696197">Kocianova S, et al.</a> 114105811 Yao, Yufeng Yao, Yufeng 0 114105812 Voyich, Jovanka NIAID - DIR Voyich, Jovanka 0 114105813 Vuong, Cuong NIAID - DIR Vuong, Cuong 0 114105814 Kocianova, Stanislava NIAID - DIR Kocianova, Stanislava 0 114106472 DeLeo, Frank NIAID - DIR NIAID DeLeo, Frank (NIAID) 0 114105815 Otto, Michael NIAID - DIR NIAID Otto, Michael (NIAID) 1 114105815 Otto, Michael NIAID - DIR NIAID Otto, Michael (NIAID) 1 114105811 Yao, Yufeng Yao, Yufeng 0 114105812 Voyich, Jovanka NIAID - DIR Voyich, Jovanka 0 114105813 Vuong, Cuong NIAID - DIR Vuong, Cuong 0 114105814 Kocianova, Stanislava NIAID - DIR Kocianova, Stanislava 0 114106472 DeLeo, Frank NIAID - DIR NIAID DeLeo, Frank (NIAID) 0 114100834 Poly-gamma-DL-glutamate Capsule Of Staphylococcus Edidermis E-263-2005-0 Filing authorized NIAID 146046171 Joyce, Terrence terrence.joyce@nih.gov
United States of America terrence.joyce@nih.gov?subject=Web Inquiry on [TAB-1591] Targeting Poly-Gamma-Glutamic Acid to Treat Staphylococcus Epidermidis and Related Infections&body=Please send me information about technology [TAB-1591] Targeting Poly-Gamma-Glutamic Acid to Treat Staphylococcus Epidermidis and Related Infections. Joyce, Terrence<br><a href="mailto:terrence.joyce@nih.gov?subject=Web Inquiry on [TAB-1591] Targeting Poly-Gamma-Glutamic Acid to Treat Staphylococcus Epidermidis and Related Infections&body=Please send me information about technology [TAB-1591] Targeting Poly-Gamma-Glutamic Acid to Treat Staphylococcus Epidermidis and Related Infections.">terrence.joyce@nih.gov</a><br> 114163957 E-263-2005-0 E-263-2005-0-US-03 Targeting Poly-Gamma-DL-Glutamic Acid To Treat Staphylococcus Epidermidis And Related Infections National Stage US 11/994,984 Abandoned US <br />National Stage 11/994,984<br />Filed on 2008-01-07<br />Status: Abandoned 114163958 E-263-2005-0 E-263-2005-0-PCT-02 Targeting Poly-gamma-glutamic acid to Treat Staphylococcus Epidermidis and Related Infections PCT Patent Cooperation Treaty PCT/US2006/026900 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2006/026900<br />Filed on 2006-07-10<br />Status: Expired 114164419 E-263-2005-0 E-263-2005-0-US-01 Poly-gamma-DL-glutamate Capsule Of Staphylococcus Edidermis PRV US 60/697,646 Abandoned US <br />Provisional (PRV) 60/697,646<br />Filed on 2005-07-08<br />Status: Abandoned 114166337 E-263-2005-0 E-263-2005-0-US-05 Targeting Poly-gamma-glutamic Acid To Treat Staphylococcus Edidermis And Related Infections DIV US 8,252,550 13/035,716 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8252550 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8252550">8,252,550</a><br />Filed on 2011-02-25<br />Status: Issued 114166876 E-263-2005-0 E-263-2005-0-US-06 Targeting Poly-gamma-glutamic acid to treat Staphylococcus Epidermidis and related infections DIV US 8,623,371 13/554,245 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8623371 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8623371">8,623,371</a><br />Filed on 2012-07-20<br />Status: Issued 114167347 E-263-2005-0 E-263-2005-0-US-07 TARGETING POLY-GAMMA-GLUTAMIC ACID TO TREAT STAPHYLOCOCCUS EPIDERSMIDIS AND RELATED INFECTIONS DIV US 8,921,071 14/058,610 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8921071 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8921071">8,921,071</a><br />Filed on 2013-10-21<br />Status: Issued 114118052 DA3XXX 114118053 DC4XXX 114118054 DDXXXX 114118055 DAXXXX 114118056 DCXXXX 114118057 DXXXXX 114135554 Poly-gamma-DL-glutamate 114135555 Capsule 114135556 Staphylococcus 114135557 Edidermis TAB-1585 114095853 Development of Dengue Virus Type 3 Vaccine Candidates NIAID Diagnostics, Infectious Disease, Licensing, Rare/Neglected Diseases, Research Materials, Vaccines Diagnostics Infectious Disease Licensing Rare/Neglected Diseases Research Materials Vaccines Joseph Blaney, Brian Murphy, Stephen Whitehead The disease burden associated with dengue virus infection has increased over the past several decades in the tropical and semi-tropical regions of the world, where over 2 billion people live at risk of dengue infection. Annually, there are an estimated fifty (50) to one hundred (100) million cases of dengue fever, making development of an effective vaccine a priority. In addition, there is a need for a "travelers vaccine" to protect those visiting dengue virus endemic areas, similar in scope to other currently available "travelers vaccines", such as hepatitis A vaccine.<br /><br /> The previously identified delta30 attenuating mutation, created in each dengue virus serotype by the removal of 30 homologous nucleotides from the 3'-UTR, is capable of attenuating wild-type strains of dengue virus type 1 (DEN1), type 4 (DEN4) and to a limited extent type 2 (DEN2). These DEN1delta30 and DEN4delta30 viruses have been shown to be both safe and immunogenic in humans. However, the delta30 mutation failed to have an attenuating effect on dengue virus type 3 (DEN3). To generate DEN3 vaccine candidates with a clearly attenuated phenotype, viruses were produced containing 3'-UTR deletions consisting of extensions of the original delta30 mutation or additional mutations which remove stem-loop structures similar to those removed by delta30. In addition, the entire 3'-UTR of DEN3 was replaced with the 3'-UTR derived from DEN4 and containing the delta30 mutation. Studies in monkeys demonstrated that these newly developed viruses are highly attenuated, yet sufficiently immunogenic to warrant their further development for use as live attenuated vaccine candidates. Such viruses are anticipated to become the DEN3 component of a tetravalent vaccine formulation designed to immunize against all four dengue virus serotypes. <ul> <li>Immunization against all four serotypes of Dengue Virus.</li> </ul> Various international filings 2022-04-25 2025-08-13 2025-08-15 2008-10-01 1, 2, 3, 30, 3'-UTR, CANDIDATES, CONSISTING, Containing, Contiguous, DA4BXX, DA4XXX, DAXXXX, DC5BXX, DC5XXX, DCXXXX, DDXXXX, Deletion, DELETIONS, Delta30, DEN4, DENGUE, Dengue (Flaviviridae), DENGUE FEVER, Dervived, Development, DXXXXX, Either, Genome, Hepatitis A, Hepatitis D, Hepatitis E, Iin, MULTIPLE, Nucleotdies, Nucleotide, ONE, Q fever, Regions, THAN, TYPE, UAXXXX, UBXXXX, Vaccine, virus False True Vaccine candidates have been synthesized and preclinical studies have been performed. The vaccine candidates of this invention are slated to enter Phase I clinical trials in the next year. Vaccine candidates have been synthesized and preclinical studies have been performed. The vaccine candidates of this invention are slated to enter Phase I clinical trials in the next year. True NIHTT 37470483 Website Abstract 114105799 Blaney, Joseph NIAID - DIR NIAID Blaney, Joseph (NIAID) 0 114105800 Murphy, Brian NIAID - DIR NIAID Murphy, Brian (NIAID) 0 114105801 Whitehead, Stephen NIAID - DIR NIAID Whitehead, Stephen (NIAID) 1 114105801 Whitehead, Stephen NIAID - DIR NIAID Whitehead, Stephen (NIAID) 1 114105799 Blaney, Joseph NIAID - DIR NIAID Blaney, Joseph (NIAID) 0 114105800 Murphy, Brian NIAID - DIR NIAID Murphy, Brian (NIAID) 0 114100825 Development Of Dengue Virus Type 3 Vaccine Candidates Containing Either 1) Nucleotide Deletions In The 3'-UTR Of The Genome Consisting Of More Than 30 Contiguous Nucleotdies Iin One Or Multiple Regions, Or 2) A 3'-UTR Dervived From DEN4 And Containin E-139-2006-0 Filing authorized NIAID 91029846 Ganelina, Anna ganelinaa@niaid.nih.gov
United States of America ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-1585] Development of Dengue Virus Type 3 Vaccine Candidates&body=Please send me information about technology [TAB-1585] Development of Dengue Virus Type 3 Vaccine Candidates. Ganelina, Anna<br><a href="mailto:ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-1585] Development of Dengue Virus Type 3 Vaccine Candidates&body=Please send me information about technology [TAB-1585] Development of Dengue Virus Type 3 Vaccine Candidates.">ganelinaa@niaid.nih.gov</a><br> 114159973 E-139-2006-0 E-139-2006-0-US-09 Development of Dengue Virus Vaccine Components National Stage US 8,337,860 12/376,756 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8337860 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8337860">8,337,860</a><br />Filed on 2009-02-06<br />Status: Issued 114163426 E-139-2006-0 E-139-2006-0-US-25 Development Of Dengue Virus Vaccine Components DIV US 10,160,957 14/742,533 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10160957 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10160957">10,160,957</a><br />Filed on 2015-06-17<br />Status: Issued 114163939 E-139-2006-0 E-139-2006-0-PCT-02 Development Of Dengue Virus Vaccine Components PCT Patent Cooperation Treaty PCT/US2007/076004 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2007/076004<br />Filed on 2007-08-15<br />Status: Expired 114163940 E-139-2006-0 E-139-2006-0-US-01 Development Of Dengue Virus Vaccine Components PRV US 60/837,723 Expired US <br />Provisional (PRV) 60/837,723<br />Filed on 2006-08-15<br />Status: Expired 114165508 E-139-2006-0 E-139-2006-0-US-27 Development Of Dengue Virus Vaccine Components CON US 15/195,406 Abandoned US <br />Continuation (CON) 15/195,406<br />Filed on 2016-06-28<br />Status: Abandoned 114166925 E-139-2006-0 E-139-2006-0-US-11 Development Of Dengue Virus Vaccine Components DIV US 9,090,873 13/692,557 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9090873 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9090873">9,090,873</a><br />Filed on 2012-12-03<br />Status: Issued 114167085 E-139-2006-0 E-139-2006-0-US-12 Development Of Dengue Virus Vaccine Components REISSUE US RE046,042 13/895,908 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/RE46042 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/RE46042">RE046,042</a><br />Filed on 2013-05-16<br />Status: Issued 114168796 E-139-2006-0 E-139-2006-0-US-65 DEVELOPMENT OF DENGUE VIRUS VACCINE COMPONENTS DIV US 10,724,007 16/173,217 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10724007 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10724007">10,724,007</a><br />Filed on 2018-10-29<br />Status: Issued 114169037 E-139-2006-0 E-139-2006-0-US-67 DEVELOPMENT OF DENGUE VIRUS VACCINE COMPONENTS DIV US 11,332,722 16/912,359 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11332722 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11332722">11,332,722</a><br />Filed on 2020-06-25<br />Status: Issued 114169331 E-139-2006-0 E-139-2006-0-US-71 DEVELOPMENT OF DENGUE VIRUS VACCINE COMPONENTS CON US 11,746,335 17/724,037 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11746335 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11746335">11,746,335</a><br />Filed on 2022-04-19<br />Status: Issued 114114248 DA4XXX 114114249 DC5XXX 114118022 DA4BXX 114118023 DC5BXX 114118024 DDXXXX 114118025 DAXXXX 114118026 DCXXXX 114118027 UBXXXX 114118028 UAXXXX 114118029 DXXXXX 114132889 Development 114132890 DENGUE 114132891 virus 114132892 TYPE 114132893 3 114132894 Vaccine 114132895 CANDIDATES 114132896 Containing 114132897 Either 114132898 1 114132899 Nucleotide 114132900 DELETIONS 114132901 3'-UTR 114132902 Genome 114132903 CONSISTING 114132904 THAN 114132905 30 114132906 Contiguous 114132907 Nucleotdies 114132908 Iin 114132909 ONE 114132910 MULTIPLE 114132911 Regions 114132912 2 114132913 Dervived 114132914 DEN4 114132915 Delta30 114132916 Deletion 114156341 Q fever 114156342 Hepatitis D 114156343 DENGUE FEVER 114156344 Hepatitis A 114156345 Hepatitis E 114157910 Dengue (Flaviviridae) TAB-1580 114095848 Monoclonal Antibodies that Neutralize <i>B. anthracis</i> Protective Antigen (PA), Lethal Factor (LF) and Edema Factor (EF) NIAID Collaboration, Diagnostics, Infectious Disease, Licensing, Rare/Neglected Diseases, Research Materials, Therapeutics, Vaccines Collaboration Diagnostics Infectious Disease Licensing Rare/Neglected Diseases Research Materials Therapeutics Vaccines Zhaochun Chen, Suzanne Emerson, Stephen Leppla, Mahtab Moayeri, Robert Purcell Anthrax, whether resulting from natural or bioterrorist-associated exposure, is a constant threat to human health. The lethality of anthrax is primarily the result of the effects of anthrax toxin, which has 3 components: a receptor-binding protein known as "protective antigen" (PA) and 2 catalytic proteins known as "lethal factor" (LF) and "edema factor" (EF). Although production of an efficient anthrax vaccine is an ultimate goal, the benefits of vaccination can be expected only if a large proportion of the population at risk is immunized. The low incidence of anthrax suggests that large-scale vaccination may not be the most efficient means of controlling this disease. In contrast, passive administration of neutralizing human or chimpanzee monoclonal antibody to a subject at risk for anthrax or exposed to anthrax could provide immediate efficacy for emergency prophylaxis against or treatment of anthrax. <br><br> Four monoclonal antibodies (mAbs) against PA, three mAbs against LF and four mAbs specific for EF of anthrax were isolated from a phage display library generated from immunized chimpanzees. Two mAbs recognizing PA (W1 and W2), two anti-LF mAbs efficiently neutralized the cytotoxicity of lethal toxin in a macrophage lysis assay. One anti-EF mAb efficiently neutralized edema toxin in cell culture. All five neutralizing mAbs protected animals from anthrax toxin challenge. Prophylactics or therapeutics against <i>B. anthracis</i>. The National Institute of Allergy and Infectious Diseases, Laboratory of Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize Chimpanzee/human neutralizing monoclonal antibodies against anthrax toxins. Please contact Dr. Robert Purcell at 301-496-5090 for more information. Available for licensing. 2022-03-08 2025-08-13 2025-08-15 2020-07-09 Anthrax, antibodies, ANTIBODY, ANTIGEN, Chimpaneze, DA3XXX, DAXXXX, DB3XXX, DBXXXX, DC4XXX, DCXXXX, DDXXXX, DXXXXX, Edema, FACTORS, Lethal, monoclonal, Neutralize, Neutralizes, PA, Protective, That, toxin, UAXXXX False True Preclinical studies have been performed. Preclinical studies have been performed. True NIHTT 37470483 Website Abstract 114170384 Z Chen et al. Efficient neutralization of anthrax toxin by chimpanzee monoclonal antibodies against protective antigen. J Infect Dis. 2006 Mar 1;193(5):625-633. http://www.ncbi.nlm.nih.gov/pubmed/16453257?dopt <a href="http://www.ncbi.nlm.nih.gov/pubmed/16453257?dopt">Z Chen et al. Efficient neutralization of anthrax toxin by chimpanzee monoclonal antibodies against protective antigen. J Infect Dis. 2006 Mar 1;193(5):625-633.</a> 114105783 Leppla, Stephen NIAID - DIR NIAID Leppla, Stephen (NIAID) 0 114105784 Emerson, Suzanne NIAID - DIR NIAID Emerson, Suzanne (NIAID) 0 114105785 Purcell, Robert NIAID - DIR NIAID Purcell, Robert (NIAID) 0 114106156 Moayeri, Mahtab NIDCR NIAID Moayeri, Mahtab (NIAID) 0 114105786 Chen, Zhaochun NIAID - DIR NIAID Chen, Zhaochun (NIAID) 1 114105786 Chen, Zhaochun NIAID - DIR NIAID Chen, Zhaochun (NIAID) 1 114105783 Leppla, Stephen NIAID - DIR NIAID Leppla, Stephen (NIAID) 0 114105784 Emerson, Suzanne NIAID - DIR NIAID Emerson, Suzanne (NIAID) 0 114105785 Purcell, Robert NIAID - DIR NIAID Purcell, Robert (NIAID) 0 114106156 Moayeri, Mahtab NIDCR NIAID Moayeri, Mahtab (NIAID) 0 114100819 Chimpaneze Monoclonal Antibody That Neutralizes Anthrax Protective Antigen (PA) Toxin E-146-2004-0 Filing authorized NIAID 114100820 Chimpaneze Monoclonal Antibodies That Neutralize Lethal And Edema Factors Of Anthrax Toxin E-123-2007-0 Filing authorized NIAID, NIDCR 91027763 Puglielli, Maryann maryann.puglielli@nih.gov
United States of America maryann.puglielli@nih.gov?subject=Web Inquiry on [TAB-1580] Monoclonal Antibodies that Neutralize <i>B. anthracis</i> Protective Antigen (PA), Lethal Factor (LF) and Edema Factor (EF)&body=Please send me information about technology [TAB-1580] Monoclonal Antibodies that Neutralize <i>B. anthracis</i> Protective Antigen (PA), Lethal Factor (LF) and Edema Factor (EF). Puglielli, Maryann<br><a href="mailto:maryann.puglielli@nih.gov?subject=Web Inquiry on [TAB-1580] Monoclonal Antibodies that Neutralize <i>B. anthracis</i> Protective Antigen (PA), Lethal Factor (LF) and Edema Factor (EF)&body=Please send me information about technology [TAB-1580] Monoclonal Antibodies that Neutralize <i>B. anthracis</i> Protective Antigen (PA), Lethal Factor (LF) and Edema Factor (EF).">maryann.puglielli@nih.gov</a><br> 114163125 E-123-2007-0 E-123-2007-0-US-34 Monoclonal Antibodies That Neutralize Anthrax Toxins DIV US 10,053,503 15/411,065 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10053503 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10053503">10,053,503</a><br />Filed on 2017-01-20<br />Status: Abandoned 114163928 E-123-2007-0 E-123-2007-0-US-01 Chimpaneze Monoclonal Antibodies That Neutralize Lethal And Edema Factors Of Anthrax Toxin PRV US 60/903,022 Abandoned US <br />Provisional (PRV) 60/903,022<br />Filed on 2007-02-23<br />Status: Abandoned 114163930 E-146-2004-0 E-146-2004-0-PCT-02 Monoclonal Antibodies That Neutralizes Anthrax Protective Antigen (PA) Toxin PCT Patent Cooperation Treaty PCT/US2005/046790 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2005/046790<br />Filed on 2005-12-21<br />Status: Expired 114164408 E-146-2004-0 E-146-2004-0-US-01 Chimpaneze Monoclonal Antibody That Neutralizes Anthrax Protective Antigen (PA) Toxin PRV US 60/639,074 Abandoned US <br />Provisional (PRV) 60/639,074<br />Filed on 2004-12-22<br />Status: Abandoned 114164461 E-146-2004-0 E-146-2004-0-US-03 Monoclonal Antibodies That Neutralize Anthrax Protective Antigen (PA) Toxin National Stage US 8,685,396 11/793,735 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8685396 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8685396">8,685,396</a><br />Filed on 2009-12-08<br />Status: Abandoned 114164571 E-123-2007-0 E-123-2007-0-PCT-02 Chimpaneze Monoclonal Antibodies That Neutralize Lethal And Edema Factors Of Anthrax Toxin PCT Patent Cooperation Treaty PCT/US2008/054609 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2008/054609<br />Filed on 2008-02-21<br />Status: Expired 114165518 E-123-2007-0 E-123-2007-0-US-04 Chimpaneze Monoclonal Antibodies That Neutralize Lethal And Edema Factors Of Anthrax Toxin National Stage US 8,071,100 12/528,427 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8071100 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8071100">8,071,100</a><br />Filed on 2009-08-24<br />Status: Abandoned 114166578 E-123-2007-0 E-123-2007-0-US-05 Monoclonal Antibodies That Neutralize Anthrax Toxin DIV US 8,574,853 13/310,463 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8574853 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8574853">8,574,853</a><br />Filed on 2011-12-02<br />Status: Abandoned 114167317 E-123-2007-0 E-123-2007-0-US-08 Monoclonal Antibodies That Neutralize Anthrax Toxin DIV US 8,961,975 14/031,508 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8961975 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8961975">8,961,975</a><br />Filed on 2013-09-19<br />Status: Abandoned 114167672 E-146-2004-0 E-146-2004-0-US-04 Monoclonal Antibodies That Neutralize Anthrax Protective Antigen (PA) Toxin DIV US 10,227,395 14/181,099 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10227395 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10227395">10,227,395</a><br />Filed on 2014-02-14<br />Status: Abandoned 114168056 E-123-2007-0 E-123-2007-0-US-33 Monoclonal Antibodies That Neutralize Anthrax Toxin DIV US 9,580,492 14/595,475 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9580492 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9580492">9,580,492</a><br />Filed on 2015-01-13<br />Status: Abandoned 114168830 E-146-2004-0 E-146-2004-0-US-05 Monoclonal Antibodies that Neutralize Anthrax Protective Antigen (PA) Toxin DIV US 16/253,077 Abandoned US <br />Divisional (DIV) 16/253,077<br />Filed on 2019-01-21<br />Status: Abandoned 114117990 DA3XXX 114117991 DB3XXX 114117992 DC4XXX 114117993 DDXXXX 114117994 DAXXXX 114117995 DBXXXX 114117996 DCXXXX 114117997 DXXXXX 114117998 UAXXXX 114132760 Chimpaneze 114132761 monoclonal 114132762 antibodies 114132763 That 114132764 Neutralize 114132765 Lethal 114132766 Edema 114132767 FACTORS 114132768 Anthrax 114132769 toxin 114132770 ANTIBODY 114132771 Neutralizes 114132772 Protective 114132773 ANTIGEN 114132774 PA TAB-1519 114095787 Codon Optimized Genes for Subunit Vaccines NIAID Infectious Disease, Licensing, Vaccines Infectious Disease Licensing Vaccines Barney Graham, Teresa Johnson Available for licensing from the NIH are gene constructs that express immunogenic proteins based on viral genes that have been optimized for expression in mammalian cells. Using vaccine vectors expressing respiratory syncytial virus (RSV) proteins from the optimized genes, this technology was shown to result in a potent RSV-specific cellular immune responses with favorable phenotypic patterns. This technology was shown to generate a superior immune (both humoral and cellular) response when utilized as part of a heterologous vector prime-boost regimen. Such optimized genes could be an important component of an effective RSV vaccine. Further, this optimization could have possible application of to other viral genes and their respective vaccines. <ul> <li>Vaccines</li> <li>Improved protein expression</li> </ul> Available for non-exclusive or exclusive licensing. 2022-03-08 2025-08-13 2025-08-15 2008-04-01 Biotechnology, Codon-modified, DC5BXX, DC5XXX, DCXXXX, Development, DXXXXX, Gene, Patent Category - Biotechnology, respiratory, RSV, Sequences, Syncytial, Vaccine False True Animal (mouse) data available. Animal (mouse) data available. True NIHTT 37470483 Website Abstract 114105700 Johnson, Teresa NIAID - VRC Johnson, Teresa 0 114105701 Graham, Barney NIAID - VRC NIAID Graham, Barney (NIAID) 1 114105701 Graham, Barney NIAID - VRC NIAID Graham, Barney (NIAID) 1 114105700 Johnson, Teresa NIAID - VRC Johnson, Teresa 0 114100714 Use Of Codon-modified Respiratory Syncytial Gene (RSV) Sequences For Vaccine Development E-326-2006-1 Filing authorized NIAID 148673287 Hafiz, Sabrina sabrina.hafiz@nih.gov
United States of America sabrina.hafiz@nih.gov?subject=Web Inquiry on [TAB-1519] Codon Optimized Genes for Subunit Vaccines&body=Please send me information about technology [TAB-1519] Codon Optimized Genes for Subunit Vaccines. Hafiz, Sabrina<br><a href="mailto:sabrina.hafiz@nih.gov?subject=Web Inquiry on [TAB-1519] Codon Optimized Genes for Subunit Vaccines&body=Please send me information about technology [TAB-1519] Codon Optimized Genes for Subunit Vaccines.">sabrina.hafiz@nih.gov</a><br> 114163679 E-326-2006-1 E-326-2006-1-PCT-01 Codon-modified Immunogenic Compositions and Methods of Use PCT COMB Patent Cooperation Treaty PCT/US2007/024625 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2007/024625<br />Filed on 2007-11-30<br />Status: Expired 114165381 E-326-2006-1 E-326-2006-1-US-03 Codon Modified Immunogenic Compositions and Methods of Use National Stage US 8,772,256 12/517,194 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8772256 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8772256">8,772,256</a><br />Filed on 2009-06-01<br />Status: Abandoned 114117671 DC5BXX 114117672 DCXXXX 114117673 DXXXXX 114117707 DC5XXX 114136565 Codon-modified 114136566 respiratory 114136567 Syncytial 114136568 Gene 114136569 RSV 114136570 Sequences 114136571 Vaccine 114136572 Development 114136573 Biotechnology 114136574 Patent Category - Biotechnology TAB-1503 114095772 Model for Study of Glomerular Disorders: Conditionally-Immortalized Mouse Podocyte Cell Line with Tet-on-Regulated Gene Expression NIDDK Collaboration, Diagnostics, Licensing, Materials Available, Rare/Neglected Diseases, Research Materials, Therapeutics Collaboration Diagnostics Licensing Materials Available Rare/Neglected Diseases Research Materials Therapeutics Jeffrey Kopp Podocytes, cells of the visceral epithelium in the kidneys, are a key component of the glomerular filtration barrier. As such, they play a vital role in glomerular disorders, which are a major cause of chronic kidney disease. Examples of these disorders include focal segmental glomerulosclerosis, membranous glomerulonephritis, minimal change disease, and diabetic nephropathy.<br /><br /> The inventors have developed a conditionally-immortalized mouse podocyte cell line with tightly controlled conditional gene expression. The cell line has been conditionally immortalized through the introduction of the H-2Kb-tsA58 transgene, which is a temperature-sensitive mutant of the SV40T antigen. Inducible gene expression is tightly controlled through two introduced transgenes, podocin-rtTA and CMV-tTS, that produce a "Tet-on" system wherein gene expression is induced by tetracycline or doxycycline. The combination of the two transgenes for Tet-on gene expression has resulted in much tighter regulation and lower background expression compared to cells carrying the podocin-rtTA transgene alone. <ul> <li>Model system for study of glomerular disorders</li> <li>Model system for podocyte cell biology</li> </ul> The <a href="https://www.niddk.nih.gov/research-funding/at-niddk/labs-branches/kidney-disease-branch/kidney-diseases-section/Pages/About.aspx" target="blank" title="Kidney Disease Section website">NIDDK Kidney Disease Section</a> is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize a model system for the study of glomerular disorders. Please contact Jeffrey B. Kopp, M.D., by phone (301/594-3403), fax (301/402-0014) or e-mail (<a href="mailto:jbkopp@nih.gov">jbkopp@nih.gov</a>) for more information. Research Material – Patent protection is not being pursued for this technology. This technology is available as a research tool under a Biological Materials License. 2022-03-08 2025-08-13 2025-08-15 2007-03-01 ACXXXX, AXXXXX, Focal segmental glomerulosclerosis, Focal segmental glomerulosclerosis; Focal segmental glomerul, Glomerulonephritis, Idiopathic minimal change nephrotic syndrome, IDXXXX, IXXXXX, Minimal Change Disease, UAXXXX False True True NIHTT 37470483 Website Abstract 114170276 Shigehara T, et al. https://www.ncbi.nlm.nih.gov/pubmed/12874453 <a href="https://www.ncbi.nlm.nih.gov/pubmed/12874453">Shigehara T, et al.</a> 114105669 Kopp, Jeffrey NIDDK Kopp, Jeffrey (NIDDK) 0 114105669 Kopp, Jeffrey NIDDK Kopp, Jeffrey (NIDDK) 0 114100693 Conditionally Immortalized Mouse Podocyte Cell Line With Tet-on System E-049-2007-0 Research Material Gunma University, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83698007 Rooke, Agnes rookeab@mail.nih.gov
United States of America Technology Advancement Office rookeab@mail.nih.gov?subject=Web Inquiry on [TAB-1503] Model for Study of Glomerular Disorders: Conditionally-Immortalized Mouse Podocyte Cell Line with Tet-on-Regulated Gene Expression&body=Please send me information about technology [TAB-1503] Model for Study of Glomerular Disorders: Conditionally-Immortalized Mouse Podocyte Cell Line with Tet-on-Regulated Gene Expression. Rooke, Agnes<br><a href="mailto:rookeab@mail.nih.gov?subject=Web Inquiry on [TAB-1503] Model for Study of Glomerular Disorders: Conditionally-Immortalized Mouse Podocyte Cell Line with Tet-on-Regulated Gene Expression&body=Please send me information about technology [TAB-1503] Model for Study of Glomerular Disorders: Conditionally-Immortalized Mouse Podocyte Cell Line with Tet-on-Regulated Gene Expression.">rookeab@mail.nih.gov</a><br> 114117600 ACXXXX 114117601 IDXXXX 114117602 UAXXXX 114117603 AXXXXX 114117604 IXXXXX 114156266 Idiopathic minimal change nephrotic syndrome 114156267 Glomerulonephritis 114156268 Focal segmental glomerulosclerosis 114158241 Minimal Change Disease 114158242 Focal segmental glomerulosclerosis; Focal segmental glomerul TAB-1501 114095770 A Varicella-Zoster Virus Mutant that is Markedly Impaired for Latent Infection Available for the Development of Shingles Vaccines and Diagnostics NIAID Collaboration, Diagnostics, Infectious Disease, Licensing, Vaccines Collaboration Diagnostics Infectious Disease Licensing Vaccines Jeffrey Cohen, Lesley Pesnicak Reactivation of latent Varicella-Zoster virus (VZV) infection is the cause of shingles, which is prominent in adults over the age of 60 and individuals who have compromised immune systems, due to HIV infection, cancer treatment and/or transplant. Shingles is a worldwide health concern that affects approximately 600,000 Americans each year. The incidence of shingles is also high in Europe, South America, and India; the latter having an estimated two million individuals affected, yearly. Recent research studies show that VZV vaccines have a significant effect on decreasing the incidence of shingles in elderly. <br><br> The current technology describes compositions, cells and methods related to the production and use of a mutant VZV and the development of vaccines against the infectious agent. Latent VZV expresses a limited repertoire of viral genes including the following six open reading frames (ORFs): 4, 21, 29, 62, 63, and 66. The present invention describes an ORF29 mutant VZV that demonstrates a weakened ability to establish latency in animal studies. The current technology provides methods for using the mutant in the development of live vaccines and diagnostic tools. A related invention is described in PCT/US05/021788 (publication number WO2006012092). Development of vaccines and diagnostics for prevention of shingles The NIAID Laboratory of Clinical Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize vaccine strains of VZV vaccine with impaired latency. Please contact Jason Freeman, J.D., at 301/451-5054 or <a href="mailto:freemanch@mail.nih.gov">freemanch@mail.nih.gov</a> for more information. Available for licensing and commercial development. 2022-03-18 2025-08-13 2025-08-15 2020-07-06 DA4BXX, DA4XXX, DAXXXX, DC5BXX, DC5XXX, DCXXXX, DXXXXX, imparied latency, Infection, Latent, MUTANT, ORF29 mutant, Varicella Zoster, VARICELLA-ZOSTER, virus False True Pre-clinical studies have been performed to demonstrate the reduced latency of the ORF29 mutant VZV in animals. Pre-clinical studies have been performed to demonstrate the reduced latency of the ORF29 mutant VZV in animals. True NIHTT 37470483 Website Abstract 114105665 Pesnicak, Lesley NIAID - DIR Pesnicak, Lesley 0 114105666 Cohen, Jeffrey NIAID - DIR NIAID Cohen, Jeffrey (NIAID) 1 114105666 Cohen, Jeffrey NIAID - DIR NIAID Cohen, Jeffrey (NIAID) 1 114105665 Pesnicak, Lesley NIAID - DIR Pesnicak, Lesley 0 114100691 A Varicella-zoster Virus Mutant That Is Markedly Impaired For Latent Infection E-029-2007-0 Filing authorized NIAID 91029846 Ganelina, Anna ganelinaa@niaid.nih.gov
United States of America ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-1501] A Varicella-Zoster Virus Mutant that is Markedly Impaired for Latent Infection Available for the Development of Shingles Vaccines and Diagnostics&body=Please send me information about technology [TAB-1501] A Varicella-Zoster Virus Mutant that is Markedly Impaired for Latent Infection Available for the Development of Shingles Vaccines and Diagnostics. Ganelina, Anna<br><a href="mailto:ganelinaa@niaid.nih.gov?subject=Web Inquiry on [TAB-1501] A Varicella-Zoster Virus Mutant that is Markedly Impaired for Latent Infection Available for the Development of Shingles Vaccines and Diagnostics&body=Please send me information about technology [TAB-1501] A Varicella-Zoster Virus Mutant that is Markedly Impaired for Latent Infection Available for the Development of Shingles Vaccines and Diagnostics.">ganelinaa@niaid.nih.gov</a><br> 114163629 E-029-2007-0 E-029-2007-0-PCT-02 A Varicella-zoster Virus Mutant That Is Markedly Impaired For Latent Infection PCT Patent Cooperation Treaty PCT/US2007/084331 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2007/084331<br />Filed on 2007-11-09<br />Status: Expired 114164541 E-029-2007-0 E-029-2007-0-US-01 Absence or Over-expression of the Varicella-Zoster Virus (VZV) ORF29 Latency Associated Protein Impairs Late Gene Expressions and Reduces VZV Latency in Rodents4 PRV US 60/857,766 Abandoned US <br />Provisional (PRV) 60/857,766<br />Filed on 2006-11-09<br />Status: Abandoned 114165196 E-029-2007-0 E-029-2007-0-US-03 Recombinant Virus with Diminished Latency and Methods of Using Same National Stage US 10,166,285 12/514,011 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10166285 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10166285">10,166,285</a><br />Filed on 2009-05-07<br />Status: Issued 114168809 E-029-2007-0 E-029-2007-0-US-04 RECOMBINANT VIRUS WITH DIMINISHED LATENCY AND METHODS OF USING SAME DIV US 11,305,009 16/195,247 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11305009 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11305009">11,305,009</a><br />Filed on 2018-11-19<br />Status: Issued 114169283 E-029-2007-0 E-029-2007-0-US-05 RECOMBINANT VIRUS WITH DIMINISHED LATENCY AND METHODS OF USING SAME DIV US 12,296,004 17/692,540 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12296004 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12296004">12,296,004</a><br />Filed on 2022-03-11<br />Status: Issued 114117592 DA4BXX 114117593 DC5BXX 114117594 DAXXXX 114117595 DCXXXX 114117596 DXXXXX 114119366 DA4XXX 114119367 DC5XXX 114133745 VARICELLA-ZOSTER 114133746 virus 114133747 MUTANT 114133748 ORF29 mutant 114133749 imparied latency 114133750 Latent 114133751 Infection 114156265 Varicella Zoster TAB-1473 114095742 ARH3, a Therapeutic Target for Cancer, Ischemia, and Inflammation NHLBI Collaboration, Diagnostics, Immunology, Licensing, Oncology, Reproductive Health, Research Materials, Therapeutics, Vaccines Collaboration Diagnostics Immunology Licensing Oncology Reproductive Health Research Materials Therapeutics Vaccines Joel Moss ADP-ribosylation is important in many cellular processes, including DNA replication and repair, maintenance of genomic stability, telomere dynamics, cell differentiation and proliferation, and necrosis and apoptosis. Poly-ADP-ribose is important in a number of critical physiological processes such as DNA repair, cellular differentiation, and carcinogenesis. Until recently, only one human enzyme, PARG, had been identified that degrades the ADP-ribose polymer. Another ADP-ribose, O-acetyl-ADP ribose, is formed via the deacetylation of proteins, such as acetyl-histone, by proteins in the Sir2 family. Sir2 proteins have been implicated in regulation of chromatin structure and longevity.<br><br> The NIH announces the discovery of a novel PARG-like enzyme, ARH3. ARH3 possesses PARG activity, yet is structurally distinct from PARG. ARH3 also hydrolyzes O-acetyl-ADP-ribose, and is the only protein recognized to date with such activity. ARH3 thus appears to function in two important signaling pathways, serving to regulate both poly-ADP-ribose and O-acetyl-ADP-ribose levels. It may affect chromatin structure through effects on both pathways. Since ARH3 structures differs from PARG or other enzymes that participate in these pathways, it may be possible to design specific inhibitors to target both the poly-ADP-ribose and Sir2 pathways. These drugs may be used as anticancer agents, radiosensitizers or antiviral agents, or for treating disorders involving oxidative damage, such as acute tissue injury, ischemia, and inflammation. <ul> <li>Development of therapeutics for cancer or disorders associated with excessive DNA damage</li> <li>Development of therapeutics for diseases involving oxidative damage, such as acute tissue injury, ischemia and inflammation</li> </ul> The Pulmonary Critical Care Medicine Branch in the National Heart, Lung, and Blood Institute is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize the invention. Please contact Brian W. Bailey, Ph.D. at 301-594-4094 or <a href="mailto:bbailey@mail.nih.gov">bbailey@mail.nih.gov</a> for more information. Available for licensing. 2022-03-08 2025-08-13 2025-08-15 2006-12-01 Activity, Alpha-NAD, Alpha-NADase, ARH3, CB6XXX, CBXXXX, Cell, CXXXXX, Enzyme, Hydrolase:, IB6XXX, IBXXXX, Ihe, IXXXXX, LEVELS, Maintenance, MAMMALIAN, MAY, PAR, PARG-like, Patent Category - Biotechnology, Poly-ADP-ribose, RELEVANT False True Early stage Early stage True NIHTT 37470483 Website Abstract 114170242 S Oka, J Kato, J Moss. Identification and characterization of a mammalian 39-kDa poly(ADP-ribose) glycohydrolase. J Biol Chem. 2006 Jan 13;281(2):705-713. http://preview.ncbi.nlm.nih.gov/pubmed/16278211 <a href="http://preview.ncbi.nlm.nih.gov/pubmed/16278211">S Oka, J Kato, J Moss. Identification and characterization of a mammalian 39-kDa poly(ADP-ribose) glycohydrolase. J Biol Chem. 2006 Jan 13;281(2):705-713.</a> 114170243 T Ono, A Kasamatsu, S Oka, J Moss. The 39-kDa poly(ADP-ribose) glycohydrolase ARH3 hydrolyzes O-acetyl-ADP-ribose, a product of the Sir2 family of acetyl-histone deacetylases. Proc Natl Acad Sci USA 2006 Nov 7;103(45):16687-16691. http://preview.ncbi.nlm.nih.gov/pubmed/17075046 <a href="http://preview.ncbi.nlm.nih.gov/pubmed/17075046">T Ono, A Kasamatsu, S Oka, J Moss. The 39-kDa poly(ADP-ribose) glycohydrolase ARH3 hydrolyzes O-acetyl-ADP-ribose, a product of the Sir2 family of acetyl-histone deacetylases. Proc Natl Acad Sci USA 2006 Nov 7;103(45):16687-16691.</a> 114105618 Moss, Joel NHLBI Moss, Joel (NHLBI) 0 114105618 Moss, Joel NHLBI Moss, Joel (NHLBI) 0 114100660 Alpha-NADase Activity Of ARH3 May Be Relevant To The Maintenance Of Alpha-NAD Levels In Ihe Mammalian Cell E-347-2004-1 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 83739538 Choudhry, Vidita vidita.choudhry@nih.gov
United States of America Office of Technology Transfer and Development vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-1473] ARH3, a Therapeutic Target for Cancer, Ischemia, and Inflammation&body=Please send me information about technology [TAB-1473] ARH3, a Therapeutic Target for Cancer, Ischemia, and Inflammation. Choudhry, Vidita<br><a href="mailto:vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-1473] ARH3, a Therapeutic Target for Cancer, Ischemia, and Inflammation&body=Please send me information about technology [TAB-1473] ARH3, a Therapeutic Target for Cancer, Ischemia, and Inflammation.">vidita.choudhry@nih.gov</a><br> 114163569 E-347-2004-1 E-347-2004-1-US-01 ADP-RIBOSYL ACCEPTOR HYDROLASE 3 (ARH3) POLYPEPTIDES AND METHODS OF USE CIP US 7,670,806 12/047,185 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7670806 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7670806">7,670,806</a><br />Filed on 2008-03-12<br />Status: Issued 114117470 CB6XXX 114117471 IB6XXX 114117472 CBXXXX 114117473 IBXXXX 114117474 CXXXXX 114117475 IXXXXX 114139966 Poly-ADP-ribose 114139967 PAR 114139968 Hydrolase: 114139969 PARG-like 114139970 Enzyme 114139971 Alpha-NADase 114139972 Activity 114139973 ARH3 114139974 MAY 114139975 RELEVANT 114139976 Maintenance 114139977 Alpha-NAD 114139978 LEVELS 114139979 Ihe 114139980 MAMMALIAN 114139981 Cell 114139982 Patent Category - Biotechnology TAB-1393 114095699 Model Th1 Clone Producing IFN-gamma and IL-2 NIAID Licensing, Research Materials Licensing Research Materials Toby Hecht, Dan Longo, Louis Matis, Ronald Schwartz Available for licensing is the A.E7 T cell clone, a model Th1 clone described in Matis et al., J Immunol. 1983 Apr;130(4):1527-1535 [<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=6187812&query_hl=8&itool=pubmed_DocSum" target="blank">PubMed abs</a>] and J Immunol. 1983 Sep;131(3):1049-1055 [<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=6193170&query_hl=8&itool=pubmed_DocSum" target="blank">PubMed abs</a>]. This clone has been further utilized as a model for studying T cell clonal anergy. <ul> <li>Model Th1 clone capable of making IFN-gamma and IL-2</li> <li>Model T cell clone for studying T cell clonal anergy</li> </ul> Available for non-exclusive licensing. 2022-03-08 2025-08-13 2025-08-15 2006-08-01 RXXXXX False True True NIHTT 37470483 Website Abstract 114105531 Schwartz, Ronald NIAID Schwartz, Ronald (NIAID) 0 114105532 Matis, Louis Matis, Louis 0 114105533 Longo, Dan NIA Longo, Dan (NIA) 0 114105534 Hecht, Toby NCI Hecht, Toby (NCI) 0 114105531 Schwartz, Ronald NIAID Schwartz, Ronald (NIAID) 0 114105532 Matis, Louis Matis, Louis 0 114105533 Longo, Dan NIA Longo, Dan (NIA) 0 114105534 Hecht, Toby NCI Hecht, Toby (NCI) 0 114100615 A.E7 CD4+ Thl Murine T Cell Clone E-214-2006-0 Research Material NCI, NIAID 148673287 Hafiz, Sabrina sabrina.hafiz@nih.gov
United States of America sabrina.hafiz@nih.gov?subject=Web Inquiry on [TAB-1393] Model Th1 Clone Producing IFN-gamma and IL-2&body=Please send me information about technology [TAB-1393] Model Th1 Clone Producing IFN-gamma and IL-2. Hafiz, Sabrina<br><a href="mailto:sabrina.hafiz@nih.gov?subject=Web Inquiry on [TAB-1393] Model Th1 Clone Producing IFN-gamma and IL-2&body=Please send me information about technology [TAB-1393] Model Th1 Clone Producing IFN-gamma and IL-2.">sabrina.hafiz@nih.gov</a><br> 114117285 RXXXXX TAB-1344 114095670 Identification of Candidate Ligands which Modulate Antigen Presenting Cells NIAID Collaboration, Diagnostics, Immunology, Infectious Disease, Licensing, Oncology, Research Materials, Therapeutics, Vaccines Collaboration Diagnostics Immunology Infectious Disease Licensing Oncology Research Materials Therapeutics Vaccines Polly Matzinger, John Ridge Available for licensing and commercial development are novel biotechnological tools, prophylactics, therapeutics, and methods for modulating the activation state of an antigen presenting cell (APC) and thereby modulating the activation of a killer T cell. The activation of a killer T cell can occur in a two cell complex and two sequential steps: a) in the first step, an APC stimulates a T helper T cell, which in turn stimulates or "superactivates" the APC to differentiate to a state where it can independently stimulate a killer T cell; b) in the second step, the APC encounters the killer T cell and stimulates it so that killer T cell priming is achieved in a helper independent fashion. The first step can be bypassed altogether by viral infection or an interaction with certain molecules at the cell surface of APCs, such as CD40. More specifically, the invention consists of a method of identifying a ligand as a candidate for incorporation into a pharmaceutical composition, such as a therapeutic or prophylactic product, that modulates antigen presenting cell activity, comprising contacting an APC with a candidate ligand which interacts with the APC, analyzing the activation state of the APC; and selecting ligands that activate a killer T cell in the absence of a helper T cells as the candidates for incorporation into the pharmaceutical. Also claimed are related methods where the ligand interacts with CD40 or where the APC is a dendritic cell. The embodiments have several applications in the field of immunology, and enable to manufacture novel pharmaceuticals and vaccine components for the treatment and prevention of cancer, systemic infection, and autoimmune responses. In addition to licensing, the technology is available for further development through collaborative research opportunities with the inventors. 2022-03-08 2025-08-13 2025-08-15 2006-05-01 CB6XXX, CBXXXX, CXXXXX, DB4XXX, DBXXXX, DC5XXX, DCXXXX, DXXXXX, IB3XXX, IBXXXX, IXXXXX False True True NIHTT 37470483 Website Abstract 114170150 JP Ridge, F Di Rosa, and P Matzinger, "A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell," Nature 1998 Jun 4; 393(6684):474-8. JP Ridge, F Di Rosa, and P Matzinger, "A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell," Nature 1998 Jun 4; 393(6684):474-8. 114105454 Matzinger, Polly NIAID Matzinger, Polly (NIAID) 0 114105455 Ridge, John Ridge, John 0 114105454 Matzinger, Polly NIAID Matzinger, Polly (NIAID) 0 114105455 Ridge, John Ridge, John 0 114100584 Identification and use of High Efficacy Vaccine Antigens Which Modulate Antigen Presenting Cells E-055-1999-0 Filing authorized NIAID 148673287 Hafiz, Sabrina sabrina.hafiz@nih.gov
United States of America sabrina.hafiz@nih.gov?subject=Web Inquiry on [TAB-1344] Identification of Candidate Ligands which Modulate Antigen Presenting Cells&body=Please send me information about technology [TAB-1344] Identification of Candidate Ligands which Modulate Antigen Presenting Cells. Hafiz, Sabrina<br><a href="mailto:sabrina.hafiz@nih.gov?subject=Web Inquiry on [TAB-1344] Identification of Candidate Ligands which Modulate Antigen Presenting Cells&body=Please send me information about technology [TAB-1344] Identification of Candidate Ligands which Modulate Antigen Presenting Cells.">sabrina.hafiz@nih.gov</a><br> 114163401 E-055-1999-0 E-055-1999-0-US-01 Identification of Candidate Ligands Which Modulate Antigen Presenting Cells ORD US 6,680,176 09/313,487 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6680176 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6680176">6,680,176</a><br />Filed on 1999-05-17<br />Status: Expired 114164713 E-055-1999-0 E-055-1999-0-US-03 Identification and use of High Efficacy Vaccine Antigens Which Modulate Antigen Presenting Cells CON US 11/315,081 Abandoned US <br />Continuation (CON) 11/315,081<br />Filed on 2005-12-22<br />Status: Abandoned 114165399 E-055-1999-0 E-055-1999-0-US-02 Identification and use of High Efficacy Vaccine Antigens Which Modulate Antigen Presenting Cells vbbb CON US 10/246,086 Abandoned US <br />Continuation (CON) 10/246,086<br />Filed on 2002-09-16<br />Status: Abandoned 114117134 CB6XXX 114117135 DB4XXX 114117136 DC5XXX 114117137 IB3XXX 114117138 CBXXXX 114117139 DBXXXX 114117140 DCXXXX 114117141 IBXXXX 114117142 CXXXXX 114117143 DXXXXX 114117144 IXXXXX TAB-1329 114095655 Monoclonal Antibody for Lyme Disease Diagnostic and Research NIAID Infectious Disease, Licensing, Research Materials Infectious Disease Licensing Research Materials Alan Barbour The hybridoma producing a monoclonal antibody against the major flagellin protein (FlaB) is available for licensing. This antibody can be used in diagnostic and research applications related to Lyme disease or other Borrelia-caused conditions. More information about this antibody can be found in Barbour et al., Infection and Immunity, May 1986, volume 52(5), pages 549-554. 2022-10-08 2025-08-13 2025-08-15 2006-05-01 Borreliosis, DDXXXX, DXXXXX, Lyme Disease False True True NIHTT 37470483 Website Abstract 114105426 Barbour, Alan NIAID Barbour, Alan (NIAID) 0 114105426 Barbour, Alan NIAID Barbour, Alan (NIAID) 0 114100564 Monoclonal Antibody To The Major Flagellin Protein (FLaB) Of Species Of The Bacterial Genus Borrelia. (Mab H9724) E-075-2006-0 Research Material NIAID 146046171 Joyce, Terrence terrence.joyce@nih.gov
United States of America terrence.joyce@nih.gov?subject=Web Inquiry on [TAB-1329] Monoclonal Antibody for Lyme Disease Diagnostic and Research&body=Please send me information about technology [TAB-1329] Monoclonal Antibody for Lyme Disease Diagnostic and Research. Joyce, Terrence<br><a href="mailto:terrence.joyce@nih.gov?subject=Web Inquiry on [TAB-1329] Monoclonal Antibody for Lyme Disease Diagnostic and Research&body=Please send me information about technology [TAB-1329] Monoclonal Antibody for Lyme Disease Diagnostic and Research.">terrence.joyce@nih.gov</a><br> 114117062 DDXXXX 114117063 DXXXXX 114156133 Borreliosis 114158151 Lyme Disease TAB-1302 114095628 Human Sweet and Umami Taste Receptor Variants NIDCD Collaboration, Diagnostics, Licensing, Research Materials, Therapeutics Collaboration Diagnostics Licensing Research Materials Therapeutics Dennis Drayna, Un-kyung Kim The complexity of taste discrimination (salty, sour, sweet, umami and bitter) varies between human individuals and populations. Sweet and umami (the taste of glutamate) tastes play a major role in the perception of calorically-rich and essential nutrients and there are well-documented differences in individual perception of sweet and umami flavorings, many of which appear to be genetic in origin. Studies of individuals within and between populations that vary in any of the taste receptors should be of direct interest to the multi-billion dollar food and flavoring industry as the characterization of such variants could be used to aid in the development of a variety of taste improvements in foods and orally administered medications. NIH researchers previously characterized bitter taste receptor variants in world wide populations [Human Mutation 26, 199-204; HHS Ref. No. E-222-2003/0] and have now extended their studies to the sweet and umami receptors in global populations. <br><br> The group of Dr. Dennis Drayna at NIDCD have now discovered novel coding sequence polymorphisms in the human TAS1R genes. These genes encode dimeric receptors that sense sweet taste (as TAS1R2+TAS1R3) and the taste of umami (as TAS1R1+TAS1R3). To achieve maximum genetic diversity, TAS1R receptors from a panel of 30 Europeans, 20 East Asian, 10 Native Americans, 8 South Asians and 20 sub-Saharan Africans were sequenced. Approximately 60% of the identified SNPs caused an amino acid substitution in the encoded receptor protein. This variation may account for individual preferences in sweet and umami tastes in foods and could be of use in the understanding and control of dietary preferences that lead to obesity and diabetes. <br><br> These novel variants and methods of use are available for licensing and should be of particular use to those using sensorial analysis in the food and flavoring industry where the use of taster panels in the development of flavors and flavor enhancers for different foods is key to the development of new food products and taste masking compounds. The ability, for example, to genetically match taster individuals employed by industry with the target consumer populations can both guide improved formulations and marketing decisions as well as reducing the total sample size in the testing of new products in this highly competitive industry. In addition to licensing, the technology is available for further development through collaborative research opportunities with the inventors. 2022-03-08 2025-08-13 2025-08-15 2006-02-01 AC4XXX, ACXXXX, AXXXXX, GENOTYPES, Haplotypes, Human, ICXXXX, IXXXXX, population genetics, SNPs, sweet taste, TASTE, taste evaluation, taste receptors, umamai taste, VARIANTS False True True NIHTT 37470483 Website Abstract E-222-2003-1 E-169-2001-0 114105379 Kim, Un-kyung Kim, Un-kyung 0 114105378 Drayna, Dennis National Institute on Deafness and Other Communication Disorders (NIDCD) NIDCD Drayna, Dennis (NIDCD) 1 114105378 Drayna, Dennis National Institute on Deafness and Other Communication Disorders (NIDCD) NIDCD Drayna, Dennis (NIDCD) 1 114105379 Kim, Un-kyung Kim, Un-kyung 0 114100533 Human Sweet And Umami Taste Receptor Variants E-099-2005-0 Filing authorized National Institute on Deafness and Other Communication Disorders (NIDCD) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-1302] Human Sweet and Umami Taste Receptor Variants&body=Please send me information about technology [TAB-1302] Human Sweet and Umami Taste Receptor Variants. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-1302] Human Sweet and Umami Taste Receptor Variants&body=Please send me information about technology [TAB-1302] Human Sweet and Umami Taste Receptor Variants.">shmilovm@nih.gov</a><br> 114161879 E-099-2005-0 E-099-2005-0-PCT-02 Human Sweet And Umami Taste Receptor Variants PCT Patent Cooperation Treaty PCT/US2006/014045 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2006/014045<br />Filed on 2006-04-13<br />Status: Expired 114162358 E-099-2005-0 E-099-2005-0-US-01 Human Sweet And Umami Taste Receptor Variants PRV US 60/671,173 Abandoned US <br />Provisional (PRV) 60/671,173<br />Filed on 2005-04-13<br />Status: Abandoned 114163268 E-099-2005-0 E-099-2005-0-US-03 Human Sweet And Umami Taste Receptor Variants National Stage US 8,796,441 11/911,517 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8796441 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8796441">8,796,441</a><br />Filed on 2007-10-12<br />Status: Issued 114116894 AC4XXX 114116895 ACXXXX 114116896 ICXXXX 114116898 AXXXXX 114116899 IXXXXX 114136358 Human 114136359 Haplotypes 114136360 umamai taste 114136361 TASTE 114136362 sweet taste 114136363 VARIANTS 114136364 taste receptors 114136365 GENOTYPES 114136366 taste evaluation 114136367 population genetics 114136368 SNPs TAB-1290 114095615 Active MRI Compatible and Visible iMRI Catheter NHLBI Collaboration Collaboration Ozgur Kocaturk MRI is a promising imaging modality that provides superior soft tissue contrast and multi planar real-time imaging without harmful ionizing radiation for therapeutic procedures. Interventional magnetic resonance imaging (iMRI) has gained important popularity in many fields such as interventional cardiology and radiology, owing to the development of minimally invasive techniques and visible catheters under MRI for conducting MRI-guided procedures and therapies. This invention relates to a novel MRI compatible and active visible catheter for conducting interventional and intraoperative procedures under the guidance of MRI. The catheter features a non conductive transmission line and the use of ultrasonic transducers that transform RF signals to ultrasonic signals for transmitting RF signal to the MRI scanner. The unique design of this catheter overcomes the concern of patient/sample heating (due to the coupling between RF transmission energy and long conductors within catheter) associated with the design of conventional active MRI catheters. The National Heart, Lung, and Blood Institute, Cardiovascular Intervention Program, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize the alternative Active MRI compatible and visible catheters using ultrasonic technology. Please contact Peg Koelble at <a href="mailto:koelblep@nhlbi.nih.gov">koelblep@nhlbi.nih.gov</a> for more information. 2022-03-08 2025-08-13 2025-08-15 2008-03-01 AA3XXX, AA4XXX, AAXXXX, AXXXXX False True True NIHTT 37470483 Website Abstract 114105362 Kocaturk, Ozgur NHLBI Kocaturk, Ozgur (NHLBI) 0 114105362 Kocaturk, Ozgur NHLBI Kocaturk, Ozgur (NHLBI) 0 114100521 Active MRI Compatible And Visible IMRI Catheter With A Wireless Solution E-298-2005-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-1290] Active MRI Compatible and Visible iMRI Catheter&body=Please send me information about technology [TAB-1290] Active MRI Compatible and Visible iMRI Catheter. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-1290] Active MRI Compatible and Visible iMRI Catheter&body=Please send me information about technology [TAB-1290] Active MRI Compatible and Visible iMRI Catheter.">shmilovm@nih.gov</a><br> 114163231 E-298-2005-0 E-298-2005-0-US-01 Active MRI Compatible And Visible IMRI Catheter PRV US 60/716,503 Abandoned US <br />Provisional (PRV) 60/716,503<br />Filed on 2005-09-14<br />Status: Abandoned 114163232 E-298-2005-0 E-298-2005-0-PCT-02 Active MRI Compatible And Visible IMRI Catheter PCT Patent Cooperation Treaty PCT/US2006/035636 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2006/035636<br />Filed on 2006-09-13<br />Status: Expired 114163233 E-298-2005-0 E-298-2005-0-US-03 Active MRI Compatible And Visible IMRI Catheter ORD US 11/992,064 Abandoned US <br />Ordinary Patent (ORD) 11/992,064<br />Filed on 2008-03-14<br />Status: Abandoned 114163234 E-298-2005-0 E-298-2005-0-EP-04 MRI Cathether Comprising Means For Suppressing National Stage European Patent 1943535 06803494.1 Issued European Patent <br />National Stage 06803494.1<br />Filed on 2006-09-13<br />Status: Issued 114116847 AA3XXX 114116848 AA4XXX 114116849 AAXXXX 114116850 AXXXXX TAB-1241 114095567 Conjugate Vaccine for Neisseria Meningitidis NIDCD Infectious Disease, Licensing, Vaccines Infectious Disease Licensing Vaccines Xinxing Gu, Chao-ming Tsai The invention discloses a vaccine which comprises lipooligosaccharide (LOS) isolated from N. meningitidis and conjugated to a carrier protein. The invention also discloses a method of making the acellular vaccine. The method consists of two main steps. In the first step the lipooligosaccharide (LOS), chosen so it does not contain the lacto-N-neotetraose human antigen (LNnT), is detoxified by a novel procedure which uses hydrazine to remove the O-linked fatty acids. In the second step, the detoxified LOS (dLOS) is covalently conjugated to a carrier protein such as Tetanus Toxoid (TT). The dLOS produced in step 1 is 10,000 fold less toxic than the parent LOS. The conjugate vaccine exhibited a high level of immunogenicity as evidenced by the high titer of IgG antibody to native LOS, obtained in mice and rabbits. The rabbit antisera produced by the conjugate vaccine of one N.meningitidis strain (strain 7880, A,L10) exhibited bactericidal activity and cross reactivity with heterologous N. meningitidis strains. A conjugate vaccine made in this method may be multivalent, composed of dLOSs from different strains and/or immunotypes of N. meningitidis and will thus protect against all types of N. meningitidis, including type B. 2022-03-08 2025-08-13 2025-08-15 2000-04-01 DC4XXX, DCXXXX, DXXXXX, Neisseria meningitidis, Tetanus False True True NIHTT 37470483 Website Abstract 114105284 Gu, Xinxing NIAID Gu, Xinxing (NIAID) 0 114105285 Tsai, Chao-ming FDA Tsai, Chao-ming (FDA) 0 114105284 Gu, Xinxing NIAID Gu, Xinxing (NIAID) 0 114105285 Tsai, Chao-ming FDA Tsai, Chao-ming (FDA) 0 114100476 Conjugate Vaccine for Neisseria Meningitidis E-078-1999-0 FDA, National Institute on Deafness and Other Communication Disorders (NIDCD) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-1241] Conjugate Vaccine for Neisseria Meningitidis&body=Please send me information about technology [TAB-1241] Conjugate Vaccine for Neisseria Meningitidis. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-1241] Conjugate Vaccine for Neisseria Meningitidis&body=Please send me information about technology [TAB-1241] Conjugate Vaccine for Neisseria Meningitidis.">shmilovm@nih.gov</a><br> 114163119 E-078-1999-0 E-078-1999-0-US-02 Conjugate Vaccine for Neisseria Meningitidis ORD US 6,531,131 09/626,003 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6531131 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6531131">6,531,131</a><br />Filed on 2000-07-26<br />Status: Expired 114165594 E-078-1999-0 E-078-1999-0-US-01 Conjugate Vaccine for Neisseria Meningitidis PRV US 60/148,021 Abandoned US <br />Provisional (PRV) 60/148,021<br />Filed on 1999-08-10<br />Status: Abandoned 114116627 DC4XXX 114116628 DCXXXX 114116629 DXXXXX 114156007 Neisseria meningitidis 114156008 Tetanus TAB-124 114094464 Versatile Reagent For Detecting Murine Leukemia Viruses NIAID Diagnostics, Infectious Disease, Licensing, Research Materials Diagnostics Infectious Disease Licensing Research Materials William Britt, Leonard Evans Monoclonal antibodies directed at the proteins of murine leukemia viruses (MuLVs) have some value as immunological reagents, but differ greatly in their applicability. The kit described in this invention uses a monoclonal antibody designated 83A25, which identifies almost all ecotropic, xenotropic, polytropic, and amphotropic MuLVs. It can be used in a wide variety of procedures, including focal immunofluorescence assays on live or fixed monolayers, immunoblotting, immunoprecipitation, immunohistochemical, and flow cytometric procedures. This kit overcomes some of the problems associated with prior methods, which may not efficiently precipitate proteins or react in immunoblots, are not capable of detecting MuLVs belonging to all classes with a single reagent, and may not efficiently neutralize all MuLVs. 2022-03-08 2025-08-13 2025-08-15 1997-10-01 DA4BXX, DAXXXX, DDXXXX, DXXXXX False True True NIHTT 37470483 Website Abstract 114103167 Evans, Leonard NIAID Evans, Leonard (NIAID) 0 114103168 Britt, William Britt, William 0 114103167 Evans, Leonard NIAID Evans, Leonard (NIAID) 0 114103168 Britt, William Britt, William 0 114099250 VERSATILE REAGENT FOR DETECTING MURINE LEUKEMIA VIRUSES E-059-1990-0 Filing authorized NIAID 146046171 Joyce, Terrence terrence.joyce@nih.gov
United States of America terrence.joyce@nih.gov?subject=Web Inquiry on [TAB-124] Versatile Reagent For Detecting Murine Leukemia Viruses&body=Please send me information about technology [TAB-124] Versatile Reagent For Detecting Murine Leukemia Viruses. Joyce, Terrence<br><a href="mailto:terrence.joyce@nih.gov?subject=Web Inquiry on [TAB-124] Versatile Reagent For Detecting Murine Leukemia Viruses&body=Please send me information about technology [TAB-124] Versatile Reagent For Detecting Murine Leukemia Viruses.">terrence.joyce@nih.gov</a><br> 114160177 E-059-1990-0 E-059-1990-0-US-02 A VERSATILE REAGENT FOR DETECTING LEUKEMIA VIRUS FWC US 6,709,811 08/046,352 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6709811 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6709811">6,709,811</a><br />Filed on 1993-04-08<br />Status: Expired 114165875 E-059-1990-0 E-059-1990-0-US-01 VERSATILE REAGENT FOR DETECTING MURINE LEUKEMIA VIRUSES ORD US 07/528,714 Abandoned US <br />Ordinary Patent (ORD) 07/528,714<br />Filed on 1990-05-24<br />Status: Abandoned 114165910 E-059-1990-0 E-059-1990-0-PCT-03 MONOCLONAL ANTIBODIES FOR DETECTION OF FRIEND MURINE LEUKEMIA VIRUS PCT Patent Cooperation Treaty PCT/US1992/003567 Expired Patent Cooperation Treaty <br />(PCT) PCT/US1992/003567<br />Filed on 1992-05-04<br />Status: Expired 114112108 DA4BXX 114112109 DDXXXX 114112110 DAXXXX 114112111 DXXXXX TAB-1217 114095544 Attenuated Human Parainfluenza Virus (PIV) for Use as Live, Attenuated Vaccines and as Vector Vaccines NIAID Collaboration, Infectious Disease, Licensing, Rare/Neglected Diseases, Vaccines Collaboration Infectious Disease Licensing Rare/Neglected Diseases Vaccines Peter Collins, Brian Murphy, Sheila Nolan, Mario Skiadopoulos The identified technologies describe self-replicating infectious recombinant paramyxoviruses with one or more attenuating mutations, such as a separate variant polynucleotide encoding a P protein and a separate monocistronic polynucleotide encoding a V protein, or at least one temperature sensitive mutation and one non-temperature sensitive mutation. Compositions and methods for recovering, making and using the infectious, recombinant paramyxoviruses as described are also included (e.g. recombinant human parainfluenza virus type 2 (HPIV2)). In addition, these inventions provide novel tools and methods for introducing defined, predetermined structural and phenotypic changes into an infectious HPIV2 candidate for use in immunogenic compositions, including live attenuated virus vaccines. Furthermore, these inventions describe the recombinant HPIV2 P+V can be used to introduce attenuating mutations to develop live attenuated virus vaccines. The paramyxoviruses of the invention are also useful as vectors for expressing heterologous antigens (e.g. RSV, HMPV, measles or mumps viruses) in an immunogenic composition. As members of the paramyxoviruses, HPIVs are important pathogens causing severe lower respiratory tract infections in infants and young children. Despite considerable efforts, there are currently no parainfluenza virus vaccines available. <br><br> Advantages of the subject technologies to generate live attenuated viruses or vectored vaccine candidates via multiple mutations are the design of safe and stable viral vaccine candidates. Since two common vaccine development approaches (viral subunit vaccines and inactivated whole virus preparations) elicited either short-lived, inadequate immunity or unfavorable immune responses, the identified technologies provide a promising means to develop vaccines against HPIVs and other human pathogens. In addition, live attenuated viruses are the most promising candidate vaccines because they induce both local and systemic immunity and are efficacious even in the presence of passively transferred serum antibodies, the very situation found in the target population of infants with maternally derived antibodies. In addition to licensing, the technology is available for further development through collaborative research opportunities with the inventors. 2022-03-08 2025-08-13 2025-08-15 2005-09-01 cDNA, CIS-ACTING, Complete, DC5BXX, DC5XXX, DCXXXX, Determination, DXXXXX, FOR..., FRAMES, Gene, Generate, Generation, Genomic, HPIV2, HPIV2., HPIV2/V94, Identification, MEASLES, Mumps, MUTATION, Novel, Nucleotide, Overlapping, P/V, Parainfluenza virus type 3, Parainfluenza virus type 3; Human parainfluenza virus type 3, Reading, recombinant, rHPIV2, Separated, sequence, Strain, UA1XXX, USEFUL, V94 False True True NIHTT 37470483 Website Abstract 114106358 Collins, Peter NIAID - DIR NIAID Collins, Peter (NIAID) 0 114106359 Nolan, Sheila NIAID - DIR Nolan, Sheila 0 114106361 Skiadopoulos, Mario NIAID - DIR NIAID Skiadopoulos, Mario (NIAID) 0 114106357 Murphy, Brian NIAID - DIR NIAID Murphy, Brian (NIAID) 1 114106357 Murphy, Brian NIAID - DIR NIAID Murphy, Brian (NIAID) 1 114106358 Collins, Peter NIAID - DIR NIAID Collins, Peter (NIAID) 0 114106359 Nolan, Sheila NIAID - DIR Nolan, Sheila 0 114106361 Skiadopoulos, Mario NIAID - DIR NIAID Skiadopoulos, Mario (NIAID) 0 114100447 Complete Genomic Nucleotide Sequence Determination of HPIV2 Strain V94 and Generation of a Recombinant HPIV2/V94 From cDNA Useful For... E-092-2002-0 Filing authorized NIAID 114100448 Separated Overlapping Reading Frames Of The P/V Gene HPIV2 To Generate A Recombinant HPIV2 (rHPIV2) And Identification Of A Novel Cis-acting Mutation In HPIV2. E-295-2004-0 Filing authorized NIAID 91027763 Puglielli, Maryann maryann.puglielli@nih.gov
United States of America maryann.puglielli@nih.gov?subject=Web Inquiry on [TAB-1217] Attenuated Human Parainfluenza Virus (PIV) for Use as Live, Attenuated Vaccines and as Vector Vaccines&body=Please send me information about technology [TAB-1217] Attenuated Human Parainfluenza Virus (PIV) for Use as Live, Attenuated Vaccines and as Vector Vaccines. Puglielli, Maryann<br><a href="mailto:maryann.puglielli@nih.gov?subject=Web Inquiry on [TAB-1217] Attenuated Human Parainfluenza Virus (PIV) for Use as Live, Attenuated Vaccines and as Vector Vaccines&body=Please send me information about technology [TAB-1217] Attenuated Human Parainfluenza Virus (PIV) for Use as Live, Attenuated Vaccines and as Vector Vaccines.">maryann.puglielli@nih.gov</a><br> 114163050 E-092-2002-0 E-092-2002-0-US-10 Recovery of Recombinant Human Parainfluenza Virus Type 2 (HPIV2) From cDNA and Use of Recombinant HPIV2 in Immunogenic Compositions and as Vectors to Elicit Immune Responses Against PIV and Other Human Pathogens DIV US 8,367,074 11/863,196 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8367074 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8367074">8,367,074</a><br />Filed on 2007-09-27<br />Status: Issued 114163051 E-092-2002-0 E-092-2002-0-US-09 Recovery of Recombinant Human Parainfluenza Virus Type 2 (HPIV2) from cDNA and Use of Recombinant HPIV2 in Immunogenic Compositions and as Vectors to Elicit Immune Responses Against PIV and other Human Pathogens DIV US 7,919,301 11/864,120 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7919301 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7919301">7,919,301</a><br />Filed on 2007-09-28<br />Status: Expired 114163052 E-092-2002-0 E-092-2002-0-PCT-03 (HPIV2) Form cDNA and Use of Recombinant HPIV2 in Immunogenic Compositions and as Vectors to Elicit Immune Responses Against PIV and Other Human Pathogens PCT Patent Cooperation Treaty PCT/US03/29685 Expired Patent Cooperation Treaty <br />(PCT) PCT/US03/29685<br />Filed on 2003-09-18<br />Status: Expired 114163053 E-092-2002-0 E-092-2002-0-US-02 Recovery of Recombinant Human Parainfluenza Virus Type 2 (HPIV2) From cDNA and Use of Recombinant HPIV2 in Immunogenic Compositions and as Vectors to Elicit Immune Responses Against PIV and Other Human Pathogens ORD US 7,820,181 10/667,141 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7820181 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7820181">7,820,181</a><br />Filed on 2003-09-18<br />Status: Expired 114163054 E-092-2002-0 E-092-2002-0-US-01 Recovery of Recombinant Human Parainfluenza Virus Type 2 (HPIV2) From cDNA and Use of Recombinant HPIV2 in Immunogenic Compositions and as Vectors to Elicit Immune Responses Against PIV and Other Human Pathogens. PRV US 60/412,053 Abandoned US <br />Provisional (PRV) 60/412,053<br />Filed on 2002-09-18<br />Status: Abandoned 114164149 E-295-2004-0 E-295-2004-0-US-07 Attenuated Human Parainfluenza Virus, Methods, And Uses Thereof National Stage US 9,034,343 13/501,447 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9034343 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9034343">9,034,343</a><br />Filed on 2006-01-10<br />Status: Issued 114164150 E-295-2004-0 E-295-2004-0-PCT-02 Attenuated Human Parainfluenza Virus, Methods And Uses Thereof PCT COMB Patent Cooperation Treaty PCT/US2006/000666 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2006/000666<br />Filed on 2006-01-10<br />Status: Expired 114164430 E-295-2004-0 E-295-2004-0-US-01 ATTENUATED HUMAN PARAINFLUENZA VIRUS, METHODS AND USES THEREOF PRV US 60/643,310 Abandoned US <br />Provisional (PRV) 60/643,310<br />Filed on 2005-01-12<br />Status: Abandoned 114116538 DC5BXX 114116539 DCXXXX 114116540 DXXXXX 114119392 UA1XXX 114119393 DC5XXX 114133939 Separated 114133940 Overlapping 114133941 Reading 114133942 FRAMES 114133943 P/V 114133944 Gene 114133945 HPIV2 114133946 Generate 114133947 recombinant 114133948 rHPIV2 114133949 Identification 114133950 Novel 114133951 CIS-ACTING 114133952 MUTATION 114133953 HPIV2. 114133954 Complete 114133955 Genomic 114133956 Nucleotide 114133957 sequence 114133958 Determination 114133959 Strain 114133960 V94 114133961 Generation 114133962 HPIV2/V94 114133963 cDNA 114133964 USEFUL 114133965 FOR... 114155966 MEASLES 114155967 Mumps 114155968 Parainfluenza virus type 3 114158060 Parainfluenza virus type 3; Human parainfluenza virus type 3 TAB-119 114094459 Human T Cell Line Chronically Infected With HIV NIAID Infectious Disease, Licensing Infectious Disease Licensing Kathleen Clouse, Douglas Powell A stable line of human T cells (ACH-2) was developed in which cells infected chronically with the AIDS virus (HIV) remained nonproductive prior to exposure to phorbol esters or human cytokines. This situation mimics the latent state of HIV and the development of AIDS in humans and indicates that the full-blown disease may be triggered by cellular-derived substances (e.g., cytokines). This is the first description of such a cell line. 2022-03-08 2025-08-13 2025-08-15 2001-01-01 DEXXXX, DXXXXX False True True NIHTT 37470483 Website Abstract 114103153 Powell, Douglas NIAID Powell, Douglas (NIAID) 0 114103154 Clouse, Kathleen FDA Clouse, Kathleen (FDA) 0 114103153 Powell, Douglas NIAID Powell, Douglas (NIAID) 0 114103154 Clouse, Kathleen FDA Clouse, Kathleen (FDA) 0 114099245 HIV CHRONICALLY INFECTED HUMAN T CELL CLONE E-143-1989-0 Filing authorized NIAID 83724572 Tung, Peter peter.tung@nih.gov
United States of America DIR peter.tung@nih.gov?subject=Web Inquiry on [TAB-119] Human T Cell Line Chronically Infected With HIV&body=Please send me information about technology [TAB-119] Human T Cell Line Chronically Infected With HIV. Tung, Peter<br><a href="mailto:peter.tung@nih.gov?subject=Web Inquiry on [TAB-119] Human T Cell Line Chronically Infected With HIV&body=Please send me information about technology [TAB-119] Human T Cell Line Chronically Infected With HIV.">peter.tung@nih.gov</a><br> 114160165 E-143-1989-0 E-143-1989-0-US-02 HUMAN T CELL LINE CHRONICALLY INFECTED WITH HIV FWC US 5,459,056 07/919,378 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/5459056 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/5459056">5,459,056</a><br />Filed on 1992-07-29<br />Status: Expired 114165568 E-143-1989-0 E-143-1989-0-US-01 HIV CHRONICALLY INFECTED HUMAN T CELL CLONE ORD US 07/399,079 Abandoned US <br />Ordinary Patent (ORD) 07/399,079<br />Filed on 1989-08-28<br />Status: Abandoned 114112090 DEXXXX 114112091 DXXXXX TAB-1045 114095375 Modified Bacterial Strain for Otitis Media Vaccine NIDCD Collaboration, Infectious Disease, Licensing, Materials Available, Vaccines Collaboration Infectious Disease Licensing Materials Available Vaccines Xinxing Gu, Daxin Peng This invention relates to a strain of Moraxella catarrhalis containing a gene mutation that prevents endotoxic lipooligosaccharide (LOS) synthesis and potential use of the mutant for developing novel vaccines against the pathogen, for which there is currently no licensed vaccine. M. catarrhalis is one of the causative agents of otitis media (middle ear infection), sinusitis, and lung infections. The mutant is defective in the lpxA gene, whose enzyme product is relevant in lipid A biosynthesis (lipid A is part of the LOS). The nontoxic mutant was found to elicit high levels of antibodies with bactericidal activity and provided protection against wild type bacterial challenge. Use of this mutant bacterium is envisioned as a new approach for vaccines against M. catarrhalis. <ul> <li>Otitis media vaccine</li> <li>Sinusitis</li> <li>Lung infections</li> </ul> The Vaccine Research Section in the National Institute on Deafness and Other Communication Disorders (NIDCD) is seeking statements of capability or interest from parties interested in collaborative research. NIDCD is interested in developing outer membrane proteins (OMP), outer membrane vesicle (OMV), and whole cell vaccines generated from the mutant. The mutant strain can also be used as an effective vehicle to express and deliver protective antigens from other important human pathogens. Please contact Dr. Xin-Xing Gu by phone (301/402-2456) or email (<a href="mailto:guxx@nidcd.nih.gov">guxx@nidcd.nih.gov</a>) for more information. Available for non-exclusive licensing - biological materials 2022-03-08 2025-08-13 2025-08-15 2006-12-01 DC4XXX, DCXXXX, DXXXXX False True True NIHTT 37470483 Website Abstract 114104970 Gu, Xinxing NIAID Gu, Xinxing (NIAID) 0 114104971 Peng, Daxin Peng, Daxin 0 114104970 Gu, Xinxing NIAID Gu, Xinxing (NIAID) 0 114104971 Peng, Daxin Peng, Daxin 0 114100263 Moraxella (or Branhamella) Catarrhalis Is Viable Without Endotoxin, A Potential Vaccine Candidate E-174-2004-0 Filing authorized National Institute on Deafness and Other Communication Disorders (NIDCD) 114100264 Moraxella (or Branhamella) Catarrhalis Is Viable Without Endotoxin, A Potential Vaccine Candidate E-174-2004-1 Filing authorized National Institute on Deafness and Other Communication Disorders (NIDCD) 114100265 Moraxella (or Branhamella) Catarrhalis Is Viable Without Endotoxin, A Potential Vaccine Candidate E-174-2004-2 Filing authorized National Institute on Deafness and Other Communication Disorders (NIDCD) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-1045] Modified Bacterial Strain for Otitis Media Vaccine&body=Please send me information about technology [TAB-1045] Modified Bacterial Strain for Otitis Media Vaccine. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-1045] Modified Bacterial Strain for Otitis Media Vaccine&body=Please send me information about technology [TAB-1045] Modified Bacterial Strain for Otitis Media Vaccine.">shmilovm@nih.gov</a><br> 114162632 E-174-2004-0 E-174-2004-0-US-01 Moraxella (or Branhamella) Catarrhalis Is Viable Without Endotoxin, A Potential Vaccine Candidate PRV US 60/577,244 Abandoned US <br />Provisional (PRV) 60/577,244<br />Filed on 2004-06-04<br />Status: Abandoned 114162634 E-174-2004-1 E-174-2004-1-US-01 Moraxella (or Branhamella) Catarrhalis Is Viable Without Endotoxin, A Potential Vaccine Candidate PRV US 60/613,139 Abandoned US <br />Provisional (PRV) 60/613,139<br />Filed on 2004-09-23<br />Status: Abandoned 114162636 E-174-2004-2 E-174-2004-2-PCT-01 Moraxella-Free Moraxella Catarrhalis PCT COMB Patent Cooperation Treaty PCT/US2005/019479 Abandoned Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2005/019479<br />Filed on 2005-06-03<br />Status: Abandoned 114115827 DC4XXX 114115828 DCXXXX 114115829 DXXXXX TAB-1003 114095335 Accelerated Vaccination Strategies to Provide Protection Against Viral Infections NIAID Infectious Disease, Licensing, Vaccines Infectious Disease Licensing Vaccines Gary Nabel The technology described in this patent application relates to recombinant viruses for use as vaccines. These viruses contain a single or plurality of sequences encoding antigens from pathogenic viruses heterologous to the recombinant virus. The antigenic sequences from pathogens such as influenza, RSV, measles, HPV, Epstein-Barr, Lassa, Polio, West Nile, Dengue, HIV-1 and 2, HTLV, herpes simplex virus, hepatitis viruses A, B, C, D, and E, Marburg, Ebola, and SARS are inserted into non-essential regions of either replication-competent or replication-defective adenovirus, adeno-associated virus (AAV), SV40 virus, herpes simplex virus, or vaccinia virus vectors that retain elements necessary for infectivity but are devoid of any pathogenic sequence elements. In these recombinant viruses, the antigenic sequences are operably linked to viral control elements. Thus, these recombinant viruses are capable of infecting a host and mounting an immune response specific to a given virus(es) without eliciting pathogenicity. In addition to the above, the technology also describes methods of accelerated pre-exposure or post-exposure vaccination comprising single-dose administration. The attractive features of this invention include the broad applicability of the recombinant viruses against a number of common pathogens and the potential of using them against other emergent infectious viruses; the ability of the vaccines to stimulate both cellular and humoral immune responses in humans and other hosts; and the ease of administration in single dose form via a number of routes. This technology is now available for licensing. Some fields of use may not be available. 2022-03-08 2025-08-13 2025-08-15 2004-11-01 DC5BXX, DCXXXX, Dengue (Flaviviridae), DXXXXX, Hepatitis A, Hepatitis D, Hepatitis E, HTLV-1, HTLV-2, HTLV-3, Human T Cell Leukemia Virus 1, Human T-cell leukemia viruses type 2, Human T-lymphotropic virus type 3, MEASLES False True True NIHTT 37470483 Website Abstract 114104905 Nabel, Gary NIAID Nabel, Gary (NIAID) 0 114104905 Nabel, Gary NIAID Nabel, Gary (NIAID) 0 114100214 Accelerated Vaccination Strategies To Provide Protection Against Viral Infection E-317-2003-0 Filing authorized NIAID, US Army Medical Research Institute of Infectious Disease 148673287 Hafiz, Sabrina sabrina.hafiz@nih.gov
United States of America sabrina.hafiz@nih.gov?subject=Web Inquiry on [TAB-1003] Accelerated Vaccination Strategies to Provide Protection Against Viral Infections&body=Please send me information about technology [TAB-1003] Accelerated Vaccination Strategies to Provide Protection Against Viral Infections. Hafiz, Sabrina<br><a href="mailto:sabrina.hafiz@nih.gov?subject=Web Inquiry on [TAB-1003] Accelerated Vaccination Strategies to Provide Protection Against Viral Infections&body=Please send me information about technology [TAB-1003] Accelerated Vaccination Strategies to Provide Protection Against Viral Infections.">sabrina.hafiz@nih.gov</a><br> 114160525 E-317-2003-0 E-317-2003-0-US-06 Accelerated Vaccination National Stage US 7,635,485 11/332,976 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7635485 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7635485">7,635,485</a><br />Filed on 2006-01-17<br />Status: Expired 114162515 E-317-2003-0 E-317-2003-0-US-01 Accelerated Vaccination PRV US 60/491,933 Abandoned US <br />Provisional (PRV) 60/491,933<br />Filed on 2003-08-01<br />Status: Abandoned 114164587 E-317-2003-0 E-317-2003-0-PCT-02 Accelerated Vaccination PCT Patent Cooperation Treaty PCT/US2004/024781 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2004/024781<br />Filed on 2004-08-02<br />Status: Expired 114165665 E-317-2003-0 E-317-2003-0-US-07 Accelerated Vaccination Strategies To Provide Protection Against Viral Infection CON US 8,017,130 12/613,018 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8017130 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8017130">8,017,130</a><br />Filed on 2009-11-05<br />Status: Expired 114115658 DC5BXX 114115659 DCXXXX 114115660 DXXXXX 114155780 Hepatitis D 114155781 MEASLES 114155782 Hepatitis A 114155783 Human T-cell leukemia viruses type 2 114155784 Human T Cell Leukemia Virus 1 114155785 Hepatitis E 114155786 Human T-lymphotropic virus type 3 114157888 Dengue (Flaviviridae) 114157968 HTLV-2 114157969 HTLV-1 114157970 HTLV-3 TAB-1531 114095799 Antibodies Against TL1A, a TNF-Family Cytokine, for the Treatment and Diagnosis of Autoimmune Inflammatory Diseases NIAMS Diagnostics, Immunology, Research Materials, Therapeutics Diagnostics Immunology Research Materials Therapeutics Francoise Meylan, Richard Siegel, Yun-Jeong Song Autoimmune inflammatory diseases occur in greater than five percent of the United States population; this disease group includes asthma, multiple sclerosis, rheumatoid arthritis, and lupus. Treatments generally include immunosuppressants or anti-inflammatory drugs, which can have serious side effects; recently, more specific immunomodulatory therapies such as TNF-alpha antagonists have been developed.<br /><br /> In experiments with mice, NIAMS inventors have shown that the interaction between the TNF family ligand TL1A with its receptor, DR3, is critical for development of disease in asthma, inflammatory bowel disease and multiple sclerosis. They have also developed anti-TL1A antibodies that prevent disease in mouse models of rheumatoid arthritis and inflammatory bowel disease.<br /><br /> This technology describes anti-mouse TL1A and anti-human TL1A monoclonal antibodies that may be useful for the development of diagnostics and therapeutics for autoimmune inflammatory disease, as well as methods of treating such disease by blocking the interaction between TL1A and DR3. <ul> <li>Specific immunomodulatory effect provides potential for potent therapy without inducing global immunosuppression</li> <li>Anti-TL1A monoclonal antibodies available for further development</li> </ul> <ul> <li>Antibody-based therapeutics for autoimmune inflammatory disease</li> <li>Diagnostics for autoimmune inflammatory disease</li> <li>Research tools to probe the role of TL1A-DR3 interactions in the development of autoimmune disease</li> </ul> Research Tool — Patent protection is not being pursued for this technology. Available for non-exclusive licensing. It can be purchased from BioXCell (Catalog #BE0323) 2022-03-08 2025-08-15 2025-08-15 2007-04-01 antibodies, ANTIBODY, ANTI-HUMAN, Anti-mouse, Autoimmune, diagnostic, DR3, IA3XXX, IAXXXX, IB3XXX, IBXXXX, Immunomodulation, immuno-modulator, immunomodulatory, INFLAMMATORY, inflammatory disease, IXXXXX, monoclonal, Monoclonal Antibodies, Monoclonal Antibody, Patent Category - Biotechnology, therapeutic, TL1A, tnf, TNFRSF25, TNFSF15, tumor necrosis factor, USES False True Early stage <ul> <li>Early-stage</li> <li>In vitro data available</li> <li>In vivo data available (animal)</li> </ul> True NIHTT 37470483 Website Abstract 114171393 Meylan F, et al. http://www.ncbi.nlm.nih.gov/pubmed/20980995 <a href="http://www.ncbi.nlm.nih.gov/pubmed/20980995">Meylan F, et al.</a> 157465001 Richard, et al. https://pubmed.ncbi.nlm.nih.gov/25786692/ <a href="https://pubmed.ncbi.nlm.nih.gov/25786692/">Richard, et al.</a> 114107659 Meylan, Francoise NIAMS - IRP NIAMS Meylan, Francoise (NIAMS) 0 114107660 Song, Yun-Jeong NIAMS - IRP Song, Yun-Jeong 0 114107658 Siegel, Richard NIAMS - IRP NIAMS Siegel, Richard (NIAMS) 1 114107658 Siegel, Richard NIAMS - IRP NIAMS Siegel, Richard (NIAMS) 1 114107659 Meylan, Francoise NIAMS - IRP NIAMS Meylan, Francoise (NIAMS) 0 114107660 Song, Yun-Jeong NIAMS - IRP Song, Yun-Jeong 0 114101787 Monoclonal Anti-mouse And Anti-human TL1A Antibodies For Diagnostic And Therapeutic Uses E-073-2011-1 Filing authorized NIAMS 83656052 Knezevic, Vladimir vlado.knezevic@nih.gov
United States of America Technology Advancement Office vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-1531] Antibodies Against TL1A, a TNF-Family Cytokine, for the Treatment and Diagnosis of Autoimmune Inflammatory Diseases&body=Please send me information about technology [TAB-1531] Antibodies Against TL1A, a TNF-Family Cytokine, for the Treatment and Diagnosis of Autoimmune Inflammatory Diseases. Knezevic, Vladimir<br><a href="mailto:vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-1531] Antibodies Against TL1A, a TNF-Family Cytokine, for the Treatment and Diagnosis of Autoimmune Inflammatory Diseases&body=Please send me information about technology [TAB-1531] Antibodies Against TL1A, a TNF-Family Cytokine, for the Treatment and Diagnosis of Autoimmune Inflammatory Diseases.">vlado.knezevic@nih.gov</a><br> 114166848 E-073-2011-1 E-073-2011-1-US-01 ANTIBODIES THAT BIND TO TL1A AND METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASE ADMINISTERING SUCH ANTIBODIES CIP US 9,068,003 13/419,203 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9068003 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9068003">9,068,003</a><br />Filed on 2012-03-13<br />Status: Issued 114117724 IB3XXX 114117725 IBXXXX 114117726 IXXXXX 114122235 IAXXXX 114122236 IA3XXX 114136494 TL1A 114136495 tumor necrosis factor 114136496 tnf 114136497 INFLAMMATORY 114136498 Autoimmune 114136499 inflammatory disease 114136500 DR3 114136501 immuno-modulator 114136502 immunomodulatory 114136503 Patent Category - Biotechnology 114141837 monoclonal 114141838 Anti-mouse 114141839 ANTI-HUMAN 114141840 antibodies 114141841 diagnostic 114141842 therapeutic 114141843 ANTIBODY 114141844 TNFRSF25 114141845 TNFSF15 114141846 Immunomodulation 114141847 Monoclonal Antibodies 114141848 Monoclonal Antibody 114143449 USES TAB-4517 151718075 Enhanced Immune Response With Stabilized Norovirus VLPs: A Next-Generation Vaccine Approach NIAID Collaboration, Gastroenterology, Licensing, Research Materials, Vaccines Collaboration Gastroenterology Licensing Research Materials Vaccines Ralph Baric, Gwo-Yu Chuang, George Georgiou, Jason Gorman, Peter Kwong, Lisa Lindesmith, Li Ou, Yaroslav Tsybovsky, Raffaello Verardi <p>This technology includes a novel advancement in developing vaccines targeting norovirus, tailored specifically for a more robust and effective response. It centers around an improved version of Virus-Like Particles (VLPs) uniquely engineered for greater stability and efficacy. These enhanced VLPs are designed to remain intact even when faced with the body&#39;s immune responses, overcoming a key limitation of previous vaccine designs. This stability is crucial in ensuring the vaccine&#39;s effectiveness, particularly in individuals with more robust immune systems who have shown limited response to traditional vaccines. Additionally, the modified VLPs are likely more resistant to degradation, making them a more reliable and durable solution in vaccination campaigns. This innovation could be a significant step in offering a more effective vaccine option for widespread use.</p> <ul> <li>Provides enhanced stability and efficacy in norovirus VLP vaccines, ensuring effectiveness even in individuals with strong immune responses who have previously shown limited vaccine response.</li> <li>Its innovative design increases the VLPs' resistance to degradation, offering a more durable and reliable option for large-scale immunization programs.</li> </ul> <ul> <li>Enhanced Norovirus Vaccination: Specially designed to improve the effectiveness of vaccines against norovirus, particularly in individuals with previously low response rates to traditional vaccines.</li> <li>Broad-Scale Immunization Programs: Suitable for large-scale public health initiatives due to its increased stability and durability, potentially reducing the frequency of booster shots.</li> <li>Platform for Future Vaccine Development: The stabilization techniques used in this technology could be applied to other vaccine formulations, paving the way for more robust and effective vaccines against various pathogens.</li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. For collaboration opportunities, please contact Brian Bailey, PhD at <a href="mailto:bbailey@mail.nih.gov"> bbailey@mail.nih.gov</a> or 240-669-5128 or 301-201-9217. 2023-12-08 2024-08-12 2025-08-14 2024-01-17 immune response, IMMUNOGENS, Norovirus, VLPs False False True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 152124231 Lu, Yuan et al. “Assessing sequence plasticity of a virus-like nanoparticle by evolution toward a versatile scaffold for vaccines and drug delivery.” Proceedings of the National Academy of Sciences of the United States of America vol. 112,40 (2015): 12360-5. DOI: 10.1073/pnas.1510533112 https://doi.org/10.1073/pnas.1510533112 <a href="https://doi.org/10.1073/pnas.1510533112">Lu, Yuan et al. “Assessing sequence plasticity of a virus-like nanoparticle by evolution toward a versatile scaffold for vaccines and drug delivery.” Proceedings of the National Academy of Sciences of the United States of America vol. 112,40 (2015): 12360-5. DOI: 10.1073/pnas.1510533112</a> 152124314 Porta, Claudine et al. “Rational engineering of recombinant picornavirus capsids to produce safe, protective vaccine antigen.” PLoS pathogens vol. 9,3 (2013): e1003255. DOI: 10.1371/journal.ppat.1003255 https://doi.org/10.1371/journal.ppat.1003255 <a href="https://doi.org/10.1371/journal.ppat.1003255">Porta, Claudine et al. “Rational engineering of recombinant picornavirus capsids to produce safe, protective vaccine antigen.” PLoS pathogens vol. 9,3 (2013): e1003255. DOI: 10.1371/journal.ppat.1003255</a> 152124322 Mateo, Roberto et al. “Engineering viable foot-and-mouth disease viruses with increased thermostability as a step in the development of improved vaccines.” Journal of virology vol. 82,24 (2008): 12232-40. DOI: 10.1128/JVI.01553-08 https://doi.org/10.1128/jvi.01553-08 <a href="https://doi.org/10.1128/jvi.01553-08">Mateo, Roberto et al. “Engineering viable foot-and-mouth disease viruses with increased thermostability as a step in the development of improved vaccines.” Journal of virology vol. 82,24 (2008): 12232-40. DOI: 10.1128/JVI.01553-08</a> 152124337 Bertolotti-Ciarlet, Andrea et al. “Structural requirements for the assembly of Norwalk virus-like particles.” Journal of virology vol. 76,8 (2002): 4044-55. DOI: 10.1128/jvi.76.8.4044-4055.2002 https://doi.org/10.1128/jvi.76.8.4044-4055.2002 <a href="https://doi.org/10.1128/jvi.76.8.4044-4055.2002">Bertolotti-Ciarlet, Andrea et al. “Structural requirements for the assembly of Norwalk virus-like particles.” Journal of virology vol. 76,8 (2002): 4044-55. DOI: 10.1128/jvi.76.8.4044-4055.2002</a> 152124349 Prasad, B V et al. “X-ray crystallographic structure of the Norwalk virus capsid.” Science (New York, N.Y.) vol. 286,5438 (1999): 287-90. DOI: 10.1126/science.286.5438.287 https://doi.org/10.1126/science.286.5438.287 <a href="https://doi.org/10.1126/science.286.5438.287">Prasad, B V et al. “X-ray crystallographic structure of the Norwalk virus capsid.” Science (New York, N.Y.) vol. 286,5438 (1999): 287-90. DOI: 10.1126/science.286.5438.287</a> 151718352 Kwong, Peter NIAID - VRC NIAID Kwong, Peter (NIAID) 1 151718412 Verardi, Raffaello NIAID - VRC NIAID Verardi, Raffaello (NIAID) 2 151718424 Chuang, Gwo-Yu NIAID - DIR NIAID Chuang, Gwo-Yu (NIAID) 3 151718434 Tsybovsky, Yaroslav Leidos Biomedical Research, Inc NIAID Tsybovsky, Yaroslav (NIAID) 4 151718438 Gorman, Jason NIAID - VRC NIAID Gorman, Jason (NIAID) 5 151718445 Ou, Li NIAID - VRC NIAID Ou, Li (NIAID) 6 151718461 Lindesmith, Lisa University of North Carolina, Chapel Hill Lindesmith, Lisa 7 151718465 Baric, Ralph University of North Carolina, Chapel Hill Baric, Ralph 8 151718474 Georgiou, George Board of Regents of The University of Texas System Georgiou, George 9 151718352 Kwong, Peter NIAID - VRC NIAID Kwong, Peter (NIAID) 1 151718412 Verardi, Raffaello NIAID - VRC NIAID Verardi, Raffaello (NIAID) 2 151718424 Chuang, Gwo-Yu NIAID - DIR NIAID Chuang, Gwo-Yu (NIAID) 3 151718434 Tsybovsky, Yaroslav Leidos Biomedical Research, Inc NIAID Tsybovsky, Yaroslav (NIAID) 4 151718438 Gorman, Jason NIAID - VRC NIAID Gorman, Jason (NIAID) 5 151718445 Ou, Li NIAID - VRC NIAID Ou, Li (NIAID) 6 151718461 Lindesmith, Lisa University of North Carolina, Chapel Hill Lindesmith, Lisa 7 151718465 Baric, Ralph University of North Carolina, Chapel Hill Baric, Ralph 8 151718474 Georgiou, George Board of Regents of The University of Texas System Georgiou, George 9 151718222 Stabilized Norovirus VLPs As Vaccine Immunogens E-178-2019-0 Filing authorized Board of Regents of The University of Texas System, NCI, NIAID, University of North Carolina, Chapel Hill 151718238 Stabilized Norovirus VLPs As Vaccine Immunogens E-178-2019-1 Filing authorized Board of Regents of The University of Texas System, NCI, NIAID, University of North Carolina, Chapel Hill 83682222 Bailey, Brian bbailey@mail.nih.gov
United States of America TTIPO bbailey@mail.nih.gov?subject=Web Inquiry on [TAB-4517] Enhanced Immune Response With Stabilized Norovirus VLPs: A Next-Generation Vaccine Approach&body=Please send me information about technology [TAB-4517] Enhanced Immune Response With Stabilized Norovirus VLPs: A Next-Generation Vaccine Approach. Bailey, Brian<br><a href="mailto:bbailey@mail.nih.gov?subject=Web Inquiry on [TAB-4517] Enhanced Immune Response With Stabilized Norovirus VLPs: A Next-Generation Vaccine Approach&body=Please send me information about technology [TAB-4517] Enhanced Immune Response With Stabilized Norovirus VLPs: A Next-Generation Vaccine Approach.">bbailey@mail.nih.gov</a><br> 151718227 E-178-2019-0 E-178-2019-0-US-01 STABILIZED NOROVIRUS VIRUS-LIKE PARTICLES AS VACCINE IMMUNOGENS PRV US 63/091,824 Abandoned US <br />Provisional (PRV) 63/091,824<br />Filed on 2020-10-14<br />Status: Abandoned 151718243 E-178-2019-1 E-178-2019-1-PCT-01 STABILIZED NOROVIRUS VIRUS-LIKE PARTICLES AS VACCINE IMMUNOGENS PCT COMB Patent Cooperation Treaty PCT/US2021/055018 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2021/055018<br />Filed on 2021-10-14<br />Status: Expired 151718244 E-178-2019-1 E-178-2019-1-US-01 STABILIZED NOROVIRUS VIRUS-LIKE PARTICLES AS VACCINE IMMUNOGENS National Stage US 18/031,602 Pending US <br />National Stage 18/031,602<br />Filed on 2023-04-12<br />Status: Pending 152143465 immune response 152143756 Norovirus 152143770 VLPs 152143802 IMMUNOGENS TAB-4865 152516124 Vesicular Stomatitis virus (VSV)-based Vaccine against Sudan Virus NIAID Animal Models, Collaboration, Immunology, Infectious Disease, Licensing, Therapeutics, Vaccines Animal Models Collaboration Immunology Infectious Disease Licensing Therapeutics Vaccines Heinrich (Heinz) Feldmann, Andrea Marzi <p>There are five known Ebolavirus species: Ebola virus (Zaire ebolavirus); Sudan virus (Sudan ebolavirus or SUDV); Ta&iuml; Forest virus (Ta&iuml; Forest ebolavirus, formerly Cote d&#39;Ivoire ebolavirus); Bundibugyo virus (Bundibugyo ebolavirus); and Reston virus (Reston ebolavirus). Last year an ebolavirus outbreak resulted in 164 cases and 55 deaths. While there is an FDA-approved Ebola virus vaccine authorized for use against Ebola virus infections, ERVEBO, this vaccine is not effective against SUDV due to the significant variation between Ebola virus and SUDV. ERVEBO is a live recombinant viral vaccine consisting of a vesicular stomatitis virus (VSV) backbone deleted for the VSV envelope glycoprotein and substituted with the envelope glycoprotein of the Ebola virus (Kikwit 1995 strain).</p> <p>This invention provides a VSV-based vaccine expressing the SUDV-Gulu GP (VSV-SUDV). The VSV backbone of this vaccine appears to be very similar to the VSV backbone used in the ERVEBO vaccine discussed above. This could allow for a quicker and more efficient regulatory approval pathway through the FDA. Efficacy studies in non-human primates demonstrated that a single intramuscular vaccination protected animals from a lethal challenge dose of SUDV even when vaccination occurred only seven days prior to challenge. In addition, pre-exposure to the VSV vector did not inhibit a robust response to the SUDV GP component of the vaccine.</p> <ul> <li>Uses a VSV-based system to express antigens thereby increasing safety of the vaccine.</li> <li>Efficacious after single low dose vaccination in NHPs.</li> <li>VSV-platform induces a strong & rapid immune response.</li> </ul> <ul> <li>Prophylactic usage against SUDV infections in normal or high-risk populations</li> <li>Therapeutic treatment, alone or in combination, in patients with SUDV infection</li> <li>Assay development for surveillance, diagnostic, and prevention measures</li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. For collaboration opportunities, please contact Dr. Terrence Joyce at (240)-987-2347, or at <a href="mailto:Terrence.joyce@NIH.gov"> Terrence.joyce@NIH.gov</a>. 2024-02-01 2025-08-13 2025-08-13 2024-02-14 stomatitis, Sudan, Vaccine, Vesicular, virus, VIRUS-BASED False False True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 152516237 Marzi, A, et al., “Species-specific immunogenicity and protective efficacy of a vesicular stomatitis virus-based Sudan virus vaccine: a challenge study in macaques,” Lancet Microbe, 2023 Mar;4(3): e171-e178. doi: 10.1016/S2666-5247(23)00001-0. Epub 2023 Feb 2. Marzi, A, et al., “Species-specific immunogenicity and protective efficacy of a vesicular stomatitis virus-based Sudan virus vaccine: a challenge study in macaques,” Lancet Microbe, 2023 Mar;4(3): e171-e178. doi: 10.1016/S2666-5247(23)00001-0. Epub 2023 Feb 2. 152519361 Marzi, Andrea NIAID - DIR NIAID Marzi, Andrea (NIAID) 1 152519365 Feldmann, Heinrich (Heinz) NIAID - DIR NIAID Feldmann, Heinrich (Heinz) (NIAID) 2 152519361 Marzi, Andrea NIAID - DIR NIAID Marzi, Andrea (NIAID) 1 152519365 Feldmann, Heinrich (Heinz) NIAID - DIR NIAID Feldmann, Heinrich (Heinz) (NIAID) 2 152518881 Vesicular Stomatitis Virus-Based Sudan Virus Vaccine E-002-2023-0 Filing authorized NIAID 152518920 Vesicular Stomatitis Virus-Based Sudan Virus Vaccine E-002-2023-1 Filing authorized NIAID 152518941 Vesicular Stomatitis Virus-Based Sudan Virus Vaccine E-002-2023-2 Filing authorized NIH - NIAID 146046171 Joyce, Terrence terrence.joyce@nih.gov
United States of America terrence.joyce@nih.gov?subject=Web Inquiry on [TAB-4865] Vesicular Stomatitis virus (VSV)-based Vaccine against Sudan Virus&body=Please send me information about technology [TAB-4865] Vesicular Stomatitis virus (VSV)-based Vaccine against Sudan Virus. Joyce, Terrence<br><a href="mailto:terrence.joyce@nih.gov?subject=Web Inquiry on [TAB-4865] Vesicular Stomatitis virus (VSV)-based Vaccine against Sudan Virus&body=Please send me information about technology [TAB-4865] Vesicular Stomatitis virus (VSV)-based Vaccine against Sudan Virus.">terrence.joyce@nih.gov</a><br> 152518955 E-002-2023-0 E-002-2023-0-US-01 VESICULAR STOMATITIS VIRUS (VSV)-BASED VACCINE AGAINST SUDAN VIRUS PRV US 63/419,637 Expired US <br />Provisional (PRV) 63/419,637<br />Filed on 2022-10-26<br />Status: Expired 152519082 E-002-2023-1 E-002-2023-1-US-01 VESICULAR STOMATITIS VIRUS (VSV)-BASED VACCINE AGAINST SUDAN VIRUS PRV US 63/517,246 Expired US <br />Provisional (PRV) 63/517,246<br />Filed on 2023-08-02<br />Status: Expired 152519090 E-002-2023-2 E-002-2023-2-PC-01 Vesicular Stomatitis Virus-Based Sudan Virus Vaccine PCT Patent Cooperation Treaty PCT/US2023/077444 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2023/077444<br />Filed on 2023-10-20<br />Status: Expired 152848968 VIRUS-BASED 152848972 virus 152848976 Vesicular 152849031 Vaccine 152849045 Sudan 152849095 stomatitis TAB-3810 114097659 High-Resolution and Artifact-Free Measurement and Visualization of Tissue Strain by Processing MRI Using a Deep Learning Approach NIDDK Cardiology, Computational models/software, Dental, Diagnostics, Endocrinology, Infectious Disease, Medical Devices, Neurology, Non-Medical Devices, Oncology, Ophthalmology, Research Materials, Software / Apps Cardiology Computational models/software Dental Diagnostics Endocrinology Infectious Disease Medical Devices Neurology Non-Medical Devices Oncology Ophthalmology Research Materials Software / Apps Ahmed Abdelfadeel, Khaled Abd-Elmoniem, Ahmed Gharib, Inas Yassine This technology includes a system for automatic artifact-free measurement and visualization of tissue strain by MRI at native resolution. The investigation of regional soft tissue mechanical strain can serve as a unique indicator for different related disorders. For example, measurement of myocardial tissue during contraction can help calculate, track, and assess cardiac stress. Currently, methods such as tagging MRI (tMRI) are used for imaging soft tissue deformation. Despite being well validated, methods such as tMRI suffer from low spatial and temporal resolution. The current described technology obtains pixelwise native high-resolution imagery for strain-mapping using a deep learning convolutional neural network. This method provides for a high anatomic, functional, and temporal resolution of tissue strain and deformation with unprecedented clarity. High-resolution imaging and analysis of tissue strain can be used to reduce the time to diagnosis and provide more informative information for the treatment of a variety of disorders, including: <ul> <li>liver inflammation and fibrosis assessment</li> <li>heart strain, cardiac function early assessment</li> <li>brain damage and tumor detection</li> <li>tongue tumors and speech problems</li> </ul> 2022-08-31 2025-08-13 2025-08-13 2022-08-31 2022-08-28 CALCULATING, Deformation, System, Tissue, VCXXXX, VDXXXX, VEXXXX, VPXXXX, WBXXXX, WIXXXX, XBXXXX, XFXXXX, XJXXXX False True True NIHTT 37470483 Website Abstract 114172971 Yassine IA, Ghanem AM, et al. https://pubmed.ncbi.nlm.nih.gov/34836627/ <a href="https://pubmed.ncbi.nlm.nih.gov/34836627/">Yassine IA, Ghanem AM, et al.</a> 114172972 Abd-Elmoniem KZ, Yassine IA, et al. https://pubmed.ncbi.nlm.nih.gov/34836988/ <a href="https://pubmed.ncbi.nlm.nih.gov/34836988/">Abd-Elmoniem KZ, Yassine IA, et al.</a> 114111628 Abdelfadeel, Ahmed National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Abdelfadeel, Ahmed 0 114111629 Gharib, Ahmed National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Gharib, Ahmed (NIDDK) 0 114111630 Yassine, Inas Cairo University Yassine, Inas 0 114111627 Abd-Elmoniem, Khaled National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Abd-Elmoniem, Khaled (NIDDK) 1 114111627 Abd-Elmoniem, Khaled National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Abd-Elmoniem, Khaled (NIDDK) 1 114111628 Abdelfadeel, Ahmed National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Abdelfadeel, Ahmed 0 114111629 Gharib, Ahmed National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Gharib, Ahmed (NIDDK) 0 114111630 Yassine, Inas Cairo University Yassine, Inas 0 114102911 A System For Calculating Tissue Deformation E-203-2022-0 Research Material Cairo University, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83739611 Yonter, Ediz ediz.yonter@nih.gov
United States of America Technology Advancement Office ediz.yonter@nih.gov?subject=Web Inquiry on [TAB-3810] High-Resolution and Artifact-Free Measurement and Visualization of Tissue Strain by Processing MRI Using a Deep Learning Approach&body=Please send me information about technology [TAB-3810] High-Resolution and Artifact-Free Measurement and Visualization of Tissue Strain by Processing MRI Using a Deep Learning Approach. Yonter, Ediz<br><a href="mailto:ediz.yonter@nih.gov?subject=Web Inquiry on [TAB-3810] High-Resolution and Artifact-Free Measurement and Visualization of Tissue Strain by Processing MRI Using a Deep Learning Approach&body=Please send me information about technology [TAB-3810] High-Resolution and Artifact-Free Measurement and Visualization of Tissue Strain by Processing MRI Using a Deep Learning Approach.">ediz.yonter@nih.gov</a><br> 114129689 VCXXXX 114129690 VDXXXX 114129691 VEXXXX 114129692 VPXXXX 114129693 WBXXXX 114129694 WIXXXX 114129695 XBXXXX 114129696 XJXXXX 114129697 XFXXXX 114155611 System 114155612 CALCULATING 114155613 Tissue 114155614 Deformation TAB-4950 153931020 SARS-CoV-2 Spike Fused to Hepatitis B Surface Antigen NIAID Antibodies, Collaboration, Diagnostics, Infectious Disease, Licensing, Therapeutics, Vaccines Antibodies Collaboration Diagnostics Infectious Disease Licensing Therapeutics Vaccines Wing-pui Kong, Cuiping ("Catherine" Liu, John Mascola, Amarendra ("Amar") Pegu, Wei Shi, Lingshu Wang <p>The emergence of the SARS-CoV-2 virus and its immune-escaping variants have led to global COVID-19 pandemic/endemic, underscoring the urgent need for effective vaccines with strong and durable immune responses.</p> <p>Researchers at the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID) used a novel approach to SARS-CoV-2 vaccine development by leveraging hepatitis B surface antigen (HBsAg), which has a proven track record of safety and efficacy in hepatitis B vaccines. They designed fusion protein constructs comprised of HBsAg linked by a series of glycine-serine residues to the prefusion stabilized spike protein of SARS-CoV-2. These constructs can self-assemble into nanoparticles in mammalian cells and bind monoclonal antibodies (mAbs) that are specific to different domains of the SARS-CoV-2 spike. The nanoparticles elicit potent and durable immune responses including neutralizing antibody response. In vitro and in vivo experiments demonstrate that this nanoparticle platform has the potential for use as a robust SARS-CoV-2 vaccine.</p> <ul> <li>Higher potency, potentially longer protection compared to other SARS-CoV-2 vaccine formulations</li> <li>Potent immune response via genetic delivery, including DNA and RNA immunization</li> <li>Improved immunogenicity compared to other nanoparticle or virus-like-particle (VLP)-based vaccines for SARS-CoV-2 spike protein</li> </ul> <ul> <li>Novel SARS-CoV-2 vaccine and universal vaccines against coronavirus</li> <li>Vaccine development against other viral pathogens such as HIV and flu</li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. Areas of specific interest include (a) testing developability of the antibodies elicited by SARS-CoV-2 spike-HBsAg nanoparticles (e.g., biophysical characteristics, cross-reactivity, pharmacokinetics, toxicity), (b) pre-clinical model assessment, and (c) human clinical trials. For collaboration opportunities, please contact Brian Bailey, PhD; 240-669-5128 or 301-201-9217, <a href="mailto:bbailey@mail.nih.gov"> bbailey@mail.nih.gov</a> 2024-03-19 2025-08-13 2025-08-13 2024-06-21 Antigen-based, HEPATITIS B, IMMUNOGENS, Nanoparticle, SARS-CoV-2, spike, Surface False False True 37470483 Website Abstract 153931990 Liu, C., Wang, L., Merriam, J.S. et al. Self-assembling SARS-CoV-2 spike-HBsAg nanoparticles elicit potent and durable neutralizing antibody responses via genetic delivery. npj Vaccines 8, 111, 2023. https://doi.org/10.1038/s41541-023-00707-w <a href="https://doi.org/10.1038/s41541-023-00707-w">Liu, C., Wang, L., Merriam, J.S. et al. Self-assembling SARS-CoV-2 spike-HBsAg nanoparticles elicit potent and durable neutralizing antibody responses via genetic delivery. npj Vaccines 8, 111, 2023.</a> 153931486 Mascola, John NIH - NIAID NIAID Mascola, John (NIAID) 1 153931490 Liu, Cuiping ("Catherine") NIH - NIAID NIAID Liu, Cuiping ("Catherine") (NIAID) 2 153931496 Shi, Wei NIH - NIAID NIAID Shi, Wei (NIAID) 3 153931544 Pegu, Amarendra ("Amar") NIH - NIAID NIAID Pegu, Amarendra ("Amar") (NIAID) 4 153931548 Wang, Lingshu NIH - NIAID NIAID Wang, Lingshu (NIAID) 5 153931552 Kong, Wing-pui NIH - NIAID NIAID Kong, Wing-pui (NIAID) 6 153931486 Mascola, John NIH - NIAID NIAID Mascola, John (NIAID) 1 153931490 Liu, Cuiping ("Catherine") NIH - NIAID NIAID Liu, Cuiping ("Catherine") (NIAID) 2 153931496 Shi, Wei NIH - NIAID NIAID Shi, Wei (NIAID) 3 153931544 Pegu, Amarendra ("Amar") NIH - NIAID NIAID Pegu, Amarendra ("Amar") (NIAID) 4 153931548 Wang, Lingshu NIH - NIAID NIAID Wang, Lingshu (NIAID) 5 153931552 Kong, Wing-pui NIH - NIAID NIAID Kong, Wing-pui (NIAID) 6 153931023 Hepatitis B Surface Antigen-based Nanoparticle Immunogens Of SARS-CoV-2 Spike E-171-2021-0 Filing authorized NIAID 83682222 Bailey, Brian bbailey@mail.nih.gov
United States of America TTIPO bbailey@mail.nih.gov?subject=Web Inquiry on [TAB-4950] SARS-CoV-2 Spike Fused to Hepatitis B Surface Antigen&body=Please send me information about technology [TAB-4950] SARS-CoV-2 Spike Fused to Hepatitis B Surface Antigen. Bailey, Brian<br><a href="mailto:bbailey@mail.nih.gov?subject=Web Inquiry on [TAB-4950] SARS-CoV-2 Spike Fused to Hepatitis B Surface Antigen&body=Please send me information about technology [TAB-4950] SARS-CoV-2 Spike Fused to Hepatitis B Surface Antigen.">bbailey@mail.nih.gov</a><br> 153931749 E-171-2021-0 E-171-2021-0-US-01 SARS-COV-2 SPIKE FUSED TO HEPATITIS B SURFACE ANTIGEN PRV US 63/278,956 Abandoned US <br />Provisional (PRV) 63/278,956<br />Filed on 2021-11-12<br />Status: Abandoned 153931754 E-171-2021-0 E-171-2021-0-PCT-02 SARS-COV-2 SPIKE FUSED TO HEPATITIS B SURFACE ANTIGEN PCT Patent Cooperation Treaty PCT/US2022/079750 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2022/079750<br />Filed on 2022-11-11<br />Status: Expired 155050203 E-171-2021-0 E-171-2021-0-US-02 SARS-COV-2 SPIKE FUSED TO A HEPATITIS B SURFACE ANTIGEN National Stage US 18/709,441 Pending US <br />National Stage 18/709,441<br />Filed on 2024-05-10<br />Status: Pending 155050943 Antigen-based 155050949 HEPATITIS B 155050953 IMMUNOGENS 155050987 Nanoparticle 155050997 SARS-CoV-2 155051005 spike 155051009 Surface TAB-3840 144859680 Antibodies With Potent and Broad Neutralizing Activity Against Antigenically Diverse and Highly Transmissible SARS-CoV-2 Variants NIAID Kevina Birungi-Huff, Sabrina Bush, Man Chen, Nicole Doria-Rose, Daniel Douek, Richard Koup, John Mascola, John Misasi, Maryam Musayev, Chaim Schramm, Wei Shi, Nancy Sullivan, Lingshu Wang, Eun Yang, Yi Zhang <p>&nbsp; &nbsp; &nbsp; &nbsp;Emergence of highly transmissible SARS-CoV-2 variants of concern that are resistant to current therapeutic antibodies highlights the need for continuing discovery of broadly reactive antibodies.<br /> &nbsp; &nbsp; &nbsp; &nbsp;Scientists at the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases have engineered a group of human monoclonal antibodies that target epitopes on the receptor binding domain of SARS-CoV-2 spike protein. &nbsp;These engineered antibodies ultra-potently neutralize &gt;12 variants of SARS-CoV-2, including the highly transmissible BA.4 and BA.5 subvariants of Omicron, as shown in a pseudovirus neutralization assay. &nbsp;These engineered antibodies target 3 distinct epitopes in the receptor binding domain of the spike protein and function by blocking ACE2 binding. &nbsp;These engineered antibodies are not impacted by spike mutations that knockout binding to other therapeutic antibodies, including E484K, N439K, Y453F, L452R and K417N. &nbsp;Several of the engineered antibodies are able to simultaneously bind to the spike protein and are compatible for use in combination therapies. &nbsp;In in vitro assays, these combinations were shown to decrease the appearance of escape mutants suggesting the potential to mitigate resistance development when used as combination therapy. Additionally, these engineered antibodies are better suited for manufacturing than the parental antibodies.<br /> &nbsp; &nbsp; &nbsp; &nbsp;This technology is available for licensing for commercial development in accordance with 35 U.S.C. &sect; 209 and 37 CFR Part 404.<br /> &nbsp;</p> <ul> <li>Ultra-potent neutralization of currently identified SARS-CoV-2 variants including Omicron subvariants</li> <li>Combinations show the potential to mitigate resistance</li> <li>Improved manufacturability relative to parental antibodies</li> <li>Mechanism of Action – These antibodies bind to block ACE2 receptor binding to the SARS CoV-2 spike protein</li> </ul> <ul> <li>Treatment of SARS-CoV-2 infection</li> </ul> 2023-04-12 2025-08-13 2025-08-13 2023-01-25 False False Preclinical Research True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 144859829 Misasi, John NIAID - VRC NIAID Misasi, John (NIAID) 1 144859833 Wang, Lingshu NIAID - VRC NIAID Wang, Lingshu (NIAID) 2 144859838 Mascola, John ModeX Therapeutics, Inc. NIAID Mascola, John (NIAID) 3 144859961 Douek, Daniel NIAID - DIR NIAID Douek, Daniel (NIAID) 4 144859968 Sullivan, Nancy NIAID - VRC NIAID Sullivan, Nancy (NIAID) 5 144860097 Koup, Richard NIAID - VRC NIAID Koup, Richard (NIAID) 6 144860101 Chen, Man NIAID - VRC NIAID Chen, Man (NIAID) 7 144860147 Shi, Wei NIAID - VRC NIAID Shi, Wei (NIAID) 8 144860151 Zhang, Yi NIAID - VRC NIAID Zhang, Yi (NIAID) 9 144860161 Yang, Eun NIAID - VRC NIAID Yang, Eun (NIAID) 10 144860165 Doria-Rose, Nicole NIAID - VRC NIAID Doria-Rose, Nicole (NIAID) 11 144860169 Schramm, Chaim NIAID - DIR NIAID Schramm, Chaim (NIAID) 12 144860173 Birungi-Huff, Kevina National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Birungi-Huff, Kevina (NIAID) 13 144860181 Bush, Sabrina NIAID - VRC NIAID Bush, Sabrina (NIAID) 14 144860195 Musayev, Maryam National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Musayev, Maryam (NIAID) 15 144859829 Misasi, John NIAID - VRC NIAID Misasi, John (NIAID) 1 144859833 Wang, Lingshu NIAID - VRC NIAID Wang, Lingshu (NIAID) 2 144859838 Mascola, John ModeX Therapeutics, Inc. NIAID Mascola, John (NIAID) 3 144859961 Douek, Daniel NIAID - DIR NIAID Douek, Daniel (NIAID) 4 144859968 Sullivan, Nancy NIAID - VRC NIAID Sullivan, Nancy (NIAID) 5 144860097 Koup, Richard NIAID - VRC NIAID Koup, Richard (NIAID) 6 144860101 Chen, Man NIAID - VRC NIAID Chen, Man (NIAID) 7 144860147 Shi, Wei NIAID - VRC NIAID Shi, Wei (NIAID) 8 144860151 Zhang, Yi NIAID - VRC NIAID Zhang, Yi (NIAID) 9 144860161 Yang, Eun NIAID - VRC NIAID Yang, Eun (NIAID) 10 144860165 Doria-Rose, Nicole NIAID - VRC NIAID Doria-Rose, Nicole (NIAID) 11 144860169 Schramm, Chaim NIAID - DIR NIAID Schramm, Chaim (NIAID) 12 144860173 Birungi-Huff, Kevina National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Birungi-Huff, Kevina (NIAID) 13 144860181 Bush, Sabrina NIAID - VRC NIAID Bush, Sabrina (NIAID) 14 144860195 Musayev, Maryam National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Musayev, Maryam (NIAID) 15 144859683 Engineered SARS-CoV-2 Antibodies With Increased Neutralization Breadth E-185-2022-0 Filing authorized NIAID 83682222 Bailey, Brian bbailey@mail.nih.gov
United States of America TTIPO bbailey@mail.nih.gov?subject=Web Inquiry on [TAB-3840] Antibodies With Potent and Broad Neutralizing Activity Against Antigenically Diverse and Highly Transmissible SARS-CoV-2 Variants&body=Please send me information about technology [TAB-3840] Antibodies With Potent and Broad Neutralizing Activity Against Antigenically Diverse and Highly Transmissible SARS-CoV-2 Variants. Bailey, Brian<br><a href="mailto:bbailey@mail.nih.gov?subject=Web Inquiry on [TAB-3840] Antibodies With Potent and Broad Neutralizing Activity Against Antigenically Diverse and Highly Transmissible SARS-CoV-2 Variants&body=Please send me information about technology [TAB-3840] Antibodies With Potent and Broad Neutralizing Activity Against Antigenically Diverse and Highly Transmissible SARS-CoV-2 Variants.">bbailey@mail.nih.gov</a><br> 152519133 E-185-2022-0 E-185-2022-0-US-01 Engineered SARS-CoV-2 Antibodies With Increased Neutralization Breadth PRV US 63/404,473 Expired US <br />Provisional (PRV) 63/404,473<br />Filed on 2022-09-07<br />Status: Expired TAB-4827 152144153 Immortalized Rhesus macaque Bcl-6/Bcl-xL Stable B Cell Lines as Tools for HIV Antibody Discovery NIAID Animal Models, Antibodies, Infectious Disease, Research Materials, Vaccines Animal Models Antibodies Infectious Disease Research Materials Vaccines Kristin Boswell, Richard Koup, Jakob Samsel <p>Scientists at NIAID have developed two immortalized stable B cell lines from rhesus macaques that can have value as research tools for the discovery of neutralizing antibodies of simian origin against HIV and that may have value in the development of an HIV vaccine. These B cell lines encode human Bcl-6 and Bcl-xL proteins, which are major regulators of apoptosis. These B cell lines are derived from the lymph node of a rhesus macaque (RM) that was infected with SHIV.CH505. It was discovered that, unlike in humans, rhesus macaque B cells from lymph nodes are more effectively immortalized than B cells from Peripheral Blood Mononuclear Cells (PBMCs).</p> <p>After sample collection and cryopreservation, pro B cells were isolated, sorted by flow cytometry for populations of interest, then activated with CD40 ligand and RM IL-2 followed by transduction with a retroviral vector encoding Bcl-6, Bcl-xL, and green fluorescent protein (GFL), thereby creating immortalized clonal lines. Two clones were down selected for their in vitro neutralizing ability against HIV pseudovirus CH505.</p> <ul> <li>The cell lines have been characterized and are readily expandable for bulk applications as well as for making high-throughput clonal cultures with or without antigen probes in 384-well plates.</li> </ul> <ul> <li>Bcl-6 and Bc-xL immortalization is a valuable and flexible tool for HIV antibody discovery in rhesus macaques.</li> <li>Contributes to pre-clinical therapeutic and vaccine development.</li> </ul> To license this technology, please contact Brian Bailey, PhD at <a href="mailto:bbailey@mail.nih.gov"> bbailey@mail.nih.gov</a> or 240-669-5128 or 301-201-9217. 2024-01-10 2025-08-13 2025-08-13 2024-01-17 AIDS, ANTIBODY, B cells, cell lines, HIV, immortalized False False Research Materials True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 152145427 Samsel, Jakob, et al. “Rhesus macaque bcl-6/bcl-XL B cell immortalization: Discovery of HIV-1 neutralizing antibodies from lymph node.” Journal of Immunological Methods, vol. 516, May 2023, p. 113445 https://doi.org/10.1016/j.jim.2023.113445 <a href="https://doi.org/10.1016/j.jim.2023.113445">Samsel, Jakob, et al. “Rhesus macaque bcl-6/bcl-XL B cell immortalization: Discovery of HIV-1 neutralizing antibodies from lymph node.” Journal of Immunological Methods, vol. 516, May 2023, p. 113445</a> 152145430 Samsel, Jakob NIH - NIAID Samsel, Jakob 1 152145434 Koup, Richard NIH - NIAID NIAID Koup, Richard (NIAID) 2 152145447 Boswell, Kristin NIAID - VRC NIAID Boswell, Kristin (NIAID) 3 152145430 Samsel, Jakob NIH - NIAID Samsel, Jakob 1 152145434 Koup, Richard NIH - NIAID NIAID Koup, Richard (NIAID) 2 152145447 Boswell, Kristin NIAID - VRC NIAID Boswell, Kristin (NIAID) 3 152145454 Immortalized Rhesus macaque Bcl-6/Bcl-xL B Stable Cell Lines E-196-2023-0 Research Material NIAID - VRC, NIH - NIAID 83682222 Bailey, Brian bbailey@mail.nih.gov
United States of America TTIPO bbailey@mail.nih.gov?subject=Web Inquiry on [TAB-4827] Immortalized Rhesus macaque Bcl-6/Bcl-xL Stable B Cell Lines as Tools for HIV Antibody Discovery&body=Please send me information about technology [TAB-4827] Immortalized Rhesus macaque Bcl-6/Bcl-xL Stable B Cell Lines as Tools for HIV Antibody Discovery. Bailey, Brian<br><a href="mailto:bbailey@mail.nih.gov?subject=Web Inquiry on [TAB-4827] Immortalized Rhesus macaque Bcl-6/Bcl-xL Stable B Cell Lines as Tools for HIV Antibody Discovery&body=Please send me information about technology [TAB-4827] Immortalized Rhesus macaque Bcl-6/Bcl-xL Stable B Cell Lines as Tools for HIV Antibody Discovery.">bbailey@mail.nih.gov</a><br> 152165880 HIV 152165897 AIDS 152165901 cell lines 152165905 immortalized 152165909 B cells 152165948 ANTIBODY TAB-4431 147157726 Nanoparticle delivery of lung cancer therapeutic NCI Licensing, Oncology, Therapeutics Licensing Oncology Therapeutics Dennis Klinman, Takashi Sato (Unable To Locate) <p>Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related deaths in developed countries.  Despite the availability of several synergistic, targeted therapy regiments, the 5-year survival rate for NSCLC is only 15%.  The poor prognosis of NSCLS is due in part to limitations of current treatments, which do not trigger an immune response against NSCLC, nor can they be directly delivered into the lungs.  </p> <p>Researchers at NCI developed a novel method for synthesizing polyketal nanoparticles with adsorbed CpG oligonucleotides (NP-CpG) that possess immunomodulatory and potent anti-tumor activity, and can be safely delivered to the lungs. The researchers have demonstrated a link between NP-CpG accumulation in pulmonary tumors and an increase in TH1 cells and decrease in Treg cells <em>in vivo</em>.  They have optimized particle size for intratracheal delivery, and <em>in vivo</em> studies showed improved efficacy, PK, and PD compared to other CpG formulations. The novel NP-CpG preparation can be made reproducibly and to scale for expanded <em>in vivo</em> studies. </p> <p>The NCI seeks partners interested in licensing this therapeutic with an initial goal of preclinical evaluation leading to clinical testing.</p> <h2>Competitive Advantages:</h2> <ul><li>Optimized particle size for intratracheal delivery</li> <li>Improved efficacy, PK, and PD compared to other CpG formulations</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Adjuvant or synergistic therapeutic to enhance efficacy of existing treatment regimes for NSCLC</li> </ul> 2016-02-16 2025-08-06 2020-05-18 2025-08-06 2017-08-23 Immunotherapy, Nanoparticle, Non-small cell lung cancer, NSCLC False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-05-18 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147161886 Klinman D, et al. http://www.ncbi.nlm.nih.gov/pubmed/18430787 <a href="http://www.ncbi.nlm.nih.gov/pubmed/18430787">Klinman D, et al.</a> 147164722 Klinman, Dennis NIH - NCI NCI Klinman, Dennis (NCI) 1 147164723 Sato (Unable To Locate), Takashi NIH - NCI NCI Sato (Unable To Locate), Takashi (NCI) 2 147164722 Klinman, Dennis NIH - NCI NCI Klinman, Dennis (NCI) 1 147164723 Sato (Unable To Locate), Takashi NIH - NCI NCI Sato (Unable To Locate), Takashi (NCI) 2 147158105 Intra-pulmonary Delivery Of CpG ODN Adsorbed Onto Polyketal Nanoparticles (CpG-NP) Significantly Reduced Lung Tumor Burden E-159-2014-0 Filing authorized NCI 83732213 Dick, Taryn taryn.dick@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB taryn.dick@nih.gov?subject=Web Inquiry on [TAB-4431] Nanoparticle delivery of lung cancer therapeutic&body=Please send me information about technology [TAB-4431] Nanoparticle delivery of lung cancer therapeutic.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dick, Taryn<br><a href="mailto:taryn.dick@nih.gov?subject=Web Inquiry on [TAB-4431] Nanoparticle delivery of lung cancer therapeutic&body=Please send me information about technology [TAB-4431] Nanoparticle delivery of lung cancer therapeutic.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">taryn.dick@nih.gov</a><br> 147161121 E-159-2014-0 E-159-2014-0-US-01 Polyketal Nanoparticles Including A CPG Oligodeoxynucleotide For The Treatment of Lung Cancer PRV US 62/024,657 Abandoned US <br />Provisional (PRV) 62/024,657<br />Filed on 2014-07-15<br />Status: Abandoned 147168889 E-159-2014-0 E-159-2014-0-PCT-02 Polyketal Particles Including a CPG Oligodeoxynucleotide for the Treatment of Lung Cancer PCT Patent Cooperation Treaty PCT/US2015/039574 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2015/039574<br />Filed on 2015-07-08<br />Status: Expired 147168890 E-159-2014-0 E-159-2014-0-US-03 POLYKETAL PARTICLES INCLUDING A CPG OLIGODEOXYNUCLEOTIDE FOR THE TREATMENT OF LUNG CANCER National Stage US 9,919,058 15/326,387 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9919058 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9919058">9,919,058</a><br />Filed on 2017-01-13<br />Status: Issued 147172603 Immunotherapy 147172604 Nanoparticle 147172605 Non-small cell lung cancer 147172606 NSCLC TAB-4090 147157372 Topical Antibiotic for Faster Wound Healing NCI Dermatology, Licensing, Therapeutics Dermatology Licensing Therapeutics Hiroyasu Ito, Dennis Klinman <p>Currently available topical antibiotic formulations effectively eliminate bacteria at a wound site. Eliminating bacteria in the wound also eliminates the molecular signals present in bacterial DNA that stimulate the immune system's wound healing processes. Without these signals, the rate of wound healing is diminished.  </p> <p>The present technology provides a means of improving the activity of topical antibiotics by supplementing the antibiotic formulation with immunostimulatory oligodeoxynucleotides (ODN).  These ODN express the CpG motifs present in bacterial DNA and safely mimic the immune stimulation induced by bacterial DNA.  The formulation may be applied directly to a wide variety of wounds to  skin (such as traumatic, burn, or surgical wound, or the eyes (such as corneal abrasions) to effectively eliminate infection and stimulate rapid healing of the wound<strong>.</strong>      </p> <h2>Competitive Advantages:</h2> <ul><li>Eliminates wound site bacteria while retaining immune stimulating properties</li> <li>Promotes faster wound  healing</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Topical antibiotic</li> <li>Wound healing for burn patients, patients with major surgeries and wounds.</li> </ul> 2016-02-16 2025-08-06 2020-04-07 2025-08-06 2016-09-12 CpG motifs, Immunostimulation, ODN., Oigodeoxynucleotides, TLR7, TLR9, Wound healing False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-04-07 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-242-2007 147161979 Sato T, et al. Accelerated wound healing mediated by activation of Toll-like receptor 9. https://www.ncbi.nlm.nih.gov/pubmed?term=20946144 <a href="https://www.ncbi.nlm.nih.gov/pubmed?term=20946144">Sato T, et al. Accelerated wound healing mediated by activation of Toll-like receptor 9.</a> 147162366 Ito H, et al. Antibiotics delay wound healing: an effect reversed by co-administering TLR7 and 9 ligands. http://www.eurekaselect.com/96543 <a href="http://www.eurekaselect.com/96543">Ito H, et al. Antibiotics delay wound healing: an effect reversed by co-administering TLR7 and 9 ligands.</a> 147162404 Yamamoto M, et al. The acceleration of wound healing in primates by the local administration of immunostimulatory CpG oligonucleotides. https://www.ncbi.nlm.nih.gov/pubmed/21421264 <a href="https://www.ncbi.nlm.nih.gov/pubmed/21421264">Yamamoto M, et al. The acceleration of wound healing in primates by the local administration of immunostimulatory CpG oligonucleotides.</a> 147163475 Klinman, Dennis NIH - NCI NCI Klinman, Dennis (NCI) 1 147163476 Ito, Hiroyasu Ito, Hiroyasu 2 147163475 Klinman, Dennis NIH - NCI NCI Klinman, Dennis (NCI) 1 147163476 Ito, Hiroyasu Ito, Hiroyasu 2 147158332 Use Of CpG Oligonucleotides And/or Imiquimod Co-formulated In Antibiotic Cream To Accelerate Wound Healing E-294-2011-0 Filing authorized NCI 83732213 Dick, Taryn taryn.dick@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB taryn.dick@nih.gov?subject=Web Inquiry on [TAB-4090] Topical Antibiotic for Faster Wound Healing&body=Please send me information about technology [TAB-4090] Topical Antibiotic for Faster Wound Healing.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dick, Taryn<br><a href="mailto:taryn.dick@nih.gov?subject=Web Inquiry on [TAB-4090] Topical Antibiotic for Faster Wound Healing&body=Please send me information about technology [TAB-4090] Topical Antibiotic for Faster Wound Healing.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">taryn.dick@nih.gov</a><br> 147166422 E-294-2011-0 E-294-2011-0-US-01 Use Of CpG Oligonucleotides Co-formulated With An Antibiotic To Accelerate Wound Healing PRV US 61/639,688 Abandoned US <br />Provisional (PRV) 61/639,688<br />Filed on 2012-04-27<br />Status: Abandoned 147166423 E-294-2011-0 E-294-2011-0-PCT-02 Use Of CpG Oligonucleotides Co-formulated With an Antibiotic To Accelerate Wound Healing PCT Patent Cooperation Treaty PCT/US2013/034639 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2013/034639<br />Filed on 2013-03-29<br />Status: Expired 147166424 E-294-2011-0 E-294-2011-0-AU-03 Use Of CpG Oligonucleotides Co-formulated With an Antibiotic To Accelerate Wound Healing National Stage Australia 2013252785 2013252785 Issued Australia <br />National Stage 2013252785<br />Filed on 2013-03-29<br />Status: Issued 147166425 E-294-2011-0 E-294-2011-0-CA-04 Use Of CpG Oligonucleotides Co-formulated With an Antibiotic To Accelerate Wound Healing National Stage Canada 2871490 2871490 Issued Canada <br />National Stage 2871490<br />Filed on 2013-03-29<br />Status: Issued 147166426 E-294-2011-0 E-294-2011-0-US-05 Use Of CpG Oligonucleotides Co-formulated With an Antibiotic To Accelerate Wound Healing National Stage US 10,076,535 14/397,156 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10076535 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10076535">10,076,535</a><br />Filed on 2014-10-24<br />Status: Issued 147174741 CpG motifs 147174743 Immunostimulation 147174745 ODN. 147174747 Oigodeoxynucleotides 147174748 TLR7 147174749 TLR9 147174750 Wound healing TAB-4412 147157707 Methods For Treating or Preventing Inflammation and Periodontitis NCI Collaboration, Immunology, Licensing, Therapeutics Collaboration Immunology Licensing Therapeutics John Beutler, Marcos Da Cunha, Marcelo Franchin, Pedro Rosalan <p>Bone-loss-related diseases, such as periodontitis, are characterized by an imbalance between the formation and activity of osteoblasts and osteoclasts, leading to bone loss. There are several signaling pathways that participate in the osteoclastogenesis process. Finding inhibitors of these pathways and other osteoclastogenesis-related pathways may have an effect on bone-loss diseases.</p> <p>Researchers at the National Cancer Institute (NCI), in collaboration with researchers at the University of Campinas, Brazil, have identified cinnamolyoxy-mammeisin (CNM), a 4-phenylcoumarin, which can be isolated from Brazilian geopropolis, as active against osteoclastogeneis pathways. CNM demonstrates anti-inflammatory activity and inhibition of oral bone loss in a mouse model of periodontitis. </p> <h2>Competitive Advantages:</h2> <ul><li>Lack of cytotoxicity</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Alternative to commercial antiresorptive agents</li> </ul> 2018-10-12 2025-08-06 2018-10-12 2025-08-06 2018-10-12 Beutler, Bone Loss, Cinnamolyoxy-mammeisin, CNM, Geopropolis, Osteoclastogeneis, PERIODONTITIS False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2018-10-12 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147162254 Da Cunha M, et al. Effects of Cinnamoyloxy-mammeisin from Geopropolis on Osteoclast Differentiation and Porphyromonas gingivalis-Induced Periodontitis. https://www.ncbi.nlm.nih.gov/pubmed/28570825 <a href="https://www.ncbi.nlm.nih.gov/pubmed/28570825">Da Cunha M, et al. Effects of Cinnamoyloxy-mammeisin from Geopropolis on Osteoclast Differentiation and Porphyromonas gingivalis-Induced Periodontitis.</a> 147162407 Franchin M, et al. Cinnamoyloxy-mammeisin Isolated from Geopropolis Attenuates Inflammatory Process by Inhibiting Cytokine Production: Involvement of MAPK, AP-1 and NF-kB. https://www.ncbi.nlm.nih.gov/pubmed/27367493 <a href="https://www.ncbi.nlm.nih.gov/pubmed/27367493">Franchin M, et al. Cinnamoyloxy-mammeisin Isolated from Geopropolis Attenuates Inflammatory Process by Inhibiting Cytokine Production: Involvement of MAPK, AP-1 and NF-kB.</a> 147164648 Beutler, John NIH - NCI NCI Beutler, John (NCI) 1 147164649 Da Cunha, Marcos NIH - NCI Da Cunha, Marcos 2 147164650 Rosalan, Pedro University of Campinas Rosalan, Pedro 3 147164651 Franchin, Marcelo University of Campinas Franchin, Marcelo 4 147164648 Beutler, John NIH - NCI NCI Beutler, John (NCI) 1 147164649 Da Cunha, Marcos NIH - NCI Da Cunha, Marcos 2 147164650 Rosalan, Pedro University of Campinas Rosalan, Pedro 3 147164651 Franchin, Marcelo University of Campinas Franchin, Marcelo 4 147157794 Periodontitis Treatment E-015-2018-0 Filing authorized NCI, University of Campinas 147162487 Periodontitis Treatment E-015-2018-1 Filing authorized NCI, University of Campinas 83732213 Dick, Taryn taryn.dick@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB taryn.dick@nih.gov?subject=Web Inquiry on [TAB-4412] Methods For Treating or Preventing Inflammation and Periodontitis&body=Please send me information about technology [TAB-4412] Methods For Treating or Preventing Inflammation and Periodontitis.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dick, Taryn<br><a href="mailto:taryn.dick@nih.gov?subject=Web Inquiry on [TAB-4412] Methods For Treating or Preventing Inflammation and Periodontitis&body=Please send me information about technology [TAB-4412] Methods For Treating or Preventing Inflammation and Periodontitis.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">taryn.dick@nih.gov</a><br> 147160903 E-015-2018-0 E-015-2018-0-US-01 METHOD FOR TREATING OR PREVENTING PERIODONTITIS WITH GEOPROPOLIS EXTRACT PRV US 62/678,774 Abandoned US <br />Provisional (PRV) 62/678,774<br />Filed on 2018-05-31<br />Status: Abandoned 147168773 E-015-2018-1 E-015-2018-1-BR-01 Periodontitis Treatment ORD Brazil BR1020160262569 Pending Brazil <br />Ordinary Patent (ORD) BR1020160262569<br />Filed on 2016-11-07<br />Status: Pending 147168774 E-015-2018-1 E-015-2018-1-PCT-02 Periodontitis Treatment PCT Patent Cooperation Treaty PCT/BR2017/000051 Expired Patent Cooperation Treaty <br />(PCT) PCT/BR2017/000051<br />Filed on 2017-05-16<br />Status: Expired 147169536 Beutler 147169538 Bone Loss 147169540 Cinnamolyoxy-mammeisin 147169542 CNM 147169544 Geopropolis 147169546 Osteoclastogeneis 147169547 PERIODONTITIS TAB-4303 147157593 Anti-Viral Compounds that Inhibit HIV Activity NCI Collaboration, Infectious Disease, Licensing, Therapeutics Collaboration Infectious Disease Licensing Therapeutics John Beutler, Suhman Chung, Jiankang Jiang, Stuart LeGrice, Craig Thomas, Jennifer Wilson <p>Several novel tropolone derivatives have been identified that inhibit HIV-1 RNase H function and have potential for anti-viral activity due to reduced cellular toxicity.  Inhibiting RNase H function is a potential treatment for many viral infections, since RNase H function is essential for viral replication for many pathogenic retroviruses such as HIV-1 and HIV-2.  Although many hydroxytropolone compounds are potent RNase H inhibitors biding at the enzymatic active site, they are limited as therapeutic candidates by their toxicity in mammalian cells.  The toxicity thought to be a result of inhibition of multiple essential mammalian metalloenzymes.  We reasoned that the potential beneficial application of tropolone RNase H inhibition might be of therapeutic use if the toxic effects in mammalian cell were eliminated.  By selectively adding steric bulk to add new drug-enzyme contacts for the RNase H active site, a number of novel compounds, that have initially demonstrated reduced cytotoxicity, have been produced.  Importantly, these novel compounds appear to retain antiviral activity essential for use as therapeutics.</p> <h2>Competitive Advantages:</h2> <ul><li>Potentially reduced toxicity</li> <li>Availability of x-ray crystallographic information to guide analog design</li> </ul> <h2>Commercial Applications:</h2> <ul><li>As an HIV-1 therapeutic</li> </ul> 2016-02-16 2025-08-06 2021-06-10 2025-08-06 2016-08-30 AIDS, HIV, ribonuclease H, RNase H, tropolone derivative, viral replication False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2021-06-10 52406768 Discovery 52406768 NCI 37470483 Website Abstract E-183-2009 147162264 Chung S, et al. Synthesis, activity and structural analysis of novel alpha-hydroxytropolone inhibitors of human immunodeficiency virus reverse transcriptase-associated ribonuclease H. https://www.ncbi.nlm.nih.gov/pubmed/21568335 <a href="https://www.ncbi.nlm.nih.gov/pubmed/21568335">Chung S, et al. Synthesis, activity and structural analysis of novel alpha-hydroxytropolone inhibitors of human immunodeficiency virus reverse transcriptase-associated ribonuclease H.</a> 147164227 Beutler, John NIH - NCI NCI Beutler, John (NCI) 1 147164231 Jiang, Jiankang NIH - NCATS NCATS Jiang, Jiankang (NCATS) 2 147164232 Chung, Suhman NIH - NCI NCI Chung, Suhman (NCI) 3 147164229 Thomas, Craig NIH - NCATS NCATS Thomas, Craig (NCATS) 4 147164228 LeGrice, Stuart NIH - NCI NCI LeGrice, Stuart (NCI) 5 147164230 Wilson, Jennifer NIH - NCI Leidos Wilson, Jennifer (Leidos) 6 147164227 Beutler, John NIH - NCI NCI Beutler, John (NCI) 1 147164231 Jiang, Jiankang NIH - NCATS NCATS Jiang, Jiankang (NCATS) 2 147164232 Chung, Suhman NIH - NCI NCI Chung, Suhman (NCI) 3 147164229 Thomas, Craig NIH - NCATS NCATS Thomas, Craig (NCATS) 4 147164228 LeGrice, Stuart NIH - NCI NCI LeGrice, Stuart (NCI) 5 147164230 Wilson, Jennifer NIH - NCI Leidos Wilson, Jennifer (Leidos) 6 147157945 Hydroxytropolone Inhibitors Of HIV-1 And XMRV Ribonuclease H E-081-2011-0 Filing authorized NCATS - NCGC, NCI 83732213 Dick, Taryn taryn.dick@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB taryn.dick@nih.gov?subject=Web Inquiry on [TAB-4303] Anti-Viral Compounds that Inhibit HIV Activity&body=Please send me information about technology [TAB-4303] Anti-Viral Compounds that Inhibit HIV Activity.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dick, Taryn<br><a href="mailto:taryn.dick@nih.gov?subject=Web Inquiry on [TAB-4303] Anti-Viral Compounds that Inhibit HIV Activity&body=Please send me information about technology [TAB-4303] Anti-Viral Compounds that Inhibit HIV Activity.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">taryn.dick@nih.gov</a><br> 147168039 E-081-2011-0 E-081-2011-0-US-01 Tropolone Compounds For Treating Or Preventing Retroviral Infection PRV US 61/484,779 Abandoned US <br />Provisional (PRV) 61/484,779<br />Filed on 2011-05-11<br />Status: Abandoned 147168040 E-081-2011-0 E-081-2011-0-PCT-02 Tropolone Compounds For Treating Or Preventing Retroviral Infection PCT Patent Cooperation Treaty PCT/US2012/037208 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2012/037208<br />Filed on 2012-05-10<br />Status: Expired 147168041 E-081-2011-0 E-081-2011-0-US-03 Tropolone Compounds for Treating or Preventing Retroviral Infection National Stage US 8,993,768 14/116,423 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8993768 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8993768">8,993,768</a><br />Filed on 2013-11-08<br />Status: Issued 147170991 AIDS 147170992 HIV 147170994 ribonuclease H 147170995 RNase H 147170997 tropolone derivative 147170999 viral replication TAB-4262 147157549 Cancer Inhibitors Isolated from an African Plant NCI Licensing, Oncology, Therapeutics Licensing Oncology Therapeutics John Beutler, David Covell, Tanya Ransom, Ranjala Ratnayake <p>The <a href="https://ccrod.cancer.gov/confluence/display/CCRMTDPBeu/Introduction+to+MTP" rel="nofollow" target="_blank">National Cancer Institute&#39;s Molecular Targets Development Program</a> is seeking parties interested in collaborative research to further develop, evaluate, or commercialize cancer inhibitors isolated from the African plant Phyllanthus englerii. The technology is also available for exclusive or non-exclusive licensing.</p> <p>This invention involves compounds extracted from the African plant Phyllanthus englerii that have potential cancer-inhibiting activity. Bioassay-guided fractionation of the purified extracts revealed a series of novel chemical entities which are named Englerin A-F. The englerins and their derivatives are useful in the treatment of a number of cancers, particularly renal cancer. The englerins exhibit selective and potent renal cell inhibitory activity in vitro.</p> <p>These compounds can be recovered in reasonable yield from natural product extracts and are well suited for synthetic chemistry derivativization. A sufficient supply of several analogs was extracted for identification and initial biological characterization. A National Cancer Institute NCI60 anti-cancer screening program confirmed renal-selective activity.</p> <p><strong>Further R&amp;D Needed:</strong></p> <ul> <li>Assess toxicity of the compounds in mice and other experimental animals</li> <li>Studies to determine if therapeutic blood levels of the compound can be obtained.</li> <li>Conduct animal studies to establish efficacy against tumors.</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Ability to develop therapeutics for renal and other types of cancer</li> <li>Reasonable yield and recovery of the compounds from the natural product extracts</li> <li>Tractable synthetic chemistry schemes for synthesis of these compounds</li> </ul> <h2>Commercial Applications:</h2> 2016-02-16 2025-08-06 2017-11-20 2025-08-06 2016-08-29 Englerin A. False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2017-11-20 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147164089 Beutler, John NIH - NCI NCI Beutler, John (NCI) 1 147164091 Ratnayake, Ranjala NIH - NCI NCI Ratnayake, Ranjala (NCI) 2 147164090 Covell, David NIH - NCI NCI Covell, David (NCI) 3 147164092 Ransom, Tanya NIH - NCI NCI Ransom, Tanya (NCI) 4 147164089 Beutler, John NIH - NCI NCI Beutler, John (NCI) 1 147164091 Ratnayake, Ranjala NIH - NCI NCI Ratnayake, Ranjala (NCI) 2 147164090 Covell, David NIH - NCI NCI Covell, David (NCI) 3 147164092 Ransom, Tanya NIH - NCI NCI Ransom, Tanya (NCI) 4 147157905 Epoxy-guaiane Selective Renal Cancer Inhbitors E-064-2008-0 Filing authorized NCI 147162509 Epoxy-guaiane Selective Renal Cancer Inhbitors E-064-2008-1 Filing authorized NCI 147162510 Epoxy-guaiane Selective Renal Cancer Inhibitors E-064-2008-2 Filing authorized NCI 83732213 Dick, Taryn taryn.dick@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB taryn.dick@nih.gov?subject=Web Inquiry on [TAB-4262] Cancer Inhibitors Isolated from an African Plant&body=Please send me information about technology [TAB-4262] Cancer Inhibitors Isolated from an African Plant.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dick, Taryn<br><a href="mailto:taryn.dick@nih.gov?subject=Web Inquiry on [TAB-4262] Cancer Inhibitors Isolated from an African Plant&body=Please send me information about technology [TAB-4262] Cancer Inhibitors Isolated from an African Plant.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">taryn.dick@nih.gov</a><br> 147160983 E-064-2008-0 E-064-2008-0-US-01 Epoxy-guaiane Selective Renal Cancer Inhbitors PRV US 61/018,938 Abandoned US <br />Provisional (PRV) 61/018,938<br />Filed on 2008-01-04<br />Status: Abandoned 147167737 E-064-2008-1 E-064-2008-1-US-01 EPOXY-GUAIANE DERIVATIVES AND TREATMENT OF CANCER PRV US 61/082,850 Abandoned US <br />Provisional (PRV) 61/082,850<br />Filed on 2008-07-23<br />Status: Abandoned 147167738 E-064-2008-2 E-064-2008-2-AT-07 Epoxy-Guaiane Derivatives And Treatment of Cancer EP Austria 2235021 08869946.7 Issued Austria <br />European patent (EP) 08869946.7<br />Filed on 2008-12-30<br />Status: Issued 147167740 E-064-2008-2 E-064-2008-2-PCT-01 Epoxy-guaiane Selective Renal Cancer Inhibitors PCT COMB Patent Cooperation Treaty PCT/US2008/088529 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2008/088529<br />Filed on 2008-12-30<br />Status: Expired 147167741 E-064-2008-2 E-064-2008-2-AU-02 Epoxy-guaiane Derivatives And Treatment Of Cancer National Stage Australia 2008347299 2008347299 Issued Australia <br />National Stage 2008347299<br />Filed on 2008-12-30<br />Status: Issued 147167742 E-064-2008-2 E-064-2008-2-CA-03 Epoxy-guaiane Derivatives and Treatment of Cancer National Stage Canada 2711434 2711434 Issued Canada <br />National Stage 2711434<br />Filed on 2013-12-13<br />Status: Issued 147167743 E-064-2008-2 E-064-2008-2-EP-04 Epoxy-Guaiane Derivatives And Treatment of Cancer National Stage European Patent 2235021 08869946.7 Issued European Patent <br />National Stage 08869946.7<br />Filed on 2008-12-30<br />Status: Issued 147167744 E-064-2008-2 E-064-2008-2-JP-05 Epoxy-guaiane Derivatives and Treatment of Cancer National Stage Japan 5547653 2010-541518 Issued Japan <br />National Stage 2010-541518<br />Filed on 2008-12-30<br />Status: Issued 147167745 E-064-2008-2 E-064-2008-2-US-06 Epoxy-guaiane Derivatives And Treatment of Cancer National Stage US 8,410,292 12/811,245 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8410292 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8410292">8,410,292</a><br />Filed on 2011-09-22<br />Status: Issued 147167746 E-064-2008-2 E-064-2008-2-BE-08 Epoxy-Guaiane Derivatives And Treatment of Cancer EP Belgium 2235021 08869946.7 Issued Belgium <br />European patent (EP) 08869946.7<br />Filed on 2008-12-30<br />Status: Issued 147167747 E-064-2008-2 E-064-2008-2-CH-09 Epoxy-Guaiane Derivatives And Treatment of Cancer EP Switzerland 2235021 08869946.7 Issued Switzerland <br />European patent (EP) 08869946.7<br />Filed on 2008-12-30<br />Status: Issued 147167748 E-064-2008-2 E-064-2008-2-DE-10 Epoxy-Guaiane Derivatives And Treatment of Cancer EP Germany 2235021 08869946.7 Issued Germany <br />European patent (EP) 08869946.7<br />Filed on 2008-12-30<br />Status: Issued 147167749 E-064-2008-2 E-064-2008-2-DK-11 Epoxy-Guaiane Derivatives And Treatment of Cancer EP Denmark 2235021 08869946.7 Issued Denmark <br />European patent (EP) 08869946.7<br />Filed on 2008-12-30<br />Status: Issued 147167750 E-064-2008-2 E-064-2008-2-ES-12 Epoxy-Guaiane Derivatives And Treatment of Cancer EP Spain 2235021 08869946.7 Issued Spain <br />European patent (EP) 08869946.7<br />Filed on 2008-12-30<br />Status: Issued 147167751 E-064-2008-2 E-064-2008-2-FR-13 Epoxy-Guaiane Derivatives And Treatment of Cancer EP France 2235021 08869946.7 Issued France <br />European patent (EP) 08869946.7<br />Filed on 2008-12-30<br />Status: Issued 147167752 E-064-2008-2 E-064-2008-2-GB-14 Epoxy-Guaiane Derivatives And Treatment of Cancer EP United Kingdom 2235021 08869946.7 Issued United Kingdom <br />European patent (EP) 08869946.7<br />Filed on 2008-12-30<br />Status: Issued 147167753 E-064-2008-2 E-064-2008-2-IE-15 Epoxy-Guaiane Derivatives And Treatment of Cancer EP Ireland 2235021 08869946.7 Issued Ireland <br />European patent (EP) 08869946.7<br />Filed on 2008-12-30<br />Status: Issued 147167754 E-064-2008-2 E-064-2008-2-IT-16 Epoxy-Guaiane Derivatives And Treatment of Cancer EP Italy 2235021 08869946.7 Issued Italy <br />European patent (EP) 08869946.7<br />Filed on 2008-12-30<br />Status: Issued 147167755 E-064-2008-2 E-064-2008-2-LU-17 Epoxy-Guaiane Derivatives And Treatment of Cancer EP Luxembourg 2235021 08869946.7 Issued Luxembourg <br />European patent (EP) 08869946.7<br />Filed on 2008-12-30<br />Status: Issued 147167756 E-064-2008-2 E-064-2008-2-NL-18 Epoxy-Guaiane Derivatives And Treatment of Cancer EP The Netherlands 2235021 08869946.7 Issued The Netherlands <br />European patent (EP) 08869946.7<br />Filed on 2008-12-30<br />Status: Issued 147167757 E-064-2008-2 E-064-2008-2-SE-19 Epoxy-Guaiane Derivatives And Treatment of Cancer EP Sweden 2235021 08869946.7 Issued Sweden <br />European patent (EP) 08869946.7<br />Filed on 2008-12-30<br />Status: Issued 147167758 E-064-2008-2 E-064-2008-2-NO-20 Epoxy-Guaiane Derivatives And Treatment of Cancer EP Norway 2235021 08869946.7 Issued Norway <br />European patent (EP) 08869946.7<br />Filed on 2008-12-30<br />Status: Issued 147170618 Englerin A. TAB-4191 147157476 Renal Selective Unsaturated Englerin Analogues NCI Collaboration, Endocrinology, Infectious Disease, Licensing, Oncology, Therapeutics Collaboration Endocrinology Infectious Disease Licensing Oncology Therapeutics John Beutler, Antonio Echavarren, Tanya Ransom, Frederic Ratel <p>Englerin A, a natural product, has shown growth-inhibiting activity against renal cancer cell lines. The compound is an agonist of protein kinase C (PCK) theta, which results in cell cytotoxicity, insulin inhibition, and selective activation of viral replication in T cells.  Englerin A derivatives are promising treatment strategies for any diseases associated with PKC theta and/or ion channel proteins.</p> <p>Researchers at the National Cancer Institute have developed a series of Englerin A analogs for the treatment of renal cancer. The new derivatives are less toxic than the parent compound and have shown effective inhibition of growth in vitro.</p> <h2>Competitive Advantages:</h2> <ul><li>PKC theta associated with a number of immune disorders, cancers, and HIV</li> <li>Reduced toxicity compared to parent Englerin A compounds</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Renal cancer therapeutic</li> <li>HIV therapeutic</li> </ul> 2018-08-01 2025-08-06 2018-08-01 2025-08-06 2018-08-01 Beutler, DIABETES, HIV, renal cancer, small molecule False True Basic (Target Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2018-08-01 52406768 Discovery 52406768 NCI 37470483 Website Abstract E-064-2008 E-090-2014 E-140-2017 147161952 Lopez-Suarez L, et al. Synthesis and Biological Evaluation of New (-)-Englerin Analogues. https://www.ncbi.nlm.nih.gov/pubmed/27005578 <a href="https://www.ncbi.nlm.nih.gov/pubmed/27005578">Lopez-Suarez L, et al. Synthesis and Biological Evaluation of New (-)-Englerin Analogues.</a> 147163847 Beutler, John NIH - NCI NCI Beutler, John (NCI) 1 147163849 Ransom, Tanya NIH - NCI NCI Ransom, Tanya (NCI) 2 147163850 Echavarren, Antonio Institute of Chemical Research of Catalonia (ICIQ) Echavarren, Antonio 3 147163848 Ratel, Frederic Institute of Chemical Research of Catalonia (ICIQ) Ratel, Frederic 4 147163847 Beutler, John NIH - NCI NCI Beutler, John (NCI) 1 147163849 Ransom, Tanya NIH - NCI NCI Ransom, Tanya (NCI) 2 147163850 Echavarren, Antonio Institute of Chemical Research of Catalonia (ICIQ) Echavarren, Antonio 3 147163848 Ratel, Frederic Institute of Chemical Research of Catalonia (ICIQ) Ratel, Frederic 4 147157926 Renal Selective Unsaturated Englerin Analogues E-072-2014-0 Filing authorized Institute of Chemical Research of Catalonia (ICIQ), NCI 83732213 Dick, Taryn taryn.dick@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB taryn.dick@nih.gov?subject=Web Inquiry on [TAB-4191] Renal Selective Unsaturated Englerin Analogues&body=Please send me information about technology [TAB-4191] Renal Selective Unsaturated Englerin Analogues.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dick, Taryn<br><a href="mailto:taryn.dick@nih.gov?subject=Web Inquiry on [TAB-4191] Renal Selective Unsaturated Englerin Analogues&body=Please send me information about technology [TAB-4191] Renal Selective Unsaturated Englerin Analogues.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">taryn.dick@nih.gov</a><br> 147160997 E-072-2014-0 E-072-2014-0-US-01 Compounds for Treating Cancer, Diabetes, and HIV PRV US 62/146,805 Abandoned US <br />Provisional (PRV) 62/146,805<br />Filed on 2015-04-13<br />Status: Abandoned 147167248 E-072-2014-0 E-072-2014-0-PCT-02 EPOXYAZULENE DERIVATIVES USEFUL FOR TREATING CANCER AND DIABETES PCT Patent Cooperation Treaty PCT/US2016/027262 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2016/027262<br />Filed on 2016-04-13<br />Status: Expired 147167249 E-072-2014-0 E-072-2014-0-AU-03 EPOXYAZULENE DERIVATIVES USEFUL FOR TREATING CANCER National Stage Australia 2016247920 2016247920 Issued Australia <br />National Stage 2016247920<br />Filed on 2016-04-13<br />Status: Issued 147167250 E-072-2014-0 E-072-2014-0-CA-04 COMPOUNDS FOR TREATING CANCER AND DIABETES National Stage Canada 2982564 2982564 Issued Canada <br />National Stage 2982564<br />Filed on 2016-04-13<br />Status: Issued 147167251 E-072-2014-0 E-072-2014-0-EP-05 EPOXYAZULENE DERIVATIVES USEFUL FOR TREATING CANCER National Stage European Patent 3283489 16718144.5 Issued European Patent <br />National Stage 16718144.5<br />Filed on 2016-04-13<br />Status: Issued 147167252 E-072-2014-0 E-072-2014-0-JP-06 EPOXYAZULENE DERIVATIVES USEFUL FOR TREATING CANCER AND DIABETES National Stage Japan 6727231 2017-554513 Issued Japan <br />National Stage 2017-554513<br />Filed on 2016-04-13<br />Status: Issued 147167253 E-072-2014-0 E-072-2014-0-US-07 EPOXYAZULENE DERIVATIVES USEFUL FOR TREATING CANCER AND DIABETES National Stage US 10,287,297 15/564,353 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10287297 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10287297">10,287,297</a><br />Filed on 2016-04-13<br />Status: Issued 147167254 E-072-2014-0 E-072-2014-0-BE-08 EPOXYAZULENE DERIVATIVES USEFUL FOR TREATING CANCER EP Belgium 3283489 16718144.5 Issued Belgium <br />European patent (EP) 16718144.5<br />Filed on 2016-04-13<br />Status: Issued 147167255 E-072-2014-0 E-072-2014-0-CH-09 EPOXYAZULENE DERIVATIVES USEFUL FOR TREATING CANCER EP Switzerland 3283489 16718144.5 Issued Switzerland <br />European patent (EP) 16718144.5<br />Filed on 2016-04-13<br />Status: Issued 147167256 E-072-2014-0 E-072-2014-0-DE-10 EPOXYAZULENE DERIVATIVES USEFUL FOR TREATING CANCER EP Germany 3283489 16718144.5 Issued Germany <br />European patent (EP) 16718144.5<br />Filed on 2016-04-13<br />Status: Issued 147167257 E-072-2014-0 E-072-2014-0-DK-11 EPOXYAZULENE DERIVATIVES USEFUL FOR TREATING CANCER EP Denmark 3283489 16718144.5 Issued Denmark <br />European patent (EP) 16718144.5<br />Filed on 2016-04-13<br />Status: Issued 147167258 E-072-2014-0 E-072-2014-0-ES-12 EPOXYAZULENE DERIVATIVES USEFUL FOR TREATING CANCER EP Spain 3283489 16718144.5 Issued Spain <br />European patent (EP) 16718144.5<br />Filed on 2016-04-13<br />Status: Issued 147167259 E-072-2014-0 E-072-2014-0-FR-13 EPOXYAZULENE DERIVATIVES USEFUL FOR TREATING CANCER EP France 3283489 16718144.5 Issued France <br />European patent (EP) 16718144.5<br />Filed on 2016-04-13<br />Status: Issued 147167260 E-072-2014-0 E-072-2014-0-GB-14 EPOXYAZULENE DERIVATIVES USEFUL FOR TREATING CANCER EP United Kingdom 3 283 489 16718144.5 Issued United Kingdom <br />European patent (EP) 16718144.5<br />Filed on 2016-04-13<br />Status: Issued 147167261 E-072-2014-0 E-072-2014-0-IT-15 EPOXYAZULENE DERIVATIVES USEFUL FOR TREATING CANCER EP Italy 3283489 16718144.5 Issued Italy <br />European patent (EP) 16718144.5<br />Filed on 2016-04-13<br />Status: Issued 147167262 E-072-2014-0 E-072-2014-0-NO-16 EPOXYAZULENE DERIVATIVES USEFUL FOR TREATING CANCER EP Norway 3283489 16718144.5 Issued Norway <br />European patent (EP) 16718144.5<br />Filed on 2016-04-13<br />Status: Issued 147167263 E-072-2014-0 E-072-2014-0-SE-17 EPOXYAZULENE DERIVATIVES USEFUL FOR TREATING CANCER EP Sweden 3283489 16718144.5 Issued Sweden <br />European patent (EP) 16718144.5<br />Filed on 2016-04-13<br />Status: Issued 147170781 Beutler 147170782 DIABETES 147170783 HIV 147170784 renal cancer 147170785 small molecule TAB-4263 147157550 Therapeutic Antitumor Combination Containing TLR4 Agonist HMGN1 NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Michael Bustin, Joost Oppenheim, De Yang <p>Immune checkpoint inhibitors (e.g. CTLA-4, PD-L1) have recently shown significant promise in the treatment of cancer.  However, when used alone, these checkpoint inhibitors are limited by the absence or repression of immune cells within the targeted cancer.  For those cancers associated with these limited immune systems, there remains a need for effective therapies.  Agents capable of recruiting and activating immune cells to these types of cancers could extend the overall and complete response rates of combination therapies within the immunooncology domain. </p> <p>Researchers at the National Cancer Institute (NCI) have developed a combination therapy capable of recruiting and activating immune cells for the treatment of cancer.  This therapy incorporates, HMGN1, an alarmin, which recruits immune cells using its chemotactic-induction capabilities, and activates dendritic cell maturation via its TLR4 agonism. The combination of HMGN1 with TLR7/8 agonism and immune-checkpoint inhibition has been tested in xenograft models. In those models, mice bearing ~1cm tumors were successfully treated and resistant to re-challenge. Development of this combination continues and is available for in-licensing and co-development. </p> <h2>Competitive Advantages:</h2> <ul><li>Superior to TLR7/8 agonism and/or checkpoint inhibitors alone</li> <li>No need for the exogenous inclusion of tumor-associated antigen</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Treatment of solid tumors</li> </ul> 2018-10-15 2025-08-06 2018-10-15 2025-08-06 2018-10-15 Alarmin, Checkpoint Inhibitor, CTLA-4, HMGN1, Immunooncology, Oppenheim, TLR4, TLR7/8 False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2018-10-15 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-185-2008 E-269-2016 147161874 Han Z, et al. Therapeutic vaccine to cure large mouse hepatocellular carcinomas. https://www.ncbi.nlm.nih.gov/pubmed/28881713 <a href="https://www.ncbi.nlm.nih.gov/pubmed/28881713">Han Z, et al. Therapeutic vaccine to cure large mouse hepatocellular carcinomas.</a> 147162262 Nie Y, et al. Development of a Curative Therapeutic Vaccine (TheraVac) for the Treatment of Large Established Tumors. https://www.ncbi.nlm.nih.gov/pubmed/29079801 <a href="https://www.ncbi.nlm.nih.gov/pubmed/29079801">Nie Y, et al. Development of a Curative Therapeutic Vaccine (TheraVac) for the Treatment of Large Established Tumors.</a> 147164093 Oppenheim, Joost NIH - NCI NCI Oppenheim, Joost (NCI) 1 147164094 Yang, De NIH - NCI Leidos Yang, De (Leidos) 2 147164095 Bustin, Michael NIH - NCI NCI Bustin, Michael (NCI) 3 147164093 Oppenheim, Joost NIH - NCI NCI Oppenheim, Joost (NCI) 1 147164094 Yang, De NIH - NCI Leidos Yang, De (Leidos) 2 147164095 Bustin, Michael NIH - NCI NCI Bustin, Michael (NCI) 3 147157921 Synergistic Therapeutic Antitumor Effect Of HMGN1 With Other Antitumor Treatments E-069-2016-0 Filing authorized NCI 83732213 Dick, Taryn taryn.dick@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB taryn.dick@nih.gov?subject=Web Inquiry on [TAB-4263] Therapeutic Antitumor Combination Containing TLR4 Agonist HMGN1&body=Please send me information about technology [TAB-4263] Therapeutic Antitumor Combination Containing TLR4 Agonist HMGN1.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dick, Taryn<br><a href="mailto:taryn.dick@nih.gov?subject=Web Inquiry on [TAB-4263] Therapeutic Antitumor Combination Containing TLR4 Agonist HMGN1&body=Please send me information about technology [TAB-4263] Therapeutic Antitumor Combination Containing TLR4 Agonist HMGN1.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">taryn.dick@nih.gov</a><br> 147160993 E-069-2016-0 E-069-2016-0-US-01 Therapeutic Antitumor Combination Of A TLR4 Ligand With Other Treatments PRV US 62/355,134 Abandoned US <br />Provisional (PRV) 62/355,134<br />Filed on 2016-06-27<br />Status: Abandoned 147167760 E-069-2016-0 E-069-2016-0-PCT-02 Therapeutic Antitumor Combination of a TLR4 Ligand With Other Treatments PCT Patent Cooperation Treaty PCT/US17/019342 Expired Patent Cooperation Treaty <br />(PCT) PCT/US17/019342<br />Filed on 2017-02-24<br />Status: Expired 147167761 E-069-2016-0 E-069-2016-0-AU-03 Therapeutic Antitumor Combination of a TLR4 Ligand With Other Treatments National Stage Australia 2017289450 2017289450 Issued Australia <br />National Stage 2017289450<br />Filed on 2017-02-24<br />Status: Issued 147167762 E-069-2016-0 E-069-2016-0-CA-04 Therapeutic Antitumor Combination of a TLR4 Ligand With Other Treatments National Stage Canada 3028654 Pending Canada <br />National Stage 3028654<br />Filed on 2017-02-24<br />Status: Pending 147167763 E-069-2016-0 E-069-2016-0-US-05 Synergistic Therapeutic Antitumor Effect Of HMGN1 With Other Antitumor Treatments National Stage US 11,266,746 16/313,454 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11266746 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11266746">11,266,746</a><br />Filed on 2017-02-24<br />Status: Issued 147170739 Alarmin 147170741 Checkpoint Inhibitor 147170743 CTLA-4 147170744 HMGN1 147170746 Immunooncology 147170747 Oppenheim 147170748 TLR4 147170749 TLR7/8 TAB-4190 147157475 Fully Human Antibody Targeting Tumor Necrosis Factor Receptor Type 2 (TNFR2) for Cancer Immunotherapy NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Xin Chen, Dimiter Dimitrov, Joost Oppenheim, De Yang, Zhongyu Zhu <p>Tumor necrosis factor receptor type 2 (TNFR2)-expressing regulatory T cells (Tregs), present in the tumor microenvironment, play an important role in tumor immune evasion. TNFR2 plays a crucial role in stimulating the activation and proliferation of Tregs, a major checkpoint of antitumor immune responses. In addition to its expression on Tregs, TNFR2 is also known to be overexpressed on some types of tumors and the survival and growth of these tumor cells is promoted by ligands of TNFR2. Therefore, antagonists of TNFR2 may act as checkpoint inhibitors that suppress Tregs but may also be cytotoxic to tumor cells whose survival is promoted by TNFR2 ligands. Targeting TNFR2 in this manner could be a feasible approach to the treatment of cancer and other immune diseases.  </p> <p>NCI researchers have isolated and engineered a fully human TNFR2-specific monoclonal antibody capable of inducing cell killing of Tregs. The monoclonal antibody, named E4, was isolated from a phage display scFv library. The antibody has also been produced in a defucosylated form, denoted E4F6, in an engineered CHO mutant cell.  Experimental data has shown that the defucosylated antibody can specifically bind human TNFR2 on Treg cells and eliminate those cells through antibody-dependent cellular cytotoxicity (ADCC).  This technology has potential uses in cancer immunotherapy to enhance antitumor responses or for targeting TNFR2-positive cancers.  </p> <h2>Competitive Advantages:</h2> <ul><li>Less crowded IP and commercial landscape than traditional checkpoint inhibitors</li> <li>Fully human antibody likely to have a lower toxicity and side effect profile than cross-species antibodies</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Immunotherapeutic for the treatment of cancer </li> <li>Potential for synergistic effect to enhance the antitumor response to existing chemotherapeutics</li> </ul> 2018-09-05 2025-08-06 2018-09-05 2025-08-06 2018-09-05 ADCC, ANTIBODY, Antibody-dependent Cellular Cytotoxicity, CANCER, Immunotherapy, Oppenheim, TNFR2, Tregs, Tumor Necrosis Factor Receptor Type 2 False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2018-09-05 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147162185 Chen X, Oppenheim JJ. Targeting TNFR2, an immune checkpoint stimulator and oncoprotein, is a promising treatment for cancer. http://stke.sciencemag.org/content/10/462/eaal2328.full <a href="http://stke.sciencemag.org/content/10/462/eaal2328.full">Chen X, Oppenheim JJ. Targeting TNFR2, an immune checkpoint stimulator and oncoprotein, is a promising treatment for cancer.</a> 147163842 Oppenheim, Joost NIH - NCI NCI Oppenheim, Joost (NCI) 1 147163843 Dimitrov, Dimiter NIH - NCI NCI Dimitrov, Dimiter (NCI) 2 147163845 Yang, De NIH - NCI Leidos Yang, De (Leidos) 3 147163844 Chen, Xin NIH - NCI Leidos Chen, Xin (Leidos) 4 147163846 Zhu, Zhongyu NIH - NCI NCI Zhu, Zhongyu (NCI) 5 147163842 Oppenheim, Joost NIH - NCI NCI Oppenheim, Joost (NCI) 1 147163843 Dimitrov, Dimiter NIH - NCI NCI Dimitrov, Dimiter (NCI) 2 147163845 Yang, De NIH - NCI Leidos Yang, De (Leidos) 3 147163844 Chen, Xin NIH - NCI Leidos Chen, Xin (Leidos) 4 147163846 Zhu, Zhongyu NIH - NCI NCI Zhu, Zhongyu (NCI) 5 147157910 Defucosylated Fully Human Antibody Targeting TNFR2 On Treg For Cancer Immunotherapy E-065-2017-0 Filing authorized NCI 83732213 Dick, Taryn taryn.dick@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB taryn.dick@nih.gov?subject=Web Inquiry on [TAB-4190] Fully Human Antibody Targeting Tumor Necrosis Factor Receptor Type 2 (TNFR2) for Cancer Immunotherapy&body=Please send me information about technology [TAB-4190] Fully Human Antibody Targeting Tumor Necrosis Factor Receptor Type 2 (TNFR2) for Cancer Immunotherapy.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dick, Taryn<br><a href="mailto:taryn.dick@nih.gov?subject=Web Inquiry on [TAB-4190] Fully Human Antibody Targeting Tumor Necrosis Factor Receptor Type 2 (TNFR2) for Cancer Immunotherapy&body=Please send me information about technology [TAB-4190] Fully Human Antibody Targeting Tumor Necrosis Factor Receptor Type 2 (TNFR2) for Cancer Immunotherapy.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">taryn.dick@nih.gov</a><br> 147167241 E-065-2017-0 E-065-2017-0-US-01 HUMAN MONOCLONAL ANTIBODY TARGETING TNFR2 FOR CANCER IMMUNOTHERAPY PRV US 62/508,827 Abandoned US <br />Provisional (PRV) 62/508,827<br />Filed on 2017-05-19<br />Status: Abandoned 147167242 E-065-2017-0 E-065-2017-0-PCT-02 HUMAN MONOCLONAL ANTIBODY TARGETING TNFR2 FOR CANCER IMMUNOTHERAPY PCT Patent Cooperation Treaty PCT/US2018/031618 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2018/031618<br />Filed on 2018-05-08<br />Status: Expired 147167243 E-065-2017-0 E-065-2017-0-AU-03 HUMAN MONOCLONAL ANTIBODY TARGETING TNFR2 FOR CANCER IMMUNOTHERAPY National Stage Australia 2018268970 2018268970 Issued Australia <br />National Stage 2018268970<br />Filed on 2018-05-08<br />Status: Issued 147167244 E-065-2017-0 E-065-2017-0-CA-04 HUMAN MONOCLONAL ANTIBODY TARGETING TNFR2 FOR CANCER IMMUNOTHERAPY National Stage Canada 3059472 Pending Canada <br />National Stage 3059472<br />Filed on 2018-05-08<br />Status: Pending 147167245 E-065-2017-0 E-065-2017-0-EP-05 HUMAN MONOCLONAL ANTIBODY TARGETING TNFR2 FOR CANCER IMMUNOTHERAPY National Stage European Patent 18727536.7 Abandoned European Patent <br />National Stage 18727536.7<br />Filed on 2018-05-08<br />Status: Abandoned 147167246 E-065-2017-0 E-065-2017-0-US-06 HUMAN MONOCLONAL ANTIBODY TARGETING TNFR2 FOR CANCER IMMUNOTHERAPY National Stage US 11,389,480 16/614,652 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11389480 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11389480">11,389,480</a><br />Filed on 2019-11-18<br />Status: Issued 147170635 ADCC 147170636 ANTIBODY 147170637 Antibody-dependent Cellular Cytotoxicity 147170638 CANCER 147170639 Immunotherapy 147170641 Oppenheim 147170642 TNFR2 147170643 Tregs 147170645 Tumor Necrosis Factor Receptor Type 2 TAB-4253 147157540 Novel Biased Potent Opioid-Like Agonists as Improved Medications to Treat Chronic and Acute Pain NIDA Collaboration, Licensing, Neurology, Therapeutics Collaboration Licensing Neurology Therapeutics Arthur Jacobson, Fuying Li, Kenner Rice <p>There are no analgesics to ameliorate chronic pain without adverse side-effects (e.g., respiratory depression, gastrointestinal effects, tolerance, dependence), thus forcing patients into a difficult choice of negative impacts on quality of life. Most of the analgesics used for chronic and acute pain are drugs such as oxycodone, morphine, oxymorphone, and codeine. All of these opioids have been subject to misuse; prescription drug abuse is a severe problem worldwide, causing high mortality and greatly increased emergency room visits.</p> <p>Recently, research indicated that the analgesic and side-effects of opioids may be separable. Initial work in 1999 by Bohn et al. using -arrestin 2 knockout mice showed that antinociception was enhanced when morphine could not recruit -arrestin. During the next 19 years, Bohn and others showed that the unwanted side-effects of morphine, and presumably all of the classical opioids, such as respiratory depression, life-threatening gastrointestinal effects, tolerance, and dependence, were at least in part due to their ability to recruit -arrestin. Recently, bias factor and a defined therapeutic window were correlated to predict safer analgesics for respiratory depression. Based on this theory,  the compounds that are noted in the preliminary patent of the Drug Design and Synthesis Section (DDSS), Molecular Targets and Medications Discovery Branch (MTMDB), National Institutes on Drug Abuse (NIDA), would be enormously useful. According to in vitro assays, two of these compounds have been shown to be G-protein biased, have potent agonist activity, and do not recruit -arrestin.  Given these characteristics, the compounds should be capable of ameliorating chronic and acute pain without, or with lessened, side-effects. Undoubtedly, there will be a worldwide market for analgesics of this new type. </p> <p>The DDSS at NIDA would like to collaborate with companies that have the ability to expedite clinical trials and the introduction of these drugs worldwide. </p> <h2>Competitive Advantages:</h2> <ul><li>Potential reduction in risk of respiratory depression</li> <li>lessening chronic and acute pain without causing tolerance that would necessitate ever-increasing dosages, or life-threatening side-effects </li> <li>impact prescription drug abuse because of their decreased ability to induce drug dependence</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Acute and chronic pain</li> </ul> 2018-09-18 2025-08-06 2021-01-26 2025-08-06 2018-09-18 Chronic Pain Treatment, G-protein biased, National Institute on Drug Abuse, NIDA, Novel Analgesics, Rice False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-01-26 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147164056 Rice, Kenner NIH - NIDA NIDA Rice, Kenner (NIDA) 1 147164057 Jacobson, Arthur NIH - NIDA NIDA Jacobson, Arthur (NIDA) 2 147164058 Li, Fuying NIH - NIDA Li, Fuying 3 147164056 Rice, Kenner NIH - NIDA NIDA Rice, Kenner (NIDA) 1 147164057 Jacobson, Arthur NIH - NIDA NIDA Jacobson, Arthur (NIDA) 2 147164058 Li, Fuying NIH - NIDA Li, Fuying 3 147157799 Novel Biased Potent Opioid-like Agonists As Improved Medications To Treat Chronic And Acute Pain E-017-2018-0 Filing authorized National Institute on Drug Abuse (NIDA) 91828357 Bernier, Nicholas nicholas.bernier@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America nicholas.bernier@nih.gov?subject=Web Inquiry on [TAB-4253] Novel Biased Potent Opioid-Like Agonists as Improved Medications to Treat Chronic and Acute Pain&body=Please send me information about technology [TAB-4253] Novel Biased Potent Opioid-Like Agonists as Improved Medications to Treat Chronic and Acute Pain.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Bernier, Nicholas<br><a href="mailto:nicholas.bernier@nih.gov?subject=Web Inquiry on [TAB-4253] Novel Biased Potent Opioid-Like Agonists as Improved Medications to Treat Chronic and Acute Pain&body=Please send me information about technology [TAB-4253] Novel Biased Potent Opioid-Like Agonists as Improved Medications to Treat Chronic and Acute Pain.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">nicholas.bernier@nih.gov</a><br> 147160908 E-017-2018-0 E-017-2018-0-US-01 Novel Biased Potent Opioid-like Agonists As Improved Medications To Treat Chronic And Acute Pain PRV US 62/644,791 Abandoned US <br />Provisional (PRV) 62/644,791<br />Filed on 2018-03-19<br />Status: Abandoned 147167691 E-017-2018-0 E-017-2018-0-PCT-02 BIASED POTENT OPIOID-LIKE AGONISTS AS IMPROVED MEDICATIONS TO TREAT CHRONIC AND ACUTE PAIN AND METHODS OF USING THE SAME PCT Patent Cooperation Treaty PCT/US2019/022701 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2019/022701<br />Filed on 2019-03-18<br />Status: Expired 147167692 E-017-2018-0 E-017-2018-0-EP-03 BIASED POTENT OPIOID-LIKE AGONISTS AS IMPROVED MEDICATIONS TO TREAT CHRONIC AND ACUTE PAIN AND METHODS OF USING THE SAME National Stage European Patent 3768679 19714936.2 Issued European Patent <br />National Stage 19714936.2<br />Filed on 2019-03-18<br />Status: Issued 147167693 E-017-2018-0 E-017-2018-0-US-04 Novel Biased Potent Opioid-like Agonists As Improved Medications To Treat Chronic And Acute Pain National Stage US 11,352,365 16/982,196 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11352365 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11352365">11,352,365</a><br />Filed on 2020-09-18<br />Status: Issued 147169590 Chronic Pain Treatment 147169592 G-protein biased 147169594 National Institute on Drug Abuse 147169596 NIDA 147169598 Novel Analgesics 147169599 Rice TAB-3865 147157144 Systems and Devices for Training and Imaging an Awake Test Animal NIDA Licensing, Medical Devices, Neurology, Non-Medical Devices Licensing Medical Devices Neurology Non-Medical Devices Hanbing Lu, Elliot Stein, Yihong Yang <p>Typical MRI imaging sessions can last over 45 minutes and depend on the subject remaining still during the procedure for accurate imaging. In particular, animals being imaged, such as rodents (rats) in an awakened state, are not readily compliant with the restricted movement required when being imaged. Current techniques for imaging awake animals focus on training them with full body restraints and head fixation using a bite bar and/or ear bars. Physically restraining the animal can induce stress, thereby resulting in unavoidable movement of the stressed animal and likely inaccurate imaging.</p> <p>Researchers at the National Institute on Drug Abuse (NIDA) developed an invention that permits prolonged imaging of awake rodents (no anesthesia needed) with minimal confinement and reduces stress. The invention is an apparatus and training system for rodents to maintain its head substantially motionless during an imaging (e.g. MRI) procedure. The system includes a frame defining an enclosure for enclosing an animal therein during the imaging procedure. The system has a head post attached to the head of the animal and a treadmill having a plurality of rollers that the animal walks on such that one or more of the wheels rotate when the animal is in walking motion and stop rotating when the animal is substantially motionless. This arrangement trains the animal to remain substantially motionless when disposed within an imaging apparatus for more accurate imaging and fewer artifacts.</p> <h2>Competitive Advantages:</h2> <ul><li>Imaging while an animal is awake (no anesthesia needed)</li> <li>Less stress-inducing imaging and minimal confinement</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Imaging awake rodents</li> <li>Imaging pharmacological agent distribution in rodents</li> <li>Monitoring the therapeutic effects of a pharmacological agent</li> </ul> 2017-05-01 2025-08-06 2021-01-26 2025-08-06 2017-05-01 Imaging awake rodents, MRI False True Prototype True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2021-01-26 52406769 Prototype 52406769 NCI 37470483 Website Abstract 147162661 Lu, Hanbing NIH - NIDA NIDA Lu, Hanbing (NIDA) 1 147162659 Yang, Yihong NIH - NIDA NIDA Yang, Yihong (NIDA) 2 147162660 Stein, Elliot NIH - NIDA NIDA Stein, Elliot (NIDA) 3 147162661 Lu, Hanbing NIH - NIDA NIDA Lu, Hanbing (NIDA) 1 147162659 Yang, Yihong NIH - NIDA NIDA Yang, Yihong (NIDA) 2 147162660 Stein, Elliot NIH - NIDA NIDA Stein, Elliot (NIDA) 3 147157852 Methods And Apparatus For Imaging Awake Rodents E-043-2015-0 Filing authorized National Institute on Drug Abuse (NIDA) 91828357 Bernier, Nicholas nicholas.bernier@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America nicholas.bernier@nih.gov?subject=Web Inquiry on [TAB-3865] Systems and Devices for Training and Imaging an Awake Test Animal&body=Please send me information about technology [TAB-3865] Systems and Devices for Training and Imaging an Awake Test Animal.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Bernier, Nicholas<br><a href="mailto:nicholas.bernier@nih.gov?subject=Web Inquiry on [TAB-3865] Systems and Devices for Training and Imaging an Awake Test Animal&body=Please send me information about technology [TAB-3865] Systems and Devices for Training and Imaging an Awake Test Animal.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">nicholas.bernier@nih.gov</a><br> 147160951 E-043-2015-0 E-043-2015-0-US-01 Systems and Methods for Training and Imaging an Animal in an Awaken State ORD US 9,717,946 14/589,725 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9717946 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9717946">9,717,946</a><br />Filed on 2015-01-05<br />Status: Issued 147170119 Imaging awake rodents 147170120 MRI TAB-4407 147157702 Convolutional Neural Networks for Organ Segmentation CC Collaboration, Licensing, Software / Apps Collaboration Licensing Software / Apps Adam Harrison, Le Lu, Holger Roth, Ronald Summers <p>Accurate automated organ and disease feature segmentation is a challenge for medical imaging analysis. The pancreas, for example, is a small, soft, organ with low uniformity of shape and volume between patients. Because of the lack of uniform image patterns, there are few features that can be used to aid in automated identification of anatomy and boundaries. Segmentation of high variability features is uniquely difficult for a computer to perform. Due to these difficulties, high variability anatomical features are currently analyzed and determined only by trained physicians who can read the images. Another challenge is that there is a shortage of trained physicians relative to the amount of image data generated.  While computer automation may help solve many limitations for human image analysis, which is time consuming and labor intensive, it has been difficult to achieve.</p> <p> </p> <p>To help solve some of these challenges, researchers at the National Institutes of Health Clinical Center (NIHCC) have developed a technology that trains a computer to read and segment certain highly variable images features, such as the pancreas. This analysis is done by employing Holistically-Nested Convolutional Neural Network (HNNs) and deep learning. The resulting biomarkers are far more precise compared to other approaches and outperform current methods for automated image localization and segmentation of high variability image features. The training methods may be generalizable to enable automation of segmentation for many high variability image structures, such as tumors and diseased organs. This advancement has application for improving computer assisted diagnostic capabilities, and disease monitoring and surgical planning abilities for many diseases.</p> <h2>Competitive Advantages:</h2> <ul><li>Improved segmentation and automation of highly variable medical image features</li> <li>Reduced physical time in image analysis</li> <li>Data mining and more complete analysis of medical image datasets</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Computer Assisted Diagnostics</li> <li>Computer assisted disease monitoring</li> <li>Computer assisted surgical planning</li> </ul> 2017-06-23 2025-08-06 2017-06-23 2025-08-06 2017-06-23 Computer Assisted Diagnostics, Computer Vision, Deep Learning, HNN, Holistically-Nested Convolutional Neural Network, Medical Imaging Informatics, National Institutes of Health Clinical Center, NIHCC False True Basic (Target Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2017-06-23 52406768 Discovery 52406768 NCI 37470483 Website Abstract E-182-2016 147164627 Roth, Holger NIH - CC Roth, Holger 1 147164626 Lu, Le NIH - CC CC Lu, Le (CC) 2 147164628 Harrison, Adam NIH - CC CC Harrison, Adam (CC) 3 147164625 Summers, Ronald NIH - CC CC Summers, Ronald (CC) 4 147164627 Roth, Holger NIH - CC Roth, Holger 1 147164626 Lu, Le NIH - CC CC Lu, Le (CC) 2 147164628 Harrison, Adam NIH - CC CC Harrison, Adam (CC) 3 147164625 Summers, Ronald NIH - CC CC Summers, Ronald (CC) 4 147157883 Spatial Aggregation Of Holistically-Nested Convolutional Neural Networks For Automated Organ (Pancreas) Localization And Segmentation In 3D Medical Scans E-056-2017-0 Filing authorized Clinical Center (CC) 91828331 Beka, Lidia lidia.beka@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America lidia.beka@nih.gov?subject=Web Inquiry on [TAB-4407] Convolutional Neural Networks for Organ Segmentation&body=Please send me information about technology [TAB-4407] Convolutional Neural Networks for Organ Segmentation.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Beka, Lidia<br><a href="mailto:lidia.beka@nih.gov?subject=Web Inquiry on [TAB-4407] Convolutional Neural Networks for Organ Segmentation&body=Please send me information about technology [TAB-4407] Convolutional Neural Networks for Organ Segmentation.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">lidia.beka@nih.gov</a><br> 147168754 E-056-2017-0 E-056-2017-0-US-01 SPATIAL AGGREGATION OF HOLISTICALLY-NESTED CONVOLUTIONAL NEURAL NETWORKS FOR AUTOMATED ORGAN LOCALIZATION AND SEGMENTATION IN 3D MEDICAL SCANS PRV US 62/450,681 Abandoned US <br />Provisional (PRV) 62/450,681<br />Filed on 2017-01-26<br />Status: Abandoned 147170407 Computer Assisted Diagnostics 147170408 Computer Vision 147170409 Deep Learning 147170411 HNN 147170413 Holistically-Nested Convolutional Neural Network 147170415 Medical Imaging Informatics 147170416 National Institutes of Health Clinical Center 147170418 NIHCC TAB-4374 147157668 Convolutional Neural Networks for Organ Segmentation CC Licensing, Software / Apps Licensing Software / Apps Le Lu, Isabelle-Emmanu Nogues, Holger Roth, Ronald Summers, Xiaosong Wang <p>Accurate automated organ and disease feature segmentation is a challenge for medical imaging analysis. The pancreas, for example, is a small, soft, organ with low uniformity of shape and volume between patients. Because of the lack of uniform image patterns, there are few features that can be used to aid in automated identification of anatomy and boundaries. Segmentation of high variability features is uniquely difficult for a computer to perform. Due to these difficulties, high variability anatomical features are currently analyzed and determined only by trained physicians who can read the images. Another challenge is that there is a shortage of trained physicians relative to the amount of image data generated.  While computer automation may help solve many limitations for human image analysis, which is time consuming and labor intensive, it has been difficult to achieve.</p> <p>To help solve some of these challenges, researchers at the National Institutes of Health Clinical Center (NIHCC) have developed a technology that trains a computer to read and segment certain highly variable images features, such as the pancreas. This analysis is done by employing Holistically-Nested Convolutional Neural Network (HNNs) and deep learning. The resulting biomarkers are far more precise compared to other approaches and outperform current methods for automated image localization and segmentation of high variability image features. The training methods may be generalizable to enable automation of segmentation for many high variability image structures, such as tumors and diseased organs. This advancement has application for improving computer assisted diagnostic capabilities, and disease monitoring and surgical planning abilities for many diseases.</p> <p>This technology is currently available for licensing.</p> <h2>Competitive Advantages:</h2> <ul><li>Improved segmentation and automation of highly variable medical image features</li> <li>Reduced physical time in image analysis</li> <li>Data mining and more complete analysis of medical image datasets</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Computer Assisted Diagnostics</li> <li>Computer assisted disease monitoring</li> <li>Computer assisted surgical planning</li> </ul> 2017-06-23 2025-08-06 2020-08-17 2025-08-06 2017-06-23 Computer Assisted Diagnostics, Computer Vision, Deep Learning, HNN, Holistically-Nested Convolutional Neural Network, Medical Imaging Informatics, National Institutes of Health Clinical Center, NIHCC False True Basic (Target Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-08-17 52406768 Discovery 52406768 NCI 37470483 Website Abstract E-056-2017 147164495 Lu, Le NIH - CC CC Lu, Le (CC) 1 147164497 Roth, Holger NIH - CC Roth, Holger 2 147164498 Nogues, Isabelle-Emmanu NIH - CC Nogues, Isabelle-Emmanu 3 147164494 Summers, Ronald NIH - CC CC Summers, Ronald (CC) 4 147164496 Wang, Xiaosong NIH - CC Wang, Xiaosong 5 147164495 Lu, Le NIH - CC CC Lu, Le (CC) 1 147164497 Roth, Holger NIH - CC Roth, Holger 2 147164498 Nogues, Isabelle-Emmanu NIH - CC Nogues, Isabelle-Emmanu 3 147164494 Summers, Ronald NIH - CC CC Summers, Ronald (CC) 4 147164496 Wang, Xiaosong NIH - CC Wang, Xiaosong 5 147158163 Integrating Deep Boundary And Appearance Convolutional Neural Networks For Bottom-up Organ Segmentation: Spatial Aggregation And Structured Optimization E-182-2016-0 Filing authorized Clinical Center (CC) 91828331 Beka, Lidia lidia.beka@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America lidia.beka@nih.gov?subject=Web Inquiry on [TAB-4374] Convolutional Neural Networks for Organ Segmentation&body=Please send me information about technology [TAB-4374] Convolutional Neural Networks for Organ Segmentation.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Beka, Lidia<br><a href="mailto:lidia.beka@nih.gov?subject=Web Inquiry on [TAB-4374] Convolutional Neural Networks for Organ Segmentation&body=Please send me information about technology [TAB-4374] Convolutional Neural Networks for Organ Segmentation.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">lidia.beka@nih.gov</a><br> 147168519 E-182-2016-0 E-182-2016-0-US-01 INTEGRATING DEEP BOUNDARY AND APPEARANCE CONVOLUTIONAL NEURAL NETWORKS FOR BOTTOM-UP ORGAN SEGMENTATION PRV US 62/345,606 Abandoned US <br />Provisional (PRV) 62/345,606<br />Filed on 2016-06-03<br />Status: Abandoned 147168520 E-182-2016-0 E-182-2016-0-PCT-02 SPATIAL AGGREGATION OF HOLISTICALLY-NESTED CONVOLUTIONAL NEURAL NETWORKS FOR AUTOMATED ORGAN LOCALIZATION AND SEGMENTATION IN 3D MEDICAL SCANS PCT Patent Cooperation Treaty PCT/US17/035974 Expired Patent Cooperation Treaty <br />(PCT) PCT/US17/035974<br />Filed on 2017-06-05<br />Status: Expired 147173175 Computer Assisted Diagnostics 147173176 Computer Vision 147173177 Deep Learning 147173178 HNN 147173179 Holistically-Nested Convolutional Neural Network 147173180 Medical Imaging Informatics 147173181 National Institutes of Health Clinical Center 147173182 NIHCC TAB-4333 147157624 Learning to Read Chest X-Rays: Recurrent Neural Cascade Model for Automated Image Annotation CC Cardiology, Collaboration, Licensing, Oncology, Software / Apps Cardiology Collaboration Licensing Oncology Software / Apps Le Lu, Hoo Chang Shin, Ronald Summers <p>Medical image datasets are an important clinical resource. Effectively referencing patient images against similar related images and case histories can inform and produce better treatment outcomes. Labeling and identifying disease features and relations between images within a large image database has not been a task capable of automation. Rather, it is a task that must be performed by highly trained clinicians who can identify and label the medically meaningful image features. The time constraints on clinicians versus the size of these data sets greatly limits the ability to analyze, annotate, and interrelate images in such a database, so these efforts are not routinely completed for large datasets.<br /> Researchers from the National Institutes of Health - Clinical Center (NIH-CC) have developed a technology that automatically detects disease features and applies labels &amp; annotation of clinical findings in a chest x-rays’ images using deep learning methods. A training set of image annotations is mined for disease names to train convolutional neural networks (CNNs). Recurrent neural networks (RNNs) are then trained to describe the context of a detected disease’s features, building on top of the deep CNN features. Feedback from the trained pair of CNN/RNN can then be used to infer the joint image/text contexts for composite image labeling (location, severity, and the affected organs). The capability for automation of methods to search and extract meaningful medical information from images might transform the usefulness of medical image databases, making them searchable and usable for detection and diagnostic applications in cloud-based services. </p> <h2>Competitive Advantages:</h2> <ul><li>Automated diseases detection</li> <li>Ability to automatically annotate contexts </li> </ul> <h2>Commercial Applications:</h2> <ul><li>Computer assisted diagnostic</li> <li>Medical image data set mining </li> <li>Cloud-based services </li> </ul> 2018-08-16 2025-08-06 2020-08-16 2025-08-06 2018-08-16 Chest X-Rays, CNN, Computer Assisted Diagnostics, Convolutional Neural Networks, Deep Learning Model, Disease Mining from Images, Radiology, Recurrent Neural Networks, RNN, Shin False True Prototype True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-08-16 52406769 Prototype 52406769 NCI 37470483 Website Abstract 147161987 Shin H, et al. Learning to read Chest X-Rays: Recurrent Neural Cascade Model for Automated Image Annotation https://arxiv.org/pdf/1603.08486.pdf <a href="https://arxiv.org/pdf/1603.08486.pdf">Shin H, et al. Learning to read Chest X-Rays: Recurrent Neural Cascade Model for Automated Image Annotation</a> 147164342 Shin, Hoo Chang NIH - CC CC Shin, Hoo Chang (CC) 1 147164343 Lu, Le NIH - CC CC Lu, Le (CC) 2 147164341 Summers, Ronald NIH - CC CC Summers, Ronald (CC) 3 147164342 Shin, Hoo Chang NIH - CC CC Shin, Hoo Chang (CC) 1 147164343 Lu, Le NIH - CC CC Lu, Le (CC) 2 147164341 Summers, Ronald NIH - CC CC Summers, Ronald (CC) 3 147157860 Learning To Read Chest X-Rays: Recurrent Neural Feedback Model For Automated Image Annotation E-045-2016-0 Filing authorized Clinical Center (CC) 91828331 Beka, Lidia lidia.beka@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America lidia.beka@nih.gov?subject=Web Inquiry on [TAB-4333] Learning to Read Chest X-Rays: Recurrent Neural Cascade Model for Automated Image Annotation&body=Please send me information about technology [TAB-4333] Learning to Read Chest X-Rays: Recurrent Neural Cascade Model for Automated Image Annotation.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Beka, Lidia<br><a href="mailto:lidia.beka@nih.gov?subject=Web Inquiry on [TAB-4333] Learning to Read Chest X-Rays: Recurrent Neural Cascade Model for Automated Image Annotation&body=Please send me information about technology [TAB-4333] Learning to Read Chest X-Rays: Recurrent Neural Cascade Model for Automated Image Annotation.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">lidia.beka@nih.gov</a><br> 147168248 E-045-2016-0 E-045-2016-0-US-01 Recurrent Neural Feedback Model For Automated Image Annotation PRV US 62/302,084 Abandoned US <br />Provisional (PRV) 62/302,084<br />Filed on 2016-03-01<br />Status: Abandoned 147168249 E-045-2016-0 E-045-2016-0-PCT-02 Recurrent Neural Feedback Model For Automated Image Annotation PCT Patent Cooperation Treaty PCT/US2017/020183 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2017/020183<br />Filed on 2017-03-01<br />Status: Expired 147170204 Chest X-Rays 147170206 CNN 147170208 Computer Assisted Diagnostics 147170210 Convolutional Neural Networks 147170212 Deep Learning Model 147170214 Disease Mining from Images 147170215 Radiology 147170217 Recurrent Neural Networks 147170219 RNN 147170221 Shin TAB-4146 147157429 Progressive and Multipath Neural Network for Medical Image Segmentation CC Collaboration, Licensing, Software / Apps Collaboration Licensing Software / Apps Adam Harrison, Le Lu, Daniel Mollura, Ronald Summers, Ziyue Xu <p>The technology relates to software, systems, and methods for automated medical image segmentation via deep learning. Standard holistically-nested networks (HNNs) used in computer vision and medical imaging for segmentation and edge detection have a problem with coarsening resolution. The described technology addresses this.<br />  <br /> Simple, progressive multipath connections enhance the standard HNN model.  Processing in this new model achieves improved segmentations detail levels without need for additional model parameters.  Variations in appearance are handled without being affected by variations in shape for a given image feature. Early experiments improved segmentation masks compared to standard HNN. Anatomical regions, often misidentified, are correctly captured via this approach.</p> <p>This technology is generalizable to image segmentation across multiple imaging modalities, including CT, MRI and X-ray.  The improved image segmentation detail levels may have clinically relevant applications to high variability image features, such as tumors and pathologies of the lung. This technology has potential to improve diagnostic capabilities and treatment outcomes in many disease conditions. </p> <h2>Competitive Advantages:</h2> <ul><li>Improved detail in automated medical image segmentation without need for additional training or processing of images on other parameters. </li> <li>Generalizable to image segmentation across multiple imaging modalities, including CT, MRI and X-ray</li> <li>Improved segmentations detail levels without need for additional model parameters</li> <li>Improved segmentation masks compared to standard HNN</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Computer assisted diagnostics and medical imaging processing</li> <li>Tumor imaging/diagnosis </li> <li>Imaging pathologies of the lung</li> <li>Diagnostic capabilities for a range of disease conditions; e.g., cardiovascular and neurodegenerative</li> <li>Providing framework to develop more cost-effective health care</li> </ul> 2017-10-23 2025-08-06 2020-08-17 2025-08-06 2017-10-23 Automated Medical Image, Coarsening Resolution, Computer Assisted Diagnostic, Deep Learning, Diagnostics, Holistically-nested networks (HNNs), Image Segmentation, Medical Imaging, Medical Imaging Processing, Segmentation False True Prototype True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2020-08-17 52406769 Prototype 52406769 NCI 37470483 Website Abstract 147163682 Harrison, Adam NIH - CC CC Harrison, Adam (CC) 1 147163683 Xu, Ziyue NIH - CC Xu, Ziyue 2 147163681 Lu, Le NIH - CC CC Lu, Le (CC) 3 147163680 Summers, Ronald NIH - CC CC Summers, Ronald (CC) 4 147163684 Mollura, Daniel NIH - CC Mollura, Daniel 5 147163682 Harrison, Adam NIH - CC CC Harrison, Adam (CC) 1 147163683 Xu, Ziyue NIH - CC Xu, Ziyue 2 147163681 Lu, Le NIH - CC CC Lu, Le (CC) 3 147163680 Summers, Ronald NIH - CC CC Summers, Ronald (CC) 4 147163684 Mollura, Daniel NIH - CC Mollura, Daniel 5 147158007 Progressive Holistically Nested Networks For Pathological Lung Segmentation E-109-2017-0 Filing authorized Clinical Center (CC) 91828331 Beka, Lidia lidia.beka@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America lidia.beka@nih.gov?subject=Web Inquiry on [TAB-4146] Progressive and Multipath Neural Network for Medical Image Segmentation&body=Please send me information about technology [TAB-4146] Progressive and Multipath Neural Network for Medical Image Segmentation.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Beka, Lidia<br><a href="mailto:lidia.beka@nih.gov?subject=Web Inquiry on [TAB-4146] Progressive and Multipath Neural Network for Medical Image Segmentation&body=Please send me information about technology [TAB-4146] Progressive and Multipath Neural Network for Medical Image Segmentation.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">lidia.beka@nih.gov</a><br> 147161055 E-109-2017-0 E-109-2017-0-US-01 PROGRESSIVE AND MULTI-PATH HOLISTICALLY NESTED NETWORKS FOR SEGMENTATION PRV US 62/516,948 Abandoned US <br />Provisional (PRV) 62/516,948<br />Filed on 2017-06-08<br />Status: Abandoned 147166918 E-109-2017-0 E-109-2017-0-PCT-02 PROGRESSIVE AND MULTI-PATH HOLISTICALLY NESTED NETWORKS FOR SEGMENTATION PCT Patent Cooperation Treaty PCT/US2018/036682 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2018/036682<br />Filed on 2018-06-08<br />Status: Expired 147166919 E-109-2017-0 E-109-2017-0-US-03 PROGRESSIVE AND MULTI-PATH HOLISTICALLY NESTED NETWORKS FOR SEGMENTATION National Stage US 11,195,280 16/620,464 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11195280 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11195280">11,195,280</a><br />Filed on 2019-12-06<br />Status: Issued 147171619 Automated Medical Image 147171621 Coarsening Resolution 147171623 Computer Assisted Diagnostic 147171624 Deep Learning 147171625 Diagnostics 147171627 Holistically-nested networks (HNNs) 147171629 Image Segmentation 147171631 Medical Imaging 147171633 Medical Imaging Processing 147171634 Segmentation TAB-4127 147157409 Computer-Aided Diagnostic for Use in Multiparametric MRI for Prostate Cancer CC Collaboration, Licensing, Oncology, Software / Apps Collaboration Licensing Oncology Software / Apps Ruida Cheng, Peter Choyke, Sonia Gaur, Matthew Greer, Nathan Lay, Matthew Mcauliffe, Francessa Mertan, Holger Roth, Ronald Summers, Yohannes Tsehay, Ismail Turkbey <p>Multiparametric MRI improves image detail and prostate cancer detection rates compared to standard MRI. Computer aided diagnostics (CAD) used in combination with multiparametric MRI images may further improve prostate cancer detection and visualization. The technology, developed by researchers at the National Institutes of Health Clinical Center (NIHCC), is an automated CAD system for use in processing and visualizing prostate lesions on multiparametric MRI images. The system uses specialized algorithms (an ensemble of multiple random decision tress, Random Forest) that is trained against: 1) hand drawn contours, 2) recorded biopsy results, and 3) normal cases from randomly sampled patient images weighted for lesion size. This CAD system produces a more accurate probability map of potential cancerous lesions in multiparametric MRI images.</p> <p> </p> <p>In addition, the CAD system may be used in several applications and settings including, but not limited to: 1) cloud-based prostate cancer screening, 2) use in under-resourced clinical settings with few or underexperienced radiologists, 3) integration into a work station or a picture archiving and communication system (PACS), 4) or serve as standalone software to be used on existing systems. This technology is currently available for licensing and co-development partnerships.</p> <h2>Competitive Advantages:</h2> <ul><li>Faster image analysis, improved workflow</li> <li>More accurate diagnosis and treatment guidance</li> <li>Potential for cloud-based prostate cancer screening</li> <li>Use in under-resourced clinical settings</li> <li>Standalone software in existing systems</li> <li>Can be integrated into a work station or PACS</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Computer Assisted Diagnostics</li> </ul> 2017-06-23 2025-08-06 2017-06-23 2025-08-06 2017-06-23 Computer-aided Diagnostic, Image Analysis System/Software, National Institutes of Health Clinical Center, NIHCC False True Basic (Target Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2017-06-23 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147162163 Nathan L, et al. Detection of prostate cancer in multiparametric MRI using random forest with instance weighting https://www.ncbi.nlm.nih.gov/pubmed/28630883 <a href="https://www.ncbi.nlm.nih.gov/pubmed/28630883">Nathan L, et al. Detection of prostate cancer in multiparametric MRI using random forest with instance weighting</a> 147163614 Lay, Nathan NIH - CC NCI Lay, Nathan (NCI) 1 147163615 Tsehay, Yohannes Clinical Center (CC) Tsehay, Yohannes 2 147163608 Summers, Ronald NIH - CC CC Summers, Ronald (CC) 3 147163612 Turkbey, Ismail NIH - NCI NCI Turkbey, Ismail (NCI) 4 147163611 Cheng, Ruida NIH - CIT Cheng, Ruida 5 147163613 Roth, Holger NIH - CC Roth, Holger 6 147163609 Mcauliffe, Matthew NIH - CIT CIT Mcauliffe, Matthew (CIT) 7 147163617 Gaur, Sonia NIH - NCI Gaur, Sonia 8 147163616 Mertan, Francessa NIH - NCI Mertan, Francessa 9 147163610 Choyke, Peter NIH - NCI NCI Choyke, Peter (NCI) 10 147163618 Greer, Matthew NIH - NCI Greer, Matthew 11 147163614 Lay, Nathan NIH - CC NCI Lay, Nathan (NCI) 1 147163615 Tsehay, Yohannes Clinical Center (CC) Tsehay, Yohannes 2 147163608 Summers, Ronald NIH - CC CC Summers, Ronald (CC) 3 147163612 Turkbey, Ismail NIH - NCI NCI Turkbey, Ismail (NCI) 4 147163611 Cheng, Ruida NIH - CIT Cheng, Ruida 5 147163613 Roth, Holger NIH - CC Roth, Holger 6 147163609 Mcauliffe, Matthew NIH - CIT CIT Mcauliffe, Matthew (CIT) 7 147163617 Gaur, Sonia NIH - NCI Gaur, Sonia 8 147163616 Mertan, Francessa NIH - NCI Mertan, Francessa 9 147163610 Choyke, Peter NIH - NCI NCI Choyke, Peter (NCI) 10 147163618 Greer, Matthew NIH - NCI Greer, Matthew 11 147158166 Computer-aided Diagnosis Of Prostate Cancer In Multi-parametric MRI E-183-2016-0 Filing authorized CIT, Clinical Center (CC), NCI 91828331 Beka, Lidia lidia.beka@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America lidia.beka@nih.gov?subject=Web Inquiry on [TAB-4127] Computer-Aided Diagnostic for Use in Multiparametric MRI for Prostate Cancer&body=Please send me information about technology [TAB-4127] Computer-Aided Diagnostic for Use in Multiparametric MRI for Prostate Cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Beka, Lidia<br><a href="mailto:lidia.beka@nih.gov?subject=Web Inquiry on [TAB-4127] Computer-Aided Diagnostic for Use in Multiparametric MRI for Prostate Cancer&body=Please send me information about technology [TAB-4127] Computer-Aided Diagnostic for Use in Multiparametric MRI for Prostate Cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">lidia.beka@nih.gov</a><br> 147166790 E-183-2016-0 E-183-2016-0-US-01 MULTI-PARAMETRIC MRI OF THE PROSTATE PRV US 62/462,256 Abandoned US <br />Provisional (PRV) 62/462,256<br />Filed on 2017-02-22<br />Status: Abandoned 147166791 E-183-2016-0 E-183-2016-0-PCT-02 DETECTION OF PROSTATE CANCER IN MULTI-PARAMETRIC MRI USING RANDOM FOREST WITH INSTANCE WEIGHTING & MR PROSTATE SEGMENTATION BY DEEP LEARNING WITH HOLISTICALLY-NESTED NETWORKS PCT Patent Cooperation Treaty PCT/US2018/019249 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2018/019249<br />Filed on 2018-02-22<br />Status: Expired 147166793 E-183-2016-0 E-183-2016-0-US-04 DETECTION OF PROSTATE CANCER IN MULTI-PARAMETRIC MRI USING RANDOM FOREST WITH INSTANCE WEIGHTING & MR PROSTATE SEGMENTATION BY DEEP LEARNING WITH HOLISTICALLY-NESTED NETWORKS National Stage US 11,200,667 16/488,127 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11200667 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11200667">11,200,667</a><br />Filed on 2019-08-22<br />Status: Issued 147166795 E-183-2016-0 E-183-2016-0-AU-06 DETECTION OF PROSTATE CANCER IN MULTI-PARAMETRIC MRI USING RANDOM FOREST WITH INSTANCE WEIGHTING & MR PROSTATE SEGMENTATION BY DEEP LEARNING WITH HOLISTICALLY-NESTED NETWORKS National Stage Australia 2018225145 2018225145 Issued Australia <br />National Stage 2018225145<br />Filed on 2018-02-22<br />Status: Issued 147166796 E-183-2016-0 E-183-2016-0-CA-07 DETECTION OF PROSTATE CANCER IN MULTI-PARAMETRIC MRI USING RANDOM FOREST WITH INSTANCE WEIGHTING & MR PROSTATE SEGMENTATION BY DEEP LEARNING WITH HOLISTICALLY-NESTED NETWORKS National Stage Canada 3053487 Pending Canada <br />National Stage 3053487<br />Filed on 2018-02-22<br />Status: Pending 147166797 E-183-2016-0 E-183-2016-0-EP-08 DETECTION OF PROSTATE CANCER IN MULTI-PARAMETRIC MRI USING RANDOM FOREST WITH INSTANCE WEIGHTING & MR PROSTATE SEGMENTATION BY DEEP LEARNING WITH HOLISTICALLY-NESTED NETWORKS National Stage European Patent 3586305 18710950.9 Issued European Patent <br />National Stage 18710950.9<br />Filed on 2018-02-22<br />Status: Issued 147166798 E-183-2016-0 E-183-2016-0-JP-09 DETECTION OF PROSTATE CANCER IN MULTI-PARAMETRIC MRI USING RANDOM FOREST WITH INSTANCE WEIGHTING & MR PROSTATE SEGMENTATION BY DEEP LEARNING WITH HOLISTICALLY-NESTED NETWORKS National Stage Japan 7293118 2019-545291 Issued Japan <br />National Stage 2019-545291<br />Filed on 2019-08-20<br />Status: Issued 147166799 E-183-2016-0 E-183-2016-0-HK-10 DETECTION OF PROSTATE CANCER IN MULTI-PARAMETRIC MRI USING RANDOM FOREST WITH INSTANCE WEIGHTING & MR PROSTATE SEGMENTATION BY DEEP LEARNING WITH HOLISTICALLY-NESTED NETWORKS EP Hong Kong HK40013587B 62020003241.0 Issued Hong Kong <br />European patent (EP) 62020003241.0<br />Filed on 2018-02-22<br />Status: Issued 147166800 E-183-2016-0 E-183-2016-0-EP-11 DETECTION OF PROSTATE CANCER IN MULTI-PARAMETRIC MRI USING RANDOM FOREST WITH INSTANCE WEIGHTING & MR PROSTATE SEGMENTATION BY DEEP LEARNING WITH HOLISTICALLY-NESTED NETWORKS DIV European Patent 21189335.9 Pending European Patent <br />Divisional (DIV) 21189335.9<br />Filed on 2021-08-03<br />Status: Pending 147166801 E-183-2016-0 E-183-2016-0-DE-12 DETECTION OF PROSTATE CANCER IN MULTI-PARAMETRIC MRI USING RANDOM FOREST WITH INSTANCE WEIGHTING & MR PROSTATE SEGMENTATION BY DEEP LEARNING WITH HOLISTICALLY-NESTED NETWORKS EP Germany 3586305 18710950.9 Issued Germany <br />European patent (EP) 18710950.9<br />Filed on 2018-02-22<br />Status: Issued 147166802 E-183-2016-0 E-183-2016-0-DK-13 DETECTION OF PROSTATE CANCER IN MULTI-PARAMETRIC MRI USING RANDOM FOREST WITH INSTANCE WEIGHTING & MR PROSTATE SEGMENTATION BY DEEP LEARNING WITH HOLISTICALLY-NESTED NETWORKS EP Denmark 3586305 18710950.9 Issued Denmark <br />European patent (EP) 18710950.9<br />Filed on 2018-02-22<br />Status: Issued 147166803 E-183-2016-0 E-183-2016-0-FR-14 DETECTION OF PROSTATE CANCER IN MULTI-PARAMETRIC MRI USING RANDOM FOREST WITH INSTANCE WEIGHTING & MR PROSTATE SEGMENTATION BY DEEP LEARNING WITH HOLISTICALLY-NESTED NETWORKS EP France 3586305 18710950.9 Issued France <br />European patent (EP) 18710950.9<br />Filed on 2018-02-22<br />Status: Issued 147166804 E-183-2016-0 E-183-2016-0-IE-15 DETECTION OF PROSTATE CANCER IN MULTI-PARAMETRIC MRI USING RANDOM FOREST WITH INSTANCE WEIGHTING & MR PROSTATE SEGMENTATION BY DEEP LEARNING WITH HOLISTICALLY-NESTED NETWORKS EP Ireland 3586305 18710950.9 Issued Ireland <br />European patent (EP) 18710950.9<br />Filed on 2018-02-22<br />Status: Issued 147166805 E-183-2016-0 E-183-2016-0-NL-16 DETECTION OF PROSTATE CANCER IN MULTI-PARAMETRIC MRI USING RANDOM FOREST WITH INSTANCE WEIGHTING & MR PROSTATE SEGMENTATION BY DEEP LEARNING WITH HOLISTICALLY-NESTED NETWORKS EP The Netherlands 3586305 18710950.9 Issued The Netherlands <br />European patent (EP) 18710950.9<br />Filed on 2018-02-22<br />Status: Issued 147166806 E-183-2016-0 E-183-2016-0-GB-17 DETECTION OF PROSTATE CANCER IN MULTI-PARAMETRIC MRI USING RANDOM FOREST WITH INSTANCE WEIGHTING & MR PROSTATE SEGMENTATION BY DEEP LEARNING WITH HOLISTICALLY-NESTED NETWORKS EP United Kingdom 3586305 18710950.9 Issued United Kingdom <br />European patent (EP) 18710950.9<br />Filed on 2018-02-22<br />Status: Issued 147166807 E-183-2016-0 E-183-2016-0-HK-18 DETECTION OF PROSTATE CANCER IN MULTI-PARAMETRIC MRI USING RANDOM FOREST WITH INSTANCE WEIGHTING & MR PROSTATE SEGMENTATION BY DEEP LEARNING WITH HOLISTICALLY-NESTED NETWORKS EP Hong Kong 42022055182.4 Pending Hong Kong <br />European patent (EP) 42022055182.4<br />Filed on 2022-06-15<br />Status: Pending 147173223 Computer-aided Diagnostic 147173225 Image Analysis System/Software 147173226 National Institutes of Health Clinical Center 147173227 NIHCC TAB-3953 147157233 Method and System of Building Hospital-Scale Medical Image Database CC Licensing, Software / Apps Licensing Software / Apps Le Lu, Zhiyong Lu, Yifan Peng, Ronald Summers, Xiaosong Wang <p>Developing computer systems that can recognize and locate image features associated with disease is a challenge for developing fully-automated and high precision computer assisted diagnostics. Joint learning of language tasks in association with vision tasks (association of image features with text annotation) adds an additional level of challenge.  Furthermore, scaling-up approaches from small to large datasets presents additional issues, particularly related to medical images. In this case, identifying such features requires specialized skill for even a human and the text descriptions from trained physicians may be variable, complex, and abstract.  The application of deep learning to medical image feature detection in association with language recognition may aid in the development of precision automated computer-aided diagnostics for a wide range of disease conditions, based on large scale PACS datasets.  </p> <p> </p> <p>The technology developed by researchers at the National Institutes of Health Clinical Center (NIHCC), applies natural language processing techniques and deep learning methods to mine PACS images and generate large-scale image databases. Diseases can be detected and spatially-located within the dataset generated by this method. The generation of such datasets is an important step toward utilizing PACS informatics and development of fully-automated high precision computer diagnostic systems.</p> <h2>Competitive Advantages:</h2> <ul><li>Ability to create large-scale labeled medical image database</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Computer Assisted Diagnostics</li> <li>Medical Image Informatics</li> </ul> 2017-06-22 2025-08-06 2018-04-04 2025-08-06 2017-06-22 Computer Assisted Diagnostics, Computer Vision, Deep Learning, Medical Imaging Informatics, National Institutes of Health Clinical Center, NIHCC, PACS, Picture Archiving and Communication Systems False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2018-04-04 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147162186 Wang X et al. ChestX-ray8: Hospital-scale Chest X-ray Database and Benchmarks on Weakly-Supervised Classification and Localization of Common Thorax Diseases https://arxiv.org/abs/1705.02315 <a href="https://arxiv.org/abs/1705.02315">Wang X et al. ChestX-ray8: Hospital-scale Chest X-ray Database and Benchmarks on Weakly-Supervised Classification and Localization of Common Thorax Diseases</a> 147163001 Wang, Xiaosong NIH - CC Wang, Xiaosong 1 147163002 Peng, Yifan NLM NLM Peng, Yifan (NLM) 2 147163000 Lu, Le NIH - CC CC Lu, Le (CC) 3 147163003 Lu, Zhiyong NIH - NLM NLM Lu, Zhiyong (NLM) 4 147162999 Summers, Ronald NIH - CC CC Summers, Ronald (CC) 5 147163001 Wang, Xiaosong NIH - CC Wang, Xiaosong 1 147163002 Peng, Yifan NLM NLM Peng, Yifan (NLM) 2 147163000 Lu, Le NIH - CC CC Lu, Le (CC) 3 147163003 Lu, Zhiyong NIH - NLM NLM Lu, Zhiyong (NLM) 4 147162999 Summers, Ronald NIH - CC CC Summers, Ronald (CC) 5 147157932 Method And System Of Building Hospital-scale Chest X-ray Database For Entity Extraction And Weakly-Supervised Classification And Localization Of Common Thorax Diseases E-076-2017-0 Filing authorized Clinical Center (CC), NLM 91828331 Beka, Lidia lidia.beka@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America lidia.beka@nih.gov?subject=Web Inquiry on [TAB-3953] Method and System of Building Hospital-Scale Medical Image Database&body=Please send me information about technology [TAB-3953] Method and System of Building Hospital-Scale Medical Image Database.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Beka, Lidia<br><a href="mailto:lidia.beka@nih.gov?subject=Web Inquiry on [TAB-3953] Method and System of Building Hospital-Scale Medical Image Database&body=Please send me information about technology [TAB-3953] Method and System of Building Hospital-Scale Medical Image Database.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">lidia.beka@nih.gov</a><br> 147161003 E-076-2017-0 E-076-2017-0-US-01 Method And System Of Building Hospital-scale Chest X-ray Database For Entity Extraction And Weakly-Supervised Classification And Localization Of Common Thorax Diseases PRV US 62/476,029 Abandoned US <br />Provisional (PRV) 62/476,029<br />Filed on 2017-03-24<br />Status: Abandoned 147165524 E-076-2017-0 E-076-2017-0-PCT-02 METHOD AND SYSTEM OF BUILDING HOSPITAL-SCALE CHEST X-RAY DATABASE FOR ENTITY EXTRACTION AND WEAKLY-SUPERVISED CLASSIFICATION AND LOCALIZATION OF COMMON THORAX DISEASES PCT Patent Cooperation Treaty PCT/US2018/024354 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2018/024354<br />Filed on 2018-03-26<br />Status: Expired 147165525 E-076-2017-0 E-076-2017-0-US-03 METHOD AND SYSTEM OF BUILDING HOSPITAL-SCALE CHEST X-RAY DATABASE FOR ENTITY EXTRACTION AND WEAKLY-SUPERVISED CLASSIFICATION AND LOCALIZATION OF COMMON THORAX DISEASES National Stage US 11,583,239 16/495,012 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11583239 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11583239">11,583,239</a><br />Filed on 2019-09-17<br />Status: Issued 147170844 Computer Assisted Diagnostics 147170845 Computer Vision 147170846 Deep Learning 147170847 Medical Imaging Informatics 147170848 National Institutes of Health Clinical Center 147170849 NIHCC 147170851 PACS 147170853 Picture Archiving and Communication Systems TAB-3946 147157226 Robotic Exoskeleton for Treatment of Crouch Gait in Children with Cerebral Palsy (CP) CC Collaboration, Licensing, Medical Devices, Non-Medical Devices Collaboration Licensing Medical Devices Non-Medical Devices Thomas Bulea, Diane Damiano, Andrew Gravunder, Zachary Lerner <p>Crouch gait is a common disorder in pediatric cerebral palsy (CP). Effective treatment of crouch during childhood is critical to maintain mobility into adulthood. Current interventions do not alleviate crouch gait long-term for most patients. This technology relates to a powered exoskeleton designed for gait assistance. The powered assistance may provide a physical therapy-type intervention to improve and maintain mobility.  </p> <p>Multiple factors contribute to crouch gait, including spasticity, contracture, muscle weakness and poor motor control. There are few effective interventions.  Current treatments for crouch gait include invasive surgery, botulinum toxin injections, physical therapy/ strengthening, and orthotic bracing. Improvements are inconsistent.  There is a need for new and effective interventions to preserve or augment mobility for pediatric crouch gait patients. </p> <p>This robotic exoskeleton is specifically designed for treatment of crouch gait in pediatric CP patients.  The wearable leg bracing system integrates robotics to provide on-demand motorized torque at the knee joint to facilitate knee extension. It contains on board sensors that track limb motion during walking and provide responsive knee extension assistance during distinct phases of the gait cycle. A customizable human-machine interface provides a personally tailored assistance strategy optimized for that individual.  The assistance improves posture to make walking easier while also providing movement training to help strengthen and maintain neuromuscular function. The design is based on the architecture of a knee-ankle-foot orthosis. It is lightweight and modular. The exoskeleton assistive therapy provides the advantages of being non-invasive, individually specific and adaptable to changing needs. Early clinical results using this intervention are promising.</p> <h2>Competitive Advantages:</h2> <ul><li>Individually tailored and customizable </li> <li>Lightweight and modular</li> <li>Adaptable to changing needs </li> <li>Noninvasive </li> </ul> <h2>Commercial Applications:</h2> <ul><li>Pediatric ambulatory therapy cerebral palsy</li> <li>Improved mobility when Crouch gait occurs as a common gait deviation – such as is seen among ambulatory diplegic and quadriplegic patients</li> <li>Enhanced success following surgery</li> </ul> 2018-04-25 2025-08-06 2018-04-25 2025-08-06 2018-04-25 cerebral palsy, Crouch gait, Exoskeleton, Lerner, National Institute of Health Clinical Center (NIHCC), NEURODEGENERATIVE, Northern Arizona University (NAU), pediatric, Robotic Exoskeleton False True Prototype True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2018-04-25 52406769 Prototype 52406769 NCI 37470483 Website Abstract 147162112 Zachary F. Lerner et al. https://www.ncbi.nlm.nih.gov/pubmed/28324959 <a href="https://www.ncbi.nlm.nih.gov/pubmed/28324959">Zachary F. Lerner et al.</a> 147162459 Zachary F. Lerner et al. https://www.ncbi.nlm.nih.gov/pubmed/27479974 <a href="https://www.ncbi.nlm.nih.gov/pubmed/27479974">Zachary F. Lerner et al.</a> 147162972 Bulea, Thomas NIH - CC CC Bulea, Thomas (CC) 1 147162974 Lerner, Zachary NIH - CC Lerner, Zachary 2 147162973 Damiano, Diane NIH - CC CC Damiano, Diane (CC) 3 147162971 Gravunder, Andrew NIH - CC Gravunder, Andrew 4 147162972 Bulea, Thomas NIH - CC CC Bulea, Thomas (CC) 1 147162974 Lerner, Zachary NIH - CC Lerner, Zachary 2 147162973 Damiano, Diane NIH - CC CC Damiano, Diane (CC) 3 147162971 Gravunder, Andrew NIH - CC Gravunder, Andrew 4 147157977 Pediatric Exoskeleton For Treatment Of Crouch Gait In Children With Cerebral Palsy E-096-2016-0 Filing authorized Clinical Center (CC) 91828331 Beka, Lidia lidia.beka@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America lidia.beka@nih.gov?subject=Web Inquiry on [TAB-3946] Robotic Exoskeleton for Treatment of Crouch Gait in Children with Cerebral Palsy (CP)&body=Please send me information about technology [TAB-3946] Robotic Exoskeleton for Treatment of Crouch Gait in Children with Cerebral Palsy (CP).&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Beka, Lidia<br><a href="mailto:lidia.beka@nih.gov?subject=Web Inquiry on [TAB-3946] Robotic Exoskeleton for Treatment of Crouch Gait in Children with Cerebral Palsy (CP)&body=Please send me information about technology [TAB-3946] Robotic Exoskeleton for Treatment of Crouch Gait in Children with Cerebral Palsy (CP).&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">lidia.beka@nih.gov</a><br> 147165479 E-096-2016-0 E-096-2016-0-US-01 Powered Gait Assistance Systems PRV US 62/368,926 Abandoned US <br />Provisional (PRV) 62/368,926<br />Filed on 2016-07-29<br />Status: Abandoned 147165480 E-096-2016-0 E-096-2016-0-PCT-02 POWERED GAIT ASSISTANCE SYSTEMS PCT Patent Cooperation Treaty PCT/US2017/044625 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2017/044625<br />Filed on 2017-07-31<br />Status: Expired 147165481 E-096-2016-0 E-096-2016-0-US-03 POWERED GAIT ASSISTANCE SYSTEMS National Stage US 11,801,153 16/321,565 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11801153 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11801153">11,801,153</a><br />Filed on 2019-01-29<br />Status: Issued 147171317 cerebral palsy 147171319 Crouch gait 147171320 Exoskeleton 147171322 Lerner 147171324 National Institute of Health Clinical Center (NIHCC) 147171325 NEURODEGENERATIVE 147171327 Northern Arizona University (NAU) 147171328 pediatric 147171330 Robotic Exoskeleton TAB-4193 147157478 Assay to Screen Anti-metastatic Drugs NCI Licensing, Oncology, Research Materials Licensing Oncology Research Materials Nadia Castro, Frank Cuttitta, David Salomon <p>Scientists at the NCI&nbsp;developed a research tool, a murine cell line model (JygMC(A)) with a reporter construct, of spontaneous metastatic mammary carcinoma that resembles the human breast cancer metastatic process in a triple negative mammary tumor. The assay is useful for screening compounds that specifically inhibit pathways involved in mammary carcinoma and can improve clinical management of of triple negative breast cancer that are greatly refractory to conventional chemo and radiotherapy. The key feature of the cell line is that when introduced orthotopically into the mammary gland of immunocompromised mice it produces murine mammary tumors that rapidly metastasize to distant sites, such as lungs, lymph nodes, liver and kidneys. This allows for precise tracking of tumor growth and metastasis.</p> <h2>Competitive Advantages:</h2> <ul> <li>Dual report construct: enhanced green fluorescent protein (eGFP) or a fusion of firefly luciferase and eGFP (ffLuc2-eFGP) and mouse Cripto-1 promoter sequence cloned into a vector for reporter assays and/or visualization of&nbsp; molecular mechanisms involved in tumorigenesis of metastatic breast cancer cells.</li> </ul> <h2>Commercial Applications:</h2> <ul> <li>Laboratory tool to investigate molecular mechanisms and/or signaling pathways involved in tumorigenesis, angiogenesis and&nbsp; metastasis of breast cancer and its response to therapy&nbsp; (in vivo and in vitro).</li> <li>Research tool for high through-put screening of libraries for compounds that specifically inhibit mechanisms and/or signaling pathways involved in metastatic triple negative breast cancer.</li> <li>Research tool to optimize therapeutic regimens.</li> </ul> 2016-02-16 2025-08-06 2018-06-07 2025-08-06 2016-07-25 ANGIOGENESIS, Cell line, Metastasis, Triple Negative Breast Cancer, tumorigenesis False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2018-06-07 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147162227 Nadia P. Castro &quot;Role of the Notch signaling in the metastasis of a murine breast cancer model.&quot; Abstract presented at the Mammary Gland Biology Gordon Research Conference, Lucca (Barga) Italy, June 10-15, 2012. Nadia P. Castro &quot;Role of the Notch signaling in the metastasis of a murine breast cancer model.&quot; Abstract presented at the Mammary Gland Biology Gordon Research Conference, Lucca (Barga) Italy, June 10-15, 2012. 147162304 Nadia P. Castro &quot;Notch pathway in an experimental model of breast cancer metastasis.&quot; Abstract presented at the Sixth AACR Special Conference on Advances in Breast Cancer Research, San Francisco, California, October 12-15, 2011. Nadia P. Castro &quot;Notch pathway in an experimental model of breast cancer metastasis.&quot; Abstract presented at the Sixth AACR Special Conference on Advances in Breast Cancer Research, San Francisco, California, October 12-15, 2011. 147163857 Castro, Nadia NIH - NCI Castro, Nadia 1 147163856 Salomon, David NIH - NCI NCI Salomon, David (NCI) 2 147163855 Cuttitta, Frank NIH - NCI NCI Cuttitta, Frank (NCI) 3 147163857 Castro, Nadia NIH - NCI Castro, Nadia 1 147163856 Salomon, David NIH - NCI NCI Salomon, David (NCI) 2 147163855 Cuttitta, Frank NIH - NCI NCI Cuttitta, Frank (NCI) 3 157797317 New Assay For Pre-clinical Studies To Screen Anti-metastatic Drugs E-088-2013-0 Research Material NCI 83732213 Dick, Taryn taryn.dick@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB taryn.dick@nih.gov?subject=Web Inquiry on [TAB-4193] Assay to Screen Anti-metastatic Drugs&body=Please send me information about technology [TAB-4193] Assay to Screen Anti-metastatic Drugs.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dick, Taryn<br><a href="mailto:taryn.dick@nih.gov?subject=Web Inquiry on [TAB-4193] Assay to Screen Anti-metastatic Drugs&body=Please send me information about technology [TAB-4193] Assay to Screen Anti-metastatic Drugs.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">taryn.dick@nih.gov</a><br> 147171139 ANGIOGENESIS 147171140 Cell line 147171141 Metastasis 147171142 Triple Negative Breast Cancer 147171143 tumorigenesis TAB-3939 147157219 Gene Therapy Vector for the Treatment of Glycogen Storage Disease Type Ia (GSD-Ia) NICHD Collaboration, Licensing, Nephrology, Therapeutics Collaboration Licensing Nephrology Therapeutics Janice Chou <p>GSD-Ia is an inherited disorder of metabolism associated with life-threatening hypoglycemia, hepatic malignancy, and renal failure caused by the deficiency of glucose-6-phosphatase-alpha (G6Pase-alpha or G6PC). Current therapy, which primarily consists of dietary modification, fails to prevent long-term complications in many patients, including growth failure, gout, pulmonary hypertension, renal dysfunction, osteoporosis, and hepatocellular adenomas (HCA). Gene therapy-based techniques, which directly address the underlying genetic deficiency driving the disorder, offer the prospect of long-term remission in patients with GSD-Ia.</p> <p>Researchers at the NIH <a href="https://www.nichd.nih.gov/Pages/index.aspx" rel="nofollow">National Insitute for Childhood Health and Diseases</a> have developed an adeno-associated viral (AAV) vector for the treatment of glycogen storage disease type Ia (GSD-Ia).This new AAV vector that expresses human G6Pase-alpha directed by the tissue-specific human <em>G6PC</em> promoter/enhancer incorporates two improvements: 1) it expresses a variant of G6Pase-alpha with enhanced enzymatic activity; 2) it is codon optimized to achieve higher enzyme expression levels and enhanced enzymatic activity.</p> <p><em>In vivo</em> data is available.</p> <h2>Competitive Advantages:</h2> <ul><li>Protein coding sequence modified for enhanced enzymatic activity.</li> <li>Codon optimized for increased enzyme expression in target organs.</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Gene therapy vector for the treatment of GSD-Ia</li> </ul> 2016-02-16 2025-08-06 2021-03-30 2025-08-06 2016-08-29 GSD-Ia, hepatic malignancy, hypoglycemia, renal failure False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-03-30 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-552-2013 147162025 Lee YM et al. https://www.ncbi.nlm.nih.gov/pubmed/22422504 <a href="https://www.ncbi.nlm.nih.gov/pubmed/22422504">Lee YM et al.</a> 147162181 Lee YM, et al. https://www.ncbi.nlm.nih.gov/pubmed/23856420 <a href="https://www.ncbi.nlm.nih.gov/pubmed/23856420">Lee YM, et al.</a> 147162938 Chou, Janice NIH - NICHD NICHD Chou, Janice (NICHD) 1 147162938 Chou, Janice NIH - NICHD NICHD Chou, Janice (NICHD) 1 147157841 Evaluation Of The Efficacy Of Human G6PC Constructs E-039-2015-0 Filing authorized NICHD 91788919 Gunas, Heather gunash@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America gunash@mail.nih.gov?subject=Web Inquiry on [TAB-3939] Gene Therapy Vector for the Treatment of Glycogen Storage Disease Type Ia (GSD-Ia)&body=Please send me information about technology [TAB-3939] Gene Therapy Vector for the Treatment of Glycogen Storage Disease Type Ia (GSD-Ia).&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Gunas, Heather<br><a href="mailto:gunash@mail.nih.gov?subject=Web Inquiry on [TAB-3939] Gene Therapy Vector for the Treatment of Glycogen Storage Disease Type Ia (GSD-Ia)&body=Please send me information about technology [TAB-3939] Gene Therapy Vector for the Treatment of Glycogen Storage Disease Type Ia (GSD-Ia).&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">gunash@mail.nih.gov</a><br> 147160942 E-039-2015-0 E-039-2015-0-US-01 Adeno-Associated Virus Vectors Encoding Modified G6PC For The Treatment of Glycogen Storage Disease PRV US 62/096,400 Abandoned US <br />Provisional (PRV) 62/096,400<br />Filed on 2014-12-23<br />Status: Abandoned 147165429 E-039-2015-0 E-039-2015-0-PCT-02 Adeno-Associated Virus Vectors Encoding Modified G6PC and Uses Thereof PCT Patent Cooperation Treaty PCT/US2015/067338 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2015/067338<br />Filed on 2015-12-22<br />Status: Expired 147165430 E-039-2015-0 E-039-2015-0-CA-03 Adeno-Associated Virus Vectors Encoding Modified G6PC and Uses Thereof National Stage Canada 2972038 2972038 Issued Canada <br />National Stage 2972038<br />Filed on 2015-12-22<br />Status: Issued 147165431 E-039-2015-0 E-039-2015-0-CN-04 Adeno-Associated Virus Vectors Encoding Modified G6PC and Uses Thereof National Stage China ZL201580076462.4 201580076462.4 Issued China <br />National Stage 201580076462.4<br />Filed on 2015-12-22<br />Status: Issued 147165432 E-039-2015-0 E-039-2015-0-EP-05 Adeno-Associated Virus Vectors Encoding Modified G6PC and Uses Thereof National Stage European Patent 3236984 15830932.8 Issued European Patent <br />National Stage 15830932.8<br />Filed on 2015-12-22<br />Status: Issued 147165433 E-039-2015-0 E-039-2015-0-IL-06 Adeno-Associated Virus Vectors Encoding Modified G6PC and Uses Thereof National Stage Israel 253103 253103 Issued Israel <br />National Stage 253103<br />Filed on 2017-06-22<br />Status: Issued 147165434 E-039-2015-0 E-039-2015-0-JP-07 Adeno-Associated Virus Vectors Encoding Modified G6PC and Uses Thereof National Stage Japan 6824169 2017-533845 Issued Japan <br />National Stage 2017-533845<br />Filed on 2017-06-22<br />Status: Issued 147165435 E-039-2015-0 E-039-2015-0-US-08 ADENO-ASSOCIATED VIRUS VECTORS ENCODING MODIFIED G6PC AND USES THEREOF National Stage US 10,415,044 15/538,852 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10415044 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10415044">10,415,044</a><br />Filed on 2017-06-22<br />Status: Issued 147165436 E-039-2015-0 E-039-2015-0-US-09 ADENO-ASSOCIATED VIRUS VECTORS ENCODING MODIFIED G6PC AND USES THEREOF DIV US 11,535,870 16/526,327 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11535870 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11535870">11,535,870</a><br />Filed on 2019-07-30<br />Status: Issued 147165437 E-039-2015-0 E-039-2015-0-JP-10 Adeno-Associated Virus Vectors Encoding Modified G6PC and Uses Thereof DIV Japan 2019-220144 Abandoned Japan <br />Divisional (DIV) 2019-220144<br />Filed on 2015-12-22<br />Status: Abandoned 147165438 E-039-2015-0 E-039-2015-0-BE-11 Adeno-Associated Virus Vectors Encoding Modified G6PC and Uses Thereof EP Belgium 3236984 15830932.8 Issued Belgium <br />European patent (EP) 15830932.8<br />Filed on 2015-12-22<br />Status: Issued 147165439 E-039-2015-0 E-039-2015-0-CH-12 Adeno-Associated Virus Vectors Encoding Modified G6PC and Uses Thereof EP Switzerland 3236984 15830932.8 Issued Switzerland <br />European patent (EP) 15830932.8<br />Filed on 2015-12-22<br />Status: Issued 147165440 E-039-2015-0 E-039-2015-0-DE-13 Adeno-Associated Virus Vectors Encoding Modified G6PC and Uses Thereof EP Germany 3236984 15830932.8 Issued Germany <br />European patent (EP) 15830932.8<br />Filed on 2015-12-22<br />Status: Issued 147165441 E-039-2015-0 E-039-2015-0-ES-14 Adeno-Associated Virus Vectors Encoding Modified G6PC and Uses Thereof EP Spain 3236984 15830932.8 Issued Spain <br />European patent (EP) 15830932.8<br />Filed on 2015-12-22<br />Status: Issued 147165442 E-039-2015-0 E-039-2015-0-FR-15 Adeno-Associated Virus Vectors Encoding Modified G6PC and Uses Thereof EP France 3236984 15830932.8 Issued France <br />European patent (EP) 15830932.8<br />Filed on 2015-12-22<br />Status: Issued 147165443 E-039-2015-0 E-039-2015-0-GB-16 Adeno-Associated Virus Vectors Encoding Modified G6PC and Uses Thereof EP United Kingdom 3236984 15830932.8 Issued United Kingdom <br />European patent (EP) 15830932.8<br />Filed on 2015-12-22<br />Status: Issued 147165444 E-039-2015-0 E-039-2015-0-IT-17 Adeno-Associated Virus Vectors Encoding Modified G6PC and Uses Thereof EP Italy 3236984 15830932.8 Issued Italy <br />European patent (EP) 15830932.8<br />Filed on 2015-12-22<br />Status: Issued 147165445 E-039-2015-0 E-039-2015-0-NL-18 Adeno-Associated Virus Vectors Encoding Modified G6PC and Uses Thereof EP The Netherlands 3236984 15830932.8 Issued The Netherlands <br />European patent (EP) 15830932.8<br />Filed on 2015-12-22<br />Status: Issued 147165446 E-039-2015-0 E-039-2015-0-SE-19 Adeno-Associated Virus Vectors Encoding Modified G6PC and Uses Thereof EP Sweden 3236984 15830932.8 Issued Sweden <br />European patent (EP) 15830932.8<br />Filed on 2015-12-22<br />Status: Issued 147165447 E-039-2015-0 E-039-2015-0-US-20 ADENO-ASSOCIATED VIRUS VECTORS ENCODING MODIFIED G6PC AND USES THEREOF CON US 12,440,580 18/058,457 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12440580 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12440580">12,440,580</a><br />Filed on 2022-11-23<br />Status: Issued 147170006 GSD-Ia 147170008 hepatic malignancy 147170010 hypoglycemia 147170012 renal failure TAB-4467 150047125 A3 Adenosine Receptor Positive Allosteric Modulators NIDDK Collaboration, Licensing, Therapeutics Collaboration Licensing Therapeutics John Auchampach, Lucas Fallot, Kenneth Jacobson, Balaram Pradhan, Rama Ravi, Courtney Zink <p>Selective A3AR agonists are sought as potential agents for treating inflammatory diseases,<br /> chronic pain, cancer and non-alcoholic steatohepatitis (NASH). NIDDK investigators have invented&nbsp;<br /> new chemical composition as positive allosteric modulators (PAMs) of the A3AR. These chemical&nbsp;<br /> compounds contain sterically constrained, bridged modifications and cycloalkyl rings of various&nbsp;<br /> sizes, as well as modifications of the 4-arylamino group. The compounds have added&nbsp;<br /> three-dimensionality to otherwise flat molecules, which helps distinguish their positive (desired)&nbsp;<br /> and negative (undesired) pharmacological effects on the action of A3AR agonists. Unlike agonists&nbsp;<br /> that have side effects, PAM action can be event- and site-specific because adenosine is&nbsp;<br /> endogenously elevated in response to localized distress<br /> signals within the body.<br /> &nbsp;</p> The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize A3 Adenosine Receptor Positive Allosteric Modulators. For collaboration opportunities, please contact: Dr. Kenneth A. Jacobson at <a href="mailto:kennethj@niddk.nih.gov">kennethj@niddk.nih.gov</a> 2023-09-22 2025-08-01 2025-08-04 2025-08-01 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 150047697 Pradhan, B., Pavan, M., Fisher, C.L., Salmaso, V., Wan, T.C., Keyes, R.F., Rollison, N., Suresh, R.R., Kumar, T.S., Gao, Z.G., Smith, B.C., Auchampach, J.A., Jacobson, K.A. Lipid trolling to optimize A3 adenosine receptor-positive allosteric modulators (PAMs). J. Med. Chem., 2024, 67(14):12221–12247 . https://pubs.acs.org/doi/10.1021/acs.jmedchem.4c00944 <a href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.4c00944">Pradhan, B., Pavan, M., Fisher, C.L., Salmaso, V., Wan, T.C., Keyes, R.F., Rollison, N., Suresh, R.R., Kumar, T.S., Gao, Z.G., Smith, B.C., Auchampach, J.A., Jacobson, K.A. Lipid trolling to optimize A3 adenosine receptor-positive allosteric modulators (PAMs). J. Med. Chem., 2024, 67(14):12221–12247 .</a> 150115501 Fallot, L.B., Suresh, R.R., Fisher, C.L., Salmaso, V., O’Connor, R.D., Kaufman, N., Gao, Z.G., Auchampach, J.A., Jacobson, K.A. Structure activity studies of 1H-imidazo[4,5-c]quinolin-4-amine derivatives as A3 adenosine receptor positive allosteric modulators. J. Med. Chem., 2022, 65(22):15238–15262 https://doi.org/10.1021/acs.jmedchem.2c01170 <a href="https://doi.org/10.1021/acs.jmedchem.2c01170">Fallot, L.B., Suresh, R.R., Fisher, C.L., Salmaso, V., O’Connor, R.D., Kaufman, N., Gao, Z.G., Auchampach, J.A., Jacobson, K.A. Structure activity studies of 1H-imidazo[4,5-c]quinolin-4-amine derivatives as A3 adenosine receptor positive allosteric modulators. J. Med. Chem., 2022, 65(22):15238–15262</a> 150047192 Jacobson, Kenneth National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Jacobson, Kenneth (NIDDK) 1 150047336 Fallot, Lucas National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Fallot, Lucas (NIDDK) 2 150047407 Ravi, Rama National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Ravi, Rama (NIDDK) 3 150047566 Pradhan, Balaram National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Pradhan, Balaram 4 150047650 Auchampach, John Medical College of Wisconsin Auchampach, John 5 150047676 Zink, Courtney Medical College of Wisconsin Zink, Courtney 6 150047192 Jacobson, Kenneth National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Jacobson, Kenneth (NIDDK) 1 150047336 Fallot, Lucas National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Fallot, Lucas (NIDDK) 2 150047407 Ravi, Rama National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Ravi, Rama (NIDDK) 3 150047566 Pradhan, Balaram National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Pradhan, Balaram 4 150047650 Auchampach, John Medical College of Wisconsin Auchampach, John 5 150047676 Zink, Courtney Medical College of Wisconsin Zink, Courtney 6 150047139 A3 Adenosine Receptor Positive Allosteric Modulators E-067-2022-1 Filing authorized Medical College of Wisconsin, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH - NIDDK 83692066 Tong, Betty tongb@niddk.nih.gov
United States of America Senior Technology Advancement Office tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-4467] A3 Adenosine Receptor Positive Allosteric Modulators&body=Please send me information about technology [TAB-4467] A3 Adenosine Receptor Positive Allosteric Modulators. Tong, Betty<br><a href="mailto:tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-4467] A3 Adenosine Receptor Positive Allosteric Modulators&body=Please send me information about technology [TAB-4467] A3 Adenosine Receptor Positive Allosteric Modulators.">tongb@niddk.nih.gov</a><br> 150047884 E-067-2022-1 E-067-2022-1-PCT-02 A3 ADENOSINE RECEPTOR POSITIVE ALLOSTERIC MODULATORS PCT Patent Cooperation Treaty PCT/US2023/016769 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2023/016769<br />Filed on 2023-03-29<br />Status: Expired 157121968 E-067-2022-1 E-067-2022-1-US-01 A3 ADENOSINE RECEPTOR POSITIVE ALLOSTERIC MODULATORS National Stage US 18/850,144 Pending US <br />National Stage 18/850,144<br />Filed on 2024-09-24<br />Status: Pending 157122070 E-067-2022-1 E-067-2022-1-EP-01 A3 ADENOSINE RECEPTOR POSITIVE ALLOSTERIC MODULATORS National Stage European Patent 23718513.7 Pending European Patent <br />National Stage 23718513.7<br />Filed on 2024-10-11<br />Status: Pending TAB-3832 144081324 Peanut therapeutics and diagnostics to treat severe food allergies NIEHS Diagnostics, Immunology, Pulmonology, Therapeutics Diagnostics Immunology Pulmonology Therapeutics Jungki Min, Geoffrey Mueller, Sarita Patil, Lars Pedersen <p>Up to 10% of the US population suffers from food allergies, with more than 40% of those experiencing life-threatening anaphylaxis. Peanut is one of the most common food allergens that give rise to persistent IgE-mediated food allergy. Oral immunotherapy (OIT) is used to reduce sensitivity to an allergen through repeated, small-dose exposure to the allergen. However, only a subset of patients develop a sustained response to the allergen and OIT carries notable side effects.&nbsp;</p> <p>Researchers were able to determine how human antibodies interact with peanut allergens. They identified three immunodominant epitopes on the major peanut allergen, Ara h 2, that led to sustained tolerance to the allergen. Select amino acid residues on Ara h 2 were mutated to abrogate binding to patient antibodies. These mutant Ara h 2 proteins could be used to determine if patients possess these key antibodies and to track patient progress towards sustained tolerance.</p> <p>The same Ara h 2 mutations that knock out individual antibody binding could be combined into a so-called hypoallergen which demonstrated a reduced ability to inhibit IgE from sera binding in allergic patients. Using a mouse model for passive cutaneous anaphylaxis, the researchers saw a reduction in anaphylactic response using the Ara h 2 hypoallergen when the mouse was primed with pooled human allergic sera. This indicates that the hypoallergenic Ara h 2 mutant could be used as a safer therapy to reduce the risk of adverse events including anaphylactic responses to peanuts.&nbsp; Using the diagnostics proposed above, the hypoallergen could be customized for individual patients to tailor the risk of anaphylaxis and therapeutic effectiveness.</p> <ul> <li>Elicits allergy protection with reduced side effects typical for oral immunotherapy</li> <li>Potential to combine multiple allergens in one treatment</li> <li>Can diagnose a sustained response to an allergen</li> <li>Treatment may be personalized to address unique patient allergenic epitopes</li> </ul> <ul> <li>Diagnostics for therapeutic progress</li> <li>A therapeutic strategy to desensitize allergenic patients</li> </ul> 2023-02-23 2025-01-22 2025-07-28 2023-02-24 False False True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 144205419 Mueller, Geoffrey NIEHS NIEHS Mueller, Geoffrey (NIEHS) 1 144207242 Pedersen, Lars NIEHS NIEHS Pedersen, Lars (NIEHS) 2 144207297 Min, Jungki NIEHS Min, Jungki 3 144207301 Patil, Sarita Massachusetts General Hospital Patil, Sarita 4 144205419 Mueller, Geoffrey NIEHS NIEHS Mueller, Geoffrey (NIEHS) 1 144207242 Pedersen, Lars NIEHS NIEHS Pedersen, Lars (NIEHS) 2 144207297 Min, Jungki NIEHS Min, Jungki 3 144207301 Patil, Sarita Massachusetts General Hospital Patil, Sarita 4 144081599 Hypoallergenic Ara H 2 E-022-2023-0 Filing authorized Massachusetts General Hospital, NIEHS 83739538 Choudhry, Vidita vidita.choudhry@nih.gov
United States of America Office of Technology Transfer and Development vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-3832] Peanut therapeutics and diagnostics to treat severe food allergies&body=Please send me information about technology [TAB-3832] Peanut therapeutics and diagnostics to treat severe food allergies. Choudhry, Vidita<br><a href="mailto:vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-3832] Peanut therapeutics and diagnostics to treat severe food allergies&body=Please send me information about technology [TAB-3832] Peanut therapeutics and diagnostics to treat severe food allergies.">vidita.choudhry@nih.gov</a><br> 144081604 E-022-2023-0 E-022-2023-0-US-01 MUTANT ARA H 2 AND ARA H 6 PROTEINS AND USES THEREOF PRV US 63/486,570 Expired US <br />Provisional (PRV) 63/486,570<br />Filed on 2023-02-23<br />Status: Expired 151623403 E-022-2023-0 E-022-2023-0-PC-01 MUTANT ARA H 2 AND ARA H 6 PROTEINS AND USES THEREOF PCT Patent Cooperation Treaty PCT/US2024/017072 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2024/017072<br />Filed on 2024-02-23<br />Status: Expired 163493125 E-022-2023-0 E-022-2023-0-AU-01 MUTANT ARA H 2 AND ARA H 6 PROTEINS AND USES THEREOF National Stage Australia 2024224738 Pending Australia <br />National Stage 2024224738<br />Filed on 2025-09-04<br />Status: Pending 163493167 E-022-2023-0 E-022-2023-0-US-02 MUTANT ARA H 2 AND ARA H 6 PROTEINS AND USES THEREOF National Stage US 19/159,114 Pending US <br />National Stage 19/159,114<br />Filed on 2025-08-22<br />Status: Pending 163493207 E-022-2023-0 E-022-2023-0-EP-01 MUTANT ARA H 2 AND ARA H 6 PROTEINS AND USES THEREOF National Stage European Patent 24716910.5 Pending European Patent <br />National Stage 24716910.5<br />Filed on 2025-08-27<br />Status: Pending TAB-4270 147157558 A Novel Transgenic Zebrafish Line Reporting Dynamic Epigenetic Changes NICHD Licensing, Oncology, Research Materials Licensing Oncology Research Materials Aniket Gore, Brant Weinstein <p>Currently, there is no other whole-animal reporter for epigenetic regulation established in any vertebrate. </p> <p>The inventors generated this novel zebrafish line using a transgene construct containing dazl gene silencing sequences (CpG island) fused to a destabilized GFPd2 gene driven by the ubiquitously expressing ef1alpha promoter. The resulting transgenic line permits detailed tissue- or cellular- level visualization of dynamic changes in GFPd2 expression in response to changes in DNA methylation or downstream epigenetic regulation in developing or adult animals. GFPd2 is “off” in the fertilized egg but turns on during early development, peaking at approximately 24 hours post-fertilization, and is then rapidly and ubiquitously silenced. The reporter is “off’ in adults, except in particular stages of germline development in the gonads.  Experimental treatments or genetic mutants that interfere with epigenetic silencing result in global or tissue-specific “reactivation” of GFPd2 expression. The reporter is also reactivated in regenerating tissues.</p> <p>The “EpiTag” zebrafish transgenic line accurately reports changes in epigenetic silencing due to altered epigenetic regulation. The line can provide a whole-animal platform for identifying and studying tissue- or even cellular- level function of genes involved in mediating epigenetic regulation, for carrying out screens for potential therapeutics targeting epigenetic regulatory mechanisms, or for studying the epigenetic effects of environmental toxins. This new model represents the first vertebrate reporter for studying epigenetic regulation in an intact, living animal, and potentially has wide applications in academic research as well as in drug development. </p> <h2>Competitive Advantages:</h2> <ul><li>This new model represents the first vertebrate reporter for studying epigenetic regulation in an intact, living animal, and potentially has wide applications in academic research as well as in drug development</li> <li>This line incorporates the benefits of using zebrafish as a model organism in research or drug development, including high-throughput chemical or genetic screening with an intact animal model</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Use of the transgenic zebrafish line: <ul><li>Examine tissue-specific gene silencing during normal or abnormal development </li> <li>Use of ENU (N-ethyl-N-nitrosourea) mutagenesis screens to identify global- or tissue-specific epigenetic regulators </li> <li>Study the tissue- and cellular-level functions of identified epigenetic regulatory genes and proteins</li> <li>Screen for therapeutic compounds that potentially modulate epigenetic regulation in certain clinical applications</li> <li>Screen for environmental toxins that potentially affect epigenetic regulation</li> <li>Visualize and study regenerating tissues and changes in epigenetic regulation that accompany regeneration</li> </ul></li> </ul> 2019-09-18 2025-04-22 2020-09-16 2025-07-14 2019-09-18 Development, DNA Methylation, Epigenetic Silencing, Eunice Kennedy Shriver National Institute of Child Health an, GFPd2, NICHD, Tissue-specific Expression, Weinstein, Zebrafish False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-09-16 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147164117 Gore, Aniket NIH - NICHD NICHD Gore, Aniket (NICHD) 1 147164116 Weinstein, Brant NIH - NICHD NICHD Weinstein, Brant (NICHD) 2 147164117 Gore, Aniket NIH - NICHD NICHD Gore, Aniket (NICHD) 1 147164116 Weinstein, Brant NIH - NICHD NICHD Weinstein, Brant (NICHD) 2 147158031 A Novel Transgenic Zebrafish Line Reporting Dynamic Epigenetic Changes E-124-2019-0 Research Material NICHD 91788919 Gunas, Heather gunash@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America gunash@mail.nih.gov?subject=Web Inquiry on [TAB-4270] A Novel Transgenic Zebrafish Line Reporting Dynamic Epigenetic Changes&body=Please send me information about technology [TAB-4270] A Novel Transgenic Zebrafish Line Reporting Dynamic Epigenetic Changes.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Gunas, Heather<br><a href="mailto:gunash@mail.nih.gov?subject=Web Inquiry on [TAB-4270] A Novel Transgenic Zebrafish Line Reporting Dynamic Epigenetic Changes&body=Please send me information about technology [TAB-4270] A Novel Transgenic Zebrafish Line Reporting Dynamic Epigenetic Changes.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">gunash@mail.nih.gov</a><br> 147171890 Development 147171891 DNA Methylation 147171893 Epigenetic Silencing 147171894 Eunice Kennedy Shriver National Institute of Child Health an 147171896 GFPd2 147171897 NICHD 147171899 Tissue-specific Expression 147171901 Weinstein 147171902 Zebrafish TAB-5064 163201196 Anti-Nucleoprotein Crimean-Congo Hemorrhagic Fever Virus Monoclonal Antibodies for Assay Creation NIAID Antibodies, Application, Collaboration Sought, Diagnostics, Immunology, Infectious Disease, Licensing, Materials Available, Rare/Neglected Diseases, TherapeuticArea Antibodies Application Collaboration Sought Diagnostics Immunology Infectious Disease Licensing Materials Available Rare/Neglected Diseases TherapeuticArea Daniel Douek, David Hawman, Amy Henry, Noemia Santana Lima, Chaim Schramm, Leonid Serebryannyy, Sarah Smith (Kerscher), Alicen Spaulding <p>Crimean-Congo hemorrhagic fever (CCHF) is the most widespread form of viral hemorrhagic fever, found in Eastern and Southern Europe, the Mediterranean, northwestern China, central Asia, Africa, the Middle East, and the Indian subcontinent. Typically beginning with non-specific fever, myalgia, nausea, diarrhea, and general malaise, symptoms of infection with the tick-borne CCHF virus (CCHFV) can rapidly progress to hemorrhagic manifestations, with case fatality rates as high as 30-40% in some regions. Critically, there are no approved vaccines for CCHF, and prevention is limited to control of exposure to infected ticks and livestock.</p> <p>Researchers at the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Disease (NIAID) have recently demonstrated robust immunogenicity and significant protection in a Rhesus macaque model of CCHF following vaccination with a novel repRNA vaccine. Single memory B cells from peripheral blood mononuclear cells (PBMCs) were isolated from the vaccinated macaques to derive monoclonal antibodies that target the nucleocapsid protein (NP) of CCHFV, which plays a critical role in the replication and pathogenesis of the virus. This technology comprises mAbs with strong potential for the development of diagnostic tools, <em>in vitro </em>assays, research reagents, and other analytical methods for CCHFV NP recognition.</p> <p>This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR part 404.</p> <ul> <li>There are no readily available antibodies that bind to the NP protein of CCHFV.</li> </ul> <ul> <li>Development of diagnostic assays for rapid, accurate CCHFV detection in clinical and non-clinical settings.</li> </ul> 2025-07-03 2025-07-03 2025-07-03 2025-07-04 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 163201503 Hawman DW, et al. A replicating RNA vaccine confers protection in a rhesus macaque model of Crimean-Congo hemorrhagic fever. NPJ Vaccines 2024;9:86. https://doi.org/​10.1038/​s41541-024-00887-z. Hawman DW, et al. A replicating RNA vaccine confers protection in a rhesus macaque model of Crimean-Congo hemorrhagic fever. NPJ Vaccines 2024;9:86. https://doi.org/​10.1038/​s41541-024-00887-z. 163201272 Douek, Daniel National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Douek, Daniel (NIAID) 1 163201279 Hawman, David NIAID - DIR NIAID Hawman, David (NIAID) 2 163201296 Serebryannyy, Leonid National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Serebryannyy, Leonid (NIAID) 3 163201300 Santana Lima, Noemia NIAID - VRC Santana Lima, Noemia 4 163201353 Schramm, Chaim National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Schramm, Chaim (NIAID) 5 163201420 Smith (Kerscher), Sarah NIAID - VRC NIAID Smith (Kerscher), Sarah (NIAID) 6 163201432 Henry, Amy NIAID - DIR NIAID Henry, Amy (NIAID) 7 163201436 Spaulding, Alicen National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Spaulding, Alicen (NIAID) 8 163201272 Douek, Daniel National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Douek, Daniel (NIAID) 1 163201279 Hawman, David NIAID - DIR NIAID Hawman, David (NIAID) 2 163201296 Serebryannyy, Leonid National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Serebryannyy, Leonid (NIAID) 3 163201300 Santana Lima, Noemia NIAID - VRC Santana Lima, Noemia 4 163201353 Schramm, Chaim National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Schramm, Chaim (NIAID) 5 163201420 Smith (Kerscher), Sarah NIAID - VRC NIAID Smith (Kerscher), Sarah (NIAID) 6 163201432 Henry, Amy NIAID - DIR NIAID Henry, Amy (NIAID) 7 163201436 Spaulding, Alicen National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Spaulding, Alicen (NIAID) 8 163201199 Anti-Nucleoprotein Crimean-Congo hemorrhagic fever virus monoclonal antibodies for assay creation E-129-2025-0 Research Material National Institute of Allergy and Infectious Diseases (NIAID/NIH), NIAID - DIR, NIAID - VRC, NIH - NIAID 83682222 Bailey, Brian bbailey@mail.nih.gov
United States of America TTIPO bbailey@mail.nih.gov?subject=Web Inquiry on [TAB-5064] Anti-Nucleoprotein Crimean-Congo Hemorrhagic Fever Virus Monoclonal Antibodies for Assay Creation&body=Please send me information about technology [TAB-5064] Anti-Nucleoprotein Crimean-Congo Hemorrhagic Fever Virus Monoclonal Antibodies for Assay Creation. Bailey, Brian<br><a href="mailto:bbailey@mail.nih.gov?subject=Web Inquiry on [TAB-5064] Anti-Nucleoprotein Crimean-Congo Hemorrhagic Fever Virus Monoclonal Antibodies for Assay Creation&body=Please send me information about technology [TAB-5064] Anti-Nucleoprotein Crimean-Congo Hemorrhagic Fever Virus Monoclonal Antibodies for Assay Creation.">bbailey@mail.nih.gov</a><br> TAB-5062 163184481 EV-D68 Monoclonal Antibodies Isolated from Immunized Rhesus Macaques NIAID Antibodies, Application, Collaboration Sought, Diagnostics, Immunology, Infectious Disease, Licensing, Materials Available, ResearchProducts, TherapeuticArea, Therapeutics, Vaccines Antibodies Application Collaboration Sought Diagnostics Immunology Infectious Disease Licensing Materials Available ResearchProducts TherapeuticArea Therapeutics Vaccines Masaru Kanekiyo, Peter Krug, Daniel Moss, Tracy Ruckwardt <p>Enterovirus D68 (EV-D68) has been linked to the widespread outbreaks of respiratory illness and acute flaccid myelitis (AFM) in the United States and Europe in 2014, 2016, and 2018. Although EV-D68 is now the most frequently encountered enterovirus (41.1% of cases), with an estimated global prevalence of 4%, there are no specific, FDA-approved therapeutic interventions targeting this virus.</p> <p>Researchers at the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Disease (NIAID) have identified four monoclonal antibodies that potently bind and neutralize multiple subclades of EV-D68, including B3 and A2 variants. Animal studies have indicated that these Rhesus macaque-derived monoclonal antibodies (mAbs) are likely to confer protection against respiratory illness in young children (particularly those under age 5) and in individuals with respiratory or immunocompromising conditions. Analyses conducted using standard techniques such as cryo-EM have enabled the inventors to further characterize the epitopes of two unique EV-D68-specific antibodies, suggesting the value of this technology for developing multi-specific approaches that confer broad protection against EV-D68.</p> <p>Humanization and combination of these mAbs with other antibodies exhibiting unique epitope specificities may prove beneficial for therapeutic or prophylactic purposes, especially within the context of a broader pandemic preparedness program. Further, these antibodies could be incorporated into diagnostic assays/kits for the rapid and accurate detection of EV-D68 in clinical or non-clinical settings.</p> <p>This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR part 404.</p> <ul> <li>Development of prophylactic or therapeutic interventions against EV-D68 that effectively induce broad protection against multiple circulating subclades</li> </ul> <ul> <li>Prevention or treatment of EV-D68 infection</li> <li>Development of diagnostic assays for rapid, accurate EV-D68 detection in clinical and non-clinical settings</li> </ul> 2025-07-02 2025-07-02 2025-07-02 2025-07-03 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 163185209 Krug et al. EV-D68 virus-like particle vaccines elicit cross-clade neutralizing antibodies that inhibit infection and block dissemination. Sci. Adv. 2023;9:eadg6076. https://doi.org/10.1126/sciadv.adg6076 Krug et al. EV-D68 virus-like particle vaccines elicit cross-clade neutralizing antibodies that inhibit infection and block dissemination. Sci. Adv. 2023;9:eadg6076. https://doi.org/10.1126/sciadv.adg6076 163184529 Ruckwardt, Tracy National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Ruckwardt, Tracy (NIAID) 1 163184765 Moss, Daniel National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Moss, Daniel (NIAID) 2 163184769 Krug, Peter National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Krug, Peter (NIAID) 3 163184784 Kanekiyo, Masaru National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Kanekiyo, Masaru (NIAID) 4 163184529 Ruckwardt, Tracy National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Ruckwardt, Tracy (NIAID) 1 163184765 Moss, Daniel National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Moss, Daniel (NIAID) 2 163184769 Krug, Peter National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Krug, Peter (NIAID) 3 163184784 Kanekiyo, Masaru National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Kanekiyo, Masaru (NIAID) 4 163184484 EV-D68 Monoclonal Antibodies Isolated from Immunized Rhesus Macaques E-041-2024-0 Filing authorized National Institute of Allergy and Infectious Diseases (NIAID/NIH), NIH - NIAID 83682222 Bailey, Brian bbailey@mail.nih.gov
United States of America TTIPO bbailey@mail.nih.gov?subject=Web Inquiry on [TAB-5062] EV-D68 Monoclonal Antibodies Isolated from Immunized Rhesus Macaques&body=Please send me information about technology [TAB-5062] EV-D68 Monoclonal Antibodies Isolated from Immunized Rhesus Macaques. Bailey, Brian<br><a href="mailto:bbailey@mail.nih.gov?subject=Web Inquiry on [TAB-5062] EV-D68 Monoclonal Antibodies Isolated from Immunized Rhesus Macaques&body=Please send me information about technology [TAB-5062] EV-D68 Monoclonal Antibodies Isolated from Immunized Rhesus Macaques.">bbailey@mail.nih.gov</a><br> 163184489 E-041-2024-0 E-041-2024-0-US-01 ANTIBODIES AGAINST EV-D68 PRV US 63/640,619 Expired US <br />Provisional (PRV) 63/640,619<br />Filed on 2024-04-30<br />Status: Expired 163184490 E-041-2024-0 E-041-2024-0-PC-01 ANTIBODIES AGAINST EV-D68 PCT Patent Cooperation Treaty PCT/US2025/027110 Pending Patent Cooperation Treaty <br />(PCT) PCT/US2025/027110<br />Filed on 2025-04-30<br />Status: Pending TAB-5060 162906659 Establishment and characterization of the A 1847 human ovarian carcinoma line NCI Licensing, Oncology, Research Materials Licensing Oncology Research Materials Stuart Aaronson, Nelson Ellmore (Estate) <h2>Summary:</h2> <p>The National Cancer Institute (NCI) seeks licensees for a tumorigenic cell line, A1847, from a patient with metastatic ovarian cancer. As a BRCA1 deficient cell line, it serves as a model to researchers studying cell cycle regulation, tumor suppression and effective drugs aiding in repair of DNA damage.</p> <h2>Description of Technology:</h2> <p>Mutations, such as loss of function, in the BRCA1 gene increase the risk of developing ovarian cancer. In its early stages, ovarian cancer may not cause any definitive symptoms but can rapidly progress within a year to advanced stage. This metastatic growth can occur by shedding cancerous cells into peritoneal fluid, often associated with epithelial ovarian cancer, its most common type. While treatments exist, it is limited by the development of drug resistance that is not succumbed to damage in cell death.</p> <p>The National Cancer Institute (NCI) researchers derived a metastatic ovarian carcinoma cell line, A1847, from a 50-year-old female. It was established as a continuous tumorigenic cell line and characterized by isozyme phenotype, short tandem repeat (STR) analysis and karyotypically with modal number 68 and 3 marker chromosomes. This cell line may be used to identify therapeutic targets and to screen drug candidates against ovarian cancer.</p> <p>NCI is seeking parties to nonexclusively license the A1847 human ovarian carcinoma cell line.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Tool to conduct preclinical proof-of-concept studies required for commercial development of anti-cancer agents and targeted therapies in ovarian cancer</li> <li>Research model to investigate epithelial ovarian cancer</li> <li>Research model for mechanistic studies of ovarian cancer and BRCA1-deficient tumors</li> </ul> <h2>Competitive Advantages:</h2> <ul> <li>Well-characterized metastatic ovarian cancer cell line</li> <li>Tumorigenic cell line to generate animal models of metastatic ovarian cancer for commercial and research development</li> </ul> Researchers at the NCI seek licensing for the A1847 ovarian cancer cell line. 2025-06-12 2025-06-27 2025-06-27 2025-06-27 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-018-2020-0 163125989 Standing, D., et al. Selective targeting of IRAK1 attenuates low molecular weight hyaluronic acid-induced stemness and non-canonical STAT3 activation in epithelial ovarian cancer. (PMID 38796478) https://pubmed.ncbi.nlm.nih.gov/38796478/ <a href="https://pubmed.ncbi.nlm.nih.gov/38796478/">Standing, D., et al. Selective targeting of IRAK1 attenuates low molecular weight hyaluronic acid-induced stemness and non-canonical STAT3 activation in epithelial ovarian cancer. (PMID 38796478)</a> 163126001 Sethi, G., et al. An RNA interference lethality screen of the human druggable genome to identify molecular vulnerabilities in epithelial ovarian cancer. (PMID 23056589) https://pubmed.ncbi.nlm.nih.gov/23056589/ <a href="https://pubmed.ncbi.nlm.nih.gov/23056589/">Sethi, G., et al. An RNA interference lethality screen of the human druggable genome to identify molecular vulnerabilities in epithelial ovarian cancer. (PMID 23056589)</a> 163126008 Godwin, A.K., et al. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. (PMID 1348364) https://pubmed.ncbi.nlm.nih.gov/1348364/ <a href="https://pubmed.ncbi.nlm.nih.gov/1348364/">Godwin, A.K., et al. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. (PMID 1348364)</a> 162906829 Aaronson, Stuart NIH - NCI Aaronson, Stuart 1 162906896 Ellmore (Estate), Nelson NIH - NCI NCI Ellmore (Estate), Nelson (NCI) 2 162906829 Aaronson, Stuart NIH - NCI Aaronson, Stuart 1 162906896 Ellmore (Estate), Nelson NIH - NCI NCI Ellmore (Estate), Nelson (NCI) 2 162906662 Establishment and characterization of the A 1847 human ovarian carcinoma line E-137-2023-0 Research Material 83694133 Gulay French, Suna suna.gulay@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB suna.gulay@nih.gov?subject=Web Inquiry on [TAB-5060] Establishment and characterization of the A 1847 human ovarian carcinoma line&body=Please send me information about technology [TAB-5060] Establishment and characterization of the A 1847 human ovarian carcinoma line.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Gulay French, Suna<br><a href="mailto:suna.gulay@nih.gov?subject=Web Inquiry on [TAB-5060] Establishment and characterization of the A 1847 human ovarian carcinoma line&body=Please send me information about technology [TAB-5060] Establishment and characterization of the A 1847 human ovarian carcinoma line.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">suna.gulay@nih.gov</a><br> TAB-5046 162067522 4-Amino-2-(piperidin-3-yl)isoindoline-1,3-diones as Anti-inflammatory Agents for Systemic Degenerative and Neurodegenerative Disorders NIA Collaboration, Geriatrics, Licensing, Neurology Collaboration Geriatrics Licensing Neurology Nigel Greig, Michael Scerba, David Tweedie <h2>Summary:</h2> <p>The National Institute on Aging (NIA) seeks research co-development partners and/or licensees for the pre-clinical and clinical development of the compounds as anti-inflammatory therapeutics for systemic degenerative and neurodegenerative disorders.</p> <h2>Description of Technology:</h2> <p>The immunomodulatory imide drugs (IMiDs) thalidomide and its close analogs (lenalidomide and pomalidomide) are widely used to treat a variety of diseases &ndash; such as inflammatory disorders, neurodegenerative diseases, multiple myeloma and other cancers. However, thalidomide is poorly soluble in water and unstable &ndash; complicating its delivery, bioavailability and subsequent evaluations. Additionally, thalidomide is plagued by teratogenic adverse effects in current human use. Therefore, there is intense interest in developing analogs that exhibit suitable properties of solubility and stability while retaining desirable biological activity safe for clinical use.</p> <p>Researchers at the National Institute on Aging (NIA) have synthesized a promising new family of IMiD compounds with improved chemical stability, enhanced water solubility, and potent anti-inflammatory properties. In cell-based studies, these compounds significantly reduced key inflammation markers, including nitrate and IL-6. Along with the ability to maintain high levels of cell viability, these improvements positionthem as promising therapeutic candidates. Unlike traditional IMiD drugs, these compounds do not bind to the cereblon protein, eliminating concerns of teratogenicity. The compounds also demonstrated a high binding affinity to the sigma and serotonin receptors, both linked to cellular inflammation, which further enhances their potential for treating neurodegenerative disorders, traumatic brain injury, inflammatory disorders, viral infections and cancer.</p> <h2>Potential Commercial Applications:</h2> <ul> <li>Anti-inflammatory therapeutics for:</li> <li>Neurodegenerative diseases</li> <li>Inflammatory disorders</li> <li>Autoimmune disorders</li> <li>Viral infections</li> <li>Cancer</li> </ul> <h2>Competitive Advantages over Clinically Available IMiDs:</h2> <ul> <li>Enhanced chemical stability and solubility</li> <li>Greater anti-inflammatory activity</li> <li>Potentially clinically safer than classic IMiDs by lower risk of fetal malformations</li> </ul> Researchers at the NIA seek licensing and/or co-development research collaborations for the pre-clinical and clinical development of the compounds as anti-inflammatory therapeutics for systemic degenerative and neurodegenerative disorders. 2025-04-25 2025-06-27 2025-06-27 2025-04-28 False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-045-2012-0 E-208-2015-0 E-151-2022-0 162067924 Scerba MT, et al. 2-(Piperidin-3-yl)phthalimides reduce classical markers of cellular inflammation in LPS-challenged RAW 264.7 cells and also demonstrate potentially relevant sigma and serotonin receptor affinity in membrane preparations. (PMID 38996940) https://pubmed.ncbi.nlm.nih.gov/38996940/ <a href="https://pubmed.ncbi.nlm.nih.gov/38996940/">Scerba MT, et al. 2-(Piperidin-3-yl)phthalimides reduce classical markers of cellular inflammation in LPS-challenged RAW 264.7 cells and also demonstrate potentially relevant sigma and serotonin receptor affinity in membrane preparations. (PMID 38996940)</a> 162067646 Greig, Nigel National Institute on Aging (NIH/NIA) NIA Greig, Nigel (NIA) 1 162067652 Scerba, Michael National Institute on Aging (NIH/NIA) NIA Scerba, Michael (NIA) 2 162067656 Tweedie, David National Institute on Aging (NIH/NIA) NIA Tweedie, David (NIA) 3 162067646 Greig, Nigel National Institute on Aging (NIH/NIA) NIA Greig, Nigel (NIA) 1 162067652 Scerba, Michael National Institute on Aging (NIH/NIA) NIA Scerba, Michael (NIA) 2 162067656 Tweedie, David National Institute on Aging (NIH/NIA) NIA Tweedie, David (NIA) 3 162067525 4-Amino-2-(piperidin-3-yl)isoindoline-1,3-diones as anti-inflammatory agents for systemic degenerative and neurodegenerative disorders E-183-2024-0 Filing authorized National Institute on Aging (NIH/NIA), NIH - NCI, NIH - NIA 91789173 Guyton, Nicole darackn@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America darackn@mail.nih.gov?subject=Web Inquiry on [TAB-5046] 4-Amino-2-(piperidin-3-yl)isoindoline-1,3-diones as Anti-inflammatory Agents for Systemic Degenerative and Neurodegenerative Disorders&body=Please send me information about technology [TAB-5046] 4-Amino-2-(piperidin-3-yl)isoindoline-1,3-diones as Anti-inflammatory Agents for Systemic Degenerative and Neurodegenerative Disorders.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Guyton, Nicole<br><a href="mailto:darackn@mail.nih.gov?subject=Web Inquiry on [TAB-5046] 4-Amino-2-(piperidin-3-yl)isoindoline-1,3-diones as Anti-inflammatory Agents for Systemic Degenerative and Neurodegenerative Disorders&body=Please send me information about technology [TAB-5046] 4-Amino-2-(piperidin-3-yl)isoindoline-1,3-diones as Anti-inflammatory Agents for Systemic Degenerative and Neurodegenerative Disorders.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov">darackn@mail.nih.gov</a><br> 162067536 E-183-2024-0 E-183-2024-0-US-02 2-(PIPERIDIN-3-YL)ISOINDOLE-1,3-DIONE ANALOGS AND USES THEREOF PRV US 63/664,442 Expired US <br />Provisional (PRV) 63/664,442<br />Filed on 2024-06-26<br />Status: Expired 162661816 E-183-2024-0 E-183-2024-0-PC-01 2-(PIPERIDIN-3-YL)ISOINDOLE-1,3-DIONE ANALOGS AND USES THEREOF PCT Patent Cooperation Treaty PCT/US2025/034951 Pending Patent Cooperation Treaty <br />(PCT) PCT/US2025/034951<br />Filed on 2025-06-24<br />Status: Pending TAB-4150 147157433 Tempol: A Commercially-Available Nitroxide as a Cancer Therapeutic NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Murali Cherukuri, William Linehan, James Mitchell, Tracey Rouault <p>The National Cancer Institute's <a href="https://ccr.cancer.gov/urologic-oncology-branch" rel="nofollow">Urologic Oncology Branch </a>is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize the use of Tempol to target HIF-2a in cancer.</p> <p> Elevated HIF-2a is associated with clear cell kidney cancer characterized by mutation of the VHL tumor suppressor gene and with many other cancers. A commercially-available stable nitroxide, TEMPOL, can effectively reduce the level of hypoxia-inducible transcription factor (HIF)-2a.  Therefore, TEMPOL can potentially be developed into a cancer drug to treat patients with elevated HIF-2a, whether due to compromised VHL function or not.</p> <p> The potential drug could target a population that suffers from genetic diseases such as inherited von Hippel-Lindau (VHL) disease and patients with kidney and other cancers characterized by elevation of HIF-2a.  Inherited VHL disease is a cancer syndrome caused by germ line mutations of the VHL tumor suppressor gene. VHL is characterized by angiomas and hemangioblastomas of the brain, spinal cord, and retina. </p> <p> Renal clear cell carcinoma (RCC) develops in approximately 75% of VHL patients by age 60 and is a leading cause of death in this population.  Inactivation (mutation or methylation) of the VHL gene is associated with greater than 90% of all clear cell RCC (including sporadic cases).  Nickerson et al. Clin Cancer Res 2008;14:4726-34. Thus, subjects with compromised VHL function represent a significant population that has or is at risk for developing cancer, including RCC.  There is data that HIF-2a may be important in all or most cancers. Franovic, et al. Proc Natl Acad Sci U S A 2009.</p> <h2>Competitive Advantages:</h2> <h2>Commercial Applications:</h2> 2016-02-16 2025-06-24 2018-07-19 2025-06-24 2016-08-30 clear cell, HIF-2, kidney cancer, NITROXIDE, Tempol False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2018-07-19 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147163698 Linehan, William NIH - NCI NCI Linehan, William (NCI) 1 147163699 Rouault, Tracey NIH - NICHD NICHD Rouault, Tracey (NICHD) 2 147163696 Mitchell, James NIH - NCI NCI Mitchell, James (NCI) 3 147163697 Cherukuri, Murali NIH - NCI NCI Cherukuri, Murali (NCI) 4 147163698 Linehan, William NIH - NCI NCI Linehan, William (NCI) 1 147163699 Rouault, Tracey NIH - NICHD NICHD Rouault, Tracey (NICHD) 2 147163696 Mitchell, James NIH - NCI NCI Mitchell, James (NCI) 3 147163697 Cherukuri, Murali NIH - NCI NCI Cherukuri, Murali (NCI) 4 147158051 Use Of Tempol For Treatment Of Cancer E-133-2009-0 Filing authorized NCI, NICHD 83691647 Chang, Kevin changke@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB changke@mail.nih.gov?subject=Web Inquiry on [TAB-4150] Tempol: A Commercially-Available Nitroxide as a Cancer Therapeutic&body=Please send me information about technology [TAB-4150] Tempol: A Commercially-Available Nitroxide as a Cancer Therapeutic.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Chang, Kevin<br><a href="mailto:changke@mail.nih.gov?subject=Web Inquiry on [TAB-4150] Tempol: A Commercially-Available Nitroxide as a Cancer Therapeutic&body=Please send me information about technology [TAB-4150] Tempol: A Commercially-Available Nitroxide as a Cancer Therapeutic.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">changke@mail.nih.gov</a><br> 147166930 E-133-2009-0 E-133-2009-0-US-01 Use Of Tempol For Treatment Of Cancer PRV US 61/265,194 Abandoned US <br />Provisional (PRV) 61/265,194<br />Filed on 2009-11-30<br />Status: Abandoned 147166931 E-133-2009-0 E-133-2009-0-PCT-02 Nitroxide Therapy For The Treatment Of Von-Hippel-Lindau Disease (VHL) And Renal Clear Cell Carcinoma (RCC) PCT Patent Cooperation Treaty PCT/US2010/058332 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2010/058332<br />Filed on 2010-11-30<br />Status: Expired 147166932 E-133-2009-0 E-133-2009-0-US-03 Nitroxide Therapy For The Treatment Of Von Hippel-Lindau Disease (VHL) And Renal Clear Cell Carcinoma (RCC) National Stage US 8,853,277 13/512,665 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8853277 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8853277">8,853,277</a><br />Filed on 2012-05-30<br />Status: Issued 147172111 clear cell 147172112 HIF-2 147172114 kidney cancer 147172115 NITROXIDE 147172116 Tempol TAB-4344 147157636 Non-invasive diagnostic and prognostic assay for early stage lung cancer NCI Collaboration, Diagnostics, Licensing, Oncology Collaboration Diagnostics Licensing Oncology Frank Gonzalez, Curtis Harris, Majda Haznadar, Kristopher Krausz, Soumen Manna, Ewy Mathe, Andrew Patterson <p>In the United States alone, one of four cancer deaths occur from lung cancer and there are over 8 million individuals considered to be at high-risk due to cigarette smoking and other behaviors. It's well known that early detection of cancer significantly improves survival of this disease, however a lack of lung cancer screenings and analysis precludes fast results at a low cost.</p> <p>Low-dose computer tomography (LD-CT) is the current standard and provides indication of potentially cancerous nodules above a certain size, however it suffers from low sensitivity and specificity (55 and 81%, respectively), can miss occult cancer (10% false negative rate), or incorrectly diagnose cancer when it is not there, with up to 90% false positive results. False negatives can lead to detection only at later-stages when treatment options are limited, while false positives can lead to additional, expensive testing, invasive biopsies, and patient anxiety. In addition, the compliance rate for LD-CT screening is less than 5% of the eligible population due to access to infrastructure and other chalenges.</p> <p>Scientists in the NCI’s <a href="https://ccr.cancer.gov/Laboratory-of-Human-Carcinogenesis" rel="nofollow">Laboratory of Human Carcinogenesis</a> have proven a unique, non-invasive screening tool and diagnostic that detects lung cancer at an early stage utilizing liquid chromatography-mass spectrometry of urine samples. Urine samples minimize patient discomfort, unlike current early detection methods that are invasive, such as a blood or tissue biopsy or bronchoscopy, could be done easily during a routine exam, and could supplement existing LD-CT that cannot detect such early-stage nodules.</p> <p>The NCI scientists validated a unique metabolite profile by profiling of urine samples obtained from smokers and non-smokers in three independent cohorts.The four componenets of the profile have shown high correlation to lung cancer (p &lt; 0.00001). Patient data indicate the methdology can also provide prognostic data on patient survival and have led to an understanding of the mechanism of action that creates the metabolic profile.</p> <p>The NCI seeks research collaborations to discover additional aspects of this methdology in patient samples, or licensing to commercialize the technology through CLIA or LDT.</p> <p> </p> <h2>Competitive Advantages:</h2> <ul><li>Greatly improves early stage cancer screening with significantly lower false positive/false negative results than LD-CT (standard of care)</li> <li>Ease of sample collection and low cost of analysis could supplement regular patient exams</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Diagnostic test for early-stage lung cancer to supplement or supplant current LD-CT-based methods</li> <li>Prognostic test for patient survival, and a method to help physicians make informed treatment decisions</li> </ul> 2016-02-16 2025-06-24 2021-03-03 2025-06-24 2017-11-21 LDCT, LD-CT, liquid biopsy, low-dose computed tomography, Non-small cell lung cancer, NSCLC, Urine False True Clinical True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-03-03 72159138 Clinical Phase I 72159138 NCI 37470483 Website Abstract E-248-2002 147162037 Mathé EA, et al. Noninvasive urinary metabolomic profiling identifies diagnostic and prognostic markers in lung cancer. http://www.ncbi.nlm.nih.gov/pubmed/24736543 <a href="http://www.ncbi.nlm.nih.gov/pubmed/24736543">Mathé EA, et al. Noninvasive urinary metabolomic profiling identifies diagnostic and prognostic markers in lung cancer.</a> 147164391 Harris, Curtis NIH - NCI NCI Harris, Curtis (NCI) 1 147164394 Mathe, Ewy NIH - NIAMS NCATS Mathe, Ewy (NCATS) 2 147164392 Gonzalez, Frank NIH - NCI NCI Gonzalez, Frank (NCI) 4 147164393 Krausz, Kristopher NIH - NCI NCI Krausz, Kristopher (NCI) 5 147164396 Manna, Soumen NIH - NCI NCI Manna, Soumen (NCI) 6 147164395 Patterson, Andrew Pennsylvania State University Patterson, Andrew 7 147164397 Haznadar, Majda NIH - NCI NCI Haznadar, Majda (NCI) 8 147164391 Harris, Curtis NIH - NCI NCI Harris, Curtis (NCI) 1 147164394 Mathe, Ewy NIH - NIAMS NCATS Mathe, Ewy (NCATS) 2 147164392 Gonzalez, Frank NIH - NCI NCI Gonzalez, Frank (NCI) 4 147164393 Krausz, Kristopher NIH - NCI NCI Krausz, Kristopher (NCI) 5 147164396 Manna, Soumen NIH - NCI NCI Manna, Soumen (NCI) 6 147164395 Patterson, Andrew Pennsylvania State University Patterson, Andrew 7 147164397 Haznadar, Majda NIH - NCI NCI Haznadar, Majda (NCI) 8 147158028 Diagnostic And Prognostic Utility Of Urinary Metabolites In Lung Cancer Patients E-121-2013-0 Filing authorized NCI, NIAMS, Pennsylvania State University 83691647 Chang, Kevin changke@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB changke@mail.nih.gov?subject=Web Inquiry on [TAB-4344] Non-invasive diagnostic and prognostic assay for early stage lung cancer&body=Please send me information about technology [TAB-4344] Non-invasive diagnostic and prognostic assay for early stage lung cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Chang, Kevin<br><a href="mailto:changke@mail.nih.gov?subject=Web Inquiry on [TAB-4344] Non-invasive diagnostic and prognostic assay for early stage lung cancer&body=Please send me information about technology [TAB-4344] Non-invasive diagnostic and prognostic assay for early stage lung cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">changke@mail.nih.gov</a><br> 147161070 E-121-2013-0 E-121-2013-0-US-01 Method for the Diagnosis And Prognosis of Cancer PRV US 61/845,055 Abandoned US <br />Provisional (PRV) 61/845,055<br />Filed on 2013-07-11<br />Status: Abandoned 147168325 E-121-2013-0 E-121-2013-0-PCT-02 METHOD FOR THE DIAGNOSIS AND PROGNOSIS OF CANCER PCT Patent Cooperation Treaty PCT/US2014/046294 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2014/046294<br />Filed on 2014-07-11<br />Status: Expired 147168326 E-121-2013-0 E-121-2013-0-EP-03 METHOD FOR THE DIAGNOSIS AND PROGNOSIS OF CANCER National Stage European Patent 3019871 14745047.2 Issued European Patent <br />National Stage 14745047.2<br />Filed on 2014-07-11<br />Status: Issued 147168327 E-121-2013-0 E-121-2013-0-US-04 Method for the Diagnosis and Prognosis of Cancer National Stage US 10,393,745 14/903,706 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10393745 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10393745">10,393,745</a><br />Filed on 2016-01-08<br />Status: Issued 147168328 E-121-2013-0 E-121-2013-0-US-05 METHOD FOR THE DIAGNOSIS AND PROGNOSIS OF CANCER CON US 11,555,818 16/412,003 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11555818 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11555818">11,555,818</a><br />Filed on 2019-05-14<br />Status: Issued 147168329 E-121-2013-0 E-121-2013-0-DE-06 METHOD FOR THE DIAGNOSIS AND PROGNOSIS OF CANCER EP Germany 3019871 14745047.2 Issued Germany <br />European patent (EP) 14745047.2<br />Filed on 2014-07-11<br />Status: Issued 147168330 E-121-2013-0 E-121-2013-0-FR-07 METHOD FOR THE DIAGNOSIS AND PROGNOSIS OF CANCER EP France 3019871 14745047.2 Issued France <br />European patent (EP) 14745047.2<br />Filed on 2014-07-11<br />Status: Issued 147168331 E-121-2013-0 E-121-2013-0-GB-08 METHOD FOR THE DIAGNOSIS AND PROGNOSIS OF CANCER EP United Kingdom 3019871 14745047.2 Issued United Kingdom <br />European patent (EP) 14745047.2<br />Filed on 2014-07-11<br />Status: Issued 147171853 LDCT 147171855 LD-CT 147171857 liquid biopsy 147171859 low-dose computed tomography 147171860 Non-small cell lung cancer 147171861 NSCLC 147171862 Urine TAB-4268 147157555 Bivalent, Dual Specific Anti-CD22 Anti-CD19 Chimeric Antigen Receptors (CARs) NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Terry Fry, Waleed Haso, Crystal Mackall, Rimas Orentas, Haiying Qin <p>Chimeric antigen receptors (CARs) combine an antibody-based binding domain (and single chain fragment variable region, scFv) with T cell receptor signaling domains (CD3 zeta with a costimulatory domain, typically CD28 or 41BB). When T cells express CARs, they are activated in a major histocompatibility complex- (MHC) independent manner to kill tumor cells expressing the target to which the scFv binds.  CAR T cells targeting the B cell antigen CD19 have resulted in remissions in 60-80% of patients with pre-B cell precursor acute lymphoblastic leukemia (BCP-ALL). However, not all patients respond, and relapses occur in 10% or more of patients who receive anti-CD19 CAR therapy for acute lymphoblastic leukemia (ALL) - primarily due to the loss of the CD19 epitope. Thus, there is a need for advanced therapeutic options to treat those patients who either relapse or are non-responders.<br />   <br /> To overcome these current limitations, the National Cancer Institute’s Pediatric Oncology Branch (NCI POB) developed an active CD19/CD22 targeted CAR that is potent at eradicating ALL in xenograft studies (Haso et al, Blood, 2013), by Targeting two antigens simultaneously could increase CAR potency and prevent antigen-loss escape. A <a href="https://clinicaltrials.gov/ct2/show/NCT03448393?term=cd19+cd22+chimeric+antigen+receptor&amp;draw=2&amp;rank=6" rel="nofollow">Phase I clinical trial</a> is currently enrolling patients at the NCI. </p> <p>NCI seeks co-development partners or licensees for dual-specific anti-CD22 anti-CD19 chimeric antigen receptors (CARs).</p> <h2>Competitive Advantages:</h2> <ul><li>CAR-T has previously been demonstrated to be effective in the treatment of b cell malignances</li> <li>Targeting two antigens on one CAR offers the advantage of better cancer cell targeting and reduces the possibility of antigen escape</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Treatment of acute lymphoblastic leukemia (ALL), the most common form of cancer for children</li> <li>Treatment of additional b cell malignancies including Diffuse Large B-Cell Lymphoma (DLBCL)</li> <li>Adoptive immunotherapy</li> </ul> 2018-08-02 2025-06-24 2021-02-24 2025-06-24 2018-08-02 Acute Lymphoblastic Leukemia, ALL, BISPECIFIC, Bivalent, CAR, CD19, CD22, Diffuse Large B-Cell Lymphoma, DLBCL, Dual-Specific Chimeric Antigen Receptors, Fry, Oncology, Pediatric Leukemia, Pediatric Lymphoma False True Clinical True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-02-24 72159138 Clinical Phase I 72159138 NCI 37470483 Website Abstract E-017-2017 E-080-2008 E-291-2012 147161996 Qin H, et. al. Preclinical development of bivalent chimeric antigen receptors targeting both CD19 and CD22 https://pubmed.ncbi.nlm.nih.gov/30581986/ <a href="https://pubmed.ncbi.nlm.nih.gov/30581986/">Qin H, et. al. Preclinical development of bivalent chimeric antigen receptors targeting both CD19 and CD22</a> 147162152 Shalabi H, et. al. Safety and efficacy of CD19/CD22 CAR T cells in children and young adults with relapsed/refractory ALL (Abstract) https://pubmed.ncbi.nlm.nih.gov/32286905/ <a href="https://pubmed.ncbi.nlm.nih.gov/32286905/">Shalabi H, et. al. Safety and efficacy of CD19/CD22 CAR T cells in children and young adults with relapsed/refractory ALL (Abstract)</a> 147164110 Fry, Terry NIH - NCI NCI Fry, Terry (NCI) 1 147164109 Mackall, Crystal NIH - NCI NCI Mackall, Crystal (NCI) 2 147164112 Orentas, Rimas NIH - NCI NCI Orentas, Rimas (NCI) 3 147164111 Qin, Haiying NIH - NCI NCI Qin, Haiying (NCI) 4 147164113 Haso, Waleed NIH - NCI Haso, Waleed 5 147164110 Fry, Terry NIH - NCI NCI Fry, Terry (NCI) 1 147164109 Mackall, Crystal NIH - NCI NCI Mackall, Crystal (NCI) 2 147164112 Orentas, Rimas NIH - NCI NCI Orentas, Rimas (NCI) 3 147164111 Qin, Haiying NIH - NCI NCI Qin, Haiying (NCI) 4 147164113 Haso, Waleed NIH - NCI Haso, Waleed 5 147158000 Chimeric Antigen Receptor (CAR) Targeting Both CD19 And CD22 E-106-2015-0 Filing authorized NCI 83673032 Whitney, Laurie WhitneyL@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC WhitneyL@mail.nih.gov?subject=Web Inquiry on [TAB-4268] Bivalent, Dual Specific Anti-CD22 Anti-CD19 Chimeric Antigen Receptors (CARs)&body=Please send me information about technology [TAB-4268] Bivalent, Dual Specific Anti-CD22 Anti-CD19 Chimeric Antigen Receptors (CARs).&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Whitney, Laurie<br><a href="mailto:WhitneyL@mail.nih.gov?subject=Web Inquiry on [TAB-4268] Bivalent, Dual Specific Anti-CD22 Anti-CD19 Chimeric Antigen Receptors (CARs)&body=Please send me information about technology [TAB-4268] Bivalent, Dual Specific Anti-CD22 Anti-CD19 Chimeric Antigen Receptors (CARs).&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">WhitneyL@mail.nih.gov</a><br> 147161049 E-106-2015-0 E-106-2015-0-US-03 DUAL SPECIFIC ANTI-CD22-ANTI-CD19 CHIMERIC ANTIGEN RECEPTORS National Stage US 10,738,116 15/559,485 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10738116 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10738116">10,738,116</a><br />Filed on 2017-09-19<br />Status: Issued 147167802 E-106-2015-0 E-106-2015-0-US-01 Dual Specific Anti-CD22-ANtiCD19 Chimeric Antigen PRV US 62/135,442 Abandoned US <br />Provisional (PRV) 62/135,442<br />Filed on 2015-03-19<br />Status: Abandoned 147167803 E-106-2015-0 E-106-2015-0-PCT-02 Dual Specific Anti-CD22-Anti-CD19 Chimeric Antigen Receptors PCT Patent Cooperation Treaty PCT/US2016/023055 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2016/023055<br />Filed on 2016-03-18<br />Status: Expired 147171538 Acute Lymphoblastic Leukemia 147171539 ALL 147171540 BISPECIFIC 147171541 Bivalent 147171542 CAR 147171543 CD19 147171544 CD22 147171545 Diffuse Large B-Cell Lymphoma 147171546 DLBCL 147171547 Dual-Specific Chimeric Antigen Receptors 147171548 Fry 147171549 Oncology 147171550 Pediatric Leukemia 147171551 Pediatric Lymphoma TAB-4246 147157533 Gene Signature for Predicting Solid Tumors Patient Prognosis NCI Collaboration, Diagnostics, Licensing, Oncology Collaboration Diagnostics Licensing Oncology Stephanie Roessler, Xin Wei Wang <p>HCC is the most frequent malignant tumor in the liver and the third leading cause of cancer death worldwide.  A progressive sequence of somatic mutations and epigenetic changes of oncogenes or tumor suppressor genes are believed to cause tumor development. However, high genomic instability in tumors causes the accumulation of genomic aberrations that do not contribute to tumor progression. Therefore, it is important to distinguish between ''driver'' mutations that are functionally important and ''passenger'' mutations that do not provide a selective advantage to the tumor cells.</p> <p> The current invention describes a driver gene signature for predicting survival in patients with solid malignancies including HCC and breast cancer.  The gene signature includes ten cancer-associated genes, and the NIH researchers further discovered that a decrease in DNA copy number or mRNA expression of some genes is associated with poor prognosis in HCC tumors and breast cancer, while a decrease in DNA copy number or mRNA expression of a few other genes is associated with good prognosis. They have also demonstrated that at least four of these cancer-associated genes are functional tumor suppressor genes. Thus, these genes may be potential molecular targets of HCC and breast cancer.<br />  </p> <h2>Competitive Advantages:</h2> <ul><li>A novel prognostic tool for HCC and breast cancer patients.</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Prognosis for hepatocellular carcinoma (HCC) and breast cancer patient survival.</li> <li>Potential new method to identify therapeutic treatment for HCC and breast cancer patients.</li> </ul> 2016-02-16 2025-06-24 2018-07-19 2025-06-24 2016-08-29 Biomarker, driver gene, gene signature, HCC, hepatocellular carcinoma, prognostic False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2018-07-19 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-101-2016 E-209-2008 E-215-2007 147164030 Wang, Xin Wei NIH - NCI NCI Wang, Xin Wei (NCI) 1 147164031 Roessler, Stephanie NIH - NCI NCI Roessler, Stephanie (NCI) 2 147164030 Wang, Xin Wei NIH - NCI NCI Wang, Xin Wei (NCI) 1 147164031 Roessler, Stephanie NIH - NCI NCI Roessler, Stephanie (NCI) 2 147157811 Molecular Prediction Of Survival Outcome Of Human Hepatocellular Carcinoma (HCC) Patients By A 'driver'-gene-signature. E-024-2009-0 Filing authorized NCI 83691647 Chang, Kevin changke@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB changke@mail.nih.gov?subject=Web Inquiry on [TAB-4246] Gene Signature for Predicting Solid Tumors Patient Prognosis&body=Please send me information about technology [TAB-4246] Gene Signature for Predicting Solid Tumors Patient Prognosis.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Chang, Kevin<br><a href="mailto:changke@mail.nih.gov?subject=Web Inquiry on [TAB-4246] Gene Signature for Predicting Solid Tumors Patient Prognosis&body=Please send me information about technology [TAB-4246] Gene Signature for Predicting Solid Tumors Patient Prognosis.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">changke@mail.nih.gov</a><br> 147160919 E-024-2009-0 E-024-2009-0-US-04 Gene Signature for Predicting Prognosis Of Patients With Solid Tumors National Stage US 8,735,082 13/127,701 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8735082 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8735082">8,735,082</a><br />Filed on 2011-05-04<br />Status: Issued 147167653 E-024-2009-0 E-024-2009-0-US-01 Molecular Prediction Of Survival Outcome Of Human Hepatocellular Carcinoma (HCC) Patients By A 'driver'-gene-signature. PRV US 61/198,813 Abandoned US <br />Provisional (PRV) 61/198,813<br />Filed on 2008-11-10<br />Status: Abandoned 147167654 E-024-2009-0 E-024-2009-0-PCT-02 Gene Signature for Prediction Prognosis of Patients with Solid Tumors PCT Patent Cooperation Treaty PCT/US2009/063883 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2009/063883<br />Filed on 2009-11-10<br />Status: Expired 147167655 E-024-2009-0 E-024-2009-0-EP-03 GENE SIGNATURE FOR PREDICTING PROGNOSIS OF PATIENTS WITH SOLID TUMORS National Stage European Patent 2352847 09752261.9 Abandoned European Patent <br />National Stage 09752261.9<br />Filed on 2009-11-10<br />Status: Abandoned 147167656 E-024-2009-0 E-024-2009-0-EP-05 GENE SIGNATURE FOR PREDICTING PROGNOSIS OF PATIENTS WITH SOLID TUMORS DIV European Patent 2687609 13188475.1 Abandoned European Patent <br />Divisional (DIV) 13188475.1<br />Filed on 2009-11-10<br />Status: Abandoned 147167657 E-024-2009-0 E-024-2009-0-DE-06 GENE SIGNATURE FOR PREDICTING PROGNOSIS OF PATIENTS WITH SOLID TUMORS EP Germany 2352847 09752261.9 Abandoned Germany <br />European patent (EP) 09752261.9<br />Filed on 2009-11-10<br />Status: Abandoned 147167658 E-024-2009-0 E-024-2009-0-FR-07 GENE SIGNATURE FOR PREDICTING PROGNOSIS OF PATIENTS WITH SOLID TUMORS EP France 2352847 09752261.9 Abandoned France <br />European patent (EP) 09752261.9<br />Filed on 2009-11-10<br />Status: Abandoned 147167659 E-024-2009-0 E-024-2009-0-GB-08 GENE SIGNATURE FOR PREDICTING PROGNOSIS OF PATIENTS WITH SOLID TUMORS EP United Kingdom 2352847 09752261.9 Abandoned United Kingdom <br />European patent (EP) 09752261.9<br />Filed on 2009-11-10<br />Status: Abandoned 147167660 E-024-2009-0 E-024-2009-0-US-09 Gene Signature For Predicting Prognosis Of Patients With Solid Tumors DIV US 9,394,358 14/252,005 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9394358 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9394358">9,394,358</a><br />Filed on 2014-04-14<br />Status: Issued 147167661 E-024-2009-0 E-024-2009-0-EP-10 GENE SIGNATURE FOR PREDICTING PROGNOSIS OF PATIENTS WITH SOLID TUMORS DIV European Patent Administratively Closed European Patent <br />Divisional (DIV) <br />Filed on None<br />Status: Administratively Closed 147167662 E-024-2009-0 E-024-2009-0-DE-11 GENE SIGNATURE FOR PREDICTING PROGNOSIS OF PATIENTS WITH SOLID TUMORS EP Germany 2687609 13188475.1 Abandoned Germany <br />European patent (EP) 13188475.1<br />Filed on 2013-10-14<br />Status: Abandoned 147167663 E-024-2009-0 E-024-2009-0-FR-12 GENE SIGNATURE FOR PREDICTING PROGNOSIS OF PATIENTS WITH SOLID TUMORS EP France 2687609 13188475.1 Abandoned France <br />European patent (EP) 13188475.1<br />Filed on 2013-10-14<br />Status: Abandoned 147167664 E-024-2009-0 E-024-2009-0-GB-13 GENE SIGNATURE FOR PREDICTING PROGNOSIS OF PATIENTS WITH SOLID TUMORS EP United Kingdom 2687609 13188475.1 Abandoned United Kingdom <br />European patent (EP) 13188475.1<br />Filed on 2013-10-14<br />Status: Abandoned 147169687 Biomarker 147169689 driver gene 147169690 gene signature 147169691 HCC 147169693 hepatocellular carcinoma 147169694 prognostic TAB-4017 147157298 Dual Specific Anti-CD22 Anti-CD19 Bicistronic Chimeric Antigen Receptors (CARs) NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Terry Fry, Crystal Mackall, Haiying Qin <p>Treatment of B-cell acute lymphoblastic leukemia (ALL) and lymphoma using chimeric antigen receptors (CARs) targeting B-cell surface protein CD19 has demonstrated impressive clinical results in children and young adults. Despite the promising results from CD19 CAR therapy, up to 40% of patients, who initially achieve remission, eventually relapse. Relapse or non-response to CD19-directed CAR therapy may be due to low or diminished CD19 expression. Such patients would be predicted to benefit from CAR therapies targeting other B-cell surface proteins, such as CD22.</p> <p>Scientists at the National Cancer Institute’s (NCI) Pediatric Oncology Branch have developed a novel, bicistronic CAR construct targeting both CD19 and CD22 simultaneously. Specifically, the construct encodes both CD19 and CD22 on the same vector, ensuring comparable levels of targeting activity against both proteins. CAR-T cells produced with this construct eradicated relapsed ALL models, including one derived from a patient that displayed relapse after CD19-directed therapy. To date, this bicistronic approach exhibits the best results in CAR-T models of pre-B cell ALL.</p> <p>NCI is actively seeking parties interested in licensing this invention to commercialize the bicistronic CAR construct targeting CD19 and CD22 for immunotherapy.</p> <h2>Competitive Advantages:</h2> <ul><li>The leukemia/lymphoma market is in need of better second-line and maintenance therapies – representing significant opportunities for development within this treatment sector</li> <li>Overcomes durability of response – currently a major limitation – resulting from resistance mechanisms involving the downregulation of target antigen CD19 from tumor cell surfaces</li> <li>First demonstration of an active dual CAR targeting two naturally expressed antigens on ALL</li> <li>Bicistronic construct ensures that CARs will target both CD19 and CD22 efficiently</li> <li>CD19/CD22 bicistronic CAR demonstrated enhanced efficacy in an ALL xenograft model derived from a patient with relapse following CD19-directed therapy</li> <li>Successful ablation of ALL in various cell line and patient-derived xenograft models</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Treatment of acute lymphoblastic leukemia (ALL), the most common form of cancer for children</li> <li>Treatment of additional b cell malignancies including Diffuse Large B-Cell Lymphoma (DLBCL)</li> <li>Adoptive immunotherapy</li> </ul> 2019-07-25 2025-06-24 2021-03-01 2025-06-24 2019-07-25 Acute Lymphoblastic Leukemia, ALL, BICISTRONIC, CAR, CD19, CD22, Diffuse Large B-Cell Lymphoma, DLBCL, Dual-Specific Chimeric Antigen Receptors, Fry, Oncology, Pediatric Leukemia, Pediatric Lymphoma False True Clinical True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2021-03-01 72159138 Clinical Phase I 72159138 NCI 37470483 Website Abstract E-080-2008 E-106-2015 E-291-2012 147162216 Qin H, et al. Novel CD19/CD22 Bicistronic Chimeric Antigen Receptors Outperform Single or Bivalent CARs in Eradicating CD19+CD22+, CD19-, and CD22- Pre-B Leukemia. http://www.bloodjournal.org/content/130/Suppl_1/810?sso-checked=true <a href="http://www.bloodjournal.org/content/130/Suppl_1/810?sso-checked=true">Qin H, et al. Novel CD19/CD22 Bicistronic Chimeric Antigen Receptors Outperform Single or Bivalent CARs in Eradicating CD19+CD22+, CD19-, and CD22- Pre-B Leukemia.</a> 147163232 Qin, Haiying NCI - CCR NCI Qin, Haiying (NCI) 1 147163231 Fry, Terry NIH - NCI NCI Fry, Terry (NCI) 2 147163230 Mackall, Crystal NIH - NCI NCI Mackall, Crystal (NCI) 3 147163232 Qin, Haiying NCI - CCR NCI Qin, Haiying (NCI) 1 147163231 Fry, Terry NIH - NCI NCI Fry, Terry (NCI) 2 147163230 Mackall, Crystal NIH - NCI NCI Mackall, Crystal (NCI) 3 147157798 CD19/CD22 Bicistronic CAR Targeting Human B-cell Malignanices E-017-2017-0 Filing authorized NCI 121111111 Greene, Jaime greenejaime@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America greenejaime@mail.nih.gov?subject=Web Inquiry on [TAB-4017] Dual Specific Anti-CD22 Anti-CD19 Bicistronic Chimeric Antigen Receptors (CARs)&body=Please send me information about technology [TAB-4017] Dual Specific Anti-CD22 Anti-CD19 Bicistronic Chimeric Antigen Receptors (CARs).&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Greene, Jaime<br><a href="mailto:greenejaime@mail.nih.gov?subject=Web Inquiry on [TAB-4017] Dual Specific Anti-CD22 Anti-CD19 Bicistronic Chimeric Antigen Receptors (CARs)&body=Please send me information about technology [TAB-4017] Dual Specific Anti-CD22 Anti-CD19 Bicistronic Chimeric Antigen Receptors (CARs).&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">greenejaime@mail.nih.gov</a><br> 147160907 E-017-2017-0 E-017-2017-0-US-01 CHIMERIC ANTIGEN RECEPTORS AND THEIR USES PRV US 62/506,268 Abandoned US <br />Provisional (PRV) 62/506,268<br />Filed on 2017-05-15<br />Status: Abandoned 147166011 E-017-2017-0 E-017-2017-0-PCT-02 BICISTRONIC CHIMERIC ANTIGEN RECEPTORS AND THEIR USES PCT Patent Cooperation Treaty PCT/US2018/032809 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2018/032809<br />Filed on 2018-05-15<br />Status: Expired 147166012 E-017-2017-0 E-017-2017-0-AU-03 BICISTRONIC CHIMERIC ANTIGEN RECEPTORS AND THEIR USES National Stage Australia 2018269194 2018269194 Issued Australia <br />National Stage 2018269194<br />Filed on 2018-05-15<br />Status: Issued 147166013 E-017-2017-0 E-017-2017-0-CA-04 BICISTRONIC CHIMERIC ANTIGEN RECEPTORS AND THEIR USES National Stage Canada 3062433 Pending Canada <br />National Stage 3062433<br />Filed on 2018-05-15<br />Status: Pending 147166014 E-017-2017-0 E-017-2017-0-CN-05 CHIMERIC ANTIGEN RECEPTORS AND THEIR USES National Stage China ZL201880032676.5 201880032676.5 Issued China <br />National Stage 201880032676.5<br />Filed on 2018-05-15<br />Status: Issued 147166015 E-017-2017-0 E-017-2017-0-EP-06 CHIMERIC ANTIGEN RECEPTORS AND THEIR USES National Stage European Patent 18733012.1 Pending European Patent <br />National Stage 18733012.1<br />Filed on 2018-05-15<br />Status: Pending 147166016 E-017-2017-0 E-017-2017-0-JP-07 BICISTRONIC CHIMERIC ANTIGEN RECEPTORS AND THEIR USES National Stage Japan 7656401 2019-563082 Issued Japan <br />National Stage 2019-563082<br />Filed on 2018-05-15<br />Status: Issued 147166017 E-017-2017-0 E-017-2017-0-KR-08 BICISTRONIC CHIMERIC ANTIGEN RECEPTORS AND THEIR USES National Stage South Korea 10-2019-7036903 Pending South Korea <br />National Stage 10-2019-7036903<br />Filed on 2019-12-13<br />Status: Pending 147166018 E-017-2017-0 E-017-2017-0-SG-09 CHIMERIC ANTIGEN RECEPTORS AND THEIR USES National Stage Singapore 11201910499V Pending Singapore <br />National Stage 11201910499V<br />Filed on 2019-11-11<br />Status: Pending 147166019 E-017-2017-0 E-017-2017-0-US-10 BICISTRONIC CHIMERIC ANTIGEN RECEPTORS AND THEIR USES National Stage US 11,980,640 16/613,187 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11980640 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11980640">11,980,640</a><br />Filed on 2019-11-13<br />Status: Issued 147169570 Acute Lymphoblastic Leukemia 147169571 ALL 147169572 BICISTRONIC 147169573 CAR 147169574 CD19 147169575 CD22 147169577 Diffuse Large B-Cell Lymphoma 147169579 DLBCL 147169581 Dual-Specific Chimeric Antigen Receptors 147169583 Fry 147169584 Oncology 147169586 Pediatric Leukemia 147169588 Pediatric Lymphoma TAB-3910 147157190 Chimeric Antigen Receptors to CD276 for Treating Cancer NCI Licensing, Oncology, Therapeutics Licensing Oncology Therapeutics Yongzhi Cui, Crystal Mackall <p>Chimeric antigen receptors (CARs) are hybrid proteins consisting of an antibody binding fragment fused to protein signaling domains that cause T-cells which express the CAR to become cytotoxic.  Once activated, these cytotoxic T-cells can selectively eliminate the cells which they recognize via the antibody binding fragment of the CAR.  By engineering a T-cell to express a CAR that is specific for a certain cell surface protein, it is possible to selectively target those cells for destruction.  This is a promising new therapeutic approach known as adoptive cell therapy.<br />  <br /> CD276 (a.k.a., B7-H3) is a tumor-associated antigen that is expressed on the cell surface of several cancers, including neuroblastomas, prostate cancer, ovarian cancer and some lung cancers.  This technology concerns the development of CARs comprising an antigen-binding fragment derived from the MGA271 antibody.  The resulting CARs can be used in adoptive cell therapy treatment for neuroblastoma and other tumors which express CD276.</p> <h2>Competitive Advantages:</h2> <p>- MGA271 is a well characterized anti-CD276 antibody, making it a known quantity regarding safety issues<br /> - High affinity of the MGA271 antibody for CD276 increases the likelihood of successful targeting<br /> - Targeted therapy decreases non-specific killing of healthy, essential cells, resulting in fewer non-specific side-effects and healthier patients</p> <h2>Commercial Applications:</h2> <p>- Treatment of cancers associated with expression of CD276<br /> - Specific cancers include neuroblastoma, prostate cancer, ovarian cancer, lung cancer and other solid tumors</p> 2016-05-25 2025-06-24 2019-01-03 2025-06-24 2016-05-31 adoptive cell therapy, ANTIBODY, antigen-binding fragment, CAR, Neuroblastoma False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2019-01-03 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147162827 Mackall, Crystal NIH - NCI NCI Mackall, Crystal (NCI) 1 147162828 Cui, Yongzhi NIH - NCI NCI Cui, Yongzhi (NCI) 2 147162827 Mackall, Crystal NIH - NCI NCI Mackall, Crystal (NCI) 1 147162828 Cui, Yongzhi NIH - NCI NCI Cui, Yongzhi (NCI) 2 147158259 Chimeric Antigen Receptor (CAR) Targeting CD276 E-243-2015-0 Filing authorized NCI 83673032 Whitney, Laurie WhitneyL@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC WhitneyL@mail.nih.gov?subject=Web Inquiry on [TAB-3910] Chimeric Antigen Receptors to CD276 for Treating Cancer&body=Please send me information about technology [TAB-3910] Chimeric Antigen Receptors to CD276 for Treating Cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Whitney, Laurie<br><a href="mailto:WhitneyL@mail.nih.gov?subject=Web Inquiry on [TAB-3910] Chimeric Antigen Receptors to CD276 for Treating Cancer&body=Please send me information about technology [TAB-3910] Chimeric Antigen Receptors to CD276 for Treating Cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">WhitneyL@mail.nih.gov</a><br> 147161223 E-243-2015-0 E-243-2015-0-US-01 ANTI-CD276 CHIMERIC ANTIGEN RECEPTORS PRV US 62/216,447 Abandoned US <br />Provisional (PRV) 62/216,447<br />Filed on 2015-09-10<br />Status: Abandoned 147165181 E-243-2015-0 E-243-2015-0-PCT-02 Anti-CD276 Chimeric Antigen Receptors PCT Patent Cooperation Treaty PCT/US2016/050887 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2016/050887<br />Filed on 2016-09-09<br />Status: Expired 147165182 E-243-2015-0 E-243-2015-0-EP-03 Anti-CD276 Chimeric Antigen Receptors National Stage European Patent 3347375 16770410.5 Issued European Patent <br />National Stage 16770410.5<br />Filed on 2018-03-21<br />Status: Issued 147165183 E-243-2015-0 E-243-2015-0-US-04 ANTI-CD276 CHIMERIC ANTIGEN RECEPTORS National Stage US 10,562,952 15/757,728 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10562952 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10562952">10,562,952</a><br />Filed on 2018-03-06<br />Status: Issued 147165184 E-243-2015-0 E-243-2015-0-US-05 ANTI-CD276 CHIMERIC ANTIGEN RECEPTORS CON US 16/788,895 Abandoned US <br />Continuation (CON) 16/788,895<br />Filed on 2020-02-12<br />Status: Abandoned 147165185 E-243-2015-0 E-243-2015-0-DE-06 Anti-CD276 Chimeric Antigen Receptors EP Germany 3347375 16770410.5 Issued Germany <br />European patent (EP) 16770410.5<br />Filed on 2018-03-21<br />Status: Issued 147165186 E-243-2015-0 E-243-2015-0-FR-07 Anti-CD276 Chimeric Antigen Receptors EP France 3347375 16770410.5 Issued France <br />European patent (EP) 16770410.5<br />Filed on 2018-03-21<br />Status: Issued 147165187 E-243-2015-0 E-243-2015-0-GB-08 Anti-CD276 Chimeric Antigen Receptors EP United Kingdom 3347375 16770410.5 Issued United Kingdom <br />European patent (EP) 16770410.5<br />Filed on 2018-03-21<br />Status: Issued 147174140 adoptive cell therapy 147174141 ANTIBODY 147174143 antigen-binding fragment 147174144 CAR 147174145 Neuroblastoma TAB-5053 162400834 Zip14-AAV Genetic MRI Reporter System for Non-Invasive Cell & Gene-Therapy Tracking NINDS Diagnostics, Licensing, Neurology, Radiology, Therapeutics Diagnostics Licensing Neurology Radiology Therapeutics Raymond (Ray) Fields, Alan Koretsky, Harikrishna (Hari) Rallapalli <p><span style="font-size:11pt"><span style="line-height:107%"><span style="font-family:Calibri,sans-serif">This technology includes a gene-based magnetic resonance imaging (MRI) reporter platform that harnesses adeno-associated virus (AAV) delivery of the metal transporter Zip14 to create image contrast wherever the gene is expressed. By driving Zip14 from cell-specific promoters, investigators obtain robust, long-lasting signal changes on standard clinical MRI sequences (e.g., MPRAGE and GRE), enabling real-time visualization of living cells and their gene-expression patterns. Because no external contrast agents, exotic pulse sequences, or tissue implantation steps are required, the system simplifies longitudinal studies and reduces safety concerns. The modular design supports rapid retargeting to other tissues, providing a scalable solution for tracking gene-therapy vectors, regenerative processes, or engineered cell therapies. Overall, Zip14-AAV reporters bridge the gap between molecular biology and routine radiology, opening a clear path toward clinically translatable, image-guided therapeutics.</span></span></span></p> <ul> <li>Contrast-agent free: generates MRI signal intrinsically through Zip14 expression, eliminating the cost, toxicity, and regulatory hurdles of injectable agents.</li> <li>Plug-and-play with existing scanners: produces high-contrast images on widely used MRI sequences, avoiding specialized hardware or pulse-sequence development.</li> <li>Promoter-based specificity: interchangeable promoters let users target neurons, glia, or peripheral cell types for precise, longitudinal monitoring across disease models.</li> </ul> <ul> <li>Non-invasive validation and dose-finding for AAV-mediated gene therapies in pre-clinical and early-phase clinical trials.</li> <li>Live mapping of neural-circuit plasticity, neuroregeneration, and brain-injury recovery in central-nervous-system (CNS) research.</li> <li>Longitudinal tracking of engineered cell therapies (e.g., CAR-T, stem cells) or oncolytic viruses without radioactive or optical labels.</li> </ul> 2025-05-13 2025-06-18 2025-06-18 2025-06-18 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 162836072 Rallapalli et al., 2024 PMID: 38573932 https://pubmed.ncbi.nlm.nih.gov/38573932/ <a href="https://pubmed.ncbi.nlm.nih.gov/38573932/">Rallapalli et al., 2024 PMID: 38573932</a> 162400890 Rallapalli, Harikrishna (Hari) NINDS Rallapalli, Harikrishna (Hari) (NINDS) 1 162400894 Koretsky, Alan NINDS Koretsky, Alan (NINDS) 2 162835910 Fields, Raymond (Ray) NINDS Fields, Raymond (Ray) (NINDS) 3 162400890 Rallapalli, Harikrishna (Hari) NINDS Rallapalli, Harikrishna (Hari) (NINDS) 1 162400894 Koretsky, Alan NINDS Koretsky, Alan (NINDS) 2 162835910 Fields, Raymond (Ray) NINDS Fields, Raymond (Ray) (NINDS) 3 162400837 Genetic control of MRI signal E-047-2023-0 Filing authorized NINDS, NINDS 162983437 Genetic control of MRI signal E-047-2023-1 Filing authorized NINDS, NINDS 83667829 Ano, Susan susan.ano@nih.gov
United States of America susan.ano@nih.gov?subject=Web Inquiry on [TAB-5053] Zip14-AAV Genetic MRI Reporter System for Non-Invasive Cell & Gene-Therapy Tracking&body=Please send me information about technology [TAB-5053] Zip14-AAV Genetic MRI Reporter System for Non-Invasive Cell & Gene-Therapy Tracking. Ano, Susan<br><a href="mailto:susan.ano@nih.gov?subject=Web Inquiry on [TAB-5053] Zip14-AAV Genetic MRI Reporter System for Non-Invasive Cell & Gene-Therapy Tracking&body=Please send me information about technology [TAB-5053] Zip14-AAV Genetic MRI Reporter System for Non-Invasive Cell & Gene-Therapy Tracking.">susan.ano@nih.gov</a><br> 162400841 E-047-2023-0 E-047-2023-0-US-01 Genetic control of MRI signal PRV US 63/479,835 Expired US <br />Provisional (PRV) 63/479,835<br />Filed on 2023-01-13<br />Status: Expired 162983442 E-047-2023-1 E-047-2023-1-PC-01 Genetic control of MRI signal PCT Patent Cooperation Treaty PCT/US2024/011377 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2024/011377<br />Filed on 2024-01-12<br />Status: Expired 162983443 E-047-2023-1 E-047-2023-1-US-01 Genetic control of MRI signal National Stage US 19/147,173 Pending US <br />National Stage 19/147,173<br />Filed on 2025-07-10<br />Status: Pending 162983444 E-047-2023-1 E-047-2023-1-EP-01 Genetic control of MRI signal National Stage European Patent 24742070.6 Pending European Patent <br />National Stage 24742070.6<br />Filed on 2025-07-23<br />Status: Pending TAB-4592 151763486 Mouse model of TRIOBP Human Deafness for Research and Drug Discovery NIDCD Animal Models, Research Materials, Therapeutics Animal Models Research Materials Therapeutics Inna Belyantseva, Wade Chien, Thomas Friedman <p>This technology includes a mouse model of TRIOBP human deafness which can be used for research and treatment development for deafness. This model contains mutations altering the TRIOP-5 isoform.</p> Novel mouse model for this condition. Mouse model for research into human deafness. 2023-12-12 2024-08-12 2025-06-13 2024-03-27 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 151763494 Friedman, Thomas National Institute on Deafness and Other Communication Disorders (NIDCD) NIDCD Friedman, Thomas (NIDCD) 1 151763498 Chien, Wade National Institute on Deafness and Other Communication Disorders (NIDCD) NIDCD Chien, Wade (NIDCD) 2 151763502 Belyantseva, Inna National Institute on Deafness and Other Communication Disorders (NIDCD) NIDCD Belyantseva, Inna (NIDCD) 3 151763494 Friedman, Thomas National Institute on Deafness and Other Communication Disorders (NIDCD) NIDCD Friedman, Thomas (NIDCD) 1 151763498 Chien, Wade National Institute on Deafness and Other Communication Disorders (NIDCD) NIDCD Chien, Wade (NIDCD) 2 151763502 Belyantseva, Inna National Institute on Deafness and Other Communication Disorders (NIDCD) NIDCD Belyantseva, Inna (NIDCD) 3 151763489 TRIOBP-5 E-066-2019-0 Research Material National Institute on Deafness and Other Communication Disorders (NIDCD) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-4592] Mouse model of TRIOBP Human Deafness for Research and Drug Discovery&body=Please send me information about technology [TAB-4592] Mouse model of TRIOBP Human Deafness for Research and Drug Discovery. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-4592] Mouse model of TRIOBP Human Deafness for Research and Drug Discovery&body=Please send me information about technology [TAB-4592] Mouse model of TRIOBP Human Deafness for Research and Drug Discovery.">shmilovm@nih.gov</a><br> TAB-2498 114096694 Novel Small Molecule Agonists of the Relaxin Receptor as Potential Therapy for Heart Failure and Fibrosis NCATS Cardiology, Collaboration, Diagnostics, Immunology, Reproductive Health, Research Materials, Therapeutics, Vaccines Cardiology Collaboration Diagnostics Immunology Reproductive Health Research Materials Therapeutics Vaccines Alexander Agoulnik, Catherine Chen, Marc Ferrer-Alegre, Juan Marugan, Noel Southall, Jingbo Xiao, Wei Zheng The present invention is directed to novel small molecule agonists of the mammalian relaxin family receptor 1 (RXFP1), including human RXFP1. Activation of RXFP1 induces: 1) vasodilation due to up-regulation of the endothelin system; 2) extracellular matrix remodeling; 3) moderation of inflammation by reducing levels of inflammatory cytokines; and 4) angiogenesis. Small molecule agonists of RXFP1 may be useful in treating acute heart failure (AHF), scleroderma, fibrosis, other conditions associated with the biology of relaxin, and in improving reproductive health and wound healing. These compounds are the first and only small molecule agonists of RXFP1. <ul> <li>First and only small molecule agonists of RXFP1</li> <li>Potent and highly selective </li> <li>Bioavailable with excellent exposure</li> <li>Easy to synthesize and scale-up</li> </ul> <ul> <li>Cardiovascular diseases</li> <li>Ischemia</li> <li>Fibrosis</li> <li>Inflammation</li> <li>Acute heart failure</li> <li>Human and animal reproductive health</li> </ul> The National Center for Advancing Translational Sciences is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize small molecule agonists of RXFP1. For collaboration opportunities, please contact Krishna (Balki) Balakrishnan, Ph.D. at 301-217-2336 or <a href="mailto:balki@nih.gov">balki@nih.gov</a>. 2022-03-08 2025-06-12 2025-06-12 2012-11-16 1, IB1XXX, IB3XXX, IB5XXX, IB6XXX, IBXXXX, IXXXXX, MODULATORS, POTENT, RECEPTOR, Relaxin, RXFP1, SELECTIVE False True <ul> <li>Early-stage</li> <li>In vitro data available</li> <li>In vivo data available (animal)</li> </ul> True 52398218 Pre-Clinical (in vivo) 52398218 NIHTT 37470483 Website Abstract 114170480 Xiao J, et al. http://www.ncbi.nlm.nih.gov/pubmed/23764525 <a href="http://www.ncbi.nlm.nih.gov/pubmed/23764525">Xiao J, et al.</a> 114171717 Chen CZ, et al. http://www.ncbi.nlm.nih.gov/pubmed/23212924 <a href="http://www.ncbi.nlm.nih.gov/pubmed/23212924">Chen CZ, et al.</a> 114107704 Zheng, Wei National Human Genome Research Institute (NHGRI) NCATS Zheng, Wei (NCATS) 0 114107705 Ferrer-Alegre, Marc NCATS - NCGC NCATS Ferrer-Alegre, Marc (NCATS) 0 114107706 Chen, Catherine National Human Genome Research Institute (NHGRI) Chen, Catherine 0 114107707 Agoulnik, Alexander Florida International University (FIU) Agoulnik, Alexander 0 114107708 Southall, Noel National Human Genome Research Institute (NHGRI) NCATS Southall, Noel (NCATS) 0 114107709 Xiao, Jingbo National Human Genome Research Institute (NHGRI) FDA Xiao, Jingbo (FDA) 0 114107703 Marugan, Juan National Human Genome Research Institute (NHGRI) NCATS Marugan, Juan (NCATS) 1 114107703 Marugan, Juan National Human Genome Research Institute (NHGRI) NCATS Marugan, Juan (NCATS) 1 114107704 Zheng, Wei National Human Genome Research Institute (NHGRI) NCATS Zheng, Wei (NCATS) 0 114107705 Ferrer-Alegre, Marc NCATS - NCGC NCATS Ferrer-Alegre, Marc (NCATS) 0 114107706 Chen, Catherine National Human Genome Research Institute (NHGRI) Chen, Catherine 0 114107707 Agoulnik, Alexander Florida International University (FIU) Agoulnik, Alexander 0 114107708 Southall, Noel National Human Genome Research Institute (NHGRI) NCATS Southall, Noel (NCATS) 0 114107709 Xiao, Jingbo National Human Genome Research Institute (NHGRI) FDA Xiao, Jingbo (FDA) 0 114101808 Selective And Potent Modulators Of The Relaxin Receptor 1 (RXFP1) E-072-2012-0 Filing authorized Florida International University (FIU), NCATS - NCGC 93911356 Kalsi, Jasmine jasmine.kalsi@nih.gov
United States of America jasmine.kalsi@nih.gov?subject=Web Inquiry on [TAB-2498] Novel Small Molecule Agonists of the Relaxin Receptor as Potential Therapy for Heart Failure and Fibrosis&body=Please send me information about technology [TAB-2498] Novel Small Molecule Agonists of the Relaxin Receptor as Potential Therapy for Heart Failure and Fibrosis. Kalsi, Jasmine<br><a href="mailto:jasmine.kalsi@nih.gov?subject=Web Inquiry on [TAB-2498] Novel Small Molecule Agonists of the Relaxin Receptor as Potential Therapy for Heart Failure and Fibrosis&body=Please send me information about technology [TAB-2498] Novel Small Molecule Agonists of the Relaxin Receptor as Potential Therapy for Heart Failure and Fibrosis.">jasmine.kalsi@nih.gov</a><br> 114166901 E-072-2012-0 E-072-2012-0-US-01 Modulators Of The Relaxin Receptor 1 PRV US 61/642,986 Abandoned US <br />Provisional (PRV) 61/642,986<br />Filed on 2012-05-04<br />Status: Abandoned 114167023 E-072-2012-0 E-072-2012-0-PCT-02 Modulators Of The Relaxin Receptor 1 PCT Patent Cooperation Treaty PCT/US13/32231 Expired Patent Cooperation Treaty <br />(PCT) PCT/US13/32231<br />Filed on 2013-03-15<br />Status: Expired 114167175 E-072-2012-0 E-072-2012-0-US-05 Modulators of the Relaxin Receptor 1 CON US 10,125,112 15/247,438 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10125112 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10125112">10,125,112</a><br />Filed on 2016-08-25<br />Status: Issued 114167993 E-072-2012-0 E-072-2012-0-US-04 Modulators Of The Relaxin Receptor 1 National Stage US 9,452,973 14/398,830 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9452973 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9452973">9,452,973</a><br />Filed on 2014-11-04<br />Status: Issued 114122997 IXXXXX 114122998 IBXXXX 114122999 IB1XXX 114123000 IB3XXX 114123001 IB5XXX 114123002 IB6XXX 114143658 SELECTIVE 114143659 POTENT 114143660 MODULATORS 114143661 Relaxin 114143662 RECEPTOR 114143663 1 114143664 RXFP1 TAB-5051 162369152 Nanobody–Antiviral Peptide Conjugates for Potent HIV Entry Inhibition NIDDK Collaboration, Immunology, Infectious Disease, Licensing, Reproductive Health, Research Materials, Therapeutics Collaboration Immunology Infectious Disease Licensing Reproductive Health Research Materials Therapeutics Ross Cheloha, Shubhra Saha <p><span style="font-size:11pt"><span style="line-height:107%"><span style="font-family:Calibri,sans-serif">This technology includes a new class of nanobody&ndash;antiviral peptide conjugates that block HIV from infecting human CD4⁺ T-cells, positioning them for future therapeutic and prophylactic use. Nanobodies&mdash;single-domain antibody fragments&mdash;guide the drug to the virus&rsquo;s docking site and impede receptor binding, while the linked peptide halts the membrane-fusion step, creating a one-two punch against viral entry. In cell-based infection assays the conjugates are markedly more potent than either the peptide alone or a widely used broadly neutralizing anti-HIV antibody, enabling lower dosing and reduced systemic toxicity. Because the construct strikes two independent stages of the viral life-cycle, it raises the genetic barrier to resistance that limits existing treatments. The modular chemistry also allows rapid retargeting to emerging HIV strains or other enveloped viruses.</span></span></span></p> <ul> <li>Dual-mechanism action (receptor blockade + fusion inhibition) dramatically reduces the likelihood of viral resistance compared with single-target drugs.</li> <li>>10× higher potency than standalone antiviral peptides in vitro, supporting lower therapeutic doses and a better safety profile.</li> <li>Scalable, plug-and-play conjugation platform that can be re-engineered for new HIV variants or other clinically relevant viruses.</li> </ul> <ul> <li>Long-acting injectable or topical HIV therapeutics for treatment and pre-exposure prophylaxis (PrEP).</li> <li>Ex vivo protection of donor cells or engineered cell therapies susceptible to HIV infection.</li> <li>Laboratory or fertility-clinic reagent to prevent HIV transmission during assisted reproductive procedures.</li> </ul> 2025-05-13 2025-05-14 2025-06-11 2025-05-14 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 162369187 Umotoy et al., 2021 PMID: 34276704 https://pubmed.ncbi.nlm.nih.gov/34276704/ <a href="https://pubmed.ncbi.nlm.nih.gov/34276704/">Umotoy et al., 2021 PMID: 34276704</a> 162369174 Cheloha, Ross National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Cheloha, Ross 1 162369178 Saha, Shubhra National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Saha, Shubhra (NIDDK) 2 162369174 Cheloha, Ross National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Cheloha, Ross 1 162369178 Saha, Shubhra National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Saha, Shubhra (NIDDK) 2 162369155 Nanobody-antiviral peptide conjugates to block HIV infection E-003-2024-0 Filing authorized National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83692066 Tong, Betty tongb@niddk.nih.gov
United States of America Senior Technology Advancement Office tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-5051] Nanobody–Antiviral Peptide Conjugates for Potent HIV Entry Inhibition&body=Please send me information about technology [TAB-5051] Nanobody–Antiviral Peptide Conjugates for Potent HIV Entry Inhibition. Tong, Betty<br><a href="mailto:tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-5051] Nanobody–Antiviral Peptide Conjugates for Potent HIV Entry Inhibition&body=Please send me information about technology [TAB-5051] Nanobody–Antiviral Peptide Conjugates for Potent HIV Entry Inhibition.">tongb@niddk.nih.gov</a><br> 162369160 E-003-2024-0 E-003-2024-0-US-01 POLYPEPTIDE CONSTRUCTS WITH POTENT ANTI-HIV ACTIVITY PRV US 63/563,741 Expired US <br />Provisional (PRV) 63/563,741<br />Filed on 2024-03-11<br />Status: Expired 162369161 E-003-2024-0 E-003-2024-0-PC-01 POLYPEPTIDE CONSTRUCTS WITH POTENT ANTI-HIV ACTIVITY PCT Patent Cooperation Treaty PCT/US2025/019228 Pending Patent Cooperation Treaty <br />(PCT) PCT/US2025/019228<br />Filed on 2025-03-10<br />Status: Pending TAB-3846 145531401 Selective A3 Adenosine Receptor Agonists for the Treatment of Chronic Neuropathic Pain and Other Conditions NIDDK Application, Cardiology, Collaboration, Dermatology, Immunology, Licensing, Oncology, Therapeutics Application Cardiology Collaboration Dermatology Immunology Licensing Oncology Therapeutics Kenneth Jacobson, Daniela Salvemini, Dilip Tosh <p>This technology includes the creation and use of A3 adenosine receptor (A3AR)-selective agonists for treating chemotherapy-induced peripheral neuropathy, chronic neuropathic pain, rheumatoid arthritis, psoriasis, and other conditions. A3 receptors for adenosine are found in most cells and endogenous activation of the A3 receptors can result in apoptosis, thereby relieving the inflammation or targeting a tumor. A3AR agonists have been a promising strategy for the treatment of various diseases. A3AR agonists can reverse neuropathic pain by modulating the production of anti-inflammatory cytokines such as IL-10. A3AR agonists can also induce apoptosis of cancer and inflammatory cells by disrupting the Wnt and NF-KB signaling pathways. The current invention includes A3AR-selective agonists that are methanocarba derivatives. This class of compounds has been shown to be highly selective for A3AR (>3000-fold affinity versus A1AR and A2AAR). This selectively is retained in mice (400-fold affinity versus A1AR), facilitating preclinical development.</p> This class of compounds produced full agonists of the human A3AR of nanomolar affinity that were consistently highly selective (>3000-fold vs. A1AR and A2AAR). The selectivity at mouse A3 receptors is retained but lower. The compounds are still effective in vivo in reducing or preventing the development of neuropathic pain. Phenotypic screening has identified in vivo activity of specific C2 substituents in a chronic neuropathic pain model. Opioid analgesics in combination with A3 agonists have reduced side effects. A3AR-selective agonists are currently in advanced clinical trials for the treatment of hepatocellular carcinoma, autoimmune inflammatory diseases (such as rheumatoid arthritis), psoriasis, dry eye disease, and other conditions. Other potential applications of such agonists could be osteoarthritis, Crohn's disease, ischemia, and other inflammatory disorders. We are seeking statements of capability or interest from parties interested in collaborative research to further developer, evaluate, or commercialize this technology. 2023-05-23 2024-08-12 2025-06-11 2023-05-23 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract E-140-2008-0 E-140-2008-1 E-742-2013-0 145531602 Tosh DK, Salmaso V, Rao H, et al., 2020 https://pubmed.ncbi.nlm.nih.gov/33062176/ <a href="https://pubmed.ncbi.nlm.nih.gov/33062176/">Tosh DK, Salmaso V, Rao H, et al., 2020</a> 145531615 Doyle TM, Largent-Milnes TM, Chen Z, et al., 2020 https://pubmed.ncbi.nlm.nih.gov/32434943/ <a href="https://pubmed.ncbi.nlm.nih.gov/32434943/">Doyle TM, Largent-Milnes TM, Chen Z, et al., 2020</a> 145531621 Tosh DK, Finley A, Paoletta S, et al., 2014 https://pubmed.ncbi.nlm.nih.gov/25422861/ <a href="https://pubmed.ncbi.nlm.nih.gov/25422861/">Tosh DK, Finley A, Paoletta S, et al., 2014</a> 145531557 Salvemini, Daniela Saint Louis University School of Medicine Salvemini, Daniela 1 145531567 Tosh, Dilip National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Tosh, Dilip (NIDDK) 2 145531587 Jacobson, Kenneth National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Jacobson, Kenneth (NIDDK) 3 145531557 Salvemini, Daniela Saint Louis University School of Medicine Salvemini, Daniela 1 145531567 Tosh, Dilip National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Tosh, Dilip (NIDDK) 2 145531587 Jacobson, Kenneth National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Jacobson, Kenneth (NIDDK) 3 145531404 Design Of (N)-Methanocarba Adenosine 5'Uronamides As Species-Independent A3 Receptor-Selective Agonists E-140-2008-0 Filing authorized National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83692066 Tong, Betty tongb@niddk.nih.gov
United States of America Senior Technology Advancement Office tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-3846] Selective A3 Adenosine Receptor Agonists for the Treatment of Chronic Neuropathic Pain and Other Conditions&body=Please send me information about technology [TAB-3846] Selective A3 Adenosine Receptor Agonists for the Treatment of Chronic Neuropathic Pain and Other Conditions. Tong, Betty<br><a href="mailto:tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-3846] Selective A3 Adenosine Receptor Agonists for the Treatment of Chronic Neuropathic Pain and Other Conditions&body=Please send me information about technology [TAB-3846] Selective A3 Adenosine Receptor Agonists for the Treatment of Chronic Neuropathic Pain and Other Conditions.">tongb@niddk.nih.gov</a><br> 157764689 E-140-2008-0 E-140-2008-0-US-01 Adenosine Receptor Agonists PRV US 61/040,985 Abandoned US <br />Provisional (PRV) 61/040,985<br />Filed on 2008-03-31<br />Status: Abandoned 157764694 E-140-2008-0 E-140-2008-0-PCT-02 Design Of (N)-Methanocarba Adenosine 5'Uronamides As Species-Independent A3 Receptor-Selective Agonists PCT Patent Cooperation Treaty PCT/US2009/038026 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2009/038026<br />Filed on 2009-03-24<br />Status: Expired 157764699 E-140-2008-0 E-140-2008-0-AU-03 Purine Derivatives As A3 Adenosine Receptor-Selective Agonists National Stage Australia 2009231978 2009231978 Issued Australia <br />National Stage 2009231978<br />Filed on 2009-03-24<br />Status: Issued 157764704 E-140-2008-0 E-140-2008-0-CA-04 Purine Derivatives As A3 Adenosine Receptor-Selective Agonists National Stage Canada 2720037 2720037 Issued Canada <br />National Stage 2720037<br />Filed on 2009-03-24<br />Status: Issued 157764709 E-140-2008-0 E-140-2008-0-EP-05 Purine Derivatives As A3 Adenosine Receptor-Selective Agonists National Stage European Patent 2260038 09728154.7 Issued European Patent <br />National Stage 09728154.7<br />Filed on 2009-03-24<br />Status: Issued 157764714 E-140-2008-0 E-140-2008-0-US-06 Purine Derivatives As A3 Adenosine Receptor-Selective Agonists National Stage US 8,735,407 12/935,461 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8735407 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8735407">8,735,407</a><br />Filed on 2010-11-01<br />Status: Issued 157764719 E-140-2008-0 E-140-2008-0-DE-07 Purine Derivatives As A3 Adenosine Receptor-Selective Agonists EP Germany 2260038 09728154.7 Issued Germany <br />European patent (EP) 09728154.7<br />Filed on 2009-03-24<br />Status: Issued 157764724 E-140-2008-0 E-140-2008-0-ES-08 Purine Derivatives As A3 Adenosine Receptor-Selective Agonists EP Spain 2260038 09728154.7 Issued Spain <br />European patent (EP) 09728154.7<br />Filed on 2009-03-24<br />Status: Issued 157764729 E-140-2008-0 E-140-2008-0-FR-09 Purine Derivatives As A3 Adenosine Receptor-Selective Agonists EP France 2260038 09728154.7 Issued France <br />European patent (EP) 09728154.7<br />Filed on 2009-03-24<br />Status: Issued 157764734 E-140-2008-0 E-140-2008-0-GB-10 Purine Derivatives As A3 Adenosine Receptor-Selective Agonists EP United Kingdom 2260038 09728154.7 Issued United Kingdom <br />European patent (EP) 09728154.7<br />Filed on 2009-03-24<br />Status: Issued 157764739 E-140-2008-0 E-140-2008-0-IT-11 Purine Derivatives As A3 Adenosine Receptor-Selective Agonists EP Italy 2260038 09728154.7 Issued Italy <br />European patent (EP) 09728154.7<br />Filed on 2009-03-24<br />Status: Issued TAB-3845 145529878 P2Y14 Receptor Antagonists for the Treatment of Inflammatory Diseases, Including Pulmonary and Renal Conditions and Chronic Pain NIDDK Collaboration, Endocrinology, Licensing, Metabolic Disease, Neurology, Pulmonology, Respiratory, Therapeutics Collaboration Endocrinology Licensing Metabolic Disease Neurology Pulmonology Respiratory Therapeutics Kenneth Jacobson, Young-Hwan Jung, Zhiwei Wen <p>This technology includes the development of selective P2Y14R antagonists for the treatment of asthma, sterile inflammation of the kidney, diabetes, and neurodegeneration. The P2Y14 receptor (P2Y14R) is a target for the treatment of inflammatory diseases, including pulmonary and renal conditions. Selective P2Y14R antagonists have demonstrated efficacy in animal models of asthma, pain, diabetes, and acute kidney injury. However, the prototypical antagonist is not optimal for in vivo administration, as it displays a low oral bioavailability. This invention includes P2Y14R antagonists that contain sterically constrained, bridged piperidine modifications or uncharged bioisosteres of the piperidine moiety. This approach aligns with a general trend to improve druglikeness in medicinal chemistry by adding three-dimensionality to otherwise flat molecules. We also invented prodrugs of the most potent analogs that display significant in vivo activity.</p> A selective antagonist for the P2Y14 receptor is a potentially useful treatment for patients with neuropathic pain. Current FDA-approved drugs for the treatment of neuropathic pain are not very effective. <ul> <li>The invention covers drugs that are selective antagonists for the P2Y14 receptor. These compounds may provide a treatment for patients with various disease conditions, including lung inflammation, kidney inflammation, asthma, diabetes, obesity, and neuropathic pain of diverse states.</li> <li>The use of P2Y14 receptor antagonists may improve metabolic disorders. Mouse models of metabolic disorders have shown improvement upon treatment with P2Y14 receptor antagonists.</li> </ul> We are seeking statements of capability or interest from parties interested in collaborative research to further developer, evaluate, or commercialize this technology. 2023-05-23 2024-08-12 2025-06-11 2023-05-23 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract E-051-2021-0 145530846 Wen Z, Salmaso V, Jung Y-H, et al., 2022 https://pubmed.ncbi.nlm.nih.gov/35113556/ <a href="https://pubmed.ncbi.nlm.nih.gov/35113556/">Wen Z, Salmaso V, Jung Y-H, et al., 2022</a> 145530850 Jung Y-H, Salmaso V, Wen Z, et al., 2021 https://pubmed.ncbi.nlm.nih.gov/33787273/ <a href="https://pubmed.ncbi.nlm.nih.gov/33787273/">Jung Y-H, Salmaso V, Wen Z, et al., 2021</a> 145530853 Mufti F, Jung YH, Giancotti LA, et al 2020 https://pubmed.ncbi.nlm.nih.gov/32551012/ <a href="https://pubmed.ncbi.nlm.nih.gov/32551012/">Mufti F, Jung YH, Giancotti LA, et al 2020</a> 145530782 Jung, Young-Hwan National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Jung, Young-Hwan (NIDDK) 1 145530791 Wen, Zhiwei National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Wen, Zhiwei (NIDDK) 2 145530795 Jacobson, Kenneth National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Jacobson, Kenneth (NIDDK) 3 145530782 Jung, Young-Hwan National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Jung, Young-Hwan (NIDDK) 1 145530791 Wen, Zhiwei National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Wen, Zhiwei (NIDDK) 2 145530795 Jacobson, Kenneth National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Jacobson, Kenneth (NIDDK) 3 145529881 Heterocyclic P2Y14 Antagonists E-051-2021-0 Filing authorized National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83692066 Tong, Betty tongb@niddk.nih.gov
United States of America Senior Technology Advancement Office tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-3845] P2Y14 Receptor Antagonists for the Treatment of Inflammatory Diseases, Including Pulmonary and Renal Conditions and Chronic Pain&body=Please send me information about technology [TAB-3845] P2Y14 Receptor Antagonists for the Treatment of Inflammatory Diseases, Including Pulmonary and Renal Conditions and Chronic Pain. Tong, Betty<br><a href="mailto:tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-3845] P2Y14 Receptor Antagonists for the Treatment of Inflammatory Diseases, Including Pulmonary and Renal Conditions and Chronic Pain&body=Please send me information about technology [TAB-3845] P2Y14 Receptor Antagonists for the Treatment of Inflammatory Diseases, Including Pulmonary and Renal Conditions and Chronic Pain.">tongb@niddk.nih.gov</a><br> 157764643 E-051-2021-0 E-051-2021-0-US-01 Heterocyclic P2Y14 Antagonists PRV US 63/138,581 Abandoned US <br />Provisional (PRV) 63/138,581<br />Filed on 2021-01-18<br />Status: Abandoned 157764648 E-051-2021-0 E-051-2021-0-PCT-01 HETEROCYCLIC P2Y14 RECEPTOR ANTAGONISTS PCT COMB Patent Cooperation Treaty PCT/US2022/011226 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2022/011226<br />Filed on 2022-01-05<br />Status: Expired 157764653 E-051-2021-0 E-051-2021-0-CA-01 HETEROCYCLIC P2Y14 RECEPTOR ANTAGONISTS National Stage Canada 3208662 Abandoned Canada <br />National Stage 3208662<br />Filed on 2023-07-18<br />Status: Abandoned 157764658 E-051-2021-0 E-051-2021-0-AU-01 HETEROCYCLIC P2Y14 RECEPTOR ANTAGONISTS National Stage Australia 2022207045 Abandoned Australia <br />National Stage 2022207045<br />Filed on 2023-07-21<br />Status: Abandoned 157764663 E-051-2021-0 E-051-2021-0-CN-01 HETEROCYCLIC P2Y14 RECEPTOR ANTAGONISTS National Stage China 202280020636.5 Abandoned China <br />National Stage 202280020636.5<br />Filed on 2023-09-11<br />Status: Abandoned 157764668 E-051-2021-0 E-051-2021-0-US-02 HETEROCYCLIC P2Y14 RECEPTOR ANTAGONISTS National Stage US 18/272,435 Pending US <br />National Stage 18/272,435<br />Filed on 2023-07-14<br />Status: Pending 157764673 E-051-2021-0 E-051-2021-0-EP-01 HETEROCYCLIC P2Y14 RECEPTOR ANTAGONISTS National Stage European Patent 22701105.3 Abandoned European Patent <br />National Stage 22701105.3<br />Filed on 2023-08-07<br />Status: Abandoned 157764678 E-051-2021-0 E-051-2021-0-EP-02 HETEROCYCLIC P2Y14 RECEPTOR ANTAGONISTS DIV European Patent 24185703.6 Pending European Patent <br />Divisional (DIV) 24185703.6<br />Filed on 2024-07-01<br />Status: Pending TAB-4465 149722478 Multichannel Individualized Seizure Therapy (MIST) Device NIMH Medical Devices, Neurology, Psychiatry/Mental Health, Therapeutics Medical Devices Neurology Psychiatry/Mental Health Therapeutics Zhi-De Deng, George Dold, Junghee Kim, Sarah Lisanby, Bruce Pritchard, Robert Schor <p>The Multichannel Individualized Stimulation Therapy (MIST) device is a multichannel electrical stimulation system that can be used for targeted, individualized electroconvulsive therapy (ECT), especially for treatment-resistant depression (TRD). Millions of individuals suffer from TRD, for which ECT is often the most efficacious and rapidly acting treatment option.</p> <p>Present clinical ECT devices use a single-channel to deliver strong electric fields broadly distributed throughout brain, producing significant memory loss and variability in clinical outcomes. These challenges result in the underutilization of this highly effective treatment. MIST is the first multichannel ECT device to address these limitations by delivering flexible and multi- focal stimulation, which has the potential to maximize clinical efficacy and minimize side effects. Thus, the technology represents a much more desirable method for delivering seizure therapy for those suffering from severe depression, which affects over 280 million people worldwide, and other serious disorders.</p> <ul> Only known multichannel ECT system that: <li>Delivers flexible and multi-focal stimulation to optimally target brain structures</li> <li>Uses targeted stimulation to mediate antidepressant action of ECT, while reducing cognitive side effects</li> <li>Uses computational models to inform personalized dosing that greatly reduces erratic ECT clinical outcome by accounting for inter-individual anatomical variability (provides an advantage over conventional fixed current-amplitude dosing)</li> <ul> <ul> Treatment of a broad range of clinical disorders for which ECT has shown efficacy, including: <li>Treatment Resistant Depression (TRD)</li> <li>Major Depressive Episode associated with major depressive disorder (MDD) or bipolar disorder (BP)</li> <li>Catatonia</li> <li>Schizophrenia</li> <li>Schizoaffective disorder</li> <li>Schizophreniform disorder</li> <li>Status epilepticus</li> </ul> The National Institute of Mental Health is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize electroconvulsive therapy devices. For collaboration opportunities, please contact: Anton Dawson, Ph.D.; 301-339-3200, anton.dawson@nih.gov 2023-09-19 2023-09-21 2025-06-11 2023-09-21 False False True 52406769 Prototype 52406769 37470483 Website Abstract 149748528 J. Kim, B. A. Pritchard, R. H. Schor, G. R. Dold, S. H. Lisanby, and Z.-D. Deng, "Multichannel Individualized Stimulation Therapy (MIST) System for treatment of depression". Annual Conference of the IEEE Engineering in Medicine and Biology Society, July 2023. J. Kim, B. A. Pritchard, R. H. Schor, G. R. Dold, S. H. Lisanby, and Z.-D. Deng, "Multichannel Individualized Stimulation Therapy (MIST) System for treatment of depression". Annual Conference of the IEEE Engineering in Medicine and Biology Society, July 2023. 149733798 Deng, Zhi-De National Institute of Mental Health (NIMH) NIMH Deng, Zhi-De (NIMH) 1 149734965 Dold, George National Institute of Mental Health (NIMH) NIMH Dold, George (NIMH) 2 149738269 Kim, Junghee National Institute of Mental Health (NIMH) NIMH Kim, Junghee (NIMH) 3 149738769 Lisanby, Sarah National Institute of Mental Health (NIMH) NIMH Lisanby, Sarah (NIMH) 4 150189349 Pritchard, Bruce National Institute of Mental Health (NIMH) NIMH Pritchard, Bruce (NIMH) 5 150189359 Schor, Robert National Institute of Mental Health (NIMH) NIMH Schor, Robert (NIMH) 6 149733798 Deng, Zhi-De National Institute of Mental Health (NIMH) NIMH Deng, Zhi-De (NIMH) 1 149734965 Dold, George National Institute of Mental Health (NIMH) NIMH Dold, George (NIMH) 2 149738269 Kim, Junghee National Institute of Mental Health (NIMH) NIMH Kim, Junghee (NIMH) 3 149738769 Lisanby, Sarah National Institute of Mental Health (NIMH) NIMH Lisanby, Sarah (NIMH) 4 150189349 Pritchard, Bruce National Institute of Mental Health (NIMH) NIMH Pritchard, Bruce (NIMH) 5 150189359 Schor, Robert National Institute of Mental Health (NIMH) NIMH Schor, Robert (NIMH) 6 149722516 Multichannel Individualized Seizure Therapy (MIST) E-070-2023-0 Filing authorized National Institute of Mental Health (NIMH), National Institute of Mental Health (NIMH), National Institute of Mental Health (NIMH) 83739514 Dawson, Anton anton.dawson@nih.gov
United States of America anton.dawson@nih.gov?subject=Web Inquiry on [TAB-4465] Multichannel Individualized Seizure Therapy (MIST) Device&body=Please send me information about technology [TAB-4465] Multichannel Individualized Seizure Therapy (MIST) Device. Dawson, Anton<br><a href="mailto:anton.dawson@nih.gov?subject=Web Inquiry on [TAB-4465] Multichannel Individualized Seizure Therapy (MIST) Device&body=Please send me information about technology [TAB-4465] Multichannel Individualized Seizure Therapy (MIST) Device.">anton.dawson@nih.gov</a><br> 152712474 E-070-2023-0 E-070-2023-0-PC-01 SYSTEMS AND METHODS FOR MULTICHANNEL INDIVIDUALIZED STIMULATION THERAPY PCT Patent Cooperation Treaty PCT/US2024/023876 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2024/023876<br />Filed on 2024-04-10<br />Status: Expired 162873108 E-070-2023-0 E-070-2023-0-US-02 SYSTEMS AND METHODS FOR MULTICHANNEL INDIVIDUALIZED STIMULATION THERAPY National Stage US 19/474,167 Pending US <br />National Stage 19/474,167<br />Filed on 2025-10-09<br />Status: Pending 162874211 E-070-2023-0 E-070-2023-0-EP-01 SYSTEMS AND METHODS FOR MULTICHANNEL INDIVIDUALIZED STIMULATION THERAPY National Stage European Patent 24723369.5 Pending European Patent <br />National Stage 24723369.5<br />Filed on 2025-10-16<br />Status: Pending TAB-5044 160834770 Precision, Optimally Targeted, ElectroConvulsive Therapy (PROTECT) NIMH Zhi-De Deng, George Dold, Junghee Kim, Sarah Lisanby, Bruce Pritchard, Robert Schor <p style="font-family:Arial Narrow; font-size:16px"><span style="font-size:12pt"><span style="tab-stops:28.0pt 56.0pt 84.0pt 112.0pt 140.0pt 168.0pt 196.0pt 224.0pt 3.5in 280.0pt 308.0pt 336.0pt"><span style="text-autospace:none"><span style="font-family:&quot;Times New Roman&quot;,serif">The PRecision, Optimally Targeted Electroconvulsive Therapy (PROTECT) is a novel stimulator device, which aims to improve the treatment of treatment-resistant depression (TRD). Millions of individuals suffer from TRD for which electroconvulsive therapy (ECT) is often the most efficacious treatment option; yet present devices lack precision in electric field delivery, leading to variable outcomes and cognitive side effects. PROTECT is a next-generation stimulator designed to revolutionize ECT through its novel waveforms and pulse patterns, which optimize brain stimulation with unparalleled precision. By integrating cutting-edge computational modeling and advanced hardware, PROTECT enables customized stimulation paradigms, enhancing efficacy while reducing unwanted side effects. This technology sets a new standard for ECT, offering clinicians and patients a more targeted, effective, and personalized approach to treatment.</span></span></span></span></p> First ECT device of its kind to: <ul> <li>offer both conventional AND complex stimulation patterns along with advanced computational modeling</li> <li>be complemented with state-of-the-art computational E-field modeling and optimization algorithms that can used to achieve optimized dosimetry for seizure therapy</li> <li>allow individualized dosing to maximize therapeutic effect, while reducing side effects of convention ECT</li> </ul> Treatment of a broad range of clinical disorders for which ECT has shown efficacy, including: <ul> <li>Treatment Resistant Depression (TRD) </li> <li>Major Depressive Episode associated with major depressive disorder (MDD) or bipolar disorder (BP) </li> <li>Catatonia</li> <li>Schizophrenia</li> <li>Schizoaffective disorder</li> <li>Schizophreniform disorder</li> <li>Status epilepticus</li> </ul> The National Institute of Mental Health is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology: electroconvulsive therapy devices. For collaboration opportunities, please contact: Jennifer Wong, MS at wongje@mail.nih.gov 2025-02-27 2025-04-08 2025-06-10 2025-03-03 False False In vivo data available (animal) True 52406769 Prototype 52406769 37470483 Website Abstract 160835133 Deng, Zhi-De National Institute of Mental Health (NIMH) NIMH Deng, Zhi-De (NIMH) 1 160835140 Pritchard, Bruce National Institute of Mental Health (NIMH) NIMH Pritchard, Bruce (NIMH) 2 160835155 Dold, George National Institute of Mental Health (NIMH) NIMH Dold, George (NIMH) 3 160835353 Kim, Junghee National Institute of Mental Health (NIMH) NIMH Kim, Junghee (NIMH) 4 160835375 Schor, Robert National Institute of Mental Health (NIMH) NIMH Schor, Robert (NIMH) 5 160835471 Lisanby, Sarah National Institute of Mental Health (NIMH) NIMH Lisanby, Sarah (NIMH) 6 160835133 Deng, Zhi-De National Institute of Mental Health (NIMH) NIMH Deng, Zhi-De (NIMH) 1 160835140 Pritchard, Bruce National Institute of Mental Health (NIMH) NIMH Pritchard, Bruce (NIMH) 2 160835155 Dold, George National Institute of Mental Health (NIMH) NIMH Dold, George (NIMH) 3 160835353 Kim, Junghee National Institute of Mental Health (NIMH) NIMH Kim, Junghee (NIMH) 4 160835375 Schor, Robert National Institute of Mental Health (NIMH) NIMH Schor, Robert (NIMH) 5 160835471 Lisanby, Sarah National Institute of Mental Health (NIMH) NIMH Lisanby, Sarah (NIMH) 6 160834773 Precision, Optimally Targeted, ElectroConvulsive Therapy (PROTECT) E-214-2023-0 Filing authorized National Institute of Mental Health (NIMH), National Institute of Mental Health (NIMH), National Institute of Mental Health (NIMH) 83739514 Dawson, Anton anton.dawson@nih.gov
United States of America anton.dawson@nih.gov?subject=Web Inquiry on [TAB-5044] Precision, Optimally Targeted, ElectroConvulsive Therapy (PROTECT)&body=Please send me information about technology [TAB-5044] Precision, Optimally Targeted, ElectroConvulsive Therapy (PROTECT). Dawson, Anton<br><a href="mailto:anton.dawson@nih.gov?subject=Web Inquiry on [TAB-5044] Precision, Optimally Targeted, ElectroConvulsive Therapy (PROTECT)&body=Please send me information about technology [TAB-5044] Precision, Optimally Targeted, ElectroConvulsive Therapy (PROTECT).">anton.dawson@nih.gov</a><br> 160834778 E-214-2023-0 E-214-2023-0-US-01 SYSTEMS AND METHODS FOR ADJUSTABLE CURRENT INDIVIDUALIZED STIMULATION THERAPY PRV US 63/656,515 Expired US <br />Provisional (PRV) 63/656,515<br />Filed on 2024-06-05<br />Status: Expired 161154641 E-214-2023-0 E-214-2023-0-PC-01 SYSTEMS AND METHODS FOR ADJUSTABLE CURRENT INDIVIDUALIZED STIMULATION THERAPY PCT Patent Cooperation Treaty PCT/US2025/027755 Pending Patent Cooperation Treaty <br />(PCT) PCT/US2025/027755<br />Filed on 2025-05-05<br />Status: Pending TAB-4608 151785477 Intralipid as a Contrast Agent to Enhance Subsurface Blood Flow Imaging NIAAA Cardiology, Collaboration, Computational models/software, Diagnostics, Licensing, Medical Devices, Neurology, Oncology, Ophthalmology, Radiology Cardiology Collaboration Computational models/software Diagnostics Licensing Medical Devices Neurology Oncology Ophthalmology Radiology Congwu Du, Yingtian Pan, Nora Volkow <p>This technology includes a blood flow imaging method that allows for a higher density of smaller particles to be detected. Current imaging methods that are based on Doppler measurements are limited by the discontinuity in the capillary flow in the space between red blood cells. The core technology is to use a scattering agent to enhance capillary flow or microcirculation. This technology has been tested for optical coherence Doppler tomography, but can be expended to any Doppler based flow imaging techniques such as laser speckle imaging. The fundamental discovery or idea is that in capillaries, red blood cells (RBC) are moving in a burst mode with high latency (large time gap between bursts). By injection of micro beads such as intralipid, the moving backscatterers will fill the gap and flow with RBCs. Since they are smaller, e.g., 1-3um, they are strong backscatterers that enhance backscattering signals and their motion with RBCs will enhance the Doppler detection (reduced latency).</p> This is a new and safe way (i.e., via a natural contrast agent) to enhance the image of subsurface vasculature and blood flow, especially in the microvasculature circulation. The preclinical and clinical impacts can be profound, ranging from physiological and functional studies of neurovascular hemodynamics, pharmacological effects on the brain, to imaging tumor vasculature (microenvironment), surgical confirmation of curtailing of tumor vascular supply during brain surgery (replacing flushing ICG in neurosurgery), assessment of wounding healing (noninvasive imaging of angiogeneisis), and OCT imaging of vascular abnormality in retina. We are seeking statements of capability or interest from parties interested in collaborative research to further developer, evaluate, or commercialize this technology. 2023-12-13 2024-08-12 2025-06-10 2024-03-20 False True True 72159144 Investigational Device Exemption - Feasibility Study 72159144 37470483 Website Abstract 151785626 Ren H, et al. https://pubmed.ncbi.nlm.nih.gov/22904572/ <a href="https://pubmed.ncbi.nlm.nih.gov/22904572/">Ren H, et al.</a> 151785484 Du, Congwu State University of New York (SUNY) at Stony Brook Du, Congwu 1 151785492 Pan, Yingtian State University of New York (SUNY) at Stony Brook Pan, Yingtian 2 151785500 Volkow, Nora National Institute on Drug Abuse (NIDA) NIDA Volkow, Nora (NIDA) 3 151785484 Du, Congwu State University of New York (SUNY) at Stony Brook Du, Congwu 1 151785492 Pan, Yingtian State University of New York (SUNY) at Stony Brook Pan, Yingtian 2 151785500 Volkow, Nora National Institute on Drug Abuse (NIDA) NIDA Volkow, Nora (NIDA) 3 151785480 Intralipid As A Contrast Agent To Enhance Subsurface Blood Flow Imaging E-210-2012-0 Filing authorized National Institute on Alcohol Abuse and Alcoholism (NIAAA), State University of New York (SUNY) at Stony Brook, State University of New York (SUNY) at Stony Brook 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-4608] Intralipid as a Contrast Agent to Enhance Subsurface Blood Flow Imaging&body=Please send me information about technology [TAB-4608] Intralipid as a Contrast Agent to Enhance Subsurface Blood Flow Imaging. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-4608] Intralipid as a Contrast Agent to Enhance Subsurface Blood Flow Imaging&body=Please send me information about technology [TAB-4608] Intralipid as a Contrast Agent to Enhance Subsurface Blood Flow Imaging.">shmilovm@nih.gov</a><br> 157764265 E-210-2012-0 E-210-2012-0-US-01 Intralipid As A Contrast Agent To Enhance Subsurface Blood Flow Imaging PRV US 61/670,954 Abandoned US <br />Provisional (PRV) 61/670,954<br />Filed on 2012-07-12<br />Status: Abandoned 157764279 E-210-2012-0 E-210-2012-0-PCT-02 INTRALIPID AS A CONTRAST AGENT TO ENHANCE SUBSURFACE BLOOD FLOW IMAGING PCT Patent Cooperation Treaty PCT/US2013/050348 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2013/050348<br />Filed on 2013-07-12<br />Status: Expired 157764284 E-210-2012-0 E-210-2012-0-US-03 Intralipid As A Contrast Agent To Enhance Subsurface Blood Flow Imaging National Stage US 10,531,803 14/414,183 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10531803 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10531803">10,531,803</a><br />Filed on 2015-01-12<br />Status: Issued TAB-4501 151705184 Monoclonal Antibody Against Human Zinc Finger RNA-binding Protein (ZFR) NHLBI Antibodies, Materials Available, Research Materials Antibodies Materials Available Research Materials Nazmul Haque, John Hogg <p>This technology includes monoclonal antibody was raised in mice against amino acids 703-1074 of ZFR. Antibody specificity was confirmed by immunoblotting lysates from cells depleted of ZFR using shRNAs.</p> The monoclonal antibody generated allows more robust and specific immunoblotting than the other commercially available ZFR antibodies, and because it was raised against the C-terminus of the protein, it detects alternative ZFR isoforms found to be regulated in a cell-type specific manner. Potential for use in research and clinical diagnosis and treatments. We are seeking statements of capability or interest from parties interested in collaborative research to further developer, evaluate, or commercialize this technology. 2023-12-07 2024-08-12 2025-06-09 2024-03-27 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 151705206 Haque N, et al. https://pubmed.ncbi.nlm.nih.gov/29559679/ <a href="https://pubmed.ncbi.nlm.nih.gov/29559679/">Haque N, et al.</a> 151705192 Hogg, John National Heart, Lung, and Blood Institute (NHLBI) NHLBI Hogg, John (NHLBI) 1 151705196 Haque, Nazmul National Heart, Lung, and Blood Institute (NHLBI) NHLBI Haque, Nazmul (NHLBI) 2 151705192 Hogg, John National Heart, Lung, and Blood Institute (NHLBI) NHLBI Hogg, John (NHLBI) 1 151705196 Haque, Nazmul National Heart, Lung, and Blood Institute (NHLBI) NHLBI Haque, Nazmul (NHLBI) 2 151705187 Monoclonal Antibody Against Human Zinc Finger RNA-binding Protein (ZFR) E-121-2018-0 Research Material National Heart, Lung, and Blood Institute (NHLBI) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-4501] Monoclonal Antibody Against Human Zinc Finger RNA-binding Protein (ZFR)&body=Please send me information about technology [TAB-4501] Monoclonal Antibody Against Human Zinc Finger RNA-binding Protein (ZFR). Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-4501] Monoclonal Antibody Against Human Zinc Finger RNA-binding Protein (ZFR)&body=Please send me information about technology [TAB-4501] Monoclonal Antibody Against Human Zinc Finger RNA-binding Protein (ZFR).">shmilovm@nih.gov</a><br> TAB-2854 114097029 Inhibition of HIV Infection through Chemoprophylaxis Using Emtricitabine and Tenofovir CDC Consumer Products, Infectious Disease, Licensing Consumer Products Infectious Disease Licensing Thomas Folks, Jose Garcia Lerma, Walid Heneine, Robert Janssen, Ronald Otten The invention is directed to prophylactic administration of emtricitabine (FTC) in combination with tenofovir or its prodrug, tenofovir disoproxil fumarate (TDF), to protect against transmission of human immunodeficiency virus (HIV) infection. Also disclosed are other nucleoside reverse transcriptase inhibitors (NRTIs) and nucleotide reverse transcriptase inhibitors (NtRTIs) that, when administered in combination, protect against HIV infection. CDC researchers demonstrated that daily pre-exposure prophylaxis (PrEP) with a combination of antiretroviral NRTI and NtTRI drugs, including FTC and TDF, significantly increases the level of protection against HIV transmission. <ul> <li>Oral, prophylactic delivery of combination drugs to inhibit HIV infection</li> </ul> and various international issued patents/pending applications 2022-03-08 2025-05-09 2025-06-09 2014-09-09 CDC Docket Import, CDC Docket Import CDC Prosecuting, Chemoprophylaxis, HIV, Infection, inhibition, OID-NCHHSTP-DHPSE, VLXXXX, WMXXXX, YCXXXX, YDXXXX False True <ul> <li>In vivo data available (animal)</li> <li>In vivo data available (human)</li> </ul> True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114172192 Garcia-Lerma J, et al. http://www.ncbi.nlm.nih.gov/pubmed/18254653 <a href="http://www.ncbi.nlm.nih.gov/pubmed/18254653">Garcia-Lerma J, et al.</a> 114172193 Garcia-Lerma J, et al. http://www.ncbi.nlm.nih.gov/pubmed/20371467 <a href="http://www.ncbi.nlm.nih.gov/pubmed/20371467">Garcia-Lerma J, et al.</a> 114108836 Folks, Thomas CDC - DIR Folks, Thomas 0 114108837 Janssen, Robert CDC - DIR CDC Janssen, Robert (CDC) 0 114108838 Otten, Ronald CDC - DIR CDC Otten, Ronald (CDC) 0 114108839 Garcia Lerma, Jose CDC - DIR CDC Garcia Lerma, Jose (CDC) 0 114108835 Heneine, Walid CDC - DIR CDC Heneine, Walid (CDC) 1 114108835 Heneine, Walid CDC - DIR CDC Heneine, Walid (CDC) 1 114108836 Folks, Thomas CDC - DIR Folks, Thomas 0 114108837 Janssen, Robert CDC - DIR CDC Janssen, Robert (CDC) 0 114108838 Otten, Ronald CDC - DIR CDC Otten, Ronald (CDC) 0 114108839 Garcia Lerma, Jose CDC - DIR CDC Garcia Lerma, Jose (CDC) 0 114102196 Inhibition Of HIV Infection Through Chemoprophylaxis E-195-2013-0 Filing authorized Centers for Disease Control and Prevention (CDC) 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2854] Inhibition of HIV Infection through Chemoprophylaxis Using Emtricitabine and Tenofovir&body=Please send me information about technology [TAB-2854] Inhibition of HIV Infection through Chemoprophylaxis Using Emtricitabine and Tenofovir. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2854] Inhibition of HIV Infection through Chemoprophylaxis Using Emtricitabine and Tenofovir&body=Please send me information about technology [TAB-2854] Inhibition of HIV Infection through Chemoprophylaxis Using Emtricitabine and Tenofovir.">jonathan.motley@nih.gov</a><br> 114161375 E-195-2013-0 E-195-2013-0-US-12 Inhibition Of HIV Infection Through Chemoprophylaxis CON US 9,937,191 15/406,344 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9937191 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9937191">9,937,191</a><br />Filed on 2017-01-13<br />Status: Issued 114164203 E-195-2013-0 E-195-2013-0-US-13 Inhibition Of HIV Infection Through Chemoprophylaxis CON US 10,335,423 15/913,750 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10335423 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10335423">10,335,423</a><br />Filed on 2018-03-06<br />Status: Issued 114167926 E-195-2013-0 E-195-2013-0-US-01 Inhibition Of HIV Infection Through Chemoprophylaxis PRV US 60/764,811 Expired US <br />Provisional (PRV) 60/764,811<br />Filed on 2006-02-03<br />Status: Expired 114167927 E-195-2013-0 E-195-2013-0-US-02 Inhibition Of HIV Infection Through Chemoprophylaxis ORD US 9,044,509 11/669,547 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9044509 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9044509">9,044,509</a><br />Filed on 2007-01-31<br />Status: Issued 114167928 E-195-2013-0 E-195-2013-0-PCT-03 Inhibition Of HIV Infection Through Chemoprophylaxis PCT Patent Cooperation Treaty PCT/US2007/002926 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2007/002926<br />Filed on 2007-02-01<br />Status: Expired 114168140 E-195-2013-0 E-195-2013-0-US-11 Inhibition Of HIV Infection Through Chemoprophylaxis CON US 9,579,333 14/679,887 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9579333 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9579333">9,579,333</a><br />Filed on 2015-04-06<br />Status: Issued 114168885 E-195-2013-0 E-195-2013-0-US-14 INHIBITION OF HIV INFECTION THROUGH CHEMOPROPHYLAXIS CON US 16/413,381 Abandoned US <br />Continuation (CON) 16/413,381<br />Filed on 2019-05-15<br />Status: Abandoned 114168992 E-195-2013-0 E-195-2013-0-US-17 Methods of Inhibiting HIV Infections by Pre-Exposure Prophylaxis CON US 16/808,135 Abandoned US <br />Continuation (CON) 16/808,135<br />Filed on 2020-03-03<br />Status: Abandoned 114168993 E-195-2013-0 E-195-2013-0-US-16 Methods of Preventing HIV Infections in Humans CON US 16/808,120 Abandoned US <br />Continuation (CON) 16/808,120<br />Filed on 2020-03-03<br />Status: Abandoned 114168994 E-195-2013-0 E-195-2013-0-US-15 Pre-Exposure Prophylaxis of HIV Infections CON US 16/808,089 Abandoned US <br />Continuation (CON) 16/808,089<br />Filed on 2020-03-03<br />Status: Abandoned 114169097 E-195-2013-0 E-195-2013-0-US-18 PRE-EXPOSURE PROPHYLAXIS OF HIV INFECTIONS CON US 17/170,535 Abandoned US <br />Continuation (CON) 17/170,535<br />Filed on 2021-02-08<br />Status: Abandoned 114169108 E-195-2013-0 E-195-2013-0-US-19 Methods of Inhibiting HIV Infections by Pre-Exposure Prophylaxis CON US 17/186,534 Abandoned US <br />Continuation (CON) 17/186,534<br />Filed on 2021-02-26<br />Status: Abandoned 114169109 E-195-2013-0 E-195-2013-0-US-21 Methods of Preventing HIV Infections in Humans CON US 17/186,583 Abandoned US <br />Continuation (CON) 17/186,583<br />Filed on 2021-02-26<br />Status: Abandoned 114169110 E-195-2013-0 E-195-2013-0-US-20 Inhibition Of HIV Infection Through Chemoprophylaxis CON US 17/186,559 Abandoned US <br />Continuation (CON) 17/186,559<br />Filed on 2021-02-26<br />Status: Abandoned 146872106 E-195-2013-0 E-195-2013-0-US-03 Inhibition Of HIV Infection Through Chemoprophylaxis CON US 18/199,776 Abandoned US <br />Continuation (CON) 18/199,776<br />Filed on 2023-05-19<br />Status: Abandoned 146872111 E-195-2013-0 E-195-2013-0-US-04 Methods of Preventing HIV Infections in Humans CON US 18/206,281 Abandoned US <br />Continuation (CON) 18/206,281<br />Filed on 2023-06-06<br />Status: Abandoned 146872123 E-195-2013-0 E-195-2013-0-AU-04 Inhibition Of HIV Infection Through Chemoprophylaxis National Stage Australia 2007212583 2007212583 Issued Australia <br />National Stage 2007212583<br />Filed on 2007-02-01<br />Status: Issued 146872246 E-195-2013-0 E-195-2013-0-DE-08 Inhibition Of HIV Infection Through Chemoprophylaxis EP Germany 2015753 07763090.3 Issued Germany <br />European patent (EP) 07763090.3<br />Filed on 2008-08-28<br />Status: Issued 146872254 E-195-2013-0 E-195-2013-0-FR-09 Inhibition Of HIV Infection Through Chemoprophylaxis EP France 2015753 07763090.3 Issued France <br />European patent (EP) 07763090.3<br />Filed on 2008-08-28<br />Status: Issued 146872261 E-195-2013-0 E-195-2013-0-GB-10 Inhibition Of HIV Infection Through Chemoprophylaxis EP United Kingdom 2015753 07763090.3 Issued United Kingdom <br />European patent (EP) 07763090.3<br />Filed on 2008-08-28<br />Status: Issued 146872268 E-195-2013-0 E-195-2013-0-CA-05 Inhibition Of HIV Infection Through Chemoprophylaxis National Stage Canada 2641388 2641388 Issued Canada <br />National Stage 2641388<br />Filed on 2008-08-01<br />Status: Issued 114126487 VLXXXX 114126488 WMXXXX 114126489 YCXXXX 114126490 YDXXXX 114147764 inhibition 114147765 HIV 114147766 Infection 114147767 Chemoprophylaxis 114147768 CDC Docket Import 114147769 CDC Docket Import CDC Prosecuting 114147770 OID-NCHHSTP-DHPSE TAB-1588 114095856 Device and Method for Protecting Against Coronary Artery Compression During Transcatheter Mitral Valve Annuloplasty NHLBI Collaboration, Licensing Collaboration Licensing June-Hong Kim, Ozgur Kocaturk, Robert Lederman Catheter-based mitral valve regurgitation treatments that use a coronary sinus trajectory or coronary sinus implant can have unwanted effects because the coronary sinus and its branches have been found to cross the outer diameter of major coronary arteries in a majority of humans. As a result, pressure applied by any prosthetic device in the coronary sinus (such as tension on the annuloplasty device) can compress the underlying coronary artery and induce myocardial ischemia or infarction. <br><br> Available for licensing and commercial development are devices and methods that avoid constricting coronary artery branches during coronary sinus-based annuloplasty. These devices and methods protect coronary artery branches from constriction during trans-sinus mitral annuloplasty. The device protects a coronary vessel from compression during mitral annuloplasty in which an annuloplasty element, such as a tensioning device, extends at least partially through the coronary sinus over a coronary artery. The device is a surgically sterile bridge configured for placement within the coronary sinus at a location where the coronary sinus passes over a coronary artery, so that the protection device provides a support for a mitral annuloplasty element, such as a compressive prosthesis, including a tension element when it is placed under tension. The protection device has an arch of sufficient rigidity and dimensions to support the tensioning element over the coronary artery, redistribute tension away from an underlying coronary artery, and inhibit application of pressure to the underlying artery, for example when an annuloplasty tension element is placed under tension during mitral annuloplasty. <br><br> In particular, the protective device can be a support interposed in the coronary sinus between the annuloplasty device and the coronary artery. The device may be substantially tubular so that the tensioning element is contained within the protective device and supported in spaced relationship to the coronary artery. An arch may be configured to extend between a proximal end and a distal end that are substantially collinear with one another so that the ends form stabilizing members such as feet that retain the bridge in position over the coronary artery. <br><br> The device may be used in methods of improving the function of a mitral valve in a subject in which an annuloplasty element, for example an element that exerts compressive remodeling forces on the mitral valve (such as a tensioning element), is introduced at least partially around the mitral valve, for example at least partially through the coronary sinus and over a coronary artery. The protective device is placed between the annuloplasty element and the coronary artery, with the annuloplasty element supported by the bridge of the device. Compressive remodeling forces are exerted by the annuloplasty device (for example by applying tension to alter the shape or configuration of the mitral valve annulus to reduce its circumference) while supporting the annuloplasty element on the bridge to inhibit application of pressure to the coronary artery. The function of the mitral valve in the patient is thereby improved without impairing coronary blood flow. <br><br> The annuloplasty element can be introduced at least partially around the mitral valve by advancing the annuloplasty element in an endovascular catheter through the vascular system to the heart and introducing the annuloplasty element and the protective device from the catheter into the coronary sinus through a coronary sinus ostium. In those embodiments in which the protective device includes an internal lumen, the annuloplasty element extends through the lumen of the protective device over the coronary artery so that the annuloplasty element is supported by the protective device. The protective device can be integrated directly into the annuloplasty element, such as a resilient or expandable device, or a tensioning element or tensioning material. <br><br> In other embodiments, this disclosure provides a method of improving function of a mitral valve in a subject who has mitral regurgitation by performing a mitral valve cerclage annuloplasty. In a particular disclosed example of the procedure, a guiding catheter is percutaneously inserted through the vasculature of a subject. The guiding catheter is introduced through the coronary sinus into the great cardiac vein, and a steerable microcatheter or other coaxial guiding catheter or steering device introduces a guidewire into a basal blood vessel such as the first septal coronary vein. From there the guidewire traverses under imaging guidance the septal myocardium or annulus fibrosis and reenters the right ventricle or right atrium. The guidewire is then retrieved using a vascular snare and the guiding catheter and guidewire are replaced with a tensioning system. The protective device is then introduced through the guiding catheter over or in tandem with the tensioning system so as to protect an underlying coronary artery when tension is introduced to perform the annuloplasty. <ul> <li>Cardiac valve repair</li> <li>Interventional Cardiology</li> <li>Cardiac Surgery</li> </ul> The NHLBI Cardiovascular Branch is seeking statements of capability or interest from parties interested in collaborative research to further development, evaluate, or commercialize catheter-based cardiovascular devices. Please contact Peg Koelble, NHLBI Office of Technology Transfer and Development, at 301-594-4095 or <a href="mailto:koelblep@nhlbi.nih.gov">koelblep@nhlbi.nih.gov</a>. Available for licensing on an exclusive or non-exclusive basis. 2022-09-28 2025-05-29 2025-05-29 2007-08-01 AA2XXX, AA4CXX, AA4XXX, AAXXXX, AB3FXX, AB3XXX, ABXXXX, Against, Annuloplasty, ARTERIAL, ARTERIES, AXXXXX, Compression, CORONARY, DEVICE, During, Mitral, PMVA, PROTECT, Transcatheter, Vale, Valve False True <ul> <li>Early-stage</li> <li>Pre-clinical data available</li> <li>Prototype</li> </ul> <ul> <li>Early-stage</li> <li>Pre-clinical data available</li> <li>Prototype</li> </ul> True NIHTT 37470483 Website Abstract 114105803 Kocaturk, Ozgur National Heart, Lung, and Blood Institute (NHLBI) NHLBI Kocaturk, Ozgur (NHLBI) 0 114105804 Lederman, Robert National Heart, Lung, and Blood Institute (NHLBI) NHLBI Lederman, Robert (NHLBI) 0 114105805 Kim, June-Hong National Heart, Lung, and Blood Institute (NHLBI) Kim, June-Hong 1 114105805 Kim, June-Hong National Heart, Lung, and Blood Institute (NHLBI) Kim, June-Hong 1 114105803 Kocaturk, Ozgur National Heart, Lung, and Blood Institute (NHLBI) NHLBI Kocaturk, Ozgur (NHLBI) 0 114105804 Lederman, Robert National Heart, Lung, and Blood Institute (NHLBI) NHLBI Lederman, Robert (NHLBI) 0 114100828 A Device To Protect Coronary Arteries Against Compression During Transcatheter Mitral Vale Annuloplasty (PMVA) E-249-2006-2 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 114100829 A Device To Protect Coronary Arteries Against Compression During Transcatheter Mitral Valve Annuloplasty (PMVA) E-249-2006-1 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 114100830 A Device To Protect Coronary Arteries Against Compression During Transcatheter Mitral Valve Annuloplasty (PMVA) E-249-2006-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-1588] Device and Method for Protecting Against Coronary Artery Compression During Transcatheter Mitral Valve Annuloplasty&body=Please send me information about technology [TAB-1588] Device and Method for Protecting Against Coronary Artery Compression During Transcatheter Mitral Valve Annuloplasty. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-1588] Device and Method for Protecting Against Coronary Artery Compression During Transcatheter Mitral Valve Annuloplasty&body=Please send me information about technology [TAB-1588] Device and Method for Protecting Against Coronary Artery Compression During Transcatheter Mitral Valve Annuloplasty.">shmilovm@nih.gov</a><br> 114163947 E-249-2006-2 E-249-2006-2-PCT-01 Transcatheter Coronary Sinus Mitral Valve Annuloplasty Procedure And Coronary Artery And Myocardial Protection Device PCT COMB Patent Cooperation Treaty PCT/US2007/023876 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2007/023876<br />Filed on 2007-11-13<br />Status: Expired 114163948 E-249-2006-1 E-249-2006-1-US-01 A Device To Protect Coronary Arteries Against Compression During Transcatheter Mitral Valve Annuloplasty (PMVA) PRV US 60/932,611 Abandoned US <br />Provisional (PRV) 60/932,611<br />Filed on 2007-05-31<br />Status: Abandoned 114163949 E-249-2006-0 E-249-2006-0-US-01 A Device To Protect Coronary Arteries Against Compression During Transcatheter Mitral Valve Annuloplasty (PMVA) PRV US 60/858,716 Abandoned US <br />Provisional (PRV) 60/858,716<br />Filed on 2006-11-14<br />Status: Abandoned 114165195 E-249-2006-2 E-249-2006-2-US-03 Transcatheter Coronary Sinus Mitral Valve Annuloplasty Procedure And Coronary Artery And Myocardial Protection Device National Stage US 8,211,171 12/514,990 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8211171 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8211171">8,211,171</a><br />Filed on 2009-05-14<br />Status: Issued 114166769 E-249-2006-2 E-249-2006-2-US-04 Transcatheter Coronary Sinus Mitral Valve Annuloplasty Procedure And Coronary Artery And Myocardial Protection Device DIV US 9,271,833 13/468,761 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9271833 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9271833">9,271,833</a><br />Filed on 2012-05-10<br />Status: Issued 114118038 AB3FXX 114118039 AB3XXX 114118040 ABXXXX 114118041 AA4CXX 114118042 AA4XXX 114118043 AA2XXX 114118044 AAXXXX 114118045 AXXXXX 114133167 DEVICE 114133168 PROTECT 114133169 CORONARY 114133170 ARTERIES 114133171 Against 114133172 Compression 114133173 During 114133174 Transcatheter 114133175 Mitral 114133176 Vale 114133177 Annuloplasty 114133178 PMVA 114133179 ARTERIAL 114133180 Valve TAB-1506 114095774 Novel System for HIV-1 Vaccine Development NIAID Infectious Disease, Licensing, Vaccines Infectious Disease Licensing Vaccines Peter Kwong The available technologies describe specific immunogenic peptides, peptide modifications and methods for identifying additional immunogens against HIV-1 surface proteins, gp120 and gp41. Additionally, detailed methods for use of the described immunogenic peptides in the development of vaccines and diagnostics for HIV-1 are disclosed. The current technologies further include a comprehensive system for immunogen design, comprising in silico design coupled to feedback from X-ray crystallography, antigenic analysis, and immunization. <br><br> The described methodology demonstrates how to transplant a given HIV-1 epitope recognized by broadly neutralizing antibodies into an appropriate scaffold, while preserving its structure and antigenicity. Conservation of the three dimensional structure may lead to the generation of antibodies with broadly neutralizing characteristics, similar to the template antibody. Such epitope-transplant scaffolds may serve as valuable diagnostics to identify specific serum reactivity against the target HIV-1 epitopes. The subject scaffolding technology may be applied to any virus for which a broadly neutralizing antibody and its respective epitope has been characterized at the atomic-level. <ul> <li>Immunogens that elicit immune responses to HIV-1</li> <li>Efficient development of vaccines against HIV-1</li> <li>Screening tool to isolate antibodies with activities similar to identified template antibody</li> </ul> Available for licensing. 2022-09-28 2025-05-29 2025-05-29 2007-03-01 Against, ANTIGENIC, Anti-HIV-1, ATOMIC, Biotechnology, Broadly, CONFORMATIONALLY, Cryptic, DC5AXX, DC5XXX, DCXXXX, DEFINITION, Details, DXXXXX, Ectodomain, ELICIT, Envelope, Epitope, Epitopes, Epitope-transplant, FUNCTION, Gp120:, gp41, HIV, HIV-1, Immunization, IMMUNOGENS, Level, Membrane-Proximal, Neutralizing, Patent Category - Biotechnology, Reveal, Scaffolds, Stabilized, Strategies, structure, Their, Triggering, V3-Loop, Vaccine False True True NIHTT 37470483 Website Abstract 114170219 G Ofek, W Schief, J Guenaga, et al. Epitope-transplant scaffolds: automated design, structural analysis, and antigenic characteristics. Manuscript in preparation (2007). G Ofek, W Schief, J Guenaga, et al. Epitope-transplant scaffolds: automated design, structural analysis, and antigenic characteristics. Manuscript in preparation (2007). 114170280 T Zhou, L Xu, B Dey, AJ Hessell, DV Ryk, SH Xiang, X Yang, MY Zhang, MB Zwick, J Arthos, DR Burton, DS Dimitrov, J Sodroski, R Wyatt, GJ Nabel, PD Kwong. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature. 2007 Feb 15;445(7129):732-737. http://www.ncbi.nlm.nih.gov/pubmed/17301785?dopt <a href="http://www.ncbi.nlm.nih.gov/pubmed/17301785?dopt">T Zhou, L Xu, B Dey, AJ Hessell, DV Ryk, SH Xiang, X Yang, MY Zhang, MB Zwick, J Arthos, DR Burton, DS Dimitrov, J Sodroski, R Wyatt, GJ Nabel, PD Kwong. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature. 2007 Feb 15;445(7129):732-737.</a> 114170281 DC Douek, PD Kwong, GJ Nabel. The rational design of an AIDS vaccine. Cell. 2006 Feb 24;124(4):677-681. http://www.ncbi.nlm.nih.gov/pubmed/16497577?dopt <a href="http://www.ncbi.nlm.nih.gov/pubmed/16497577?dopt">DC Douek, PD Kwong, GJ Nabel. The rational design of an AIDS vaccine. Cell. 2006 Feb 24;124(4):677-681.</a> 114170282 G Ofek, M Tang, A Sambor, H Katinger, JR Mascola, R Wyatt, PD Kwong. Structure and mechanistic analysis of the anti-HIV-1 antibody 2F5 in complex with its gp41 epitope. J Virol. 2004 Oct;78(19):10724-10737. http://www.ncbi.nlm.nih.gov/pubmed/15367639?dopt <a href="http://www.ncbi.nlm.nih.gov/pubmed/15367639?dopt">G Ofek, M Tang, A Sambor, H Katinger, JR Mascola, R Wyatt, PD Kwong. Structure and mechanistic analysis of the anti-HIV-1 antibody 2F5 in complex with its gp41 epitope. J Virol. 2004 Oct;78(19):10724-10737.</a> 114106534 Kwong, Peter NIAID - VRC NIAID Kwong, Peter (NIAID) 0 114106534 Kwong, Peter NIAID - VRC NIAID Kwong, Peter (NIAID) 0 114100696 Epitope-transplant Scaffolds And Their Use E-302-2006-0 Filing authorized NIAID, University of Washington 114100697 Atomic Level Details Of A Broadly Neutralizing Epitope On HIV-1 Gp120: Structure, Function, And Antigenic Definition E-280-2006-1 Filing authorized Dana-Farber Cancer Institute, NIAID, The Scripps Research Institute 114100698 Conformationally Stabilized HIV Envelope Immunogens, And Triggering HIV-1 To Reveal Cryptic V3-Loop Epitopes E-324-2005-3 Filing authorized Dana-Farber Cancer Institute, NIAID 114100699 HIV Vaccine Immunogens And Immunization Strategies To Elicit Broadly Neutralizing Anti-HIV-1 Against The Membrane-Proximal Ectodomain Of HIV Gp41 E-218-2004-0 Filing authorized NIAID 91025211 Rainwater, Charles crainwater@mail.nih.gov
United States of America crainwater@mail.nih.gov?subject=Web Inquiry on [TAB-1506] Novel System for HIV-1 Vaccine Development&body=Please send me information about technology [TAB-1506] Novel System for HIV-1 Vaccine Development. Rainwater, Charles<br><a href="mailto:crainwater@mail.nih.gov?subject=Web Inquiry on [TAB-1506] Novel System for HIV-1 Vaccine Development&body=Please send me information about technology [TAB-1506] Novel System for HIV-1 Vaccine Development.">crainwater@mail.nih.gov</a><br> 114161878 E-324-2005-3 E-324-2005-3-US-04 CONFORMATIONALLY STABILIZED HIV ENVELOPE IMMUNOGENS CON US 8,715,686 13/585,700 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8715686 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8715686">8,715,686</a><br />Filed on 2012-08-14<br />Status: Abandoned 114163642 E-280-2006-1 E-280-2006-1-PCT-01 HIV GP120 Crystal Structure and Its Use to Identify Immunogens PCT COMB Patent Cooperation Treaty PCT/US2006/034882 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2006/034882<br />Filed on 2006-09-06<br />Status: Expired 114163643 E-324-2005-3 E-324-2005-3-PCT-01 Conformationally Stabilized HIV Envelope Immunogens, And Triggering HIV-1 To Reveal Cryptic V3-Loop Epitopes (PCT) PCT COMB Patent Cooperation Treaty PCT/US2006/034681 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2006/034681<br />Filed on 2006-09-06<br />Status: Expired 114163644 E-218-2004-0 E-218-2004-0-PCT-02 HIV Vaccine Immunogens and Immunization Strategies to Elicit Broadly Neutralizing Anti-HIV-1 Against the Membrane-Proximal Ectodomain of HIV Gp41 PCT Patent Cooperation Treaty PCT/US2005/016633 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2005/016633<br />Filed on 2005-05-13<br />Status: Expired 114163645 E-218-2004-0 E-218-2004-0-US-01 HIV Vaccine Immunogens And Immunization Strategies To Elicit Broadly Neutralizing Anti-HIV-1 Against The Membrane-Proximal Ectodomain Of HIV Gp41 PRV US 60/570,883 Abandoned US <br />Provisional (PRV) 60/570,883<br />Filed on 2004-05-14<br />Status: Abandoned 114163646 E-302-2006-0 E-302-2006-0-US-01 Epitope-Transplant Scaffolds and Their Use PRV US 60/840,119 Abandoned US <br />Provisional (PRV) 60/840,119<br />Filed on 2006-08-25<br />Status: Abandoned 114163921 E-280-2006-1 E-280-2006-1-US-03 HIV-1 GP120 CRYSTAL STRUCTURE AND ITS USE TO IDENTIFY IMMUNOGENS National Stage US 12/065,883 Abandoned US <br />National Stage 12/065,883<br />Filed on 2008-03-05<br />Status: Abandoned 114164220 E-324-2005-3 E-324-2005-3-US-02 Conformationally Stabilized HIV Envelope Immunogens and Triggering HIV-1 Envelope to Reveal Cryptic V3-Loop Epitopes National Stage US 8,044,185 12/065,894 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8044185 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8044185">8,044,185</a><br />Filed on 2008-03-05<br />Status: Abandoned 114165009 E-218-2004-0 E-218-2004-0-US-03 Human Immunodeficiency Virus (HIV) Immunization Strategies Employing Conformationally-Stabilized, Surface-Occluded Peptides Comprising A GP41 2F5 Epitope in Association with Lipid National Stage US 8,147,840 11/596,494 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8147840 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8147840">8,147,840</a><br />Filed on 2006-11-13<br />Status: Expired 114166515 E-324-2005-3 E-324-2005-3-US-03 Conformationally Stabilized HIV Envelope Immunogens DIV US 8,268,323 13/232,775 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8268323 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8268323">8,268,323</a><br />Filed on 2011-09-14<br />Status: Abandoned 114117614 DC5AXX 114117615 DCXXXX 114117616 DXXXXX 114119946 DC5XXX 114136997 HIV 114136998 Vaccine 114136999 IMMUNOGENS 114137000 Immunization 114137001 Strategies 114137002 ELICIT 114137003 Broadly 114137004 Neutralizing 114137005 Anti-HIV-1 114137006 Against 114137007 Membrane-Proximal 114137008 Ectodomain 114137009 gp41 114137010 Biotechnology 114137011 Patent Category - Biotechnology 114137012 CONFORMATIONALLY 114137013 Stabilized 114137014 Envelope 114137015 Triggering 114137016 HIV-1 114137017 Reveal 114137018 Cryptic 114137019 V3-Loop 114137020 Epitopes 114137021 ATOMIC 114137022 Level 114137023 Details 114137024 Epitope 114137025 Gp120: 114137026 structure 114137027 FUNCTION 114137028 ANTIGENIC 114137029 DEFINITION 114137030 Epitope-transplant 114137031 Scaffolds 114137032 Their TAB-5031 159329764 A Rapid Method for Producing Antibodies CDC Antibodies, Collaboration, Diagnostics, Licensing, Research Materials, Therapeutics Antibodies Collaboration Diagnostics Licensing Research Materials Therapeutics Zachary Ende, Suryaprakash Sambhara <p>Antibodies are specialized proteins produced by the immune system which target and neutralize foreign materials, such as viruses or bacteria. Antibodies have a variety of useful applications in diagnostics, therapeutics, and as research reagents. Despite their widespread use there is no standard method to produce antibodies, and currently available methods are labor and time intensive.</p> <p>CDC scientists have developed a rapid method for producing antibodies with swappable DNA fragments using a PCR based assay. This method avoids lengthy cloning steps, reducing the time to produce an expression ready antibody cassette from a few days to a few hours. Further, this method uses readily available reagents and equipment.</p> <p>Antibodies produced using this method could be sold as diagnostics, therapeutics, or research reagents. This method could also be used to provide antibody manufacturing services. Potentially, host cells could be transfected with the antibody expression cassette in vivo to target a protein of interest. For instance, this could be used to target infectious agents, such as SARS‑CoV‑2, or other disease targets in cancers or autoimmune disorders.</p> <ul> <li> Eliminates lengthy and resource intensive cloning steps for producing antibodies.</li> <li> Uses readily available reagents and does not require specialized equipment.</li> </ul> <ul> <li> Use of the method to produce antibodies for sale as diagnostics, therapeutics, or as research reagents.</li> <li> A service to produce antibodies for customers.</li> <li> A kit to allow customers to produce antibodies themselves.</li> </ul> The CDC-ID is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this rapid method for producing antibodies. For collaboration opportunities, please contact: Madhavi Sriram nxu2@cdc.gov ; TTO@cdc.gov 2024-11-25 2025-05-29 2025-05-29 2024-12-06 False False Early stage In vitro data available True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract E-163-2023-0-US-01 E-163-2023-0-PC-01 159330012 Zachary Ende, et al., "Human monoclonal antibody cloning and expression with overlap extension PCR and short DNA fragments", National Library of Medicine, PubMed (Human monoclonal antibody cloning and expression with overlap extension PCR and short DNA fragments - PubMed ) Zachary Ende, et al., "Human monoclonal antibody cloning and expression with overlap extension PCR and short DNA fragments", National Library of Medicine, PubMed (Human monoclonal antibody cloning and expression with overlap extension PCR and short DNA fragments - PubMed ) 159424667 Ende, Zachary CDC - DIR CDC Ende, Zachary (CDC) 1 159424678 Sambhara, Suryaprakash CDC - DIR CDC Sambhara, Suryaprakash (CDC) 2 159424667 Ende, Zachary CDC - DIR CDC Ende, Zachary (CDC) 1 159424678 Sambhara, Suryaprakash CDC - DIR CDC Sambhara, Suryaprakash (CDC) 2 159479202 Multipurpose Antibody Cloning and Expression with Overlap Extension PCR and Short DNA Fragments E-163-2023-0 Filing authorized CDC - DIR 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-5031] A Rapid Method for Producing Antibodies&body=Please send me information about technology [TAB-5031] A Rapid Method for Producing Antibodies. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-5031] A Rapid Method for Producing Antibodies&body=Please send me information about technology [TAB-5031] A Rapid Method for Producing Antibodies.">jonathan.motley@nih.gov</a><br> TAB-4861 152463713 TACSTD2 in HCV Infection and Hepatocellular Carcinoma: Transcriptomics Insights NIAID Collaboration, Diagnostics, Infectious Disease Collaboration Diagnostics Infectious Disease Patrizia Farci, Vandana Sekhar <p>This technology involves studying the role of the Tumor-Associated Calcium Signal Transducer 2 (TACSTD2) gene in Hepatitis C Virus (HCV) infection and hepatocellular carcinoma. Researchers perform transcriptomics analysis on liver specimens from HCV-infected patients, identify TACSTD2 as a key gene, and create a stable cell line that overexpresses TACSTD2 to investigate its impact on HCV infection and replication. This technology aims to provide insights into the molecular mechanisms of HCV infection and its association with liver cancer.</p> <p>&nbsp;</p> This technology's competitive advantages stem from its focused approach on the TACSTD2 gene, leveraging cutting-edge transcriptomics analysis to identify differentially expressed genes in HCV-infected patients, and establishing a stable cell line overexpressing TACSTD2 for precise experiments. With a direct link to HCV-associated hepatocellular carcinoma, it offers clinical relevance and the potential for therapeutic insights. Its applicability extends beyond HCV research, making it a versatile tool for various biomedical investigations, ultimately contributing to advancements in understanding HCV infection and its implications in liver diseases. This technology has versatile potential applications. It can enhance our understanding of HCV infection mechanisms, leading to new treatments for HCV-related liver diseases. Additionally, the TACSTD2-overexpressing cell line offers opportunities for broader molecular studies. Its transcriptomics approach may also inspire similar investigations in other viral infections, advancing our knowledge of infectious diseases and aiding in treatment development. 2024-01-29 2025-05-29 2025-05-29 2024-12-10 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 152463786 Farci, Patrizia NIAID - DIR NIAID Farci, Patrizia (NIAID) 1 152463790 Sekhar, Vandana National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Sekhar, Vandana (NIAID) 2 152463786 Farci, Patrizia NIAID - DIR NIAID Farci, Patrizia (NIAID) 1 152463790 Sekhar, Vandana National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Sekhar, Vandana (NIAID) 2 152463716 Tumor Associated Calcium Signal Transducer 2 (TACSTD2)-overexpressing Huh7.5 Cells E-040-2020-0 Research Material NIAID 91021353 Pitts, Elizabeth elizabeth.pitts@nih.gov
United States of America elizabeth.pitts@nih.gov?subject=Web Inquiry on [TAB-4861] TACSTD2 in HCV Infection and Hepatocellular Carcinoma: Transcriptomics Insights&body=Please send me information about technology [TAB-4861] TACSTD2 in HCV Infection and Hepatocellular Carcinoma: Transcriptomics Insights. Pitts, Elizabeth<br><a href="mailto:elizabeth.pitts@nih.gov?subject=Web Inquiry on [TAB-4861] TACSTD2 in HCV Infection and Hepatocellular Carcinoma: Transcriptomics Insights&body=Please send me information about technology [TAB-4861] TACSTD2 in HCV Infection and Hepatocellular Carcinoma: Transcriptomics Insights.">elizabeth.pitts@nih.gov</a><br> TAB-4555 151738135 Engineered Human Induced Pluripotent Stell Cell (iPSC) Lines for Multiple Therapeutic and Diagnostic Uses NIAMS Diagnostics, Human iPSC Lines, Licensing, Research Materials, Therapeutics Diagnostics Human iPSC Lines Licensing Research Materials Therapeutics Mahendra Rao <p>This technology includes ten engineered human induced pluripotent stem cell (iPSC) lines with reported genes inserted into safe harbor sites for use in therapy and diagnostic screening assay development as well as basic stem cell biology research. These cell lines have the potential to differentiate into all cells in the body, and theoretically can proliferate/self-renew indefinitely.</p> The pluripotent nature of these cell lines gives them the potential to differentiate into all cells in the body, and proliferate indefinitely, giving them a wide range of uses. Utilized in studies that could facilitate the development of cellular therapies, more effective drug treatments through their use as screening assays, and improved understanding of basic stem cell biology. We are seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. 2023-12-11 2025-05-29 2025-05-29 2024-03-27 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 151738168 Rao, Mahendra New York Stem Cell Foundation Rao, Mahendra 1 151738168 Rao, Mahendra New York Stem Cell Foundation Rao, Mahendra 1 151738138 Generation Of Ten Engineered Human Induced Pluripotent Stem Cell (iPSC) Lines With Reporter Genes Inserted Into Safe Harbor Sites E-091-2012-0 Research Material National Institute on Aging (NIH/NIA) 83656052 Knezevic, Vladimir vlado.knezevic@nih.gov
United States of America Technology Advancement Office vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-4555] Engineered Human Induced Pluripotent Stell Cell (iPSC) Lines for Multiple Therapeutic and Diagnostic Uses&body=Please send me information about technology [TAB-4555] Engineered Human Induced Pluripotent Stell Cell (iPSC) Lines for Multiple Therapeutic and Diagnostic Uses. Knezevic, Vladimir<br><a href="mailto:vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-4555] Engineered Human Induced Pluripotent Stell Cell (iPSC) Lines for Multiple Therapeutic and Diagnostic Uses&body=Please send me information about technology [TAB-4555] Engineered Human Induced Pluripotent Stell Cell (iPSC) Lines for Multiple Therapeutic and Diagnostic Uses.">vlado.knezevic@nih.gov</a><br> TAB-4523 151719454 Encapsulation of Fluorescent Nanodiamonds into Poly-dopamine (PDA) Shell and Further Covalent Functionalization of the PDA Shell for Diagnostic Imaging Applications NHLBI Licensing, Medical Devices, Research Equipment Licensing Medical Devices Research Equipment Haksung Jung, Keir Neuman <p>This technology includes a new class of nanoparticles in the carbon family, fluorescent nanodiamonds (FNDs), exhibiting superb physical and chemical properties for diagnostic imaging applications. We have developed a simple, fast, and robust method to encapsulate FNDs in polydopamine that can be further functionalized. By integrating anatomical and molecular based imaging capabilities, multimodal nanoparticle probes are becoming important in the paradigm shift from conventional to future imaging technologies. FNDs provide a highly stable, biocompatible, and nontoxic multimodal nanoprobe for effective and precise integrated diagnosis applications for various disease. In the near term the FNDs have proven to be effective research tools, the effectiveness of which will be enhanced with the several multimode imaging approaches that can be achieved with the FNDs.</p> This encapsulation method is simple, robust, and reproducible. Improving diagnostic and medical imaging. We are seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. 2023-12-08 2025-05-29 2025-05-29 2024-03-27 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 151719461 Jung, Haksung National Heart, Lung, and Blood Institute (NHLBI) NHLBI Jung, Haksung (NHLBI) 1 151719469 Neuman, Keir National Heart, Lung, and Blood Institute (NHLBI) NHLBI Neuman, Keir (NHLBI) 2 151719461 Jung, Haksung National Heart, Lung, and Blood Institute (NHLBI) NHLBI Jung, Haksung (NHLBI) 1 151719469 Neuman, Keir National Heart, Lung, and Blood Institute (NHLBI) NHLBI Neuman, Keir (NHLBI) 2 151719457 Encapsulation Of Fluorescent Nanodiamonds Into Poly-dopamine (PDA Shell And Further Covalent Functionalization Of The PDA Shell E-196-2017-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-4523] Encapsulation of Fluorescent Nanodiamonds into Poly-dopamine (PDA) Shell and Further Covalent Functionalization of the PDA Shell for Diagnostic Imaging Applications&body=Please send me information about technology [TAB-4523] Encapsulation of Fluorescent Nanodiamonds into Poly-dopamine (PDA) Shell and Further Covalent Functionalization of the PDA Shell for Diagnostic Imaging Applications. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-4523] Encapsulation of Fluorescent Nanodiamonds into Poly-dopamine (PDA) Shell and Further Covalent Functionalization of the PDA Shell for Diagnostic Imaging Applications&body=Please send me information about technology [TAB-4523] Encapsulation of Fluorescent Nanodiamonds into Poly-dopamine (PDA) Shell and Further Covalent Functionalization of the PDA Shell for Diagnostic Imaging Applications.">shmilovm@nih.gov</a><br> 157755693 E-196-2017-0 E-196-2017-0-US-01 POLYDOPAMINE-ENCAPSULATED NANODIAMONDS AND METHODS PRV US 62/565,552 Abandoned US <br />Provisional (PRV) 62/565,552<br />Filed on 2017-09-29<br />Status: Abandoned 157755702 E-196-2017-0 E-196-2017-0-PCT-02 POLYDOPAMINE-ENCAPSULATED NANODIAMONDS AND METHODS PCT Patent Cooperation Treaty PCT/US2018/053010 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2018/053010<br />Filed on 2018-09-27<br />Status: Expired 157755707 E-196-2017-0 E-196-2017-0-US-03 POLYDOPAMINE-ENCAPSULATED NANODIAMONDS AND METHODS National Stage US 16/650,507 Abandoned US <br />National Stage 16/650,507<br />Filed on 2020-03-25<br />Status: Abandoned TAB-4494 151704269 General-purpose Deep Learning Image Denoising Based on Magnetic Resonance Imaging Physics NHLBI Computational models/software, Licensing, Software / Apps Computational models/software Licensing Software / Apps Peter Kellman, Hui Xue <p>This technology includes a novel method to train deep learning convolution neural network model to improve the signal-noise-ratio for the magnetic resonance (MR) imaging. The novelty lies on the fact that actual MR imaging physics information is used in the deep learning training. The resulting model achieves significant signal-to-noise ratio (SNR) improved for different acceleration factors in MR imaging. The resulting model can be used for many body anatomies (e.g., brain, heart, liver, spine, etc.) to significantly improve the SNR. This solution is fast enough to be used clinically and has already been implemented on MR scanners.</p> <ul> <li>Better/correct way to do deep learning magnetic resonance denoising</li> <li>Ability to break g-factor barrier for up to 5x acceleration</li> <li>Ability to work across scanners/anatomy/imaging protocols</li> <li>No assumption on deep learning model architecture</li> </ul> <ul> <li>The resulting model is general-purposed and is applicable to many MR imaging applications and different human anatomy.</li> <li>This is a technique which can be used in every clinical MR scan to improve SNR.</li> </ul> We are seeking statements of capability or interest from parties interested in collaborative research to further developer, evaluate, or commercialize this technology. 2023-12-07 2025-05-29 2025-05-29 2024-03-27 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 151704276 Xue, Hui National Heart, Lung, and Blood Institute (NHLBI) NHLBI Xue, Hui (NHLBI) 1 151704280 Kellman, Peter National Heart, Lung, and Blood Institute (NHLBI) NHLBI Kellman, Peter (NHLBI) 2 151704276 Xue, Hui National Heart, Lung, and Blood Institute (NHLBI) NHLBI Xue, Hui (NHLBI) 1 151704280 Kellman, Peter National Heart, Lung, and Blood Institute (NHLBI) NHLBI Kellman, Peter (NHLBI) 2 151704272 General-purpose Deep Learning Image Denoising Based On Magnetic Resonance Imaging Physics E-104-2021-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 89788013 Kolesnitchenko, Vincent vk5q@nih.gov
United States of America Office of Technology Transfer and Development vk5q@nih.gov?subject=Web Inquiry on [TAB-4494] General-purpose Deep Learning Image Denoising Based on Magnetic Resonance Imaging Physics&body=Please send me information about technology [TAB-4494] General-purpose Deep Learning Image Denoising Based on Magnetic Resonance Imaging Physics. Kolesnitchenko, Vincent<br><a href="mailto:vk5q@nih.gov?subject=Web Inquiry on [TAB-4494] General-purpose Deep Learning Image Denoising Based on Magnetic Resonance Imaging Physics&body=Please send me information about technology [TAB-4494] General-purpose Deep Learning Image Denoising Based on Magnetic Resonance Imaging Physics.">vk5q@nih.gov</a><br> TAB-4473 156318756 Human Monoclonal Antibodies That Target the RH5 Complex of Blood-Stage Plasmodium Falciparum NIAID Antibodies, Diagnostics, Licensing, Therapeutics Antibodies Diagnostics Licensing Therapeutics Andrew Cooper, Joshua Tan, Lawrence Wang <p>249 million people were afflicted with malaria in 2022. There are five Plasmodium parasite species that cause malaria in humans. Of the five, Plasmodium falciparum causes most of the incidence of human disease. Most advanced malaria vaccine candidates can confer only partial, short-term protection in malaria-endemic areas. The pathogenesis of malaria is associated with blood-stage infection and antibodies specific to the parasite blood-stage antigens may be able to control parasitemia. To address this public health need, NIAID inventors have developed 35 human monoclonal antibodies that target the RH5 complex of blood-stage Plasmodium falciparum and were found to have potent activity in in vitro growth inhibition assays.</p> <ul> <li>Most other commercially available antibodies targeting against Plasmodium target circumsporozoite protein (CSP) present in the sporozoite stage. These novel antibodies instead target a conserved and essential antigen present in the blood stage: RH5.</li> <li> These monoclonal antibodies can be used alone or in combination with existing antibodies.</li> </ul> <ul> <li>Method of prophylactic and/or therapeutic treatment by targeting blood-stage antigens of Plasmodium.</li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. For collaboration opportunities, please contact Dr. Logan Richards at 301-761-5293 or logan.richards@nih.gov. 2024-05-30 2025-05-29 2025-05-29 2024-05-31 False False Pre-clinical True 37470483 Website Abstract 156319321 Wang, L., et al., “Natural malaria infection elicits rare but potent neutralizing antibodies to the blood-stage antigen RH5.” bioRxiv. https://www.biorxiv.org/​content/​10.1101/​2023.10.04.560669v1, October 06, 2023. Wang, L., et al., “Natural malaria infection elicits rare but potent neutralizing antibodies to the blood-stage antigen RH5.” bioRxiv. https://www.biorxiv.org/​content/​10.1101/​2023.10.04.560669v1, October 06, 2023. 156318771 Tan, Joshua National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Tan, Joshua (NIAID) 1 156319000 Wang, Lawrence NIAID - VRC NIAID Wang, Lawrence (NIAID) 2 156319031 Cooper, Andrew NIH - NIAID Cooper, Andrew 3 156318771 Tan, Joshua National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Tan, Joshua (NIAID) 1 156319000 Wang, Lawrence NIAID - VRC NIAID Wang, Lawrence (NIAID) 2 156319031 Cooper, Andrew NIH - NIAID Cooper, Andrew 3 156318759 Human Monoclonal Antibodies That Target The RH5 Complex Of Blood-stage Plasmodium Falciparum” E-014-2023-0 Filing authorized NIAID 83738793 Taylor-Mulneix, Dawn dawn.taylor-mulneix@nih.gov
United States of America dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-4473] Human Monoclonal Antibodies That Target the RH5 Complex of Blood-Stage Plasmodium Falciparum&body=Please send me information about technology [TAB-4473] Human Monoclonal Antibodies That Target the RH5 Complex of Blood-Stage Plasmodium Falciparum. Taylor-Mulneix, Dawn<br><a href="mailto:dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-4473] Human Monoclonal Antibodies That Target the RH5 Complex of Blood-Stage Plasmodium Falciparum&body=Please send me information about technology [TAB-4473] Human Monoclonal Antibodies That Target the RH5 Complex of Blood-Stage Plasmodium Falciparum.">dawn.taylor-mulneix@nih.gov</a><br> TAB-4464 147519715 Alpha-galactosidase-A Knockout Mouse Model for Studying Fabry Disease NIDCR Animal Models, Materials Available, Metabolic Disease, Rare/Neglected Diseases, Research Materials, Therapeutics, Vaccines Animal Models Materials Available Metabolic Disease Rare/Neglected Diseases Research Materials Therapeutics Vaccines Roscoe Brady, Ashok Kulkarni, Gary Murray, Toshio Ohshima <p>This technology includes an alpha-galactosidase-A knockout mouse model that can be used to study Fabry disease, an X-linked lysosomal storage disorder. Alpha-galactosidase-A is a crucial enzyme responsible for the breakdown of glycolipids, particularly globotriaosylceramide (Gb3), within lysosomes. In Fabry disease, a rare and inherited lysosomal storage disorder, mutations in the GLA gene lead to deficient or non-functional alpha-galactosidase-A enzyme activity. This enzymatic deficiency results in the progressive accumulation of Gb3 and related glycolipids in various cells and tissues, causing multisystemic manifestations such as renal dysfunction, cardiac abnormalities, neuropathic pain, and skin lesions. This invention, an alpha-galactosidase-A knockout mouse model, serves as a platform for preclinical trials, enabling the evaluation of novel enzyme replacement therapies, substrate reduction therapies, and gene therapy approaches.</p> Potential for wide variety of uses for therapeutic development. Expedite the development of targeted interventions. 2023-08-30 2025-05-29 2025-05-29 2023-08-30 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 147519976 Ohshima T, et al., 1997 https://pubmed.ncbi.nlm.nih.gov/9122231/ <a href="https://pubmed.ncbi.nlm.nih.gov/9122231/">Ohshima T, et al., 1997</a> 147519985 Ohshima T, et al., 1995 https://pubmed.ncbi.nlm.nih.gov/8543175/ <a href="https://pubmed.ncbi.nlm.nih.gov/8543175/">Ohshima T, et al., 1995</a> 147519758 Ohshima, Toshio NIDCR Ohshima, Toshio 1 147519802 Kulkarni, Ashok NIDCR NIDCR Kulkarni, Ashok (NIDCR) 2 147519814 Brady, Roscoe NINDS NINDS Brady, Roscoe (NINDS) 3 147519822 Murray, Gary National Institute on Alcohol Abuse and Alcoholism (NIAAA) NIAAA Murray, Gary (NIAAA) 4 147519758 Ohshima, Toshio NIDCR Ohshima, Toshio 1 147519802 Kulkarni, Ashok NIDCR NIDCR Kulkarni, Ashok (NIDCR) 2 147519814 Brady, Roscoe NINDS NINDS Brady, Roscoe (NINDS) 3 147519822 Murray, Gary National Institute on Alcohol Abuse and Alcoholism (NIAAA) NIAAA Murray, Gary (NIAAA) 4 147519718 KNOCKOUT MOUSE MODEL FOR FABRY DISEASE E-124-1997-0 Research Material NIDCR, NINDS 83739611 Yonter, Ediz ediz.yonter@nih.gov
United States of America Technology Advancement Office ediz.yonter@nih.gov?subject=Web Inquiry on [TAB-4464] Alpha-galactosidase-A Knockout Mouse Model for Studying Fabry Disease&body=Please send me information about technology [TAB-4464] Alpha-galactosidase-A Knockout Mouse Model for Studying Fabry Disease. Yonter, Ediz<br><a href="mailto:ediz.yonter@nih.gov?subject=Web Inquiry on [TAB-4464] Alpha-galactosidase-A Knockout Mouse Model for Studying Fabry Disease&body=Please send me information about technology [TAB-4464] Alpha-galactosidase-A Knockout Mouse Model for Studying Fabry Disease.">ediz.yonter@nih.gov</a><br> TAB-4159 147157442 Murine metastatic pancreatic adenocarcinoma cell lines NCI Collaboration, Licensing, Oncology, Research Materials Collaboration Licensing Oncology Research Materials Melanie Gordon, Theresa Guerin, Myhaymin Kamal, Serguei Kozlov, Theresa O'Sullivan, Jerome Schlomer, Ludmila Szabova, Terry Van Dyke <p>Researchers at the National Cancer Institute (NCI) have developed orthotopic allograft models for pancreatic cancer that utilize low passage primary pancreatic adenocarcinoma cells or tumor fragments implanted into the cancer-free pancreata of recipient syngeneic immunocompetent mice. Tumor development in these models is more synchronized, latency is substantially shortened, and tumors develop only in one location, as pre-determined by the choice of a site for cells/tumor fragment implantation. This technology is the first in vivo model of metastatic pancreatic cancer utilizing an orthotopic transplantation procedure, which allows engrafting of tumor pieces into immunocompetent mice. This procedure can be used for the timed production of large cohorts of experimental animals developing pancreatic cancer for preclinical studies within a reasonable time frame and at a significant cost reduction.<br /> The NCI technology represents cell lines derived from primary pancreatic tumors and orthotopic mouse models for pancreatic cancer; cell lines and orthotopic mouse models are derived from following genotypes:<br /> KraslSL-G12D ki/+; Trp53LSL-R172H ki/+;Pdx-1-Cre<br /> KrasLSL-G12D ki/+; Trp53 R172H&lt;wt2mut&gt;/Koz ki/+; Pdx-1-Cre<br /> KrasLSL-G12D ki/+; Trp53 R270H&lt;wt2mut&gt;/Koz ki/+; Pdx-1-Cre<br /> KrasLSL-G12D ki/+; Trp53 LSL-R172H ki/+; ROSA-luc4 ki/+; Pdx-1-Cre<br /> KrasLSL-G12D ki/+; Pdx-1-Cre</p> <p> </p> <h2>Competitive Advantages:</h2> <ul><li>Useful as a more accurate and clinically relevant experimental platform for conducting preclinical level cytotoxicity, PK, PD, drug tolerance, and efficacy studies for cancer treatment compounds</li> <li>Also suitable for mechanistic studies on cancer disease, biomarker discovery, drug screening, high-throughput mutational analyses in cell lines and in vivo grafted tumors, translational research on drug resistance mechanisms, etc.</li> <li>As the only preclinical cancer model type featuring fully functional immune system, widely applicable for informative immuno-oncology research and evaluation of novel therapeutic strategies that include a growing spectrum of immunomodulatory agents  </li> </ul> <h2>Commercial Applications:</h2> <ul><li>Can be applied in a variety of translational projects aimed at biomarker discovery and preclinical applications</li> <li>Pharmacodynamics/pharmacokinetics, cytotoxicity and efficacy studies</li> <li>Testing of new disease-specific imaging agents, imaging modalities and therapeutic strategies, such as immunomodulatory agents or combinatorial approaches</li> <li>Models can be further optimized to better mimic clinical impact of metastatic spread after primary tumor resection</li> </ul> 2018-02-16 2025-05-29 2018-02-16 2025-05-29 2018-02-16 ADENOCARCINOMA, CANCER, GEM-Derived Allograft, Inflammation, Kozlov, Mouse Models, Pancreatic False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2018-02-16 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147163729 Kozlov, Serguei NIH - NCI Leidos Kozlov, Serguei (Leidos) 1 147163728 Szabova, Ludmila NIH - NCI Leidos Szabova, Ludmila (Leidos) 2 147163730 Gordon, Melanie NIH - NCI Leidos Gordon, Melanie (Leidos) 3 147163731 Kamal, Myhaymin NIH - NCI Kamal, Myhaymin 4 147163732 Schlomer, Jerome NIH - NCI Leidos Schlomer, Jerome (Leidos) 5 147163733 Guerin, Theresa NIH - NCI Leidos Guerin, Theresa (Leidos) 6 147163726 O'Sullivan, Theresa NIH - NCI NCI O'Sullivan, Theresa (NCI) 7 147163727 Van Dyke, Terry NIH - NCI Van Dyke, Terry 8 147163729 Kozlov, Serguei NIH - NCI Leidos Kozlov, Serguei (Leidos) 1 147163728 Szabova, Ludmila NIH - NCI Leidos Szabova, Ludmila (Leidos) 2 147163730 Gordon, Melanie NIH - NCI Leidos Gordon, Melanie (Leidos) 3 147163731 Kamal, Myhaymin NIH - NCI Kamal, Myhaymin 4 147163732 Schlomer, Jerome NIH - NCI Leidos Schlomer, Jerome (Leidos) 5 147163733 Guerin, Theresa NIH - NCI Leidos Guerin, Theresa (Leidos) 6 147163726 O'Sullivan, Theresa NIH - NCI NCI O'Sullivan, Theresa (NCI) 7 147163727 Van Dyke, Terry NIH - NCI Van Dyke, Terry 8 147158274 Derivation Of Novel Murine Metastatic Pancreatic Adenocarcinoma Cell Lines For The Purpose Of Generating Orthotopic Allograft Mouse Models Useful For Preclinical Testing E-250-2017-0 Research Material NCI 83732917 Favila, Michelle michelle.favila@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC michelle.favila@nih.gov?subject=Web Inquiry on [TAB-4159] Murine metastatic pancreatic adenocarcinoma cell lines&body=Please send me information about technology [TAB-4159] Murine metastatic pancreatic adenocarcinoma cell lines.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Favila, Michelle<br><a href="mailto:michelle.favila@nih.gov?subject=Web Inquiry on [TAB-4159] Murine metastatic pancreatic adenocarcinoma cell lines&body=Please send me information about technology [TAB-4159] Murine metastatic pancreatic adenocarcinoma cell lines.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">michelle.favila@nih.gov</a><br> 147174262 ADENOCARCINOMA 147174263 CANCER 147174265 GEM-Derived Allograft 147174266 Inflammation 147174268 Kozlov 147174270 Mouse Models 147174271 Pancreatic TAB-3723 114097575 Human Monoclonal Antibodies that Broadly Target Coronaviruses NIAID Antibodies, Infectious Disease, Licensing Antibodies Infectious Disease Licensing Cherelle Dacon, Joshua Tan <p>An abstract for this invention was published in the Federal Register on June 10, 2022. The family of coronaviruses cause upper respiratory tract disease in humans and have caused three major disease outbreaks in recent history: the 2003 SARS outbreak, the 2012 MERS outbreak, and the current SARS-CoV-2 pandemic. There is an urgent need for strategies that broadly target coronaviruses, both to deal with new SARS-CoV-2 variants and future coronavirus outbreaks.</p> <p>Scientists at NIAID have developed several novel human monoclonal antibodies that bind to conserved parts of the SARS-CoV-2 spike protein. These antibodies can neutralize SARS-CoV-2 variants of concern including Omicron BA.1 and BA.2, as well as neutralize at least one other betacoronavirus. Further, these antibodies limit disease in animal models. Broadly reactive antibodies against coronaviruses are useful tools to identify conserved sites on the coronavirus spike protein, which could be investigated for the development of broad coronavirus vaccines that aim to prevent future pandemics. Potent neutralizers that target these sites could also be useful for prevention of disease caused by diverse coronaviruses, including those that may emerge in the future.</p> <ul> <li>Antibodies can neutralize SARS-CoV-2 variants, including Omicron BA.1 and BA.2</li> <li>Antibodies can broadly target and neutralize betacoronaviruses</li> </ul> <ul>. <li>Prophylactic usage against SARS-CoV-2 and/or other betacoronaviruses in normal or high-risk populations</li> <li>Therapeutic treatment, alone or in combination, in patients with SARS-CoV-2 and/or other betacoronaviruses infections</li> <li>Assay development for surveillance, diagnostic, and prevention measures</li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. Areas of specific interest include (a) testing developability of these antibodies (e.g., biophysical characteristics, cross-reactivity, pharmacokinetics, toxicity), (b) pre-clinical model assessment, and (c) human clinical trials. For collaboration opportunities, please contact Dawn Taylor-Mulneix at <a href="mailto: dawn.taylor-mulneix@nih.gov."> dawn.taylor-mulneix@nih.gov.</a>or 1-301-767-5189 2022-09-22 2025-05-29 2025-05-29 2023-10-19 2IXXXX, 2XXXXX, antibodies, Broadly, Coronaviruses, Human, monoclonal, TARGET, That False True True NIHTT 37470483 Website Abstract 114172893 Dacon, C., et al. “Broadly neutralizing antibodies target the coronavirus fusion peptide” https://doi.org/10.1126/science.abq3773 <a href="https://doi.org/10.1126/science.abq3773">Dacon, C., et al. “Broadly neutralizing antibodies target the coronavirus fusion peptide” </a> 114111394 Dacon, Cherelle NIAID - VRC NIAID Dacon, Cherelle (NIAID) 0 114111395 Tan, Joshua NIAID - VRC NIAID Tan, Joshua (NIAID) 1 114111395 Tan, Joshua NIAID - VRC NIAID Tan, Joshua (NIAID) 1 114111394 Dacon, Cherelle NIAID - VRC NIAID Dacon, Cherelle (NIAID) 0 114102827 Human Monoclonal Antibodies That Broadly Target Coronaviruses E-047-2022-0 Filing authorized Catholic University of America, NIAID 83738793 Taylor-Mulneix, Dawn dawn.taylor-mulneix@nih.gov
United States of America dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-3723] Human Monoclonal Antibodies that Broadly Target Coronaviruses&body=Please send me information about technology [TAB-3723] Human Monoclonal Antibodies that Broadly Target Coronaviruses. Taylor-Mulneix, Dawn<br><a href="mailto:dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-3723] Human Monoclonal Antibodies that Broadly Target Coronaviruses&body=Please send me information about technology [TAB-3723] Human Monoclonal Antibodies that Broadly Target Coronaviruses.">dawn.taylor-mulneix@nih.gov</a><br> 114169556 E-047-2022-0 E-047-2022-0-US-01 Human Monoclonal Antibodies That Broadly Target Coronaviruses PRV US 63/308,898 Expired US <br />Provisional (PRV) 63/308,898<br />Filed on 2022-02-10<br />Status: Expired 114129403 2IXXXX 114129404 2XXXXX 114154822 Coronaviruses 114154823 TARGET 114154824 Broadly 114154825 That 114154826 antibodies 114154827 monoclonal 114154828 Human TAB-2486 114096683 Magnetic Resonance Arterial Wall Imaging Methods that Compensate for Patient Aperiodic Intrinsic Cardiac, Chest Wall, and Blood Flow-Induced Motions NIDDK Collaboration Collaboration Khaled Abd-Elmoniem, Ahmed Gharib, Roderic Pettigrew <p>The technology includes MRI methods, systems, and software for reliably imaging vasculature and vascular wall thickness while compensating for aperiodic intrinsic motion of a patient during respiration. To overcome the loss of the orthogonality due to uncompensated residual motions and after a lapse of time equal to the trigger delay commenced at the cardiac cycle, the system acquires multiple consecutive time-resolved images of the arterial wall. The cine images are processed offline and a wall thickness measurement is produced.</p> <p>The method improves arterial wall imaging by increasing the success rate of obtaining good and excellent quality images and imaging slice-vessel orthogonality. The method also provides more precise wall measurements and a more distinct difference between healthy subjects and patients.</p> <p>The methodology and system can be applied to any commercially available MRI scanner.</p> <p>Existing techniques suffer from image degradation due to aperiodic intrinsic cardiac, chest wall motions, or other bulk motion that often cause image blur and reduced wall sharpness. These techniques do not adequately address the time-dependent angular orientation of the arteries, whereby mispositioning of the imaged slice may cause disappearance of the lumen-wall interface altogether.</p> <p>In the new technology time-resolved arterial wall imaging overcomes the loss of the orthogonality due to uncompensated residual motion.</p> <ul> <li>early detection of vascular disease, </li> <li>research in the field of vascular disease, </li> <li>non-invasive assessment of the efficacy of medication and/or lifestyle changes in vascular health status in a particular subject, and </li> <li>assessment of the efficacy of new medications or new uses of existing medications to treat vascular disease.</li> </ul> The Biomedical and Metabolic Imaging Branch, NIDDK, NIH, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize time-resolved arterial wall imaging. For collaboration opportunities, please contact Khaled Z. Abd-Elmoniem at <a href="mailto:abdelmoniemkz@mail.nih.gov">abdelmoniemkz@mail.nih.gov</a>. 2022-03-08 2025-05-29 2025-05-29 2012-10-22 AA3AXX, AA3XXX, AAXXXX, AD3XXX, ADXXXX, Angiographic, ANGIOGRAPHY, ARTERIAL, ARTERIOSCLEROSIS, AXXXXX, Cardiac, CARDIOCIRULATORY, Cardiovascular, MRI, VASCULATURE, Vasculture False True <ul> <li>Prototype</li> <li>Early-stage</li> <li>Pre-clinical</li> <li>In vivo data available (human)</li> </ul> True NIHTT 37470483 Website Abstract 114171675 Plein S, et al. http://www.ncbi.nlm.nih.gov/pubmed/12540462 <a href="http://www.ncbi.nlm.nih.gov/pubmed/12540462">Plein S, et al.</a> 114171676 Hoffmann MH, et al. http://www.ncbi.nlm.nih.gov/pubmed/16021450 <a href="http://www.ncbi.nlm.nih.gov/pubmed/16021450">Hoffmann MH, et al.</a> 114171677 Ustun A, et al. http://www.ncbi.nlm.nih.gov/pubmed/17312038 <a href="http://www.ncbi.nlm.nih.gov/pubmed/17312038">Ustun A, et al.</a> 114171678 Roes SD, et al. http://www.ncbi.nlm.nih.gov/pubmed/18425831 <a href="http://www.ncbi.nlm.nih.gov/pubmed/18425831">Roes SD, et al.</a> 114171679 Abd-Elmoniem KZ, et al. http://www.ncbi.nlm.nih.gov/pubmed/20373403 <a href="http://www.ncbi.nlm.nih.gov/pubmed/20373403">Abd-Elmoniem KZ, et al.</a> 114171680 Spuentrup E, et al. http://www.ncbi.nlm.nih.gov/pubmed/11536409 <a href="http://www.ncbi.nlm.nih.gov/pubmed/11536409">Spuentrup E, et al.</a> 114107670 Gharib, Ahmed National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Gharib, Ahmed (NIDDK) 0 114107671 Pettigrew, Roderic NIBIB NIBIB Pettigrew, Roderic (NIBIB) 0 114107669 Abd-Elmoniem, Khaled National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Abd-Elmoniem, Khaled (NIDDK) 1 114107669 Abd-Elmoniem, Khaled National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Abd-Elmoniem, Khaled (NIDDK) 1 114107670 Gharib, Ahmed National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Gharib, Ahmed (NIDDK) 0 114107671 Pettigrew, Roderic NIBIB NIBIB Pettigrew, Roderic (NIBIB) 0 114101793 Arterial Wall MRI Using Time-Resolved Acquisition Of Phase-Sensitive DualInversion Recovery (TRAPD) E-185-2012-0 Filing authorized National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIBIB 83739611 Yonter, Ediz ediz.yonter@nih.gov
United States of America Technology Advancement Office ediz.yonter@nih.gov?subject=Web Inquiry on [TAB-2486] Magnetic Resonance Arterial Wall Imaging Methods that Compensate for Patient Aperiodic Intrinsic Cardiac, Chest Wall, and Blood Flow-Induced Motions&body=Please send me information about technology [TAB-2486] Magnetic Resonance Arterial Wall Imaging Methods that Compensate for Patient Aperiodic Intrinsic Cardiac, Chest Wall, and Blood Flow-Induced Motions. Yonter, Ediz<br><a href="mailto:ediz.yonter@nih.gov?subject=Web Inquiry on [TAB-2486] Magnetic Resonance Arterial Wall Imaging Methods that Compensate for Patient Aperiodic Intrinsic Cardiac, Chest Wall, and Blood Flow-Induced Motions&body=Please send me information about technology [TAB-2486] Magnetic Resonance Arterial Wall Imaging Methods that Compensate for Patient Aperiodic Intrinsic Cardiac, Chest Wall, and Blood Flow-Induced Motions.">ediz.yonter@nih.gov</a><br> 114166880 E-185-2012-0 E-185-2012-0-US-01 IMAGING AND DIAGNOSTIC METHODS, SYSTEMS, AND COMPUTER-READABLE MEDIA PRV US 61/692,191 Abandoned US <br />Provisional (PRV) 61/692,191<br />Filed on 2012-08-22<br />Status: Abandoned 114167230 E-185-2012-0 E-185-2012-0-PCT-02 Imaging And Diagnostic Methods, Systems, And Computer-Readable Media PCT Patent Cooperation Treaty PCT/US2013/055997 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2013/055997<br />Filed on 2013-08-21<br />Status: Expired 114168087 E-185-2012-0 E-185-2012-0-US-04 Imaging and Diagnostic Methods, Systems, and Computer-Readable Media National Stage US 11,464,413 14/423,037 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11464413 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11464413">11,464,413</a><br />Filed on 2015-02-20<br />Status: Issued 114122952 AD3XXX 114122954 AA3AXX 114122955 AXXXXX 114122956 ADXXXX 114122957 AAXXXX 114122958 AA3XXX 114143530 MRI 114143531 ANGIOGRAPHY 114143532 Angiographic 114143533 VASCULATURE 114143534 Vasculture 114143535 Cardiac 114143536 CARDIOCIRULATORY 114143537 Cardiovascular 114143538 ARTERIAL 114143539 ARTERIOSCLEROSIS TAB-4109 147157391 Glial Cell Line-Derived Neurotrophic Factor for the Treatment of Neurodegenerative Diseases and Diabetes NIDA Collaboration, Licensing, Neurology, Therapeutics Collaboration Licensing Neurology Therapeutics Qing Rong Liu <p>The <a href="http://www.drugabuse.gov/" target="_blank" rel="nofollow">National Institute on Drug Abuse</a> (NIDA) is seeking interested parties to license or co-develop GDNFOS peptides and non-coding RNAs as therapeutic agents for neurodegenerative diseases.</p> <p>Glial cell line-derived neurotrophic factor (GDNF) is a small human protein encoded by the GDNF gene. GDNF has been effective therapy in laboratory animal models of Parkinson's disease and protects several types of neurons in the brain and peripheral nervous system. Researchers at the NIDA have discovered primate-specific GDNFOS, encoded by the opposite strand of glial cell derived neurotrophic factor (GDNF) gene. The GDNFOS gene encodes for novel peptides. These secreted growth proteins have potential neurotrophic activity and were found to be reduced in the middle temporal gyrus of Alzheimer's disease patients, and they might play a synergistic role in neuroprotective effects of GDNF in the human brain. The NIDA inventors have also developed an antibody against GDNFOS3 and generated compounds that have potential pharmaceutical use. The compounds consist of GDNFOS nucleic acid transcripts, GDNFOS protein or a functional fragment for treatment of human neurodegenerative diseases. </p> <h2>Competitive Advantages:</h2> <ul><li>Secreted novel growth peptides</li> <li>An antibody against GDNFOS3 was developed</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Synergistic role in neuroprotective effects of GDNF</li> <li>Alzheimer's disease, Parkinson's disease,</li> <li>Amyotrophic lateral sclerosis, multiple sclerosis</li> <li>Diseases of peripheral organs such as diabetes mellitus type 1</li> </ul> 2016-02-16 2025-04-22 2021-01-26 2025-05-22 2017-08-30 ALS, GDNFOS3., Glial Cell Line Derived Neurotrophic Factor (GDNF), Multiple sclerosis, Parkinson's Disease False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2021-01-26 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147162026 Airavaara M, et al. Identification of novel GDNF isoforms and cis-antisense GDNFOS gene and their regulation in human middle temporal gyrus of Alzheimer disease. http://www.ncbi.nlm.nih.gov/pubmed/22081608 <a href="http://www.ncbi.nlm.nih.gov/pubmed/22081608">Airavaara M, et al. Identification of novel GDNF isoforms and cis-antisense GDNFOS gene and their regulation in human middle temporal gyrus of Alzheimer disease.</a> 162585935 per emails with M. Baxter per emails with M. Baxter 147163539 Liu, Qing Rong NIH - NIDA NIDA Liu, Qing Rong (NIDA) 1 147163539 Liu, Qing Rong NIH - NIDA NIDA Liu, Qing Rong (NIDA) 1 147157855 Novel GDNF Isoforms And Cis-antisense GDNFOS Gene E-044-2012-0 Filing authorized National Institute on Drug Abuse (NIDA) 83737255 Baxter, Merissa merissa.baxter@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB merissa.baxter@nih.gov?subject=Web Inquiry on [TAB-4109] Glial Cell Line-Derived Neurotrophic Factor for the Treatment of Neurodegenerative Diseases and Diabetes&body=Please send me information about technology [TAB-4109] Glial Cell Line-Derived Neurotrophic Factor for the Treatment of Neurodegenerative Diseases and Diabetes.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Baxter, Merissa<br><a href="mailto:merissa.baxter@nih.gov?subject=Web Inquiry on [TAB-4109] Glial Cell Line-Derived Neurotrophic Factor for the Treatment of Neurodegenerative Diseases and Diabetes&body=Please send me information about technology [TAB-4109] Glial Cell Line-Derived Neurotrophic Factor for the Treatment of Neurodegenerative Diseases and Diabetes.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">merissa.baxter@nih.gov</a><br> 147166578 E-044-2012-0 E-044-2012-0-US-01 Glial Cell Line-Derived Neurotrophic Factor (GDNF) Compositions And Use Thereof PRV US 61/619,296 Abandoned US <br />Provisional (PRV) 61/619,296<br />Filed on 2012-04-02<br />Status: Abandoned 147166579 E-044-2012-0 E-044-2012-0-US-02 GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR (GDNF) COMPOSITIONS AND USE THEREOF ORD US 8,999,927 13/855,533 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8999927 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8999927">8,999,927</a><br />Filed on 2013-04-02<br />Status: Issued 147170143 ALS 147170145 GDNFOS3. 147170147 Glial Cell Line Derived Neurotrophic Factor (GDNF) 147170148 Multiple sclerosis 147170149 Parkinson's Disease TAB-4539 151735895 Transgene Free Non-human Primate Induced Pluripotent Stem Cells (iPSCs) for Use in Pre-clinical Regenerative Medicine Research NHLBI Animal Models, Human iPSC Lines, Licensing, Research Materials Animal Models Human iPSC Lines Licensing Research Materials Cynthia Dunbar, So Gun Hong, Thomas Winkler <p>This technology includes rhesus macaque induced pluripotent stem cells (iPSCs) lines from multiple animals and various types of cells to establish this pre-clinical model. iPSCs are a type of pluripotent stem cell that can be generated from adult somatic cells. The iPSC technology holds great potential for regenerative medicine. Before clinical application, it is critical to evaluate safety and efficacy in a clinically-relevant animal model. We propose that non-human primate models are particularly relevant to test iPSC-based cell therapies.</p> Our iPSCs are transgene-free, containing a 303bp non-expressed, non-enhancer containing tag for in vivo tracking, and have been shown in vitro and in vivo to give rise to functional tissue. Potentially rhesus iPSC lines can be differentiated into any cell type of the organism, therefore, rhesus iPSCs are valuable for optimizing differentiation protocols and assessing their safety and efficacy before beginning clinical applications in regenerative medicine. We are seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. 2023-12-11 2024-08-12 2025-05-21 2024-03-27 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 151735903 Dunbar, Cynthia National Heart, Lung, and Blood Institute (NHLBI) NHLBI Dunbar, Cynthia (NHLBI) 1 151735912 Hong, So Gun National Heart, Lung, and Blood Institute (NHLBI) NHLBI Hong, So Gun (NHLBI) 2 151735916 Winkler, Thomas National Heart, Lung, and Blood Institute (NHLBI) NHLBI Winkler, Thomas (NHLBI) 3 151735903 Dunbar, Cynthia National Heart, Lung, and Blood Institute (NHLBI) NHLBI Dunbar, Cynthia (NHLBI) 1 151735912 Hong, So Gun National Heart, Lung, and Blood Institute (NHLBI) NHLBI Hong, So Gun (NHLBI) 2 151735916 Winkler, Thomas National Heart, Lung, and Blood Institute (NHLBI) NHLBI Winkler, Thomas (NHLBI) 3 151735898 Transgenic Free Non-human Primate Induced Pluripotent Stem Cells E-248-2014-0 Research Material National Heart, Lung, and Blood Institute (NHLBI) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-4539] Transgene Free Non-human Primate Induced Pluripotent Stem Cells (iPSCs) for Use in Pre-clinical Regenerative Medicine Research&body=Please send me information about technology [TAB-4539] Transgene Free Non-human Primate Induced Pluripotent Stem Cells (iPSCs) for Use in Pre-clinical Regenerative Medicine Research. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-4539] Transgene Free Non-human Primate Induced Pluripotent Stem Cells (iPSCs) for Use in Pre-clinical Regenerative Medicine Research&body=Please send me information about technology [TAB-4539] Transgene Free Non-human Primate Induced Pluripotent Stem Cells (iPSCs) for Use in Pre-clinical Regenerative Medicine Research.">shmilovm@nih.gov</a><br> TAB-4510 151706228 Use of VDAC inhibitor, VBIT4, as a Treatment for Lupus NHLBI Immunology, Licensing, Therapeutics Immunology Licensing Therapeutics Jay Chung, Jeonghan Kim, Varda Shoshan-Barmatz <p>This technology includes a small molecule drug (VDAC inhibitor, also known as VBIT4) that may be useful for inhibiting lupus disease. To test lupus animal model, VBIT4 was continuously administered for 5 weeks to mice and there was no mortality or clinical symptoms in these animals. Additionally, VBIT4 treatment blocked the development of skin lesions and alopecia of the ears and face, and suppressed the thickening of the epidermis that accompanies leukocyte infiltration. Supporting these results, VBIT4 treatment reduced both spleen and lymph node weight, as well as significantly diminished the typical symptoms of lupus. Our findings demonstrated that VBIT4 may be an effective drug for the treatment of lupus.</p> Current agents used for the treatment of lupus have several side effects and the VDAC axis exploits a completely new target in lupus therapy amenable via the use of small molecules interfering with the release of mitochondrial DNA. Treatment for lupus. We are seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. 2023-12-07 2024-08-12 2025-05-21 2024-03-20 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 151706282 Kim, Jeonghan National Heart, Lung, and Blood Institute (NHLBI) NHLBI Kim, Jeonghan (NHLBI) 1 151706286 Chung, Jay National Heart, Lung, and Blood Institute (NHLBI) NHLBI Chung, Jay (NHLBI) 2 151706290 Shoshan-Barmatz, Varda Ben-Gurion University of the Negev Shoshan-Barmatz, Varda 3 151706282 Kim, Jeonghan National Heart, Lung, and Blood Institute (NHLBI) NHLBI Kim, Jeonghan (NHLBI) 1 151706286 Chung, Jay National Heart, Lung, and Blood Institute (NHLBI) NHLBI Chung, Jay (NHLBI) 2 151706290 Shoshan-Barmatz, Varda Ben-Gurion University of the Negev Shoshan-Barmatz, Varda 3 151706231 Use Of VDAC Inhibitor VBIT 4 In Lupus Treatment E-149-2018-0 Filing authorized Ben-Gurion University of the Negev, National Heart, Lung, and Blood Institute (NHLBI) 90072936 Mistry, Pragnesh pragnesh.mistry@nih.gov
HNH6Z08 pragnesh.mistry@nih.gov?subject=Web Inquiry on [TAB-4510] Use of VDAC inhibitor, VBIT4, as a Treatment for Lupus&body=Please send me information about technology [TAB-4510] Use of VDAC inhibitor, VBIT4, as a Treatment for Lupus. Mistry, Pragnesh<br><a href="mailto:pragnesh.mistry@nih.gov?subject=Web Inquiry on [TAB-4510] Use of VDAC inhibitor, VBIT4, as a Treatment for Lupus&body=Please send me information about technology [TAB-4510] Use of VDAC inhibitor, VBIT4, as a Treatment for Lupus.">pragnesh.mistry@nih.gov</a><br> 157755266 E-149-2018-0 E-149-2018-0-US-01 VDAC INHIBITORS FOR TREATING AUTOIMMUNE DISEASES PRV US 62/771,211 Abandoned US <br />Provisional (PRV) 62/771,211<br />Filed on 2018-11-26<br />Status: Abandoned 157755271 E-149-2018-0 E-149-2018-0-PCT-02 Use Of VDAC Inhibitor VBIT 4 In Lupus Treatment PCT Patent Cooperation Treaty PCT/IL2019/051290 Expired Patent Cooperation Treaty <br />(PCT) PCT/IL2019/051290<br />Filed on 2019-11-26<br />Status: Expired 157755276 E-149-2018-0 E-149-2018-0-US-03 Use Of VDAC Inhibitor VBIT 4 In Lupus Treatment National Stage US 17/297,017 Abandoned US <br />National Stage 17/297,017<br />Filed on 2021-05-26<br />Status: Abandoned 157755281 E-149-2018-0 E-149-2018-0-EP-04 Use Of VDAC Inhibitor VBIT 4 In Lupus Treatment National Stage European Patent 19888509.7 Abandoned European Patent <br />National Stage 19888509.7<br />Filed on 2019-11-26<br />Status: Abandoned 157755286 E-149-2018-0 E-149-2018-0-CN-05 Use Of VDAC Inhibitor VBIT 4 In Lupus Treatment National Stage China 201980090212.4 Abandoned China <br />National Stage 201980090212.4<br />Filed on 2019-11-26<br />Status: Abandoned 157755297 E-149-2018-0 E-149-2018-0-IL-06 VDAC INHIBITORS FOR TREATING AUTOIMMUNE DISEASES National Stage Israel 283443 Abandoned Israel <br />National Stage 283443<br />Filed on 2021-05-25<br />Status: Abandoned TAB-4478 151643827 System for Automated Anatomical Structures Segmentation of Contrast-Enhanced Cardiac Computed Tomography Images NHLBI Cardiology, Computational models/software, Diagnostics, Licensing, Software / Apps Cardiology Computational models/software Diagnostics Licensing Software / Apps Mitchel Benovoy, Vy Bui, Marcus Chen, Li-Yueh Hsu <p>This technology includes a fully automatic 3D image processing system to segment the heart as well as other organs from contrast-enhanced cardiac computed tomography (CCT) images. Our method detects four cardiac chambers including left ventricle, right ventricle, left atrium, right atrium, as well as the ascending aorta and left ventricular myocardium. It also classifies noncardiac tissue structures in the CCT images such as lung, chest wall, spine, descending aorta, and liver. This automated system is based on computer vision algorithms to improve commonly used multi-atlas approach for automated segmentation of both cardiac and non-cardiac structures.</p> The proposed methods can be applied to standard contrast-enhanced CCT image studies to provide automated and complementary assessment of different cardiac chamber sizes, great vessel diameters, and hounsfield unit measurements in different organs, and can be extended to measure cardiac chamber size among different phases of dynamic CCT imaging to provide functional assessment. The methods can be incorporated into commercial medical imaging diagnostic workstations to assist the detection of structural anomalies or to evaluate disease progression and treatment effects. We are seeking statements of capability or interest from parties interested in collaborative research to further developer, evaluate, or commercialize this technology. 2023-12-06 2024-08-12 2025-05-20 2024-03-27 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 151644039 Bui, Vy Bui, Vy 1 151644084 Hsu, Li-Yueh National Heart, Lung, and Blood Institute (NHLBI) NHLBI Hsu, Li-Yueh (NHLBI) 2 151644088 Chen, Marcus National Heart, Lung, and Blood Institute (NHLBI) NHLBI Chen, Marcus (NHLBI) 3 151644125 Benovoy, Mitchel Circle Cardiovascular Imaging Inc Benovoy, Mitchel 4 151644039 Bui, Vy Bui, Vy 1 151644084 Hsu, Li-Yueh National Heart, Lung, and Blood Institute (NHLBI) NHLBI Hsu, Li-Yueh (NHLBI) 2 151644088 Chen, Marcus National Heart, Lung, and Blood Institute (NHLBI) NHLBI Chen, Marcus (NHLBI) 3 151644125 Benovoy, Mitchel Circle Cardiovascular Imaging Inc Benovoy, Mitchel 4 151643830 System For Automated Anatomical Structures Segmentation Of Contrast-Enhanced Cardiac Computed Tomography Images E-050-2019-0 Filing authorized Corstem Inc., National Heart, Lung, and Blood Institute (NHLBI) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-4478] System for Automated Anatomical Structures Segmentation of Contrast-Enhanced Cardiac Computed Tomography Images&body=Please send me information about technology [TAB-4478] System for Automated Anatomical Structures Segmentation of Contrast-Enhanced Cardiac Computed Tomography Images. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-4478] System for Automated Anatomical Structures Segmentation of Contrast-Enhanced Cardiac Computed Tomography Images&body=Please send me information about technology [TAB-4478] System for Automated Anatomical Structures Segmentation of Contrast-Enhanced Cardiac Computed Tomography Images.">shmilovm@nih.gov</a><br> TAB-4595 151763715 Antibodies to TMC1 Protein for Hearing Loss NIDCD Antibodies, Licensing, Materials Available, Research Materials, Therapeutics Antibodies Licensing Materials Available Research Materials Therapeutics Andrew Griffith, Valentina Labay, Tomoko Makishima <p>This technology includes antibodies for TMC1 protein as a treatment for hearing loss. TMC1 is one of the common genes causing hereditary hearing loss. Our laboratory used synthetic peptides corresponding to the TMC1 protein to immunize rabbits. The resulting antisera were shown to bind to TMC1 protein expressed in heterologous expression systems. TMC1 protein is required for the transduction of sound into electrical impulses in inner ear sensory cells.</p> <ul> <li>Antibodies that specifically bind TMC1 protein are difficult to make; there are commercially available antibodies to TMC1 but they do not appear to be as sensitive or specific or as carefully characterized as the antibodies generated in this invention. </li> </ul> <ul> <li>Future treatment for hearing loss. </li> </ul> 2023-12-12 2024-08-12 2025-05-19 2024-03-27 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 151763742 Labay V, et al. https://pubmed.ncbi.nlm.nih.gov/20672865/ <a href="https://pubmed.ncbi.nlm.nih.gov/20672865/">Labay V, et al.</a> 151763722 Griffith, Andrew National Institute on Deafness and Other Communication Disorders (NIDCD) NIDCD Griffith, Andrew (NIDCD) 1 151763726 Makishima, Tomoko University of Texas Medical Branch Makishima, Tomoko 2 151763734 Labay, Valentina Otsuka America Pharmaceutical, Inc. NCATS Labay, Valentina (NCATS) 3 151763722 Griffith, Andrew National Institute on Deafness and Other Communication Disorders (NIDCD) NIDCD Griffith, Andrew (NIDCD) 1 151763726 Makishima, Tomoko University of Texas Medical Branch Makishima, Tomoko 2 151763734 Labay, Valentina Otsuka America Pharmaceutical, Inc. NCATS Labay, Valentina (NCATS) 3 151763718 Antibodies To TMC1 Protein E-160-2016-0 Research Material National Institute on Deafness and Other Communication Disorders (NIDCD) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-4595] Antibodies to TMC1 Protein for Hearing Loss&body=Please send me information about technology [TAB-4595] Antibodies to TMC1 Protein for Hearing Loss. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-4595] Antibodies to TMC1 Protein for Hearing Loss&body=Please send me information about technology [TAB-4595] Antibodies to TMC1 Protein for Hearing Loss.">shmilovm@nih.gov</a><br> TAB-4497 151704608 Antibody to Mitochondrial Uniporter (MCU NHLBI Antibodies, Licensing, Materials Available, Research Materials Antibodies Licensing Materials Available Research Materials Toren Finkel, Xin Pan <p>This technology includes a generated polyclonal antibody in rabbit that detects the mitochondrial uniporter (MCU) protein. This antibody was created by immunizing rabbits with a synthesized sequence of the MCU protein and can be used to identify and quantify MCU protein in various tissues. The polyclonal nature of the antibody ensures it recognizes multiple epitopes on the MCU, enhancing detection reliability. This technology is crucial for understanding MCU&#39;s role in mitochondrial function and mammalian physiology.</p> The rabbit polyclonal antibody's ability to target multiple epitopes on the mitochondrial calcium uniporter (MCU) offers a competitive advantage in reliably detecting and quantifying MCU protein, crucial for in-depth studies of its role in mitochondrial function and overall cell physiology. The rabbit polyclonal antibody against the mitochondrial calcium uniporter (MCU) can be applied in biomedical research to investigate mitochondrial dysfunctions in various diseases, in drug development targeting mitochondrial pathways, and in advancing our understanding of cellular bioenergetics and apoptosis. We are seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. 2023-12-07 2024-08-12 2025-05-15 2024-03-27 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 151704833 Pan X, et al. https://pubmed.ncbi.nlm.nih.gov/24212091/ <a href="https://pubmed.ncbi.nlm.nih.gov/24212091/">Pan X, et al.</a> 151704615 Finkel, Toren National Heart, Lung, and Blood Institute (NHLBI) NHLBI Finkel, Toren (NHLBI) 1 151704619 Pan, Xin National Heart, Lung, and Blood Institute (NHLBI) NHLBI Pan, Xin (NHLBI) 2 151704615 Finkel, Toren National Heart, Lung, and Blood Institute (NHLBI) NHLBI Finkel, Toren (NHLBI) 1 151704619 Pan, Xin National Heart, Lung, and Blood Institute (NHLBI) NHLBI Pan, Xin (NHLBI) 2 151704611 Antibody To MCU E-113-2014-0 Research Material National Heart, Lung, and Blood Institute (NHLBI) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-4497] Antibody to Mitochondrial Uniporter (MCU&body=Please send me information about technology [TAB-4497] Antibody to Mitochondrial Uniporter (MCU. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-4497] Antibody to Mitochondrial Uniporter (MCU&body=Please send me information about technology [TAB-4497] Antibody to Mitochondrial Uniporter (MCU.">shmilovm@nih.gov</a><br> TAB-4480 151644437 Method to Detect and Quantify In Vivo Mitophagy NHLBI Animal Models, Diagnostics, Licensing, Materials Available, Neurology, Research Materials Animal Models Diagnostics Licensing Materials Available Neurology Research Materials Toren Finkel <p>This technology includes a transgenic reporter mouse that expresses a fluorescent protein called mt-Keima, to be used to detect and quantify in vivo mitophagy. This fluorescent protein was originally described by a group in Japan and shown to be able to measure both the general process of autophagy and mitophagy. We extended these results by creating a living animal so that we could get a measurement for in vivo mitophagy. Our results demonstrate that our mt-Keima mouse allows for a straightforward and practical way to quantify mitophagy in vivo. There is considerable interest in this process as defects in mitophagy have been linked to a number of age-related diseases including Parkinson&#39;s disease.</p> Until now the ability to measure mitophagy has been very limited and there have been no good ways of measuring this process in tissues and organs in vivo. License mouse model for detecting and quantifying in vivo mitophagy. We are seeking statements of capability or interest from parties interested in collaborative research to further developer, evaluate, or commercialize this technology. 2023-12-06 2024-08-12 2025-05-15 2024-03-20 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 151644449 Sun N, Yun J, et al. https://pubmed.ncbi.nlm.nih.gov/26549682/ [PMID 26549682] Katayama H, Kogure T, et al. https://pubmed.ncbi.nlm.nih.gov/21867919/ [PMID 21867919] https://pubmed.ncbi.nlm.nih.gov/26549682/ <a href="https://pubmed.ncbi.nlm.nih.gov/26549682/">Sun N, Yun J, et al. https://pubmed.ncbi.nlm.nih.gov/26549682/ [PMID 26549682] Katayama H, Kogure T, et al. https://pubmed.ncbi.nlm.nih.gov/21867919/ [PMID 21867919]</a> 151644445 Finkel, Toren National Heart, Lung, and Blood Institute (NHLBI) NHLBI Finkel, Toren (NHLBI) 1 151644445 Finkel, Toren National Heart, Lung, and Blood Institute (NHLBI) NHLBI Finkel, Toren (NHLBI) 1 151644440 Method To Detect In Vivo Mitophagy E-052-2016-0 Research Material National Heart, Lung, and Blood Institute (NHLBI) 83714317 Devany, John john.devany@nih.gov
United States of America Office of Technology Transfer and Development john.devany@nih.gov?subject=Web Inquiry on [TAB-4480] Method to Detect and Quantify In Vivo Mitophagy&body=Please send me information about technology [TAB-4480] Method to Detect and Quantify In Vivo Mitophagy. Devany, John<br><a href="mailto:john.devany@nih.gov?subject=Web Inquiry on [TAB-4480] Method to Detect and Quantify In Vivo Mitophagy&body=Please send me information about technology [TAB-4480] Method to Detect and Quantify In Vivo Mitophagy.">john.devany@nih.gov</a><br> TAB-2024 114096244 A Target for the Development of Diagnostics and Therapeutics for Abnormal Hematopoiesis NIEHS Collaboration, Diagnostics, Licensing, Research Materials, Therapeutics Collaboration Diagnostics Licensing Research Materials Therapeutics Perry Blackshear, Deborah Stumpo The zinc finger protein ZFP36L2 has been shown by the inventors to play an essential role in hematopoiesis, a process that is dysregulated in hematological cancers, anemia, and other conditions. Thus, ZFP36L2 has promise for use in a diagnostic test to detect abnormal hematopoiesis, or as a target for the development of therapeutics to treat abnormal hematopoiesis.<br><br> Hematopoiesis is the formation of blood cellular components, through the differentiation of hematopoietic stem cells into lineages with a variety of roles, such as carrying oxygen, immune function, and blood clotting. Abnormally high hematopoiesis can be caused by hematological cancers such as leukemia or lymphoma, or by other myeloproliferative disorders. Abnormally low hematopoiesis can be caused by diseases such as anemia, thrombocytopenia, or myelodysplastic syndrome, and is often a secondary symptom of other conditions, such as cancer, infection, or dialysis.<br><br> The inventors have discovered that Zinc finger protein 36 like type-2 (ZFP36L2) plays an essential role in hematopoiesis, possibly by affecting the stability of mRNAs involved in this process. ZFP36L2 is a member of the tristetraprolin (TTP) family, which are mRNA-binding proteins involved in mRNA processing and degradation. The invention discloses methods of detecting abnormal hematopoiesis by detecting abnormal ZFP36L2 expression or a mutation in the ZFP36L2 gene, and methods of controlling abnormal hematopoiesis by modulating levels of ZFP36L2 protein. <ul> <li>Diagnostic test to detect abnormal hematopoiesis</li> <li>Therapy for abnormal hematopoiesis</li> </ul> The NIEHS Laboratory of Signal Transduction, Polypeptide Hormone Action Group, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. Please contact Elizabeth M. Denholm, Ph.D., Director, Office of Technology Transfer, NIEHS, at <a href="mailto:denholme@niehs.nih.gov">denholme@niehs.nih.gov</a> for more information. Available for licensing. 2022-03-08 2025-05-15 2025-05-15 2009-10-12 (4)r syndrome, anemia, Blood, C syndrome, CANCER, Chromosome 4 ring syndrome, Chromosome 6 ring syndrome, Chromosome 7 ring syndrome, Chronic myelogenous leukemia, diagnostic, Diagnostic assay, diagnostic test, G syndrome, Hematologic, Hematopoiesis, Hypertelorism with esophageal abnormality and hypospadias, IAXXXX, IBXXXX, IXXXXX, Leukemia, lymphoma, N syndrome, Patent Category - Biotechnology, R(6) syndrome, R(7) syndrome, Syndrome X, therapeutic, Thrombocytopenia 2, Thrombocytopenia chromosome breakage, Tristetraprolin, W syndrome, W syndrome; Syndrome W, ZFP36L2, zinc finger False True Discovery stage True NIHTT 37470483 Website Abstract 114170945 DJ Stumpo, HE Broxmeyer, T Ward, S Cooper, G Hangoc, YJ Chung, WC Shelley, EK Richfield, MK Ray, MC Yoder, PD Aplan, PJ Blackshear. Targeted disruption of Zfp36l2, encoding a CCCH tandem zinc finger RNA-binding protein, results in defective hematopoiesis. Blood 2009 Sep 17;114(12):2401-2410. http://www.ncbi.nlm.nih.gov/pubmed/19633199?dopt <a href="http://www.ncbi.nlm.nih.gov/pubmed/19633199?dopt">DJ Stumpo, HE Broxmeyer, T Ward, S Cooper, G Hangoc, YJ Chung, WC Shelley, EK Richfield, MK Ray, MC Yoder, PD Aplan, PJ Blackshear. Targeted disruption of Zfp36l2, encoding a CCCH tandem zinc finger RNA-binding protein, results in defective hematopoiesis. Blood 2009 Sep 17;114(12):2401-2410.</a> 114106760 Stumpo, Deborah NIEHS NIEHS Stumpo, Deborah (NIEHS) 0 114106755 Blackshear, Perry NIEHS NIEHS Blackshear, Perry (NIEHS) 1 114106755 Blackshear, Perry NIEHS NIEHS Blackshear, Perry (NIEHS) 1 114106760 Stumpo, Deborah NIEHS NIEHS Stumpo, Deborah (NIEHS) 0 114101316 Controlling Hematopoiesis By Changing The Levels Or Activity Of ZFP36L2 E-255-2007-0 Filing authorized NIEHS 83739538 Choudhry, Vidita vidita.choudhry@nih.gov
United States of America Office of Technology Transfer and Development vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-2024] A Target for the Development of Diagnostics and Therapeutics for Abnormal Hematopoiesis&body=Please send me information about technology [TAB-2024] A Target for the Development of Diagnostics and Therapeutics for Abnormal Hematopoiesis. Choudhry, Vidita<br><a href="mailto:vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-2024] A Target for the Development of Diagnostics and Therapeutics for Abnormal Hematopoiesis&body=Please send me information about technology [TAB-2024] A Target for the Development of Diagnostics and Therapeutics for Abnormal Hematopoiesis.">vidita.choudhry@nih.gov</a><br> 114162985 E-255-2007-0 E-255-2007-0-US-01 DETECTING AND CONTROLLING ABNORMAL HEMATOPOIESIS PRV US 60/947,593 Abandoned US <br />Provisional (PRV) 60/947,593<br />Filed on 2007-07-02<br />Status: Abandoned 114162986 E-255-2007-0 E-255-2007-0-PCT-02 Detecting And Controlling Abnormal Hematopoiesis PCT Patent Cooperation Treaty PCT/US08/68900 Expired Patent Cooperation Treaty <br />(PCT) PCT/US08/68900<br />Filed on 2008-07-01<br />Status: Expired 114165709 E-255-2007-0 E-255-2007-0-US-05 Detecting And Controlling Abnormal Hematopoiesis National Stage US 12/667,287 Abandoned US <br />National Stage 12/667,287<br />Filed on 2009-12-30<br />Status: Abandoned 114120653 IAXXXX 114120654 IBXXXX 114120655 IXXXXX 114138819 Leukemia 114138820 Hematopoiesis 114138821 anemia 114138822 zinc finger 114138823 CANCER 114138824 ZFP36L2 114138825 Patent Category - Biotechnology 114138826 Blood 114138827 Tristetraprolin 114138828 diagnostic 114138829 Diagnostic assay 114138830 diagnostic test 114138831 therapeutic 114138832 Hematologic 114156892 Syndrome X 114156893 C syndrome 114156894 lymphoma 114156895 Thrombocytopenia chromosome breakage 114156896 Chromosome 7 ring syndrome 114156897 Chronic myelogenous leukemia 114156898 W syndrome 114156899 Hypertelorism with esophageal abnormality and hypospadias 114156900 N syndrome 114156901 Chromosome 6 ring syndrome 114156902 Chromosome 4 ring syndrome 114158535 Thrombocytopenia 2 114158536 R(7) syndrome 114158537 W syndrome; Syndrome W 114158538 G syndrome 114158539 R(6) syndrome 114158540 (4)r syndrome TAB-3880 147157160 New Class of Immunotoxins with Extended Half-Life and High Anti-Tumor Activity NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Ira Pastan <p>Recombinant immunotoxins (RITs) constitute a promising solution to hematologic cancers (e.g., Multiple Myeloma [MM]). RITs are chimeric proteins composed of a targeting domain fused to a bacterial toxin. Upon binding to a cancer cell displaying the target antigen, RITs are internalized, metabolized and the released toxin kills the cell. While highly active and effective, current RITs have short half-lives, requiring them to be used in high concentrations for treatment. At such high concentrations, RITs may show nonspecific activity and kill healthy cells.</p> <p>Scientists from the National Cancer Institute’s (NCI) Laboratory of Molecular Biology developed a new class of RITs active in low doses and demonstrating prolonged stability in the body. Specifically, albumin binding domains (ABDs) have been introduced into the toxin portion of the RIT. ABDs allow the RIT to bind to serum albumin – extending the life of the RITs while not interfering with target specificity or cytotoxicity. The inventors have shown that low doses of the novel RITs display highly specific cytotoxicity in mouse models of MM. This approach can also be applied to other cancers by changing the targeting domain on the RIT.</p> <p>NCI is seeking parties interested in licensing this invention and/or collaborating to further develop and commercialize the new class of RITs with longer half-lives for treatment of cancers, including MM.</p> <h2>Competitive Advantages:</h2> <ul><li>Addition of albumin binding domains (ABDs) to immunotoxins lowers the required dose, resulting in fewer non-specific side effects</li> <li>Addition of ABDs does not interfere with target specificity; instead, indirectly improves therapeutic activity</li> <li>Ability to change the targeting domain allows for dynamic approach to specifically treat various cancers</li> <li>ABDs introduced into the toxin portion of the RIT dramatically increases their half-life in the circulation and antitumor activity in mice</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Immunotoxins (antibody conjugates) that remain active for longer time in the body can be used for treatment of various types of cancers</li> <li>Although the technology can be applied to any cancer, the inventors have demonstrated effectiveness with MM</li> <li>The MM market has exceeded US$15B with a compound annual growth rate CAGR of 6.7%</li> </ul> 2019-08-01 2025-05-14 2019-08-01 2025-05-14 2019-08-01 Abd, Albumin Binding Domain, antibody conjugate, B-cell Maturation Antigen, BCMA, Hematologic Cancer, Mm, MULTIPLE MYELOMA, Pastan, Recombinant Immunotoxin, Rit False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2019-08-01 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-117-2011 E-262-2005 E-263-2011 E-292-2007 E-771-2013 147162475 Shancer Z, et al. Preclinical development of anti-BCMA immunotoxins targeting multiple myeloma. https://www.ncbi.nlm.nih.gov/pubmed/30272049 <a href="https://www.ncbi.nlm.nih.gov/pubmed/30272049">Shancer Z, et al. Preclinical development of anti-BCMA immunotoxins targeting multiple myeloma.</a> 147162711 Pastan, Ira NIH - NCI NCI Pastan, Ira (NCI) 1 147162711 Pastan, Ira NIH - NCI NCI Pastan, Ira (NCI) 1 147158245 Recombinant Immunotoxins With Extended Half-life And High Cytotoxic And Anti-tumor Activity By Addition Of Albumin Binding Domain E-231-2017-0 Filing authorized NCI, NIH - NCI 83673032 Whitney, Laurie WhitneyL@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC WhitneyL@mail.nih.gov?subject=Web Inquiry on [TAB-3880] New Class of Immunotoxins with Extended Half-Life and High Anti-Tumor Activity&body=Please send me information about technology [TAB-3880] New Class of Immunotoxins with Extended Half-Life and High Anti-Tumor Activity.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Whitney, Laurie<br><a href="mailto:WhitneyL@mail.nih.gov?subject=Web Inquiry on [TAB-3880] New Class of Immunotoxins with Extended Half-Life and High Anti-Tumor Activity&body=Please send me information about technology [TAB-3880] New Class of Immunotoxins with Extended Half-Life and High Anti-Tumor Activity.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">WhitneyL@mail.nih.gov</a><br> 147161212 E-231-2017-0 E-231-2017-0-US-01 IMMUNOTOXINS WITH ALBUMIN BINDING DOMAIN PRV US 62/559,926 Abandoned US <br />Provisional (PRV) 62/559,926<br />Filed on 2017-09-18<br />Status: Abandoned 147165025 E-231-2017-0 E-231-2017-0-PCT-02 IMMUNOTOXINS WITH ALBUMIN BINDING DOMAIN PCT Patent Cooperation Treaty PCT/US2018/051418 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2018/051418<br />Filed on 2018-09-18<br />Status: Expired 147165026 E-231-2017-0 E-231-2017-0-US-03 IMMUNOTOXINS WITH ALBUMIN BINDING DOMAIN National Stage US 11,795,235 16/648,369 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11795235 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11795235">11,795,235</a><br />Filed on 2020-03-18<br />Status: Issued 147174013 Abd 147174015 Albumin Binding Domain 147174016 antibody conjugate 147174017 B-cell Maturation Antigen 147174018 BCMA 147174020 Hematologic Cancer 147174021 Mm 147174022 MULTIPLE MYELOMA 147174023 Pastan 147174024 Recombinant Immunotoxin 147174025 Rit TAB-4202 147157487 Improved PE-based Targeted Toxins: A Therapeutic with Increased Effectiveness NCI Cardiology, Collaboration, Licensing, Oncology, Therapeutics Cardiology Collaboration Licensing Oncology Therapeutics Richard Beers, Masanori Onda, Ira Pastan <p>Targeted toxins (e.g., immunotoxins) are therapeutics that have at least two important components: (1) a toxin domain that is capable of killing cells and (2) a targeting domain that is capable of selectively localizing the toxic domain to only those cells which should be killed. By selecting a targeting domain that binds only to certain diseased cells (e.g., a cell which only expresses a cell surface receptor when in a diseased state), targeted toxins can kill the diseased cells while allowing healthy, essential cells to survive. As a result, patients receiving a targeted toxin are less likely to experience the deleterious side-effects associated with non-discriminate therapies such as chemotherapy or radiation therapy.</p> <p> A particular toxin that has been used in targeted toxins is Pseudomonas exotoxin A (PE). The effectiveness of PE-containing targeted toxins has been demonstrated against various forms of cancer, including hairy cell leukemia (HCL) and pediatric acute lymphocytic leukemia (pALL). Although early variations these targeted toxins have demonstrated efficacy upon first administration, the continued administration of a targeted toxin often leads to a reduced patient response. The primary cause of the reduced response is the formation of neutralizing antibodies against PE by the patient.</p> <p> Several variations of PE have been created to reduce the immunogenicity of PE as a means of increasing the therapeutic effectiveness of targeted toxins through multiple rounds of drug administration. This technology involves the identification of two important B-cell epitopes on PE, and the elimination of those epitopes by mutation. These new PE variants retain a sufficient cell killing activity while increasing their therapeutic effectiveness toward patients that receive multiple administrations. By further combining these new mutations with previously identified modifications that also improve the efficacy of PE-based targeted toxins, it may be possible to treat any disease characterized by cells that express a particular cell surface receptor when in a disease state.</p> <h2>Competitive Advantages:</h2> <ul><li>Less immunogenic targeted toxin results in improved efficacy during multiple administrations</li> <li>Targeted therapy decreases non-specific killing of healthy, essential cells, resulting in fewer side-effects and healthier patients</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Treatment of diseases that are associated with the increased expression of a cell surface receptor</li> <li>Treatment for any disease associated with cells that preferentially express a specific cell surface receptor such as various cancers, including lung, ovarian, breast, head and neck, and hematological cancers.</li> </ul> 2016-02-16 2025-05-14 2016-08-31 2025-05-14 2016-09-08 Breast, HEAD, Hematological cancer, Immunotoxin, Ligand-targeted toxin, LUNG, NECK, OVARIAN, Toxin domain False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2016-08-31 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-129-2001 147163897 Pastan, Ira NIH - NCI NCI Pastan, Ira (NCI) 1 147163898 Beers, Richard NIH - NCI NCI Beers, Richard (NCI) 2 147163899 Onda, Masanori NIH - NCI NCI Onda, Masanori (NCI) 3 147163897 Pastan, Ira NIH - NCI NCI Pastan, Ira (NCI) 1 147163898 Beers, Richard NIH - NCI NCI Beers, Richard (NCI) 2 147163899 Onda, Masanori NIH - NCI NCI Onda, Masanori (NCI) 3 147158298 Development Of An Immunotoxin In Which All B-Cell Epitopes Have Been Removed And Which As High Cytotoxic Activity E-269-2009-0 Filing authorized NCI 83673032 Whitney, Laurie WhitneyL@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC WhitneyL@mail.nih.gov?subject=Web Inquiry on [TAB-4202] Improved PE-based Targeted Toxins: A Therapeutic with Increased Effectiveness&body=Please send me information about technology [TAB-4202] Improved PE-based Targeted Toxins: A Therapeutic with Increased Effectiveness.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Whitney, Laurie<br><a href="mailto:WhitneyL@mail.nih.gov?subject=Web Inquiry on [TAB-4202] Improved PE-based Targeted Toxins: A Therapeutic with Increased Effectiveness&body=Please send me information about technology [TAB-4202] Improved PE-based Targeted Toxins: A Therapeutic with Increased Effectiveness.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">WhitneyL@mail.nih.gov</a><br> 147167320 E-269-2009-0 E-269-2009-0-US-01 Improved Pseudomonas Exotoxin A With Reduced Immunogenicity PRV US 61/241,620 Abandoned US <br />Provisional (PRV) 61/241,620<br />Filed on 2009-09-11<br />Status: Abandoned 147167321 E-269-2009-0 E-269-2009-0-PCT-02 Improved Pseudomonas Exotoxin A With Reduced Immunogenicity PCT Patent Cooperation Treaty PCT/US2010/048504 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2010/048504<br />Filed on 2010-09-10<br />Status: Expired 147167322 E-269-2009-0 E-269-2009-0-AU-03 Improved Pseudomonas Exotoxin A With Reduced Immunogenicity National Stage Australia 2010292069 2010292069 Issued Australia <br />National Stage 2010292069<br />Filed on 2010-09-10<br />Status: Issued 147167323 E-269-2009-0 E-269-2009-0-CA-04 Improved Pseudomonas Exotoxin A With Reduced Immunogenicity National Stage Canada 2773665 2773665 Issued Canada <br />National Stage 2773665<br />Filed on 2015-09-04<br />Status: Issued 147167324 E-269-2009-0 E-269-2009-0-CN-05 Improved Pseudomonas Exotoxin A With Reduced Immunogenicity National Stage China ZL201080049559.3 201080049559.3 Abandoned China <br />National Stage 201080049559.3<br />Filed on 2010-09-10<br />Status: Abandoned 147167325 E-269-2009-0 E-269-2009-0-EP-06 Improved Pseudomonas Exotoxin A With Reduced Immunogenicity National Stage European Patent 2544805 10755283.8 Issued European Patent <br />National Stage 10755283.8<br />Filed on 2010-09-10<br />Status: Issued 147167326 E-269-2009-0 E-269-2009-0-IN-07 Improved Pseudomonas Exotoxin A With Reduced Immunogenicity National Stage India 3197/CHENP/2012 Abandoned India <br />National Stage 3197/CHENP/2012<br />Filed on 2012-09-10<br />Status: Abandoned 147167327 E-269-2009-0 E-269-2009-0-JP-08 Improved Pseudomonas Exotoxin A With Reduced Immunogenicity National Stage Japan 5795765 2012-528940 Issued Japan <br />National Stage 2012-528940<br />Filed on 2010-09-10<br />Status: Issued 147167328 E-269-2009-0 E-269-2009-0-RU-09 Improved Pseudomonas Exotoxin A With Reduced Immunogenicity National Stage Russia 2012114005 Abandoned Russia <br />National Stage 2012114005<br />Filed on 2012-10-04<br />Status: Abandoned 147167329 E-269-2009-0 E-269-2009-0-US-10 Pseudomonas Exotoxin A With Reduced Immunogenicity National Stage US 8,936,792 13/395,422 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8936792 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8936792">8,936,792</a><br />Filed on 2012-06-25<br />Status: Issued 147167330 E-269-2009-0 E-269-2009-0-DE-11 Improved Pseudomonas Exotoxin A With Reduced Immunogenicity EP Germany 602010024785.6 10755283.8 Issued Germany <br />European patent (EP) 10755283.8<br />Filed on 2010-09-10<br />Status: Issued 147167331 E-269-2009-0 E-269-2009-0-ES-12 Improved Pseudomonas Exotoxin A With Reduced Immunogenicity EP Spain 2475398 10755283.8 Issued Spain <br />European patent (EP) 10755283.8<br />Filed on 2010-09-10<br />Status: Issued 147167332 E-269-2009-0 E-269-2009-0-FR-13 Improved Pseudomonas Exotoxin A With Reduced Immunogenicity EP France 2475398 10755283.8 Issued France <br />European patent (EP) 10755283.8<br />Filed on 2010-09-10<br />Status: Issued 147167333 E-269-2009-0 E-269-2009-0-GB-14 Improved Pseudomonas Exotoxin A With Reduced Immunogenicity EP United Kingdom 2475398 10755283.8 Issued United Kingdom <br />European patent (EP) 10755283.8<br />Filed on 2010-09-10<br />Status: Issued 147167334 E-269-2009-0 E-269-2009-0-IT-15 Improved Pseudomonas Exotoxin A With Reduced Immunogenicity EP Italy 2475398 10755283.8 Issued Italy <br />European patent (EP) 10755283.8<br />Filed on 2010-09-10<br />Status: Issued 147174456 Breast 147174457 HEAD 147174459 Hematological cancer 147174460 Immunotoxin 147174462 Ligand-targeted toxin 147174463 LUNG 147174464 NECK 147174465 OVARIAN 147174467 Toxin domain TAB-4371 147157665 Monoclonal Antibodies and Immunoconjugates Directed to the Non-ShedPortion (“Stalk”) of Mesothelin are Excellent Candidates for Developing Therapeutic Agents NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Tapan Bera, Mitchell Ho, Masanori Onda, Ira Pastan <p>Human mesothelin is overexpressed by various cancers such as synovial sarcoma, mesothelioma, and ovarian, lung, esophageal, and gastric cancers. This selective expression on certain cancers suggests that mesothelin is an excellent target for anticancer therapeutics. However, a large fragment (“the shed portion”) of mesothelin is constantly shed from cells, and all current anti-mesothelin antibodies bind to the shed portion. As a result, the therapeutic efficacy of these antibodies has been low because they are unable to exert their therapeutic effect on the cell before their binding region is shed.</p> <p>Fortunately, a piece (“the stalk”) of mesothelin remains attached to the cell surface after shedding.  Since antibodies to the stalk would remain bound to diseased cells, they can be more effective in killing cancer cells than currently available anti-mesothelin antibodies. Scientists at the National Cancer Institute (NCI) have invented antibodies that specifically recognize and bind to the stalk of human mesothelin with high affinity.  These antibodies represent excellent candidates for development of therapeutic agents and are available for licensing and/or co-development opportunities.</p> <h2>Competitive Advantages:</h2> <ul><li style="margin:0in 0in 0pt">This is the only antibody that binds to the stalk portion of mesothelin, allowing the antibody to remain attached to the cell to exert a therapeutic effect</li> <li style="margin:0in 0in 0pt">Specific binding to cancer cells allows selective killing, potentially limiting drug side effects and improving patient quality of life</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Therapeutic Uses <ul><li>As an unconjugated antibody</li> <li>As a targeting moiety for CARs, antibody-drug conjugates (ADC), immunotoxins, bispecific antibodies, etc.</li> </ul></li> <li>Diagnostic agent for detection and monitoring levels of mesothelin-expressing cancer cells</li> </ul> 2019-04-26 2025-05-14 2019-04-26 2025-05-14 2019-04-26 ANTIBODY, CANCER, CAR, chimeric antigen receptor, diagnostic, IMMUNOCONJUGATES, IMMUNOTOXINS, MESOTHELIN, Pastan, therapeutic False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2019-04-26 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-262-2005 E-292-2007 147161880 Awuah et al., Reduced Shedding of Surface Mesothelin Improves Efficacy of Mesothelin-Targeting Recombinant Immunotoxins. https://www.ncbi.nlm.nih.gov/pubmed/27196771 <a href="https://www.ncbi.nlm.nih.gov/pubmed/27196771">Awuah et al., Reduced Shedding of Surface Mesothelin Improves Efficacy of Mesothelin-Targeting Recombinant Immunotoxins.</a> 147164475 Pastan, Ira NIH - NCI NCI Pastan, Ira (NCI) 1 147164477 Onda, Masanori NIH - NCI NCI Onda, Masanori (NCI) 2 147164476 Bera, Tapan NIH - NCI NCI Bera, Tapan (NCI) 3 147164478 Ho, Mitchell NIH - NCI NCI Ho, Mitchell (NCI) 4 147164475 Pastan, Ira NIH - NCI NCI Pastan, Ira (NCI) 1 147164477 Onda, Masanori NIH - NCI NCI Onda, Masanori (NCI) 2 147164476 Bera, Tapan NIH - NCI NCI Bera, Tapan (NCI) 3 147164478 Ho, Mitchell NIH - NCI NCI Ho, Mitchell (NCI) 4 147158001 Monoclonal Antibodies And Immunoconjugates Directed To The Non-Shed Portion Of Mesothelin E-106-2017-0 Filing authorized NCI 83673032 Whitney, Laurie WhitneyL@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC WhitneyL@mail.nih.gov?subject=Web Inquiry on [TAB-4371] Monoclonal Antibodies and Immunoconjugates Directed to the Non-ShedPortion (“Stalk”) of Mesothelin are Excellent Candidates for Developing Therapeutic Agents&body=Please send me information about technology [TAB-4371] Monoclonal Antibodies and Immunoconjugates Directed to the Non-ShedPortion (“Stalk”) of Mesothelin are Excellent Candidates for Developing Therapeutic Agents.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Whitney, Laurie<br><a href="mailto:WhitneyL@mail.nih.gov?subject=Web Inquiry on [TAB-4371] Monoclonal Antibodies and Immunoconjugates Directed to the Non-ShedPortion (“Stalk”) of Mesothelin are Excellent Candidates for Developing Therapeutic Agents&body=Please send me information about technology [TAB-4371] Monoclonal Antibodies and Immunoconjugates Directed to the Non-ShedPortion (“Stalk”) of Mesothelin are Excellent Candidates for Developing Therapeutic Agents.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">WhitneyL@mail.nih.gov</a><br> 147161050 E-106-2017-0 E-106-2017-0-PCT-02 ANTI-MESOTHELIN POLYPEPTIDES AND PROTEINS (15B6) PCT Patent Cooperation Treaty PCT/US2018/033236 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2018/033236<br />Filed on 2018-05-17<br />Status: Expired 147168506 E-106-2017-0 E-106-2017-0-US-01 ANTI-MESOTHELIN POLYPEPTIDES AND PROTEINS (15B6) PRV US 62/508,197 Abandoned US <br />Provisional (PRV) 62/508,197<br />Filed on 2017-05-18<br />Status: Abandoned 147168507 E-106-2017-0 E-106-2017-0-US-03 ANTI-MESOTHELIN POLYPEPTIDES AND PROTEINS (15B6) National Stage US 11,390,683 16/613,971 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11390683 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11390683">11,390,683</a><br />Filed on 2019-11-15<br />Status: Issued 147168508 E-106-2017-0 E-106-2017-0-US-04 ANTI-MESOTHELIN POLYPEPTIDES AND PROTEINS CON US 17/849,951 Abandoned US <br />Continuation (CON) 17/849,951<br />Filed on 2022-06-27<br />Status: Abandoned 147171552 ANTIBODY 147171553 CANCER 147171554 CAR 147171555 chimeric antigen receptor 147171556 diagnostic 147171557 IMMUNOCONJUGATES 147171558 IMMUNOTOXINS 147171559 MESOTHELIN 147171560 Pastan 147171561 therapeutic TAB-4394 147157689 Increased Therapeutic Effectiveness of PE-Based Immunotoxins NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Wenhai Liu, Masanori Onda, Ira Pastan <p>Patients receiving immunotoxin cancer therapy are less likely to experience the deleterious side-effects associated with non-discriminate therapies such as chemotherapy or radiation therapy. Unfortunately, the continued administration of immunotoxins often leads to a reduced patient response due to the formation of neutralizing antibodies against immunogenic epitopes contained within Pseudomonas exotoxin A (PE). </p> <p> To improve the therapeutic effectiveness of PE-based immunotoxins through multiple rounds of drug administration, NIH inventors have sought to identify and remove the human B cell epitopes within PE. Previous work demonstrated that the removal of the murine B cell and T cell epitopes from PE reduced the immunogenicity of PE and resulted in immunotoxins with improved therapeutic activity.</p> <p> This technology involves the identification and removal of major human B cell epitopes on PE by mutation or deletion. Considering these immunotoxins will be administered to humans, the removal of human immunogenic epitopes is important.  The resulting PE-based immunotoxins have increased resistance to the formation of neutralizing antibodies, and are expected to have improved therapeutic efficacy.</p> <h2>Competitive Advantages:</h2> <ul><li>PE variants now include the removal of human B-cell epitopes, further reducing the formation of neutralizing antibodies against  immunotoxins which contain the PE variants</li> <li>Less immunogenic immunotoxins result in improved therapeutic efficacy by permitting multiple rounds of administration in humans</li> <li>Targeted therapy decreases non-specific killing of healthy, essential cells, resulting in fewer non-specific side-effects and healthier patients</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Treatment of diseases associated with increased or  preferential expression of a specific cell surface receptor such as  hematological cancers, lung cancer, ovarian cancer, breast cancer, and head and neck cancers</li> </ul> 2016-02-16 2025-05-14 2016-08-31 2025-05-14 2016-09-07 B-CELL, CHEMOTHERAPY, Human B cell epitopes, Immunogenic epitopes, Immunotoxin, Pseudomonas exotoxin A, T-cell False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2016-08-31 52406768 Discovery 52406768 NCI 37470483 Website Abstract E-262-2005 E-269-2009 E-292-2007 147164582 Pastan, Ira NIH - NCI NCI Pastan, Ira (NCI) 1 147164583 Onda, Masanori NIH - NCI NCI Onda, Masanori (NCI) 2 147164584 Liu, Wenhai Liu, Wenhai 3 147164582 Pastan, Ira NIH - NCI NCI Pastan, Ira (NCI) 1 147164583 Onda, Masanori NIH - NCI NCI Onda, Masanori (NCI) 2 147164584 Liu, Wenhai Liu, Wenhai 3 147158288 Identification And Removal Of Human-specific B-cell Epitopes Producing An Immunotoxin With Low Antigenicity And High Cytotoxic Activity E-263-2011-0 Filing authorized NCI 83673032 Whitney, Laurie WhitneyL@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC WhitneyL@mail.nih.gov?subject=Web Inquiry on [TAB-4394] Increased Therapeutic Effectiveness of PE-Based Immunotoxins&body=Please send me information about technology [TAB-4394] Increased Therapeutic Effectiveness of PE-Based Immunotoxins.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Whitney, Laurie<br><a href="mailto:WhitneyL@mail.nih.gov?subject=Web Inquiry on [TAB-4394] Increased Therapeutic Effectiveness of PE-Based Immunotoxins&body=Please send me information about technology [TAB-4394] Increased Therapeutic Effectiveness of PE-Based Immunotoxins.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">WhitneyL@mail.nih.gov</a><br> 147161240 E-263-2011-0 E-263-2011-0-US-08 Psuedomonas Exotoxin A with Less Immunogenic B Cell Epitopes DIV US 9,657,066 14/927,645 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9657066 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9657066">9,657,066</a><br />Filed on 2015-10-30<br />Status: Issued 147168653 E-263-2011-0 E-263-2011-0-US-01 PSEUDOMONAS EXOTOXIN A WITH LESS IMMUNOGENIC B CELL EPITOPES PRV US 61/535,668 Abandoned US <br />Provisional (PRV) 61/535,668<br />Filed on 2011-09-16<br />Status: Abandoned 147168654 E-263-2011-0 E-263-2011-0-PCT-02 Pseudomonas Exotoxin A With Less Immunogenic B Cell Epitopes PCT Patent Cooperation Treaty PCT/US2012/055034 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2012/055034<br />Filed on 2012-09-13<br />Status: Expired 147168655 E-263-2011-0 E-263-2011-0-AU-03 Pseudomonas Exotoxin A With Less Immunogenic B Cell Epitopes National Stage Australia 2012308591 2012308591 Issued Australia <br />National Stage 2012308591<br />Filed on 2012-09-13<br />Status: Issued 147168656 E-263-2011-0 E-263-2011-0-CA-04 Pseudomonas Exotoxin A With Less Immunogenic B Cell Epitopes National Stage Canada 2846608 2846608 Issued Canada <br />National Stage 2846608<br />Filed on 2017-09-12<br />Status: Issued 147168657 E-263-2011-0 E-263-2011-0-EP-05 Pseudomonas Exotoxin A With Less Immunogenic B Cell Epitopes National Stage European Patent 2755993 12766780.6 Issued European Patent <br />National Stage 12766780.6<br />Filed on 2012-09-13<br />Status: Issued 147168658 E-263-2011-0 E-263-2011-0-US-06 Pseudomonas Exotoxin A With Less Immunogenic B Cell Epitopes National Stage US 9,206,240 14/241,782 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9206240 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9206240">9,206,240</a><br />Filed on 2014-03-12<br />Status: Issued 147168659 E-263-2011-0 E-263-2011-0-HK-07 Pseudomonas Exotoxin A With Less Immunogenic B Cell Epitopes EP Hong Kong 14111650.2 Abandoned Hong Kong <br />European patent (EP) 14111650.2<br />Filed on 2014-11-18<br />Status: Abandoned 147168660 E-263-2011-0 E-263-2011-0-US-09 PSEUDOMONAS EXOTOXIN A WITH LESS IMMUNOGENIC B CELL EPITOPES DIV US 10,111,927 15/488,898 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10111927 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10111927">10,111,927</a><br />Filed on 2017-04-17<br />Status: Issued 147168661 E-263-2011-0 E-263-2011-0-BE-10 PSEUDOMONAS EXOTOXIN A WITH LESS IMMUNOGENIC B CELL EPITOPES EP Belgium 2755993 12766780.6 Issued Belgium <br />European patent (EP) 12766780.6<br />Filed on 2014-02-28<br />Status: Issued 147168662 E-263-2011-0 E-263-2011-0-DE-11 PSEUDOMONAS EXOTOXIN A WITH LESS IMMUNOGENIC B CELL EPITOPES EP Germany 2755993 12766780.6 Issued Germany <br />European patent (EP) 12766780.6<br />Filed on 2014-02-28<br />Status: Issued 147168663 E-263-2011-0 E-263-2011-0-ES-12 PSEUDOMONAS EXOTOXIN A WITH LESS IMMUNOGENIC B CELL EPITOPES EP Spain ES2656505 12766780.6 Issued Spain <br />European patent (EP) 12766780.6<br />Filed on 2014-02-28<br />Status: Issued 147168664 E-263-2011-0 E-263-2011-0-FR-13 PSEUDOMONAS EXOTOXIN A WITH LESS IMMUNOGENIC B CELL EPITOPES EP France 2755993 12766780.6 Issued France <br />European patent (EP) 12766780.6<br />Filed on 2014-02-28<br />Status: Issued 147168665 E-263-2011-0 E-263-2011-0-GB-14 PSEUDOMONAS EXOTOXIN A WITH LESS IMMUNOGENIC B CELL EPITOPES EP United Kingdom 2755993 12766780.6 Issued United Kingdom <br />European patent (EP) 12766780.6<br />Filed on 2014-02-28<br />Status: Issued 147168666 E-263-2011-0 E-263-2011-0-IT-15 PSEUDOMONAS EXOTOXIN A WITH LESS IMMUNOGENIC B CELL EPITOPES EP Italy 2755993 12766780.6 Issued Italy <br />European patent (EP) 12766780.6<br />Filed on 2014-02-28<br />Status: Issued 147168667 E-263-2011-0 E-263-2011-0-NL-16 PSEUDOMONAS EXOTOXIN A WITH LESS IMMUNOGENIC B CELL EPITOPES EP The Netherlands 2755993 12766780.6 Issued The Netherlands <br />European patent (EP) 12766780.6<br />Filed on 2014-02-28<br />Status: Issued 147168668 E-263-2011-0 E-263-2011-0-PL-17 PSEUDOMONAS EXOTOXIN A WITH LESS IMMUNOGENIC B CELL EPITOPES EP Poland 2755993 12766780.6 Issued Poland <br />European patent (EP) 12766780.6<br />Filed on 2014-02-28<br />Status: Issued 147168669 E-263-2011-0 E-263-2011-0-EP-18 Pseudomonas Exotoxin A With Less Immunogenic B Cell Epitopes DIV European Patent 12766780.6 Abandoned European Patent <br />Divisional (DIV) 12766780.6<br />Filed on 2012-09-13<br />Status: Abandoned 147174384 B-CELL 147174385 CHEMOTHERAPY 147174387 Human B cell epitopes 147174389 Immunogenic epitopes 147174390 Immunotoxin 147174391 Pseudomonas exotoxin A 147174392 T-cell TAB-4436 147157731 High-Affinity Mouse Monoclonal Antibodies to GPC-3 for Liver Cancer Research NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Wei Gao, Mitchell Ho, Yen Phung, Yifan Zhang <p>The National Cancer Institute <a href="https://ccr.cancer.gov/Laboratory-of-Molecular-Biology" rel="nofollow">Laboratory of Molecular Biology </a>seeks parties for collaborative research to co-develop and commercialize antibody drug/toxin conjugates as liver cancer therapy and diagnostics. </p> <p>There is great interest and value in developing more sensitive and efficient agents for earlier detection of hepatocellular cancer (HCC).  Glypican-3 (GPC3) is a cell surface heparin sulfate glycoprotein that is expressed on the vast majority of HCC cells. The correlation between GPC3 expression and HCC makes GPC3 an attractive candidate for studying the disease progression and treatment of HCC. The presence, progression, and treatment of HCC can potentially be monitored by tracking the level of GPC3 expression on cells.  This can be accomplished using GPC3-specific monoclonal antibodies such as those NCI researchers generated for the cell surface domain of GPC3 (YP6, YP7, YP8, YP9 and YP9.1).<br />  </p> <h2>Competitive Advantages:</h2> <ul><li>Sub-nanomolar levels of binding affinity compared to commercially available GPC3 antibodies such as 1G12</li> <li>Able to bind to wild-type GPC3 better than the GPC3 core protein that lacks heparin sulfate</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Treatment of HCC as a stand-alone antibody, or as an antibody-drug conjugate (immunotoxin)</li> <li>Detection of cells that express GPC3 for monitoring HCC disease progression and treatment</li> <li>Immunostaining for tumor imaging, or ELISA and immunohistochemistry applications</li> <li>Other antibody-related research use, including immunoprecipitation, Western blot analysis, etc.</li> </ul> 2016-02-16 2025-05-14 2018-04-24 2025-05-14 2016-08-30 ANTIBODY, GLYCOPROTEIN, Glypican-3, GPC3, HCC, hepatocellular carcinoma, liver, monoclonal False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2018-04-24 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-130-2011 147162039 Ho M and Kim H. Glypican-3: a new target for cancer immunotherapy. https://www.ncbi.nlm.nih.gov/pubmed/21112773 <a href="https://www.ncbi.nlm.nih.gov/pubmed/21112773">Ho M and Kim H. Glypican-3: a new target for cancer immunotherapy.</a> 147162078 Phung Y, et al. High-affinity monoclonal antibodies to cell surface tumor antigen glypican-3 generated through a combination of peptide immunization and flow cytometry screening. https://www.ncbi.nlm.nih.gov/pubmed/22820551 <a href="https://www.ncbi.nlm.nih.gov/pubmed/22820551">Phung Y, et al. High-affinity monoclonal antibodies to cell surface tumor antigen glypican-3 generated through a combination of peptide immunization and flow cytometry screening.</a> 147162195 Ho M. Advances in liver cancer antibody therapies: a focus on glypican-3 and mesothelin. https://www.ncbi.nlm.nih.gov/pubmed/21942912 <a href="https://www.ncbi.nlm.nih.gov/pubmed/21942912">Ho M. Advances in liver cancer antibody therapies: a focus on glypican-3 and mesothelin.</a> 147164734 Ho, Mitchell NIH - NCI NCI Ho, Mitchell (NCI) 1 147164735 Phung, Yen NIH - NCI Phung, Yen 2 147164737 Gao, Wei NIH - NCI Gao, Wei 3 147164736 Zhang, Yifan NIH - NCI Zhang, Yifan 4 147164734 Ho, Mitchell NIH - NCI NCI Ho, Mitchell (NCI) 1 147164735 Phung, Yen NIH - NCI Phung, Yen 2 147164737 Gao, Wei NIH - NCI Gao, Wei 3 147164736 Zhang, Yifan NIH - NCI Zhang, Yifan 4 147158058 High-affinity Mouse Monoclonal Antibodies To Glypican-3 For Liver Cancer Therapy And Diagnosis E-136-2012-0 Filing authorized NCI 83731987 Dhal, Abritee abritee.dhal@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-4436] High-Affinity Mouse Monoclonal Antibodies to GPC-3 for Liver Cancer Research&body=Please send me information about technology [TAB-4436] High-Affinity Mouse Monoclonal Antibodies to GPC-3 for Liver Cancer Research.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dhal, Abritee<br><a href="mailto:abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-4436] High-Affinity Mouse Monoclonal Antibodies to GPC-3 for Liver Cancer Research&body=Please send me information about technology [TAB-4436] High-Affinity Mouse Monoclonal Antibodies to GPC-3 for Liver Cancer Research.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">abritee.dhal@nih.gov</a><br> 147168902 E-136-2012-0 E-136-2012-0-US-01 High-affinity Monoclonal Antibodies To Glypican-3 And Use Thereof PRV US 61/654,232 Abandoned US <br />Provisional (PRV) 61/654,232<br />Filed on 2012-06-01<br />Status: Abandoned 147168903 E-136-2012-0 E-136-2012-0-PCT-02 High-Affinity Monoclonal Antibodies To Glypican-3 And Use Thereof PCT Patent Cooperation Treaty PCT/US2013/043633 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2013/043633<br />Filed on 2013-05-31<br />Status: Expired 147168904 E-136-2012-0 E-136-2012-0-CN-03 High-Affinity Monoclonal Antibodies To Glypican-3 And Use Thereof National Stage China ZL201380039993.7 201380039993.7 Issued China <br />National Stage 201380039993.7<br />Filed on 2015-01-27<br />Status: Issued 147168905 E-136-2012-0 E-136-2012-0-JP-04 High-Affinity Monoclonal Antibodies To Glypican-3 And Use Thereof National Stage Japan 6494507 2015-515243 Issued Japan <br />National Stage 2015-515243<br />Filed on 2014-11-27<br />Status: Issued 147168906 E-136-2012-0 E-136-2012-0-KR-05 High-Affinity Monoclonal Antibodies To Glypican-3 And Use Thereof National Stage South Korea 10-2159773 10-2014-7037046 Issued South Korea <br />National Stage 10-2014-7037046<br />Filed on 2014-12-30<br />Status: Issued 147168907 E-136-2012-0 E-136-2012-0-SG-06 High-Affinity Monoclonal Antibodies To Glypican-3 And Use Thereof National Stage Singapore 11201407972R 11201407972R Issued Singapore <br />National Stage 11201407972R<br />Filed on 2013-05-31<br />Status: Issued 147168908 E-136-2012-0 E-136-2012-0-US-07 High-Affinity Monoclonal Antibodies To Glypican-3 And Use Thereof National Stage US 9,409,994 14/403,896 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9409994 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9409994">9,409,994</a><br />Filed on 2014-11-25<br />Status: Issued 147168909 E-136-2012-0 E-136-2012-0-JP-08 High-Affinity Monoclonal Antibodies To Glypican-3 And Use Thereof DIV Japan 2019-000195 Abandoned Japan <br />Divisional (DIV) 2019-000195<br />Filed on 2019-01-04<br />Status: Abandoned 147172164 ANTIBODY 147172165 GLYCOPROTEIN 147172166 Glypican-3 147172167 GPC3 147172168 HCC 147172169 hepatocellular carcinoma 147172170 liver 147172171 monoclonal TAB-4422 147157717 Antibody and Immunotoxin Treatments for Mesothelin-expressing Cancers NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Mitchell Ho, Ira Pastan <p>Mesothelin is a cell surface protein that is highly expressed in aggressive cancers such as malignant mesothelioma, ovarian cancer, pancreatic cancer, lung cancer, breast cancer, cholangiocarcinoma, bile duct carcinoma and gastric cancer. As a result, mesothelin is an excellent candidate for tumor targeted immunotherapeutics. However, the antibodies against mesothelin that are available for clinical trials are of murine origin. These antibodies have the potential to elicit immune responses in patients, which may adversely affect the ability to provide patients with repeated doses. Thus, the clinical application of the antibodies may be limited.</p> <p> In order to address the issue of immunogenicity in patients, NIH inventors have generated anti-mesothelin antibody variable fragments (Fv) of human origin. These antibody fragments (HN1 and HN2) have the ability to efficiently recognize mesothelin on the surface of numerous cancer cells. As a result, these antibody fragments represent an attractive therapeutic alternative to the murine anti-mesothelin antibodies currently being tested in clinical trials.</p> <h2>Competitive Advantages:</h2> <table><tbody><tr><td> <ul><li>Fully human antibody reduces potential immunogenicity, thereby allowing repeated dosing</li> <li>Antibody specificity improves the therapeutic efficacy of the agent.</li> </ul></td> </tr></tbody></table> <h2>Commercial Applications:</h2> <table><tbody><tr><td> <ul><li>Use as an antibody therapeutic for mesotheliomas, pancreatic tumors and ovarian tumors</li> <li>Use in an immunotoxin therapeutic for mesotheliomas, pancreatic tumors and ovarian tumors</li> <li>Diagnostic for the detection of mesothelin positive tumors</li> <li>Research agent for the detection of mesothelin</li> </ul></td> </tr></tbody></table> 2017-06-29 2025-05-14 2017-06-29 2025-05-14 2017-06-29 ANTIBODY, Immunotherapy, MESOTHELIN, therapeutic False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2017-06-29 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-002-1996 E-021-1998 E-139-1999 147162072 Ho M, et al. http://www.ncbi.nlm.nih.gov/pubmed/20635390 <a href="http://www.ncbi.nlm.nih.gov/pubmed/20635390">Ho M, et al.</a> 147162150 Hassan R, Ho M. http://www.ncbi.nlm.nih.gov/pubmed/17945478 <a href="http://www.ncbi.nlm.nih.gov/pubmed/17945478">Hassan R, Ho M.</a> 147164692 Ho, Mitchell NIH - NCI NCI Ho, Mitchell (NCI) 1 147164691 Pastan, Ira NIH - NCI NCI Pastan, Ira (NCI) 2 147164692 Ho, Mitchell NIH - NCI NCI Ho, Mitchell (NCI) 1 147164691 Pastan, Ira NIH - NCI NCI Pastan, Ira (NCI) 2 147157965 Human Monoclonal Antibody Variable Fragments (Fvs) To Mesothelin E-091-2009-0 Filing authorized NCI 83731987 Dhal, Abritee abritee.dhal@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-4422] Antibody and Immunotoxin Treatments for Mesothelin-expressing Cancers&body=Please send me information about technology [TAB-4422] Antibody and Immunotoxin Treatments for Mesothelin-expressing Cancers.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dhal, Abritee<br><a href="mailto:abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-4422] Antibody and Immunotoxin Treatments for Mesothelin-expressing Cancers&body=Please send me information about technology [TAB-4422] Antibody and Immunotoxin Treatments for Mesothelin-expressing Cancers.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">abritee.dhal@nih.gov</a><br> 147168827 E-091-2009-0 E-091-2009-0-US-01 Human Monoclonal Antibody Variable Fragments (Fvs) To Mesothelin PRV US 61/162,778 Abandoned US <br />Provisional (PRV) 61/162,778<br />Filed on 2009-03-24<br />Status: Abandoned 147168828 E-091-2009-0 E-091-2009-0-PCT-02 Anti-Mesothelin Antibodies PCT Patent Cooperation Treaty PCT/US10/28336 Expired Patent Cooperation Treaty <br />(PCT) PCT/US10/28336<br />Filed on 2010-03-23<br />Status: Expired 147168829 E-091-2009-0 E-091-2009-0-AU-03 Anti-Mesothelin Antibodies National Stage Australia 2010230063 2010230063 Abandoned Australia <br />National Stage 2010230063<br />Filed on 2010-03-23<br />Status: Abandoned 147168830 E-091-2009-0 E-091-2009-0-CA-04 Anti-Mesothelin Antibodies National Stage Canada 2756393 2756393 Abandoned Canada <br />National Stage 2756393<br />Filed on 2010-03-23<br />Status: Abandoned 147168831 E-091-2009-0 E-091-2009-0-EP-05 Anti-Mesothelin Antibodies National Stage European Patent 10722212.7 Abandoned European Patent <br />National Stage 10722212.7<br />Filed on 2010-03-23<br />Status: Abandoned 147168832 E-091-2009-0 E-091-2009-0-US-06 ANTI-MESOTHELIN ANTIBODIES (HN1) National Stage US 8,460,660 13/259,138 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8460660 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8460660">8,460,660</a><br />Filed on 2010-03-23<br />Status: Issued 147171180 ANTIBODY 147171181 Immunotherapy 147171182 MESOTHELIN 147171183 therapeutic TAB-4345 147157637 Single-domain monoclonal antibodies for the treatment of hepatocellular carcinoma NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Dimiter Dimitrov, Mingqian Feng, Wei Gao, Mitchell Ho, Heungnam Kim <p>The National Cancer Institute seeks parties to license human monoclonal antibodies and immunoconjugates and co-develop, evaluate, and/or commercialize large-scale antibody production and hepatocellular carcinoma (HCC) xenograft mouse models. An advantage of these monoclonal antibodies as a potential therapeutic is their specificity, which would reduce deleterious side-effects. HCC is the most common form of liver cancer, and is among the more deadly cancers in the world. There is a need for new treatments that can be successfully applied to a large population of patients.</p> <p>Glypican-3 (GPC3) is a cell surface protein that is preferentially expressed on HCC cells.Researchers at the <a href="https://ccr.cancer.gov/Laboratory-of-Molecular-Biology" rel="nofollow">NCI Laboratory of Molecular Biology</a> demonstrated that a soluble form of GPC3 that is incapable of cell signaling can inhibit the growth of HCC cells. This suggests that blocking GPC3 signaling could serve as a therapeutic approach for treating HCC.</p> <p>This opportunity to collaborate with NCI researchers or license the technology covers monoclonal antibodies (mAb) against GPC3 and their use, either by themselves or as the targeting domain for an immunotoxin, antibody drug conjugate (ADC) or chimeric antigen receptors (CARs), for the treatment of GPC3-expressing cancers such as HCC.  Specifically, this involves two distinct monoclonal antibodies to GPC3 generated by the researchers. The first monoclonal antibody (HN3) binds to a conformational epitope on the cell surface domain of GPC3. The second monoclonal antibody (HS20) binds specifically to heparin sulfate chains on GPC3. By blocking GPC3 function, these antibodies can inhibit the growth of HCC cells, thereby decreasing the ability of tumors to grow and metastasize. Furthermore, by using the antibodies to target a toxin to only those cells that express GPC3, cancer cells can be eliminated while healthy, essential cells remain unharmed. Thus, monoclonal antibodies to GPC3 (and corresponding immunotoxins) represent a novel therapeutic candidate for treatment of HCC, as well as other cancers associated with the differential expression of GPC3.</p> <h2>Competitive Advantages:</h2> <ul><li>Monoclonal antibodies create a level of specificity that can reduce deleterious side-effects</li> <li>Multiple treatment strategies available including the killing of cancer cells with a toxic agent or by inhibiting cell signaling</li> <li>Non-invasive and potentially non-liver toxic alternative to current HCC treatment strategies</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Therapeutic candidates against cancers that overexpress GPC3</li> <li>Antibodies for killing cancer cells by inhibiting GPC3-based cell signaling, thereby inhibiting tumor cell growth</li> <li>CARs, immunotoxins and ADCs for killing cancer cells</li> <li>Diagnostics for detecting cancers associated with GPC3 overexpression</li> <li>Specific cancers include hepatocellular cancer (HCC), melanoma, thyroid cancer, lung squamous cell carcinoma, Wilms tumor, neuroblastoma, hepatoblastoma, and testicular germ-cell tumors</li> </ul> 2016-02-16 2025-05-14 2017-12-20 2025-05-14 2016-08-30 Antibody-drug Conjugate, chimeric antigen receptor, HCC, hepatocellular carcinoma, IMMUNOTOXINS, Liver cancer False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2017-12-20 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-136-2012 E-176-2010 E-198-2012 E-236-2012 E-302-2009 147161922 SI Zitterman, M Ho et al. http://www.ncbi.nlm.nih.gov/pubmed/19816934 <a href="http://www.ncbi.nlm.nih.gov/pubmed/19816934">SI Zitterman, M Ho et al.</a> 147162116 M Feng, M Ho et al. http://www.ncbi.nlm.nih.gov/pubmed/23471984 <a href="http://www.ncbi.nlm.nih.gov/pubmed/23471984">M Feng, M Ho et al.</a> 147162463 M Feng, M Ho et al. http://www.ncbi.nlm.nih.gov/pubmed/20617511 <a href="http://www.ncbi.nlm.nih.gov/pubmed/20617511">M Feng, M Ho et al.</a> 147164399 Ho, Mitchell NIH - NCI NCI Ho, Mitchell (NCI) 1 147164400 Feng, Mingqian NCI - CCR Feng, Mingqian 2 147164398 Dimitrov, Dimiter NIH - NCI NCI Dimitrov, Dimiter (NCI) 3 147164401 Kim, Heungnam NIH - NCI Kim, Heungnam 4 147164402 Gao, Wei NIH - NCI Gao, Wei 5 147164399 Ho, Mitchell NIH - NCI NCI Ho, Mitchell (NCI) 1 147164400 Feng, Mingqian NCI - CCR Feng, Mingqian 2 147164398 Dimitrov, Dimiter NIH - NCI NCI Dimitrov, Dimiter (NCI) 3 147164401 Kim, Heungnam NIH - NCI Kim, Heungnam 4 147164402 Gao, Wei NIH - NCI Gao, Wei 5 147158042 Human Single-domain Glypican-3 Monoclonal Antibody, HN3, Which Inhibits Hepatocellular Carcinoma Growth E-130-2011-0 Filing authorized NCI 83731987 Dhal, Abritee abritee.dhal@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-4345] Single-domain monoclonal antibodies for the treatment of hepatocellular carcinoma&body=Please send me information about technology [TAB-4345] Single-domain monoclonal antibodies for the treatment of hepatocellular carcinoma.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dhal, Abritee<br><a href="mailto:abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-4345] Single-domain monoclonal antibodies for the treatment of hepatocellular carcinoma&body=Please send me information about technology [TAB-4345] Single-domain monoclonal antibodies for the treatment of hepatocellular carcinoma.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">abritee.dhal@nih.gov</a><br> 147168333 E-130-2011-0 E-130-2011-0-US-01 Human Monoclonal Antibody Specific for Glypican-3 And Use Thereof PRV US 61/477,020 Abandoned US <br />Provisional (PRV) 61/477,020<br />Filed on 2011-04-19<br />Status: Abandoned 147168334 E-130-2011-0 E-130-2011-0-PCT-02 Human Monoclonal Antibodies Specific For Glypican-3 And Use Thereof PCT Patent Cooperation Treaty PCT/US2012/034186 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2012/034186<br />Filed on 2012-04-19<br />Status: Expired 147168335 E-130-2011-0 E-130-2011-0-CN-03 Human Monoclonal Antibodies Specific For Glypican-3 And Use Thereof National Stage China ZL201280029201.3 201280029201.3 Issued China <br />National Stage 201280029201.3<br />Filed on 2012-04-19<br />Status: Issued 147168336 E-130-2011-0 E-130-2011-0-EP-04 Human Monoclonal Antibodies Specific For Glypican-3 And Use Thereof National Stage European Patent 2699603 12717009.0 Issued European Patent <br />National Stage 12717009.0<br />Filed on 2012-04-19<br />Status: Issued 147168337 E-130-2011-0 E-130-2011-0-US-05 HUMAN MONOCLONAL ANTIBODIES SPECIFIC FOR GLYPICAN-3 AND USE THEREOF National Stage US 9,206,257 14/111,860 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9206257 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9206257">9,206,257</a><br />Filed on 2013-10-15<br />Status: Issued 147168338 E-130-2011-0 E-130-2011-0-US-06 Human Monoclonal Antibodies Specific for Glypican-3 and Uses Thereof DIV US 9,394,364 14/837,903 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9394364 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9394364">9,394,364</a><br />Filed on 2015-08-27<br />Status: Issued 147168339 E-130-2011-0 E-130-2011-0-EP-07 Human Monoclonal Antibodies Specific For Glypican-3 And Use Thereof DIV European Patent 2998320 15188264.4 Issued European Patent <br />Divisional (DIV) 15188264.4<br />Filed on 2012-04-19<br />Status: Issued 147168340 E-130-2011-0 E-130-2011-0-DE-08 Human Monoclonal Antibodies Specific For Glypican-3 And Use Thereof EP Germany 602012015186.2 12717009.0 Issued Germany <br />European patent (EP) 12717009.0<br />Filed on 2012-04-19<br />Status: Issued 147168341 E-130-2011-0 E-130-2011-0-FR-09 Human Monoclonal Antibodies Specific For Glypican-3 And Use Thereof EP France 2699603 12717009.0 Issued France <br />European patent (EP) 12717009.0<br />Filed on 2012-04-19<br />Status: Issued 147168342 E-130-2011-0 E-130-2011-0-GB-10 Human Monoclonal Antibodies Specific For Glypican-3 And Use Thereof EP United Kingdom 2699603 12717009.0 Issued United Kingdom <br />European patent (EP) 12717009.0<br />Filed on 2012-04-19<br />Status: Issued 147168343 E-130-2011-0 E-130-2011-0-HK-11 Human Monoclonal Antibodies Specific For Glypican-3 And Use Thereof National Stage Hong Kong HK1219965B 16108042.3 Issued Hong Kong <br />National Stage 16108042.3<br />Filed on 2012-04-19<br />Status: Issued 147168344 E-130-2011-0 E-130-2011-0-US-12 Human Monoclonal Antibodies Specific for Glypican-3 and Use Thereof CON US 9,932,406 15/090,873 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9932406 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9932406">9,932,406</a><br />Filed on 2016-04-05<br />Status: Issued 147168345 E-130-2011-0 E-130-2011-0-CN-13 Human Monoclonal Antibodies Specific For Glypican-3 And Use Thereof DIV China ZL201610290837.3 201610290837.3 Issued China <br />Divisional (DIV) 201610290837.3<br />Filed on 2012-04-19<br />Status: Issued 147168346 E-130-2011-0 E-130-2011-0-EP-14 Human Monoclonal Antibodies Specific For Glypican-3 And Use Thereof DIV European Patent 3070104 16166924.7 Issued European Patent <br />Divisional (DIV) 16166924.7<br />Filed on 2012-04-19<br />Status: Issued 147168347 E-130-2011-0 E-130-2011-0-HK-15 Human Monoclonal Antibodies Specific For Glypican-3 And Use Thereof EP Hong Kong HK1228931B 17102681.1 Issued Hong Kong <br />European patent (EP) 17102681.1<br />Filed on 2017-03-15<br />Status: Issued 147168348 E-130-2011-0 E-130-2011-0-DE-16 Human Monoclonal Antibodies Specific For Glypican-3 And Use Thereof EP Germany 3070104 16166924.7 Issued Germany <br />European patent (EP) 16166924.7<br />Filed on 2012-04-19<br />Status: Issued 147168349 E-130-2011-0 E-130-2011-0-ES-17 Human Monoclonal Antibodies Specific For Glypican-3 And Use Thereof EP Spain 3070104 16166924.7 Issued Spain <br />European patent (EP) 16166924.7<br />Filed on 2012-04-19<br />Status: Issued 147168350 E-130-2011-0 E-130-2011-0-FR-18 Human Monoclonal Antibodies Specific For Glypican-3 And Use Thereof EP France 3070104 16166924.7 Issued France <br />European patent (EP) 16166924.7<br />Filed on 2012-04-19<br />Status: Issued 147168351 E-130-2011-0 E-130-2011-0-GB-19 Human Monoclonal Antibodies Specific For Glypican-3 And Use Thereof EP United Kingdom 3070104 16166924.7 Issued United Kingdom <br />European patent (EP) 16166924.7<br />Filed on 2012-04-19<br />Status: Issued 147168352 E-130-2011-0 E-130-2011-0-IT-20 Human Monoclonal Antibodies Specific For Glypican-3 And Use Thereof EP Italy 502018000012150 16166924.7 Issued Italy <br />European patent (EP) 16166924.7<br />Filed on 2012-04-19<br />Status: Issued 147168353 E-130-2011-0 E-130-2011-0-US-21 HUMAN MONOCLONAL ANTIBODIES SPECIFIC FOR GLYPICAN-3 AND USE THEREOF DIV US 10,640,571 15/843,256 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10640571 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10640571">10,640,571</a><br />Filed on 2017-12-15<br />Status: Issued 147168354 E-130-2011-0 E-130-2011-0-DE-22 Human Monoclonal Antibodies Specific For Glypican-3 And Use Thereof EP Germany 2998320 15188264.4 Issued Germany <br />European patent (EP) 15188264.4<br />Filed on 2015-10-02<br />Status: Issued 147168355 E-130-2011-0 E-130-2011-0-FR-23 Human Monoclonal Antibodies Specific For Glypican-3 And Use Thereof EP France 2998320 15188264.4 Issued France <br />European patent (EP) 15188264.4<br />Filed on 2015-10-02<br />Status: Issued 147168356 E-130-2011-0 E-130-2011-0-GB-24 Human Monoclonal Antibodies Specific For Glypican-3 And Use Thereof EP United Kingdom 2998320 15188264.4 Issued United Kingdom <br />European patent (EP) 15188264.4<br />Filed on 2015-10-02<br />Status: Issued 147172034 Antibody-drug Conjugate 147172035 chimeric antigen receptor 147172036 HCC 147172037 hepatocellular carcinoma 147172038 IMMUNOTOXINS 147172040 Liver cancer TAB-4267 147157554 Synthetic Bacterial Nanoparticles as Drug and Vaccine Delivery Vehicles NCI Collaboration, Infectious Disease, Licensing, Medical Devices, Non-Medical Devices, Oncology Collaboration Infectious Disease Licensing Medical Devices Non-Medical Devices Oncology Kumaran Ramamurthi, I-Lin Wu <p>Bacterial spores can be modified to display molecules of interest, including drugs, immunogenic peptides, antibodies and other functional proteins of interest (such as enzymes).  The resulting engineered bacterial spores can provide many useful functions such as the treatment of infections, use as an adjuvant for the delivery of vaccines, and the enzymatic degradation of environmental pollutants.</p> <p>Researchers at the National Cancer Institute’s (NCI) <a href="https://ccr.cancer.gov/Laboratory-of-Molecular-Biology" rel="nofollow">Laboratory of Molecular Biology</a> have developed a novel, synthetic spore husk-encased lipid bilayer (SSHEL) particle that is uniquely suited for a variety of these functions. The assembly of SSHELs involves the insertion of the bacterial spore coat protein SpoVM into a lipid bilayer that is located on a synthetic core particle.  SpoVM serves as a structural element and recruitment factor for the bacterial spore coat protein SpoIVA.  When SpoIVA is conjugated to streptavidin, the SSHEL can bind to another molecule through a biotin linkage.  This leads to the creation of a specialized SSHEL that can serve a particular biological function.  The lab's pre-clinical work has demonstrated that SSHELs loaded with Doxorubicin reduced the tumor burden in a mouse tumor xenograft model of HER2-positive ovarian cancer.  By varying the ratio of streptavidin-conjugated and unconjugated SpoIVA protein used in the manufacture of the SSHEL, it is possible to tailor the amount of functional molecule that is present in the SSHEL.  This affords greater control over the level of activity that is provided by the SSHEL, thereby allowing the fine tuning of its function.</p> <h2>Competitive Advantages:</h2> <ul><li>The ability to display multiple types of therapeutic agents provides diversity of function</li> <li>The ability to vary the amount of SpoIVA that can bind to a functional agent (e.g. Doxorubicin through a streptavidin-biotin interaction) allows fine tuning, high targeting efficiency, and reduced toxicity</li> <li>Lack of extraneous cell surface proteins on SSHELs avoids potential interference between the SSHEL and its target</li> <li>Non-living delivery system avoids complications associated with using a living organism</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Applications for this technology are only limited by the molecules bound to the nanoparticle (SSHEL)</li> <li>Use of SSHELs that display a therapeutic agent to treat a disease, e.g. Doxorubicin for HER2-positive cancer</li> <li>Use of SSHELs to deliver vaccines to patients</li> <li>Use of SSHELs to provide particles with enzymatic functions</li> </ul> 2017-03-23 2025-05-14 2019-10-02 2025-05-14 2017-03-23 Bacterial Spore, Drug Delivery, Nanoparticle, Ramamurthi, SSHEL, Synthetic Spore Husk-encased Lipid Bilayer, VACCINE DELIVERY False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2019-10-02 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147162420 Wu et al. A Versatile Nano-Display Platform from Bacterial Spore Coat Proteins https://www.ncbi.nlm.nih.gov/pubmed/25854653 <a href="https://www.ncbi.nlm.nih.gov/pubmed/25854653">Wu et al. A Versatile Nano-Display Platform from Bacterial Spore Coat Proteins</a> 147164107 Ramamurthi, Kumaran NIH - NCI NCI Ramamurthi, Kumaran (NCI) 1 147164108 Wu, I-Lin NIH - NCI NCI Wu, I-Lin (NCI) 2 147164107 Ramamurthi, Kumaran NIH - NCI NCI Ramamurthi, Kumaran (NCI) 1 147164108 Wu, I-Lin NIH - NCI NCI Wu, I-Lin (NCI) 2 147157984 A Versatile Nano-display Platform From Bacterial Spore Coat Proteins E-098-2015-0 Filing authorized NCI 83731987 Dhal, Abritee abritee.dhal@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-4267] Synthetic Bacterial Nanoparticles as Drug and Vaccine Delivery Vehicles&body=Please send me information about technology [TAB-4267] Synthetic Bacterial Nanoparticles as Drug and Vaccine Delivery Vehicles.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dhal, Abritee<br><a href="mailto:abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-4267] Synthetic Bacterial Nanoparticles as Drug and Vaccine Delivery Vehicles&body=Please send me information about technology [TAB-4267] Synthetic Bacterial Nanoparticles as Drug and Vaccine Delivery Vehicles.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">abritee.dhal@nih.gov</a><br> 147161035 E-098-2015-0 E-098-2015-0-US-01 Display Platform From Bacterial Spore Coat Proteins PRV US 62/127,738 Abandoned US <br />Provisional (PRV) 62/127,738<br />Filed on 2015-03-03<br />Status: Abandoned 147167797 E-098-2015-0 E-098-2015-0-PCT-02 DISPLAY PLATFORM FROM BACTERIAL SPORE COAT PROTEINS PCT Patent Cooperation Treaty PCT/US2015/044316 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2015/044316<br />Filed on 2015-08-07<br />Status: Expired 147167798 E-098-2015-0 E-098-2015-0-AU-03 DISPLAY PLATFORM FROM BACTERIAL SPORE COAT PROTEINS National Stage Australia 2015384786 2015384786 Issued Australia <br />National Stage 2015384786<br />Filed on 2017-08-11<br />Status: Issued 147167799 E-098-2015-0 E-098-2015-0-CA-04 DISPLAY PLATFORM FROM BACTERIAL SPORE COAT PROTEINS National Stage Canada 2977493 2977493 Issued Canada <br />National Stage 2977493<br />Filed on 2015-08-07<br />Status: Issued 147167800 E-098-2015-0 E-098-2015-0-US-05 DISPLAY PLATFORM FROM BACTERIAL SPORE COAT PROTEINS National Stage US 10,813,993 15/555,283 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10813993 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10813993">10,813,993</a><br />Filed on 2017-09-01<br />Status: Issued 147171387 Bacterial Spore 147171388 Drug Delivery 147171389 Nanoparticle 147171391 Ramamurthi 147171393 SSHEL 147171395 Synthetic Spore Husk-encased Lipid Bilayer 147171396 VACCINE DELIVERY TAB-4233 147157518 Human Monoclonal Antibodies Targeting Glypican-2 in Neuroblastoma NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Dimiter Dimitrov, Mitchell Ho, Nan Li <p>Neuroblastoma is a rare pediatric cancer that affects one in every hundred thousand children under the age of fifteen in the United States. Current standards of care  are chemotherapy and surgery, followed by stem-cell treatments, radiation and anti-ganglioside antibody therapy, which yield an average three-year survival rate of 10-45%. This demonstrates a need for more effective therapies.</p> <p>Glypican-2 (GPC2) is a cell surface protein that has been shown to be preferentially expressed on numerous pediatric cancers, including neuroblastoma. Due to this preferential expression, GPC2 represents a potential candidate for targeted therapy.</p> <p>Researchers at the National Cancer Institute’s <a href="https://ccr.cancer.gov/Laboratory-of-Molecular-Biology" rel="nofollow">Laboratory of Molecular Biology</a> (NCI LMB) have developed and isolated several single domain monoclonal human antibodies against GPC2. This technology covers the naked GPC2 antibodies as well as their use as targeting domains in recombinant immunotoxins (RITs) and chimeric antigen receptors (CARs). RITs (using clones LH1, LH4, or LH7) and CARs (using LH7) have shown specific killing activity against GPC2-expressing cells, suggesting that these candidates may be further developed as therapeutics.</p> <p>The technology has been validated with <em>in-vitro</em> studies (human anti-GPC2 RITs and CARs can bind to, and kill, GPC2-positive tumor cells) and the researchers are currently developing mouse models to further develop GPC2-targeted therapies.</p> <h2>Competitive Advantages:</h2> <p>- First to market potential – No current clinical trials with GPC2-targeted therapies<br /> - Human antibody with high specificity and binding to targets results in less non-specific cell killing, therefore fewer potential side-effects for the patient<br /> - Small size of single domain antibodies enhances stability, solubility, and target recognition  </p> <h2>Commercial Applications:</h2> <p>- Therapeutic applications include unconjugated antibodies and use as targeting moieties for immunoconjugates such as CARs, ADCs, immunotoxins, and bispecific antibodies<br /> - Diagnostic agent for detecting and monitoring target-expressing malignancies</p> 2016-08-08 2025-05-14 2018-12-19 2025-05-14 2016-08-08 ADC, ANTIBODY, Antibody-drug Conjugate, Bispecific Antibody, CAR, chimeric antigen receptor, Glypican-2, GPC2, Immunotoxin, Neuroblastoma, Recombinant Immunotoxin, Rit False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2018-12-19 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147162009 Li N, et al. Therapeutically targeting glypican-2 via single-domain antibody-based chimeric antigen receptors and immunotoxins in neuroblastoma. https://www.ncbi.nlm.nih.gov/pubmed/28739923 <a href="https://www.ncbi.nlm.nih.gov/pubmed/28739923">Li N, et al. Therapeutically targeting glypican-2 via single-domain antibody-based chimeric antigen receptors and immunotoxins in neuroblastoma.</a> 147163992 Ho, Mitchell NIH - NCI NCI Ho, Mitchell (NCI) 1 147163993 Li, Nan NIH - NCI NCI Li, Nan (NCI) 2 147163991 Dimitrov, Dimiter NIH - NCI NCI Dimitrov, Dimiter (NCI) 3 147163992 Ho, Mitchell NIH - NCI NCI Ho, Mitchell (NCI) 1 147163993 Li, Nan NIH - NCI NCI Li, Nan (NCI) 2 147163991 Dimitrov, Dimiter NIH - NCI NCI Dimitrov, Dimiter (NCI) 3 147158215 Human Monoclonal Antibodies Targeting Glypican-2 In Neuroblastoma E-211-2016-0 Filing authorized NCI 83731987 Dhal, Abritee abritee.dhal@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-4233] Human Monoclonal Antibodies Targeting Glypican-2 in Neuroblastoma&body=Please send me information about technology [TAB-4233] Human Monoclonal Antibodies Targeting Glypican-2 in Neuroblastoma.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dhal, Abritee<br><a href="mailto:abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-4233] Human Monoclonal Antibodies Targeting Glypican-2 in Neuroblastoma&body=Please send me information about technology [TAB-4233] Human Monoclonal Antibodies Targeting Glypican-2 in Neuroblastoma.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">abritee.dhal@nih.gov</a><br> 147161196 E-211-2016-0 E-211-2016-0-US-01 MONOCLONAL ANTIBODIES TARGETING GLYPICAN-2 (GPC2) AND USE THEREOF PRV US 62/369,861 Abandoned US <br />Provisional (PRV) 62/369,861<br />Filed on 2016-08-02<br />Status: Abandoned 147167569 E-211-2016-0 E-211-2016-0-PCT-02 MONOCLONAL ANTIBODIES TARGETING GLYPICAN-2 (GPC2) AND USE THEREOF PCT Patent Cooperation Treaty PCT/US2017/043112 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2017/043112<br />Filed on 2017-07-20<br />Status: Expired 147167570 E-211-2016-0 E-211-2016-0-AU-03 MONOCLONAL ANTIBODIES TARGETING GLYPICAN-2 (GPC2) AND USE THEREOF National Stage Australia 2017305170 Abandoned Australia <br />National Stage 2017305170<br />Filed on 2017-07-20<br />Status: Abandoned 147167571 E-211-2016-0 E-211-2016-0-CA-04 MONOCLONAL ANTIBODIES TARGETING GLYPICAN-2 (GPC2) AND USE THEREOF National Stage Canada 3031559 Pending Canada <br />National Stage 3031559<br />Filed on 2017-07-20<br />Status: Pending 147167572 E-211-2016-0 E-211-2016-0-US-05 MONOCLONAL ANTIBODIES TARGETING GLYPICAN-2 (GPC2) AND USE THEREOF National Stage US 11,066,479 16/322,712 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11066479 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11066479">11,066,479</a><br />Filed on 2019-02-01<br />Status: Issued 147167573 E-211-2016-0 E-211-2016-0-EP-06 MONOCLONAL ANTIBODIES TARGETING GLYPICAN-2 (GPC2) AND USE THEREOF National Stage European Patent 17746316.3 Abandoned European Patent <br />National Stage 17746316.3<br />Filed on 2017-07-20<br />Status: Abandoned 147173713 ADC 147173714 ANTIBODY 147173715 Antibody-drug Conjugate 147173716 Bispecific Antibody 147173717 CAR 147173718 chimeric antigen receptor 147173719 Glypican-2 147173720 GPC2 147173721 Immunotoxin 147173722 Neuroblastoma 147173723 Recombinant Immunotoxin 147173724 Rit TAB-4199 147157484 Anti-Mesothelin Monoclonal Antibodies for the Treatment of Cancer NCI Licensing, Oncology, Therapeutics Licensing Oncology Therapeutics Dimiter Dimitrov, Mingqian Feng, Wei Gao, Mitchell Ho, Ira Pastan, Zhewei Tang <p>The National Cancer Institute seeks parties interested in collaborative research to further co-develop monoclonal antibodies for the treatment of mesothelin-expressing cancers. The antibody was able to inhibit tumor growth in mouse xenograft models, and corresponding immunotoxins were able to inhibit tumor cell growth in vitro</p> <p>Mesothelin is a cell surface protein that is highly expressed in aggressive cancers such as malignant mesothelioma, ovarian cancer, pancreatic cancer, lung cancer, breast cancer, cholangiocarcinoma, bile duct carcinoma and gastric cancer. This selective expression makes mesothelin an excellent candidate for targeted therapeutics such as monoclonal antibodies (mAbs) and corresponding chimeric molecules. Unfortunately, current anti-mesothelin mAb candidates have drawbacks, such as competition with a serum protein (MUC16/CA125) for binding to mesothelin, the formation of neutralizing antibodies because they are non-human antibodies, and the inability to trigger complement-dependent cytotoxicity (CDC).   </p> <p>In order to address this concern, NIH inventors generated two single domain human mAbs: SD1 and SD2.  SD1 recognizes a unique epitope in region III of mesothelin which is not out-competed for binding by MUC16/CA125.  SD1 was also capable of triggering CDC, as well as antibody-dependent cellular cytotoxicity (ADCC). Due to its human origin, SD1 is also less likely to elicit the formation of neutralizing antibodies when administered to patients. Each of these characteristics suggests SD1 may be an effective therapeutic agent. Indeed, SD1 was able to inhibit tumor growth in mouse xenograft models, and corresponding immunotoxins were able to inhibit tumor cell growth <em>in vitro</em>, supporting the use of SD1 as a therapeutic mAb.       </p> <h2>Competitive Advantages:</h2> <ul><li>Binding of a new epitope on mesothelin may improve therapeutic applications due to non-competition from serum proteins</li> <li>Human origin may significantly limit the formation of neutralizing antibodies, thereby increasing therapeutic potential of the mAb</li> <li>Ability to trigger both CDC and ADCC may elicit a more complete therapeutic response</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Therapeutic use in the treatment of mesothelin-expressing cancers as a stand-alone mAbs or as an mAb-drug conjugate (e.g., an immunotoxin)</li> <li>Diagnosis of mesothelin-expressing cancers</li> <li>Antibody-related research use, including immunoprecipitation, western blot analysis, immunohistochemistry, ELISA, etc.</li> </ul> 2016-02-16 2025-05-14 2018-06-07 2025-05-14 2013-03-18 Epitopes, MESOTHELIN, Monoclonal Antibodies False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2018-06-07 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147162011 R. Hassan et al. http://www.ncbi.nlm.nih.gov/pubmed/17945478 <a href="http://www.ncbi.nlm.nih.gov/pubmed/17945478">R. Hassan et al.</a> 147162167 Z. Tang et al. http://www.ncbi.nlm.nih.gov/pubmed/23371858 <a href="http://www.ncbi.nlm.nih.gov/pubmed/23371858">Z. Tang et al.</a> 147163881 Ho, Mitchell NIH - NCI NCI Ho, Mitchell (NCI) 1 147163879 Pastan, Ira NIH - NCI NCI Pastan, Ira (NCI) 2 147163880 Dimitrov, Dimiter NIH - NCI NCI Dimitrov, Dimiter (NCI) 3 147163883 Tang, Zhewei NIH - NCI NCI Tang, Zhewei (NCI) 4 147163882 Feng, Mingqian NCI - CCR Feng, Mingqian 5 147163884 Gao, Wei NIH - NCI Gao, Wei 6 147163881 Ho, Mitchell NIH - NCI NCI Ho, Mitchell (NCI) 1 147163879 Pastan, Ira NIH - NCI NCI Pastan, Ira (NCI) 2 147163880 Dimitrov, Dimiter NIH - NCI NCI Dimitrov, Dimiter (NCI) 3 147163883 Tang, Zhewei NIH - NCI NCI Tang, Zhewei (NCI) 4 147163882 Feng, Mingqian NCI - CCR Feng, Mingqian 5 147163884 Gao, Wei NIH - NCI Gao, Wei 6 147158250 A Single-domain Human Antibody, SD1, Elicits Potent Antitumor Activity By Targeting A Novel Epitope In Mesothelin Close To The Cancer Cell Surface E-236-2012-0 Filing authorized NCI 83731987 Dhal, Abritee abritee.dhal@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-4199] Anti-Mesothelin Monoclonal Antibodies for the Treatment of Cancer&body=Please send me information about technology [TAB-4199] Anti-Mesothelin Monoclonal Antibodies for the Treatment of Cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dhal, Abritee<br><a href="mailto:abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-4199] Anti-Mesothelin Monoclonal Antibodies for the Treatment of Cancer&body=Please send me information about technology [TAB-4199] Anti-Mesothelin Monoclonal Antibodies for the Treatment of Cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">abritee.dhal@nih.gov</a><br> 147161216 E-236-2012-0 E-236-2012-0-US-01 Mesothelin Antibodies And Methods For Eliciting Potent Antitumor Activity PRV US 61/706,396 Abandoned US <br />Provisional (PRV) 61/706,396<br />Filed on 2012-09-27<br />Status: Abandoned 147167299 E-236-2012-0 E-236-2012-0-PCT-02 MESOTHELIN ANTIBODIES AND METHODS FOR ELICITING POTENT ANTITUMOR ACTIVITY PCT Patent Cooperation Treaty PCT/US2013/059883 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2013/059883<br />Filed on 2013-09-16<br />Status: Expired 147167300 E-236-2012-0 E-236-2012-0-AU-03 MESOTHELIN ANTIBODIES AND METHODS FOR ELICITING POTENT ANTITUMOR ACTIVITY National Stage Australia 2013324049 2013324049 Issued Australia <br />National Stage 2013324049<br />Filed on 2013-09-16<br />Status: Issued 147167301 E-236-2012-0 E-236-2012-0-CA-04 MESOTHELIN ANTIBODIES AND METHODS FOR ELICITING POTENT ANTITUMOR ACTIVITY National Stage Canada 2885761 2885761 Issued Canada <br />National Stage 2885761<br />Filed on 2013-09-16<br />Status: Issued 147167302 E-236-2012-0 E-236-2012-0-CN-05 MESOTHELIN ANTIBODIES AND METHODS FOR ELICITING POTENT ANTITUMOR ACTIVITY National Stage China ZL201380060415.1 201380060415.1 Issued China <br />National Stage 201380060415.1<br />Filed on 2013-09-16<br />Status: Issued 147167303 E-236-2012-0 E-236-2012-0-EP-06 MESOTHELIN ANTIBODIES AND METHODS FOR ELICITING POTENT ANTITUMOR ACTIVITY National Stage European Patent 2900695 13766859.6 Issued European Patent <br />National Stage 13766859.6<br />Filed on 2013-09-16<br />Status: Issued 147167304 E-236-2012-0 E-236-2012-0-JP-07 MESOTHELIN ANTIBODIES AND METHODS FOR ELICITING POTENT ANTITUMOR ACTIVITY National Stage Japan 6307085 2015-534544 Issued Japan <br />National Stage 2015-534544<br />Filed on 2015-03-25<br />Status: Issued 147167305 E-236-2012-0 E-236-2012-0-US-08 MESOTHELIN ANTIBODIES AND METHODS FOR ELICITING POTENT ANTITUMOR ACTIVITY National Stage US 9,416,190 14/428,771 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9416190 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9416190">9,416,190</a><br />Filed on 2015-03-17<br />Status: Issued 147167306 E-236-2012-0 E-236-2012-0-HK-09 MESOTHELIN ANTIBODIES AND METHODS FOR ELICITING POTENT ANTITUMOR ACTIVITY EP Hong Kong HK1213000B 16100885.0 Issued Hong Kong <br />European patent (EP) 16100885.0<br />Filed on 2013-09-16<br />Status: Issued 147167307 E-236-2012-0 E-236-2012-0-GB-13 MESOTHELIN ANTIBODIES AND METHODS FOR ELICITING POTENT ANTITUMOR ACTIVITY EP United Kingdom 2900695 13766859.6 Issued United Kingdom <br />European patent (EP) 13766859.6<br />Filed on 2015-03-03<br />Status: Issued 147167308 E-236-2012-0 E-236-2012-0-DE-10 MESOTHELIN ANTIBODIES AND METHODS FOR ELICITING POTENT ANTITUMOR ACTIVITY EP Germany 2900695 13766859.6 Issued Germany <br />European patent (EP) 13766859.6<br />Filed on 2015-03-03<br />Status: Issued 147167309 E-236-2012-0 E-236-2012-0-ES-11 MESOTHELIN ANTIBODIES AND METHODS FOR ELICITING POTENT ANTITUMOR ACTIVITY EP Spain 2900695 13766859.6 Issued Spain <br />European patent (EP) 13766859.6<br />Filed on 2015-03-03<br />Status: Issued 147167310 E-236-2012-0 E-236-2012-0-FR-12 MESOTHELIN ANTIBODIES AND METHODS FOR ELICITING POTENT ANTITUMOR ACTIVITY EP France 2900695 13766859.6 Issued France <br />European patent (EP) 13766859.6<br />Filed on 2015-03-03<br />Status: Issued 147167311 E-236-2012-0 E-236-2012-0-IT-14 MESOTHELIN ANTIBODIES AND METHODS FOR ELICITING POTENT ANTITUMOR ACTIVITY EP Italy 2900695 13766859.6 Issued Italy <br />European patent (EP) 13766859.6<br />Filed on 2015-03-03<br />Status: Issued 147174047 Epitopes 147174048 MESOTHELIN 147174049 Monoclonal Antibodies TAB-4129 147157411 High-Affinity Rabbit Monoclonal Antibodies for Cancer Treatment NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Wei Gao, Raffit Hassan, Mitchell Ho, Ira Pastan, Yen Phung, Yifan Zhang <p>Mesothelin is a cell surface protein that is highly expressed in aggressive cancers, such as malignant mesothelioma, ovarian cancer and pancreatic cancer, lung cancer, breast cancer, cholangiocarcinoma, bile duct carcinoma and gastric cancer.  Because of this selective expression, mesothelin is an excellent candidate for targeted therapeutics, such as monoclonal antibodies (mAbs) and chimeric molecules.  Current anti-mesothelin therapeutic mAb candidates bind to an epitope in Region I of mesothelin.  Unfortunately, Region I contains the interaction site MUC16/CA125, a mesothelin-interacting protein that is present in the serum of patients with mesothelin-related cancers.  Because the current therapeutic mAb candidates must compete with MUC16/CA125 for binding to mesothelin, they may not reach their full therapeutic potential due to interference.</p> <p>NIH inventors generated several rabbit mAbs that recognize unique epitopes of mesothelin: (1) YP223, which recognizes region II; (2) YYP218, which recognizes region III; and (3) YP3 which recognizes a native conformation epitope of mesothelin. These mAbs bind to mesothelin with sub-nanomolar affinity and are not out-competed for binding by the current anti-mesothelin therapeutic mAb candidates or MUC16/CA125.  This strong binding affinity for an alternative binding site on mesothelin suggests that these mAbs are excellent therapeutic candidates.</p> <h2>Competitive Advantages:</h2> <ul><li>Binding of new epitope on mesothelin may improve therapeutic applications due to non-competition from serum proteins</li> <li>High binding affinity (sub-nanomolar levels) also increases chances of binding and subsequent therapeutic activity</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Therapeutic use in the treatment of mesothelin-expressing cancers as a stand-alone mAbs or as an mAb-drug conjugate (e.g., an immunotoxin)</li> <li>Diagnosis of mesothelin-expressing cancers</li> <li>Antibody-related research use, including immunoprecipitation, western blot analysis, immunohistochemistry, ELISA, etc.</li> </ul> 2016-02-16 2025-05-14 2016-09-06 2025-05-14 2016-08-31 Epitope, MESOTHELIN False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2016-09-06 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147162242 Hassan R, et al. Mesothelin targeted cancer immunotherapy. http://www.ncbi.nlm.nih.gov/pubmed/17945478 <a href="http://www.ncbi.nlm.nih.gov/pubmed/17945478">Hassan R, et al. Mesothelin targeted cancer immunotherapy.</a> 147163622 Ho, Mitchell NIH - NCI NCI Ho, Mitchell (NCI) 1 147163621 Pastan, Ira NIH - NCI NCI Pastan, Ira (NCI) 2 147163624 Phung, Yen NIH - NCI Phung, Yen 3 147163625 Zhang, Yifan NIH - NCI Zhang, Yifan 4 147163623 Hassan, Raffit NIH - NCI NCI Hassan, Raffit (NCI) 5 147163626 Gao, Wei NIH - NCI Gao, Wei 6 147163622 Ho, Mitchell NIH - NCI NCI Ho, Mitchell (NCI) 1 147163621 Pastan, Ira NIH - NCI NCI Pastan, Ira (NCI) 2 147163624 Phung, Yen NIH - NCI Phung, Yen 3 147163625 Zhang, Yifan NIH - NCI Zhang, Yifan 4 147163623 Hassan, Raffit NIH - NCI NCI Hassan, Raffit (NCI) 5 147163626 Gao, Wei NIH - NCI Gao, Wei 6 147158198 Novel Mesothelin Domain Rabbit Monoclonal Antibodies E-198-2012-0 Filing authorized NCI 83731987 Dhal, Abritee abritee.dhal@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-4129] High-Affinity Rabbit Monoclonal Antibodies for Cancer Treatment&body=Please send me information about technology [TAB-4129] High-Affinity Rabbit Monoclonal Antibodies for Cancer Treatment.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dhal, Abritee<br><a href="mailto:abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-4129] High-Affinity Rabbit Monoclonal Antibodies for Cancer Treatment&body=Please send me information about technology [TAB-4129] High-Affinity Rabbit Monoclonal Antibodies for Cancer Treatment.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">abritee.dhal@nih.gov</a><br> 147166816 E-198-2012-0 E-198-2012-0-US-01 Mesothelin Domain-Specific Monoclonal Antibodies And Use Thereof PRV US 61/691,719 Abandoned US <br />Provisional (PRV) 61/691,719<br />Filed on 2012-08-21<br />Status: Abandoned 147166817 E-198-2012-0 E-198-2012-0-PCT-02 MESOTHELIN DOMAIN-SPECIFIC MONOCLONAL ANTIBODIES AND USE THEREOF PCT Patent Cooperation Treaty PCT/US2013/055273 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2013/055273<br />Filed on 2013-08-16<br />Status: Expired 147166818 E-198-2012-0 E-198-2012-0-AU-03 MESOTHELIN DOMAIN-SPECIFIC MONOCLONAL ANTIBODIES AND USE THEREOF National Stage Australia 2013306076 2013306076 Issued Australia <br />National Stage 2013306076<br />Filed on 2013-08-16<br />Status: Issued 147166819 E-198-2012-0 E-198-2012-0-CA-04 MESOTHELIN DOMAIN-SPECIFIC MONOCLONAL ANTIBODIES AND USE THEREOF National Stage Canada 2882753 2882753 Issued Canada <br />National Stage 2882753<br />Filed on 2013-08-16<br />Status: Issued 147166820 E-198-2012-0 E-198-2012-0-EP-05 MESOTHELIN DOMAIN-SPECIFIC MONOCLONAL ANTIBODIES AND USE THEREOF National Stage European Patent 2888282 13753475.6 Issued European Patent <br />National Stage 13753475.6<br />Filed on 2013-08-16<br />Status: Issued 147166821 E-198-2012-0 E-198-2012-0-US-06 Mesothelin Domain-Specific Monoclonal Antibodies and Use Thereof National Stage US 9,409,992 14/421,599 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9409992 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9409992">9,409,992</a><br />Filed on 2015-02-13<br />Status: Issued 147166822 E-198-2012-0 E-198-2012-0-CN-07 MESOTHELIN DOMAIN-SPECIFIC MONOCLONAL ANTIBODIES AND USE THEREOF National Stage China ZL201380053870.9 201380053870.9 Issued China <br />National Stage 201380053870.9<br />Filed on 2015-04-15<br />Status: Issued 147166823 E-198-2012-0 E-198-2012-0-US-08 Mesothelin Domain-Specific Monoclonal Antibodies and Use Thereof DIV US 9,803,022 15/141,006 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9803022 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9803022">9,803,022</a><br />Filed on 2016-04-28<br />Status: Issued 147166824 E-198-2012-0 E-198-2012-0-DE-09 MESOTHELIN DOMAIN-SPECIFIC MONOCLONAL ANTIBODIES AND USE THEREOF EP Germany 2888282 13753475.6 Issued Germany <br />European patent (EP) 13753475.6<br />Filed on 2015-02-20<br />Status: Issued 147166825 E-198-2012-0 E-198-2012-0-FR-10 MESOTHELIN DOMAIN-SPECIFIC MONOCLONAL ANTIBODIES AND USE THEREOF EP France 2888282 13753475.6 Issued France <br />European patent (EP) 13753475.6<br />Filed on 2015-02-20<br />Status: Issued 147166826 E-198-2012-0 E-198-2012-0-GB-11 MESOTHELIN DOMAIN-SPECIFIC MONOCLONAL ANTIBODIES AND USE THEREOF EP United Kingdom 2888282 13753475.6 Issued United Kingdom <br />European patent (EP) 13753475.6<br />Filed on 2015-02-20<br />Status: Issued 147166827 E-198-2012-0 E-198-2012-0-EP-12 MESOTHELIN DOMAIN-SPECIFIC MONOCLONAL ANTIBODIES AND USE THEREOF DIV European Patent 3327037 17210140.4 Issued European Patent <br />Divisional (DIV) 17210140.4<br />Filed on 2013-08-16<br />Status: Issued 147166828 E-198-2012-0 E-198-2012-0-AU-13 MESOTHELIN DOMAIN-SPECIFIC MONOCLONAL ANTIBODIES AND USE THEREOF DIV Australia 2018202446 2018202446 Issued Australia <br />Divisional (DIV) 2018202446<br />Filed on 2013-08-16<br />Status: Issued 147166829 E-198-2012-0 E-198-2012-0-FR-14 MESOTHELIN DOMAIN-SPECIFIC MONOCLONAL ANTIBODIES AND USE THEREOF EP France 3327037 17210140.4 Issued France <br />European patent (EP) 17210140.4<br />Filed on 2013-08-16<br />Status: Issued 147166830 E-198-2012-0 E-198-2012-0-DE-15 MESOTHELIN DOMAIN-SPECIFIC MONOCLONAL ANTIBODIES AND USE THEREOF EP Germany 3327037 17210140.4 Issued Germany <br />European patent (EP) 17210140.4<br />Filed on 2013-08-16<br />Status: Issued 147166831 E-198-2012-0 E-198-2012-0-GB-16 MESOTHELIN DOMAIN-SPECIFIC MONOCLONAL ANTIBODIES AND USE THEREOF EP United Kingdom 3327037 17210140.4 Issued United Kingdom <br />European patent (EP) 17210140.4<br />Filed on 2013-08-16<br />Status: Issued 147173530 Epitope 147173531 MESOTHELIN TAB-4113 147157395 New Chimeric Antigen Receptor (CAR) Format for Developing Improved Adoptive Cell Therapies NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Mitchell Ho, Dan Li, Nan Li <p>Adoptive cell therapy (ACT) is an attractive new therapeutic approach for treating various cancers. ACT has recently demonstrated a high degree of efficacy when treating patients with hematological malignancies. However, to date, no effective Chimeric Antigen Receptors (CAR) T cell therapy exists for solid tumors.<br /> Researchers in the National Cancer Institute (NCI) Laboratory of Molecular Biology (LMB) have created a new CAR format that is available for licensing and further co-development. This new format uses a specific promoter and signal peptide in a specific order allowing for increased efficiency of CAR T therapy. The inventors found that there was an increased therapeutic effect when using their proprietary (anti-glypican 3 [GPC3]) hYP7 antibody in this format. <br /> Additionally, the inventors are exploring the use of this new CAR T format in conjunction with other antibodies against multiple other cancer antigens, including mesothelin and glypican 2 (GPC2). </p> <h2>Competitive Advantages:</h2> <ul><li>The novel technology (new CAR format) can increase therapeutic effectiveness of CAR T therapies for patients with solid tumor cancers (i.e., hepatocellular carcinoma or pancreatic cancer) where no long term or effective therapy currently exists</li> <li>The novel technology (new CAR format) when used for immunotherapy in preclinical in vivo studies is already known to have a greater decrease in tumor size compared to those mice treated with other CAR formats</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Treating cancer patients eligible for ACT</li> <li>Treating patients with diseases associated with expression of GPC3, GPC2, and other tumor antigens (e.g. mesothelin)  </li> </ul> 2018-08-03 2025-05-14 2018-08-03 2025-05-14 2018-08-03 CANCER, chimeric antigen receptor (CAR), GPC2, GPC3, HO, MESOTHELIN, solid tumor, tumor antigen False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2018-08-03 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-091-2009 E-130-2011 E-136-2012 E-198-2012 E-211-2016 147163552 Ho, Mitchell NIH - NCI NCI Ho, Mitchell (NCI) 1 147163553 Li, Nan NIH - NCI NCI Li, Nan (NCI) 2 147163554 Li, Dan NCI - CCR NCI Li, Dan (NCI) 3 147163552 Ho, Mitchell NIH - NCI NCI Ho, Mitchell (NCI) 1 147163553 Li, Nan NIH - NCI NCI Li, Nan (NCI) 2 147163554 Li, Dan NCI - CCR NCI Li, Dan (NCI) 3 147157797 New CAR Format For Use Of Anti-GPC3, Anti-GPC2, And Anti-mesothelin E-016-2018-0 Filing authorized NCI 83731987 Dhal, Abritee abritee.dhal@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-4113] New Chimeric Antigen Receptor (CAR) Format for Developing Improved Adoptive Cell Therapies&body=Please send me information about technology [TAB-4113] New Chimeric Antigen Receptor (CAR) Format for Developing Improved Adoptive Cell Therapies.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dhal, Abritee<br><a href="mailto:abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-4113] New Chimeric Antigen Receptor (CAR) Format for Developing Improved Adoptive Cell Therapies&body=Please send me information about technology [TAB-4113] New Chimeric Antigen Receptor (CAR) Format for Developing Improved Adoptive Cell Therapies.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">abritee.dhal@nih.gov</a><br> 147160906 E-016-2018-0 E-016-2018-0-US-01 CHIMERIC ANTIGEN RECEPTORS TARGETING TUMOR ANTIGENS PRV US 62/584,421 Abandoned US <br />Provisional (PRV) 62/584,421<br />Filed on 2017-11-10<br />Status: Abandoned 147166601 E-016-2018-0 E-016-2018-0-PCT-02 CHIMERIC ANTIGEN RECEPTORS TARGETING TUMOR ANTIGENS PCT Patent Cooperation Treaty PCT/US2018/059645 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2018/059645<br />Filed on 2018-11-07<br />Status: Expired 147166602 E-016-2018-0 E-016-2018-0-CN-03 CHIMERIC ANTIGEN RECEPTORS TARGETING TUMOR ANTIGENS National Stage China ZL201880073043.9 201880073043.9 Issued China <br />National Stage 201880073043.9<br />Filed on 2018-11-07<br />Status: Issued 147166603 E-016-2018-0 E-016-2018-0-EP-04 CHIMERIC ANTIGEN RECEPTORS TARGETING TUMOR ANTIGENS National Stage European Patent 18822526.2 Pending European Patent <br />National Stage 18822526.2<br />Filed on 2018-11-07<br />Status: Pending 147166604 E-016-2018-0 E-016-2018-0-KR-05 CHIMERIC ANTIGEN RECEPTORS TARGETING TUMOR ANTIGENS National Stage South Korea 10-2020-7014565 Pending South Korea <br />National Stage 10-2020-7014565<br />Filed on 2020-05-21<br />Status: Pending 147166605 E-016-2018-0 E-016-2018-0-US-06 CHIMERIC ANTIGEN RECEPTORS TARGETING GLYPICAN-3 OR MESOTHELIN National Stage US 11,802,163 16/762,459 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11802163 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11802163">11,802,163</a><br />Filed on 2020-05-07<br />Status: Issued 147166606 E-016-2018-0 E-016-2018-0-HK-07 CHIMERIC ANTIGEN RECEPTORS TARGETING TUMOR ANTIGENS EP Hong Kong 62021026654.5 Pending Hong Kong <br />European patent (EP) 62021026654.5<br />Filed on 2018-11-07<br />Status: Pending 147166607 E-016-2018-0 E-016-2018-0-US-02 CHIMERIC ANTIGEN RECEPTORS TARGETING TUMOR ANTIGENS DIV US 18/359,071 Pending US <br />Divisional (DIV) 18/359,071<br />Filed on 2023-07-26<br />Status: Pending 147169560 CANCER 147169561 chimeric antigen receptor (CAR) 147169562 GPC2 147169563 GPC3 147169564 HO 147169565 MESOTHELIN 147169567 solid tumor 147169568 tumor antigen TAB-4230 147157515 Fully-human Heavy-chain-only Anti-B-cell Maturation Antigen (BCMA) Chimeric Antigen Receptors (CARs) NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Benjamin Buelow, James Kochenderfer, Norris Lam <p>Immortalization of plasma cells leads to plasma cell malignancy diseases such as multiple myeloma (MM). B-cell maturation antigen (BCMA) is a protein that is preferentially expressed by malignant and normal B cells and plasma cells, butnot on other cells in the body. This limited expression profile suggests that BCMA is a promising target for anticancer therapeutics for cancers in which there is excess production of plasma cells and B cells. <br /> Researchers in the National Cancer Institute (NCI) <a href="https://ccr.cancer.gov/Experimental-Transplantation-and-Immunology-Branch" rel="nofollow">Experimental Transplantation and Immunology Branch (ETIB)</a> previously reported anti-BCMA CARs, which are currently being tested in the clinic for patients with multiple myeloma. While the results from clinical trials have demonstrated the efficacy of anti-BCMA CARs, the CAR being used in this clinical trial has an antigen recognition domain derived from mouse antibody; this allows <br /> for the possibility of an immune response by the patient against the CAR. The development of CARs with antigen-recognition domains comprising a fully human heavy chain variable region can mitigate this potential immunogenicity against the CAR T cells, thereby enhancing therapeutic function.  <br /> The inventors have developed 12 novel anti-BCMA CARs with fully human heavy chain variable region sequences, each of which specifically recognizes BCMA in vitro and in vivo. Each of these CARs is available for licensing under a variety of conditions, including expression on autologous or allogeneic T cells.</p> <h2>Competitive Advantages:</h2> <ul><li>The fully human nature of this anti-BCMA CAR can increase therapeutic effectiveness because it is less immunogenic to human patients </li> <li>The fully human CARs are already known to bind to BCMA in vitro and in vivo </li> </ul> <h2>Commercial Applications:</h2> <ul><li>Treatment of plasma cell malignancy diseases such as multiple myeloma</li> <li>Treatment of B cell malignancy diseases such as Hodgkin’s lymphoma and non-Hodgkin’s lymphoma </li> </ul> 2018-03-13 2025-05-14 2018-03-13 2025-05-14 2018-03-13 act, adoptive cell therapy, B-cell Malignancies, B-cell Maturation Antigen, BCMA, BIOLOGIC, CANCER, CAR, chimeric antigen receptor, Hodgkin Lymphoma, Hodgkin’s Lymphoma, Kochenderfer, Mm, MULTIPLE MYELOMA, Non-Hodgkin Lymphoma, Non-Hodgkin’s Lymphoma, Plasma Cell Malignancies False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2018-03-13 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-040-2012 147162007 Ali S.A, et al. T cells expressing an anti&ndash;B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. https://www.ncbi.nlm.nih.gov/pubmed/27412889 <a href="https://www.ncbi.nlm.nih.gov/pubmed/27412889">Ali S.A, et al. T cells expressing an anti&ndash;B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma.</a> 147163984 Kochenderfer, James NIH - NCI NCI Kochenderfer, James (NCI) 1 147163985 Lam, Norris NIH - NCI NCI Lam, Norris (NCI) 2 147163986 Buelow, Benjamin University of California, San Francisco (UCSF) Buelow, Benjamin 3 147163984 Kochenderfer, James NIH - NCI NCI Kochenderfer, James (NCI) 1 147163985 Lam, Norris NIH - NCI NCI Lam, Norris (NCI) 2 147163986 Buelow, Benjamin University of California, San Francisco (UCSF) Buelow, Benjamin 3 147158167 Fully-human Heavy-chain-only Anti-B-cell Maturation Antigen Chimeric Antigen Receptors E-183-2017-0 Filing authorized NCI, University of California, San Francisco (UCSF) 83709866 Burke, Andrew burkear@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC burkear@nih.gov?subject=Web Inquiry on [TAB-4230] Fully-human Heavy-chain-only Anti-B-cell Maturation Antigen (BCMA) Chimeric Antigen Receptors (CARs)&body=Please send me information about technology [TAB-4230] Fully-human Heavy-chain-only Anti-B-cell Maturation Antigen (BCMA) Chimeric Antigen Receptors (CARs).&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Burke, Andrew<br><a href="mailto:burkear@nih.gov?subject=Web Inquiry on [TAB-4230] Fully-human Heavy-chain-only Anti-B-cell Maturation Antigen (BCMA) Chimeric Antigen Receptors (CARs)&body=Please send me information about technology [TAB-4230] Fully-human Heavy-chain-only Anti-B-cell Maturation Antigen (BCMA) Chimeric Antigen Receptors (CARs).&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">burkear@nih.gov</a><br> 147161162 E-183-2017-0 E-183-2017-0-US-01 Anti-B-cell Maturation Antigen Chimeric Antigen Receptors With Human Domains PRV US 62/527,556 Abandoned US <br />Provisional (PRV) 62/527,556<br />Filed on 2017-06-30<br />Status: Abandoned 147167542 E-183-2017-0 E-183-2017-0-PCT-02 ANTI-B-CELL MATURATION ANTIGEN CHIMERIC ANTIGEN RECEPTORS WITH HUMAN DOMAINS PCT Patent Cooperation Treaty PCT/US2018/039917 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2018/039917<br />Filed on 2018-06-28<br />Status: Expired 147167543 E-183-2017-0 E-183-2017-0-AU-03 Anti-B-cell Maturation Antigen Chimeric Antigen Receptors With Human Domains National Stage Australia 2018291128 2018291128 Issued Australia <br />National Stage 2018291128<br />Filed on 2018-06-28<br />Status: Issued 147167545 E-183-2017-0 E-183-2017-0-CA-05 Anti-B-cell Maturation Antigen Chimeric Antigen Receptors With Human Domains National Stage Canada 3068444 3068444 Issued Canada <br />National Stage 3068444<br />Filed on 2019-12-23<br />Status: Issued 147167546 E-183-2017-0 E-183-2017-0-CN-06 Anti-B-cell Maturation Antigen Chimeric Antigen Receptors With Human Domains National Stage China ZL201880044208.X 201880044208.X Issued China <br />National Stage 201880044208.X<br />Filed on 2019-12-30<br />Status: Issued 147167547 E-183-2017-0 E-183-2017-0-EP-07 Anti-B-cell Maturation Antigen Chimeric Antigen Receptors With Human Domains National Stage European Patent 3645568 18759189.6 Issued European Patent <br />National Stage 18759189.6<br />Filed on 2018-06-28<br />Status: Issued 147167548 E-183-2017-0 E-183-2017-0-IL-08 Anti-B-cell Maturation Antigen Chimeric Antigen Receptors With Human Domains National Stage Israel 271597 271597 Issued Israel <br />National Stage 271597<br />Filed on 2019-12-19<br />Status: Issued 147167549 E-183-2017-0 E-183-2017-0-JP-09 Anti-B-cell Maturation Antigen Chimeric Antigen Receptors With Human Domains National Stage Japan 7288405 2019-572798 Issued Japan <br />National Stage 2019-572798<br />Filed on 2018-06-28<br />Status: Issued 147167550 E-183-2017-0 E-183-2017-0-KR-10 Anti-B-cell Maturation Antigen Chimeric Antigen Receptors With Human Domains National Stage South Korea 10-2757010 10-2020-7002752 Issued South Korea <br />National Stage 10-2020-7002752<br />Filed on 2020-01-29<br />Status: Issued 147167552 E-183-2017-0 E-183-2017-0-SG-12 Anti-B-cell Maturation Antigen Chimeric Antigen Receptors With Human Domains National Stage Singapore 11201913175T Pending Singapore <br />National Stage 11201913175T<br />Filed on 2018-06-28<br />Status: Pending 147167553 E-183-2017-0 E-183-2017-0-US-13 ANTI-B-CELL MATURATION ANTIGEN CHIMERIC ANTIGEN RECEPTORS WITH HUMAN DOMAINS National Stage US 16/626,991 Abandoned US <br />National Stage 16/626,991<br />Filed on 2019-12-27<br />Status: Abandoned 147167554 E-183-2017-0 E-183-2017-0-HK-14 Anti-B-cell Maturation Antigen Chimeric Antigen Receptors With Human Domains EP Hong Kong HK40030302B 62020019504.3 Issued Hong Kong <br />European patent (EP) 62020019504.3<br />Filed on 2020-11-04<br />Status: Issued 147167556 E-183-2017-0 E-183-2017-0-EP-16 Anti-B-cell Maturation Antigen Chimeric Antigen Receptors With Human Domains DIV European Patent 22187063.7 Pending European Patent <br />Divisional (DIV) 22187063.7<br />Filed on 2022-07-26<br />Status: Pending 147167557 E-183-2017-0 E-183-2017-0-FR-17 Anti-B-cell Maturation Antigen Chimeric Antigen Receptors With Human Domains EP France 3645568 18759189.6 Issued France <br />European patent (EP) 18759189.6<br />Filed on 2018-06-28<br />Status: Issued 147167558 E-183-2017-0 E-183-2017-0-GB-18 Anti-B-cell Maturation Antigen Chimeric Antigen Receptors With Human Domains EP United Kingdom 3645568 18759189.6 Issued United Kingdom <br />European patent (EP) 18759189.6<br />Filed on 2018-06-28<br />Status: Issued 147167559 E-183-2017-0 E-183-2017-0-IT-19 Anti-B-cell Maturation Antigen Chimeric Antigen Receptors With Human Domains EP Italy 3645568 18759189.6 Issued Italy <br />European patent (EP) 18759189.6<br />Filed on 2018-06-28<br />Status: Issued 147167560 E-183-2017-0 E-183-2017-0-DE-20 Anti-B-cell Maturation Antigen Chimeric Antigen Receptors With Human Domains EP Germany 3645568 18759189.6 Issued Germany <br />European patent (EP) 18759189.6<br />Filed on 2018-06-28<br />Status: Issued 147167561 E-183-2017-0 E-183-2017-0-ES-21 Anti-B-cell Maturation Antigen Chimeric Antigen Receptors With Human Domains EP Spain 3645568 18759189.6 Issued Spain <br />European patent (EP) 18759189.6<br />Filed on 2018-06-28<br />Status: Issued 147167562 E-183-2017-0 E-183-2017-0-JP-01 ANTI-B-CELL MATURATION ANTIGEN CHIMERIC ANTIGEN RECEPTORS WITH HUMAN DOMAINS DIV Japan 7527419 2023-020373 Issued Japan <br />Divisional (DIV) 2023-020373<br />Filed on 2023-02-13<br />Status: Issued 147167563 E-183-2017-0 E-183-2017-0-HK-01 Anti-B-cell Maturation Antigen Chimeric Antigen Receptors With Human Domains EP Hong Kong 42023078902.6 Pending Hong Kong <br />European patent (EP) 42023078902.6<br />Filed on 2018-06-28<br />Status: Pending 147173228 act 147173229 adoptive cell therapy 147173231 B-cell Malignancies 147173233 B-cell Maturation Antigen 147173234 BCMA 147173235 BIOLOGIC 147173236 CANCER 147173237 CAR 147173238 chimeric antigen receptor 147173240 Hodgkin Lymphoma 147173242 Hodgkin’s Lymphoma 147173243 Kochenderfer 147173244 Mm 147173245 MULTIPLE MYELOMA 147173247 Non-Hodgkin Lymphoma 147173248 Non-Hodgkin’s Lymphoma 147173250 Plasma Cell Malignancies TAB-4164 147157447 Chimeric Antigen Receptors (CARs) for Treating Lymphoma and Other Cancers NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics James Kochenderfer <p>Chimeric antigen receptors (CARs) are hybrid proteins that consist of two major components: a targeting domain and a signaling domain.  The targeting domain allows T cells which express the CAR to selectively recognize and bind to diseased cells that express a particular protein.  Once the diseased cell is bound by the targeting domain of the CAR, the signaling domain of the CAR activates the T cell, thereby allowing it to kill the diseased cell.  This is a promising new therapeutic approach known as adoptive cell therapy (ACT).</p> <p>Researchers at the NCI <a href="https://ccr.cancer.gov/Experimental-Transplantation-and-Immunology-Branch/james-n-kochenderfer" rel="nofollow">Experimental Transplantation and Immunology Branch</a> developed a CAR that recognizes human tumor necrosis factor receptor superfamily member 8 (TNFRSF8, also known as CD30). The expression of CD30 is deregulated in a variety of human cancers, including many lymphomas.  By creating a CAR that recognizes CD30, it may be possible to treat these cancers using adoptive cell therapy.</p> <h2>Competitive Advantages:</h2> <ul><li>Human components are less likely to cause adverse or neutralizing immune response in patients</li> <li>Targeted therapies decrease non-specific killing of healthy cells and tissues, resulting in fewer off-target side-effects and healthier patients</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Treatment of human cancers associated with expression of CD30 or variants thereof</li> <li>Specific cancers include: Non-Hodgkins Lymphomas, Hodgkin's Lymphomas, several solid malignancies</li> </ul> 2016-02-16 2025-05-14 2018-03-23 2025-05-14 2016-08-23 adoptive cell therapy, CAR, CD30 False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2018-03-23 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147163746 Kochenderfer, James NIH - NCI NCI Kochenderfer, James (NCI) 1 147163746 Kochenderfer, James NIH - NCI NCI Kochenderfer, James (NCI) 1 147157760 A Novel Fully-Human Anti-CD30 Chimeric Antigen Receptor For Treatment Of CD30+ Lymphoma E-001-2016-0 Filing authorized NCI 83709866 Burke, Andrew burkear@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC burkear@nih.gov?subject=Web Inquiry on [TAB-4164] Chimeric Antigen Receptors (CARs) for Treating Lymphoma and Other Cancers&body=Please send me information about technology [TAB-4164] Chimeric Antigen Receptors (CARs) for Treating Lymphoma and Other Cancers.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Burke, Andrew<br><a href="mailto:burkear@nih.gov?subject=Web Inquiry on [TAB-4164] Chimeric Antigen Receptors (CARs) for Treating Lymphoma and Other Cancers&body=Please send me information about technology [TAB-4164] Chimeric Antigen Receptors (CARs) for Treating Lymphoma and Other Cancers.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">burkear@nih.gov</a><br> 147160875 E-001-2016-0 E-001-2016-0-US-01 Anti-CD30 Chimeric Antigen Receptors PRV US 62/241,896 Abandoned US <br />Provisional (PRV) 62/241,896<br />Filed on 2015-10-15<br />Status: Abandoned 147167030 E-001-2016-0 E-001-2016-0-PCT-02 ANTI-CD30 CHIMERIC ANTIGEN RECEPTORS PCT Patent Cooperation Treaty PCT/US2016/056262 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2016/056262<br />Filed on 2016-10-10<br />Status: Expired 147167031 E-001-2016-0 E-001-2016-0-AU-03 ANTI-CD30 CHIMERIC ANTIGEN RECEPTORS National Stage Australia 2016338747 Abandoned Australia <br />National Stage 2016338747<br />Filed on 2016-10-10<br />Status: Abandoned 147167032 E-001-2016-0 E-001-2016-0-BR-04 ANTI-CD30 CHIMERIC ANTIGEN RECEPTORS National Stage Brazil BR112018006995-7 Abandoned Brazil <br />National Stage BR112018006995-7<br />Filed on 2018-04-06<br />Status: Abandoned 147167033 E-001-2016-0 E-001-2016-0-CA-05 ANTI-CD30 CHIMERIC ANTIGEN RECEPTORS National Stage Canada 3002000 Abandoned Canada <br />National Stage 3002000<br />Filed on 2016-10-10<br />Status: Abandoned 147167034 E-001-2016-0 E-001-2016-0-CN-06 ANTI-CD30 CHIMERIC ANTIGEN RECEPTORS National Stage China 201680059341.3 Abandoned China <br />National Stage 201680059341.3<br />Filed on 2016-10-10<br />Status: Abandoned 147167035 E-001-2016-0 E-001-2016-0-EP-07 ANTI-CD30 CHIMERIC ANTIGEN RECEPTORS National Stage European Patent 3362476 16784695.5 Issued European Patent <br />National Stage 16784695.5<br />Filed on 2016-10-10<br />Status: Issued 147167036 E-001-2016-0 E-001-2016-0-IN-08 ANTI-CD30 CHIMERIC ANTIGEN RECEPTORS National Stage India 201847016354 Abandoned India <br />National Stage 201847016354<br />Filed on 2016-10-10<br />Status: Abandoned 147167037 E-001-2016-0 E-001-2016-0-JP-09 ANTI-CD30 CHIMERIC ANTIGEN RECEPTORS National Stage Japan 2018-518999 Abandoned Japan <br />National Stage 2018-518999<br />Filed on 2018-04-12<br />Status: Abandoned 147167038 E-001-2016-0 E-001-2016-0-MX-10 ANTI-CD30 CHIMERIC ANTIGEN RECEPTORS National Stage Mexico MX/a/2018/004503 Abandoned Mexico <br />National Stage MX/a/2018/004503<br />Filed on 2016-10-10<br />Status: Abandoned 147167039 E-001-2016-0 E-001-2016-0-US-11 ANTI-CD30 CHIMERIC ANTIGEN RECEPTORS National Stage US 10,815,301 15/766,948 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10815301 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10815301">10,815,301</a><br />Filed on 2018-04-09<br />Status: Issued 147167040 E-001-2016-0 E-001-2016-0-IL-12 Anti-CD30 Chimeric Antigen Receptors ORD Israel 258527 Abandoned Israel <br />Ordinary Patent (ORD) 258527<br />Filed on 2018-04-08<br />Status: Abandoned 147167041 E-001-2016-0 E-001-2016-0-KR-13 Anti-CD30 Chimeric Antigen Receptors National Stage South Korea 10-2018-7013573 Abandoned South Korea <br />National Stage 10-2018-7013573<br />Filed on 2018-05-14<br />Status: Abandoned 147167042 E-001-2016-0 E-001-2016-0-SA-14 Anti-CD30 Chimeric Antigen Receptors ORD Saudi Arabia 518391355 Abandoned Saudi Arabia <br />Ordinary Patent (ORD) 518391355<br />Filed on 2018-04-12<br />Status: Abandoned 147167043 E-001-2016-0 E-001-2016-0-DE-15 ANTI-CD30 CHIMERIC ANTIGEN RECEPTORS EP Germany 3362476 16784695.5 Abandoned Germany <br />European patent (EP) 16784695.5<br />Filed on 2016-10-10<br />Status: Abandoned 147167044 E-001-2016-0 E-001-2016-0-FR-16 ANTI-CD30 CHIMERIC ANTIGEN RECEPTORS EP France 3362476 16784695.5 Abandoned France <br />European patent (EP) 16784695.5<br />Filed on 2016-10-10<br />Status: Abandoned 147167045 E-001-2016-0 E-001-2016-0-GB-17 ANTI-CD30 CHIMERIC ANTIGEN RECEPTORS EP United Kingdom 3362476 16784695.5 Abandoned United Kingdom <br />European patent (EP) 16784695.5<br />Filed on 2016-10-10<br />Status: Abandoned 147169190 adoptive cell therapy 147169191 CAR 147169193 CD30 TAB-4492 151704035 Human Monoclonal Antibodies to Generate Chimeric Antigen Receptor (CAR) T-cells to Treat Patients with Advanced Clear Cell Renal Cell Carcinoma (ccRCC). NHLBI Antibodies, Diagnostics, Licensing, Materials Available, Oncology, Research Materials Antibodies Diagnostics Licensing Materials Available Oncology Research Materials Long Chen, Elena Cherkasova, Richard Childs <p>This technology includes six human monoclonal antibodies (mAbs) that target tumor antigens derived from the CT-RCC HERV-E (human endogenous retrovirus type E) to generate Chimeric Antigen Receptor (CAR) T cells to treat patients with advanced clear cell renal cell carcinoma (ccRCC). These mAbs were identified from Adagene Inc&rsquo;s human antibody phage library, and data show that majority of these mAbs only bind to CT-RCC HERV-E+ ccRCC cells, which express TM but not CT-RCC HERV-E non-expressing ccRCC cells nor non-RCC cells. None of them showed non-specific binding to peripheral blood cells from healthy donors or human normal cell lines. Our data are consistent with the identification of several novel human mAbs that bind to the CT-RCC HERV-E Env TM with high specificity and no cross-activity. These mAbs have the potential to be used to generate CAR-T cells targeting HERV-E TM as a treatment for advanced ccRCC.</p> <ul> <li>First ever discovered mAbs targeting a highly specific antigen in ccRCC with minimal to no cross-activity.</li> <li>These mAbs are human antibodies that won’t trigger human anti-idiotype antibody formation when used in treating kidney cancer patients, which is an advantage compared to mice mAbs or chimeric mAbs.</li> <li>These mAbs are screened from patented human antibody phage library (Dynamic Precision Library Platform- Adagene INC) ensuring them to hit the unique epitopes of the target TMN protein, which would not be achieved by standard mAbs discovering methods.</li> <li>CAR-T cells that would be derived from these mAbs would potentially be the first CAR -T therapy targeting an antigen restricted to ccRCC.</li> </ul> Treatment for renal cell carcinoma. We are seeking statements of capability or interest from parties interested in collaborative research to further developer, evaluate, or commercialize this technology. 2023-12-07 2024-08-12 2025-05-14 2024-03-27 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 151704049 Childs, Richard National Heart, Lung, and Blood Institute (NHLBI) NHLBI Childs, Richard (NHLBI) 1 151704053 Chen, Long National Heart, Lung, and Blood Institute (NHLBI) NHLBI Chen, Long (NHLBI) 2 151704057 Cherkasova, Elena National Heart, Lung, and Blood Institute (NHLBI) NHLBI Cherkasova, Elena (NHLBI) 3 151704049 Childs, Richard National Heart, Lung, and Blood Institute (NHLBI) NHLBI Childs, Richard (NHLBI) 1 151704053 Chen, Long National Heart, Lung, and Blood Institute (NHLBI) NHLBI Chen, Long (NHLBI) 2 151704057 Cherkasova, Elena National Heart, Lung, and Blood Institute (NHLBI) NHLBI Cherkasova, Elena (NHLBI) 3 151704038 Using Human Monoclonal Antibodies That Target Tumor Antigens Derived From The CT-RCC HERV-E To Generate Chimeric Antigen Receptor (CAR) T Cells To Treat Patients With Advanced Clear Cell Renal Cell Carcinoma (ccRCC). E-087-2020-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-4492] Human Monoclonal Antibodies to Generate Chimeric Antigen Receptor (CAR) T-cells to Treat Patients with Advanced Clear Cell Renal Cell Carcinoma (ccRCC).&body=Please send me information about technology [TAB-4492] Human Monoclonal Antibodies to Generate Chimeric Antigen Receptor (CAR) T-cells to Treat Patients with Advanced Clear Cell Renal Cell Carcinoma (ccRCC).. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-4492] Human Monoclonal Antibodies to Generate Chimeric Antigen Receptor (CAR) T-cells to Treat Patients with Advanced Clear Cell Renal Cell Carcinoma (ccRCC).&body=Please send me information about technology [TAB-4492] Human Monoclonal Antibodies to Generate Chimeric Antigen Receptor (CAR) T-cells to Treat Patients with Advanced Clear Cell Renal Cell Carcinoma (ccRCC)..">shmilovm@nih.gov</a><br> 157754657 E-087-2020-0 E-087-2020-0-US-01 HERV-E ANTIBODIES AND METHODS OF THEIR USE PRV US 63/539,170 Expired US <br />Provisional (PRV) 63/539,170<br />Filed on 2023-09-19<br />Status: Expired 157754666 E-087-2020-0 E-087-2020-0-PC-01 HERV-E ANTIBODIES AND METHODS OF THEIR USE PCT Patent Cooperation Treaty PCT/US2024/047278 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2024/047278<br />Filed on 2024-09-18<br />Status: Expired TAB-4505 151705473 Blocking CD38 using Protein G Complexed Daratumumab Antibodies (PGDARA) to Protect Natural Killer Cells from Daratumumab-induced Apoptosis and Cell Death for the Treatment of Multiple Myeloma NHLBI Human Cell Lines, Licensing, Materials Available, Oncology, Research Materials Human Cell Lines Licensing Materials Available Oncology Research Materials Maria Berg, Richard Childs, Jorge Luis Espinoza-Calderon <p>This technology includes the method of blocking CD38 in expanded natural killer (NK) cell therapy in combination with daratumumab in patients with multiple myeloma. Our in vitro studies have already confirmed the addition of NK cells to myeloma cells that have been exposed to daratumumab enhances myeloma killing compared to single agent treatment. Studies exploring adoptive NK cell transfer after daratumumab treatment to bolster daratumumab-mediated killing of myeloma via ADCC could be limited by the fact that these transferred NK cells might be killed by the antibody before they could reach their antibody-bound tumor targets. To overcome this obstacle, we have explored blocking CD38 on the surface of NK cells with protein G complexed daratumumab antibodies (PGDARA) as a method to prevent daratumumab- induced apoptosis of NK cells. This effect could potentiate daratumumab killing of myeloma cells via ADCC mediated by adoptively transferred NK cells following daratumumab treatment.</p> We have generated PGDARA which protect NK cells from daratumumab-mediated killing. At present, there exists no method to protect NK cells from Daratumumab-mediated killing. Therapeutic advancement to improve treatment for multiple myeloma patients. We are seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. 2023-12-07 2024-08-12 2025-05-14 2024-03-20 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 151705602 Childs, Richard National Heart, Lung, and Blood Institute (NHLBI) NHLBI Childs, Richard (NHLBI) 1 151705612 Espinoza-Calderon, Jorge Luis Espinoza-Calderon, Jorge Luis 2 151705623 Berg, Maria National Heart, Lung, and Blood Institute (NHLBI) NHLBI Berg, Maria (NHLBI) 3 151705602 Childs, Richard National Heart, Lung, and Blood Institute (NHLBI) NHLBI Childs, Richard (NHLBI) 1 151705612 Espinoza-Calderon, Jorge Luis Espinoza-Calderon, Jorge Luis 2 151705623 Berg, Maria National Heart, Lung, and Blood Institute (NHLBI) NHLBI Berg, Maria (NHLBI) 3 151705590 Blocking CD38 Using Daratumumab Conjugated To Protein G To Protect NK Cells From Daratumumab Induced Apotosis And Cell Death E-134-2014-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 83685986 Crooks, Denise crooksd@mail.nih.gov
United States of America Office of Technology Transfer and Development crooksd@mail.nih.gov?subject=Web Inquiry on [TAB-4505] Blocking CD38 using Protein G Complexed Daratumumab Antibodies (PGDARA) to Protect Natural Killer Cells from Daratumumab-induced Apoptosis and Cell Death for the Treatment of Multiple Myeloma&body=Please send me information about technology [TAB-4505] Blocking CD38 using Protein G Complexed Daratumumab Antibodies (PGDARA) to Protect Natural Killer Cells from Daratumumab-induced Apoptosis and Cell Death for the Treatment of Multiple Myeloma. Crooks, Denise<br><a href="mailto:crooksd@mail.nih.gov?subject=Web Inquiry on [TAB-4505] Blocking CD38 using Protein G Complexed Daratumumab Antibodies (PGDARA) to Protect Natural Killer Cells from Daratumumab-induced Apoptosis and Cell Death for the Treatment of Multiple Myeloma&body=Please send me information about technology [TAB-4505] Blocking CD38 using Protein G Complexed Daratumumab Antibodies (PGDARA) to Protect Natural Killer Cells from Daratumumab-induced Apoptosis and Cell Death for the Treatment of Multiple Myeloma.">crooksd@mail.nih.gov</a><br> 157755159 E-134-2014-0 E-134-2014-0-US-01 Blocking CD38 Using Anti-CD38 Antibody Conjugated To Protein G To Protect NK Cells PRV US 62/012,873 Abandoned US <br />Provisional (PRV) 62/012,873<br />Filed on 2014-06-16<br />Status: Abandoned 157755164 E-134-2014-0 E-134-2014-0-PCT-02 Blocking CD38 Using Anti-CD38 Antibody Conjugated To Protein G To Protect NK Cells PCT Patent Cooperation Treaty PCT/US2015/035831 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2015/035831<br />Filed on 2015-06-15<br />Status: Expired TAB-4490 151703159 Epstein-Barr Virus (EBV)-feeder Cell Line NHLBI Human Cell Lines, Infectious Disease, Licensing, Oncology, Research Materials, Therapeutics Human Cell Lines Infectious Disease Licensing Oncology Research Materials Therapeutics Richard Childs <p>This technology includes irradiated Epstein-Barr virus-transformed lymphoblastoid cell lines (EBV-LCL) as feeder cells for the ex vivo expansion of natural killer (NK) cells. EBV-LCL feeder cells, altered by radiation to prevent uncontrolled growth, provide a supportive environment for NK cells to multiply effectively. This method addresses the challenge of obtaining sufficient quantities of functionally active NK cells, which are crucial components of the immune system known for their ability to target and destroy tumor cells and virally infected cells. The use of EBV-LCL feeder cells permits improved scalability and effectiveness of NK cell-based therapies for cancer and infectious diseases.</p> This technology offers a competitive advantage by enabling efficient and large-scale production of functionally active natural killer cells, enhancing the potential of NK cell-based therapies in treating cancer and infectious diseases. This method potentially allows for a more efficient expansion of NK cells compared to current techniques, resulting in a higher yield of cells for therapeutic use. We are seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. 2023-12-07 2024-08-12 2025-05-14 2024-03-27 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 151703577 Childs, Richard National Heart, Lung, and Blood Institute (NHLBI) NHLBI Childs, Richard (NHLBI) 1 151703577 Childs, Richard National Heart, Lung, and Blood Institute (NHLBI) NHLBI Childs, Richard (NHLBI) 1 151703162 EBV-feeder Cell Line E-084-2021-0 Research Material National Heart, Lung, and Blood Institute (NHLBI) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-4490] Epstein-Barr Virus (EBV)-feeder Cell Line&body=Please send me information about technology [TAB-4490] Epstein-Barr Virus (EBV)-feeder Cell Line. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-4490] Epstein-Barr Virus (EBV)-feeder Cell Line&body=Please send me information about technology [TAB-4490] Epstein-Barr Virus (EBV)-feeder Cell Line.">shmilovm@nih.gov</a><br> TAB-4332 147157623 High Affinity Cross Species Single Domain Antibodies Targeting Mesothelin NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Mitchell Ho, Jessica Hong, Nan Li, Ira Pastan <p>Mesothelin is a cell surface protein that is an excellent target for immunotherapy because of its limited expression on normal tissues and its high expression on many cancers, including mesothelioma, cholangiocarcinoma, pancreatic, ovarian, lung, stomach, bile duct, and triple-negative breast cancer.</p> <p>Researchers at the National Cancer Institute’s (NCI) <a href="https://ccr.cancer.gov/Laboratory-of-Molecular-Biology" rel="nofollow">Laboratory of Molecular Biology</a> have isolated two anti-mesothelin single domain antibodies (also known as nanobodies), A101 and G8. These antibodies have been isolated from newly developed camel single domain (VHH) libraries by phage display and have been used to shown to specifically target mesothelin-expressing cell lines with high affinity. Additionally, these mesothelin antibodies can be used as either independent agents or targeting domains in recombinant immunotoxins (RITs), antibody-drug conjugates (ADCs), bispecific antibodies, and chimeric antigen receptors (CARs). Significantly, CARs using these antibodies have shown specific killing activity against mesothelin positive tumors including mesothelioma cell and mouse models, strongly supporting that these candidates may be further developed as therapeutics.  </p> <h2>Competitive Advantages:</h2> <ul><li>New A101 and G8 antibodies with high mesothelin binding specificity should result in less non-specific cell killing and lower-grade potential side-effects</li> <li>Similarity of camel and human VH sequences suggests humanization of these antibodies is not necessary, and that the product is ready for immediate clinical testing</li> <li>CARs using the A101 and G8 antibodies are available for immediate testing</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Therapeutic applications include the unconjugated antibodies and their use as a targeting moiety for CARs, RITs, ADCs, and bispecific antibodies</li> <li>Diagnostic agent for detection and monitoring levels of mesothelin expressing cancers</li> </ul> 2019-05-15 2025-05-14 2019-05-15 2025-05-14 2019-05-15 ADC, Antibody-drug Conjugate, Bispecific Antibody, CAR, chimeric antigen receptor, HO, MESOTHELIN, Mesothelioma, Recombinant Immunotoxins, RITs False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2019-05-15 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147164338 Ho, Mitchell NIH - NCI NCI Ho, Mitchell (NCI) 1 147164337 Pastan, Ira NIH - NCI NCI Pastan, Ira (NCI) 2 147164340 Hong, Jessica NIH - NCI NCI Hong, Jessica (NCI) 3 147164339 Li, Nan NIH - NCI NCI Li, Nan (NCI) 4 147164338 Ho, Mitchell NIH - NCI NCI Ho, Mitchell (NCI) 1 147164337 Pastan, Ira NIH - NCI NCI Pastan, Ira (NCI) 2 147164340 Hong, Jessica NIH - NCI NCI Hong, Jessica (NCI) 3 147164339 Li, Nan NIH - NCI NCI Li, Nan (NCI) 4 147157844 Cross Species Single Domain Antibodies Targeting Mesothelin For Treating Solid Tumors E-040-2019-0 Filing authorized NCI 83731987 Dhal, Abritee abritee.dhal@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-4332] High Affinity Cross Species Single Domain Antibodies Targeting Mesothelin&body=Please send me information about technology [TAB-4332] High Affinity Cross Species Single Domain Antibodies Targeting Mesothelin.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dhal, Abritee<br><a href="mailto:abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-4332] High Affinity Cross Species Single Domain Antibodies Targeting Mesothelin&body=Please send me information about technology [TAB-4332] High Affinity Cross Species Single Domain Antibodies Targeting Mesothelin.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">abritee.dhal@nih.gov</a><br> 147160945 E-040-2019-0 E-040-2019-0-US-01 Cross Species Single Domain Antibodies Targeting Mesothelin For Treating Solid Tumors PRV US 62/789,650 Abandoned US <br />Provisional (PRV) 62/789,650<br />Filed on 2019-01-08<br />Status: Abandoned 147168241 E-040-2019-0 E-040-2019-0-PCT-02 Cross Species Single Domain Antibodies Targeting Mesothelin For Treating Solid Tumors PCT Patent Cooperation Treaty PCT/US2020/012021 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2020/012021<br />Filed on 2020-01-02<br />Status: Expired 147168242 E-040-2019-0 E-040-2019-0-AU-03 Cross Species Single Domain Antibodies Targeting Mesothelin For Treating Solid Tumors National Stage Australia 2020206308 Pending Australia <br />National Stage 2020206308<br />Filed on 2020-01-02<br />Status: Pending 147168243 E-040-2019-0 E-040-2019-0-CA-04 Cross Species Single Domain Antibodies Targeting Mesothelin For Treating Solid Tumors National Stage Canada 3125484 Pending Canada <br />National Stage 3125484<br />Filed on 2020-01-02<br />Status: Pending 147168244 E-040-2019-0 E-040-2019-0-CN-05 Cross Species Single Domain Antibodies Targeting Mesothelin For Treating Solid Tumors National Stage China ZL202080008456.6 202080008456.6 Issued China <br />National Stage 202080008456.6<br />Filed on 2020-01-02<br />Status: Issued 147168245 E-040-2019-0 E-040-2019-0-EP-06 Cross Species Single Domain Antibodies Targeting Mesothelin For Treating Solid Tumors National Stage European Patent 20703568.4 Pending European Patent <br />National Stage 20703568.4<br />Filed on 2020-01-02<br />Status: Pending 147168246 E-040-2019-0 E-040-2019-0-US-07 Cross Species Single Domain Antibodies Targeting Mesothelin For Treating Solid Tumors National Stage US 12,180,296 17/421,334 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12180296 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12180296">12,180,296</a><br />Filed on 2021-07-07<br />Status: Issued 147170034 ADC 147170035 Antibody-drug Conjugate 147170036 Bispecific Antibody 147170037 CAR 147170038 chimeric antigen receptor 147170039 HO 147170040 MESOTHELIN 147170041 Mesothelioma 147170043 Recombinant Immunotoxins 147170044 RITs TAB-4215 147157500 High Affinity Monoclonal Antibodies Targeting Glypican-2 for Treating Childhood Cancers NCI Licensing, Oncology, Therapeutics Licensing Oncology Therapeutics Bryan Fleming, Mitchell Ho, Nan Li <p>Neuroblastoma is a rare pediatric cancer with approximately 1,000 new cases arising annually. Current therapies have a less than forty-five percent (45%), three-year survival rate which demonstrate a need for a more effective treatment against this disease. Glypican-2 (GPC2) is a cell surface protein that is preferentially expressed in pediatric cancers including neuroblastoma, which makes GPC2 an attractive candidate for targeted therapy. <br />  <br /> Researchers at the National Cancer Institute’s (NCI) <a href="https://ccr.cancer.gov/Laboratory-of-Molecular-Biology" rel="nofollow">Laboratory of Molecular Biology</a> have developed and isolated two new antibodies that target GPC2 (CT3 and CT5). These new antibodies have been shown to specifically target GPC2-expressing neuroblastoma, medulloblastoma, and retinoblastoma cell lines. These GPC2 antibodies can be used as either independent agents or targeting domains in recombinant immunotoxins (RITs), antibody-drug conjugates (ADCs), and chimeric antigen receptors (CARs). Significantly, RITs and CARs (using the CT3 clone) have shown specific killing activity against GPC2-positive neuroblastoma cells, strongly supporting that these candidates may be further developed as therapeutics for patients with GPC2-positive pediatric cancers. </p> <h2>Competitive Advantages:</h2> <ul><li>New CT3 antibody with high GPC2 binding specificity will result in less non-specific cell killing and lower potential side-effects</li> <li>There is a first to market potential because there are no known effective GPC2-targeted therapies currently available</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Therapeutic applications include the unconjugated antibodies and their use as a targeting moiety for CARs, RITs, ADCs, and bispecific antibodies</li> <li>Diagnostic application for detecting and monitoring GPC2-expressing malignancies</li> </ul> 2018-10-15 2025-05-14 2018-10-15 2025-05-14 2018-10-15 ADC, Antibody-drug Conjugate, CAR, chimeric antigen receptor, Glypican 2, GPC2, HO, Immunotoxin, Medulloblastoma, Neuroblastoma, Recombinant Immunotoxin, Retinoblastoma, Rit False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2018-10-15 52406768 Discovery 52406768 NCI 37470483 Website Abstract E-211-2016 147163935 Ho, Mitchell NIH - NCI NCI Ho, Mitchell (NCI) 1 147163937 Li, Nan NIH - NCI NCI Li, Nan (NCI) 2 147163936 Fleming, Bryan NIH - NCI NCATS Fleming, Bryan (NCATS) 3 147163935 Ho, Mitchell NIH - NCI NCI Ho, Mitchell (NCI) 1 147163937 Li, Nan NIH - NCI NCI Li, Nan (NCI) 2 147163936 Fleming, Bryan NIH - NCI NCATS Fleming, Bryan (NCATS) 3 147158200 High Affinity Monoclonal Antibodies Targeting Glypican-2 For Treating Childhood Cancers E-198-2018-0 Filing authorized NCI 83731987 Dhal, Abritee abritee.dhal@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-4215] High Affinity Monoclonal Antibodies Targeting Glypican-2 for Treating Childhood Cancers&body=Please send me information about technology [TAB-4215] High Affinity Monoclonal Antibodies Targeting Glypican-2 for Treating Childhood Cancers.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dhal, Abritee<br><a href="mailto:abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-4215] High Affinity Monoclonal Antibodies Targeting Glypican-2 for Treating Childhood Cancers&body=Please send me information about technology [TAB-4215] High Affinity Monoclonal Antibodies Targeting Glypican-2 for Treating Childhood Cancers.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">abritee.dhal@nih.gov</a><br> 147161185 E-198-2018-0 E-198-2018-0-US-01 HIGH AFFINITY MONOCLONAL ANTIBODIES TARGETING GLYPICAN-2 AND USES THEREOF PRV US 62/716,169 Abandoned US <br />Provisional (PRV) 62/716,169<br />Filed on 2018-08-08<br />Status: Abandoned 147167456 E-198-2018-0 E-198-2018-0-PCT-02 High Affinity Monoclonal Antibodies Targeting Glypican-2 For Treating Childhood Cancers PCT Patent Cooperation Treaty PCT/US2019/045338 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2019/045338<br />Filed on 2019-08-06<br />Status: Expired 147167457 E-198-2018-0 E-198-2018-0-AU-03 HIGH AFFINITY MONOCLONAL ANTIBODIES TARGETING GLYPICAN-2 AND USES THEREOF National Stage Australia 2019317565 Pending Australia <br />National Stage 2019317565<br />Filed on 2019-08-06<br />Status: Pending 147167458 E-198-2018-0 E-198-2018-0-CA-04 HIGH AFFINITY MONOCLONAL ANTIBODIES TARGETING GLYPICAN-2 AND USES THEREOF National Stage Canada 3106544 Pending Canada <br />National Stage 3106544<br />Filed on 2019-08-06<br />Status: Pending 147167459 E-198-2018-0 E-198-2018-0-CN-05 High Affinity Monoclonal Antibodies Targeting Glypican-2 For Treating Childhood Cancers National Stage China ZL201980053942.7 201980053942.7 Issued China <br />National Stage 201980053942.7<br />Filed on 2019-08-06<br />Status: Issued 147167460 E-198-2018-0 E-198-2018-0-EP-06 HIGH AFFINITY MONOCLONAL ANTIBODIES TARGETING GLYPICAN-2 AND USES THEREOF National Stage European Patent 19759784.2 Pending European Patent <br />National Stage 19759784.2<br />Filed on 2019-08-06<br />Status: Pending 147167461 E-198-2018-0 E-198-2018-0-US-07 HIGH AFFINITY MONOCLONAL ANTIBODIES TARGETING GLYPICAN-2 AND USES THEREOF National Stage US 12,012,463 17/266,419 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12012463 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12012463">12,012,463</a><br />Filed on 2021-02-05<br />Status: Issued 147173544 ADC 147173545 Antibody-drug Conjugate 147173546 CAR 147173547 chimeric antigen receptor 147173548 Glypican 2 147173549 GPC2 147173550 HO 147173551 Immunotoxin 147173552 Medulloblastoma 147173553 Neuroblastoma 147173554 Recombinant Immunotoxin 147173555 Retinoblastoma 147173556 Rit TAB-4107 147157389 High Affinity Monoclonal Antibodies Targeting Glypican-1 NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Mitchell Ho, Nan Li <p>Pancreatic cancer is the fourth most common cause of death from cancer in the U.S. The overall 5-year survival rate for this disease is 8.5%. Glypican-1 (GPC1), a cell surface heparan sulfate proteoglycan protein that is overexpressed in pancreatic cancer. Due to this preferential expression, GPC1 represents a potential candidate for targeted therapy for patients with pancreatic cancer and other GPC1 expressing cancers such as prostate cancer.</p> <p>Researchers at the National Cancer Institute’s (NCI) <a href="https://ccr.cancer.gov/Laboratory-of-Molecular-Biology" rel="nofollow"><u>Laboratory of Molecular Biology</u></a> have developed and isolated two new antibodies that target GPC1 (HM2 and D4). These new antibodies have been shown to specifically target GPC1-expressing cell lines. These GPC1 antibodies can be used as either independent agents or targeting domains in immunoconjugates such as recombinant immunotoxins (RITs), antibody-drug conjugates (ADCs), chimeric antigen receptors (CARs), bispecific antibodies, etc. Significantly, CARs using these antibodies have shown specific killing activity against GPC1 positive tumors – including GPC1 expressing cell and mouse models. Such data strongly support that these candidates may be further developed as therapeutics. </p> <h2>Competitive Advantages:</h2> <ul><li style="margin:0in 0in 0pt">New HM2 and D4 antibodies with high GPC1 binding specificity will result in less non-specific cell killing and lower potential side-effects</li> <li>There is a first to market potential because there are no known clinical trials using GPC1-targeted therapies</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Therapeutic applications include the unconjugated antibodies and their use as a targeting moiety for CARs, RITs, ADCs, and bispecific antibodies</li> <li>Potential therapeutic benefit for several cancer types with few treatment options – including uterine cervical cancer and pancreatic adenocarcinoma</li> <li>Diagnostic agent for detection and monitoring levels of GPC1-expressing cancers</li> </ul> 2019-04-26 2025-05-14 2019-12-10 2025-05-14 2019-04-26 ADC, Antibody-drug Conjugate, Bispecific Antibody, CAR, chimeric antigen receptor, Glypican-1, GPC1, HO, Immunotoxin, NANOBODY, Pancreatic Cancer, Recombinant Immunotoxin, Rit, Single Domain Antibody False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2019-12-10 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147163533 Ho, Mitchell NIH - NCI NCI Ho, Mitchell (NCI) 1 147163534 Li, Nan NIH - NCI NCI Li, Nan (NCI) 2 147163533 Ho, Mitchell NIH - NCI NCI Ho, Mitchell (NCI) 1 147163534 Li, Nan NIH - NCI NCI Li, Nan (NCI) 2 147157823 High Affinity Monoclonal Antibodies Targeting Glypican-1 For Treating Pancreatic Cancer E-028-2019-0 Filing authorized National Cancer Institute (NCI), NCI 83731987 Dhal, Abritee abritee.dhal@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-4107] High Affinity Monoclonal Antibodies Targeting Glypican-1&body=Please send me information about technology [TAB-4107] High Affinity Monoclonal Antibodies Targeting Glypican-1.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dhal, Abritee<br><a href="mailto:abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-4107] High Affinity Monoclonal Antibodies Targeting Glypican-1&body=Please send me information about technology [TAB-4107] High Affinity Monoclonal Antibodies Targeting Glypican-1.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">abritee.dhal@nih.gov</a><br> 147160928 E-028-2019-0 E-028-2019-0-US-01 High Affinity Monoclonal Antibodies Targeting Glypican-1 For Treating Pancreatic Cancer PRV US 62/795,415 Abandoned US <br />Provisional (PRV) 62/795,415<br />Filed on 2019-01-22<br />Status: Abandoned 147166570 E-028-2019-0 E-028-2019-0-PCT-02 HIGH AFFINITY MONOCLONAL ANTIBODIES TARGETING GLYPICAN-1 AND METHODS OF USE PCT Patent Cooperation Treaty PCT/US2020/013739 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2020/013739<br />Filed on 2020-01-15<br />Status: Expired 147166571 E-028-2019-0 E-028-2019-0-CA-03 HIGH AFFINITY MONOCLONAL ANTIBODIES TARGETING GLYPICAN-1 AND METHODS OF USE National Stage Canada 3125033 Pending Canada <br />National Stage 3125033<br />Filed on 2020-01-15<br />Status: Pending 147166572 E-028-2019-0 E-028-2019-0-CN-04 HIGH AFFINITY MONOCLONAL ANTIBODIES TARGETING GLYPICAN-1 AND METHODS OF USE National Stage China ZL202080010178.8 202080010178.8 Issued China <br />National Stage 202080010178.8<br />Filed on 2020-01-15<br />Status: Issued 147166573 E-028-2019-0 E-028-2019-0-EP-05 HIGH AFFINITY MONOCLONAL ANTIBODIES TARGETING GLYPICAN-1 AND METHODS OF USE National Stage European Patent 20704743.2 Pending European Patent <br />National Stage 20704743.2<br />Filed on 2020-01-15<br />Status: Pending 147166574 E-028-2019-0 E-028-2019-0-US-06 HIGH AFFINITY MONOCLONAL ANTIBODIES TARGETING GLYPICAN-1 AND METHODS OF USE National Stage US 12,122,843 17/422,609 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12122843 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12122843">12,122,843</a><br />Filed on 2021-07-13<br />Status: Issued 147166575 E-028-2019-0 E-028-2019-0-AU-07 HIGH AFFINITY MONOCLONAL ANTIBODIES TARGETING GLYPICAN-1 AND METHODS OF USE National Stage Australia 2020212534 Pending Australia <br />National Stage 2020212534<br />Filed on 2020-01-15<br />Status: Pending 147169795 ADC 147169797 Antibody-drug Conjugate 147169799 Bispecific Antibody 147169800 CAR 147169801 chimeric antigen receptor 147169802 Glypican-1 147169804 GPC1 147169805 HO 147169806 Immunotoxin 147169807 NANOBODY 147169809 Pancreatic Cancer 147169811 Recombinant Immunotoxin 147169812 Rit 147169814 Single Domain Antibody TAB-3928 147157208 Optical Trap Methods to Determine the Viscoelastic Properties of Biological Materials NCI Collaboration, Diagnostics, Licensing, Oncology Collaboration Diagnostics Licensing Oncology Benjamin Blehm, Alexus Devine, Kandice Tanner <p>Optical traps (optical tweezers) have a focused laser beam able to trap a small bead at its focus, and are used to measure the microrheology of gels and other materials. They have recently been used to characterize properties of living cells, however issues of image spatial resolution and limited depth of interrogation have prevented application of an optical trap to measure microrheological (flow of matter) properties in complex (non-uniform) materials, such as multi-cellular systems or living organisms. </p> <p>Scientists at the National Cancer Institute have developed optical trapping procedures that provide significant improvements in spatial resolution and tissue depth when measuring the microrheology of living cells such as clinically relevant tissue samples.  The viscoelastic measurements obtained using the disclosed systems and methods have a surprisingly high contrast-to-noise ratio compared to prior methods of obtaining viscoelastic measurements for complex materials.  The increased contrast-to-noise ratio allows for more sensitive detection of changes in viscoelastic properties across materials than what was possible using prior methods.  Thus, the disclosed systems and methods can be used to measure the properties of a wide variety of complex materials (such as biological materials), from 3D tissue culture models to tissue in or from living zebrafish to mammals, such as mice and humans. </p> <h2>Competitive Advantages:</h2> <ul><li>Increased sensitivity in the detection of changes in viscoelastic properties across materials.</li> <li>Improvements in spatial resolution and tissue depth.</li> <li>Localized, precise application of force compared to magnetic bead microrheology.</li> <li>Greater dynamic range and can probe outside the thermal energy range compared to passive, thermally driven techniques.</li> <li>Selection of multiple probe sites at once allows for increased throughput.</li> <li>Automated probe selection reduces assay time.</li> <li>Personalized patient treatment.</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Microrheological measurements can increase knowledge of the cancer microenvironment.</li> <li>Diagnosis and/or treatment of a condition or disease associated with tissue/cell remodeling, including tumor state.</li> <li>Determine the effectiveness of a particular compound or treatment or regimen (e.g cosmetic products for reducing wrinkles, scarring, etc.).</li> <li>Evaluate wound healing.</li> </ul> 2016-04-18 2025-05-14 2018-04-23 2025-05-14 2016-04-18 microrheology, optical trapping, viscoelastic False True Basic (Target Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2018-04-23 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147162052 Benjamin H. Blehm et al. In vivo tissue has non-linear rheological behavior distinct from 3D biomimetic hydrogels, as determined by AMOTIV microscopy. https://www.ncbi.nlm.nih.gov/pubmed/26773661 <a href="https://www.ncbi.nlm.nih.gov/pubmed/26773661">Benjamin H. Blehm et al. In vivo tissue has non-linear rheological behavior distinct from 3D biomimetic hydrogels, as determined by AMOTIV microscopy.</a> 147162893 Tanner, Kandice NIH - NCI NCI Tanner, Kandice (NCI) 1 147162894 Blehm, Benjamin NIH - NCI NCI Blehm, Benjamin (NCI) 2 147162895 Devine, Alexus NIH - NCI NCI Devine, Alexus (NCI) 3 147162893 Tanner, Kandice NIH - NCI NCI Tanner, Kandice (NCI) 1 147162894 Blehm, Benjamin NIH - NCI NCI Blehm, Benjamin (NCI) 2 147162895 Devine, Alexus NIH - NCI NCI Devine, Alexus (NCI) 3 147158276 An In Situ Calibrated Optical Trap For Rheological Characterization Of Complex Materials E-251-2015-0 Filing authorized NCI 121111111 Greene, Jaime greenejaime@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America greenejaime@mail.nih.gov?subject=Web Inquiry on [TAB-3928] Optical Trap Methods to Determine the Viscoelastic Properties of Biological Materials&body=Please send me information about technology [TAB-3928] Optical Trap Methods to Determine the Viscoelastic Properties of Biological Materials.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Greene, Jaime<br><a href="mailto:greenejaime@mail.nih.gov?subject=Web Inquiry on [TAB-3928] Optical Trap Methods to Determine the Viscoelastic Properties of Biological Materials&body=Please send me information about technology [TAB-3928] Optical Trap Methods to Determine the Viscoelastic Properties of Biological Materials.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">greenejaime@mail.nih.gov</a><br> 147165323 E-251-2015-0 E-251-2015-0-US-01 OPTICAL TRAP FOR RHEOLOGICAL CHARACTERIZATION OF COMPLEX MATERIALS PRV US 62/198,554 Abandoned US <br />Provisional (PRV) 62/198,554<br />Filed on 2015-07-29<br />Status: Abandoned 147165324 E-251-2015-0 E-251-2015-0-PCT-02 Optical Trap for Rheological Characterization of Biological Materials PCT Patent Cooperation Treaty PCT/US2016/044850 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2016/044850<br />Filed on 2016-07-29<br />Status: Expired 147165325 E-251-2015-0 E-251-2015-0-US-03 OPTICAL TRAP FOR RHEOLOGICAL CHARACTERIZATION OF BIOLOGICAL MATERIALS National Stage US 10,459,212 15/744,672 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10459212 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10459212">10,459,212</a><br />Filed on 2018-01-12<br />Status: Issued 147174279 microrheology 147174281 optical trapping 147174283 viscoelastic TAB-3991 147157272 Anti-SLAMF7 Chimeric Antigen Receptors NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Steven Feldman, James Kochenderfer <p>Immortalization of plasma cells leads to Multiple Myeloma (MM). Signaling Lymphocyte Activation Molecule F7 (SLAMF7) is highly expressed on the malignant plasma cells that constitute Multiple Myeloma. The expression of SLAMF7 by MM cells and lack of expression on nonhematologic cells makes SLAMF7 a promising target for chimeric antigen receptor (CAR) T cell therapies for the treatment of MM. </p> <p>In addition to expression on normal and malignant plasma cells, SLAMF7 is also known to be expressed on a variety of other leukocytes including most natural killer (NK) cells, some CD8+ T cells, a small fraction of CD4+ T cells, NKT cells, some monocytes, and some dendritic cells. Therefore, a CAR targeting SLAMF7 may also eliminate SLAMF7-expressing leukocytes such as NK cells and dendritic cells, which could increase the risk of unwanted side effects from cancer therapies, such as infections. As a way to overcome such unwanted side effects, a “suicide gene” is needed to eliminate anti-SLAMF7 CAR T cells. Furthermore, a suicide gene might also be useful in controlling other types of toxicity such as severe cytokine-release syndrome. </p> <p>Researchers at the National Cancer Institute (NCI) have created anti- SLAMF7 CAR constructs that allow genetically-modified T cells to express both anti-SLAMF7 antibody and a suicide gene. These CAR constructs allow T cells to specifically recognize and kill SLAMF7-expressing cells, and also allow for on-demand and reliable elimination of anti-SLAMF7 CAR T cells.</p> <h2>Competitive Advantages:</h2> <ul><li>First in class CAR treatment targeting SLAMF7 </li> <li>The suicide gene can help eliminate potential side effects </li> </ul> <h2>Commercial Applications:</h2> <ul><li>Treatment of Multiple Myeloma </li> <li>Avoid unwanted effects from treatment of CAR T therapies, such as infections </li> </ul> 2018-10-15 2025-05-14 2018-10-15 2025-05-14 2018-10-15 act, adoptive cell therapy, CAR, chimeric antigen receptor, Kochenderfer, Multiple Myeloma MM, SLAMF7 False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2018-10-15 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147163146 Kochenderfer, James NIH - NCI NCI Kochenderfer, James (NCI) 1 147163145 Feldman, Steven NIH - NCI Feldman, Steven 2 147163146 Kochenderfer, James NIH - NCI NCI Kochenderfer, James (NCI) 1 147163145 Feldman, Steven NIH - NCI Feldman, Steven 2 147158102 Genetic Modification Of T Cells With A Chimeric Antigen Receptor Targeting Signaling Lymphocyte Molecule F7 And A Suicide Gene E-158-2018-0 Filing authorized NCI 83709866 Burke, Andrew burkear@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC burkear@nih.gov?subject=Web Inquiry on [TAB-3991] Anti-SLAMF7 Chimeric Antigen Receptors&body=Please send me information about technology [TAB-3991] Anti-SLAMF7 Chimeric Antigen Receptors.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Burke, Andrew<br><a href="mailto:burkear@nih.gov?subject=Web Inquiry on [TAB-3991] Anti-SLAMF7 Chimeric Antigen Receptors&body=Please send me information about technology [TAB-3991] Anti-SLAMF7 Chimeric Antigen Receptors.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">burkear@nih.gov</a><br> 147161118 E-158-2018-0 E-158-2018-0-US-01 ANTI-SLAMF7 CHIMERIC ANTIGEN RECEPTORS PRV US 62/693,779 Abandoned US <br />Provisional (PRV) 62/693,779<br />Filed on 2018-07-03<br />Status: Abandoned 147165756 E-158-2018-0 E-158-2018-0-PCT-02 ANTI-SLAMF7 CHIMERIC ANTIGEN RECEPTORS PCT Patent Cooperation Treaty PCT/US2019/039239 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2019/039239<br />Filed on 2019-06-26<br />Status: Expired 147165757 E-158-2018-0 E-158-2018-0-US-03 ANTI-SLAMF7 CHIMERIC ANTIGEN RECEPTORS National Stage US 11,951,131 17/255,005 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11951131 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11951131">11,951,131</a><br />Filed on 2020-12-22<br />Status: Issued 147172577 act 147172578 adoptive cell therapy 147172579 CAR 147172580 chimeric antigen receptor 147172581 Kochenderfer 147172583 Multiple Myeloma MM 147172585 SLAMF7 TAB-4082 147157364 Bicistronic Chimeric Antigen Receptor (CAR) Constructs Targeting CD19 and CD20 NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics James Kochenderfer, Shicheng Yang <p>CD19 and CD20 are promising targets for the treatment of B-Cell malignancies.  Unfortunately, some clinical studies have shown that there is a loss of CD19 or CD20 expression in various cases of lymphomas and leukemias, particularly after treatment with an agent that targets CD19 (e.g., anti-CD19 CAR-T). However, studies have shown that expression of one protein is retained when the other is lost. This suggests that a therapeutic with the ability to simultaneously target both CD19 and CD20 could represent a solution to the drawbacks of current therapies. </p> <p>Researchers at the National Cancer Institute (NCI) have developed the current invention which is an expression construct for a CAR that targets both CD19 and CD20. Specifically, a bicistronic construct has been created for expressing the two CARs from a single vector, thereby allowing for a more efficient transfection of T cells. The result is a more efficient and simultaneous targeting of both CD19 and CD20 by the same T cell.  </p> <h2>Competitive Advantages:</h2> <ul><li>First in class CAR treatment targeting both CD19 and CD20 simultaneously</li> <li>Simultaneous targeting of two antigens decreases the chance that a patient will acquire a non-responsive disease condition </li> <li>A single, bicistronic expression vector (rather than two separate vectors) allows for more efficient transfection of cells that can target two antigens</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Treatment of cancers and B cell malignancies expressing CD19, CD20, or both</li> </ul> 2018-11-08 2025-05-14 2018-11-08 2025-05-14 2018-11-08 act, adoptive cell therapy, B Cell Malignancies, BICISTRONIC, CAR, CD19, CD20, chimeric antigen receptor, Kochenderfer, Leukemia, lymphoma False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2018-11-08 52406768 Discovery 52406768 NCI 37470483 Website Abstract E-042-2014 147163452 Kochenderfer, James NIH - NCI NCI Kochenderfer, James (NCI) 1 147163453 Yang, Shicheng NIH - NCI NCI Yang, Shicheng (NCI) 2 147163452 Kochenderfer, James NIH - NCI NCI Kochenderfer, James (NCI) 1 147163453 Yang, Shicheng NIH - NCI NCI Yang, Shicheng (NCI) 2 147158206 Bicistronic Chimeric Antigen Receptor Constructs Targeting CD19 And CD20 E-205-2018-0 Filing authorized NCI 83709866 Burke, Andrew burkear@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC burkear@nih.gov?subject=Web Inquiry on [TAB-4082] Bicistronic Chimeric Antigen Receptor (CAR) Constructs Targeting CD19 and CD20&body=Please send me information about technology [TAB-4082] Bicistronic Chimeric Antigen Receptor (CAR) Constructs Targeting CD19 and CD20.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Burke, Andrew<br><a href="mailto:burkear@nih.gov?subject=Web Inquiry on [TAB-4082] Bicistronic Chimeric Antigen Receptor (CAR) Constructs Targeting CD19 and CD20&body=Please send me information about technology [TAB-4082] Bicistronic Chimeric Antigen Receptor (CAR) Constructs Targeting CD19 and CD20.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">burkear@nih.gov</a><br> 147161190 E-205-2018-0 E-205-2018-0-US-01 BICISTRONIC CHIMERIC ANTIGEN RECEPTORS TARGETING CD19 AND CD20 AND THEIR USES PRV US 62/732,263 Abandoned US <br />Provisional (PRV) 62/732,263<br />Filed on 2018-09-17<br />Status: Abandoned 147166388 E-205-2018-0 E-205-2018-0-PCT-02 Bicistronic Chimeric Antigen Receptor Constructs Targeting CD19 And CD20 PCT Patent Cooperation Treaty PCT/US2019/051517 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2019/051517<br />Filed on 2019-09-17<br />Status: Expired 147166389 E-205-2018-0 E-205-2018-0-AU-03 BICISTRONIC CHIMERIC ANTIGEN RECEPTORS TARGETING CD19 AND CD20 AND THEIR USES National Stage Australia 2019344795 Pending Australia <br />National Stage 2019344795<br />Filed on 2021-03-02<br />Status: Pending 147166390 E-205-2018-0 E-205-2018-0-CA-04 BICISTRONIC CHIMERIC ANTIGEN RECEPTORS TARGETING CD19 AND CD20 AND THEIR USES National Stage Canada 3112584 Pending Canada <br />National Stage 3112584<br />Filed on 2021-03-11<br />Status: Pending 147166391 E-205-2018-0 E-205-2018-0-CN-05 Bicistronic Chimeric Antigen Receptor Constructs Targeting CD19 And CD20 National Stage China 201980060609.9 Pending China <br />National Stage 201980060609.9<br />Filed on 2021-03-16<br />Status: Pending 147166392 E-205-2018-0 E-205-2018-0-EP-06 BICISTRONIC CHIMERIC ANTIGEN RECEPTORS TARGETING CD19 AND CD20 AND THEIR USES National Stage European Patent 19787115.5 Pending European Patent <br />National Stage 19787115.5<br />Filed on 2021-03-15<br />Status: Pending 147166393 E-205-2018-0 E-205-2018-0-US-07 BICISTRONIC CHIMERIC ANTIGEN RECEPTORS TARGETING CD19 AND CD20 AND THEIR USES National Stage US 17/276,959 Pending US <br />National Stage 17/276,959<br />Filed on 2021-03-17<br />Status: Pending 147173617 act 147173618 adoptive cell therapy 147173619 B Cell Malignancies 147173620 BICISTRONIC 147173621 CAR 147173622 CD19 147173623 CD20 147173624 chimeric antigen receptor 147173625 Kochenderfer 147173626 Leukemia 147173627 lymphoma TAB-5052 162369190 Next-Generation 5-HT-2B Serotonin-Receptor Antagonists for Anti-Fibrotic & Cardiopulmonary Therapy NIDDK Cardiology, Collaboration, Dermatology, Immunology, Licensing, Metabolic Disease, Oncology, Pulmonology, Research Materials, Respiratory, Therapeutics Cardiology Collaboration Dermatology Immunology Licensing Metabolic Disease Oncology Pulmonology Research Materials Respiratory Therapeutics Kenneth Jacobson, Dilip Tosh <p><span style="font-size:11pt"><span style="line-height:107%"><span style="font-family:Calibri,sans-serif">This technology includes a family of small-molecule antagonists that selectively block the 5-HT<sub>2B</sub> serotonin receptor&mdash;an upstream driver of tissue-remodeling&mdash;to address fibrotic, cardiopulmonary and related disorders. Built on a conformationally-locked &ldquo;(N)-methanocarba&rdquo; nucleoside scaffold, the compounds show nanomolar potency, &gt;30&ndash;400-fold selectivity over the closely related 5-HT<sub>2C</sub> receptor, and favorable oral bioavailability in rodents. In vivo mouse studies confirm functional antagonism without central nervous system side-effects, while ADMET profiling indicates metabolic stability and no hERG liability. The result is a drug-like, patent-protected platform ready for lead optimization or IND-enabling studies in lung, liver and cardiac fibrosis, pulmonary arterial hypertension, and other high-value indications.</span></span></span></p> <ul> <li>First-in-class selectivity: nanomolar 5-HT<sub>2B</sub> blockade with minimal activity at 5-HT-2A/C, GPCR off-targets or ion channels, reducing risk of valvulopathy and CNS effects.</li> <li>Drug-friendly chemistry: orally bioavailable, chemically stable small molecules amenable to cost-efficient tablet or inhaled formulations.</li> <li>Broad disease leverage: single mechanism addresses multiple fibrosis-driven pathologies—enabling portfolio or companion-therapy strategies.</li> </ul> <ul> <li>Disease-modifying treatment for systemic, pulmonary and hepatic fibrosis (e.g., idiopathic pulmonary fibrosis, NASH, systemic sclerosis).</li> <li>Oral or inhaled therapy for pulmonary arterial hypertension and serotonin-mediated valvular heart disease.</li> <li>Adjunct management of chronic neuropathic pain, cancer-associated cachexia and autoimmune inflammation where 5-HT-2B signaling is implicated.</li> </ul> 2025-05-13 2025-05-14 2025-05-14 2025-05-14 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 162369212 Jacobson, Kenneth National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Jacobson, Kenneth (NIDDK) 1 162369216 Tosh, Dilip National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Tosh, Dilip (NIDDK) 2 162369212 Jacobson, Kenneth National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Jacobson, Kenneth (NIDDK) 1 162369216 Tosh, Dilip National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Tosh, Dilip (NIDDK) 2 162369193 Nucleoside 5-HT2B serotonin receptor antagonists E-162-2023-0 Filing authorized National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83692066 Tong, Betty tongb@niddk.nih.gov
United States of America Senior Technology Advancement Office tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-5052] Next-Generation 5-HT-2B Serotonin-Receptor Antagonists for Anti-Fibrotic & Cardiopulmonary Therapy&body=Please send me information about technology [TAB-5052] Next-Generation 5-HT-2B Serotonin-Receptor Antagonists for Anti-Fibrotic & Cardiopulmonary Therapy. Tong, Betty<br><a href="mailto:tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-5052] Next-Generation 5-HT-2B Serotonin-Receptor Antagonists for Anti-Fibrotic & Cardiopulmonary Therapy&body=Please send me information about technology [TAB-5052] Next-Generation 5-HT-2B Serotonin-Receptor Antagonists for Anti-Fibrotic & Cardiopulmonary Therapy.">tongb@niddk.nih.gov</a><br> 162369198 E-162-2023-0 E-162-2023-0-US-01 5-HT2B SEROTONIN RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE THEREOF PRV US 63/527,244 Expired US <br />Provisional (PRV) 63/527,244<br />Filed on 2023-07-17<br />Status: Expired 162369199 E-162-2023-0 E-162-2023-0-PC-01 5-HT2B SEROTONIN RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE THEREOF PCT COMB Patent Cooperation Treaty PCT/US2024/038286 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2024/038286<br />Filed on 2024-07-17<br />Status: Expired TAB-3849 146970336 Dual-Germline Antibody Engager Chimeric HIV–1 Immunogens NIAID Collaboration, Infectious Disease, Licensing, Therapeutics, Vaccines Collaboration Infectious Disease Licensing Therapeutics Vaccines Paolo Lusso, Ping Zhang <p>Despite four decades of intensive research, a safe and effective HIV-1 vaccine remains elusive due to the extreme difficulty in eliciting broadly neutralizing antibodies (bNAbs), which recognize and block HIV-1 from entering healthy cells. Only rare natural HIV-1 envelopes (Envs) promote the activation and expansion of naive B cells expressing unmutated germline antibodies of various bNAb lineages, but they typically do so for a single lineage for the same neutralization site. To overcome this challenge, NIAID has designed and characterized two chimeric HIV-1 Env immunogens capable of simultaneously engaging multiple germline bNAb lineages. Both chimeric Env immunogens maintain native-like folding and engage two lineages of germline bNAbs directed against two independent sites of HIV&ndash;1 vulnerability.</p> <ul> <li>Dual-germline engager HIV–1 Env immunogens are inherently superior to the currently available single-germlineengagers for eliciting bNAbs.</li> <li>The chimeric design could be expanded to generate HIV–1 Env trimers with even more germline bNAbspecificities to enable a broader immunogenic response against HIV.</li> </ul> <ul> <li>Immunization: The dual-germline engager HIV–1 immunogens could be employed during the priming phase of an HIV vaccine to trigger multiple bNAb lineages simultaneously, resulting in a multi-target protective antibody response.</li> <li> Clinical Treatment: The dualgermline engager HIV–1 immunogens could serve as an alternative to current anti-retrovirals or incorporated into current HIV treatment strategies.</li> </ul> The Technology Transfer and Intellectual Property Office is seeking parties interested in collaborative research to further develop this technology by manufacturing non-MRNA virus-like particles incorporating dual germline engager HIV–1 immunogens and subsequently testing immunogenicity in non-human primates. For collaborationopportunities, please contact Chris Kornak; 240–627–3705, chris.kornak@nih.gov. 2023-07-21 2025-05-13 2025-05-13 2023-07-07 False False True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 146970905 Publication pending. Intellectual Property: HHS Reference No. E–140–2022; US Provisional Application No. 63/397,789. Publication pending. Intellectual Property: HHS Reference No. E–140–2022; US Provisional Application No. 63/397,789. 146970445 Zhang, Ping National Cancer Institute (NCI) NCI Zhang, Ping (NCI) 1 146970454 Lusso, Paolo National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Lusso, Paolo (NIAID) 2 146970445 Zhang, Ping National Cancer Institute (NCI) NCI Zhang, Ping (NCI) 1 146970454 Lusso, Paolo National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Lusso, Paolo (NIAID) 2 146970381 Dual-Germline Antibody Engager HIV-1 Envelope Chimeric Immunogens E-140-2022-0 Filing authorized NIAID 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-3849] Dual-Germline Antibody Engager Chimeric HIV–1 Immunogens&body=Please send me information about technology [TAB-3849] Dual-Germline Antibody Engager Chimeric HIV–1 Immunogens. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-3849] Dual-Germline Antibody Engager Chimeric HIV–1 Immunogens&body=Please send me information about technology [TAB-3849] Dual-Germline Antibody Engager Chimeric HIV–1 Immunogens.">benjamin.hurley@nih.gov</a><br> TAB-3579 114097435 Replication-Competent Adenovirus Type-4 HIV Env Vaccines and Their Use NIAID Collaboration Collaboration Mark Connors NIAID, IAVI, Emergent, and Scripps have developed two recombinant adenovirus type 4 (Ad4) vector-based vaccine candidates. These replicating Ad4 vector-based candidates have shown improved activity against tier 2 HIV-1 isolates in experimental animals. Tier 2 isolates are among the most prevalent in infected populations. The two candidates, Ad4-Env150KN and Ad4-Env145NFL, incorporate novel design features based on Ad4-EnvC150 (1086c). Specifically, the truncation of the cytoplasmic tail of Env increases cell surface expression and has resulted in improved antigenicity from both candidates. <br /><br /> Additionally, the upper respiratory tract administration offers a way to bypass pre-existing Ad4 immunity in most people. Furthermore, unlike non-replicating vectors, these vaccines may evoke a durable immune response. <ul> <li>Replicating vector may invoke durable immunity against HIV-1</li> <li>Potential for prophylactic use in high-risk populations</li> <li>Upper-respiratory (intranasal) administration will bypass pre-existing Ad4 immunity in most people</li> </ul> </ul> <ul> <li>Prophylaxis against HIV-1</li> </ul> For collaboration opportunities, please contact Chris Kornak at <a href="mailto:chris.kornak@nih.gov">chris.kornak@nih.gov</a>or 1-240-627-3705. 2022-06-08 2025-05-13 2025-05-13 2022-05-06 2KXXXX, 4-HIV, ADENOVIRUS, ENV, Replication-competent, Their, TYPE, vaccines, YXXXXX False True True NIHTT 37470483 Website Abstract 114172746 Alexander J. et al., Vector Vaccine Expressing HIV-1 Envelope 1086 Clade C. PLOS ONE 8(12): e82380. https://doi.org/10.1371/journal.pone.0082380 <a href="https://doi.org/10.1371/journal.pone.0082380">Alexander J. et al., Vector Vaccine Expressing HIV-1 Envelope 1086 Clade C. PLOS ONE 8(12): e82380. </a> 114110886 Connors, Mark NIAID - DIR NIAID Connors, Mark (NIAID) 1 114110886 Connors, Mark NIAID - DIR NIAID Connors, Mark (NIAID) 1 114102689 Replication-Competent Adenovirus Type 4-HIV Env Vaccines And Their Use E-105-2020-0 Filing authorized NIAID 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-3579] Replication-Competent Adenovirus Type-4 HIV Env Vaccines and Their Use&body=Please send me information about technology [TAB-3579] Replication-Competent Adenovirus Type-4 HIV Env Vaccines and Their Use. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-3579] Replication-Competent Adenovirus Type-4 HIV Env Vaccines and Their Use&body=Please send me information about technology [TAB-3579] Replication-Competent Adenovirus Type-4 HIV Env Vaccines and Their Use.">benjamin.hurley@nih.gov</a><br> 114169424 E-105-2020-0 E-105-2020-0-US-01 Replication-Competent Adenovirus Type 4-HIV Env Vaccines And Their Use PRV US 63/063,810 Abandoned US <br />Provisional (PRV) 63/063,810<br />Filed on 2020-08-10<br />Status: Abandoned 114169425 E-105-2020-0 E-105-2020-0-PCT-02 Replication-Competent Adenovirus Type 4-HIV Env Vaccines And Their Use PCT Patent Cooperation Treaty PCT/US2021/045389 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/045389<br />Filed on 2021-08-10<br />Status: Expired 114128825 YXXXXX 114128826 2KXXXX 114153384 Replication-competent 114153385 ADENOVIRUS 114153386 TYPE 114153387 4-HIV 114153388 ENV 114153389 vaccines 114153390 Their TAB-3529 114097389 Humanized Murine Monoclonal Antibodies That Neutralize Type-1 Interferon (IFN) Activity NIAID Collaboration Collaboration Qingbo Liu, Paolo Lusso, Hana Schmeisser, Kathryn Zoon Interferons (IFNs) are a family of cytokines that function in response to an immune challenge such as a viral or bacterial infection. Type I IFNs are produced by immune cells (predominantly monocytes and dendritic cells) as well as fibroblasts and signal through a specific cell surface receptor complex (IFNAR) that consist of IFNAR1 and IFNAR2 chains. Type-I IFNs exert several common effects including antiviral, antiproliferative, and immunomodulatory activities. However, Type I IFNs also have pro-inflammatory effects, especially in the presence of TNF-a. Therefore, neutralizing the proinflammatory effect of Type I interferon could have wide clinical applications in autoimmune diseases like SLE, or in acute and chronic viral diseases like SARS–CoV–2, HIV or HCV infection, respectively, in which IFN-induced inflammation may be detrimental. <br /><br /> Scientists at the National Institute of Allergy and Infectious Diseases (NIAID) have developed two anti-IFN receptor 2 (IFNAR2) antibodies, B7 and A10, that are effective in vitro at neutralizing Type I IFN activities. The antibodies are comprised of two heavy chains and two light chains of amino acids. Both antibodies are able to bind to the extracellular domain of IFNAR2, Type I IFN receptor subunit 2, thus suppressing IFN signaling. <br /><br /> Because there are no potent IFNAR2 antibodies for therapies commercially available at this time, these antibodies are a novel therapeutic tool that could be used exclusively or in combination to treat chronic inflammatory diseases (like autoimmune disorders such as SLE) in which sustained IFN production may lead to both systemic and specific organ dysfunctions or chronic viral diseases (such as HIV, HCV) in which sustained IFN production has deleterious effects on immunologic function. <ul> Therapeutics for the treatment of chronic inflammatory conditions: <li> In chronic inflammatory diseases (e.g., autoimmune disorders such as SLE).</li> <li> In chronic viral diseases (such as HIV, HCV infection).</li> <li> In acute viral or inflammatory diseases (e.g., SARS–CoV–2).</li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize this technology. For collaboration opportunities, please contact Chris Kornak at <a href="mailto:chris.kornak@nih.gov">chris.kornak@nih.gov</a>or 1-240-627-3705 2022-04-25 2025-05-13 2025-05-13 2022-04-25 2IXXXX, 2JXXXX, 2XXXXX, A-481-2020, Activity, antibodies, HUMANIZED, IFN, INTERFERON, monoclonal, Murine, Neutralize, That, TYPE-I False True True 52398218 Pre-Clinical (in vivo) 52398218 NIHTT 37470483 Website Abstract 114172690 Morrow Angel N. J Immunol. 2011 Feb 1;186(3):1685-93 https://doi.org/10.4049/jimmunol.1001359 <a href="https://doi.org/10.4049/jimmunol.1001359">Morrow Angel N. J Immunol. 2011 Feb 1;186(3):1685-93</a> 114172691 Balinsky Corey A. et al https://www.ncbi.nlm.nih.gov/pubmed/24027323 <a href="https://www.ncbi.nlm.nih.gov/pubmed/24027323">Balinsky Corey A. et al</a> 114172693 Schmeisser, H et al https://www.ncbi.nlm.nih.gov/pubmed/23419269 <a href="https://www.ncbi.nlm.nih.gov/pubmed/23419269">Schmeisser, H et al</a> 114172694 J Virol. 2015 Nov 15; 89(22): 11534–11548 https://doi.org/10.1128/JVI.01727-15 <a href="https://doi.org/10.1128/JVI.01727-15">J Virol. 2015 Nov 15; 89(22): 11534–11548</a> 114172695 Balinsky, C.A. et al https://pubmed.ncbi.nlm.nih.gov/27974568 <a href="https://pubmed.ncbi.nlm.nih.gov/27974568">Balinsky, C.A. et al</a> 114172696 Chiang Austin W. T. et al https://pubmed.ncbi.nlm.nih.gov/31222165 <a href="https://pubmed.ncbi.nlm.nih.gov/31222165">Chiang Austin W. T. et al</a> 114110581 Zoon, Kathryn NIAID - DIR NIAID Zoon, Kathryn (NIAID) 0 114110582 Liu, Qingbo NIAID - DIR NIAID Liu, Qingbo (NIAID) 0 114110583 Lusso, Paolo NIAID - DIR NIAID Lusso, Paolo (NIAID) 0 114110580 Schmeisser, Hana NIAID - DIR NIAID Schmeisser, Hana (NIAID) 1 114110580 Schmeisser, Hana NIAID - DIR NIAID Schmeisser, Hana (NIAID) 1 114110581 Zoon, Kathryn NIAID - DIR NIAID Zoon, Kathryn (NIAID) 0 114110582 Liu, Qingbo NIAID - DIR NIAID Liu, Qingbo (NIAID) 0 114110583 Lusso, Paolo NIAID - DIR NIAID Lusso, Paolo (NIAID) 0 114102642 Humanized Murine Monoclonal Antibodies That Neutralize Type-I Interferon (IFN) Activity E-220-2020-0 Filing authorized NIAID 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-3529] Humanized Murine Monoclonal Antibodies That Neutralize Type-1 Interferon (IFN) Activity&body=Please send me information about technology [TAB-3529] Humanized Murine Monoclonal Antibodies That Neutralize Type-1 Interferon (IFN) Activity. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-3529] Humanized Murine Monoclonal Antibodies That Neutralize Type-1 Interferon (IFN) Activity&body=Please send me information about technology [TAB-3529] Humanized Murine Monoclonal Antibodies That Neutralize Type-1 Interferon (IFN) Activity.">benjamin.hurley@nih.gov</a><br> 114169328 E-220-2020-0 E-220-2020-0-US-01 ANTIBODIES THAT NEUTRALIZE TYPE-I INTERFERON (IFN) ACTIVITY PRV US 63/094,572 Abandoned US <br />Provisional (PRV) 63/094,572<br />Filed on 2020-10-21<br />Status: Abandoned 114169329 E-220-2020-0 E-220-2020-0-PCT-02 ANTIBODIES THAT NEUTRALIZE TYPE-I INTERFERON (IFN) ACTIVITY PCT Patent Cooperation Treaty PCT/US2021/056067 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/056067<br />Filed on 2021-10-21<br />Status: Expired 114128683 2XXXXX 114128684 2IXXXX 114128685 2JXXXX 114152893 A-481-2020 114152894 HUMANIZED 114152895 Murine 114152896 monoclonal 114152897 antibodies 114152898 That 114152899 Neutralize 114152900 TYPE-I 114152901 INTERFERON 114152902 IFN 114152903 Activity TAB-3434 114097305 Replication-Competent Adenovirus Type 4 SARS-CoV-2 Vaccines and Their Use NIAID Collaboration Collaboration Mark Connors NIAID has produced recombinant adenovirus type 4 (Ad4), SARS-CoV-2 spike, vectors for administration to humans. These recombinant vaccines permit rapid development of high levels of neutralizing antibodies to SARS-CoV-2 in experimental animals. This vaccine is designed to improve the durability of the immune response by inducing mucosal and systemic immunity. Further, this system should be incredibly simple and efficient when producing vaccine at scale. This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as well as for further development and evaluation under a research collaboration. <ul> <li>Stimulates a durable immune response</li> <li>Induction of mucosal and systemic immunity</li> <li>Potential for transmission interruption</li> <li>Intranasal administration minimizes the impact of pre-existing immunity</li> <li>Notable improvement for manufacturing yield and cost, ease of administration, and distribution as compared to current candidates</li> </ul> <ul> <li>Vaccine Composition(s)</li> </ul> For collaboration opportunities, please contact Chris Kornak at <a href="mailto:chris.kornak@nih.gov">chris.kornak@nih.gov</a>or 1-240-627-3705 2022-11-10 2025-05-13 2025-05-13 2021-02-19 ADENOVIRUS, Replication-competent, SARS-CoV-2, Their, TYPE, vaccines False True True NIHTT 37470483 Website Abstract 114172596 Matsuda et al. Journal of Clinical Investigation, 2021 https://doi.org/10.1172/JCI140794 <a href="https://doi.org/10.1172/JCI140794">Matsuda et al. Journal of Clinical Investigation, 2021</a> 114172597 Matsuda et al., Science Immunology 2019 https://doi.org/?10.1126/?sciimmunol.aau2710 <a href="https://doi.org/?10.1126/?sciimmunol.aau2710">Matsuda et al., Science Immunology 2019</a> 114110175 Connors, Mark NIAID - DIR NIAID Connors, Mark (NIAID) 1 114110175 Connors, Mark NIAID - DIR NIAID Connors, Mark (NIAID) 1 114102557 Replication-Competent Adenovirus Type 4-SARS-CoV-2 Vaccines And Their Use E-055-2021-0 Filing authorized NIAID 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-3434] Replication-Competent Adenovirus Type 4 SARS-CoV-2 Vaccines and Their Use&body=Please send me information about technology [TAB-3434] Replication-Competent Adenovirus Type 4 SARS-CoV-2 Vaccines and Their Use. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-3434] Replication-Competent Adenovirus Type 4 SARS-CoV-2 Vaccines and Their Use&body=Please send me information about technology [TAB-3434] Replication-Competent Adenovirus Type 4 SARS-CoV-2 Vaccines and Their Use.">benjamin.hurley@nih.gov</a><br> 114169100 E-055-2021-0 E-055-2021-0-US-01 REPLICATION-COMPETENT ADENOVIRUS TYPE 4 SARS-COV-2 VACCINES AND THEIR USE PRV US 63/138,221 Abandoned US <br />Provisional (PRV) 63/138,221<br />Filed on 2021-01-15<br />Status: Abandoned 114169186 E-055-2021-0 E-055-2021-0-PCT-02 Replication-Competent Adenovirus Type 4-SARS-CoV-2 Vaccines And Their Use PCT Patent Cooperation Treaty PCT/US2022/012530 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2022/012530<br />Filed on 2022-01-14<br />Status: Expired 114152064 Replication-competent 114152065 ADENOVIRUS 114152066 TYPE 114152067 vaccines 114152068 Their 114152069 SARS-CoV-2 TAB-3386 114097275 Improvement of Broadly HIV-Neutralizing Antibodies; Anti-HIV-1 Antibody VRC01.23 for Prevention or Treatment of HIV Infection NIAID Collaboration Collaboration Young Do Kwon, Peter Kwong, Qingbo Liu, Paolo Lusso, John Mascola Scientists at NIAID have developed broadly neutralizing antibodies (bNAbs) with enhanced neutralizing activity against HIV-1. Specifically, previously unknown gp120 interactions with a newly elucidated quaternary receptor (CD4)-binding site in the HIV-1 envelope have been discovered by engrafting the extended heavy-chain framework region 3 (FR3) loop of VRC03 onto several potent bNAbs (including VRC01, VRC07 and N6). The new antibodies show improved neutralizaton of gp120 binding to CD4 by interacting with both CD4 binding sites and as a result show improved neutralization of various HIV-1 strains. Furthermore, they show reduced autoreactivity and, as a result, have prolonged in vivo half-life.<br /><br /> One of several antibodies that were developed using this technology is VRC01.23. It combines the VRC03 framework 3 alteration, with a G54W mutation in the heavy chain, and a 3 amino acid deletion in the light chain. The modifications improved the potency while reducing the autoreactivity. In particular, VRC01.23 is capable of neutralizing 96% of HIV-1 viruses tested at geometric mean IC50 =0.042 ug/ml, which is ~10-fold more potent than VRC01.<br /><br /> This technology is available for licensing for commercial development in accordance with 35 U.S.C. § 209 and 37 CFR Part 404, as well as for further development and evaluation under a research collaboration. <ul> <li> Interaction with multiple CD4 binding sites on gp120</li> <li>Reduced autoreactivity when using the VRC03 framework 3 region mutation<li> <li>Improved neutralization breadth and potency over existing antibodies</li> <li>Extended in vivo half-life</li> </ul> <ul> <li>Improving human monoclonal antibodies for HIV treatment or prevention</li> <li>New candidates for use as a therapeutic or as a prophylactic</li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize this technology. For collaboration opportunities, please contact Chris Kornak at <a href="mailto:chris.kornak@nih.gov">chris.kornak@nih.gov</a>or 1-240-627-3705. 2022-03-08 2025-05-13 2025-05-13 2020-03-09 antibodies, Broadly, HIV-neutralizing, IMPROVEMENT False True True NIHTT 37470483 Website Abstract 114172556 Liu, Qingbo, et al. "Improvement of antibody functionality by structure-guided paratope engraftment." Nature Communications 10.1 (2019): 721. https://doi.org/10.1038/s41467-019-08658-4 <a href="https://doi.org/10.1038/s41467-019-08658-4">Liu, Qingbo, et al. "Improvement of antibody functionality by structure-guided paratope engraftment." Nature Communications 10.1 (2019): 721.</a> 114110040 Liu, Qingbo NIAID - DIR NIAID Liu, Qingbo (NIAID) 0 114110042 Kwong, Peter NIAID - VRC NIAID Kwong, Peter (NIAID) 0 114110043 Kwon, Young Do NIAID - VRC NIAID Kwon, Young Do (NIAID) 0 114110044 Mascola, John NIAID - VRC NIAID Mascola, John (NIAID) 0 114110041 Lusso, Paolo NIAID - DIR NIAID Lusso, Paolo (NIAID) 1 114110041 Lusso, Paolo NIAID - DIR NIAID Lusso, Paolo (NIAID) 1 114110040 Liu, Qingbo NIAID - DIR NIAID Liu, Qingbo (NIAID) 0 114110042 Kwong, Peter NIAID - VRC NIAID Kwong, Peter (NIAID) 0 114110043 Kwon, Young Do NIAID - VRC NIAID Kwon, Young Do (NIAID) 0 114110044 Mascola, John NIAID - VRC NIAID Mascola, John (NIAID) 0 114102519 Improvement Of Broadly HIV-neutralizing Antibodies E-034-2018-0 Filing authorized NIAID 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-3386] Improvement of Broadly HIV-Neutralizing Antibodies; Anti-HIV-1 Antibody VRC01.23 for Prevention or Treatment of HIV Infection&body=Please send me information about technology [TAB-3386] Improvement of Broadly HIV-Neutralizing Antibodies; Anti-HIV-1 Antibody VRC01.23 for Prevention or Treatment of HIV Infection. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-3386] Improvement of Broadly HIV-Neutralizing Antibodies; Anti-HIV-1 Antibody VRC01.23 for Prevention or Treatment of HIV Infection&body=Please send me information about technology [TAB-3386] Improvement of Broadly HIV-Neutralizing Antibodies; Anti-HIV-1 Antibody VRC01.23 for Prevention or Treatment of HIV Infection.">benjamin.hurley@nih.gov</a><br> 114168915 E-034-2018-0 E-034-2018-0-PCT-01 NEUTRALIZING ANTIBODIES TO HIV-1 ENV AND THEIR USE PCT COMB Patent Cooperation Treaty PCT/US2019/019021 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2019/019021<br />Filed on 2019-02-21<br />Status: Expired 114168916 E-034-2018-0 E-034-2018-0-US-01 NEUTRALIZING ANTIBODIES TO HIV-1 ENV AND THEIR USE PRV US 62/633,517 Abandoned US <br />Provisional (PRV) 62/633,517<br />Filed on 2018-02-21<br />Status: Abandoned 114169049 E-034-2018-0 E-034-2018-0-US-08 NEUTRALIZING ANTIBODIES TO HIV-1 ENV AND THEIR USE National Stage US 11,760,790 16/971,826 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11760790 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11760790">11,760,790</a><br />Filed on 2020-08-21<br />Status: Issued 114151688 IMPROVEMENT 114151689 Broadly 114151690 HIV-neutralizing 114151691 antibodies TAB-3370 114097265 Continuous Cell Lines Persistently Expressing High Levels of Native HIV-1 Envelope Trimers on their Surface Membrane NIAID Collaboration Collaboration Paolo Lusso, Peng Zhang Transduced human cell lines expressing high levels of native HIV-1 Envelope on their surface membrane, in the unmodified or interdomain stabilized form. These cell lines provide a stable source of native HIV-1 envelope for multiple uses, including the high-efficiency production of virus-like particles (VLPs) for use as vaccines, testing new inhibitors or neutralizing antibodies, or identifying/capturing B cells that produce broadly neutralizing antibodies from infected/vaccinated humans or animals. <br/><br/> This technology is available for licensing for commercial development in accordance with 35 U.S.C. § 209 and 37 CFR Part 404, as well as for further development and evaluation under a research collaboration. <ul> <li> The interdomain-stabilized form does not bind CD4 and is locked in the native prefusion form</li> </ul> <ul> <li>High-efficiency production of virus-like particles (VLPs)</li> <li>A means to test new inhibitors or neutralizing antibodies targeting HIV-1 envelope trimers</li> <li>Probe for identifying/capturing B cells that produce broadly neutralizing antibodies</li> </ul> </li< The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize this technology. For collaboration opportunities, please contact Chris Kornak at <a href="mailto:Chris.Kornak@nih.gov</a>or 1-240-627-3705. ">james.robinson4@nih.gov</a>or 1-301-761-7542. 2022-03-08 2025-05-13 2025-05-13 2020-03-09 Cell, continuous, Envelope, ESTABLISHMENT, Expressing, HIV-1, Lines, NATIVE, Persistently, Trimers, YXXXXX False True True NIHTT 37470483 Website Abstract 114172551 Zhang, Peng, et al https://doi.org/10.1016/j.chom.2018.05.002 <a href="https://doi.org/10.1016/j.chom.2018.05.002 ">Zhang, Peng, et al</a> 114110029 Zhang, Peng NIAID - DIR NIAID Zhang, Peng (NIAID) 0 114110028 Lusso, Paolo NIAID - DIR NIAID Lusso, Paolo (NIAID) 1 114110028 Lusso, Paolo NIAID - DIR NIAID Lusso, Paolo (NIAID) 1 114110029 Zhang, Peng NIAID - DIR NIAID Zhang, Peng (NIAID) 0 114102514 Establishment Of Continuous Cell Lines Persistently Expressing Native HIV-1 Envelope Trimers E-185-2018-0 Research Material NIAID 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-3370] Continuous Cell Lines Persistently Expressing High Levels of Native HIV-1 Envelope Trimers on their Surface Membrane&body=Please send me information about technology [TAB-3370] Continuous Cell Lines Persistently Expressing High Levels of Native HIV-1 Envelope Trimers on their Surface Membrane. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-3370] Continuous Cell Lines Persistently Expressing High Levels of Native HIV-1 Envelope Trimers on their Surface Membrane&body=Please send me information about technology [TAB-3370] Continuous Cell Lines Persistently Expressing High Levels of Native HIV-1 Envelope Trimers on their Surface Membrane.">benjamin.hurley@nih.gov</a><br> 114128267 YXXXXX 114151611 Lines 114151612 Cell 114151613 continuous 114151614 ESTABLISHMENT 114151615 Persistently 114151616 Expressing 114151617 NATIVE 114151618 HIV-1 114151619 Envelope 114151620 Trimers TAB-2777 114096956 Recombinant Sulfated HIV Envelope Protein and Methods for Making Protein NIAID Collaboration, Infectious Disease, Research Materials, Therapeutics, Vaccines Collaboration Infectious Disease Research Materials Therapeutics Vaccines Raffaello Cimbro, Paolo Lusso This technology comprises sulfated recombinant gp120 proteins and peptides. Also included are methods for producing sulfated recombinant gp120 proteins. The focus of this technology is on sulfation of two tyrosines in the V2 loop of the HIV major envelope glycoprotein, gp120, which increase the stability of gp120 and promote the synthesis of gp120 protein in its native "closed" conformation. Gp120 in its native form is highly sulfated; however, recombinant gp120 produced for vaccines or structural analyses typically display low levels of V2 tyrosine sulfation. Sulfation of the V2 loop results in increased binding to trimer-recognizing anti-HIV antibodies specific to the V2 loop region of gp120 (PG9, PG16, CH01, PGT145) and decreased binding of CD4. The sulfation of recombinant gp120 is accomplished by over expression of a tyrosyl sulfotransferase in the producing cell line. Preliminary experiments indicate the recombinant sulfated gp120 proteins can be used to elicit the formation of HIV neutralizing antibodies in immunized animals. <ul> <li>Consistent sulfation/production of gp120</li> <li>Gp120 vaccine component with improved stability and immunogenicity</li> <li>Recombinant gp120 vaccine component in native conformation</li> </ul> <ul> <li>Design of HIV vaccines</li> <li>Production of HIV vaccines</li> <li>Induction of Neutralizing Antibodies</li> <li>HIV vaccine booster protein</li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize this technology as a HIV vaccine component or a therapeutic for treating HIV. For collaboration opportunities, please contact Bill Ronnenberg at <a href="mailto:wronnenberg@niaid.nih.gov">wronnenberg@niaid.nih.gov</a> or 301-451-3522. Related Technology: Unpublished modifications to recombinant GP120. 2022-03-08 2025-05-13 2025-05-13 2014-02-19 BETWEEN, CD4, DB4XXX, DBXXXX, DC5XXX, DCXXXX, DXXXXX, Envelope, gp120, HIV, INHIBIT, INTERACTION, Mimics, Peptide, Protein, RECEPTOR, That, V2-loop, VLXXXX, WIXXXX, WJXXXX, WKXXXX, YAXXXX, YBXXXX, YCXXXX, YFXXXX False True <ul> <li>Early-stage</li> <li>In vitro data available</li> <li>In vivo data available (animal)</li> <li>Prototype</li> </ul> True 52406769 Prototype 52406769 NIHTT 37470483 Website Abstract 114172082 Cimbro R, et al. http://www.ncbi.nlm.nih.gov/pubmed/24569807 <a href="http://www.ncbi.nlm.nih.gov/pubmed/24569807">Cimbro R, et al.</a> 114108569 Cimbro, Raffaello NIAID - DIR NIAID Cimbro, Raffaello (NIAID) 0 114108568 Lusso, Paolo NIAID - DIR NIAID Lusso, Paolo (NIAID) 1 114108568 Lusso, Paolo NIAID - DIR NIAID Lusso, Paolo (NIAID) 1 114108569 Cimbro, Raffaello NIAID - DIR NIAID Cimbro, Raffaello (NIAID) 0 114102102 Peptide And Mimics That Inhibit The Interaction Between The HIV Envelope Protein GP120 (at V2-loop) And The HIV Receptor, CD4 E-067-2012-0 Filing authorized NIAID, San Raffaele Scientific Institute, University of MIlano-Bicocca 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-2777] Recombinant Sulfated HIV Envelope Protein and Methods for Making Protein&body=Please send me information about technology [TAB-2777] Recombinant Sulfated HIV Envelope Protein and Methods for Making Protein. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-2777] Recombinant Sulfated HIV Envelope Protein and Methods for Making Protein&body=Please send me information about technology [TAB-2777] Recombinant Sulfated HIV Envelope Protein and Methods for Making Protein.">benjamin.hurley@nih.gov</a><br> 114163731 E-067-2012-0 E-067-2012-0-US-03 HIV THERAPEUTICS AND METHODS OF MAKING AND USING SAME National Stage US 9,775,895 14/651,635 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9775895 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9775895">9,775,895</a><br />Filed on 2015-06-11<br />Status: Abandoned 114167666 E-067-2012-0 E-067-2012-0-US-01 HIV NEUTRALIZING PEPTIDES AND METHODS OF THEIR USE PRV US 61/736,350 Abandoned US <br />Provisional (PRV) 61/736,350<br />Filed on 2012-12-12<br />Status: Abandoned 114167667 E-067-2012-0 E-067-2012-0-PCT-02 HIV THERAPEUTICS AND METHODS OF MAKING AND USING SAME PCT Patent Cooperation Treaty PCT/US2013/074801 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2013/074801<br />Filed on 2013-12-12<br />Status: Expired 114125524 DXXXXX 114125525 DBXXXX 114125526 DB4XXX 114125527 DCXXXX 114125528 DC5XXX 114125529 VLXXXX 114125530 WIXXXX 114125531 WJXXXX 114125532 WKXXXX 114125533 YAXXXX 114125534 YBXXXX 114125535 YCXXXX 114125536 YFXXXX 114146680 Peptide 114146681 Mimics 114146682 That 114146683 INHIBIT 114146684 INTERACTION 114146685 BETWEEN 114146686 HIV 114146687 Envelope 114146688 Protein 114146689 gp120 114146690 V2-loop 114146691 RECEPTOR 114146692 CD4 TAB-3114 114096741 N6, A Novel, Broad, Highly Potent HIV-specific Antibody NIAID Collaboration Collaboration Mark Connors, Jinghe Huang, Elise Ishida, Byong Kang, Peter Kwong, John Mascola, Anqi Zheng, Tongqing Zhou This is a new antibody coming out of NIAID’s intramural program. N6 has evolved a unique mode of binding that depends less on a variable area of the HIV envelope known as the V5 region and focuses more on conserved regions, which change relatively little among HIV strains. This allows N6 to tolerate changes in the HIV envelope, including the attachment of sugars in the V5 region, a major mechanism by which HIV develops resistance to other VRC01-class antibodies. N6 was shown in pre-clinical studies to neutralize 98 percent of HIV isolates tested. The studies also demonstrate that N6 neutralizes 80 percent of HIV isolates which were resistant to other antibodies of the same class, and does so very potently. Its breadth and potency makes N6 a highly desirable candidate for development in therapeutic or prophylactic strategies. <ul> <li>Neutralized 98 percent of HIV isolates tested</li> <li>Neutralized 80 percent of HIV isolates which were resistant to other antibodies of the same class, and does so very potently</li> </ul> <ul> <li>HIV therapeutic</li> <li>HIV prophylactic</li> </ul> The Technology Transfer and Intellectual Property Office (TTIPO) is seeking parties interested in collaborative research to further co-develop this technology. For collaboration opportunities, please contact Chris Kornak at <a href="mailto:chris.kornak@nih.gov">chris.kornak@nih.gov</a> or 240-627-3705. 2022-07-18 2025-05-13 2025-05-13 2017-03-15 ANTIBODY, bNAb, Broad, Highly, HIV-soecific, HIV-Specific, Listed LPM Thalhammer-Reyero as of 4/15/2015, N6, Novel, Ootent, Post LPM Assignment Set 20150420, POTENT, Pre LPM working set 20150418 False True True NIHTT 37470483 Website Abstract 114172302 Huang J, et al. http://www.ncbi.nlm.nih.gov/pubmed/27851912 <a href="http://www.ncbi.nlm.nih.gov/pubmed/27851912">Huang J, et al.</a> 114109181 Kwong, Peter NIAID - VRC NIAID Kwong, Peter (NIAID) 0 114109183 Huang, Jinghe NIAID - DIR NIAID Huang, Jinghe (NIAID) 0 114109184 Kang, Byong NIAID - DIR NIAID Kang, Byong (NIAID) 0 114109185 Mascola, John NIAID - VRC NIAID Mascola, John (NIAID) 0 114109186 Ishida, Elise NIAID - DIR NIAID Ishida, Elise (NIAID) 0 114109187 Zhou, Tongqing NIAID - VRC NIAID Zhou, Tongqing (NIAID) 0 114109188 Zheng, Anqi NIAID - VRC NIAID Zheng, Anqi (NIAID) 0 114109182 Connors, Mark NIAID - DIR NIAID Connors, Mark (NIAID) 1 114109182 Connors, Mark NIAID - DIR NIAID Connors, Mark (NIAID) 1 114109181 Kwong, Peter NIAID - VRC NIAID Kwong, Peter (NIAID) 0 114109183 Huang, Jinghe NIAID - DIR NIAID Huang, Jinghe (NIAID) 0 114109184 Kang, Byong NIAID - DIR NIAID Kang, Byong (NIAID) 0 114109185 Mascola, John NIAID - VRC NIAID Mascola, John (NIAID) 0 114109186 Ishida, Elise NIAID - DIR NIAID Ishida, Elise (NIAID) 0 114109187 Zhou, Tongqing NIAID - VRC NIAID Zhou, Tongqing (NIAID) 0 114109188 Zheng, Anqi NIAID - VRC NIAID Zheng, Anqi (NIAID) 0 114099625 N6, A Novel, Broad, Highly Potent HIV-specific Antibody E-131-2015-0 Filing authorized NIAID 114099727 N6, A Novel, Broad, Highly Potent HIV-specific Antibody E-131-2015-1 Filing authorized NIAID 114100446 N6, A Novel, Broad, Highly Potent HIV-specific Antibody E-131-2015-2 Filing authorized NIAID 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-3114] N6, A Novel, Broad, Highly Potent HIV-specific Antibody&body=Please send me information about technology [TAB-3114] N6, A Novel, Broad, Highly Potent HIV-specific Antibody. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-3114] N6, A Novel, Broad, Highly Potent HIV-specific Antibody&body=Please send me information about technology [TAB-3114] N6, A Novel, Broad, Highly Potent HIV-specific Antibody.">benjamin.hurley@nih.gov</a><br> 114163492 E-131-2015-2 E-131-2015-2-US-07 NEUTRALIZING ANTIBODIES TO GP120 AND THEIR USE National Stage US 10,562,960 15/559,791 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10562960 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10562960">10,562,960</a><br />Filed on 2017-09-19<br />Status: Issued 114168225 E-131-2015-0 E-131-2015-0-US-01 NEUTRALIZING ANTIBODIES TO GP120 AND THEIR USE PRV US 62/136,228 Abandoned US <br />Provisional (PRV) 62/136,228<br />Filed on 2015-03-20<br />Status: Abandoned 114168226 E-131-2015-1 E-131-2015-1-US-01 Neutralizing Antibodies to GP120 and Their Use PRV US 62/250,378 Abandoned US <br />Provisional (PRV) 62/250,378<br />Filed on 2015-11-03<br />Status: Abandoned 114168227 E-131-2015-2 E-131-2015-2-PCT-01 Neutralizing Antibodies to GP120 and Their Use PCT COMB Patent Cooperation Treaty PCT/US2016/023145 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2016/023145<br />Filed on 2016-03-18<br />Status: Expired 114168961 E-131-2015-2 E-131-2015-2-US-09 lNEUTRALIZING ANTIBODIES TO GP120 AND THEIR USE CON US 16/786,267 Abandoned US <br />Continuation (CON) 16/786,267<br />Filed on 2020-02-10<br />Status: Abandoned 114169137 E-131-2015-2 E-131-2015-2-US-49 NEUTRALIZING ANTIBODIES TO GP120 AND THEIR USE CON US 17/358,522 Abandoned US <br />Continuation (CON) 17/358,522<br />Filed on 2021-06-25<br />Status: Abandoned 114169602 E-131-2015-2 E-131-2015-2-US-50 NEUTRALIZING ANTIBODIES TO GP120 AND THEIR USE CON US 12,202,886 17/855,553 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12202886 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12202886">12,202,886</a><br />Filed on 2022-06-30<br />Status: Issued 114148868 N6 114148869 Novel 114148870 Broad 114148871 Highly 114148872 Ootent 114148873 HIV-soecific 114148874 ANTIBODY 114148875 HIV-Specific 114148876 POTENT 114148877 Listed LPM Thalhammer-Reyero as of 4/15/2015 114148878 Pre LPM working set 20150418 114148879 Post LPM Assignment Set 20150420 114148880 bNAb TAB-2428 114096631 Broadly Neutralizing Human Anti-HIV Monoclonal Antibody 10E8 and Related Antibodies Capable of Neutralizing Most HIV-1 Strains NIAID Antibodies, Collaboration, Immunology, Infectious Disease, Therapeutics, Vaccines Antibodies Collaboration Immunology Infectious Disease Therapeutics Vaccines Mark Connors, Ivelin Georgiev, Jinghe Huang, Peter Kwong, Leo Laub, John Mascola, Gary Nabel, Gilad Ofek, Rebecca Rudicell, Yongping Yang, Jiang Zhu The uses for human anti-HIV monoclonal antibody 10E8 and its variants include passive immunization, therapeutic vaccination, and the development of vaccine immunogens. 10E8 is one of the most potent HIV-neutralizing antibodies isolated and it neutralizes up to 98% of diverse HIV-1 strains. 10E8 is specific to the membrane-proximal external region (MPER) of the HIV envelope protein gp41 and 10E8 is orthogonal to other anti-HIV antibodies. In combination with other antibodies 10E8 may provide an antibody response that neutralizes nearly all strains of HIV-1. Additionally, 10E8 effectively induces antibody-dependent cellular cytotoxicity (ADCC) indicating its potential use for therapeutic vaccine strategies. Further, 10E8 is a tool for immunogen design and validation of immunogen structure.<br /><br /> NIAID is currently developing certain embodiments of 10E8 for clinical use. Therefore, for some fields of use, NIH will evaluate a license applicant's capabilities and experience in advancing similar technologies through the regulatory process. This technology is not eligible for the NIH's start-up license program. <ul> <li>One of the most potent Human broadly-neutralizing anti HIV antibodies isolated to date</li> <li>Broad reactivity and high affinity to most HIV-1 strains</li> <li>Activity is highly complementary to existing broadly neutralizing antibodies, such as CD4 binding site antibodies</li> <li>Not auto-reactive</li> </ul> <ul> <li>Passive protection to prevent HIV infection</li> <li>Passive protection to prevent mother-to-infant HIV transmission</li> <li>Topical microbicide to prevent HIV infection</li> <li>Gene-based vectors for anti-gp41 antibody expression</li> <li>Therapeutic for the elimination of HIV infected cells that are actively producing virus</li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize 10E8-related vaccines or immunotherapies. For collaboration opportunities, please contact Bill Ronnenberg at +1 240-627-3726 or <a href="mailto:wronnenberg@niaid.nih.gov">wronnenberg@niaid.nih.gov</a>. 2022-03-08 2025-05-13 2025-05-13 2012-05-01 antibodies, ANTIBODY, ANTI-HIV, Anti-HIV-1, Anti-HIV-l, Broadly Neutralizing Antibody, DB4AXX, DB4XXX, DBXXXX, DC5AXX, DC5XXX, DCXXXX, DXXXXX, gp41, Human, ISOLATING, Knowledge, mabs, Membrane-Proximal, Method, monoclonal, Neutralizing, prior, Producing, Specificity, VLXXXX, WITHOUT, WJXXXX, XAXXXX, YBXXXX, YCXXXX False True <ul> <li>In vitro data available</li> <li>In vivo data available (animal)</li> </ul> True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114171577 Huang J, et al. http://www.ncbi.nlm.nih.gov/pubmed/23151583 <a href="http://www.ncbi.nlm.nih.gov/pubmed/23151583">Huang J, et al.</a> 114108765 Mascola, John NIAID - VRC NIAID Mascola, John (NIAID) 0 114108766 Laub, Leo NIAID - DIR Laub, Leo 0 114108767 Huang, Jinghe NIAID - DIR NIAID Huang, Jinghe (NIAID) 0 114108768 Kwong, Peter NIAID - VRC NIAID Kwong, Peter (NIAID) 0 114108769 Ofek, Gilad NIAID - VRC NIAID Ofek, Gilad (NIAID) 0 114108770 Zhu, Jiang NIAID - VRC NIAID Zhu, Jiang (NIAID) 0 114108771 Nabel, Gary NIAID - VRC NIAID Nabel, Gary (NIAID) 0 114108773 Georgiev, Ivelin NIAID - VRC NIAID Georgiev, Ivelin (NIAID) 0 114108774 Yang, Yongping NIAID - VRC NIAID Yang, Yongping (NIAID) 0 114108776 Rudicell, Rebecca NIAID - VRC NIAID Rudicell, Rebecca (NIAID) 0 114107540 Connors, Mark NIAID - DIR NIAID Connors, Mark (NIAID) 1 114107540 Connors, Mark NIAID - DIR NIAID Connors, Mark (NIAID) 1 114108765 Mascola, John NIAID - VRC NIAID Mascola, John (NIAID) 0 114108766 Laub, Leo NIAID - DIR Laub, Leo 0 114108767 Huang, Jinghe NIAID - DIR NIAID Huang, Jinghe (NIAID) 0 114108768 Kwong, Peter NIAID - VRC NIAID Kwong, Peter (NIAID) 0 114108769 Ofek, Gilad NIAID - VRC NIAID Ofek, Gilad (NIAID) 0 114108770 Zhu, Jiang NIAID - VRC NIAID Zhu, Jiang (NIAID) 0 114108771 Nabel, Gary NIAID - VRC NIAID Nabel, Gary (NIAID) 0 114108773 Georgiev, Ivelin NIAID - VRC NIAID Georgiev, Ivelin (NIAID) 0 114108774 Yang, Yongping NIAID - VRC NIAID Yang, Yongping (NIAID) 0 114108776 Rudicell, Rebecca NIAID - VRC NIAID Rudicell, Rebecca (NIAID) 0 114101730 A Broadly Neutralizing Human Anti-HIV-1 GP41 (membrane-proximal External Region) Monoclonal Antibody (SE 1 0) And Related Anti-HIV MAbs E-253-2011-0 Filing authorized NIAID, NIEHS, NIH - NIAID 114102172 Method For Isolating And Producing Neutralizing Monoclonal Antibodies Without Prior Knowledge Of Specificity E-253-2011-1 Filing authorized NIAID 114102173 Method For Isolating And Producing Neutralizing Monoclonal Antibodies Without Prior Knowledge Of Specificity E-253-2011-2 Filing authorized NIAID, NIH - NIAID 114102174 Method For Isolating And Producing Neutralizing Monoclonal Antibodies Without Prior Knowledge Of Specificity E-253-2011-3 Filing authorized NIAID 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-2428] Broadly Neutralizing Human Anti-HIV Monoclonal Antibody 10E8 and Related Antibodies Capable of Neutralizing Most HIV-1 Strains&body=Please send me information about technology [TAB-2428] Broadly Neutralizing Human Anti-HIV Monoclonal Antibody 10E8 and Related Antibodies Capable of Neutralizing Most HIV-1 Strains. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-2428] Broadly Neutralizing Human Anti-HIV Monoclonal Antibody 10E8 and Related Antibodies Capable of Neutralizing Most HIV-1 Strains&body=Please send me information about technology [TAB-2428] Broadly Neutralizing Human Anti-HIV Monoclonal Antibody 10E8 and Related Antibodies Capable of Neutralizing Most HIV-1 Strains.">benjamin.hurley@nih.gov</a><br> 114163330 E-253-2011-0 E-253-2011-0-US-01 NEUTRALIZING GP41 ANTIBODIES AND THEIR USE PRV US 61/556,660 Abandoned US <br />Provisional (PRV) 61/556,660<br />Filed on 2011-11-07<br />Status: Abandoned 114166748 E-253-2011-3 E-253-2011-3-US-09 NEUTRALIZING GP41 ANTIBODIES AND THEIR USE DIV US 9,783,595 15/226,744 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9783595 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9783595">9,783,595</a><br />Filed on 2016-08-02<br />Status: Issued 114167845 E-253-2011-1 E-253-2011-1-US-01 NEUTRALIZING GP41 ANTIBODIES AND THEIR USE PRV US 61/672,708 Abandoned US <br />Provisional (PRV) 61/672,708<br />Filed on 2012-07-17<br />Status: Abandoned 114167846 E-253-2011-2 E-253-2011-2-US-01 Method For Isolating And Producing Neutralizing Monoclonal Antibodies Without Prior Knowledge Of Specificity PRV US 61/698,480 Abandoned US <br />Provisional (PRV) 61/698,480<br />Filed on 2012-09-07<br />Status: Abandoned 114167847 E-253-2011-3 E-253-2011-3-PCT-01 NEUTRALIZING GP41 ANTIBODIES AND THEIR USE PCT COMB Patent Cooperation Treaty PCT/US2012/063958 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2012/063958<br />Filed on 2012-11-07<br />Status: Expired 114167848 E-253-2011-3 E-253-2011-3-US-05 Neutralizing GP41 Antibodies And Their Use National Stage US 9,475,862 14/356,557 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9475862 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9475862">9,475,862</a><br />Filed on 2014-05-06<br />Status: Issued 114168362 E-253-2011-3 E-253-2011-3-US-13 NEUTRALIZING GP41 ANTIBODIES AND THEIR USE DIV US 10,047,148 15/699,902 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10047148 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10047148">10,047,148</a><br />Filed on 2017-09-08<br />Status: Issued 114122759 DB4AXX 114122760 DC5AXX 114122761 DXXXXX 114122762 DBXXXX 114122763 DB4XXX 114122764 DCXXXX 114122765 DC5XXX 114126309 VLXXXX 114126310 WJXXXX 114126311 XAXXXX 114126312 YBXXXX 114126313 YCXXXX 114142963 Neutralizing 114142964 Human 114142965 Anti-HIV-l 114142966 gp41 114142967 Membrane-Proximal 114142968 monoclonal 114142969 ANTIBODY 114142970 ANTI-HIV 114142971 mabs 114142972 Broadly Neutralizing Antibody 114147559 Anti-HIV-1 114147560 Method 114147561 ISOLATING 114147562 Producing 114147563 antibodies 114147564 WITHOUT 114147565 prior 114147566 Knowledge 114147567 Specificity TAB-1708 114095937 The Use of alpha-4 beta-7 integrin Inhibitors to Inhibit HIV Transmission and Infection NIAID Collaboration, Infectious Disease, Therapeutics Collaboration Infectious Disease Therapeutics James Arthos, Claudia Cicala, Anthony Fauci, Diana Goode This invention involves the use of inhibitors of alpha-4 beta-7 (a4b7) integrin to inhibit HIV transmission/infection, as a prophylactic to inhibit onset of the acute stage of HIV infection or to treat HIV infection. The a4b7 integrin inhibitors were previously developed for use in other diseases, such as multiple sclerosis or inflammatory bowel disease.<br /><br /> a4b7 integrin is a multifaceted target for HIV infection and recent studies indicate that it is important for establishing HIV infection through multiple paths. Studies indicate that: 1) CD4 T-cells present in vaginal and anal mucosa have high levels of a4b7 integrin, making CD4 T-cells permissive to HIV infection; 2) a4b7 integrin is important for cell to cell transmission of HIV; 3) a4b7 integrin is used to dysregulate the host humoral response to HIV; and 4) HIV acts on a4b7 integrin through an epitope in V2 loop of GP120, identified as important for HIV vaccine protection. Additionally, primate studies indicate that a4b7 integrin inhibition of HIV infection preserves gut-associated lymphoid tissue (GALT) generally destroyed during the acute phase of HIV infection. <ul> <li>a4b7 integrin is a multifaceted target for HIV infection</li> <li>Previously developed a4b7 integrin inhibitors can be used for a new purpose</li> </ul> <ul> <li>Prevention and treatment of HIV infection</li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize alpha-4 beta-7 integrin inhibitors. For collaboration opportunities, please contact Bill Ronnenberg, JD/MIP, MS at 301-451-3522 or <a href="mailto:wr78k@nih.gov">wr78k@nih.gov</a>. 2022-03-08 2025-05-13 2025-05-13 2008-02-01 ANTAGONISTS, BBXXXX, BETWEEN, DB4AXX, DB4XXX, DBXXXX, Direct, DXXXXX, gp120, HIV, INTERACTION, Intregrin, VLXXXX, YBXXXX, YCXXXX False True In vitro data <ul> <li>Pre-clinical</li> <li>In vitro data available</li> <li>In vivo data available (animal)</li> </ul> True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114172093 Martinelli E, et al. http://www.ncbi.nlm.nih.gov/pubmed/23797688 <a href="http://www.ncbi.nlm.nih.gov/pubmed/23797688">Martinelli E, et al.</a> 114172094 Nawaz F, et.al. http://www.ncbi.nlm.nih.gov/pubmed/21383973 <a href="http://www.ncbi.nlm.nih.gov/pubmed/21383973">Nawaz F, et.al.</a> 114172095 Cicala C, et al. http://www.ncbi.nlm.nih.gov/pubmed/19933330 <a href="http://www.ncbi.nlm.nih.gov/pubmed/19933330">Cicala C, et al.</a> 114172096 Arthos J, et al. http://www.ncbi.nlm.nih.gov/pubmed/18264102 <a href="http://www.ncbi.nlm.nih.gov/pubmed/18264102">Arthos J, et al.</a> 114105963 Fauci, Anthony NIAID - DIR NIAID Fauci, Anthony (NIAID) 0 114105964 Cicala, Claudia NIAID - DIR NIAID Cicala, Claudia (NIAID) 0 114105965 Goode, Diana NIAID - DIR Goode, Diana 0 114105966 Arthos, James NIAID - DIR NIAID Arthos, James (NIAID) 1 114105966 Arthos, James NIAID - DIR NIAID Arthos, James (NIAID) 1 114105963 Fauci, Anthony NIAID - DIR NIAID Fauci, Anthony (NIAID) 0 114105964 Cicala, Claudia NIAID - DIR NIAID Cicala, Claudia (NIAID) 0 114105965 Goode, Diana NIAID - DIR Goode, Diana 0 114100929 Antagonists Of The Direct Interaction Between HIV Gp120 And Integrin E-055-2007-3 Filing authorized NIAID 114100930 Antagonists Of The Direct Interaction Between HIV Gp120 And Intregrin E-055-2007-2 Filing authorized NIAID 114100931 Antagonists Of The Direct Interaction Between HIV Gp120 And Intregrin E-055-2007-1 Filing authorized NIAID 114100932 Antagonists Of The Direct Interaction Between HIV Gp120 And Intregrin E-055-2007-0 Filing authorized NIAID 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-1708] The Use of alpha-4 beta-7 integrin Inhibitors to Inhibit HIV Transmission and Infection&body=Please send me information about technology [TAB-1708] The Use of alpha-4 beta-7 integrin Inhibitors to Inhibit HIV Transmission and Infection. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-1708] The Use of alpha-4 beta-7 integrin Inhibitors to Inhibit HIV Transmission and Infection&body=Please send me information about technology [TAB-1708] The Use of alpha-4 beta-7 integrin Inhibitors to Inhibit HIV Transmission and Infection.">benjamin.hurley@nih.gov</a><br> 114163030 E-055-2007-3 E-055-2007-3-US-04 Use of Antagonists Of The Interaction Between HIV Gp120 And A4B7 Intregrin DIV US 9,441,041 14/859,675 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9441041 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9441041">9,441,041</a><br />Filed on 2015-09-21<br />Status: Abandoned 114164153 E-055-2007-3 E-055-2007-3-PCT-01 Use of Antagonists Of The Interaction Between HIV Gp120 And a4ß7 Intregrin PCT COMB Patent Cooperation Treaty PCT/US2007/086663 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2007/086663<br />Filed on 2007-12-06<br />Status: Expired 114164154 E-055-2007-2 E-055-2007-2-US-01 Use of Antagonists of the Interaction Between HIV Gp120 And Intregrin PRV US 60/957,140 Abandoned US <br />Provisional (PRV) 60/957,140<br />Filed on 2007-08-21<br />Status: Abandoned 114164155 E-055-2007-1 E-055-2007-1-US-01 Antagonists Of The Direct Interaction Between HIV Gp120 And Intregrin PRV US 60/920,880 Abandoned US <br />Provisional (PRV) 60/920,880<br />Filed on 2007-03-30<br />Status: Abandoned 114164156 E-055-2007-0 E-055-2007-0-US-01 Use of Antagonists of the Interaction Between HIV Gp120 And Intregrin PRV US 60/873,884 Abandoned US <br />Provisional (PRV) 60/873,884<br />Filed on 2006-12-07<br />Status: Abandoned 114165265 E-055-2007-3 E-055-2007-3-US-03 Use of Antagonists Of The Interaction Between HIV Gp120 And A4B7 Integrin National Stage US 9,193,790 12/518,035 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9193790 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9193790">9,193,790</a><br />Filed on 2010-12-08<br />Status: Issued 114167960 E-055-2007-3 E-055-2007-3-US-05 USE OF ANTAGONISTS OF THE INTERACTION BETWEEN HIV GP120 AND A4B7 INTEGRIN CON US 9,896,509 15/227,879 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9896509 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9896509">9,896,509</a><br />Filed on 2016-08-03<br />Status: Abandoned 114118450 DB4AXX 114118451 DBXXXX 114118452 DXXXXX 114118936 DB4XXX 114120880 BBXXXX 114125621 VLXXXX 114125622 YBXXXX 114125623 YCXXXX 114131611 ANTAGONISTS 114131612 Direct 114131613 INTERACTION 114131614 BETWEEN 114131615 HIV 114131616 gp120 114131617 Intregrin TAB-5048 162270279 Francisella Lipids as Broad Anti-inflammatory Therapeutics NIAID Application, Collaboration, Immunology, Licensing, Materials Available, Therapeutics Application Collaboration Immunology Licensing Materials Available Therapeutics Catharine Bosio, Robin Ireland, Glenn Nardone <p>Anti-inflammatory treatments, particularly those used in the context of viral infection, have been shown to greatly inhibit the overall immune response, which can result in poor immunity and failure to control or clear the infection. Novel alternatives that can effectively attenuate inflammation without the more serious side effects of steroid medications (e.g., global immune suppression, muscle weakness, etc.) may have substantial use across a wide range of disease areas.</p> <p><em>Francisella tularensis</em> (FT), the causative agent of tularemia, exhibits a potent ability to induce rapid suppression of inflammatory responses in host cells. Building on prior work that demonstrated the ability of crude and enriched lipids from virulent FT strains to dampen inflammation triggered by a variety of sources, researchers at the National Institute of Allergy and Infectious Disease (NIAID) have developed FT lipid preparations with strong potential for the prophylactic/therapeutic treatment of viral-mediated inflammation&mdash;without deleterious effects on the development of anti-viral immunity.</p> <p>The NIAID data further show that these FT lipid preparations are relatively non-toxic to cells, do not adversely affect the functioning of T cells, and act in part by inhibiting production of inflammatory mediators, highlighting other potential therapeutic targets such as allergic and autoimmune-associated inflammation.</p> <p>This technology is available for licensing for commercial development in accordance with 35 U.S.C. &sect; 209 and 37 CFR part 404.</p> <ul> <li>Potential alternative that can overcome compromises to immunity and other side effects associated with traditional anti-inflammatory treatment</li> </ul> <ul> <li>Well-tolerated, short-term prophylactic or therapeutic treatment of inflammation across multiple disease areas (viral infection, autoimmunity, etc.) </li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. For collaboration opportunities, please contact Terrence Joyce at 240-987-2347 or terrence.joyce@nih.gov, and reference E-142-2016. 2025-05-08 2025-05-08 2025-05-13 2025-05-09 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 162270793 Crane DD, et al. Lipids derived from virulent Francisella tularensis broadly inhibit pulmonary inflammation via toll-like receptor 2 and peroxisome proliferator-activated receptor α. Clin Vaccine Immunol. 2013;20(10):1531–1540. https://doi.org/10.1128/CVI.00319-13 <a href="https://doi.org/10.1128/CVI.00319-13">Crane DD, et al. Lipids derived from virulent Francisella tularensis broadly inhibit pulmonary inflammation via toll-like receptor 2 and peroxisome proliferator-activated receptor α. Clin Vaccine Immunol. 2013;20(10):1531–1540.</a> 162270800 Ireland R, et al. Francisella tularensis SchuS4 and SchuS4 lipids inhibit IL-12p40 in primary human dendritic cells by inhibition of IRF1 and IRF8. J Immunol. 2013;191(3):1276–1286. . https://doi.org/10.4049/jimmunol.1300867 <a href="https://doi.org/10.4049/jimmunol.1300867">Ireland R, et al. Francisella tularensis SchuS4 and SchuS4 lipids inhibit IL-12p40 in primary human dendritic cells by inhibition of IRF1 and IRF8. J Immunol. 2013;191(3):1276–1286. .</a> 162270427 Bosio, Catharine National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Bosio, Catharine (NIAID) 1 162270446 Nardone, Glenn NIAID - DIR NIAID Nardone, Glenn (NIAID) 2 162270489 Ireland, Robin NIAID - DIR NIAID Ireland, Robin (NIAID) 3 162270427 Bosio, Catharine National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Bosio, Catharine (NIAID) 1 162270446 Nardone, Glenn NIAID - DIR NIAID Nardone, Glenn (NIAID) 2 162270489 Ireland, Robin NIAID - DIR NIAID Ireland, Robin (NIAID) 3 162270282 Francisella Lipids As Broad Anti-inflammatory Therapeutics E-142-2016-0 Filing authorized NIAID 146046171 Joyce, Terrence terrence.joyce@nih.gov
United States of America terrence.joyce@nih.gov?subject=Web Inquiry on [TAB-5048] Francisella Lipids as Broad Anti-inflammatory Therapeutics&body=Please send me information about technology [TAB-5048] Francisella Lipids as Broad Anti-inflammatory Therapeutics. Joyce, Terrence<br><a href="mailto:terrence.joyce@nih.gov?subject=Web Inquiry on [TAB-5048] Francisella Lipids as Broad Anti-inflammatory Therapeutics&body=Please send me information about technology [TAB-5048] Francisella Lipids as Broad Anti-inflammatory Therapeutics.">terrence.joyce@nih.gov</a><br> 162270287 E-142-2016-0 E-142-2016-0-US-01 Francisella Lipids As Broad Anti-inflammatory Therapeutics and Associated Methods of Use PRV US 62/319,692 Abandoned US <br />Provisional (PRV) 62/319,692<br />Filed on 2016-04-07<br />Status: Abandoned 162270288 E-142-2016-0 E-142-2016-0-PCT-02 FRANCISELLA LIPIDS AS BROAD ANTI-INFLAMMATORY THERAPEUTICS AND ASSOCIATED METHODS OF USE PCT Patent Cooperation Treaty PCT/US2017/026467 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2017/026467<br />Filed on 2017-04-06<br />Status: Expired 162270289 E-142-2016-0 E-142-2016-0-EP-03 FRANCISELLA LIPIDS AS BROAD ANTI-INFLAMMATORY THERAPEUTICS AND ASSOCIATED METHODS OF USE National Stage European Patent 17721893.0 Pending European Patent <br />National Stage 17721893.0<br />Filed on 2017-04-06<br />Status: Pending 162270290 E-142-2016-0 E-142-2016-0-US-04 FRANCISELLA LIPIDS AS BROAD ANTI-INFLAMMATORY THERAPEUTICS AND ASSOCIATED METHODS OF USE National Stage US 11,529,312 16/091,768 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11529312 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11529312">11,529,312</a><br />Filed on 2018-10-05<br />Status: Issued TAB-4838 152382112 Hybridoma Cell Lines 2A4 And 5B12 Against Puromycin NIAID Collaboration, Licensing, Materials Available Collaboration Licensing Materials Available Alexandre David, Jonathan (Jon) Yewdell <p>Protein translation is a central cellular function attracting increasing attention from cell biologists as they integrate gene product specific information into a systems view of cellular function. Scientists at NIAID developed the puromycin-specific antibodies that allow for the specific detection of puromycin-containing nascent polypeptides via standard immunofluorescence or flow cytometry. The resulting ribopuromycylation method (RPM) localizes translation in cells and can be applied to any PMY-sensitive eukaryotic or prokaryotic cell to study the dynamics of protein synthesis at the cellular level and investigate translational processes. It can also be used in vitro or in vivo to measure the number of translating ribosomes using flow cytometry.</p> <p>This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as well as for further development and evaluation under a research collaboration.</p> <ul> <li> This technology generates antibodies specific for puromycin that can be used to localize translating ribosomes in all cell types.</li> </ul> <ul> <li> Broad application for studying protein translation.</li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. For collaboration opportunities, please contact Ben Hurley at 240–669–5092, or benjamin.hurley@nih.gov. 2024-01-25 2025-05-12 2025-05-12 2024-01-24 Hybridoma, Monoclonal Antibodies, PROTEIN., Puromycin False False Research Materials True 37470483 Website Abstract 152384717 David A. Dolan BP, Hickman HD, Knowlton JJ, Clavarino G, Pierre P, Bennink JR, Yewdell JW. Nuclear translation visualized by ribosome-bound nascent chain puromycylation. J Cell Biol. 2012 Apr 2;197(1):45–57. (doi: 10.1083/jcb.201112145. PMID: 22472439; PMCID: PMC3317795) https://pubmed.ncbi.nlm.nih.gov/22472439/ <a href="https://pubmed.ncbi.nlm.nih.gov/22472439/">David A. Dolan BP, Hickman HD, Knowlton JJ, Clavarino G, Pierre P, Bennink JR, Yewdell JW. Nuclear translation visualized by ribosome-bound nascent chain puromycylation. J Cell Biol. 2012 Apr 2;197(1):45–57. (doi: 10.1083/jcb.201112145. PMID: 22472439; PMCID: PMC3317795)</a> 152382201 Yewdell, Jonathan (Jon) NIAID - DIR NIAID Yewdell, Jonathan (Jon) (NIAID) 1 152382486 David, Alexandre INSERM David, Alexandre 2 152382201 Yewdell, Jonathan (Jon) NIAID - DIR NIAID Yewdell, Jonathan (Jon) (NIAID) 1 152382486 David, Alexandre INSERM David, Alexandre 2 152382115 Hybridoma Cell Lines 2A4 And 5B12 Against Puromycin E-003-2021-0 Research Material NIAID 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-4838] Hybridoma Cell Lines 2A4 And 5B12 Against Puromycin&body=Please send me information about technology [TAB-4838] Hybridoma Cell Lines 2A4 And 5B12 Against Puromycin. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-4838] Hybridoma Cell Lines 2A4 And 5B12 Against Puromycin&body=Please send me information about technology [TAB-4838] Hybridoma Cell Lines 2A4 And 5B12 Against Puromycin.">jonathan.motley@nih.gov</a><br> 152423029 Hybridoma 152423033 Monoclonal Antibodies 152423037 Puromycin 152423054 PROTEIN. TAB-4831 152365936 Anti-Puromycin Antibodies Illuminate the World of Cellular Protein Translation NIAID Collaboration, Computational models/software, Diagnostics, Research Equipment Collaboration Computational models/software Diagnostics Research Equipment Alexandre David, Jonathan (Jon) Yewdell <p>The Ribopuromycylation (RPM) technology, developed by Dr. Jon Yewdell and Dr. Alexandre David, offers a powerful and universal method for visualizing and studying protein translation within cells. RPM involves the use of puromycin, a molecule that mimics a tyrosyl-tRNA and terminates translation by becoming covalently incorporated into the nascent protein chain&#39;s C-terminus within the ribosome&#39;s A site. This technique enables the immobilization of puromycylated nascent protein chains on ribosomes when chain elongation inhibitors like cycloheximide or emetine are utilized. Anti-puromycin monoclonal antibodies (mAbs) are then employed to localize actively translating ribosomes through immunofluorescence analysis of fixed and permeabilized cells or tissues. RPM has revolutionized the study of protein translation, providing researchers with a straightforward and versatile tool to investigate this fundamental cellular process in various biological contexts.</p> <p>&nbsp;</p> Ribopuromycylation (RPM) offers a competitive edge in cellular biology due to its universality, specificity, and compatibility with fluorescence detection. This versatile method simplifies the study of protein translation, making it accessible to a broader range of researchers, and provides accurate insights into active translation processes within cells. With various pathological conditions and advancing our understanding of cellular processes. Ribopuromycylation (RPM) finds diverse applications in cellular and molecular biology. It enables the exploration of dynamic protein translation regulation in response to environmental stressors, infections, and differentiation states, offering valuable insights into cellular adaptations. RPM also facilitates the specific investigation of individual gene expression patterns, aiding in the comprehension of gene-specific translation dynamics. Its versatility extends to drug discovery and disease research, making it a valuable tool for uncovering translation abnormalities associated 2024-01-24 2025-05-12 2025-05-12 2024-12-10 False False True 52406769 Prototype 52406769 37470483 Website Abstract 152365968 David, Alexandre INSERM David, Alexandre 2 152366109 Yewdell, Jonathan (Jon) NIAID - DIR NIAID Yewdell, Jonathan (Jon) (NIAID) 3 152365968 David, Alexandre INSERM David, Alexandre 2 152366109 Yewdell, Jonathan (Jon) NIAID - DIR NIAID Yewdell, Jonathan (Jon) (NIAID) 3 152365939 Hybridoma Cell Lines 2A4 And 5B12 Against Puromycin E-003-2021-0 Research Material NIAID 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-4831] Anti-Puromycin Antibodies Illuminate the World of Cellular Protein Translation&body=Please send me information about technology [TAB-4831] Anti-Puromycin Antibodies Illuminate the World of Cellular Protein Translation. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-4831] Anti-Puromycin Antibodies Illuminate the World of Cellular Protein Translation&body=Please send me information about technology [TAB-4831] Anti-Puromycin Antibodies Illuminate the World of Cellular Protein Translation.">jonathan.motley@nih.gov</a><br> TAB-3847 145815189 Multi Protein Nanoparticle Monkeypox Vaccine NIAID Collaboration, Licensing Collaboration Licensing Bernard Moss <p><strong style="font-weight:bold">In 2022, the World Health Organization declared an atypical outbreak of monkeypox (Mpox), which has caused approximately 30,000 cases of Mpox infection within the United States as of April 2023. Mpox represents a current threat to public health, and there is an immediate need for an effective vaccine. To address this, NIAID has developed a vaccine approach comprising virus-like nanoparticles coated with modified Mpox proteins. NIAID investigations have demonstrated that immunization has elicited a robust immune response in mice and provided protection against a lethal infection of Vaccinia virus. </strong></p> <p><strong style="font-weight:bold">This technology is available for licensing for commercial development in accordance with 35 U.S.C. &sect; 209 and 37 CFR Part 404, as well as for further development and evaluation under a research collaboration.</strong></p> <ul> <li>A Mpox nanoparticle vaccine may have fewer side effects than available MVA based vaccines.</li> <li>The storage and transport requirements of a Mpox nanoparticle vaccine are better suited to low resource settings than MVA vaccines.</li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this invention. 2023-06-05 2025-05-12 2025-05-12 2023-04-25 False False True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract E-183-2022-0 145816947 Moss, Bernard National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Moss, Bernard (NIAID) 1 145816947 Moss, Bernard National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Moss, Bernard (NIAID) 1 145815193 Multi Protein Nanoparticle Monkeypox Vaccine E-183-2022-0 Filing authorized NIAID 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-3847] Multi Protein Nanoparticle Monkeypox Vaccine&body=Please send me information about technology [TAB-3847] Multi Protein Nanoparticle Monkeypox Vaccine. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-3847] Multi Protein Nanoparticle Monkeypox Vaccine&body=Please send me information about technology [TAB-3847] Multi Protein Nanoparticle Monkeypox Vaccine.">jonathan.motley@nih.gov</a><br> TAB-3450 114097321 FRugally Optimized DNA Octamer (FRODO): DNA Vector and Uses Thereof For Detecting HIV and SIV NIAID Collaboration Collaboration Jason Brenchley, Charlotte Langner Quantitative polymerase chain reactions (qPCRs) are commonly employed to enumerate genes of interest among particular biological samples. Insertion of PCR amplicons into plasmid DNA is a mainstay for creation of known quantities of target sequences to standardize quantitative PCRs. Typically, one amplicon is inserted into one plasmid construct, the plasmid is then amplified, purified, serially diluted, and then quantified to be used to enumerate target sequences in unknown samples. As qPCR is often used to detect multiple amplicons simultaneously, individual qPCR standards are often desired to be normalized one to another. Unlike prior methods using separate plasmid constructs for each target sequence, FRODO incorporates eight amplicons into one plasmid construct ensuring equivalent template copy numbers for all amplicons. Amplifying, purifying, diluting and quantifying one plasmid construct rather than eight individual constructs streamlines standard curve qPCR analyses, reducing reagents and simplifying normalization between amplicons. <ul> <li>A simplified workflow for qPCR testing. Amplifying, purifying, diluting and quantifying one plasmid construct rather than multiple, individual constructs streamlines standard curve qPCR analyses, reducing reagents and simplifying normalization between amplicons.</li> <li>At present, there are a number of antibody-based clinical tools that may be used for diagnosing/detecting HIV, but there are fewer products that affordably detect/monitor nucleic acids of HIV within cells, and immunological health, and efficacy of medicaments aimed at reducing cells infected with HIV.</li> </ul> </li> <ul> <li>Clinical Detection, Monitoring of Nucleic Acid Markers of HIV and Immunological Health: FRODO may be used to efficiently quantify target sequences in unknown samples. </li> <li>FRODO is a single plasmid containing 8 amplicons which can be used to quantify several different strains of SIV and HIV, cell number equivalents for humans and nonhuman primates, T cell receptor excision circles (humans and nonhuman primates), and bacterial 16S and ampicillin resistance DNA.</li> <li>FRODO may offer improved, more affordable, highly-sensitive nucleic acid-based HIV quantification and/or diagnostic response times, enhancing patient treatment and interventions.</li> <li>FRODO can be used to quantify levels of bacterial DNA in clinical samples to determine potential sepsis.</li> <li>This technology is especially useful in translational HIV research in which human and nonhuman primate models are used to study HIV pathogenesis, informing public health responses.</li> </ul> For collaboration opportunities, please contact Benjamin Hurley, PhD at <a href="mailto:benjamin.hurley@nih.gov">benjamin.hurley@nih.gov</a>or 1-240-669-5092. 2022-03-08 2025-05-12 2025-05-12 2021-10-05 DNA, FRODO, FRugally, Octomer, OPTIMIZED, PLASMID False True True NIHTT 37470483 Website Abstract 114172610 Langer C.A. and Brenchley J.M. Wiley online library https://doi.org/10.1002/cpz1.93 <a href="https://doi.org/10.1002/cpz1.93">Langer C.A. and Brenchley J.M. Wiley online library</a> 114110239 Langner, Charlotte NIAID - DIR NIAID Langner, Charlotte (NIAID) 0 114110238 Brenchley, Jason NIAID - DIR NIAID Brenchley, Jason (NIAID) 1 114110238 Brenchley, Jason NIAID - DIR NIAID Brenchley, Jason (NIAID) 1 114110239 Langner, Charlotte NIAID - DIR NIAID Langner, Charlotte (NIAID) 0 114102571 FRugally Optimized DNA Octomer (FRODO) Plasmid E-024-2021-0 Filing authorized NIAID 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-3450] FRugally Optimized DNA Octamer (FRODO): DNA Vector and Uses Thereof For Detecting HIV and SIV&body=Please send me information about technology [TAB-3450] FRugally Optimized DNA Octamer (FRODO): DNA Vector and Uses Thereof For Detecting HIV and SIV. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-3450] FRugally Optimized DNA Octamer (FRODO): DNA Vector and Uses Thereof For Detecting HIV and SIV&body=Please send me information about technology [TAB-3450] FRugally Optimized DNA Octamer (FRODO): DNA Vector and Uses Thereof For Detecting HIV and SIV.">jonathan.motley@nih.gov</a><br> 114169133 E-024-2021-0 E-024-2021-0-US-01 DNA VECTOR AND USES THEREOF FOR DETECTING HIV AND SIV PRV US 63/128,392 Expired US <br />Provisional (PRV) 63/128,392<br />Filed on 2020-12-21<br />Status: Expired 114169176 E-024-2021-0 E-024-2021-0-PCT-02 DNA VECTOR AND USES THEREOF FOR DETECTING HIV AND SIV PCT Patent Cooperation Treaty PCT/US2021/063514 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/063514<br />Filed on 2021-12-15<br />Status: Expired 114152204 FRugally 114152205 OPTIMIZED 114152206 DNA 114152207 Octomer 114152208 FRODO 114152209 PLASMID TAB-3288 114097215 WR (Western Reserve) Strain of Vaccinia Virus with K151E Mutation in A34R Gene NIAID Infectious Disease, Licensing, Research Materials, Therapeutics, Vaccines Infectious Disease Licensing Research Materials Therapeutics Vaccines Rafael Blasco, Bernard Moss Mutation in gene A34R can regulate the release of progeny virions from the surface of parental cells. <ul> <li>Speed up product development with NIH developed material that has already been tested and validated.</li> </ul> <ul> <li>A research material that can be used in the development of assays, validation of products or in quality control.</li> </ul> Research Material – Patent protection is not being pursued for this technology. (IC Reference No. 2015-020) 2022-03-08 2025-05-12 2025-05-12 2018-06-07 A34, AC4XXX, AC5XXX, ACXXXX, AXXXXX, Cell, DDXXXX, DISSOCIATION, DXXXXX, GCXXXX, GLYCOPROTEIN, MEMBRANE, Progeny, REGULATED, research, RESEARCH MATERIAL, research reagent, RESEARCH TOOL, RM, RXXXXX, vaccinia, viral, virus, WIXXXX, XEXXXX, XKXXXX False True True NIHTT 37470483 Website Abstract 114172492 Blasco R, et al. https://www.ncbi.nlm.nih.gov/pubmed/8497053 <a href="https://www.ncbi.nlm.nih.gov/pubmed/8497053">Blasco R, et al.</a> 114109739 Blasco, Rafael Instituto Nacional de Investigacion y Tecnologia Agraria y A Blasco, Rafael 0 114109738 Moss, Bernard NIAID - DIR NIAID Moss, Bernard (NIAID) 1 114109738 Moss, Bernard NIAID - DIR NIAID Moss, Bernard (NIAID) 1 114109739 Blasco, Rafael Instituto Nacional de Investigacion y Tecnologia Agraria y A Blasco, Rafael 0 114102449 Dissociation Of Progeny Vaccinia Virus From The Cell Membrane Is Regulated By The A34 Viral Glycoprotein E-263-2015-0 Research Material NIAID 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-3288] WR (Western Reserve) Strain of Vaccinia Virus with K151E Mutation in A34R Gene&body=Please send me information about technology [TAB-3288] WR (Western Reserve) Strain of Vaccinia Virus with K151E Mutation in A34R Gene. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-3288] WR (Western Reserve) Strain of Vaccinia Virus with K151E Mutation in A34R Gene&body=Please send me information about technology [TAB-3288] WR (Western Reserve) Strain of Vaccinia Virus with K151E Mutation in A34R Gene.">jonathan.motley@nih.gov</a><br> 114127938 DDXXXX 114127939 DXXXXX 114127940 AXXXXX 114127941 ACXXXX 114127942 AC4XXX 114127943 AC5XXX 114127944 GCXXXX 114127945 XEXXXX 114127946 XKXXXX 114127947 RXXXXX 114127948 WIXXXX 114150917 research 114150918 DISSOCIATION 114150919 Progeny 114150920 vaccinia 114150921 virus 114150922 Cell 114150923 MEMBRANE 114150924 REGULATED 114150925 A34 114150926 viral 114150927 GLYCOPROTEIN 114150928 research reagent 114150929 RESEARCH TOOL 114150930 RESEARCH MATERIAL 114150968 RM TAB-3276 114097148 pLAS-1 Plasmid NIAID Infectious Disease, Licensing, Research Materials Infectious Disease Licensing Research Materials Bernard Moss, Linda Wyatt Shuttle vector for construction of recombinant MVA viruses. <ul> <li>Speed up product development with NIH developed material that has already been tested and validated.</li> </ul> <ul> <li>A research material that can be used in the development of assays, validation of products or in quality control.</li> </ul> Research Material – Patent protection is not being pursued for this technology. (IC Reference No. 2016-036) 2022-03-08 2025-05-12 2025-05-12 2018-06-07 Biological, Construction, E-023-2003, LVD, Material:, MVA, pLAS1, pLAS-1, recombinant, RM, SHUTTLE, Vector, Viruses, VLXXXX, WIXXXX False True True NIHTT 37470483 Website Abstract E-023-2003-0 114109715 Wyatt, Linda NIAID - DIR NIAID Wyatt, Linda (NIAID) 0 114109714 Moss, Bernard NIAID - DIR NIAID Moss, Bernard (NIAID) 1 114109714 Moss, Bernard NIAID - DIR NIAID Moss, Bernard (NIAID) 1 114109715 Wyatt, Linda NIAID - DIR NIAID Wyatt, Linda (NIAID) 0 114102438 Biological Material: PLAS-1 Shuttle Vector For Construction Of Recombinant MVA Viruses E-034-2017-0 Research Material NIAID 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-3276] pLAS-1 Plasmid&body=Please send me information about technology [TAB-3276] pLAS-1 Plasmid. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-3276] pLAS-1 Plasmid&body=Please send me information about technology [TAB-3276] pLAS-1 Plasmid.">jonathan.motley@nih.gov</a><br> 114127917 VLXXXX 114127918 WIXXXX 114150779 Biological 114150780 Material: 114150781 pLAS-1 114150782 SHUTTLE 114150783 Vector 114150784 Construction 114150785 recombinant 114150786 MVA 114150787 Viruses 114150788 LVD 114150789 E-023-2003 114150790 pLAS1 114150791 RM TAB-2969 114097095 Prevention or Treatment of Viral Infections by Inhibition of the Histone Methyltransferases EZH1/2 NIAID Infectious Disease, Licensing, Therapeutics, Vaccines Infectious Disease Licensing Therapeutics Vaccines Jesse Arbuckle, Thomas Kristie Herpes simplex viral infections, including herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2), are exceptionally common worldwide. These viruses establish lifelong persistent infections with cycles of lytic reactivation to produce recurrent diseases including oral and genital lesions, herpetic keratitis/blindness, congenital-developmental syndromes, and viral encephalitis. Infection with HSV-2 increases the rate of human immunodeficiency virus (HIV) transmission in coinfected individuals. DNA replication inhibitors are typically used to treat herpesvirus infections. However, these compounds do not completely suppress infection, viral shedding, reactivation from latency, and the inflammation that contributes to diseases such as keratitis. An unmet need continues to exist for methods of preventing or treating herpesviral infections. The application claims methods of preventing or treating herpesviral infection of a host, comprising administering to the host an effective amount of an inhibitor of the EZH1/2 histone methyltransferase activities. The application is not limited to herpes simplex virus but rather is applicable to other viral infections as well. <ul> <li>Low-cost production</li> <li>Ease of synthesis</li> </ul> <ul> <li>HSV therapeutics</li> <li>HSV vaccines</li> </ul> 2022-03-08 2025-05-12 2025-05-12 2015-08-10 DB4BXX, DB4XXX, DBXXXX, DC5BXX, DC5XXX, DCXXXX, DEXXXX, DXXXXX, EZH1/2, HERPESVIRUS, Infection, Inhibitors, Latency, Listed LPM Fenn as of 4/15/2015, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Reactivation, Suppresses, VLXXXX, WKXXXX, WNXXXX, XKXXXX, YBXXXX, YCXXXX False True <ul> <li>In vitro data available</li> <li>In vivo data available (animal)</li> </ul> True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract E-275-2008-2 E-184-2010-0 E-184-2010-1 114109060 Arbuckle, Jesse NIAID - DIR NIAID Arbuckle, Jesse (NIAID) 0 114109059 Kristie, Thomas NIAID - DIR NIAID Kristie, Thomas (NIAID) 1 114109059 Kristie, Thomas NIAID - DIR NIAID Kristie, Thomas (NIAID) 1 114109060 Arbuckle, Jesse NIAID - DIR NIAID Arbuckle, Jesse (NIAID) 0 114102280 Inhibitors Of EZH1/2 Suppresses Herpesvirus Infection And Reactivation From Latency E-141-2015-0 Filing authorized NIAID 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2969] Prevention or Treatment of Viral Infections by Inhibition of the Histone Methyltransferases EZH1/2&body=Please send me information about technology [TAB-2969] Prevention or Treatment of Viral Infections by Inhibition of the Histone Methyltransferases EZH1/2. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2969] Prevention or Treatment of Viral Infections by Inhibition of the Histone Methyltransferases EZH1/2&body=Please send me information about technology [TAB-2969] Prevention or Treatment of Viral Infections by Inhibition of the Histone Methyltransferases EZH1/2.">jonathan.motley@nih.gov</a><br> 114162973 E-141-2015-0 E-141-2015-0-PCT-02 Preventing or Treating Viral Infection by Inhibition of the Histone Methyltransferase EZH1 or EZH2 PCT Patent Cooperation Treaty PCT/US2016/030089 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2016/030089<br />Filed on 2016-04-29<br />Status: Expired 114166954 E-141-2015-0 E-141-2015-0-US-03 PREVENTING OR TREATING VIRAL INFECTION BY INHIBITION OF THE HISTONE METHYLTRANSFERASE EZH1 OR EZH2 National Stage US 15/800,515 Abandoned US <br />National Stage 15/800,515<br />Filed on 2017-11-01<br />Status: Abandoned 114168174 E-141-2015-0 E-141-2015-0-US-01 Preventing or Treating Viral Infection by Inhibition of the Histone Methyltransferase EZH1 or EZH2 PRV US 62/155,704 Abandoned US <br />Provisional (PRV) 62/155,704<br />Filed on 2015-05-01<br />Status: Abandoned 114127118 DXXXXX 114127119 DBXXXX 114127120 DCXXXX 114127121 DEXXXX 114127122 DB4XXX 114127123 DB4BXX 114127124 DC5XXX 114127125 DC5BXX 114127126 VLXXXX 114127127 WKXXXX 114127128 WNXXXX 114127129 XKXXXX 114127130 YBXXXX 114127131 YCXXXX 114148461 Inhibitors 114148462 EZH1/2 114148463 Suppresses 114148464 HERPESVIRUS 114148465 Infection 114148466 Reactivation 114148467 Latency 114148468 Listed LPM Fenn as of 4/15/2015 114148469 Pre LPM working set 20150418 114148470 Post LPM Assignment Set 20150420 TAB-2895 114097056 A Novel Virus-Based Expression System NIAID Collaboration, Consumer Products, Diagnostics, Infectious Disease, Research Materials, Therapeutics, Vaccines Collaboration Consumer Products Diagnostics Infectious Disease Research Materials Therapeutics Vaccines Bernard Moss, Linda Wyatt The present invention is related to a recombinant viral vector for vaccines.<br /><br /> Currently available poxvirus vectors for humans and other animals exhibit suboptimal expression of recombinant gene(s) and high expression of vector proteins which causes weak immunogenicity and high anti-vector immune response.<br /><br /> The present novel virus-based expression vectors are non-replicating in human and animals, have high expression of exogenous genes to achieve strong immunogenicity, demonstrate low expression of vector proteins to minimize anti-vector immune responses and minimize competition with expression of recombinant proteins and are capable of stable propagation in a continuous cell line. The present virus based expression vectors may be suitable for manufacturing vaccines for inducing an immune response in vaccinated individuals. <ul> <li>Non-replicating in human and animals</li> <li>Achieve high expression of recombinant genes</li> <li>Low expression of vector genes</li> <li>Stable propagation in a continuous cell line</li> </ul> <ul> <li>Vaccine</li> <li>Tool for studying immune responses</li> </ul> The National Institute of Allergy and Infectious Diseases, Laboratory of Viral Diseases, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize A Novel Virus-Based Expression System. For collaboration opportunities, please contact Chris Kornak at <a href="mailto:chris.kornak@nih.gov">chris.kornak@nih.gov</a>. 2022-03-08 2025-05-12 2025-05-12 2014-12-11 Expression, Gene, GENES, High, LOW, Non-Replicating, System, TARGET, vaccinia, Vector, virus, VJXXXX, VKXXXX, VLXXXX, VOXXXX, WAXXXX, WIXXXX, WNXXXX, XEXXXX, YAXXXX, YBXXXX, YFXXXX False True <ul> <li>Early-stage</li> <li>In vitro data available</li> <li>Prototype</li> </ul> True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract E-402-1986-1 E-552-1982-2 114108927 Wyatt, Linda NIAID - DIR NIAID Wyatt, Linda (NIAID) 0 114108926 Moss, Bernard NIAID - DIR NIAID Moss, Bernard (NIAID) 1 114108926 Moss, Bernard NIAID - DIR NIAID Moss, Bernard (NIAID) 1 114108927 Wyatt, Linda NIAID - DIR NIAID Wyatt, Linda (NIAID) 0 114102228 A New Non-replicating Vaccinia Virus Expression System With Low Expression Of Vector Genes And High Expression Of The Target Gene E-181-2014-0 Filing authorized NIAID 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2895] A Novel Virus-Based Expression System&body=Please send me information about technology [TAB-2895] A Novel Virus-Based Expression System. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2895] A Novel Virus-Based Expression System&body=Please send me information about technology [TAB-2895] A Novel Virus-Based Expression System.">jonathan.motley@nih.gov</a><br> 114161208 E-181-2014-0 E-181-2014-0-PCT-02 Virus-Based Expression Vectors and Uses Thereof PCT Patent Cooperation Treaty PCT/US2015/052295 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2015/052295<br />Filed on 2015-09-25<br />Status: Expired 114168018 E-181-2014-0 E-181-2014-0-US-01 Novel Virus-Based Expression Vectors And Uses Thereof PRV US 62/055,989 Abandoned US <br />Provisional (PRV) 62/055,989<br />Filed on 2014-09-26<br />Status: Abandoned 114168241 E-181-2014-0 E-181-2014-0-US-06 Virus-Based Expression Vectors and Use Thereof National Stage US 10,894,966 15/514,119 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10894966 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10894966">10,894,966</a><br />Filed on 2017-03-24<br />Status: Issued 114126723 VJXXXX 114126724 VKXXXX 114126725 VLXXXX 114126726 VOXXXX 114126727 WAXXXX 114126728 WIXXXX 114126729 WNXXXX 114126730 XEXXXX 114126731 YAXXXX 114126732 YBXXXX 114126733 YFXXXX 114147969 Non-Replicating 114147970 vaccinia 114147971 virus 114147972 Expression 114147973 System 114147974 LOW 114147975 Vector 114147976 GENES 114147977 High 114147978 TARGET 114147979 Gene TAB-2174 114096390 Prevention and Treatment of Herpes Virus Infection by Inhibition of the JMJD2 Family of Histone Demethylases NIAID Collaboration, Infectious Disease, Licensing, Therapeutics Collaboration Infectious Disease Licensing Therapeutics Jesse Arbuckle, Thomas Kristie, Yu Liang, Jodi Vogel Investigators at the NIH have discovered a potential means for preventing or treating a herpes virus infection by inhibiting the activity of the host cell’s histone demethylases. When herpesviruses enter a cell, they are inactivated by cellular defense mechanisms that wrap the viral genome in repressive chromatin structures. In order for viral replication to progress, the host’s own histone demethylases are recruited to the viral genome to reverse this repression. In a preceding invention, the laboratory disclosed that viral replication and reactivation can be significantly reduced through inhibition of the histone demethylase LSD1 using Mono-Amino Oxidase Inhibitors (MAOIs); drugs that are in clinical use. The current invention further discloses that inhibition of a second set of histone demethylases (JMJD2 family) using a specific JMJD2 inhibitor, dimethyloxaloylglycine (DMOG), also results in significant repression of herpes viral replication.<br /><br /> Either alone or in combination, small molecule inhibition of LSD1 and the JMJD2 family present novel approaches for preventing herpes virus infection and halting viral reactivation that can lead to a disease that ranges from mild core sores to herpesvirus keratitis and life threatening encephalitis. Additionally, chromatin-mediated repression of viral genomes and the requirement to de-repress these genomes for productive infection appears to be general to herpesviruses. Therefore, this treatment could also be applicable to chicken pox, shingles, CMV disease, mononucleosis, and Kaposi's sarcoma. Inhibition of histone demethylases provides an alternative pathway for repressing herpes virus infection as compared to purine analog antivirals. While purine analogs are the most widely prescribed treatment for herpes infection, drug resistance is prevalent. Additionally, inhibition of histone demethylases results in no expression of viral gene products; in contrast to DNA replication inhibitors. Prevention or treatment of infection by herpes simplex virus and other diseases caused by herpesviruses (i.e. Epstein-Barr virus, cytomegalovirus, varicella zoster, and Kaposi's sarcoma-associated herpesvirus) The NIAID Laboratory of Viral Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize prevention and treatment of viral diseases. Please contact Thomas Kristie, Ph.D. at 301.496.3854 or <a href="mailto:tkristie@niaid.nih.gov">tkristie@niaid.nih.gov</a> for more information. Available for licensing. 2022-03-08 2025-05-12 2025-05-12 2010-10-12 Analogs, Chicken pox, CYTOMEGALOVIRUS, DB4XXX, DBXXXX, DEPLETION, Dimethyloxalylglycine, DMOG, DXXXXX, ENZYMES, Ester, FAMILY, HERPES, INFECTIONS, Inhibitors, JMJD, Kaposi Sarcoma, Kaposi's sarcoma; Kaposi sarcoma, Latency, Methyl, N-methoxyoxoacetyl-glycine, Patent Category - Chemistry, Prevent, Reactivation, simplex, Varicella Zoster, virus False True <ul> <li>Early-stage development</li> <li>Pre-clinical data available for mice</li> <li>Further pre-clinical and clinical development is needed</li> </ul> True NIHTT 37470483 Website Abstract E-275-2008-2 114171182 None related to this invention available at this time. None related to this invention available at this time. 114108980 Liang, Yu NIAID - DIR Liang, Yu 0 114108981 Vogel, Jodi NIAID - DIR NIAID Vogel, Jodi (NIAID) 0 114108982 Arbuckle, Jesse NIAID Arbuckle, Jesse (NIAID) 0 114107012 Kristie, Thomas NIAID - DIR NIAID Kristie, Thomas (NIAID) 1 114107012 Kristie, Thomas NIAID - DIR NIAID Kristie, Thomas (NIAID) 1 114108980 Liang, Yu NIAID - DIR Liang, Yu 0 114108981 Vogel, Jodi NIAID - DIR NIAID Vogel, Jodi (NIAID) 0 114108982 Arbuckle, Jesse NIAID Arbuckle, Jesse (NIAID) 0 114101475 Use Of Dimethyloxalylglycine (N-methoxyoxoacetyl-glycine Methyl Ester, "DMOG") And Analogs As Inhibitors For Depletion Of The JMJD Family Of Enzymes To Prevent Herpes Simplex Virus Infections And Reactivation From Latency E-184-2010-0 Filing authorized NIAID 114102253 Use Of Dimethyloxalylglycine (N-methoxyoxoacetyl-glycine Methyl Ester, "DMOG") And Analogs As Inhibitors For Depletion Of The JMJD Family Of Enzymes To Prevent Herpes Simplex Virus Infections And Reactivation From Latency E-184-2010-1 Filing authorized NIAID 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2174] Prevention and Treatment of Herpes Virus Infection by Inhibition of the JMJD2 Family of Histone Demethylases&body=Please send me information about technology [TAB-2174] Prevention and Treatment of Herpes Virus Infection by Inhibition of the JMJD2 Family of Histone Demethylases. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2174] Prevention and Treatment of Herpes Virus Infection by Inhibition of the JMJD2 Family of Histone Demethylases&body=Please send me information about technology [TAB-2174] Prevention and Treatment of Herpes Virus Infection by Inhibition of the JMJD2 Family of Histone Demethylases.">jonathan.motley@nih.gov</a><br> 114166196 E-184-2010-0 E-184-2010-0-US-01 Use Of Dimethyloxalylglycine (N-methoxyoxoacetyl-glycine Methyl Ester, "DMOG") And Analogs As Inhibitors For Depletion Of The JMJD Family Of Enzymes To Prevent Herpes Simplex Virus Infections And Reactivation From Latency PRV US 61/366,563 Abandoned US <br />Provisional (PRV) 61/366,563<br />Filed on 2010-07-22<br />Status: Abandoned 114166481 E-184-2010-0 E-184-2010-0-PCT-02 METHOD OF PREVENTING OR TREATING VIRAL INFECTION PCT Patent Cooperation Treaty PCT/US2011/044835 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2011/044835<br />Filed on 2011-07-21<br />Status: Expired 114166988 E-184-2010-1 E-184-2010-1-US-01 Method Of Preventing Or Treating Viral Infection CIP US 8,871,789 13/747,406 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8871789 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8871789">8,871,789</a><br />Filed on 2013-01-22<br />Status: Abandoned 114121627 DB4XXX 114121628 DXXXXX 114121629 DBXXXX 114140583 Dimethyloxalylglycine 114140584 N-methoxyoxoacetyl-glycine 114140585 Methyl 114140586 Ester 114140587 DMOG 114140588 Analogs 114140589 Inhibitors 114140590 DEPLETION 114140591 JMJD 114140592 FAMILY 114140593 ENZYMES 114140594 Prevent 114140595 HERPES 114140596 simplex 114140597 virus 114140598 INFECTIONS 114140599 Reactivation 114140600 Latency 114140601 Patent Category - Chemistry 114157164 Varicella Zoster 114157165 Kaposi Sarcoma 114157166 CYTOMEGALOVIRUS 114157167 Chicken pox 114158678 Kaposi's sarcoma; Kaposi sarcoma TAB-2149 114096367 Method of Producing Immortalized Primary Human Keratinocytes for HPV Investigation, Testing of Therapeutics, and Skin Graft Generation NIAID Collaboration, Dermatology, Diagnostics, Infectious Disease, Oncology, Research Materials, Therapeutics Collaboration Dermatology Diagnostics Infectious Disease Oncology Research Materials Therapeutics Sandra Chapman, Alison McBride, Atsushi Terunuma, Jonathan Vogel One of the major limitations of using cultured keratinocytes for research studies is that primary keratinocytes senesce after a few passages. Keratinocytes from specific anatomical sites are also difficult to culture. Scientists at the NIH have demonstrated that primary keratinocytes, from several anatomical sites, when treated with a small-molecule inhibitor of the ROCK protein maintain a proliferative state and become immortal without genetic modification to the cells. Keratinocytes are also the host cells for human papillomaviruses (HPVs) and other viruses and this technology enables the study of those viruses that do not immortalize cells. In addition, this technology may enhance the quantity of material available for skin grafts, as current grafting techniques are limited by the amount of donor material immediately available. Thus, this technology may provide an ideal model environment for producing large quantities of both normal and diseased primary human keratinocytes from small numbers of primary cells from individual hosts or anatomical sites for research purposes, testing of therapeutics, skin graft generation and HPV investigation. <ul> <li>Allows culture and immortalization of many types of keratinocytes that are difficult to establish and pass in culture.</li> <li>Allows isolation of diseased and normal keratinocytes from individual hosts for research and therapeutic purposes.</li> <li>Current HPV investigations are limited by keratinocyte senescence.</li> <li>Skin graft generation is currently dependent on slow culture of limited quantities of donor material.</li> </ul> <ul> <li>Promotion of sustained primary human keratinocyte proliferation <i>in vitro</i>.</li> <li>Human skin graft cultures and techniques.</li> <li>Immortalization of both normal and diseased cells from individual hosts.</li> <li>Immortalization of "difficult to establish" keratinocytes from different anatomical sites.</li> <li><i>In vitro</i> assay for investigating the full life cycle of HPV.</li> <li><i>In vitro</i> screen for HPV inhibitors.</li> </ul> The National Institute of Allergy and Infectious Diseases, Laboratory of Viral Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize methods of producing immortalized primary human keratinocytes. Please contact the NIAID Technology Transfer and Intellectual Property Office at 301-496-2644 for more information. 2022-03-08 2025-05-12 2025-05-12 2010-08-23 AC4XXX, ACXXXX, AXXXXX, CC3XXX, CCXXXX, Complete, CXXXXX, DDXXXX, DXXXXX, EXTENDED, grafting, Human, IB2BXX, IB2XXX, IBXXXX, inhibitor, IXXXXX, KERATINOCYTES, Keratinocytes., Life-cycle, LONG-TERM, Maintenance, Papillomaviruses., Patent Category - Biotechnology, Persistence, Primary, PROLIFERATIVE, REPLICATION, ROCK, RXXXXX, SKIN, STATE, Studies., Sustain, Y-27632 False True Early-stage True NIHTT 37470483 Website Abstract 114171136 Chapman S, et al. http://www.ncbi.nlm.nih.gov/pubmed/20516646 <a href="http://www.ncbi.nlm.nih.gov/pubmed/20516646">Chapman S, et al.</a> 114105636 Chapman, Sandra NIAID - DIR Chapman, Sandra 0 114106953 Vogel, Jonathan NCI - CCR NCI Vogel, Jonathan (NCI) 0 114106954 Terunuma, Atsushi NCI - CCR Terunuma, Atsushi 0 114105637 McBride, Alison NIAID - DIR NIAID McBride, Alison (NIAID) 1 114105637 McBride, Alison NIAID - DIR NIAID McBride, Alison (NIAID) 1 114105636 Chapman, Sandra NIAID - DIR Chapman, Sandra 0 114106953 Vogel, Jonathan NCI - CCR NCI Vogel, Jonathan (NCI) 0 114106954 Terunuma, Atsushi NCI - CCR Terunuma, Atsushi 0 114101450 Use Of The ROCK Inhibitor, Y-27632, To Sustain Primary Human Keratinocytes In A Proliferative State To Study Long-term Replication, The Persistence And The Complete Life-cycle Of Papillomaviruses. Maintenance Of Primary Human Keratinocytes. In An E E-055-2009-0 Filing authorized NCI, NIAID 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2149] Method of Producing Immortalized Primary Human Keratinocytes for HPV Investigation, Testing of Therapeutics, and Skin Graft Generation&body=Please send me information about technology [TAB-2149] Method of Producing Immortalized Primary Human Keratinocytes for HPV Investigation, Testing of Therapeutics, and Skin Graft Generation. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2149] Method of Producing Immortalized Primary Human Keratinocytes for HPV Investigation, Testing of Therapeutics, and Skin Graft Generation&body=Please send me information about technology [TAB-2149] Method of Producing Immortalized Primary Human Keratinocytes for HPV Investigation, Testing of Therapeutics, and Skin Graft Generation.">jonathan.motley@nih.gov</a><br> 114165360 E-055-2009-0 E-055-2009-0-US-03 Use Of The ROCK Inhibitor to Sustain Primary Human Keratinocytes In A Proliferative State National Stage US 8,637,310 13/132,391 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8637310 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8637310">8,637,310</a><br />Filed on 2011-06-02<br />Status: Issued 114166131 E-055-2009-0 E-055-2009-0-PCT-02 USE OF A ROCK INHIBITOR TO SUSTAIN PRIMARY HUMAN KERATINOCYTES IN A PROLIFERATIVE STATE PCT Patent Cooperation Treaty PCT/US2009/066844 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2009/066844<br />Filed on 2009-12-04<br />Status: Expired 114166132 E-055-2009-0 E-055-2009-0-US-01 Use of a ROCK Inhibitor to Sustain Primary Human Keratinocytes in a Proliferative State PRV US 61/120,272 Abandoned US <br />Provisional (PRV) 61/120,272<br />Filed on 2008-12-05<br />Status: Abandoned 114121485 AC4XXX 114121486 CXXXXX 114121487 ACXXXX 114121488 AXXXXX 114121489 IB2BXX 114121490 CCXXXX 114121491 CC3XXX 114121492 DXXXXX 114121493 DDXXXX 114121494 RXXXXX 114121495 IXXXXX 114121496 IBXXXX 114121497 IB2XXX 114140340 Y-27632 114140341 inhibitor 114140342 ROCK 114140343 Sustain 114140344 Primary 114140345 Human 114140346 KERATINOCYTES 114140347 PROLIFERATIVE 114140348 STATE 114140349 LONG-TERM 114140350 REPLICATION 114140351 Persistence 114140352 Complete 114140353 Life-cycle 114140354 Papillomaviruses. 114140355 Maintenance 114140356 Keratinocytes. 114140357 EXTENDED 114140358 SKIN 114140359 grafting 114140360 Studies. 114140361 Patent Category - Biotechnology TAB-2068 114096285 Methods to Increase Stability of Recombinant Vaccinia-Vectored Vaccines and Increase Expression of a Foreign Gene Inserted in Such Vaccines NIAID Licensing, Therapeutics Licensing Therapeutics Patricia Earl, Bernard Moss, Linda Wyatt The technology offered for licensing is in the field of vaccinia-based recombinant vaccines. In particular the invention relates to methods of stabilizing the recombinant virus, thus resulting in efficient production of the vaccine and efficient expression of the inserted gene. Stabilization of the recombinant virus is achieved by the insertion of the exogenous gene into an intergenic region (IGR) of the viral genome (i.e. Modified Vaccinia Ankara, MVA), where the IGR is flanked by open reading frames of conserved poxvirus genes. Furthermore, the invention relates to plasmids vectors useful to insert the exogenous DNA into the genome of a vaccinia virus. Stability can be further enhanced by incorporating silent mutations that decrease the lengths of homopolynucleotide runs in the foreign gene. <ul> <li>Enhancing stability of foreign genes in vaccinia-vectored constructs</li> <li>Increasing efficiency of vaccine production and gene expression</li> </ul> <ul> <li>Efficient production of vaccinia-vectored vaccines for infectious diseases and other diseases such as cancer</li> <li>Efficient production of therapeutic proteins from vaccinia-vectored exogenous genes</li> </ul> 2022-03-08 2025-05-12 2025-05-12 2010-03-01 ANKARA, Del, Expression, Fied, Foreign, GB1DXX, GB1XXX, GBXXXX, Gene, GENES, GXXXXX, INCREASE, Insertion, LIl, Modi, Modified, MVA, Patent Category - Biotechnology, PLASMID, SHUTTLE, SITE, STABILITY, vaccinia, Vector, virus False True The invention is fully developed. True NIHTT 37470483 Website Abstract E-248-2006-0 E-552-1982-2 114171017 Wyatt LS, et al. http://www.ncbi.nlm.nih.gov/pubmed/19420086 <a href="http://www.ncbi.nlm.nih.gov/pubmed/19420086">Wyatt LS, et al.</a> 114107141 Earl, Patricia NIAID - DIR NIAID Earl, Patricia (NIAID) 0 114109081 Wyatt, Linda NIAID - DIR NIAID Wyatt, Linda (NIAID) 0 114106824 Moss, Bernard NIAID - DIR NIAID Moss, Bernard (NIAID) 1 114106824 Moss, Bernard NIAID - DIR NIAID Moss, Bernard (NIAID) 1 114107141 Earl, Patricia NIAID - DIR NIAID Earl, Patricia (NIAID) 0 114109081 Wyatt, Linda NIAID - DIR NIAID Wyatt, Linda (NIAID) 0 114101357 Plasmid Shuttle Vector For Insertion Of Foreign Genes Into Del LIl Site Of ModiFied Vaccinia Virus Ankara (MVA) To Increase Stability Of Foreign Gene Expression In This Site E-018-2010-0 Filing authorized NIAID 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2068] Methods to Increase Stability of Recombinant Vaccinia-Vectored Vaccines and Increase Expression of a Foreign Gene Inserted in Such Vaccines&body=Please send me information about technology [TAB-2068] Methods to Increase Stability of Recombinant Vaccinia-Vectored Vaccines and Increase Expression of a Foreign Gene Inserted in Such Vaccines. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2068] Methods to Increase Stability of Recombinant Vaccinia-Vectored Vaccines and Increase Expression of a Foreign Gene Inserted in Such Vaccines&body=Please send me information about technology [TAB-2068] Methods to Increase Stability of Recombinant Vaccinia-Vectored Vaccines and Increase Expression of a Foreign Gene Inserted in Such Vaccines.">jonathan.motley@nih.gov</a><br> 114161024 E-018-2010-0 E-018-2010-0-US-08 Recombinant Modified Vaccinia Ankara (MVA) Vaccinia Virus Containing Restructured Insertion Sites National Stage US 9,133,480 13/502,205 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9133480 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9133480">9,133,480</a><br />Filed on 2012-07-02<br />Status: Issued 114165755 E-018-2010-0 E-018-2010-0-US-01 Plasmid Shuttle Vector For Insertion Of Foreign Genes Into Del LIl Site Of Modi Fied Vaccinia Virus Ankara (MVA) To Increase Stability Of Foreign Gene Expression In This Site PRV US 61/252,326 Abandoned US <br />Provisional (PRV) 61/252,326<br />Filed on 2009-10-16<br />Status: Abandoned 114166221 E-018-2010-0 E-018-2010-0-PCT-02 Recombinant Modified Vaccinia Virus Ankara (MVA) Vaccinia Virus Containing Restructures Insertion Sites PCT Patent Cooperation Treaty PCT/US2010/052929 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2010/052929<br />Filed on 2010-10-15<br />Status: Expired 114168198 E-018-2010-0 E-018-2010-0-US-10 Recombinant Modified Vaccina Ankara (MVA) Vaccina Virus Containing Restructured Insertion Sites DIV US 9,879,231 14/837,382 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9879231 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9879231">9,879,231</a><br />Filed on 2015-08-27<br />Status: Issued 114120906 GB1DXX 114120907 GXXXXX 114120908 GBXXXX 114120909 GB1XXX 114139318 PLASMID 114139319 SHUTTLE 114139320 Vector 114139321 Insertion 114139322 Foreign 114139323 GENES 114139324 Del 114139325 LIl 114139326 SITE 114139327 Modi 114139328 Fied 114139329 vaccinia 114139330 virus 114139331 ANKARA 114139332 MVA 114139333 INCREASE 114139334 STABILITY 114139335 Gene 114139336 Expression 114139337 Patent Category - Biotechnology 114139338 Modified TAB-2023 114096243 Biological/Research Material for HIV Vaccine Research NIAID Infectious Disease, Licensing, Vaccines Infectious Disease Licensing Vaccines Bernard Moss, Linda Wyatt Offered for licensing is a recombinant attenuated vaccinia virus, MVA, that expresses SIV 239gagpol. The materials can be used for research purposes and in particular in the area of HIV/AIDS vaccines.<br /><br /> Plasmid insertion vector pJH-4, containing the foreign gene SIV 239 GagPol controlled by vaccinia early/late promoter, inserts into del III of attenuated vaccinia MVA virus to make recombinant MVA virus. The resulting recombinant virus made from pJH4, MVA/SIV239gagpol, expresses the SIV 239gagpol gene and thus can be used to conduct vaccine studies in animal models such as Rhesus macaques.<br /><br /> The list of publications shown below demonstrates the usefulness of this biological material in HIV vaccine research. <ul> <li>Research reagents useful in research and development in the area of HIV/AIDS vaccines.</li> </ul> Research Material - Patent protection is not being pursued for this technology. 2022-03-08 2025-05-12 2025-05-12 2009-10-12 239gagpol, ACXXXX, AXXXXX, DC5XXX, DCXXXX, DXXXXX, EXPRESSES, Gene, MVA/SIV239gagpol, MVNSIV239gagpoi, PJH4, recombinant, RESEARCH MATERIAL, SIV, SIV239gagpol, That, virus False True Fully developed. Material has been used extensively in research. True NIHTT 37470483 Website Abstract E-552-1982-2 114170940 Amara RR, et al. http://www.ncbi.nlm.nih.gov/pubmed/11393868 <a href="http://www.ncbi.nlm.nih.gov/pubmed/11393868">Amara RR, et al.</a> 114170941 Earl PL, et al. http://www.ncbi.nlm.nih.gov/pubmed/12009868 <a href="http://www.ncbi.nlm.nih.gov/pubmed/12009868">Earl PL, et al.</a> 114170942 Amara RR, et al. http://www.ncbi.nlm.nih.gov/pubmed/12021347 <a href="http://www.ncbi.nlm.nih.gov/pubmed/12021347">Amara RR, et al.</a> 114170943 Amara RR, et al. http://www.ncbi.nlm.nih.gov/pubmed/12097576 <a href="http://www.ncbi.nlm.nih.gov/pubmed/12097576">Amara RR, et al.</a> 114170944 Sadagopal S, et al. http://www.ncbi.nlm.nih.gov/pubmed/15731219 <a href="http://www.ncbi.nlm.nih.gov/pubmed/15731219">Sadagopal S, et al.</a> 114106756 Wyatt, Linda NIAID - DIR NIAID Wyatt, Linda (NIAID) 0 114106757 Moss, Bernard NIAID - DIR NIAID Moss, Bernard (NIAID) 1 114106757 Moss, Bernard NIAID - DIR NIAID Moss, Bernard (NIAID) 1 114106756 Wyatt, Linda NIAID - DIR NIAID Wyatt, Linda (NIAID) 0 114101315 A Recombinant Virus Made From PJH4, MVA/SIV239gagpol That Expresses The SIV 239gagpol Gene E-258-2009-0 Closed NIAID 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2023] Biological/Research Material for HIV Vaccine Research&body=Please send me information about technology [TAB-2023] Biological/Research Material for HIV Vaccine Research. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2023] Biological/Research Material for HIV Vaccine Research&body=Please send me information about technology [TAB-2023] Biological/Research Material for HIV Vaccine Research.">jonathan.motley@nih.gov</a><br> 114120648 ACXXXX 114120649 DC5XXX 114120650 AXXXXX 114120651 DXXXXX 114120652 DCXXXX 114138807 recombinant 114138808 virus 114138809 PJH4 114138810 MVNSIV239gagpoi 114138811 That 114138812 EXPRESSES 114138813 SIV239gagpol 114138814 Gene 114138815 SIV 114138816 239gagpol 114138817 MVA/SIV239gagpol 114138818 RESEARCH MATERIAL TAB-2022 114096242 Biological/Research Material for H1N1 Influenza Virus Vaccine Research NIAID Infectious Disease, Licensing, Research Materials, Vaccines Infectious Disease Licensing Research Materials Vaccines Bernard Moss, Linda Wyatt Offered for licensing is a recombinant attenuated vaccinia virus, MVA, that expresses the haemagglutinin (HA) and nucleoprotein (NP) of influenza virus A/PR/8/34 (H1N1). The virus has been shown to stimulate protective immunity to influenza virus in mice.<br /><br /> The materials can be used for research purposes and in particular in the area of influenza virus vaccines.<br /><br /> The related publications listed below demonstrate the usefulness of this biological material in influenza virus vaccine research. <ul> <li>Research reagents useful in research and development in the area of H1N1 Influenza virus vaccines.</li> </ul> Research Material - Patent protection is not being pursued for this technology. 2022-03-08 2025-05-12 2025-05-12 2009-10-12 A/PR/8/34, Attenuated, AXXXXX, DCXXXX, DDXXXX, DXXXXX, EXPRESSES, H1N1, Ha, Haemagglutinin, INFLUENZA, MVA, Np, NUCLEOPROTEIN, RESEARCH MATERIAL, That, vaccinia, virus False True Fully developed. The usefulness of the materials has been shown in Dr. Moss' laboratory. True NIHTT 37470483 Website Abstract E-552-1982-2 114170938 Sutter G, et al. http://www.ncbi.nlm.nih.gov/pubmed/7975844 <a href="http://www.ncbi.nlm.nih.gov/pubmed/7975844">Sutter G, et al.</a> 114170939 Bender B, et al. http://www.ncbi.nlm.nih.gov/pubmed/8709274 <a href="http://www.ncbi.nlm.nih.gov/pubmed/8709274">Bender B, et al.</a> 114106758 Wyatt, Linda NIAID - DIR NIAID Wyatt, Linda (NIAID) 0 114106759 Moss, Bernard NIAID - DIR NIAID Moss, Bernard (NIAID) 1 114106759 Moss, Bernard NIAID - DIR NIAID Moss, Bernard (NIAID) 1 114106758 Wyatt, Linda NIAID - DIR NIAID Wyatt, Linda (NIAID) 0 114101314 An Attenuated Vaccinia Virus, MVA, That Expresses The Haemagglutinin (HA) And Nucleoprotein (NP) Of Influenza Virus A/PR/8/34 (H1N1) E-260-2009-0 Research Material NIAID 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2022] Biological/Research Material for H1N1 Influenza Virus Vaccine Research&body=Please send me information about technology [TAB-2022] Biological/Research Material for H1N1 Influenza Virus Vaccine Research. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2022] Biological/Research Material for H1N1 Influenza Virus Vaccine Research&body=Please send me information about technology [TAB-2022] Biological/Research Material for H1N1 Influenza Virus Vaccine Research.">jonathan.motley@nih.gov</a><br> 114120644 AXXXXX 114120645 DCXXXX 114120646 DDXXXX 114120647 DXXXXX 114138793 Attenuated 114138794 vaccinia 114138795 virus 114138796 MVA 114138797 That 114138798 EXPRESSES 114138799 Haemagglutinin 114138800 Ha 114138801 NUCLEOPROTEIN 114138802 Np 114138803 INFLUENZA 114138804 A/PR/8/34 114138805 H1N1 114138806 RESEARCH MATERIAL TAB-2000 114096220 Recombinant Vaccines Based on Poxvirus Vectors NIAID Consumer Products, Infectious Disease, Licensing, Vaccines Consumer Products Infectious Disease Licensing Vaccines Bernard Moss The technology offered for licensing is foundational in the area of recombinant DNA vaccines. In the last several years, facilitated through a licensing program of the NIH, the technology has been broadly applied in the development and commercialization of several novel human and veterinary vaccines in the areas of infectious disease as well as cancer therapeutics. The NIH wishes to expand its licensing program of the subject technology in a variety of applications that will benefit public health.<br /><br /> Briefly, the technology describes and claims methods of constructing recombinant vaccines utilizing any recombinant poxvirus, and in particular vaccinia virus (i.e. Modified Vaccinia Ankara or other strains) as a backbone that carries a foreign DNA. The foreign DNA can be related to a viral pathogen for example, or to a tumor-associated antigen. Upon administration of the recombinant virus to a human or animal subject, the foreign gene is expressed in vivo to elicit an immune response against the respective pathogen or the respective tumor.<br /><br /> The technology takes advantage of the unique properties of poxviruses as a delivering vehicle and of the ease of preparation of such constructs.<br /><br /> The applications of this technology have been extensively covered by many publications, including more than 100 publications from the inventor (see sampling below). The publications cover a wide variety of vaccines such as HIV, papilloma virus, influenza and others.<br /><br /> Note: Samples of plasmids and vaccinia virus used in the invention are deposited in the American Type Culture Collection and in the NIH and may be available for licensees upon request. Recombinant Poxviruses vectors in DNA vaccines have exhibited some advantages as compared to other viral vectors such as adenovirus, retrovirus or papillomavirus: <ul> <li>High safety profile</li> <li>Wide host range</li> <li>Ability to accommodate large amounts of foreign DNA including multiple genes</li> <li>No loss of infectivity upon insertion of foreign DNA</li> <li>Unique transcriptional regulatory signals of the virus facilitates flexibility in genome strategy</li> </ul> In addition, the following properties have been demonstrated: <ul> <li>Immunization with vaccinia-vectored vaccines provides long-lasting protection</li> <li>Vaccinia virus is very stable and no cold-chain is required in distribution network</li> <li>Induce mucosal immune response</li> <li>Induce humeral and cellular immunity</li> </ul> <ul> <li>Prophylactic and/or therapeutic vaccines</li> <li>Infectious disease and cancer</li> <li>Human and animal vaccines</li> <li>Immunotherapy</li> <li>Protein expression system</li> </ul> 2022-03-08 2025-05-12 2025-05-12 2009-08-11 B, BBXXXX, BCXXXX, DC5BXX, DC5XXX, DCXXXX, Duke DNA Project, Hepatitis, INFLUENZA, POX VIRUS, rabies, recombinant, vaccines, vaccinia, virus, VLXXXX, VOXXXX, WNXXXX, XKXXXX False True Fully developed. The technology has been already successfully implemented in commercial veterinary vaccines (i.e. rabies) and is in advance clinical trials in several companies in the area of cancer immunotherapy. True 52398218 Pre-Clinical (in vivo) 52398218 NIHTT 37470483 Website Abstract 114170899 Moss B and Earl PL. http://www.ncbi.nlm.nih.gov/pubmed/18265301 <a href="http://www.ncbi.nlm.nih.gov/pubmed/18265301">Moss B and Earl PL.</a> 114170900 Robinson HL, et al. http://www.ncbi.nlm.nih.gov/pubmed/18160013 <a href="http://www.ncbi.nlm.nih.gov/pubmed/18160013">Robinson HL, et al.</a> 114170901 Wyatt LS, et al. http://www.ncbi.nlm.nih.gov/pubmed/18155813 <a href="http://www.ncbi.nlm.nih.gov/pubmed/18155813">Wyatt LS, et al.</a> 114170902 Hebben M, et al. http://www.ncbi.nlm.nih.gov/pubmed/17892951 <a href="http://www.ncbi.nlm.nih.gov/pubmed/17892951">Hebben M, et al.</a> 114106715 Moss, Bernard NIAID Moss, Bernard (NIAID) 1 114106715 Moss, Bernard NIAID Moss, Bernard (NIAID) 1 114101283 Recombinant Vaccines for Influenza and Hepatitis B Virus E-552-1982-2 Filing authorized NIAID 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2000] Recombinant Vaccines Based on Poxvirus Vectors&body=Please send me information about technology [TAB-2000] Recombinant Vaccines Based on Poxvirus Vectors. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2000] Recombinant Vaccines Based on Poxvirus Vectors&body=Please send me information about technology [TAB-2000] Recombinant Vaccines Based on Poxvirus Vectors.">jonathan.motley@nih.gov</a><br> 114160310 E-552-1982-2 E-552-1982-2-US-03 RECOMBINANT VACCINIA VIRUS CONTAINING A CHIMERIC GENE HAVING FOREIGN DNA FLANKED BY VACCINIA REGULATORY DNA FWC US 7,045,313 07/987,546 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7045313 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7045313">7,045,313</a><br />Filed on 1992-12-07<br />Status: Expired 114165435 E-552-1982-2 E-552-1982-2-US-04 COMPOSITIONS CONTAINING RECOMBINANT POXVIRUSES HAVING FOREIGN DNA EXPRESSED UNDER THE CONTROL OF POXVIRUS REGULATORY SEQUENCES DIV US 7,015,024 08/470,357 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7015024 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7015024">7,015,024</a><br />Filed on 1995-06-06<br />Status: Expired 114165436 E-552-1982-2 E-552-1982-2-US-06 RECOMBINANT POXVIRUS HAVING FOREIGN DNA EXPRESSED UNDER THE CONTROL OF POXVIRUS REGULATORY SEQUENCES CON US 6,998,252 08/470,360 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6998252 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6998252">6,998,252</a><br />Filed on 1995-06-06<br />Status: Expired 114165437 E-552-1982-2 E-552-1982-2-US-05 Methods of Immunization Using Recombinant Poxviruses Having Foreign DNA Expressed Under The Control of Poxvirus Regulatory Sequences DIV US 7,045,136 08/470,359 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7045136 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7045136">7,045,136</a><br />Filed on 1995-06-06<br />Status: Expired 114165654 E-552-1982-2 E-552-1982-2-US-01 Recombinant Vaccines for Influenza and Hepatitis B Virus CIP US 06/555,811 Abandoned US <br />Continuation in Part (CIP) 06/555,811<br />Filed on 1983-11-28<br />Status: Abandoned 114165923 E-552-1982-2 E-552-1982-2-US-02 Recombinant Vaccinia Virus Containing a Chimeric Gene Having Foreign DNA Flanked by Vaccinia Regulatory DNA CON US 07/539,169 Abandoned US <br />Continuation (CON) 07/539,169<br />Filed on 1990-06-18<br />Status: Abandoned 114165926 E-552-1982-2 E-552-1982-2-PCT-07 PROCESS FOR PRODUCING POXVIRUS RECOMBINANTS FOR EXPRESSION OF FOREIGN GEN-ES PCT COMB Patent Cooperation Treaty PCT/US1983/001863 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US1983/001863<br />Filed on 1983-11-28<br />Status: Expired 114120531 DCXXXX 114120532 DC5XXX 114120533 DC5BXX 114121220 BBXXXX 114121308 BCXXXX 114127150 VLXXXX 114127151 VOXXXX 114127152 WNXXXX 114127153 XKXXXX 114138458 vaccinia 114138459 POX VIRUS 114138460 recombinant 114138461 vaccines 114138462 INFLUENZA 114138463 Hepatitis 114138464 B 114138465 virus 114138466 Duke DNA Project 114156871 rabies TAB-1720 114095948 HIV Monoclonal Antibodies NIAID Collaboration, Infectious Disease, Research Materials Collaboration Infectious Disease Research Materials Christopher Broder, Robert Doms, Patricia Earl, Bernard Moss This technology describes several hybridomas that produce monoclonal antibodies (mAbs) useful in HIV research applications. The mAbs are specific for either gp41 or gp120. In particular, the hybridomas producing mAbs designated D19, D56, M12, T8 and T24 (all anti-gp120), and T32 and T33 (gp41 specific) were found to be of particular utility. Additional hybridomas expressing mAbs disclosed in the publications may also be available. <ul> <li>HIV research</li> </ul> The National Institute of Allergy and Infectious Dieases, Laboratory of Viral Diseases, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize HIV Monoclonal Antibodies. Please contact either Michael Pizali or Dana Hsu at 301-496-2644 for more information. Research Tool (anti-gp41mAbs) -- Patent protection is not being pursued for this technology. 2022-03-08 2025-05-12 2025-05-12 2008-03-01 597-613, Anti-gp41, DDXXXX, DXXXXX, mabs, T32, T33, T40, VLXXXX, WIXXXX False True <ul> <li>Murine hybridomas available</li> <li>T32 mAb available</li> </ul> <ul> <li>Murine hybridomas available</li> <li>T32 mAb available</li> </ul> True NIHTT 37470483 Website Abstract E-200-1993-1 114170464 Earl PL, et al https://www.ncbi.nlm.nih.gov/pubmed/9060620 <a href="https://www.ncbi.nlm.nih.gov/pubmed/9060620">Earl PL, et al</a> 114170466 Earl PL, et al. https://www.ncbi.nlm.nih.gov/pubmed/7512157 <a href="https://www.ncbi.nlm.nih.gov/pubmed/7512157">Earl PL, et al.</a> 114170929 Earl PL, et al. https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6039957 <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6039957">Earl PL, et al.</a> 114171342 Earl PL, et al. https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6171596 <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6171596">Earl PL, et al.</a> 114105981 Earl, Patricia NIAID - DIR NIAID Earl, Patricia (NIAID) 0 114105983 Broder, Christopher NIAID Broder, Christopher (NIAID) 0 114105984 Doms, Robert NIAID Doms, Robert (NIAID) 0 114105982 Moss, Bernard NIAID - DIR NIAID Moss, Bernard (NIAID) 1 114105982 Moss, Bernard NIAID - DIR NIAID Moss, Bernard (NIAID) 1 114105981 Earl, Patricia NIAID - DIR NIAID Earl, Patricia (NIAID) 0 114105983 Broder, Christopher NIAID Broder, Christopher (NIAID) 0 114105984 Doms, Robert NIAID Doms, Robert (NIAID) 0 114100945 Anti-gp41 Mabs T32 (597-613), T33, And T40 E-109-2008-0 Closed NIAID 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-1720] HIV Monoclonal Antibodies&body=Please send me information about technology [TAB-1720] HIV Monoclonal Antibodies. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-1720] HIV Monoclonal Antibodies&body=Please send me information about technology [TAB-1720] HIV Monoclonal Antibodies.">jonathan.motley@nih.gov</a><br> 114118501 DDXXXX 114118502 DXXXXX 114122031 VLXXXX 114122032 WIXXXX 114131432 Anti-gp41 114131433 mabs 114131434 T32 114131435 597-613 114131436 T33 114131437 T40 TAB-1589 114095857 A Shuttle Plasmid, Recombinant MVA/HIV1 Clinical Vaccine Constructs and a Mechanism for Enhanced Stability of Foreign Gene Inserts by Codon Alternation and for Insertion of the Foreign Gene Between Two Vaccinia Virus Essential Genes NIAID Infectious Disease, Licensing, Research Materials, Vaccines Infectious Disease Licensing Research Materials Vaccines Patricia Earl, Bernard Moss, Linda Wyatt Since the onset of the AIDS epidemic more than two decades ago, enormous efforts have been directed to making a vaccine that will protect against human immunodeficiency virus-1 (HIV); an effective vaccine is thought to require the induction of cellular and humoral responses. Vaccine candidates have included a variety of HIV immunogens delivered as DNA, attenuated poxviruses, adenoviruses, vesicular stomatitis virus, proteins, and various combinations thereof. The inventors' efforts to design an HIV vaccine have focused on modified vaccinia virus Ankara (MVA) as a vector.<br /><br /> The patent application describes (1) the shuttle plasmid, pLW73, used for insertion of a foreign gene between two essential vaccinia virus genes (in this case, I8R, G1L), (2) an MVA/Ugandan Clade D (UGD) construct, and (3) an MVA/HIV 75 AG construct using pLW73 as a vector. Additionally, the invention provides two methods: (1) a method useful for large-scale production of recombinant vaccinia viruses, and (2) a method for stabilizing foreign gene inserts that undergo mutation after repeated passages, again useful in large-scale production of recombinant vaccinia viruses. <ul> <li>Immunization against HIV</li> </ul> 2022-03-08 2025-05-12 2025-05-12 2007-08-01 Alteration, Alternation, BETWEEN, Clinical, CODON, Constructs, DC5AXX, DC5XXX, DCXXXX, DDXXXX, DXXXXX, Enhanced, ESSENTIAL, Foreign, Gene, Genebetween, GENES, Hyper IgM syndrome, Immunodeficiency 2, Immunodeficiency 4, Immunodeficiency-3, Insertion, Inserts, Mechanism, MVA/HIV1, PLASMID, recombinant, Severe combined immunodeficiency, x-linked, SHUTTLE, STABILITY, TWO, Vaccine, vaccinia, virus, Wiskott Aldrich syndrome False True Vaccine candidates have been synthesized and preclinical studies have been performed. The vaccine candidates of this invention are slated to enter Phase I clinical trials in the next year. Vaccine candidates have been synthesized and preclinical studies have been performed. The vaccine candidates of this invention are slated to enter Phase I clinical trials in the next year. True NIHTT 37470483 Website Abstract 114105806 Earl, Patricia NIAID - DIR NIAID Earl, Patricia (NIAID) 0 114105807 Wyatt, Linda NIAID - DIR NIAID Wyatt, Linda (NIAID) 0 114105808 Moss, Bernard NIAID - DIR NIAID Moss, Bernard (NIAID) 1 114105808 Moss, Bernard NIAID - DIR NIAID Moss, Bernard (NIAID) 1 114105806 Earl, Patricia NIAID - DIR NIAID Earl, Patricia (NIAID) 0 114105807 Wyatt, Linda NIAID - DIR NIAID Wyatt, Linda (NIAID) 0 114100832 A Shuttle Plasmid, Recombinant MVA/HIV1 Clinical Vaccine Constructs And A Mechanism For Enhanced Stability Of Foreign Gene Inserts By Codon Alteration And For Insertion Of Foreign Gene Between Two Vaccinia Virus Essential Genes E-248-2006-0 Filing authorized NIAID 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-1589] A Shuttle Plasmid, Recombinant MVA/HIV1 Clinical Vaccine Constructs and a Mechanism for Enhanced Stability of Foreign Gene Inserts by Codon Alternation and for Insertion of the Foreign Gene Between Two Vaccinia Virus Essential Genes&body=Please send me information about technology [TAB-1589] A Shuttle Plasmid, Recombinant MVA/HIV1 Clinical Vaccine Constructs and a Mechanism for Enhanced Stability of Foreign Gene Inserts by Codon Alternation and for Insertion of the Foreign Gene Between Two Vaccinia Virus Essential Genes. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-1589] A Shuttle Plasmid, Recombinant MVA/HIV1 Clinical Vaccine Constructs and a Mechanism for Enhanced Stability of Foreign Gene Inserts by Codon Alternation and for Insertion of the Foreign Gene Between Two Vaccinia Virus Essential Genes&body=Please send me information about technology [TAB-1589] A Shuttle Plasmid, Recombinant MVA/HIV1 Clinical Vaccine Constructs and a Mechanism for Enhanced Stability of Foreign Gene Inserts by Codon Alternation and for Insertion of the Foreign Gene Between Two Vaccinia Virus Essential Genes.">jonathan.motley@nih.gov</a><br> 114160341 E-248-2006-0 E-248-2006-0-US-05 Modified Vaccinia Ankara (MVA) Virus Recombinants Comprising Heterologous Coding Sequences Inserted Into the Intergenic Regions Between Essential Genes National Stage US 9,133,478 12/377,847 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9133478 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9133478">9,133,478</a><br />Filed on 2010-02-17<br />Status: Issued 114163953 E-248-2006-0 E-248-2006-0-PCT-02 Intergenic Sites Between Conserved Genes In The Genome Of Modified Vaccinia Ankara (MVA) Vaccinia Virus PCT Patent Cooperation Treaty PCT/IB2007/004575 Expired Patent Cooperation Treaty <br />(PCT) PCT/IB2007/004575<br />Filed on 2007-08-24<br />Status: Expired 114163954 E-248-2006-0 E-248-2006-0-US-01 A Shuttle Plasmid, Recombinant MVA/HIV1 Clinical Vaccine Constructs And A Mechanism For Enhanced Stability Of Foreign Gene Inserts By Codon Alteration And For Insertion Of Foreign Gene between Two Vaccinia Virus Essential Genes PRV US 60/840,093 Abandoned US <br />Provisional (PRV) 60/840,093<br />Filed on 2006-08-25<br />Status: Abandoned 114168197 E-248-2006-0 E-248-2006-0-US-19 Intergenic Sites Between Conserved Genes in the Genome of Modified Vaccinia Ankara (MVA) Vaccinia Virus DIV US 10,421,978 14/833,913 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10421978 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10421978">10,421,978</a><br />Filed on 2015-08-24<br />Status: Issued 114168924 E-248-2006-0 E-248-2006-0-US-26 INTERGENIC SITES BETWEEN CONSERVED GENES IN THE GENOME OF MODIFIED VACCINIA ANKARA (MVA) VACCINIA VIRUS DIV US 16/579,276 Abandoned US <br />Divisional (DIV) 16/579,276<br />Filed on 2019-09-23<br />Status: Abandoned 114118046 DC5AXX 114118047 DDXXXX 114118048 DCXXXX 114118049 DXXXXX 114119680 DC5XXX 114135566 SHUTTLE 114135567 PLASMID 114135568 recombinant 114135569 MVA/HIV1 114135570 Clinical 114135571 Vaccine 114135572 Constructs 114135573 Mechanism 114135574 Enhanced 114135575 STABILITY 114135576 Foreign 114135577 Gene 114135578 Inserts 114135579 CODON 114135580 Alternation 114135581 Insertion 114135582 Genebetween 114135583 TWO 114135584 vaccinia 114135585 virus 114135586 ESSENTIAL 114135587 GENES 114135588 Alteration 114135589 BETWEEN 114156350 Severe combined immunodeficiency, x-linked 114156351 Hyper IgM syndrome 114156352 Wiskott Aldrich syndrome 114158278 Immunodeficiency 4 114158279 Immunodeficiency-3 114158280 Immunodeficiency 2 TAB-1185 114095511 Transmission-Blocking Vaccine Against Malaria (1) NIAID Infectious Disease, Licensing, Vaccines Infectious Disease Licensing Vaccines David Kaslow A transmission blocking vaccine developed against malaria contains a recombinant virus, which encodes a unique portion of the sexual stage surface antigen of <i>Plasmodium falciparum</i> (referred to as Pfs25), or the Pfs25 protein purified from infected host cells. Mice inoculated with the recombinant virus developed antibodies capable of blocking transmission of the virus. None of the monoclonal antibodies known to block transmission recognize the reduced Pfs25 antigen. This vaccine, which induces high, long-lasting titers at low cost, can be useful for controlling malaria. 2022-03-08 2025-05-12 2025-05-12 1995-05-01 DC2XXX, DCXXXX, DXXXXX, Malaria, Malaria (Plasmodium sp.) False True True NIHTT 37470483 Website Abstract 114105198 Kaslow, David Kaslow, David 0 114105198 Kaslow, David Kaslow, David 0 114100409 TRANSMISSION BLOCKING VACCINE AGAINST MALARIA E-035-1991-0 NIAID 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-1185] Transmission-Blocking Vaccine Against Malaria (1)&body=Please send me information about technology [TAB-1185] Transmission-Blocking Vaccine Against Malaria (1). Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-1185] Transmission-Blocking Vaccine Against Malaria (1)&body=Please send me information about technology [TAB-1185] Transmission-Blocking Vaccine Against Malaria (1).">jonathan.motley@nih.gov</a><br> 114162704 E-035-1991-0 E-035-1991-0-US-01 TRANSMISSION BLOCKING VACCINE AGAINST MALARIA CIP US 07/658,845 Abandoned US <br />Continuation in Part (CIP) 07/658,845<br />Filed on 1991-02-22<br />Status: Abandoned 114162959 E-035-1991-0 E-035-1991-0-US-04 TRANSMISSION BLOCKING VACCINE AGAINST MALARIA FWC US 6,780,417 08/400,421 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6780417 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6780417">6,780,417</a><br />Filed on 1995-03-02<br />Status: Expired 114164747 E-035-1991-0 E-035-1991-0-PCT-05 TRANSMISSION BLOCKING VACCINE AGAINST MALARIA PCT Patent Cooperation Treaty PCT/US1992/001124 Abandoned Patent Cooperation Treaty <br />(PCT) PCT/US1992/001124<br />Filed on 1992-02-21<br />Status: Abandoned 114165876 E-035-1991-0 E-035-1991-0-US-02 TRANSMISSION-BLOCKING VACCINE AGAINST MALARIA FWC US 07/908,765 Abandoned US <br />File wrapper continuation (FWC) 07/908,765<br />Filed on 1992-07-01<br />Status: Abandoned 114165877 E-035-1991-0 E-035-1991-0-US-03 TRANSMISSION BLOCKING VACCINE AGAINST MALARIA CON US 08/110,457 Abandoned US <br />Continuation (CON) 08/110,457<br />Filed on 1993-08-23<br />Status: Abandoned 114116411 DC2XXX 114116412 DCXXXX 114116413 DXXXXX 114155945 Malaria 114157944 Malaria (Plasmodium sp.) TAB-1142 114095468 Recombinant MVA Viruses Expressing Clade A/G and Clade B Modified HIV Env, Gag and Pol Genes Useful for HIV Vaccine Development NIAID Infectious Disease, Licensing, Vaccines Infectious Disease Licensing Vaccines Bernard Moss, Linda Wyatt The current technology relates to the construction, characterization and immunogenicity of modified vaccinia Ankara (MVA) recombinant viruses. The MVA double recombinant viruses express modified/truncated HIV-1 Env and mutated HIV Gag Pol under the control of vaccinia virus early/late promoters. This technology describes the MVA double recombinant viruses made by homologous recombination of single MVA recombinants, one expressing Env and one expressing Gag Pol. These single MVA recombinants are made using a transiently expressed GFP marker that is deleted in the final viruses. Two recombinant MVA viruses (MVA 65A/G and MVA 62B) made by this technology have been shown to produce HIV virus-like-particles that are immunogenic in mice. In addition, these two recombinant MVA viruses demonstrate stability through repeated passage of the LVD Seed Stock. This invention provides safe and stable immunogenic clade A/G and clade B vectors that may be tested as an AIDS vaccine candidate. Therefore, it is a promising technology to develop prophylactic and therapeutic AIDS vaccines for U.S. and for West Africa, particularly when used in combination with a DNA vaccine. 2022-03-08 2025-05-12 2025-05-12 2005-08-01 47 XYY syndrome, DC5AXX, DCXXXX, Double Y, DXXXXX False True True NIHTT 37470483 Website Abstract 114105125 Wyatt, Linda NIAID Wyatt, Linda (NIAID) 0 114105124 Moss, Bernard NIAID Moss, Bernard (NIAID) 1 114105124 Moss, Bernard NIAID Moss, Bernard (NIAID) 1 114105125 Wyatt, Linda NIAID Wyatt, Linda (NIAID) 0 114100361 Recombinant MVA Viruses Expressing Clade A/G And Clade B Modified HIV Env, Gag, And Pol Genes E-337-2004-0 Filing authorized Emory University, NIAID 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-1142] Recombinant MVA Viruses Expressing Clade A/G and Clade B Modified HIV Env, Gag and Pol Genes Useful for HIV Vaccine Development&body=Please send me information about technology [TAB-1142] Recombinant MVA Viruses Expressing Clade A/G and Clade B Modified HIV Env, Gag and Pol Genes Useful for HIV Vaccine Development. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-1142] Recombinant MVA Viruses Expressing Clade A/G and Clade B Modified HIV Env, Gag and Pol Genes Useful for HIV Vaccine Development&body=Please send me information about technology [TAB-1142] Recombinant MVA Viruses Expressing Clade A/G and Clade B Modified HIV Env, Gag and Pol Genes Useful for HIV Vaccine Development.">jonathan.motley@nih.gov</a><br> 114162838 E-337-2004-0 E-337-2004-0-US-01 Recombinant MVA Viruses Expressing Clade A/G and Clade B Modified HIV Env, Gag, and POL Genes PRV US 60/604,918 Abandoned US <br />Provisional (PRV) 60/604,918<br />Filed on 2004-08-27<br />Status: Abandoned 114164546 E-337-2004-0 E-337-2004-0-US-08 Recombinant MVA Viruses Expressing Clade A/G And Clade B Modified HIV Env, Gag, And Pol Genes National Stage US 9,453,239 11/574,285 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9453239 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9453239">9,453,239</a><br />Filed on 2007-02-26<br />Status: Issued 114165007 E-337-2004-0 E-337-2004-0-PCT-02 Recombinant MVA Viruses Expressing Clade A/G, Clade B, and C Modified HIV Env, Gag, And Pol Genes PCT Patent Cooperation Treaty PCT/US2005/030977 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2005/030977<br />Filed on 2005-08-29<br />Status: Expired 114116232 DC5AXX 114116233 DCXXXX 114116234 DXXXXX 114155908 47 XYY syndrome 114158039 Double Y TAB-978 114095311 Anti-Vaccinia Monoclonal Antibody NIAID Infectious Disease, Licensing, Research Materials Infectious Disease Licensing Research Materials Jonathan (Jon) Yewdell The current technology describes a monoclonal antibody that reacts with a vaccinia virus protein abundantly expressed under an early viral promoter after infection of cells. The antibody is useful for quantitating vaccinia virus infected cells and for studying the function of the protein to which it binds, which is known to be a double stranded RNA binding protein involved in resistance of the virus to interferons. This antibody is available for licensing through a biological materials license agreement. Research Material – Patent protection is not being pursued for this technology 2022-03-08 2025-05-12 2025-05-12 2004-09-01 47 XYY syndrome, DDXXXX, Double Y, DXXXXX False True True NIHTT 37470483 Website Abstract 114104855 Yewdell, Jonathan (Jon) NIAID Yewdell, Jonathan (Jon) (NIAID) 0 114104855 Yewdell, Jonathan (Jon) NIAID Yewdell, Jonathan (Jon) (NIAID) 0 114100185 Anti-vaccinia MAb E-123-2004-0 Research Material NIAID 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-978] Anti-Vaccinia Monoclonal Antibody&body=Please send me information about technology [TAB-978] Anti-Vaccinia Monoclonal Antibody. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-978] Anti-Vaccinia Monoclonal Antibody&body=Please send me information about technology [TAB-978] Anti-Vaccinia Monoclonal Antibody.">jonathan.motley@nih.gov</a><br> 114115545 DDXXXX 114115546 DXXXXX 114157863 47 XYY syndrome 114159057 Double Y TAB-911 114095245 MVA Expressing Modified HIV envelope, gag, and pol Genes NIAID Infectious Disease, Licensing, Therapeutics, Vaccines Infectious Disease Licensing Therapeutics Vaccines Patricia Earl, Bernard Moss, Linda Wyatt This invention claims Modified Vaccinia Ankara (MVA), a replication-deficient strain of vaccinia virus, expressing Human Immunodeficiency Virus (HIV) env, gag, and pol genes, where the genes are isolated from Ugandan Clade D isolates, Kenyan Clade A isolates, and Tanzanian Clade C isolates. In a rhesus macaque SHIV model, DNA priming followed by a recombinant MVA (rMVA) booster controlled a highly pathogenic immunodeficiency challenge. Both the DNA and the rMVA components of the vaccine expressed multiple immunodeficiency virus proteins. Two DNA inoculations at zero (0) and eight (8) weeks and a single rMVA booster at twenty-four (24) weeks effectively controlled an intrarectal challenge administered seven (7) months after the booster. Additionally, the inventors have generated data showing that inoculations of rMVA induce good immune responses even without DNA priming. <br><br> The inventors are continuing preclinical work on the vaccine, and have generated further data on the vaccine. Furthermore, the inventors are continuing to optimize the vaccine by genetically modifying the genes. This vaccine will be the subject of an upcoming Phase I clinical trial. These findings provide hope that a relatively simple multiprotein DNA/MVA vaccine can help to control the Acquired Immune Deficiency Syndrome (AIDS) epidemic. 2022-03-08 2025-05-12 2025-05-12 2005-04-01 (4)r syndrome, 3-@hydroxyacyl-coa dehydrogenase deficiency, Altered, C syndrome, Chromosome 4 ring syndrome, Chromosome 6 ring syndrome, Chromosome 7 ring syndrome, D, DB4AXX, DB4XXX, DBXXXX, DC5AXX, DC5XXX, DCXXXX, DXXXXX, Envelope, Expressing, G syndrome, GAG, GENES, HAD deficiency, HIS deficiency, Histidinemia, HIV, Hyper IgM syndrome, Hypertelorism with esophageal abnormality and hypospadias, Immunodeficiency 2, Immunodeficiency 4, Immunodeficiency-3, MVA, N syndrome, polymerase, R(6) syndrome, R(7) syndrome, Severe combined immunodeficiency, x-linked, Subtype, Syndrome X, W syndrome, W syndrome; Syndrome W, Wiskott Aldrich syndrome False True True NIHTT 37470483 Website Abstract 114104730 Wyatt, Linda NIAID - DIR NIAID Wyatt, Linda (NIAID) 0 114104733 Earl, Patricia NIAID - DIR NIAID Earl, Patricia (NIAID) 0 114104732 Moss, Bernard NIAID - DIR NIAID Moss, Bernard (NIAID) 1 114104732 Moss, Bernard NIAID - DIR NIAID Moss, Bernard (NIAID) 1 114104730 Wyatt, Linda NIAID - DIR NIAID Wyatt, Linda (NIAID) 0 114104733 Earl, Patricia NIAID - DIR NIAID Earl, Patricia (NIAID) 0 114100103 MVA Expressing Altered Envelope, Gag, And Polymerase Genes From HIV Subtype D E-023-2003-0 Filing authorized Department of the Army, Henry M. Jackson Foundation (HJF), NIAID 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-911] MVA Expressing Modified HIV envelope, gag, and pol Genes&body=Please send me information about technology [TAB-911] MVA Expressing Modified HIV envelope, gag, and pol Genes. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-911] MVA Expressing Modified HIV envelope, gag, and pol Genes&body=Please send me information about technology [TAB-911] MVA Expressing Modified HIV envelope, gag, and pol Genes.">jonathan.motley@nih.gov</a><br> 114162271 E-023-2003-0 E-023-2003-0-US-01 MVA Expressing Modified HIV Envelope, Gag, and Pol Genes from HIV Subtype D PRV US 60/459,175 Abandoned US <br />Provisional (PRV) 60/459,175<br />Filed on 2003-03-28<br />Status: Abandoned 114162275 E-023-2003-0 E-023-2003-0-US-07 MVA EXPRESSING MODIFIED HIV ENVELOPE, GAG, AND POL GENES DIV US 11/975,643 Abandoned US <br />Divisional (DIV) 11/975,643<br />Filed on 2007-10-19<br />Status: Abandoned 114164567 E-023-2003-0 E-023-2003-0-US-03 MVA Expressing Modified HIV Envelope, Gag, And Pol Genes National Stage US 7,303,754 11/238,155 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7303754 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7303754">7,303,754</a><br />Filed on 2005-09-28<br />Status: Abandoned 114165225 E-023-2003-0 E-023-2003-0-PCT-02 MVA Expressing Modified HIV Envelope, GAG, and POL Genes PCT Patent Cooperation Treaty PCT/US2004/009906 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2004/009906<br />Filed on 2004-03-29<br />Status: Expired 114115260 DB4AXX 114115261 DC5AXX 114115262 DBXXXX 114115263 DCXXXX 114115264 DXXXXX 114119607 DC5XXX 114119608 DB4XXX 114135183 MVA 114135184 Expressing 114135185 Altered 114135186 Envelope 114135187 GAG 114135188 polymerase 114135189 GENES 114135190 HIV 114135191 Subtype 114135192 D 114157798 Syndrome X 114157799 C syndrome 114157800 Chromosome 7 ring syndrome 114157801 Severe combined immunodeficiency, x-linked 114157802 W syndrome 114157803 Hypertelorism with esophageal abnormality and hypospadias 114157804 3-@hydroxyacyl-coa dehydrogenase deficiency 114157805 N syndrome 114157806 Chromosome 6 ring syndrome 114157807 Hyper IgM syndrome 114157808 Wiskott Aldrich syndrome 114157809 Histidinemia 114157810 Chromosome 4 ring syndrome 114159014 R(7) syndrome 114159015 Immunodeficiency 4 114159016 W syndrome; Syndrome W 114159017 G syndrome 114159018 HAD deficiency 114159019 R(6) syndrome 114159020 Immunodeficiency-3 114159021 Immunodeficiency 2 114159022 HIS deficiency 114159023 (4)r syndrome TAB-695 114095031 4G10, a Monoclonal Antibody Against the Chemokine Receptor CXCR4, Raised Against a Synthetic Peptide of 38 Residues in Length Derived from the N-terminal Sequence of CXCR4 NIAID Diagnostics, Infectious Disease, Licensing, Oncology, Research Materials, Therapeutics Diagnostics Infectious Disease Licensing Oncology Research Materials Therapeutics Edward Berger, Christopher Broder This invention identifies a monoclonal antibody (4G10) against the chemokine receptor CXCR4 and is a mouse IgG1 antibody. CXCR4 has been identified as a co-receptor mediating entry of HIV-1 into T cells. Subsequently, CXCR4 has been implicated in normal physiological functions, including activation of B cells and B cell progenitors and guiding their migration into the bone marrow (via its ligand SDF-1). CXCR4 also functions in T cell progenitor migration and neural progenitor stem cell activation. Since 4G10 is a monoclonal antibody raised against a synthetic peptide derived from the N- terminus of CXCR4 that may prove useful in the context of the above CXCR4 functions, 4G10 is an excellent reagent for detection and quantitation of CXCR4 by Western blot, immunoprecipitation, ELISA, and flow cytometry. It can also be used to purify CXCR4 by affinity chromatography. With these known characteristics, it would also function in immuno-histochemical assays as well. Thus, this invention is a good research tool and is available for licensing through a Biological Materials License Agreement as no patent application has been filed. 2022-03-08 2025-05-12 2025-05-12 2003-02-01 CC2XXX, CCXXXX, CXXXXX, DDXXXX, DXXXXX, IDXXXX, IXXXXX False True True NIHTT 37470483 Website Abstract 114104354 Berger, Edward NIAID Berger, Edward (NIAID) 0 114104355 Broder, Christopher NIAID Broder, Christopher (NIAID) 0 114104354 Berger, Edward NIAID Berger, Edward (NIAID) 0 114104355 Broder, Christopher NIAID Broder, Christopher (NIAID) 0 114099843 4G10, A Monoclonal Anitbody Against the Chemokine Receptor CXCR4, Raised Against a Synthetic Peptide of 38 Residues in Length... E-340-2002-0 Research Material NIAID 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-695] 4G10, a Monoclonal Antibody Against the Chemokine Receptor CXCR4, Raised Against a Synthetic Peptide of 38 Residues in Length Derived from the N-terminal Sequence of CXCR4&body=Please send me information about technology [TAB-695] 4G10, a Monoclonal Antibody Against the Chemokine Receptor CXCR4, Raised Against a Synthetic Peptide of 38 Residues in Length Derived from the N-terminal Sequence of CXCR4. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-695] 4G10, a Monoclonal Antibody Against the Chemokine Receptor CXCR4, Raised Against a Synthetic Peptide of 38 Residues in Length Derived from the N-terminal Sequence of CXCR4&body=Please send me information about technology [TAB-695] 4G10, a Monoclonal Antibody Against the Chemokine Receptor CXCR4, Raised Against a Synthetic Peptide of 38 Residues in Length Derived from the N-terminal Sequence of CXCR4.">jonathan.motley@nih.gov</a><br> 114114333 CC2XXX 114114334 CCXXXX 114114335 DDXXXX 114114336 IDXXXX 114114337 CXXXXX 114114338 DXXXXX 114114339 IXXXXX TAB-672 114095008 VAC-BAC Shuttle Vector System for Generating Recombinant Poxviruses NIAID Infectious Disease, Licensing, Therapeutics, Vaccines Infectious Disease Licensing Therapeutics Vaccines Arban Domi, Bernard Moss This invention relates to a VAC-BAC shuttle vector system for the creation of recombinant poxviruses from DNA cloned in a bacterial artificial chromosome. A VAC-BAC is a bacterial artificial chromosome (BAC) containing a vaccinia virus genome (VAC) that can replicate in bacteria and produce infectious virus in mammalian cells. <ul> <li>VAC-BACs are clonally purified from bacterial colonies before virus reconstitution in mammalian cells.</li> <li>Manipulation of DNA is much simpler and faster in bacteria than in mammalian cells.</li> <li>Modified genomes can be characterized prior to virus reconstitution.</li> <li>Only virus with modified genomes will be produced so that virus plaque isolations are not needed.</li> <li>Generation of a stock of virus from a VAC-BAC is accomplished within a week rather than many weeks.</li> <li>Multiple viruses can be generated at the same time since plaque purification is unnecessary.</li> </ul> <ul> <li>VAC-BACs can be used to modify vaccinia virus DNA by deletion, insertion or point mutation or add new DNA to the VAC genome with methods developed for bacterial plasmids, rather than by recombination in mammalian cells.</li> <li>It can be used to produce recombinant vaccinia viruses for gene expression.</li> <li>It can be used for the production of modified vaccinia viruses that have improved safety or immunogenicity.</li> </ul> 2022-03-08 2025-05-12 2025-05-12 2005-05-01 Chromosome 7, monosomy, DB4BXX, DB4XXX, DBXXXX, DC1XXX, DCXXXX, Deletion 7, DXXXXX, SHUTTLE, System, VAC-BAC, Vector False True True NIHTT 37470483 Website Abstract 114169872 Domi A, Moss B. http://www.ncbi.nlm.nih.gov/pubmed/12196634 <a href="http://www.ncbi.nlm.nih.gov/pubmed/12196634">Domi A, Moss B.</a> 114169873 Domi A, Moss B. http://www.ncbi.nlm.nih.gov/pubmed/15782205 <a href="http://www.ncbi.nlm.nih.gov/pubmed/15782205">Domi A, Moss B.</a> 114104306 Domi, Arban NIAID - DIR Domi, Arban 0 114104307 Moss, Bernard NIAID - DIR NIAID Moss, Bernard (NIAID) 1 114104307 Moss, Bernard NIAID - DIR NIAID Moss, Bernard (NIAID) 1 114104306 Domi, Arban NIAID - DIR Domi, Arban 0 114099817 VAC-BAC Shuttle Vector System E-355-2001-2 Filing authorized NIAID 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-672] VAC-BAC Shuttle Vector System for Generating Recombinant Poxviruses&body=Please send me information about technology [TAB-672] VAC-BAC Shuttle Vector System for Generating Recombinant Poxviruses. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-672] VAC-BAC Shuttle Vector System for Generating Recombinant Poxviruses&body=Please send me information about technology [TAB-672] VAC-BAC Shuttle Vector System for Generating Recombinant Poxviruses.">jonathan.motley@nih.gov</a><br> 114161621 E-355-2001-2 E-355-2001-2-US-02 VAC-BAC Shuttle Vector System National Stage US 7,494,813 10/959,392 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7494813 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7494813">7,494,813</a><br />Filed on 2004-10-05<br />Status: Expired 114161624 E-355-2001-2 E-355-2001-2-PCT-01 VAC-BAC Shuttle Vector System PCT COMB Patent Cooperation Treaty PCT/US03/11183 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US03/11183<br />Filed on 2003-04-10<br />Status: Expired 114114258 DC1XXX 114114259 DCXXXX 114114260 DXXXXX 114119640 DB4BXX 114119641 DBXXXX 114119642 DB4XXX 114135303 VAC-BAC 114135304 SHUTTLE 114135305 Vector 114135306 System 114157587 Chromosome 7, monosomy 114158894 Deletion 7 TAB-337 114094676 CC Chemokine Receptor 5 DNA, New Animal Models and Therapeutic Agents for HIV Infection NIAID Collaboration, Infectious Disease, Licensing, Research Materials, Therapeutics Collaboration Infectious Disease Licensing Research Materials Therapeutics Ghalib Alkhatib, Edward Berger, Christopher Broder, Christophe Combadiere, Yu Feng, Paul Kennedy, Philip Murphy Chemokine receptors are expressed by many cells, including lymphoid cells, and function to mediate cell trafficking and localization. CC chemokine receptor 5 (CCR5) is a seven-transmembrane, G protein-coupled receptor (GPCR) which regulates trafficking and effector functions of memory/effector T-lymphocytes, macrophages, and immature dendritic cells. Chemokine binding to CCR5 leads to cellular activation through pertussis toxin-sensitive heterotrimeric G proteins as well as G protein-independent signalling pathways. Like many other GPCRs, CCR5 is regulated by agonist-dependent processes which involve G protein coupled receptor kinase (GRK)-dependent phosphorylation, beta-arrestin-mediated desensitization and internalization. <br><br> Human CCR5 also functions as the main coreceptor for the fusion and entry of many strains of human immunodeficiency virus (HIV-1, HIV-2). HIV-1 transmission almost invariably involves such CCR5-specific variants (designated R5); individuals lacking functional CCR5 (by virtue of homozygosity for a defective CCR5 allele) are almost completely resistant to HIV-1 infection. Specific blocking of CCR5 (e.g. with chemokine ligands, anti-CCR5 antibodies, CCR5-blocking low MW inhibitors, etc.) inhibits entry/infection of target cells by R5 HIV strains. Cells expressing CCR5 and CD4 are useful for screening for agents that inhibit HIV by binding to CCR5. Such agents represent potential new approaches to block HIV transmission and to treat infected people. A small animal expressing both human CCR5 along with human CD4 supports entry of HIV into target cells, a necessary hurdle that must be overcome for development of a small animal model (e.g. transgenic mouse, rat, rabbit, mink) to study HIV infection and its inhibition. <br><br> The invention embodies the CCR5 genetic sequence, cell lines and transgenic animals, the cells of which coexpress human CD4 and CCR5, and which may represent valuable tools for the study of HIV infection and for screening anti-HIV agents. The invention also embodies anti-CCR5 agents that block HIV env-mediated membrane fusion associated with HIV entry into human CD4-positive target cells or between HIV-infected cells and uninfected human CD4-positive target cells. The NIAID Laboratory of Molecular Immunology and Laboratory of Viral Diseases are seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize CCR5-related products. Please contact Philip Murphy (301-496-8616, <a href="mailto:pmm@nih.gov">pmm@nih.gov</a>) or Edward Berger (301-402-2481, <a href="mailto:edward_berger@nih.gov">edward_berger@nih.gov</a>) for more information. This technology is available for exclusive or nonexclusive licensing. 2022-03-08 2025-05-12 2025-05-12 2007-06-01 5, Agents, AIDS, also designated as CKR5, ANIMAL, antiretroviral, ANTIVIRAL, cc, CC-CKR5 chemokine receptor, CCR5 and CMKBR5, Chemokine, DB4AXX, DB4XXX, DBXXXX, DDXXXX, DNA, DXXXXX, HIV, Hyper IgM syndrome, Immunodeficiency 2, Immunodeficiency 4, Immunodeficiency-3, Infection, MIP-1a & MIP-1b, Models, Patent Category - Biotechnology, Patent Category - Contested Proceedings, RECEPTOR, receptor for RANTES, Severe combined immunodeficiency, x-linked, therapeutic, Wiskott Aldrich syndrome False True True NIHTT 37470483 Website Abstract 114169793 G Alkhatib et al. CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science. 1996 Jun 28;272(5270):1955-1958. http://www.ncbi.nlm.nih.gov/pubmed/8658171?dopt <a href="http://www.ncbi.nlm.nih.gov/pubmed/8658171?dopt">G Alkhatib et al. CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science. 1996 Jun 28;272(5270):1955-1958.</a> 114103591 Broder, Christopher NIAID - DIR NIAID Broder, Christopher (NIAID) 0 114103592 Murphy, Philip NIAID - DIR NIAID Murphy, Philip (NIAID) 0 114103593 Alkhatib, Ghalib NIAID - DIR Alkhatib, Ghalib 0 114103594 Berger, Edward NIAID - DIR NIAID Berger, Edward (NIAID) 0 114103595 Feng, Yu NIAID - DIR Feng, Yu 0 114106482 Kennedy, Paul NIAID - DIR NIAID Kennedy, Paul (NIAID) 0 114103596 Combadiere, Christophe NIAID - DIR Combadiere, Christophe 1 114103596 Combadiere, Christophe NIAID - DIR Combadiere, Christophe 1 114103591 Broder, Christopher NIAID - DIR NIAID Broder, Christopher (NIAID) 0 114103592 Murphy, Philip NIAID - DIR NIAID Murphy, Philip (NIAID) 0 114103593 Alkhatib, Ghalib NIAID - DIR Alkhatib, Ghalib 0 114103594 Berger, Edward NIAID - DIR NIAID Berger, Edward (NIAID) 0 114103595 Feng, Yu NIAID - DIR Feng, Yu 0 114106482 Kennedy, Paul NIAID - DIR NIAID Kennedy, Paul (NIAID) 0 114099475 CC CHEMOKINE RECEPTOR 5 DNA, NEW ANIMAL MODELS AND THERAPEUTIC AGENTS FOR HIV INFECTION E-090-1996-0 NIAID 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-337] CC Chemokine Receptor 5 DNA, New Animal Models and Therapeutic Agents for HIV Infection&body=Please send me information about technology [TAB-337] CC Chemokine Receptor 5 DNA, New Animal Models and Therapeutic Agents for HIV Infection. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-337] CC Chemokine Receptor 5 DNA, New Animal Models and Therapeutic Agents for HIV Infection&body=Please send me information about technology [TAB-337] CC Chemokine Receptor 5 DNA, New Animal Models and Therapeutic Agents for HIV Infection.">jonathan.motley@nih.gov</a><br> 114160758 E-090-1996-0 E-090-1996-0-US-09 CC CHEMOKINE RECEPTOR 5 DNA, NEW ANIMAL MODELS AND THERAPEUTIC AGENTS FOR HIV INFECTION DIV US 12/044,845 Abandoned US <br />Divisional (DIV) 12/044,845<br />Filed on 2008-03-07<br />Status: Abandoned 114160759 E-090-1996-0 E-090-1996-0-US-08 CC CHEMOKINE RECEPTOR 5 DNA, NEW ANIMAL MODELS AND THERAPEUTIC AGENTS FOR HIV INFECTION DIV US 7,374,872 11/594,375 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7374872 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7374872">7,374,872</a><br />Filed on 2006-11-07<br />Status: Abandoned 114160760 E-090-1996-0 E-090-1996-0-US-07 CC CHEMOKINE RECEPTOR 5 DNA, NEW ANIMAL MODELS AND THERAPEUTIC AGENTS FOR HIV INFECTION CON US 8,198,042 10/846,185 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8198042 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8198042">8,198,042</a><br />Filed on 2004-05-14<br />Status: Abandoned 114160761 E-090-1996-0 E-090-1996-0-US-06 CC CHEMOKINE RECEPTOR 5 DNA, NEW ANIMAL MODELS AND THERAPEUTIC AGENTS FOR HIV INFECTION CON US 7,151,087 10/700,313 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7151087 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7151087">7,151,087</a><br />Filed on 2003-10-31<br />Status: Abandoned 114160762 E-090-1996-0 E-090-1996-0-US-05 CC CHEMOKINE RECEPTOR 5 DNA, NEW ANIMAL MODELS AND THERAPEUTIC AGENTS FOR HIV INFECTION [Aron Diamond Cell Line] CON US 10/439,845 Abandoned US <br />Continuation (CON) 10/439,845<br />Filed on 2003-05-15<br />Status: Abandoned 114160763 E-090-1996-0 E-090-1996-0-PCT-02 CC CHEMOKINE RECEPTOR 5, ANTIBODIES THERETO, TRANSGENIC ANIMALS PCT Patent Cooperation Treaty PCT/US1997/009586 Expired Patent Cooperation Treaty <br />(PCT) PCT/US1997/009586<br />Filed on 1997-05-28<br />Status: Expired 114160764 E-090-1996-0 E-090-1996-0-US-04 CC CHEMOKINE RECEPTOR 5 DNA, NEW ANIMAL MODELS AND THERAPEUTIC AGENTS FOR HIV INFECTION ORD US 08/864,458 Abandoned US <br />Ordinary Patent (ORD) 08/864,458<br />Filed on 1997-05-28<br />Status: Abandoned 114164487 E-090-1996-0 E-090-1996-0-US-01 CC CHEMOKINE RECEPTOR 5 DNA, NEW ANIMAL MODELS AND THERAPEUTIC AGENTS FOR HIV INFECTION PRV US 60/018,508 Abandoned US <br />Provisional (PRV) 60/018,508<br />Filed on 1996-05-28<br />Status: Abandoned 114166305 E-090-1996-0 E-090-1996-0-US-10 METHOD OF INHIBITING MEMBRANE FUSION BETWEEN HIV AND A CCR5-EXPRESSING TARGET CELL CON US 13/012,482 Abandoned US <br />Continuation (CON) 13/012,482<br />Filed on 2011-01-24<br />Status: Abandoned 114112938 DB4AXX 114112939 DDXXXX 114112940 DBXXXX 114112941 DXXXXX 114119841 DB4XXX 114136454 HIV 114136455 AIDS 114136456 ANTIVIRAL 114136457 antiretroviral 114136458 receptor for RANTES 114136459 MIP-1a & MIP-1b 114136460 CC-CKR5 chemokine receptor 114136461 also designated as CKR5 114136462 CCR5 and CMKBR5 114136463 cc 114136464 Chemokine 114136465 RECEPTOR 114136466 5 114136467 DNA 114136468 ANIMAL 114136469 Models 114136470 therapeutic 114136471 Agents 114136472 Infection 114136473 Patent Category - Biotechnology 114136474 Patent Category - Contested Proceedings 114157275 Severe combined immunodeficiency, x-linked 114157276 Hyper IgM syndrome 114157277 Wiskott Aldrich syndrome 114158731 Immunodeficiency 4 114158732 Immunodeficiency-3 114158733 Immunodeficiency 2 TAB-4537 151735530 An Automated System for Myocardial Perfusion Mapping and Machine Diagnosis to Detect Ischemic Heart Disease with First-pass Perfusion Cardiac Magnetic Resonance Imaging NHLBI Cardiology, Computational models/software, Licensing, Research Equipment, Software / Apps Cardiology Computational models/software Licensing Research Equipment Software / Apps Andrew Arai, Mitchel Benovoy, Li-Yueh Hsu, Matthew Jacobs <p>This technology includes a fully automated computer aided diagnosis system to quantify myocardial blood flow (MBF) and myocardial perfusion reserve (MPR) pixel maps from the first-pass contrast-enhanced cardiac magnetic resonance (CMR) perfusion images. This system performs automated image registration, motion compensation, segmentation, and modeling to extract quantitative features from different myocardial regions of interest. It then performs automated classification to detect potential lesions in the myocardium and generates analysis reports to summarize global and regional myocardial perfusion, possible myocardial sectors/territories and coronary arteries that may be diseased to assist physicians in clinical decision making.</p> Current similar system still requires manual segmentation of the myocardium on the pixel maps to depict different coronary distributions; this fully automated system contains important features beyond prior technology as a computer- aided diagnosis system to assist physician to make This will be the first of its kind system to generate MBF and MPR maps, detect cardiac lesion, and generate a machine diagnostic report from CMR perfusion fully automatically. We are seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. 2023-12-11 2024-08-12 2025-05-12 2024-03-27 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 151735550 Hsu, Li-Yueh National Heart, Lung, and Blood Institute (NHLBI) NHLBI Hsu, Li-Yueh (NHLBI) 1 151735554 Arai, Andrew National Heart, Lung, and Blood Institute (NHLBI) NHLBI Arai, Andrew (NHLBI) 2 151735559 Jacobs, Matthew National Heart, Lung, and Blood Institute (NHLBI) NHLBI Jacobs, Matthew (NHLBI) 3 151735567 Benovoy, Mitchel Circle Cardiovascular Imaging Inc Benovoy, Mitchel 4 151735550 Hsu, Li-Yueh National Heart, Lung, and Blood Institute (NHLBI) NHLBI Hsu, Li-Yueh (NHLBI) 1 151735554 Arai, Andrew National Heart, Lung, and Blood Institute (NHLBI) NHLBI Arai, Andrew (NHLBI) 2 151735559 Jacobs, Matthew National Heart, Lung, and Blood Institute (NHLBI) NHLBI Jacobs, Matthew (NHLBI) 3 151735567 Benovoy, Mitchel Circle Cardiovascular Imaging Inc Benovoy, Mitchel 4 151735533 A Fully Automated System For Quantitative Myocardial Perfusion Pixel Mapping And Machine Diagnosis To Detect Ischemic Heart Disease With First-pass Perfusion Cardiac Magnetic Resonance Imaging E-219-2018-0 Filing authorized Corstem Inc., National Heart, Lung, and Blood Institute (NHLBI) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-4537] An Automated System for Myocardial Perfusion Mapping and Machine Diagnosis to Detect Ischemic Heart Disease with First-pass Perfusion Cardiac Magnetic Resonance Imaging&body=Please send me information about technology [TAB-4537] An Automated System for Myocardial Perfusion Mapping and Machine Diagnosis to Detect Ischemic Heart Disease with First-pass Perfusion Cardiac Magnetic Resonance Imaging. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-4537] An Automated System for Myocardial Perfusion Mapping and Machine Diagnosis to Detect Ischemic Heart Disease with First-pass Perfusion Cardiac Magnetic Resonance Imaging&body=Please send me information about technology [TAB-4537] An Automated System for Myocardial Perfusion Mapping and Machine Diagnosis to Detect Ischemic Heart Disease with First-pass Perfusion Cardiac Magnetic Resonance Imaging.">shmilovm@nih.gov</a><br> 157756158 E-219-2018-0 E-219-2018-0-US-01 A Fully Automated System For Quantitative Myocardial Perfusion Pixel Mapping And Machine Diagnosis To Detect Ischemic Heart Disease With First-pass Perfusion Cardiac Magnetic Resonance Imaging PRV US 62/672,787 Abandoned US <br />Provisional (PRV) 62/672,787<br />Filed on 2018-05-17<br />Status: Abandoned TAB-3818 114097665 Multiplexing Homocysteine in Primary Newborn Screening Assays Using Maleimides as Select Derivatization Agents CDC Cardiology, Consumer Products, Dental, Diagnostics, Endocrinology, Infectious Disease, Occupational Safety and Health, Oncology, Ophthalmology, Research Equipment, Research Materials Cardiology Consumer Products Dental Diagnostics Endocrinology Infectious Disease Occupational Safety and Health Oncology Ophthalmology Research Equipment Research Materials Konstantinos Petritis, Charles Pickens Homocystinuria (HCU), a group of inherited disorders, causes symptoms ranging from failure to thrive and developmental delays in infants or young children to abnormal blood clots with onset in adults.1 Approximately 1 in 200,000 to 335,000 people have HCU globally.2 <br /><br /> Various clinical settings use the dried blood spot (DBS) for sample collection methods such as newborn screening tests for HCU. Due to the complex chemistry of homocysteine (Hcy), which is elevated in people with HCU, and known interferences, labs cannot screen DBS for this biomarker in primary-tier newborn screening assays. Instead, labs use methionine as a surrogate marker for dysfunction in the Hcy metabolic pathway, although methionine has poor sensitivity and specificity for HCU. This impacts false positive rates, causing parental anxiety and unnecessary burden for follow up teams, and false negative rates which increase the morbidity and mortality of newborns with HCU. There are reports of HCU cases having been missed.3 Another approach uses second-tier screening following the primary assay to test presumed positive specimens with elevated methionine for Hcy after a chromatographic separation step. This also has disadvantages in that specimens may not exceed the methionine cutoff to receive second-tier screening and added time (+1-5 days) before referral affects treatment delivery. <br /><br /> CDC has developed a workflow to selectively convert Hcy to a derivative using a maleimide reagent in a sample matrix. The process allows accurate quantification by shifting Hcy’s mass, thus, removing any undesired interferences. The specific derivative agent, N-ethylmaleimide, is widely available and has a very low price. CDC’s method screens Hcy during primary newborn screening from the DBS, along with dozens of other newborn screening biomarkers without adding substantial time or efforts to the screening process. No currently reported methods use this workflow to screen for Hcy in DBS. Current commercial products cannot screen for Hcy from DBS in areas of newborn screening and other clinical sciences that desire to quantify Hcy as a biomarker. This technology can potentially revolutionize HCU screening via DBS in newborns globally. DBS is also becoming more widely adopted as a sample collection method in other clinical areas. Eventually, clinical labs may begin to screen Hcy as a risk for cardiometabolic diseases/disorders and can benefit from the new workflow. CDC has demonstrated the workflow in DBS from HCU positive, presumptive normal, and those with reported administration of total parenteral nutrition.<br /><br /> Sources: <ul> <li>1. https://rarediseases.info.nih.gov/diseases/10770/homocystinuria</li> <li>2. https://medlineplus.gov/genetics/condition/homocystinuria/</li> <li>3. Bowron et al. Clinical Chemistry. 51, No.1, 2005.</li> </ul> <ul> <li>Allows detection of Hcy in first-tier newborn screening in DBS with higher precision and does not affect other biomarkers co-analyzed in newborn DBS screening</li> <li>Improved HCU screening sensitivity and specificity - with reduced false negative and false positive results over current methods</li> <li>Workflow does not add significant time to the total assay preparation and added reagents are low cost and widely available</li> <li>New method uses lower proportions of water (i.e., 20%) and allows for faster sample drying and cleaner flow injection analysis (FIA) injection ports in-turn</li> <li>Readily adaptable to existing DBS screening kits or new screening test kit format</li> <li>Avoids the need for additional specimen (urine or blood) collection while saving time, cost, and mental burden on parents</li> <li>Enables healthcare providers to deliver needed treatment sooner at very early stages without the delay of second-tier screening</li> </ul> <ul> <li>DBS screening test kits for homocystinuria in newborn primary screening</li> <li>DBS or blood sample screening test kit identifying Hcy as a biomarker for detecting heart disease, vitamin B12, vitamin B6, or folate deficiencies, diabetes, cancer, neurodegenerative diseases, etc.</li> <li>Monitoring/public health surveillance</li> <li>Quality control/quality assurance</li> <li>Research tool</li> </ul> The CDC Technology Transfer Office (TTO) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize: Multiplexing homocysteine in primary newborn screening assays using maleimides as select derivatization agents. For collaboration opportunities, please contact CDC TTO at <a href=mailto:tto@cdc.gov>tto@cdc.gov</a> or 1-404-639-1330. 2022-09-28 2025-05-09 2025-05-09 2022-09-28 4AXXXX, Agents, ASSAYS, Derivatization, Hcy, HOMOCYSTEINE, Maleimides, Multiplexing, Newborn, Primary, screening, SELECTIVE, VDXXXX, VPXXXX, WFXXXX, WHXXXX, WIXXXX, XCXXXX, XHXXXX, YAXXXX, YDXXXX, YFXXXX False True True 52406769 Prototype 52406769 NIHTT 37470483 Website Abstract 114172973 Pickens CA, et al. https://www.ncbi.nlm.nih.gov/pubmed/34606607 <a href="https://www.ncbi.nlm.nih.gov/pubmed/34606607">Pickens CA, et al.</a> 114111642 Pickens, Charles CDC - DIR Pickens, Charles 0 114111641 Petritis, Konstantinos CDC - DIR Petritis, Konstantinos 1 114111641 Petritis, Konstantinos CDC - DIR Petritis, Konstantinos 1 114111642 Pickens, Charles CDC - DIR Pickens, Charles 0 114102915 Multiplexing Homocysteine (Hcy) In Primary Newborn Screening Assays Through Selective Derivatization Of Hcy Using Maleimides As Derivatization Agents E-066-2022-0 Filing authorized Centers for Disease Control and Prevention (CDC) 83738793 Taylor-Mulneix, Dawn dawn.taylor-mulneix@nih.gov
United States of America dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-3818] Multiplexing Homocysteine in Primary Newborn Screening Assays Using Maleimides as Select Derivatization Agents&body=Please send me information about technology [TAB-3818] Multiplexing Homocysteine in Primary Newborn Screening Assays Using Maleimides as Select Derivatization Agents. Taylor-Mulneix, Dawn<br><a href="mailto:dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-3818] Multiplexing Homocysteine in Primary Newborn Screening Assays Using Maleimides as Select Derivatization Agents&body=Please send me information about technology [TAB-3818] Multiplexing Homocysteine in Primary Newborn Screening Assays Using Maleimides as Select Derivatization Agents.">dawn.taylor-mulneix@nih.gov</a><br> 114169658 E-066-2022-0 E-066-2022-0-US-01 MULTIPLEXING HOMOCYSTEINE IN FIRST-TIER SCREENING ASSAYS PRV US 63/333,647 Expired US <br />Provisional (PRV) 63/333,647<br />Filed on 2022-04-22<br />Status: Expired 114129712 VPXXXX 114129713 VDXXXX 114129714 4AXXXX 114129715 WHXXXX 114129716 WFXXXX 114129717 WIXXXX 114129718 XCXXXX 114129719 YDXXXX 114129720 YAXXXX 114129721 XHXXXX 114129722 YFXXXX 114155660 Multiplexing 114155661 HOMOCYSTEINE 114155662 Hcy 114155663 Primary 114155664 Newborn 114155665 screening 114155666 ASSAYS 114155667 SELECTIVE 114155668 Derivatization 114155669 Maleimides 114155670 Agents TAB-2752 114096930 Improved Botulism, Botulinum Neurotoxin Type-E Diagnostics CDC Consumer Products, Diagnostics, Infectious Disease, Licensing, Medical Devices, Non-Medical Devices, Occupational Safety and Health, Research Equipment, Research Materials, Therapeutics, Vaccines Consumer Products Diagnostics Infectious Disease Licensing Medical Devices Non-Medical Devices Occupational Safety and Health Research Equipment Research Materials Therapeutics Vaccines John Barr, Suzanne Kalb, Dongxia Wang CDC researchers have improved upon a prior, HHS patented mass spectrometry-based Endopep-MS assay that is able to rapidly detect and differentiate all seven botulinum neurotoxin (BoNT) types A to G. This current improvement comprises the addition of two optimized substrate peptides that increases the assay's sensitivity,relative to prior substrates, for botulinum neurotoxin type-E (BoNT/E) by greater than 100 fold.<br /><br /> Currently, the primary method of detecting BoNT contamination entails mouse lethality bioassays. In addition to the sacrifice of numerous animals, these lethality assays are expensive and require several days to obtain results. During a suspected BoNT exposure, time is of the essence. The previously patented mass spectrometry approach can provide diagnostic results for all seven BoNT types in a matter of hours, at greater cost-efficiency and without animal toxicity studies. The specific innovation builds upon those earlier improvements by providing new substrates that allow for tremendous increases in the degree of sensitivity for BoNT/E-specific detection within clinical samples. <ul> <li>More sensitive, greater cost-efficiency and provides results significantly faster than traditional BoNT/E mouse lethality assays</li> <li>Builds upon a previously established and patented mass spectrometry-based Endopep-MS assay, adding optimized peptides that improve current BoNT/E detection sensitivity >100 fold</li> </ul> <ul> <li>Detection of bolulinum neurotoxin type-E (BoNT/E) in clinical samples</li> <li>Basic research investigating neurotoxin activity, Clostridium botulinum and botulism</li> <li>Biodefense, biosecurity</li> <li>Food safety assurance</li> </ul> 2022-11-17 2025-05-09 2025-05-09 2014-01-29 AAXXXX, ACXXXX, BACTERIA, Bacterial, Biodefense, Biodetection, Bolulinum, CDC Docket Import, CDC Docket Import CDC Prosecuting, DA3XXX, DA5XXX, DAXXXX, DXXXXX, e, MASS SPECTROMETER, Mass spectrometry, Neurotoxin, Novel, Peptide, Recognizable, SUBSTRATES, toxin, TYPE, VBXXXX, VJXXXX, VKXXXX, VLXXXX, WAXXXX, WBXXXX, WCXXXX, WFXXXX, WIXXXX, WMXXXX, XCXXXX, XDXXXX, XHXXXX, YBXXXX False True In vitro data available True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract E-460-2013-0 114172040 Kalb SR, et al. http://www.ncbi.nlm.nih.gov/pubmed/16500606 <a href="http://www.ncbi.nlm.nih.gov/pubmed/16500606">Kalb SR, et al.</a> 114172041 Boyer AE, et al. http://www.ncbi.nlm.nih.gov/pubmed/15987092 <a href="http://www.ncbi.nlm.nih.gov/pubmed/15987092">Boyer AE, et al.</a> 114108484 Kalb, Suzanne CDC - DIR CDC Kalb, Suzanne (CDC) 0 114108485 Barr, John CDC - DIR CDC Barr, John (CDC) 0 114108483 Wang, Dongxia CDC - DIR CDC Wang, Dongxia (CDC) 1 114108483 Wang, Dongxia CDC - DIR CDC Wang, Dongxia (CDC) 1 114108484 Kalb, Suzanne CDC - DIR CDC Kalb, Suzanne (CDC) 0 114108485 Barr, John CDC - DIR CDC Barr, John (CDC) 0 114102072 Novel Peptide Substrates Recognizable By Type E Botulinum Neurotoxin E-528-2013-0 Filing authorized Centers for Disease Control and Prevention (CDC) 83738793 Taylor-Mulneix, Dawn dawn.taylor-mulneix@nih.gov
United States of America dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-2752] Improved Botulism, Botulinum Neurotoxin Type-E Diagnostics&body=Please send me information about technology [TAB-2752] Improved Botulism, Botulinum Neurotoxin Type-E Diagnostics. Taylor-Mulneix, Dawn<br><a href="mailto:dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-2752] Improved Botulism, Botulinum Neurotoxin Type-E Diagnostics&body=Please send me information about technology [TAB-2752] Improved Botulism, Botulinum Neurotoxin Type-E Diagnostics.">dawn.taylor-mulneix@nih.gov</a><br> 114166637 E-528-2013-0 E-528-2013-0-US-02 PEPTIDE SUBSTRATES RECOGNIZABLE BY TYPE E BOLULINUM NEUROTOXIN National Stage US 10,408,837 15/103,295 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10408837 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10408837">10,408,837</a><br />Filed on 2016-06-09<br />Status: Issued 114167581 E-528-2013-0 E-528-2013-0-PCT-01 Peptide Substrates For Detection of Type E Botulinum Neurotoxin And Methods Of Use PCT Patent Cooperation Treaty PCT/US2013/073885 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2013/073885<br />Filed on 2013-12-09<br />Status: Expired 114125067 DXXXXX 114125068 DAXXXX 114125069 DA3XXX 114125070 DA5XXX 114125071 ACXXXX 114125072 AAXXXX 114125073 VBXXXX 114125074 VJXXXX 114125075 VKXXXX 114125076 VLXXXX 114125077 WAXXXX 114125078 WBXXXX 114125079 WCXXXX 114125080 WFXXXX 114125081 WIXXXX 114125082 WMXXXX 114125083 XCXXXX 114125084 XDXXXX 114125085 XHXXXX 114125086 YBXXXX 114146336 Novel 114146337 Peptide 114146338 SUBSTRATES 114146339 Recognizable 114146340 TYPE 114146341 e 114146342 Bolulinum 114146343 Neurotoxin 114146344 CDC Docket Import 114146345 CDC Docket Import CDC Prosecuting 114146346 Biodefense 114146347 Biodetection 114146348 toxin 114146349 BACTERIA 114146350 Bacterial 114146351 MASS SPECTROMETER 114146352 Mass spectrometry TAB-2735 114096914 Exposure and Activity Detection Assays for Anthrax Lethal Factor and Lethal Toxin CDC Antibodies, Consumer Products, Diagnostics, Immunology, Infectious Disease, Licensing, Occupational Safety and Health, Research Materials, Therapeutics, Vaccines Antibodies Consumer Products Diagnostics Immunology Infectious Disease Licensing Occupational Safety and Health Research Materials Therapeutics Vaccines John Barr, Anne Boyer, Conrad Quinn This CDC developed invention identifies an assay for extremely fast and sensitive detection of <em>Bacillus anthracis</em> lethal toxin (LTx), the toxin responsible for the lethal effects of anthrax infection. This assay has already been successfully tested in animals and will allow for early detection of anthrax exposure and screening of lethal factors to monitor anthrax toxicity, for example for vaccine trial candidates.<br /><br /> LTx is composed of two proteins, protective antigen (PA) and lethal factor (LF). In one scenario, the assay effectively detects LF by first using magnetic protein G beads to capture and concentrate LF in samples, then testing for LF on the bead by reacting it with a peptide substrate designed to mimic LF's natural target. By using techniques such as mass spectrometry, FRET or liquid chromatography, this test can check for LF rapidly and with extraordinary specificity and sensitivity. Methodology and basic assay validation have been confirmed in animals and naturally-exposed (by contaminated meat in a Bangladesh processing facility) human serum samples. <ul> <li>Rapid turnaround</li> <li>Highly sensitive-detects picomolar toxin levels</li> <li>Reproducible and quantitative anthrax lethal factor (LF) assessment</li> <li>Easily adaptable for high-throughput screening of numerous specimens</li> </ul> <ul> <li>Emergency anthrax exposure diagnostics</li> <li>Testing of and research into anthrax therapeutics, vaccines</li> <li>Biodefense, biosecurity</li> <li>Livestock health screening</li> </ul> Various international filings pending or issued 2022-03-27 2025-05-09 2025-05-09 2014-01-27 02706, AA5XXX, AAXXXX, Anthrax, AXXXXX, CDC Docket Import, CDC Docket Import CDC Prosecuting, DA3XXX, DA5XXX, DAXXXX, Detection, Diagnosis, diagnostic, Diagnostic assay, diagnostic in vitro, DXXXXX, FACTORS, I01306, I-013-06, I-027-06, ONDIEH-NCEH, Pathogenicity, VBXXXX, VJXXXX, VOXXXX, WAXXXX, WBXXXX, WFXXXX, WHXXXX, WIXXXX, WJXXXX, WKXXXX, WMXXXX, XAXXXX, XCXXXX, YBXXXX, YCXXXX, YDXXXX, YEXXXX False True <ul> <li>In vitro data available</li> <li>In vivo data available (animal)</li> <li>In vivo data available (human)</li> <li>In situ data available (on-site)</li> </ul> True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract E-158-2013-2 E-167-2013-0 E-203-2013-0 E-210-2013-0 E-474-2013-0 114172012 Boyer AE, et al http://www.ncbi.nlm.nih.gov/pubmed/17929949 <a href="http://www.ncbi.nlm.nih.gov/pubmed/17929949">Boyer AE, et al</a> 114172013 Boyer AE, et al http://www.ncbi.nlm.nih.gov/pubmed/19506008 <a href="http://www.ncbi.nlm.nih.gov/pubmed/19506008">Boyer AE, et al</a> 114172014 Kuklenyik Z, et al. http://www.ncbi.nlm.nih.gov/pubmed/21302970 <a href="http://www.ncbi.nlm.nih.gov/pubmed/21302970">Kuklenyik Z, et al.</a> 114172015 Boyer AE, et al. http://www.ncbi.nlm.nih.gov/pubmed/21908727 <a href="http://www.ncbi.nlm.nih.gov/pubmed/21908727">Boyer AE, et al.</a> 114108436 Quinn, Conrad CDC - DIR CDC Quinn, Conrad (CDC) 0 114108437 Barr, John CDC - DIR CDC Barr, John (CDC) 0 114108435 Boyer, Anne CDC - DIR CDC Boyer, Anne (CDC) 1 114108435 Boyer, Anne CDC - DIR CDC Boyer, Anne (CDC) 1 114108436 Quinn, Conrad CDC - DIR CDC Quinn, Conrad (CDC) 0 114108437 Barr, John CDC - DIR CDC Barr, John (CDC) 0 114102052 Detection Of Anthrax Pathogenicity Factors (I-013-06, I-027-06) E-196-2013-0 Filing authorized Centers for Disease Control and Prevention (CDC) 83738793 Taylor-Mulneix, Dawn dawn.taylor-mulneix@nih.gov
United States of America dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-2735] Exposure and Activity Detection Assays for Anthrax Lethal Factor and Lethal Toxin&body=Please send me information about technology [TAB-2735] Exposure and Activity Detection Assays for Anthrax Lethal Factor and Lethal Toxin. Taylor-Mulneix, Dawn<br><a href="mailto:dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-2735] Exposure and Activity Detection Assays for Anthrax Lethal Factor and Lethal Toxin&body=Please send me information about technology [TAB-2735] Exposure and Activity Detection Assays for Anthrax Lethal Factor and Lethal Toxin.">dawn.taylor-mulneix@nih.gov</a><br> 114167521 E-196-2013-0 E-196-2013-0-US-01 Detection Of Anthrax Pathogenicity Factors PRV US 60/773,489 Abandoned US <br />Provisional (PRV) 60/773,489<br />Filed on 2006-02-15<br />Status: Abandoned 114167522 E-196-2013-0 E-196-2013-0-PCT-02 Detection Of Anthrax Pathogenicity Factors PCT Patent Cooperation Treaty PCT/US2007/004156 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2007/004156<br />Filed on 2007-02-15<br />Status: Expired 114167523 E-196-2013-0 E-196-2013-0-US-03 Detection Of Anthrax Pathogenicity Factors ORD US 8,663,926 11/675,233 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8663926 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8663926">8,663,926</a><br />Filed on 2007-02-15<br />Status: Abandoned 114124713 AAXXXX 114124714 AA5XXX 114124715 DXXXXX 114124716 DAXXXX 114124717 DA3XXX 114124718 DA5XXX 114124719 AXXXXX 114124720 VBXXXX 114124721 VJXXXX 114124722 VOXXXX 114124723 WAXXXX 114124724 WBXXXX 114124725 WFXXXX 114124726 WHXXXX 114124727 WIXXXX 114124728 WJXXXX 114124729 WKXXXX 114124730 WMXXXX 114124731 XAXXXX 114124732 XCXXXX 114124733 YBXXXX 114124734 YCXXXX 114124735 YDXXXX 114124736 YEXXXX 114146129 Detection 114146130 Anthrax 114146131 Pathogenicity 114146132 FACTORS 114146133 I-027-06 114146134 I-013-06 114146135 02706 114146136 I01306 114146137 CDC Docket Import 114146138 CDC Docket Import CDC Prosecuting 114146139 ONDIEH-NCEH 114146140 Diagnosis 114146141 Diagnostic assay 114146142 diagnostic 114146143 diagnostic in vitro TAB-2733 114096912 Sensitive Method for Detection and Quantification of Anthrax, Bordetella pertussis, Clostridium difficile, Clostridium botulinum and Other Pathogen-Derived Toxins in Human and Animal Plasma CDC Computational models/software, Consumer Products, Diagnostics, Infectious Disease, Licensing, Medical Devices, Non-Medical Devices, Occupational Safety and Health, Research Equipment, Research Materials, Software / Apps, Therapeutics, Vaccines Computational models/software Consumer Products Diagnostics Infectious Disease Licensing Medical Devices Non-Medical Devices Occupational Safety and Health Research Equipment Research Materials Software / Apps Therapeutics Vaccines John Barr, Anne Boyer, Zsuzsanna Kuklenyik, Renato Lins, Conrad Quinn CDC research scientists have developed a method to identify and quantify the activity of pathogenic bacterial adenylate cyclase toxins by liquid chromatography tandem mass spectrometry (LC-MS/MS). Bacterial protein toxins are among the most potent natural poisons known, causing paralysis, immune system collapse, hemorrhaging and death in some cases. A useful tool for quantitative detection of specific toxin activity in clinical samples will provide insights into the kinetics of intoxication, stage of infection and present stage of pathogenesis. <p>This rapid, high-throughput analysis method will provide measurements that quantify the efficacy of toxin-based therapeutics and support patient management decisions during treatment. This technology is specific, ultrasensitive and can be implemented to detect toxins from a wide range of pathogenic bacteria. This method could be fabricated into a kit format to deliver to state or research laboratories for use during an anthrax emergency or for research purposes, i.e. animal studies evaluating anthrax therapeutics. This technology may be easily applied to detection/diagnosis of additional pathogenic bacterial species infections as well.</p> <ul> <li>Presently no individual patient screening assay for anthrax-exposure is widely available; exposure is determined by public health investigation and environmental-sampling tests</li> <li>Current tests lack sensitivity and evidence of effectiveness</li> <li>Relatively rapid and exquisitely sensitive method for the detection and quantification of bacterial toxin activity from very small blood samples, accurately assessing exposure and infection</li> </ul> <ul> <li>Detect toxins from a wide range of pathogenic bacteria</li> <li>Biodefense, biosecurity diagnostics</li> </ul> 2022-03-27 2025-05-09 2025-05-09 2014-01-20 AA5XXX, ADENYLATE, CDC Docket Import, CDC Docket Import CDC Prosecuting, CYCLASE, DA3XXX, DAXXXX, Detection, DXXXXX, ONDIEH-NCEH, VBXXXX, VJXXXX, WAXXXX, WBXXXX, WCXXXX, WIXXXX, WMXXXX, XCXXXX, XDXXXX, XHXXXX, XJXXXX, YBXXXX, YCXXXX, YDXXXX False True <ul> <li>In vitro data available</li> <li>In vivo data available (animal)</li> <li>In vivo data available (human)</li> </ul> True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract E-157-2013-0 E-158-2013-2 E-196-2013-0 E-203-2013-0 E-210-2013-0 E-474-2013-0 114172009 Duriez E, et al. http://www.ncbi.nlm.nih.gov/pubmed/19522516 <a href="http://www.ncbi.nlm.nih.gov/pubmed/19522516">Duriez E, et al.</a> 114172010 Boyer AE, et al. http://www.ncbi.nlm.nih.gov/pubmed/21403598 <a href="http://www.ncbi.nlm.nih.gov/pubmed/21403598">Boyer AE, et al.</a> 114108426 Lins, Renato CDC - DIR CDC Lins, Renato (CDC) 0 114108427 Kuklenyik, Zsuzsanna CDC - DIR CDC Kuklenyik, Zsuzsanna (CDC) 0 114108428 Quinn, Conrad CDC - DIR CDC Quinn, Conrad (CDC) 0 114108429 Barr, John CDC - DIR CDC Barr, John (CDC) 0 114108425 Boyer, Anne CDC - DIR CDC Boyer, Anne (CDC) 1 114108425 Boyer, Anne CDC - DIR CDC Boyer, Anne (CDC) 1 114108426 Lins, Renato CDC - DIR CDC Lins, Renato (CDC) 0 114108427 Kuklenyik, Zsuzsanna CDC - DIR CDC Kuklenyik, Zsuzsanna (CDC) 0 114108428 Quinn, Conrad CDC - DIR CDC Quinn, Conrad (CDC) 0 114108429 Barr, John CDC - DIR CDC Barr, John (CDC) 0 114102049 Detection Of Adenylate Cyclase E-167-2013-0 Closed Centers for Disease Control and Prevention (CDC) 83738793 Taylor-Mulneix, Dawn dawn.taylor-mulneix@nih.gov
United States of America dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-2733] Sensitive Method for Detection and Quantification of Anthrax, Bordetella pertussis, Clostridium difficile, Clostridium botulinum and Other Pathogen-Derived Toxins in Human and Animal Plasma&body=Please send me information about technology [TAB-2733] Sensitive Method for Detection and Quantification of Anthrax, Bordetella pertussis, Clostridium difficile, Clostridium botulinum and Other Pathogen-Derived Toxins in Human and Animal Plasma. Taylor-Mulneix, Dawn<br><a href="mailto:dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-2733] Sensitive Method for Detection and Quantification of Anthrax, Bordetella pertussis, Clostridium difficile, Clostridium botulinum and Other Pathogen-Derived Toxins in Human and Animal Plasma&body=Please send me information about technology [TAB-2733] Sensitive Method for Detection and Quantification of Anthrax, Bordetella pertussis, Clostridium difficile, Clostridium botulinum and Other Pathogen-Derived Toxins in Human and Animal Plasma.">dawn.taylor-mulneix@nih.gov</a><br> 114167511 E-167-2013-0 E-167-2013-0-US-01 Detection Of Adenylate Cyclase PRV US 61/411,056 Abandoned US <br />Provisional (PRV) 61/411,056<br />Filed on 2010-11-08<br />Status: Abandoned 114167512 E-167-2013-0 E-167-2013-0-PCT-02 Detection Of Adenylate Cyclase PCT Patent Cooperation Treaty PCT/US2011/059739 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2011/059739<br />Filed on 2011-11-08<br />Status: Expired 114167513 E-167-2013-0 E-167-2013-0-US-06 Detection Of Adenylate Cyclase National Stage US 13/878,378 Abandoned US <br />National Stage 13/878,378<br />Filed on 2013-04-08<br />Status: Abandoned 114124679 AA5XXX 114124680 DXXXXX 114124681 DAXXXX 114124682 DA3XXX 114124683 VBXXXX 114124684 VJXXXX 114124685 WAXXXX 114124686 WBXXXX 114124687 WCXXXX 114124688 WIXXXX 114124689 WMXXXX 114124690 XCXXXX 114124691 XDXXXX 114124692 XHXXXX 114124693 XJXXXX 114124694 YBXXXX 114124695 YCXXXX 114124696 YDXXXX 114146094 Detection 114146095 ADENYLATE 114146096 CYCLASE 114146097 CDC Docket Import 114146098 CDC Docket Import CDC Prosecuting 114146099 ONDIEH-NCEH TAB-2702 114096883 Improved Protein Quantification Process and Vaccine Quality Control Production CDC Consumer Products, Diagnostics, Infectious Disease, Licensing, Occupational Safety and Health, Research Equipment, Research Materials Consumer Products Diagnostics Infectious Disease Licensing Occupational Safety and Health Research Equipment Research Materials John Barr, Ruben Donis, Zhu Guo, Leah Luna, James (Jim) Pirkle, Tracie Williams This CDC invention is a method for identifying and quantifying a group of proteins in a complex mixture by a liquid chromatography-tandem mass spectrometry assay. The technology was developed for influenza although it can be used for a wide variety of protein quantification applications. As specifically developed, conserved peptides from the proteins of influenza (hemagglutinin, neuramidase, matrix 1 and 2, and nucleoprotein) have been synthesized and labeled to be used as internal standards for the quantification of those proteins in a complex (biological or manufactured) matrix. One or more of these peptides can be used to simultaneously detect and quantify the target proteins by establishing mass ratios and calibration curve comparison. This method for quantifying influenza proteins and peptides in samples has potential for improving vaccine production quality control and therefore, the effectiveness and overall cost-efficiency of influenza vaccines. <ul> <li>Simultaneous, precise protein detection and quantification for complex mixtures</li> <li>Rapid; method cuts investigation/research time needed to formulate and optimize novel vaccines for emergent influenza strains</li> <li>Improved vaccine cost and production efficiency</li> </ul> <ul> <li>Vaccine production, especially influenza-related</li> <li>Quality assurance, quality control</li> <li>Influenza surveillance programs</li> </ul> 2022-03-27 2025-05-09 2025-05-09 2013-12-23 AA2XXX, AA5XXX, AA6XXX, AG2XXX, AXXXXX, CDC Docket Import, CDC Docket Import CDC Prosecuting, CONTROL, DA4BXX, DA4XXX, DAXXXX, DDXXXX, DXXXXX, Improved, PROCESS, Protein, Quality, QUANTIFICATION, Therewith, Vaccine, viral, VJXXXX, VKXXXX, VLXXXX, WBXXXX, WFXXXX, WHXXXX, WIXXXX, WMXXXX, XCXXXX, XHXXXX, YAXXXX, YBXXXX False True <ul> <li>Early-stage</li> <li>In vitro data available</li> </ul> True 52406768 Discovery 52406768 NIHTT 37470483 Website Abstract 114171970 Williams TL, et al. http://www.ncbi.nlm.nih.gov/pubmed/18440105 <a href="http://www.ncbi.nlm.nih.gov/pubmed/18440105">Williams TL, et al.</a> 114171971 Pierce CL, et al. http://www.ncbi.nlm.nih.gov/pubmed/21591780 <a href="http://www.ncbi.nlm.nih.gov/pubmed/21591780">Pierce CL, et al.</a> 114171972 Williams TL, et al. http://www.ncbi.nlm.nih.gov/pubmed/22197963 <a href="http://www.ncbi.nlm.nih.gov/pubmed/22197963">Williams TL, et al.</a> 114171973 Woolfitt AR, et al. http://www.ncbi.nlm.nih.gov/pubmed/19364092 <a href="http://www.ncbi.nlm.nih.gov/pubmed/19364092">Woolfitt AR, et al.</a> 114108337 Pirkle, James (Jim) CDC - DIR CDC Pirkle, James (Jim) (CDC) 0 114108338 Donis, Ruben CDC - DIR CDC Donis, Ruben (CDC) 0 114108339 Luna, Leah CDC - DIR CDC Luna, Leah (CDC) 0 114108340 Guo, Zhu CDC - DIR CDC Guo, Zhu (CDC) 0 114108341 Barr, John CDC - DIR CDC Barr, John (CDC) 0 114108336 Williams, Tracie CDC - DIR CDC Williams, Tracie (CDC) 1 114108336 Williams, Tracie CDC - DIR CDC Williams, Tracie (CDC) 1 114108337 Pirkle, James (Jim) CDC - DIR CDC Pirkle, James (Jim) (CDC) 0 114108338 Donis, Ruben CDC - DIR CDC Donis, Ruben (CDC) 0 114108339 Luna, Leah CDC - DIR CDC Luna, Leah (CDC) 0 114108340 Guo, Zhu CDC - DIR CDC Guo, Zhu (CDC) 0 114108341 Barr, John CDC - DIR CDC Barr, John (CDC) 0 114102012 Improved Viral Protein Quantification Process And Vaccine Quality Control Therewith E-212-2013-0 Closed Centers for Disease Control and Prevention (CDC) 83738793 Taylor-Mulneix, Dawn dawn.taylor-mulneix@nih.gov
United States of America dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-2702] Improved Protein Quantification Process and Vaccine Quality Control Production&body=Please send me information about technology [TAB-2702] Improved Protein Quantification Process and Vaccine Quality Control Production. Taylor-Mulneix, Dawn<br><a href="mailto:dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-2702] Improved Protein Quantification Process and Vaccine Quality Control Production&body=Please send me information about technology [TAB-2702] Improved Protein Quantification Process and Vaccine Quality Control Production.">dawn.taylor-mulneix@nih.gov</a><br> 114167435 E-212-2013-0 E-212-2013-0-US-01 Improved Viral Protein Quantification Process And Vaccine Quality Control Therewith PRV US 60/992,520 Abandoned US <br />Provisional (PRV) 60/992,520<br />Filed on 2007-12-05<br />Status: Abandoned 114167436 E-212-2013-0 E-212-2013-0-PCT-02 Improved Viral Protein Quantification Process And Vaccine Quality Control Therewith PCT Patent Cooperation Treaty PCT/US2008/013396 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2008/013396<br />Filed on 2008-12-05<br />Status: Expired 114167437 E-212-2013-0 E-212-2013-0-US-04 Improved Viral Protein Quantification Process And Vaccine Quality Control Therewith National Stage US 8,530,182 12/746,649 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8530182 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8530182">8,530,182</a><br />Filed on 2011-04-15<br />Status: Abandoned 114124205 AXXXXX 114124206 AA2XXX 114124207 AA5XXX 114124208 DXXXXX 114124209 DAXXXX 114124210 DDXXXX 114124211 DA4XXX 114124212 DA4BXX 114124213 AA6XXX 114124214 AG2XXX 114124215 VJXXXX 114124216 VKXXXX 114124217 VLXXXX 114124218 WBXXXX 114124219 WFXXXX 114124220 WHXXXX 114124221 WIXXXX 114124222 WMXXXX 114124223 XCXXXX 114124224 XHXXXX 114124225 YAXXXX 114124226 YBXXXX 114145818 Improved 114145819 viral 114145820 Protein 114145821 QUANTIFICATION 114145822 PROCESS 114145823 Vaccine 114145824 Quality 114145825 CONTROL 114145826 Therewith 114145827 CDC Docket Import 114145828 CDC Docket Import CDC Prosecuting TAB-5026 158755950 Bioplatform to Identify and Characterize Pathogens and Therapies against Tuberculosis and Other Granulomatous Diseases. CDC Collaboration, Infectious Disease, Licensing, Research Materials, Therapeutics Collaboration Infectious Disease Licensing Research Materials Therapeutics Allison Kline, Wen Li, James Posey, Suraj Sable <p>Treatment for human tuberculosis (TB) and other granulomatous diseases would benefit from high- throughput screening (HTS)-compatible platform replicating physiological conditions in hallmark granuloma lesions. However, currently available screening platforms and 2-D and 3-D cell culture systems lack throughput and key features, and relevant microenvironments present in human TB granulomas, such as the formation of well-organized tuberculoma structure, granuloma lesions, biochemical and physiological gradients, diverse forms, and development of features like enhanced central hypoxia, necrosis, acidosis, and cavity formation. This technology is for bioengineering an HTS-compatible and shelf-stable in vitro tuberculoma bioplatform similar to human tuberculous granuloma lesions for rapid screening of pathogen-targeted and host-directed compounds and other therapeutics against the mycobacterial strains causing TB. This robust 3-D bioplatform exhibits the key attributes and microenvironments of human TB granuloma lesions. The bioplatform can be used to investigate host-pathogen interactions and trained immunity against mycobacterial infections and identify and characterize antimicrobial therapeutics, biologics, and immunotherapies against TB, other mycobacterial diseases, and associated co-infections and morbidities. This tool can accelerate drug discovery efforts and translational advances against various granulomatous diseases.</p> <ul> <li>Robust, tractable, and HTS-compatible.</li> <li>Freshly bio-engineered and cryo-stable versions. A cryo-stable version of the 3D tuberculoma bioplatform can be frozen for future use and revived on demand.</li> <li>Can be used at a BSL-2 laboratory.</li> <li>Can be easily transformed and scaled up for fully automated screening applications.</li> </ul> <ul> <li>Rapid screening of pathogen-targeted and host- directed compounds against TB and other mycobacterial diseases.</li> <li>Efficacy determination for TB therapeutic candidates.</li> <li>Identification of mode of action of TB therapeutic compounds.</li> <li>Identification and optimization of lead therapeutic candidate against TB and other mycobacterial diseases.</li> <li>Commercially available tool to study mycobacterial and granulomatous diseases.</li> </ul> CDC Division of Tuberculosis Elimination is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize 3D tuberculoma bioplatform and identify and characterize lead therapeutics for TB & co-infections. For collaboration opportunities, please contact: Technology Transfer Office TTO@cdc.gov; nxu2@cdc.gov 2024-10-23 2025-05-09 2025-05-09 2024-10-25 False True In vivo data available (animal) in situ data available True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract E-151-2023-0 158755987 Sable, Suraj CDC - DIR CDC Sable, Suraj (CDC) 1 158755991 Posey, James CDC - DIR CDC Posey, James (CDC) 2 158756020 Li, Wen CDC - DIR CDC Li, Wen (CDC) 3 158756024 Kline, Allison CDC - DIR CDC Kline, Allison (CDC) 4 158755987 Sable, Suraj CDC - DIR CDC Sable, Suraj (CDC) 1 158755991 Posey, James CDC - DIR CDC Posey, James (CDC) 2 158756020 Li, Wen CDC - DIR CDC Li, Wen (CDC) 3 158756024 Kline, Allison CDC - DIR CDC Kline, Allison (CDC) 4 158755953 Development of a Novel Tuberculoma Bioplatform for the Identification and Characterization of Pathogen and Host-directed Therapies against Tuberculosis. E-151-2023-0 Filing authorized CDC - DIR, Centers for Disease Control and Prevention (CDC), Centers for Disease Control and Prevention (CDC) 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-5026] Bioplatform to Identify and Characterize Pathogens and Therapies against Tuberculosis and Other Granulomatous Diseases.&body=Please send me information about technology [TAB-5026] Bioplatform to Identify and Characterize Pathogens and Therapies against Tuberculosis and Other Granulomatous Diseases.. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-5026] Bioplatform to Identify and Characterize Pathogens and Therapies against Tuberculosis and Other Granulomatous Diseases.&body=Please send me information about technology [TAB-5026] Bioplatform to Identify and Characterize Pathogens and Therapies against Tuberculosis and Other Granulomatous Diseases..">jonathan.motley@nih.gov</a><br> TAB-4994 157260493 Monoclonal Antibodies for the Detection of Antiretroviral Integrase Inhibitors CDC Infectious Disease, Materials Available Infectious Disease Materials Available Jeffrey Johnson, Jan Pohl, Xierong Wei, Ae Saekhou Youngpairoj <p>Pre-exposure prophylaxis (PrEP) is a critical component in the fight against HIV but is only effective if persons prescribed PrEP are adhering to the regimens to maintain appropriate drug levels. As PrEP regimens have moved from daily pills to longer lasting injections, the ability to quickly measure and monitor the circulating drug levels of PrEP drugs has increased importance.</p> <p>The CDC designed and developed the first monoclonal antibodies (clones 3H9E4 and 6E6F1) that have cross-reactivity to the key HIV integrase inhibitors cabotegravir, dolutegravir and bictegravir. These are key inhibitors in highly active HIV treatment and prevention. The monoclonal antibodies can be used for specific and sensitive detection of cabotegravir, dolutegravir and bictegravir integrase inhibitors and allow for both rapid, low-complexity point-of-care with finger-stick blood and high-throughput enzyme immunoassay (EIA) testing to determine if protective levels of the inhibitors are present.</p> <ul> <li> The sensitivity exceeds that of mass spectrometry to allow for flexible assay use-cases, including rapid point of care and self-testing using fingerstick whole blood. </ul> <ul> <li> Clinical monitoring of HIV integrase inhibitor concentrations following delays in long-acting pre-exposure prophylaxis (PrEP) visits; may avoid the need to re-initiate the need to restart taking oral pills before resuming injections.</li> <li> Self-testing for assurances of protective levels by persons taking integrase inhibitor PrEP regimens. </li> <li> HIV integrase inhibitor detection for treatment adherence evaluation and national adherence surveillance.</li> <li> Help clinicians determine if the presence of HIV integrase inhibitors are affecting HIV diagnostic test results as HIV diagnostic tests were not validated and approved with persons receiving antiretroviral drugs.</li> </ul> The CDC is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize assays for point of care testing. For collaboration opportunities, please contact the CDC Technology Transfer Office at tto@cdc.gov. 2024-07-23 2025-05-09 2025-05-09 2024-09-27 False False In vitro data available True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract E-009-2024 157260631 Johnson, Jeffrey CDC - DIR CDC Johnson, Jeffrey (CDC) 1 157260638 Youngpairoj, Ae Saekhou CDC - DIR CDC Youngpairoj, Ae Saekhou (CDC) 2 157260643 Wei, Xierong CDC - DIR CDC Wei, Xierong (CDC) 3 157260659 Pohl, Jan CDC - DIR CDC Pohl, Jan (CDC) 4 157260631 Johnson, Jeffrey CDC - DIR CDC Johnson, Jeffrey (CDC) 1 157260638 Youngpairoj, Ae Saekhou CDC - DIR CDC Youngpairoj, Ae Saekhou (CDC) 2 157260643 Wei, Xierong CDC - DIR CDC Wei, Xierong (CDC) 3 157260659 Pohl, Jan CDC - DIR CDC Pohl, Jan (CDC) 4 157260496 Monoclonal antibodies for the detection of the antiretroviral integrase inhibitors cabotegravir, dolutegravir and bictegravir E-009-2024-0 Research Material CDC - DIR 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-4994] Monoclonal Antibodies for the Detection of Antiretroviral Integrase Inhibitors&body=Please send me information about technology [TAB-4994] Monoclonal Antibodies for the Detection of Antiretroviral Integrase Inhibitors. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-4994] Monoclonal Antibodies for the Detection of Antiretroviral Integrase Inhibitors&body=Please send me information about technology [TAB-4994] Monoclonal Antibodies for the Detection of Antiretroviral Integrase Inhibitors.">jonathan.motley@nih.gov</a><br> TAB-3423 114097297 Simian T-Cell Lymphotropic Virus Strain Type 3 (STLV-3) Subtype D Variant, a Highly Divergent STLV-3, for Development of Diagnostics, Therapeutics, Vaccines and Research Tools CDC Collaboration, Consumer Products, Diagnostics, Infectious Disease, Licensing, Occupational Safety and Health, Research Materials, Therapeutics, Vaccines Collaboration Consumer Products Diagnostics Infectious Disease Licensing Occupational Safety and Health Research Materials Therapeutics Vaccines Donald Burke, Thomas Folks, Walid Heneine, David Sintasath, William Switzer, Nathan Wolfe Simian T-cell lymphotropic viruses (STLV) are nonhuman primate retroviruses closely related to the human T-lymphotropic virus (HTLV). Types I, II, and III of HTLV have been found in humans and are believed to have originated from cross-species transmission of STLV from infected nonhuman primates. The HTLV viruses are known to cause leukemia, lymphoma, and neurological disorders.<br /><br/> CDC researchers discovered a strain of simian T-cell lymphotropic virus type 3 known as STLV-3 subtype D variant. STLV-3 may be widespread in primates hunted in West-Central Africa, including the monkey Cercopithecus mona, which has a known geographic habitat range from Ghana to Cameroon. This increases the risk to hunters and persons in contact with primate bushmeat for infection with STLV-3-like viruses. Thus, the discovery of the highly divergent STLV-3 subtype D variant implies that a similar virus (HTLV-3) subtype D variant could be spreading undetected in humans. <ul> <li>Allows for detection of STLV strain STLV-3 subtype D variant</li> <li> Facilitates monitoring of viral diversity and study of zoonotic disease transmission</li> </ul> <ul> <li>Diagnostic reagents for clinical and research testing for STLV-3-like viruses in humans</li> <li> Diagnostic reagents for screening the blood supply for STLV-3 subtype D variant</li> <li>Testing of divergent strains of STLV and HTLV for susceptibility to known or experimental antiretrovirals (ARV drugs) using in vitro assays</li> <li>Reagents for vaccines to HTLV</li> <li>Zoonosis monitoring and surveillance</li> <li>Simian/human T-cell lymphotropic virus research</li> </ul> The CDC Technology Transfer Office (TTO) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize: Simian T-Cell Lymphotropic Virus Strain Type 3 (STLV-3) Subtype D Variant, a Highly Divergent STLV-3, for Development of Diagnostics, Therapeutics, Vaccines and Research Tools For collaboration opportunities, please contact CDC TTO at <a href="mailto:tto@cdc.gov">tto@cdc.gov</a>or 1-404-639-1330. For collaboration opportunities, please contact CDC TTO at <a href="mailto:tto@cdc.gov">tto@cdc.gov</a> or 1-404-639-1330. 2022-03-08 2025-05-09 2025-05-09 2020-10-26 CDC Docket Import, CDC Docket Import CDC Prosecuting, Listed LPM Houze as of 4/15/2015, lymphotropic, Novel, OID-NCHHSTP-DHPSE, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Simian, T-cell, virus, VLXXXX, VOXXXX, WBXXXX, WFXXXX, WHXXXX, WIXXXX, WKXXXX, WMXXXX, WNXXXX, XEXXXX, XKXXXX False True True NIHTT 37470483 Website Abstract E-281-2013-0 114172586 Liégeois, F. et al. https://www.ncbi.nlm.nih.gov/pubmed/17976676 <a href="https://www.ncbi.nlm.nih.gov/pubmed/17976676">Liégeois, F. et al. </a> 114172587 Sintasath, DM et al. https://www.ncbi.nlm.nih.gov/pubmed/19193260 <a href="https://www.ncbi.nlm.nih.gov/pubmed/19193260">Sintasath, DM et al. </a> 114110131 Heneine, Walid CDC - DIR CDC Heneine, Walid (CDC) 0 114110132 Folks, Thomas CDC - DIR Folks, Thomas 0 114110133 Burke, Donald CDC Burke, Donald (CDC) 0 114110134 Sintasath, David CDC Sintasath, David (CDC) 0 114110135 Wolfe, Nathan Wolfe, Nathan 0 114110130 Switzer, William CDC - DIR CDC Switzer, William (CDC) 1 114110130 Switzer, William CDC - DIR CDC Switzer, William (CDC) 1 114110131 Heneine, Walid CDC - DIR CDC Heneine, Walid (CDC) 0 114110132 Folks, Thomas CDC - DIR Folks, Thomas 0 114110133 Burke, Donald CDC Burke, Donald (CDC) 0 114110134 Sintasath, David CDC Sintasath, David (CDC) 0 114110135 Wolfe, Nathan Wolfe, Nathan 0 114102545 NOVEL SIMIAN T-CELL LYMPHOTROPIC VIRUS E-303-2013-2 Filing authorized Centers for Disease Control and Prevention (CDC), Johns Hopkins University 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-3423] Simian T-Cell Lymphotropic Virus Strain Type 3 (STLV-3) Subtype D Variant, a Highly Divergent STLV-3, for Development of Diagnostics, Therapeutics, Vaccines and Research Tools&body=Please send me information about technology [TAB-3423] Simian T-Cell Lymphotropic Virus Strain Type 3 (STLV-3) Subtype D Variant, a Highly Divergent STLV-3, for Development of Diagnostics, Therapeutics, Vaccines and Research Tools. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-3423] Simian T-Cell Lymphotropic Virus Strain Type 3 (STLV-3) Subtype D Variant, a Highly Divergent STLV-3, for Development of Diagnostics, Therapeutics, Vaccines and Research Tools&body=Please send me information about technology [TAB-3423] Simian T-Cell Lymphotropic Virus Strain Type 3 (STLV-3) Subtype D Variant, a Highly Divergent STLV-3, for Development of Diagnostics, Therapeutics, Vaccines and Research Tools.">jonathan.motley@nih.gov</a><br> 114169062 E-303-2013-2 E-303-2013-2-PCT-01 NOVEL SIMIAN T-CELL LYMPHOTROPIC VIRUS PCT COMB Patent Cooperation Treaty PCT/US2008/064270 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2008/064270<br />Filed on 2008-05-20<br />Status: Expired 114169063 E-303-2013-2 E-303-2013-2-US-05 NOVEL SIMIAN T-CELL LYMPHOTROPIC VIRUS National Stage US 8,663,968 12/600,995 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8663968 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8663968">8,663,968</a><br />Filed on 2009-11-19<br />Status: Abandoned 114169064 E-303-2013-2 E-303-2013-2-US-12 NOVEL SIMIAN T-CELL LYMPHOTROPIC VIRUS DIV US 14/013,947 Abandoned US <br />Divisional (DIV) 14/013,947<br />Filed on 2013-08-29<br />Status: Abandoned 114128343 VOXXXX 114128344 VLXXXX 114128345 WBXXXX 114128346 WFXXXX 114128347 WHXXXX 114128348 WIXXXX 114128349 WKXXXX 114128350 WNXXXX 114128351 WMXXXX 114128352 XEXXXX 114128353 XKXXXX 114151953 Novel 114151954 Simian 114151955 T-cell 114151956 lymphotropic 114151957 virus 114151958 CDC Docket Import 114151959 CDC Docket Import CDC Prosecuting 114151960 OID-NCHHSTP-DHPSE 114151961 Listed LPM Houze as of 4/15/2015 114151962 Pre LPM working set 20150418 114151963 Post LPM Assignment Set 20150420 TAB-3368 114097269 Monoclonal Antibody to Detect the Antiretroviral Drug Emtricitabine – for HIV Drug Adherence Monitoring CDC Antibodies, Collaboration, Consumer Products, Diagnostics, Immunology, Infectious Disease, Licensing, Occupational Safety and Health, Research Materials Antibodies Collaboration Consumer Products Diagnostics Immunology Infectious Disease Licensing Occupational Safety and Health Research Materials Timothy Granade, Walid Heneine, Chou-Pong Pau, Jan Pohl, William Switzer, Ae Saekhou Youngpairoj, HaoQiang Zheng The U.S. Food and Drug Administration and World Health Organization (WHO) approved the antiretroviral drug emtricitabine (FTC)/ tenofovir disoproxil fumurate (TDF) combination for HIV pre-exposure prophylaxis (PrEP) in high risk populations. Efficacy of PrEP depends strongly on adherence to taking the FTC/TDF pill daily. In the US, the Centers for Disease Control and Prevention (CDC) estimates that 1.2 million Americans will benefit from PrEP. FTC is also a key component of antiretroviral therapy (ART) regimens of HIV-infected persons and significantly associated with adherence. According to reports from the WHO, 21.7 million HIV-infected persons worldwide were receiving ART by the end of 2017. Currently, laboratories use costly, complex, and time- consuming mass-spectrometry blood tests to monitor compliance in patients receiving PrEP and ART treatment.<br /><br /> CDC recently developed a monoclonal antibody (mAb) that specifically reacts with FTC. An enzyme immunoassay (EIA) test developed from the mAb could potentially maximize efficacy in PrEP users. The competitive EIA has clinically relevant sensitivity and specificity to FTC in urine. The mAb is also able to detect FTC in a lateral flow assay. These FTC assays may also aid ART management in HIV-infected persons to optimize treatment efficacy and maximize viral suppression. <ul> <li>The mAb has high sensitivity and specificity to FTC – does not react with naturally occurring similar molecules in humans</li> <li>Does not require costly mass spectrometry equipment and complex processing</li> <li> The technology can be used by a variety of healthcare providers </li> <li> Rapid results vs. a few weeks for standard lab results</li> <li>No need for blood collection or finger stick by healthcare workers – reducing risk of HIV exposure</li> <li> Pain-free, non-invasive testing of urine specimens</li> </ul> <ul> <li>Development of plate-based enzyme immunoassays (EIAs) for a manufactured diagnostic kit and lateral flow assays for Point-of-care (POC) rapid diagnostics for antiretroviral drug emtricitabine (FTC) treatment adherence</li> <li>Testing to monitor at-risk populations for HIV on PrEP</li> <li>Testing to monitor HIV-infected populations on ART</li> <li>Testing in surveillance programs and clinical research (e.g., clinical trials)</li> <li> Use of assays and monoclonal antibody in laboratory research, in vitro and in vivo (e.g., animal models)</li> </ul> The CDC Technology Transfer Office (TTO) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize: - Monoclonal Antibody to Detect the Antiretroviral Drug Emtricitabine – for HIV Drug Adherence Monitoring. For collaboration opportunities, please contact CDC TTO at <a href="mailto:tto@cdc.gov">tto@cdc.gov</a> or 1-404-639-1330. 2022-03-08 2025-05-09 2025-05-09 2019-04-11 3'-dideoxy-5-fluoro-3'-thiacytidine, ANTIBODY, antiretroviral, Detection, Development, DRUG, emtricitabine, FTC:2', monoclonal, VLXXXX, WBXXXX, WFXXXX, WHXXXX, WIXXXX, XAXXXX, YAXXXX, YBXXXX False True True 52406768 Discovery 52406768 NIHTT 37470483 Website Abstract 114110022 Youngpairoj, Ae Saekhou CDC - DIR CDC Youngpairoj, Ae Saekhou (CDC) 0 114110023 Switzer, William CDC - DIR CDC Switzer, William (CDC) 0 114110024 Heneine, Walid CDC - DIR CDC Heneine, Walid (CDC) 0 114110025 Pau, Chou-Pong CDC - DIR CDC Pau, Chou-Pong (CDC) 0 114110026 Zheng, HaoQiang CDC - DIR CDC Zheng, HaoQiang (CDC) 0 114110027 Pohl, Jan CDC - DIR CDC Pohl, Jan (CDC) 0 114110021 Granade, Timothy CDC - DIR CDC Granade, Timothy (CDC) 1 114110021 Granade, Timothy CDC - DIR CDC Granade, Timothy (CDC) 1 114110022 Youngpairoj, Ae Saekhou CDC - DIR CDC Youngpairoj, Ae Saekhou (CDC) 0 114110023 Switzer, William CDC - DIR CDC Switzer, William (CDC) 0 114110024 Heneine, Walid CDC - DIR CDC Heneine, Walid (CDC) 0 114110025 Pau, Chou-Pong CDC - DIR CDC Pau, Chou-Pong (CDC) 0 114110026 Zheng, HaoQiang CDC - DIR CDC Zheng, HaoQiang (CDC) 0 114110027 Pohl, Jan CDC - DIR CDC Pohl, Jan (CDC) 0 114102513 Development Of A Monoclonal Antibody For The Detection Of The Antiretroviral Drug Emtricitabine (FTC:2',3'-dideoxy-5-fluoro-3'-thiacytidine) E-134-2018-0 Filing authorized Centers for Disease Control and Prevention (CDC) 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-3368] Monoclonal Antibody to Detect the Antiretroviral Drug Emtricitabine – for HIV Drug Adherence Monitoring &body=Please send me information about technology [TAB-3368] Monoclonal Antibody to Detect the Antiretroviral Drug Emtricitabine – for HIV Drug Adherence Monitoring . Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-3368] Monoclonal Antibody to Detect the Antiretroviral Drug Emtricitabine – for HIV Drug Adherence Monitoring &body=Please send me information about technology [TAB-3368] Monoclonal Antibody to Detect the Antiretroviral Drug Emtricitabine – for HIV Drug Adherence Monitoring .">jonathan.motley@nih.gov</a><br> 114168865 E-134-2018-0 E-134-2018-0-US-01 MONOCLONAL ANTIBODY FOR THE DETECTION OF THE ANTIRETROVIRAL DRUG EMTRICITABINE (FTC, 2',3'-DIDEOXY-5-FLUORO-3'-THIACYTIDINE) PRV US 62/696,751 Expired US <br />Provisional (PRV) 62/696,751<br />Filed on 2018-07-11<br />Status: Expired 114168895 E-134-2018-0 E-134-2018-0-PCT-02 MONOCLONAL ANTIBODY FOR THE DETECTION OF THE ANTIRETROVIRAL DRUG EMTRICITABINE (FTC, 2',3'-DIDEOXY-5-FLUORO-3'-THIACYTIDINE) PCT Patent Cooperation Treaty PCT/US2019/041195 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2019/041195<br />Filed on 2019-07-10<br />Status: Expired 114169084 E-134-2018-0 E-134-2018-0-US-06 MONOCLONAL ANTIBODY FOR THE DETECTION OF THE ANTIRETROVIRAL DRUG EMTRICITABINE (FTC, 2',3'-DIDEOXY-5-FLUORO-3'-THIACYTIDINE) National Stage US 11,186,651 17/255,763 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11186651 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11186651">11,186,651</a><br />Filed on 2020-12-23<br />Status: Issued 114128258 YAXXXX 114128260 YBXXXX 114128261 VLXXXX 114128262 WBXXXX 114128263 WFXXXX 114128264 WHXXXX 114128265 WIXXXX 114128266 XAXXXX 114151602 3'-dideoxy-5-fluoro-3'-thiacytidine 114151603 FTC:2' 114151604 emtricitabine 114151605 DRUG 114151606 antiretroviral 114151607 Detection 114151608 ANTIBODY 114151609 monoclonal 114151610 Development TAB-3325 114097244 Diagnostic Assay with Modified Cardiolipin for Detecting Active Syphilis Infections CDC Collaboration, Consumer Products, Diagnostics, Infectious Disease, Licensing, Occupational Safety and Health, Research Materials Collaboration Consumer Products Diagnostics Infectious Disease Licensing Occupational Safety and Health Research Materials Arnold Castro, Huiying Wang Syphilis is a sexually transmitted infection that remains a global health threat. The World Health Organization estimates that more than 12 million new cases are reported in adults annually worldwide. Syphilis rates are rising domestically as well. The rapid plasma reagin (RPR) test (including automated version) and the Venereal Disease Research Laboratory (VDRL) test are commercially available and used to detect/screen active infection. <br /><br /> CDC researchers have also developed a rapid serological test that detects active syphilis infections. The test is an immunoassay that uses modified cardiolipin as an antigen to detect anti-cardiolipin antibodies produced in response to lipoidal components released from host cells or <em>Treponema pallidum</em> cells damaged during the course of infection, offering a method of detecting active syphilis infections. This invention also comprises a method for preparing oxidized cardiolipin so that it is capable of linking to a protein for attachment to a solid support (such as a microporous membrane (i.e., nitrocellulose) or multi-well plate). <ul> <li>Can differentiate between prior exposure and active infection of syphilis</li> <li>Can be used in lateral flow, flow-through, or enzyme-linked immunosorbent assay (ELISA) testing formats</li> <li>Can be used in a point-of-care assay allowing for convenience, rapid results, low cost, and field use</li> </ul> <ul> <li>Clinical diagnosis of active syphilis infections</li> <li> Monitoring of infection status in response to standard syphilis treatment</li> <li>Can be used to detect nontreponemal antibodies only or used in assays which co-detect nontreponemal and treponemal antibodies </li> <li>Monitoring and public health surveillance</li> </ul> The CDC Technology Transfer Office (TTO) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize- Diagnostic Assay with Modified Cardiolipin for Detecting Active Syphilis Infections. For collaboration opportunities, please contact CDC TTO at <a href="mailto:tto@cdc.gov">tto@cdc.gov</a> or 1-404-639-1330. International patents issued in Brazil, China, Japan, and Europe 2022-03-08 2025-05-09 2025-05-09 2018-09-27 AA4BXX, AA5XXX, AAXXXX, AXXXXX, cardiolipin, CDC Docket Import, CDC Docket Import CDC Prosecuting, DA3XXX, DA5XXX, DAXXXX, DXXXXX, Listed LPM Houze as of 4/15/2015, Modified, OID-NCHHSTP-DSTDP, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, THEREFOR, USES, WBXXXX, WFXXXX, WHXXXX, WIXXXX, XCXXXX, YBXXXX, YDXXXX False True True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract E-574-2013-0 E-321-2013-1 E-334-2013-0 114172536 Marks M. et al. https://www.ncbi.nlm.nih.gov/pubmed/27217216 <a href="https://www.ncbi.nlm.nih.gov/pubmed/27217216 ">Marks M. et al. </a> 114172537 Kalou MB et al. https://www.ncbi.nlm.nih.gov/pubmed/28879115 <a href="https://www.ncbi.nlm.nih.gov/pubmed/28879115">Kalou MB et al. </a> 114109822 Wang, Huiying CDC - DIR CDC Wang, Huiying (CDC) 0 114109824 Castro, Arnold CDC - DIR CDC Castro, Arnold (CDC) 1 114109824 Castro, Arnold CDC - DIR CDC Castro, Arnold (CDC) 1 114109822 Wang, Huiying CDC - DIR CDC Wang, Huiying (CDC) 0 114102479 MODIFIED CARDIOLIPIN AND USES THEREFOR E-310-2013-0 Filing authorized Centers for Disease Control and Prevention (CDC), EM 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-3325] Diagnostic Assay with Modified Cardiolipin for Detecting Active Syphilis Infections&body=Please send me information about technology [TAB-3325] Diagnostic Assay with Modified Cardiolipin for Detecting Active Syphilis Infections. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-3325] Diagnostic Assay with Modified Cardiolipin for Detecting Active Syphilis Infections&body=Please send me information about technology [TAB-3325] Diagnostic Assay with Modified Cardiolipin for Detecting Active Syphilis Infections.">jonathan.motley@nih.gov</a><br> 114168743 E-310-2013-0 E-310-2013-0-US-01 MODIFIED CARDIOLIPIN AND USES THEREFOR PRV US 60/737,901 Abandoned US <br />Provisional (PRV) 60/737,901<br />Filed on 2005-11-18<br />Status: Abandoned 114168744 E-310-2013-0 E-310-2013-0-PCT-02 MODIFIED CARDIOLIPIN AND USES THEREFOR PCT Patent Cooperation Treaty PCT/US2006/044572 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2006/044572<br />Filed on 2006-11-17<br />Status: Expired 114168745 E-310-2013-0 E-310-2013-0-US-06 MODIFIED CARDIOLIPIN AND USES THEREFOR National Stage US 7,888,043 12/094,144 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7888043 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7888043">7,888,043</a><br />Filed on 2008-05-16<br />Status: Abandoned 114168746 E-310-2013-0 E-310-2013-0-US-09 MODIFIED CARDIOLIPIN AND USES THEREFOR DIV US 8,906,603 13/027,224 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8906603 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8906603">8,906,603</a><br />Filed on 2011-02-14<br />Status: Issued 114128136 AXXXXX 114128137 AAXXXX 114128138 AA4BXX 114128139 AA5XXX 114128140 DXXXXX 114128141 DAXXXX 114128142 DA3XXX 114128143 DA5XXX 114128144 YBXXXX 114128145 YDXXXX 114128146 WBXXXX 114128147 WFXXXX 114128148 WHXXXX 114128149 WIXXXX 114128150 XCXXXX 114151328 Modified 114151329 cardiolipin 114151330 USES 114151331 THEREFOR 114151332 CDC Docket Import 114151333 CDC Docket Import CDC Prosecuting 114151334 OID-NCHHSTP-DSTDP 114151335 Listed LPM Houze as of 4/15/2015 114151336 Pre LPM working set 20150418 114151337 Post LPM Assignment Set 20150420 TAB-3322 114097242 Immunoassays and Methods to Diagnose Syphilis by Immobilizing a Lipoidal Antigen on a Solid Support CDC Antibodies, Collaboration, Consumer Products, Immunology, Infectious Disease, Licensing, Medical Devices, Non-Medical Devices, Occupational Safety and Health, Research Equipment, Research Materials Antibodies Collaboration Consumer Products Immunology Infectious Disease Licensing Medical Devices Non-Medical Devices Occupational Safety and Health Research Equipment Research Materials Arnold Castro, Robert George Syphilis, a genital ulcerative disease caused by the bacterium Treponema pallidum, is associated with significant complications if left untreated. Syphilis rates in the United States have been increasing.<br /><br /> CDC scientists have developed a method for capturing anti-lipoidal antibodies that are produced during syphilis infection. This method works by immobilizing a lipoidal antigen including (but not limited to) cardiolipin, lecithin and cholesterol on a solid support such as a nitrocellulose membrane. When the membrane-bound lipoidal antigen is exposed to a patient serum sample, any antibodies specific for the lipoidal antigen will be captured, allowing for easy detection. Detection may be accomplished by a visual, qualitative method producing results that are easy to read and interpret. The test can be used at the point-of-care (POC), in rural areas and/or in field studies. This method is adaptable for use with other antigen-antibody interactions and diagnostics for additional diseases characterized by the presence of anti-lipoidal antibodies. <ul> <li>Easy to interpret results</li> <li> Requires no specialty equipment or refrigeration</li> <li>Detects syphilis antibodies in serum samples</li> <li>Combination screening and confirmatory test in one device</li> <li>Can be used in a point-of-care assay allowing for convenience, rapid results, low costs, and field use</li> </ul> <ul> <li>Point-of-care diagnostic testing for syphilis</li> <li>Rapid lateral flow or flow-through combination (nontreponemal/treponemal) screening for syphilis</li> <li> Monitoring and public health surveillance</li> <li> Syphilis research</li> </ul> The CDC Technology Transfer Office (TTO) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize: Immunoassays and Methods to Diagnose Syphilis by Immobilizing a Lipoidal Antigen on a Solid Support. For collaboration opportunities, please contact CDC TTO at <a href="mailto:tto@cdc.gov">tto@cdc.gov</a> or 1-404-639-1330. 2022-03-08 2025-05-09 2025-05-09 2018-09-11 antibodies, ANTI-LIPOIDAL, CDC Docket Import, CDC Docket Import CDC Prosecuting, Detection, Devices, IMMUNOASSAYS, Listed LPM Houze as of 4/15/2015, Methods, OID-NCHHSTP-DSTDP, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, VJXXXX, WFXXXX, WIXXXX, XAXXXX, XDXXXX, XHXXXX, YAXXXX, YBXXXX, YDXXXX False True True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract E-310-2013-0 E-574-2013-0 E-334-2013-0 114109841 George, Robert CDC - DIR CDC George, Robert (CDC) 0 114109840 Castro, Arnold CDC - DIR CDC Castro, Arnold (CDC) 1 114109840 Castro, Arnold CDC - DIR CDC Castro, Arnold (CDC) 1 114109841 George, Robert CDC - DIR CDC George, Robert (CDC) 0 114102477 METHODS, IMMUNOASSAYS AND DEVICES FOR DETECTION OF ANTI-LIPOIDAL ANTIBODIES E-321-2013-0 Filing authorized Centers for Disease Control and Prevention (CDC) 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-3322] Immunoassays and Methods to Diagnose Syphilis by Immobilizing a Lipoidal Antigen on a Solid Support &body=Please send me information about technology [TAB-3322] Immunoassays and Methods to Diagnose Syphilis by Immobilizing a Lipoidal Antigen on a Solid Support . Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-3322] Immunoassays and Methods to Diagnose Syphilis by Immobilizing a Lipoidal Antigen on a Solid Support &body=Please send me information about technology [TAB-3322] Immunoassays and Methods to Diagnose Syphilis by Immobilizing a Lipoidal Antigen on a Solid Support .">jonathan.motley@nih.gov</a><br> 114168733 E-321-2013-0 E-321-2013-0-US-01 METHODS, IMMUNOASSAYS AND DEVICES FOR DETECTION OF ANTI-LIPOIDAL ANTIBODIES PRV US 60/693,120 Abandoned US <br />Provisional (PRV) 60/693,120<br />Filed on 2005-06-21<br />Status: Abandoned 114168734 E-321-2013-0 E-321-2013-0-PCT-02 METHODS, IMMUNOASSAYS AND DEVICES FOR DETECTION OF ANTI-LIPOIDAL ANTIBODIES PCT Patent Cooperation Treaty PCT/US2006/024117 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2006/024117<br />Filed on 2006-06-20<br />Status: Expired 114168735 E-321-2013-0 E-321-2013-0-US-11 METHODS, IMMUNOASSAYS AND DEVICES FOR DETECTION OF ANTI-LIPOIDAL ANTIBODIES National Stage US 11/993,213 Abandoned US <br />National Stage 11/993,213<br />Filed on 2008-01-11<br />Status: Abandoned 114168736 E-321-2013-0 E-321-2013-0-US-12 METHODS, IMMUNOASSAYS AND DEVICES FOR DETECTION OF ANTI-LIPOIDAL ANTIBODIES CON US 8,389,229 13/421,681 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8389229 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8389229">8,389,229</a><br />Filed on 2012-03-15<br />Status: Issued 114128127 YAXXXX 114128128 YBXXXX 114128129 YDXXXX 114128130 VJXXXX 114128131 WFXXXX 114128132 WIXXXX 114128133 XAXXXX 114128134 XDXXXX 114128135 XHXXXX 114151309 Methods 114151310 IMMUNOASSAYS 114151311 Devices 114151312 Detection 114151313 ANTI-LIPOIDAL 114151314 antibodies 114151315 CDC Docket Import 114151316 CDC Docket Import CDC Prosecuting 114151317 OID-NCHHSTP-DSTDP 114151318 Listed LPM Houze as of 4/15/2015 114151319 Pre LPM working set 20150418 114151320 Post LPM Assignment Set 20150420 TAB-3319 114097241 Cardiolipin Modification for Immunoassay Detection of Syphilis CDC Antibodies, Collaboration, Consumer Products, Diagnostics, Immunology, Infectious Disease, Licensing, Occupational Safety and Health, Research Materials Antibodies Collaboration Consumer Products Diagnostics Immunology Infectious Disease Licensing Occupational Safety and Health Research Materials Arnold Castro, John Deutsch, Himanshu Mody Syphilis is a sexually transmitted disease (STD) that remains a global health threat. Syphilis rates in the United States have also been increasing. Left untreated, syphilis infection can span decades and have serious complications including blindness, dementia and paralysis. Syphilis in pregnancy causes prematurity, low birthweight, neonatal death, and infections in newborns. Improvements in syphilis detection are needed to facilitate early diagnosis of active infections and monitor treatment with antibiotics.<br/><br/> Researchers at the CDC have developed a rapid, serological test that detects active syphilis infections. The test is an immunoassay (e.g., enzyme immunoassay (EIA), Treponema pallidum particle agglutination assay (TPPA), enzyme-linked immunosorbent assay (ELISA), lateral flow device, dipstick or flow-through device) that uses modified cardiolipin, a lipoidal entity thought to be released from host cells and/or Treponema pallidum (bacterial) cells that are damaged over the course of infection, as an antigen to detect anti-cardiolipin antibodies in blood samples. CDC’s technology offers a method of quantitatively or qualitatively detecting active syphilis infections and other autoimmune diseases such as lupus. <ul> <li>Rapid test that’s adaptable for automation and high throughput (large scale testing)</li> <li>Method can detect an anti-lipoidal antibody/oxidized complex quantitatively or qualitatively</li> </ul> <ul> <li>Immunoassay that detects active syphilis infections</li> <li>Suitable for EIA, multi-well plate ELISA, flow-through, dipstick, lateral flow, TPPA or the rapid test assay</li> <li>Methods permit determining the stage of syphilis infection (i.e., monitoring disease progression), monitoring of syphilis therapy, or combinations thereof</li> <li>Monitoring and public health surveillance</li> <li>Research tool to study active syphilis infections</li> </ul> The CDC Technology Transfer Office (TTO) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize: Cardiolipin Modification for Immunoassay Detection of Syphilis. For collaboration opportunities, please contact CDC TTO at <a href="mailto:tto@cdc.gov">tto@cdc.gov</a> or 1-404-639-1330. 2022-03-08 2025-05-09 2025-05-09 2018-09-11 antibodies, Anti-Cardiolipin, bejel, Biomarker, Biomarkers, cardiolipin, CDC, CDC Docket Import, CDC Docket Import CDC Prosecuting, DA3XXX, DAXXXX, Detection, diagnostic, DXXXXX, IMMUNOASSAYS, Listed LPM Houze as of 4/15/2015, MODIFICATION, NCHHSTP-DSTDP, PALLIDUM, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, std, sti, Syphilis, TREPONEMA, TREPONEMAL, VJXXXX, WBXXXX, WFXXXX, WIXXXX, XAXXXX, yaws, YBXXXX False True True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114109838 Mody, Himanshu Arlington Scientific, Inc. (ASI) Mody, Himanshu 0 114109839 Deutsch, John CDC - DIR CDC Deutsch, John (CDC) 0 114109837 Castro, Arnold CDC - DIR CDC Castro, Arnold (CDC) 1 114109837 Castro, Arnold CDC - DIR CDC Castro, Arnold (CDC) 1 114109838 Mody, Himanshu Arlington Scientific, Inc. (ASI) Mody, Himanshu 0 114109839 Deutsch, John CDC - DIR CDC Deutsch, John (CDC) 0 114102476 Cardiolipin Modification For Detection Of Anti-Cardiolipin Antibodies In Immunoassays E-574-2013-0 Filing authorized Arlington Scientific, Inc. (ASI), Centers for Disease Control and Prevention (CDC) 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-3319] Cardiolipin Modification for Immunoassay Detection of Syphilis&body=Please send me information about technology [TAB-3319] Cardiolipin Modification for Immunoassay Detection of Syphilis. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-3319] Cardiolipin Modification for Immunoassay Detection of Syphilis&body=Please send me information about technology [TAB-3319] Cardiolipin Modification for Immunoassay Detection of Syphilis.">jonathan.motley@nih.gov</a><br> 114168731 E-574-2013-0 E-574-2013-0-US-01 OXIDIZED CARDIOLIPIN AND USES TO DETECT CARDIOLIPIN ANTIBODIES CIP US 8,778,619 14/079,634 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8778619 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8778619">8,778,619</a><br />Filed on 2013-11-13<br />Status: Abandoned 114168732 E-574-2013-0 E-574-2013-0-US-02 Oxidized Cardiolipin And Uses To Detect Cardiolipin Antibodies CON US 9,081,009 14/329,236 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9081009 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9081009">9,081,009</a><br />Filed on 2014-07-11<br />Status: Abandoned 114128118 DXXXXX 114128119 DAXXXX 114128120 DA3XXX 114128121 YBXXXX 114128122 VJXXXX 114128123 WBXXXX 114128124 WFXXXX 114128125 WIXXXX 114128126 XAXXXX 114151285 cardiolipin 114151286 MODIFICATION 114151287 Detection 114151288 Anti-Cardiolipin 114151289 antibodies 114151290 IMMUNOASSAYS 114151291 CDC Docket Import 114151292 CDC Docket Import CDC Prosecuting 114151293 Syphilis 114151294 yaws 114151295 CDC 114151296 bejel 114151297 diagnostic 114151298 Biomarker 114151299 Biomarkers 114151300 TREPONEMA 114151301 TREPONEMAL 114151302 PALLIDUM 114151303 sti 114151304 std 114151305 NCHHSTP-DSTDP 114151306 Listed LPM Houze as of 4/15/2015 114151307 Pre LPM working set 20150418 114151308 Post LPM Assignment Set 20150420 TAB-3317 114097240 Methods for Detecting Syphilis Using Synthetic Antigens CDC Collaboration, Consumer Products, Diagnostics, Infectious Disease, Licensing, Occupational Safety and Health, Research Materials Collaboration Consumer Products Diagnostics Infectious Disease Licensing Occupational Safety and Health Research Materials Arnold Castro, William Morrill, Victoria Pope Syphilis is a highly contagious sexually transmitted disease caused by the bacterium, <em>Treponema pallidum</em> (<em>T. pallidum</em>). If left untreated, syphilis can cause serious complications including blindness, paralysis and dementia. <br/><br/> The venereal disease research laboratory (VDRL) test is one type of screening test used to detect syphilis. This blood test first detects antibodies responding to antigens produced by cells damaged by <em>Treponema pallidum</em> bacteria. Note that some literature suggest that these antigens could also come from dead/dying <em>T. pallidum</em> cells. Due to the high incidence of false positive and false negative results, however, secondary confirmation of the test results must be done using an alternative, more specific assay. CDC and partner researchers developed a VDRL antigen using synthetic components (cardiolipin and lecithin) instead of native, purified components for improved detection of syphilis. The sensitivity has been increased to be comparable to that of the present RPR (rapid plasma reagin) test antigen, by eliminating portions of the natural components that cross-react with diseases other than syphilis. Use of synthetic components also makes the reagent more stable than the prior version, which results in extended shelf life at the same temperature (usually room temperature) due to elimination of impurities and possible oxidation sites. <ul> <li>Increased sensitivity and specificity with the synthetic VDRL antigen</li> <li>Rapid, inexpensive method of detecting syphilis</li> <li> Increased VDRL assay reagent stability at room temperature (68-72<sup>o</sup>F or 20-22<sup>o</sup>C) versus RPR and TRUST assays where the antigen is stored at refrigerated temperature (34-40<sup>o</sup>F or 1.5-4.5<sup>o</sup>C)</li> </ul> <ul> <li>For use in assays or diagnostic kits for the detection of syphilis</li> <li>For use in <em>in vitro</em> research tools for studying syphilis</li> </ul> The CDC Technology Transfer Office (TTO) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize: Methods for Detecting Syphilis Using Synthetic Antigens. For collaboration opportunities, please contact CDC TTO at <a href="mailto:tto@cdc.gov">tto@cdc.gov</a> or 1-404-639-1330. 2022-03-08 2025-05-09 2025-05-09 2018-09-27 ANTIGENS, CDC Docket Import, CDC Docket Import CDC Prosecuting, COMPOSITION, DA3XXX, DAXXXX, DETECTING, DXXXXX, Listed LPM Houze as of 4/15/2015, Method, OID-NCHHSTP-DSTDP, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Synthetic, Syphilis, WBXXXX, WFXXXX, WIXXXX, YBXXXX False True True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114172534 Castro AR, et al. https://www.ncbi.nlm.nih.gov/pubmed/10882668 <a href="https://www.ncbi.nlm.nih.gov/pubmed/10882668">Castro AR, et al. </a> 114109835 Pope, Victoria CDC - DIR CDC Pope, Victoria (CDC) 0 114109836 Morrill, William CDC - DIR CDC Morrill, William (CDC) 0 114109834 Castro, Arnold CDC - DIR CDC Castro, Arnold (CDC) 1 114109834 Castro, Arnold CDC - DIR CDC Castro, Arnold (CDC) 1 114109835 Pope, Victoria CDC - DIR CDC Pope, Victoria (CDC) 0 114109836 Morrill, William CDC - DIR CDC Morrill, William (CDC) 0 114102475 COMPOSITION AND METHOD FOR DETECTING SYPHILIS USING SYNTHETIC ANTIGENS E-334-2013-0 Closed Centers for Disease Control and Prevention (CDC) 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-3317] Methods for Detecting Syphilis Using Synthetic Antigens&body=Please send me information about technology [TAB-3317] Methods for Detecting Syphilis Using Synthetic Antigens. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-3317] Methods for Detecting Syphilis Using Synthetic Antigens&body=Please send me information about technology [TAB-3317] Methods for Detecting Syphilis Using Synthetic Antigens.">jonathan.motley@nih.gov</a><br> 114168725 E-334-2013-0 E-334-2013-0-US-01 COMPOSITION AND METHOD FOR DETECTING SYPHILIS USING SYNTHETIC ANTIGENS PRV US 60/138,192 Abandoned US <br />Provisional (PRV) 60/138,192<br />Filed on 1999-06-09<br />Status: Abandoned 114168726 E-334-2013-0 E-334-2013-0-PCT-02 COMPOSITION AND METHOD FOR DETECTING SYPHILIS USING SYNTHETIC ANTIGENS PCT Patent Cooperation Treaty PCT/US2000/015828 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2000/015828<br />Filed on 2000-06-08<br />Status: Expired 114168727 E-334-2013-0 E-334-2013-0-US-10 COMPOSITION AND METHOD FOR DETECTING SYPHILIS USING SYNTHETIC ANTIGENS National Stage US 6,815,173 10/009,698 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6815173 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6815173">6,815,173</a><br />Filed on 2001-12-05<br />Status: Expired 114168728 E-334-2013-0 E-334-2013-0-US-11 COMPOSITION AND METHOD FOR DETECTING SYPHILIS USING SYNTHETIC ANTIGENS REISSUE US RE43,914 13/333,849 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/RE43914 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/RE43914">RE43,914</a><br />Filed on 2011-12-21<br />Status: Expired 114128111 DXXXXX 114128112 DAXXXX 114128113 DA3XXX 114128114 YBXXXX 114128115 WBXXXX 114128116 WFXXXX 114128117 WIXXXX 114151273 COMPOSITION 114151274 Method 114151275 DETECTING 114151276 Syphilis 114151277 Synthetic 114151278 ANTIGENS 114151279 CDC Docket Import 114151280 CDC Docket Import CDC Prosecuting 114151281 OID-NCHHSTP-DSTDP 114151282 Listed LPM Houze as of 4/15/2015 114151283 Pre LPM working set 20150418 114151284 Post LPM Assignment Set 20150420 TAB-3313 114097236 Human Retrovirus Obtained from Infected Chimpanzee Exposure CDC Collaboration, Consumer Products, Diagnostics, Infectious Disease, Licensing, Occupational Safety and Health, Research Materials, Therapeutics, Vaccines Collaboration Consumer Products Diagnostics Infectious Disease Licensing Occupational Safety and Health Research Materials Therapeutics Vaccines Thomas Folks, Walid Heneine, Paul Sandstrom, William Switzer A retrovirus can be any of a group of RNA viruses (i.e., HIV) that insert a DNA copy of their genome into the host cell in order to replicate. Retroviruses can cause persistent and often lifelong infections.<br/><br/> As a result of a voluntary study of nonhuman primate workers in zoos and primate centers, CDC scientists have isolated a retrovirus (spumavirus) from an individual that had a rare occupational exposure to an infected chimpanzee. The isolated virus is genetically and antigenically similar to the strain from the infected chimpanzee but distinct from other human spumaviruses. This discovery has potential in various research and commercial applications. It can be provided as a research tool for screening spumavirus infections or used as a reagent in pathogenicity studies. Being a retrovirus, this discovery can be used as a vector for gene therapy or a recombinant virus vaccine. Finally, sera have been generated against this retrovirus for serological studies of spumaviruses. <ul> <li>Closer genetic sequence to humans may make this retrovirus a superior candidate as a spumavirus gene therapy vector</li> </ul> <ul> <li>Screening of retrovirus infection in humans</li> <li>Use as a vector for gene therapy</li> <li>Recombinant virus vaccine</li> <li>Public health monitoring and surveillance</li> <li>Research tool for screening spumavirus infections or reagent use in pathogenicity studies</li> </ul> </li></< The CDC Technology Transfer Office (TTO) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize: Human Retrovirus Obtained From Infected Chimpanzee Exposure. For collaboration opportunities, please contact CDC TTO at <a href="mailto:tto@cdc.gov">tto@cdc.gov</a> or 1-404-639-1330. 2022-03-08 2025-05-09 2025-05-09 2018-09-10 CDC Docket Import, CDC Docket Import CDC Prosecuting, DA4XXX, DB4XXX, DC5XXX, DDXXXX, DXXXXX, Human, Isolation, Listed LPM Houze as of 4/15/2015, OID-NCHHSTP-DHPSE, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Retrovirus, VOXXXX, WBXXXX, WFXXXX, WIXXXX, WJXXXX, WNXXXX, XEXXXX, XKXXXX False True True NIHTT 37470483 Website Abstract E-232-1993-0 114172531 Heneine W., et al. https://www.ncbi.nlm.nih.gov/pubmed/9546784 <a href="https://www.ncbi.nlm.nih.gov/pubmed/9546784">Heneine W., et al.</a> 114172532 Chapman L., et al. https://www.ncbi.nlm.nih.gov/pubmed/10083399 <a href="https://www.ncbi.nlm.nih.gov/pubmed/10083399">Chapman L., et al. </a> 114172533 Sandstrom P., et al. https://www.ncbi.nlm.nih.gov/pubmed/10683011 <a href="https://www.ncbi.nlm.nih.gov/pubmed/10683011 ">Sandstrom P., et al. </a> 114109826 Heneine, Walid CDC - DIR CDC Heneine, Walid (CDC) 0 114109827 Sandstrom, Paul CDC - DIR CDC Sandstrom, Paul (CDC) 0 114109828 Folks, Thomas CDC - DIR Folks, Thomas 0 114109825 Switzer, William CDC - DIR CDC Switzer, William (CDC) 1 114109825 Switzer, William CDC - DIR CDC Switzer, William (CDC) 1 114109826 Heneine, Walid CDC - DIR CDC Heneine, Walid (CDC) 0 114109827 Sandstrom, Paul CDC - DIR CDC Sandstrom, Paul (CDC) 0 114109828 Folks, Thomas CDC - DIR Folks, Thomas 0 114102472 ISOLATION OF A HUMAN RETROVIRUS E-251-2013-0 Research Material Centers for Disease Control and Prevention (CDC) 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-3313] Human Retrovirus Obtained from Infected Chimpanzee Exposure&body=Please send me information about technology [TAB-3313] Human Retrovirus Obtained from Infected Chimpanzee Exposure. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-3313] Human Retrovirus Obtained from Infected Chimpanzee Exposure&body=Please send me information about technology [TAB-3313] Human Retrovirus Obtained from Infected Chimpanzee Exposure.">jonathan.motley@nih.gov</a><br> 114168719 E-251-2013-0 E-251-2013-0-US-01 ISOLATION OF A HUMAN RETROVIRUS PRV US 60/139,219 Abandoned US <br />Provisional (PRV) 60/139,219<br />Filed on 1999-06-14<br />Status: Abandoned 114168720 E-251-2013-0 E-251-2013-0-PCT-02 ISOLATION OF A HUMAN RETROVIRUS PCT Patent Cooperation Treaty PCT/US2000/016433 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2000/016433<br />Filed on 2000-06-14<br />Status: Expired 114168721 E-251-2013-0 E-251-2013-0-US-04 ISOLATION OF A HUMAN RETROVIRUS National Stage US 6,800,475 10/018,627 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6800475 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6800475">6,800,475</a><br />Filed on 2000-06-14<br />Status: Expired 114128085 DXXXXX 114128086 DA4XXX 114128087 DB4XXX 114128088 DC5XXX 114128089 DDXXXX 114128090 VOXXXX 114128091 WBXXXX 114128092 WFXXXX 114128093 WIXXXX 114128094 WJXXXX 114128095 WNXXXX 114128096 XEXXXX 114128097 XKXXXX 114151249 Isolation 114151250 Human 114151251 Retrovirus 114151252 CDC Docket Import 114151253 CDC Docket Import CDC Prosecuting 114151254 OID-NCHHSTP-DHPSE 114151255 Listed LPM Houze as of 4/15/2015 114151256 Pre LPM working set 20150418 114151257 Post LPM Assignment Set 20150420 TAB-3248 114097182 Personalized Cancer Evaluation (PERCEVAL) Method and Software CDC Collaboration, Computational models/software, Diagnostics, Licensing, Software / Apps Collaboration Computational models/software Diagnostics Licensing Software / Apps David Campo Cancer represents the leading cause of morbidity and mortality worldwide, with approximately 14 million new cases and 8.2 million cancer related deaths in 2012. This number is predicted to rise by approximately 70% over the next two decades according to the World Health Organization. Prognosis depends heavily on both early detection and frequent monitoring of the patient's response to treatment. Cancerous tumors shed nucleic acids into blood, which can be detected by ultra-deep sequencing of mitochondrial DNA (mtDNA). This method has the potential to provide early detection in asymptomatic individuals or those with vague, undefined symptoms. Currently, researchers are identifying specific changes in the whole human genome that occur in tumors of patients. These targeted sequences are then compared to other individuals.<br/><br/> Unfortunately, cancer mutations are often unique to a patient or are uncommon across patients with similar cancers. CDC researchers developed PERCEVAL, a software that is capable of detecting cancer in asymptomatic individuals based on mitochondrial DNA (mtDNA). In addition to early detection, PERCEVAL has the potential to determine the severity of the cancer and monitor whether a given therapy is working for an individual patient.<br/><br/> <ul> <li> The model correctly classified 232 Liver Cancer and 232 Non-cancer samples with accuracy of 99.78% and average accuracy of 92.23% in 10-fold cross-validation. In further validation, the model accurately separated 93.08% of Liver cancer samples (n=61) and Non-cancer samples (n=159) that were not previously seen by the model.</li> <li>For liver cancer, detection method does not rely on biomarkers that can result in false positives (e.g., for acetaminophen or alcohol abuse)</li> <li>Non-invasive method </li> <li>May be capable of cancer detection before the patient exhibits symptoms</li> <li>System runs on Linux and applies machine learning algorithms to create a model that better generalizes prediction to new samples</li> <li>Uses a single region, mtDNA, circulating in blood which has been shown to mutate in a wide array of cancers</li> </ul> <ul> <li>Method and software with initial accuracy in detecting liver cancer in samples</li> <li>Method and software for early detection of universal cancers</li> <li>Method and software for determining cancer severity and tumor stages of patients already diagnosed</li> <li>Method and software to monitor if cancer treatment is working</li> </ul> The CDC Technology Transfer Office (TTO) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize: Personalized Cancer Evaluation (PERCEVAL) Software and Method. For collaboration opportunities, please contact CDC TTO at <a href="mailto: tto@cdc.gov">tto@cdc.gov</a> or 1-404-639-1330. 2022-03-08 2025-05-09 2025-05-09 2018-02-12 CANCER, EVALUATION, NCHHSTP, NCHHSTP-DVH, PERCEVAL, Personalized, WBXXXX, XBXXXX, YDXXXX False True True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114109629 Campo, David CDC - DIR CDC Campo, David (CDC) 1 114109629 Campo, David CDC - DIR CDC Campo, David (CDC) 1 114102408 PERCEVAL (Personalized Cancer Evaluation) E-289-2016-0 Closed Centers for Disease Control and Prevention (CDC) 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-3248] Personalized Cancer Evaluation (PERCEVAL) Method and Software&body=Please send me information about technology [TAB-3248] Personalized Cancer Evaluation (PERCEVAL) Method and Software. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-3248] Personalized Cancer Evaluation (PERCEVAL) Method and Software&body=Please send me information about technology [TAB-3248] Personalized Cancer Evaluation (PERCEVAL) Method and Software.">jonathan.motley@nih.gov</a><br> 114168551 E-289-2016-0 E-289-2016-0-US-01 METHOD OF DIAGNOSING CANCER USING MITOCHONDRIAL DNA HETEROGENEITY PRV US 62/459,406 Abandoned US <br />Provisional (PRV) 62/459,406<br />Filed on 2017-02-15<br />Status: Abandoned 114168556 E-289-2016-0 E-289-2016-0-PCT-02 METHOD OF DIAGNOSING CANCER USING MITOCHONDRIAL DNA HETEROGENEITY PCT Patent Cooperation Treaty PCT/US2018/017962 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2018/017962<br />Filed on 2018-02-13<br />Status: Expired 114168903 E-289-2016-0 E-289-2016-0-US-03 METHOD OF DIAGNOSING CANCER USING MITOCHONDRIAL DNA HETEROGENEITY National Stage US 16/485,714 Abandoned US <br />National Stage 16/485,714<br />Filed on 2019-08-13<br />Status: Abandoned 114127749 YDXXXX 114127750 WBXXXX 114127751 XBXXXX 114150432 PERCEVAL 114150433 Personalized 114150434 CANCER 114150435 EVALUATION 114150436 NCHHSTP 114150437 NCHHSTP-DVH TAB-3162 114097109 Improved simian HIV (SHIV) prevention in non-human primate models with chemoprophylaxis combination that can be taken in one or two oral doses before or after exposure CDC Collaboration, Licensing Collaboration Licensing Jose Garcia Lerma, Walid Heneine, Ivana Massud HIV and AIDS remain persistent problems for the United States and countries around the world. In 2015, nearly 40,000 people were diagnosed with HIV in the US alone. Pre-exposure prophylaxis (PrEP) can help prevent HIV infections in people who are not infected with HIV but are at high risk of becoming infected with HIV. PrEP involves taking daily medications and is the most effective when medications are taken consistently. However, many people find it challenging to adhere to a daily pill schedule and cannot fully benefit from PrEP. CDC researchers have developed a medication dosing regimen with a combination consisting of a pharmacokinetic enhancer, integrase inhibitor, and nucleoside reverse transcriptase inhibitors that can be effective in primates against simian HIV if taken in one or two pill doses either immediately before or after SHIV exposure to prevent infection. Initial research has likely shown success in protecting against simian HIV infection in primates who received a combination of emtricitabine, tenofovir alafenamide, elvitegravir, and cobicistat (referred to as FTC/TAF/EVG/COBI). Further research would be needed to determine if this limited dosing regimen could prevent HIV (for humans), increase medication adherence, lower costs, and reduce potentially harmful side effects of daily chemoprophylaxis. <ul> <li>Doesn't require daily medications and can enhance medication adherence</li> <li>New drug combination with 1 or 2 pill doses before or after simian HIV exposure shown to be effective in first primate study</li> <li>On-demand dosing regimen can be more cost effective than daily medications</li> <li>Limited dosing regimen can reduce potentially harmful side effects of daily chemoprophylaxis </li> </ul> <ul> <li>Initial prevention of simian HIV; potential prevention of HIV in persons at high risk of infection</li> <li>A “before sex” or “after sex” pill dosing regimen that can prevent infection with HIV </li> </ul> The CDC is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize improved HIV chemoprophylaxis with reverse transcriptase and integrase inhibitors . For collaboration opportunities, please contact CDC Technology Transfer Office at <a href="mailto: tto@cdc.gov ">tto@cdc.gov </a> or 1-404-639-1330. Foreign counterpart applications in Australia, Canada, Europe, Germany, and India. (Inhibition of HIV Infection Through Chemoprophylaxis - CDC Reference I-022-06) 2022-03-08 2025-05-09 2025-05-09 2017-09-07 Chemoprophylaxis, Combinations, Containing, HIV, Improved, Inhibitors, Integrase, NCHHSTP, NCHHSTP-DHAP, Reverse, TRANSCRIPTASE False True True NIHTT 37470483 Website Abstract E-195-2013-0 114172345 Garcia Lerma, JG, et al. https://pubmed.ncbi.nlm.nih.gov/20371467/ <a href="https://pubmed.ncbi.nlm.nih.gov/20371467/">Garcia Lerma, JG, et al.</a> 114172346 Massud, I, et al. https://pubmed.ncbi.nlm.nih.gov/25630643/ <a href="https://pubmed.ncbi.nlm.nih.gov/25630643/">Massud, I, et al.</a> 114172347 Massud, I, et al. https://pubmed.ncbi.nlm.nih.gov/27465645/ <a href="https://pubmed.ncbi.nlm.nih.gov/27465645/">Massud, I, et al.</a> 114109327 Massud, Ivana CDC - DIR CDC Massud, Ivana (CDC) 0 114109328 Heneine, Walid CDC - DIR CDC Heneine, Walid (CDC) 0 114109326 Garcia Lerma, Jose CDC - DIR CDC Garcia Lerma, Jose (CDC) 1 114109326 Garcia Lerma, Jose CDC - DIR CDC Garcia Lerma, Jose (CDC) 1 114109327 Massud, Ivana CDC - DIR CDC Massud, Ivana (CDC) 0 114109328 Heneine, Walid CDC - DIR CDC Heneine, Walid (CDC) 0 114102310 Improved HIV Chemoprophylaxis With Combinations Containing Reverse Transcriptase And Integrase Inhibitors E-037-2017-0 Filing authorized Centers for Disease Control and Prevention (CDC) 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-3162] Improved simian HIV (SHIV) prevention in non-human primate models with chemoprophylaxis combination that can be taken in one or two oral doses before or after exposure&body=Please send me information about technology [TAB-3162] Improved simian HIV (SHIV) prevention in non-human primate models with chemoprophylaxis combination that can be taken in one or two oral doses before or after exposure. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-3162] Improved simian HIV (SHIV) prevention in non-human primate models with chemoprophylaxis combination that can be taken in one or two oral doses before or after exposure&body=Please send me information about technology [TAB-3162] Improved simian HIV (SHIV) prevention in non-human primate models with chemoprophylaxis combination that can be taken in one or two oral doses before or after exposure.">jonathan.motley@nih.gov</a><br> 114168357 E-037-2017-0 E-037-2017-0-US-01 HIV POST-EXPOSURE PROPHYLAXIS PRV US 62/473,799 Abandoned US <br />Provisional (PRV) 62/473,799<br />Filed on 2017-03-20<br />Status: Abandoned 114168581 E-037-2017-0 E-037-2017-0-PCT-02 HIV POST-EXPOSURE PROPHYLAXIS PCT Patent Cooperation Treaty PCT/US2018/023152 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2018/023152<br />Filed on 2018-03-19<br />Status: Expired 114168914 E-037-2017-0 E-037-2017-0-US-06 HIV POST-EXPOSURE PROPHYLAXIS National Stage US 11,191,763 16/494,696 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11191763 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11191763">11,191,763</a><br />Filed on 2019-09-16<br />Status: Issued 114149336 Improved 114149337 HIV 114149338 Chemoprophylaxis 114149339 Combinations 114149340 Containing 114149341 Reverse 114149342 TRANSCRIPTASE 114149343 Integrase 114149344 Inhibitors 114149345 NCHHSTP 114149346 NCHHSTP-DHAP TAB-2938 114097089 Monoclonal Antibodies to the HIV-1 Core Protein p24 CDC Antibodies, Diagnostics, Immunology, Infectious Disease, Licensing, Research Equipment, Research Materials Antibodies Diagnostics Immunology Infectious Disease Licensing Research Equipment Research Materials Dennis Bagarozzi, Jason Goldstein, Timothy Granade, Shon Nguyen, Sherry Owen, Chou-Pong Pau, Susan Wells The core proteins of HIV-1 are secreted into the environment during replication in the human body. The detection of the core protein p24 (molecular mass of 24 kilodaltons) serves as an indicator of early HIV-1 infection, and assays detecting it have been available since the late 1980s. However, the development of a rapid assay for the detection of HIV-1 p24 has only recently become available. Monoclonal antibodies developed in our laboratory for research and development of a rapid HIV-1 p24 assay would provide large quantities of material at a much lower price than could be obtained in the commercial market. <ul> <li>Inexpensive antibodies to HIV-1 core proteins</li> <li>Larger source of HIV-1 monoclonal antibodies</li> </ul> <ul> <li>Diagnostic assay for the detection of HIV-1</li> <li>Research tool used to study HIV-1</li> </ul> Research Tool - Patent protection is not being pursued for this technology. 2022-03-08 2025-05-09 2025-05-09 2015-05-19 antibodies, Core, DA4XXX, DDXXXX, HIV-1, Listed LPM Houze as of 4/15/2015, monoclonal, NCHHSTP-DHAP, P24, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Protein, VLXXXX, WBXXXX, WIXXXX, XAXXXX, XHXXXX, YBXXXX, YFXXXX False True <ul> <li>In vitro data available</li> <li>Prototype</li> </ul> True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114172258 Workman S, et al. http://www.ncbi.nlm.nih.gov/pubmed/19482361 <a href="http://www.ncbi.nlm.nih.gov/pubmed/19482361">Workman S, et al.</a> 114172259 Ly TD, et al. http://www.ncbi.nlm.nih.gov/pubmed/15542143 <a href="http://www.ncbi.nlm.nih.gov/pubmed/15542143">Ly TD, et al.</a> 114172260 Miles SA, et al. http://www.ncbi.nlm.nih.gov/pubmed/8419814 <a href="http://www.ncbi.nlm.nih.gov/pubmed/8419814">Miles SA, et al.</a> 114172261 Schupbach J, Boni J. http://www.ncbi.nlm.nih.gov/pubmed/8366170 <a href="http://www.ncbi.nlm.nih.gov/pubmed/8366170">Schupbach J, Boni J.</a> 114172262 Weber B, et al. http://www.ncbi.nlm.nih.gov/pubmed/9665998 <a href="http://www.ncbi.nlm.nih.gov/pubmed/9665998">Weber B, et al.</a> 114109039 Pau, Chou-Pong CDC - DIR CDC Pau, Chou-Pong (CDC) 0 114109040 Nguyen, Shon CDC - DIR CDC Nguyen, Shon (CDC) 0 114109041 Wells, Susan CDC - DIR CDC Wells, Susan (CDC) 0 114109042 Owen, Sherry CDC - DIR CDC Owen, Sherry (CDC) 0 114109043 Goldstein, Jason CDC - DIR CDC Goldstein, Jason (CDC) 0 114109044 Bagarozzi, Dennis CDC - DIR CDC Bagarozzi, Dennis (CDC) 0 114109038 Granade, Timothy CDC - DIR CDC Granade, Timothy (CDC) 1 114109038 Granade, Timothy CDC - DIR CDC Granade, Timothy (CDC) 1 114109039 Pau, Chou-Pong CDC - DIR CDC Pau, Chou-Pong (CDC) 0 114109040 Nguyen, Shon CDC - DIR CDC Nguyen, Shon (CDC) 0 114109041 Wells, Susan CDC - DIR CDC Wells, Susan (CDC) 0 114109042 Owen, Sherry CDC - DIR CDC Owen, Sherry (CDC) 0 114109043 Goldstein, Jason CDC - DIR CDC Goldstein, Jason (CDC) 0 114109044 Bagarozzi, Dennis CDC - DIR CDC Bagarozzi, Dennis (CDC) 0 114102273 Monoclonal Antibodies To The HIV-1 Core Protein P24 E-150-2014-0 Research Material Centers for Disease Control and Prevention (CDC) 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2938] Monoclonal Antibodies to the HIV-1 Core Protein p24&body=Please send me information about technology [TAB-2938] Monoclonal Antibodies to the HIV-1 Core Protein p24. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2938] Monoclonal Antibodies to the HIV-1 Core Protein p24&body=Please send me information about technology [TAB-2938] Monoclonal Antibodies to the HIV-1 Core Protein p24.">jonathan.motley@nih.gov</a><br> 114127030 DA4XXX 114127031 DDXXXX 114127032 VLXXXX 114127033 WBXXXX 114127034 WIXXXX 114127035 XAXXXX 114127036 XHXXXX 114127037 YBXXXX 114127038 YFXXXX 114148352 antibodies 114148353 monoclonal 114148354 HIV-1 114148355 Core 114148356 Protein 114148357 P24 114148358 NCHHSTP-DHAP 114148359 Listed LPM Houze as of 4/15/2015 114148360 Pre LPM working set 20150418 114148361 Post LPM Assignment Set 20150420 TAB-2839 114097017 Novel Enzyme-Based Immunoassay for Simultaneous Detection of Hepatitis C Virus Antigen and Antibody in Human Serum or Plasma CDC Antibodies, Consumer Products, Diagnostics, Immunology, Infectious Disease, Licensing, Occupational Safety and Health, Research Materials Antibodies Consumer Products Diagnostics Immunology Infectious Disease Licensing Occupational Safety and Health Research Materials Yury Khudyakov CDC scientists have developed a novel enzyme immunoassay for the simultaneous detection of hepatitis C virus (HCV) core antigen and circulating HCV antibodies. Serological testing procedures for HCV circulating antibodies are well established. There is, however, a window of time between HCV infection and seroconversion that generates an opportunity for false negative results. This period varies from two months in immunocompetent subjects to six to twelve months in immunodeficient patients. Combination testing, utilizing both serological testing and PCR-based techniques, can be used to overcome this limitation. PCR-based techniques, however, are costly and time-consuming and present considerable challenges to clinical laboratories, due to equipment requirements and sensitivity to cross-contamination.<br /><br /> This technology overcomes these challenges through simultaneous detection of both HCV core antigen and HCV antibody in an immunoassay format, which both significantly improves the sensitive diagnosis of hepatitis C among blood donors at any stage of infection and is also simpler to perform than combination testing utilizing PCR-based techniques. <ul> <li>Efficiently overcomes the window of potential false-negative diagnosis between time of inital hepatitis C infection and patient seroconversion by implementation of an accurate, sensitive immunoassay</li> <li>Assay significantly improves diagnosis beyond stand-alone HCV core antigen or antibody measures</li> <li>Detects the presence of HCV both prior to and following seroconversion without reliance on PCR-based techniques</li> </ul> <ul> <li>Monitoring and early, accurate diagnosis of hepatitis C virus (HCV) infected individuals</li> <li>Rapid screening tool for blood donations and high-risk individuals</li> <li>Lateral-flow assays, HCV detection kits</li> </ul> 2022-03-08 2025-05-09 2025-05-09 2014-07-09 ANTIBODY, Antibody-based, Antibody-dependent, ANTIGEN, Antigen Antibody, ANTIGEN CAPTURE ASSAY, Antigen/Ab, Antigen/antibody, ANTIGEN-ANTIBODY, Antigen-binding, CDC Docket Import, CDC Docket Import CDC Prosecuting, DA4BXX, DA4XXX, DAXXXX, Detection, detection system, Diagnosis, diagnostic, diagnostic in vitro, Diagnostic Kit, EIA, HCV, Hepatitis, HEPATITIS C, HEPATITIS C DIAGNOSTIC, HEPATITIS C HCV, Human, ivd, LATERAL, Novel, OID-NCHHSTP-DVH, PLASMA, SERA, SIMULTANEOUS, viral, VIRAL DIAGNOSTIC, virus, VLXXXX, WBXXXX, WFXXXX, WIXXXX, XAXXXX, XCXXXX, YBXXXX False True In vitro data available True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114108795 Khudyakov, Yury CDC - DIR CDC Khudyakov, Yury (CDC) 1 114108795 Khudyakov, Yury CDC - DIR CDC Khudyakov, Yury (CDC) 1 114102183 Novel EIA For Simultaneous Detection Of HCV Antigen/Ab In Human Sera Or Plasma E-190-2013-0 Filing authorized Centers for Disease Control and Prevention (CDC), RPC Diagnostic Systems, Ltd. 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2839] Novel Enzyme-Based Immunoassay for Simultaneous Detection of Hepatitis C Virus Antigen and Antibody in Human Serum or Plasma&body=Please send me information about technology [TAB-2839] Novel Enzyme-Based Immunoassay for Simultaneous Detection of Hepatitis C Virus Antigen and Antibody in Human Serum or Plasma. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2839] Novel Enzyme-Based Immunoassay for Simultaneous Detection of Hepatitis C Virus Antigen and Antibody in Human Serum or Plasma&body=Please send me information about technology [TAB-2839] Novel Enzyme-Based Immunoassay for Simultaneous Detection of Hepatitis C Virus Antigen and Antibody in Human Serum or Plasma.">jonathan.motley@nih.gov</a><br> 114163227 E-190-2013-0 E-190-2013-0-US-05 Compositions and Methods for Simultaneous Detection of HCV Antigen/Antibody National Stage US 9,891,225 14/890,299 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9891225 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9891225">9,891,225</a><br />Filed on 2015-11-10<br />Status: Issued 114167875 E-190-2013-0 E-190-2013-0-US-01 COMPOSITIONS AND METHODS FOR SIMULTANEOUS DETECTION OF HCV ANTIGEN/ANTIBODY PRV US 61/821,953 Abandoned US <br />Provisional (PRV) 61/821,953<br />Filed on 2013-05-10<br />Status: Abandoned 114167876 E-190-2013-0 E-190-2013-0-PCT-02 COMPOSITIONS AND METHODS FOR SIMULTANEOUS DETECTION OF HCV ANTIGEN/ANTIBODY PCT Patent Cooperation Treaty PCT/US2014/037648 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2014/037648<br />Filed on 2014-05-12<br />Status: Expired 114126358 DA4BXX 114126359 DAXXXX 114126360 DA4XXX 114126361 WFXXXX 114126362 WBXXXX 114126363 VLXXXX 114126364 WIXXXX 114126365 XAXXXX 114126366 XCXXXX 114126367 YBXXXX 114147608 Novel 114147609 EIA 114147610 SIMULTANEOUS 114147611 Detection 114147612 HCV 114147613 Antigen/Ab 114147614 Human 114147615 SERA 114147616 PLASMA 114147617 CDC Docket Import 114147618 CDC Docket Import CDC Prosecuting 114147619 OID-NCHHSTP-DVH 114147620 ANTIBODY 114147621 detection system 114147622 virus 114147623 VIRAL DIAGNOSTIC 114147624 viral 114147625 diagnostic in vitro 114147626 Diagnostic Kit 114147627 diagnostic 114147628 Diagnosis 114147629 LATERAL 114147630 ivd 114147631 HEPATITIS C HCV 114147632 HEPATITIS C DIAGNOSTIC 114147633 HEPATITIS C 114147634 Hepatitis 114147635 Antibody-based 114147636 Antibody-dependent 114147637 ANTIGEN 114147638 Antigen Antibody 114147639 ANTIGEN CAPTURE ASSAY 114147640 ANTIGEN-ANTIBODY 114147641 Antigen-binding 114147642 Antigen/antibody TAB-2828 114097007 On-site in vitro Diagnostic: Real-time Loop-Mediated Isothermal Amplification Detection of HIV-2 Groups A and B CDC Consumer Products, Diagnostics, Infectious Disease, Licensing, Occupational Safety and Health, Research Materials, Therapeutics Consumer Products Diagnostics Infectious Disease Licensing Occupational Safety and Health Research Materials Therapeutics Kelly Curtis, Timothy Granade, Philip Niedzwiedz, Sherry Owen, Chou-Pong Pau, Donna Rudolph, Ae Saekhou Youngpairoj This CDC-developed technology entails a nucleic acid-based HIV-2 in vitro diagnostic assay that is well-suited for use in mobile testing units/vehicles or resource-limited settings, for example, many areas of West Africa. Because HIV-2 requires unique treatment regimens, accurate, early diagnosis is crucial for effective care and directing treatment. Recently, new HIV testing recommendations have been proposed for laboratory settings, which include the use of a HIV-1/HIV-2 discriminatory assay. The use of a discriminatory assay will aid clinicians in the detection of HIV-2 infection; however, current HIV screening tests are antibody-based and frequently yield a false-negative result if a patient is tested during early infection, prior to seroconversion.<br /><br /> In this technology, RT-LAMP (Reverse Transcription-Loop-mediated Isothermal Amplification) provides a rapid, portable, easy to perform assay that can be used for early-stage HIV confirmation, bypassing the risk of false-negative results. The HIV-2 RT-LAMP assay can detect both HIV-2 RNA and DNA in the same reaction, and greatly narrows the window from infection to detection through observation of peak levels of virus replication that are a characteristic of early infection. Further, the assay as developed can also detect sequences from both circulating HIV-2 groups, A and B. This assay brings the potential for viral nucleic acid-based HIV diagnosis to millions of people living in low-resource settings, and may be quite useful for mobilized HIV/AIDS testing and control units operating around the world. <ul> <li>Extraordinary flexibility for testing settings; assay is well-suited for use at the point-of-care or in resource-limited regions</li> <li>Detects both HIV-2 RNA and DNA in the same reaction</li> <li>Easy to perform, and can be incorporated into a portable kit format</li> <li>Can provide rapid on-the-spot diagnosis</li> </ul> <ul> <li>HIV/AIDS screening and control programs in low-resource settings</li> <li>Nucleic acid-based, early-stage diagnosis of HIV-2 infection (both groups A and B) in locales where thermocyclers are not available</li> <li>Screening blood donations in emergency transfusion scenarios</li> </ul> 2022-03-08 2025-05-09 2025-05-09 2014-06-02 AIDS, amplification, B, DA4AXX, DA4XXX, DAXXXX, Detection, diagnostic, Diagnostic assay, diagnostic in vitro, Diagnostic System, DXXXXX, Field-usable, GCXXXX, Groups, HIV-2, Isothermal, LAMP, Loop-Mediated, LOW INPUT, OID-NCHHSTP-DHPSE, Reverse-Transcription, RT-LAMP, VLXXXX, WBXXXX, WFXXXX, WIXXXX, WMXXXX, XEXXXX, YBXXXX, YEXXXX False True <ul> <li>In vitro data available</li> <li>In situ data available (on-site)</li> </ul> True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract E-625-2013-0 E-173-2013-0 E-273-2013-0 E-128-2013-0 114172154 Curtis KA, et al. http://www.ncbi.nlm.nih.gov/pubmed/24789187 <a href="http://www.ncbi.nlm.nih.gov/pubmed/24789187">Curtis KA, et al.</a> 114172155 Curtis KA, et al. http://www.ncbi.nlm.nih.gov/pubmed/22384022 <a href="http://www.ncbi.nlm.nih.gov/pubmed/22384022">Curtis KA, et al.</a> 114172156 Curtis KA, et al. http://www.ncbi.nlm.nih.gov/pubmed/19382260 <a href="http://www.ncbi.nlm.nih.gov/pubmed/19382260">Curtis KA, et al.</a> 114172157 Curtis KA, et al. http://www.ncbi.nlm.nih.gov/pubmed/18524393 <a href="http://www.ncbi.nlm.nih.gov/pubmed/18524393">Curtis KA, et al.</a> 114108744 Owen, Sherry CDC - DIR CDC Owen, Sherry (CDC) 0 114108746 Rudolph, Donna CDC - DIR CDC Rudolph, Donna (CDC) 0 114108747 Granade, Timothy CDC - DIR CDC Granade, Timothy (CDC) 0 114108748 Youngpairoj, Ae Saekhou CDC - DIR CDC Youngpairoj, Ae Saekhou (CDC) 0 114108749 Pau, Chou-Pong CDC - DIR CDC Pau, Chou-Pong (CDC) 0 114108743 Curtis, Kelly CDC - DIR CDC Curtis, Kelly (CDC) 1 144229813 Niedzwiedz, Philip CDC - DIR CDC Niedzwiedz, Philip (CDC) 3 114108743 Curtis, Kelly CDC - DIR CDC Curtis, Kelly (CDC) 1 114108744 Owen, Sherry CDC - DIR CDC Owen, Sherry (CDC) 0 114108746 Rudolph, Donna CDC - DIR CDC Rudolph, Donna (CDC) 0 114108747 Granade, Timothy CDC - DIR CDC Granade, Timothy (CDC) 0 114108748 Youngpairoj, Ae Saekhou CDC - DIR CDC Youngpairoj, Ae Saekhou (CDC) 0 114108749 Pau, Chou-Pong CDC - DIR CDC Pau, Chou-Pong (CDC) 0 144229813 Niedzwiedz, Philip CDC - DIR CDC Niedzwiedz, Philip (CDC) 3 114102165 Detection Of Groups A And B HIV-2 By Reverse-Transcription, Loop-Mediated Isothermal Amplification (RT-LAMP) E-020-2014-0 Closed Centers for Disease Control and Prevention (CDC) 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2828] On-site in vitro Diagnostic: Real-time Loop-Mediated Isothermal Amplification Detection of HIV-2 Groups A and B&body=Please send me information about technology [TAB-2828] On-site in vitro Diagnostic: Real-time Loop-Mediated Isothermal Amplification Detection of HIV-2 Groups A and B. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2828] On-site in vitro Diagnostic: Real-time Loop-Mediated Isothermal Amplification Detection of HIV-2 Groups A and B&body=Please send me information about technology [TAB-2828] On-site in vitro Diagnostic: Real-time Loop-Mediated Isothermal Amplification Detection of HIV-2 Groups A and B.">jonathan.motley@nih.gov</a><br> 114160788 E-020-2014-0 E-020-2014-0-US-04 HIV-2 NUCLEIC ACIDS AND METHODS OF DETECTION National Stage US 15/120,270 Abandoned US <br />National Stage 15/120,270<br />Filed on 2016-08-19<br />Status: Abandoned 114167822 E-020-2014-0 E-020-2014-0-US-01 HIV-2 Nucleic Acids And Methods Of Detection PRV US 61/943,001 Abandoned US <br />Provisional (PRV) 61/943,001<br />Filed on 2014-02-21<br />Status: Abandoned 114168085 E-020-2014-0 E-020-2014-0-PCT-02 HIV-2 NUCLEIC ACIDS AND METHODS OF DETECTION PCT Patent Cooperation Treaty PCT/US2015/016814 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2015/016814<br />Filed on 2015-02-20<br />Status: Expired 114126259 DXXXXX 114126260 DAXXXX 114126261 DA4XXX 114126262 DA4AXX 114126263 GCXXXX 114126264 VLXXXX 114126265 WBXXXX 114126266 WFXXXX 114126267 WIXXXX 114126268 WMXXXX 114126269 XEXXXX 114126270 YBXXXX 114126271 YEXXXX 114147489 Detection 114147490 Groups 114147491 B 114147492 HIV-2 114147493 Reverse-Transcription 114147494 Loop-Mediated 114147495 Isothermal 114147496 amplification 114147497 RT-LAMP 114147498 OID-NCHHSTP-DHPSE 114147499 LAMP 114147500 AIDS 114147501 LOW INPUT 114147502 Field-usable 114147503 diagnostic 114147504 Diagnostic assay 114147505 diagnostic in vitro 114147506 Diagnostic System TAB-2819 114096998 A Device for Simultaneous and Rapid Diagnosis and Detection of Recent and Long Term HIV-1 Infection CDC Antibodies, Consumer Products, Diagnostics, Immunology, Infectious Disease, Licensing, Medical Devices, Non-Medical Devices, Occupational Safety and Health, Research Materials, Therapeutics Antibodies Consumer Products Diagnostics Immunology Infectious Disease Licensing Medical Devices Non-Medical Devices Occupational Safety and Health Research Materials Therapeutics Timothy Granade, Steve McDougal, Chou-Pong Pau CDC scientists have developed a device for simultaneous rapid diagnosis of HIV infection and for identification of recent HIV-1 infection. The device utilizes immunochromatographic or flow-through principles to detect HIV antibodies within clinical samples. This device may be used for diagnosis of HIV infection, as well as to distinguish between recent infection (<6 months) and long-term infection (>1 year). This latter application has added significance for surveillance, counseling, partner notification and other related prevention concerns, including the estimation of HIV incidence in cross-sectional populations. The device, if formatted as a self-contained kit, would utilize a single platform containing all required reagents, making it simple and easy for use by minimally trained technicians. The entire testing process, including the determination of incident infections, has been designed to minimize assay processing time. This device has potential as an important tool for regional incidence measurements, which can aid targeting of prevention activities and allocation of resources by HIV/AIDS prevention programs, as well as serve as an indicator of the effectiveness of intervention strategies. <ul> <li>Simple, single platform testing</li> <li>Greater cost efficiency than current immunoassays in terms of resource input and labor investment</li> <li>Exceptionally rapid assay processing</li> <li>Permits early-as-possible diagnosis, counseling, partner notification and early treatment</li> <li>Assay can be developed for on-site testing, at-home use or resource-limited environments using finger prick blood samples</li> </ul> <ul> <li>Routine HIV screening and diagnostics</li> <li>Establishment of a specific "window-of-infection" timeframe</li> <li>HIV/AIDS surveillance programs and evaluation of prevention program effectiveness</li> <li>Identification of high-risk cohorts for vaccine development, microbicide research and targeting resources</li> <li>HIV/AIDS research tool</li> <li>Screening tool for emergency blood donation</li> </ul> Research Tool – Patent protection is not being pursued for this technology. Research Tools – Patent protection is not being pursued for these technologies. 2022-03-08 2025-05-09 2025-05-09 2014-05-15 assay, CDC Docket Import, CDC Docket Import CDC Prosecuting, Detection, Development, Diagnosis, diagnostic, HIV, HIV-1, Infection, LONG, RAPID, RECENT, TERM, VLXXXX, WBXXXX, WFXXXX, WIXXXX, WMXXXX, XAXXXX, XCXXXX, XDXXXX, XEXXXX, YAXXXX, YFXXXX False True <ul> <li>Early-stage</li> <li>Prototype</li> </ul> True 52406769 Prototype 52406769 NIHTT 37470483 Website Abstract E-358-2013-0 E-555-2013-0 114172141 Granade TC. http://www.ncbi.nlm.nih.gov/pubmed/23281586 <a href="http://www.ncbi.nlm.nih.gov/pubmed/23281586">Granade TC.</a> 114108722 Pau, Chou-Pong CDC - DIR CDC Pau, Chou-Pong (CDC) 0 114108723 McDougal, Steve CDC - DIR CDC McDougal, Steve (CDC) 0 114108721 Granade, Timothy CDC - DIR CDC Granade, Timothy (CDC) 1 114108721 Granade, Timothy CDC - DIR CDC Granade, Timothy (CDC) 1 114108722 Pau, Chou-Pong CDC - DIR CDC Pau, Chou-Pong (CDC) 0 114108723 McDougal, Steve CDC - DIR CDC McDougal, Steve (CDC) 0 114102152 DEVELOPMENT OF A RAPID HIV DIAGNOSTIC ASSAY FOR DIAGNOSIS AND DETECTION OF RECENT AND LONG TERM HIV-1 INFECTION E-357-2013-0 Research Material Centers for Disease Control and Prevention (CDC) 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2819] A Device for Simultaneous and Rapid Diagnosis and Detection of Recent and Long Term HIV-1 Infection&body=Please send me information about technology [TAB-2819] A Device for Simultaneous and Rapid Diagnosis and Detection of Recent and Long Term HIV-1 Infection. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2819] A Device for Simultaneous and Rapid Diagnosis and Detection of Recent and Long Term HIV-1 Infection&body=Please send me information about technology [TAB-2819] A Device for Simultaneous and Rapid Diagnosis and Detection of Recent and Long Term HIV-1 Infection.">jonathan.motley@nih.gov</a><br> 114126052 VLXXXX 114126053 WBXXXX 114126054 WFXXXX 114126055 WIXXXX 114126056 WMXXXX 114126057 XAXXXX 114126058 XCXXXX 114126059 XDXXXX 114126060 XEXXXX 114126061 YAXXXX 114126062 YFXXXX 114147301 Development 114147302 RAPID 114147303 HIV 114147304 diagnostic 114147305 assay 114147306 Diagnosis 114147307 Detection 114147308 RECENT 114147309 LONG 114147310 TERM 114147311 HIV-1 114147312 Infection 114147313 CDC Docket Import 114147314 CDC Docket Import CDC Prosecuting TAB-2779 114096958 Multivalent, Multiple-Antigenic-Peptides for Serological Detection of HIV-1 Groups -M, -N, -O, and HIV-2 CDC Antibodies, Consumer Products, Diagnostics, Immunology, Infectious Disease, Licensing, Occupational Safety and Health, Research Materials, Therapeutics Antibodies Consumer Products Diagnostics Immunology Infectious Disease Licensing Occupational Safety and Health Research Materials Therapeutics Chou-Pong Pau This CDC-developed invention pertains to multivalent antigenic peptides (MAPs) that can be used in a variety of HIV/AIDS diagnostics. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is subdivided into groups M, N, and O, while HIV-2 is subdivided into subtypes A and B. Within HIV -1 group M, several different subtypes and numerous forms of recombinant viruses exist. To detect all types, groups, and subtypes of HIV by serological methods, a mixture of antigens derived from different viral strains representing different HIV types and subtypes is needed. However, due to the competition and dilution effect, mixing multiple antigens may reduce the amount of individual antigen bound to the solid phase and lead to a reduction in assay sensitivity.<br /><br /> It is known that MAPs, which contain multiple branches of an oligopeptide sequence, are more antigenic than the corresponding single chain linear peptides. The MAPs encompassed by this technology contain multiple branches of oligopeptides of different sequences, derived from HIV-1 group M, N, O, and HIV-2. Thus, depending on the peptide sequences incorporated, a single MAP can be used to detect HIV-1 group M alone, HIV-2 alone, or to simultaneously detect HIV-1 groups M, N, O, and HIV-2 with high sensitivity and specificity. <ul> <li>Lateral flow assays for HIV detection and discrimination</li> <li>On-site, point-of-care testing and diagnosis</li> <li>Easily formulated as an ELISA kit for commercial or research applications</li> <li>Technology can be used to develop a rapid, low-cost method of determining HIV status for home-use or low-resource settings</li> </ul> <ul> <li>Diagnostic test for HIV-1 and/or HIV-2 infection</li> <li>Blood and plasma donation screening</li> <li>HIV/AIDS surveillance and monitoring programs</li> </ul> Research Tool – Patent protection is not being pursued for this technology. 2022-03-08 2025-05-09 2025-05-09 2014-02-28 0, AAXXXX, AIDS, antibodies, ANTIGEN, AXXXXX, CDC Docket Import, CDC Docket Import CDC Prosecuting, DA4AXX, DA4XXX, DAXXXX, Detection, DEVELOPING, DXXXXX, GROUP, HIV-1, HIV-2., LATERAL, M, MAPS, Multiple-antigenic-peptides, MULTIVALENT, N, RESEARCH MATERIAL, virus, VLXXXX, WBXXXX, WFXXXX, WIXXXX, XAXXXX, XCXXXX, XEXXXX, YBXXXX False True In vitro data available True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract E-173-2013-0 E-053-2013-0 E-052-2013-0 E-232-2013-0 E-259-2013-0 E-294-2013-0 E-357-2013-0 E-358-2013-0 E-522-2013-0 E-555-2013-0 E-638-2013-0 114172086 Granade TC, et al. http://www.ncbi.nlm.nih.gov/pubmed/20410326 <a href="http://www.ncbi.nlm.nih.gov/pubmed/20410326">Granade TC, et al.</a> 114172087 Pau C, et al. http://www.ncbi.nlm.nih.gov/pubmed/17169369 <a href="http://www.ncbi.nlm.nih.gov/pubmed/17169369">Pau C, et al.</a> 114172088 Kim P and Pau CP. http://www.ncbi.nlm.nih.gov/pubmed/11687238 <a href="http://www.ncbi.nlm.nih.gov/pubmed/11687238">Kim P and Pau CP.</a> 114108575 Pau, Chou-Pong CDC - DIR CDC Pau, Chou-Pong (CDC) 1 114108575 Pau, Chou-Pong CDC - DIR CDC Pau, Chou-Pong (CDC) 1 114102104 Multivalent Multiple-antigenic-peptides (MAPs) For The Detection Of Antibodies To HIV-1 Group M, N, 0, And HIV-2. E-604-2013-0 Research Material Centers for Disease Control and Prevention (CDC) 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2779] Multivalent, Multiple-Antigenic-Peptides for Serological Detection of HIV-1 Groups -M, -N, -O, and HIV-2&body=Please send me information about technology [TAB-2779] Multivalent, Multiple-Antigenic-Peptides for Serological Detection of HIV-1 Groups -M, -N, -O, and HIV-2. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2779] Multivalent, Multiple-Antigenic-Peptides for Serological Detection of HIV-1 Groups -M, -N, -O, and HIV-2&body=Please send me information about technology [TAB-2779] Multivalent, Multiple-Antigenic-Peptides for Serological Detection of HIV-1 Groups -M, -N, -O, and HIV-2.">jonathan.motley@nih.gov</a><br> 114125555 AAXXXX 114125556 DXXXXX 114125557 DAXXXX 114125558 DA4XXX 114125559 DA4AXX 114125560 AXXXXX 114125561 VLXXXX 114125562 WBXXXX 114125563 WFXXXX 114125564 WIXXXX 114125565 XAXXXX 114125566 XCXXXX 114125567 XEXXXX 114125568 YBXXXX 114146698 MULTIVALENT 114146699 Multiple-antigenic-peptides 114146700 MAPS 114146701 Detection 114146702 antibodies 114146703 HIV-1 114146704 GROUP 114146705 M 114146706 N 114146707 0 114146708 HIV-2. 114146709 CDC Docket Import 114146710 CDC Docket Import CDC Prosecuting 114146711 RESEARCH MATERIAL 114146712 virus 114146713 ANTIGEN 114146714 AIDS 114146715 DEVELOPING 114146716 LATERAL TAB-2775 114096954 Multiple Antigenic Peptide Assays for Detection of HIV and SIV Type Retroviruses CDC Antibodies, Consumer Products, Diagnostics, Immunology, Infectious Disease, Licensing, Occupational Safety and Health, Research Materials, Therapeutics Antibodies Consumer Products Diagnostics Immunology Infectious Disease Licensing Occupational Safety and Health Research Materials Therapeutics Thomas Folks, Marcia Kalish, Clement Ndongmo, Chou-Pong Pau, William Switzer CDC scientists have developed multiple antigenic peptide immunoassays for the detection of human immunodeficiency virus (HIV) and/or simian immunodeficiency virus (SIV). HIV can be subdivided into two major types, HIV-1 and HIV-2, both of which are believed to have originated as result of zoonotic transmission. Humans are increasingly exposed to many different SIVs by wild primates. For example, human exposure to SIVs frequently occurs as a consequence of the bush meat hunting and butchering trade in Africa. Human exposure to SIVs may lead, or may have already led, to transmission of SIVs with potential for new virus induced immunodeficiency epidemics. Unfortunately, new cases of zoonotic virus transmission may go undetected because of the lack of SIV-specific tests. Thus, there is the potential to compromise the safety of the blood donor supply system and seed a new HIV-like epidemic. This invention addresses these problems by providing a way to test all primates for the many divergent lentivirus strains to identify primary infections and prevent secondary transmission. <ul> <li>Fills an unmet need for SIV-specific tests</li> <li>Sensitive and specific</li> <li>Easily adapted to kit/array format</li> <li>Research indicates greater sensitivity than standard HIV enzyme immunoassays (EIAs) for detecting SIV infections</li> </ul> <ul> <li>Detection and differentiation of HIV-1, HIV-2 and SIVs</li> <li>HIV/SIV surveillance</li> <li>SIV/HIV/AIDS research</li> <li>Sero-monitoring of potential zoonotic transmissions</li> <li>Blood-donation supply assurance tool</li> </ul> Various international patent applications pending or issued 2022-03-08 2025-05-09 2025-05-09 2014-02-07 ANTIGENIC, assay, CDC Docket Import, CDC Docket Import CDC Prosecuting, DA4AXX, DA4BXX, DA4XXX, DAXXXX, DDXXXX, Detection, DXXXXX, HIV, MULTIPLE, OID-NCHHSTP-DHPSE, Peptide, Retroviruses, Serologic, SEROLOGICAL, SIV, TYPE, VLXXXX, VOXXXX, WBXXXX, WFXXXX, WIXXXX, WMXXXX, XAXXXX, XCXXXX, XEXXXX, YBXXXX False True In vitro data available True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114172070 Ndongmo CB, et al. http://www.ncbi.nlm.nih.gov/pubmed/15528710 <a href="http://www.ncbi.nlm.nih.gov/pubmed/15528710">Ndongmo CB, et al.</a> 114172071 Kalish ML, et al. http://www.ncbi.nlm.nih.gov/pubmed/16485481 <a href="http://www.ncbi.nlm.nih.gov/pubmed/16485481">Kalish ML, et al.</a> 114108560 Ndongmo, Clement CDC - DIR CDC Ndongmo, Clement (CDC) 0 114108561 Pau, Chou-Pong CDC - DIR CDC Pau, Chou-Pong (CDC) 0 114108562 Switzer, William CDC - DIR CDC Switzer, William (CDC) 0 114108563 Folks, Thomas CDC - DIR Folks, Thomas 0 114108559 Kalish, Marcia CDC - DIR CDC Kalish, Marcia (CDC) 1 114108559 Kalish, Marcia CDC - DIR CDC Kalish, Marcia (CDC) 1 114108560 Ndongmo, Clement CDC - DIR CDC Ndongmo, Clement (CDC) 0 114108561 Pau, Chou-Pong CDC - DIR CDC Pau, Chou-Pong (CDC) 0 114108562 Switzer, William CDC - DIR CDC Switzer, William (CDC) 0 114108563 Folks, Thomas CDC - DIR Folks, Thomas 0 114102097 Multiple Antigenic Peptide Assay For Detection Of HIV Or SIV Type Retroviruses E-294-2013-0 Closed Centers for Disease Control and Prevention (CDC) 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2775] Multiple Antigenic Peptide Assays for Detection of HIV and SIV Type Retroviruses&body=Please send me information about technology [TAB-2775] Multiple Antigenic Peptide Assays for Detection of HIV and SIV Type Retroviruses. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2775] Multiple Antigenic Peptide Assays for Detection of HIV and SIV Type Retroviruses&body=Please send me information about technology [TAB-2775] Multiple Antigenic Peptide Assays for Detection of HIV and SIV Type Retroviruses.">jonathan.motley@nih.gov</a><br> 114167655 E-294-2013-0 E-294-2013-0-US-07 Multiple Antigenic Peptide Assay For Detection Of HIV Or SIV Type Retroviruses National Stage US 10/552,182 Abandoned US <br />National Stage 10/552,182<br />Filed on 2005-10-05<br />Status: Abandoned 114167656 E-294-2013-0 E-294-2013-0-PCT-02 Multiple Antigenic Peptide Assay For Detection Of HIV Or SIV Type Retroviruses PCT Patent Cooperation Treaty PCT/US2004/011022 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2004/011022<br />Filed on 2004-04-08<br />Status: Expired 114167657 E-294-2013-0 E-294-2013-0-US-01 Multiple Antigenic Peptide Assay For Detection Of HIV Or SIV Type Retroviruses PRV US 60/462,071 Abandoned US <br />Provisional (PRV) 60/462,071<br />Filed on 2003-04-11<br />Status: Abandoned 114167658 E-294-2013-0 E-294-2013-0-US-09 Multiple Antigenic Peptide Assay For Detection Of HIV Or SIV Type Retroviruses CON US 8,524,461 12/717,276 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8524461 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8524461">8,524,461</a><br />Filed on 2010-03-04<br />Status: Abandoned 114125474 DXXXXX 114125475 DAXXXX 114125476 DA4XXX 114125477 DA4AXX 114125478 DA4BXX 114125479 DDXXXX 114125480 VLXXXX 114125481 VOXXXX 114125482 WBXXXX 114125483 WFXXXX 114125484 WIXXXX 114125485 WMXXXX 114125486 XAXXXX 114125487 XCXXXX 114125488 XEXXXX 114125489 YBXXXX 114146616 MULTIPLE 114146617 ANTIGENIC 114146618 Peptide 114146619 assay 114146620 Detection 114146621 HIV 114146622 SIV 114146623 TYPE 114146624 Retroviruses 114146625 CDC Docket Import 114146626 CDC Docket Import CDC Prosecuting 114146627 OID-NCHHSTP-DHPSE 114146628 Serologic 114146629 SEROLOGICAL TAB-2773 114096952 Diagnostic Antigens for the Identification of Latent Tuberculosis Infection CDC Antibodies, Consumer Products, Diagnostics, Geriatrics, Immunology, Infectious Disease, Licensing, Occupational Safety and Health, Research Materials, Vaccines Antibodies Consumer Products Diagnostics Geriatrics Immunology Infectious Disease Licensing Occupational Safety and Health Research Materials Vaccines Bernard Beall, Kristin Birkness, Manon Deslauriers, Peter King, Frederick Quinn CDC researchers have developed technology for sero-diagnosis of typically symptomless latent stage tuberculosis disease, posing a threat to individuals under immunosuppressive or anti-inflammatory therapies. Specifically, this diagnostic approach exploits <em>M. tuberculosis</em> secreted latency specific antigens, such as alpha-crystallin, in the blood or urine of patients. This type of test could easily be developed into an inexpensive dip-stick format with high specificity (no cross-reactivity with other mycobacteria), rapidity, and sensitivity (fewer bacteria needed for a positive identification). Because secreted antigens are recognized more readily by the immune system, serum-derived antibodies to these antigens can correspondingly be used for diagnostic or research use. <ul> <li>Rapid and inexpensive diagnostic for latent stage tuberculosis</li> <li>Specific for latent form, unlike current IGRA/TST diagnostics</li> <li>Easily developed as a cost effective dip-stick test</li> <li>Provides high specificity (no cross-reactivity with other mycobacteria) and sensitivity (fewer bacteria needed for a positive identification)</li> </ul> <ul> <li>Development of a latent tuberculosis diagnostic</li> <li>Improvements to current diagnostics</li> <li>Public health/tuberculosis monitoring programs</li> <li>Screening elderly patients before beginning anti-inflammatory and/or anti-arthritis therapy</li> </ul> Various international patents issued or pending 2022-03-08 2025-05-09 2025-05-09 2014-02-07 ANTIGENS, CDC Docket Import, CDC Docket Import CDC Prosecuting, DA3XXX, DAXXXX, DC4XXX, DCXXXX, DDXXXX, DEXXXX, diagnostic, DXXXXX, Granuloma, Human, IA3XXX, Identification, Latent, Methods, Model, OID-NCHHSTP-DTE, TUBERCULOSIS, VAXXXX, Vitro, VJXXXX, WBXXXX, WFXXXX, WIXXXX, XAXXXX, XCXXXX, YBXXXX, YDXXXX False True <ul> <li>In vitro data available</li> <li>In vivo data available (human)</li> </ul> True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114172067 Stewart JN, et al. http://www.ncbi.nlm.nih.gov/pubmed/16385133 <a href="http://www.ncbi.nlm.nih.gov/pubmed/16385133">Stewart JN, et al.</a> 114108549 Deslauriers, Manon CDC - DIR CDC Deslauriers, Manon (CDC) 0 114108550 Birkness, Kristin CDC - DIR CDC Birkness, Kristin (CDC) 0 114108552 King, Peter CDC - DIR CDC King, Peter (CDC) 0 114108553 Beall, Bernard CDC - DIR CDC Beall, Bernard (CDC) 0 114108551 Quinn, Frederick CDC - DIR CDC Quinn, Frederick (CDC) 1 114108551 Quinn, Frederick CDC - DIR CDC Quinn, Frederick (CDC) 1 114108549 Deslauriers, Manon CDC - DIR CDC Deslauriers, Manon (CDC) 0 114108550 Birkness, Kristin CDC - DIR CDC Birkness, Kristin (CDC) 0 114108552 King, Peter CDC - DIR CDC King, Peter (CDC) 0 114108553 Beall, Bernard CDC - DIR CDC Beall, Bernard (CDC) 0 114102094 Diagnostic Antigens For The Identification Of Latent Human Tuberculosis E-249-2013-1 Closed Centers for Disease Control and Prevention (CDC) 114102095 LATENT HUMAN TUBERCULOSIS MODEL, DIAGNOSTIC ANTIGENS, AND METHODS OF USE E-249-2013-2 Closed Centers for Disease Control and Prevention (CDC) 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2773] Diagnostic Antigens for the Identification of Latent Tuberculosis Infection&body=Please send me information about technology [TAB-2773] Diagnostic Antigens for the Identification of Latent Tuberculosis Infection. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2773] Diagnostic Antigens for the Identification of Latent Tuberculosis Infection&body=Please send me information about technology [TAB-2773] Diagnostic Antigens for the Identification of Latent Tuberculosis Infection.">jonathan.motley@nih.gov</a><br> 114167650 E-249-2013-1 E-249-2013-1-US-01 Diagnostic Antigens For The Identification Of Latent Human Tuberculosis PRV US 60/311,235 Abandoned US <br />Provisional (PRV) 60/311,235<br />Filed on 2011-08-09<br />Status: Abandoned 114167651 E-249-2013-2 E-249-2013-2-PCT-01 LATENT HUMAN TUBERCULOSIS MODEL, DIAGNOSTIC ANTIGENS, AND METHODS OF USE PCT COMB Patent Cooperation Treaty PCT/US2002/000309 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2002/000309<br />Filed on 2002-01-07<br />Status: Expired 114167652 E-249-2013-2 E-249-2013-2-US-06 LATENT HUMAN TUBERCULOSIS MODEL, DIAGNOSTIC ANTIGENS, AND METHODS OF USE National Stage US 7,105,170 10/250,930 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7105170 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7105170">7,105,170</a><br />Filed on 2004-02-17<br />Status: Expired 114125426 DXXXXX 114125427 DAXXXX 114125428 DA3XXX 114125429 DCXXXX 114125430 DC4XXX 114125431 DEXXXX 114125432 DDXXXX 114125433 IA3XXX 114125434 VAXXXX 114125435 VJXXXX 114125436 WBXXXX 114125437 WFXXXX 114125438 WIXXXX 114125439 XAXXXX 114125440 XCXXXX 114125441 YBXXXX 114125442 YDXXXX 114146597 Vitro 114146598 Granuloma 114146599 Model 114146600 Methods 114146601 diagnostic 114146602 ANTIGENS 114146603 Identification 114146604 Latent 114146605 Human 114146606 TUBERCULOSIS 114146607 CDC Docket Import 114146608 CDC Docket Import CDC Prosecuting 114146609 OID-NCHHSTP-DTE TAB-2772 114096951 Novel In Vitro Granuloma Model for Studying Tuberculosis and Drug Efficacy CDC Consumer Products, Diagnostics, Immunology, Infectious Disease, Licensing, Occupational Safety and Health, Research Equipment, Research Materials, Vaccines Consumer Products Diagnostics Immunology Infectious Disease Licensing Occupational Safety and Health Research Equipment Research Materials Vaccines Bernard Beall, Kristin Birkness, Manon Deslauriers, Peter King, Frederick Quinn CDC researchers have developed an <em>in vitro</em> model system designed to simulate early-stage <em>Mycobacterium tuberculosis</em> infection and induced granuloma formation. This modeling platform can be used for studying tuberculosis pathogenicity, identifying phenotypically-interesting clinical isolates, studying early-stage host cytokine/chemokine responses, and <em>in vitro</em> candidate-drug screening. The approach incorporates autologous human macrophages, human peripheral blood mononuclear cells, and mycobacteria to mimic <em>in situ</em> granuloma formation in a controllable <em>in vitro</em> environment. This technology would be broadly useful for investigations into the numerous facets of early granuloma host-pathogen interaction, ultimately leading to improved prevention, intervention, and treatment strategies. <ul> <li>Low-cost alternative for modeling mycobacterial infections within complex tissue systems</li> <li>Allows researchers to examine early-stage granuloma formation in a highly controllable, human-based modeling system</li> <li>Cost-effective screening of potential therapeutic compounds and/or phenotypically-interesting mycobacteria</li> </ul> <ul> <li>In vitro modeling system</li> <li>Basic research into tuberculosis-host interactions</li> <li>Drug candidate screening</li> </ul> Various international patents issued or pending 2022-03-08 2025-05-09 2025-05-09 2014-02-07 AC4XXX, AC5XXX, ACXXXX, ANTIGENS, AXXXXX, CDC Docket Import, CDC Docket Import CDC Prosecuting, DA3XXX, DAXXXX, DC4XXX, DCXXXX, DDXXXX, DEXXXX, diagnostic, DXXXXX, Granuloma, Human, IA3XXX, Identification, Latent, Methods, Model, OID-NCHHSTP-DTE, TUBERCULOSIS, Vitro, VJXXXX, WBXXXX, WFXXXX, WIXXXX, WMXXXX, XHXXXX, YBXXXX, YFXXXX False True <ul> <li>In vitro data available</li> <li>Prototype</li> </ul> True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114172066 Birkness KA, et al. http://www.ncbi.nlm.nih.gov/pubmed/17199112 <a href="http://www.ncbi.nlm.nih.gov/pubmed/17199112">Birkness KA, et al.</a> 114108544 Deslauriers, Manon CDC - DIR CDC Deslauriers, Manon (CDC) 0 114108545 Birkness, Kristin CDC - DIR CDC Birkness, Kristin (CDC) 0 114108547 King, Peter CDC - DIR CDC King, Peter (CDC) 0 114108548 Beall, Bernard CDC - DIR CDC Beall, Bernard (CDC) 0 114108546 Quinn, Frederick CDC - DIR CDC Quinn, Frederick (CDC) 1 114108546 Quinn, Frederick CDC - DIR CDC Quinn, Frederick (CDC) 1 114108544 Deslauriers, Manon CDC - DIR CDC Deslauriers, Manon (CDC) 0 114108545 Birkness, Kristin CDC - DIR CDC Birkness, Kristin (CDC) 0 114108547 King, Peter CDC - DIR CDC King, Peter (CDC) 0 114108548 Beall, Bernard CDC - DIR CDC Beall, Bernard (CDC) 0 114102092 In Vitro Granuloma Model And Methods Of Use E-249-2013-0 Closed Centers for Disease Control and Prevention (CDC) 114102093 LATENT HUMAN TUBERCULOSIS MODEL, DIAGNOSTIC ANTIGENS, AND METHODS OF USE E-249-2013-2 Closed Centers for Disease Control and Prevention (CDC) 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2772] Novel In Vitro Granuloma Model for Studying Tuberculosis and Drug Efficacy&body=Please send me information about technology [TAB-2772] Novel In Vitro Granuloma Model for Studying Tuberculosis and Drug Efficacy. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2772] Novel In Vitro Granuloma Model for Studying Tuberculosis and Drug Efficacy&body=Please send me information about technology [TAB-2772] Novel In Vitro Granuloma Model for Studying Tuberculosis and Drug Efficacy.">jonathan.motley@nih.gov</a><br> 114167647 E-249-2013-0 E-249-2013-0-US-01 In Vitro Granuloma Model And Methods Of Use PRV US 60/260,348 Abandoned US <br />Provisional (PRV) 60/260,348<br />Filed on 2001-01-08<br />Status: Abandoned 114167648 E-249-2013-2 E-249-2013-2-PCT-01 LATENT HUMAN TUBERCULOSIS MODEL, DIAGNOSTIC ANTIGENS, AND METHODS OF USE PCT COMB Patent Cooperation Treaty PCT/US2002/000309 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2002/000309<br />Filed on 2002-01-07<br />Status: Expired 114167649 E-249-2013-2 E-249-2013-2-US-06 LATENT HUMAN TUBERCULOSIS MODEL, DIAGNOSTIC ANTIGENS, AND METHODS OF USE National Stage US 7,105,170 10/250,930 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7105170 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7105170">7,105,170</a><br />Filed on 2004-02-17<br />Status: Expired 114125406 DXXXXX 114125407 DDXXXX 114125408 AXXXXX 114125409 ACXXXX 114125410 AC4XXX 114125411 AC5XXX 114125412 VJXXXX 114125413 XHXXXX 114125414 DAXXXX 114125415 DA3XXX 114125416 DCXXXX 114125417 DC4XXX 114125418 DEXXXX 114125419 IA3XXX 114125420 WBXXXX 114125421 WFXXXX 114125422 WIXXXX 114125423 WMXXXX 114125424 YBXXXX 114125425 YFXXXX 114146584 Vitro 114146585 Granuloma 114146586 Model 114146587 Methods 114146588 CDC Docket Import 114146589 CDC Docket Import CDC Prosecuting 114146590 OID-NCHHSTP-DTE 114146591 diagnostic 114146592 ANTIGENS 114146593 Identification 114146594 Latent 114146595 Human 114146596 TUBERCULOSIS TAB-2751 114096931 Novel One-Well Limiting-Antigen Avidity Enzyme Immunoassay to Detect Recent HIV-1 Infection Using a Multi-subtype Recombinant Protein CDC Antibodies, Collaboration, Consumer Products, Diagnostics, Immunology, Infectious Disease, Licensing, Occupational Safety and Health, Research Materials, Therapeutics Antibodies Collaboration Consumer Products Diagnostics Immunology Infectious Disease Licensing Occupational Safety and Health Research Materials Therapeutics Bharat Parekh This CDC developed Limiting-Antigen avidity Enzyme Immunoassay (LAg-avidity-EIA) provides an easy way to measure increasing binding strength (avidity) of HIV antibodies as part of maturation HIV antibodies after seroconversion, providing a method to distinguish early-stage from long-term HIV-1 infection. Surveillance of HIV-1 provides information on prevalence rates of the disease, but determination of new infection rates (HIV-1 incidence) is difficult to deduce. Longitudinal follow up is expensive and can be biased.<br /><br /> Unlike assays which use antigens derived from only one subtype and use two wells, this new approach employs a multi-subtype recombinant protein, rIDR-M, to permit equivalent detection of antibody avidity among different subtypes, and measures binding strength of antibody in one well. This assay will allow the simultaneous testing of more specimens and better overall reproducibility due to its design. Further, the approach is likely to be more robust and provide more accurate results. The assay may be used for individual diagnosis of recent or long-term infection, but may also act as an important tool for worldwide HIV-1 surveillance, assessing new trends of infections, and monitoring success of varied and comparable prevention efforts implemented by major public health agencies. <ul> <li>Assay permits equivalent detection of HIV antibody avidity among different subtypes</li> <li>Design of LAg avidity-EIA allows for testing more samples and better reproducibility when compared to two-well avidity index EIA</li> </ul> <ul> <li>Population surveillance: estimation of HIV-1 incidence in cross-sectional specimens</li> <li>Identifying recent infection risk factors</li> <li>Following antibody avidity maturation over time</li> </ul> The CDC Technology Transfer Office (TTO) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize a system to monitor water supplies for a variety of pathogens. For collaboration opportunities, please contact CDC TTO at <a href="mailto:tto@cdc.gov">tto@cdc.gov</a> or 1-404-639-1330. Research Tool – Patent protection is not being pursued for this technology. 2022-03-08 2025-05-09 2025-05-09 2021-11-15 AA5XXX, AAXXXX, Avidity, Avidity-EIA, AXXXXX, CDC Docket Import, CDC Docket Import CDC Prosecuting, CGH-DGHA, DA4AXX, DA4XXX, DAXXXX, DDXXXX, Detect, Development, DXXXXX, Enzyme, HIV, IMMUNOASSAY, Infection, Inmunoassay, LAg, Limiting-antigen, Listed LPM Houze as of 4/15/2015, Multi-subtype, NCHHSTP, One-well, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Protein, RECENT, recombinant, RIDR-M, VLXXXX, WBXXXX, WFXXXX, WIXXXX, XAXXXX, XCXXXX, XEXXXX, YBXXXX False True In vitro data available True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 114172038 Duong YT, et al. http://www.ncbi.nlm.nih.gov/pubmed/22479384 <a href="http://www.ncbi.nlm.nih.gov/pubmed/22479384">Duong YT, et al.</a> 114172039 Wei X, et al. http://www.ncbi.nlm.nih.gov/pubmed/20063992 <a href="http://www.ncbi.nlm.nih.gov/pubmed/20063992">Wei X, et al.</a> 114108482 Parekh, Bharat CDC - DIR CDC Parekh, Bharat (CDC) 1 114108482 Parekh, Bharat CDC - DIR CDC Parekh, Bharat (CDC) 1 114102579 Development Of A New One-well Limiting-antigen Avidity Enzyme Immunoassay (LAg Avidity-EIA) To Detect Recent HIV I Infection Using A Multi-subtype Recombinant Protein, RIDR-M E-522-2013-0 Research Material Centers for Disease Control and Prevention (CDC) 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2751] Novel One-Well Limiting-Antigen Avidity Enzyme Immunoassay to Detect Recent HIV-1 Infection Using a Multi-subtype Recombinant Protein&body=Please send me information about technology [TAB-2751] Novel One-Well Limiting-Antigen Avidity Enzyme Immunoassay to Detect Recent HIV-1 Infection Using a Multi-subtype Recombinant Protein. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2751] Novel One-Well Limiting-Antigen Avidity Enzyme Immunoassay to Detect Recent HIV-1 Infection Using a Multi-subtype Recombinant Protein&body=Please send me information about technology [TAB-2751] Novel One-Well Limiting-Antigen Avidity Enzyme Immunoassay to Detect Recent HIV-1 Infection Using a Multi-subtype Recombinant Protein.">jonathan.motley@nih.gov</a><br> 114125051 AXXXXX 114125052 AAXXXX 114125053 AA5XXX 114125054 DXXXXX 114125055 DAXXXX 114125056 DDXXXX 114125057 DA4XXX 114125058 DA4AXX 114125059 VLXXXX 114125060 WBXXXX 114125061 WFXXXX 114125062 WIXXXX 114125063 XAXXXX 114125064 XCXXXX 114125065 XEXXXX 114125066 YBXXXX 114146318 Detect 114146319 Avidity-EIA 114146320 LAg 114146321 Inmunoassay 114146322 Enzyme 114146323 Avidity 114146324 Limiting-antigen 114146325 One-well 114146326 Development 114146327 RECENT 114146328 HIV 114146329 Infection 114146330 Multi-subtype 114146331 recombinant 114146332 Protein 114146333 RIDR-M 114146334 CDC Docket Import 114146335 CDC Docket Import CDC Prosecuting 114152312 NCHHSTP 114152313 CGH-DGHA 114152314 Listed LPM Houze as of 4/15/2015 114152315 Pre LPM working set 20150418 114152316 Post LPM Assignment Set 20150420 114152317 IMMUNOASSAY TAB-2750 114096929 Simple, Rapid, and Sensitive Real-Time PCR Assays for Detecting Drug Resistance of HIV CDC Cardiology, Computational models/software, Consumer Products, Dental, Diagnostics, Endocrinology, Infectious Disease, Licensing, Occupational Safety and Health, Oncology, Ophthalmology, Research Materials, Software / Apps, Therapeutics Cardiology Computational models/software Consumer Products Dental Diagnostics Endocrinology Infectious Disease Licensing Occupational Safety and Health Oncology Ophthalmology Research Materials Software / Apps Therapeutics Walid Heneine, Jeffrey Johnson, Jonathan Lipscomb This novel assay features real-time PCR reagents and methods for detecting drug-resistance related mutations in HIV, for newly diagnosed patients and those individuals currently receiving antiretroviral therapies. As the use of antiretroviral compounds to treat HIV infection proliferates, viruses adapt and evolve mutations limiting the efficacy of these drugs and disrupting the success of treatment. To address this problem, CDC researchers have developed this RT-PCR assay, intended for diagnosis of different point mutations in patient samples at an achievable sensitivity of 1-2 log greater than conventional point-mutation sequencing methods. More specifically, this assay measures the differential amplifications of common and mutation-specific reactions that target specific codons of interest. Given its low cost, simplicity, high-throughput capability, and tremendous diagnostic sensitivity, this assay will be useful for detection and surveillance of drug resistance-associated mutations and will aid in the clinical management of HIV infection. <ul> <li>Cost-effective</li> <li>Sensitive and rapid</li> <li>Capable of resistance mutation detection in both subtype B and non-B subtypes of HIV -1, and in HIV-2</li> <li>Easily formatted for use in kits</li> <li>High-throughput capable</li> </ul> <ul> <li>Clinical management of HIV infected patients</li> <li>Pre-treatment evaluation baseline HIV infection to tailor appropriate drug combinations</li> <li>Monitor the spread of resistant viruses</li> <li>Blood donation screening</li> <li>Research tool to study emergence and biology of drug resistance mutations</li> </ul> 2022-03-08 2025-05-09 2025-05-09 2014-01-28 1, ANTIVIRAL, Anti-Viral, ASSAYS, CDC Docket Import, CDC Docket Import CDC Prosecuting, DA4XXX, DAXXXX, DETECTING, DRUGS, DXXXXX, HIV, HIV-1, Listed LPM Houze as of 4/15/2015, MUTATION, NCHHSTP-DHPSE, OID-NCHHSTP-DHPSE, PCR, POINT, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, REAL-TIME, Resistance, VLXXXX, VPXXXX, WBXXXX, WFXXXX, XBXXXX, XCXXXX, XEXXXX, YBXXXX False True In vitro data available True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114172032 Johnson JA, et al. http://www.ncbi.nlm.nih.gov/pubmed/17653265 <a href="http://www.ncbi.nlm.nih.gov/pubmed/17653265">Johnson JA, et al.</a> 114172033 Johnson JA, et al. http://www.ncbi.nlm.nih.gov/pubmed/18666824 <a href="http://www.ncbi.nlm.nih.gov/pubmed/18666824">Johnson JA, et al.</a> 114172034 Li JF, et al. http://www.ncbi.nlm.nih.gov/pubmed/21257741 <a href="http://www.ncbi.nlm.nih.gov/pubmed/21257741">Li JF, et al.</a> 114172035 Nishizawa M, et al. http://www.ncbi.nlm.nih.gov/pubmed/24358257 <a href="http://www.ncbi.nlm.nih.gov/pubmed/24358257">Nishizawa M, et al.</a> 114172036 Wei X, et al. http://www.ncbi.nlm.nih.gov/pubmed/21130027 <a href="http://www.ncbi.nlm.nih.gov/pubmed/21130027">Wei X, et al.</a> 114108480 Lipscomb, Jonathan CDC - DIR CDC Lipscomb, Jonathan (CDC) 0 114108481 Heneine, Walid CDC - DIR CDC Heneine, Walid (CDC) 0 114109640 Johnson, Jeffrey CDC - DIR CDC Johnson, Jeffrey (CDC) 1 114109640 Johnson, Jeffrey CDC - DIR CDC Johnson, Jeffrey (CDC) 1 114108480 Lipscomb, Jonathan CDC - DIR CDC Lipscomb, Jonathan (CDC) 0 114108481 Heneine, Walid CDC - DIR CDC Heneine, Walid (CDC) 0 114102068 Real-Time PCR Point Mutation Assays For Detecting HIV-1 Resistance To Anti-Viral Drugs E-198-2013-0 Filing authorized Centers for Disease Control and Prevention (CDC) 114102069 Real-Time PCR Point Mutation Assays For Detecting HIV-1 Resistance To Anti-Viral Drugs E-214-2013-0 Filing authorized Centers for Disease Control and Prevention (CDC) 114102070 REAL-TIME PCR POINT MUTATION ASSAYS FOR DETECTING HIV - 1 RESISTANCE TO ANTIVIRAL DRUGS E-511-2013-0 Filing authorized Centers for Disease Control and Prevention (CDC) 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2750] Simple, Rapid, and Sensitive Real-Time PCR Assays for Detecting Drug Resistance of HIV&body=Please send me information about technology [TAB-2750] Simple, Rapid, and Sensitive Real-Time PCR Assays for Detecting Drug Resistance of HIV. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2750] Simple, Rapid, and Sensitive Real-Time PCR Assays for Detecting Drug Resistance of HIV&body=Please send me information about technology [TAB-2750] Simple, Rapid, and Sensitive Real-Time PCR Assays for Detecting Drug Resistance of HIV.">jonathan.motley@nih.gov</a><br> 114164061 E-198-2013-0 E-198-2013-0-US-13 REAL-TIME PCR POINT MUTATION ASSAYS FOR DETECTING HIV - 1 RESISTANCE TO ANTIVIRAL DRUGS DIV US 10,519,518 15/271,269 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10519518 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10519518">10,519,518</a><br />Filed on 2016-09-21<br />Status: Abandoned 114165469 E-511-2013-0 E-511-2013-0-US-07 REAL-TIME PCR POINT MUTATION ASSAYS FOR DETECTING HIV - 1 RESISTANCE TO ANTIVIRAL DRUGS National Stage US 10,738,365 14/894,737 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10738365 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10738365">10,738,365</a><br />Filed on 2015-11-30<br />Status: Issued 114167568 E-511-2013-0 E-511-2013-0-US-01 REAL-TIME PCR POINT MUTATION ASSAYS FOR DETECTING HIV - 1 RESISTANCE TO ANTIVIRAL DRUGS PRV US 61/829,473 Abandoned US <br />Provisional (PRV) 61/829,473<br />Filed on 2013-05-31<br />Status: Abandoned 114167569 E-198-2013-0 E-198-2013-0-PCT-02 Real-Time PCR Point Mutation Assays For Detecting HIV-1 Resistance To Anti-Viral Drugs PCT Patent Cooperation Treaty PCT/US2005/019907 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2005/019907<br />Filed on 2005-06-07<br />Status: Expired 114167570 E-198-2013-0 E-198-2013-0-US-07 Real-Time PCR Point Mutation Assays For Detecting HIV-1 Resistance To Anti-Viral Drugs National Stage US 8,043,809 11/570,138 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8043809 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8043809">8,043,809</a><br />Filed on 2006-12-07<br />Status: Expired 114167571 E-198-2013-0 E-198-2013-0-US-08 Real-Time PCR Point Mutation Assays For Detecting HIV-1 Resistance To Anti-Viral Drugs CON US 8,318,428 13/253,463 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8318428 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8318428">8,318,428</a><br />Filed on 2012-01-24<br />Status: Expired 114167572 E-198-2013-0 E-198-2013-0-US-09 Real-Time PCR Point Mutation Assays For Detecting HIV-1 Resistance To Anti-Viral Drugs DIV US 8,592,146 13/602,366 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8592146 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8592146">8,592,146</a><br />Filed on 2012-09-04<br />Status: Abandoned 114167573 E-198-2013-0 E-198-2013-0-US-11 Real-Time PCR Point Mutation Assays For Detecting HIV-1 Resistance To Anti-Viral Drugs DIV US 9,476,103 14/059,085 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9476103 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9476103">9,476,103</a><br />Filed on 2013-10-21<br />Status: Abandoned 114167574 E-214-2013-0 E-214-2013-0-US-06 Real-Time PCR Point Mutation Assays For Detecting HIV-1 Resistance To Anti-Viral Drugs National Stage US 9,879,317 13/985,499 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9879317 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9879317">9,879,317</a><br />Filed on 2013-08-14<br />Status: Issued 114167577 E-198-2013-0 E-198-2013-0-US-01 Real-Time PCR Point Mutation Assays For Detecting HIV-1 Resistance To Anti-Viral Drugs PRV US 60/577,696 Abandoned US <br />Provisional (PRV) 60/577,696<br />Filed on 2004-06-07<br />Status: Abandoned 114167578 E-214-2013-0 E-214-2013-0-PCT-02 Real-Time PCR Point Mutation Assays For Detecting HIV-1 Resistance To Anti-Viral Drugs PCT Patent Cooperation Treaty PCT/US2012/025638 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2012/025638<br />Filed on 2012-02-17<br />Status: Expired 114167829 E-511-2013-0 E-511-2013-0-PCT-02 REAL-TIME PCR POINT MUTATION ASSAYS FOR DETECTING HIV - 1 RESISTANCE TO ANTIVIRAL DRUGS PCT Patent Cooperation Treaty PCT/US2014/040514 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2014/040514<br />Filed on 2014-06-02<br />Status: Expired 114168516 E-214-2013-0 E-214-2013-0-US-01 Real-Time PCR Point Mutation Assays For Detecting HIV-1 Resistance To Anti-Viral Drugs PRV US 61/443,926 Abandoned US <br />Provisional (PRV) 61/443,926<br />Filed on 2011-02-17<br />Status: Abandoned 114168569 E-214-2013-0 E-214-2013-0-US-07 Real-Time PCR Point Mutation Assays For Detecting HIV-1 Resistance To Anti-Viral Drugs DIV US 10,793,902 15/848,555 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10793902 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10793902">10,793,902</a><br />Filed on 2017-12-20<br />Status: Issued 114125040 DXXXXX 114125041 DAXXXX 114125042 DA4XXX 114125043 VLXXXX 114125044 VPXXXX 114125045 WBXXXX 114125046 WFXXXX 114125047 XBXXXX 114125048 XCXXXX 114125049 XEXXXX 114125050 YBXXXX 114146302 REAL-TIME 114146303 PCR 114146304 POINT 114146305 MUTATION 114146306 ASSAYS 114146307 DETECTING 114146308 HIV-1 114146309 Resistance 114146310 Anti-Viral 114146311 DRUGS 114146312 CDC Docket Import 114146313 CDC Docket Import CDC Prosecuting 114146314 OID-NCHHSTP-DHPSE 114146315 HIV 114146316 1 114146317 ANTIVIRAL 114150478 NCHHSTP-DHPSE 114150479 Listed LPM Houze as of 4/15/2015 114150480 Pre LPM working set 20150418 114150481 Post LPM Assignment Set 20150420 TAB-2743 114096922 Molecular Detection and Viral-Load Quantification for HIV-1 Groups M, N and O, and Simian Immunodeficiency Virus-cpz (SIVcpz) CDC Cardiology, Consumer Products, Dental, Diagnostics, Endocrinology, Infectious Disease, Licensing, Materials Available, Occupational Safety and Health, Oncology, Ophthalmology, Research Materials, Therapeutics Cardiology Consumer Products Dental Diagnostics Endocrinology Infectious Disease Licensing Materials Available Occupational Safety and Health Oncology Ophthalmology Research Materials Therapeutics Renu Lal, Danuta Pieniazek This invention provides materials, methods, and assays for detecting HIV-1 groups M and O and optionally HIV-1 group N and simian immunodeficiency virus-cpz (SIV-cpz). Specific nucleic acid primers for hybridization, amplification, and detection of HIV-1 are also provided for. The nucleic acid amplification assays can detect small concentrations of HIV-1 and are also useful for quantitative examinations of viral load concentrations within biological samples. <ul> <li>Broad-use, generic viral detection for groups M, N and O HIV-1, and also SIVcpz</li> <li>Requires minute quantities of virus for use, making this assay ideal for confirmation of early-stage infection</li> <li>Sensitive and highly specific</li> <li>Easily formulated for kits</li> <li>Established efficacy in patient samples</li> </ul> <ul> <li>Blood and plasma donation screening</li> <li>Diagnostic detection of HIV-1</li> <li>Public health programs</li> <li>Monitoring HIV treatment and disease inhibition/progression</li> </ul> 2022-03-08 2025-05-09 2025-05-09 2014-01-28 CDC Docket Import, CDC Docket Import CDC Prosecuting, DA4AXX, DA4XXX, DAXXXX, Detection, DXXXXX, Groups, HIV-1, M, Methods, Molecular, N, O, OID-NCHHSTP-DHPSE, REAGENTS, VLXXXX, VOXXXX, VPXXXX, WBXXXX, WFXXXX, WIXXXX, WMXXXX, XCXXXX, XEXXXX, YBXXXX, YEXXXX False True <ul> <li>In vitro data available</li> <li>In situ data available (on-site)</li> </ul> True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114172024 Yang C, et al. http://www.ncbi.nlm.nih.gov/pubmed/10823786 <a href="http://www.ncbi.nlm.nih.gov/pubmed/10823786">Yang C, et al.</a> 114108460 Pieniazek, Danuta CDC - DIR CDC Pieniazek, Danuta (CDC) 0 114108459 Lal, Renu CDC - DIR CDC Lal, Renu (CDC) 1 114108459 Lal, Renu CDC - DIR CDC Lal, Renu (CDC) 1 114108460 Pieniazek, Danuta CDC - DIR CDC Pieniazek, Danuta (CDC) 0 114102061 METHODS AND REAGENTS FOR MOLECULAR DETECTION OF HIV-1 GROUPS M, N AND O E-271-2013-0 Closed Centers for Disease Control and Prevention (CDC) 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2743] Molecular Detection and Viral-Load Quantification for HIV-1 Groups M, N and O, and Simian Immunodeficiency Virus-cpz (SIVcpz)&body=Please send me information about technology [TAB-2743] Molecular Detection and Viral-Load Quantification for HIV-1 Groups M, N and O, and Simian Immunodeficiency Virus-cpz (SIVcpz). Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2743] Molecular Detection and Viral-Load Quantification for HIV-1 Groups M, N and O, and Simian Immunodeficiency Virus-cpz (SIVcpz)&body=Please send me information about technology [TAB-2743] Molecular Detection and Viral-Load Quantification for HIV-1 Groups M, N and O, and Simian Immunodeficiency Virus-cpz (SIVcpz).">jonathan.motley@nih.gov</a><br> 114167546 E-271-2013-0 E-271-2013-0-US-04 METHODS AND REAGENTS FOR MOLECULAR DETECTION OF HIV-1 GROUPS M, N AND O CON US 10/980,660 Abandoned US <br />Continuation (CON) 10/980,660<br />Filed on 2004-08-01<br />Status: Abandoned 114167547 E-271-2013-0 E-271-2013-0-US-03 METHODS AND REAGENTS FOR MOLECULAR DETECTION OF HIV-1 GROUPS M, N AND O National Stage US 09/890,551 Abandoned US <br />National Stage 09/890,551<br />Filed on 2001-08-01<br />Status: Abandoned 114167548 E-271-2013-0 E-271-2013-0-PCT-02 METHODS AND REAGENTS FOR MOLECULAR DETECTION OF HIV-1 GROUPS M, N AND O PCT Patent Cooperation Treaty PCT/US2000/002498 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2000/002498<br />Filed on 2000-02-01<br />Status: Expired 114167549 E-271-2013-0 E-271-2013-0-US-01 METHODS AND REAGENTS FOR MOLECULAR DETECTION OF HIV-1 GROUPS M, N AND O PRV US 60/118,357 Abandoned US <br />Provisional (PRV) 60/118,357<br />Filed on 1999-02-03<br />Status: Abandoned 114167550 E-271-2013-0 E-271-2013-0-US-05 METHODS AND REAGENTS FOR MOLECULAR DETECTION OF HIV-1 GROUPS M, N AND O DIV US 8,575,324 11/645,988 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8575324 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8575324">8,575,324</a><br />Filed on 2006-12-27<br />Status: Expired 114124870 DXXXXX 114124871 DAXXXX 114124872 DA4XXX 114124873 DA4AXX 114124874 VLXXXX 114124875 VOXXXX 114124876 VPXXXX 114124877 WBXXXX 114124878 WFXXXX 114124879 WIXXXX 114124880 WMXXXX 114124881 XCXXXX 114124882 XEXXXX 114124883 YBXXXX 114124884 YEXXXX 114146234 Methods 114146235 REAGENTS 114146236 Molecular 114146237 Detection 114146238 HIV-1 114146239 Groups 114146240 M 114146241 N 114146242 O 114146243 CDC Docket Import 114146244 CDC Docket Import CDC Prosecuting 114146245 OID-NCHHSTP-DHPSE TAB-2734 114096913 Select M. tuberculosis Peptides as Mucosal Vaccines Against Pulmonary Tuberculosis CDC Cardiology, Dental, Diagnostics, Endocrinology, Infectious Disease, Licensing, Oncology, Ophthalmology, Research Equipment, Research Materials, Therapeutics, Vaccines Cardiology Dental Diagnostics Endocrinology Infectious Disease Licensing Oncology Ophthalmology Research Equipment Research Materials Therapeutics Vaccines Rama Amara, Mani Cheruvu, Bonnie Plikaytis, Suraj Sable, Thomas Shinnick This CDC-developed technology relates to novel vaccines or boosters directed against pulmonary tuberculosis. There is currently only a single vaccine against tuberculosis, the (Bacillus Calmette-Guérin) BCG vaccine. Reports suggest widely variable effectiveness for the BCG vaccine and that BCG administration has very limited success against prevention of the primary pulmonary form of the disease. With a marginally useful vaccine and rising rates of multidrug-resistant and extensively drug-resistant (MDR and XDR) tuberculosis strains, it is clear there is a public health need that must be met.<br /><br /> Researchers working at CDC have developed improved vaccine formulations and processes of delivery for enhancing the immune response against <em>M. tuberculosis</em>. These improvements may be implemented as stand-alone vaccines or in conjunction with BCG as part of a prime-boost strategy. Intranasal immunization engenders a strong immune response in the lungs, which is beneficial because the <em>M. tuberculosis</em> pathogen primarily gains entry through the respiratory/alveolar mucosa. By specifically stimulating mucosal immunity with select recombinant <em>M. tuberculosis</em> polypeptides at the typical site of pathogen entry, it is envisioned that these formulations and delivery methods will be able to prevent M. tuberculosis infection and subsequent pulmonary tuberculosis disease. <ul> <li>Versatile, has potential as stand-alone vaccine or booster for use with current BCG vaccine</li> <li>Peptides specifically selected for generating mucosal immunity, to address the protective-failings of the BCG vaccine</li> <li>Potential for needle-free delivery that elicits robust, well-directed immune response</li> </ul> <ul> <li>Tuberculosis vaccine development and improvement</li> <li>Public health and BCG vaccination programs</li> </ul> Various international patents issued or pending 2022-03-08 2025-05-09 2025-05-09 2014-01-27 Alaine, ANTIGEN, CDC Docket Import, CDC Docket Import CDC Prosecuting, DA3XXX, DAXXXX, DC1XXX, DC4XXX, DCXXXX, DXXXXX, Identification, Mucosal, MYCOBACTERIUM, OID-NCHHSTP-DTE, PROLINE, Pulmonary, respiratory, Respiratory Diseases, respiratory INFECTION, Rich, TUBERCULOSIS, Vaccine, VACCINE DEVELOPMENT, VJXXXX, VPXXXX, WIXXXX, WJXXXX, XCXXXX, XEXXXX, XHXXXX, YBXXXX, YCXXXX False True <ul> <li>In vitro data available</li> <li>In vivo data available (animal)</li> </ul> True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114172011 Sable SB, et al. http://www.ncbi.nlm.nih.gov/pubmed/21799939 <a href="http://www.ncbi.nlm.nih.gov/pubmed/21799939">Sable SB, et al.</a> 114108431 Plikaytis, Bonnie CDC - DIR CDC Plikaytis, Bonnie (CDC) 0 114108432 Shinnick, Thomas CDC - DIR CDC Shinnick, Thomas (CDC) 0 114108433 Amara, Rama Amara, Rama 0 114108434 Cheruvu, Mani CDC - DIR CDC Cheruvu, Mani (CDC) 0 114108430 Sable, Suraj CDC - DIR CDC Sable, Suraj (CDC) 1 114108430 Sable, Suraj CDC - DIR CDC Sable, Suraj (CDC) 1 114108431 Plikaytis, Bonnie CDC - DIR CDC Plikaytis, Bonnie (CDC) 0 114108432 Shinnick, Thomas CDC - DIR CDC Shinnick, Thomas (CDC) 0 114108433 Amara, Rama Amara, Rama 0 114108434 Cheruvu, Mani CDC - DIR CDC Cheruvu, Mani (CDC) 0 114102051 Identification Of Mycobacterium Tuberculosis Alaine Proline Rich Antigen As Mucosal Vaccine For Tuberculosis E-192-2013-0 Filing authorized Centers for Disease Control and Prevention (CDC), Emory University 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2734] Select M. tuberculosis Peptides as Mucosal Vaccines Against Pulmonary Tuberculosis&body=Please send me information about technology [TAB-2734] Select M. tuberculosis Peptides as Mucosal Vaccines Against Pulmonary Tuberculosis. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2734] Select M. tuberculosis Peptides as Mucosal Vaccines Against Pulmonary Tuberculosis&body=Please send me information about technology [TAB-2734] Select M. tuberculosis Peptides as Mucosal Vaccines Against Pulmonary Tuberculosis.">jonathan.motley@nih.gov</a><br> 114167518 E-192-2013-0 E-192-2013-0-US-01 Polypeptide Vaccine And Vaccination Strategy Against Mycobacterium PRV US 61/020,573 Abandoned US <br />Provisional (PRV) 61/020,573<br />Filed on 2008-01-11<br />Status: Abandoned 114167519 E-192-2013-0 E-192-2013-0-PCT-02 Polypeptide Vaccine And Vaccination Strategy Against Mycobacterium* PCT Patent Cooperation Treaty PCT/US2009/030754 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2009/030754<br />Filed on 2009-01-12<br />Status: Expired 114167520 E-192-2013-0 E-192-2013-0-US-07 Polypeptide Vaccine And Vaccination Strategy Against Mycobacterium National Stage US 8,741,313 12/812,541 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8741313 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8741313">8,741,313</a><br />Filed on 2010-10-08<br />Status: Issued 114124698 DXXXXX 114124699 DCXXXX 114124700 DC4XXX 114124701 DC1XXX 114124702 DA3XXX 114124703 DAXXXX 114124704 VJXXXX 114124705 VPXXXX 114124706 WIXXXX 114124707 WJXXXX 114124708 XCXXXX 114124709 XEXXXX 114124710 XHXXXX 114124711 YBXXXX 114124712 YCXXXX 114146112 Identification 114146113 MYCOBACTERIUM 114146114 TUBERCULOSIS 114146115 Alaine 114146116 PROLINE 114146117 Rich 114146118 ANTIGEN 114146119 Mucosal 114146120 Vaccine 114146121 CDC Docket Import 114146122 CDC Docket Import CDC Prosecuting 114146123 OID-NCHHSTP-DTE 114146124 respiratory 114146125 Respiratory Diseases 114146126 respiratory INFECTION 114146127 Pulmonary 114146128 VACCINE DEVELOPMENT TAB-2727 114096906 Rapid Detection of Antiretroviral(s) Drug-Resistant HIV-1 within Clinical Samples CDC Cardiology, Consumer Products, Dental, Diagnostics, Endocrinology, Infectious Disease, Licensing, Occupational Safety and Health, Oncology, Ophthalmology, Research Materials, Therapeutics Cardiology Consumer Products Dental Diagnostics Endocrinology Infectious Disease Licensing Occupational Safety and Health Oncology Ophthalmology Research Materials Therapeutics Thomas Folks, Walid Heneine, Gerardo Lerma, William Switzer, Shinji Yamamoto One of the problems with the development of current therapies for HIV infection is that the virus rapidly develops resistance to drugs such as reverse transcriptase (RT) inhibitors. CDC researchers have developed an enzyme-based methodology for detecting phenotypic resistance to antiretroviral drugs whose mode of action decreases the efficiency of the HIV-1 RT enzyme. <p>This invention will enhance clinical monitoring by providing data that tells physicians if and when the HIV-1 infecting a patient has become resistant to commonly used antiretroviral drugs, such as zidovudine/azidothymidine (AZT), nevirapine and lamivudine (3TC). This invention provides physicians and patient care facilities with a simple, rapid lab test that will tell them when a particular antiviral drug is not or no longer beneficial for a patient. Additionally this technology is superior to current culture-based methods for determining phenotypic resistance to HIV antiviral drugs, which are time-consuming and labor-intensive and therefore impractical for clinical monitoring.</p> <ul> <li>Rapid diagnostic which greatly reduces time and labor for improved clinical monitoring of HIV treatment</li> <li>Ready for commercialization</li> <li>Easily adapted to kit format</li> <li>Assists continued usefulness of common antiretroviral therapeutics</li> </ul> <ul> <li>Clinical monitoring of individual patient antiretroviral therapy</li> <li>HIV/AIDS public health programs</li> <li>Surveillance of retroviral drug resistance</li> </ul> Various international patents issued Various international patents issued or pending 2022-03-08 2025-05-09 2025-05-09 2014-01-20 ANTIVIRAL, CDC Docket Import, CDC Docket Import CDC Prosecuting, DA4AXX, DA4XXX, DAXXXX, DB4AXX, DETECTING, DRUGS, DXXXXX, KIT, Method, OID-NCHHSTP-DHPSE, Resistance, VLXXXX, VPXXXX, WBXXXX, WFXXXX, WIXXXX, XCXXXX, XEXXXX, YBXXXX False True In vitro data available True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract E-232-1993-0 E-232-1993-1 114172001 Qari SH, et al. http://www.ncbi.nlm.nih.gov/pubmed/12212925 <a href="http://www.ncbi.nlm.nih.gov/pubmed/12212925">Qari SH, et al.</a> 114108409 Lerma, Gerardo CDC - DIR CDC Lerma, Gerardo (CDC) 0 114108411 Yamamoto, Shinji CDC - DIR CDC Yamamoto, Shinji (CDC) 0 114108412 Switzer, William CDC - DIR CDC Switzer, William (CDC) 0 114108413 Folks, Thomas CDC - DIR Folks, Thomas 0 114108410 Heneine, Walid CDC - DIR CDC Heneine, Walid (CDC) 1 114108410 Heneine, Walid CDC - DIR CDC Heneine, Walid (CDC) 1 114108409 Lerma, Gerardo CDC - DIR CDC Lerma, Gerardo (CDC) 0 114108411 Yamamoto, Shinji CDC - DIR CDC Yamamoto, Shinji (CDC) 0 114108412 Switzer, William CDC - DIR CDC Switzer, William (CDC) 0 114108413 Folks, Thomas CDC - DIR Folks, Thomas 0 114102042 METHOD AND KIT FOR DETECTING RESISTANCE TO ANTIVIRAL DRUGS E-129-2013-0 Closed Centers for Disease Control and Prevention (CDC) 114102043 METHOD AND KIT FOR DETECTING RESISTANCE TO ANTIVIRAL DRUGS E-129-2013-1 Closed Centers for Disease Control and Prevention (CDC) 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2727] Rapid Detection of Antiretroviral(s) Drug-Resistant HIV-1 within Clinical Samples&body=Please send me information about technology [TAB-2727] Rapid Detection of Antiretroviral(s) Drug-Resistant HIV-1 within Clinical Samples. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2727] Rapid Detection of Antiretroviral(s) Drug-Resistant HIV-1 within Clinical Samples&body=Please send me information about technology [TAB-2727] Rapid Detection of Antiretroviral(s) Drug-Resistant HIV-1 within Clinical Samples.">jonathan.motley@nih.gov</a><br> 114167495 E-129-2013-1 E-129-2013-1-US-01 METHOD AND KIT FOR DETECTING RESISTANCE TO ANTIVIRAL DRUGS CIP US 10/190,101 Abandoned US <br />Continuation in Part (CIP) 10/190,101<br />Filed on 2002-07-03<br />Status: Abandoned 114167496 E-129-2013-0 E-129-2013-0-PCT-02 METHOD AND KIT FOR DETECTING RESISTANCE TO ANTIVIRAL DRUGS PCT Patent Cooperation Treaty PCT/US1999/013957 Expired Patent Cooperation Treaty <br />(PCT) PCT/US1999/013957<br />Filed on 1999-06-18<br />Status: Expired 114167497 E-129-2013-0 E-129-2013-0-US-11 METHOD AND KIT FOR DETECTING RESISTANCE TO ANTIVIRAL DRUGS National Stage US 6,787,126 09/719,906 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6787126 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6787126">6,787,126</a><br />Filed on 2001-07-30<br />Status: Expired 114167498 E-129-2013-0 E-129-2013-0-US-01 METHOD AND KIT FOR DETECTING RESISTANCE TO ANTIVIRAL DRUGS PRV US 60/090,051 Abandoned US <br />Provisional (PRV) 60/090,051<br />Filed on 1998-06-19<br />Status: Abandoned 114167499 E-129-2013-1 E-129-2013-1-US-02 METHOD AND KIT FOR DETECTING RESISTANCE TO ANTIVIRAL DRUGS DIV US 7,691,572 11/054,023 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7691572 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7691572">7,691,572</a><br />Filed on 2005-02-09<br />Status: Expired 114124545 DXXXXX 114124546 DAXXXX 114124547 DA4XXX 114124548 DA4AXX 114124549 DB4AXX 114124550 VLXXXX 114124551 VPXXXX 114124552 WBXXXX 114124553 WFXXXX 114124554 WIXXXX 114124555 XCXXXX 114124556 XEXXXX 114124557 YBXXXX 114146042 DRUGS 114146043 ANTIVIRAL 114146044 Resistance 114146045 DETECTING 114146046 KIT 114146047 Method 114146048 CDC Docket Import 114146049 CDC Docket Import CDC Prosecuting 114146050 OID-NCHHSTP-DHPSE TAB-2725 114096904 Novel Primate T-cell Lymphotropic Viruses (HTLV, STLV) for Development of Diagnostics, Therapeutics, Research Tools, and Vaccines CDC Cardiology, Consumer Products, Dental, Diagnostics, Endocrinology, Infectious Disease, Licensing, Occupational Safety and Health, Oncology, Ophthalmology, Research Equipment, Research Materials, Therapeutics, Vaccines Cardiology Consumer Products Dental Diagnostics Endocrinology Infectious Disease Licensing Occupational Safety and Health Oncology Ophthalmology Research Equipment Research Materials Therapeutics Vaccines Thomas Folks, Walid Heneine, William Switzer CDC researchers have isolated and characterized the novel primate T-lymphotropic viruses denoted human T-lymphotropic viruses 3 and 4 (HTLV-3 and HTLV4), that are believed to have resulted from cross-species transmission at some point in the past. It has been previously established that HTLV-1 causes adult T cell leukemia and other inflammatory diseases; HTLV-2 is considered less pathogenic than HTLV-1 and has been associated with a neurologic disease similar to HTLV-1-associated myelopathy. At present, the human pathologies of HTLV-3 and HTLV-4 are yet uncharacterized, but have been identified as infecting rural Central African hunters who have much greater risk of contact with non-human primates, sometimes infected with simian T-lymphotropic viruses (STLVs). As HTLV infected individuals from rural, isolated populations have increasing contact with their urban brethren, there is increased potential for the rapid spread of new viral zoonotic-originating pathogens, much like the theorized "bushmeat" origins of HIV. There is a present and unmet need for increased surveillance, study, and preventative therapeutics directed towards mitigating the public health impact of these viruses. This CDC developed technology provides methods and tools to that end. <ul> <li>Provides tremendous opportunity for phylogenetic, clinical and epidemiological investigations of HTLV and STLV</li> <li>Facilitates monitoring of viral diversity and study of zoonotic disease transmission</li> <li>Provides tools needed to address and mitigate a newly emergent blood-borne disease before widespread, regional/global viral dissemination occurs</li> </ul> <ul> <li>Development of HTLV diagnostics</li> <li>Simian/human T-cell lymphotropic virus research</li> <li>Zoonosis surveillance</li> <li>Vaccine design and development</li> </ul> Various international patents granted and pending Various international patents granted and pending 2022-03-08 2025-05-09 2025-05-09 2014-01-16 CDC Docket Import, CDC Docket Import CDC Prosecuting, DA4BXX, DA4XXX, DAXXXX, DC5BXX, DC5XXX, DCXXXX, DDXXXX, DXXXXX, OID-NCHHSTP-DHPSE, OID-NCHHSTP-DSTDP, primate, T-LYMPHOTROPIC, Viruses, VLXXXX, VOXXXX, VPXXXX, WBXXXX, WFXXXX, WIXXXX, WJXXXX, WMXXXX, XCXXXX, XEXXXX, XHXXXX, YAXXXX, YBXXXX False True <ul> <li>Early-stage</li> <li>In vitro data available</li> </ul> True 52406768 Discovery 52406768 NIHTT 37470483 Website Abstract E-303-2013-2 114171997 Wolfe ND, et al. http://www.ncbi.nlm.nih.gov/pubmed/15911757 <a href="http://www.ncbi.nlm.nih.gov/pubmed/15911757">Wolfe ND, et al.</a> 114171998 Switzer WM, et al. http://www.ncbi.nlm.nih.gov/pubmed/19187529 <a href="http://www.ncbi.nlm.nih.gov/pubmed/19187529">Switzer WM, et al.</a> 114108402 Switzer, William CDC - DIR CDC Switzer, William (CDC) 0 114108403 Heneine, Walid CDC - DIR CDC Heneine, Walid (CDC) 0 114108404 Folks, Thomas CDC - DIR Folks, Thomas 0 114108402 Switzer, William CDC - DIR CDC Switzer, William (CDC) 0 114108403 Heneine, Walid CDC - DIR CDC Heneine, Walid (CDC) 0 114108404 Folks, Thomas CDC - DIR Folks, Thomas 0 114102039 PRIMATE T-LYMPHOTROPIC VIRUSES E-281-2013-0 Research Material Centers for Disease Control and Prevention (CDC), Johns Hopkins University 114102040 PRIMATE T-LYMPHOTROPIC VIRUSES E-281-2013-1 Research Material Centers for Disease Control and Prevention (CDC) 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2725] Novel Primate T-cell Lymphotropic Viruses (HTLV, STLV) for Development of Diagnostics, Therapeutics, Research Tools, and Vaccines&body=Please send me information about technology [TAB-2725] Novel Primate T-cell Lymphotropic Viruses (HTLV, STLV) for Development of Diagnostics, Therapeutics, Research Tools, and Vaccines. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2725] Novel Primate T-cell Lymphotropic Viruses (HTLV, STLV) for Development of Diagnostics, Therapeutics, Research Tools, and Vaccines&body=Please send me information about technology [TAB-2725] Novel Primate T-cell Lymphotropic Viruses (HTLV, STLV) for Development of Diagnostics, Therapeutics, Research Tools, and Vaccines.">jonathan.motley@nih.gov</a><br> 114167487 E-281-2013-0 E-281-2013-0-US-01 NOVEL PRIMATE T-LYMPHOTROPIC VIRUSES PRV US 60/654,484 Abandoned US <br />Provisional (PRV) 60/654,484<br />Filed on 2005-02-21<br />Status: Abandoned 114167488 E-281-2013-0 E-281-2013-0-PCT-02 NOVEL PRIMATE T-LYMPHOTROPIC VIRUSES PCT Patent Cooperation Treaty PCT/US2006/005869 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2006/005869<br />Filed on 2006-02-21<br />Status: Expired 114167489 E-281-2013-1 E-281-2013-1-US-01 PRIMATE T-LYMPHOTROPIC VIRUSES CIP US 7,794,998 11/678,596 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7794998 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7794998">7,794,998</a><br />Filed on 2007-02-24<br />Status: Abandoned 114167490 E-281-2013-1 E-281-2013-1-US-02 PRIMATE T-LYMPHOTROPIC VIRUSES CON US 8,541,221 12/829,125 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8541221 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8541221">8,541,221</a><br />Filed on 2010-07-01<br />Status: Abandoned 114167491 E-281-2013-1 E-281-2013-1-US-03 PRIMATE T-LYMPHOTROPIC VIRUSES DIV US 9,435,000 14/032,914 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9435000 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9435000">9,435,000</a><br />Filed on 2013-09-20<br />Status: Abandoned 114124507 DXXXXX 114124508 DAXXXX 114124509 DA4XXX 114124510 DA4BXX 114124511 DCXXXX 114124512 DC5XXX 114124513 DC5BXX 114124514 DDXXXX 114124515 VLXXXX 114124516 VOXXXX 114124517 VPXXXX 114124518 WBXXXX 114124519 WFXXXX 114124520 WIXXXX 114124521 WJXXXX 114124522 WMXXXX 114124523 XCXXXX 114124524 XEXXXX 114124525 XHXXXX 114124526 YAXXXX 114124527 YBXXXX 114146026 primate 114146027 T-LYMPHOTROPIC 114146028 Viruses 114146029 CDC Docket Import 114146030 CDC Docket Import CDC Prosecuting 114146031 OID-NCHHSTP-DHPSE 114146032 OID-NCHHSTP-DSTDP TAB-2663 114096847 HIV-1 Multi-Clade, Multivalent Recombinant Vaccine Construct CDC Infectious Disease, Licensing, Therapeutics, Vaccines Infectious Disease Licensing Therapeutics Vaccines Renu Lal, Sherry Owen CDC scientists developed immunogenic multi-clade, multivalent (HIV1MCMV) recombinant constructs for use as HIV-1 vaccines. These polypeptides include immunogenic CTL, T- and/or B-cell determinants that are capable of eliciting broad and effective immune responses against diverse subtypes of HIV-1. It is believed that these HIV-1 constructs provide universal vaccines, capable of effective use in any part of the world affected by the HIV-1 epidemic. The construct contains specific cellular targeting epitopes that allow optimized antigen processing and recognition, and the design of the construct allows for the addition or deletion of epitopes. Additionally, the construct may be used to develop multi-pathogen vaccines by combination with other epitope-based constructs. <ul> <li>Allows easy epitope-tailoring</li> <li>Broad spectrum protection against HIV-1</li> <li>Unlike other HIV-vaccination strategies, this approach specifically primes both arms of the immune system for improved protection</li> <li>Can be combined with other epitope-based constructs to generate multi-pathogen vaccines</li> </ul> <ul> <li>Development of HIV-1 vaccine</li> </ul> Various international patent applications pending or issued 2022-03-08 2025-05-09 2025-05-09 2013-10-23 CDC Docket Import, CDC Docket Import CDC Prosecuting, Constructs, DB4AXX, DB4XXX, DBXXXX, DC1XXX, DC5AXX, DC5XXX, DCXXXX, HIV-1, Immunogenic, Methods, Multi-clade, MULTIVALENT, OID-NCHHSTP-DHPSE, Their False True <ul> <li>Early-stage</li> <li>In vitro data available</li> </ul> True NIHTT 37470483 Website Abstract 114108199 Owen, Sherry CDC - DIR CDC Owen, Sherry (CDC) 0 114108198 Lal, Renu CDC - DIR CDC Lal, Renu (CDC) 1 114108198 Lal, Renu CDC - DIR CDC Lal, Renu (CDC) 1 114108199 Owen, Sherry CDC - DIR CDC Owen, Sherry (CDC) 0 114101974 Immunogenic HIV-1 Multi-clade, Multivalent Constructs And Methods Of Their Use E-231-2013-0 Closed Centers for Disease Control and Prevention (CDC) 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2663] HIV-1 Multi-Clade, Multivalent Recombinant Vaccine Construct&body=Please send me information about technology [TAB-2663] HIV-1 Multi-Clade, Multivalent Recombinant Vaccine Construct. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2663] HIV-1 Multi-Clade, Multivalent Recombinant Vaccine Construct&body=Please send me information about technology [TAB-2663] HIV-1 Multi-Clade, Multivalent Recombinant Vaccine Construct.">jonathan.motley@nih.gov</a><br> 114167329 E-231-2013-0 E-231-2013-0-US-01 Immunogenic HIV-1 Multi-clade, Multivalent Constructs And Methods Of Their Use PRV US 60/458,880 Abandoned US <br />Provisional (PRV) 60/458,880<br />Filed on 2003-03-28<br />Status: Abandoned 114167330 E-231-2013-0 E-231-2013-0-PCT-02 Immunogenic HIV-1 Multi-clade, Multivalent Constructs And Methods Of Their Use PCT Patent Cooperation Treaty PCT/US2004/009767 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2004/009767<br />Filed on 2004-03-26<br />Status: Expired 114167331 E-231-2013-0 E-231-2013-0-US-07 Immunogenic HIV-1 Multi-clade, Multivalent Constructs And Methods Of Their Use National Stage US 7,425,611 10/550,651 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7425611 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7425611">7,425,611</a><br />Filed on 2005-09-26<br />Status: Abandoned 114123828 DCXXXX 114123829 DC5XXX 114123830 DC5AXX 114123831 DC1XXX 114123832 DBXXXX 114123833 DB4XXX 114123834 DB4AXX 114145226 HIV-1 114145227 Immunogenic 114145228 Multi-clade 114145229 MULTIVALENT 114145230 Constructs 114145231 Methods 114145232 Their 114145233 CDC Docket Import 114145234 CDC Docket Import CDC Prosecuting 114145235 OID-NCHHSTP-DHPSE TAB-2659 114096843 Real-time RT-PCR Assay For Detection and Quantification of Hepatitis D Virus Infection CDC Diagnostics, Infectious Disease, Licensing Diagnostics Infectious Disease Licensing Saleem Kamili, Maja Kodani, Tonya Mixson-Hayden CDC scientists have developed a one-step TaqMan quantitative/real-time reverse transcription-polymerase chain reaction (qRT-PCR) assay for detecting hepatitis D virus (HDV) RNA. Additionally, a quantifiable synthetic RNA control to determine viral load has been created. <br /><br /> HDV is an operatively defective virus that requires hepatitis B virus (HBV) surface antigen (HBsAg) for its assembly. Compared to individuals infected with HBV alone, individuals infected with both HDV and HBV viruses present with more severe hepatitis, progress to liver disease more quickly, and have a higher mortality rate. Currently, there are no regulated tests available for detection and quantification of HDV RNA. This assay directly addresses this unmet need and has been validated with clinical samples of HDV genotypes 1 and 3. It has the potential to detect all eight HDV genotypes. <ul> <li>Rapid, accurate, inexpensive and stable</li> <li>Unique RNA transcript for this assay can be successfully used as a quantitative standard</li> <li>Current anti-HDV antibody assay identifies individuals exposed to HDV, but cannot identify current infection</li> <li>Easily adapted for inclusion in a hepatitis testing kit, especially when paired with a hepatitis B diagnostic</li> </ul> <ul> <li>Development of a commercial nucleic acid assay for diagnosis of current hepatitis D virus (HDV) infection</li> <li>Public health and vaccination programs</li> <li>Testing of individuals infected with hepatitis B and/or liver disease</li> </ul> 2022-03-08 2025-05-09 2025-05-09 2013-10-18 assay, CDC Docket Import, CDC Docket Import CDC Prosecuting, cirrhosis, D, DA4BXX, DA4XXX, DAXXXX, Detection, diagnostic, Diagnostic assay, DXXXXX, HBV, HDV, Hepatitis, HEPATITIS B, liver, liver disease, Liver disorders, Liver-Disease, OID-NCHHSTP-DVH, PCR, QUANTITATIVE, REAL, real time, REAL-TIME, RT-PCR, viral, virus False True <ul> <li>Pre-clinical</li> <li>In vitro data available</li> </ul> True NIHTT 37470483 Website Abstract 114171924 Kodani M, et al. http://www.ncbi.nlm.nih.gov/pubmed/23896020 <a href="http://www.ncbi.nlm.nih.gov/pubmed/23896020">Kodani M, et al.</a> 114108187 Mixson-Hayden, Tonya CDC - DIR CDC Mixson-Hayden, Tonya (CDC) 0 114108188 Kamili, Saleem CDC - DIR CDC Kamili, Saleem (CDC) 0 114108186 Kodani, Maja CDC - DIR CDC Kodani, Maja (CDC) 1 114108186 Kodani, Maja CDC - DIR CDC Kodani, Maja (CDC) 1 114108187 Mixson-Hayden, Tonya CDC - DIR CDC Mixson-Hayden, Tonya (CDC) 0 114108188 Kamili, Saleem CDC - DIR CDC Kamili, Saleem (CDC) 0 114101969 Quantitative Real-time PCR Assay For Detection Of Hepatitis D Virus E-510-2013-0 Closed Centers for Disease Control and Prevention (CDC) 114102158 Quantitative Real-time PCR Assay For Detection Of Hepatitis D Virus E-510-2013-1 Closed Centers for Disease Control and Prevention (CDC) 114102159 Quantitative Real-time PCR Assay For Detection Of Hepatitis D Virus E-510-2013-2 Closed Centers for Disease Control and Prevention (CDC) 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2659] Real-time RT-PCR Assay For Detection and Quantification of Hepatitis D Virus Infection&body=Please send me information about technology [TAB-2659] Real-time RT-PCR Assay For Detection and Quantification of Hepatitis D Virus Infection. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2659] Real-time RT-PCR Assay For Detection and Quantification of Hepatitis D Virus Infection&body=Please send me information about technology [TAB-2659] Real-time RT-PCR Assay For Detection and Quantification of Hepatitis D Virus Infection.">jonathan.motley@nih.gov</a><br> 114165583 E-510-2013-2 E-510-2013-2-US-03 SELECTIVE DETECTION OF HEPATITIS A, B, C, D, OR E VIRUSES OR COMBINATION THEREOF National Stage US 14/777,353 Abandoned US <br />National Stage 14/777,353<br />Filed on 2015-09-15<br />Status: Abandoned 114167321 E-510-2013-0 E-510-2013-0-US-01 Selective Detection Of Hepatitis D Virus PRV US 61/792,293 Abandoned US <br />Provisional (PRV) 61/792,293<br />Filed on 2013-03-15<br />Status: Abandoned 114167803 E-510-2013-1 E-510-2013-1-US-01 SELECTIVE DETECTION OF HEPATITIS A, B, C, D, OR E VIRUSES OR COMBINATIONS THEREOF PRV US 61/938,220 Abandoned US <br />Provisional (PRV) 61/938,220<br />Filed on 2014-02-11<br />Status: Abandoned 114167804 E-510-2013-2 E-510-2013-2-PCT-01 SELECTIVE DETECTION OF HEPATITIS A, B, C, D, OR E VIRUSES OR COMBINATIONS THEREOF PCT COMB Patent Cooperation Treaty PCT/US2014/029049 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2014/029049<br />Filed on 2014-03-14<br />Status: Expired 114123805 DXXXXX 114123806 DAXXXX 114123807 DA4XXX 114123808 DA4BXX 114145186 QUANTITATIVE 114145187 REAL-TIME 114145188 PCR 114145189 assay 114145190 Detection 114145191 Hepatitis 114145192 D 114145193 virus 114145194 CDC Docket Import 114145195 CDC Docket Import CDC Prosecuting 114145196 OID-NCHHSTP-DVH 114147374 RT-PCR 114147375 REAL 114147376 real time 114147377 HDV 114147378 HBV 114147379 diagnostic 114147380 Diagnostic assay 114147381 liver 114147382 liver disease 114147383 Liver disorders 114147384 Liver-Disease 114147385 HEPATITIS B 114147386 cirrhosis 114147387 viral TAB-2622 114096816 Composition and Methods for Rapid Detection of HIV by Loop-mediated Isothermal Amplification CDC Diagnostics, Infectious Disease, Licensing Diagnostics Infectious Disease Licensing Kelly Curtis, Donna Rudolph This invention relates to methods and compositions for rapid detection of HIV nucleic acids in a biological sample. Specifically, it involves the use of the loop-mediated isothermal amplification (LAMP) for rapid detection of HIV-1 and/or HIV-2. The use of rapid HIV tests is highly attractive for screening of patient samples, especially in developing countries where resources are limited, because they are quick, easy to perform, and do not require any special equipment. Rapid tests for the identification of HIV antibody, however, will remain negative during the 4 to 5 week window post-infection and pre-seroconversion, necessitating the need for a diagnosis based on HIV nucleic acid. <ul> <li>High sensitivity and specificity.</li> <li>No need for thermal cyclers or gel electrophoresis <li>Assay can be used in limited-resource settings.</li> <li>A rapid, portable and cost-effective alternative to PCR and enzyme immune assays.</li> </ul> <ul> <li>Diagnostic test for HIV-1 and/or HIV-2 infection</li> <li>Kits for detection of HIV nucleic acids</li> </ul> 2022-03-08 2025-05-09 2025-05-09 2013-08-23 AA2XXX, AA5XXX, AAXXXX, AC1XXX, AC3XXX, AC4XXX, ACXXXX, amplification, AXXXXX, Compositions, DA4AXX, DA4XXX, DAXXXX, Detection, DXXXXX, HIV, Isothermal, LAMP, Loop-Mediated, Methods, RAPID False True <ul> <li>Pre-clinical</li> <li>In vitro data available</li> </ul> True NIHTT 37470483 Website Abstract 114171887 Curtis KA, et al. http://www.ncbi.nlm.nih.gov/pubmed/18524393 <a href="http://www.ncbi.nlm.nih.gov/pubmed/18524393">Curtis KA, et al.</a> 114171939 Curtis KA, et al. http://www.ncbi.nlm.nih.gov/pubmed/22384022 <a href="http://www.ncbi.nlm.nih.gov/pubmed/22384022">Curtis KA, et al.</a> 114171940 Curtis KA, et al. http://www.ncbi.nlm.nih.gov/pubmed/19382260 <a href="http://www.ncbi.nlm.nih.gov/pubmed/19382260">Curtis KA, et al.</a> 114108090 Curtis, Kelly CDC - DIR CDC Curtis, Kelly (CDC) 0 114108091 Rudolph, Donna CDC - DIR CDC Rudolph, Donna (CDC) 0 114108090 Curtis, Kelly CDC - DIR CDC Curtis, Kelly (CDC) 0 114108091 Rudolph, Donna CDC - DIR CDC Rudolph, Donna (CDC) 0 114101940 Compositions And Methods For Rapid Detection Of HIV By Loop-Mediated Isothermal Amplification (LAMP) E-173-2013-0 Filing authorized Centers for Disease Control and Prevention (CDC) 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2622] Composition and Methods for Rapid Detection of HIV by Loop-mediated Isothermal Amplification&body=Please send me information about technology [TAB-2622] Composition and Methods for Rapid Detection of HIV by Loop-mediated Isothermal Amplification. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2622] Composition and Methods for Rapid Detection of HIV by Loop-mediated Isothermal Amplification&body=Please send me information about technology [TAB-2622] Composition and Methods for Rapid Detection of HIV by Loop-mediated Isothermal Amplification.">jonathan.motley@nih.gov</a><br> 114167216 E-173-2013-0 E-173-2013-0-US-01 Compositions And Methods For Rapid Detection Of HIV By Loop-Mediated Isothermal Amplification (LAMP) PRV US 61/031,128 Abandoned US <br />Provisional (PRV) 61/031,128<br />Filed on 2008-02-25<br />Status: Abandoned 114167217 E-173-2013-0 E-173-2013-0-PCT-02 Compositions And Methods For Rapid Detection Of HIV By Loop-Mediated Isothermal Amplification (LAMP) PCT Patent Cooperation Treaty PCT/US2009/035130 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2009/035130<br />Filed on 2009-02-25<br />Status: Expired 114167218 E-173-2013-0 E-173-2013-0-US-03 Compositions And Methods For Rapid Detection Of HIV By Loop-Mediated Isothermal Amplification (LAMP) National Stage US 8,900,807 12/918,536 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8900807 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8900807">8,900,807</a><br />Filed on 2010-08-20<br />Status: Issued 114123637 AXXXXX 114123638 AAXXXX 114123639 AA2XXX 114123640 AA5XXX 114123641 ACXXXX 114123642 AC1XXX 114123643 AC4XXX 114123644 AC3XXX 114123645 DXXXXX 114123646 DAXXXX 114123647 DA4XXX 114123648 DA4AXX 114144932 Compositions 114144933 Methods 114144934 RAPID 114144935 Detection 114144936 HIV 114144937 Loop-Mediated 114144938 Isothermal 114144939 amplification 114144940 LAMP TAB-2611 114096805 Rapid Detection of Multi-Drug-Resistant Mycobacterium tuberculosis Using Real-Time PCR and High-Resolution Melt Analysis CDC Diagnostics, Infectious Disease, Licensing Diagnostics Infectious Disease Licensing Kelley Cowart, James Posey, Melissa Ramirez, Jonas Winchell CDC scientists have developed a rapid, sensitive, and specific real-time PCR assay that is capable of detecting the presence of <em>Mycobacterium tuberculosis</em> and determining its resistance profile to antibiotics, such as rifampicin and isoniazid. Currently, there are few assays available that are capable of both detecting <em>M. tuberculosis</em> and determining the bacteria's drug resistance. This assay incorporates multiple fluorescent chemistries, providing a simple and cost-effective method of determining the bacteria's drug resistance. Additionally, this assay may be used to quickly discriminate <em>Mycobacterium tuberculosis</em> complex (MTBC) strains from non-MTBC strains. <ul> <li>Robust and inexpensive way to detect dominant <em>M. tuberculosis</em> mutations</li> <li>Rapid results within 5 hours of obtaining DNA</li> <li>More cost-efficient and less complex than culturing and sequencing methods of determining drug-resistant status</li> </ul> <ul> <li>Rapid screening of potential multi-drug-resistant <em>M. tuberculosis</em></li> <li>Kits for diagnosis of <em>M. tuberculosis</em></li> <li>Public health programs combating emerging drug-resistance in <em>M. tuberculosis</em>; clinics working with at-risk populations</li> </ul> 2022-03-08 2025-05-09 2025-05-09 2013-08-13 analysis, DA3XXX, DAXXXX, Detection, DXXXXX, High, Melt, Multidrug, PCR, PROCESS, REAL-TIME, RESISTANT, RESOLUTION, TUBERCULOSIS, Tuberculosis (Mycobacterium tuberculosis) False True <ul> <li>Early-stage</li> <li>In vitro data available</li> </ul> True NIHTT 37470483 Website Abstract 114171876 Ramirez MV, et al. http://www.ncbi.nlm.nih.gov/pubmed/20810777 <a href="http://www.ncbi.nlm.nih.gov/pubmed/20810777">Ramirez MV, et al.</a> 114108054 Winchell, Jonas CDC - DIR CDC Winchell, Jonas (CDC) 0 114108055 Cowart, Kelley CDC - DIR CDC Cowart, Kelley (CDC) 0 114108056 Ramirez, Melissa CDC - DIR CDC Ramirez, Melissa (CDC) 0 114108053 Posey, James CDC - DIR CDC Posey, James (CDC) 1 114108053 Posey, James CDC - DIR CDC Posey, James (CDC) 1 114108054 Winchell, Jonas CDC - DIR CDC Winchell, Jonas (CDC) 0 114108055 Cowart, Kelley CDC - DIR CDC Cowart, Kelley (CDC) 0 114108056 Ramirez, Melissa CDC - DIR CDC Ramirez, Melissa (CDC) 0 114101929 Process For Detection Of Multidrug Resistant Tuberculosis Using Real-Time PCR And High Resolution Melt Analysis E-160-2013-0 Closed Centers for Disease Control and Prevention (CDC) 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2611] Rapid Detection of Multi-Drug-Resistant Mycobacterium tuberculosis Using Real-Time PCR and High-Resolution Melt Analysis&body=Please send me information about technology [TAB-2611] Rapid Detection of Multi-Drug-Resistant Mycobacterium tuberculosis Using Real-Time PCR and High-Resolution Melt Analysis. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2611] Rapid Detection of Multi-Drug-Resistant Mycobacterium tuberculosis Using Real-Time PCR and High-Resolution Melt Analysis&body=Please send me information about technology [TAB-2611] Rapid Detection of Multi-Drug-Resistant Mycobacterium tuberculosis Using Real-Time PCR and High-Resolution Melt Analysis.">jonathan.motley@nih.gov</a><br> 114167192 E-160-2013-0 E-160-2013-0-PCT-02 Process For Detection Of Multidrug Resistant Tuberculosis Using Real-Time PCR And High Resolution Melt Analysis PCT Patent Cooperation Treaty PCT/US2011/035217 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2011/035217<br />Filed on 2011-05-04<br />Status: Expired 114167193 E-160-2013-0 E-160-2013-0-US-01 Process For Detection Of Multidrug Resistant Tuberculosis Using Real-Time PCR And High Resolution Melt Analysis PRV US 61/331,189 Abandoned US <br />Provisional (PRV) 61/331,189<br />Filed on 2010-05-04<br />Status: Abandoned 114167194 E-160-2013-0 E-160-2013-0-US-04 Process For Detection Of Multidrug Resistant Tuberculosis Using Real-Time PCR And High Resolution Melt Analysis National Stage US 13/695,935 Abandoned US <br />National Stage 13/695,935<br />Filed on 2012-11-02<br />Status: Abandoned 114168142 E-160-2013-0 E-160-2013-0-US-05 Process For Detection Of Multidrug Resistant Tuberculosis Using Real-Time PCR And High Resolution Melt Analysis CON US 14/703,019 Abandoned US <br />Continuation (CON) 14/703,019<br />Filed on 2015-05-04<br />Status: Abandoned 114123570 DAXXXX 114123571 DA3XXX 114123572 DXXXXX 114144833 PROCESS 114144834 Detection 114144835 Multidrug 114144836 RESISTANT 114144837 TUBERCULOSIS 114144838 REAL-TIME 114144839 PCR 114144840 High 114144841 RESOLUTION 114144842 Melt 114144843 analysis 114157967 Tuberculosis (Mycobacterium tuberculosis) TAB-3113 114095775 Simple and Rapid Assay to Detect Acute Subtype B and Group M HIV-1 Infections CDC Diagnostics, Infectious Disease, Licensing, Research Equipment, Research Materials, Therapeutics Diagnostics Infectious Disease Licensing Research Equipment Research Materials Therapeutics Kelly Curtis, Philip Niedzwiedz, Sherry Owen, Donna Rudolph Within recent years, point-of-care (POC) testing has allowed for many individuals to be screened for and provided with HIV test results. It is critical to be able to accurately detect acute HIV infections as this is a stage where the risk of transmission is great. Additionally, early HIV detection could lead to less high-risk behavior, thereby reducing transmission. Currently, there are no rapid, cost-effective diagnostic tests sensitive enough to detect acute HIV-1 infections for the POC setting.<br /><br /> Researchers at the CDC have developed an HIV-1 detection assay using reverse-transcription loop-mediated isothermal amplification (RT-LAMP) that is quick, easy to perform, and does not require complex, dedicated equipment or laboratory space. These features are ideal for POC and could increase the percentage of individuals who receive their HIV status, while immediately linking them to counseling and medical care. Also, the early knowledge of their HIV status could lead to reduced high-risk behavior at a time when individuals exhibit a greater risk for transmitting the virus. <ul> <li>Rapid, easy to perform, cost-effective and can be portable - ideal for POC.</li> <li>Sample versatility: isolated DNA/RNA, blood, urine, saliva, tissue biopsy, fine needle aspirate, surgical specimen.</li> <li>Detection of HIV-1 RNA/DNA in the same reaction.</li> <li>Primers designed based on highly conserved regions within the HIV-1 integrase gene for detection of subtype B infections and of all group M isolates.</li> </ul> <ul> <li>Diagnosis of acute HIV-1 infection.</li> <li>Diagnosis of infants from HIV-1 infected mothers.</li> <li>Test methods are ideal for use in POC or resource-limited settings.</li> </ul> 2022-03-08 2025-05-09 2025-05-09 2017-03-15 AA2XXX, AA5XXX, AAXXXX, AC1XXX, AC3XXX, AC4XXX, ACXXXX, AIDS, amplification, AXXXXX, B, CDC Docket Import, CDC Docket Import CDC Prosecuting, Compositions, DA4AXX, DA4XXX, DAXXXX, Detection, diagnostic, DXXXXX, Field, Field-diagnostic, Field-usable, GROUP, HIV, HIV-1, HIV-2, IN-SITU, Isothermal, LAMP, LIMITED-RESOURCE, Listed LPM Houze as of 4/15/2015, Loop-Mediated, LOW INPUT, M, Methods, NCHHSTP, OID-NCHHSTP-DHPSE, On-demand, PCR, PCR ALTERNATIVE, Portable, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, RAPID, Reverse-Transcription, RT-LAMP, Subtype, viral, VIRAL DIAGNOSTIC, virus, VLXXXX, WBXXXX, WIXXXX, XCXXXX, XEXXXX, XHXXXX, YAXXXX, YBXXXX False True True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract E-173-2013-0 114172301 Curtis KA, et al. https://www.ncbi.nlm.nih.gov/pubmed/22384022 <a href="https://www.ncbi.nlm.nih.gov/pubmed/22384022">Curtis KA, et al.</a> 114107626 Owen, Sherry CDC - DIR CDC Owen, Sherry (CDC) 0 114107633 Rudolph, Donna CDC - DIR CDC Rudolph, Donna (CDC) 0 114107634 Curtis, Kelly CDC - DIR CDC Curtis, Kelly (CDC) 1 144229818 Niedzwiedz, Philip CDC - DIR CDC Niedzwiedz, Philip (CDC) 3 114107634 Curtis, Kelly CDC - DIR CDC Curtis, Kelly (CDC) 1 114107626 Owen, Sherry CDC - DIR CDC Owen, Sherry (CDC) 0 114107633 Rudolph, Donna CDC - DIR CDC Rudolph, Donna (CDC) 0 144229818 Niedzwiedz, Philip CDC - DIR CDC Niedzwiedz, Philip (CDC) 3 114101770 Detection Of Subtype B And Group M HIV-1 By Reverse-Transcription, Loop-Mediated Isothermal Amplification (RT-LAMP) E-014-2015-0 Filing authorized Centers for Disease Control and Prevention (CDC) 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-3113] Simple and Rapid Assay to Detect Acute Subtype B and Group M HIV-1 Infections&body=Please send me information about technology [TAB-3113] Simple and Rapid Assay to Detect Acute Subtype B and Group M HIV-1 Infections. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-3113] Simple and Rapid Assay to Detect Acute Subtype B and Group M HIV-1 Infections&body=Please send me information about technology [TAB-3113] Simple and Rapid Assay to Detect Acute Subtype B and Group M HIV-1 Infections.">jonathan.motley@nih.gov</a><br> 114168223 E-014-2015-0 E-014-2015-0-US-01 DETECTION OF HIV-1 NUCLEIC ACIDS BY REVERSE-TRANSCRIPTION LOOP-MEDIATED ISOTHERMAL AMPLIFICATION PRV US 62/076,334 Abandoned US <br />Provisional (PRV) 62/076,334<br />Filed on 2014-11-06<br />Status: Abandoned 114168224 E-014-2015-0 E-014-2015-0-PCT-02 Detection of HIV-1 Nucleic Acids by Reverse-Transcription Loop-Mediated Isothermal Amplification PCT Patent Cooperation Treaty PCT/US2015/057861 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2015/057861<br />Filed on 2015-10-28<br />Status: Expired 114168267 E-014-2015-0 E-014-2015-0-US-05 DETECTION OF HIV-1 NUCLEIC ACIDS BY REVERSE-TRANSCRIPTION LOOP-MEDIATED ISOTHERMAL AMPLIFICATION National Stage US 10,697,028 15/524,209 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10697028 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10697028">10,697,028</a><br />Filed on 2017-05-03<br />Status: Issued 114112354 AC4XXX 114112355 AC3XXX 114113465 DAXXXX 114113466 DA4XXX 114113467 DA4AXX 114113468 VLXXXX 114113469 WBXXXX 114113470 WIXXXX 114113471 XCXXXX 114113472 XEXXXX 114113473 XHXXXX 114113474 YAXXXX 114113475 YBXXXX 114117617 AXXXXX 114117618 AA2XXX 114117619 AA5XXX 114117620 ACXXXX 114119900 AC1XXX 114123252 DXXXXX 114126711 AAXXXX 114148829 CDC Docket Import CDC Prosecuting 114148830 CDC Docket Import 114148831 LAMP 114148832 amplification 114148833 Isothermal 114148834 Loop-Mediated 114148835 HIV 114148836 Detection 114148837 RAPID 114148838 Methods 114148839 Compositions 114148840 OID-NCHHSTP-DHPSE 114148841 PCR 114148842 PCR ALTERNATIVE 114148843 HIV-1 114148844 HIV-2 114148845 On-demand 114148846 diagnostic 114148847 LIMITED-RESOURCE 114148848 LOW INPUT 114148849 Portable 114148850 virus 114148851 viral 114148852 VIRAL DIAGNOSTIC 114148853 IN-SITU 114148854 Field-diagnostic 114148855 Field-usable 114148856 Field 114148857 AIDS 114148858 Subtype 114148859 B 114148860 GROUP 114148861 M 114148862 Reverse-Transcription 114148863 RT-LAMP 114148864 NCHHSTP 114148865 Listed LPM Houze as of 4/15/2015 114148866 Pre LPM working set 20150418 114148867 Post LPM Assignment Set 20150420 TAB-3384 114097274 Real-Time PCR Assay for HIV-1 Subtype Diagnosis and Global Surveillance of Drug Resistance CDC Collaboration, Diagnostics, Infectious Disease, Licensing Collaboration Diagnostics Infectious Disease Licensing Joshua Devos, Nicholas Wagar, Chunfu Yang, Zhiyong Zhou CDC researchers have developed a patented set of RT-PCR and sequencing primers based on HIV-1 group M sequences. Evaluation of the primers using samples collected around the world demonstrated broad detection capacity for multiple HIV-1 group subtypes and predominant circulating recombinant forms. Commercially available HIV-1 drug resistance (HIVDR) genotyping assays are expensive and have limited ability to detect non-B subtypes. This optimized assay is broadly sensitive in genotyping HIV-1 group M viral strains and more sensitive than other assays in detecting mixed viral populations. This technology can be used in resource-limited settings where HIVDR surveillance is recommended to minimize the development and transmission of HIVDR.<br /><br /> <ul> <li>Utility for HIV-1 sub-typing detection, evaluation of anti-HIV therapeutic efficacy, and HIV drug resistance (HIVDR) surveillance and monitoring</li> <li>Rapid, accurate, and cost-effective technology easily adapted as a kit</li> </li> <ul> <li>Cost-effective</li> <li>Simple to implement</li> <li>Rapid, accurate and objectively conclusive</li> <li>Easily implemented as a kit</li> <li>Assay could be applicable to HIVDR genotyping in both ART-naive and ART-experienced populations</li> </ul> <ul> <li>HIV-1 sub-typing diagnostic</li> <li>Evaluation of efficacy of anti-HIV therapeutics</li> <li>HIV drug resistance (HIVDR) surveillance and monitoring</li> </ul> The Centers for Disease Control and Prevention (CDC) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize Real-time PCR Assay for HIV-1 Subtype Diagnosis and Global Surveillance of Drug Resistance. For collaboration opportunities, please contact CDC TTO at <a href="mailto:tto@cdc.gov">tto@cdc.gov</a> or 1-404-639-1330. 2022-03-08 2025-05-09 2025-05-09 2019-09-16 AIDS, assay, blood-borne, CDC Docket Import, CDC Docket Import CDC Prosecuting, CGH-DGHA, DA4AXX, DA4XXX, DAXXXX, DEVELOPING, Diagnosis, diagnostic, DRUG, drug resistance, drug resistant, DXXXXX, EMERGING, EPIDEMIOLOGIC, Genotype, Genotyping, Global, HIV, HIV-1, Listed LPM Houze as of 4/15/2015, PCR, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Resistance, RESISTANT, RT-PCR, Surveillance, therapeutic, tropical, viral, virus False True True NIHTT 37470483 Website Abstract 114172554 Zhou Z, et. al. https://www.ncbi.nlm.nih.gov/pubmed/22132237 <a href="https://www.ncbi.nlm.nih.gov/pubmed/22132237">Zhou Z, et. al.</a> 114172555 Yang C, et al. https://www.ncbi.nlm.nih.gov/pubmed/20660209 <a href="https://www.ncbi.nlm.nih.gov/pubmed/20660209">Yang C, et al.</a> 114108138 Devos, Joshua CDC - DIR CDC Devos, Joshua (CDC) 0 114108139 Wagar, Nicholas CDC - DIR CDC Wagar, Nicholas (CDC) 0 114110039 Zhou, Zhiyong CDC - DIR CDC Zhou, Zhiyong (CDC) 0 114108140 Yang, Chunfu CDC - DIR CDC Yang, Chunfu (CDC) 1 114108140 Yang, Chunfu CDC - DIR CDC Yang, Chunfu (CDC) 1 114108138 Devos, Joshua CDC - DIR CDC Devos, Joshua (CDC) 0 114108139 Wagar, Nicholas CDC - DIR CDC Wagar, Nicholas (CDC) 0 114110039 Zhou, Zhiyong CDC - DIR CDC Zhou, Zhiyong (CDC) 0 114101956 HIV-1 GENOTYPING ASSAY FOR GLOBAL SURVEILLANCE OF HIV-1 DRUG RESISTANCE E-259-2013-0 Filing authorized Centers for Disease Control and Prevention (CDC) 83724572 Tung, Peter peter.tung@nih.gov
United States of America DIR peter.tung@nih.gov?subject=Web Inquiry on [TAB-3384] Real-Time PCR Assay for HIV-1 Subtype Diagnosis and Global Surveillance of Drug Resistance&body=Please send me information about technology [TAB-3384] Real-Time PCR Assay for HIV-1 Subtype Diagnosis and Global Surveillance of Drug Resistance. Tung, Peter<br><a href="mailto:peter.tung@nih.gov?subject=Web Inquiry on [TAB-3384] Real-Time PCR Assay for HIV-1 Subtype Diagnosis and Global Surveillance of Drug Resistance&body=Please send me information about technology [TAB-3384] Real-Time PCR Assay for HIV-1 Subtype Diagnosis and Global Surveillance of Drug Resistance.">peter.tung@nih.gov</a><br> 114167270 E-259-2013-0 E-259-2013-0-US-06 HIV-1 GENOTYPING ASSAY FOR GLOBAL SURVEILLANCE OF HIV-1 DRUG RESISTANCE DIV US 10,053,741 14/719,338 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10053741 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10053741">10,053,741</a><br />Filed on 2015-05-22<br />Status: Issued 114167271 E-259-2013-0 E-259-2013-0-US-05 HIV-1 GENOTYPING ASSAY FOR GLOBAL SURVEILLANCE OF HIV-1 DRUG RESISTANCE National Stage US 9,040,244 14/125,564 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9040244 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9040244">9,040,244</a><br />Filed on 2013-12-11<br />Status: Issued 114167403 E-259-2013-0 E-259-2013-0-PCT-02 HIV-1 GENOTYPING ASSAY FOR GLOBAL SURVEILLANCE OF HIV-1 DRUG RESISTANCE PCT Patent Cooperation Treaty PCT/US2012/045523 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2012/045523<br />Filed on 2012-07-05<br />Status: Expired 114168166 E-259-2013-0 E-259-2013-0-US-01 HIV-1 GENOTYPING ASSAY FOR GLOBAL SURVEILLANCE OF HIV-1 DRUG RESISTANCE PRV US 61/504,522 Abandoned US <br />Provisional (PRV) 61/504,522<br />Filed on 2011-07-05<br />Status: Abandoned 114128281 DXXXXX 114128282 DAXXXX 114128283 DA4XXX 114128284 DA4AXX 114151657 HIV-1 114151658 Genotyping 114151659 assay 114151660 Global 114151661 Surveillance 114151662 DRUG 114151663 Resistance 114151664 CDC Docket Import 114151665 CDC Docket Import CDC Prosecuting 114151666 Diagnosis 114151667 diagnostic 114151668 therapeutic 114151669 Genotype 114151670 RT-PCR 114151671 PCR 114151672 drug resistant 114151673 drug resistance 114151674 RESISTANT 114151675 virus 114151676 viral 114151677 EMERGING 114151678 HIV 114151679 AIDS 114151680 EPIDEMIOLOGIC 114151681 DEVELOPING 114151682 tropical 114151683 blood-borne 114151684 CGH-DGHA 114151685 Listed LPM Houze as of 4/15/2015 114151686 Pre LPM working set 20150418 114151687 Post LPM Assignment Set 20150420 TAB-3316 114097239 Method to remove human DNA when sequencing for parasite infection CDC Collaboration, Consumer Products, Diagnostics, Infectious Disease, Licensing, Medical Devices, Non-Medical Devices, Occupational Safety and Health, Research Materials Collaboration Consumer Products Diagnostics Infectious Disease Licensing Medical Devices Non-Medical Devices Occupational Safety and Health Research Materials Richard Bradbury, Briana Flaherty, Christian Olsen, Eldin Talundzic A major challenge to sequencing eukaryotic parasites present in clinical samples is the abundance of ‘contaminating’ human DNA in samples. CDC has developed a method to reduce host DNA from biological samples prior to sequencing of the 18s gene, a universal gene which allows scientists to detect any parasitic organism by one DNA test. <br/><br/> Use of this technology will allow for 18s sequencing of parasites found in biological samples for pathogen identification, surveillance, and detection of new parasite pathogens. This technique could decrease the time required to diagnose infections in patients. Initial test results showed that samples not treated with restriction enzymes retain >95% human DNA, while treated samples yield five to ten fold increase in parasite DNA and one to two fold reduction in human DNA, allowing far greater capacity to detect parasite DNA in these treated samples. Thus far, this method was validated using 16 human blood-borne parasite species and was effective in detecting both single and mixed parasite infections. <ul> <li>Reduces human DNA in clinical samples and enriches pathogen DNA to facilitate detection</li> <li>Increased sensitivity towards amplifying pathogens in clinical samples</li> <li>A single test for the detection of all potential parasites in a blood sample</li> </ul> <ul> <li>A potential next-generation sequencing-based platform for universal parasite detection</li> <li>Monitoring and disease surveillance</li> <li>Detection and identification of new and emerging parasitic pathogens</li> </ul> The CDC Technology Transfer Office (TTO) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize: A method to remove human DNA when sequencing for parasite infection. For collaboration opportunities, please contact CDC TTO at <a href="mailto:tto@cdc.gov">tto@cdc.gov</a> or 1-404-639-1330. 2022-03-08 2025-05-09 2025-05-09 2018-09-10 CGH-DPDM, DNA, Human, Method, Microbes, Remove, sequencing, VQXXXX, WBXXXX, WFXXXX, WHEN, WIXXXX, XDXXXX False True True NIHTT 37470483 Website Abstract 114109831 Bradbury, Richard CDC - DIR CDC Bradbury, Richard (CDC) 0 114109832 Olsen, Christian CDC - DIR CDC Olsen, Christian (CDC) 0 114109833 Flaherty, Briana CDC - DIR Flaherty, Briana 0 114109830 Talundzic, Eldin CDC - DIR CDC Talundzic, Eldin (CDC) 1 114109830 Talundzic, Eldin CDC - DIR CDC Talundzic, Eldin (CDC) 1 114109831 Bradbury, Richard CDC - DIR CDC Bradbury, Richard (CDC) 0 114109832 Olsen, Christian CDC - DIR CDC Olsen, Christian (CDC) 0 114109833 Flaherty, Briana CDC - DIR Flaherty, Briana 0 114102474 A Method To Remove Human DNA When Sequencing Microbes E-113-2017-0 Closed Centers for Disease Control and Prevention (CDC) 83724572 Tung, Peter peter.tung@nih.gov
United States of America DIR peter.tung@nih.gov?subject=Web Inquiry on [TAB-3316] Method to remove human DNA when sequencing for parasite infection&body=Please send me information about technology [TAB-3316] Method to remove human DNA when sequencing for parasite infection. Tung, Peter<br><a href="mailto:peter.tung@nih.gov?subject=Web Inquiry on [TAB-3316] Method to remove human DNA when sequencing for parasite infection&body=Please send me information about technology [TAB-3316] Method to remove human DNA when sequencing for parasite infection.">peter.tung@nih.gov</a><br> 114168724 E-113-2017-0 E-113-2017-0-US-01 REMOVING INTERFERING HOST NUCLEIC ACIDS FOR MOLECULAR PARASITE DETECTION PRV US 62/562,262 Abandoned US <br />Provisional (PRV) 62/562,262<br />Filed on 2017-09-22<br />Status: Abandoned 114168741 E-113-2017-0 E-113-2017-0-PCT-02 REMOVING INTERFERING HOST NUCLEIC ACIDS FOR MOLECULAR PARASITE DETECTION PCT Patent Cooperation Treaty PCT/US2018/052469 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2018/052469<br />Filed on 2018-09-24<br />Status: Expired 114128106 VQXXXX 114128107 WBXXXX 114128108 WFXXXX 114128109 WIXXXX 114128110 XDXXXX 114151265 Method 114151266 Remove 114151267 Human 114151268 DNA 114151269 WHEN 114151270 sequencing 114151271 Microbes 114151272 CGH-DPDM TAB-3240 114097174 Portable Laser-Operated Counterfeit Drug Identifier (CoDI) for Tablets CDC Cardiology, Collaboration, Consumer Products, Dental, Endocrinology, Infectious Disease, Licensing, Materials Available, Medical Devices, Non-Medical Devices, Occupational Safety and Health, Oncology, Ophthalmology, Research Materials Cardiology Collaboration Consumer Products Dental Endocrinology Infectious Disease Licensing Materials Available Medical Devices Non-Medical Devices Occupational Safety and Health Oncology Ophthalmology Research Materials Michael Green Counterfeit drugs (also known as “fake or falsified medicines”) have become a major world-wide public health concern. Falsified medicines may contain toxic substances, the wrong active ingredients, suboptimal amounts of active ingredients, or no active ingredients at all. CDC researchers developed a portable (handheld), battery-operated, and relatively inexpensive device that non-trained personnel can use quickly to evaluate a particular branded tablet for authenticity. The low-cost and simple-to-use CoDI can aid the general public as well as hospitals, clinics, and pharmacies to assess drug quality. The CoDI does not require the use of consumables such as solvents or chemicals, and does not destroy the sample. Thus, the device is safe to use and allows the samples to be available for subsequent analysis if necessary. The CoDI can benefit drug regulatory, Customs and law enforcement agencies for testing and screening large amounts of samples. CoDI provides instantaneous results that can allow agencies to rapidly begin searching for counterfeit drug sources and implement intervening measures to stem the production and availability of counterfeit drugs. CDC researchers successfully tested the CoDI prototype in Ghana on a project to detect falsified, degraded, and expired ingredients in antimalarial tablets. Field trials to test additional drug samples are underway. Matchbook sized versions with yes/no indicator lights are being developed for specific brands. These are even simpler to use and lessen any chance of operator error. <ul> <li>Simple, efficient, and quick detection of counterfeit and poor quality drugs</li> <li> CoDI uses inexpensive laser technology versus other analytical equipment</li> <li>Does not destroy sample</li> <li> First field trials to test antimalarial drug samples with the device in Ghana were successful</li> <li>Field trials to test additional drug samples are underway</li> </ul> <ul> <li>Instrument can detect counterfeit, degraded, and expired drugs in tablet formation</li> <li>The general public as well as hospitals, clinics, and pharmacies can assess drug quality</li> <li>Drug regulatory, Customs and law enforcement agencies may test and screen large amounts of samples</li> <li>Pharmaceutical companies may use the device for quality control purposes or generic drug testing</li> </ul> The CDC Technology Transfer Office (TTO) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize: Portable Laser-Operated Counterfeit Drug Identifier (CoDI). For collaboration opportunities, please contact CDC TTO at <a href="mailto: tto@cdc.gov">tto@cdc.gov</a> or 1-404-639-1330 . 2022-03-08 2025-05-09 2025-05-09 2018-01-16 CDC Docket Import, CDC Docket Import CDC Prosecuting, CoDI, CoDI., Counterfeit, DRUG, INDICATOR, Laser-operated, Listed LPM Houze as of 4/15/2015, Listed LPM Kirby as of 4/15/2015, Portable, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, VPXXXX, WFXXXX, WHXXXX, XDXXXX False True True NIHTT 37470483 Website Abstract E-161-2013-0 114172442 Yong YL, et al https://www.ncbi.nlm.nih.gov/pubmed/25897069 <a href="https://www.ncbi.nlm.nih.gov/pubmed/25897069">Yong YL, et al</a> 114172443 Green MD, et al. https://www.ncbi.nlm.nih.gov/pubmed/25897066 <a href="https://www.ncbi.nlm.nih.gov/pubmed/25897066">Green MD, et al.</a> 114109606 Green, Michael CDC - DIR CDC Green, Michael (CDC) 1 114109606 Green, Michael CDC - DIR CDC Green, Michael (CDC) 1 114102400 Laser-operated Portable Counterfeit Drug Indicator (CoDI) E-572-2013-1 Filing authorized Centers for Disease Control and Prevention (CDC) 83724572 Tung, Peter peter.tung@nih.gov
United States of America DIR peter.tung@nih.gov?subject=Web Inquiry on [TAB-3240] Portable Laser-Operated Counterfeit Drug Identifier (CoDI) for Tablets&body=Please send me information about technology [TAB-3240] Portable Laser-Operated Counterfeit Drug Identifier (CoDI) for Tablets. Tung, Peter<br><a href="mailto:peter.tung@nih.gov?subject=Web Inquiry on [TAB-3240] Portable Laser-Operated Counterfeit Drug Identifier (CoDI) for Tablets&body=Please send me information about technology [TAB-3240] Portable Laser-Operated Counterfeit Drug Identifier (CoDI) for Tablets.">peter.tung@nih.gov</a><br> 114168532 E-572-2013-1 E-572-2013-1-US-01 Device And Method For Detection Of Counterfeit Pharmaceuticals PRV US 62/287,711 Abandoned US <br />Provisional (PRV) 62/287,711<br />Filed on 2016-01-27<br />Status: Abandoned 114168533 E-572-2013-1 E-572-2013-1-PCT-02 Device and Methods for Detection of Counterfeit Pharmaceuticals PCT Patent Cooperation Treaty PCT/US2017/015324 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2017/015324<br />Filed on 2017-01-27<br />Status: Expired 114168718 E-572-2013-1 E-572-2013-1-US-04 DEVICE AND METHOD FOR DETECTION OF COUNTERFEIT PHARMACEUTICALS National Stage US 11,162,892 16/071,843 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11162892 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11162892">11,162,892</a><br />Filed on 2018-07-20<br />Status: Issued 114127735 VPXXXX 114127736 WFXXXX 114127737 WHXXXX 114127738 XDXXXX 114150331 Laser-operated 114150332 Portable 114150333 Counterfeit 114150334 DRUG 114150335 INDICATOR 114150336 CoDI. 114150337 CDC Docket Import 114150338 CDC Docket Import CDC Prosecuting 114150339 Listed LPM Kirby as of 4/15/2015 114150340 Pre LPM working set 20150418 114150341 Post LPM Assignment Set 20150420 114150342 CoDI 114150343 Listed LPM Houze as of 4/15/2015 TAB-3031 114096523 Field-Adapted Spot Test for Evaluating Materials Treated with Permethrin Insect Repellent CDC Collaboration, Consumer Products, Diagnostics, Infectious Disease, Licensing, Materials Available, Research Materials Collaboration Consumer Products Diagnostics Infectious Disease Licensing Materials Available Research Materials Michael Green Military uniforms and mosquito nets are treated with permethrin, a repellent and insecticide used for personal protection against biting flies, mosquitoes, and other disease-carrying insects. Vector-borne diseases such as malaria, leishmaniasis (a parasitic infection spread by sandflies), Zika virus, West Nile virus, Lyme disease, and more can be diminished if treated nets or clothing containing the proper amount of permethrin are utilized. Washing and wear depletes the insecticide on the material, eventually rendering it ineffective. Currently, there are no commercially available colorimetric (color-changing) tests available to gauge the amount of permethrin left in fabrics after use and repeated washes. CDC researchers developed a rapid and simple technique using a reagent to quantify the amount of permethrin in the treated fabric. The low cost colorimetric spot test yields color intensity proportional to the permethrin concentration levels and has been adapted into a prototype for field testing. The technology provides a rapid means to evaluate permethrin-treated materials, such as military uniforms, outdoor gear, mosquito nets, and curtains. <ul> <li>First to market potential – currently, there are no commercially-available colorimetric assays for permethrin although they are available for other synthetic pyrethroids (insecticides) such as deltamethrin</li> <li>Low-cost kit is ideal for field use</li> <li>Spot tests are rapid and easy to use</li> <li>The kit can be adapted to provide an indication by color intensity of whether the material needs to be retreated or discarded</li> </ul> <ul> <li>Kits containing spot test for military personnel operating in the field</li> <li>Kits can be available for use in programs aimed to reduce the spread of diseases caused by insect bites such as malaria or Lyme disease</li> <li>Kits can be made available to frequent outdoorsmen/women (e.g., hikers, campers, and hunters) who use permethrin-treated clothing, tents, camping gear, etc.</li> </ul> The Centers for Disease Control and Prevention is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize the field-adapted spot test for evaluating materials treated with permethrin insect repellent. For collaboration opportunities, please contact Tara Kirby, Ph.D. at <a href="mailto:tara.kirby@nih.gov">tara.kirby@nih.gov</a>. 2022-03-08 2025-05-09 2025-05-09 2016-07-19 CGH, DPDM, EVALUATION, Listed LPM Houze as of 4/15/2015, military, Mosquito, Nets, Parasitic Diseases, Permethrin, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, SPOT, test, TREATED, Uniforms, Vector-borne, Vector-borne diseases, VJXXXX, VLXXXX, VOXXXX, VQXXXX, WBXXXX, WDXXXX, WHXXXX, YFXXXX, Zika False True Prototype True 52406769 Prototype 52406769 NIHTT 37470483 Website Abstract 114104206 Green, Michael CDC - DIR CDC Green, Michael (CDC) 1 114104206 Green, Michael CDC - DIR CDC Green, Michael (CDC) 1 114101428 Spot Test For The Evaluation Of Permethrin On Treated Military Uniforms And Mosquito Nets E-085-2015-0 Filing authorized Centers for Disease Control and Prevention (CDC) 83724572 Tung, Peter peter.tung@nih.gov
United States of America DIR peter.tung@nih.gov?subject=Web Inquiry on [TAB-3031] Field-Adapted Spot Test for Evaluating Materials Treated with Permethrin Insect Repellent&body=Please send me information about technology [TAB-3031] Field-Adapted Spot Test for Evaluating Materials Treated with Permethrin Insect Repellent. Tung, Peter<br><a href="mailto:peter.tung@nih.gov?subject=Web Inquiry on [TAB-3031] Field-Adapted Spot Test for Evaluating Materials Treated with Permethrin Insect Repellent&body=Please send me information about technology [TAB-3031] Field-Adapted Spot Test for Evaluating Materials Treated with Permethrin Insect Repellent.">peter.tung@nih.gov</a><br> 114166631 E-085-2015-0 E-085-2015-0-PCT-02 COLORIMETRIC ASSAY FOR MEASURING TYPE I PYRETHROIDS ON TREATED OBJECTS PCT Patent Cooperation Treaty PCT/US2016/036935 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2016/036935<br />Filed on 2016-06-10<br />Status: Expired 114166873 E-085-2015-0 E-085-2015-0-US-01 Colorimetric Assay For Measuring Type 1 Pyrethriods On Treated Objects PRV US 62/174,852 Abandoned US <br />Provisional (PRV) 62/174,852<br />Filed on 2015-06-12<br />Status: Abandoned 114168504 E-085-2015-0 E-085-2015-0-US-03 COLORIMETRIC ASSAY FOR MEASURING TYPE I PYRETHROIDS ON TREATED OBJECTS National Stage US 10,598,643 15/735,800 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10598643 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10598643">10,598,643</a><br />Filed on 2017-12-12<br />Status: Issued 114121839 VJXXXX 114121840 VQXXXX 114121841 VLXXXX 114121842 VOXXXX 114122017 WHXXXX 114122023 YFXXXX 114122036 WBXXXX 114122037 WDXXXX 114140085 Uniforms 114140086 TREATED 114140087 Listed LPM Houze as of 4/15/2015 114140088 Pre LPM working set 20150418 114140089 Post LPM Assignment Set 20150420 114140090 DPDM 114140091 Parasitic Diseases 114140092 Zika 114140093 Vector-borne 114140094 Vector-borne diseases 114141473 test 114141474 Mosquito 114141475 Nets 114141476 EVALUATION 114141477 military 114141478 CGH 114141519 SPOT 114141520 Permethrin TAB-2818 114096997 Simple, Field-Usable Fluorescence-Based Isothermal LAMP Assay for the On-Site Diagnosis of Malaria CDC Consumer Products, Diagnostics, Infectious Disease, Licensing, Occupational Safety and Health, Research Materials, Therapeutics, Vaccines Consumer Products Diagnostics Infectious Disease Licensing Occupational Safety and Health Research Materials Therapeutics Vaccines Allison Demas, Naomi Lucchi, Venkatachalam Udhayakumar CDC researchers have developed improved Loop-Mediated Isothermal Amplification (LAMP) assays for the nucleic acid-based diagnosis of malaria in field settings. The approach employs <em>Plasmodium</em> genus-specific LAMP primers and a portable tube scanner to run the LAMP reaction and measure fluorescence signal (e.g., SYBR green) as a measure of DNA amplification in real time. Using this platform, the researchers were able to detect several different species of the human malaria parasites.<br /><br /> This LAMP approach has demonstrated the ability of this assay to detect <em>P. falciparum</em> in clinical samples with approximately 99-100% sensitivity, an improvement over standard nested PCR methodology. Additionally, DNA extracted by direct boiling of whole blood works well in this assay. Further, several important practical aspects of the method make it an attractive method for on-site uses. For example, it is portable to remote locales, required equipment is easily powered by battery or other alternate power sources, and no post-assay tasks, such as gel electrophoresis, are required. This method is also technically easier to perform than nested PCR, has automation features allowing direct reporting of results from remote locations, and can be modified to handle large sample numbers. <ul> <li>Qualitative malaria diagnostic suitable for field use or use in resource-limited environments</li> <li>Assay can provide quantitative feedback when integrated with computational devices capable of plotting real-time data</li> <li>Simple method can be implemented by technicians with minimal training</li> <li>Results can be obtained in less than one hour</li> <li>Adaptable for high-throughput analyses</li> <li>Method can be used with DNA extracted by boiling of whole blood</li> </ul> <ul> <li>Diagnosis of malaria in point-of-care settings</li> <li>Rapid feedback for directing anti-malarial therapy</li> <li>Replacement or improvement of existing methods for malaria diagnosis</li> <li>Useful for monitoring and evaluation of malaria control and elimination programs in the field</li> <li>Potential military and humanitarian applications</li> </ul> Research Tool – Patent protection is not being pursued for this technology. 2022-03-08 2025-05-09 2025-05-09 2014-05-15 assay, Based, CDC Docket Import, CDC Docket Import CDC Prosecuting, CDCRM, DA2XXX, DAXXXX, DDXXXX, DEVELOPING, Development, Diagnosis, diagnostic, DXXXXX, Field-usable, Fluorescence, Isothermal, ivd, LAMP, LIMITED-RESOURCE, LOW INPUT, Malaria, Mosquito, Mosquitoes, nucleic acid, NUCLEIC ACID DETECTION, PCR ALTERNATIVE, real time, REAL-TIME, SIMPLE, travel, traveler, travelers, VBXXXX, Vector-borne, Vector-borne diseases, VJXXXX, VKXXXX, VLXXXX, VOXXXX, WAXXXX, WBXXXX, WDXXXX, WFXXXX, WIXXXX, WMXXXX, YBXXXX, Zoonotic False True <ul> <li>In vitro data available</li> </ul> True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114172139 Lucchi NW, et al. http://www.ncbi.nlm.nih.gov/pubmed/21060829 <a href="http://www.ncbi.nlm.nih.gov/pubmed/21060829">Lucchi NW, et al.</a> 114172140 Patel JC, et al. http://www.ncbi.nlm.nih.gov/pubmed/23349994 <a href="http://www.ncbi.nlm.nih.gov/pubmed/23349994">Patel JC, et al.</a> 114108719 Demas, Allison CDC - DIR CDC Demas, Allison (CDC) 0 114108720 Lucchi, Naomi CDC - DIR CDC Lucchi, Naomi (CDC) 0 114108718 Udhayakumar, Venkatachalam CDC - DIR CDC Udhayakumar, Venkatachalam (CDC) 1 114108718 Udhayakumar, Venkatachalam CDC - DIR CDC Udhayakumar, Venkatachalam (CDC) 1 114108719 Demas, Allison CDC - DIR CDC Demas, Allison (CDC) 0 114108720 Lucchi, Naomi CDC - DIR CDC Lucchi, Naomi (CDC) 0 114102151 Development Of Simple, Field-usable Fluorescence Based LAMP Assay For The Diagnosis Of Malaria E-625-2013-0 Research Material Centers for Disease Control and Prevention (CDC) 83724572 Tung, Peter peter.tung@nih.gov
United States of America DIR peter.tung@nih.gov?subject=Web Inquiry on [TAB-2818] Simple, Field-Usable Fluorescence-Based Isothermal LAMP Assay for the On-Site Diagnosis of Malaria&body=Please send me information about technology [TAB-2818] Simple, Field-Usable Fluorescence-Based Isothermal LAMP Assay for the On-Site Diagnosis of Malaria. Tung, Peter<br><a href="mailto:peter.tung@nih.gov?subject=Web Inquiry on [TAB-2818] Simple, Field-Usable Fluorescence-Based Isothermal LAMP Assay for the On-Site Diagnosis of Malaria&body=Please send me information about technology [TAB-2818] Simple, Field-Usable Fluorescence-Based Isothermal LAMP Assay for the On-Site Diagnosis of Malaria.">peter.tung@nih.gov</a><br> 114126036 DAXXXX 114126037 DA2XXX 114126038 DXXXXX 114126039 DDXXXX 114126040 VBXXXX 114126041 VJXXXX 114126042 VKXXXX 114126043 VLXXXX 114126044 VOXXXX 114126045 WAXXXX 114126046 WBXXXX 114126047 WDXXXX 114126048 WFXXXX 114126049 WIXXXX 114126050 WMXXXX 114126051 YBXXXX 114147270 Development 114147271 SIMPLE 114147272 Field-usable 114147273 Fluorescence 114147274 Based 114147275 LAMP 114147276 assay 114147277 Diagnosis 114147278 Malaria 114147279 CDC Docket Import 114147280 CDC Docket Import CDC Prosecuting 114147281 CDCRM 114147282 Isothermal 114147283 PCR ALTERNATIVE 114147284 diagnostic 114147285 ivd 114147286 real time 114147287 REAL-TIME 114147288 nucleic acid 114147289 NUCLEIC ACID DETECTION 114147290 Mosquito 114147291 Mosquitoes 114147292 DEVELOPING 114147293 LOW INPUT 114147294 LIMITED-RESOURCE 114147295 Vector-borne 114147296 Vector-borne diseases 114147297 Zoonotic 114147298 travel 114147299 traveler 114147300 travelers TAB-2768 114096947 Recombinant Polypeptides for Clinical Detection of Taenia solium and Diagnosis of Cysticercosis CDC Antibodies, Cardiology, Consumer Products, Dental, Diagnostics, Endocrinology, Immunology, Infectious Disease, Licensing, Occupational Safety and Health, Oncology, Ophthalmology, Research Materials, Therapeutics Antibodies Cardiology Consumer Products Dental Diagnostics Endocrinology Immunology Infectious Disease Licensing Occupational Safety and Health Oncology Ophthalmology Research Materials Therapeutics Ryan Greene, Kathy Hancock, Victor Tsang, Patricia Wilkins CDC scientists have developed synthetic/recombinant polypeptides that can be used for the creation of inexpensive, high-quality cysticercosis diagnostic assays. <em>Taenia solium</em> is a species of pathogenic tapeworm. Intestinal infection with this parasite is referred to as taeniasis and it is acquired by ingestion of <em>T. solium</em> cysticerci found in raw and undercooked pork, or food contaminated with human or porcine excrement. Many infections are asymptomatic, but infection may be characterized by insomnia, anorexia, abdominal pain and weight loss. Cysticercosis is the formation of cysticerci in various body tissues resulting from the migration of the <em>T. solium</em> larvae out of the intestine. Although infection with <em>T. solium</em> is itself not dangerous, cysticercosis can be fatal. In the present invention, specific antigen encoding nucleotide sequences have been cloned; assays based on the produced antigens may be useful for improvements over the existing Western blot diagnostic method for identifying individuals with cysticercosis. Additionally, these polypeptides may have applications in developing vaccines and therapeutics to prevent taeniasis. <ul> <li>May provide a rapid, accurate, sensitive and safe alternative to current radiologic, Western blot and biopsy diagnostic methods</li> <li>Can be easily formatted as a simple-to-use assay kit for FAST-ELISA</li> <li>Cost-effective, and quite useful for developing regions of the world</li> </ul> <ul> <li>Diagnosis of <em>T. solium</em> infection and confirmation of cysticercosis</li> <li>Zoonotic disease research and surveillance</li> <li>Public health monitoring programs</li> <li>Livestock health and food-source monitoring</li> <li>Therapeutics/vaccine development</li> </ul> 2022-03-08 2025-05-09 2025-05-09 2014-02-06 ANTIGEN, CDC Docket Import, CDC Docket Import CDC Prosecuting, CGH-DPDM, Cloned, Compositions, DA2XXX, DAXXXX, DETECTING, diagnostic, DXXXXX, I-031-98, I-031-99, Larval, Methods, SOLIUM, TAENIA, VJXXXX, VKXXXX, VLXXXX, VOXXXX, VPXXXX, WBXXXX, WFXXXX, WJXXXX, WMXXXX, XAXXXX, XCXXXX, XEXXXX, YBXXXX False True In vitro data available True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114172060 Greene RM, et al. http://www.ncbi.nlm.nih.gov/pubmed/11128471 <a href="http://www.ncbi.nlm.nih.gov/pubmed/11128471">Greene RM, et al.</a> 114108528 Greene, Ryan CDC - DIR CDC Greene, Ryan (CDC) 0 114108529 Wilkins, Patricia CDC - DIR CDC Wilkins, Patricia (CDC) 0 114108530 Hancock, Kathy CDC - DIR CDC Hancock, Kathy (CDC) 0 114108527 Tsang, Victor CDC - DIR CDC Tsang, Victor (CDC) 1 114108527 Tsang, Victor CDC - DIR CDC Tsang, Victor (CDC) 1 114108528 Greene, Ryan CDC - DIR CDC Greene, Ryan (CDC) 0 114108529 Wilkins, Patricia CDC - DIR CDC Wilkins, Patricia (CDC) 0 114108530 Hancock, Kathy CDC - DIR CDC Hancock, Kathy (CDC) 0 114102088 Methods And Compositions For Detecting Larval Taenia Solium With A Cloned Diagnostic Antigen (I-031-98, I-031-99) E-230-2013-0 Closed Centers for Disease Control and Prevention (CDC) 83724572 Tung, Peter peter.tung@nih.gov
United States of America DIR peter.tung@nih.gov?subject=Web Inquiry on [TAB-2768] Recombinant Polypeptides for Clinical Detection of Taenia solium and Diagnosis of Cysticercosis&body=Please send me information about technology [TAB-2768] Recombinant Polypeptides for Clinical Detection of Taenia solium and Diagnosis of Cysticercosis. Tung, Peter<br><a href="mailto:peter.tung@nih.gov?subject=Web Inquiry on [TAB-2768] Recombinant Polypeptides for Clinical Detection of Taenia solium and Diagnosis of Cysticercosis&body=Please send me information about technology [TAB-2768] Recombinant Polypeptides for Clinical Detection of Taenia solium and Diagnosis of Cysticercosis.">peter.tung@nih.gov</a><br> 114167633 E-230-2013-0 E-230-2013-0-US-01 Methods And Compositions For Detecting Larval Taenia Solium With A Cloned Diagnostic Antigen PRV US 60/194,148 Abandoned US <br />Provisional (PRV) 60/194,148<br />Filed on 2000-04-04<br />Status: Abandoned 114167634 E-230-2013-0 E-230-2013-0-PCT-02 Methods And Compositions For Detecting Larval Taenia Solium With A Cloned Diagnostic Antigen PCT Patent Cooperation Treaty PCT/US2001/010392 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2001/010392<br />Filed on 2001-03-30<br />Status: Expired 114167635 E-230-2013-0 E-230-2013-0-US-06 Methods And Compositions For Detecting Larval Taenia Solium With A Cloned Diagnostic Antigen National Stage US 7,094,576 10/240,982 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7094576 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7094576">7,094,576</a><br />Filed on 2003-02-20<br />Status: Expired 114167636 E-230-2013-0 E-230-2013-0-US-12 Methods And Compositions For Detecting Larval Taenia Solium With A Cloned Diagnostic Antigen DIV US 7,595,059 11/508,046 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7595059 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7595059">7,595,059</a><br />Filed on 2006-08-21<br />Status: Abandoned 114125332 DXXXXX 114125333 DAXXXX 114125334 DA2XXX 114125335 VJXXXX 114125336 VKXXXX 114125337 VLXXXX 114125338 VOXXXX 114125339 VPXXXX 114125340 WBXXXX 114125341 WFXXXX 114125342 WJXXXX 114125343 WMXXXX 114125344 XAXXXX 114125345 XCXXXX 114125346 XEXXXX 114125347 YBXXXX 114146536 Larval 114146537 DETECTING 114146538 Compositions 114146539 Methods 114146540 ANTIGEN 114146541 diagnostic 114146542 Cloned 114146543 SOLIUM 114146544 TAENIA 114146545 I-031-99 114146546 I-031-98 114146547 CDC Docket Import 114146548 CDC Docket Import CDC Prosecuting 114146549 CGH-DPDM TAB-2732 114096911 A Simple Colorimetric Assay for Anti-malarial Drugs Quality Assurance and Rapid, On-site Counterfeit Detection CDC Cardiology, Consumer Products, Dental, Diagnostics, Endocrinology, Infectious Disease, Licensing, Medical Devices, Non-Medical Devices, Occupational Safety and Health, Oncology, Ophthalmology, Research Materials, Software / Apps Cardiology Consumer Products Dental Diagnostics Endocrinology Infectious Disease Licensing Medical Devices Non-Medical Devices Occupational Safety and Health Oncology Ophthalmology Research Materials Software / Apps Michael Green This CDC assay aims to lessen the anti-malarial drug counterfeiting epidemic by testing for the artemisinin-type drugs (the active compound), through the use of a simple, inexpensive colorimetric test. Poor quality and counterfeit drugs pose an immediate threat to public health and undermine malaria control efforts, resulting in resistant-parasites and invalidates effective compounds, i.e. the artemisinins. <p>In response to this threat, CDC researchers have developed a simple, inexpensive, field-adapted colorimetric test to determine artemesin-derivative authenticity in anti-malarial tablets. This assay exploits a chemical reaction in which the active element in question readily reacts under mild conditions with diazonium salts producing a visually distinct green-colored product. The resultant product delineates a positive correlation between color intensity and the drug's concentration of active-compound; counterfeit drugs will have no or little change in color.</p> <ul> <li>Potentially life-saving technology in developing nations and malaria affected regions</li> <li>Simple assay with an unaided-eye readout</li> <li>Inexpensive and field-adapted for use in low-resource environments</li> </ul> <ul> <li>Quality assurance, fraud prevention for anti-malarials</li> <li>Public health and humanitarian concerns</li> <li>Artesunate, artemisinin sales and distributions</li> </ul> 2022-03-08 2025-05-09 2025-05-09 2014-01-20 AA2XXX, AA5XXX, AA6XXX, AAXXXX, AB2XXX, AB4XXX, AC5XXX, AE2BXX, AE2CXX, AE2XXX, AE3XXX, AEXXXX, AG2XXX, AG3XXX, AGXXXX, ANTIMALARIAL, Artemesin, AXXXXX, CDC Docket Import, CDC Docket Import CDC Prosecuting, CGH-DPDM, COLORIMETRIC, Derivatives, test, VJXXXX, VKXXXX, VLXXXX, VOXXXX, VPXXXX, WBXXXX, WCXXXX, WDXXXX, WFXXXX, WHXXXX, WMXXXX, XCXXXX, XDXXXX, XFXXXX, XIXXXX, YBXXXX, YEXXXX False True <ul> <li>In vitro data available</li> <li>In situ data available (on-site)</li> </ul> True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114172007 Green MD, et al. http://www.ncbi.nlm.nih.gov/pubmed/11108540 <a href="http://www.ncbi.nlm.nih.gov/pubmed/11108540">Green MD, et al.</a> 114172008 Green MD, et al. http://www.ncbi.nlm.nih.gov/pubmed/11737833 <a href="http://www.ncbi.nlm.nih.gov/pubmed/11737833">Green MD, et al.</a> 114108424 Green, Michael CDC - DIR CDC Green, Michael (CDC) 1 114108424 Green, Michael CDC - DIR CDC Green, Michael (CDC) 1 114102048 Colorimetric Test For Antimalarial Artemesin Derivatives E-161-2013-0 Closed Centers for Disease Control and Prevention (CDC) 83724572 Tung, Peter peter.tung@nih.gov
United States of America DIR peter.tung@nih.gov?subject=Web Inquiry on [TAB-2732] A Simple Colorimetric Assay for Anti-malarial Drugs Quality Assurance and Rapid, On-site Counterfeit Detection&body=Please send me information about technology [TAB-2732] A Simple Colorimetric Assay for Anti-malarial Drugs Quality Assurance and Rapid, On-site Counterfeit Detection. Tung, Peter<br><a href="mailto:peter.tung@nih.gov?subject=Web Inquiry on [TAB-2732] A Simple Colorimetric Assay for Anti-malarial Drugs Quality Assurance and Rapid, On-site Counterfeit Detection&body=Please send me information about technology [TAB-2732] A Simple Colorimetric Assay for Anti-malarial Drugs Quality Assurance and Rapid, On-site Counterfeit Detection.">peter.tung@nih.gov</a><br> 114167508 E-161-2013-0 E-161-2013-0-US-01 Colorimetric Test For Antimalarial Artemesin Derivatives PRV US 61/985,399 Abandoned US <br />Provisional (PRV) 61/985,399<br />Filed on 2007-11-05<br />Status: Abandoned 114167509 E-161-2013-0 E-161-2013-0-PCT-02 Colorimetric Test For Antimalarial Artemesin Derivatives PCT Patent Cooperation Treaty PCT/US2008/082466 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2008/082466<br />Filed on 2008-11-05<br />Status: Expired 114167510 E-161-2013-0 E-161-2013-0-US-03 Colorimetric Test For Antimalarial Artemesin Derivatives National Stage US 8,435,794 12/741,434 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8435794 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8435794">8,435,794</a><br />Filed on 2010-07-21<br />Status: Abandoned 114124646 AXXXXX 114124647 AAXXXX 114124648 AA2XXX 114124649 AA5XXX 114124650 AA6XXX 114124651 AB4XXX 114124652 AB2XXX 114124653 AC5XXX 114124654 AEXXXX 114124655 AE2XXX 114124656 AE2CXX 114124657 AE2BXX 114124658 AE3XXX 114124659 AGXXXX 114124660 AG2XXX 114124661 AG3XXX 114124662 VJXXXX 114124663 VKXXXX 114124664 VLXXXX 114124665 VOXXXX 114124666 VPXXXX 114124667 WBXXXX 114124668 WCXXXX 114124669 WDXXXX 114124670 WFXXXX 114124671 WHXXXX 114124672 WMXXXX 114124673 XCXXXX 114124674 XDXXXX 114124675 XFXXXX 114124676 XIXXXX 114124677 YBXXXX 114124678 YEXXXX 114146086 test 114146087 ANTIMALARIAL 114146088 Derivatives 114146089 COLORIMETRIC 114146090 Artemesin 114146091 CDC Docket Import 114146092 CDC Docket Import CDC Prosecuting 114146093 CGH-DPDM TAB-2718 114096897 Entangling/Entrapping Synthetic Setae for Control of Insects and Other Pests CDC Consumer Products, Diagnostics, Infectious Disease, Licensing, Medical Devices, Non-Medical Devices, Occupational Safety and Health, Rare/Neglected Diseases, Research Materials, Therapeutics Consumer Products Diagnostics Infectious Disease Licensing Medical Devices Non-Medical Devices Occupational Safety and Health Rare/Neglected Diseases Research Materials Therapeutics Robert Wirtz In nature, some beetle larvae possess specialized barbed hastate setae that serve as an entanglement defense mechanism and incapacitate other insects. CDC researchers have developed synthetic setae for control and entrapment of insects and other pests. While smaller synthetic setae can trap mosquitoes and small insects, larger “macro” setae can be used for entrapment of bats, rodents, etc. Once used, the setae can be "reset" by a vigorous shaking of the fabric. This solution to pest control would be long-lasting and non-toxic, with the additional benefit of avoiding the evolutionary selection of pesticide resistant organisms. <ul> <li>Fine entanglement setae can be used anywhere insects congregate, including mosquito bed netting, resting boxes, curtains, or wall linings</li> <li>Mosquitoes and other pests trapped in the setae will quickly desiccate</li> <li>Easy reuse of setae by shaking</li> <li>Long-lasting, non-toxic (no insecticide) alternative to insect control</li> </ul> <ul> <li>Insect and pest control agents</li> <li>Population sampling and monitoring</li> </ul> 2022-03-08 2025-05-09 2025-05-09 2014-01-16 AE2BXX, AE2XXX, AEXXXX, AFXXXX, AXXXXX, CDC Docket Import, CDC Docket Import CDC Prosecuting, CGH-DPDM, CONTROL, DB2XXX, DB4XXX, DBXXXX, DEVICE, Devices, DEXXXX, DXXXXX, Entangling, Entrapment, insect, Insects, Mosquito, Mosquitoes, Net, Pest, Pests, population sampling, PXXXXX, Setae, TRAP, UBXXXX, UXXXXX, Vector-borne, Vector-borne diseases, VJXXXX, VKXXXX, VLXXXX, VOXXXX, WCXXXX, WDXXXX, WFXXXX, WIXXXX, WMXXXX, XDXXXX, XIXXXX, YFXXXX, Zoo False True Prototype True 52406769 Prototype 52406769 NIHTT 37470483 Website Abstract E-223-2013-0 E-166-2013-0 114108388 Wirtz, Robert CDC - DIR CDC Wirtz, Robert (CDC) 1 114108388 Wirtz, Robert CDC - DIR CDC Wirtz, Robert (CDC) 1 114102031 Entangling Setae For Control Of Insects And Other Pests E-175-2013-0 Closed Centers for Disease Control and Prevention (CDC) 83724572 Tung, Peter peter.tung@nih.gov
United States of America DIR peter.tung@nih.gov?subject=Web Inquiry on [TAB-2718] Entangling/Entrapping Synthetic Setae for Control of Insects and Other Pests&body=Please send me information about technology [TAB-2718] Entangling/Entrapping Synthetic Setae for Control of Insects and Other Pests. Tung, Peter<br><a href="mailto:peter.tung@nih.gov?subject=Web Inquiry on [TAB-2718] Entangling/Entrapping Synthetic Setae for Control of Insects and Other Pests&body=Please send me information about technology [TAB-2718] Entangling/Entrapping Synthetic Setae for Control of Insects and Other Pests.">peter.tung@nih.gov</a><br> 114167471 E-175-2013-0 E-175-2013-0-US-01 Entangling Setae For Control Of Insects And Other Pests PRV US 61/772,790 Abandoned US <br />Provisional (PRV) 61/772,790<br />Filed on 2013-03-05<br />Status: Abandoned 114167719 E-175-2013-0 E-175-2013-0-PCT-02 Entangling Hastate Setae For Pest Control PCT Patent Cooperation Treaty PCT/US2014/020541 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2014/020541<br />Filed on 2014-03-05<br />Status: Expired 114168201 E-175-2013-0 E-175-2013-0-US-03 Entangling Setae For Control Of Insects And Other Pests National Stage US 14/772,973 Abandoned US <br />National Stage 14/772,973<br />Filed on 2015-09-04<br />Status: Abandoned 114124383 PXXXXX 114124384 AXXXXX 114124385 AFXXXX 114124386 AEXXXX 114124387 AE2XXX 114124388 AE2BXX 114124389 DXXXXX 114124390 UXXXXX 114124391 UBXXXX 114124392 DEXXXX 114124393 DB2XXX 114124394 DB4XXX 114124395 DBXXXX 114124396 VJXXXX 114124397 VKXXXX 114124398 VLXXXX 114124399 VOXXXX 114124400 WCXXXX 114124401 WDXXXX 114124402 WFXXXX 114124403 WIXXXX 114124404 WMXXXX 114124405 XDXXXX 114124406 XIXXXX 114124407 YFXXXX 114145944 Entangling 114145945 Setae 114145946 CONTROL 114145947 Insects 114145948 Pests 114145949 CDC Docket Import 114145950 CDC Docket Import CDC Prosecuting 114145951 CGH-DPDM 114145952 Mosquito 114145953 Mosquitoes 114145954 Pest 114145955 Net 114145956 TRAP 114145957 Entrapment 114145958 insect 114145959 population sampling 114145960 DEVICE 114145961 Devices 114145962 Vector-borne diseases 114145963 Vector-borne 114145964 Zoo TAB-3819 114097666 Novel Inactivated Zika Vaccine Candidate Based on Purified Wild-type Zika Virus — for Zika Vaccine and Diagnostic Assay Development CDC Infectious Disease Infectious Disease Windy Baldwin, Holli Giebler, Claire Kinney, Jill Livengood Zika virus (ZIKV) spreads to people primarily through bite by infected Aedes mosquitoes. ZIKV infection during pregnancy can cause stillbirths or affect the fetus by causing serious birth defects, such as microcephaly and other brain defects. Although uncommon, adults with ZIKV can also develop Guillain-Barre syndrome and other neurological disorders. According to the World Health Organization’s July 2019 report, a total of 87 countries and territories have had evidence of mosquito-borne transmission of ZIKV. <br /><br /> While Zika virus poses a substantial public health threat, no FDA-approved vaccine or treatment currently exists, and the only preventive measures for Zika virus involve mosquito population control or repellents. CDC and a partner co-developed an inactivated Zika virus vaccine candidate from a purified wild-type Zika virus isolate. CDC’s multiple plaque purification steps, genomic sequencing, and virus growth/kinetic analysis procedures enabled a more uniform, well-characterized, and clean virus stock without potential contaminants that were present in the original human virus isolate. Researchers used formalin and processes to ensure full virus inactivation, while retaining optimal viral particle structure and antigenicity. Studies showed that a single purified inactivated Zika vaccine (PIZV) candidate dose provided protection against ZIKV challenge in mice and rhesus macaques. In phase I clinical trials of healthy human volunteers not previously exposed to flaviviruses, intramuscular injections of the PIZV vaccine candidate were immunogenic, safe, and well tolerated up to 52 weeks of follow-up. Zika virus protection in humans was highest after two doses were administered. Biomedical Advanced Research and Development Authority (BARDA) funding supported this effort. Additional studies to optimize dosing schedules are ongoing. <ul> <li>Safe, immunogenic, and effective at preventing Zika virus infection in multiple animal models (mice and rhesus macaques) and human Phase I trials, warranting continued development.</br> o A single purified inactivated Zika vaccine candidate dose provided protection against ZIKV challenge in mice and rhesus macaques.</br> o A human phase I trial supported by federal funding was successful, showing that the vaccine candidate was protective against Zika virus, safe, and well-tolerated up to 52 weeks of follow-up. Protection was determined by measuring the presence or absence of neutralizing antibodies for ZIKV in the participating groups. Two dose administrations provided optimal protection. </li> <li>This technology enabled a more uniform, well-characterized, and clean virus stock without other potential contaminants that were present in the original human virus isolate.</li> <li>PIZV vaccines and/or immunogenic compounds may also be administered by intranasal, oral, intravenous, subcutaneous, or other routes.</li> </ul> <ul> <li>Inactivated Zika vaccine candidate development</li> <li>Vaccine production and efficacy testing</li> <li>Diagnostic assay development for Zika virus</li> <li>Other research purposes</li> </ul> The CDC Technology Transfer Office (TTO) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize: - Novel Inactivated Zika Vaccine Candidate Based on Purified Wild-type Zika Virus — for Zika Vaccine and Diagnostic Assay Development.For collaboration opportunities, please contact CDC TTO at <a href=mailto:tto@cdc.gov>tto@cdc.gov</a> or 1-404-639-1330. 2022-10-17 2025-05-09 2025-05-09 2022-10-17 Compositions, Immunogenic, Methods, SAME, vaccines, YBXXXX, YCXXXX, YDXXXX, YXXXXX, Zika False True True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract E-177-2016-0 E-178-2016-0 E-118-2016-0 114172974 Baldwin, WR et al. https://www.ncbi.nlm.nih.gov/pubmed/30405178 <a href="https://www.ncbi.nlm.nih.gov/pubmed/30405178">Baldwin, WR et al.</a> 114172975 Young, G et al. https://www.ncbi.nlm.nih.gov/pubmed/32103097 <a href="https://www.ncbi.nlm.nih.gov/pubmed/32103097">Young, G et al.</a> 114172976 Han, HH et al. https://www.ncbi.nlm.nih.gov/pubmed/32103097 <a href="https://www.ncbi.nlm.nih.gov/pubmed/32103097">Han, HH et al.</a> 114172977 Safety, Immunogenicity, and Dose Ranging Study of Inactivated Zika Virus Vaccine in Healthy Participants. ClinicalTrials.gov Identifier: NCT03343626. https://clinicaltrials.gov/ct2/show/results/NCT03343626 <a href="https://clinicaltrials.gov/ct2/show/results/NCT03343626">Safety, Immunogenicity, and Dose Ranging Study of Inactivated Zika Virus Vaccine in Healthy Participants. ClinicalTrials.gov Identifier: NCT03343626.</a> 114172978 ASTMH 66th annual meeting October 28, 2017: poster presentation “Development, characterization, and pre-clinical immunogenicity and efficacy of a purified, inactivated Zika virus vaccine (PIZV) candidate” ASTMH 66th annual meeting October 28, 2017: poster presentation “Development, characterization, and pre-clinical immunogenicity and efficacy of a purified, inactivated Zika virus vaccine (PIZV) candidate” 114111644 Giebler, Holli Takeda Vaccines, Inc. Giebler, Holli 0 114111645 Baldwin, Windy Takeda Vaccines, Inc. Baldwin, Windy 0 114111646 Kinney, Claire CDC - DIR CDC Kinney, Claire (CDC) 0 114111643 Livengood, Jill Takeda Vaccines, Inc. Livengood, Jill 1 114111643 Livengood, Jill Takeda Vaccines, Inc. Livengood, Jill 1 114111644 Giebler, Holli Takeda Vaccines, Inc. Giebler, Holli 0 114111645 Baldwin, Windy Takeda Vaccines, Inc. Baldwin, Windy 0 114111646 Kinney, Claire CDC - DIR CDC Kinney, Claire (CDC) 0 114102916 ZIKA VACCINES AND IMMUNOGENIC COMPOSITIONS, AND METHODS OF USING THE SAMe E-076-2018-0 Filing authorized Centers for Disease Control and Prevention (CDC), Takeda Vaccines, Inc. 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-3819] Novel Inactivated Zika Vaccine Candidate Based on Purified Wild-type Zika Virus — for Zika Vaccine and Diagnostic Assay Development&body=Please send me information about technology [TAB-3819] Novel Inactivated Zika Vaccine Candidate Based on Purified Wild-type Zika Virus — for Zika Vaccine and Diagnostic Assay Development. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-3819] Novel Inactivated Zika Vaccine Candidate Based on Purified Wild-type Zika Virus — for Zika Vaccine and Diagnostic Assay Development&body=Please send me information about technology [TAB-3819] Novel Inactivated Zika Vaccine Candidate Based on Purified Wild-type Zika Virus — for Zika Vaccine and Diagnostic Assay Development.">benjamin.hurley@nih.gov</a><br> 114169663 E-076-2018-0 E-076-2018-0-US-01 ZIKA VACCINES AND IMMUNOGENIC COMPOSITIONS, AND METHODS OF USING THE SAME PRV US 62/581,500 Abandoned US <br />Provisional (PRV) 62/581,500<br />Filed on 2017-11-03<br />Status: Abandoned 114129723 YXXXXX 114129724 YBXXXX 114129725 YCXXXX 114129726 YDXXXX 114155671 Zika 114155672 vaccines 114155673 Immunogenic 114155674 Compositions 114155675 Methods 114155676 SAME TAB-2664 114096848 T24 Antigen for Diagnosing or Treating Taenia solium Cysticercosis CDC Diagnostics, Infectious Disease, Licensing, Rare/Neglected Diseases, Therapeutics, Vaccines Diagnostics Infectious Disease Licensing Rare/Neglected Diseases Therapeutics Vaccines Kathy Hancock, Sowmya Pattabhi, Victor Tsang, Fatima Williams, Melinda Yushak In order to develop a simple detection assay for field use, CDC researchers cloned and sequenced the <em>Taenia solium</em> T24 diagnostic protein. The T24 sequences can be used to detect and diagnose <em>T. solium</em> infection or can be formulated into a pharmaceutical composition. <em>T. solium</em> is a species of tapeworm. Intestinal infection with <em>T. solium</em> is referred to as taeniasis. Many taeniasis infections are asymptomatic but may be characterized by insomnia, anorexia, abdominal pain and weight loss. Cysticercosis infection, which can be fatal, may develop if <em>T. solium</em> larvae migrate out of the intestine and form cysticerci in various body tissues. This technology may be used to develop a diagnostic, vaccine, or therapeutic for infection related to <em>T. solium</em>. <ul> <li>Rapid, accurate, sensitive, and safe compared to current radiologic and biopsy diagnostic methods</li> <li>Easy-to-use diagnostic kit that doesn't require abnormal temperatures or specialized equipment</li> <li>Can be developed for serologic and/or nucleic acid diagnostics</li> <li>Cost-effective; useful for developing countries</li> </ul> <ul> <li>Vaccine or therapeutic for taeniasis or cysticercosis resulting from T. solium infection</li> <li>Diagnosis of T. solium infection</li> <li>Zoonotic disease research and surveillance</li> <li>Public health monitoring programs</li> <li>Livestock health and food-source monitoring</li> </ul> 2022-03-08 2025-05-09 2025-05-09 2013-10-23 AFXXXX, ANTIGEN, CDC Docket Import, CDC Docket Import CDC Prosecuting, CGH-DPDM, Cysticercosis, DA2XXX, DAXXXX, DB2XXX, DBXXXX, DC2XXX, DCXXXX, Immunodiagnosis, SOLIUM, T24, TAENIA, UBXXXX, UXXXXX False True <ul> <li>Early-stage</li> <li>In vitro data available</li> </ul> True NIHTT 37470483 Website Abstract E-247-2013-0 114108201 Williams, Fatima CDC - DIR CDC Williams, Fatima (CDC) 0 114108202 Yushak, Melinda CDC - DIR CDC Yushak, Melinda (CDC) 0 114108203 Pattabhi, Sowmya CDC - DIR CDC Pattabhi, Sowmya (CDC) 0 114108204 Tsang, Victor CDC - DIR CDC Tsang, Victor (CDC) 0 114108200 Hancock, Kathy CDC - DIR CDC Hancock, Kathy (CDC) 1 114108200 Hancock, Kathy CDC - DIR CDC Hancock, Kathy (CDC) 1 114108201 Williams, Fatima CDC - DIR CDC Williams, Fatima (CDC) 0 114108202 Yushak, Melinda CDC - DIR CDC Yushak, Melinda (CDC) 0 114108203 Pattabhi, Sowmya CDC - DIR CDC Pattabhi, Sowmya (CDC) 0 114108204 Tsang, Victor CDC - DIR CDC Tsang, Victor (CDC) 0 114101975 T24 Antigen For Immunodiagnosis Of Taenia Solium Cysticercosis E-237-2013-0 Closed Centers for Disease Control and Prevention (CDC) 83724572 Tung, Peter peter.tung@nih.gov
United States of America DIR peter.tung@nih.gov?subject=Web Inquiry on [TAB-2664] T24 Antigen for Diagnosing or Treating Taenia solium Cysticercosis&body=Please send me information about technology [TAB-2664] T24 Antigen for Diagnosing or Treating Taenia solium Cysticercosis. Tung, Peter<br><a href="mailto:peter.tung@nih.gov?subject=Web Inquiry on [TAB-2664] T24 Antigen for Diagnosing or Treating Taenia solium Cysticercosis&body=Please send me information about technology [TAB-2664] T24 Antigen for Diagnosing or Treating Taenia solium Cysticercosis.">peter.tung@nih.gov</a><br> 114167332 E-237-2013-0 E-237-2013-0-PCT-02 T24 Antigen For Immunodiagnosis Of Taenia Solium Cysticercosis PCT Patent Cooperation Treaty PCT/US2004/015041 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2004/015041<br />Filed on 2004-05-13<br />Status: Expired 114167333 E-237-2013-0 E-237-2013-0-US-01 T24 Antigen For Immunodiagnosis Of Taenia Solium Cysticercosis PRV US 60/471,950 Abandoned US <br />Provisional (PRV) 60/471,950<br />Filed on 2003-05-19<br />Status: Abandoned 114167334 E-237-2013-0 E-237-2013-0-US-08 T24 Antigen For Immunodiagnosis Of Taenia Solium Cysticercosis National Stage US 7,547,762 10/557,265 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7547762 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7547762">7,547,762</a><br />Filed on 2005-11-18<br />Status: Abandoned 114167335 E-237-2013-0 E-237-2013-0-US-09 T24 Antigen For Immunodiagnosis Of Taenia Solium Cysticercosis DIV US 7,972,606 12/431,928 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7972606 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7972606">7,972,606</a><br />Filed on 2009-04-29<br />Status: Abandoned 114123835 DAXXXX 114123836 DA2XXX 114123837 DBXXXX 114123838 DB2XXX 114123839 DCXXXX 114123840 DC2XXX 114123841 UXXXXX 114123842 UBXXXX 114123843 AFXXXX 114145236 T24 114145237 ANTIGEN 114145238 Immunodiagnosis 114145239 TAENIA 114145240 SOLIUM 114145241 Cysticercosis 114145242 CDC Docket Import 114145243 CDC Docket Import CDC Prosecuting 114145244 CGH-DPDM TAB-5047 162132627 A Broadly Protective Human Antibody for GI Genogroup Noroviruses NIAID Antibodies, Collaboration, Collaboration Sought, Diagnostics, Gastroenterology, Infectious Disease, Licensing, Therapeutics, Vaccines Antibodies Collaboration Collaboration Sought Diagnostics Gastroenterology Infectious Disease Licensing Therapeutics Vaccines Peter Kwong, Adam Olia, Inga Rimkute, Mario Roederer, Raffaello Verardi <p>Norovirus is a leading cause of vomiting, diarrhea, and foodborne illness worldwide, with 700 million cases and 200,000 deaths occurring each year. Despite decades of work in the field, there are no preventive or therapeutic strategies specifically approved for even the most prevalent forms of human norovirus (i.e., GI, GII genogroups), which are highly contagious and carry an increased risk of severe complications in children, older adults, and those with immunocompromising conditions.&nbsp;</p> <p>Researchers at the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases (NIAID) have isolated the first broadly reactive monoclonal antibody against GI genogroup noroviruses (mAbs16E10) using samples from a human blood donor. Results of in vitro and in vivo analyses further supported the antibody&rsquo;s broad binding and blocking specificity to the entire GI norovirus genogroup, neutralization of the GI.1 type, and abrogation of infection in a non-human primate challenge. These complementary findings highlight the technology as a promising candidate for clinical applications, including prophylaxis for at-risk populations, diagnostics, and the development of candidate vaccines based on the newly discovered epitope.</p> <p>This technology is available for licensing for commercial development in accordance with 35 U.S.C. &sect; 209 and 37 CFR part 404.<br /> &nbsp;</p> <ul> <li>First broadly reactive monoclonal antibody against GI genogroup</li> <li>Exceptionally large binding epitope with high binding affinity</li> <li>Promising preliminary results in non-human primates</li> </ul> <ul> <li>Immunotherapy for immunocompromised populations</li> <li>Prophylactic treatment for at-risk populations</li> <li>Development of novel diagnostic, detection, and isolation methods</li> <li>Development of vaccine candidates that effectively induce broadly neutralizing antibodies with the potential to intervene against multiple noroviruses within the GI genogroup</li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. For collaboration opportunities, please contact Brian Bailey at 240-669-5128 or brian.bailey@nih.gov, and reference E-025-2024. 2025-04-30 2025-05-08 2025-05-08 2025-05-09 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 162133178 Rimkute I, et al. A broadly protective human antibody for GI genogroup noroviruses. Nat Microbiol. 2025. https://doi.org/10.1038/s41564-025-01952-6 <a href="https://doi.org/10.1038/s41564-025-01952-6">Rimkute I, et al. A broadly protective human antibody for GI genogroup noroviruses. Nat Microbiol. 2025.</a> 162132862 Roederer, Mario NIAID - VRC NIAID Roederer, Mario (NIAID) 1 162132961 Rimkute, Inga NIAID - VRC NIAID Rimkute, Inga (NIAID) 2 162132987 Kwong, Peter Columbia University NIAID Kwong, Peter (NIAID) 3 162132991 Olia, Adam NIAID - VRC NIAID Olia, Adam (NIAID) 4 162132995 Verardi, Raffaello NIAID - VRC NIAID Verardi, Raffaello (NIAID) 5 162132862 Roederer, Mario NIAID - VRC NIAID Roederer, Mario (NIAID) 1 162132961 Rimkute, Inga NIAID - VRC NIAID Rimkute, Inga (NIAID) 2 162132987 Kwong, Peter Columbia University NIAID Kwong, Peter (NIAID) 3 162132991 Olia, Adam NIAID - VRC NIAID Olia, Adam (NIAID) 4 162132995 Verardi, Raffaello NIAID - VRC NIAID Verardi, Raffaello (NIAID) 5 162132630 Pan-GI norovirus monoclonal antibody 16E10 and its use E-025-2024-0 Filing authorized NIAID - VRC 83682222 Bailey, Brian bbailey@mail.nih.gov
United States of America TTIPO bbailey@mail.nih.gov?subject=Web Inquiry on [TAB-5047] A Broadly Protective Human Antibody for GI Genogroup Noroviruses&body=Please send me information about technology [TAB-5047] A Broadly Protective Human Antibody for GI Genogroup Noroviruses. Bailey, Brian<br><a href="mailto:bbailey@mail.nih.gov?subject=Web Inquiry on [TAB-5047] A Broadly Protective Human Antibody for GI Genogroup Noroviruses&body=Please send me information about technology [TAB-5047] A Broadly Protective Human Antibody for GI Genogroup Noroviruses.">bbailey@mail.nih.gov</a><br> 162132635 E-025-2024-0 E-025-2024-0-US-01 Pan-GI norovirus monoclonal antibody 16E10 and its use PRV US 63/653,691 Expired US <br />Provisional (PRV) 63/653,691<br />Filed on 2024-05-30<br />Status: Expired 162132790 E-025-2024-0 E-025-2024-0-PC-01 PAN-GI NOROVIRUS MONOCLONAL ANTIBODY AND ITS USE PCT Patent Cooperation Treaty PCT/US2025/031764 Pending Patent Cooperation Treaty <br />(PCT) PCT/US2025/031764<br />Filed on 2025-05-30<br />Status: Pending TAB-1288 114095614 A Nurr1-Knockout Mouse Model for Parkinson's Disease and Stem Cell Differentiation NIDDK Animal Models, Licensing, Materials Available Animal Models Licensing Materials Available Vera Nikodem The researchers have generated Nurr1-knockout mice via genomic locus inactivation using homologous recombination.<br /><br /> Transcription factor Nurr1 is an obligatory factor for neurotransmitter dopamine biosynthesis in ventral midbrain. From a neurological and clinical perspective, it suggests an entirely new mechanism for dopamine depletion in a region where dopamine is known to be involved in Parkinson's disease. Activation of Nurr1 may be therapeutically useful for Parkinson's disease patients; therefore, the mice would be useful in Parkinson's disease research.<br /><br /> Additionally, Nurr1 has been shown to be critical for development of midbrain dopaminergic neurons, and thus may contribute to stem cell-based therapies for neurological disorders. Nurr1 is also important for osteoblast differentiation, suggesting a general role in stem cell differentiation and growth. <ul> <li>Research and drug testing for Parkinson's disease and other neurological disorders</li> <li>Stem cell research relating to neurological and other disorders and bone formation</li> </ul> HHS Reference Nos. E-024-1999/0 and E-172-2006/0 -- Research Material. Patent protection is not being pursued for this technology. This technology is available under a Biological Materials License. 2022-03-08 2025-05-07 2025-05-07 2006-09-01 AC5XXX, ACXXXX, Affected, AS..., AXXXXX, BAXXXX, BIOSYNTHESIS, DIFFERENTIATION, Disease, Dopamine, DOPAMINERGIC, ESSENTIAL, factor, Midbrain, Neurons, NEUROTRANSMITTER, Nurr1, Obligatory, Parkinson disease 2, Parkinson disease 3, Parkinson disease 9, Parkinson disease, juvenile, autosomal recessive, Parkinsons, Region, TERMINAL, transcription, VENTRAL False True True NIHTT 37470483 Website Abstract 114170113 Lee MK, Choi H, Gil M, Nikodem VM. Regulation of osteoblast differentiation by Nurr1 in MC3T3-E1 cell line and mouse calvarial osteoblasts. J Cell Biochem. 2006 Oct 15;99(3):986-994. http://www.ncbi.nlm.nih.gov/pubmed/16741951 <a href="http://www.ncbi.nlm.nih.gov/pubmed/16741951">Lee MK, Choi H, Gil M, Nikodem VM. Regulation of osteoblast differentiation by Nurr1 in MC3T3-E1 cell line and mouse calvarial osteoblasts. J Cell Biochem. 2006 Oct 15;99(3):986-994.</a> 114170114 Jankovic J, Chen S, Le WD. The role of Nurr1 in the development of dopaminergic neurons and Parkinson's disease. Prog Neurobiol. 2005 Sep-Oct, 77(1-2):128-138. http://www.ncbi.nlm.nih.gov/pubmed/16243425 <a href="http://www.ncbi.nlm.nih.gov/pubmed/16243425">Jankovic J, Chen S, Le WD. The role of Nurr1 in the development of dopaminergic neurons and Parkinson's disease. Prog Neurobiol. 2005 Sep-Oct, 77(1-2):128-138.</a> 114105359 Nikodem, Vera Nikodem, Vera 0 114105359 Nikodem, Vera Nikodem, Vera 0 114101457 Transcription Factor Nurr1 Is An Obligatory Factor For Neurotransmitter Dopamine Biosynthesis Only In Ventral Midbrain As... E-024-1999-0 Research Material National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 114101458 Nurr1 Transcription Factor, Is Essential For Terminal Differentiation Of Dopaminergic Neurons In Ventral Midbrain The Region Affected By Parkinsons Disease E-172-2006-0 Research Material National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83739550 Shastri, Mythreyi shastrim@mail.nih.gov
United States of America Technology Advancement Office shastrim@mail.nih.gov?subject=Web Inquiry on [TAB-1288] A Nurr1-Knockout Mouse Model for Parkinson's Disease and Stem Cell Differentiation&body=Please send me information about technology [TAB-1288] A Nurr1-Knockout Mouse Model for Parkinson's Disease and Stem Cell Differentiation. Shastri, Mythreyi<br><a href="mailto:shastrim@mail.nih.gov?subject=Web Inquiry on [TAB-1288] A Nurr1-Knockout Mouse Model for Parkinson's Disease and Stem Cell Differentiation&body=Please send me information about technology [TAB-1288] A Nurr1-Knockout Mouse Model for Parkinson's Disease and Stem Cell Differentiation.">shastrim@mail.nih.gov</a><br> 114116837 AC5XXX 114116838 ACXXXX 114116839 AXXXXX 114121341 BAXXXX 114140403 transcription 114140404 factor 114140405 Nurr1 114140406 Obligatory 114140407 NEUROTRANSMITTER 114140408 Dopamine 114140409 BIOSYNTHESIS 114140410 VENTRAL 114140411 Midbrain 114140412 AS... 114140413 ESSENTIAL 114140414 TERMINAL 114140415 DIFFERENTIATION 114140416 Neurons 114140417 Region 114140418 Affected 114140419 Parkinsons 114140420 Disease 114140421 DOPAMINERGIC 114156085 Parkinson disease, juvenile, autosomal recessive 114156086 Parkinson disease 9 114156087 Parkinson disease 3 114158122 Parkinson disease 2 TAB-1061 114095391 Generation of Smad3-null Mice and Smad4-conditional Mice NIDDK Animal Models, Collaboration, Diagnostics, Licensing, Research Materials, Therapeutics Animal Models Collaboration Diagnostics Licensing Research Materials Therapeutics Chuxia Deng SMADs are a novel set of mammalian proteins that act downstream of TGF-beta family ligands. These proteins can be categorized into three distinct functional sets, receptor-activated SMADs (SMADs 1,2,3,5, and 8), the common mediator SMAD (SMAD 4), and inhibitory SMADs (SMADs 6 and 7). SMAD proteins are thought to play a role in vertebrate development and tumorigenesis. <br><br> One of the research tools our NIH inventors have prepared is the Smad3-null mice model, created by disrupting exon 8 on the <i>Smad3</i> gene. Symptomatic mice exhibit leukocytosis, with massive inflammation and pyogenous abscess formation adjacent to mucosal surfaces. Smad3 plays an important role in mediating TGF-beta signals in T lymphocytes and in neutrophils, and demonstrate that Smad3 deficiency results in immune dysregulation and susceptibility to opportunistic infection, ultimately leading to the lethality of the mice between 1 and 8 months. TGF-beta signals also play a role in cancer formation in multiple organs and tissues. Smad3-null mice could be used to clone downstream target genes for TGF-beta signals, which may be used in gene therapy and chemoprevention studies. <br><br> Smad4-null mice die around embryonic day 6.5, so the inventors prepared the SMAD4-conditional mice model, created by a <i>Smad4</i> conditional knockout allele at exon 8 using Cre-mediated recombination. PCR analysis determined Cre-mediated recombination in the pancreas but not in a number of other organs, indicating that the <i>Smad4</i> conditional allele can be recombined to delete exon 8 in a tissue-specific fashion. This knockout mouse could be used to test the function of TGF-beta/Smad4 signals at all stages of mouse development. Interestingly, mutation of human <i>Smad4</i> has been found in approximately half of all pancreatic cancers, 30% of colon cancers, and about 10% in other cancers. The Smad4-conditional mice could be used to study pathways that are involved in formation of these tumors or to clone downstream target genes that may be used in gene therapy and chemoprevention studies. Research Material – patent protection is not being pursued for this technology In addition to licensing, the technology is available for further development through collaborative research opportunities with the inventors. 2022-03-08 2025-05-07 2025-05-07 2005-01-01 3-@hydroxyacyl-coa dehydrogenase deficiency, BAXXXX, HAD deficiency, HIS deficiency, Histidinemia, IDXXXX, IXXXXX False True True NIHTT 37470483 Website Abstract 114170028 Yang X, et al. Generation of Smad4/Dpc4 conditional knockout mice. https://www.ncbi.nlm.nih.gov/pubmed/11857783 <a href="https://www.ncbi.nlm.nih.gov/pubmed/11857783">Yang X, et al. Generation of Smad4/Dpc4 conditional knockout mice.</a> 114170029 Yang X, et al. Targeted disruption of SMAD3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF-beta. https://www.ncbi.nlm.nih.gov/pubmed/10064594 <a href="https://www.ncbi.nlm.nih.gov/pubmed/10064594">Yang X, et al. Targeted disruption of SMAD3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF-beta.</a> 114105001 Deng, Chuxia NIDDK Deng, Chuxia (NIDDK) 0 114105001 Deng, Chuxia NIDDK Deng, Chuxia (NIDDK) 0 114100281 Generation Of Smad3-null Mice E-349-2003-0 Research Material National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 114100282 Generation Of Smad4-conditional Mice E-350-2003-0 Research Material National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83739550 Shastri, Mythreyi shastrim@mail.nih.gov
United States of America Technology Advancement Office shastrim@mail.nih.gov?subject=Web Inquiry on [TAB-1061] Generation of Smad3-null Mice and Smad4-conditional Mice&body=Please send me information about technology [TAB-1061] Generation of Smad3-null Mice and Smad4-conditional Mice. Shastri, Mythreyi<br><a href="mailto:shastrim@mail.nih.gov?subject=Web Inquiry on [TAB-1061] Generation of Smad3-null Mice and Smad4-conditional Mice&body=Please send me information about technology [TAB-1061] Generation of Smad3-null Mice and Smad4-conditional Mice.">shastrim@mail.nih.gov</a><br> 114115898 IDXXXX 114115899 IXXXXX 114121332 BAXXXX 114155855 3-@hydroxyacyl-coa dehydrogenase deficiency 114155856 Histidinemia 114158008 HAD deficiency 114158009 HIS deficiency TAB-2888 114097049 Autodock Vina Software Process for Efficient Large-Scale Cognate Ligand Screening NIDDK Collaboration, Computational models/software, Consumer Products, Research Materials, Software / Apps Collaboration Computational models/software Consumer Products Research Materials Software / Apps Elizabeth Geras-Raaka, Marvin Gershengorn, Umesh Padia The invention pertains to software processes, additions, and docking approaches to Autodock Vina that speeds the rate and efficiency of analyzing ligand interactions with a receptor by cognate ligands and rewards conformations in the scoring algorithm for residue interactions that are based on the biological data. The score is multiplied by a weighting factor to control the degree of ligand-residue interactions that are considered. This multiplier is then added to the docking score for confirmation. This new scoring mechanism is used to score each compound in each generation of the evolutionary genetic algorithm. This docking approach can be used to score and rank compounds in large-scale virtual screening applications. The software includes logic for converting SDF formatted to an Autodock Vina compatible format (containing approx. 25,000 compounds each) and submits the job to the portable batch system on the computing cluster to convert into PDBC files (a concatenated filed type). Modified Vina software stores the analyzed binding pocket in RAM that does not have to be recomputed upon every docking process. This increases the efficiency of the docking algorithm by several orders of magnitude. The software on the head node intelligently monitors memory usage, CPU usage and docking speed. Based on this information, the head node elastically controls the load on each node. <ul> <li>Speed</li> <li>Batch processing</li> <li>Efficient CPU processing</li> </ul> <ul> <li>Drug screening</li> <li>Ligand identification</li> </ul> The National Institutes of Diabetes and Digestive and Kidney Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize Cognate Ligand Identification. For collaboration opportunities, please contact Anna Amar at 301-451-2305 or <a href="mailto:aamar@mail.nih.gov">aamar@mail.nih.gov</a>. Software Tool - Patent protection is not being pursued for this technology. 2022-03-08 2025-05-07 2025-05-07 2014-11-05 AD3XXX, ADXXXX, Autodock, COGNATE, Cognate Ligand, Drug Screening, drug screening tool, LIGAND-BINDING, Vina, WIXXXX, WMXXXX, XJXXXX, YBXXXX False True In vitro data available True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114108908 Padia, Umesh National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Padia, Umesh (NIDDK) 0 114108909 Geras-Raaka, Elizabeth National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Geras-Raaka, Elizabeth 0 114108907 Gershengorn, Marvin National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Gershengorn, Marvin (NIDDK) 1 114108907 Gershengorn, Marvin National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Gershengorn, Marvin (NIDDK) 1 114108908 Padia, Umesh National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Padia, Umesh (NIDDK) 0 114108909 Geras-Raaka, Elizabeth National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Geras-Raaka, Elizabeth 0 162240076 A Novel Process For Efficient Large-Scale Virtual Screening With Quantitative Residue Interaction Scoring In Combination With Autodock Vina E-289-2014-0 Closed National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83739550 Shastri, Mythreyi shastrim@mail.nih.gov
United States of America Technology Advancement Office shastrim@mail.nih.gov?subject=Web Inquiry on [TAB-2888] Autodock Vina Software Process for Efficient Large-Scale Cognate Ligand Screening&body=Please send me information about technology [TAB-2888] Autodock Vina Software Process for Efficient Large-Scale Cognate Ligand Screening. Shastri, Mythreyi<br><a href="mailto:shastrim@mail.nih.gov?subject=Web Inquiry on [TAB-2888] Autodock Vina Software Process for Efficient Large-Scale Cognate Ligand Screening&body=Please send me information about technology [TAB-2888] Autodock Vina Software Process for Efficient Large-Scale Cognate Ligand Screening.">shastrim@mail.nih.gov</a><br> 114126662 ADXXXX 114126663 AD3XXX 114126664 WIXXXX 114126665 WMXXXX 114126666 XJXXXX 114126667 YBXXXX 114147907 Autodock 114147908 Vina 114147909 Drug Screening 114147910 drug screening tool 114147911 COGNATE 114147912 Cognate Ligand 114147913 LIGAND-BINDING TAB-2413 114096615 UTX LoxP Mouse Model for Oncology Research NIDDK Licensing, Oncology, Research Materials Licensing Oncology Research Materials Kai Ge UTX-flox. Conditional knockout mice for the histone demethylase UTX (Kdm6a) conditional knockout will help understand its role as a tumor suppressor. <br /><br /> Di- and tri-methylations on histone H3 lysine 27 (H3K27me2 and H3K27me3) are epigenetic marks for gene repression. UTX (ubiquitously transcribed X chromosome protein), also known as Kdm6a (lysine (K)-specific demethylase 6a) is a histone demethylase that specifically removes H3K27me2 and H3K27me3. UTX knockout mice are embryonic lethal, so we have generated UTX conditional knockout mice (UTX-flox) in which exon 24 is flanked with loxP sites. UTX has been found to be a tumor suppressor gene mutated in a wide variety of human cancers. The UTX-flox mice provide a valuable tool to study how UTX functions as a tumor suppressor and as an epigenetic regulator of gene expression. Mouse model for Oncology research. Research Tool — Patent protection is not being pursued for this technology. 2022-03-08 2025-05-07 2025-05-07 2012-04-19 CCXXXX, CXXXXX, LOXP, Mouse, UTX False True Pre-clinical True NIHTT 37470483 Website Abstract 114171557 Unpublished. Gene ID: 22289 Unpublished. Gene ID: 22289 114107516 Ge, Kai National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Ge, Kai (NIDDK) 1 114107516 Ge, Kai National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Ge, Kai (NIDDK) 1 114101715 UTX LoxP Mouse E-118-2012-0 Closed National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83739550 Shastri, Mythreyi shastrim@mail.nih.gov
United States of America Technology Advancement Office shastrim@mail.nih.gov?subject=Web Inquiry on [TAB-2413] UTX LoxP Mouse Model for Oncology Research&body=Please send me information about technology [TAB-2413] UTX LoxP Mouse Model for Oncology Research. Shastri, Mythreyi<br><a href="mailto:shastrim@mail.nih.gov?subject=Web Inquiry on [TAB-2413] UTX LoxP Mouse Model for Oncology Research&body=Please send me information about technology [TAB-2413] UTX LoxP Mouse Model for Oncology Research.">shastrim@mail.nih.gov</a><br> 114122703 CXXXXX 114122704 CCXXXX 114142868 UTX 114142869 LOXP 114142870 Mouse TAB-1781 114096008 Rapid and Sensitive Detection of Nucleic Acid Sequence Variations NIDDK Collaboration, Diagnostics, Licensing, Oncology, Research Materials, Therapeutics Collaboration Diagnostics Licensing Oncology Research Materials Therapeutics Kenji Adzuma, Kiyoshi Mizuuchi, Katsuhiko Yanagihara The ability to easily detect small mutations in nucleic acids, such as single base substitutions, can provide a powerful tool for use in cancer detection, perinatal screens for inherited diseases, and analysis of genetic polymorphisms such as genetic mapping or for identification purposes. Current approaches make use of the mismatch that occurs between complimentary strands of DNA when there is a genetic mutation, the electrophoretic mobility differences caused by small sequence changes, and chemicals or enzymes that can cleave heteroduplex sites. Some of these methods, however, prove to be too cumbersome, are unable to pinpoint mutations, only detect a subset of mutations, or involve the use of hazardous materials. <br><br> The current invention takes advantage of the ability of transposons, or mobile genetic elements, to move from one part of the genome to another by the cleavage and joining of their sequences into the target site; a reaction facilitated by a transposase enzyme. The phage Mu transposase is capable of inserting the right end sequence of the Mu transposon into any DNA sequence both <i>in vitro</i> and <i>in vivo</i>. The surprising discovery that the Mu transposase displays a strong preference for inserting Mu-end DNA into mismatched sites, the very sites which occur when DNA is mutated and paired with its complimentary strand that does not have the corresponding mutation, makes it a powerful tool for detecting variations in nucleic acid sequences. In this system, the transposition of Mu-end DNA at a site is used to indicate the presence of a nucleic acid mismatch or mutation at that site. The invention can be used with labeled Mu-end DNA to further facilitate the precise mapping of the mutations. This specificity allows Mu to detect even single base mutations amongst a large quantity of non-specific DNA. The Mu detection system is simple, rapid, and highly sensitive compared to current methods and can find a broad range of use in genetic research and the diagnosis of several diseases such as cystic fibrosis, spinal and bulbar muscular dystrophy, human fragile-X syndrome and Huntington’s disease. <ul> <li>Fast, simple screening for genetic mutations in several diseases such as cystic fibrosis, spinal and bulbar muscular dystrophy, human fragile-X syndrome, Huntington’s disease, detection of birth defects and paternity testing etc.</li> <li>Genetic mapping and identification.</li> </ul> The Section on Genetic Mechanisms, LMB, NIDDK is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize Mu transposition system as a tool for mutation detection and other genetic research/manipulation. Please contact Kiyoshi Mizuuchi at <a href="mailto:kmizu@helix.nih.gov">kmizu@helix.nih.gov</a> for more information. Available for licensing. 2022-03-08 2025-05-07 2025-05-07 2008-07-01 (4)r syndrome, AC6XXX, ACXXXX, AXXXXX, C syndrome, CA1AXX, CA1XXX, CAXXXX, Chromosome 4 ring syndrome, Chromosome 6 ring syndrome, Chromosome 7 ring syndrome, CXXXXX, Cystic fibrosis, Detection, DNA, Fragile X syndrome, G syndrome, Genetic, Huntington disease, Huntington disease; Huntington's disease, Hypertelorism with esophageal abnormality and hypospadias, IA6XXX, IAXXXX, Insertion, IXXXXX, Method, Mismatch-Targeted, Muscular dystrophy, Mutations, N syndrome, R(6) syndrome, R(7) syndrome, Syndrome X, Transposon, W syndrome, W syndrome; Syndrome W False True Early stage True NIHTT 37470483 Website Abstract 114170534 Yanagihara K and Mizuuchi K. Mismatch-targeted transposition of Mu: a new strategy to map genetic polymorphism. Proc Natl Acad Sci USA. 2002 Aug 20; 99(17):11317-11321. http://www.ncbi.nlm.nih.gov/pubmed/12177413?dopt <a href="http://www.ncbi.nlm.nih.gov/pubmed/12177413?dopt">Yanagihara K and Mizuuchi K. Mismatch-targeted transposition of Mu: a new strategy to map genetic polymorphism. Proc Natl Acad Sci USA. 2002 Aug 20; 99(17):11317-11321.</a> 114106191 Adzuma, Kenji National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Adzuma, Kenji (NIDDK) 0 114106395 Mizuuchi, Kiyoshi National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Mizuuchi, Kiyoshi (NIDDK) 0 114106193 Yanagihara, Katsuhiko National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Yanagihara, Katsuhiko 1 114106193 Yanagihara, Katsuhiko National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Yanagihara, Katsuhiko 1 114106191 Adzuma, Kenji National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Adzuma, Kenji (NIDDK) 0 114106395 Mizuuchi, Kiyoshi National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Mizuuchi, Kiyoshi (NIDDK) 0 114101007 A New Method For The Detection Of Genetic Mutations By DNA Mismatch-Targeted Insertion Of A DNA Transposon E-071-2003-0 National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83739550 Shastri, Mythreyi shastrim@mail.nih.gov
United States of America Technology Advancement Office shastrim@mail.nih.gov?subject=Web Inquiry on [TAB-1781] Rapid and Sensitive Detection of Nucleic Acid Sequence Variations&body=Please send me information about technology [TAB-1781] Rapid and Sensitive Detection of Nucleic Acid Sequence Variations. Shastri, Mythreyi<br><a href="mailto:shastrim@mail.nih.gov?subject=Web Inquiry on [TAB-1781] Rapid and Sensitive Detection of Nucleic Acid Sequence Variations&body=Please send me information about technology [TAB-1781] Rapid and Sensitive Detection of Nucleic Acid Sequence Variations.">shastrim@mail.nih.gov</a><br> 114162692 E-071-2003-0 E-071-2003-0-US-01 Detection of Nucleic Acid Sequence Variations Using Phage Mu Transposase PRV US 60/457,934 Abandoned US <br />Provisional (PRV) 60/457,934<br />Filed on 2003-03-28<br />Status: Abandoned 114164555 E-071-2003-0 E-071-2003-0-US-02 A New Method For The Detection Of Genetic Mutations By DNA Mismatch-Targeted Insertion Of A DNA Transposon ORD US 7,316,903 10/809,688 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7316903 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7316903">7,316,903</a><br />Filed on 2004-03-26<br />Status: Abandoned 114116019 IA6XXX 114118850 CA1AXX 114118851 AC6XXX 114119514 AXXXXX 114119515 ACXXXX 114119516 CXXXXX 114119517 CAXXXX 114119518 CA1XXX 114119519 IXXXXX 114119520 IAXXXX 114130828 Method 114130829 Detection 114130830 Genetic 114130831 Mutations 114130832 DNA 114130833 Mismatch-Targeted 114130834 Insertion 114130835 Transposon 114156570 Syndrome X 114156571 C syndrome 114156572 Muscular dystrophy 114156573 Chromosome 7 ring syndrome 114156574 Fragile X syndrome 114156575 W syndrome 114156576 Cystic fibrosis 114156577 Hypertelorism with esophageal abnormality and hypospadias 114156578 Huntington disease 114156579 N syndrome 114156580 Chromosome 6 ring syndrome 114156581 Chromosome 4 ring syndrome 114158368 R(7) syndrome 114158369 W syndrome; Syndrome W 114158370 G syndrome 114158371 Huntington disease; Huntington's disease 114158372 R(6) syndrome 114158373 (4)r syndrome TAB-1308 114095634 Methods for Rapid and Specific Fluorescent Staining of Biological Tissue for Laser Capture Microdissection NIDDK Licensing Licensing Lance Liotta, Hiroshi Murakami, Kenneth Spring, Robert Star Available for licensing and commercial development are methods for rapid and specific fluorescent staining of biological tissue samples that substantially preserve biological molecules such as mRNA. Also within the scope of the invention are methods for microdissecting tissue to obtain pure populations of cells or tissue structures based upon identifying and excising cells or tissue structures that are labeled with fluorescent specific binding agents. A laser capture microdissection (LCM) apparatus useful for identifying and isolating cells and tissue structures following rapid immunofluorescent staining is also disclosed. Other LCM devices are available for purchase from Arcturus Engineering. 2022-03-08 2025-05-07 2025-05-07 2006-03-01 AA2XXX, AA5XXX, AAXXXX, AXXXXX False True True NIHTT 37470483 Website Abstract 114105390 Star, Robert NIDDK Star, Robert (NIDDK) 0 114105391 Murakami, Hiroshi NIDDK Murakami, Hiroshi (NIDDK) 0 114105392 Liotta, Lance NCI Liotta, Lance (NCI) 0 114105393 Spring, Kenneth NHLBI Spring, Kenneth (NHLBI) 0 114105390 Star, Robert NIDDK Star, Robert (NIDDK) 0 114105391 Murakami, Hiroshi NIDDK Murakami, Hiroshi (NIDDK) 0 114105392 Liotta, Lance NCI Liotta, Lance (NCI) 0 114105393 Spring, Kenneth NHLBI Spring, Kenneth (NHLBI) 0 114100539 Rapid Fluorescence Labeling Of Tissue For Microdissection Using Fluorescent Specific Binding Agents E-133-2000-0 National Heart, Lung, and Blood Institute (NHLBI), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NCI 83739550 Shastri, Mythreyi shastrim@mail.nih.gov
United States of America Technology Advancement Office shastrim@mail.nih.gov?subject=Web Inquiry on [TAB-1308] Methods for Rapid and Specific Fluorescent Staining of Biological Tissue for Laser Capture Microdissection&body=Please send me information about technology [TAB-1308] Methods for Rapid and Specific Fluorescent Staining of Biological Tissue for Laser Capture Microdissection. Shastri, Mythreyi<br><a href="mailto:shastrim@mail.nih.gov?subject=Web Inquiry on [TAB-1308] Methods for Rapid and Specific Fluorescent Staining of Biological Tissue for Laser Capture Microdissection&body=Please send me information about technology [TAB-1308] Methods for Rapid and Specific Fluorescent Staining of Biological Tissue for Laser Capture Microdissection.">shastrim@mail.nih.gov</a><br> 114161150 E-133-2000-0 E-133-2000-0-US-03 Rapid Fluorescence Labeling Of Tissue For Microdissection Using Fluorescent Specific Binding Agents DIV US 10/903,324 Abandoned US <br />Divisional (DIV) 10/903,324<br />Filed on 2004-07-30<br />Status: Abandoned 114163285 E-133-2000-0 E-133-2000-0-US-02 Rapid Fluorescenct Labeling of Tissue for Microdissection Using Fluorescent Specific Binding Agents ORD US 6,790,636 09/881,446 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6790636 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6790636">6,790,636</a><br />Filed on 2001-06-13<br />Status: Abandoned 114165789 E-133-2000-0 E-133-2000-0-US-01 Rapid Fluorescence Labeling Of Tissue For Microdissection Using Fluorescent Specific Binding Agents PRV US 60/211,698 Abandoned US <br />Provisional (PRV) 60/211,698<br />Filed on 2000-06-14<br />Status: Abandoned 114116923 AA2XXX 114116924 AA5XXX 114116925 AAXXXX 114116926 AXXXXX TAB-1283 114095609 A Mouse with a Targeted Mutation in the Uncoupling Protein-3 (upc3) Gene NIDDK Animal Models, Licensing Animal Models Licensing Dawei Gong, Marc Reitman The NIH announces the development of a transgenic mouse with a targeted mutation in the ucp3 gene. The ucp3 gene is implicated I the function of regulating energy metabolism. This regulatory function is thought to be accomplished by changing metabolic efficiency (causing energy expended as heat rather than used for ADP/ATP conversion) and/or by participating in fat metabolism. The mutation should inactivate the ucp3 function and the mouse provided a testing vehicle for the above hypotheses. <br><br> If in fact ucp3 is involved in energy efficiency and/or fat metabolism, then variation in its sequence or level of expression may explain some of human obesity. If ucp3 is involved in fever generation, it would be of interest in testing inactivating drugs. <br><br> In summary, this mouse model provides a model for evaluating the role of ucp3 in obesity, energy efficiency, and selective use of energy sources (i.e. fat vs. carbohydrates), body temperature regulation, such as fever, or other forms of stimulated thermogenesis (e.g. by diet of dietary fat). For example, a drug candidate thought to act via ucp3 should have no effect in these mice. Research Tool -- patent protection is not being pursued for this technology 2022-03-08 2025-05-07 2025-05-07 2005-12-01 AC5XXX, ACXXXX, Animal Model, AXXXXX, BAXXXX, Gene, Mouse, MUTATION, Protein-3, Q fever, Targeted, UCP3, Uncoupling False True True NIHTT 37470483 Website Abstract 162240296 Reitman, Marc NIDDK Reitman, Marc (NIDDK) 1 162240408 Gong, Dawei University of Maryland, School of Medicine Gong, Dawei 2 162240296 Reitman, Marc NIDDK Reitman, Marc (NIDDK) 1 162240408 Gong, Dawei University of Maryland, School of Medicine Gong, Dawei 2 114101103 A Mouse with a Targeted Mutation in the Uncoupling Protein-3 (UCP3) Gene E-031-1999-0 Research Material National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83739550 Shastri, Mythreyi shastrim@mail.nih.gov
United States of America Technology Advancement Office shastrim@mail.nih.gov?subject=Web Inquiry on [TAB-1283] A Mouse with a Targeted Mutation in the Uncoupling Protein-3 (upc3) Gene&body=Please send me information about technology [TAB-1283] A Mouse with a Targeted Mutation in the Uncoupling Protein-3 (upc3) Gene. Shastri, Mythreyi<br><a href="mailto:shastrim@mail.nih.gov?subject=Web Inquiry on [TAB-1283] A Mouse with a Targeted Mutation in the Uncoupling Protein-3 (upc3) Gene&body=Please send me information about technology [TAB-1283] A Mouse with a Targeted Mutation in the Uncoupling Protein-3 (upc3) Gene.">shastrim@mail.nih.gov</a><br> 114116818 AC5XXX 114116819 ACXXXX 114116820 AXXXXX 114121340 BAXXXX 114134867 Animal Model 114134868 Mouse 114134869 Targeted 114134870 MUTATION 114134871 Uncoupling 114134872 Protein-3 114134873 UCP3 114134874 Gene 114156080 Q fever TAB-814 114095149 A Mouse Model for Systemic Inflammation in Glucocerebrosidase-Deficient Mice with Minimal Glucosylceramide Storage NIDDK Diagnostics, Licensing, Research Materials, Therapeutics Diagnostics Licensing Research Materials Therapeutics Richard Proia Gaucher disease, the most common lysosomal storage disease, is an inherited metabolic disorder in which harmful quantities of the lipid glucocerebroside accumulate in the spleen, liver, lungs, bone marrow and in rare cases in the brain, due to a deficiency of the enzyme glucocerebrosidase (Gba) that catalyses the first step in the biodegradation of glucocerebrosides. Type 1 Gaucher disease is the most common and is distinguished from the other forms of the disease, types 2 and 3, by the lack of neurologic involvement. The clinical features of Type 1 are heterogeneous, vary broadly in clinical severity and affect many organ systems. The major disease manifestations include enlarged spleen and liver, bone lesions, hematologic abnormalities and lung involvement. The disease has also been associated with a sustained inflammatory reaction. Gaucher disease is most prevalent in the Ashkenazi Jewish population with an incidence of approximately 1 in 450 persons while in the general public the incidence is 1 in 100,000. There are an estimated 30,000 Gaucher disease patients world-wide with approximately 3000 patients currently receiving enzyme replacement therapy which has been shown to be highly effective in treatment of the disease. The cost of therapy is approximately $100,000-$300,000 annually and is a life-long treatment, which makes the case for affordable new therapies urgent. <p>The etiology of the disease has been difficult to study due to the absence of viable mouse models for the disease, as a complete disruption of the glucocerebrosidase (Gba) gene results in rapid neonatal death. In an attempt to produce a viable model scientists at the NIDDK introduced a human Gaucher disease point mutation, L444P, into the mouse Gba gene in order to cause a partial enzyme deficiency (<i>J. Clin. Invest.</i> (2002) 109, 1215-1221; <i>Proc. Natl. Acad. Sci. USA</i> (1998) 95, 2503-2508).</p> <p>The mice exhibit a partial glucocerebrosidase deficiency (15-20% of normal activity), without bulk accumulation of glucosylceramide or the presence of Gaucher cells. The mice demonstrate other clinical features of Gaucher disease, including multisystem inflammation, B cell hyperproliferation, skin abnormalities, anemia and lymphadenopathy. These mice provide a useful model for studying certain aspects of Gaucher disease pathology and in evaluating new therapeutic treatments.</p> 2022-03-08 2025-05-07 2025-05-07 2003-12-01 3-@hydroxyacyl-coa dehydrogenase deficiency, Gaucher Disease, Glucocerebrosidase deficiency; Gaucher Disease, HAD deficiency, HIS deficiency, Histidinemia, IDXXXX, IXXXXX, metabolic disorder False True True NIHTT 37470483 Website Abstract 114104554 Proia, Richard NIDDK Proia, Richard (NIDDK) 0 114104554 Proia, Richard NIDDK Proia, Richard (NIDDK) 0 114099984 Mice Carrying The L444P Gaucher Disease Mutation (Gba-L444P Mice) E-256-2003-0 Research Material National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83739550 Shastri, Mythreyi shastrim@mail.nih.gov
United States of America Technology Advancement Office shastrim@mail.nih.gov?subject=Web Inquiry on [TAB-814] A Mouse Model for Systemic Inflammation in Glucocerebrosidase-Deficient Mice with Minimal Glucosylceramide Storage&body=Please send me information about technology [TAB-814] A Mouse Model for Systemic Inflammation in Glucocerebrosidase-Deficient Mice with Minimal Glucosylceramide Storage. Shastri, Mythreyi<br><a href="mailto:shastrim@mail.nih.gov?subject=Web Inquiry on [TAB-814] A Mouse Model for Systemic Inflammation in Glucocerebrosidase-Deficient Mice with Minimal Glucosylceramide Storage&body=Please send me information about technology [TAB-814] A Mouse Model for Systemic Inflammation in Glucocerebrosidase-Deficient Mice with Minimal Glucosylceramide Storage.">shastrim@mail.nih.gov</a><br> 114114798 IDXXXX 114114799 IXXXXX 114157715 3-@hydroxyacyl-coa dehydrogenase deficiency 114157716 Histidinemia 114157717 metabolic disorder 114157718 Gaucher Disease 114158969 HAD deficiency 114158970 HIS deficiency 114158971 Glucocerebrosidase deficiency; Gaucher Disease TAB-686 114095022 Fibroblast Growth Factor 3 (FGFR3) Receptor Knockin Mice NIDDK Licensing, Research Materials Licensing Research Materials Chuxia Deng Missense mutations in Fibroblast Growth Factor Receptor 3 (FGFR3) result in several human skeletal dysplasias, including the most common form of dwarfism, achondroplasia. <br><br> The NIH announces the generation of FGFR3 knockin mice, which have a Gly369Cys mutation, inserted into the mouse genome. Phenotypic analysis of the mice reveals that the FGF/FGFR3 signals affect both chondrogenesis and osteogenesis by regulating Stat proteins and cell-cycle inhibitors, and the activities of chondrocytes, osteoclasts, and osteoblasts during endochondral ossification. These mice provide a new animal model to study functions of FGF/FGFR3 signals in achondroplasia patients, which could lead to new drug discovery and therapeutic treatments. Research Tool – Patent protection is not being pursued for this technology. 2022-03-08 2025-05-07 2025-05-07 2003-02-01 Achondroplasia, Dwarfism, RXXXXX, Skeletal dysplasias False True True NIHTT 37470483 Website Abstract 114104339 Deng, Chuxia NIDDK Deng, Chuxia (NIDDK) 0 114104339 Deng, Chuxia NIDDK Deng, Chuxia (NIDDK) 0 114099835 Generation Of Fibroblast Growth Factor 3 (FGFR3) Receptor Knockin Mice E-060-2003-0 Research Material National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83739550 Shastri, Mythreyi shastrim@mail.nih.gov
United States of America Technology Advancement Office shastrim@mail.nih.gov?subject=Web Inquiry on [TAB-686] Fibroblast Growth Factor 3 (FGFR3) Receptor Knockin Mice&body=Please send me information about technology [TAB-686] Fibroblast Growth Factor 3 (FGFR3) Receptor Knockin Mice. Shastri, Mythreyi<br><a href="mailto:shastrim@mail.nih.gov?subject=Web Inquiry on [TAB-686] Fibroblast Growth Factor 3 (FGFR3) Receptor Knockin Mice&body=Please send me information about technology [TAB-686] Fibroblast Growth Factor 3 (FGFR3) Receptor Knockin Mice.">shastrim@mail.nih.gov</a><br> 114114306 RXXXXX 114157599 Skeletal dysplasias 114157600 Achondroplasia 114157601 Dwarfism TAB-478 114094816 Vitamin D Receptor Antagonists for Treating Breast Cancer NIDDK Licensing, Oncology, Therapeutics Licensing Oncology Therapeutics Julianna Barsony Vitamin D receptor (VDR) is a nuclear receptor that is activated by calcitriol, the active form of vitamin D. It is best known for regulating dietary calcium uptake necessary for bone growth, but it also affects cell proliferation and differentiation. Therefore, it was thought that treatment with calcitriol or its derivatives could be useful to treat the uncontrolled proliferation typical of cancer cells. However, this approach has been unsuccessful to date because it leads to toxic levels of calcium in the blood. <br><br> This invention relates to derivatives of calcitriol that can block cell growth without harmfully raising calcium levels. Specifically, these compounds act as antagonists of VDR blocking its ability to stimulate cell proliferation. This technology can be useful in treating breast cancer or other malignancies. <ul> <li>Potential drugs for treating breast cancer and possibly also prostate cancer, colorectal cancer, leukemia, melanoma, or glioma</li> <li>Prevention of cancer in high-risk population</li> <li>Research on vitamin D receptor functions and cancer</li> </ul> Available for licensing. 2022-03-08 2025-05-07 2025-05-07 2008-09-01 ANTAGONISTS, ANTICANCER, CB7XXX, CBXXXX, CXXXXX, D, EFFECTS, Glioma, Novel, RECEPTOR, Vitamin False True Pre-clinical data available True NIHTT 37470483 Website Abstract 114170612 J Barsony et al. Development of a biologically active fluorescent-labeled calcitriol and its use to study hormone binding to the vitamin D receptor. Anal Biochem. 1995 Jul 20;229(1):68-79. http://www.ncbi.nlm.nih.gov/pubmed/8533897?dopt <a href="http://www.ncbi.nlm.nih.gov/pubmed/8533897?dopt">J Barsony et al. Development of a biologically active fluorescent-labeled calcitriol and its use to study hormone binding to the vitamin D receptor. Anal Biochem. 1995 Jul 20;229(1):68-79.</a> 114103920 Barsony, Julianna National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Barsony, Julianna (NIDDK) 1 114103920 Barsony, Julianna National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Barsony, Julianna (NIDDK) 1 114099623 Anticancer Effects Of A Novel Vitamin D Receptor Antagonists E-213-2001-2 National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83739550 Shastri, Mythreyi shastrim@mail.nih.gov
United States of America Technology Advancement Office shastrim@mail.nih.gov?subject=Web Inquiry on [TAB-478] Vitamin D Receptor Antagonists for Treating Breast Cancer&body=Please send me information about technology [TAB-478] Vitamin D Receptor Antagonists for Treating Breast Cancer. Shastri, Mythreyi<br><a href="mailto:shastrim@mail.nih.gov?subject=Web Inquiry on [TAB-478] Vitamin D Receptor Antagonists for Treating Breast Cancer&body=Please send me information about technology [TAB-478] Vitamin D Receptor Antagonists for Treating Breast Cancer.">shastrim@mail.nih.gov</a><br> 114161124 E-213-2001-2 E-213-2001-2-US-02 Vitamin D Receptor Antagonists and Related Compositions and Methods of Use National Stage US 7,361,664 10/481,052 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7361664 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7361664">7,361,664</a><br />Filed on 2003-12-16<br />Status: Abandoned 114164705 E-213-2001-2 E-213-2001-2-PCT-01 Vitamin D Receptor Antagonists and Related Compositions and Methods of Use PCT COMB Patent Cooperation Treaty PCT/US02/19774 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US02/19774<br />Filed on 2002-06-20<br />Status: Expired 114113461 CBXXXX 114113462 CXXXXX 114119157 CB7XXX 114132348 ANTICANCER 114132349 EFFECTS 114132350 Novel 114132351 Vitamin 114132352 D 114132353 RECEPTOR 114132354 ANTAGONISTS 114157415 Glioma TAB-2410 114096612 Bcl-x LoxP (Bcl2l1 tm1.1Mam) Mouse Model for Developmental Biology Studies NIDDK Diagnostics, Licensing, Research Materials, Therapeutics Diagnostics Licensing Research Materials Therapeutics Lothar Hennighausen Floxed Bcl-x: Conditional knockout of pro-survival Bcl-x in primordial germ cells was used to study the balance between pro-apoptotic Bax during embryogenesis. <br /><br /> Bcl-x is a pro-survival protein that opposes the pro-apoptotic action of Bax which interacts with mitochondria to activate the caspase 9 pathway. Mice in which the Bcl-x gene is inactivated die at E12.5. To be able to study lineage-specific activities of Bcl-x at different stages of development, the Cre-LoxP recombination system was used. Homologous recombination was used to flank the promoter, exon1, and major coding exon2 of the Bcl-x gene with loxP sites. The targeted allele contained a loxP flanked (or floxed) neomycin cassette in the Bcl-x promoter, and an additional loxP site in intron 2. Floxed Bcl-x has been used to study the balance between Bcl-x and Bax in primordial germ cells that undergo controlled levels of cell reduction due to apoptosis, the induction of hemolytic anemia and splenomegaly following conditional deletion of the Bcl-x gene from erythroid cells, the protection of hepatocytes from apoptosis and ensuing fibrotic response by Bcl-x, and the demonstration that Bcl-x is critical for the survival of dendritic cells, important regulators of immune function. Developmental Biology Research Tool — Patent protection is not being pursued for this technology. 2022-03-08 2025-05-07 2025-05-07 2012-04-19 Bcl, Bcl2l1, IDXXXX, IXXXXX, LOXP, Mouse, R1XXXX, RXXXXX, Tm1/Mam False True Pre-clinical True NIHTT 37470483 Website Abstract 114171554 Rucker EB 3rd, et al. http://www.ncbi.nlm.nih.gov/pubmed/10894153 <a href="http://www.ncbi.nlm.nih.gov/pubmed/10894153">Rucker EB 3rd, et al.</a> 114107513 Hennighausen, Lothar National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Hennighausen, Lothar (NIDDK) 1 114107513 Hennighausen, Lothar National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Hennighausen, Lothar (NIDDK) 1 114101712 Bcl LoxP (Bcl2l1 Tm1/Mam) Mouse E-115-2012-0 Closed National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83739550 Shastri, Mythreyi shastrim@mail.nih.gov
United States of America Technology Advancement Office shastrim@mail.nih.gov?subject=Web Inquiry on [TAB-2410] Bcl-x LoxP (Bcl2l1 tm1.1Mam) Mouse Model for Developmental Biology Studies&body=Please send me information about technology [TAB-2410] Bcl-x LoxP (Bcl2l1 tm1.1Mam) Mouse Model for Developmental Biology Studies. Shastri, Mythreyi<br><a href="mailto:shastrim@mail.nih.gov?subject=Web Inquiry on [TAB-2410] Bcl-x LoxP (Bcl2l1 tm1.1Mam) Mouse Model for Developmental Biology Studies&body=Please send me information about technology [TAB-2410] Bcl-x LoxP (Bcl2l1 tm1.1Mam) Mouse Model for Developmental Biology Studies.">shastrim@mail.nih.gov</a><br> 114122688 RXXXXX 114122689 R1XXXX 114122690 IXXXXX 114122691 IDXXXX 114142853 Bcl 114142854 LOXP 114142855 Bcl2l1 114142856 Tm1/Mam 114142857 Mouse TAB-2403 114096605 Fgfr4 Knockout Mouse Model for Respiratory System Studies NIDDK Diagnostics, Licensing, Research Materials, Therapeutics Diagnostics Licensing Research Materials Therapeutics Chuxia Deng FGFR4 knockout: Lung alveoli fail to develop normally in double mutant with FGFR4 and FGFR3 knockouts.<br /><br /> The fibroblast growth factor receptor 4 (<i>fgfr-4</i>) gene was inactivated by targeted disruption and homozygous recombination to study its possible role in lung development. FGFR-4 is expressed in postnatal lung, and FGFR-4 null mice have no obvious abnormalities. However, mice that are doubly homozygous for targeted disruptions of FGFR3 and FGFR4 display novel phenotypes, including pronounced dwarfism and lung abnormalities. The lungs of the double knockout mice are normal at birth, but they fail to develop secondary septae that delimit alveoli and increase the surface area of the lung. Although lung function is impaired, the double homozygous knockout mice are viable but sickly. <ul> <li>Model for the study of respiratory system and potential treatments.</li> </ul> Research Tool -- Patent protection is not being pursued for this technology. 2022-03-08 2025-05-07 2025-05-07 2012-04-19 4, factor, FGFR4, Fibroblast, Generation, Growth, IDXXXX, IXXXXX, Knockout, Mice, RECEPTOR False True Pre-clinical True NIHTT 37470483 Website Abstract 114171547 Weinstein M, et al. https://www.ncbi.nlm.nih.gov/pubmed/9716527 <a href="https://www.ncbi.nlm.nih.gov/pubmed/9716527">Weinstein M, et al.</a> 114107506 Deng, Chuxia National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Deng, Chuxia (NIDDK) 1 114107506 Deng, Chuxia National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Deng, Chuxia (NIDDK) 1 162239986 Generation of Fibroblast Growth Factor 4 (FGFR4) Receptor Knockout Mice E-125-2000-0 Research Material National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83739550 Shastri, Mythreyi shastrim@mail.nih.gov
United States of America Technology Advancement Office shastrim@mail.nih.gov?subject=Web Inquiry on [TAB-2403] Fgfr4 Knockout Mouse Model for Respiratory System Studies&body=Please send me information about technology [TAB-2403] Fgfr4 Knockout Mouse Model for Respiratory System Studies. Shastri, Mythreyi<br><a href="mailto:shastrim@mail.nih.gov?subject=Web Inquiry on [TAB-2403] Fgfr4 Knockout Mouse Model for Respiratory System Studies&body=Please send me information about technology [TAB-2403] Fgfr4 Knockout Mouse Model for Respiratory System Studies.">shastrim@mail.nih.gov</a><br> 114122662 IXXXXX 114122663 IDXXXX 114142818 Generation 114142819 Fibroblast 114142820 Growth 114142821 factor 114142822 4 114142823 FGFR4 114142824 RECEPTOR 114142825 Knockout 114142826 Mice TAB-2407 114096609 Tg(Wap-cre)11738Mam Mouse Model for Developmental Biology Studies NIDDK Licensing, Research Materials Licensing Research Materials Lothar Hennighausen Cre-recombinase under the control of the whey acidic acid protein was only detected in alveolar epithelial cells of mammary tissue during lactation, and transcription occurred at all stages of mammary development. <br /><br /> The Cre recombinase from bacteriophage P1 excises intervening DNA sequences located between two unidirectional lox sites positioned on the same linear DNA segment, leaving one lox site behind. Through insertion of lox sites via homologous recombination into the gene of interest and targeting Cre recombinase expression to a specific cell type using a tissue-specific promoter, it is possible to introduce predetermined deletions into the mammalian genome. To delete genes specifically from mammary gland, transgenic mice were created carrying the Cre gene under the control of the whey acidic protein (WAP) gene promoter. Expression of WAP-Cre was only detected in alveolar epithelial cells of mammary tissue during lactation. Recombination mediated by Cre under control of the WAP gene promoter was largely restricted to the mammary gland but occasionally was observed in the brain. High-level transcriptional activity of WAP-based transgenes can be obtained at every stage of mammary development. Developmental Biology Research Tool — Patent protection is not being pursued for this technology. 2022-03-08 2025-05-07 2025-05-07 2012-04-19 Mouse, R1XXXX, RXXXXX, TgWap-cre11738Mam False True Pre-clinical True NIHTT 37470483 Website Abstract 114171551 Wagner KU, et al. http://www.ncbi.nlm.nih.gov/pubmed/9336464 <a href="http://www.ncbi.nlm.nih.gov/pubmed/9336464">Wagner KU, et al.</a> 114107509 Hennighausen, Lothar National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Hennighausen, Lothar (NIDDK) 1 114107509 Hennighausen, Lothar National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Hennighausen, Lothar (NIDDK) 1 114101709 Tg(Wap-cre)11738Mam Mouse E-112-2012-0 Closed National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83739550 Shastri, Mythreyi shastrim@mail.nih.gov
United States of America Technology Advancement Office shastrim@mail.nih.gov?subject=Web Inquiry on [TAB-2407] Tg(Wap-cre)11738Mam Mouse Model for Developmental Biology Studies&body=Please send me information about technology [TAB-2407] Tg(Wap-cre)11738Mam Mouse Model for Developmental Biology Studies. Shastri, Mythreyi<br><a href="mailto:shastrim@mail.nih.gov?subject=Web Inquiry on [TAB-2407] Tg(Wap-cre)11738Mam Mouse Model for Developmental Biology Studies&body=Please send me information about technology [TAB-2407] Tg(Wap-cre)11738Mam Mouse Model for Developmental Biology Studies.">shastrim@mail.nih.gov</a><br> 114122673 RXXXXX 114122674 R1XXXX 114142843 TgWap-cre11738Mam 114142844 Mouse TAB-2406 114096608 Stat1LoxP (Stat1 tm1Mam ) Mouse Model for Oncology and Immunology Studies NIDDK Licensing, Oncology, Research Materials Licensing Oncology Research Materials Lothar Hennighausen Selective inactivation of Stat1 in mammary cells indicates that its effect as a tumor suppressor in breast is direct. <br /><br /> STAT1 is considered a tumor suppressor, but it is not known if this effect occurs directly in mammary cells or secondarily by disrupting interferon signaling through the JAK/STAT1 pathway to induce immune responses. ERBB2/neu-induced breast cancer appeared sooner in mice lacking STAT1 only in mammary cells than in wild-type mice, indicating that STAT1 tumor suppression was intrinsic to mammary cells and not secondary to an induced immune response. Oncology<br /> Immunology Research Tool — Patent protection is not being pursued for this technology. 2022-03-08 2025-05-07 2025-05-07 2012-04-19 CCXXXX, CXXXXX, Mouse, STAT1, Stat1LoxP, Tm1Mam False True Pre-clinical True NIHTT 37470483 Website Abstract 114171550 Klover PJ, et al. http://www.ncbi.nlm.nih.gov/pubmed/21076615 <a href="http://www.ncbi.nlm.nih.gov/pubmed/21076615">Klover PJ, et al.</a> 114107510 Hennighausen, Lothar National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Hennighausen, Lothar (NIDDK) 1 114107510 Hennighausen, Lothar National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Hennighausen, Lothar (NIDDK) 1 114101708 Stat1LoxP (Stat1 Tm1Mam) Mouse E-111-2012-0 Closed National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83739550 Shastri, Mythreyi shastrim@mail.nih.gov
United States of America Technology Advancement Office shastrim@mail.nih.gov?subject=Web Inquiry on [TAB-2406] Stat1LoxP (Stat1 tm1Mam ) Mouse Model for Oncology and Immunology Studies&body=Please send me information about technology [TAB-2406] Stat1LoxP (Stat1 tm1Mam ) Mouse Model for Oncology and Immunology Studies. Shastri, Mythreyi<br><a href="mailto:shastrim@mail.nih.gov?subject=Web Inquiry on [TAB-2406] Stat1LoxP (Stat1 tm1Mam ) Mouse Model for Oncology and Immunology Studies&body=Please send me information about technology [TAB-2406] Stat1LoxP (Stat1 tm1Mam ) Mouse Model for Oncology and Immunology Studies.">shastrim@mail.nih.gov</a><br> 114122671 CXXXXX 114122672 CCXXXX 114142839 Stat1LoxP 114142840 STAT1 114142841 Tm1Mam 114142842 Mouse TAB-2402 114096604 Smad4 Knockout (Smad4tm1Cxd) Mouse Model for Developmental Biology Studies NIDDK Diagnostics, Licensing, Research Materials, Therapeutics Diagnostics Licensing Research Materials Therapeutics Chuxia Deng Smad4 knockout: Smad4 is essential for epiblast proliferation, egg cylinder formation and mesoderm induction in early embryogenesis. <br /><br /> The TGF-beta-related superfamily plays an important role in multiple biological systems including embryogenesis. TGF-beta ligands activate specific receptors, which interact with specific Smad proteins, which in turn form a complex with a common partner, Smad4, that conveys the signal to downstream targets. Exon 8 of the <i>Smad4</i> gene was disrupted using homologous recombination in embryonic stem cells. Exon 8 encodes the C-terminal domain of <i>Smad4</i> that is essential for the formation of heteromeric complexes with the other Smads. Mice heterozygous for the Smad4 mutation are phenotypically normal. Homozygotes, however, die early in embryonic development (day E6.5-8.5). <i>Smad4</i> is required for three essential functions in early embryogenesis: epiblast proliferation, egg cylinder formation, and mesoderm induction. <ul> <li>Study of developmental biology in conjunction with compounds.</li> </ul> Research Tool – Patent protection is not being pursued for this technology. 2022-03-08 2025-05-07 2025-05-07 2012-04-19 DPC4-Null, Generation, IDXXXX, IXXXXX, Mice, SUPPRESSOR, tumor False True Pre-clinical True NIHTT 37470483 Website Abstract 114171546 Yang X, et al. https://www.ncbi.nlm.nih.gov/pubmed/9520423 <a href="https://www.ncbi.nlm.nih.gov/pubmed/9520423">Yang X, et al.</a> 114107505 Deng, Chuxia National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Deng, Chuxia (NIDDK) 1 114107505 Deng, Chuxia National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Deng, Chuxia (NIDDK) 1 114101704 Generation of Tumor Suppressor DPC4-Null Mice E-133-1999-0 Research Material National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83739550 Shastri, Mythreyi shastrim@mail.nih.gov
United States of America Technology Advancement Office shastrim@mail.nih.gov?subject=Web Inquiry on [TAB-2402] Smad4 Knockout (Smad4tm1Cxd) Mouse Model for Developmental Biology Studies&body=Please send me information about technology [TAB-2402] Smad4 Knockout (Smad4tm1Cxd) Mouse Model for Developmental Biology Studies. Shastri, Mythreyi<br><a href="mailto:shastrim@mail.nih.gov?subject=Web Inquiry on [TAB-2402] Smad4 Knockout (Smad4tm1Cxd) Mouse Model for Developmental Biology Studies&body=Please send me information about technology [TAB-2402] Smad4 Knockout (Smad4tm1Cxd) Mouse Model for Developmental Biology Studies.">shastrim@mail.nih.gov</a><br> 114122660 IXXXXX 114122661 IDXXXX 114142813 Generation 114142814 tumor 114142815 SUPPRESSOR 114142816 DPC4-Null 114142817 Mice TAB-1836 114096058 Prostatic Adenocarcinoma Cells Expressing or Lacking the Tumor Suppressor Gene PTEN NIDDK Diagnostics, Licensing, Oncology, Research Materials Diagnostics Licensing Oncology Research Materials Derek Leroith, Michael Quon PTEN is a tumor suppressor gene that is frequently deleted or mutated in a variety of human cancers, including prostate, breast, endometrial, lung, and ovarian cancers. In prostate cancer cells, PTEN deletion is the most common event observed. The loss of PTEN is thought to play and important role in tumor cell proliferation and metastasis due to a lack of control of the signaling pathways that mediate cellular processes such as apoptosis and migration. Previously PTEN had been shown to down regulate cyclin D1 expression as well as regulate p53 protein levels and transcriptional activity, and recently the inventors of this technology have shown that PTEN decreases surface IGF-IR protein levels in prostate cancer cell lines in an Akt-independent manner. <br><br> PC3 cells are prostate cancer cells that lack PTEN gene. This technology describes PC3 cells that overexpress the PTEN gene. These cell lines can be used to study the role of the PTEN gene in cancer growth and metastasis. Research Tool -- patent protection is not being pursued for this technology Available for licensing. 2022-03-08 2025-05-07 2025-05-07 2008-10-01 ADENOCARCINOMA, BREAST CANCER, CA1XXX, CANCER, CAXXXX, CCXXXX, Cells, CHARACTERIZATION, Chromosome 7, monosomy, CXXXXX, Deletion 7, endometrial, Expressing, Gene, IGF1R, lung cancer, MEN 1, OVARIAN CANCER, PROSTATE CANCER, PTEN, tumor suppressor, Zollinger-Ellison syndrome False True The technology is currently in the pre-clinical stage of development. True NIHTT 37470483 Website Abstract 114170643 H Zhao et al. PTEN inhibits cell proliferation and induces apoptosis by downregulating cell surface IGF-IR expression in prostate cancer cells. Oncogene 2004 Jan 22;23(3):786-794. http://www.ncbi.nlm.nih.gov/pubmed/14737113?dopt <a href="http://www.ncbi.nlm.nih.gov/pubmed/14737113?dopt">H Zhao et al. PTEN inhibits cell proliferation and induces apoptosis by downregulating cell surface IGF-IR expression in prostate cancer cells. Oncogene 2004 Jan 22;23(3):786-794.</a> 114106305 Quon, Michael Quon, Michael 0 114106304 Leroith, Derek Leroith, Derek 1 114106304 Leroith, Derek Leroith, Derek 1 114106305 Quon, Michael Quon, Michael 0 114101079 Construction Of, And Characterization Of The Properties Of Cancer Cells Expressing Or Lacking The Tumor Suppressor Gene PTEN E-292-2008-0 Research Material National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83739550 Shastri, Mythreyi shastrim@mail.nih.gov
United States of America Technology Advancement Office shastrim@mail.nih.gov?subject=Web Inquiry on [TAB-1836] Prostatic Adenocarcinoma Cells Expressing or Lacking the Tumor Suppressor Gene PTEN&body=Please send me information about technology [TAB-1836] Prostatic Adenocarcinoma Cells Expressing or Lacking the Tumor Suppressor Gene PTEN. Shastri, Mythreyi<br><a href="mailto:shastrim@mail.nih.gov?subject=Web Inquiry on [TAB-1836] Prostatic Adenocarcinoma Cells Expressing or Lacking the Tumor Suppressor Gene PTEN&body=Please send me information about technology [TAB-1836] Prostatic Adenocarcinoma Cells Expressing or Lacking the Tumor Suppressor Gene PTEN.">shastrim@mail.nih.gov</a><br> 114119271 CA1XXX 114119272 CCXXXX 114119273 CXXXXX 114119274 CAXXXX 114132840 endometrial 114132841 Expressing 114132842 Cells 114132843 CANCER 114132844 BREAST CANCER 114132845 CHARACTERIZATION 114132846 lung cancer 114132847 PROSTATE CANCER 114132848 ADENOCARCINOMA 114132849 Gene 114132850 PTEN 114132851 OVARIAN CANCER 114132852 tumor suppressor 114132853 IGF1R 114156655 Zollinger-Ellison syndrome 114156656 Chromosome 7, monosomy 114158417 MEN 1 114158418 Deletion 7 TAB-2515 114096711 SIRT2 Inhibitors as Novel Therapeutics for Myocardial Infarction and Ischemic Stroke and to Prevent Necrosis NHLBI Cardiology, Collaboration, Diagnostics, Neurology, Research Materials, Therapeutics Cardiology Collaboration Diagnostics Neurology Research Materials Therapeutics Toren Finkel, Nisha Narayan Sirtuin 2 (SIRT2) inhibitors to reduce necrosis and, thereby, as novel therapeutics to treat ischemic stroke and myocardial infarction. Accumulating evidence indicates that programmed necrosis plays a critical role in cell death during ischemia-reperfusion. NIH investigators have shown that the NAD-dependent deacetylase SIRT2 binds constitutively to receptor-interacting protein 3 (RIP3) and that deletion or knockdown of SIRT2 prevents formation of the RIP1-RIP3 complex in mice. These investigators also found that genetic or pharmacological inhibition of SIRT2 blocks cellular necrosis induced by TNF-alpha and RIP1 is a critical target of SIRT2-dependent deacetylation. Further studies also showed that the hearts of <em>Sirt2<sup>–/–</sup></em> mice, or wild-type mice treated with a specific pharmacological inhibitor of SIRT2, show marked protection from ischemic injury. These results implicate SIRT2 as an important regulator of programmed necrosis and indicate that SIRT2 inhibitors may constitute a novel approach to protect against necrotic injuries, including ischemic stroke and myocardial infarction. <ul> <li>None of the currently available drugs address the necrotic damage caused due to ischemia and reperfusion.</li> <li>Using a Sirt2 inhibitor could limit the damage caused by necrosis and contribute to accelerated recovery in patients suffering from these conditions.</li> </ul> <ul> <li>Novel therapeutics to protect against necrotic injuries.</li> <li>Novel therapeutics to treat ischemic stroke and myocardial infarction.</li> <li>Novel therapeutics to treat diseases in which necrosis is involved.</li> </ul> The NHLBI is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize retinoid-related orphan receptors (RORs) function in chronic diseases. For collaboration opportunities, please contact Ms. Peg Koelble at <a href="mailto:koelblep@mail.nih.gov">koelblep@mail.nih.gov</a> or 301-594-4095. 2022-03-08 2025-05-06 2025-05-06 2013-01-23 Against, AGK2, deacetylase, IB1FXX, IB1XXX, IBXXXX, inhibitor, IXXXXX, NAD-dependent, NB1HXX, NB1XXX, NBXXXX, NECROSIS, NXXXXX, PROTECTS, Sirt2 False True <ul> <li>Early-stage</li> <li>Pre-clinical</li> <li>In vitro data available</li> <li>In vivo data available (animal)</li> </ul> True NIHTT 37470483 Website Abstract 114171736 Narayan N, et al. https://www.ncbi.nlm.nih.gov/pubmed/23201684 <a href="https://www.ncbi.nlm.nih.gov/pubmed/23201684">Narayan N, et al.</a> 114107751 Finkel, Toren National Heart, Lung, and Blood Institute (NHLBI) NHLBI Finkel, Toren (NHLBI) 0 114107750 Narayan, Nisha National Heart, Lung, and Blood Institute (NHLBI) FDA Narayan, Nisha (FDA) 1 114107750 Narayan, Nisha National Heart, Lung, and Blood Institute (NHLBI) FDA Narayan, Nisha (FDA) 1 114107751 Finkel, Toren National Heart, Lung, and Blood Institute (NHLBI) NHLBI Finkel, Toren (NHLBI) 0 114101826 NAD-dependent Deacetylase Sirt2 Inhibitor AGK2 Protects Against Necrosis E-003-2013-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 83739538 Choudhry, Vidita vidita.choudhry@nih.gov
United States of America Office of Technology Transfer and Development vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-2515] SIRT2 Inhibitors as Novel Therapeutics for Myocardial Infarction and Ischemic Stroke and to Prevent Necrosis&body=Please send me information about technology [TAB-2515] SIRT2 Inhibitors as Novel Therapeutics for Myocardial Infarction and Ischemic Stroke and to Prevent Necrosis. Choudhry, Vidita<br><a href="mailto:vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-2515] SIRT2 Inhibitors as Novel Therapeutics for Myocardial Infarction and Ischemic Stroke and to Prevent Necrosis&body=Please send me information about technology [TAB-2515] SIRT2 Inhibitors as Novel Therapeutics for Myocardial Infarction and Ischemic Stroke and to Prevent Necrosis.">vidita.choudhry@nih.gov</a><br> 114166949 E-003-2013-0 E-003-2013-0-US-01 Methods For Treating Or Preventing Necrosis PRV US 61/723,496 Abandoned US <br />Provisional (PRV) 61/723,496<br />Filed on 2012-11-07<br />Status: Abandoned 114112112 IB1FXX 114123101 NB1HXX 114123102 IXXXXX 114123103 IBXXXX 114123104 IB1XXX 114123105 NXXXXX 114123106 NBXXXX 114123107 NB1XXX 114143833 NECROSIS 114143834 Against 114143835 PROTECTS 114143836 AGK2 114143837 inhibitor 114143838 Sirt2 114143839 deacetylase 114143840 NAD-dependent TAB-3461 114097329 Oxytocin Conditional Knockout Mouse Model for Studying Behavioral Effects NIMH Animal Models, Neurology Animal Models Neurology Heon-JIn Lee, Walter Young This invention relates to a novel mouse model that permits temporal and spatial inactivation of the oxytocin receptor. Oxytocin is a neurohormone that has been associated with human diseases such as autism and schizophrenia. The use of animal models to study oxytocin disease progression has been invaluable. However, existing mouse models have been limited to knockouts which leads to early mortality. Researchers at the National Institute of Mental Health (NIMH) generated the conditional oxytocin receptor knockout mice using the Cre-loxP and FLP-FRT systems. The use of this system allows the oxytocin receptor to function normally early in development and selectively inactivated in brain regions after development has been complete. This approach allows teasing apart the functional and developmental roles of oxytocin, furthering our basic understanding of oxytocin's roles in brain function. The mouse models allow conditional deactivation of the oxytocin receptor as oppose to simple knockouts. Test pharmacological agents for behavioral effects in mouse models. Research Material – Patent protection is not being pursued for this technology. 2022-06-02 2025-05-06 2025-05-06 2022-06-02 2022-01-27 ALLOW, Changed, Genome, Inactivation, Listed LPM Contreras as of 4/15/2015, Mouse, OXYTOCIN, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, RECEPTOR, REGULATED False True True NIHTT 37470483 Website Abstract 114172617 Lee HJ, Caldwell HK https://pubmed.ncbi.nlm.nih.gov/18655873/ <a href="https://pubmed.ncbi.nlm.nih.gov/18655873/">Lee HJ, Caldwell HK</a> 114172618 MacBeth AH, Lii HJ https://pubmed.ncbi.nlm.nih.gov/19531157/ <a href="https://pubmed.ncbi.nlm.nih.gov/19531157/">MacBeth AH, Lii HJ</a> 114110244 Lee, Heon-JIn National Institute of Mental Health (NIMH) Lee, Heon-JIn 0 114110243 Young, Walter National Institute of Mental Health (NIMH) NIMH Young, Walter (NIMH) 1 114110243 Young, Walter National Institute of Mental Health (NIMH) NIMH Young, Walter (NIMH) 1 114110244 Lee, Heon-JIn National Institute of Mental Health (NIMH) Lee, Heon-JIn 0 114102071 Mouse Genome Was Changed To Allow Regulated Inactivation Of The Oxytocin Receptor E-116-2013-0 Research Material National Institute of Mental Health (NIMH) 83739514 Dawson, Anton anton.dawson@nih.gov
United States of America anton.dawson@nih.gov?subject=Web Inquiry on [TAB-3461] Oxytocin Conditional Knockout Mouse Model for Studying Behavioral Effects&body=Please send me information about technology [TAB-3461] Oxytocin Conditional Knockout Mouse Model for Studying Behavioral Effects. Dawson, Anton<br><a href="mailto:anton.dawson@nih.gov?subject=Web Inquiry on [TAB-3461] Oxytocin Conditional Knockout Mouse Model for Studying Behavioral Effects&body=Please send me information about technology [TAB-3461] Oxytocin Conditional Knockout Mouse Model for Studying Behavioral Effects.">anton.dawson@nih.gov</a><br> 114152332 RECEPTOR 114152333 OXYTOCIN 114152334 Inactivation 114152335 REGULATED 114152336 ALLOW 114152337 Changed 114152338 Genome 114152339 Mouse 114152340 Listed LPM Contreras as of 4/15/2015 114152341 Pre LPM working set 20150418 114152342 Post LPM Assignment Set 20150420 TAB-3813 114097661 SARS-CoV-2 Iinfection of Human Lung Epithelial Cells Triggers a Cell-Mediated Acute Fibrin Fibrosis NIAID Rachel Erickson, Peter Sun Scientists at NIAID have developed a method of treatment for virus-induced lung fibrosis using nebulized thrombin inhibitors. Since March 2020, the WHO estimates that 564 million people have been infected with SARS-CoV-2 world-wide. Lung fibrosis is a major factor associated with SARS-CoV-2 infections and can contribute to mortality. Additionally, severe SARS-CoV-2 cases can result in long-term pulmonary disease due to lung fibrosis. At present, attempts to treat lung fibrosis developed during a SARS-CoV-2 infection using intravenous heparin have been unsuccessful. <br /><br /> NIAID scientists have discovered a previously unknown acute fibrosis mechanism mediated by SARS-CoV-2 infected primary lung epithelium, and have developed an innovative method of treating lung fibrosis using nebulized thrombin inhibitors. <ul> <li>Addresses the pathology at the proper location instead of indiscriminately</li> </ul> <ul> <li>Innovative method of treatment for virus-induced lung fibrosis</li> <li>A multi-targeted approach could decrease lung-term symptoms associated with SARS-CoV-2</li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize this technology. For collaboration opportunities, please contact Dawn Taylor-Mulneix at <a href="mailto: dawn.taylor-mulneix@nih.gov."> dawn.taylor-mulneix@nih.gov.</a>or 1-301-767-5189. 2022-09-12 2025-05-06 2025-05-06 2022-09-09 ACUTE, Cell, Cells, Epithelial, Fibrin, FIBROSIS, Human, Infection, LUNG, Mediated, SARS-CoV-2, TRIGGERS, YCXXXX False False True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114111636 Erickson, Rachel University of Pennsylvania Erickson, Rachel 0 114111635 Sun, Peter NIAID - DIR NIAID Sun, Peter (NIAID) 1 114111635 Sun, Peter NIAID - DIR NIAID Sun, Peter (NIAID) 1 114111636 Erickson, Rachel University of Pennsylvania Erickson, Rachel 0 114102913 SARS-CoV-2 Infection Of Human Lung Epithelial Cells Triggers A Cell Mediated Acute Fibrin Fibrosis E-157-2022-0 Filing authorized NIAID, University of Pennsylvania 83738793 Taylor-Mulneix, Dawn dawn.taylor-mulneix@nih.gov
United States of America dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-3813] SARS-CoV-2 Iinfection of Human Lung Epithelial Cells Triggers a Cell-Mediated Acute Fibrin Fibrosis&body=Please send me information about technology [TAB-3813] SARS-CoV-2 Iinfection of Human Lung Epithelial Cells Triggers a Cell-Mediated Acute Fibrin Fibrosis. Taylor-Mulneix, Dawn<br><a href="mailto:dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-3813] SARS-CoV-2 Iinfection of Human Lung Epithelial Cells Triggers a Cell-Mediated Acute Fibrin Fibrosis&body=Please send me information about technology [TAB-3813] SARS-CoV-2 Iinfection of Human Lung Epithelial Cells Triggers a Cell-Mediated Acute Fibrin Fibrosis.">dawn.taylor-mulneix@nih.gov</a><br> 114169652 E-157-2022-0 E-157-2022-0-US-01 SARS-CoV-2 COMPOSITIONS AND METHODS FOR TREATMENT OF VIRUS-INDUCED AIRWAY FIBROSIS PRV US 63/388,498 Expired US <br />Provisional (PRV) 63/388,498<br />Filed on 2022-07-12<br />Status: Expired 114129709 YCXXXX 114155624 SARS-CoV-2 114155625 Infection 114155626 Human 114155627 LUNG 114155628 Epithelial 114155629 Cells 114155630 TRIGGERS 114155631 Cell 114155632 Mediated 114155633 ACUTE 114155634 Fibrin 114155635 FIBROSIS TAB-3724 114097576 Human lgA Monoclonal Antibody that Targets a Conserved Site on the Plasmodium Falciparum Circumsporozoite Protein NIAID Antibodies, Collaboration Antibodies Collaboration Hyeseon Cho, Peter Crompton, Robert Seder, Joshua Tan Scientists at NIAID have isolated MAD2-6, an IgA antibody active against Plasmodium falciparum sporozoites, the infectious agent of malaria. In 2019, the majority of the 229 million cases resulted from P. falciparum infections. Because P. falciparum has a complex lifecycle during human infection, most advanced malaria vaccine candidates and current chemoprophylaxis drugs can confer only partial, short-term protection in malaria-endemic areas. Thus, the MAD2-6 antibody could be used alone or in combination with current technology.<br /><br /> MAD2-6 binds to a unique epitope overlapping with region I, a functionally important region of the Plasmodium falciparum circumsporozoite protein (PfCSP). This binding site of PfCSP is a previously unknown target for protective antibodies, which may be useful as a new target. Monoclonal antibodies are promising tools for prevention of malaria and could replace or be combined with malaria chemoprevention in areas with seasonal malaria. <ul> <li>Antibodies can be effective as prophylactics, alone or in combination with other treatments</li> </ul> <ul> <li>Alternate technologies are required to address drug resistance</li> <li>A multi-targeted approach can combat all stages of the parasite life­cycle</li> <li>Prophylactic treatment for neutralization of P. falciparum in normal or at-risk populations including pregnant women</li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize this technology. For collaboration opportunities, please contact Dawn Taylor-Mulneix at <a href="mailto: dawn.taylor-mulneix@nih.gov."> dawn.taylor-mulneix@nih.gov.</a>or 1-301-767-5189. 2022-06-10 2025-05-06 2025-05-06 2022-06-10 2IXXXX, 2XXXXX, ANTIBODY, CIRCUMSPOROZOITE, Conserved, FALCIPARUM, Human, IgA, monoclonal, PLASMODIUM, Protein, SITE, Targets, That False True True NIHTT 37470483 Website Abstract 114172894 Tan, J., et al., “Functional human IgA targets a conserved site on malaria sporozoites”, Science Translational Medicine, Vol. 13(599), 23 June 2021 https://doi.org/10.1126/scitranslmed.abg2344 <a href="https://doi.org/10.1126/scitranslmed.abg2344 ">Tan, J., et al., “Functional human IgA targets a conserved site on malaria sporozoites”, Science Translational Medicine, Vol. 13(599), 23 June 2021</a> 114111396 Cho, Hyeseon NIAID - DMID NIAID Cho, Hyeseon (NIAID) 0 114111397 Seder, Robert NIAID - VRC NIAID Seder, Robert (NIAID) 0 114111398 Crompton, Peter NIAID - DMID NIAID Crompton, Peter (NIAID) 0 114111399 Tan, Joshua NIAID - VRC NIAID Tan, Joshua (NIAID) 1 114111399 Tan, Joshua NIAID - VRC NIAID Tan, Joshua (NIAID) 1 114111396 Cho, Hyeseon NIAID - DMID NIAID Cho, Hyeseon (NIAID) 0 114111397 Seder, Robert NIAID - VRC NIAID Seder, Robert (NIAID) 0 114111398 Crompton, Peter NIAID - DMID NIAID Crompton, Peter (NIAID) 0 114102828 Human IgA Monoclonal Antibody That Targets A Conserved Site On The Plasmodium Falciparum Circumsporozoite Protein E-130-2020-0 Filing authorized NIAID 83738793 Taylor-Mulneix, Dawn dawn.taylor-mulneix@nih.gov
United States of America dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-3724] Human lgA Monoclonal Antibody that Targets a Conserved Site on the Plasmodium Falciparum Circumsporozoite Protein&body=Please send me information about technology [TAB-3724] Human lgA Monoclonal Antibody that Targets a Conserved Site on the Plasmodium Falciparum Circumsporozoite Protein. Taylor-Mulneix, Dawn<br><a href="mailto:dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-3724] Human lgA Monoclonal Antibody that Targets a Conserved Site on the Plasmodium Falciparum Circumsporozoite Protein&body=Please send me information about technology [TAB-3724] Human lgA Monoclonal Antibody that Targets a Conserved Site on the Plasmodium Falciparum Circumsporozoite Protein.">dawn.taylor-mulneix@nih.gov</a><br> 114169557 E-130-2020-0 E-130-2020-0-US-01 HUMAN IGA MONOCLONAL ANTIBODY THAT TARGETS A CONSERVED SITE ON THE PLASMODIUM FALCIPARUM CIRCUMSPOROZOITE PROTEIN PRV US 63/041,439 Abandoned US <br />Provisional (PRV) 63/041,439<br />Filed on 2020-06-19<br />Status: Abandoned 114169558 E-130-2020-0 E-130-2020-0-PCT-02 Human IgA Monoclonal Antibody That Targets A Conserved Site On The Plasmodium Falciparum Circumsporozoite Protein PCT Patent Cooperation Treaty PCT/US2021/037571 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/037571<br />Filed on 2021-06-16<br />Status: Expired 114129405 2XXXXX 114129406 2IXXXX 114154829 Human 114154830 IgA 114154831 monoclonal 114154832 ANTIBODY 114154833 That 114154834 Targets 114154835 Conserved 114154836 SITE 114154837 PLASMODIUM 114154838 FALCIPARUM 114154839 CIRCUMSPOROZOITE 114154840 Protein TAB-3421 114097296 Rescue of AAV Production by shRNA Co-transfection NIDDK Collaboration, Research Materials Collaboration Research Materials Sandra Afione-Wainer, John (Jay) Chiorini Recombinant adeno-associated virus (rAAV) vectors are proving to be a valid, safe and efficient gene transfer system for clinical applications. As most vectors utilize constitutive promoters, this results in transgene expression in the producer cell. Some of these transgene products can induce proapoptotic, cytostatic or other unknown effects that interfere with producer cell function. Therefore, this reduces the viral vector yield and is a major limitation when trying to characterize poorly described genes. NIDCR developed a method of expression of the transgene product during the vector production in the produce cell but not in the target cell. This novel approach allowed the production of a vector with a proapoptotic transgene. <ul> <li>This novel approach allowed the production of a vector with a proapoptotic transgene.</li> Research Material - Patent protections is not being pursued for this technology. 2022-03-08 2025-05-06 2025-05-06 2020-10-23 AAV, AC4XXX, Cotransfection, production, rescue, ShRNA False True True NIHTT 37470483 Website Abstract 114110129 Afione-Wainer, Sandra NIDCR NIDCR Afione-Wainer, Sandra (NIDCR) 0 114109875 Chiorini, John (Jay) NIDCR NIDCR Chiorini, John (Jay) (NIDCR) 1 114109875 Chiorini, John (Jay) NIDCR NIDCR Chiorini, John (Jay) (NIDCR) 1 114110129 Afione-Wainer, Sandra NIDCR NIDCR Afione-Wainer, Sandra (NIDCR) 0 114102544 Rescue Of AAV Production By ShRNA Cotransfection E-072-2020-0 Closed NIDCR 83656052 Knezevic, Vladimir vlado.knezevic@nih.gov
United States of America Technology Advancement Office vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-3421] Rescue of AAV Production by shRNA Co-transfection&body=Please send me information about technology [TAB-3421] Rescue of AAV Production by shRNA Co-transfection. Knezevic, Vladimir<br><a href="mailto:vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-3421] Rescue of AAV Production by shRNA Co-transfection&body=Please send me information about technology [TAB-3421] Rescue of AAV Production by shRNA Co-transfection.">vlado.knezevic@nih.gov</a><br> 114128335 AC4XXX 114151948 rescue 114151949 AAV 114151950 production 114151951 ShRNA 114151952 Cotransfection TAB-2970 114097096 Genome Wide DNase I Hypersensitive Sites Detection in Formalin-Fixed Paraffin-Embedded Single Cells NHLBI Consumer Products, Diagnostics, Licensing, Oncology, Research Equipment, Research Materials, Therapeutics Consumer Products Diagnostics Licensing Oncology Research Equipment Research Materials Therapeutics Qingsong Tang, Keji Zhao A method of detecting DNase I hypersensitive sites ((DHS) in a single cell or very small number of cells, including cells recovered from formalin-fixed paraffin-embedded (FFPE) tissue slides of patient samples. DHS has revealed a large number of potential regulatory elements for transcriptional regulation in various cell types. The application of DNase-Seq techniques to patient samples can elucidate pathophysiological mechanisms of gene function in a variety of diseases as well as provide potentially important diagnostic and prognostic information. Unfortunately, the current DNase-Seq techniques require large number of cells and are applicable only to larger biopsies and surgical specimens. This technique, called Pico-Seq, allows detection when only very small population of cells are available, such as rare primary tumor cells and circulating-tumor-cells, isolated by a variety of methods. Pico-Seq uses conditions capable of restoring the DNase I sensitivity, similar to native/fresh cells, in tissue/cells from slides processed by extremely harsh conditions, such as in FFPE tissues. <ul> <li>Applicable to very small number of cells down to a single cell.</li> <li>Capable of using cells isolated by any of the available methods, including flow cytometry, biopsies, laser capture microdissection, and even cells recovered from formalin-fixed paraffin-embedded tissue slides of patient samples.</li> </ul> <ul> <li>Diagnostic and prognostic kits</li> <li>Research kits</li> </ul> 2022-03-08 2025-05-06 2025-05-06 2015-08-17 amplification, AMPLIFICATION-BASED, assay, CHROMATIN, DNase-Seq, Listed LPM Contreras as of 4/15/2015, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Single-cell, TECHNIQUE, VCXXXX, WBXXXX, WIXXXX, XGXXXX, XHXXXX, YAXXXX, YBXXXX False True <ul> <li>Early-stage</li> <li>In vitro data available</li> </ul> True 52406768 Discovery 52406768 NIHTT 37470483 Website Abstract 114109062 Tang, Qingsong National Heart, Lung, and Blood Institute (NHLBI) NHLBI Tang, Qingsong (NHLBI) 0 114109061 Zhao, Keji National Heart, Lung, and Blood Institute (NHLBI) NHLBI Zhao, Keji (NHLBI) 1 114109061 Zhao, Keji National Heart, Lung, and Blood Institute (NHLBI) NHLBI Zhao, Keji (NHLBI) 1 114109062 Tang, Qingsong National Heart, Lung, and Blood Institute (NHLBI) NHLBI Tang, Qingsong (NHLBI) 0 114100458 Single Cell DNase-Seq Technique E-254-2014-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 89788013 Kolesnitchenko, Vincent vk5q@nih.gov
United States of America Office of Technology Transfer and Development vk5q@nih.gov?subject=Web Inquiry on [TAB-2970] Genome Wide DNase I Hypersensitive Sites Detection in Formalin-Fixed Paraffin-Embedded Single Cells&body=Please send me information about technology [TAB-2970] Genome Wide DNase I Hypersensitive Sites Detection in Formalin-Fixed Paraffin-Embedded Single Cells. Kolesnitchenko, Vincent<br><a href="mailto:vk5q@nih.gov?subject=Web Inquiry on [TAB-2970] Genome Wide DNase I Hypersensitive Sites Detection in Formalin-Fixed Paraffin-Embedded Single Cells&body=Please send me information about technology [TAB-2970] Genome Wide DNase I Hypersensitive Sites Detection in Formalin-Fixed Paraffin-Embedded Single Cells.">vk5q@nih.gov</a><br> 114166960 E-254-2014-0 E-254-2014-0-US-01 Genome-Wide Detection of Dnase I Hypersensitive Sites PRV US 62/118,574 Abandoned US <br />Provisional (PRV) 62/118,574<br />Filed on 2015-02-20<br />Status: Abandoned 114127143 VCXXXX 114127144 WBXXXX 114127145 WIXXXX 114127146 XGXXXX 114127147 XHXXXX 114127148 YAXXXX 114127149 YBXXXX 114148474 Single-cell 114148475 CHROMATIN 114148476 assay 114148477 amplification 114148478 AMPLIFICATION-BASED 114148479 DNase-Seq 114148480 TECHNIQUE 114148481 Listed LPM Contreras as of 4/15/2015 114148482 Pre LPM working set 20150418 114148483 Post LPM Assignment Set 20150420 TAB-2433 114096634 Multilayer X-Ray Transmission Grating Array for Phase-Contrast Imaging and Tomography NHLBI Collaboration Collaboration Han Wen Classical X-ray Computed Tomography (CT) and radiography are based on X-ray absorption and cannot show soft tissue structures as well as Magnetic Resonance Imaging (MRI). Detecting the phase delay/advance of X-rays that travel through the body could enhance soft tissue contrast 10 - 100 times. Submicron-period X-ray transmission gratings for medical x-ray energies can substantially enhance the phase detection sensitivity, but fabrication is a great challenge. This invention includes a method to fabricate multilayer transmission gratings of large areas. The design uses multilayer deposition of alternating materials on a staircase substrate to form micro grating arrays of extremely small periods and high aspect ratio in large areas. This invention should substantially improve the visibility of soft tissue structures and reduce radiation dose to patients. <ul> <li>Gratings of ultra-high aspect ratio and small period allow phase-contrast imaging at high x-ray energies which are suitable for human body CT, and provide better soft tissue contrast in radiography and CT</li> <li>Reduces radiation exposure to patient</li> <li>Large area gratings enable full field imaging without raster or line scanning</li> </ul> <ul> <li>X-ray diagnostic imaging</li> <li>X-ray non-destructive materials testing</li> <li>X-ray security screening</li> <li>X-ray lithography of nanostructures</li> <li>Also applies to neutron beam or proton beam imaging</li> </ul> The Imaging Physics Lab, Biophysics and Biochemistry Center, NHLBI/NIH, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize multilayer-coated gratings for phase-contrast CT. For collaboration opportunities, please contact Dr. Han Wen at <a href="mailto:wenh@nhlbi.nih.gov">wenh@nhlbi.nih.gov</a>. 2022-03-08 2025-05-06 2025-05-06 2012-05-09 AA3XXX, AAXXXX, ARRAY, AXXXXX, GRATING, IMAGING, MICRO, Multilayer-coated, PHASE, SENSITIVE, X-RAY False True <ul> <li>Pre-clinical</li> <li>Early-stage</li> </ul> True NIHTT 37470483 Website Abstract 114171582 Lynch SK, et al. Multilayer-coated micro-grating array for x-ray phase-contrast imaging. Proc. SPIE 8076, 80760F (2011) http://dx.doi.org/10.1117/12.888939 <a href="http://dx.doi.org/10.1117/12.888939">Lynch SK, et al. Multilayer-coated micro-grating array for x-ray phase-contrast imaging. Proc. SPIE 8076, 80760F (2011)</a> 114107548 Wen, Han National Heart, Lung, and Blood Institute (NHLBI) NHLBI Wen, Han (NHLBI) 1 114107548 Wen, Han National Heart, Lung, and Blood Institute (NHLBI) NHLBI Wen, Han (NHLBI) 1 114101734 Multilayer-coated Micro Grating Array For X-ray Phase Sensitive Imaging E-207-2011-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 114102247 Multilayer-coated Micro Grating Array For X-ray Phase Sensitive Imaging E-207-2011-1 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 83685986 Crooks, Denise crooksd@mail.nih.gov
United States of America Office of Technology Transfer and Development crooksd@mail.nih.gov?subject=Web Inquiry on [TAB-2433] Multilayer X-Ray Transmission Grating Array for Phase-Contrast Imaging and Tomography&body=Please send me information about technology [TAB-2433] Multilayer X-Ray Transmission Grating Array for Phase-Contrast Imaging and Tomography. Crooks, Denise<br><a href="mailto:crooksd@mail.nih.gov?subject=Web Inquiry on [TAB-2433] Multilayer X-Ray Transmission Grating Array for Phase-Contrast Imaging and Tomography&body=Please send me information about technology [TAB-2433] Multilayer X-Ray Transmission Grating Array for Phase-Contrast Imaging and Tomography.">crooksd@mail.nih.gov</a><br> 114166751 E-207-2011-0 E-207-2011-0-US-01 Multilayer-Coated Micro Grating Array For X-Ray Phase Sensitive And Scattering Sensitive Imaging PRV US 61/578,719 Abandoned US <br />Provisional (PRV) 61/578,719<br />Filed on 2011-12-21<br />Status: Abandoned 114168071 E-207-2011-1 E-207-2011-1-PCT-01 Multilayer-coated Micro Grating Array For X-ray Phase Sensitive and Scattering Sensitive Imaging PCT Patent Cooperation Treaty PCT/US2013/020561 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2013/020561<br />Filed on 2013-01-07<br />Status: Expired 114122773 AA3XXX 114122774 AXXXXX 114122775 AAXXXX 114143005 Multilayer-coated 114143006 MICRO 114143007 GRATING 114143008 ARRAY 114143009 X-RAY 114143010 PHASE 114143011 SENSITIVE 114143012 IMAGING TAB-2096 114096313 Reversible SNAP-Tag and CLIP-Tag Ligands for Live Cell Imaging NHLBI Licensing Licensing Nelson Cole, Julie Donaldson Recently-developed protein tags enable the specific covalent attachment of synthetic ligands, incorporating fluorophores or other substituted groups, to fusion proteins containing these tags. For example, SNAP and CLIP tags bind O<sup>6</sup>-benzylguanine-containing and O<sup>2</sup>-benzylcytosine containing ligands respectively, which can be derivatized with a wide variety of labels, including fluorescent dyes, affinity probes, and cross-linkers. This system provides a powerful tool to study a variety of highly dynamic processes within cells, including protein trafficking, turnover, and complex formation. However, a substantial limitation to this approach is that labeling is irreversible, due to the formation of a covalent bond between the probe and the protein tag.<br><br> The inventors have developed ligands that incorporate a disulfide linkage between the O<sup>6</sup>-benzylguanine moiety and the label, allowing selective release of the label from the tagged protein when treated with a reducing agent. The inventors have shown that use of these ligands in conjunction with cell-impermeable reducing agents allows visualization of internalization and trafficking in live cells; these ligands may also be used in other applications in which a cleavable label would be desirable, such as protein purification. This strategy is also applicable to other covalent protein tags, such as the ACP/MCP protein tag system. <ul> <li>Allows for selective release of label</li> <li>Accommodates intra- or extra-cellular labeling, and dual labeling</li> <li>Ligands may be derivatized with a wide variety of labels, including fluorescent dyes, affinity probes, and cross-linkers</li> <li>Lower background fluorescence and higher contrast than other systems, such as FlAsH</li> </ul> <ul> <li>Visualization of dynamic processes within cells, including protein trafficking, turnover, and complex formation</li> <li>Live cell imaging</li> <li>Protein purification</li> </ul> Available for licensing. 2022-03-08 2025-05-06 2025-05-06 2010-04-20 ACXXXX, AXXXXX, CLIP, CLIP-tag, fluorescent, Fluorescent probe, IMAGING, LIGANDS, Patent Category - Biotechnology, REVERSIBLE, SNAP, SNAP-tag, Trafficking False True True NIHTT 37470483 Website Abstract 114171053 In preparation. In preparation. 114106867 Donaldson, Julie National Heart, Lung, and Blood Institute (NHLBI) NHLBI Donaldson, Julie (NHLBI) 0 114106866 Cole, Nelson National Heart, Lung, and Blood Institute (NHLBI) NCI Cole, Nelson (NCI) 1 114106866 Cole, Nelson National Heart, Lung, and Blood Institute (NHLBI) NCI Cole, Nelson (NCI) 1 114106867 Donaldson, Julie National Heart, Lung, and Blood Institute (NHLBI) NHLBI Donaldson, Julie (NHLBI) 0 114101390 Reversible SNAP-tag Ligands E-057-2010-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 83685986 Crooks, Denise crooksd@mail.nih.gov
United States of America Office of Technology Transfer and Development crooksd@mail.nih.gov?subject=Web Inquiry on [TAB-2096] Reversible SNAP-Tag and CLIP-Tag Ligands for Live Cell Imaging&body=Please send me information about technology [TAB-2096] Reversible SNAP-Tag and CLIP-Tag Ligands for Live Cell Imaging. Crooks, Denise<br><a href="mailto:crooksd@mail.nih.gov?subject=Web Inquiry on [TAB-2096] Reversible SNAP-Tag and CLIP-Tag Ligands for Live Cell Imaging&body=Please send me information about technology [TAB-2096] Reversible SNAP-Tag and CLIP-Tag Ligands for Live Cell Imaging.">crooksd@mail.nih.gov</a><br> 114166009 E-057-2010-0 E-057-2010-0-US-01 RELEASIBLE SNAP-TAG LIGANDS AND METHODS OF MAKING AND USING SAME PRV US 61/312,814 Abandoned US <br />Provisional (PRV) 61/312,814<br />Filed on 2010-03-11<br />Status: Abandoned 114121020 ACXXXX 114121021 AXXXXX 114139673 LIGANDS 114139674 SNAP-tag 114139675 REVERSIBLE 114139676 Patent Category - Biotechnology 114139677 CLIP 114139678 SNAP 114139679 CLIP-tag 114139680 fluorescent 114139681 Fluorescent probe 114139682 IMAGING 114139683 Trafficking TAB-2100 114096317 A Method of Reducing Cholesterol Biosynthesis with Specific MicroRNAs NHLBI Collaboration, Diagnostics, Licensing, Research Materials, Therapeutics Collaboration Diagnostics Licensing Research Materials Therapeutics Alan Remaley, Kasey Vickers This technology is directed to the discovery of specific microRNAs that target and downregulate enzymes within the cholesterol biosynthetic pathway and is currently being tested in vivo.<br><br> Briefly, microRNAs regulate the translation of messenger RNAs (mRNAs) into protein. The inventors have discovered a set of specific microRNAs that downregulate the expression of multiple enzymes in the cholesterol biosynthetic pathway. Importantly, this technology may provide the benefits of cholesterol lowering therapies to patients that are not suited for statin-based treatments. Statins block the cholesterol biosynthetic pathway at a single enzymatic step and may result in the deleterious build-up of a metabolic intermediate. In contrast, this technology simultaneously targets the expression of multiple enzymes required for cholesterol biosynthesis and thus may avoid the build-up of metabolic intermediates. The reduction of cholesterol biosynthesis has been indicated for improved cardiovascular health and lowers the risk for heart disease, heart attack, and stroke. <ul> <li>May be effective for patients not suited for statin-based treatment.</li> <li>Targets multiple enzymes in the cholesterol biosynthetic pathway simultaneously.</li> </ul> <ul> <li>A method of reducing cellular cholesterol biosynthesis.</li> <li>A method of reducing systemic cholesterol in a subject.</li> </ul> The National Heart, Lung and Blood Institute, Pulmonary Vascular Medicine Branch, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize microRNA regulation of the cholesterol biosynthetic pathway. Please contact Dr. Denise M. Crooks at 301-435-0103, <a href="mailto:crooksd@nhlbi.nih.gov">crooksd@nhlbi.nih.gov</a> for more information. Available for licensing. 2022-03-08 2025-05-06 2025-05-06 2010-04-20 BBXXXX, BIOSYNTHESIS, CHOLESTEROL, ICXXXX, IXXXXX, MicroRNAs, Novel, Patent Category - Biotechnology, REGULATE, STRATEGY False True Early stage True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114171065 Vickers KC and Remaley AT. MicroRNAs in atherosclerosis and lipoprotein metabolism. Curr Opin Endocrinol Diabetes Obesity. 2010 Apr;17(2):150-155; DOI 10.1097/MED.0b013e32833727a1. http://preview.ncbi.nlm.nih.gov/pubmed/20150807 <a href="http://preview.ncbi.nlm.nih.gov/pubmed/20150807">Vickers KC and Remaley AT. MicroRNAs in atherosclerosis and lipoprotein metabolism. Curr Opin Endocrinol Diabetes Obesity. 2010 Apr;17(2):150-155; DOI 10.1097/MED.0b013e32833727a1.</a> 114106873 Remaley, Alan NHLBI Remaley, Alan (NHLBI) 0 114106874 Vickers, Kasey National Heart, Lung, and Blood Institute (NHLBI) Vickers, Kasey 1 114106874 Vickers, Kasey National Heart, Lung, and Blood Institute (NHLBI) Vickers, Kasey 1 114106873 Remaley, Alan NHLBI Remaley, Alan (NHLBI) 0 114101394 A Novel Strategy To Regulate Cholesterol Biosynthesis With MicroRNAs E-142-2009-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 157176205 Townsend, Donald donald.townsend@nih.gov
United States of America donald.townsend@nih.gov?subject=Web Inquiry on [TAB-2100] A Method of Reducing Cholesterol Biosynthesis with Specific MicroRNAs&body=Please send me information about technology [TAB-2100] A Method of Reducing Cholesterol Biosynthesis with Specific MicroRNAs. Townsend, Donald<br><a href="mailto:donald.townsend@nih.gov?subject=Web Inquiry on [TAB-2100] A Method of Reducing Cholesterol Biosynthesis with Specific MicroRNAs&body=Please send me information about technology [TAB-2100] A Method of Reducing Cholesterol Biosynthesis with Specific MicroRNAs.">donald.townsend@nih.gov</a><br> 114161896 E-142-2009-0 E-142-2009-0-US-01 A Novel Strategy To Regulate Cholesterol Biosynthesis With MicroRNAs PRV US 61/280,170 Abandoned US <br />Provisional (PRV) 61/280,170<br />Filed on 2009-10-30<br />Status: Abandoned 114121028 ICXXXX 114121029 IXXXXX 114121316 BBXXXX 114139706 Novel 114139707 STRATEGY 114139708 REGULATE 114139709 CHOLESTEROL 114139710 BIOSYNTHESIS 114139711 MicroRNAs 114139712 Patent Category - Biotechnology TAB-1101 114095430 The Use of Rabbits with Defined Immunoglobulin Light Chain Genes (C<sub>kappa</sub> b allotypes) to Optimize Production of Chimeric and Humanized Monoclonal Antibodies for Therapeutic, Imaging and Diagnostic Applications NIAID Diagnostics, Licensing, Materials Available, Research Materials, Therapeutics Diagnostics Licensing Materials Available Research Materials Therapeutics Cornelius Alexander, Rose Mage Biological materials are important research tools that can be used for diagnostic as well as therapeutic purposes. Antibodies have become viable drugs in the market today and there is a general market need for systems that may facilitate production of efficient and effective antibodies. In recent years, monoclonal antibodies have gained significant importance in their use, both as diagnostics and therapeutics, to intervene and combat diseases such as cancer, cardiovascular diseases, and infections. The present invention relates to the discovery of rabbits, genetically defined as b9, as the biological vehicle for the isolation of chimeric phage displaying Fab with human constant regions and rabbit immunoglobulin heavy and light chain variable regions for the development of diagnostic antibodies and humanized monoclonal therapeutic antibodies of high affinity and specificity (Popkov et al., J. Molec. Biol. 325: 325-335, 2003; Popkov et al., J. Immunol. Methods 288: 149-164, 2004). Recently, many effective antibodies have been developed as a result of the integration of antibody libraries with phage display technology. The rabbit model described in this invention may be used for production of antibodies that may cross react with both human and mouse antigens. Rabbit monoclonal antibodies that react with both human and mouse antigens are of particular relevance for the preclinical evaluation of therapeutic antibodies in mouse models of human diseases. Therefore, this invention has a broad commercial potential in its use as a source for producing monoclonal antibodies for therapeutic interventions in infectious, autoimmune and neurological diseases, nerve damage and cancer. 2022-03-08 2025-05-06 2025-05-06 2004-12-01 AA3XXX, AAXXXX, AXXXXX, IBXXXX, IXXXXX False True True NIHTT 37470483 Website Abstract 114105065 Mage, Rose NIAID Mage, Rose (NIAID) 0 114105066 Alexander, Cornelius NIAID Alexander, Cornelius (NIAID) 0 114105065 Mage, Rose NIAID Mage, Rose (NIAID) 0 114105066 Alexander, Cornelius NIAID Alexander, Cornelius (NIAID) 0 114100324 The Use Of Rabbits With Defined Immunoglobulin Light Chain Genes (c-kappa B Allotypes) To Optimize Production Of Chimeric And Humanized Monoclonal Antibodies For Therapeutic, Imaging And Diagnostic Applications E-332-2004-0 Research Material NIAID 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-1101] The Use of Rabbits with Defined Immunoglobulin Light Chain Genes (C<sub>kappa</sub> b allotypes) to Optimize Production of Chimeric and Humanized Monoclonal Antibodies for Therapeutic, Imaging and Diagnostic Applications&body=Please send me information about technology [TAB-1101] The Use of Rabbits with Defined Immunoglobulin Light Chain Genes (C<sub>kappa</sub> b allotypes) to Optimize Production of Chimeric and Humanized Monoclonal Antibodies for Therapeutic, Imaging and Diagnostic Applications. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-1101] The Use of Rabbits with Defined Immunoglobulin Light Chain Genes (C<sub>kappa</sub> b allotypes) to Optimize Production of Chimeric and Humanized Monoclonal Antibodies for Therapeutic, Imaging and Diagnostic Applications&body=Please send me information about technology [TAB-1101] The Use of Rabbits with Defined Immunoglobulin Light Chain Genes (C<sub>kappa</sub> b allotypes) to Optimize Production of Chimeric and Humanized Monoclonal Antibodies for Therapeutic, Imaging and Diagnostic Applications.">yogikala.prabhu@nih.gov</a><br> 114116085 AA3XXX 114116086 AAXXXX 114116087 IBXXXX 114116088 AXXXXX 114116089 IXXXXX TAB-903 114095237 Full-Length cDNA Clone Representing the Consensus Sequence of the RNA Genome of a Human Norovirus (strain MD145-12) That Encodes Biologically Active Proteins NIAID Collaboration, Infectious Disease, Licensing, Materials Available, Research Materials, Vaccines Collaboration Infectious Disease Licensing Materials Available Research Materials Vaccines Gael Belliot, Lisbeth Kim Green, Stanislav Sosnovtsev The invention provides for a full-length cloned cDNA copy of the RNA genome of a predominant norovirus strain (Genogroup II.4) designated MD145-12 that was associated with human gastrointestinal illness. The noroviruses, which were formerly known as "Norwalk-like" viruses are estimated to cause 23 million cases of acute gastroenteritis in the USA each year. The virus has been designated into category B of the CDC biodefense-related priority pathogens because it can be used as an agent of bioterrorism. The subject cDNA clone of the virus encodes proteins of the MD145-12 strain that, when expressed in vitro, exhibit properties that would be expected from those produced by the original infectious virus. This cDNA clone is presently the only source to obtain norovirus proteins to facilitate studies aimed at developing control strategies such as vaccines and therapeutic drugs. The Laboratory of Infectious Diseases, NIAID, NIH, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize reagents derived from a cDNA clone of the genome of a predominant human norovirus strain, Genogroup II.4. Please contact Kim Y. Green at <a href="mailto:kgreen@niaid.nih.gov">kgreen@niaid.nih.gov</a> for more information. Research Material -- Patent protection is not being pursued for this technology Research Material -- Patent protection is not being pursued for these technologies The cDNA clone for norovirus strain MD145-12 is available for licensing via a biological material license (BML). 2022-03-08 2025-05-06 2025-05-06 2008-06-01 Active, Biological, cDNA, CLONE, CONSENSUS, DC5BXX, DCXXXX, DDXXXX, DXXXXX, ENCODES, FULL-LENGTH, Genome, Human, MD145-12, Norovirus, proteins, Respresenting, RNA, sequence, Strain, That False True True NIHTT 37470483 Website Abstract E-283-2003-0 E-214-2003-0 E-198-2003-0 114104705 Sosnovtsev, Stanislav NIAID - DIR NIAID Sosnovtsev, Stanislav (NIAID) 0 114104706 Green, Lisbeth Kim NIAID - DIR NIAID Green, Lisbeth Kim (NIAID) 0 114104707 Belliot, Gael NIAID - DIR NIAID Belliot, Gael (NIAID) 1 114104707 Belliot, Gael NIAID - DIR NIAID Belliot, Gael (NIAID) 1 114104705 Sosnovtsev, Stanislav NIAID - DIR NIAID Sosnovtsev, Stanislav (NIAID) 0 114104706 Green, Lisbeth Kim NIAID - DIR NIAID Green, Lisbeth Kim (NIAID) 0 114100095 Full-Length CDNA Clone Respresenting The Consensus Sequence Of The RNA Genome Of A Human Norovirus (strain MD145-12) That Encodes Biological Active Proteins E-212-2003-0 Research Material NIAID 83643855 Soukas, Peter peter.soukas@nih.gov
United States of America Technology Transfer and Intellectual Property Office peter.soukas@nih.gov?subject=Web Inquiry on [TAB-903] Full-Length cDNA Clone Representing the Consensus Sequence of the RNA Genome of a Human Norovirus (strain MD145-12) That Encodes Biologically Active Proteins&body=Please send me information about technology [TAB-903] Full-Length cDNA Clone Representing the Consensus Sequence of the RNA Genome of a Human Norovirus (strain MD145-12) That Encodes Biologically Active Proteins. Soukas, Peter<br><a href="mailto:peter.soukas@nih.gov?subject=Web Inquiry on [TAB-903] Full-Length cDNA Clone Representing the Consensus Sequence of the RNA Genome of a Human Norovirus (strain MD145-12) That Encodes Biologically Active Proteins&body=Please send me information about technology [TAB-903] Full-Length cDNA Clone Representing the Consensus Sequence of the RNA Genome of a Human Norovirus (strain MD145-12) That Encodes Biologically Active Proteins.">peter.soukas@nih.gov</a><br> 114115202 DC5BXX 114115203 DDXXXX 114115204 DCXXXX 114115205 DXXXXX 114130384 FULL-LENGTH 114130385 cDNA 114130386 CLONE 114130387 Respresenting 114130388 CONSENSUS 114130389 sequence 114130390 RNA 114130391 Genome 114130392 Human 114130393 Norovirus 114130394 Strain 114130395 MD145-12 114130396 That 114130397 ENCODES 114130398 Biological 114130399 Active 114130400 proteins TAB-2603 114096797 Multiplex Assay for Detection of Dengue Virus CDC Diagnostics, Infectious Disease, Licensing, Rare/Neglected Diseases Diagnostics Infectious Disease Licensing Rare/Neglected Diseases Jorge Munoz-Jordan, Gilberto Santiago, Edgardo Vergne Dengue virus (DENV) is the cause of dengue illness (dengue fever, dengue hemorrhagic fever, and dengue shock syndrome). CDC researchers have developed a RT-PCR multiplex assay that, prior to sero-conversion, selectively detects dengue virus in biological or other fluid media, such as whole blood, plasma, or serum. The primers and probes from this assay are sufficiently specific to amplify and detect all four DENV serotypes. This FDA-approved technology may provide an improved method for rapid and accurate serotyping of dengue virus in clinical and research settings. <ul> <li>Increased sensitivity and efficiency compared to current antigen-based assays and single reaction real-time RT-PCR analyses</li> <li>Addresses need for accurate molecular diagnosis of DENV</li> <li>FDA approved technology</li> </ul> <ul> <li>Rapid, simple and accurate dengue virus (DENV) serotype identification</li> <li>Diagnostic tool for clinical or research settings</li> </ul> 2022-03-08 2025-04-24 2025-04-24 2013-08-02 Broad, DA4BXX, DA4XXX, DAXXXX, DENGUE, Detection, DXXXXX, Serotypes, UB1XXX, virus False True <ul> <li>In vitro data available</li> <li>In situ data available (on-site)</li> </ul> True NIHTT 37470483 Website Abstract 114171859 Munoz-Jordan JL, et al. http://www.ncbi.nlm.nih.gov/pubmed/23632064 <a href="http://www.ncbi.nlm.nih.gov/pubmed/23632064">Munoz-Jordan JL, et al.</a> 114171923 Santiago GA, et al. http://www.ncbi.nlm.nih.gov/pubmed/23875046 <a href="http://www.ncbi.nlm.nih.gov/pubmed/23875046">Santiago GA, et al.</a> 114108042 Vergne, Edgardo CDC - DIR CDC Vergne, Edgardo (CDC) 0 114108043 Santiago, Gilberto CDC - DIR CDC Santiago, Gilberto (CDC) 0 114108041 Munoz-Jordan, Jorge CDC - DIR CDC Munoz-Jordan, Jorge (CDC) 1 114108041 Munoz-Jordan, Jorge CDC - DIR CDC Munoz-Jordan, Jorge (CDC) 1 114108042 Vergne, Edgardo CDC - DIR CDC Vergne, Edgardo (CDC) 0 114108043 Santiago, Gilberto CDC - DIR CDC Santiago, Gilberto (CDC) 0 114101921 Broad Detection Of Dengue Virus Serotypes E-148-2013-0 Filing authorized Centers for Disease Control and Prevention (CDC) 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-2603] Multiplex Assay for Detection of Dengue Virus&body=Please send me information about technology [TAB-2603] Multiplex Assay for Detection of Dengue Virus. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-2603] Multiplex Assay for Detection of Dengue Virus&body=Please send me information about technology [TAB-2603] Multiplex Assay for Detection of Dengue Virus.">benjamin.hurley@nih.gov</a><br> 114167177 E-148-2013-0 E-148-2013-0-US-01 Broad Detection Of Dengue Virus Serotypes PRV US 61/554,126 Abandoned US <br />Provisional (PRV) 61/554,126<br />Filed on 2011-11-01<br />Status: Abandoned 114167178 E-148-2013-0 E-148-2013-0-PCT-02 Broad Detection Of Dengue Virus Serotypes PCT Patent Cooperation Treaty PCT/US2012/061828 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2012/061828<br />Filed on 2012-10-25<br />Status: Expired 114167807 E-148-2013-0 E-148-2013-0-US-06 Broad Detection Of Dengue Virus Serotypes National Stage US 9,657,361 14/354,972 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9657361 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9657361">9,657,361</a><br />Filed on 2014-04-29<br />Status: Issued 114168250 E-148-2013-0 E-148-2013-0-US-08 Broad Detection Of Dengue Virus Serotypes DIV US 10,563,269 15/488,946 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10563269 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10563269">10,563,269</a><br />Filed on 2017-04-17<br />Status: Issued 114123523 DA4BXX 114123528 UB1XXX 114123529 DXXXXX 114123530 DAXXXX 114123531 DA4XXX 114144772 Broad 114144773 Detection 114144774 DENGUE 114144775 virus 114144776 Serotypes TAB-2601 114096795 Use of Vitronectin as a Biomarker for the Detection of Dengue Hemorrhagic Fever CDC Diagnostics, Infectious Disease, Licensing, Rare/Neglected Diseases Diagnostics Infectious Disease Licensing Rare/Neglected Diseases Elizabeth Hunsperger, Momar Ndao, Betty Poole-Smith, Kay Tomashek Dengue hemorrhagic fever (DHF) is a severe, potentially deadly infection spread by mosquitos. CDC scientists have identified vitronectin as an important biomarker of DHF. They have shown vitronectin is significantly reduced in DHF and severe dengue infections when compared to dengue non-hemorrhagic fever patients. Presently, DHF is established by assessing antibody concentrations and other rule-of-thumb criteria, but often these assays can be difficult to interpret and lead to false conclusions. Establishing vitronectin levels provides a specific, novel biomarker for DHF, leading to increased accuracy in clinical diagnoses and improved patient outcomes. <ul> <li>While there are commercially-available ELISAs to detect vitronectin, these products have not been used for dengue diagnosis</li> <li>Vitronectin assessment assays provide a novel, specific biomarker for the DHF disease state</li> <li>Easily developed for serologic diagnostic assays</li> </ul> <ul> <li>Diagnostic biomarker of DHF</li> <li>Point-of-care diagnostic testing</li> <li>Enzyme-linked immunosorbent assay (ELISA) for clinical and laboratory use</li> </ul> 2022-03-08 2025-04-24 2025-04-24 2013-08-02 assay, Biomarker, DA4BXX, DA4XXX, DAXXXX, DENGUE, Detection, diagnostic, DIFFERENTIATION, DXXXXX, FEVER, HEMORRHAGIC, HOST, UB1XXX False True <ul> <li>Pre-clinical</li> <li>In vitro data available</li> </ul> True NIHTT 37470483 Website Abstract 114171857 Poole-Smith BK, et al. Discovery and Validation of Prognostic Biomarkers for Severe Dengue by Proteomic Screening. International Conference on Emerging Infectious Diseases 2012: poster and oral presentation abstracts. Emerg Infect Dis. 2012 Mar. http://wwwnc.cdc.gov/eid/pdfs/ICEID2012.pdf http://wwwnc.cdc.gov/eid/pdfs/ICEID2012.pdf <a href="http://wwwnc.cdc.gov/eid/pdfs/ICEID2012.pdf">Poole-Smith BK, et al. Discovery and Validation of Prognostic Biomarkers for Severe Dengue by Proteomic Screening. International Conference on Emerging Infectious Diseases 2012: poster and oral presentation abstracts. Emerg Infect Dis. 2012 Mar. http://wwwnc.cdc.gov/eid/pdfs/ICEID2012.pdf</a> 114108035 Ndao, Momar McGill University CDC Ndao, Momar (CDC) 0 114108036 Tomashek, Kay CDC - DIR CDC Tomashek, Kay (CDC) 0 114108037 Poole-Smith, Betty CDC - DIR CDC Poole-Smith, Betty (CDC) 0 114108034 Hunsperger, Elizabeth CDC - DIR CDC Hunsperger, Elizabeth (CDC) 1 114108034 Hunsperger, Elizabeth CDC - DIR CDC Hunsperger, Elizabeth (CDC) 1 114108035 Ndao, Momar McGill University CDC Ndao, Momar (CDC) 0 114108036 Tomashek, Kay CDC - DIR CDC Tomashek, Kay (CDC) 0 114108037 Poole-Smith, Betty CDC - DIR CDC Poole-Smith, Betty (CDC) 0 114101919 Detection Of Host Biomarker Diagnostic Assay For Dengue Fever And The Differentiation Of Dengue Hemorrhagic Fever E-147-2013-0 Closed Centers for Disease Control and Prevention (CDC), McGill University 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-2601] Use of Vitronectin as a Biomarker for the Detection of Dengue Hemorrhagic Fever&body=Please send me information about technology [TAB-2601] Use of Vitronectin as a Biomarker for the Detection of Dengue Hemorrhagic Fever. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-2601] Use of Vitronectin as a Biomarker for the Detection of Dengue Hemorrhagic Fever&body=Please send me information about technology [TAB-2601] Use of Vitronectin as a Biomarker for the Detection of Dengue Hemorrhagic Fever.">benjamin.hurley@nih.gov</a><br> 114167172 E-147-2013-0 E-147-2013-0-US-01 Detection Of Host Biomarker Diagnostic Assay For Dengue Fever And The Differentiation Of Dengue Hemorrhagic Fever PRV US 61/443,554 Abandoned US <br />Provisional (PRV) 61/443,554<br />Filed on 2011-02-16<br />Status: Abandoned 114167173 E-147-2013-0 E-147-2013-0-PCT-02 Detection Of Host Biomarker Diagnostic Assay For Dengue Fever And The Differentiation Of Dengue Hemorrhagic Fever PCT Patent Cooperation Treaty PCT/US2012/025472 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2012/025472<br />Filed on 2012-02-16<br />Status: Expired 114167299 E-147-2013-0 E-147-2013-0-US-03 Detection Of Host Biomarker Diagnostic Assay For Dengue Fever And The Differentiation Of Dengue Hemorrhagic Fever National Stage US 13/985,507 Abandoned US <br />National Stage 13/985,507<br />Filed on 2015-05-07<br />Status: Abandoned 114123517 DA4BXX 114123518 UB1XXX 114123519 DXXXXX 114123520 DAXXXX 114123521 DA4XXX 114144758 Detection 114144759 HOST 114144760 Biomarker 114144761 diagnostic 114144762 assay 114144763 DENGUE 114144764 FEVER 114144765 DIFFERENTIATION 114144766 HEMORRHAGIC TAB-2624 114096818 Reduced Virulence Crimean-Congo Hemorrhagic Fever Virus for Vaccine Development CDC Infectious Disease, Licensing, Materials Available, Research Materials, Vaccines Infectious Disease Licensing Materials Available Research Materials Vaccines Eric Bergeron, MIchelle Deaton, Stuart Nichol, Scott Pegan This invention relates to a genetically modified hemorrhagic fever virus that can be used as an effective live vaccine agent. Hemorrhagic fever evades the human immune response using the viral ovarian tumor domain (vOTU) protease, which inhibits critical host-immunity functions. The present genetically modified virus has a vOTU protease with decreased ability to remove ubiquitin (Ub) and ISG15 tags from proteins in cells it infects. Thus, the virulence is reduced, creating an immunogenic and non-pathogenic virus for use as a live vaccine against Crimean-Congo hemorrhagic fever (CCHF) virus. Unlike strains with complete ablation of the vOTU protease, the present modified virus retains enough activity for replication in a human cell line, making vaccine production possible. This technology may be used to create vaccines or therapeutics for other nairoviruses, including the Dugbe, Hazara, and Nairobi sheep disease viruses. <ul> <li>Increased safety for CCHF laboratory research (Biosafety Level 2).</li> <li>Use of human cell lines allows large-scale manufacturing of vaccines.</li> <li>vOTU domain-disruption may be used to develop vaccines for all nairovirus viruses affecting humans and/or livestock.</li> </ul> <ul> <li>Development of vaccines or therapeutics for CCHF virus and other nairoviruses, including Dugbe, Hazara and Nairobi sheep disease viruses.</li> </ul> 2022-03-08 2025-04-24 2025-04-24 2013-08-23 ABLATION, Activities, Crimean-Congo, DC5BXX, DC5XXX, DCXXXX, DDXXXX, DeiSGylating, Deubiqutinating, Domain, DXXXXX, FEVER, HEMORRHAGIC, OVARIAN, Protease's, SIMULTANEOUS, tumor, Vaccine, virus False True <ul> <li>Pre-clinical</li> <li>In vitro data available</li> </ul> True NIHTT 37470483 Website Abstract 114171888 Bergeron E, et al. http://www.ncbi.nlm.nih.gov/pubmed/19864393 <a href="http://www.ncbi.nlm.nih.gov/pubmed/19864393">Bergeron E, et al.</a> 114171889 Capodagli GC, et al. http://www.ncbi.nlm.nih.gov/pubmed/21228232 <a href="http://www.ncbi.nlm.nih.gov/pubmed/21228232">Capodagli GC, et al.</a> 114108097 Pegan, Scott University of Colorado, Denver Pegan, Scott 0 114108098 Deaton, MIchelle University of Colorado, Denver Deaton, MIchelle 0 114108099 Nichol, Stuart CDC - DIR CDC Nichol, Stuart (CDC) 0 114108096 Bergeron, Eric CDC - DIR CDC Bergeron, Eric (CDC) 1 114108096 Bergeron, Eric CDC - DIR CDC Bergeron, Eric (CDC) 1 114108097 Pegan, Scott University of Colorado, Denver Pegan, Scott 0 114108098 Deaton, MIchelle University of Colorado, Denver Deaton, MIchelle 0 114108099 Nichol, Stuart CDC - DIR CDC Nichol, Stuart (CDC) 0 114101942 Crimean-Congo Hemorrhagic Fever Virus Vaccine Through Simultaneous Ablation Of The Virus Ovarian Tumor Domain Protease's Deubiqutinating And DeiSGylating Activities E-486-2013-0 Filing authorized Centers for Disease Control and Prevention (CDC), University of Denver 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-2624] Reduced Virulence Crimean-Congo Hemorrhagic Fever Virus for Vaccine Development&body=Please send me information about technology [TAB-2624] Reduced Virulence Crimean-Congo Hemorrhagic Fever Virus for Vaccine Development. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-2624] Reduced Virulence Crimean-Congo Hemorrhagic Fever Virus for Vaccine Development&body=Please send me information about technology [TAB-2624] Reduced Virulence Crimean-Congo Hemorrhagic Fever Virus for Vaccine Development.">benjamin.hurley@nih.gov</a><br> 114167222 E-486-2013-0 E-486-2013-0-US-01 Crimean-Congo Hemorrhagic Fever Virus Vaccine PRV US 61/683,132 Abandoned US <br />Provisional (PRV) 61/683,132<br />Filed on 2012-08-14<br />Status: Abandoned 114167223 E-486-2013-0 E-486-2013-0-US-02 Crimean-Congo Hemorrhagic Fever Virus Vaccine ORD US 9,474,796 13/829,105 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9474796 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9474796">9,474,796</a><br />Filed on 2013-03-14<br />Status: Issued 114167224 E-486-2013-0 E-486-2013-0-PCT-03 Attenuated live vaccine for Crimean Congo hemorrhagic fever virus and Erve virus PCT Patent Cooperation Treaty PCT/US13/054760 Expired Patent Cooperation Treaty <br />(PCT) PCT/US13/054760<br />Filed on 2013-08-13<br />Status: Expired 114168075 E-486-2013-0 E-486-2013-0-US-06 ATTENUATED LIVE VACCINE FOR CRIMEAN-CONGO HEMORRHAGIC FEVER VIRUS AND ERVE VIRUS National Stage US 9,795,665 14/421,120 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9795665 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9795665">9,795,665</a><br />Filed on 2015-02-11<br />Status: Issued 114123670 DXXXXX 114123671 DCXXXX 114123672 DC5XXX 114123673 DC5BXX 114123674 DDXXXX 114144946 Crimean-Congo 114144947 HEMORRHAGIC 114144948 FEVER 114144949 virus 114144950 Vaccine 114144951 SIMULTANEOUS 114144952 ABLATION 114144953 OVARIAN 114144954 tumor 114144955 Domain 114144956 Protease's 114144957 Deubiqutinating 114144958 DeiSGylating 114144959 Activities TAB-2642 114096830 Recombinant Pan-Lyssavirus for Use in Rabies and Broad-Lyssavirus Vaccination CDC Infectious Disease, Licensing, Therapeutics, Vaccines Infectious Disease Licensing Therapeutics Vaccines Ivan Kuzmin, Charles Rupprecht, Xianfu Wu CDC researchers have developed recombinant lyssaviruses that can be used for the development of an improved, broad-spectrum vaccine against several rabies genotypes. Lyssaviruses are single-stranded RNA viruses that cause rabies and rabies-like diseases in mammals. Currently, there are commercially available vaccines that are considered to be effective against infections from a single viral phylogroup; however, these vaccines confer little or no protection against viruses outside of the phylogroup. The present recombinants have glycoprotein-encoding genes from at least two different lyssaviruses and can be used as pan-lyssaviral vaccines to provide protection against infection by multiple lyssavirus phylogroups. <ul> <li>Broad-spectrum vaccine potential</li> <li>Pan-lyssavirus vaccination tools will be particularly beneficial in endemic and developing regions</li> <li>Employs a presently commercialized vaccine backbone/platform, making this innovation easily adaptable for industrial R&D and subsequent large-scale production</li> </ul> <ul> <li>Pan-lyssavirus vaccines</li> <li>Rabies surveillance and vaccination programs</li> </ul> 2022-03-08 2025-04-24 2025-04-24 2013-09-17 Against, CDC Docket Import, CDC Docket Import CDC Prosecuting, DB4XXX, DBXXXX, DC1XXX, DC5BXX, DC5XXX, DCXXXX, DXXXXX, PAN-LYSSAVIRUS, rabies, vaccines False True Pre-clinical True NIHTT 37470483 Website Abstract E-326-2013-0 114171906 Kuzmin IV, et al. http://www.ncbi.nlm.nih.gov/pubmed/18514350 <a href="http://www.ncbi.nlm.nih.gov/pubmed/18514350">Kuzmin IV, et al.</a> 114108136 Rupprecht, Charles CDC - DIR CDC Rupprecht, Charles (CDC) 0 114108137 Kuzmin, Ivan CDC - DIR CDC Kuzmin, Ivan (CDC) 0 114108135 Wu, Xianfu CDC - DIR CDC Wu, Xianfu (CDC) 1 114108135 Wu, Xianfu CDC - DIR CDC Wu, Xianfu (CDC) 1 114108136 Rupprecht, Charles CDC - DIR CDC Rupprecht, Charles (CDC) 0 114108137 Kuzmin, Ivan CDC - DIR CDC Kuzmin, Ivan (CDC) 0 114101955 PAN-LYSSAVIRUS VACCINES AGAINST RABIES E-256-2013-0 Closed Centers for Disease Control and Prevention (CDC) 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-2642] Recombinant Pan-Lyssavirus for Use in Rabies and Broad-Lyssavirus Vaccination&body=Please send me information about technology [TAB-2642] Recombinant Pan-Lyssavirus for Use in Rabies and Broad-Lyssavirus Vaccination. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-2642] Recombinant Pan-Lyssavirus for Use in Rabies and Broad-Lyssavirus Vaccination&body=Please send me information about technology [TAB-2642] Recombinant Pan-Lyssavirus for Use in Rabies and Broad-Lyssavirus Vaccination.">benjamin.hurley@nih.gov</a><br> 114160720 E-256-2013-0 E-256-2013-0-US-09 PAN-LYSSAVIRUS VACCINES AGAINST RABIES CON US 14/978,135 Abandoned US <br />Continuation (CON) 14/978,135<br />Filed on 2015-12-22<br />Status: Abandoned 114167264 E-256-2013-0 E-256-2013-0-US-01 PAN-LYSSAVIRUS VACCINES AGAINST RABIES PRV US 61/358,288 Abandoned US <br />Provisional (PRV) 61/358,288<br />Filed on 2010-06-24<br />Status: Abandoned 114167265 E-256-2013-0 E-256-2013-0-PCT-02 PAN-LYSSAVIRUS VACCINES AGAINST RABIES PCT Patent Cooperation Treaty PCT/US2011/041579 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2011/041579<br />Filed on 2011-06-23<br />Status: Expired 114167266 E-256-2013-0 E-256-2013-0-US-08 PAN-LYSSAVIRUS VACCINES AGAINST RABIES National Stage US 9,248,179 13/806,622 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9248179 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9248179">9,248,179</a><br />Filed on 2012-12-21<br />Status: Abandoned 114123737 DXXXXX 114123738 DBXXXX 114123739 DB4XXX 114123740 DCXXXX 114123741 DC5XXX 114123742 DC5BXX 114123743 DC1XXX 114145069 PAN-LYSSAVIRUS 114145070 vaccines 114145071 Against 114145072 rabies 114145073 CDC Docket Import 114145074 CDC Docket Import CDC Prosecuting TAB-2639 114096827 Antigen-capture Electrochemiluminescent Assay for Determining Rabies Vaccine Potency CDC Diagnostics, Infectious Disease, Licensing, Vaccines Diagnostics Infectious Disease Licensing Vaccines Charles Rupprecht CDC researchers developed a more efficient method of assessing rabies vaccine potency using an antigen-capture electrochemiluminescent (ECL) assay. This assay utilizes SULFO-NHS-Ester labeled murine monoclonal antibodies to quantify glycoprotein concentration, which is an indicator of vaccine potency. Currently, the potency of rabies vaccines is determined by the effective-dose (ED50) mouse study evaluation method, which is more than 50 years old. The labor-intensive ED50 evaluation method has high operating costs, extensive biosafety requirements, and requires the sacrifice of a large number of animals. CDC researchers have addressed these issues by developing a competitive in vitro antigen-capture assay that is rapid, highly robust, reproducible, flexible and much less expensive to implement than the traditional ED50-mouse study evaluation. <ul> <li>Efficient vaccine evaluation</li> <li>Highly robust, reproducible and flexible</li> <li>Easily standardized for consistent, universal usage and assurance of batch-to-batch vaccine homogeneity</li> <li>In vitro assay may replace the 50 year old ED50 mouse procedure</li> </ul> <ul> <li>Rabies vaccine design and development</li> <li>Vaccine quality control and quality assurance testing</li> <li>In vitro assay for rabies virus glycoprotein</li> </ul> 2022-03-08 2025-04-24 2025-04-24 2013-09-17 AAXXXX, ABXXXX, AG1XXX, AG2XXX, AGXXXX, ANALYSES, assay, AXXXXX, CDC Docket Import, CDC Docket Import CDC Prosecuting, DA4BXX, DA4XXX, DAXXXX, DC5BXX, DC5XXX, DCXXXX, DXXXXX, GLYCOPROTEIN, rabies, virus False True <ul> <li>Pre-clinical</li> <li>In vitro data available</li> <li>In vivo data available (animal)</li> </ul> True NIHTT 37470483 Website Abstract E-256-2013-0 E-326-2013-0 114171903 Smith TG, et al. http://www.ncbi.nlm.nih.gov/pubmed/23742991 <a href="http://www.ncbi.nlm.nih.gov/pubmed/23742991">Smith TG, et al.</a> 114108126 Rupprecht, Charles CDC - DIR CDC Rupprecht, Charles (CDC) 0 114108126 Rupprecht, Charles CDC - DIR CDC Rupprecht, Charles (CDC) 0 114101952 Assay For Analyses Of Rabies Virus Glycoprotein E-180-2013-0 Closed Centers for Disease Control and Prevention (CDC) 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-2639] Antigen-capture Electrochemiluminescent Assay for Determining Rabies Vaccine Potency&body=Please send me information about technology [TAB-2639] Antigen-capture Electrochemiluminescent Assay for Determining Rabies Vaccine Potency. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-2639] Antigen-capture Electrochemiluminescent Assay for Determining Rabies Vaccine Potency&body=Please send me information about technology [TAB-2639] Antigen-capture Electrochemiluminescent Assay for Determining Rabies Vaccine Potency.">benjamin.hurley@nih.gov</a><br> 114167258 E-180-2013-0 E-180-2013-0-US-01 Assay For Analyses Of Rabies Virus Glycoprotein PRV US 61/713,130 Abandoned US <br />Provisional (PRV) 61/713,130<br />Filed on 2012-10-12<br />Status: Abandoned 114167327 E-180-2013-0 E-180-2013-0-PCT-02 Assay For Analyses Of Rabies Virus Glycoprotein PCT Patent Cooperation Treaty PCT/US2013/064911 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2013/064911<br />Filed on 2013-10-15<br />Status: Expired 114168126 E-180-2013-0 E-180-2013-0-US-04 Assay For Analyses Of Rabies Virus Glycoprotein National Stage US 14/434,910 Abandoned US <br />National Stage 14/434,910<br />Filed on 2015-04-10<br />Status: Abandoned 114123718 AXXXXX 114123719 AG2XXX 114123720 AAXXXX 114123721 ABXXXX 114123722 AGXXXX 114123723 AG1XXX 114123724 DXXXXX 114123725 DAXXXX 114123726 DA4XXX 114123727 DA4BXX 114123728 DCXXXX 114123729 DC5XXX 114123730 DC5BXX 114145045 assay 114145046 ANALYSES 114145047 rabies 114145048 virus 114145049 GLYCOPROTEIN 114145050 CDC Docket Import 114145051 CDC Docket Import CDC Prosecuting TAB-2649 114096837 Novel Live-Attenuated Rabies Vaccine CDC Infectious Disease, Licensing, Vaccines Infectious Disease Licensing Vaccines Charles Rupprecht, Xianfu Wu The critical feature of this technology is the Evelyn-Rokitnicki-Abelseth (ERA) rabies whole genome DNA sequence. With the availability of the entire rabies genome, a recombinant vaccine can be developed using reverse genetics. Using this technology, CDC researchers have developed a recombinant, live-attenuated vaccine shown to confer protection against lethal doses of live, street-rabies virus in multiple survival studies. This vaccine offers better protection than traditional inactivated vaccinations, as demonstrated in co-infection studies. Further, a single intramuscular vaccination with the CDC's attenuated-virus was sufficient for survival of 100% of hamsters and mice following lethal challenge. <ul> <li>Live attenuated vaccine shows greater efficacy than older inactivated vaccine</li> <li>100% animal survival conferred by a single inoculation before lethal challenge</li> </ul> <ul> <li>Rabies vaccine design and development</li> <li>Immunogenic compositions for both prevention and treatment of rabies virus</li> <li>Rabies virus research</li> </ul> 2022-03-08 2025-04-24 2025-04-24 2013-09-19 CDC Docket Import, CDC Docket Import CDC Prosecuting, Compositions, DC1XXX, DC5BXX, DC5XXX, DCXXXX, DXXXXX, Genome, Genomes, Method, OID-NCEZID-DHCPP, RELATED, Sequences, sequencing, viral, Whole False True <ul> <li>Pre-clinical</li> <li>In vitro data available</li> <li>In vivo data available (animal)</li> </ul> True NIHTT 37470483 Website Abstract E-256-2013-0 114171914 Wu X, et al. http://www.ncbi.nlm.nih.gov/pubmed/21514343 <a href="http://www.ncbi.nlm.nih.gov/pubmed/21514343">Wu X, et al.</a> 114171930 Wu X, et al. http://www.ncbi.nlm.nih.gov/pubmed/17681631 <a href="http://www.ncbi.nlm.nih.gov/pubmed/17681631">Wu X, et al.</a> 114171931 Bankovskiy D, et al. http://www.ncbi.nlm.nih.gov/pubmed/18634508 <a href="http://www.ncbi.nlm.nih.gov/pubmed/18634508">Bankovskiy D, et al.</a> 114171932 Wu X, Rupprecht CE. http://www.ncbi.nlm.nih.gov/pubmed/17850911 <a href="http://www.ncbi.nlm.nih.gov/pubmed/17850911">Wu X, Rupprecht CE.</a> 114171933 Franka R, et al. http://www.ncbi.nlm.nih.gov/pubmed/21514343 <a href="http://www.ncbi.nlm.nih.gov/pubmed/21514343">Franka R, et al.</a> 114108154 Wu, Xianfu CDC - DIR CDC Wu, Xianfu (CDC) 0 114108153 Rupprecht, Charles CDC - DIR CDC Rupprecht, Charles (CDC) 1 114108153 Rupprecht, Charles CDC - DIR CDC Rupprecht, Charles (CDC) 1 114108154 Wu, Xianfu CDC - DIR CDC Wu, Xianfu (CDC) 0 114101962 METHOD OF SEQUENCING WHOLE VIRAL GENOMES, RELATED COMPOSITIONS, AND GENOME SEQUENCES E-326-2013-0 Filing authorized Centers for Disease Control and Prevention (CDC) 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-2649] Novel Live-Attenuated Rabies Vaccine&body=Please send me information about technology [TAB-2649] Novel Live-Attenuated Rabies Vaccine. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-2649] Novel Live-Attenuated Rabies Vaccine&body=Please send me information about technology [TAB-2649] Novel Live-Attenuated Rabies Vaccine.">benjamin.hurley@nih.gov</a><br> 114167287 E-326-2013-0 E-326-2013-0-PCT-02 Rabies virus vector systems and compositions and methods thereof PCT Patent Cooperation Treaty PCT/US2006/040134 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2006/040134<br />Filed on 2006-10-13<br />Status: Expired 114167288 E-326-2013-0 E-326-2013-0-US-01 METHOD OF SEQUENCING WHOLE VIRAL GENOMES, RELATED COMPOSITIONS, AND GENOME SEQUENCES PRV US 60/727,038 Abandoned US <br />Provisional (PRV) 60/727,038<br />Filed on 2005-10-14<br />Status: Abandoned 114167289 E-326-2013-0 E-326-2013-0-US-11 METHOD OF SEQUENCING WHOLE VIRAL GENOMES, RELATED COMPOSITIONS, AND GENOME SEQUENCES National Stage US 7,863,041 12/090,083 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7863041 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7863041">7,863,041</a><br />Filed on 2008-04-11<br />Status: Issued 114167290 E-326-2013-0 E-326-2013-0-US-13 RABIES VIRUS VECTOR SYSTEMS AND COMPOSITIONS AND METHODS THEREOF DIV US 8,865,461 12/956,949 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8865461 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8865461">8,865,461</a><br />Filed on 2010-11-30<br />Status: Issued 114123778 DXXXXX 114123779 DCXXXX 114123780 DC5XXX 114123781 DC5BXX 114123782 DC1XXX 114145128 Method 114145129 sequencing 114145130 Whole 114145131 viral 114145132 Genomes 114145133 RELATED 114145134 Compositions 114145135 Genome 114145136 Sequences 114145137 CDC Docket Import 114145138 CDC Docket Import CDC Prosecuting 114145139 OID-NCEZID-DHCPP TAB-2647 114096835 Novel Recombinant Rabies Vaccine Also Capable of Immunocontraception CDC Diagnostics, Infectious Disease, Licensing, Vaccines Diagnostics Infectious Disease Licensing Vaccines Charles Rupprecht, Xianfu Wu This invention relates to a recombinant, attenuated rabies vaccine that is also capable of inhibiting reproductive fertility. An Evelyn-Rokitnicki-Abelseth (ERA) rabies vaccine backbone, combined with a reproductive-specific protein, such as gonadotropin-releasing hormone (GnRH) or the sperm-binding zona-pellucida-glycoprotein-3 (ZP3) receptor, allows reduction in both rabies transmission and uncontrolled reproduction in stray animals. The ERA rabies vaccine backbone has previously shown strong efficacy in animal studies. This vaccine may be delivered via injection or orally, including in an animal's food. <ul> <li>Live, attenuated rabies vaccines show greater efficacy than older, inactivated rabies vaccine in prior animal studies</li> <li>Potential for oral delivery, enabling vaccination of feral and difficult-to-reach animal populations</li> <li>Novel approach to simultaneously addressing rabies transmission and uncontrolled wild animal reproduction</li> </ul> <ul> <li>Development of rabies and immunocontraceptive vaccines</li> <li>Immunogenic compositions for both prevention and treatment of rabies virus</li> <li>Animal welfare initiatives and rabies vaccination programs</li> </ul> 2022-03-08 2025-04-24 2025-04-24 2013-09-19 AFXXXX, Agents, AXXXXX, CDC Docket Import, CDC Docket Import CDC Prosecuting, Compositions, DA4BXX, DA4XXX, DAXXXX, DC5BXX, DC5XXX, DCXXXX, DETECTING, DEXXXX, DXXXXX, IMMUNOCONTRACEPTIVE, Methods, OID-NCEZID-DHCPP, OID-NCIRD-DVD, PARECHOVIRUS, rabies, recombinant, VIRUS-BASED False True <ul> <li>Pre-clinical</li> <li>In vitro data available</li> <li>In vivo data available (animal)</li> </ul> True NIHTT 37470483 Website Abstract E-256-2013-0 E-326-2013-0 114171912 Wu X, et al. http://www.ncbi.nlm.nih.gov/pubmed/19925954 <a href="http://www.ncbi.nlm.nih.gov/pubmed/19925954">Wu X, et al.</a> 114108151 Rupprecht, Charles CDC - DIR CDC Rupprecht, Charles (CDC) 0 114108150 Wu, Xianfu CDC - DIR CDC Wu, Xianfu (CDC) 1 114108150 Wu, Xianfu CDC - DIR CDC Wu, Xianfu (CDC) 1 114108151 Rupprecht, Charles CDC - DIR CDC Rupprecht, Charles (CDC) 0 114101961 RABIES VIRUS-BASED RECOMBINANT IMMUNOCONTRACEPTIVE COMPOSITIONS AND METHODS OF USE E-298-2013-0 Filing authorized Centers for Disease Control and Prevention (CDC) 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-2647] Novel Recombinant Rabies Vaccine Also Capable of Immunocontraception&body=Please send me information about technology [TAB-2647] Novel Recombinant Rabies Vaccine Also Capable of Immunocontraception. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-2647] Novel Recombinant Rabies Vaccine Also Capable of Immunocontraception&body=Please send me information about technology [TAB-2647] Novel Recombinant Rabies Vaccine Also Capable of Immunocontraception.">benjamin.hurley@nih.gov</a><br> 114167281 E-298-2013-0 E-298-2013-0-US-01 RABIES VIRUS-BASED RECOMBINANT IMMUNOCONTRACEPTIVE COMPOSITIONS AND METHODS OF USE PRV US 61/097,748 Abandoned US <br />Provisional (PRV) 61/097,748<br />Filed on 2008-09-17<br />Status: Abandoned 114167282 E-298-2013-0 E-298-2013-0-PCT-02 RABIES VIRUS-BASED RECOMBINANT IMMUNOCONTRACEPTIVE COMPOSITIONS AND METHODS OF USE PCT Patent Cooperation Treaty PCT/US2009/054502 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2009/054502<br />Filed on 2009-08-20<br />Status: Expired 114167283 E-298-2013-0 E-298-2013-0-US-08 RABIES VIRUS-BASED RECOMBINANT IMMUNOCONTRACEPTIVE COMPOSITIONS AND METHODS OF USE National Stage US 8,524,247 13/062,680 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8524247 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8524247">8,524,247</a><br />Filed on 2011-03-07<br />Status: Abandoned 114123762 DXXXXX 114123763 DAXXXX 114123764 DA4XXX 114123765 DA4BXX 114123766 DC5BXX 114123767 DC5XXX 114123768 DCXXXX 114123769 DEXXXX 114123771 AFXXXX 114123772 AXXXXX 114145103 Methods 114145104 Agents 114145105 DETECTING 114145106 PARECHOVIRUS 114145107 CDC Docket Import 114145108 CDC Docket Import CDC Prosecuting 114145109 OID-NCIRD-DVD 114145110 rabies 114145111 VIRUS-BASED 114145112 recombinant 114145113 IMMUNOCONTRACEPTIVE 114145114 Compositions 114145115 OID-NCEZID-DHCPP TAB-2671 114096855 Diagnostics, Vaccines, and Delivery-Vehicles Related to Novel Phlebovirus CDC Antibodies, Consumer Products, Diagnostics, Immunology, Infectious Disease, Licensing, Occupational Safety and Health, Research Equipment, Research Materials, Therapeutics, Vaccines Antibodies Consumer Products Diagnostics Immunology Infectious Disease Licensing Occupational Safety and Health Research Equipment Research Materials Therapeutics Vaccines Cynthia Goldsmith, Aubree Kelly, Laura McMullan, Stuart Nichol, William Nicholson This CDC invention relates to primers and probes that specifically hybridize with Heartland virus (HRTLDV), a unique member of the genus <em>Phlebovirus</em>. It further relates to polyclonal antibodies specific for HRTLDV proteins. Serological detection assays using HRTLDV nucleic acid molecules, proteins, probes, primers, and antibodies are provided. Importantly, the HRTLDV genome can be engineered using reverse genetics to be attenuated, allowing development of a vaccine for other viruses within the <em>Phlebovirus</em> genus or <em>Bunyaviridae</em> family. Individual proteins or peptides of the HRTLDV can also be used in other FDA-approved virus backbones to act as vaccines. Further, since HRTLDV targets the bone marrow, disclosed HRTLDV delivery vehicles may be used to deliver therapeutic agents to the bone marrow. <ul> <li>Antigens and antibodies for diagnostic use have been developed</li> <li>RT-PCR allows rapid, quantitative diagnosis</li> <li>Potential use as bone marrow therapeutic delivery tools</li> <li>Recombinant, pseudo-phlebovirus reporter systems have potential for a wide range of high-throughput drug-screening and research applications</li> </ul> <ul> <li>Development of nucleic acid (RT-PCR) and serologic diagnostic assays for phleboviruses</li> <li>Phlebovirus vaccines</li> <li>Novel delivery vehicles for bone marrow-originating diseases</li> <li>Research tool for phlebovirus virulence mechanisms</li> <li>Vector or tick-borne illness monitoring programs for both humans and wildlife</li> </ul> 2022-03-08 2025-04-24 2025-04-24 2013-11-19 AC4XXX, ACXXXX, ANTIBODY, ANTIGEN, AXXXXX, CDC Docket Import, CDC Docket Import CDC Prosecuting, Compositions, DA4BXX, DA4XXX, DAXXXX, DC1XXX, DC5BXX, DC5XXX, DCXXXX, DDXXXX, Delivery, delivery system, DEVELOPED, diagnostic, DXXXXX, GB2CXX, GB2XXX, GBXXXX, GCXXXX, GENE THERAPY, gene transfer, GXXXXX, heartland, heartland virus, Hospitalized, Identification, ISOLATES, Isolation, Methods, Missouri, Novel, PATHOGENIC, PHLEBOVIRUS, PLATFORM, Platforms, sequence, therapeutic, therapeutic candidates, THEREOF, TICK, TICK-BORNE, TICKS, TWO, Vaccine, VACCINE VECTORS, Vector, Vector-based, Vector-borne, Vector-borne diseases, VETERINARY, VETERINARY vaccine, viral, virus, VLXXXX, VOXXXX, WBXXXX, WDXXXX, WFXXXX, WIXXXX, WJXXXX, XAXXXX, XCXXXX, XHXXXX, YAXXXX, YBXXXX, Zoo False True <ul> <li>Early stage</li> <li>In vitro data available</li> </ul> True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114171934 McMullan LK, et al. http://www.ncbi.nlm.nih.gov/pubmed/22931317 <a href="http://www.ncbi.nlm.nih.gov/pubmed/22931317">McMullan LK, et al.</a> 114171935 CDC FAQs: Novel phlebovirus (Heartland virus) http://www.cdc.gov/ncezid/dvbd/heartland/index.html <a href="http://www.cdc.gov/ncezid/dvbd/heartland/index.html">CDC FAQs: Novel phlebovirus (Heartland virus)</a> 114108224 Nichol, Stuart CDC - DIR CDC Nichol, Stuart (CDC) 0 114108225 Nicholson, William CDC - DIR CDC Nicholson, William (CDC) 0 114108226 Goldsmith, Cynthia CDC - DIR CDC Goldsmith, Cynthia (CDC) 0 114108227 Kelly, Aubree CDC - DIR CDC Kelly, Aubree (CDC) 0 114108223 McMullan, Laura CDC - DIR CDC McMullan, Laura (CDC) 1 114108223 McMullan, Laura CDC - DIR CDC McMullan, Laura (CDC) 1 114108224 Nichol, Stuart CDC - DIR CDC Nichol, Stuart (CDC) 0 114108225 Nicholson, William CDC - DIR CDC Nicholson, William (CDC) 0 114108226 Goldsmith, Cynthia CDC - DIR CDC Goldsmith, Cynthia (CDC) 0 114108227 Kelly, Aubree CDC - DIR CDC Kelly, Aubree (CDC) 0 114101982 Isolation And Sequence Identification Of A Novel, Pathogenic Phlebovirus E-269-2013-0 Filing authorized Centers for Disease Control and Prevention (CDC) 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-2671] Diagnostics, Vaccines, and Delivery-Vehicles Related to Novel Phlebovirus&body=Please send me information about technology [TAB-2671] Diagnostics, Vaccines, and Delivery-Vehicles Related to Novel Phlebovirus. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-2671] Diagnostics, Vaccines, and Delivery-Vehicles Related to Novel Phlebovirus&body=Please send me information about technology [TAB-2671] Diagnostics, Vaccines, and Delivery-Vehicles Related to Novel Phlebovirus.">benjamin.hurley@nih.gov</a><br> 114167364 E-269-2013-0 E-269-2013-0-US-01 PATHOGENIC PHLEBOVIRUS ISOLATES AND COMPOSITIONS AND METHODS THEREOF PRV US 61/614,926 Abandoned US <br />Provisional (PRV) 61/614,926<br />Filed on 2012-03-23<br />Status: Abandoned 114167365 E-269-2013-0 E-269-2013-0-PCT-02 PATHOGENIC PHLEBOVIRUS ISOLATES AND COMPOSITIONS AND METHODS THEREOF PCT Patent Cooperation Treaty PCT/US2013/033541 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2013/033541<br />Filed on 2013-03-22<br />Status: Expired 114167944 E-269-2013-0 E-269-2013-0-US-04 Pathogenic Phlebovirus Isolates and Compositions and Methods of Use National Stage US 9,421,250 14/386,923 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9421250 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9421250">9,421,250</a><br />Filed on 2014-09-22<br />Status: Issued 114123893 VLXXXX 114123894 DXXXXX 114123895 DAXXXX 114123896 DA4XXX 114123897 DA4BXX 114123898 DCXXXX 114123899 DC1XXX 114123900 DC5XXX 114123901 DC5BXX 114123902 DDXXXX 114123903 AC4XXX 114123904 GCXXXX 114123905 GB2CXX 114123906 AXXXXX 114123907 ACXXXX 114123908 GXXXXX 114123909 GBXXXX 114123910 GB2XXX 114124025 VOXXXX 114124026 WBXXXX 114124027 WDXXXX 114124028 WFXXXX 114124029 WIXXXX 114124030 WJXXXX 114124031 XAXXXX 114124032 XCXXXX 114124033 XHXXXX 114124042 YAXXXX 114124043 YBXXXX 114145335 PATHOGENIC 114145336 PHLEBOVIRUS 114145337 ISOLATES 114145338 Compositions 114145339 Methods 114145340 THEREOF 114145341 Isolation 114145342 sequence 114145343 Identification 114145344 Novel 114145345 TWO 114145346 Hospitalized 114145347 Missouri 114145348 CDC Docket Import 114145349 CDC Docket Import CDC Prosecuting 114145350 heartland 114145351 heartland virus 114145352 Vaccine 114145353 VACCINE VECTORS 114145354 PLATFORM 114145355 Platforms 114145356 ANTIBODY 114145357 ANTIGEN 114145358 DEVELOPED 114145359 diagnostic 114145360 therapeutic 114145361 therapeutic candidates 114145362 GENE THERAPY 114145363 gene transfer 114145364 virus 114145365 viral 114145366 Vector 114145367 Vector-based 114145368 Vector-borne 114145369 Vector-borne diseases 114145370 TICK 114145371 TICK-BORNE 114145372 TICKS 114145373 VETERINARY 114145374 VETERINARY vaccine 114145375 Zoo 114145376 Delivery 114145377 delivery system TAB-2703 114096884 Nucleic Acid-based Compositions and Methods for the Species-Specific Detection of Pathogenic Candida Fungi CDC Cardiology, Consumer Products, Dental, Diagnostics, Endocrinology, Infectious Disease, Licensing, Occupational Safety and Health, Oncology, Ophthalmology, Research Materials, Therapeutics Cardiology Consumer Products Dental Diagnostics Endocrinology Infectious Disease Licensing Occupational Safety and Health Oncology Ophthalmology Research Materials Therapeutics Cheryl Elie, Timonthy Lott, Christine Morrison, Errol Reiss This invention pertains to the development of oligonucleotides for the rapid nucleic acid-based identification of the Candida fungi species <em>C. haemulonii</em>, <em>C. kefyr</em>, <em>C. lambica</em>, <em>C. lusitaniae</em>, <em>C. norvegensis</em>, <em>C. norvegica</em>, <em>C. rugosa</em>, <em>C. utilis</em>, <em>C. viswanathii</em>, <em>C. zeylanoides</em>, <em>C. dubliniensis</em>, and <em>C. pelliculosa</em> within biological samples. This identification is accomplished by the targeting the internally transcribed spacer-2 (ITS2) region that are specific for each species. The assay is sensitive, specific and rapid. Implementation of the technology will facilitate earlier specific diagnoses, and lead to better antifungal therapy implementation for infected patients. <ul> <li>Easily adapted for use in kits</li> <li>High-throughput capable</li> <li>Rapid and cost-effective</li> </ul> <ul> <li>Directing antifungal drug therapy for improved patient outcomes</li> <li>Detection, discrimination of Candida species from biological samples</li> <li>Addressing secondary infections of immunosuppressed individuals</li> </ul> 2022-03-08 2025-04-24 2025-04-24 2013-12-23 Acid, CANDIDA, CDC Docket Import, CDC Docket Import CDC Prosecuting, DA1XXX, DAXXXX, DETECTING, DXXXXX, Nucleic, OID-NCEZID-DFWED, Probes, Species, VKXXXX, VOXXXX, VPXXXX, WBXXXX, WCXXXX, WIXXXX, XCXXXX, XEXXXX, YBXXXX False True In vitro data available True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract E-293-2013-0 E-332-2013-0 E-232-2013-0 E-335-2013-0 E-339-2013-0 114171974 Shin JH, et al. http://www.ncbi.nlm.nih.gov/pubmed/9854084 <a href="http://www.ncbi.nlm.nih.gov/pubmed/9854084">Shin JH, et al.</a> 114108343 Elie, Cheryl CDC - DIR CDC Elie, Cheryl (CDC) 0 114108344 Morrison, Christine CDC - DIR CDC Morrison, Christine (CDC) 0 114108345 Reiss, Errol CDC - DIR CDC Reiss, Errol (CDC) 0 114108342 Lott, Timonthy CDC - DIR CDC Lott, Timonthy (CDC) 1 114108342 Lott, Timonthy CDC - DIR CDC Lott, Timonthy (CDC) 1 114108343 Elie, Cheryl CDC - DIR CDC Elie, Cheryl (CDC) 0 114108344 Morrison, Christine CDC - DIR CDC Morrison, Christine (CDC) 0 114108345 Reiss, Errol CDC - DIR CDC Reiss, Errol (CDC) 0 114102013 NUCLEIC ACID PROBES FOR DETECTING CANDIDA SPECIES E-340-2013-0 Closed Centers for Disease Control and Prevention (CDC) 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-2703] Nucleic Acid-based Compositions and Methods for the Species-Specific Detection of Pathogenic Candida Fungi&body=Please send me information about technology [TAB-2703] Nucleic Acid-based Compositions and Methods for the Species-Specific Detection of Pathogenic Candida Fungi. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-2703] Nucleic Acid-based Compositions and Methods for the Species-Specific Detection of Pathogenic Candida Fungi&body=Please send me information about technology [TAB-2703] Nucleic Acid-based Compositions and Methods for the Species-Specific Detection of Pathogenic Candida Fungi.">benjamin.hurley@nih.gov</a><br> 114167438 E-340-2013-0 E-340-2013-0-US-01 NUCLEIC ACID PROBES FOR DETECTING CANDIDA SPECIES ORD US 6,242,178 08/903,446 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6242178 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6242178">6,242,178</a><br />Filed on 1997-07-30<br />Status: Expired 114167439 E-340-2013-0 E-340-2013-0-PCT-02 NUCLEIC ACID PROBES FOR DETECTING CANDIDA SPECIES PCT Patent Cooperation Treaty PCT/US1998/015840 Expired Patent Cooperation Treaty <br />(PCT) PCT/US1998/015840<br />Filed on 1998-07-30<br />Status: Expired 114124227 DXXXXX 114124228 DAXXXX 114124229 DA1XXX 114124230 VKXXXX 114124231 VOXXXX 114124232 VPXXXX 114124233 WBXXXX 114124234 WCXXXX 114124235 WIXXXX 114124236 XCXXXX 114124237 XEXXXX 114124238 YBXXXX 114145829 Nucleic 114145830 Acid 114145831 Probes 114145832 DETECTING 114145833 CANDIDA 114145834 Species 114145835 CDC Docket Import 114145836 CDC Docket Import CDC Prosecuting 114145837 OID-NCEZID-DFWED TAB-2701 114096882 Nucleic Acid-based Compositions and Methods for the Detection of Pathogenic Candida or Aspergillus Fungi Species CDC Cardiology, Consumer Products, Dental, Diagnostics, Endocrinology, Infectious Disease, Licensing, Occupational Safety and Health, Oncology, Ophthalmology, Research Materials, Therapeutics Cardiology Consumer Products Dental Diagnostics Endocrinology Infectious Disease Licensing Occupational Safety and Health Oncology Ophthalmology Research Materials Therapeutics Brian Holloway, Christine Morrison, Errol Reiss, Jong Shin This invention pertains to the development of oligonucleotides for the rapid nucleic acid-based identification of Candida or Aspergillus fungi species in biological samples. This identification is accomplished by the targeting the internally transcribed spacer-2 (ITS2) region that are unique to various Candida species. The assay is sensitive, specific and rapid. Implementation of the technology will facilitate earlier specific diagnoses, and lead to better antifungal therapy implementation for infected patients. <ul> <li>Easily adapted for use in kits</li> <li>High-throughput capable</li> <li>Rapid and cost-effective</li> </ul> <ul> <li>Directing antifungal drug therapy for improved patient outcomes</li> <li>Detection, discrimination of Candida and Aspergillus species from biological samples</li> <li>Addressing secondary infections of immunosuppressed individuals</li> </ul> 2022-03-08 2025-04-24 2025-04-24 2013-12-23 AIDS, Aspergilli, Aspergillus, assay, CANDIDA, CANDIDA ALBICANS, candidiasis, CDC Docket Import, CDC Docket Import CDC Prosecuting, Compositions, DA1XXX, DAXXXX, Detection, diagnostic, DXXXXX, FUNGAL, FUNGI, FUNGI COMPONENTS, fungus, HIV, Immuno-comprimised, IMMUNOCOMPROMISED, Methods, Spp, thrush, VKXXXX, VOXXXX, VPXXXX, WBXXXX, WCXXXX, WIXXXX, XCXXXX, XEXXXX, YBXXXX False True In vitro data available True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract E-293-2013-0 E-332-2013-0 E-232-2013-0 E-335-2013-0 114171969 Shin JH, et al. http://www.ncbi.nlm.nih.gov/pubmed/9854084 <a href="http://www.ncbi.nlm.nih.gov/pubmed/9854084">Shin JH, et al.</a> 114108333 Reiss, Errol CDC - DIR CDC Reiss, Errol (CDC) 0 114108334 Holloway, Brian CDC - DIR CDC Holloway, Brian (CDC) 0 114108335 Shin, Jong CDC - DIR CDC Shin, Jong (CDC) 0 114108332 Morrison, Christine CDC - DIR CDC Morrison, Christine (CDC) 1 114108332 Morrison, Christine CDC - DIR CDC Morrison, Christine (CDC) 1 114108333 Reiss, Errol CDC - DIR CDC Reiss, Errol (CDC) 0 114108334 Holloway, Brian CDC - DIR CDC Holloway, Brian (CDC) 0 114108335 Shin, Jong CDC - DIR CDC Shin, Jong (CDC) 0 114102011 METHODS AND COMPOSITIONS FOR THE DETECTION OF CANDIDA SPP E-339-2013-0 Closed Centers for Disease Control and Prevention (CDC) 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-2701] Nucleic Acid-based Compositions and Methods for the Detection of Pathogenic Candida or Aspergillus Fungi Species&body=Please send me information about technology [TAB-2701] Nucleic Acid-based Compositions and Methods for the Detection of Pathogenic Candida or Aspergillus Fungi Species. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-2701] Nucleic Acid-based Compositions and Methods for the Detection of Pathogenic Candida or Aspergillus Fungi Species&body=Please send me information about technology [TAB-2701] Nucleic Acid-based Compositions and Methods for the Detection of Pathogenic Candida or Aspergillus Fungi Species.">benjamin.hurley@nih.gov</a><br> 114167432 E-339-2013-0 E-339-2013-0-US-01 METHODS AND COMPOSITIONS FOR THE DETECTION OF CANDIDA SPP PRV US 60/026,387 Abandoned US <br />Provisional (PRV) 60/026,387<br />Filed on 1996-09-16<br />Status: Abandoned 114167433 E-339-2013-0 E-339-2013-0-PCT-02 METHODS AND COMPOSITIONS FOR THE DETECTION OF CANDIDA SPP PCT Patent Cooperation Treaty PCT/US1997/016423 Expired Patent Cooperation Treaty <br />(PCT) PCT/US1997/016423<br />Filed on 1997-09-15<br />Status: Expired 114167434 E-339-2013-0 E-339-2013-0-US-07 METHODS AND COMPOSITIONS FOR THE DETECTION OF CANDIDA SPP National Stage US 6,235,890 09/269,136 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6235890 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6235890">6,235,890</a><br />Filed on 1999-07-12<br />Status: Expired 114124193 DXXXXX 114124194 DAXXXX 114124195 DA1XXX 114124196 VKXXXX 114124197 VOXXXX 114124198 VPXXXX 114124199 WBXXXX 114124200 WCXXXX 114124201 WIXXXX 114124202 XCXXXX 114124203 XEXXXX 114124204 YBXXXX 114145796 Methods 114145797 Compositions 114145798 Detection 114145799 CANDIDA 114145800 Spp 114145801 CDC Docket Import 114145802 CDC Docket Import CDC Prosecuting 114145803 FUNGI COMPONENTS 114145804 FUNGI 114145805 FUNGAL 114145806 fungus 114145807 CANDIDA ALBICANS 114145808 candidiasis 114145809 thrush 114145810 diagnostic 114145811 assay 114145812 Aspergilli 114145813 Aspergillus 114145814 HIV 114145815 AIDS 114145816 Immuno-comprimised 114145817 IMMUNOCOMPROMISED TAB-2700 114096881 Nucleic Acid Assays for the Detection and Discrimination of Aspergillus Fungi Species within Biological Samples CDC Cardiology, Consumer Products, Dental, Diagnostics, Endocrinology, Infectious Disease, Licensing, Occupational Safety and Health, Oncology, Ophthalmology, Research Equipment, Research Materials, Therapeutics Cardiology Consumer Products Dental Diagnostics Endocrinology Infectious Disease Licensing Occupational Safety and Health Oncology Ophthalmology Research Equipment Research Materials Therapeutics Hans Hinrikson, Christine Morrison This invention relates to assays for the detection and species-specific identification of Aspergillus fungi. Accurate clinical diagnosis of Aspergillus species has become increasingly important as certain species, such as <em>A. terreus</em> and <em>A. fumigatus</em>, are resistant to specific commonly employed antifungal compounds. Most contemporary fungal diagnostic methods are time-consuming and inaccurate. This invention directly addresses those inadequacies by providing a method to rapidly and accurately differentiate all medically important species of Aspergillus based on differences in the DNA sequences of the internal transcribed spacer 1 region of ribosomal DNA. <ul> <li>Easily adapted for use in kits</li> <li>Assay may be used in real-time PCR, in enzyme immunoassays and/or in microarrays</li> <li>High-throughput capable</li> </ul> <ul> <li>Directing antifungal drug therapy for improved patient outcomes</li> <li>Detection, discrimination of Aspergillus species from biological samples</li> <li>Addressing secondary infections of immunosuppressed individuals or asthmatics</li> </ul> 2022-03-08 2025-04-24 2025-04-24 2013-12-23 Aspergillus, CDC Docket Import, CDC Docket Import CDC Prosecuting, DAXXXX, DXXXXX, Identification, Molecular, OID-NCEZID-DFWED, Species, VKXXXX, VPXXXX, WBXXXX, WCXXXX, WFXXXX, WGXXXX, WIXXXX, XCXXXX, XEXXXX, XHXXXX, XIXXXX, YBXXXX False True In vitro data available True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract E-232-2013-0 E-332-2013-0 E-293-2013-0 114171967 Hinrikson HP, et al. https://www.ncbi.nlm.nih.gov/pubmed/15872227 <a href="https://www.ncbi.nlm.nih.gov/pubmed/15872227">Hinrikson HP, et al.</a> 114108331 Hinrikson, Hans CDC - DIR CDC Hinrikson, Hans (CDC) 0 114108330 Morrison, Christine CDC - DIR CDC Morrison, Christine (CDC) 1 114108330 Morrison, Christine CDC - DIR CDC Morrison, Christine (CDC) 1 114108331 Hinrikson, Hans CDC - DIR CDC Hinrikson, Hans (CDC) 0 114102010 Molecular Identification Of Aspergillus Species E-335-2013-0 Closed Centers for Disease Control and Prevention (CDC) 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-2700] Nucleic Acid Assays for the Detection and Discrimination of Aspergillus Fungi Species within Biological Samples&body=Please send me information about technology [TAB-2700] Nucleic Acid Assays for the Detection and Discrimination of Aspergillus Fungi Species within Biological Samples. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-2700] Nucleic Acid Assays for the Detection and Discrimination of Aspergillus Fungi Species within Biological Samples&body=Please send me information about technology [TAB-2700] Nucleic Acid Assays for the Detection and Discrimination of Aspergillus Fungi Species within Biological Samples.">benjamin.hurley@nih.gov</a><br> 114167428 E-335-2013-0 E-335-2013-0-US-01 Molecular Identification Of Aspergillus Species PRV US 60/381,463 Abandoned US <br />Provisional (PRV) 60/381,463<br />Filed on 2002-05-17<br />Status: Abandoned 114167429 E-335-2013-0 E-335-2013-0-PCT-02 Molecular Identification Of Aspergillus Species PCT Patent Cooperation Treaty PCT/US2003/016076 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2003/016076<br />Filed on 2003-05-16<br />Status: Expired 114167430 E-335-2013-0 E-335-2013-0-US-07 Molecular Identification Of Aspergillus Species National Stage US 7,384,741 10/514,861 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7384741 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7384741">7,384,741</a><br />Filed on 2004-11-16<br />Status: Abandoned 114167431 E-335-2013-0 E-335-2013-0-US-08 Molecular Identification Of Aspergillus Species DIV US 7,871,779 12/115,493 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7871779 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7871779">7,871,779</a><br />Filed on 2008-05-05<br />Status: Abandoned 114124179 DXXXXX 114124180 DAXXXX 114124181 VKXXXX 114124182 VPXXXX 114124183 WBXXXX 114124184 WCXXXX 114124185 WFXXXX 114124186 WGXXXX 114124187 WIXXXX 114124188 XCXXXX 114124189 XEXXXX 114124190 XHXXXX 114124191 XIXXXX 114124192 YBXXXX 114145789 Molecular 114145790 Identification 114145791 Aspergillus 114145792 Species 114145793 CDC Docket Import 114145794 CDC Docket Import CDC Prosecuting 114145795 OID-NCEZID-DFWED TAB-2697 114096878 Species-specific Nucleic Acid Detection Assay for Fungi CDC Cardiology, Consumer Products, Dental, Diagnostics, Endocrinology, Infectious Disease, Licensing, Occupational Safety and Health, Oncology, Ophthalmology, Research Equipment, Research Materials, Therapeutics Cardiology Consumer Products Dental Diagnostics Endocrinology Infectious Disease Licensing Occupational Safety and Health Oncology Ophthalmology Research Equipment Research Materials Therapeutics Lilianna Aidorevich, Jong Soo Choi, Christine Morrison, Errol Reiss This invention pertains to nucleic acid-based assays for the detection of <em>Aspergillus</em> and other filamentous fungi. Assays cover the species-specific detection and diagnosis of infection by <em>Aspergillus</em>, <em>Fusarium</em>, <em>Mucor</em>, <em>Penecillium</em>, <em>Rhizomucor</em>, <em>Absidia</em>, <em>Cunninghamella</em>, <em>Pseudallescheria</em> or <em>Sporthrix</em> in a subject. This can reduce identification time from several days by conventional culture methods to a matter of hours. Furthermore, genus-specific probes are also provided for <em>Aspergillus</em>, <em>Fusarium</em> and <em>Mucor</em>, in addition to an "all-fungus" nucleic acid probe. This technology is readily adaptable as kits used for species-specific identification of opportunistic pathogen infections or possible work/home contamination. <ul> <li>Rapid, sensitive, simple and specific</li> <li>Cost-efficiency compared to culture or sero-diagnostic methods</li> <li>Easily adaptable to kit form</li> <li>High-throughput screening</li> </ul> <ul> <li>Directing antifungal drug therapy for improved patient outcomes</li> <li>Detection, discrimination of fungal species from biological samples</li> <li>Addressing secondary infections of immunosuppressed individuals or asthmatics</li> </ul> 2022-03-08 2025-04-24 2025-04-24 2013-12-23 Acids, Aspergillus, CANDIDA, CANDIDA ALBICANS, candidiasis, CDC Docket Import, CDC Docket Import CDC Prosecuting, DA1XXX, DAXXXX, DETECTING, Detection, diagnostic, discrimination, DXXXXX, FUNGAL, FUNGI, fungus, I-016-96, I-016-96/0, Mold, Molds, Nucleic, nucleic acid, NUCLEIC ACID DETECTION, OID-NCEZID-DFWED, PCR, PCR ASSAY, PRIMERS, Species, VKXXXX, VPXXXX, WBXXXX, WCXXXX, WFXXXX, WGXXXX, WIXXXX, XEXXXX, XHXXXX, XIXXXX, YBXXXX False True In vitro data available True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract E-335-2013-0 E-332-2013-0 E-293-2013-0 114108321 Reiss, Errol CDC - DIR CDC Reiss, Errol (CDC) 0 114108322 Aidorevich, Lilianna CDC - DIR CDC Aidorevich, Lilianna (CDC) 0 114108323 Choi, Jong Soo CDC - DIR CDC Choi, Jong Soo (CDC) 0 114108320 Morrison, Christine CDC - DIR CDC Morrison, Christine (CDC) 1 114108320 Morrison, Christine CDC - DIR CDC Morrison, Christine (CDC) 1 114108321 Reiss, Errol CDC - DIR CDC Reiss, Errol (CDC) 0 114108322 Aidorevich, Lilianna CDC - DIR CDC Aidorevich, Lilianna (CDC) 0 114108323 Choi, Jong Soo CDC - DIR CDC Choi, Jong Soo (CDC) 0 114102007 NUCLEIC ACIDS FOR DETECTING ASPERGILLUS SPECIES (I-016-96, I-016-96/0) E-232-2013-0 Closed Centers for Disease Control and Prevention (CDC) 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-2697] Species-specific Nucleic Acid Detection Assay for Fungi&body=Please send me information about technology [TAB-2697] Species-specific Nucleic Acid Detection Assay for Fungi. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-2697] Species-specific Nucleic Acid Detection Assay for Fungi&body=Please send me information about technology [TAB-2697] Species-specific Nucleic Acid Detection Assay for Fungi.">benjamin.hurley@nih.gov</a><br> 114167418 E-232-2013-0 E-232-2013-0-PCT-02 NUCLEIC ACIDS FOR DETECTING ASPERGILLUS SPECIES AND OTHER FILAMENTOUS FUNGI PCT Patent Cooperation Treaty PCT/US1998/008926 Expired Patent Cooperation Treaty <br />(PCT) PCT/US1998/008926<br />Filed on 1998-05-01<br />Status: Expired 114167419 E-232-2013-0 E-232-2013-0-US-01 NUCLEIC ACIDS FOR DETECTING ASPERGILLUS SPECIES PRV US 60/045,400 Abandoned US <br />Provisional (PRV) 60/045,400<br />Filed on 1997-05-01<br />Status: Abandoned 114167420 E-232-2013-0 E-232-2013-0-US-07 NUCLEIC ACIDS FOR DETECTING ASPERGILLUS SPECIES National Stage US 6,372,430 09/423,233 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6372430 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6372430">6,372,430</a><br />Filed on 2000-06-27<br />Status: Expired 114167421 E-232-2013-0 E-232-2013-0-US-16 NUCLEIC ACIDS FOR DETECTING ASPERGILLUS SPECIES DIV US 7,052,836 10/046,955 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7052836 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7052836">7,052,836</a><br />Filed on 2002-01-14<br />Status: Expired 114124131 DXXXXX 114124132 DAXXXX 114124133 DA1XXX 114124134 VKXXXX 114124135 VPXXXX 114124136 WBXXXX 114124137 WCXXXX 114124138 WFXXXX 114124139 WGXXXX 114124140 WIXXXX 114124141 XEXXXX 114124142 XHXXXX 114124143 XIXXXX 114124144 YBXXXX 114145705 Nucleic 114145706 Acids 114145707 DETECTING 114145708 Aspergillus 114145709 Species 114145710 I-016-96/0 114145711 I-016-96 114145712 CDC Docket Import 114145713 CDC Docket Import CDC Prosecuting 114145714 OID-NCEZID-DFWED 114145715 nucleic acid 114145716 NUCLEIC ACID DETECTION 114145717 PCR 114145718 PCR ASSAY 114145719 PRIMERS 114145720 FUNGAL 114145721 FUNGI 114145722 fungus 114145723 CANDIDA 114145724 CANDIDA ALBICANS 114145725 candidiasis 114145726 diagnostic 114145727 Detection 114145728 discrimination 114145729 Molds 114145730 Mold TAB-2696 114096877 Novel Rift Valley Fever Virus Vaccines CDC Consumer Products, Diagnostics, Infectious Disease, Licensing, Research Equipment, Research Materials, Therapeutics, Vaccines Consumer Products Diagnostics Infectious Disease Licensing Research Equipment Research Materials Therapeutics Vaccines Cesar Albarino, Brian Bird, Thomas Ksiazek, Stuart Nichol This invention relates to recombinant Rift Valley fever (RVF) viruses containing deletions in one or more virulence genes. The recombinant RVF viruses, generated using a plasmid-based reverse genetics system, can be used as vaccines to prevent RVF infection in livestock and humans. The recombinant RVF viruses grow to high titers, provide protective immunity following a single injection, and allow for the differentiation between vaccinated animals and animals infected with wild-type RVF virus. Additionally, this technology relates to a method of using reverse genetics to generate recombinant RVF viruses. <ul> <li>In vivo evidence shows single-dose protection</li> <li>Allows for discrimination between vaccinated and naturally-infected subjects</li> <li>Useful for controlled screening of therapeutic compounds</li> </ul> <ul> <li>Rift Valley fever (RVF) virus vaccine development or improvement</li> <li>Prevention of RVF virus infection in livestock and humans</li> <li>Biodefense, biosecurity</li> </ul> Additional applications granted and pending 2022-03-08 2025-04-24 2025-04-24 2013-12-23 Biodefense, bioterrorism, Bioterrorist, CDC Docket Import, CDC Docket Import CDC Prosecuting, DB4BXX, DB4XXX, DC1XXX, DC5BXX, DC5XXX, DCXXXX, DEVELOPING, DXXXXX, FEVER, Livestock, Method, methodology, Methods, Mosquito, Mosquitoes, OID-NCEZID-DHCPP, recombinant, Recombinant DNA, RIFT, rift valley, rift valley fever, rift valley fever virus, RVF, travel, traveler, travelers, tropical, Vaccine, Valley, VBXXXX, Vector, Vector-based, Vector-borne, Vector-borne diseases, VETERINARY, VETERINARY vaccine, viral, virus, Viruses, VLXXXX, VOXXXX, WAXXXX, WIXXXX, WMXXXX, XEXXXX, XHXXXX, YBXXXX, YCXXXX, Zoo, Zoonotic False True <ul> <li>In vitro data available</li> <li>In vivo data available (animal)</li> </ul> True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114171962 Bird BH, et al. http://www.ncbi.nlm.nih.gov/pubmed/18199647 <a href="http://www.ncbi.nlm.nih.gov/pubmed/18199647">Bird BH, et al.</a> 114171963 CDC Fact Sheet: Rift Valley Fever http://www.cdc.gov/vhf/rvf/ <a href="http://www.cdc.gov/vhf/rvf/">CDC Fact Sheet: Rift Valley Fever</a> 114108317 Albarino, Cesar CDC - DIR CDC Albarino, Cesar (CDC) 0 114108318 Nichol, Stuart CDC - DIR CDC Nichol, Stuart (CDC) 0 114108319 Ksiazek, Thomas CDC - DIR CDC Ksiazek, Thomas (CDC) 0 114108316 Bird, Brian CDC - DIR CDC Bird, Brian (CDC) 1 114108316 Bird, Brian CDC - DIR CDC Bird, Brian (CDC) 1 114108317 Albarino, Cesar CDC - DIR CDC Albarino, Cesar (CDC) 0 114108318 Nichol, Stuart CDC - DIR CDC Nichol, Stuart (CDC) 0 114108319 Ksiazek, Thomas CDC - DIR CDC Ksiazek, Thomas (CDC) 0 114102006 RECOMBINANT RIFT VALLEY FEVER (RVF) VIRUSES AND METHODS OF USE E-254-2013-2 Filing authorized Centers for Disease Control and Prevention (CDC) 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-2696] Novel Rift Valley Fever Virus Vaccines&body=Please send me information about technology [TAB-2696] Novel Rift Valley Fever Virus Vaccines. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-2696] Novel Rift Valley Fever Virus Vaccines&body=Please send me information about technology [TAB-2696] Novel Rift Valley Fever Virus Vaccines.">benjamin.hurley@nih.gov</a><br> 114166691 E-254-2013-2 E-254-2013-2-US-10 RECOMBINANT RIFT VALLEY FEVER (RVF) VIRUSES AND METHODS OF USE DIV US 10,064,933 15/227,321 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10064933 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10064933">10,064,933</a><br />Filed on 2016-08-03<br />Status: Issued 114167416 E-254-2013-2 E-254-2013-2-PCT-01 RECOMBINANT RIFT VALLEY FEVER (RVF) VIRUSES AND METHODS OF USE PCT COMB Patent Cooperation Treaty PCT/US2008/087023 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2008/087023<br />Filed on 2008-12-16<br />Status: Expired 114167417 E-254-2013-2 E-254-2013-2-US-04 RECOMBINANT RIFT VALLEY FEVER (RVF) VIRUSES AND METHODS OF USE National Stage US 8,673,629 12/809,561 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8673629 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8673629">8,673,629</a><br />Filed on 2010-06-18<br />Status: Issued 114167579 E-254-2013-2 E-254-2013-2-US-06 RECOMBINANT RIFT VALLEY FEVER (RVF) VIRUSES AND METHODS OF USE DIV US 9,439,935 14/163,058 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9439935 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9439935">9,439,935</a><br />Filed on 2014-01-24<br />Status: Issued 114124114 DXXXXX 114124115 DCXXXX 114124116 DC5XXX 114124117 DC5BXX 114124118 DC1XXX 114124119 DB4XXX 114124120 DB4BXX 114124121 VBXXXX 114124122 VLXXXX 114124123 VOXXXX 114124124 WAXXXX 114124125 WIXXXX 114124126 WMXXXX 114124127 XEXXXX 114124128 XHXXXX 114124129 YBXXXX 114124130 YCXXXX 114145667 recombinant 114145668 RIFT 114145669 Valley 114145670 FEVER 114145671 RVF 114145672 Viruses 114145673 Methods 114145674 CDC Docket Import 114145675 CDC Docket Import CDC Prosecuting 114145676 OID-NCEZID-DHCPP 114145677 Method 114145678 methodology 114145679 Vaccine 114145680 Recombinant DNA 114145681 rift valley 114145682 rift valley fever 114145683 rift valley fever virus 114145684 virus 114145685 viral 114145686 Zoo 114145687 Zoonotic 114145688 Livestock 114145689 VETERINARY 114145690 VETERINARY vaccine 114145691 Vector 114145692 Vector-based 114145693 Vector-borne 114145694 Vector-borne diseases 114145695 Mosquito 114145696 Mosquitoes 114145697 tropical 114145698 DEVELOPING 114145699 travel 114145700 traveler 114145701 travelers 114145702 Biodefense 114145703 bioterrorism 114145704 Bioterrorist TAB-2694 114096875 Novel Epitopes of Bacillus anthracis Lethal Factor for Development of Diagnostics and Therapeutics CDC Antibodies, Consumer Products, Diagnostics, Immunology, Infectious Disease, Licensing, Occupational Safety and Health, Research Equipment, Research Materials, Therapeutics, Vaccines Antibodies Consumer Products Diagnostics Immunology Infectious Disease Licensing Occupational Safety and Health Research Equipment Research Materials Therapeutics Vaccines Dennis Bagarozzi, Anne Boyer, Jason Goldstein, Conrad Quinn CDC researchers have characterized epitopes of <em>Bacillus anthracis</em> Lethal Factor (LF), a critical component of the <em>B. anthracis</em> lethal toxin. These epitopes may allow for development of therapeutics for the treatment or prevention of <em>B. anthracis</em> infection. They may also allow screening for <em>B. anthracis</em> LF in a sample and development of a peptide anthrax vaccine. <ul> <li>Potentially faster, lower-input assay compared to current Edema Factor detection methods</li> <li>Easily adaptable for high-throughput screening of numerous specimens</li> <ul> <li>Diagnostic tests assessing active Lethal Factor in a sample</li> <li>Anthrax neutralizing therapeutics and vaccines for <em>B. anthracis</em></li> <li>Biodefense, biosecurity</li> </ul> 2022-03-08 2025-04-24 2025-04-24 2013-12-23 Activiating, Activity, Anthracis, Anthrax, AnthraxToxins, Bacillus, Biodefense, biosecurity, bioterrorism, Bioterrorist, CDC Docket Import, CDC Docket Import CDC Prosecuting, DA3XXX, DA5XXX, DAXXXX, DB3XXX, DB5XXX, DBXXXX, DC4XXX, DCXXXX, DXXXXX, Epitope, factor, INFECTIOUS, Lethal, MONITOR, MONITORING, Neutralize, Neutralizing, Region, REGULATING, SCREEN, screening, SERODIAGNOSIS, SERODIAGNOSTIC, Serologic, SEROLOGICAL, therapeutic, Therapeutic/Diagnostic, THERAPY, toxin, TOXIN-BINDING, Vaccine, VBXXXX, VETERINARY, Via, VJXXXX, VOXXXX, WAXXXX, WBXXXX, WFXXXX, WJXXXX, WKXXXX, WMXXXX, XAXXXX, XCXXXX, XHXXXX, YAXXXX, YBXXXX, Zoo, Zoonotic False True <ul> <li>Early-stage</li> <li>In vitro data available</li> </ul> True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract E-158-2013-2 E-167-2013-0 E-196-2013-0 E-203-2013-0 E-474-2013-0 114171959 Boyer AE, et al. http://www.ncbi.nlm.nih.gov/pubmed/17929949 <a href="http://www.ncbi.nlm.nih.gov/pubmed/17929949">Boyer AE, et al.</a> 114108309 Bagarozzi, Dennis CDC - DIR CDC Bagarozzi, Dennis (CDC) 0 114108310 Boyer, Anne CDC - DIR CDC Boyer, Anne (CDC) 0 114108311 Quinn, Conrad CDC - DIR CDC Quinn, Conrad (CDC) 0 114108308 Goldstein, Jason CDC - DIR CDC Goldstein, Jason (CDC) 1 114108308 Goldstein, Jason CDC - DIR CDC Goldstein, Jason (CDC) 1 114108309 Bagarozzi, Dennis CDC - DIR CDC Bagarozzi, Dennis (CDC) 0 114108310 Boyer, Anne CDC - DIR CDC Boyer, Anne (CDC) 0 114108311 Quinn, Conrad CDC - DIR CDC Quinn, Conrad (CDC) 0 114102004 Regulating Bacillus Anthracis Lethal Factor Activity Via An Activiating Epitope Region E-210-2013-0 Research Material Centers for Disease Control and Prevention (CDC) 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-2694] Novel Epitopes of Bacillus anthracis Lethal Factor for Development of Diagnostics and Therapeutics&body=Please send me information about technology [TAB-2694] Novel Epitopes of Bacillus anthracis Lethal Factor for Development of Diagnostics and Therapeutics. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-2694] Novel Epitopes of Bacillus anthracis Lethal Factor for Development of Diagnostics and Therapeutics&body=Please send me information about technology [TAB-2694] Novel Epitopes of Bacillus anthracis Lethal Factor for Development of Diagnostics and Therapeutics.">benjamin.hurley@nih.gov</a><br> 114167411 E-210-2013-0 E-210-2013-0-US-01 Regulating Bacillus Anthracis Lethal Factor Activity Via An Activiating Epitope Region PRV US 61/699,738 Abandoned US <br />Provisional (PRV) 61/699,738<br />Filed on 2012-09-11<br />Status: Abandoned 114167412 E-210-2013-0 E-210-2013-0-PCT-02 Regulating Bacillus anthracis Lethal Factor Activity Via An Activating Epitope Region PCT Patent Cooperation Treaty PCT/US2013/059179 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2013/059179<br />Filed on 2013-09-11<br />Status: Expired 114168098 E-210-2013-0 E-210-2013-0-US-05 Regulating Bacillus Anthracis Lethal Factor Activity Via An Activiating Epitope Region National Stage US 14/427,329 Abandoned US <br />National Stage 14/427,329<br />Filed on 2015-03-11<br />Status: Abandoned 114124080 DXXXXX 114124081 DAXXXX 114124082 DA3XXX 114124083 DA5XXX 114124084 DBXXXX 114124085 DB3XXX 114124086 DB5XXX 114124087 DCXXXX 114124088 DC4XXX 114124089 VBXXXX 114124090 VJXXXX 114124091 VOXXXX 114124092 WAXXXX 114124093 WBXXXX 114124094 WFXXXX 114124095 WJXXXX 114124096 WKXXXX 114124097 WMXXXX 114124098 XAXXXX 114124099 XCXXXX 114124100 XHXXXX 114124101 YAXXXX 114124102 YBXXXX 114145604 REGULATING 114145605 Bacillus 114145606 Anthracis 114145607 Lethal 114145608 factor 114145609 Activity 114145610 Via 114145611 Activiating 114145612 Epitope 114145613 Region 114145614 CDC Docket Import 114145615 CDC Docket Import CDC Prosecuting 114145616 biosecurity 114145617 Biodefense 114145618 bioterrorism 114145619 Bioterrorist 114145620 SCREEN 114145621 screening 114145622 toxin 114145623 TOXIN-BINDING 114145624 Neutralize 114145625 Neutralizing 114145626 Anthrax 114145627 AnthraxToxins 114145628 SERODIAGNOSIS 114145629 SERODIAGNOSTIC 114145630 Serologic 114145631 SEROLOGICAL 114145632 INFECTIOUS 114145633 Zoo 114145634 Zoonotic 114145635 Vaccine 114145636 MONITOR 114145637 MONITORING 114145638 VETERINARY 114145639 therapeutic 114145640 Therapeutic/Diagnostic 114145641 THERAPY TAB-2712 114096891 Detection and Differentiation of Pathogenic Fungi in Clinical Samples Using a Multi-Analyte Profiling System CDC Consumer Products, Diagnostics, Infectious Disease, Licensing, Occupational Safety and Health, Research Equipment, Research Materials, Therapeutics Consumer Products Diagnostics Infectious Disease Licensing Occupational Safety and Health Research Equipment Research Materials Therapeutics Teresa Brown, Sanchita Das, Brian Holloway, Christine Morrison This invention provides a rapid, sensitive and specific diagnostic tool for the detection of pathogenic fungi and subsequent species-specific discrimination. CDC scientists have developed nucleic acid probes to identify the six most medically important <em>Candida</em> species and endemic mycoses, and to differentiate them from other medically important fungi in a multi-analyte profiling system. <em>Candida</em> fungi are one of the leading causes of clinically-acquired bloodstream infections and, although improved antifungal compounds have been recently introduced, they have unique, species-specific treatment responses. <br /><br /> This multi-analyte approach has the potential to simultaneously identify up to 100 different fungi in one assay. Additionally, the assay is quite cost effective in terms of resource input, time invested and technician labor. Used in conjunction with contemporary antifungal medications, this assay provides a very rapid and specific diagnosis allowing for the selective administration of appropriate compounds and ultimately improved patient outcomes. <ul> <li>Rapid, sensitive, simple and specific</li> <li>Multi-analyte nature provides cost-efficiency</li> <li>Easily adaptable to kit form</li> <li>Permits the multiplexing of up to 100 different hybridization reactions in a single sample</li> </ul> <ul> <li>Directing antifungal drug therapy for improved patient outcomes</li> <li>Detection, discrimination of Candida species from biological samples</li> <li>High-throughput screening</li> <li>Liquid or solid phase microarray development to detect medically important fungi</li> </ul> Several international filings issued or pending. 2022-03-08 2025-04-24 2025-04-24 2014-01-08 Bead, Beads, CANDIDA, CDC Docket Import, CDC Docket Import CDC Prosecuting, Clinical, Clinical SAMPLE, Compositions, DA1XXX, DAXXXX, Detection, Diagnose, Diagnosis, diagnostic, Diagnostic assay, Discriminate, discrimination, DXXXXX, FUNGAL, FUNGI, fungus, Methods, microarray, Nucleic, nucleic acid, OID-NCEZID-DFWED, PATHOGEN, PATHOGENIC, Probe, Species, VKXXXX, WBXXXX, WCXXXX, WFXXXX, WGXXXX, WIXXXX, XEXXXX, XHXXXX, YAXXXX, YBXXXX False True <ul> <li>Early-stage</li> <li>In vitro data available</li> </ul> True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract E-232-2013-0 E-332-2013-0 E-335-2013-0 E-339-2013-0 114171984 Das, S. et al. http://www.ncbi.nlm.nih.gov/pubmed/16487306 <a href="http://www.ncbi.nlm.nih.gov/pubmed/16487306">Das, S. et al.</a> 114108369 Das, Sanchita CDC - DIR CDC Das, Sanchita (CDC) 0 114108370 Brown, Teresa CDC - DIR CDC Brown, Teresa (CDC) 0 114108371 Holloway, Brian CDC - DIR CDC Holloway, Brian (CDC) 0 114108368 Morrison, Christine CDC - DIR CDC Morrison, Christine (CDC) 1 114108368 Morrison, Christine CDC - DIR CDC Morrison, Christine (CDC) 1 114108369 Das, Sanchita CDC - DIR CDC Das, Sanchita (CDC) 0 114108370 Brown, Teresa CDC - DIR CDC Brown, Teresa (CDC) 0 114108371 Holloway, Brian CDC - DIR CDC Holloway, Brian (CDC) 0 114102021 Compositions And Methods For The Detection Of Candida Species E-293-2013-0 Closed Centers for Disease Control and Prevention (CDC) 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-2712] Detection and Differentiation of Pathogenic Fungi in Clinical Samples Using a Multi-Analyte Profiling System&body=Please send me information about technology [TAB-2712] Detection and Differentiation of Pathogenic Fungi in Clinical Samples Using a Multi-Analyte Profiling System. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-2712] Detection and Differentiation of Pathogenic Fungi in Clinical Samples Using a Multi-Analyte Profiling System&body=Please send me information about technology [TAB-2712] Detection and Differentiation of Pathogenic Fungi in Clinical Samples Using a Multi-Analyte Profiling System.">benjamin.hurley@nih.gov</a><br> 114167457 E-293-2013-0 E-293-2013-0-US-01 Compositions And Methods For The Detection Of Candida Species PRV US 60/721,419 Abandoned US <br />Provisional (PRV) 60/721,419<br />Filed on 2005-09-27<br />Status: Abandoned 114167458 E-293-2013-0 E-293-2013-0-PCT-02 Compositions And Methods For The Detection Of Candida Species PCT Patent Cooperation Treaty PCT/US2006/037640 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2006/037640<br />Filed on 2006-09-26<br />Status: Expired 114167459 E-293-2013-0 E-293-2013-0-US-07 Compositions And Methods For The Detection Of Candida Species National Stage US 8,119,788 12/088,235 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8119788 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8119788">8,119,788</a><br />Filed on 2008-03-26<br />Status: Abandoned 114124313 DAXXXX 114124314 DXXXXX 114124332 DA1XXX 114124333 VKXXXX 114124334 WBXXXX 114124335 WCXXXX 114124336 WFXXXX 114124337 WGXXXX 114124338 WIXXXX 114124339 XEXXXX 114124340 XHXXXX 114124341 YAXXXX 114124342 YBXXXX 114145885 Compositions 114145886 Methods 114145887 Detection 114145888 CANDIDA 114145889 Species 114145890 CDC Docket Import 114145891 CDC Docket Import CDC Prosecuting 114145892 OID-NCEZID-DFWED 114145893 FUNGAL 114145894 FUNGI 114145895 fungus 114145896 Clinical 114145897 Clinical SAMPLE 114145898 Bead 114145899 Beads 114145900 Probe 114145901 Nucleic 114145902 nucleic acid 114145903 microarray 114145904 PATHOGEN 114145905 PATHOGENIC 114145906 Diagnose 114145907 Diagnosis 114145908 diagnostic 114145909 Diagnostic assay 114145910 Discriminate 114145911 discrimination TAB-2722 114096901 Universal Diagnostic Assay for Detection and Identification of Poxviruses in Clinical Samples CDC Consumer Products, Diagnostics, Infectious Disease, Licensing, Occupational Safety and Health, Research Materials, Therapeutics Consumer Products Diagnostics Infectious Disease Licensing Occupational Safety and Health Research Materials Therapeutics Inger Damon, Yu Li, Hui Zhao CDC researchers have developed an assay for detection and diagnosis of poxviruses within clinical samples or from lab culture-systems. The assay specifically targets chordopoxviruses (except avipoxviruses) for PCR-based identification; an improvement upon the current standard of cell culturing methodologies. Individual chordopoxvirus species can cause disease in humans (e.g., vaccinia, cowpox, monkeypox/Molluscum contagiosum) and animals (e.g., sheeppox, myxoma, swinepox, mule deer pox, tanapox/Orf virus, Bovine popular stomatitis virus). Some poxvirus species impart unique and obvious symptoms making them easy to diagnose, while many others are clinically ambiguous. For instance, parapoxvirus infections are often misdiagnosed as cutaneous anthrax, which unnecessarily contributes to overuse of antibacterial agents. There is therefore a demonstrated need to develop better diagnostic tools to detect and properly identify the agent of poxvirus infections. Regardless of the symptoms, this universal assay can quickly and reliably detect chordopoxvirus presence in clinical samples, allowing for proper identification, diagnosis, treatment, and improved patient outcomes. <ul> <li>Rapid and simple</li> <li>Allows for high-throughput, simultaneous sample screening</li> <li>Detects, identifies all low-G/C content non-avipox chordopoxviruses and most known high-G/C content chordopoxviruses</li> </ul> <ul> <li>Nucleic acid-based diagnostic for 'unknown rash' illnesses and identifying novel poxviruses</li> <li>Disease surveillance programs, including public health and veterinary (livestock, domestic, wild/exotic)</li> </ul> Various international patent applications pending 2022-03-08 2025-04-24 2025-04-24 2014-01-16 ASSAYS, CDC Docket Import, CDC Docket Import CDC Prosecuting, CHORDOPOXVIRUSES, DA4BXX, DA4XXX, DAXXXX, diagnostic, DXXXXX, OID-NCEZID-DHCPP, VLXXXX, VOXXXX, WBXXXX, WFXXXX, WIXXXX, WMXXXX, XCXXXX, XEXXXX, YBXXXX False True In vitro data available True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114171994 Li Y, et al. http://www.ncbi.nlm.nih.gov/pubmed/19906902 <a href="http://www.ncbi.nlm.nih.gov/pubmed/19906902">Li Y, et al.</a> 114108396 Damon, Inger CDC - DIR CDC Damon, Inger (CDC) 0 114108397 Zhao, Hui CDC - DIR CDC Zhao, Hui (CDC) 0 114108395 Li, Yu CDC - DIR CDC Li, Yu (CDC) 1 114108395 Li, Yu CDC - DIR CDC Li, Yu (CDC) 1 114108396 Damon, Inger CDC - DIR CDC Damon, Inger (CDC) 0 114108397 Zhao, Hui CDC - DIR CDC Zhao, Hui (CDC) 0 114102036 DIAGNOSTIC ASSAYS FOR CHORDOPOXVIRUSES E-265-2013-0 Filing authorized Centers for Disease Control and Prevention (CDC) 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-2722] Universal Diagnostic Assay for Detection and Identification of Poxviruses in Clinical Samples&body=Please send me information about technology [TAB-2722] Universal Diagnostic Assay for Detection and Identification of Poxviruses in Clinical Samples. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-2722] Universal Diagnostic Assay for Detection and Identification of Poxviruses in Clinical Samples&body=Please send me information about technology [TAB-2722] Universal Diagnostic Assay for Detection and Identification of Poxviruses in Clinical Samples.">benjamin.hurley@nih.gov</a><br> 114167478 E-265-2013-0 E-265-2013-0-US-01 DIAGNOSTIC ASSAYS FOR CHORDOPOXVIRUSES PRV US 61/257,582 Abandoned US <br />Provisional (PRV) 61/257,582<br />Filed on 2009-11-03<br />Status: Abandoned 114167479 E-265-2013-0 E-265-2013-0-PCT-02 DIAGNOSTIC ASSAYS FOR CHORDOPOXVIRUSES PCT Patent Cooperation Treaty PCT/US2010/055061 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2010/055061<br />Filed on 2010-11-02<br />Status: Expired 114167480 E-265-2013-0 E-265-2013-0-US-06 DIAGNOSTIC ASSAYS FOR CHORDOPOXVIRUSES National Stage US 8,859,742 13/505,719 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8859742 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8859742">8,859,742</a><br />Filed on 2012-05-02<br />Status: Issued 114124460 DXXXXX 114124461 DAXXXX 114124462 DA4XXX 114124463 DA4BXX 114124464 VLXXXX 114124465 VOXXXX 114124466 WBXXXX 114124467 WFXXXX 114124468 WIXXXX 114124469 WMXXXX 114124470 XCXXXX 114124471 XEXXXX 114124472 YBXXXX 114146002 diagnostic 114146003 ASSAYS 114146004 CHORDOPOXVIRUSES 114146005 CDC Docket Import 114146006 CDC Docket Import CDC Prosecuting 114146007 OID-NCEZID-DHCPP TAB-2719 114096898 Real-time RT-PCR Assay for the Detection of Rift Valley Fever Virus in Humans and Livestock CDC Consumer Products, Diagnostics, Infectious Disease, Licensing, Occupational Safety and Health, Research Materials, Therapeutics, Vaccines Consumer Products Diagnostics Infectious Disease Licensing Occupational Safety and Health Research Materials Therapeutics Vaccines Brian Bird, Stuart Nichol A quantitative RT-PCR-based assay has been developed to rapidly detect all known strains of Rift Valley fever virus (RVFV). RVFV infections occur in both humans and livestock animals resulting in significant mortality and economic loss. Upon outbreak, RVFV has been known to cause devastating loss among livestock (primarily sheep and cattle) with outbreaks characterized by sweeping "abortion storms" and elevation newborn animal mortality approaching 100% in affected areas. The CDC-developed assay is capable of detecting and quantifying RVFV infection in both human and veterinary samples. <ul> <li>Assay detects positive infections for 33 known variants of Rift Valley fever virus.</li> <li>Easily adaptable to kits for high-throughput screening of a large number of samples at once, useful for ensuring herd-health for example.</li> </ul> <ul> <li>Diagnostic assay for the detection of Rift Valley fever virus in human and veterinary samples</li> <li>Research tool to quantitatively measure viral load in laboratory specimens</li> </ul> Research Tool – Patent protection is not being pursued for this technology. 2022-03-08 2025-04-24 2025-04-24 2014-01-16 CDC Docket Import, CDC Docket Import CDC Prosecuting, Compositions, DDXXXX, Diagnosis, DXXXXX, FEVER, Kits, Methods, Pan-Rift, QUANTITATIVE, REAL-TIME, RT-PCR, Valley, VBXXXX, virus, VLXXXX, VOXXXX, WAXXXX, WDXXXX, WFXXXX, WIXXXX, WMXXXX, XEXXXX, YBXXXX False True In vitro data available True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114171989 Bird BH, et al. http://www.ncbi.nlm.nih.gov/pubmed/17192303 <a href="http://www.ncbi.nlm.nih.gov/pubmed/17192303">Bird BH, et al.</a> 114171990 Bird BH, et al. http://www.ncbi.nlm.nih.gov/pubmed/18786992 <a href="http://www.ncbi.nlm.nih.gov/pubmed/18786992">Bird BH, et al.</a> 114108390 Nichol, Stuart CDC - DIR CDC Nichol, Stuart (CDC) 0 114108389 Bird, Brian CDC - DIR CDC Bird, Brian (CDC) 1 114108389 Bird, Brian CDC - DIR CDC Bird, Brian (CDC) 1 114108390 Nichol, Stuart CDC - DIR CDC Nichol, Stuart (CDC) 0 114102032 Methods, Compositions, And Kits For Pan-Rift Valley Fever Virus Real-Time Quantitative RT-PCR Diagnosis E-187-2013-0 Closed Centers for Disease Control and Prevention (CDC) 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-2719] Real-time RT-PCR Assay for the Detection of Rift Valley Fever Virus in Humans and Livestock&body=Please send me information about technology [TAB-2719] Real-time RT-PCR Assay for the Detection of Rift Valley Fever Virus in Humans and Livestock. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-2719] Real-time RT-PCR Assay for the Detection of Rift Valley Fever Virus in Humans and Livestock&body=Please send me information about technology [TAB-2719] Real-time RT-PCR Assay for the Detection of Rift Valley Fever Virus in Humans and Livestock.">benjamin.hurley@nih.gov</a><br> 114167472 E-187-2013-0 E-187-2013-0-US-01 Methods, Compositions, And Kits For Pan-Rift Valley Fever Virus Real-Time Quantitative RT-PCR Diagnosis PRV US 60/869,324 Abandoned US <br />Provisional (PRV) 60/869,324<br />Filed on 2006-12-09<br />Status: Abandoned 114124408 DXXXXX 114124409 DDXXXX 114124411 YBXXXX 114124412 VBXXXX 114124413 VLXXXX 114124414 VOXXXX 114124415 WAXXXX 114124416 WDXXXX 114124417 WFXXXX 114124418 WIXXXX 114124419 WMXXXX 114124420 XEXXXX 114145965 Methods 114145966 Compositions 114145967 Kits 114145968 Pan-Rift 114145969 Valley 114145970 FEVER 114145971 virus 114145972 REAL-TIME 114145973 QUANTITATIVE 114145974 RT-PCR 114145975 Diagnosis 114145976 CDC Docket Import 114145977 CDC Docket Import CDC Prosecuting TAB-2726 114096905 Multiplexed Immunoassay for Rapid Serological Diagnosis of a Specific Viral Infection in Clinical Samples CDC Antibodies, Cardiology, Consumer Products, Dental, Diagnostics, Endocrinology, Immunology, Infectious Disease, Licensing, Occupational Safety and Health, Oncology, Ophthalmology, Research Equipment, Research Materials, Therapeutics, Vaccines Antibodies Cardiology Consumer Products Dental Diagnostics Endocrinology Immunology Infectious Disease Licensing Occupational Safety and Health Oncology Ophthalmology Research Equipment Research Materials Therapeutics Vaccines Alison Basile, Bradley Biggerstaff CDC researchers have developed a multiplexed diagnostic assay for sensitive detection and distinction between viral group members based on the presence/absence of infection-generated antibodies within a clinical serum sample. For example, this assay can be used for rapid discrimination of a clinical unknown as specifically a West Nile or St. Louis encephalitis viral infection. This is particularly beneficial as these two viruses are typically difficult to distinguish by standard serological assays. <p>This new technique uses microsphere/microbead-based flow-analysis as a platform. Because of a basis in a pre-existing technology, the technique can be easily incorporated into current state and health department diagnostic testing protocols. The method is particularly unique because the assay-generated data can be standardized and then classified via discriminant analysis to determine the presence or absence of antibodies of interest within the clinical sample tested.</p> <p>Furthermore, along with allowances for single-result generation, data manipulation and classification algorithms allow for assay output comparisons to the original large data set references used in development. In this way, results from different laboratories can now be directly compared to one another, provided that the same controls are used.</p> <ul> <li>Increased efficiency compared to single-antibody diagnostic approaches</li> <li>Easily implemented and integrated into present protocols and techniques, as this technology is based on current, widely used flow-analysis platforms</li> <li>Can be formatted as customizable kits for detection of viral group antibodies</li> <li>Rapid and precise</li> <li>Ideal for high-throughput analyses</li> </ul> <ul> <li>Clinical diagnostics for specific identification and discrimination of viral infections</li> <li>Research tool for evaluation of vaccine candidates</li> <li>Assay standardization and quality control</li> <li>Public health and viral outbreak surveillance programs</li> </ul> Various international patent applications pending or issued 2022-03-08 2025-04-24 2025-04-24 2014-01-17 analysis, CDC Docket Import, CDC Docket Import CDC Prosecuting, DA4XXX, DAXXXX, DETERMINING, DXXXXX, Infection, Multiplexed, OID-NCEZID-DVBD, SERODIAGNOSIS, VBXXXX, viral, VLXXXX, VOXXXX, VPXXXX, WAXXXX, WBXXXX, WCXXXX, WFXXXX, WIXXXX, WMXXXX, XAXXXX, XCXXXX, XHXXXX, YBXXXX False True In vitro data available True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114171999 Basile AJ, et al. http://www.ncbi.nlm.nih.gov/pubmed/19923570 <a href="http://www.ncbi.nlm.nih.gov/pubmed/19923570">Basile AJ, et al.</a> 114172000 Basile AJ, et al. http://www.ncbi.nlm.nih.gov/pubmed/24086608 <a href="http://www.ncbi.nlm.nih.gov/pubmed/24086608">Basile AJ, et al.</a> 114108408 Biggerstaff, Bradley CDC - DIR CDC Biggerstaff, Bradley (CDC) 0 114108407 Basile, Alison CDC - DIR CDC Basile, Alison (CDC) 1 114108407 Basile, Alison CDC - DIR CDC Basile, Alison (CDC) 1 114108408 Biggerstaff, Bradley CDC - DIR CDC Biggerstaff, Bradley (CDC) 0 114102041 Multiplexed Analysis For Determining A Serodiagnosis Of Viral Infection E-302-2013-0 Closed Centers for Disease Control and Prevention (CDC) 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-2726] Multiplexed Immunoassay for Rapid Serological Diagnosis of a Specific Viral Infection in Clinical Samples&body=Please send me information about technology [TAB-2726] Multiplexed Immunoassay for Rapid Serological Diagnosis of a Specific Viral Infection in Clinical Samples. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-2726] Multiplexed Immunoassay for Rapid Serological Diagnosis of a Specific Viral Infection in Clinical Samples&body=Please send me information about technology [TAB-2726] Multiplexed Immunoassay for Rapid Serological Diagnosis of a Specific Viral Infection in Clinical Samples.">benjamin.hurley@nih.gov</a><br> 114167492 E-302-2013-0 E-302-2013-0-US-01 Multiplexed Analysis For Determining A Serodiagnosis Of Viral Infection PRV US 60/645,768 Abandoned US <br />Provisional (PRV) 60/645,768<br />Filed on 2005-01-20<br />Status: Abandoned 114167493 E-302-2013-0 E-302-2013-0-US-02 Multiplexed Analysis For Determining A Serodiagnosis Of Viral Infection ORD US 7,933,721 11/336,639 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7933721 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7933721">7,933,721</a><br />Filed on 2006-01-20<br />Status: Abandoned 114167494 E-302-2013-0 E-302-2013-0-US-03 Multiplexed Analysis For Determining A Serodiagnosis Of Viral Infection DIV US 8,433,523 13/093,671 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8433523 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8433523">8,433,523</a><br />Filed on 2011-04-25<br />Status: Abandoned 114124528 DXXXXX 114124529 DAXXXX 114124530 DA4XXX 114124531 VBXXXX 114124532 VLXXXX 114124533 VOXXXX 114124534 VPXXXX 114124535 WAXXXX 114124536 WBXXXX 114124537 WCXXXX 114124538 WFXXXX 114124539 WIXXXX 114124540 WMXXXX 114124541 XAXXXX 114124542 XCXXXX 114124543 XHXXXX 114124544 YBXXXX 114146033 Multiplexed 114146034 analysis 114146035 DETERMINING 114146036 SERODIAGNOSIS 114146037 viral 114146038 Infection 114146039 CDC Docket Import 114146040 CDC Docket Import CDC Prosecuting 114146041 OID-NCEZID-DVBD TAB-2731 114096910 Use of Detector Response Curves to Optimize Settings for Mass Spectrometry CDC Cardiology, Computational models/software, Consumer Products, Dental, Diagnostics, Endocrinology, Geriatrics, Immunology, Infectious Disease, Licensing, Medical Devices, Neurology, Non-Medical Devices, Occupational Safety and Health, Oncology, Ophthalmology, Research Equipment, Research Materials, Software / Apps, Therapeutics, Vaccines Cardiology Computational models/software Consumer Products Dental Diagnostics Endocrinology Geriatrics Immunology Infectious Disease Licensing Medical Devices Neurology Non-Medical Devices Occupational Safety and Health Oncology Ophthalmology Research Equipment Research Materials Software / Apps Therapeutics Vaccines Vincent Emanuele, Brian Gurbaxani This CDC developed optimization technology allows one to characterize the behavior of the coefficient of variation (CV) for a range of mass spectrometer machine settings. Surface-enhanced laser desorption/ionization (SELDI) and matrix-assisted laser desorption/ionization (MALDI) are used for the early detection of numerous diseases, for example cervical cancer . A critical step in the analytical process is the optimization of experiment and machine settings to ensure the best possible reproducibility of results, as measured by the CV. The high cost of this procedure includes man hours spent optimizing the machine, opportunity cost, materials used, and spent biological samples used in the optimization process. <p>This technology can be used to optimize the CV with the following advantages over conventional methods: 1) no need to use biological samples, 2) fewer materials are consumed in the process, 3) improved CV and thus more reproducible results, 4) fewer man hours required to find ideal machine settings, and 5) potential full-automation of the process of optimizing CV. This idea is beneficial to all scientists and clinicians that use MALDI/SELDI for biomarker discovery and clinical diagnostics. Further, manufacturers of MALDI/SELDI mass spectrometer devices would find incorporation of this technology quite beneficial.</p> <ul> <li>Lower resource input requirement</li> <li>Increased cost efficiency</li> <li>Simplifies SELDI/MALDI setup, reducing technician man-hours and need for extensive training</li> <li>Improves experimental optimization providing greater reproducibility</li> <li>Potential for automation of CV optimization</li> </ul> <ul> <li>MALDI/SELDI mass spectrometer calibration improvement</li> <li>Biomarker discovery studies</li> <li>Quality control techniques</li> <li>Automated coefficient of variation (CV) optimization of mass spectrometer devices</li> </ul> 2022-03-08 2025-04-24 2025-04-24 2014-01-20 AA2XXX, AC3XXX, ADXXXX, ASSISTED, CDC Docket Import, CDC Docket Import CDC Prosecuting, CURVES, DESORPTION/IONIZATION, DETECTOR, Laser, Mass, MATRIX, OID-NCEZID-DHCPP, Optimize, RESPONSE, SETTINGS, SPECTROSCOPY, VAXXXX, VBXXXX, VCXXXX, VDXXXX, VEXXXX, VFXXXX, VGXXXX, VHXXXX, VIXXXX, VJXXXX, VKXXXX, VLXXXX, VMXXXX, VOXXXX, VPXXXX, WAXXXX, WBXXXX, WCXXXX, WFXXXX, WHXXXX, WIXXXX, WMXXXX, XDXXXX, XFXXXX, XHXXXX, XJXXXX, YBXXXX False True In vitro data available True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract E-167-2013-0 114172005 Emanuele VA 2nd, Gurbaxani BM. http://www.ncbi.nlm.nih.gov/pubmed/20942945 <a href="http://www.ncbi.nlm.nih.gov/pubmed/20942945">Emanuele VA 2nd, Gurbaxani BM.</a> 114172006 Emanuele VA 2nd, et al. http://www.ncbi.nlm.nih.gov/pubmed/23152765 <a href="http://www.ncbi.nlm.nih.gov/pubmed/23152765">Emanuele VA 2nd, et al.</a> 114108423 Gurbaxani, Brian CDC - DIR CDC Gurbaxani, Brian (CDC) 0 114108422 Emanuele, Vincent CDC - DIR CDC Emanuele, Vincent (CDC) 1 114108422 Emanuele, Vincent CDC - DIR CDC Emanuele, Vincent (CDC) 1 114108423 Gurbaxani, Brian CDC - DIR CDC Gurbaxani, Brian (CDC) 0 114102047 USE OF DETECTOR RESPONSE CURVES TO OPTIMIZE SETTINGS FOR MATRIX ASSISTED LASER DESORPTION/IONIZATION IN MASS SPECTROSCOPY E-157-2013-0 Closed Centers for Disease Control and Prevention (CDC) 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-2731] Use of Detector Response Curves to Optimize Settings for Mass Spectrometry&body=Please send me information about technology [TAB-2731] Use of Detector Response Curves to Optimize Settings for Mass Spectrometry. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-2731] Use of Detector Response Curves to Optimize Settings for Mass Spectrometry&body=Please send me information about technology [TAB-2731] Use of Detector Response Curves to Optimize Settings for Mass Spectrometry.">benjamin.hurley@nih.gov</a><br> 114167504 E-157-2013-0 E-157-2013-0-US-01 USE OF DETECTOR RESPONSE CURVES TO OPTIMIZE SETTINGS FOR MATRIX ASSISTED LASER DESORPTION/IONIZATION IN MASS SPECTROSCOPY PRV US 61/390,910 Abandoned US <br />Provisional (PRV) 61/390,910<br />Filed on 2010-10-07<br />Status: Abandoned 114167506 E-157-2013-0 E-157-2013-0-PCT-02 USE OF DETECTOR RESPONSE CURVES TO OPTIMIZE SETTINGS FOR MATRIX ASSISTED LASER DESORPTION/IONIZATION IN MASS SPECTROSCOPY PCT Patent Cooperation Treaty PCT/US2011/055376 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2011/055376<br />Filed on 2011-10-07<br />Status: Expired 114167507 E-157-2013-0 E-157-2013-0-US-04 USE OF DETECTOR RESPONSE CURVES TO OPTIMIZE SETTINGS FOR MATRIX ASSISTED LASER DESORPTION/IONIZATION IN MASS SPECTROSCOPY National Stage US 13/575,317 Abandoned US <br />National Stage 13/575,317<br />Filed on 2012-07-26<br />Status: Abandoned 114124616 ADXXXX 114124617 AA2XXX 114124618 AC3XXX 114124619 VAXXXX 114124620 VBXXXX 114124621 VCXXXX 114124622 VDXXXX 114124623 VEXXXX 114124624 VFXXXX 114124625 VGXXXX 114124626 VHXXXX 114124627 VIXXXX 114124628 VJXXXX 114124629 VKXXXX 114124630 VLXXXX 114124631 VMXXXX 114124632 VOXXXX 114124633 VPXXXX 114124634 WAXXXX 114124635 WBXXXX 114124636 WCXXXX 114124637 WFXXXX 114124638 WHXXXX 114124639 WIXXXX 114124640 WMXXXX 114124641 XDXXXX 114124642 XFXXXX 114124643 XHXXXX 114124644 XJXXXX 114124645 YBXXXX 114146072 DETECTOR 114146073 RESPONSE 114146074 CURVES 114146075 Optimize 114146076 SETTINGS 114146077 MATRIX 114146078 ASSISTED 114146079 Laser 114146080 DESORPTION/IONIZATION 114146081 Mass 114146082 SPECTROSCOPY 114146083 CDC Docket Import 114146084 CDC Docket Import CDC Prosecuting 114146085 OID-NCEZID-DHCPP TAB-2737 114096916 A Bias-free Sampling and Collection Trap for Resting Mosquitoes CDC Cardiology, Consumer Products, Dental, Diagnostics, Endocrinology, Infectious Disease, Licensing, Medical Devices, Non-Medical Devices, Occupational Safety and Health, Oncology, Ophthalmology, Research Materials, Therapeutics, Vaccines Cardiology Consumer Products Dental Diagnostics Endocrinology Infectious Disease Licensing Medical Devices Non-Medical Devices Occupational Safety and Health Oncology Ophthalmology Research Materials Therapeutics Vaccines Rebekah Kent, Nicholas Komar, Nicholas Panella This CDC developed collection device is a small (approximately 1 cubic foot) open-sided container that attracts mosquitoes seeking a daytime resting location. The container is dark-colored and constructed of molded wood-fiber or recycled, high-density plastic. Mosquitoes that enter the dark space of the container are aspirated through a battery-powered fan into a collection receptacle. The receptacle is especially attractive to <em>Culex</em> and <em>Anopheles</em> mosquitos' vectors of West Nile Virus and malaria parasites, respectively.<br /><br /> For research aims, this device avoids the sampling biases associated with CO<sub>2</sub>-baited traps (attracting mosquitoes in host-seeking mode, about a tenth of the population, and only females) or ovitraps/gravid traps (attract egg-laying females, again about a tenth of the population), making this device superior to other mosquito-sampling traps currently in use. Because all adult mosquitoes must find secluded locations to rest every day, this device samples all sectors of the mosquito population. It also represents a highly effective trap for blood-engorged mosquitoes that rarely enter other types of traps. <ul> <li>Receptacle circumvents sampling biases inherent to other mosquito traps</li> <li>Device is particularly adept at luring Culex and Anopheles mosquitoes</li> </ul> <ul> <li>Mosquito sampling for research and epidemiological surveillance purposes</li> <li>Mosquito control programs</li> <li>Ecological and/or population-genetics interests</li> </ul> 2022-03-08 2025-04-24 2025-04-24 2014-01-27 AC1XXX, ACXXXX, AE2BXX, AE3XXX, AEXXXX, AXXXXX, CDC Docket Import, CDC Docket Import CDC Prosecuting, COLLECTING, DDXXXX, DEXXXX, insect, Malaria, MALARIAL, Mosquito, Mosquitoes, OID-NCEZID-DVBD, Pest, Pests, Resting, SAMPLER, Sampling, SUCTION, TRAP, TRAPPING, VBXXXX, Vector-borne, Vector-borne diseases, VLXXXX, VOXXXX, VPXXXX, WAXXXX, WCXXXX, WDXXXX, WEST NILE, WEST NILE VIRUS, WFXXXX, WIXXXX, WMXXXX, XDXXXX, XIXXXX, YEXXXX False True In situ data available (on-site) True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract E-166-2013-0 E-175-2013-0 E-641-2013-0 114172017 Panella NA, et al. http://www.ncbi.nlm.nih.gov/pubmed/22017100 <a href="http://www.ncbi.nlm.nih.gov/pubmed/22017100">Panella NA, et al.</a> 114108441 Kent, Rebekah CDC - DIR CDC Kent, Rebekah (CDC) 0 114108442 Komar, Nicholas CDC - DIR CDC Komar, Nicholas (CDC) 0 114108440 Panella, Nicholas CDC - DIR CDC Panella, Nicholas (CDC) 1 114108440 Panella, Nicholas CDC - DIR CDC Panella, Nicholas (CDC) 1 114108441 Kent, Rebekah CDC - DIR CDC Kent, Rebekah (CDC) 0 114108442 Komar, Nicholas CDC - DIR CDC Komar, Nicholas (CDC) 0 114102054 SUCTION TRAP FOR COLLECTING RESTING MOSQUITOES E-223-2013-0 Filing authorized Centers for Disease Control and Prevention (CDC) 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-2737] A Bias-free Sampling and Collection Trap for Resting Mosquitoes&body=Please send me information about technology [TAB-2737] A Bias-free Sampling and Collection Trap for Resting Mosquitoes. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-2737] A Bias-free Sampling and Collection Trap for Resting Mosquitoes&body=Please send me information about technology [TAB-2737] A Bias-free Sampling and Collection Trap for Resting Mosquitoes.">benjamin.hurley@nih.gov</a><br> 114167527 E-223-2013-0 E-223-2013-0-US-01 SUCTION TRAP FOR COLLECTING RESTING MOSQUITOES PRV US 61/219,684 Abandoned US <br />Provisional (PRV) 61/219,684<br />Filed on 2009-06-23<br />Status: Abandoned 114167528 E-223-2013-0 E-223-2013-0-US-02 SUCTION TRAP FOR COLLECTING RESTING MOSQUITOES ORD US 8,667,731 12/813,279 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8667731 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8667731">8,667,731</a><br />Filed on 2010-06-10<br />Status: Issued 114124748 AXXXXX 114124749 ACXXXX 114124750 AC1XXX 114124751 AEXXXX 114124752 AE3XXX 114124753 AE2BXX 114124754 DDXXXX 114124755 DEXXXX 114124756 VBXXXX 114124757 VLXXXX 114124758 VOXXXX 114124759 VPXXXX 114124760 WAXXXX 114124761 WCXXXX 114124762 WDXXXX 114124763 WFXXXX 114124764 WIXXXX 114124765 WMXXXX 114124766 XDXXXX 114124767 XIXXXX 114124768 YEXXXX 114146165 SUCTION 114146166 TRAP 114146167 COLLECTING 114146168 Resting 114146169 Mosquitoes 114146170 CDC Docket Import 114146171 CDC Docket Import CDC Prosecuting 114146172 OID-NCEZID-DVBD 114146173 WEST NILE 114146174 WEST NILE VIRUS 114146175 Malaria 114146176 MALARIAL 114146177 Vector-borne 114146178 Vector-borne diseases 114146179 TRAPPING 114146180 Mosquito 114146181 SAMPLER 114146182 Sampling 114146183 Pest 114146184 Pests 114146185 insect TAB-2747 114096926 Recombinant Nucleic-Acid Based Flavivirus Nucleic Acids for Development of Vaccines and/or Sero-diagnostics CDC Consumer Products, Diagnostics, Infectious Disease, Licensing, Research Equipment, Research Materials, Therapeutics, Vaccines Consumer Products Diagnostics Infectious Disease Licensing Research Equipment Research Materials Therapeutics Vaccines Gwong-Jen Chang CDC scientists have developed recombinant flavivirus nucleic acids for the generation of broad protective immunity against flaviviruses, as well as the development of sensitive serologic diagnostic tools. Mosquito borne viral encephalitis is often caused by a flavivirus, such as Japanese encephalitis virus, dengue virus or West Nile virus. Infection by these pathogens is often lethal to both humans and animals.<br /><br /> Specifically, these novel recombinant nucleic acids encode critical structural proteins of flaviviruses, such as yellow fever virus. The invention provides for a method of immunizing a subject against infection by a number of pathogenic flaviviruses. Furthermore, generated antigenic subviral particles can also serve as a tool for the development of specific, antibody detection-based flavivirus diagnostic assays. <ul> <li>In vivo animal studies demonstrate specific antibody generation and complete protection</li> <li>Desired immune response provided by a single intramuscular injection in both murine and equine studies</li> <li>Potential for vaccine use and the development of commercial flavivirus infection diagnostic assays and kits</li> </ul> <ul> <li>Development of a broadly useful commercial vaccine for pathogenic flaviviruses</li> <li>Insect-borne disease monitoring and surveillance programs</li> <li>Generated antigen can be used for high-specificity serologic diagnostic assays</li> </ul> Various international patent applications pending or issued Various international patent applications pending or issued 2022-03-08 2025-04-24 2025-04-24 2014-01-28 Acid, CDC Docket Import, CDC Docket Import CDC Prosecuting, DA4BXX, DA4XXX, DAXXXX, DC1XXX, DC5BXX, DC5XXX, DCXXXX, DXXXXX, Flavivirus, Infection, Nucleic, OID-NCEZID-DVBD, Prevention, vaccines, VLXXXX, VOXXXX, WBXXXX, WDXXXX, WIXXXX, WMXXXX, XEXXXX, XHXXXX, YBXXXX, YCXXXX False True <ul> <li>In vitro data available</li> <li>In vivo data available (animal)</li> </ul> True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract E-341-2013-1 114172028 Chang GJ, et al. http://www.ncbi.nlm.nih.gov/pubmed/11797784 <a href="http://www.ncbi.nlm.nih.gov/pubmed/11797784">Chang GJ, et al.</a> 114172029 Chang GJ, et al. http://www.ncbi.nlm.nih.gov/pubmed/10756038 <a href="http://www.ncbi.nlm.nih.gov/pubmed/10756038">Chang GJ, et al.</a> 114108472 Chang, Gwong-Jen CDC - DIR CDC Chang, Gwong-Jen (CDC) 1 114108472 Chang, Gwong-Jen CDC - DIR CDC Chang, Gwong-Jen (CDC) 1 114102065 NUCLEIC ACID VACCINES FOR PREVENTION OF FLAVIVIRUS INFECTION E-341-2013-0 Research Material Centers for Disease Control and Prevention (CDC) 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-2747] Recombinant Nucleic-Acid Based Flavivirus Nucleic Acids for Development of Vaccines and/or Sero-diagnostics&body=Please send me information about technology [TAB-2747] Recombinant Nucleic-Acid Based Flavivirus Nucleic Acids for Development of Vaccines and/or Sero-diagnostics. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-2747] Recombinant Nucleic-Acid Based Flavivirus Nucleic Acids for Development of Vaccines and/or Sero-diagnostics&body=Please send me information about technology [TAB-2747] Recombinant Nucleic-Acid Based Flavivirus Nucleic Acids for Development of Vaccines and/or Sero-diagnostics.">benjamin.hurley@nih.gov</a><br> 114167559 E-341-2013-0 E-341-2013-0-US-16 NUCLEIC ACID VACCINES FOR PREVENTION OF FLAVIVIRUS INFECTION CON US 11/182,029 Abandoned US <br />Continuation (CON) 11/182,029<br />Filed on 2005-07-13<br />Status: Abandoned 114167560 E-341-2013-0 E-341-2013-0-PCT-02 NUCLEIC ACID VACCINES FOR PREVENTION OF FLAVIVIRUS INFECTION PCT Patent Cooperation Treaty PCT/US1999/012298 Expired Patent Cooperation Treaty <br />(PCT) PCT/US1999/012298<br />Filed on 1999-06-03<br />Status: Expired 114167561 E-341-2013-0 E-341-2013-0-US-09 NUCLEIC ACID VACCINES FOR PREVENTION OF FLAVIVIRUS INFECTION National Stage US 7,417,136 09/701,536 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7417136 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7417136">7,417,136</a><br />Filed on 2001-06-18<br />Status: Expired 114167562 E-341-2013-0 E-341-2013-0-US-14 NUCLEIC ACID VACCINES FOR PREVENTION OF FLAVIVIRUS INFECTION DIV US 8,105,609 12/122,330 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8105609 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8105609">8,105,609</a><br />Filed on 2008-05-16<br />Status: Expired 114167563 E-341-2013-0 E-341-2013-0-US-15 METHODS OF INDUCING AN IMMUNE RESPONSE IN A HOST BY ADMINISTERING FLAVIVIRUS IMMUNOGENS COMPRISING EXTRACELLULAR VIRAL PARTICLES COMPOSED OF THE PREMEMBRANE (PRM) AND ENVELOPE (E) ANTIGENS DIV US 8,728,488 13/338,529 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8728488 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8728488">8,728,488</a><br />Filed on 2011-12-28<br />Status: Expired 114167564 E-341-2013-0 E-341-2013-0-US-01 NUCLEIC ACID VACCINES FOR PREVENTION OF FLAVIVIRUS INFECTION PRV US 60/087,908 Abandoned US <br />Provisional (PRV) 60/087,908<br />Filed on 1998-06-04<br />Status: Abandoned 114124958 DXXXXX 114124959 DAXXXX 114124960 DA4XXX 114124961 DA4BXX 114124962 DCXXXX 114124963 DC5XXX 114124964 DC5BXX 114124965 DC1XXX 114124966 VLXXXX 114124967 VOXXXX 114124968 WBXXXX 114124969 WDXXXX 114124970 WIXXXX 114124971 WMXXXX 114124972 XEXXXX 114124973 XHXXXX 114124974 YBXXXX 114124975 YCXXXX 114146276 Nucleic 114146277 Acid 114146278 vaccines 114146279 Prevention 114146280 Flavivirus 114146281 Infection 114146282 CDC Docket Import 114146283 CDC Docket Import CDC Prosecuting 114146284 OID-NCEZID-DVBD TAB-2744 114096923 Virus Replicon Particles as Rift Valley Fever Vaccines CDC Antibodies, Cardiology, Consumer Products, Dental, Diagnostics, Endocrinology, Immunology, Infectious Disease, Licensing, Occupational Safety and Health, Oncology, Ophthalmology, Research Materials, Therapeutics, Vaccines Antibodies Cardiology Consumer Products Dental Diagnostics Endocrinology Immunology Infectious Disease Licensing Occupational Safety and Health Oncology Ophthalmology Research Materials Therapeutics Vaccines Cesar Albarino, Brian Bird, Kimberly Dodd, Stuart Nichol Rift Valley fever (RVF) virus primarily infects animals but also has the capacity to infect humans. The disease causes abortion and death among RVF-infected livestock, resulting in substantial economic loss to people living in many parts of Africa and Arabian Peninsula. Currently, there is no commercial vaccine for RVF. CDC scientists have developed a RVF virus replicon particle (VRP) vaccine candidate. Research findings revealed that immunization of mice with a single dose of the RVF-VRP was found to be safe and elicited immune response that offered 100% protection following exposure to lethal dose of virulent virus. RVF-VRPs have the potential to become effective and efficient RVF vaccines in livestock animals and humans. <ul> <li>Murine survival study showed single-dose immunization completely protected mice against a virulent RVFV challenge at 100,000-fold greater than the 50% lethal dose (LD(50))</li> <li>Rapid onset of a systematic antiviral response suggests conference of early protection</li> <li>Low genetic diversity for RVF virus indicates a strong potential for broad-use effectiveness with this vaccine</li> </ul> <ul> <li>Rift Valley fever vaccine for livestock and/or humans</li> <li>VRPs may serve as useful laboratory tool to study the basic mechanisms of virus replication, assembly, kinetics, and virus maturation</li> </ul> 2022-03-08 2025-04-24 2025-04-24 2014-01-28 CDC Docket Import, CDC Docket Import CDC Prosecuting, DC5BXX, DC5XXX, DCXXXX, DXXXXX, FEVER, OID-NCEZID-DHCPP, PARTICLES, Replicon, RIFT, THEREOF, Valley, virus, VLXXXX, VOXXXX, VPXXXX, WAXXXX, WFXXXX, WIXXXX, WJXXXX, WMXXXX, XAXXXX, XCXXXX, XEXXXX, YBXXXX, YCXXXX False True <ul> <li>In vitro data available</li> <li>In vivo data available (animal)</li> </ul> True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract E-254-2013-2 114172025 Dodd KA, et al. http://www.ncbi.nlm.nih.gov/pubmed/22345465 <a href="http://www.ncbi.nlm.nih.gov/pubmed/22345465">Dodd KA, et al.</a> 114108462 Albarino, Cesar CDC - DIR CDC Albarino, Cesar (CDC) 0 114108463 Bird, Brian CDC - DIR CDC Bird, Brian (CDC) 0 114108464 Nichol, Stuart CDC - DIR CDC Nichol, Stuart (CDC) 0 114108461 Dodd, Kimberly CDC - DIR CDC Dodd, Kimberly (CDC) 1 114108461 Dodd, Kimberly CDC - DIR CDC Dodd, Kimberly (CDC) 1 114108462 Albarino, Cesar CDC - DIR CDC Albarino, Cesar (CDC) 0 114108463 Bird, Brian CDC - DIR CDC Bird, Brian (CDC) 0 114108464 Nichol, Stuart CDC - DIR CDC Nichol, Stuart (CDC) 0 114102062 RIFT VALLEY FEVER VIRUS REPLICON PARTICLES AND USE THEREOF E-272-2013-0 Filing authorized Centers for Disease Control and Prevention (CDC) 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-2744] Virus Replicon Particles as Rift Valley Fever Vaccines&body=Please send me information about technology [TAB-2744] Virus Replicon Particles as Rift Valley Fever Vaccines. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-2744] Virus Replicon Particles as Rift Valley Fever Vaccines&body=Please send me information about technology [TAB-2744] Virus Replicon Particles as Rift Valley Fever Vaccines.">benjamin.hurley@nih.gov</a><br> 114167551 E-272-2013-0 E-272-2013-0-US-01 RIFT VALLEY FEVER VIRUS REPLICON PARTICLES AND USE THEREOF PRV US 61/661,614 Abandoned US <br />Provisional (PRV) 61/661,614<br />Filed on 2012-06-19<br />Status: Abandoned 114167552 E-272-2013-0 E-272-2013-0-PCT-02 RIFT VALLEY FEVER VIRUS REPLICON PARTICLES AND USE THEREOF PCT Patent Cooperation Treaty PCT/US2013/046250 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2013/046250<br />Filed on 2013-06-18<br />Status: Expired 114168028 E-272-2013-0 E-272-2013-0-US-03 RIFT VALLEY FEVER VIRUS REPLICON PARTICLES AND USE THEREOF National Stage US 9,687,542 14/408,389 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9687542 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9687542">9,687,542</a><br />Filed on 2014-12-16<br />Status: Issued 114124885 DXXXXX 114124886 DCXXXX 114124887 DC5XXX 114124888 DC5BXX 114124889 VLXXXX 114124890 VOXXXX 114124891 VPXXXX 114124892 WAXXXX 114124893 WFXXXX 114124894 WIXXXX 114124895 WJXXXX 114124896 WMXXXX 114124897 XAXXXX 114124898 XCXXXX 114124899 XEXXXX 114124900 YBXXXX 114124901 YCXXXX 114146246 RIFT 114146247 Valley 114146248 FEVER 114146249 virus 114146250 Replicon 114146251 PARTICLES 114146252 THEREOF 114146253 CDC Docket Import 114146254 CDC Docket Import CDC Prosecuting 114146255 OID-NCEZID-DHCPP TAB-2785 114096964 Rabies Vaccine for the Oral Immunization of Domesticated Animals, Wildlife and Feral Animals CDC Collaboration, Consumer Products, Infectious Disease, Occupational Safety and Health, Therapeutics, Vaccines Collaboration Consumer Products Infectious Disease Occupational Safety and Health Therapeutics Vaccines Charles Rupprecht This invention, developed by the CDC and collaborators, entails a live, attenuated recombinant rabies virus vaccine that can elicit an effective anti-rabies immune response in animal recipients. Inoculation with a live, attenuated, rabies virus allows for the optimized production of immunity in the absence of pathogenicity. Oral administration of rabies vaccines is often a preferred route of vaccine delivery because it is most effective in wildlife. Unfortunately, availability of an oral vaccine for canines has been a significant hurdle to date.<br /><br /> This vaccine technology could be used for immunization of stray dogs by an oral route. In developing nations, more than 90% of human exposure events and 99% of human deaths due to rabies are caused by rabid dogs. Using this vaccine with a broadly implemented oral vaccination strategy provides a promising opportunity for reducing transmission of rabies between stray dogs and, thereby, increasing protection for people. <ul> <li>Safe and effective</li> <li>Oral immunization is the most practical and efficient method of rabies vaccination of wildlife and feral animals</li> <li>Vaccine has demonstrated protection in vivo</li> <li>Recombinant, non-neuroinvasive virus expressing a neuroinvasive glycoprotein and/or pro-apoptotis gene safely induces a robust and desirable immunological response</li> </ul> <ul> <li>Wildlife and humane shelter rabies prevention and control programs</li> <li>Improved rabies vaccines for pets and livestock</li> <li>Humane, targeted approach to elimination of rabies reservoirs in feral animal populations</li> </ul> 2022-03-08 2025-04-24 2025-04-24 2014-03-07 CDC Docket Import, CDC Docket Import NP, DC5BXX, DC5XXX, DCXXXX, Dogs, DXXXXX, ENGINEERED, GENETICALLY, Immunization, rabies, recombinant, Stray, Vaccine, VLXXXX, VOXXXX, WFXXXX, Wildlife, WJXXXX, WMXXXX, XEXXXX, YBXXXX, YCXXXX False True <ul> <li>In vitro data available</li> <li>In vivo data available (animal)</li> </ul> True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114172116 Morimoto K, et al. http://www.ncbi.nlm.nih.gov/pubmed/11348722 <a href="http://www.ncbi.nlm.nih.gov/pubmed/11348722">Morimoto K, et al.</a> 114108595 Rupprecht, Charles CDC - DIR CDC Rupprecht, Charles (CDC) 1 114108595 Rupprecht, Charles CDC - DIR CDC Rupprecht, Charles (CDC) 1 114102110 Genetically Engineered Rabies Recombinant Vaccine For Immunization Of Stray Dogs And Wildlife E-470-2013-0 Closed Centers for Disease Control and Prevention (CDC), Thomas Jefferson University 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-2785] Rabies Vaccine for the Oral Immunization of Domesticated Animals, Wildlife and Feral Animals&body=Please send me information about technology [TAB-2785] Rabies Vaccine for the Oral Immunization of Domesticated Animals, Wildlife and Feral Animals. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-2785] Rabies Vaccine for the Oral Immunization of Domesticated Animals, Wildlife and Feral Animals&body=Please send me information about technology [TAB-2785] Rabies Vaccine for the Oral Immunization of Domesticated Animals, Wildlife and Feral Animals.">benjamin.hurley@nih.gov</a><br> 114167685 E-470-2013-0 E-470-2013-0-US-04 Genetically Engineered Rabies Recombinant Vaccine For Immunization Of Stray Dogs And Wildlife DIV US 11/174,796 Abandoned US <br />Divisional (DIV) 11/174,796<br />Filed on 2005-07-05<br />Status: Abandoned 114167686 E-470-2013-0 E-470-2013-0-PCT-02 Genetically Engineered Rabies Recombinant Vaccine For Immunization Of Stray Dogs And Wildlife PCT Patent Cooperation Treaty PCT/US2001/009529 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2001/009529<br />Filed on 2001-03-23<br />Status: Expired 114167687 E-470-2013-0 E-470-2013-0-US-03 Genetically Engineered Rabies Recombinant Vaccine For Immunization Of Stray Dogs And Wildlife ORD US 7,074,413 09/816,531 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7074413 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7074413">7,074,413</a><br />Filed on 2001-03-23<br />Status: Expired 114167688 E-470-2013-0 E-470-2013-0-US-01 Genetically Engineered Rabies Recombinant Vaccine For Immunization Of Stray Dogs And Wildlife PRV US 60/191,510 Abandoned US <br />Provisional (PRV) 60/191,510<br />Filed on 2000-03-23<br />Status: Abandoned 114125629 DC5XXX 114125636 DCXXXX 114125638 DXXXXX 114125646 DC5BXX 114125647 VLXXXX 114125648 VOXXXX 114125649 WFXXXX 114125650 WJXXXX 114125651 WMXXXX 114125652 XEXXXX 114125653 YBXXXX 114125654 YCXXXX 114146794 GENETICALLY 114146795 ENGINEERED 114146796 rabies 114146797 recombinant 114146798 Vaccine 114146799 Immunization 114146800 Stray 114146801 Dogs 114146802 Wildlife 114146803 CDC Docket Import 114146804 CDC Docket Import NP TAB-2794 114096973 Dengue Vaccines: Tools for Redirecting the Immune Response for Safe, Efficacious Dengue Vaccination CDC Consumer Products, Diagnostics, Infectious Disease, Licensing, Research Materials, Therapeutics, Vaccines Consumer Products Diagnostics Infectious Disease Licensing Research Materials Therapeutics Vaccines Gwong-Jen Chang, Wayne Crill, Brent Davis, Holly Hughes This CDC-developed invention relates to dengue vaccines that have been specifically developed for improved efficacy and directed immune response to avoid antibody-dependent enhancement (ADE) safety issues that, theoretically, may be associated with dengue vaccines and vaccinations. Dengue viral infection typically causes a debilitating but non-lethal illness in hosts. However, dengue hemorrhagic fever (DHF), the much more severe and life-threatening condition, is generally attributed to secondary dengue infections caused by a serotype different from the initial infection serotype by way of ADE. This effect, particularly notable in dengue viruses, should be given special consideration during vaccine design and construction.<br /><br /> This <em>in vivo</em>-validated technology provides a strategy and mechanism for increasing the safety of dengue vaccines and diminishing the likelihood of such vaccines inadvertently harming a recipient due to ADE-mediated effects. Any safe, effective dengue vaccine must produce well-balanced and tetravalent (for all four dengue serotypes) protective immunity. Despite decades of investigative effort there remains no effective, commercially available dengue vaccine and the greatest hurdle has been the difficulty of rapidly inducing this balanced immunity to all four dengue serotypes.<br /><br /> With this invention, CDC researchers have developed a cross-reactivity reduced dengue serotype 1 (DENV-1) DNA vaccine engineered to directly address ADE-related vaccine safety concerns. <em>In vivo</em> murine testing of wild-type and cross-reactivity-reduced vaccines demonstrated that this theoretical vaccine safety concern is real and that the cross-reactivity reduced DNA vaccine dramatically reduces dengue vaccination safety risk while increasing protective antibody responses. Properly developed and implemented, this novel vaccination strategy should help overcome this previously-unaddressed hindrance to dengue vaccine development. <ul> <li>Murine in vivo studies indicating proof-of-principle, safety and efficacy</li> <li>Addresses a long-standing “serotype immunity balancing” issue for dengue vaccine development</li> <li>Presently there are no safe, effective commercially available dengue vaccines</li> </ul> <ul> <li>Creation of a safe, efficacious and well-balanced dengue virus vaccine</li> <li>Improving currently developed/developing dengue vaccines to mitigate potential antibody-dependent enhancement safety issues</li> <li>Research tools for vaccine development programs for other flaviviruses, HIV</li> </ul> 2022-03-08 2025-04-24 2025-04-24 2014-03-18 CDC Docket Import, CDC Docket Import CDC Prosecuting, Containing, Cross-Reactive, DB4BXX, DB4XXX, DC5BXX, DC5XXX, DCXXXX, DDXXXX, DENGUE, DNA vaccine, DXXXXX, E-GLYCOPROTEIN, Eliminate, Epitopes, Immunodominant, insect, Insects, Mosquito, Mosquitoes, MULTIVALENT, Mutations, OID-NCEZID-DVBD, POLYPEPTIDES, Serotype, Serotypes, That, Vacccination, Vaccine, Vector-borne, Vector-borne diseases, virus, VLXXXX, WJXXXX, WMXXXX, XCXXXX, XEXXXX, YBXXXX, YCXXXX False True <ul> <li>In vitro data available</li> <li>In vivo data available (animal)</li> </ul> True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114172114 Crill WD, et al. http://www.ncbi.nlm.nih.gov/pubmed/23162552 <a href="http://www.ncbi.nlm.nih.gov/pubmed/23162552">Crill WD, et al.</a> 114108625 Crill, Wayne CDC - DIR CDC Crill, Wayne (CDC) 0 114108626 Hughes, Holly CDC - DIR CDC Hughes, Holly (CDC) 0 114108627 Davis, Brent CDC - DIR CDC Davis, Brent (CDC) 0 114108624 Chang, Gwong-Jen CDC - DIR CDC Chang, Gwong-Jen (CDC) 1 114108624 Chang, Gwong-Jen CDC - DIR CDC Chang, Gwong-Jen (CDC) 1 114108625 Crill, Wayne CDC - DIR CDC Crill, Wayne (CDC) 0 114108626 Hughes, Holly CDC - DIR CDC Hughes, Holly (CDC) 0 114108627 Davis, Brent CDC - DIR CDC Davis, Brent (CDC) 0 114102119 DENGUE VIRUS E-GLYCOPROTEIN POLYPEPTIDES CONTAINING MUTATIONS THAT ELIMINATE IMMUNODOMINANT CROSS-REACTIVE EPITOPES E-289-2013-0 Filing authorized Centers for Disease Control and Prevention (CDC) 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-2794] Dengue Vaccines: Tools for Redirecting the Immune Response for Safe, Efficacious Dengue Vaccination&body=Please send me information about technology [TAB-2794] Dengue Vaccines: Tools for Redirecting the Immune Response for Safe, Efficacious Dengue Vaccination. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-2794] Dengue Vaccines: Tools for Redirecting the Immune Response for Safe, Efficacious Dengue Vaccination&body=Please send me information about technology [TAB-2794] Dengue Vaccines: Tools for Redirecting the Immune Response for Safe, Efficacious Dengue Vaccination.">benjamin.hurley@nih.gov</a><br> 114166643 E-289-2013-0 E-289-2013-0-US-08 DENGUE VIRUS E-GLYCOPROTEIN POLYPEPTIDES CONTAINING MUTATIONS THAT ELIMINATE IMMUNODOMINANT CROSS-REACTIVE EPITOPES DIV US 10,092,637 15/262,268 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10092637 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10092637">10,092,637</a><br />Filed on 2016-09-12<br />Status: Issued 114167707 E-289-2013-0 E-289-2013-0-US-01 Compositions and Methods for Redirecting the Immune Response to Dengue Vaccination PRV US 61/549,348 Abandoned US <br />Provisional (PRV) 61/549,348<br />Filed on 2011-10-20<br />Status: Abandoned 114167708 E-289-2013-0 E-289-2013-0-PCT-02 Compositions and Methods for Redirecting the Immune Response to Dengue Vaccination PCT Patent Cooperation Treaty PCT/US2012/060872 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2012/060872<br />Filed on 2012-10-18<br />Status: Expired 114167757 E-289-2013-0 E-289-2013-0-US-07 DENGUE VIRUS E-GLYCOPROTEIN POLYPEPTIDES CONTAINING MUTATIONS THAT ELIMINATE IMMUNODOMINANT CROSS-REACTIVE EPITOPES National Stage US 14/352,812 Abandoned US <br />National Stage 14/352,812<br />Filed on 2014-04-18<br />Status: Abandoned 114168710 E-289-2013-0 E-289-2013-0-US-10 DENGUE VIRUS E-GLYCOPROTEIN POLYPEPTIDES CONTAINING MUTATIONS THAT ELIMINATE IMMUNODOMINANT CROSS-REACTIVE EPITOPES DIV US 10,568,956 16/107,119 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10568956 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10568956">10,568,956</a><br />Filed on 2018-08-21<br />Status: Issued 114168955 E-289-2013-0 E-289-2013-0-US-11 DENGUE VIRUS E-GLYCOPROTEIN POLYPEPTIDES CONTAINING MUTATIONS THAT ELIMINATE IMMUNODOMINANT CROSS-REACTIVE EPITOPES CON US 11,154,608 16/745,986 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11154608 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11154608">11,154,608</a><br />Filed on 2020-01-17<br />Status: Issued 114125789 DXXXXX 114125790 DCXXXX 114125791 DC5XXX 114125792 DC5BXX 114125793 DDXXXX 114125794 DB4XXX 114125795 DB4BXX 114125796 VLXXXX 114125797 WJXXXX 114125798 WMXXXX 114125799 XCXXXX 114125800 XEXXXX 114125801 YCXXXX 114125802 YBXXXX 114146965 DENGUE 114146966 virus 114146967 E-GLYCOPROTEIN 114146968 POLYPEPTIDES 114146969 Containing 114146970 Mutations 114146971 That 114146972 Eliminate 114146973 Immunodominant 114146974 Cross-Reactive 114146975 Epitopes 114146976 CDC Docket Import 114146977 CDC Docket Import CDC Prosecuting 114146978 OID-NCEZID-DVBD 114146979 Mosquito 114146980 Mosquitoes 114146981 insect 114146982 Insects 114146983 Vector-borne 114146984 Vector-borne diseases 114146985 Serotype 114146986 Serotypes 114146987 MULTIVALENT 114146988 Vacccination 114146989 Vaccine 114146990 DNA vaccine TAB-2800 114096979 Compositions and Methods for Improved Lyme Disease Diagnosis CDC Consumer Products, Diagnostics, Infectious Disease, Licensing, Occupational Safety and Health, Research Materials Consumer Products Diagnostics Infectious Disease Licensing Occupational Safety and Health Research Materials Barbara Johnson, Theresa Russell This CDC-developed technology entails novel compositions and methods related to the diagnosis of Lyme disease. Lyme disease, caused by the <em>Borrelia burgdorferi</em> bacterium, is the most common tick-borne infectious disease in the US and Europe. Diagnosis of Lyme disease is particularly challenging as symptoms often appear long after exposure. At present, the only FDA-approved diagnostic for Lyme disease involves patient blood tests for particular antibodies; these include an ELISA to measure patient antibody levels and a Western blot assay to detect antibodies specific to <em>B. burgdorferi</em>. One problem with the current diagnostic approach is that patient antibodies for the bacterium are not detectable until two to five weeks following the initial tick bite, and there is no way to differentiate between antibodies generated by a current infection or by a prior exposure.<br /><br /> This technology hinges on a unique approach that would detect whether a patient has a presently active <em>B. burgdorferi</em> infection. A fully developed assay based on these innovations would exploit the detection of the <em>B. burgdorferi</em> BbHtrA protease and/or its unique cleavage products to carry out a timely diagnosis of infection. While other direct detection methods, such as culturing, PCR and antigen capture, are often used in research laboratory settings, they have not demonstrated consistent efficacy as clinical diagnostic tools in the first few weeks following tick bite exposure. Further, despite the lack of a rapid and efficient readout for the aforementioned antibody-based Lyme disease diagnostics, there are currently no FDA-approved comparable alternatives. This technology provides a unique opportunity for rapid and accurate identification of <em>B. burgdorferi</em> infection, as well as distinguishing current bacterium exposure from prior exposure, thereby providing critical information to better inform treatment strategy and improve patient outcomes. <ul> <li>Present Lyme disease diagnostics cannot distinguish between current bacterium infections and prior exposures; this technology will provide such distinctions.</li> <li>Predominant antibody-based diagnostics currently available require weeks before efficacy and may require re-testing at later dates to avoid false negatives; this technology directly addresses this problem.</li> <li>Other alternative direct detection methods (e.g., PCR, culturing) have shown limited efficacy as clinical diagnostics.</li> </ul> <ul> <li>Lyme disease/<em>B. burgdorferi</em> diagnostics</li> <li>Zoonotic/tick-borne disease surveillance</li> <li>Informing clinician strategies and improving patient outcomes</li> <li>Reducing diagnosis time for patients concerned about tick bites</li> </ul> 2022-03-08 2025-04-24 2025-04-24 2014-04-03 BACTERIA, BORRELIA BURGDORFERI, BORRELLIA, BURGDORFERI, CDC Docket Import, CDC Docket Import CDC Prosecuting, Compositions, DA3XXX, DAXXXX, diagnostic, Diagnostic assay, diagnostic in vitro, Disease, DXXXXX, ivd, LYME, Methods, Relating, TICK, TICK-BORNE, TICKS, Vector-borne, Vector-borne diseases, VETERINARY, VJXXXX, VOXXXX, WBXXXX, WCXXXX, WDXXXX, WFXXXX, WIXXXX, WMXXXX, XCXXXX, YBXXXX, Zoonotic False True In vitro data available True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract E-573-2013-0 114172121 Stricker RB, et al. http://www.ncbi.nlm.nih.gov/pubmed/23967405 <a href="http://www.ncbi.nlm.nih.gov/pubmed/23967405">Stricker RB, et al.</a> 114172122 Russell TM, et al. http://www.ncbi.nlm.nih.gov/pubmed/23710801 <a href="http://www.ncbi.nlm.nih.gov/pubmed/23710801">Russell TM, et al.</a> 114172123 Russell TM, et al. http://www.ncbi.nlm.nih.gov/pubmed/23980719 <a href="http://www.ncbi.nlm.nih.gov/pubmed/23980719">Russell TM, et al.</a> 114108651 Russell, Theresa CDC - DIR CDC Russell, Theresa (CDC) 0 114108643 Johnson, Barbara CDC - DIR Johnson, Barbara 1 114108643 Johnson, Barbara CDC - DIR Johnson, Barbara 1 114108651 Russell, Theresa CDC - DIR CDC Russell, Theresa (CDC) 0 114102125 Compositions And Methods Relating To Lyme Disease E-204-2013-0 Closed Centers for Disease Control and Prevention (CDC) 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-2800] Compositions and Methods for Improved Lyme Disease Diagnosis&body=Please send me information about technology [TAB-2800] Compositions and Methods for Improved Lyme Disease Diagnosis. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-2800] Compositions and Methods for Improved Lyme Disease Diagnosis&body=Please send me information about technology [TAB-2800] Compositions and Methods for Improved Lyme Disease Diagnosis.">benjamin.hurley@nih.gov</a><br> 114164013 E-204-2013-0 E-204-2013-0-US-05 Compositions And Methods Relating To Lyme Disease CON US 9,816,992 15/200,657 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9816992 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9816992">9,816,992</a><br />Filed on 2016-07-01<br />Status: Abandoned 114167731 E-204-2013-0 E-204-2013-0-US-01 Compositions And Methods Relating To Lyme Disease PRV US 61/588,820 Abandoned US <br />Provisional (PRV) 61/588,820<br />Filed on 2012-01-20<br />Status: Abandoned 114167732 E-204-2013-0 E-204-2013-0-PCT-02 Compositions And Methods Relating To Lyme Disease PCT Patent Cooperation Treaty PCT/US2013/022379 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2013/022379<br />Filed on 2013-01-21<br />Status: Expired 114167914 E-204-2013-0 E-204-2013-0-US-04 Compositions And Methods Relating To Lyme Disease National Stage US 9,383,360 14/372,171 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9383360 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9383360">9,383,360</a><br />Filed on 2014-07-14<br />Status: Abandoned 114125860 DXXXXX 114125861 DAXXXX 114125862 DA3XXX 114125863 VJXXXX 114125864 VOXXXX 114125865 WBXXXX 114125866 WCXXXX 114125867 WDXXXX 114125868 WFXXXX 114125869 WIXXXX 114125870 WMXXXX 114125871 XCXXXX 114125872 YBXXXX 114147032 Compositions 114147033 Methods 114147034 Relating 114147035 LYME 114147036 Disease 114147037 CDC Docket Import 114147038 CDC Docket Import CDC Prosecuting 114147039 TICK 114147040 TICK-BORNE 114147041 TICKS 114147042 Vector-borne 114147043 Vector-borne diseases 114147044 Zoonotic 114147045 VETERINARY 114147046 diagnostic 114147047 Diagnostic assay 114147048 diagnostic in vitro 114147049 ivd 114147050 BACTERIA 114147051 BORRELLIA 114147052 BORRELIA BURGDORFERI 114147053 BURGDORFERI TAB-2822 114097001 Multiplex Assay for Rapid Salmonella Serotyping from Human, Animal, Food and Environmental Sources CDC Consumer Products, Diagnostics, Infectious Disease, Licensing, Occupational Safety and Health, Therapeutics Consumer Products Diagnostics Infectious Disease Licensing Occupational Safety and Health Therapeutics Patricia Fields, Collette Fitzgerald Leaumont, John McQuiston CDC researchers have developed a bead-based nucleic acid assay for serotyping members of the <em>Salmonella</em> genus; this assay will identify serotypes for approximately 95% of all human-obtained <em>Salmonella</em> isolates in the United States.<br /><br /> Presently, production and quality control for the more than 250 antisera required to cover the >2,500 known serotypes using current methods is difficult, expensive and laborious. Many clinical <em>Salmonella</em> isolates can require three to five days to determine serotype, delaying conclusive serotype identification and postponing alerts to public health monitoring programs. To that end, this new assay provides improved diagnostic identification and discrimination as well as reducing reagent consumption and technician labor. The assay has been developed and optimized in parallel with traditional serotyping methods on a panel of 368 isolates that represents all subspecies/serogroup combinations in the current Kauffmann-White <em>Salmonella</em> classification scheme, and the assay has been shown to be more specific than traditional molecular assay formats. This diagnostic assay will improve the rate and accuracy of <em>Salmonella</em> detection serotyping within human, animal, food and environmental samples. <ul> <li>Rapid detection and quantification of <em>Salmonella</em> serotypes from fluidic human, animal, food and environmental samples</li> <li>Increased sensitivity and efficiency compared to current serotyping assays</li> <li>Addresses critical need for improvement in accurate molecular diagnosis for multiple <em>Salmonella</em> serotypes</li> <li>Ready for commercialization, allows for easy addition/modification for future assay expansions</li> <li>Easily implemented as a kit</li> </ul> <ul> <li>Rapid, simple and accurate <em>Salmonella</em> serotype identification</li> <li>Diagnostic tool for clinical or research settings</li> <li>Food-safety, food-source monitoring</li> <li><em>Salmonella</em>-outbreak monitoring, prevention and mitigation</li> </ul> Various international patents pending 2022-03-08 2025-04-24 2025-04-24 2014-05-15 AA5XXX, AAXXXX, AFXXXX, assay, Bead, Beads, CDC Docket Import, CDC Docket Import CDC Prosecuting, DA3XXX, DAXXXX, diagnostic, Diagnostic assay, DXXXXX, FOOD, FOOD PATHOGEN, FOOD-ASSOCIATED, Foodborne, ivd, NAT, Nucleic, OID-NCEZID-DFWED, PLATE-BASED, RAPID, SALMONELLA, Serotype, SEROTYPING, VETERINARY, VJXXXX, VOXXXX, WBXXXX, WCXXXX, WFXXXX, WMXXXX, XEXXXX, YBXXXX, Zoonotic False True <ul> <li>In vitro data available</li> </ul> True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114172145 Fitzgerald C, et al. http://www.ncbi.nlm.nih.gov/pubmed/17634307 <a href="http://www.ncbi.nlm.nih.gov/pubmed/17634307">Fitzgerald C, et al.</a> 114172146 McQuiston JR, et al. http://www.ncbi.nlm.nih.gov/pubmed/21159932 <a href="http://www.ncbi.nlm.nih.gov/pubmed/21159932">McQuiston JR, et al.</a> 114108730 McQuiston, John CDC - DIR CDC McQuiston, John (CDC) 0 114108731 Fitzgerald Leaumont, Collette CDC - DIR CDC Fitzgerald Leaumont, Collette (CDC) 0 114108729 Fields, Patricia CDC - DIR CDC Fields, Patricia (CDC) 1 114108729 Fields, Patricia CDC - DIR CDC Fields, Patricia (CDC) 1 114108730 McQuiston, John CDC - DIR CDC McQuiston, John (CDC) 0 114108731 Fitzgerald Leaumont, Collette CDC - DIR CDC Fitzgerald Leaumont, Collette (CDC) 0 114102155 RAPID SALMONELLA SEROTYPING ASSAY E-149-2013-0 Filing authorized Centers for Disease Control and Prevention (CDC) 114102156 RAPID SALMONELLA SEROTYPING ASSAY E-149-2013-1 Filing authorized Centers for Disease Control and Prevention (CDC) 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-2822] Multiplex Assay for Rapid Salmonella Serotyping from Human, Animal, Food and Environmental Sources&body=Please send me information about technology [TAB-2822] Multiplex Assay for Rapid Salmonella Serotyping from Human, Animal, Food and Environmental Sources. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-2822] Multiplex Assay for Rapid Salmonella Serotyping from Human, Animal, Food and Environmental Sources&body=Please send me information about technology [TAB-2822] Multiplex Assay for Rapid Salmonella Serotyping from Human, Animal, Food and Environmental Sources.">benjamin.hurley@nih.gov</a><br> 114161390 E-149-2013-1 E-149-2013-1-US-03 RAPID SALMONELLA SEROTYPING ASSAY CON US 9,932,642 14/803,194 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9932642 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9932642">9,932,642</a><br />Filed on 2015-07-20<br />Status: Issued 114162334 E-149-2013-0 E-149-2013-0-US-06 RAPID SALMONELLA SEROTYPING ASSAY DIV US 14/845,907 Abandoned US <br />Divisional (DIV) 14/845,907<br />Filed on 2015-09-04<br />Status: Abandoned 114167793 E-149-2013-0 E-149-2013-0-US-01 RAPID SALMONELLA SEROTYPING ASSAY PRV US 61/406,797 Abandoned US <br />Provisional (PRV) 61/406,797<br />Filed on 2010-10-26<br />Status: Abandoned 114167794 E-149-2013-1 E-149-2013-1-US-01 RAPID SALMONELLA SEROTYPING ASSAY CIP US 9,115,408 13/871,098 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9115408 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9115408">9,115,408</a><br />Filed on 2013-04-26<br />Status: Issued 114167795 E-149-2013-0 E-149-2013-0-US-05 RAPID SALMONELLA SEROTYPING ASSAY National Stage US 9,163,287 13/877,467 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9163287 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9163287">9,163,287</a><br />Filed on 2013-04-03<br />Status: Issued 114167796 E-149-2013-0 E-149-2013-0-PCT-02 RAPID SALMONELLA SEROTYPING ASSAY PCT Patent Cooperation Treaty PCT/US2011/057875 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2011/057875<br />Filed on 2011-10-26<br />Status: Expired 114167888 E-149-2013-1 E-149-2013-1-PCT-02 RAPID SALMONELLA SEROTYPING ASSAY PCT Patent Cooperation Treaty PCT/US2013/038380 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2013/038380<br />Filed on 2013-04-26<br />Status: Expired 114126089 DXXXXX 114126090 DAXXXX 114126091 DA3XXX 114126092 AFXXXX 114126093 AA5XXX 114126094 VJXXXX 114126095 VOXXXX 114126096 WBXXXX 114126097 WCXXXX 114126098 WFXXXX 114126099 WMXXXX 114126100 XEXXXX 114126101 YBXXXX 114126102 AAXXXX 114147336 RAPID 114147337 SALMONELLA 114147338 SEROTYPING 114147339 assay 114147340 CDC Docket Import 114147341 CDC Docket Import CDC Prosecuting 114147342 OID-NCEZID-DFWED 114147343 Bead 114147344 Beads 114147345 PLATE-BASED 114147346 Nucleic 114147347 NAT 114147348 Serotype 114147349 FOOD 114147350 FOOD PATHOGEN 114147351 FOOD-ASSOCIATED 114147352 Foodborne 114147353 Zoonotic 114147354 VETERINARY 114147355 diagnostic 114147356 Diagnostic assay 114147357 ivd TAB-2820 114096999 Discrete Cross-Reactive Epitopes for Flavivirus Serological Diagnostics and Vaccines CDC Antibodies, Consumer Products, Diagnostics, Immunology, Infectious Disease, Licensing, Occupational Safety and Health, Research Materials, Therapeutics Antibodies Consumer Products Diagnostics Immunology Infectious Disease Licensing Occupational Safety and Health Research Materials Therapeutics Gwong-Jen Chang, Wayne Crill CDC researchers have identified and characterized discrete flavivirus cross-reactive epitopes useful for improving serodiagnosis and vaccination of flaviviruses, such as dengue virus, yellow fever virus, Japanese encephalitis virus, West Nile virus and the tick-borne encephalitis viruses.<br /><br /> The flavivirus envelope glycoprotein is one of the primary antigens inducing protective immunity in a host. Human flavivirus infections stimulate virus species-specific as well as flavivirus-genus cross-reactive immune responses. These cross-reactive antibodies create a serious problem for serodiagnosis, especially for secondary flavivirus infections, due to the difficulty of differentiating primary from secondary cross-reactive serum antibodies. Additionally, the presence of subneutralizing levels of flavivirus cross-reactive serum antibodies in an individual may result in a dramatic increase in the severity of secondary flavivirus infections via antibody-dependent enhancement (ADE), as commonly seen with multi-serotype dengue virus infection.<br /><br /> To that end, the identification and characterization of amino acids incorporated into these flavivirus cross-reactive epitopes extends practical understanding of structure-function relationships important for flavivirus immunopathology. This CDC antigen-epitope technology provides important tools and insights for improving flavivirus serodiagnosis, researching the pathogenesis of ADE, and advancing the development of safe and effective flavivirus vaccines. <ul> <li>Technology circumvents flavivirus serodiagnostic issues associated with cross-reactive antibody detection and non-specific flavivirus infection diagnoses</li> <li>May provide unique solutions for development of flavivirus-genus or species-specific vaccines</li> </ul> <ul> <li>Flavivirus vaccine development</li> <li>Improved serological diagnostics for flaviviruses such as dengue, yellow fever, Japanese encephalitis, West Nile and the tick-borne encephalitis viruses</li> <li>Research of flavivirus-related antibody-dependent enhancement (ADE) pathologies</li> </ul> Various international patents pending and issued 2022-03-08 2025-04-24 2025-04-24 2014-05-15 CDC Docket Import, CDC Docket Import CDC Prosecuting, CHARACTERIZATION, Cross-Reactive, Envelope, Epitopes, Flavivirus, GLYCOPROTEIN, LOCALIZATION, Methods, OID-NCEZID-DVBD, Their, VLXXXX, VOXXXX, WBXXXX, WFXXXX, WIXXXX, WJXXXX, XAXXXX, XCXXXX, XEXXXX, YBXXXX False True <ul> <li>In vitro data available</li> </ul> True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114172142 Crill WD, et al. http://www.ncbi.nlm.nih.gov/pubmed/15564505 <a href="http://www.ncbi.nlm.nih.gov/pubmed/15564505">Crill WD, et al.</a> 114172143 Chang GJ, et al. http://www.ncbi.nlm.nih.gov/pubmed/12620809 <a href="http://www.ncbi.nlm.nih.gov/pubmed/12620809">Chang GJ, et al.</a> 114108725 Crill, Wayne CDC - DIR CDC Crill, Wayne (CDC) 0 114108724 Chang, Gwong-Jen CDC - DIR CDC Chang, Gwong-Jen (CDC) 1 114108724 Chang, Gwong-Jen CDC - DIR CDC Chang, Gwong-Jen (CDC) 1 114108725 Crill, Wayne CDC - DIR CDC Crill, Wayne (CDC) 0 114102153 Localization And Characterization Of Flavivirus Envelope Glycoprotein Cross-reactive Epitopes And Methods For Their Use E-333-2013-0 Filing authorized Centers for Disease Control and Prevention (CDC) 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-2820] Discrete Cross-Reactive Epitopes for Flavivirus Serological Diagnostics and Vaccines&body=Please send me information about technology [TAB-2820] Discrete Cross-Reactive Epitopes for Flavivirus Serological Diagnostics and Vaccines. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-2820] Discrete Cross-Reactive Epitopes for Flavivirus Serological Diagnostics and Vaccines&body=Please send me information about technology [TAB-2820] Discrete Cross-Reactive Epitopes for Flavivirus Serological Diagnostics and Vaccines.">benjamin.hurley@nih.gov</a><br> 114167788 E-333-2013-0 E-333-2013-0-PCT-02 Localization And Characterization Of Flavivirus Envelope Glycoprotein Cross-reactive Epitopes And Methods For Their Use PCT Patent Cooperation Treaty PCT/US2005/026672 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2005/026672<br />Filed on 2005-07-27<br />Status: Expired 114167789 E-333-2013-0 E-333-2013-0-US-01 Localization And Characterization Of Flavivirus Envelope Glycoprotein Cross-reactive Epitopes And Methods For Their Use PRV US 60/591,898 Abandoned US <br />Provisional (PRV) 60/591,898<br />Filed on 2004-07-27<br />Status: Abandoned 114167790 E-333-2013-0 E-333-2013-0-US-07 Localization And Characterization Of Flavivirus Envelope Glycoprotein Cross-reactive Epitopes And Methods For Their Use National Stage US 7,906,292 11/572,805 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7906292 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7906292">7,906,292</a><br />Filed on 2007-01-26<br />Status: Expired 114167791 E-333-2013-0 E-333-2013-0-US-10 Localization And Characterization Of Flavivirus Envelope Glycoprotein Cross-reactive Epitopes And Methods For Their Use DIV US 9,000,141 12/892,714 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9000141 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9000141">9,000,141</a><br />Filed on 2010-09-28<br />Status: Issued 114168103 E-333-2013-0 E-333-2013-0-US-15 Localization And Characterization Of Flavivirus Envelope Glycoprotein Cross-reactive Epitopes And Methods For Their Use DIV US 9,650,422 14/659,251 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9650422 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9650422">9,650,422</a><br />Filed on 2015-03-16<br />Status: Expired 114126063 VLXXXX 114126064 VOXXXX 114126065 WBXXXX 114126066 WFXXXX 114126067 WIXXXX 114126068 WJXXXX 114126069 XAXXXX 114126070 XCXXXX 114126071 XEXXXX 114126072 YBXXXX 114147315 LOCALIZATION 114147316 CHARACTERIZATION 114147317 Flavivirus 114147318 Envelope 114147319 GLYCOPROTEIN 114147320 Cross-Reactive 114147321 Epitopes 114147322 Methods 114147323 Their 114147324 CDC Docket Import 114147325 CDC Docket Import CDC Prosecuting 114147326 OID-NCEZID-DVBD TAB-2840 114097018 Polypeptides and Methods for Enhancing and Balancing Monovalent or Multivalent Flavivirus Vaccines CDC Consumer Products, Diagnostics, Infectious Disease, Licensing, Rare/Neglected Diseases, Research Materials, Therapeutics, Vaccines Consumer Products Diagnostics Infectious Disease Licensing Rare/Neglected Diseases Research Materials Therapeutics Vaccines Gwong-Jen Chang, Holly Hughes CDC researchers have developed a potent immunogenic enhancer polypeptide useful for improving flavivirus vaccines. Flaviviruses such as dengue virus (1, 2, 3 and 4), Japanese encephalitis virus, Murray Valley encephalitis virus, St. Louis encephalitis virus, yellow fever virus and tick-borne encephalitis virus are a great burden on public health. This technology describes an identified CD4+ T cell epitope occurring within the E-glycoprotein of West Nile virus and methods of using this polypeptide to increase vaccine immunogenicity in monovalent vaccines.<br /><br /> Many attempts to develop multivalent flavivirus vaccines have encountered difficulties due to widely variable immunogenicity between serotypes and related interference issues. This technology will be useful for stabilizing and enhancing efficacy by increasing immunogenicity of the weaker components of the vaccine, creating a more balanced vaccine. Additionally, <em>in vivo</em> murine studies have demonstrated efficacy and proof of concept, suggesting that this technology can confer priming and/or boosting capabilities to flavivirus vaccine development. <ul> <li>In vivo studies indicating proof-of-principle and efficacy</li> <li>Presently there are no safe, effective commercially available dengue vaccines</li> <li>Provides unique solutions for development of flavivirus-genus or species-specific vaccines</li> </ul> <ul> <li>Creation of a safe, efficacious and immunogenically balanced dengue virus vaccine</li> <li>Additions to the weaker elements of multivalent flavivirus vaccines, providing vaccines with improved immunogenic balance</li> <li>Research tools for vaccine development, improvement programs for flaviviruses</li> <li>Improving the immunogenecity of monovalent vaccines, candidate vaccines</li> </ul> Various international applications pending 2022-03-08 2025-04-24 2025-04-24 2014-07-09 ADJUSTMENT, adjuvant, Adjuvant-like, BCXXXX, Boost, BOOSTING, CD4, CDC Docket Import, CDC Docket Import CDC Prosecuting, Cell, DB4BXX, DB4XXX, DC1XXX, DC5BXX, DC5XXX, DCXXXX, DDXXXX, DENGUE, DENGUE FEVER, Dengue Vaccine, Dengue-1, Dengue-2, Dengue-Like, DXXXXX, Epitope, Flavivirus, FLAVIVIRUSES, Identification, in vivo, JAPANESE ENCEPHALITIS VIRUS, Listed LPM Houze as of 4/15/2015, Mosquito, Mosquitoes, Nile, OID-NCEZID-DVBD, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, PRIMER, T, THEREOF, Tick-Bone, TICK-BORNE, UBXXXX, Vaccine, Vaccine Design, VACCINE DEVELOPMENT, VBXXXX, Vector-borne, Vector-borne diseases, virus, VLXXXX, VOXXXX, WAXXXX, West, WIXXXX, WJXXXX, WMXXXX, XCXXXX, YBXXXX, YCXXXX False True <ul> <li>In vitro data available</li> <li>In vivo data available (animal)</li> </ul> True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract E-341-2013-0 E-289-2013-0 E-333-2013-0 114172180 Crill WD, et al. http://www.ncbi.nlm.nih.gov/pubmed/23162552 <a href="http://www.ncbi.nlm.nih.gov/pubmed/23162552">Crill WD, et al.</a> 114172181 Hughes HR, et al. http://www.ncbi.nlm.nih.gov/pubmed/22244913 <a href="http://www.ncbi.nlm.nih.gov/pubmed/22244913">Hughes HR, et al.</a> 114104915 Hughes, Holly CDC - DIR CDC Hughes, Holly (CDC) 0 114107426 Chang, Gwong-Jen CDC - DIR CDC Chang, Gwong-Jen (CDC) 1 114107426 Chang, Gwong-Jen CDC - DIR CDC Chang, Gwong-Jen (CDC) 1 114104915 Hughes, Holly CDC - DIR CDC Hughes, Holly (CDC) 0 114100224 IDENTIFICATION OF A WEST NILE VIRUS CD4 T CELL EPITOPE AND USE THEREOF E-275-2013-0 Filing authorized Centers for Disease Control and Prevention (CDC) 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-2840] Polypeptides and Methods for Enhancing and Balancing Monovalent or Multivalent Flavivirus Vaccines&body=Please send me information about technology [TAB-2840] Polypeptides and Methods for Enhancing and Balancing Monovalent or Multivalent Flavivirus Vaccines. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-2840] Polypeptides and Methods for Enhancing and Balancing Monovalent or Multivalent Flavivirus Vaccines&body=Please send me information about technology [TAB-2840] Polypeptides and Methods for Enhancing and Balancing Monovalent or Multivalent Flavivirus Vaccines.">benjamin.hurley@nih.gov</a><br> 114165369 E-275-2013-0 E-275-2013-0-US-05 IDENTIFICATION OF A WEST NILE VIRUS CD4 T CELL EPITOPE AND USE THEREOF National Stage US 9,284,356 14/130,839 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9284356 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9284356">9,284,356</a><br />Filed on 2014-01-03<br />Status: Issued 114166036 E-275-2013-0 E-275-2013-0-PCT-02 IDENTIFICATION OF A WEST NILE VIRUS CD4 T CELL EPITOPE AND USE THEREOF PCT Patent Cooperation Treaty PCT/US2012/046269 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2012/046269<br />Filed on 2012-07-11<br />Status: Expired 114166664 E-275-2013-0 E-275-2013-0-US-01 IDENTIFICATION OF A WEST NILE VIRUS CD4 T CELL EPITOPE AND USE THEREOF PRV US 61/506,934 Abandoned US <br />Provisional (PRV) 61/506,934<br />Filed on 2011-07-12<br />Status: Abandoned 114126368 DXXXXX 114126369 DCXXXX 114126370 DB4XXX 114126371 BCXXXX 114126372 DB4BXX 114126373 DC1XXX 114126374 DC5XXX 114126375 UBXXXX 114126376 DDXXXX 114126377 DC5BXX 114126378 VBXXXX 114126379 VLXXXX 114126380 VOXXXX 114126381 WAXXXX 114126382 WIXXXX 114126383 WJXXXX 114126384 WMXXXX 114126385 XCXXXX 114126386 YBXXXX 114126387 YCXXXX 114142460 Post LPM Assignment Set 20150420 114142461 Pre LPM working set 20150418 114144711 Listed LPM Houze as of 4/15/2015 114147643 Identification 114147644 West 114147645 Nile 114147646 virus 114147647 CD4 114147648 T 114147649 Cell 114147650 Epitope 114147651 THEREOF 114147652 CDC Docket Import 114147653 CDC Docket Import CDC Prosecuting 114147654 OID-NCEZID-DVBD 114147655 PRIMER 114147656 Boost 114147657 BOOSTING 114147658 Adjuvant-like 114147659 ADJUSTMENT 114147660 adjuvant 114147661 Vaccine 114147662 Vaccine Design 114147663 VACCINE DEVELOPMENT 114147664 Flavivirus 114147665 FLAVIVIRUSES 114147666 in vivo 114147667 DENGUE 114147668 DENGUE FEVER 114147669 Dengue Vaccine 114147670 Dengue-1 114147671 Dengue-2 114147672 Dengue-Like 114147673 JAPANESE ENCEPHALITIS VIRUS 114147674 Tick-Bone 114147675 TICK-BORNE 114147676 Mosquito 114147677 Mosquitoes 114147678 Vector-borne 114147679 Vector-borne diseases TAB-2891 114097052 Novel Method and Kit Using Monoclonal Antibodies for More Sensitive Detection of Dengue Virus CDC Antibodies, Diagnostics, Immunology, Infectious Disease, Licensing, Medical Devices, Non-Medical Devices, Research Equipment, Research Materials Antibodies Diagnostics Immunology Infectious Disease Licensing Medical Devices Non-Medical Devices Research Equipment Research Materials Elizabeth Hunsperger, Betty Poole-Smith, Tesfaye Taye Following primary dengue virus (DENV) infection, non-structural protein 1 (NS1), a dengue-specific glycoprotein, is present in blood and is easily detected by various assays. However, for any infection thereafter (secondary infection), bioavailability of the glycoprotein greatly reduces sensitivity of DENV detection. Since secondary DENV infection is a risk factor for developing hemorrhagic fever, there is increasing need for more sensitive detection at this stage.<br /><br /> CDC investigators have developed a versatile method and monoclonal antibodies for detection of primary and secondary DENV infection. The antibodies specifically bind to heat-denatured NS1, allowing the addition of a heat denaturation step which greatly improves sensitivity of the detection assay. The assay was validated using actual dengue patient samples. <ul> <li>More sensitive DENV detection better for secondary infection.</li> <li>Novel antibodies and methods can be applied to existing kits to increase sensitivity and ease of use.</li> </ul> <ul> <li>Use of novel antibodies and methods for development of more sensitive diagnostics for primary and secondary DENV infection, including immunofluorescence assays, enzyme-linked immunosorbent assays, lateral flow assays and microsphere-based assay systems.</li> </ul> 2022-03-08 2025-04-24 2025-04-24 2014-11-14 1NS1, ACUTE, antibodies, Anti-dengue, DA4XXX, DDXXXX, DENV, Diagnosis, Infection, monoclonal, Mouse, NCEZID/DVBD, Non-structural, Protein, virus, VLXXXX, WBXXXX, WIXXXX, XAXXXX, XCXXXX, XDXXXX, XHXXXX, YBXXXX, YFXXXX False True <ul> <li>In vitro data available</li> <li>Prototype</li> </ul> True 52406769 Prototype 52406769 NIHTT 37470483 Website Abstract E-148-2013-0 114172218 Sharp TM, et al. http://www.ncbi.nlm.nih.gov/pubmed/24452132 <a href="http://www.ncbi.nlm.nih.gov/pubmed/24452132">Sharp TM, et al.</a> 114108914 Taye, Tesfaye CDC - DIR CDC Taye, Tesfaye (CDC) 0 114108915 Poole-Smith, Betty CDC - DIR CDC Poole-Smith, Betty (CDC) 0 114108913 Hunsperger, Elizabeth CDC - DIR CDC Hunsperger, Elizabeth (CDC) 1 114108913 Hunsperger, Elizabeth CDC - DIR CDC Hunsperger, Elizabeth (CDC) 1 114108914 Taye, Tesfaye CDC - DIR CDC Taye, Tesfaye (CDC) 0 114108915 Poole-Smith, Betty CDC - DIR CDC Poole-Smith, Betty (CDC) 0 114102222 Anti-dengue Virus (DENV) Non-structural Protein 1(NS1) Mouse Monoclonal Antibodies For The Diagnosis Of Acute DENV Infection E-182-2014-0 Research Material Centers for Disease Control and Prevention (CDC) 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-2891] Novel Method and Kit Using Monoclonal Antibodies for More Sensitive Detection of Dengue Virus&body=Please send me information about technology [TAB-2891] Novel Method and Kit Using Monoclonal Antibodies for More Sensitive Detection of Dengue Virus. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-2891] Novel Method and Kit Using Monoclonal Antibodies for More Sensitive Detection of Dengue Virus&body=Please send me information about technology [TAB-2891] Novel Method and Kit Using Monoclonal Antibodies for More Sensitive Detection of Dengue Virus.">benjamin.hurley@nih.gov</a><br> 114166947 E-182-2014-0 E-182-2014-0-PCT-02 Methods and Compositions Relating to Dengue Virus PCT Patent Cooperation Treaty PCT/US2015/036939 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2015/036939<br />Filed on 2015-06-22<br />Status: Expired 114167997 E-182-2014-0 E-182-2014-0-US-01 METHODS AND COMPOSITIONS RELATING TO DENGUE VIRUS PRV US 62/014,982 Abandoned US <br />Provisional (PRV) 62/014,982<br />Filed on 2014-06-20<br />Status: Abandoned 114126686 DA4XXX 114126687 DDXXXX 114126688 VLXXXX 114126689 WBXXXX 114126690 WIXXXX 114126691 XAXXXX 114126692 XCXXXX 114126693 XDXXXX 114126694 XHXXXX 114126695 YBXXXX 114126696 YFXXXX 114147932 Anti-dengue 114147933 virus 114147934 DENV 114147935 Non-structural 114147936 Protein 114147937 1NS1 114147938 Mouse 114147939 monoclonal 114147940 antibodies 114147941 Diagnosis 114147942 ACUTE 114147943 Infection 114147944 NCEZID/DVBD TAB-2889 114097050 High-Titer, Fast-Growth Chimeric Dengue/West Nile Viruses for Vaccine and Diagnostics Development CDC Diagnostics, Infectious Disease, Licensing, Research Materials, Therapeutics, Vaccines Diagnostics Infectious Disease Licensing Research Materials Therapeutics Vaccines Claire Kinney Mosquito-transmitted dengue virus is one of the leading causes of illness in the tropics and subtropics. There is currently no vaccine available and a number of DENV diagnostic and research applications depend on the production of large amounts of these viruses. However, due to the slow growing nature of DENVs these protocols are very time-consuming.<br /><br /> Researchers at the CDC have engineered stable, rapidly growing dengue-like viruses by combining the fast replicative ability of the West Nile virus with the immunogenic premembrane and envelope surface proteins of DENV serotypes 1, 2, 3, and 4, respectively. These DENV structural features are involved in a number of biological functions including virus-cell attachment and initiation of virus-specific antibody production. In turn, the chimeric viruses are more infectious and virulent than wild type DENV, but they do respond similarly in neutralization assays. The investigators also describe methods to use the inactivated form of these chimeras to elicit protective immune responses. Thus, these chimeric viruses can be used to enhance the efficiency of DENV diagnostics, vaccine development and testing, and basic dengue virology. <ul> <li>Faster production of dengue-like viruses for more efficient use in many applications.</li> <li>Methods and inactivated compositions of chimeric viruses are described for use in DENV vaccine development.</li> </ul> <ul> <li>Dengue virus diagnostics</li> <li>Inactivated dengue vaccine development and testing</li> <li>Dengue virus-related biomedical research</li> </ul> 2022-03-08 2025-04-24 2025-04-24 2014-11-14 chimeric, DA4XXX, DC5XXX, DDXXXX, Dengue-Like, ENGINEERING, Fast-Growth, NILE/DENGUE, Viruses, VLXXXX, WBXXXX, West, WIXXXX, XEXXXX, YBXXXX, YCXXXX False True <ul> <li>In vitro data available</li> <li>In vivo data available (animal)</li> </ul> True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114172216 Osorio JE, et al. http://www.ncbi.nlm.nih.gov/pubmed/21633037 <a href="http://www.ncbi.nlm.nih.gov/pubmed/21633037">Osorio JE, et al.</a> 114172217 Huang CY, et al. http://www.ncbi.nlm.nih.gov/pubmed/15919884 <a href="http://www.ncbi.nlm.nih.gov/pubmed/15919884">Huang CY, et al.</a> 114108910 Kinney, Claire CDC - DIR CDC Kinney, Claire (CDC) 1 114108910 Kinney, Claire CDC - DIR CDC Kinney, Claire (CDC) 1 114102220 Engineering Of Chimeric West Nile/Dengue Viruses (Fast-Growth Dengue-Like Viruses) E-168-2014-0 Filing authorized Centers for Disease Control and Prevention (CDC) 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-2889] High-Titer, Fast-Growth Chimeric Dengue/West Nile Viruses for Vaccine and Diagnostics Development&body=Please send me information about technology [TAB-2889] High-Titer, Fast-Growth Chimeric Dengue/West Nile Viruses for Vaccine and Diagnostics Development. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-2889] High-Titer, Fast-Growth Chimeric Dengue/West Nile Viruses for Vaccine and Diagnostics Development&body=Please send me information about technology [TAB-2889] High-Titer, Fast-Growth Chimeric Dengue/West Nile Viruses for Vaccine and Diagnostics Development.">benjamin.hurley@nih.gov</a><br> 114162538 E-168-2014-0 E-168-2014-0-US-08 CHIMERIC WEST NILE/DENGUE VIRUSES AND METHODS OF USE National Stage US 10,428,313 15/318,334 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10428313 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10428313">10,428,313</a><br />Filed on 2016-12-12<br />Status: Issued 114164117 E-168-2014-0 E-168-2014-0-PCT-02 Chimeric West Nile/Dengue Viruses and Methods of Use PCT Patent Cooperation Treaty PCT/US2015/036728 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2015/036728<br />Filed on 2015-06-19<br />Status: Expired 114167995 E-168-2014-0 E-168-2014-0-US-01 Chimeric West Nile/Dengue Viruses And Methods of Use PRV US 62/015,265 Abandoned US <br />Provisional (PRV) 62/015,265<br />Filed on 2014-06-20<br />Status: Abandoned 114126668 DC5XXX 114126669 DA4XXX 114126670 DDXXXX 114126671 VLXXXX 114126672 WBXXXX 114126673 WIXXXX 114126674 XEXXXX 114126675 YBXXXX 114126676 YCXXXX 114147914 ENGINEERING 114147915 chimeric 114147916 West 114147917 NILE/DENGUE 114147918 Viruses 114147919 Fast-Growth 114147920 Dengue-Like TAB-2936 114097087 Rapid Method for the Detection of Antigen-Specific Antibodies in Any Species CDC Antibodies, Consumer Products, Diagnostics, Immunology, Infectious Disease, Licensing, Research Equipment, Research Materials Antibodies Consumer Products Diagnostics Immunology Infectious Disease Licensing Research Equipment Research Materials Alison Basile Currently available identification methods for antigen-specific antibodies require live pathogens, antisera (that are only available for a limited number of species), and species-specific secondary antibodies (also a limited resource). Thus, detection or surveillance of pathogens in wild avian species or zoo animals, for example, is complex and cumbersome.<br /><br /> Researchers at the CDC have developed methods to rapidly detect antigen-specific antibodies in any species, including those for which secondary antibodies and/or antisera are unavailable. The unique methods involve direct labelling of biological samples, such as with biotinylation, thereby eliminating the need for species-specific conjugates. Thereafter, target-antigen detection can be completed by using a flow instrument or a plate-based immunological assay. Also, the assay can screen a large number of samples and can be adapted for use with many etiologic agents relevant to the mammalian, reptilian, and avian species, plants, or insects. Furthermore, this assay can detect one or more antibody classes simultaneously, rather than being limited to one particular type. <ul> <li>Universal antigen-specific antibody detection in any species.</li> <li>Rapid and safe screen that can detect one or more antibody classes simultaneously.</li> <li>The assay is not limited by species-specific secondary antibody or antisera availability.</li> <li>The assay can screen a variety of samples, such as serum, plasma, blood, urine, feces, saliva, tears, semen, mucous, or cerebral spinal fluid.</li> </ul> <ul> <li>Pathogen detection/diagnostic for veterinary applications, especially useful in wild or exotic species.</li> <li>Research tool for surveillance studies of pathogens in any species.</li> </ul> Foreign counterparts pending in Canada, Europe, and Australia 2022-03-08 2025-04-24 2025-04-24 2015-05-19 antibodies, ANTIGEN-SPECIFIC, Biological, CDC Docket Import, CDC Docket Import CDC Prosecuting, DA1XXX, DA3XXX, DA4XXX, DAXXXX, DDXXXX, Detection, Listed LPM Houze as of 4/15/2015, Method, OID-NCEZID-DVBD, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, SAMPLES, VJXXXX, VKXXXX, VLXXXX, VOXXXX, WBXXXX, WIXXXX, WMXXXX, XAXXXX, XCXXXX, XHXXXX, YBXXXX False True In vitro data available True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114172255 Blitvich BJ, et al. http://www.ncbi.nlm.nih.gov/pubmed/12791902 <a href="http://www.ncbi.nlm.nih.gov/pubmed/12791902">Blitvich BJ, et al.</a> 114172256 Johnson AJ, et al. http://www.ncbi.nlm.nih.gov/pubmed/15879016 <a href="http://www.ncbi.nlm.nih.gov/pubmed/15879016">Johnson AJ, et al.</a> 114109032 Basile, Alison CDC - DIR CDC Basile, Alison (CDC) 1 114109032 Basile, Alison CDC - DIR CDC Basile, Alison (CDC) 1 114102270 METHOD FOR DETECTION OF ANTIGEN-SPECIFIC ANTIBODIES IN BIOLOGICAL SAMPLES E-299-2013-0 Filing authorized Centers for Disease Control and Prevention (CDC) 114102271 METHOD FOR DETECTION OF ANTIGEN-SPECIFIC ANTIBODIES IN BIOLOGICAL SAMPLES E-299-2013-3 Filing authorized Centers for Disease Control and Prevention (CDC) 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-2936] Rapid Method for the Detection of Antigen-Specific Antibodies in Any Species&body=Please send me information about technology [TAB-2936] Rapid Method for the Detection of Antigen-Specific Antibodies in Any Species. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-2936] Rapid Method for the Detection of Antigen-Specific Antibodies in Any Species&body=Please send me information about technology [TAB-2936] Rapid Method for the Detection of Antigen-Specific Antibodies in Any Species.">benjamin.hurley@nih.gov</a><br> 114168152 E-299-2013-0 E-299-2013-0-US-01 METHOD FOR DETECTION OF ANTIGEN-SPECIFIC ANTIBODIES IN BIOLOGICAL SAMPLES PRV US 61/093,605 Abandoned US <br />Provisional (PRV) 61/093,605<br />Filed on 2008-09-02<br />Status: Abandoned 114168153 E-299-2013-3 E-299-2013-3-PCT-01 METHOD FOR DETECTION OF ANTIGEN-SPECIFIC ANTIBODIES IN BIOLOGICAL SAMPLES PCT COMB Patent Cooperation Treaty PCT/US2009/054916 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2009/054916<br />Filed on 2009-08-25<br />Status: Expired 114168154 E-299-2013-3 E-299-2013-3-US-05 METHOD FOR DETECTION OF ANTIGEN-SPECIFIC ANTIBODIES IN BIOLOGICAL SAMPLES National Stage US 9,063,150 13/060,399 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9063150 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9063150">9,063,150</a><br />Filed on 2011-02-23<br />Status: Issued 114127007 DAXXXX 114127008 DA3XXX 114127009 DA1XXX 114127010 DA4XXX 114127011 DDXXXX 114127012 VJXXXX 114127013 VKXXXX 114127014 VLXXXX 114127015 VOXXXX 114127016 WBXXXX 114127017 WIXXXX 114127018 WMXXXX 114127019 XAXXXX 114127020 XCXXXX 114127021 XHXXXX 114127022 YBXXXX 114148313 Method 114148314 Detection 114148315 ANTIGEN-SPECIFIC 114148316 antibodies 114148317 Biological 114148318 SAMPLES 114148319 CDC Docket Import 114148320 CDC Docket Import CDC Prosecuting 114148321 OID-NCEZID-DVBD 114148322 Listed LPM Houze as of 4/15/2015 114148323 Pre LPM working set 20150418 114148324 Post LPM Assignment Set 20150420 TAB-3161 114097108 CDC Trioplex – A Real-Time RT-PCR Assay for the Diagnosis of Zika, and Differentiation from Dengue & Chikungunya Virus Infections CDC Collaboration, Licensing Collaboration Licensing Robert Lanciotti, Jorge Munoz-Jordan, Gilberto Santiago As of March 2017, 64 countries and territories had travel notices for active Zika virus transmissions. CDC developed the Trioplex rRT-PCR test to detect evidence of Zika virus infection and aid in differentiating this infection from dengue and chikungunya virus infections, all of which are spread by the same types of Aedes species mosquitoes and cause similar illness. The Trioplex Real-time RT-PCR assay is for qualitative detection and differentiation of RNA from dengue, chikungunya and Zika viruses in serum, whole blood, urine, amniotic fluid and cerebral spinal fluid, and for the qualitative detection of Zika virus RNA in urine and amniotic fluid. This assay protocol is designed to facilitate simultaneous testing for the three viruses using a single sample in the same plate well (multiplex). A singleplex reaction (measuring one analyte at a time) is also an option for chikungunya and dengue testing in serum, whole blood, and cerebrospinal fluid (other specimen types if one primer/probe set per well is preferred). The U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the Trioplex assay on March 17, 2016. <ul> <li>Currently, there is no multiplex PCR assay on the market that can detect and differentiate Zika, dengue and chikungunya in one test</li> <li>There is no FDA-approved chikungunya test on the market and current Zika and dengue tests must be run separately</li> <li>This was the second diagnostic assay that tests for Zika to receive FDA's EUA (CDC has the first two tests, Trioplex and the Zika MAC-ELISA assay, to receive FDA's EUA for diagnosing Zika)</ul> </ul> <ul> <li>Assay is currently in use by public health labs to support the 2016 Zika outbreak; licensee(s) can potentially take over providing these assays</li> <li>Diagnostic assay for the detection and differentiation of Zika, chikungunya and dengue viruses</li> <li>Quality Assurance/Quality Control (QA/QC) testing</li> </ul> The CDC is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize the CDC RT-PCR Trioplex assay. For collaboration opportunities, please contact the CDC Technology Transfer Office at <a href="mailto: tto@cdc.gov">tto@cdc.gov</a> or 1-404-639-1330. 2022-03-08 2025-04-24 2025-04-24 2017-09-06 assay, NCEZID, NCEZID-DVBD, REAL-TIME, RT-PCR, Trioplex False True True NIHTT 37470483 Website Abstract E-107-2016-0 E-148-2013-0 114172468 Santiago G.A., et al. Performance of the Trioplex Real-Time RT-PCR Assay for Detection of Zika, Dengue, and Chikungunya Viruses, Nature Communications 2018 Apr 11;9(1):1391. http://dx.doi.org/10.1038/s41467-018-03772-1 <a href="http://dx.doi.org/10.1038/s41467-018-03772-1">Santiago G.A., et al. Performance of the Trioplex Real-Time RT-PCR Assay for Detection of Zika, Dengue, and Chikungunya Viruses, Nature Communications 2018 Apr 11;9(1):1391.</a> 114109324 Lanciotti, Robert CDC - DIR CDC Lanciotti, Robert (CDC) 0 114109325 Santiago, Gilberto CDC - DIR CDC Santiago, Gilberto (CDC) 0 114109323 Munoz-Jordan, Jorge CDC - DIR CDC Munoz-Jordan, Jorge (CDC) 1 114109323 Munoz-Jordan, Jorge CDC - DIR CDC Munoz-Jordan, Jorge (CDC) 1 114109324 Lanciotti, Robert CDC - DIR CDC Lanciotti, Robert (CDC) 0 114109325 Santiago, Gilberto CDC - DIR CDC Santiago, Gilberto (CDC) 0 114102309 Trioplex Real-time RT-PCR Assay E-081-2017-0 Closed Centers for Disease Control and Prevention (CDC) 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-3161] CDC Trioplex – A Real-Time RT-PCR Assay for the Diagnosis of Zika, and Differentiation from Dengue & Chikungunya Virus Infections&body=Please send me information about technology [TAB-3161] CDC Trioplex – A Real-Time RT-PCR Assay for the Diagnosis of Zika, and Differentiation from Dengue & Chikungunya Virus Infections. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-3161] CDC Trioplex – A Real-Time RT-PCR Assay for the Diagnosis of Zika, and Differentiation from Dengue & Chikungunya Virus Infections&body=Please send me information about technology [TAB-3161] CDC Trioplex – A Real-Time RT-PCR Assay for the Diagnosis of Zika, and Differentiation from Dengue & Chikungunya Virus Infections.">benjamin.hurley@nih.gov</a><br> 114168356 E-081-2017-0 E-081-2017-0-PCT-01 REAL-TIME RT-PCR ASSAY FOR DETECTION OF DENGUE, CHIKUNGUNYA, AND ZIKA VIRUSES PCT Patent Cooperation Treaty PCT/US2017/023021 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2017/023021<br />Filed on 2017-03-17<br />Status: Expired 114149330 Trioplex 114149331 REAL-TIME 114149332 RT-PCR 114149333 assay 114149334 NCEZID 114149335 NCEZID-DVBD TAB-3164 114097111 Nucleic Acid Primers and Probes for Detecting Ebola Virus (species <em>Zaire ebolavirus</em>) CDC Collaboration, Licensing Collaboration Licensing Stuart Nichol, Tara Sealy, Ute Stroeher, Jonathan Towner The 2014-2016 Ebola Virus Disease (EVD) outbreak in West Africa was the largest in history, causing more than 28,000 suspected, probable, and confirmed infections and more than 11,000 deaths across nine countries. CDC scientists designed nucleic acid primers and probes which can be used in a sensitive test for detecting all known strains of Ebola virus (species<em> Zaire ebolavirus</em>) including the 2014/2015 strain that emerged in West Africa and the more recent strain that caused an EVD outbreak in the Democratic Republic of Congo in 2017. The primer and probe set can be used on blood samples for both a one-step and two-step RT-PCR. The U.S. Food and Drug Administration (FDA) issued two emergency use authorizations (EUAs) for this technology on October 10, 2014 and reissued them on March 2, 2015. The technology has been utilized in field testing and would just need 510(k) completion to be sold. <ul> <li>A sensitive, highly specific method for the detection of all known strains of Ebola virus (species<em>Zaire ebolavirus</em>), including all strains that circulated during the 2014-2016 outbreak in West Africa</li> <li> Primers and probes for two different Ebola virus gene targets can be used sequentially or in parallel as primary and confirmatory tests</li> </ul> <ul> <li>Diagnostic panel for detecting Ebola virus disease caused by Ebola virus (species<em>Zaire ebolavirus</em>)</li> <li>The primer and probe sets can be included in a test kit with other reagents and controls for performing nucleic acid amplification testing for all known strains of Ebola virus</li> </ul> The CDC Technology Transfer Office (TTO) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize these nucleic acid primers and probes for detecting the species <em>Zaire Ebolavirus</em>. For collaboration opportunities, please contact CDC TTO at <a href ="mailto: tto@cdc.gov ">tto@cdc.gov </a> or 404-639-1330. 2022-03-08 2025-04-24 2025-04-24 2017-09-13 7, Acid, antibodies, ANTIGENS, assay, DETECTING, Detection, Ebola, Ebolavirus, ELISA, Enzyme, Identification, immunosorbent, LINKED, Listed LPM Kirby as of 4/15/2015, Mab, monoclonal, Mouse, NCEZID, NCEZID-DHCPP, Nucleic, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, PRIMERS, Probes, Species, Used, virus, Viruses, Zaire False True True NIHTT 37470483 Website Abstract E-057-2015-0 114172348 Emergency Preparedness and Response https://www.fda.gov/EmergencyPreparedness/Counterterrorism/MedicalCountermeasures/MCMLegalRegulatoryandPolicyFramework/ucm182568.htm#ebola <a href="https://www.fda.gov/EmergencyPreparedness/Counterterrorism/MedicalCountermeasures/MCMLegalRegulatoryandPolicyFramework/ucm182568.htm#ebola">Emergency Preparedness and Response</a> 114109332 Sealy, Tara CDC - DIR CDC Sealy, Tara (CDC) 0 114109333 Stroeher, Ute CDC - DIR CDC Stroeher, Ute (CDC) 0 114109337 Nichol, Stuart CDC - DIR CDC Nichol, Stuart (CDC) 0 114109336 Towner, Jonathan CDC - DIR CDC Towner, Jonathan (CDC) 1 114109336 Towner, Jonathan CDC - DIR CDC Towner, Jonathan (CDC) 1 114109332 Sealy, Tara CDC - DIR CDC Sealy, Tara (CDC) 0 114109333 Stroeher, Ute CDC - DIR CDC Stroeher, Ute (CDC) 0 114109337 Nichol, Stuart CDC - DIR CDC Nichol, Stuart (CDC) 0 114102312 Nucleic Acid Primers And Probes For Detecting Viruses Of The Species Zaire Ebolavirus E-056-2015-0 Filing authorized Centers for Disease Control and Prevention (CDC) 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-3164] Nucleic Acid Primers and Probes for Detecting Ebola Virus (species <em>Zaire ebolavirus</em>)&body=Please send me information about technology [TAB-3164] Nucleic Acid Primers and Probes for Detecting Ebola Virus (species <em>Zaire ebolavirus</em>). Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-3164] Nucleic Acid Primers and Probes for Detecting Ebola Virus (species <em>Zaire ebolavirus</em>)&body=Please send me information about technology [TAB-3164] Nucleic Acid Primers and Probes for Detecting Ebola Virus (species <em>Zaire ebolavirus</em>).">benjamin.hurley@nih.gov</a><br> 114168363 E-056-2015-0 E-056-2015-0-US-01 METHODS AND REAGENTS FOR DETECTING EBOLA VIRUS PRV US 62/118,989 Abandoned US <br />Provisional (PRV) 62/118,989<br />Filed on 2015-02-20<br />Status: Abandoned 114168364 E-056-2015-0 E-056-2015-0-PCT-02 METHODS AND REAGENTS FOR DETECTING EBOLA VIRUS PCT Patent Cooperation Treaty PCT/US2016/018468 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2016/018468<br />Filed on 2016-02-18<br />Status: Expired 114168365 E-056-2015-0 E-056-2015-0-US-03 METHODS AND REAGENTS FOR DETECTING EBOLA VIRUS National Stage US 10,119,172 15/552,157 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10119172 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10119172">10,119,172</a><br />Filed on 2017-08-18<br />Status: Issued 114149363 7 114149364 Mouse 114149365 monoclonal 114149366 antibodies 114149367 Mab 114149368 Used 114149369 Enzyme 114149370 LINKED 114149371 immunosorbent 114149372 assay 114149373 ELISA 114149374 Detection 114149375 Identification 114149376 Ebola 114149377 virus 114149378 ANTIGENS 114149379 NCEZID-DHCPP 114149380 Listed LPM Kirby as of 4/15/2015 114149381 Pre LPM working set 20150418 114149382 Post LPM Assignment Set 20150420 114149383 NCEZID 114149384 Nucleic 114149385 Acid 114149386 PRIMERS 114149387 Probes 114149388 DETECTING 114149389 Viruses 114149390 Species 114149391 Zaire 114149392 Ebolavirus TAB-3205 114097145 Real-Time RT-PCR Assay for the Rapid Detection of Rabies and Other Lyssaviruses CDC Collaboration, Consumer Products, Diagnostics, Infectious Disease, Licensing, Occupational Safety and Health, Research Materials, Therapeutics Collaboration Consumer Products Diagnostics Infectious Disease Licensing Occupational Safety and Health Research Materials Therapeutics Yu Li Rabies occurs in more than 150 countries and territories, resulting in at least 55,000 human deaths per year worldwide according to World Health Organization estimates. Rabies is a vaccine-preventable viral disease caused by numerous lyssaviruses that are found in a variety of animal species throughout the world. Rabies virus infects the central nervous system, causing disease in the brain with almost 100% mortality once clinical symptoms manifest. Rapid and accurate laboratory diagnosis of rabies in humans and other animals is essential for timely administration of post-exposure prophylaxis.<br /><br /> Due to significant sequence variation among rabies and related lyssaviruses, no single molecular diagnostic test detects all species that may cause fatal human rabies. Using modified nucleotide detection technologies, CDC scientists have developed a real-time RT-PCR assay that can detect all current known lyssaviruses (up to 15 species) responsible for rabies. This one-step test has improved sensitivity and specificity compared to current rabies diagnostic assays; it is also simpler to run and ready for field use. The real-time RT-PCR assay allows for rapid and efficient detection of rabies in both humans and animals, with an ability to distinguish between all known lyssavirus species that cause rabies. <ul> <li>Increased sensitivity and specificity compared to standard methods</li> <li>Detects all currently known species of lyssaviruses that cause rabies as well as other lyssaviruses</li> <li> This simple, one-step assay provides rapid results in approximately 90 minutes</li> <li> Currently, there are no other commercial test kits available for complete rabies diagnosis from lyssaviruses</li> </ul> <ul> <li>A one-step PCR assay adaptable to kit format for the diagnosis of rabies in humans and animals</li> <li>Quantification of viral RNA to assess rabies viral load, disease progression, and efficacy of experimental therapeutics – this may be valuable as newer treatment options become available</li> <li>Assist efforts for canine rabies surveillance, control, and eradication</li> </ul> The CDC Technology Transfer Office (TTO) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize: Real-Time RT-PCR Diagnostic Assay for Rabies and Other Lyssaviruses. 2022-03-08 2025-04-24 2025-04-24 2017-11-17 assay, DA4XXX, DDXXXX, Diagnostics, LYSSAVIRUSES, Modified, NCEZID, NCEZID-DHCPP, Non-rabies, Probe, rabies, REAL-TIME, RT-PCR, VLXXXX, VOXXXX, WBXXXX, WGXXXX, WHXXXX, WIXXXX, XEXXXX, YBXXXX, YGXXXX False True True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract E-180-2013-0 E-326-2013-0 114172388 Wadhwa A, et al. https://www.ncbi.nlm.nih.gov/pubmed/28081126 <a href="https://www.ncbi.nlm.nih.gov/pubmed/28081126">Wadhwa A, et al.</a> 114109472 Li, Yu CDC - DIR CDC Li, Yu (CDC) 1 114109472 Li, Yu CDC - DIR CDC Li, Yu (CDC) 1 114102367 A Real-time RT-PCR Assay With Modified Probe For The Diagnostics Of Rabies And Non-rabies Lyssaviruses E-070-2016-0 Filing authorized Centers for Disease Control and Prevention (CDC) 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-3205] Real-Time RT-PCR Assay for the Rapid Detection of Rabies and Other Lyssaviruses&body=Please send me information about technology [TAB-3205] Real-Time RT-PCR Assay for the Rapid Detection of Rabies and Other Lyssaviruses. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-3205] Real-Time RT-PCR Assay for the Rapid Detection of Rabies and Other Lyssaviruses&body=Please send me information about technology [TAB-3205] Real-Time RT-PCR Assay for the Rapid Detection of Rabies and Other Lyssaviruses.">benjamin.hurley@nih.gov</a><br> 114168452 E-070-2016-0 E-070-2016-0-US-01 REAL-TIME REVERSE TRANSCRIPTASE-POLYMERASE CHAIN REACTION ASSAY WITH MODIFIED PROBE FOR THE DIAGNOSIS OF RABIES VIRUSES AND OTHER LYSSAVIRUSES PRV US 62/339,323 Abandoned US <br />Provisional (PRV) 62/339,323<br />Filed on 2016-05-20<br />Status: Abandoned 114168453 E-070-2016-0 E-070-2016-0-PCT-02 REAL-TIME REVERSE TRANSCRIPTASE-POLYMERASE CHAIN REACTION ASSAY WITH MODIFIED PROBE FOR THE DIAGNOSIS OF RABIES VIRUSES AND OTHER LYSSAVIRUSES PCT Patent Cooperation Treaty PCT/US17/031595 Expired Patent Cooperation Treaty <br />(PCT) PCT/US17/031595<br />Filed on 2017-05-08<br />Status: Expired 114168810 E-070-2016-0 E-070-2016-0-US-04 REAL-TIME REVERSE TRANSCRIPTASE-POLYMERASE CHAIN REACTION ASSAY WITH MODIFIED PROBE FOR THE DIAGNOSIS OF RABIES VIRUSES AND OTHER LYSSAVIRUSES National Stage US 11,155,885 16/303,006 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11155885 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11155885">11,155,885</a><br />Filed on 2018-11-19<br />Status: Issued 114127572 VLXXXX 114127573 VOXXXX 114127574 WBXXXX 114127575 DA4XXX 114127576 WGXXXX 114127577 WHXXXX 114127578 WIXXXX 114127579 XEXXXX 114127580 YBXXXX 114127581 YGXXXX 114127582 DDXXXX 114149957 NCEZID 114149958 REAL-TIME 114149959 RT-PCR 114149960 assay 114149961 Modified 114149962 Probe 114149963 Diagnostics 114149964 rabies 114149965 Non-rabies 114149966 LYSSAVIRUSES 114149967 NCEZID-DHCPP TAB-3226 114097162 Chimeric Dengue/Zika Viruses for Live-Attenuated Zika Vaccine Development CDC Collaboration, Diagnostics, Infectious Disease, Licensing, Research Materials, Therapeutics, Vaccines Collaboration Diagnostics Infectious Disease Licensing Research Materials Therapeutics Vaccines Claire Kinney Zika virus (ZIKV) can be passed from a pregnant woman to her fetus. Infection during pregnancy can cause microcephaly and other severe birth defects. Currently, there are no vaccines to prevent or medications to treat Zika infections.<br /><br /> CDC engineered chimeric Zika viruses on the dengue virus (DENV) sub-type 2 (D2) PDK-53 vaccine backbone (D2 PDK-53) for potential development of a live-attenuated Zika vaccine. These chimeric viruses could also be used for other research purposes such as development of diagnostic tests. The cDNA genetic clones for the chimeric constructs have been successfully engineered, and scientists in the laboratory are in the process of deriving infectious chimeric D2 PDK-53/Zika viruses. <ul> <li>Potential inclusion in combination flavivirus vaccines</li> <li>Faster production of Zika-like viruses for more efficient use in different applications such as vaccine candidate and diagnostic development</li> </ul> <ul> <li>Zika vaccine development or combined vaccination strategies using both live-attenuated and inactivated ZIKV vaccine (West Nile/ZKV) candidates</li> <li>Combination vaccine with other flaviviruses such as dengue or chikungunya</li> <li>Zika virus diagnostics</li> <li>Zika virus-related biomedical research</li> </ul> The CDC Technology Transfer Office (TTO) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize: Chimeric Dengue/Zika Viruses for Zika Vaccine Development. For collaboration opportunities, please contact CDC TTO at <a href="mailto:tto@cdc.gov">tto@cdc.gov</a>. 2022-03-08 2025-04-24 2025-04-24 2017-12-04 chimeric, Dengue/Zika, Development, Live-Attenuated, NCEZID-DVBD, Vaccine, Viruses, VLXXXX, WBXXXX, WIXXXX, WNXXXX, XEXXXX, XKXXXX, YAXXXX, YBXXXX, Zika False True True 52406768 Discovery 52406768 NIHTT 37470483 Website Abstract E-118-2016-0 114172406 [EMPTY] https://www.ncbi.nlm.nih.gov/pubmed/21777638 <a href="https://www.ncbi.nlm.nih.gov/pubmed/21777638">[EMPTY]</a> 114172407 [EMPTY] https://www.ncbi.nlm.nih.gov/pubmed/21633037 <a href="https://www.ncbi.nlm.nih.gov/pubmed/21633037">[EMPTY]</a> 114172408 [EMPTY] https://www.ncbi.nlm.nih.gov/pubmed/15919884 <a href="https://www.ncbi.nlm.nih.gov/pubmed/15919884">[EMPTY]</a> 114172409 [EMPTY] https://www.ncbi.nlm.nih.gov/pubmed/14557629 <a href="https://www.ncbi.nlm.nih.gov/pubmed/14557629">[EMPTY]</a> 114109557 Kinney, Claire CDC - DIR CDC Kinney, Claire (CDC) 1 114109557 Kinney, Claire CDC - DIR CDC Kinney, Claire (CDC) 1 114102382 Chimeric Dengue/Zika Viruses For Live-Attenuated Zika Vaccine Development E-178-2016-0 Filing authorized Centers for Disease Control and Prevention (CDC) 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-3226] Chimeric Dengue/Zika Viruses for Live-Attenuated Zika Vaccine Development&body=Please send me information about technology [TAB-3226] Chimeric Dengue/Zika Viruses for Live-Attenuated Zika Vaccine Development. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-3226] Chimeric Dengue/Zika Viruses for Live-Attenuated Zika Vaccine Development&body=Please send me information about technology [TAB-3226] Chimeric Dengue/Zika Viruses for Live-Attenuated Zika Vaccine Development.">benjamin.hurley@nih.gov</a><br> 114160443 E-178-2016-0 E-178-2016-0-US-01 CHIMERIC DENGUE/ZIKA VIRUSES AS LIVE-ATTENUATED ZIKA VIRUS VACCINES PRV US 62/359,812 Abandoned US <br />Provisional (PRV) 62/359,812<br />Filed on 2016-07-08<br />Status: Abandoned 114168482 E-178-2016-0 E-178-2016-0-PCT-02 CHIMERIC DENGUE/ZIKA VIRUSES AS LIVE-ATTENUATED ZIKA VIRUS VACCINES PCT Patent Cooperation Treaty PCT/US2017/040820 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2017/040820<br />Filed on 2017-07-06<br />Status: Expired 114168827 E-178-2016-0 E-178-2016-0-US-07 Chimeric Dengue/Zika Viruses For Live-Attenuated Zika Vaccine Development National Stage US 11,344,615 16/316,005 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11344615 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11344615">11,344,615</a><br />Filed on 2019-01-07<br />Status: Issued 114127649 YBXXXX 114127650 YAXXXX 114127651 WBXXXX 114127652 VLXXXX 114127653 WIXXXX 114127654 WNXXXX 114127655 XEXXXX 114127656 XKXXXX 114150143 NCEZID-DVBD 114150144 chimeric 114150145 Dengue/Zika 114150146 Viruses 114150147 Live-Attenuated 114150148 Zika 114150149 Vaccine 114150150 Development TAB-3218 114097160 Real-Time PCR Assay for Detection of Carbapenem Antibiotic Resistance Genes of the IMP-type CDC Collaboration, Consumer Products, Diagnostics, Infectious Disease, Licensing, Occupational Safety and Health, Research Materials, Therapeutics Collaboration Consumer Products Diagnostics Infectious Disease Licensing Occupational Safety and Health Research Materials Therapeutics Davina Campbell, Linda Karlsson Antibiotic resistance is one of the world's most pressing health concerns. ß-lactamases, such as carbapenemases, are enzymes produced by bacteria that provide resistance to multiple ß-lactam antibiotics (e.g., penicillins, cephamycins, and carbapenems) by breaking down the antibiotic molecules and deactivating their antibacterial properties. Carbapenems are broad-spectrum antibiotics often prescribed to treat serious infections in hospitalized patients, and infections with carbapenem-resistant Enterobacteriaceae (CRE) have become a challenge in healthcare settings. Clinical laboratories frequently use phenotypic tests to screen for carbapenemase-producing isolates. However, these phenotypic tests can be difficult to interpret and are unable to identify specific resistance genes. PCR can be utilized to detect the presence of specific resistance genes, such as IMP, and produces rapid results that are easily interpretable. To date, the only FDA-approved and commercially available test for carbapenemase gene screening is restricted to a subset of all IMP genes (IMP-1 subgroup). CDC has developed a primer and probe-based real-time PCR assay with the capacity to detect carbapenemase genes of all currently described IMP variants. CDC's assay has successfully detected IMP genes in multiple bacterial isolates submitted to CDC in cases where the state or public health lab was unable to do so. This assay is easy to perform and implement, and offers a more cost- effective approach than whole genome sequencing. <ul> <li>Can be used to identify all known IMP variants in carbapenem-resistant bacteria versus currently available tests that can only detect limited IMP sub-groups</li> <li>More cost effective than whole genome sequencing for detecting IMP-variants</li> <li>Easy to perform and implement; results are easy to interpret</li> <li>Assay protocol will be shared with Antimicrobial Resistance Laboratory Network of 7 regional and 55 state and public health laboratories</li> </ul> <ul> <li>Real-time PCR diagnostic assay for detection of IMP genes important in carbapenem antibiotic resistance and in patients with serious infections in healthcare settings</li> <li>Monitoring and public health surveillance for antimicrobial resistance</li> </ul> The CDC Technology Transfer Office (TTO) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize: Real-time PCR assay for IMP-type genes important in carbapenem antibiotic resistance. For collaboration opportunities, please contact CDC TTO at <a href="mailto:tto@cdc.gov"> tto@cdc.gov. 2022-03-08 2025-04-24 2025-04-24 2017-12-04 assay, BlaIMP, Detection, GENES, NCEZID-DHQP, PCR, REAL-TIME, VJXXXX, WBXXXX, WFXXXX, WIXXXX, XEXXXX, YBXXXX False True True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114108350 Campbell, Davina CDC - DIR CDC Campbell, Davina (CDC) 0 114106026 Karlsson, Linda CDC - DIR CDC Karlsson, Linda (CDC) 1 114106026 Karlsson, Linda CDC - DIR CDC Karlsson, Linda (CDC) 1 114108350 Campbell, Davina CDC - DIR CDC Campbell, Davina (CDC) 0 114100967 Real-time PCR Assay For The Detection Of BlaIMP Genes E-156-2017-0 Filing authorized Centers for Disease Control and Prevention (CDC) 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-3218] Real-Time PCR Assay for Detection of Carbapenem Antibiotic Resistance Genes of the IMP-type&body=Please send me information about technology [TAB-3218] Real-Time PCR Assay for Detection of Carbapenem Antibiotic Resistance Genes of the IMP-type. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-3218] Real-Time PCR Assay for Detection of Carbapenem Antibiotic Resistance Genes of the IMP-type&body=Please send me information about technology [TAB-3218] Real-Time PCR Assay for Detection of Carbapenem Antibiotic Resistance Genes of the IMP-type.">benjamin.hurley@nih.gov</a><br> 114166173 E-156-2017-0 E-156-2017-0-US-01 Real-time PCR Assay For The Detection Of BlaIMP Genes PRV US 62/519,663 Abandoned US <br />Provisional (PRV) 62/519,663<br />Filed on 2017-06-14<br />Status: Abandoned 114168656 E-156-2017-0 E-156-2017-0-PCT-02 DETECTION OF BLAIMP ANTIBACTERIAL RESISTANCE GENES PCT Patent Cooperation Treaty PCT/US2018/037395 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2018/037395<br />Filed on 2018-06-13<br />Status: Expired 114168935 E-156-2017-0 E-156-2017-0-US-03 DETECTION OF BLAIMP ANTIBACTERIAL RESISTANCE GENES National Stage US 11,466,329 16/615,725 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11466329 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11466329">11,466,329</a><br />Filed on 2019-12-05<br />Status: Issued 114127645 WFXXXX 114127646 WBXXXX 114127647 VJXXXX 114127648 YBXXXX 114127657 WIXXXX 114127658 XEXXXX 114150121 REAL-TIME 114150122 PCR 114150123 assay 114150124 Detection 114150125 BlaIMP 114150126 GENES 114150127 NCEZID-DHQP TAB-3233 114097169 Rapid Colorimetric Detection of Zika Virus from Serum and Urine Specimens by RT-LAMP (Reverse Transcription Loop-Mediated Isothermal Amplification). CDC Collaboration, Consumer Products, Diagnostics, Infectious Disease, Licensing, Occupational Safety and Health, Research Materials, Therapeutics Collaboration Consumer Products Diagnostics Infectious Disease Licensing Occupational Safety and Health Research Materials Therapeutics Amanda Calvert The Zika virus (ZIKV) can be passed from a pregnant woman to her fetus. Resulting infection by this virus can cause early miscarriage and a pattern of severe birth defects in fetuses and infants. Therefore, a rapid diagnostic assay that can be performed throughout pregnancy in a clinical setting is vital for prenatal care of women living in areas where this virus may be transmitted.<br /><br /> CDC has developed a RT-LAMP assay for the rapid screening of ZIKV RNA from urine and serum. As few as 10 copies of ZIKV RNA per microliter can be detected using this assay, showing that it is highly sensitive. It was also shown to be highly specific for ZIKV RNA when tested against a panel of urine samples spiked with other flaviviruses such as dengue virus sub-types 1-4, West Nile virus, St. Louis encephalitis virus, and chikungunya virus, most viruses that circulate in the same geographic regions as ZIKV. This assay offers a rapid, reliable, sensitive, and specific means to detect ZIKV that can be performed in a clinical point-of-care (POC) or field setting with minimal equipment and technological expertise. The assay is fast to set up and perform (total time 1 hour). Additionally, it is approximately as sensitive and specific as RT-PCR detection methods. Thus far, 178 clinical samples collected from the 2015/2016 Zika virus outbreak were tested using this assay. CDC is currently working with a group to test a prototype point of care (POC) test in a clinical setting and develop a POC. <ul> <li>The assay offers a fast, reliable, highly sensitive, and specific means to detect ZIKV from urine or serum without apparent cross-reactivity to other flaviviruses</li> <li>As little as 1 RNA copy/µl was detected in clinical specimens. There was no detection of viral RNA from clinical specimens positive for DENV or CHIKV by RT-qPCR</li> <li>The technology is easy to perform, likely cost-effective, and portable</li> <li>Currently, there are no rapid, cost-effective diagnostic tests sensitive enough to detect ZIKV infections for the POC setting</li> <li>The assay can be set up and performed in 1 hour</li> <li>With lyophilized reagents, no cold chain storage or transportation is needed</li> </ul> <ul> <li>Rapid diagnostic screening for Zika virus infection in critical patient populations such as pregnant women</li> <li>Suitable for use in POC, field, or resource-limited settings</li> <li>Mosquito surveillance for ZIKV by mosquito control districts, state public health laboratories, and universities</li> <li>Quality control/quality assurance testing for ZIKV vaccine candidates</li> </ul> The CDC Technology Transfer Office (TTO) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize Rapid Colorimetric RT-LAMP Zika Virus Detection Assay. For collaboration opportunities, please contact CDC TTO at <a href="mailto: tto@cdc.gov">tto@cdc.gov. 2022-03-08 2025-04-24 2025-04-24 2017-12-18 amplification, COLORIMETRIC, Detection, Isothermal, Loop-, Mediated, NCEZID-DVBD, RAPID, Reverse, RT-LAMP, RT-LAMP., SERUM, SPECIMENS, transcription, Urine, virus, VLXXXX, WBXXXX, WFXXXX, WHXXXX, WIXXXX, XEXXXX, YBXXXX, YDXXXX, YFXXXX, Zika False True True 52406769 Prototype 52406769 NIHTT 37470483 Website Abstract 114172435 Calvert A.,et al. https://www.ncbi.nlm.nih.gov/pubmed/28945787 <a href="https://www.ncbi.nlm.nih.gov/pubmed/28945787">Calvert A.,et al.</a> 114109594 Calvert, Amanda CDC - DIR CDC Calvert, Amanda (CDC) 1 114109594 Calvert, Amanda CDC - DIR CDC Calvert, Amanda (CDC) 1 114102394 Rapid Colorimetric Detection Of Zika Virus From Serum And Urine Specimens By Reverse Transcription Loop- Mediated Isothermal Amplification (RT-LAMP). E-041-2017-0 Filing authorized Centers for Disease Control and Prevention (CDC) 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-3233] Rapid Colorimetric Detection of Zika Virus from Serum and Urine Specimens by RT-LAMP (Reverse Transcription Loop-Mediated Isothermal Amplification).&body=Please send me information about technology [TAB-3233] Rapid Colorimetric Detection of Zika Virus from Serum and Urine Specimens by RT-LAMP (Reverse Transcription Loop-Mediated Isothermal Amplification).. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-3233] Rapid Colorimetric Detection of Zika Virus from Serum and Urine Specimens by RT-LAMP (Reverse Transcription Loop-Mediated Isothermal Amplification).&body=Please send me information about technology [TAB-3233] Rapid Colorimetric Detection of Zika Virus from Serum and Urine Specimens by RT-LAMP (Reverse Transcription Loop-Mediated Isothermal Amplification)..">benjamin.hurley@nih.gov</a><br> 114161937 E-041-2017-0 E-041-2017-0-PCT-02 RAPID DETECTION OF ZIKA VIRUS BY REVERSE TRANSCRIPTION LOOP-MEDIATED ISOTHERMAL AMPLIFICATION PCT Patent Cooperation Treaty PCT/US2018/029738 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2018/029738<br />Filed on 2018-04-27<br />Status: Expired 114168508 E-041-2017-0 E-041-2017-0-US-01 RAPID DETECTION OF ZIKA VIRUS BY REVERSE TRANSCRIPTION LOOP-MEDIATED ISOTHERMAL AMPLIFICATION PRV US 62/500,866 Abandoned US <br />Provisional (PRV) 62/500,866<br />Filed on 2017-05-03<br />Status: Abandoned 114168929 E-041-2017-0 E-041-2017-0-US-03 RAPID DETECTION OF ZIKA VIRUS BY REVERSE TRANSCRIPTION LOOP-MEDIATED ISOTHERMAL AMPLIFICATION National Stage US 11,708,613 16/609,994 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11708613 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11708613">11,708,613</a><br />Filed on 2019-11-01<br />Status: Issued 114127700 YBXXXX 114127701 YDXXXX 114127702 YFXXXX 114127703 VLXXXX 114127704 WBXXXX 114127705 WFXXXX 114127706 WHXXXX 114127707 WIXXXX 114127708 XEXXXX 114150257 amplification 114150258 Isothermal 114150259 Mediated 114150260 Loop- 114150261 transcription 114150262 Reverse 114150263 SPECIMENS 114150264 Urine 114150265 SERUM 114150266 virus 114150267 Zika 114150268 Detection 114150269 COLORIMETRIC 114150270 RAPID 114150271 RT-LAMP 114150272 NCEZID-DVBD 114150273 RT-LAMP. TAB-3234 114097170 West Nile/Zika Virus Chimeras for Inactivated Zika Vaccine and Diagnostic Assay Development CDC Collaboration, Diagnostics, Infectious Disease, Licensing, Research Equipment, Research Materials, Therapeutics, Vaccines Collaboration Diagnostics Infectious Disease Licensing Research Equipment Research Materials Therapeutics Vaccines Claire Kinney Zika virus (ZIKV) is a flavivirus primarily transmitted by infected Aedes mosquitoes. Infection with ZIKV during pregnancy can affect the fetus causing microcephaly, neurological complications, and other birth defects. Adults are also at risk of developing Guillain-Barre syndrome and other neurological disorders from ZIKV infection. In response to the 2015-2016 Zika outbreak, CDC researchers developed new Zika virus chimeras that can be used for inactivated Zika vaccine candidates and faster Zika antibody (Ab) neutralization assay testing. CDC scientists successfully engineered cDNA clones for the chimeric constructs based on a West Nile (WN) Virus NY99 genetic backbone and recovered three fast-growth chimeric WN/Zika viruses. These chimeric viruses replicate significantly faster and produce a more uniform virus population than the parental wild-type Zika virus from cell culture. Future research will include inactivated vaccine efficacy testing in mouse models. Preliminary data shows that the WN/Zika chimeras reduce the gold standard plaque neutralization reduction Ab assay testing time from 6 to 4 days. The chimeric constructs also include reporter genes for diagnostic use with automated plate readers. The reporter chimeric virus permits direct live-image based cell cytometry analysis for an easy, fast, and high throughput micro-neutralization Ab assay within 24 hours without any cell overlay, cell detaching, cell fixation, or staining process. <ul> <li>The WN viral genetic background of this construct offers applications in inactivated Zika vaccine and diagnostic assay development</li> <li>New chimeras express the whole Zika virion</li> <li>Enhanced chimeric growth efficiency may facilitate vaccine production</li> <li>The chimeric virus reduced traditional plaque-reduction neutralization test time from 6 to 4 days, and reduced the micro-focus reduction neutralization assay from 2-3 days to 1-2 days after cell infection</li> <li>The addition of fluorescent reporter gene in the reporter chimeric virus can be used with automated plate readers/image analysis for high-throughput assay and further streamline the neutralization assay to an easy and high-throughput platform. Furthermore, reporter chimeric dengue viruses (type 1-4), another CDC patent, were also developed with the same platform, and therefore allow simultaneous obtaining fast neutralization test results to Zika and all 4 dengue viruses within 24 hours post cell infection.</li> </ul> <ul> <li> Inactivated Zika vaccine candidate development</li> <li>Vaccine production and efficacy testing</li> <li>Diagnostic assay development for Zika virus</li> <li>Other research purposes</li> </ul> The CDC Technology Transfer Office (TTO) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize West Nile/Zika Chimeras for Inactivated Zika Vaccine and Diagnostic Assay Development. For collaboration opportunities, please contact CDC TTO at <a href="mailto: tto@cdc.gov">tto@cdc.gov. Foreign counterpart patent applications in Australia, Brazil, India, and Singapore. 2022-03-08 2025-04-24 2025-04-24 2017-12-19 assay, Chimera, Development, INACTIVATED, NCEZID, NCEZID-DVBD, Neutralization, Nile/Zika, Vaccine, VLXXXX, WBXXXX, West, WIXXXX, WNXXXX, XEXXXX, XHXXXX, XKXXXX, YBXXXX, Zika False True True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract E-307-2013-0 114109597 Kinney, Claire CDC - DIR CDC Kinney, Claire (CDC) 1 114109597 Kinney, Claire CDC - DIR CDC Kinney, Claire (CDC) 1 114102396 West Nile/Zika Chimera For Inactivated Zika Vaccine Development And Neutralization Assay E-177-2016-0 Filing authorized Centers for Disease Control and Prevention (CDC) 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-3234] West Nile/Zika Virus Chimeras for Inactivated Zika Vaccine and Diagnostic Assay Development&body=Please send me information about technology [TAB-3234] West Nile/Zika Virus Chimeras for Inactivated Zika Vaccine and Diagnostic Assay Development. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-3234] West Nile/Zika Virus Chimeras for Inactivated Zika Vaccine and Diagnostic Assay Development&body=Please send me information about technology [TAB-3234] West Nile/Zika Virus Chimeras for Inactivated Zika Vaccine and Diagnostic Assay Development.">benjamin.hurley@nih.gov</a><br> 114168513 E-177-2016-0 E-177-2016-0-US-01 CHIMERIC WEST NILE/ZIKA VIRUSES AND METHODS OF USE PRV US 62/359,807 Abandoned US <br />Provisional (PRV) 62/359,807<br />Filed on 2016-07-08<br />Status: Abandoned 114168514 E-177-2016-0 E-177-2016-0-PCT-02 CHIMERIC WEST NILE/ZIKA VIRUSES AND METHODS OF USE PCT Patent Cooperation Treaty PCT/US2017/040818 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2017/040818<br />Filed on 2017-07-06<br />Status: Expired 114168826 E-177-2016-0 E-177-2016-0-US-03 CHIMERIC WEST NILE/ZIKA VIRUSES AND METHODS OF USE National Stage US 10,632,185 16/315,897 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10632185 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10632185">10,632,185</a><br />Filed on 2019-01-07<br />Status: Issued 114127711 YBXXXX 114127712 VLXXXX 114127713 WBXXXX 114127714 WIXXXX 114127715 WNXXXX 114127716 XEXXXX 114127717 XHXXXX 114127718 XKXXXX 114150293 West 114150294 Nile/Zika 114150295 Chimera 114150296 INACTIVATED 114150297 Zika 114150298 Vaccine 114150299 Development 114150300 Neutralization 114150301 assay 114150302 NCEZID 114150303 NCEZID-DVBD TAB-3243 114097177 Heartland Virus Humanized Monoclonal Antibodies for Diagnostic and Therapeutic Development CDC Antibodies, Collaboration, Consumer Products, Diagnostics, Immunology, Licensing, Occupational Safety and Health, Therapeutics Antibodies Collaboration Consumer Products Diagnostics Immunology Licensing Occupational Safety and Health Therapeutics Aaron Brault, Amanda Calvert Heartland virus (HRTV) is a novel tick-borne virus first discovered in 2009 that causes flu-like symptoms such as fever, headaches, fatigue, muscle aches, and diarrhea. Patients with HRTV often have low white blood cell counts, low platelet counts, and abnormal liver function tests which can become severe. Cases of Heartland virus disease have been identified in the Midwestern and southern United States. There are no vaccines to prevent or medications to treat Heartland virus infections. HRTV presents symptoms and generates a similar immune response to other tick-borne viruses, making diagnosis difficult. In order to develop a diagnostic assay that can detect HRTV and distinguish it from other infections, CDC scientists developed and characterized anti-HRTV murine monoclonal antibodies. These monoclonal antibodies (mAbs) react to the viral nucleocapsid (N) protein. The mouse monoclonal antibodies can detect both recent and past infections with specificity to HRTV in diagnostic assays developed by the CDC. These monoclonal antibodies can be engineered to have the murine variable regions reactive with the viral antigen cloned for use as positive controls in assays to detect recent and past infections in humans. These mAbs have been integrated by CDC’s diagnostic lab into a multi-bead array assay, IgM antibody capture ELISA (MAC-ELISA) and IgG ELISA for the detection of recent and past HRTV infections for diagnostic purposes. In addition, research with the humanized antibodies can be done to determine their usefulness as a therapeutic in humans for HRTV infection. <ul> <li>The only characterized antibodies against HRTV</li> <li>Potential use as a diagnostic, therapeutic, or research tool</li> <li>Differentiation between recent and past infections</li> <li>Ability to perform diagnostic assay without biosafety level 3 containment</li> <li> Currently, no diagnostic tests exist for HRTV except for plaque reduction neutralization tests</li> <li>MAb 2AF11 is the only mAb available in the U.S. that recognizes both HRTV and SFTSV, the latter which has caused several thousand cases of severe disease throughout China, Korea and Japan</li> </ul> <ul> <li>Development of immunoassay diagnostics in IgG and IgM ELISA formats and other serological diagnostics (e.g., immunofluorescence, multi-bead array, and lateral flow assays for point of care diagnostics) for Heartland virus infections</li> <li>Development of immunoassay diagnostics for the detection of severe fever with thrombocytopenia syndrome virus (SFTSV), another tick-borne virus similar to HRTV</li> <li>Research tools to characterize this newly discovered virus which causes severe diseases in humans</li> <li>Tick-borne virus monitoring programs</li> <li> Development of therapeutics to treat Heartland virus infections in humans</li> </ul> The CDC Technology Transfer Office (TTO) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize Heartland Virus Humanized Monoclonal Antibodies for Diagnostic and Therapeutic Development. For collaboration opportunities, please contact CDC Technology Transfer Office at <a href="mailto: tto@cdc.gov">tto@cdc.gov</a> or 1-404-639-1330. 2022-03-08 2025-04-24 2025-04-24 2018-01-30 antibodies, Diagnostics, heartland, Listed LPM Houze as of 4/15/2015, monoclonal, NCEZID, NCEZID-DVBD, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Specific, therapeutics, virus, WBXXXX, WFXXXX, WJXXXX, XAXXXX, YAXXXX, YBXXXX, YCXXXX, YFXXXX False True True 52406769 Prototype 52406769 NIHTT 37470483 Website Abstract E-269-2013-0 114172445 CDC FAQs https://www.cdc.gov/heartland-virus/index.html <a href="https://www.cdc.gov/heartland-virus/index.html">CDC FAQs</a> 114172450 Calvert, A., et al. https://www.ncbi.nlm.nih.gov/pubmed/26503274 <a href="https://www.ncbi.nlm.nih.gov/pubmed/26503274">Calvert, A., et al.</a> 114109616 Brault, Aaron CDC - DIR CDC Brault, Aaron (CDC) 0 114109615 Calvert, Amanda CDC - DIR CDC Calvert, Amanda (CDC) 1 114109615 Calvert, Amanda CDC - DIR CDC Calvert, Amanda (CDC) 1 114109616 Brault, Aaron CDC - DIR CDC Brault, Aaron (CDC) 0 114102403 Monoclonal Antibodies Specific To Heartland Virus For Diagnostics And Therapeutics E-293-2014-1 Research Material Centers for Disease Control and Prevention (CDC) 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-3243] Heartland Virus Humanized Monoclonal Antibodies for Diagnostic and Therapeutic Development&body=Please send me information about technology [TAB-3243] Heartland Virus Humanized Monoclonal Antibodies for Diagnostic and Therapeutic Development. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-3243] Heartland Virus Humanized Monoclonal Antibodies for Diagnostic and Therapeutic Development&body=Please send me information about technology [TAB-3243] Heartland Virus Humanized Monoclonal Antibodies for Diagnostic and Therapeutic Development.">benjamin.hurley@nih.gov</a><br> 114168543 E-293-2014-1 E-293-2014-1-US-01 Monoclonal Antibodies Specific To Heartland Virus For Diagnostics And Therapeutics PRV US 62/221,431 Abandoned US <br />Provisional (PRV) 62/221,431<br />Filed on 2015-09-21<br />Status: Abandoned 114168544 E-293-2014-1 E-293-2014-1-PCT-02 Monoclonal Antibodies Specific for Heartland Virus and Methods of Their Use PCT Patent Cooperation Treaty PCT/US2016/013073 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2016/013073<br />Filed on 2016-01-12<br />Status: Expired 114168583 E-293-2014-1 E-293-2014-1-US-03 MONOCLONAL ANTIBODIES SPECIFIC FOR HEARTLAND VIRUS AND METHODS OF THEIR USE National Stage US 10,584,161 15/761,789 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10584161 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10584161">10,584,161</a><br />Filed on 2018-03-20<br />Status: Issued 114127780 YAXXXX 114127781 YBXXXX 114127782 YCXXXX 114127783 YFXXXX 114127784 WBXXXX 114127785 WFXXXX 114127786 WJXXXX 114127787 XAXXXX 114150370 monoclonal 114150371 antibodies 114150372 Specific 114150373 heartland 114150374 virus 114150375 Diagnostics 114150376 therapeutics 114150377 NCEZID 114150378 NCEZID-DVBD 114150379 Listed LPM Houze as of 4/15/2015 114150380 Pre LPM working set 20150418 114150381 Post LPM Assignment Set 20150420 TAB-3245 114097179 Zika Virus NS1 Protein Monoclonal Antibodies for Research, Development, and Novel Diagnostics CDC Antibodies, Collaboration, Diagnostics, Immunology, Infectious Disease, Licensing, Research Materials Antibodies Collaboration Diagnostics Immunology Infectious Disease Licensing Research Materials Dennis Bagarozzi, Jason Goldstein Zika virus is a flavivirus that is spread by the bite of infected Aedes mosquitoes. The current outbreak and swift dissemination/spread of Zika virus (ZIKV) and its linkage to birth defects and neurological syndromes has prompted the development of novel diagnostic tests. Because ZIKV is serologically similar to other flaviviruses such as dengue virus (DNV), cross-reactivity occurs in diagnostic tests and can result in misdiagnoses. This is especially evident in populations that live in dengue-endemic regions or have received heterologous flaviviral vaccines (i.e., yellow fever 17D). CDC researchers have developed seven monoclonal antibodies (mAbs) that are highly specific to the Zika virus non-structural protein 1 (NS1 protein) without cross-reactivity to other flaviviruses. These antibodies can be used to create rapid and more specific diagnostic tests. Data to support ZIKV-specific and DENV-specific mAbs include immunofluorescence, immunoblots of r-protein and viral lysates, recombinant proteins in label-free binding, and indirect ELISA studies. Platforms such as lateral flow diagnostics and nanotechnology devices capable of interfacing with smartphone/digital devices are possible. <ul> <li>Higher sensitivity than many commercially available and academic available antibodies for Zika</li> <li>Differentiate between Zika virus and other flaviviruses such as dengue, West Nile virus, and yellow fever virus</li> <li> Differentiate between Zika virus and prior vaccinations to dengue or yellow fever virus which can impact Zika test results</li> </ul> <ul> <li>Zika diagnostic immunoassay for clinical sample and tissue confirmation of Zika virus</li> <li>Zika immunodiagnostic reagent</li> <li>Differentiation between Zika virus and other flaviviruses</li> <li>Platforms such as lateral flow diagnostics and nanotechnology devices capable of interfacing with smartphone/digital devices are possible</li> <li>Research and development</li> </ul> The CDC Technology Transfer Office (TTO) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize: Zika Virus NS1 Protein mAbs for Research, Development, and Diagnostics. For collaboration opportunities, please contact CDC TTO at <a href="mailto: tto@cdc.gov">tto@cdc.gov</a>. 2022-03-08 2025-04-24 2025-04-24 2018-02-09 antibodies, Development, Diagnostics, monoclonal, NCEZID, NCEZID-DSR, Novel, virus, VLXXXX, WBXXXX, WIXXXX, XAXXXX, YBXXXX, Zika False True True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract E-107-2016-1 E-341-2013-0 E-341-2013-1 E-081-2017-0 114109623 Bagarozzi, Dennis CDC - DIR CDC Bagarozzi, Dennis (CDC) 0 114109622 Goldstein, Jason CDC - DIR CDC Goldstein, Jason (CDC) 1 114109622 Goldstein, Jason CDC - DIR CDC Goldstein, Jason (CDC) 1 114109623 Bagarozzi, Dennis CDC - DIR CDC Bagarozzi, Dennis (CDC) 0 114102405 Development Of Zika Virus Monoclonal Antibodies For Research, Development And Novel Diagnostics E-286-2016-0 Research Material Centers for Disease Control and Prevention (CDC) 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-3245] Zika Virus NS1 Protein Monoclonal Antibodies for Research, Development, and Novel Diagnostics&body=Please send me information about technology [TAB-3245] Zika Virus NS1 Protein Monoclonal Antibodies for Research, Development, and Novel Diagnostics. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-3245] Zika Virus NS1 Protein Monoclonal Antibodies for Research, Development, and Novel Diagnostics&body=Please send me information about technology [TAB-3245] Zika Virus NS1 Protein Monoclonal Antibodies for Research, Development, and Novel Diagnostics.">benjamin.hurley@nih.gov</a><br> 114168546 E-286-2016-0 E-286-2016-0-US-01 Compositions and Methods for the Diagnosis and Treatment of Zika Virus Infection PRV US 62/460,635 Abandoned US <br />Provisional (PRV) 62/460,635<br />Filed on 2017-02-17<br />Status: Abandoned 114168563 E-286-2016-0 E-286-2016-0-PCT-02 COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF ZIKA VIRUS INFECTION PCT Patent Cooperation Treaty PCT/US2018/018709 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2018/018709<br />Filed on 2018-02-20<br />Status: Expired 114127788 YBXXXX 114127789 VLXXXX 114127790 WBXXXX 114127791 WIXXXX 114127792 XAXXXX 114150403 Development 114150404 Zika 114150405 virus 114150406 monoclonal 114150407 antibodies 114150408 Novel 114150409 Diagnostics 114150410 NCEZID 114150411 NCEZID-DSR TAB-3246 114097180 Monoclonal Antibodies for Specific Detection of Dengue Virus Sub-type 4 in Human Serum CDC Antibodies, Collaboration, Diagnostics, Immunology, Infectious Disease, Licensing, Research Materials, Therapeutics Antibodies Collaboration Diagnostics Immunology Infectious Disease Licensing Research Materials Therapeutics Elizabeth Hunsperger, Tesfaye Taye Dengue Virus (DENV) non-structural protein 1 (NS1) is secreted in blood during the acute phase of viremic DENV infection. While there are commercially available ELISA assays for DENV NS1 detection, these tests have limited sensitivity (50-70%), do not determine the serotype of the infecting DENV, do not detect all four serotypes equally, or are less sensitive in subsequent DENV infections. There is a critical need for serotype specific diagnostics to inform public health and potentially clinical care interventions. CDC developed three hybridoma cell lines and three DENV-4 serotype-specific monoclonal antibodies (mAbs) for the detection of DENV-4 NS1 in human serum. These mAbs do not cross-react with other dengue virus subtypes (DENV 1, 2, and 3) or other flaviviruses (e.g., West Nile virus or Yellow fever virus) and can be used to develop ELISA and rapid diagnostic tests for dengue detection in resource poor settings. A NS1 DENV serotype specific ELISA would improve disease surveillance by providing early DENV detection and serotype identification, which would improve clinical case management of dengue infections, since early patient diagnosis is critical. <ul> <li>The three mAbs are specific to DENV serotype 4 NS1 and have no cross-reactivity with West Nile virus, Yellow fever virus, or DENV 1, 2, and 3</li> <li>Early DENV-4 detection and serotype identification is not possible with current diagnostic tests</li> <li> Novel antibodies can be applied to existing kits to increase sensitivity and ease of use</li> <li>Technology may improve DENV-4 detection in resource-limited countries</li> </ul> <ul> <li>May be used in several different types of DENV-4 diagnostics: <li> 1) Immunoassay for clinical samples, fixed cell lines, postmortem tissues, and mosquitoes 2) Immunofluorescence assay (IFA) 3) Enzyme linked immunosorbent assay 4) ELISA 5) Microsphere-based assay</ul> <li>Government and regional surveillance programs</li> <li>Quality control/quality assurance testing for dengue vaccine candidates</li> </ul> The CDC Technology Transfer Office (TTO) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize: Monoclonal Antibodies for Detecting Dengue Virus Sub-type 4 in Human Serum. For collaboration opportunities, please contact CDC TTO at <a href="mailto: tto@cdc.gov">tto@cdc.gov. 2022-03-08 2025-04-24 2025-04-24 2018-02-12 1, 4, antibodies, DENGUE, DENV, monoclonal, NCEZID, NCEZID-DVBD, Non-structural, NS1, Protein, Serotype, Specific, virus, VLXXXX, WBXXXX, WHXXXX, WIXXXX, XAXXXX, XEXXXX, YBXXXX, YDXXXX False True True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract E-182-2014-0 E-148-2013-0 114172451 Hunsperger et al. https://www.ncbi.nlm.nih.gov/pubmed/27225409 <a href="https://www.ncbi.nlm.nih.gov/pubmed/27225409">Hunsperger et al.</a> 114109625 Taye, Tesfaye CDC - DIR CDC Taye, Tesfaye (CDC) 0 114109624 Hunsperger, Elizabeth CDC - DIR CDC Hunsperger, Elizabeth (CDC) 1 114109624 Hunsperger, Elizabeth CDC - DIR CDC Hunsperger, Elizabeth (CDC) 1 114109625 Taye, Tesfaye CDC - DIR CDC Taye, Tesfaye (CDC) 0 114102406 Dengue Virus (DENV) Serotype 4 Specific Non-Structural Protein 1 (NS1) Monoclonal Antibodies E-057-2016-0 Filing authorized Centers for Disease Control and Prevention (CDC) 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-3246] Monoclonal Antibodies for Specific Detection of Dengue Virus Sub-type 4 in Human Serum&body=Please send me information about technology [TAB-3246] Monoclonal Antibodies for Specific Detection of Dengue Virus Sub-type 4 in Human Serum. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-3246] Monoclonal Antibodies for Specific Detection of Dengue Virus Sub-type 4 in Human Serum&body=Please send me information about technology [TAB-3246] Monoclonal Antibodies for Specific Detection of Dengue Virus Sub-type 4 in Human Serum.">benjamin.hurley@nih.gov</a><br> 114168548 E-057-2016-0 E-057-2016-0-US-01 DENGUE VIRUS NON-STRUCTURAL PROTEIN 1 SPECIFIC BINDING POLYPEPTIDES AND METHODS OF USING THE SAME PRV US 62/353,690 Abandoned US <br />Provisional (PRV) 62/353,690<br />Filed on 2016-06-23<br />Status: Abandoned 114168549 E-057-2016-0 E-057-2016-0-PCT-02 DENGUE VIRUS NON-STRUCTURAL PROTEIN 1 SPECIFIC BINDING POLYPEPTIDES AND METHODS OF USING THE SAME PCT Patent Cooperation Treaty PCT/US17/038703 Expired Patent Cooperation Treaty <br />(PCT) PCT/US17/038703<br />Filed on 2017-06-22<br />Status: Expired 114168836 E-057-2016-0 E-057-2016-0-US-03 DENGUE VIRUS NON-STRUCTURAL PROTEIN 1 SPECIFIC BINDING POLYPEPTIDES AND METHODS OF USING THE SAME National Stage US 11,407,818 16/310,964 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11407818 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11407818">11,407,818</a><br />Filed on 2018-12-18<br />Status: Issued 114127752 YBXXXX 114127753 YDXXXX 114127754 VLXXXX 114127755 WBXXXX 114127756 WHXXXX 114127757 WIXXXX 114127758 XAXXXX 114127759 XEXXXX 114150412 DENGUE 114150413 virus 114150414 DENV 114150415 Serotype 114150416 4 114150417 Specific 114150418 Non-structural 114150419 Protein 114150420 1 114150421 NS1 114150422 monoclonal 114150423 antibodies 114150424 NCEZID 114150425 NCEZID-DVBD TAB-3267 114097202 Novel Fourth Human Ebolavirus species, <em>Bundibugyo ebolavirus</em> – Compositions and Methods for Vaccine, Therapeutics and Highly Sensitive Diagnostic Assay Development CDC Antibodies, Collaboration, Diagnostics, Immunology, Infectious Disease, Licensing, Research Materials, Therapeutics, Vaccines Antibodies Collaboration Diagnostics Immunology Infectious Disease Licensing Research Materials Therapeutics Vaccines James Comer, Thomas Ksiazek, Stuart Nichol, Pierre Rollin, Jonathan Towner Ebola Virus Disease (EVD) is a disease caused by infection with viruses from the family <em>Filoviridae</em>, genus <em>Ebolavirus</em>. Ebola virus was first discovered in 1976 in Africa and has since caused numerous outbreaks throughout the continent including the largest outbreak in history in West Africa during 2014-2016. Previously, there were three identified Ebolavirus species which were known to cause disease in humans: Ebola virus (<em>Zaire ebolavirus</em>); Sudan virus (<em>Sudan ebolavirus</em>); and Tai Forest virus (<em>Tai Forest ebolavirus</em>). CDC discovered a fourth novel virus, first identified in Uganda, Bundibugyo virus (<em>Bundibugyo ebolavirus</em>). This virus species is significantly different from other ebolaviruses previously identified, therefore, current genetic-based (RT-PCR) assays may fail.<br /><br /> CDC’s technology includes compositions and methods for nucleic and immunological protection from, detection of, and treatment of EVD caused by Bundibugyo virus. Uses of this technology could include a recombinant vesicular stomatitis virus-Bundibugyo virus (rVSV-BDBV) construct for vaccine development. Such a rVSV-BDBV construct could be created on the same VSV platform as other vaccine candidates for Ebola virus, which could then be combined to create a multivalent Ebola vaccine. Identification of the immunogenic region will allow for the rapid development of commercial and non-commercial ebolavirus vaccines. This technology also includes primer sequences for assays to detect BDBV. Additional animal model testing is planned. <br/>< <ul> <li>Vaccine constructs using Bundibugyo virus sequences can be built on the same platform as existing vaccines to other Ebola virus species</li> <li> Knowledge of the surface glycoprotein amino acid sequence will be particularly useful because it is the primary target of a number of commercial and non-commercial ebolavirus vaccine strategies currently in development</li> <li>Inclusion of the novel Bundibugyo virus in the development of vaccines and treatments against ebolaviruses would increase the robustness of countermeasures against EVD outbreaks and potential bio-terrorism threats</li> <li> Potential therapeutic against new ebolavirus species</li> <li>Highly specific and sensitive for Bundibugyo virus infection</li> </ul> <ul> <li>Vaccines against Bundibugyo virus – both preventive and prophylactic if high risk</li> <li> Vaccine for biodefense purposes</li> <li>Nucleic acid-based assays such as real-time RT-PCR and antibody-based (i.e., ELISA) assays for detection of Bundibugyo virus (<em>Bundibugyo ebolavirus</em>) infection</li> <li>Can be useful in more generalized diagnostic assay development to detect all ebolaviruses or filoviruses</li> <li> Treatments to neutralize Bundibugyo virus</li> <li>Vaccine candidate and antiviral efficacy testing in animal models</li> </ul> The CDC Technology Transfer Office (TTO) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize: Novel Fourth Human Ebolavirus species, <em>Bundibugyo ebolavirus</em> – Compositions and Methods for Vaccine, Therapeutics and Highly Sensitive Diagnostic Assay Development. For collaboration opportunities, please contact CDC TTO at <a href="mailto:tto@cdc.gov">tto@cdc.gov</a>or 1-404-639-1330. 2022-03-08 2025-04-24 2025-04-24 2018-06-05 CDC Docket Import, CDC Docket Import CDC Prosecuting, Compositions, Ebola, Human, Listed LPM Kirby as of 4/15/2015, Methods, OID-NCEZID-DHCPP, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Species, THEREOF, VBXXXX, virus, VJXXXX, WAXXXX, WBXXXX, WHXXXX, WJXXXX, WNXXXX, XAXXXX, XEXXXX, XKXXXX, YBXXXX, YCXXXX False True True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114172481 Towner JS, et al. https://pubmed.ncbi.nlm.nih.gov/19023410/ <a href="https://pubmed.ncbi.nlm.nih.gov/19023410/">Towner JS, et al.</a> 114109693 Rollin, Pierre CDC - DIR CDC Rollin, Pierre (CDC) 0 114109694 Ksiazek, Thomas CDC - DIR CDC Ksiazek, Thomas (CDC) 0 114109696 Nichol, Stuart CDC - DIR CDC Nichol, Stuart (CDC) 0 114109697 Comer, James CDC - DIR CDC Comer, James (CDC) 0 114109695 Towner, Jonathan CDC - DIR CDC Towner, Jonathan (CDC) 1 114109695 Towner, Jonathan CDC - DIR CDC Towner, Jonathan (CDC) 1 114109693 Rollin, Pierre CDC - DIR CDC Rollin, Pierre (CDC) 0 114109694 Ksiazek, Thomas CDC - DIR CDC Ksiazek, Thomas (CDC) 0 114109696 Nichol, Stuart CDC - DIR CDC Nichol, Stuart (CDC) 0 114109697 Comer, James CDC - DIR CDC Comer, James (CDC) 0 114102431 Human Ebola Virus Species And Compositions And Methods Thereof E-159-2013-0 Filing authorized Centers for Disease Control and Prevention (CDC) 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-3267] Novel Fourth Human Ebolavirus species, <em>Bundibugyo ebolavirus</em> – Compositions and Methods for Vaccine, Therapeutics and Highly Sensitive Diagnostic Assay Development&body=Please send me information about technology [TAB-3267] Novel Fourth Human Ebolavirus species, <em>Bundibugyo ebolavirus</em> – Compositions and Methods for Vaccine, Therapeutics and Highly Sensitive Diagnostic Assay Development. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-3267] Novel Fourth Human Ebolavirus species, <em>Bundibugyo ebolavirus</em> – Compositions and Methods for Vaccine, Therapeutics and Highly Sensitive Diagnostic Assay Development&body=Please send me information about technology [TAB-3267] Novel Fourth Human Ebolavirus species, <em>Bundibugyo ebolavirus</em> – Compositions and Methods for Vaccine, Therapeutics and Highly Sensitive Diagnostic Assay Development.">benjamin.hurley@nih.gov</a><br> 114168617 E-159-2013-0 E-159-2013-0-US-01 Genomic Nucleotide Sequence of New Ebola Virus Strain PRV US 61/108,175 Abandoned US <br />Provisional (PRV) 61/108,175<br />Filed on 2008-10-24<br />Status: Abandoned 114168618 E-159-2013-0 E-159-2013-0-PCT-02 Human Ebola Virus Species And Compositions And Methods Thereof PCT Patent Cooperation Treaty PCT/US2009/062079 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2009/062079<br />Filed on 2009-10-26<br />Status: Expired 114168619 E-159-2013-0 E-159-2013-0-US-07 Human Ebola Virus Species And Compositions And Methods Thereof National Stage US 13/125,890 Abandoned US <br />National Stage 13/125,890<br />Filed on 2011-06-21<br />Status: Abandoned 114168620 E-159-2013-0 E-159-2013-0-US-08 Human Ebola Virus Species And Compositions And Methods Thereof DIV US 9,790,473 14/694,036 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9790473 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9790473">9,790,473</a><br />Filed on 2015-04-23<br />Status: Issued 114168621 E-159-2013-0 E-159-2013-0-US-09 Human Ebola Virus Species And Compositions And Methods Thereof CON US 10,428,314 15/688,421 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10428314 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10428314">10,428,314</a><br />Filed on 2017-08-28<br />Status: Issued 114127869 VJXXXX 114127870 YBXXXX 114127871 YCXXXX 114127872 WAXXXX 114127873 VBXXXX 114127874 WBXXXX 114127875 WHXXXX 114127876 WJXXXX 114127877 WNXXXX 114127878 XAXXXX 114127879 XEXXXX 114127880 XKXXXX 114150683 Human 114150684 Ebola 114150685 virus 114150686 Species 114150687 Compositions 114150688 Methods 114150689 THEREOF 114150690 CDC Docket Import 114150691 CDC Docket Import CDC Prosecuting 114150692 OID-NCEZID-DHCPP 114150693 Listed LPM Kirby as of 4/15/2015 114150694 Pre LPM working set 20150418 114150695 Post LPM Assignment Set 20150420 TAB-3271 114097204 Novel UNEX Buffer and Disk for Safe Storage and Transport at Ambient Temperatures of Clinical Specimens for Molecular Testing of Pathogens CDC Collaboration, Consumer Products, Diagnostics, Infectious Disease, Licensing, Occupational Safety and Health, Research Materials Collaboration Consumer Products Diagnostics Infectious Disease Licensing Occupational Safety and Health Research Materials Theresa Cromeans, Vincent Hill, Jothikumar Narayanan, Jan Vinje The development of genomic approaches and nucleic acid based techniques has led to a large number of biological samples, including DNA, RNA, cells, tissues, and environmental samples that require storage. Typically, microbial DNA and RNA samples are stored long-term in laboratory freezers at temperatures ranging from -20°C to -196°C, the lower ranges utilizing liquid nitrogen. This often requires the use of several freezer boxes that can take up space and become difficult to sort through. Additionally, freezer equipment and cold chain transport measures needed for specimen stability are costly and difficult to maintain over time.<br /><br /> CDC developed the universal nucleic acid extraction (UNEX) buffer and disk for stable storage and transport of microbial samples at ambient (room) temperatures, bypassing the need for expensive cold chain (dry-ice) transit. Microbial RNA and DNA in water samples were stable for more than 2 years and 6 months (951 days) in UNEX lysis buffer stored at 4o C. The UNEX buffer inactivates bacteria (e.g., Salmonella serovar Typhimurium, and E. coli) and viruses (e.g., measles, adenovirus, poliovirus and three different strains of Middle East Respiratory Syndrome (MERS) Coronavirus, hepatitis A virus) tested thus far. In addition, a simple heat-elution step enables successful post specimen recovery of microbial RNA and DNA for up to 3 months from UNEX buffer treated cellulose- disks (UNEX disks). CDC’s invention inactivates pathogens and stores total nucleic acid (DNA and RNA) versus current commercial cards that primarily target either DNA or RNA storage only. This technology has great potential as nucleic acid transport and storage media for microbial specimens prior to molecular testing. This can help meet a critical need for safe and inexpensive shipping of nucleic acids from microbial specimens potentially containing pathogens, especially in resource-limited settings. <ul> <li>Liquid and solid phase storage of nucleic acids</li> <li>Storage of nucleic acids at room temperature</li> <li>UNEX disk can be used for inactivation of bacteria and viruses</li> <li> Loading samples on UNEX disks is easy to perform without advanced training and ideal for shipping of samples from resource-limited environments to reference laboratories</li> <li>Frees up costly freezer space in the short-term and saves expense of cold chain transit for microbial specimens</li> <li>Extraction of nucleic acid from UNEX cards can be automated and does not require silica columns or centrifuge</li> </ul> <ul> <li>Stable method for the storage and transport of microbial specimens at ambient temperatures for downstream molecular testing</li> <li>Applicability in developed countries, rural areas, and developing countries with limited resources lacking laboratory facilities and lacking cold chain transit capabilities</li> <li>Use for shipping of specimens containing other bacteria, viruses including those of high consequence (i.e., flaviviruses), and parasites</li> <li> Monitoring and public health surveillance</li> <li>Research purposes</li> <li>Quality control/quality assurance (e.g., proficiency panels)</li> </ul> The CDC Technology Transfer Office (TTO) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize: Novel UNEX Buffer and Disk for Safe Storage and Transport at Ambient Temperatures of Clinical Specimens for Molecular Testing of Pathogens. For collaboration opportunities, please contact CDC TTO at <a href="mailto:tto@cdc.gov">tto@cdc.gov</a>or 1-404-639-1330. 2022-03-08 2025-04-24 2025-04-24 2018-06-06 BUFFER, Media, Microbiological, Molecular, NCEZID, NCEZID-DFWED, SAFE, SOLID, SPECIMENS, STABLE, STATE, Storage, TESTING, Transport, UNEX, VJXXXX, VLXXXX, WBXXXX, WFXXXX, WHXXXX, WIXXXX, WMXXXX, YAXXXX, YBXXXX False True True 52406768 Discovery 52406768 NIHTT 37470483 Website Abstract 114172489 Hill VR, et al. http://www.ncbi.nlm.nih.gov/pubmed/26016775 <a href="http://www.ncbi.nlm.nih.gov/pubmed/26016775">Hill VR, et al.</a> 114109701 Hill, Vincent CDC - DIR CDC Hill, Vincent (CDC) 0 114109702 Vinje, Jan CDC - DIR CDC Vinje, Jan (CDC) 0 114109703 Cromeans, Theresa CDC - DIR CDC Cromeans, Theresa (CDC) 0 114109700 Narayanan, Jothikumar CDC - DIR CDC Narayanan, Jothikumar (CDC) 1 114109700 Narayanan, Jothikumar CDC - DIR CDC Narayanan, Jothikumar (CDC) 1 114109701 Hill, Vincent CDC - DIR CDC Hill, Vincent (CDC) 0 114109702 Vinje, Jan CDC - DIR CDC Vinje, Jan (CDC) 0 114109703 Cromeans, Theresa CDC - DIR CDC Cromeans, Theresa (CDC) 0 114102433 UNEX Storage Buffer And Solid State Storage Media For Safe And Stable Transport Microbiological Specimens For Molecular Testing E-211-2015-0 Closed Centers for Disease Control and Prevention (CDC) 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-3271] Novel UNEX Buffer and Disk for Safe Storage and Transport at Ambient Temperatures of Clinical Specimens for Molecular Testing of Pathogens&body=Please send me information about technology [TAB-3271] Novel UNEX Buffer and Disk for Safe Storage and Transport at Ambient Temperatures of Clinical Specimens for Molecular Testing of Pathogens. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-3271] Novel UNEX Buffer and Disk for Safe Storage and Transport at Ambient Temperatures of Clinical Specimens for Molecular Testing of Pathogens&body=Please send me information about technology [TAB-3271] Novel UNEX Buffer and Disk for Safe Storage and Transport at Ambient Temperatures of Clinical Specimens for Molecular Testing of Pathogens.">benjamin.hurley@nih.gov</a><br> 114168624 E-211-2015-0 E-211-2015-0-US-01 Buffer For Solid State Storage of Nucleic Acid Molecules PRV US 62/168,582 Abandoned US <br />Provisional (PRV) 62/168,582<br />Filed on 2015-05-29<br />Status: Abandoned 114168625 E-211-2015-0 E-211-2015-0-US-02 EXTRACTION AND PRESERVATION OF NUCLEIC ACID MOLECULES FROM PATHOGENS ORD US 15/169,404 Abandoned US <br />Ordinary Patent (ORD) 15/169,404<br />Filed on 2016-05-31<br />Status: Abandoned 114127889 YAXXXX 114127890 YBXXXX 114127891 VJXXXX 114127892 VLXXXX 114127893 WBXXXX 114127894 WFXXXX 114127895 WHXXXX 114127896 WIXXXX 114127897 WMXXXX 114150712 NCEZID-DFWED 114150713 UNEX 114150714 Storage 114150715 BUFFER 114150716 SOLID 114150717 STATE 114150718 Media 114150719 SAFE 114150720 STABLE 114150721 Transport 114150722 Microbiological 114150723 SPECIMENS 114150724 Molecular 114150725 TESTING 114150726 NCEZID TAB-3291 114097218 Method to Remove Mycoplasma Contamination from Virus Stocks CDC Collaboration, Consumer Products, Diagnostics, Infectious Disease, Licensing, Research Materials, Vaccines Collaboration Consumer Products Diagnostics Infectious Disease Licensing Research Materials Vaccines Victoria Olson, Xianfu Wu, Yong Yang Mycoplasma are a form of bacteria that are commonly found as contaminants in cell cultures. They adversely affect cell line growth rates and viral vaccine production. Mycoplasma contamination is a challenge for the vaccine industry and virology researchers. Current commercial reagents or kits only temporarily inhibit the growth of mycoplasma, but cannot eliminate the contaminants. <br /><br /> CDC has developed a method that can reliably eliminate mycoplasma from enveloped virus stock. This method allows for the removal of the mycoplasma without harming harvested virus. The harvested virus can then be transfected back into a clean cell line for continued virus production. Although designed for purification of rabies virus stocks, the method may successfully remove mycoplasma contamination from stocks of other enveloped viruses such as measles, mumps, respiratory syncytial virus, and influenza virus. Additional in vitro testing is planned for other virus purification. Rabies strains treated using this method are available. <ul> <li>Permanent removal of mycoplasma</li> <li>Increased cell growth rate and improved vaccine production</li> </ul> <ul> <li>Restore a clean vaccine repository from historical old strains for vaccine research and development</li> <li>A kit to selectively remove mycoplasma from virus seed stocks</li> <li> Research tool for virus study</li> </ul> The CDC Technology Transfer Office (TTO) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize: Method to Remove Mycoplasma Contamination from Virus Stocks. For collaboration opportunities, please contact CDC TTO at <a href="mailto:tto@cdc.gov">tto@cdc.gov</a>or 1-404-639-1330. 2022-03-08 2025-04-24 2025-04-24 2018-06-13 Contaminations, Method, Novel, REMOVING, Stocks, virus, VLXXXX, VOXXXX, WBXXXX, WHXXXX, WIXXXX, WMXXXX, WNXXXX, XKXXXX False True True NIHTT 37470483 Website Abstract E-040-2018-0 E-099-2018-0 114109745 Olson, Victoria CDC - DIR CDC Olson, Victoria (CDC) 0 114109746 Yang, Yong CDC - DIR CDC Yang, Yong (CDC) 0 114109744 Wu, Xianfu CDC - DIR CDC Wu, Xianfu (CDC) 1 114109744 Wu, Xianfu CDC - DIR CDC Wu, Xianfu (CDC) 1 114109745 Olson, Victoria CDC - DIR CDC Olson, Victoria (CDC) 0 114109746 Yang, Yong CDC - DIR CDC Yang, Yong (CDC) 0 114102453 A Novel Method For Removing Contaminations From Virus Stocks E-039-2018-0 Closed Centers for Disease Control and Prevention (CDC) 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-3291] Method to Remove Mycoplasma Contamination from Virus Stocks &body=Please send me information about technology [TAB-3291] Method to Remove Mycoplasma Contamination from Virus Stocks . Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-3291] Method to Remove Mycoplasma Contamination from Virus Stocks &body=Please send me information about technology [TAB-3291] Method to Remove Mycoplasma Contamination from Virus Stocks .">benjamin.hurley@nih.gov</a><br> 114168651 E-039-2018-0 E-039-2018-0-US-01 METHOD FOR REMOVING CONTAMINATION FROM VIRUS STOCKS PRV US 62/645,002 Abandoned US <br />Provisional (PRV) 62/645,002<br />Filed on 2018-03-19<br />Status: Abandoned 114127952 VLXXXX 114127953 VOXXXX 114127954 WBXXXX 114127955 WHXXXX 114127956 WIXXXX 114127957 WNXXXX 114127958 WMXXXX 114127959 XKXXXX 114150988 Novel 114150989 Method 114150990 REMOVING 114150991 Contaminations 114150992 virus 114150993 Stocks TAB-3299 114097225 Assay for Early Diagnosis of Anthrax Using Monoclonal Antibodies Against Anthrax Toxin CDC Antibodies, Collaboration, Consumer Products, Diagnostics, Immunology, Infectious Disease, Licensing, Research Materials Antibodies Collaboration Consumer Products Diagnostics Immunology Infectious Disease Licensing Research Materials Dennis Bagarozzi, Monica Epperson, Jason Goldstein, Nazia Kamal, Panagiotis Maniatis, Conrad Quinn Anthrax is a serious infectious disease caused by bacteria known as <em>Bacillus anthracis</em>. Anthrax-contaminated spores can be found naturally in soil and they commonly affect domestic and wild animals around the world. Although rare in the United States, people can get sick with anthrax if they come in contact with infected animals or contaminated animal products. <br /><br/> CDC researchers have developed a lateral flow immunoassay using monoclonal antibodies against <em>Bacillus anthracis</em> toxin and its components, lethal factor (LF) and protective antigen (PA). These antibodies have been screened and optimized into anti-LF and anti-PA pairs, which allows capture and detection of the anthrax antigens. These antibodies can be used in multiple combinations for rapid, simple, sensitive and specific assays for culture-free anthrax diagnosis. The lateral flow immunoassay can be used as a rapid point-of-care assay for detection of anthrax antigens like LF before onset of symptoms, which may allow prophylactic measures, early intervention and successful disease treatment. In addition to this, these antibodies can be used in enzyme linked immunoassays and hybrid real-time PCR immunodetection assays for anthrax diagnosis, as well as research. <ul> <li>Antibodies targeting multiple sites in anthrax toxin increase the sensitivity of detection</li> <li>Monoclonal antibodies allow better diagnostic specificity than polyclonal antibodies</li> <li>Adaptable for high-throughput screening assays</li> <li>Allows culture-free diagnosis that can help in early intervention and successful disease control</li> <li>These monoclonal antibodies can be used to improve currently available anthrax diagnostics</li> </ul> <ul> <li>Lateral flow immunoassay for detection of anthrax antigens before symptom onset</li> <li>Anthrax specific enzyme-linked immunoassay</li> <li>Hybrid real-time PCR and immunodetection assay for anthrax diagnosis</li> <li>Quality control for inactivated anthrax toxin preparations used in anthrax vaccine</li> <li>Livestock screening</li> <li>Diagnosis in the field to identify livestock/wildlife outbreaks earlier and potentially avoid spillover to human cases</li> <li>Research tools</li> </ul> < < </li> The CDC Technology Transfer Office (TTO) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize: Assay for Early Diagnosis of Anthrax Using Monoclonal Antibodies Against Anthrax Toxin. For collaboration opportunities, please contact CDC TTO at <a href="mailto:tto@cdc.gov">tto@cdc.gov</a>or 1-404-639-1330. Patent protection is not being pursued for this technology. 2022-03-08 2025-04-24 2025-04-24 2018-06-22 Against, Anthracis, antibodies, ANTIGEN, Antrax, assay, AVR1046, AVR1162, AVR1675, AVR3134, AVR3139, Bacillus, Detect, Detection, factor, Lethal, monoclonal, NCEZID, NCEZID-DSR, NCIRD, Novel, Protective, UTILIZING, VJXXXX, VOXXXX, WBXXXX, WHXXXX, WIXXXX, XAXXXX, YBXXXX, YFXXXX False True True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract E-196-2013-0 114109167 Goldstein, Jason CDC - DIR CDC Goldstein, Jason (CDC) 0 114109772 Quinn, Conrad CDC - DIR CDC Quinn, Conrad (CDC) 0 114109773 Bagarozzi, Dennis CDC - DIR CDC Bagarozzi, Dennis (CDC) 0 114109774 Maniatis, Panagiotis CDC - DIR CDC Maniatis, Panagiotis (CDC) 0 114109776 Epperson, Monica CDC - DIR CDC Epperson, Monica (CDC) 0 114109775 Kamal, Nazia CDC - DIR CDC Kamal, Nazia (CDC) 1 114109775 Kamal, Nazia CDC - DIR CDC Kamal, Nazia (CDC) 1 114109167 Goldstein, Jason CDC - DIR CDC Goldstein, Jason (CDC) 0 114109772 Quinn, Conrad CDC - DIR CDC Quinn, Conrad (CDC) 0 114109773 Bagarozzi, Dennis CDC - DIR CDC Bagarozzi, Dennis (CDC) 0 114109774 Maniatis, Panagiotis CDC - DIR CDC Maniatis, Panagiotis (CDC) 0 114109776 Epperson, Monica CDC - DIR CDC Epperson, Monica (CDC) 0 114102459 Novel Monoclonal Antibodies For Detection Of Bacillus Anthracis Protective Antigen And Lethal Factor E-071-2016-0 Research Material Centers for Disease Control and Prevention (CDC) 114102460 Assay To Detect Antrax Utilizing Monoclonal Antibodies E-071-2016-1 Research Material Centers for Disease Control and Prevention (CDC) 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-3299] Assay for Early Diagnosis of Anthrax Using Monoclonal Antibodies Against Anthrax Toxin&body=Please send me information about technology [TAB-3299] Assay for Early Diagnosis of Anthrax Using Monoclonal Antibodies Against Anthrax Toxin. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-3299] Assay for Early Diagnosis of Anthrax Using Monoclonal Antibodies Against Anthrax Toxin&body=Please send me information about technology [TAB-3299] Assay for Early Diagnosis of Anthrax Using Monoclonal Antibodies Against Anthrax Toxin.">benjamin.hurley@nih.gov</a><br> 114127999 YBXXXX 114128000 YFXXXX 114128001 VJXXXX 114128002 VOXXXX 114128003 WBXXXX 114128004 WHXXXX 114128005 WIXXXX 114128006 XAXXXX 114151063 NCEZID 114151064 Novel 114151065 monoclonal 114151066 antibodies 114151067 Detection 114151068 Bacillus 114151069 Anthracis 114151070 Protective 114151071 ANTIGEN 114151072 Lethal 114151073 factor 114151074 NCEZID-DSR 114151075 Against 114151076 AVR1675 114151077 AVR3134 114151078 AVR3139 114151079 AVR1046 114151080 AVR1162 114151081 NCIRD 114151082 assay 114151083 Detect 114151084 Antrax 114151085 UTILIZING TAB-3307 114097230 Antibodies for Rabies Post-exposure Prophylaxis or Antiviral Therapy of Clinical Rabies CDC Antibodies, Collaboration, Diagnostics, Immunology, Infectious Disease, Licensing, Research Materials, Therapeutics, Vaccines Antibodies Collaboration Diagnostics Immunology Infectious Disease Licensing Research Materials Therapeutics Vaccines Todd Smith, Xianfu Wu Lyssaviruses are single-stranded RNA viruses that cause rabies and rabies-like diseases in mammals. According to the World Health Organization, human rabies caused by the classical rabies virus continues to be almost 100% fatal once clinical symptoms of rabies appear, with no specific treatment available anywhere in the world.<br /><br /> CDC researchers have identified lyssavirus-specific antibodies for the treatment and prevention of rabies in humans post-exposure. They have also developed a method using a naïve antibody phage display library to identify phage clones that bind recombinant rabies virus or cells from multiple lyssaviruses. The sequence of domain antibodies specific for lyssaviruses can be used to engineer a monoclonal antibody for targeting in human rabies post-exposure prophylaxis or antiviral therapy of clinical rabies (when a patient manifests with rabies symptoms such as headache, confusion, agitation, delirium, etc.). This technology also offers the support to improve the spectrum of biological activity against non-rabies lyssaviruses. <ul> <li>Currently, there are no specific treatments available to treat and cure clinical rabies after the onset of symptoms</li> <li>Commercial anti-rabies immune globulins (Ig) do not neutralize other lyssaviruses, such as Lagos Bat, Mokola (MOK) and West Caucasian Bat viruses (WCBV)</li> </ul> </li> <ul> <li>Antibodies can be used directly in rabies post-exposure prophylaxis or antiviral therapy of clinical rabies</li> <li>Method offers support to improve the spectrum of biological activity against non-rabies lyssaviruses</li> <li>Antibody phage library can be used for additional research</li> </ul> << The CDC Technology Transfer Office (TTO) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize Antibodies for Rabies Post-exposure Prophylaxis or Antiviral Therapy of Clinical Rabies. For collaboration opportunities, please contact CDC TTO at <a href="mailto:tto@cdc.gov">tto@cdc.gov</a> or 1-404-639-1330. International patents issued in Europe and Canada 2022-03-08 2025-04-24 2025-04-24 2018-07-11 AA5XXX, AAXXXX, ABXXXX, antibodies, AXXXXX, CDC Docket Import, CDC Docket Import CDC Prosecuting, DA4BXX, DA4XXX, DAXXXX, DB4BXX, DB4XXX, DBXXXX, DDXXXX, DXXXXX, Identification, Listed LPM Kirby as of 4/15/2015, LYSSAVIRUSES, Methods, OID-NCEZID-DHCPP, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Specific, Their, WIXXXX, WKXXXX, WNXXXX, XAXXXX, XKXXXX False True True NIHTT 37470483 Website Abstract E-256-2013-0 114172519 Smith TG, et al. https://www.ncbi.nlm.nih.gov/pubmed/21601054 <a href="https://www.ncbi.nlm.nih.gov/pubmed/21601054 ">Smith TG, et al. </a> 114109792 Wu, Xianfu CDC - DIR CDC Wu, Xianfu (CDC) 0 114109791 Smith, Todd CDC - DIR CDC Smith, Todd (CDC) 1 114109791 Smith, Todd CDC - DIR CDC Smith, Todd (CDC) 1 114109792 Wu, Xianfu CDC - DIR CDC Wu, Xianfu (CDC) 0 114102466 IDENTIFICATION OF ANTIBODIES SPECIFIC FOR LYSSAVIRUSES AND METHODS OF THEIR USE E-263-2013-0 Filing authorized Centers for Disease Control and Prevention (CDC) 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-3307] Antibodies for Rabies Post-exposure Prophylaxis or Antiviral Therapy of Clinical Rabies&body=Please send me information about technology [TAB-3307] Antibodies for Rabies Post-exposure Prophylaxis or Antiviral Therapy of Clinical Rabies. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-3307] Antibodies for Rabies Post-exposure Prophylaxis or Antiviral Therapy of Clinical Rabies&body=Please send me information about technology [TAB-3307] Antibodies for Rabies Post-exposure Prophylaxis or Antiviral Therapy of Clinical Rabies.">benjamin.hurley@nih.gov</a><br> 114168686 E-263-2013-0 E-263-2013-0-US-01 IDENTIFICATION OF ANTIBODIES SPECIFIC FOR LYSSAVIRUSES AND METHODS OF THEIR USE PRV US 61/394,651 Abandoned US <br />Provisional (PRV) 61/394,651<br />Filed on 2010-10-19<br />Status: Abandoned 114168687 E-263-2013-0 E-263-2013-0-PCT-02 IDENTIFICATION OF ANTIBODIES SPECIFIC FOR LYSSAVIRUSES AND METHODS OF THEIR USE PCT Patent Cooperation Treaty PCT/US2011/056738 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2011/056738<br />Filed on 2011-10-18<br />Status: Expired 114168688 E-263-2013-0 E-263-2013-0-US-05 IDENTIFICATION OF ANTIBODIES SPECIFIC FOR LYSSAVIRUSES AND METHODS OF THEIR USE National Stage US 9,115,187 13/879,782 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9115187 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9115187">9,115,187</a><br />Filed on 2013-04-16<br />Status: Issued 114168689 E-263-2013-0 E-263-2013-0-US-06 IDENTIFICATION OF ANTIBODIES SPECIFIC FOR AT LEAST TWO DIFFERENT LYSSAVIRUSES DIV US 9,809,643 14/813,427 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9809643 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9809643">9,809,643</a><br />Filed on 2015-07-30<br />Status: Issued 114168690 E-263-2013-0 E-263-2013-0-US-07 IDENTIFICATION OF ANTIBODIES SPECIFIC FOR LYSSAVIRUSES AND METHODS OF THEIR USE DIV US 10,400,031 15/725,557 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10400031 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10400031">10,400,031</a><br />Filed on 2017-10-05<br />Status: Issued 114128035 DXXXXX 114128036 DBXXXX 114128037 DB4XXX 114128038 DB4BXX 114128039 DAXXXX 114128040 DA4XXX 114128041 DA4BXX 114128042 DDXXXX 114128043 AXXXXX 114128044 ABXXXX 114128045 AAXXXX 114128046 AA5XXX 114128047 WIXXXX 114128048 WKXXXX 114128049 WNXXXX 114128050 XAXXXX 114128051 XKXXXX 114151153 Identification 114151154 antibodies 114151155 Specific 114151156 LYSSAVIRUSES 114151157 Methods 114151158 Their 114151159 CDC Docket Import 114151160 CDC Docket Import CDC Prosecuting 114151161 OID-NCEZID-DHCPP 114151162 Listed LPM Kirby as of 4/15/2015 114151163 Pre LPM working set 20150418 114151164 Post LPM Assignment Set 20150420 TAB-3314 114097238 Chimeric Reporter West Nile/Dengue Viruses and Their Use for Assay Development CDC Collaboration, Consumer Products, Diagnostics, Infectious Disease, Licensing, Occupational Safety and Health, Research Equipment, Research Materials Collaboration Consumer Products Diagnostics Infectious Disease Licensing Occupational Safety and Health Research Equipment Research Materials Claire Kinney CDC researchers have engineered West Nile/dengue virus (WN/DENV) chimeras utilizing the replicative ability of the West Nile (WN) virus but presenting the immunogenic pre-membrane and envelope surface proteins of each of the four dengue virus serotypes (DENV 1-4). When coupled with a fluorescent reporter gene, each chimera is able to generate live chimeric reporter WN/DENV (R-WN/DENV) expressing the fluorescent protein in infected cells. These chimeric reporter viruses (CRVs) are used to develop faster and less hands-on high throughput neutralization assays for DENV. In addition, the same CRV platform was also used to develop a chimeric reporter-West Nile/Zika virus (R-WN/ZIKV) (see related technologies below) for the ZIKV neutralization assay. Using a robust WNV replicative vector combined with a reporter that emits a very strong signal, this platform permits live-image detection and measurement of infectivity in 24-30 hours after cell infection by these reporter viruses. A high throughput neutralization assay without labor intensive procedures (such as cell overlay, cell fixation, and/or immunostaining) has been successfully developed for all these 5 CRVs using a live-image based plate reader. With similar replication kinetics for these CRVs, the test protocols can be synchronized for all of these 5 viruses, which is advantageous for samples that may need to be tested against more than one of these viruses for confirmative serologic diagnosis. <ul> <li>Offers high throughput (scale), easy-to-use procedures and a potentially more sensitive assay</li> <li> Allows fast neutralizing antibody detection in as little as 24-30 hours post-infection</li> <li>Removes the requirement of cellulose or agar overlay, cell fixation, and virus foci/plaque staining in assays</li> <li>The reporter chimeric WN/DENVs replicate faster and more robustly than the whole DENVs</li> <li>The assay developed with these reporter viruses can be directly measured from live cell cultures (live imaging by image-based cytometers or plate readers)</li> <li> Easy and high yield production of the chimeric reporter viruses</li> <li>Genetic and cytometry assays available to confirm the integrity of the reporter gene in the generated CRV stocks</li> </ul> <ul> <li>Diagnostic assays for antibody detection of all 4 serotypes of dengue virus</li> <li>High throughput, rapid neutralization assays</li> <li>Same chimeric reporter virus platform for dengue and Zika viruses, and likely for other flaviviruses</li> <li>Antiviral screening and virology research (infection, replication, and pathogenesis) </li> <li>Vaccine candidate immunogenicity testing and validation</li> <li>Monitoring and public health surveillance studies</li> </ul> The CDC Technology Transfer Office (TTO) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize: Chimeric Reporter West Nile/Dengue Viruses and Their Use for Assay Development. For collaboration opportunities, please contact CDC TTO at <a href="mailto:tto@cdc.gov">tto@cdc.gov</a> or 1-404-639-1330. 2022-03-08 2025-04-24 2025-04-24 2018-09-10 assay, chimeric, Development, NCEZID-DVBD, Nile/DENV, REPORTER, VLXXXX, WBXXXX, West, WFXXXX, WHXXXX, WIXXXX, XHXXXX, YAXXXX, YBXXXX False True True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract E-178-2016-0 E-168-2014-0 E-177-2016-0 114109829 Kinney, Claire CDC - DIR CDC Kinney, Claire (CDC) 1 114109829 Kinney, Claire CDC - DIR CDC Kinney, Claire (CDC) 1 114102473 Chimeric Reporter West Nile/DENV For Assay Development E-126-2017-0 Filing authorized Centers for Disease Control and Prevention (CDC) 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-3314] Chimeric Reporter West Nile/Dengue Viruses and Their Use for Assay Development&body=Please send me information about technology [TAB-3314] Chimeric Reporter West Nile/Dengue Viruses and Their Use for Assay Development. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-3314] Chimeric Reporter West Nile/Dengue Viruses and Their Use for Assay Development&body=Please send me information about technology [TAB-3314] Chimeric Reporter West Nile/Dengue Viruses and Their Use for Assay Development.">benjamin.hurley@nih.gov</a><br> 114168722 E-126-2017-0 E-126-2017-0-US-01 CHIMERIC REPORTER WEST NILE/DENGUE VIRUSES AND THEIR USE PRV US 62/547,527 Abandoned US <br />Provisional (PRV) 62/547,527<br />Filed on 2017-08-18<br />Status: Abandoned 114168723 E-126-2017-0 E-126-2017-0-PCT-02 CHIMERIC REPORTER WEST NILE/DENGUE VIRUSES AND THEIR USE PCT Patent Cooperation Treaty PCT/US2018/046909 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2018/046909<br />Filed on 2018-08-17<br />Status: Expired 114168972 E-126-2017-0 E-126-2017-0-US-03 CHIMERIC REPORTER WEST NILE/DENGUE VIRUSES AND THEIR USE National Stage US 11,634,459 16/639,652 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11634459 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11634459">11,634,459</a><br />Filed on 2020-02-17<br />Status: Issued 114128098 YAXXXX 114128099 YBXXXX 114128100 VLXXXX 114128101 WBXXXX 114128102 WFXXXX 114128103 WHXXXX 114128104 WIXXXX 114128105 XHXXXX 114151258 chimeric 114151259 REPORTER 114151260 West 114151261 Nile/DENV 114151262 assay 114151263 Development 114151264 NCEZID-DVBD TAB-3334 114097250 High-throughput assay for detection of rabies neutralizing antibodies CDC Antibodies, Collaboration, Diagnostics, Immunology, Infectious Disease, Licensing, Research Materials, Vaccines Antibodies Collaboration Diagnostics Immunology Infectious Disease Licensing Research Materials Vaccines Jillybeth Burgado, Lauren Greenberg, Victoria Olson, Subbian Panayampalli, Xianfu Wu According to 2010-2014 World Health Organization (WHO) research, dog-transmitted human rabies was present or suspected in 150 countries and territories worldwide. Domestic dogs were the most common reservoir of the rabies virus in these countries, and more than 99% of human deaths were caused by dog-transmitted rabies. Rabies is 100% preventable in dogs with appropriate administration of vaccines. <br /><br /> Virus neutralization assays are essential for assessing vaccine efficacy. Current methods to detect rabies-specific neutralizing antibodies involve skilled personnel using a traditional 8-well slide and manually reading a microscope after staining rabies virus (RABV)-infected cells with fluorescently-labelled antibodies. Results are qualitative, time-consuming, labor-intensive, and low throughput. Additionally, images cannot be stored for future analysis. <br /><br /> To address these current limitations, CDC researchers developed high-throughput neutralization assays across two testing platforms using a recombinant RABV expressing green fluorescent protein (GFP) that can assess the presence of neutralizing antibodies in serum. Presence of neutralizing antibodies can then be detected using high-throughput flow cytometry, or automated microscopy and image analysis. Both methods provide unbiased and quantitative values of RABV-infected cells to determine anti-rabies neutralizing antibody titers in test samples. <ul> <li>High-throughput testing capability </li> <li>Results are quantitative, not qualitative</li> <li> Offers the ability to store and analyze images for future analysis and reference</li> </ul> <ul> <li>A diagnostic for rabies neutralizing antibody detection</li> <li>Neutralization assays for determining rabies vaccine efficacy in manufacturing</li> </ul> The CDC Technology Transfer Office (TTO) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize: High-throughput assay for detection of rabies neutralizing antibodies. For collaboration opportunities, please contact CDC TTO at <a href="mailto:tto@cdc.gov">tto@cdc.gov</a> or 1-404-639-1330. 2022-03-08 2025-04-24 2025-04-24 2018-10-17 antibodies, Anti-rabies, assay, Based, Detection, Fluorescence, GREEN, High-throughput, Neutralizing, Protein, VLXXXX, WBXXXX, WHXXXX, WNXXXX, XAXXXX, YAXXXX, YBXXXX False True True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114109881 Wu, Xianfu CDC - DIR CDC Wu, Xianfu (CDC) 0 114109882 Burgado, Jillybeth CDC - DIR CDC Burgado, Jillybeth (CDC) 0 114109883 Greenberg, Lauren CDC - DIR CDC Greenberg, Lauren (CDC) 0 114109884 Olson, Victoria CDC - DIR CDC Olson, Victoria (CDC) 0 114109885 Panayampalli, Subbian CDC - DIR CDC Panayampalli, Subbian (CDC) 1 114109885 Panayampalli, Subbian CDC - DIR CDC Panayampalli, Subbian (CDC) 1 114109881 Wu, Xianfu CDC - DIR CDC Wu, Xianfu (CDC) 0 114109882 Burgado, Jillybeth CDC - DIR CDC Burgado, Jillybeth (CDC) 0 114109883 Greenberg, Lauren CDC - DIR CDC Greenberg, Lauren (CDC) 0 114109884 Olson, Victoria CDC - DIR CDC Olson, Victoria (CDC) 0 114102488 Green Fluorescence Protein Based High-throughput Assay For Detection Of Anti-rabies Neutralizing Antibodies E-224-2018-0 Research Material Centers for Disease Control and Prevention (CDC) 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-3334] High-throughput assay for detection of rabies neutralizing antibodies &body=Please send me information about technology [TAB-3334] High-throughput assay for detection of rabies neutralizing antibodies . Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-3334] High-throughput assay for detection of rabies neutralizing antibodies &body=Please send me information about technology [TAB-3334] High-throughput assay for detection of rabies neutralizing antibodies .">benjamin.hurley@nih.gov</a><br> 114128184 YAXXXX 114128185 YBXXXX 114128186 VLXXXX 114128187 WBXXXX 114128188 WHXXXX 114128189 WNXXXX 114128190 XAXXXX 114151386 GREEN 114151387 Fluorescence 114151388 Protein 114151389 Based 114151390 High-throughput 114151391 assay 114151392 Detection 114151393 Anti-rabies 114151394 Neutralizing 114151395 antibodies TAB-3312 114097235 Methods to Regulate Biofilm Development to Prevent Infection on Indwelling or Implantable Medical Devices CDC Collaboration, Infectious Disease, Licensing, Therapeutics Collaboration Infectious Disease Licensing Therapeutics Rodney Donlan, Andres Garcia, Susan Lehman Formation of biofilms (microorganisms) on medical devices is a common cause of infection and device replacement. For example, biofilm formation on urinary catheters is associated with the development of catheter-associated urinary tract infections (CAUTI), and recent studies indicate that approximately 9% of HAIs stem from CAUTI. Urinary catheters are also thought to be one of the largest reservoirs of nosocomial antibiotic-resistant pathogens. The related increases in patient morbidity, mortality, and costs with CAUTI are substantial.<br/><br /> CDC and partner researchers have designed methods for controlled attachment of bioactive bacteriophages to medical devices for reducing bacterial colonization and regulating biofilm development. With collaborators at the Georgia Institute of Technology, CDC has developed and patented a novel approach to covalently attach bacteriophages to hydrogel-coated catheters. These tethered bacteriophages can reduce bacterial attachment and biofilm formation on the catheter surface. Additional formulations could be developed for a range of other indwelling or implanted medical devices such as stents, shunts, feeding tubes, and artificial joints and maximal impact on infections could be achieved using a diverse cocktail of relatively broad host-ranged phages. <ul> <li>Natural, specific, infection-responsive approach</li> <li> Effective against multi-drug resistant bacteria</li> <li>Flexible technology applicable to various coatings/devices & phage strains or mixtures</li> <li>Localization/retention of bioactive phage to device</li> </ul> <ul> <li>Reduction of biofilm formation and microbial colonization on indwelling and implanted medical devices</li> </ul> The CDC Technology Transfer Office (TTO) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize: Methods to regulate biofilm development to prevent infection on indwelling or implantable medical devices. For collaboration opportunities, please contact CDC TTO at <a href="mailto:tto@cdc.gov">tto@cdc.gov</a> or 1-404-639-1330. Also Included, Canadian Patent 2,837,731 2022-03-08 2025-04-24 2025-04-24 2018-10-22 AA4XXX, AB3CXX, AB3DXX, AB3FXX, AB3XXX, Attached, ATTACHMENT, AXXXXX, Bacterial, BACTERIOPHAGE, Bacteriophages, BIOACTIVE, Biofilm, CDC Docket Import, CDC Docket Import CDC Prosecuting, Colonization, Controlled, COVALENT, DB3XXX, Development, Devices, Listed LPM Houze as of 4/15/2015, Methods, OID-NCEZID-DHQP, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Purpose, REDUCING, REGULATING False True True NIHTT 37470483 Website Abstract 114172523 Lehman SM, Donlan RM. https://www.ncbi.nlm.nih.gov/pubmed/25487795 <a href="https://www.ncbi.nlm.nih.gov/pubmed/25487795">Lehman SM, Donlan RM.</a> 114172524 Donlan RM. https://www.ncbi.nlm.nih.gov/pubmed/24795474 <a href="https://www.ncbi.nlm.nih.gov/pubmed/24795474">Donlan RM.</a> 114172525 Donlan RM. https://www.ncbi.nlm.nih.gov/pubmed/19162482 <a href="https://www.ncbi.nlm.nih.gov/pubmed/19162482">Donlan RM.</a> 114172526 Curtin JJ, Donlan RM. https://www.ncbi.nlm.nih.gov/pubmed/16569839 <a href="https://www.ncbi.nlm.nih.gov/pubmed/16569839">Curtin JJ, Donlan RM.</a> 114172527 Goeres, DM et al. https://www.ncbi.nlm.nih.gov/pubmed/15758222 <a href="https://www.ncbi.nlm.nih.gov/pubmed/15758222">Goeres, DM et al. </a> 114172528 Donlan RM. https://www.ncbi.nlm.nih.gov/pubmed/11565080 <a href="https://www.ncbi.nlm.nih.gov/pubmed/11565080">Donlan RM.</a> 114172529 Donlan RM. https://www.ncbi.nlm.nih.gov/pubmed/11294723 <a href="https://www.ncbi.nlm.nih.gov/pubmed/11294723">Donlan RM.</a> 114172530 Fu W, et al. https://www.ncbi.nlm.nih.gov/pubmed/19822702 <a href="https://www.ncbi.nlm.nih.gov/pubmed/19822702">Fu W, et al. </a> 114109823 Garcia, Andres Georgia Institute of Technology Garcia, Andres 0 114109858 Lehman, Susan Georgia Institute of Technology Lehman, Susan 0 114109859 Donlan, Rodney CDC - DIR CDC Donlan, Rodney (CDC) 1 114109859 Donlan, Rodney CDC - DIR CDC Donlan, Rodney (CDC) 1 114109823 Garcia, Andres Georgia Institute of Technology Garcia, Andres 0 114109858 Lehman, Susan Georgia Institute of Technology Lehman, Susan 0 114102498 Methods For Controlled Attachment Of Bioactive Bacteriophages To Devices For The Purpose Of Reducing Bacterial Colonization E-171-2013-0 Filing authorized Centers for Disease Control and Prevention (CDC), Georgia Institute of Technology 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-3312] Methods to Regulate Biofilm Development to Prevent Infection on Indwelling or Implantable Medical Devices &body=Please send me information about technology [TAB-3312] Methods to Regulate Biofilm Development to Prevent Infection on Indwelling or Implantable Medical Devices . Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-3312] Methods to Regulate Biofilm Development to Prevent Infection on Indwelling or Implantable Medical Devices &body=Please send me information about technology [TAB-3312] Methods to Regulate Biofilm Development to Prevent Infection on Indwelling or Implantable Medical Devices .">benjamin.hurley@nih.gov</a><br> 114168776 E-171-2013-0 E-171-2013-0-US-01 Controlled Covalent Attached Of Bioactive Bacteriophage For Regulating Biofilm Development PRV US 61/501,975 Abandoned US <br />Provisional (PRV) 61/501,975<br />Filed on 2011-06-28<br />Status: Abandoned 114168777 E-171-2013-0 E-171-2013-0-PCT-02 Controlled Covalent Attached Of Bioactive Bacteriophage For Regulating Biofilm Development PCT Patent Cooperation Treaty PCT/US2012/044707 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2012/044707<br />Filed on 2012-06-28<br />Status: Expired 114168778 E-171-2013-0 E-171-2013-0-US-03 Controlled Covalent Attachment Of Bioactive Bacteriophage For Regulating Biofilm Development National Stage US 9,457,132 14/119,716 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9457132 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9457132">9,457,132</a><br />Filed on 2013-11-22<br />Status: Issued 114128078 AXXXXX 114128079 AA4XXX 114128080 AB3XXX 114128081 AB3CXX 114128082 AB3DXX 114128083 AB3FXX 114128084 DB3XXX 114151227 Controlled 114151228 COVALENT 114151229 Attached 114151230 BIOACTIVE 114151231 BACTERIOPHAGE 114151232 REGULATING 114151233 Biofilm 114151234 Development 114151235 Methods 114151236 ATTACHMENT 114151237 Bacteriophages 114151238 Devices 114151239 Purpose 114151240 REDUCING 114151241 Bacterial 114151242 Colonization 114151243 CDC Docket Import 114151244 CDC Docket Import CDC Prosecuting 114151245 OID-NCEZID-DHQP 114151246 Listed LPM Houze as of 4/15/2015 114151247 Pre LPM working set 20150418 114151248 Post LPM Assignment Set 20150420 TAB-2602 114096796 CDC Mosquito Trap for Control and Surveillance of Mosquitoes Including Carriers of Zika & Other Viruses CDC Consumer Products, Diagnostics, Infectious Disease, Licensing, Medical Devices, Non-Medical Devices, Occupational Safety and Health, Rare/Neglected Diseases, Research Materials, Therapeutics Consumer Products Diagnostics Infectious Disease Licensing Medical Devices Non-Medical Devices Occupational Safety and Health Rare/Neglected Diseases Research Materials Therapeutics Manuel Amador, Andrew Mackay Mosquitoes are responsible for spreading many viruses that can make people sick, including dengue, Zika, chikungunya, yellow fever, and more. The Centers for Disease Control and Prevention's (CDC's) new autocidal gravid ovitrap (AGO) mosquito trap is an inexpensive, simple-to-assemble, and easy-to-maintain trap that targets female mosquitoes looking for a place to lay eggs. The current trap model stands 18 inches (45cm) tall and is made of a 5-gallon (18L) bucket. The AGO trap's unique design lures mosquitoes by using water and an all-natural, organic hay attractant. Once inside, female mosquitoes are captured on a nontoxic, sticky glue adhesive placed inside the capture chamber. The AGO trap has been successfully used by mosquito control programs for mosquito surveillance and control. Field trials in which the AGO trap has been installed in most homes in a community have shown it not only reduces mosquito populations but also rates of infection. This means that, in the community where AGO traps were installed, fewer people become sick from mosquito bites. Smaller scale field trials were so successful that CDC and the Puerto Rico Department of Health are implementing large-scale installation of AGO traps throughout several communities to help reduce mosquito populations and the viruses they spread. <ul> <li>Ovitraps attract female mosquitoes looking for a place to lay eggs</li> <li>100% nontoxic trap that does not use insecticide</li> <li>Successfully field tested in communities and shown to reduce mosquito populations and the viruses they spread</li> <li>Currently being used in Puerto Rico to help control the spread of Zika virus through mosquitoes</li> </ul> <ul> <li>Trap can be used for surveillance and control of <em>Aedes aegypti</em> and <em>Ae. albopictus</em> mosquitoes known to spread Zika, dengue, yellow fever, chikungunya, and other viruses</li> <li><em>Ae. aegypti</em> and <em>Ae. albopictus</em> mosquitoes are found throughout tropical and subtropical countries throughout the world, including United States territories and the southern United States</li> </ul> Foreign counterparts in Australia, Brazil, India, and Mexico 2022-03-08 2025-04-24 2025-04-24 2019-07-23 Aedes, Aegypti, AFXXXX, AUTOCIDAL, AXXXXX, CDC Docket Import, CDC Docket Import CDC Prosecuting, CONTROL, DENGUE, DENGUE FEVER, DEXXXX, DXXXXX, GRAVID, insect, Insecticides, Insects, Listed LPM Houze as of 4/15/2015, Malaria, MALARIAL, Mosquito, Mosquitoes, MXXXXX, NON-TOXIC, OID-NCEZID-DVBD, OVITRAP, Pest, PESTICIDE, PESTICIDES, Pests, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Surveillance, Targeting, Tool, TRAP, TRAPPING, UB1XXX, Vector, Vector-based, Vector-borne, Vector-borne diseases, VLXXXX, VOXXXX, VQXXXX, WDXXXX, WEST NILE, WEST NILE VIRUS, WFXXXX, XDXXXX, YFXXXX, Zika, Zoonotic False True <ul> <li>Prototype</li> <li>In vitro data available</li> </ul> True 52406769 Prototype 52406769 NIHTT 37470483 Website Abstract E-223-2013-0 E-175-2013-0 114170773 Barrera R, et al. https://www.ncbi.nlm.nih.gov/pubmed/24551969 <a href="https://www.ncbi.nlm.nih.gov/pubmed/24551969">Barrera R, et al.</a> 114170917 Cornel AJ, et al. https://www.ncbi.nlm.nih.gov/pubmed/27158450 <a href="https://www.ncbi.nlm.nih.gov/pubmed/27158450">Cornel AJ, et al.</a> 114170918 Barrera R, et al. https://www.ncbi.nlm.nih.gov/pubmed/25223937 <a href="https://www.ncbi.nlm.nih.gov/pubmed/25223937">Barrera R, et al.</a> 114171858 Barrera, R. et al. 2010. “Field Trials of a New Gravid-ovitrap for Integrated Area-wide Control of Aedes Aegypti in Puerto Rico.” In Abstract Book, 83 (5 Supplement):179. The American Journal of Tropical Medicine and Hygiene. Atlanta, GA, USA. http://www.astmh.org/ASTMH/media/Documents/AbstractBook3.pdf <a href="http://www.astmh.org/ASTMH/media/Documents/AbstractBook3.pdf">Barrera, R. et al. 2010. “Field Trials of a New Gravid-ovitrap for Integrated Area-wide Control of Aedes Aegypti in Puerto Rico.” In Abstract Book, 83 (5 Supplement):179. The American Journal of Tropical Medicine and Hygiene. Atlanta, GA, USA.</a> 114171899 Acevedo V, et al. https://www.ncbi.nlm.nih.gov/pubmed/27802402 <a href="https://www.ncbi.nlm.nih.gov/pubmed/27802402">Acevedo V, et al.</a> 114172286 Barrera R, et al. https://www.ncbi.nlm.nih.gov/pubmed/24199506 <a href="https://www.ncbi.nlm.nih.gov/pubmed/24199506">Barrera R, et al.</a> 114172287 Mackay AJ, et al. https://www.ncbi.nlm.nih.gov/pubmed/23919568 <a href="https://www.ncbi.nlm.nih.gov/pubmed/23919568">Mackay AJ, et al.</a> 114108117 Amador, Manuel CDC - DIR CDC Amador, Manuel (CDC) 0 114108118 Mackay, Andrew CDC - DIR CDC Mackay, Andrew (CDC) 0 114108117 Amador, Manuel CDC - DIR CDC Amador, Manuel (CDC) 0 114108118 Mackay, Andrew CDC - DIR CDC Mackay, Andrew (CDC) 0 114101949 A Tool For The Control And Surveillance Of Aedes Aegypti E-166-2013-0 Filing authorized Centers for Disease Control and Prevention (CDC) 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-2602] CDC Mosquito Trap for Control and Surveillance of Mosquitoes Including Carriers of Zika & Other Viruses&body=Please send me information about technology [TAB-2602] CDC Mosquito Trap for Control and Surveillance of Mosquitoes Including Carriers of Zika & Other Viruses. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-2602] CDC Mosquito Trap for Control and Surveillance of Mosquitoes Including Carriers of Zika & Other Viruses&body=Please send me information about technology [TAB-2602] CDC Mosquito Trap for Control and Surveillance of Mosquitoes Including Carriers of Zika & Other Viruses.">benjamin.hurley@nih.gov</a><br> 114161552 E-166-2013-0 E-166-2013-0-PCT-02 METHODS AND APPARATUS FOR SURVEILLANCE AND CONTROL OF INSECT VECTORS PCT Patent Cooperation Treaty PCT/US2012/025462 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2012/025462<br />Filed on 2012-02-16<br />Status: Expired 114162834 E-166-2013-0 E-166-2013-0-US-08 Methods and Apparatus for Surveillance and Control of Insect Vectors DIV US 10,219,505 14/965,230 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10219505 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10219505">10,219,505</a><br />Filed on 2015-12-10<br />Status: Issued 114162919 E-166-2013-0 E-166-2013-0-US-06 METHODS AND APPARATUS FOR SURVEILLANCE AND CONTROL OF INSECT VECTORS National Stage US 9,237,741 13/822,598 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9237741 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9237741">9,237,741</a><br />Filed on 2013-03-12<br />Status: Issued 114167246 E-166-2013-0 E-166-2013-0-US-01 A Tool For The Control And Surveillance Of Aedes Aegypti PRV US 61/443,588 Expired US <br />Provisional (PRV) 61/443,588<br />Filed on 2011-02-16<br />Status: Expired 114114607 WDXXXX 114114608 WFXXXX 114114609 XDXXXX 114114610 YFXXXX 114122967 MXXXXX 114122968 VQXXXX 114122969 VLXXXX 114122970 VOXXXX 114123522 UB1XXX 114123524 AFXXXX 114123525 DEXXXX 114123526 AXXXXX 114123527 DXXXXX 114133254 CDC Docket Import 114133257 CDC Docket Import CDC Prosecuting 114133258 OID-NCEZID-DVBD 114133259 Mosquito 114133260 Mosquitoes 114133261 Vector 114136759 Zoonotic 114136760 Malaria 114136761 MALARIAL 114136762 DENGUE 114136763 DENGUE FEVER 114136764 WEST NILE 114136765 WEST NILE VIRUS 114136766 Targeting 114136767 AUTOCIDAL 114144767 Tool 114144768 CONTROL 114144769 Surveillance 114144770 Aedes 114144771 Aegypti 114145931 Insecticides 114145932 Insects 114145933 Pest 114146991 Vector-based 114146992 Vector-borne 114146993 Vector-borne diseases 114146994 insect 114147952 Pests 114147953 PESTICIDE 114147954 PESTICIDES 114147955 TRAP 114147956 TRAPPING 114147957 GRAVID 114147958 OVITRAP 114147959 NON-TOXIC 114148666 Listed LPM Houze as of 4/15/2015 114148667 Pre LPM working set 20150418 114148668 Post LPM Assignment Set 20150420 114148669 Zika TAB-3365 114097268 Real-Time RT-PCR Detection of Scrub Typhus Total Nucleic Acid Assay with High Sensitivity and Specificity CDC Collaboration, Consumer Products, Diagnostics, Infectious Disease, Licensing, Medical Devices, Non-Medical Devices, Occupational Safety and Health, Research Materials, Therapeutics Collaboration Consumer Products Diagnostics Infectious Disease Licensing Medical Devices Non-Medical Devices Occupational Safety and Health Research Materials Therapeutics Ida Chung, Cecilia Kato Scrub typhus is a bacterial disease caused by Orientia tsutsugamushi (O. tsutsugamushi or Ots) that is spread to people through bites of infected chiggers (larval mites). The most common symptoms can include fever, headache, body aches, and sometimes rash. Severe illness can lead to organ failure and bleeding which can be fatal if left untreated. Most cases of scrub typhus occur in Asia Pacific countries, however, recent reports document establishment in the Arabian Peninsula, Chile, and possibly Kenya. Anyone living in or traveling to areas where scrub typhus is found could get infected if they come in contact with infected mites. Currently available DNA molecular tests lack sensitivity to reproducibly detect the low level of scrub typhus bacteria circulating in blood. <br /><br /> CDC scientists developed a real-time reverse transcriptase PCR (real-time RT PCR) assay targeting both ribosomal RNA (rRNA) and ribosomal DNA (rDNA) in total nucleic acid (TNA) to detect Ots. Analytical specificity was tested with 17 Ots strains for inclusivity, and exclusivity with 7 near neighbors and 9 background clinical and environmental Ots DNAs. Initial tests on patient samples show high specificity and sensitivity. CDC’s assay improves diagnostic accuracy by increasing Ots detection sensitivity 10 to 100 times over current molecular DNA tests. CDC technology uses uncomplicated steps so that early acute stage diagnosis of scrub typhus now becomes feasible. <ul> <li>Requires uncomplicated steps and enables early, acute stage diagnosis not previously possible</li> <li>Initial data shows new scrub typhus assay offers 10 to 100 times greater detection sensitivity v. standard PCR assays</li> <li>CDC’s scrub typhus assay has high specificity to 17 Ots strains tested for inclusivity</li> </ul> <ul> <li>Real-time RT PCR kits for scrub typhus infections</li> <li>Potential development into point-of-care diagnostic assays</li> <li> Quality assurance/quality control (QA/QC) testing for vaccine candidate development</li> <li>Licensee may potentially distribute assay technology to CDC laboratory response network (LRN) partners</li> <li>Technology may be used in human and veterinary tick-borne disease differential testing (as tick-borne illnesses and scrub typhus may present with similar symptoms) </li> <li>Public health monitoring and surveillance</li> </ul> The CDC Technology Transfer Office (TTO) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize: Real-Time RT-PCR Detection of Scrub Typhus Total Nucleic Acid Assay with High Sensitivity and Specificity. For collaboration opportunities, please contact CDC TTO at <a href="mailto:tto@cdc.gov">tto@cdc.gov</a> or 1-404-639-1330. 2022-03-08 2025-04-24 2025-04-24 2020-03-09 Acid, Detection, Genus, NCEZID-DVBD, Nucleic, Rickettsia, Scrub, TOTAL, Typhus, VJXXXX, VOXXXX, WBXXXX, WFXXXX, WIXXXX, WMXXXX, XDXXXX, XEXXXX, YBXXXX, YDXXXX False True True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract E-230-2017-0 114110019 Chung, Ida CDC - DIR CDC Chung, Ida (CDC) 0 114110020 Kato, Cecilia CDC - DIR CDC Kato, Cecilia (CDC) 1 114110020 Kato, Cecilia CDC - DIR CDC Kato, Cecilia (CDC) 1 114110019 Chung, Ida CDC - DIR CDC Chung, Ida (CDC) 0 114102512 Scrub Typhus Total Nucleic Acid Detection E-230-2017-1 Closed Centers for Disease Control and Prevention (CDC) 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-3365] Real-Time RT-PCR Detection of Scrub Typhus Total Nucleic Acid Assay with High Sensitivity and Specificity&body=Please send me information about technology [TAB-3365] Real-Time RT-PCR Detection of Scrub Typhus Total Nucleic Acid Assay with High Sensitivity and Specificity. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-3365] Real-Time RT-PCR Detection of Scrub Typhus Total Nucleic Acid Assay with High Sensitivity and Specificity&body=Please send me information about technology [TAB-3365] Real-Time RT-PCR Detection of Scrub Typhus Total Nucleic Acid Assay with High Sensitivity and Specificity.">benjamin.hurley@nih.gov</a><br> 114168860 E-230-2017-1 E-230-2017-1-PCT-01 METHODS AND COMPOSITIONS FOR RICKETTSIACEAE DETECTION PCT COMB Patent Cooperation Treaty PCT/US2019/018039 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2019/018039<br />Filed on 2019-02-14<br />Status: Expired 114169059 E-230-2017-1 E-230-2017-1-US-03 METHODS AND COMPOSITIONS FOR RICKETTSIACEAE DETECTION National Stage US 16/970,318 Abandoned US <br />National Stage 16/970,318<br />Filed on 2020-08-14<br />Status: Abandoned 114128249 YBXXXX 114128250 YDXXXX 114128251 VJXXXX 114128252 VOXXXX 114128253 WBXXXX 114128254 WFXXXX 114128255 WIXXXX 114128256 WMXXXX 114128257 XDXXXX 114128259 XEXXXX 114151593 Nucleic 114151594 Acid 114151595 NCEZID-DVBD 114151596 Detection 114151597 Rickettsia 114151598 Genus 114151599 TOTAL 114151600 Scrub 114151601 Typhus TAB-3309 114097232 Monitoring Public Water Supply for a Variety of Pathogens CDC Collaboration, Consumer Products, Diagnostics, Infectious Disease, Medical Devices, Non-Medical Devices, Occupational Safety and Health, Research Equipment, Research Materials, Therapeutics, Vaccines Collaboration Consumer Products Diagnostics Infectious Disease Medical Devices Non-Medical Devices Occupational Safety and Health Research Equipment Research Materials Therapeutics Vaccines Eric Cummings, Yolanda Fintschenko, Vincent Hill, Blake Simmons The simultaneous concentration and recovery of microbes in drinking water is important for responding to potential water-related events such as pathogen contamination or bioterrorism and could be a cost-effective technique for routine monitoring of drinking water quality. Scientists at the CDC have combined two techniques, ultrafiltration (UF) and insulator-based dielectrophoresis (iDEP) in series, to achieve significant concentration of microbes and pathogens for analysis. UF can concentrate a water sample =200X, depending on turbidity; if a secondary concentration step is applied, then a =25,000X can be achieved. Research has shown that UF can be an effective technique for simultaneously concentrating viruses, bacteria, and parasites in larger samples of drinking water. A second technique, the iDEP system, is known to be capable of capturing, concentrating, and separating microbes in very small water samples. The combination of UF with iDEP holds potential promise for allowing water utilities and associated industries to accurately detect low levels of pathogens in drinking water samples. This technology has the capability to separate live from non-viable microbes, thereby decreasing the chances of generating false-positive PCR results due to the presence of free nucleic acid or non-viable microbes. <ul> <li>A rapid method for detecting the presence of a variety of microbes such as Cryptosporidium parvum oocysts and Enterococcus faecalis</li> <li>Uses a combination of ultrafiltration and dielectrophoretic separation techniques versus available single method technology</li> <li>Ability to separate live from non-viable microbes, thereby decreasing the chances of generating false-positive PCR results due to the presence of naked nucleic acid or non-viable microbes</li> <li>Accurately assess low levels of pathogens in finished drinking water samples, whether due to natural or intentional contamination</li> </ul> <ul> <li>Monitoring of municipal, commercial, public, and individual water supplies for drinking water quality</li> <li>Monitoring source water, industrial effluent, hospital discharge, and military water infrastructures for pathogens</li> <li>Assessing water in agricultural settings</li> <li>Monitoring water quality in pools and other recreational settings</li> </ul> The CDC Technology Transfer Office (TTO) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize a system to monitor water supplies for a variety of pathogens. For collaboration opportunities, please contact CDC TTO at <a href="mailto:tto@cdc.gov">tto@cdc.gov</a> or 1-404-639-1330. 2022-03-08 2025-04-24 2025-04-24 2020-03-09 Biological, CDC Docket Import, CDC Docket Import NP, Concentration, Dielectrophoresis, Listed LPM Houze as of 4/15/2015, NCEZID-DFWED, Organisms, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, SEPARATION, Ultrafiltration, VJXXXX, VKXXXX, VLXXXX, VQXXXX, WAXXXX, WCXXXX, WFXXXX, WHXXXX, WIXXXX, WMXXXX, XDXXXX, XHXXXX, XIXXXX, YBXXXX, YFXXXX False True True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract E-252-2013-0 E-273-2013-0 E-292-2013-0 114172521 Hill VR, et al. https://www.ncbi.nlm.nih.gov/pubmed/16269722 <a href="https://www.ncbi.nlm.nih.gov/pubmed/16269722 ">Hill VR, et al. </a> 114172522 Hill VR, et al. https://www.ncbi.nlm.nih.gov/pubmed/17483281 <a href="https://www.ncbi.nlm.nih.gov/pubmed/17483281">Hill VR, et al. </a> 114109798 Cummings, Eric Cummings, Eric 0 114109799 Fintschenko, Yolanda Fintschenko, Yolanda 0 114109800 Simmons, Blake Simmons, Blake 0 114109797 Hill, Vincent CDC - DIR CDC Hill, Vincent (CDC) 1 114109797 Hill, Vincent CDC - DIR CDC Hill, Vincent (CDC) 1 114109798 Cummings, Eric Cummings, Eric 0 114109799 Fintschenko, Yolanda Fintschenko, Yolanda 0 114109800 Simmons, Blake Simmons, Blake 0 114102468 Concentration And Separation Of Biological Organisms By Ultrafiltration And Dielectrophoresis E-458-2013-0 Filing authorized Centers for Disease Control and Prevention (CDC), Sandia National Laboratories-California 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-3309] Monitoring Public Water Supply for a Variety of Pathogens&body=Please send me information about technology [TAB-3309] Monitoring Public Water Supply for a Variety of Pathogens. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-3309] Monitoring Public Water Supply for a Variety of Pathogens&body=Please send me information about technology [TAB-3309] Monitoring Public Water Supply for a Variety of Pathogens.">benjamin.hurley@nih.gov</a><br> 114168699 E-458-2013-0 E-458-2013-0-US-03 METHOD FOR CONCENTRATION AND SEPARATION OF BIOLOGICAL ORGANISMS BY ULTRAFILTRATION AND DIELECTROPHORESIS DIV US 8,257,568 12/899,671 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8257568 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8257568">8,257,568</a><br />Filed on 2010-10-07<br />Status: Expired 114168700 E-458-2013-0 E-458-2013-0-US-02 Concentration And Separation Of Biological Organisms By Ultrafiltration And Dielectrophoresis ORD US 7,811,439 11/499,371 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7811439 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7811439">7,811,439</a><br />Filed on 2006-08-03<br />Status: Abandoned 114168701 E-458-2013-0 E-458-2013-0-US-01 Concentration And Separation Of Biological Organisms By Ultrafiltration And Dielectrophoresis PRV US 60/705,933 Abandoned US <br />Provisional (PRV) 60/705,933<br />Filed on 2005-08-03<br />Status: Abandoned 114128053 XHXXXX 114128054 XDXXXX 114128055 WMXXXX 114128056 WIXXXX 114128057 WHXXXX 114128058 WFXXXX 114128059 WCXXXX 114128060 WAXXXX 114128061 VLXXXX 114128062 VQXXXX 114128063 VKXXXX 114128064 VJXXXX 114128065 YFXXXX 114128066 YBXXXX 114128067 XIXXXX 114151174 Concentration 114151175 SEPARATION 114151176 Biological 114151177 Organisms 114151178 Ultrafiltration 114151179 Dielectrophoresis 114151180 CDC Docket Import 114151181 CDC Docket Import NP 114151182 NCEZID-DFWED 114151183 Listed LPM Houze as of 4/15/2015 114151184 Pre LPM working set 20150418 114151185 Post LPM Assignment Set 20150420 TAB-3251 114097185 Real-Time RT-PCR Detection of Rickettsia species -- PanR6/Total Nucleic Acid Assay with High Sensitivity and Specificity CDC Collaboration, Consumer Products, Diagnostics, Infectious Disease, Licensing, Medical Devices, Non-Medical Devices, Occupational Safety and Health, Research Materials, Therapeutics Collaboration Consumer Products Diagnostics Infectious Disease Licensing Medical Devices Non-Medical Devices Occupational Safety and Health Research Materials Therapeutics Ida Chung, Cecilia Kato Rickettsial infections are caused by bacteria from the Rickettsia genus which are often spread by biting ticks, fleas, mites or lice. Rickettsia can cause mild to severe illness and Rickettsia species can be found worldwide. Early stage, nonspecific symptoms of infections can make clinical diagnosis difficult. Rickettsial infection symptoms, if present, typically develop within 1 -2 weeks of exposure and include fever, headache, malaise, rash, nausea, and vomiting. Some rickettsial diseases such as Rocky Mountain spotted fever (RMSF), Mediterranean spotted fever, and typhus fever, can be life threatening and even fatal in 20% - 60% of untreated cases. Prompt identification of rickettsioses and treatment are essential. No vaccine is available for preventing rickettsial infections.<br/><br/> CDC scientists have developed a Pan-Rickettsia genus (PanR6) real-time reverse transcriptase PCR (real-time RT PCR) assay targeting both rRNA and rDNA in total nucleic acid (TNA). With high specificity, PanR6 detects 16 Rickettsia species and excludes 15 near neighbors (similar species). Increased sensitivity and accuracy of Rickettsia genus real-time RT PCR detection in clinical samples provides an important step towards early and more effective diagnosis of rickettsial infections. In patient sample testing, the sensitivity of the new PanR6/TNA assay increases diagnostic accuracy by increasing detection sensitivity 100 to 1000 times over current molecular DNA, southern blot, and serological tests which depend upon the specimen collected. A mock clinical specimen panel is being assembled for additional PanR6/TNA assay precision and accuracy validation.<br/><br/> <ul> <li>High sensitivity and specificity for Rickettsia</li> <li>Enables early, acute stage diagnosis not previously possible</li> <li> Initial data shows new PanR6/TNA assay offers 100 to 1000 times greater detection v. standard assays</li> </ul> <ul> <li>Human and animal diagnosis of rickettsial infections</li> <li>Real-time RT PCR kit</li> <li> Potential for development into point-of-care diagnostic assay</li> <li> Can be used for outbreak testing and cases of unknown febrile illnesses</li> <li> Quality assurance/quality control (QA/QC) testing for vaccine candidate development</li> <li>Licensee may potentially distribute assay to CDC laboratory response network (LRN) partners</li> </ul> The CDC Technology Transfer Office (TTO) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize: Real-Time RT-PCR Detection of Rickettsia Genus - PanR6/TNA Assay. For collaboration opportunities, please contact CDC TTO at <a href="mailto: tto@cdc.gov">tto@cdc.gov. 2022-03-08 2025-04-24 2025-04-24 2020-03-09 Acid, Detection, Genus, NCEZID-DVBD, Nucleic, Rickettsia, TOTAL, VJXXXX, WBXXXX, WFXXXX, WHXXXX, WIXXXX, WMXXXX, XDXXXX, XEXXXX, YBXXXX, YDXXXX False True True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114109635 Chung, Ida CDC - DIR CDC Chung, Ida (CDC) 0 114109634 Kato, Cecilia CDC - DIR CDC Kato, Cecilia (CDC) 1 114109634 Kato, Cecilia CDC - DIR CDC Kato, Cecilia (CDC) 1 114109635 Chung, Ida CDC - DIR CDC Chung, Ida (CDC) 0 114102411 Rickettsia Genus Total Nucleic Acid Detection E-230-2017-0 Closed Centers for Disease Control and Prevention (CDC) 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-3251] Real-Time RT-PCR Detection of Rickettsia species -- PanR6/Total Nucleic Acid Assay with High Sensitivity and Specificity&body=Please send me information about technology [TAB-3251] Real-Time RT-PCR Detection of Rickettsia species -- PanR6/Total Nucleic Acid Assay with High Sensitivity and Specificity. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-3251] Real-Time RT-PCR Detection of Rickettsia species -- PanR6/Total Nucleic Acid Assay with High Sensitivity and Specificity&body=Please send me information about technology [TAB-3251] Real-Time RT-PCR Detection of Rickettsia species -- PanR6/Total Nucleic Acid Assay with High Sensitivity and Specificity.">benjamin.hurley@nih.gov</a><br> 114168558 E-230-2017-0 E-230-2017-0-US-01 METHODS AND COMPOSITIONS FOR RICKETTSIA DETECTION PRV US 62/630,949 Abandoned US <br />Provisional (PRV) 62/630,949<br />Filed on 2018-02-15<br />Status: Abandoned 114127793 YBXXXX 114127794 YDXXXX 114127795 VJXXXX 114127796 WBXXXX 114127797 WFXXXX 114127798 WIXXXX 114127799 WMXXXX 114127800 WHXXXX 114127801 XDXXXX 114127802 XEXXXX 114150457 Acid 114150458 Nucleic 114150459 TOTAL 114150460 Genus 114150461 Rickettsia 114150462 Detection 114150463 NCEZID-DVBD TAB-3165 114097114 Zika Virus VLP (Virus-like Particle) Antigens for Vaccine Candidate and Diagnostic Development CDC Collaboration, Licensing Collaboration Licensing Gwong-Jen Chang, Brent Davis Zika virus (ZIKV) is a flavivirus primarily transmitted by infected Aedes mosquitoes. Infection with ZIKV during pregnancy can affect the fetus causing microcephaly, neurological complications, and other birth defects. Adults are also at a heightened risk of developing Guillain-Barre syndrome and other neurological disorders. In response to the 2015-2016 Zika outbreak, CDC scientists developed a recombinant vaccine candidate as well as reagents and methods to detect ZIKV infection. The recombinant vaccine candidate utilizes adenovirus vector expressed viral envelope proteins. This vector-based vaccine candidate is an efficient platform that elicits a strong response in mouse models; added vaccine testing in rabbit models is underway. Virus-like particles generated from the vector are also being used for ZIKV diagnostics. The US Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for CDC's Zika IgM antibody capture enzyme-linked immunosorbent assay (Zika MAC-ELISA) that utilizes VLP technology for in vitro qualitative detection of human IgM antibodies to Zika virus in serum. It can also be used to test cerebrospinal fluid (CSF) when submitted with a patient-matched serum sample. The CDC Zika MAC-ELISA assay is currently in use at qualified laboratories designated by CDC. <ul> <li>VLP strategy has proven to be very effective inCDC's West Nile virus (WNV) and dengue vaccine development</li> <li>Vaccine research in mouse and rabbit models underway</li> <li>FDA issued an EUA for CDC's Zika MAC-ELISA assay with VLP technology as a component of the assay; the assay is currently in use</li> </ul></li> </ul> <ul> <li>Development of a Zika virus vaccine</li> <li>Zika VLPs can be used for immunoassay diagnostic development</li> </ul> The Centers for Disease Control and Prevention Technology Transfer Office (TTO) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize Zika Virus VLP for Vaccine & Diagnostic Development. For collaboration opportunities, please contact CDC TTO at <a href="mailto:tto@cdc.gov">tto@cdc.gov</a> or 404-639-1330. Various international patent applications pending or issued 2022-03-08 2025-04-24 2025-04-24 2020-03-09 antibodies, ANTIGENS, NCEZID-DVBD, Vaccine, virus, VLP, Zika False True True NIHTT 37470483 Website Abstract E-341-2013-0 E-341-2013-1 E-081-2017-0 114172349 Zika MAC-ELISA https://www.cdc.gov/zika/pdfs/zika-mac-elisa-instructions-for-use.pdf <a href="https://www.cdc.gov/zika/pdfs/zika-mac-elisa-instructions-for-use.pdf">Zika MAC-ELISA</a> 114172350 Non-EUA ZIKA MAC-ELISA https://www.cdc.gov/zika/pdfs/non-eua-zika-mac-elisa-protocol.pdf <a href="https://www.cdc.gov/zika/pdfs/non-eua-zika-mac-elisa-protocol.pdf">Non-EUA ZIKA MAC-ELISA</a> 114172351 Zika MAC-ELISA Fact Sheet for Health Care Providers https://www.cdc.gov/zika/pdfs/interpreting-zika-mac-elisa-results.pdf <a href="https://www.cdc.gov/zika/pdfs/interpreting-zika-mac-elisa-results.pdf">Zika MAC-ELISA Fact Sheet for Health Care Providers</a> 114172352 Medical Device Safety - Emergency Situations https://www.fda.gov/MedicalDevices/Safety/EmergencySituations/ucm161496.htm#zika <a href="https://www.fda.gov/MedicalDevices/Safety/EmergencySituations/ucm161496.htm#zika">Medical Device Safety - Emergency Situations</a> 114109335 Davis, Brent CDC - DIR CDC Davis, Brent (CDC) 0 114109334 Chang, Gwong-Jen CDC - DIR CDC Chang, Gwong-Jen (CDC) 1 114109334 Chang, Gwong-Jen CDC - DIR CDC Chang, Gwong-Jen (CDC) 1 114109335 Davis, Brent CDC - DIR CDC Davis, Brent (CDC) 0 114102313 Zika Virus VLP Antigens, Antibodies And Vaccine E-107-2016-0 Filing authorized Centers for Disease Control and Prevention (CDC) 114102314 Zika Virus VLP Antigens, Antibodies And Vaccine E-107-2016-1 Filing authorized Centers for Disease Control and Prevention (CDC) 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-3165] Zika Virus VLP (Virus-like Particle) Antigens for Vaccine Candidate and Diagnostic Development&body=Please send me information about technology [TAB-3165] Zika Virus VLP (Virus-like Particle) Antigens for Vaccine Candidate and Diagnostic Development. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-3165] Zika Virus VLP (Virus-like Particle) Antigens for Vaccine Candidate and Diagnostic Development&body=Please send me information about technology [TAB-3165] Zika Virus VLP (Virus-like Particle) Antigens for Vaccine Candidate and Diagnostic Development.">benjamin.hurley@nih.gov</a><br> 114168366 E-107-2016-0 E-107-2016-0-US-01 NUCLEIC ACIDS ENCODING ZIKA VIRUS-LIKE PARTICLES AND THEIR USE IN ZIKA VIRUS VACCINES AND DIAGNOSTIC ASSAYS PRV US 62/349,537 Abandoned US <br />Provisional (PRV) 62/349,537<br />Filed on 2016-06-13<br />Status: Abandoned 114168367 E-107-2016-1 E-107-2016-1-PCT-01 NUCLEIC ACIDS ENCODING ZIKA VIRUS-LIKE PARTICLES AND THEIR USE IN ZIKA VIRUS VACCINES AND DIAGNOSTIC ASSAYS PCT COMB Patent Cooperation Treaty PCT/US2017/036762 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2017/036762<br />Filed on 2017-06-09<br />Status: Expired 114168817 E-107-2016-1 E-107-2016-1-US-06 Nucleic Acids Encoding Zika Virus-Like Particles and Their Use in Zika Virus Vaccines and Diagnostic Assays National Stage US 10,947,277 16/309,288 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10947277 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10947277">10,947,277</a><br />Filed on 2018-12-12<br />Status: Issued 114169096 E-107-2016-1 E-107-2016-1-US-07 NUCLEIC ACIDS ENCODING ZIKA VIRUS-LIKE PARTICLES AND THEIR USE IN ZIKA VIRUS VACCINES AND DIAGNOSTIC ASSAYS DIV US 11,578,103 17/168,889 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11578103 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11578103">11,578,103</a><br />Filed on 2021-02-05<br />Status: Issued 114149393 Vaccine 114149394 antibodies 114149395 ANTIGENS 114149396 VLP 114149397 virus 114149398 Zika 114149399 NCEZID-DVBD TAB-2745 114096924 Photoinduced Electron Transfer Fluorescent Primer for Nucleic Acid Amplification CDC Cardiology, Computational models/software, Consumer Products, Dental, Diagnostics, Endocrinology, Geriatrics, Immunology, Infectious Disease, Licensing, Neurology, Occupational Safety and Health, Oncology, Ophthalmology, Psychiatry/Mental Health, Research Equipment, Research Materials, Software / Apps, Therapeutics, Vaccines Cardiology Computational models/software Consumer Products Dental Diagnostics Endocrinology Geriatrics Immunology Infectious Disease Licensing Neurology Occupational Safety and Health Oncology Ophthalmology Psychiatry/Mental Health Research Equipment Research Materials Software / Apps Therapeutics Vaccines Vincent Hill, Brian Holloway, Jothikumar Narayanan CDC scientists have developed a rapid and cost-efficient method for generating fluorescently labeled primers for PCR and real-time PCR. At present, fluorescent primers are useful for detecting and identifying microbes and specific nucleic acid sequences, amplifying nucleic acids for pyro-sequencing, determining the levels of gene expression, and many other uses. However, problems exist with current techniques used to create fluorescent primers. For one, labeling is not one hundred percent efficient, leading to inaccurate results. Further, it is expensive and time consuming for researchers to make and label their own unique primers. This technology allows for the creation of custom primers in which fluorescent dye attaches to all oligomers.<br /><br /> This technology employs photoinduced electron transfer (PET) nucleic acid molecules that can be used detect and amplify target nucleic acid molecules. PET tags are attached to the 5'-end of a target-specific oligo for fluorescent labeling of the primer. PET tag activity can be quenched by at least two consecutive guanosines (G-G) within the tag sequence and activity is un-quenched when the PET tag hybridizes with its complementary nucleic acid molecule. <ul> <li>Avoids aberrant quantitative data generation resulting from inefficient fluorescent labeling reactions</li> <li>Allows for multiplex reactions</li> <li>Cost-efficient for time, sample preservation and cost of analysis</li> <li>Method can readily be used as part of an oligo-labeling kit</li> <li>No need for HPLC purification</li> <li>Does not require a quencher dye</li> </ul> <ul> <li>Efficient fluorescence-labeling of oligonucleotides</li> <li>Quantitative methods</li> <li>Pyro-sequencing</li> <li>Basic laboratory research</li> </ul> Various international filings pending 2022-03-08 2025-04-24 2025-04-24 2020-03-09 AA2XXX, AA5XXX, AAXXXX, AC4XXX, AC5XXX, AC6XXX, Acid, ACXXXX, AE1BXX, AG1XXX, amplification, AXXXXX, CDC Docket Import, CDC Docket Import CDC Prosecuting, ELECTRON, Nucleic, OID-NCEZID-DFWED, PET, PHOTOINDUCED, PRIMER, TRANSFER, VAXXXX, VBXXXX, VCXXXX, VDXXXX, VEXXXX, VGXXXX, VHXXXX, VIXXXX, VJXXXX, VKXXXX, VLXXXX, VMXXXX, VNXXXX, VOXXXX, VPXXXX, WAXXXX, WBXXXX, WCXXXX, WFXXXX, WGXXXX, WHXXXX, WIXXXX, WMXXXX, XBXXXX, XCXXXX, XEXXXX, XHXXXX, YBXXXX False True In vitro data available True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract E-252-2013-0 E-273-2013-0 E-458-2013-0 114172026 Jothikumar N, Hill VR. http://www.ncbi.nlm.nih.gov/pubmed/23727382 <a href="http://www.ncbi.nlm.nih.gov/pubmed/23727382">Jothikumar N, Hill VR.</a> 114108466 Hill, Vincent CDC - DIR CDC Hill, Vincent (CDC) 0 114108467 Holloway, Brian CDC - DIR CDC Holloway, Brian (CDC) 0 114108465 Narayanan, Jothikumar CDC - DIR CDC Narayanan, Jothikumar (CDC) 1 114108465 Narayanan, Jothikumar CDC - DIR CDC Narayanan, Jothikumar (CDC) 1 114108466 Hill, Vincent CDC - DIR CDC Hill, Vincent (CDC) 0 114108467 Holloway, Brian CDC - DIR CDC Holloway, Brian (CDC) 0 114102063 PHOTOINDUCED ELECTRON TRANSFER (PET) PRIMER FOR NUCLEIC ACID AMPLIFICATION E-292-2013-0 Filing authorized Centers for Disease Control and Prevention (CDC) 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-2745] Photoinduced Electron Transfer Fluorescent Primer for Nucleic Acid Amplification&body=Please send me information about technology [TAB-2745] Photoinduced Electron Transfer Fluorescent Primer for Nucleic Acid Amplification. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-2745] Photoinduced Electron Transfer Fluorescent Primer for Nucleic Acid Amplification&body=Please send me information about technology [TAB-2745] Photoinduced Electron Transfer Fluorescent Primer for Nucleic Acid Amplification.">benjamin.hurley@nih.gov</a><br> 114161992 E-292-2013-0 E-292-2013-0-US-05 PHOTOINDUCED ELECTRON TRANSFER (PET) PRIMER FOR NUCLEIC ACID AMPLIFICATION DIV US 15/043,713 Abandoned US <br />Divisional (DIV) 15/043,713<br />Filed on 2016-02-15<br />Status: Abandoned 114167553 E-292-2013-0 E-292-2013-0-US-01 PHOTOINDUCED ELECTRON TRANSFER (PET) PRIMER FOR NUCLEIC ACID AMPLIFICATION PRV US 60/989,768 Abandoned US <br />Provisional (PRV) 60/989,768<br />Filed on 2007-11-21<br />Status: Abandoned 114167554 E-292-2013-0 E-292-2013-0-PCT-02 PHOTOINDUCED ELECTRON TRANSFER (PET) PRIMER FOR NUCLEIC ACID AMPLIFICATION PCT Patent Cooperation Treaty PCT/US2008/084347 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2008/084347<br />Filed on 2008-11-21<br />Status: Expired 114167555 E-292-2013-0 E-292-2013-0-US-04 PHOTOINDUCED ELECTRON TRANSFER (PET) PRIMER FOR NUCLEIC ACID AMPLIFICATION National Stage US 9,260,746 12/743,607 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9260746 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9260746">9,260,746</a><br />Filed on 2010-05-19<br />Status: Issued 114124902 AXXXXX 114124903 ACXXXX 114124904 AC4XXX 114124905 AC5XXX 114124906 AC6XXX 114124907 AAXXXX 114124908 AA5XXX 114124909 AE1BXX 114124910 AG1XXX 114124912 AA2XXX 114124913 VAXXXX 114124914 VBXXXX 114124915 VCXXXX 114124916 VDXXXX 114124917 VEXXXX 114124918 VGXXXX 114124919 VHXXXX 114124920 VIXXXX 114124921 VJXXXX 114124922 VKXXXX 114124923 VLXXXX 114124924 VMXXXX 114124925 VNXXXX 114124926 VOXXXX 114124927 VPXXXX 114124928 WAXXXX 114124929 WBXXXX 114124930 WCXXXX 114124931 WFXXXX 114124932 WGXXXX 114124933 WHXXXX 114124934 WIXXXX 114124935 WMXXXX 114124936 XBXXXX 114124937 XCXXXX 114124938 XEXXXX 114124939 XHXXXX 114124940 YBXXXX 114146256 PHOTOINDUCED 114146257 ELECTRON 114146258 TRANSFER 114146259 PET 114146260 PRIMER 114146261 Nucleic 114146262 Acid 114146263 amplification 114146264 CDC Docket Import 114146265 CDC Docket Import CDC Prosecuting 114146266 OID-NCEZID-DFWED TAB-2741 114096920 Fluorescent Primer(s) Creation for Nucleic Acid Detection and Amplification CDC Cardiology, Computational models/software, Consumer Products, Dental, Diagnostics, Endocrinology, Geriatrics, Immunology, Infectious Disease, Licensing, Neurology, Occupational Safety and Health, Oncology, Ophthalmology, Psychiatry/Mental Health, Research Equipment, Research Materials, Software / Apps, Therapeutics, Vaccines Cardiology Computational models/software Consumer Products Dental Diagnostics Endocrinology Geriatrics Immunology Infectious Disease Licensing Neurology Occupational Safety and Health Oncology Ophthalmology Psychiatry/Mental Health Research Equipment Research Materials Software / Apps Therapeutics Vaccines Vincent Hill, Jothikumar Narayanan CDC researchers have developed technology that consists of a simple and inexpensive technique for creating fluorescent labeled primers for nucleic acid amplification. Fluorescent chemical-labeled probes and primers are extensively used in clinical and research laboratories for rapid, real-time detection and identification of microbes and genetic sequences. During nucleic acid amplification, the "UniFluor" primer is incorporated into newly synthesized double stranded DNA. As a consequence, quenching of the dye's fluorescent signal occurs decreasing the fluorescence of the sample several fold. The decrease in fluorescence can be measured and observed using any commercially available nucleic acid amplification system that measures fluorescence (e.g., real-time PCR/thermocyclers). Because many real-time PCR applications require a multitude of fluorescently labeled primers or probes, the single-labeled primer technique also allows researchers and clinicians to perform their work at lower cost. <ul> <li>Simple to implement</li> <li>Rapid, real-time detection</li> <li>Used with standard laboratory equipment capable of monitoring fluorescence-intensity shifts</li> <li>Cost-effective</li> <li>Easily adapted for use in kits or arrays</li> </ul> <ul> <li>Quantitative detection and/or amplification of specified nucleic acid sequences</li> <li>Efficient fluorescence-labeling of oligonucleotides</li> <li>Pyro-sequencing</li> <li>Basic laboratory research</li> </ul> Several international patent applications pending or issued 2022-03-08 2025-04-24 2025-04-24 2020-03-09 AA5XXX, AAXXXX, AC3XXX, AC4XXX, AC5XXX, Acid, ACXXXX, AXXXXX, CDC Docket Import, CDC Docket Import CDC Prosecuting, Detection, Nucleic, OID-NCEZID-DFWED, PRIMER, VAXXXX, VBXXXX, VCXXXX, VDXXXX, VEXXXX, VFXXXX, VGXXXX, VHXXXX, VIXXXX, VJXXXX, VKXXXX, VLXXXX, VMXXXX, VNXXXX, VOXXXX, VPXXXX, WAXXXX, WBXXXX, WCXXXX, WFXXXX, WIXXXX, XBXXXX, XEXXXX, XHXXXX, YBXXXX False True In vitro data available True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract E-273-2013-0 E-292-2013-0 E-458-2013-0 114108456 Hill, Vincent CDC - DIR CDC Hill, Vincent (CDC) 0 114108455 Narayanan, Jothikumar CDC - DIR CDC Narayanan, Jothikumar (CDC) 1 114108455 Narayanan, Jothikumar CDC - DIR CDC Narayanan, Jothikumar (CDC) 1 114108456 Hill, Vincent CDC - DIR CDC Hill, Vincent (CDC) 0 114102059 Primer For Nucleic Acid Detection E-252-2013-0 Closed Centers for Disease Control and Prevention (CDC) 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-2741] Fluorescent Primer(s) Creation for Nucleic Acid Detection and Amplification&body=Please send me information about technology [TAB-2741] Fluorescent Primer(s) Creation for Nucleic Acid Detection and Amplification. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-2741] Fluorescent Primer(s) Creation for Nucleic Acid Detection and Amplification&body=Please send me information about technology [TAB-2741] Fluorescent Primer(s) Creation for Nucleic Acid Detection and Amplification.">benjamin.hurley@nih.gov</a><br> 114167539 E-252-2013-0 E-252-2013-0-US-03 Primer For Nucleic Acid Detection ORD US 11/325,270 Abandoned US <br />Ordinary Patent (ORD) 11/325,270<br />Filed on 2006-01-03<br />Status: Abandoned 114167540 E-252-2013-0 E-252-2013-0-PCT-02 Primer For Nucleic Acid Detection PCT Patent Cooperation Treaty PCT/US2006/000175 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2006/000175<br />Filed on 2006-01-03<br />Status: Expired 114167541 E-252-2013-0 E-252-2013-0-US-01 Primer For Nucleic Acid Detection PRV US 60/641,303 Abandoned US <br />Provisional (PRV) 60/641,303<br />Filed on 2005-01-03<br />Status: Abandoned 114167542 E-252-2013-0 E-252-2013-0-US-08 Primer For Nucleic Acid Detection CON US 7,709,626 12/267,869 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7709626 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7709626">7,709,626</a><br />Filed on 2006-01-03<br />Status: Abandoned 114124814 AXXXXX 114124815 AAXXXX 114124816 AA5XXX 114124817 ACXXXX 114124818 AC3XXX 114124819 AC4XXX 114124820 AC5XXX 114124821 VAXXXX 114124822 VBXXXX 114124823 VCXXXX 114124824 VDXXXX 114124825 VEXXXX 114124826 VFXXXX 114124827 VGXXXX 114124828 VHXXXX 114124829 VIXXXX 114124830 VJXXXX 114124831 VKXXXX 114124832 VLXXXX 114124833 VMXXXX 114124834 VNXXXX 114124835 VOXXXX 114124836 VPXXXX 114124837 WAXXXX 114124838 WBXXXX 114124839 WCXXXX 114124840 WFXXXX 114124841 WIXXXX 114124842 XBXXXX 114124843 XEXXXX 114124844 XHXXXX 114124845 YBXXXX 114146219 PRIMER 114146220 Nucleic 114146221 Acid 114146222 Detection 114146223 CDC Docket Import 114146224 CDC Docket Import CDC Prosecuting 114146225 OID-NCEZID-DFWED TAB-2615 114096809 Nucleic Acid Amplification Technique for Rapid Diagnostic Analysis CDC Diagnostics, Infectious Disease, Licensing, Rare/Neglected Diseases Diagnostics Infectious Disease Licensing Rare/Neglected Diseases Vincent Hill, Prithiviraj Jothikumar, Jothikumar Narayanan CDC researchers developed a simple target-specific isothermal nucleic acid amplification technique, termed Genome Exponential Amplification Reaction (GEAR). The method employs a set of four primers (two inner and two outer). The outer primer pair targets three specific nucleic acid sequences at a constant 60°C, while the inner pair of primers accelerates and improves the sensitivity of the assay. The GEAR technique is an improvement over loop-mediated isothermal amplification (LAMP) in three ways. First, the GEAR method uses two Tab primers which target three genomic regions (corresponding LAMP primers target four regions). Second, the GEAR method features complementary 5' ends between the forward and reverse primers. Third, the GEAR method does not require a second set of outer primers (LAMP requires two outermost primers). Additionally, the GEAR isothermal method can be performed in a relatively inexpensive water bath or heating block, with detection of amplification products by fluorescence, thus making it suitable for low resource settings. <ul> <li>Rapid, portable, cost-effective</li> <li>Useful in low resource settings</li> <li>A “single-tube” assay that eliminates need for thermal cyclers or gel electrophoresis</li> <li>Unlike many other isothermal amplification approaches, GEAR can be efficiently performed at temperatures exceeding 60 °C, increasing specificity and accuracy</li> </ul> <ul> <li>Rapid diagnostic analysis of biological samples</li> <li>Qualitative and quantitative analysis of nucleic acids</li> <li>Low-cost diagnostics for malaria, tuberculosis, and other infectious diseases</li> </ul> 2022-03-08 2025-04-24 2025-04-24 2020-03-09 AA2XXX, AA5XXX, AAXXXX, AC4XXX, AC5XXX, Acids, ACXXXX, amplification, AMPLIFYING, AXXXXX, DA1XXX, DA2XXX, DA3XXX, DA4XXX, DA5XXX, DAXXXX, DXXXXX, Exponential, Gear, Genome, Isothermal, Methods, Nucleic, REACTION, REAGENTS, UBXXXX False True <ul> <li>Pre-clinical</li> <li>In vitro data available</li> </ul> True NIHTT 37470483 Website Abstract E-252-2013-0 E-292-2013-0 E-458-2013-0 114171879 Prithiviraj J, et al. http://www.ncbi.nlm.nih.gov/pubmed/22450319 <a href="http://www.ncbi.nlm.nih.gov/pubmed/22450319">Prithiviraj J, et al.</a> 114172072 Jothikumar P, et al. http://www.ncbi.nlm.nih.gov/pubmed/24424127 <a href="http://www.ncbi.nlm.nih.gov/pubmed/24424127">Jothikumar P, et al.</a> 114108066 Jothikumar, Prithiviraj CDC - DIR Jothikumar, Prithiviraj 0 114108067 Hill, Vincent CDC - DIR CDC Hill, Vincent (CDC) 0 114108065 Narayanan, Jothikumar CDC - DIR CDC Narayanan, Jothikumar (CDC) 1 114108065 Narayanan, Jothikumar CDC - DIR CDC Narayanan, Jothikumar (CDC) 1 114108066 Jothikumar, Prithiviraj CDC - DIR Jothikumar, Prithiviraj 0 114108067 Hill, Vincent CDC - DIR CDC Hill, Vincent (CDC) 0 114101933 Isothermal Genome Exponential Amplification Reaction ("GEAR") E-273-2013-0 Filing authorized Centers for Disease Control and Prevention (CDC) 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-2615] Nucleic Acid Amplification Technique for Rapid Diagnostic Analysis&body=Please send me information about technology [TAB-2615] Nucleic Acid Amplification Technique for Rapid Diagnostic Analysis. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-2615] Nucleic Acid Amplification Technique for Rapid Diagnostic Analysis&body=Please send me information about technology [TAB-2615] Nucleic Acid Amplification Technique for Rapid Diagnostic Analysis.">benjamin.hurley@nih.gov</a><br> 114167202 E-273-2013-0 E-273-2013-0-PCT-01 METHODS AND REAGENTS FOR AMPLIFYING NUCLEIC ACIDS PCT Patent Cooperation Treaty PCT/US2012/049784 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2012/049784<br />Filed on 2012-08-06<br />Status: Expired 114168063 E-273-2013-0 E-273-2013-0-US-02 METHODS AND REAGENTS FOR AMPLIFYING NUCLEIC ACIDS National Stage US 9,809,845 14/419,641 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9809845 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9809845">9,809,845</a><br />Filed on 2015-02-04<br />Status: Issued 114123587 AA2XXX 114123588 AA5XXX 114123589 AC5XXX 114123590 AC4XXX 114123591 DAXXXX 114123592 UBXXXX 114123593 DA1XXX 114123594 DA2XXX 114123595 DA3XXX 114123596 DA4XXX 114123597 DA5XXX 114123598 DXXXXX 114123599 AXXXXX 114123600 AAXXXX 114123601 ACXXXX 114144862 Methods 114144863 REAGENTS 114144864 AMPLIFYING 114144865 Nucleic 114144866 Acids 114144867 Isothermal 114144868 Genome 114144869 Exponential 114144870 amplification 114144871 REACTION 114144872 Gear TAB-3433 114097308 Stable Human Cell Lines Expressing Flavivirus Virus-Like Particles (VLPs) for Vaccine, Biologics, and Diagnostic Development CDC Antibodies, Collaboration, Consumer Products, Diagnostics, Immunology, Infectious Disease, Licensing, Occupational Safety and Health, Research Materials, Therapeutics, Vaccines Antibodies Collaboration Consumer Products Diagnostics Immunology Infectious Disease Licensing Occupational Safety and Health Research Materials Therapeutics Vaccines Gwong-Jen Chang, Brent Davis Flaviviruses such as Zika virus, dengue virus, West Nile virus, yellow fever virus, and Japanese encephalitis virus cause widespread illness and death throughout the world. Typically, flaviviruses get transmitted through the bite of infected mosquitoes and ticks. <br /><br /> CDC has identified and characterized distinct flavivirus cross-reactive epitopes (specific pieces of the antigen to which an antibody binds) that can improve serodiagnosis and vaccination against flaviviruses. CDC’s new flavivirus VLPs have structural proteins as the basis to form the viral particles. They do not have a viral genome so they are non-infectious. <br /><br /> For the base, CDC researchers adapted human embryonic kidney 293 (HEK-293) cells, which are FDA-approved for use in producing biologics, in a serum-free and animal protein-free culture media, then propagated these as suspension cells. Researchers introduced an optimized plasmid to form the virus-like particles (VLPs) or non-structural protein 1 (NS1) into the cells and selected stably expressing cell populations for use to produce diagnostic antigens or immunogens for human and animal flavivirus vaccines. CDC’s method of selecting cell lines does not use an antibiotic to obtain the VLP- or NS1-expressed HEK-293 cell clone versus traditional clonal selection methods which rely on antibiotics. CDC inventors further optimized the cell lines for stability over time. Some VLP-expressed clones to date have stayed in continuous culture and maintained VLP expression level for a year without sign of gene expression deterioration. Thus far, some in vivo data is available in rabbits and mice. Partners can incorporate the technology directly into a manufacturing pipeline for vaccines, biologics, or diagnostics. <ul> <li>Suitable for use as human and animal vaccines and diagnostic antigens</li> <li>VLP strategy has proven effectiveness in CDC's West Nile virus (WNV) and dengue vaccine development</li> <li>Some of these antigens are being utilized in commercially available FDA-approved diagnostic test kits</li> <li>Stable over time (e.g., some clones for a year) without sign of gene expression deterioration</li> <li>Produced from FDA-approved cell lines</li> <li>Selected without antibiotics and propagated in a serum-free and animal protein-free culture media </li> <li>Partners can directly incorporate the cell lines into a manufacturing pipeline for vaccines, biologics, or diagnostics</li> </ul> <ul> <li>For use in human and animal vaccine and biologics development against flaviviruses such as dengue virus, yellow fever virus, Zika virus, Japanese encephalitis, West Nile virus, Japanese encephalitis virus, St. Louis encephalitis virus, Powassan virus, and others</li> <li>Improved serological diagnostics for flaviviruses in humans and animals and adaptable to kit format</li> <li>Public health monitoring and surveillance for flaviviruses</li> <li>Quality assurance and quality control for vaccine development</li> <li>Research and development </li> </ul> The CDC Technology Transfer Office (TTO) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize: Stable Human Cell Lines Expressing Flavivirus Virus-Like Particles (VLPs) for Vaccine, Biologics, and Diagnostic Development. For collaboration opportunities, please contact CDC TTO at <a href="mailto:tto@cdc.gov">tto@cdc.gov</a> or 1-404-639-1330. 2022-03-08 2025-04-24 2025-04-24 2021-02-19 1, 293, Cell, CLONES, Expressing, HEK, Method, NONSTRUCTURAL, NS1, Premembrane/envelop, prM/E, Protein, SELECTING, VLXXXX, VOXXXX, WBXXXX, WFXXXX, WHXXXX, WIXXXX, WMXXXX, WNXXXX, XAXXXX, XEXXXX, XKXXXX, YBXXXX, YCXXXX False True True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract E-030-2017-0 114110174 Chang, Gwong-Jen CDC - DIR CDC Chang, Gwong-Jen (CDC) 0 114110173 Davis, Brent CDC - DIR CDC Davis, Brent (CDC) 1 114110173 Davis, Brent CDC - DIR CDC Davis, Brent (CDC) 1 114110174 Chang, Gwong-Jen CDC - DIR CDC Chang, Gwong-Jen (CDC) 0 114102556 Method Of Selecting HEK 293 Cell Clones Expressing Premembrane/envelop Or Nonstructural Protein 1 (prM/E Or NS1) E-203-2018-0 Research Material Centers for Disease Control and Prevention (CDC) 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-3433] Stable Human Cell Lines Expressing Flavivirus Virus-Like Particles (VLPs) for Vaccine, Biologics, and Diagnostic Development&body=Please send me information about technology [TAB-3433] Stable Human Cell Lines Expressing Flavivirus Virus-Like Particles (VLPs) for Vaccine, Biologics, and Diagnostic Development. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-3433] Stable Human Cell Lines Expressing Flavivirus Virus-Like Particles (VLPs) for Vaccine, Biologics, and Diagnostic Development&body=Please send me information about technology [TAB-3433] Stable Human Cell Lines Expressing Flavivirus Virus-Like Particles (VLPs) for Vaccine, Biologics, and Diagnostic Development.">benjamin.hurley@nih.gov</a><br> 114168278 E-203-2018-0 E-203-2018-0-PCT-02 STABLE HUMAN CELL LINES EXPRESSING FLAVIVIRUS VIRUS-LIKE PARTICLES AND USES THEREOF PCT Patent Cooperation Treaty PCT/US2021/030823 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/030823<br />Filed on 2021-05-05<br />Status: Expired 114169099 E-203-2018-0 E-203-2018-0-US-01 Method Of Selecting HEK 293 Cell Clones Expressing Premembrane/envelop Or Nonstructural Protein 1 (prM/E Or NS1) PRV US 63/021,852 Abandoned US <br />Provisional (PRV) 63/021,852<br />Filed on 2020-05-08<br />Status: Abandoned 114128397 YBXXXX 114128398 YCXXXX 114128399 VLXXXX 114128400 VOXXXX 114128401 WBXXXX 114128402 WFXXXX 114128403 WHXXXX 114128404 WIXXXX 114128405 WNXXXX 114128406 WMXXXX 114128407 XAXXXX 114128408 XEXXXX 114128409 XKXXXX 114152051 Method 114152052 SELECTING 114152053 HEK 114152054 293 114152055 Cell 114152056 CLONES 114152057 Expressing 114152058 Premembrane/envelop 114152059 NONSTRUCTURAL 114152060 Protein 114152061 1 114152062 prM/E 114152063 NS1 TAB-3438 114097312 Monoclonal Antibodies for Detection of Rabies Virus Antigen and Confirmatory Rabies Diagnosis CDC Antibodies, Collaboration, Consumer Products, Diagnostics, Immunology, Infectious Disease, Licensing, Occupational Safety and Health, Research Materials Antibodies Collaboration Consumer Products Diagnostics Immunology Infectious Disease Licensing Occupational Safety and Health Research Materials Asiya Chida, Jason Goldstein, Claire Hartloge, Joo Lee, Michael Niezgoda, Lillian Orciari, Subbian Panayampalli, Xiaoling Tang, Pamela Yager According to the World Health Organization (WHO), rabies causes greater than 59,000 deaths every year in over 150 countries as of 2017. A rapid and reliable diagnostic test for rabies is critical for prophylaxis considerations in humans bitten by animals as well as for basic surveillance and animal rabies control programs. The World Organization of Animal Health (OIE) and WHO Expert Committee on Rabies recently approved the direct rapid immunohistochemical test (DRIT) for rabies diagnostics. DRIT uses a light microscope and does not require any specialized equipment such as a freezer and incubator. There is a critical need for the reagents used for DRIT, however, as they are not currently available from any commercial source.<br /><br/> To meet this need, CDC researchers developed four murine anti-rabies monoclonal antibodies (mAbs), then prepared two cocktails for use in DRIT as reagents to detect rabies virus (RABV) antigen in just over 1 hour using a light microscope to read slides. The mAbs have demonstrated high sensitivity and specificity for detection of RABV and non-rabies lyssaviruses antigen. The first cocktail has the ability to detect all the RABV variants that circulate in North America, and the second cocktail of two mAbs has the ability to recognize non-rabies lyssaviruses found outside the Americas. The DRIT technique with CDC’s technology can be used for routine rabies diagnosis and enhanced rabies surveillance, particularly in conjunction with oral rabies wildlife vaccination and canine rabies elimination programs. A diagnostic DRIT kit has been designed in quantities compatible with use by low and high volume laboratories without wastage packaged in convenient 10 ml bottles capable of testing 100-200 samples. This technique offers an alternative method to direct fluorescent antibody testing (DFA) for primary diagnosis of RABV infection in infected patients or animals and adaptability for field testing. The mAbs are currently in production. <ul> <li> The first cocktail of two monoclonal antibodies has the ability to detect all the rabies virus (RABV) variants that circulate in North America</li> <li> The second cocktail of two different mAbs should be able to detect non-rabies lyssaviruses found outside the Americas</li> <li> DRIT Reagent 1 has demonstrated sensitivity greater than 99% and specificity of 100% for detection of RABV antigen and non-rabies lyssaviruses antigen. DRIT Reagent 2 is still under evaluation and its sensitivity and specificity information will be updated in the future.</li> <li> Rapid test for the detection of RABV antigen in approximately 1 hour</li> <li> Alternative method for primary diagnosis of RABV in infected humans or animals</li> <li>Useful test for low-resource settings requiring only a light microscope and refrigeration for long-term storage of reagents</li> </ul> <ul> <li> Part of a DRIT kit for rapid detection of RABV antigen</li> <li> Alternative rabies diagnostic and confirmatory testing when the routine DFA test is unavailable</li> <li>Microscopic antigen detection test for field use if held on icepacks or where refrigeration is available</li> <li> Human or veterinary/zoonotic specimen testing</li> <li> Monitoring and public health surveillance</li> <li>Research tool</li> </ul> The CDC Technology Transfer Office (TTO) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize - Monoclonal Antibodies for Detection of Rabies Virus Antigen and Definitive Rabies Diagnosis. For collaboration opportunities, please contact CDC TTO at <a href="mailto:tto@cdc.gov">tto@cdc.gov</a> or 1-404-639-1330. 2022-03-08 2025-04-24 2025-04-24 2021-03-12 antibodies, ANTIGEN, Detection, Direct, DRIT, IMMUNOHISTOCHEMICAL, Lyssavirus, monoclonal, NUCLEOPROTEIN, rabies, RAPID, Specific, test, VLXXXX, VOXXXX, WBXXXX, WFXXXX, WHXXXX, WIXXXX, WMXXXX, XAXXXX, YBXXXX, YCXXXX False True True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract E-070-2016-0 E-180-2013-0 E-224-2018-0 E-263-2013-0 E-470-2013-0 E-326-2013-0 E-298-2013-0 E-256-2013-0 114172599 Lembo, T et al. https://www.ncbi.nlm.nih.gov/pubmed/16494761 <a href="https://www.ncbi.nlm.nih.gov/pubmed/16494761">Lembo, T et al.</a> 114172600 Dyer, JL et al. https://www.ncbi.nlm.nih.gov/pubmed/23541783 <a href="https://www.ncbi.nlm.nih.gov/pubmed/23541783">Dyer, JL et al.</a> 114110183 Niezgoda, Michael CDC - DIR CDC Niezgoda, Michael (CDC) 0 114110184 Yager, Pamela CDC - DIR CDC Yager, Pamela (CDC) 0 114110185 Panayampalli, Subbian CDC - DIR CDC Panayampalli, Subbian (CDC) 0 114110186 Goldstein, Jason CDC - DIR CDC Goldstein, Jason (CDC) 0 114110187 Lee, Joo CDC - DIR CDC Lee, Joo (CDC) 0 114110188 Tang, Xiaoling CDC - DIR CDC Tang, Xiaoling (CDC) 0 114110189 Chida, Asiya CDC - DIR CDC Chida, Asiya (CDC) 0 114110190 Hartloge, Claire CDC - DIR CDC Hartloge, Claire (CDC) 0 114110182 Orciari, Lillian CDC - DIR CDC Orciari, Lillian (CDC) 1 114110182 Orciari, Lillian CDC - DIR CDC Orciari, Lillian (CDC) 1 114110183 Niezgoda, Michael CDC - DIR CDC Niezgoda, Michael (CDC) 0 114110184 Yager, Pamela CDC - DIR CDC Yager, Pamela (CDC) 0 114110185 Panayampalli, Subbian CDC - DIR CDC Panayampalli, Subbian (CDC) 0 114110186 Goldstein, Jason CDC - DIR CDC Goldstein, Jason (CDC) 0 114110187 Lee, Joo CDC - DIR CDC Lee, Joo (CDC) 0 114110188 Tang, Xiaoling CDC - DIR CDC Tang, Xiaoling (CDC) 0 114110189 Chida, Asiya CDC - DIR CDC Chida, Asiya (CDC) 0 114110190 Hartloge, Claire CDC - DIR CDC Hartloge, Claire (CDC) 0 114102562 Direct Rapid Immunohistochemical Test (DRIT) For Lyssavirus Antigen Detection Using Rabies Nucleoprotein Specific Monoclonal Antibodies E-054-2021-0 Research Material Centers for Disease Control and Prevention (CDC) 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-3438] Monoclonal Antibodies for Detection of Rabies Virus Antigen and Confirmatory Rabies Diagnosis&body=Please send me information about technology [TAB-3438] Monoclonal Antibodies for Detection of Rabies Virus Antigen and Confirmatory Rabies Diagnosis. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-3438] Monoclonal Antibodies for Detection of Rabies Virus Antigen and Confirmatory Rabies Diagnosis&body=Please send me information about technology [TAB-3438] Monoclonal Antibodies for Detection of Rabies Virus Antigen and Confirmatory Rabies Diagnosis.">benjamin.hurley@nih.gov</a><br> 114128435 YBXXXX 114128436 YCXXXX 114128437 VLXXXX 114128438 VOXXXX 114128439 WBXXXX 114128440 WFXXXX 114128441 WHXXXX 114128442 WIXXXX 114128443 WMXXXX 114128444 XAXXXX 114152104 Direct 114152105 RAPID 114152106 IMMUNOHISTOCHEMICAL 114152107 test 114152108 DRIT 114152109 Lyssavirus 114152110 ANTIGEN 114152111 Detection 114152112 rabies 114152113 NUCLEOPROTEIN 114152114 Specific 114152115 monoclonal 114152116 antibodies TAB-3440 114097310 Monoclonal Antibody that Detects a Subclass of Dog IgG—for Diagnostic and Research Applications CDC Antibodies, Collaboration, Consumer Products, Diagnostics, Immunology, Infectious Disease, Licensing, Research Materials Antibodies Collaboration Consumer Products Diagnostics Immunology Infectious Disease Licensing Research Materials Vitaliano Cama, Jeffrey Priest, Sharon Roy CDC and collaborating researchers have developed a new monoclonal antibody that recognizes canine IgG (likely IgG4 subclass). This anti-dog IgG reagent could be used to detect antibody reactions to a variety of antigens and has potential use in a wide variety of diagnostic or research applications.<br /><br /> The team used the published method of Mazza et al. (1993) to isolate a canine IgG fraction (peak Z) and used that fraction to create a new monoclonal antibody. The new monoclonal antibody appears to specifically recognize a particular subclass of canine IgG (likely IgG4) with high reactivity and low background. Very few commercial reagents are available for the detection of canine IgG antibodies, and none react as well as the newly created monoclonal antibody. <ul> <li>Improved detection of canine IgG antibodies over the limited, currently available commercial reagents</li> <li>Specific recognition of a particular subclass of canine IgG (likely IgG4) with high reactivity and low background</li> </ul> <ul> <li>Anti-dog IgG reagent to detect antibody reactions to a variety of antigens</li> <li>Use in a wide variety of diagnostic or research applications</li> <li> Use to develop or improve diagnostic or research methods that require canine antibody detection</li> <li> IgG4 responses are typically observed during parasitic infections with roundworms such as heartworm and hookworm</li> </ul> For collaboration opportunities, please contact CDC TTO at <a href="mailto:tto@cdc.gov">tto@cdc.gov</a> or 1-404-639-1330 2022-03-08 2025-04-24 2025-04-24 2021-04-27 ANTIBODY, Anti-IgG4, Dog, IgG, Likely, monoclonal, Recognizes, SPECIFICALLY, Subclass, That, VOXXXX, VQXXXX, WBXXXX, WIXXXX, WMXXXX, XAXXXX, YBXXXX, YCXXXX False True True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114109233 Roy, Sharon CDC - DIR CDC Roy, Sharon (CDC) 0 114109234 Cama, Vitaliano CDC - DIR CDC Cama, Vitaliano (CDC) 0 114109235 Priest, Jeffrey CDC - DIR CDC Priest, Jeffrey (CDC) 1 114109235 Priest, Jeffrey CDC - DIR CDC Priest, Jeffrey (CDC) 1 114109233 Roy, Sharon CDC - DIR CDC Roy, Sharon (CDC) 0 114109234 Cama, Vitaliano CDC - DIR CDC Cama, Vitaliano (CDC) 0 114101200 Monoclonal Antibody That Specifically Recognizes A Subclass Of Dog IgG (likely Anti-IgG4) E-001-2021-0 Research Material Centers for Disease Control and Prevention (CDC) 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-3440] Monoclonal Antibody that Detects a Subclass of Dog IgG—for Diagnostic and Research Applications&body=Please send me information about technology [TAB-3440] Monoclonal Antibody that Detects a Subclass of Dog IgG—for Diagnostic and Research Applications. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-3440] Monoclonal Antibody that Detects a Subclass of Dog IgG—for Diagnostic and Research Applications&body=Please send me information about technology [TAB-3440] Monoclonal Antibody that Detects a Subclass of Dog IgG—for Diagnostic and Research Applications.">benjamin.hurley@nih.gov</a><br> 114128445 YBXXXX 114128446 YCXXXX 114128447 VQXXXX 114128448 VOXXXX 114128449 WBXXXX 114128450 WIXXXX 114128451 WMXXXX 114128452 XAXXXX 114152129 monoclonal 114152130 ANTIBODY 114152131 That 114152132 SPECIFICALLY 114152133 Recognizes 114152134 Subclass 114152135 Dog 114152136 IgG 114152137 Likely 114152138 Anti-IgG4 TAB-3458 114097327 Novel Antiviral—Griffithsin Derived from Algae—for Prophylaxis or Treatment of Rabies Infection CDC Collaboration, Licensing Collaboration Licensing Nadia Gallardo Romero, Barry O'Keefe, Kenneth Palmer Rabies virus (RABV) infection leads to fatal encephalitis—inflammation of the brain—if left untreated. Millions of people survive RABV infection each year due to timely administration of post-exposure treatment, however, nearly 60,000 people die from rabies each year according to the World Health Organization. Obstacles to timely treatment for RABV infection include the high cost and burdensome storage requirements (i.e., refrigeration) of current post-exposure treatments (i.e., rabies immunoglobulin (RIG)). <br /><br /> CDC tested a broad-spectrum antiviral from a protein found in red alga, <em>Griffitshia</em> sp., that offers a low-cost way to potentially prevent or treat infections from rabies virus. Researchers determined that <em>Griffithsin</em> (GRFT) neutralizes rabies virus (RABV) activity <em>in vitro and in vivo</em>. Currently, with the exception of RIG and another international monoclonal antibody-based product, no other antiviral compounds have approvals for prophylaxis or treatment of rabies infection.<br /><br /> In CDC experiments, 100% of hamsters treated initially with one dose of GRFT, in combination with four dose of rabies vaccine, survived when challenged with a high dose of rabies virus 28 days later. GRFT also has some effect against rabies virus when used alone and can potentially replace RIG for rabies post-exposure therapeutics.<br /><br /> Manufacturers have already recombined and mass-produced GRFT as a biological active compound in E. coli and tobacco plants which could make this an easy to manufacture and low-cost antiviral. Lastly, GRFT has high thermostability with a melting temperature of 80°C/176°F so it can remain stable if cold chain interruptions occur during transportation or storage. This characteristic makes it ideal for rural areas. <ul> <li>Broad spectrum antiviral activity</li> <li> May prevent rabies infection pre-exposure) and potentially may treat humans and animals post-exposure to rabies virus (e.g., if given shortly after potential rabies exposure)</li> <li> Cost-effective and easy to manufacture; already being manufactured and available</li> <li> Compound has improved thermal stability (only melts at high temperatures of 80°C/176°F) and does not require refrigeration.</li> <li>Experiments showed that 100% of hamsters treated initially with one dose of GRFT, in combination with four dose of rabies vaccine, survived when challenged with a high dose of rabies virus 28 days later</li> </ul> <ul> <li>Human or animal rabies antiviral / therapeutic </li> <li>Stabilizer of rabies vaccine and/or RIG at room temperature</li> <li>Substitute of rabies immune globulin (RIG) in post-exposure prophylaxis</li> <li>Post-exposure (before symptom onset) prophylactic drug either alone or in conjunction with rabies vaccine and/or RIG</li> <li>Vaccine research</li> </ul> The CDC Technology Transfer Office (TTO) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize: Novel Antiviral—<em>Griffithsin</em> Derived from Algae—for Prophylaxis or Treatment of Rabies Infection. For collaboration opportunities, please contact CDC TTO at <a href="mailto:tto@cdc.gov">tto@cdc.gov</a> or 1-404-639-1330. 2022-03-08 2025-04-24 2025-04-24 2021-10-28 2021-10-27 2XXXXX, Against, Algae, ANTIVIRAL, Broad, Combat, DISEASE:, EVALUATION, Fatal, Griffithsin, Infection., Novel, rabies, Spectrum, UTILIZING, virus False True True NIHTT 37470483 Website Abstract E-263-2013-0 E-326-2013-0 E-298-2013-0 114172615 Rabies in the Americas (RITA) Conference 2019 abstract and presentation. Gallardo-Romero, Nadia et al. Rabies in the Americas (RITA) Conference 2019 abstract and presentation. Gallardo-Romero, Nadia et al. 114110266 Palmer, Kenneth University of Louisville Palmer, Kenneth 0 114110267 O'Keefe, Barry NCI - CCR NCI O'Keefe, Barry (NCI) 0 114110265 Gallardo Romero, Nadia CDC - DIR CDC Gallardo Romero, Nadia (CDC) 1 114110265 Gallardo Romero, Nadia CDC - DIR CDC Gallardo Romero, Nadia (CDC) 1 114110266 Palmer, Kenneth University of Louisville Palmer, Kenneth 0 114110267 O'Keefe, Barry NCI - CCR NCI O'Keefe, Barry (NCI) 0 114102578 Utilizing An Algae To Combat A Fatal Disease: Evaluation Of A Novel Broad Spectrum Antiviral Griffithsin Against Rabies Virus Infection. E-036-2020-0 Filing authorized Centers for Disease Control and Prevention (CDC), NCI, University of Louisville 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-3458] Novel Antiviral—Griffithsin Derived from Algae—for Prophylaxis or Treatment of Rabies Infection &body=Please send me information about technology [TAB-3458] Novel Antiviral—Griffithsin Derived from Algae—for Prophylaxis or Treatment of Rabies Infection . Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-3458] Novel Antiviral—Griffithsin Derived from Algae—for Prophylaxis or Treatment of Rabies Infection &body=Please send me information about technology [TAB-3458] Novel Antiviral—Griffithsin Derived from Algae—for Prophylaxis or Treatment of Rabies Infection .">benjamin.hurley@nih.gov</a><br> 114169166 E-036-2020-0 E-036-2020-0-PCT-01 GRIFFITHSIN FOR RHABDOVIRIDAE INFECTIONS PCT Patent Cooperation Treaty PCT/US2020/054930 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2020/054930<br />Filed on 2020-10-09<br />Status: Expired 114128493 2XXXXX 114152297 UTILIZING 114152298 Algae 114152299 Combat 114152300 Fatal 114152301 DISEASE: 114152302 EVALUATION 114152303 Novel 114152304 Broad 114152305 Spectrum 114152306 ANTIVIRAL 114152307 Griffithsin 114152308 Against 114152309 rabies 114152310 virus 114152311 Infection. TAB-3656 114097510 Bat Restraint for Blood Sample Collection CDC Consumer Products, Infectious Disease, Medical Devices, Non-Medical Devices, Occupational Safety and Health, Research Materials Consumer Products Infectious Disease Medical Devices Non-Medical Devices Occupational Safety and Health Research Materials Jeremy Jones, Matthew Mauldin, Clint Morgan Many agencies, universities, zoos, and research labs need to collect blood from bats. Currently, disease surveillance in bats has high costs and requires considerable time and a high degree of skill for blood collection. In addition, current collection techniques for non-sedated bats typically require two people, with one restraining the bat while the other collects the blood sample. This can cause stress to the animal, inefficient blood draws (both for sample quality and potential additional attempts), and a safety risk to the field researchers or laboratory scientists (for potential bites or needle sticks while handling the animal). Bats and rodents are important zoonotic disease reservoirs with need for continued research. Although there are restraint devices designed for rodents, no commercially available blood collection restraints exist for bats. <br /><br /> The team developed a proof-of-concept bat restraint and successfully used it in the lab. Researchers then consulted 3D printing experts to develop this product for CDC’s internal uses. Collaborators designed a prototype and produced 3D printed model iterations. All laboratory scientists that participated in piloting the device agreed the device improved safety for both the bats and staff. These safety concerns are important in all animal handling settings, especially when handling infected animals. <br /><br /> The adapted device reduces the potential risks of needle sticks to researchers, reduces the stress on the animal, and increases the efficiency of blood collection and blood sample quality. The restraint lessens the need for bat manipulation and enables a safer and more efficient collection of blood performed by a single individual. This device can help public health efforts by improving techniques involved with bat-disease surveillance and laboratory study activities, leading to more successful outcomes and higher quality lab analyses. This device will work for use in field and laboratory settings.<br /><br /> CDC plans to further develop this device by adjusting the bat capsule dimensions and augmenting the restraint size to accommodate multiple bat species. The device can be scaled easily and made into multiple sizes/configurations for needed fit. CDC would like to produce and market these devices through a corporate partnership — or license them to laboratory research and/or bat research supply companies for sale on their existing platforms. <ul> <li>Increased safety for researchers handling bats</li> <li> Less handling and stress to the bats with improved blood draw efficiency (both for sample quality/quantity and potentially fewer attempts needed)</li> <li>Time and cost savings with less need for highly skilled workers to collect blood</li> <li>Blood collection performed by only one individual</li> <li> Easily scaled and adaptable for different bat sizes and species</li> <li>Appropriate for field and laboratory use</li> </ul> <ul> <li>Restraint method for blood sample collection in bats</li> <li>Monitoring and public health surveillance</li> <li> Research studies/research tool</li> <li>A tool for use in therapeutic and vaccine development</li> <li>Quality assurance/quality control</li> <li> Veterinary use</li> </ul> The CDC Technology Transfer Office (TTO) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize Bat Restraint for Blood Sample Collection. For collaboration opportunities, please contact CDC TTO at <a href="mailto:tto@cdc.gov">tto@cdc.gov</a> or 1-404-639-1330. 2022-05-23 2025-04-24 2025-04-24 2022-05-20 2AXXXX, 2XXXXX, Bat, Blood, COLLECTION, Restraint, VJXXXX, VKXXXX, VLXXXX, VOXXXX, VQXXXX, WFXXXX, WGXXXX, WHXXXX, WIXXXX, WMXXXX, XDXXXX False True True 52406769 Prototype 52406769 NIHTT 37470483 Website Abstract 114172812 Clint N. Morgan, A Novel Restraint Device to Improve Safety and Efficacy of Blood Collection During Non-Terminal Sampling of Bats; biorxiv.org 2022 March 25 https://doi.org/10.1101/2022.03.22.483499 <a href="https://doi.org/10.1101/2022.03.22.483499">Clint N. Morgan, A Novel Restraint Device to Improve Safety and Efficacy of Blood Collection During Non-Terminal Sampling of Bats; biorxiv.org 2022 March 25</a> 114111173 Mauldin, Matthew CDC - NIOSH Mauldin, Matthew 0 114111174 Jones, Jeremy Produced Better INC. Jones, Jeremy 0 114111172 Morgan, Clint CDC - NIOSH Morgan, Clint 1 114111172 Morgan, Clint CDC - NIOSH Morgan, Clint 1 114111173 Mauldin, Matthew CDC - NIOSH Mauldin, Matthew 0 114111174 Jones, Jeremy Produced Better INC. Jones, Jeremy 0 114102761 Bat Restraint For Blood Collection E-180-2021-0 Closed Centers for Disease Control and Prevention (CDC), Produced Better INC. 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-3656] Bat Restraint for Blood Sample Collection&body=Please send me information about technology [TAB-3656] Bat Restraint for Blood Sample Collection. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-3656] Bat Restraint for Blood Sample Collection&body=Please send me information about technology [TAB-3656] Bat Restraint for Blood Sample Collection.">benjamin.hurley@nih.gov</a><br> 114169498 E-180-2021-0 E-180-2021-0-US-01 BAT RESTRAINT PRV US 63/311,887 Expired US <br />Provisional (PRV) 63/311,887<br />Filed on 2022-02-18<br />Status: Expired 114129098 2XXXXX 114129099 2AXXXX 114129100 WFXXXX 114129101 VJXXXX 114129102 VKXXXX 114129103 VQXXXX 114129104 VLXXXX 114129105 VOXXXX 114129106 WGXXXX 114129107 WHXXXX 114129108 WIXXXX 114129109 WMXXXX 114129110 XDXXXX 114154129 Bat 114154130 Restraint 114154131 Blood 114154132 COLLECTION TAB-5030 159328089 Monoclonal Antibodies to Fentanyl Analogs for Research, Therapeutics, and Novel Diagnostics CDC Antibodies, Diagnostics, Licensing, Research Materials, Therapeutics Antibodies Diagnostics Licensing Research Materials Therapeutics Jason Goldstein, Rebekah Wharton <p>Fentanyl is a synthetic opioid drug approved by the Food and Drug Administration for use as an analgesic (pain relief) and anesthetic. However, synthetic opioids, such as fentanyl, are prone to abuse and are the primary drivers of overdose related deaths in the United States. As little as two milligrams of fentanyl can be lethal. Furthermore, structural variants of fentanyl, often mixed with other drugs or counterfeit pills are illegally distributed without the user&rsquo;s knowledge. There is great need for assay methods that could simultaneously detect fentanyl variants and provide information about their cross-reactivity and the metabolites. Law enforcement and emergency responders who encounter overdose victims or illegal drugs in the field would benefit from reliable, rapid, inexpensive, and easily interpreted assays to better treat patients, protect themselves from exposure, and trace the origins of the hazardous compounds.</p> <p>Using immunogenic virus-like particles (VLPs) carrying various fentanyl analogs, CDC researchers have developed new monoclonal antibodies (mAbs) that are specifically designed to detect multiple fentanyl analogs simultaneously with high affinity and at lower limits of detection when compared to current immunoassay methods. These mAbs have the potential to be developed into a rapid, sensitive, point of care lateral flow assay to improve detection of fentanyl analogs compared to existing commercial products for diagnostic or harm reduction purposes. These antibodies could also be used in development of therapeutic agents to help prevent deaths from fentanyl related overdose.</p> <ul> <li> High affinity and at lower limits of detection for fentanyl analogs </li> </ul> <ul> <li> Detection of fentanyl and its analogs in biological and non-biological specimens.</li> <li> Development of point of care devices for detection of fentanyl and its analogs.</li> <li> Development of therapeutics to treat fentanyl overdose in patients.</li> </ul> The CDC is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize development of POC for detecting fentanyl analogs and therapeutics to treat fentanyl related overdose. For collaboration opportunities, please contact: Madhavi Sriram nxu2@cdc.gov ; TTO@cdc.gov 2024-11-25 2025-04-24 2025-04-24 2024-12-06 False False Early Stage In vitro data available True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 159402829 Goldstein, Jason CDC - DIR CDC Goldstein, Jason (CDC) 1 159402833 Wharton, Rebekah CDC - DIR Wharton, Rebekah 2 159402829 Goldstein, Jason CDC - DIR CDC Goldstein, Jason (CDC) 1 159402833 Wharton, Rebekah CDC - DIR Wharton, Rebekah 2 159328092 Development of Monoclonal Antibodies to Fentanyl Analogs for Research, Therapeutics, and Novel Diagnostics E-014-2025-0 Research Material CDC - DIR, Georgia Institute of Technology 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-5030] Monoclonal Antibodies to Fentanyl Analogs for Research, Therapeutics, and Novel Diagnostics&body=Please send me information about technology [TAB-5030] Monoclonal Antibodies to Fentanyl Analogs for Research, Therapeutics, and Novel Diagnostics. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-5030] Monoclonal Antibodies to Fentanyl Analogs for Research, Therapeutics, and Novel Diagnostics&body=Please send me information about technology [TAB-5030] Monoclonal Antibodies to Fentanyl Analogs for Research, Therapeutics, and Novel Diagnostics.">benjamin.hurley@nih.gov</a><br> TAB-5041 159674720 Henipavirus Vaccine CDC Collaboration, Diagnostics, Infectious Disease, Licensing, Respiratory, Vaccines Collaboration Diagnostics Infectious Disease Licensing Respiratory Vaccines Markus Kainulainen, Michael Lo, Stuart Nichol, Jessica Spengler, Christina Spiropoulou, Stephen Welch <p>Henipaviruses are RNA viruses containing two high consequence human pathogens: Nipah virus (NiV) and Hendra virus (HeV). Both NiV and HeV infection in humans can result in severe respiratory disease and/or severe neurological manifestations, with mortality rates as high as 80%. There are currently no FDA-approved vaccines or therapeutics, and both NiV and HeV are considered dangerous emerging human pathogens with pandemic potential.</p> <p>CDC researchers have developed novel Nipah Virus Replicon Particles (VRPs) using reverse genetics-based system. The developed VRP vaccine has been shown to be safe and effective in preventing NiV disease in highly sensitive small animal model of disease (Syrian hamster and immunodeficient mice). In these studies, single-dose vaccination at 28, 14, and 7 days prior to challenge resulted in up to 100% survival, and significant reduction in incidence of clinical disease. All unvaccinated animals exhibited clinical signs of infection, and 50&ndash;100 % mortality, depending on the model. Importantly, the vaccine was given intranasally and efficacy via this route of vaccination has not been previously shown. The production system of the VRP vaccine does not use infectious NiV which minimizes safety concerns regarding incomplete removal of any infectious component of the final product, and the VRP platform could be rapidly modified to produce analogous vaccine candidates for any emerging, high-consequence, pathogenic henipaviruses.</p> <ul> <li> Public Health: Vaccine delivery as a nasal spray; evidence of rapid onset of protective efficacy after a single dose. </li> <li> Antiviral screening: BSL-2 tool that covers all authentic viral processes aside from egress, therefore multiple advantages over traditional VLPs, pseudo virus, mini-genome approaches. </li> <li> Diagnostics: Removes need for BSL4 facilities to generate reagents and assays needed for NiV/HeV diagnostic assays. </li> </ul> <ul> <li> Public Health: Human NiV vaccine. </li> <li> Agriculture: Animal/Veterinary NiV vaccine (pigs, horses). </li> <li> Antiviral screening: BSL-2 antiviral screening tool Pandemic response: Platform can be adapted to rapidly produce analogous vaccine candidates for any newly emerging henipaviruses based on nucleotide information alone. </li> <li> Diagnostics: Allows generation of diagnostic assays and reagents in BSL-2 facilities. </li> </ul> The CDC is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize these VRPs as potential vaccines candidates against Nipah and Henipavirus infections and/or as diagnostic platforms to detect such infections. For collaboration opportunities, please contact: Madhavi Sriram nxu2@cdc.gov ; TTO@cdc.gov 2024-12-17 2025-04-24 2025-04-24 2024-12-17 False False True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 159675255 Stephen R. Welch, et al., "Defective Interfering Viral Particle Treatment Reduces Clinical Signs and Protects Hamsters from Lethal Nipah Virus disease", Pub Med (Defective Interfering Viral Particle Treatment Reduces Clinical Signs and Protects Hamsters from Lethal Nipah Virus Disease - PubMed). Stephen R. Welch, et al., "Defective Interfering Viral Particle Treatment Reduces Clinical Signs and Protects Hamsters from Lethal Nipah Virus disease", Pub Med (Defective Interfering Viral Particle Treatment Reduces Clinical Signs and Protects Hamsters from Lethal Nipah Virus Disease - PubMed). 159674826 Welch, Stephen NIH - CDC CDC Welch, Stephen (CDC) 1 159674851 Lo, Michael NIH - CDC CDC Lo, Michael (CDC) 2 159674872 Kainulainen, Markus NIH - CDC CDC Kainulainen, Markus (CDC) 3 159675095 Spengler, Jessica NIH - CDC CDC Spengler, Jessica (CDC) 4 159675101 Spiropoulou, Christina NIH - CDC CDC Spiropoulou, Christina (CDC) 5 159675107 Nichol, Stuart NIH - CDC Nichol, Stuart 6 159674826 Welch, Stephen NIH - CDC CDC Welch, Stephen (CDC) 1 159674851 Lo, Michael NIH - CDC CDC Lo, Michael (CDC) 2 159674872 Kainulainen, Markus NIH - CDC CDC Kainulainen, Markus (CDC) 3 159675095 Spengler, Jessica NIH - CDC CDC Spengler, Jessica (CDC) 4 159675101 Spiropoulou, Christina NIH - CDC CDC Spiropoulou, Christina (CDC) 5 159675107 Nichol, Stuart NIH - CDC Nichol, Stuart 6 159674723 Henipavirus Virus Replicon Particles (VRP) System Based Vaccine E-182-2021-0 Filing authorized Centers for Disease Control and Prevention (CDC) 91016739 Hurley, Benjamin benjamin.hurley@nih.gov
United States of America benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-5041] Henipavirus Vaccine&body=Please send me information about technology [TAB-5041] Henipavirus Vaccine. Hurley, Benjamin<br><a href="mailto:benjamin.hurley@nih.gov?subject=Web Inquiry on [TAB-5041] Henipavirus Vaccine&body=Please send me information about technology [TAB-5041] Henipavirus Vaccine.">benjamin.hurley@nih.gov</a><br> 159795132 E-182-2021-0 E-182-2021-0-PC-01 NIPAH HENIPAVIRUS VIRUS REPLICON PARTICLES AND THEIR USE PCT Patent Cooperation Treaty PCT/US2022/082645 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2022/082645<br />Filed on 2022-12-30<br />Status: Expired TAB-3955 147157235 Video Monitoring and Analysis System for Vivarium Cage Racks NCI Collaboration, Licensing, Oncology, Software / Apps Collaboration Licensing Oncology Software / Apps James Mitchell, Thomas Pohida, Ghadi Salem <p>This invention pertains to a system for continuous observation of rodents in home-cage environments with the specific aim to facilitate the quantification of activity levels and behavioral patterns for mice housed in a commercial ventilated cage rack.  The home-cage in-rack provides daytime and nighttime monitoring with the stability and consistency of a home cage environment. The system is made up of a dual-video camera hardware design mounted on a video rack and an executable software means for automatic detection and processing for tracking multiple animals. The <a href="https://ccr.cancer.gov/Radiation-Biology-Branch" target="_blank" rel="nofollow">National Cancer Institute’s Radiation Biology Branch</a> seeks partners interested in licensing or collaborative research to co-develop a video monitoring system for laboratory animals.</p> <h2>Competitive Advantages:</h2> <ul><li>Real-time monitoring</li> <li>Continuous day/night monitoring</li> <li>Multiple circadian cycle activity and behavior data</li> <li>Home-cage environment video</li> <li>Scalable system – easy installation of large number of units per rack</li> <li>Low real-estate consumption</li> <li>High throughput</li> <li>Low-cost</li> <li>Ability to monitoring multiple mice.</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Laboratory animals health monitoring</li> <li>Laboratory rodents activity profiling</li> <li>Laboratory rodents behavior analysis</li> <li>Video-monitoring for rodent therapeutic and drug effect studies</li> <li>Behavior and activity analysis for animal model characterization</li> <li>Rodent circadian/sleep cycle studies</li> <li>Vivarium rodents birth/death monitoring.</li> </ul> 2016-02-16 2025-04-24 2018-07-19 2025-04-24 2016-08-30 behavior analysis, home-cage, VIDEO, vivarium monitoring False True Prototype True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2018-07-19 52406769 Prototype 52406769 NCI 37470483 Website Abstract 147163006 Mitchell, James NIH - NCI NCI Mitchell, James (NCI) 1 147163008 Salem, Ghadi NIH - CIT CIT Salem, Ghadi (CIT) 2 147163007 Pohida, Thomas NIH - CIT CIT Pohida, Thomas (CIT) 3 147163006 Mitchell, James NIH - NCI NCI Mitchell, James (NCI) 1 147163008 Salem, Ghadi NIH - CIT CIT Salem, Ghadi (CIT) 2 147163007 Pohida, Thomas NIH - CIT CIT Pohida, Thomas (CIT) 3 147157963 A Video-based Monitoring System For Continuous In-ventilated Rack Video Acquisition And Analysis To Assess Mouse Activit And Behavior E-090-2013-0 Filing authorized CIT, NCI 83673032 Whitney, Laurie WhitneyL@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC WhitneyL@mail.nih.gov?subject=Web Inquiry on [TAB-3955] Video Monitoring and Analysis System for Vivarium Cage Racks&body=Please send me information about technology [TAB-3955] Video Monitoring and Analysis System for Vivarium Cage Racks.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Whitney, Laurie<br><a href="mailto:WhitneyL@mail.nih.gov?subject=Web Inquiry on [TAB-3955] Video Monitoring and Analysis System for Vivarium Cage Racks&body=Please send me information about technology [TAB-3955] Video Monitoring and Analysis System for Vivarium Cage Racks.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">WhitneyL@mail.nih.gov</a><br> 147165528 E-090-2013-0 E-090-2013-0-US-01 Systems and Methods of Video Monitoring for Vivarium Cage Racks PRV US 61/841,064 Abandoned US <br />Provisional (PRV) 61/841,064<br />Filed on 2013-06-28<br />Status: Abandoned 147165529 E-090-2013-0 E-090-2013-0-PCT-02 Systems and Methods of Video Monitoring for Vivarium Cages PCT Patent Cooperation Treaty PCT/US2014/044923 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2014/044923<br />Filed on 2014-06-30<br />Status: Expired 147165530 E-090-2013-0 E-090-2013-0-US-06 Systems and Methods of Video Monitoring for Vivarium Cages National Stage US 10,905,094 14/901,130 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10905094 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10905094">10,905,094</a><br />Filed on 2015-12-28<br />Status: Abandoned 147165531 E-090-2013-0 E-090-2013-0-CA-03 Systems and Methods of Video Monitoring for Vivarium Cages National Stage Canada 2916975 Abandoned Canada <br />National Stage 2916975<br />Filed on 2014-06-30<br />Status: Abandoned 147165532 E-090-2013-0 E-090-2013-0-EP-04 Systems and Methods of Video Monitoring for Vivarium Cages National Stage European Patent 3013141 14816642.4 Abandoned European Patent <br />National Stage 14816642.4<br />Filed on 2014-06-30<br />Status: Abandoned 147165533 E-090-2013-0 E-090-2013-0-AU-05 Systems and Methods of Video Monitoring for Vivarium Cages National Stage Australia 2014302060 2014302060 Abandoned Australia <br />National Stage 2014302060<br />Filed on 2014-06-30<br />Status: Abandoned 147165534 E-090-2013-0 E-090-2013-0-AU-07 Systems and Methods of Video Monitoring for Vivarium Cages DIV Australia 2017265176 Abandoned Australia <br />Divisional (DIV) 2017265176<br />Filed on 2017-11-27<br />Status: Abandoned 147171168 behavior analysis 147171170 home-cage 147171171 VIDEO 147171173 vivarium monitoring TAB-4060 147157342 Biomarker for Predicting Taxane Chemotherapy Outcome NCI Diagnostics, Licensing, Oncology Diagnostics Licensing Oncology Sandra Swain, Sherry Yang <p>Over the past decades, taxanes such as paclitaxel and docetaxel have emerged as effective chemotherapy agents for breast cancer and other malignancies. Taxanes are effective in many patients, however, not all patients benefit from this type of chemotherapy. A significant need remains for a means of predicting clinical outcome from taxane-based chemotherapy.</p> <p> Akt, a serine/threonine kinase that can block apoptosis, has been implicated in the regulation of microtubule dynamics and organization. Akt phosphorylation and its transducing downstream events play a central role in cell survival and cell cycle progression at the G2/M transition. Paclitaxel or docetaxel inhibits Akt-Ser473 phosphorylation (pAkt) and induces mitotic arrest. Therefore, taxanes may cause more damage to tumor cells that are dependent on pAkt for survival and cell cycle progression, significantly impacting treatment outcome.</p> <p> Researchers at the National Cancer Institute identified pAkt as having predictive significance for paclitaxel chemotherapy outcome in patients with early stage breast cancer. The researchers have developed an immunohistochemistry method for determining pAkt status with appropriate controls for assay performance and cutoff for pAkt positivity. They also discovered methods of correlating pAkt expression with clinical outcome (disease-free survival and overall survival). pAkt is a novel predictive marker of taxane chemotherapy, and can be applied to indicate which patients should receive taxane-based chemotherapy.</p> <h2>Competitive Advantages:</h2> <p>pAkt is a useful clinical predictive marker to determine which patients should or should not receive taxane-based chemotherapy for cancer. Determining pAkt status would allow patients with pAkt-positive tumors to elect taxane therapy for whom are likely to benefit, and allow patients with pAkt-negative tumors for whom are unlikely to benefit to be spared from taxane therapy as well as toxicity, and earlier use of other therapies that could be more effective.</p> <h2>Commercial Applications:</h2> <p>- A kit for identifying pAkt-positive tumors in surgical tumor specimens or tumor biopsies prior to treatment (adjuvant, neoadjuvant therapy or therapy for metastatic disease);<br /> - Methods for predicting clinical outcome from taxane chemotherapy.</p> 2016-02-16 2025-04-24 2017-08-09 2025-04-24 2017-08-09 APOPTOSIS, Biomarkers, Docetaxel, Immunohistochemistry, PACLITAXEL, pAkt, taxane False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2017-08-09 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147163383 Yang, Sherry NIH - NCI NCI Yang, Sherry (NCI) 1 147163382 Swain, Sandra NCI Swain, Sandra (NCI) 2 147163383 Yang, Sherry NIH - NCI NCI Yang, Sherry (NCI) 1 147163382 Swain, Sandra NCI Swain, Sandra (NCI) 2 147158179 Akt-Ser473 Phosphorylation And Taxane-Based Chemotherapy E-191-2009-0 Filing authorized NCI 83673032 Whitney, Laurie WhitneyL@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC WhitneyL@mail.nih.gov?subject=Web Inquiry on [TAB-4060] Biomarker for Predicting Taxane Chemotherapy Outcome&body=Please send me information about technology [TAB-4060] Biomarker for Predicting Taxane Chemotherapy Outcome.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Whitney, Laurie<br><a href="mailto:WhitneyL@mail.nih.gov?subject=Web Inquiry on [TAB-4060] Biomarker for Predicting Taxane Chemotherapy Outcome&body=Please send me information about technology [TAB-4060] Biomarker for Predicting Taxane Chemotherapy Outcome.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">WhitneyL@mail.nih.gov</a><br> 147166263 E-191-2009-0 E-191-2009-0-US-01 Akt-Ser473 Phosphorylation And Taxane-Based Chemotherapy PRV US 61/180,558 Abandoned US <br />Provisional (PRV) 61/180,558<br />Filed on 2009-05-22<br />Status: Abandoned 147166264 E-191-2009-0 E-191-2009-0-PCT-02 AKT PHOSPHORYLATION AT SER473 AS AN INDICATOR FOR TAXANE-BASED CHEMOTHERAPY PCT Patent Cooperation Treaty PCT/US2010/035816 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2010/035816<br />Filed on 2010-05-21<br />Status: Expired 147166265 E-191-2009-0 E-191-2009-0-AU-03 Akt Phosphorylation at SER473 as an Indicator for Taxane-Based Chemotherapy National Stage Australia 2010249401 2010249401 Abandoned Australia <br />National Stage 2010249401<br />Filed on 2010-05-21<br />Status: Abandoned 147166266 E-191-2009-0 E-191-2009-0-CA-04 Akt Phosphorylation at SER473 as an Indicator for Taxane-Based Chemotherapy National Stage Canada 2762983 Abandoned Canada <br />National Stage 2762983<br />Filed on 2010-05-21<br />Status: Abandoned 147166267 E-191-2009-0 E-191-2009-0-EP-05 Akt Phosphorylation at SER473 as an Indicator for Taxane-Based Chemotherapy National Stage European Patent 2432872 10722881.9 Issued European Patent <br />National Stage 10722881.9<br />Filed on 2010-05-21<br />Status: Issued 147166268 E-191-2009-0 E-191-2009-0-JP-06 Akt Phosphorylation at SER473 as an Indicator for Taxane-Based Chemotherapy National Stage Japan 2012-512066 Abandoned Japan <br />National Stage 2012-512066<br />Filed on 2010-05-21<br />Status: Abandoned 147166269 E-191-2009-0 E-191-2009-0-US-07 AKT PHOSPHORYLATION AT SER473 AS AN INDICATOR FOR TAXANE-BASED CHEMOTHERAPY National Stage US 8,546,091 13/322,140 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8546091 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8546091">8,546,091</a><br />Filed on 2010-05-21<br />Status: Abandoned 147166270 E-191-2009-0 E-191-2009-0-US-08 AKT PHOSPHORYLATION AT SER473 AS AN INDICATOR FOR TAXANE-BASED CHEMOTHERAPY DIV US 14/031,699 Abandoned US <br />Divisional (DIV) 14/031,699<br />Filed on 2013-09-19<br />Status: Abandoned 147166271 E-191-2009-0 E-191-2009-0-JP-09 Akt Phosphorylation at SER473 as an Indicator for Taxane-Based Chemotherapy DIV Japan 2015-030517 Abandoned Japan <br />Divisional (DIV) 2015-030517<br />Filed on 2015-02-19<br />Status: Abandoned 147166272 E-191-2009-0 E-191-2009-0-CH-10 Akt Phosphorylation at SER473 as an Indicator for Taxane-Based Chemotherapy EP Switzerland 2432872 10722881.9 Abandoned Switzerland <br />European patent (EP) 10722881.9<br />Filed on 2010-05-21<br />Status: Abandoned 147166273 E-191-2009-0 E-191-2009-0-DE-11 Akt Phosphorylation at SER473 as an Indicator for Taxane-Based Chemotherapy EP Germany 2432872 10722881.9 Abandoned Germany <br />European patent (EP) 10722881.9<br />Filed on 2010-05-21<br />Status: Abandoned 147166274 E-191-2009-0 E-191-2009-0-FR-12 Akt Phosphorylation at SER473 as an Indicator for Taxane-Based Chemotherapy EP France 2432872 10722881.9 Abandoned France <br />European patent (EP) 10722881.9<br />Filed on 2010-05-21<br />Status: Abandoned 147166275 E-191-2009-0 E-191-2009-0-GB-13 Akt Phosphorylation at SER473 as an Indicator for Taxane-Based Chemotherapy EP United Kingdom 2432872 10722881.9 Abandoned United Kingdom <br />European patent (EP) 10722881.9<br />Filed on 2010-05-21<br />Status: Abandoned 147173361 APOPTOSIS 147173362 Biomarkers 147173363 Docetaxel 147173364 Immunohistochemistry 147173365 PACLITAXEL 147173367 pAkt 147173369 taxane TAB-4192 147157477 89Zr-Oxine Complex for In Vivo PET Imaging of Labelled Cells and Associated Methods NCI Collaboration, Licensing, Oncology, Research Materials Collaboration Licensing Oncology Research Materials Peter Choyke, Gary Griffiths, Noriko Sato, Haitao Wu <p>This technology from the <a href="https://ccr.cancer.gov/Molecular-Imaging-Program" rel="nofollow">NCI Molecular Imaging Program</a> relates to a Zirconium-89 (89Zr)-oxine complex for cell labeling, tracking of labeled cells by whole-body positron emission tomography/computed tomography (PET/CT) imaging, and associated methods. A long half-life of 89Zr (78.4 hours), high sensitivity of PET, and absence of background signal in the recipient enable tracking cells over a week using low levels of labeling radioactivity without causing cellular toxicity.</p> <p>The 89Zr-oxine complex is synthesized quickly by mixing components at room temperature and produces high yields. Cell labeling is achieved by a short, room temperature incubation. The 89Zr-oxine complex is capable of labeling a wide range of cell types of therapeutic or pathogenic relevance (natural, disease, engineered cells), independent of factors such as cell cycle or receptor expression. The label is retained during cell division. 89Zr-oxine labeled cells can also be easily cross labeled (for example, optically or magnetically) for multi-modality imaging and analysis.  Labeled cell migration and kinetics can be analyzed and quantified <em>in vivo</em> over a week, improving research strategies and ability to develop and improve cell therapies and diagnostics.</p> <p>This technology will be of interest to those engaged in cell-based therapies during which cells of various types are infused for therapeutic purposes.   A broad range of cells can be labeled, tracked throughout the entire body and the method is applicable to human applications.  In addition to improving the understanding of cell trafficking in general, the technology could be useful in determining whether cellular engineering improves the delivery of cells to their intended target.   </p> <p> This technology will also be of interest to those engaged in basic research on the behavior of cells of various types in the body under various physical or manipulated conditions.</p> <h2>Competitive Advantages:</h2> <ul><li>Simple preparation of a broadly-applicable cell label</li> <li>Provides high resolution imaging and monitoring over period of a week</li> <li>Low toxicity, easily combined with labeling technologies and cell therapies.</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Cell-based therapies during which cells of various types are infused for therapeutic purposes:   A broad range of cells can be labeled, tracked throughout the entire body and the method is applicable to human applications.  In addition to improving the understanding of cell trafficking in general, the technology could be useful in determining whether cellular engineering improves the delivery of cells to their intended target</li> <li>Studying behavior of cells of various types in the body under various physical or manipulated conditions.</li> </ul> 2016-02-16 2025-04-24 2016-08-31 2025-04-24 2016-08-30 89Zr, cell labeling, Oxine, zirconium-89 False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2016-08-31 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147163854 Sato, Noriko NIH - NCI NCI Sato, Noriko (NCI) 1 147163853 Wu, Haitao NIH - NHLBI NHLBI Wu, Haitao (NHLBI) 2 147163852 Griffiths, Gary NIH - NCI Griffiths, Gary 3 147163851 Choyke, Peter NIH - NCI NCI Choyke, Peter (NCI) 4 147163854 Sato, Noriko NIH - NCI NCI Sato, Noriko (NCI) 1 147163853 Wu, Haitao NIH - NHLBI NHLBI Wu, Haitao (NHLBI) 2 147163852 Griffiths, Gary NIH - NCI Griffiths, Gary 3 147163851 Choyke, Peter NIH - NCI NCI Choyke, Peter (NCI) 4 147157942 Generation And Use Of Zr-89 Oxine Complex, A Long-lasting Cell Labeling Agent For Positron EmissionTomography (PET) Imaging E-080-2014-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI), NCI 83736770 Cheng, Eric eric.cheng2@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB eric.cheng2@nih.gov?subject=Web Inquiry on [TAB-4192] 89Zr-Oxine Complex for In Vivo PET Imaging of Labelled Cells and Associated Methods&body=Please send me information about technology [TAB-4192] 89Zr-Oxine Complex for In Vivo PET Imaging of Labelled Cells and Associated Methods.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Cheng, Eric<br><a href="mailto:eric.cheng2@nih.gov?subject=Web Inquiry on [TAB-4192] 89Zr-Oxine Complex for In Vivo PET Imaging of Labelled Cells and Associated Methods&body=Please send me information about technology [TAB-4192] 89Zr-Oxine Complex for In Vivo PET Imaging of Labelled Cells and Associated Methods.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">eric.cheng2@nih.gov</a><br> 147161008 E-080-2014-0 E-080-2014-0-US-01 ZIRCONIUM-89 OXINE COMPLEX AS A CELL LABELING AGENT FOR POSITRON EMISSION TOMOGRAPHY PRV US 61/973,706 Abandoned US <br />Provisional (PRV) 61/973,706<br />Filed on 2014-04-01<br />Status: Abandoned 147167265 E-080-2014-0 E-080-2014-0-PCT-02 Zirconium-89 Oxine Complex As A Cell Labeling Agent For Positron Emission Tomography PCT Patent Cooperation Treaty PCT/US2015/023897 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2015/023897<br />Filed on 2015-04-01<br />Status: Expired 147167266 E-080-2014-0 E-080-2014-0-US-03 ZIRCONIUM-89 OXINE COMPLEX AS A CELL LABELING AGENT FOR POSITRON EMISSION TOMOGRAPHY National Stage US 10,556,916 15/300,883 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10556916 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10556916">10,556,916</a><br />Filed on 2016-09-30<br />Status: Issued 147167267 E-080-2014-0 E-080-2014-0-US-04 ZIRCONIUM-89 OXINE COMPLEX AS A CELL LABELING AGENT FOR POSITRON EMISSION TOMOGRAPHY DIV US 11,192,903 16/723,601 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11192903 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11192903">11,192,903</a><br />Filed on 2019-12-20<br />Status: Issued 147167268 E-080-2014-0 E-080-2014-0-US-05 METHOD OF PREPARING ZIRCONIUM-89 OXINE COMPLEX DIV US 12,473,307 17/532,083 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12473307 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12473307">12,473,307</a><br />Filed on 2021-11-22<br />Status: Issued 147167269 E-080-2014-0 E-080-2014-0-US-06 ZIRCONIUM-89 OXINE COMPLEX AS A CELL LABELING AGENT FOR POSITRON EMISSION TOMOGRAPHY CON US 12,649,752 17/532,109 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12649752 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12649752">12,649,752</a><br />Filed on 2021-11-22<br />Status: Issued 147170960 89Zr 147170962 cell labeling 147170963 Oxine 147170964 zirconium-89 TAB-3907 147157187 Removal of Selected Proteins Using Light Energy: Photoimmunotherapy NCI Collaboration, Licensing, Oncology, Research Materials Collaboration Licensing Oncology Research Materials Peter Choyke, Hisataka Kobayashi, Martin Schnermann <p>Researchers at the NCI  <a href="https://ccr.cancer.gov/Molecular-Imaging-Program" rel="nofollow">Laboratory of Molecular Theranostics </a>and the <a href="https://ccr.cancer.gov/Molecular-Imaging-Program" rel="nofollow">Molecular Imaging Program</a> have developed a new method to modify, isolate and remove a single chemically-labeled molecule or a cluster of proteins associated with the chemically-labeled protein. The chemical label can be an antigen-antibody complex. This discovery is based on the mechanism of photo-immunotherapy (PIT). Unlike PIT, however, which is used for direct therapy, the above-identified technology can be used for controlled drug delivery (e.g., removing unbound drug moieties from circulation) and active detoxification of potentially poisonous material (e.g. bacteria, toxins, virus, venom etc.).</p> <p>The current state of the art does not readily allow for simple labeling and isolation of proteins or other biomolecules from complex tissue samples or bodily fluids. The technology consists of using a conjugate of the dye IR700 and a biomolecule with specific binding activity, such as an antibody, to label the cell type or target molecule of interest, followed by irradiation of the sample with light in the near IR spectrum.  Upon exposure, the IR700 moiety becomes hydrophobic and aggregates, allowing for mechanical separation of the target molecule or cell type of interest as a complex with the IR700 conjugate. Labeling of cancerous cells <em>in vivo</em> with IR700 conjugates, followed by irradiation in the near IR spectrum, causes cell death.</p> <h2>Competitive Advantages:</h2> <p>Simple and versatile way to separate and remove molecules or cells from a complex mixture.</p> <h2>Commercial Applications:</h2> <p>- <em>In vivo</em> removal of toxins, pathogens or drugs from a subject<br /> - Cancer imunotherapy</p> 2016-02-16 2025-04-24 2018-04-26 2025-04-24 2016-08-31 AGGREGATION, Fluorophore, IR700, photoactivation, Photoimmunotherapy False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2018-04-26 52406768 Discovery 52406768 NCI 37470483 Website Abstract E-205-2010 147162817 Kobayashi, Hisataka NIH - NCI NCI Kobayashi, Hisataka (NCI) 1 147162819 Schnermann, Martin NIH - NCI NCI Schnermann, Martin (NCI) 2 147162818 Choyke, Peter NIH - NCI NCI Choyke, Peter (NCI) 3 147162817 Kobayashi, Hisataka NIH - NCI NCI Kobayashi, Hisataka (NCI) 1 147162819 Schnermann, Martin NIH - NCI NCI Schnermann, Martin (NCI) 2 147162818 Choyke, Peter NIH - NCI NCI Choyke, Peter (NCI) 3 147158212 Photo-controlled Modification On Selected Proteins; For Chemical Analysis, Altering Pharmacokinetics, And Targeted Cancer Therapy E-209-2014-0 Filing authorized NCI 83736770 Cheng, Eric eric.cheng2@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB eric.cheng2@nih.gov?subject=Web Inquiry on [TAB-3907] Removal of Selected Proteins Using Light Energy: Photoimmunotherapy&body=Please send me information about technology [TAB-3907] Removal of Selected Proteins Using Light Energy: Photoimmunotherapy.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Cheng, Eric<br><a href="mailto:eric.cheng2@nih.gov?subject=Web Inquiry on [TAB-3907] Removal of Selected Proteins Using Light Energy: Photoimmunotherapy&body=Please send me information about technology [TAB-3907] Removal of Selected Proteins Using Light Energy: Photoimmunotherapy.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">eric.cheng2@nih.gov</a><br> 147165154 E-209-2014-0 E-209-2014-0-US-01 PHOTO-CONTROLLED REMOVAL OF TARGETS IN VITRO AND IN VIVO PRV US 62/034,990 Abandoned US <br />Provisional (PRV) 62/034,990<br />Filed on 2014-08-08<br />Status: Abandoned 147165155 E-209-2014-0 E-209-2014-0-PCT-02 PHOTO-CONTROLLED REMOVAL OF TARGETS IN VITRO AND IN VIVO PCT Patent Cooperation Treaty PCT/US2015/044168 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2015/044168<br />Filed on 2015-08-07<br />Status: Expired 147165156 E-209-2014-0 E-209-2014-0-AU-03 PHOTO-CONTROLLED REMOVAL OF TARGETS IN VITRO AND IN VIVO National Stage Australia 2015300915 2015300915 Issued Australia <br />National Stage 2015300915<br />Filed on 2015-08-07<br />Status: Issued 147165157 E-209-2014-0 E-209-2014-0-CA-04 PHOTO-CONTROLLED REMOVAL OF TARGETS IN VITRO AND IN VIVO National Stage Canada 2954463 2954463 Issued Canada <br />National Stage 2954463<br />Filed on 2015-08-07<br />Status: Issued 147165158 E-209-2014-0 E-209-2014-0-CN-05 PHOTO-CONTROLLED REMOVAL OF TARGETS IN VITRO AND IN VIVO National Stage China ZL201580034715.1 201580034715.1 Issued China <br />National Stage 201580034715.1<br />Filed on 2015-08-07<br />Status: Issued 147165159 E-209-2014-0 E-209-2014-0-EP-06 PHOTO-CONTROLLED REMOVAL OF TARGETS IN VITRO AND IN VIVO National Stage European Patent 3177323 15760320.0 Issued European Patent <br />National Stage 15760320.0<br />Filed on 2015-08-07<br />Status: Issued 147165160 E-209-2014-0 E-209-2014-0-JP-07 PHOTO-CONTROLLED REMOVAL OF TARGETS IN VITRO AND IN VIVO National Stage Japan 6796058 2017-506895 Issued Japan <br />National Stage 2017-506895<br />Filed on 2015-08-07<br />Status: Issued 147165161 E-209-2014-0 E-209-2014-0-SG-08 PHOTO-CONTROLLED REMOVAL OF TARGETS IN VITRO AND IN VIVO National Stage Singapore 11201610052T 11201610052T Issued Singapore <br />National Stage 11201610052T<br />Filed on 2016-11-30<br />Status: Issued 147165162 E-209-2014-0 E-209-2014-0-US-09 Photo-Controlled Removal of Targets in Vitro and in Vivo National Stage US 10,830,678 15/318,104 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10830678 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10830678">10,830,678</a><br />Filed on 2016-12-12<br />Status: Issued 147165163 E-209-2014-0 E-209-2014-0-CH-10 PHOTO-CONTROLLED REMOVAL OF TARGETS IN VITRO AND IN VIVO EP Switzerland 3177323 15760320.0 Issued Switzerland <br />European patent (EP) 15760320.0<br />Filed on 2015-08-07<br />Status: Issued 147165164 E-209-2014-0 E-209-2014-0-DE-11 PHOTO-CONTROLLED REMOVAL OF TARGETS IN VITRO AND IN VIVO EP Germany 3177323 15760320.0 Issued Germany <br />European patent (EP) 15760320.0<br />Filed on 2015-08-07<br />Status: Issued 147165165 E-209-2014-0 E-209-2014-0-ES-12 PHOTO-CONTROLLED REMOVAL OF TARGETS IN VITRO AND IN VIVO EP Spain 3177323 15760320.0 Issued Spain <br />European patent (EP) 15760320.0<br />Filed on 2015-08-07<br />Status: Issued 147165166 E-209-2014-0 E-209-2014-0-FR-13 PHOTO-CONTROLLED REMOVAL OF TARGETS IN VITRO AND IN VIVO EP France 3177323 15760320.0 Issued France <br />European patent (EP) 15760320.0<br />Filed on 2015-08-07<br />Status: Issued 147165167 E-209-2014-0 E-209-2014-0-GB-14 PHOTO-CONTROLLED REMOVAL OF TARGETS IN VITRO AND IN VIVO EP United Kingdom 3177323 15760320.0 Issued United Kingdom <br />European patent (EP) 15760320.0<br />Filed on 2015-08-07<br />Status: Issued 147165168 E-209-2014-0 E-209-2014-0-IT-15 PHOTO-CONTROLLED REMOVAL OF TARGETS IN VITRO AND IN VIVO EP Italy 3177323 15760320.0 Issued Italy <br />European patent (EP) 15760320.0<br />Filed on 2015-08-07<br />Status: Issued 147165169 E-209-2014-0 E-209-2014-0-CN-16 PHOTO-CONTROLLED REMOVAL OF TARGETS IN VITRO AND IN VIVO DIV China 202010317977.1 Pending China <br />Divisional (DIV) 202010317977.1<br />Filed on 2015-08-07<br />Status: Pending 147165170 E-209-2014-0 E-209-2014-0-JP-17 PHOTO-CONTROLLED REMOVAL OF TARGETS IN VITRO AND IN VIVO DIV Japan 7075435 2020-068338 Issued Japan <br />Divisional (DIV) 2020-068338<br />Filed on 2020-04-06<br />Status: Issued 147165171 E-209-2014-0 E-209-2014-0-US-18 PHOTO-CONTROLLED REMOVAL OF TARGETS IN VITRO AND IN VIVO CON US 11,781,955 17/026,724 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11781955 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11781955">11,781,955</a><br />Filed on 2020-09-21<br />Status: Issued 147165172 E-209-2014-0 E-209-2014-0-AU-19 PHOTO-CONTROLLED REMOVAL OF TARGETS IN VITRO AND IN VIVO DIV Australia 2020294224 2020294224 Issued Australia <br />Divisional (DIV) 2020294224<br />Filed on 2020-12-23<br />Status: Issued 147165173 E-209-2014-0 E-209-2014-0-JP-20 PHOTO-CONTROLLED REMOVAL OF TARGETS IN VITRO AND IN VIVO DIV Japan 7546013 2022-079474 Issued Japan <br />Divisional (DIV) 2022-079474<br />Filed on 2022-05-13<br />Status: Issued 147173691 AGGREGATION 147173692 Fluorophore 147173694 IR700 147173696 photoactivation 147173697 Photoimmunotherapy TAB-4158 147157441 Micro-Dose Calibrator for Pre-clinical Radiotracer Assays NCI Collaboration, Immunology, Infectious Disease, Licensing, Medical Devices, Non-Medical Devices, Oncology Collaboration Immunology Infectious Disease Licensing Medical Devices Non-Medical Devices Oncology Stephen Adler <p>Molecular imaging is a disease-specific targeting modality that promises much more accurate diagnoses of serious diseases such as cancer and infections. Agents are being continually developed with a view to clinical translation, with several such therapies requiring measurement of very small doses. Currently, there is no way of accurately measuring small amounts of radioactivity used in many pre-clinical tracer studies, as on-the-market commercial dose calibrators measure at too high a dose range, typically at 10-1000 &micro;Ci and higher. Using such commercial calibrators to estimate micro-doses (0.01-10 &micro;Ci) results in unavoidable and up to &plusmn; 20% measurement errors. Alternatively, well-counters that can measure small doses are not suited for measurements of doses greater than 1 &micro;Ci, resulting in a coverage gap (1-10 &micro;Ci), a critical range for bio-distribution studies, cell binding studies, immune cell labeling techniques, and &alpha;-based therapies.</p> <p>To solve the problem of measuring a wider range of radioactivity doses, and without the need of a volumetric correction, the <a href="https://ccr.cancer.gov/Molecular-Imaging-Program" rel="nofollow">NCI </a><a href="https://ccr.cancer.gov/Molecular-Imaging-Program" rel="nofollow">Molecular Imaging Program</a> invented a device (see images below) that can accurately measure radioactivity doses between 0.1-100 &micro;Ci, &nbsp;with 1% error. The device is a working prototype and requires collaboration to manufacture it. NCI seeks parties to commercialize this technology through collaborative co-development or licensing.</p> <p><a href="https://youtu.be/6IBdHKawSds" rel="nofollow">Video abstract:</a> New and improved micro dose-calibrator designed to accurately measure radioactive doses in the range of 50 nCi to 100 &micro;Ci with 99% precision, useful in radio-ligand bio-distribution studies, cell binding studies, immune cell labeling techniques, and &alpha;-based therapies.</p> <p><img alt=" An improved device for accurately measuring the injectable dose of small amounts of radioactivity used in many pre-clinical tracer studies. The improved device can accurately measure radioactivity doses between 0.1-100 μCi with 1% error. It also replaces the need for two less accurate commercially available devices; one covering the low end of the measurement range and the other covering the high end of the range. " height="338" src="https://nih.technologypublisher.com/files/sites/e-241-2016_image_micro-dose_calibrator1.png" width="450" /></p> <p><img alt="" height="150" src="https://nih.technologypublisher.com/files/sites/small_microdosecalibrator2_01.jpg" width="150" /></p> <h2>Competitive Advantages:</h2> <ul> <li>Measure small doses between 50 nCi (1.8 kBq) and 100 &micro;Ci (3.7 MBq) with 1% accuracy</li> <li>Measure volumes of activity up to 20cc without volumetric correction to 1% accuracy</li> </ul> <h2>Commercial Applications:</h2> <ul> <li>Bio-distribution pre-clinical studies Immune cell cancer therapy</li> </ul> 2018-02-27 2025-04-24 2019-07-27 2025-04-24 2018-02-27 Adler, Dose Calibrator, imaging agent, Medical Radioisotope False True Prototype True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2019-07-27 52406769 Prototype 52406769 NCI 37470483 Website Abstract 147163725 Adler, Stephen NIH - NCI Leidos Adler, Stephen (Leidos) 1 147163725 Adler, Stephen NIH - NCI Leidos Adler, Stephen (Leidos) 1 147158258 Micro-Dose Calibrator E-241-2016-0 Filing authorized NCI 83736770 Cheng, Eric eric.cheng2@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB eric.cheng2@nih.gov?subject=Web Inquiry on [TAB-4158] Micro-Dose Calibrator for Pre-clinical Radiotracer Assays&body=Please send me information about technology [TAB-4158] Micro-Dose Calibrator for Pre-clinical Radiotracer Assays.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Cheng, Eric<br><a href="mailto:eric.cheng2@nih.gov?subject=Web Inquiry on [TAB-4158] Micro-Dose Calibrator for Pre-clinical Radiotracer Assays&body=Please send me information about technology [TAB-4158] Micro-Dose Calibrator for Pre-clinical Radiotracer Assays.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">eric.cheng2@nih.gov</a><br> 147161222 E-241-2016-0 E-241-2016-0-US-01 Micro-Dose Calibrator PRV US 62/554,980 Abandoned US <br />Provisional (PRV) 62/554,980<br />Filed on 2017-09-06<br />Status: Abandoned 147166990 E-241-2016-0 E-241-2016-0-PCT-02 Micro-Dose Calibrator PCT Patent Cooperation Treaty PCT/US2018/049399 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2018/049399<br />Filed on 2018-09-04<br />Status: Expired 147166991 E-241-2016-0 E-241-2016-0-AU-03 Micro-Dose Calibrator National Stage Australia 2018329661 2018329661 Issued Australia <br />National Stage 2018329661<br />Filed on 2018-09-04<br />Status: Issued 147166992 E-241-2016-0 E-241-2016-0-CA-04 Micro-Dose Calibrator National Stage Canada 3073559 3073559 Issued Canada <br />National Stage 3073559<br />Filed on 2018-09-04<br />Status: Issued 147166993 E-241-2016-0 E-241-2016-0-EP-05 Micro-Dose Calibrator National Stage European Patent 3679405 18779123.1 Issued European Patent <br />National Stage 18779123.1<br />Filed on 2018-09-04<br />Status: Issued 147166994 E-241-2016-0 E-241-2016-0-US-06 Micro-Dose Calibrator National Stage US 11,029,418 16/644,441 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11029418 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11029418">11,029,418</a><br />Filed on 2020-03-04<br />Status: Issued 147166995 E-241-2016-0 E-241-2016-0-US-07 RADIOACTIVE SOURCE CALIBRATION CON US 11,614,548 17/314,355 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11614548 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11614548">11,614,548</a><br />Filed on 2021-05-07<br />Status: Issued 147174134 Adler 147174136 Dose Calibrator 147174137 imaging agent 147174139 Medical Radioisotope TAB-4511 151706390 Programmable and Modular Nucleic Acid Nanoassemblies-based (NAN) Platforms to Regulate Mechanosensitive Activation of T-cells NHLBI Licensing, Research Materials Licensing Research Materials Kirill Afonin, Erdem Tabdanov, Alexander Zhovmer <p>This technology includes mechanobiological nucleic acid nanoassemblies-based platforms with dynamically controlled efficiency of T-cell activation. T-cells are the central players in adaptive immune response led by a T-cell receptor (TCR) centric machinery. Current T-cell activation strategy (e.g., micron-scale beads) focuses on 2D TCR-agonist biomimetic surfaces and biomimetic 2D immune synapses with planar traction, which requires non-physiological hyper-stimulatory cytokines levels (e.g., IL-2), and thus, is incompatible with clinical applications. This described technology is based on the programmability of nucleic acids, and is modular, user-friendly, and inexpensive platforms with spatiotemporal regulation of T-cell activation.</p> The objective of this technology is to engineer customizable, modular, and biocompatible immunostimulatory platform based on nucleic acid nanoassemblies suitable for precise and efficient mechano-spatiotemporal programming of TCR and co-receptors. This nucleic acid nanoassemblies-based technology will allow for an unprecedented control over dynamics of T-cell activation setting a stepping stone towards clinically-relevant applications of self-assembling nucleic acid nanoparticles with controlled physicochemical and biological properties and dynamically programmable mechano-spatiotemporal immunostimulatory properties. Diagnostic tests, T-cell expansion kits, and immunotherapeutic adjuvants We are seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. 2023-12-07 2024-08-12 2025-04-24 2024-03-20 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 151706397 Afonin, Kirill University of North Carolina, Charlotte Afonin, Kirill 1 151706405 Tabdanov, Erdem Pennsylvania State University Tabdanov, Erdem 2 151706409 Zhovmer, Alexander National Heart, Lung, and Blood Institute (NHLBI) NHLBI Zhovmer, Alexander (NHLBI) 3 151706397 Afonin, Kirill University of North Carolina, Charlotte Afonin, Kirill 1 151706405 Tabdanov, Erdem Pennsylvania State University Tabdanov, Erdem 2 151706409 Zhovmer, Alexander National Heart, Lung, and Blood Institute (NHLBI) NHLBI Zhovmer, Alexander (NHLBI) 3 151706393 Programmable And Modular Nucleic Acid Nanoassemblies-based (NAN) Platforms To Regulate Mechanosensitive Activation Of Tcells E-149-2020-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI), Pennsylvania State College of Medicine, University of North Carolina, Charlotte (UNC) 83739538 Choudhry, Vidita vidita.choudhry@nih.gov
United States of America Office of Technology Transfer and Development vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-4511] Programmable and Modular Nucleic Acid Nanoassemblies-based (NAN) Platforms to Regulate Mechanosensitive Activation of T-cells&body=Please send me information about technology [TAB-4511] Programmable and Modular Nucleic Acid Nanoassemblies-based (NAN) Platforms to Regulate Mechanosensitive Activation of T-cells. Choudhry, Vidita<br><a href="mailto:vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-4511] Programmable and Modular Nucleic Acid Nanoassemblies-based (NAN) Platforms to Regulate Mechanosensitive Activation of T-cells&body=Please send me information about technology [TAB-4511] Programmable and Modular Nucleic Acid Nanoassemblies-based (NAN) Platforms to Regulate Mechanosensitive Activation of T-cells.">vidita.choudhry@nih.gov</a><br> 157755318 E-149-2020-0 E-149-2020-0-US-01 PROGRAMMABLE MECHANOBIOLOGICAL PLATFORM PRV US 63/014,981 Abandoned US <br />Provisional (PRV) 63/014,981<br />Filed on 2020-04-24<br />Status: Abandoned TAB-667 114095003 Increased Protein Expression Vector for Vaccine Applications NIAID Infectious Disease, Licensing, Vaccines Infectious Disease Licensing Vaccines Gary Nabel, Zhi-yong Yang An expression vector with a unique promoter that results in higher level of protein expression than vectors currently in use is available for licensing from the NIH. The elevated levels of expression are achieved through use of a specific promoter, known as CMV/R, in which the Human T-Lymphotrophic Virus (HTLV-1) Long Terminal Repeat (LTR) R-U5 region is substituted for a portion of the intron downstream of the CMV immediate early region 1 enhancer (Barouch et al., 2005). Sequences of 95% or better homology to CMV/R can be used as well. CMV/R vectors are currently being used in a number of clinical trials, including vaccines against West Nile Virus, Ebola virus, and HIV and achieving promising results. The related HIV vaccine technology is available for licensing, as is the Ebola DNA vaccine technology (non-exclusive licensing only). The CMV/R vector can be used for any DNA vaccine or for the production of recombinant proteins in high yields. <ul> <li>Vector for DNA vaccines</li> <li>High yield expression of recombinant proteins</li> </ul> Available for non-exclusive licensing. 2022-09-28 2025-04-23 2025-04-23 2007-06-01 DCXXXX, DXXXXX, HTLV-1, HTLV-2, HTLV-3, Human T Cell Leukemia Virus 1, Human T-cell leukemia viruses type 2, Human T-lymphotropic virus type 3, WEST NILE VIRUS False True True NIHTT 37470483 Website Abstract 114104294 Nabel, Gary NIAID Nabel, Gary (NIAID) 0 114104295 Yang, Zhi-yong NIAID Yang, Zhi-yong (NIAID) 0 114104294 Nabel, Gary NIAID Nabel, Gary (NIAID) 0 114104295 Yang, Zhi-yong NIAID Yang, Zhi-yong (NIAID) 0 114099810 Development of a Preventive Vaccine for Filovirus Infection in Primate E-241-2001-0 Filing authorized Centers for Disease Control and Prevention (CDC), NIAID 114099811 Development Of A Preventive Vaccine For Filovirus Infection In Primate E-241-2001-1 Filing authorized NIAID 114099812 New Vaccine Constructs And Combinations Of Vaccines Designed To Improve The Breadth Of The Immune Response To Diverise Strains And Clades Of HIV E-267-2004-1 Filing authorized GenVec, Inc., NIAID 148673287 Hafiz, Sabrina sabrina.hafiz@nih.gov
United States of America sabrina.hafiz@nih.gov?subject=Web Inquiry on [TAB-667] Increased Protein Expression Vector for Vaccine Applications&body=Please send me information about technology [TAB-667] Increased Protein Expression Vector for Vaccine Applications. Hafiz, Sabrina<br><a href="mailto:sabrina.hafiz@nih.gov?subject=Web Inquiry on [TAB-667] Increased Protein Expression Vector for Vaccine Applications&body=Please send me information about technology [TAB-667] Increased Protein Expression Vector for Vaccine Applications.">sabrina.hafiz@nih.gov</a><br> 114161598 E-241-2001-0 E-241-2001-0-US-01 Development of a Preventive Vaccine for Filovirus Infection in Primates PRV US 60/326,476 Abandoned US <br />Provisional (PRV) 60/326,476<br />Filed on 2001-10-01<br />Status: Abandoned 114161600 E-241-2001-0 E-241-2001-0-PCT-02 Development of a Preventive Vaccine for Filovirus Infection in Primates PCT Patent Cooperation Treaty PCT/US2002/030251 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2002/030251<br />Filed on 2002-09-24<br />Status: Expired 114161601 E-241-2001-0 E-241-2001-0-US-07 Development of a Preventive Vaccine for Filovirus Infection in Primates National Stage US 7,635,688 10/491,121 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7635688 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7635688">7,635,688</a><br />Filed on 2004-08-23<br />Status: Expired 114161602 E-241-2001-1 E-241-2001-1-US-01 Development of a Preventive Vaccine for Filovirus Infection in Primate DIV US 7,094,598 10/997,120 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7094598 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7094598">7,094,598</a><br />Filed on 2004-11-24<br />Status: Expired 114161605 E-267-2004-1 E-267-2004-1-PCT-01 Vaccine Against AIDS Comprising CMV/R-Nucleic Acid Constructs PCT COMB Patent Cooperation Treaty PCT/US2005/025219 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2005/025219<br />Filed on 2005-07-15<br />Status: Expired 114161606 E-267-2004-1 E-267-2004-1-US-08 VACCINES AGAINST AIDS COMPRISING CMV/R-NUCLEIC ACID CONSTRUCTS National Stage US 11/632,522 Abandoned US <br />National Stage 11/632,522<br />Filed on 2007-01-16<br />Status: Abandoned 114165657 E-241-2001-0 E-241-2001-0-US-08 Development of a Preventive Vaccine for Filovirus Infection in Primate DIV US 8,106,026 12/612,579 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8106026 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8106026">8,106,026</a><br />Filed on 2009-11-04<br />Status: Expired 114165659 E-241-2001-0 E-241-2001-0-US-09 Development of a Preventive Vaccine for Filovirus Infection in Primates DIV US 8,106,027 12/612,621 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8106027 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8106027">8,106,027</a><br />Filed on 2009-11-04<br />Status: Expired 114165661 E-241-2001-0 E-241-2001-0-US-10 Development of a Preventive Vaccine for Filovirus Infection in Primates DIV US 8,124,592 12/612,625 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8124592 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8124592">8,124,592</a><br />Filed on 2009-11-04<br />Status: Expired 114166306 E-267-2004-1 E-267-2004-1-US-12 Method For Inducing A Multiclade Immune Response Against HIV Utilizing A Multigene and Multicalde Immunogen DIV US 8,454,972 13/010,141 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8454972 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8454972">8,454,972</a><br />Filed on 2011-01-20<br />Status: Abandoned 114114235 DCXXXX 114114236 DXXXXX 114157582 WEST NILE VIRUS 114157583 Human T-cell leukemia viruses type 2 114157584 Human T Cell Leukemia Virus 1 114157585 Human T-lymphotropic virus type 3 114158890 HTLV-2 114158891 HTLV-1 114158892 HTLV-3 TAB-1698 114095926 Chimeric SHIV Gag Proteins Optimize T-Cell Response Against HIV Gag NIAID Infectious Disease, Licensing, Vaccines Infectious Disease Licensing Vaccines Gary Nabel HIV Gag has been included in nearly all HIV vaccines entering clinical trials because of its importance in SIV models and its correlation with protection in HIV-infected long-term non-progressors. However, HIV Gag has proven less immunogenic than Env in phase I clinical trial studies. Through sequence comparison, two regions in HIV Gag have been identified as contributing to the decreased immunogenicity observed for HIV Gag. Replacement of these regions with corresponding SIV sequences significantly increased the resulting T-cell response to HIV Gag in mice. Utilization of these chimera in an HIV vaccine could significantly enhance the overall immunogenicity of the vaccine. HIV vaccine Available for licensing. 2022-09-28 2025-04-23 2025-04-23 2007-12-01 Against, Cell, chimeric, DC5AXX, DC5XXX, DCXXXX, Development, Duke DNA Project, DXXXXX, Filovirus, GAG, HIV, HIV/SIV, Infection, Optimize, PREVENTIVE, primate, proteins, Responses, T, Vaccine, Vaccine-Induced False True Animal (mouse) data available Animal (mouse) data available True NIHTT 37470483 Website Abstract 114105945 Nabel, Gary NIAID - VRC NIAID Nabel, Gary (NIAID) 1 114105945 Nabel, Gary NIAID - VRC NIAID Nabel, Gary (NIAID) 1 114100916 Development Of A Preventive Vaccine For Filovirus Infection In Primate E-241-2001-1 Filing authorized NIAID 114100917 Use Of Chimeric HIV/SIV Gag Proteins To Optimize Vaccine-Induced T Cell Responses Against HIV Gag E-304-2007-0 Filing authorized Beth Israel Deaconess Medical Center, NIAID 148673287 Hafiz, Sabrina sabrina.hafiz@nih.gov
United States of America sabrina.hafiz@nih.gov?subject=Web Inquiry on [TAB-1698] Chimeric SHIV Gag Proteins Optimize T-Cell Response Against HIV Gag&body=Please send me information about technology [TAB-1698] Chimeric SHIV Gag Proteins Optimize T-Cell Response Against HIV Gag. Hafiz, Sabrina<br><a href="mailto:sabrina.hafiz@nih.gov?subject=Web Inquiry on [TAB-1698] Chimeric SHIV Gag Proteins Optimize T-Cell Response Against HIV Gag&body=Please send me information about technology [TAB-1698] Chimeric SHIV Gag Proteins Optimize T-Cell Response Against HIV Gag.">sabrina.hafiz@nih.gov</a><br> 114164124 E-241-2001-1 E-241-2001-1-US-01 Development of a Preventive Vaccine for Filovirus Infection in Primate DIV US 7,094,598 10/997,120 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7094598 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7094598">7,094,598</a><br />Filed on 2004-11-24<br />Status: Expired 114164125 E-304-2007-0 E-304-2007-0-US-01 Use Of Chimeric HIV/SIV Gag Proteins To Optimize Vaccine-Induced T Cell Responses Against HIV Gag PRV US 60/965,268 Abandoned US <br />Provisional (PRV) 60/965,268<br />Filed on 2007-08-17<br />Status: Abandoned 114164622 E-304-2007-0 E-304-2007-0-PCT-02 Use Of Chimeric HIV/SIV Gag Proteins To Optimize Vaccine-Induced T Cell Responses Against HIV Gag PCT Patent Cooperation Treaty PCT/US2008/073395 Abandoned Patent Cooperation Treaty <br />(PCT) PCT/US2008/073395<br />Filed on 2008-08-15<br />Status: Abandoned 114118401 DC5AXX 114118402 DCXXXX 114118403 DXXXXX 114118949 DC5XXX 114131714 chimeric 114131715 HIV/SIV 114131716 GAG 114131717 proteins 114131718 Optimize 114131719 Vaccine-Induced 114131720 T 114131721 Cell 114131722 Responses 114131723 Against 114131724 HIV 114131725 Development 114131726 PREVENTIVE 114131727 Vaccine 114131728 Filovirus 114131729 Infection 114131730 primate 114131731 Duke DNA Project TAB-3335 114097251 Self-assembling Insect Ferritin Nanoparticles for Display of Co-assembled Trimeric Antigens NIAID Licensing Licensing Ulrich Baxa, Rita Chen, Cheng Cheng, Aliaksandr Druz, Ivelin Georgiev, Barney Graham, Michael Joyce, Masaru Kanekiyo, Peter Kwong, John Mascola, Guillaume Stewart-Jones, Paul Thomas, Yaroslav Tsybovsky, Joseph Van Galen, Yongping Yang Antigens on the surface of virus particles are displayed in a regular, repetitive pattern which facilitates B cell activation. Presenting trimeric antigens on engineered particles that mimic the geometric patterns observed for native viral proteins can lead to an improved host antibody response.<br /><br /> Self-assembling globular ferritin nanoparticles have previously been used to display multiple copies of a co-assembled trimeric antigen to the immune system. However, prior ferritin nanoparticle technologies only permit a random co-assembly of diverse trimeric antigens, and therefore cannot guarantee the pattern and ratio of diverse trimeric antigens on a single ferritin nanoparticle.<br /><br /> Researchers at the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases are developing novel recombinant ferritin nanoparticles that are based on insect ferritin proteins, and that have been engineered to display two different trimeric antigens in a defined ratio and geometric pattern. This system has been tested with antigens derived from HIV-1 envelope (Env) and influenza hemagglutinin (HA). Interestingly, when guinea pigs are immunized with ferritin nanoparticles displaying two different trimeric antigens, induced B cells could simultaneously recognize both trimeric antigens, thus leading to an immune response with improved neutralization breadth.<br /><br /> This technology can be used as a platform for multimerized display of trimeric antigens such as viral type I fusion glycoproteins, and may be applied to many high-priority vaccine targets, such as HIV-1, influenza, respiratory syncytial virus, parainfluenza viruses, and coronaviruses. <ul> <li>Particles have equal fractions of two different antigens in a specific configuration on the nanoparticle surface (unlike regular ferritin used previously)</li> <li>Designed particles have a geometry that allows for attachment of trimeric antigens (unlike the native insect ferritin).</li> </ul> <ul> <li>Platform for multimerized immunogen presentation and vaccine design.</li> <li>Vaccines for pathogens that use genetic diversity to escape the immune response.</li> </ul> 2022-07-27 2025-04-23 2025-04-23 2018-10-17 ANTIGENS, Bi-component, Coassembled, DISPLAY, Nanoparticles, SELF-ASSEMBLING, Trimeric False True True NIHTT 37470483 Website Abstract E-531-2013-0 E-293-2011-0 E-060-2015-0 114172541 Georgiev I, et al. I https://pubs.acs.org/doi/10.1021/acsinfecdis.7b00192 <a href="https://pubs.acs.org/doi/10.1021/acsinfecdis.7b00192">Georgiev I, et al. I</a> 114109887 Georgiev, Ivelin NIAID - VRC NIAID Georgiev, Ivelin (NIAID) 0 114109888 Joyce, Michael NIAID - VRC NIAID Joyce, Michael (NIAID) 0 114109889 Stewart-Jones, Guillaume NIAID - VRC NIAID Stewart-Jones, Guillaume (NIAID) 0 114109890 Kanekiyo, Masaru NIAID - VRC NIAID Kanekiyo, Masaru (NIAID) 0 114109891 Druz, Aliaksandr NIAID - DIR NIAID Druz, Aliaksandr (NIAID) 0 114109892 Baxa, Ulrich NIAID - VRC NIDDK Baxa, Ulrich (NIDDK) 0 114109893 Van Galen, Joseph NIAID - DIR Van Galen, Joseph 0 114109894 Cheng, Cheng NIAID - VRC NIAID Cheng, Cheng (NIAID) 0 114109895 Mascola, John NIAID - VRC NIAID Mascola, John (NIAID) 0 114109896 Tsybovsky, Yaroslav Leidos Biomedical Research, Inc NIAID Tsybovsky, Yaroslav (NIAID) 0 114109897 Yang, Yongping NIAID - VRC NIAID Yang, Yongping (NIAID) 0 114109898 Thomas, Paul NIAID - VRC NIAID Thomas, Paul (NIAID) 0 114109899 Graham, Barney NIAID - VRC NIAID Graham, Barney (NIAID) 0 114109900 Chen, Rita NIAID - VRC Chen, Rita 0 114109886 Kwong, Peter NIAID - VRC NIAID Kwong, Peter (NIAID) 1 114109886 Kwong, Peter NIAID - VRC NIAID Kwong, Peter (NIAID) 1 114109887 Georgiev, Ivelin NIAID - VRC NIAID Georgiev, Ivelin (NIAID) 0 114109888 Joyce, Michael NIAID - VRC NIAID Joyce, Michael (NIAID) 0 114109889 Stewart-Jones, Guillaume NIAID - VRC NIAID Stewart-Jones, Guillaume (NIAID) 0 114109890 Kanekiyo, Masaru NIAID - VRC NIAID Kanekiyo, Masaru (NIAID) 0 114109891 Druz, Aliaksandr NIAID - DIR NIAID Druz, Aliaksandr (NIAID) 0 114109892 Baxa, Ulrich NIAID - VRC NIDDK Baxa, Ulrich (NIDDK) 0 114109893 Van Galen, Joseph NIAID - DIR Van Galen, Joseph 0 114109894 Cheng, Cheng NIAID - VRC NIAID Cheng, Cheng (NIAID) 0 114109895 Mascola, John NIAID - VRC NIAID Mascola, John (NIAID) 0 114109896 Tsybovsky, Yaroslav Leidos Biomedical Research, Inc NIAID Tsybovsky, Yaroslav (NIAID) 0 114109897 Yang, Yongping NIAID - VRC NIAID Yang, Yongping (NIAID) 0 114109898 Thomas, Paul NIAID - VRC NIAID Thomas, Paul (NIAID) 0 114109899 Graham, Barney NIAID - VRC NIAID Graham, Barney (NIAID) 0 114109900 Chen, Rita NIAID - VRC Chen, Rita 0 114102489 Self-assembling Bi-component Nanoparticles For Display Of Coassembled Trimeric Antigens E-270-2015-0 Filing authorized Leidos Biomedical Research, Inc, NIAID, NIAID - VRC 91026778 Green, Wade wade.green@nih.gov
United States of America TTIPO wade.green@nih.gov?subject=Web Inquiry on [TAB-3335] Self-assembling Insect Ferritin Nanoparticles for Display of Co-assembled Trimeric Antigens&body=Please send me information about technology [TAB-3335] Self-assembling Insect Ferritin Nanoparticles for Display of Co-assembled Trimeric Antigens. Green, Wade<br><a href="mailto:wade.green@nih.gov?subject=Web Inquiry on [TAB-3335] Self-assembling Insect Ferritin Nanoparticles for Display of Co-assembled Trimeric Antigens&body=Please send me information about technology [TAB-3335] Self-assembling Insect Ferritin Nanoparticles for Display of Co-assembled Trimeric Antigens.">wade.green@nih.gov</a><br> 114168762 E-270-2015-0 E-270-2015-0-US-01 SELF-ASSEMBLING INSECT FERRITIN NANOPARTICLES FOR DISPLAY OF CO-ASSEMBLED TRIMERIC ANTIGENS PRV US 62/355,212 Abandoned US <br />Provisional (PRV) 62/355,212<br />Filed on 2016-06-27<br />Status: Abandoned 114168763 E-270-2015-0 E-270-2015-0-PCT-02 SELF-ASSEMBLING INSECT FERRITIN NANOPARTICLES FOR DISPLAY OF CO-ASSEMBLED TRIMERIC ANTIGENS PCT Patent Cooperation Treaty PCT/US17/039595 Expired Patent Cooperation Treaty <br />(PCT) PCT/US17/039595<br />Filed on 2017-06-27<br />Status: Expired 114168821 E-270-2015-0 E-270-2015-0-US-04 Self-assembling Bi-component Nanoparticles For Display Of Coassembled Trimeric Antigens National Stage US 10,961,283 16/312,166 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10961283 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10961283">10,961,283</a><br />Filed on 2018-12-20<br />Status: Issued 114169113 E-270-2015-0 E-270-2015-0-US-05 SELF-ASSEMBLING INSECT FERRITIN NANOPARTICLES DIV US 11,939,356 17/202,231 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11939356 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11939356">11,939,356</a><br />Filed on 2021-03-15<br />Status: Issued 114151396 SELF-ASSEMBLING 114151397 Bi-component 114151398 Nanoparticles 114151399 DISPLAY 114151400 Coassembled 114151401 Trimeric 114151402 ANTIGENS TAB-3260 114097195 Novel Multivalent Nanoparticle Vaccines NIAID Licensing Licensing Barney Graham, Masaru Kanekiyo, Hadi Yassine Current seasonal influenza vaccines are designed to elicit immunity to circulating strains of influenza each year. The targeted strains are selected based on predictions of which strains are likely to be predominant in the human population for a given year. This prediction must be made well ahead of the influenza season to allow time for vaccine production and can be inaccurate.<br /><br /> Scientists at NIAID's Vaccine Research Center are developing an alternative approach for design and production of seasonal influenza vaccines. The design includes recombinant fusion proteins that self-assemble into nanoparticles with influenza antigenic proteins displayed on the nanoparticle surface (Nature 499, 102-106 (2013)). Further engineering these recombinant fusion proteins, the scientists have developed nanoparticles that simultaneously display multiple strains of influenza viral protein antigens (the receptor-binding domain of hemagglutinin) on their surface. Due to the heterogeneity of the antigenic protein derived from multiple strains, these nanoparticles are referred to as mosaic nanoparticles.<br /><br /> Upon immunization of mice with mosaic nanoparticles displaying antigens from eight different H1N1 strains, the elicited antibodies neutralized a panel of H1N1 strains from 1918 through 2009 including the strains that had not been displayed on the mosaic nanoparticle. However, mice immunized with a mixture of the eight types of nanoparticles, each displaying a single antigenic protein, did not elicit a similar breadth of neutralizing antibody response.<br /><br /> NIAID is continuing development of these vaccine candidates through animal studies and moving toward clinical evaluation.<br /><br /> This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as well as for further development and evaluation under a research collaboration. <ul> <li>Nucleic acid or recombinant protein-based vaccine</li> <li>Increased ease of production compared to current seasonal influenza vaccines</li> </ul> <ul> <li>Vaccine platform for seasonal influenza with broader protection coverage</li> </ul> Various international patent applications may also be available. 2022-04-12 2025-04-23 2025-04-23 2018-05-15 ARRAY, Broader, DOMAINS, HEMAGGLUTININ, INFLUENZA, Listed LPM Thalhammer-Reyero as of 4/15/2015, MOSAIC, Nanoparticulate, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Receptor-Binding, Receptor-bindingdomains, Spectrum, Vaccine False True True NIHTT 37470483 Website Abstract E-293-2011-0 114172476 Kanekiyo, M, et al. Manuscript under revision. Kanekiyo, M, et al. Manuscript under revision. 114103451 Kanekiyo, Masaru NIAID - VRC NIAID Kanekiyo, Masaru (NIAID) 0 114103452 Yassine, Hadi NIAID - VRC NIAID Yassine, Hadi (NIAID) 0 114103453 Graham, Barney NIAID - VRC NIAID Graham, Barney (NIAID) 1 114103453 Graham, Barney NIAID - VRC NIAID Graham, Barney (NIAID) 1 114103451 Kanekiyo, Masaru NIAID - VRC NIAID Kanekiyo, Masaru (NIAID) 0 114103452 Yassine, Hadi NIAID - VRC NIAID Yassine, Hadi (NIAID) 0 114099403 Use Of Nanoparticulate Mosaic Array Of Hemagglutinin Receptor-binding Domains As A Broader Spectrum Influenza Vaccine E-060-2015-0 Filing authorized NIAID 91026778 Green, Wade wade.green@nih.gov
United States of America TTIPO wade.green@nih.gov?subject=Web Inquiry on [TAB-3260] Novel Multivalent Nanoparticle Vaccines&body=Please send me information about technology [TAB-3260] Novel Multivalent Nanoparticle Vaccines. Green, Wade<br><a href="mailto:wade.green@nih.gov?subject=Web Inquiry on [TAB-3260] Novel Multivalent Nanoparticle Vaccines&body=Please send me information about technology [TAB-3260] Novel Multivalent Nanoparticle Vaccines.">wade.green@nih.gov</a><br> 114160497 E-060-2015-0 E-060-2015-0-US-07 Novel Multivalent Nanoparticle-Based Vaccines National Stage US 11,191,727 15/540,898 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11191727 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11191727">11,191,727</a><br />Filed on 2017-06-29<br />Status: Issued 114160498 E-060-2015-0 E-060-2015-0-PCT-02 Novel Multivalent Nanoparticle-Based Vaccines PCT Patent Cooperation Treaty PCT/US2015/068272 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2015/068272<br />Filed on 2015-12-31<br />Status: Expired 114160582 E-060-2015-0 E-060-2015-0-US-01 NOVEL, MULTIVALENT, NANOPARTICLE-BASED VACCINES FOR INFLUENZA VIRUS PRV US 62/098,755 Abandoned US <br />Provisional (PRV) 62/098,755<br />Filed on 2014-12-31<br />Status: Abandoned 114169169 E-060-2015-0 E-060-2015-0-US-17 NOVEL MULTIVALENT NANOPARTICLE-BASED VACCINES DIV US 11,938,221 17/519,142 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11938221 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11938221">11,938,221</a><br />Filed on 2021-11-04<br />Status: Issued 114150619 Post LPM Assignment Set 20150420 114150620 Pre LPM working set 20150418 114150621 Listed LPM Thalhammer-Reyero as of 4/15/2015 114150622 DOMAINS 114150623 Receptor-Binding 114150624 Vaccine 114150625 INFLUENZA 114150626 Spectrum 114150627 Broader 114150628 Receptor-bindingdomains 114150629 HEMAGGLUTININ 114150630 ARRAY 114150631 MOSAIC 114150632 Nanoparticulate TAB-3337 114097237 Stabilized Group 2 Influenza Hemagglutinin Stem Region Trimers and Uses Thereof NIAID Infectious Disease, Licensing, Vaccines Infectious Disease Licensing Vaccines Jeffrey Boyington, Kizzmekia Corbett, Barney Graham, Masaru Kanekiyo, John Mascola, Syed Moin, Lingshu Wang, Hadi Yassine Researchers at the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases (NIAID) have designed influenza vaccine candidates based on group 2 influenza hemagglutinin (HA) proteins. These group 2 HA proteins were engineered to remove the highly variable head region and stabilize the remaining stem region. The researchers then fused the engineered group 2 HA stabilized stem with a ferritin subunit. The resulting fusion protein can self-assemble into nanoparticles which display group 2 HA stem domain trimers on their surface.<br /><br /> These immunogens elicit cross-reactive antibodies to group 2 influenza viruses and could be used in combination with group 1 HA stem-ferritin immunogens as a universal influenza vaccine. Interestingly, a recent study by Andrews et al., Sci. Immunol. 2, eaan2676 (2017), suggests that cross-reactive group 1/group 2 HA stem antibodies may be more likely to be elicited in humans by a group 2 HA immunogen.<br /><br /> This technology is available for licensing for commercial development in accordance with 35 U.S.C. § 209 and 37 CFR Part 404, as well as for further development and evaluation under a research collaboration. <ul> <li>Elicits antibodies to both group 1 and group 2 influenza A viruses</li> <li>Nucleic acid or recombinant protein-based vaccine</li> <li>Increased ease of production compared to current seasonal influenza vaccines</li> </ul> <ul> <li>Use as a broadly protective influenza vaccine</li> </ul> </li> 2022-05-18 2025-04-23 2025-04-23 2018-10-17 2, Broad, DC5BXX, Development, ELICIT, GROUP, H3, H7, HEMAGGLUTININ, IMMUNE, INFLUENZA, Modified, Nanoparticles, Responses, Stem False True True NIHTT 37470483 Website Abstract E-293-2011-0 114109922 Graham, Barney NIAID - VRC NIAID Graham, Barney (NIAID) 0 114109923 Mascola, John NIAID - VRC NIAID Mascola, John (NIAID) 0 114109924 Yassine, Hadi NIAID - VRC NIAID Yassine, Hadi (NIAID) 0 114109925 Moin, Syed NIAID - VRC NIAID Moin, Syed (NIAID) 0 114109926 Wang, Lingshu NIAID - VRC NIAID Wang, Lingshu (NIAID) 0 114109927 Corbett, Kizzmekia NIAID - DIR NIAID Corbett, Kizzmekia (NIAID) 0 114109928 Kanekiyo, Masaru NIAID - VRC NIAID Kanekiyo, Masaru (NIAID) 0 114109921 Boyington, Jeffrey NIAID - VRC NIAID Boyington, Jeffrey (NIAID) 1 114109921 Boyington, Jeffrey NIAID - VRC NIAID Boyington, Jeffrey (NIAID) 1 114109922 Graham, Barney NIAID - VRC NIAID Graham, Barney (NIAID) 0 114109923 Mascola, John NIAID - VRC NIAID Mascola, John (NIAID) 0 114109924 Yassine, Hadi NIAID - VRC NIAID Yassine, Hadi (NIAID) 0 114109925 Moin, Syed NIAID - VRC NIAID Moin, Syed (NIAID) 0 114109926 Wang, Lingshu NIAID - VRC NIAID Wang, Lingshu (NIAID) 0 114109927 Corbett, Kizzmekia NIAID - DIR NIAID Corbett, Kizzmekia (NIAID) 0 114109928 Kanekiyo, Masaru NIAID - VRC NIAID Kanekiyo, Masaru (NIAID) 0 114102492 Development Of Modified Group 2 Hemagglutinin Stem Nanoparticles To Elicit Broad Immune Responses To Influenza E-228-2016-0 Filing authorized NIAID 114102493 Development Of Modified Group 2 Hemagglutinin Stem Nanoparticles To Elicit Broad Immune Responses To Influenza E-228-2016-1 Filing authorized NIAID 91026778 Green, Wade wade.green@nih.gov
United States of America TTIPO wade.green@nih.gov?subject=Web Inquiry on [TAB-3337] Stabilized Group 2 Influenza Hemagglutinin Stem Region Trimers and Uses Thereof&body=Please send me information about technology [TAB-3337] Stabilized Group 2 Influenza Hemagglutinin Stem Region Trimers and Uses Thereof. Green, Wade<br><a href="mailto:wade.green@nih.gov?subject=Web Inquiry on [TAB-3337] Stabilized Group 2 Influenza Hemagglutinin Stem Region Trimers and Uses Thereof&body=Please send me information about technology [TAB-3337] Stabilized Group 2 Influenza Hemagglutinin Stem Region Trimers and Uses Thereof.">wade.green@nih.gov</a><br> 114168767 E-228-2016-0 E-228-2016-0-US-01 STABILIZED GROUP 2 INFLUENZA HEMAGGLUTININ STEM REGION TRIMERS AND USES THEREOF PRV US 62/383,267 Abandoned US <br />Provisional (PRV) 62/383,267<br />Filed on 2016-09-02<br />Status: Abandoned 114168768 E-228-2016-1 E-228-2016-1-PCT-01 Stabilized Group 2 Influenza Hemagglutinin Stem Region Trimers and Uses Thereof PCT COMB Patent Cooperation Treaty PCT/US2017/049894 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2017/049894<br />Filed on 2017-09-01<br />Status: Expired 114168853 E-228-2016-1 E-228-2016-1-US-02 STABILIZED GROUP 2 INFLUENZA HEMAGGLUTININ STEM REGION TRIMERS AND USES THEREOF National Stage US 11,338,033 16/329,592 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11338033 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11338033">11,338,033</a><br />Filed on 2019-02-28<br />Status: Issued 114169483 E-228-2016-1 E-228-2016-1-US-14 STABILIZED GROUP 2 INFLUENZA HEMAGGLUTININ STEM REGION TRIMERS AND USES THEREOF CON US 11,793,871 17/742,201 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11793871 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11793871">11,793,871</a><br />Filed on 2022-05-11<br />Status: Issued 114128191 DC5BXX 114151416 Development 114151417 Modified 114151418 GROUP 114151419 2 114151420 HEMAGGLUTININ 114151421 Stem 114151422 Nanoparticles 114151423 ELICIT 114151424 Broad 114151425 IMMUNE 114151426 Responses 114151427 INFLUENZA 114151428 H7 114151429 H3 TAB-3175 114097125 Neutralizing Antibodies to Influenza HA and Their Use and Identification NIAID Antibodies, Immunology, Infectious Disease, Licensing, Therapeutics, Vaccines Antibodies Immunology Infectious Disease Licensing Therapeutics Vaccines Sarah Andrews, Robert Bailer, Gwo-Yu Chuang, Michael Joyce, Peter Kwong, John Mascola, Adrian McDermott, Paul Thomas, Adam Wheatley, James Whittle, Yi Zhang The effectiveness of current influenza vaccines varies by strain and season, in part because influenza viruses continuously evolve to evade human immune responses. While the majority of seasonal influenza infections cause relatively mild symptoms, each year influenza virus infections result in over 500,000 hospitalizations in the United States and Europe. Current standard of care for individuals hospitalized with uncomplicated influenza infection is administration of neuraminidase inhibitors. However, frequent use of such antiviral drugs increases the risk that the virus will develop drug resistance, especially in high-risk populations. Thus, alternative strategies are required to protect or treat vulnerable populations who have been hospitalized with severe influenza.<br /><br /> Using a combination of recombinant proteins and sophisticated flow cytometry, scientists at NIAID isolated families of antibodies capable of neutralizing diverse group 1 and group 2 influenza A viruses. Specifically, the families of antibodies identified precisely target parts of the hemagglutinin (HA) protein, present on the surface of the influenza virus, that are least variable from season to season (Joyce, M.G., et al. Cell (2016) 166 (3): 609-623). Therefore, it is hypothesized that passive administration of members of these families of antibodies to individuals would represent an alternative to the current standard of care for severe influenza virus infection. Additionally, these families of antibodies could be useful for development of a product aimed at conferring passive immunity in vulnerable populations during the time of an outbreak or emergence of a pandemic strain of influenza.<br /><br /> This technology is available for licensing for commercial development in accordance with 35 U.S.C. § 209 and 37 CFR Part 404, as well as for further development and evaluation under a research collaboration.<br /><br /> NIAID is continuing development of these neutralizing antibodies to influenza toward a clinical product for treatment and/or prevention of influenza virus infection. Consequently, for some fields of use, NIAID will evaluate a license applicant’s capabilities and experience in advancing similar technologies through the regulatory process. <ul> <li>Ability to potently neutralize both group 1 and group 2 influenza A strains</li> </ul> <ul> <li>Prevention of influenza A virus infection</li> <li>Therapeutic intervention to treat influenza infection</li> </ul> 2022-03-08 2025-04-23 2025-04-23 2017-10-30 1, 2, antibodies, DB4XXX, DBXXXX, DC5XXX, DCXXXX, DXXXXX, GROUP, INFLUENZA, Neutralize, That, Their, Viruses, VLXXXX, WJXXXX, WNXXXX, XAXXXX, XKXXXX, YCXXXX False True True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114170872 Joyce MG, et al. https://www.ncbi.nlm.nih.gov/pubmed/27453470 <a href="https://www.ncbi.nlm.nih.gov/pubmed/27453470">Joyce MG, et al.</a> 114108690 Bailer, Robert NIAID - VRC NIAID Bailer, Robert (NIAID) 0 114108694 Joyce, Michael NIAID - VRC NIAID Joyce, Michael (NIAID) 0 114108695 Mascola, John NIAID - VRC NIAID Mascola, John (NIAID) 0 114108696 Kwong, Peter NIAID - VRC NIAID Kwong, Peter (NIAID) 0 114109401 Andrews, Sarah NIAID - VRC NIAID Andrews, Sarah (NIAID) 0 114109402 Thomas, Paul NIAID - VRC NIAID Thomas, Paul (NIAID) 0 114109403 Chuang, Gwo-Yu NIAID - DIR NIAID Chuang, Gwo-Yu (NIAID) 0 114109404 Wheatley, Adam NIAID - VRC NIAID Wheatley, Adam (NIAID) 0 114109405 Zhang, Yi NIAID - VRC NIAID Zhang, Yi (NIAID) 0 114109406 Whittle, James George Washington University Whittle, James 0 114108697 McDermott, Adrian NIAID - VRC NIAID McDermott, Adrian (NIAID) 1 114108697 McDermott, Adrian NIAID - VRC NIAID McDermott, Adrian (NIAID) 1 114108690 Bailer, Robert NIAID - VRC NIAID Bailer, Robert (NIAID) 0 114108694 Joyce, Michael NIAID - VRC NIAID Joyce, Michael (NIAID) 0 114108695 Mascola, John NIAID - VRC NIAID Mascola, John (NIAID) 0 114108696 Kwong, Peter NIAID - VRC NIAID Kwong, Peter (NIAID) 0 114109401 Andrews, Sarah NIAID - VRC NIAID Andrews, Sarah (NIAID) 0 114109402 Thomas, Paul NIAID - VRC NIAID Thomas, Paul (NIAID) 0 114109403 Chuang, Gwo-Yu NIAID - DIR NIAID Chuang, Gwo-Yu (NIAID) 0 114109404 Wheatley, Adam NIAID - VRC NIAID Wheatley, Adam (NIAID) 0 114109405 Zhang, Yi NIAID - VRC NIAID Zhang, Yi (NIAID) 0 114109406 Whittle, James George Washington University Whittle, James 0 114102145 Antibodies That Neutralize Group 1 And Group 2 Influenza A Viruses And Their Use E-061-2016-0 Filing authorized NIAID 91026778 Green, Wade wade.green@nih.gov
United States of America TTIPO wade.green@nih.gov?subject=Web Inquiry on [TAB-3175] Neutralizing Antibodies to Influenza HA and Their Use and Identification&body=Please send me information about technology [TAB-3175] Neutralizing Antibodies to Influenza HA and Their Use and Identification. Green, Wade<br><a href="mailto:wade.green@nih.gov?subject=Web Inquiry on [TAB-3175] Neutralizing Antibodies to Influenza HA and Their Use and Identification&body=Please send me information about technology [TAB-3175] Neutralizing Antibodies to Influenza HA and Their Use and Identification.">wade.green@nih.gov</a><br> 114162576 E-061-2016-0 E-061-2016-0-US-01 NEUTRALIZING ANTIBODIES TO INFLUENZA HA AND THEIR USE AND IDENTIFICATION PRV US 62/330,837 Abandoned US <br />Provisional (PRV) 62/330,837<br />Filed on 2016-05-02<br />Status: Abandoned 114163388 E-061-2016-0 E-061-2016-0-PCT-02 NEUTRALIZING ANTIBODIES TO INFLUENZA HA AND THEIR USE AND IDENTIFICATION PCT Patent Cooperation Treaty PCT/US2017/030641 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2017/030641<br />Filed on 2017-05-02<br />Status: Expired 114127481 DXXXXX 114127482 DBXXXX 114127483 DB4XXX 114127484 DCXXXX 114127485 DC5XXX 114127486 VLXXXX 114127487 WJXXXX 114127488 WNXXXX 114127489 XAXXXX 114127490 XKXXXX 114127491 YCXXXX 114149558 antibodies 114149559 That 114149560 Neutralize 114149561 GROUP 114149562 1 114149563 2 114149564 INFLUENZA 114149565 Viruses 114149566 Their TAB-3263 114097189 Stabilized Influenza Hemagglutinin Stem Region Trimers and Uses Thereof NIAID Licensing Licensing Jeffrey Boyington, Barney Graham, Masaru Kanekiyo, Peter Kwong, John Mascola, Hadi Yassine An effective universal influenza vaccine would eliminate the uncertain and costly process of seasonal influenza vaccine development each year. Researchers at the National Institute of Allergy and Infectious Diseases (NIAID) are developing immunogens which elicit neutralizing antibodies to the highly conserved stem region of the influenza viral protein hemagglutinin. By targeting this highly conserved region, which is nearly identical in various strains of influenza virus, these immunogens could train the immune system to defend against a wide variety of influenza strains including pandemic strains derived from animal reservoirs.<br /><br /> This vaccine candidate employs a protein nanoparticle platform to display portions of the highly conserved stem region of the group 1 hemagglutinin (HA) viral surface protein in its native, trimeric conformation. Animal studies have shown that the HA stem region trimers displayed on a nanoparticle are more immunogenic compared to HA stem region trimers alone. Immunization of mice and ferrets with an H1N1 nanoparticle HA stem immunogen conferred protection from a lethal dose of H5N1 virus.<br /><br /> NIAID is continuing development of these vaccine candidates through animal studies and moving toward clinical evaluation.<br /><br /> This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as well as for further development and evaluation under a research collaboration. <ul> <li>Nucleic acid or recombinant protein-based vaccine</li> <li>Increased ease of production relative to current seasonal influenza vaccines</li> </ul> <ul> <li>Universal influenza vaccine</li> </ul> 2022-04-12 2025-04-23 2025-04-23 2018-05-15 Broad, Development, ELICIT, HEMAGGLUTININ, IMMUNE, INFLUENZA, Listed LPM Thalhammer-Reyero as of 4/15/2015, Modified, Nanoparticles, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, RESPONSE, Stem False True True NIHTT 37470483 Website Abstract E-293-2011-0 114172478 Yassine, H.M., et al. (2015) Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection. Nature Medicine 21: 1065-1070. [PMID: 26301691] https://www.ncbi.nlm.nih.gov/pubmed/?term=Hemagglutinin-stem+nanoparticles+generate+heterosubtypic+influenza+protection <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Hemagglutinin-stem+nanoparticles+generate+heterosubtypic+influenza+protection">Yassine, H.M., et al. (2015) Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection. Nature Medicine 21: 1065-1070. [PMID: 26301691]</a> 114109679 Boyington, Jeffrey NIAID - VRC NIAID Boyington, Jeffrey (NIAID) 0 114109680 Yassine, Hadi NIAID - VRC NIAID Yassine, Hadi (NIAID) 0 114109681 Kwong, Peter NIAID - VRC NIAID Kwong, Peter (NIAID) 0 114109682 Kanekiyo, Masaru NIAID - VRC NIAID Kanekiyo, Masaru (NIAID) 0 114109683 Graham, Barney NIAID - VRC NIAID Graham, Barney (NIAID) 0 114109678 Mascola, John NIAID - VRC NIAID Mascola, John (NIAID) 1 114109678 Mascola, John NIAID - VRC NIAID Mascola, John (NIAID) 1 114109679 Boyington, Jeffrey NIAID - VRC NIAID Boyington, Jeffrey (NIAID) 0 114109680 Yassine, Hadi NIAID - VRC NIAID Yassine, Hadi (NIAID) 0 114109681 Kwong, Peter NIAID - VRC NIAID Kwong, Peter (NIAID) 0 114109682 Kanekiyo, Masaru NIAID - VRC NIAID Kanekiyo, Masaru (NIAID) 0 114109683 Graham, Barney NIAID - VRC NIAID Graham, Barney (NIAID) 0 114102426 Development Of Modified Hemagglutinin Stem Nanoparticles To Elicit Broad Immune Response To Influenza E-066-2014-0 Filing authorized NIAID 91026778 Green, Wade wade.green@nih.gov
United States of America TTIPO wade.green@nih.gov?subject=Web Inquiry on [TAB-3263] Stabilized Influenza Hemagglutinin Stem Region Trimers and Uses Thereof&body=Please send me information about technology [TAB-3263] Stabilized Influenza Hemagglutinin Stem Region Trimers and Uses Thereof. Green, Wade<br><a href="mailto:wade.green@nih.gov?subject=Web Inquiry on [TAB-3263] Stabilized Influenza Hemagglutinin Stem Region Trimers and Uses Thereof&body=Please send me information about technology [TAB-3263] Stabilized Influenza Hemagglutinin Stem Region Trimers and Uses Thereof.">wade.green@nih.gov</a><br> 114162947 E-066-2014-0 E-066-2014-0-US-07 Stabilized Influenza Hemagglutinin Stem Region Trimers and Uses Thereof National Stage US 10,363,301 15/313,265 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10363301 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10363301">10,363,301</a><br />Filed on 2015-05-27<br />Status: Issued 114163100 E-066-2014-0 E-066-2014-0-PCT-02 STABILIZED INFLUENZA HEMAGGLUTININ STEM REGION TRIMERS AND USES THEREOF PCT Patent Cooperation Treaty PCT/US2015/032695 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2015/032695<br />Filed on 2015-05-27<br />Status: Expired 114164135 E-066-2014-0 E-066-2014-0-US-01 Stabilized Influenza Hemagglutinin Stem Region Trimers & Uses Thereof PRV US 62/003,471 Abandoned US <br />Provisional (PRV) 62/003,471<br />Filed on 2014-05-27<br />Status: Abandoned 114168892 E-066-2014-0 E-066-2014-0-US-08 STABILIZED INFLUENZA HEMAGGLUTININ STEM REGION TRIMERS AND USES THEREOF DIV US 11,147,867 16/455,242 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11147867 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11147867">11,147,867</a><br />Filed on 2019-06-27<br />Status: Issued 114169167 E-066-2014-0 E-066-2014-0-US-10 STABILIZED INFLUENZA HEMAGGLUTININ STEM REGION TRIMERS AND USES THEREOF DIV US 11,679,151 17/504,002 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11679151 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11679151">11,679,151</a><br />Filed on 2021-10-18<br />Status: Issued 114150640 Development 114150641 Modified 114150642 HEMAGGLUTININ 114150643 Stem 114150644 Nanoparticles 114150645 ELICIT 114150646 Broad 114150647 IMMUNE 114150648 RESPONSE 114150649 INFLUENZA 114150650 Listed LPM Thalhammer-Reyero as of 4/15/2015 114150651 Pre LPM working set 20150418 114150652 Post LPM Assignment Set 20150420 TAB-2463 114096663 Self-Assembled Ferritin Nanoparticles Expressing Hemagglutinin as an Influenza Vaccine NIAID Infectious Disease, Licensing, Vaccines Infectious Disease Licensing Vaccines Jeffrey Boyington, Masaru Kanekiyo, Gary Nabel NIH inventors at the Vaccine Research Center have developed a novel influenza virus hemagglutinin (HA)-ferritin nanoparticle influenza vaccine that is easily manufactured, potent, and elicits broadly neutralizing influenza antibodies against multiple strains of influenza. This novel influenza nanoparticle vaccine elicited two types of broadly neutralizing, cross-protective antibodies, one directed to the highly conserved HA stem and a second proximal to the conserved receptor binding site (RBS) of the viral HA, providing a new platform for universal and seasonal influenza. In addition, HA-ferritin nanoparticles can be easily produced from simple expression vectors and without the production of infectious virus in eggs, and will facilitate influenza preparedness in the face of emerging epidemics.<br /><br /> This technology exploits ferritin, a ubiquitous iron storage protein, that self-assembles into spherical nanoparticles and could serve as a scaffold to express a heterologous protein, such as influenza HA, so it mimics a physiologically relevant trimeric viral spike. Immunization with the HA-ferritin nanoparticle elicited neutralizing antibody titers that were >10-fold higher than a matched inactivated vaccine. The immune sera raised by HA-ferritin nanoparticles expressing a 1999 HA neutralized seasonal H1N1 viruses from 1934 to 2007 and protected ferrets from an unmatched 2007 H1N1 virus challenge. This extended neutralization coverage is partially explained by the presence of both type of antibodies, antibodies directed to the conserved HA stem and against the RBS region. Finally, this ferritin nanoparticle vaccine platform has significant advantages in the ability to utilize specific multimerized spikes and it may be applicable to other viral proteins. <ul> <li>Forms an octahedron consisting of 24 subunits, allowing for greatly increased presentation of heterologous protein on the ferritin nanoparticles surface, compared to other vaccine platforms.</li> <li><em>In vivo</em> data in multiple animal models demonstrated induction of broader and more potent antibody responses.</li> <li>Vaccine stimulated broadly neutralizing antibodies against the highly conserved epitope on the HA stem region and against the RBS, thus targeting two independent sites of vulnerability on HA.</li> <li>Multivalent influenza HA ferritin vaccines have been tested in animal models.</li> <li>Ferritin is extremely stable to temperature ranges, pH, detergent and other factors.</li> <li>Easily manufactured, will facilitate influenza preparedness in the face of emerging epidemics.</li> </ul> <ul> <li>The ferritin nanoparticles as a vaccine platform can be used to deliver vaccines, such as influenza vaccines, with enhanced magnitude and breadth of the neutralizing antibody responses. This vaccine platform may be applicable to other viral proteins.</li> </ul> 2022-04-12 2025-04-23 2025-04-23 2020-08-03 assay, DC5BXX, DC5XXX, DCXXXX, Development, DXXXXX, Ferritin, HA-Ferritin, HEMAGGLUTINATION, HEMAGGLUTININ, INFLUENZA, inhibition, Nanoparticles, SELF-ASSEMBLING, Vaccine False True <ul> <li>Preclinical</li> <li>In vitro data available</li> <li>In vivo data available (animal)</li> </ul> True NIHTT 37470483 Website Abstract 114171628 Kanekiyo M, et al. http://www.ncbi.nlm.nih.gov/pubmed/23698367 <a href="http://www.ncbi.nlm.nih.gov/pubmed/23698367">Kanekiyo M, et al.</a> 114107620 Kanekiyo, Masaru NIAID - VRC NIAID Kanekiyo, Masaru (NIAID) 0 114107621 Boyington, Jeffrey NIAID - VRC NIAID Boyington, Jeffrey (NIAID) 0 114107619 Nabel, Gary NIAID - VRC NIAID Nabel, Gary (NIAID) 1 114107619 Nabel, Gary NIAID - VRC NIAID Nabel, Gary (NIAID) 1 114107620 Kanekiyo, Masaru NIAID - VRC NIAID Kanekiyo, Masaru (NIAID) 0 114107621 Boyington, Jeffrey NIAID - VRC NIAID Boyington, Jeffrey (NIAID) 0 114101767 Development Of Self-Assembling Ferritin Nanoparticles Expressing Hemagglutinin As An Influenza Vaccine E-293-2011-0 Filing authorized NIAID 114101768 Development Of Self-Assembling Ferritin Nanoparticles Expressing Hemagglutinin As An Influenza Vaccine E-293-2011-1 Filing authorized NIAID 114102245 Development Of Self-Assembling Ferritin Nanoparticles Expressing Hemagglutinin As An Influenza Vaccine E-293-2011-2 Filing authorized NIAID 91026778 Green, Wade wade.green@nih.gov
United States of America TTIPO wade.green@nih.gov?subject=Web Inquiry on [TAB-2463] Self-Assembled Ferritin Nanoparticles Expressing Hemagglutinin as an Influenza Vaccine&body=Please send me information about technology [TAB-2463] Self-Assembled Ferritin Nanoparticles Expressing Hemagglutinin as an Influenza Vaccine. Green, Wade<br><a href="mailto:wade.green@nih.gov?subject=Web Inquiry on [TAB-2463] Self-Assembled Ferritin Nanoparticles Expressing Hemagglutinin as an Influenza Vaccine&body=Please send me information about technology [TAB-2463] Self-Assembled Ferritin Nanoparticles Expressing Hemagglutinin as an Influenza Vaccine.">wade.green@nih.gov</a><br> 114161391 E-293-2011-2 E-293-2011-2-US-07 NUCLEIC ACID MOLECULES ENCODING FERRITIN-HEMAGGLUTININ FUSION PROTEINS DIV US 10,137,190 15/244,321 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10137190 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10137190">10,137,190</a><br />Filed on 2016-08-23<br />Status: Issued 114166820 E-293-2011-0 E-293-2011-0-US-01 Self-Assembled Ferritin Nanoparticles Expressing Hemagglutinin As An Influenza Vaccine PRV US 61/538,663 Abandoned US <br />Provisional (PRV) 61/538,663<br />Filed on 2011-09-23<br />Status: Abandoned 114166821 E-293-2011-1 E-293-2011-1-US-01 Self-Assembled Ferritin Nanoparticles Expressing Hemagglutinin As An Influenza Vaccine PRV US 61/661,209 Abandoned US <br />Provisional (PRV) 61/661,209<br />Filed on 2012-06-18<br />Status: Abandoned 114168067 E-293-2011-2 E-293-2011-2-PCT-01 NOVEL INFLUENZA HEMAGGLUTININ PROTEIN-BASED VACCINES PCT COMB Patent Cooperation Treaty PCT/US2012/056822 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2012/056822<br />Filed on 2012-09-24<br />Status: Expired 114168068 E-293-2011-2 E-293-2011-2-US-06 Novel Influenza Hemagglutinin Protein-Based Vaccines National Stage US 9,441,019 14/346,849 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9441019 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9441019">9,441,019</a><br />Filed on 2014-03-24<br />Status: Issued 114122915 DC5BXX 114122916 DXXXXX 114122917 DCXXXX 114122918 DC5XXX 114143344 SELF-ASSEMBLING 114143345 Ferritin 114143346 Nanoparticles 114143347 HEMAGGLUTININ 114143348 INFLUENZA 114143349 Vaccine 114148069 Development 114148070 HEMAGGLUTINATION 114148071 inhibition 114148072 assay 114148073 HA-Ferritin TAB-5005 158091390 Monoclonal Antibodies That Bind to the Underside of Influenza Viral Neuraminidase NIAID Antibodies, Consumer Products, Immunology, Infectious Disease, Research Materials, Therapeutics, Vaccines Antibodies Consumer Products Immunology Infectious Disease Research Materials Therapeutics Vaccines Sarah Andrews, Masaru Kanekiyo, Julia Lederhofer, Yaroslav Tsybovsky <p>Current influenza vaccines mainly induce antibodies against the surface glycoprotein hemagglutinin (HA) that block viral attachment to its host receptors and viral membrane fusion to the host cell. The immunodominant head region of HA undergoes antigenic drift and antibodies directed to the head confer little cross-protections between strains or subtypes.<br /> &nbsp; &nbsp; &nbsp; &nbsp;Researchers at the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases have identified human monoclonal antibodies that each bind distinct epitopes on the less abundant yet critical viral surface glycoprotein neuraminidase (NA). &nbsp;<br /> These antibodies, isolated from convalescent individuals with confirmed influenza A H3N2 infection, inhibit viral propagation of a wide range of human H3N2, swine-origin variant H3N2, and H2N2 viruses and confer pre-exposure and post-exposure protection from lethal H3N2 infection in mice. Cryo-electron microscopy revealed that two of these antibodies bind non-overlapping epitopes covering the underside of the NA head, thus defining a potential vaccine target.<br /> &nbsp; &nbsp; &nbsp; &nbsp;This technology is available for licensing for commercial development in accordance with 35 U.S.C. &sect; 209 and 37 CFR part 404.<br /> &nbsp;</p> <ul> <li>Improved breadth of protection relative to influenza HA-targeting antibodies</li> </ul> <ul> <li>Prevention or treatment of influenza infection</li> <li>Testing influenza antigens</li> </ul> 2024-09-05 2025-04-23 2025-04-23 2024-09-24 False True Preclinical True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 158092557 Publications: Lederhofer, Julia et al., "Protective human monoclonal antibodies target conserved sites of vulnerability on the underside of influenza virus neuraminidase", Immunity, Volume 57, Issue 3, 574 - 586.e7. Publications: Lederhofer, Julia et al., "Protective human monoclonal antibodies target conserved sites of vulnerability on the underside of influenza virus neuraminidase", Immunity, Volume 57, Issue 3, 574 - 586.e7. 158092568 Intellectual Property: PCT/US2023/071194 filed 28 July 2023 (NIH Ref. No. E-177-2022) Intellectual Property: PCT/US2023/071194 filed 28 July 2023 (NIH Ref. No. E-177-2022) 158091968 Kanekiyo, Masaru NIAID - VRC NIAID Kanekiyo, Masaru (NIAID) 1 158091986 Andrews, Sarah NIAID - VRC NIAID Andrews, Sarah (NIAID) 2 158091992 Lederhofer, Julia NIAID - VRC NIAID Lederhofer, Julia (NIAID) 3 158092002 Tsybovsky, Yaroslav Leidos Biomedical Research, Inc NIAID Tsybovsky, Yaroslav (NIAID) 4 158091968 Kanekiyo, Masaru NIAID - VRC NIAID Kanekiyo, Masaru (NIAID) 1 158091986 Andrews, Sarah NIAID - VRC NIAID Andrews, Sarah (NIAID) 2 158091992 Lederhofer, Julia NIAID - VRC NIAID Lederhofer, Julia (NIAID) 3 158092002 Tsybovsky, Yaroslav Leidos Biomedical Research, Inc NIAID Tsybovsky, Yaroslav (NIAID) 4 158091393 Monoclonal Antibodies That Bind To The Under Site Of Influenza Viral Neuraminidase E-177-2022-0 Filing authorized NCI, NIAID 91026778 Green, Wade wade.green@nih.gov
United States of America TTIPO wade.green@nih.gov?subject=Web Inquiry on [TAB-5005] Monoclonal Antibodies That Bind to the Underside of Influenza Viral Neuraminidase&body=Please send me information about technology [TAB-5005] Monoclonal Antibodies That Bind to the Underside of Influenza Viral Neuraminidase. Green, Wade<br><a href="mailto:wade.green@nih.gov?subject=Web Inquiry on [TAB-5005] Monoclonal Antibodies That Bind to the Underside of Influenza Viral Neuraminidase&body=Please send me information about technology [TAB-5005] Monoclonal Antibodies That Bind to the Underside of Influenza Viral Neuraminidase.">wade.green@nih.gov</a><br> 158093826 E-177-2022-0 E-177-2022-0-US-01 Monoclonal Antibodies that bind to the underside of Influenza Viral Neuraminidase PRV US 63/394,243 Expired US <br />Provisional (PRV) 63/394,243<br />Filed on 2022-08-01<br />Status: Expired 158093834 E-177-2022-0 E-177-2022-0-PCT-02 Monoclonal Antibodies that bind to the underside of Influenza Viral Neuraminidase PCT Patent Cooperation Treaty PCT/US2023/071194 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2023/071194<br />Filed on 2023-07-28<br />Status: Expired 159710763 E-177-2022-0 E-177-2022-0-US-02 MONOCLONAL ANTIBODIES THAT BIND TO THE UNDERSIDE OF INFLUENZA VIRAL NEURAMINIDASE National Stage US 19/100,498 Pending US <br />National Stage 19/100,498<br />Filed on 2025-01-31<br />Status: Pending 159710808 E-177-2022-0 E-177-2022-0-EP-01 MONOCLONAL ANTIBODIES THAT BIND TO THE UNDERSIDE OF INFLUENZA VIRAL NEURAMINIDASE National Stage European Patent 23761340.1 Pending European Patent <br />National Stage 23761340.1<br />Filed on 2025-01-11<br />Status: Pending TAB-4298 147157588 IL7Rα-Specific Antibody for Treating Acute Lymphoblastic Leukemia (ALL) NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Scott Durum, Julie Hixon, Lila Kashi, Wenqing Li, Scott Walsh <p>Acute lymphoblastic leukemia (ALL) is the most common cancer in children with approximately 3,250 new cases occurring per year in the United States. About 20% of cases are refractory to current treatment protocols and there is a desperate need for targeted therapies that do not result in adverse side effects such as cognitive impairment. </p> <p>The Interleukin-7 receptor-α (IL-7Rα) was identified as a major pathway driving T-cell derived ALL (T-ALL). Researchers at the National Cancer Institute (NCI) developed antibodies selectively targeting IL-7Rα. Two lead antibody candidates, designated 4A10 and 2B8, selectively bind IL-7Rα with nanomolar affinity. Each lead antibody mediates leukemic cell killing by antibody-dependent cellular cytotoxicity (ADCC) and causes a significant reduction in T-ALL cell burden when administered in a xenograft mouse model harboring patient derived leukemia. Tumor reduction occurred despite the absence of ADCC immune effector cells in the xenograft mouse model. Furthermore, a synergistic effect occurred when combining the IL-7Rα antibody with AMD3100, a commercially available CXCR4 antagonist approved as a therapeutic in humans. The combination treatment resulted in a significant improvement in clearance of T-ALL cell burden in a xenograft mouse model.</p> <p>The National Cancer Institute (NCI) seeks licensing and/or co-development research collaborations for the further development of these IL-7Rα-selective antibodies as targeted therapies for a range of indications including oncology and autoimmune disorders. Examples include cell acute lymphoblastic leukemia (T-ALL), B-cell acute lymphoblastic leukemia (B-ALL), several autoimmune disorders (Type 1 diabetes and multiple sclerosis) and organ transplant rejection.</p> <h2>Competitive Advantages:</h2> <ul><li>Selectively bind IL-7Rα with high (nanomolar) affinity</li> <li>Mediates cancer cell killing through antibody-dependent cellular cytotoxicity (ADCC)</li> <li>Targeted therapy with potential for fewer and less severe adverse events</li> <li>Well-established regulatory path</li> <li>Numerous approved products using same approach (e.g., Rituximab, and Cetuximab)</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Targeted therapy for various cancers including T-cell acute lymphoblastic leukemia (T-ALL) and B-cell acute lymphoblastic leukemia (B-ALL)</li> <li>Targeted therapy for several autoimmune disorders (Type 1 diabetes and multiple sclerosis), organ transplant rejection, Type 1 diabetes, and multiple sclerosis</li> </ul> 2017-12-07 2025-04-22 2018-01-17 2025-04-23 2017-12-07 Acute lymphoblastic leukemia (ALL), ANTIBODY, Antibody-Dependent Cellular Cytotoxicity (ADCC), Autoimmunity, CANCER, DIABETES, Durum, Interleukin-7 receptor-α (IL-7Rα), Multiple sclerosis, personalized medicine, Targeted therapy, THERAPY, TRANSPLANTATION False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2018-01-17 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147164213 Durum, Scott NIH - NCI NCI Durum, Scott (NCI) 1 147164214 Hixon, Julie NIH - NCI NCI Hixon, Julie (NCI) 2 147164215 Li, Wenqing NIH - NCI NCI Li, Wenqing (NCI) 3 147164216 Walsh, Scott University of Maryland Walsh, Scott 4 147164217 Kashi, Lila University of Maryland Kashi, Lila 5 147164213 Durum, Scott NIH - NCI NCI Durum, Scott (NCI) 1 147164214 Hixon, Julie NIH - NCI NCI Hixon, Julie (NCI) 2 147164215 Li, Wenqing NIH - NCI NCI Li, Wenqing (NCI) 3 147164216 Walsh, Scott University of Maryland Walsh, Scott 4 147164217 Kashi, Lila University of Maryland Kashi, Lila 5 147158268 Anti-interleukin 7 Receptor Monoclonal Antibody For Treatment Of Acute Lymphoblastic Leukemia E-247-2015-0 Filing authorized NCI, University of Maryland 83732213 Dick, Taryn taryn.dick@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB taryn.dick@nih.gov?subject=Web Inquiry on [TAB-4298] IL7Rα-Specific Antibody for Treating Acute Lymphoblastic Leukemia (ALL)&body=Please send me information about technology [TAB-4298] IL7Rα-Specific Antibody for Treating Acute Lymphoblastic Leukemia (ALL).&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dick, Taryn<br><a href="mailto:taryn.dick@nih.gov?subject=Web Inquiry on [TAB-4298] IL7Rα-Specific Antibody for Treating Acute Lymphoblastic Leukemia (ALL)&body=Please send me information about technology [TAB-4298] IL7Rα-Specific Antibody for Treating Acute Lymphoblastic Leukemia (ALL).&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">taryn.dick@nih.gov</a><br> 147161228 E-247-2015-0 E-247-2015-0-US-01 Anti-interleukin 7 Receptor Monoclonal Antibody For Treating Acute Lymphoblastic Leukemia PRV US 62/238,612 Abandoned US <br />Provisional (PRV) 62/238,612<br />Filed on 2015-10-07<br />Status: Abandoned 147168017 E-247-2015-0 E-247-2015-0-PCT-02 IL-7R-ALPHA SPECIFIC ANTIBODIES FOR TREATING ACUTE LYMPHOBLASTIC LEUKEMIA PCT Patent Cooperation Treaty PCT/US2016/055957 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2016/055957<br />Filed on 2016-10-07<br />Status: Expired 147168018 E-247-2015-0 E-247-2015-0-AU-03 SPECIFIC ANTIBODIES FOR TREATING ACUTE LYMPHOBLASTIC LEUKEMIA National Stage Australia 2016335750 2016335750 Issued Australia <br />National Stage 2016335750<br />Filed on 2016-10-07<br />Status: Issued 147168019 E-247-2015-0 E-247-2015-0-CA-04 IL-7R-ALPHA SPECIFIC ANTIBODIES FOR TREATING ACUTE LYMPHOBLASTIC LEUKEMIA National Stage Canada 2997809 Pending Canada <br />National Stage 2997809<br />Filed on 2016-10-07<br />Status: Pending 147168020 E-247-2015-0 E-247-2015-0-EP-05 IL-7R-ALPHA SPECIFIC ANTIBODIES FOR TREATING ACUTE LYMPHOBLASTIC LEUKEMIA National Stage European Patent 16784678.1 Pending European Patent <br />National Stage 16784678.1<br />Filed on 2016-10-07<br />Status: Pending 147168021 E-247-2015-0 E-247-2015-0-US-06 IL-7R-ALPHA SPECIFIC ANTIBODIES FOR TREATING ACUTE LYMPHOBLASTIC LEUKEMIA National Stage US 10,392,441 15/760,193 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10392441 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10392441">10,392,441</a><br />Filed on 2018-03-14<br />Status: Issued 147168022 E-247-2015-0 E-247-2015-0-US-07 IL-7R-ALPHA SPECIFIC ANTIBODIES FOR TREATING ACUTE LYMPHOBLASTIC LEUKEMIA DIV US 11,111,306 16/459,396 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11111306 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11111306">11,111,306</a><br />Filed on 2019-07-01<br />Status: Issued 147168023 E-247-2015-0 E-247-2015-0-US-08 IL-7R-ALPHA SPECIFIC ANTIBODIES FOR TREATING ACUTE LYMPHOBLASTIC LEUKEMIA CON US 12,371,500 17/392,075 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12371500 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12371500">12,371,500</a><br />Filed on 2021-08-02<br />Status: Issued 147174201 Acute lymphoblastic leukemia (ALL) 147174202 ANTIBODY 147174203 Antibody-Dependent Cellular Cytotoxicity (ADCC) 147174204 Autoimmunity 147174205 CANCER 147174206 DIABETES 147174208 Durum 147174210 Interleukin-7 receptor-α (IL-7Rα) 147174211 Multiple sclerosis 147174212 personalized medicine 147174213 Targeted therapy 147174214 THERAPY 147174215 TRANSPLANTATION TAB-3583 114097438 Use of the Ketamine Metabolite (R,6R)-hydroxynorketamine in Depression NCATS Neurology, Psychiatry/Mental Health, Research Materials, Therapeutics Neurology Psychiatry/Mental Health Research Materials Therapeutics Todd Gould, Ruin Moaddel, Patrick Morris, Craig Thomas, Irving Wainer, Panos Zanos, Carlos Zarate This technology includes the identification and use of a ketamine metabolite, (2R,6R)-2-amino-2-(2-chlorophenyl)-6-hydroxycyclohexanone (HNK), for the treatment of depression. Ketamine is an NMDA receptor antagonist that exerts a rapid and sustained antidepressant and anti-suicidal effect. However, even low doses of ketamine has addictive and psychomimetic effects. The downstream metabolite, (2R,6R)-HNK, does not inhibit the NMDA receptor but recapitulates the antidepressant and anti-suicidal effect of ketamine. Further clinical work could establish a ketamine metabolite, such as (2R,6R)-HNK, for the treatment of depression. While ketamine has already been demonstrated as a robust and acute antidepressant, its use is limited due to multiple liabilities, including its addictive potential. The use of ketamine metabolites, including (2R,6R)-HNK, retains all of the antidepressant effects of ketamine without the associated liabilities. Further work with the product (2R,6R)-hydroxynorketamine (HNK) could establish its use for the treatment of depression. 2022-08-01 2024-10-28 2025-04-23 2022-08-01 2022-05-06 2R, 6R-hydroxynorketamine, depression, Ketamine, METABOLITE, VEXXXX, VNXXXX, WIXXXX, WKXXXX False True True NIHTT 37470483 Website Abstract E-116-2016-0 E-096-2018-0 114172755 Zanos P, Moaddel R, et al. https://pubmed.ncbi.nlm.nih.gov/27144355/ <a href="https://pubmed.ncbi.nlm.nih.gov/27144355/">Zanos P, Moaddel R, et al.</a> 114110899 Gould, Todd University of Maryland Gould, Todd 0 114110900 Wainer, Irving National Institute on Aging (NIH/NIA) Wainer, Irving 0 114110901 Zarate, Carlos National Institute of Mental Health (NIMH) NIMH Zarate, Carlos (NIMH) 0 114110902 Moaddel, Ruin National Institute on Aging (NIH/NIA) NIA Moaddel, Ruin (NIA) 0 114110903 Morris, Patrick NCATS - NCGC NCATS Morris, Patrick (NCATS) 0 114110904 Zanos, Panos University of Maryland, School of Medicine Zanos, Panos 0 114110898 Thomas, Craig NCATS - NCGC NCATS Thomas, Craig (NCATS) 1 114110898 Thomas, Craig NCATS - NCGC NCATS Thomas, Craig (NCATS) 1 114110899 Gould, Todd University of Maryland Gould, Todd 0 114110900 Wainer, Irving National Institute on Aging (NIH/NIA) Wainer, Irving 0 114110901 Zarate, Carlos National Institute of Mental Health (NIMH) NIMH Zarate, Carlos (NIMH) 0 114110902 Moaddel, Ruin National Institute on Aging (NIH/NIA) NIA Moaddel, Ruin (NIA) 0 114110903 Morris, Patrick NCATS - NCGC NCATS Morris, Patrick (NCATS) 0 114110904 Zanos, Panos University of Maryland, School of Medicine Zanos, Panos 0 114102692 Use Of The Ketamine Metabolite (2R,6R)-hydroxynorketamine In Depression E-036-2016-0 Filing authorized National Institute of Mental Health (NIMH), National Institute on Aging (NIH/NIA), NCATS - NCGC, University of Maryland 83682485 Vepa, Suryanarayana sury.vepa@nih.gov
United States of America Office of Strategic Alliances (OSA) sury.vepa@nih.gov?subject=Web Inquiry on [TAB-3583] Use of the Ketamine Metabolite (R,6R)-hydroxynorketamine in Depression&body=Please send me information about technology [TAB-3583] Use of the Ketamine Metabolite (R,6R)-hydroxynorketamine in Depression. Vepa, Suryanarayana<br><a href="mailto:sury.vepa@nih.gov?subject=Web Inquiry on [TAB-3583] Use of the Ketamine Metabolite (R,6R)-hydroxynorketamine in Depression&body=Please send me information about technology [TAB-3583] Use of the Ketamine Metabolite (R,6R)-hydroxynorketamine in Depression.">sury.vepa@nih.gov</a><br> 114169427 E-036-2016-0 E-036-2016-0-US-01 METHODS OF USING (2R, 6R)-HYDROXYNORKETAMINE AND (2S, 6S)-HYDROXYNORKETAMINE IN THE TREATMENT OF DEPRESSION,ANXIETY, ANHEDONIA,SUICIDAL IDEATION, AND POST TRAUMATIC STRESS DISORDERS PRV US 62/313,317 Abandoned US <br />Provisional (PRV) 62/313,317<br />Filed on 2016-03-25<br />Status: Abandoned 114169428 E-036-2016-0 E-036-2016-0-PCT-02 Methods of Using (2R,6R)-Hydroxynorketamine and (2S, 6S)-Hydroxynorketamine in the Treatment of Depression, Anxiety, Anhedonia, Suicidal Ideation, and Post Traumatic Stress Disorders PCT Patent Cooperation Treaty PCT/US2017/024238 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2017/024238<br />Filed on 2017-03-27<br />Status: Expired 114169429 E-036-2016-0 E-036-2016-0-US-08 METHODS OF USING (2R, 6R)-HYDROXYNORKETAMINE AND (2S, 6S)-HYDROXYNORKETAMINE IN THE TREATMENT OF DEPRESSION, ANXIETY, ANHEDONIA, FATIGUE, SUICIDAL IDEATION, AND POST TRAUMATIC STRESS DISORDERS National Stage US 16/088,294 Abandoned US <br />National Stage 16/088,294<br />Filed on 2018-09-25<br />Status: Abandoned 114128831 VEXXXX 114128832 VNXXXX 114128833 WIXXXX 114128834 WKXXXX 114153410 Ketamine 114153411 METABOLITE 114153412 2R 114153413 6R-hydroxynorketamine 114153414 depression TAB-3466 114097331 Methods of Synthesis of the Ketamine Analogs (2R, 6R)-kydroxynorketamine and (2S, 6S)-hydroxynorketamine for the Treatment of Pain and other Anxiety-related Disorders NCATS Neurology, Psychiatry/Mental Health, Therapeutics Neurology Psychiatry/Mental Health Therapeutics Todd Gould, Ruin Moaddel, Patrick Morris, Craig Thomas, Panos Zanos, Carlos Zarate This technology includes a method for synthesizing the ketamine analogs (2R,6R)-hydroxynorketamine (HNK) and (2S,6S)-hydroxynorketamine that may be useful for the treatment of pain, depression, anxiety, and related disorders. The drug ketamine was first used as an anesthetic but was found to be an effective treatment in a range of conditions, including paint, treatment-resistant bipolar depression, and other anxiety-related disorders. However, the routine use of ketamine is hindered by unwanted side effects, including the potential for abuse. Ketamine analogs have the potential advantage of retaining the efficacy of ketamine while limiting unwanted side effects. Ketamine analogs including (2R,6R)-hydroxynorketamine (HNK) and (2S,6S)-hydroxynorketamine have the potential advantage of retaining the efficacy of ketamine while limiting unwanted side effects. Further clinical work with these ketamine analogs could establish these as effective treatments for pain, depression, anxiety, and related disorders. 2022-08-01 2024-10-28 2025-04-23 2022-08-01 2022-02-04 2R, 2S, 6R-hydroxynorketamine, 6S-hydroxynorketamine, Crystal, Forms, Methods, Synthesis, VEXXXX, VMXXXX, VNXXXX, WKXXXX False True True NIHTT 37470483 Website Abstract E-096-2018-0 E-036-2016-0 E-128-2019-0 114110269 Zanos, Panos University of Maryland, School of Medicine Zanos, Panos 0 114110270 Gould, Todd University of Maryland Gould, Todd 0 114110271 Morris, Patrick NCATS - NCGC NCATS Morris, Patrick (NCATS) 0 114110272 Moaddel, Ruin National Institute on Aging (NIH/NIA) NIA Moaddel, Ruin (NIA) 0 114110273 Zarate, Carlos National Institute of Mental Health (NIMH) NIMH Zarate, Carlos (NIMH) 0 114110274 Thomas, Craig NCATS - NCGC NCATS Thomas, Craig (NCATS) 1 114110274 Thomas, Craig NCATS - NCGC NCATS Thomas, Craig (NCATS) 1 114110269 Zanos, Panos University of Maryland, School of Medicine Zanos, Panos 0 114110270 Gould, Todd University of Maryland Gould, Todd 0 114110271 Morris, Patrick NCATS - NCGC NCATS Morris, Patrick (NCATS) 0 114110272 Moaddel, Ruin National Institute on Aging (NIH/NIA) NIA Moaddel, Ruin (NIA) 0 114110273 Zarate, Carlos National Institute of Mental Health (NIMH) NIMH Zarate, Carlos (NIMH) 0 114102581 CRYSTAL FORMS AND METHODS OF SYNTHESIS OF (2R, 6R)-HYDROXYNORKETAMINE AND (2S, 6S)-HYDROXYNORKETAMINE E-116-2016-0 Filing authorized National Institute of Mental Health (NIMH), National Institute on Aging (NIH/NIA), NCATS - NCGC, University of Maryland 83682485 Vepa, Suryanarayana sury.vepa@nih.gov
United States of America Office of Strategic Alliances (OSA) sury.vepa@nih.gov?subject=Web Inquiry on [TAB-3466] Methods of Synthesis of the Ketamine Analogs (2R, 6R)-kydroxynorketamine and (2S, 6S)-hydroxynorketamine for the Treatment of Pain and other Anxiety-related Disorders&body=Please send me information about technology [TAB-3466] Methods of Synthesis of the Ketamine Analogs (2R, 6R)-kydroxynorketamine and (2S, 6S)-hydroxynorketamine for the Treatment of Pain and other Anxiety-related Disorders. Vepa, Suryanarayana<br><a href="mailto:sury.vepa@nih.gov?subject=Web Inquiry on [TAB-3466] Methods of Synthesis of the Ketamine Analogs (2R, 6R)-kydroxynorketamine and (2S, 6S)-hydroxynorketamine for the Treatment of Pain and other Anxiety-related Disorders&body=Please send me information about technology [TAB-3466] Methods of Synthesis of the Ketamine Analogs (2R, 6R)-kydroxynorketamine and (2S, 6S)-hydroxynorketamine for the Treatment of Pain and other Anxiety-related Disorders.">sury.vepa@nih.gov</a><br> 114169189 E-116-2016-0 E-116-2016-0-PCT-02 CRYSTAL FORMS AND METHODS OF SYNTHESIS OF (2R, 6R)-HYDROXYNORKETAMINE AND (2S, 6S)-HYDROXYNORKETAMINE PCT Patent Cooperation Treaty PCT/US17/024241 Expired Patent Cooperation Treaty <br />(PCT) PCT/US17/024241<br />Filed on 2017-03-27<br />Status: Expired 114169190 E-116-2016-0 E-116-2016-0-US-01 CRYSTAL FORMS AND METHODS OF SYNTHESIS OF (2R, 6R)-HYDROXYNORKETAMINE AND (2S, 6S)-HYDROXYNORKETAMINE PRV US 62/313,309 Abandoned US <br />Provisional (PRV) 62/313,309<br />Filed on 2016-03-25<br />Status: Abandoned 114169192 E-116-2016-0 E-116-2016-0-US-08 CRYSTAL FORMS AND METHODS OF SYNTHESIS OF (2R, 6R)-HYDROXYNORKETAMINE AND (2S, 6S)-HYDROXYNORKETAMINE National Stage US 10,919,842 16/088,371 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10919842 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10919842">10,919,842</a><br />Filed on 2018-09-25<br />Status: Issued 114169193 E-116-2016-0 E-116-2016-0-US-09 CRYSTAL FORMS AND METHODS OF SYNTHESIS OF (2R, 6R)-HYDROXYNORKETAMINE AND (2S, 6S)-HYDROXYNORKETAMINE DIV US 11,613,514 17/155,162 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11613514 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11613514">11,613,514</a><br />Filed on 2021-01-22<br />Status: Issued 114128501 WKXXXX 114128502 VNXXXX 114128503 VMXXXX 114128504 VEXXXX 114152376 6S-hydroxynorketamine 114152377 2S 114152378 6R-hydroxynorketamine 114152379 2R 114152380 Synthesis 114152381 Methods 114152382 Forms 114152383 Crystal TAB-2307 114096511 Methods of Treating Giardiasis Using FDA-Approved Compounds NCATS Collaboration, Infectious Disease, Therapeutics Collaboration Infectious Disease Therapeutics Christopher Austin, Catherine Chen, Andrey Galkin, Osnat Herzberg, Juan Marugan, Noel Southall, Wei Zheng This technology includes a group of at least twenty-nine, diverse, commercially available compounds that are newly identified for activity against <i>Giardia lamblia</i> parasites. At least six of the candidate compounds, Bortezomib, Decitabine, Hydroxocobalamin, Amlexanox, Idarubicin, and Auranofin have preexisting FDA approval for human use for other (non-Giardia) conditions. Another three compounds, Fumagillin, Nitarsone and Carbadox have preexisting approval for veterinary use for non-Giardia conditions. Additional active compounds identified include: Acivicin, Riboflavin butyrate, BTO-1, GW9662, Dinitroph-dfgp, Deserpidine, Tetramethylthiuram disulsulfide, Disulfiram, Mitoxantrone, Ecteinascidin 743, 17-allyaminogeldanamycin, Carboquone and Nocodazole. The anti-Giardial activity of these compounds presents a cost saving opportunity for the rapid development of new, better tolerated treatments for the most prevalent human intestinal parasite infection in the United States and the world. These compounds have currently been approved for human and veterinary uses of other indications which provides an opportunity to greatly reduce risk and pre-market investments both in terms of time and costs associated with development and regulatory approval for new Giardia applications including the drug resistant Giardiasis. <ul> <li>Treatment of Giardia in humans</li> <li>Treatment of Giardia in animals - dogs and cats</li> </ul> The NHGRI is seeking stateents of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize Novel Compounds for Treatment of Giardiasis. For collaboration opportunities, please contact Claire Driscoll, NHGRI, at <a href="mailto:cdriscol@mail.nih.gov">cdriscol@mail.nih.gov</a>. 2022-03-08 2024-10-28 2025-04-23 2011-08-12 compounds, DB2XXX, DBXXXX, DXXXXX, Giardiasis, NCTT, Novel, treatment False True <ul> <li>Early-stage</li> <li>Pre-clinical</li> <li>In vitro data available</li> </ul> True NIHTT 37470483 Website Abstract 114171391 Chen CZ, et al. http://www.ncbi.nlm.nih.gov/pubmed/21078930 <a href="http://www.ncbi.nlm.nih.gov/pubmed/21078930">Chen CZ, et al.</a> 114107273 Chen, Catherine National Human Genome Research Institute (NHGRI) Chen, Catherine 0 114107274 Marugan, Juan National Human Genome Research Institute (NHGRI) NCATS Marugan, Juan (NCATS) 0 114107275 Southall, Noel National Human Genome Research Institute (NHGRI) NCATS Southall, Noel (NCATS) 0 114107276 Austin, Christopher National Human Genome Research Institute (NHGRI) NCATS Austin, Christopher (NCATS) 0 114107277 Herzberg, Osnat University of Maryland Herzberg, Osnat 0 114107278 Galkin, Andrey University of Maryland Galkin, Andrey 0 114107272 Zheng, Wei National Human Genome Research Institute (NHGRI) NCATS Zheng, Wei (NCATS) 1 114107272 Zheng, Wei National Human Genome Research Institute (NHGRI) NCATS Zheng, Wei (NCATS) 1 114107273 Chen, Catherine National Human Genome Research Institute (NHGRI) Chen, Catherine 0 114107274 Marugan, Juan National Human Genome Research Institute (NHGRI) NCATS Marugan, Juan (NCATS) 0 114107275 Southall, Noel National Human Genome Research Institute (NHGRI) NCATS Southall, Noel (NCATS) 0 114107276 Austin, Christopher National Human Genome Research Institute (NHGRI) NCATS Austin, Christopher (NCATS) 0 114107277 Herzberg, Osnat University of Maryland Herzberg, Osnat 0 114107278 Galkin, Andrey University of Maryland Galkin, Andrey 0 114101615 Novel Compounds For Treatment Of Giardiasis E-211-2010-1 Filing authorized NCATS - NCGC, University of Maryland, University of Maryland Biotechnology Institute 114101776 Novel Compounds For Treatment Of Giardiasis E-211-2010-2 Filing authorized NCATS - NCGC, University of Maryland, University of Maryland Biotechnology Institute, University of Maryland, College Park 83682485 Vepa, Suryanarayana sury.vepa@nih.gov
United States of America Office of Strategic Alliances (OSA) sury.vepa@nih.gov?subject=Web Inquiry on [TAB-2307] Methods of Treating Giardiasis Using FDA-Approved Compounds&body=Please send me information about technology [TAB-2307] Methods of Treating Giardiasis Using FDA-Approved Compounds. Vepa, Suryanarayana<br><a href="mailto:sury.vepa@nih.gov?subject=Web Inquiry on [TAB-2307] Methods of Treating Giardiasis Using FDA-Approved Compounds&body=Please send me information about technology [TAB-2307] Methods of Treating Giardiasis Using FDA-Approved Compounds.">sury.vepa@nih.gov</a><br> 114164890 E-211-2010-2 E-211-2010-2-US-06 Methods for Treating Giardiasis National Stage US 9,173,898 13/878,832 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9173898 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9173898">9,173,898</a><br />Filed on 2013-04-11<br />Status: Issued 114164901 E-211-2010-2 E-211-2010-2-PCT-01 Method For Treating Giardiasis PCT COMB Patent Cooperation Treaty PCT/US2011/055902 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2011/055902<br />Filed on 2011-10-12<br />Status: Expired 114166495 E-211-2010-1 E-211-2010-1-US-01 Methods of Treating Giardiasis PRV US 61/411,509 Abandoned US <br />Provisional (PRV) 61/411,509<br />Filed on 2010-11-09<br />Status: Abandoned 114122232 DB2XXX 114122233 DXXXXX 114122234 DBXXXX 114141832 Novel 114141833 compounds 114141834 treatment 114141835 Giardiasis 114141836 NCTT TAB-4449 147157744 Lentiviral Vectors with Dual Fluorescence/Luminescence Reporters NCI Licensing, Oncology, Research Materials Licensing Oncology Research Materials Chi-Ping Day, Dominic Esposito, Glenn Merlino <p>The National Cancer Institute’s <a href="https://frederick.cancer.gov/science/Pel/Default.aspx" rel="nofollow">Protein Expression Laboratory</a> seeks parties to co-develop dual luminescent/fluorescent cancer biomarkers.</p> <p>In research settings, visualization of  tumors or tumor cells is often done using either bioluminescence or fluorescence.  However, both of these methods have shortcomings: bioluminescence is not sensitive enough to sort individual tumor cells, and fluorescence cannot be used effectively to view internal tumors and is best used with surface tumors.</p> <p>Researchers at NCI developed twelve lentiviral vectors that express both fluorescent and luminescent markers as a single fusion protein under various gene promoters.  By combining the two reporters into a single fusion protein, the tumor can be visualized within the animal as well as sorted from non-tumor cells for post-necropsy experiments.  The advantage of bioluminescent visualization allows for <em>in vivo</em> experiments that more closely simulate the biological development of tumors in organs, rather than at the skin surface. Additionally, since twelve different vectors with different gene promoters were constructed, they can be tested in individual tumor models to find the best vector for visualizing that particular tumor cell line. The vectors are able to sustain long-term expression of both visualization markers, depending on the cell type and promoter in each vector.</p> <h2>Competitive Advantages:</h2> <ul><li>The bioluminescent marker allows for effective visualization of deep (non-surface) tumors in mice</li> <li>The fluorescence label permits efficient sorting of tumor cells from normal (non-labeled) cells after tumors are excised from the mice</li> <li>The vectors allow <em>in vivo </em>experiments that more closely simulate the biological development of tumors in organs rather than at surface of skin</li> <li>The vectors sustain long-term expression</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Useful for experiments in which both <em>in vivo</em> and <em>in vitro </em>analysis is desired</li> <li>For screening cancer cell lines and in tumor models for reporter gene activity</li> <li>Useful in drug development</li> </ul> 2016-02-16 2025-04-22 2020-08-12 2025-04-22 2016-08-11 Bioluminescence, Fluorescence, tumor visualization, vectors False True Prototype True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-08-12 52406769 Prototype 52406769 NCI 37470483 Website Abstract 147161883 Day CP, et al. Lentivirus-mediated bifunctional cell labeling for in vivo melanoma study. https://www.ncbi.nlm.nih.gov/pubmed/19175523 <a href="https://www.ncbi.nlm.nih.gov/pubmed/19175523">Day CP, et al. Lentivirus-mediated bifunctional cell labeling for in vivo melanoma study.</a> 147164777 Esposito, Dominic NIH - NCI Leidos Esposito, Dominic (Leidos) 1 147164778 Day, Chi-Ping NIH - NCI NCI Day, Chi-Ping (NCI) 2 147164776 Merlino, Glenn NIH - NCI NCI Merlino, Glenn (NCI) 3 147164777 Esposito, Dominic NIH - NCI Leidos Esposito, Dominic (Leidos) 1 147164778 Day, Chi-Ping NIH - NCI NCI Day, Chi-Ping (NCI) 2 147164776 Merlino, Glenn NIH - NCI NCI Merlino, Glenn (NCI) 3 147158047 Lentiviral Vectors For Long-term In Vivo Expression Of Dual Luorescence/luminescence Reporters E-132-2011-0 Research Material NCI 91814193 Freel, Rose rose.freel@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America rose.freel@nih.gov?subject=Web Inquiry on [TAB-4449] Lentiviral Vectors with Dual Fluorescence/Luminescence Reporters&body=Please send me information about technology [TAB-4449] Lentiviral Vectors with Dual Fluorescence/Luminescence Reporters.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Freel, Rose<br><a href="mailto:rose.freel@nih.gov?subject=Web Inquiry on [TAB-4449] Lentiviral Vectors with Dual Fluorescence/Luminescence Reporters&body=Please send me information about technology [TAB-4449] Lentiviral Vectors with Dual Fluorescence/Luminescence Reporters.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">rose.freel@nih.gov</a><br> 147172069 Bioluminescence 147172070 Fluorescence 147172072 tumor visualization 147172073 vectors TAB-4433 147157728 Improved Antibodies Against ERBB4/HER4 NICHD Licensing, Oncology, Research Materials Licensing Oncology Research Materials Andres Buonanno, Detlef Vullhorst <p>The Eunice Kennedy Shriver National Institute of Child Health and Human Development, Section on Molecular Neurobiology is seeking statements of capability or interest from parties interested in collaborative research to further evaluate or commercialize specific rabbit monoclonal antibodies generated against the ErbB4 receptor (also known as HER4) that have been validated for specificity using tissue sections and extracts from ErbB4 knockout mice.</p> <p>ErbB4/Her4 is a receptor tyrosine kinase that regulates cell proliferation, cell differentiation and cell survival.  ErbB4 has been implicated in the pathology of numerous cancers (e.g., breast cancer, non-small cell lung carcinoma, adenocarcinoma), as well as psychiatric disorders (e.g., schizophrenia).  As a result, ErbB4 is an excellent target for developing therapies against these diseases.  Unfortunately, the study of ErbB4 has been slowed by the lack of highly specific and functional antibodies against the receptor.</p> <p> In order to overcome the deficiencies with current ErbB4 antibodies, NIH inventors have generated three rabbit monoclonal antibodies with improved properties and versatility.  Specifically, the mAb-6, mAb-7 and mAb-10 hybridomas produce antibodies with a high degree of specificity and affinity for ErbB4.  These antibodies recognize specific epitopes on the intracellular domains of ErbB4 without cross-reaction against other proteins, and can be used successfully in the immunostaining of fixed tissue.  </p> <h2>Competitive Advantages:</h2> <ul><li>Potential to be the gold standard for ErbB4 antibodies due to its specificity and affinity, as confirmed by using tissue extracts and sections from ErbB4 knockouts.</li> <li>Greater affinity for ErbB4 than currently available antibodies, giving them superior properties in diagnostic and biochemical applications</li> <li>Unlike currently available polyclonal antibodies to ErbB4, the monoclonal antibodies do not cross-react with other proteins</li> <li>Unlike currently available antibodies, these antibodies are capable of immunostaining fixed tissue samples</li> <li>The epitopes on ErbB4 that are recognized by each monoclonal antibody have been mapped</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Basic research tool for the study of ErbB4</li> <li>Reagent for diagnostic applications such as Western Blotting, ELISA, immunofluorescence and immunohistochemistry in fixed tissue samples</li> <li>Reagent for biochemical techniques such as immunoprecipitation</li> </ul> 2016-02-16 2025-04-22 2018-04-20 2025-04-22 2016-08-24 ErbB4/Her4, receptor tyrosine kinase False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2018-04-20 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147161928 Vullhorst D, et al. Selective expression of ErbB4 in interneurons, but not pyramidal cells, of the rodent hippocampus. http://www.ncbi.nlm.nih.gov/pubmed/19793984 <a href="http://www.ncbi.nlm.nih.gov/pubmed/19793984">Vullhorst D, et al. Selective expression of ErbB4 in interneurons, but not pyramidal cells, of the rodent hippocampus.</a> 147161966 Neddens J, et al. Expression of the neuregulin receptor ErbB4 in the brain of the rhesus monkey (Macaca mulatta). http://www.ncbi.nlm.nih.gov/pubmed/22087295 <a href="http://www.ncbi.nlm.nih.gov/pubmed/22087295">Neddens J, et al. Expression of the neuregulin receptor ErbB4 in the brain of the rhesus monkey (Macaca mulatta).</a> 147162353 Neddens J and Buonanno A, et al. Selective populations of hippocampal interneurons express ErbB4 and their number and distribution is altered in ErbB4 knockout mice. http://www.ncbi.nlm.nih.gov/pubmed/19655320 <a href="http://www.ncbi.nlm.nih.gov/pubmed/19655320">Neddens J and Buonanno A, et al. Selective populations of hippocampal interneurons express ErbB4 and their number and distribution is altered in ErbB4 knockout mice.</a> 147162391 Neddens J, et al. Conserved interneuron-specific ErbB4 expression in frontal cortex of rodents, monkeys, and humans: implications for schizophrenia. http://www.ncbi.nlm.nih.gov/pubmed/21664604 <a href="http://www.ncbi.nlm.nih.gov/pubmed/21664604">Neddens J, et al. Conserved interneuron-specific ErbB4 expression in frontal cortex of rodents, monkeys, and humans: implications for schizophrenia.</a> 147164726 Buonanno, Andres NIH - NICHD NICHD Buonanno, Andres (NICHD) 1 147164727 Vullhorst, Detlef NIH - NICHD NINDS Vullhorst, Detlef (NINDS) 2 147164726 Buonanno, Andres NIH - NICHD NICHD Buonanno, Andres (NICHD) 1 147164727 Vullhorst, Detlef NIH - NICHD NINDS Vullhorst, Detlef (NINDS) 2 147158137 Generation Of Potent And Highly Specific Rabbit Monoclonal Antibodies Against Cancer- And Psychosis- Associated Tyrosine Kinase Receptor ErbB4 E-171-2009-0 Research Material NICHD 91788919 Gunas, Heather gunash@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America gunash@mail.nih.gov?subject=Web Inquiry on [TAB-4433] Improved Antibodies Against ERBB4/HER4&body=Please send me information about technology [TAB-4433] Improved Antibodies Against ERBB4/HER4.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Gunas, Heather<br><a href="mailto:gunash@mail.nih.gov?subject=Web Inquiry on [TAB-4433] Improved Antibodies Against ERBB4/HER4&body=Please send me information about technology [TAB-4433] Improved Antibodies Against ERBB4/HER4.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">gunash@mail.nih.gov</a><br> 147172944 ErbB4/Her4 147172946 receptor tyrosine kinase TAB-4430 147157725 Radioprotectants and Tumor Radiosensitizers Targeting Thrombospondin-1 and CD47 NCI Licensing Licensing Jeff Isenberg, Justin Maxhimer, David Roberts <p>The National Cancer Institute''s Laboratory of Pathology is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize CD47-targeting agents as radioprotectants and tumor sensitizers.</p> <p>Radiation therapy not only damages cancer cells, but it also damages healthy cells and can cause serious side effects for patients.  One effort to enhance the therapeutic potential of radiotherapy, while reducing its detrimental effects on normal tissue and maintaining tumor sensitivity, is centered upon the development of radioprotective agents. </p> <p> NIH inventors previously discovered that when the secreted protein, thrombospondin-1 (TSP1) binds to its receptor CD47, this signaling pathway prevents nitric oxide from dilating blood vessels and increasing blood flow to organs and tissues.  They found that blocking TSP1-CD47 interaction through the use of antisense morpholino oligonucleotides, peptides or antibodies has several therapeutic benefits; one of them being increased blood flow to ischemic tissues. </p> <p> In the present technology, the inventors discovered that hindlimb irradiated TSP1 and CD47 null mice have less hair loss, and decreased cell death in muscle and bone marrow than untreated TSP1 and CD47 null mice.  They also discovered that when irradiated human vascular cells are treated with antibodies towards TSP1 or CD47, viability and proliferative capacity are preserved.  Furthermore, the inventors determined that irradiation of wild type mice following treatment with CD47 antisense morpholino resulted in decreased apoptosis in irradiated tissues at 24 hours, preservation of hematopoietic stem cell proliferative capacity in irradiated bone marrow, and less alopecia, ulceration, and desquamation at the end of eight weeks.  These results led the inventors to propose that antagonists of TSP1 and/or CD47 preserve cell viability and tissue function following radiation treatment, and these antagonists may be useful as radioprotective agents to reduce side effects associated with radiation therapy. Remarkably, the same treatment dramatically enhanced the delay in melanoma and squamous carcinoma tumor regrowth following irradiation. Thus, these agents are radioprotective agents for normal tissue but radiosensitizers for tumor tissue.</p> <p> The present technology describes the use of morpholinos, peptides and antibodies that block the TSP1/CD47 signaling pathway as radioprotectants for normal tissue, radioenhancers for tumor tissue, and methods of selectively protecting normal tissue from damage caused by radiation exposure by contacting the tissue with these agents. </p> <p> Development Status: <br /> Mouse data available. In vitro data available in mouse, bovine, porcine, and human cells.<br />  </p> <h2>Competitive Advantages:</h2> <h2>Commercial Applications:</h2> <ul><li>Protect normal tissue from damage following radiation therapy.</li> <li>Enhance tumor responses to radiotherapy.</li> <li>Enable use of higher therapeutic doses for radiotherapy of cancer.</li> <li>Protect personnel from radiation injuries resulting from occupational exposure to ionizing radiation, military exposure, or terrorist acts.</li> </ul> 2016-02-16 2025-04-22 2018-07-13 2025-04-22 2010-03-31 CANCER, CD47, Morpholinos, Radioprotective Agents, Radiotherapeutics, Thrombospondin-1 (TSP1), Tumor Sensitizers False True True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2018-07-13 52406768 Discovery 52406768 NCI 37470483 Website Abstract E-086-2012 E-227-2006 E-263-2014 E-296-2011 147164719 Roberts, David NIH - NCI NCI Roberts, David (NCI) 1 147164721 Maxhimer, Justin NIH - NCI NCI Maxhimer, Justin (NCI) 2 147164720 Isenberg, Jeff NCI - CCR Isenberg, Jeff 3 147164719 Roberts, David NIH - NCI NCI Roberts, David (NCI) 1 147164721 Maxhimer, Justin NIH - NCI NCI Maxhimer, Justin (NCI) 2 147164720 Isenberg, Jeff NCI - CCR Isenberg, Jeff 3 147158089 Radioprotectants Targeting Thrombospondin-1 And CD47 E-153-2008-0 Filing authorized NCI 121111111 Greene, Jaime greenejaime@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America greenejaime@mail.nih.gov?subject=Web Inquiry on [TAB-4430] Radioprotectants and Tumor Radiosensitizers Targeting Thrombospondin-1 and CD47&body=Please send me information about technology [TAB-4430] Radioprotectants and Tumor Radiosensitizers Targeting Thrombospondin-1 and CD47.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Greene, Jaime<br><a href="mailto:greenejaime@mail.nih.gov?subject=Web Inquiry on [TAB-4430] Radioprotectants and Tumor Radiosensitizers Targeting Thrombospondin-1 and CD47&body=Please send me information about technology [TAB-4430] Radioprotectants and Tumor Radiosensitizers Targeting Thrombospondin-1 and CD47.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">greenejaime@mail.nih.gov</a><br> 147168879 E-153-2008-0 E-153-2008-0-US-01 Radioprotectants Targeting Thrombospondin-1 And CD47 PRV US 61/086,991 Abandoned US <br />Provisional (PRV) 61/086,991<br />Filed on 2008-08-07<br />Status: Abandoned 147168880 E-153-2008-0 E-153-2008-0-PCT-02 Radioprotectants Targeting Thrombospondin-1 And CD47 PCT Patent Cooperation Treaty PCT/US2009/052902 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2009/052902<br />Filed on 2009-08-05<br />Status: Expired 147168881 E-153-2008-0 E-153-2008-0-AU-03 Radioprotectants Targeting Thrombospondin-1 And CD47 National Stage Australia 2009279676 2009279676 Issued Australia <br />National Stage 2009279676<br />Filed on 2009-08-05<br />Status: Issued 147168882 E-153-2008-0 E-153-2008-0-CA-04 Radioprotectants Targeting Thrombospondin-1 And CD47 National Stage Canada 2732102 2732102 Issued Canada <br />National Stage 2732102<br />Filed on 2011-01-26<br />Status: Issued 147168883 E-153-2008-0 E-153-2008-0-EP-05 Radioprotectants Targeting Thrombospondin-1 And CD47 National Stage European Patent 2340034 09791202.6 Issued European Patent <br />National Stage 09791202.6<br />Filed on 2009-08-05<br />Status: Issued 147168884 E-153-2008-0 E-153-2008-0-US-06 Radioprotectants Targeting Thrombospondin-1 And CD47 National Stage US 8,951,527 13/057,447 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8951527 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8951527">8,951,527</a><br />Filed on 2011-02-03<br />Status: Issued 147168885 E-153-2008-0 E-153-2008-0-DE-07 Radioprotectants Targeting Thrombospondin-1 And CD47 EP Germany 602009036069.8 09791202.6 Issued Germany <br />European patent (EP) 09791202.6<br />Filed on 2009-08-05<br />Status: Issued 147168886 E-153-2008-0 E-153-2008-0-FR-08 Radioprotectants Targeting Thrombospondin-1 And CD47 EP France 2340034 09791202.6 Issued France <br />European patent (EP) 09791202.6<br />Filed on 2009-08-05<br />Status: Issued 147168887 E-153-2008-0 E-153-2008-0-GB-09 Radioprotectants Targeting Thrombospondin-1 And CD47 EP United Kingdom 2340034 09791202.6 Issued United Kingdom <br />European patent (EP) 09791202.6<br />Filed on 2009-08-05<br />Status: Issued 147172467 CANCER 147172468 CD47 147172470 Morpholinos 147172472 Radioprotective Agents 147172474 Radiotherapeutics 147172476 Thrombospondin-1 (TSP1) 147172478 Tumor Sensitizers TAB-4410 147157705 Human Antibodies Against Middle East Respiratory Syndrome Coronavirus NCI Collaboration, Infectious Disease, Licensing, Therapeutics Collaboration Infectious Disease Licensing Therapeutics Dimiter Dimitrov, Tina Ju, Tianlei Ying, Kwok-Yung Yuen <p>No effective therapeutics or vaccines against Middle East Respiratory Syndrome Coronavirus (MERS-CoV) are available. The human-to-human aspect of transmission and the high mortality rate associated with MERS-CoV infection have raised concerns over the potential for a future MERS-CoV pandemic and emphasized the need for development of effective therapeutics and vaccines.</p> <p>The MERS-CoV-S protein is believed to be required for binding and virus entry during MERS-CoV infection. The antibodies of this technology represent candidate antibody-based therapeutics for treatment of MERS-CoV infection.  Researchers at the NCI have developed human antibodies that target MERS-CoV.  Certain of these antibodies bind with epitopes of the MERS-CoV receptor binding domain (RBD) of MERS-CoV spike (S) protein with high affinity and are capable of neutralizing the virus as demonstrated in a pseudovirus assay.</p> <h2>Competitive Advantages:</h2> <ul><li>No vaccine or other biologic therapy is available, and this antibody provides high binding (sub-nanomolar) affinity, and relative safety with long half-lives.</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Antibody-based therapeutics for treatment of MERS-CoV infection</li> </ul> 2016-02-16 2025-04-22 2018-05-30 2025-04-22 2014-03-24 ANTIBODY, CORONAVIRUS, MERs, middle east respiratory syndrome False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2018-05-30 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147162020 Zhu Z, et al. https://www.ncbi.nlm.nih.gov/pubmed/18271743 <a href="https://www.ncbi.nlm.nih.gov/pubmed/18271743">Zhu Z, et al.</a> 147162098 Zhu Z, et al. http://www.ncbi.nlm.nih.gov/pubmed/17620608 <a href="http://www.ncbi.nlm.nih.gov/pubmed/17620608">Zhu Z, et al.</a> 147162176 Zaki AM, et al. https://www.ncbi.nlm.nih.gov/pubmed/23075143 <a href="https://www.ncbi.nlm.nih.gov/pubmed/23075143">Zaki AM, et al.</a> 147164640 Dimitrov, Dimiter NIH - NCI NCI Dimitrov, Dimiter (NCI) 1 147164641 Ying, Tianlei NIH - NCI Ying, Tianlei 2 147164642 Ju, Tina NIH - NCI Ju, Tina 3 147164643 Yuen, Kwok-Yung University of Hong Kong (HKU) Yuen, Kwok-Yung 4 147164640 Dimitrov, Dimiter NIH - NCI NCI Dimitrov, Dimiter (NCI) 1 147164641 Ying, Tianlei NIH - NCI Ying, Tianlei 2 147164642 Ju, Tina NIH - NCI Ju, Tina 3 147164643 Yuen, Kwok-Yung University of Hong Kong (HKU) Yuen, Kwok-Yung 4 147157762 Human Monoclonal Antibodies Against The Middle East Respiratory Syndrome CoronaVirus (MERS-CoV) And Engineered Bispecific Fusions With Inhibitory Peptides E-002-2014-0 Filing authorized NCI, University of Hong Kong (HKU) 91814193 Freel, Rose rose.freel@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America rose.freel@nih.gov?subject=Web Inquiry on [TAB-4410] Human Antibodies Against Middle East Respiratory Syndrome Coronavirus&body=Please send me information about technology [TAB-4410] Human Antibodies Against Middle East Respiratory Syndrome Coronavirus.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Freel, Rose<br><a href="mailto:rose.freel@nih.gov?subject=Web Inquiry on [TAB-4410] Human Antibodies Against Middle East Respiratory Syndrome Coronavirus&body=Please send me information about technology [TAB-4410] Human Antibodies Against Middle East Respiratory Syndrome Coronavirus.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">rose.freel@nih.gov</a><br> 147160877 E-002-2014-0 E-002-2014-0-US-01 Human Monoclonal Antibodies Against The Middle East Respiratory Syndrome CoronaVirus (MERS-CoV) And Engineered Bispecific Fusions With Inhibitory Peptides PRV US 61/892,750 Abandoned US <br />Provisional (PRV) 61/892,750<br />Filed on 2013-10-18<br />Status: Abandoned 147168760 E-002-2014-0 E-002-2014-0-PCT-02 Human Monoclonal Antibodies Against The Middle East Respiratory Syndrome CoronaVirus (MERS-CoV) And Engineered Bispecific Fusions With Inhibitory Peptides PCT Patent Cooperation Treaty PCT/US2014/060863 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2014/060863<br />Filed on 2014-10-16<br />Status: Expired 147168761 E-002-2014-0 E-002-2014-0-SA-03 Human Monoclonal Antibodies Against The Middle East Respiratory Syndrome CoronaVirus (MERS-CoV) And Engineered Bispecific Fusions With Inhibitory Peptides National Stage Saudi Arabia 516370963 Abandoned Saudi Arabia <br />National Stage 516370963<br />Filed on 2014-10-16<br />Status: Abandoned 147168762 E-002-2014-0 E-002-2014-0-US-04 Human Monoclonal Antibodies Against The Middle East Respiratory Syndrome CoronaVirus (MERS-CoV) And Engineered Bispecific Fusions With Inhibitory Peptides National Stage US 10,421,802 15/030,165 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10421802 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10421802">10,421,802</a><br />Filed on 2014-10-16<br />Status: Issued 147169201 ANTIBODY 147169202 CORONAVIRUS 147169203 MERs 147169205 middle east respiratory syndrome TAB-4404 147157699 Modified griffithsin tandemers for enhanced activity and reduced viral aggregation NCI Infectious Disease, Licensing, Therapeutics Infectious Disease Licensing Therapeutics Tinoush Moulaei, Barry O'Keefe, Alexander Wlodawer <p>Griffithsin (GRFT) is a lectin with potent antiviral properties that is capable of preventing and treating infections caused by a number of enveloped viruses (including HIV, SARS, HCV, HSV, and Japanese encephalitis) and is currently in clinical development as an anti-HIV microbicide. In addition to its broad antiviral activity, GRFT is stable at high temperature and at a broad pH range, displays low toxicity and immunogenicity, and is amenable to large-scale manufacturing. Native GRFT is a domain-swapped homodimer that binds to viral envelope glycoproteins and has displayed mid-picomolar activity in cell-based anti-HIV assays.</p> <p>Researchers at <a href="https://ccr.cancer.gov/Molecular-Targets-Laboratory" rel="nofollow">NCI's Molecular Targets Lab </a>developed synthetic proteins that comprise two (or more) obligate monomers (“mGRFT”) joined by an amino acid linker to form tandemers (“mGRFT tandemers”). Each obligate monomer is generated by the addition of Gly-Ser residues in the hinge region of wild-type GRFT. Two or more obligate monomers are joined by an amino acid linker to form the mGRFT tandamers. The properties of the mGRFT tandemers can be modulated by the length of the amino acid linker and the number of obligate monomers co-joined. mGRFT tandemers exhibit gore potent anti-viral properties when compared against native GRFT and are equipotent against viruses that are both sensitive and resistant to naive GRFT. As such, potential uses of the invention tandemers include topical and intravenous therapy to treat HIV infection, particularly to treat HIV infections that are resistant to native GRFT.</p> <h2>Competitive Advantages:</h2> <ul><li>Broad antiviral activity and stable at high temperature and at a broad pH range</li> <li>Displays low toxicity and immunogenicity</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Broad-spectrum antiviral agent similar to wild type GRFT</li> <li>Potential activity against SARS CoV, MERS, Ebola, HCV and influenza</li> </ul> 2016-02-16 2025-04-22 2018-03-29 2025-04-22 2016-08-29 ANTIVIRAL, mGRFT tandemers False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2018-03-29 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147161985 A. Chatterjee et al. Griffithsin and Carrageenan Combination To Target Herpes Simplex Virus 2 and Human Papillomavirus. https://www.ncbi.nlm.nih.gov/pubmed/26369967 <a href="https://www.ncbi.nlm.nih.gov/pubmed/26369967">A. Chatterjee et al. Griffithsin and Carrageenan Combination To Target Herpes Simplex Virus 2 and Human Papillomavirus.</a> 147162141 Moulaei T et al. Griffithsin tandemers: flexible and potent lectin inhibitors of the human immunodeficiency virus. https://www.ncbi.nlm.nih.gov/pubmed/25613831 <a href="https://www.ncbi.nlm.nih.gov/pubmed/25613831">Moulaei T et al. Griffithsin tandemers: flexible and potent lectin inhibitors of the human immunodeficiency virus.</a> 147164610 O'Keefe, Barry NIH - NCI NCI O'Keefe, Barry (NCI) 1 147164609 Wlodawer, Alexander NIH - NCI NCI Wlodawer, Alexander (NCI) 2 147164611 Moulaei, Tinoush NIH - NCI NCI Moulaei, Tinoush (NCI) 3 147164610 O'Keefe, Barry NIH - NCI NCI O'Keefe, Barry (NCI) 1 147164609 Wlodawer, Alexander NIH - NCI NCI Wlodawer, Alexander (NCI) 2 147164611 Moulaei, Tinoush NIH - NCI NCI Moulaei, Tinoush (NCI) 3 147157835 Modified Griffithsin Tandemers For Enhanced Activity And Reduced Viral Aggregation E-034-2013-0 Filing authorized NCI 83732213 Dick, Taryn taryn.dick@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB taryn.dick@nih.gov?subject=Web Inquiry on [TAB-4404] Modified griffithsin tandemers for enhanced activity and reduced viral aggregation&body=Please send me information about technology [TAB-4404] Modified griffithsin tandemers for enhanced activity and reduced viral aggregation.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dick, Taryn<br><a href="mailto:taryn.dick@nih.gov?subject=Web Inquiry on [TAB-4404] Modified griffithsin tandemers for enhanced activity and reduced viral aggregation&body=Please send me information about technology [TAB-4404] Modified griffithsin tandemers for enhanced activity and reduced viral aggregation.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">taryn.dick@nih.gov</a><br> 147168736 E-034-2013-0 E-034-2013-0-US-01 Monomeric Griffithsin Tandemers PRV US 61/831,336 Abandoned US <br />Provisional (PRV) 61/831,336<br />Filed on 2013-06-05<br />Status: Abandoned 147168737 E-034-2013-0 E-034-2013-0-PCT-02 Monomeric Griffithsin Tandemers PCT Patent Cooperation Treaty PCT/US2014/040992 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2014/040992<br />Filed on 2014-06-05<br />Status: Expired 147168738 E-034-2013-0 E-034-2013-0-CA-03 Monomeric Griffithsin Tandemers National Stage Canada 2914498 2914498 Issued Canada <br />National Stage 2914498<br />Filed on 2014-06-05<br />Status: Issued 147168739 E-034-2013-0 E-034-2013-0-US-04 MONOMERIC GRIFFITHSIN TANDEMERS National Stage US 9,982,025 14/895,349 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9982025 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9982025">9,982,025</a><br />Filed on 2015-12-02<br />Status: Issued 147168740 E-034-2013-0 E-034-2013-0-AU-05 Monomeric Griffithsin Tandemers National Stage Australia 2014274927 2014274927 Issued Australia <br />National Stage 2014274927<br />Filed on 2014-06-05<br />Status: Issued 147168741 E-034-2013-0 E-034-2013-0-EP-06 Monomeric Griffithsin Tandemers National Stage European Patent 3003388 14736527.4 Issued European Patent <br />National Stage 14736527.4<br />Filed on 2014-06-05<br />Status: Issued 147168743 E-034-2013-0 E-034-2013-0-DE-08 Monomeric Griffithsin Tandemers EP Germany 3003388 14736527.4 Issued Germany <br />European patent (EP) 14736527.4<br />Filed on 2014-06-05<br />Status: Issued 147168744 E-034-2013-0 E-034-2013-0-FR-09 Monomeric Griffithsin Tandemers EP France 3003388 14736527.4 Issued France <br />European patent (EP) 14736527.4<br />Filed on 2014-06-05<br />Status: Issued 147168745 E-034-2013-0 E-034-2013-0-GB-10 Monomeric Griffithsin Tandemers EP United Kingdom 3003388 14736527.4 Issued United Kingdom <br />European patent (EP) 14736527.4<br />Filed on 2014-06-05<br />Status: Issued 147169953 ANTIVIRAL 147169955 mGRFT tandemers TAB-4401 147157696 Methods for Selection of Cancer Patients and Predicting Efficacy of Combination Therapy NCI Collaboration, Diagnostics, Licensing, Oncology Collaboration Diagnostics Licensing Oncology Aleksandra Michalowski, Beverly Mock, Jyoti Patel, John Simmons <p>Available for licensing from the <a href="https://ccr.cancer.gov/Laboratory-of-Cancer-Biology-and-Genetics" target="_blank" rel="nofollow">Laboratory of Cancer Biology and Genetics</a> of the National Cancer Institute (NCI) is a novel gene signature of thirty-seven drug-responsive genes that links changes in gene expression to the clinically desirable outcome of improved overall survival. Expression of these genes has been linked to prognosis in several cancers, including, but not limited to: multiple myeloma, melanoma, and lung and breast cancers. Patients identified by this signature would be predicted to benefit from combined HDAC inhibitor/mTOR inhibitor therapy.</p> <h2>Competitive Advantages:</h2> <ul><li>Implements a smaller gene set compared to current diagnostic gene signatures.</li> <li>Provides a basis for the development of a diagnostic for patient stratification or a response measurement related to the combined use of mTOR and HDAC inhibitors for cancer treatment.</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Development of a clinical diagnostic test to identify cancer patients who would benefit most from mTOR and HDAC combination therapy.</li> <li>Use as a surrogate biomarker related to drug response.</li> <li>Development of therapeutics targeting several cancers, including multiple myeloma.</li> </ul> 2016-02-16 2025-04-22 2017-03-06 2025-04-22 2016-08-24 Histone Deacetylase (HDAC), MELANOMA, mTOR, Myeloma, Rapamycin False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2017-03-06 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147164599 Mock, Beverly NCI - CCR NCI Mock, Beverly (NCI) 1 147164598 Simmons, John NIH - NCI Simmons, John 2 147164600 Michalowski, Aleksandra NIH - NCI NCI Michalowski, Aleksandra (NCI) 3 147164601 Patel, Jyoti NIH - NCI FDA Patel, Jyoti (FDA) 4 147164599 Mock, Beverly NCI - CCR NCI Mock, Beverly (NCI) 1 147164598 Simmons, John NIH - NCI Simmons, John 2 147164600 Michalowski, Aleksandra NIH - NCI NCI Michalowski, Aleksandra (NCI) 3 147164601 Patel, Jyoti NIH - NCI FDA Patel, Jyoti (FDA) 4 147157787 Clinically Correlated Biomarker Response Signature For The Therapeutic Combination Of Histone Deacetylase (HDAC) And MTOR Inhibitors For Cancer E-013-2012-0 Filing authorized NCI 121111111 Greene, Jaime greenejaime@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America greenejaime@mail.nih.gov?subject=Web Inquiry on [TAB-4401] Methods for Selection of Cancer Patients and Predicting Efficacy of Combination Therapy&body=Please send me information about technology [TAB-4401] Methods for Selection of Cancer Patients and Predicting Efficacy of Combination Therapy.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Greene, Jaime<br><a href="mailto:greenejaime@mail.nih.gov?subject=Web Inquiry on [TAB-4401] Methods for Selection of Cancer Patients and Predicting Efficacy of Combination Therapy&body=Please send me information about technology [TAB-4401] Methods for Selection of Cancer Patients and Predicting Efficacy of Combination Therapy.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">greenejaime@mail.nih.gov</a><br> 147160897 E-013-2012-0 E-013-2012-0-US-04 Gene Expression Signatures of Neoplasm Responsiveness to Therapy National Stage US 9,670,549 14/357,191 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9670549 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9670549">9,670,549</a><br />Filed on 2014-05-08<br />Status: Issued 147168715 E-013-2012-0 E-013-2012-0-US-01 GENE EXPRESSION SIGNATURES OF NEOPLASM RESPONSIVENESS TO THERAPY PRV US 61/558,402 Abandoned US <br />Provisional (PRV) 61/558,402<br />Filed on 2011-11-10<br />Status: Abandoned 147168716 E-013-2012-0 E-013-2012-0-PCT-02 GENE EXPRESSION SIGNATURES OF NEOPLASM RESPONSIVENESS TO THERAPY PCT Patent Cooperation Treaty PCT/US2012/064693 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2012/064693<br />Filed on 2012-11-12<br />Status: Expired 147168717 E-013-2012-0 E-013-2012-0-CA-03 GENE EXPRESSION SIGNATURES OF NEOPLASM RESPONSIVENESS TO THERAPY National Stage Canada 2854665 Abandoned Canada <br />National Stage 2854665<br />Filed on 2012-11-12<br />Status: Abandoned 147169461 Histone Deacetylase (HDAC) 147169462 MELANOMA 147169463 mTOR 147169464 Myeloma 147169465 Rapamycin TAB-4402 147157697 Novel Anti-HIV Compounds Using Peptides or Peptide Mimetics NCI Infectious Disease, Licensing, Therapeutics Infectious Disease Licensing Therapeutics Ina O'Carroll, Yun-Xing Wang, Liu Yu, Ping Yu <p>The subject invention describes a new class of compounds (such as peptides or mimetics) that target viral RNAs and inhibit the viral life cycle by blocking the viral recognition process. More specifically, these compounds are the first against an RNA Target - currently there are no clinical drugs against RNA targets in the treatment of any type of human disease. Anti-HIV drugs currently on the market are complicated by the development of resistance and substantial side-effects; however, these compounds would unlikely develop any side effects because of their very high specificity against only viral RNA. In addition, these compounds may be further linked to a detectable label. Thus, these compounds have the potential to be used as a new class of systemic drugs for the treatment of HIV infection and to be developed into diagnostic kits or devices.</p> <h2>Competitive Advantages:</h2> <ul><li>New class of compound</li> <li>Inhibits the viral recognition process and nuclear export activity</li> <li>High specifity only to HIV RNA</li> <li>Ease of permeability through cell membrane because compound is positively charged.</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Anti-viral HIV therapeutic</li> <li>HIV Diagnostic</li> </ul> 2016-02-16 2025-04-22 2018-07-19 2025-04-22 2016-08-29 Anti-Viral, HIV False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2018-07-19 52406768 Discovery 52406768 NCI 37470483 Website Abstract E-119-2013 147162178 Fang X, et al. http://www.ncbi.nlm.nih.gov/pubmed/24243017 <a href="http://www.ncbi.nlm.nih.gov/pubmed/24243017">Fang X, et al.</a> 147164602 Wang, Yun-Xing NIH - NCI NCI Wang, Yun-Xing (NCI) 1 147164603 Yu, Liu NCI - CCR NCI Yu, Liu (NCI) 2 147164604 Yu, Ping NIH - NCI Leidos Yu, Ping (Leidos) 3 147164605 O'Carroll, Ina NIH - NCI NCI O'Carroll, Ina (NCI) 4 147164602 Wang, Yun-Xing NIH - NCI NCI Wang, Yun-Xing (NCI) 1 147164603 Yu, Liu NCI - CCR NCI Yu, Liu (NCI) 2 147164604 Yu, Ping NIH - NCI Leidos Yu, Ping (Leidos) 3 147164605 O'Carroll, Ina NIH - NCI NCI O'Carroll, Ina (NCI) 4 147157803 A Class Of Compounds That Bind To The HIV-1 Rev Response Element Much Tighter Than The Rev E-019-2014-0 Filing authorized NCI 147162492 A Class Of Compounds That Bind To The HIV-1 Rev Response Element Much Tighter Than The Rev E-019-2014-1 Filing authorized NCI 147162493 A Class Of Compounds That Bind To The HIV-1 Rev Response Element Much Tighter Than The Rev E-019-2014-2 Filing authorized NCI 83704821 Nguyen-Antczak, Lauren lauren.nguyen-antczak@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-4402] Novel Anti-HIV Compounds Using Peptides or Peptide Mimetics&body=Please send me information about technology [TAB-4402] Novel Anti-HIV Compounds Using Peptides or Peptide Mimetics.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Nguyen-Antczak, Lauren<br><a href="mailto:lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-4402] Novel Anti-HIV Compounds Using Peptides or Peptide Mimetics&body=Please send me information about technology [TAB-4402] Novel Anti-HIV Compounds Using Peptides or Peptide Mimetics.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">lauren.nguyen-antczak@nih.gov</a><br> 147160911 E-019-2014-0 E-019-2014-0-US-01 COMPOUNDS THAT BIND TO HIV-1 REV RESPONSE ELEMENTT PRV US 61/894,849 Abandoned US <br />Provisional (PRV) 61/894,849<br />Filed on 2013-10-23<br />Status: Abandoned 147168720 E-019-2014-1 E-019-2014-1-US-01 Compounds that Bind to Human Immunodeficiency Virus Rev Response Element PRV US 61/934,379 Abandoned US <br />Provisional (PRV) 61/934,379<br />Filed on 2014-01-31<br />Status: Abandoned 147168722 E-019-2014-2 E-019-2014-2-PCT-01 COMPOUNDS THAT BIND TO HUMAN IMMUNODEFICIENCY VIRUS REV RESPONSE ELEMENT PCT COMB Patent Cooperation Treaty PCT/US2014/061975 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2014/061975<br />Filed on 2014-10-23<br />Status: Expired 147168723 E-019-2014-2 E-019-2014-2-US-02 COMPOUNDS THAT BIND TO HUMAN IMMUNODEFICIENCY VIRUS REV RESPONSE ELEMENT National Stage US 10,464,970 15/031,232 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10464970 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10464970">10,464,970</a><br />Filed on 2016-04-21<br />Status: Issued 147168724 E-019-2014-2 E-019-2014-2-US-03 COMPOUNDS THAT BIND TO HUMAN IMMUNODEFICIENCY VIRUS REV RESPONSE ELEMENT CON US 11,692,010 16/664,523 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11692010 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11692010">11,692,010</a><br />Filed on 2019-10-25<br />Status: Issued 147169619 Anti-Viral 147169620 HIV TAB-4358 147157651 Osmogels: A New Method for Stabilizing Weak Molecular Complex Interactions NICHD Collaboration, Licensing, Oncology, Research Materials Collaboration Licensing Oncology Research Materials Donald Rau, Nina Sidorova <p>The <em>Eunice Kennedy Schriver</em> National Institute of Child Health and Human Development is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize a new method for stabilizing molecular complexes in polyacrylamide gels.</p> <p> This invention describes a new method for stabilizing molecular complexes in polyacrylamide gels for analysis by the electrophoretic mobility shift assay. By adding specific osmolytes directly to the gel, investigators have found that weakly interacting molecular complexes can be sufficiently stabilized to allow quantitative analysis of the binding. Experiments with nonspecific labile complexes of two restriction endonucleases, EcoRI and BamHI, show that one of these added solutes is particularly effective at inhibiting complex dissociation, does not interfere with normal gel polymerization, and does not significantly slow normal gel migration. The results also demonstrate that sharp bands can be obtained for non-specific complexes of both enzymes on gels prepared with this solute while only smeared and distorted bands are observed on regular gels prepared without the solute. This method can be used for protein-protein, DNA-protein, and RNA-protein complexes, and can also be extended to include other techniques for separating complexes from free components using gel chromatography and capillary electrophoresis.</p> <p> The potential market for gels that allow researchers to detect and quantify weak molecular complex interactions is significant; ranging from molecular biologists searching for novel regulatory DNA-binding proteins and convenient ways to detect protein-protein, or protein-DNA/RNA complexes to crystallographers needing reliable techniques to search for optimal conditions of complex formation. This technology has the potential to significantly impact biomedical research and development across many fields.</p> <p> Development Status: <br /> Late stage</p> <h2>Competitive Advantages:</h2> <h2>Commercial Applications:</h2> <p>Detection of weak molecular complex interactions for research and commercial use</p> 2016-02-16 2025-04-22 2016-09-06 2025-04-22 2016-08-31 Diagnostic Assays Kits and/or Regeants, Electrophoretic Mobility Shift Assay, Osmogels, Polyacrylamide Gels, RESEARCH TOOL False True Clinical True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2016-09-06 72159138 Clinical Phase I 72159138 NCI 37470483 Website Abstract 147164438 Sidorova, Nina NIH - NICHD NICHD Sidorova, Nina (NICHD) 1 147164439 Rau, Donald NIH - NICHD Rau, Donald 2 147164438 Sidorova, Nina NIH - NICHD NICHD Sidorova, Nina (NICHD) 1 147164439 Rau, Donald NIH - NICHD Rau, Donald 2 147158220 Osmo-gels: Stabilizing Labile DNA-protein Complexes For Analysis By The GeI Mobility Shift Assay E-214-2009-0 Filing authorized NICHD 83657698 Specialist (ALS), Admin. Licensing nihott@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
nihott@mail.nih.gov?subject=Web Inquiry on [TAB-4358] Osmogels: A New Method for Stabilizing Weak Molecular Complex Interactions&body=Please send me information about technology [TAB-4358] Osmogels: A New Method for Stabilizing Weak Molecular Complex Interactions.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Specialist (ALS), Admin. Licensing<br><a href="mailto:nihott@mail.nih.gov?subject=Web Inquiry on [TAB-4358] Osmogels: A New Method for Stabilizing Weak Molecular Complex Interactions&body=Please send me information about technology [TAB-4358] Osmogels: A New Method for Stabilizing Weak Molecular Complex Interactions.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">nihott@mail.nih.gov</a><br> 147168410 E-214-2009-0 E-214-2009-0-US-01 Stabilization Of Complexes For GeI Mobility Shift, Chromatography, And Capillary Electrophoresis ORD US 12/485,481 Abandoned US <br />Ordinary Patent (ORD) 12/485,481<br />Filed on 2009-06-16<br />Status: Abandoned 147173797 Diagnostic Assays Kits and/or Regeants 147173799 Electrophoretic Mobility Shift Assay 147173801 Osmogels 147173803 Polyacrylamide Gels 147173804 RESEARCH TOOL TAB-4363 147157656 Human T Cell Receptors for Treating Cancer NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Nachimuthu Chinnasamy, Richard Morgan, Steven Rosenberg <p>T cell receptors (TCRs) are proteins that recognize antigens in the context of infected or transformed cells and activate T cells to mediate an immune response and destroy abnormal cells. TCRs consist of two domains, one variable domain that recognizes the antigen and one constant region that helps the TCR anchor to the membrane and transmit recognition signals by interacting with other proteins. When a TCR is stimulated by an antigen, such as a tumor antigen, some signaling pathways activated in the cell lead to the production of cytokines, which mediate the immune response.</p> <p> There are ten (10) known members of the synovial sarcoma breakpoint X (SSX) protein family designated SSX-1 through SSX-10. The T cell receptors (TCRs) developed by these NCI scientists have specificity for SSX-2 and deliver a robust immune response when they encounter SSX-2 expressing cells. However, these TCRs also recognize five (5) other SSX family members, including SSX-3, SSX-4, SSX-5, SSX-9, and/or SSX-10, and deliver a productive, intermediate immune response in the context of target cells expressing these antigens. This versatile antigen coverage could allow these SSX-specific TCRs to be utilized in the treatment of multiple types of cancer in a wide array of cancer patients.  Infusing cancer patients with SSX-2 specific T cells via adoptive immunotherapy could prove to be a powerful approach for selectively attacking tumors without generating toxicity against noncancerous cells.</p> <h2>Competitive Advantages:</h2> <ul><li>Selective toxicity for tumor cells</li> <li>Ability to recognize multiple SSX antigens </li> <li>Versatile antigen recognition </li> </ul> <h2>Commercial Applications:</h2> <ul><li>Immunotherapeutics to treat and/or prevent the recurrence of a variety of human cancers;</li> <li>A research tool to investigate signaling pathways in SSX-2 expressing cancer cells;</li> <li>An in vitro diagnostic tool to screen for cells expressing an SSX antigen from a recognized member of the SSX protein family.</li> </ul> 2016-02-16 2025-04-22 2018-05-04 2025-04-22 2016-09-08 COLON CANCER, Hepatocellular cancer, MELANOMA, PROSTATE CANCER, SSX False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2018-05-04 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-105-2012 E-236-2010 147161938 G. Bricard, et al. http://www.ncbi.nlm.nih.gov/pubmed/15661935 <a href="http://www.ncbi.nlm.nih.gov/pubmed/15661935">G. Bricard, et al.</a> 147162132 N. Chinnasamy et al. http://www.ncbi.nlm.nih.gov/pubmed/21149604 <a href="http://www.ncbi.nlm.nih.gov/pubmed/21149604">N. Chinnasamy et al.</a> 147162479 D. Valmori et al. http://www.ncbi.nlm.nih.gov/pubmed/ <a href="http://www.ncbi.nlm.nih.gov/pubmed/">D. Valmori et al.</a> 147164448 Morgan, Richard NIH - NCI NCI Morgan, Richard (NCI) 1 147164450 Chinnasamy, Nachimuthu NIH - NCI NCI Chinnasamy, Nachimuthu (NCI) 2 147164449 Rosenberg, Steven NIH - NCI NCI Rosenberg, Steven (NCI) 3 147164448 Morgan, Richard NIH - NCI NCI Morgan, Richard (NCI) 1 147164450 Chinnasamy, Nachimuthu NIH - NCI NCI Chinnasamy, Nachimuthu (NCI) 2 147164449 Rosenberg, Steven NIH - NCI NCI Rosenberg, Steven (NCI) 3 147158299 Isolation And Analysis Of A Human TCR Recognizing Cancer Testis Antigen SSX2 And Use In Adaptive Immunotherapy E-269-2010-0 Filing authorized NCI 83709866 Burke, Andrew burkear@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC burkear@nih.gov?subject=Web Inquiry on [TAB-4363] Human T Cell Receptors for Treating Cancer&body=Please send me information about technology [TAB-4363] Human T Cell Receptors for Treating Cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Burke, Andrew<br><a href="mailto:burkear@nih.gov?subject=Web Inquiry on [TAB-4363] Human T Cell Receptors for Treating Cancer&body=Please send me information about technology [TAB-4363] Human T Cell Receptors for Treating Cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">burkear@nih.gov</a><br> 147168421 E-269-2010-0 E-269-2010-0-US-01 Anti SSX2 T Cell Receptors And Related Materials and Methods of Use PRV US 61/384,931 Abandoned US <br />Provisional (PRV) 61/384,931<br />Filed on 2010-09-21<br />Status: Abandoned 147168422 E-269-2010-0 E-269-2010-0-PCT-02 ANTI-SSX-2 T CELL RECEPTORS AND RELATED MATERIALS AND METHODS OF USE PCT Patent Cooperation Treaty PCT/US11/51537 Expired Patent Cooperation Treaty <br />(PCT) PCT/US11/51537<br />Filed on 2011-09-14<br />Status: Expired 147168423 E-269-2010-0 E-269-2010-0-AU-03 ANTI-SSX-2 T CELL RECEPTORS AND RELATED MATERIALS AND METHODS OF USE National Stage Australia 2011305817 2011305817 Issued Australia <br />National Stage 2011305817<br />Filed on 2011-09-14<br />Status: Issued 147168424 E-269-2010-0 E-269-2010-0-CA-04 ANTI-SSX-2 T CELL RECEPTORS AND RELATED MATERIALS AND METHODS OF USE National Stage Canada 2811788 2811788 Issued Canada <br />National Stage 2811788<br />Filed on 2016-09-09<br />Status: Issued 147168425 E-269-2010-0 E-269-2010-0-EP-05 ANTI-SSX-2 T CELL RECEPTORS AND RELATED MATERIALS AND METHODS OF USE National Stage European Patent 2619223 11763819.7 Issued European Patent <br />National Stage 11763819.7<br />Filed on 2011-09-14<br />Status: Issued 147168426 E-269-2010-0 E-269-2010-0-CN-06 ANTI-SSX-2 T CELL RECEPTORS AND RELATED MATERIALS AND METHODS OF USE National Stage China ZL201180045492.0 201180045492.0 Issued China <br />National Stage 201180045492.0<br />Filed on 2011-09-14<br />Status: Issued 147168427 E-269-2010-0 E-269-2010-0-JP-07 ANTI-SSX-2 T CELL RECEPTORS AND RELATED MATERIALS AND METHODS OF USE National Stage Japan 6133209 2013-529285 Issued Japan <br />National Stage 2013-529285<br />Filed on 2013-03-19<br />Status: Issued 147168428 E-269-2010-0 E-269-2010-0-IL-08 ANTI-SSX-2 T CELL RECEPTORS AND RELATED MATERIALS AND METHODS OF USE National Stage Israel 225063 225063 Issued Israel <br />National Stage 225063<br />Filed on 2013-03-05<br />Status: Issued 147168429 E-269-2010-0 E-269-2010-0-US-09 Anti-SSX-2 T Cell Receptors and Related Materials and Methods of Use National Stage US 9,345,748 13/820,802 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9345748 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9345748">9,345,748</a><br />Filed on 2013-06-07<br />Status: Issued 147168430 E-269-2010-0 E-269-2010-0-US-10 Anti-SSX-2 T Cell Receptors and Related Materials and Methods of Use CON US 10,143,724 15/132,863 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10143724 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10143724">10,143,724</a><br />Filed on 2016-04-19<br />Status: Issued 147168431 E-269-2010-0 E-269-2010-0-JP-11 ANTI-SSX-2 T CELL RECEPTORS AND RELATED MATERIALS AND METHODS OF USE DIV Japan 2017-082965 Abandoned Japan <br />Divisional (DIV) 2017-082965<br />Filed on 2017-04-19<br />Status: Abandoned 147168432 E-269-2010-0 E-269-2010-0-IL-12 ANTI-SSX-2 T CELL RECEPTORS AND RELATED MATERIALS AND METHODS OF USE DIV Israel 254469 254469 Issued Israel <br />Divisional (DIV) 254469<br />Filed on 2017-09-13<br />Status: Issued 147168433 E-269-2010-0 E-269-2010-0-US-13 ANTI-SSX-2 T CELL RECEPTORS AND RELATED MATERIALS AND METHODS OF USE CON US 10,864,252 16/173,701 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10864252 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10864252">10,864,252</a><br />Filed on 2018-10-29<br />Status: Issued 147168434 E-269-2010-0 E-269-2010-0-EP-14 ANTI-SSX-2 T CELL RECEPTORS AND RELATED MATERIALS AND METHODS OF USE DIV European Patent 3533802 19166061.2 Issued European Patent <br />Divisional (DIV) 19166061.2<br />Filed on 2019-03-29<br />Status: Issued 147168435 E-269-2010-0 E-269-2010-0-AT-15 ANTI-SSX-2 T CELL RECEPTORS AND RELATED MATERIALS AND METHODS OF USE EP Austria 2619223 11763819.7 Issued Austria <br />European patent (EP) 11763819.7<br />Filed on 2011-09-14<br />Status: Issued 147168436 E-269-2010-0 E-269-2010-0-BE-16 ANTI-SSX-2 T CELL RECEPTORS AND RELATED MATERIALS AND METHODS OF USE EP Belgium 2619223 11763819.7 Issued Belgium <br />European patent (EP) 11763819.7<br />Filed on 2011-09-14<br />Status: Issued 147168437 E-269-2010-0 E-269-2010-0-CH-17 ANTI-SSX-2 T CELL RECEPTORS AND RELATED MATERIALS AND METHODS OF USE EP Switzerland 2619223 11763819.7 Issued Switzerland <br />European patent (EP) 11763819.7<br />Filed on 2011-09-14<br />Status: Issued 147168438 E-269-2010-0 E-269-2010-0-DE-18 ANTI-SSX-2 T CELL RECEPTORS AND RELATED MATERIALS AND METHODS OF USE EP Germany 2619223 11763819.7 Issued Germany <br />European patent (EP) 11763819.7<br />Filed on 2011-09-14<br />Status: Issued 147168439 E-269-2010-0 E-269-2010-0-ES-19 ANTI-SSX-2 T CELL RECEPTORS AND RELATED MATERIALS AND METHODS OF USE EP Spain 2619223 11763819.7 Issued Spain <br />European patent (EP) 11763819.7<br />Filed on 2011-09-14<br />Status: Issued 147168440 E-269-2010-0 E-269-2010-0-FR-20 ANTI-SSX-2 T CELL RECEPTORS AND RELATED MATERIALS AND METHODS OF USE EP France 2619223 11763819.7 Issued France <br />European patent (EP) 11763819.7<br />Filed on 2011-09-14<br />Status: Issued 147168441 E-269-2010-0 E-269-2010-0-GB-21 ANTI-SSX-2 T CELL RECEPTORS AND RELATED MATERIALS AND METHODS OF USE EP United Kingdom 2619223 11763819.7 Issued United Kingdom <br />European patent (EP) 11763819.7<br />Filed on 2011-09-14<br />Status: Issued 147168442 E-269-2010-0 E-269-2010-0-IE-22 ANTI-SSX-2 T CELL RECEPTORS AND RELATED MATERIALS AND METHODS OF USE EP Ireland 2619223 11763819.7 Issued Ireland <br />European patent (EP) 11763819.7<br />Filed on 2011-09-14<br />Status: Issued 147168443 E-269-2010-0 E-269-2010-0-IT-23 ANTI-SSX-2 T CELL RECEPTORS AND RELATED MATERIALS AND METHODS OF USE EP Italy 2619223 11763819.7 Issued Italy <br />European patent (EP) 11763819.7<br />Filed on 2011-09-14<br />Status: Issued 147168444 E-269-2010-0 E-269-2010-0-NL-24 ANTI-SSX-2 T CELL RECEPTORS AND RELATED MATERIALS AND METHODS OF USE EP The Netherlands 2619223 11763819.7 Issued The Netherlands <br />European patent (EP) 11763819.7<br />Filed on 2011-09-14<br />Status: Issued 147168445 E-269-2010-0 E-269-2010-0-PT-25 ANTI-SSX-2 T CELL RECEPTORS AND RELATED MATERIALS AND METHODS OF USE EP Portugal 2619223 11763819.7 Issued Portugal <br />European patent (EP) 11763819.7<br />Filed on 2011-09-14<br />Status: Issued 147168446 E-269-2010-0 E-269-2010-0-IL-26 ANTI-SSX-2 T CELL RECEPTORS AND RELATED MATERIALS AND METHODS OF USE DIV Israel 271021 271021 Issued Israel <br />Divisional (DIV) 271021<br />Filed on 2019-11-28<br />Status: Issued 147168447 E-269-2010-0 E-269-2010-0-AT-27 ANTI-SSX-2 T CELL RECEPTORS AND RELATED MATERIALS AND METHODS OF USE EP Austria 3533802 19166061.2 Issued Austria <br />European patent (EP) 19166061.2<br />Filed on 2019-03-29<br />Status: Issued 147168448 E-269-2010-0 E-269-2010-0-BE-28 ANTI-SSX-2 T CELL RECEPTORS AND RELATED MATERIALS AND METHODS OF USE EP Belgium 3533802 19166061.2 Issued Belgium <br />European patent (EP) 19166061.2<br />Filed on 2019-03-29<br />Status: Issued 147168449 E-269-2010-0 E-269-2010-0-CH-29 ANTI-SSX-2 T CELL RECEPTORS AND RELATED MATERIALS AND METHODS OF USE EP Switzerland 3533802 19166061.2 Issued Switzerland <br />European patent (EP) 19166061.2<br />Filed on 2019-03-29<br />Status: Issued 147168450 E-269-2010-0 E-269-2010-0-DE-30 ANTI-SSX-2 T CELL RECEPTORS AND RELATED MATERIALS AND METHODS OF USE EP Germany 3533802 19166061.2 Issued Germany <br />European patent (EP) 19166061.2<br />Filed on 2019-03-29<br />Status: Issued 147168451 E-269-2010-0 E-269-2010-0-ES-31 ANTI-SSX-2 T CELL RECEPTORS AND RELATED MATERIALS AND METHODS OF USE EP Spain 3533802 19166061.2 Issued Spain <br />European patent (EP) 19166061.2<br />Filed on 2019-03-29<br />Status: Issued 147168452 E-269-2010-0 E-269-2010-0-FR-32 ANTI-SSX-2 T CELL RECEPTORS AND RELATED MATERIALS AND METHODS OF USE EP France 3533802 19166061.2 Issued France <br />European patent (EP) 19166061.2<br />Filed on 2019-03-29<br />Status: Issued 147168453 E-269-2010-0 E-269-2010-0-GB-33 ANTI-SSX-2 T CELL RECEPTORS AND RELATED MATERIALS AND METHODS OF USE EP United Kingdom 3533802 19166061.2 Issued United Kingdom <br />European patent (EP) 19166061.2<br />Filed on 2019-03-29<br />Status: Issued 147168454 E-269-2010-0 E-269-2010-0-IE-34 ANTI-SSX-2 T CELL RECEPTORS AND RELATED MATERIALS AND METHODS OF USE EP Ireland 3533802 19166061.2 Issued Ireland <br />European patent (EP) 19166061.2<br />Filed on 2019-03-29<br />Status: Issued 147168455 E-269-2010-0 E-269-2010-0-IT-35 ANTI-SSX-2 T CELL RECEPTORS AND RELATED MATERIALS AND METHODS OF USE EP Italy 3533802 19166061.2 Issued Italy <br />European patent (EP) 19166061.2<br />Filed on 2019-03-29<br />Status: Issued 147168456 E-269-2010-0 E-269-2010-0-NL-36 ANTI-SSX-2 T CELL RECEPTORS AND RELATED MATERIALS AND METHODS OF USE EP The Netherlands 3533802 19166061.2 Issued The Netherlands <br />European patent (EP) 19166061.2<br />Filed on 2019-03-29<br />Status: Issued 147168457 E-269-2010-0 E-269-2010-0-PT-37 ANTI-SSX-2 T CELL RECEPTORS AND RELATED MATERIALS AND METHODS OF USE EP Portugal 3533802 19166061.2 Issued Portugal <br />European patent (EP) 19166061.2<br />Filed on 2019-03-29<br />Status: Issued 147174468 COLON CANCER 147174469 Hepatocellular cancer 147174470 MELANOMA 147174471 PROSTATE CANCER 147174472 SSX TAB-4337 147157628 Human Monoclonal Antibodies Cross-reacting to Insulin-like Growth Factors IGF-I and IGF-II as Potential Anti-tumor Agents NCI Licensing, Oncology, Therapeutics Licensing Oncology Therapeutics Dimiter Dimitrov, Qi Zhao, Zhongyu Zhu <p>The National Cancer Institute's  Cancer and Inflammation Program is seeking statements of capability or interest from parties interested in licensing this technology. </p> <p>The type 1 insulin-like growth factor (IGF) receptor (IGF1R) is over-expressed by many tumors and mediates proliferation, motility, and protection from apoptosis. Agents that inhibit IGF1R expression or function can potentially block tumor growth and metastasis. Its major ligands, IGF-I, and IGF-II are over-expressed by multiple tumor types. Previous studies indicate that inhibition of IGF-I, and/or IGF-II binding to its cognizant receptor negatively modulates signal transduction through the IGF pathway and concomitant cell proliferation and growth. Therefore, use of humanized or fully human antibodies against IGFs represents a valid approach to inhibit tumor growth.</p> <p>The present invention discloses the identification and characterization of a fully human monoclonal antibody designated m708.5 that has been affinity maturated against IGF-I and IGF-II and displays extremely high affinities for IGF-I and IGF-II in the picoM range.  The m708.5 antibody potently inhibited signal transduction mediated by the IGF-1R interaction with IGF-I and IGF-II and blocked phosphorylation of IGF-IR and the insulin receptor.  Further, this antibody inhibited migration in the MCF-7 breast cancer cell line at the picoM range.  Therefore, this antibody can be used to prevent binding of IGF-I and/or IGF-II to its concomitant receptor IGFIR, consequently, modulating diseases such as cancer.</p> <h2>Competitive Advantages:</h2> <ul><li>Antibodies against the ligands IGF-I and IGF-II, such as this invention, inhibit the interaction with IGF-IR yet likely do not have the type of toxicity associated with IGF-1R antibodies.</li> <li>High concentrations of IGF-II are found in cancer patients, on average several fold higher than IGF-I, thus this cross-reacting IGF-I/IGF-II antibody could be more effective than existing IGF-IR and/or IGF-I currently in the clinic.</li> <li>This novel IGF antibody may provide therapeutic intervention for multiple carcinomas.</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Therapeutic for the treatment of various human diseases associated with aberrant cell growth and motility such as breast, prostate, and leukemia carcinomas.</li> <li>Research regent to study IGF-I and/or IGF-II binding and its association with tumor growth.</li> </ul> 2016-02-16 2025-04-22 2018-05-04 2025-04-22 2017-08-29 Dimitrov, IGF-I, IGF-II, insulin-like growth factor, Monoclonal Antibody False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2018-05-04 52406768 Discovery 52406768 NCI 37470483 Website Abstract E-217-2005 E-336-2005 147161990 Feng Y, et al.; Novel human monoclonal antibodies to insulin-like growth factor (IGF)-II that potently inhibit the IGF receptor type I signal transduction function. https://www.ncbi.nlm.nih.gov/pubmed/18283605 <a href="https://www.ncbi.nlm.nih.gov/pubmed/18283605">Feng Y, et al.; Novel human monoclonal antibodies to insulin-like growth factor (IGF)-II that potently inhibit the IGF receptor type I signal transduction function.</a> 147162068 Zhao Q, et al.; Human monoclonal antibody fragments binding to insulin-like growth factors 1 and 2 with picomolar affinity. https://www.ncbi.nlm.nih.gov/pubmed/21750218 <a href="https://www.ncbi.nlm.nih.gov/pubmed/21750218">Zhao Q, et al.; Human monoclonal antibody fragments binding to insulin-like growth factors 1 and 2 with picomolar affinity.</a> 147162146 Kimura T, et al.; Targeting of bone-derived insulin-like growth factor-II by a human neutralizing antibody suppresses the growth of prostate cancer cells in a human bone environment. https://www.ncbi.nlm.nih.gov/pubmed/20028742 <a href="https://www.ncbi.nlm.nih.gov/pubmed/20028742">Kimura T, et al.; Targeting of bone-derived insulin-like growth factor-II by a human neutralizing antibody suppresses the growth of prostate cancer cells in a human bone environment.</a> 147164360 Dimitrov, Dimiter NIH - NCI NCI Dimitrov, Dimiter (NCI) 1 147164362 Zhao, Qi NIH - NCI Zhao, Qi 2 147164361 Zhu, Zhongyu NIH - NCI NCI Zhu, Zhongyu (NCI) 3 147164360 Dimitrov, Dimiter NIH - NCI NCI Dimitrov, Dimiter (NCI) 1 147164362 Zhao, Qi NIH - NCI Zhao, Qi 2 147164361 Zhu, Zhongyu NIH - NCI NCI Zhu, Zhongyu (NCI) 3 147157917 Human Monoclonal Antibodies Cross-reacting To Insulin-like Growth Factor (IGF) I And II E-068-2011-0 Filing authorized NCI 91814193 Freel, Rose rose.freel@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America rose.freel@nih.gov?subject=Web Inquiry on [TAB-4337] Human Monoclonal Antibodies Cross-reacting to Insulin-like Growth Factors IGF-I and IGF-II as Potential Anti-tumor Agents&body=Please send me information about technology [TAB-4337] Human Monoclonal Antibodies Cross-reacting to Insulin-like Growth Factors IGF-I and IGF-II as Potential Anti-tumor Agents.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Freel, Rose<br><a href="mailto:rose.freel@nih.gov?subject=Web Inquiry on [TAB-4337] Human Monoclonal Antibodies Cross-reacting to Insulin-like Growth Factors IGF-I and IGF-II as Potential Anti-tumor Agents&body=Please send me information about technology [TAB-4337] Human Monoclonal Antibodies Cross-reacting to Insulin-like Growth Factors IGF-I and IGF-II as Potential Anti-tumor Agents.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">rose.freel@nih.gov</a><br> 147160990 E-068-2011-0 E-068-2011-0-US-01 Human Monoclonal Antibodies That Bind Insulin-like Growth Factor (IGF) I And II PRV US 61/474,664 Abandoned US <br />Provisional (PRV) 61/474,664<br />Filed on 2011-04-12<br />Status: Abandoned 147168271 E-068-2011-0 E-068-2011-0-PCT-02 Human Monoclonal Antibodies That Bind Insulin-Like Growth Factor (IGF) I and II PCT Patent Cooperation Treaty PCT/US2012/033128 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2012/033128<br />Filed on 2012-04-11<br />Status: Expired 147168272 E-068-2011-0 E-068-2011-0-US-03 Human Monoclonal Antibodies That Bind Insulin-Like Growth Factor (IGF) I And II ORD US 9,150,644 14/111,507 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9150644 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9150644">9,150,644</a><br />Filed on 2013-10-11<br />Status: Issued 147168273 E-068-2011-0 E-068-2011-0-US-04 Human Monoclonal Antibodies That Bind Insulin-Like Growth Factor (IGF) I and II DIV US 9,676,846 14/832,803 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9676846 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9676846">9,676,846</a><br />Filed on 2015-08-21<br />Status: Issued 147170703 Dimitrov 147170704 IGF-I 147170705 IGF-II 147170706 insulin-like growth factor 147170707 Monoclonal Antibody TAB-4315 147157605 Modulating Chemotherapeutic Cytotoxicity NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics David Roberts, David Soto Pantoja <p>Many chemotherapeutic agents cause significant cytotoxicity to non-cancer ("normal") cells, resulting in undesirable side-effects and often limiting the dose and/or duration of chemotherapy that can be administered to a patient.</p> <p>Investigators at the National Cancer Institute’s <a href="https://ccr.cancer.gov/Laboratory-of-Pathology" rel="nofollow">Laboratory of Pathology</a> have demonstrated that deficiency or blockade of the ubiquitously expressed receptor CD47 results in remarkable cell and tissue protection against ischemic and radiation stress. Antagonists of CD47 or its ligand THBS1/thrombospondin 1 enhance cell survival and preserve their proliferative capacity. The researchers found that using CD47-modulating compounds in combination with a chemotherapeutic agent increases the efficacy of that agent against inhibiting tumor growth. This discovery builds on previous discoveries of antibodies, antisense morpholino oligonucleotides, and peptide compounds that modulate CD47.</p> <p>The results have been observed in mouse and pig models. Potential research collaborations could include clinical demonstration of effects.</p> <h2>Competitive Advantages:</h2> <ul><li>Enhances effectiveness of chemotherapeutic agents while limiting off-target effects on normal tissue</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Combination chemotherapy</li> </ul> 2016-02-16 2025-04-22 2016-09-06 2025-04-22 2016-09-12 CD47, morpholino False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2016-09-06 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-086-2012 E-153-2008 E-227-2006 E-263-2014 147162135 Soto-Pantoja, D. R. et al http://www.ncbi.nlm.nih.gov/pubmed/23301159 <a href="http://www.ncbi.nlm.nih.gov/pubmed/23301159">Soto-Pantoja, D. R. et al</a> 147162482 Soto-Pantoja, D. R. et al http://www.ncbi.nlm.nih.gov/pubmed/22874555 <a href="http://www.ncbi.nlm.nih.gov/pubmed/22874555">Soto-Pantoja, D. R. et al</a> 147164275 Roberts, David NIH - NCI NCI Roberts, David (NCI) 1 147164276 Soto Pantoja, David NIH - NCI NCI Soto Pantoja, David (NCI) 2 147164275 Roberts, David NIH - NCI NCI Roberts, David (NCI) 1 147164276 Soto Pantoja, David NIH - NCI NCI Soto Pantoja, David (NCI) 2 147158336 Protecting Normal Tissue And Enhancing Tumor Control By Combining Chemotherapy With CD47 Blockade E-296-2011-0 Filing authorized NCI 121111111 Greene, Jaime greenejaime@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America greenejaime@mail.nih.gov?subject=Web Inquiry on [TAB-4315] Modulating Chemotherapeutic Cytotoxicity&body=Please send me information about technology [TAB-4315] Modulating Chemotherapeutic Cytotoxicity.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Greene, Jaime<br><a href="mailto:greenejaime@mail.nih.gov?subject=Web Inquiry on [TAB-4315] Modulating Chemotherapeutic Cytotoxicity&body=Please send me information about technology [TAB-4315] Modulating Chemotherapeutic Cytotoxicity.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">greenejaime@mail.nih.gov</a><br> 147161268 E-296-2011-0 E-296-2011-0-PCT-02 METHODS FOR MODULATING CHEMOTHERAPEUTIC CYTOTOXICITY PCT Patent Cooperation Treaty PCT/US2014/025989 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2014/025989<br />Filed on 2014-03-13<br />Status: Expired 147168105 E-296-2011-0 E-296-2011-0-US-01 Methods For Modulating Chemotherapeutic Cytotoxicity PRV US 61/779,587 Abandoned US <br />Provisional (PRV) 61/779,587<br />Filed on 2013-03-13<br />Status: Abandoned 147168106 E-296-2011-0 E-296-2011-0-AU-03 METHODS FOR MODULATING CHEMOTHERAPEUTIC CYTOTOXICITY National Stage Australia 2014244083 2014244083 Issued Australia <br />National Stage 2014244083<br />Filed on 2014-03-13<br />Status: Issued 147168107 E-296-2011-0 E-296-2011-0-CA-04 METHODS FOR MODULATING CHEMOTHERAPEUTIC CYTOTOXICITY National Stage Canada 2905418 2905418 Issued Canada <br />National Stage 2905418<br />Filed on 2014-03-13<br />Status: Issued 147168108 E-296-2011-0 E-296-2011-0-EP-05 METHODS FOR MODULATING CHEMOTHERAPEUTIC CYTOTOXICITY National Stage European Patent 2968536 14718255.4 Abandoned European Patent <br />National Stage 14718255.4<br />Filed on 2014-03-13<br />Status: Abandoned 147168109 E-296-2011-0 E-296-2011-0-US-06 Methods for Modulating Chemotherapeutic Cytotoxicity National Stage US 11,285,169 14/775,428 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11285169 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11285169">11,285,169</a><br />Filed on 2015-09-11<br />Status: Issued 147168110 E-296-2011-0 E-296-2011-0-US-07 METHODS FOR MODULATING CHEMOTHERAPEUTIC CYTOTOXICITY DIV US 17/682,655 Abandoned US <br />Divisional (DIV) 17/682,655<br />Filed on 2022-02-28<br />Status: Abandoned 147168111 E-296-2011-0 E-296-2011-0-FR-01 METHODS FOR MODULATING CHEMOTHERAPEUTIC CYTOTOXICITY EP France 2968536 14718255.4 Abandoned France <br />European patent (EP) 14718255.4<br />Filed on 2014-03-13<br />Status: Abandoned 147168112 E-296-2011-0 E-296-2011-0-DE-01 METHODS FOR MODULATING CHEMOTHERAPEUTIC CYTOTOXICITY EP Germany 2968536 14718255.4 Abandoned Germany <br />European patent (EP) 14718255.4<br />Filed on 2014-03-13<br />Status: Abandoned 147168113 E-296-2011-0 E-296-2011-0-GB-01 METHODS FOR MODULATING CHEMOTHERAPEUTIC CYTOTOXICITY EP United Kingdom 2968536 14718255.4 Abandoned United Kingdom <br />European patent (EP) 14718255.4<br />Filed on 2014-03-13<br />Status: Abandoned 147174758 CD47 147174760 morpholino TAB-4312 147157602 Use of Anti-CD47 Antibodies for the Treatment of Cancer NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Sukhbir Kaur, Chengyu Liu, David Roberts <p>High expression of CD47, a cell surface receptor on several types of cancer cells, has been identified as a ‘don’t eat me signal’ that inhibits their killing by macrophages or NK cells. Conversely, the CD47 antibody B6H12 that blocks SIRPα binding enhances macrophage-dependent clearance of tumors in several mouse models, although others have shown that such clearance can be independent of SIRPα signaling.</p> <p>Cancer stems cells (CSCs) are tumorigenic cells that are difficult to target with conventional chemotherapies due to their undifferentiated state. Stem cells also play an important role in the pathogenesis of cancer. CSCs have been reported to express elevated CD47 levels, but the role of CD47 in directly regulating cancer stem cell function has not been examined. </p> <p>Researchers at the National Cancer Institute's <a href="https://ccr.cancer.gov/Laboratory-of-Pathology" rel="nofollow">Laboratory of Pathology</a> found that the absence of CD47 enhances stem cell renewal <em>in vitro</em> and <em>in vivo</em> by increasing expression of four stem cell transcription factors (see related technologies below). More recently, they discovered methods to force differentiation of breast cancer stem cells by targeting the receptor CD47. These methods disrupt EGF receptor signaling and up-regulate tumor suppressor gene expression in breast cancer stem cells from triple negative breast cancers, but have no effect on normal mammary epithelial cells.</p> <p>Related technologies include:<br /> U. S. Patent 8,236,313; U. S. Patent 8,557,788; U. S. Patent 8,865,672; U. S. Patent No. 8,951,527<br /> U.S. Patent Application No. 61/735,701 filed December 11, 2012<br /> Application PCT/US2014/025989 filed March 13, 2014</p> <h2>Competitive Advantages:</h2> <p>Monoclonal antibodies that directly target CD47-expressing cancers</p> <h2>Commercial Applications:</h2> <p>- Treatment for breast cancer and other cancers<br /> - Antibodies for biomedical research</p> 2016-02-16 2025-04-22 2016-08-31 2025-04-22 2016-09-07 CD47, Stem Cell False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2016-08-31 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-086-2012 E-153-2008 E-227-2006 E-296-2011 147164269 Roberts, David NIH - NCI NCI Roberts, David (NCI) 1 147164271 Kaur, Sukhbir NIH - NCI NCI Kaur, Sukhbir (NCI) 2 147164270 Liu, Chengyu NIH - NHLBI NHLBI Liu, Chengyu (NHLBI) 3 147164269 Roberts, David NIH - NCI NCI Roberts, David (NCI) 1 147164271 Kaur, Sukhbir NIH - NCI NCI Kaur, Sukhbir (NCI) 2 147164270 Liu, Chengyu NIH - NHLBI NHLBI Liu, Chengyu (NHLBI) 3 147158289 Methods To Eliminate Cancer Stem Cells By Targeting CD47 E-263-2014-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI), NCI 121111111 Greene, Jaime greenejaime@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America greenejaime@mail.nih.gov?subject=Web Inquiry on [TAB-4312] Use of Anti-CD47 Antibodies for the Treatment of Cancer&body=Please send me information about technology [TAB-4312] Use of Anti-CD47 Antibodies for the Treatment of Cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Greene, Jaime<br><a href="mailto:greenejaime@mail.nih.gov?subject=Web Inquiry on [TAB-4312] Use of Anti-CD47 Antibodies for the Treatment of Cancer&body=Please send me information about technology [TAB-4312] Use of Anti-CD47 Antibodies for the Treatment of Cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">greenejaime@mail.nih.gov</a><br> 147161241 E-263-2014-0 E-263-2014-0-US-01 Methods To Eliminate Cancer Stem Cells By Targeting CD47 PRV US 62/062,675 Abandoned US <br />Provisional (PRV) 62/062,675<br />Filed on 2014-10-10<br />Status: Abandoned 147168081 E-263-2014-0 E-263-2014-0-PCT-02 Methods To Eliminate Cancer Stem Cells By Targeting CD47 PCT Patent Cooperation Treaty PCT/US2015/055029 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2015/055029<br />Filed on 2015-10-09<br />Status: Expired 147168082 E-263-2014-0 E-263-2014-0-AU-03 Methods To Eliminate Cancer Stem Cells By Targeting CD47 National Stage Australia 2015329696 Abandoned Australia <br />National Stage 2015329696<br />Filed on 2015-10-09<br />Status: Abandoned 147168083 E-263-2014-0 E-263-2014-0-CA-04 Methods To Eliminate Cancer Stem Cells By Targeting CD47 National Stage Canada 2964173 Abandoned Canada <br />National Stage 2964173<br />Filed on 2015-10-09<br />Status: Abandoned 147168084 E-263-2014-0 E-263-2014-0-EP-05 Methods To Eliminate Cancer Stem Cells By Targeting CD47 National Stage European Patent 3204420 15788253.1 Issued European Patent <br />National Stage 15788253.1<br />Filed on 2015-10-09<br />Status: Issued 147168085 E-263-2014-0 E-263-2014-0-US-06 METHODS TO ELIMINATE CANCER STEM CELLS BY TARGETING CD47 National Stage US 11,053,314 15/517,345 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11053314 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11053314">11,053,314</a><br />Filed on 2017-04-06<br />Status: Issued 147168086 E-263-2014-0 E-263-2014-0-DE-07 Methods To Eliminate Cancer Stem Cells By Targeting CD47 EP Germany 3204420 15788253.1 Issued Germany <br />European patent (EP) 15788253.1<br />Filed on 2015-10-09<br />Status: Issued 147168087 E-263-2014-0 E-263-2014-0-FR-08 Methods To Eliminate Cancer Stem Cells By Targeting CD47 EP France 3204420 15788253.1 Issued France <br />European patent (EP) 15788253.1<br />Filed on 2015-10-09<br />Status: Issued 147168088 E-263-2014-0 E-263-2014-0-GB-09 Methods To Eliminate Cancer Stem Cells By Targeting CD47 EP United Kingdom 3204420 15788253.1 Issued United Kingdom <br />European patent (EP) 15788253.1<br />Filed on 2015-10-09<br />Status: Issued 147168089 E-263-2014-0 E-263-2014-0-US-10 Methods To Eliminate Cancer Stem Cells By Targeting CD47 CON US 17/346,630 Abandoned US <br />Continuation (CON) 17/346,630<br />Filed on 2021-06-14<br />Status: Abandoned 147168090 E-263-2014-0 E-263-2014-0-AU-11 Methods To Eliminate Cancer Stem Cells By Targeting CD47 DIV Australia 2021204818 2021204818 Issued Australia <br />Divisional (DIV) 2021204818<br />Filed on 2021-07-09<br />Status: Issued 147174393 CD47 147174394 Stem Cell TAB-4310 147157600 Synthetic lipopeptide inhibitors of RAS oncoproteins NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Michael Dean, Vadim Gaponenko, Alla Ivanova, Joseph Kates, Sergey Tarasov, Nadya Tarasova <p>It is well known that overactive Ras signaling is linked to many forms of cancer, and despite intensive efforts worldwide to develop effective inhibitors of Ras, to date there is no anti-Ras inhibitor in clinical use.</p> <p>Researchers at the NCI’s <a href="https://ccr.cancer.gov/Cancer-and-Inflammation-Program" rel="nofollow">Cancer and Inflammation Program</a>, in collaboration with scientists at Vanderbilt University and the University of Illinois in Chicago, have identified a number of small peptidomimetic compounds that bind to Ras proteins with nanomolar affinity.  The development of compounds was based on two previously unknown mechanisms of Ras regulation uncovered due collaborative efforts of the three groups. The researchers have found that hypervariable regions (HVR) of some isoforms of Ras proteins function as negative regulators of Ras activity. Rational design lead to generation of metabolically stable cell-permeable analogs of HVRs with much improved binding affinity and anti-tumor activity.  The second class of inhibitory compounds targets Ras dimerization interface. Compounds inhibit RAS-dependent growth of cancer cells at low nanomolar and subnanomolar concentrations.</p> <p><em>In vitro</em> data indicate that the inhibitors are effective at inhibiting growth in a number of cancer cell lines including lung cancer. In addition, <em>in vivo</em> data indidate that the inhibitors are effective at  inhibiting tumor growth in mouse xenograft models. </p> <p>The inventors are interested in collaborations to help optimize PK/PD properties of Ras inhibitors and conduct preclinical <em>in vivo</em> studies.</p> <h2>Competitive Advantages:</h2> <p>- Synthetic compounds binding to Ras proteins with high affinity<br /> - Cell permeable peptidomimetics<br /> - Membrane-anchored inhibitors</p> <h2>Commercial Applications:</h2> <p>- Novel cancer therapeutic (prostate cancer, colon cancer, pancreatic cancer, ovarian cancer, lung cancer, breast cancer, thyroid cancer, leukemia, bladder cancer, salivary gland cancer, melanoma, myeloid malignancy, or germ cell tumors)</p> 2016-02-16 2025-04-22 2016-08-31 2025-04-22 2016-09-12 COLON, LUNG, MULTIPLE MYELOMA, Pancreatic Cancer, RAS, THYROID CANCER False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2016-08-31 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147162251 Jang, H., et al. http://www.ncbi.nlm.nih.gov/pubmed/25713064 <a href="http://www.ncbi.nlm.nih.gov/pubmed/25713064">Jang, H., et al.</a> 147164256 Tarasova, Nadya NIH - NCI NCI Tarasova, Nadya (NCI) 1 147164257 Tarasov, Sergey NIH - NCI NCI Tarasov, Sergey (NCI) 2 147164259 Gaponenko, Vadim University of Illinois at Chicago Gaponenko, Vadim 3 147164260 Kates, Joseph Calidris Therapeutics, Inc. Kates, Joseph 4 147164255 Dean, Michael NIH - NCI NCI Dean, Michael (NCI) 5 147164258 Ivanova, Alla Vanderbilt University Ivanova, Alla 6 147164256 Tarasova, Nadya NIH - NCI NCI Tarasova, Nadya (NCI) 1 147164257 Tarasov, Sergey NIH - NCI NCI Tarasov, Sergey (NCI) 2 147164259 Gaponenko, Vadim University of Illinois at Chicago Gaponenko, Vadim 3 147164260 Kates, Joseph Calidris Therapeutics, Inc. Kates, Joseph 4 147164255 Dean, Michael NIH - NCI NCI Dean, Michael (NCI) 5 147164258 Ivanova, Alla Vanderbilt University Ivanova, Alla 6 147158330 Lipopeptide Inhibitors Of RAS Oncoprotein E-293-2010-0 Filing authorized Calidris Therapeutics, Inc., NCI, University of Illinois at Chicago, Vanderbilt University 83732213 Dick, Taryn taryn.dick@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB taryn.dick@nih.gov?subject=Web Inquiry on [TAB-4310] Synthetic lipopeptide inhibitors of RAS oncoproteins&body=Please send me information about technology [TAB-4310] Synthetic lipopeptide inhibitors of RAS oncoproteins.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dick, Taryn<br><a href="mailto:taryn.dick@nih.gov?subject=Web Inquiry on [TAB-4310] Synthetic lipopeptide inhibitors of RAS oncoproteins&body=Please send me information about technology [TAB-4310] Synthetic lipopeptide inhibitors of RAS oncoproteins.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">taryn.dick@nih.gov</a><br> 147168071 E-293-2010-0 E-293-2010-0-US-01 Lipopeptide Inhibitors Of RAS Oncoprotein PRV US 61/489,919 Abandoned US <br />Provisional (PRV) 61/489,919<br />Filed on 2011-05-25<br />Status: Abandoned 147168072 E-293-2010-0 E-293-2010-0-PCT-02 Lipopeptide Inhibitors Of RAS Oncoproteins PCT Patent Cooperation Treaty PCT/US12/39623 Expired Patent Cooperation Treaty <br />(PCT) PCT/US12/39623<br />Filed on 2012-05-25<br />Status: Expired 147168073 E-293-2010-0 E-293-2010-0-US-03 Lipopeptide Inhibitors Of RAS Oncoprotein National Stage US 9,328,142 14/119,596 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9328142 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9328142">9,328,142</a><br />Filed on 2014-01-30<br />Status: Issued 147168074 E-293-2010-0 E-293-2010-0-US-04 Lipopeptide Inhibitors Of RAS Oncoprotein DIV US 15/015,940 Abandoned US <br />Divisional (DIV) 15/015,940<br />Filed on 2016-02-04<br />Status: Abandoned 147174729 COLON 147174730 LUNG 147174731 MULTIPLE MYELOMA 147174732 Pancreatic Cancer 147174733 RAS 147174734 THYROID CANCER TAB-4265 147157552 Method for Generating Pluripotent and Multipotent Cells NCI Collaboration, Licensing, Oncology, Research Materials Collaboration Licensing Oncology Research Materials Jeff Isenberg, Sukhbir Kaur, David Roberts <p>Research and clinical applications of induced pluripotent stem (iPS) cells are currently limited by reprogramming methods that may modify the host genome, and therefore be potentially unsafe and problematic for use in basic research, cell-based therapies, and drug-discovery applications. </p> <p>Researchers at the National Cancer Institute’s <a href="https://ccr.cancer.gov/Laboratory-of-Pathology" rel="nofollow">Laboratory of Pathology</a> have overcome this challenge by using CD47 inhibiting peptides, antibodies, and morpholinos to generate and expand iPS cells.  This technology represents a safe yet highly efficient strategy for somatic cell reprogramming, and has broad applicability for basic research and disease modeling. The NCI seeks partners interested in licensing or collaborative research to co-develop methods for generating and expanding iPS cells and lineage-committed stem cells using a single agent.</p> <h2>Competitive Advantages:</h2> <ul><li>Virus-free reprogramming</li> <li>Genomic integration-free</li> <li>Allows generation and maintenance of a ready supply of iPS cells and using a single defined agent</li> <li>Maintains cell growth and morphology for at least 6 months</li> </ul> <h2>Commercial Applications:</h2> <ul><li>iPS cell generation (human and murine)</li> <li>Lineage-committed stem cell generation</li> <li>Stem cell therapy</li> </ul> 2016-02-16 2025-04-22 2018-04-17 2025-04-22 2016-08-30 cell-based therapies, cell-reprogramming, iPS cells False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2018-04-17 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-158-2008 E-227-2006 E-263-2014 E-296-2011 147162457 Kaur S et al. Thrombospondin-1 signaling through CD47 inhibits self-renewal by regulating c-Myc and other stem cell transcription factors https://www.ncbi.nlm.nih.gov/pubmed/23591719 <a href="https://www.ncbi.nlm.nih.gov/pubmed/23591719">Kaur S et al. Thrombospondin-1 signaling through CD47 inhibits self-renewal by regulating c-Myc and other stem cell transcription factors</a> 147164098 Roberts, David NIH - NCI NCI Roberts, David (NCI) 1 147164100 Kaur, Sukhbir NIH - NCI NCI Kaur, Sukhbir (NCI) 2 147164099 Isenberg, Jeff NCI - CCR Isenberg, Jeff 3 147164098 Roberts, David NIH - NCI NCI Roberts, David (NCI) 1 147164100 Kaur, Sukhbir NIH - NCI NCI Kaur, Sukhbir (NCI) 2 147164099 Isenberg, Jeff NCI - CCR Isenberg, Jeff 3 147157952 Methods For Cell Immortalization And Generation Of Pluripotent Cells E-086-2012-0 Filing authorized NCI 147162518 Methods For Cell Immortalization And Generation Of Pluripotent Cells E-086-2012-1 Filing authorized NCI 147162519 Methods For Cell Immortalization And Generation Of Pluripotent Cells E-086-2012-2 Filing authorized NCI, University of Pittsburgh 121111111 Greene, Jaime greenejaime@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America greenejaime@mail.nih.gov?subject=Web Inquiry on [TAB-4265] Method for Generating Pluripotent and Multipotent Cells&body=Please send me information about technology [TAB-4265] Method for Generating Pluripotent and Multipotent Cells.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Greene, Jaime<br><a href="mailto:greenejaime@mail.nih.gov?subject=Web Inquiry on [TAB-4265] Method for Generating Pluripotent and Multipotent Cells&body=Please send me information about technology [TAB-4265] Method for Generating Pluripotent and Multipotent Cells.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">greenejaime@mail.nih.gov</a><br> 147161014 E-086-2012-2 E-086-2012-2-US-05 Methods For Generation Of Pluripotent And Multipotent Cells National Stage US 10,407,665 14/390,134 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10407665 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10407665">10,407,665</a><br />Filed on 2014-10-02<br />Status: Issued 147167772 E-086-2012-0 E-086-2012-0-US-01 Methods For Generation Of Pluripotent And Multipotent Cells PRV US 61/621,994 Abandoned US <br />Provisional (PRV) 61/621,994<br />Filed on 2012-04-09<br />Status: Abandoned 147167774 E-086-2012-1 E-086-2012-1-US-01 Methods For Generation Of Pluripotent and Multipotent Cells PRV US 61/735,701 Abandoned US <br />Provisional (PRV) 61/735,701<br />Filed on 2012-12-11<br />Status: Abandoned 147167776 E-086-2012-2 E-086-2012-2-PCT-01 Methods For Cell Generation Of Pluripotent And Multipotent Cells PCT COMB Patent Cooperation Treaty PCT/US2013/035838 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2013/035838<br />Filed on 2013-04-09<br />Status: Expired 147167777 E-086-2012-2 E-086-2012-2-AU-02 Methods For Cell Generation Of Pluripotent And Multipotent Cells National Stage Australia 2013246040 2013246040 Issued Australia <br />National Stage 2013246040<br />Filed on 2013-04-09<br />Status: Issued 147167778 E-086-2012-2 E-086-2012-2-CA-03 Methods For Generation Of Pluripotent And Multipotent Cells National Stage Canada 2869913 2869913 Issued Canada <br />National Stage 2869913<br />Filed on 2013-04-09<br />Status: Issued 147167779 E-086-2012-2 E-086-2012-2-EP-04 Methods For Generation Of Pluripotent And Multipotent Cells National Stage European Patent 2836591 13718439.6 Issued European Patent <br />National Stage 13718439.6<br />Filed on 2013-04-09<br />Status: Issued 147167781 E-086-2012-2 E-086-2012-2-DE-07 Methods For Generation Of Pluripotent And Multipotent Cells EP Germany 2836591 13718439.6 Issued Germany <br />European patent (EP) 13718439.6<br />Filed on 2013-04-09<br />Status: Issued 147167782 E-086-2012-2 E-086-2012-2-FR-08 Methods For Generation Of Pluripotent And Multipotent Cells EP France 2836591 13718439.6 Issued France <br />European patent (EP) 13718439.6<br />Filed on 2013-04-09<br />Status: Issued 147167783 E-086-2012-2 E-086-2012-2-GB-09 Methods For Generation Of Pluripotent And Multipotent Cells EP United Kingdom 2836591 13718439.6 Issued United Kingdom <br />European patent (EP) 13718439.6<br />Filed on 2013-04-09<br />Status: Issued 147167784 E-086-2012-2 E-086-2012-2-US-10 Methods for Generation of Pluripotent and Multipotent Cells CON US 11,692,175 16/521,251 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11692175 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11692175">11,692,175</a><br />Filed on 2019-07-24<br />Status: Issued 147167785 E-086-2012-2 E-086-2012-2-US-11 Methods for Generation of Pluripotent and Multipotent Cells CON US 18/320,244 Abandoned US <br />Continuation (CON) 18/320,244<br />Filed on 2023-05-19<br />Status: Abandoned 147171090 cell-based therapies 147171092 cell-reprogramming 147171094 iPS cells TAB-4296 147157586 Methods of preventing tissue ischemia NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics William Frazier, Jeff Isenberg, David Roberts <p>The National Cancer Institute's Laboratory of Pathology is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize therapeutics targeting vasodialation.</p> <p> Nitric oxide (NO) plays an important role as a major intrinsic vasodilator, and increases blood flow to tissues and organs. Disruption of this process leads to peripheral vascular disease, ischemic heart disease, stroke, vascular insufficiency associated with diabetes, and many more diseases that are significant.</p> <p> Researchers at the NIH have discovered that the matrix protein thrombospondin-1 blocks the beneficial effects of NO, and prevents it from dilating blood vessels and increasing blood flow to organs and tissues.  Additionally, the inventors discovered that this regulation requires interaction with thrombospondin-1's cell receptor CD47. Murine studies revealed that, in the presence of NO, genetically altered mice, lacking either thrombospondin-1 or CD47, showed dramatically improved blood flow and tissue oxygenation.  The inventors have also shown in mice, rats, and pigs that by targeting thrombospondin-1 and/or CD47, blood flow can be dramatically increased to ischemic tissues.   Pre-clinical data includes<em> in vivo</em> data for mice, rats, and pigs.</p> <p> Further R&amp;D Needed:</p> <ul><li>Pharmacokinetic and dosing optimization of existing antisense therapeutics</li> <li>Humanization of antibody therapeutics</li> <li>Development and optimization of small molecule analogs with oral availability</li> </ul> <h2>Competitive Advantages:</h2> <ul><li>Ability to develop therapeutics for precise regulation of blood flow to tissues and organs</li> <li>Potential to treat tissue ischemia, tissue damage due to ischemia, stroke, heart disease, diabetes, cancer, and numerous other significant diseases</li> <li>Ability to develop efficient methods to increase tissue survival under conditions of trauma and surgery</li> </ul> <h2>Commercial Applications:</h2> <p>This invention has numerous potential applications, including increasing tissue survival under conditions of trauma and surgery, including skin grafting, as well as potential therapeutics for vascular disease, ischemic heart disease, stroke, and diabetes.  In addition to increasing blood flow to tissues and organs, this technology can be used to decrease blood flow and may have potential applications in cancer treatment.</p> 2016-02-16 2025-04-22 2021-01-26 2025-04-22 2018-01-01 CD47, ISCHEMIA, nitric oxide, NO, THROMBOSPONDIN False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2021-01-26 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-086-2012 E-153-2008 E-263-2014 E-296-2011 147164202 Isenberg, Jeff NIH - NCI Isenberg, Jeff 1 147164201 Roberts, David NIH - NCI NCI Roberts, David (NCI) 2 147164203 Frazier, William Washington University School of Medicine Frazier, William 3 147164202 Isenberg, Jeff NIH - NCI Isenberg, Jeff 1 147164201 Roberts, David NIH - NCI NCI Roberts, David (NCI) 2 147164203 Frazier, William Washington University School of Medicine Frazier, William 3 147158236 Prevention Of Tissue Ischemia By Functional Suppression Of CD47 E-227-2006-0 Filing authorized NCI, Washington University in St. Louis 147162564 Prevention Of Tissue Ischemia And Related Methods And Compositions E-227-2006-1 Filing authorized NCI, Washington University in St. Louis 147162565 Prevention Of Tissue Ischemia And Related Methods And Compositions E-227-2006-2 Filing authorized NCI, Washington University in St. Louis 147162566 Increased Skin Graft Survival And Healing Through CD47 Ligation E-227-2006-3 Filing authorized NCI, Washington University in St. Louis 147162567 Targeting Of CD47 Or Thrombospondin 1 Reverses Vascular System Aging E-227-2006-4 Filing authorized NCI, Washington University in St. Louis 147162568 Regulating Blood Pressure Through Targeting Thrombospondin-l And CD47 E-227-2006-5 Filing authorized NCI, Washington University in St. Louis 121111111 Greene, Jaime greenejaime@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America greenejaime@mail.nih.gov?subject=Web Inquiry on [TAB-4296] Methods of preventing tissue ischemia&body=Please send me information about technology [TAB-4296] Methods of preventing tissue ischemia.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Greene, Jaime<br><a href="mailto:greenejaime@mail.nih.gov?subject=Web Inquiry on [TAB-4296] Methods of preventing tissue ischemia&body=Please send me information about technology [TAB-4296] Methods of preventing tissue ischemia.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">greenejaime@mail.nih.gov</a><br> 147167950 E-227-2006-0 E-227-2006-0-US-01 Prevention Of Tissue Ischemia PRV US 60/850,132 Abandoned US <br />Provisional (PRV) 60/850,132<br />Filed on 2006-10-06<br />Status: Abandoned 147167952 E-227-2006-1 E-227-2006-1-US-01 Prevention Of Tissue Ischemia PRV US 60/864,153 Abandoned US <br />Provisional (PRV) 60/864,153<br />Filed on 2006-11-02<br />Status: Abandoned 147167954 E-227-2006-2 E-227-2006-2-US-01 Prevention Of Tissue Ischemia PRV US 60/888,754 Abandoned US <br />Provisional (PRV) 60/888,754<br />Filed on 2007-02-07<br />Status: Abandoned 147167956 E-227-2006-3 E-227-2006-3-US-01 Increased Skin Graft Survival And Healing Through CD47 Ligation PRV US 60/910,549 Abandoned US <br />Provisional (PRV) 60/910,549<br />Filed on 2007-04-06<br />Status: Abandoned 147167958 E-227-2006-4 E-227-2006-4-US-01 INCREASING BLOOD FLOW AND TISSUE HEALING IN THE ELDERLY PRV US 60/956,375 Abandoned US <br />Provisional (PRV) 60/956,375<br />Filed on 2007-08-16<br />Status: Abandoned 147167959 E-227-2006-5 E-227-2006-5-PCT-01 PREVENTION OF TISSUE ISCHEMIA, RELATED METHODS AND COMPOSITIONS PCT COMB Patent Cooperation Treaty PCT/US2007/080647 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2007/080647<br />Filed on 2007-10-05<br />Status: Expired 147167961 E-227-2006-5 E-227-2006-5-AU-04 PREVENTION OF TISSUE ISCHEMIA, RELATED METHODS AND COMPOSITIONS National Stage Australia 2007319576 2007319576 Issued Australia <br />National Stage 2007319576<br />Filed on 2007-10-05<br />Status: Issued 147167962 E-227-2006-5 E-227-2006-5-US-02 Prevention Of Tissue Ischemia, Related Methods and Compositions ORD US 8,236,313 12/444,364 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8236313 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8236313">8,236,313</a><br />Filed on 2009-04-03<br />Status: Issued 147167963 E-227-2006-5 E-227-2006-5-CA-03 PREVENTION OF TISSUE ISCHEMIA, RELATED METHODS AND COMPOSITIONS National Stage Canada 2665287 2665287 Issued Canada <br />National Stage 2665287<br />Filed on 2012-10-04<br />Status: Issued 147167964 E-227-2006-5 E-227-2006-5-EP-05 PREVENTION OF TISSUE ISCHEMIA, RELATED METHODS AND COMPOSITIONS National Stage European Patent 2076537 07868382.8 Issued European Patent <br />National Stage 07868382.8<br />Filed on 2007-10-05<br />Status: Issued 147167965 E-227-2006-5 E-227-2006-5-US-06 Prevention Of Tissue Ischemia And Related Methods DIV US 8,865,672 13/546,931 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8865672 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8865672">8,865,672</a><br />Filed on 2012-07-11<br />Status: Issued 147167966 E-227-2006-5 E-227-2006-5-US-07 Prevention of Tissue Ischemia And Related Compositions DIV US 8,557,788 13/546,941 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8557788 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8557788">8,557,788</a><br />Filed on 2012-07-11<br />Status: Issued 147167967 E-227-2006-5 E-227-2006-5-EP-08 PREVENTION OF TISSUE ISCHEMIA, RELATED METHODS AND COMPOSITIONS DIV European Patent 2695896 13180563.2 Issued European Patent <br />Divisional (DIV) 13180563.2<br />Filed on 2007-10-05<br />Status: Issued 147167968 E-227-2006-5 E-227-2006-5-AU-09 PREVENTION OF TISSUE ISCHEMIA, RELATED METHODS AND COMPOSITIONS DIV Australia 2014201936 2014201936 Issued Australia <br />Divisional (DIV) 2014201936<br />Filed on 2014-04-04<br />Status: Issued 147167969 E-227-2006-5 E-227-2006-5-US-10 PREVENTION OF TISSUE ISCHEMIA, RELATED METHODS AND COMPOSITIONS DIV US 10,370,439 14/500,861 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10370439 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10370439">10,370,439</a><br />Filed on 2014-09-29<br />Status: Issued 147167970 E-227-2006-5 E-227-2006-5-AU-11 PREVENTION OF TISSUE ISCHEMIA, RELATED METHODS AND COMPOSITIONS DIV Australia 2016238894 2016238894 Issued Australia <br />Divisional (DIV) 2016238894<br />Filed on 2016-10-06<br />Status: Issued 147167971 E-227-2006-5 E-227-2006-5-AU-12 PREVENTION OF TISSUE ISCHEMIA, RELATED METHODS AND COMPOSITIONS DIV Australia 2018200921 2018200921 Issued Australia <br />Divisional (DIV) 2018200921<br />Filed on 2018-02-08<br />Status: Issued 147167972 E-227-2006-5 E-227-2006-5-EP-13 PREVENTION OF TISSUE ISCHEMIA, RELATED METHODS AND COMPOSITIONS DIV European Patent 18183780.8 Abandoned European Patent <br />Divisional (DIV) 18183780.8<br />Filed on 2018-07-16<br />Status: Abandoned 147167973 E-227-2006-5 E-227-2006-5-DE-14 PREVENTION OF TISSUE ISCHEMIA, RELATED METHODS AND COMPOSITIONS EP Germany 2076537 07868382.8 Issued Germany <br />European patent (EP) 07868382.8<br />Filed on 2009-03-27<br />Status: Issued 147167974 E-227-2006-5 E-227-2006-5-FR-15 PREVENTION OF TISSUE ISCHEMIA, RELATED METHODS AND COMPOSITIONS EP France 2076537 07868382.8 Issued France <br />European patent (EP) 07868382.8<br />Filed on 2009-03-27<br />Status: Issued 147167975 E-227-2006-5 E-227-2006-5-GB-16 PREVENTION OF TISSUE ISCHEMIA, RELATED METHODS AND COMPOSITIONS EP United Kingdom 2076537 07868382.8 Issued United Kingdom <br />European patent (EP) 07868382.8<br />Filed on 2009-03-27<br />Status: Issued 147167976 E-227-2006-5 E-227-2006-5-DE-17 PREVENTION OF TISSUE ISCHEMIA, RELATED METHODS AND COMPOSITIONS EP Germany 2695896 13180563.2 Issued Germany <br />European patent (EP) 13180563.2<br />Filed on 2007-10-05<br />Status: Issued 147167977 E-227-2006-5 E-227-2006-5-FR-18 PREVENTION OF TISSUE ISCHEMIA, RELATED METHODS AND COMPOSITIONS EP France 2695896 13180563.2 Issued France <br />European patent (EP) 13180563.2<br />Filed on 2007-10-05<br />Status: Issued 147167978 E-227-2006-5 E-227-2006-5-GB-19 PREVENTION OF TISSUE ISCHEMIA, RELATED METHODS AND COMPOSITIONS EP United Kingdom 2695896 13180563.2 Issued United Kingdom <br />European patent (EP) 13180563.2<br />Filed on 2007-10-05<br />Status: Issued 147167979 E-227-2006-5 E-227-2006-5-US-20 PREVENTION OF TISSUE ISCHEMIA AND RELATED METHODS DIV US 11,254,735 16/443,415 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11254735 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11254735">11,254,735</a><br />Filed on 2019-06-17<br />Status: Issued 147167980 E-227-2006-5 E-227-2006-5-AU-21 PREVENTION OF TISSUE ISCHEMIA, RELATED METHODS AND COMPOSITIONS DIV Australia 2020230283 2020230283 Issued Australia <br />Divisional (DIV) 2020230283<br />Filed on 2020-09-10<br />Status: Issued 147167981 E-227-2006-5 E-227-2006-5-CA-22 PREVENTION OF TISSUE ISCHEMIA, RELATED METHODS AND COMPOSITIONS DIV Canada 3163418 Pending Canada <br />Divisional (DIV) 3163418<br />Filed on 2022-06-15<br />Status: Pending 147173936 CD47 147173937 ISCHEMIA 147173938 nitric oxide 147173939 NO 147173940 THROMBOSPONDIN TAB-4255 147157542 HIV-1 Therapeutic Inhibits Viral Entry NCI Infectious Disease, Licensing, Oncology, Therapeutics Infectious Disease Licensing Oncology Therapeutics Weizao Chen, Dimiter Dimitrov, Prabakaran Ponraj <p>Soluble forms (sCD4) of human CD4, the HIV-1 primary receptor, are potent HIV-1 entry inhibitors. Both four-domain (D1-4) and two-domain (D1D2) sCD4 and their fusion proteins have been tested as candidate therapeutics in animal models and in human clinical trials and were well tolerated by patients with no significant clinical or immunologic toxicities and exhibited significant inhibitory activities. However, their activities were transient and the virus rapidly rebound. Additionally, sCD4 is known to interact with the class II major histocompatibility complex (MHCII) and, at low concentrations, it could enhance the HIV-1 infectivity. Researchers at the National Cancer Institute’s Nanobiology Program generated a novel polypeptide comprising a single human CD4 domain (mD1.22) that is highly soluble, stable and shows significantly increased neutralizing activity without measurable interaction with MHCII.</p> <ul></ul> <h2>Competitive Advantages:</h2> <ul><li>Enhanced safety profile due to a lack of measurable interaction with MHCII</li> <li>Can be solubly expressed in <em>E. coli</em> with high yields leading to decreased production costs</li> </ul> <h2>Commercial Applications:</h2> <ul><li>As a prophylactic or an HIV therapeutic when conjugated with cytotoxic molecules</li> <li>Reagents for the rapid detection of HIV</li> </ul> 2016-02-16 2025-04-22 2018-05-30 2025-04-22 2013-08-06 CD4, entry inhibitor, HIV, MHCII, soluble expression False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2018-05-30 52406768 Discovery 52406768 NCI 37470483 Website Abstract E-103-2010 147161908 W. Chen et al. http://www.ncbi.nlm.nih.gov/pubmed/21715496 <a href="http://www.ncbi.nlm.nih.gov/pubmed/21715496">W. Chen et al.</a> 147162449 W. Chen et al. http://www.ncbi.nlm.nih.gov/pubmed/20709110 <a href="http://www.ncbi.nlm.nih.gov/pubmed/20709110">W. Chen et al.</a> 147164062 Dimitrov, Dimiter NIH - NCI NCI Dimitrov, Dimiter (NCI) 1 147164063 Chen, Weizao NIH - NCI Chen, Weizao 2 147164064 Ponraj, Prabakaran NIH - NCI Ponraj, Prabakaran 3 147164062 Dimitrov, Dimiter NIH - NCI NCI Dimitrov, Dimiter (NCI) 1 147164063 Chen, Weizao NIH - NCI Chen, Weizao 2 147164064 Ponraj, Prabakaran NIH - NCI Ponraj, Prabakaran 3 147157831 Stabilized Single Human CD4 Domains And Fusion Proteins As Exceptionally Potent HIV-1 Entry Inhibitors E-033-2013-0 Filing authorized NCI 147162497 Stabilized Single Human CD4 Domains And Fusion Proteins As Exceptionally Potent HIV-1 Entry Inhibitors E-033-2013-1 Filing authorized NCI 91814193 Freel, Rose rose.freel@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America rose.freel@nih.gov?subject=Web Inquiry on [TAB-4255] HIV-1 Therapeutic Inhibits Viral Entry&body=Please send me information about technology [TAB-4255] HIV-1 Therapeutic Inhibits Viral Entry.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Freel, Rose<br><a href="mailto:rose.freel@nih.gov?subject=Web Inquiry on [TAB-4255] HIV-1 Therapeutic Inhibits Viral Entry&body=Please send me information about technology [TAB-4255] HIV-1 Therapeutic Inhibits Viral Entry.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">rose.freel@nih.gov</a><br> 147160934 E-033-2013-1 E-033-2013-1-US-05 STABILIZED SINGLE HUMAN CD4 DOMAINS AND FUSION PROTEINS CON US 10,647,754 15/784,988 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10647754 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10647754">10,647,754</a><br />Filed on 2017-10-16<br />Status: Issued 147167699 E-033-2013-0 E-033-2013-0-US-01 Stabilized Single Human CD4 Domains And Fusion Proteins PRV US 61/791,885 Abandoned US <br />Provisional (PRV) 61/791,885<br />Filed on 2013-03-15<br />Status: Abandoned 147167701 E-033-2013-1 E-033-2013-1-PCT-01 Stabilized Single Human CD4 Domains And Fusion Proteins PCT COMB Patent Cooperation Treaty PCT/US2014/024120 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2014/024120<br />Filed on 2014-03-12<br />Status: Expired 147167702 E-033-2013-1 E-033-2013-1-CN-02 Stabilized Single Human CD4 Domains And Fusion Proteins National Stage China ZL201480026873.8 201480026873.8 Issued China <br />National Stage 201480026873.8<br />Filed on 2015-11-11<br />Status: Issued 147167703 E-033-2013-1 E-033-2013-1-EP-03 Stabilized Single Human CD4 Domains And Fusion Proteins National Stage European Patent 2968453 14717291.0 Issued European Patent <br />National Stage 14717291.0<br />Filed on 2014-03-12<br />Status: Issued 147167704 E-033-2013-1 E-033-2013-1-US-04 Stabilized Single Human CD4 Domains And Fusion Proteins National Stage US 14/777,245 Abandoned US <br />National Stage 14/777,245<br />Filed on 2015-09-15<br />Status: Abandoned 147167705 E-033-2013-1 E-033-2013-1-DE-06 Stabilized Single Human CD4 Domains And Fusion Proteins EP Germany 2968453 14717291.0 Issued Germany <br />European patent (EP) 14717291.0<br />Filed on 2014-03-12<br />Status: Issued 147167706 E-033-2013-1 E-033-2013-1-FR-07 Stabilized Single Human CD4 Domains And Fusion Proteins EP France 2968453 14717291.0 Issued France <br />European patent (EP) 14717291.0<br />Filed on 2014-03-12<br />Status: Issued 147167707 E-033-2013-1 E-033-2013-1-GB-08 Stabilized Single Human CD4 Domains And Fusion Proteins EP United Kingdom 2968453 14717291.0 Issued United Kingdom <br />European patent (EP) 14717291.0<br />Filed on 2014-03-12<br />Status: Issued 147169914 CD4 147169916 entry inhibitor 147169917 HIV 147169919 MHCII 147169921 soluble expression TAB-4252 147157539 Method for Targeted Therapeutic Delivery of Proteins into Cells NCI Licensing, Medical Devices, Non-Medical Devices, Oncology Licensing Medical Devices Non-Medical Devices Oncology Deb Chatterjee, Stanislaw Kaczmarczyk <p>Current methods to deliver proteins into cells (e.g., using retrovirus, DNA transfection, protein transduction, microinjection, complexing the protein with lipids, etc.) have many shortcomings, such as lack of target specificity toxicity, or unwanted random integration into the host chromosome.  Protein transduction is an emerging technology for delivering proteins into cells by exploiting the ability of certain proteins to penetrate the cell membrane.  However, the majority of the proteins delivered by this means are usually trapped and subsequently degraded in the endosomes-lysosomes of recipient cells. </p> <p> This invention describes a method for the delivery of proteins into cells using virus-like particles (VLPs) either in a non-targeted or a targeted way. VLPs are structures resembling a virus particle capable of self-assembly into nanoparticles, but are non-replicating because they lack viral nucleic acids.  The technology is based on fusion of protein(s) of interest with GAG structural protein of Rous Sarcoma Virus (RSV) pseudotyped with VSV-G (glycoprotein envelope) or its mutant form for targeted delivery.   In addition, a chimeric VLP could be used to deliver functional fusion proteins or fully-processed proteins (protease) into the cytoplasm or nucleus of target cells.  Since the problem of endosomal entrapment is eliminated, proteins can be delivered to target cells more efficiently than existing protein transduction methods.  Contrary to retroviral-mediated gene delivery, no genetic retroviral material is incorporated into VLP. This allows for safe protein delivery and eliminates unsafe incorporation of retroviral DNA into the host chromosome.</p> <p> The inventors have validated the biological activity of Cre recombinase and cytotoxic enzymes delivered using VLPs in a human prostate cancer cell line.  Specific ligands such as TNF-related apoptosis-inducing ligand (TRAIL) can be displayed on the surface of hybrid VLPs.  In vitro assays indicated that VLP-mediated TRAIL delivery is at least twice as effective and required 1000 times less peptide than soluble TRAIL, which is currently under clinical trial elsewhere.     </p> <p> In addition to protein therapy that might be used to treat numerous diseases and disorders, this technology can also be used for expansion of stem cells for transplantation as well as for the development of cancer vaccines.    </p> <p> Further R&amp;D Needed:</p> <ul><li>In vivo studies on mouse models</li> <li>Capability of conducting in vivo studies in larger animals is desired.</li> <li>Collaborations regarding any aspect of the VLP-delivery platform technology will be considered</li> </ul><p>R&amp;D Status: Pre-clinical in-vitro proof of concept with human prostate cancer cell lines indicated VLP-mediated TRAIL delivery is at least twice as effective and requires 1000 times less peptide than soluble TRAIL.</p> <h2>Competitive Advantages:</h2> <ul><li>Platform technology that could be applied to the targeted killing of tumors, protein therapy, stem cell generation, and cancer vaccine development</li> <li>Transformations of VLPs permits targeting of specific receptors on cells</li> <li>Proteins are not trapped and degraded in the endosomes/lysosomes of target cells.</li> <li>Lack of genetic retroviral materials in VLP allows safe protein delivery and eliminates potentially unsafe incorporation of retroviral DNA into host chromosome.</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Intracellular targeted delivery of therapeutic proteins.</li> <li>Ex vivo use for expansion of stem cells for transplantation.</li> <li>Antigen loading of dendritic cells for cancer vaccination.</li> </ul> 2016-02-16 2025-04-22 2018-07-13 2025-04-22 2016-08-24 virus-like particles, VLP False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2018-07-13 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147164055 Chatterjee, Deb NIH - NCI Leidos Chatterjee, Deb (Leidos) 1 147164054 Kaczmarczyk, Stanislaw NIH - NCI Leidos Kaczmarczyk, Stanislaw (Leidos) 2 147164055 Chatterjee, Deb NIH - NCI Leidos Chatterjee, Deb (Leidos) 1 147164054 Kaczmarczyk, Stanislaw NIH - NCI Leidos Kaczmarczyk, Stanislaw (Leidos) 2 147157783 Novel Protein Delivery System For Mammalian Cells E-010-2008-0 Filing authorized NCI 83704821 Nguyen-Antczak, Lauren lauren.nguyen-antczak@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-4252] Method for Targeted Therapeutic Delivery of Proteins into Cells&body=Please send me information about technology [TAB-4252] Method for Targeted Therapeutic Delivery of Proteins into Cells.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Nguyen-Antczak, Lauren<br><a href="mailto:lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-4252] Method for Targeted Therapeutic Delivery of Proteins into Cells&body=Please send me information about technology [TAB-4252] Method for Targeted Therapeutic Delivery of Proteins into Cells.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">lauren.nguyen-antczak@nih.gov</a><br> 147160893 E-010-2008-0 E-010-2008-0-US-01 METHODS AND COMPOSITIONS FOR PROTEIN DELIVERY PRV US 61/195,084 Abandoned US <br />Provisional (PRV) 61/195,084<br />Filed on 2008-10-03<br />Status: Abandoned 147167686 E-010-2008-0 E-010-2008-0-PCT-02 Novel Protein Delivery System For Mammalian Cells PCT Patent Cooperation Treaty PCT/US2009/59328 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2009/59328<br />Filed on 2009-10-02<br />Status: Expired 147167687 E-010-2008-0 E-010-2008-0-US-03 METHODS AND COMPOSITIONS FOR PROTEIN DELIVERY National Stage US 9,296,790 13/122,513 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9296790 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9296790">9,296,790</a><br />Filed on 2011-04-04<br />Status: Issued 147167688 E-010-2008-0 E-010-2008-0-US-04 Methods and Compositions for Protein Delivery DIV US 10,040,830 15/082,401 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10040830 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10040830">10,040,830</a><br />Filed on 2016-03-28<br />Status: Issued 147167689 E-010-2008-0 E-010-2008-0-US-05 METHODS AND COMPOSITIONS FOR PROTEIN DELIVERY CON US 10,577,397 16/041,395 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10577397 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10577397">10,577,397</a><br />Filed on 2018-07-20<br />Status: Issued 147169418 virus-like particles 147169419 VLP TAB-4220 147157505 3D Image Rendering Software for Biological Tissues NCI Licensing, Oncology, Software / Apps Licensing Oncology Software / Apps Jack Collins, Curtis Lisle, Yanling Liu <p>Available for commercial development is software that provides automatic visualization of features inside biological image volumes in 3D. The software provides a simple and interactive visualization for the exploration of biological datasets through dataset-specific transfer functions and direct volume rendering. The method employs a K-Means++ clustering algorithm to classify a two-dimensional histogram created from the input volume. The classification process utilizes spatial and data properties from the volume. Then using properties derived from the classified clusters, the software automatically generates color and opacity transfer functions and presents the user with a high quality initial rendering of the volume data.  The user input can be incorporated through a simple yet intuitive interface for transfer function manipulation included in our framework. Our new interface helps users focus on feature space exploration instead of the usual effort intensive, low-level manipulation.</p> <h2>Competitive Advantages:</h2> <ul><li>User Friendly, intuitive interface</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Biological Tissue Visualization in 3D</li> </ul> 2016-02-16 2025-04-22 2021-01-26 2025-04-22 2016-09-07 3D Imaging, Biological imaging, K-means++ clustering algorithm, Tissue rendering False True Prototype True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2021-01-26 52406769 Prototype 52406769 NCI 37470483 Website Abstract 147162013 Maciejewski R, et al. http://www.ncbi.nlm.nih.gov/pubmed/19834223 <a href="http://www.ncbi.nlm.nih.gov/pubmed/19834223">Maciejewski R, et al.</a> 147162169 Zhou J, Takatsuka M. http://www.ncbi.nlm.nih.gov/pubmed/19834224 <a href="http://www.ncbi.nlm.nih.gov/pubmed/19834224">Zhou J, Takatsuka M.</a> 147163948 Liu, Yanling NIH - NCI Leidos Liu, Yanling (Leidos) 1 147163947 Collins, Jack NIH - NCI Leidos Collins, Jack (Leidos) 2 147163949 Lisle, Curtis NIH - NCI Leidos Lisle, Curtis (Leidos) 3 147163948 Liu, Yanling NIH - NCI Leidos Liu, Yanling (Leidos) 1 147163947 Collins, Jack NIH - NCI Leidos Collins, Jack (Leidos) 2 147163949 Lisle, Curtis NIH - NCI Leidos Lisle, Curtis (Leidos) 3 147158279 Quick2lnsight: A User-Friendly Framework For Interactive Rendering Of Biological Image Volumes E-254-2012-0 Research Material NCI 83704821 Nguyen-Antczak, Lauren lauren.nguyen-antczak@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-4220] 3D Image Rendering Software for Biological Tissues&body=Please send me information about technology [TAB-4220] 3D Image Rendering Software for Biological Tissues.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Nguyen-Antczak, Lauren<br><a href="mailto:lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-4220] 3D Image Rendering Software for Biological Tissues&body=Please send me information about technology [TAB-4220] 3D Image Rendering Software for Biological Tissues.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">lauren.nguyen-antczak@nih.gov</a><br> 147174300 3D Imaging 147174302 Biological imaging 147174304 K-means++ clustering algorithm 147174306 Tissue rendering TAB-4169 147157453 Nanoparticles for the targeted treatment of infected cells NCI Collaboration, Infectious Disease, Licensing, Oncology, Therapeutics Collaboration Infectious Disease Licensing Oncology Therapeutics Kirill Afonin, Eckart Bindewald, Luc Jaeger, Arti Santhanam, Bruce Shapiro, Mathias Viard <p>Current treatments for cancer and viral infection are limited remedies that often suppress cell or viral replication rather than eliminate diseased cells entirely from the body. A further limitation is that these therapies often compromise healthy cells as well, leaving problems of recurrence and side effects.</p> <p>Researchers at developed a novel therapeutic nanoparticle (NP) system harboring therapeutic small siRNA that can significantly enhance effectiveness and specificity of treatments by killing diseased cells.</p> <p>Nanoparticles attached to RNA/DNA hybrids encode recognition sites for target genes and partial siRNA sequences of human anti-apoptotic genes. Individually, each of the hybrids is functionally inactive and functional representation can only be activated by the re-association of at least two cognate hybrids simultaneously present in the same cell. Overall, this novel approach allows each NP to have recognition sites for different target genes (e.g. viral genes in viral infection, abnormally regulated genes in cancer), providing versatile options for selecting cells to kill with far greater specificity. Besides therapeutic siRNA, RNA/DNA hybrids on NPs can encode fluorescent markers to specifically visualize the diseased cells.</p> <h2>Competitive Advantages:</h2> <ul><li>Novel way for multiple functionality delivery and activation</li> <li>Enhanced chemical stability and pharmacokinetics due to the average size of nanoparticles exceeding 10nm</li> <li>Increased specificity for selecting cells of interest  using more than one target gene</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Therapeutic siRNA for cancer and viral infections </li> <li>Diagnostic to visualize cancerous or virus-infected cells or track delivery and effectiveness of siRNA treatment.</li> <li>Research tool to study cancer, viral infection, or other diseases</li> </ul> 2016-02-16 2025-04-22 2018-06-08 2025-04-22 2017-08-29 RNA nanoparticles, SiRNA, viral infections False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2018-06-08 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147161909 K.A. Afonin et al. http://www.ncbi.nlm.nih.gov/pubmed/23016824 <a href="http://www.ncbi.nlm.nih.gov/pubmed/23016824">K.A. Afonin et al.</a> 147162103 W. Grabow et al. http://www.ncbi.nlm.nih.gov/pubmed/21229999 <a href="http://www.ncbi.nlm.nih.gov/pubmed/21229999">W. Grabow et al.</a> 147162450 K.A. Afonin et al. http://www.ncbi.nlm.nih.gov/pubmed/22134126 <a href="http://www.ncbi.nlm.nih.gov/pubmed/22134126">K.A. Afonin et al.</a> 147163756 Shapiro, Bruce NIH - NCI NCI Shapiro, Bruce (NCI) 1 147163757 Afonin, Kirill NIH - NCI Afonin, Kirill 2 147163761 Santhanam, Arti NCI - CCR NCI Santhanam, Arti (NCI) 3 147163758 Viard, Mathias NIH - NCI Leidos Viard, Mathias (Leidos) 4 147163759 Jaeger, Luc Jaeger, Luc 5 147163760 Bindewald, Eckart NIH - NCI Leidos Bindewald, Eckart (Leidos) 6 147163756 Shapiro, Bruce NIH - NCI NCI Shapiro, Bruce (NCI) 1 147163757 Afonin, Kirill NIH - NCI Afonin, Kirill 2 147163761 Santhanam, Arti NCI - CCR NCI Santhanam, Arti (NCI) 3 147163758 Viard, Mathias NIH - NCI Leidos Viard, Mathias (Leidos) 4 147163759 Jaeger, Luc Jaeger, Luc 5 147163760 Bindewald, Eckart NIH - NCI Leidos Bindewald, Eckart (Leidos) 6 147157840 Auto-recognizing Therapeutic R/DNA Chimeric Nanoparticles (NP), A Novel Concept For HIV Treatment E-039-2012-0 Filing authorized NCI 147162500 Auto-recognizing Therapeutic R/DNA Chimeric Nanoparticles (NP), A Novel Concept For HIV Treatment E-039-2012-1 Filing authorized NCI, University of California, Santa Barbara 147162501 Auto-recognizing Therapeutic R/DNA Chimeric Nanoparticles (NP), A Novel Concept For HIV Treatment E-039-2012-2 Filing authorized NCI, University of California, Santa Barbara 83732917 Favila, Michelle michelle.favila@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC michelle.favila@nih.gov?subject=Web Inquiry on [TAB-4169] Nanoparticles for the targeted treatment of infected cells&body=Please send me information about technology [TAB-4169] Nanoparticles for the targeted treatment of infected cells.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Favila, Michelle<br><a href="mailto:michelle.favila@nih.gov?subject=Web Inquiry on [TAB-4169] Nanoparticles for the targeted treatment of infected cells&body=Please send me information about technology [TAB-4169] Nanoparticles for the targeted treatment of infected cells.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">michelle.favila@nih.gov</a><br> 147160941 E-039-2012-0 E-039-2012-0-US-01 Auto-recognizing Therapeutic R/DNA Chimeric Nanoparticles (NP): A Novel Concept For HIV Treatment PRV US 61/561,257 Abandoned US <br />Provisional (PRV) 61/561,257<br />Filed on 2011-11-17<br />Status: Abandoned 147167065 E-039-2012-1 E-039-2012-1-US-01 Auto-recognizing Therapeutic R/DNA Chimeric Nanoparticles (NP) PRV US 61/698,113 Abandoned US <br />Provisional (PRV) 61/698,113<br />Filed on 2012-09-07<br />Status: Abandoned 147167067 E-039-2012-2 E-039-2012-2-PCT-01 Auto-recognizing Therapeutic R/DNA Chimeric Nanoparticles (NP) PCT Patent Cooperation Treaty PCT/US2012/065945 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2012/065945<br />Filed on 2012-11-19<br />Status: Expired 147167068 E-039-2012-2 E-039-2012-2-AU-02 Auto-recognizing Therapeutic R/DNA Chimeric Nanoparticles (NP) National Stage Australia 2012340094 Abandoned Australia <br />National Stage 2012340094<br />Filed on 2012-11-19<br />Status: Abandoned 147167069 E-039-2012-2 E-039-2012-2-CA-03 Auto-recognizing Therapeutic R/DNA Chimeric Nanoparticles (NP) National Stage Canada 2856117 Pending Canada <br />National Stage 2856117<br />Filed on 2012-11-19<br />Status: Pending 147167070 E-039-2012-2 E-039-2012-2-JP-04 Auto-recognizing Therapeutic R/DNA Chimeric Nanoparticles (NP) National Stage Japan 6093775 2014-542565 Issued Japan <br />National Stage 2014-542565<br />Filed on 2012-11-19<br />Status: Issued 147167071 E-039-2012-2 E-039-2012-2-US-05 Auto-recognizing Therapeutic RNA/DNA Chimeric Nanoparticles (NP)58942 National Stage US 9,631,192 14/358,942 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9631192 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9631192">9,631,192</a><br />Filed on 2014-05-16<br />Status: Issued 147167072 E-039-2012-2 E-039-2012-2-EP-06 Auto-recognizing Therapeutic R/DNA Chimeric Nanoparticles (NP) National Stage European Patent 2780455 12795973.2 Issued European Patent <br />National Stage 12795973.2<br />Filed on 2012-11-19<br />Status: Issued 147167073 E-039-2012-2 E-039-2012-2-GB-07 Auto-recognizing Therapeutic R/DNA Chimeric Nanoparticles (NP) EP United Kingdom 2780455 12795973.2 Issued United Kingdom <br />European patent (EP) 12795973.2<br />Filed on 2012-11-19<br />Status: Issued 147170002 RNA nanoparticles 147170003 SiRNA 147170004 viral infections TAB-4160 147157443 Virus-Like Particles That Can Deliver Proteins and RNA NCI Infectious Disease, Licensing, Oncology, Therapeutics Infectious Disease Licensing Oncology Therapeutics Deb Chatterjee, Stanislaw Kaczmarczyk <p>The National Cancer Institute's <a href="https://frederick.cancer.gov/Science/Pel/Default.aspx" target="_blank" rel="nofollow">Protein Expression Laboratory</a> seeks parties interested in licensing the novel delivery of RNA to mammalian cells using virus-like particles.</p> <p>Current methods of delivering proteins or RNA to mammalian cells are limited by a lack of target specificity and toxicity, among other shortcomings.  NCI researchers have created novel virus-like particles (VLPs) that are capable of binding to and replicating within a target mammalian cell, including human cells.  The claimed VLPs are safer than viral delivery because they are incapable of re-infecting target cells.  The present VLPs can optionally comprise inhibitory recombinant polynucleotides, such as microRNA, antisense RNA or small hairpin RNA, to down regulate or turn off expression of a particular gene within the target cell.  Alternatively, recombinant polynucleotides packaged within VLPs can comprise a gene encoding a therapeutic protein so as to enable expression of that protein within the target cell.   Specifically, VLPs of the invention are composed of an alphavirus replicon that contains a recombinant polynucleotide, a retroviral gag protein, and a fusogenic envelope glycoprotein.</p> <p> While the claimed VLPs have a variety of applications, therapeutic uses of the VLPs include directing antibody synthesis and converting cancer cells into antigen presenting cells. Additional applications include using VLPs to induce fast (approx. 3-4 hrs) and high levels of protein production in mammalian cells.</p> <h2>Competitive Advantages:</h2> <ul><li>Obviates the need to use expensive antigen purification for proteins or antigens produced inside target cells</li> <li>High level (~million copies per cell) of RNA production/synthesis within target cell</li> <li>Fast expression (approx. 3-4 hrs compared to 1-2 days) following VLP introduction into target cells</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Delivery of microRNA and small hairpin RNA to reduce expression of targeted genes in a human cell</li> <li>Delivery of coding RNA for robust expression in mammalian systems</li> <li>Direct antibody production by in vivo injection of replicons (no antigen purification)</li> </ul> 2016-02-16 2025-04-22 2016-09-30 2025-04-22 2016-09-08 antibody synthesis, Protein Expression, RNA delivery, virus-like particles False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2016-09-30 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-010-2008 147163734 Kaczmarczyk, Stanislaw NIH - NCI Leidos Kaczmarczyk, Stanislaw (Leidos) 1 147163735 Chatterjee, Deb NIH - NCI Leidos Chatterjee, Deb (Leidos) 2 147163734 Kaczmarczyk, Stanislaw NIH - NCI Leidos Kaczmarczyk, Stanislaw (Leidos) 1 147163735 Chatterjee, Deb NIH - NCI Leidos Chatterjee, Deb (Leidos) 2 147158290 Novel Delivery Of Packaged RNA In Mammalian Cells E-264-2011-0 Filing authorized NCI 83704821 Nguyen-Antczak, Lauren lauren.nguyen-antczak@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-4160] Virus-Like Particles That Can Deliver Proteins and RNA&body=Please send me information about technology [TAB-4160] Virus-Like Particles That Can Deliver Proteins and RNA.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Nguyen-Antczak, Lauren<br><a href="mailto:lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-4160] Virus-Like Particles That Can Deliver Proteins and RNA&body=Please send me information about technology [TAB-4160] Virus-Like Particles That Can Deliver Proteins and RNA.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">lauren.nguyen-antczak@nih.gov</a><br> 147166998 E-264-2011-0 E-264-2011-0-US-01 Novel Delivery Of Packaged RNA In Mammalian Cells PRV US 61/615,687 Abandoned US <br />Provisional (PRV) 61/615,687<br />Filed on 2012-03-26<br />Status: Abandoned 147166999 E-264-2011-0 E-264-2011-0-PCT-02 Novel Delivery Of Packaged RNA To Mammalian Cells PCT Patent Cooperation Treaty PCT/US2013/031876 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2013/031876<br />Filed on 2013-03-15<br />Status: Expired 147167000 E-264-2011-0 E-264-2011-0-AU-03 Delivery Of Packaged RNA To Mammalian Cells National Stage Australia 2013240248 2013240248 Issued Australia <br />National Stage 2013240248<br />Filed on 2013-03-15<br />Status: Issued 147167001 E-264-2011-0 E-264-2011-0-EP-04 Delivery Of Packaged RNA To Mammalian Cells National Stage European Patent 13712661.1 Abandoned European Patent <br />National Stage 13712661.1<br />Filed on 2013-03-15<br />Status: Abandoned 147167002 E-264-2011-0 E-264-2011-0-JP-05 Delivery Of Packaged RNA To Mammalian Cells National Stage Japan 2015-503322 Abandoned Japan <br />National Stage 2015-503322<br />Filed on 2014-09-25<br />Status: Abandoned 147167003 E-264-2011-0 E-264-2011-0-US-06 Delivery Of Packaged RNA to Mammalian Cells National Stage US 9,506,041 14/388,441 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9506041 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9506041">9,506,041</a><br />Filed on 2014-09-26<br />Status: Issued 147167004 E-264-2011-0 E-264-2011-0-US-07 Delivery Of Packaged RNA In Mammalian Cells DIV US 10,538,743 15/190,992 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10538743 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10538743">10,538,743</a><br />Filed on 2016-06-23<br />Status: Issued 147167005 E-264-2011-0 E-264-2011-0-JP-08 Delivery Of Packaged RNA To Mammalian Cells DIV Japan 6585237 2018-111489 Issued Japan <br />Divisional (DIV) 2018-111489<br />Filed on 2018-06-12<br />Status: Issued 147167006 E-264-2011-0 E-264-2011-0-AU-09 Delivery Of Packaged RNA To Mammalian Cells DIV Australia 2019201911 Abandoned Australia <br />Divisional (DIV) 2019201911<br />Filed on 2019-03-19<br />Status: Abandoned 147167007 E-264-2011-0 E-264-2011-0-EP-10 Delivery Of Packaged RNA To Mammalian Cells DIV European Patent 3663395 19207297.3 Issued European Patent <br />Divisional (DIV) 19207297.3<br />Filed on 2019-11-05<br />Status: Issued 147167008 E-264-2011-0 E-264-2011-0-US-11 DELIVERY OF PACKAGED RNA TO MAMMALIAN CELLS DIV US 16/709,147 Abandoned US <br />Divisional (DIV) 16/709,147<br />Filed on 2019-12-10<br />Status: Abandoned 147167009 E-264-2011-0 E-264-2011-0-AU-12 Delivery Of Packaged RNA To Mammalian Cells DIV Australia 2021240286 2021240286 Issued Australia <br />Divisional (DIV) 2021240286<br />Filed on 2021-10-01<br />Status: Issued 147174396 antibody synthesis 147174397 Protein Expression 147174399 RNA delivery 147174400 virus-like particles TAB-4163 147157446 Mouse Model for the Preclinical Study of Metastatic Disease NCI Licensing, Oncology, Research Materials Licensing Oncology Research Materials Chi-Ping Day, Glenn Merlino, Zoe Ohler, Terry Van Dyke <p>The successful development of new cancer therapeutics requires reliable preclinical data that are obtained from mouse models for cancer. Human tumor xenografts, which require transplantation of human tumor cells into an immune compromised mouse, represent the current standard mouse model for cancer. Since the immune system plays an important role in tumor growth, progression and metastasis, the current standard mouse model is not ideal for accurate prediction of therapeutic effectiveness in patients. This may contribute to increased failure in later phases of clinical trials, as appropriate tumor-host interactions are not preserved.</p> <p>This technology developed by the NCI establishes a system for producing mouse cancer models where the model is not immune compromised, providing an environment which is more akin to the disease state of cancer patients. To establish the model, a tumor is (a) developed in tissue that has been propagated by serial transplantation (rather than cell culture), (b) labeled (using lentiviral vectors) with bioimaging markers (e.g., green fluorescent protein (GFP) and luciferase), and (c) transplanted into immunocompetent mice. Once established, the model can be used to monitor tumor growth, progression and metastasis through standard imaging techniques. The effectiveness of a given therapeutic approach can also be monitored using the same techniques.</p> <p>Available data include <em>in vitro</em>, <em>in vivo</em> (animal and human), and <em>in situ </em>(on-site). The model is available as a prototype.</p> <h2>Competitive Advantages:</h2> <ul><li>Labeling markers are tolerized, allowing consistent expression in this mouse; </li> <li>Increased accuracy in prediction of drug effectiveness during preclinical stages--allows better prediction of success at later clinical stages; </li> <li>Mice are not immunocompromised, and thereby more accurately representing in vivo disease states; </li> <li>Labeling of tumors for transplantation allows tumors to be traced during growth, progression and metastasis in normal immune context; </li> <li>Labeling also allows more efficient study of the effectiveness of treatments.</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Improved mouse model for preclinical testing of drugs to treat metastatic disease; </li> <li>Can be applied to any cancer where tumor cell lines can be developed without cell culture propagation; </li> <li>Can be used to build preclinical models that require consistent disease tracking and normal immune context (e.g. bone marrow transplantation, stem cell therapy, tissue regeneration).</li> </ul> 2016-02-16 2025-04-22 2018-06-07 2025-04-22 2013-09-12 Carcinoma, neoplasm, non small cell lung, treatment outcome, xenograft mouse False True Prototype True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2018-06-07 52406769 Prototype 52406769 NCI 37470483 Website Abstract 147162057 Chi-Ping Day et al. Preclinical therapeutic response of residual metastatic disease is distinct from its primary tumor of origin. http://www.ncbi.nlm.nih.gov/pubmed/21312195 <a href="http://www.ncbi.nlm.nih.gov/pubmed/21312195">Chi-Ping Day et al. Preclinical therapeutic response of residual metastatic disease is distinct from its primary tumor of origin.</a> 147162213 Chi-Ping Day et al. Immunological naturalization of immunocompetent host mice to luciferase-GFP for consistent tracking of transplanted tumors. http://cancerres.aacrjournals.org/content/73/8_Supplement/1556 <a href="http://cancerres.aacrjournals.org/content/73/8_Supplement/1556">Chi-Ping Day et al. Immunological naturalization of immunocompetent host mice to luciferase-GFP for consistent tracking of transplanted tumors.</a> 147163743 Day, Chi-Ping NIH - NCI NCI Day, Chi-Ping (NCI) 1 147163742 Merlino, Glenn NIH - NCI NCI Merlino, Glenn (NCI) 2 147163744 Van Dyke, Terry NIH - NCI Van Dyke, Terry 3 147163745 Ohler, Zoe NIH - NCI Leidos Ohler, Zoe (Leidos) 4 147163743 Day, Chi-Ping NIH - NCI NCI Day, Chi-Ping (NCI) 1 147163742 Merlino, Glenn NIH - NCI NCI Merlino, Glenn (NCI) 2 147163744 Van Dyke, Terry NIH - NCI Van Dyke, Terry 3 147163745 Ohler, Zoe NIH - NCI Leidos Ohler, Zoe (Leidos) 4 147158337 Genetically Engineered Mouse-Derived Allograft (GDA) Technology For Preclinical Analysis Of Metastatic Disease E-296-2012-0 Research Material NCI 121111111 Greene, Jaime greenejaime@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America greenejaime@mail.nih.gov?subject=Web Inquiry on [TAB-4163] Mouse Model for the Preclinical Study of Metastatic Disease&body=Please send me information about technology [TAB-4163] Mouse Model for the Preclinical Study of Metastatic Disease.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Greene, Jaime<br><a href="mailto:greenejaime@mail.nih.gov?subject=Web Inquiry on [TAB-4163] Mouse Model for the Preclinical Study of Metastatic Disease&body=Please send me information about technology [TAB-4163] Mouse Model for the Preclinical Study of Metastatic Disease.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">greenejaime@mail.nih.gov</a><br> 147174761 Carcinoma 147174762 neoplasm 147174764 non small cell lung 147174766 treatment outcome 147174768 xenograft mouse TAB-4153 147157436 Agonistic Human Monoclonal Antibodies against Death Receptor 4 (DR4) NCI Licensing, Oncology, Therapeutics Licensing Oncology Therapeutics Dimiter Dimitrov, Yang Feng <p>The National Cancer Institute is seeking parties interested in licensing human monoclonal antibodies (mAbs) that bind to death receptor 4 ("DR4").</p> <p>The tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and its functional receptors, DR4 and DR5, have been recognized as promising targets for cancer treatment.  Therapeutics targeting TRAIL and its receptors are not only effective in killing many types of tumors but they also synergize with traditional therapies, and show efficacy against tumors that are otherwise resistant to conventional treatments.<br />  <br /> Researchers at NCI have developed two human monoclonal antibodies (mAbs) that bind to death receptor 4 ("DR4"). One of the mAbs is agonistic and inhibits the growth of ST486 cells with IC50 of about 10nM.  The two mAbs were selected from a human phage-displayed Fab library by panning against a recombinant DR4 extracellular domain.  Therefore the two mAbs are fully human.  These antibodies could have considerable potential as cancer therapeutics alone or in combination with other drugs. Further, these antibodies could be used as a research tool for the study of DR4.</p> <h2>Competitive Advantages:</h2> <ul><li>Clinical trials with mostly DR5-targeting agonistic antibodies have indicated that they could be safe and efficacious for certain indications</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Cancer therapeutics</li> <li>Tools: Antibodies to study DR4 expression in a broad range of solid tumors and malignancies</li> </ul> 2016-02-16 2025-04-22 2018-02-05 2025-04-22 2011-03-23 ANTIBODY, death receptor, Dr4, Mab, TRAIL False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2018-02-05 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147162041 Feng Y, et al. Identification and characterization of a novel agonistic anti-DR4 human monoclonal antibody. https://www.ncbi.nlm.nih.gov/pubmed/20581445 <a href="https://www.ncbi.nlm.nih.gov/pubmed/20581445">Feng Y, et al. Identification and characterization of a novel agonistic anti-DR4 human monoclonal antibody.</a> 147163705 Dimitrov, Dimiter NIH - NCI NCI Dimitrov, Dimiter (NCI) 1 147163706 Feng, Yang NIH - NCI NCI Feng, Yang (NCI) 2 147163705 Dimitrov, Dimiter NIH - NCI NCI Dimitrov, Dimiter (NCI) 1 147163706 Feng, Yang NIH - NCI NCI Feng, Yang (NCI) 2 147158099 Agonistic Human Monoclonal Antibody Against DR4 E-158-2010-0 Filing authorized NCI 91814193 Freel, Rose rose.freel@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America rose.freel@nih.gov?subject=Web Inquiry on [TAB-4153] Agonistic Human Monoclonal Antibodies against Death Receptor 4 (DR4)&body=Please send me information about technology [TAB-4153] Agonistic Human Monoclonal Antibodies against Death Receptor 4 (DR4).&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Freel, Rose<br><a href="mailto:rose.freel@nih.gov?subject=Web Inquiry on [TAB-4153] Agonistic Human Monoclonal Antibodies against Death Receptor 4 (DR4)&body=Please send me information about technology [TAB-4153] Agonistic Human Monoclonal Antibodies against Death Receptor 4 (DR4).&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">rose.freel@nih.gov</a><br> 147166952 E-158-2010-0 E-158-2010-0-US-01 Agonistic Human Monoclonal Antibody Against DR4 PRV US 61/355,349 Abandoned US <br />Provisional (PRV) 61/355,349<br />Filed on 2010-06-16<br />Status: Abandoned 147166953 E-158-2010-0 E-158-2010-0-PCT-02 ANTI-DR4 AGONIST ANTIBODIES PCT Patent Cooperation Treaty PCT/US2011/040750 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2011/040750<br />Filed on 2011-06-16<br />Status: Expired 147166954 E-158-2010-0 E-158-2010-0-CA-03 ANTI-DR4 AGONIST ANTIBODIES National Stage Canada 2802349 Abandoned Canada <br />National Stage 2802349<br />Filed on 2011-06-16<br />Status: Abandoned 147166955 E-158-2010-0 E-158-2010-0-EP-04 ANTI-DR4 AGONIST ANTIBODIES National Stage European Patent 11796455.1 Abandoned European Patent <br />National Stage 11796455.1<br />Filed on 2011-06-16<br />Status: Abandoned 147166956 E-158-2010-0 E-158-2010-0-US-05 ANTI-DR4 AGONIST ANTIBODIES National Stage US 9,044,457 13/704,577 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9044457 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9044457">9,044,457</a><br />Filed on 2013-02-26<br />Status: Issued 147172542 ANTIBODY 147172544 death receptor 147172545 Dr4 147172546 Mab 147172547 TRAIL TAB-4156 147157439 PARP Inhibitor and NO-Donor Dual Prodrugs as Anticancer Agents NCI Licensing, Oncology, Therapeutics Licensing Oncology Therapeutics Xinhua Ji, Larry Keefer, Vandana Kumari, Anna Maciag, Joseph Saavedra <p>Poly-ADP ribose polymerase-1 (PARP-1) is a critical enzyme involved in DNA repair.  The inhibition of PARP has emerged as a promising strategy in cancer therapy.  Numerous PARP inhibitors have been developed and advanced into clinical trials, both for use as single agents in specific patient populations and as combination therapies with various chemotherapeutics.  The induction of strand break damage to DNA, as has been demonstrated in cancer cells treated with O2-arylated diazeniumdiolates, coupled with inhibition of DNA repair by PARP inhibitors, represents a novel rationale for effective combination therapy.</p> <p>Scientists at NCI developed prodrugs that combine structural features of the known PARP inhibitor olaparib  with an O2-arylated diazeniumdiolate in one hybrid molecule.  The two-component prodrug has the advantage of delivering both a DNA damaging agent (NO) and an inhibitor of DNA repair (PARP inhibitor) simultaneously to a cancer cell.  The prodrugs are activated by glutathione (GSH) and the reaction accelerated by glutathione S-transferase P1 (GSTP1), an enzyme frequently overexpressed in cancer.  This mechanism consumes GSH while releasing cytotoxic NO and a PARP inhibitor simultaneously in the target cancer cell.  As high levels of GSH/GSTP1 are often a feature of cancer cells, the compound is predicted to have strong synergy with other anticancer therapeutics. When compared to the PARP inhibitor olaparib, these hybrid molecules exceeded the <em>in vivo</em> anticancer potency in xenograft models, resulting in more extensive DNA strand break damage, and ultimately greater apoptosis induction, as observed <em>in vitro</em>. These compounds are predicted to have strong radio- and chemosensitizing effects.</p> <h2>Competitive Advantages:</h2> <ul><li>Combination of a DNA damaging agent and a DNA repair inhibitor in one molecule eliminates the need to administer two separate treatments;</li> <li>Activation mechanism that involves overexpressed in cancers GSTP1 targets drugs to cancer cell</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Stand-alone cancer therapeutics or as part of a combination therapy with other cancer therapies</li> </ul> 2016-02-16 2025-04-22 2018-05-30 2025-04-22 2016-08-31 nitric oxide, PARP, poly-ADP-ribose polymerase, prodrug False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2018-05-30 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147163719 Maciag, Anna NIH - NCI Leidos Maciag, Anna (Leidos) 1 147163717 Saavedra, Joseph NIH - NCI NCI Saavedra, Joseph (NCI) 2 147163716 Keefer, Larry NIH - NCI NCI Keefer, Larry (NCI) 3 147163718 Ji, Xinhua NIH - NCI NCI Ji, Xinhua (NCI) 4 147163720 Kumari, Vandana NCI - FCRDC (Leidos) Leidos Kumari, Vandana (Leidos) 5 147163719 Maciag, Anna NIH - NCI Leidos Maciag, Anna (Leidos) 1 147163717 Saavedra, Joseph NIH - NCI NCI Saavedra, Joseph (NCI) 2 147163716 Keefer, Larry NIH - NCI NCI Keefer, Larry (NCI) 3 147163718 Ji, Xinhua NIH - NCI NCI Ji, Xinhua (NCI) 4 147163720 Kumari, Vandana NCI - FCRDC (Leidos) Leidos Kumari, Vandana (Leidos) 5 147158227 PARP-inhibitor/NO-donor Dual Prodrugs As Anticancer Agents E-220-2011-0 Filing authorized NCI 91814193 Freel, Rose rose.freel@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America rose.freel@nih.gov?subject=Web Inquiry on [TAB-4156] PARP Inhibitor and NO-Donor Dual Prodrugs as Anticancer Agents&body=Please send me information about technology [TAB-4156] PARP Inhibitor and NO-Donor Dual Prodrugs as Anticancer Agents.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Freel, Rose<br><a href="mailto:rose.freel@nih.gov?subject=Web Inquiry on [TAB-4156] PARP Inhibitor and NO-Donor Dual Prodrugs as Anticancer Agents&body=Please send me information about technology [TAB-4156] PARP Inhibitor and NO-Donor Dual Prodrugs as Anticancer Agents.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">rose.freel@nih.gov</a><br> 147166966 E-220-2011-0 E-220-2011-0-US-01 HYBRID DIAZENIUMDIOLATED COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHOD OF TREATING CANCER PRV US 61/549,862 Abandoned US <br />Provisional (PRV) 61/549,862<br />Filed on 2011-10-21<br />Status: Abandoned 147166967 E-220-2011-0 E-220-2011-0-PCT-02 HYBRID DIAZENIUMDIOLATED COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHOD OF TREATING CANCER PCT Patent Cooperation Treaty PCT/US2012/060785 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2012/060785<br />Filed on 2012-10-18<br />Status: Expired 147166968 E-220-2011-0 E-220-2011-0-AU-03 HYBRID DIAZENIUMDIOLATED COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHOD OF TREATING CANCER National Stage Australia 2012326105 2012326105 Issued Australia <br />National Stage 2012326105<br />Filed on 2012-10-18<br />Status: Issued 147166969 E-220-2011-0 E-220-2011-0-CA-04 HYBRID DIAZENIUMDIOLATED COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHOD OF TREATING CANCER National Stage Canada 2852682 2852682 Issued Canada <br />National Stage 2852682<br />Filed on 2017-10-18<br />Status: Issued 147166970 E-220-2011-0 E-220-2011-0-EP-05 HYBRID DIAZENIUMDIOLATED COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHOD OF TREATING CANCER National Stage European Patent 2768824 12841601.3 Issued European Patent <br />National Stage 12841601.3<br />Filed on 2012-10-18<br />Status: Issued 147166971 E-220-2011-0 E-220-2011-0-US-06 HYBRID DIAZENIUMDIOLATED COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHOD OF TREATING CANCER National Stage US 9,168,266 14/352,096 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9168266 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9168266">9,168,266</a><br />Filed on 2014-04-16<br />Status: Issued 147166972 E-220-2011-0 E-220-2011-0-DE-07 HYBRID DIAZENIUMDIOLATED COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHOD OF TREATING CANCER EP Germany 602012026435.7 12841601.3 Issued Germany <br />European patent (EP) 12841601.3<br />Filed on 2014-04-14<br />Status: Issued 147166973 E-220-2011-0 E-220-2011-0-FR-08 HYBRID DIAZENIUMDIOLATED COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHOD OF TREATING CANCER EP France 2768824 12841601.3 Issued France <br />European patent (EP) 12841601.3<br />Filed on 2014-04-14<br />Status: Issued 147166974 E-220-2011-0 E-220-2011-0-GB-09 HYBRID DIAZENIUMDIOLATED COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHOD OF TREATING CANCER EP United Kingdom 2768824 12841601.3 Issued United Kingdom <br />European patent (EP) 12841601.3<br />Filed on 2014-04-14<br />Status: Issued 147173847 nitric oxide 147173848 PARP 147173850 poly-ADP-ribose polymerase 147173851 prodrug TAB-4131 147157413 Target for Anti-Tumor Immune Responses NCI Licensing, Oncology, Research Materials Licensing Oncology Research Materials Steven Rosenberg, Suzanne Topalian <p>The Surgery Branch of the National Cancer Institute is seeking statements of capability or interest from parties interested in collaborative research to carry out genotypic as well as phenotypic analysis of the 888 mel cell line in order to better understand the nature of tumor cells that respond to therapy. In addition, this cell line can be used as a target of humoral or cell mediated immune responses as a part of studies characterizing the nature of immune responses directed against tumor cells. </p> <p>A human melanoma cell line designated 888-mel has been developed from the resected tumor of a 26-year old Caucasian female (patient 888) diagnosed with metastatic melanoma, a frequently terminal cancer. The 888-mel cell line was derived from three separate subcutaneous melanoma lesions on the patient and possesses many characteristics representative of melanoma cell lines developed by these researchers. Most prominently, the 888-mel cell line was used to develop a tumor infiltrating lymphocyte (TIL) culture with high affinity for the tumor cells of patient 888. When the TIL 888 culture was provided as an autologous adoptive immunotherapy treatment to patient 888 in combination with interleukin-2 (IL-2), a complete remission of subcutaneous, lung, and mucosal metastases was observed in the patient for over three years.</p> <p> Since this medical breakthrough, the 888-mel cell line has been well characterized through various laboratory procedures and data involving this cell line has been published as part of numerous articles. Studies have shown that the cell line expresses a variety of tumor associated antigens (TAAs), including tyrosinase, TRP1, TRP2, gp100, MART-1, p15, gp75, mutated beta-catenin, and p53. However, 888-mel does not normally express the MAGE 1, 2, or 3 TAAs. Many melanoma cell lines are HLA-A2 restricted, but the 888-mel cell line is HLA-A2 negative. The HLA class I typing for this cell line is as follows: HLA-A0101, A2402, B55, B62, Cw5201, Cw55, DRbl*1502, DRbl*1610, DQbl*0601, DRb5*0102, DRb50*203. 888-mel is a validated source of HLA class I peptides utilized in screens that test the reactivity of TIL cultures that are candidates for adoptive immunotherapy trials. 888-mel is also a standard cell line for studying immune responses in cancer, particularly T cell responses. Other experiments show that roscovitine, a cyclin-dependent kinase inhibitor, can induce apoptosis in the 888-mel cell line, so these cells may be useful in various cell death studies.</p> <h2>Competitive Advantages:</h2> <ul><li>Cell line is derived from a melanoma patient that underwent complete tumor remission: Immune cell cultures capable of treating melanoma patients in adoptive immunotherapy protocols could be derived from the tumor associated antigen epitopes found on the 888-mel cell line. This cell line may be a source of novel antigenic peptides capable of triggering immune responses in melanoma patients that lead to tumor regression or stabilization. 888-mel cells have been shown to retain many features of primary melanoma samples, including the expression of common tumor associated antigens.</li> <li>888-mel is an HLA-A2 negative cell line: A majority of the cancer vaccines and immunotherapies developed to date have focused on utilizing HLA-A2 restricted tumor epitopes since this HLA allele is largely expressed in the human population. However, therapies restricted to HLA-A2 recognition will not be successful in melanoma patients that do not express this allele.  For these patients, additional therapies are needed that are directed against melanoma tumor epitopes presented by different HLA alleles.</li> <li>The 888-mel cell line has been well characterized through multiple years of study and is a fundamental cell line for melanoma studies: The collection of tumor associated antigens expressed by this cell line have been determined through multiple studies, many of which were performed by researchers in the inventors¿¿¿ laboratory. A significant amount of data has also been compiled detailing the immune responses triggered by 888-mel cells.</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Research tool for investigating the key immune responses required to mediate the remission of metastatic melanoma in order to identify the immune cell types necessary to produce an effective immunotherapy</li> <li>Research tool for investigating the tumor associated antigens that contribute to the dampening of the immune response in many melanoma tumors so that researchers can better understand how to boost immunogenicity against these antigens</li> <li>Source material for tumor associated peptides that could serve as melanoma vaccine candidates or utilized to determine the reactivity of tumor infiltrating lymphocyte (TIL) cultures being considered for clinical trials</li> <li>Source material for the development of TIL cultures for use in adoptive immunotherapy protocols to treat melanoma patients</li> </ul> 2016-02-16 2025-04-22 2018-04-19 2025-04-22 2016-07-28 888-mel, CANCER, Cell line, MELANOMA False True Basic (Target Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2018-04-19 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147162224 P.F. Robbins et al. Multiple HLA class II-restricted melanocyte differentiation antigens are recognized by tumor-infiltrating lymphocytes from a patient with melanoma. https://www.ncbi.nlm.nih.gov/pubmed/12421991 <a href="https://www.ncbi.nlm.nih.gov/pubmed/12421991">P.F. Robbins et al. Multiple HLA class II-restricted melanocyte differentiation antigens are recognized by tumor-infiltrating lymphocytes from a patient with melanoma.</a> 147162301 J Weber et al. Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2&#39;&#39;-deoxycytidine. https://www.ncbi.nlm.nih.gov/pubmed/7511051 <a href="https://www.ncbi.nlm.nih.gov/pubmed/7511051">J Weber et al. Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2&#39;&#39;-deoxycytidine.</a> 147162377 P.F. Robbins et al. Recognition of tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunotherapy. https://www.ncbi.nlm.nih.gov/pubmed/8205528 <a href="https://www.ncbi.nlm.nih.gov/pubmed/8205528">P.F. Robbins et al. Recognition of tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunotherapy.</a> 147163633 Rosenberg, Steven NIH - NCI NCI Rosenberg, Steven (NCI) 1 147163634 Topalian, Suzanne NIH - NCI Topalian, Suzanne 2 147163633 Rosenberg, Steven NIH - NCI NCI Rosenberg, Steven (NCI) 1 147163634 Topalian, Suzanne NIH - NCI Topalian, Suzanne 2 147157924 888 Mel Cell Line E-070-2010-0 Research Material NCI 147162514 Melanoma Cell Lines E-070-2010-1 Research Material NCI 83709866 Burke, Andrew burkear@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC burkear@nih.gov?subject=Web Inquiry on [TAB-4131] Target for Anti-Tumor Immune Responses&body=Please send me information about technology [TAB-4131] Target for Anti-Tumor Immune Responses.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Burke, Andrew<br><a href="mailto:burkear@nih.gov?subject=Web Inquiry on [TAB-4131] Target for Anti-Tumor Immune Responses&body=Please send me information about technology [TAB-4131] Target for Anti-Tumor Immune Responses.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">burkear@nih.gov</a><br> 147170770 888-mel 147170771 CANCER 147170772 Cell line 147170773 MELANOMA TAB-4141 147157424 Analogues of Modafinil for treating sleep and attention disorders NIDA Licensing, Therapeutics Licensing Therapeutics Jianjing Cao, Amy Newman, Oluyomi Okunola-Bakare (Estate) <p>Modafinil has attracted attention for the treatment of cognitive dysfunction in disorders such as attention-deficit/hyperactivity disorder (ADHD) as well as cocaine and methamphetamine dependence.  However, modafinil has relatively low affinity for binding to the dopamine transporter (DAT) to block dopamine reuptake, and is water-insoluble, thus requiring large doses to achieve pharmacological effects.</p> <p>Investigators at the <a href="https://www.drugabuse.gov/" rel="nofollow">National Institute of Drug Abuse</a> have synthesized a series of modafinil analogues that have higher affinity for the dopamine (DAT), serotonin (SERT) and/or norepinephrine (NET) transporters and improved water solubility.  These novel analogues present the advantage of higher potency, which may translate into lower effective doses and better bioavailability over modafinil.</p> <h2>Competitive Advantages:</h2> <ul><li>Higher affinity for monoamine transporters (DAT, SERT, and NET) compared to modafinil</li> <li>Analogues have lower effective doses</li> <li>Better bioavailability than modafinil</li> <li>Improved water solubility over modafinil</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Therapeutic agent for substance abuse (such as nicotine, cocaine, methamphetamine, opioids), for attention/cognitive disorders (such as ADHD), and for sleep disorders.</li> </ul> 2016-02-16 2025-04-22 2017-12-20 2025-04-22 2016-08-29 attention deficit/hyperactivity disorder (ADHD), dopamine (DAT), Modafinil, Narcolepsy, norepinephrine (NET), serotonin (SERT) False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2017-12-20 52406768 Discovery 52406768 NCI 37470483 Website Abstract E-251-2002 147163661 Newman, Amy NIH - NIDA NIDA Newman, Amy (NIDA) 1 147163663 Okunola-Bakare (Estate), Oluyomi NIH - NIDA Okunola-Bakare (Estate), Oluyomi 2 147163662 Cao, Jianjing NIH - NIDA NIDA Cao, Jianjing (NIDA) 3 147163661 Newman, Amy NIH - NIDA NIDA Newman, Amy (NIDA) 1 147163663 Okunola-Bakare (Estate), Oluyomi NIH - NIDA Okunola-Bakare (Estate), Oluyomi 2 147163662 Cao, Jianjing NIH - NIDA NIDA Cao, Jianjing (NIDA) 3 147157928 Phenyl-substituted Thioacetimide And Sulfinylacetamide Modafinil Derivatives As Monamine Transport Inhibitors: Preparation And Use In The Treatment Of CNS Disorders E-073-2013-0 Filing authorized National Institute on Drug Abuse (NIDA) 83737255 Baxter, Merissa merissa.baxter@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB merissa.baxter@nih.gov?subject=Web Inquiry on [TAB-4141] Analogues of Modafinil for treating sleep and attention disorders&body=Please send me information about technology [TAB-4141] Analogues of Modafinil for treating sleep and attention disorders.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Baxter, Merissa<br><a href="mailto:merissa.baxter@nih.gov?subject=Web Inquiry on [TAB-4141] Analogues of Modafinil for treating sleep and attention disorders&body=Please send me information about technology [TAB-4141] Analogues of Modafinil for treating sleep and attention disorders.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">merissa.baxter@nih.gov</a><br> 147160999 E-073-2013-0 E-073-2013-0-US-06 POTENT AND SELECTIVE INHIBITORS OF MONOAMINE TRANSPORTERS; METHOD OF MAKING; AND USE THEREOF National Stage US 9,862,679 14/772,486 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9862679 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9862679">9,862,679</a><br />Filed on 2015-09-03<br />Status: Issued 147166884 E-073-2013-0 E-073-2013-0-US-01 Potent and Selective Inhibitors Of Monoamine Transporters; Method of Making; and Use Thereof PRV US 61/774,878 Abandoned US <br />Provisional (PRV) 61/774,878<br />Filed on 2013-03-08<br />Status: Abandoned 147166885 E-073-2013-0 E-073-2013-0-PCT-02 Potent and Selective Inhibitors Of Monoamine Transporters; Method of Making; and Use Thereof PCT Patent Cooperation Treaty PCT/US2014/021514 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2014/021514<br />Filed on 2014-03-07<br />Status: Expired 147166886 E-073-2013-0 E-073-2013-0-AU-03 Potent and Selective Inhibitors Of Monoamine Transporters; Method of Making; and Use Thereof National Stage Australia 2014225550 2014225550 Issued Australia <br />National Stage 2014225550<br />Filed on 2014-03-07<br />Status: Issued 147166887 E-073-2013-0 E-073-2013-0-CA-04 Potent and Selective Inhibitors Of Monoamine Transporters; Method of Making; and Use Thereof National Stage Canada 2903746 2903746 Issued Canada <br />National Stage 2903746<br />Filed on 2014-03-07<br />Status: Issued 147166888 E-073-2013-0 E-073-2013-0-EP-05 POTENT AND SELECTIVE INHIBITORS OF MONOAMINE TRANSPORTERS; METHOD OF MAKING; AND USE THEREOF National Stage European Patent 2964611 14714043.8 Issued European Patent <br />National Stage 14714043.8<br />Filed on 2014-03-07<br />Status: Issued 147166889 E-073-2013-0 E-073-2013-0-AU-07 Potent and Selective Inhibitors Of Monoamine Transporters; Method of Making; and Use Thereof DIV Australia 2017202849 2017202849 Issued Australia <br />Divisional (DIV) 2017202849<br />Filed on 2017-04-28<br />Status: Issued 147166890 E-073-2013-0 E-073-2013-0-US-08 POTENT AND SELECTIVE INHIBITORS OF MONOAMINE TRANSPORTERS; METHOD OF MAKING; AND USE THEREOF DIV US 10,590,074 15/830,244 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10590074 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10590074">10,590,074</a><br />Filed on 2017-12-04<br />Status: Issued 147166891 E-073-2013-0 E-073-2013-0-US-09 POTENT AND SELECTIVE INHIBITORS OF MONOAMINE TRANSPORTERS; METHOD OF MAKING; AND USE THEREOF DIV US 10,913,711 16/282,894 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10913711 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10913711">10,913,711</a><br />Filed on 2019-02-22<br />Status: Issued 147166892 E-073-2013-0 E-073-2013-0-US-10 POTENT AND SELECTIVE INHIBITORS OF MONOAMINE TRANSPORTERS; METHOD OF MAKING; AND USE THEREOF DIV US 11,555,013 17/139,583 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11555013 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11555013">11,555,013</a><br />Filed on 2020-12-31<br />Status: Issued 147166893 E-073-2013-0 E-073-2013-0-GB-11 Potent and Selective Inhibitors Of Monoamine Transporters; Method of Making; and Use Thereof EP United Kingdom 2964611 14714043.8 Issued United Kingdom <br />European patent (EP) 14714043.8<br />Filed on 2014-03-07<br />Status: Issued 147170807 attention deficit/hyperactivity disorder (ADHD) 147170809 dopamine (DAT) 147170810 Modafinil 147170811 Narcolepsy 147170813 norepinephrine (NET) 147170815 serotonin (SERT) TAB-4112 147157394 Improved Production of Prenylated Protein in Insect Cells NCI Licensing, Oncology, Research Materials Licensing Oncology Research Materials Dominic Esposito, William Gillette, Carissa Grose <p>KRAS and other Ras-family enzymes are an important component of over 30% of human cancers, however, no effective therapeutics targeting Ras or Ras-driven cancers are currently available.  The production of Ras proteins <em>in vitro</em> is required for the identification and characterization of Ras targeting drugs.  An important step in producing the Ras protein involves prenylation of the C-terminus of the protein via farnesyltransferase, a modification that does not occur in prokaryotic organisms.  Previous attempts to generate properly processed Ras in eukaryotic cells has produced only low levels of protein which has not been useful for structural studies or biochemical work.</p> <p>Researchers at the <a href="https://ostr.ccr.cancer.gov/partnerships/pap/pep/" rel="nofollow">FNL Protein Expression Lab </a> developed reagents that can be used to produce prenylated proteins such as KRAS in high yield.  Available for licensing are baculovirus vectors for overexpression of human FNTA and FNTB; recombinant baculovirus genomes (bacmids) containing overexpression constructs of FNTA, FNTB, or combinations thereof; and DH10BAC cell lines that contain the modified bacmids and the baculovirus vectors. Baculovirus reagents for high-yield (&gt;10 mg/L) production of properly processed KRAS are also available.</p> <h2>Competitive Advantages:</h2> <ul><li>Production of prenylated proteins, such as Ras, in high yield</li> <li>Prenylated proteins produced using this method show membrane interaction activities that recapitulate in vivo activities not observed with bacterial produced proteins</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Production of proteins for use in identification and characterization of drugs targeting Ras</li> <li>Potential to generate other prenylated proteins</li> </ul> 2016-02-16 2025-04-22 2020-04-07 2025-04-22 2015-12-18 CANCER, KRAS, RAS, RESEARCH MATERIAL False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2020-04-07 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147163549 Esposito, Dominic NIH - NCI Leidos Esposito, Dominic (Leidos) 1 147163551 Grose, Carissa NIH - NCI Leidos Grose, Carissa (Leidos) 2 147163550 Gillette, William NIH - NCI Leidos Gillette, William (Leidos) 3 147163549 Esposito, Dominic NIH - NCI Leidos Esposito, Dominic (Leidos) 1 147163551 Grose, Carissa NIH - NCI Leidos Grose, Carissa (Leidos) 2 147163550 Gillette, William NIH - NCI Leidos Gillette, William (Leidos) 3 147157781 Improved Method For Production Of Prenlyated Protein In Insect Cells E-009-2015-0 Research Material NCI 91814193 Freel, Rose rose.freel@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America rose.freel@nih.gov?subject=Web Inquiry on [TAB-4112] Improved Production of Prenylated Protein in Insect Cells&body=Please send me information about technology [TAB-4112] Improved Production of Prenylated Protein in Insect Cells.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Freel, Rose<br><a href="mailto:rose.freel@nih.gov?subject=Web Inquiry on [TAB-4112] Improved Production of Prenylated Protein in Insect Cells&body=Please send me information about technology [TAB-4112] Improved Production of Prenylated Protein in Insect Cells.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">rose.freel@nih.gov</a><br> 147169401 CANCER 147169402 KRAS 147169403 RAS 147169404 RESEARCH MATERIAL TAB-4097 147157379 Cancer Therapeutic based on Stimulation of Natural Killer T-cell Anti-tumor Activity NCI Immunology, Licensing, Oncology, Therapeutics Immunology Licensing Oncology Therapeutics Jay Berzofsky, Gurdyal Besra, Petr Illarionov, Jessica O'Konek, Masaki Terabe <p>Natural killer T cells (NKT) are a unique lymphocyte population that has T-cell and NK cell functional properties in order to rapidly elicit an immune response.  alpha-galactosylceramide (alpha-GalCer) is a potent NKT stimulator and induces of IFN-gamma release to promote immunity against tumors and infectious agents.  Humans have natural antibodies against alpha-galactose, which may be one of the reasons why the human clinical trials of alpha-GalCer or KRN7000 were not very successful.</p> <p>Beta-ManCer is a new class of NKT agonist that induces immune responses alone, through nitric oxide and TNF-alpha-dependent mechanisms, or synergistically with alpha-GalCer to enhance alpha-GalCer''s efficacy.  Since beta-ManCer does not have alpha-galactose, which can be neutralized by natural antibodies, patients could be treated with multiple doses without negative side effects associated with the loss of IFN-gamma production.  Hence, beta-ManCer is a promising anti-cancer treatment either alone or in combinatorial therapies with alpha-GalCer to selectively induce immune responses.</p> <h2>Competitive Advantages:</h2> <ul><li>Induces tumor immunity through a novel mechanism</li> <li>Decreased possibility of neutralization by natural antibodies</li> <li>Synergize with alpha-GalCer</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Cancer therapeutics</li> <li>Potent stimulator of NKT activity</li> </ul> 2016-02-16 2025-04-22 2020-04-07 2025-04-22 2016-08-29 ANTIBODY, Immunity, NKT activity False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2020-04-07 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147163492 Terabe, Masaki NIH - NCI NCI Terabe, Masaki (NCI) 1 147163493 O'Konek, Jessica NIH - NCI NCI O'Konek, Jessica (NCI) 2 147163494 Illarionov, Petr University of Birmingham Illarionov, Petr 3 147163491 Berzofsky, Jay NIH - NCI NCI Berzofsky, Jay (NCI) 4 147163495 Besra, Gurdyal University of Birmingham Besra, Gurdyal 5 147163492 Terabe, Masaki NIH - NCI NCI Terabe, Masaki (NCI) 1 147163493 O'Konek, Jessica NIH - NCI NCI O'Konek, Jessica (NCI) 2 147163494 Illarionov, Petr University of Birmingham Illarionov, Petr 3 147163491 Berzofsky, Jay NIH - NCI NCI Berzofsky, Jay (NCI) 4 147163495 Besra, Gurdyal University of Birmingham Besra, Gurdyal 5 147157834 A New Type Of GlycolipId Antigen Stimulating NKT Cells To Induce Anti-tumor Immunity E-034-2010-0 Filing authorized NCI, University of Birmingham 83724826 Pollard, Ricquita ricquita.pollard@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4097] Cancer Therapeutic based on Stimulation of Natural Killer T-cell Anti-tumor Activity&body=Please send me information about technology [TAB-4097] Cancer Therapeutic based on Stimulation of Natural Killer T-cell Anti-tumor Activity.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollard, Ricquita<br><a href="mailto:ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4097] Cancer Therapeutic based on Stimulation of Natural Killer T-cell Anti-tumor Activity&body=Please send me information about technology [TAB-4097] Cancer Therapeutic based on Stimulation of Natural Killer T-cell Anti-tumor Activity.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">ricquita.pollard@nih.gov</a><br> 147160937 E-034-2010-0 E-034-2010-0-US-01 A New Type of GlycolipId Antigen Stimulating NKT Cells to Induce Anti-Tumor Immunity PRV US 61/313,508 Abandoned US <br />Provisional (PRV) 61/313,508<br />Filed on 2010-03-12<br />Status: Abandoned 147166470 E-034-2010-0 E-034-2010-0-PCT-02 Beta-Mannosylceramide And Stimulation Of NKT Cell Anti-tumor Immunity PCT Patent Cooperation Treaty PCT/US2011/028024 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2011/028024<br />Filed on 2011-03-11<br />Status: Expired 147166471 E-034-2010-0 E-034-2010-0-US-03 B- Mannosylceramide And Stimulation Of NKT Cell Anti-Tumor Immunity National Stage US 8,835,613 13/582,612 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8835613 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8835613">8,835,613</a><br />Filed on 2012-10-02<br />Status: Issued 147166472 E-034-2010-0 E-034-2010-0-CA-04 .BETA.-MANNOSYLCERAMIDE AND STIMULATION OF NKT CELL ANTI-TUMOR IMMUNITY National Stage Canada 2792754 2792754 Issued Canada <br />National Stage 2792754<br />Filed on 2016-03-02<br />Status: Issued 147166473 E-034-2010-0 E-034-2010-0-US-05 Beta-Mannosylceramide and Stimulation of NKT Cell Anti-Tumor Immunity CON US 9,168,291 14/453,829 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9168291 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9168291">9,168,291</a><br />Filed on 2014-08-07<br />Status: Issued 147166474 E-034-2010-0 E-034-2010-0-US-06 BETA-MANNOSYLCERAMIDE AND STIMULATION OF NKT CELL ANTI-TUMOR IMMUNITY CON US 9,517,243 14/879,476 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9517243 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9517243">9,517,243</a><br />Filed on 2015-10-09<br />Status: Issued 147169949 ANTIBODY 147169950 Immunity 147169952 NKT activity TAB-4106 147157388 Novel Immunotherapy for Cancer Treatment: Chimeric Antigen Receptors Targeting CD70 Antigen NCI Licensing, Oncology, Therapeutics Licensing Oncology Therapeutics Qiong Wang, James Yang, Zhiya Yu <p>Scientists at the NCI's <a href="https://ccr.cancer.gov/Surgery-Branch" rel="nofollow">Surgery Branch</a> have developed anti-CD70 chimeric antigen receptors (CARs) to treat cancers. CD70 is an antigen that is expressed on a variety of human cancers such as renal cell carcinoma, glioblastoma, non-Hodgkin's lymphoma, and chronic lymphocytic leukemia. The anti-CD70 CARs are hybrid proteins consisting of a receptor portion that recognizes CD70 antigen, and intracellular T cell signaling domains selected to optimally activate the CAR expressing T cells.  Genetically engineered T cells that express this CARs will bind to CD70 on the cancer cells and will be activated to induce an immune response that promotes robust tumor cell elimination when infused into cancer patients.  This technology can rapidly generate a vigorous T-cell response from the patient's own blood, targeting CD70 expressing cancer cells, and potentially induce tumor rejection.</p> <h2>Competitive Advantages:</h2> <ul><li>CD70-specific CARs expressed on T cells will increase the likelihood of successful targeted therapy.  </li> <li>CAR-T cells targeting only CD70 expressing cells and thus may generate fewer side effects than other cancer treatment approaches.  </li> <li>T-cell transfer can provide much larger numbers of anti-tumor immune cells compared to other approaches such as vaccines.</li> <li>With the advent of Provenge(R),  and Yervoy(R), immunotherapy is now more widely accepted as a viable cancer treatment option.   </li> </ul> <h2>Commercial Applications:</h2> <ul><li>Immunotherapeutics to treat cancers that overexpress CD70, such as renal cell carcinoma, glioblastoma, non-Hodgkin’s lymphoma, and chronic lymphocytic leukemia.  </li> <li>A personalized cancer treatment strategy for patients whose tumor cells express CD70 whereby the patient’s own T cells are isolated, engineered to express the anti-CD70 CARs, and re-infused into the same patient to attack the tumor(s).</li> </ul> 2016-02-16 2025-04-22 2018-07-19 2025-04-22 2016-08-29 CARS, CD70, chimeric antigen receptor, T-cell reprogramming False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2018-07-19 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147161983 Wang QJ, et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=23071066 <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=23071066">Wang QJ, et al.</a> 147163531 Wang, Qiong NIH - NCI NCI Wang, Qiong (NCI) 1 147163532 Yu, Zhiya NIH - NCI NCI Yu, Zhiya (NCI) 2 147163530 Yang, James NIH - NCI NCI Yang, James (NCI) 3 147163531 Wang, Qiong NIH - NCI NCI Wang, Qiong (NCI) 1 147163532 Yu, Zhiya NIH - NCI NCI Yu, Zhiya (NCI) 2 147163530 Yang, James NIH - NCI NCI Yang, James (NCI) 3 147157807 Targeting Human CD70-Expressing Tumors Using A Retroviral Vector That Encodes A Receptor Using CD27 Fused With 41BB And CD3 Signaling Domains E-021-2015-0 Filing authorized NCI 83709866 Burke, Andrew burkear@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC burkear@nih.gov?subject=Web Inquiry on [TAB-4106] Novel Immunotherapy for Cancer Treatment: Chimeric Antigen Receptors Targeting CD70 Antigen&body=Please send me information about technology [TAB-4106] Novel Immunotherapy for Cancer Treatment: Chimeric Antigen Receptors Targeting CD70 Antigen.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Burke, Andrew<br><a href="mailto:burkear@nih.gov?subject=Web Inquiry on [TAB-4106] Novel Immunotherapy for Cancer Treatment: Chimeric Antigen Receptors Targeting CD70 Antigen&body=Please send me information about technology [TAB-4106] Novel Immunotherapy for Cancer Treatment: Chimeric Antigen Receptors Targeting CD70 Antigen.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">burkear@nih.gov</a><br> 147160915 E-021-2015-0 E-021-2015-0-US-01 Anti-CD70 Chimeric Antigen Receptors PRV US 62/088,882 Abandoned US <br />Provisional (PRV) 62/088,882<br />Filed on 2014-12-08<br />Status: Abandoned 147166522 E-021-2015-0 E-021-2015-0-PCT-02 Anti-CD70 Chimeric Antigen Receptors PCT Patent Cooperation Treaty PCT/US2015/025047 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2015/025047<br />Filed on 2015-04-09<br />Status: Expired 147166523 E-021-2015-0 E-021-2015-0-AU-03 Anti-CD70 Chimeric Antigen Receptors National Stage Australia 2015361261 2015361261 Issued Australia <br />National Stage 2015361261<br />Filed on 2015-04-09<br />Status: Issued 147166524 E-021-2015-0 E-021-2015-0-CA-04 Anti-CD70 Chimeric Antigen Receptors National Stage Canada 2970280 Pending Canada <br />National Stage 2970280<br />Filed on 2015-04-09<br />Status: Pending 147166525 E-021-2015-0 E-021-2015-0-CN-05 Anti-CD70 Chimeric Antigen Receptors National Stage China ZL201580066498.4 201580066498.4 Issued China <br />National Stage 201580066498.4<br />Filed on 2017-06-07<br />Status: Issued 147166526 E-021-2015-0 E-021-2015-0-EP-06 Anti-CD70 Chimeric Antigen Receptors National Stage European Patent 3 230 310 15718065.4 Issued European Patent <br />National Stage 15718065.4<br />Filed on 2015-04-09<br />Status: Issued 147166527 E-021-2015-0 E-021-2015-0-JP-07 Anti-CD70 Chimeric Antigen Receptors National Stage Japan 6724009 2017-530742 Issued Japan <br />National Stage 2017-530742<br />Filed on 2017-06-08<br />Status: Issued 147166528 E-021-2015-0 E-021-2015-0-US-08 ANTI-CD70 CHIMERIC ANTIGEN RECEPTORS National Stage US 10,689,456 15/531,626 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10689456 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10689456">10,689,456</a><br />Filed on 2017-05-30<br />Status: Issued 147166529 E-021-2015-0 E-021-2015-0-EP-09 Anti-CD70 Chimeric Antigen Receptors DIV European Patent 3597663 19178931.2 Issued European Patent <br />Divisional (DIV) 19178931.2<br />Filed on 2019-06-07<br />Status: Issued 147166530 E-021-2015-0 E-021-2015-0-DE-10 Anti-CD70 Chimeric Antigen Receptors EP Germany 3230310 15718065.4 Issued Germany <br />European patent (EP) 15718065.4<br />Filed on 2015-04-09<br />Status: Issued 147166531 E-021-2015-0 E-021-2015-0-ES-11 Anti-CD70 Chimeric Antigen Receptors EP Spain 3230310 15718065.4 Issued Spain <br />European patent (EP) 15718065.4<br />Filed on 2015-04-09<br />Status: Issued 147166532 E-021-2015-0 E-021-2015-0-FR-12 Anti-CD70 Chimeric Antigen Receptors EP France 3230310 15718065.4 Issued France <br />European patent (EP) 15718065.4<br />Filed on 2015-04-09<br />Status: Issued 147166533 E-021-2015-0 E-021-2015-0-GB-13 Anti-CD70 Chimeric Antigen Receptors EP United Kingdom 3230310 15718065.4 Issued United Kingdom <br />European patent (EP) 15718065.4<br />Filed on 2015-04-09<br />Status: Issued 147166534 E-021-2015-0 E-021-2015-0-IE-14 Anti-CD70 Chimeric Antigen Receptors EP Ireland 3230310 15718065.4 Issued Ireland <br />European patent (EP) 15718065.4<br />Filed on 2015-04-09<br />Status: Issued 147166535 E-021-2015-0 E-021-2015-0-IT-15 Anti-CD70 Chimeric Antigen Receptors EP Italy 3230310 15718065.4 Issued Italy <br />European patent (EP) 15718065.4<br />Filed on 2015-04-09<br />Status: Issued 147166536 E-021-2015-0 E-021-2015-0-AT-16 Anti-CD70 Chimeric Antigen Receptors EP Austria 3230310 15718065.4 Issued Austria <br />European patent (EP) 15718065.4<br />Filed on 2015-04-09<br />Status: Issued 147166537 E-021-2015-0 E-021-2015-0-BE-17 Anti-CD70 Chimeric Antigen Receptors EP Belgium 3230310 15718065.4 Issued Belgium <br />European patent (EP) 15718065.4<br />Filed on 2015-04-09<br />Status: Issued 147166538 E-021-2015-0 E-021-2015-0-CH-18 Anti-CD70 Chimeric Antigen Receptors EP Switzerland 3230310 15718065.4 Issued Switzerland <br />European patent (EP) 15718065.4<br />Filed on 2015-04-09<br />Status: Issued 147166539 E-021-2015-0 E-021-2015-0-CZ-19 Anti-CD70 Chimeric Antigen Receptors EP Czech Republic 3230310 15718065.4 Issued Czech Republic <br />European patent (EP) 15718065.4<br />Filed on 2015-04-09<br />Status: Issued 147166540 E-021-2015-0 E-021-2015-0-GR-20 Anti-CD70 Chimeric Antigen Receptors EP Greece 3230310 15718065.4 Issued Greece <br />European patent (EP) 15718065.4<br />Filed on 2015-04-09<br />Status: Issued 147166541 E-021-2015-0 E-021-2015-0-LI-21 Anti-CD70 Chimeric Antigen Receptors EP Liechtenstein 3230310 15718065.4 Issued Liechtenstein <br />European patent (EP) 15718065.4<br />Filed on 2015-04-09<br />Status: Issued 147166542 E-021-2015-0 E-021-2015-0-NL-22 Anti-CD70 Chimeric Antigen Receptors EP The Netherlands 3230310 15718065.4 Issued The Netherlands <br />European patent (EP) 15718065.4<br />Filed on 2015-04-09<br />Status: Issued 147166543 E-021-2015-0 E-021-2015-0-NO-23 Anti-CD70 Chimeric Antigen Receptors EP Norway 3230310 15718065.4 Issued Norway <br />European patent (EP) 15718065.4<br />Filed on 2015-04-09<br />Status: Issued 147166544 E-021-2015-0 E-021-2015-0-PL-24 Anti-CD70 Chimeric Antigen Receptors EP Poland 3230310 15718065.4 Issued Poland <br />European patent (EP) 15718065.4<br />Filed on 2015-04-09<br />Status: Issued 147166545 E-021-2015-0 E-021-2015-0-PT-25 Anti-CD70 Chimeric Antigen Receptors EP Portugal 3230310 15718065.4 Issued Portugal <br />European patent (EP) 15718065.4<br />Filed on 2015-04-09<br />Status: Issued 147166546 E-021-2015-0 E-021-2015-0-SE-26 Anti-CD70 Chimeric Antigen Receptors EP Sweden 3230310 15718065.4 Issued Sweden <br />European patent (EP) 15718065.4<br />Filed on 2015-04-09<br />Status: Issued 147166547 E-021-2015-0 E-021-2015-0-SI-27 Anti-CD70 Chimeric Antigen Receptors EP Slovenia 3230310 15718065.4 Issued Slovenia <br />European patent (EP) 15718065.4<br />Filed on 2015-04-09<br />Status: Issued 147166548 E-021-2015-0 E-021-2015-0-SK-28 Anti-CD70 Chimeric Antigen Receptors EP Slovakia 3230310 15718065.4 Issued Slovakia <br />European patent (EP) 15718065.4<br />Filed on 2015-04-09<br />Status: Issued 147166549 E-021-2015-0 E-021-2015-0-TR-29 Anti-CD70 Chimeric Antigen Receptors EP Turkey 3230310 15718065.4 Issued Turkey <br />European patent (EP) 15718065.4<br />Filed on 2015-04-09<br />Status: Issued 147166550 E-021-2015-0 E-021-2015-0-HK-30 Anti-CD70 Chimeric Antigen Receptors EP Hong Kong HK40021099B 42020011615.0 Issued Hong Kong <br />European patent (EP) 42020011615.0<br />Filed on 2020-07-17<br />Status: Issued 147166551 E-021-2015-0 E-021-2015-0-US-31 ANTI-CD70 CHIMERIC ANTIGEN RECEPTORS DIV US 11,999,796 16/906,061 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11999796 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11999796">11,999,796</a><br />Filed on 2020-06-19<br />Status: Issued 147166552 E-021-2015-0 E-021-2015-0-AU-32 Anti-CD70 Chimeric Antigen Receptors DIV Australia 2020203836 2020203836 Issued Australia <br />Divisional (DIV) 2020203836<br />Filed on 2020-06-10<br />Status: Issued 147166553 E-021-2015-0 E-021-2015-0-JP-33 Anti-CD70 Chimeric Antigen Receptors DIV Japan 7128860 2020-109158 Issued Japan <br />Divisional (DIV) 2020-109158<br />Filed on 2020-06-24<br />Status: Issued 147166554 E-021-2015-0 E-021-2015-0-CN-34 Anti-CD70 Chimeric Antigen Receptors DIV China 202111253336.5 Pending China <br />Divisional (DIV) 202111253336.5<br />Filed on 2021-10-27<br />Status: Pending 147166555 E-021-2015-0 E-021-2015-0-AU-35 Anti-CD70 Chimeric Antigen Receptors DIV Australia 2021277627 2021277627 Issued Australia <br />Divisional (DIV) 2021277627<br />Filed on 2021-11-30<br />Status: Issued 147166556 E-021-2015-0 E-021-2015-0-EP-36 Anti-CD70 Chimeric Antigen Receptors DIV European Patent 22164990.8 Pending European Patent <br />Divisional (DIV) 22164990.8<br />Filed on 2022-03-29<br />Status: Pending 147166557 E-021-2015-0 E-021-2015-0-JP-37 Anti-CD70 Chimeric Antigen Receptors DIV Japan 7574243 2022-092594 Issued Japan <br />Divisional (DIV) 2022-092594<br />Filed on 2022-06-07<br />Status: Issued 147166558 E-021-2015-0 E-021-2015-0-BE-38 Anti-CD70 Chimeric Antigen Receptors EP Belgium 3597663 19178931.2 Issued Belgium <br />European patent (EP) 19178931.2<br />Filed on 2019-06-07<br />Status: Issued 147166559 E-021-2015-0 E-021-2015-0-DK-39 Anti-CD70 Chimeric Antigen Receptors EP Denmark 3597663 19178931.2 Issued Denmark <br />European patent (EP) 19178931.2<br />Filed on 2019-06-07<br />Status: Issued 147166560 E-021-2015-0 E-021-2015-0-FR-40 Anti-CD70 Chimeric Antigen Receptors EP France 3597663 19178931.2 Issued France <br />European patent (EP) 19178931.2<br />Filed on 2019-06-07<br />Status: Issued 147166561 E-021-2015-0 E-021-2015-0-DE-41 Anti-CD70 Chimeric Antigen Receptors EP Germany 3597663 19178931.2 Issued Germany <br />European patent (EP) 19178931.2<br />Filed on 2019-06-07<br />Status: Issued 147166562 E-021-2015-0 E-021-2015-0-IT-42 Anti-CD70 Chimeric Antigen Receptors EP Italy 3597663 19178931.2 Issued Italy <br />European patent (EP) 19178931.2<br />Filed on 2019-06-07<br />Status: Issued 147166563 E-021-2015-0 E-021-2015-0-NL-43 Anti-CD70 Chimeric Antigen Receptors EP The Netherlands 3597663 19178931.2 Issued The Netherlands <br />European patent (EP) 19178931.2<br />Filed on 2019-06-07<br />Status: Issued 147166564 E-021-2015-0 E-021-2015-0-NO-44 Anti-CD70 Chimeric Antigen Receptors EP Norway 3597663 19178931.2 Issued Norway <br />European patent (EP) 19178931.2<br />Filed on 2019-06-07<br />Status: Issued 147166565 E-021-2015-0 E-021-2015-0-ES-45 Anti-CD70 Chimeric Antigen Receptors EP Spain 3597663 19178931.2 Issued Spain <br />European patent (EP) 19178931.2<br />Filed on 2019-06-07<br />Status: Issued 147166566 E-021-2015-0 E-021-2015-0-SE-46 Anti-CD70 Chimeric Antigen Receptors EP Sweden 3597663 19178931.2 Issued Sweden <br />European patent (EP) 19178931.2<br />Filed on 2019-06-07<br />Status: Issued 147166567 E-021-2015-0 E-021-2015-0-CH-47 Anti-CD70 Chimeric Antigen Receptors EP Switzerland 3597663 19178931.2 Issued Switzerland <br />European patent (EP) 19178931.2<br />Filed on 2019-06-07<br />Status: Issued 147166568 E-021-2015-0 E-021-2015-0-GB-48 Anti-CD70 Chimeric Antigen Receptors EP United Kingdom 3597663 19178931.2 Issued United Kingdom <br />European patent (EP) 19178931.2<br />Filed on 2019-06-07<br />Status: Issued 147169654 CARS 147169656 CD70 147169657 chimeric antigen receptor 147169659 T-cell reprogramming TAB-4095 147157377 Cancer Therapies Using Engineered Monomeric Fc Molecules NCI Licensing, Oncology, Therapeutics Licensing Oncology Therapeutics Dimiter Dimitrov, Tianlei Ying <p>The National Cancer Institute, Nanobiology Program seeks parties interested in collaborative research to co-develop engineered molecules therapies.</p> <p>Efforts to engineer antibody-based therapeutics, to date, have encountered technical limitations due to the relatively large fragment size and short fragment half-life. Antibody fragments are emerging as promising biopharmaceuticals because of their relatively small size and other unique properties. However, compared with full-size antibodies, these antibody fragments lack the ability to bind to some Fc receptor and have reduced half-lives.</p> <p>NCI scientists have developed small (∼27 kDa) antibody fragments that are potentially useful for therapeutic development.  These are monomeric IgG fragment (mFc) compositions; they have long half-lives, are functional (pH dependent binders of neonatal Fc receptor - FcRn); soluble, and they express in <em>E. coli</em> efficiently.  The molecules may serve as a platform for development of engineered mFc-based antibodies and fusion proteins with therapeutic applications: the smaller size may allow for superior access to targets and tissues compared to full sized mAbs and larger fragment-based therapeutics, while also retaining important functional characteristics. The IgG Fc is a dimer of two constant domains (CH2-CH3 chains). The Fc has a long half-life, which makes it promising as a candidate for engineering antibody therapeutics.  </p> <h2>Competitive Advantages:</h2> <ul><li>Smaller size results in reduced steric hindrance</li> <li>Increased therapeutic efficiency</li> </ul> <h2>Commercial Applications:</h2> <p>Therapeutics - human and veterinary, engineered antibody and fusion proteins.</p> 2016-02-16 2025-04-22 2020-04-13 2025-04-22 2016-08-29 FcRn, IgG1, mabs, MFC, neonatal Fc receptor False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-04-13 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147162100 Ying T, et al. Soluble monomeric IgG1 Fc. https://www.ncbi.nlm.nih.gov/pubmed/22518843 <a href="https://www.ncbi.nlm.nih.gov/pubmed/22518843">Ying T, et al. Soluble monomeric IgG1 Fc.</a> 147163487 Dimitrov, Dimiter NIH - NCI NCI Dimitrov, Dimiter (NCI) 1 147163488 Ying, Tianlei NIH - NCI Ying, Tianlei 2 147163487 Dimitrov, Dimiter NIH - NCI NCI Dimitrov, Dimiter (NCI) 1 147163488 Ying, Tianlei NIH - NCI Ying, Tianlei 2 147157802 Soluble Engineered Monomeric IgG 1 Fc E-019-2012-0 Filing authorized NCI 91814193 Freel, Rose rose.freel@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America rose.freel@nih.gov?subject=Web Inquiry on [TAB-4095] Cancer Therapies Using Engineered Monomeric Fc Molecules&body=Please send me information about technology [TAB-4095] Cancer Therapies Using Engineered Monomeric Fc Molecules.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Freel, Rose<br><a href="mailto:rose.freel@nih.gov?subject=Web Inquiry on [TAB-4095] Cancer Therapies Using Engineered Monomeric Fc Molecules&body=Please send me information about technology [TAB-4095] Cancer Therapies Using Engineered Monomeric Fc Molecules.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">rose.freel@nih.gov</a><br> 147166459 E-019-2012-0 E-019-2012-0-US-01 Soluble Engineered Monomeric FC PRV US 61/612,138 Abandoned US <br />Provisional (PRV) 61/612,138<br />Filed on 2012-03-16<br />Status: Abandoned 147166460 E-019-2012-0 E-019-2012-0-PCT-02 Soluble Engineered Monomeric FC PCT Patent Cooperation Treaty PCT/US13/31593 Expired Patent Cooperation Treaty <br />(PCT) PCT/US13/31593<br />Filed on 2013-03-14<br />Status: Expired 147166461 E-019-2012-0 E-019-2012-0-EP-03 Soluble Engineered Monomeric FC National Stage European Patent 2825557 13713301.3 Issued European Patent <br />National Stage 13713301.3<br />Filed on 2013-03-14<br />Status: Issued 147166462 E-019-2012-0 E-019-2012-0-US-04 Soluble Engineered Monomeric FC National Stage US 9,676,857 14/385,133 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9676857 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9676857">9,676,857</a><br />Filed on 2014-09-12<br />Status: Issued 147166463 E-019-2012-0 E-019-2012-0-US-05 SOLUBLE ENGINEERED MONOMERIC FC DIV US 10,633,447 15/590,981 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10633447 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10633447">10,633,447</a><br />Filed on 2017-05-09<br />Status: Issued 147166464 E-019-2012-0 E-019-2012-0-DE-06 Soluble Engineered Monomeric FC EP Germany 602013022827.2 13713301.3 Issued Germany <br />European patent (EP) 13713301.3<br />Filed on 2013-03-14<br />Status: Issued 147166465 E-019-2012-0 E-019-2012-0-FR-07 Soluble Engineered Monomeric FC EP France 2825557 13713301.3 Issued France <br />European patent (EP) 13713301.3<br />Filed on 2013-03-14<br />Status: Issued 147166466 E-019-2012-0 E-019-2012-0-GB-08 Soluble Engineered Monomeric FC EP United Kingdom 2825557 13713301.3 Issued United Kingdom <br />European patent (EP) 13713301.3<br />Filed on 2013-03-14<br />Status: Issued 147169613 FcRn 147169614 IgG1 147169615 mabs 147169616 MFC 147169618 neonatal Fc receptor TAB-4071 147157353 Peptide Inhibitors for Viral Infections and as Anti-inflammatory Agents NCI Collaboration, Dermatology, Immunology, Infectious Disease, Licensing, Oncology, Therapeutics Collaboration Dermatology Immunology Infectious Disease Licensing Oncology Therapeutics Marco Cardone, Alan Perantoni, C. Andrew Stewart, Nadya Tarasova, Giorgio Trinchieri, Howard Young <p>IFN-gamma and IL-10 are cytokine signaling molecules that play fundamental roles in inflammation, cancer growth and autoimmune diseases.  Unfortunately, there are no specific inhibitors of IFN-gamma or IL-10 on the market to date.</p> <p>NCI investigators at the <a href="https://ccr.cancer.gov/Cancer-and-Inflammation-Program" target="_blank" rel="nofollow">Cancer and Inflammation Program</a> have synthesized short peptides that selectively interfere with dimerization of the cytokines and their binding to the corresponding receptor. The peptides include metabolically stable lipopeptides mimicking conserved regions of IL-10 and IFN-gamma receptors that interfere with STAT3 and STAT1 phosphorylation and subsequent signaling. The lipopeptides strongly inhibit STAT3 and STAT1-dependent growth of cancer cells. These compounds are promising drug candidates for the treatment of cancer and many infectious and inflammatory diseases. </p> <h2>Competitive Advantages:</h2> <p>- Rationally designed and synthesized to be potent, metabolically stable, and more therapeutic<br /> - Highly selective IL-10 and IFN-gamma inhibitors</p> <h2>Commercial Applications:</h2> <p>- Cancer, viral infections and anti-inflammatory treatments<br /> - Dermatological treatment for psoriasis</p> 2016-02-16 2025-04-22 2016-08-31 2025-04-22 2016-08-30 IFN-gamma, Interferon gamma, INTERLEUKIN, Peptide, Peptidometic, psoriasis, Synthetic Peptide Inhibitors False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2016-08-31 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147162121 Timofeeva OA, et al. http://www.ncbi.nlm.nih.gov/pubmed/18154267 <a href="http://www.ncbi.nlm.nih.gov/pubmed/18154267">Timofeeva OA, et al.</a> 147163415 Tarasova, Nadya NIH - NCI NCI Tarasova, Nadya (NCI) 1 147163418 Trinchieri, Giorgio NIH - NCI NCI Trinchieri, Giorgio (NCI) 2 147163416 Young, Howard NIH - NCI NCI Young, Howard (NCI) 3 147163419 Stewart, C. Andrew NIH - NCI NCI Stewart, C. Andrew (NCI) 4 147163420 Cardone, Marco NIH - NCI NCI Cardone, Marco (NCI) 5 147163417 Perantoni, Alan NIH - NCI NCI Perantoni, Alan (NCI) 6 147163415 Tarasova, Nadya NIH - NCI NCI Tarasova, Nadya (NCI) 1 147163418 Trinchieri, Giorgio NIH - NCI NCI Trinchieri, Giorgio (NCI) 2 147163416 Young, Howard NIH - NCI NCI Young, Howard (NCI) 3 147163419 Stewart, C. Andrew NIH - NCI NCI Stewart, C. Andrew (NCI) 4 147163420 Cardone, Marco NIH - NCI NCI Cardone, Marco (NCI) 5 147163417 Perantoni, Alan NIH - NCI NCI Perantoni, Alan (NCI) 6 147158123 Peptide Inhibitors Of Interferon Gamma And Interleukin 10 Signaling E-167-2010-0 Filing authorized NCI 83732213 Dick, Taryn taryn.dick@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB taryn.dick@nih.gov?subject=Web Inquiry on [TAB-4071] Peptide Inhibitors for Viral Infections and as Anti-inflammatory Agents&body=Please send me information about technology [TAB-4071] Peptide Inhibitors for Viral Infections and as Anti-inflammatory Agents.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dick, Taryn<br><a href="mailto:taryn.dick@nih.gov?subject=Web Inquiry on [TAB-4071] Peptide Inhibitors for Viral Infections and as Anti-inflammatory Agents&body=Please send me information about technology [TAB-4071] Peptide Inhibitors for Viral Infections and as Anti-inflammatory Agents.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">taryn.dick@nih.gov</a><br> 147161134 E-167-2010-0 E-167-2010-0-US-04 Peptide-Based Inhibitor Of Interleukin-10 Or Interferon-Gamma Signaling National Stage US 9,475,839 13/697,259 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9475839 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9475839">9,475,839</a><br />Filed on 2012-12-19<br />Status: Issued 147166328 E-167-2010-0 E-167-2010-0-US-01 Peptide Inhibitors Of Interferon Gamma And Interleukin 10 Signaling PRV US 61/333,512 Abandoned US <br />Provisional (PRV) 61/333,512<br />Filed on 2010-05-11<br />Status: Abandoned 147166329 E-167-2010-0 E-167-2010-0-PCT-02 Peptide-Based Inhibitor Of Interleukin 10 Or Interferon-Gamma Signaling PCT Patent Cooperation Treaty PCT/US2011/036010 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2011/036010<br />Filed on 2011-05-11<br />Status: Expired 147166330 E-167-2010-0 E-167-2010-0-EP-03 Peptide-Based Inhibitor Of Interleukin-10 Or Interferon-Gamma Signaling National Stage European Patent 2569326 11720697.9 Issued European Patent <br />National Stage 11720697.9<br />Filed on 2011-05-11<br />Status: Issued 147166331 E-167-2010-0 E-167-2010-0-DE-05 Peptide-Based Inhibitor Of Interleukin-10 Or Interferon-Gamma Signaling EP Germany 60 2011 028 998.5 11720697.9 Issued Germany <br />European patent (EP) 11720697.9<br />Filed on 2011-05-11<br />Status: Issued 147166332 E-167-2010-0 E-167-2010-0-ES-06 Peptide-Based Inhibitor Of Interleukin-10 Or Interferon-Gamma Signaling EP Spain 2569326 11720697.9 Issued Spain <br />European patent (EP) 11720697.9<br />Filed on 2011-05-11<br />Status: Issued 147166333 E-167-2010-0 E-167-2010-0-FR-07 Peptide-Based Inhibitor Of Interleukin-10 Or Interferon-Gamma Signaling EP France 2569326 11720697.9 Issued France <br />European patent (EP) 11720697.9<br />Filed on 2011-05-11<br />Status: Issued 147166334 E-167-2010-0 E-167-2010-0-GB-08 Peptide-Based Inhibitor Of Interleukin-10 Or Interferon-Gamma Signaling EP United Kingdom 2569326 11720697.9 Issued United Kingdom <br />European patent (EP) 11720697.9<br />Filed on 2011-05-11<br />Status: Issued 147166335 E-167-2010-0 E-167-2010-0-IT-09 Peptide-Based Inhibitor Of Interleukin-10 Or Interferon-Gamma Signaling EP Italy 502016000109625 11720697.9 Issued Italy <br />European patent (EP) 11720697.9<br />Filed on 2011-05-11<br />Status: Issued 147166336 E-167-2010-0 E-167-2010-0-EP-10 Peptide-Based Inhibitor Of Interleukin-10 Or Interferon-Gamma Signaling DIV European Patent 16181625.1 Abandoned European Patent <br />Divisional (DIV) 16181625.1<br />Filed on 2016-07-28<br />Status: Abandoned 147172785 IFN-gamma 147172786 Interferon gamma 147172787 INTERLEUKIN 147172788 Peptide 147172790 Peptidometic 147172791 psoriasis 147172793 Synthetic Peptide Inhibitors TAB-4077 147157359 Multifunctional RNA Nanoparticles as Cancer and HIV Therapeutics NCI Collaboration, Infectious Disease, Licensing, Oncology, Therapeutics Collaboration Infectious Disease Licensing Oncology Therapeutics Kirill Afonin, Angelica Martins, Bruce Shapiro, Mathias Viard <p>The promise of RNA interference based therapeutics is made evident by the recent surge of biotechnological drug companies that pursue such therapies and their progression into human clinical trials. The present invention discloses novel RNA  and RNA/DNA nanoparticles including  multiple siRNAs, RNA aptamers, fluorescent dyes, and proteins. These RNA nanoparticles are useful for various nanotechnological applications. This technology has a higher detection sensitivity and higher silencing efficiencies of targeted genes than conventional siRNAs.  This technology has significant therapeutic potential against multiple disease types, including, cancer and viral infections.  Xxenograft mouse models indicated uptake of the nanoparticles, and six different HIV targets were validated with cell cultures.</p> <h2>Competitive Advantages:</h2> <ul><li>Potential for higher sensitivity, higher efficiency, low cytotoxicity, multiple functionality, multiple targets, and controlled activation</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Treatment for cancer and HIV</li> </ul> 2016-02-16 2025-04-22 2018-06-18 2025-04-22 2016-09-12 BREAST CANCER, Nanoparticle, nanotechnology, RNAi, SiRNA False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2018-06-18 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-039-2012 E-156-2014 147162444 Kirill A. Afonin, et al. &quot;Triggering of RNA Interference with RNA-RNA, RNA-DNA, and DNA- RNA Nanoparticles&quot; https://www.ncbi.nlm.nih.gov/pubmed/25521794 <a href="https://www.ncbi.nlm.nih.gov/pubmed/25521794">Kirill A. Afonin, et al. &quot;Triggering of RNA Interference with RNA-RNA, RNA-DNA, and DNA- RNA Nanoparticles&quot;</a> 147163433 Shapiro, Bruce NIH - NCI NCI Shapiro, Bruce (NCI) 1 147163435 Afonin, Kirill NIH - NCI Afonin, Kirill 2 147163436 Martins, Angelica NIH - NCI NCI Martins, Angelica (NCI) 3 147163434 Viard, Mathias NIH - NCI Leidos Viard, Mathias (Leidos) 4 147163433 Shapiro, Bruce NIH - NCI NCI Shapiro, Bruce (NCI) 1 147163435 Afonin, Kirill NIH - NCI Afonin, Kirill 2 147163436 Martins, Angelica NIH - NCI NCI Martins, Angelica (NCI) 3 147163434 Viard, Mathias NIH - NCI Leidos Viard, Mathias (Leidos) 4 147158358 Multifunctional RNA Nanoparticles E-765-2013-0 Filing authorized NCI 83732917 Favila, Michelle michelle.favila@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC michelle.favila@nih.gov?subject=Web Inquiry on [TAB-4077] Multifunctional RNA Nanoparticles as Cancer and HIV Therapeutics&body=Please send me information about technology [TAB-4077] Multifunctional RNA Nanoparticles as Cancer and HIV Therapeutics.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Favila, Michelle<br><a href="mailto:michelle.favila@nih.gov?subject=Web Inquiry on [TAB-4077] Multifunctional RNA Nanoparticles as Cancer and HIV Therapeutics&body=Please send me information about technology [TAB-4077] Multifunctional RNA Nanoparticles as Cancer and HIV Therapeutics.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">michelle.favila@nih.gov</a><br> 147161279 E-765-2013-0 E-765-2013-0-US-07 Multifunctional RNA Nanoparticles and Methods of Use National Stage US 10/301,621 15/022,530 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10301621 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10301621">10/301,621</a><br />Filed on 2016-03-16<br />Status: Issued 147166355 E-765-2013-0 E-765-2013-0-US-01 Multifunctional RNA Nanoparticles and Methods of Use PRV US 61/878,758 Abandoned US <br />Provisional (PRV) 61/878,758<br />Filed on 2013-09-17<br />Status: Abandoned 147166356 E-765-2013-0 E-765-2013-0-PCT-02 Multifunctional RNA Nanoparticles and Methods of Use PCT Patent Cooperation Treaty PCT/US2014/056007 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2014/056007<br />Filed on 2014-09-17<br />Status: Expired 147166357 E-765-2013-0 E-765-2013-0-EP-03 Multifunctional RNA Nanoparticles and Methods of Use National Stage European Patent 3047026 14780963.6 Issued European Patent <br />National Stage 14780963.6<br />Filed on 2014-09-17<br />Status: Issued 147166358 E-765-2013-0 E-765-2013-0-AU-04 Multifunctional RNA Nanoparticles and Methods of Use National Stage Australia 2014321443 2014321443 Issued Australia <br />National Stage 2014321443<br />Filed on 2014-09-17<br />Status: Issued 147166359 E-765-2013-0 E-765-2013-0-CA-05 Multifunctional RNA Nanoparticles and Methods of Use National Stage Canada 2924509 2924509 Issued Canada <br />National Stage 2924509<br />Filed on 2014-09-17<br />Status: Issued 147166360 E-765-2013-0 E-765-2013-0-JP-06 Multifunctional RNA Nanoparticles and Methods of Use National Stage Japan 6669655 2016-543964 Issued Japan <br />National Stage 2016-543964<br />Filed on 2014-09-17<br />Status: Issued 147166361 E-765-2013-0 E-765-2013-0-US-08 MULTIFUNCTIONAL RNA NANOPARTICLES AND METHODS OF USE CON US 16/397,534 Abandoned US <br />Continuation (CON) 16/397,534<br />Filed on 2019-04-29<br />Status: Abandoned 147166362 E-765-2013-0 E-765-2013-0-DE-09 Multifunctional RNA Nanoparticles and Methods of Use EP Germany 3047026 14780963.6 Issued Germany <br />European patent (EP) 14780963.6<br />Filed on 2014-09-17<br />Status: Issued 147166363 E-765-2013-0 E-765-2013-0-FR-10 Multifunctional RNA Nanoparticles and Methods of Use EP France 3047026 14780963.6 Issued France <br />European patent (EP) 14780963.6<br />Filed on 2014-09-17<br />Status: Issued 147166364 E-765-2013-0 E-765-2013-0-GB-11 Multifunctional RNA Nanoparticles and Methods of Use EP United Kingdom 3047026 14780963.6 Issued United Kingdom <br />European patent (EP) 14780963.6<br />Filed on 2014-09-17<br />Status: Issued 147174911 BREAST CANCER 147174912 Nanoparticle 147174913 nanotechnology 147174914 RNAi 147174915 SiRNA TAB-4065 147157347 Novel Anti-HIV Proteins from Coral Reefs NCI Collaboration, Infectious Disease, Licensing, Therapeutics Collaboration Infectious Disease Licensing Therapeutics James McMahon, Barry O'Keefe, Koreen Ramessar, Chang-yun Xiong <p>Scientists at the National Cancer Institute's <a href="https://ccr.cancer.gov/Molecular-Targets-Laboratory" rel="nofollow">Molecular Targets Laboratory</a> have discovered that Cnidarins as a novel class of highly potent proteins capable of blocking the HIV virus from penetrating T-cells. Cnidarins were found in a soft coral collected in waters off Australia's northern coast. Cnidarins can block virus fusion/entry but do not block viral attachment. In addition, Cnidarins do not have lectin-like activity and therefore possibly a unique mechanism of action. Thus, Cnidarins may represent important new leads for HIV microbicides or for systemic therapeutics for HIV.</p> <h2>Competitive Advantages:</h2> <ul><li>High potency against HIV</li> <li>Novel Chemical composition</li> <li>Family of related proteins</li> <li>Unique mechanism of action</li> </ul> <h2>Commercial Applications:</h2> <p>Microbicide, Therapeutic, Research tool</p> 2016-02-16 2025-04-22 2018-03-26 2025-04-22 2016-09-12 Anti-Viral, cnidarin, HIV False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2018-03-26 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147163400 O'Keefe, Barry NIH - NCI NCI O'Keefe, Barry (NCI) 1 147163399 McMahon, James NIH - NCI NCI McMahon, James (NCI) 2 147163402 Ramessar, Koreen NIH - NCI NCI Ramessar, Koreen (NCI) 3 147163401 Xiong, Chang-yun NIH - NCI Xiong, Chang-yun 4 147163400 O'Keefe, Barry NIH - NCI NCI O'Keefe, Barry (NCI) 1 147163399 McMahon, James NIH - NCI NCI McMahon, James (NCI) 2 147163402 Ramessar, Koreen NIH - NCI NCI Ramessar, Koreen (NCI) 3 147163401 Xiong, Chang-yun NIH - NCI Xiong, Chang-yun 4 147158334 Novel Anti-HIV Proteins, Named Cnidarins-1, -2, And -3, Have Been Isolated From The Soft Coral (cnidarians) Synthecium Sp E-295-2012-0 Filing authorized NCI 83732213 Dick, Taryn taryn.dick@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB taryn.dick@nih.gov?subject=Web Inquiry on [TAB-4065] Novel Anti-HIV Proteins from Coral Reefs&body=Please send me information about technology [TAB-4065] Novel Anti-HIV Proteins from Coral Reefs.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dick, Taryn<br><a href="mailto:taryn.dick@nih.gov?subject=Web Inquiry on [TAB-4065] Novel Anti-HIV Proteins from Coral Reefs&body=Please send me information about technology [TAB-4065] Novel Anti-HIV Proteins from Coral Reefs.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">taryn.dick@nih.gov</a><br> 147166297 E-295-2012-0 E-295-2012-0-US-01 Anti-Viral Cnidarins PRV US 61/925,347 Abandoned US <br />Provisional (PRV) 61/925,347<br />Filed on 2014-01-09<br />Status: Abandoned 147166298 E-295-2012-0 E-295-2012-0-PCT-02 Anti-Viral Cnidarins PCT Patent Cooperation Treaty PCT/US2015/010797 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2015/010797<br />Filed on 2015-01-09<br />Status: Expired 147166299 E-295-2012-0 E-295-2012-0-AU-03 Anti-Viral Cnidarins National Stage Australia 2015204680 2015204680 Issued Australia <br />National Stage 2015204680<br />Filed on 2015-01-09<br />Status: Issued 147166300 E-295-2012-0 E-295-2012-0-CA-04 Anti-Viral Cnidarins National Stage Canada 2935123 Pending Canada <br />National Stage 2935123<br />Filed on 2015-01-09<br />Status: Pending 147166301 E-295-2012-0 E-295-2012-0-EP-05 Anti-Viral Cnidarins National Stage European Patent 3091994 15701450.7 Issued European Patent <br />National Stage 15701450.7<br />Filed on 2015-01-09<br />Status: Issued 147166302 E-295-2012-0 E-295-2012-0-US-06 Anti-Viral Cnidarins National Stage US 11,034,736 15/110,156 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11034736 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11034736">11,034,736</a><br />Filed on 2016-07-07<br />Status: Issued 147166303 E-295-2012-0 E-295-2012-0-DE-07 Anti-Viral Cnidarins EP Germany 3091994 15701450.7 Issued Germany <br />European patent (EP) 15701450.7<br />Filed on 2016-06-29<br />Status: Issued 147166304 E-295-2012-0 E-295-2012-0-FR-08 Anti-Viral Cnidarins EP France 3091994 15701450.7 Issued France <br />European patent (EP) 15701450.7<br />Filed on 2016-06-29<br />Status: Issued 147166305 E-295-2012-0 E-295-2012-0-GB-09 Anti-Viral Cnidarins EP United Kingdom 3091994 15701450.7 Issued United Kingdom <br />European patent (EP) 15701450.7<br />Filed on 2016-06-29<br />Status: Issued 147174751 Anti-Viral 147174752 cnidarin 147174753 HIV TAB-4062 147157344 Thalidomide Analogs that Inhibit Inflammation and Angiogenesis NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Shaunna Beedle, William Figg, Nigel Greig, Weiming Luo, David Tweedie, Nell Vargesson <p>Thalidomide and its close analogs (lenalidomide and pomalidomide) are widely used to treat a variety of diseases, such as multiple myeloma and other cancers as well as the symptoms of several inflammatory disorders. However, thalidomide is known for its teratogenic adverse effects when first clinically introduced in the 1950s, and is associated with drowsiness and peripheral neuropathy. Hence, there is intense interest to synthesize, identify and develop safer analogs. </p> <p>Researchers at the National Cancer Institute<a href="https://www.irp.nia.nih.gov/branches/tgb/ddds.htm" rel="nofollow">n</a> synthesized novel thalidomide analogs that demonstrate clinical potential without being teratogenic, as initially evaluated in <em>in vivo</em> zebrafish and chicken embryo model systems and in cell culture.  These new compounds differentially provide potent anti-angiogenesis and/or anti-inflammatory action. The agents have potential for development of new cancer therapies and treatment of a number of  neurological and systemic disorders involving chronic inflammation and elevated TNF-alpha levels.</p> <h2>Competitive Advantages:</h2> <p>- Non-teratogenic<br /> - Potent</p> <h2>Commercial Applications:</h2> <p>- Cancer therapeutics<br /> - Inflammatory disorders such as Crohn's disease, sarcoidosis, graft-versus-host disease, and rheumatoid arthritis<br /> - Neuroinflammatory disorders (acute: traumatic brain injury and stroke; chronic: Parkinson's disease, Alzheimer's disease, multiple sclerosis)</p> 2016-02-16 2025-04-22 2021-01-26 2025-04-22 2016-08-31 anti-angiogenesis, ANTI-INFLAMMATORY, Lenalidomide, Pomalidomide, THALIDOMIDE False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2021-01-26 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147163387 Greig, Nigel NIH - NIA NIA Greig, Nigel (NIA) 1 147163389 Luo, Weiming NIH - NIA NIA Luo, Weiming (NIA) 2 147163390 Tweedie, David NIH - NIA NIA Tweedie, David (NIA) 3 147163391 Vargesson, Nell University of Aberdeen Vargesson, Nell 4 147163392 Beedle, Shaunna University of Aberdeen Beedle, Shaunna 5 147163388 Figg, William NIH - NCI NCI Figg, William (NCI) 6 147163387 Greig, Nigel NIH - NIA NIA Greig, Nigel (NIA) 1 147163389 Luo, Weiming NIH - NIA NIA Luo, Weiming (NIA) 2 147163390 Tweedie, David NIH - NIA NIA Tweedie, David (NIA) 3 147163391 Vargesson, Nell University of Aberdeen Vargesson, Nell 4 147163392 Beedle, Shaunna University of Aberdeen Beedle, Shaunna 5 147163388 Figg, William NIH - NCI NCI Figg, William (NCI) 6 147158211 Thalidomide/lenolidomide/pomalidomide Analogs That Inhibit Inflammation, Angiogenesis E-208-2015-0 Filing authorized National Institute on Aging (NIH/NIA), NCI, University of Aberdeen 83691647 Chang, Kevin changke@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB changke@mail.nih.gov?subject=Web Inquiry on [TAB-4062] Thalidomide Analogs that Inhibit Inflammation and Angiogenesis&body=Please send me information about technology [TAB-4062] Thalidomide Analogs that Inhibit Inflammation and Angiogenesis.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Chang, Kevin<br><a href="mailto:changke@mail.nih.gov?subject=Web Inquiry on [TAB-4062] Thalidomide Analogs that Inhibit Inflammation and Angiogenesis&body=Please send me information about technology [TAB-4062] Thalidomide Analogs that Inhibit Inflammation and Angiogenesis.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">changke@mail.nih.gov</a><br> 147166279 E-208-2015-0 E-208-2015-0-US-01 THALIDOMIDE ANALOGS AND METHODS OF USE PRV US 62/235,105 Abandoned US <br />Provisional (PRV) 62/235,105<br />Filed on 2015-09-30<br />Status: Abandoned 147166280 E-208-2015-0 E-208-2015-0-PCT-02 Thalidomide Analogs and Methods of Use PCT Patent Cooperation Treaty PCT/US2016/054430 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2016/054430<br />Filed on 2016-09-29<br />Status: Expired 147166281 E-208-2015-0 E-208-2015-0-AU-03 Thalidomide Analogs and Methods of Use National Stage Australia 2016330967 2016330967 Issued Australia <br />National Stage 2016330967<br />Filed on 2016-09-29<br />Status: Issued 147166282 E-208-2015-0 E-208-2015-0-CA-04 Thalidomide Analogs and Methods of Use National Stage Canada 3000661 3000661 Issued Canada <br />National Stage 3000661<br />Filed on 2016-09-29<br />Status: Issued 147166283 E-208-2015-0 E-208-2015-0-EP-05 Thalidomide Analogs and Methods of Use National Stage European Patent 3356346 16782148.7 Issued European Patent <br />National Stage 16782148.7<br />Filed on 2016-09-29<br />Status: Issued 147166284 E-208-2015-0 E-208-2015-0-KR-06 Thalidomide Analogs and Methods of Use National Stage South Korea 10-2838444 10-2018-7012347 Issued South Korea <br />National Stage 10-2018-7012347<br />Filed on 2018-04-30<br />Status: Issued 147166285 E-208-2015-0 E-208-2015-0-US-07 THALIDOMIDE ANALOGS AND METHODS OF USE National Stage US 10,730,835 15/764,193 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10730835 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10730835">10,730,835</a><br />Filed on 2018-03-28<br />Status: Issued 147166286 E-208-2015-0 E-208-2015-0-US-08 THALIDOMIDE ANALOGS AND METHODS OF USE CON US 10,836,721 16/910,708 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10836721 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10836721">10,836,721</a><br />Filed on 2020-06-24<br />Status: Issued 147166287 E-208-2015-0 E-208-2015-0-US-09 THALIDOMIDE ANALOGS AND METHODS OF USE CON US 11,440,880 17/083,898 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11440880 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11440880">11,440,880</a><br />Filed on 2020-10-29<br />Status: Issued 147173686 anti-angiogenesis 147173687 ANTI-INFLAMMATORY 147173688 Lenalidomide 147173689 Pomalidomide 147173690 THALIDOMIDE TAB-4056 147157338 Cancer Therapeutic Agents that Bind to STAT Proteins NCI Immunology, Licensing, Oncology, Therapeutics Immunology Licensing Oncology Therapeutics Vadim Gaponenko, Christopher Michejda, Alan Perantoni, Sergey Tarasov, Nadya Tarasova, Olga Timofeeva <p>The National Cancer Institute, <a href="http://ccr.cancer.gov/labs/lab.asp?labid=790" target="_blank" rel="nofollow">Cancer and Inflammation Program</a><a href="http://ccr.cancer.gov/labs/lab.asp?labid=790" target="_blank" rel="nofollow"> </a>seeks parties interested in collaborative research to further co-develop inhibitors of STAT proteins for the treatment of cancer.</p> <p>Signal transducer and activator transcription (STAT) proteins, specifically STAT1, 2, 3, 4, 5a, 5b, and 6, are involved in the cellular and biological processes of cell proliferation, differentiation, apoptosis, host defense, and transformation. Constitutively active STAT proteins occur in many human tumor cells and cells transformed by oncoproteins. Inhibiting these STAT proteins has great therapeutic potential in the treatment of certain cancers and a common approach to inhibition of these proteins involves targeting the kinases that activate STAT.  This method typically leads to non-selective inhibitors and is associated with off-target related toxicity. </p> <p>NCI scientists discovered a family of short peptides that bind to the N-terminal domains of STAT proteins and have shown that they can be used as therapeutic agents for certain types of cancer. These compounds are the first inhibitors that can directly bind to N-domains of STATs and exhibit a direct inhibitory effect. The selective nature of this direct approach suggests a more favorable toxicity profile than observed through the non-selective inhibition of kinases. STAT1, 3, and 5 inhibitors can serve as potent therapeutic agents for the treatment of a variety of tumors and STAT 4 inhibitors can be used to control autoimmune disorders.</p> <h2>Competitive Advantages:</h2> <ul><li>The common method of down-regulation of STAT proteins</li> <li>Direct inhibition of STAT is associated with a reduced toxicity profile compared to down-regulation through inhibition of related kinases</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Therapeutic potential for the treatment of various cancer types, particularly for breast and prostate tumors.</li> <li>Potential use in the management of autoimmune disorders.</li> <li>As a research tool to study the function of STAT proteins</li> </ul> 2016-02-16 2025-04-22 2017-11-20 2025-04-22 2013-02-19 Autoimmune, N-terminal domain, STAT False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2017-11-20 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147162275 Timofeeva, OA, et al., STAT3 suppresses transcription of proapoptotic genes in cancer cells with the involvement of its N-terminal domain. PNAS. 110(4): 1267-1272, 2013. http://www.ncbi.nlm.nih.gov/pubmed/?term=STAT3+suppresses+transcription+of+proapoptotic+genes+in+cancer+cells+with+the+involvement+of+its+N-terminal+domain <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=STAT3+suppresses+transcription+of+proapoptotic+genes+in+cancer+cells+with+the+involvement+of+its+N-terminal+domain">Timofeeva, OA, et al., STAT3 suppresses transcription of proapoptotic genes in cancer cells with the involvement of its N-terminal domain. PNAS. 110(4): 1267-1272, 2013.</a> 147163357 Tarasova, Nadya NIH - NCI NCI Tarasova, Nadya (NCI) 1 147163358 Timofeeva, Olga NIH - NCI Timofeeva, Olga 2 147163361 Gaponenko, Vadim Gaponenko, Vadim 3 147163356 Michejda, Christopher NIH - NCI Michejda, Christopher 4 147163359 Perantoni, Alan NIH - NCI NCI Perantoni, Alan (NCI) 5 147163360 Tarasov, Sergey NIH - NCI NCI Tarasov, Sergey (NCI) 6 147163357 Tarasova, Nadya NIH - NCI NCI Tarasova, Nadya (NCI) 1 147163358 Timofeeva, Olga NIH - NCI Timofeeva, Olga 2 147163361 Gaponenko, Vadim Gaponenko, Vadim 3 147163356 Michejda, Christopher NIH - NCI Michejda, Christopher 4 147163359 Perantoni, Alan NIH - NCI NCI Perantoni, Alan (NCI) 5 147163360 Tarasov, Sergey NIH - NCI NCI Tarasov, Sergey (NCI) 6 147158116 Compounds Binding To The N-terminal Domains Of STAT Proteins As Therapeutic Agents E-164-2007-0 Filing authorized NCI 83732213 Dick, Taryn taryn.dick@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB taryn.dick@nih.gov?subject=Web Inquiry on [TAB-4056] Cancer Therapeutic Agents that Bind to STAT Proteins&body=Please send me information about technology [TAB-4056] Cancer Therapeutic Agents that Bind to STAT Proteins.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dick, Taryn<br><a href="mailto:taryn.dick@nih.gov?subject=Web Inquiry on [TAB-4056] Cancer Therapeutic Agents that Bind to STAT Proteins&body=Please send me information about technology [TAB-4056] Cancer Therapeutic Agents that Bind to STAT Proteins.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">taryn.dick@nih.gov</a><br> 147161128 E-164-2007-0 E-164-2007-0-US-03 Peptide-Based Stat Inhibitor National Stage US 9,540,427 12/601,711 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9540427 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9540427">9,540,427</a><br />Filed on 2010-02-05<br />Status: Issued 147166239 E-164-2007-0 E-164-2007-0-US-01 Compounds Binding To The N-terminal Domains Of STAT Proteins As Therapeutic Agents PRV US 60/940,916 Abandoned US <br />Provisional (PRV) 60/940,916<br />Filed on 2007-05-30<br />Status: Abandoned 147166240 E-164-2007-0 E-164-2007-0-PCT-02 PEPTIDE-BASED STAT INHIBITOR PCT Patent Cooperation Treaty PCT/US2008/065352 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2008/065352<br />Filed on 2008-05-30<br />Status: Expired 147166241 E-164-2007-0 E-164-2007-0-US-04 Peptide-Based Stat Inhibitor CON US 15/397,053 Abandoned US <br />Continuation (CON) 15/397,053<br />Filed on 2017-01-03<br />Status: Abandoned 147172717 Autoimmune 147172719 N-terminal domain 147172720 STAT TAB-4026 147157307 Brain endothelial reporter cells NCI Collaboration, Licensing, Oncology, Research Materials Collaboration Licensing Oncology Research Materials Brad St. Croix <p>Aberrant function of the WNT-b-catenin pathway is a common underlying cause of tumorigenesis.  Despite the attractiveness of the WNT-b-catenin pathway as a therapeutic target, WNT dependent cell signaling is also crucial for normal tissue development, and is ubiquitous in all organs.  As a result, WNT-b-catenin pathway inhibitors cause many side effects and fail to meet FDA safety standards.  A more targeted approach is needed to develop safe and effective WNT signaling inhibitors.</p> <p>Researchers at the NCI <a href="https://ccr.cancer.gov/Mouse-Cancer-Genetics-Program" rel="nofollow">Mouse Cancer Genetics Program</a> have developed a reporter cell based assay to identify inhibitors of TEM5 (GPR124), a co-receptor for Wnt7 that is primarily localized in the cerebrovascular tissue and further enriched in tumor vasculature.  Therapeutics specifically targeting TEM5, which is locally enriched in and required for the formation of tumor associated vasculature, have greater potential to avoid the development and regulatory pitfalls associated with other WNT signaling inhibitors. The National Cancer Institute therefore seeks parties interested in co-discovery and co-development of safe and effective TEM5 agonists and/or antagonists that modulate WNT signaling.</p> <h2>Competitive Advantages:</h2> <ul><li>TEM5 is selectively upregulated in cerebrovasculature of tumors</li> <li>TEM5 inhibitors have less potential for causing side effects compared to other Wnt signaling inhibitors</li> </ul> <h2>Commercial Applications:</h2> <ul><li>High throughput screen for TEM5 (GPR12) inhibitors</li> </ul> 2016-02-16 2025-04-22 2021-01-27 2025-04-22 2017-12-07 catenin, GPR 124, St. Croix, TEM5, WNT False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2021-01-27 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147162031 Cullen M et al. https://www.ncbi.nlm.nih.gov/pubmed/21421844 <a href="https://www.ncbi.nlm.nih.gov/pubmed/21421844">Cullen M et al.</a> 147162070 Posokhova E et al. http://www.ncbi.nlm.nih.gov/pubmed/25558062 <a href="http://www.ncbi.nlm.nih.gov/pubmed/25558062">Posokhova E et al.</a> 147163264 St. Croix, Brad NIH - NCI NCI St. Croix, Brad (NCI) 1 147163264 St. Croix, Brad NIH - NCI NCI St. Croix, Brad (NCI) 1 147157939 Development Of GPR124 Wildtype And Knockout Brain Endothelial Reporter Cells E-079-2015-0 Research Material NCI 91814193 Freel, Rose rose.freel@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America rose.freel@nih.gov?subject=Web Inquiry on [TAB-4026] Brain endothelial reporter cells&body=Please send me information about technology [TAB-4026] Brain endothelial reporter cells.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Freel, Rose<br><a href="mailto:rose.freel@nih.gov?subject=Web Inquiry on [TAB-4026] Brain endothelial reporter cells&body=Please send me information about technology [TAB-4026] Brain endothelial reporter cells.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">rose.freel@nih.gov</a><br> 147170923 catenin 147170925 GPR 124 147170927 St. Croix 147170929 TEM5 147170930 WNT TAB-4036 147157317 Nitric Oxide-Releasing Polymers for Wound Healing NCI Collaboration, Dermatology, Immunology, Licensing, Therapeutics Collaboration Dermatology Immunology Licensing Therapeutics Joseph Hrabie, Larry Keefer <p> A number of factors can play a detrimental role in the process of wound healing such as poor nutritional status, smoking, various drugs, cancer, and diabetes.  Wound healing impairment is a challenging clinical problem with no efficacious treatments currently available.  Nitric oxide (NO) has been shown to play a role in the process of wound healing by promoting both the proliferative and remodeling phases of healing. </p> <p>The present invention from NCI's <a href="https://ccr.cancer.gov/Chemical-Biology-Laboratory" rel="nofollow">Chemical Biology Laboratory </a>is a polyvinylpyrrolidone (PVP)-based polymer that is capable of releasing NO at therapeutic levels over a prolonged period of time when applied to a moist wound.  The polymers can also be incorporated into wound dressing and bandages for enhanced wound healing compared to the bandage alone.  These wound dressings and bandages may be useful in the treatment of wounds, various infections and dermatological conditions, and for follow-up to cancer treatments generating wounds.  Polyvinylpyrrolidone (PVP; povidone) has already been approved for a number of clinical applications such as betadine (povidone-iodine) topical antiseptics.</p> <h2>Competitive Advantages:</h2> <ul><li>The base polymer, PVP, has already been approved for clinical applications.</li> <li>The slow release of nitric oxide over a prolonged time period makes this technology attractive for its potential use in a controlled release patch or bandage.</li> </ul> <h2>Commercial Applications:</h2> <p>Controlled release of NO for potential use in wound healing, infection control, dermatological conditions or stomach irritation by non-steroidal anti-inflammatory drugs (NSAIDs)</p> 2016-02-16 2025-04-22 2021-06-10 2025-04-22 2016-08-30 Bioabsorption, Dermatological conditions, nitric oxide, Polyvinyl Pyrrolidone (povidone), Wound healing False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2021-06-10 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-188-2004 147163297 Hrabie, Joseph NIH - NCI Leidos Hrabie, Joseph (Leidos) 1 147163296 Keefer, Larry NIH - NCI NCI Keefer, Larry (NCI) 2 147163297 Hrabie, Joseph NIH - NCI Leidos Hrabie, Joseph (Leidos) 1 147163296 Keefer, Larry NIH - NCI NCI Keefer, Larry (NCI) 2 147158096 Polyvinylpyrrolidone (povidone) Derivatives Capable Of Serving As Nitric Oxide Donors E-157-2012-0 Filing authorized NCI 91814193 Freel, Rose rose.freel@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America rose.freel@nih.gov?subject=Web Inquiry on [TAB-4036] Nitric Oxide-Releasing Polymers for Wound Healing&body=Please send me information about technology [TAB-4036] Nitric Oxide-Releasing Polymers for Wound Healing.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Freel, Rose<br><a href="mailto:rose.freel@nih.gov?subject=Web Inquiry on [TAB-4036] Nitric Oxide-Releasing Polymers for Wound Healing&body=Please send me information about technology [TAB-4036] Nitric Oxide-Releasing Polymers for Wound Healing.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">rose.freel@nih.gov</a><br> 147161113 E-157-2012-0 E-157-2012-0-US-04 Nitric Oxide-Releasing Diazeniumdiolated Polyvinylpyrrolidone-Based Polymers, and Compositions, Medical Devices, and Uses Thereof National Stage US 9,540,471 14/414,765 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9540471 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9540471">9,540,471</a><br />Filed on 2015-01-14<br />Status: Issued 147166139 E-157-2012-0 E-157-2012-0-US-01 Nitric Oxide-Releasing Diazeniumdiolated Polyvinylpyrrolidone-Based Polymers, And Compositions, Medical Devices, And Uses Thereof PRV US 61/672,486 Abandoned US <br />Provisional (PRV) 61/672,486<br />Filed on 2012-07-17<br />Status: Abandoned 147166140 E-157-2012-0 E-157-2012-0-PCT-02 Nitric Oxide Releasing Diazeniumdiolated Polyvinylpyrrolidone Based Polymers, and Compositions, Medical Devices, and Uses Thereof PCT Patent Cooperation Treaty PCT/US2013/050793 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2013/050793<br />Filed on 2013-07-17<br />Status: Expired 147166141 E-157-2012-0 E-157-2012-0-AU-03 Nitric Oxide Releasing Diazeniumdiolated Polyvinylpyrrolidone Based Polymers, and Compositions, Medical Devices, and Uses Thereof National Stage Australia 2013292695 2013292695 Issued Australia <br />National Stage 2013292695<br />Filed on 2013-07-17<br />Status: Issued 147166142 E-157-2012-0 E-157-2012-0-CA-05 Nitric Oxide Releasing Diazeniumdiolated Polyvinylpyrrolidone Based Polymers, and Compositions, Medical Devices, and Uses Thereof National Stage Canada 2879843 2879843 Issued Canada <br />National Stage 2879843<br />Filed on 2013-07-17<br />Status: Issued 147166143 E-157-2012-0 E-157-2012-0-EP-06 Nitric Oxide Releasing Diazeniumdiolated Polyvinylpyrrolidone Based Polymers, and Compositions, Medical Devices, and Uses Thereof National Stage European Patent 2875056 13819293.5 Abandoned European Patent <br />National Stage 13819293.5<br />Filed on 2013-07-17<br />Status: Abandoned 147172525 Bioabsorption 147172527 Dermatological conditions 147172528 nitric oxide 147172530 Polyvinyl Pyrrolidone (povidone) 147172531 Wound healing TAB-4018 147157299 Nitric Oxide Based Therapeutics for the Treatment of Lung Cancer NCI Licensing, Oncology, Therapeutics Licensing Oncology Therapeutics Lucy Anderson, Harinath Chakrapani, Larry Keefer, Anna Maciag, Joseph Saavedra <p>Nitric oxide (NO) has a broad spectrum of actions in physiological and pathological processes.  NO-donor drugs have shown therapeutic effect in several cancer types by inducing apoptosis but the concentrations required have suggested limited clinical applicability.  For cancers such as non-small cell lung cancer where most therapies are not curative, there remains a need for effective treatments. </p> <p>Scientists at the National Cancer Institute have identified a diazeniumdiolate-based NO releasing prodrug, JS-36-25, with selective cytotoxicity towards cancer cells.  This prodrug has potent tumoristatic activity in lung cancer cells <em>in vitro</em> and in mice xenografts.  Treatment with JS-36-25 <em>in vivo </em>led to 85% reduction of tumor growth.  The tumoristatic potency of the compound had a negative correlation with the level of endogenous reactive oxygen species (ROS) in the cancer cells.  Thus, in addition to potent tumoristatic activity when administered alone, this compound is predicted to have a strong synergy with therapeutics that act through generation of ROS, such as bortezomib, doxorubicin, as well as high-energy radiation.</p> <h2>Competitive Advantages:</h2> <ul><li>Potent tumoristatic activity with selective cytotoxicity for cancer cells over normal cells</li> <li>Demonstrated 85% reduction of tumor growth <em>in vivo</em></li> <li>Predicted synergy with other therapeutics</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Could be used as a stand-alone therapy or in combination with currently available therapeutics </li> </ul> 2016-02-16 2025-04-22 2018-04-24 2025-04-22 2016-08-29 Diazeniumdiolate, nitric oxide, NO, prodrug, Reactive Oxygen Species, ROS False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2018-04-24 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147162217 Nandurdikar R, et al. Structural modifications modulate stability of glutathione-activated arylated diazeniumdiolate prodrugs. https://www.ncbi.nlm.nih.gov/pubmed/22480849 <a href="https://www.ncbi.nlm.nih.gov/pubmed/22480849">Nandurdikar R, et al. Structural modifications modulate stability of glutathione-activated arylated diazeniumdiolate prodrugs.</a> 147162332 Maciag A, et al. Activation of the c-Jun N-terminal kinase/activating transcription factor 3 (ATF3) pathway characterizes effective arylated diazeniumdiolate-based nitric oxide-releasing anticancer prodrugs. https://www.ncbi.nlm.nih.gov/pubmed/?term=Activation+of+the+c-Jun+N-terminal+kinase%2Factivating+transcription+factor+3+(ATF3)+pathway+characterizes+effective+arylated+diazeniumdiolate-based+nitric+oxide-releasing+anticancer+prodrugs. <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Activation+of+the+c-Jun+N-terminal+kinase%2Factivating+transcription+factor+3+(ATF3)+pathway+characterizes+effective+arylated+diazeniumdiolate-based+nitric+oxide-releasing+anticancer+prodrugs.">Maciag A, et al. Activation of the c-Jun N-terminal kinase/activating transcription factor 3 (ATF3) pathway characterizes effective arylated diazeniumdiolate-based nitric oxide-releasing anticancer prodrugs.</a> 147162370 Maciag A, et al. The nitric oxide prodrug JS-K is effective against non-small-cell lung cancer cells in vitro and in vivo: involvement of reactive oxygen species. https://www.ncbi.nlm.nih.gov/pubmed/?term=The+Nitric+Oxide+Prodrug+JS-K+Is+Effective+against+Non%E2%80%93Small-Cell+Lung+Cancer+Cells+In+Vitro+and+In+Vivo%3A+Involvement+of+Reactive+Oxygen+Species <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=The+Nitric+Oxide+Prodrug+JS-K+Is+Effective+against+Non%E2%80%93Small-Cell+Lung+Cancer+Cells+In+Vitro+and+In+Vivo%3A+Involvement+of+Reactive+Oxygen+Species">Maciag A, et al. The nitric oxide prodrug JS-K is effective against non-small-cell lung cancer cells in vitro and in vivo: involvement of reactive oxygen species.</a> 147163237 Maciag, Anna NIH - NCI Leidos Maciag, Anna (Leidos) 1 147163236 Chakrapani, Harinath NIH - NCI Chakrapani, Harinath 2 147163234 Saavedra, Joseph NIH - NCI NCI Saavedra, Joseph (NCI) 3 147163235 Anderson, Lucy NIH - NCI NCI Anderson, Lucy (NCI) 4 147163233 Keefer, Larry NIH - NCI NCI Keefer, Larry (NCI) 5 147163237 Maciag, Anna NIH - NCI Leidos Maciag, Anna (Leidos) 1 147163236 Chakrapani, Harinath NIH - NCI Chakrapani, Harinath 2 147163234 Saavedra, Joseph NIH - NCI NCI Saavedra, Joseph (NCI) 3 147163235 Anderson, Lucy NIH - NCI NCI Anderson, Lucy (NCI) 4 147163233 Keefer, Larry NIH - NCI NCI Keefer, Larry (NCI) 5 147157814 Nitric Oxide-based Cancer Therapeutic Agents For Lung Cancers With Elevated Levels Of Reactive Oxygen Species (ROS) And/or Low Levels Of Antioxidant Defense/DNA Repair Mechanisms. E-025-2010-0 Filing authorized NCI 91814193 Freel, Rose rose.freel@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America rose.freel@nih.gov?subject=Web Inquiry on [TAB-4018] Nitric Oxide Based Therapeutics for the Treatment of Lung Cancer&body=Please send me information about technology [TAB-4018] Nitric Oxide Based Therapeutics for the Treatment of Lung Cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Freel, Rose<br><a href="mailto:rose.freel@nih.gov?subject=Web Inquiry on [TAB-4018] Nitric Oxide Based Therapeutics for the Treatment of Lung Cancer&body=Please send me information about technology [TAB-4018] Nitric Oxide Based Therapeutics for the Treatment of Lung Cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">rose.freel@nih.gov</a><br> 147160921 E-025-2010-0 E-025-2010-0-US-06 Diazeniumdiolated Compounds, Pharmaceutical Compositions, and Method of Treating Cancer National Stage US 9,205,091 13/509,431 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9205091 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9205091">9,205,091</a><br />Filed on 2012-06-01<br />Status: Issued 147166021 E-025-2010-0 E-025-2010-0-US-01 Nitric Oxide-based Cancer Therapeutic Agents For Lung Cancers With Elevated Levels Of Reactive Oxygen Species (ROS) And/or Low Levels Of Antioxidant Defense/DNA Repair mechanisms. PRV US 61/261,175 Abandoned US <br />Provisional (PRV) 61/261,175<br />Filed on 2009-11-13<br />Status: Abandoned 147166022 E-025-2010-0 E-025-2010-0-PCT-02 Diazeniumdiolated Compounds, Pharmaceutical Compositions, And Methods of Treating Cancer PCT Patent Cooperation Treaty PCT/US2010/056446 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2010/056446<br />Filed on 2010-11-12<br />Status: Expired 147166023 E-025-2010-0 E-025-2010-0-AU-03 Diazeniumdiolated Compounds, Pharmaceutical Compositions, And Methods of Treating Cancer National Stage Australia 2010319398 2010319398 Issued Australia <br />National Stage 2010319398<br />Filed on 2010-11-12<br />Status: Issued 147166024 E-025-2010-0 E-025-2010-0-CA-04 Diazeniumdiolated Compounds, Pharmaceutical Compositions, And Methods of Treating Cancer National Stage Canada 2780633 2780633 Issued Canada <br />National Stage 2780633<br />Filed on 2015-11-06<br />Status: Issued 147166025 E-025-2010-0 E-025-2010-0-EP-05 Diazeniumdiolated Compounds, Pharmaceutical Compositions, And Method of Treating Cancer National Stage European Patent 10778814.3 Abandoned European Patent <br />National Stage 10778814.3<br />Filed on 2012-05-14<br />Status: Abandoned 147169710 Diazeniumdiolate 147169711 nitric oxide 147169712 NO 147169713 prodrug 147169714 Reactive Oxygen Species 147169715 ROS TAB-4023 147157304 Improved Personalized Cancer Immunotherapy NCI Licensing, Oncology, Therapeutics Licensing Oncology Therapeutics Alena Gros, Steven Rosenberg <p>Scientists at NIH have identified a process to select highly tumor-reactive T cells from a patient tumor sample based on the expression of four specific T cell surface markers: programmed cell death protein 1 (PD-1; CD279), 4-1BB (CD137), T cell lg-and mucin-domain-containing molecule-3 (TIM-3), and/or lymphocyte activation gene 3 (LAG-3). After this enriched population of tumor fighting T cells, primarily tumor infiltrating lymphocytes (TIL), is selected and expanded to large quantities, it gets re-infused into the patient via an adoptive cell transfer (ACT) regimen. The key finding for this process is that the most tumor-reactive TIL found in a bulk population of cells obtained from a patient tumor sample reliably exhibit high expression of one or more of these four markers.</p> <p>By selecting cancer attacking TIL from a patient's tumor based on these markers prior to re-infusion, in vitro culture time is reduced to grow up the desired T cells and a more effective anti-cancer T cell product can be produced. In comparison to previous TIL immunotherapy approaches, this new method for selecting tumor-reactive T cells/TIL from tumor samples should help TIL immunotherapy become more GMP compliant and allow greater standardized of the TIL production process to enable more widespread utilization of this personalized cancer treatment approach outside of NIH.</p> <h2>Competitive Advantages:</h2> <ul><li>Simpler: Tumor-reactive T cells/TIL can be selected for ACT from a bulk population derived from a tumor sample using common laboratory techniques</li> <li>More rapid: Selection of T cells/TIL based on expression of specific cell surface markers will reduce the culture time for these T cells before infusion into the patient to fight the tumor</li> <li>Less screening: This selection method eliminates the need to screen T cells/TIL for autologous tumor recognition before re-infusion into the patient</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Personalized ACT immunotherapy to treat human cancers using T cells obtained from a tumor sample</li> <li>Possible integration into a standard procedure for obtaining tumor-reactive T cells/TIL from a tumor as part of a GMP-compliant TIL manufacturing process that gains regulatory approval as a personalized cancer treatment option</li> <li>The immunotherapy component of a combination cancer therapy cancer regiment targeting specific tumor antigens in individual patients</li> <li>More rapid tumor-reactive T cell culturing process for laboratory testing</li> </ul> 2016-02-16 2025-04-22 2018-03-09 2025-04-22 2013-06-18 adoptive cell transfer (ACT), T Cells, tumor infiltrating leukocytes (TIL) False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2018-03-09 52406768 Discovery 52406768 NCI 37470483 Website Abstract E-085-2013 E-273-2009 E-275-2002 147163257 Gros, Alena NIH - NCI NCI Gros, Alena (NCI) 1 147163256 Rosenberg, Steven NIH - NCI NCI Rosenberg, Steven (NCI) 2 147163257 Gros, Alena NIH - NCI NCI Gros, Alena (NCI) 1 147163256 Rosenberg, Steven NIH - NCI NCI Rosenberg, Steven (NCI) 2 147157891 Selection Of CD8+ PD-1+, 41BB+ TIM-3+ Or LAG-3+ Cells From Tumor-infiltrating Lymphocytes (TIL) Enriches For Tumor-reactive Cells That Can Be Adoptively Transferred For The Treatment Of Cancer E-059-2013-0 Filing authorized NCI 83709866 Burke, Andrew burkear@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC burkear@nih.gov?subject=Web Inquiry on [TAB-4023] Improved Personalized Cancer Immunotherapy&body=Please send me information about technology [TAB-4023] Improved Personalized Cancer Immunotherapy.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Burke, Andrew<br><a href="mailto:burkear@nih.gov?subject=Web Inquiry on [TAB-4023] Improved Personalized Cancer Immunotherapy&body=Please send me information about technology [TAB-4023] Improved Personalized Cancer Immunotherapy.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">burkear@nih.gov</a><br> 147160976 E-059-2013-0 E-059-2013-0-US-01 Methods of Producing Enriched Populations Of Tumor-Reactive T Cells From Tumor PRV US 61/771,247 Abandoned US <br />Provisional (PRV) 61/771,247<br />Filed on 2013-03-01<br />Status: Abandoned 147166058 E-059-2013-0 E-059-2013-0-PCT-02 Methods of Producing Enriched Populations of Tumor-Reactive T Cells From Tumor PCT Patent Cooperation Treaty PCT/US2013/038799 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2013/038799<br />Filed on 2013-04-30<br />Status: Expired 147166059 E-059-2013-0 E-059-2013-0-AU-03 Methods of Producing Enriched Populations of Tumor-Reactive T Cells From Tumor National Stage Australia 2013379772 2013379772 Issued Australia <br />National Stage 2013379772<br />Filed on 2013-04-30<br />Status: Issued 147166060 E-059-2013-0 E-059-2013-0-CA-04 Methods of Producing Enriched Populations of Tumor-Reactive T Cells From Tumor National Stage Canada 2902423 2902423 Issued Canada <br />National Stage 2902423<br />Filed on 2013-04-30<br />Status: Issued 147166061 E-059-2013-0 E-059-2013-0-CN-05 Methods of Producing Enriched Populations of Tumor-Reactive T Cells From Tumor National Stage China 201380075798.X Abandoned China <br />National Stage 201380075798.X<br />Filed on 2015-10-20<br />Status: Abandoned 147166062 E-059-2013-0 E-059-2013-0-EP-06 Methods of Producing Enriched Populations of Tumor-Reactive T Cells From Tumor National Stage European Patent 2961415 13722922.5 Issued European Patent <br />National Stage 13722922.5<br />Filed on 2013-04-30<br />Status: Issued 147166063 E-059-2013-0 E-059-2013-0-JP-07 Methods of Producing Enriched Populations of Tumor-Reactive T Cells From Tumor National Stage Japan 6416131 2015-560159 Issued Japan <br />National Stage 2015-560159<br />Filed on 2015-09-01<br />Status: Issued 147166064 E-059-2013-0 E-059-2013-0-RU-08 Methods of Producing Enriched Populations of Tumor-Reactive T Cells From Tumor National Stage Russia 2671897 2015138483 Issued Russia <br />National Stage 2015138483<br />Filed on 2015-09-10<br />Status: Issued 147166065 E-059-2013-0 E-059-2013-0-US-09 METHODS OF PRODUCING ENRICHED POPULATIONS OF TUMOR REACTIVE T CELLS FROM TUMOR National Stage US 14/771,615 Abandoned US <br />National Stage 14/771,615<br />Filed on 2015-08-31<br />Status: Abandoned 147166066 E-059-2013-0 E-059-2013-0-JP-10 Methods of Producing Enriched Populations of Tumor-Reactive T Cells From Tumor DIV Japan 6788629 2018-085761 Issued Japan <br />Divisional (DIV) 2018-085761<br />Filed on 2018-04-26<br />Status: Issued 147166067 E-059-2013-0 E-059-2013-0-RU-11 Methods of Producing Enriched Populations of Tumor-Reactive T Cells From Tumor DIV Russia 2808817 2018136226 Issued Russia <br />Divisional (DIV) 2018136226<br />Filed on 2018-10-15<br />Status: Issued 147166068 E-059-2013-0 E-059-2013-0-AU-12 Methods of Producing Enriched Populations of Tumor-Reactive T Cells From Tumor DIV Australia 2018274874 2018274874 Issued Australia <br />Divisional (DIV) 2018274874<br />Filed on 2018-12-04<br />Status: Issued 147166069 E-059-2013-0 E-059-2013-0-AU-13 Methods of Producing Enriched Populations of Tumor-Reactive T Cells From Tumor DIV Australia 2020220209 Abandoned Australia <br />Divisional (DIV) 2020220209<br />Filed on 2020-08-21<br />Status: Abandoned 147166070 E-059-2013-0 E-059-2013-0-JP-14 Methods of Producing Enriched Populations of Tumor-Reactive T Cells From Tumor DIV Japan 7181917 2020-182208 Issued Japan <br />Divisional (DIV) 2020-182208<br />Filed on 2020-10-30<br />Status: Issued 147166071 E-059-2013-0 E-059-2013-0-EP-15 Methods of Producing Enriched Populations of Tumor-Reactive T Cells From Tumor DIV European Patent 20217061.9 Pending European Patent <br />Divisional (DIV) 20217061.9<br />Filed on 2020-12-23<br />Status: Pending 147166072 E-059-2013-0 E-059-2013-0-CH-16 Methods of Producing Enriched Populations of Tumor-Reactive T Cells From Tumor EP Switzerland 2961415 13722922.5 Issued Switzerland <br />European patent (EP) 13722922.5<br />Filed on 2013-04-30<br />Status: Issued 147166073 E-059-2013-0 E-059-2013-0-DE-17 Methods of Producing Enriched Populations of Tumor-Reactive T Cells From Tumor EP Germany 2961415 13722922.5 Issued Germany <br />European patent (EP) 13722922.5<br />Filed on 2013-04-30<br />Status: Issued 147166074 E-059-2013-0 E-059-2013-0-ES-18 Methods of Producing Enriched Populations of Tumor-Reactive T Cells From Tumor EP Spain 2961415 13722922.5 Issued Spain <br />European patent (EP) 13722922.5<br />Filed on 2013-04-30<br />Status: Issued 147166075 E-059-2013-0 E-059-2013-0-FR-19 Methods of Producing Enriched Populations of Tumor-Reactive T Cells From Tumor EP France 2961415 13722922.5 Issued France <br />European patent (EP) 13722922.5<br />Filed on 2013-04-30<br />Status: Issued 147166076 E-059-2013-0 E-059-2013-0-GB-20 Methods of Producing Enriched Populations of Tumor-Reactive T Cells From Tumor EP United Kingdom 2961415 13722922.5 Issued United Kingdom <br />European patent (EP) 13722922.5<br />Filed on 2013-04-30<br />Status: Issued 147166077 E-059-2013-0 E-059-2013-0-IT-21 Methods of Producing Enriched Populations of Tumor-Reactive T Cells From Tumor EP Italy 2961415 13722922.5 Issued Italy <br />European patent (EP) 13722922.5<br />Filed on 2013-04-30<br />Status: Issued 147166078 E-059-2013-0 E-059-2013-0-NL-22 Methods of Producing Enriched Populations of Tumor-Reactive T Cells From Tumor EP The Netherlands 2961415 13722922.5 Issued The Netherlands <br />European patent (EP) 13722922.5<br />Filed on 2013-04-30<br />Status: Issued 147166079 E-059-2013-0 E-059-2013-0-HK-23 Methods of Producing Enriched Populations of Tumor-Reactive T Cells From Tumor EP Hong Kong 42021042576.5 Pending Hong Kong <br />European patent (EP) 42021042576.5<br />Filed on 2021-11-17<br />Status: Pending 147166080 E-059-2013-0 E-059-2013-0-AU-24 Methods of Producing Enriched Populations of Tumor-Reactive T Cells From Tumor DIV Australia 2022235535 2022235535 Issued Australia <br />Divisional (DIV) 2022235535<br />Filed on 2022-09-20<br />Status: Issued 147166081 E-059-2013-0 E-059-2013-0-JP-25 Methods of Producing Enriched Populations of Tumor-Reactive T Cells From Tumor DIV Japan 7653962 2022-185113 Issued Japan <br />Divisional (DIV) 2022-185113<br />Filed on 2022-11-18<br />Status: Issued 147166082 E-059-2013-0 E-059-2013-0-US-02 METHODS OF PRODUCING ENRICHED POPULATIONS OF TUMOR-REACTIVE T CELLS FROM TUMOR CON US 18/093,902 Pending US <br />Continuation (CON) 18/093,902<br />Filed on 2023-01-06<br />Status: Pending 147170483 adoptive cell transfer (ACT) 147170484 T Cells 147170486 tumor infiltrating leukocytes (TIL) TAB-4013 147157294 Cancer Immunotherapy Using Virus-like Particles NCI Licensing, Oncology, Therapeutics Licensing Oncology Therapeutics Deb Chatterjee, Stanislaw Kaczmarczyk <p>One major challenge in the development of effective cancer therapies is a lack of universal, cancer specific markers in target cells. The current standard therapies rely on surgery, chemotherapy, and radiation therapy. Such procedures lead to a population of resistant cancer cells that makes further applications of chemotherapy/radiation therapy ineffective. Additionally, the systemic application of chemotherapy lacks specificity and has  off-target systemic effects that lead to adverse side effects. A considerable effort has been devoted to identifying and targeting specific extracellular cancer markers using antibody based therapies. However, diminished access to new cancer cell surface markers has limited the development of corresponding antibodies.</p> <p>Investigators at the National Cancer Institute have discovered a novel method that employs presentation of intracellular cancer antigens on the cell surface to convert the tumor into induced antigen presenting cells. The technology utilizes virus-like particle (VLP)-mediated RNA delivery of therapeutic proteins, HLA II and CD80, to directly convert cancer cells into antigen presenting cells (APC) that activate helper and cytotoxic T cells against the tumor. This immunotherapy has the potential to induce tumor specific responses with minimal toxicity to healthy cells.</p> <h2>Competitive Advantages:</h2> <ul><li>Simple procedure for targeted delivery</li> <li>Therapy is effective for any cancer antigen, known or unknown</li> <li>More robust immune response</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Cancer immunotherapy</li> <li>Cancer vaccine</li> </ul> 2016-02-16 2025-04-22 2018-03-26 2025-04-22 2014-09-08 virus-like particle, VLP False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2018-03-26 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-264-2011 147163216 Kaczmarczyk, Stanislaw NIH - NCI Leidos Kaczmarczyk, Stanislaw (Leidos) 1 147163217 Chatterjee, Deb NIH - NCI Leidos Chatterjee, Deb (Leidos) 2 147163216 Kaczmarczyk, Stanislaw NIH - NCI Leidos Kaczmarczyk, Stanislaw (Leidos) 1 147163217 Chatterjee, Deb NIH - NCI Leidos Chatterjee, Deb (Leidos) 2 147157870 Cancer Immunotherapy: Delivering HLA-11 Using VLP-replicon E-050-2014-0 Filing authorized NCI 83704821 Nguyen-Antczak, Lauren lauren.nguyen-antczak@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-4013] Cancer Immunotherapy Using Virus-like Particles&body=Please send me information about technology [TAB-4013] Cancer Immunotherapy Using Virus-like Particles.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Nguyen-Antczak, Lauren<br><a href="mailto:lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-4013] Cancer Immunotherapy Using Virus-like Particles&body=Please send me information about technology [TAB-4013] Cancer Immunotherapy Using Virus-like Particles.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">lauren.nguyen-antczak@nih.gov</a><br> 147160967 E-050-2014-0 E-050-2014-0-US-07 Cancer Immunotherapy by Delivering Class II MHC Antigens Using A VLP-Replicon National Stage US 15/104,785 Abandoned US <br />National Stage 15/104,785<br />Filed on 2016-06-15<br />Status: Abandoned 147165953 E-050-2014-0 E-050-2014-0-US-01 Cancer Immunotherapy By Delivering Class II MHC Antigens Using a VLP Replicon PRV US 61/916,394 Abandoned US <br />Provisional (PRV) 61/916,394<br />Filed on 2013-12-16<br />Status: Abandoned 147165954 E-050-2014-0 E-050-2014-0-PCT-02 Cancer Immunotherapy by Delivering Class II MHC Antigens Using a VLP-Replicon PCT Patent Cooperation Treaty PCT/US2014/070552 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2014/070552<br />Filed on 2014-12-16<br />Status: Expired 147165955 E-050-2014-0 E-050-2014-0-AU-03 Cancer Immunotherapy by Delivering Class II MHC Antigens Using a VLP-Replicon National Stage Australia 2014365777 2014365777 Issued Australia <br />National Stage 2014365777<br />Filed on 2014-12-16<br />Status: Issued 147165956 E-050-2014-0 E-050-2014-0-CA-04 Cancer Immunotherapy by Delivering Class II MHC Antigens Using a VLP-Replicon National Stage Canada 2934075 2934075 Issued Canada <br />National Stage 2934075<br />Filed on 2014-12-16<br />Status: Issued 147165957 E-050-2014-0 E-050-2014-0-EP-05 Cancer Immunotherapy by Delivering Class II MHC Antigens Using a VLP-Replicon National Stage European Patent 14824680.4 Abandoned European Patent <br />National Stage 14824680.4<br />Filed on 2014-12-16<br />Status: Abandoned 147165958 E-050-2014-0 E-050-2014-0-JP-06 Cancer Immunotherapy by Delivering Class II MHC Antigens Using a VLP-Replicon National Stage Japan 6861516 2016-558546 Issued Japan <br />National Stage 2016-558546<br />Filed on 2014-12-16<br />Status: Issued 147165959 E-050-2014-0 E-050-2014-0-BR-08 Cancer Immunotherapy by Delivering Class II MHC Antigens Using a VLP-Replicon National Stage Brazil BR112016013804-0 Abandoned Brazil <br />National Stage BR112016013804-0<br />Filed on 2014-12-16<br />Status: Abandoned 147165960 E-050-2014-0 E-050-2014-0-CN-09 Cancer Immunotherapy by Delivering Class II MHC Antigens Using a VLP-Replicon National Stage China 201480074163.2 Abandoned China <br />National Stage 201480074163.2<br />Filed on 2014-12-16<br />Status: Abandoned 147165961 E-050-2014-0 E-050-2014-0-HK-10 Cancer Immunotherapy by Delivering Class II MHC Antigens Using a VLP-Replicon CN Hong Kong 17105504.9 Abandoned Hong Kong <br />China Patent (CN) 17105504.9<br />Filed on 2017-06-02<br />Status: Abandoned 147165962 E-050-2014-0 E-050-2014-0-IN-11 CANCER IMMUNOTHERAPY BY DELIVERING CLASS II MHC ANTIGENS USING A VLP REPLICON National Stage India 367744 201617023312 Issued India <br />National Stage 201617023312<br />Filed on 2014-12-16<br />Status: Issued 147165963 E-050-2014-0 E-050-2014-0-KR-12 Cancer Immunotherapy by Delivering Class II MHC Antigens Using a VLP-Replicon National Stage South Korea 10-2467982 10-2016-7019097 Issued South Korea <br />National Stage 10-2016-7019097<br />Filed on 2016-07-14<br />Status: Issued 147165964 E-050-2014-0 E-050-2014-0-MX-13 Cancer Immunotherapy by Delivering Class II MHC Antigens Using a VLP-Replicon National Stage Mexico 387755 MX/a/2016/007726 Issued Mexico <br />National Stage MX/a/2016/007726<br />Filed on 2014-12-16<br />Status: Issued 147165965 E-050-2014-0 E-050-2014-0-SG-14 Cancer Immunotherapy by Delivering Class II MHC Antigens Using a VLP-Replicon National Stage Singapore 11201604868Y 11201604868Y Issued Singapore <br />National Stage 11201604868Y<br />Filed on 2014-12-16<br />Status: Issued 147165966 E-050-2014-0 E-050-2014-0-SG-15 Cancer Immunotherapy by Delivering Class II MHC Antigens Using a VLP-Replicon DIV Singapore 10201811190S Pending Singapore <br />Divisional (DIV) 10201811190S<br />Filed on 2018-12-14<br />Status: Pending 147165967 E-050-2014-0 E-050-2014-0-EP-16 CANCER IMMUNOTHERAPY BY DELIVERING CLASS II MHC ANTIGENS AND A COSTIMULATORY SIGNAL PROTEIN USING A VLP-REPLICON DIV European Patent 3659620 20150087.3 Issued European Patent <br />Divisional (DIV) 20150087.3<br />Filed on 2020-01-02<br />Status: Issued 147165968 E-050-2014-0 E-050-2014-0-JP-17 Cancer Immunotherapy by Delivering Class II MHC Antigens Using a VLP-Replicon DIV Japan 2020-001954 Abandoned Japan <br />Divisional (DIV) 2020-001954<br />Filed on 2020-01-09<br />Status: Abandoned 147165969 E-050-2014-0 E-050-2014-0-US-18 CANCER IMMUNOTHERAPY BY DELIVERING CLASS II MHC ANTIGENS USING A VLP-REPLICON DIV US 11,718,861 17/120,497 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11718861 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11718861">11,718,861</a><br />Filed on 2020-12-14<br />Status: Issued 147165970 E-050-2014-0 E-050-2014-0-IN-19 Cancer Immunotherapy by Delivering Class II MHC Antigens Using a VLP-Replicon DIV India 202118011347 Pending India <br />Divisional (DIV) 202118011347<br />Filed on 2021-03-17<br />Status: Pending 147165971 E-050-2014-0 E-050-2014-0-EP-20 Cancer Immunotherapy by Delivering Class II MHC Antigens Using a VLP-Replicon DIV European Patent 21190529.4 Pending European Patent <br />Divisional (DIV) 21190529.4<br />Filed on 2021-08-10<br />Status: Pending 147165972 E-050-2014-0 E-050-2014-0-CN-21 Cancer Immunotherapy by Delivering Class II MHC Antigens Using a VLP-Replicon DIV China 202110829496.3 Abandoned China <br />Divisional (DIV) 202110829496.3<br />Filed on 2021-07-22<br />Status: Abandoned 147165973 E-050-2014-0 E-050-2014-0-BE-22 CANCER IMMUNOTHERAPY BY DELIVERING CLASS II MHC ANTIGENS AND A COSTIMULATORY SIGNAL PROTEIN USING A VLP-REPLICON EP Belgium 3659620 20150087.3 Issued Belgium <br />European patent (EP) 20150087.3<br />Filed on 2014-12-16<br />Status: Issued 147165974 E-050-2014-0 E-050-2014-0-CH-23 CANCER IMMUNOTHERAPY BY DELIVERING CLASS II MHC ANTIGENS AND A COSTIMULATORY SIGNAL PROTEIN USING A VLP-REPLICON EP Switzerland 3659620 20150087.3 Issued Switzerland <br />European patent (EP) 20150087.3<br />Filed on 2014-12-16<br />Status: Issued 147165975 E-050-2014-0 E-050-2014-0-DE-24 CANCER IMMUNOTHERAPY BY DELIVERING CLASS II MHC ANTIGENS AND A COSTIMULATORY SIGNAL PROTEIN USING A VLP-REPLICON EP Germany 3659620 20150087.3 Issued Germany <br />European patent (EP) 20150087.3<br />Filed on 2014-12-16<br />Status: Issued 147165976 E-050-2014-0 E-050-2014-0-ES-25 CANCER IMMUNOTHERAPY BY DELIVERING CLASS II MHC ANTIGENS AND A COSTIMULATORY SIGNAL PROTEIN USING A VLP-REPLICON EP Spain 3659620 20150087.3 Issued Spain <br />European patent (EP) 20150087.3<br />Filed on 2014-12-16<br />Status: Issued 147165977 E-050-2014-0 E-050-2014-0-FR-26 CANCER IMMUNOTHERAPY BY DELIVERING CLASS II MHC ANTIGENS AND A COSTIMULATORY SIGNAL PROTEIN USING A VLP-REPLICON EP France 3659620 20150087.3 Issued France <br />European patent (EP) 20150087.3<br />Filed on 2014-12-16<br />Status: Issued 147165978 E-050-2014-0 E-050-2014-0-GB-27 CANCER IMMUNOTHERAPY BY DELIVERING CLASS II MHC ANTIGENS AND A COSTIMULATORY SIGNAL PROTEIN USING A VLP-REPLICON EP United Kingdom 3659620 20150087.3 Issued United Kingdom <br />European patent (EP) 20150087.3<br />Filed on 2014-12-16<br />Status: Issued 147165979 E-050-2014-0 E-050-2014-0-IE-28 CANCER IMMUNOTHERAPY BY DELIVERING CLASS II MHC ANTIGENS AND A COSTIMULATORY SIGNAL PROTEIN USING A VLP-REPLICON EP Ireland 3659620 20150087.3 Issued Ireland <br />European patent (EP) 20150087.3<br />Filed on 2014-12-16<br />Status: Issued 147165980 E-050-2014-0 E-050-2014-0-IT-29 CANCER IMMUNOTHERAPY BY DELIVERING CLASS II MHC ANTIGENS AND A COSTIMULATORY SIGNAL PROTEIN USING A VLP-REPLICON EP Italy 3659620 20150087.3 Issued Italy <br />European patent (EP) 20150087.3<br />Filed on 2014-12-16<br />Status: Issued 147165981 E-050-2014-0 E-050-2014-0-NL-30 CANCER IMMUNOTHERAPY BY DELIVERING CLASS II MHC ANTIGENS AND A COSTIMULATORY SIGNAL PROTEIN USING A VLP-REPLICON EP The Netherlands 3659620 20150087.3 Issued The Netherlands <br />European patent (EP) 20150087.3<br />Filed on 2014-12-16<br />Status: Issued 147165982 E-050-2014-0 E-050-2014-0-US-02 CANCER IMMUNOTHERAPY BY DELIVERING CLASS II MHC ANTIGENS USING A VLP-REPLICON DIV US 12,049,639 18/174,013 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12049639 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12049639">12,049,639</a><br />Filed on 2023-02-24<br />Status: Issued 147170312 virus-like particle 147170313 VLP TAB-4015 147157296 Monoclonal Antibody Fragments for Targeting Therapeutics to Growth Plate Cartilage NICHD Collaboration, Licensing, Therapeutics Collaboration Licensing Therapeutics Jeffrey Baron, Sao Fong (Crystal) Cheung, Dimiter Dimitrov, Chun Lui, Zhongyu Zhu <p>A child's growth is dependent on the proper functioning of the growth plate, a specialized cartilage structure located at the ends of long bones and within the vertebrae. The primary function of the growth plate is to generate new cartilage, which is then converted into bone tissue and results in the lengthening of bones. Failure of the growth plate to function properly can result in short stature or sometimes a skeletal dysplasia, such as achondroplasia, in which the bones are not just short but also malformed. Current treatments for severe short stature and skeletal growth disorders are limited. Recombinant human growth hormone (GH) is typically used, but the results are often less than optimal and growth hormone has potential adverse effects.</p> <p>Researchers at the <a href="https://science.nichd.nih.gov/confluence/display/sgd/Home" rel="nofollow">Eunice Kennedy Shriver National Institute on Child Health and Human Development (NICHD) Section on Growth and Development</a>, collaborating with the <a href="https://ccr.cancer.gov/Experimental-Immunology-Branch" rel="nofollow">NCI Laboratory of Experimental Immunology</a>, created human monoclonal antibody fragments that bind to matrilin-3, a protein specifically expressed in cartilage tissue. When injected intravenously in mice, these antibody fragments honed to cartilage and were not detectable in other tissues. Coupling these cartilage-binding antibodies to growth-stimulating endocrine factors, such as growth hormone and IGF-I, and paracrine factors, such as CNP, could allow therapy targeted specifically to growth plate, and also articular cartilage, thereby opening up broad new pharmacological approaches to treat skeletal dysplasias and short stature. The same approach could also be used in adults to treat articular cartilage diseases like osteoarthritis. The research is currently in preclinical development, with <em>in vitro</em> data and<em> in vivo</em> mouse model data demonstrating that these antibody fragments target cartilage <em>in vivo</em>.</p> <p>The researchers are interested in licensing this technology or for a collaboration to explore applications of this new approach. For example, a collaborator could produce fusion proteins combining the antibody fragments with various chondrogenic proteins that enhance growth. The collaborator might produce and purify the fusion proteins, which could then be tested for therapeutic effects in mice by the NICHD investigators.</p> <h2>Competitive Advantages:</h2> <ul><li>Avoidance of the risks associated with systemic treatment using growth hormone, such as increased intracranial pressure, slipped capital femoral epiphysis, insulin resistance, and possibly type II diabetes</li> </ul> <h2>Commercial Applications:</h2> <ul><li>A new treatment option for cartilage disorders, such as (1) skeletal dysplasias, (2) short stature, and (3) articular diseases like osteoarthritis</li> </ul> 2016-02-16 2025-04-22 2020-08-07 2025-04-22 2019-08-01 Anti-mantrilin-3 Antibody, ARTHRITIS, Baron, Cartilage, Dimitrov, Eunice Kennedy Shriver National Institute on Child Health an, Growth plate, Human Growth Hormone, monoclonal, NICHD, OSTEOARTHRITIS, Short Stature, Skeletal Dysplasia False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-08-07 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147162059 Lui JC, et. al. Cartilage-Targeted IGF-1 Treatment to Promote Longitudinal Bone Growth. https://www.ncbi.nlm.nih.gov/pubmed/30765323 <a href="https://www.ncbi.nlm.nih.gov/pubmed/30765323">Lui JC, et. al. Cartilage-Targeted IGF-1 Treatment to Promote Longitudinal Bone Growth.</a> 147162137 C.S. Cheung et al., Human monoclonal antibody fragments targeting matrilin-3 in growth plate cartilage. http://www.ncbi.nlm.nih.gov/pubmed/25690340 <a href="http://www.ncbi.nlm.nih.gov/pubmed/25690340">C.S. Cheung et al., Human monoclonal antibody fragments targeting matrilin-3 in growth plate cartilage.</a> 147163223 Baron, Jeffrey NIH - NICHD NICHD Baron, Jeffrey (NICHD) 1 147163225 Cheung, Sao Fong (Crystal) NIH - NICHD Cheung, Sao Fong (Crystal) 2 147163226 Lui, Chun NIH - NICHD NICHD Lui, Chun (NICHD) 3 147163222 Dimitrov, Dimiter NIH - NCI NCI Dimitrov, Dimiter (NCI) 4 147163224 Zhu, Zhongyu NIH - NCI NCI Zhu, Zhongyu (NCI) 5 147163223 Baron, Jeffrey NIH - NICHD NICHD Baron, Jeffrey (NICHD) 1 147163225 Cheung, Sao Fong (Crystal) NIH - NICHD Cheung, Sao Fong (Crystal) 2 147163226 Lui, Chun NIH - NICHD NICHD Lui, Chun (NICHD) 3 147163222 Dimitrov, Dimiter NIH - NCI NCI Dimitrov, Dimiter (NCI) 4 147163224 Zhu, Zhongyu NIH - NCI NCI Zhu, Zhongyu (NCI) 5 147157766 Human Monoclonal Antibody Fragments For Targeting Therapeutics To Growth Plate Cartilage E-003-2014-0 Filing authorized NCI, NICHD 83682895 Girards, Richard richard.girards@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB richard.girards@nih.gov?subject=Web Inquiry on [TAB-4015] Monoclonal Antibody Fragments for Targeting Therapeutics to Growth Plate Cartilage&body=Please send me information about technology [TAB-4015] Monoclonal Antibody Fragments for Targeting Therapeutics to Growth Plate Cartilage.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Girards, Richard<br><a href="mailto:richard.girards@nih.gov?subject=Web Inquiry on [TAB-4015] Monoclonal Antibody Fragments for Targeting Therapeutics to Growth Plate Cartilage&body=Please send me information about technology [TAB-4015] Monoclonal Antibody Fragments for Targeting Therapeutics to Growth Plate Cartilage.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">richard.girards@nih.gov</a><br> 147160881 E-003-2014-0 E-003-2014-0-US-01 Cartilage Targeting Agents And Their Use PRV US 61/927,904 Abandoned US <br />Provisional (PRV) 61/927,904<br />Filed on 2014-01-15<br />Status: Abandoned 147165992 E-003-2014-0 E-003-2014-0-PCT-02 Cartilage Targeting Agents And Their Use PCT Patent Cooperation Treaty PCT/US2015/011433 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2015/011433<br />Filed on 2015-01-14<br />Status: Expired 147165993 E-003-2014-0 E-003-2014-0-AU-03 Cartilage Targeting Agents And Their Use National Stage Australia 2015206515 2015206515 Issued Australia <br />National Stage 2015206515<br />Filed on 2015-01-14<br />Status: Issued 147165994 E-003-2014-0 E-003-2014-0-CA-04 Cartilage Targeting Agents And Their Use National Stage Canada 2931005 2931005 Issued Canada <br />National Stage 2931005<br />Filed on 2015-01-14<br />Status: Issued 147165995 E-003-2014-0 E-003-2014-0-EP-05 Cartilage Targeting Agents And Their Use National Stage European Patent 3094350 15704405.8 Issued European Patent <br />National Stage 15704405.8<br />Filed on 2015-01-14<br />Status: Issued 147165996 E-003-2014-0 E-003-2014-0-US-06 AGENTS THAT SPECIFICALLY BIND MATRILIN-3 AND THEIR USE National Stage US 10,323,083 15/111,773 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10323083 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10323083">10,323,083</a><br />Filed on 2016-07-14<br />Status: Issued 147165997 E-003-2014-0 E-003-2014-0-US-07 CARTILAGE TARGETING AGENTS AND THEIR USE DIV US 10,954,291 16/391,101 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10954291 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10954291">10,954,291</a><br />Filed on 2019-04-22<br />Status: Issued 147165998 E-003-2014-0 E-003-2014-0-DE-08 Cartilage Targeting Agents And Their Use EP Germany 3094350 15704405.8 Issued Germany <br />European patent (EP) 15704405.8<br />Filed on 2015-01-14<br />Status: Issued 147165999 E-003-2014-0 E-003-2014-0-FR-09 Cartilage Targeting Agents And Their Use EP France 3094350 15704405.8 Issued France <br />European patent (EP) 15704405.8<br />Filed on 2015-01-14<br />Status: Issued 147166000 E-003-2014-0 E-003-2014-0-GB-10 Cartilage Targeting Agents And Their Use EP United Kingdom 3094350 15704405.8 Issued United Kingdom <br />European patent (EP) 15704405.8<br />Filed on 2015-01-14<br />Status: Issued 147166001 E-003-2014-0 E-003-2014-0-EP-11 Cartilage Targeting Agents And Their Use DIV European Patent 3659624 19219282.1 Issued European Patent <br />Divisional (DIV) 19219282.1<br />Filed on 2015-01-14<br />Status: Issued 147166002 E-003-2014-0 E-003-2014-0-US-12 MONOCLONAL ANTIBODIES THAT SPECIFICALLY BIND TO MATRILIN 3 AND THEIR USE CON US 11,680,093 17/177,644 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11680093 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11680093">11,680,093</a><br />Filed on 2021-02-17<br />Status: Issued 147166003 E-003-2014-0 E-003-2014-0-DE-13 Cartilage Targeting Agents And Their Use EP Germany 3659624 19219282.1 Issued Germany <br />European patent (EP) 19219282.1<br />Filed on 2015-01-14<br />Status: Issued 147166004 E-003-2014-0 E-003-2014-0-FR-14 Cartilage Targeting Agents And Their Use EP France 3659624 19219282.1 Issued France <br />European patent (EP) 19219282.1<br />Filed on 2015-01-14<br />Status: Issued 147166005 E-003-2014-0 E-003-2014-0-GB-15 Cartilage Targeting Agents And Their Use EP United Kingdom 3659624 19219282.1 Issued United Kingdom <br />European patent (EP) 19219282.1<br />Filed on 2015-01-14<br />Status: Issued 147166006 E-003-2014-0 E-003-2014-0-US-02 MONOCLONAL ANTIBODIES THAT SPECIFICALLY BIND TO MATRILIN 3 AND THEIR USE CON US 18/317,869 Abandoned US <br />Continuation (CON) 18/317,869<br />Filed on 2023-05-15<br />Status: Abandoned 147169223 Anti-mantrilin-3 Antibody 147169224 ARTHRITIS 147169226 Baron 147169227 Cartilage 147169229 Dimitrov 147169231 Eunice Kennedy Shriver National Institute on Child Health an 147169233 Growth plate 147169235 Human Growth Hormone 147169236 monoclonal 147169238 NICHD 147169239 OSTEOARTHRITIS 147169241 Short Stature 147169243 Skeletal Dysplasia TAB-4006 147157287 MUC-1 Tumor Antigen Agonist Epitopes for Enhancing T-cell Responses to Human Tumors NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Jeffrey Schlom, Kwong-Yok Tsang <p>The MUC-1 tumor associated antigen has been shown to be overexpressed and/or underglycosylated in a wide range of human cancers.  The C-terminus region of MUC-1 (MUC-1C) has been shown to be an oncogene and has been associated with a more aggressive phenotype in several different cancers.</p> <p> Scientists at NIH have identified 7 new agonist epitopes of the MUC-1 tumor associated antigen.  Compared to their native epitope counterparts, peptides reflecting these agonist epitopes have been shown to enhance the generation of human tumor cells, which in turn have a greater ability to kill human tumor cells endogenously expressing the native MUC-1 epitope.  The agonist epitopes span both the VNTR region of MUC-1 and the C-terminus region.  The epitopes encompass 2 major MHC alleles reflecting the majority of the population.</p> <p> Along with the method of use, the technology encompasses the use of these agonist epitopes in peptide- and protein-based vaccines, with dendritic cells or other antigen presenting cells, or encoding sequences in DNA, viral, bacterial, yeast, or other types of vectors, or to stimulate T-cells in vitro for adoptive immunotherapy protocols.</p> <h2>Competitive Advantages:</h2> <ul><li>The agonist epitopes have been shown to be much more potent than their natural counterparts in activating human T-cells to MUC-1.</li> <li>Compared to T-cells activated with the corresponding native epitopes, the T-cells activated by the agonist epitopes lyse tumor cells to a greater extent.</li> <li>The technology can be used in a wide range of cancer vaccine platforms and in adoptive immunotherapy protocols.</li> <li>The technology can be combined with existing vaccine platforms including those currently showing patient benefit, as well as with other therapeutic modalities.</li> </ul> <h2>Commercial Applications:</h2> <ul><li>As a therapeutic vaccine to enhance patient's immune responses to a range of human cancers</li> <li>As a preventive vaccine for patients with preneoplastic conditions or a high risk of developing cancer</li> <li>As a preventive vaccine for cancers</li> <li>For in vitro stimulation of lymphocytes for adoptive transfer protocols for cancer</li> </ul> 2016-02-16 2025-04-22 2018-05-30 2025-04-22 2012-03-19 AGONIST, ANTIGEN, Epitope, MUC-1 False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2018-05-30 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147163196 Schlom, Jeffrey NIH - NCI NCI Schlom, Jeffrey (NCI) 1 147163197 Tsang, Kwong-Yok NIH - NCI NCI Tsang, Kwong-Yok (NCI) 2 147163196 Schlom, Jeffrey NIH - NCI NCI Schlom, Jeffrey (NCI) 1 147163197 Tsang, Kwong-Yok NIH - NCI NCI Tsang, Kwong-Yok (NCI) 2 147157758 The Identification Of Enhancer Agonist Epitopes In The C Terminus And N Terminus Of The MUC-1 Tumor Antigen E-001-2012-0 Filing authorized NCI 83687903 Pollack, Michael michael.pollack@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC michael.pollack@nih.gov?subject=Web Inquiry on [TAB-4006] MUC-1 Tumor Antigen Agonist Epitopes for Enhancing T-cell Responses to Human Tumors&body=Please send me information about technology [TAB-4006] MUC-1 Tumor Antigen Agonist Epitopes for Enhancing T-cell Responses to Human Tumors.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollack, Michael<br><a href="mailto:michael.pollack@nih.gov?subject=Web Inquiry on [TAB-4006] MUC-1 Tumor Antigen Agonist Epitopes for Enhancing T-cell Responses to Human Tumors&body=Please send me information about technology [TAB-4006] MUC-1 Tumor Antigen Agonist Epitopes for Enhancing T-cell Responses to Human Tumors.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">michael.pollack@nih.gov</a><br> 147160873 E-001-2012-0 E-001-2012-0-PCT-02 Native and Agonist CTL Epitopes of The MUC1 Tumor Antigen PCT Patent Cooperation Treaty PCT/US2013/020058 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2013/020058<br />Filed on 2013-01-03<br />Status: Expired 147165854 E-001-2012-0 E-001-2012-0-US-01 NATIVE AND AGONIST CTL EPITOPES OF THE MUC1 TUMOR ANTIGEN PRV US 61/582,723 Abandoned US <br />Provisional (PRV) 61/582,723<br />Filed on 2012-01-03<br />Status: Abandoned 147165855 E-001-2012-0 E-001-2012-0-AU-03 Native and Agonist CTL Epitopes of The MUC1 Tumor Antigen National Stage Australia 2013206896 2013206896 Issued Australia <br />National Stage 2013206896<br />Filed on 2013-01-03<br />Status: Issued 147165856 E-001-2012-0 E-001-2012-0-CA-04 Native and Agonist CTL Epitopes of The MUC1 Tumor Antigen National Stage Canada 2860599 2860599 Issued Canada <br />National Stage 2860599<br />Filed on 2013-01-03<br />Status: Issued 147165857 E-001-2012-0 E-001-2012-0-EP-05 Native and Agonist CTL Epitopes of The MUC1 Tumor Antigen National Stage European Patent 2800762 13700352.1 Issued European Patent <br />National Stage 13700352.1<br />Filed on 2013-01-03<br />Status: Issued 147165858 E-001-2012-0 E-001-2012-0-US-06 NATIVE AND AGONIST CTL EPITOPES OF THE MUC1 TUMOR ANTIGEN National Stage US 10,138,271 14/370,595 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10138271 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10138271">10,138,271</a><br />Filed on 2014-07-03<br />Status: Issued 147165859 E-001-2012-0 E-001-2012-0-JP-07 Native and Agonist CTL Epitopes of The MUC1 Tumor Antigen National Stage Japan 6523685 2014-551304 Issued Japan <br />National Stage 2014-551304<br />Filed on 2013-01-03<br />Status: Issued 147165860 E-001-2012-0 E-001-2012-0-BE-08 Native and Agonist CTL Epitopes of The MUC1 Tumor Antigen EP Belgium 2800762 13700352.1 Issued Belgium <br />European patent (EP) 13700352.1<br />Filed on 2013-01-03<br />Status: Issued 147165861 E-001-2012-0 E-001-2012-0-CH-09 Native and Agonist CTL Epitopes of The MUC1 Tumor Antigen EP Switzerland 2800762 13700352.1 Issued Switzerland <br />European patent (EP) 13700352.1<br />Filed on 2013-01-03<br />Status: Issued 147165862 E-001-2012-0 E-001-2012-0-DE-10 Native and Agonist CTL Epitopes of The MUC1 Tumor Antigen EP Germany 2800762 13700352.1 Issued Germany <br />European patent (EP) 13700352.1<br />Filed on 2013-01-03<br />Status: Issued 147165863 E-001-2012-0 E-001-2012-0-DK-11 Native and Agonist CTL Epitopes of The MUC1 Tumor Antigen EP Denmark 2800762 13700352.1 Issued Denmark <br />European patent (EP) 13700352.1<br />Filed on 2013-01-03<br />Status: Issued 147165864 E-001-2012-0 E-001-2012-0-ES-12 Native and Agonist CTL Epitopes of The MUC1 Tumor Antigen EP Spain 2800762 13700352.1 Issued Spain <br />European patent (EP) 13700352.1<br />Filed on 2013-01-03<br />Status: Issued 147165865 E-001-2012-0 E-001-2012-0-FR-13 Native and Agonist CTL Epitopes of The MUC1 Tumor Antigen EP France 2800762 13700352.1 Issued France <br />European patent (EP) 13700352.1<br />Filed on 2013-01-03<br />Status: Issued 147165866 E-001-2012-0 E-001-2012-0-GB-14 Native and Agonist CTL Epitopes of The MUC1 Tumor Antigen EP United Kingdom 2800762 13700352.1 Issued United Kingdom <br />European patent (EP) 13700352.1<br />Filed on 2013-01-03<br />Status: Issued 147165867 E-001-2012-0 E-001-2012-0-IE-15 Native and Agonist CTL Epitopes of The MUC1 Tumor Antigen EP Ireland 2800762 13700352.1 Issued Ireland <br />European patent (EP) 13700352.1<br />Filed on 2013-01-03<br />Status: Issued 147165868 E-001-2012-0 E-001-2012-0-NL-16 Native and Agonist CTL Epitopes of The MUC1 Tumor Antigen EP The Netherlands 2800762 13700352.1 Issued The Netherlands <br />European patent (EP) 13700352.1<br />Filed on 2013-01-03<br />Status: Issued 147165869 E-001-2012-0 E-001-2012-0-SE-17 Native and Agonist CTL Epitopes of The MUC1 Tumor Antigen EP Sweden 2800762 13700352.1 Issued Sweden <br />European patent (EP) 13700352.1<br />Filed on 2013-01-03<br />Status: Issued 147169176 AGONIST 147169177 ANTIGEN 147169178 Epitope 147169179 MUC-1 TAB-4010 147157291 Novel Cancer Immunotherapy: A T Cell Receptor That Specifically Recognizes Common KRAS Mutations NCI Licensing, Oncology, Therapeutics Licensing Oncology Therapeutics Qiong Wang, James Yang, Zhiya Yu <p>Several malignancies associated with a poor prognosis such as lung, pancreatic and colorectal cancers frequently harbor constitutively active KRAS mutants, which play a pivotal role in oncogenesis.  Currently, there are no potentially curative treatments against most mutant KRAS harboring cancers once they become metastatic and unresectable.  Despite intensive efforts to develop potent mutant KRAS inhibitors, none have shown a significant improvement to patients.</p> <p>Researchers at NCI’s <a href="https://ccr.cancer.gov/Surgery-Branch" rel="nofollow">Surgery Branch</a><a href="http://ccr.cancer.gov/james-c-yang" rel="nofollow"> </a>have used their expertise in T-cell based therapies to develop a T cell receptor (TCR) that specifically recognizes G12D KRAS, a common driver of oncogenesis.  This invention offers an alternative therapy to direct inhibition of mutant KRAS that has been demonstrative to be an effective treatment for advanced melanoma, lymphoma and sarcomas.  The inventors have demonstrated that lymphocytes expressing the engineered TCR selectively target pancreatic G12D KRAS cells.</p> <p>The NCI seeks co-development or licensing partners to extend the research toward <em>in vivo</em> efficacy testing and clinical trials.</p> <h2>Competitive Advantages:</h2> <ul><li>Proven therapeutic strategy for targeting cancers that harbor mutant target proteins</li> <li>Alternative strategy to previously unsuccessful small molecule KRAS inhibitors</li> </ul> <h2>Commercial Applications:</h2> <ul><li>T-cell therapy to treat a variety of cancers that harbor KRAS mutations, in particular, G12D mutation</li> <li>Therapy for cancers that harbor additional constitutively active KRAS mutations</li> </ul><p> </p> 2016-02-16 2025-04-22 2017-12-07 2025-04-22 2016-08-29 Colorectal, Immunotherapy, KRAS, LUNG, oncogenesis, PANCREAS, PROSTATE, T cell, TCR False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2017-12-07 52406768 Discovery 52406768 NCI 37470483 Website Abstract E-106-2006 E-226-2014 147163208 Wang, Qiong NIH - NCI NCI Wang, Qiong (NCI) 1 147163207 Yang, James NIH - NCI NCI Yang, James (NCI) 2 147163209 Yu, Zhiya NIH - NCI NCI Yu, Zhiya (NCI) 3 147163208 Wang, Qiong NIH - NCI NCI Wang, Qiong (NCI) 1 147163207 Yang, James NIH - NCI NCI Yang, James (NCI) 2 147163209 Yu, Zhiya NIH - NCI NCI Yu, Zhiya (NCI) 3 147157822 T-cell Epitopes From Mutated KRAS Presented By HLA-A 11 And A T-cell Receptor That Recognizes KRAS G12D Mutated Cells And Human Cancers E-028-2015-0 Filing authorized NCI 147162496 T-cell Epitopes From Mutated KRAS Presented By HLA-A 11 And A T-cell Receptor That Recognizes KRAS G12D Mutated Cells And Human Cancers E-028-2015-1 Filing authorized NCI 83709866 Burke, Andrew burkear@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC burkear@nih.gov?subject=Web Inquiry on [TAB-4010] Novel Cancer Immunotherapy: A T Cell Receptor That Specifically Recognizes Common KRAS Mutations&body=Please send me information about technology [TAB-4010] Novel Cancer Immunotherapy: A T Cell Receptor That Specifically Recognizes Common KRAS Mutations.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Burke, Andrew<br><a href="mailto:burkear@nih.gov?subject=Web Inquiry on [TAB-4010] Novel Cancer Immunotherapy: A T Cell Receptor That Specifically Recognizes Common KRAS Mutations&body=Please send me information about technology [TAB-4010] Novel Cancer Immunotherapy: A T Cell Receptor That Specifically Recognizes Common KRAS Mutations.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">burkear@nih.gov</a><br> 147160927 E-028-2015-0 E-028-2015-0-US-01 Anti-Mutated KRAS T Cell Receptors PRV US 62/084,654 Abandoned US <br />Provisional (PRV) 62/084,654<br />Filed on 2014-11-26<br />Status: Abandoned 147165890 E-028-2015-1 E-028-2015-1-PCT-01 Anti-Mutated Kras T Cell Receptors PCT COMB Patent Cooperation Treaty PCT/US2015/062269 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2015/062269<br />Filed on 2015-11-24<br />Status: Expired 147165891 E-028-2015-1 E-028-2015-1-AU-02 Anti-Mutated Kras T Cell Receptors National Stage Australia 2015353720 2015353720 Issued Australia <br />National Stage 2015353720<br />Filed on 2015-11-24<br />Status: Issued 147165892 E-028-2015-1 E-028-2015-1-CA-03 Anti-Mutated Kras T Cell Receptors National Stage Canada 2968399 2968399 Issued Canada <br />National Stage 2968399<br />Filed on 2015-11-24<br />Status: Issued 147165893 E-028-2015-1 E-028-2015-1-CN-04 Anti-Mutated Kras T Cell Receptors National Stage China ZL201580070673.7 201580070673.7 Issued China <br />National Stage 201580070673.7<br />Filed on 2015-11-24<br />Status: Issued 147165894 E-028-2015-1 E-028-2015-1-EP-05 Anti-Mutated Kras T Cell Receptors National Stage European Patent 3223850 15807756.0 Issued European Patent <br />National Stage 15807756.0<br />Filed on 2015-11-24<br />Status: Issued 147165895 E-028-2015-1 E-028-2015-1-IL-06 Anti-Mutated Kras T Cell Receptors National Stage Israel 252258 252258 Issued Israel <br />National Stage 252258<br />Filed on 2017-05-14<br />Status: Issued 147165896 E-028-2015-1 E-028-2015-1-JP-07 Anti-Mutated Kras T Cell Receptors National Stage Japan 6863893 2017-527874 Issued Japan <br />National Stage 2017-527874<br />Filed on 2015-11-24<br />Status: Issued 147165897 E-028-2015-1 E-028-2015-1-KR-08 Anti-Mutated Kras T Cell Receptors National Stage South Korea 10-2622784 10-2017-7017289 Issued South Korea <br />National Stage 10-2017-7017289<br />Filed on 2017-06-23<br />Status: Issued 147165898 E-028-2015-1 E-028-2015-1-MX-09 Anti-Mutated Kras T Cell Receptors National Stage Mexico 384919 MX/a/2017/006865 Issued Mexico <br />National Stage MX/a/2017/006865<br />Filed on 2015-11-24<br />Status: Issued 147165899 E-028-2015-1 E-028-2015-1-NZ-10 Anti-Mutated Kras T Cell Receptors National Stage New Zealand 732045 732045 Issued New Zealand <br />National Stage 732045<br />Filed on 2017-05-18<br />Status: Issued 147165900 E-028-2015-1 E-028-2015-1-SA-11 Anti-Mutated Kras T Cell Receptors National Stage Saudi Arabia 7697 517381608 Issued Saudi Arabia <br />National Stage 517381608<br />Filed on 2015-11-24<br />Status: Issued 147165901 E-028-2015-1 E-028-2015-1-SG-12 Anti-Mutated Kras T Cell Receptors National Stage Singapore 11201704155U 11201704155U Issued Singapore <br />National Stage 11201704155U<br />Filed on 2015-11-24<br />Status: Issued 147165902 E-028-2015-1 E-028-2015-1-US-13 ANTI-MUTATED KRAS T CELL RECEPTORS National Stage US 11,207,394 15/528,813 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11207394 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11207394">11,207,394</a><br />Filed on 2017-05-23<br />Status: Issued 147165903 E-028-2015-1 E-028-2015-1-HK-14 Anti-Mutated Kras T Cell Receptors EP Hong Kong HK1243642B 18103250.9 Issued Hong Kong <br />European patent (EP) 18103250.9<br />Filed on 2018-03-07<br />Status: Issued 147165904 E-028-2015-1 E-028-2015-1-EP-15 Anti-Mutated Kras T Cell Receptors DIV European Patent 3666288 20150279.6 Issued European Patent <br />Divisional (DIV) 20150279.6<br />Filed on 2020-01-03<br />Status: Issued 147165905 E-028-2015-1 E-028-2015-1-SG-16 Anti-Mutated Kras T Cell Receptors DIV Singapore 10201913978R Pending Singapore <br />Divisional (DIV) 10201913978R<br />Filed on 2019-12-31<br />Status: Pending 147165906 E-028-2015-1 E-028-2015-1-AT-17 Anti-Mutated Kras T Cell Receptors EP Austria 3223850 15807756.0 Issued Austria <br />European patent (EP) 15807756.0<br />Filed on 2015-11-24<br />Status: Issued 147165907 E-028-2015-1 E-028-2015-1-BE-18 Anti-Mutated Kras T Cell Receptors EP Belgium 3223850 15807756.0 Issued Belgium <br />European patent (EP) 15807756.0<br />Filed on 2015-11-24<br />Status: Issued 147165908 E-028-2015-1 E-028-2015-1-CH-19 Anti-Mutated Kras T Cell Receptors EP Switzerland 3223850 15807756.0 Issued Switzerland <br />European patent (EP) 15807756.0<br />Filed on 2015-11-24<br />Status: Issued 147165909 E-028-2015-1 E-028-2015-1-CZ-20 Anti-Mutated Kras T Cell Receptors EP Czech Republic 3223850 15807756.0 Issued Czech Republic <br />European patent (EP) 15807756.0<br />Filed on 2015-11-24<br />Status: Issued 147165910 E-028-2015-1 E-028-2015-1-DE-21 Anti-Mutated Kras T Cell Receptors EP Germany 3223850 15807756.0 Issued Germany <br />European patent (EP) 15807756.0<br />Filed on 2015-11-24<br />Status: Issued 147165911 E-028-2015-1 E-028-2015-1-ES-22 Anti-Mutated Kras T Cell Receptors EP Spain 3223850 15807756.0 Issued Spain <br />European patent (EP) 15807756.0<br />Filed on 2015-11-24<br />Status: Issued 147165912 E-028-2015-1 E-028-2015-1-FR-23 Anti-Mutated Kras T Cell Receptors EP France 3223850 15807756.0 Issued France <br />European patent (EP) 15807756.0<br />Filed on 2015-11-24<br />Status: Issued 147165913 E-028-2015-1 E-028-2015-1-GB-24 Anti-Mutated Kras T Cell Receptors EP United Kingdom 3223850 15807756.0 Issued United Kingdom <br />European patent (EP) 15807756.0<br />Filed on 2015-11-24<br />Status: Issued 147165914 E-028-2015-1 E-028-2015-1-GR-25 Anti-Mutated Kras T Cell Receptors EP Greece 3223850 15807756.0 Issued Greece <br />European patent (EP) 15807756.0<br />Filed on 2015-11-24<br />Status: Issued 147165915 E-028-2015-1 E-028-2015-1-IE-26 Anti-Mutated Kras T Cell Receptors EP Ireland 3223850 15807756.0 Issued Ireland <br />European patent (EP) 15807756.0<br />Filed on 2015-11-24<br />Status: Issued 147165916 E-028-2015-1 E-028-2015-1-IT-27 Anti-Mutated Kras T Cell Receptors EP Italy 3223850 15807756.0 Issued Italy <br />European patent (EP) 15807756.0<br />Filed on 2015-11-24<br />Status: Issued 147165917 E-028-2015-1 E-028-2015-1-NL-28 Anti-Mutated Kras T Cell Receptors EP The Netherlands 3223850 15807756.0 Issued The Netherlands <br />European patent (EP) 15807756.0<br />Filed on 2015-11-24<br />Status: Issued 147165918 E-028-2015-1 E-028-2015-1-NO-29 Anti-Mutated Kras T Cell Receptors EP Norway 3223850 15807756.0 Issued Norway <br />European patent (EP) 15807756.0<br />Filed on 2015-11-24<br />Status: Issued 147165919 E-028-2015-1 E-028-2015-1-PL-30 Anti-Mutated Kras T Cell Receptors EP Poland 3223850 15807756.0 Issued Poland <br />European patent (EP) 15807756.0<br />Filed on 2015-11-24<br />Status: Issued 147165920 E-028-2015-1 E-028-2015-1-PT-31 Anti-Mutated Kras T Cell Receptors EP Portugal 3223850 15807756.0 Issued Portugal <br />European patent (EP) 15807756.0<br />Filed on 2015-11-24<br />Status: Issued 147165921 E-028-2015-1 E-028-2015-1-SE-32 Anti-Mutated Kras T Cell Receptors EP Sweden 3223850 15807756.0 Issued Sweden <br />European patent (EP) 15807756.0<br />Filed on 2015-11-24<br />Status: Issued 147165922 E-028-2015-1 E-028-2015-1-SI-33 Anti-Mutated Kras T Cell Receptors EP Slovenia 3223850 15807756.0 Issued Slovenia <br />European patent (EP) 15807756.0<br />Filed on 2015-11-24<br />Status: Issued 147165923 E-028-2015-1 E-028-2015-1-SK-34 Anti-Mutated Kras T Cell Receptors EP Slovakia 3223850 15807756.0 Issued Slovakia <br />European patent (EP) 15807756.0<br />Filed on 2015-11-24<br />Status: Issued 147165924 E-028-2015-1 E-028-2015-1-TR-35 Anti-Mutated Kras T Cell Receptors EP Turkey 3223850 15807756.0 Issued Turkey <br />European patent (EP) 15807756.0<br />Filed on 2015-11-24<br />Status: Issued 147165925 E-028-2015-1 E-028-2015-1-AU-36 ANTI-MUTATED KRAS T CELL RECEPTORS DIV Australia 2020203465 2020203465 Issued Australia <br />Divisional (DIV) 2020203465<br />Filed on 2020-05-26<br />Status: Issued 147165926 E-028-2015-1 E-028-2015-1-SA-37 T CELL RECEPTORS SPECIFIC FOR MUTATED KIRSTEN RAT SARCOMA VIRAL ONCOGENE HOMOLOG DIV Saudi Arabia 520420365 Pending Saudi Arabia <br />Divisional (DIV) 520420365<br />Filed on 2020-10-15<br />Status: Pending 147165927 E-028-2015-1 E-028-2015-1-HK-38 Anti-Mutated Kras T Cell Receptors EP Hong Kong HK40031837B 42020021375.9 Issued Hong Kong <br />European patent (EP) 42020021375.9<br />Filed on 2020-12-01<br />Status: Issued 147165929 E-028-2015-1 E-028-2015-1-JP-40 Anti-Mutated Kras T Cell Receptors DIV Japan 7297807 2021-063092 Issued Japan <br />Divisional (DIV) 2021-063092<br />Filed on 2021-04-01<br />Status: Issued 147165930 E-028-2015-1 E-028-2015-1-CN-41 Anti-Mutated Kras T Cell Receptors DIV China ZL202111263859.8 202111263859.8 Issued China <br />Divisional (DIV) 202111263859.8<br />Filed on 2021-10-27<br />Status: Issued 147165931 E-028-2015-1 E-028-2015-1-US-42 ANTI-MUTATED KRAS T CELL RECEPTORS CON US 12,312,391 17/535,318 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12312391 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12312391">12,312,391</a><br />Filed on 2021-11-24<br />Status: Issued 147165932 E-028-2015-1 E-028-2015-1-HK-43 Anti-Mutated Kras T Cell Receptors CN Hong Kong HK40065450 42022054674.1 Issued Hong Kong <br />China Patent (CN) 42022054674.1<br />Filed on 2022-06-07<br />Status: Issued 147165933 E-028-2015-1 E-028-2015-1-AU-01 Anti-Mutated Kras T Cell Receptors DIV Australia 2023200614 Pending Australia <br />Divisional (DIV) 2023200614<br />Filed on 2023-02-07<br />Status: Pending 147169785 Colorectal 147169786 Immunotherapy 147169787 KRAS 147169788 LUNG 147169790 oncogenesis 147169791 PANCREAS 147169792 PROSTATE 147169793 T cell 147169794 TCR TAB-3993 147157274 Cancer Therapeutic Based on T Cell Receptors Designed to Regiospecifically Release Interleukin-12 NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Richard Morgan, Nicholas Restifo, Steven Rosenberg, Ling Zhang <p>Adoptive immunotherapy is a promising new approach to cancer treatment that engineers an individual''s innate and adaptive immune system to fight against specific diseases, including cancer with fewer side-effects and more specific anti-tumor activity in individual patients. T cell receptors (TCRs) and Chimeric Antigen Receptors (CARs) are proteins that recognize antigens in the context of infected or transformed cells and activate T cells to mediate an immune response to destroy abnormal cells. When a TCR/CAR is stimulated by an antigen,  signaling pathways activated in the T cell lead to the production of proteins such as cytokines, which mediate the immune response and ultimately lead to the death of the diseased target cell.</p> <p> Scientists at the National Cancer Institute (NCI) <a href="https://ccr.cancer.gov/Surgery-Branch" target="_blank" rel="nofollow">Surgery Branch</a> have developed T cells genetically engineered to express the human interleukin 12 (IL-12) cytokine only in the tumor environment. Thus, IL-12 is only released at the cancer site and only after the activation of the T cell.  This technology makes it possible to control the expression of IL-12 to enhance T cell cytolytic activity while also reducing or eliminating the IL-12 toxicity observed with other IL-12 related therapies. Infusing these IL-12 expressing T cells into patients via adoptive immunotherapy could prove to be powerful new tools for attacking tumors. Further R&amp;D Needed:  Testing of function at scale-up levels required for clinical trials.</p> <h2>Competitive Advantages:</h2> <ul><li>The combination of enhanced T cell activity with reduced IL-12 toxicity: IL-12 has shown remarkable properties as an anti-tumor agent, but its clinical development has been hindered by its toxicity. This current technology delivers IL-12 only when and where it is needed - at the tumor site or site of infection.</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Immunotherapeutics to treat and/or prevent the recurrence of a variety of human cancers by adoptively transferring the gene-modified T cells into patients.</li> <li>Immunotherapeutics to treat and/or prevent the recurrence of a variety of human infectious agents by adoptively transferring the gene-modified T cells into patients.</li> <li>A drug component of a combination immunotherapy regimen aimed at targeting the specific tumor-associated antigens expressed by cancer cells within individual patients</li> </ul> 2016-02-16 2025-04-22 2016-08-31 2025-04-22 2016-08-30 CARS, chimeric antigen receptor, human interleukin 12, IL-12, T Cell Receptor, TCRs False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2016-08-31 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147163152 Morgan, Richard NIH - NCI NCI Morgan, Richard (NCI) 1 147163153 Restifo, Nicholas NIH - NCI NCI Restifo, Nicholas (NCI) 2 147163154 Rosenberg, Steven NIH - NCI NCI Rosenberg, Steven (NCI) 3 147163155 Zhang, Ling NIH - NCI NCI Zhang, Ling (NCI) 4 147163152 Morgan, Richard NIH - NCI NCI Morgan, Richard (NCI) 1 147163153 Restifo, Nicholas NIH - NCI NCI Restifo, Nicholas (NCI) 2 147163154 Rosenberg, Steven NIH - NCI NCI Rosenberg, Steven (NCI) 3 147163155 Zhang, Ling NIH - NCI NCI Zhang, Ling (NCI) 4 147158134 Methods Of Preparing Lymphocytes That Express Interleukin-12 And Their Use In The Treatment Of Cancer E-170-2009-0 Filing authorized NCI 83709866 Burke, Andrew burkear@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC burkear@nih.gov?subject=Web Inquiry on [TAB-3993] Cancer Therapeutic Based on T Cell Receptors Designed to Regiospecifically Release Interleukin-12&body=Please send me information about technology [TAB-3993] Cancer Therapeutic Based on T Cell Receptors Designed to Regiospecifically Release Interleukin-12.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Burke, Andrew<br><a href="mailto:burkear@nih.gov?subject=Web Inquiry on [TAB-3993] Cancer Therapeutic Based on T Cell Receptors Designed to Regiospecifically Release Interleukin-12&body=Please send me information about technology [TAB-3993] Cancer Therapeutic Based on T Cell Receptors Designed to Regiospecifically Release Interleukin-12.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">burkear@nih.gov</a><br> 147165771 E-170-2009-0 E-170-2009-0-US-01 Methods Of Preparing Lymphocytes That Express Interleukin-12 And Their Use In The Treatment Of Cancer PRV US 61/174,046 Abandoned US <br />Provisional (PRV) 61/174,046<br />Filed on 2009-04-30<br />Status: Abandoned 147165772 E-170-2009-0 E-170-2009-0-PCT-02 Inducible Interleukin-12 PCT Patent Cooperation Treaty PCT/US2010/031988 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2010/031988<br />Filed on 2010-04-22<br />Status: Expired 147165773 E-170-2009-0 E-170-2009-0-AU-03 Inducible Interleukin-12 National Stage Australia 2010241864 2010241864 Issued Australia <br />National Stage 2010241864<br />Filed on 2010-04-22<br />Status: Issued 147165774 E-170-2009-0 E-170-2009-0-CA-04 Inducible Interleukin-12 National Stage Canada 2760446 2760446 Issued Canada <br />National Stage 2760446<br />Filed on 2015-04-22<br />Status: Issued 147165775 E-170-2009-0 E-170-2009-0-EP-05 Inducible Interleukin-12 National Stage European Patent 2424887 10717361.9 Issued European Patent <br />National Stage 10717361.9<br />Filed on 2010-04-22<br />Status: Issued 147165776 E-170-2009-0 E-170-2009-0-US-06 Inducible Interleukin-12 National Stage US 8,556,882 13/266,280 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8556882 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8556882">8,556,882</a><br />Filed on 2010-04-22<br />Status: Issued 147165777 E-170-2009-0 E-170-2009-0-DE-07 Inducible Interleukin-12 EP Germany 60 2010 027 873.5 10717361.9 Issued Germany <br />European patent (EP) 10717361.9<br />Filed on 2010-04-22<br />Status: Issued 147165778 E-170-2009-0 E-170-2009-0-FR-08 Inducible Interleukin-12 EP France 2424887 10717361.9 Issued France <br />European patent (EP) 10717361.9<br />Filed on 2010-04-22<br />Status: Issued 147165779 E-170-2009-0 E-170-2009-0-GB-09 Inducible Interleukin-12 EP United Kingdom 2424887 10717361.9 Issued United Kingdom <br />European patent (EP) 10717361.9<br />Filed on 2010-04-22<br />Status: Issued 147172917 CARS 147172918 chimeric antigen receptor 147172920 human interleukin 12 147172921 IL-12 147172922 T Cell Receptor 147172923 TCRs TAB-3995 147157276 Her2 Monoclonal Antibodies, Antibody Drug Conjugates as Cancer Therapeutics NCI Licensing, Oncology, Therapeutics Licensing Oncology Therapeutics Dimiter Dimitrov, Pradman Qasba, Boopathy Ramakrishnan, Zhongyu Zhu <p>Antibody drug conjugates (ADC) can demonstrate high efficacy as cancer therapeutics, however, much more can be done to improve their efficacy and safety profile. Site-specific antibody drug conjugation is a promising way to do this. Scientists at the NCI’s <a href="https://ccr.cancer.gov/Experimental-Immunology-Branch" rel="nofollow">Laboratory of Experimental Immunology</a> have identified a fully human monoclonal antibody, m860, that binds to cell surface-associated Her2 with affinity comparable to that of Trastuzumab (Herceptin) but to a different epitope. In addition, the scientist developed a site-specific glycan engineering method to conjugate the antibody to the small molecule drug auristatin F. The ADC prepared though this site-specific approach shows very good stability, cell surface binding activity and also potent specific cell killing activity against Her2 positive cancer cells, including Trastuzumab resistant breast cancer cells. This ADC has the potential to be developed as a targeted therapeutic for Her2-overexpressing cancers and this site-specific strategy could be readily applied to develop ADCs targeting other cancers that express cell surface markers or other disease targets.</p> <h2>Competitive Advantages:</h2> <ul><li>Could be used in combination with Trastuzumab or for patients who have developed resistance to Trastuzumab treatment, since this antibody targets a different epitope.</li> <li>Site specific conjugation provides better efficacy and less side effects than ADCs produced using traditional strategies.</li> <li>Can be readily applied to develop ADCs targeting other cancers that express cell surface markers or other disease targets, such as HIV.</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Therapeutic for the treatment of Her2 positive cancers.</li> <li>Method for producing safer and more effective ADCs.</li> </ul> 2016-02-16 2025-04-22 2017-11-14 2025-04-22 2016-09-12 ADC, antibody drug conjugate, Dimitrov, HER2, Her2 positive, Her2-overexpression False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2017-11-14 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147163158 Dimitrov, Dimiter NIH - NCI NCI Dimitrov, Dimiter (NCI) 1 147163161 Zhu, Zhongyu NIH - NCI NCI Zhu, Zhongyu (NCI) 2 147163159 Qasba, Pradman NIH - NCI NCI Qasba, Pradman (NCI) 3 147163160 Ramakrishnan, Boopathy NIH - NCI Ramakrishnan, Boopathy 4 147163158 Dimitrov, Dimiter NIH - NCI NCI Dimitrov, Dimiter (NCI) 1 147163161 Zhu, Zhongyu NIH - NCI NCI Zhu, Zhongyu (NCI) 2 147163159 Qasba, Pradman NIH - NCI NCI Qasba, Pradman (NCI) 3 147163160 Ramakrishnan, Boopathy NIH - NCI Ramakrishnan, Boopathy 4 147158353 Site Specific Antibody Drug Conjugation Through Glycan Engineering For Targeted Cancer Therapeutics Development E-351-2013-0 Filing authorized NCI 91814193 Freel, Rose rose.freel@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America rose.freel@nih.gov?subject=Web Inquiry on [TAB-3995] Her2 Monoclonal Antibodies, Antibody Drug Conjugates as Cancer Therapeutics&body=Please send me information about technology [TAB-3995] Her2 Monoclonal Antibodies, Antibody Drug Conjugates as Cancer Therapeutics.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Freel, Rose<br><a href="mailto:rose.freel@nih.gov?subject=Web Inquiry on [TAB-3995] Her2 Monoclonal Antibodies, Antibody Drug Conjugates as Cancer Therapeutics&body=Please send me information about technology [TAB-3995] Her2 Monoclonal Antibodies, Antibody Drug Conjugates as Cancer Therapeutics.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">rose.freel@nih.gov</a><br> 147161276 E-351-2013-0 E-351-2013-0-PCT-02 HER2-SPECIFIC MONOCLONAL ANTIBODIES AND CONJUGATES THEREOF PCT Patent Cooperation Treaty PCT/US2014/041492 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2014/041492<br />Filed on 2014-06-09<br />Status: Expired 147165785 E-351-2013-0 E-351-2013-0-US-01 HER2-SPECIFIC MONOCLONAL ANTIBODIES AND CONJUGATES THEREOF PRV US 61/833,732 Abandoned US <br />Provisional (PRV) 61/833,732<br />Filed on 2013-06-11<br />Status: Abandoned 147165786 E-351-2013-0 E-351-2013-0-US-03 HER2-Specific Monoclonal Antibodies and Conjugates Thereof National Stage US 9,738,726 14/897,389 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9738726 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9738726">9,738,726</a><br />Filed on 2015-12-10<br />Status: Issued 147174863 ADC 147174864 antibody drug conjugate 147174865 Dimitrov 147174866 HER2 147174868 Her2 positive 147174870 Her2-overexpression TAB-3988 147157269 Engineered Biological Pacemakers NIA Cardiology, Collaboration, Licensing, Medical Devices, Non-Medical Devices Cardiology Collaboration Licensing Medical Devices Non-Medical Devices Edward Lakatta, Victor Maltsev, Maxim Mikheev, Syevda Sirenko, Yoram Vodovotz, Ihor Zahanich <p>The National Institute on Aging's (NIA) Cellular Biophysics Section is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize biological pacemakers.</p> <p>A common symptom of many heart diseases is an abnormal heart rhythm or arrhythmia. While effectively improving the lives of many patients, implantable pacemakers have significant limitations such as limited power sources, risk of infections, potential for interference from other devices, and absence of autonomic rate modulation.</p> <p> The technology developed by the NIA, consists of biological pacemakers engineered to generate normal heart rhythm. The biological pacemakers are created by administering <em>in vivo</em> a viral vector comprising a nucleic acid that encodes an adenylyl cyclase into electrically excitable cardiomyocytes of the heart of a patient. Generation of rhythmic electric impulses involves coupling factors, such as cAMP-dependent PKA and Ca2+-dependent CaMK II, which are regulatory proteins capable of modulating/enhancing interactions (i.e. coupling) of the sarcoplasmic reticulum-based, intracellular Ca2+ clock and the surface membrane voltage clock, thereby converting irregularly or rarely spontaneously active cells into pacemakers generating rhythmic excitations.</p> <p> Development Status: <br /> Early stage</p> <h2>Competitive Advantages:</h2> <ul><li>In contrast to current implantable cardiac pacemaker technology, this technology is not externally powered, has a lower risk of infection, has decreased potential for interference from other devices, and has full autonomic rate modulation</li> </ul> <h2>Commercial Applications:</h2> <ul><li>This technology can be utilized in heart disease characterized by arrhythmia or situations requiring an implantable cardiac pacemaker<br />  </li> </ul> 2016-02-16 2025-04-22 2018-11-05 2025-04-22 2010-02-02 Biological Pacemaker False True Basic (Target Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2018-11-05 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147163136 Maltsev, Victor NIH - NIA NIA Maltsev, Victor (NIA) 1 147163135 Lakatta, Edward NIH - NIA NIA Lakatta, Edward (NIA) 2 147163137 Zahanich, Ihor NIH - NIA NIA Zahanich, Ihor (NIA) 3 147163138 Sirenko, Syevda NIH - NIA NIA Sirenko, Syevda (NIA) 4 147163139 Vodovotz, Yoram University of Pittsburgh Vodovotz, Yoram 5 147163140 Mikheev, Maxim University of Pittsburgh Mikheev, Maxim 6 147163136 Maltsev, Victor NIH - NIA NIA Maltsev, Victor (NIA) 1 147163135 Lakatta, Edward NIH - NIA NIA Lakatta, Edward (NIA) 2 147163137 Zahanich, Ihor NIH - NIA NIA Zahanich, Ihor (NIA) 3 147163138 Sirenko, Syevda NIH - NIA NIA Sirenko, Syevda (NIA) 4 147163139 Vodovotz, Yoram University of Pittsburgh Vodovotz, Yoram 5 147163140 Mikheev, Maxim University of Pittsburgh Mikheev, Maxim 6 147158054 Engineering Rhythmic And Responsive Biological Pacemakers Based On The Enhancement Of Cell Intracellular Signaling Targeting Both Ca Cycling And Sarcolemma E-134-2009-0 Filing authorized National Institute on Aging (NIH/NIA), University of Pittsburgh 83682895 Girards, Richard richard.girards@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB richard.girards@nih.gov?subject=Web Inquiry on [TAB-3988] Engineered Biological Pacemakers&body=Please send me information about technology [TAB-3988] Engineered Biological Pacemakers.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Girards, Richard<br><a href="mailto:richard.girards@nih.gov?subject=Web Inquiry on [TAB-3988] Engineered Biological Pacemakers&body=Please send me information about technology [TAB-3988] Engineered Biological Pacemakers.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">richard.girards@nih.gov</a><br> 147161088 E-134-2009-0 E-134-2009-0-US-01 Engineering Rhythmic And Responsive Biological Pacemakers Based on The Enhancement Of Cell Intracellular Signaling Targeting Both Ca Cycling And Sarcolemma PRV US 61/180,491 Abandoned US <br />Provisional (PRV) 61/180,491<br />Filed on 2009-05-22<br />Status: Abandoned 147165748 E-134-2009-0 E-134-2009-0-PCT-02 Engineered Biological Pacemakers PCT Patent Cooperation Treaty PCT/US2010/035823 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2010/035823<br />Filed on 2010-05-21<br />Status: Expired 147165749 E-134-2009-0 E-134-2009-0-US-03 Engineered Biological Pacemakers National Stage US 9,506,032 13/322,066 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9506032 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9506032">9,506,032</a><br />Filed on 2012-02-06<br />Status: Issued 147172135 Biological Pacemaker TAB-3965 147157245 Nucleic Acid Nanoparticles for Triggering RNA Interference NCI Collaboration, Infectious Disease, Licensing, Oncology, Therapeutics Collaboration Infectious Disease Licensing Oncology Therapeutics Kirill Afonin, Bruce Shapiro, Mathias Viard <p>RNA interference (RNAi) is a naturally occurring cellular post-transcriptional gene regulation process that utilizes small double-stranded RNAs to trigger and guide gene silencing. By introducing synthetic RNA duplexes called small-interfering RNAs (siRNAs), we can harness the RNAi machinery for therapeutic gene control and the treatment of various diseases.<br />  <br /> NCI researchers created RNA, RNA-DNA, or DNA-RNA hybrid nanocubes consisting of a DNA or RNA core (composed of six strands) with attached RNA or DNA hybrid duplexes. The nanocubes can induce the reassociation of the RNA duplexes, which can then be processed by the human recombinant DICER enzyme, thus activating RNAi. This technology opens a new route for the development of “smart” nucleic acid based nanoparticles for a wide range of biomedical applications.  Immune responses can be controlled by altering the composition of the particle.</p> <p>The researchers are conducting preliminary mouse xenograft studies on a related potential therapeutic, and seek collaborators for scale-up, animal models, developing particles for multiple targets, and RNAi delivery methods.</p> <h2>Competitive Advantages:</h2> <p>• Low cytotoxicity</p> <h2>Commercial Applications:</h2> <p>• Treatment for cancer and infectious diseases.</p> 2016-02-16 2025-04-22 2020-04-07 2025-04-22 2016-08-30 nanotechnology, RNAi, SiRNA False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2020-04-07 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-039-2012 E-078-2016 E-765-2013 147162235 Kirill A. Afonin et al. http://www.ncbi.nlm.nih.gov/pubmed/24189588 <a href="http://www.ncbi.nlm.nih.gov/pubmed/24189588">Kirill A. Afonin et al.</a> 147163040 Shapiro, Bruce NIH - NCI NCI Shapiro, Bruce (NCI) 1 147163041 Viard, Mathias NIH - NCI Leidos Viard, Mathias (Leidos) 2 147163042 Afonin, Kirill NIH - NCI Afonin, Kirill 3 147163040 Shapiro, Bruce NIH - NCI NCI Shapiro, Bruce (NCI) 1 147163041 Viard, Mathias NIH - NCI Leidos Viard, Mathias (Leidos) 2 147163042 Afonin, Kirill NIH - NCI Afonin, Kirill 3 147158093 Triggering RNA Interference With RNA, RNA-DNA And DNA-RNA Nanoparticles E-156-2014-0 Filing authorized NCI 147162536 Triggering RNA Interference With RNA, RNA-DNA And DNA-RNA Nanoparticles E-156-2014-1 Filing authorized NCI 147162537 Triggering RNA Interference With RNA, RNA-DNA And DNA-RNA Nanoparticles E-156-2014-2 Filing authorized NCI 83732917 Favila, Michelle michelle.favila@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC michelle.favila@nih.gov?subject=Web Inquiry on [TAB-3965] Nucleic Acid Nanoparticles for Triggering RNA Interference&body=Please send me information about technology [TAB-3965] Nucleic Acid Nanoparticles for Triggering RNA Interference.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Favila, Michelle<br><a href="mailto:michelle.favila@nih.gov?subject=Web Inquiry on [TAB-3965] Nucleic Acid Nanoparticles for Triggering RNA Interference&body=Please send me information about technology [TAB-3965] Nucleic Acid Nanoparticles for Triggering RNA Interference.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">michelle.favila@nih.gov</a><br> 147165578 E-156-2014-0 E-156-2014-0-US-01 Triggering RNA Interference With RNA-DNA And DNA-RNA Nanoparticles PRV US 61/989,520 Abandoned US <br />Provisional (PRV) 61/989,520<br />Filed on 2014-05-06<br />Status: Abandoned 147165579 E-156-2014-0 E-156-2014-0-PCT-02 Triggering RNA Interference With RNA-DNA And DNA-RNA Nanoparticles PCT Patent Cooperation Treaty PCT/US2015/029553 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2015/029553<br />Filed on 2015-05-06<br />Status: Expired 147165580 E-156-2014-0 E-156-2014-0-US-03 Triggering RNA Interference With RNA-DNA And DNA-RNA Cube Nanoparticles National Stage US 10,517,890 15/309,157 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10517890 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10517890">10,517,890</a><br />Filed on 2016-11-04<br />Status: Issued 147165582 E-156-2014-1 E-156-2014-1-US-01 Triggering RNA Interference With RNA, RNA-DNA And DNA-RNA Nanoparticles PRV US 61/990,094 Abandoned US <br />Provisional (PRV) 61/990,094<br />Filed on 2014-05-07<br />Status: Abandoned 147165584 E-156-2014-2 E-156-2014-2-US-01 Triggering RNA Interference With RNA, RNA-DNA And DNA-RNA Nanoparticles CIP US 16/717,060 Abandoned US <br />Continuation in Part (CIP) 16/717,060<br />Filed on 2019-12-17<br />Status: Abandoned 147172501 nanotechnology 147172502 RNAi 147172503 SiRNA TAB-3948 147157228 Zirconium-89 PET Imaging Agent for Cancer NCI Collaboration, Licensing, Oncology, Research Materials Collaboration Licensing Oncology Research Materials Martin Brechbiel, Francois Guerard, Yong-Sok Lee <p>Researchers at the NCI <a href="https://ccr.cancer.gov/Radiation-Oncology-Branch" rel="nofollow">Radiation Oncology Branch</a>  and NIH CIT <a href="http://cmm.cit.nih.gov/" rel="nofollow">Center for Molecular Modeling</a> developed a tetrahydroxamate chelation technology that provides a more-stable Zr-89 complex as an immuno-PET cancer imaging agent. In either the linear or the macrocyclic form, the tetrahydroxamate complexes exhibit greater stability as chelating agents compared to Zr-89 complexed to the siderophore desferrioxamine B (DFB), a trihydroxamate, which represents the current state of the art chemistry and the agent currently in clinical use. </p> <p>In the Zr-89-DFB imaging agents, Zr-89 dissociates from the chelate, resulting in an increasing radioisotope accumulation in the bone 2-3 days after injection. <em>In vitro</em> studies demonstrate the tetrahydroxamate-chelated Zr-89 remained kinetically inert for seven or more days, thereby reducing the amount of Zr-89 that is released compared to the complex containing DFB.</p> <h2>Competitive Advantages:</h2> <ul><li>High stability  with low toxicity</li> </ul> <h2>Commercial Applications:</h2> <ul><li>PET imaging, especially for cancer and in particular Immuno-PET imaging</li> </ul> 2016-02-16 2025-04-22 2018-07-19 2025-04-22 2016-08-30 imaging agent, PET, zirconium-89 False True Prototype True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2018-07-19 52406769 Prototype 52406769 NCI 37470483 Website Abstract E-067-1990 E-194-2007 E-226-2006 147161920 Guerard F, et al. http://www.ncbi.nlm.nih.gov/pubmed/24740517 <a href="http://www.ncbi.nlm.nih.gov/pubmed/24740517">Guerard F, et al.</a> 147161958 Guerard F, et al. http://www.ncbi.nlm.nih.gov/pubmed/23250287 <a href="http://www.ncbi.nlm.nih.gov/pubmed/23250287">Guerard F, et al.</a> 147162981 Guerard, Francois NIH - NCI Guerard, Francois 1 147162980 Lee, Yong-Sok NIH - CIT NIAID Lee, Yong-Sok (NIAID) 2 147162979 Brechbiel, Martin NIH - NCI NCI Brechbiel, Martin (NCI) 3 147162981 Guerard, Francois NIH - NCI Guerard, Francois 1 147162980 Lee, Yong-Sok NIH - CIT NIAID Lee, Yong-Sok (NIAID) 2 147162979 Brechbiel, Martin NIH - NCI NCI Brechbiel, Martin (NCI) 3 147158009 Hydroxomate-based Chelators For The Complexation Of Zr-89 For Nuclear Imaging Of Cancers E-111-2013-0 Filing authorized CIT, NCI 121111111 Greene, Jaime greenejaime@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America greenejaime@mail.nih.gov?subject=Web Inquiry on [TAB-3948] Zirconium-89 PET Imaging Agent for Cancer&body=Please send me information about technology [TAB-3948] Zirconium-89 PET Imaging Agent for Cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Greene, Jaime<br><a href="mailto:greenejaime@mail.nih.gov?subject=Web Inquiry on [TAB-3948] Zirconium-89 PET Imaging Agent for Cancer&body=Please send me information about technology [TAB-3948] Zirconium-89 PET Imaging Agent for Cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">greenejaime@mail.nih.gov</a><br> 147161057 E-111-2013-0 E-111-2013-0-US-01 TetraHydroxamate Chelators of Zirconium89 For Use In Diagnostic Applications PRV US 61/779,016 Abandoned US <br />Provisional (PRV) 61/779,016<br />Filed on 2013-03-13<br />Status: Abandoned 147165499 E-111-2013-0 E-111-2013-0-PCT-02 TetraHydroxomate Chelators of Zirconium89 and Niobium90 for use in Diagnostic Applications PCT Patent Cooperation Treaty PCT/US2014/24048 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2014/24048<br />Filed on 2014-03-12<br />Status: Expired 147165500 E-111-2013-0 E-111-2013-0-EP-03 TetraHydroxomate Chelators of Zirconium89 and Niobium90 for use in Diagnostic Applications National Stage European Patent 2970154 14779019.0 Issued European Patent <br />National Stage 14779019.0<br />Filed on 2014-03-12<br />Status: Issued 147165501 E-111-2013-0 E-111-2013-0-US-04 Tetrahydroxamate Chelators of Zirconium89 and Niobium90 for Use in Diagnostic Applications National Stage US 10,137,212 14/774,831 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10137212 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10137212">10,137,212</a><br />Filed on 2015-09-11<br />Status: Issued 147165502 E-111-2013-0 E-111-2013-0-DE-05 TetraHydroxomate Chelators of Zirconium89 and Niobium90 for use in Diagnostic Applications EP Germany 2970154 14779019.0 Issued Germany <br />European patent (EP) 14779019.0<br />Filed on 2014-03-12<br />Status: Issued 147165503 E-111-2013-0 E-111-2013-0-FR-06 TetraHydroxomate Chelators of Zirconium89 and Niobium90 for use in Diagnostic Applications EP France 2970154 14779019.0 Issued France <br />European patent (EP) 14779019.0<br />Filed on 2014-03-12<br />Status: Issued 147165504 E-111-2013-0 E-111-2013-0-GB-07 TetraHydroxomate Chelators of Zirconium89 and Niobium90 for use in Diagnostic Applications EP United Kingdom 2970154 14779019.0 Issued United Kingdom <br />European patent (EP) 14779019.0<br />Filed on 2014-03-12<br />Status: Issued 147171651 imaging agent 147171652 PET 147171653 zirconium-89 TAB-3952 147157232 Reporter Plasmid to Identify Cancer Stem Cells NCI Licensing, Oncology, Research Materials Licensing Oncology Research Materials Binwu Tang, Lalage Wakefield <p>Cancer stem cells are a minority population of cells in tumors that initiate and sustain the cancer and which are resistant to therapy; they may cause tumors to recur after curative treatment.  Current therapies generally do not target cancer stem cells.</p> <p>Scientists at the National Cancer Institute <a href="https://ccr.cancer.gov/Laboratory-of-Cancer-Biology-and-Genetics" rel="nofollow">Laboratory of Cancer Biology and Genetics</a> have developed an efficient lentiviral plasmid to visualize and purify cancer stem cells, which is useful for screening compounds that specifically kill or inhibit cancer stem cells.  The NCI lentiviral plasmid can identify the putative cancer stem cell population through the expression of fluorescent or luminescent proteins and has the potential to advance new therapies. The key feature of the plasmid is a reporter system that only detects cells expressing the core stem cell transcription factors Sox2 and Oct4.</p> <h2>Competitive Advantages:</h2> <ul><li>Visualization of cancer stem cells by functional property rather than by use of highly variable cell surface markers</li> <li>Flexible, modular gateway cloning technology allows constructs with alternative reporters to be readily generated</li> <li>Independent of cell-of-origin of tumor</li> <li>Cancer stem cell behavior can be monitored in real-time</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Visualize, quantify and purify cancer stem cells</li> <li>Monitor cancer stem cells in transplanted tumors in vivo.Identify cancer stem cells in high throughput screening of libraries for compounds that specifically inhibit or kill cancer stem cells</li> <li>Optimize therapeutic regimens in preclinical models</li> <li>Potential to support precision medicine approach by screening therapeutics for efficacy against cancer stem cells in patient-derived xenografts</li> </ul> 2016-02-16 2025-04-22 2020-12-14 2025-04-22 2014-05-16 Lentiviral, Oct4, PLASMID, reporter construct, Sox2 False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2020-12-14 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147162387 Tang B, et al. A flexible reporter system for direct observation and isolation of cancer stem cells. https://www.ncbi.nlm.nih.gov/pubmed/25497455 <a href="https://www.ncbi.nlm.nih.gov/pubmed/25497455">Tang B, et al. A flexible reporter system for direct observation and isolation of cancer stem cells.</a> 147162997 Wakefield, Lalage NIH - NCI NCI Wakefield, Lalage (NCI) 1 147162998 Tang, Binwu NIH - NCI NCI Tang, Binwu (NCI) 2 147162997 Wakefield, Lalage NIH - NCI NCI Wakefield, Lalage (NCI) 1 147162998 Tang, Binwu NIH - NCI NCI Tang, Binwu (NCI) 2 147158071 Novel Reporter Construct For The Identification Of Cancer Stem Cells E-141-2011-0 Research Material NCI 121111111 Greene, Jaime greenejaime@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America greenejaime@mail.nih.gov?subject=Web Inquiry on [TAB-3952] Reporter Plasmid to Identify Cancer Stem Cells&body=Please send me information about technology [TAB-3952] Reporter Plasmid to Identify Cancer Stem Cells.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Greene, Jaime<br><a href="mailto:greenejaime@mail.nih.gov?subject=Web Inquiry on [TAB-3952] Reporter Plasmid to Identify Cancer Stem Cells&body=Please send me information about technology [TAB-3952] Reporter Plasmid to Identify Cancer Stem Cells.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">greenejaime@mail.nih.gov</a><br> 147172263 Lentiviral 147172265 Oct4 147172266 PLASMID 147172268 reporter construct 147172270 Sox2 TAB-3942 147157222 In silico design of RNA nanoparticles NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Kirill Afonin, Eckart Bindewald, Cody Geary, Luc Jaeger, Wojciech Kasprzak, Isil Severcan, Bruce Shapiro, Yaroslava Yingling <p>RNA nanoparticles have the potential to serve as excellent drug or imaging delivery systems due to their designability and versatility. Furthermore, the RNA nanoparticles of the invention are also capable of self-assembly and potentially form nanotubes of various shapes which offer potentially broad uses in medical implants, gene therapy, nanocircuits, scaffolds and medical testing.</p> <p>This technology, which was co-invented by researchers at National Cancer Institute and the University of California at Santa Barbara (UCSB), describes the computational design of various RNA nanoparticles. These polyvalent nanoparticles utilize RNA motifs as building blocks that give the particles their unique characteristics.  The motifs can be pre-defined and chosen to give the particles desired characteristics (e.g. size and shape) tailored for a variety of applications. The polyvalent particles can utilize multiple unique positions to carry functional groups for cell recognition (e.g. cancer cells), therapy and detection. For therapeutic or detection applications the particles typically encompass at least two functional groups, a therapeutic or imaging agent and a targeting agent that will direct the particles to the targeted tissue.</p> <p> Proof of concept has been demonstrated computationally and experimentally for a variety of RNA nanoparticle structures, including synthesis of an RNA Nanoring. NCI is seeking collaborators to perform the laboratory testing necessary to translate computational RNA nanoparticle research into therapeutics, diagnostics, and other applications. Collaborations regarding any aspect of the technology will be considered. </p> <h2>Competitive Advantages:</h2> <ul><li>RNA nanoparticles potentially offer advantages compared to other conventional nanoparticles:</li> <li>They are compatible with biological systems and thus may be readily used for in vivo applications such as therapeutic and diagnostic.</li> <li>They are small and have a potential to move efficiently through biological barriers to a target tissue.</li> <li>They have multiple binding sites and thus can readily be conjugated with several functional groups (e.g. therapeutic molecule and targeting molecule).</li> <li>They are versatile and can be designed in different shapes and sizes for different applications and can alter their shapes and functionality under different environmental conditions.</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Cancer therapeutics</li> <li>Diagnostic and imaging tools</li> <li>Gene Therapy</li> <li>Nanocircuits</li> <li>Medical Implants</li> </ul> 2016-02-16 2025-04-22 2018-06-08 2025-04-22 2017-08-29 nanobiology, Nanoparticle, nanotechnology, RNAi, SiRNA False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2018-06-08 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-078-2016 147162953 Shapiro, Bruce NIH - NCI NCI Shapiro, Bruce (NCI) 1 147162952 Yingling, Yaroslava NIH - NCI Yingling, Yaroslava 2 147162955 Jaeger, Luc Jaeger, Luc 3 147162956 Severcan, Isil Severcan, Isil 4 147162957 Geary, Cody Geary, Cody 5 147162958 Bindewald, Eckart NIH - NCI Leidos Bindewald, Eckart (Leidos) 6 147162954 Kasprzak, Wojciech NIH - NCI Leidos Kasprzak, Wojciech (Leidos) 7 147162959 Afonin, Kirill NIH - NCI Afonin, Kirill 8 147162953 Shapiro, Bruce NIH - NCI NCI Shapiro, Bruce (NCI) 1 147162952 Yingling, Yaroslava NIH - NCI Yingling, Yaroslava 2 147162955 Jaeger, Luc Jaeger, Luc 3 147162956 Severcan, Isil Severcan, Isil 4 147162957 Geary, Cody Geary, Cody 5 147162958 Bindewald, Eckart NIH - NCI Leidos Bindewald, Eckart (Leidos) 6 147162954 Kasprzak, Wojciech NIH - NCI Leidos Kasprzak, Wojciech (Leidos) 7 147162959 Afonin, Kirill NIH - NCI Afonin, Kirill 8 147157889 RNA Hexagonal Ring And RNA Nanotube, RNA Nanorings, RNA Three-dimensional Cages And Functionalized RNA-based Nanoparticles E-059-2009-0 Filing authorized NCI, University of California, Santa Barbara 83732917 Favila, Michelle michelle.favila@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC michelle.favila@nih.gov?subject=Web Inquiry on [TAB-3942] In silico design of RNA nanoparticles&body=Please send me information about technology [TAB-3942] In silico design of RNA nanoparticles.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Favila, Michelle<br><a href="mailto:michelle.favila@nih.gov?subject=Web Inquiry on [TAB-3942] In silico design of RNA nanoparticles&body=Please send me information about technology [TAB-3942] In silico design of RNA nanoparticles.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">michelle.favila@nih.gov</a><br> 147165455 E-059-2009-0 E-059-2009-0-US-01 RNA Nanoparticles and Methods of Use PRV US 61/187,495 Abandoned US <br />Provisional (PRV) 61/187,495<br />Filed on 2009-06-16<br />Status: Abandoned 147165456 E-059-2009-0 E-059-2009-0-PCT-02 RNA Nanoparticles and Methods of Use PCT Patent Cooperation Treaty PCT/US2010/038818 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2010/038818<br />Filed on 2010-06-16<br />Status: Expired 147165457 E-059-2009-0 E-059-2009-0-US-03 RNA Nanoparticles And Nanotubes National Stage US 9,732,337 13/378,935 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9732337 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9732337">9,732,337</a><br />Filed on 2012-03-13<br />Status: Issued 147170469 nanobiology 147170470 Nanoparticle 147170471 nanotechnology 147170472 RNAi 147170473 SiRNA TAB-3926 147157206 Angiogenesis-Based Cancer Therapeutic NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Donald Bottaro, Fabiola Cecchi <p>Vascular Endothelial Growth Factor-A (VEGF-A) is an angiogenic agent that drives blood vessel formation in solid tumors and other diseases, such as macular degeneration and diabetic retinopathy. Several therapies that target the ability of VEGF to stimulate angiogenesis have been approved. These therapies regulate VEGF-A activity by binding VEGF-A, thereby blocking VEGF-A from binding to its receptor on target cells. This technology utilizes a different approach to regulating VEGF-A activity by providing a VEGF-A protein antagonist that is produced by engineering native VEGF-A protein. The engineered VEGF-A protein disrupts heparin sulfate proteoglycan binding to the VEGF-A/VEGF receptor complex, an activity that is essential for the angiogenic properties of native VEGF-A. The antagonist has a binding affinity for both FLT-1 (VEGFR-1) and KDR/FLK-1 (VEGFR-2) that is equivalent to that of native VEGF-A and specifically antagonizes all VEGF-A-stimulated signaling events.</p> <h2>Competitive Advantages:</h2> <ul><li>Cost effective in terms of production</li> <li>High Specificity/Selectivity</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Therapy for solid tumors or other diseases associated with angiogenic activity modulated by Vascular Endothelial Growth Factor-A expression.</li> </ul> 2016-02-16 2025-04-22 2020-09-17 2025-04-22 2016-08-31 ANGIOGENESIS, CHEMOTHERAPY, Diabetic Retinopathy, FLT-1, Heparin sulfate proteoglycan, Hepatocyte growth factor (HGF), KDR/FLK-1, Macular degeneration, VEGF-A False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-09-17 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147162890 Bottaro, Donald NIH - NCI NCI Bottaro, Donald (NCI) 1 147162891 Cecchi, Fabiola NIH - NCI Cecchi, Fabiola 2 147162890 Bottaro, Donald NIH - NCI NCI Bottaro, Donald (NCI) 1 147162891 Cecchi, Fabiola NIH - NCI Cecchi, Fabiola 2 147158244 A Vascular Endothelial Growth Factor (VEGF) Antagonist Engineered By Disruption Of Heparin Sulfate Binding E-230-2011-0 Filing authorized NCI 147162573 A Vascular Endothelial Growth Factor (VEGF) Antagonist Engineered By Disruption Of Heparin Sulfate Binding E-230-2011-1 Filing authorized NCI 83643835 Rucker, Susan susan.rucker@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC susan.rucker@nih.gov?subject=Web Inquiry on [TAB-3926] Angiogenesis-Based Cancer Therapeutic&body=Please send me information about technology [TAB-3926] Angiogenesis-Based Cancer Therapeutic.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Rucker, Susan<br><a href="mailto:susan.rucker@nih.gov?subject=Web Inquiry on [TAB-3926] Angiogenesis-Based Cancer Therapeutic&body=Please send me information about technology [TAB-3926] Angiogenesis-Based Cancer Therapeutic.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">susan.rucker@nih.gov</a><br> 147165299 E-230-2011-0 E-230-2011-0-US-01 Vascular Endothelial Growth Factor Antagonists And Methods For Their Use PRV US 61/639,230 Abandoned US <br />Provisional (PRV) 61/639,230<br />Filed on 2012-04-27<br />Status: Abandoned 147165301 E-230-2011-1 E-230-2011-1-PCT-01 Vascular Endothelial Growth Factor Antagonist And Methods For Their Use PCT COMB Patent Cooperation Treaty PCT/US2013/038506 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2013/038506<br />Filed on 2013-04-26<br />Status: Expired 147165302 E-230-2011-1 E-230-2011-1-AU-02 VASCULAR ENDOTHELIAL GROWTH FACTOR ANTAGONISTS AND METHODS FOR THEIR USE National Stage Australia 2013251375 2013251375 Issued Australia <br />National Stage 2013251375<br />Filed on 2013-04-26<br />Status: Issued 147165303 E-230-2011-1 E-230-2011-1-CA-03 Vascular Endothelial Growth Factor Antagonist And Methods For Their Use National Stage Canada 2870769 2870769 Issued Canada <br />National Stage 2870769<br />Filed on 2013-04-26<br />Status: Issued 147165304 E-230-2011-1 E-230-2011-1-EP-04 Vascular Endothelial Growth Factor Antagonist And Methods For Their Use National Stage European Patent 2841087 13720737.9 Issued European Patent <br />National Stage 13720737.9<br />Filed on 2013-04-26<br />Status: Issued 147165305 E-230-2011-1 E-230-2011-1-US-05 Vascular Endothelial Growth Factor Antagonists And Methods For Their Use National Stage US 9,550,818 14/397,435 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9550818 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9550818">9,550,818</a><br />Filed on 2014-10-27<br />Status: Issued 147165306 E-230-2011-1 E-230-2011-1-HK-06 Vascular Endothelial Growth Factor Antagonist And Methods For Their Use National Stage Hong Kong HK1205929B 15105159.9 Issued Hong Kong <br />National Stage 15105159.9<br />Filed on 2015-05-29<br />Status: Issued 147165307 E-230-2011-1 E-230-2011-1-US-07 Vascular Endothelial Growth Factor Antagonist DIV US 10,035,833 15/411,112 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10035833 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10035833">10,035,833</a><br />Filed on 2017-01-20<br />Status: Issued 147165308 E-230-2011-1 E-230-2011-1-BE-08 Vascular Endothelial Growth Factor Antagonist And Methods For Their Use EP Belgium 2841087 13720737.9 Issued Belgium <br />European patent (EP) 13720737.9<br />Filed on 2014-11-26<br />Status: Issued 147165309 E-230-2011-1 E-230-2011-1-CH-09 Vascular Endothelial Growth Factor Antagonist And Methods For Their Use EP Switzerland 2841087 13720737.9 Issued Switzerland <br />European patent (EP) 13720737.9<br />Filed on 2014-11-26<br />Status: Issued 147165310 E-230-2011-1 E-230-2011-1-DE-10 Vascular Endothelial Growth Factor Antagonist And Methods For Their Use EP Germany 2841087 13720737.9 Issued Germany <br />European patent (EP) 13720737.9<br />Filed on 2014-11-26<br />Status: Issued 147165311 E-230-2011-1 E-230-2011-1-DK-11 Vascular Endothelial Growth Factor Antagonist And Methods For Their Use EP Denmark 2841087 13720737.9 Issued Denmark <br />European patent (EP) 13720737.9<br />Filed on 2014-11-26<br />Status: Issued 147165312 E-230-2011-1 E-230-2011-1-ES-12 Vascular Endothelial Growth Factor Antagonist And Methods For Their Use EP Spain 2841087 13720737.9 Issued Spain <br />European patent (EP) 13720737.9<br />Filed on 2014-11-26<br />Status: Issued 147165313 E-230-2011-1 E-230-2011-1-FR-13 Vascular Endothelial Growth Factor Antagonist And Methods For Their Use EP France 2841087 13720737.9 Issued France <br />European patent (EP) 13720737.9<br />Filed on 2014-11-26<br />Status: Issued 147165314 E-230-2011-1 E-230-2011-1-GB-14 Vascular Endothelial Growth Factor Antagonist And Methods For Their Use EP United Kingdom 2841087 13720737.9 Issued United Kingdom <br />European patent (EP) 13720737.9<br />Filed on 2014-11-26<br />Status: Issued 147165315 E-230-2011-1 E-230-2011-1-IE-15 Vascular Endothelial Growth Factor Antagonist And Methods For Their Use EP Ireland 2841087 13720737.9 Issued Ireland <br />European patent (EP) 13720737.9<br />Filed on 2014-11-26<br />Status: Issued 147165316 E-230-2011-1 E-230-2011-1-IT-16 Vascular Endothelial Growth Factor Antagonist And Methods For Their Use EP Italy 502017000132655 13720737.9 Issued Italy <br />European patent (EP) 13720737.9<br />Filed on 2014-11-26<br />Status: Issued 147165317 E-230-2011-1 E-230-2011-1-LI-17 Vascular Endothelial Growth Factor Antagonist And Methods For Their Use EP Liechtenstein 2841087 13720737.9 Issued Liechtenstein <br />European patent (EP) 13720737.9<br />Filed on 2014-11-26<br />Status: Issued 147165318 E-230-2011-1 E-230-2011-1-NL-18 Vascular Endothelial Growth Factor Antagonist And Methods For Their Use EP The Netherlands 2841087 13720737.9 Issued The Netherlands <br />European patent (EP) 13720737.9<br />Filed on 2014-11-26<br />Status: Issued 147165319 E-230-2011-1 E-230-2011-1-PT-19 Vascular Endothelial Growth Factor Antagonist And Methods For Their Use EP Portugal 2841087 13720737.9 Issued Portugal <br />European patent (EP) 13720737.9<br />Filed on 2014-11-26<br />Status: Issued 147165320 E-230-2011-1 E-230-2011-1-US-20 VASCULAR ENDOTHELIAL GROWTH FACTOR ANTAGONISTS CON US 11,434,268 16/051,062 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11434268 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11434268">11,434,268</a><br />Filed on 2018-07-31<br />Status: Issued 147173999 ANGIOGENESIS 147174000 CHEMOTHERAPY 147174001 Diabetic Retinopathy 147174003 FLT-1 147174005 Heparin sulfate proteoglycan 147174007 Hepatocyte growth factor (HGF) 147174009 KDR/FLK-1 147174010 Macular degeneration 147174012 VEGF-A TAB-3931 147157211 Optical Microscope Software for Breast Cancer Diagnosis NCI Licensing, Oncology, Software / Apps Licensing Oncology Software / Apps William Cukierski, Prabhakar Gudia, Stephen Lockett, Karen Meaburn, Thomas ("Tom") Misteli, Kaustav Nandy, Renee Qian <p>The successful treatment of cancer is correlated with the early detection of the cancerous cells. Conventional cancer diagnosis is largely based on qualitative morphological criteria, but more accurate quantitative tests could greatly increase early detection of malignant cells. It has been observed that the spatial arrangement of DNA in the nucleus is altered in cancer cells in comparison to normal cells. Therefore, it is possible to distinguish malignant cells by mapping the position of labeled marker genes in the nucleus.</p> <p> Researchers from NCI and Rudgers University developed  methods of detecting abnormal cells in a sample using the spatial position of one or more genes within the nucleus of a cell, as well as a kit for detecting abnormal cells using such methods. The invention also provides methods of identifying gene markers for abnormal cells using the spatial position of one or more genes within the nucleus of a cell. The application is called PAGODA: Parallel annotation genome organization diagnosis software for breast cancer:</p> <h2>Competitive Advantages:</h2> <ul><li>Sensitive detection of cancerVery small sample (100-200 cells) reduces the need for invasive procedures</li> <li>Does not require mitotic chromosomesApplicable to solid tumors and blood cancers</li> <li>Single cell assay allows analysis of subpopulations from biopsy</li> <li>Probes to all genomic regions are availableAlternative or complementary to conventional diagnostics</li> <li>Measures metastatic potential of cancer cellsDetermination of tumor type</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Software tool for tissue nuclei segmentation, annotation, screening and spartial FISH analysis.</li> <li>Diagnostic for cancer from tumor biopsies after non-invasive techniques such as a mammogram or PSA assay have suggested cancer.</li> </ul> 2016-02-16 2025-04-22 2023-01-09 2025-04-22 2016-09-12 spatial genome organization False True Prototype True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2023-01-09 52406769 Prototype 52406769 NCI 37470483 Website Abstract 147162056 KJ Meaburn et al. Locus-specific and activity-independent gene repositioning during early tumorigenesis. https://www.ncbi.nlm.nih.gov/pubmed/18195100 <a href="https://www.ncbi.nlm.nih.gov/pubmed/18195100">KJ Meaburn et al. Locus-specific and activity-independent gene repositioning during early tumorigenesis.</a> 147162910 Nandy, Kaustav NIH - NCI Leidos Nandy, Kaustav (Leidos) 1 147162913 Gudia, Prabhakar NIH - NCI Leidos Gudia, Prabhakar (Leidos) 2 147162911 Cukierski, William Rutgers, The State University of New Jersey Cukierski, William 3 147162908 Lockett, Stephen NIH - NCI Leidos Lockett, Stephen (Leidos) 4 147162909 Meaburn, Karen NIH - NCI NCI Meaburn, Karen (NCI) 5 147162907 Misteli, Thomas ("Tom") NIH - NCI NCI Misteli, Thomas ("Tom") (NCI) 6 147162912 Qian, Renee Northwestern University Qian, Renee 7 147162910 Nandy, Kaustav NIH - NCI Leidos Nandy, Kaustav (Leidos) 1 147162913 Gudia, Prabhakar NIH - NCI Leidos Gudia, Prabhakar (Leidos) 2 147162911 Cukierski, William Rutgers, The State University of New Jersey Cukierski, William 3 147162908 Lockett, Stephen NIH - NCI Leidos Lockett, Stephen (Leidos) 4 147162909 Meaburn, Karen NIH - NCI NCI Meaburn, Karen (NCI) 5 147162907 Misteli, Thomas ("Tom") NIH - NCI NCI Misteli, Thomas ("Tom") (NCI) 6 147162912 Qian, Renee Northwestern University Qian, Renee 7 147158323 PAGODA (Parallel Annotation Genome Organization Diagnosis SoftwAre) For Breast Cancer: Software Tool For Tissue Nuclei Segmentation, Annotation, Screening And Spatial FISH Analysis E-286-2012-0 Research Material NCI, Northwestern University, Rutgers, The State University of New Jersey 83704821 Nguyen-Antczak, Lauren lauren.nguyen-antczak@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-3931] Optical Microscope Software for Breast Cancer Diagnosis&body=Please send me information about technology [TAB-3931] Optical Microscope Software for Breast Cancer Diagnosis.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Nguyen-Antczak, Lauren<br><a href="mailto:lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-3931] Optical Microscope Software for Breast Cancer Diagnosis&body=Please send me information about technology [TAB-3931] Optical Microscope Software for Breast Cancer Diagnosis.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">lauren.nguyen-antczak@nih.gov</a><br> 147174668 spatial genome organization TAB-3925 147157205 Co-Transcriptional Assembly of Modified RNA Nanoparticles NCI Diagnostics, Licensing, Oncology Diagnostics Licensing Oncology Kirill Afonin, Wade Grabow, Luc Jaeger, Mikhail Kashlev, Maria Kireeva, Bruce Shapiro <p>The National Cancer Institute seeks parties interested in collaborative research to co-develop a method to generate RNA molecules suitable for nanoparticle and biomedical applications.</p> <p>The development of nanoparticles as a method of drug delivery is paving the way for precise targeted therapy making it a more attractive and effective method for treating cancer. However, the current methods of designing RNA nanoparticles are limited by three factors: 1) the cost and size limitations associated with chemical synthesis of RNA; 2) the complexity of RNA nanoparticle production; and 3) low retention time of RNA nanoparticles in the patient bloodstream due to their susceptibility to nuclease degradation. </p> <p>NCI scientists have developed a method to overcome these challenges in RNA nanoparticle design. The method entails generating RNA nanoparticles having modified nucleotides and/or having increased nuclease resistance where the RNA nanoparticles are formed co-transcriptionally by T7 RNA polymerase in the presence of manganese ions. In essence, the technology results in high-yield production of chemically modified RNA nanoparticles functionalized with siRNAs that are resistant to nucleases from human blood serum</p> <h2>Competitive Advantages:</h2> <ul><li>Reduces the cost and size limitations of solid-phase RNA synthesis.</li> <li>Simplifies production of complex RNA nanoparticles.</li> <li>Increases retention time of RNA nanoparticles.</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Inexpensive and efficient method of producing chemically modified RNA nanoparticles for diagnostic or therapeutic applications.</li> </ul> 2016-02-16 2025-04-22 2018-06-07 2025-04-22 2016-08-31 Drug Delivery, Nanoparticle, RNA False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2018-06-07 52406768 Discovery 52406768 NCI 37470483 Website Abstract E-039-2012 E-059-2009 147162884 Shapiro, Bruce NIH - NCI NCI Shapiro, Bruce (NCI) 1 147162887 Afonin, Kirill NIH - NCI Afonin, Kirill 2 147162888 Kireeva, Maria NIH - NCI Kireeva, Maria 3 147162885 Kashlev, Mikhail NIH - NCI NCI Kashlev, Mikhail (NCI) 4 147162889 Grabow, Wade University of California, Santa Barbara Grabow, Wade 5 147162886 Jaeger, Luc University of California, Santa Barbara Jaeger, Luc 6 147162884 Shapiro, Bruce NIH - NCI NCI Shapiro, Bruce (NCI) 1 147162887 Afonin, Kirill NIH - NCI Afonin, Kirill 2 147162888 Kireeva, Maria NIH - NCI Kireeva, Maria 3 147162885 Kashlev, Mikhail NIH - NCI NCI Kashlev, Mikhail (NCI) 4 147162889 Grabow, Wade University of California, Santa Barbara Grabow, Wade 5 147162886 Jaeger, Luc University of California, Santa Barbara Jaeger, Luc 6 147158229 Co-Transcriptional Production Of Chemically Modified Functional Therapeutic RNA Nanoparticles E-223-2012-0 Filing authorized NCI, University of California, Santa Barbara 83732917 Favila, Michelle michelle.favila@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC michelle.favila@nih.gov?subject=Web Inquiry on [TAB-3925] Co-Transcriptional Assembly of Modified RNA Nanoparticles&body=Please send me information about technology [TAB-3925] Co-Transcriptional Assembly of Modified RNA Nanoparticles.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Favila, Michelle<br><a href="mailto:michelle.favila@nih.gov?subject=Web Inquiry on [TAB-3925] Co-Transcriptional Assembly of Modified RNA Nanoparticles&body=Please send me information about technology [TAB-3925] Co-Transcriptional Assembly of Modified RNA Nanoparticles.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">michelle.favila@nih.gov</a><br> 147165294 E-223-2012-0 E-223-2012-0-US-01 CO-TRANSCRIPTIONAL ASSEMBLY OF MODIFIED RNA NANOPARTICLES PRV US 61/698,227 Abandoned US <br />Provisional (PRV) 61/698,227<br />Filed on 2012-09-07<br />Status: Abandoned 147165295 E-223-2012-0 E-223-2012-0-PCT-02 Co-Transcriptional Assembly of Modified RNA Nanoparticles PCT Patent Cooperation Treaty PCT/US2013/058492 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2013/058492<br />Filed on 2013-09-06<br />Status: Expired 147165296 E-223-2012-0 E-223-2012-0-US-03 Co-Transcriptional Assembly of Modified RNA Nanoparticles National Stage US 9,719,084 14/426,707 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9719084 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9719084">9,719,084</a><br />Filed on 2015-03-06<br />Status: Issued 147165297 E-223-2012-0 E-223-2012-0-US-04 CO-TRANSCRIPTIONAL ASSEMBLY OF MODIFIED RNA NANOPARTICLES CON US 15/666,326 Abandoned US <br />Continuation (CON) 15/666,326<br />Filed on 2017-08-01<br />Status: Abandoned 147173860 Drug Delivery 147173861 Nanoparticle 147173862 RNA TAB-3917 147157197 T-Cell Therapy Against Patient-Specific Cancer Mutations NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Yong-Chen Lu, Paul Robbins, Steven Rosenberg, Eric Tran <p>Human cancers contain genetic mutations that are unique to each patient. Some of the mutated peptides are immunogenic, can be recognized by T cells, and therefore, may serve as therapeutic targets.</p> <p>Scientists at the National Cancer Institute's <a href="https://ccr.cancer.gov/Surgery-Branch" rel="nofollow">Surgery Branch</a> developed a method to identify T cells that specifically recognize immunogenic mutations expressed only by cancer cells. The scientists identified cancer-specific mutations from a patient with widely metastatic cholangiocarcinoma by sequencing tumor samples and comparing with normal cells. Using tandem minigene constructs encoding all of the mutations expressed by a patient's tumor, the inventors identified T cells that recognized the immunogenic mutations from the same patient. These mutation-reactive T cells have the potential to eliminate the cancer cells while sparing normal tissues since normal tissues do not express the mutations. The mutation-reactive T cells were expanded <em>in vitro</em>, and then infused as a highly pure population back into the same patient. The patient experienced tumor regression when treated with this approach.</p> <h2>Competitive Advantages:</h2> <ul><li>This patient-specific therapy has the potential application to most epithelial cancers, which account for about 90% of cancer deaths in the United States.</li> <li>Personalized mutation-specific T cells recognize mutations harboring tumor cells only and spare normal tissues. This therapy has no tissue toxicities comparing to traditional chemotherapy and radiotherapy. </li> <li>The infusion of a highly pure population of these mutation-specific T cells may maximize therapy and result in regression of all target lesions.</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Personalized immunotherapy with mutation-reactive T cells for mediating tumor regression in patients with immunogenic mutations.</li> <li>Mutation-reactive T cell therapy especially beneficial for cancer patients refractory to other therapies.</li> <li>A research tool to identify patient-specific immunogenic mutations in the tumor.</li> </ul> 2016-02-16 2025-04-22 2020-10-19 2025-04-22 2019-11-19 Cholangiocarcinoma, Immunogenic, T cell, T-cell False True Clinical True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-10-19 72159138 Clinical Phase I 72159138 NCI 37470483 Website Abstract 147162050 Robbins P, et al. http://www.ncbi.nlm.nih.gov/pubmed/23644516 <a href="http://www.ncbi.nlm.nih.gov/pubmed/23644516">Robbins P, et al.</a> 147162089 Tran E, et al. http://www.ncbi.nlm.nih.gov/pubmed/25046408 <a href="http://www.ncbi.nlm.nih.gov/pubmed/25046408">Tran E, et al.</a> 147162206 Tran E, et al. http://www.ncbi.nlm.nih.gov/pubmed/24812403 <a href="http://www.ncbi.nlm.nih.gov/pubmed/24812403">Tran E, et al.</a> 147162861 Tran, Eric NIH - NCI Tran, Eric 1 147162860 Robbins, Paul NIH - NCI NCI Robbins, Paul (NCI) 2 147162862 Lu, Yong-Chen NIH - NCI NCI Lu, Yong-Chen (NCI) 3 147162859 Rosenberg, Steven NIH - NCI NCI Rosenberg, Steven (NCI) 4 147162861 Tran, Eric NIH - NCI Tran, Eric 1 147162860 Robbins, Paul NIH - NCI NCI Robbins, Paul (NCI) 2 147162862 Lu, Yong-Chen NIH - NCI NCI Lu, Yong-Chen (NCI) 3 147162859 Rosenberg, Steven NIH - NCI NCI Rosenberg, Steven (NCI) 4 147158248 Genomics-based Approach For Developing Personalized T-Cell Receptor (TCR) Gene Engineered T Cells Targeting Tumor-specific Mutations For Use In Adoptive Cell Therapies To Treat Cancer E-233-2014-0 Filing authorized NCI 83709866 Burke, Andrew burkear@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC burkear@nih.gov?subject=Web Inquiry on [TAB-3917] T-Cell Therapy Against Patient-Specific Cancer Mutations&body=Please send me information about technology [TAB-3917] T-Cell Therapy Against Patient-Specific Cancer Mutations.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Burke, Andrew<br><a href="mailto:burkear@nih.gov?subject=Web Inquiry on [TAB-3917] T-Cell Therapy Against Patient-Specific Cancer Mutations&body=Please send me information about technology [TAB-3917] T-Cell Therapy Against Patient-Specific Cancer Mutations.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">burkear@nih.gov</a><br> 147161215 E-233-2014-0 E-233-2014-0-PCT-01 Methods of Isolating T Cell Receptors Having Antigenic Specificity for a Cancer-Specific Mutation PCT Patent Cooperation Treaty PCT/US2014/058796 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2014/058796<br />Filed on 2014-10-02<br />Status: Expired 147165230 E-233-2014-0 E-233-2014-0-AU-02 Methods of Isolating T Cell Receptors Having Antigenic Specificity for a Cancer-Specific Mutation National Stage Australia 2014407539 2014407539 Issued Australia <br />National Stage 2014407539<br />Filed on 2014-10-02<br />Status: Issued 147165231 E-233-2014-0 E-233-2014-0-CA-03 Methods of Isolating T Cell Receptors Having Antigenic Specificity for a Cancer-Specific Mutation National Stage Canada 2963362 Pending Canada <br />National Stage 2963362<br />Filed on 2017-03-31<br />Status: Pending 147165232 E-233-2014-0 E-233-2014-0-CN-04 Methods of Isolating T Cell Receptors Having Antigenic Specificity for a Cancer-Specific Mutation National Stage China 201480082932.3 Abandoned China <br />National Stage 201480082932.3<br />Filed on 2014-10-02<br />Status: Abandoned 147165233 E-233-2014-0 E-233-2014-0-EP-05 Methods of Isolating T Cell Receptors Having Antigenic Specificity for a Cancer-Specific Mutation National Stage European Patent 3200818 14796317.7 Issued European Patent <br />National Stage 14796317.7<br />Filed on 2014-10-02<br />Status: Issued 147165234 E-233-2014-0 E-233-2014-0-JP-06 Methods of Isolating T Cell Receptors Having Antigenic Specificity for a Cancer-Specific Mutation National Stage Japan 6686008 2017-517662 Issued Japan <br />National Stage 2017-517662<br />Filed on 2014-10-02<br />Status: Issued 147165235 E-233-2014-0 E-233-2014-0-US-07 METHODS OF ISOLATING T CELL RECEPTORS HAVING ANTIGENIC SPECIFICITY FOR A CANCER-SPECIFIC MUTATION National Stage US 15/514,942 Abandoned US <br />National Stage 15/514,942<br />Filed on 2017-03-28<br />Status: Abandoned 147165236 E-233-2014-0 E-233-2014-0-JP-08 METHODS FOR ISOLATING T CELL RECEPTORS HAVING ANTIGEN SPECIFICITY TO CANCER SPECIFIC MUTATIONS DIV Japan 2020-066108 Abandoned Japan <br />Divisional (DIV) 2020-066108<br />Filed on 2020-04-01<br />Status: Abandoned 147165237 E-233-2014-0 E-233-2014-0-AU-09 Methods of isolating T cell receptors having antigenic specificity for a cancer specific mutation DIV Australia 2021200388 2021200388 Issued Australia <br />Divisional (DIV) 2021200388<br />Filed on 2021-01-21<br />Status: Issued 147165238 E-233-2014-0 E-233-2014-0-EP-10 Methods of Isolating T Cell Receptors Having Antigenic Specificity for a Cancer-Specific Mutation DIV European Patent 22166152.3 Pending European Patent <br />Divisional (DIV) 22166152.3<br />Filed on 2022-03-31<br />Status: Pending 147165239 E-233-2014-0 E-233-2014-0-JP-11 METHODS FOR ISOLATING T CELL RECEPTORS HAVING ANTIGEN SPECIFICITY TO CANCER SPECIFIC MUTATIONS DIV Japan 7437444 2022-077983 Issued Japan <br />Divisional (DIV) 2022-077983<br />Filed on 2022-05-11<br />Status: Issued 147165240 E-233-2014-0 E-233-2014-0-BE-12 Methods of Isolating T Cell Receptors Having Antigenic Specificity for a Cancer-Specific Mutation EP Belgium 3 200 818 14796317.7 Issued Belgium <br />European patent (EP) 14796317.7<br />Filed on 2014-10-02<br />Status: Issued 147165241 E-233-2014-0 E-233-2014-0-DK-13 Methods of Isolating T Cell Receptors Having Antigenic Specificity for a Cancer-Specific Mutation EP Denmark 3 200 818 14796317.7 Issued Denmark <br />European patent (EP) 14796317.7<br />Filed on 2014-10-02<br />Status: Issued 147165242 E-233-2014-0 E-233-2014-0-FR-14 Methods of Isolating T Cell Receptors Having Antigenic Specificity for a Cancer-Specific Mutation EP France 3 200 818 14796317.7 Issued France <br />European patent (EP) 14796317.7<br />Filed on 2014-10-02<br />Status: Issued 147165243 E-233-2014-0 E-233-2014-0-DE-15 Methods of Isolating T Cell Receptors Having Antigenic Specificity for a Cancer-Specific Mutation EP Germany 3 200 818 14796317.7 Issued Germany <br />European patent (EP) 14796317.7<br />Filed on 2014-10-02<br />Status: Issued 147165244 E-233-2014-0 E-233-2014-0-IT-16 Methods of Isolating T Cell Receptors Having Antigenic Specificity for a Cancer-Specific Mutation EP Italy 3 200 818 14796317.7 Issued Italy <br />European patent (EP) 14796317.7<br />Filed on 2014-10-02<br />Status: Issued 147165245 E-233-2014-0 E-233-2014-0-NL-17 Methods of Isolating T Cell Receptors Having Antigenic Specificity for a Cancer-Specific Mutation EP The Netherlands 3 200 818 14796317.7 Issued The Netherlands <br />European patent (EP) 14796317.7<br />Filed on 2014-10-02<br />Status: Issued 147165246 E-233-2014-0 E-233-2014-0-NO-18 Methods of Isolating T Cell Receptors Having Antigenic Specificity for a Cancer-Specific Mutation EP Norway 3 200 818 14796317.7 Issued Norway <br />European patent (EP) 14796317.7<br />Filed on 2014-10-02<br />Status: Issued 147165247 E-233-2014-0 E-233-2014-0-ES-19 Methods of Isolating T Cell Receptors Having Antigenic Specificity for a Cancer-Specific Mutation EP Spain 3 200 818 14796317.7 Issued Spain <br />European patent (EP) 14796317.7<br />Filed on 2014-10-02<br />Status: Issued 147165248 E-233-2014-0 E-233-2014-0-SE-20 Methods of Isolating T Cell Receptors Having Antigenic Specificity for a Cancer-Specific Mutation EP Sweden 3 200 818 14796317.7 Issued Sweden <br />European patent (EP) 14796317.7<br />Filed on 2014-10-02<br />Status: Issued 147165249 E-233-2014-0 E-233-2014-0-CH-21 Methods of Isolating T Cell Receptors Having Antigenic Specificity for a Cancer-Specific Mutation EP Switzerland 3 200 818 14796317.7 Issued Switzerland <br />European patent (EP) 14796317.7<br />Filed on 2014-10-02<br />Status: Issued 147165250 E-233-2014-0 E-233-2014-0-GB-22 Methods of Isolating T Cell Receptors Having Antigenic Specificity for a Cancer-Specific Mutation EP United Kingdom 3 200 818 14796317.7 Issued United Kingdom <br />European patent (EP) 14796317.7<br />Filed on 2014-10-02<br />Status: Issued 147165251 E-233-2014-0 E-233-2014-0-US-23 METHODS OF ISOLATING T CELL RECEPTORS HAVING ANTIGENIC SPECIFICITY FOR A CANCER-SPECIFIC MUTATION DIV US 18/147,786 Pending US <br />Divisional (DIV) 18/147,786<br />Filed on 2022-12-29<br />Status: Pending 147174043 Cholangiocarcinoma 147174044 Immunogenic 147174045 T cell 147174046 T-cell TAB-3905 147157185 Transgenic Mouse Model of Human Basal Triple Negative Breast Cancer NCI Licensing, Oncology, Research Materials Licensing Oncology Research Materials Jeffrey Green <p>The NCI Laboratory of Cancer Biology and Genetics seeks parties interested in collaborative research to further develop this mouse model of triple-negative breast cancer (TNBC) to study cancer biology and for preclinical testing.  As a Research Tool, patent protection is not being pursued for this technology; more information to access this strain can be found here: <a href="https://www.jax.org/strain/030386" rel="nofollow">https://www.jax.org/strain/030386</a>.</p> <p> Basal triple-negative breast cancer (TNBC) is a common form of human breast cancer for which there are no specific, targeted therapies, unlike hormone-responsive or Her2+ breast cancers. TNBC has a much worse prognosis than hormone receptor + cancer and is disproportionately high in the African-American population. NIH scientists have created and characterized a transgenic model that is currently an excellent mouse model for TNBC that shares important molecular characteristics of human TNBC making it highly useful for preclinical testing of drugs and novel therapies. This model may provide a valuable means of identifying new drugs and therapies that could be translated to human clinical trials. The mouse model also develops prostate intraepithelial neoplasia and prostate cancer, therefore has also been used for studies of prostate cancer.</p> <h2>Competitive Advantages:</h2> <ul><li>Shares important molecular characteristics of human TNBC making it highly useful for preclinical testing of drugs and novel therapies</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Mouse model for pre-clinical validations</li> </ul> 2016-02-16 2025-04-22 2018-12-14 2025-04-22 2016-08-29 Mouse, Murine, PROSTATE, triple-negative breast cancer False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2018-12-14 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147162814 Green, Jeffrey NIH - NCI NCI Green, Jeffrey (NCI) 1 147162814 Green, Jeffrey NIH - NCI NCI Green, Jeffrey (NCI) 1 147158180 Development Of A Transgenic Model Of Human Basal Triple Negative Breast Cancer [C3(1)-tag Mice] E-191-2010-0 Research Material NCI 121111111 Greene, Jaime greenejaime@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America greenejaime@mail.nih.gov?subject=Web Inquiry on [TAB-3905] Transgenic Mouse Model of Human Basal Triple Negative Breast Cancer&body=Please send me information about technology [TAB-3905] Transgenic Mouse Model of Human Basal Triple Negative Breast Cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Greene, Jaime<br><a href="mailto:greenejaime@mail.nih.gov?subject=Web Inquiry on [TAB-3905] Transgenic Mouse Model of Human Basal Triple Negative Breast Cancer&body=Please send me information about technology [TAB-3905] Transgenic Mouse Model of Human Basal Triple Negative Breast Cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">greenejaime@mail.nih.gov</a><br> 147173370 Mouse 147173371 Murine 147173372 PROSTATE 147173374 triple-negative breast cancer TAB-3902 147157182 Method and Device for Selectively Labeling RNA NCI Diagnostics, Licensing, Oncology Diagnostics Licensing Oncology Rui Sousa, Yun-Xing Wang, Liu Yu <p>Current methods of labeling and synthesizing RNA do not allow for multiple labels or long RNA segments to be synthesized for large RNA on a milligram scale.</p> <p>Investigators at the NCI <a href="https://ccr.cancer.gov/Structural-Biophysics-Laboratory" rel="nofollow">Structure Biophysics Lab</a> and UT Health Science Center have developed a method to selectively label RNA at specific residues and/or segments using a hybrid solid-liquid phase enzymatic method.  Moreover, they have developed an automated robotic platform capable of performing this method.  The invention overcomes the limitations of current methods of synthesizing and labeling RNA by allowing synthesis of longer RNAs (&gt;60 nt), labeling uniformity, and labeling by multiple base types on milligram scales. </p> <p>The inventors have demonstrated its utility by producing a 71-nucleotides aptamer labeled with a fluorophore attached or isotope ribonucleotides for use in smRET and NMR spectroscopy, respectively.  They also demonstrated the method for synthesis of milligrams of selectively isotope-selectively labeled 103-nt RNA.   In principle the method can be used for synthesis of even longer RNA because of the excellent processibility of the enzyme. </p> <h2>Competitive Advantages:</h2> <ul><li>Uniform, potentially automated production of long labeled RNAs in milligram quantities</li> <li>Specific segments or discrete residues within the RNA can be selectively labeled</li> <li>Different labels can be made in different segments</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Region/position-specific isotope and fluorophore labeling of RNA greatly simplifying interpretation of NMR spectroscopy, enhanced applicability/capability of smFRET, and solving the phase problem in X-ray crystallography</li> <li>Therapeutic and molecular sensor</li> <li>Molecular marker/tracer</li> <li>RNA-aptamer-based detection of substances</li> </ul> 2016-02-16 2025-04-22 2021-01-27 2025-04-22 2015-04-14 crystallography, Fluorophore labeling, FRET, Isotope labeling, Labeling sensor, NMR Spectroscopy False True Prototype True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2021-01-27 52406769 Prototype 52406769 NCI 37470483 Website Abstract 147162804 Wang, Yun-Xing NIH - NCI NCI Wang, Yun-Xing (NCI) 1 147162805 Yu, Liu NCI - CCR NCI Yu, Liu (NCI) 2 147162806 Sousa, Rui University of Texas Health Science Center at San Antonio Sousa, Rui 3 147162804 Wang, Yun-Xing NIH - NCI NCI Wang, Yun-Xing (NCI) 1 147162805 Yu, Liu NCI - CCR NCI Yu, Liu (NCI) 2 147162806 Sousa, Rui University of Texas Health Science Center at San Antonio Sousa, Rui 3 147158026 A Technology And Prototype Of An Automated Instrument For The Synthesis Of Selectively Labeled RNA At Specific Residue(s) And/or Specific Segment(s) E-119-2013-0 Filing authorized NCI, University of Texas Health Science Center at San Antonio 83704821 Nguyen-Antczak, Lauren lauren.nguyen-antczak@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-3902] Method and Device for Selectively Labeling RNA&body=Please send me information about technology [TAB-3902] Method and Device for Selectively Labeling RNA.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Nguyen-Antczak, Lauren<br><a href="mailto:lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-3902] Method and Device for Selectively Labeling RNA&body=Please send me information about technology [TAB-3902] Method and Device for Selectively Labeling RNA.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">lauren.nguyen-antczak@nih.gov</a><br> 147165141 E-119-2013-0 E-119-2013-0-US-01 Method for Synthesizing Selectively Labeled RNA PRV US 61/843,864 Abandoned US <br />Provisional (PRV) 61/843,864<br />Filed on 2013-07-08<br />Status: Abandoned 147165142 E-119-2013-0 E-119-2013-0-PCT-02 Method for Synthesizing Selectively Labeled RNA PCT Patent Cooperation Treaty PCT/US2014/045784 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2014/045784<br />Filed on 2014-07-08<br />Status: Expired 147165143 E-119-2013-0 E-119-2013-0-US-03 Method for Synthesizing Selectively Labeled RNA National Stage US 10,190,143 14/903,738 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10190143 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10190143">10,190,143</a><br />Filed on 2016-01-08<br />Status: Issued 147165144 E-119-2013-0 E-119-2013-0-US-04 METHOD FOR SYNTHESIZING SELECTIVELY LABELED RNA CON US 11,041,182 16/258,021 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11041182 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11041182">11,041,182</a><br />Filed on 2019-01-25<br />Status: Issued 147171826 crystallography 147171828 Fluorophore labeling 147171829 FRET 147171831 Isotope labeling 147171833 Labeling sensor 147171835 NMR Spectroscopy TAB-3894 147157174 Immunocompetent Mouse Model for Tracking Cancer Progression NCI Licensing, Oncology, Research Materials Licensing Oncology Research Materials Chi-Ping Day, Glenn Merlino, Lalage Wakefield <p>The National Cancer Institute seeks interested parties to co-develop transgenic mice having immunocompetent rat growth hormone-firefly Luciferase-enhanced green fluorescent protein.</p> <p>The technology is a transgenic mouse model tolerized to firefly Luciferase (ffLuc)- and enhanced green fluorescent protein (eGFP)-labeled tissue whilst maintaining normal immune function. Luc and eGFP are the most frequently used bioimaging markers to track cancer progression in pre-clinical mouse models. As these markers are immunogenic, their reporter activity becomes diminished over time and so their use has largely been limited to immunodeficient mice. However, immune function is crucial for tumor development and progression, making the use of immunocompetent mice more desirable.</p> <p>The immunocompetent mouse model described in this invention was generated using the rat growth hormone gene promoter (rGH) to target ffLuc-eGFP fusion gene expression to the pituitary gland, restricting any resulting interfering reporter signal within the head. This allows the tracking of cancer progression throughout the body, where the reporter activity of introduced ffLuc/eGFP-labeled tumors is maintained, despite normal immune function. These immunocompetent rGH-ffLuc-eGFP transgenic mice can be used as hosts in cancer models, allowing long-term in vivo monitoring of the progression of ffLuc/eGFP-labeled tumor cells in the body, which may lead to more clinically relevant insights into cancer progression, metastases and response to therapies.</p> <h2>Competitive Advantages:</h2> <ul><li>A more clinically relevant in vivo model of cancer progression for testing anti-cancer therapeutics</li> <li>A novel pre-clinical immunodeficient mouse model that better tracks tumor development and progression.</li> </ul> <h2>Commercial Applications:</h2> <ul><li>In vivo model for studying tumor progression and testing anti-cancer therapeutics using ffLuc or eGFP labeling for bioimaging</li> <li>Used to screen growth-hormone stimulating drugs for treating Achondroplasia (dwarf syndrome) or as a test for illegal performance-enhancing drugs</li> </ul> 2016-02-16 2025-04-22 2018-06-18 2025-04-22 2016-08-24 Achondroplasia, Bioimaging, Immunocompetent, Rat growth hormone False True Prototype True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2018-06-18 52406769 Prototype 52406769 NCI 37470483 Website Abstract 147162083 C.P. Day, et al. Preclinical therapeutic response of residual metastatic disease is distinct from its primary tumor of origin. https://www.ncbi.nlm.nih.gov/pubmed/21312195 <a href="https://www.ncbi.nlm.nih.gov/pubmed/21312195">C.P. Day, et al. Preclinical therapeutic response of residual metastatic disease is distinct from its primary tumor of origin.</a> 147162775 Merlino, Glenn NIH - NCI NCI Merlino, Glenn (NCI) 1 147162776 Day, Chi-Ping NIH - NCI NCI Day, Chi-Ping (NCI) 2 147162777 Wakefield, Lalage NIH - NCI NCI Wakefield, Lalage (NCI) 3 147162775 Merlino, Glenn NIH - NCI NCI Merlino, Glenn (NCI) 1 147162776 Day, Chi-Ping NIH - NCI NCI Day, Chi-Ping (NCI) 2 147162777 Wakefield, Lalage NIH - NCI NCI Wakefield, Lalage (NCI) 3 147158142 A Bioimaging Marker-tolerant Mouse Allowing Consistent Tumor Labeling And Monitoring In An Immunocompetent Mouse Model (C57BL/6) - (Glowing Head Mice) E-173-2010-0 Research Material NCI 147162547 A Bioimaging Marker-tolerant Mouse Allowing Consistent Tumor Labeling And Monitoring In An Immunocompetent Mouse Model (Balb/c) - (Glowing Head Mice) E-173-2010-1 Research Material NCI 121111111 Greene, Jaime greenejaime@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America greenejaime@mail.nih.gov?subject=Web Inquiry on [TAB-3894] Immunocompetent Mouse Model for Tracking Cancer Progression&body=Please send me information about technology [TAB-3894] Immunocompetent Mouse Model for Tracking Cancer Progression.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Greene, Jaime<br><a href="mailto:greenejaime@mail.nih.gov?subject=Web Inquiry on [TAB-3894] Immunocompetent Mouse Model for Tracking Cancer Progression&body=Please send me information about technology [TAB-3894] Immunocompetent Mouse Model for Tracking Cancer Progression.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">greenejaime@mail.nih.gov</a><br> 147172989 Achondroplasia 147172990 Bioimaging 147172991 Immunocompetent 147172993 Rat growth hormone TAB-3868 147157147 Therapeutic Management of Menkes Disease and Related Copper Transport Disorders NICHD Licensing, Neurology, Therapeutics Licensing Neurology Therapeutics Stephen Kaler <p>The only currently available treatment for Menkes disease, subcutaneous copper histidinate injections, is successful only in patients with ATP7A gene mutations that do not completely corrupt ATP7A copper transport function (estimated 20-25% of affected patients) and when started at a very early age (first month of life). The combination of viral gene therapy with copper injections provides working copies of the ATP7A copper transporter into the brain, together with a source of the substrate (copper)  needed for proper brain growth and clinical neurodevelopment.</p> <p>Codon-optimized nucleic acids encoding a reduced-size ATP7A protein and compositions of AAV vectors were discovered by NICHD researchers  along with methods of administering this therapy. Human P-type ATPase copper-transporting ATPase 1 (ATP7A) transports copper from enterocytes (where it is taken up from dietary copper) into the blood. ATP7A also mediates passage of copper across the blood-cerebrospinal fluid (CSF) barrier and the blood-brain barrier. In Menkes disease and occipital horn syndrome (OHS), copper accumulates in intestinal cells and less copper is absorbed into the blood, resulting in restricted copper supply to other tissues, particularly the brain. Death in infancy or early childhood is a common consequence. Therapeutic delivery of the copper transport protein via an AAV vector, combined with subcutaneous copper histidinate treatment will relieve the copper deficiency to the brain and permit normal neurological development and function.   </p> <h2>Competitive Advantages:</h2> <p>Provides working copies of the ATP7A copper transporter into the brain, together with a source of the substrate (copper)  needed for proper brain growth and clinical neurodevelopment. </p> <h2>Commercial Applications:</h2> <p>- Treatment of Menkes Disease, Occipital Horn Syndrome, and of ATP7A-related distal motor neuropathy</p> 2016-02-16 2025-04-22 2021-01-26 2025-04-22 2016-08-30 occipital horn syndrome False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2021-01-26 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147162671 Kaler, Stephen NIH - NICHD NICHD Kaler, Stephen (NICHD) 1 147162671 Kaler, Stephen NIH - NICHD NICHD Kaler, Stephen (NICHD) 1 147157900 Codon-optimized Reduced-size ATP7A Complementary DNA For Treatment Of Menkes Disease And Related Copper Transport Disorders E-062-2015-0 Filing authorized NICHD 91789173 Guyton, Nicole darackn@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America darackn@mail.nih.gov?subject=Web Inquiry on [TAB-3868] Therapeutic Management of Menkes Disease and Related Copper Transport Disorders&body=Please send me information about technology [TAB-3868] Therapeutic Management of Menkes Disease and Related Copper Transport Disorders.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Guyton, Nicole<br><a href="mailto:darackn@mail.nih.gov?subject=Web Inquiry on [TAB-3868] Therapeutic Management of Menkes Disease and Related Copper Transport Disorders&body=Please send me information about technology [TAB-3868] Therapeutic Management of Menkes Disease and Related Copper Transport Disorders.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">darackn@mail.nih.gov</a><br> 147164892 E-062-2015-0 E-062-2015-0-US-01 Codon-optimized Reduced-size ATP7A CDNA and Uses for Treatment of Copper Transport Disorders PRV US 62/244,594 Abandoned US <br />Provisional (PRV) 62/244,594<br />Filed on 2015-10-21<br />Status: Abandoned 147164893 E-062-2015-0 E-062-2015-0-PCT-02 CODON-OPTIMIZED REDUCED-SIZE ATP7A CDNA AND USES FOR TREATMENT OF COPPER TRANSPORT DISORDERS PCT Patent Cooperation Treaty PCT/US2016/058124 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2016/058124<br />Filed on 2016-10-21<br />Status: Expired 147164894 E-062-2015-0 E-062-2015-0-US-03 Codon-optimized Reduced-size ATP7A Complementary DNA And Uses for Treatment of Copper Transport Disorders National Stage US 10,988,778 15/769,294 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10988778 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10988778">10,988,778</a><br />Filed on 2018-04-18<br />Status: Issued 147164895 E-062-2015-0 E-062-2015-0-EP-04 CODON-OPTIMIZED REDUCED-SIZE ATP7A CDNA AND USES FOR TREATMENT OF COPPER TRANSPORT DISORDERS National Stage European Patent 3365438 16794111.1 Issued European Patent <br />National Stage 16794111.1<br />Filed on 2016-10-21<br />Status: Issued 147164896 E-062-2015-0 E-062-2015-0-AU-05 CODON-OPTIMIZED REDUCED-SIZE ATP7A CDNA AND USES FOR TREATMENT OF COPPER TRANSPORT DISORDERS National Stage Australia 2016341983 2016341983 Issued Australia <br />National Stage 2016341983<br />Filed on 2016-10-21<br />Status: Issued 147164897 E-062-2015-0 E-062-2015-0-CA-06 CODON-OPTIMIZED REDUCED-SIZE ATP7A CDNA AND USES FOR TREATMENT OF COPPER TRANSPORT DISORDERS National Stage Canada 3001574 3001574 Issued Canada <br />National Stage 3001574<br />Filed on 2016-10-21<br />Status: Issued 147164898 E-062-2015-0 E-062-2015-0-CN-07 CODON-OPTIMIZED REDUCED-SIZE ATP7A CDNA AND USES FOR TREATMENT OF COPPER TRANSPORT DISORDERS National Stage China ZL201680074686.6 201680074686.6 Issued China <br />National Stage 201680074686.6<br />Filed on 2018-06-20<br />Status: Issued 147164899 E-062-2015-0 E-062-2015-0-JP-08 CODON-OPTIMIZED REDUCED-SIZE ATP7A CDNA AND USES FOR TREATMENT OF COPPER TRANSPORT DISORDERS National Stage Japan 6854286 2018-520100 Issued Japan <br />National Stage 2018-520100<br />Filed on 2016-10-21<br />Status: Issued 147164900 E-062-2015-0 E-062-2015-0-JP-09 CODON-OPTIMIZED REDUCED-SIZE ATP7A CDNA AND USES FOR TREATMENT OF COPPER TRANSPORT DISORDERSRFQ KS-BIO-0766-19 DIV Japan 2020-218556 Abandoned Japan <br />Divisional (DIV) 2020-218556<br />Filed on 2016-10-21<br />Status: Abandoned 147164902 E-062-2015-0 E-062-2015-0-US-11 CODON-OPTIMIZED REDUCED-SIZE ATP7A CDNA AND USES FOR TREATMENT OF COPPER TRANSPORT DISORDERS DIV US 12,173,306 17/217,961 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12173306 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12173306">12,173,306</a><br />Filed on 2021-03-30<br />Status: Issued 147164903 E-062-2015-0 E-062-2015-0-AT-12 CODON-OPTIMIZED REDUCED-SIZE ATP7A CDNA AND USES FOR TREATMENT OF COPPER TRANSPORT DISORDERS EP Austria 3365438 16794111.1 Issued Austria <br />European patent (EP) 16794111.1<br />Filed on 2016-10-21<br />Status: Issued 147164904 E-062-2015-0 E-062-2015-0-BE-13 CODON-OPTIMIZED REDUCED-SIZE ATP7A CDNA AND USES FOR TREATMENT OF COPPER TRANSPORT DISORDERS EP Belgium 3365438 16794111.1 Issued Belgium <br />European patent (EP) 16794111.1<br />Filed on 2016-10-21<br />Status: Issued 147164905 E-062-2015-0 E-062-2015-0-CH-14 CODON-OPTIMIZED REDUCED-SIZE ATP7A CDNA AND USES FOR TREATMENT OF COPPER TRANSPORT DISORDERS EP Switzerland 3365438 16794111.1 Issued Switzerland <br />European patent (EP) 16794111.1<br />Filed on 2016-10-21<br />Status: Issued 147164906 E-062-2015-0 E-062-2015-0-CZ-15 CODON-OPTIMIZED REDUCED-SIZE ATP7A CDNA AND USES FOR TREATMENT OF COPPER TRANSPORT DISORDERS EP Czech Republic 3365438 16794111.1 Issued Czech Republic <br />European patent (EP) 16794111.1<br />Filed on 2016-10-21<br />Status: Issued 147164907 E-062-2015-0 E-062-2015-0-DE-16 CODON-OPTIMIZED REDUCED-SIZE ATP7A CDNA AND USES FOR TREATMENT OF COPPER TRANSPORT DISORDERS EP Germany 3365438 16794111.1 Issued Germany <br />European patent (EP) 16794111.1<br />Filed on 2016-10-21<br />Status: Issued 147164908 E-062-2015-0 E-062-2015-0-DK-17 CODON-OPTIMIZED REDUCED-SIZE ATP7A CDNA AND USES FOR TREATMENT OF COPPER TRANSPORT DISORDERS EP Denmark 3365438 16794111.1 Issued Denmark <br />European patent (EP) 16794111.1<br />Filed on 2016-10-21<br />Status: Issued 147164909 E-062-2015-0 E-062-2015-0-ES-18 CODON-OPTIMIZED REDUCED-SIZE ATP7A CDNA AND USES FOR TREATMENT OF COPPER TRANSPORT DISORDERS EP Spain 3365438 16794111.1 Issued Spain <br />European patent (EP) 16794111.1<br />Filed on 2016-10-21<br />Status: Issued 147164910 E-062-2015-0 E-062-2015-0-FR-19 CODON-OPTIMIZED REDUCED-SIZE ATP7A CDNA AND USES FOR TREATMENT OF COPPER TRANSPORT DISORDERS EP France 3365438 16794111.1 Issued France <br />European patent (EP) 16794111.1<br />Filed on 2016-10-21<br />Status: Issued 147164911 E-062-2015-0 E-062-2015-0-GB-20 CODON-OPTIMIZED REDUCED-SIZE ATP7A CDNA AND USES FOR TREATMENT OF COPPER TRANSPORT DISORDERS EP United Kingdom 3365438 16794111.1 Issued United Kingdom <br />European patent (EP) 16794111.1<br />Filed on 2016-10-21<br />Status: Issued 147164912 E-062-2015-0 E-062-2015-0-HU-21 CODON-OPTIMIZED REDUCED-SIZE ATP7A CDNA AND USES FOR TREATMENT OF COPPER TRANSPORT DISORDERS EP Hungary 3365438 16794111.1 Issued Hungary <br />European patent (EP) 16794111.1<br />Filed on 2016-10-21<br />Status: Issued 147164913 E-062-2015-0 E-062-2015-0-IE-22 CODON-OPTIMIZED REDUCED-SIZE ATP7A CDNA AND USES FOR TREATMENT OF COPPER TRANSPORT DISORDERS EP Ireland 3365438 16794111.1 Issued Ireland <br />European patent (EP) 16794111.1<br />Filed on 2016-10-21<br />Status: Issued 147164914 E-062-2015-0 E-062-2015-0-IT-23 CODON-OPTIMIZED REDUCED-SIZE ATP7A CDNA AND USES FOR TREATMENT OF COPPER TRANSPORT DISORDERS EP Italy 3365438 16794111.1 Issued Italy <br />European patent (EP) 16794111.1<br />Filed on 2016-10-21<br />Status: Issued 147164915 E-062-2015-0 E-062-2015-0-NL-24 CODON-OPTIMIZED REDUCED-SIZE ATP7A CDNA AND USES FOR TREATMENT OF COPPER TRANSPORT DISORDERS EP The Netherlands 3365438 16794111.1 Issued The Netherlands <br />European patent (EP) 16794111.1<br />Filed on 2016-10-21<br />Status: Issued 147164916 E-062-2015-0 E-062-2015-0-NO-25 CODON-OPTIMIZED REDUCED-SIZE ATP7A CDNA AND USES FOR TREATMENT OF COPPER TRANSPORT DISORDERS EP Norway 3365438 16794111.1 Issued Norway <br />European patent (EP) 16794111.1<br />Filed on 2016-10-21<br />Status: Issued 147164917 E-062-2015-0 E-062-2015-0-PL-26 CODON-OPTIMIZED REDUCED-SIZE ATP7A CDNA AND USES FOR TREATMENT OF COPPER TRANSPORT DISORDERS EP Poland 3365438 16794111.1 Issued Poland <br />European patent (EP) 16794111.1<br />Filed on 2016-10-21<br />Status: Issued 147164918 E-062-2015-0 E-062-2015-0-PT-27 CODON-OPTIMIZED REDUCED-SIZE ATP7A CDNA AND USES FOR TREATMENT OF COPPER TRANSPORT DISORDERS EP Portugal 3365438 16794111.1 Issued Portugal <br />European patent (EP) 16794111.1<br />Filed on 2016-10-21<br />Status: Issued 147164919 E-062-2015-0 E-062-2015-0-SE-28 CODON-OPTIMIZED REDUCED-SIZE ATP7A CDNA AND USES FOR TREATMENT OF COPPER TRANSPORT DISORDERS EP Sweden 3365438 16794111.1 Issued Sweden <br />European patent (EP) 16794111.1<br />Filed on 2016-10-21<br />Status: Issued 147164920 E-062-2015-0 E-062-2015-0-TR-29 CODON-OPTIMIZED REDUCED-SIZE ATP7A CDNA AND USES FOR TREATMENT OF COPPER TRANSPORT DISORDERS EP Turkey 3365438 16794111.1 Issued Turkey <br />European patent (EP) 16794111.1<br />Filed on 2016-10-21<br />Status: Issued 147170565 occipital horn syndrome TAB-3871 147157151 Radiographic Marker for Portable Chest and Abdominal X-Rays CC Diagnostics, Licensing Diagnostics Licensing Les Folio, Lucas Folio <p>The <a href="http://clinicalcenter.nih.gov/" rel="nofollow">NIH Clinical Center</a> seeks parties interested to license a method and apparatus that can significantly improve the diagnostic performance of portable chest (CXR) and abdominal x-rays.&nbsp; This device (see image below)&nbsp;quantifies angulation of a patient to provide for a better comparison of day-to-day improvement. Potential applications include portable chest and abdominal x-rays performed at patient&#39;s hospital bedside.</p> <p>Development Status:</p> <ul> <li>A performance of a visual prototype was demonstrated. The visual prototype was imaged at 5 selected angles with a chest phantom. Initial in-vitro results demonstrate that angles can be quantified to within 30 degrees.</li> <li>Improved prototypes with more accuracy are currently being manufactured for patient use. In-vivo studies will soon be underway to validate clinical utility.</li> </ul> <p><img alt=" An x-ray marker that attaches to an x-ray cassette and can indicate that the angular position of a patient receiving a bed-side chest x-ray. The device has a curved configuration with a channel containing a bead that tracks the patient’s bed’s incline angle and shows up on the x-ray film. " height="475" src="https://nih.technologypublisher.com/files/sites/e-063-2011_image_a_radiographic_marker_that_displays_upright_angle_in_degrees_on_portable_x-rays3.png" width="610" /></p> <h2>Competitive Advantages:</h2> <ul> <li>Currently, there is no quantitative marker to indicate degree of the upright position. This technology introduces a simple dynamic marker that can quantify the angle at a glance for the radiologist to best compare patient condition over time.</li> <li>The technology improves performance of CXR, allowing reliable comparisons of patient conditions over time. Thus, better therapies can be planned and unnecessary CT (Computerized Tomography) can be prevented.</li> <li>The technology improves care for Intensive Care Unit patients, as developing effusion and the need for immediate drainage (as one of many examples) can be more effectively assessed with the apparatus.</li> </ul> <h2>Commercial Applications:</h2> <ul> <li>Portable chest and abdominal x-rays</li> </ul> 2016-02-16 2025-04-22 2018-07-19 2025-04-22 2016-08-29 Abdominal x-ray., Chest x-ray, IMAGING, RADIOGRAPHY False True Prototype True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2018-07-19 52406769 Prototype 52406769 NCI 37470483 Website Abstract 147162223 I. Pneumatikos et al. Pleural effusions in critically ill patients. https://www.ncbi.nlm.nih.gov/pubmed/18824883 <a href="https://www.ncbi.nlm.nih.gov/pubmed/18824883">I. Pneumatikos et al. Pleural effusions in critically ill patients.</a> 147162376 M. Fartoukh, et al Clinically documented pleural effusions in medical ICU patients: how useful is routine thoracentesis? https://www.ncbi.nlm.nih.gov/pubmed/11796448 <a href="https://www.ncbi.nlm.nih.gov/pubmed/11796448">M. Fartoukh, et al Clinically documented pleural effusions in medical ICU patients: how useful is routine thoracentesis?</a> 147162679 Folio, Les NIH - CC CC Folio, Les (CC) 1 147162680 Folio, Lucas Folio, Lucas 2 147162679 Folio, Les NIH - CC CC Folio, Les (CC) 1 147162680 Folio, Lucas Folio, Lucas 2 147157903 X-Clometer: A Radiographic Marker That Displays And Transmits Upright Angle In Degrees On Portable Chest And Abdomen X-Rays E-063-2011-0 Filing authorized Clinical Center (CC), None 83703238 Fenn, Edward (Tedd) tedd.fenn@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-3871] Radiographic Marker for Portable Chest and Abdominal X-Rays&body=Please send me information about technology [TAB-3871] Radiographic Marker for Portable Chest and Abdominal X-Rays.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Fenn, Edward (Tedd)<br><a href="mailto:tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-3871] Radiographic Marker for Portable Chest and Abdominal X-Rays&body=Please send me information about technology [TAB-3871] Radiographic Marker for Portable Chest and Abdominal X-Rays.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">tedd.fenn@nih.gov</a><br> 147160982 E-063-2011-0 E-063-2011-0-US-01 Radiographic Marker That Displays An Angle In Degrees On Portable X-Rays PRV US 61/452,364 Abandoned US <br />Provisional (PRV) 61/452,364<br />Filed on 2011-03-14<br />Status: Abandoned 147164938 E-063-2011-0 E-063-2011-0-PCT-02 A Radiographic Marker That Displays An Angle In Degrees On Portable X-Rays PCT Patent Cooperation Treaty PCT/US2012/029108 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2012/029108<br />Filed on 2012-03-14<br />Status: Expired 147164939 E-063-2011-0 E-063-2011-0-US-03 Radiographic Marker That Displays An Angle In Degrees On Portable X-Rays National Stage US 9,541,822 14/005,024 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9541822 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9541822">9,541,822</a><br />Filed on 2014-01-07<br />Status: Issued 147170592 Abdominal x-ray. 147170594 Chest x-ray 147170595 IMAGING 147170596 RADIOGRAPHY TAB-3864 147157143 Hydrocarbon Stapled Peptides that Inhibit the Linear Ubiquitin Chain Assembly Complex (LUBAC) for the Therapy of the Activated B Cell-like (ABC) Subtype of Diffuse Large B Bell Lymphoma (A Type of Non-Hodgkin’s Lymphoma) NCI Collaboration, Immunology, Licensing, Oncology, Therapeutics Collaboration Immunology Licensing Oncology Therapeutics Federico Bernal, Louis Staudt, Yiban Yang <p>Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin’s lymphoma and consists of three subtypes: activated B-cell (ABC), germinal center B-cell (GBC), and primary mediastinal B-cell (PMB). Despite advances in the front-line therapy for DLBCL, approximately one-third of patients will relapse. Substantially worse outcomes have been reported for patients diagnosed with ABC DLBCL and treated with standard chemoimmunotherapy, suggesting the need for novel strategies that improve treatment outcomes.</p> <p>ABC DLBCL cell survival depends largely upon NF-κB signaling being constitutively active. The linear ubiquitin chain assembly complex (LUBAC) participates in NF-κB signaling, consists of three proteins (HOIP, HOIL-1L, and SHARPIN), and protects against apoptosis. Inhibiting LUBAC using HOIP and/or SHARPIN peptide inhibitors attenuates LUBAC activity and promotes ABC DLBCL cell death.</p> <p>LUBAC peptide inhibitors present a new therapeutic strategy for the treatment of ABC DLBCL and could be combined with radiation, chemotherapy, or CAR-T therapy for ABC DLBCL or other cancers. Researchers at the National Cancer Institute (NCI) have developed HOIP and SHARPIN peptides that inhibit HOIP/HOIL-IL (E-035-2013) and SHARPIN/HOIL-IL (E-019-2017) interactions, respectively. Additionally, these peptides could be applied to treat rheumatoid arthritis, chronic autoinflammation, systemic lupus erythematosus, Crohn's inflammatory bowel disease, polyglucosan body myopathy, or psoriasis. The NCI is seeking statements of capability or interest from parties interested in licensing or in collaborative research to co-develop technologies that disrupt NF-B signaling and present new therapeutic strategies for ABC DLBCL and inflammatory disease treatment. </p> <h2>Competitive Advantages:</h2> <ul><li>Novel composition of inhibitors for advanced stage ABC DLBCL</li> <li>Effective therapies targeting the NF-κB pathway</li> <li>Novel therapeutic for ABC DLBCL not responsive to R-CHOP or EPOCH therapies</li> <li>In HeLa cells, SHARPIN-LTM peptides (E-019-2017) reduce Human Papilloma Virus-E6 and E7 expression at a dose of 10 µM, 5 times lower as curcumin, does to have the same effect;, and also, in half theof time thatof standard treatment needsed to reach a 50% decrease in viability (24h for LTM compared to 48 h for curcumin) (Molecules. 2015; 20:11830-60). Importantly thise SHARPIN peptide (E-019-2017) synergizes with Nutlin (currently in clinical trials) to reactivate p53 and decrease viability on HeLa cells at a 1:1 molar ratio (20 μM final concentration), which is lower than the 80 µM Nutlin dose needed to reach a similar effect.</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Targeted therapies of ABC DLBCL</li> <li>Combination cytotoxic chemotherapies for ABC DLBCL treatment</li> <li>Treatment of inflammatory diseases, such as polyglucosan body myopathy, rheumatoid arthritis, chronic autoinflammation, systemic lupus erythematosus, Crohn's inflammatory bowel disease, and psoriasis</li> </ul> 2016-02-16 2025-04-22 2023-01-09 2025-04-22 2016-08-29 ABC DLBCL, Activated B Cell-like, Autoimmune, Bernal, CANCER, Diffuse Large B Cell Lymphoma, INFLAMMATORY, Linear Ubiquitin-chain Assembly Complex, LUBAC, NF-κB, Non-Hodgkin’s Lymphoma, Peptide Inhibitor, Staudt, therapeutic False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2023-01-09 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147161869 Yang Y et al. Essential role of the linear ubiquitin chain assembly complex in lymphoma revealed by rare germline polymorphisms. https://www.ncbi.nlm.nih.gov/pubmed/24491438 <a href="https://www.ncbi.nlm.nih.gov/pubmed/24491438">Yang Y et al. Essential role of the linear ubiquitin chain assembly complex in lymphoma revealed by rare germline polymorphisms.</a> 147162257 Fujita, H, et al. Cooperative Domain Formation by Homologous Motifs in HOIL-1L and SHARPIN Plays a Crucial Role in LUBAC Stabilization. https://www.ncbi.nlm.nih.gov/pubmed/29694895 <a href="https://www.ncbi.nlm.nih.gov/pubmed/29694895">Fujita, H, et al. Cooperative Domain Formation by Homologous Motifs in HOIL-1L and SHARPIN Plays a Crucial Role in LUBAC Stabilization.</a> 147162656 Staudt, Louis NIH - NCI NCI Staudt, Louis (NCI) 1 147162657 Yang, Yiban NIH - NCI Yang, Yiban 2 147162658 Bernal, Federico NIH - NCI NIGMS Bernal, Federico (NIGMS) 3 147162656 Staudt, Louis NIH - NCI NCI Staudt, Louis (NCI) 1 147162657 Yang, Yiban NIH - NCI Yang, Yiban 2 147162658 Bernal, Federico NIH - NCI NIGMS Bernal, Federico (NIGMS) 3 147157836 Inhibitors Of The Linear Ubiquitin Chain Assembly Complex (LUBAC) For The Therapy Of The Activated B Cell-like (ABC) Subtype Of Diffuse Large B Cell Lymphoma E-035-2013-0 Filing authorized NCI 83704821 Nguyen-Antczak, Lauren lauren.nguyen-antczak@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-3864] Hydrocarbon Stapled Peptides that Inhibit the Linear Ubiquitin Chain Assembly Complex (LUBAC) for the Therapy of the Activated B Cell-like (ABC) Subtype of Diffuse Large B Bell Lymphoma (A Type of Non-Hodgkin’s Lymphoma)&body=Please send me information about technology [TAB-3864] Hydrocarbon Stapled Peptides that Inhibit the Linear Ubiquitin Chain Assembly Complex (LUBAC) for the Therapy of the Activated B Cell-like (ABC) Subtype of Diffuse Large B Bell Lymphoma (A Type of Non-Hodgkin’s Lymphoma).&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Nguyen-Antczak, Lauren<br><a href="mailto:lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-3864] Hydrocarbon Stapled Peptides that Inhibit the Linear Ubiquitin Chain Assembly Complex (LUBAC) for the Therapy of the Activated B Cell-like (ABC) Subtype of Diffuse Large B Bell Lymphoma (A Type of Non-Hodgkin’s Lymphoma)&body=Please send me information about technology [TAB-3864] Hydrocarbon Stapled Peptides that Inhibit the Linear Ubiquitin Chain Assembly Complex (LUBAC) for the Therapy of the Activated B Cell-like (ABC) Subtype of Diffuse Large B Bell Lymphoma (A Type of Non-Hodgkin’s Lymphoma).&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">lauren.nguyen-antczak@nih.gov</a><br> 147160938 E-035-2013-0 E-035-2013-0-US-01 Inhibitors Of The Linear Ubiquitin Chain Assembly Complex (LUBAC) and Related Methods PRV US 61/789,064 Abandoned US <br />Provisional (PRV) 61/789,064<br />Filed on 2013-03-15<br />Status: Abandoned 147164882 E-035-2013-0 E-035-2013-0-PCT-02 Inhibitors Of The Linear Ubiquitin Chain Assembly Complex (LUBAC) and Related Methods PCT Patent Cooperation Treaty PCT/US2014/023006 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2014/023006<br />Filed on 2014-03-11<br />Status: Expired 147164883 E-035-2013-0 E-035-2013-0-US-03 Inhibitors Of The Linear Ubiquitin Chain Assembly Complex (LUBAC) and Related Methods National Stage US 9,783,586 14/774,478 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9783586 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9783586">9,783,586</a><br />Filed on 2015-09-10<br />Status: Issued 147169956 ABC DLBCL 147169957 Activated B Cell-like 147169958 Autoimmune 147169959 Bernal 147169960 CANCER 147169961 Diffuse Large B Cell Lymphoma 147169962 INFLAMMATORY 147169963 Linear Ubiquitin-chain Assembly Complex 147169964 LUBAC 147169965 NF-κB 147169966 Non-Hodgkin’s Lymphoma 147169967 Peptide Inhibitor 147169968 Staudt 147169969 therapeutic TAB-4390 147157684 Diagnostic Marker for Improving Treatment Outcomes of Hepatitis C NCI Collaboration, Diagnostics, Infectious Disease, Licensing Collaboration Diagnostics Infectious Disease Licensing Raymond Donnelly, Brian Muchmore, Thomas O'Brien, Patricia Porter-Gill, Liudmila Prokunina-Olsson <p>The National Cancer Institute (NCI) <a href="http://dceg.cancer.gov/" rel="nofollow">Division of Cancer Epidemiology and Genetics (DCEG)</a><a href="http://dceg.cancer.gov/about/contact-dceg" target="_blank" rel="nofollow"> </a> Immunoepidemiology Branch is seeking statements of capability or interest from parties interested in collaborative research to further co-develop a gene-based diagnostic for Hepatitis C virus (HepC, HCV).</p> <p>NCI Researchers have discovered Interferon-lambda 4 (IFNL4), a protein found through analysis of genomic data. Preliminary studies indicate that this protein may play a role in the clearance of HCV and may be a new target for diagnosing and treating HCV infection.</p> <p>One of the unfortunate aspects of (HCV) infection is that the majority of infected individuals will develop a chronic HCV infection. Not all patients respond to current treatments, which themselves can cause severe adverse effects. <em>IFNL4-ΔG</em> is a novel genetic polymorphism in the newly discovered gene that is a better predictor of clinical outcome for treatment in people of African descent than the currently available diagnostic test, while the predictive value in HCV-infected Caucasians and Asians is comparable to current diagnostics. In addition, <em>IFNL4-ΔG </em>can predict the likelihood of a whether a person who is acutely infected with HCV infection will spontaneously clear the infection or develop chronic infection.</p> <h2>Competitive Advantages:</h2> <ul><li>IFNL4 is not an essential protein and its functional inactivation may be well-tolerated.</li> <li>Better than current ‘IL28B’ based diagnostics for predicting response to current HCV treatments for people of African descent.</li> <li>Comparable predictive capabilities to current ‘IL28B’ based diagnostics for response to current HCV treatments in Caucasians and Asians.</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Novel target for treatment of HCV infection </li> <li>Diagnostics for detection of IFNL4 mRNA or protein</li> <li>Biological reagents for detection of IFNL4 – expression assays, antibodies and protein.</li> </ul> 2016-03-18 2025-04-22 2018-04-20 2025-04-22 2016-08-31 HCV, hepatitis C virus, HepC, IFN L4, IL28B, INTERFERON, Interferon-lambda 4 False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2018-04-20 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-217-2011 147162396 Prokunina-Olsson L, et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus https://www.ncbi.nlm.nih.gov/pubmed/23291588 <a href="https://www.ncbi.nlm.nih.gov/pubmed/23291588">Prokunina-Olsson L, et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus</a> 147164559 Prokunina-Olsson, Liudmila NIH - NCI NCI Prokunina-Olsson, Liudmila (NCI) 1 147164557 O'Brien, Thomas NIH - NCI NCI O'Brien, Thomas (NCI) 2 147164558 Muchmore, Brian NIH - NCI Muchmore, Brian 3 147164560 Donnelly, Raymond NIH - FDA FDA Donnelly, Raymond (FDA) 4 147164561 Porter-Gill, Patricia NIH - NCI NCI Porter-Gill, Patricia (NCI) 5 147164559 Prokunina-Olsson, Liudmila NIH - NCI NCI Prokunina-Olsson, Liudmila (NCI) 1 147164557 O'Brien, Thomas NIH - NCI NCI O'Brien, Thomas (NCI) 2 147164558 Muchmore, Brian NIH - NCI Muchmore, Brian 3 147164560 Donnelly, Raymond NIH - FDA FDA Donnelly, Raymond (FDA) 4 147164561 Porter-Gill, Patricia NIH - NCI NCI Porter-Gill, Patricia (NCI) 5 147158225 Identification Of A Novel Genetic Marker For Predicting Outcome Of Treatment And Natural Clearance Of Hepatitis C Virus (HCV) In Humans E-217-2011-0 Filing authorized FDA, NCI 147162561 Identification Of A Novel Interferon-analog (IFNAN) Human Protein That Impairs Spontaneous And Treatment-induced Clearance Of Hepatitis C Virus In Humans E-217-2011-1 Filing authorized FDA, NCI 147162562 Identification Of A Novel Interferon-analog (IFNAN) Human Protein That Impairs Spontaneous And Treatment-induced Clearance Of Hepatitis C Virus In Humans E-217-2011-2 Research Material NCI 83691647 Chang, Kevin changke@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB changke@mail.nih.gov?subject=Web Inquiry on [TAB-4390] Diagnostic Marker for Improving Treatment Outcomes of Hepatitis C&body=Please send me information about technology [TAB-4390] Diagnostic Marker for Improving Treatment Outcomes of Hepatitis C.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Chang, Kevin<br><a href="mailto:changke@mail.nih.gov?subject=Web Inquiry on [TAB-4390] Diagnostic Marker for Improving Treatment Outcomes of Hepatitis C&body=Please send me information about technology [TAB-4390] Diagnostic Marker for Improving Treatment Outcomes of Hepatitis C.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">changke@mail.nih.gov</a><br> 147168584 E-217-2011-0 E-217-2011-0-US-01 Genetic Marker For Predicting Prognosis In Patients Infected With Hepatitis C Virus PRV US 61/543,620 Abandoned US <br />Provisional (PRV) 61/543,620<br />Filed on 2011-10-05<br />Status: Abandoned 147168585 E-217-2011-0 E-217-2011-0-PCT-02 GENETIC MARKER FOR PREDICTING PROGNOSIS IN PATIENTS INFECTED WITH HEPATITIS C VIRUS PCT Patent Cooperation Treaty PCT/US2012/59048 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2012/59048<br />Filed on 2012-10-05<br />Status: Expired 147168586 E-217-2011-0 E-217-2011-0-US-03 Genetic Marker For Predicting Prognosis In Patients Infected With Hepatitis C Virus National Stage US 14/349,395 Abandoned US <br />National Stage 14/349,395<br />Filed on 2014-04-03<br />Status: Abandoned 147168587 E-217-2011-0 E-217-2011-0-US-04 GENETIC MARKER FOR PREDICTING PROGNOSIS IN PATIENTS INFECTED WITH HEPATITIS C VIRUS CON US 15/453,903 Abandoned US <br />Continuation (CON) 15/453,903<br />Filed on 2017-03-08<br />Status: Abandoned 147168589 E-217-2011-1 E-217-2011-1-US-01 A NOVEL INTERFERON-ANALOG (IFNAN) PROTEIN, RELATED NUCLEIC ACID MOLECULES, AND USES THEREOF PRV US 61/616,664 Abandoned US <br />Provisional (PRV) 61/616,664<br />Filed on 2012-03-28<br />Status: Abandoned 147168590 E-217-2011-1 E-217-2011-1-PCT-02 Novel Interferon-Lambda4 (IFNL4) Protein, Related Nucleic Acid Molecules, and Uses Thereof PCT Patent Cooperation Treaty PCT/US2013/031624 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2013/031624<br />Filed on 2013-03-14<br />Status: Expired 147168591 E-217-2011-1 E-217-2011-1-AU-03 Novel Interferon-Lambda4 (IFNL4) Protein, Related Nucleic Acid Molecules, and Uses Thereof National Stage Australia 2013240301 2013240301 Issued Australia <br />National Stage 2013240301<br />Filed on 2013-03-14<br />Status: Issued 147168592 E-217-2011-1 E-217-2011-1-BR-04 Novel Interferon-Lambda4 (IFNL4) Protein, Related Nucleic Acid Molecules, and Uses Thereof National Stage Brazil BR112014023642-9 Abandoned Brazil <br />National Stage BR112014023642-9<br />Filed on 2013-03-14<br />Status: Abandoned 147168593 E-217-2011-1 E-217-2011-1-CA-05 Novel Interferon-Lambda4 (IFNL4) Protein, Related Nucleic Acid Molecules, and Uses Thereof National Stage Canada 2869899 2869899 Issued Canada <br />National Stage 2869899<br />Filed on 2013-03-14<br />Status: Issued 147168594 E-217-2011-1 E-217-2011-1-CN-06 Novel Interferon-Lambda4 (IFNL4) Protein, Related Nucleic Acid Molecules, and Uses Thereof National Stage China ZL201380028364.4 201380028364.4 Issued China <br />National Stage 201380028364.4<br />Filed on 2013-03-14<br />Status: Issued 147168595 E-217-2011-1 E-217-2011-1-EP-07 Novel Interferon-Lambda4 (IFNL4) Protein, Related Nucleic Acid Molecules, and Uses Thereof National Stage European Patent 2831106 13712655.3 Issued European Patent <br />National Stage 13712655.3<br />Filed on 2013-03-14<br />Status: Issued 147168596 E-217-2011-1 E-217-2011-1-IN-08 Novel Interferon-LambdA4 (IFNL4) Protein, Related Nucleic Acid Molecules, and Uses Thereof National Stage India 8806/DELNP/2014 Abandoned India <br />National Stage 8806/DELNP/2014<br />Filed on 2013-03-14<br />Status: Abandoned 147168597 E-217-2011-1 E-217-2011-1-JP-09 Novel Interferon-Lambda4 (IFNL4) Protein, Related Nucleic Acid Molecules, and Uses Thereof National Stage Japan 6120944 2015-503310 Issued Japan <br />National Stage 2015-503310<br />Filed on 2013-03-14<br />Status: Issued 147168598 E-217-2011-1 E-217-2011-1-US-10 Novel Interferon-Lambda4 (IFNL4) Protein, Related Nucleic Acid Molecules, and Uses Thereof National Stage US 9,678,074 14/388,293 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9678074 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9678074">9,678,074</a><br />Filed on 2014-09-26<br />Status: Issued 147168599 E-217-2011-1 E-217-2011-1-US-11 Novel Interferon-Lambda4 (IFNL4) Protein, Related Nucleic Acid Molecules, and Uses Thereof DIV US 10,962,539 15/597,459 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10962539 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10962539">10,962,539</a><br />Filed on 2017-05-17<br />Status: Issued 147168600 E-217-2011-1 E-217-2011-1-US-12 A NOVEL INTERFERON-(lambda)4 (IFNL-4) PROTEIN, RELATED NUCLEIC ACID MOLECULES, AND USES THEREOF CON US 16/752,105 Abandoned US <br />Continuation (CON) 16/752,105<br />Filed on 2020-01-24<br />Status: Abandoned 147168601 E-217-2011-1 E-217-2011-1-CH-13 Novel Interferon-Lambda4 (IFNL4) Protein, Related Nucleic Acid Molecules, and Uses Thereof EP Switzerland 2831106 13712655.3 Issued Switzerland <br />European patent (EP) 13712655.3<br />Filed on 2013-03-14<br />Status: Issued 147168602 E-217-2011-1 E-217-2011-1-DE-14 Novel Interferon-Lambda4 (IFNL4) Protein, Related Nucleic Acid Molecules, and Uses Thereof EP Germany 2831106 13712655.3 Issued Germany <br />European patent (EP) 13712655.3<br />Filed on 2013-03-14<br />Status: Issued 147168603 E-217-2011-1 E-217-2011-1-FR-15 Novel Interferon-Lambda4 (IFNL4) Protein, Related Nucleic Acid Molecules, and Uses Thereof EP France 2831106 13712655.3 Issued France <br />European patent (EP) 13712655.3<br />Filed on 2013-03-14<br />Status: Issued 147168604 E-217-2011-1 E-217-2011-1-GB-16 Novel Interferon-Lambda4 (IFNL4) Protein, Related Nucleic Acid Molecules, and Uses Thereof EP United Kingdom 2831106 13712655.3 Issued United Kingdom <br />European patent (EP) 13712655.3<br />Filed on 2013-03-14<br />Status: Issued 147173836 HCV 147173837 hepatitis C virus 147173839 HepC 147173841 IFN L4 147173843 IL28B 147173844 INTERFERON 147173846 Interferon-lambda 4 TAB-3908 147157188 Therapeutic antibody-drug conjugates targeting CD56-positive cancers NCI Licensing, Oncology, Therapeutics Licensing Oncology Therapeutics Dimiter Dimitrov, Yang Feng, John Maris, Robyn Sussman, Zhongyu Zhu <p>The glycoprotein CD56, also known as a neural cell adhesion molecule (NCAM), plays an important role in normal physiological functions.  It is expressed in low levels in normal cells such as neurons, glia, skeletal muscle and natural killer cells. It is highly expressed on a variety of cancerous cells including those of neuroblastoma, small-cell lung cancer, and multiple myeloma.  In neuroblastoma, patients undergo a very aggressive standard of care regimen that results in a high mortality rate.  Many neuroblastomas have increased expression of CD56, which represents a possible therapeutic target for these aggressive and hard to treat cancers. </p> <p>Researchers at the National Cancer Institute's <a href="https://ccr.cancer.gov/Cancer-and-Inflammation-Program" style="text-decoration:underline; font-size:15.4px; font-style:normal; font-variant:normal; font-weight:bold; letter-spacing:-1px; line-height:23.1px; text-indent:0px; text-transform:none; white-space:normal; word-spacing:0px" target="_blank" rel="nofollow">Cancer and Inflammation Program</a>, in collaboration with the Children’s Hospital of Philadelphia (CHOP), have developed antibody-drug conjugates (ADC) that incorporate one of two novel human CD56 antibodies, known as m900 and m906, in combination with a known cytotoxic drug, pyrrolobenzodiazepine (PBD).  Other PBD-ADCs have demonstrated the ability to overcome resistance in some multi-drug resistant cancers that could present additional benefits for the ADCs of the current invention.  The m900 and m906 ADCs have been shown to induce cell death and CD56 down regulation <em>in vitro</em> in four different CD56-positive neuroblastoma cell lines.  Preliminary studies in animals have also shown promising results and additional <em>in vivo</em> work is ongoing.</p> <h2>Competitive Advantages:</h2> <ul><li>Fully human antibodies (m900 or m906) targeting CD56 may offer improved properties over the humanized antibody IMGN901    </li> </ul> <h2>Commercial Applications:</h2> <ul><li>Therapeutic for the treatment of neuroblastoma</li> <li>Therapeutic for the treatment of other CD56-positive cancers including small cell lung cancer, multiple myeloma, pancreatic cancer, ovarian cancer, acute myeloid leukemia, NK-T lymphoma, and neuroendocrine cancer </li> </ul> 2016-06-02 2025-04-22 2020-04-07 2025-04-22 2016-06-02 ADC, GLYCOPROTEIN, MULTIPLE MYELOMA, Neuroblastoma, pyrrolobenzodiazepine, small-cell lung cancer False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2020-04-07 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-142-2014 147162358 Y. Feng et al. Differential killing of CD56-expressing cells by drug-conjugated human antibodies targeting membrane-distal and membrane-proximal non-overlapping epitopes. https://www.ncbi.nlm.nih.gov/pubmed/26910291 <a href="https://www.ncbi.nlm.nih.gov/pubmed/26910291">Y. Feng et al. Differential killing of CD56-expressing cells by drug-conjugated human antibodies targeting membrane-distal and membrane-proximal non-overlapping epitopes.</a> 147162820 Dimitrov, Dimiter NIH - NCI NCI Dimitrov, Dimiter (NCI) 1 147162821 Feng, Yang NIH - NCI NCI Feng, Yang (NCI) 2 147162822 Zhu, Zhongyu NIH - NCI NCI Zhu, Zhongyu (NCI) 3 147162823 Maris, John Children's Hospital of Philadelphia Maris, John 4 147162824 Sussman, Robyn Children's Hospital of Philadelphia Sussman, Robyn 5 147162820 Dimitrov, Dimiter NIH - NCI NCI Dimitrov, Dimiter (NCI) 1 147162821 Feng, Yang NIH - NCI NCI Feng, Yang (NCI) 2 147162822 Zhu, Zhongyu NIH - NCI NCI Zhu, Zhongyu (NCI) 3 147162823 Maris, John Children's Hospital of Philadelphia Maris, John 4 147162824 Sussman, Robyn Children's Hospital of Philadelphia Sussman, Robyn 5 147158228 Antibody-drug Conjugates M900PBD And M906PBD Targeting Neuroblastoma And Other CD56-positive Tumors E-221-2015-0 Filing authorized Children's Hospital of Philadelphia, NCI 91814193 Freel, Rose rose.freel@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America rose.freel@nih.gov?subject=Web Inquiry on [TAB-3908] Therapeutic antibody-drug conjugates targeting CD56-positive cancers&body=Please send me information about technology [TAB-3908] Therapeutic antibody-drug conjugates targeting CD56-positive cancers.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Freel, Rose<br><a href="mailto:rose.freel@nih.gov?subject=Web Inquiry on [TAB-3908] Therapeutic antibody-drug conjugates targeting CD56-positive cancers&body=Please send me information about technology [TAB-3908] Therapeutic antibody-drug conjugates targeting CD56-positive cancers.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">rose.freel@nih.gov</a><br> 147161203 E-221-2015-0 E-221-2015-0-US-01 ANTIBODY-DRUG CONJUGATES FOR TARGETING CD56-POSITIVE TUMORS PRV US 62/199,707 Abandoned US <br />Provisional (PRV) 62/199,707<br />Filed on 2015-07-31<br />Status: Abandoned 147165175 E-221-2015-0 E-221-2015-0-PCT-02 ANTIBODY-DRUG CONJUGATES FOR TARGETING CD56-POSITIVE TUMORS PCT Patent Cooperation Treaty PCT/US2016/044777 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2016/044777<br />Filed on 2016-07-29<br />Status: Expired 147165176 E-221-2015-0 E-221-2015-0-US-03 ANTIBODY-DRUG CONJUGATES FOR TARGETING CD56-POSITIVE TUMORS National Stage US 10,548,987 15/747,620 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10548987 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10548987">10,548,987</a><br />Filed on 2018-01-25<br />Status: Issued 147173852 ADC 147173853 GLYCOPROTEIN 147173854 MULTIPLE MYELOMA 147173855 Neuroblastoma 147173857 pyrrolobenzodiazepine 147173859 small-cell lung cancer TAB-4182 147157467 Metastatic ovarian cancer mouse models and cell lines for preclinical studies NCI Licensing, Oncology, Research Materials Licensing Oncology Research Materials Simone Difilippantonio, Yurong Song, Ludmila Szabova, Terry Van Dyke, Chaoying Yin <p>The high mortality rate from ovarian cancers can be attributed to late-stage diagnosis and lack of effective treatment. Despite enormous effort to develop better targeted therapies, platinum-based chemotherapy still remains the standard of care for ovarian cancer patients, and resistance occurs at a high rate. One of the rate limiting factors for translation of new drug discoveries into clinical treatments has been the lack of suitable preclinical cancer models with high predictive value.</p> <p>Researchers at <a href="https://ccr.cancer.gov/capr/about" rel="nofollow">NCI's Center for Advanced Preclinical Research (CAPR)</a> developed Tri-allelic K18-T121<sup>tg/+</sup>/Brca1<sup>fl/fl</sup>/p53<sup>fl/fl  </sup>SEOC GEM Model, GEM-derived SEOC orthotopic mouse model, and biological materials derived therefrom, with several key histopathologic, immunophenotypical, and genetic features of human SEOC. SEOC GEMs were utilized to create orthotopic immunocompetent transplant models, and to generate synchronized cohorts of mice suitable for preclinical studies. NCI CAPR conducted studies that determine these models are tractable for use in routine efficacy studies and demonstrate the utility of these models in evaluating the potential efficacy of novel therapeutics for ovarian cancer.</p> <h2>Competitive Advantages:</h2> <p>- Novel resource for evaluating disease etiology and biomarkers, therapeutic evaluation, and improved imaging strategies in epithelial ovarian cancer;<br /> - Similarity to human ovarian cancer based on transcriptional profiling;<br /> - Suitable preclinical cancer models with high predictive value.</p> <h2>Commercial Applications:</h2> <p>- Foundation for preclinical research and evaluation of efficacy of novel therapeutics for ovarian cancer;<br /> - Can be used to develop cell lines and allograft models for evaluating drug potency relative to Brca1 mutation status;<br /> - Opportunity to evaluate therapeutic efficacy, including prediction of differential responses in Brca1-wild type and Brca1–deficient tumors and development of relevant biomarkers.</p> 2016-07-25 2025-04-22 2017-11-20 2025-04-22 2016-07-25 GDA, GEM Derived Allograft Mouse Model, Genetically Engineered Mouse (GEM) Model, OVARIAN CANCER, SEOC, Serous Epithelial Ovarian Cancer False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2017-11-20 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-182-2012 147163806 Difilippantonio, Simone NIH - NCI Leidos Difilippantonio, Simone (Leidos) 1 147163807 Van Dyke, Terry NIH - NCI Van Dyke, Terry 2 147163808 Szabova, Ludmila NIH - NCI Leidos Szabova, Ludmila (Leidos) 3 147163809 Yin, Chaoying University of North Carolina, Chapel Hill Yin, Chaoying 4 147163810 Song, Yurong NIH - NCI NCI Song, Yurong (NCI) 5 147163806 Difilippantonio, Simone NIH - NCI Leidos Difilippantonio, Simone (Leidos) 1 147163807 Van Dyke, Terry NIH - NCI Van Dyke, Terry 2 147163808 Szabova, Ludmila NIH - NCI Leidos Szabova, Ludmila (Leidos) 3 147163809 Yin, Chaoying University of North Carolina, Chapel Hill Yin, Chaoying 4 147163810 Song, Yurong NIH - NCI NCI Song, Yurong (NCI) 5 147157920 Novel Metastatic Serous Epithelial Ovarian Cancer (SEOC) Mouse Models Based On Rb, P53 And/or Brca 1/2 Inactivation Useful For Biomarker Discovery And Preclinical Testing E-069-2012-0 Research Material NCI, University of North Carolina, Chapel Hill 83732917 Favila, Michelle michelle.favila@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC michelle.favila@nih.gov?subject=Web Inquiry on [TAB-4182] Metastatic ovarian cancer mouse models and cell lines for preclinical studies&body=Please send me information about technology [TAB-4182] Metastatic ovarian cancer mouse models and cell lines for preclinical studies.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Favila, Michelle<br><a href="mailto:michelle.favila@nih.gov?subject=Web Inquiry on [TAB-4182] Metastatic ovarian cancer mouse models and cell lines for preclinical studies&body=Please send me information about technology [TAB-4182] Metastatic ovarian cancer mouse models and cell lines for preclinical studies.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">michelle.favila@nih.gov</a><br> 147170729 GDA 147170731 GEM Derived Allograft Mouse Model 147170733 Genetically Engineered Mouse (GEM) Model 147170734 OVARIAN CANCER 147170735 SEOC 147170737 Serous Epithelial Ovarian Cancer TAB-4347 147157640 Vaccines for HIV NCI Collaboration, Infectious Disease, Licensing, Vaccines Collaboration Infectious Disease Licensing Vaccines Barbara Felber, James Mullins, George Pavlakis, Antonio Valentin <p>The development of an effective HIV vaccine has been an ongoing area of research. The high variability in HIV-1 virus strains has represented a major challenge in successful development.  Ideally, an effective candidate vaccine would provide protection against the majority of clades of HIV.  Two major hurdles to overcome are immunodominance and sequence diversity.  This vaccine utilizes a strategy for overcoming these two issues by identifying the conserved regions of the virus and exploiting them for use in a targeted therapy. </p> <p>Researchers at the National Cancer Institute's<a href="https://ccr.cancer.gov/Vaccine-Branch" target="_blank" rel="nofollow"> Vaccine Branch</a> used conserved elements (CEs) of the polypeptides Gag and Env as immunogenic compositions to induce an immune response to HIV-1 envelope polypeptides and Gag polypeptides.  This invention is based, in part, on the discovery that the administration of one or more polypeptides comprising CEs, separated by linkers and collinearly arranged, of HIV Env or Gag CE proteins, can provide a robust immune response compared to administration of a full-length Env or Gag protein.  The Env-CE DNA vaccines were tested in a rhesus macaque model and were able to induce a cellular and humoral immune response in this model whereas vaccination with the full length DNA did not produce the same effect. </p> <p>A robust increase in immunity was observed when rhesus macaques were subjected to a prime-boost protocol.  First, rhesus macaques were primed with Env-CE DNA and boosted with full length Env resulting in an observed increase in both the cellular and humoral responses.  A further increase in immune response was observed from priming with CE and boosting with a combination of CE and full length DNA resulting in a significantly improved breadth of immune responses.  These improved protocols may help solve the immunodominance problem observed in current protocols. This is considered a major obstacle for HIV vaccine development. The CE vaccines described by this invention have potential for use as prophylactic and therapeutic HIV vaccines. </p> <h2>Competitive Advantages:</h2> <ul><li>Addresses two key hurdles faced by current HIV vaccines: sequence diversity of HIV and immunodominance.</li> <li>Induces cross-clade specific immune response. </li> <li>The prime-boost immunization regimen is not limited to HIV, but can be employed to improve the induction of immune responses to any subdominant epitopes (cellular or humoral) to increase breadth, magnitude and quality of the immune response.</li> </ul> <h2>Commercial Applications:</h2> <ul><li>HIV vaccines</li> </ul> 2016-07-28 2025-04-22 2018-04-17 2025-04-22 2016-07-28 ENV, GAG, HIV Vaccine, immunogenic conserved elements False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2018-04-17 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-132-2012 147162265 Kulkarni, V. et al. HIV-1 conserved elements p24CE DNA vaccine induces humoral immune responses with broad epitope recognition in macaques https://www.ncbi.nlm.nih.gov/pubmed/25338098 <a href="https://www.ncbi.nlm.nih.gov/pubmed/25338098">Kulkarni, V. et al. HIV-1 conserved elements p24CE DNA vaccine induces humoral immune responses with broad epitope recognition in macaques</a> 147162418 Kulkarni, V. et al. Altered response hierarchy and increased T-cell breadth upon HIV-1 conserved element DNA vaccination in macaques https://www.ncbi.nlm.nih.gov/pubmed/24465991 <a href="https://www.ncbi.nlm.nih.gov/pubmed/24465991">Kulkarni, V. et al. Altered response hierarchy and increased T-cell breadth upon HIV-1 conserved element DNA vaccination in macaques</a> 147164407 Felber, Barbara NIH - NCI NCI Felber, Barbara (NCI) 1 147164406 Pavlakis, George NIH - NCI NCI Pavlakis, George (NCI) 2 147164408 Valentin, Antonio NIH - NCI Valentin, Antonio 3 147164409 Mullins, James University of Washington Mullins, James 4 147164407 Felber, Barbara NIH - NCI NCI Felber, Barbara (NCI) 1 147164406 Pavlakis, George NIH - NCI NCI Pavlakis, George (NCI) 2 147164408 Valentin, Antonio NIH - NCI Valentin, Antonio 3 147164409 Mullins, James University of Washington Mullins, James 4 147157956 HIV Env Conserved Element DNA Vaccine To Alter Immunity Breadth E-087-2015-0 Filing authorized NCI, University of Washington 147162520 HIV Env Conserved Element DNA Vaccine To Alter Immunity Breadth E-087-2015-1 Filing authorized NCI, University of Washington 91814193 Freel, Rose rose.freel@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America rose.freel@nih.gov?subject=Web Inquiry on [TAB-4347] Vaccines for HIV&body=Please send me information about technology [TAB-4347] Vaccines for HIV.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Freel, Rose<br><a href="mailto:rose.freel@nih.gov?subject=Web Inquiry on [TAB-4347] Vaccines for HIV&body=Please send me information about technology [TAB-4347] Vaccines for HIV.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">rose.freel@nih.gov</a><br> 147161017 E-087-2015-0 E-087-2015-0-US-01 HIV Env Conserved Element DNA Vaccine PRV US 62/161,123 Abandoned US <br />Provisional (PRV) 62/161,123<br />Filed on 2015-05-13<br />Status: Abandoned 147168366 E-087-2015-1 E-087-2015-1-PCT-01 Methods and Compositions for Inducing an Immune Response Using Conserved Element Constructs PCT COMB Patent Cooperation Treaty PCT/US2016/032317 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2016/032317<br />Filed on 2016-05-13<br />Status: Expired 147168367 E-087-2015-1 E-087-2015-1-EP-02 Methods and Compositions for Inducing an Immune Response Using Conserved Element Constructs National Stage European Patent 3294755 16725323.6 Issued European Patent <br />National Stage 16725323.6<br />Filed on 2016-05-13<br />Status: Issued 147168368 E-087-2015-1 E-087-2015-1-US-03 METHODS AND COMPOSITIONS FOR INDUCING AN IMMUNE RESPONSE USING CONSERVED ELEMENT CONSTRUCTS National Stage US 15/573,701 Pending US <br />National Stage 15/573,701<br />Filed on 2017-11-13<br />Status: Pending 147168369 E-087-2015-1 E-087-2015-1-US-04 METHODS AND COMPOSITIONS FOR INDUCING AN IMMUNE RESPONSE USING CONSERVED ELEMENT CONSTRUCTS CON US 18/171,804 Pending US <br />Continuation (CON) 18/171,804<br />Filed on 2023-02-21<br />Status: Pending 147168370 E-087-2015-1 E-087-2015-1-EP-05 Methods and Compositions for Inducing an Immune Response Using Conserved Element Constructs DIV European Patent 23185862.2 Pending European Patent <br />Divisional (DIV) 23185862.2<br />Filed on 2023-07-17<br />Status: Pending 147171134 ENV 147171135 GAG 147171136 HIV Vaccine 147171138 immunogenic conserved elements TAB-3975 147157256 B-cell Surface Reactive Antibodies for the Treatment of B-Cell Chronic Lymphocytic Leukemia NCI Licensing, Oncology, Therapeutics Licensing Oncology Therapeutics Sivasubramanian Baskar, Michael Bishop, Christoph Rader, Ivan Samija, Jessica Suschak <p>B-cell chronic lymphocytic leukemia (B-CLL) is a cancer characterized by a progressive accumulation of functionally incompetent lymphocytes.  Despite high morbidity and mortality, the only available potential cure is allogeneic hematopoietic stem cell transplantation (alloHSCST).  However, there is less than a 50% chance of finding a matching bone marrow or blood donor for B-CLL patients.  Other clinically tested targeted therapies such as rituximab and alemtuzumab target both malignant and normal B cells, resulting in immunosuppression.</p> <p>Available for licensing are fully human monoclonal antibodies that were selected from the first human post-alloHSCT antibody library.  The library was generated from a time point after transplantation at which antibodies to B-CLL cell surface antigens peaked, thus indicating its therapeutic value.  Utilizing phage display, the investigators generated a panel of fully human monoclonal antibodies that strongly bind to the same epitope on a B-CLL cell surface antigen.   Weaker binding to normal B cells, but not to other lymphocytes, was observed.  These fully human monoclonal antibodies provide readily available treatment that selectively targets malignant B cells.</p> <h2>Competitive Advantages:</h2> <ul><li>Selective targeting of malignant B-cell surface antigens that are minimally non-damaging to non-diseased cells</li> <li>Readily available therapeutics without the need for bone marrow or blood transplantation</li> </ul> <h2>Commercial Applications:</h2> <ul><li>B-cell chronic lymphocytic leukemia therapeutics</li> <li>Method to inhibit the growth of malignant B-cells</li> <li>Method to detect B-cell tumors</li> </ul> 2016-08-12 2025-04-22 2018-04-17 2025-04-22 2016-08-12 alloHSCST, B-CELL, Leukemia, Lymphocytic False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2018-04-17 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147162003 S Baskar, et al. A human monoclonal antibody drug and target discovery platform for B-cell chronic lymphocytic leukemia based on allogeneic hematopoietic stem cell transplantation and phage display. https://www.ncbi.nlm.nih.gov/pubmed/19667400 <a href="https://www.ncbi.nlm.nih.gov/pubmed/19667400">S Baskar, et al. A human monoclonal antibody drug and target discovery platform for B-cell chronic lymphocytic leukemia based on allogeneic hematopoietic stem cell transplantation and phage display.</a> 147163092 Rader, Christoph NIH - NCI NCI Rader, Christoph (NCI) 1 147163093 Baskar, Sivasubramanian NIH - NCI NHLBI Baskar, Sivasubramanian (NHLBI) 2 147163094 Suschak, Jessica NIH - NCI Suschak, Jessica 3 147163095 Samija, Ivan NIH - NCI Samija, Ivan 4 147163091 Bishop, Michael NIH - NCI NCI Bishop, Michael (NCI) 5 147163092 Rader, Christoph NIH - NCI NCI Rader, Christoph (NCI) 1 147163093 Baskar, Sivasubramanian NIH - NCI NHLBI Baskar, Sivasubramanian (NHLBI) 2 147163094 Suschak, Jessica NIH - NCI Suschak, Jessica 3 147163095 Samija, Ivan NIH - NCI Samija, Ivan 4 147163091 Bishop, Michael NIH - NCI NCI Bishop, Michael (NCI) 5 147158113 A Panel Of Fully Human Monoclonal Antibodies To The Same Epitope Of An Unknown Cell Surface Antigen Expressed In B-cell Lymphocytic Leukemia (B-CLL) E-163-2009-0 Filing authorized NCI 83731987 Dhal, Abritee abritee.dhal@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-3975] B-cell Surface Reactive Antibodies for the Treatment of B-Cell Chronic Lymphocytic Leukemia&body=Please send me information about technology [TAB-3975] B-cell Surface Reactive Antibodies for the Treatment of B-Cell Chronic Lymphocytic Leukemia.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dhal, Abritee<br><a href="mailto:abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-3975] B-cell Surface Reactive Antibodies for the Treatment of B-Cell Chronic Lymphocytic Leukemia&body=Please send me information about technology [TAB-3975] B-cell Surface Reactive Antibodies for the Treatment of B-Cell Chronic Lymphocytic Leukemia.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">abritee.dhal@nih.gov</a><br> 147161126 E-163-2009-0 E-163-2009-0-US-01 A Panel Of Fully Human Monoclonal Antibodies To The Same Epitope Of An Unknown Cell Surface Antigen Expressed In B-cell Lymphocytic Leukemia (B-CLL) PRV US 61/178,688 Abandoned US <br />Provisional (PRV) 61/178,688<br />Filed on 2009-05-15<br />Status: Abandoned 147165642 E-163-2009-0 E-163-2009-0-PCT-02 B-cell Surface Reactive Antibodies(B-CLL) PCT Patent Cooperation Treaty PCT/US2010/034491 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2010/034491<br />Filed on 2010-05-12<br />Status: Expired 147165643 E-163-2009-0 E-163-2009-0-US-03 B CELL SURFACE REACTIVE ANTIBODIES National Stage US 8,877,199 13/320,630 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8877199 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8877199">8,877,199</a><br />Filed on 2012-02-01<br />Status: Issued 147165644 E-163-2009-0 E-163-2009-0-US-04 B Cell Surface Reactive Antibodies CON US 14/514,851 Abandoned US <br />Continuation (CON) 14/514,851<br />Filed on 2014-10-15<br />Status: Abandoned 147172680 alloHSCST 147172681 B-CELL 147172682 Leukemia 147172683 Lymphocytic TAB-4114 147157396 Ratio Based Biomarkers for the Prediction of Cancer Survival NCI Collaboration, Diagnostics, Licensing, Oncology Collaboration Diagnostics Licensing Oncology Joon-Yong Chung, Udayan Guha, Stephen Hewitt <p>The AKT pathway plays a key role in the regulation of cellular survival, apoptosis, and protein translation and has been shown to have prognostic significance in a number of cancers.  Recently, the inventors have identified several functions of the AKT pathway in certain cancers, such as extrahepatic cholangiocarcinoma (EHCC).</p> <p>The NCI seeks partners to license or co-develop this technology, which describes compositions, methods and kits for identifying, characterizing biomolecules expressed in a sample that are associated with the presence, the development, or progression of cancer.  Utilizing multiplex tissue immunoblotting, the inventors have demonstrated that PTEN expression, PTEN/p-AKT ratios, and PTEN/p-mTOR ratios can predict the survival of cancer patients.  These biomarkers may provide useful diagnostic information for cancer patients as well as identify patients appropriate for mTOR analog-based chemotherapy or agents directed against AKT.</p> <h2>Competitive Advantages:</h2> <ul><li>Useful to predict cancer patient survival</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Diagnostic and Prognostic tool to detect the presence of cancer and predict the relative cancer survival rate for a subject with cancer</li> <li>Method of identifying patients appropriate for therapies targeted to the AKT pathway</li> <li>A kit for detecting cancer associated proteins in a sample</li> </ul> 2016-08-12 2025-04-22 2018-03-29 2025-04-22 2016-08-12 AKT pathway, diagnostic, extrahepatic cholangiocarcinoma, prognostic False True Prototype True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2018-03-29 52406769 Prototype 52406769 NCI 37470483 Website Abstract 147162294 Chung J, et al. The expression of phospho-AKT, phospho-mTOR, and PTEN in extrahepatic cholangiocarcinoma. https://www.ncbi.nlm.nih.gov/pubmed/19147772 <a href="https://www.ncbi.nlm.nih.gov/pubmed/19147772">Chung J, et al. The expression of phospho-AKT, phospho-mTOR, and PTEN in extrahepatic cholangiocarcinoma.</a> 147163555 Hewitt, Stephen NIH - NCI NCI Hewitt, Stephen (NCI) 1 147163556 Chung, Joon-Yong NCI - CCR NCI Chung, Joon-Yong (NCI) 2 147163557 Guha, Udayan NCI - CCR NCI Guha, Udayan (NCI) 3 147163555 Hewitt, Stephen NIH - NCI NCI Hewitt, Stephen (NCI) 1 147163556 Chung, Joon-Yong NCI - CCR NCI Chung, Joon-Yong (NCI) 2 147163557 Guha, Udayan NCI - CCR NCI Guha, Udayan (NCI) 3 147157813 Ratio Based Biomarker Of Survival Utilizing PTEN And Phospho-AKT E-025-2009-0 Filing authorized NCI 147162495 Ratio Based Biomarker Of Survival Utilizing PTEN And Phospho-AKT E-025-2009-1 Filing authorized NCI 121111111 Greene, Jaime greenejaime@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America greenejaime@mail.nih.gov?subject=Web Inquiry on [TAB-4114] Ratio Based Biomarkers for the Prediction of Cancer Survival&body=Please send me information about technology [TAB-4114] Ratio Based Biomarkers for the Prediction of Cancer Survival.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Greene, Jaime<br><a href="mailto:greenejaime@mail.nih.gov?subject=Web Inquiry on [TAB-4114] Ratio Based Biomarkers for the Prediction of Cancer Survival&body=Please send me information about technology [TAB-4114] Ratio Based Biomarkers for the Prediction of Cancer Survival.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">greenejaime@mail.nih.gov</a><br> 147166609 E-025-2009-0 E-025-2009-0-US-01 Ratio Based Biomarker Of Survival Utilizing PTEN And Phospho-AKT PRV US 61/144,501 Abandoned US <br />Provisional (PRV) 61/144,501<br />Filed on 2009-01-14<br />Status: Abandoned 147166610 E-025-2009-0 E-025-2009-0-PCT-02 Ratio Based Biomarkers And Methods of Use Thereof PCT Patent Cooperation Treaty PCT/US2010/020944 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2010/020944<br />Filed on 2010-01-13<br />Status: Expired 147166611 E-025-2009-0 E-025-2009-0-US-03 Ratio Based Biomarkers And Methods of Use Thereof National Stage US 13/144,474 Abandoned US <br />National Stage 13/144,474<br />Filed on 2011-07-13<br />Status: Abandoned 147166612 E-025-2009-0 E-025-2009-0-AU-04 Ratio Based Biomarkers And Methods of Use Thereof National Stage Australia 2010204741 2010204741 Issued Australia <br />National Stage 2010204741<br />Filed on 2010-01-13<br />Status: Issued 147166613 E-025-2009-0 E-025-2009-0-CA-05 Ratio Based Biomarkers And Methods of Use Thereof National Stage Canada 2749601 2749601 Issued Canada <br />National Stage 2749601<br />Filed on 2011-07-13<br />Status: Issued 147166614 E-025-2009-0 E-025-2009-0-EP-06 Ratio Based Biomarkers And Methods of Use Thereof National Stage European Patent 2380025 10700363.4 Issued European Patent <br />National Stage 10700363.4<br />Filed on 2010-01-13<br />Status: Issued 147166615 E-025-2009-0 E-025-2009-0-IL-07 Ratio Based Biomarkers And Methods of Use Thereof National Stage Israel 214046 214046 Issued Israel <br />National Stage 214046<br />Filed on 2011-07-12<br />Status: Issued 147166616 E-025-2009-0 E-025-2009-0-JP-08 Ratio Based Biomarkers And Methods of Use Thereof National Stage Japan 5907732 2011-545543 Issued Japan <br />National Stage 2011-545543<br />Filed on 2010-01-13<br />Status: Issued 147166617 E-025-2009-0 E-025-2009-0-NZ-09 Ratio Based Biomarkers And Methods of Use Thereof National Stage New Zealand 593514 593514 Issued New Zealand <br />National Stage 593514<br />Filed on 2011-06-16<br />Status: Issued 147166618 E-025-2009-0 E-025-2009-0-NZ-10 Ratio Based Biomarkers And Methods of Use Thereof DIV New Zealand 606687 606687 Issued New Zealand <br />Divisional (DIV) 606687<br />Filed on 2013-02-05<br />Status: Issued 147166619 E-025-2009-0 E-025-2009-0-EP-11 Ratio Based Biomarkers And Methods of Use Thereof DIV European Patent 13180742.2 Abandoned European Patent <br />Divisional (DIV) 13180742.2<br />Filed on 2010-01-13<br />Status: Abandoned 147166620 E-025-2009-0 E-025-2009-0-EP-12 Ratio Based Biomarkers And Methods of Use Thereof DIV European Patent 2667195 13180760.4 Issued European Patent <br />Divisional (DIV) 13180760.4<br />Filed on 2010-01-13<br />Status: Issued 147166621 E-025-2009-0 E-025-2009-0-DE-13 Ratio Based Biomarkers And Methods of Use Thereof EP Germany 2380025 10700363.4 Issued Germany <br />European patent (EP) 10700363.4<br />Filed on 2010-01-13<br />Status: Issued 147166622 E-025-2009-0 E-025-2009-0-FR-14 Ratio Based Biomarkers And Methods of Use Thereof EP France 2380025 10700363.4 Issued France <br />European patent (EP) 10700363.4<br />Filed on 2010-01-13<br />Status: Issued 147166623 E-025-2009-0 E-025-2009-0-GB-15 Ratio Based Biomarkers And Methods of Use Thereof EP United Kingdom 2380025 10700363.4 Issued United Kingdom <br />European patent (EP) 10700363.4<br />Filed on 2010-01-13<br />Status: Issued 147166624 E-025-2009-0 E-025-2009-0-JP-16 Ratio Based Biomarkers And Methods of Use Thereof DIV Japan 2013-247548 Abandoned Japan <br />Divisional (DIV) 2013-247548<br />Filed on 2013-11-29<br />Status: Abandoned 147166625 E-025-2009-0 E-025-2009-0-NZ-17 Ratio Based Biomarkers And Methods of Use Thereof DIV New Zealand 624816 624816 Issued New Zealand <br />Divisional (DIV) 624816<br />Filed on 2014-05-12<br />Status: Issued 147166626 E-025-2009-0 E-025-2009-0-IL-18 METHODS FOR DETECTING CANCER AND DETERMINING PROGNOSIS AND SURVIVAL PROBABILITIES AND RATIO BASED BIOMARKERS FOR USE THEREIN DIV Israel 233095 233095 Issued Israel <br />Divisional (DIV) 233095<br />Filed on 2014-06-12<br />Status: Issued 147166627 E-025-2009-0 E-025-2009-0-IL-19 METHODS FOR DETECTING CANCER AND DETERMINING PROGNOSIS AND SURVIVAL PROBABILITIES AND RATIO BASED BIOMARKERS FOR USE THEREIN DIV Israel 233096 233096 Issued Israel <br />Divisional (DIV) 233096<br />Filed on 2014-06-12<br />Status: Issued 147166628 E-025-2009-0 E-025-2009-0-IL-20 METHODS FOR DETECTING CANCER AND DETERMINING PROGNOSIS AND SURVIVAL PROBABILITIES AND RATIO BASED BIOMARKERS FOR USE THEREIN DIV Israel 233097 233097 Issued Israel <br />Divisional (DIV) 233097<br />Filed on 2014-06-12<br />Status: Issued 147166629 E-025-2009-0 E-025-2009-0-IL-21 METHODS FOR DETECTING CANCER AND DETERMINING PROGNOSIS AND SURVIVAL PROBABILITIES AND RATIO BASED BIOMARKERS FOR USE THEREIN DIV Israel 233098 233098 Issued Israel <br />Divisional (DIV) 233098<br />Filed on 2014-06-12<br />Status: Issued 147166630 E-025-2009-0 E-025-2009-0-NZ-22 Ratio Based Biomarkers And Methods of Use Thereof DIV New Zealand 628463 628463 Issued New Zealand <br />Divisional (DIV) 628463<br />Filed on 2014-08-08<br />Status: Issued 147166631 E-025-2009-0 E-025-2009-0-JP-23 Ratio Based Biomarkers And Methods of Use Thereof DIV Japan 6502839 2015-241016 Issued Japan <br />Divisional (DIV) 2015-241016<br />Filed on 2010-01-13<br />Status: Issued 147166632 E-025-2009-0 E-025-2009-0-AU-24 Ratio Based Biomarkers And Methods of Use Thereof DIV Australia 2016202107 2016202107 Issued Australia <br />Divisional (DIV) 2016202107<br />Filed on 2016-04-05<br />Status: Issued 147166633 E-025-2009-0 E-025-2009-0-DE-25 Ratio Based Biomarkers And Methods of Use Thereof EP Germany 2667195 13180760.4 Issued Germany <br />European patent (EP) 13180760.4<br />Filed on 2010-01-13<br />Status: Issued 147166634 E-025-2009-0 E-025-2009-0-FR-26 Ratio Based Biomarkers And Methods of Use Thereof EP France 2667195 13180760.4 Issued France <br />European patent (EP) 13180760.4<br />Filed on 2010-01-13<br />Status: Issued 147166635 E-025-2009-0 E-025-2009-0-GB-27 Ratio Based Biomarkers And Methods of Use Thereof EP United Kingdom 2667195 13180760.4 Issued United Kingdom <br />European patent (EP) 13180760.4<br />Filed on 2010-01-13<br />Status: Issued 147166636 E-025-2009-0 E-025-2009-0-US-28 Ratio Based Biomarkers and Methods of Use Thereof CON US 15/349,991 Abandoned US <br />Continuation (CON) 15/349,991<br />Filed on 2016-11-11<br />Status: Abandoned 147166637 E-025-2009-0 E-025-2009-0-US-29 Ratio Based Biomarker Of Survival Utilizing PTEN And Phospho-AKT CON US 11,237,169 16/217,540 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11237169 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11237169">11,237,169</a><br />Filed on 2018-12-12<br />Status: Issued 147166639 E-025-2009-1 E-025-2009-1-US-01 Ratio Based Biomarkers and Methods of Use Thereof CIP US 13/841,176 Abandoned US <br />Continuation in Part (CIP) 13/841,176<br />Filed on 2013-03-15<br />Status: Abandoned 147166640 E-025-2009-1 E-025-2009-1-PCT-02 Ratio Based Biomarkers And Methods Of Use Thereof PCT Patent Cooperation Treaty PCT/US2014/024936 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2014/024936<br />Filed on 2014-03-12<br />Status: Expired 147166641 E-025-2009-1 E-025-2009-1-CA-03 Ratio Based Biomarkers And Methods Of Use Thereof for the Detection and Prognosis of Cancer National Stage Canada 2904973 Abandoned Canada <br />National Stage 2904973<br />Filed on 2014-03-12<br />Status: Abandoned 147166642 E-025-2009-1 E-025-2009-1-EP-04 Ratio Based Biomarkers And Methods Of Use Thereof National Stage European Patent 14723537.8 Abandoned European Patent <br />National Stage 14723537.8<br />Filed on 2014-03-12<br />Status: Abandoned 147166643 E-025-2009-1 E-025-2009-1-US-05 RATIO BASED BIOMARKERS AND METHODS OF USE THEREOF CON US 15/676,194 Abandoned US <br />Continuation (CON) 15/676,194<br />Filed on 2017-08-14<br />Status: Abandoned 147169705 AKT pathway 147169706 diagnostic 147169708 extrahepatic cholangiocarcinoma 147169709 prognostic TAB-4002 147157283 Oligonucleotide Production Process NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Trevor Broadt, Gautam ("George") Mitra, Samir Shaban, Yueqing Xie, Jianwei Zhu <p>This technology provides improved processes for production and purification of nucleic acid-containing compositions, such as non-naturally occurring viruses, for example, recombinant polioviruses that can be employed as oncolytic agents. Some of the improved processes relate to improved processes for producing viral DNA template. Also provided are improved processes for chromatography purification of nucleic acid-containing compositions, in which the nucleic acid is quantified in chromatography fractions using a rapid detection method of the one or more nucleic acid sequences of the nucleic acid-containing composition, such as detection by real time RT-qPCR. In addition, improved processes for production and purification of oncolytic poliovirus, such as PVSRIPO, are described. Compositions generated using these methods are also provided.</p> <h2>Competitive Advantages:</h2> <ul><li>Cost and time effective means of producing highly purified virus-based GMP products, such as oncolytic viruses, for regulatory approval.</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Large-scale manufacturing for producing highly purified, live virus. </li> <li>Improved viral purification process that:  <ul><li>increases the yield and/or purity of the resulting product, while decreasing the purification time;</li> <li>is generally applicable to purification of any nucleic acid molecule-containing composition, such as virus-based composition, and can be used for the purification of live native or recombinant viruses necessary for clinical applications.</li> </ul></li> <li>Improved process for generating viral template plasmid (such as one that includes a DNA template for an RNA virus), which addresses the problem of genetic instability of the plasmids containing the viral genome (e.g., of a recombinant polio virus) in host (e.g., bacterial) cells, in which the plasmids are typically propagated.</li> </ul> 2016-08-17 2025-04-22 2021-01-27 2025-04-22 2016-08-17 False True Clinical True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2021-01-27 72159138 Clinical Phase I 72159138 NCI 37470483 Website Abstract 147161976 Ouellette T, et al. Large-Scale Chromatographic Purification of an Attenuated Chimeric Poliovirus. https://www.bioprocessingjournal.com/index.php/article-downloads/211-j42-large-scale-chromatographic-purification-of-an-attenuated-chimeric-poliovirus <a href="https://www.bioprocessingjournal.com/index.php/article-downloads/211-j42-large-scale-chromatographic-purification-of-an-attenuated-chimeric-poliovirus">Ouellette T, et al. Large-Scale Chromatographic Purification of an Attenuated Chimeric Poliovirus.</a> 147163179 Zhu, Jianwei NIH - NCI Leidos Zhu, Jianwei (Leidos) 1 147163180 Shaban, Samir NIH - NCI Leidos Shaban, Samir (Leidos) 2 147163178 Xie, Yueqing NIH - NCI Xie, Yueqing 3 147163177 Broadt, Trevor NIH - NCI Leidos Broadt, Trevor (Leidos) 4 147163176 Mitra, Gautam ("George") NIH - NCI Leidos Mitra, Gautam ("George") (Leidos) 5 147163179 Zhu, Jianwei NIH - NCI Leidos Zhu, Jianwei (Leidos) 1 147163180 Shaban, Samir NIH - NCI Leidos Shaban, Samir (Leidos) 2 147163178 Xie, Yueqing NIH - NCI Xie, Yueqing 3 147163177 Broadt, Trevor NIH - NCI Leidos Broadt, Trevor (Leidos) 4 147163176 Mitra, Gautam ("George") NIH - NCI Leidos Mitra, Gautam ("George") (Leidos) 5 147158297 Novel Robust Production Process Of High Purity Polio Virus And Polio Virus Variants (PVS-RIPO) E-267-2014-0 Filing authorized NCI 83732213 Dick, Taryn taryn.dick@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB taryn.dick@nih.gov?subject=Web Inquiry on [TAB-4002] Oligonucleotide Production Process&body=Please send me information about technology [TAB-4002] Oligonucleotide Production Process.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dick, Taryn<br><a href="mailto:taryn.dick@nih.gov?subject=Web Inquiry on [TAB-4002] Oligonucleotide Production Process&body=Please send me information about technology [TAB-4002] Oligonucleotide Production Process.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">taryn.dick@nih.gov</a><br> 147161245 E-267-2014-0 E-267-2014-0-US-07 PROCESSES FOR PRODUCTION AND PURIFICATION OF NUCLEIC ACID-CONTAINING COMPOSITIONS National Stage US 10,954,492 15/579,137 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10954492 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10954492">10,954,492</a><br />Filed on 2017-12-01<br />Status: Issued 147165827 E-267-2014-0 E-267-2014-0-US-01 PROCESS FOR PRODUCTION AND PURIFICATION OF NUCLEIC ACID-CONTAINING COMPOSITIONS PRV US 62/173,777 Abandoned US <br />Provisional (PRV) 62/173,777<br />Filed on 2015-06-10<br />Status: Abandoned 147165828 E-267-2014-0 E-267-2014-0-PCT-02 PROCESSES FOR PRODUCTION AND PURIFICATION OF NUCLEIC ACID-CONTAINING COMPOSITIONS PCT Patent Cooperation Treaty PCT/US2016/036888 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2016/036888<br />Filed on 2016-06-10<br />Status: Expired 147165829 E-267-2014-0 E-267-2014-0-CN-03 PROCESSES FOR PRODUCTION AND PURIFICATION OF NUCLEIC ACID-CONTAINING COMPOSITIONS National Stage China ZL201680034090.3 201680034090.3 Issued China <br />National Stage 201680034090.3<br />Filed on 2016-06-10<br />Status: Issued 147165830 E-267-2014-0 E-267-2014-0-EP-04 PROCESSES FOR PRODUCTION AND PURIFICATION OF NUCLEIC ACID-CONTAINING COMPOSITIONS National Stage European Patent 3307878 16732426.8 Issued European Patent <br />National Stage 16732426.8<br />Filed on 2016-06-10<br />Status: Issued 147165831 E-267-2014-0 E-267-2014-0-JP-05 PROCESSES FOR PRODUCTION AND PURIFICATION OF NUCLEIC ACID-CONTAINING COMPOSITIONS National Stage Japan 6886410 2017-563547 Issued Japan <br />National Stage 2017-563547<br />Filed on 2016-06-10<br />Status: Issued 147165832 E-267-2014-0 E-267-2014-0-SG-06 PROCESSES FOR PRODUCTION AND PURIFICATION OF NUCLEIC ACID-CONTAINING COMPOSITIONS National Stage Singapore 11201709382T Pending Singapore <br />National Stage 11201709382T<br />Filed on 2017-11-14<br />Status: Pending 147165833 E-267-2014-0 E-267-2014-0-BE-08 PROCESSES FOR PRODUCTION AND PURIFICATION OF NUCLEIC ACID-CONTAINING COMPOSITIONS EP Belgium 3307878 16732426.8 Issued Belgium <br />European patent (EP) 16732426.8<br />Filed on 2016-06-10<br />Status: Issued 147165834 E-267-2014-0 E-267-2014-0-CH-09 PROCESSES FOR PRODUCTION AND PURIFICATION OF NUCLEIC ACID-CONTAINING COMPOSITIONS EP Switzerland 3307878 16732426.8 Issued Switzerland <br />European patent (EP) 16732426.8<br />Filed on 2016-06-10<br />Status: Issued 147165835 E-267-2014-0 E-267-2014-0-DE-10 PROCESSES FOR PRODUCTION AND PURIFICATION OF NUCLEIC ACID-CONTAINING COMPOSITIONS EP Germany 3307878 16732426.8 Issued Germany <br />European patent (EP) 16732426.8<br />Filed on 2016-06-10<br />Status: Issued 147165836 E-267-2014-0 E-267-2014-0-DK-11 PROCESSES FOR PRODUCTION AND PURIFICATION OF NUCLEIC ACID-CONTAINING COMPOSITIONS EP Denmark 3307878 16732426.8 Issued Denmark <br />European patent (EP) 16732426.8<br />Filed on 2016-06-10<br />Status: Issued 147165837 E-267-2014-0 E-267-2014-0-ES-12 PROCESSES FOR PRODUCTION AND PURIFICATION OF NUCLEIC ACID-CONTAINING COMPOSITIONS EP Spain 3307878 16732426.8 Issued Spain <br />European patent (EP) 16732426.8<br />Filed on 2016-06-10<br />Status: Issued 147165838 E-267-2014-0 E-267-2014-0-FR-13 PROCESSES FOR PRODUCTION AND PURIFICATION OF NUCLEIC ACID-CONTAINING COMPOSITIONS EP France 3307878 16732426.8 Issued France <br />European patent (EP) 16732426.8<br />Filed on 2016-06-10<br />Status: Issued 147165839 E-267-2014-0 E-267-2014-0-GB-14 PROCESSES FOR PRODUCTION AND PURIFICATION OF NUCLEIC ACID-CONTAINING COMPOSITIONS EP United Kingdom 3307878 16732426.8 Issued United Kingdom <br />European patent (EP) 16732426.8<br />Filed on 2016-06-10<br />Status: Issued 147165840 E-267-2014-0 E-267-2014-0-IE-15 PROCESSES FOR PRODUCTION AND PURIFICATION OF NUCLEIC ACID-CONTAINING COMPOSITIONS EP Ireland 3307878 16732426.8 Issued Ireland <br />European patent (EP) 16732426.8<br />Filed on 2016-06-10<br />Status: Issued 147165841 E-267-2014-0 E-267-2014-0-IT-16 PROCESSES FOR PRODUCTION AND PURIFICATION OF NUCLEIC ACID-CONTAINING COMPOSITIONS EP Italy 3307878 16732426.8 Issued Italy <br />European patent (EP) 16732426.8<br />Filed on 2016-06-10<br />Status: Issued 147165842 E-267-2014-0 E-267-2014-0-NL-17 PROCESSES FOR PRODUCTION AND PURIFICATION OF NUCLEIC ACID-CONTAINING COMPOSITIONS EP The Netherlands 3307878 16732426.8 Issued The Netherlands <br />European patent (EP) 16732426.8<br />Filed on 2016-06-10<br />Status: Issued 147165843 E-267-2014-0 E-267-2014-0-NO-18 PROCESSES FOR PRODUCTION AND PURIFICATION OF NUCLEIC ACID-CONTAINING COMPOSITIONS EP Norway 3307878 16732426.8 Issued Norway <br />European patent (EP) 16732426.8<br />Filed on 2016-06-10<br />Status: Issued 147165844 E-267-2014-0 E-267-2014-0-SE-19 PROCESSES FOR PRODUCTION AND PURIFICATION OF NUCLEIC ACID-CONTAINING COMPOSITIONS EP Sweden 3307878 16732426.8 Issued Sweden <br />European patent (EP) 16732426.8<br />Filed on 2016-06-10<br />Status: Issued TAB-4392 147157687 Methods of analyzing virus-derived therapeutics NCI Collaboration, Diagnostics, Immunology, Infectious Disease, Licensing, Oncology Collaboration Diagnostics Immunology Infectious Disease Licensing Oncology Trevor Broadt, William Budd, Michael Harwich, Gregory Meyers <p>Researchers at the <a href="https://dtp.cancer.gov/" target="_blank" rel="nofollow">National Cancer Institute’s Biopharmaceutical Development Program</a> recently developed massively parallel sequencing methods for virus-derived therapeutics such as viral vaccines and oncolytic immunotherapies. The methods allow for the determination of micro-heterogeneity and quantitation of low frequency sequence variants, which have the possibility of supplanting monkey neurovirulence safety testing (MNVT), mutant analysis by PCR, and restriction enzyme cleavage (MAPREC) methods that are currently used to screen RNA virus-derived therapeutics. The technology is currently in clinical stage.</p> <h2>Competitive Advantages:</h2> <ul><li>Provides a cost- and time-effective means of assaying a virus-derived therapeutic, such as oncolytic viruses, for viral sequence variants, for regulatory approval;</li> <li>RNA virus preparation steps increase the amount of viral RNA obtained;</li> <li>Demonstrated superiority of massively parallel sequencing (“MPS”) over mutant analysis by PCR and restriction enzyme cleavage (“MAPREC”) analysis.</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Improved methods for detecting mutations in GMP-manufactured virus-derived therapeutics, including viruses, viral template plasmids, or vaccines;</li> <li>The method allows for at least two different virus-derived therapeutics to be assayed simultaneously.</li> </ul> 2016-08-18 2025-04-22 2017-12-19 2025-04-22 2016-08-18 MAPREC, massively parallel sequencing, MNVT, monkey neurovirulence safety testing, mutant analysis, oncolytic immunotherapy, restriction enzyme cleavage, RNA virus-derived, viral vaccines, virus-derived therapeutic False True Clinical True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2017-12-19 72159138 Clinical Phase I 72159138 NCI 37470483 Website Abstract E-267-2014 147164570 Broadt, Trevor NIH - NCI Leidos Broadt, Trevor (Leidos) 1 147164571 Harwich, Michael American International Biotechnology, LLC Harwich, Michael 2 147164572 Budd, William American International Biotechnology, LLC Budd, William 3 147164573 Meyers, Gregory American International Biotechnology, LLC Meyers, Gregory 4 147164570 Broadt, Trevor NIH - NCI Leidos Broadt, Trevor (Leidos) 1 147164571 Harwich, Michael American International Biotechnology, LLC Harwich, Michael 2 147164572 Budd, William American International Biotechnology, LLC Budd, William 3 147164573 Meyers, Gregory American International Biotechnology, LLC Meyers, Gregory 4 147158256 Use Of Massively Parallel Sequencing Methods With High Titer Viral Therapeutics And Vaccines For The Detection Of Micro-heterogeneity And Quantitation Of Low Frequency Sequence Variants E-240-2015-0 Filing authorized American International Biotechnology, LLC, NCI 147162578 Use Of Massively Parallel Sequencing Methods With High Titer Viral Therapeutics And Vaccines For The Detection Of Micro-heterogeneity And Quantitation Of Low Frequency Sequence Variants E-240-2015-1 Filing authorized American International Biotechnology, LLC, NCI 83732917 Favila, Michelle michelle.favila@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC michelle.favila@nih.gov?subject=Web Inquiry on [TAB-4392] Methods of analyzing virus-derived therapeutics&body=Please send me information about technology [TAB-4392] Methods of analyzing virus-derived therapeutics.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Favila, Michelle<br><a href="mailto:michelle.favila@nih.gov?subject=Web Inquiry on [TAB-4392] Methods of analyzing virus-derived therapeutics&body=Please send me information about technology [TAB-4392] Methods of analyzing virus-derived therapeutics.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">michelle.favila@nih.gov</a><br> 147161221 E-240-2015-1 E-240-2015-1-US-05 METHODS OF ANALYZING VIRUS-DERIVED THERAPEUTICS National Stage US 10,662,464 15/580,299 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10662464 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10662464">10,662,464</a><br />Filed on 2017-12-07<br />Status: Issued 147168628 E-240-2015-0 E-240-2015-0-US-01 METHODS OF ANALYSIS OF RNA VIRUS-DERIVED THERAPEUTICS PRV US 62/199,663 Abandoned US <br />Provisional (PRV) 62/199,663<br />Filed on 2015-07-31<br />Status: Abandoned 147168630 E-240-2015-1 E-240-2015-1-PCT-01 Methods of Analyzing Virus-Derived Therapeutics PCT COMB Patent Cooperation Treaty PCT/US2016/044788 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2016/044788<br />Filed on 2016-07-29<br />Status: Expired 147168631 E-240-2015-1 E-240-2015-1-CN-02 Methods of Analyzing Virus-Derived Therapeutics National Stage China ZL201680045182.1 201680045182.1 Issued China <br />National Stage 201680045182.1<br />Filed on 2016-07-29<br />Status: Issued 147168632 E-240-2015-1 E-240-2015-1-EP-03 Methods of Analyzing Virus-Derived Therapeutics National Stage European Patent 3329013 16750580.9 Issued European Patent <br />National Stage 16750580.9<br />Filed on 2016-07-29<br />Status: Issued 147168633 E-240-2015-1 E-240-2015-1-JP-04 Methods of Analyzing Virus-Derived Therapeutics National Stage Japan 6907202 2018-525528 Issued Japan <br />National Stage 2018-525528<br />Filed on 2016-07-29<br />Status: Issued 147168634 E-240-2015-1 E-240-2015-1-DE-06 Methods of Analyzing Virus-Derived Therapeutics EP Germany 3329013 16750580.9 Issued Germany <br />European patent (EP) 16750580.9<br />Filed on 2016-07-29<br />Status: Issued 147168635 E-240-2015-1 E-240-2015-1-FR-07 Methods of Analyzing Virus-Derived Therapeutics EP France 3329013 16750580.9 Issued France <br />European patent (EP) 16750580.9<br />Filed on 2016-07-29<br />Status: Issued 147168636 E-240-2015-1 E-240-2015-1-GB-08 Methods of Analyzing Virus-Derived Therapeutics EP United Kingdom 3329013 16750580.9 Issued United Kingdom <br />European patent (EP) 16750580.9<br />Filed on 2016-07-29<br />Status: Issued 147168637 E-240-2015-1 E-240-2015-1-CN-09 Methods of Analyzing Virus-Derived Therapeutics DIV China 202111246733X Abandoned China <br />Divisional (DIV) 202111246733X<br />Filed on 2021-10-26<br />Status: Abandoned 147168638 E-240-2015-1 E-240-2015-1-MO-10 Methods of Analyzing Virus-Derived Therapeutics CN Macao J/005746 J/005746 Issued Macao <br />China Patent (CN) J/005746<br />Filed on 2022-01-19<br />Status: Issued 147174103 MAPREC 147174105 massively parallel sequencing 147174107 MNVT 147174109 monkey neurovirulence safety testing 147174111 mutant analysis 147174113 oncolytic immunotherapy 147174115 restriction enzyme cleavage 147174117 RNA virus-derived 147174119 viral vaccines 147174121 virus-derived therapeutic TAB-4207 147157492 Novel Fixative for Improved Biomolecule Quality from Paraffin-Embedded Tissue NCI Licensing, Medical Devices, Non-Medical Devices, Oncology Licensing Medical Devices Non-Medical Devices Oncology Joon-Yong Chung, Stephen Hewitt, Candice Perry, Robert Star <p>Tissues samples collected during medical procedures, such as biopsies, are used to diagnose a wide variety of diseases. Before diagnosis, patient samples are typically processed by fixation and paraffin embedding. This fixation/embedding process is used to preserve tissue morphology and histology for subsequent evaluation. Unfortunately, most fixative agents can damage or destroy nucleic acids (RNA and DNA) and damage proteins during the fixation process, thereby potentially impairing diagnostic assessment of tissue.</p> <p>Researchers in the National Cancer Institute’s <a href="https://ccr.cancer.gov/Laboratory-of-Pathology" rel="nofollow">Laboratory of Pathology</a> have developed an improved tissue fixative solution that is formaldehyde-free. This novel fixative, BE70, significantly improves DNA, RNA, and protein biomolecule integrity in histological samples compared to traditional fixatives. Additionally, BE70 is compatible with current protocols and does not alter tissue processing.</p> <h2>Competitive Advantages:</h2> <ul><li>There is substantial interest in new fixatives to replace neutral buffered formalin (a carcinogen) as primary fixative agent for surgical pathology</li> <li>BE70 overcomes several limitations of other fixatives, including cost and disposal issues</li> <li>Could be formulated as a concentrate, and marketed as an additive (to be added during dilution of ethanol)</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Improve integrity of fixed tissue samples</li> <li>Improve RNA/DNA quality in fixed tissue samples</li> <li>Non-cross linking, improved protein quality</li> </ul> 2016-09-22 2025-04-22 2018-07-19 2025-04-22 2016-09-22 CULTURE, fixative, Histology, PARAFFIN, PATHOLOGY, Tissue False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2018-07-19 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-128-2017 E-173-2015 147162234 Perry C, et al. A Buffered Alcohol-Based Fixative for Histomorphologic and Molecular Applications. https://www.ncbi.nlm.nih.gov/pubmed/27221702 <a href="https://www.ncbi.nlm.nih.gov/pubmed/27221702">Perry C, et al. A Buffered Alcohol-Based Fixative for Histomorphologic and Molecular Applications.</a> 147163915 Hewitt, Stephen NIH - NCI NCI Hewitt, Stephen (NCI) 1 147163917 Perry, Candice NIH - NCI Leidos Perry, Candice (Leidos) 2 147163916 Chung, Joon-Yong NIH - NCI NCI Chung, Joon-Yong (NCI) 3 147163914 Star, Robert NIH - NIDDK NIDDK Star, Robert (NIDDK) 4 147163915 Hewitt, Stephen NIH - NCI NCI Hewitt, Stephen (NCI) 1 147163917 Perry, Candice NIH - NCI Leidos Perry, Candice (Leidos) 2 147163916 Chung, Joon-Yong NIH - NCI NCI Chung, Joon-Yong (NCI) 3 147163914 Star, Robert NIH - NIDDK NIDDK Star, Robert (NIDDK) 4 147158069 Novel Fixative For Improved Biomolecule Quality From Paraffin Embedded Tissue E-139-2015-0 Filing authorized National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NCI 121111111 Greene, Jaime greenejaime@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America greenejaime@mail.nih.gov?subject=Web Inquiry on [TAB-4207] Novel Fixative for Improved Biomolecule Quality from Paraffin-Embedded Tissue&body=Please send me information about technology [TAB-4207] Novel Fixative for Improved Biomolecule Quality from Paraffin-Embedded Tissue.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Greene, Jaime<br><a href="mailto:greenejaime@mail.nih.gov?subject=Web Inquiry on [TAB-4207] Novel Fixative for Improved Biomolecule Quality from Paraffin-Embedded Tissue&body=Please send me information about technology [TAB-4207] Novel Fixative for Improved Biomolecule Quality from Paraffin-Embedded Tissue.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">greenejaime@mail.nih.gov</a><br> 147161101 E-139-2015-0 E-139-2015-0-US-01 Fixatives and Methods of Use PRV US 62/255,030 Abandoned US <br />Provisional (PRV) 62/255,030<br />Filed on 2015-11-13<br />Status: Abandoned 147167355 E-139-2015-0 E-139-2015-0-PCT-02 FIXATIVES AND METHODS OF USE PCT Patent Cooperation Treaty PCT/US2016/061642 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2016/061642<br />Filed on 2016-11-11<br />Status: Expired 147167356 E-139-2015-0 E-139-2015-0-EP-03 FIXATIVES AND METHODS OF USE National Stage European Patent 3374751 16809238.5 Issued European Patent <br />National Stage 16809238.5<br />Filed on 2016-11-11<br />Status: Issued 147167357 E-139-2015-0 E-139-2015-0-US-04 FIXATIVES AND METHODS OF USE National Stage US 11,313,772 15/774,480 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11313772 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11313772">11,313,772</a><br />Filed on 2018-05-08<br />Status: Issued 147167358 E-139-2015-0 E-139-2015-0-US-05 FIXATIVES AND METHODS OF USE DIV US 12,270,738 17/716,606 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12270738 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12270738">12,270,738</a><br />Filed on 2022-04-08<br />Status: Issued 147167359 E-139-2015-0 E-139-2015-0-FR-01 FIXATIVES AND METHODS OF USE EP France 3374751 16809238.5 Issued France <br />European patent (EP) 16809238.5<br />Filed on 2016-11-11<br />Status: Issued 147167360 E-139-2015-0 E-139-2015-0-DE-01 FIXATIVES AND METHODS OF USE EP Germany 3374751 16809238.5 Issued Germany <br />European patent (EP) 16809238.5<br />Filed on 2016-11-11<br />Status: Issued 147167361 E-139-2015-0 E-139-2015-0-GB-01 FIXATIVES AND METHODS OF USE EP United Kingdom 3374751 16809238.5 Issued United Kingdom <br />European patent (EP) 16809238.5<br />Filed on 2016-11-11<br />Status: Issued 147172251 CULTURE 147172252 fixative 147172253 Histology 147172254 PARAFFIN 147172255 PATHOLOGY 147172256 Tissue TAB-3903 147157183 A549 Cells: Lung Carcinoma Cell Line for Adenovirus NCI Licensing, Oncology, Research Materials Licensing Oncology Research Materials Stuart Aaronson, Donald Giard, Wade Parks <p>Scientists at the National Cancer Institute developed a cell line designated A549 that was derived from explanted cultures of human lung cancer tissue. The A549 cell line has been tested under the guidance of the United States Food and Drug Administration (FDA) so, under current Good Manufacturing Practices (GMP), these cells may be suitable for use in manufacturing constructs for use in clinical trials. The A549 cell line has also been found to be suitable for adenovirus production, most notably replicating adenovirus constructs that do not require complementation by the viral oncogene, early region 1A (E1A), which is responsible for viral gene transcription. This cell line is further utilized as a negative control in assays to measure the replication of adenoviruses that lack E1A and as a target cell line to detect replication competent adenoviruses (RCA). A549 cells have been well characterized through their use in a wide variety of molecular studies, such as anti-tumor drug permeability and efficacy analysis, infection assays, respiratory immunotoxicity tests, cell senescence studies, and cytokine expression profiling. These cells can also be utilized to study a variety of molecular characteristics for human tumors in culture.</p> <h2>Competitive Advantages:</h2> <ul><li>A549 cells are a well-characterized standard among the human lung carcinoma/alveolar cell lines used in molecular biology.</li> <li>The A549 cells stored at the NIH were tested under the guidance of the FDA’s cGMP regulations and may be suitable for producing adenoviruses that can be used in clinical trials and analyzing adenoviral-based therapies and vaccine strategies.</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Cell bank tested under cGMP-compliance regulations and used to produce adenoviruses for use in clinical trials</li> <li>Research tool to analyze the efficacy of potential anti-cancer agents to devise better cancer treatments for malignancies, such as non-small cell lung cancer (NSCLC)</li> <li>Research tool to study the infectivity of viruses that cause asthma in order to develop better asthma treatments</li> <li>Standard research tool to analyze a variety of molecular biology procedures, for example, cell senescence, cytokine induction, protein expression, apoptosis, and receptor-ligand interactions</li> </ul> 2016-11-02 2025-04-22 2018-05-30 2025-04-22 2016-11-02 A549, ADENOVIRUS, human lung cancer False True Basic (Target Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2018-05-30 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147161960 D.J. Giard et al. In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors. J Natl Cancer Inst. 1973 Nov;51(5):1417-1423. https://www.ncbi.nlm.nih.gov/pubmed/4357758 <a href="https://www.ncbi.nlm.nih.gov/pubmed/4357758">D.J. Giard et al. In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors. J Natl Cancer Inst. 1973 Nov;51(5):1417-1423.</a> 147162808 Parks, Wade NIH - NCI Parks, Wade 1 147162807 Aaronson, Stuart NIH - NCI Aaronson, Stuart 2 147162809 Giard, Donald NIH - NCI Giard, Donald 3 147162808 Parks, Wade NIH - NCI Parks, Wade 1 147162807 Aaronson, Stuart NIH - NCI Aaronson, Stuart 2 147162809 Giard, Donald NIH - NCI Giard, Donald 3 147158040 In Vitro Cultivation Of Human Tumors: Establishment Of Cell Lines Derived From A Series Of Solid Tumors (A549) E-129-2009-0 Research Material NCI 91814193 Freel, Rose rose.freel@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America rose.freel@nih.gov?subject=Web Inquiry on [TAB-3903] A549 Cells: Lung Carcinoma Cell Line for Adenovirus&body=Please send me information about technology [TAB-3903] A549 Cells: Lung Carcinoma Cell Line for Adenovirus.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Freel, Rose<br><a href="mailto:rose.freel@nih.gov?subject=Web Inquiry on [TAB-3903] A549 Cells: Lung Carcinoma Cell Line for Adenovirus&body=Please send me information about technology [TAB-3903] A549 Cells: Lung Carcinoma Cell Line for Adenovirus.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">rose.freel@nih.gov</a><br> 147172018 A549 147172019 ADENOVIRUS 147172021 human lung cancer TAB-4028 147157309 Small Molecule Inhibitors of Drug Resistant Forms of HIV-1 Integrase NCI Collaboration, Infectious Disease, Licensing, Therapeutics Collaboration Infectious Disease Licensing Therapeutics Terrence Burke, Stephen Hughes, Barry Johnson, Christophe Marchand, Mathieu Metifiot, Yves Pommier, Stephen Smith, Xue Zhao <p>Integrase strand transfer inhibitors (“INSTIs”) are currently in use as a component of prophylactic antiretroviral therapy for preventing HIV-1 infection from progressing to AIDS. Three INSTIs are approved by the FDA for inclusion in antiretroviral regiments: raltegravir (RAL), elvitegravir (EVG) and dolutegravir (DTG). Clinicians have already identified several HIV-1 integrase mutations that confer resistance to RAL and EVG, and additional mutations that confer resistance to all three INSTIs has been identified in the laboratory.</p> <p>Researchers at the National Cancer Institute discovered small-molecule compounds containing 1-hydroxy-2-oxo-1,8-naphthyridine moieties whose activity against HIV-1 integrase mutants confer resistance to currently approved INSTIs. These new compounds exhibit potent and selective activity against comprehensive and varied panels of INSTI-resistant mutants of HIV-1 integrase. Preliminary metabolic and pharmacokinetic studies have been completed by the NCI researchers.</p> <p>The National Cancer Institute (NCI) seeks partners to in-license or co-develop this class of compounds for therapeutic use. Parties interested in licensing the technology should submit an Application for Licensing, and seek detailed information from the Licensing and Patenting Manager indicated below.</p> <p>Co-development partners would apply under a Cooperative Research and Development (CRADA) to conduct pre-clinical studies. Under the CRADA, further <em>in vitro</em> and <em>in vivo</em> ADME, as well as IND-enabling studies, will be conducted by the partner on current and optimized lead compounds. Efficacy studies in non-human primates of select compounds are needed and will be part of the CRADA program.  The CRADA scope will also include all aspects of toxicity studies, and synthesis scale up under GMP of optimized lead compounds to support submission of a successful IND application.</p> <p>Licensing of background technology related to this CRADA opportunity is also available to potential collaborators. </p> <h2>Competitive Advantages:</h2> <ul><li>Currently, the only INSTI effective against drug resistant mutants of HIV-1 integrase</li> </ul> <h2>Commercial Applications:</h2> <ul><li>HIV therapeutic for drug-resistant mutants of HIV-1 integrase</li> </ul> 2016-10-21 2025-04-22 2021-08-25 2025-04-22 2016-10-25 dolutegravir, drug resistant HIV, elvitegravir, HIV therapy, Integrase, raltegravir, strand transfer False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-08-25 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147161878 Smith, S.J. Integrase Strand Transfer Inhibitors Are Effective Anti-HIV Drugs https://pubmed.ncbi.nlm.nih.gov/33572956/ <a href="https://pubmed.ncbi.nlm.nih.gov/33572956/">Smith, S.J. Integrase Strand Transfer Inhibitors Are Effective Anti-HIV Drugs</a> 147162266 Zhao X, et al. HIV-1 Integrase Strand Transfer Inhibitors with Reduced Susceptibility to Drug Resistant Mutant Integrases. https://www.ncbi.nlm.nih.gov/pubmed/26808478 <a href="https://www.ncbi.nlm.nih.gov/pubmed/26808478">Zhao X, et al. HIV-1 Integrase Strand Transfer Inhibitors with Reduced Susceptibility to Drug Resistant Mutant Integrases.</a> 147162419 Smith, S.J. HIV-1 Integrase Inhibitors That Are Active against Drug-Resistant Integrase Mutants https://pubmed.ncbi.nlm.nih.gov/32601157/ <a href="https://pubmed.ncbi.nlm.nih.gov/32601157/">Smith, S.J. HIV-1 Integrase Inhibitors That Are Active against Drug-Resistant Integrase Mutants</a> 147163272 Zhao, Xue NIH - NCI NCI Zhao, Xue (NCI) 1 147163271 Burke, Terrence NIH - NCI NCI Burke, Terrence (NCI) 2 147163268 Pommier, Yves NIH - NCI NCI Pommier, Yves (NCI) 3 147163269 Hughes, Stephen NIH - NCI NCI Hughes, Stephen (NCI) 4 147163275 Metifiot, Mathieu NIH - NCI Metifiot, Mathieu 5 147163274 Smith, Stephen NIH - NCI NCI Smith, Stephen (NCI) 6 147163273 Johnson, Barry NIH - NCI Johnson, Barry 7 147163270 Marchand, Christophe NIH - NCI NCI Marchand, Christophe (NCI) 8 147163272 Zhao, Xue NIH - NCI NCI Zhao, Xue (NCI) 1 147163271 Burke, Terrence NIH - NCI NCI Burke, Terrence (NCI) 2 147163268 Pommier, Yves NIH - NCI NCI Pommier, Yves (NCI) 3 147163269 Hughes, Stephen NIH - NCI NCI Hughes, Stephen (NCI) 4 147163275 Metifiot, Mathieu NIH - NCI Metifiot, Mathieu 5 147163274 Smith, Stephen NIH - NCI NCI Smith, Stephen (NCI) 6 147163273 Johnson, Barry NIH - NCI Johnson, Barry 7 147163270 Marchand, Christophe NIH - NCI NCI Marchand, Christophe (NCI) 8 147157970 Hydroxylamide-containing Compounds With Improved Efficacy Against Raltegravir-resistant Strains Of HIV-1 Integrase E-093-2013-0 Filing authorized NCI 147162523 Substituted 4-amino-N-(2,4-difluorobenzyl)-1-hydroxy-2-oxo-1,2-dihydro-1,8-naphthyridine-3-carboxamides With Improved Efficacy Against Viral Constructs Harboring Mutant Strains Of HIV-1 Integrase E-093-2013-1 Filing authorized NCI 147162524 Substituted 4-amino-N-(2,4-difluorobenzyl)-1-hydroxy-2-oxo-1,2-dihydro-1,8-naphthyridine-3-carboxamides With Improved Efficacy Against Viral Constructs Harboring Mutant Strains Of HIV-1 Integrase E-093-2013-2 Filing authorized NCI 91814193 Freel, Rose rose.freel@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America rose.freel@nih.gov?subject=Web Inquiry on [TAB-4028] Small Molecule Inhibitors of Drug Resistant Forms of HIV-1 Integrase&body=Please send me information about technology [TAB-4028] Small Molecule Inhibitors of Drug Resistant Forms of HIV-1 Integrase.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Freel, Rose<br><a href="mailto:rose.freel@nih.gov?subject=Web Inquiry on [TAB-4028] Small Molecule Inhibitors of Drug Resistant Forms of HIV-1 Integrase&body=Please send me information about technology [TAB-4028] Small Molecule Inhibitors of Drug Resistant Forms of HIV-1 Integrase.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">rose.freel@nih.gov</a><br> 147161027 E-093-2013-2 E-093-2013-2-US-10 COMPOUNDS FOR INHIBITING DRUG-RESISTANT STRAINS OF HIV-1 INTEGRASE DIV US 10,208,035 15/589,590 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10208035 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10208035">10,208,035</a><br />Filed on 2017-05-08<br />Status: Issued 147166097 E-093-2013-0 E-093-2013-0-US-01 Compounds For Inhibiting Drug-Resistant Strains Of HIV-1 Integrase PRV US 61/824,306 Abandoned US <br />Provisional (PRV) 61/824,306<br />Filed on 2013-05-16<br />Status: Abandoned 147166099 E-093-2013-1 E-093-2013-1-US-01 COMPOUNDS FOR INHIBITING DRUG-RESISTANT STRAINS OF HIV-1 INTEGRASE PRV US 61/899,061 Abandoned US <br />Provisional (PRV) 61/899,061<br />Filed on 2013-11-01<br />Status: Abandoned 147166100 E-093-2013-2 E-093-2013-2-PCT-01 Compounds For Inhibiting Drug-Resistant Strains Of HIV-1 Integrase PCT Patent Cooperation Treaty PCT/US2014/037905 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2014/037905<br />Filed on 2014-05-13<br />Status: Expired 147166102 E-093-2013-2 E-093-2013-2-US-08 Compounds for Inhibiting Drug-Resistant Strains of HIV-1 Integrase National Stage US 9,676,771 14/891,309 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9676771 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9676771">9,676,771</a><br />Filed on 2015-11-13<br />Status: Issued 147166103 E-093-2013-2 E-093-2013-2-BR-02 Compounds For Inhibiting Drug-Resistant Strains Of HIV-1 Integrase National Stage Brazil BR1120150287603 Abandoned Brazil <br />National Stage BR1120150287603<br />Filed on 2014-05-13<br />Status: Abandoned 147166104 E-093-2013-2 E-093-2013-2-CA-03 Compounds For Inhibiting Drug-Resistant Strains Of HIV-1 Integrase National Stage Canada 2912064 Abandoned Canada <br />National Stage 2912064<br />Filed on 2014-05-13<br />Status: Abandoned 147166105 E-093-2013-2 E-093-2013-2-CN-04 Compounds For Inhibiting Drug-Resistant Strains Of HIV-1 Integrase National Stage China 201480039611.5 Abandoned China <br />National Stage 201480039611.5<br />Filed on 2014-05-13<br />Status: Abandoned 147166106 E-093-2013-2 E-093-2013-2-EP-05 Compounds For Inhibiting Drug-Resistant Strains Of HIV-1 Integrase National Stage European Patent 14728395.6 Abandoned European Patent <br />National Stage 14728395.6<br />Filed on 2014-05-13<br />Status: Abandoned 147166107 E-093-2013-2 E-093-2013-2-IN-06 Compounds For Inhibiting Drug-Resistant Strains Of HIV-1 Integrase National Stage India 3937/KOLNP/2015 Abandoned India <br />National Stage 3937/KOLNP/2015<br />Filed on 2014-05-13<br />Status: Abandoned 147166108 E-093-2013-2 E-093-2013-2-JP-07 Compounds For Inhibiting Drug-Resistant Strains Of HIV-1 Integrase National Stage Japan 2016-514045 Abandoned Japan <br />National Stage 2016-514045<br />Filed on 2014-05-13<br />Status: Abandoned 147166109 E-093-2013-2 E-093-2013-2-ZA-09 Compounds For Inhibiting Drug-Resistant Strains Of HIV-1 Integrase National Stage South Africa 2015/08408 Abandoned South Africa <br />National Stage 2015/08408<br />Filed on 2014-05-13<br />Status: Abandoned 147171225 dolutegravir 147171227 drug resistant HIV 147171229 elvitegravir 147171231 HIV therapy 147171232 Integrase 147171234 raltegravir 147171236 strand transfer TAB-4004 147157285 Genetically Engineered Mouse-Derived Allograft for Preclinical Studies of Metastatic Melanoma NCI Collaboration, Licensing, Oncology, Research Materials Collaboration Licensing Oncology Research Materials Chi-Ping Day, Rajaa El Meskini, Glenn Merlino, Zoe Ohler, Thomas Tuting, Terry Van Dyke <p>The invention listed below is owned by an agency of the U.S. Government and is available for licensing and/or co-development in the U.S. in accordance with 35 U.S.C. 209 and 37 CFR part 404 to achieve expeditious commercialization of results of federally-funded research and development.</p> <p>Before testing drugs in humans, drug developers are required to demonstrate a reasonable expectation of safety and efficacy by performing so-called pre-clinical studies.  A key element of such trials is the use of animal models, typically mice or rats that are selected for demonstrating hallmarks of a given disease.  For cancer research, while many mouse models exist to simulate the response of the cancer to a particular drug, all of the current models have some limitations in their ability to fully predict the concomitant physiological or immunological response that might result when the drug progresses to clinical trials.  This is problematic both in models in which the cancer spontaneously develops in the animal as well as models in which cancerous cells or tumors, i.e. allografts (derived from cells of the same organism) or xenografts (derived from cells of different organism, usually humans) are transplanted into an otherwise cancer-free animal. </p> <p>To address these issues, researchers at NCI have developed a means of more closely simulating in mouse models both melanoma cancer itself and the resulting physiological an immunological response by creating a genetically engineered mice (GEM)-derived allograft (GDA).  This allograft both resembles human-like melanoma and has features that will stimulate a normal immunological response in the mouse.  Thus, when transplanted into a host, the resulting tumor-containing mouse may be used to test conventional cancer therapies (e.g., chemotherapy and radiotherapy), targeted drugs (e.g., kinase inhibitors), and immunotherapies with an expectation that the response in the mouse will more closely mimic the types of responses expected in humans if the therapy progresses to clinical trials.  Further this melanoma-based GDA approach may represent a new standard for building or improving preclinical models of other types of cancer.</p> <h2>Competitive Advantages:</h2> <ul><li>Hgf-tg;Cdk4R24C C57BL/6 mouse-derived melanoma allograft with humanized pathogenetics allows adoption of clinically relevant procedures and endpoints, facilitating clinical translation.</li> <li>Features a constitutively activated MET/MAPK pathway and disrupted CDKN2A pathway.</li> <li>Expresses typical diagnostic markers of human melanoma such as DCT and TRP1.</li> <li>Exhibits progression patterns relevant to human disease.</li> </ul> <h2>Commercial Applications:</h2> <ul><li>A mouse allograft model that provides a preclinical model of human-like advanced-stage melanoma.</li> <li>Allograft model may be useful for preclinical testing of conventional cancer therapies, targeted cancer therapies, and cancer immunotherapies.</li> </ul> 2016-11-25 2025-04-22 2018-07-19 2025-04-22 2016-11-29 Allograft, GDA, Genetically Engineered Mouse-Derived Allograft, MELANOMA, Metastasis, mouse model, Preclinical, therapeutics False True Basic (Target Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2018-07-19 52406768 Discovery 52406768 NCI 37470483 Website Abstract E-173-2010 E-246-2014 E-296-2012 147162289 Day CP, et al. &quot;Glowing head&quot; mice: a genetic tool enabling reliable preclinical image-based evaluation of cancers in immunocompetent allografts. https://www.ncbi.nlm.nih.gov/pubmed/25369133 <a href="https://www.ncbi.nlm.nih.gov/pubmed/25369133">Day CP, et al. &quot;Glowing head&quot; mice: a genetic tool enabling reliable preclinical image-based evaluation of cancers in immunocompetent allografts.</a> 147162442 Day CP, et al. Preclinical mouse cancer models: a maze of opportunities and challenges https://www.ncbi.nlm.nih.gov/pubmed/26406370 <a href="https://www.ncbi.nlm.nih.gov/pubmed/26406370">Day CP, et al. Preclinical mouse cancer models: a maze of opportunities and challenges</a> 147163189 Day, Chi-Ping NIH - NCI NCI Day, Chi-Ping (NCI) 1 147163188 Merlino, Glenn NIH - NCI NCI Merlino, Glenn (NCI) 2 147163191 Ohler, Zoe NIH - NCI Leidos Ohler, Zoe (Leidos) 3 147163192 El Meskini, Rajaa NIH - NCI Leidos El Meskini, Rajaa (Leidos) 4 147163190 Van Dyke, Terry NIH - NCI Van Dyke, Terry 5 147163193 Tuting, Thomas University of Bonn [Rheinische Friedrich-Wilhelms-Universitat] Tuting, Thomas 6 147163189 Day, Chi-Ping NIH - NCI NCI Day, Chi-Ping (NCI) 1 147163188 Merlino, Glenn NIH - NCI NCI Merlino, Glenn (NCI) 2 147163191 Ohler, Zoe NIH - NCI Leidos Ohler, Zoe (Leidos) 3 147163192 El Meskini, Rajaa NIH - NCI Leidos El Meskini, Rajaa (Leidos) 4 147163190 Van Dyke, Terry NIH - NCI Van Dyke, Terry 5 147163193 Tuting, Thomas University of Bonn [Rheinische Friedrich-Wilhelms-Universitat] Tuting, Thomas 6 147158328 A Novel Genetically Engineered Mouse-Derived Allograft (GDA) For Preclinical Study Of Therapies For Metastatic Melanoma E-291-2015-0 Research Material NCI, University of Bonn [Rheinische Friedrich-Wilhelms-Universitat] 121111111 Greene, Jaime greenejaime@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America greenejaime@mail.nih.gov?subject=Web Inquiry on [TAB-4004] Genetically Engineered Mouse-Derived Allograft for Preclinical Studies of Metastatic Melanoma&body=Please send me information about technology [TAB-4004] Genetically Engineered Mouse-Derived Allograft for Preclinical Studies of Metastatic Melanoma.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Greene, Jaime<br><a href="mailto:greenejaime@mail.nih.gov?subject=Web Inquiry on [TAB-4004] Genetically Engineered Mouse-Derived Allograft for Preclinical Studies of Metastatic Melanoma&body=Please send me information about technology [TAB-4004] Genetically Engineered Mouse-Derived Allograft for Preclinical Studies of Metastatic Melanoma.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">greenejaime@mail.nih.gov</a><br> 147174712 Allograft 147174713 GDA 147174715 Genetically Engineered Mouse-Derived Allograft 147174716 MELANOMA 147174717 Metastasis 147174718 mouse model 147174719 Preclinical 147174720 therapeutics TAB-4118 147157400 Methods of making and using dopamine receptor selective antagonists/partial agonists NIDA Collaboration, Licensing, Neurology, Therapeutics Collaboration Licensing Neurology Therapeutics Vivek Kumar, Amy Newman, Anverbasha Shaik <p>Dopamine is a major neurotransmitter in the central nervous system and among other functions is directly related to the rewarding effects of drugs of abuse.  Dopamine signaling is mediated by D1, D2, D3, D4 and D5 receptors.  The dopamine D3 receptor is a known target to treat a variety of neuropsychiatric disorders, including substance use disorders (e.g. cocaine and opioid), schizophrenia and depression.  Despite extensive efforts, it has proven difficult to identify a lead molecule that selectively binds to D3 receptors (versus D2 receptors, for example), with the desired pharmacological and pharmacokinetic profile.  For example, metabolic instability or predicted toxicity has precluded successful translation of previously reported D3R-selective antagonists to clinical use for cocaine abuse.</p> <p>The library of compounds of this technology is designed to have high affinity and specificity for the dopamine D3 receptor.  Preliminary studies at NIDA indicate that selected lead compounds have promising in vivo activity in rodents, including reduced acquisition to self-administration of oxycodone, inhibition of reinstatement to oxycodone seeking, and ameliorating naloxone-precipitated withdrawal from oxycodone dependence, and that these lead compounds are metabolically stable.</p> <h2>Competitive Advantages:</h2> <ul><li>Despite extensive efforts to develop  D<sub>3</sub> receptor-selective compounds, it has proven difficult to identify a ligand with the desired pharmacological and pharmacokinetic profile for translation to the clinic.   The D<sub>3</sub> receptor ligands described herein may be useful to treat a variety of diseases, including opioid use disorders and schizophrenia.</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Treatment of Opioid Use Disorders, Schizophrenia, Bipolar Disorder, and of cannabis (Tetrahydrocannabinol, THC) dependence</li> </ul> 2016-11-10 2025-04-22 2018-11-13 2025-04-22 2016-11-10 Bipolar Disorder, Cannabis, DEPENDENCE, dopamine D3 receptor, drug addiction, oxycodone, SCHIZOPHRENIA False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2018-11-13 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147162413 A. Newman et al. https://www.ncbi.nlm.nih.gov/pubmed/27508895 <a href="https://www.ncbi.nlm.nih.gov/pubmed/27508895">A. Newman et al.</a> 147163570 Newman, Amy NIH - NIDA NIDA Newman, Amy (NIDA) 1 147163571 Kumar, Vivek NIH - NIDA NIDA Kumar, Vivek (NIDA) 2 147163572 Shaik, Anverbasha NIH - NIDA NIDA Shaik, Anverbasha (NIDA) 3 147163570 Newman, Amy NIH - NIDA NIDA Newman, Amy (NIDA) 1 147163571 Kumar, Vivek NIH - NIDA NIDA Kumar, Vivek (NIDA) 2 147163572 Shaik, Anverbasha NIH - NIDA NIDA Shaik, Anverbasha (NIDA) 3 147157877 Novel Dopamine D3 Receptor Selective Antagonists/partial Agonists With High Affinity And Metabolic Stability For Treatment Of Neuropsychiatric Disorders E-053-2016-0 Filing authorized National Institute on Drug Abuse (NIDA) 147162504 Novel Dopamine D3 Receptor Selective Antagonists/partial Agonists With High Affinity And Metabolic Stability For Treatment Of Neuropsychiatric Disorders E-053-2016-1 Filing authorized National Institute on Drug Abuse (NIDA) 147162505 Use Of Dopamine D3R Antagonist To Mitigate Development Of Opioid Addiction E-053-2016-2 Filing authorized National Institute on Drug Abuse (NIDA) 83737255 Baxter, Merissa merissa.baxter@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB merissa.baxter@nih.gov?subject=Web Inquiry on [TAB-4118] Methods of making and using dopamine receptor selective antagonists/partial agonists&body=Please send me information about technology [TAB-4118] Methods of making and using dopamine receptor selective antagonists/partial agonists.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Baxter, Merissa<br><a href="mailto:merissa.baxter@nih.gov?subject=Web Inquiry on [TAB-4118] Methods of making and using dopamine receptor selective antagonists/partial agonists&body=Please send me information about technology [TAB-4118] Methods of making and using dopamine receptor selective antagonists/partial agonists.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">merissa.baxter@nih.gov</a><br> 147166649 E-053-2016-0 E-053-2016-0-US-01 Dopamine D3 Receptor Selective Antagonists/Partial Agonists; Method of Making; and Use Thereof PRV US 62/307,600 Abandoned US <br />Provisional (PRV) 62/307,600<br />Filed on 2016-03-14<br />Status: Abandoned 147166650 E-053-2016-1 E-053-2016-1-PCT-01 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders PCT COMB Patent Cooperation Treaty PCT/US2017/021328 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2017/021328<br />Filed on 2017-03-08<br />Status: Expired 147166652 E-053-2016-1 E-053-2016-1-CA-02 DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS; METHOD OF MAKING; AND USE THEREOF National Stage Canada 3017342 Pending Canada <br />National Stage 3017342<br />Filed on 2017-03-08<br />Status: Pending 147166653 E-053-2016-1 E-053-2016-1-EP-03 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders National Stage European Patent 3429993 17711971.6 Issued European Patent <br />National Stage 17711971.6<br />Filed on 2018-09-11<br />Status: Issued 147166654 E-053-2016-1 E-053-2016-1-US-04 Novel Dopamine D3 Receptor Selective Antagonists/partial Agonists With High Affinity And Metabolic Stability For Treatment Of Neuropsychiatric Disorders National Stage US 11,299,476 16/084,093 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11299476 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11299476">11,299,476</a><br />Filed on 2018-09-11<br />Status: Issued 147166655 E-053-2016-1 E-053-2016-1-AU-05 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders National Stage Australia 2017233716 2017233716 Issued Australia <br />National Stage 2017233716<br />Filed on 2017-03-08<br />Status: Issued 147166656 E-053-2016-1 E-053-2016-1-EP-06 DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS; METHOD OF MAKING; AND USE THEREOF DIV European Patent 3848351 21158632.6 Issued European Patent <br />Divisional (DIV) 21158632.6<br />Filed on 2021-02-23<br />Status: Issued 147166657 E-053-2016-1 E-053-2016-1-AT-07 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders EP Austria 3429993 17711971.6 Issued Austria <br />European patent (EP) 17711971.6<br />Filed on 2018-09-11<br />Status: Issued 147166658 E-053-2016-1 E-053-2016-1-BE-08 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders EP Belgium 3429993 17711971.6 Issued Belgium <br />European patent (EP) 17711971.6<br />Filed on 2018-09-11<br />Status: Issued 147166659 E-053-2016-1 E-053-2016-1-CH-09 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders EP Switzerland 3429993 17711971.6 Issued Switzerland <br />European patent (EP) 17711971.6<br />Filed on 2018-09-11<br />Status: Issued 147166660 E-053-2016-1 E-053-2016-1-CZ-10 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders EP Czech Republic 3429993 17711971.6 Issued Czech Republic <br />European patent (EP) 17711971.6<br />Filed on 2018-09-11<br />Status: Issued 147166661 E-053-2016-1 E-053-2016-1-DE-11 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders EP Germany 3429993 17711971.6 Issued Germany <br />European patent (EP) 17711971.6<br />Filed on 2018-09-11<br />Status: Issued 147166662 E-053-2016-1 E-053-2016-1-DK-12 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders EP Denmark 3429993 17711971.6 Issued Denmark <br />European patent (EP) 17711971.6<br />Filed on 2018-09-11<br />Status: Issued 147166663 E-053-2016-1 E-053-2016-1-ES-13 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders EP Spain 3429993 17711971.6 Issued Spain <br />European patent (EP) 17711971.6<br />Filed on 2018-09-11<br />Status: Issued 147166664 E-053-2016-1 E-053-2016-1-FI-14 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders EP Finland 3429993 17711971.6 Issued Finland <br />European patent (EP) 17711971.6<br />Filed on 2018-09-11<br />Status: Issued 147166665 E-053-2016-1 E-053-2016-1-FR-15 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders EP France 3429993 17711971.6 Issued France <br />European patent (EP) 17711971.6<br />Filed on 2018-09-11<br />Status: Issued 147166666 E-053-2016-1 E-053-2016-1-GB-16 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders EP United Kingdom 3429993 17711971.6 Issued United Kingdom <br />European patent (EP) 17711971.6<br />Filed on 2018-09-11<br />Status: Issued 147166667 E-053-2016-1 E-053-2016-1-GR-17 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders EP Greece 3429993 17711971.6 Issued Greece <br />European patent (EP) 17711971.6<br />Filed on 2018-09-11<br />Status: Issued 147166668 E-053-2016-1 E-053-2016-1-HR-18 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders EP Croatia 3429993 17711971.6 Issued Croatia <br />European patent (EP) 17711971.6<br />Filed on 2018-09-11<br />Status: Issued 147166669 E-053-2016-1 E-053-2016-1-HU-19 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders EP Hungary 3429993 17711971.6 Issued Hungary <br />European patent (EP) 17711971.6<br />Filed on 2018-09-11<br />Status: Issued 147166670 E-053-2016-1 E-053-2016-1-IE-20 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders EP Ireland 3429993 17711971.6 Issued Ireland <br />European patent (EP) 17711971.6<br />Filed on 2018-09-11<br />Status: Issued 147166671 E-053-2016-1 E-053-2016-1-IT-21 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders EP Italy 3429993 17711971.6 Issued Italy <br />European patent (EP) 17711971.6<br />Filed on 2018-09-11<br />Status: Issued 147166672 E-053-2016-1 E-053-2016-1-NL-22 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders EP The Netherlands 3429993 17711971.6 Issued The Netherlands <br />European patent (EP) 17711971.6<br />Filed on 2018-09-11<br />Status: Issued 147166673 E-053-2016-1 E-053-2016-1-NO-23 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders EP Norway 3429993 17711971.6 Issued Norway <br />European patent (EP) 17711971.6<br />Filed on 2018-09-11<br />Status: Issued 147166674 E-053-2016-1 E-053-2016-1-PL-24 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders EP Poland 3429993 17711971.6 Issued Poland <br />European patent (EP) 17711971.6<br />Filed on 2018-09-11<br />Status: Issued 147166675 E-053-2016-1 E-053-2016-1-PT-25 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders EP Portugal 3429993 17711971.6 Issued Portugal <br />European patent (EP) 17711971.6<br />Filed on 2018-09-11<br />Status: Issued 147166676 E-053-2016-1 E-053-2016-1-RO-26 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders EP Romania 3429993 17711971.6 Issued Romania <br />European patent (EP) 17711971.6<br />Filed on 2018-09-11<br />Status: Issued 147166677 E-053-2016-1 E-053-2016-1-RS-27 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders EP Serbia 3429993 17711971.6 Issued Serbia <br />European patent (EP) 17711971.6<br />Filed on 2018-09-11<br />Status: Issued 147166678 E-053-2016-1 E-053-2016-1-SE-28 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders EP Sweden 3429993 17711971.6 Issued Sweden <br />European patent (EP) 17711971.6<br />Filed on 2018-09-11<br />Status: Issued 147166679 E-053-2016-1 E-053-2016-1-SI-29 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders EP Slovenia 3429993 17711971.6 Issued Slovenia <br />European patent (EP) 17711971.6<br />Filed on 2018-09-11<br />Status: Issued 147166680 E-053-2016-1 E-053-2016-1-SK-30 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders EP Slovakia 3429993 17711971.6 Issued Slovakia <br />European patent (EP) 17711971.6<br />Filed on 2018-09-11<br />Status: Issued 147166681 E-053-2016-1 E-053-2016-1-TR-31 Novel Dopamine D3 Receptor Selective Anatgonists/Partial Agonists with High Affinity and Metabolic Stability for Treatment of Neuropsychiatric Disorders EP Turkey 3429993 17711971.6 Issued Turkey <br />European patent (EP) 17711971.6<br />Filed on 2018-09-11<br />Status: Issued 147166682 E-053-2016-1 E-053-2016-1-US-32 DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS; METHOD OF MAKING; AND USE THEREOF DIV US 12,162,861 17/685,709 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12162861 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12162861">12,162,861</a><br />Filed on 2022-03-03<br />Status: Issued 147166684 E-053-2016-2 E-053-2016-2-US-01 DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS AND USES THEREOF PRV US 62/729,709 Abandoned US <br />Provisional (PRV) 62/729,709<br />Filed on 2018-09-11<br />Status: Abandoned 147166685 E-053-2016-2 E-053-2016-2-PCT-02 DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS AND USES THEREOF PCT Patent Cooperation Treaty PCT/US2019/050165 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2019/050165<br />Filed on 2019-09-09<br />Status: Expired 147166686 E-053-2016-2 E-053-2016-2-AU-03 DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS AND USES THEREOF National Stage Australia 2019340675 2019340675 Issued Australia <br />National Stage 2019340675<br />Filed on 2021-02-12<br />Status: Issued 147166687 E-053-2016-2 E-053-2016-2-CA-04 DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS AND USES THEREOF National Stage Canada 3111785 Pending Canada <br />National Stage 3111785<br />Filed on 2019-09-09<br />Status: Pending 147166688 E-053-2016-2 E-053-2016-2-EP-05 DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS AND USES THEREOF National Stage European Patent 19773300.9 Pending European Patent <br />National Stage 19773300.9<br />Filed on 2019-09-09<br />Status: Pending 147166689 E-053-2016-2 E-053-2016-2-US-06 DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS AND USES THEREOF National Stage US 11,337,971 17/265,150 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11337971 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11337971">11,337,971</a><br />Filed on 2021-02-01<br />Status: Issued 147166690 E-053-2016-2 E-053-2016-2-US-07 DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS AND USES THEREOF CON US 12,097,196 17/738,301 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12097196 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12097196">12,097,196</a><br />Filed on 2022-05-06<br />Status: Issued 147170368 Bipolar Disorder 147170369 Cannabis 147170370 DEPENDENCE 147170372 dopamine D3 receptor 147170374 drug addiction 147170376 oxycodone 147170377 SCHIZOPHRENIA TAB-4203 147157488 Anti-bacterial Treatments Using Peptide-Based Inhibitors of the STAT3-IL10 Pathway NCI Collaboration, Immunology, Infectious Disease, Licensing, Therapeutics Collaboration Immunology Infectious Disease Licensing Therapeutics Mercedes Gonzalez-Juarreto, Nadya Tarasova <p>Tuberculosis (TB) is an infectious disease that typically affects the lungs. Current therapies include a panel of antibiotics given over a range of 6-9 months. As a result of the expense of treatment, the extended timeframe needed for effective treatment, and the scarcity of medicines in some developing countries, patient compliance with TB treatment is very low and results in multi-drug resistant TB (MDR-TB). There remains a need for a faster, more effective treatment for TB.</p> <p>Short, metabolically stable, cell-penetrating lipopeptide mimics of conserved regions of IL-10 and STAT3 inhibit those proteins’ signaling to become a host-directed therapy against TB. Intrapulmonary aerosol delivery of the peptides results in increased bactericidal capacity of the host immune system (e.g., increased nitric oxide, NADPH oxidase, lysozyme activities).</p> <p>Researchers at the National Cancer Institute's <a href="https://ccr.cancer.gov/Cancer-and-Inflammation-Program" target="_blank" rel="nofollow">Cancer and Inflammation Program</a> developed peptide inhibitors of the STAT3-IL10 pathway, and are studying the peptide inhibitors use in treating bacterial infection. The inventors have shown that the inhibitors can reduce the Mycobacterium tuberculosis (Mtb) bacterial load by &gt;90% in mice, without the use of antibiotics in two weeks. The inhibitors modulate the host’s lung immune response, enhancing its bactericidal capacity. The inventors would be pleased to enter into collaborations, particularly those that explore efficacy against multi-drug resistant Mtb, and/or combination with traditional antibiotics in hopes of shortening treatment time.</p> <p>Please click <a href="mailto:ncitechtransfer@mail.nih.gov?subject=Information%20Request%3A%20E-278-2014">here</a> to request more information on this technology.</p> <h2>Competitive Advantages:</h2> <ul><li>Chronic infections that induce immune-privilege (e.g. via granuloma) may be combatted via these inhibitors, as shown in this mouse model of TB.</li> <li>Specific to TB, shorter and more effective treatments against TB are needed. Host-directed therapy, in combination with traditional antibiotics, could meet that need.</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Activation of immune system against immune-privileged infections.</li> <li>Anti-tuberculosis treatment, alone or in combination with traditional antibiotics.</li> </ul> 2017-01-18 2025-04-22 2017-01-18 2025-04-22 2017-01-18 Anti-infective, IL-10, immunomodulatory, Immunotherapy, INTERLEUKIN, STAT3, TUBERCULOSIS False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2017-01-18 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-164-2007 E-167-2010 147163900 Tarasova, Nadya NIH - NCI NCI Tarasova, Nadya (NCI) 1 147163901 Gonzalez-Juarreto, Mercedes Colorado State University Gonzalez-Juarreto, Mercedes 2 147163900 Tarasova, Nadya NIH - NCI NCI Tarasova, Nadya (NCI) 1 147163901 Gonzalez-Juarreto, Mercedes Colorado State University Gonzalez-Juarreto, Mercedes 2 147158313 Synthetic Peptide Inhibitors Of The Interleukin 10 (IL-10) And Stat3 N-terminal Domain For The Treatment Of Infectious Diseases E-278-2014-0 Filing authorized Colorado State University, NCI 83732213 Dick, Taryn taryn.dick@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB taryn.dick@nih.gov?subject=Web Inquiry on [TAB-4203] Anti-bacterial Treatments Using Peptide-Based Inhibitors of the STAT3-IL10 Pathway&body=Please send me information about technology [TAB-4203] Anti-bacterial Treatments Using Peptide-Based Inhibitors of the STAT3-IL10 Pathway.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dick, Taryn<br><a href="mailto:taryn.dick@nih.gov?subject=Web Inquiry on [TAB-4203] Anti-bacterial Treatments Using Peptide-Based Inhibitors of the STAT3-IL10 Pathway&body=Please send me information about technology [TAB-4203] Anti-bacterial Treatments Using Peptide-Based Inhibitors of the STAT3-IL10 Pathway.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">taryn.dick@nih.gov</a><br> 147161256 E-278-2014-0 E-278-2014-0-PCT-02 Treatment Methods Using Peptide-Based Inhibitors of the STAT3-IL10 Pathway PCT Patent Cooperation Treaty PCT/US2016/012493 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2016/012493<br />Filed on 2016-01-07<br />Status: Expired 147167336 E-278-2014-0 E-278-2014-0-US-01 Treatment Methods Using Peptide-Based Inhibitors of the Stat3-IL10 Pathway PRV US 62/100,763 Abandoned US <br />Provisional (PRV) 62/100,763<br />Filed on 2015-01-07<br />Status: Abandoned 147167337 E-278-2014-0 E-278-2014-0-US-03 USE OF PEPTIDE-BASED INHIBITORS OF THE STAT3-IL 10 PATHWAY FOR TREATING BACTERIAL INFECTION AND GRANULOMATOUS DISEASE National Stage US 10,512,673 15/541,871 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10512673 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10512673">10,512,673</a><br />Filed on 2017-07-06<br />Status: Issued 147174590 Anti-infective 147174591 IL-10 147174592 immunomodulatory 147174593 Immunotherapy 147174594 INTERLEUKIN 147174595 STAT3 147174596 TUBERCULOSIS TAB-4450 147157745 A Sensitive, High Throughput Pseudovirus-Based Papillomavirus Neutralization Assay for HPV 16 and HPV 18 NCI Infectious Disease, Licensing, Oncology, Research Materials Infectious Disease Licensing Oncology Research Materials Christopher Buck, Douglas Lowy, Diana Pastrana, Richard Roden, John Schiller <p>Human Papilloma Viruses (HPV) is a very common virus; nearly 80 million people—about one in four—are currently infected in the United States. HPV is a group of more than 150 related viruses. Each HPV virus in this large group is given a number which is called its HPV type. HPV is named for the warts (papillomas) some that HPV types can cause. Some other HPV types can lead to cancer, especially cervical cancer. There are more than 40 HPV types that can infect the genital areas of males and females. Each year, about 38,793 new cases of cancer are found in parts of the body where HPV is often found. HPV causes about 30,700 of these cancers. Cervical cancer is the most common HPV-associated cancer among women, and oropharyngeal cancers (cancers of the back of the throat, including the base of the tongue and tonsils) are the most common among men.</p> <p>Researchers at the National Cancer Institute invented a research tool for measuring protective antibody responses against HPV. Sensitive high-throughput neutralization assays, based upon pseudoviruses carrying a secreted alkaline phosphatase (SEAP) reporter gene, were developed and validated by the inventors for HPV 16, HPV 18, and bovine papillomavirus 1 (BPV1). In a 96-well plate format, the assay was reproducible and appears to be as sensitive as, but more type-specific than, a standard papillomavirus-like particle (VLP)-based enzyme-linked immunosorbent assay (ELISA). The SEAP pseudovirus-based neutralization assay should be a practical method for quantifying potentially protective antibody responses in HPV natural history and prophylactic vaccine studies. The invention is available for non-exclusive license.</p> <h2>Competitive Advantages:</h2> <ul><li>Sensitive high-throughput neutralization assays, based upon pseudoviruses carrying a secreted alkaline phosphatase (SEAP) reporter gene, developed and validated by the inventors for HPV 16, HPV 18, and bovine papillomavirus 1 (BPV1)</li> <li>Reproducible assay that appears to be as sensitive as, but more type-specific than, a standard papillomavirus-like particle (VLP)-based enzyme-linked immunosorbent assay (ELISA)</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Research tool for measuring protective antibody responses against HPV</li> <li>Secreted alkaline phosphatase (SEAP) pseudovirus-based neutralization assay should be a practical method for quantifying potentially protective antibody responses in HPV natural history and prophylactic vaccine studies</li> </ul> 2016-12-16 2025-04-22 2018-07-19 2025-04-22 2016-12-16 assay, bovine papillomavirus, HPV, Human Papilloma Viruses False True Prototype True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2018-07-19 52406769 Prototype 52406769 NCI 37470483 Website Abstract 147161884 Pastrana DV, et al. Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. https://www.ncbi.nlm.nih.gov/pubmed/15051381 <a href="https://www.ncbi.nlm.nih.gov/pubmed/15051381">Pastrana DV, et al. Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18.</a> 147164780 Schiller, John NIH - NCI NCI Schiller, John (NCI) 1 147164782 Buck, Christopher NIH - NCI NCI Buck, Christopher (NCI) 2 147164783 Pastrana, Diana NIH - NCI NCI Pastrana, Diana (NCI) 3 147164779 Lowy, Douglas NIH - NCI NCI Lowy, Douglas (NCI) 4 147164781 Roden, Richard NIH - NCI Roden, Richard 5 147164780 Schiller, John NIH - NCI NCI Schiller, John (NCI) 1 147164782 Buck, Christopher NIH - NCI NCI Buck, Christopher (NCI) 2 147164783 Pastrana, Diana NIH - NCI NCI Pastrana, Diana (NCI) 3 147164779 Lowy, Douglas NIH - NCI NCI Lowy, Douglas (NCI) 4 147164781 Roden, Richard NIH - NCI Roden, Richard 5 147158063 Reactivity Of Human Sera In A Sensitive, High-throughput Pseudovirus-based Papillomavirus Neutralization Assay For HPV16 And HPV18. E-137-2004-0 Research Material NCI 83691647 Chang, Kevin changke@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB changke@mail.nih.gov?subject=Web Inquiry on [TAB-4450] A Sensitive, High Throughput Pseudovirus-Based Papillomavirus Neutralization Assay for HPV 16 and HPV 18&body=Please send me information about technology [TAB-4450] A Sensitive, High Throughput Pseudovirus-Based Papillomavirus Neutralization Assay for HPV 16 and HPV 18.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Chang, Kevin<br><a href="mailto:changke@mail.nih.gov?subject=Web Inquiry on [TAB-4450] A Sensitive, High Throughput Pseudovirus-Based Papillomavirus Neutralization Assay for HPV 16 and HPV 18&body=Please send me information about technology [TAB-4450] A Sensitive, High Throughput Pseudovirus-Based Papillomavirus Neutralization Assay for HPV 16 and HPV 18.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">changke@mail.nih.gov</a><br> 147172207 assay 147172209 bovine papillomavirus 147172210 HPV 147172212 Human Papilloma Viruses TAB-4254 147157541 Anti-CD133 Monoclonal Antibodies as Cancer Therapeutics NCI Collaboration, Immunology, Licensing, Oncology, Therapeutics Collaboration Immunology Licensing Oncology Therapeutics Robert Kinders, Allison Marrero, Thomas Pfister <p>Most early work on CD133 was carried out using one of two monoclonal antibodies (mAbs), AC133 and AC141, which recognize an undefined glycosylated epitope of CD 133.</p> <p>Researchers from NCI's Pharmacodynamic Assay Development and Implementation Section generated novel anti-human CD133 monoclonal antibodies from large extracellular domain loops of CD133 using peptide residues selected from the native extracellular domains of CD133 protein as an immunogen. They selected sequences for immunization that do not overlap with known glycosylation sites. Peptide antigens comprising the amino acids in the extracellular domain were synthesized and conjugated to carrier proteins as the immunogen.  A key step was screening for specificity using peptides and expressed recombinant extracellular domains of CD133. The resulting antibodies recognize both glycosylated and non-glycosylated regions of the cognate antigen. The inventors have demonstrated the utility of this invention in immunofluorescence assay, western blotting and ELISA, flow cytometry, and immunoprecipitation. NCI seeks licensing and/or co-development research collaborations for commercializing the use of antibodies against CD-1333. </p> <h2>Competitive Advantages:</h2> <p>- High specificity anti-CD133 monoclonal antibody that has the ability to bind to both glycosylated and unglycosylated epitope of CD133</p> <h2>Commercial Applications:</h2> <p>- Biomarker to CD133 useful for immunofluorescence assay<br /> - Western blot <br /> - ELISA <br /> - Flow cytometry<br /> - Immunoprecipitation</p> 2017-02-13 2025-04-22 2017-02-13 2025-04-22 2017-02-13 Anti-CD133, Biomarker, CANCER, Diagnostic Tool, Immunology, Rabbit Monoclonal Antibodies, screening False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2017-02-13 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147164059 Pfister, Thomas NIH - NCI Leidos Pfister, Thomas (Leidos) 1 147164060 Kinders, Robert NIH - NCI Leidos Kinders, Robert (Leidos) 2 147164061 Marrero, Allison NIH - NCI Leidos Marrero, Allison (Leidos) 3 147164059 Pfister, Thomas NIH - NCI Leidos Pfister, Thomas (Leidos) 1 147164060 Kinders, Robert NIH - NCI Leidos Kinders, Robert (Leidos) 2 147164061 Marrero, Allison NIH - NCI Leidos Marrero, Allison (Leidos) 3 147157815 Development Of Rabbit Anti-CD133 Monoclonal Antibodies For Use In Immunoassays E-025-2015-0 Filing authorized NCI 83704821 Nguyen-Antczak, Lauren lauren.nguyen-antczak@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-4254] Anti-CD133 Monoclonal Antibodies as Cancer Therapeutics&body=Please send me information about technology [TAB-4254] Anti-CD133 Monoclonal Antibodies as Cancer Therapeutics.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Nguyen-Antczak, Lauren<br><a href="mailto:lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-4254] Anti-CD133 Monoclonal Antibodies as Cancer Therapeutics&body=Please send me information about technology [TAB-4254] Anti-CD133 Monoclonal Antibodies as Cancer Therapeutics.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">lauren.nguyen-antczak@nih.gov</a><br> 147160922 E-025-2015-0 E-025-2015-0-PCT-02 ANTI-CD133 MONOCLONAL ANTIBODIES AND RELATED COMPOSITIONS AND METHODS PCT Patent Cooperation Treaty PCT/US2016/024531 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2016/024531<br />Filed on 2016-03-28<br />Status: Expired 147167695 E-025-2015-0 E-025-2015-0-US-01 Development Of Rabbit Anti-CD133 Monoclonal Antibodies For Use In Immunoassays PRV US 62/138,825 Abandoned US <br />Provisional (PRV) 62/138,825<br />Filed on 2015-03-26<br />Status: Abandoned 147167696 E-025-2015-0 E-025-2015-0-US-03 ANTI-CD133 MONOCLONAL ANTIBODIES AND RELATED COMPOSITIONS AND METHODS National Stage US 10,711,068 15/561,403 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10711068 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10711068">10,711,068</a><br />Filed on 2017-09-25<br />Status: Issued 147167697 E-025-2015-0 E-025-2015-0-US-04 ANTI-CD133 MONOCLONAL ANTIBODIES AND RELATED COMPOSITIONS AND METHODS DIV US 11,352,435 16/900,596 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11352435 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11352435">11,352,435</a><br />Filed on 2020-06-12<br />Status: Issued 147169716 Anti-CD133 147169717 Biomarker 147169718 CANCER 147169720 Diagnostic Tool 147169721 Immunology 147169723 Rabbit Monoclonal Antibodies 147169724 screening TAB-4427 147157722 Anti-Py1235-Met Immunological Binding Reagent as Cancer Diagnostic NCI Collaboration, Diagnostics, Licensing, Oncology Collaboration Diagnostics Licensing Oncology James Doroshow, Mario Navas, Ralph Parchment, Thomas Pfister, Apurva Srivastava <p>This technology consists of highly specific rabbit monoclonal antibodies reactive with phosphorylated tyrosine located at amino acid 1235 in the human MET sequence. Binding to this pYl235 residue is independent of the phosphorylation of other tyrosines in the vicinity (1230 and 1234), does not cross-react with these nearby phosphotyrosine residues, and does not occur when Y1235 is unphosphorylated.</p> <p>The receptor tyrosine kinase MET is an important drug target for treatment of various diseases including diseases mediated by dysregulated cell proliferation <em>(e.g., </em>cancer). A key event involved in MET activation and/or signaling is phosphorylation at the Y1235 position. However, MET activation and/or signaling is difficult to assess due to the lack of specific binding reagents that detect phosphorylation at Y1235 of MET without cross-reacting with one or more other phosphorylation sites.  Inventors from NCI’s DCTD have developed an invention that enables specific quantitation of the phosphorylation status of the 1235-tyrosine residue, which is a key post-translational modification that activates MET receptor signaling. Specific pY1235 measurement will have many useful applications including (but not limited to): 1) pharmacodynamic assessments of the molecular response of the MET receptor to inhibitors, proving target engagement,  providing evidence for mechanism-of-action, developing optimized dosing schedules, and enabling proof-of-concept; 2) comparison of potency of multiple MET inhibitors in preclinical and clinical studies to identify best in class agent; 3) identifying patients with activated MET status - a more discriminating measurement of MET-dependency of tumors than current genomic measurements – as a diagnostic test for selecting the ideal group of patients for treatment with MET inhibitor(s); and 4) test and confirm hypothesis of MET activation in preclinical and clinical studies to develop combinations of MET inhibitors and other agents targeting cancers. </p> <p>Researchers at the NCI seek licensing and/or co-development research collaborations  to commercialize and develop a companion diagnostic for selective MET inhibitors.</p> <h2>Competitive Advantages:</h2> <ul><li>This invention differs from existing antibodies directed at MET in that the antibody binds specifically to phosphorylated MET Y1235 and measures the level of MET kinase activation</li> <li>Can be used to measure the pharmacodynamic and molecular target response to candidate MET inhibitors to inform and guide drug development and clinical trials</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Reagent to quantify the activation of the MET pathway</li> <li>Companion diagnostic tool for selective MET inhibitors</li> <li>​Diagnostic tool for induced activation of the MET pathway by other therapeutics</li> </ul> 2017-02-13 2025-04-22 2017-02-13 2025-04-22 2017-02-13 ANTIBODY, Companion Diagnostic, diagnostic, MET, Rabbit Monoclonal Antibody, tyrosine kinase inhibitor False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2017-02-13 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147162194 Srivastava AK, et al. Pharmacodynamic Response of the MET/HGF Receptor to Small-Molecule Tyrosine Kinase Inhibitors Examined with Validated, Fit-for-Clinic Immunoassays. https://www.ncbi.nlm.nih.gov/pubmed/27001313 <a href="https://www.ncbi.nlm.nih.gov/pubmed/27001313">Srivastava AK, et al. Pharmacodynamic Response of the MET/HGF Receptor to Small-Molecule Tyrosine Kinase Inhibitors Examined with Validated, Fit-for-Clinic Immunoassays.</a> 147164709 Srivastava, Apurva NIH - NCI Leidos Srivastava, Apurva (Leidos) 1 147164706 Pfister, Thomas NIH - NCI Leidos Pfister, Thomas (Leidos) 2 147164710 Navas, Mario NIH - NCI Leidos Navas, Mario (Leidos) 3 147164708 Doroshow, James NIH - NCI NCI Doroshow, James (NCI) 4 147164707 Parchment, Ralph NIH - NCI Leidos Parchment, Ralph (Leidos) 5 147164709 Srivastava, Apurva NIH - NCI Leidos Srivastava, Apurva (Leidos) 1 147164706 Pfister, Thomas NIH - NCI Leidos Pfister, Thomas (Leidos) 2 147164710 Navas, Mario NIH - NCI Leidos Navas, Mario (Leidos) 3 147164708 Doroshow, James NIH - NCI NCI Doroshow, James (NCI) 4 147164707 Parchment, Ralph NIH - NCI Leidos Parchment, Ralph (Leidos) 5 147158043 Development Of PY1235-MET Specific Rabbit Monoclonal Antibodies For Use In Diagnosis And Detection Of MET Activation E-130-2016-0 Filing authorized NCI 83704821 Nguyen-Antczak, Lauren lauren.nguyen-antczak@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-4427] Anti-Py1235-Met Immunological Binding Reagent as Cancer Diagnostic&body=Please send me information about technology [TAB-4427] Anti-Py1235-Met Immunological Binding Reagent as Cancer Diagnostic.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Nguyen-Antczak, Lauren<br><a href="mailto:lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-4427] Anti-Py1235-Met Immunological Binding Reagent as Cancer Diagnostic&body=Please send me information about technology [TAB-4427] Anti-Py1235-Met Immunological Binding Reagent as Cancer Diagnostic.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">lauren.nguyen-antczak@nih.gov</a><br> 147161080 E-130-2016-0 E-130-2016-0-US-01 ANTI-pY1235-MET IMMUNOLOGICAL BINDING REAGENT PRV US 62/309,920 Abandoned US <br />Provisional (PRV) 62/309,920<br />Filed on 2016-03-17<br />Status: Abandoned 147168854 E-130-2016-0 E-130-2016-0-PCT-02 ANTI-PY1235-MET IMMUNOLOGICAL BINDING REAGENT PCT Patent Cooperation Treaty PCT/US2017/022783 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2017/022783<br />Filed on 2017-03-16<br />Status: Expired 147168855 E-130-2016-0 E-130-2016-0-EP-03 ANTI-PY1235-MET IMMUNOLOGICAL BINDING REAGENT National Stage European Patent 3430051 17714118.1 Issued European Patent <br />National Stage 17714118.1<br />Filed on 2018-10-01<br />Status: Issued 147168856 E-130-2016-0 E-130-2016-0-US-04 ANTI-pY1235-MET IMMUNOLOGICAL BINDING REAGENT National Stage US 11,340,219 16/085,999 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11340219 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11340219">11,340,219</a><br />Filed on 2018-09-17<br />Status: Issued 147168857 E-130-2016-0 E-130-2016-0-DE-05 ANTI-PY1235-MET IMMUNOLOGICAL BINDING REAGENT EP Germany 3430051 17714118.1 Issued Germany <br />European patent (EP) 17714118.1<br />Filed on 2018-10-01<br />Status: Issued 147168858 E-130-2016-0 E-130-2016-0-FR-06 ANTI-PY1235-MET IMMUNOLOGICAL BINDING REAGENT EP France 3430051 17714118.1 Issued France <br />European patent (EP) 17714118.1<br />Filed on 2018-10-01<br />Status: Issued 147168859 E-130-2016-0 E-130-2016-0-GB-07 ANTI-PY1235-MET IMMUNOLOGICAL BINDING REAGENT EP United Kingdom 3430051 17714118.1 Issued United Kingdom <br />European patent (EP) 17714118.1<br />Filed on 2018-10-01<br />Status: Issued 147172041 ANTIBODY 147172042 Companion Diagnostic 147172043 diagnostic 147172044 MET 147172046 Rabbit Monoclonal Antibody 147172047 tyrosine kinase inhibitor TAB-4130 147157412 Griffithsin-Based Anti-viral Therapeutics with Improved Stability and Solubility NCI Collaboration, Infectious Disease, Licensing, Therapeutics Collaboration Infectious Disease Licensing Therapeutics Joshua Fuqua, Lindsay Kramzer, Tinoush Moulaei, Barry O'Keefe, Kenneth Palmer, Lisa Rohan <p>Griffithsin is a potent anti-viral protein with activity against HIV, HCV, Sars, HSV 1 &amp; 2 and other viruses.  It is active against HIV and HCV at picomolar concentrations.  Griffithsin is moving into clinical trials as an anti-HIV microbicide. Based on the structure of griffithsin and the necessities of pharmaceutical product development and regulatory approval, certain mutations in the sequence of griffithsin have been generated which could add to the stability and solubility of the protein. These mutants have all been tested for biological activity, solubility and thermal stability. They possess modified physiological attributes that would be advantageous for subsequent development for both systemic and topical administration.</p> <p>Scientists in NCI's <a href="https://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;source=web&amp;cd=1&amp;cad=rja&amp;uact=8&amp;ved=0ahUKEwjYtOy0543SAhXH8CYKHeH3A2QQFggcMAA&amp;url=https%3A%2F%2Fccr.cancer.gov%2FMolecular-Targets-Laboratory%2Fbarry-r-okeefe&amp;usg=AFQjCNGLKq5OVE44ZZdu1jd4ZUjpTP8vHw" target="_blank" rel="nofollow">Molecular Targets Laboratory</a> and collaborators modified the griffithsins to have a mutation position #77 (Met), which eliminates the possibility of Methionine oxidation at this solvent-exposed position, preventing oxidation and increasing the usable shelf-life of griffithsin formulations. Additional mutations include changes in the isoelectric point of the protein, which alter its solubility in various pH ranges allowing for improved product release in alternately formulated products.</p> <p>The modified griffithsins will be used to provide an active pharmaceutical ingredient with improved properties including reduced oxidation, improved solubility and bioavailability over a range of pH values and thermal stability.</p> <h2>Competitive Advantages:</h2> <ul><li>Increased stability: The modified griffithsins has greater shelf-life due to reduced oxidation and improved solubility; </li> <li>Increased bioavailability due to other mutations including those that change the isoelectric point.</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Microbicide, Therapeutic, Research tool</li> </ul> 2017-02-13 2025-04-22 2017-02-13 2025-04-22 2017-02-13 Anti-Viral, cnidarin, Griffithsin, HCV, HIV, HSV, SARS False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2017-02-13 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147163627 O'Keefe, Barry NIH - NCI NCI O'Keefe, Barry (NCI) 1 147163629 Palmer, Kenneth University of Louisville Palmer, Kenneth 2 147163628 Moulaei, Tinoush NIH - NCI NCI Moulaei, Tinoush (NCI) 3 147163630 Rohan, Lisa University of Pittsburgh Rohan, Lisa 4 147163631 Fuqua, Joshua University of Louisville Fuqua, Joshua 5 147163632 Kramzer, Lindsay University of Pittsburgh Kramzer, Lindsay 6 147163627 O'Keefe, Barry NIH - NCI NCI O'Keefe, Barry (NCI) 1 147163629 Palmer, Kenneth University of Louisville Palmer, Kenneth 2 147163628 Moulaei, Tinoush NIH - NCI NCI Moulaei, Tinoush (NCI) 3 147163630 Rohan, Lisa University of Pittsburgh Rohan, Lisa 4 147163631 Fuqua, Joshua University of Louisville Fuqua, Joshua 5 147163632 Kramzer, Lindsay University of Pittsburgh Kramzer, Lindsay 6 147157908 Second Generation Griffithsin Mutants For Improved Stability And Solubility E-065-2015-0 Filing authorized Intrucept Biomedicine, LLC, NCI, University of Louisville, University of Pittsburgh 83732213 Dick, Taryn taryn.dick@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB taryn.dick@nih.gov?subject=Web Inquiry on [TAB-4130] Griffithsin-Based Anti-viral Therapeutics with Improved Stability and Solubility&body=Please send me information about technology [TAB-4130] Griffithsin-Based Anti-viral Therapeutics with Improved Stability and Solubility.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dick, Taryn<br><a href="mailto:taryn.dick@nih.gov?subject=Web Inquiry on [TAB-4130] Griffithsin-Based Anti-viral Therapeutics with Improved Stability and Solubility&body=Please send me information about technology [TAB-4130] Griffithsin-Based Anti-viral Therapeutics with Improved Stability and Solubility.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">taryn.dick@nih.gov</a><br> 147166833 E-065-2015-0 E-065-2015-0-US-01 Griffithsin Mutants PRV US 62/114,217 Abandoned US <br />Provisional (PRV) 62/114,217<br />Filed on 2015-02-10<br />Status: Abandoned 147166834 E-065-2015-0 E-065-2015-0-PCT-02 Griffithsin Mutants PCT Patent Cooperation Treaty PCT/US2016/017267 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2016/017267<br />Filed on 2016-02-10<br />Status: Expired 147166835 E-065-2015-0 E-065-2015-0-AU-03 Griffithsin Mutants National Stage Australia 2016219434 2016219434 Issued Australia <br />National Stage 2016219434<br />Filed on 2016-02-10<br />Status: Issued 147166836 E-065-2015-0 E-065-2015-0-CA-04 Griffithsin Mutants National Stage Canada 2976337 2976337 Issued Canada <br />National Stage 2976337<br />Filed on 2016-02-10<br />Status: Issued 147166837 E-065-2015-0 E-065-2015-0-EP-05 Griffithsin Mutants National Stage European Patent 3256486 16710345.6 Issued European Patent <br />National Stage 16710345.6<br />Filed on 2016-02-10<br />Status: Issued 147166838 E-065-2015-0 E-065-2015-0-US-06 GRIFFITHSIN MUTANTS National Stage US 10,501,507 15/550,323 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10501507 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10501507">10,501,507</a><br />Filed on 2017-08-10<br />Status: Issued 147166839 E-065-2015-0 E-065-2015-0-US-07 GRIFFITHSIN MUTANTS CON US 11,339,195 16/697,685 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11339195 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11339195">11,339,195</a><br />Filed on 2019-11-27<br />Status: Issued 147166840 E-065-2015-0 E-065-2015-0-DE-08 Griffithsin Mutants EP Germany 3256486 16710345.6 Issued Germany <br />European patent (EP) 16710345.6<br />Filed on 2016-02-10<br />Status: Issued 147166841 E-065-2015-0 E-065-2015-0-ES-09 Griffithsin Mutants EP Spain 3256486 16710345.6 Issued Spain <br />European patent (EP) 16710345.6<br />Filed on 2016-02-10<br />Status: Issued 147166842 E-065-2015-0 E-065-2015-0-FR-10 Griffithsin Mutants EP France 3256486 16710345.6 Issued France <br />European patent (EP) 16710345.6<br />Filed on 2016-02-10<br />Status: Issued 147166843 E-065-2015-0 E-065-2015-0-GB-11 Griffithsin Mutants EP United Kingdom 3256486 16710345.6 Issued United Kingdom <br />European patent (EP) 16710345.6<br />Filed on 2016-02-10<br />Status: Issued 147166844 E-065-2015-0 E-065-2015-0-IE-12 Griffithsin Mutants EP Ireland 3256486 16710345.6 Issued Ireland <br />European patent (EP) 16710345.6<br />Filed on 2016-02-10<br />Status: Issued 147166845 E-065-2015-0 E-065-2015-0-LT-13 Griffithsin Mutants EP Lithuania 3256486 16710345.6 Issued Lithuania <br />European patent (EP) 16710345.6<br />Filed on 2016-02-10<br />Status: Issued 147166846 E-065-2015-0 E-065-2015-0-US-14 GRIFFITHSIN MUTANTS CON US 12,384,820 17/724,342 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12384820 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12384820">12,384,820</a><br />Filed on 2022-04-19<br />Status: Issued 147170622 Anti-Viral 147170624 cnidarin 147170625 Griffithsin 147170626 HCV 147170627 HIV 147170628 HSV 147170629 SARS TAB-4415 147157710 Treatment of GPR101-Related, Growth Hormone-Related Disorders Such as Gigantism, Dwarfism or Acromegaly NICHD Collaboration, Endocrinology, Licensing, Therapeutics Collaboration Endocrinology Licensing Therapeutics Albert Beckets, Adrian Daly, Fabio Faucz, Constantine Stratakis, Giampaolo Trivellin <p>Microduplications of the GPR101 gene (located on chromosome Xq26.3 and encodes a G-protein coupled receptor) can result in an excess of growth hormone causing gigantism, that has an onset in early childhood. It is also associated with the growth of sporadic growth hormone producing adenomas in some patients with acromegaly.</p> <p>Current therapies (such as surgical resection of tumors or treatment with somatostatin analogs) for acromegaly, gigantism and other disorders of pituitary hormone hypersecretion can be ineffective, thereby creating a need for alternative therapies in this space.</p> <p>The inventors at the <a href="https://www.nichd.nih.gov/Pages/index.aspx" target="_blank" rel="nofollow"><em>Eunice Kennedy Shriver</em> National Institute of Child Health and Human Development</a> (NICHD) have developed a cell line that stably over-expresses GPR101.</p> <p>Agents which inhibit the expression the GPR101-encoded protein or the biological activity of the protein can be used to treat gigantism.</p> <p>Alternatively, agents that increase expression of the GPR101-encoded protein or the biological activity of the protein can be used:</p> <ul><li>To treat dwarfism and short stature and</li> <li>To increase the body mass of livestock.</li> </ul><p>The NICHD seeks licensing and/or co-development research partners to collaborate on the identification and characterization of GPR101 inhibitors (antagonists and inverse agonists) and agonists with the goal of identifying agents to treat gigantism, acromegaly or dwarfism.</p> <h2>Competitive Advantages:</h2> <ul><li>Current therapies (surgical resection of tumors or treatment with somatostatin analogs) can be ineffective. <ul><li>Alternate therapies for acromegaly, gigantism and other disorders of pituitary hormone hypersecretion could be medically useful.</li> </ul></li> </ul> <h2>Commercial Applications:</h2> <ul><li>Treatment of gigantism</li> <li>Treatment of sporadic growth hormone-producing adenomas in some patients with acromegaly</li> <li>Treatment of dwarfism</li> <li>Methods of increasing body mass and/or body size in livestock (cattle, chicken, etc.)</li> </ul> 2017-04-18 2025-04-22 2019-01-03 2025-04-22 2017-04-25 acromegaly, Dwarfism, Eunice Kennedy Shriver National Institute of Child Health an, Gigantism, GPR101, growth hormone regulation, NICHD False True Basic (Target Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2019-01-03 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147161870 Trivellin G et al. Gigantism and acromegaly due to Xq26 microduplications and GPR101 mutation. https://www.ncbi.nlm.nih.gov/pubmed/25470569 <a href="https://www.ncbi.nlm.nih.gov/pubmed/25470569">Trivellin G et al. Gigantism and acromegaly due to Xq26 microduplications and GPR101 mutation.</a> 147161986 Trivellin G et al. Characterization of GPR101 transcripts structure and expression patterns. https://www.ncbi.nlm.nih.gov/pubmed/27282544 <a href="https://www.ncbi.nlm.nih.gov/pubmed/27282544">Trivellin G et al. Characterization of GPR101 transcripts structure and expression patterns.</a> 147162064 Beckers A et al. X-linked acrogigantism syndrome: clinical profile and therapeutic responses. https://www.ncbi.nlm.nih.gov/pubmed/25712922 <a href="https://www.ncbi.nlm.nih.gov/pubmed/25712922">Beckers A et al. X-linked acrogigantism syndrome: clinical profile and therapeutic responses.</a> 147162142 Iacovazzo D et al. Germline or somatic GPR101 duplication leads to X-linked acrogigantism: a clinico-pathological and genetic study. https://actaneurocomms.biomedcentral.com/articles/10.1186/s40478-016-0328-1 <a href="https://actaneurocomms.biomedcentral.com/articles/10.1186/s40478-016-0328-1">Iacovazzo D et al. Germline or somatic GPR101 duplication leads to X-linked acrogigantism: a clinico-pathological and genetic study.</a> 147164658 Daly, Adrian Universite de Liege Daly, Adrian 1 147164659 Beckets, Albert Universite de Liege Beckets, Albert 2 147164661 Faucz, Fabio NIH - NICHD NICHD Faucz, Fabio (NICHD) 3 147164660 Trivellin, Giampaolo NIH - NICHD NICHD Trivellin, Giampaolo (NICHD) 4 147164657 Stratakis, Constantine NIH - NICHD NICHD Stratakis, Constantine (NICHD) 5 147164658 Daly, Adrian Universite de Liege Daly, Adrian 1 147164659 Beckets, Albert Universite de Liege Beckets, Albert 2 147164661 Faucz, Fabio NIH - NICHD NICHD Faucz, Fabio (NICHD) 3 147164660 Trivellin, Giampaolo NIH - NICHD NICHD Trivellin, Giampaolo (NICHD) 4 147164657 Stratakis, Constantine NIH - NICHD NICHD Stratakis, Constantine (NICHD) 5 147157842 METHOD FOR TREATMENT OF HORMONAL DISORDERS OF GROWTH USING ANTAGONlSTS AND AGONISTS OF THE ORPHAN G-PROTEIN COUPLED RECEPTOR {GPCR), GPR101 E-039-2016-0 Filing authorized NICHD, Universite de Liege 147162502 Method For Treatment Of Disorders Of Growth, Puberty And Appetite Regulation Using Antagonists And Agonists Of The Orphan G-protein Coupled Receptor (GPCR), GPR101 E-039-2016-1 Filing authorized NICHD, Universite de Liege 83682895 Girards, Richard richard.girards@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB richard.girards@nih.gov?subject=Web Inquiry on [TAB-4415] Treatment of GPR101-Related, Growth Hormone-Related Disorders Such as Gigantism, Dwarfism or Acromegaly&body=Please send me information about technology [TAB-4415] Treatment of GPR101-Related, Growth Hormone-Related Disorders Such as Gigantism, Dwarfism or Acromegaly.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Girards, Richard<br><a href="mailto:richard.girards@nih.gov?subject=Web Inquiry on [TAB-4415] Treatment of GPR101-Related, Growth Hormone-Related Disorders Such as Gigantism, Dwarfism or Acromegaly&body=Please send me information about technology [TAB-4415] Treatment of GPR101-Related, Growth Hormone-Related Disorders Such as Gigantism, Dwarfism or Acromegaly.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">richard.girards@nih.gov</a><br> 147160943 E-039-2016-1 E-039-2016-1-PCT-01 Treatment of Hormonal Disorders of Growth PCT COMB Patent Cooperation Treaty PCT/US2015/060442 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2015/060442<br />Filed on 2015-11-12<br />Status: Expired 147168782 E-039-2016-0 E-039-2016-0-US-01 METHOD FOR TREATMENT OF HORMONAL DISORDERS OF GROWTH USING ANTAGONlSTS AND AGONISTS OF THE ORPHAN G-PROTEIN COUPLED RECEPTOR {GPCR), GPR101 PRV US 62/078,517 Abandoned US <br />Provisional (PRV) 62/078,517<br />Filed on 2014-11-12<br />Status: Abandoned 147168784 E-039-2016-1 E-039-2016-1-US-02 TREATMENT OF HORMONAL DISORDERS OF GROWTH ORD US 10,350,273 15/525,928 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10350273 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10350273">10,350,273</a><br />Filed on 2017-05-10<br />Status: Issued 147168785 E-039-2016-1 E-039-2016-1-AU-03 Treatment of Hormonal Disorders of Growth National Stage Australia 2015346277 2015346277 Issued Australia <br />National Stage 2015346277<br />Filed on 2017-04-28<br />Status: Issued 147168786 E-039-2016-1 E-039-2016-1-CA-04 Treatment of Hormonal Disorders of Growth National Stage Canada 2965696 2965696 Issued Canada <br />National Stage 2965696<br />Filed on 2015-11-12<br />Status: Issued 147168787 E-039-2016-1 E-039-2016-1-EP-05 Treatment of Hormonal Disorders of Growth National Stage European Patent 3218395 15798305.7 Issued European Patent <br />National Stage 15798305.7<br />Filed on 2015-11-12<br />Status: Issued 147168788 E-039-2016-1 E-039-2016-1-US-06 TREATMENT OF HORMONAL DISORDERS OF GROWTH CON US 16/430,079 Abandoned US <br />Continuation (CON) 16/430,079<br />Filed on 2019-06-03<br />Status: Abandoned 147168789 E-039-2016-1 E-039-2016-1-AU-07 Treatment of Hormonal Disorders of Growth DIV Australia 2020203709 2020203709 Issued Australia <br />Divisional (DIV) 2020203709<br />Filed on 2020-06-04<br />Status: Issued 147168790 E-039-2016-1 E-039-2016-1-DE-08 Treatment of Hormonal Disorders of Growth EP Germany 3218395 15798305.7 Issued Germany <br />European patent (EP) 15798305.7<br />Filed on 2015-11-12<br />Status: Issued 147168791 E-039-2016-1 E-039-2016-1-FR-09 Treatment of Hormonal Disorders of Growth EP France 3218395 15798305.7 Issued France <br />European patent (EP) 15798305.7<br />Filed on 2015-11-12<br />Status: Issued 147168792 E-039-2016-1 E-039-2016-1-GB-10 Treatment of Hormonal Disorders of Growth EP United Kingdom 3218395 15798305.7 Issued United Kingdom <br />European patent (EP) 15798305.7<br />Filed on 2015-11-12<br />Status: Issued 147170014 acromegaly 147170015 Dwarfism 147170016 Eunice Kennedy Shriver National Institute of Child Health an 147170018 Gigantism 147170019 GPR101 147170021 growth hormone regulation 147170022 NICHD TAB-4078 147157360 Module to Freeze and Store Frozen Tissue NCI Collaboration, Licensing, Medical Devices, Non-Medical Devices, Oncology Collaboration Licensing Medical Devices Non-Medical Devices Oncology Jeffrey Hanson, Stephen Hewitt, Michael Oshetski, Kristofferson Ylaya <p>Tissue obtained for both clinical and research purposes is routinely frozen, commonly in Optimal Cutting Temperature (OCT), an embedding media, for eventual downstream analysis, commonly including sectioning on a cryostat. Though OCT is the standard compound used for freezing, there is no standard freezing protocol. Thus, current methods of handling, labeling, and storing OCT-embedded tissue vary widely, and specimens are often damaged or degraded due to undesirable temperature fluctuations during handling and freezing.</p> <p>To address these issues, researchers from the NCI <a href="https://ccr.cancer.gov/Laboratory-of-Pathology" rel="nofollow">Laboratory of Pathology (LP)</a> have engineered a system that employs a plastic enclosure that also functions as a tissue platen for cryosectioning, which is then enclosed with a lid for storage. This plastic enclosure also has an integrated space for labeling (written, barcode, RFID, etc.). The lid snaps closed to protect the specimen from deformation and/or thermal shock. This ‘freezing system’ is particularly unique since it is modular (i.e. designed to fit in commonly used research/clinical storage units) and affordable. Additionally, the module can be designed to work with any manufacturer’s tissue holders for cryosectioning.</p> <h2>Competitive Advantages:</h2> <ul><li>This is a novel device that addresses an unmet need in frozen tissue storage and evaluation</li> <li>Enclosure has integrated external labeling, for minimal disturbance of sample</li> <li>Enclosure has a snap-closed lid for added sample protection</li> <li>Enclosure is plastic–insulative properties (i.e. slow to adjust to changes in external temperature)</li> <li>Enclosure is modular and versatile; it will fit in most commonly used storage units in research and clinical settings</li> <li>Enclosure is affordable; each unit is designed for single use</li> <li>A model is available for clinical application, in which a frozen specimen can be subject to cryosectioning and then directly enclosed into an open unit for immediate fixation and processing as formalin fixed, paraffin embedded tissue, for confirmation of diagnosis</li> </ul> <h2>Commercial Applications:</h2> <ul><li>This is a novel enclosure that provides a standardized method of freezing, labeling, and storing fresh tissue samples for diagnostic and/or research purposes</li> <li>This ‘freezing system’ would be particularly useful for rare or fragile specimens, since it can significantly reduce the possibility of deformation or thermal shock</li> <li>Tissue is frozen as a sandwich directly onto plastic enclosure, using an OCT and a pre-existing mold </li> </ul> 2017-08-03 2025-04-22 2021-01-27 2025-04-22 2017-08-03 Biopsy, Biorepository, Cryosectioning, diagnostic, Freezing, Frozen Tissue, PATHOLOGY, Storage False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2021-01-27 52406768 Discovery 52406768 NCI 37470483 Website Abstract E-052-2013 E-128-2017 E-139-2015 147163437 Hewitt, Stephen NIH - NCI NCI Hewitt, Stephen (NCI) 1 147163438 Hanson, Jeffrey NIH - NCI NCI Hanson, Jeffrey (NCI) 2 147163439 Ylaya, Kristofferson NIH - NCI NCI Ylaya, Kristofferson (NCI) 3 147163440 Oshetski, Michael Micatu, Inc Oshetski, Michael 4 147163437 Hewitt, Stephen NIH - NCI NCI Hewitt, Stephen (NCI) 1 147163438 Hanson, Jeffrey NIH - NCI NCI Hanson, Jeffrey (NCI) 2 147163439 Ylaya, Kristofferson NIH - NCI NCI Ylaya, Kristofferson (NCI) 3 147163440 Oshetski, Michael Micatu, Inc Oshetski, Michael 4 147158143 Module For Freezing And Storage Of Frozen Tissue E-173-2015-0 Filing authorized Micatu, Inc, NCI 121111111 Greene, Jaime greenejaime@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America greenejaime@mail.nih.gov?subject=Web Inquiry on [TAB-4078] Module to Freeze and Store Frozen Tissue&body=Please send me information about technology [TAB-4078] Module to Freeze and Store Frozen Tissue.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Greene, Jaime<br><a href="mailto:greenejaime@mail.nih.gov?subject=Web Inquiry on [TAB-4078] Module to Freeze and Store Frozen Tissue&body=Please send me information about technology [TAB-4078] Module to Freeze and Store Frozen Tissue.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">greenejaime@mail.nih.gov</a><br> 147161146 E-173-2015-0 E-173-2015-0-US-01 Module For Freezing And Storage Of Frozen Tissue PRV US 62/403,585 Abandoned US <br />Provisional (PRV) 62/403,585<br />Filed on 2016-10-03<br />Status: Abandoned 147166366 E-173-2015-0 E-173-2015-0-PCT-02 Module For Freezing And Storage Of Frozen Tissue PCT Patent Cooperation Treaty PCT/US2017/054531 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2017/054531<br />Filed on 2017-09-29<br />Status: Expired 147166367 E-173-2015-0 E-173-2015-0-EP-03 Module For Freezing And Storage Of Frozen Tissue National Stage European Patent 3519795 17785103.7 Issued European Patent <br />National Stage 17785103.7<br />Filed on 2017-09-29<br />Status: Issued 147166368 E-173-2015-0 E-173-2015-0-US-04 Module For Freezing And Storage Of Frozen Tissue National Stage US 11,802,821 16/338,860 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11802821 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11802821">11,802,821</a><br />Filed on 2019-04-02<br />Status: Issued 147166369 E-173-2015-0 E-173-2015-0-DE-05 Module For Freezing And Storage Of Frozen Tissue EP Germany 3519795 17785103.7 Issued Germany <br />European patent (EP) 17785103.7<br />Filed on 2017-09-29<br />Status: Issued 147166370 E-173-2015-0 E-173-2015-0-FR-06 Module For Freezing And Storage Of Frozen Tissue EP France 3519795 17785103.7 Issued France <br />European patent (EP) 17785103.7<br />Filed on 2017-09-29<br />Status: Issued 147166371 E-173-2015-0 E-173-2015-0-GB-07 Module For Freezing And Storage Of Frozen Tissue EP United Kingdom 3519795 17785103.7 Issued United Kingdom <br />European patent (EP) 17785103.7<br />Filed on 2017-09-29<br />Status: Issued 147166372 E-173-2015-0 E-173-2015-0-EP-08 Module For Freezing And Storage Of Frozen Tissue DIV European Patent 4086606 22169969.7 Issued European Patent <br />Divisional (DIV) 22169969.7<br />Filed on 2017-09-29<br />Status: Issued 147172994 Biopsy 147172995 Biorepository 147172997 Cryosectioning 147172998 diagnostic 147172999 Freezing 147173001 Frozen Tissue 147173002 PATHOLOGY 147173003 Storage TAB-4458 147157753 Photoactivatable Lipid-based Nanoparticles as a Vehicle for Dual Agent Delivery NCI Cardiology, Collaboration, Dermatology, Ear, Nose, & Throat, Infectious Disease, Licensing, Oncology, Ophthalmology, Therapeutics Cardiology Collaboration Dermatology Ear Nose & Throat Infectious Disease Licensing Oncology Ophthalmology Therapeutics Robert Blumenthal, Amit Joshi, Anu Puri, Darayash Tata, Mathias Viard <p>The invention relates to novel lipid-based nanoparticles (liposomes) for use in targeted, on demand and on site drug delivery. The particles include a wall surrounding a cavity, wherein the wall is comprised of:</p> <ol> <li>A lipid bilayer comprising 1,2-bis(tricosa-10,12-diynoyl)-sn-glycero-3-phosphocholine (DC<sub>8,9</sub>PC), dipalmitoylphosphatidylcholine (DPPC), and 1,2-distearoyl-<em>sn</em>-glycero-3-</li> </ol> <p>phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (DSPE-PEG2000), and</p> <ol> <li>A tetrapyrollic photosensitizer, 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a (HPPH) within the lipid bilayer.</li> </ol> <p>The photosensitive lipid nanoparticles are capable of containing water-soluble agents (e.g., topotecan) in their cavity and designed to be 80-200nm in diameter. The release of agents is triggered by the disruption of the lipid bilayer when light (near-infrared wavelength of 650-670nm) is discretely applied. The concurrent activation of the photosensitizing agent, HPPH may be advantageous in the treatment of certain cancers, especially since this agent possesses therapeutic ability. The inventors have also shown the cytotoxicity of the lipid nanoparticles in T24 bladder cancer cells in the presence and absence of light, drug, and HPPH. The lipid nanoparticles containing the water-soluble agent, topotecan, and HPPH, in the presence of light exhibit superior toxicity as compared to either lipid-nanoparticle encapsulated topotecan or HPPH alone.</p> <blockquote> <p><img alt="" height="548" src="https://nih.technologypublisher.com/files/sites/figure_1_for_abstract_e-482-2013_12.png" width="600" />&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<img alt="" height="241" src="https://nih.technologypublisher.com/files/sites/figure_2_for_abstract_e-482-2013_02.png" width="200" /></p> </blockquote> <p>&nbsp;</p> <h2>Competitive Advantages:</h2> <ul> <li>Stable nanoparticles</li> <li>Platform technology applicable to several major, unmet medical needs</li> <li>Nanoparticles can be activated upon demand to release a therapeutic agent at a desired site</li> <li>The concurrent activation of the photosensitizing agent, HPPH may be advantageous in the treatment of certain types of cancer</li> <li>Potential for topical products having shorter time- and cost-to-market; additional licensing opportunities in the cosmetics sector</li> <li>Compared with standard emulsions and other types of particle-based delivery, better control of &ndash; and prolonged &ndash; delivery</li> <li>Faster degradation versus particles comprised made from many other polymeric formulations</li> <li>Potential for superior tolerability</li> </ul> <h2>Commercial Applications:</h2> <ul> <li>The nanoparticles can be used for targeted multiple drug delivery</li> <li>Cancer, cardiovascular and musculoskeletal disorders, infectious disease</li> <li>Cosmetic/topical products</li> </ul> 2017-08-10 2025-04-22 2020-04-13 2025-04-22 2017-08-15 Combination Therapy, Delivery Agent, Infections (bacteria and viruses), Lipid nanoparticle, liposome, On-demand Drug Release, photoactivation, therapeutic delivery False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-04-13 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147164809 Puri, Anu NIH - NCI NCI Puri, Anu (NCI) 1 147164808 Blumenthal, Robert NIH - NCI NCI Blumenthal, Robert (NCI) 2 147164812 Joshi, Amit Baylor College of Medicine Joshi, Amit 3 147164811 Tata, Darayash NIH - FDA FDA Tata, Darayash (FDA) 4 147164810 Viard, Mathias NIH - NCI Leidos Viard, Mathias (Leidos) 5 147164809 Puri, Anu NIH - NCI NCI Puri, Anu (NCI) 1 147164808 Blumenthal, Robert NIH - NCI NCI Blumenthal, Robert (NCI) 2 147164812 Joshi, Amit Baylor College of Medicine Joshi, Amit 3 147164811 Tata, Darayash NIH - FDA FDA Tata, Darayash (FDA) 4 147164810 Viard, Mathias NIH - NCI Leidos Viard, Mathias (Leidos) 5 147158354 Photo-activable Lipid-based Nanoparticles ("POCKET" Liposomes) As Vehicles For On-demand DUAL Drug Delivery And Combination Therapy For Improved Cancer Treatment E-482-2013-0 Filing authorized Baylor College of Medicine, FDA, NCI 83732917 Favila, Michelle michelle.favila@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC michelle.favila@nih.gov?subject=Web Inquiry on [TAB-4458] Photoactivatable Lipid-based Nanoparticles as a Vehicle for Dual Agent Delivery&body=Please send me information about technology [TAB-4458] Photoactivatable Lipid-based Nanoparticles as a Vehicle for Dual Agent Delivery.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Favila, Michelle<br><a href="mailto:michelle.favila@nih.gov?subject=Web Inquiry on [TAB-4458] Photoactivatable Lipid-based Nanoparticles as a Vehicle for Dual Agent Delivery&body=Please send me information about technology [TAB-4458] Photoactivatable Lipid-based Nanoparticles as a Vehicle for Dual Agent Delivery.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">michelle.favila@nih.gov</a><br> 147169083 E-482-2013-0 E-482-2013-0-US-01 PHOTOACTIVATABLE LIPID-BASED NANOPARTICLES AS VEHICLES FOR DUAL AGENT DELIVERY PRV US 61/845,861 Abandoned US <br />Provisional (PRV) 61/845,861<br />Filed on 2013-07-12<br />Status: Abandoned 147169084 E-482-2013-0 E-482-2013-0-PCT-02 Photo-activable Lipid-based Nanoparticles As Vehicles For Dual Agent Delivery PCT Patent Cooperation Treaty PCT/US2014/045922 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2014/045922<br />Filed on 2014-07-09<br />Status: Expired 147169085 E-482-2013-0 E-482-2013-0-CA-03 PHOTOACTIVATABLE LIPID-BASED NANOPARTICLES AS VEHICLES FOR DUAL AGENT DELIVERY National Stage Canada 2917545 2917545 Issued Canada <br />National Stage 2917545<br />Filed on 2014-07-09<br />Status: Issued 147169086 E-482-2013-0 E-482-2013-0-EP-04 Photoactivable Lipid-based Nanoparticles As Vehicles For Dual Agent Delivery National Stage European Patent 3019201 14745037.3 Issued European Patent <br />National Stage 14745037.3<br />Filed on 2014-07-09<br />Status: Issued 147169087 E-482-2013-0 E-482-2013-0-US-05 Photoactivable Lipid-based Nanoparticles As Vehicles For Dual Agent Delivery National Stage US 10,117,942 14/904,385 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10117942 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10117942">10,117,942</a><br />Filed on 2016-01-11<br />Status: Issued 147169088 E-482-2013-0 E-482-2013-0-CH-06 Photoactivable Lipid-based Nanoparticles As Vehicles For Dual Agent Delivery EP Switzerland 3019201 14745037.3 Issued Switzerland <br />European patent (EP) 14745037.3<br />Filed on 2014-07-09<br />Status: Issued 147169089 E-482-2013-0 E-482-2013-0-DE-07 Photoactivable Lipid-based Nanoparticles As Vehicles For Dual Agent Delivery EP Germany 3019201 14745037.3 Issued Germany <br />European patent (EP) 14745037.3<br />Filed on 2014-07-09<br />Status: Issued 147169090 E-482-2013-0 E-482-2013-0-FR-08 Photoactivable Lipid-based Nanoparticles As Vehicles For Dual Agent Delivery EP France 3019201 14745037.3 Issued France <br />European patent (EP) 14745037.3<br />Filed on 2014-07-09<br />Status: Issued 147169091 E-482-2013-0 E-482-2013-0-GB-09 Photoactivable Lipid-based Nanoparticles As Vehicles For Dual Agent Delivery EP United Kingdom 3019201 14745037.3 Issued United Kingdom <br />European patent (EP) 14745037.3<br />Filed on 2014-07-09<br />Status: Issued 147174871 Combination Therapy 147174873 Delivery Agent 147174875 Infections (bacteria and viruses) 147174877 Lipid nanoparticle 147174878 liposome 147174880 On-demand Drug Release 147174881 photoactivation 147174882 therapeutic delivery TAB-4167 147157450 Gene-based Diagnostic Predicts Patient Response to Cancer Immunotherapy NCI Diagnostics, Licensing, Oncology Diagnostics Licensing Oncology Shashankkumar Patel, Nicholas Restifo <p>Immunotherapy is a promising method of treating cancer that leverages the immune system to promote tumor rejection. However, certain somatic mutations in cancer cells confer resistance to T cell-mediated cytolysis. To improve the effectiveness of immunotherapies for cancer, there exists a need to prospectively identify patients who are most likely to respond to such therapies.</p> <p>Researchers at the National Cancer Institute (NCI) have developed a method of selecting a therapy for a cancer patient by screening for known mutations which confer immune resistance. By performing a whole genome wide CRISPR-Cas9 screen, the researchers discovered a novel set of genes required for T-cell mediated tumor clearance. The results of this screen were combined with The Cancer Genome Atlas (TCGA) datasets and then cross-validated to determine immune sensitivity in multiple human cancers. Through their studies, the researchers have identified genes that are essential for eliciting an effective T-cell response.</p> <p>The National Cancer Institute, Surgery Branch, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize this method of using a set of novel genes to determine an appropriate therapy for a cancer patient.</p> <h2>Competitive Advantages:</h2> <ul><li>Resistant properties imparted by these genes has been validated by functionally knocking them out in cancer cells</li> <li>These genes correlate with T cell cytolytic activity across most cancer types</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Development of a companion diagnostic for cancer immunotherapies, particularly adoptive cell therapies</li> </ul> 2017-08-15 2025-04-22 2020-08-12 2025-04-22 2017-10-06 CRISPR, diagnostic, Gene, Immunotherapy, T-cell, tumor False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-08-12 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-059-2013 E-085-2013 E-229-2014 E-233-2014 147161867 Patel, S. et al. Identification of essential genes for cancer immunotherapy. Nature, (2017). doi:10.1038/nature23477 Patel, S. et al. Identification of essential genes for cancer immunotherapy. Nature, (2017). doi:10.1038/nature23477 147163753 Patel, Shashankkumar NIH - NCI NCI Patel, Shashankkumar (NCI) 1 147163752 Restifo, Nicholas NIH - NCI NCI Restifo, Nicholas (NCI) 2 147163753 Patel, Shashankkumar NIH - NCI NCI Patel, Shashankkumar (NCI) 1 147163752 Restifo, Nicholas NIH - NCI NCI Restifo, Nicholas (NCI) 2 147157808 Essential Genes For Cancer Immunotherapies E-022-2017-0 Filing authorized NCI 83709866 Burke, Andrew burkear@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC burkear@nih.gov?subject=Web Inquiry on [TAB-4167] Gene-based Diagnostic Predicts Patient Response to Cancer Immunotherapy&body=Please send me information about technology [TAB-4167] Gene-based Diagnostic Predicts Patient Response to Cancer Immunotherapy.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Burke, Andrew<br><a href="mailto:burkear@nih.gov?subject=Web Inquiry on [TAB-4167] Gene-based Diagnostic Predicts Patient Response to Cancer Immunotherapy&body=Please send me information about technology [TAB-4167] Gene-based Diagnostic Predicts Patient Response to Cancer Immunotherapy.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">burkear@nih.gov</a><br> 147160916 E-022-2017-0 E-022-2017-0-US-01 METHODS FOR SELECTING THERAPY FOR A CANCER PATIENT PRV US 62/418,461 Abandoned US <br />Provisional (PRV) 62/418,461<br />Filed on 2016-11-07<br />Status: Abandoned 147167052 E-022-2017-0 E-022-2017-0-PCT-02 METHODS FOR SELECTING THERAPY FOR A CANCER PATIENT PCT Patent Cooperation Treaty PCT/US2017/60304 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2017/60304<br />Filed on 2017-11-07<br />Status: Expired 147167053 E-022-2017-0 E-022-2017-0-EP-03 METHODS FOR SELECTING THERAPY FOR A CANCER PATIENT National Stage European Patent 3535423 17805342.7 Issued European Patent <br />National Stage 17805342.7<br />Filed on 2019-05-06<br />Status: Issued 147167054 E-022-2017-0 E-022-2017-0-US-04 METHODS FOR SELECTING THERAPY FOR A CANCER PATIENT National Stage US 11,312,998 16/347,778 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11312998 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11312998">11,312,998</a><br />Filed on 2019-05-06<br />Status: Issued 147167055 E-022-2017-0 E-022-2017-0-EP-05 METHODS FOR SELECTING THERAPY FOR A CANCER PATIENT DIV European Patent 21217161.5 Abandoned European Patent <br />Divisional (DIV) 21217161.5<br />Filed on 2021-12-22<br />Status: Abandoned 147167056 E-022-2017-0 E-022-2017-0-FR-06 METHODS FOR SELECTING THERAPY FOR A CANCER PATIENT EP France 3535423 17805342.7 Issued France <br />European patent (EP) 17805342.7<br />Filed on 2019-05-06<br />Status: Issued 147167057 E-022-2017-0 E-022-2017-0-DE-07 METHODS FOR SELECTING THERAPY FOR A CANCER PATIENT EP Germany 3535423 17805342.7 Issued Germany <br />European patent (EP) 17805342.7<br />Filed on 2019-05-06<br />Status: Issued 147167058 E-022-2017-0 E-022-2017-0-GB-08 METHODS FOR SELECTING THERAPY FOR A CANCER PATIENT EP United Kingdom 3535423 17805342.7 Issued United Kingdom <br />European patent (EP) 17805342.7<br />Filed on 2019-05-06<br />Status: Issued 147167060 E-022-2017-0 E-022-2017-0-US-10 METHODS FOR SELECTING THERAPY FOR A CANCER PATIENT CON US 17/703,005 Abandoned US <br />Continuation (CON) 17/703,005<br />Filed on 2022-03-24<br />Status: Abandoned 147169660 CRISPR 147169661 diagnostic 147169662 Gene 147169663 Immunotherapy 147169664 T-cell 147169665 tumor TAB-4000 147157281 Near-IR Light-Cleavable Antibody Conjugates and Conjugate Precursors NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Alexander Gorka, Hisataka Kobayashi, Roger Nani, Martin Schnermann <p>This invention describes a general way to trigger the release of a bioactive small molecule from a targeting antibody. The key “trigger” is a fluorescent linker that is chemically disassembled upon irradiation with light in the near-IR range (~800 nm).</p> <p>This linker technology is a dramatic step forward for the field. The molecules can be tracked using conventional fluorescence imaging technology, and with the application of a higher light dose, drug-release can be initiated in a targeted manner. In current clinical practice, a bulk tumor is often removed through a guided surgical approach with the tumor margins cleared by targeted irradiation. This technology promises fewer side-effects and the potential to pre-empt resistance issues by achieving higher, otherwise unattainable, drug doses. Compared to existing photodynamic therapy approaches, this technology relies on the activity of highly potent drug molecules, leading to dramatically improved potency.</p> <p>To date, the inventors have demonstrated the ability to synthesize and use antibody conjugates that release the bioactive molecule duocarmycin. These ADCs display potent and highly selective activity in cellular assays. <em>In vivo</em> imaging has proven the ability to track and subsequently release the compounds with external irradiation from a continuous wave laser source. Significant antitumor efficacy has been observed following a single dose. Future studies are aimed at optimizing the physical properties of the conjugates and detailed <em>in vivo</em> efficacy and toxicology studies.</p> <h2>Competitive Advantages:</h2> <ul><li>These studies are the first to illustrate <em>in vivo</em> drug delivery using antibody and light-based targeting</li> <li>Light in the near-IR range exhibits meaningful tissue penetration (up to several cms) and is non-toxic</li> <li>Enhanced potency compared to existing photodynamic therapies (PDT) that rely on the use of ROS as the major mediator of biological function</li> <li>In comparison to other ADCs, this approach should provide reduced off target release, while providing highly controlled delivery to irradiated areas of interest. These features should reduce toxicity, while providing improved efficacy for certain solid tumor applications (e.g. head and neck, bladder, and glioblastoma)</li> </ul> <h2>Commercial Applications:</h2> <ul><li>To deliver a potent ADC payload with otherwise unattainable control through local irradiation</li> <li>Targeted cancer therapy</li> <li>In a basic research context, could be used to test the effect of timing, dose, and location of <em>in vivo</em> activity of payloads</li> </ul> 2017-09-29 2025-04-22 2017-09-29 2025-04-22 2017-10-03 ADC, Antibody-drug Conjugate, Chemical linkers, Fluorescent linker, PDT, personalized medicine, Photodynamic therapy, Targeted drug release, Targeted therapy False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2017-09-29 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-204-2015 147161896 Nani RR, et al. Near-IR Light-Mediated Cleavage of Antibody-Drug Conjugates Using Cyanine Photocages. https://www.ncbi.nlm.nih.gov/pubmed/26403799 <a href="https://www.ncbi.nlm.nih.gov/pubmed/26403799">Nani RR, et al. Near-IR Light-Mediated Cleavage of Antibody-Drug Conjugates Using Cyanine Photocages.</a> 147162012 Gorka A, et al. A Near-IR Uncaging Strategy Based on Cyanine Photochemistry. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4195383/ <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4195383/">Gorka A, et al. A Near-IR Uncaging Strategy Based on Cyanine Photochemistry.</a> 147162284 Nani RR, et al. In Vivo Activation of Duocarmycin-Antibody Conjugates by Near-Infrared Light. https://www.ncbi.nlm.nih.gov/pubmed/28470051 <a href="https://www.ncbi.nlm.nih.gov/pubmed/28470051">Nani RR, et al. In Vivo Activation of Duocarmycin-Antibody Conjugates by Near-Infrared Light.</a> 147163171 Schnermann, Martin NIH - NCI NCI Schnermann, Martin (NCI) 1 147163173 Gorka, Alexander NIH - NCI NCI Gorka, Alexander (NCI) 2 147163170 Kobayashi, Hisataka NIH - NCI NCI Kobayashi, Hisataka (NCI) 3 147163172 Nani, Roger NIH - NCI Nani, Roger 4 147163171 Schnermann, Martin NIH - NCI NCI Schnermann, Martin (NCI) 1 147163173 Gorka, Alexander NIH - NCI NCI Gorka, Alexander (NCI) 2 147163170 Kobayashi, Hisataka NIH - NCI NCI Kobayashi, Hisataka (NCI) 3 147163172 Nani, Roger NIH - NCI Nani, Roger 4 147158265 Improved Near-IR Light Antibody Drug Conjugates (ADCs) E-245-2016-0 Filing authorized NCI 83704821 Nguyen-Antczak, Lauren lauren.nguyen-antczak@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-4000] Near-IR Light-Cleavable Antibody Conjugates and Conjugate Precursors&body=Please send me information about technology [TAB-4000] Near-IR Light-Cleavable Antibody Conjugates and Conjugate Precursors.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Nguyen-Antczak, Lauren<br><a href="mailto:lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-4000] Near-IR Light-Cleavable Antibody Conjugates and Conjugate Precursors&body=Please send me information about technology [TAB-4000] Near-IR Light-Cleavable Antibody Conjugates and Conjugate Precursors.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">lauren.nguyen-antczak@nih.gov</a><br> 147161226 E-245-2016-0 E-245-2016-0-US-01 NEAR-IR LIGHT-CLEAVABLE CONJUGATES AND CONJUGATE PRECURSORSNguy PRV US 62/373,666 Abandoned US <br />Provisional (PRV) 62/373,666<br />Filed on 2016-08-11<br />Status: Abandoned 147165820 E-245-2016-0 E-245-2016-0-PCT-02 NEAR-IR LIGHT-CLEAVABLE CONJUGATES AND CONJUGATE PRECURSORS PCT Patent Cooperation Treaty PCT/US2017/045694 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2017/045694<br />Filed on 2017-08-07<br />Status: Expired 147165821 E-245-2016-0 E-245-2016-0-EP-03 NEAR-IR LIGHT-CLEAVABLE CONJUGATES AND CONJUGATE PRECURSORS National Stage European Patent 17754556.3 Abandoned European Patent <br />National Stage 17754556.3<br />Filed on 2017-08-07<br />Status: Abandoned 147165822 E-245-2016-0 E-245-2016-0-JP-04 NEAR-IR LIGHT-CLEAVABLE CONJUGATES AND CONJUGATE PRECURSORS National Stage Japan 7042254 2019-506725 Issued Japan <br />National Stage 2019-506725<br />Filed on 2017-08-07<br />Status: Issued 147165823 E-245-2016-0 E-245-2016-0-US-05 NEAR-IR LIGHT-CLEAVABLE CONJUGATES AND CONJUGATE PRECURSORS National Stage US 10,561,729 16/323,747 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10561729 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10561729">10,561,729</a><br />Filed on 2019-02-06<br />Status: Issued 147165824 E-245-2016-0 E-245-2016-0-US-06 Improved Near-IR Light Antibody Drug Conjugates (ADCs) DIV US 10,874,739 16/723,482 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10874739 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10874739">10,874,739</a><br />Filed on 2019-12-20<br />Status: Issued 147174171 ADC 147174172 Antibody-drug Conjugate 147174174 Chemical linkers 147174176 Fluorescent linker 147174177 PDT 147174178 personalized medicine 147174179 Photodynamic therapy 147174181 Targeted drug release 147174183 Targeted therapy TAB-3869 147157148 A Rapid Method of Isolating Neoantigen-specific T Cell Receptor Sequences NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Peter Fitzgerald, Yong-Chen Lu, Steven Rosenberg, Zhili Zheng <p>Tumors can develop unique genetic mutations which are specific to an individual patient. Some of these mutations are immunogenic; giving rise to autologous T cells which are tumor-reactive. Once isolated and sequenced, these neoantigen-specific TCRs can form the basis of effective adoptive cell therapy cancer treatment regimens; however, current methods of isolation are inefficient. Moreover, the process is technically challenging due to TCR sequence diversity and the need to correctly pair the a and b chain of each receptor. Thus, there is an urgent need for more robust methods of identifying paired sequences of mutation-specific TCRs for cancer immunotherapy.</p> <p>Researchers at the NCI have developed an efficient method for isolating the paired sequences of TCRs. Using single-cell methodology, next generation sequencing and custom bioinformatics software, the researchers can isolate full-length TCR α and β chain sequences from mutation-reactive T cells. These isolated sequences can facilitate adoptive cell therapy for cancer patients.</p> <h2>Competitive Advantages:</h2> <ul><li>Broadly applicable to different types of malignant tumors</li> <li>Limited off-target effects</li> <li>Patient-specificity to improve efficacy of adoptive cell therapy</li> <li>Rapid and scalable method of isolating neoantigen-specific TCRs</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Personalized immunotherapy to treat cancer patients</li> <li>​Research tool to identify mutation-specific T-cell receptors</li> </ul> 2017-10-06 2025-04-22 2017-10-06 2025-04-22 2017-10-06 CANCER, Immunotherapy, Single Cell, T-cell Receptors, TCR, tumor False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2017-10-06 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-229-2014 E-233-2014 147162673 Lu, Yong-Chen NIH - NCI NCI Lu, Yong-Chen (NCI) 1 147162674 Zheng, Zhili NIH - NCI NCI Zheng, Zhili (NCI) 2 147162675 Fitzgerald, Peter NIH - NCI NCI Fitzgerald, Peter (NCI) 3 147162672 Rosenberg, Steven NIH - NCI NCI Rosenberg, Steven (NCI) 4 147162673 Lu, Yong-Chen NIH - NCI NCI Lu, Yong-Chen (NCI) 1 147162674 Zheng, Zhili NIH - NCI NCI Zheng, Zhili (NCI) 2 147162675 Fitzgerald, Peter NIH - NCI NCI Fitzgerald, Peter (NCI) 3 147162672 Rosenberg, Steven NIH - NCI NCI Rosenberg, Steven (NCI) 4 147157916 A Novel Method To Isolate The Paired Sequences Of Neoantigen-specific T Cell Receptors E-067-2017-0 Filing authorized NCI 83709866 Burke, Andrew burkear@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC burkear@nih.gov?subject=Web Inquiry on [TAB-3869] A Rapid Method of Isolating Neoantigen-specific T Cell Receptor Sequences&body=Please send me information about technology [TAB-3869] A Rapid Method of Isolating Neoantigen-specific T Cell Receptor Sequences.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Burke, Andrew<br><a href="mailto:burkear@nih.gov?subject=Web Inquiry on [TAB-3869] A Rapid Method of Isolating Neoantigen-specific T Cell Receptor Sequences&body=Please send me information about technology [TAB-3869] A Rapid Method of Isolating Neoantigen-specific T Cell Receptor Sequences.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">burkear@nih.gov</a><br> 147160989 E-067-2017-0 E-067-2017-0-US-01 Methods of Isolating Neoantigen-Specific T Cell Receptor Sequences PRV US 62/479,398 Abandoned US <br />Provisional (PRV) 62/479,398<br />Filed on 2017-03-31<br />Status: Abandoned 147164923 E-067-2017-0 E-067-2017-0-PCT-02 METHODS OF ISOLATING NEOANTIGEN-SPECIFIC T CELL RECEPTOR SEQUENCES PCT Patent Cooperation Treaty PCT/US2018/024828 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2018/024828<br />Filed on 2018-03-28<br />Status: Expired 147164924 E-067-2017-0 E-067-2017-0-AU-03 METHODS OF ISOLATING NEOANTIGEN-SPECIFIC T CELL RECEPTOR SEQUENCES National Stage Australia 2018244371 2018244371 Issued Australia <br />National Stage 2018244371<br />Filed on 2019-10-03<br />Status: Issued 147164925 E-067-2017-0 E-067-2017-0-CA-04 METHODS OF ISOLATING NEOANTIGEN-SPECIFIC T CELL RECEPTOR SEQUENCES National Stage Canada 3057375 3057375 Issued Canada <br />National Stage 3057375<br />Filed on 2018-03-28<br />Status: Issued 147164926 E-067-2017-0 E-067-2017-0-CN-05 METHODS OF ISOLATING NEOANTIGEN-SPECIFIC T CELL RECEPTOR SEQUENCES National Stage China ZL201880022673.3 201880022673.3 Issued China <br />National Stage 201880022673.3<br />Filed on 2019-09-29<br />Status: Issued 147164927 E-067-2017-0 E-067-2017-0-EP-06 METHODS OF ISOLATING NEOANTIGEN-SPECIFIC T CELL RECEPTOR SEQUENCES National Stage European Patent 3602053 18721882.1 Issued European Patent <br />National Stage 18721882.1<br />Filed on 2019-09-30<br />Status: Issued 147164928 E-067-2017-0 E-067-2017-0-JP-07 METHODS OF ISOLATING NEOANTIGEN-SPECIFIC T CELL RECEPTOR SEQUENCES National Stage Japan 7317712 2019-553512 Issued Japan <br />National Stage 2019-553512<br />Filed on 2019-09-27<br />Status: Issued 147164929 E-067-2017-0 E-067-2017-0-US-08 METHODS OF ISOLATING NEOANTIGEN-SPECIFIC T CELL RECEPTOR SEQUENCES National Stage US 11,898,207 16/495,508 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11898207 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11898207">11,898,207</a><br />Filed on 2019-09-19<br />Status: Issued 147164930 E-067-2017-0 E-067-2017-0-HK-09 METHODS OF ISOLATING NEOANTIGEN-SPECIFIC T CELL RECEPTOR SEQUENCES EP Hong Kong HK40023788B 62020013025.5 Issued Hong Kong <br />European patent (EP) 62020013025.5<br />Filed on 2020-07-31<br />Status: Issued 147164931 E-067-2017-0 E-067-2017-0-EP-01 METHODS OF ISOLATING NEOANTIGEN-SPECIFIC T CELL RECEPTOR SEQUENCES DIV European Patent 23176735.1 Pending European Patent <br />Divisional (DIV) 23176735.1<br />Filed on 2023-06-01<br />Status: Pending 147164932 E-067-2017-0 E-067-2017-0-CN-01 METHODS OF ISOLATING NEOANTIGEN-SPECIFIC T CELL RECEPTOR SEQUENCES DIV China 202310701331.7 Pending China <br />Divisional (DIV) 202310701331.7<br />Filed on 2023-06-13<br />Status: Pending 147164933 E-067-2017-0 E-067-2017-0-JP-01 METHODS OF ISOLATING NEOANTIGEN-SPECIFIC T CELL RECEPTOR SEQUENCES DIV Japan 7569416 2023-117842 Issued Japan <br />Divisional (DIV) 2023-117842<br />Filed on 2023-07-19<br />Status: Issued 147170696 CANCER 147170697 Immunotherapy 147170698 Single Cell 147170700 T-cell Receptors 147170701 TCR 147170702 tumor TAB-4179 147157464 Multi-epitope Vaccines against TARP (ME-TARP) for Treating Prostate and Breast Cancer NCI Collaboration, Licensing, Oncology, Vaccines Collaboration Licensing Oncology Vaccines Jay Berzofsky, Brenda Roberson, Masaki Terabe, Lauren Wood <p>The development of more targeted means of treating cancer is vital. One option for a targeted treatment is the creation of a vaccine that induces an immune response only against cancer cells. In this sense, vaccination involves the introduction of a peptide into a patient that causes the formation of antibodies or T cells that recognize the peptide. If the peptide is from a protein found selectively on/in cancer cells, those antibodies or T cells can trigger the death of those cancer cells without harming non-cancer cells. This can result in fewer side effects for the patient.</p> <p>TARP (T cell receptor gamma alternate reading frame protein) is a protein that is selectively expressed on the cells of about 95% of prostate cancers and about 50% of breast cancers. This invention concerns the identification of a combination of seven (7) immunogenic peptides within TARP and their use to create an anti-cancer immune response in patients. The vaccine includes two synthetic 9-mer TARP peptides covered by E-116-2003 and five additional 20-mer peptides overlapping by 10-mer and covering the entire 58-residue sequence of the TARP protein.  Because the additional peptides are overlapping, they can stimulate both humoral and cellular killing responses.  By introducing these seven peptides into a patient, an immune response against these cancer cells can be initiated by the peptides, resulting in treatment of the cancer.  </p> <p>NCI seeks licensees or co-development partners to commercialize this invention.</p> <h2>Competitive Advantages:</h2> <ul><li>Targeted therapy decreases non-specific killing of healthy, essential cells, resulting in fewer non-specific side-effects and healthier patients</li> <li>Not restricted to tissue type</li> <li>Use of multiple peptides permits production of a more thorough complement of T cells against the antigen</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Peptides can be used as vaccines to induce an immune response against cancer.</li> <li>Treatment of any cancer associated with increased or preferential expression of TARP.</li> <li>Specific diseases include breast cancer and prostate cancer.</li> </ul> 2017-10-06 2025-04-22 2021-10-27 2025-04-22 2017-10-06 BREAST CANCER, CANCER VACCINE, Immunotherapy, PROSTATE CANCER False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2021-10-27 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147162259 Oh S et al. http://www.ncbi.nlm.nih.gov/pubmed/15059918 <a href="http://www.ncbi.nlm.nih.gov/pubmed/15059918">Oh S et al.</a> 147162298 Wood L, et al. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5007958/ <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5007958/">Wood L, et al.</a> 147162412 Epel M et al. http://www.ncbi.nlm.nih.gov/pubmed/18446790 <a href="http://www.ncbi.nlm.nih.gov/pubmed/18446790">Epel M et al.</a> 147163795 Wood, Lauren NIH - NCI Wood, Lauren 1 147163793 Berzofsky, Jay NIH - NCI NCI Berzofsky, Jay (NCI) 2 147163796 Roberson, Brenda NIH - NCI NCI Roberson, Brenda (NCI) 3 147163794 Terabe, Masaki NIH - NCI NCI Terabe, Masaki (NCI) 4 147163795 Wood, Lauren NIH - NCI Wood, Lauren 1 147163793 Berzofsky, Jay NIH - NCI NCI Berzofsky, Jay (NCI) 2 147163796 Roberson, Brenda NIH - NCI NCI Roberson, Brenda (NCI) 3 147163794 Terabe, Masaki NIH - NCI NCI Terabe, Masaki (NCI) 4 147157864 Multi-Epitope TARP PeptideTherapeutic Cancer Vaccine E-047-2014-0 Filing authorized NCI 83740301 Dattaroy, Diptadip diptadip.dattaroy@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB diptadip.dattaroy@nih.gov?subject=Web Inquiry on [TAB-4179] Multi-epitope Vaccines against TARP (ME-TARP) for Treating Prostate and Breast Cancer&body=Please send me information about technology [TAB-4179] Multi-epitope Vaccines against TARP (ME-TARP) for Treating Prostate and Breast Cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dattaroy, Diptadip<br><a href="mailto:diptadip.dattaroy@nih.gov?subject=Web Inquiry on [TAB-4179] Multi-epitope Vaccines against TARP (ME-TARP) for Treating Prostate and Breast Cancer&body=Please send me information about technology [TAB-4179] Multi-epitope Vaccines against TARP (ME-TARP) for Treating Prostate and Breast Cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">diptadip.dattaroy@nih.gov</a><br> 147160961 E-047-2014-0 E-047-2014-0-US-01 Multi-Epitope TARP Peptide Vaccine And Uses Thereof PRV US 61/915,948 Abandoned US <br />Provisional (PRV) 61/915,948<br />Filed on 2013-12-13<br />Status: Abandoned 147167147 E-047-2014-0 E-047-2014-0-PCT-02 Multi-Epitope TARP Peptide Vaccine And Uses Thereof PCT Patent Cooperation Treaty PCT/US2014/070144 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2014/070144<br />Filed on 2014-12-12<br />Status: Expired 147167148 E-047-2014-0 E-047-2014-0-CA-03 Multi-Epitope TARP Peptide Vaccine And Uses Thereof National Stage Canada 2932248 2932248 Issued Canada <br />National Stage 2932248<br />Filed on 2014-12-12<br />Status: Issued 147167149 E-047-2014-0 E-047-2014-0-EP-04 Multi-Epitope TARP Peptide Vaccine And Uses Thereof National Stage European Patent 3079716 14831120.2 Issued European Patent <br />National Stage 14831120.2<br />Filed on 2014-12-12<br />Status: Issued 147167150 E-047-2014-0 E-047-2014-0-JP-05 Multi-Epitope TARP Peptide Vaccine And Uses Thereof National Stage Japan 6758185 2016-538101 Issued Japan <br />National Stage 2016-538101<br />Filed on 2016-06-09<br />Status: Issued 147167151 E-047-2014-0 E-047-2014-0-US-06 Multi-Epitope TARP PeptideTherapeutic Cancer Vaccine National Stage US 10,286,050 15/102,996 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10286050 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10286050">10,286,050</a><br />Filed on 2016-06-09<br />Status: Issued 147167152 E-047-2014-0 E-047-2014-0-AU-07 Multi-Epitope TARP Peptide Vaccine And Uses Thereof National Stage Australia 2014361788 2014361788 Issued Australia <br />National Stage 2014361788<br />Filed on 2014-12-12<br />Status: Issued 147167153 E-047-2014-0 E-047-2014-0-DE-08 Multi-Epitope TARP Peptide Vaccine And Uses Thereof EP Germany 3079716 14831120.2 Issued Germany <br />European patent (EP) 14831120.2<br />Filed on 2014-12-12<br />Status: Issued 147167154 E-047-2014-0 E-047-2014-0-FR-09 Multi-Epitope TARP Peptide Vaccine And Uses Thereof EP France 3079716 14831120.2 Issued France <br />European patent (EP) 14831120.2<br />Filed on 2014-12-12<br />Status: Issued 147167155 E-047-2014-0 E-047-2014-0-GB-10 Multi-Epitope TARP Peptide Vaccine And Uses Thereof EP United Kingdom 3079716 14831120.2 Issued United Kingdom <br />European patent (EP) 14831120.2<br />Filed on 2014-12-12<br />Status: Issued 147167156 E-047-2014-0 E-047-2014-0-CH-11 Multi-Epitope TARP Peptide Vaccine And Uses Thereof EP Switzerland 3079716 14831120.2 Issued Switzerland <br />European patent (EP) 14831120.2<br />Filed on 2014-12-12<br />Status: Issued 147167157 E-047-2014-0 E-047-2014-0-DK-12 Multi-Epitope TARP Peptide Vaccine And Uses Thereof EP Denmark 3079716 14831120.2 Issued Denmark <br />European patent (EP) 14831120.2<br />Filed on 2014-12-12<br />Status: Issued 147167158 E-047-2014-0 E-047-2014-0-NL-13 Multi-Epitope TARP Peptide Vaccine And Uses Thereof EP The Netherlands 3079716 14831120.2 Issued The Netherlands <br />European patent (EP) 14831120.2<br />Filed on 2014-12-12<br />Status: Issued 147170260 BREAST CANCER 147170261 CANCER VACCINE 147170262 Immunotherapy 147170263 PROSTATE CANCER TAB-4226 147157511 Use of a Modified Adaptor Molecule LAT to Improve Immunotherapy for Cancer and Other Diseases NCI Collaboration, Immunology, Infectious Disease, Licensing, Oncology, Therapeutics Collaboration Immunology Infectious Disease Licensing Oncology Therapeutics Lakshmi Balagopalan, Lawrence Samelson <p>One problem with the development of immunotherapy for cancer or other diseases is the inability to stimulate a sufficient immune response in patients to tumor associated antigens. The Linker Adapted for T Cell Signaling molecule (LAT) has been shown to be an important molecule in T cell signaling. The inventions described and claimed in this patent application illustrate a new supportive role for LAT which may be harnessed to improve a patient's immune response to tumor-associated antigens.</p> <p>A number of approaches to improving the immune response in cancer immunotherapy have been investigated. One such approach is to be able to influence the potency of T Cell Signaling. This invention exploits the role of LAT in T Cell signaling and provides a means to create a more intense and effective T Cell response. This would have the end result of improving the overall response of a patient's immune system to the presence of tumor-associated antigens.</p> <p>With T Cell signaling being important in the body's immune response to bacterial and viral antigens it may also be possible to harness the modified LAT molecules to improve the immune response in developing immunotherapy for infectious disease.</p> <h2>Competitive Advantages:</h2> <ul><li>Enhanced T Cell Signaling should improve the overall effectiveness of immunotherapy producing a more robust patient response.</li> </ul> <h2>Commercial Applications:</h2> <p>Improve the overall response of a patient's immune system to tumor associated antigens.<br /> Improve the overall response of a patient's immune system to bacterial associated antigens.<br /> Improve the overall response of a patient's immune system to viral associated antigens.</p> 2017-10-10 2025-04-22 2017-10-10 2025-04-22 2017-10-10 Immunotherapy, LAT, T-CELLS, TCR False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2017-10-10 52406768 Discovery 52406768 NCI 37470483 Website Abstract E-010-1998 147163971 Samelson, Lawrence NIH - NCI NCI Samelson, Lawrence (NCI) 1 147163972 Balagopalan, Lakshmi NIH - NCI NCI Balagopalan, Lakshmi (NCI) 2 147163971 Samelson, Lawrence NIH - NCI NCI Samelson, Lawrence (NCI) 1 147163972 Balagopalan, Lakshmi NIH - NCI NCI Balagopalan, Lakshmi (NCI) 2 147158104 Mutation Of Critcal Lysines In The LAT Adapter Molecular Leads To Enhance T Cell Signalling E-159-2009-0 Filing authorized NCI 147162541 LAT2KR For Adoptive Immunotherapy E-159-2009-1 Filing authorized NCI 83643835 Rucker, Susan susan.rucker@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC susan.rucker@nih.gov?subject=Web Inquiry on [TAB-4226] Use of a Modified Adaptor Molecule LAT to Improve Immunotherapy for Cancer and Other Diseases&body=Please send me information about technology [TAB-4226] Use of a Modified Adaptor Molecule LAT to Improve Immunotherapy for Cancer and Other Diseases.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Rucker, Susan<br><a href="mailto:susan.rucker@nih.gov?subject=Web Inquiry on [TAB-4226] Use of a Modified Adaptor Molecule LAT to Improve Immunotherapy for Cancer and Other Diseases&body=Please send me information about technology [TAB-4226] Use of a Modified Adaptor Molecule LAT to Improve Immunotherapy for Cancer and Other Diseases.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">susan.rucker@nih.gov</a><br> 147161120 E-159-2009-0 E-159-2009-0-US-01 Mutation Of Critcal Lysines In The LAT Adapter Molecular Leads To Enhance T Cell Signalling PRV US 61/176,231 Abandoned US <br />Provisional (PRV) 61/176,231<br />Filed on 2009-05-07<br />Status: Abandoned 147167528 E-159-2009-1 E-159-2009-1-PCT-01 LAT2KR For Adoptive Immunotherapy PCT COMB Patent Cooperation Treaty PCT/US2010/033186 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2010/033186<br />Filed on 2010-04-30<br />Status: Expired 147167529 E-159-2009-1 E-159-2009-1-US-02 LAT ADAPTER MOLECULE FOR ENHANCED T-CELL SIGNALING AND METHOD OF USE National Stage US 8,779,095 13/319,263 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8779095 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8779095">8,779,095</a><br />Filed on 2011-11-07<br />Status: Issued 147167530 E-159-2009-1 E-159-2009-1-US-03 LAT Adapter Molecule for Enhanced T-Cell Signaling and Method of Use CON US 9,649,339 14/329,736 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9649339 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9649339">9,649,339</a><br />Filed on 2014-07-11<br />Status: Issued 147172599 Immunotherapy 147172600 LAT 147172601 T-CELLS 147172602 TCR TAB-4304 147157594 Immunogenic Antigen Selective Cancer Immunotherapy NIA Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Bira Arya, Vladimir Larionov <p>Melanoma is a particularly aggressive form of cancer primarily caused by over-exposure to sunlight.  Although melanoma can strike at any age, the malignancy disproportionately impacts persons of advanced age, as these individuals often have decades of repeated exposure to harmful levels of ultraviolet radiation.  Scientists at NIH among others have clarified the link between advanced melanoma and other malignancies and expression of SPANX-B.</p> <p><a href="https://www.nia.nih.gov/research/labs/lmbi/immunoregulation-section" target="_blank" rel="nofollow">Researchers at the National Institutes of Health (NIH)</a> characterized this novel tumor-associated antigen, SPANX-B, as naturally immunogenic and expressed in a variety of human malignancies, including melanoma and lung, colon, renal, ovarian and breast carcinomas.  In melanoma specifically, SPANX-B expression associates with advanced and metastatic disease.  Moreover, the researchers found several agonist epitope peptides from SPANX-B that can be used to activate the immune system to eradicate tumors utilizing T cells.  SPANX-B peptides have significant clinical and immunotherapeutic potential for the development of cancer diagnostic assays and potent protective and/or therapeutic vaccines to combat a wide-range of cancers. </p> <p>      The <a href="https://www.nia.nih.gov/" rel="nofollow">National Institute on Aging, a division of NIH</a>, seeks statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize SPANX-B polypeptides in the treatment and identification of cancer.  In addition, NIA is interested in collaborative research relationships whereby resources such as intellectual property can be pooled and applied to the development of therapies with respect to melanoma and lung, colon, renal, ovarian and breast carcinomas.</p> <h2>Competitive Advantages:</h2> <p>* Immunogenic: SPANX-B peptides are naturally able to elicit immune response.<br /> * SPANX-B expressed in a wide-range of cancers.<br /> * Use of epitope peptides disclosed by NIH facilitates the activation of cells of the more therapeutically effective branch of the immune system.<br /> * Small epitope peptides of this disclosure more easily manufactured in contrast to recombinant proteins.</p> <h2>Commercial Applications:</h2> <p>* In vitro diagnostic assays for highly-metastatic melanomas or other cancers<br /> * Therapeutic monoclonal antibodies<br /> * Cancer vaccine development</p> 2017-10-10 2025-04-22 2018-03-21 2025-04-22 2017-10-10 MELANOMA, POLYPEPTIDES, SPANX-B False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2018-03-21 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147161955 Almanzar G et al. https://www.ncbi.nlm.nih.gov/pubmed/19276289 <a href="https://www.ncbi.nlm.nih.gov/pubmed/19276289">Almanzar G et al.</a> 147164233 Arya, Bira NIH - NIA NIA Arya, Bira (NIA) 1 147164234 Larionov, Vladimir NIH - NCI NCI Larionov, Vladimir (NCI) 2 147164233 Arya, Bira NIH - NIA NIA Arya, Bira (NIA) 1 147164234 Larionov, Vladimir NIH - NCI NCI Larionov, Vladimir (NCI) 2 147157960 Sperm-derived SPANX-B Is A Clinically Relevant Tumor Antigen That Is Expressed In Human Tumors And Readily Recognized By Human CD4+ And CD8+ T Cells E-089-2009-0 Filing authorized National Institute on Aging (NIH/NIA), NCI 91789173 Guyton, Nicole darackn@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America darackn@mail.nih.gov?subject=Web Inquiry on [TAB-4304] Immunogenic Antigen Selective Cancer Immunotherapy&body=Please send me information about technology [TAB-4304] Immunogenic Antigen Selective Cancer Immunotherapy.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Guyton, Nicole<br><a href="mailto:darackn@mail.nih.gov?subject=Web Inquiry on [TAB-4304] Immunogenic Antigen Selective Cancer Immunotherapy&body=Please send me information about technology [TAB-4304] Immunogenic Antigen Selective Cancer Immunotherapy.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">darackn@mail.nih.gov</a><br> 147168043 E-089-2009-0 E-089-2009-0-US-01 Sperm-derived SPANX-B Is A Clinically Relevant Tumor Antigen That Is Expressed In human Tumors And Readily Recognized By Human CD4+ And CD8+ T Cells PRV US 61/156,435 Abandoned US <br />Provisional (PRV) 61/156,435<br />Filed on 2009-02-27<br />Status: Abandoned 147168044 E-089-2009-0 E-089-2009-0-PCT-02 SPANX-B Polypeptides And Their Use PCT Patent Cooperation Treaty PCT/US2010/025633 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2010/025633<br />Filed on 2010-02-26<br />Status: Expired 147168045 E-089-2009-0 E-089-2009-0-US-03 SPANX-B Polypeptides And Their Use National Stage US 8,664,183 13/203,042 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8664183 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8664183">8,664,183</a><br />Filed on 2010-02-26<br />Status: Issued 147168046 E-089-2009-0 E-089-2009-0-US-04 SPANX-B POLYPEPTIDES AND THEIR USE DIV US 9,238,684 14/155,230 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9238684 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9238684">9,238,684</a><br />Filed on 2014-01-14<br />Status: Issued 147171156 MELANOMA 147171157 POLYPEPTIDES 147171159 SPANX-B TAB-4420 147157715 Chimeric Antigen Receptors that Recognize Mesothelin for Cancer Immunotherapy NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Steven Feldman, Ira Pastan, Steven Rosenberg <p>Chimeric antigen receptors (CARs) with high affinity for mesothelin that can be used as an immunotherapy to treat cancers that express mesothelin, such as pancreatic cancer, ovarian cancer, and mesothelioma. The technology includes CAR constructs with one of three different mesothelin-specific antibody portions, including either the mouse-derived SS or SS1 antibody fragments or the human HN1 antibody fragment.</p> <p>Mesothelin is a protein cancer antigen with limited expression on normal cells that is overexpressed by cancer cells. CARs are hybrid proteins consisting of an antibody portion that recognizes a cancer antigen, such as a mesothelin-specific antibody, fused to receptor signaling domains that serve to activate the CAR-expressing cell to kill tumor cells. Cells that express CARs, most notably T cells, are highly reactive against their specific tumor antigen in an MHC-unrestricted manner to generate an immune response that promotes robust tumor cell elimination when infused into cancer patients. Infusion of cells expressing these mesothelin-specific CARs into patients could prove to be a powerful new immunotherapeutic tool for treating various cancers that express mesothelin.</p> <h2>Competitive Advantages:</h2> <p>• Generates fewer side effects than other cancer treatment approaches.<br /> • Immunotoxins containing the antibody portions of some of these CARs have shown promising results in clinical studies for cancer treatment.<br /> • Immunotherapy is more widely accepted as a viable cancer treatment option.</p> <h2>Commercial Applications:</h2> <p>• Immunotherapeutics to treat and/or prevent the reoccurrence of cancers that overexpress mesothelin.<br /> • A personalized cancer treatment strategy for patients whose tumor cells express mesothelin.<br /> • Tools to diagnose the presence of mesothelin-expressing tumors in patients.</p> 2017-10-11 2025-04-22 2017-10-11 2025-04-22 2017-10-11 CAR, Immunotherapy, MESOTHELIN, T-CELLS False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2017-10-11 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-002-1996 E-021-1998 E-091-2009 E-093-1995 E-139-1999 147164685 Feldman, Steven NIH - NCI Feldman, Steven 1 147164684 Rosenberg, Steven NIH - NCI NCI Rosenberg, Steven (NCI) 2 147164683 Pastan, Ira NIH - NCI NCI Pastan, Ira (NCI) 3 147164685 Feldman, Steven NIH - NCI Feldman, Steven 1 147164684 Rosenberg, Steven NIH - NCI NCI Rosenberg, Steven (NCI) 2 147164683 Pastan, Ira NIH - NCI NCI Pastan, Ira (NCI) 3 147157934 A Chimeric Antigen Receptor Targeting The Tumor Antigen Mesothelin E-078-2012-0 Filing authorized NCI 83709866 Burke, Andrew burkear@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC burkear@nih.gov?subject=Web Inquiry on [TAB-4420] Chimeric Antigen Receptors that Recognize Mesothelin for Cancer Immunotherapy&body=Please send me information about technology [TAB-4420] Chimeric Antigen Receptors that Recognize Mesothelin for Cancer Immunotherapy.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Burke, Andrew<br><a href="mailto:burkear@nih.gov?subject=Web Inquiry on [TAB-4420] Chimeric Antigen Receptors that Recognize Mesothelin for Cancer Immunotherapy&body=Please send me information about technology [TAB-4420] Chimeric Antigen Receptors that Recognize Mesothelin for Cancer Immunotherapy.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">burkear@nih.gov</a><br> 147161005 E-078-2012-0 E-078-2012-0-US-01 Anti-Mesothelin Chimeric Antigen Receptors PRV US 61/614,612 Abandoned US <br />Provisional (PRV) 61/614,612<br />Filed on 2012-03-23<br />Status: Abandoned 147168809 E-078-2012-0 E-078-2012-0-PCT-02 Anti-Mesothelin Chimeric Antigen Receptors PCT Patent Cooperation Treaty PCT/US13/28980 Expired Patent Cooperation Treaty <br />(PCT) PCT/US13/28980<br />Filed on 2013-03-05<br />Status: Expired 147168810 E-078-2012-0 E-078-2012-0-AU-03 Anti-Mesothelin Chimeric Antigen Receptors National Stage Australia 2013235726 2013235726 Issued Australia <br />National Stage 2013235726<br />Filed on 2013-03-05<br />Status: Issued 147168811 E-078-2012-0 E-078-2012-0-CA-04 Anti-Mesothelin Chimeric Antigen Receptors National Stage Canada 2868121 2868121 Issued Canada <br />National Stage 2868121<br />Filed on 2013-03-05<br />Status: Issued 147168812 E-078-2012-0 E-078-2012-0-EP-05 Anti-Mesothelin Chimeric Antigen Receptors National Stage European Patent 2828290 13717593.1 Issued European Patent <br />National Stage 13717593.1<br />Filed on 2013-03-05<br />Status: Issued 147168813 E-078-2012-0 E-078-2012-0-US-06 Anti-Mesothelin Chimeric Antigen Receptors National Stage US 9,359,447 14/384,282 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9359447 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9359447">9,359,447</a><br />Filed on 2014-09-10<br />Status: Issued 147168814 E-078-2012-0 E-078-2012-0-EP-07 Anti-Mesothelin Chimeric Antigen Receptors DIV European Patent 3421489 18187755.6 Issued European Patent <br />Divisional (DIV) 18187755.6<br />Filed on 2018-08-07<br />Status: Issued 147168815 E-078-2012-0 E-078-2012-0-DE-08 Anti-Mesothelin Chimeric Antigen Receptors EP Germany 2828290 13717593.1 Issued Germany <br />European patent (EP) 13717593.1<br />Filed on 2014-09-17<br />Status: Issued 147168816 E-078-2012-0 E-078-2012-0-FR-09 Anti-Mesothelin Chimeric Antigen Receptors EP France 2828290 13717593.1 Issued France <br />European patent (EP) 13717593.1<br />Filed on 2014-09-17<br />Status: Issued 147168817 E-078-2012-0 E-078-2012-0-GB-10 Anti-Mesothelin Chimeric Antigen Receptors EP United Kingdom 2828290 13717593.1 Issued United Kingdom <br />European patent (EP) 13717593.1<br />Filed on 2014-09-17<br />Status: Issued 147168818 E-078-2012-0 E-078-2012-0-CA-11 Anti-Mesothelin Chimeric Antigen Receptors DIV Canada 3116051 3116051 Issued Canada <br />Divisional (DIV) 3116051<br />Filed on 2021-04-23<br />Status: Issued 147168819 E-078-2012-0 E-078-2012-0-FR-12 Anti-Mesothelin Chimeric Antigen Receptors EP France 3421489 18187755.6 Issued France <br />European patent (EP) 18187755.6<br />Filed on 2018-08-07<br />Status: Issued 147168820 E-078-2012-0 E-078-2012-0-DE-13 Anti-Mesothelin Chimeric Antigen Receptors EP Germany 3421489 18187755.6 Issued Germany <br />European patent (EP) 18187755.6<br />Filed on 2018-08-07<br />Status: Issued 147168821 E-078-2012-0 E-078-2012-0-GB-14 Anti-Mesothelin Chimeric Antigen Receptors EP United Kingdom 3421489 18187755.6 Issued United Kingdom <br />European patent (EP) 18187755.6<br />Filed on 2018-08-07<br />Status: Issued 147168822 E-078-2012-0 E-078-2012-0-CA-01 Anti-Mesothelin Chimeric Antigen Receptors DIV Canada 3209571 Pending Canada <br />Divisional (DIV) 3209571<br />Filed on 2023-08-17<br />Status: Pending 147170865 CAR 147170866 Immunotherapy 147170867 MESOTHELIN 147170868 T-CELLS TAB-4447 147157742 Cancer Therapeutic Based on Hypoxia Inducible Factor 1 (HIF-1) Inhibitors NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Susanna Chan, William Figg, Kirk Gustafson, James McMahon, Paresma Patel, Martin Schnermann <p>Hypoxia is a characteristic of many solid tumors resulting from accelerated cellular proliferation and inadequate vascularization. HIF-1 is a transcription factor critical for maintaining cellular homeostasis in, and adaptively responding to, low oxygen environments. HIF-1 becomes activated through binding to the transcriptional co-activator protein p300. Disruption of the HIF-1/p300 interaction could potentially modulate HIF-1 activity.</p> <p>Researchers at the National Cancer Institute (NCI) have developed small molecule compounds that inhibit the activity of HIF-1. The HIF-1 inhibitor compounds are designed around the scaffold of naturally occurring metabolite eudistidine. Compounds eudistidine A and C have been shown to disrupt the HIF-1/p300 interaction in vitro. Eudistidine C has also inhibited growth of malaria at low micromolar concentrations.  </p> <h2>Competitive Advantages:</h2> <ul><li>Lack of general cytotoxic effects</li> <li>Novel molecular scaffolds and chemotypes</li> <li>Attractive molecular target</li> <li>Concise and high-yielding synthesis of compounds</li> <li>Potent at low micromolar concentrations</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Therapeutic against cancer that may leave normal cells unaffected. While the HIF-1α protein occurs in a wide range of human primary tumors, it is only produced at very low levels in normal tissue. </li> <li>Therapeutic against malaria – especially at the liver-infection phase. Malaria remains one of the most severe global health issues. According to the World Health Organization, 3.2 billion people (half the world’s population) live in areas at risk of malaria transmission in 106 countries and territories. In 2012, malaria caused nearly 207 million clinical episodes and 627,000 deaths – primarily (91%) in the African Region.</li> </ul> 2017-10-23 2025-04-22 2017-04-18 2025-04-22 2017-10-23 CANCER, Hypoxia Inhibitor, Malaria, small molecule False True Basic (Target Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2017-04-18 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147161997 S. Chan S et al. Characterization and Synthesis of Eudistidine C, a Bioactive Marine Alkaloid with an Intriguing Molecular Scaffold. https://www.ncbi.nlm.nih.gov/pubmed/27934476 <a href="https://www.ncbi.nlm.nih.gov/pubmed/27934476">S. Chan S et al. Characterization and Synthesis of Eudistidine C, a Bioactive Marine Alkaloid with an Intriguing Molecular Scaffold.</a> 147162153 Chan S, et al. Structural Elucidation and Synthesis of Eudistidine A: An Unusual Polycyclic Marine Alkaloid that Blocks Interaction of the Protein Binding Domains of p300 and HIF-1α. https://www.ncbi.nlm.nih.gov/pubmed/25892103 <a href="https://www.ncbi.nlm.nih.gov/pubmed/25892103">Chan S, et al. Structural Elucidation and Synthesis of Eudistidine A: An Unusual Polycyclic Marine Alkaloid that Blocks Interaction of the Protein Binding Domains of p300 and HIF-1α.</a> 147164771 Gustafson, Kirk NIH - NCI NCI Gustafson, Kirk (NCI) 1 147164774 Schnermann, Martin NIH - NCI NCI Schnermann, Martin (NCI) 2 147164775 Chan, Susanna NIH - NCI Chan, Susanna 3 147164773 Patel, Paresma NIH - NCATS FDA Patel, Paresma (FDA) 4 147164770 Figg, William NIH - NCI NCI Figg, William (NCI) 5 147164772 McMahon, James NIH - NCI NCI McMahon, James (NCI) 6 147164771 Gustafson, Kirk NIH - NCI NCI Gustafson, Kirk (NCI) 1 147164774 Schnermann, Martin NIH - NCI NCI Schnermann, Martin (NCI) 2 147164775 Chan, Susanna NIH - NCI Chan, Susanna 3 147164773 Patel, Paresma NIH - NCATS FDA Patel, Paresma (FDA) 4 147164770 Figg, William NIH - NCI NCI Figg, William (NCI) 5 147164772 McMahon, James NIH - NCI NCI McMahon, James (NCI) 6 147158017 The Eudistidines: A Novel Molecular Scaffold For Inhibitors Of 300/HIF-1 A Interactions E-115-2015-0 Filing authorized NCATS - NCGC, NCI 91814193 Freel, Rose rose.freel@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America rose.freel@nih.gov?subject=Web Inquiry on [TAB-4447] Cancer Therapeutic Based on Hypoxia Inducible Factor 1 (HIF-1) Inhibitors&body=Please send me information about technology [TAB-4447] Cancer Therapeutic Based on Hypoxia Inducible Factor 1 (HIF-1) Inhibitors.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Freel, Rose<br><a href="mailto:rose.freel@nih.gov?subject=Web Inquiry on [TAB-4447] Cancer Therapeutic Based on Hypoxia Inducible Factor 1 (HIF-1) Inhibitors&body=Please send me information about technology [TAB-4447] Cancer Therapeutic Based on Hypoxia Inducible Factor 1 (HIF-1) Inhibitors.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">rose.freel@nih.gov</a><br> 147161063 E-115-2015-0 E-115-2015-0-US-01 HYPOXIA-INDUCIBLE FACTOR 1 HIF-1 INHIBITORS PRV US 62/144,182 Abandoned US <br />Provisional (PRV) 62/144,182<br />Filed on 2015-04-07<br />Status: Abandoned 147168979 E-115-2015-0 E-115-2015-0-PCT-02 Hypoxia Inducible Factor 1 (HIF-1) Inhibitors PCT Patent Cooperation Treaty PCT/US2016/026145 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2016/026145<br />Filed on 2016-04-06<br />Status: Expired 147168980 E-115-2015-0 E-115-2015-0-US-03 HYPOXIA INDUCIBLE FACTOR 1 (HIF-1) INHIBITORS National Stage US 10,246,463 15/563,851 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10246463 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10246463">10,246,463</a><br />Filed on 2017-10-02<br />Status: Issued 147171733 CANCER 147171735 Hypoxia Inhibitor 147171736 Malaria 147171737 small molecule TAB-4444 147157739 Nitric Oxide-Releasing Polysaccharide Materials NCI Immunology, Licensing, Materials Available, Therapeutics Immunology Licensing Materials Available Therapeutics Joseph Hrabie, Larry Keefer <p>Diazeniumdiolates comprise a diverse class of NO-releasing compounds and materials that are known to exhibit sufficient stability to be useful as therapeutics. Diazeniumdiolated compounds have been attached to polymers, substrates, and medical devices for the treatment and management of a variety of diseases including cancer, inflammation, heart disease, and hypertension.  Despite the extensive literature available on NO and nitric oxide-releasing compounds, there remains a need for stable nitric oxide-releasing polymers, such as polysaccharides, or small molecules, such as monosaccharides and disaccharides, that exhibit a sustained release of nitric oxide for the treatment of disease.</p> <p>This invention discloses novel materials and a method for producing nitric oxide (NO)-releasing derivatives of any material containing a reducing sugar component. It may be used to produce NO-releasing cotton bandages or surgical fabrics, cellulose filters or dialysis membranes, and drug formulating/compounding agents to prevent stomach irritation. The method involves incorporation of a diazeniumdiolate (-N2O2) group at one or more carbons via the base-catalyzed replacement of acidic hydrogens and is thus compatible with traditional polysaccharide processing techniques. Monosaccharides such as glucose may also be derivatized.</p> <h2>Competitive Advantages:</h2> <p>• Advanced wound healing compared to conventional bandages due to the incorporation of nitric oxide to facilitate healing and inhibit the formation of biofilms </p> <h2>Commercial Applications:</h2> <p>• Delivery of nitric oxide to a desired area by incorporation of the nitric oxide-releasing polysaccharides into bandages, surgical dressings, or other cotton or saccharide based medical material.  </p> 2017-10-23 2025-04-22 2017-10-23 2025-04-22 2017-10-23 bandages, biofilm dispersal, Cellulose, Diazeniumdiolate, Nitric Oxide (NO), POLYSACCHARIDE, Wound healing False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2017-10-23 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147164760 Hrabie, Joseph NIH - NCI Leidos Hrabie, Joseph (Leidos) 1 147164759 Keefer, Larry NIH - NCI NCI Keefer, Larry (NCI) 2 147164760 Hrabie, Joseph NIH - NCI Leidos Hrabie, Joseph (Leidos) 1 147164759 Keefer, Larry NIH - NCI NCI Keefer, Larry (NCI) 2 147158315 Poly-saccharide-derived Nitric Oxide-releasing Carbon-bound Diazeniumdiolates E-279-2005-0 Filing authorized NCI 91814193 Freel, Rose rose.freel@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America rose.freel@nih.gov?subject=Web Inquiry on [TAB-4444] Nitric Oxide-Releasing Polysaccharide Materials&body=Please send me information about technology [TAB-4444] Nitric Oxide-Releasing Polysaccharide Materials.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Freel, Rose<br><a href="mailto:rose.freel@nih.gov?subject=Web Inquiry on [TAB-4444] Nitric Oxide-Releasing Polysaccharide Materials&body=Please send me information about technology [TAB-4444] Nitric Oxide-Releasing Polysaccharide Materials.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">rose.freel@nih.gov</a><br> 147168957 E-279-2005-0 E-279-2005-0-US-01 Polysaccharide-derived Nitric Oxide-releasing Carbon-bound Diazeniumdiolates PRV US 60/731,946 Abandoned US <br />Provisional (PRV) 60/731,946<br />Filed on 2005-10-31<br />Status: Abandoned 147168958 E-279-2005-0 E-279-2005-0-PCT-02 Poly-saccharide-derived Nitric Oxide-releasing Carbon-bound Diazeniumdiolates PCT Patent Cooperation Treaty PCT/US2006/040456 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2006/040456<br />Filed on 2006-10-16<br />Status: Expired 147168959 E-279-2005-0 E-279-2005-0-AU-03 Polysaccharide-derived Nitric Oxide-releasing Carbon-bound Diazeniumdiolates National Stage Australia 2006309212 2006309212 Abandoned Australia <br />National Stage 2006309212<br />Filed on 2006-10-16<br />Status: Abandoned 147168960 E-279-2005-0 E-279-2005-0-CA-04 Polysaccharide-derived Nitric Oxide-releasing Carbon-bound Diazeniumdiolates National Stage Canada 2628055 2628055 Abandoned Canada <br />National Stage 2628055<br />Filed on 2006-10-16<br />Status: Abandoned 147168961 E-279-2005-0 E-279-2005-0-EP-05 Poly-saccharide-derived Nitric Oxide-releasing Carbon-bound Diazeniumdiolates National Stage European Patent 06826062.9 Abandoned European Patent <br />National Stage 06826062.9<br />Filed on 2006-10-16<br />Status: Abandoned 147168962 E-279-2005-0 E-279-2005-0-US-06 Poly-saccharide-derived Nitric Oxide-releasing Carbon-bound Diazeniumdiolates National Stage US 7,928,079 12/092,184 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7928079 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7928079">7,928,079</a><br />Filed on 2008-05-22<br />Status: Issued 147174607 bandages 147174609 biofilm dispersal 147174610 Cellulose 147174611 Diazeniumdiolate 147174613 Nitric Oxide (NO) 147174614 POLYSACCHARIDE 147174615 Wound healing TAB-4103 147157385 A Rabbit Anti-pT1989 ATR Monoclonal Antibody for Use in Immunoassays NCI Diagnostics, Licensing, Oncology Diagnostics Licensing Oncology James Doroshow, Robert Kinders, Allison Marrero, Ralph Parchment, Thomas Pfister <p>Ataxia telangiectasia mutated and Rad3 Related (ATR) protein kinase is essential for regulating DNA damage checkpoints during the cell cycle. ATR, is phosphorylated at threonine 1989 site (T1989) in response to DNA damage and ATR activation leads to activation of downstream substrates, signaling cascades and cell cycle arrest. ATR is a potential target for anticancer therapeutics to induce cancer cell death by inhibiting cell cycle arrest pathways in response to chemotherapeutics.</p> <p>Researchers at the National Cancer Institute (NCI) have developed a monoclonal antibody against ATR. The invention antibody specifically binds to the phosphorylated threonine 1989 position. The antibody can be used in immunoassays to detect ATR in a sample, to determine the inhibitory activity of ATR agents, and to measure the effectiveness of an ATR modulator agent or ATR inhibitor as therapeutics. </p> <h2>Competitive Advantages:</h2> <p>• Antibody works in Western Blot on crude lysates and in IFA.<br /> • Antibody works for standard processed preclinical and clinical samples.<br /> • Antibody staining pattern specificity can be demonstrated with available blocking phosphopeptides. </p> <h2>Commercial Applications:</h2> <p>• Improved method to detect a rare, genetic disease that is debilitating and often life-shortening. <br /> • Antibody for detection of pATR-T1989 in biological samples, including biopsies. <br /> • Antibody for determination of activation of ATR by phosphorylation of T1989 by DNA damaging agents or genotoxic chemotherapeutic agents.<br /> • Antibody for measuring ATR activation, inhibition or modulation.</p> 2017-10-23 2025-04-22 2017-10-23 2025-04-22 2017-10-23 ANTIBODY, assay, Ataxia telangiectasia mutated and Rad3-related kinase, CANCER, diagnostic, DNA checkpoint, monoclonal False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2017-10-23 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147163515 Pfister, Thomas NIH - NCI Leidos Pfister, Thomas (Leidos) 1 147163519 Marrero, Allison NIH - NCI Leidos Marrero, Allison (Leidos) 2 147163517 Parchment, Ralph NIH - NCI Leidos Parchment, Ralph (Leidos) 3 147163518 Doroshow, James NIH - NCI NCI Doroshow, James (NCI) 4 147163516 Kinders, Robert NIH - NCI Leidos Kinders, Robert (Leidos) 5 147163515 Pfister, Thomas NIH - NCI Leidos Pfister, Thomas (Leidos) 1 147163519 Marrero, Allison NIH - NCI Leidos Marrero, Allison (Leidos) 2 147163517 Parchment, Ralph NIH - NCI Leidos Parchment, Ralph (Leidos) 3 147163518 Doroshow, James NIH - NCI NCI Doroshow, James (NCI) 4 147163516 Kinders, Robert NIH - NCI Leidos Kinders, Robert (Leidos) 5 147157759 Development For A Rabbit Anti-pT1989 ATR Monoclonal Antibody For Use In IFA And Other Immunoassays E-001-2014-0 Filing authorized NCI 83732917 Favila, Michelle michelle.favila@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC michelle.favila@nih.gov?subject=Web Inquiry on [TAB-4103] A Rabbit Anti-pT1989 ATR Monoclonal Antibody for Use in Immunoassays&body=Please send me information about technology [TAB-4103] A Rabbit Anti-pT1989 ATR Monoclonal Antibody for Use in Immunoassays.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Favila, Michelle<br><a href="mailto:michelle.favila@nih.gov?subject=Web Inquiry on [TAB-4103] A Rabbit Anti-pT1989 ATR Monoclonal Antibody for Use in Immunoassays&body=Please send me information about technology [TAB-4103] A Rabbit Anti-pT1989 ATR Monoclonal Antibody for Use in Immunoassays.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">michelle.favila@nih.gov</a><br> 147166501 E-001-2014-0 E-001-2014-0-US-01 ANTIBODIES THAT SPECIFICALLY BIND ATAXIA TELANGIECTASIA-MUTATED AND RAD3-RELATED KINASE PHOSPHORYLATED AT POSITION 1989 AND THEIR USE PRV US 61/893,070 Abandoned US <br />Provisional (PRV) 61/893,070<br />Filed on 2013-10-18<br />Status: Abandoned 147166502 E-001-2014-0 E-001-2014-0-PCT-02 ANTIBODIES THAT SPECIFICALLY BIND ATAXIA TELANGIECTASIA-MUTATED AND RAD3-RELATED KINASE PHOSPHORYLATED AT POSITION 1989 AND THEIR USE PCT Patent Cooperation Treaty PCT/US2014/059759 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2014/059759<br />Filed on 2014-10-08<br />Status: Expired 147166503 E-001-2014-0 E-001-2014-0-US-03 Antibodies That Specifically Bind Ataxia Telangiectasia-Mutated and RAD3-Related Kinase Phosphorylated at Positions 1989 and Their Use National Stage US 9,644,037 15/027,997 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9644037 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9644037">9,644,037</a><br />Filed on 2016-04-07<br />Status: Issued 147169180 ANTIBODY 147169181 assay 147169183 Ataxia telangiectasia mutated and Rad3-related kinase 147169184 CANCER 147169185 diagnostic 147169187 DNA checkpoint 147169188 monoclonal TAB-3888 147157168 Clinical Outcome Predictors for Mantle Cell Lymphoma NCI Collaboration, Diagnostics, Licensing, Oncology Collaboration Diagnostics Licensing Oncology Pau Abrisqueta, Rita Braziel, Wing Chan, Joseph Connors, James Cook, Jan Delabie, Kai Fu, Randy Gascoyne, Timothy Greiner, Elias Guerri, Elaine Jaffe, Pedro Jares, Anja Mottok, German Ott, Lisa Rimsza, Andreas Rosenwald, David Scott, Graham Slack, Louis Staudt, Diego Villa, Dennis Weisenburger, George Wright <p>Mantle cell lymphoma (MCL) is a group of aggressive B-cell lymphomas displaying heterogeneous outcomes after treatment.  Some patients have the slowly progressing disease that does not require immediate treatment, while others have a disease that rapidly progresses despite highly aggressive treatment. A number of prognostic tools have been described to determine whether patients have slow or rapidly progressing diseases, including the mantle cell lymphoma International Prognostic Index (MIPI) and biomarkers, such as KI-67.</p> <p>Researchers have discovered a novel method of predicting a MCL patient’s overall survival prognosis (poor, intermediate, or good) by measuring the gene expression profile of a specific subset of biomarkers from a biopsy and using a set of statistical algorithms to analyze the results and produce a “survival score”.  The survival score enables a physician to determine the best course of treatment, such as a less aggressive or more aggressive treatment protocol or an experimental treatment that would be the most beneficial for an MCL patient.</p> <h2>Competitive Advantages:</h2> <ul><li>Does not require fresh frozen samples, utilizes formalin-fixed paraffin-embedded (FFPE) samples</li> <li>In contrast to current KI-67 assay, the subject technology is reproducible</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Mantle cell lymphoma prognostic tool</li> </ul> 2017-10-25 2025-04-22 2017-10-25 2025-04-22 2017-10-25 B-cell lymphomas, Gene expression profile, Mantle cell lymphoma, Prognostic tool False True Clinical True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2017-10-25 72159138 Clinical Phase I 72159138 NCI 37470483 Website Abstract E-108-2004 E-256-2008 E-750-2013 147161999 Scott DW, et al. New Molecular Assay for the Proliferation Signature in Mantle Cell Lymphoma Applicable to Formalin-Fixed Paraffin-Embedded Biopsies. https://www.ncbi.nlm.nih.gov/pubmed/28291392 <a href="https://www.ncbi.nlm.nih.gov/pubmed/28291392">Scott DW, et al. New Molecular Assay for the Proliferation Signature in Mantle Cell Lymphoma Applicable to Formalin-Fixed Paraffin-Embedded Biopsies.</a> 147162728 Staudt, Louis NIH - NCI NCI Staudt, Louis (NCI) 1 147162743 Scott, David BC Cancer Scott, David 2 147162730 Wright, George NIH - NCI NCI Wright, George (NCI) 3 147162729 Rosenwald, Andreas University Of Wurzburg Rosenwald, Andreas 4 147162746 Abrisqueta, Pau BC Cancer Abrisqueta, Pau 5 147162742 Braziel, Rita Oregon Health and Science University (OHSU) Braziel, Rita 6 147162744 Guerri, Elias University of Barcelona [Universitat de Barcelona] Guerri, Elias 7 147162732 Chan, Wing City of Hope National Medical Center Chan, Wing 8 147162737 Connors, Joseph BC Cancer Connors, Joseph 9 147162747 Villa, Diego BC Cancer Villa, Diego 10 147162735 Fu, Kai University of Nebraska Medical Center Fu, Kai 11 147162739 Gascoyne, Randy BC Cancer Gascoyne, Randy 12 147162733 Greiner, Timothy University of Nebraska Medical Center Greiner, Timothy 13 147162731 Jaffe, Elaine NIH - NCI NCI Jaffe, Elaine (NCI) 14 147162749 Slack, Graham BC Cancer Slack, Graham 15 147162745 Cook, James Cleveland Clinic Foundation Cook, James 16 147162740 Delabie, Jan University Health Network, University of Toronto Delabie, Jan 17 147162738 Ott, German Robert Bosch Stiftung Ott, German 18 147162736 Rimsza, Lisa Mayo Clinic, Arizona Rimsza, Lisa 19 147162734 Weisenburger, Dennis City of Hope National Medical Center Weisenburger, Dennis 20 147162748 Mottok, Anja BC Cancer Mottok, Anja 21 147162741 Jares, Pedro Hospital Clinic of Barcelona [Hospital Clinico de Barcelona] Jares, Pedro 22 147162728 Staudt, Louis NIH - NCI NCI Staudt, Louis (NCI) 1 147162743 Scott, David BC Cancer Scott, David 2 147162730 Wright, George NIH - NCI NCI Wright, George (NCI) 3 147162729 Rosenwald, Andreas University Of Wurzburg Rosenwald, Andreas 4 147162746 Abrisqueta, Pau BC Cancer Abrisqueta, Pau 5 147162742 Braziel, Rita Oregon Health and Science University (OHSU) Braziel, Rita 6 147162744 Guerri, Elias University of Barcelona [Universitat de Barcelona] Guerri, Elias 7 147162732 Chan, Wing City of Hope National Medical Center Chan, Wing 8 147162737 Connors, Joseph BC Cancer Connors, Joseph 9 147162747 Villa, Diego BC Cancer Villa, Diego 10 147162735 Fu, Kai University of Nebraska Medical Center Fu, Kai 11 147162739 Gascoyne, Randy BC Cancer Gascoyne, Randy 12 147162733 Greiner, Timothy University of Nebraska Medical Center Greiner, Timothy 13 147162731 Jaffe, Elaine NIH - NCI NCI Jaffe, Elaine (NCI) 14 147162749 Slack, Graham BC Cancer Slack, Graham 15 147162745 Cook, James Cleveland Clinic Foundation Cook, James 16 147162740 Delabie, Jan University Health Network, University of Toronto Delabie, Jan 17 147162738 Ott, German Robert Bosch Stiftung Ott, German 18 147162736 Rimsza, Lisa Mayo Clinic, Arizona Rimsza, Lisa 19 147162734 Weisenburger, Dennis City of Hope National Medical Center Weisenburger, Dennis 20 147162748 Mottok, Anja BC Cancer Mottok, Anja 21 147162741 Jares, Pedro Hospital Clinic of Barcelona [Hospital Clinico de Barcelona] Jares, Pedro 22 147158046 Molecular Prognostic Evaluation Of Mantle Cell Lymphoma Using Formalin-fixed, Paraffin-embedded Biopsy Specimens E-131-2016-0 Filing authorized BC Cancer, Cleveland Clinic Foundation, Hospital Clinic of Barcelona [Hospital Clinico de Barcelona], Julius Maximilian University of Wuerzburg, Mayo Clinic, Arizona, NCI, Oregon Health and Science University (OHSU), Oslo University Hospital, University of Barcelona [Universitat de Barcelona], University of Nebraska Medical Center, University of Wuerzburg 83707317 Bhattacharya, Ramona ramona.bhattacharya@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB ramona.bhattacharya@nih.gov?subject=Web Inquiry on [TAB-3888] Clinical Outcome Predictors for Mantle Cell Lymphoma&body=Please send me information about technology [TAB-3888] Clinical Outcome Predictors for Mantle Cell Lymphoma.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Bhattacharya, Ramona<br><a href="mailto:ramona.bhattacharya@nih.gov?subject=Web Inquiry on [TAB-3888] Clinical Outcome Predictors for Mantle Cell Lymphoma&body=Please send me information about technology [TAB-3888] Clinical Outcome Predictors for Mantle Cell Lymphoma.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">ramona.bhattacharya@nih.gov</a><br> 147161082 E-131-2016-0 E-131-2016-0-PCT-02 EVALUATION OF MANTLE CELL LYMPHOMA AND METHODS RELATED THERETO PCT Patent Cooperation Treaty PCT/US2017/028628 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2017/028628<br />Filed on 2017-04-20<br />Status: Expired 147165049 E-131-2016-0 E-131-2016-0-US-01 Evaluation Of Mantle Cell Lymphoma and Methods Related Thereto PRV US 62/325,213 Abandoned US <br />Provisional (PRV) 62/325,213<br />Filed on 2016-04-20<br />Status: Abandoned 147165050 E-131-2016-0 E-131-2016-0-AU-03 EVALUATION OF MANTLE CELL LYMPHOMA AND METHODS RELATED THERETO National Stage Australia 2017254645 2017254645 Issued Australia <br />National Stage 2017254645<br />Filed on 2018-10-05<br />Status: Issued 147165051 E-131-2016-0 E-131-2016-0-CA-04 EVALUATION OF MANTLE CELL LYMPHOMA AND METHODS RELATED THERETO National Stage Canada 3021569 Pending Canada <br />National Stage 3021569<br />Filed on 2017-04-20<br />Status: Pending 147165052 E-131-2016-0 E-131-2016-0-EP-05 EVALUATION OF MANTLE CELL LYMPHOMA AND METHODS RELATED THERETO National Stage European Patent 3445873 17724960.4 Issued European Patent <br />National Stage 17724960.4<br />Filed on 2018-10-10<br />Status: Issued 147165053 E-131-2016-0 E-131-2016-0-JP-06 EVALUATION OF MANTLE CELL LYMPHOMA AND METHODS RELATED THERETO National Stage Japan 7075896 2018-555639 Issued Japan <br />National Stage 2018-555639<br />Filed on 2017-04-20<br />Status: Issued 147165054 E-131-2016-0 E-131-2016-0-US-07 EVALUATON OF MANTLE CELL LYMPHOMA AND METHODS RELATED THERETO National Stage US 11,725,248 16/094,965 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11725248 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11725248">11,725,248</a><br />Filed on 2018-10-19<br />Status: Issued 147165055 E-131-2016-0 E-131-2016-0-CH-08 EVALUATION OF MANTLE CELL LYMPHOMA AND METHODS RELATED THERETO EP Switzerland 3445873 17724960.4 Issued Switzerland <br />European patent (EP) 17724960.4<br />Filed on 2018-10-10<br />Status: Issued 147165056 E-131-2016-0 E-131-2016-0-DE-09 EVALUATION OF MANTLE CELL LYMPHOMA AND METHODS RELATED THERETO EP Germany 3445873 17724960.4 Issued Germany <br />European patent (EP) 17724960.4<br />Filed on 2018-10-10<br />Status: Issued 147165057 E-131-2016-0 E-131-2016-0-ES-10 EVALUATION OF MANTLE CELL LYMPHOMA AND METHODS RELATED THERETO EP Spain 3445873 17724960.4 Issued Spain <br />European patent (EP) 17724960.4<br />Filed on 2018-10-10<br />Status: Issued 147165058 E-131-2016-0 E-131-2016-0-FR-11 EVALUATION OF MANTLE CELL LYMPHOMA AND METHODS RELATED THERETO EP France 3445873 17724960.4 Issued France <br />European patent (EP) 17724960.4<br />Filed on 2018-10-10<br />Status: Issued 147165059 E-131-2016-0 E-131-2016-0-GB-12 EVALUATION OF MANTLE CELL LYMPHOMA AND METHODS RELATED THERETO EP United Kingdom 3445873 17724960.4 Issued United Kingdom <br />European patent (EP) 17724960.4<br />Filed on 2018-10-10<br />Status: Issued 147165060 E-131-2016-0 E-131-2016-0-IT-13 EVALUATION OF MANTLE CELL LYMPHOMA AND METHODS RELATED THERETO EP Italy 3445873 17724960.4 Issued Italy <br />European patent (EP) 17724960.4<br />Filed on 2018-10-10<br />Status: Issued 147172063 B-cell lymphomas 147172065 Gene expression profile 147172066 Mantle cell lymphoma 147172068 Prognostic tool TAB-4003 147157284 Functionally-Interdependent Shape-Switching Nucleic Acid Nanoparticles NCI Collaboration, Infectious Disease, Licensing, Oncology, Therapeutics Collaboration Infectious Disease Licensing Oncology Therapeutics Kirill Afonin, Eckart Bindewald, Marina Dobrovolskaia, Justin Halman, Wojciech Kasprzak, Bruce Shapiro, Mathias Viard <p>RNA interference (RNAi) is a naturally occurring post-transcriptional gene regulation process that represses the expression of specific genes. Exploiting endogenous RNAi by externally-delivered small-interfering RNA (siRNA) is a promising therapeutic for the treatment of various diseases representing several major unmet medical needs. </p> <p>Researchers at the National Cancer Institute (NCI) have developed DNA- and RNA-based nanoparticles that can induce RNA interference (RNAi), molecular imaging, or a combination thereof. Two DNA- or RNA-based nanoparticles are required to induce RNAi: one nanoparticle comprising up to six (6) DNA or RNA strands and the other nanoparticle comprising the complementary DNA or RNA strands. Upon association of two complementary nanoparticles, conformational changes (or “shape switching”) occurs to both nanoparticles. Nucleic acid duplexes are released upon shape-switching, which activates functional units capable of delivering siRNA and/or transcribable DNA templates. </p> <p>The National Cancer Institute is seeking statements of capability or interest from parties interested in licensing or in collaborative research to co-develop RNAi-based nanoparticle therapeutics for cancer, viral infection, and genetic diseases.</p> <h2>Competitive Advantages:</h2> <p>• Increased potency<br /> • Low cytotoxicity<br /> • Tunable stability<br /> • Multiple functionalities and targets<br /> • Controlled activation<br /> • Dynamic interaction or “Shape-Switching”<br /> • Activation from only two particles for simple delivery and functionality</p> <h2>Commercial Applications:</h2> <p>• Cancer, infectious disease, and genetic disease therapeutics<br /> • Research tool to study cancer, viral infection, and other diseases<br /> • Molecular imaging<br /> • Drug delivery</p> 2017-10-23 2025-04-22 2017-10-23 2025-04-22 2017-10-23 CANCER, Drug Delivery, Molecular imaging, Nanoparticle, RNA interference, RNAi, SiRNA, Small-interfering RNA False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2017-10-23 52406768 Discovery 52406768 NCI 37470483 Website Abstract E-038-2012 E-039-2012 E-059-2009 E-156-2014 E-223-2012 E-765-2013 147161900 Kirill Afonin et al. https://www.ncbi.nlm.nih.gov/pubmed/24189588 <a href="https://www.ncbi.nlm.nih.gov/pubmed/24189588">Kirill Afonin et al.</a> 147162016 Kirill Afonin et al. https://www.ncbi.nlm.nih.gov/pubmed/20802494 <a href="https://www.ncbi.nlm.nih.gov/pubmed/20802494">Kirill Afonin et al.</a> 147162288 Wojciech Khisamutdinov et al. https://www.ncbi.nlm.nih.gov/pubmed/25967062 <a href="https://www.ncbi.nlm.nih.gov/pubmed/25967062">Wojciech Khisamutdinov et al.</a> 147163181 Shapiro, Bruce NIH - NCI NCI Shapiro, Bruce (NCI) 1 147163186 Afonin, Kirill University of North Carolina, Charlotte Afonin, Kirill 2 147163185 Bindewald, Eckart NIH - NCI Leidos Bindewald, Eckart (Leidos) 3 147163182 Viard, Mathias NIH - NCI Leidos Viard, Mathias (Leidos) 4 147163184 Kasprzak, Wojciech NIH - NCI Leidos Kasprzak, Wojciech (Leidos) 5 147163187 Halman, Justin University of North Carolina, Charlotte Halman, Justin 6 147163183 Dobrovolskaia, Marina NIH - NCI Leidos Dobrovolskaia, Marina (Leidos) 7 147163181 Shapiro, Bruce NIH - NCI NCI Shapiro, Bruce (NCI) 1 147163186 Afonin, Kirill University of North Carolina, Charlotte Afonin, Kirill 2 147163185 Bindewald, Eckart NIH - NCI Leidos Bindewald, Eckart (Leidos) 3 147163182 Viard, Mathias NIH - NCI Leidos Viard, Mathias (Leidos) 4 147163184 Kasprzak, Wojciech NIH - NCI Leidos Kasprzak, Wojciech (Leidos) 5 147163187 Halman, Justin University of North Carolina, Charlotte Halman, Justin 6 147163183 Dobrovolskaia, Marina NIH - NCI Leidos Dobrovolskaia, Marina (Leidos) 7 147158312 Functionally-interdependent Shape-switching Nucleic Acid Nanoparticles E-277-2016-0 Filing authorized NCI, University of North Carolina, Charlotte (UNC) 83732917 Favila, Michelle michelle.favila@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC michelle.favila@nih.gov?subject=Web Inquiry on [TAB-4003] Functionally-Interdependent Shape-Switching Nucleic Acid Nanoparticles&body=Please send me information about technology [TAB-4003] Functionally-Interdependent Shape-Switching Nucleic Acid Nanoparticles.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Favila, Michelle<br><a href="mailto:michelle.favila@nih.gov?subject=Web Inquiry on [TAB-4003] Functionally-Interdependent Shape-Switching Nucleic Acid Nanoparticles&body=Please send me information about technology [TAB-4003] Functionally-Interdependent Shape-Switching Nucleic Acid Nanoparticles.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">michelle.favila@nih.gov</a><br> 147161255 E-277-2016-0 E-277-2016-0-US-01 Functionally-interdependent Shape-switching Nucleic Acid Anticubes and Other Nanoparticles PRV US 62/480,899 Abandoned US <br />Provisional (PRV) 62/480,899<br />Filed on 2017-04-03<br />Status: Abandoned 147165846 E-277-2016-0 E-277-2016-0-PCT-02 Functionally-interdependent Shape-switching Nucleic Acid Nanoparticles PCT Patent Cooperation Treaty PCT/US2018/025953 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2018/025953<br />Filed on 2018-04-03<br />Status: Expired 147165847 E-277-2016-0 E-277-2016-0-US-03 FUNCTIONALLY-INTERDEPENDENT SHAPE SWITCHING NUCLEIC ACID NANOPARTICLES National Stage US 11,512,313 16/500,765 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11512313 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11512313">11,512,313</a><br />Filed on 2019-10-03<br />Status: Issued 147174582 CANCER 147174583 Drug Delivery 147174584 Molecular imaging 147174585 Nanoparticle 147174586 RNA interference 147174587 RNAi 147174588 SiRNA 147174589 Small-interfering RNA TAB-4334 147157625 Small Molecule Anti-cancer Agents that Stabilize the MYC-G-Quadruplex NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics David Calabrese, Kenneth Felsenstein, Peter Gareiss, Elena Leon, Beverly Mock, Lindsey Saunders, John (Jay) Schneekloth, John Simmons <p>The proto-oncogene c-Myc is deregulated and overexpressed in ~70% of all cancers. Thus, c-Myc is an attractive therapeutic target since disrupting c-Myc activity could be used as pan-chemotherapy. Beyond cancer, Myc is also a positive effector of tissue inflammation, and its function has been implicated in the pathophysiology of heart failure. Because c-Myc is a transcription factor, a rationally designed small molecule targeting c-Myc would be required to exhibit significant specificity. Unfortunately, several physical characteristics of Myc make it a very difficult protein to target and, to date, there are no approved drugs targeting c-Myc.</p> <p>The invention is directed to small molecules that stabilize the transcription repressing quadruplex in the c-Myc gene promoter region. Invention compounds target c-Myc at the transcriptional level are shown to inhibit c-Myc expression. Invention compounds are effective in selective killing in a variety of c-Myc driven cancer cell lines, including leukemia, non-small-cell lung cancer, colon, central nervous system, melanoma, ovarian, renal prostate and breast. Minimal unwanted activity is observed in peripheral blood mononucleocytes or cancer cell lines that resist inhibition of c-Myc protein expression.</p> <p>Current efforts are focused on developing more potent molecules with improved ability to decrease c-Myc expression and superior bioavailability.&nbsp; Through synthesis of a focused library of analogs, we have identified inhibitors with improved Kd values for the quadruplex, improved toxicity towards c-Myc-driven cancer cells, and improved efficacy for decreasing c-Myc expression.&nbsp; By solving an NMR structure of the quadruplex in complex with the small molecule, we have begun to establish a molecular basis for selectivity observed in cell-based and biophysical assays and are working to use this information to design improved inhibitors.&nbsp; Additionally, we&nbsp; show that one compound of interest is orally bioavailable, albeit with a Cmax in oral dosing slightly below the concentration required for oral efficacy.</p> <p>This technology is available for licensing and co-development to qualified entities.</p> <h2>Competitive Advantages:</h2> <ul> <li>First in class drug since no c-Myc drugs have been approved for any cancer indication</li> <li>Drug-like in nature, satisfying all of Lipinski&rsquo;s rule of five parameters&nbsp;</li> <li>Orally bioavailable&nbsp;</li> <li>Decreasing c-Myc expression without affecting expression from other quadruplex-driven genes</li> <li>Compound has significant potential for improvement with very minor structural alternations</li> <li>The methodologies used by the lab have explored the biological potential of c-Myc G-quadruplex-stabilizing agents to a degree of complexity greater than what has ever been done before.</li> </ul> <h2>Commercial Applications:</h2> <ul> <li>Therapeutic for multiple myeloma, carcinoma of the cervix, colon, breast, lung and stomach&nbsp;</li> <li>Tissue Inflammation</li> </ul> 2017-10-27 2025-04-22 2018-04-03 2025-04-22 2017-10-27 C-MYC, G-Quadruplex (G4), MULTIPLE MYELOMA, Schneekloth False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2018-04-03 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147162260 Kenneth M. Felsenstein et al. https://www.ncbi.nlm.nih.gov/pubmed/26462961 <a href="https://www.ncbi.nlm.nih.gov/pubmed/26462961">Kenneth M. Felsenstein et al.</a> 147164346 Schneekloth, John (Jay) NIH - NCI NCI Schneekloth, John (Jay) (NCI) 1 147164347 Felsenstein, Kenneth NIH - NCI Felsenstein, Kenneth 2 147164344 Simmons, John NIH - NCI Simmons, John 3 147164348 Saunders, Lindsey NIH - NCI Saunders, Lindsey 4 147164345 Mock, Beverly NIH - NCI NCI Mock, Beverly (NCI) 5 147164349 Gareiss, Peter Yale University Gareiss, Peter 6 147164350 Calabrese, David NIH - NCI Leidos Calabrese, David (Leidos) 7 147164351 Leon, Elena NIH - NLM Leon, Elena 8 147164346 Schneekloth, John (Jay) NIH - NCI NCI Schneekloth, John (Jay) (NCI) 1 147164347 Felsenstein, Kenneth NIH - NCI Felsenstein, Kenneth 2 147164344 Simmons, John NIH - NCI Simmons, John 3 147164348 Saunders, Lindsey NIH - NCI Saunders, Lindsey 4 147164345 Mock, Beverly NIH - NCI NCI Mock, Beverly (NCI) 5 147164349 Gareiss, Peter Yale University Gareiss, Peter 6 147164350 Calabrese, David NIH - NCI Leidos Calabrese, David (Leidos) 7 147164351 Leon, Elena NIH - NLM Leon, Elena 8 147157876 A New Class Of C-Myc G-quadruplex Stabilizing Small Molecules With Anticancer Activity E-053-2015-0 Filing authorized NCI, Yale University 147162503 A New Class Of C-Myc G-quadruplex Stabilizing Small Molecules With Anticancer Activity E-053-2015-1 Filing authorized NCI, NLM, Yale University 83704821 Nguyen-Antczak, Lauren lauren.nguyen-antczak@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-4334] Small Molecule Anti-cancer Agents that Stabilize the MYC-G-Quadruplex&body=Please send me information about technology [TAB-4334] Small Molecule Anti-cancer Agents that Stabilize the MYC-G-Quadruplex.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Nguyen-Antczak, Lauren<br><a href="mailto:lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-4334] Small Molecule Anti-cancer Agents that Stabilize the MYC-G-Quadruplex&body=Please send me information about technology [TAB-4334] Small Molecule Anti-cancer Agents that Stabilize the MYC-G-Quadruplex.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">lauren.nguyen-antczak@nih.gov</a><br> 147160970 E-053-2015-1 E-053-2015-1-PCT-01 MYC G-Quadruplex Stabilizing Small Molecules and Their Use PCT COMB Patent Cooperation Treaty PCT/US2016/012222 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2016/012222<br />Filed on 2016-01-05<br />Status: Expired 147168251 E-053-2015-0 E-053-2015-0-US-01 Myc G-quadruplex Stabilizing Small Molecules And Their Use PRV US 62/099,938 Abandoned US <br />Provisional (PRV) 62/099,938<br />Filed on 2015-01-05<br />Status: Abandoned 147168252 E-053-2015-1 E-053-2015-1-US-02 MYC G-QUADRUPLEX STABILIZING SMALL MOLECULES AND THEIR USE National Stage US 10,196,372 15/541,676 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10196372 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10196372">10,196,372</a><br />Filed on 2017-07-05<br />Status: Issued 147168253 E-053-2015-1 E-053-2015-1-EP-03 MYC G-Quadruplex Stabilizing Small Molecules and Their Use EP European Patent 3242661 16709158.6 Issued European Patent <br />European patent (EP) 16709158.6<br />Filed on 2016-01-05<br />Status: Issued 147168254 E-053-2015-1 E-053-2015-1-US-04 MYC G-QUADRUPLEX STABILIZING SMALL MOLECULES AND THEIR USE DIV US 10,604,499 16/218,341 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10604499 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10604499">10,604,499</a><br />Filed on 2018-12-12<br />Status: Issued 147168256 E-053-2015-1 E-053-2015-1-EP-05 MYC G-Quadruplex Stabilizing Small Molecules and Their Use DIV European Patent 3597186 19185807.5 Issued European Patent <br />Divisional (DIV) 19185807.5<br />Filed on 2019-07-11<br />Status: Issued 147168257 E-053-2015-1 E-053-2015-1-CH-06 MYC G-Quadruplex Stabilizing Small Molecules and Their Use EP Switzerland 3242661 16709158.6 Issued Switzerland <br />European patent (EP) 16709158.6<br />Filed on 2016-01-05<br />Status: Issued 147168258 E-053-2015-1 E-053-2015-1-DE-07 MYC G-Quadruplex Stabilizing Small Molecules and Their Use EP Germany 3242661 16709158.6 Issued Germany <br />European patent (EP) 16709158.6<br />Filed on 2016-01-05<br />Status: Issued 147168259 E-053-2015-1 E-053-2015-1-FR-08 MYC G-Quadruplex Stabilizing Small Molecules and Their Use EP France 3242661 16709158.6 Issued France <br />European patent (EP) 16709158.6<br />Filed on 2016-01-05<br />Status: Issued 147168260 E-053-2015-1 E-053-2015-1-GB-09 MYC G-Quadruplex Stabilizing Small Molecules and Their Use EP United Kingdom 3242661 16709158.6 Issued United Kingdom <br />European patent (EP) 16709158.6<br />Filed on 2016-01-05<br />Status: Issued 147168261 E-053-2015-1 E-053-2015-1-US-10 MYC G-QUADRUPLEX STABILIZING SMALL MOLECULES AND THEIR USE DIV US 11,014,902 16/835,102 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11014902 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11014902">11,014,902</a><br />Filed on 2020-03-30<br />Status: Issued 147168262 E-053-2015-1 E-053-2015-1-US-11 MYC G-QUADRUPLEX STABILIZING SMALL MOLECULES AND THEIR USE CON US 17/306,756 Abandoned US <br />Continuation (CON) 17/306,756<br />Filed on 2021-05-03<br />Status: Abandoned 147168263 E-053-2015-1 E-053-2015-1-DE-13 MYC G-Quadruplex Stabilizing Small Molecules and Their Use EP Germany 3597186 19185807.5 Issued Germany <br />European patent (EP) 19185807.5<br />Filed on 2019-07-11<br />Status: Issued 147168264 E-053-2015-1 E-053-2015-1-CH-12 MYC G-Quadruplex Stabilizing Small Molecules and Their Use EP Switzerland 3597186 19185807.5 Issued Switzerland <br />European patent (EP) 19185807.5<br />Filed on 2019-07-11<br />Status: Issued 147168265 E-053-2015-1 E-053-2015-1-FR-14 MYC G-Quadruplex Stabilizing Small Molecules and Their Use EP France 3597186 19185807.5 Issued France <br />European patent (EP) 19185807.5<br />Filed on 2019-07-11<br />Status: Issued 147168266 E-053-2015-1 E-053-2015-1-GB-15 MYC G-Quadruplex Stabilizing Small Molecules and Their Use EP United Kingdom 3597186 19185807.5 Issued United Kingdom <br />European patent (EP) 19185807.5<br />Filed on 2019-07-11<br />Status: Issued 147170361 C-MYC 147170363 G-Quadruplex (G4) 147170364 MULTIPLE MYELOMA 147170366 Schneekloth TAB-4063 147157345 A New Class of Stable Heptamethine Cyanine Fluorophores and Biomedical Applications Thereof NCI Collaboration, Licensing, Oncology, Research Materials Collaboration Licensing Oncology Research Materials Roger Nani, Martin Schnermann, James Shaum <p>Heptamethine cyanines are among the most widely used near-IR fluorophores. The near-IR range (between about 650 nm and 900 nm) is very useful for imaging applications due to the absence of background autofluorescence. Despite extensive use, many of these fluorophores suffer from chemical instability. Specifically, most of the current and commonly used fluorophores undergo a phenoxy to thiol exchange reaction in the presence of primary thiols. This exchange reaction is problematic during conjugation reactions of cysteine containing macromolecules. These exchange reactions are further complication by the fact that they occur intracellularly.</p> <p>Researchers at the National Cancer Institute (NCI) have developed an improved class of fluorophore dyes comprised of heptamethine cyanines. These improved dyes present a novel and much needed tool for imaging applications in the near-IR range. Specifically, these dyes display greater resistance to thiol nucleophiles, and are therefore, more robust while maintaining their useful optical properties. The preparation of these dyes is more facile with higher yields than preparative routes for other competing fluorphore dyes. The inventors have taken advantage of these useful properties to apply the dyes to various in vivo imaging applications.<br /> The researchers at the National Cancer Institute (NCI) continue to develop these dyes as targetable agents for optical-guided surgical interventions.</p> <p> This technology is available for licensing and collaboration opportunities for joint development are available to qualified entities.</p> <h2>Competitive Advantages:</h2> <p>• Greater chemical stability in the presence of thiol nucleophiles<br /> • More facile and higher yielding synthetic preparation<br /> • More robust while maintaining excellent optical properties<br /> • Successfully utilized for in vivo imaging application</p> <h2>Commercial Applications:</h2> <p>• Antibody labeling<br /> • FACS and related microscopy<br /> • Imaging reagent <br /> • Imaging microscopy<br /> • In vivo imaging applications<br /> • Optical-guided surgical interventions</p> 2017-10-27 2025-04-22 2018-03-20 2025-04-22 2017-10-27 Antibody labeling, DYE, Fluorescence-activated cell sorting (FACS), Fluorophore, Heptamethine Cyanines, IMAGING, Imaging Microscopy, Imaging reagent, MICROSCOPY, near-IR fluorophores, Optical-Guided Surgery False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2018-03-20 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-143-2017 147161939 K Sato et al. https://www.ncbi.nlm.nih.gov/pubmed/26261913 <a href="https://www.ncbi.nlm.nih.gov/pubmed/26261913">K Sato et al.</a> 147162480 RR Nani et al. http://pubs.acs.org/doi/10.1021/ol503398f <a href="http://pubs.acs.org/doi/10.1021/ol503398f">RR Nani et al.</a> 147163393 Schnermann, Martin NIH - NCI NCI Schnermann, Martin (NCI) 1 147163394 Nani, Roger NIH - NCI Nani, Roger 2 147163395 Shaum, James NIH - NCI NCI Shaum, James (NCI) 3 147163393 Schnermann, Martin NIH - NCI NCI Schnermann, Martin (NCI) 1 147163394 Nani, Roger NIH - NCI Nani, Roger 2 147163395 Shaum, James NIH - NCI NCI Shaum, James (NCI) 3 147158302 A New Class Of Stable Heptamethine Cyanine Fluorophores And Biomedical Applications Thereof E-271-2014-0 Filing authorized NCI 83704821 Nguyen-Antczak, Lauren lauren.nguyen-antczak@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-4063] A New Class of Stable Heptamethine Cyanine Fluorophores and Biomedical Applications Thereof&body=Please send me information about technology [TAB-4063] A New Class of Stable Heptamethine Cyanine Fluorophores and Biomedical Applications Thereof.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Nguyen-Antczak, Lauren<br><a href="mailto:lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-4063] A New Class of Stable Heptamethine Cyanine Fluorophores and Biomedical Applications Thereof&body=Please send me information about technology [TAB-4063] A New Class of Stable Heptamethine Cyanine Fluorophores and Biomedical Applications Thereof.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">lauren.nguyen-antczak@nih.gov</a><br> 147161250 E-271-2014-0 E-271-2014-0-PCT-01 A New Class Of Stable Heptamethine Cyanine Fluorophores And Biomedical Applications Thereof PCT Patent Cooperation Treaty PCT/US2014/064136 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2014/064136<br />Filed on 2014-11-05<br />Status: Expired 147166289 E-271-2014-0 E-271-2014-0-US-02 A New Class Of Stable Heptamethine Cyanine Fluorophores And Biomedical Applications Thereof National Stage US 10,280,307 15/524,567 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10280307 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10280307">10,280,307</a><br />Filed on 2017-05-04<br />Status: Issued 147166290 E-271-2014-0 E-271-2014-0-US-03 A New Class Of Stable Heptamethine Cyanine Fluorophores And Biomedical Applications Thereof CON US 10,876,003 16/374,642 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10876003 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10876003">10,876,003</a><br />Filed on 2019-04-03<br />Status: Issued 147174508 Antibody labeling 147174509 DYE 147174511 Fluorescence-activated cell sorting (FACS) 147174512 Fluorophore 147174514 Heptamethine Cyanines 147174515 IMAGING 147174517 Imaging Microscopy 147174519 Imaging reagent 147174520 MICROSCOPY 147174522 near-IR fluorophores 147174524 Optical-Guided Surgery TAB-4105 147157387 Antibodies and CARs Targeting FLT3 for the Treatment of Acute Myeloid Leukemia and Acute Lymphoid Leukemia NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Weizao Chen, Christopher Chien, Dimiter Dimitrov, Terry Fry, Haiying Qin <p>Fms-like tyrosine kinase 3 (FLT3) is a cytokine receptor which belongs in the receptor tyrosine kinase class III.  FLT3 is expressed on the surface of many hematopoietic progenitor cells and plays an important role in hematopoietic stem/progenitor cell survival and proliferation.  It is often overexpressed in acute lymphoblastic leukemia (ALL) and is frequently mutated in acute myeloid leukemia (AML).  The standard therapies for ALL and AML are still suboptimal for many patients, especially pediatric.  In certain types of ALL or AML, the survival rate is less than 40 and 60%, respectively.  There remains a need for effective treatments for ALL and AML.  </p> <p>Inventors have discovered five high-affinity, fully human monoclonal antibodies (m1006, m1007, m1008, m1009, and m1012) targeting FLT3.  Since the antibodies are fully human, they are expected to have lower toxicity and will not require humanization or affinity maturation for clinical development.  Chimeric antigen receptor (CAR) based upon antibody-derived binding fragments of the identified antibodies were also developed.  The CAR was tested in animal models of AML and ALL and showed good efficacy against both AML and ALL in vivo. </p> <h2>Competitive Advantages:</h2> <p>• Pediatric patients with ALL and AML have poor prognoses from the currently available treatments.  This technology represents an alternative approach to treating these patients who are unsuccessfully treated using standard chemotherapeutics.  <br /> • Fully human antibodies expected to have lower toxicity and will not require humanization or affinity maturation for clinical development.<br /> • Animal proof-of-concept completed.</p> <h2>Commercial Applications:</h2> <p>• Treatment of cancers that express FLT3, including ALL and AML <br /> • Pediatric patients with ALL and AML</p> 2017-10-27 2025-04-22 2017-10-27 2025-04-22 2017-10-27 acute lymphocytic leukemia, acute myeloid leukemia, ALL, AML, CANCER, cancer therapeutic, chimeric antigen receptor (CAR), Flt3, Monoclonal Antibody False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2017-10-27 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147163525 Dimitrov, Dimiter NIH - NCI NCI Dimitrov, Dimiter (NCI) 1 147163527 Chen, Weizao NIH - NCI Chen, Weizao 2 147163526 Fry, Terry NIH - NCI NCI Fry, Terry (NCI) 3 147163529 Chien, Christopher NIH - NCI NCI Chien, Christopher (NCI) 4 147163528 Qin, Haiying NIH - NCI NCI Qin, Haiying (NCI) 5 147163525 Dimitrov, Dimiter NIH - NCI NCI Dimitrov, Dimiter (NCI) 1 147163527 Chen, Weizao NIH - NCI Chen, Weizao 2 147163526 Fry, Terry NIH - NCI NCI Fry, Terry (NCI) 3 147163529 Chien, Christopher NIH - NCI NCI Chien, Christopher (NCI) 4 147163528 Qin, Haiying NIH - NCI NCI Qin, Haiying (NCI) 5 147157791 Human Monoclonal Antibodies Against FLT3 E-014-2017-0 Filing authorized NCI 91814193 Freel, Rose rose.freel@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America rose.freel@nih.gov?subject=Web Inquiry on [TAB-4105] Antibodies and CARs Targeting FLT3 for the Treatment of Acute Myeloid Leukemia and Acute Lymphoid Leukemia&body=Please send me information about technology [TAB-4105] Antibodies and CARs Targeting FLT3 for the Treatment of Acute Myeloid Leukemia and Acute Lymphoid Leukemia.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Freel, Rose<br><a href="mailto:rose.freel@nih.gov?subject=Web Inquiry on [TAB-4105] Antibodies and CARs Targeting FLT3 for the Treatment of Acute Myeloid Leukemia and Acute Lymphoid Leukemia&body=Please send me information about technology [TAB-4105] Antibodies and CARs Targeting FLT3 for the Treatment of Acute Myeloid Leukemia and Acute Lymphoid Leukemia.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">rose.freel@nih.gov</a><br> 147160900 E-014-2017-0 E-014-2017-0-US-01 Human Monoclonal Antibodies Against FLT3 and Uses Thereof PRV US 62/437,547 Abandoned US <br />Provisional (PRV) 62/437,547<br />Filed on 2016-12-21<br />Status: Abandoned 147166511 E-014-2017-0 E-014-2017-0-PCT-02 HUMAN MONOCLONAL ANTIBODIES SPECIFIC FOR FLT3 AND USES THEREOF PCT Patent Cooperation Treaty PCT/US2017/067974 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2017/067974<br />Filed on 2017-12-21<br />Status: Expired 147166512 E-014-2017-0 E-014-2017-0-AU-03 HUMAN MONOCLONAL ANTIBODIES SPECIFIC FOR FLT3 AND USES THEREOF National Stage Australia 2017382883 2017382883 Issued Australia <br />National Stage 2017382883<br />Filed on 2017-12-21<br />Status: Issued 147166513 E-014-2017-0 E-014-2017-0-CA-04 HUMAN MONOCLONAL ANTIBODIES SPECIFIC FOR FLT3 AND USES THEREOF National Stage Canada 3045902 3045902 Issued Canada <br />National Stage 3045902<br />Filed on 2017-12-21<br />Status: Issued 147166514 E-014-2017-0 E-014-2017-0-EP-05 HUMAN MONOCLONAL ANTIBODIES SPECIFIC FOR FLT3 AND USES THEREOF National Stage European Patent 3559038 17835904.8 Issued European Patent <br />National Stage 17835904.8<br />Filed on 2017-12-21<br />Status: Issued 147166515 E-014-2017-0 E-014-2017-0-US-06 HUMAN MONOCLONAL ANTIBODIES SPECIFIC FOR FLT3 AND USES THEREOF National Stage US 11,236,171 16/471,485 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11236171 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11236171">11,236,171</a><br />Filed on 2019-06-19<br />Status: Issued 147166516 E-014-2017-0 E-014-2017-0-US-07 HUMAN MONOCLONAL ANTIBODIES SPECIFIC FOR FLT3 AND USES THEREOF DIV US 12,012,455 17/570,248 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12012455 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12012455">12,012,455</a><br />Filed on 2022-01-06<br />Status: Issued 147166517 E-014-2017-0 E-014-2017-0-EP-08 HUMAN MONOCLONAL ANTIBODIES SPECIFIC FOR FLT3 AND USES THEREOF DIV European Patent 22209293.4 Pending European Patent <br />Divisional (DIV) 22209293.4<br />Filed on 2022-11-24<br />Status: Pending 147166518 E-014-2017-0 E-014-2017-0-FR-01 HUMAN MONOCLONAL ANTIBODIES SPECIFIC FOR FLT3 AND USES THEREOF EP France 3559038 17835904.8 Issued France <br />European patent (EP) 17835904.8<br />Filed on 2017-12-21<br />Status: Issued 147166519 E-014-2017-0 E-014-2017-0-DE-01 HUMAN MONOCLONAL ANTIBODIES SPECIFIC FOR FLT3 AND USES THEREOF EP Germany 3559038 17835904.8 Issued Germany <br />European patent (EP) 17835904.8<br />Filed on 2017-12-21<br />Status: Issued 147166520 E-014-2017-0 E-014-2017-0-GB-01 HUMAN MONOCLONAL ANTIBODIES SPECIFIC FOR FLT3 AND USES THEREOF EP United Kingdom 3559038 17835904.8 Issued United Kingdom <br />European patent (EP) 17835904.8<br />Filed on 2017-12-21<br />Status: Issued 147169497 acute lymphocytic leukemia 147169499 acute myeloid leukemia 147169501 ALL 147169502 AML 147169503 CANCER 147169504 cancer therapeutic 147169506 chimeric antigen receptor (CAR) 147169507 Flt3 147169508 Monoclonal Antibody TAB-3998 147157279 Quantitative In Vivo Methods for Measuring Brain Networks NICHD Collaboration, Diagnostics, Licensing Collaboration Diagnostics Licensing Peter Basser <p>The pattern or latency connectome was hypothesized to change in physiological development and disease.  For example, in amyotrophic lateral sclerosis (ALS), large diameter axons are damaged selectively – while in autism, small-diameter axons may be over-expressed. These anatomical changes are expected to alter the latency connectome or pattern of delays of information transmission between different gray matter areas involved in salient brain networks. </p> <p>Researchers at the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) developed Magnetic Resonance Imaging (MRI) methods to measure the axon diameter distribution (ADD) within nerve fascicles (e.g., by AxCaliber MRI). A new technology extends this prior work by combining it with the non-invasive measurement of the path length of white matter fascicles (e.g., using DTI tractography or other tractography methods). </p> <p>The technology combines and integrates information obtained from two different diffusion MRI methods (with the possible addition of other neurophysiological and imaging methods) to estimate the mean latency and latency distribution between different gray matter regions in the brain. The technology also uses AxCaliber MRI to estimate the ADD along white matter pathways, known to scale with conduction velocity.  Diffusion-based tractography determines the path lengths of these white matter fascicles. Together, these data can be used to estimate the latencies or time delays for neural impulses travelling along these pathways, between the different gray matter areas they connect.  </p> <p>The technology is directed toward measuring the latency connectome in each subject <em>in vivo</em>. Data produced by this method include latency matrices. Latency matrices are data arrays that indicate the latency or latency distribution between any two functional gray matter regions in the brain. This method could be used to diagnose abnormalities in nerve conduction in brain regions and providing a neuroanatomical basis for many cognitive and behavior disorders. Techniques such as electroencephalography (EEG), magnetoencephalography (MEG), transcranial magnetic stimulation (TMS) and function MRI (fMRI) could be used in conjunction with this new invention - improving estimates of mean latencies and latency distributions.</p> <h2>Competitive Advantages:</h2> <ul><li>Diagnose several cognitive and behavioral abnormalities, disease and disorders that are currently only assessed using psychological or psychiatric testing;</li> <li>Provides new quantitative imaging biomarkers;</li> <li>Used to understand and follow brain changes during normal aging and in disorders and - diseases like MS and Alzheimer's disease;</li> <li>Used to explain motor deficits in ALS disease;</li> <li>Provides way of classifying and understanding various neurological and neuropsychiatric conditions per conduction delays.</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Characterize normal and abnormal brain network function in development</li> <li>Diagnose brain network abnormalities in diseases and disorders of the brain such as Peripheral Nervous System (PNS), Alzheimer, autism, and Amyotrophic Lateral Sclerosis (ALS);</li> <li>A neuroanatomical basis for many cognitive and behavioral disorders.</li> <li>A basic tool in neuroscience and neuropsychological research to explore the dynamic functioning of the brain.</li> </ul> 2017-11-02 2025-04-22 2018-11-08 2025-04-22 2017-11-02 Axon diameter distribution, connectome, DTI Tractography, Magnetic Resonance Imaging, MRI, MRI diagnostic False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2018-11-08 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-079-2003 147162049 A.V. Avram, et al. https://science.nichd.nih.gov/confluence/download/attachments/117212440/AVRAM%20Latency%20Matrix%206968.pdf <a href="https://science.nichd.nih.gov/confluence/download/attachments/117212440/AVRAM%20Latency%20Matrix%206968.pdf">A.V. Avram, et al.</a> 147162127 R.D. Fields et al. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC442649 <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC442649">R.D. Fields et al.</a> 147162205 D. Barazany et al. http://www.ncbi.nlm.nih.gov/pubmed/19403788 <a href="http://www.ncbi.nlm.nih.gov/pubmed/19403788">D. Barazany et al.</a> 147162474 Y. Assaf et al. http://www.ncbi.nlm.nih.gov/pubmed/18506799 <a href="http://www.ncbi.nlm.nih.gov/pubmed/18506799">Y. Assaf et al.</a> 147163165 Basser, Peter NIH - NICHD NICHD Basser, Peter (NICHD) 1 147163165 Basser, Peter NIH - NICHD NICHD Basser, Peter (NICHD) 1 147158234 A Non-invasive Method To Measure [predict] Conduction Delays Of Nerve Impulses Along White Matter Pathways E-226-2010-0 Filing authorized NICHD 119617417 Ravilious, Geoffrey geoffrey.ravilious@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
geoffrey.ravilious@nih.gov?subject=Web Inquiry on [TAB-3998] Quantitative In Vivo Methods for Measuring Brain Networks&body=Please send me information about technology [TAB-3998] Quantitative In Vivo Methods for Measuring Brain Networks.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Ravilious, Geoffrey<br><a href="mailto:geoffrey.ravilious@nih.gov?subject=Web Inquiry on [TAB-3998] Quantitative In Vivo Methods for Measuring Brain Networks&body=Please send me information about technology [TAB-3998] Quantitative In Vivo Methods for Measuring Brain Networks.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">geoffrey.ravilious@nih.gov</a><br> 147161205 E-226-2010-0 E-226-2010-0-US-01 Tractography Based Transit Time Determination PRV US 61/535,851 Abandoned US <br />Provisional (PRV) 61/535,851<br />Filed on 2011-09-16<br />Status: Abandoned 147165799 E-226-2010-0 E-226-2010-0-PCT-02 Tractography Based Transit Time Determination PCT Patent Cooperation Treaty PCT/US2012/055458 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2012/055458<br />Filed on 2012-09-14<br />Status: Expired 147165800 E-226-2010-0 E-226-2010-0-EP-03 Tractography Based Transit Time Determination National Stage European Patent 2756324 12777958.5 Issued European Patent <br />National Stage 12777958.5<br />Filed on 2012-09-14<br />Status: Issued 147165801 E-226-2010-0 E-226-2010-0-US-04 MRI Tractography Based Transit Time Determination For Nerve or Muscle Fibers National Stage US 10,996,303 14/345,219 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10996303 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10996303">10,996,303</a><br />Filed on 2014-06-16<br />Status: Issued 147165802 E-226-2010-0 E-226-2010-0-US-05 MRI TRACTOGRAPHY BASED TRANSIT TIME DETERMINATION FOR NERVE FIBERS CON US 12,345,788 17/306,841 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12345788 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12345788">12,345,788</a><br />Filed on 2021-05-03<br />Status: Issued 147165803 E-226-2010-0 E-226-2010-0-DE-06 Tractography Based Transit Time Determination EP Germany 2756324 12777958.5 Issued Germany <br />European patent (EP) 12777958.5<br />Filed on 2012-09-14<br />Status: Issued 147165804 E-226-2010-0 E-226-2010-0-FR-07 Tractography Based Transit Time Determination EP France 2756324 12777958.5 Issued France <br />European patent (EP) 12777958.5<br />Filed on 2012-09-14<br />Status: Issued 147165805 E-226-2010-0 E-226-2010-0-GB-08 Tractography Based Transit Time Determination EP United Kingdom 2756324 12777958.5 Issued United Kingdom <br />European patent (EP) 12777958.5<br />Filed on 2012-09-14<br />Status: Issued 147173896 Axon diameter distribution 147173898 connectome 147173900 DTI Tractography 147173901 Magnetic Resonance Imaging 147173902 MRI 147173903 MRI diagnostic TAB-4165 147157448 MRI-Based Method for Characterizing Axonal Microstructure in Traumatic Brain Injury NICHD Collaboration, Diagnostics, Licensing, Neurology Collaboration Diagnostics Licensing Neurology Peter Basser, Dan Benjamini, Michal Komlosh <p>Neurites of the central nervous system can be conceptualized as cylindrical pores with finite lengths and radii. In response to physical trauma, axons may assume a “beaded” morphology which alters their ability to conduct electrical impulses, impairing brain function. These microstructural changes are thought to underlie some of the cognitive defects observed in patients with traumatic brain injury (TBI). Current methods for characterizing traumatic brain injury (TBI) cannot provide microstructural detail on the 3-dimensional shape of axonal segments. Such detail is useful for the clinical management of patients with TBI. </p> <p>Researchers at the Eunice Kennedy Shriver National Institute of Child Health and Human Development developed a magnetic resonance imaging (MRI)-based data acquisition pipeline and processing framework to non-invasively characterize axonal shape and structure. The invention provides a method for non-invasively determining the joint distribution of pore lengths and radii within white matter pathways. </p> <h2>Competitive Advantages:</h2> <ul><li>Provides 3-dimensional data about axonal structure</li> <li>Provides microstructural detail</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Diagnosis and monitoring patients with insults or injuries to white matter in the brain or nerves in the PNS </li> <li>Traumatic Brain Injury</li> </ul> 2017-11-02 2025-04-22 2021-01-26 2025-04-22 2017-11-02 Magnetic Resonance Imaging, MRI, MRI diagnostic, Neurites, Peripheral Nervous System, PNS, TBI, Traumatic Brain Injury False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2021-01-26 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-079-2003 E-173-2016 E-226-2010 147162099 Komlosh ME, et al. Submitted to Microporous and Mesoporous Materials. In press. Komlosh ME, et al. Submitted to Microporous and Mesoporous Materials. In press. 147162446 Benjamini D, et al. White matter microstructure from nonparametric axon diameter distribution mapping. https://www.ncbi.nlm.nih.gov/pubmed/27126002 <a href="https://www.ncbi.nlm.nih.gov/pubmed/27126002">Benjamini D, et al. White matter microstructure from nonparametric axon diameter distribution mapping.</a> 147163747 Basser, Peter NIH - NICHD NICHD Basser, Peter (NICHD) 1 147163749 Benjamini, Dan NIH - NICHD NIA Benjamini, Dan (NIA) 2 147163748 Komlosh, Michal NIH - NICHD NICHD Komlosh, Michal (NICHD) 3 147163747 Basser, Peter NIH - NICHD NICHD Basser, Peter (NICHD) 1 147163749 Benjamini, Dan NIH - NICHD NIA Benjamini, Dan (NIA) 2 147163748 Komlosh, Michal NIH - NICHD NICHD Komlosh, Michal (NICHD) 3 147157776 MRI Detection Of Neurite Beading Using A Novel Experiment, Model, And Experimental Design E-008-2015-0 Filing authorized NICHD 119617417 Ravilious, Geoffrey geoffrey.ravilious@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
geoffrey.ravilious@nih.gov?subject=Web Inquiry on [TAB-4165] MRI-Based Method for Characterizing Axonal Microstructure in Traumatic Brain Injury&body=Please send me information about technology [TAB-4165] MRI-Based Method for Characterizing Axonal Microstructure in Traumatic Brain Injury.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Ravilious, Geoffrey<br><a href="mailto:geoffrey.ravilious@nih.gov?subject=Web Inquiry on [TAB-4165] MRI-Based Method for Characterizing Axonal Microstructure in Traumatic Brain Injury&body=Please send me information about technology [TAB-4165] MRI-Based Method for Characterizing Axonal Microstructure in Traumatic Brain Injury.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">geoffrey.ravilious@nih.gov</a><br> 147160889 E-008-2015-0 E-008-2015-0-PCT-02 Joint Probability Distribution Determinations for Material Assessments PCT Patent Cooperation Treaty PCT/US2015/062489 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2015/062489<br />Filed on 2015-11-24<br />Status: Expired 147167047 E-008-2015-0 E-008-2015-0-US-01 Joint Probability Distrbution Determinations for Material Assessments PRV US 62/083,834 Abandoned US <br />Provisional (PRV) 62/083,834<br />Filed on 2014-11-24<br />Status: Abandoned 147167048 E-008-2015-0 E-008-2015-0-US-03 DETERMINATION OF A JOINT PROBABILITY DISTRIBUTION OF RADIUS AND LENGTH OF ANISOTROPIC PORES FROM DOUBLE PULSED FIELD GRADIENT MRI DATA National Stage US 10,871,539 15/529,412 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10871539 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10871539">10,871,539</a><br />Filed on 2017-05-24<br />Status: Issued 147169340 Magnetic Resonance Imaging 147169341 MRI 147169343 MRI diagnostic 147169345 Neurites 147169347 Peripheral Nervous System 147169349 PNS 147169350 TBI 147169351 Traumatic Brain Injury TAB-3884 147157164 Magnetic Resonance Specimen Evaluation Using Multiple Pulse Field Gradient Sequences NICHD Collaboration, Diagnostics, Licensing, Neurology Collaboration Diagnostics Licensing Neurology Peter Basser, Evren Ozarslan <p>Researchers at the <a href="https://www.nichd.nih.gov/" rel="nofollow">Eunice Kennedy Shriver National Institute of Child Health and Human Development</a> (NICHD) developed an MRI-method that is based on the acquisition of multiple pulsed field gradient (m-PFG) rather than single-pulsed field gradient (s-PFG) MRI sequences. In particular, double PFG (dPFG) MRI sequences offer higher sensitivity and greater robustness, as they are more sensitive to the effects of “restriction;” i.e., to water trapped within the axon’s intracellular space, and thus to the diameter of the axons. Thus, it renders the MRI data more sensitive to “pore size” and “pore shape,” making the measurement of the average axon diameter (AAD), and the axon diameter distribution (ADD) more sensitive and accurate. Moreover, measurements using the multiple-PFG sequence can be performed readily at ‘low b” or “low q” – making it biologically relevant and clinically feasible. </p> <h2>Competitive Advantages:</h2> <ul><li>Non-invasive, painless, in vivo measurement of tissue microstructure and the microenvironment;</li> <li>Contrast agents not required;</li> <li>Modest data requirements allow for scans to be performed in a clinically feasible time-frame.</li> </ul> <h2>Commercial Applications:</h2> <ul><li>In vivo MRI of humans and animals;</li> <li>Drug development;</li> <li>Material Science;</li> <li>Food processing.</li> </ul> 2017-11-02 2025-04-22 2023-01-09 2025-04-22 2017-11-02 Axon diameter distribution, double PFG, d-PFG, MRI diagnostic, Multiple Pulsed Field Gradient False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2023-01-09 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147162720 Basser, Peter NIH - NICHD NICHD Basser, Peter (NICHD) 1 147162721 Ozarslan, Evren NIH - NICHD NICHD Ozarslan, Evren (NICHD) 2 147162720 Basser, Peter NIH - NICHD NICHD Basser, Peter (NICHD) 1 147162721 Ozarslan, Evren NIH - NICHD NICHD Ozarslan, Evren (NICHD) 2 147158308 A Sensitive And Robust Method To Measure The Axon Diameter Distribution In Nerve Fascicles Employing Multiple Pulsed-field Gradient MR Sequences E-276-2008-0 Filing authorized NICHD 119617417 Ravilious, Geoffrey geoffrey.ravilious@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
geoffrey.ravilious@nih.gov?subject=Web Inquiry on [TAB-3884] Magnetic Resonance Specimen Evaluation Using Multiple Pulse Field Gradient Sequences&body=Please send me information about technology [TAB-3884] Magnetic Resonance Specimen Evaluation Using Multiple Pulse Field Gradient Sequences.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Ravilious, Geoffrey<br><a href="mailto:geoffrey.ravilious@nih.gov?subject=Web Inquiry on [TAB-3884] Magnetic Resonance Specimen Evaluation Using Multiple Pulse Field Gradient Sequences&body=Please send me information about technology [TAB-3884] Magnetic Resonance Specimen Evaluation Using Multiple Pulse Field Gradient Sequences.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">geoffrey.ravilious@nih.gov</a><br> 147165038 E-276-2008-0 E-276-2008-0-US-01 MAGNETIC RESONANCE SPECIMEN EVALUATION USING MULTIPLE PULSED FIELD GRADIENT SEQUENCES PRV US 61/087,968 Abandoned US <br />Provisional (PRV) 61/087,968<br />Filed on 2008-08-11<br />Status: Abandoned 147165039 E-276-2008-0 E-276-2008-0-US-02 MAGNETIC RESONANCE SPECIMEN EVALUATION USING MULTIPLE PULSED FIELD GRADIENT SEQUENCES WITH A WAVENUMBER MAGNITUDE LOCAL MINIMUM AND RESTRICTED COMPARTMENT ESTIMATION ORD US 8,704,515 12/539,462 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8704515 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8704515">8,704,515</a><br />Filed on 2009-08-11<br />Status: Issued 147174544 Axon diameter distribution 147174546 double PFG 147174548 d-PFG 147174549 MRI diagnostic 147174551 Multiple Pulsed Field Gradient TAB-3962 147157242 NSAIDs that Assist the Treatment of Human Diseases NCI Collaboration, Immunology, Licensing, Oncology, Therapeutics Collaboration Immunology Licensing Oncology Therapeutics Murali Cherukuri, Wilmarie Flores-Santana, S. Bruce King, James Mitchell, David Wink <p>Non-steroidal anti-inflammatory drugs (NSAIDs) have long been used to treat a variety of inflammatory conditions.  Many of these conditions, such as cancer or arthritis, require long term use of the NSAIDs due to the chronic nature of the disease.  However, the NSAIDs in current use have toxicities associated with their long-term use that hinder their use for these chronic conditions.    </p> <p>Researchers at the NCI, in collaboration with Wake Forest University, have developed novel hybrid compounds which combine a NSAID with a nitroxyl (HNO) releasing agent. These modified NSAIDs have significantly reduced toxicity compared to the conventionally used NSAIDs which may allow their administration for the extended periods needed for more chronic conditions without severe side effects.  The adverse side effects (i.e. heart attack, thrombosis and severe gut toxicity) observed with conventional NSAIDs are well documented.  In fact, some of these drugs (i.e. Vioxx) were withdrawn from the market as a result of these adverse events. The compounds of the invention may alleviate these problems due to their lower toxicity. The HNO releasing moiety contained in the invention may expand the medical utility of NSAIDs. HNO releasing agents possess anticancer activity as well as good antioxidant properties, which has potential benefit for a variety of human diseases, including acute and chronic inflammation. </p> <h2>Competitive Advantages:</h2> <ul><li>Reduced toxicity compared to conventionally used NSAIDs</li> </ul><p> </p> <h2>Commercial Applications:</h2> <ul><li>Therapeutic for the treatment of inflammatory diseases </li> <li>Preventative drug for cardiovascular disease, diabetes and cancer </li> </ul> 2017-11-02 2025-04-22 2018-02-21 2025-04-22 2017-11-02 David Wink, HNO, Inflammation, nitric oxide, NITROXYL, non-steroidal anti-inflammatory drugs, NSAID False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2018-02-21 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147162155 W. Flores-Santana et al. https://www.ncbi.nlm.nih.gov/pubmed/21658022 <a href="https://www.ncbi.nlm.nih.gov/pubmed/21658022">W. Flores-Santana et al.</a> 147163028 Wink, David NIH - NCI NCI Wink, David (NCI) 1 147163032 Flores-Santana, Wilmarie NIH - NCI Flores-Santana, Wilmarie 2 147163031 King, S. Bruce Wake Forest University King, S. Bruce 3 147163030 Cherukuri, Murali NIH - NCI NCI Cherukuri, Murali (NCI) 4 147163029 Mitchell, James NIH - NCI NCI Mitchell, James (NCI) 5 147163028 Wink, David NIH - NCI NCI Wink, David (NCI) 1 147163032 Flores-Santana, Wilmarie NIH - NCI Flores-Santana, Wilmarie 2 147163031 King, S. Bruce Wake Forest University King, S. Bruce 3 147163030 Cherukuri, Murali NIH - NCI NCI Cherukuri, Murali (NCI) 4 147163029 Mitchell, James NIH - NCI NCI Mitchell, James (NCI) 5 147158045 The Development Of Antioxidant NSAID For Chronic Treatment Of Diseases Related To Inflammation E-131-2011-0 Filing authorized NCI, Wake Forest University 83732213 Dick, Taryn taryn.dick@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB taryn.dick@nih.gov?subject=Web Inquiry on [TAB-3962] NSAIDs that Assist the Treatment of Human Diseases&body=Please send me information about technology [TAB-3962] NSAIDs that Assist the Treatment of Human Diseases.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dick, Taryn<br><a href="mailto:taryn.dick@nih.gov?subject=Web Inquiry on [TAB-3962] NSAIDs that Assist the Treatment of Human Diseases&body=Please send me information about technology [TAB-3962] NSAIDs that Assist the Treatment of Human Diseases.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">taryn.dick@nih.gov</a><br> 147161081 E-130-2016-0 E-130-2016-0-US-01 ANTI-pY1235-MET IMMUNOLOGICAL BINDING REAGENT PRV US 62/309,920 Abandoned US <br />Provisional (PRV) 62/309,920<br />Filed on 2016-03-17<br />Status: Abandoned 147165573 E-131-2011-0 E-131-2011-0-US-01 Nitric Oxide Releasing Non-Steroidal Anti-Inflammatory Compounds And Uses Thereof In The Treatment And Prevention Of Diseases Or Disorders PRV US 61/472,770 Abandoned US <br />Provisional (PRV) 61/472,770<br />Filed on 2011-04-07<br />Status: Abandoned 147165574 E-131-2011-0 E-131-2011-0-US-02 Nitroxide Modified Non-Steroidal Anti-Inflammatory Compounds And Uses Thereof In The Treatment And Prevention Of Diseases or Disorders ORD US 9,012,647 13/440,092 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9012647 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9012647">9,012,647</a><br />Filed on 2012-04-05<br />Status: Issued 147172055 David Wink 147172056 HNO 147172057 Inflammation 147172058 nitric oxide 147172059 NITROXYL 147172061 non-steroidal anti-inflammatory drugs 147172062 NSAID TAB-4212 147157497 T Cell Receptors Targeting KRAS Mutants for Cancer Immunotherapy/Adoptive Cell Therapy NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Yong-Chen Lu, Anna Pasetto, Paul Robbins, Steven Rosenberg, Eric Tran, Zhili Zheng <p style="font-family:Arial; font-size:16px">Mutations in the Kirsten rat sarcoma viral oncogene homolog (KRAS) gene are among the most common oncogenic drivers in human cancers, affecting nearly a third of all solid tumors. Point mutations in the KRAS gene most frequently affect amino acid position 12, resulting in the substitution of the native glycine (G) residue for other amino acids (e.g., aspartic acid (D), valine (V), cysteine (C) or arginine (R)). The mutations in KRAS occur early in the process of carcinogenesis, and only tumor cells express driver mutations, making them an attractive cancer-specific therapeutic target. However, despite decades of research into the signaling of mutated KRAS and druggability of these mutations with selective inhibitors, no effective therapy has been developed for these common mutated KRAS-driven cancers.</p> <p style="font-family:Arial; font-size:16px">T cell receptors (TCRs) are proteins expressed on the cell surface of T lymphocytes that can recognize peptide antigens from infected and malignant cells in the context of human leukocytes antigen (HLA) molecules with exquisite specificity. Subsequent T cell activation leads to an immune response which aims to eliminate the abnormal cells. T lymphocytes that naturally lack specificity for a tumor antigen can be equipped to express a tumor antigen-specific TCR using genetic engineering. Adoptive transfer of these tumor antigen-specific TCR-engineered T cells into patients with cancer has demonstrated to be a promising cancer treatment strategy.&nbsp;</p> <p style="font-family:Arial; font-size:16px">Scientists at the NIH identified a collection of TCRs that specifically recognize mutated KRAS variants (Table 1). These variants cover the most common KRAS driver mutations expressed by a variety of epithelial cancers, including pancreatic, colorectal and lung cancer. The mutated KRAS variants are recognized by the TCRs in the context of specific Class I/Class II HLA alleles. These TCRs are expected to eliminate human cancer cells that express both the appropriate mutated KRAS variant and HLA molecule upon adoptive transfer into patients with cancer. Furthermore, these TCRs can be used for a variety of other experimental therapeutic, diagnostic and research applications.</p> <h2><strong>Table 1: Collection of mutated KRAS TCRs</strong></h2> <h2><strong><img alt="Collection of mutated KRAS TCRs" src="https://nih.technologypublisher.com/files/sites/table_1_kras_tcrs.jpg" style="height:2201px; width:1701px" /></strong><img alt="" src="C:\Users\jonestil\AppData\Local\Microsoft\Windows\INetCache\Content.Outlook\22JAU93I\Table 1_KRAS TCRs_updated 2-12-25.jpg" /></h2> <h2><strong>Table 2:</strong>&nbsp;<em>Priority Patent Filings by Invention Reference</em><img alt="Priority Patent Applications" src="https://nih.technologypublisher.com/files/sites/table_2_priority_patent_applications_2-12-25_(002)1.jpg" /></h2> <h2>Competitive Advantages:</h2> <ul> <li>Highly expressed target antigens: mutated KRAS variants are frequently expressed by the most common epithelial cancers, including pancreatic, colorectal and lung cancer</li> <li>Cancer-specific driver mutations: mutated KRAS variants are solely expressed by cancer cells, and not by healthy tissues&nbsp;</li> <li>Variety of HLA-restriction elements: extends the applicability of TCRs as they recognize mutated KRAS variants in the context of multiple HLA molecules</li> </ul> <p style="font-family:Arial; font-size:16px">&nbsp;</p> <h2>Commercial Applications:</h2> <ul> <li>A component of a combination immunotherapy aimed at targeting mutated KRAS-driven cancers</li> <li>An in vitro diagnostic tool to screen for cells expressing mutated KRAS in antigen detection assays</li> <li>A research tool to investigate signaling in mutated KRAS antigen expressing cells</li> <li>Use of portions of the TCRs in chimeric proteins for research and therapeutic purposes in mutated KRAS-driven cancers</li> </ul> 2017-11-28 2025-04-22 2022-06-02 2025-04-22 2017-11-28 CANCER, Immunotherapy, Mutated KRAS, Rosenberg, T-cell Receptors False True Clinical True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2022-06-02 72159138 Clinical Phase I 72159138 NCI 37470483 Website Abstract E-028-2015 E-029-2019 E-031-2020 E-074-2020 E-088-2020 E-105-2012 E-165-2020 E-166-2018 E-172-2020 E-176-2014 E-180-2015 E-181-2016 E-189-2020 E-190-2020 E-239-2017 E-265-2015 E-495-2013 147162045 Tran et al. Science 2015. &quot;Immunogenicity of somatic mutations in human gastrointestinal cancers&quot; https://www.ncbi.nlm.nih.gov/pubmed/26516200 <a href="https://www.ncbi.nlm.nih.gov/pubmed/26516200">Tran et al. Science 2015. &quot;Immunogenicity of somatic mutations in human gastrointestinal cancers&quot;</a> 147162084 Tran et al. N Engl J Med 2016. &quot;T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer&quot; https://www.ncbi.nlm.nih.gov/pubmed/27959684 <a href="https://www.ncbi.nlm.nih.gov/pubmed/27959684">Tran et al. N Engl J Med 2016. &quot;T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer&quot;</a> 147162162 Wang QJ et al. Cancer Immunol Res 2016. &quot;Identification of T-cell Receptors Targeting KRAS-mutated Human Tumors&quot; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4775432/ <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4775432/">Wang QJ et al. Cancer Immunol Res 2016. &quot;Identification of T-cell Receptors Targeting KRAS-mutated Human Tumors&quot;</a> 147163931 Tran, Eric NIH - NCI Tran, Eric 1 147163932 Lu, Yong-Chen NIH - NCI NCI Lu, Yong-Chen (NCI) 2 147163929 Robbins, Paul NIH - NCI NCI Robbins, Paul (NCI) 3 147163928 Rosenberg, Steven NIH - NCI NCI Rosenberg, Steven (NCI) 4 147163930 Pasetto, Anna NIH - NCI Pasetto, Anna 5 147163933 Zheng, Zhili NIH - NCI NCI Zheng, Zhili (NCI) 6 147163931 Tran, Eric NIH - NCI Tran, Eric 1 147163932 Lu, Yong-Chen NIH - NCI NCI Lu, Yong-Chen (NCI) 2 147163929 Robbins, Paul NIH - NCI NCI Robbins, Paul (NCI) 3 147163928 Rosenberg, Steven NIH - NCI NCI Rosenberg, Steven (NCI) 4 147163930 Pasetto, Anna NIH - NCI Pasetto, Anna 5 147163933 Zheng, Zhili NIH - NCI NCI Zheng, Zhili (NCI) 6 147158149 HLA-CWB -restricted T-cell Receptors Against The KRAs120 Mutation E-175-2016-0 Filing authorized NCI 83709866 Burke, Andrew burkear@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC burkear@nih.gov?subject=Web Inquiry on [TAB-4212] T Cell Receptors Targeting KRAS Mutants for Cancer Immunotherapy/Adoptive Cell Therapy&body=Please send me information about technology [TAB-4212] T Cell Receptors Targeting KRAS Mutants for Cancer Immunotherapy/Adoptive Cell Therapy.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Burke, Andrew<br><a href="mailto:burkear@nih.gov?subject=Web Inquiry on [TAB-4212] T Cell Receptors Targeting KRAS Mutants for Cancer Immunotherapy/Adoptive Cell Therapy&body=Please send me information about technology [TAB-4212] T Cell Receptors Targeting KRAS Mutants for Cancer Immunotherapy/Adoptive Cell Therapy.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">burkear@nih.gov</a><br> 147167373 E-175-2016-0 E-175-2016-0-US-01 ANTI-KRAS-G12D T Cell Receptors PRV US 62/369,883 Abandoned US <br />Provisional (PRV) 62/369,883<br />Filed on 2016-08-02<br />Status: Abandoned 147167374 E-175-2016-0 E-175-2016-0-PCT-02 ANTI-KRAS-G12D T CELL RECEPTORS PCT Patent Cooperation Treaty PCT/US2017/044615 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2017/044615<br />Filed on 2017-07-31<br />Status: Expired 147167375 E-175-2016-0 E-175-2016-0-AU-03 ANTI-KRAS-G12D T CELL RECEPTORS National Stage Australia 2017306038 2017306038 Issued Australia <br />National Stage 2017306038<br />Filed on 2017-07-31<br />Status: Issued 147167376 E-175-2016-0 E-175-2016-0-CA-04 ANTI-KRAS-G12D T CELL RECEPTORS National Stage Canada 3032870 3032870 Issued Canada <br />National Stage 3032870<br />Filed on 2017-07-31<br />Status: Issued 147167377 E-175-2016-0 E-175-2016-0-CN-05 ANTI-KRAS-G12D T CELL RECEPTORS National Stage China ZL201780059356.4 201780059356.4 Issued China <br />National Stage 201780059356.4<br />Filed on 2017-07-31<br />Status: Issued 147167378 E-175-2016-0 E-175-2016-0-EP-06 ANTI-KRAS-G12D T CELL RECEPTORS National Stage European Patent 3494133 17749580.1 Issued European Patent <br />National Stage 17749580.1<br />Filed on 2019-01-30<br />Status: Issued 147167379 E-175-2016-0 E-175-2016-0-JP-07 ANTI-KRAS-G12D T CELL RECEPTORS National Stage Japan 6993402 2019-505220 Issued Japan <br />National Stage 2019-505220<br />Filed on 2017-07-31<br />Status: Issued 147167380 E-175-2016-0 E-175-2016-0-US-08 ANTI-KRAS-G12D T CELL RECEPTORS National Stage US 10,611,816 16/321,899 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10611816 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10611816">10,611,816</a><br />Filed on 2019-01-30<br />Status: Issued 147167381 E-175-2016-0 E-175-2016-0-IL-09 ANTI-KRAS-G12D T CELL RECEPTORS National Stage Israel 264425 264425 Issued Israel <br />National Stage 264425<br />Filed on 2019-01-23<br />Status: Issued 147167382 E-175-2016-0 E-175-2016-0-KR-10 ANTI-KRAS-G12D T CELL RECEPTORS National Stage South Korea 10-2527052 10-2019-7005837 Issued South Korea <br />National Stage 10-2019-7005837<br />Filed on 2019-02-27<br />Status: Issued 147167383 E-175-2016-0 E-175-2016-0-SG-11 ANTI-KRAS-G12D T CELL RECEPTORS National Stage Singapore 11201900654Q 11201900654Q Issued Singapore <br />National Stage 11201900654Q<br />Filed on 2019-01-24<br />Status: Issued 147167384 E-175-2016-0 E-175-2016-0-HK-12 ANTI-KRAS-G12D T CELL RECEPTORS EP Hong Kong HK40009637B 19133082.8 Issued Hong Kong <br />European patent (EP) 19133082.8<br />Filed on 2019-12-03<br />Status: Issued 147167385 E-175-2016-0 E-175-2016-0-HK-13 ANTI-KRAS-G12D T CELL RECEPTORS CN Hong Kong HK40008470B 19132196.7 Issued Hong Kong <br />China Patent (CN) 19132196.7<br />Filed on 2019-11-14<br />Status: Issued 147167386 E-175-2016-0 E-175-2016-0-SG-14 ANTI-KRAS-G12D T CELL RECEPTORS DIV Singapore 10201913959W Pending Singapore <br />Divisional (DIV) 10201913959W<br />Filed on 2019-12-31<br />Status: Pending 147167387 E-175-2016-0 E-175-2016-0-US-15 ANTI-KRAS-G12D T CELL RECEPTORS DIV US 11,208,456 16/838,395 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11208456 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11208456">11,208,456</a><br />Filed on 2020-04-02<br />Status: Issued 147167388 E-175-2016-0 E-175-2016-0-US-16 ANTI-KRAS-G12D T CELL RECEPTORS CON US 11,897,933 17/345,390 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11897933 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11897933">11,897,933</a><br />Filed on 2021-06-11<br />Status: Issued 147167389 E-175-2016-0 E-175-2016-0-US-17 ANTI-KRAS-G12D T CELL RECEPTORS CON US 11,840,561 17/541,619 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11840561 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11840561">11,840,561</a><br />Filed on 2021-12-03<br />Status: Issued 147167390 E-175-2016-0 E-175-2016-0-JP-18 ANTI-KRAS-G12D T CELL RECEPTORS DIV Japan 7413338 2021-199878 Issued Japan <br />Divisional (DIV) 2021-199878<br />Filed on 2021-12-09<br />Status: Issued 147167391 E-175-2016-0 E-175-2016-0-EP-19 ANTI-KRAS-G12D T CELL RECEPTORS DIV European Patent 22182473.3 Pending European Patent <br />Divisional (DIV) 22182473.3<br />Filed on 2022-07-01<br />Status: Pending 147167392 E-175-2016-0 E-175-2016-0-AL-20 ANTI-KRAS-G12D T CELL RECEPTORS EP Albania 3494133 17749580.1 Issued Albania <br />European patent (EP) 17749580.1<br />Filed on 2017-07-31<br />Status: Issued 147167393 E-175-2016-0 E-175-2016-0-AT-21 ANTI-KRAS-G12D T CELL RECEPTORS EP Austria 3494133 17749580.1 Issued Austria <br />European patent (EP) 17749580.1<br />Filed on 2017-07-31<br />Status: Issued 147167394 E-175-2016-0 E-175-2016-0-BE-22 ANTI-KRAS-G12D T CELL RECEPTORS EP Belgium 3494133 17749580.1 Issued Belgium <br />European patent (EP) 17749580.1<br />Filed on 2017-07-31<br />Status: Issued 147167395 E-175-2016-0 E-175-2016-0-BG-23 ANTI-KRAS-G12D T CELL RECEPTORS EP Bulgaria 3494133 17749580.1 Issued Bulgaria <br />European patent (EP) 17749580.1<br />Filed on 2017-07-31<br />Status: Issued 147167396 E-175-2016-0 E-175-2016-0-HR-24 ANTI-KRAS-G12D T CELL RECEPTORS EP Croatia 3494133 17749580.1 Issued Croatia <br />European patent (EP) 17749580.1<br />Filed on 2017-07-31<br />Status: Issued 147167397 E-175-2016-0 E-175-2016-0-CY-25 ANTI-KRAS-G12D T CELL RECEPTORS EP Cyprus 3494133 17749580.1 Issued Cyprus <br />European patent (EP) 17749580.1<br />Filed on 2017-07-31<br />Status: Issued 147167398 E-175-2016-0 E-175-2016-0-CZ-26 ANTI-KRAS-G12D T CELL RECEPTORS EP Czech Republic 3494133 17749580.1 Issued Czech Republic <br />European patent (EP) 17749580.1<br />Filed on 2017-07-31<br />Status: Issued 147167399 E-175-2016-0 E-175-2016-0-DK-27 ANTI-KRAS-G12D T CELL RECEPTORS EP Denmark 3494133 17749580.1 Issued Denmark <br />European patent (EP) 17749580.1<br />Filed on 2017-07-31<br />Status: Issued 147167400 E-175-2016-0 E-175-2016-0-EE-28 ANTI-KRAS-G12D T CELL RECEPTORS EP Estonia 3494133 17749580.1 Issued Estonia <br />European patent (EP) 17749580.1<br />Filed on 2017-07-31<br />Status: Issued 147167401 E-175-2016-0 E-175-2016-0-FI-29 ANTI-KRAS-G12D T CELL RECEPTORS EP Finland 3494133 17749580.1 Issued Finland <br />European patent (EP) 17749580.1<br />Filed on 2017-07-31<br />Status: Issued 147167402 E-175-2016-0 E-175-2016-0-FR-30 ANTI-KRAS-G12D T CELL RECEPTORS EP France 3494133 17749580.1 Issued France <br />European patent (EP) 17749580.1<br />Filed on 2017-07-31<br />Status: Issued 147167403 E-175-2016-0 E-175-2016-0-DE-31 ANTI-KRAS-G12D T CELL RECEPTORS EP Germany 3494133 17749580.1 Issued Germany <br />European patent (EP) 17749580.1<br />Filed on 2017-07-31<br />Status: Issued 147167404 E-175-2016-0 E-175-2016-0-GR-32 ANTI-KRAS-G12D T CELL RECEPTORS EP Greece 3494133 17749580.1 Issued Greece <br />European patent (EP) 17749580.1<br />Filed on 2017-07-31<br />Status: Issued 147167405 E-175-2016-0 E-175-2016-0-HU-33 ANTI-KRAS-G12D T CELL RECEPTORS EP Hungary 3494133 17749580.1 Issued Hungary <br />European patent (EP) 17749580.1<br />Filed on 2017-07-31<br />Status: Issued 147167406 E-175-2016-0 E-175-2016-0-IS-34 ANTI-KRAS-G12D T CELL RECEPTORS EP Iceland 3494133 17749580.1 Issued Iceland <br />European patent (EP) 17749580.1<br />Filed on 2017-07-31<br />Status: Issued 147167407 E-175-2016-0 E-175-2016-0-IE-35 ANTI-KRAS-G12D T CELL RECEPTORS EP Ireland 3494133 17749580.1 Issued Ireland <br />European patent (EP) 17749580.1<br />Filed on 2017-07-31<br />Status: Issued 147167408 E-175-2016-0 E-175-2016-0-IT-36 ANTI-KRAS-G12D T CELL RECEPTORS EP Italy 3494133 17749580.1 Issued Italy <br />European patent (EP) 17749580.1<br />Filed on 2017-07-31<br />Status: Issued 147167409 E-175-2016-0 E-175-2016-0-LV-37 ANTI-KRAS-G12D T CELL RECEPTORS EP Latvia 3494133 17749580.1 Issued Latvia <br />European patent (EP) 17749580.1<br />Filed on 2017-07-31<br />Status: Issued 147167410 E-175-2016-0 E-175-2016-0-LT-38 ANTI-KRAS-G12D T CELL RECEPTORS EP Lithuania 3494133 17749580.1 Issued Lithuania <br />European patent (EP) 17749580.1<br />Filed on 2017-07-31<br />Status: Issued 147167411 E-175-2016-0 E-175-2016-0-LU-39 ANTI-KRAS-G12D T CELL RECEPTORS EP Luxembourg 3494133 17749580.1 Issued Luxembourg <br />European patent (EP) 17749580.1<br />Filed on 2017-07-31<br />Status: Issued 147167412 E-175-2016-0 E-175-2016-0-MK-40 ANTI-KRAS-G12D T CELL RECEPTORS EP North Macedonia 3494133 17749580.1 Issued North Macedonia <br />European patent (EP) 17749580.1<br />Filed on 2017-07-31<br />Status: Issued 147167413 E-175-2016-0 E-175-2016-0-MT-41 ANTI-KRAS-G12D T CELL RECEPTORS EP Malta 3494133 17749580.1 Issued Malta <br />European patent (EP) 17749580.1<br />Filed on 2017-07-31<br />Status: Issued 147167414 E-175-2016-0 E-175-2016-0-MC-42 ANTI-KRAS-G12D T CELL RECEPTORS EP Monaco 3494133 17749580.1 Issued Monaco <br />European patent (EP) 17749580.1<br />Filed on 2017-07-31<br />Status: Issued 147167415 E-175-2016-0 E-175-2016-0-NL-43 ANTI-KRAS-G12D T CELL RECEPTORS EP The Netherlands 3494133 17749580.1 Issued The Netherlands <br />European patent (EP) 17749580.1<br />Filed on 2017-07-31<br />Status: Issued 147167416 E-175-2016-0 E-175-2016-0-NO-44 ANTI-KRAS-G12D T CELL RECEPTORS EP Norway 3494133 17749580.1 Issued Norway <br />European patent (EP) 17749580.1<br />Filed on 2017-07-31<br />Status: Issued 147167417 E-175-2016-0 E-175-2016-0-PL-45 ANTI-KRAS-G12D T CELL RECEPTORS EP Poland 3494133 17749580.1 Issued Poland <br />European patent (EP) 17749580.1<br />Filed on 2017-07-31<br />Status: Issued 147167418 E-175-2016-0 E-175-2016-0-PT-46 ANTI-KRAS-G12D T CELL RECEPTORS EP Portugal 3494133 17749580.1 Issued Portugal <br />European patent (EP) 17749580.1<br />Filed on 2017-07-31<br />Status: Issued 147167419 E-175-2016-0 E-175-2016-0-RO-47 ANTI-KRAS-G12D T CELL RECEPTORS EP Romania 3494133 17749580.1 Issued Romania <br />European patent (EP) 17749580.1<br />Filed on 2017-07-31<br />Status: Issued 147167420 E-175-2016-0 E-175-2016-0-RS-48 ANTI-KRAS-G12D T CELL RECEPTORS EP Serbia 3494133 17749580.1 Issued Serbia <br />European patent (EP) 17749580.1<br />Filed on 2017-07-31<br />Status: Issued 147167421 E-175-2016-0 E-175-2016-0-SM-49 ANTI-KRAS-G12D T CELL RECEPTORS EP San Marino 3494133 17749580.1 Issued San Marino <br />European patent (EP) 17749580.1<br />Filed on 2017-07-31<br />Status: Issued 147167422 E-175-2016-0 E-175-2016-0-SK-50 ANTI-KRAS-G12D T CELL RECEPTORS EP Slovakia 3494133 17749580.1 Issued Slovakia <br />European patent (EP) 17749580.1<br />Filed on 2017-07-31<br />Status: Issued 147167423 E-175-2016-0 E-175-2016-0-SI-51 ANTI-KRAS-G12D T CELL RECEPTORS EP Slovenia 3494133 17749580.1 Issued Slovenia <br />European patent (EP) 17749580.1<br />Filed on 2017-07-31<br />Status: Issued 147167424 E-175-2016-0 E-175-2016-0-ES-52 ANTI-KRAS-G12D T CELL RECEPTORS EP Spain 3494133 17749580.1 Issued Spain <br />European patent (EP) 17749580.1<br />Filed on 2017-07-31<br />Status: Issued 147167425 E-175-2016-0 E-175-2016-0-SE-53 ANTI-KRAS-G12D T CELL RECEPTORS EP Sweden 3494133 17749580.1 Issued Sweden <br />European patent (EP) 17749580.1<br />Filed on 2017-07-31<br />Status: Issued 147167426 E-175-2016-0 E-175-2016-0-CH-54 ANTI-KRAS-G12D T CELL RECEPTORS EP Switzerland 3494133 17749580.1 Issued Switzerland <br />European patent (EP) 17749580.1<br />Filed on 2017-07-31<br />Status: Issued 147167427 E-175-2016-0 E-175-2016-0-GB-55 ANTI-KRAS-G12D T CELL RECEPTORS EP United Kingdom 3494133 17749580.1 Issued United Kingdom <br />European patent (EP) 17749580.1<br />Filed on 2017-07-31<br />Status: Issued 147167428 E-175-2016-0 E-175-2016-0-TR-56 ANTI-KRAS-G12D T CELL RECEPTORS EP Turkey 3494133 17749580.1 Issued Turkey <br />European patent (EP) 17749580.1<br />Filed on 2017-07-31<br />Status: Issued 147167429 E-175-2016-0 E-175-2016-0-IL-01 ANTI-KRAS-G12D T CELL RECEPTORS DIV Israel 301894 301894 Issued Israel <br />Divisional (DIV) 301894<br />Filed on 2023-04-03<br />Status: Issued 147167430 E-175-2016-0 E-175-2016-0-KR-01 ANTI-KRAS-G12D T CELL RECEPTORS DIV South Korea Administratively Closed South Korea <br />Divisional (DIV) None<br />Filed on None<br />Status: Administratively Closed 147173056 CANCER 147173057 Immunotherapy 147173059 Mutated KRAS 147173060 Rosenberg 147173061 T-cell Receptors TAB-3982 147157263 Cell Line for Production of Recombinant Human Tissue Inhibitor of Metalloproteinase-2 NCI Cardiology, Licensing, Oncology, Research Materials Cardiology Licensing Oncology Research Materials William Stetler-Stevens, Beiyang Wei <p>Studies have shown that Tissue Inhibitor of Metalloproteinases 2 (TIMP-2) suppresses tumor growth and tumor-associated angiogenesis. Currently, the main obstacle in using TIMP-2 as a biologic therapeutic has been the inability to produce sufficient quantities of the protein for testing and development. <br /> NCI <a href="https://ccr.cancer.gov/Radiation-Oncology-Branch" rel="nofollow">Radiation Oncology Branch</a> (ROB) researchers have developed a unique HEK-293F cell line that stably expresses rhTIMP-2, increasing the production of TIMP-2 to quantities sufficient to be used for testing and development as a therapeutic for various cancers, ischemic diseases (myocardial infarct and cerebrovascular infarct), and neurodegenerative diseases. Importantly, this inventive cell line can also be produced in great quantities using good laboratory practice (GLP) manufacturing. </p> <h2>Competitive Advantages:</h2> <p>o This is the first time TIMP-2 can be produced in quantities sufficient for testing and development as a novel biologic therapeutic for the treatment of cancer, ischemic diseases (myocardial infarct and cerebrovascular infarct), and neurodegenerative diseases.</p> <h2>Commercial Applications:</h2> <p>Therapeutic Use<br /> • Use as a biological suppressor of tumor growth, vascular proliferation, and neurodegeneration<br /> Drug Discovery<br /> • Enhance public health by providing a method for production scale, good laboratory practice (GLP) manufacturing of biologic therapies for cancer, ischemic diseases, and neurodegenerative diseases treatment</p> 2017-12-04 2025-04-22 2020-08-13 2025-04-22 2017-12-04 CANCER, Cerebrovascular Infarct, HEK-293F Cell Line, Ischemic and Neurodegenerative Diseases, Myocardial Infarct, Stetler-Stevenson, TIMP-2, Tissue Inhibitor of Metalloproteinases 2, tumor suppressor False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2020-08-13 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147162243 Ananda Chowdhury, et al. Recombinant human Tissue Inhibitor of Metalloprotease‐2; a novel anti‐cancer therapeutic. Ananda Chowdhury, et al. Recombinant human Tissue Inhibitor of Metalloprotease‐2; a novel anti‐cancer therapeutic. 147163113 Stetler-Stevens, William NIH - NCI NCI Stetler-Stevens, William (NCI) 1 147163114 Wei, Beiyang NIH - NCI NCI Wei, Beiyang (NCI) 2 147163113 Stetler-Stevens, William NIH - NCI NCI Stetler-Stevens, William (NCI) 1 147163114 Wei, Beiyang NIH - NCI NCI Wei, Beiyang (NCI) 2 147158224 Codon-optimized Tissue Inhibitor Of Metalloproteinase-2 Stable HEK-293F Cells For Enhanced Expression And Production Of Recombinant HTIMP-2 Protein For Preclinical Testing E-216-2017-0 Research Material NCI 121111111 Greene, Jaime greenejaime@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America greenejaime@mail.nih.gov?subject=Web Inquiry on [TAB-3982] Cell Line for Production of Recombinant Human Tissue Inhibitor of Metalloproteinase-2&body=Please send me information about technology [TAB-3982] Cell Line for Production of Recombinant Human Tissue Inhibitor of Metalloproteinase-2.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Greene, Jaime<br><a href="mailto:greenejaime@mail.nih.gov?subject=Web Inquiry on [TAB-3982] Cell Line for Production of Recombinant Human Tissue Inhibitor of Metalloproteinase-2&body=Please send me information about technology [TAB-3982] Cell Line for Production of Recombinant Human Tissue Inhibitor of Metalloproteinase-2.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">greenejaime@mail.nih.gov</a><br> 147173821 CANCER 147173823 Cerebrovascular Infarct 147173825 HEK-293F Cell Line 147173827 Ischemic and Neurodegenerative Diseases 147173829 Myocardial Infarct 147173831 Stetler-Stevenson 147173832 TIMP-2 147173834 Tissue Inhibitor of Metalloproteinases 2 147173835 tumor suppressor TAB-4416 147157711 Therapeutics for Neurodegenerative Disorders and Cancer Using Lenalidomide Analogs NIA Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Edward Goetzl, Nigel Greig, Harold Holloway, Weiming Luo, David Tweedie, Qian-sheng Yu <p>Inflammatory processes associated with the over-production of tumor necrosis-alpha (TNF-alpha), a potent activator of the immune system accompany numerous neurodegenerative diseases. TNF-alpha has been validated as a drug target with the development of the inhibitors Enbrel and Remicade (fusion antibodies) as prescription medications. Both, however, are large macromolecules that require direct injection and have limited brain access. The classical drug, thalidomide is being increasingly used in the clinical management of a wide spectrum of immunologically-mediated and infectious diseases, and cancers. The NIA inventors developed and assessed novel thio analogs of lenalidomide (Celegene's Revlimid and an analog of thalidomide) as immunomodulatory agents, with the potential to reduce chronic systemic and central nervous system inflammation. These compounds were synthesized and evaluated for their TNF-alpha inhibitory activity. This invention was extended from the inventors' prior work to develop potent compounds to reduce neuroinflammation as a treatment strategy for neurodegenerative disorders. The current studies focus the compounds activity in classical models of neurodegeneration as well as cancer.</p> <h2>Competitive Advantages:</h2> <ul><li>Effective smaller molecular weight compound that can enter brain among current agents</li> <li>Experimental therapeutic to reduce inflammation systematically and within the brain</li> <li>More effective in reducing proinflammatory cytokines than existing agent</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Treatment for blood disorders (myelodysplastic syndrome), cancer (multiple myeloma), inflammatory processes and erythema</li> <li>Immunomodulatory agents</li> <li>Reduce chronic systemic and central nervous system inflammation</li> </ul> 2017-12-06 2025-04-22 2018-04-03 2025-04-22 2017-12-06 CNS, Holloway, Immunomodulatory Agents, Inflammation, Lenalidomide, National Institute on Aging, Neurodegenerative Disorders, NIA, THALIDOMIDE, TNF-alpha, Tumor Necrosis-alpha False True Clinical True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2018-04-03 72159138 Clinical Phase I 72159138 NCI 37470483 Website Abstract E-189-2003 147162143 W. Luo et al. https://www.ncbi.nlm.nih.gov/pubmed/21658960 <a href="https://www.ncbi.nlm.nih.gov/pubmed/21658960">W. Luo et al.</a> 147164663 Greig, Nigel NIH - NIA NIA Greig, Nigel (NIA) 1 147164665 Luo, Weiming NIH - NIA NIA Luo, Weiming (NIA) 2 147164666 Tweedie, David NIH - NIA NIA Tweedie, David (NIA) 3 147164662 Holloway, Harold NIH - NIA Holloway, Harold 4 147164664 Yu, Qian-sheng NIH - NIA NIA Yu, Qian-sheng (NIA) 5 147164667 Goetzl, Edward NIH - NIA Goetzl, Edward 6 147164663 Greig, Nigel NIH - NIA NIA Greig, Nigel (NIA) 1 147164665 Luo, Weiming NIH - NIA NIA Luo, Weiming (NIA) 2 147164666 Tweedie, David NIH - NIA NIA Tweedie, David (NIA) 3 147164662 Holloway, Harold NIH - NIA Holloway, Harold 4 147164664 Yu, Qian-sheng NIH - NIA NIA Yu, Qian-sheng (NIA) 5 147164667 Goetzl, Edward NIH - NIA Goetzl, Edward 6 147157858 THIO ANALOGS OF LENALIDOMIDE E-045-2012-0 Filing authorized National Institute on Aging (NIH/NIA) 91789173 Guyton, Nicole darackn@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America darackn@mail.nih.gov?subject=Web Inquiry on [TAB-4416] Therapeutics for Neurodegenerative Disorders and Cancer Using Lenalidomide Analogs&body=Please send me information about technology [TAB-4416] Therapeutics for Neurodegenerative Disorders and Cancer Using Lenalidomide Analogs.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Guyton, Nicole<br><a href="mailto:darackn@mail.nih.gov?subject=Web Inquiry on [TAB-4416] Therapeutics for Neurodegenerative Disorders and Cancer Using Lenalidomide Analogs&body=Please send me information about technology [TAB-4416] Therapeutics for Neurodegenerative Disorders and Cancer Using Lenalidomide Analogs.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">darackn@mail.nih.gov</a><br> 147168794 E-045-2012-0 E-045-2012-0-US-01 THIO COMPOUNDS ORD US 8,927,725 13/310,242 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8927725 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8927725">8,927,725</a><br />Filed on 2011-12-02<br />Status: Issued 147168795 E-045-2012-0 E-045-2012-0-US-02 THIO COMPOUNDS DIV US 9,084,783 14/571,138 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9084783 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9084783">9,084,783</a><br />Filed on 2014-12-15<br />Status: Issued 147168796 E-045-2012-0 E-045-2012-0-US-03 THIO COMPOUNDS CON US 9,623,020 14/746,512 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9623020 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9623020">9,623,020</a><br />Filed on 2015-06-22<br />Status: Issued 147168797 E-045-2012-0 E-045-2012-0-US-04 THIO COMPOUNDS DIV US 10,220,028 15/457,156 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10220028 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10220028">10,220,028</a><br />Filed on 2017-03-13<br />Status: Issued 147170183 CNS 147170185 Holloway 147170187 Immunomodulatory Agents 147170188 Inflammation 147170189 Lenalidomide 147170190 National Institute on Aging 147170192 Neurodegenerative Disorders 147170193 NIA 147170194 THALIDOMIDE 147170195 TNF-alpha 147170197 Tumor Necrosis-alpha TAB-4039 147157320 MADCO-Accelerated Multidimensional Diffusion MRI NICHD Collaboration, Diagnostics, Immunology, Licensing, Materials Available, Oncology Collaboration Diagnostics Immunology Licensing Materials Available Oncology Peter Basser, Dan Benjamini <p>Although multidimensional diffusion/relaxation NMR experiments are widely used in materials sciences and engineering applications, preclinical and clinical MRI applications of these techniques were not feasible. Moreover, higher-field MRI scanners posed another obstacle to translation of this NMR method. Their specific absorption rate (SAR) limits the use of multi-echo or CPMG pulse trains, so that the large amounts of data required by these methods cannot be collected in vivo due to exceedingly long scan times. Therefore, the primary challenges this invention overcomes are the migration of NMR methods to MRI and to vastly shorten scan times.&nbsp;</p> <p>The &ldquo;Marginal Distributions Constrained Optimization (MADCO)&rdquo; methodology provides a novel framework to accelerate and improve the reconstruction of multidimensional NMR relaxation/diffusion spectra suitable for use in MRI applications on a voxel-by-voxel basis. This approach uses 1D acquired spectra as a priori information to estimate a 2D (or higher dimensional) spectrum. 1D marginal distributions are used as constraints when the 2D spectra are reconstructed.&nbsp; &nbsp;</p> <p>The MADCO methodology was demonstrated with polyvinylpyrrolidone-water solution phantoms, which contains 3 species of diffusivities and T1 relaxation times (i.e., 3 peaks in the D-T1 space). With a reasonably accurate estimate of the 1D marginal distributions, MADCO accelerated the acquisition of the 2D spectra by more than a factor of 200 (i.e., two orders of magnitude) with a high level of accuracy, compared to conventional, unconstrained methods.</p> <blockquote> <p><img alt="" height="375" src="https://nih.technologypublisher.com/files/sites/e-173-2016_abstract_figure4.png" width="1000" /></p> </blockquote> <h2>Competitive Advantages:</h2> <ul> <li>Disruptive technologies can positively impact market penetration in a large and growing medical sector. In 2016, an estimated 39 million magnetic resonance imaging (MRI) procedures were performed &ndash; reflecting an average annual growth rate of ~4% since 2011. In the same year, over 8500 clinical sites offered the procedure</li> <li>Metabolomics; increased use in quantitative and metabolic screening applications, where the bottleneck in exploiting the higher information content of multidimensional spectra is the time required to acquire the magnetic resonance data</li> <li>The MADCO method would accelerate and improve the reconstruction of multidimensional NMR relaxation/diffusion spectra suitable for use in MRI, where reducing the amount of data required, reduces the time of scanning, and reduces the cost</li> <li>Imaging procedures such as MRIs use lower radiation levels compared with CT and PET scans, lowering patients risk</li> <li>Shortens scan time using MADCO, resulting in reduced patient discomfort as well as improve diagnostic accuracy</li> <li>Decreases probability of overuse and increases patient benefit for what can be a costly diagnostic procedure</li> </ul> <h2>Commercial Applications:</h2> <ul> <li>Incorporation into neuro or whole-body MRI suites to measure changes in neural and other human tissue within a clinically feasible time-frame</li> <li>Monitoring and mapping brain injury and other pathologies, including inflammation</li> <li>Cardiovascular disease; e.g., stroke, thrombolysis</li> <li>Dental diseases for which standard x-rays do not provide adequate resolution</li> <li>New quantitative imaging biomarkers for improved radiological assessment of normal and abnormal development, various diseases and disorders that have neuroanatomical and microstructural sequelae (e.g., TIA, cancer, Alzheimer&rsquo;s disease, inflammatory diseases)</li> <li>Investigation of fixed tissue, living organotypic neural or other tissue or pre-clinical in vivo animal models in a feasible time frame</li> <li>Producing new quantitative radiological biomarkers, stains or contrasts. Providing a new method for scanning and assessing foods safety and storage life&nbsp; &nbsp;&nbsp;</li> <li>Characterization of rock and soil samples in situ or in a laboratory setting for the oil, gas and water exploration fields</li> <li>Assessing materials and material properties, such as polymers, gels, composites, concrete, and other man-made and natural materials</li> </ul> 2017-12-07 2025-04-22 2017-12-07 2025-04-22 2017-12-07 Basser, Biomarkers, Diffusion MRI, IMAGING, Marginal-Distributions, MRI, MRI diagnostic, Multidimensional-NMR, NMR-Spectroscopy, Relaxometry Diffusometry, T1, T2 False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2017-12-07 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147161889 Benjamini D, et al. Clinically feasible relaxation-diffusion correlation MRI using MADCO. https://science.nichd.nih.gov/confluence/display/sqits/Abstracts <a href="https://science.nichd.nih.gov/confluence/display/sqits/Abstracts">Benjamini D, et al. Clinically feasible relaxation-diffusion correlation MRI using MADCO.</a> 147162005 Benjamini D, et al. Towards clinically feasible relaxation-diffusion correlation MRI using MADCO. https://doi.org/10.1016/j.micromeso.2017.02.001 <a href="https://doi.org/10.1016/j.micromeso.2017.02.001">Benjamini D, et al. Towards clinically feasible relaxation-diffusion correlation MRI using MADCO.</a> 147162161 Bai R, et al. Fast, accurate 2D-MR relaxation exchange spectroscopy (REXSY): Beyond compressed sensing. https://www.ncbi.nlm.nih.gov/pubmed/27782473 <a href="https://www.ncbi.nlm.nih.gov/pubmed/27782473">Bai R, et al. Fast, accurate 2D-MR relaxation exchange spectroscopy (REXSY): Beyond compressed sensing.</a> 147162239 Benjamini D, et al. Imaging Local Diffusive Dynamics Using Diffusion Exchange Spectroscopy MRI. https://www.ncbi.nlm.nih.gov/pubmed/28452522 <a href="https://www.ncbi.nlm.nih.gov/pubmed/28452522">Benjamini D, et al. Imaging Local Diffusive Dynamics Using Diffusion Exchange Spectroscopy MRI.</a> 147162277 Benjamini D, et al. Water exchange in a white matter tissue phantom measured using clinically feasible diffusion exchange spectroscopy (DEXSY) MRI. https://science.nichd.nih.gov/confluence/display/sqits/Abstracts <a href="https://science.nichd.nih.gov/confluence/display/sqits/Abstracts">Benjamini D, et al. Water exchange in a white matter tissue phantom measured using clinically feasible diffusion exchange spectroscopy (DEXSY) MRI.</a> 147162316 Benjamini D, et al. Use of marginal distributions constrained optimization (MADCO) for accelerated 2D MRI relaxometry and diffusometry. https://www.ncbi.nlm.nih.gov/pubmed/27543810 <a href="https://www.ncbi.nlm.nih.gov/pubmed/27543810">Benjamini D, et al. Use of marginal distributions constrained optimization (MADCO) for accelerated 2D MRI relaxometry and diffusometry.</a> 147162430 Benjamini D, et al. Marginal distributions constrained optimization (MADCO) used to accelerate 2D MRI relaxometry. https://science.nichd.nih.gov/confluence/display/sqits/Abstracts <a href="https://science.nichd.nih.gov/confluence/display/sqits/Abstracts">Benjamini D, et al. Marginal distributions constrained optimization (MADCO) used to accelerate 2D MRI relaxometry.</a> 147163304 Basser, Peter NIH - NICHD NICHD Basser, Peter (NICHD) 1 147163305 Benjamini, Dan NIH - NICHD NIA Benjamini, Dan (NIA) 2 147163304 Basser, Peter NIH - NICHD NICHD Basser, Peter (NICHD) 1 147163305 Benjamini, Dan NIH - NICHD NIA Benjamini, Dan (NIA) 2 147158144 Multi-dimensional Spectroscopic NMR And MRI Using Marginal Distributions To Reduce Acquired Data E-173-2016-0 Filing authorized NICHD 119617417 Ravilious, Geoffrey geoffrey.ravilious@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
geoffrey.ravilious@nih.gov?subject=Web Inquiry on [TAB-4039] MADCO-Accelerated Multidimensional Diffusion MRI&body=Please send me information about technology [TAB-4039] MADCO-Accelerated Multidimensional Diffusion MRI.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Ravilious, Geoffrey<br><a href="mailto:geoffrey.ravilious@nih.gov?subject=Web Inquiry on [TAB-4039] MADCO-Accelerated Multidimensional Diffusion MRI&body=Please send me information about technology [TAB-4039] MADCO-Accelerated Multidimensional Diffusion MRI.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">geoffrey.ravilious@nih.gov</a><br> 147161147 E-173-2016-0 E-173-2016-0-US-01 Multi-Dimensional Spectroscopic NMR And MRI Using Marginal Distributions PRV US 62/373,497 Abandoned US <br />Provisional (PRV) 62/373,497<br />Filed on 2016-08-11<br />Status: Abandoned 147166150 E-173-2016-0 E-173-2016-0-PCT-02 MULTI-DIMENSIONAL SPECTROSCOPIC NMR AND MRI USING MARGINAL DISTRIBUTIONS PCT Patent Cooperation Treaty PCT/US2017/046615 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2017/046615<br />Filed on 2017-08-11<br />Status: Expired 147166151 E-173-2016-0 E-173-2016-0-AU-03 MULTI-DIMENSIONAL SPECTROSCOPIC NMR AND MRI USING MARGINAL DISTRIBUTIONS National Stage Australia 2017310513 2017310513 Issued Australia <br />National Stage 2017310513<br />Filed on 2019-01-23<br />Status: Issued 147166152 E-173-2016-0 E-173-2016-0-CA-04 MULTI-DIMENSIONAL SPECTROSCOPIC NMR AND MRI USING MARGINAL DISTRIBUTIONS National Stage Canada 3032154 Pending Canada <br />National Stage 3032154<br />Filed on 2017-08-11<br />Status: Pending 147166153 E-173-2016-0 E-173-2016-0-EP-05 MULTI-DIMENSIONAL SPECTROSCOPIC NMR AND MRI USING MARGINAL DISTRIBUTIONS National Stage European Patent 3497460 17755012.6 Issued European Patent <br />National Stage 17755012.6<br />Filed on 2019-02-05<br />Status: Issued 147166154 E-173-2016-0 E-173-2016-0-JP-06 MULTI-DIMENSIONAL SPECTROSCOPIC NMR AND MRI USING MARGINAL DISTRIBUTIONS National Stage Japan 7058259 2019-506625 Issued Japan <br />National Stage 2019-506625<br />Filed on 2019-02-07<br />Status: Issued 147166155 E-173-2016-0 E-173-2016-0-US-07 MULTI-DIMENSIONAL SPECTROSCOPIC NMR AND MRI USING MARGINAL DISTRIBUTIONS National Stage US 11,415,652 16/324,413 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11415652 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11415652">11,415,652</a><br />Filed on 2019-02-08<br />Status: Issued 147166156 E-173-2016-0 E-173-2016-0-US-08 MULTI-DIMENSIONAL SPECTROSCOPIC NMR AND MRI USING MARGINAL DISTRIBUTIONS CON US 11,846,690 17/863,846 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11846690 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11846690">11,846,690</a><br />Filed on 2022-07-13<br />Status: Issued 147173004 Basser 147173005 Biomarkers 147173007 Diffusion MRI 147173008 IMAGING 147173010 Marginal-Distributions 147173011 MRI 147173012 MRI diagnostic 147173014 Multidimensional-NMR 147173016 NMR-Spectroscopy 147173018 Relaxometry Diffusometry 147173019 T1 147173020 T2 TAB-4033 147157314 Conserved Elements Vaccine for HIV NCI Collaboration, Infectious Disease, Licensing, Vaccines Collaboration Infectious Disease Licensing Vaccines Barbara Felber, James Mullins, George Pavlakis <p>The development of an effective HIV vaccine has been an ongoing area of research. High variability in HIV-1 virus strains, however,  represents a major challenge.  Ideally, an effective candidate vaccine would provide protection against the majority of clades of HIV.  Two major hurdles to overcome are immunodominance and sequence diversity. Researchers at the National Cancer Institute (NCI) have developed a vaccine that overcomes these major hurdles by utilizing a strategy that identifies conserved regions of the virus and exploits them for use in a targeted therapy.</p> <p>NCI researchers used conserved elements (CEs) of the polypeptide Gag as an immunogenic composition to induce an immune response to HIV-1.  This invention is based, in part, on the discovery that the administration of one or more polypeptides comprising seven CEs of HIV Gag provides a robust immune response compared to administration of a full-length Gag protein.  In vivo studies of rhesus macaques vaccinated with variants of these constructs elicited strong, cellular T-cell and humoral antibody immune responses. The Gag-specific antibody responses were high titer and cross-clade. </p> <p>A robust increase in immunity was observed when rhesus macaques were subjected to a prime-boost protocol.  Rhesus macaques primed with Gag-CE DNA and boosted with full length Gag had increased cellular and humoral responses.  The CE vaccines described in this invention are potential prophylactic and therapeutic HIV vaccines.</p> <h2>Competitive Advantages:</h2> <ul><li>Addresses two key hurdles faced by current HIV vaccines: sequence diversity of HIV and immunodominance.</li> <li>Induces cross-clade cellular and humoral responses. </li> </ul> <h2>Commercial Applications:</h2> <ul><li>Prophylactic and therapeutic vaccines for HIV-1 infection </li> </ul> 2017-12-07 2025-04-22 2019-06-28 2025-04-22 2017-12-07 Conserved Elements, DNA vaccine, HIV, Pavlakis, Prime-boost Vaccination, Vaccine False True Clinical True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2019-06-28 72159138 Clinical Phase I 72159138 NCI 37470483 Website Abstract E-087-2015 147162271 Hu X., et al. https://www.ncbi.nlm.nih.gov/pubmed/28678607 <a href="https://www.ncbi.nlm.nih.gov/pubmed/28678607">Hu X., et al.</a> 147162424 Hu X., et al. https://www.ncbi.nlm.nih.gov/pubmed/27733554 <a href="https://www.ncbi.nlm.nih.gov/pubmed/27733554">Hu X., et al.</a> 147163287 Pavlakis, George NIH - NCI NCI Pavlakis, George (NCI) 1 147163288 Felber, Barbara NIH - NCI NCI Felber, Barbara (NCI) 2 147163289 Mullins, James University of Washington Mullins, James 3 147163287 Pavlakis, George NIH - NCI NCI Pavlakis, George (NCI) 1 147163288 Felber, Barbara NIH - NCI NCI Felber, Barbara (NCI) 2 147163289 Mullins, James University of Washington Mullins, James 3 147158048 Novel Vaccination Method To Alter The Breath And Immunodominant Hierarchy Of Immune Responses E-132-2012-0 Filing authorized NCI, University of Washington 91814193 Freel, Rose rose.freel@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America rose.freel@nih.gov?subject=Web Inquiry on [TAB-4033] Conserved Elements Vaccine for HIV&body=Please send me information about technology [TAB-4033] Conserved Elements Vaccine for HIV.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Freel, Rose<br><a href="mailto:rose.freel@nih.gov?subject=Web Inquiry on [TAB-4033] Conserved Elements Vaccine for HIV&body=Please send me information about technology [TAB-4033] Conserved Elements Vaccine for HIV.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">rose.freel@nih.gov</a><br> 147166122 E-132-2012-0 E-132-2012-0-US-01 Altering the Immunodominance Hierarchy of HIV GAG by DNA Vaccine Expressing Conserved Regions PRV US 61/606,265 Abandoned US <br />Provisional (PRV) 61/606,265<br />Filed on 2012-03-02<br />Status: Abandoned 147166123 E-132-2012-0 E-132-2012-0-PCT-02 Method of Altering the Immunodominance Hierarchy of HIV Gag by DNA Vaccine Expressing Conserved Regions PCT Patent Cooperation Treaty PCT/US2013/028932 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2013/028932<br />Filed on 2013-03-04<br />Status: Expired 147166124 E-132-2012-0 E-132-2012-0-EP-03 Method of Altering the Immunodominance Hierarchy of HIV Gag by DNA Vaccine Expressing Conserved Regions National Stage European Patent 2820035 13710247.1 Issued European Patent <br />National Stage 13710247.1<br />Filed on 2013-03-04<br />Status: Issued 147166125 E-132-2012-0 E-132-2012-0-US-04 Method of Altering the Immunodominance Hierarchy of HIV Gag by DNA Vaccine Expressing Conserved Regions National Stage US 9,415,099 14/382,281 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9415099 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9415099">9,415,099</a><br />Filed on 2014-08-29<br />Status: Issued 147166126 E-132-2012-0 E-132-2012-0-US-05 ALTERING THE IMMUNODOMINANCE HIERARCHY USING A DNA VACCINE EXPRESSING CONSERVED REGIONS CON US 10,426,830 15/235,430 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10426830 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10426830">10,426,830</a><br />Filed on 2016-08-12<br />Status: Issued 147166127 E-132-2012-0 E-132-2012-0-CH-06 Method of Altering the Immunodominance Hierarchy of HIV Gag by DNA Vaccine Expressing Conserved Regions EP Switzerland 2820035 13710247.1 Issued Switzerland <br />European patent (EP) 13710247.1<br />Filed on 2013-03-04<br />Status: Issued 147166128 E-132-2012-0 E-132-2012-0-DE-07 Method of Altering the Immunodominance Hierarchy of HIV Gag by DNA Vaccine Expressing Conserved Regions EP Germany 2820035 13710247.1 Issued Germany <br />European patent (EP) 13710247.1<br />Filed on 2013-03-04<br />Status: Issued 147166129 E-132-2012-0 E-132-2012-0-ES-08 Method of Altering the Immunodominance Hierarchy of HIV Gag by DNA Vaccine Expressing Conserved Regions EP Spain 2820035 13710247.1 Issued Spain <br />European patent (EP) 13710247.1<br />Filed on 2013-03-04<br />Status: Issued 147166130 E-132-2012-0 E-132-2012-0-FR-09 Method of Altering the Immunodominance Hierarchy of HIV Gag by DNA Vaccine Expressing Conserved Regions EP France 2820035 13710247.1 Issued France <br />European patent (EP) 13710247.1<br />Filed on 2013-03-04<br />Status: Issued 147166131 E-132-2012-0 E-132-2012-0-GB-10 Method of Altering the Immunodominance Hierarchy of HIV Gag by DNA Vaccine Expressing Conserved Regions EP United Kingdom 2820035 13710247.1 Issued United Kingdom <br />European patent (EP) 13710247.1<br />Filed on 2013-03-04<br />Status: Issued 147166132 E-132-2012-0 E-132-2012-0-US-11 Altering the lmmundominance Hierarchy Using a DNA Vaccine Expressing Conserved Regions DIV US 11,167,025 16/554,133 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11167025 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11167025">11,167,025</a><br />Filed on 2019-08-28<br />Status: Issued 147166133 E-132-2012-0 E-132-2012-0-US-12 ALTERING THE IMMUNDOMINANCE HIERARCHY USING A DNA VACCINE EXPRESSING CONSERVED REGIONS CON US 17/511,499 Abandoned US <br />Continuation (CON) 17/511,499<br />Filed on 2021-10-26<br />Status: Abandoned 147172075 Conserved Elements 147172076 DNA vaccine 147172077 HIV 147172078 Pavlakis 147172080 Prime-boost Vaccination 147172081 Vaccine TAB-4451 147157746 Cancer-reactive T cells from Peripheral Blood NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Alena Gros, Steven Rosenberg <p>Adoptive cell therapy (ACT) using genetically engineered T-cell receptors (TCRs) is a promising cancer treatment. These TCRs target genetic mutations unique to patients and play an important role in tumor regression. However, mutation-reactive T-cells and their TCRs can be difficult to identify and isolate from patients. Therefore, we need more efficient methods of isolating mutation-reactive T-cells for use with ACT. </p> <p>Researchers at the National Cancer Institute (NCI) have developed a novel method of isolating mutation-reactive T-cells from a patient’s peripheral blood lymphocytes (PBL). The researchers found that mutation-reactive T-cells in the PBL are enriched with various markers including CD8, programmed cell death 1 (PD-1), and T cell immunoglobulin and mucin domain 3 (TIM-3). These T-cells and their TCRs can be isolated from the blood and then administered to patients as a cancer therapeutic.</p> <p>The National Cancer Institute, Surgery Branch, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this method of isolating mutation-reactive T-cells from peripheral blood.</p> <h2>Competitive Advantages:</h2> <p>• Applicable to patients without tumors available for resection<br /> • More cost effective compared to surgical resection for procurement of tumor infiltrating lymphocytes</p> <h2>Commercial Applications:</h2> <p>• Personalized immunotherapy to treat cancer patients<br /> • Research tool to identify T-cells and TCRs targeting patient-specific mutation</p> 2018-02-16 2025-04-22 2018-02-16 2025-04-22 2018-02-16 CANCER, Gros, Immunotherapy, mutation-reactive T-cells, Rosenberg, T-Cell Receptor, T-CELLS, TCR False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2018-02-16 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-229-2014 E-233-2014 E-269-2015 147162118 Gros A, et al, Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients. https://www.ncbi.nlm.nih.gov/pubmed/26901407 <a href="https://www.ncbi.nlm.nih.gov/pubmed/26901407">Gros A, et al, Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients.</a> 147162196 Gros A, et al. PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors. https://www.ncbi.nlm.nih.gov/pubmed/24667641 <a href="https://www.ncbi.nlm.nih.gov/pubmed/24667641">Gros A, et al. PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors.</a> 147164785 Gros, Alena NIH - NCI NCI Gros, Alena (NCI) 1 147164784 Rosenberg, Steven NIH - NCI NCI Rosenberg, Steven (NCI) 2 147164785 Gros, Alena NIH - NCI NCI Gros, Alena (NCI) 1 147164784 Rosenberg, Steven NIH - NCI NCI Rosenberg, Steven (NCI) 2 147158079 Selection Of CD8+ PD-1+, CD8+PD-1+TIM-3+CD8+TIM-3+CD27hi Cells From Peripheral Blood Of Cancer Patients For The Isolation Of Mutation Specific T-cells And T-cell Receptors To Treat Patients With Cancer E-149-2015-0 Filing authorized NCI 83709866 Burke, Andrew burkear@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC burkear@nih.gov?subject=Web Inquiry on [TAB-4451] Cancer-reactive T cells from Peripheral Blood&body=Please send me information about technology [TAB-4451] Cancer-reactive T cells from Peripheral Blood.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Burke, Andrew<br><a href="mailto:burkear@nih.gov?subject=Web Inquiry on [TAB-4451] Cancer-reactive T cells from Peripheral Blood&body=Please send me information about technology [TAB-4451] Cancer-reactive T cells from Peripheral Blood.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">burkear@nih.gov</a><br> 147161106 E-149-2015-0 E-149-2015-0-US-01 Methods of Isolating T Cells and T Cell Receptors Having Antigenic Specificity for a Cancer-Specific Mutation From Peripheral Blood PRV US 62/155,830 Abandoned US <br />Provisional (PRV) 62/155,830<br />Filed on 2015-05-01<br />Status: Abandoned 147168984 E-149-2015-0 E-149-2015-0-PCT-02 METHODS OF ISOLATING T CELLS AND T CELL RECEPTORS HAVING ANTIGENIC SPECIFICITY FOR A CANCER-SPECIFIC MUTATION FROM PERIPHERAL BLOOD PCT Patent Cooperation Treaty PCT/US2016/030137 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2016/030137<br />Filed on 2016-04-29<br />Status: Expired 147168985 E-149-2015-0 E-149-2015-0-AU-03 Methods of Isolating T Cells and T Cell Receptors Having Antigen Specificaity for a Cancer-Specific Mutation from Peripheral Blood National Stage Australia 2016258845 2016258845 Issued Australia <br />National Stage 2016258845<br />Filed on 2017-10-20<br />Status: Issued 147168986 E-149-2015-0 E-149-2015-0-CA-04 Methods of Isolating T Cells and T Cell Receptors Having Antigen Specificaity for a Cancer-Specific Mutation from Peripheral Blood National Stage Canada 2984234 2984234 Issued Canada <br />National Stage 2984234<br />Filed on 2016-04-29<br />Status: Issued 147168987 E-149-2015-0 E-149-2015-0-US-05 METHODS OF ISOLATING T CELLS AND T CELL RECEPTORS HAVING ANTIGENIC SPECIFICITY FOR A CANCER-SPECIFIC MUTATION FROM PERIPHERAL BLOOD National Stage US 10,544,392 15/567,157 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10544392 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10544392">10,544,392</a><br />Filed on 2017-10-17<br />Status: Issued 147168988 E-149-2015-0 E-149-2015-0-US-06 METHODS OF ISOLATING T CELLS AND T CELL RECEPTORS HAVING ANTIGENIC SPECIFICITY FOR A CANCER-SPECIFIC MUTATION FROM PERIPHERAL BLOOD DIV US 11,629,334 16/710,287 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11629334 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11629334">11,629,334</a><br />Filed on 2019-12-11<br />Status: Issued 147168989 E-149-2015-0 E-149-2015-0-AU-07 Methods of Isolating T Cells and T Cell Receptors Having Antigen Specificity for a Cancer-Specific Mutation from Peripheral Blood DIV Australia 2022203507 2022203507 Issued Australia <br />Divisional (DIV) 2022203507<br />Filed on 2022-05-24<br />Status: Issued 147168990 E-149-2015-0 E-149-2015-0-US-02 METHODS OF ISOLATING T CELLS AND T CELL RECEPTORS HAVING ANTIGENIC SPECIFICITY FOR A CANCER-SPECIFIC MUTATION FROM PERIPHERAL BLOOD CON US 12,630,802 18/174,928 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12630802 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12630802">12,630,802</a><br />Filed on 2023-02-27<br />Status: Issued 147172352 CANCER 147172354 Gros 147172355 Immunotherapy 147172357 mutation-reactive T-cells 147172358 Rosenberg 147172359 T-Cell Receptor 147172360 T-CELLS 147172361 TCR TAB-4194 147157479 Peptide Mimetic Ligands of Polo-like Kinase 1 Polo Box Domain NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Terrence Burke, James Kelley, Kyung Lee, Jung-Eun Park, Wen-Jian Qian <p>Polo-like kinase 1 (Plk1) is a critical protein involved in regulation of mitosis, and aberrant expression of this kinase is found in various cancer types.  Inhibition of Plk1 is currently being pursued in pre-clinical drug development for novel anti-cancer therapeutics.  Plk1 contains an allosteric domain, known as the polo-box domain (PBD), that is responsible for localizing the kinase domain to mitotic structures through protein-protein interactions.  </p> <p>This technology is an improvement and continuation of Dr. Terry Burke’s research program centered around PBD modulation. The “Plk1 PBD” portfolio focuses on compounds that disrupt Plk1-mediated protein interactions. These compounds are designed to selectively cause mitotic arrest in cancer cells with abnormal Plk1 expression by inhibiting proper localization of Plk1.  </p> <p>The invention is directed to improved design and synthesis of peptidomimetic ligands that bind PBD by attaching a pivaloyloxymethyl (“POM”) group and/or by utilizing intramolecular charge masking. Invention peptides exhibit enhanced bioavailability and good efficacy. The invention also provides design and synthesis of phosphoryl-derived peptidomimetics that bind PBD.   </p> <p>Related technologies within the Plk1 PBD portfolio currently consist of:</p> <p>(1) E-181-2009 “Peptide Mimetic Ligands of Polo-like Kinase 1 Polo Box Domain”;<br /> (2) E-186-2015 “Efficient synthesis of 2-amino-3-methyl-4-phosphonobutanoic acid, a phosphatase stable phosphor-amino acid analog”;<br /> (3) E-254-2016 (closed) “Fragment-based Optimization of Ligand interactions within a key cryptic binding pocket of Plk1 PBD;<br /> (4) E-178-2017 “Bivalent Ligands of Plk-1 that exhibit Exceptional Affinity”; and<br /> (5) E-179-2017 “Macrocyclic Peptidomimetic of Plk-1 PBD”.</p> <h2>Competitive Advantages:</h2> <ul><li>Mechanism of Plk1 down-regulation is different from agents that bind at the Plk1 kinase domain ("classical kinase inhibitors")</li> <li>Due to the uniqueness of polo-box domains to the Plk family of kinases, PBD-directed inhibitors may afford selectivity advantages over classical kinase inhibitors</li> <li>Among the highest affinity Plk1 PBD-binding ligands known</li> <li>Enhanced bioavailability and good efficacy</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Disruption of Plk1-driven cellular proliferation</li> <li>Anticancer therapies</li> <li>Complimentarity to anticancer treatment when used with Plk1 kinase inhibitors</li> </ul> 2018-02-16 2025-04-22 2018-04-18 2025-04-22 2018-02-16 Burke, CANCER, mitosis, Peptide Inhibitor, polo-box domain (PBD), Polo-like kinase 1 (Plk1), therapeutic False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2018-04-18 52406768 Discovery 52406768 NCI 37470483 Website Abstract E-178-2017 E-179-2017 E-181-2009 E-186-2015 E-254-2016 147161918 X. Zhao et al. Application of oxime-diversification to optimize ligand interactions within a crytpic pocket of the polo-like kinase 1 polo-box domain. https://www.ncbi.nlm.nih.gov/pubmed/27624074 <a href="https://www.ncbi.nlm.nih.gov/pubmed/27624074">X. Zhao et al. Application of oxime-diversification to optimize ligand interactions within a crytpic pocket of the polo-like kinase 1 polo-box domain.</a> 147161956 D. Hymel et al. Phosphatase-stable phosphoamino acid mimetics that enhance binding affinities with the polo-box domain of polo-like kinase 1. https://www.ncbi.nlm.nih.gov/pubmed/27992122 <a href="https://www.ncbi.nlm.nih.gov/pubmed/27992122">D. Hymel et al. Phosphatase-stable phosphoamino acid mimetics that enhance binding affinities with the polo-box domain of polo-like kinase 1.</a> 147162343 X. Zhao et al. Enhancing polo-like kinase 1 selectivity of polo-box domain-binding peptides https://www.ncbi.nlm.nih.gov/pubmed/28285924 <a href="https://www.ncbi.nlm.nih.gov/pubmed/28285924">X. Zhao et al. Enhancing polo-like kinase 1 selectivity of polo-box domain-binding peptides</a> 147163859 Burke, Terrence NIH - NCI NCI Burke, Terrence (NCI) 1 147163861 Qian, Wen-Jian NIH - NCI Qian, Wen-Jian 2 147163858 Lee, Kyung NIH - NCI NCI Lee, Kyung (NCI) 3 147163860 Park, Jung-Eun NIH - NCI NCI Park, Jung-Eun (NCI) 4 147163862 Kelley, James NIH - NCI NCI Kelley, James (NCI) 6 147163859 Burke, Terrence NIH - NCI NCI Burke, Terrence (NCI) 1 147163861 Qian, Wen-Jian NIH - NCI Qian, Wen-Jian 2 147163858 Lee, Kyung NIH - NCI NCI Lee, Kyung (NCI) 3 147163860 Park, Jung-Eun NIH - NCI NCI Park, Jung-Eun (NCI) 4 147163862 Kelley, James NIH - NCI NCI Kelley, James (NCI) 6 147157973 Pivaloyloxymethyl (POM)-protected Peptide And Peptide Mimetic Binding Antagonists Of Polo-like Kinase 1 Polo Box Domain And Methods Of Use E-094-2013-0 Filing authorized NCI 147162525 Peptide And Peptide Mimetic Binding Antagonists Of Polo-like Kinase 1 Polo Box Domain E-094-2013-1 Closed NCI 91814193 Freel, Rose rose.freel@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America rose.freel@nih.gov?subject=Web Inquiry on [TAB-4194] Peptide Mimetic Ligands of Polo-like Kinase 1 Polo Box Domain&body=Please send me information about technology [TAB-4194] Peptide Mimetic Ligands of Polo-like Kinase 1 Polo Box Domain.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Freel, Rose<br><a href="mailto:rose.freel@nih.gov?subject=Web Inquiry on [TAB-4194] Peptide Mimetic Ligands of Polo-like Kinase 1 Polo Box Domain&body=Please send me information about technology [TAB-4194] Peptide Mimetic Ligands of Polo-like Kinase 1 Polo Box Domain.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">rose.freel@nih.gov</a><br> 147167272 E-094-2013-0 E-094-2013-0-US-01 Peptide and Peptide Mimetic Binding Antagonists of Polo-like Kinase 1 Polo Box Domain and Methods of Use PRV US 61/784,971 Abandoned US <br />Provisional (PRV) 61/784,971<br />Filed on 2013-03-14<br />Status: Abandoned 147167273 E-094-2013-0 E-094-2013-0-PCT-02 PEPTIDE AND PEPTIDE MIMETIC BINDING ANTAGONISTS OF POLO-LIKE KINASE 1 POLO BOX DOMAIN AND METHODS OF USE PCT Patent Cooperation Treaty PCT/US2014/029071 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2014/029071<br />Filed on 2014-03-14<br />Status: Expired 147167274 E-094-2013-0 E-094-2013-0-US-03 Peptide And Peptide Mimetic Binding Antagonists Of Polo-like Kinase 1 Polo Box Domain And Methods Of Use National Stage US 10,047,122 14/776,512 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10047122 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10047122">10,047,122</a><br />Filed on 2015-09-14<br />Status: Issued 147171272 Burke 147171273 CANCER 147171274 mitosis 147171275 Peptide Inhibitor 147171277 polo-box domain (PBD) 147171279 Polo-like kinase 1 (Plk1) 147171280 therapeutic TAB-3895 147157175 Peptide Mimetic Ligands of Polo-like Kinase 1 Polo Box Domain (“Plk1 PBD Portfolio”) NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Terrence Burke, Kyung Lee, Fa Liu, Jung-Eun Park, Wen-Jian Qian <p>Polo-like kinase 1 (Plk1) is a critical protein involved in regulation of mitosis, and aberrant expression of this kinase is found in various cancer types.  Inhibition of Plk1 is currently being pursued in pre-clinical drug development for novel anti-cancer therapeutics.  Plk1 contains an allosteric domain, known as the polo-box domain (PBD), that is responsible for localizing the kinase domain to mitotic structures through protein-protein interactions.  </p> <p>The invention is directed to improved peptidomimetic inhibitors that disrupt Plk1-mediated protein interactions by targeting PBD.  These compounds are designed to selectively cause mitotic arrest in cancer cells with abnormal Plk1 expression by inhibiting proper localization of Plk1.  In doing so, such ligands could avoid issues of off-target activity and dose-limiting toxicities that are characteristic of some ATP-competitive kinase inhibitors. </p> <p>This invention is an improvement and continuation of Dr. Terry Burke’s research program centered around PBD inhibition. Related technologies within the “Plk1 PBD” portfolio currently consist of:</p> <p>(1) E-181-2009;<br /> (2) E-094-2013 “Peptidomimetic antagonists of Plk-1 PBD”;<br /> (3) E-186-2015 “Efficient synthesis of 2-amino-3-methyl-4-phosphonobutanoic acid, a phosphatase stable phosphor-amino acid analog”;<br /> (4) E-254-2016 (closed) “Fragment-based Optimization of Ligand interactions within a key cryptic binding pocket of Plk1 PBD;<br /> (5) E-178-2017 “Bivalent Ligands of Plk-1 that exhibit Exceptional Affinity”; and<br /> (6) E-179-2017 “Macrocyclic Peptidomimetic of Plk-1 PBD”.</p> <h2>Competitive Advantages:</h2> <p>• Mechanism of Plk1 down-regulation is different from agents that bind at the Plk1 kinase domain ("classical kinase inhibitors").<br /> • Due to the uniqueness of polo-box domains to the Plk family of kinases, selectivity, PBD-directed inhibitors may afford selectivity advantages over classical kinase inhibitors. <br /> • Among the highest affinity Plk1 PBD-binding ligands known.</p> <h2>Commercial Applications:</h2> <p>• Disruption of Plk1-driven cellular proliferation.<br /> • Potential new approach to anticancer therapies.<br /> • May afford complementarity to anticancer treatment when used with Plk1 kinase inhibitors.</p> 2018-02-16 2025-04-22 2018-02-16 2025-04-22 2018-02-16 Burke, CANCER, mitosis, Peptide Inhibitor, polo-box domain (PBD), Polo-like kinase 1 (Plk1), therapeutic False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2018-02-16 52406768 Discovery 52406768 NCI 37470483 Website Abstract E-094-2013 E-178-2017 E-179-2017 E-186-2015 E-254-2016 147161930 Zhao XZ, et al. Enhancing polo-like kinase 1 selectivity of polo-box domain-binding peptides, (Symposium in Print on &quot;Bioactive Molecules&quot;). https://www.ncbi.nlm.nih.gov/pubmed/?term=PMID%3A+28285924 <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=PMID%3A+28285924">Zhao XZ, et al. Enhancing polo-like kinase 1 selectivity of polo-box domain-binding peptides, (Symposium in Print on &quot;Bioactive Molecules&quot;).</a> 147161968 Hymel D, et al. Phosphatase-stable phosphoamino acid mimetics that enhance binding affinities with the polo-box domain of polo-like kinase 1. https://www.ncbi.nlm.nih.gov/pubmed/27992122 <a href="https://www.ncbi.nlm.nih.gov/pubmed/27992122">Hymel D, et al. Phosphatase-stable phosphoamino acid mimetics that enhance binding affinities with the polo-box domain of polo-like kinase 1.</a> 147162471 Zhao XZ, et al. Application of oxime-diversification to optimize ligand interactions within a crytpic pocket of the polo-like kinase 1 polo-box domain. https://www.ncbi.nlm.nih.gov/pubmed/?term=PMID%3A+27624074 <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=PMID%3A+27624074">Zhao XZ, et al. Application of oxime-diversification to optimize ligand interactions within a crytpic pocket of the polo-like kinase 1 polo-box domain.</a> 147162779 Burke, Terrence NIH - NCI NCI Burke, Terrence (NCI) 1 147162781 Park, Jung-Eun NIH - NCI NCI Park, Jung-Eun (NCI) 2 147162782 Qian, Wen-Jian NIH - NCI Qian, Wen-Jian 2 147162780 Liu, Fa NIH - NCI Liu, Fa 3 147162778 Lee, Kyung NIH - NCI NCI Lee, Kyung (NCI) 4 147162779 Burke, Terrence NIH - NCI NCI Burke, Terrence (NCI) 1 147162781 Park, Jung-Eun NIH - NCI NCI Park, Jung-Eun (NCI) 2 147162782 Qian, Wen-Jian NIH - NCI Qian, Wen-Jian 2 147162780 Liu, Fa NIH - NCI Liu, Fa 3 147162778 Lee, Kyung NIH - NCI NCI Lee, Kyung (NCI) 4 147158158 Development Of Peptide Mimetic Ligands Of Polo-like Kinase L Polo Box Domain E-181-2009-0 Filing authorized NCI 147162548 Development Of Novel Peptide Mimetic Ligands Of Polo-like Kinase 1 Polo Box Domain:Part 2 E-181-2009-1 Filing authorized NCI 147162549 Development Of Peptide Mimetic Ligands Of Polo-like Kinase L Polo Box Domain E-181-2009-2 Filing authorized NCI 147162550 Development Of Peptide Mimetic Ligands Of Polo-like Kinase 1 Polo Box Domain: Part 3 E-181-2009-3 Filing authorized NCI 147162551 Development Of Peptide Mimetic Ligands Of Polo-like Kinase 1 Polo Box Domain: Part 3 E-181-2009-4 Filing authorized Eli Lilly and Company, NCI 91814193 Freel, Rose rose.freel@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America rose.freel@nih.gov?subject=Web Inquiry on [TAB-3895] Peptide Mimetic Ligands of Polo-like Kinase 1 Polo Box Domain (“Plk1 PBD Portfolio”)&body=Please send me information about technology [TAB-3895] Peptide Mimetic Ligands of Polo-like Kinase 1 Polo Box Domain (“Plk1 PBD Portfolio”).&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Freel, Rose<br><a href="mailto:rose.freel@nih.gov?subject=Web Inquiry on [TAB-3895] Peptide Mimetic Ligands of Polo-like Kinase 1 Polo Box Domain (“Plk1 PBD Portfolio”)&body=Please send me information about technology [TAB-3895] Peptide Mimetic Ligands of Polo-like Kinase 1 Polo Box Domain (“Plk1 PBD Portfolio”).&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">rose.freel@nih.gov</a><br> 147165103 E-181-2009-0 E-181-2009-0-US-01 Development Of Peptide Mimetic Ligands Of Polo-like Kinase L Polo Box Domain PRV US 61/178,593 Abandoned US <br />Provisional (PRV) 61/178,593<br />Filed on 2009-05-15<br />Status: Abandoned 147165105 E-181-2009-1 E-181-2009-1-US-01 Development Of Novel Peptide Mimetic Ligands Of Polo-like Kinase 1 Polo Box Domain:Part 2 PRV US 61/300,349 Abandoned US <br />Provisional (PRV) 61/300,349<br />Filed on 2010-02-01<br />Status: Abandoned 147165106 E-181-2009-2 E-181-2009-2-PCT-01 Development Of Peptide Mimetic Ligands Of Polo-like Kinase L Polo Box Domain PCT COMB Patent Cooperation Treaty PCT/US2010/035069 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2010/035069<br />Filed on 2010-05-17<br />Status: Expired 147165108 E-181-2009-2 E-181-2009-2-US-02 Peptide Mimetic Ligands Of Polo-like Kinase L Polo Box Domain and Methods of Use National Stage US 9,175,038 13/320,726 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9175038 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9175038">9,175,038</a><br />Filed on 2011-11-15<br />Status: Abandoned 147165110 E-181-2009-3 E-181-2009-3-US-01 Peptide Mimetic Ligands Of Polo-like Kinase 1 Polo Box Domain And Methods of Use PRV US 61/474,621 Abandoned US <br />Provisional (PRV) 61/474,621<br />Filed on 2011-04-12<br />Status: Abandoned 147165112 E-181-2009-4 E-181-2009-4-PCT-01 Peptide Mimetic Ligands of Polo-like Kinase1 Polo Box Domain and Method of Use PCT COMB Patent Cooperation Treaty PCT/US2012/033259 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2012/033259<br />Filed on 2012-04-12<br />Status: Expired 147165113 E-181-2009-4 E-181-2009-4-AU-02 Peptide and Peptide Mimetic Binding Antagonists of Polo-like Kinase1 Polo Box Domain and Methods of Use National Stage Australia 2012242784 2012242784 Abandoned Australia <br />National Stage 2012242784<br />Filed on 2012-04-12<br />Status: Abandoned 147165114 E-181-2009-4 E-181-2009-4-CA-03 Peptide Mimetic Ligands of Polo-like Kinase1 Polo Box Domain and Method of Use National Stage Canada 2832073 Abandoned Canada <br />National Stage 2832073<br />Filed on 2012-04-12<br />Status: Abandoned 147165115 E-181-2009-4 E-181-2009-4-EP-04 Peptide Mimetic Binding Ligands of Polo-like Kinase1 Polo Box Domain and Methods of Use National Stage European Patent 12722945.8 Abandoned European Patent <br />National Stage 12722945.8<br />Filed on 2012-04-12<br />Status: Abandoned 147165116 E-181-2009-4 E-181-2009-4-JP-05 Peptide Mimetic Ligands of Polo-like Kinase1 Polo Box Domain and Method of Use National Stage Japan 2014-505275 Abandoned Japan <br />National Stage 2014-505275<br />Filed on 2013-10-11<br />Status: Abandoned 147165117 E-181-2009-4 E-181-2009-4-US-06 Peptide Mimetic Ligands Of Polo-like Kinase 1 Polo Box Domain and Methods of Use National Stage US 10,266,565 14/111,540 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10266565 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10266565">10,266,565</a><br />Filed on 2013-10-11<br />Status: Issued 147173116 Burke 147173117 CANCER 147173118 mitosis 147173119 Peptide Inhibitor 147173120 polo-box domain (PBD) 147173121 Polo-like kinase 1 (Plk1) 147173122 therapeutic TAB-3964 147157244 Tni-FNL: An Improved Trichoplusia Ni Cell Line for Protein Expression NCI Licensing, Oncology, Research Materials Licensing Oncology Research Materials Dominic Esposito, Ralph (Butch) Hopkins, Veronica Roberts <p>Researchers at the National Cancer Institute (NCI) have developed an improved insect cell line, Tni-FNL, derived from the cabbage looper, Trichoplusia ni.  The Tni-FNL cell line is capable of high level expression of heterologous proteins using baculovirus-based expression systems.  When compared to commercially available cell lines used for the same purpose, the Tni-FNL cell line often outperforms those for protein expression.  These cells have a high growth rate and are capable of growth at a lower temperature. The complete genome sequence of the Tni-FNL cell line has been determined, opening the door to systems biology approaches to further improve the protein expression capabilities of the cell line. </p> <h2>Competitive Advantages:</h2> <ul><li>In side-by-side comparisons with other insect cell lines, this cell line outperforms for protein production for several different proteins tested</li> <li>Cell line has a highly robust growth rate, including at lower temperatures</li> <li>Cell line genome sequence was determined to a coverage and accuracy far exceeding any other lepidopteran cell line or host organism</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Research tool for production of protein</li> <li>Target organism for advanced systems biology approaches to improve protein production </li> </ul> 2018-03-02 2025-04-22 2021-01-26 2025-04-22 2018-03-02 Baculovirus, Cell line, Esposito, Insect Cell, Protein Expression, Tni-FNL False True Prototype True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-01-26 52406769 Prototype 52406769 NCI 37470483 Website Abstract E-009-2015 147161924 Gillette WK, et al. Farnesylated and methylated KRAS4b: high yield production of protein suitable for biophysical studies of prenylated protein-lipid interactions. (PMID: 26522388) https://www.ncbi.nlm.nih.gov/pubmed/26522388 <a href="https://www.ncbi.nlm.nih.gov/pubmed/26522388">Gillette WK, et al. Farnesylated and methylated KRAS4b: high yield production of protein suitable for biophysical studies of prenylated protein-lipid interactions. (PMID: 26522388)</a> 147163037 Esposito, Dominic NIH - NCI Leidos Esposito, Dominic (Leidos) 1 147163038 Hopkins, Ralph (Butch) NIH - NCI Leidos Hopkins, Ralph (Butch) (Leidos) 2 147163039 Roberts, Veronica NIH - NCI Leidos Roberts, Veronica (Leidos) 3 147163037 Esposito, Dominic NIH - NCI Leidos Esposito, Dominic (Leidos) 1 147163038 Hopkins, Ralph (Butch) NIH - NCI Leidos Hopkins, Ralph (Butch) (Leidos) 2 147163039 Roberts, Veronica NIH - NCI Leidos Roberts, Veronica (Leidos) 3 147158077 Tni-FNL: An Improved Trichopulusia Ni Cell Line For Protein Expression E-146-2017-0 Research Material NCI 91814193 Freel, Rose rose.freel@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America rose.freel@nih.gov?subject=Web Inquiry on [TAB-3964] Tni-FNL: An Improved Trichoplusia Ni Cell Line for Protein Expression&body=Please send me information about technology [TAB-3964] Tni-FNL: An Improved Trichoplusia Ni Cell Line for Protein Expression.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Freel, Rose<br><a href="mailto:rose.freel@nih.gov?subject=Web Inquiry on [TAB-3964] Tni-FNL: An Improved Trichoplusia Ni Cell Line for Protein Expression&body=Please send me information about technology [TAB-3964] Tni-FNL: An Improved Trichoplusia Ni Cell Line for Protein Expression.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">rose.freel@nih.gov</a><br> 147172326 Baculovirus 147172327 Cell line 147172328 Esposito 147172330 Insect Cell 147172331 Protein Expression 147172333 Tni-FNL TAB-4366 147157660 Methods for Single Cell Analysis of the Epigenome, Transcriptome, and Genome NCI Collaboration, Diagnostics, Licensing, Oncology Collaboration Diagnostics Licensing Oncology Hidetaka Ohnuki, Giovanna Tosato <p>There are currently no methodologies that allow for epigenome, genome and transcriptome analysis all in a single cell. In addition, there are currently no methodologies that permit repeating the results of these analyses on the same single cells.</p> <p>Scientists at the National Cancer Institute (NCI) <a href="https://ccr.cancer.gov/Laboratory-of-Cellular-Oncology" rel="nofollow">Laboratory of Cellular Oncology</a> have developed a method for generating a “reusable” single cell by crosslinking cellular proteins and DNA to a polyacrylamide scaffold, thus preserving the proteins and genomic DNA in their location even after repeated experiments on the same cell. Given the reusability of the cell, each experiment can be repeated multiple times, and statistical analysis can be applied to validate the results from single cells.  Methods for detecting epigenetic changes using this methodology are also disclosed.  </p> <h2>Competitive Advantages:</h2> <ul><li>The ability to “reuse” a single cell overcomes major issues that currently impair single cell analysis, such as analyzing multiple epigenetic modifications, lack of reproducibility controls, and statistical analysis</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Research Tool</li> <li>Diagnostic Assays</li> </ul><p> </p> 2018-03-13 2025-04-22 2018-03-13 2025-04-22 2018-03-13 diagnostic, Epigenomic, Genomic, RESEARCH TOOL, Single Cell Analysis, Tosato, Transcriptomic False True Basic (Target Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2018-03-13 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147164456 Tosato, Giovanna NIH - NCI NCI Tosato, Giovanna (NCI) 1 147164457 Ohnuki, Hidetaka NIH - NCI NCI Ohnuki, Hidetaka (NCI) 2 147164456 Tosato, Giovanna NIH - NCI NCI Tosato, Giovanna (NCI) 1 147164457 Ohnuki, Hidetaka NIH - NCI NCI Ohnuki, Hidetaka (NCI) 2 147157922 A New Method For Single-cell, Triple Omics Analysis E-069-2017-0 Filing authorized NCI 83691647 Chang, Kevin changke@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB changke@mail.nih.gov?subject=Web Inquiry on [TAB-4366] Methods for Single Cell Analysis of the Epigenome, Transcriptome, and Genome&body=Please send me information about technology [TAB-4366] Methods for Single Cell Analysis of the Epigenome, Transcriptome, and Genome.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Chang, Kevin<br><a href="mailto:changke@mail.nih.gov?subject=Web Inquiry on [TAB-4366] Methods for Single Cell Analysis of the Epigenome, Transcriptome, and Genome&body=Please send me information about technology [TAB-4366] Methods for Single Cell Analysis of the Epigenome, Transcriptome, and Genome.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">changke@mail.nih.gov</a><br> 147160994 E-069-2017-0 E-069-2017-0-US-01 METHODS OF PREPARING A RE-USABLE SINGLE CELL AND METHODS FOR ANALYZING THE EPIGENOME, TRANSCRIPTOME, AND GENOME OF A SINGLE CELL PRV US 62/502,247 Abandoned US <br />Provisional (PRV) 62/502,247<br />Filed on 2017-05-05<br />Status: Abandoned 147168465 E-069-2017-0 E-069-2017-0-PCT-02 METHODS OF PREPARING A RE-USABLE SINGLE CELL AND METHODS FOR ANALYZING THE EPIGENOME, TRANSCRIPTOME, AND GENOME OF A SINGLE CELL PCT Patent Cooperation Treaty PCT/US2018/031201 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2018/031201<br />Filed on 2018-05-04<br />Status: Expired 147168466 E-069-2017-0 E-069-2017-0-US-03 METHODS OF PREPARING A RE-USABLE SINGLE CELL AND METHODS FOR ANALYZING THE EPIGENOME, TRANSCRIPTOME, AND GENOME OF A SINGLE CELL National Stage US 11,401,544 16/611,098 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11401544 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11401544">11,401,544</a><br />Filed on 2019-11-05<br />Status: Issued 147168467 E-069-2017-0 E-069-2017-0-EP-04 METHODS OF PREPARING A RE-USABLE SINGLE CELL AND METHODS FOR ANALYZING THE EPIGENOME, TRANSCRIPTOME, AND GENOME OF A SINGLE CELL National Stage European Patent 3619307 18727506.0 Issued European Patent <br />National Stage 18727506.0<br />Filed on 2018-05-04<br />Status: Issued 147168468 E-069-2017-0 E-069-2017-0-CH-05 METHODS OF PREPARING A RE-USABLE SINGLE CELL AND METHODS FOR ANALYZING THE EPIGENOME, TRANSCRIPTOME, AND GENOME OF A SINGLE CELL EP Switzerland 3619307 18727506.0 Issued Switzerland <br />European patent (EP) 18727506.0<br />Filed on 2018-05-04<br />Status: Issued 147168469 E-069-2017-0 E-069-2017-0-DE-06 METHODS OF PREPARING A RE-USABLE SINGLE CELL AND METHODS FOR ANALYZING THE EPIGENOME, TRANSCRIPTOME, AND GENOME OF A SINGLE CELL EP Germany 3619307 18727506.0 Issued Germany <br />European patent (EP) 18727506.0<br />Filed on 2018-05-04<br />Status: Issued 147168470 E-069-2017-0 E-069-2017-0-FR-07 METHODS OF PREPARING A RE-USABLE SINGLE CELL AND METHODS FOR ANALYZING THE EPIGENOME, TRANSCRIPTOME, AND GENOME OF A SINGLE CELL EP France 3619307 18727506.0 Issued France <br />European patent (EP) 18727506.0<br />Filed on 2018-05-04<br />Status: Issued 147168471 E-069-2017-0 E-069-2017-0-GB-08 METHODS OF PREPARING A RE-USABLE SINGLE CELL AND METHODS FOR ANALYZING THE EPIGENOME, TRANSCRIPTOME, AND GENOME OF A SINGLE CELL EP United Kingdom 3619307 18727506.0 Issued United Kingdom <br />European patent (EP) 18727506.0<br />Filed on 2018-05-04<br />Status: Issued 147170750 diagnostic 147170752 Epigenomic 147170753 Genomic 147170754 RESEARCH TOOL 147170756 Single Cell Analysis 147170758 Tosato 147170760 Transcriptomic TAB-3860 147157139 Atypical Inhibitors of Monoamine Transporters; Method of Making; and Use Thereof NIDA Collaboration, Licensing, Neurology, Therapeutics Collaboration Licensing Neurology Therapeutics Jianjing Cao, JoLynn Giancola, Amy Newman, Rachel Slack <p>Substance use disorder is a chronic medical condition, taking its toll on our public health care and judicial systems in an economically unsustainable way.  More than 20 million Americans suffer from substance use disorders. Certainly, the development of prevention and treatment options as alternatives to incarceration is the appropriate and ethical solution to this escalating global problem.  Although the recent opioid epidemic has redefined public perception of drug dependence, addiction is not a single illness for which one treatment modality will cure all.  Efforts to develop medications to treat this family of disorders must be tailored to the specific substance or substances of abuse, co-morbidities with other neuropsychiatric illnesses, and ultimately individual treatment needs, which significantly increases the challenge.</p> <p>The development of medications to treat cocaine and methamphetamine use disorders has been unsuccessful, leaving this patient population without pharmacotherapeutic options.  As the dopamine transporter (DAT) plays a prominent role in the reinforcing effects of these psychostimulant drugs that can lead to addiction, atypical DAT inhibitors have been developed that prevent cocaine or methamphetamine from binding to DAT, but they themselves do not display the psychostimulant or rewarding properties that would predict their addictive liability. </p> <h2>Competitive Advantages:</h2> <ul><li>There are currently no FDA approved medications to treat cocaine and/or methamphetamine use disorders </li> <li>Compounds do not produce psychostimulant-like behavioral effects and attenuate behaviors induced by cocaine and/or methamphetamine </li> <li>Mild elevation of brain dopamine and serotonin levels</li> <li>Analogues have potentially lower effective doses</li> <li>Potentially bioavailability than modafinil</li> <li>Potentially improved water solubility over modafinil</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Treatment of substance use disorders</li> <li>Treatment of ADHD</li> <li>Treatment of depression</li> <li>Treatment of narcolepsy</li> <li>Treatment of cognitive impairment</li> </ul> 2018-04-20 2025-04-22 2021-01-26 2025-04-22 2018-04-20 ADHD, dopamine reuptake inhibitor, Newman, sleep disorders, Substance use disorder False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-01-26 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-073-2013 147162215 Giancola JB, et al. Discovery of novel DAT inhibitors based on the modafinil scaffold for the treatment of psychostimulant abuse. Poster at: the Soc. For Neurosciences meeting, Nov. 14, 2017, Washington D.C. Giancola JB, et al. Discovery of novel DAT inhibitors based on the modafinil scaffold for the treatment of psychostimulant abuse. Poster at: the Soc. For Neurosciences meeting, Nov. 14, 2017, Washington D.C. 147162642 Newman, Amy NIH - NIDA NIDA Newman, Amy (NIDA) 1 147162644 Giancola, JoLynn NIH - NIDA NIDA Giancola, JoLynn (NIDA) 2 147162645 Slack, Rachel NIH - NIDA NIDA Slack, Rachel (NIDA) 3 147162643 Cao, Jianjing NIH - NIDA NIDA Cao, Jianjing (NIDA) 4 147162642 Newman, Amy NIH - NIDA NIDA Newman, Amy (NIDA) 1 147162644 Giancola, JoLynn NIH - NIDA NIDA Giancola, JoLynn (NIDA) 2 147162645 Slack, Rachel NIH - NIDA NIDA Slack, Rachel (NIDA) 3 147162643 Cao, Jianjing NIH - NIDA NIDA Cao, Jianjing (NIDA) 4 147157772 ATYPICAL INHIBITORS OF MONOAMINE TRANSPORTERS; METHOD OF MAKING; AND USE THEREOF E-005-2018-0 Filing authorized National Institute on Drug Abuse (NIDA) 147162486 ATYPICAL INHIBITORS OF MONOAMINE TRANSPORTERS; METHOD OF MAKING; AND USE THEREOF E-005-2018-1 Filing authorized National Institute on Drug Abuse (NIDA) 83737255 Baxter, Merissa merissa.baxter@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB merissa.baxter@nih.gov?subject=Web Inquiry on [TAB-3860] Atypical Inhibitors of Monoamine Transporters; Method of Making; and Use Thereof&body=Please send me information about technology [TAB-3860] Atypical Inhibitors of Monoamine Transporters; Method of Making; and Use Thereof.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Baxter, Merissa<br><a href="mailto:merissa.baxter@nih.gov?subject=Web Inquiry on [TAB-3860] Atypical Inhibitors of Monoamine Transporters; Method of Making; and Use Thereof&body=Please send me information about technology [TAB-3860] Atypical Inhibitors of Monoamine Transporters; Method of Making; and Use Thereof.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">merissa.baxter@nih.gov</a><br> 147160886 E-005-2018-0 E-005-2018-0-US-01 ATYPICAL INHIBITORS OF MONOAMINE TRANSPORTERS; METHOD OF MAKING; AND USE THEREOF PRV US 62/585,058 Abandoned US <br />Provisional (PRV) 62/585,058<br />Filed on 2017-11-13<br />Status: Abandoned 147164862 E-005-2018-1 E-005-2018-1-PCT-01 ATYPICAL INHIBITORS OF MONOAMINE TRANSPORTERS; METHOD OF MAKING; AND USE THEREOF PCT COMB Patent Cooperation Treaty PCT/US2018/060260 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2018/060260<br />Filed on 2018-11-12<br />Status: Expired 147164863 E-005-2018-1 E-005-2018-1-US-02 ATYPICAL INHIBITORS OF MONOAMINE TRANSPORTERS; METHOD OF MAKING; AND USE THEREOF National Stage US 11,365,195 16/762,998 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11365195 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11365195">11,365,195</a><br />Filed on 2020-05-11<br />Status: Issued 147169303 ADHD 147169305 dopamine reuptake inhibitor 147169307 Newman 147169309 sleep disorders 147169311 Substance use disorder TAB-4204 147157489 A peptide hydrogel for use in vascular anastomosis NCI Cardiology, Collaboration, Dermatology, Ear, Nose, & Throat, Endocrinology, Gastroenterology, Immunology, Infectious Disease, Licensing, Medical Devices, Nephrology, Non-Medical Devices, Oncology, Ophthalmology, Reproductive Health Cardiology Collaboration Dermatology Ear Nose & Throat Endocrinology Gastroenterology Immunology Infectious Disease Licensing Medical Devices Nephrology Non-Medical Devices Oncology Ophthalmology Reproductive Health Gerald Brandacher, Gabriel Brat, Johanna Grahammer, Joel Schneider, Daniel Smith <p>In collaboration with surgery specialists from Johns Hopkins University, researchers at the National Cancer Institute (NCI) developed novel hydrogel compositions and methods of using them in the microsurgical suturing of blood vessels, which is particularly beneficial for surgeons in whole tissue transplant procedures. The lead candidate electropositive hydrogels, called APC1, was demonstrated in anastomosis mice models to be well tolerated, biocompatible, and non-toxic. Synthetic preparation of APC1 is simple, and has been easy to use by surgeons to accomplish anastomosis in animal models.</p> <p>Studies demonstrate that performing anastomosis with the aid of APC improves vessel patency and drastically decreases the time of the suturing. Additionally, in comparison studies, APC1 hydrogel treatment is associated with less inflammation and scar tissue formation. There are potential additional applications for the APC1 hydrogel in military operations, commercial veterinary applications, and scientific operations of laboratory animal models.</p> <p>This technology is co-owned by and was co-developed with surgical specialists from Johns Hopkins University. Experiments are underway to test biocompatibility and toxicity in rhesus macaques and pigs.</p> <h2>Competitive Advantages:</h2> <ul><li>Greater stability in the presence of thiol nucleophiles</li> <li>More facile and higher yielding synthetic preparation</li> <li>Successfully utilized for in vivo surgical applications</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Vascular surgical aid</li> <li>Utilized by the military in combat surgeries</li> <li>Clinical research to suture laboratory animals</li> <li>Commercial veterinary applications</li> </ul> 2018-04-30 2025-04-22 2019-11-27 2025-04-22 2018-04-30 Anastomosis, Hydrogel, Microsurgery, Peptide, Schneider, Surgery False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2019-11-27 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147162328 Smith DJ, et al. A multiphase transitioning peptide hydrogel for suturing ultra-small vessels https://www.ncbi.nlm.nih.gov/pubmed/26524396 <a href="https://www.ncbi.nlm.nih.gov/pubmed/26524396">Smith DJ, et al. A multiphase transitioning peptide hydrogel for suturing ultra-small vessels</a> 147163902 Schneider, Joel NIH - NCI NCI Schneider, Joel (NCI) 1 147163903 Brandacher, Gerald Johns Hopkins School of Medicine Brandacher, Gerald 2 147163904 Smith, Daniel NIH - NCI NCI Smith, Daniel (NCI) 3 147163905 Brat, Gabriel Johns Hopkins School of Medicine Brat, Gabriel 4 147163906 Grahammer, Johanna Johns Hopkins School of Medicine Grahammer, Johanna 5 147163902 Schneider, Joel NIH - NCI NCI Schneider, Joel (NCI) 1 147163903 Brandacher, Gerald Johns Hopkins School of Medicine Brandacher, Gerald 2 147163904 Smith, Daniel NIH - NCI NCI Smith, Daniel (NCI) 3 147163905 Brat, Gabriel Johns Hopkins School of Medicine Brat, Gabriel 4 147163906 Grahammer, Johanna Johns Hopkins School of Medicine Grahammer, Johanna 5 147158329 A Multiple Phase Transitioning Peptide Hydrogel For Use In Vascular Anastamosis E-292-2014-0 Filing authorized Johns Hopkins School of Medicine, NCI 83704821 Nguyen-Antczak, Lauren lauren.nguyen-antczak@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-4204] A peptide hydrogel for use in vascular anastomosis&body=Please send me information about technology [TAB-4204] A peptide hydrogel for use in vascular anastomosis.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Nguyen-Antczak, Lauren<br><a href="mailto:lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-4204] A peptide hydrogel for use in vascular anastomosis&body=Please send me information about technology [TAB-4204] A peptide hydrogel for use in vascular anastomosis.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">lauren.nguyen-antczak@nih.gov</a><br> 147167339 E-292-2014-0 E-292-2014-0-US-01 HYDROGELS AND USE THEREOF IN ANASTOMOSIS PROCEDURES; JHU Ref. C13279 PRV US 62/106,548 Abandoned US <br />Provisional (PRV) 62/106,548<br />Filed on 2015-01-22<br />Status: Abandoned 147167340 E-292-2014-0 E-292-2014-0-PCT-02 Hydrogels and Use Thereof in Anastomosis Procedures PCT Patent Cooperation Treaty PCT/US2016/014534 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2016/014534<br />Filed on 2016-01-22<br />Status: Expired 147167341 E-292-2014-0 E-292-2014-0-EP-03 Hydrogels and Use Thereof in Anastomosis Procedures National Stage European Patent 16703211.9 Abandoned European Patent <br />National Stage 16703211.9<br />Filed on 2016-01-22<br />Status: Abandoned 147167342 E-292-2014-0 E-292-2014-0-US-04 HYDROGELS AND USE THEREOF IN ANASTOMOSIS PROCEDURES National Stage US 10,086,108 15/545,647 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10086108 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10086108">10,086,108</a><br />Filed on 2017-07-21<br />Status: Issued 147174722 Anastomosis 147174723 Hydrogel 147174725 Microsurgery 147174726 Peptide 147174727 Schneider 147174728 Surgery TAB-4393 147157688 Fully Human Antibodies and Antibody Drug Conjugates Targeting CD276 (B7-H3) for the Treatment of Cancer NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Gary Decrescenzo, Dimiter Dimitrov, Saurabh Saha, Steven Seaman, Brad St. Croix, Dean Welsch, Xaioyan Zhang, Zhongyu Zhu <p>Angiogenesis is the formation of new blood vessels from pre-existing blood vessels. Angiogenesis occurs during normal growth and development, where it is known as physiological angiogenesis, and during the growth of solid tumors, where it is known as pathological angiogenesis. CD276, also known as B7-H3, is a cell surface tumor endothelial marker that is highly expressed in the tumor vessels of human lung, breast, colon, endometrial, renal, and ovarian cancer, but not in the angiogenic vessels of healthy tissue. This differential expression makes CD276 an attractive target for cancer treatment due to the ability to selectively target pathological angiogenesis without impacting physiological angiogenesis. In fact, CD276-directed therapeutic antibodies may have a higher degree of specificity for tumor vessels than current antiangiogenic agents that cannot distinguish physiological and pathological angiogenesis. Moreover, CD276 protein is also frequently overexpressed on tumor cells. The ability to target the vasculature as well as tumor cells directly makes CD276 a potentially ideal dual-compartment therapeutic target.</p> <p>Researchers at the National Cancer Institute (NCI) have developed fully human monoclonal antibodies and antibody-drug conjugates (ADCs) that target CD276. The antibodies and ADCs have been tested both in vitro and in vivo and have shown promising data.  Pyrrolobenzodiazepine (PBD)-conjugated CD276 ADCs killed both cancer cells and tumor vasculature, eradicating large established tumors and metastases, and improving long-term overall survival in mouse models. In addition, the ADCs have been evaluated in preliminary toxicology studies where they showed limited, if any, off-target toxicity.</p> <h2>Competitive Advantages:</h2> <ul><li>Simultaneously targets both tumor cells and tumor vasculature</li> <li>Potentially superior adverse events profile than existing anti-angiogenic agents due to the differential expression of CD276 on tumor and normal vasculature</li> <li>Fully human antibodies are less likely to be recognized and cleared by the immune system upon repeated administration.   </li> <li>Relevance to a wide range of cancers – representing several major market opportunities.</li> <li>High cellular internalization. </li> <li>Cross-reactive with mouse, rat, and monkey CD276 making preclinical studies easier and more informative.</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Antibody-drug conjugates (ADCs) for the treatment of cancer</li> <li>CAR-T cell therapy </li> <li>Diagnostic agent for detecting and monitoring CD276-expressing malignancies</li> </ul> 2018-05-14 2025-04-22 2021-06-10 2025-04-22 2018-05-14 Antibody Drug Conjugate (ADC), B7-H3, CANCER, CD276, Dimitrov, immuno-oncology, Immunotherapy, Monoclonal Antibody False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2021-06-10 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147162130 Seaman S, et al. Eradication of Tumors through Simultaneous Ablation of CD276/B7-H3-Positive Tumor Cells and Tumor Vasculature. https://www.ncbi.nlm.nih.gov/pubmed/28399408 <a href="https://www.ncbi.nlm.nih.gov/pubmed/28399408">Seaman S, et al. Eradication of Tumors through Simultaneous Ablation of CD276/B7-H3-Positive Tumor Cells and Tumor Vasculature.</a> 147164574 Dimitrov, Dimiter NIH - NCI NCI Dimitrov, Dimiter (NCI) 1 147164577 Zhu, Zhongyu NIH - NCI NCI Zhu, Zhongyu (NCI) 2 147164576 St. Croix, Brad NIH - NCI NCI St. Croix, Brad (NCI) 3 147164578 Seaman, Steven NIH - NCI NCI Seaman, Steven (NCI) 4 147164575 Saha, Saurabh BioMed Valley Discoveries, Inc. Saha, Saurabh 5 147164579 Zhang, Xaioyan BioMed Valley Discoveries, Inc. Zhang, Xaioyan 6 147164580 Welsch, Dean BioMed Valley Discoveries, Inc. Welsch, Dean 7 147164581 Decrescenzo, Gary BioMed Valley Discoveries, Inc. Decrescenzo, Gary 8 147164574 Dimitrov, Dimiter NIH - NCI NCI Dimitrov, Dimiter (NCI) 1 147164577 Zhu, Zhongyu NIH - NCI NCI Zhu, Zhongyu (NCI) 2 147164576 St. Croix, Brad NIH - NCI NCI St. Croix, Brad (NCI) 3 147164578 Seaman, Steven NIH - NCI NCI Seaman, Steven (NCI) 4 147164575 Saha, Saurabh BioMed Valley Discoveries, Inc. Saha, Saurabh 5 147164579 Zhang, Xaioyan BioMed Valley Discoveries, Inc. Zhang, Xaioyan 6 147164580 Welsch, Dean BioMed Valley Discoveries, Inc. Welsch, Dean 7 147164581 Decrescenzo, Gary BioMed Valley Discoveries, Inc. Decrescenzo, Gary 8 147158272 Development Of Human Monoclonal Antibodies And Antibody Drug Conjugates Against CD276 As Cancer Diagnostics And Therapeutic Agents E-250-2014-0 Filing authorized BioMed Valley Discoveries, Inc., BioMed Valley Discoveries, Inc., NCI 91814193 Freel, Rose rose.freel@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America rose.freel@nih.gov?subject=Web Inquiry on [TAB-4393] Fully Human Antibodies and Antibody Drug Conjugates Targeting CD276 (B7-H3) for the Treatment of Cancer&body=Please send me information about technology [TAB-4393] Fully Human Antibodies and Antibody Drug Conjugates Targeting CD276 (B7-H3) for the Treatment of Cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Freel, Rose<br><a href="mailto:rose.freel@nih.gov?subject=Web Inquiry on [TAB-4393] Fully Human Antibodies and Antibody Drug Conjugates Targeting CD276 (B7-H3) for the Treatment of Cancer&body=Please send me information about technology [TAB-4393] Fully Human Antibodies and Antibody Drug Conjugates Targeting CD276 (B7-H3) for the Treatment of Cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">rose.freel@nih.gov</a><br> 147161231 E-250-2014-0 E-250-2014-0-US-04 ANTI-CD276 ANTIBODIES (B7H3) National Stage US 10,604,582 15/512,000 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10604582 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10604582">10,604,582</a><br />Filed on 2017-03-16<br />Status: Issued 147168640 E-250-2014-0 E-250-2014-0-US-01 Anti-CD276 Polypeptides and Proteins PRV US 62/051,650 Abandoned US <br />Provisional (PRV) 62/051,650<br />Filed on 2014-09-17<br />Status: Abandoned 147168641 E-250-2014-0 E-250-2014-0-PCT-02 ANTI-CD276 ANTIBODIES (B7H3) PCT Patent Cooperation Treaty PCT/US2015/050365 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2015/050365<br />Filed on 2015-09-16<br />Status: Expired 147168642 E-250-2014-0 E-250-2014-0-CA-03 Anti-CD276 Antibodies (B7H3) National Stage Canada 2961609 2961609 Issued Canada <br />National Stage 2961609<br />Filed on 2015-09-16<br />Status: Issued 147168643 E-250-2014-0 E-250-2014-0-JP-05 ANTI-CD276 ANTIBODIES (B7H3) National Stage Japan 6613304 2017-514697 Issued Japan <br />National Stage 2017-514697<br />Filed on 2015-09-16<br />Status: Issued 147168644 E-250-2014-0 E-250-2014-0-EP-06 Anti-CD276 Antibodies (B7H3) National Stage European Patent 3193933 15772128.3 Issued European Patent <br />National Stage 15772128.3<br />Filed on 2015-09-16<br />Status: Issued 147168645 E-250-2014-0 E-250-2014-0-JP-07 Anti-CD276 Polypeptides and Proteins DIV Japan 6734227 2017-103551 Issued Japan <br />Divisional (DIV) 2017-103551<br />Filed on 2017-05-25<br />Status: Issued 147168646 E-250-2014-0 E-250-2014-0-US-08 ANTI-CD276 ANTIBODIES (B7H3) DIV US 11,851,498 16/812,980 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11851498 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11851498">11,851,498</a><br />Filed on 2020-03-09<br />Status: Issued 147168647 E-250-2014-0 E-250-2014-0-ES-01 Anti-CD276 Antibodies (B7H3) EP Spain 3193933 15772128.3 Issued Spain <br />European patent (EP) 15772128.3<br />Filed on 2015-09-16<br />Status: Issued 147168648 E-250-2014-0 E-250-2014-0-FR-01 Anti-CD276 Antibodies (B7H3) EP France 3193933 15772128.3 Issued France <br />European patent (EP) 15772128.3<br />Filed on 2015-09-16<br />Status: Issued 147168649 E-250-2014-0 E-250-2014-0-IT-01 Anti-CD276 Antibodies (B7H3) EP Italy 3193933 15772128.3 Issued Italy <br />European patent (EP) 15772128.3<br />Filed on 2015-09-16<br />Status: Issued 147168650 E-250-2014-0 E-250-2014-0-DE-01 Anti-CD276 Antibodies (B7H3) EP Germany 3193933 15772128.3 Issued Germany <br />European patent (EP) 15772128.3<br />Filed on 2015-09-16<br />Status: Issued 147168651 E-250-2014-0 E-250-2014-0-GB-01 Anti-CD276 Antibodies (B7H3) EP United Kingdom 3193933 15772128.3 Issued United Kingdom <br />European patent (EP) 15772128.3<br />Filed on 2015-09-16<br />Status: Issued 147174245 Antibody Drug Conjugate (ADC) 147174246 B7-H3 147174247 CANCER 147174248 CD276 147174249 Dimitrov 147174250 immuno-oncology 147174251 Immunotherapy 147174252 Monoclonal Antibody TAB-4423 147157718 Polymeric Delivery Platform for Therapeutics NCI Collaboration, Immunology, Infectious Disease, Licensing, Neurology, Oncology, Therapeutics Collaboration Immunology Infectious Disease Licensing Neurology Oncology Therapeutics Marina Dobrovolskaia, Scott McNeil, Stephan Stern, David Stevens <p>Drug delivery technologies have long claimed the ability to selectively deliver therapeutic cargo to target cells. Despite advances in nanomedicine and drug delivery systems, there are no targeted nanoscale drug delivery technologies on the market. Thus, there is still tremendous potential in improved therapeutic efficacy when targeted drug delivery is achieved. </p> <p>Investigators at the <a href="https://ncl.cancer.gov/" rel="nofollow">Nanotechnology Characterization Laboratory</a> at the National Cancer Institute (NCI) developed a drug delivery platform that targets scavenger receptor A1 (SR-A1), a receptor highly expressed in macrophages, monocytes, mast cells, dendritic cells (myeloid lineages), and endothelial cells. The platform is based on the anionic polymer poly (L-lysine succinylated), which contains side chains with pendant carboxylic acids that allow conjugation of small molecule drugs through hydrolysable ester bonds and have demonstrated drug release half-lives greater than 10 hours. Peptide therapeutics and vaccine antigens can also be conjugated to the polymer platform. Through such conjugation, improved delivery of peptide vaccines to target macrophages and dendritic cells (antigen presenting cells [APCs]) can be achieved for better vaccine efficacy. </p> <p>Through this approach, high levels of prodrug will be preferentially distributed to SR-A1 expressing cells, such as myeloid/APC, but also to the entire lymphatic system as a result of SR-A1-mediated endothelial transcytosis. Furthermore, active drug is released in a controlled manner – a milestone not yet achieved with current nanomedicine platforms. There is the potential for numerous applications and products as detailed below. </p> <p>Recent similar technologies are emtricitabine (HIV nucleoside analog reverse transcriptase inhibitor) and PI-103 (pan-class I PI3K/mTOR inhibitor) prodrug versions of the delivery platform. In support of the platform’s ability to target latent lymphatic HIV reservoirs, the emtricitabine prodrug demonstrated increased active drug concentrations in lymphatic tissues 10-fold over the unformulated drug in a rat model. Several PI3K-Akt-mTOR pathway inhibitors are currently in clinical stage development for treatment of diverse cancers, despite autoimmunity and glucose-insulin axis derangement as common side effects of this drug class. Such adverse events are thought to be due to PI3K-Akt-mTOR pathway inhibition effects on non-target-tissues. In a syngeneic mouse B16 melanoma model, the PI-103 prodrug significantly reduced tumor growth at doses as low as 0.1 mg/kg and increased the targeted-tumor associated macrophage M1 (anti-tumor):M2 (pro-tumor) ratio by ~4 fold. Even 100-fold higher doses (10 mg/kg) were without clinically apparent toxicity! As supported by these various in vitro and in vivo studies, the highly selective SR-A1 targeted macromolecular platform has tremendous potential for both cancer and anti-viral immunotherapies. </p> <h2>Competitive Advantages:</h2> <ul><li>High levels of prodrug preferentially distributed to SR-A1-expressing cells, including myeloid/APC </li> <li>Active drug is released slowly in a controlled manner, without burst release, which has not yet been achieved with current nanomedicine platforms</li> <li>The prodrug preferentially accumulates in the lymphatic system because of SR-A1-mediated transcytosis</li> <li>Application in a wide range of therapeutics requiring crossing the blood-brain barrier</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Targeted drug delivery of immunomodulatory small molecule drugs, peptide therapeutics, and vaccine antigens</li> <li>Cancer therapeutics</li> <li>Immunotherapies</li> <li>Immunomodulatory therapies</li> <li>Vaccines</li> <li>Anti-viral therapeutic; anti-viral approaches against infectious diseases (e.g., HIV)</li> <li>CNS therapeutic; e.g., brain delivery for neurodegenerative conditions and glioma</li> </ul> 2018-05-03 2025-04-22 2022-07-12 2025-04-22 2018-05-03 Drug Delivery, Immunotherapy, Scavenger Receptor A1, SR-A1 False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2022-07-12 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147164696 Stevens, David NIH - NCI Stevens, David 1 147164695 Stern, Stephan NIH - NCI Leidos Stern, Stephan (Leidos) 2 147164694 McNeil, Scott NIH - NCI Leidos McNeil, Scott (Leidos) 3 147164693 Dobrovolskaia, Marina NIH - NCI Leidos Dobrovolskaia, Marina (Leidos) 4 147164696 Stevens, David NIH - NCI Stevens, David 1 147164695 Stern, Stephan NIH - NCI Leidos Stern, Stephan (Leidos) 2 147164694 McNeil, Scott NIH - NCI Leidos McNeil, Scott (Leidos) 3 147164693 Dobrovolskaia, Marina NIH - NCI Leidos Dobrovolskaia, Marina (Leidos) 4 147157981 Macromolecular Platform For Targeting Scavenger Receptor A1 E-097-2017-0 Filing authorized NCI 83704821 Nguyen-Antczak, Lauren lauren.nguyen-antczak@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-4423] Polymeric Delivery Platform for Therapeutics&body=Please send me information about technology [TAB-4423] Polymeric Delivery Platform for Therapeutics.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Nguyen-Antczak, Lauren<br><a href="mailto:lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-4423] Polymeric Delivery Platform for Therapeutics&body=Please send me information about technology [TAB-4423] Polymeric Delivery Platform for Therapeutics.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">lauren.nguyen-antczak@nih.gov</a><br> 147161033 E-097-2017-0 E-097-2017-0-US-01 Macromolecular Platform For Targeting Scavenger Receptor A1 PRV US 62/572,733 Abandoned US <br />Provisional (PRV) 62/572,733<br />Filed on 2017-10-16<br />Status: Abandoned 147168834 E-097-2017-0 E-097-2017-0-PCT-02 Macromolecular Platform For Targeting Scavenger Receptor A1 PCT Patent Cooperation Treaty PCT/US2018/055794 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2018/055794<br />Filed on 2018-10-15<br />Status: Expired 147168835 E-097-2017-0 E-097-2017-0-AU-03 Macromolecular Platform For Targeting Scavenger Receptor A1 National Stage Australia 2018350825 2018350825 Issued Australia <br />National Stage 2018350825<br />Filed on 2018-10-15<br />Status: Issued 147168836 E-097-2017-0 E-097-2017-0-CA-04 Macromolecular Platform For Targeting Scavenger Receptor A1 National Stage Canada 3079121 Pending Canada <br />National Stage 3079121<br />Filed on 2018-10-15<br />Status: Pending 147168837 E-097-2017-0 E-097-2017-0-US-05 Macromolecular Platform For Targeting Scavenger Receptor A1 National Stage US 16/756,259 Pending US <br />National Stage 16/756,259<br />Filed on 2020-04-15<br />Status: Pending 147168838 E-097-2017-0 E-097-2017-0-EP-06 Macromolecular Platform For Targeting Scavenger Receptor A1 National Stage European Patent 18867617.5 Pending European Patent <br />National Stage 18867617.5<br />Filed on 2018-10-15<br />Status: Pending 147171359 Drug Delivery 147171360 Immunotherapy 147171362 Scavenger Receptor A1 147171364 SR-A1 TAB-4198 147157483 Novel Murine T-Cell Receptors for Treating Metastatic Thyroid Cancer NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Kenichi Hanada, Qiong Wang, James Yang, Zhiya Yu <p>The occurrence of thyroid cancer has been increasing in the United States. For some patients, with particularly advanced and metastatic cancer, current treatments such as thyroidectomy and adjuvant radioactive iodine therapy can lead to poor outcomes. Hence, there is a need for new thyroid cancer treatments.</p> <p>Researchers at the NCI have developed novel T-cell receptors (TCRs) to target thyroid cancer. They immunized HLA-A2+ transgenic mice to generate TCRs that recognize human thyroglobulin (TG). TG, a tissue-differentiation antigen, is only expressed in thyroid cancer and normal thyroid tissues. The anti-TG TCRs can be expressed in a patient’s peripheral blood lymphocytes as part of adoptive cell therapy (ACT) to treat cancer. This discovery, along with hormonal therapy to replace normal thyroid function, can be used to eradicate tumor cells. <br />  <br /> The National Cancer Institute, <a href="https://ccr.cancer.gov/Surgery-Branch" rel="nofollow">Surgery Branch</a>, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize novel T-cell receptors for the treatment of metastatic thyroid cancer.</p> <h2>Competitive Advantages:</h2> <ul><li>Target specificity due to tissue-differentiation antigen that is only expressed in the thyroid</li> <li>Alternative treatment for patients with metastatic thyroid cancer that is resistant to the current standard of care</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Immunotherapy for metastatic thyroid cancer</li> </ul> 2018-05-16 2025-04-22 2018-05-16 2025-04-22 2018-05-16 act, adoptive cell therapy, Human Thyroglobulin, Immunotherapy, METASTATIC, T-cell Receptors, TCR, TCRs, Tg, THYROID CANCER, Yang False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2018-05-16 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-149-2015 147162088 Kloos RT, Approach to the patient with a positive serum thyroglobulin and a negative radioiodine scan after initial therapy for differentiated thyroid cancer https://www.ncbi.nlm.nih.gov/pubmed/18463349 <a href="https://www.ncbi.nlm.nih.gov/pubmed/18463349">Kloos RT, Approach to the patient with a positive serum thyroglobulin and a negative radioiodine scan after initial therapy for differentiated thyroid cancer</a> 147162166 Kochenderfer JN, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells https://www.ncbi.nlm.nih.gov/pubmed/22160384 <a href="https://www.ncbi.nlm.nih.gov/pubmed/22160384">Kochenderfer JN, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells</a> 147163875 Hanada, Kenichi NIH - NCI NCI Hanada, Kenichi (NCI) 1 147163877 Wang, Qiong NIH - NCI NCI Wang, Qiong (NCI) 2 147163876 Yang, James NIH - NCI NCI Yang, James (NCI) 3 147163878 Yu, Zhiya NIH - NCI NCI Yu, Zhiya (NCI) 4 147163875 Hanada, Kenichi NIH - NCI NCI Hanada, Kenichi (NCI) 1 147163877 Wang, Qiong NIH - NCI NCI Wang, Qiong (NCI) 2 147163876 Yang, James NIH - NCI NCI Yang, James (NCI) 3 147163878 Yu, Zhiya NIH - NCI NCI Yu, Zhiya (NCI) 4 147158235 Retroviral Vector That Encodes A Murine (100%) T-cell Receptor (TCR) Targeting An HLA-A2-restricted Epitope In Human Thyroglobulin For The Treatment Of Metastatic Thyroid Cancer E-226-2014-0 Filing authorized NCI 83709866 Burke, Andrew burkear@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC burkear@nih.gov?subject=Web Inquiry on [TAB-4198] Novel Murine T-Cell Receptors for Treating Metastatic Thyroid Cancer&body=Please send me information about technology [TAB-4198] Novel Murine T-Cell Receptors for Treating Metastatic Thyroid Cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Burke, Andrew<br><a href="mailto:burkear@nih.gov?subject=Web Inquiry on [TAB-4198] Novel Murine T-Cell Receptors for Treating Metastatic Thyroid Cancer&body=Please send me information about technology [TAB-4198] Novel Murine T-Cell Receptors for Treating Metastatic Thyroid Cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">burkear@nih.gov</a><br> 147161206 E-226-2014-0 E-226-2014-0-US-01 Anti-Human Thyroglobulin T Cell Receptors PRV US 62/079,713 Abandoned US <br />Provisional (PRV) 62/079,713<br />Filed on 2014-11-14<br />Status: Abandoned 147167285 E-226-2014-0 E-226-2014-0-PCT-02 HUMAN ANTI-THYROGLOBULIN T CELL RECEPTORS PCT Patent Cooperation Treaty PCT/US2015/060282 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2015/060282<br />Filed on 2015-11-12<br />Status: Expired 147167286 E-226-2014-0 E-226-2014-0-AU-03 ANTI-THYROGLOBULIN T CELL RECEPTORS National Stage Australia 2015346350 2015346350 Issued Australia <br />National Stage 2015346350<br />Filed on 2015-11-12<br />Status: Issued 147167287 E-226-2014-0 E-226-2014-0-CA-04 Anti-Human Thyroglobulin T Cell Receptors National Stage Canada 2967778 2967778 Issued Canada <br />National Stage 2967778<br />Filed on 2015-11-12<br />Status: Issued 147167288 E-226-2014-0 E-226-2014-0-EP-05 Anti-Human Thyroglobulin T Cell Receptors National Stage European Patent 3218404 15801054.6 Issued European Patent <br />National Stage 15801054.6<br />Filed on 2015-11-12<br />Status: Issued 147167289 E-226-2014-0 E-226-2014-0-JP-06 Anti-Human Thyroglobulin T Cell Receptors National Stage Japan 6666342 2017-525625 Issued Japan <br />National Stage 2017-525625<br />Filed on 2015-11-12<br />Status: Issued 147167290 E-226-2014-0 E-226-2014-0-US-07 HUMAN ANTI-THYROGLOBULIN T CELL RECEPTORS National Stage US 10,450,372 15/524,869 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10450372 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10450372">10,450,372</a><br />Filed on 2017-05-05<br />Status: Issued 147167291 E-226-2014-0 E-226-2014-0-US-08 ANTI-THYROGLOBULIN T CELL RECEPTORS DIV US 11,440,956 16/586,310 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11440956 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11440956">11,440,956</a><br />Filed on 2019-09-27<br />Status: Issued 147167292 E-226-2014-0 E-226-2014-0-EP-09 ANTI-THYROGLOBULIN T CELL RECEPTORS DIV European Patent 3808770 20208238.4 Issued European Patent <br />Divisional (DIV) 20208238.4<br />Filed on 2020-11-17<br />Status: Issued 147167293 E-226-2014-0 E-226-2014-0-FR-10 Anti-Human Thyroglobulin T Cell Receptors EP France 3218404 15801054.6 Issued France <br />European patent (EP) 15801054.6<br />Filed on 2015-11-12<br />Status: Issued 147167294 E-226-2014-0 E-226-2014-0-DE-11 Anti-Human Thyroglobulin T Cell Receptors EP Germany 3218404 15801054.6 Issued Germany <br />European patent (EP) 15801054.6<br />Filed on 2015-11-12<br />Status: Issued 147167295 E-226-2014-0 E-226-2014-0-GB-12 Anti-Human Thyroglobulin T Cell Receptors EP United Kingdom 3218404 15801054.6 Issued United Kingdom <br />European patent (EP) 15801054.6<br />Filed on 2015-11-12<br />Status: Issued 147167297 E-226-2014-0 E-226-2014-0-US-14 ANTI-THYROGLOBULIN T CELL RECEPTORS CON US 12,275,786 17/817,599 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12275786 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12275786">12,275,786</a><br />Filed on 2022-08-04<br />Status: Issued 147173904 act 147173905 adoptive cell therapy 147173907 Human Thyroglobulin 147173908 Immunotherapy 147173909 METASTATIC 147173910 T-cell Receptors 147173911 TCR 147173912 TCRs 147173913 Tg 147173914 THYROID CANCER 147173915 Yang TAB-4218 147157503 Inhibition of T Cell Differentiation and Senescence by Overexpression of Transcription Factor c-Myb NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Luca Gattinoni, Sanjivan Gautam, Yun Ji <p>Adoptive Cell Therapy (ACT) is a promising technique that uses a patient's own T cells to treat cancer. The process requires removing and engineering a patient's T cells to express a chimeric antigen receptor (CAR) or T cell receptor (TCR) that targets a specific cancer antigen. When the modified T cells are reintroduced into the patient, the T cells attack and kill cancer cells that express the antigen, thereby treating the patient. Although ACT holds a great deal of promise, there are still technical drawbacks to be overcome, such as loss of anti-tumor activity due to T cell senescence.</p> <p>This invention addresses this technical drawback by using T cells that express the transcription factor c-Myb (or a functional variant thereof) at elevated levels as the host for transduction with CARs or TCRs. T cells that exhibit elevated expression of c-Myb display inhibited differentiation, allowing the cells to survive, proliferate and serve in a therapeutic capacity for a longer duration. Since it is believed that these characteristics can increase the effectiveness of ACT, T cells with elevated levels of c-Myb expression are strong candidates for use in ACT.</p> <h2>Competitive Advantages:</h2> <ul><li>Elevated expression of c-Myb in T cells allows them to resist differentiation, thus cells survive and proliferate in greater numbers</li> <li>Increased survival and proliferation of T cells allows for a prolonged therapeutic effect</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Adoptive Cell Therapy (ACT) using chimeric antigen receptors (CARs), or engineered T cell receptors (TCRs)</li> <li>Treatment of cancers that express specific cell surface proteins</li> </ul> 2018-05-16 2025-04-22 2020-04-07 2025-04-22 2018-05-16 act, Adoptive Cell Transfer, CANCER, CAR, chimeric antigen receptor, Gattinoni, Immunotherapy, Infectious Disease, Stem Cell, T cell, T Cell Receptor, TCR False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2020-04-07 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147163945 Gautam, Sanjivan NIH - NCI NCI Gautam, Sanjivan (NCI) 1 147163944 Ji, Yun NIH - NCI NCI Ji, Yun (NCI) 2 147163943 Gattinoni, Luca NIH - NCI NCI Gattinoni, Luca (NCI) 3 147163945 Gautam, Sanjivan NIH - NCI NCI Gautam, Sanjivan (NCI) 1 147163944 Ji, Yun NIH - NCI NCI Ji, Yun (NCI) 2 147163943 Gattinoni, Luca NIH - NCI NCI Gattinoni, Luca (NCI) 3 147158247 Inhibition Of T Cell Differentiation And Senescence By Overexpression Of Transcription Factor C-Myb E-232-2015-0 Filing authorized NCI 83731987 Dhal, Abritee abritee.dhal@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-4218] Inhibition of T Cell Differentiation and Senescence by Overexpression of Transcription Factor c-Myb&body=Please send me information about technology [TAB-4218] Inhibition of T Cell Differentiation and Senescence by Overexpression of Transcription Factor c-Myb.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dhal, Abritee<br><a href="mailto:abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-4218] Inhibition of T Cell Differentiation and Senescence by Overexpression of Transcription Factor c-Myb&body=Please send me information about technology [TAB-4218] Inhibition of T Cell Differentiation and Senescence by Overexpression of Transcription Factor c-Myb.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">abritee.dhal@nih.gov</a><br> 147161214 E-232-2015-0 E-232-2015-0-PCT-02 T Cells Modified to Overexpress C-MYB PCT Patent Cooperation Treaty PCT/US2016/048435 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2016/048435<br />Filed on 2016-08-24<br />Status: Expired 147167471 E-232-2015-0 E-232-2015-0-US-01 T Cells Modified to Overexpress C-MYB PRV US 62/209,497 Abandoned US <br />Provisional (PRV) 62/209,497<br />Filed on 2015-08-25<br />Status: Abandoned 147167472 E-232-2015-0 E-232-2015-0-US-03 T CELLS MODIFIED TO OVEREXPRESS C-MYB National Stage US 11,098,283 15/754,078 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11098283 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11098283">11,098,283</a><br />Filed on 2018-02-21<br />Status: Issued 147174031 act 147174032 Adoptive Cell Transfer 147174033 CANCER 147174034 CAR 147174035 chimeric antigen receptor 147174036 Gattinoni 147174037 Immunotherapy 147174038 Infectious Disease 147174039 Stem Cell 147174040 T cell 147174041 T Cell Receptor 147174042 TCR TAB-4030 147157311 Overexpression of Phf19 on T Cells Enhances Therapeutic Effects of T Cell-Based Therapies (such as Chimeric Antigen Receptor [CAR] Therapies) NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Luca Gattinoni, Yun Ji <p>T cell-based immunotherapy (such as CAR therapies) is a promising approach for the treatment of several cancers. However, T cells currently employed for various T cell-based immunotherapies are usually senescent and terminally differentiated leading to poor proliferative and survival capacity, limiting their therapeutic effectiveness once transferred into a patient’s blood. </p> <p>Researchers in the National Cancer Institute (NCI) <a href="https://ccr.cancer.gov/Experimental-Transplantation-and-Immunology-Branch" rel="nofollow">Experimental Transplantation and Immunology Branch (ETIB)</a> have epigenetically reprogrammed CD8+ T cell fate by overexpressing Phf19. The inventors found that overexpression of Phf19 in tumor-reactive CD8+ T cells limits T cell terminal differentiation and exhaustion. In addition, it was found that Phf19 overexpressing T cells exhibit enhanced proliferation and cytokine production, resulting in augmented anti-tumor activity in vivo. This technology is available for licensing and/or co-development.</p> <h2>Competitive Advantages:</h2> <ul><li>T cells overexpressing Phf19 can increase therapeutic effectiveness of adoptive immunotherapy because it improves T cell proliferation increasing the number of T cells that can be used for T cell-based immunotherapies</li> <li>T cells, overexpressing Phf19 used for immunotherapy in preclinical in vivo studies, are already known to induce a greater decrease in tumor size compared to mice treated with T cell-based immunotherapies using unmodified T cells</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Treating cancer patients receiving T cell-based immunotherapy </li> </ul> 2018-05-16 2025-04-22 2021-06-10 2025-04-22 2018-05-16 CAR-T Therapy, CD8, chimeric antigen receptor, Gattinoni, Phf19, T cell False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2021-06-10 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147163283 Ji, Yun NIH - NCI NCI Ji, Yun (NCI) 1 147163282 Gattinoni, Luca NIH - NCI NCI Gattinoni, Luca (NCI) 2 147163283 Ji, Yun NIH - NCI NCI Ji, Yun (NCI) 1 147163282 Gattinoni, Luca NIH - NCI NCI Gattinoni, Luca (NCI) 2 147158002 Enhancing Cancer Immunotherapy By Epigenetically Reprogramming Tumor-reactive CD8+ T Cells With The Ploycomb-like Protein Phf19 E-107-2017-0 Filing authorized NCI 83731987 Dhal, Abritee abritee.dhal@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-4030] Overexpression of Phf19 on T Cells Enhances Therapeutic Effects of T Cell-Based Therapies (such as Chimeric Antigen Receptor [CAR] Therapies)&body=Please send me information about technology [TAB-4030] Overexpression of Phf19 on T Cells Enhances Therapeutic Effects of T Cell-Based Therapies (such as Chimeric Antigen Receptor [CAR] Therapies).&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dhal, Abritee<br><a href="mailto:abritee.dhal@nih.gov?subject=Web Inquiry on [TAB-4030] Overexpression of Phf19 on T Cells Enhances Therapeutic Effects of T Cell-Based Therapies (such as Chimeric Antigen Receptor [CAR] Therapies)&body=Please send me information about technology [TAB-4030] Overexpression of Phf19 on T Cells Enhances Therapeutic Effects of T Cell-Based Therapies (such as Chimeric Antigen Receptor [CAR] Therapies).&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">abritee.dhal@nih.gov</a><br> 147161051 E-107-2017-0 E-107-2017-0-US-01 T CELLS MODIFIED TO OVEREXPRESS PHF19 PRV US 62/515,105 Abandoned US <br />Provisional (PRV) 62/515,105<br />Filed on 2017-06-05<br />Status: Abandoned 147166113 E-107-2017-0 E-107-2017-0-PCT-02 T-CELLS MODIFIED TO OVEREXPRESS PHF19 PCT Patent Cooperation Treaty PCT/US2018/036125 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2018/036125<br />Filed on 2018-06-05<br />Status: Expired 147166114 E-107-2017-0 E-107-2017-0-EP-03 T CELLS MODIFIED TO OVEREXPRESS PHF19 National Stage European Patent 3635098 18737062.2 Issued European Patent <br />National Stage 18737062.2<br />Filed on 2019-12-19<br />Status: Issued 147166115 E-107-2017-0 E-107-2017-0-US-04 T-CELLS MODIFIED TO OVEREXPRESS PHF19 National Stage US 11,883,431 16/619,570 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11883431 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11883431">11,883,431</a><br />Filed on 2019-12-05<br />Status: Issued 147166116 E-107-2017-0 E-107-2017-0-DE-05 T CELLS MODIFIED TO OVEREXPRESS PHF19 EP Germany 3635098 18737062.2 Issued Germany <br />European patent (EP) 18737062.2<br />Filed on 2019-12-19<br />Status: Issued 147166117 E-107-2017-0 E-107-2017-0-FR-06 T CELLS MODIFIED TO OVEREXPRESS PHF19 EP France 3635098 18737062.2 Issued France <br />European patent (EP) 18737062.2<br />Filed on 2019-12-19<br />Status: Issued 147166118 E-107-2017-0 E-107-2017-0-GB-07 T CELLS MODIFIED TO OVEREXPRESS PHF19 EP United Kingdom 3635098 18737062.2 Issued United Kingdom <br />European patent (EP) 18737062.2<br />Filed on 2019-12-19<br />Status: Issued 147171563 CAR-T Therapy 147171564 CD8 147171565 chimeric antigen receptor 147171567 Gattinoni 147171568 Phf19 147171569 T cell TAB-4316 147157606 Fully Human Antibodies and Antibody Drug Conjugates Targeting Tumor Endothelial Marker 8 (TEM8) for the Treatment of Cancer NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Gary Decrescenzo, Dimiter Dimitrov, Saurabh Saha, Brad St. Croix, Dean Welsch, Xaioyan Zhang, Zhongyu Zhu, Enrique Zudaire Ubani <p>The tumor microenvironment consists of a heterogenous population of cells which includes tumor cells and tumor-associated stroma cells (TASCs). The TASCs promote tumor angiogenesis, proliferation, invasion and metastasis. Because stroma cells are found in both healthy and cancerous tissue, targeting the tumor stroma has been difficult due to the lack of targets with high tumor specificity. TEM8 (also known as ANTXR1) is a cell surface tumor endothelial marker that is most highly expressed in human tumor-associated stroma of pancreatic, breast, colon, lung, esophageal, bladder, and ovarian cancers. While low levels of expression are seen in healthy kidney, lung, and brain tissue, preliminary toxicity studies suggest limited, if any, toxic effects in these tissues. This differential expression makes TEM8 an attractive potential target for ADC development due to the ability to selectively target TASCs in many different tumor types.</p> <p>Researchers at the National Cancer Institute (NCI) have developed fully human monoclonal antibodies and antibody-drug conjugates (ADCs) that target TEM8. The antibodies and ADCs have been tested both <em>in vitro </em>and <em>in vivo</em> and have shown promising data. Monomethyl auristatin E (MMAE)-conjugated TEM8 ADCs led to the eradication of large established tumors and metastases and improved long-term overall survival in mouse models. In addition, the ADC was evaluated in preliminary toxicology studies where it showed limited off-target toxicity.</p> <h2>Competitive Advantages:</h2> <ul><li>Possible to simultaneously target both tumor cells and tumor stroma;</li> <li>Potentially superior adverse events profile than existing agents due to the differential expression of TEM8 on tumor and normal stroma;</li> <li>Fully human antibodies are less likely to be recognized and cleared by the immune system upon repeated administration;</li> <li>Relevance to a wide range of cancers – representing several major market opportunities;</li> <li>High cellular internalization;</li> <li>Cross-reactive with mouse and monkey TEM8 making preclinical studies easier and more informative.</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Antibody-drug conjugates (ADCs) for the treatment of cancer</li> <li>CAR-T cell therapy</li> <li>Diagnostic agent for detecting and monitoring TEM8-expressing malignancies.</li> <li>A component of multi-specific antibody therapies</li> </ul> 2018-06-19 2025-04-22 2020-04-07 2025-04-22 2018-06-19 Antibody Drug Conjugate (ADC), ANTXR1, TEM8, Tumor Microenvironment, Tumor Stroma False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2020-04-07 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147162058 C. Szot et al. Tumor stroma-targeted antibody-drug conjugate triggers localized anticancer drug release. https://www.ncbi.nlm.nih.gov/pubmed/29863500 <a href="https://www.ncbi.nlm.nih.gov/pubmed/29863500">C. Szot et al. Tumor stroma-targeted antibody-drug conjugate triggers localized anticancer drug release.</a> 147164277 Dimitrov, Dimiter NIH - NCI NCI Dimitrov, Dimiter (NCI) 1 147164281 Zhu, Zhongyu NIH - NCI NCI Zhu, Zhongyu (NCI) 2 147164280 St. Croix, Brad NIH - NCI NCI St. Croix, Brad (NCI) 3 147164278 Zudaire Ubani, Enrique NIH - NCI NCI Zudaire Ubani, Enrique (NCI) 4 147164279 Saha, Saurabh BioMed Valley Discoveries, Inc. Saha, Saurabh 5 147164282 Zhang, Xaioyan Novartis Zhang, Xaioyan 6 147164283 Welsch, Dean BioMed Valley Discoveries, Inc. Welsch, Dean 7 147164284 Decrescenzo, Gary BioMed Valley Discoveries, Inc. Decrescenzo, Gary 8 147164277 Dimitrov, Dimiter NIH - NCI NCI Dimitrov, Dimiter (NCI) 1 147164281 Zhu, Zhongyu NIH - NCI NCI Zhu, Zhongyu (NCI) 2 147164280 St. Croix, Brad NIH - NCI NCI St. Croix, Brad (NCI) 3 147164278 Zudaire Ubani, Enrique NIH - NCI NCI Zudaire Ubani, Enrique (NCI) 4 147164279 Saha, Saurabh BioMed Valley Discoveries, Inc. Saha, Saurabh 5 147164282 Zhang, Xaioyan Novartis Zhang, Xaioyan 6 147164283 Welsch, Dean BioMed Valley Discoveries, Inc. Welsch, Dean 7 147164284 Decrescenzo, Gary BioMed Valley Discoveries, Inc. Decrescenzo, Gary 8 147158352 Development Of Human Monoclonal Antibodies Against Tumor Endothelial Marker 8 (TEM8) As Cancer Diagnostic And Therapeutic agents E-344-2013-0 Filing authorized BioMed Valley Discoveries, Inc., BioMed Valley Discoveries, Inc., NCI 91814193 Freel, Rose rose.freel@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America rose.freel@nih.gov?subject=Web Inquiry on [TAB-4316] Fully Human Antibodies and Antibody Drug Conjugates Targeting Tumor Endothelial Marker 8 (TEM8) for the Treatment of Cancer&body=Please send me information about technology [TAB-4316] Fully Human Antibodies and Antibody Drug Conjugates Targeting Tumor Endothelial Marker 8 (TEM8) for the Treatment of Cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Freel, Rose<br><a href="mailto:rose.freel@nih.gov?subject=Web Inquiry on [TAB-4316] Fully Human Antibodies and Antibody Drug Conjugates Targeting Tumor Endothelial Marker 8 (TEM8) for the Treatment of Cancer&body=Please send me information about technology [TAB-4316] Fully Human Antibodies and Antibody Drug Conjugates Targeting Tumor Endothelial Marker 8 (TEM8) for the Treatment of Cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">rose.freel@nih.gov</a><br> 147168115 E-344-2013-0 E-344-2013-0-US-01 TEM8 ANTIBODIES AND THEIR USE PRV US 61/889,958 Abandoned US <br />Provisional (PRV) 61/889,958<br />Filed on 2013-10-11<br />Status: Abandoned 147168116 E-344-2013-0 E-344-2013-0-PCT-02 Development of Human Monoclonal Antibodies Against Tumor Endothelial Marker 8 (TEM8) as Cancer Diagnostic and Therapeutic PCT Patent Cooperation Treaty PCT/US2014/060299 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2014/060299<br />Filed on 2014-10-13<br />Status: Expired 147168117 E-344-2013-0 E-344-2013-0-AU-03 TEM8 Antibodies and Their Use National Stage Australia 2014331667 2014331667 Issued Australia <br />National Stage 2014331667<br />Filed on 2014-10-13<br />Status: Issued 147168118 E-344-2013-0 E-344-2013-0-CA-04 TEM8 Antibodies and Their Use National Stage Canada 2925393 2925393 Issued Canada <br />National Stage 2925393<br />Filed on 2014-10-13<br />Status: Issued 147168119 E-344-2013-0 E-344-2013-0-CN-05 TEM8 ANTIBODIES AND THEIR USE National Stage China ZL201480066451.3 201480066451.3 Issued China <br />National Stage 201480066451.3<br />Filed on 2014-10-13<br />Status: Issued 147168120 E-344-2013-0 E-344-2013-0-EP-06 TEM8 ANTIBODIES AND THEIR USE National Stage European Patent 3054987 14789480.2 Issued European Patent <br />National Stage 14789480.2<br />Filed on 2014-10-13<br />Status: Issued 147168121 E-344-2013-0 E-344-2013-0-JP-07 TEM8 ANTIBODIES AND THEIR USE National Stage Japan 6502931 2016-521982 Issued Japan <br />National Stage 2016-521982<br />Filed on 2016-04-08<br />Status: Issued 147168122 E-344-2013-0 E-344-2013-0-MX-08 TEM8 Antibodies and Their Use National Stage Mexico 377297 MX/a/2016/003744 Issued Mexico <br />National Stage MX/a/2016/003744<br />Filed on 2014-10-13<br />Status: Issued 147168123 E-344-2013-0 E-344-2013-0-US-09 TEM8 Antibodies and Their Use in Treatment and Detection of Tumors National Stage US 9,765,142 15/028,337 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9765142 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9765142">9,765,142</a><br />Filed on 2016-04-08<br />Status: Issued 147168124 E-344-2013-0 E-344-2013-0-US-10 TEM8 Antibodies and Their Use in Treatment and Detection of Tumors CON US 10,196,443 15/680,177 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10196443 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10196443">10,196,443</a><br />Filed on 2017-08-17<br />Status: Issued 147168125 E-344-2013-0 E-344-2013-0-EP-11 TEM8 ANTIBODIES AND THEIR USE DIV European Patent 3620470 19201975.0 Issued European Patent <br />Divisional (DIV) 19201975.0<br />Filed on 2019-10-08<br />Status: Issued 147168126 E-344-2013-0 E-344-2013-0-DE-12 TEM8 ANTIBODIES AND THEIR USE EP Germany 3054987 14789480.2 Issued Germany <br />European patent (EP) 14789480.2<br />Filed on 2014-10-13<br />Status: Issued 147168127 E-344-2013-0 E-344-2013-0-ES-13 TEM8 ANTIBODIES AND THEIR USE EP Spain 3054987 14789480.2 Issued Spain <br />European patent (EP) 14789480.2<br />Filed on 2014-10-13<br />Status: Issued 147168128 E-344-2013-0 E-344-2013-0-FR-14 TEM8 ANTIBODIES AND THEIR USE EP France 3054987 14789480.2 Issued France <br />European patent (EP) 14789480.2<br />Filed on 2014-10-13<br />Status: Issued 147168129 E-344-2013-0 E-344-2013-0-GB-15 TEM8 ANTIBODIES AND THEIR USE EP United Kingdom 3054987 14789480.2 Issued United Kingdom <br />European patent (EP) 14789480.2<br />Filed on 2014-10-13<br />Status: Issued 147168130 E-344-2013-0 E-344-2013-0-IT-16 TEM8 ANTIBODIES AND THEIR USE EP Italy 3054987 14789480.2 Issued Italy <br />European patent (EP) 14789480.2<br />Filed on 2014-10-13<br />Status: Issued 147168131 E-344-2013-0 E-344-2013-0-AU-17 TEM8 Antibodies and Their Use DIV Australia 2019253864 2019253864 Issued Australia <br />Divisional (DIV) 2019253864<br />Filed on 2019-10-24<br />Status: Issued 147174857 Antibody Drug Conjugate (ADC) 147174858 ANTXR1 147174859 TEM8 147174860 Tumor Microenvironment 147174862 Tumor Stroma TAB-4459 147157754 Transperineal Ultrasound-Guided Prostate Biopsy CC Collaboration, Licensing, Medical Devices, Non-Medical Devices, Oncology Collaboration Licensing Medical Devices Non-Medical Devices Oncology Reza Seifabadi, Bradford Wood, Sheng Xu <p>Prostate cancer is the most common male cancer in the United States, and the third most common worldwide. Prostate biopsies are often performed to confirm a cancer diagnosis and examine suspect tissue. Prostate biopsies are most often performed under transrectal ultrasound imaging (TRUS) guidance. TRUS images in real-time, at relatively low cost, and shows both prostate and boundaries. However, major problems with TRUS imaging are poor spatial resolution and low sensitivity for cancer detection. Fusion of TRUS images with preoperative images such as Magnetic Resonance (MR) or CAT may improve accuracy and resolution. But, this approach still requires TRUS imaging during the procedure and negates some of the relatively low cost. In addition, fusion of TRUS and MR images requires sensors  such as electromagnetic (EM) tracking to determine position and orientation. This increases the expense and complicates the process. The TRUS imaging process itself is invasive, stressful to patients, and increases infection risk. </p> <p>Researchers at Clinical Center (CC) developed a system that enables less-invasive prostate biopsies without the need for a tracking sensor. This is done through elimination of the TRUS probe in favor of a 3D ultrasound probe and custom image pre-registration to preoperative high-resolution volume scan (such as MR or CAT). The use of the 3-D probe allows for ultrasound image acquisition via perineal placement. The ultrasound images are registered to a biopsy needle guidance grid. To improve accuracy, the image registration to the grid trajectories is fused with grid registration images from preoperative MR or CAT images. The specific apertures in the needle guidance grid is selected based on the optimal trajectories to target tissue area for biopsy. This system offers a simpler, more accurate, less invasive and less expensive procedure than traditional TRUS-guided fusion biopsy. </p> <h2>Competitive Advantages:</h2> <ul><li>Real-time modality for lower cost</li> <li>Improved detection sensitivity;</li> <li>Sensorless</li> <li>Minimally noninvasive ultrasound imaging of prostate</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Cancer screening</li> <li>Prostate biopsy</li> </ul> 2018-07-09 2025-04-22 2018-07-09 2025-04-22 2018-07-09 guided biopsy, Prostate biopsy, Sensorless, transperineal 3-D ultrasound imaging, ultrasound-fusion image, WOOD False True Prototype True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2018-07-09 52406769 Prototype 52406769 NCI 37470483 Website Abstract 147164813 Wood, Bradford NIH - CC CC Wood, Bradford (CC) 1 147164814 Xu, Sheng NIH - CC CC Xu, Sheng (CC) 2 147164815 Seifabadi, Reza NIH - CC CC Seifabadi, Reza (CC) 3 147164813 Wood, Bradford NIH - CC CC Wood, Bradford (CC) 1 147164814 Xu, Sheng NIH - CC CC Xu, Sheng (CC) 2 147164815 Seifabadi, Reza NIH - CC CC Seifabadi, Reza (CC) 3 147158311 Sensorless Transperineal Ultrasound-MRI Fusion Guided Prostate Biopsy E-277-2015-0 Filing authorized Clinical Center (CC) 83703238 Fenn, Edward (Tedd) tedd.fenn@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-4459] Transperineal Ultrasound-Guided Prostate Biopsy&body=Please send me information about technology [TAB-4459] Transperineal Ultrasound-Guided Prostate Biopsy.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Fenn, Edward (Tedd)<br><a href="mailto:tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-4459] Transperineal Ultrasound-Guided Prostate Biopsy&body=Please send me information about technology [TAB-4459] Transperineal Ultrasound-Guided Prostate Biopsy.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">tedd.fenn@nih.gov</a><br> 147169093 E-277-2015-0 E-277-2015-0-US-01 TRANSPERINEAL ULTRASOUND-GUIDED PROSTATE BIOPSY PRV US 62/367,923 Abandoned US <br />Provisional (PRV) 62/367,923<br />Filed on 2016-07-28<br />Status: Abandoned 147169094 E-277-2015-0 E-277-2015-0-PCT-02 TRANSPERINEAL IMAGING-GUIDED PROSTATE NEEDLE PLACEMENT PCT Patent Cooperation Treaty PCT/US2017/044344 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2017/044344<br />Filed on 2017-07-28<br />Status: Expired 147169096 E-277-2015-0 E-277-2015-0-US-04 Sensorless Transperineal Ultrasound-MRI Fusion Guided Prostate Biopsy National Stage US 11,504,154 16/320,980 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11504154 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11504154">11,504,154</a><br />Filed on 2019-01-25<br />Status: Issued 147174573 guided biopsy 147174575 Prostate biopsy 147174576 Sensorless 147174578 transperineal 3-D ultrasound imaging 147174580 ultrasound-fusion image 147174581 WOOD TAB-4280 147157568 Scytovirin Domain 1 Related Polypeptides NCI Infectious Disease, Licensing, Therapeutics Infectious Disease Licensing Therapeutics Andrew Byrd, James McMahon, Barry O'Keefe, Chang-yun Xiong <p>Despite therapeutic advances, human immunodeficiency virus (HIV) is still a pervasive disease, with approximately 37 million people infected worldwide. Peptides have become popular therapeutic agents, as these proteins offer structural diversity for many different diseases. Several peptides were commercially developed as HIV therapeutics, demonstrating the high potential for peptides in treating HIV. </p> <p>Researchers at the National Cancer Institute developed a novel small polypeptide, known as SD1, for use as an HIV therapeutic. SD1 is derived from scytovirin, a potent anti-HIV protein isolated from the cyanobacterium Scytonema varium. SD1 has demonstrated low nanomolar activity against laboratory HIV strains and inhibits HIV by blocking viral fusion. SD1 is a lectin with specificity for viral envelope glycoproteins. </p> <h2>Competitive Advantages:</h2> <ul><li>Small size allows for decreased immunogenicity</li> <li>Small size allows for easy synthesis using automated techniques</li> <li>Low nanomolar activity against HIV strains</li> <li>Possible activity against additional viruses due to its ability to target viral envelope glycoproteins through a lectin mechanism</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Anti-HIV microbicide</li> <li>Anti-HIV therapeutic</li> </ul> 2018-07-27 2025-04-22 2018-07-27 2025-04-22 2018-07-27 HIV, O’Keefe, POLYPEPTIDES, Scytovirin False True Basic (Target Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2018-07-27 52406768 Discovery 52406768 NCI 37470483 Website Abstract E-017-2002 147162317 Xiong C, et al. Potent anti-HIV activity of scytovirin domain 1 peptide https://www.ncbi.nlm.nih.gov/pubmed/16647158 <a href="https://www.ncbi.nlm.nih.gov/pubmed/16647158">Xiong C, et al. Potent anti-HIV activity of scytovirin domain 1 peptide</a> 147164141 O'Keefe, Barry NIH - NCI NCI O'Keefe, Barry (NCI) 1 147164143 Xiong, Chang-yun NIH - NCI Xiong, Chang-yun 2 147164140 McMahon, James NIH - NCI NCI McMahon, James (NCI) 3 147164142 Byrd, Andrew NIH - NCI NCI Byrd, Andrew (NCI) 4 147164141 O'Keefe, Barry NIH - NCI NCI O'Keefe, Barry (NCI) 1 147164143 Xiong, Chang-yun NIH - NCI Xiong, Chang-yun 2 147164140 McMahon, James NIH - NCI NCI McMahon, James (NCI) 3 147164142 Byrd, Andrew NIH - NCI NCI Byrd, Andrew (NCI) 4 147158156 Scytovirin Domain 1 (SD1), An Antiviral Protein E-180-2005-0 Filing authorized NCI 83732213 Dick, Taryn taryn.dick@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB taryn.dick@nih.gov?subject=Web Inquiry on [TAB-4280] Scytovirin Domain 1 Related Polypeptides&body=Please send me information about technology [TAB-4280] Scytovirin Domain 1 Related Polypeptides.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dick, Taryn<br><a href="mailto:taryn.dick@nih.gov?subject=Web Inquiry on [TAB-4280] Scytovirin Domain 1 Related Polypeptides&body=Please send me information about technology [TAB-4280] Scytovirin Domain 1 Related Polypeptides.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">taryn.dick@nih.gov</a><br> 147167841 E-180-2005-0 E-180-2005-0-US-01 Scytovirin Domain 1 Related Polypeptides PRV US 60/684,353 Abandoned US <br />Provisional (PRV) 60/684,353<br />Filed on 2005-05-25<br />Status: Abandoned 147167842 E-180-2005-0 E-180-2005-0-PCT-02 Scytovirin Domain 1 (SD1) Related Polypeptides PCT Patent Cooperation Treaty PCT/US06/20100 Expired Patent Cooperation Treaty <br />(PCT) PCT/US06/20100<br />Filed on 2006-05-24<br />Status: Expired 147167843 E-180-2005-0 E-180-2005-0-EP-03 Scytovirin Domain 1 (SD1) Related Polypeptides National Stage European Patent 1891094 06771079.8 Expired European Patent <br />National Stage 06771079.8<br />Filed on 2006-05-24<br />Status: Expired 147167844 E-180-2005-0 E-180-2005-0-US-04 Scytovirin Domain 1 Related Polypeptides ORD US 8,067,530 11/914,833 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8067530 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8067530">8,067,530</a><br />Filed on 2007-11-19<br />Status: Issued 147167845 E-180-2005-0 E-180-2005-0-FR-05 Scytovirin Domain 1 (SD1) Related Polypeptides EP France 1891094 06771079.8 Expired France <br />European patent (EP) 06771079.8<br />Filed on 2007-11-23<br />Status: Expired 147167846 E-180-2005-0 E-180-2005-0-DE-06 Scytovirin Domain 1 (SD1) Related Polypeptides EP Germany 1891094 06771079.8 Expired Germany <br />European patent (EP) 06771079.8<br />Filed on 2007-11-23<br />Status: Expired 147167847 E-180-2005-0 E-180-2005-0-IE-07 Scytovirin Domain 1 (SD1) Related Polypeptides EP Ireland 1891094 06771079.8 Expired Ireland <br />European patent (EP) 06771079.8<br />Filed on 2007-11-23<br />Status: Expired 147167848 E-180-2005-0 E-180-2005-0-GB-08 Scytovirin Domain 1 (SD1) Related Polypeptides EP United Kingdom 1891094 06771079.8 Expired United Kingdom <br />European patent (EP) 06771079.8<br />Filed on 2007-11-23<br />Status: Expired 147167849 E-180-2005-0 E-180-2005-0-US-09 Scytovirin Domain 1 Related Polypeptides DIV US 8,481,255 13/250,309 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8481255 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8481255">8,481,255</a><br />Filed on 2006-05-24<br />Status: Expired 147173101 HIV 147173102 O’Keefe 147173103 POLYPEPTIDES 147173104 Scytovirin TAB-3873 147157153 RNA/DNA Nanoparticles as Cancer Therapeutics NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Kirill Afonin, Eckart Bindewald, Lorena Parlea, Bruce Shapiro, Mathias Viard <p>The development of RNA-based nanostructures and their use in a variety of applications, including RNA interference (RNAi) and drug delivery, represents an emerging field of science, technology, and biomedicine.  RNA is a dynamic material because of its natural functionalities, its ability to fold into complex small structures, and its capacity to self-assemble. <br /> Taking advantage of these characteristic, NCI Researchers have improved upon their existing invention of multi-functional RNA/DNA nanoparticles by adding a RNA toehold instead of a DNA toehold.  In in vitro studies, they have shown that the nanoparticles are capable of inhibiting HIV-1 gene expression in Hela cells transfected with a HIV-1 infectious clone and GFP expression in MDA-MB231 breast cancer cell lines transfected with eGFP. </p> <h2>Competitive Advantages:</h2> <ul><li>Small size</li> <li>Chemical stability</li> <li>Less immunogenic</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Therapeutic siRNA for cancer, CNS, and viral infections</li> <li>Diagnostic to visualize cancerous or virus-infected cells</li> <li>Increasing market for RNA-based therapeutics expected to continue by &gt;25% annually through 2020</li> </ul> 2018-07-27 2025-04-22 2022-12-05 2025-04-22 2018-07-27 Gene silencing, nanobiology, RNAi, Shapiro False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2022-12-05 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-038-2012 E-039-2012 E-059-2009 E-156-2014 E-277-2016 E-765-2013 147162069 Afonin K, et al. The use of minimal RNA toeholds to trigger the activation of multiple functionalities. https://www.ncbi.nlm.nih.gov/pubmed/26926382 <a href="https://www.ncbi.nlm.nih.gov/pubmed/26926382">Afonin K, et al. The use of minimal RNA toeholds to trigger the activation of multiple functionalities.</a> 147162147 Bindewald E, et al. Multistrand structure prediction of nucleic acid assemblies and design of RNA switches. https://www.ncbi.nlm.nih.gov/pubmed/26926528 <a href="https://www.ncbi.nlm.nih.gov/pubmed/26926528">Bindewald E, et al. Multistrand structure prediction of nucleic acid assemblies and design of RNA switches.</a> 147162683 Shapiro, Bruce NIH - NCI NCI Shapiro, Bruce (NCI) 1 147162684 Viard, Mathias NIH - NCI Leidos Viard, Mathias (Leidos) 2 147162685 Bindewald, Eckart NIH - NCI Leidos Bindewald, Eckart (Leidos) 3 147162686 Afonin, Kirill NIH - NCI Afonin, Kirill 4 147162687 Parlea, Lorena NIH - NCI NCI Parlea, Lorena (NCI) 5 147162683 Shapiro, Bruce NIH - NCI NCI Shapiro, Bruce (NCI) 1 147162684 Viard, Mathias NIH - NCI Leidos Viard, Mathias (Leidos) 2 147162685 Bindewald, Eckart NIH - NCI Leidos Bindewald, Eckart (Leidos) 3 147162686 Afonin, Kirill NIH - NCI Afonin, Kirill 4 147162687 Parlea, Lorena NIH - NCI NCI Parlea, Lorena (NCI) 5 147157935 Triggering Of Multiple Functionalities Using Minimal RNA Toeholds In RNA-based Nanoparticles E-078-2016-0 Filing authorized NCI 83732917 Favila, Michelle michelle.favila@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC michelle.favila@nih.gov?subject=Web Inquiry on [TAB-3873] RNA/DNA Nanoparticles as Cancer Therapeutics&body=Please send me information about technology [TAB-3873] RNA/DNA Nanoparticles as Cancer Therapeutics.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Favila, Michelle<br><a href="mailto:michelle.favila@nih.gov?subject=Web Inquiry on [TAB-3873] RNA/DNA Nanoparticles as Cancer Therapeutics&body=Please send me information about technology [TAB-3873] RNA/DNA Nanoparticles as Cancer Therapeutics.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">michelle.favila@nih.gov</a><br> 147161006 E-078-2016-0 E-078-2016-0-PCT-02 RNA/DNA HYBRID NANOPARTICLES MODIFIED WITH SINGLE STRANDED RNA TOEHOLDS AND USES THEREOF PCT Patent Cooperation Treaty PCT/US2017/017661 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2017/017661<br />Filed on 2017-02-13<br />Status: Expired 147164951 E-078-2016-0 E-078-2016-0-US-01 RNA/DNA Hybrid Nanoparticles Modified with Single Stranded RNA Toeholds and Uses Thereof PRV US 62/294,848 Abandoned US <br />Provisional (PRV) 62/294,848<br />Filed on 2016-02-12<br />Status: Abandoned 147164952 E-078-2016-0 E-078-2016-0-US-03 RNA/DNA HYBRID NANOPARTICLES MODIFIED WITH SINGLE STRANDED RNA TOEHOLDS AND USES THEREOF National Stage US 16/076,878 Abandoned US <br />National Stage 16/076,878<br />Filed on 2018-08-09<br />Status: Abandoned 147164953 E-078-2016-0 E-078-2016-0-EP-04 RNA/DNA HYBRID NANOPARTICLES MODIFIED WITH SINGLE STRANDED RNA TOEHOLDS AND USES THEREOF National Stage European Patent 17706653.7 Abandoned European Patent <br />National Stage 17706653.7<br />Filed on 2018-09-12<br />Status: Abandoned 147164954 E-078-2016-0 E-078-2016-0-US-05 RNA/DNA HYBRID NANOPARTICLES MODIFIED WITH SINGLE STRANDED RNA TOEHOLDS AND USES THEREOF DIV US 17/102,786 Abandoned US <br />Divisional (DIV) 17/102,786<br />Filed on 2020-11-24<br />Status: Abandoned 147170869 Gene silencing 147170870 nanobiology 147170871 RNAi 147170872 Shapiro TAB-4027 147157308 Fusion Proteins as HIV-1 Entry Inhibitors NCI Infectious Disease, Licensing, Therapeutics Infectious Disease Licensing Therapeutics Weizao Chen, Dimiter Dimitrov, Tianlei Ying <p>Soluble forms of human CD4 (sCD4) inhibit HIV-1 entry into immune cells.  Different forms of sCD4 and their fusion proteins have been extensively studied as promising HIV-1 inhibitors – including in animal models and clinical trials.  However, they have not been successful in human studies due to their transient efficacy.  sCD4 is also known to interact with class II major histocompatibility complex (MHCII) and, at low concentrations, could enhance HIV-1 infectivity. </p> <p>NCI researchers previously described a novel bispecific multivalent fusion protein called 4Dm2m which contains a single human CD4 domain (mD1.22) and a potent HIV-1 inhibitor (m36.4) (NIH Reference No. E-033-2013).  mD1.22 is highly soluble and stable with good neutralizing activity without measurable interaction with MHCII.  The NCI inventors have recently discovered new variants of 4Dm2m with increased stability and potency in mediating antibody dependent cellular cytotoxicity (ADCC) against cells expressing the HIV-1 envelope glycoprotein.  The newly identified variants also have increased half-lives in vivo and enhanced antibody binding. </p> <h2>Competitive Advantages:</h2> <ul><li>Increased stability and half-life over previously identified fusion protein </li> <li>Enhanced potency in mediating ADCC against HIV-1 infected cells</li> <li>Continuous  expression of high levels of these soluble receptors in vivo may overcome biggest challenge to efficacy in patients with HIV-1 infection</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Prophylactic or therapeutic against HIV-1 infection</li> <li>Rapid detection of HIV virus </li> </ul> 2018-07-27 2025-04-22 2018-07-27 2025-04-22 2018-07-27 antibody dependent cellular cytotoxicity (ADCC), Class II major histocompatibility complex (MHCII), Dimitrov, fusion protein, HIV-1, sCD4 False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2018-07-27 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-033-2013 E-103-2010 E-203-2015 E-210-2016 147161993 Chen W, et al. Exceptionally potent and broadly cross-reactive, bispecific multivalent HIV-1 inhibitors based on single human CD4 and antibody domains. https://www.ncbi.nlm.nih.gov/pubmed/24198429 <a href="https://www.ncbi.nlm.nih.gov/pubmed/24198429">Chen W, et al. Exceptionally potent and broadly cross-reactive, bispecific multivalent HIV-1 inhibitors based on single human CD4 and antibody domains.</a> 147162149 Chen W, et al. Improving the CH1-CK heterodimerization and pharmacokinetics of 4Dm2m, a novel potent CD4-antibody fusion protein against HIV-1. https://www.ncbi.nlm.nih.gov/pubmed/26963639 <a href="https://www.ncbi.nlm.nih.gov/pubmed/26963639">Chen W, et al. Improving the CH1-CK heterodimerization and pharmacokinetics of 4Dm2m, a novel potent CD4-antibody fusion protein against HIV-1.</a> 147163265 Dimitrov, Dimiter NIH - NCI NCI Dimitrov, Dimiter (NCI) 1 147163266 Chen, Weizao NIH - NCI Chen, Weizao 2 147163267 Ying, Tianlei NIH - NCI Ying, Tianlei 3 147163265 Dimitrov, Dimiter NIH - NCI NCI Dimitrov, Dimiter (NCI) 1 147163266 Chen, Weizao NIH - NCI Chen, Weizao 2 147163267 Ying, Tianlei NIH - NCI Ying, Tianlei 3 147157954 Defucosylated Bispecific Multivalent Fusion Proteins Of Single Human CD4 And Antibody Domains For Therapy Of HIV-1 Infection E-086-2015-0 Filing authorized NCI 91814193 Freel, Rose rose.freel@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America rose.freel@nih.gov?subject=Web Inquiry on [TAB-4027] Fusion Proteins as HIV-1 Entry Inhibitors&body=Please send me information about technology [TAB-4027] Fusion Proteins as HIV-1 Entry Inhibitors.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Freel, Rose<br><a href="mailto:rose.freel@nih.gov?subject=Web Inquiry on [TAB-4027] Fusion Proteins as HIV-1 Entry Inhibitors&body=Please send me information about technology [TAB-4027] Fusion Proteins as HIV-1 Entry Inhibitors.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">rose.freel@nih.gov</a><br> 147166091 E-086-2015-0 E-086-2015-0-US-01 Defucosylated Bispecific Multivalent Fusion Proteins PRV US 62/138,003 Abandoned US <br />Provisional (PRV) 62/138,003<br />Filed on 2015-03-25<br />Status: Abandoned 147166092 E-086-2015-0 E-086-2015-0-PCT-02 Bispecific Multivalent Fusion Proteins PCT Patent Cooperation Treaty PCT/US2015/066131 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2015/066131<br />Filed on 2015-12-16<br />Status: Expired 147166093 E-086-2015-0 E-086-2015-0-EP-03 Bispecific Multivalent Fusion Proteins National Stage European Patent 15823452.6 Abandoned European Patent <br />National Stage 15823452.6<br />Filed on 2015-12-16<br />Status: Abandoned 147166094 E-086-2015-0 E-086-2015-0-US-04 BISPECIFIC MULTIVALENT FUSION PROTEINS National Stage US 10,472,412 15/561,268 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10472412 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10472412">10,472,412</a><br />Filed on 2017-09-25<br />Status: Issued 147166095 E-086-2015-0 E-086-2015-0-EP-05 Bispecific Multivalent Fusion Proteins DIV European Patent 19189394.0 Pending European Patent <br />Divisional (DIV) 19189394.0<br />Filed on 2019-07-31<br />Status: Pending 147171109 antibody dependent cellular cytotoxicity (ADCC) 147171111 Class II major histocompatibility complex (MHCII) 147171112 Dimitrov 147171113 fusion protein 147171114 HIV-1 147171116 sCD4 TAB-4068 147157350 Conformational Restriction of Cyanine Fluorophores in Far-Red and Near-IR Range NCI Cardiology, Collaboration, Diagnostics, Gastroenterology, Licensing, Nephrology, Oncology Cardiology Collaboration Diagnostics Gastroenterology Licensing Nephrology Oncology Megan Michie, Martin Schnermann <p>Small molecule fluorescent probes are important tools in diagnostic medicine. Existing far-red and near-IR cyanine fluorophores (e.g. Cy5, Alexa 647, Cy7, ICG) are active in the far-red and near-range, but these agents suffer from modest quantum yields (brightness) which limit wide utility. It has been reported that the limited brightness of these fluorophores is due to an excited-state C-C rotation pathway.</p> <p>The invention is directed to a new class of conformationally restricted cyanines that exhibit significantly improved quantum yield (3-4-fold increase in fluorescence quantum yield). These compounds are active in the long wavelength range (absorbance maxima = 661nm, emission maxima = 681nm). Additionally, these compounds are detectable at lower concentrations with concurrent improvements in signal to noise. While these compounds can be readily appended to antibodies and small-molecule based targeting motifs, these compounds are particularly useful for imaging procedures where photon count is limiting, e.g., FACS procedures, super resolution microscopy, and fluorescence guided surgery applications.</p> <p>The invention is also directed to a generalized approach for synthesizing variants of the invention cyanine fluorophores prepared thus far.</p> <h2>Competitive Advantages:</h2> <ul><li>Improved quantum yield (3-4-fold increase in fluorescent emission over normal Cy5-type dyes (Absorbance maxima = 661 nm, Emission maxima= 681 nm, fluorescence quantum yield = 0.70)   </li> <li>Excellent recovery from NaBH4 reduction </li> <li>Improved photon output in single molecule localization microscopy</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Fluorescence guided surgery </li> <li>Tumor visualization </li> <li>In vivo imaging</li> <li>Fluorescent marker of the bile duct and ureter during abdominal surgery</li> <li>Diagnostic medicine</li> <li>Super resolution microscopy</li> <li>FACS and other microscopy procedures where photon count is limiting</li> </ul> 2018-07-27 2025-04-22 2018-07-27 2025-04-22 2018-07-27 CANCER, Cardiovascular, cyanine fluorophores, FACS, Fluorescence guided surgery, Fluorescent probes, gastrointestinal (GI), IMAGING, KIDNEY, Schnermann, super resolution microscopy False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2018-07-27 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-036-2018 E-139-2018 E-271-2014 147161962 Michie M, et al. Cyanine Conformational Restraint in the Far-Red Range. https://www.ncbi.nlm.nih.gov/pubmed/28862842 <a href="https://www.ncbi.nlm.nih.gov/pubmed/28862842">Michie M, et al. Cyanine Conformational Restraint in the Far-Red Range.</a> 147163408 Schnermann, Martin NIH - NCI NCI Schnermann, Martin (NCI) 1 147163409 Michie, Megan NIH - NCI Michie, Megan 2 147163408 Schnermann, Martin NIH - NCI NCI Schnermann, Martin (NCI) 1 147163409 Michie, Megan NIH - NCI Michie, Megan 2 147158075 Conformational Restriction Of Cyanine Fluorophores In Far-red And Near-lR Range E-143-2017-0 Filing authorized NCI 83704821 Nguyen-Antczak, Lauren lauren.nguyen-antczak@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-4068] Conformational Restriction of Cyanine Fluorophores in Far-Red and Near-IR Range&body=Please send me information about technology [TAB-4068] Conformational Restriction of Cyanine Fluorophores in Far-Red and Near-IR Range.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Nguyen-Antczak, Lauren<br><a href="mailto:lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-4068] Conformational Restriction of Cyanine Fluorophores in Far-Red and Near-IR Range&body=Please send me information about technology [TAB-4068] Conformational Restriction of Cyanine Fluorophores in Far-Red and Near-IR Range.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">lauren.nguyen-antczak@nih.gov</a><br> 147161103 E-143-2017-0 E-143-2017-0-US-01 Conformational Restriction Of Cyanine Fluorophores In Far-red And Near-lR Range PRV US 62/549,566 Abandoned US <br />Provisional (PRV) 62/549,566<br />Filed on 2017-08-24<br />Status: Abandoned 147166312 E-143-2017-0 E-143-2017-0-PCT-02 Conformational Restriction Of Cyanine Fluorophores In Far-red And Near-lR Range PCT Patent Cooperation Treaty PCT/US2018/047876 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2018/047876<br />Filed on 2018-08-24<br />Status: Expired 147166313 E-143-2017-0 E-143-2017-0-US-03 Conformational Restriction Of Cyanine Fluorophores In Far-red And Near-lR Range National Stage US 10,994,029 16/640,620 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10994029 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10994029">10,994,029</a><br />Filed on 2020-02-20<br />Status: Issued 147166314 E-143-2017-0 E-143-2017-0-EP-04 Conformational Restriction Of Cyanine Fluorophores In Far-red And Near-lR Range National Stage European Patent 3655408 18765321.7 Issued European Patent <br />National Stage 18765321.7<br />Filed on 2018-08-24<br />Status: Issued 147166315 E-143-2017-0 E-143-2017-0-JP-05 Conformational Restriction Of Cyanine Fluorophores In Far-red And Near-lR Range National Stage Japan 7418323 2020-510560 Issued Japan <br />National Stage 2020-510560<br />Filed on 2018-08-24<br />Status: Issued 147166316 E-143-2017-0 E-143-2017-0-US-06 CONFORMATIONAL RESTRICTION OF CYANINE FLUOROPHORES IN FAR-RED AND NEAR-IR RANGE CON US 11,707,537 17/198,004 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11707537 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11707537">11,707,537</a><br />Filed on 2021-03-10<br />Status: Issued 147166317 E-143-2017-0 E-143-2017-0-CH-07 Conformational Restriction Of Cyanine Fluorophores In Far-red And Near-lR Range EP Switzerland 3655408 18765321.7 Issued Switzerland <br />European patent (EP) 18765321.7<br />Filed on 2018-08-24<br />Status: Issued 147166318 E-143-2017-0 E-143-2017-0-DE-08 Conformational Restriction Of Cyanine Fluorophores In Far-red And Near-lR Range EP Germany 3655408 18765321.7 Issued Germany <br />European patent (EP) 18765321.7<br />Filed on 2018-08-24<br />Status: Issued 147166319 E-143-2017-0 E-143-2017-0-GB-09 Conformational Restriction Of Cyanine Fluorophores In Far-red And Near-lR Range EP United Kingdom 3655408 18765321.7 Issued United Kingdom <br />European patent (EP) 18765321.7<br />Filed on 2018-08-24<br />Status: Issued 147166320 E-143-2017-0 E-143-2017-0-NL-10 Conformational Restriction Of Cyanine Fluorophores In Far-red And Near-lR Range EP The Netherlands 3655408 18765321.7 Issued The Netherlands <br />European patent (EP) 18765321.7<br />Filed on 2018-08-24<br />Status: Issued 147166321 E-143-2017-0 E-143-2017-0-SE-11 Conformational Restriction Of Cyanine Fluorophores In Far-red And Near-lR Range EP Sweden 3655408 18765321.7 Issued Sweden <br />European patent (EP) 18765321.7<br />Filed on 2018-08-24<br />Status: Issued 147172303 CANCER 147172304 Cardiovascular 147172306 cyanine fluorophores 147172307 FACS 147172309 Fluorescence guided surgery 147172311 Fluorescent probes 147172313 gastrointestinal (GI) 147172314 IMAGING 147172315 KIDNEY 147172316 Schnermann 147172318 super resolution microscopy TAB-4250 147157537 Argon to Improve Bioanalyte Stability in Fixed Tissue Specimens NCI Diagnostics, Licensing, Oncology Diagnostics Licensing Oncology Joon-Yong Chung, Stephen Hewitt, Sagar Joshi, Vasuhi Rasanayagam, Meenakshi Sundar <p>The degradation of archival surgical and biospecimen limits the utility of many biomarkers that may have prognostic or predictive significance in guiding a patient’s therapy. Previous methods at preventing the degradation of RNA and proteins in formalin fixed, paraffin embedded (FFPE) tissue blocks &amp; slides have no protective benefit. </p> <p>Researchers at the National Institutes of Health (NIH) and American Air Liquide have demonstrated that dissolved reactive gasses entrapped in the fixative and solutions used in tissue preparation contribute to this degradation. Removal of these reactive gasses, and replacement with argon, improves biomolecule stability.  The primary evaluation was based on measurements of RNA stability, however the investigator’s work demonstrates the relationships between RNA, protein, and DNA quality. </p> <h2>Competitive Advantages:</h2> <ul><li>The addition of argon to FFPE procedures has been shown to improve RNA integrity by over 40% over standard FFPE procedures</li> <li>The use of the new argon FFPE procedure has been demonstrated to improve protein integrity in tissue fixed with FFPE compared with non-argon FFPE procedures</li> </ul> <h2>Commercial Applications:</h2> <ul><li>This novel technology may be used to generate new argon-containing fixatives to improve specimen quality without affecting traditional histopathology methods</li> <li>The novel technology includes the fixation of tissue in solutions that have been sparged with argon, as well as technology for the impregnation of tissue with solutions sparged with argon </li> </ul> 2018-08-03 2025-04-22 2018-08-03 2025-04-22 2018-08-03 Anatomic Pathology Tissue Handling Improvements, ARGON, DNA, FFPE, formaldehyde, Formalin Fixed Paraffin Embedded, Hewitt, Paraffin Embedded, RNA False True Prototype True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2018-08-03 52406769 Prototype 52406769 NCI 37470483 Website Abstract E-128-2017 E-139-2015 147164044 Hewitt, Stephen NIH - NCI NCI Hewitt, Stephen (NCI) 1 147164046 Rasanayagam, Vasuhi American Air Liquide, Inc Rasanayagam, Vasuhi 2 147164045 Chung, Joon-Yong NIH - NCI NCI Chung, Joon-Yong (NCI) 3 147164047 Joshi, Sagar American Air Liquide, Inc Joshi, Sagar 4 147164048 Sundar, Meenakshi American Air Liquide, Inc Sundar, Meenakshi 5 147164044 Hewitt, Stephen NIH - NCI NCI Hewitt, Stephen (NCI) 1 147164046 Rasanayagam, Vasuhi American Air Liquide, Inc Rasanayagam, Vasuhi 2 147164045 Chung, Joon-Yong NIH - NCI NCI Chung, Joon-Yong (NCI) 3 147164047 Joshi, Sagar American Air Liquide, Inc Joshi, Sagar 4 147164048 Sundar, Meenakshi American Air Liquide, Inc Sundar, Meenakshi 5 147157875 Use Of Argon As A Tissue Fixation Preservative E-052-2013-0 Filing authorized American Air Liquide, Inc, NCI 121111111 Greene, Jaime greenejaime@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America greenejaime@mail.nih.gov?subject=Web Inquiry on [TAB-4250] Argon to Improve Bioanalyte Stability in Fixed Tissue Specimens&body=Please send me information about technology [TAB-4250] Argon to Improve Bioanalyte Stability in Fixed Tissue Specimens.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Greene, Jaime<br><a href="mailto:greenejaime@mail.nih.gov?subject=Web Inquiry on [TAB-4250] Argon to Improve Bioanalyte Stability in Fixed Tissue Specimens&body=Please send me information about technology [TAB-4250] Argon to Improve Bioanalyte Stability in Fixed Tissue Specimens.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">greenejaime@mail.nih.gov</a><br> 147160969 E-052-2013-0 E-052-2013-0-US-03 Use Of Argon As A Tissue Fixation Preservative National Stage US 9,714,409 14/422,062 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9714409 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9714409">9,714,409</a><br />Filed on 2015-02-17<br />Status: Issued 147167678 E-052-2013-0 E-052-2013-0-US-01 Use Of Argon As A Tissue Fixation Preservative PRV US 61/684,204 Abandoned US <br />Provisional (PRV) 61/684,204<br />Filed on 2012-08-17<br />Status: Abandoned 147167679 E-052-2013-0 E-052-2013-0-PCT-02 Use Of Argon As A Tissue Fixation Preservative PCT Patent Cooperation Treaty PCT/US2013/55337 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2013/55337<br />Filed on 2013-08-16<br />Status: Expired 147170350 Anatomic Pathology Tissue Handling Improvements 147170351 ARGON 147170352 DNA 147170353 FFPE 147170354 formaldehyde 147170356 Formalin Fixed Paraffin Embedded 147170357 Hewitt 147170359 Paraffin Embedded 147170360 RNA TAB-4025 147157306 Nucleic Acid Nanoparticles (NANP) and Methods of Using Same for Controlled Immunomodulation NCI Collaboration, Immunology, Licensing, Oncology, Therapeutics Collaboration Immunology Licensing Oncology Therapeutics Kirill Afonin, Marina Dobrovolskaia, Justin Halman, Enping Hong <p>The technology is directed to compositions and methods of designing nucleic acid nanoparticles (NANPs) composed entirely of DNA, RNA, or DNA and RNA to achieve desirable immunostimulation and decrease undesirable effects on the immune system by changing the composition of the NANP. Benefits of the invention include the desirable activation of the immune system by these particles to increase the efficacy of vaccines and immunotherapies.</p> <p>In contrast, the NANPs with minimal to no recognition by the host's immune cells serve as an effective tool for the delivery of therapeutic payloads (small molecules and therapeutic oligonucleotides) without the induction of undesirable immunostimulatory side-effects. These NANPs are highly tunable and can assume various shapes, sizes, compositions, and immunostimulatory effects; additionally, they can be designed to carry a variety of pharmaceutically active payloads simultaneously.</p> <h2>Competitive Advantages:</h2> <ul><li>Reduces immunological side effects often seen with TNAS</li> <li>Overcomes the instability in the biological matrices often found with immunostimulatory oligonucleotides used for vaccines and immunotherapies</li> <li>Overcomes systemic toxicity and broad spectrum of immunostimulatory effects (i.e. induction of pro-inflammatory cytokines) which often occurs with current immunostimulatory oligonucleotides used for vaccines and immunotherapies</li> <li>Highly tunable and can assume various shapes, sizes, compositions, and immunostimulatory effects</li> <li>Can be designed to carry a variety of pharmaceutically active payloads simultaneously</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Development of vaccines and drug delivery platforms</li> </ul> 2018-08-14 2025-04-22 2018-08-14 2025-04-22 2018-08-14 CANCER, Dobrovolskaia, IMMUNE, Immunomodulation, Inflammation, Nucleic Acid Nanoparticle False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2018-08-14 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147162415 Sajja S, et al. Dynamic Behavior of RNA Nanoparticles Analyzed by AFM on a Mica/Air Interface. https://www.ncbi.nlm.nih.gov/pubmed/29669419 <a href="https://www.ncbi.nlm.nih.gov/pubmed/29669419">Sajja S, et al. Dynamic Behavior of RNA Nanoparticles Analyzed by AFM on a Mica/Air Interface.</a> 147163261 Afonin, Kirill University of North Carolina, Charlotte Afonin, Kirill 1 147163262 Halman, Justin University of North Carolina, Charlotte Halman, Justin 2 147163260 Dobrovolskaia, Marina NIH - NCI Leidos Dobrovolskaia, Marina (Leidos) 3 147163263 Hong, Enping NCI - CCR Leidos Hong, Enping (Leidos) 4 147163261 Afonin, Kirill University of North Carolina, Charlotte Afonin, Kirill 1 147163262 Halman, Justin University of North Carolina, Charlotte Halman, Justin 2 147163260 Dobrovolskaia, Marina NIH - NCI Leidos Dobrovolskaia, Marina (Leidos) 3 147163263 Hong, Enping NCI - CCR Leidos Hong, Enping (Leidos) 4 147157923 Nucleic Acid Nanoparticles (NANP) As Efficient Tools For Controlled Immunomodulation E-069-2018-0 Filing authorized NCI, University of North Carolina, Charlotte (UNC) 147162512 Nucleic Acid Nanoparticles (NANP) As Efficient Tools For Controlled Immunomodulation E-069-2018-1 Filing authorized NCI, University of North Carolina, Charlotte (UNC) 147162513 Nucleic Acid Nanoparticles (NANP) As Efficient Tools For Controlled Immunomodulation E-069-2018-2 Closed NCI, University of North Carolina, Charlotte (UNC) 83704821 Nguyen-Antczak, Lauren lauren.nguyen-antczak@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-4025] Nucleic Acid Nanoparticles (NANP) and Methods of Using Same for Controlled Immunomodulation&body=Please send me information about technology [TAB-4025] Nucleic Acid Nanoparticles (NANP) and Methods of Using Same for Controlled Immunomodulation.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Nguyen-Antczak, Lauren<br><a href="mailto:lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-4025] Nucleic Acid Nanoparticles (NANP) and Methods of Using Same for Controlled Immunomodulation&body=Please send me information about technology [TAB-4025] Nucleic Acid Nanoparticles (NANP) and Methods of Using Same for Controlled Immunomodulation.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">lauren.nguyen-antczak@nih.gov</a><br> 147160995 E-069-2018-0 E-069-2018-0-US-01 Nucleic Acid Nanoparticles (NANP) and Methods of Using Same for Controlled Immunomodulation PRV US 62/623,496 Abandoned US <br />Provisional (PRV) 62/623,496<br />Filed on 2018-01-29<br />Status: Abandoned 147166087 E-069-2018-1 E-069-2018-1-US-01 Nucleic Acid Nanoparticles (NANP) As Efficient Tools For Controlled Immunomodulation PRV US 62/789,033 Abandoned US <br />Provisional (PRV) 62/789,033<br />Filed on 2019-01-07<br />Status: Abandoned 147170761 CANCER 147170763 Dobrovolskaia 147170764 IMMUNE 147170765 Immunomodulation 147170766 Inflammation 147170768 Nucleic Acid Nanoparticle TAB-4289 147157578 A Dendritic Cell Vaccine to Immunize Cancer Patients Against Mutated Neoantigens Expressed by the Autologous Cancer NCI Collaboration, Licensing, Oncology, Vaccines Collaboration Licensing Oncology Vaccines Gal Cafri, Jared Gartner, Paul Robbins, Steven Rosenberg <p>Vaccines against non-viral cancers target mainly differentiation antigens, cancer testis antigens, and overexpressed antigens.  One common feature to these antigens is their presence in central immunological tolerance. Using these vaccines, T cells underwent depletion of high avidity clones directed against such antigens. This depletion can cause the loss of T cells bearing high affinity T cell receptors (TCRs) for their cognate antigens which have superior cytotoxic capacity, longer persistence in the tumor microenvironment, and decreased susceptibility to immune suppression.</p> <p>The Surgery Branch of the National Cancer Institute (NCI) has identified more than 200 immunogenic epitopes from multiple cancer types including melanoma, ovarian, colorectal, lung and breast cancers. To use those defined neoantigens for therapeutic purposes, NCI researchers have developed a personalized dendritic cell (DC) vaccine.  Monocytes are isolated from patients’ apheresis, differentiated into DCs, loaded with immunogenic peptides and matured using a combination of cytokines and Toll-Like Receptor (TLR) ligands. These cells can then be administered to patients to prompt tumor-specific high avidity T cells against cancer-specific antigens.  This pipeline can be applied to any cancer type and can be completed rapidly.</p> <p>The NCI, Surgery Branch, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize this dendritic cell vaccine. </p> <h2>Competitive Advantages:</h2> <ul><li>Increased cytotoxic capacity</li> <li>Increased persistence in the tumor microenvironment</li> <li>Decreased susceptibility to immune suppression</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Treatment of multiple cancer types</li> <li>Personalized to the patient </li> </ul> 2018-08-15 2025-04-22 2018-08-15 2025-04-22 2018-08-15 CANCER, Dendritic cells, Immunotherapy, Neoantigens, Rosenberg, T Cells, vaccines False True Clinical True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2018-08-15 72159138 Clinical Phase I 72159138 NCI 37470483 Website Abstract 147161978 Gros et al., Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients. https://www.ncbi.nlm.nih.gov/pubmed/26901407 <a href="https://www.ncbi.nlm.nih.gov/pubmed/26901407">Gros et al., Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients.</a> 147162365 Tran et al., Immunogenicity of somatic mutations in human gastrointestinal cancers. https://www.ncbi.nlm.nih.gov/pubmed/26516200 <a href="https://www.ncbi.nlm.nih.gov/pubmed/26516200">Tran et al., Immunogenicity of somatic mutations in human gastrointestinal cancers.</a> 147164177 Cafri, Gal NIH - NCI NCI Cafri, Gal (NCI) 1 147164175 Robbins, Paul NIH - NCI NCI Robbins, Paul (NCI) 2 147164176 Gartner, Jared NIH - NCI NCI Gartner, Jared (NCI) 3 147164174 Rosenberg, Steven NIH - NCI NCI Rosenberg, Steven (NCI) 4 147164177 Cafri, Gal NIH - NCI NCI Cafri, Gal (NCI) 1 147164175 Robbins, Paul NIH - NCI NCI Robbins, Paul (NCI) 2 147164176 Gartner, Jared NIH - NCI NCI Gartner, Jared (NCI) 3 147164174 Rosenberg, Steven NIH - NCI NCI Rosenberg, Steven (NCI) 4 147158317 Dendritic Cell Vaccine To Immunize Cancer Patients Against Mutated Neoantigens Expressed By The Autologous Cancer E-280-2016-0 Filing authorized NCI 83709866 Burke, Andrew burkear@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC burkear@nih.gov?subject=Web Inquiry on [TAB-4289] A Dendritic Cell Vaccine to Immunize Cancer Patients Against Mutated Neoantigens Expressed by the Autologous Cancer&body=Please send me information about technology [TAB-4289] A Dendritic Cell Vaccine to Immunize Cancer Patients Against Mutated Neoantigens Expressed by the Autologous Cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Burke, Andrew<br><a href="mailto:burkear@nih.gov?subject=Web Inquiry on [TAB-4289] A Dendritic Cell Vaccine to Immunize Cancer Patients Against Mutated Neoantigens Expressed by the Autologous Cancer&body=Please send me information about technology [TAB-4289] A Dendritic Cell Vaccine to Immunize Cancer Patients Against Mutated Neoantigens Expressed by the Autologous Cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">burkear@nih.gov</a><br> 147161258 E-280-2016-0 E-280-2016-0-US-01 METHODS OF PREPARING AN ISOLATED POPULATION OF DENDRITIC CELLS AND METHODS OF TREATING CANCER USING SAME PRV US 62/398,963 Abandoned US <br />Provisional (PRV) 62/398,963<br />Filed on 2016-09-23<br />Status: Abandoned 147167916 E-280-2016-0 E-280-2016-0-PCT-02 METHODS OF PREPARING AN ISOLATED POPULATION OF DENDRITIC CELLS AND METHODS OF TREATING CANCER USING SAME PCT Patent Cooperation Treaty PCT/US2017/051981 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2017/051981<br />Filed on 2017-09-18<br />Status: Expired 147167917 E-280-2016-0 E-280-2016-0-CA-03 METHODS OF PREPARING AN ISOLATED POPULATION OF DENDRITIC CELLS AND METHODS OF TREATING CANCER USING SAME National Stage Canada 3037882 Pending Canada <br />National Stage 3037882<br />Filed on 2017-09-18<br />Status: Pending 147167918 E-280-2016-0 E-280-2016-0-EP-04 METHODS OF PREPARING AN ISOLATED POPULATION OF DENDRITIC CELLS AND METHODS OF TREATING CANCER USING SAME National Stage European Patent 17784443.8 Pending European Patent <br />National Stage 17784443.8<br />Filed on 2019-03-21<br />Status: Pending 147167919 E-280-2016-0 E-280-2016-0-US-05 METHODS OF PREPARING AN ISOLATED POPULATION OF DENDRITIC CELLS AND METHODS OF TREATING CANCER USING SAME National Stage US 11,976,299 16/334,872 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11976299 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11976299">11,976,299</a><br />Filed on 2019-03-20<br />Status: Issued 147174638 CANCER 147174639 Dendritic cells 147174640 Immunotherapy 147174641 Neoantigens 147174642 Rosenberg 147174643 T Cells 147174644 vaccines TAB-4385 147157679 Methods for Producing Stem Cell-Like Memory T Cells for Use in T Cell-Based Immunotherapies NCI Collaboration, Infectious Disease, Licensing, Oncology, Therapeutics Collaboration Infectious Disease Licensing Oncology Therapeutics Luca Gattinoni, Enrico Lugli, Nicholas Restifo, Mario Roederer <p>T cells currently employed for T cell-based immunotherapies are often senescent, terminally differentiated cells with poor proliferative and survival capacity. Recently, however, scientists at the National Cancer Institute (NCI) identified and characterized a new human memory T cell population with stem cell-like properties. Since these T cells have limited quantities in vivo, the scientists have developed methods by which high numbers of these cells can be generated ex vivo for use in T cell-based immunotherapies. Specifically, this invention describes a method for generating the stem cell-like memory T cells by stimulating naive T cells in the presence of GSK-3beta inhibitors. The invention also provides methodology for obtaining the stem cell-like memory T cells by sorting T cell lymphocytes using flow cytometry. These stem cell-like memory T cells display enhanced proliferation and survival upon transfer, have the multipotent capacity to generate all memory and effector T cell subsets, and show increased anti-tumor activity in a humanized mouse tumor model. Consequently, the coupling of T cell receptor or chimeric receptor gene transfer with this method will enable the generation of a large number of memory stem cells with the desired specificity to effectively treat patients with cancer and chronic infectious diseases.</p> <h2>Competitive Advantages:</h2> <ul><li>Enhanced proliferation and survival upon transfer</li> <li>Multipotent capacity to generate all memory and effector T cell subsets</li> <li>Increased anti-tumor activity</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Ex vivo generation of stem cell-like memory T cells for T cell-based immunotherapy</li> <li>Treatment for patients with cancer and chronic infectious diseases</li> </ul> 2018-08-15 2025-04-22 2021-06-10 2025-04-22 2018-08-15 anti-tumor activity, CANCER, Gattinoni, GSK-3beta, Immunotherapy, Infection, Stem Cell, T cell, WNT False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-06-10 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147161967 Lugli E, et al., Identification, isolation and in vitro expansion of human and nonhuman primate T stem cell memory cells. https://www.ncbi.nlm.nih.gov/pubmed/23222456 <a href="https://www.ncbi.nlm.nih.gov/pubmed/23222456">Lugli E, et al., Identification, isolation and in vitro expansion of human and nonhuman primate T stem cell memory cells.</a> 147162354 Gattinoni L, et al., Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells. https://www.ncbi.nlm.nih.gov/pubmed/19525962 <a href="https://www.ncbi.nlm.nih.gov/pubmed/19525962">Gattinoni L, et al., Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells.</a> 147162392 Gattinoni L, et al., A human memory T cell subset with stem cell-like properties. https://www.ncbi.nlm.nih.gov/pubmed/21926977 <a href="https://www.ncbi.nlm.nih.gov/pubmed/21926977">Gattinoni L, et al., A human memory T cell subset with stem cell-like properties.</a> 147164535 Gattinoni, Luca NIH - NCI NCI Gattinoni, Luca (NCI) 1 147164533 Restifo, Nicholas NIH - NCI NCI Restifo, Nicholas (NCI) 2 147164534 Roederer, Mario NIH - NIAID NIAID Roederer, Mario (NIAID) 3 147164536 Lugli, Enrico NIAID - VRC NIAID Lugli, Enrico (NIAID) 4 147164535 Gattinoni, Luca NIH - NCI NCI Gattinoni, Luca (NCI) 1 147164533 Restifo, Nicholas NIH - NCI NCI Restifo, Nicholas (NCI) 2 147164534 Roederer, Mario NIH - NIAID NIAID Roederer, Mario (NIAID) 3 147164536 Lugli, Enrico NIAID - VRC NIAID Lugli, Enrico (NIAID) 4 147158146 In Vitro Generation Of Memory Stem Cell-like T Cells E-174-2012-0 Filing authorized NCI, NIAID 83709866 Burke, Andrew burkear@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC burkear@nih.gov?subject=Web Inquiry on [TAB-4385] Methods for Producing Stem Cell-Like Memory T Cells for Use in T Cell-Based Immunotherapies&body=Please send me information about technology [TAB-4385] Methods for Producing Stem Cell-Like Memory T Cells for Use in T Cell-Based Immunotherapies.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Burke, Andrew<br><a href="mailto:burkear@nih.gov?subject=Web Inquiry on [TAB-4385] Methods for Producing Stem Cell-Like Memory T Cells for Use in T Cell-Based Immunotherapies&body=Please send me information about technology [TAB-4385] Methods for Producing Stem Cell-Like Memory T Cells for Use in T Cell-Based Immunotherapies.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">burkear@nih.gov</a><br> 147161149 E-174-2012-0 E-174-2012-0-PCT-01 Methods Of Producing T Memory Stem Cell Populations PCT Patent Cooperation Treaty PCT/US2012/053947 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2012/053947<br />Filed on 2012-09-06<br />Status: Expired 147168572 E-174-2012-0 E-174-2012-0-US-02 Methods of Producing T Memory Stem Cell Populations National Stage US 10,316,289 14/425,713 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10316289 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10316289">10,316,289</a><br />Filed on 2015-07-06<br />Status: Issued 147168573 E-174-2012-0 E-174-2012-0-US-03 METHODS OF PRODUCING T MEMORY STEM CELL POPULATIONS DIV US 11,111,478 16/410,327 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11111478 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11111478">11,111,478</a><br />Filed on 2019-05-13<br />Status: Issued 147168574 E-174-2012-0 E-174-2012-0-US-04 METHODS OF PRODUCING T MEMORY STEM CELL POPULATIONS CON US 12,516,289 17/465,577 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12516289 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12516289">12,516,289</a><br />Filed on 2021-09-02<br />Status: Issued 147173035 anti-tumor activity 147173036 CANCER 147173037 Gattinoni 147173039 GSK-3beta 147173040 Immunotherapy 147173041 Infection 147173042 Stem Cell 147173043 T cell 147173044 WNT TAB-3890 147157170 Topical Sodium Nitrate Ointment for Sickle Cell Disease CC Cardiology, Endocrinology, Licensing, Therapeutics Cardiology Endocrinology Licensing Therapeutics George Grimes, Haksong Jin, Gregory Kato, Caterina Minniti-Crouch, Gopal Potti, Deborah Sperling <p>Chronic leg ulcers are a debilitating vasculopathic complication for some patients with sickle cell disease (SCD). Prevalence of leg ulcers varies based on age and geographic location; about 5-10% of all SCD patients may suffer leg ulcers. These leg ulcers are painful, result in infections, hospitalization, disability, and negatively impact the patient’s social and psychological wellbeing on an ongoing basis. Until recently, patients with SCD only had one drug treatment option: hydroxyurea, which was approved by the Food and Drug Administration (FDA) in 1998 in adults and in 2017, in children age 2 and older. <br /> However, there are no FDA-approved treatments specifically to treat SCD ulcers. The ulcer may take months or even years to heal. Opioid drugs are often administered to relieve intense pain symptoms, but the opioids do not treat the underlying wound conditions and carry addiction risks with chronic use. Thus, there is an unmet medical need to develop therapies that heal SCD ulcers. <br /> Scientists at the National Institutes of Health (NIH) have developed a novel medical formulation; a promising sodium-nitrite cream for treating leg ulcers in SCD patients. The topical ointment helps increase nitric oxide levels in the wound. The specific formulation allows nitric oxide gas to dilate vessels by relaxing their smooth muscle cells. This aids healing the wound by increasing the amount of oxygenated blood that reaches the ulcer. A completed Phase 1 clinical trial of this sodium-nitrite cream has demonstrated that the therapy is safe, well-tolerated, and significantly reduces ulcer size and pain in the patients enrolled. This promising treatment has now received funding from a U.S. FDA-awarded grant through the Orphan Products Clinical Trials Grant Program to fund Phase 2 clinical studies for this treatment.  </p> <h2>Competitive Advantages:</h2> <ul><li>Completed Phase 1 studies</li> <li>Funded for Phase II studies - through the FDA Orphan Products Clinical Trials Grant Program</li> <li>Possible Orphan Drug Designation</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Cream/ointment for the treatment of ulcers related to sickle cell anemia</li> <li>Treatment for localized deficiency in nitric oxide </li> </ul> 2018-08-15 2025-04-22 2018-08-15 2025-04-22 2018-08-15 Blood Disorder, CREAM, Haksong, nitric oxide, Ointment, SCD, sickle cell disease, Sodium Nitrate, TOPICAL, Topical Therapeutic, Vascular Ulcers, Wound healing False True Clinical True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2018-08-15 72159138 Clinical Phase I 72159138 NCI 37470483 Website Abstract 147162465 Minniti C, et al. Topical sodium nitrite for chronic leg ulcers in patients with sickle cell anaemia: a phase 1 dose-finding safety and tolerability trial. https://www.ncbi.nlm.nih.gov/pubmed/25938131 <a href="https://www.ncbi.nlm.nih.gov/pubmed/25938131">Minniti C, et al. Topical sodium nitrite for chronic leg ulcers in patients with sickle cell anaemia: a phase 1 dose-finding safety and tolerability trial.</a> 147162758 Jin, Haksong NIH - CC NCATS Jin, Haksong (NCATS) 1 147162756 Grimes, George NIH - CC Grimes, George 2 147162761 Sperling, Deborah NIH - CC Sperling, Deborah 3 147162757 Potti, Gopal NIH - CC Potti, Gopal 4 147162759 Minniti-Crouch, Caterina NIH - NHLBI Minniti-Crouch, Caterina 5 147162760 Kato, Gregory NIH - NHLBI CC Kato, Gregory (CC) 6 147162758 Jin, Haksong NIH - CC NCATS Jin, Haksong (NCATS) 1 147162756 Grimes, George NIH - CC Grimes, George 2 147162761 Sperling, Deborah NIH - CC Sperling, Deborah 3 147162757 Potti, Gopal NIH - CC Potti, Gopal 4 147162759 Minniti-Crouch, Caterina NIH - NHLBI Minniti-Crouch, Caterina 5 147162760 Kato, Gregory NIH - NHLBI CC Kato, Gregory (CC) 6 147158078 New Formulation Of Topical Sodium Nitrate Ointment E-149-2014-0 Filing authorized Clinical Center (CC), National Heart, Lung, and Blood Institute (NHLBI) 83703238 Fenn, Edward (Tedd) tedd.fenn@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-3890] Topical Sodium Nitrate Ointment for Sickle Cell Disease&body=Please send me information about technology [TAB-3890] Topical Sodium Nitrate Ointment for Sickle Cell Disease.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Fenn, Edward (Tedd)<br><a href="mailto:tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-3890] Topical Sodium Nitrate Ointment for Sickle Cell Disease&body=Please send me information about technology [TAB-3890] Topical Sodium Nitrate Ointment for Sickle Cell Disease.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">tedd.fenn@nih.gov</a><br> 147161105 E-149-2014-0 E-149-2014-0-US-04 TOPICAL SODIUM NITRITE FORMULATION National Stage US 10,272,039 15/525,557 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10272039 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10272039">10,272,039</a><br />Filed on 2017-05-09<br />Status: Issued 147165069 E-149-2014-0 E-149-2014-0-US-01 Topical Sodium Nitrate Formulation PRV US 62/077,622 Abandoned US <br />Provisional (PRV) 62/077,622<br />Filed on 2014-11-10<br />Status: Abandoned 147165070 E-149-2014-0 E-149-2014-0-PCT-02 Topical Sodium Nitrite Formulation PCT Patent Cooperation Treaty PCT/US2015/060015 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2015/060015<br />Filed on 2015-11-10<br />Status: Expired 147165071 E-149-2014-0 E-149-2014-0-EP-03 Topical Sodium Nitrite Formulation National Stage European Patent 3217960 15798623.3 Issued European Patent <br />National Stage 15798623.3<br />Filed on 2015-11-10<br />Status: Issued 147165072 E-149-2014-0 E-149-2014-0-DE-05 Topical Sodium Nitrite Formulation EP Germany 3217960 15798623.3 Issued Germany <br />European patent (EP) 15798623.3<br />Filed on 2015-11-10<br />Status: Issued 147165073 E-149-2014-0 E-149-2014-0-FR-06 Topical Sodium Nitrite Formulation EP France 3217960 15798623.3 Issued France <br />European patent (EP) 15798623.3<br />Filed on 2015-11-10<br />Status: Issued 147165074 E-149-2014-0 E-149-2014-0-IE-07 Topical Sodium Nitrite Formulation EP Ireland 3217960 15798623.3 Issued Ireland <br />European patent (EP) 15798623.3<br />Filed on 2015-11-10<br />Status: Issued 147165075 E-149-2014-0 E-149-2014-0-GB-08 Topical Sodium Nitrite Formulation EP United Kingdom 3217960 15798623.3 Issued United Kingdom <br />European patent (EP) 15798623.3<br />Filed on 2015-11-10<br />Status: Issued 147172335 Blood Disorder 147172336 CREAM 147172338 Haksong 147172339 nitric oxide 147172340 Ointment 147172342 SCD 147172343 sickle cell disease 147172345 Sodium Nitrate 147172346 TOPICAL 147172348 Topical Therapeutic 147172350 Vascular Ulcers 147172351 Wound healing TAB-4308 147157598 Eye Tracking Application in Computer Aided Diagnosis and Image Processing in Radiology CC Cardiology, Collaboration, Licensing, Oncology, Software / Apps Cardiology Collaboration Licensing Oncology Software / Apps Ulas Bagci, Haydar Celik, Ismail Turkbey, Bradford Wood <p>Medical imaging is an important resource for early diagnostic, detection, and effective treatment of cancers. However, the screening and review processes for radiologists have been shown to overlook a certain percentage of potentially cancerous image features. Such review errors may result in misdiagnosis and failure to identify tumors. These errors result from human fallibility, fatigue, and from the complexity of visual search required. Screening for early detection of cancers in visual images requires physicians to scan vast amounts of complex visual information thoroughly and interpret it correctly. Small abnormalities must be identified as potentially cancerous while avoiding false positive identifications.  Fatigue and bias during this review can cause physicians to favor certain locations for review and overlook other regions that may contain important abnormalities. <br /> The Centers for Medicare and Medicaid Services have recently approved screening computed tomography (CT) scans for patients ages 55-75 with a 15-year smoking history, which is expected to drastically increase the number of radiologic image reviews. Computer aided diagnosis (CAD) tools may become more important for radiologists to reduce diagnostic errors when screening medical images. <br /> Scientists at the National Institutes of Health – Clinical Center (NIH-CC) have developed a technology that is a CAD and eye-tracking system suitable for real-world radiology reading room settings. The system consists of an eye-tracking interface and novel algorithms to unify eye-tracking data and a CAD system. The system coordinates eye tracking and processes gaze patterns simultaneously with a deep learning algorithm in a multi-task learning platform to segment and assist the diagnosis of suspicious image features. Testing of this system in a lung cancer screening experiment with multiple radiologists shows improved accuracy in reducing false positives. The system is also generalizable to more complex applications such as prostate cancer screening with multi-parametric magnetic resonance imaging. This CAD system is able to improve radiologist diagnostic decisions during screening/diagnosis performance by determining where they have looked and tracking where they have a history of under-looking.</p> <h2>Competitive Advantages:</h2> <ul><li>Significantly improve detection of tumors</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Cancer screening</li> <li>Computer aided diagnosis (CAD)</li> <li>Software for coordinated human/computer vision tumor detection</li> </ul> 2018-08-16 2025-04-22 2018-08-16 2025-04-22 2018-08-16 CAD, cc, Clinical Center, Computer Aided Diagnostics, DEVICE, Eye tracking, Image Processing, National Institutes of Health, NIH, Radiology, software, WOOD False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2018-08-16 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147162193 Khosravan N, et al. A Collaborative Computer Aided Diagnosis (C-CAD) System with Eye-Tracking, Sparse Attentional Model, and Deep Learning. https://arxiv.org/pdf/1802.06260.pdf <a href="https://arxiv.org/pdf/1802.06260.pdf">Khosravan N, et al. A Collaborative Computer Aided Diagnosis (C-CAD) System with Eye-Tracking, Sparse Attentional Model, and Deep Learning.</a> 147164248 Wood, Bradford NIH - CC CC Wood, Bradford (CC) 1 147164249 Celik, Haydar NIH - CC Celik, Haydar 2 147164250 Bagci, Ulas University of Central Florida Bagci, Ulas 3 147164251 Turkbey, Ismail NIH - NCI NCI Turkbey, Ismail (NCI) 4 147164248 Wood, Bradford NIH - CC CC Wood, Bradford (CC) 1 147164249 Celik, Haydar NIH - CC Celik, Haydar 2 147164250 Bagci, Ulas University of Central Florida Bagci, Ulas 3 147164251 Turkbey, Ismail NIH - NCI NCI Turkbey, Ismail (NCI) 4 147158024 Eye Tracking Applications In Computeraided Diagnosis And Image Processing In Radiology E-118-2015-0 Filing authorized Clinical Center (CC), NCI, University of Central Florida 83703238 Fenn, Edward (Tedd) tedd.fenn@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-4308] Eye Tracking Application in Computer Aided Diagnosis and Image Processing in Radiology&body=Please send me information about technology [TAB-4308] Eye Tracking Application in Computer Aided Diagnosis and Image Processing in Radiology.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Fenn, Edward (Tedd)<br><a href="mailto:tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-4308] Eye Tracking Application in Computer Aided Diagnosis and Image Processing in Radiology&body=Please send me information about technology [TAB-4308] Eye Tracking Application in Computer Aided Diagnosis and Image Processing in Radiology.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">tedd.fenn@nih.gov</a><br> 147161067 E-118-2015-0 E-118-2015-0-US-01 Eye Tracking Applications In Computeraided Diagnosis And Image Processing In Radiology PRV US 62/466,516 Abandoned US <br />Provisional (PRV) 62/466,516<br />Filed on 2017-03-03<br />Status: Abandoned 147168065 E-118-2015-0 E-118-2015-0-US-02 Eye Tracking Applications In Computer aided Diagnosis And Image Processing In Radiology ORD US 10,839,520 15/912,126 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10839520 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10839520">10,839,520</a><br />Filed on 2018-03-05<br />Status: Issued 147171796 CAD 147171797 cc 147171799 Clinical Center 147171801 Computer Aided Diagnostics 147171802 DEVICE 147171804 Eye tracking 147171805 Image Processing 147171807 National Institutes of Health 147171808 NIH 147171809 Radiology 147171810 software 147171811 WOOD TAB-4274 147157562 Synthesis and Characterization of Bismuth Beads for Trans Arterial Chemo Embolization Under Computed Tomography (CT) Guidance CC Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Ayele Negussie, Bradford Wood <p>Existing microsphere technologies are used as therapy for certain cancers. The therapy is by way of occlusion, when the microspheres are delivered into blood vessels that feed a tumor. The physical dimensions of the microspheres occlude the blood supply and thus, killing the tumor. Some microspheres have also been modified to bind protein, elute drugs, and reduce inflammatory reactions as part of the therapy. However, one technical short-coming of existing microsphere technology is a limited capability to be visualized in real-time. The inability to visualize embolic microspheres during treatment and post treatment could lead to complications and the need for additional treatments, thereby increasing the chance of additional complications.</p> <p>Researchers at the National Institutes of Health – Clinical Center (NIH-CC) have developed a technology that uses bismuth-based beads with a hydrophilic polymer to allow for real-time tracking with a computed tomography (CT) scanner of loco regional treatments. Visualization capability is important for confirmation of proper delivery to the targeted vessels and monitoring of treatment after surgery. The real-time CT visualization capability helps solve a major shortcoming of current embolic microsphere treatments. The beads can be differentiated from other clinical imaging contrast agents – making it easier for physicians to identify the location of the loco-regional treatment, and may improve therapeutic outcomes.</p> <h2>Competitive Advantages:</h2> <ul><li>Capable of being tracked in real-time</li> <li>Capable of being differentiated from conventional iodine contrast</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Trackable beads for loco-regional treatments </li> </ul> 2018-08-16 2025-04-22 2018-08-16 2025-04-22 2018-08-16 Bismus, Blood Vessel Occlusion, Image-able Bead, Loco-regional Treatment, Negussie, TACE, Trans-arterial Chemoembolization False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2018-08-16 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147164127 Negussie, Ayele NIH - CC CC Negussie, Ayele (CC) 1 147164126 Wood, Bradford NIH - CC CC Wood, Bradford (CC) 2 147164127 Negussie, Ayele NIH - CC CC Negussie, Ayele (CC) 1 147164126 Wood, Bradford NIH - CC CC Wood, Bradford (CC) 2 147158060 Synthesis And Characterization Of Bismuth Beads For Trans Arterial Chemo Embolization Under CT Guidance E-136-2016-0 Filing authorized Clinical Center (CC) 147162534 Synthesis And Characterization Of Bismuth Beads For Trans Arterial Chemo Embolization Under CT Guidance E-136-2016-1 Filing authorized Clinical Center (CC) 83703238 Fenn, Edward (Tedd) tedd.fenn@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-4274] Synthesis and Characterization of Bismuth Beads for Trans Arterial Chemo Embolization Under Computed Tomography (CT) Guidance&body=Please send me information about technology [TAB-4274] Synthesis and Characterization of Bismuth Beads for Trans Arterial Chemo Embolization Under Computed Tomography (CT) Guidance.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Fenn, Edward (Tedd)<br><a href="mailto:tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-4274] Synthesis and Characterization of Bismuth Beads for Trans Arterial Chemo Embolization Under Computed Tomography (CT) Guidance&body=Please send me information about technology [TAB-4274] Synthesis and Characterization of Bismuth Beads for Trans Arterial Chemo Embolization Under Computed Tomography (CT) Guidance.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">tedd.fenn@nih.gov</a><br> 147161094 E-136-2016-1 E-136-2016-1-US-01 IMAGEABLE PARTICLES, METHODS OF MAKING AND METHODS OF USE THEREOF PRV US 62/459,242 Abandoned US <br />Provisional (PRV) 62/459,242<br />Filed on 2017-02-15<br />Status: Abandoned 147167810 E-136-2016-0 E-136-2016-0-US-01 Imageable Particles, Methods of Making and Methods of Use Thereof PRV US 62/422,972 Abandoned US <br />Provisional (PRV) 62/422,972<br />Filed on 2016-11-16<br />Status: Abandoned 147167812 E-136-2016-1 E-136-2016-1-PCT-02 IMAGEABLE PLOLYMERS, METHODS OF MAKING AND METHODS OF USE THEREOF PCT Patent Cooperation Treaty PCT/US2017/059406 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2017/059406<br />Filed on 2017-10-31<br />Status: Expired 147167813 E-136-2016-1 E-136-2016-1-US-03 Imageable Polymers, Methods of Making and Methods of Use Thereof National Stage US 11,382,990 16/349,458 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11382990 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11382990">11,382,990</a><br />Filed on 2019-05-13<br />Status: Issued 147167814 E-136-2016-1 E-136-2016-1-EP-04 IMAGEABLE PLOLYMERS, METHODS OF MAKING AND METHODS OF USE THEREOF National Stage European Patent 3541368 17808643.5 Issued European Patent <br />National Stage 17808643.5<br />Filed on 2017-10-31<br />Status: Issued 147172175 Bismus 147172177 Blood Vessel Occlusion 147172179 Image-able Bead 147172181 Loco-regional Treatment 147172183 Negussie 147172184 TACE 147172186 Trans-arterial Chemoembolization TAB-4209 147157494 AngleNav: Micro-Electro-Mechanical Systems (MEMs) Trackers to Facilitate Computed Topography (CT)-Guided Needle Puncture CC Collaboration, Licensing, Medical Devices, Non-Medical Devices Collaboration Licensing Medical Devices Non-Medical Devices Tsz Ho “Zion” Tse, Bradford Wood, Sheng Xu <p>Conventional free-hand needle puncture procedures for biopsy and other procedures, often rely on unguided manual movements to guide a needle to its destination. Freehand procedures risk missing the tumor, or accidental injury, such as puncturing a vital organ. Needle guidance systems may improve accuracy and reduce risks but available guidance technologies are cumbersome and expensive and may carry other risks. For example, Computed Topography (CT)-guided fluoroscopy for needle guidance may be used, but fluoroscopy requires expensive bulky equipment and exposes patients to increased radiation. The high costs, cumbersome ergonomics, complex usability, and longer procedure times have limited wider adoption of needle guidance. Therefore, a nimble, low-cost, user-friendly, safer, guidance technology may improve accuracy and usage of guided biopsy for physicians and improve outcome &amp; safety for patients.</p> <p>Scientists at the National Institutes of Health - Clinical Center (NIH-CC) have developed a nimble, low-cost, user-friendly, needle guidance system (AngleNav). The AngleNav system requires minimal equipment, a tracker, software, and display.  The tracker is attached to the needle and consists of a Micro-Electro-Mechanical Systems, (MEMs)-based measurement unit including gyroscope, magnetometer sensors, and accelerometer to provide accurate three-axis angular data. The tracker wirelessly transmits positional information to a portable display, such as a smartphone or tablet. Phantom and preclinical animal studies with an AngleNav prototype system in live pigs have been completed and show improved accuracy using the AngleNav system versus freehand procedures. These advantages address many of the issues that have limited wider adoption of needle navigation systems; significantly improving usability, portability, and safety. </p> <h2>Competitive Advantages:</h2> <ul><li>Safer than conventional needle puncture procedures</li> <li>Highly portable</li> <li>Inexpensive to produce and operate</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Tumor biopsy </li> <li>Tumor ablation</li> <li>Targeted drug delivery</li> </ul> 2018-08-16 2025-04-22 2020-04-13 2025-04-22 2018-08-16 Angular Tracking, Computed Topography, CT, CT Guided Needle Puncture, Gyroscope, MEMS sensor, Micro-Electro-Mechanical Systems, Surgical Biopsy System, Xu False True Prototype True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-04-13 52406769 Prototype 52406769 NCI 37470483 Website Abstract 147162158 Li R, et al. AngleNav: MEMS Tracker to Facilitate CT-Guided Puncture. Annals of Biomedical Engineering, Vol 46, No. 3, March 2018, pp 452-463 https://link.springer.com/article/10.1007%2Fs10439-017-1968-4 <a href="https://link.springer.com/article/10.1007%2Fs10439-017-1968-4">Li R, et al. AngleNav: MEMS Tracker to Facilitate CT-Guided Puncture. Annals of Biomedical Engineering, Vol 46, No. 3, March 2018, pp 452-463</a> 147163921 Xu, Sheng NIH - CC CC Xu, Sheng (CC) 1 147163920 Wood, Bradford NIH - CC CC Wood, Bradford (CC) 2 147163922 Tse, Tsz Ho “Zion” 3T Technologies, LLC Tse, Tsz Ho “Zion” 3 147163921 Xu, Sheng NIH - CC CC Xu, Sheng (CC) 1 147163920 Wood, Bradford NIH - CC CC Wood, Bradford (CC) 2 147163922 Tse, Tsz Ho “Zion” 3T Technologies, LLC Tse, Tsz Ho “Zion” 3 147158101 Needle Tracking System Based On MEMS Gyroscopes E-158-2017-0 Filing authorized 3T Technologies, LLC, Clinical Center (CC) 83703238 Fenn, Edward (Tedd) tedd.fenn@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-4209] AngleNav: Micro-Electro-Mechanical Systems (MEMs) Trackers to Facilitate Computed Topography (CT)-Guided Needle Puncture&body=Please send me information about technology [TAB-4209] AngleNav: Micro-Electro-Mechanical Systems (MEMs) Trackers to Facilitate Computed Topography (CT)-Guided Needle Puncture.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Fenn, Edward (Tedd)<br><a href="mailto:tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-4209] AngleNav: Micro-Electro-Mechanical Systems (MEMs) Trackers to Facilitate Computed Topography (CT)-Guided Needle Puncture&body=Please send me information about technology [TAB-4209] AngleNav: Micro-Electro-Mechanical Systems (MEMs) Trackers to Facilitate Computed Topography (CT)-Guided Needle Puncture.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">tedd.fenn@nih.gov</a><br> 147167364 E-158-2017-0 E-158-2017-0-US-01 SYSTEMS, METHODS, AND DEVICES FOR ASSISTING OR PERFORMING GUIDED INTERVENTIONAL PROCEDURES USING INERIAL MEASUREMENT UNITS AND MAGNETOMETER SENSORS PRV US 62/506,872 Abandoned US <br />Provisional (PRV) 62/506,872<br />Filed on 2017-05-16<br />Status: Abandoned 147167365 E-158-2017-0 E-158-2017-0-PCT-02 SYSTEMS, METHODS, AND DEVICES FOR ASSISTING OR PERFORMING GUIDED INTERVENTIONAL PROCEDURES USING INERTIAL MEASUREMENT UNITS AND MAGNETOMETER SENSORS PCT Patent Cooperation Treaty PCT/US2018/033025 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2018/033025<br />Filed on 2018-05-16<br />Status: Expired 147167366 E-158-2017-0 E-158-2017-0-US-03 SYSTEMS, METHOD AND DEVICES FOR ASSISTING OR PERFORMING GUIDING INTERVENTIONAL PROCEDURES USING INERTIAL MEASUREMENT UNITS AND MAGNETOMETER SENSORS National Stage US 12,320,646 16/613,591 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12320646 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12320646">12,320,646</a><br />Filed on 2019-11-14<br />Status: Issued 147172561 Angular Tracking 147172563 Computed Topography 147172564 CT 147172566 CT Guided Needle Puncture 147172568 Gyroscope 147172570 MEMS sensor 147172572 Micro-Electro-Mechanical Systems 147172574 Surgical Biopsy System 147172576 Xu TAB-4134 147157416 Isotropic Generalized Diffusion Tensor MRI NICHD Collaboration, Licensing, Neurology, Software / Apps Collaboration Licensing Neurology Software / Apps Alexandru Avram, Peter Basser <p>Scientists at the Eunice Kennedy Shriver National Institute for Child Health and Human Development (NICHD) have developed a method implemented as pulse sequences and software to be used with magnetic resonance imaging (MRI) scanners and systems. This technology is available for licensing and commercial development. The method allows for measuring and mapping features of the bulk or average apparent diffusion coefficient (ADC) of water in tissue &ndash; aiding in stroke diagnosis and cancer therapy assessment. The pulse sequences and software enable MRI scanners to yield diffusion weighted images (DWI) that are orientationally averaged. The resulting bulk diffusion signals are describable by second and higher-order tensors (HOT). This is most notably beneficial for resolving intrinsic differences in tissue water diffusivities between white and gray matter.&nbsp;&nbsp;</p> <p>The mean apparent diffusion coefficient (mADC), or the Trace of the 2nd-order diffusion tensor, has revolutionized the diagnosis of stroke and cancer. It quantifies orientationally-averaged bulk properties of tissue water in the central nervous system while removing or averaging over the orientational bias in diffusion within white matter. However, mADC use has been limited to low diffusion sensitization. At higher diffusion sensitization (as measured by b-values substantially greater than 1000 s/mm2), DWI signal modulations due to diffusion anisotropy becomes more pronounced, especially in regions with complex microstructure, confounding the clinical evaluation. This invention overcomes this limitation by extending the range of diffusion sensitization or b-values producing DWIs that are isotropically weighted.</p> <p>The technology, called isotropic-diffusometry imaging or isotropic generalized diffusion tensor imaging (IGDTI), permits measurements within clinically feasible scan times of orientationally averaged DWIs and mADCs over a wide range of b-values, and estimation of various rotation-invariant microstructural parameters, such as HOT-Traces or mean t-kurtosis, as well as estimation of the probability density function or spectrum of orientationally averaged mADCs, p(mADC), as a function of the isotropic mADC, within each imaging voxel. It also furnishes estimates of the signal fractions of various tissue types based on tissue-specific isotropic diffusivity spectra. The method selects sets of applied magnetic field gradient magnitudes and directions whose averages produce mADCs over a wide range of b-values especially those required to measure HOTs. These experimental designs are based on analytical descriptions of the tensors and can be combined to produce mADCs or probability density functions of intravoxel mADC distributions (figure below).</p> <p><img alt="These experimental designs are based on analytical descriptions of the tensors and can be combined to produce mADCs or probability density functions of intravoxel mADC distributions." height="423" src="https://nih.technologypublisher.com/files/sites/e-093-2017_image_abstract4.png" width="800" /></p> <h2>Competitive Advantages:</h2> <ul> <li>Enables diffusion MRI methods that estimate biologically-specific rotation-invariant parameters for quantifying tissue water motilities or other intrinsic tissue characteristics within clinically feasible scan durations</li> <li>Suitable for imaging moving tissue, such as whole-body imaging, including fetal and placental MRI application</li> <li>Offers greater dynamic b-value range than other DWI based methods</li> <li>Can provide sub-voxel resolution, revealing distinct water compartments</li> <li>Enhances tissue segmentation, clustering and classification applications</li> <li>Expected to be useful in assessing a variety biological processes, pathologies, disorders and diseases</li> </ul> <h2>Commercial Applications:</h2> <ul> <li>Potential diagnosis of disorders in the CNS and PNS, e.g., stroke, Amyotrophic lateral sclerosis (ALS), Alzheimer&rsquo;s disease, Traumatic brain injury (TBI)/concussion, Cancer, Multiple sclerosis (MS)</li> <li>Incorporation within a &ldquo;suite&rdquo; of neuro and whole-body radiology packages</li> <li>Measuring and mapping new quantitative imaging biomarkers</li> <li>Potentially repurposing MR data already used to produce and implement other advanced diffusion MRI applications, such as Mean Apparent Propagator (MAP) MRI, Diffusion Kurtosis Imaging (DKI), or diffusion spectrum imaging (DSI)</li> </ul> 2018-08-16 2025-04-22 2021-01-26 2025-04-22 2018-08-16 ADC, Basser, Central Nervous System, CNS, diffusion, Diffusion Weighted Images, Distribution, DWI, Fetus, High-Order Tensor, Image Analysis, Isotropic Diffusion Tensor Imaging, mADC, Mean Apparent Diffusion Coefficient, MRI Pulse Sequences, PATHOLOGY, Peripheral Nervous System, Placenta, PNS, STROKE, TRACE, Whole-Body False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-01-26 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147162228 Avram, AV, et al. Efficient experimental designs for isotropic generalized diffusion tensor MRI (IGDTI). https://www.ncbi.nlm.nih.gov/pubmed/28480613 <a href="https://www.ncbi.nlm.nih.gov/pubmed/28480613">Avram, AV, et al. Efficient experimental designs for isotropic generalized diffusion tensor MRI (IGDTI).</a> 147162305 Avram AV, et al. Isotropic Diffusion Relaxometry Imaging (IDRI). (Isotropic Diffusion Relaxometry Imaging (IDRI). (Abstract Proc. Intl. Soc. Mag. Reson. Med. 25:840, Honolulu, Hawaii, 22-27 April 2017) Avram AV, et al. Isotropic Diffusion Relaxometry Imaging (IDRI). (Isotropic Diffusion Relaxometry Imaging (IDRI). (Abstract Proc. Intl. Soc. Mag. Reson. Med. 25:840, Honolulu, Hawaii, 22-27 April 2017) 147162381 Avram AV, et al. Isotropic Diffusion Weighted MRI (IDWI) &ndash; a novel, efficient clinical method for quantifying orientationally-averaged features of water diffusion in tissues. (Abstract Proc. Intl. Soc. Mag. Reson. Med. 25:1092, Honolulu, Hawaii, 22-27 April 2017) Avram AV, et al. Isotropic Diffusion Weighted MRI (IDWI) &ndash; a novel, efficient clinical method for quantifying orientationally-averaged features of water diffusion in tissues. (Abstract Proc. Intl. Soc. Mag. Reson. Med. 25:1092, Honolulu, Hawaii, 22-27 April 2017) 147163641 Avram, Alexandru NIH - NIBIB NIBIB Avram, Alexandru (NIBIB) 1 147163640 Basser, Peter NIH - NICHD NICHD Basser, Peter (NICHD) 2 147163641 Avram, Alexandru NIH - NIBIB NIBIB Avram, Alexandru (NIBIB) 1 147163640 Basser, Peter NIH - NICHD NICHD Basser, Peter (NICHD) 2 147157971 Isotropic Diffusion-Weighted And Diffusometry Magnetic Resonance Imaging E-093-2017-0 Filing authorized NIBIB, NICHD 119617417 Ravilious, Geoffrey geoffrey.ravilious@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
geoffrey.ravilious@nih.gov?subject=Web Inquiry on [TAB-4134] Isotropic Generalized Diffusion Tensor MRI&body=Please send me information about technology [TAB-4134] Isotropic Generalized Diffusion Tensor MRI.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Ravilious, Geoffrey<br><a href="mailto:geoffrey.ravilious@nih.gov?subject=Web Inquiry on [TAB-4134] Isotropic Generalized Diffusion Tensor MRI&body=Please send me information about technology [TAB-4134] Isotropic Generalized Diffusion Tensor MRI.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">geoffrey.ravilious@nih.gov</a><br> 147161028 E-093-2017-0 E-093-2017-0-US-01 DIFFUSION TENSOR IMAGING IN MRI PRV US 62/482,637 Abandoned US <br />Provisional (PRV) 62/482,637<br />Filed on 2017-04-06<br />Status: Abandoned 147166861 E-093-2017-0 E-093-2017-0-PCT-02 ISOTROPIC GENERALIZED DIFFUSION TENSOR MRI PCT Patent Cooperation Treaty PCT/US2018/026584 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2018/026584<br />Filed on 2018-04-06<br />Status: Expired 147166862 E-093-2017-0 E-093-2017-0-US-03 ISOTROPIC GENERALIZED DIFFUSION TENSOR MRI National Stage US 11,835,611 16/603,205 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11835611 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11835611">11,835,611</a><br />Filed on 2019-10-04<br />Status: Issued 147171237 ADC 147171238 Basser 147171239 Central Nervous System 147171240 CNS 147171241 diffusion 147171243 Diffusion Weighted Images 147171244 Distribution 147171246 DWI 147171247 Fetus 147171249 High-Order Tensor 147171251 Image Analysis 147171253 Isotropic Diffusion Tensor Imaging 147171255 mADC 147171257 Mean Apparent Diffusion Coefficient 147171259 MRI Pulse Sequences 147171260 PATHOLOGY 147171261 Peripheral Nervous System 147171262 Placenta 147171263 PNS 147171264 STROKE 147171265 TRACE 147171266 Whole-Body TAB-4288 147157577 Transformation of Weak or Non-Immunogenic Antigens to Produce an Immune Response and Therapeutic Polypeptides for the Treatment and Prevention of Cancer NIA Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Bira Arya, Igor Espinoza-Delgado, Dan Longo <p>A significant challenge in developing therapies for the treatment and prevention of cancer has been the discovery, selection, and exploitation of antigens.</p> <p>Researchers at the National Institute on Aging (NIA) have partially circumvented this issue in their development of novel strategies for rendering weakly or non-immunogenic, shared antigens immunogenic, or able to produce an immune response.  These strategies use proinflammatory chemokines to deliver antigens to immature dendritic cells (DCs) by targeting chemokine receptors differentially expressed on antigen presenting cells (APCs).  Their work builds upon the discovery that tumor-associated, embryonic antigens (e.g., OFA-iLRP) – though non-antigenic alone – are effective for the treatment and/or prevention of cancer when linked to a chemoattractant ligand. Examples of such ligands include proinflammatory chemokines such as MIP3α/CCL20 or β-defensin mDF2β.  Multiple vaccines may be developed based upon individualized treatments for patients facing, or at risk of developing, the most aggressive forms of cancer.</p> <p>The NIA is seeking statements of capability or interest from parties interested in licensing or collaborative research and development that can be applied to many cancer types. Such co-development opportunities would aim to further develop, evaluate, or commercialize simple and potent vaccines targeting embryonic and other antigens expressed in tumors.</p> <h2>Competitive Advantages:</h2> <ul><li>Potential development of a prophylactic vaccine</li> <li>Simple and less invasive approach; easily deliverable to the skin, muscle, and other tissues</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Treatment and prevention of solid tumors</li> <li>Treatment and prevention of blood-borne tumors</li> </ul> 2018-08-23 2025-04-22 2018-08-23 2025-04-22 2018-08-23 ANTIGEN, Biragyn, CANCER VACCINE, Chemokine, National Institute on Aging, NIA False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2018-08-23 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147161977 Biragyn A, et al. Tumor-associated embryonic antigen-expressing vaccines that target CCR6 elicit potent CD8+ T cell- mediated protective and therapeutic antitumor immunity https://www.ncbi.nlm.nih.gov/pubmed/17617631 <a href="https://www.ncbi.nlm.nih.gov/pubmed/17617631">Biragyn A, et al. Tumor-associated embryonic antigen-expressing vaccines that target CCR6 elicit potent CD8+ T cell- mediated protective and therapeutic antitumor immunity</a> 147162364 Schiavo, R, et al. Chemokine receptor targeting efficiently cross presents antigens to MHC class I and elicit CD8+ T cell responses both in vitro and in vivo https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1895803/ <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1895803/">Schiavo, R, et al. Chemokine receptor targeting efficiently cross presents antigens to MHC class I and elicit CD8+ T cell responses both in vitro and in vivo</a> 147162402 Biragyn A, et al. Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity https://www.ncbi.nlm.nih.gov/pubmed/10096292 <a href="https://www.ncbi.nlm.nih.gov/pubmed/10096292">Biragyn A, et al. Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity</a> 147164172 Arya, Bira NIH - NIA NIA Arya, Bira (NIA) 1 147164171 Longo, Dan NIH - NIA NIA Longo, Dan (NIA) 2 147164173 Espinoza-Delgado, Igor NIH - NIA Espinoza-Delgado, Igor 3 147164172 Arya, Bira NIH - NIA NIA Arya, Bira (NIA) 1 147164171 Longo, Dan NIH - NIA NIA Longo, Dan (NIA) 2 147164173 Espinoza-Delgado, Igor NIH - NIA Espinoza-Delgado, Igor 3 147158301 DNA-based Strategy To Elicit Anti-tumor Responses Against Tumors Expressing Oncofetal Antigen/immature Laminin Receptor Protein E-271-2006-0 Filing authorized National Institute on Aging (NIH/NIA) 91789173 Guyton, Nicole darackn@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America darackn@mail.nih.gov?subject=Web Inquiry on [TAB-4288] Transformation of Weak or Non-Immunogenic Antigens to Produce an Immune Response and Therapeutic Polypeptides for the Treatment and Prevention of Cancer&body=Please send me information about technology [TAB-4288] Transformation of Weak or Non-Immunogenic Antigens to Produce an Immune Response and Therapeutic Polypeptides for the Treatment and Prevention of Cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Guyton, Nicole<br><a href="mailto:darackn@mail.nih.gov?subject=Web Inquiry on [TAB-4288] Transformation of Weak or Non-Immunogenic Antigens to Produce an Immune Response and Therapeutic Polypeptides for the Treatment and Prevention of Cancer&body=Please send me information about technology [TAB-4288] Transformation of Weak or Non-Immunogenic Antigens to Produce an Immune Response and Therapeutic Polypeptides for the Treatment and Prevention of Cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">darackn@mail.nih.gov</a><br> 147167911 E-271-2006-0 E-271-2006-0-US-01 DNA-based Strategy To Elicit Anti-tumor Responses Against Tumors Expressing Oncofetal Antigen/immature Laminin Receptor Protein PRV US 60/841,927 Abandoned US <br />Provisional (PRV) 60/841,927<br />Filed on 2006-09-01<br />Status: Abandoned 147167912 E-271-2006-0 E-271-2006-0-CA-02 METHODS AND COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF CANCER ORD Canada 2598060 Abandoned Canada <br />Ordinary Patent (ORD) 2598060<br />Filed on 2007-09-04<br />Status: Abandoned 147167913 E-271-2006-0 E-271-2006-0-US-03 METHODS AND COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF CANCER ORD US 8,258,278 11/899,165 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8258278 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8258278">8,258,278</a><br />Filed on 2007-09-03<br />Status: Issued 147167914 E-271-2006-0 E-271-2006-0-US-04 METHODS AND COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF CANCER DIV US 10,077,296 13/587,515 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10077296 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10077296">10,077,296</a><br />Filed on 2012-08-16<br />Status: Issued 147174500 ANTIGEN 147174502 Biragyn 147174503 CANCER VACCINE 147174504 Chemokine 147174505 National Institute on Aging 147174506 NIA TAB-4297 147157587 T Cell Receptors Targeting p53 Mutations for Cancer Immunotherapy and Adoptive Cell Therapy NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Drew Deniger, Winifred Lo, Yong-Chen Lu, Parisa Malekzadeh, Maria Parkhurst, Anna Pasetto, Paul Robbins, Steven Rosenberg, Rami Yoseph <p>The tumor protein p53 is a cell cycle regulator. It responds to DNA damage by triggering the DNA repair pathway and allowing cell division to occur or inducing cell growth arrest, cellular senescence, and/or apoptosis. p53 therefore acts as a tumor suppressor by preventing uncontrolled cell division. However, mutations in p53 that impair its cell cycle regulatory functions can induce uncontrolled cell division leading to cancer. Certain p53 mutations, termed &lsquo;hotspot&rsquo; mutations, occur at high frequency across patients and diverse cancer types, such as cholangiocarcinoma, melanoma, colon cancer, rectal cancer, ovarian cancer, endometrial cancer, non-small cell lung cancer (NSCLC), glioblastoma, uterine cervical cancer, head and neck cancers, breast cancer, pancreatic cancer, and bladder cancer. Novel therapeutics that specifically target mutant p53 proteins may be useful for the treatment of many common malignancies.</p> <p>Researchers at the National Cancer Institute (NCI) have identified a collection of novel T-cell receptors (TCRs) targeting defined hotspot mutations in the p53 tumor suppressor protein (Table 1). These p53 hotspot mutations, including I135Y, R175H, Y220C, M237I, G245D, G245S, R248L, R248Q, R248W, R249S, R273C, R273L, R273H and R282W, are prevalent in cancer cells and are therefore attractive targets for TCR T cell therapy. These TCRs are expected to specifically eliminate human cancer cells bearing these p53 mutations upon adoptive transfer into cancer patients.&nbsp;</p> <p>The NCI Surgery Branch is seeking research co-development partners and/or licensees for these T Cell Receptors Targeting Mutated p53.</p> <p><img alt="Researchers at the National Cancer Institute (NCI) have identified a collection of novel T-cell receptors (TCRs) targeting defined hotspot mutations in the p53 tumor suppressor protein (Table 1)" src="https://nih.technologypublisher.com/files/sites/table_1_5.png" /></p> <p><img alt="Intellectual Property Information " src="https://nih.technologypublisher.com/files/sites/table_25.png" /></p> <h2>Competitive Advantages:</h2> <ul> <li>Mutated p53 is not expressed in normal cells, suggesting the TCR therapy will have a low toxicity profile</li> <li>Variety of HLA-restriction elements: extends the applicability of TCRs as they recognize mutated p53 variants in the context of multiple HLA molecules</li> </ul> <h2>Commercial Applications:</h2> <ul> <li>T-cell therapy against a variety of human cancers as p53 is a commonly mutated gene in several human cancers including melanoma, breast cancer, colon cancer, and bladder cancer</li> <li>TCRs can be used in diagnostic tools to identify presence of p53 hotspot mutations in cancer cells</li> <li>Use of the TCRs in chimeric proteins for research purposes in cancers with mutated p53</li> </ul> 2018-09-05 2025-04-22 2023-05-30 2025-04-22 2018-09-05 Immunotherapy, p53, Rosenberg, T Cell Receptor, TCR, Tumor Protein P53 False True Clinical True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2023-05-30 72159138 Clinical Phase I 72159138 NCI 37470483 Website Abstract 147161895 Malekzadeh P, et al. Antigen experienced T cells from peripheral blood recognize p53 neoantigens. https://pubmed.ncbi.nlm.nih.gov/31996390/ <a href="https://pubmed.ncbi.nlm.nih.gov/31996390/">Malekzadeh P, et al. Antigen experienced T cells from peripheral blood recognize p53 neoantigens.</a> 147162283 Deniger et al. T-cell responses to TP53 &ldquo;hotspot&rdquo; mutations and unique neoantigens expressed by human ovarian cancers. https://www.ncbi.nlm.nih.gov/pubmed/29853601 <a href="https://www.ncbi.nlm.nih.gov/pubmed/29853601">Deniger et al. T-cell responses to TP53 &ldquo;hotspot&rdquo; mutations and unique neoantigens expressed by human ovarian cancers.</a> 147162436 Malekzadeh P, et al. Neoantigen screening identified broad TP53 mutant immunogenicity in patients with epitheleal cancers. https://pubmed.ncbi.nlm.nih.gov/30714987/ <a href="https://pubmed.ncbi.nlm.nih.gov/30714987/">Malekzadeh P, et al. Neoantigen screening identified broad TP53 mutant immunogenicity in patients with epitheleal cancers.</a> 147164211 Deniger, Drew NCI - CCR Deniger, Drew 1 147164207 Malekzadeh, Parisa NIH - NCI NCI Malekzadeh, Parisa (NCI) 2 147164212 Lo, Winifred NIH - NCI Lo, Winifred 3 147164210 Yoseph, Rami NIH - NCI NCI Yoseph, Rami (NCI) 4 147164205 Robbins, Paul NIH - NCI NCI Robbins, Paul (NCI) 5 147164206 Parkhurst, Maria NIH - NCI NCI Parkhurst, Maria (NCI) 6 147164208 Pasetto, Anna NIH - NCI Pasetto, Anna 7 147164209 Lu, Yong-Chen NIH - NCI NCI Lu, Yong-Chen (NCI) 8 147164204 Rosenberg, Steven NIH - NCI NCI Rosenberg, Steven (NCI) 9 147164211 Deniger, Drew NCI - CCR Deniger, Drew 1 147164207 Malekzadeh, Parisa NIH - NCI NCI Malekzadeh, Parisa (NCI) 2 147164212 Lo, Winifred NIH - NCI Lo, Winifred 3 147164210 Yoseph, Rami NIH - NCI NCI Yoseph, Rami (NCI) 4 147164205 Robbins, Paul NIH - NCI NCI Robbins, Paul (NCI) 5 147164206 Parkhurst, Maria NIH - NCI NCI Parkhurst, Maria (NCI) 6 147164208 Pasetto, Anna NIH - NCI Pasetto, Anna 7 147164209 Lu, Yong-Chen NIH - NCI NCI Lu, Yong-Chen (NCI) 8 147164204 Rosenberg, Steven NIH - NCI NCI Rosenberg, Steven (NCI) 9 147158252 TCRs Specific For P53 Hotspot Mutations E-237-2017-0 Filing authorized NCI 147162576 Method For Identification Of T Cells Reactive To Mutated P53 E-237-2017-1 Filing authorized NCI 147162577 TCRs Specific For P53 Mutations R175H, Y220C And G245S. E-237-2017-2 Filing authorized NCI 83709866 Burke, Andrew burkear@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC burkear@nih.gov?subject=Web Inquiry on [TAB-4297] T Cell Receptors Targeting p53 Mutations for Cancer Immunotherapy and Adoptive Cell Therapy&body=Please send me information about technology [TAB-4297] T Cell Receptors Targeting p53 Mutations for Cancer Immunotherapy and Adoptive Cell Therapy.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Burke, Andrew<br><a href="mailto:burkear@nih.gov?subject=Web Inquiry on [TAB-4297] T Cell Receptors Targeting p53 Mutations for Cancer Immunotherapy and Adoptive Cell Therapy&body=Please send me information about technology [TAB-4297] T Cell Receptors Targeting p53 Mutations for Cancer Immunotherapy and Adoptive Cell Therapy.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">burkear@nih.gov</a><br> 147161218 E-237-2017-2 E-237-2017-2-US-16 T CELL RECEPTORS RECOGNIZING MUTATED P53 National Stage US 11,939,365 16/651,242 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11939365 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11939365">11,939,365</a><br />Filed on 2020-03-26<br />Status: Issued 147167983 E-237-2017-0 E-237-2017-0-US-01 T CELL RECEPTORS RECOGNIZING MUTATED P53 PRV US 62/565,383 Abandoned US <br />Provisional (PRV) 62/565,383<br />Filed on 2017-09-29<br />Status: Abandoned 147167985 E-237-2017-1 E-237-2017-1-US-01 METHODS OF ISOLATING T CELLS HAVING ANTIGENIC SPECIFICITY FOR A P53 CANCER-SPECIFIC MUTATION PRV US 62/565,464 Abandoned US <br />Provisional (PRV) 62/565,464<br />Filed on 2017-09-29<br />Status: Abandoned 147167986 E-237-2017-1 E-237-2017-1-PCT-02 METHODS OF ISOLATING T CELLS HAVING ANTIGENIC SPECIFICITY FOR A P53 CANCER-SPECIFIC MUTATION PCT Patent Cooperation Treaty PCT/US2018/051280 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2018/051280<br />Filed on 2018-09-17<br />Status: Expired 147167987 E-237-2017-1 E-237-2017-1-AU-03 METHODS OF ISOLATING T CELLS HAVING ANTIGENIC SPECIFICITY FOR A P53 CANCER-SPECIFIC MUTATION National Stage Australia 2018342245 2018342245 Issued Australia <br />National Stage 2018342245<br />Filed on 2018-09-17<br />Status: Issued 147167988 E-237-2017-1 E-237-2017-1-CA-04 METHODS OF ISOLATING T CELLS HAVING ANTIGENIC SPECIFICITY FOR A P53 CANCER-SPECIFIC MUTATION National Stage Canada 3080274 Pending Canada <br />National Stage 3080274<br />Filed on 2018-09-17<br />Status: Pending 147167989 E-237-2017-1 E-237-2017-1-CN-05 METHODS OF ISOLATING T CELLS HAVING ANTIGENIC SPECIFICITY FOR A P53 CANCER-SPECIFIC MUTATION National Stage China 201880063656.4 Pending China <br />National Stage 201880063656.4<br />Filed on 2018-09-17<br />Status: Pending 147167990 E-237-2017-1 E-237-2017-1-EP-06 METHODS OF ISOLATING T CELLS HAVING ANTIGENIC SPECIFICITY FOR A P53 CANCER-SPECIFIC MUTATION National Stage European Patent 3688142 18782605.2 Issued European Patent <br />National Stage 18782605.2<br />Filed on 2018-09-17<br />Status: Issued 147167991 E-237-2017-1 E-237-2017-1-IL-07 METHODS OF ISOLATING T CELLS HAVING ANTIGENIC SPECIFICITY FOR A P53 CANCER-SPECIFIC MUTATION National Stage Israel 273516 273516 Issued Israel <br />National Stage 273516<br />Filed on 2020-03-23<br />Status: Issued 147167992 E-237-2017-1 E-237-2017-1-JP-08 METHODS OF ISOLATING T CELLS HAVING ANTIGENIC SPECIFICITY FOR A P53 CANCER-SPECIFIC MUTATION National Stage Japan 7391015 2020-517553 Issued Japan <br />National Stage 2020-517553<br />Filed on 2020-03-26<br />Status: Issued 147167993 E-237-2017-1 E-237-2017-1-KR-09 METHODS OF ISOLATING T CELLS HAVING ANTIGENIC SPECIFICITY FOR A P53 CANCER-SPECIFIC MUTATION National Stage South Korea 10-2809909 10-2020-7012343 Issued South Korea <br />National Stage 10-2020-7012343<br />Filed on 2020-04-28<br />Status: Issued 147167994 E-237-2017-1 E-237-2017-1-SG-10 METHODS OF ISOLATING T CELLS HAVING ANTIGENIC SPECIFICITY FOR A P53 CANCER-SPECIFIC MUTATION National Stage Singapore 11202002635R Abandoned Singapore <br />National Stage 11202002635R<br />Filed on 2018-09-17<br />Status: Abandoned 147167995 E-237-2017-1 E-237-2017-1-US-11 METHODS OF ISOLATING T CELLS HAVING ANTIGENIC SPECIFICITY FOR A P53 CANCER-SPECIFIC MUTATION National Stage US 16/650,696 Pending US <br />National Stage 16/650,696<br />Filed on 2020-03-25<br />Status: Pending 147167996 E-237-2017-1 E-237-2017-1-HK-12 METHODS OF ISOLATING T CELLS HAVING ANTIGENIC SPECIFICITY FOR A P53 CANCER-SPECIFIC MUTATION EP Hong Kong HK40031141B 62020021274.9 Issued Hong Kong <br />European patent (EP) 62020021274.9<br />Filed on 2020-11-30<br />Status: Issued 147167998 E-237-2017-2 E-237-2017-2-PCT-01 T CELL RECEPTORS RECOGNIZING MUTATED P53 PCT COMB Patent Cooperation Treaty PCT/US2018/051285 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2018/051285<br />Filed on 2018-09-17<br />Status: Expired 147167999 E-237-2017-2 E-237-2017-2-AU-02 T CELL RECEPTORS RECOGNIZING MUTATED P53 National Stage Australia 2018342246 2018342246 Issued Australia <br />National Stage 2018342246<br />Filed on 2018-09-17<br />Status: Issued 147168000 E-237-2017-2 E-237-2017-2-BR-03 T CELL RECEPTORS RECOGNIZING MUTATED P53 National Stage Brazil BR112020006012-7 Pending Brazil <br />National Stage BR112020006012-7<br />Filed on 2018-09-17<br />Status: Pending 147168001 E-237-2017-2 E-237-2017-2-CA-04 T CELL RECEPTORS RECOGNIZING MUTATED P53 National Stage Canada 3077024 Pending Canada <br />National Stage 3077024<br />Filed on 2018-09-17<br />Status: Pending 147168002 E-237-2017-2 E-237-2017-2-CN-05 T CELL RECEPTORS RECOGNIZING MUTATED P53 National Stage China ZL201880074539.8 201880074539.8 Issued China <br />National Stage 201880074539.8<br />Filed on 2018-09-17<br />Status: Issued 147168003 E-237-2017-2 E-237-2017-2-CR-06 T CELL RECEPTORS RECOGNIZING MUTATED P53 National Stage Costa Rica 2020-0170 Pending Costa Rica <br />National Stage 2020-0170<br />Filed on 2018-09-17<br />Status: Pending 147168004 E-237-2017-2 E-237-2017-2-EA-07 T CELL RECEPTORS RECOGNIZING MUTATED P53 National Stage Eurasian Patent 045595 202090757 Issued Eurasian Patent <br />National Stage 202090757<br />Filed on 2018-09-17<br />Status: Issued 147168005 E-237-2017-2 E-237-2017-2-EP-08 T CELL RECEPTORS RECOGNIZING MUTATED P53 National Stage European Patent 3688027 18780006.5 Issued European Patent <br />National Stage 18780006.5<br />Filed on 2018-09-17<br />Status: Issued 147168006 E-237-2017-2 E-237-2017-2-IL-09 T CELL RECEPTORS RECOGNIZING MUTATED P53 National Stage Israel 273515 273515 Issued Israel <br />National Stage 273515<br />Filed on 2020-03-23<br />Status: Issued 147168007 E-237-2017-2 E-237-2017-2-IN-10 T CELL RECEPTORS RECOGNIZING MUTATED P53 National Stage India 202047013911 Pending India <br />National Stage 202047013911<br />Filed on 2018-09-17<br />Status: Pending 147168008 E-237-2017-2 E-237-2017-2-JP-11 T CELL RECEPTORS RECOGNIZING MUTATED P53 National Stage Japan 7324193 2020-517556 Issued Japan <br />National Stage 2020-517556<br />Filed on 2018-09-17<br />Status: Issued 147168009 E-237-2017-2 E-237-2017-2-KR-12 T CELL RECEPTORS RECOGNIZING MUTATED P53 National Stage South Korea 10-2762272 10-2020-7012344 Issued South Korea <br />National Stage 10-2020-7012344<br />Filed on 2020-04-28<br />Status: Issued 147168010 E-237-2017-2 E-237-2017-2-MX-13 T CELL RECEPTORS RECOGNIZING MUTATED P53 National Stage Mexico 421596 MX/a/2020/003504 Issued Mexico <br />National Stage MX/a/2020/003504<br />Filed on 2018-09-17<br />Status: Issued 147168011 E-237-2017-2 E-237-2017-2-NZ-14 T CELL RECEPTORS RECOGNIZING MUTATED P53 National Stage New Zealand 763023 Pending New Zealand <br />National Stage 763023<br />Filed on 2020-03-27<br />Status: Pending 147168012 E-237-2017-2 E-237-2017-2-SG-15 T CELL RECEPTORS RECOGNIZING MUTATED P53 National Stage Singapore 11202002636P Pending Singapore <br />National Stage 11202002636P<br />Filed on 2018-09-17<br />Status: Pending 147168013 E-237-2017-2 E-237-2017-2-HK-17 T CELL RECEPTORS RECOGNIZING MUTATED P53 EP Hong Kong HK40031140B 62020021272.3 Issued Hong Kong <br />European patent (EP) 62020021272.3<br />Filed on 2020-11-30<br />Status: Issued 147168014 E-237-2017-2 E-237-2017-2-BR-18 T CELL RECEPTORS RECOGNIZING MUTATED P53 DIV Brazil BR122021018454-2 Pending Brazil <br />Divisional (DIV) BR122021018454-2<br />Filed on 2021-09-16<br />Status: Pending 147168015 E-237-2017-2 E-237-2017-2-JP-01 T CELL RECEPTORS RECOGNIZING MUTATED P53 DIV Japan 7573075 2023-123893 Issued Japan <br />Divisional (DIV) 2023-123893<br />Filed on 2023-07-28<br />Status: Issued 147174065 Immunotherapy 147174066 p53 147174067 Rosenberg 147174068 T Cell Receptor 147174069 TCR 147174071 Tumor Protein P53 TAB-4306 147157596 Single domain CD4, HIV-1 Antibodies, and Fusion Proteins for treatment of HIV NCI Infectious Disease, Licensing, Therapeutics Infectious Disease Licensing Therapeutics Weizao Chen, Dimiter Dimitrov <p>Soluble forms of human CD4 (sCD4) inhibit HIV-1 entry into immune cells.  Different forms of sCD4 and their fusion proteins have been extensively studied in animal models and clinical trials as promising HIV-1 inhibitors. However, they have not been successful in clinical trials due to their transient efficacy.  sCD4 is also known to interact with class II major histocompatibility complex (MHCII) and, at low concentrations, could enhance HIV-1 infectivity. </p> <p>NCI researchers developed highly soluble, stable single-domain sCD4 with increased neutralizing activity and decreased non-specific binding compared to two-domain sCD4.  This invention describes this single-domain sCD4, designated D1, and mutants such as mD1.22 which is highly soluble and stable with good neutralizing activity without measurable interaction with MHCII.  The inventors have previously described a novel human domain antibody against HIV-1, designated m36.  Due to its small size, this domain antibody targets a hidden CD4-induced (CD4i) epitope on HIV-1 and has the ability to neutralize primary isolates of HIV-1 from different clades more efficiently than full-size antibodies.  As part of this invention, the inventors have developed improved domain antibodies based upon the earlier described m36.  </p> <p>NCI researchers have further developed fusion proteins that combine a single human CD4 domain and a potent HIV-1 inhibitor. These fusion proteins exhibit better neutralizing activity than m36 or sCD4 alone.  </p> <h2>Competitive Advantages:</h2> <ul><li>Small size of single domain antibodies allows access to areas of HIV-1 that are hidden and inaccessible by larger antibodies</li> <li>Decreased non-specific binding of single CD4 domains to MHCII </li> <li>Fusion proteins of the inventions have very potent and broad HIV-1 neutralizing activity</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Therapeutic for the treatment of HIV-1 infection</li> </ul> 2018-09-05 2025-04-22 2023-01-09 2025-04-22 2018-09-05 CD4, Dimitrov, fusion protein, HIV-1, Single Domain Antibodies (sdAb) False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2023-01-09 52406768 Discovery 52406768 NCI 37470483 Website Abstract E-033-2013 E-086-2015 147162229 Chen W, et al. Exceptionally Potent and Broadly Cross-Reactive, Bispecific Multivalent HIV-1 Inhibitors Based on Single Human CD4 and Antibody Domains. https://www.ncbi.nlm.nih.gov/pubmed/24198429 <a href="https://www.ncbi.nlm.nih.gov/pubmed/24198429">Chen W, et al. Exceptionally Potent and Broadly Cross-Reactive, Bispecific Multivalent HIV-1 Inhibitors Based on Single Human CD4 and Antibody Domains.</a> 147162382 Chen W, et al. Engineered Single Human CD4 Domains as Potent HIV-1 Inhibitors and Components of Vaccine Immunogens. https://www.ncbi.nlm.nih.gov/pubmed/21715496 <a href="https://www.ncbi.nlm.nih.gov/pubmed/21715496">Chen W, et al. Engineered Single Human CD4 Domains as Potent HIV-1 Inhibitors and Components of Vaccine Immunogens.</a> 147164241 Dimitrov, Dimiter NIH - NCI NCI Dimitrov, Dimiter (NCI) 1 147164242 Chen, Weizao NIH - NCI Chen, Weizao 2 147164241 Dimitrov, Dimiter NIH - NCI NCI Dimitrov, Dimiter (NCI) 1 147164242 Chen, Weizao NIH - NCI Chen, Weizao 2 147157992 Bispecific Antibody Soluble Receptor Fc Fusion Proteins With Potent And Broad HIV-1 Neutralizing Activity E-103-2010-0 Filing authorized NCI 147162527 Bispecific Antibody Soluble Receptor FcFusion Proteins With Potent And Broad HIV-1 Neutralizing Activity E-103-2010-1 Filing authorized NCI 91814193 Freel, Rose rose.freel@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America rose.freel@nih.gov?subject=Web Inquiry on [TAB-4306] Single domain CD4, HIV-1 Antibodies, and Fusion Proteins for treatment of HIV&body=Please send me information about technology [TAB-4306] Single domain CD4, HIV-1 Antibodies, and Fusion Proteins for treatment of HIV.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Freel, Rose<br><a href="mailto:rose.freel@nih.gov?subject=Web Inquiry on [TAB-4306] Single domain CD4, HIV-1 Antibodies, and Fusion Proteins for treatment of HIV&body=Please send me information about technology [TAB-4306] Single domain CD4, HIV-1 Antibodies, and Fusion Proteins for treatment of HIV.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">rose.freel@nih.gov</a><br> 147168050 E-103-2010-0 E-103-2010-0-US-01 Bispecific Antibody Soluble Receptor Fc Fusion Proteins With Potent And Broad HIV-1 Neutralizing Activity PRV US 61/347,088 Abandoned US <br />Provisional (PRV) 61/347,088<br />Filed on 2010-05-21<br />Status: Abandoned 147168052 E-103-2010-1 E-103-2010-1-PCT-01 High-Affinity Fully Functional Soluble Single-Domain Human CD4, Antibodies, and Related Fusion Proteins PCT COMB Patent Cooperation Treaty PCT/US2011/037439 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2011/037439<br />Filed on 2011-05-20<br />Status: Expired 147168053 E-103-2010-1 E-103-2010-1-EP-02 High-Affinity Fully Functional Soluble Single-Domain Human CD4, Antibodies, and Related Fusion Proteins National Stage European Patent 2571898 11722270.3 Issued European Patent <br />National Stage 11722270.3<br />Filed on 2011-05-20<br />Status: Issued 147168054 E-103-2010-1 E-103-2010-1-US-03 High-Affinity Fully Functional Soluble Single-Domain Human CD4, Antibodies, and Related Fusion Proteins. National Stage US 8,911,728 13/699,535 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8911728 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8911728">8,911,728</a><br />Filed on 2013-01-11<br />Status: Issued 147168055 E-103-2010-1 E-103-2010-1-EP-04 High-Affinity Fully Functional Soluble Single-Domain Human CD4, Antibodies, and Related Fusion Proteins DIV European Patent 21185510.1 Pending European Patent <br />Divisional (DIV) 21185510.1<br />Filed on 2021-07-14<br />Status: Pending 147168056 E-103-2010-1 E-103-2010-1-DE-05 High-Affinity Fully Functional Soluble Single-Domain Human CD4, Antibodies, and Related Fusion Proteins EP Germany 2571898 11722270.3 Issued Germany <br />European patent (EP) 11722270.3<br />Filed on 2011-05-20<br />Status: Issued 147168057 E-103-2010-1 E-103-2010-1-FR-06 High-Affinity Fully Functional Soluble Single-Domain Human CD4, Antibodies, and Related Fusion Proteins EP France 2571898 11722270.3 Issued France <br />European patent (EP) 11722270.3<br />Filed on 2011-05-20<br />Status: Issued 147168058 E-103-2010-1 E-103-2010-1-GB-07 High-Affinity Fully Functional Soluble Single-Domain Human CD4, Antibodies, and Related Fusion Proteins EP United Kingdom 2571898 11722270.3 Issued United Kingdom <br />European patent (EP) 11722270.3<br />Filed on 2011-05-20<br />Status: Issued 147171473 CD4 147171474 Dimitrov 147171475 fusion protein 147171476 HIV-1 147171478 Single Domain Antibodies (sdAb) TAB-3950 147157230 A Specialized Tissue Collection Device for the Preservation and Transportation of Needle Biopsies NCI Collaboration, Licensing, Medical Devices, Non-Medical Devices, Oncology Collaboration Licensing Medical Devices Non-Medical Devices Oncology Russell Bandle, Armando Filie, Jeffrey Hanson, Stephen Hewitt, Hiroshi Kijoma, Robert Star <p>The ability to hold and transport tissue, especially needle biopsies in a pre-defined and controlled environment is critical for the preservation of biopsy samples in downstream analytic applications. Currently, tissue specimens are placed in open containers with variable, poorly controlled solutions applied to them, often in less than sterile conditions.&nbsp; Evaluation of the tissue by examination through a stereoscope or similar approaches to determine adequacy is limited and requires manipulation of the tissue that can further damage the tissue. The entire process lacks standardization, which is in stark contrast to the handling of blood, that is collected and transported in well-defined containers that have individualized pre-analytic preservatives and downstream protocols.&nbsp;<br /> &nbsp;<br /> Researchers at National Institutes of Health (NIH) have developed a tissue collection and storage container that allows for the direct deposition of tissue into the container while stabilizing the sample for transport in a specific solution and/or gas. This new device will primarily be used for needle biopsies to collect tissue samples and maintain their integrity for subsequent analysis. Additional features of the tissue storage container will include materials to physically stabilize and allow for direct examination of the sample by microscopy.</p> <p>This system is available for co-development or licensing to interested companies.</p> <h2>Competitive Advantages:</h2> <ul> <li>No devices currently allow for tissue storage in a sterile, pre-defined, and controlled environment, and can be used to prepare the sample for further analysis</li> </ul> <h2>Commercial Applications:</h2> <ul> <li>Tissue storage container for collecting samples obtained by biopsy gun, manual biopsy, or interventional radiology such as computed tomography (CT)-guided transvascular, transcutaneous, transvascular sampling, or needle aspiration</li> <li>Sterile and controlled storage environment for the transport of tissue, cell, and liquid samples. Can be combined with the tissue fixative agent, BE70 [<a href="https://techtransfer.cancer.gov/available-technologies?abstract=TAB-4207" target="_blank">NIH Reference # E-139-2015</a>]</li> </ul> 2018-09-05 2025-04-22 2021-01-26 2025-04-22 2018-09-05 COLLECTION, DEVICE, FIXATION, Hewitt, KIDNEY, liver, LUNG, Needle Biopsy, PANCREAS, PRESERVATION, STERILE, Storage, Tissue, Transportation False True Prototype True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-01-26 52406769 Prototype 52406769 NCI 37470483 Website Abstract E-139-2015 E-173-2015 147162988 Hewitt, Stephen NIH - NCI NCI Hewitt, Stephen (NCI) 1 147162987 Star, Robert NIH - NIDDK NIDDK Star, Robert (NIDDK) 2 147162990 Kijoma, Hiroshi NIH - NIDDK NIDDK Kijoma, Hiroshi (NIDDK) 3 147162989 Hanson, Jeffrey NIH - NCI NCI Hanson, Jeffrey (NCI) 4 147162991 Filie, Armando NIH - NCI NCI Filie, Armando (NCI) 5 147162992 Bandle, Russell NCI - CCR NCI Bandle, Russell (NCI) 6 147162988 Hewitt, Stephen NIH - NCI NCI Hewitt, Stephen (NCI) 1 147162987 Star, Robert NIH - NIDDK NIDDK Star, Robert (NIDDK) 2 147162990 Kijoma, Hiroshi NIH - NIDDK NIDDK Kijoma, Hiroshi (NIDDK) 3 147162989 Hanson, Jeffrey NIH - NCI NCI Hanson, Jeffrey (NCI) 4 147162991 Filie, Armando NIH - NCI NCI Filie, Armando (NCI) 5 147162992 Bandle, Russell NCI - CCR NCI Bandle, Russell (NCI) 6 147158039 Device For Transportation Of Needle Biopsy Specimens (Tissue Vacutainer) E-128-2017-0 Filing authorized National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NCI 121111111 Greene, Jaime greenejaime@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America greenejaime@mail.nih.gov?subject=Web Inquiry on [TAB-3950] A Specialized Tissue Collection Device for the Preservation and Transportation of Needle Biopsies&body=Please send me information about technology [TAB-3950] A Specialized Tissue Collection Device for the Preservation and Transportation of Needle Biopsies.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Greene, Jaime<br><a href="mailto:greenejaime@mail.nih.gov?subject=Web Inquiry on [TAB-3950] A Specialized Tissue Collection Device for the Preservation and Transportation of Needle Biopsies&body=Please send me information about technology [TAB-3950] A Specialized Tissue Collection Device for the Preservation and Transportation of Needle Biopsies.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">greenejaime@mail.nih.gov</a><br> 147161077 E-128-2017-0 E-128-2017-0-US-01 DEVICE FOR STORING AND TRANSPORTING TISSUE SPECIMENS PRV US 62/490,415 Abandoned US <br />Provisional (PRV) 62/490,415<br />Filed on 2017-04-26<br />Status: Abandoned 147165508 E-128-2017-0 E-128-2017-0-PCT-02 DEVICE FOR STORING AND TRANSPORTING TISSUE SPECIMENS PCT Patent Cooperation Treaty PCT/US2018/029623 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2018/029623<br />Filed on 2018-04-26<br />Status: Expired 147165509 E-128-2017-0 E-128-2017-0-EP-03 DEVICE FOR STORING AND TRANSPORTING TISSUE SPECIMENS National Stage European Patent 18724092.4 Pending European Patent <br />National Stage 18724092.4<br />Filed on 2018-04-26<br />Status: Pending 147165510 E-128-2017-0 E-128-2017-0-US-04 DEVICE FOR STORING AND TRANSPORTING TISSUE SPECIMENS National Stage US 11,623,220 16/606,555 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11623220 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11623220">11,623,220</a><br />Filed on 2019-10-18<br />Status: Issued 147172003 COLLECTION 147172004 DEVICE 147172005 FIXATION 147172006 Hewitt 147172007 KIDNEY 147172008 liver 147172009 LUNG 147172011 Needle Biopsy 147172012 PANCREAS 147172013 PRESERVATION 147172014 STERILE 147172015 Storage 147172016 Tissue 147172017 Transportation TAB-3912 147157192 Fibroblast Growth Factor Receptor 4 (FGFR4) Monoclonal Antibodies and Methods of Their Use NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Sivasubramanian Baskar, Adam Cheuk, Dimiter Dimitrov, Javed Khan, Rimas Orentas, Zhongyu Zhu <p>Several Fibroblast Growth Factor Receptor 4 (FGFR4) specific antibodies with binding affinity at the nanomolar range have been successfully developed at the Genetics Branch. These antibodies have been made into different formats of therapeutic including Antibody Drug Conjugate (ADC), Bispecific T cell engager (BiTE) ae well as Chimeric Antigen Receptor (CAR)-T cells.</p> <p>Proof of principle experiments have shown that when treated with FGFR4 positive tumor cells:  </p> <ol><li>FGFR4 specific antibodies were able to deliver cytotoxic agents and killed those cells.  </li> <li>CD3 FGFR4 BiTE were able to recruit T cells to kill those cells. </li> <li>FGFR4 CAR-T cell was activated by cancer cells overexpressed FGFR4 and FGFR4 CAR-T cells were able to eliminate target cells both in vitro and in vivo </li> </ol><p>These findings are important in Rhabdomyosarcoma (RMS) as researchers at <a href="https://ccr.cancer.gov/Genetics-Branch" target="_blank" rel="nofollow">NCI's Genetics Branch</a> found that high FGFR4 is overexpressed in RMS tumors compared with other normal tissue. RMS patients with higher FGFR4 expression is often associated with advanced disease, rapid disease progression, and poor survival. The correlation between FGFR4 expression and highly aggressive RMS makes the protein an attractive target for treatment. </p> <p>RMS is a rare, yet the most common, soft tissue sarcoma in children and adolescents. Although current treatments for primary disease are relatively successful, metastatic RMS is generally accompanied by a dismal prognosis. Thus, these FGFR4 antibody- based therapeutics may fulfill the unmet medical needs for this disease.  Moreover, over expression of FGFR4 has also been reported in other common malignancies including liver, lung, pancreas, ovary and prostate cancers. Therefore, FGFR4 specific therapeutics can also be used for treatment of these diseases. </p> <h2>Competitive Advantages:</h2> <ul><li>High affinity and specificity of the antibodies allows more selective targeting of cancer cells, reducing the potential for side effects during therapy</li> <li>Multiple antibodies available</li> <li>Potential to address significant unmet medical need</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Development of unconjugated antibody therapeutics</li> <li>Development of antibody-drug conjugates (ADCs) and recombinant immunotoxins</li> <li>Development of chimeric antigen receptors (CARs) and T cell receptors</li> <li>Development of bispecific antibody therapeutics</li> <li>Development of diagnostic agents for detecting FGFR4-positive cancers</li> </ul> 2018-09-05 2025-04-22 2020-09-16 2025-04-22 2018-09-05 FGFR4, Fibroblast Growth Factor Receptor 4, Immunotherapy, Khan, Monoclonal Antibodies, Rhabdomyosarcoma, RMS False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-09-16 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147162836 Khan, Javed NIH - NCI NCI Khan, Javed (NCI) 1 147162838 Baskar, Sivasubramanian NIH - NCI NHLBI Baskar, Sivasubramanian (NHLBI) 2 147162835 Dimitrov, Dimiter NIH - NCI NCI Dimitrov, Dimiter (NCI) 3 147162837 Zhu, Zhongyu NIH - NCI NCI Zhu, Zhongyu (NCI) 4 147162840 Orentas, Rimas NIH - NCI NCI Orentas, Rimas (NCI) 5 147162839 Cheuk, Adam NIH - NCI NCI Cheuk, Adam (NCI) 6 147162836 Khan, Javed NIH - NCI NCI Khan, Javed (NCI) 1 147162838 Baskar, Sivasubramanian NIH - NCI NHLBI Baskar, Sivasubramanian (NHLBI) 2 147162835 Dimitrov, Dimiter NIH - NCI NCI Dimitrov, Dimiter (NCI) 3 147162837 Zhu, Zhongyu NIH - NCI NCI Zhu, Zhongyu (NCI) 4 147162840 Orentas, Rimas NIH - NCI NCI Orentas, Rimas (NCI) 5 147162839 Cheuk, Adam NIH - NCI NCI Cheuk, Adam (NCI) 6 147158291 Monoclonal Antibody-based Therapeutics Targeting Fibroblast Growth Factor Receptor 4 (FGFR4) For Potential Treatment Of Human Cancers Expressing FGFR4 E-264-2015-0 Filing authorized NCI 121111111 Greene, Jaime greenejaime@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America greenejaime@mail.nih.gov?subject=Web Inquiry on [TAB-3912] Fibroblast Growth Factor Receptor 4 (FGFR4) Monoclonal Antibodies and Methods of Their Use&body=Please send me information about technology [TAB-3912] Fibroblast Growth Factor Receptor 4 (FGFR4) Monoclonal Antibodies and Methods of Their Use.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Greene, Jaime<br><a href="mailto:greenejaime@mail.nih.gov?subject=Web Inquiry on [TAB-3912] Fibroblast Growth Factor Receptor 4 (FGFR4) Monoclonal Antibodies and Methods of Their Use&body=Please send me information about technology [TAB-3912] Fibroblast Growth Factor Receptor 4 (FGFR4) Monoclonal Antibodies and Methods of Their Use.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">greenejaime@mail.nih.gov</a><br> 147161242 E-264-2015-0 E-264-2015-0-PCT-02 MONOCLONAL ANTIBODIES SPECIFIC FOR FIBROBLAST GROWTH FACTOR RECEPTOR 4 (FGFR4)AND METHODS OF THEIR USE PCT Patent Cooperation Treaty PCT/US2016/052496 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2016/052496<br />Filed on 2016-09-19<br />Status: Expired 147165213 E-264-2015-0 E-264-2015-0-US-01 Monoclonal Antibodies Specific for Fibroblast Growth Factor Receptor 4 (FGFR4) and Methods of Their Use PRV US 62/221,045 Abandoned US <br />Provisional (PRV) 62/221,045<br />Filed on 2015-09-20<br />Status: Abandoned 147165214 E-264-2015-0 E-264-2015-0-CA-03 MONOCLONAL ANTIBODIES SPECIFIC FOR FIBROBLAST GROWTH FACTOR RECEPTOR 4 (FGFR4)AND METHODS OF THEIR USE National Stage Canada 2996205 2996205 Issued Canada <br />National Stage 2996205<br />Filed on 2016-09-19<br />Status: Issued 147165215 E-264-2015-0 E-264-2015-0-EP-04 MONOCLONAL ANTIBODIES SPECIFIC FOR FIBROBLAST GROWTH FACTOR RECEPTOR 4 (FGFR4)AND METHODS OF THEIR USE National Stage European Patent 3350224 16778536.9 Issued European Patent <br />National Stage 16778536.9<br />Filed on 2016-09-19<br />Status: Issued 147165216 E-264-2015-0 E-264-2015-0-US-05 MONOCLONAL ANTIBODIES SPECIFIC FOR FIBROBLAST GROWTH FACTOR RECEPTOR 4 (FGFR4) AND METHODS OF THEIR USE National Stage US 11,078,286 15/761,398 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11078286 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11078286">11,078,286</a><br />Filed on 2018-03-19<br />Status: Issued 147165217 E-264-2015-0 E-264-2015-0-US-06 MONOCLONAL ANTIBODIES SPECIFIC FOR FIBROBLAST GROWTH FACTOR RECEPTOR 4 (FGFR4) AND METHODS OF THEIR USE DIV US 12,453,780 17/355,703 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12453780 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12453780">12,453,780</a><br />Filed on 2021-06-23<br />Status: Issued 147174401 FGFR4 147174403 Fibroblast Growth Factor Receptor 4 147174404 Immunotherapy 147174405 Khan 147174406 Monoclonal Antibodies 147174407 Rhabdomyosarcoma 147174408 RMS TAB-3885 147157165 Bac-2-the-Future: An Improved System for Production of Recombinant Baculovirus NCI Cardiology, Dermatology, Ear, Nose, & Throat, Endocrinology, Gastroenterology, Immunology, Infectious Disease, Licensing, Nephrology, Oncology, Ophthalmology, Reproductive Health, Research Materials Cardiology Dermatology Ear Nose & Throat Endocrinology Gastroenterology Immunology Infectious Disease Licensing Nephrology Oncology Ophthalmology Reproductive Health Research Materials Dominic Esposito, Carissa Grose <p>Baculoviruses have been used for decades to produce proteins in insect cell hosts. Current systems for generating recombinant baculovirus have several shortcomings which prevent their easy use in high-throughput applications. </p> <p>Researchers within the Frederick National Laboratory for Cancer Research have developed an improved system called Bac-2-the-future, or B2F, to quickly and efficiently generate recombinant baculoviruses which produce recombinant proteins. In the new system, the baculovirus transfer vector, transposition helper plasmid, and E. coli strain carrying the bacmid DNA were modified to eliminate the need for screening positive clones and improve the efficiency of baculovirus production. Taken together, these improvements permit facile high-throughput recombinant baculovirus production at reduced cost and improved speed over the currently available systems.  The new transfer vectors and E. coli strains of the B2F system are available for licensing.  </p> <h2>Competitive Advantages:</h2> <ul><li>Elimination of background plasmid DNA during recombinant baculovirus production</li> <li>Elimination of nonproductive transposition events leading to false positives</li> <li>Lower cost production of baculovirus</li> <li>Increased speed of baculovirus production (allowing high-throughput production with limited screening)</li> <li>Higher efficiency cloning of baculovirus constructs</li> </ul> <h2>Commercial Applications:</h2> <ul><li>High-throughput protein production</li> <li>Generation of virus-like particles in insect cells</li> </ul> 2018-10-01 2025-04-22 2018-10-01 2025-04-22 2018-10-01 B2F, Bac-2-the-Future, Baculovirus, Esposito, Insect Cells, Protein Production False True Prototype True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2018-10-01 52406769 Prototype 52406769 NCI 37470483 Website Abstract E-164-2011 147162095 Mehalko JL, et al. Engineering the transposition-based baculovirus expression vector system for higher efficiency protein production from insect cells. https://www.ncbi.nlm.nih.gov/pubmed/27616621 <a href="https://www.ncbi.nlm.nih.gov/pubmed/27616621">Mehalko JL, et al. Engineering the transposition-based baculovirus expression vector system for higher efficiency protein production from insect cells.</a> 147162722 Esposito, Dominic NIH - NCI Leidos Esposito, Dominic (Leidos) 1 147162723 Grose, Carissa NIH - NCI Leidos Grose, Carissa (Leidos) 2 147162722 Esposito, Dominic NIH - NCI Leidos Esposito, Dominic (Leidos) 1 147162723 Grose, Carissa NIH - NCI Leidos Grose, Carissa (Leidos) 2 147158324 Improved Vectors For Production Of Recombinant Baculovirus E-287-2012-0 Research Material NCI 147162597 Improved Bacmid Strain To Eliminate Transpostion Into The E.coli Chromosome E-287-2012-1 Research Material NCI 147162598 Improved Bacmid Strains With Higher Protein Expression And Virus Stability E-287-2012-2 Research Material NCI 91814193 Freel, Rose rose.freel@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America rose.freel@nih.gov?subject=Web Inquiry on [TAB-3885] Bac-2-the-Future: An Improved System for Production of Recombinant Baculovirus&body=Please send me information about technology [TAB-3885] Bac-2-the-Future: An Improved System for Production of Recombinant Baculovirus.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Freel, Rose<br><a href="mailto:rose.freel@nih.gov?subject=Web Inquiry on [TAB-3885] Bac-2-the-Future: An Improved System for Production of Recombinant Baculovirus&body=Please send me information about technology [TAB-3885] Bac-2-the-Future: An Improved System for Production of Recombinant Baculovirus.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">rose.freel@nih.gov</a><br> 147174670 B2F 147174672 Bac-2-the-Future 147174673 Baculovirus 147174674 Esposito 147174676 Insect Cells 147174678 Protein Production TAB-4354 147157647 Highly Soluble Pyrimido-Dione-Quinoline Compounds: Small Molecules that Stabilize and Activate p53 in Transformed Cells NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Allan Weissman, Yili Yang <p>The tumor-suppressor p53 protein plays a major role in tumor development. Most human cancers fail to normally activate wild-type p53, which is at least partly responsible for the unregulated growth of cancer cells and their failure to undergo apoptosis. While many chemotherapeutics enhance p53 levels, their non-specific DNA damage (genotoxicity) causes unfavorable side effects.<br />  <br /> Defects in the pathways that control the stabilization and activation of p53 in response to stress can contribute to cancer development, without the requirement for mutation within the p53 gene itself. Many tumors that retain wild-type p53 show evidence of alterations that prevent efficient activation of p53 in response to stress, linked to a failure to inactivate HDM2. In these tumors, inhibition of HDM2 and reactivation of p53 is an attractive therapeutic strategy. Researchers at the National Cancer Institute (NCI) have developed a water-soluble, small molecule inhibitor of HDM2’s E3 activity resulting in activation of p53 in tumors that retain wild-type p53.</p> <p>This invention does not lead to the genotoxicity commonly observed when using other therapeutics directed at activating p53, making it an attractive option for cancer therapy. The NCI is seeking statements of capability or interest from parties interested in licensing or in collaborative research to co-develop technologies that inhibit HDM2’s activity and reactivate p53 activity for the treatment of cancer.</p> <h2>Competitive Advantages:</h2> <ul><li>Reduced genotoxicity compared to many chemotherapeutics</li> <li>Water-soluble with improved potency in stabilizing p53 and activating a p53 response</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Targeted therapies for activating wild-type p53 in tumors to induce apoptosis</li> <li>Inhibits unregulated growth of cancer cells</li> </ul> 2018-10-12 2025-04-22 2018-10-12 2025-04-22 2018-10-12 APOPTOSIS, CANCER, HDM2 Inhibitor, p53 Activation, Weissman False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2018-10-12 52406768 Discovery 52406768 NCI 37470483 Website Abstract E-070-2005 147162425 Yang Y et al. Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells https://www.ncbi.nlm.nih.gov/pubmed/15950904 <a href="https://www.ncbi.nlm.nih.gov/pubmed/15950904">Yang Y et al. Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells</a> 147164427 Weissman, Allan NIH - NCI NCI Weissman, Allan (NCI) 1 147164428 Yang, Yili NIH - NCI Yang, Yili 2 147164427 Weissman, Allan NIH - NCI NCI Weissman, Allan (NCI) 1 147164428 Yang, Yili NIH - NCI Yang, Yili 2 147158066 A Water Soluble Small Molecule Inhibitor Of P53 Degradation: Pyrimido[4,5]quinoline-2,4(3H,10H)-dione,5-[[3-(dimethylamino)proopyl]amino]3,10-dimethyl-,monohydrochloride (NCS # 373989) E-138-2006-0 Filing authorized NCI 83704821 Nguyen-Antczak, Lauren lauren.nguyen-antczak@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-4354] Highly Soluble Pyrimido-Dione-Quinoline Compounds: Small Molecules that Stabilize and Activate p53 in Transformed Cells&body=Please send me information about technology [TAB-4354] Highly Soluble Pyrimido-Dione-Quinoline Compounds: Small Molecules that Stabilize and Activate p53 in Transformed Cells.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Nguyen-Antczak, Lauren<br><a href="mailto:lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-4354] Highly Soluble Pyrimido-Dione-Quinoline Compounds: Small Molecules that Stabilize and Activate p53 in Transformed Cells&body=Please send me information about technology [TAB-4354] Highly Soluble Pyrimido-Dione-Quinoline Compounds: Small Molecules that Stabilize and Activate p53 in Transformed Cells.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">lauren.nguyen-antczak@nih.gov</a><br> 147161098 E-138-2006-0 E-138-2006-0-US-01 A Water Soluble Small Molecule Inhibitor Of P53 Degradation: Pyrimido[4,5]quinoline-2,4(3H,10H)-dione,5-[[3-(dimethylamino)proopyl]amino]3,10-dimethyl-,monohydrochloride (NCS # 373989) PRV US 60/813,946 Abandoned US <br />Provisional (PRV) 60/813,946<br />Filed on 2006-06-14<br />Status: Abandoned 147168396 E-138-2006-0 E-138-2006-0-PCT-02 HIGHLY SOLUBLE PYRIMIDO-DIONE-QUINOLINE COMPOUNDS AND METHODS OF TREATING CANCER PCT Patent Cooperation Treaty PCT/US2007/013952 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2007/013952<br />Filed on 2007-06-13<br />Status: Expired 147168397 E-138-2006-0 E-138-2006-0-US-03 Highly Soluble Pyrimido-Dione-Quinoline Compounds and Their Use In The Treatment of Cancer National Stage US 8,877,765 12/304,980 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8877765 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8877765">8,877,765</a><br />Filed on 2009-10-28<br />Status: Issued 147172230 APOPTOSIS 147172231 CANCER 147172233 HDM2 Inhibitor 147172235 p53 Activation 147172237 Weissman TAB-4370 147157664 T cell Receptors Which Recognize Mutated EGFR NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Kenichi Hanada, Anna Pasetto, James Yang, Chihao Zhao <p>Epidermal growth factor receptor (EGFR) is a transmembrane protein involved in cell growth and proliferation. Mutations in this protein can lead to overexpression, causing several types of cancer; notably, non-small cell lung cancer (NSCLC). For example, mutations in EGFR are found in up to 50% of NSCLC patients and the E746-A750 deletion accounts for 30-40% of such EGFR mutations. Currently, there are no available therapeutics that specifically target the E746-A750 deletion. </p> <p>Researchers at the National Cancer Institute (NCI) have isolated T cells that recognize the EGFR E746-A750 deletion. Retroviral transfer of the TCR genes conferred recognition of tumor cell lines with EGFR E746-A750 deletion in the context of HLA DPA1*02:01 and DPB1*01:01. These HLAs exists in about 10% of Caucasians and 50% African Americans, respectively, in the US. This discovery allows for the specific elimination of tumor cells with E746-A750 deletion mutation present in a significant portion of the more than 222,500 NSCLC patients. </p> <p>The <a href="https://ccr.cancer.gov/Surgery-Branch" rel="nofollow">National Cancer Institute, Surgery Branch</a>, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize these novel, EGFR mutation-reactive TCRs.</p> <h2>Competitive Advantages:</h2> <ul><li>First T cell receptor that can kill tumors by targeting the EGFR E746-A750 deletion</li> <li>EGFR mutations common in non-small cell lung cancer patients</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Significant number of lung cancer patients may benefit from this receptor</li> <li>Use of the TCRs in chimeric proteins for research purposes in cancers with mutated EGFR</li> </ul> 2018-10-12 2025-04-22 2018-10-12 2025-04-22 2018-10-12 EGFR mutation, Epidermal Growth Factor Receptor, Hanada, Immunotherapy, T Cell Receptor, TCR False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2018-10-12 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-028-2015 E-181-2017 E-237-2017 147164471 Hanada, Kenichi NIH - NCI NCI Hanada, Kenichi (NCI) 1 147164474 Zhao, Chihao NIH - NCI NCI Zhao, Chihao (NCI) 2 147164473 Pasetto, Anna NIH - NCI Pasetto, Anna 3 147164472 Yang, James NIH - NCI NCI Yang, James (NCI) 4 147164471 Hanada, Kenichi NIH - NCI NCI Hanada, Kenichi (NCI) 1 147164474 Zhao, Chihao NIH - NCI NCI Zhao, Chihao (NCI) 2 147164473 Pasetto, Anna NIH - NCI Pasetto, Anna 3 147164472 Yang, James NIH - NCI NCI Yang, James (NCI) 4 147157985 Isotation Of EGFR E746-A750 Deletion Specific T Cell Recerptors Restricted By HLA DPA1*02:01 DPB1*01:01 E-098-2018-0 Filing authorized NCI 83709866 Burke, Andrew burkear@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC burkear@nih.gov?subject=Web Inquiry on [TAB-4370] T cell Receptors Which Recognize Mutated EGFR&body=Please send me information about technology [TAB-4370] T cell Receptors Which Recognize Mutated EGFR.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Burke, Andrew<br><a href="mailto:burkear@nih.gov?subject=Web Inquiry on [TAB-4370] T cell Receptors Which Recognize Mutated EGFR&body=Please send me information about technology [TAB-4370] T cell Receptors Which Recognize Mutated EGFR.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">burkear@nih.gov</a><br> 147161036 E-098-2018-0 E-098-2018-0-US-01 T CELL RECEPTORS WHICH RECOGNIZE MUTATED EGFR PRV US 62/665,234 Abandoned US <br />Provisional (PRV) 62/665,234<br />Filed on 2018-05-01<br />Status: Abandoned 147168499 E-098-2018-0 E-098-2018-0-PCT-02 T CELL RECEPTORS WHICH RECOGNIZE MUTATED EGFR PCT Patent Cooperation Treaty PCT/US2019/030108 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2019/030108<br />Filed on 2019-05-01<br />Status: Expired 147168500 E-098-2018-0 E-098-2018-0-AU-03 T CELL RECEPTORS WHICH RECOGNIZE MUTATED EGFR National Stage Australia 2019263233 2019263233 Issued Australia <br />National Stage 2019263233<br />Filed on 2020-11-30<br />Status: Issued 147168501 E-098-2018-0 E-098-2018-0-CA-04 T CELL RECEPTORS WHICH RECOGNIZE MUTATED EGFR National Stage Canada 3099106 Pending Canada <br />National Stage 3099106<br />Filed on 2020-11-02<br />Status: Pending 147168502 E-098-2018-0 E-098-2018-0-EP-05 T CELL RECEPTORS WHICH RECOGNIZE MUTATED EGFR National Stage European Patent 19723615.1 Pending European Patent <br />National Stage 19723615.1<br />Filed on 2020-11-22<br />Status: Pending 147168503 E-098-2018-0 E-098-2018-0-US-06 T CELL RECEPTORS WHICH RECOGNIZE MUTATED EGFR National Stage US 12,577,286 17/051,860 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12577286 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12577286">12,577,286</a><br />Filed on 2020-10-30<br />Status: Issued 147168504 E-098-2018-0 E-098-2018-0-HK-07 T CELL RECEPTORS WHICH RECOGNIZE MUTATED EGFR EP Hong Kong 62021037536.1 Pending Hong Kong <br />European patent (EP) 62021037536.1<br />Filed on 2021-08-25<br />Status: Pending 147171398 EGFR mutation 147171399 Epidermal Growth Factor Receptor 147171401 Hanada 147171402 Immunotherapy 147171403 T Cell Receptor 147171404 TCR TAB-3909 147157189 Bile Acids and Other Agents that Modulate the Gut Microbiome for the Treatment of Liver Cancer NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Tim Greten, Chi Ma <p>Primary liver tumors and secondary hepatic malignancies are among the leading causes of cancer-related deaths. Liver metastases account for 95% of all hepatic cancers, and the liver is the most common site for organ metastasis in the body. The gut microbiome serves an important role in antitumor immunity regulating the efficacy of chemo- and immunotherapies. The liver is exposed to gut bacteria through blood from the intestine, with 70% of the whole liver’s blood supply coming from intestinal blood. Changes in the commensal microbiome may affect immune cell function in the liver. Commensal bacteria have been shown to metabolize primary bile acids to secondary bile acids, and researchers at the National Cancer Institute (NCI) have found that the balance of primary versus secondary bile acids plays a role in liver cancer development.  </p> <p>Researchers at the NCI have identified a novel mechanism to enhance anti-tumor immunity in the liver by using primary bile acids or antibiotics that increase primary bile acids which attract natural killer T (NKT) cells. Mechanistically, primary bile acid induces the expression of chemokine (C-X-C motif) ligand 16 (CXCL16) on liver sinusoidal endothelial cells leading to an accumulation of C-C chemokine receptor type 6 (CCR6) -positive NKT cells in the liver. The inventors have demonstrated in vivo that primary bile acids or antibiotics increase the accumulation of NKT cells in the liver and decrease the number of liver surface metastases in mice. </p> <p> The <a href="https://ccr.cancer.gov/thoracic-and-gi-malignancies-branch" rel="nofollow">National Cancer Institute, Thoracic and GI Malignancies Branch</a>, is seeking statements of capability or interest from parties interested in licensing this invention and/or collaborative research to further develop, evaluate, or commercialize primary bile acids or antibiotics for the treatment of liver cancer and/or liver metastases. </p> <h2>Competitive Advantages:</h2> <ul><li>Various formulations of bile acids are already in clinical use and are FDA-approved for the treatment of biliary cirrhosis and bile acid synthesis disorders</li> <li>Bile acid formulations and antibiotics are well-tolerated and are biological agents</li> <li>Novel anti-tumor function </li> </ul> <h2>Commercial Applications:</h2> <ul><li>Treatment of liver cancer and liver metastases</li> <li>Therapeutic use as a combination therapy with immune checkpoint inhibitors and/or chemotherapy  </li> </ul> 2018-10-12 2025-04-22 2018-10-12 2025-04-22 2018-10-12 Bile Acid, Greten, Liver cancer, Natural Killer T Cells, NKT cells False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2018-10-12 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-034-2010 147161934 Ma C, et al. Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells https://www.ncbi.nlm.nih.gov/pubmed/29798856 <a href="https://www.ncbi.nlm.nih.gov/pubmed/29798856">Ma C, et al. Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells</a> 147162825 Greten, Tim NIH - NCI NCI Greten, Tim (NCI) 1 147162826 Ma, Chi NCI - CCR NCI Ma, Chi (NCI) 2 147162825 Greten, Tim NIH - NCI NCI Greten, Tim (NCI) 1 147162826 Ma, Chi NCI - CCR NCI Ma, Chi (NCI) 2 147158243 Bile Acids Induce NKT Cell Accumulation In The Liver E-229-2017-0 Filing authorized NCI 83724826 Pollard, Ricquita ricquita.pollard@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-3909] Bile Acids and Other Agents that Modulate the Gut Microbiome for the Treatment of Liver Cancer&body=Please send me information about technology [TAB-3909] Bile Acids and Other Agents that Modulate the Gut Microbiome for the Treatment of Liver Cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollard, Ricquita<br><a href="mailto:ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-3909] Bile Acids and Other Agents that Modulate the Gut Microbiome for the Treatment of Liver Cancer&body=Please send me information about technology [TAB-3909] Bile Acids and Other Agents that Modulate the Gut Microbiome for the Treatment of Liver Cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">ricquita.pollard@nih.gov</a><br> 147161211 E-229-2017-0 E-229-2017-0-US-01 TREATING OR PREVENTING ADVERSE LIVER CONDITIONS BY ADMINISTERING A PRIMARY BILE ACID PRV US 62/578,176 Abandoned US <br />Provisional (PRV) 62/578,176<br />Filed on 2017-10-27<br />Status: Abandoned 147165178 E-229-2017-0 E-229-2017-0-PCT-02 TREATING OR PREVENTING ADVERSE LIVER CONDITIONS PCT Patent Cooperation Treaty PCT/US2018/057946 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2018/057946<br />Filed on 2018-10-29<br />Status: Expired 147165179 E-229-2017-0 E-229-2017-0-US-03 TREATING OR PREVENTING ADVERSE LIVER CONDITIONS National Stage US 11,771,737 16/756,926 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11771737 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11771737">11,771,737</a><br />Filed on 2020-04-17<br />Status: Issued 147173993 Bile Acid 147173995 Greten 147173996 Liver cancer 147173997 Natural Killer T Cells 147173998 NKT cells TAB-3872 147157152 Tethered Interleukin-15 (IL-15)/IL-21 to Enhance T Cells for Cellular Therapy NCI Licensing, Oncology, Therapeutics Licensing Oncology Therapeutics Christian Hinrichs, Benjamin Jin <p>Interleukin-15 (IL-15) and IL-21 have been reported to support the function of anti-tumor T cells.  However, their use in the clinic has been constrained, in part, by dose-limiting toxicity and the need for repeated administration.  To overcome these limitations, researchers in the National Cancer Institute (NCI) <a href="https://ccr.cancer.gov/Experimental-Transplantation-and-Immunology-Branch" rel="nofollow">Experimental Transplantation and Immunology Branch (ETIB)</a> have developed synthetic IL-15 and IL-21 molecules for autocrine expression by the engineered therapeutic T cells. These molecules were designed with flexible linkers that connect to cell membrane anchors.  This, in turn, reduces systemic toxicity caused by free cytokine molecules. The inventors have shown that co-expression of the novel IL-15 and IL-21 tethered molecules improves the anti-tumor efficacy of the therapeutic engineered T cells in vivo. </p> <h2>Competitive Advantages:</h2> <ul><li>T cells that co-express the tethered IL-15 and IL-21 on their cell membrane can increase therapeutic effectiveness of adoptive immunotherapy because it can reduce systemic toxicity caused by free cytokine molecules</li> <li>T cells that co-express the tethered IL-15 and IL-21 on their cell membrane are already known to have a greater decrease in tumor size compared to those mice treated with T cell-based immunotherapies using unmodified T cells </li> </ul> <h2>Commercial Applications:</h2> <ul><li>Treatment of cancer patients receiving T cell-based immunotherapy </li> </ul> 2018-10-12 2025-04-22 2023-04-03 2025-04-22 2018-10-12 act, adoptive cell therapy, CANCER, CAR, chimeric antigen receptor, Hinrichs, IL-15, IL-21, INTERLEUKIN-15, Interleukin-21, T Cells False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2023-04-03 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147162681 Hinrichs, Christian NIH - NCI Hinrichs, Christian 1 147162682 Jin, Benjamin NCI - CCR NCI Jin, Benjamin (NCI) 2 147162681 Hinrichs, Christian NIH - NCI Hinrichs, Christian 1 147162682 Jin, Benjamin NCI - CCR NCI Jin, Benjamin (NCI) 2 147157919 Tethered Interleukin-15 (IL-15)/IL-21 To Enhance T Cells For Cellular Therapy E-068-2018-0 Filing authorized NCI 83709866 Burke, Andrew burkear@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC burkear@nih.gov?subject=Web Inquiry on [TAB-3872] Tethered Interleukin-15 (IL-15)/IL-21 to Enhance T Cells for Cellular Therapy&body=Please send me information about technology [TAB-3872] Tethered Interleukin-15 (IL-15)/IL-21 to Enhance T Cells for Cellular Therapy.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Burke, Andrew<br><a href="mailto:burkear@nih.gov?subject=Web Inquiry on [TAB-3872] Tethered Interleukin-15 (IL-15)/IL-21 to Enhance T Cells for Cellular Therapy&body=Please send me information about technology [TAB-3872] Tethered Interleukin-15 (IL-15)/IL-21 to Enhance T Cells for Cellular Therapy.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">burkear@nih.gov</a><br> 147160992 E-068-2018-0 E-068-2018-0-US-01 TETHERED INTERLEUKIN-15 AND INTERLEUKIN-21 PRV US 62/628,454 Abandoned US <br />Provisional (PRV) 62/628,454<br />Filed on 2018-02-09<br />Status: Abandoned 147164941 E-068-2018-0 E-068-2018-0-PCT-02 TETHERED INTERLEUKIN-15 AND INTERLEUKIN-21 PCT Patent Cooperation Treaty PCT/US2019/016975 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2019/016975<br />Filed on 2019-02-07<br />Status: Expired 147164942 E-068-2018-0 E-068-2018-0-AU-03 TETHERED INTERLEUKIN-15 AND INTERLEUKIN-21 National Stage Australia 2019218785 2019218785 Issued Australia <br />National Stage 2019218785<br />Filed on 2020-08-07<br />Status: Issued 147164943 E-068-2018-0 E-068-2018-0-CN-04 TETHERED INTERLEUKIN-15 AND INTERLEUKIN-21 National Stage China 201980012443.3 Pending China <br />National Stage 201980012443.3<br />Filed on 2020-08-07<br />Status: Pending 147164944 E-068-2018-0 E-068-2018-0-EP-05 TETHERED INTERLEUKIN-15 AND INTERLEUKIN-21 National Stage European Patent 3749770 19709154.9 Issued European Patent <br />National Stage 19709154.9<br />Filed on 2020-08-18<br />Status: Issued 147164945 E-068-2018-0 E-068-2018-0-US-06 TETHERED INTERLEUKIN-15 AND INTERLEUKIN-21 National Stage US 12,617,833 16/964,796 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12617833 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12617833">12,617,833</a><br />Filed on 2020-07-24<br />Status: Issued 147164946 E-068-2018-0 E-068-2018-0-CA-07 TETHERED INTERLEUKIN-15 AND INTERLEUKIN-21 National Stage Canada 3090512 Pending Canada <br />National Stage 3090512<br />Filed on 2020-08-05<br />Status: Pending 147164947 E-068-2018-0 E-068-2018-0-HK-08 TETHERED INTERLEUKIN-15 AND INTERLEUKIN-21 EP Hong Kong 62021033097.8 Abandoned Hong Kong <br />European patent (EP) 62021033097.8<br />Filed on 2021-06-15<br />Status: Abandoned 147164948 E-068-2018-0 E-068-2018-0-US-02 TETHERED INTERLEUKIN-15 AND INTERLEUKIN-21 CON US 12,157,762 18/310,744 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12157762 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12157762">12,157,762</a><br />Filed on 2023-05-02<br />Status: Issued 147164949 E-068-2018-0 E-068-2018-0-US-03 TETHERED INTERLEUKIN-15 AND INTERLEUKIN-21 CON US Administratively Closed US <br />Continuation (CON) None<br />Filed on None<br />Status: Administratively Closed 147170718 act 147170719 adoptive cell therapy 147170720 CANCER 147170721 CAR 147170722 chimeric antigen receptor 147170723 Hinrichs 147170724 IL-15 147170725 IL-21 147170726 INTERLEUKIN-15 147170727 Interleukin-21 147170728 T Cells TAB-3881 147157161 The UBE2G2 Binding Domain in the Ubiquitin Ligase GP78 and Methods of Use Thereof NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Bo Chen, Jennifer Mariano, Yien-Che Tsai, Allan Weissman <p>Cancer is the second leading cause of death worldwide. The primary cause of mortality from cancer is metastasis. While the underlying mechanisms of cancer metastasis are still being unraveled, the gp78 protein involved in ER-associated degradation (ERAD) appears to play a role in metastasis in sarcoma. Targeting gp78 may be a therapeutic option in cancer treatment.</p> <p>The prometastatic activity of ERAD requires the E3 ubiquitin ligase activity of gp78. Gp78 targets the transmembrane metastasis suppressor, KAI1, for degradation. Suppression of gp78 results in the accumulation of KAI1 and a reduced metastatic potency of sarcoma cells.</p> <p>Regulating gp78 presents a new therapeutic strategy for the treatment of sarcomas. The National Cancer Institute (NCI) is seeking statements of capability or interest from parties interested in licensing or in collaborative research to co-develop technologies that disrupt gp78 activity and/or ERAD activity for the treatment of cancer.</p> <h2>Competitive Advantages:</h2> <ul><li>The G2BR is the only reagent specific for targeting the endoplasmic reticulum-associated degradation E2, Ube2G2</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Targeted therapies for sarcomas, melanoma, breast cancer, myeloma and other solid tumors and leukemias</li> <li>Reducing activation of SREBP pathway for lipid and cholesterol synthesis</li> <li>Reducing degradation and improving maturation of cell surface or secreted proteins</li> <li>Developing a method to identify more robust gp78 inhibitors</li> </ul> 2018-10-12 2025-04-22 2018-10-12 2025-04-22 2018-10-12 APOPTOSIS, CANCER, Endoplasmic Reticulum, er, ERAD, ER-associated Degradation, Gp78, Metastasis, STRESS, Ube2G2, Ubiquitin, Weissman False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2018-10-12 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147161935 Chen B et al. The activity of a human endoplasmic reticulum-associated degradation E3, gp78, requires its Cue domain, RING finger, and an E2-binding site https://www.ncbi.nlm.nih.gov/pubmed/16407162 <a href="https://www.ncbi.nlm.nih.gov/pubmed/16407162">Chen B et al. The activity of a human endoplasmic reticulum-associated degradation E3, gp78, requires its Cue domain, RING finger, and an E2-binding site</a> 147161973 Tsai YC et al. The ubiquitin ligase gp78 promotes sarcoma metastasis by targeting KAI1 for degradation https://www.ncbi.nlm.nih.gov/pubmed/18037895 <a href="https://www.ncbi.nlm.nih.gov/pubmed/18037895">Tsai YC et al. The ubiquitin ligase gp78 promotes sarcoma metastasis by targeting KAI1 for degradation</a> 147162476 Das R et al. Allosteric Activation of Ubiquitin Ligase Activity by a Structurally-Defined Specific E2 Binding Region of gp78 https://www.ncbi.nlm.nih.gov/pubmed/19560420 <a href="https://www.ncbi.nlm.nih.gov/pubmed/19560420">Das R et al. Allosteric Activation of Ubiquitin Ligase Activity by a Structurally-Defined Specific E2 Binding Region of gp78</a> 147162712 Weissman, Allan NIH - NCI NCI Weissman, Allan (NCI) 1 147162713 Mariano, Jennifer NIH - NCI NCI Mariano, Jennifer (NCI) 2 147162714 Chen, Bo NIH - NCI Chen, Bo 3 147162715 Tsai, Yien-Che NIH - NCI NCI Tsai, Yien-Che (NCI) 4 147162712 Weissman, Allan NIH - NCI NCI Weissman, Allan (NCI) 1 147162713 Mariano, Jennifer NIH - NCI NCI Mariano, Jennifer (NCI) 2 147162714 Chen, Bo NIH - NCI Chen, Bo 3 147162715 Tsai, Yien-Che NIH - NCI NCI Tsai, Yien-Che (NCI) 4 147158261 Binding Site For The Ubiquitin Conjugating Enzyme Ube2G2 Within The Ubiquitin Ligase Gp78. Over-expression Of This Region Confers An Inhibtory Effect On Endoplasmic Reticulum (ER)-Associated Degradation (EGAD) E-244-2004-0 Filing authorized NCI 83704821 Nguyen-Antczak, Lauren lauren.nguyen-antczak@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-3881] The UBE2G2 Binding Domain in the Ubiquitin Ligase GP78 and Methods of Use Thereof&body=Please send me information about technology [TAB-3881] The UBE2G2 Binding Domain in the Ubiquitin Ligase GP78 and Methods of Use Thereof.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Nguyen-Antczak, Lauren<br><a href="mailto:lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-3881] The UBE2G2 Binding Domain in the Ubiquitin Ligase GP78 and Methods of Use Thereof&body=Please send me information about technology [TAB-3881] The UBE2G2 Binding Domain in the Ubiquitin Ligase GP78 and Methods of Use Thereof.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">lauren.nguyen-antczak@nih.gov</a><br> 147161224 E-244-2004-0 E-244-2004-0-US-01 The UBE2G2 Binding Domain in the Ubiquitin Ligase GP78 and Methods of Use Thereof PRV US 60/583,263 Abandoned US <br />Provisional (PRV) 60/583,263<br />Filed on 2004-06-26<br />Status: Abandoned 147165028 E-244-2004-0 E-244-2004-0-PCT-02 The Ube2G2 Binding Domain in The Ubiquitin Ligase Gp78 and Methods of Use Thereof PCT Patent Cooperation Treaty PCT/US2005/14635 Abandoned Patent Cooperation Treaty <br />(PCT) PCT/US2005/14635<br />Filed on 2005-04-27<br />Status: Abandoned 147165029 E-244-2004-0 E-244-2004-0-US-03 THE UBE2GE BINDING DOMAIN IN THE UBIQUITIN LIGASE GP78 AND METHODS OF USE THEREOF National Stage US 8,420,776 11/597,453 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8420776 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8420776">8,420,776</a><br />Filed on 2006-11-21<br />Status: Expired 147174147 APOPTOSIS 147174148 CANCER 147174150 Endoplasmic Reticulum 147174151 er 147174152 ERAD 147174154 ER-associated Degradation 147174155 Gp78 147174156 Metastasis 147174157 STRESS 147174158 Ube2G2 147174159 Ubiquitin 147174160 Weissman TAB-3861 147157140 Multi-Foci Sonications For Hyperthermia Treatments Using Magnetic Resource-Guided High-Intensity Focused Ultrasound (MR-HIFU) CC Licensing, Oncology, Therapeutics Licensing Oncology Therapeutics Matthew Dreher, Max Koehler, Ari Partanen, Matti Tillander, Bradford Wood <p>Hyperthermia has been used extensively and successfully in the treatment of solid tumors. For accessible solid tumors with impressive efficacy not amenable to surgery, ablative hyperthermia (&gt;55°C for 20 s to 15 min) has been used as a definitive treatment. By contrast, for both radiotherapy and chemotherapy, mild hyperthermia (40-45°C for up to 1 hour) has been shown useful as an adjuvant. It induces a multitude of changes to the physiology and biology of the target tumor that improve the effectiveness of other treatments and make mild hyperthermia synergistic with many chemotherapeutic agents and radiation therapies. Many currently available devices, including but not limited to radiofrequency (RF) applicators, microwave applicators, hot water baths, lasers, and magnetic fluids, can heat the target tissue to the mild hyperthermic range. However, these suffer from drawbacks: limited or superficial heating, hot and cold spots, inaccurate or spatially uneven heating, and a lack of spatiotemporal feedback control. </p> <p>To resolve these challenges and safely heat anatomical regions with Magnetic Resource-Guided High-Intensity Focused Ultrasound (MR-HIFU), researchers at the National Institutes of Health Clinical Center (NIH CC) have developed a multi-foci sonication technology for sustained mild hyperthermia over an extended period. The multi-foci sonication approach controls temperature accuracy and uniformity, confines heated volumes, and lower peaks acoustic pressures in the heated region. The refined multi-foci sonication heating strategy is combined with a heating algorithm, and results in accurate and precise heating within the targeted region with significantly lower acoustic pressures and spatially more confined heating in the beam path direction (compared to the single focus sonication method). This multi-foci sonication hyperthermia technology may be implemented on a clinical MR-HIFU platform for oncology therapy.</p> <p>The multi-foci heating strategy may also have other applications such as in MR-HIFU thermal ablations. The more even thermal profile may be utilized in drug delivery or gene therapy to obtain a more even drug release or gene expression, which can be combined with large area sonication strategies. Moreover, the multi-foci sonication approach can be combined with any control algorithm with an additional constraint on the allowed peak pressure which can be estimated based on quick Rayleigh integral evaluation or more sophisticated acoustic simulations in heterogeneous media.<br />  <br /> This technology is currently available for licensing opportunities.</p> <h2>Competitive Advantages:</h2> <ul><li>Compared to the single focus approach, multi-foci sonications showed significantly lower, 67% reduction, peak acoustic pressures in simulations and hydrophone measurements</li> <li>Heated regions were significantly shorter in the beam path direction, 35% reduction, for multi-foci sonications</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Improved treatments for the target tumor</li> <li>Synergistic application with chemotherapeutic agents and radiation therapies</li> <li>Utilization in drug delivery or gene therapy</li> <li>Can be combined with any control algorithm</li> </ul> 2018-10-12 2025-04-22 2018-10-12 2025-04-22 2018-10-12 Dreher, Magnetic Resonance-Guided High Intensity Focused Ultrasound, Mild Hyperthermia, MR-HIFU, Multi-Foci Sonications, National Institutes of Health Clinical Center, NIH CC, Therapeutic Technique, Thermotherapy False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2018-10-12 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147162060 Partanen A, et al. Reduction of peak acoustic pressure and shaping of heated region by use of multi-foci sonications in MR-guided high-intensity focused ultrasound mediated mild hyperthermia. https://www.ncbi.nlm.nih.gov/pubmed/23298120 <a href="https://www.ncbi.nlm.nih.gov/pubmed/23298120">Partanen A, et al. Reduction of peak acoustic pressure and shaping of heated region by use of multi-foci sonications in MR-guided high-intensity focused ultrasound mediated mild hyperthermia.</a> 147162648 Partanen, Ari Philips Medical Systems Partanen, Ari 1 147162649 Tillander, Matti Philips Electronics North America Corp. Tillander, Matti 2 147162650 Koehler, Max Philips Electronics North America Corp. Koehler, Max 3 147162647 Dreher, Matthew NIH - CC Dreher, Matthew 4 147162646 Wood, Bradford NIH - CC CC Wood, Bradford (CC) 5 147162648 Partanen, Ari Philips Medical Systems Partanen, Ari 1 147162649 Tillander, Matti Philips Electronics North America Corp. Tillander, Matti 2 147162650 Koehler, Max Philips Electronics North America Corp. Koehler, Max 3 147162647 Dreher, Matthew NIH - CC Dreher, Matthew 4 147162646 Wood, Bradford NIH - CC CC Wood, Bradford (CC) 5 147157788 Multi-foci Sonications For Hyperthermia Treatments Using MR-HIFU E-013-2013-0 Filing authorized Clinical Center (CC), Philips Electronics North America Corp., Philips Medical Systems 83703238 Fenn, Edward (Tedd) tedd.fenn@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-3861] Multi-Foci Sonications For Hyperthermia Treatments Using Magnetic Resource-Guided High-Intensity Focused Ultrasound (MR-HIFU)&body=Please send me information about technology [TAB-3861] Multi-Foci Sonications For Hyperthermia Treatments Using Magnetic Resource-Guided High-Intensity Focused Ultrasound (MR-HIFU).&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Fenn, Edward (Tedd)<br><a href="mailto:tedd.fenn@nih.gov?subject=Web Inquiry on [TAB-3861] Multi-Foci Sonications For Hyperthermia Treatments Using Magnetic Resource-Guided High-Intensity Focused Ultrasound (MR-HIFU)&body=Please send me information about technology [TAB-3861] Multi-Foci Sonications For Hyperthermia Treatments Using Magnetic Resource-Guided High-Intensity Focused Ultrasound (MR-HIFU).&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">tedd.fenn@nih.gov</a><br> 147160898 E-013-2013-0 E-013-2013-0-US-01 MULTI-FOCI SONICATIONS FOR HYPERTHERMIA TREATMENTS USING MAGNETIC RESONANCE-GUIDED FOCUSED ULTRASOUND PRV US 61/713,132 Abandoned US <br />Provisional (PRV) 61/713,132<br />Filed on 2012-10-12<br />Status: Abandoned 147164865 E-013-2013-0 E-013-2013-0-PCT-02 MULTI-FOCI SONICATIONS FOR HYPERTHERMIA TREATMENTS USING MAGNETIC RESONANCE-GUIDED FOCUSSED ULTRASOUND. PCT Patent Cooperation Treaty PCT/IB2013/059001 Expired Patent Cooperation Treaty <br />(PCT) PCT/IB2013/059001<br />Filed on 2013-09-30<br />Status: Expired 147164866 E-013-2013-0 E-013-2013-0-BR-03 MULTI-FOCI SONICATIONS FOR HYPERTHERMIA TREATMENTS USING MAGNETIC RESONANCE-GUIDED FOCUSSED ULTRASOUND National Stage Brazil 112015007848-6 Pending Brazil <br />National Stage 112015007848-6<br />Filed on 2015-04-08<br />Status: Pending 147164867 E-013-2013-0 E-013-2013-0-CN-04 MULTI-FOCI SONICATIONS FOR HYPERTHERMIA TREATMENTS USING MAGNETIC RESONANCE-GUIDED FOCUSSED ULTRASOUND National Stage China ZL201380053265.1 201380053265.1 Abandoned China <br />National Stage 201380053265.1<br />Filed on 2015-04-10<br />Status: Abandoned 147164868 E-013-2013-0 E-013-2013-0-EP-05 MULTI-FOCI SONICATIONS FOR HYPERTHERMIA TREATMENTS USING MAGNETIC RESONANCE-GUIDED FOCUSSED ULTRASOUND National Stage European Patent 2906291 13814610.5 Issued European Patent <br />National Stage 13814610.5<br />Filed on 2013-09-30<br />Status: Issued 147164869 E-013-2013-0 E-013-2013-0-IN-06 MULTI FOCI SONICATIONS FOR HYPERTHERMIA TREATMENTS USING MAGNETIC RESONANCE GUIDED FOCUSSED ULTRASOUND National Stage India 2632/CHENP/2015 Abandoned India <br />National Stage 2632/CHENP/2015<br />Filed on 2013-09-30<br />Status: Abandoned 147164870 E-013-2013-0 E-013-2013-0-US-07 MULTI-FOCI SONICATIONS FOR HYPERTHERMIA TREATMENTS USING MAGNETIC RESONANCE-GUIDED FOCUSSED ULTRASOUND National Stage US 14/433,468 Abandoned US <br />National Stage 14/433,468<br />Filed on 2015-04-03<br />Status: Abandoned 147164871 E-013-2013-0 E-013-2013-0-RU-08 MULTI-FOCI SONICATIONS FOR HYPERTHERMIA TREATMENTS USING MAGNETIC RESONANCE-GUIDED FOCUSSED ULTRASOUND National Stage Russia 2015117609 Pending Russia <br />National Stage 2015117609<br />Filed on 2015-05-08<br />Status: Pending 147164872 E-013-2013-0 E-013-2013-0-JP-09 MULTI-FOCI SONICATIONS FOR HYPERTHERMIA TREATMENTS USING MAGNETIC RESONANCE-GUIDED FOCUSSED ULTRASOUND National Stage Japan 6496662 2015-536248 Issued Japan <br />National Stage 2015-536248<br />Filed on 2013-09-30<br />Status: Issued 147169467 Dreher 147169469 Magnetic Resonance-Guided High Intensity Focused Ultrasound 147169471 Mild Hyperthermia 147169472 MR-HIFU 147169474 Multi-Foci Sonications 147169476 National Institutes of Health Clinical Center 147169478 NIH CC 147169480 Therapeutic Technique 147169482 Thermotherapy TAB-4244 147157531 New Insect Sf9-ET Cell Line for Determining Baculovirus Titers NCI Cardiology, Dermatology, Ear, Nose, & Throat, Endocrinology, Gastroenterology, Immunology, Infectious Disease, Licensing, Nephrology, Oncology, Ophthalmology, Reproductive Health, Research Materials Cardiology Dermatology Ear Nose & Throat Endocrinology Gastroenterology Immunology Infectious Disease Licensing Nephrology Oncology Ophthalmology Reproductive Health Research Materials Dominic Esposito, Ralph (Butch) Hopkins <p>The baculovirus-based protein expression system has gained increased prominence as a method for expressing recombinant proteins that are used in a wide range of biomedical applications. An important step in the use of this system is the ability to determine the virus infectious titer, i.e., the number of active baculovirus particles produced during an infection of the insect host cell. The current “gold standard” methods used for determining baculovirus titers, such as the plaque and end point dilution assays, can be costly, take a long time to complete (up to 7-8 days), and are sometimes difficult to interpret as they involve observing the cytopathic effects (CPE) that baculovirus infection has on the infected insect host cell. </p> <p>To solve these problems, researchers at the National Cancer Institute (NCI) have developed a modified insect cell line, Sf9-ET, to genetically express the green fluorescent protein (GFP) when infected with baculovirus. In these cells, the gene for GFP is placed under the control of a baculovirus promoter so that the cells express GFP when they are infected with the virus. The baculovirus titer can then be quantitated from the level of GFP expression in the insect host cell. The results are obtained within 3 days compared to the 7-8 day period typical of the traditional CPE-based methods.</p> <p>The GFP-based system is capable of replacing the traditional methods as it is faster, more accurate, and may be less expensive than the currently used systems. This proprietary technology can become an indispensable tool for the quantitation of baculovirus titers; a step that is important in the production of recombinant proteins and vaccine like particles (VLPs) for academic and commercial purposes.</p> <h2>Competitive Advantages:</h2> <ul><li>Fast, accurate, and inexpensive determination of baculovirus titers for protein expression</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Baculovirus-based recombinant protein expression</li> </ul> 2018-10-15 2025-04-22 2018-10-15 2025-04-22 2018-10-15 Baculovirus, Baculovirus Titer, Esposito, IMMUNE, Inflammation, Insect Cell Line, Protein Expression Sf9-ET False True Prototype True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2018-10-15 52406769 Prototype 52406769 NCI 37470483 Website Abstract 147162177 Hopkins R, et al. A rapid method for titrating baculovirus stocks using the Sf-9 Easy Titer cell line. https://www.ncbi.nlm.nih.gov/pubmed/19852765 <a href="https://www.ncbi.nlm.nih.gov/pubmed/19852765">Hopkins R, et al. A rapid method for titrating baculovirus stocks using the Sf-9 Easy Titer cell line.</a> 147164023 Hopkins, Ralph (Butch) NIH - NCI Leidos Hopkins, Ralph (Butch) (Leidos) 1 147164022 Esposito, Dominic NIH - NCI Leidos Esposito, Dominic (Leidos) 2 147164023 Hopkins, Ralph (Butch) NIH - NCI Leidos Hopkins, Ralph (Butch) (Leidos) 1 147164022 Esposito, Dominic NIH - NCI Leidos Esposito, Dominic (Leidos) 2 147157779 Development Of The Sf-9ET (Easy Titer) Insect For Determining Baculovirus Titers E-009-2008-0 Filing authorized NCI 91814193 Freel, Rose rose.freel@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America rose.freel@nih.gov?subject=Web Inquiry on [TAB-4244] New Insect Sf9-ET Cell Line for Determining Baculovirus Titers&body=Please send me information about technology [TAB-4244] New Insect Sf9-ET Cell Line for Determining Baculovirus Titers.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Freel, Rose<br><a href="mailto:rose.freel@nih.gov?subject=Web Inquiry on [TAB-4244] New Insect Sf9-ET Cell Line for Determining Baculovirus Titers&body=Please send me information about technology [TAB-4244] New Insect Sf9-ET Cell Line for Determining Baculovirus Titers.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">rose.freel@nih.gov</a><br> 147167649 E-009-2008-0 E-009-2008-0-US-01 EUKARYOTIC CELL COMPOSITIONS AND METHODS FOR PRODUCING RECOMBINANT PROTEIN IN A CELL PRV US 61/019,562 Abandoned US <br />Provisional (PRV) 61/019,562<br />Filed on 2008-01-07<br />Status: Abandoned 147169384 Baculovirus 147169386 Baculovirus Titer 147169388 Esposito 147169389 IMMUNE 147169390 Inflammation 147169392 Insect Cell Line 147169394 Protein Expression Sf9-ET TAB-4144 147157427 Potassium Hydroxy Citrate Promotes Longevity and Efficacy of Anti-Tumor T cells for Adoptive Cell Therapy (ACT) NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Robert Eil, Rigel Kishton, Nicholas Restifo, Suman Vodnala <p>Adoptive cell therapy (ACT) using tumor-specific T cells can produce positive clinical responses in some cancer patients. Nevertheless, several obstacles to the successful use of ACT for the treatment of cancer and other conditions remain. For example, one or more of the in vivo persistence, survival, and antitumor activity of tumor-specific T cells can, in some cases, decrease following adoptive transfer. Accordingly, there is a need for methods of obtaining a robust population of tumor-specific T cells for ACT.</p> <p>Researchers at the National Cancer Institute (NCI) have discovered a novel method to generate long-lived memory tumor-specific T cells with enhanced anti-tumor activity for ACT using potassium hydroxy citrate. Tumor-specific murine T cells grown ex vivo in potassium hydroxy citrate demonstrate enhanced tumor clearance and persistence upon transfer to tumor-bearing mice. Mechanistically, potassium hydroxy citrate treatment leads to reduced glycolysis and cytoplasmic acetyl-CoA levels and activates autophagy in tumor-specific T cells. Furthermore, potassium hydroxy citrate-treated T cells express enhanced levels of markers consistent with long-lived memory anti-tumor T cells. </p> <p>The <a href="https://ccr.cancer.gov/Surgery-Branch" rel="nofollow">NCI, Surgery Branch</a>, is seeking statements of capability or interest from parties interested in licensing this invention and/or collaborative research to further develop, evaluate, or commercialize potassium hydroxy citrate to enhance the anti-tumor activity of tumor-specific T cells for ACT. </p> <h2>Competitive Advantages:</h2> <ul><li>Potassium hydroxy citrate-containing media can be readily incorporated into existing T cell therapy manufacturing processes</li> <li>Potassium hydroxy citrate activates autophagy in tumor-specific T cells which is critical for survival and memory formation </li> </ul> <h2>Commercial Applications:</h2> <ul><li>Improved in vivo effector function and longevity of adoptively transferred T cells</li> </ul> 2018-10-15 2025-04-22 2018-10-15 2025-04-22 2018-10-15 act, adoptive cell therapy, Memory T Cells, Potassium Hydroxy Citrate, Restifo, Vodnala False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2018-10-15 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-002-2018 E-084-2016 147163672 Vodnala, Suman NIH - NCI NCI Vodnala, Suman (NCI) 1 147163670 Restifo, Nicholas NIH - NCI NCI Restifo, Nicholas (NCI) 2 147163673 Kishton, Rigel NIH - NCI NCI Kishton, Rigel (NCI) 3 147163671 Eil, Robert NIH - NCI Eil, Robert 4 147163672 Vodnala, Suman NIH - NCI NCI Vodnala, Suman (NCI) 1 147163670 Restifo, Nicholas NIH - NCI NCI Restifo, Nicholas (NCI) 2 147163673 Kishton, Rigel NIH - NCI NCI Kishton, Rigel (NCI) 3 147163671 Eil, Robert NIH - NCI Eil, Robert 4 147157975 Ex Vivo Expansion Of T Cells In The Presence Of Potassium Hydroxy Citrate Promotes Longeveity And Efficacy Anti-tumor T Cells E-094-2018-0 Filing authorized NCI 83709866 Burke, Andrew burkear@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC burkear@nih.gov?subject=Web Inquiry on [TAB-4144] Potassium Hydroxy Citrate Promotes Longevity and Efficacy of Anti-Tumor T cells for Adoptive Cell Therapy (ACT)&body=Please send me information about technology [TAB-4144] Potassium Hydroxy Citrate Promotes Longevity and Efficacy of Anti-Tumor T cells for Adoptive Cell Therapy (ACT).&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Burke, Andrew<br><a href="mailto:burkear@nih.gov?subject=Web Inquiry on [TAB-4144] Potassium Hydroxy Citrate Promotes Longevity and Efficacy of Anti-Tumor T cells for Adoptive Cell Therapy (ACT)&body=Please send me information about technology [TAB-4144] Potassium Hydroxy Citrate Promotes Longevity and Efficacy of Anti-Tumor T cells for Adoptive Cell Therapy (ACT).&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">burkear@nih.gov</a><br> 147161031 E-094-2018-0 E-094-2018-0-US-01 METHODS OF PRODUCING T CELL POPULATIONS USING A HYDROXCITRATE SALT PRV US 62/661,941 Abandoned US <br />Provisional (PRV) 62/661,941<br />Filed on 2018-04-24<br />Status: Abandoned 147166899 E-094-2018-0 E-094-2018-0-PCT-02 METHODS OF PRODUCING T CELL POPULATIONS USING HYDROXYCITRIC ACID AND/OR A SALT THEREOF PCT Patent Cooperation Treaty PCT/US2019/028513 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2019/028513<br />Filed on 2019-04-22<br />Status: Expired 147166900 E-094-2018-0 E-094-2018-0-AU-03 METHODS OF PRODUCING T CELL POPULATIONS USING HYDROXYCITRIC ACID AND/OR A SALT THEREOF National Stage Australia 2019260656 2019260656 Issued Australia <br />National Stage 2019260656<br />Filed on 2020-11-19<br />Status: Issued 147166901 E-094-2018-0 E-094-2018-0-CA-04 METHODS OF PRODUCING T CELL POPULATIONS USING HYDROXYCITRIC ACID AND/OR A SALT THEREOF National Stage Canada 3097858 Pending Canada <br />National Stage 3097858<br />Filed on 2020-10-20<br />Status: Pending 147166902 E-094-2018-0 E-094-2018-0-CN-05 METHODS OF PRODUCING T CELL POPULATIONS USING HYDROXYCITRIC ACID AND/OR A SALT THEREOF National Stage China ZL201980037634.5 201980037634.5 Issued China <br />National Stage 201980037634.5<br />Filed on 2020-12-04<br />Status: Issued 147166903 E-094-2018-0 E-094-2018-0-EP-06 METHODS OF PRODUCING T CELL POPULATIONS USING HYDROXYCITRIC ACID AND/OR A SALT THEREOF National Stage European Patent 3784774 19726230.6 Issued European Patent <br />National Stage 19726230.6<br />Filed on 2020-11-03<br />Status: Issued 147166904 E-094-2018-0 E-094-2018-0-JP-07 METHODS OF PRODUCING T CELL POPULATIONS USING HYDROXYCITRIC ACID AND/OR A SALT THEREOF National Stage Japan 7342030 2020-559481 Issued Japan <br />National Stage 2020-559481<br />Filed on 2020-10-23<br />Status: Issued 147166905 E-094-2018-0 E-094-2018-0-US-08 METHODS OF PRODUCING T CELL POPULATIONS USING HYDROXYCITRIC ACID AND/OR A SALT THEREOF National Stage US 12,415,845 17/050,045 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12415845 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12415845">12,415,845</a><br />Filed on 2020-10-23<br />Status: Issued 147166906 E-094-2018-0 E-094-2018-0-HK-09 METHODS OF PRODUCING T CELL POPULATIONS USING HYDROXYCITRIC ACID AND/OR A SALT THEREOF EP Hong Kong 62021038049.4 Pending Hong Kong <br />European patent (EP) 62021038049.4<br />Filed on 2021-09-02<br />Status: Pending 147171293 act 147171294 adoptive cell therapy 147171296 Memory T Cells 147171298 Potassium Hydroxy Citrate 147171299 Restifo 147171301 Vodnala TAB-3874 147157154 Polarimetric Accessory for Colposcope NICHD Collaboration, Licensing, Medical Devices, Non-Medical Devices, Oncology Collaboration Licensing Medical Devices Non-Medical Devices Oncology Zachary Alissi, Albert Boccara, Victor Chernomordik, Amir Gandjbakhche, Moinuddin Hassan, Paul Smith, Alexander Sviridov <p>In medical diagnostic procedures for examining the cervix and the tissues of the vagina and vulva, long working-distance (-30 cm) lighted binocular microscopes (colposcope) that provide up to 25x optical magnification are used to create an illuminated magnified view. Speculum dilations can give rise to specular reflections from the tissue surface, causing physicians to overlook possible abnormalities – thus decreasing the quality of a colposcopy. </p> <p>Researchers at the National Institute of Child Health and Human Development (NICHD) developed a polarimetric accessory that overcomes this limitation and enhances the visibility of subsurface structures of the scattering object. Linearly polarized light is used for cervical illumination and imaging performed through an additional polarizer that separates the specularly reflected light from the diffusely backscattered light originating in deeper tissue layers. This technology provides enhanced imaging of the hidden subsurface tissue structure (texture). The region of interest is illuminated by linearly polarized light, and backscattered light passes through the polarization filter that is detected by a digital camera. A custom optical design preserves the polarization state of the backscattered light in the microscope, without interfering with the standard optical path and operation of the microscope – including its binocular system. Special algorithms to visualize regions of statistical similarity in the image were developed. </p> <p>Though the diffusely backscattered light presents only a small fraction of the detected light, its analysis – using the customized design and image processing procedures – provides useful information about internal structures of biological tissues. The polarimetric accessory includes a linear polarizer for the illuminating beam, two beam splitters for preserving polarization state, lens system for imaging, polarization analyzer, band-pass optical filter, digital camera, and electronic triggering system.</p> <h2>Competitive Advantages:</h2> <ul><li>Improves colposcope image quality</li> <li>Improves resolution of tissue structures at close microscope distances</li> <li>Ability to penetrate a growing market limited to date by technical inadequacies</li> <li>Ability to penetrate a large patient pool with increasing activities of healthcare organizations</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Cancer diagnosis and detection via examination of the cervix, vagina, and vulva</li> <li>Attachment for colposcopes to resolve tissue-borne specular flare</li> </ul> 2018-10-23 2025-04-22 2018-10-23 2025-04-22 2018-10-23 Colposcopy, Gandjbakhche, Tissue borne specular flare False True Clinical True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2018-10-23 72159138 Clinical Phase I 72159138 NCI 37470483 Website Abstract 147161916 Ramella-Roman JC, et al. Design, testing, and clinical studies of a handheld polarized light camera. https://preview.ncbi.nlm.nih.gov/pubmed/15568952 <a href="https://preview.ncbi.nlm.nih.gov/pubmed/15568952">Ramella-Roman JC, et al. Design, testing, and clinical studies of a handheld polarized light camera.</a> 147161954 Jacques SL, et al. Imaging superficial tissues with polarized light. https://www.ncbi.nlm.nih.gov/pubmed/10685085 <a href="https://www.ncbi.nlm.nih.gov/pubmed/10685085">Jacques SL, et al. Imaging superficial tissues with polarized light.</a> 147162341 Sviridov AP, et al. Analysis of Biological Tissue Textures Using Measurements of Backscattered Polarized Light. https://www.ncbi.nlm.nih.gov/pubmed/17212522 <a href="https://www.ncbi.nlm.nih.gov/pubmed/17212522">Sviridov AP, et al. Analysis of Biological Tissue Textures Using Measurements of Backscattered Polarized Light.</a> 147162379 Jacques SL, et al. Imaging skin pathology with polarized light. https://www.ncbi.nlm.nih.gov/pubmed/12175282 <a href="https://www.ncbi.nlm.nih.gov/pubmed/12175282">Jacques SL, et al. Imaging skin pathology with polarized light.</a> 147162688 Gandjbakhche, Amir NIH - NICHD NICHD Gandjbakhche, Amir (NICHD) 1 147162690 Chernomordik, Victor NIH - NICHD NICHD Chernomordik, Victor (NICHD) 2 147162691 Hassan, Moinuddin NIH - NICHD Hassan, Moinuddin 3 147162692 Sviridov, Alexander NIH - NICHD NICHD Sviridov, Alexander (NICHD) 4 147162693 Alissi, Zachary NIH - NICHD NICHD Alissi, Zachary (NICHD) 5 147162689 Smith, Paul NIH - NIBIB NIBIB Smith, Paul (NIBIB) 6 147162694 Boccara, Albert NICHD Boccara, Albert 7 147162688 Gandjbakhche, Amir NIH - NICHD NICHD Gandjbakhche, Amir (NICHD) 1 147162690 Chernomordik, Victor NIH - NICHD NICHD Chernomordik, Victor (NICHD) 2 147162691 Hassan, Moinuddin NIH - NICHD Hassan, Moinuddin 3 147162692 Sviridov, Alexander NIH - NICHD NICHD Sviridov, Alexander (NICHD) 4 147162693 Alissi, Zachary NIH - NICHD NICHD Alissi, Zachary (NICHD) 5 147162689 Smith, Paul NIH - NIBIB NIBIB Smith, Paul (NIBIB) 6 147162694 Boccara, Albert NICHD Boccara, Albert 7 147157950 Polarmetric Accessory For Colposcope E-084-2012-0 Filing authorized NIBIB, NICHD 91827321 Jinnah, Zarpheen zarpheen.jinnah@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
zarpheen.jinnah@nih.gov?subject=Web Inquiry on [TAB-3874] Polarimetric Accessory for Colposcope&body=Please send me information about technology [TAB-3874] Polarimetric Accessory for Colposcope.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Jinnah, Zarpheen<br><a href="mailto:zarpheen.jinnah@nih.gov?subject=Web Inquiry on [TAB-3874] Polarimetric Accessory for Colposcope&body=Please send me information about technology [TAB-3874] Polarimetric Accessory for Colposcope.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">zarpheen.jinnah@nih.gov</a><br> 147161013 E-084-2012-0 E-084-2012-0-US-01 Polarmetric Accessory For Colposcope PRV US 61/620,295 Abandoned US <br />Provisional (PRV) 61/620,295<br />Filed on 2012-04-04<br />Status: Abandoned 147164956 E-084-2012-0 E-084-2012-0-PCT-02 Polarimetric Accessory For Colposcope PCT Patent Cooperation Treaty PCT/US2013/035223 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2013/035223<br />Filed on 2013-04-04<br />Status: Expired 147164957 E-084-2012-0 E-084-2012-0-EP-03 Polarimetric Accessory For Colposcope National Stage European Patent 2833777 13772208.8 Issued European Patent <br />National Stage 13772208.8<br />Filed on 2013-04-04<br />Status: Issued 147164958 E-084-2012-0 E-084-2012-0-US-04 Polarmetric Accessory For Colposcope National Stage US 9,801,536 14/390,354 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9801536 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9801536">9,801,536</a><br />Filed on 2014-10-02<br />Status: Issued 147164959 E-084-2012-0 E-084-2012-0-FR-06 Polarimetric Accessory For Colposcope EP France 2833777 13772208.8 Issued France <br />European patent (EP) 13772208.8<br />Filed on 2013-04-04<br />Status: Issued 147164960 E-084-2012-0 E-084-2012-0-DE-05 Polarimetric Accessory For Colposcope EP Germany 2833777 13772208.8 Issued Germany <br />European patent (EP) 13772208.8<br />Filed on 2013-04-04<br />Status: Issued 147164961 E-084-2012-0 E-084-2012-0-GB-07 Polarimetric Accessory For Colposcope EP United Kingdom 2833777 13772208.8 Issued United Kingdom <br />European patent (EP) 13772208.8<br />Filed on 2013-04-04<br />Status: Issued 147171076 Colposcopy 147171078 Gandjbakhche 147171080 Tissue borne specular flare TAB-3919 147157199 Self-Assembling Nanoparticles Composed of Transmembrane Peptides and Their Application for Specific Intra-Tumor Delivery of Anti-Cancer Drugs NCI Licensing, Oncology, Therapeutics Licensing Oncology Therapeutics Christopher Michejda, Sergey Tarasov, Nadya Tarasova <p>Peptides corresponding to transmembrane domains of a number of integral proteins were discovered to spontaneously self-assemble in aqueous solutions into stable and remarkably uniform nanoparticles.&nbsp; Researchers at the NCI&rsquo;s Cancer and Inflammation Program have developed fully synthetic, peptide-based, virus-like nanoparticles capable of delivering cytotoxic, radioactive, and imaging agents.&nbsp;</p> <p>Structure and function of tumor-target self-assembling particles:</p> <p><img alt="" height="554" src="https://nih.technologypublisher.com/files/sites/e-256-2006_image3.png" width="800" /></p> <p>The current invention discloses peptide based fusogenic virus-like nanoparticles that can be targeted to tumors.&nbsp; The nanoparticles have a diameter of 8-10 nm and, being much smaller than a liposome, demonstrate better tumor penetration.&nbsp; The body of the nanoparticle is comprised of a G-protein coupled receptor or an ABC transporter antagonist. The technology solves the problem of delivering therapeutic, theranostic and imaging agents &ndash; and is an alternative to liposome-based nanoparticles.&nbsp;&nbsp;</p> <p>Nanoparticles constructed from transmembrane domains of certain receptors and transporters have their own biological activity. They inhibit metastasis, reduce inflammation or reverse drug resistance thus sensitizing tumors to therapy.&nbsp; Particles allow for easy attachments of tumor-selective ligands, therapeutic agents and can encapsulate hydrophobic drugs &ndash; thus addressing the problem of selective tumor delivery.</p> <h2>Competitive Advantages:</h2> <ul> <li>Alternative to liposome-based nanoparticles.&nbsp;</li> <li>Promising biocompatibility profile</li> <li>Potential to target numerous cell types and receptors, whose clinical relevance may vary between individuals.</li> <li>Avoids the costly and impractical approach of developing numerous treatments for every specific cell type and receptor.</li> <li>Superior in stability, uniformity, ease and reproducibility of preparation compared to conventional liposomes.</li> <li>Much more uniform and less toxic than inorganic, polymeric or dendrimeric nanoparticles.</li> <li>The nanoparticles are much smaller than a liposome thus providing better tumor penetration.&nbsp;</li> <li>Synthetic nanoparticles can be easily coated with receptor ligands and loaded or derivatized with cytotoxic drugs for specific tumor targeting.&nbsp; Nanoparticles have biological activity of their own and can inhibit metastasis (CXCR4 receptor antagonists) or drug resistance (inhibitors of ABCG2 transporter and p-glycoprotein) thus sensitizing tumors to therapy.&nbsp;&nbsp;</li> </ul> <h2>Commercial Applications:</h2> <ul> <li>Self-assembling nano-particles as an alternative to liposomes, inorganic, dendrimeric or polymeric nanoparticles.&nbsp;</li> <li>Targeted anti-cancer agent</li> <li>Personalized medicine</li> <li>Drug delivery</li> <li>Theranostic tool</li> <li>Tumor imaging agent</li> </ul> 2018-10-23 2025-04-22 2018-10-23 2025-04-22 2018-10-23 Drug Delivery, GPCR, Hydrophobic Agent, Nanoparticle, Peptide-based Nanoparticle, Synthetic Peptide, Tarasova, VIRUS-LIKE False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2018-10-23 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147161897 Tarasov SG, et al. Structural plasticity of a transmembrane peptide allows self-assembly into biologically active nanoparticles. https://www.ncbi.nlm.nih.gov/pubmed/21628584 <a href="https://www.ncbi.nlm.nih.gov/pubmed/21628584">Tarasov SG, et al. Structural plasticity of a transmembrane peptide allows self-assembly into biologically active nanoparticles.</a> 147162866 Tarasova, Nadya NIH - NCI NCI Tarasova, Nadya (NCI) 1 147162867 Tarasov, Sergey NIH - NCI NCI Tarasov, Sergey (NCI) 2 147162865 Michejda, Christopher NIH - NCI Michejda, Christopher 3 147162866 Tarasova, Nadya NIH - NCI NCI Tarasova, Nadya (NCI) 1 147162867 Tarasov, Sergey NIH - NCI NCI Tarasov, Sergey (NCI) 2 147162865 Michejda, Christopher NIH - NCI Michejda, Christopher 3 147158280 Self-assembling Nanoparticles Composed Of Transmembrane Peptides And Their Application For Specific Intra-tumor Delivery Of Anti-cancer Drugs E-256-2006-0 Filing authorized NCI 83732213 Dick, Taryn taryn.dick@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB taryn.dick@nih.gov?subject=Web Inquiry on [TAB-3919] Self-Assembling Nanoparticles Composed of Transmembrane Peptides and Their Application for Specific Intra-Tumor Delivery of Anti-Cancer Drugs&body=Please send me information about technology [TAB-3919] Self-Assembling Nanoparticles Composed of Transmembrane Peptides and Their Application for Specific Intra-Tumor Delivery of Anti-Cancer Drugs.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Dick, Taryn<br><a href="mailto:taryn.dick@nih.gov?subject=Web Inquiry on [TAB-3919] Self-Assembling Nanoparticles Composed of Transmembrane Peptides and Their Application for Specific Intra-Tumor Delivery of Anti-Cancer Drugs&body=Please send me information about technology [TAB-3919] Self-Assembling Nanoparticles Composed of Transmembrane Peptides and Their Application for Specific Intra-Tumor Delivery of Anti-Cancer Drugs.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">taryn.dick@nih.gov</a><br> 147161234 E-256-2006-0 E-256-2006-0-US-11 Self-assembling Nanoparticles Composed Of Transmembrane Peptides And Their Application For Specific Intra-tumor Delivery Of Anti-cancer Drugs National Stage US 9,326,950 12/513,950 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9326950 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9326950">9,326,950</a><br />Filed on 2009-09-22<br />Status: Issued 147165254 E-256-2006-0 E-256-2006-0-US-01 Self-assembling Nanoparticles Composed Of Transmembrane Peptides And Their Application For Specific Intra-tumor Delivery Of Anti-cancer Drugs PRV US 60/864,665 Abandoned US <br />Provisional (PRV) 60/864,665<br />Filed on 2006-11-07<br />Status: Abandoned 147165255 E-256-2006-0 E-256-2006-0-PCT-02 Self-assembling Nanoparticles Composed Of Transmembrane Peptides And Their Application For Specific Intra-tumor Delivery Of Anti-cancer Drugs PCT Patent Cooperation Treaty PCT/US2007/083772 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2007/083772<br />Filed on 2007-11-06<br />Status: Expired 147165256 E-256-2006-0 E-256-2006-0-AU-03 Self-assembling Nanoparticles Composed Of Transmembrane Peptides And Their Application For Specific Intra-tumor Delivery Of Anti-cancer Drugs National Stage Australia 2007316416 Abandoned Australia <br />National Stage 2007316416<br />Filed on 2007-11-06<br />Status: Abandoned 147165257 E-256-2006-0 E-256-2006-0-CA-04 Self-assembling Nanoparticles Composed Of Transmembrane Peptides And Their Application For Specific Intra-tumor Delivery Of Anti-cancer Drugs National Stage Canada 2668638 Abandoned Canada <br />National Stage 2668638<br />Filed on 2007-11-06<br />Status: Abandoned 147165258 E-256-2006-0 E-256-2006-0-CN-05 Self-assembling Nanoparticles Composed Of Transmembrane Peptides And Their Application For Specific Intra-tumor Delivery Of Anti-cancer Drugs National Stage China 200780045937.9 Abandoned China <br />National Stage 200780045937.9<br />Filed on 2009-06-12<br />Status: Abandoned 147165259 E-256-2006-0 E-256-2006-0-EP-06 Self-assembling Nanoparticles Composed Of Transmembrane Peptides And Their Application For Specific Intra-tumor Delivery Of Anti-cancer Drugs National Stage European Patent 07868671.4 Abandoned European Patent <br />National Stage 07868671.4<br />Filed on 2007-11-06<br />Status: Abandoned 147165260 E-256-2006-0 E-256-2006-0-IN-07 Self-assembling Nanoparticles Composed Of Transmembrane Peptides And Their Application For Specific Intra-tumor Delivery Of Anti-cancer Drugs National Stage India 2947/DELNP/2009 Abandoned India <br />National Stage 2947/DELNP/2009<br />Filed on 2007-11-06<br />Status: Abandoned 147165261 E-256-2006-0 E-256-2006-0-JP-08 Self-assembling Nanoparticles Composed Of Transmembrane Peptides And Their Application For Specific Intra-tumor Delivery Of Anti-cancer Drugs National Stage Japan 2009-535502 Abandoned Japan <br />National Stage 2009-535502<br />Filed on 2009-05-01<br />Status: Abandoned 147165262 E-256-2006-0 E-256-2006-0-NZ-09 Self-assembling Nanoparticles Composed Of Transmembrane Peptides And Their Application For Specific Intra-tumor Delivery Of Anti-cancer Drugs National Stage New Zealand 576769 576769 Abandoned New Zealand <br />National Stage 576769<br />Filed on 2009-05-06<br />Status: Abandoned 147165263 E-256-2006-0 E-256-2006-0-SG-10 Self-assembling Nanoparticles Composed Of Transmembrane Peptides And Their Application For Specific Intra-tumor Delivery Of Anti-cancer Drugs National Stage Singapore 152018 200903196-4 Abandoned Singapore <br />National Stage 200903196-4<br />Filed on 2009-05-06<br />Status: Abandoned 147165264 E-256-2006-0 E-256-2006-0-ZA-12 Self-assembling Nanoparticles Composed Of Transmembrane Peptides And Their Application For Specific Intra-tumor Delivery Of Anti-cancer Drugs National Stage South Africa 2009/03125 2009/03125 Abandoned South Africa <br />National Stage 2009/03125<br />Filed on 2009-05-06<br />Status: Abandoned 147174307 Drug Delivery 147174308 GPCR 147174310 Hydrophobic Agent 147174311 Nanoparticle 147174313 Peptide-based Nanoparticle 147174315 Synthetic Peptide 147174317 Tarasova 147174318 VIRUS-LIKE TAB-3943 147157223 siRNA Delivery Using Hexameric Tetrahedral RNA Nanostructures for Gene Silencing NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Luc Jaeger, Bruce Shapiro, Paul Zakrevsky <p>RNA interference (RNAi) is a biological response to double-stranded RNA that regulates expression of protein-coding genes and is a natural mechanism for gene silencing. Delivery of short, interfering RNA (siRNA) leads to RNAi of the targeted genes. </p> <p>Researchers at the National Cancer Institute (NCI), in collaboration with researchers at the University of California, Santa Barbara (UCSB), developed a tetrahedral-shaped RNA nanoparticle for the delivery of siRNA to activate RNAi. The tetrahedral RNA nanoparticle is comprised of four RNA nanorings as the “faces” of the tetrahedral scaffold. </p> <p>The tetrahedral RNA nanoparticles can contain up to twelve Dicer substrate RNA duplexes, enabling the simultaneous targeting of multiple genes with several siRNA copies. </p> <h2>Competitive Advantages:</h2> <ul><li>Increased functional capacity of RNA nanoparticles</li> <li>Can contain up to 12 targeting siRNAs while maintaining thermodynamic stability</li> <li>Allows for substitution of several siRNAs with other functional moieties while still maintaining large number of targeting siRNAs</li> <li>Shown to have superior cell uptake capabilities and silencing capacity compared to some other RNA-based nanoconstructs</li> <li>Can be assembled by co-transcriptional folding or one-pot processes</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Targeted therapeutic for cancer</li> <li>Research tool to study cancer</li> <li>Targeted therapeutic for RNA-based viruses</li> </ul> 2018-12-14 2025-04-22 2018-12-14 2025-04-22 2018-12-14 Gene silencing, Nanoparticle, RNA, RNA interference, RNAi, Shapiro, SiRNA False True Basic (Target Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2018-12-14 52406768 Discovery 52406768 NCI 37470483 Website Abstract E-765-2013 147162960 Shapiro, Bruce NIH - NCI NCI Shapiro, Bruce (NCI) 1 147162962 Zakrevsky, Paul NIH - NCI NCI Zakrevsky, Paul (NCI) 2 147162961 Jaeger, Luc University of California, Santa Barbara Jaeger, Luc 3 147162960 Shapiro, Bruce NIH - NCI NCI Shapiro, Bruce (NCI) 1 147162962 Zakrevsky, Paul NIH - NCI NCI Zakrevsky, Paul (NCI) 2 147162961 Jaeger, Luc University of California, Santa Barbara Jaeger, Luc 3 147157930 Tetrahedral RNA Scaffold For Biological Application E-075-2018-0 Filing authorized NCI, University of California, Santa Barbara 147162516 Tetrahedral RNA Scaffold For Biological Application E-075-2018-1 Filing authorized NCI, University of California, Santa Barbara 83732917 Favila, Michelle michelle.favila@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC michelle.favila@nih.gov?subject=Web Inquiry on [TAB-3943] siRNA Delivery Using Hexameric Tetrahedral RNA Nanostructures for Gene Silencing&body=Please send me information about technology [TAB-3943] siRNA Delivery Using Hexameric Tetrahedral RNA Nanostructures for Gene Silencing.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Favila, Michelle<br><a href="mailto:michelle.favila@nih.gov?subject=Web Inquiry on [TAB-3943] siRNA Delivery Using Hexameric Tetrahedral RNA Nanostructures for Gene Silencing&body=Please send me information about technology [TAB-3943] siRNA Delivery Using Hexameric Tetrahedral RNA Nanostructures for Gene Silencing.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">michelle.favila@nih.gov</a><br> 147161001 E-075-2018-1 E-075-2018-1-US-01 HEXAMERIC TETRAHEDRAL RNA NANOSTRUCTURES PRV US 62/696,619 Abandoned US <br />Provisional (PRV) 62/696,619<br />Filed on 2018-07-11<br />Status: Abandoned 147165459 E-075-2018-0 E-075-2018-0-US-01 TETRAHEDRAL RNA SCAFFOLD FOR BIOLOGICAL APPLICATIONS PRV US 62/668,653 Abandoned US <br />Provisional (PRV) 62/668,653<br />Filed on 2018-05-08<br />Status: Abandoned 147165460 E-075-2018-0 E-075-2018-0-PCT-01 HEXAMERIC TETRAHEDRAL RNA NANOSTRUCTURES PCT COMB Patent Cooperation Treaty PCT/US2019/031356 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2019/031356<br />Filed on 2019-05-08<br />Status: Expired 147165461 E-075-2018-0 E-075-2018-0-EP-02 HEXAMERIC TETRAHEDRAL RNA NANOSTRUCTURES National Stage European Patent 3790841 19727193.5 Issued European Patent <br />National Stage 19727193.5<br />Filed on 2020-12-04<br />Status: Issued 147165462 E-075-2018-0 E-075-2018-0-JP-03 HEXAMERIC TETRAHEDRAL RNA NANOSTRUCTURES National Stage Japan 7364194 2020-563479 Issued Japan <br />National Stage 2020-563479<br />Filed on 2020-11-06<br />Status: Issued 147165463 E-075-2018-0 E-075-2018-0-US-04 HEXAMERIC TETRAHEDRAL RNA NANOSTRUCTURES National Stage US 11,666,663 17/053,615 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11666663 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11666663">11,666,663</a><br />Filed on 2020-11-06<br />Status: Issued 147165464 E-075-2018-0 E-075-2018-0-DE-05 HEXAMERIC TETRAHEDRAL RNA NANOSTRUCTURES EP Germany 3790841 19727193.5 Issued Germany <br />European patent (EP) 19727193.5<br />Filed on 2020-12-04<br />Status: Issued 147165465 E-075-2018-0 E-075-2018-0-GB-06 HEXAMERIC TETRAHEDRAL RNA NANOSTRUCTURES EP United Kingdom 3790841 19727193.5 Issued United Kingdom <br />European patent (EP) 19727193.5<br />Filed on 2020-12-04<br />Status: Issued 147170826 Gene silencing 147170827 Nanoparticle 147170828 RNA 147170829 RNA interference 147170830 RNAi 147170831 Shapiro 147170832 SiRNA TAB-4381 147157675 Methods of Producing Thymic Emigrants from Induced Pluripotent Stem Cells NCI Infectious Disease, Licensing, Oncology, Therapeutics Infectious Disease Licensing Oncology Therapeutics Nicholas Klemen, Nicholas Restifo, Raul Sakoda <p>Hematopoietic and pluripotent stem cells can be differentiated into T cells with potential clinical utility. Current approaches for in vitro T cell production rely on Notch signaling and artificial mimicry of thymic selection. However, these approaches result in unconventional or phenotypically aberrant T cells; which may lead to unpredictable behavior in clinical use. Thus, there exists a need for improved methods of generating conventional T cells in vitro from stem cells.<br /> &nbsp;<br /> Researchers at the National Cancer Institute (NCI) have developed a novel method for the in vitro differentiation of induced pluripotent stem cells (iPSCs) into induced pluripotent stem cell thymic emigrant (iTE) cells. Cells produced by this method are functionally equivalent to natural na&iuml;ve CD8&alpha;&beta;+ T cells. The approach utilizes improved fetal thymic organ culture methodology to mature progenitor cells into conventional T cells in the presence of extrinsic Notch signaling. Cell culture conditions further provide for positive and negative selection to ensure proper maturation. This method produces conventional T cells that are suitable for clinical applications such adoptive cell therapy.&nbsp;</p> <p>The NCI, Surgery Branch, is seeking statements of capability or interest from parties interested in licensing or collaborative research to further develop, evaluate, or commercialize this method of generating na&iuml;ve T cells from iPSCs.</p> <p><a href="https://ccr.cancer.gov/news/article/stem-cell-technology-rejuvenates-cancer-fighting-cells-used-in-immunotherapy" rel="nofollow"><img alt="A visual allegory of the generation of iPSC-derived thymic emigrants (in red)" height="229" src="https://nih.technologypublisher.com/files/sites/e-250-2016_image_-_restifo_article1.jpg" width="400" /></a></p> <p>Image: A visual allegory of the generation of iPSC-derived thymic emigrants (in red).<br /> Photo credit: Michael J. Kruhlak, Experimental Transplantation and Immunology Branch (ETIB)</p> <p>CCR News: <a href="https://ccr.cancer.gov/news/article/stem-cell-technology-rejuvenates-cancer-fighting-cells-used-in-immunotherapy" rel="nofollow">https://ccr.cancer.gov/news/article/stem-cell-technology-rejuvenates-can...</a></p> <h2>Competitive Advantages:</h2> <ul> <li>Long term development of this technology can be applied to a wide range of services in regenerative medicine and immunology&nbsp;</li> <li>Improved fetal thymic organ culture methodology using a hanging-drop system</li> </ul> <h2>Commercial Applications:</h2> <ul> <li>Applicable for the generation of minimally differentiated T-cells for cancer therapy and broad repertoires of T-cells for patients with lymphopenia</li> </ul> 2018-12-14 2025-04-22 2020-08-13 2025-04-22 2018-12-14 DIFFERENTIATION, Induced Pluripotent Stem Cells, IPSCS, RESEARCH MATERIAL, Restifo, T Cells, Thymic Environment, Tool False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-08-13 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-133-2017 147162208 Vizcardo, R, et al. Generation of tumor antigen-specific iPSC-derived thymic emigrants using a 3D thymic culture system. https://www.ncbi.nlm.nih.gov/pubmed/29562175 <a href="https://www.ncbi.nlm.nih.gov/pubmed/29562175">Vizcardo, R, et al. Generation of tumor antigen-specific iPSC-derived thymic emigrants using a 3D thymic culture system.</a> 147164519 Sakoda, Raul NIH - NCI Sakoda, Raul 1 147164520 Klemen, Nicholas NIH - NCI Klemen, Nicholas 2 147164518 Restifo, Nicholas NIH - NCI NCI Restifo, Nicholas (NCI) 3 147164519 Sakoda, Raul NIH - NCI Sakoda, Raul 1 147164520 Klemen, Nicholas NIH - NCI Klemen, Nicholas 2 147164518 Restifo, Nicholas NIH - NCI NCI Restifo, Nicholas (NCI) 3 147158273 Ex-vivo Thymic Microenvironment As A Method To Produce Naive T Cells From Hematopoietic And Pluripotent Stem Cells E-250-2016-0 Filing authorized NCI 83709866 Burke, Andrew burkear@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC burkear@nih.gov?subject=Web Inquiry on [TAB-4381] Methods of Producing Thymic Emigrants from Induced Pluripotent Stem Cells&body=Please send me information about technology [TAB-4381] Methods of Producing Thymic Emigrants from Induced Pluripotent Stem Cells.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Burke, Andrew<br><a href="mailto:burkear@nih.gov?subject=Web Inquiry on [TAB-4381] Methods of Producing Thymic Emigrants from Induced Pluripotent Stem Cells&body=Please send me information about technology [TAB-4381] Methods of Producing Thymic Emigrants from Induced Pluripotent Stem Cells.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">burkear@nih.gov</a><br> 147161232 E-250-2016-0 E-250-2016-0-US-04 METHODS OF PREPARING AN ISOLATED OR PURIFIED POPULATION OF THYMIC EMIGRANT CELLS AND MEHTODS OF TREATMENT USING SAME National Stage US 12,215,349 16/468,890 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12215349 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12215349">12,215,349</a><br />Filed on 2019-06-12<br />Status: Issued 147168536 E-250-2016-0 E-250-2016-0-US-01 Methods of Preparing an Isolated or Purified Population of Thymic Emigrant Cells and Methods of Treatment Using Same PRV US 62/433,591 Abandoned US <br />Provisional (PRV) 62/433,591<br />Filed on 2016-12-13<br />Status: Abandoned 147168537 E-250-2016-0 E-250-2016-0-PCT-02 METHODS OF PREPARING AN ISOLATED OR PURIFIED POPULATION OF THYMIC EMIGRANT CELLS AND METHODS OF TREATMENT USING SAME PCT Patent Cooperation Treaty PCT/US2017/065986 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2017/065986<br />Filed on 2017-12-13<br />Status: Expired 147168538 E-250-2016-0 E-250-2016-0-EP-03 METHODS OF PREPARING AN ISOLATED OR PURIFIED POPULATION OF THYMIC EMIGRANT CELLS AND METHODS OF TREATMENT USING SAME National Stage European Patent 3555266 17825696.2 Issued European Patent <br />National Stage 17825696.2<br />Filed on 2019-06-11<br />Status: Issued 147174253 DIFFERENTIATION 147174254 Induced Pluripotent Stem Cells 147174255 IPSCS 147174256 RESEARCH MATERIAL 147174257 Restifo 147174258 T Cells 147174260 Thymic Environment 147174261 Tool TAB-4045 147157327 Nanoparticle-hydrogel Composite for Nucleic Acid Molecule Delivery NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Chuong Hoang, Poulami Majumder, Joel Schneider, Anand Singh <p>Mesothelioma is an aggressive cancer covering anatomic surfaces (e.g. lining of the lungs, heart, abdomen, etc.) that resists multi-modality therapies. Regional recurrence of mesothelioma from residual tumor cells prevents long-term benefits after surgical resection. Furthermore, there is no clinical consensus on intracavitary adjuvants that are effective in extending the tumor reduction effect of surgery.</p> <p>Researchers at the National Cancer Institute (NCI) have developed a new technology which fulfills this unmet clinical need by providing a local regional therapeutic platform to shuttle cancer-specific microRNA, thereby circumventing systemic administration challenges. This technology showcases nanoparticles comprised of microRNA bound to disordered peptides that are embedded in a hydrogel engineered from self-assembling β-hairpin peptides. The nanoparticle hydrogel composition is a shear-thinning composite, capable of being syringe-injected or sprayed onto body cavities harboring mesothelioma xenografts. This biodegradable material can be fine-tuned by choice of self-assembling peptides in the gel matrix, of disordered peptides, and of microRNA to produce an optimal anti-cancer effect with a time-released delivery profile. After administration of a single application, this hydrogel composite produced a durable pre-clinical response in multiple xenograft cancer models. In principle, this localized regional treatment strategy could be applied to other surface cancers.</p> <h2>Competitive Advantages:</h2> <ul><li>Biodegradable and biocompatible material that minimizes cytotoxic side effect in vitro and in vivo</li> <li>Can be fine-tuned by choice of self-assembling peptides in the gel matrix, of disordered peptides in the nanoparticles, and of nucleic acids to produce an optimal therapeutic effect with time-released delivery</li> <li>Both syringe-injectable and sprayable to effectively cover complex tissue surface topology </li> <li>Only needing a single administration should reduce clinical trial, manufacturing, and commercialization costs</li> <li>Only needing a single administration should improve patient compliance for future applications</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Platform for delivery of nucleic acid molecules</li> <li>Could be used for treatment of all surface tumors including, but not limited to, all anatomic locations of mesothelioma, metastatic tumors involving pleural surfaces (e.g. lung, breast, colon, renal, esophageal, thymic/ thymoma, etc), and/ or metastatic tumors involving peritoneal surfaces (e.g. ovarian cancer) Specific nucleic acids could be selected and loaded into the hydrogel for use in treating these diverse types of malignancies</li> </ul> 2019-04-25 2025-04-22 2019-05-14 2025-04-22 2019-04-25 Hoang, Hydrogel, Mesothelioma, MicroRNA, Nanoparticle, Schneider, Surface Cancer False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2019-05-14 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147161992 Research Festival Abstract Research Festival Abstract 147163318 Schneider, Joel NIH - NCI NCI Schneider, Joel (NCI) 1 147163319 Majumder, Poulami NIH - NCI NCI Majumder, Poulami (NCI) 2 147163320 Hoang, Chuong NIH - NCI NCI Hoang, Chuong (NCI) 3 147163321 Singh, Anand NIH - NCI NCI Singh, Anand (NCI) 4 147163318 Schneider, Joel NIH - NCI NCI Schneider, Joel (NCI) 1 147163319 Majumder, Poulami NIH - NCI NCI Majumder, Poulami (NCI) 2 147163320 Hoang, Chuong NIH - NCI NCI Hoang, Chuong (NCI) 3 147163321 Singh, Anand NIH - NCI NCI Singh, Anand (NCI) 4 147157943 A Nanoparticle Hydrogel Composite Material As A Vehicle To Deliver Ribonucleic Acids For Cancer Therapy E-080-2018-0 Filing authorized NCI 83724826 Pollard, Ricquita ricquita.pollard@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4045] Nanoparticle-hydrogel Composite for Nucleic Acid Molecule Delivery&body=Please send me information about technology [TAB-4045] Nanoparticle-hydrogel Composite for Nucleic Acid Molecule Delivery.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Pollard, Ricquita<br><a href="mailto:ricquita.pollard@nih.gov?subject=Web Inquiry on [TAB-4045] Nanoparticle-hydrogel Composite for Nucleic Acid Molecule Delivery&body=Please send me information about technology [TAB-4045] Nanoparticle-hydrogel Composite for Nucleic Acid Molecule Delivery.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">ricquita.pollard@nih.gov</a><br> 147161009 E-080-2018-0 E-080-2018-0-US-01 NANOPARTICLE-HYDROGEL COMPOSITE FOR NUCLEIC ACID MOLECULE DELIVERY PRV US 62/628,961 Abandoned US <br />Provisional (PRV) 62/628,961<br />Filed on 2018-02-10<br />Status: Abandoned 147166179 E-080-2018-0 E-080-2018-0-PCT-02 NANOPARTICLE-HYDROGEL COMPOSITE FOR NUCLEIC ACID MOLECULE DELIVERY PCT Patent Cooperation Treaty PCT/US2019/017354 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2019/017354<br />Filed on 2019-02-08<br />Status: Expired 147166180 E-080-2018-0 E-080-2018-0-AU-03 NANOPARTICLE-HYDROGEL COMPOSITE FOR NUCLEIC ACID MOLECULE DELIVERY National Stage Australia 2019216781 2019216781 Issued Australia <br />National Stage 2019216781<br />Filed on 2019-02-08<br />Status: Issued 147166181 E-080-2018-0 E-080-2018-0-CA-04 NANOPARTICLE-HYDROGEL COMPOSITE FOR NUCLEIC ACID MOLECULE DELIVERY National Stage Canada 3089396 Pending Canada <br />National Stage 3089396<br />Filed on 2019-02-08<br />Status: Pending 147166182 E-080-2018-0 E-080-2018-0-CN-05 NANOPARTICLE-HYDROGEL COMPOSITE FOR NUCLEIC ACID MOLECULE DELIVERY National Stage China 201980012620.8 Pending China <br />National Stage 201980012620.8<br />Filed on 2019-02-08<br />Status: Pending 147166183 E-080-2018-0 E-080-2018-0-EP-06 NANOPARTICLE-HYDROGEL COMPOSITE FOR NUCLEIC ACID MOLECULE DELIVERY National Stage European Patent 3749288 19707555.9 Issued European Patent <br />National Stage 19707555.9<br />Filed on 2019-02-08<br />Status: Issued 147166184 E-080-2018-0 E-080-2018-0-IN-07 NANOPARTICLE-HYDROGEL COMPOSITE FOR NUCLEIC ACID MOLECULE DELIVERY National Stage India 550209 202037038092 Issued India <br />National Stage 202037038092<br />Filed on 2019-02-08<br />Status: Issued 147166185 E-080-2018-0 E-080-2018-0-JP-08 NANOPARTICLE-HYDROGEL COMPOSITE FOR NUCLEIC ACID MOLECULE DELIVERY National Stage Japan 7424984 2020-542544 Issued Japan <br />National Stage 2020-542544<br />Filed on 2019-02-08<br />Status: Issued 147166186 E-080-2018-0 E-080-2018-0-US-09 NANOPARTICLE-HYDROGEL COMPOSITE FOR NUCLEIC ACID MOLECULE DELIVERY National Stage US 11,904,057 16/967,302 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11904057 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11904057">11,904,057</a><br />Filed on 2020-08-04<br />Status: Issued 147170966 Hoang 147170967 Hydrogel 147170968 Mesothelioma 147170969 MicroRNA 147170970 Nanoparticle 147170972 Schneider 147170974 Surface Cancer TAB-4299 147157589 Chimeric Antigen Receptor (CAR) that Targets Chemokine Receptor CCR4 and its Use in Treating Cancer NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Liyanage Perera, Thomas Waldmann (Estate) <p>The chemokine receptor, CCR4 is a seven transmembrane G protein-coupled cell surface receptor molecule with selective expression on cells of the hematopoietic system. In adult T cell leukemia (ATL), the cell-surface expression of CCR4 on leukemic cells has been found to be nearly universal. Therefore, a CCR4-directed chimeric antigen receptor (CAR) -cell may provide an effective therapeutic against ATL.</p> <p>Researchers at the National Cancer Institute (NCI), Lymphoid Malignancies Branch, developed a lentivirus-derived CAR against the CCR4 molecule. The CAR can be directed to either genetically modified autologous or to allogeneic T or natural killer (NK) -cells to develop the ATL therapy. This technology includes a method of identifying lymphoid or solid tumors that produce CCR4 mRNA and then utilizing CD3+ T cells and/or NK cells to generate genetically modified T cells and/or NK cells (autologous or allogeneic) that express the CCR4 directed CAR. The identified malignancy can then be treated with the infusion of genetically modified T/NK cells. </p> <p>The NCI seeks licensing and/or co-development of an adoptive cellular therapeutic modality that targets CCR4, which is overexpressed in certain lymphoid malignancies as well as solid tumors.</p> <h2>Competitive Advantages:</h2> <ul><li>CCR4 is a more recent target for cell-based immunotherapy</li> <li>Allogenic NK cells would enable wider use of cell-based therapies</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Identification and treatment of CCR4 mRNA producing lymphoid or solid neoplasms</li> <li>CCR4 putative biomarker in lung adenocarcinoma and other cancers</li> </ul> 2019-04-23 2025-04-22 2019-06-10 2025-04-22 2019-04-23 Adult T Cell Leukemia, ALLOGENIC, ATL, CCR4, CD3+, Chemokine Receptor 4, Immunotherapy, Lymphoid Malignancy, mRNA, natural killer cell, NK, Perera, solid tumor, T cell False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2019-06-10 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147161975 Perera, LP, et al. Chimeric antigen receptor modified T cells that target chemokine receptor CCR4 as a therapeutic modality for T-cell malignancies. https://www.ncbi.nlm.nih.gov/pubmed/28543380 <a href="https://www.ncbi.nlm.nih.gov/pubmed/28543380">Perera, LP, et al. Chimeric antigen receptor modified T cells that target chemokine receptor CCR4 as a therapeutic modality for T-cell malignancies.</a> 147164219 Perera, Liyanage NIH - NCI NCI Perera, Liyanage (NCI) 1 147164218 Waldmann (Estate), Thomas NIH - NCI NCI Waldmann (Estate), Thomas (NCI) 2 147164219 Perera, Liyanage NIH - NCI NCI Perera, Liyanage (NCI) 1 147164218 Waldmann (Estate), Thomas NIH - NCI NCI Waldmann (Estate), Thomas (NCI) 2 147158284 Development Of A Lenti-viral Transduction System To Genetically Engineer Autologous T Cells To Express A Chimeric Antigen Receptor (CAR) That Targets Chemokine Receptor CCR4 E-258-2016-0 Filing authorized NCI 83707317 Bhattacharya, Ramona ramona.bhattacharya@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB ramona.bhattacharya@nih.gov?subject=Web Inquiry on [TAB-4299] Chimeric Antigen Receptor (CAR) that Targets Chemokine Receptor CCR4 and its Use in Treating Cancer&body=Please send me information about technology [TAB-4299] Chimeric Antigen Receptor (CAR) that Targets Chemokine Receptor CCR4 and its Use in Treating Cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Bhattacharya, Ramona<br><a href="mailto:ramona.bhattacharya@nih.gov?subject=Web Inquiry on [TAB-4299] Chimeric Antigen Receptor (CAR) that Targets Chemokine Receptor CCR4 and its Use in Treating Cancer&body=Please send me information about technology [TAB-4299] Chimeric Antigen Receptor (CAR) that Targets Chemokine Receptor CCR4 and its Use in Treating Cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">ramona.bhattacharya@nih.gov</a><br> 147161237 E-258-2016-0 E-258-2016-0-PCT-02 CHIMERIC ANTIGEN RECEPTOR (CAR) THAT TARGETS CHEMOKINE RECEPTOR CCR4 AND ITS USE PCT Patent Cooperation Treaty PCT/US2017/052437 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2017/052437<br />Filed on 2017-09-20<br />Status: Expired 147168025 E-258-2016-0 E-258-2016-0-US-01 CHIMERIC ANTIGEN RECEPTOR (CAR) THAT TARGETS CHEMOKINE RECEPTOR CCR4 AND ITS USE PRV US 62/397,810 Abandoned US <br />Provisional (PRV) 62/397,810<br />Filed on 2016-09-21<br />Status: Abandoned 147168026 E-258-2016-0 E-258-2016-0-AU-03 CHIMERIC ANTIGEN RECEPTOR (CAR) THAT TARGETS CHEMOKINE RECEPTOR CCR4 AND ITS USE National Stage Australia 2017332161 2017332161 Issued Australia <br />National Stage 2017332161<br />Filed on 2017-09-20<br />Status: Issued 147168027 E-258-2016-0 E-258-2016-0-CA-04 CHIMERIC ANTIGEN RECEPTOR (CAR) THAT TARGETS CHEMOKINE RECEPTOR CCR4 AND ITS USE National Stage Canada 3037518 Pending Canada <br />National Stage 3037518<br />Filed on 2017-09-20<br />Status: Pending 147168028 E-258-2016-0 E-258-2016-0-EP-05 CHIMERIC ANTIGEN RECEPTOR (CAR) THAT TARGETS CHEMOKINE RECEPTOR CCR4 AND ITS USE National Stage European Patent 3515475 17778069.9 Abandoned European Patent <br />National Stage 17778069.9<br />Filed on 2017-09-20<br />Status: Abandoned 147168029 E-258-2016-0 E-258-2016-0-JP-06 CHIMERIC ANTIGEN RECEPTOR (CAR) THAT TARGETS CHEMOKINE RECEPTOR CCR4 AND ITS USE National Stage Japan 6908710 2019-537030 Issued Japan <br />National Stage 2019-537030<br />Filed on 2017-09-20<br />Status: Issued 147168030 E-258-2016-0 E-258-2016-0-US-07 CHIMERIC ANTIGEN RECEPTOR (CAR) THAT TARGETS CHEMOKINE RECEPTOR CCR4 AND ITS USE National Stage US 11,077,178 16/334,724 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11077178 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11077178">11,077,178</a><br />Filed on 2019-03-19<br />Status: Issued 147168031 E-258-2016-0 E-258-2016-0-JP-08 CHIMERIC ANTIGEN RECEPTOR (CAR) THAT TARGETS CHEMOKINE RECEPTOR CCR4 AND ITS USE DIV Japan 2021-003261 Abandoned Japan <br />Divisional (DIV) 2021-003261<br />Filed on 2017-09-20<br />Status: Abandoned 147168032 E-258-2016-0 E-258-2016-0-US-09 CHIMERIC ANTIGEN RECEPTOR (CAR) THAT TARGETS CHEMOKINE RECEPTOR CCR4 AND ITS USE CON US 11,992,519 17/353,054 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11992519 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11992519">11,992,519</a><br />Filed on 2021-06-21<br />Status: Issued 147174342 Adult T Cell Leukemia 147174343 ALLOGENIC 147174345 ATL 147174346 CCR4 147174348 CD3+ 147174350 Chemokine Receptor 4 147174351 Immunotherapy 147174353 Lymphoid Malignancy 147174354 mRNA 147174355 natural killer cell 147174356 NK 147174358 Perera 147174359 solid tumor 147174360 T cell TAB-3967 147157247 Cancer Immunotherapies That Harness Pre-Existing Antiviral Immunity NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Nicolas Cuburu, Douglas Lowy, John Schiller <p>The treatment of cancer using immunotherapies has garnered substantial attention and excitement considering the clinical benefits observed in patient populations previously refractory to treatment. Tumor infiltrating T cells can significantly impact cancer progression and immunotherapy response; however, immunosuppressive tumor microenvironments can impede antitumor T cell induction, trafficking, and local activity. Thus, personalized immunotherapy approaches have shown limited efficacy against most solid tumors. In addition, manufacturing complexities remain, with high costs of development and implementation. Novel approaches are needed to effectively induce antitumor T cell responses despite heterogeneity in the tumor microenvironment and antigen landscape. Improved development costs and strategies for these approaches are also desired.</p> <p>Researchers at the NCI developed a method to harness heterogenous antigens for the effective induction of antitumor T cell responses. This method is a tumor antigen-agnostic approach based on virus-derived peptide epitopes to mobilize dynamic antiviral T cell responses. In particular, it harnesses the potent pre-existing cellular immunity against a commonly acquired virus, human cytomegalovirus (HCMV) that causes well controlled chronic infection in immunocompetent people.  This methodology does not require clonal T-cell expansion or other complex manufacturing strategies, instead using either tumor tropic human papillomavirus pseudovirions that contain plasmids expressing HCMV peptides or direct intratumoral injection of HCMV peptides, thus directing the pre-existing anti-HCMV immunity against those peptides to the tumors.</p> <p>In mouse models, intratumoral injection of murine CMV (MCMV)-derived T cell epitopes triggered local and systemic expansion of MCMV-specific CD4+ or CD8+ T cells when challenged with lung, colon or melanoma tumor cells. CMV-derived CD8+ T cell epitopes alone or CD4+ T cell epitopes in the presence of an immune response modifier – such as polyinosinic acid:polycytidylic acid (pI:C), elicited T cell responses – enhanced tumor growth arrest and clearance, and conferred durable remission and protection against tumor rechallenge. Thus, persistent infection with MCMV-derived peptide epitopes has been validated in vivo to promote potent cytotoxic T cell responses in the tumor microenvironment and promote epitope spreading against tumor-associated antigens, as well as provide long-term antitumor immunity.</p> <p>The NCI seeks licensing and/or co-development partners for a cancer immunotherapy based on harnessing the pre-existing immune response to a chronic viral pathogen, such as HCMV, to target solid tumors.</p> <h2>Competitive Advantages:</h2> <ul><li>No requirement to characterize tumor-associated antigens</li> <li>The tumor antigen–agnostic nature of this approach is applicable across a broad range of solid tumors, regardless of origin</li> <li>No requirement for the laborious process of clonal T-cell expansion versus CAR-T cell-based immunotherapies</li> <li>More patients potentially treated in shorter amount of time from diagnosis to treatment</li> <li>“Off the shelf” capabilities provide easier scale-up manufacturing and cost-of-goods</li> </ul><p> </p> <h2>Commercial Applications:</h2> <ul><li>Therapeutic for the treatment of cancer</li> <li>Immunotherapy in solid tumors leverage pre-existing immunity to chronic viral pathogen, such as HCMV</li> <li>Cell therapies for which clonal T-cell expansion is challenging from either a technically or manufacturing standpoint </li> </ul><p> </p> 2019-06-28 2025-04-22 2022-08-17 2025-04-22 2019-06-28 Antiviral Cellular Immunity, Epitope Spreading, HCMV Antigens, human cytomegalovirus, Immunotherapy, Schiller, solid tumor False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2022-08-17 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147162199 Çuburu, N., Bialkowski, L., Pontejo, S. M., Sethi, S. K., Bell, A. T., Kim, R., Thompson, C. D., Lowy, D. R., &amp; Schiller, J. T. (2022). Harnessing anti-cytomegalovirus immunity for local immunotherapy against solid tumors. Proceedings of the National Academy of Sciences, 119(26), e2116738119. Çuburu, N., Bialkowski, L., Pontejo, S. M., Sethi, S. K., Bell, A. T., Kim, R., Thompson, C. D., Lowy, D. R., &amp; Schiller, J. T. (2022). Harnessing anti-cytomegalovirus immunity for local immunotherapy against solid tumors. Proceedings of the National Academy of Sciences, 119(26), e2116738119. 147163050 Schiller, John NIH - NCI NCI Schiller, John (NCI) 1 147163051 Cuburu, Nicolas NIH - NCI NCI Cuburu, Nicolas (NCI) 2 147163049 Lowy, Douglas NIH - NCI NCI Lowy, Douglas (NCI) 3 147163050 Schiller, John NIH - NCI NCI Schiller, John (NCI) 1 147163051 Cuburu, Nicolas NIH - NCI NCI Cuburu, Nicolas (NCI) 2 147163049 Lowy, Douglas NIH - NCI NCI Lowy, Douglas (NCI) 3 147158125 Harnessing Antiviral Immunity To Treat Cancer E-167-2017-0 Filing authorized NCI 83691647 Chang, Kevin changke@mail.nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB changke@mail.nih.gov?subject=Web Inquiry on [TAB-3967] Cancer Immunotherapies That Harness Pre-Existing Antiviral Immunity&body=Please send me information about technology [TAB-3967] Cancer Immunotherapies That Harness Pre-Existing Antiviral Immunity.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Chang, Kevin<br><a href="mailto:changke@mail.nih.gov?subject=Web Inquiry on [TAB-3967] Cancer Immunotherapies That Harness Pre-Existing Antiviral Immunity&body=Please send me information about technology [TAB-3967] Cancer Immunotherapies That Harness Pre-Existing Antiviral Immunity.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">changke@mail.nih.gov</a><br> 147161135 E-167-2017-0 E-167-2017-0-US-01 NOVEL CANCER TREATMENT UTILIZING PREEXISTING MICROBIAL IMMUNITY PRV US 62/582,097 Abandoned US <br />Provisional (PRV) 62/582,097<br />Filed on 2017-11-06<br />Status: Abandoned 147165593 E-167-2017-0 E-167-2017-0-PCT-02 CANCER TREATMENT UTILIZING PRE-EXISTING MICROBIAL IMMUNITY PCT Patent Cooperation Treaty PCT/US2018/059384 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2018/059384<br />Filed on 2018-11-06<br />Status: Expired 147165594 E-167-2017-0 E-167-2017-0-AU-03 CANCER TREATMENT UTILIZING PRE-EXISTING MICROBIAL IMMUNITY National Stage Australia 2018360784 Abandoned Australia <br />National Stage 2018360784<br />Filed on 2020-05-01<br />Status: Abandoned 147165595 E-167-2017-0 E-167-2017-0-CA-04 NOVEL CANCER TREATMENT UTILIZING PRE-EXISTING MICROBIAL IMMUNITY National Stage Canada 3081757 3081757 Issued Canada <br />National Stage 3081757<br />Filed on 2018-11-06<br />Status: Issued 147165596 E-167-2017-0 E-167-2017-0-CN-05 NOVEL CANCER TREATMENT UTILIZING PRE-EXISTING MICROBIAL IMMUNITY National Stage China 201880071646.5 Abandoned China <br />National Stage 201880071646.5<br />Filed on 2018-11-06<br />Status: Abandoned 147165597 E-167-2017-0 E-167-2017-0-EP-06 CANCER TREATMENT UTILIZING PRE-EXISTING MICROBIAL IMMUNITY National Stage European Patent 18819232.2 Pending European Patent <br />National Stage 18819232.2<br />Filed on 2020-05-07<br />Status: Pending 147165598 E-167-2017-0 E-167-2017-0-JP-07 NOVEL CANCER TREATMENT UTILIZING PRE-EXISTING MICROBIAL IMMUNITY National Stage Japan 2020-524774 Abandoned Japan <br />National Stage 2020-524774<br />Filed on 2020-05-07<br />Status: Abandoned 147165599 E-167-2017-0 E-167-2017-0-KR-08 CANCER TREATMENT USING EXISTING MICROBIAL IMMUNITY National Stage South Korea 10-2020-7016052 Abandoned South Korea <br />National Stage 10-2020-7016052<br />Filed on 2020-06-04<br />Status: Abandoned 147165600 E-167-2017-0 E-167-2017-0-US-09 CANCER TREATMENT UTILIZING PRE-EXISTING MICROBIAL IMMUNITY National Stage US 16/760,138 Abandoned US <br />National Stage 16/760,138<br />Filed on 2020-04-29<br />Status: Abandoned 147165601 E-167-2017-0 E-167-2017-0-HK-10 CANCER TREATMENT UTILIZING PRE-EXISTING MICROBIAL IMMUNITY EP Hong Kong 62021027359.0 Pending Hong Kong <br />European patent (EP) 62021027359.0<br />Filed on 2021-03-16<br />Status: Pending 147165602 E-167-2017-0 E-167-2017-0-JP-01 NOVEL CANCER TREATMENT UTILIZING PRE-EXISTING MICROBIAL IMMUNITY DIV Japan 2023-090523 Abandoned Japan <br />Divisional (DIV) 2023-090523<br />Filed on 2023-05-31<br />Status: Abandoned 147165603 E-167-2017-0 E-167-2017-0-US-02 CANCER TREATMENT UTILIZING PRE-EXISTING MICROBIAL IMMUNITY DIV US 18/346,680 Pending US <br />Divisional (DIV) 18/346,680<br />Filed on 2023-07-03<br />Status: Pending 147172803 Antiviral Cellular Immunity 147172805 Epitope Spreading 147172807 HCMV Antigens 147172809 human cytomegalovirus 147172810 Immunotherapy 147172812 Schiller 147172813 solid tumor TAB-3984 147157265 A Method to Isolate Tumor Specific T-Cells or T-Cell Receptors from Peripheral Blood using In-vitro Stimulation of Memory T-Cells NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Gal Cafri, Steven Rosenberg <p>Adoptive cell transfer (ACT) and T-cell receptor (TCR) therapies use lymphocytes that target somatic mutations expressed by tumors cells to treat cancer patients. One of the challenges of these therapies is the identification and isolation of mutation-specific cells and TCRs. While neoantigen specific cells are relatively abundant in the tumor, they are far less common in peripheral blood, a more accessible source of T cells. </p> <p>Researchers at the National Cancer Institute (NCI) have developed a method to isolate neoantigen specific cells or TCRs from selected populations of peripheral T-cells by performing in-vitro stimulation (IVS) on autologous memory T-cells. These cells have been stimulated by their cognate antigens at the tumor site or its draining lymph nodes, and therefore are more relevant for clinical use.  </p> <p>The NCI, Surgery Branch, is seeking licensing and/or co-development research collaborations for the development of a method to isolate tumor specific T-cells or T-cell receptors from peripheral blood. For collaboration opportunities, please contact Steven A. Rosenberg, M.D., Ph.D. at <a href="mailto:sar@nih.gov">sar@nih.gov</a>.</p> <h2>Competitive Advantages:</h2> <ul><li>Capable of identifying T-cells or TCRs against mutated epitopes that can be processed and presented in vivo by antigen-presenting cells</li> <li>Capable of isolating very low-frequency T-cell clones, e.g. neoantigen specific cells in the blood</li> <li>Useful for isolating neoantigen specific TCRs that can be transduced into autologous T-cells for ACT therapy </li> <li>Isolates T-cells or TCRs against known mutated driver genes to build a library of TCRs that can be used to treat multiple cancer patients across different histologies</li> </ul> <h2>Commercial Applications:</h2> <ul><li>T-cell isolation for ACT or TCR therapy</li> <li>Solid or blood-borne cancers</li> </ul> 2019-06-28 2025-04-22 2019-06-28 2025-04-22 2019-06-28 act, Adoptive Cell Transfer therapy, Immunotherapy, In-vitro Stimulation, IVS, Rosenberg, T-cell Isolation, T-Cell Receptor, TCR False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2019-06-28 52406768 Discovery 52406768 NCI 37470483 Website Abstract E-085-2013 E-149-2015 147162398 Cafri G, et al. Memory T cells targeting oncogenic mutations detected in peripheral blood of epithelial cancer patients. https://www.ncbi.nlm.nih.gov/pubmed/30683863 <a href="https://www.ncbi.nlm.nih.gov/pubmed/30683863">Cafri G, et al. Memory T cells targeting oncogenic mutations detected in peripheral blood of epithelial cancer patients.</a> 147163123 Cafri, Gal NIH - NCI NCI Cafri, Gal (NCI) 1 147163122 Rosenberg, Steven NIH - NCI NCI Rosenberg, Steven (NCI) 2 147163123 Cafri, Gal NIH - NCI NCI Cafri, Gal (NCI) 1 147163122 Rosenberg, Steven NIH - NCI NCI Rosenberg, Steven (NCI) 2 147158255 A Method To Isolate Tumor Specific T Cells Or T Cell Receptors From Peripheral Blood Using In-vitro Stimulation Of Memory T Cells E-238-2017-0 Filing authorized NCI 83709866 Burke, Andrew burkear@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC burkear@nih.gov?subject=Web Inquiry on [TAB-3984] A Method to Isolate Tumor Specific T-Cells or T-Cell Receptors from Peripheral Blood using In-vitro Stimulation of Memory T-Cells&body=Please send me information about technology [TAB-3984] A Method to Isolate Tumor Specific T-Cells or T-Cell Receptors from Peripheral Blood using In-vitro Stimulation of Memory T-Cells.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Burke, Andrew<br><a href="mailto:burkear@nih.gov?subject=Web Inquiry on [TAB-3984] A Method to Isolate Tumor Specific T-Cells or T-Cell Receptors from Peripheral Blood using In-vitro Stimulation of Memory T-Cells&body=Please send me information about technology [TAB-3984] A Method to Isolate Tumor Specific T-Cells or T-Cell Receptors from Peripheral Blood using In-vitro Stimulation of Memory T-Cells.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">burkear@nih.gov</a><br> 147161220 E-238-2017-0 E-238-2017-0-PCT-02 METHODS OF ENRICHING CELL POPULATIONS FOR CANCER-SPECIFIC T CELLS USING IN VITRO STIMULATION OF MEMORY T CELLS PCT Patent Cooperation Treaty PCT/US2018/063563 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2018/063563<br />Filed on 2018-12-03<br />Status: Expired 147165725 E-238-2017-0 E-238-2017-0-US-01 METHODS OF ENRICHING CELL POPULATIONS FOR CANCER-SPECIFIC T CELLS USING IN VITRO STIMULATION OF MEMORY T CELLS PRV US 62/594,262 Abandoned US <br />Provisional (PRV) 62/594,262<br />Filed on 2017-12-04<br />Status: Abandoned 147165726 E-238-2017-0 E-238-2017-0-US-03 METHODS OF ENRICHING CELL POPULATIONS FOR CANCER-SPECIFIC T CELLS USING IN VITRO STIMULATION OF MEMORY T CELLS National Stage US 12,221,627 16/768,930 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12221627 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12221627">12,221,627</a><br />Filed on 2020-06-02<br />Status: Issued 147174089 act 147174091 Adoptive Cell Transfer therapy 147174092 Immunotherapy 147174094 In-vitro Stimulation 147174096 IVS 147174097 Rosenberg 147174099 T-cell Isolation 147174100 T-Cell Receptor 147174101 TCR TAB-3892 147157172 Improved CD22 Binders for Effective Immunotherapy Against Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) NCI Licensing, Oncology, Therapeutics Licensing Oncology Therapeutics Dimiter Dimitrov, Terry Fry, Sneha Ramakrishna, Zhongyu Zhu <p>Targeting the CD22 receptor of B-cells with chimeric antigen receptor (CAR)-T cells has been a promising new therapy to treat B-cell malignancies in clinical trials, inducing remission in 70% of patients with relapsed acute lymphoblastic leukemia (ALL). However, diminished CD22 expression on B-cell surface can lead to relapse and decreased remission duration, which may be prevented through increasing CAR-T affinity towards CD22. <br /> Researchers at the National Cancer Institute (NCI) developed an affinity-matured monoclonal antibody panel including an anti-CD22 antibody variant, L7, displaying a higher affinity against CD22 than the non-affinity matured versions. The inventors at the NCI developed CAR-T cells incorporating the L7 variable fragment and observed prolonged remission using the L7-CAR-T treatment in combination with Bryostatin1-induced CD22 expression in vivo. The L7 antibody can also be used in other antibody-based therapeutics (such as antibody drug conjugates) against B-cell malignancies.</p> <h2>Competitive Advantages:</h2> <ul><li>An established, de-risked target as other anti-CD22 targeted therapies have reached and been evaluated in clinical trials</li> <li>Prolonged remission in ALL mouse models</li> <li>High affinity antibodies against CD22 can be used to develop targeted therapies</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Adoptive immunotherapy for relapsed / refractory ALL</li> <li>Antibody drug conjugates against relapsed / refractory ALL</li> <li>Treatment of other B-cell malignancies</li> </ul> 2019-07-25 2025-04-22 2022-09-19 2025-04-22 2019-07-25 Acute Lymphoblastic Leukemia, ALL, B Cell, CAR, CAR-T, CD22, chimeric antigen receptor, Dimitrov, T cell False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov False 2022-09-19 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-106-2015 147161926 Ramakrishna S, et al. Modulation of Target Antigen Density Improves CAR T-cell Functionality and Persistence. https://www.ncbi.nlm.nih.gov/pubmed/31110075 <a href="https://www.ncbi.nlm.nih.gov/pubmed/31110075">Ramakrishna S, et al. Modulation of Target Antigen Density Improves CAR T-cell Functionality and Persistence.</a> 147162120 Fry TJ, et al. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. https://www.ncbi.nlm.nih.gov/pubmed/29155426 <a href="https://www.ncbi.nlm.nih.gov/pubmed/29155426">Fry TJ, et al. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy.</a> 147162467 Haso W, et al. Anti-CD22&ndash;chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. https://www.ncbi.nlm.nih.gov/pubmed/23243285 <a href="https://www.ncbi.nlm.nih.gov/pubmed/23243285">Haso W, et al. Anti-CD22&ndash;chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia.</a> 147162766 Dimitrov, Dimiter NIH - NCI NCI Dimitrov, Dimiter (NCI) 1 147162768 Zhu, Zhongyu NIH - NCI NCI Zhu, Zhongyu (NCI) 2 147162767 Fry, Terry NIH - NCI NCI Fry, Terry (NCI) 3 147162769 Ramakrishna, Sneha NIH - NCI NCI Ramakrishna, Sneha (NCI) 4 147162766 Dimitrov, Dimiter NIH - NCI NCI Dimitrov, Dimiter (NCI) 1 147162768 Zhu, Zhongyu NIH - NCI NCI Zhu, Zhongyu (NCI) 2 147162767 Fry, Terry NIH - NCI NCI Fry, Terry (NCI) 3 147162769 Ramakrishna, Sneha NIH - NCI NCI Ramakrishna, Sneha (NCI) 4 147158110 Affinity Matured M971 For CD22 Positive Cancer Therapeutics Development E-161-2018-0 Filing authorized NCI 91814193 Freel, Rose rose.freel@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America rose.freel@nih.gov?subject=Web Inquiry on [TAB-3892] Improved CD22 Binders for Effective Immunotherapy Against Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)&body=Please send me information about technology [TAB-3892] Improved CD22 Binders for Effective Immunotherapy Against Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL).&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Freel, Rose<br><a href="mailto:rose.freel@nih.gov?subject=Web Inquiry on [TAB-3892] Improved CD22 Binders for Effective Immunotherapy Against Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)&body=Please send me information about technology [TAB-3892] Improved CD22 Binders for Effective Immunotherapy Against Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL).&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">rose.freel@nih.gov</a><br> 147161124 E-161-2018-0 E-161-2018-0-US-01 AFFINITY MATURED CD22-SPECIFIC MONOCLONAL ANTIBODY AND USES THEREOF PRV US 62/697,185 Abandoned US <br />Provisional (PRV) 62/697,185<br />Filed on 2018-07-12<br />Status: Abandoned 147165086 E-161-2018-0 E-161-2018-0-PCT-02 Affinity Matured M971 For CD22 Positive Cancer Therapeutics Development PCT Patent Cooperation Treaty PCT/US2019/041401 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2019/041401<br />Filed on 2019-07-11<br />Status: Expired 147165087 E-161-2018-0 E-161-2018-0-AU-03 AFFINITY MATURED CD22-SPECIFIC MONOCLONAL ANTIBODY AND USES THEREOF National Stage Australia 2019301675 2019301675 Issued Australia <br />National Stage 2019301675<br />Filed on 2019-07-11<br />Status: Issued 147165088 E-161-2018-0 E-161-2018-0-CA-04 Affinity Matured M971 For CD22 Positive Cancer Therapeutics Development National Stage Canada 3105694 Pending Canada <br />National Stage 3105694<br />Filed on 2019-07-11<br />Status: Pending 147165089 E-161-2018-0 E-161-2018-0-EP-05 AFFINITY MATURED CD22-SPECIFIC MONOCLONAL ANTIBODY AND USES THEREOF National Stage European Patent 19746264.1 Pending European Patent <br />National Stage 19746264.1<br />Filed on 2019-07-11<br />Status: Pending 147165090 E-161-2018-0 E-161-2018-0-JP-06 AFFINITY MATURED CD22-SPECIFIC MONOCLONAL ANTIBODY AND USES THEREOF National Stage Japan 7459043 2021-500651 Issued Japan <br />National Stage 2021-500651<br />Filed on 2019-07-11<br />Status: Issued 147165091 E-161-2018-0 E-161-2018-0-US-07 AFFINITY MATURED CD22-SPECIFIC MONOCLONAL ANTIBODY AND USES THEREOF National Stage US 11,939,377 17/259,334 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11939377 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11939377">11,939,377</a><br />Filed on 2021-01-11<br />Status: Issued 147172657 Acute Lymphoblastic Leukemia 147172658 ALL 147172659 B Cell 147172660 CAR 147172661 CAR-T 147172662 CD22 147172663 chimeric antigen receptor 147172664 Dimitrov 147172665 T cell TAB-4251 147157538 Autophagy Modulators For Use in Treating Cancer NICHD Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Melvin DePamphilis, Marc Ferrer-Alegre, Juan Marugan, Ajit Roy, Gaurav Sharma <p>Cancer cells can upregulate autophagy – cell destruction – as a response to chemotherapy. Investigators in Dr. Melvin DePamphilis’ laboratory at the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) have shown that compounds identified by screening a library of compounds blocks autophagy in some cancer cells (e.g., melanoma) but are not toxic to normal cells. Cancer cells with mutations in the BRAF oncogene are especially dependent on autophagy. Treatment of cancer cells with the BRAF mutation can increase the efficacy of chemotherapy. Proof of concept studies in xenograft mice showed reduction of melanoma tumor size upon treatment with WX8, a lead compound described in the patent application cited below. The technology is available for licensing and/or co-development under a collaborative research agreement.  </p> <h2>Competitive Advantages:</h2> <ul><li>The compounds inhibiting autophagy are selective for cancer cells and are not toxic to normal cells </li> </ul> <h2>Commercial Applications:</h2> <ul><li>Cancer therapeutic</li> <li>Administration of the compounds that inhibit autophagy can be used to sensitize cancer cells to chemotherapeutic agents</li> </ul> 2019-08-01 2025-04-22 2020-08-06 2025-04-22 2019-08-01 BRAF Mutation, Depamphilis, Eunice Kennedy Shriver National Institute of Child Health an, Inhibition of Autophagy, NICHD, WX8 False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-08-06 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-138-2019 147161981 Sharma et al. A family of PIKFYVE inhibitors with therapeutic potential against autophagy-dependent cancer cells disrupt multiple events in lysosome homeostasis. https://www.ncbi.nlm.nih.gov/pubmed/30806145 <a href="https://www.ncbi.nlm.nih.gov/pubmed/30806145">Sharma et al. A family of PIKFYVE inhibitors with therapeutic potential against autophagy-dependent cancer cells disrupt multiple events in lysosome homeostasis.</a> 147164049 DePamphilis, Melvin NIH - NICHD NICHD DePamphilis, Melvin (NICHD) 1 147164052 Sharma, Gaurav NIH - NICHD NICHD Sharma, Gaurav (NICHD) 2 147164051 Ferrer-Alegre, Marc NIH - NCATS NCATS Ferrer-Alegre, Marc (NCATS) 3 147164050 Marugan, Juan NIH - NCATS NCATS Marugan, Juan (NCATS) 4 147164053 Roy, Ajit NIH - NICHD NICHD Roy, Ajit (NICHD) 5 147164049 DePamphilis, Melvin NIH - NICHD NICHD DePamphilis, Melvin (NICHD) 1 147164052 Sharma, Gaurav NIH - NICHD NICHD Sharma, Gaurav (NICHD) 2 147164051 Ferrer-Alegre, Marc NIH - NCATS NCATS Ferrer-Alegre, Marc (NCATS) 3 147164050 Marugan, Juan NIH - NCATS NCATS Marugan, Juan (NCATS) 4 147164053 Roy, Ajit NIH - NICHD NICHD Roy, Ajit (NICHD) 5 147157767 Novel Family Of Autophagy Modulators With Therapeutic Potential To Selectively Kill Cancer Cells E-003-2018-0 Filing authorized NCATS - NCGC, NICHD 147162485 Novel Family Of Autophagy Modulators With Therapeutic Potential To Selectively Kill Cancer Cells E-003-2018-1 Filing authorized NCATS - NCGC, NICHD 83682895 Girards, Richard richard.girards@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB richard.girards@nih.gov?subject=Web Inquiry on [TAB-4251] Autophagy Modulators For Use in Treating Cancer&body=Please send me information about technology [TAB-4251] Autophagy Modulators For Use in Treating Cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Girards, Richard<br><a href="mailto:richard.girards@nih.gov?subject=Web Inquiry on [TAB-4251] Autophagy Modulators For Use in Treating Cancer&body=Please send me information about technology [TAB-4251] Autophagy Modulators For Use in Treating Cancer.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">richard.girards@nih.gov</a><br> 147167681 E-003-2018-0 E-003-2018-0-US-01 AUTOPHAGY MODULATORS FOR USE IN TREATING CANCER PRV US 62/593,579 Abandoned US <br />Provisional (PRV) 62/593,579<br />Filed on 2017-12-01<br />Status: Abandoned 147167682 E-003-2018-1 E-003-2018-1-PCT-01 AUTOPHAGY MODULATORS FOR USE IN TREATING CANCER PCT COMB Patent Cooperation Treaty PCT/US2018/062866 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2018/062866<br />Filed on 2018-11-28<br />Status: Expired 147167684 E-003-2018-1 E-003-2018-1-US-02 AUTOPHAGY MODULATORS FOR USE IN TREATING CANCER CIP US 11,471,460 16/883,046 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11471460 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11471460">11,471,460</a><br />Filed on 2020-05-26<br />Status: Issued 147169245 BRAF Mutation 147169247 Depamphilis 147169249 Eunice Kennedy Shriver National Institute of Child Health an 147169251 Inhibition of Autophagy 147169252 NICHD 147169254 WX8 TAB-4081 147157363 Diagnostic Assay for Determining Patient Response to Apoptosis-related Cancer Therapy NCI Diagnostics, Immunology, Infectious Disease, Licensing, Oncology Diagnostics Immunology Infectious Disease Licensing Oncology James Doroshow, Dominic Esposito, Jeevan Govindharajulu, Ralph Parchment, Apurva Srivastava <p>Many known chemotherapeutic drugs kill abnormal cells through a process called apoptosis. Bcl-2 proteins are negative regulators of apoptosis that control cell survival and death. Increased expression of anti-apoptotic Bcl-2 proteins commonly occurs in up to 30% of all cancers, providing cancer cells a pro-survival advantage to evade cell death, grow, and proliferate. Drugs targeting these specific anti-apoptotic proteins are potential anti-cancer therapeutics. A need exists for improved methods to select patients that may benefit from drugs targeting apoptotic pathway, such as Bcl-2 homology domain-3 (BH3) mimetics. </p> <p>Researchers at the NCI developed a multiplex assay to determine the efficacy of apoptosis-related drugs targeting the Bcl2 family of proteins or aid in the selection of cancer patients likely to respond. The immunoassay quantitatively measures heterodimer protein complexes of specific Bcl-2 family proteins. Traditional assays performed in needle biopsies only measure individual Bcl-2 family proteins and do not capture the protein-protein interactions.   </p> <p>The assay was confirmed using tumor tissue biopsy samples and has the potential to predict drug efficacy. The assay may be useful as a companion diagnostic in conjunction with apoptosis-inducing agents.  The assay also has the potential to aid in the selection of cancer patients likely to respond to drugs targeting the apoptosis pathway.  </p> <h2>Competitive Advantages:</h2> <ul><li>Novel assay to simultaneously measure multiple indicators of apoptosis in a single sample compared to traditional assays</li> <li>Quantitative measurement of pro-apoptotic drug efficacy</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Companion diagnostic to determine efficacy of anti-apoptotic therapies such as BH3 mimetics </li> <li>Diagnostic for the selection of appropriate drug therapy for cancer patients </li> </ul> 2019-08-01 2025-04-22 2020-04-01 2025-04-22 2019-08-01 APOPTOSIS, BCL-2, IMMUNOASSAY, Pharmacodynamic Biomarkers, Pro-Apoptotic, prognostic, Srivastava False True Clinical True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2020-04-01 72159138 Clinical Phase I 72159138 NCI 37470483 Website Abstract 147162047 Srivastava AK, et al. Effect of a Smac Mimetic (TL32711, Birinapant) on the Apoptotic Program and Apoptosis Biomarkers Examined with Validated Multiplex Immunoassays Fit for Clinical Use. https://www.ncbi.nlm.nih.gov/pubmed/26446940 <a href="https://www.ncbi.nlm.nih.gov/pubmed/26446940">Srivastava AK, et al. Effect of a Smac Mimetic (TL32711, Birinapant) on the Apoptotic Program and Apoptosis Biomarkers Examined with Validated Multiplex Immunoassays Fit for Clinical Use.</a> 147163450 Srivastava, Apurva NIH - NCI Leidos Srivastava, Apurva (Leidos) 1 147163447 Esposito, Dominic NIH - NCI Leidos Esposito, Dominic (Leidos) 2 147163451 Govindharajulu, Jeevan NIH - NCI Leidos Govindharajulu, Jeevan (Leidos) 3 147163448 Parchment, Ralph NIH - NCI Leidos Parchment, Ralph (Leidos) 4 147163449 Doroshow, James NIH - NCI NCI Doroshow, James (NCI) 5 147163450 Srivastava, Apurva NIH - NCI Leidos Srivastava, Apurva (Leidos) 1 147163447 Esposito, Dominic NIH - NCI Leidos Esposito, Dominic (Leidos) 2 147163451 Govindharajulu, Jeevan NIH - NCI Leidos Govindharajulu, Jeevan (Leidos) 3 147163448 Parchment, Ralph NIH - NCI Leidos Parchment, Ralph (Leidos) 4 147163449 Doroshow, James NIH - NCI NCI Doroshow, James (NCI) 5 147158190 Measurement Of Heterodimer Complex Of BIM---Bcl-2, BIM---Bcl-xL, BIM---Mcl-1 And BAX---BAK As Diagnostic Test Of Patient Sensitivity To BH3 Mimetics E-195-2018-0 Filing authorized NCI 83704821 Nguyen-Antczak, Lauren lauren.nguyen-antczak@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-4081] Diagnostic Assay for Determining Patient Response to Apoptosis-related Cancer Therapy&body=Please send me information about technology [TAB-4081] Diagnostic Assay for Determining Patient Response to Apoptosis-related Cancer Therapy.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Nguyen-Antczak, Lauren<br><a href="mailto:lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-4081] Diagnostic Assay for Determining Patient Response to Apoptosis-related Cancer Therapy&body=Please send me information about technology [TAB-4081] Diagnostic Assay for Determining Patient Response to Apoptosis-related Cancer Therapy.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">lauren.nguyen-antczak@nih.gov</a><br> 147161179 E-195-2018-0 E-195-2018-0-US-01 Measurement Of Heterodimer Complex Of BIM---Bcl-2, BIM---Bcl-xL, BIM---Mcl-1 And BAX---BAK As Diagnostic Test Of Patient Sensitivity To BH3 Mimetics PRV US 62/798,615 Abandoned US <br />Provisional (PRV) 62/798,615<br />Filed on 2019-01-30<br />Status: Abandoned 147166385 E-195-2018-0 E-195-2018-0-PCT-02 DETECTION OF BCL-2 FAMILY HETERODIMER COMPLEXES AND USE THEREOF PCT Patent Cooperation Treaty PCT/US2020/015694 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2020/015694<br />Filed on 2020-01-29<br />Status: Expired 147166386 E-195-2018-0 E-195-2018-0-US-03 DETECTION OF BCL-2 FAMILY HETERODIMER COMPLEXES AND USE THEREOF National Stage US 12,631,645 17/422,972 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12631645 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12631645">12,631,645</a><br />Filed on 2021-07-14<br />Status: Issued 147173461 APOPTOSIS 147173462 BCL-2 147173463 IMMUNOASSAY 147173465 Pharmacodynamic Biomarkers 147173466 Pro-Apoptotic 147173467 prognostic 147173469 Srivastava TAB-4222 147157507 Novel HPPK (Bacterial Protein) Inhibitors for Use as Antibacterial Agents NCI Collaboration, Infectious Disease, Licensing, Therapeutics Collaboration Infectious Disease Licensing Therapeutics Xinhua Ji, Gary Shaw, Genbin Shi <p>Research and development leading to the discovery of novel antibiotics has waned in recent years. At the same time, the emergence and spread of antimicrobial resistance has compounded the global danger to human health from bacterial infections. </p> <p>The bacterial protein 6-hydroxymethyl-7,8-dihydropterin pyrophosphokinase (HPPK) is a key enzyme in the folate biosynthetic pathway. This pathway is essential for bacteria and microorganisms but is absent in mammals – making it an attractive target for antibiotics. HPPK is a novel target for antibiotics as none of the antimicrobial agents currently on the market or in later stage development are HPPK inhibitors.</p> <p>Researchers at the NCI have developed several novel small-molecule inhibitors directed against HPPK for potential use as antimicrobial agents. The compounds described in this invention present strong binding affinity for HPPK with Kd values as low as 50 nM. </p> <p>The NCI seeks co-development partners or licensees to further develop these novel small-molecule HPPK inhibitors as broad-spectrum bactericidal agents.</p> <h2>Competitive Advantages:</h2> <ul><li>HPPK represents a novel target for these first-in-class high-affinity antibacterial compounds</li> <li>Lack of the folate biosynthetic pathway in humans suggest anti-infectives targeting this pathway might be well-tolerated</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Potential use as a broad-spectrum or narrow-spectrum antibiotic </li> <li>Potential use in antibacterial consumer products</li> <li>Potential use as a biodefense therapeutic</li> <li>Potential use for parasitic diseases, such as malaria</li> <li>Increases in the worldwide prevalence of persistent and infectious diseases and the promise of new antibiotics to address a broad spectrum of organisms are driving growth of the global market</li> <li>Growing populations and increasing healthcare expenditures are key factors driving growth of the global market</li> </ul> 2019-08-01 2025-04-22 2019-08-01 2025-04-22 2019-08-01 ANTIBIOTIC, Bacterial Protein, BACTERICIDAL, Biodefense, Broad Spectrum, Folate Biosynthesis, HPPK, Ji, small molecule False True Discovery (Lead Identification) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2019-08-01 52406768 Discovery 52406768 NCI 37470483 Website Abstract 147163953 Ji, Xinhua NIH - NCI NCI Ji, Xinhua (NCI) 1 147163954 Shi, Genbin NIH - NCI NCI Shi, Genbin (NCI) 2 147163955 Shaw, Gary NIH - NCI NCI Shaw, Gary (NCI) 3 147163953 Ji, Xinhua NIH - NCI NCI Ji, Xinhua (NCI) 1 147163954 Shi, Genbin NIH - NCI NCI Shi, Genbin (NCI) 2 147163955 Shaw, Gary NIH - NCI NCI Shaw, Gary (NCI) 3 147158310 Three Novel Groups Of Linked Purine Pterin HPPK Inhibitors Useful As Antibacterial Agents E-276-2016-0 Filing authorized NCI 83704821 Nguyen-Antczak, Lauren lauren.nguyen-antczak@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-4222] Novel HPPK (Bacterial Protein) Inhibitors for Use as Antibacterial Agents&body=Please send me information about technology [TAB-4222] Novel HPPK (Bacterial Protein) Inhibitors for Use as Antibacterial Agents.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Nguyen-Antczak, Lauren<br><a href="mailto:lauren.nguyen-antczak@nih.gov?subject=Web Inquiry on [TAB-4222] Novel HPPK (Bacterial Protein) Inhibitors for Use as Antibacterial Agents&body=Please send me information about technology [TAB-4222] Novel HPPK (Bacterial Protein) Inhibitors for Use as Antibacterial Agents.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">lauren.nguyen-antczak@nih.gov</a><br> 147161254 E-276-2016-0 E-276-2016-0-US-01 HPPK Inhibitors Useful As Antibacterial Agents PRV US 62/406,610 Abandoned US <br />Provisional (PRV) 62/406,610<br />Filed on 2016-10-11<br />Status: Abandoned 147167480 E-276-2016-0 E-276-2016-0-PCT-02 HPPK INHIBITORS USEFUL AS ANTIBACTERIAL AGENTS PCT Patent Cooperation Treaty PCT/US2017/056124 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2017/056124<br />Filed on 2017-10-11<br />Status: Expired 147167481 E-276-2016-0 E-276-2016-0-AU-03 HPPK INHIBITORS USEFUL AS ANTIBACTERIAL AGENTS National Stage Australia 2017343643 2017343643 Issued Australia <br />National Stage 2017343643<br />Filed on 2017-10-11<br />Status: Issued 147167482 E-276-2016-0 E-276-2016-0-CA-04 HPPK INHIBITORS USEFUL AS ANTIBACTERIAL AGENTS National Stage Canada 3039997 Pending Canada <br />National Stage 3039997<br />Filed on 2017-10-11<br />Status: Pending 147167483 E-276-2016-0 E-276-2016-0-US-05 HPPK INHIBITORS USEFUL AS ANTIBACTERIAL AGENTS National Stage US 11,091,509 16/340,493 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11091509 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11091509">11,091,509</a><br />Filed on 2019-04-09<br />Status: Issued 147174559 ANTIBIOTIC 147174561 Bacterial Protein 147174562 BACTERICIDAL 147174563 Biodefense 147174565 Broad Spectrum 147174567 Folate Biosynthesis 147174568 HPPK 147174570 Ji 147174571 small molecule TAB-4353 147157646 Efficient Methods to Prepare Hematopoietic Progenitor Cells in vitro for Therapeutic Use NCI Immunology, Licensing, Oncology, Therapeutics Immunology Licensing Oncology Therapeutics Meghan Good, Nicholas Restifo, Raul Sakoda, Naritaka Tamaoki <p>Hematopoietic progenitor cells (HPC) are multi-potent hematopoietic lineage cells that can differentiate into any type of blood cell, including but not limited to erythrocytes, T cells, B cells, and natural killer cells. As such, they have high therapeutic potential in the fields of regenerative medicine and cancer immunotherapy, especially when generated from patient-derived induced pluripotent stem cells (iPSC). Currently, the most efficient protocol to produce HPCs is co-culturing human iPSCs (hiPSC) with mouse stromal cells as a two-dimensional (2D) monolayer. However, animal cells are not suitable for clinical application and two dimensional (2D) cultures are not physiologically accurate. Further, animal product free (xeno-free) systems are expensive and not efficient.</p> <p>Researchers at the National Cancer Institute (NCI) developed a novel approach to produce HPCs from hiPSCs using a human mesenchymal stem cell (hMSC) 3D co-culture condition. hiPSCs and hMSCs are first used to make spheroids, and then cultured in a 3D condition for two weeks. The inventors observed hematopoietic progenitor markers in hiPSCs cultured this way, indicating differentiation into HPCs. They also successfully adapted this protocol for use in bioreactors for mass production. This method is efficient, fast, cost-effective, and fully autologous; both hiPSCs and hMSCs may be derived from the same patient. HPCs can then be further differentiated into mature hematopoietic cells – such as T cells expressing a specific receptor to target cancer cells – used to reconstitute the whole immune system in patients with immunodeficiency.</p> <p>The NCI seeks statements of capability or interest from parties interested in licensing this method of producing HPCs for treatment of hematopoietic disorders and/or regenerative medicine.</p> <h2>Competitive Advantages:</h2> <ul><li>Fully human, autologous, high-efficiency, and cost-effective system</li> <li>3D culture creates a more physiological microenvironment</li> <li>Mass production of HPCs and further differentiated cells in bioreactors</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Treatment of hematopoietic disorders including leukemias, lymphomas, anemias, rare blood diseases, and infections</li> <li>Immune system reconstitution after irradiation and chemotherapy, or in patients with immunodeficiencies</li> <li>In vitro generation of any class of hematopoietic lineage cells, including therapeutic T cells from patient iPSCs</li> <li>Generation of other hematopoietic products such as antibodies, cytokines, and human serum</li> </ul> 2019-09-18 2025-04-22 2019-09-18 2025-04-22 2019-09-18 3D Culture, BIOREACTOR, Hematopoietic Progenitor Cells, hiPSC, hMSC, HPC, Human Mesenchymal Stem Cells, Immunotherapy, Induced Pluripotent Stem Cells, iPSC, Vizcardo False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2019-09-18 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-133-2017 E-250-2016 147162233 Vizcardo R, et al. Generation of tumor antigen-specific iPSC-derived thymic emigrants using a 3D thymic culture system. https://www.ncbi.nlm.nih.gov/pubmed/29562175 <a href="https://www.ncbi.nlm.nih.gov/pubmed/29562175">Vizcardo R, et al. Generation of tumor antigen-specific iPSC-derived thymic emigrants using a 3D thymic culture system.</a> 147164425 Sakoda, Raul NIH - NCI Sakoda, Raul 1 147164423 Restifo, Nicholas NIH - NCI NCI Restifo, Nicholas (NCI) 2 147164426 Good, Meghan NIH - NCI NCI Good, Meghan (NCI) 3 147164424 Tamaoki, Naritaka NIH - NCI NCI Tamaoki, Naritaka (NCI) 4 147164425 Sakoda, Raul NIH - NCI Sakoda, Raul 1 147164423 Restifo, Nicholas NIH - NCI NCI Restifo, Nicholas (NCI) 2 147164426 Good, Meghan NIH - NCI NCI Good, Meghan (NCI) 3 147164424 Tamaoki, Naritaka NIH - NCI NCI Tamaoki, Naritaka (NCI) 4 147158050 Generation Of Hematopoietic Progenitor Cells From Human Induced Pluripotent Stem Cells By Co-culture With Human Mesenchymal Stem Cells in A 3D Culture Condition E-132-2017-0 Filing authorized NCI 83709866 Burke, Andrew burkear@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC burkear@nih.gov?subject=Web Inquiry on [TAB-4353] Efficient Methods to Prepare Hematopoietic Progenitor Cells in vitro for Therapeutic Use&body=Please send me information about technology [TAB-4353] Efficient Methods to Prepare Hematopoietic Progenitor Cells in vitro for Therapeutic Use.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Burke, Andrew<br><a href="mailto:burkear@nih.gov?subject=Web Inquiry on [TAB-4353] Efficient Methods to Prepare Hematopoietic Progenitor Cells in vitro for Therapeutic Use&body=Please send me information about technology [TAB-4353] Efficient Methods to Prepare Hematopoietic Progenitor Cells in vitro for Therapeutic Use.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">burkear@nih.gov</a><br> 147161084 E-132-2017-0 E-132-2017-0-US-01 METHODS OF PREPARING HEMATOPOIETIC PROGENITOR CELLS IN VITRO PRV US 62/583,240 Abandoned US <br />Provisional (PRV) 62/583,240<br />Filed on 2017-11-08<br />Status: Abandoned 147168393 E-132-2017-0 E-132-2017-0-PCT-02 METHODS OF PREPARING HEMATOPOIETIC PROGENITOR CELLS IN VITRO PCT Patent Cooperation Treaty PCT/US2018/059856 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2018/059856<br />Filed on 2018-11-08<br />Status: Expired 147168394 E-132-2017-0 E-132-2017-0-US-03 METHODS OF PREPARING HEMATOPOIETIC PROGENITOR CELLS IN VITRO National Stage US 12,037,607 16/762,447 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12037607 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12037607">12,037,607</a><br />Filed on 2020-05-07<br />Status: Issued 147172094 3D Culture 147172095 BIOREACTOR 147172097 Hematopoietic Progenitor Cells 147172099 hiPSC 147172100 hMSC 147172102 HPC 147172104 Human Mesenchymal Stem Cells 147172105 Immunotherapy 147172106 Induced Pluripotent Stem Cells 147172107 iPSC 147172109 Vizcardo TAB-4022 147157303 Genetically Modified Hematopoietic Stem And Progenitor Cells (HSPCs) And Mesenchymal Cells As A Platform To Reduce Or Prevent Metastasis, Treat Autoimmune And Inflammatory Disorders, And Rebalance The Immune Milieu And Dysregulated Niches NCI Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Daniel Beury, Rosandra Kaplan, Sabina Kratzmeier, Haiying Qin <p>Cancer cells can spread to various regions in the body in a process called metastasis which is associated with non-responsive to treatment and thus reduced survival. Identifying the markers of metastasis has been a major concern in the field of cancer diagnosis and therapy. Interestingly, research has shown that there is an increase in myeloid progenitors and myeloid cells at various stages of metastasis in an attempt by the immune system to  suppress cancer cells. This presents a promising technology for cancer immunotherapy.</p> <p>Researchers at National Cancer Institute (NCI) developed a platform to culture myeloid cells from murine bone marrow cells and apheresed human peripheral blood. Myeloid cells were modified to express IL-12 to enhance anti-tumor immunity, limit inflammatory response, recruit T cells to sites of interest and specifically target and kill tumors. The inventors used these genetically modified myeloid cells (GEMys) in a metastatic embryonal rhabdomyosarcoma tumor model. They observed an activation of immune system cells, such as mature T cells, at the site of metastases, as well as an increase in myeloid cell populations with anti-tumor properties. Importantly, treatment of this orthotopic tumor model with GEMys reduced the metastatic burden and significantly improved survival in mice. These cells can be combined with traditional immunotherapies and other cell-based strategies – such as chimeric antigen receptors – to further improve anti-tumor immunity.</p> <p>The Pediatric Oncology Branch is seeking parties interested in licensing and codeveloping this invention to commercialize the GEMys for improved cancer immunotherapy. </p> <h2>Competitive Advantages:</h2> <ul><li>GEMys improved survival in an orthotopic metastatic cancer model</li> <li>GEMys can be further modified for enhanced functionality</li> <li>GEMys can be used alone or in combination with therapeutic T cells</li> <li>Potential FDA Orphan Drug Designation for pediatric and rare tumor indications</li> </ul> <h2>Commercial Applications:</h2> <ul><li>Cancer immunotherapy by GEMys alone or by coupling with T cell-based strategies</li> <li>Treatment of metastatic or recurrent cancers</li> <li>Treatment of autoimmune diseases through limiting the inflammatory response</li> </ul> 2019-09-18 2025-04-22 2021-05-21 2025-04-22 2019-09-18 adoptive cell therapy, AUTOIMMUNE DISEASE, Cancer Immunotherapy, GEMys, Genetically Engineered Myeloid Cells, Kaplan, Metastasis, Platform Technology False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2021-05-21 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract 147162299 Kaczanowska, S, et al. Genetically engineered myeloid cells rebalance the core immune suppression program in metastasis.&rdquo; Cell vol. 184,8 (2021): 2033-2052.e21. https://pubmed.ncbi.nlm.nih.gov/33765443/ <a href="https://pubmed.ncbi.nlm.nih.gov/33765443/">Kaczanowska, S, et al. Genetically engineered myeloid cells rebalance the core immune suppression program in metastasis.&rdquo; Cell vol. 184,8 (2021): 2033-2052.e21.</a> 147163255 Kaplan, Rosandra NIH - NCI NCI Kaplan, Rosandra (NCI) 1 147163253 Kratzmeier, Sabina NIH - NCI NCI Kratzmeier, Sabina (NCI) 2 147163252 Beury, Daniel NIH - NCI NCI Beury, Daniel (NCI) 3 147163254 Qin, Haiying NIH - NCI NCI Qin, Haiying (NCI) 4 147163255 Kaplan, Rosandra NIH - NCI NCI Kaplan, Rosandra (NCI) 1 147163253 Kratzmeier, Sabina NIH - NCI NCI Kratzmeier, Sabina (NCI) 2 147163252 Beury, Daniel NIH - NCI NCI Beury, Daniel (NCI) 3 147163254 Qin, Haiying NIH - NCI NCI Qin, Haiying (NCI) 4 147157878 Genetically Engineered Myeloid Cells (GEMys) As A Platform To Enhance Anti-tumor Immunity And/or Limit Inflammatory Conditions E-053-2019-0 Filing authorized NCI 83736770 Cheng, Eric eric.cheng2@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTB eric.cheng2@nih.gov?subject=Web Inquiry on [TAB-4022] Genetically Modified Hematopoietic Stem And Progenitor Cells (HSPCs) And Mesenchymal Cells As A Platform To Reduce Or Prevent Metastasis, Treat Autoimmune And Inflammatory Disorders, And Rebalance The Immune Milieu And Dysregulated Niches&body=Please send me information about technology [TAB-4022] Genetically Modified Hematopoietic Stem And Progenitor Cells (HSPCs) And Mesenchymal Cells As A Platform To Reduce Or Prevent Metastasis, Treat Autoimmune And Inflammatory Disorders, And Rebalance The Immune Milieu And Dysregulated Niches.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Cheng, Eric<br><a href="mailto:eric.cheng2@nih.gov?subject=Web Inquiry on [TAB-4022] Genetically Modified Hematopoietic Stem And Progenitor Cells (HSPCs) And Mesenchymal Cells As A Platform To Reduce Or Prevent Metastasis, Treat Autoimmune And Inflammatory Disorders, And Rebalance The Immune Milieu And Dysregulated Niches&body=Please send me information about technology [TAB-4022] Genetically Modified Hematopoietic Stem And Progenitor Cells (HSPCs) And Mesenchymal Cells As A Platform To Reduce Or Prevent Metastasis, Treat Autoimmune And Inflammatory Disorders, And Rebalance The Immune Milieu And Dysregulated Niches.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">eric.cheng2@nih.gov</a><br> 147160971 E-053-2019-0 E-053-2019-0-US-01 GENETICALLY MODIFIED HEMATOPOIETIC STEM AND PROGENITOR CELLS (HSPCs) AND MESENCHYMAL CELLS AS A PLATFORM TO REDUCE OR PREVENT METASTASIS, TREAT AUTOIMMUNE AND INFLAMMATORY DISORDERS, AND REBALANCE THE IMMUNE MILIEU PRV US 62/803,468 Abandoned US <br />Provisional (PRV) 62/803,468<br />Filed on 2019-02-09<br />Status: Abandoned 147166046 E-053-2019-0 E-053-2019-0-PCT-02 GENETICALLY MODIFIED HEMATOPOIETIC STEM AND PROGENITOR CELLS (HSPCs) AND MESENCHYMAL CELLS AS A PLATFORM TO REDUCE OR PREVENT METASTASIS, TREAT AUTOIMMUNE AND INFLAMMATORY DISORDERS, AND REBALANCE THE IMMUNE MILIEU AND DYSREGULATED NICHES PCT Patent Cooperation Treaty PCT/US2020/017515 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2020/017515<br />Filed on 2020-02-10<br />Status: Expired 147166052 E-053-2019-0 E-053-2019-0-AU-08 GENETICALLY MODIFIED HEMATOPOIETIC STEM AND PROGENITOR CELLS (HSPCs) AND MESENCHYMAL CELLS AS A PLATFORM TO REDUCE OR PREVENT METASTASIS, TREAT AUTOIMMUNE AND INFLAMMATORY DISORDERS, AND REBALANCE THE IMMUNE MILIEU AND DYSREGULATED NICHES National Stage Australia 2020219097 Pending Australia <br />National Stage 2020219097<br />Filed on 2021-08-05<br />Status: Pending 147166053 E-053-2019-0 E-053-2019-0-CA-09 GENETICALLY MODIFIED HEMATOPOIETIC STEM AND PROGENITOR CELLS (HSPCs) AND MESENCHYMAL CELLS AS A PLATFORM TO REDUCE OR PREVENT METASTASIS, TREAT AUTOIMMUNE AND INFLAMMATORY DISORDERS, AND REBALANCE THE IMMUNE MILIEU AND DYSREGULATED NICHES National Stage Canada 3128871 Pending Canada <br />National Stage 3128871<br />Filed on 2020-02-10<br />Status: Pending 147166054 E-053-2019-0 E-053-2019-0-CN-10 GENETICALLY MODIFIED HEMATOPOIETIC STEM AND PROGENITOR CELLS (HSPCs) AND MESENCHYMAL CELLS AS A PLATFORM TO REDUCE OR PREVENT METASTASIS, TREAT AUTOIMMUNE AND INFLAMMATORY DISORDERS, AND REBALANCE THE IMMUNE MILIEU AND DYSREGULATED NICHES National Stage China 202080026241.7 Pending China <br />National Stage 202080026241.7<br />Filed on 2021-09-29<br />Status: Pending 147166055 E-053-2019-0 E-053-2019-0-EP-11 GENETICALLY MODIFIED HEMATOPOIETIC STEM AND PROGENITOR CELLS (HSPCs) AND MESENCHYMAL CELLS AS A PLATFORM TO REDUCE OR PREVENT METASTASIS, TREAT AUTOIMMUNE AND INFLAMMATORY DISORDERS, AND REBALANCE THE IMMUNE MILIEU AND DYSREGULATED NICHES National Stage European Patent 20711371.3 Pending European Patent <br />National Stage 20711371.3<br />Filed on 2021-08-09<br />Status: Pending 147166056 E-053-2019-0 E-053-2019-0-US-12 GENETICALLY MODIFIED HEMATOPOIETIC STEM AND PROGENITOR CELLS (HSPCS) AND MESENCHYMAL CELLS AS A PLATFORM TO REDUCE OR PREVENT METASTASIS, TREAT AUTOIMMUNE AND INFLAMMATORY DISORDERS, AND REBALANCE THE IMMUNE MILIEU AND DYSREGULATED NICHES National Stage US 17/429,391 Pending US <br />National Stage 17/429,391<br />Filed on 2021-08-09<br />Status: Pending 147170378 adoptive cell therapy 147170379 AUTOIMMUNE DISEASE 147170381 Cancer Immunotherapy 147170382 GEMys 147170384 Genetically Engineered Myeloid Cells 147170386 Kaplan 147170387 Metastasis 147170389 Platform Technology TAB-4206 147157491 In vitro Generation of an Autologous Thymic Organoid from Human Pluripotent Stem Cells NCI Immunology, Licensing, Oncology, Therapeutics Immunology Licensing Oncology Therapeutics Nicholas Restifo, Raul Sakoda <p>The thymus is an integral part of the adaptive immune system as it generates T cells. Its function diminishes rapidly as the body ages, leading to a compromise of the immune system in the elderly. Reconstitution of adaptive immunity through mass production of different T cell types is therefore a therapeutic need in immunocompromised populations. Furthermore, production of T cells with specific receptors targeting cancer cells is an important cancer immunotherapy approach. However, current in vitro methods are not efficient in producing conventional CD4 or CD8 positive T cells, as they result in production of immature, CD4 and CD8 double positive T cells which are not useful for therapy. This problem may be solved through a three-dimensional cell culture system mimicking the human thymus.</p> <p>Researchers at the National Cancer Institute (NCI) have developed a novel approach to generate autologous thymic organoids from human pluripotent stem cells. These organoids possess many features of a physiological human thymus and form structures resembling organized thymic tissue. As such, they are very promising candidates for production of therapeutic T cells and other cells of the adaptive immune system (e.g., natural killer cells).</p> <p>The NCI is seeking statements of capability or interest from parties interested in licensing this invention to further develop, evaluate, or commercialize this method of generating thymic organoids for production of adaptive immune system cells.</p> <h2>Competitive Advantages:</h2> <ul><li>Three dimensional, fully human culture system produces an organoid which mimics the physiological properties of the thymus</li> <li>The thymic organoid form structures resembling organized thymic tissue</li> <li>The system can be adapted for mass production </li> </ul> <h2>Commercial Applications:</h2> <ul><li>Regeneration of the adaptive immune system in immunocompromised and/or the elderly population</li> <li>Organoid technology as a disease model, and to predict the outcome of drug responses in vitro </li> <li>In vitro generation of T and natural killer T (NKT) cells with specific receptors to target cancer cells</li> <li>Treatment of anemias, autoimmune disorders, rare blood diseases, and infections</li> </ul> 2019-09-18 2025-04-22 2019-09-18 2025-04-22 2019-09-18 Aging, IMMUNOCOMPROMISED, Immunotherapy, Natural Killer T Cells, NKT, Organogenesis, Organoid, Pluripotent Stem Cells, T Cells, THYMUS, Vizcardo False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2019-09-18 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-132-2017 E-250-2016 147162386 Vizcardo R, et al. Generation of tumor antigen-specific iPSC-derived thymic emigrants using a 3D thymic culture system. https://www.ncbi.nlm.nih.gov/pubmed/29562175 <a href="https://www.ncbi.nlm.nih.gov/pubmed/29562175">Vizcardo R, et al. Generation of tumor antigen-specific iPSC-derived thymic emigrants using a 3D thymic culture system.</a> 147163913 Sakoda, Raul NIH - NCI Sakoda, Raul 1 147163912 Restifo, Nicholas NIH - NCI NCI Restifo, Nicholas (NCI) 2 147163913 Sakoda, Raul NIH - NCI Sakoda, Raul 1 147163912 Restifo, Nicholas NIH - NCI NCI Restifo, Nicholas (NCI) 2 147158053 In Vitro Generation Of An Autologous Thymic Organoid From Human Pluripotent Stem Cells E-133-2017-0 Filing authorized NCI 83709866 Burke, Andrew burkear@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC burkear@nih.gov?subject=Web Inquiry on [TAB-4206] In vitro Generation of an Autologous Thymic Organoid from Human Pluripotent Stem Cells&body=Please send me information about technology [TAB-4206] In vitro Generation of an Autologous Thymic Organoid from Human Pluripotent Stem Cells.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Burke, Andrew<br><a href="mailto:burkear@nih.gov?subject=Web Inquiry on [TAB-4206] In vitro Generation of an Autologous Thymic Organoid from Human Pluripotent Stem Cells&body=Please send me information about technology [TAB-4206] In vitro Generation of an Autologous Thymic Organoid from Human Pluripotent Stem Cells.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">burkear@nih.gov</a><br> 147161087 E-133-2017-0 E-133-2017-0-US-01 IN VITRO GENERATION OF THYMIC ORGANOID FROM HUMAN PLURIPOTENT STEM CELLS PRV US 62/560,908 Abandoned US <br />Provisional (PRV) 62/560,908<br />Filed on 2017-09-20<br />Status: Abandoned 147167350 E-133-2017-0 E-133-2017-0-PCT-02 IN VITRO GENERATION OF THYMIC ORGANOID FROM HUMAN PLURIPOTENT STEM CELLS PCT Patent Cooperation Treaty PCT/US2018/051625 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2018/051625<br />Filed on 2018-09-19<br />Status: Expired 147167351 E-133-2017-0 E-133-2017-0-EP-03 IN VITRO GENERATION OF THYMIC ORGANOID FROM HUMAN PLURIPOTENT STEM CELLS National Stage European Patent 18783234.0 Pending European Patent <br />National Stage 18783234.0<br />Filed on 2020-03-26<br />Status: Pending 147167352 E-133-2017-0 E-133-2017-0-JP-04 IN VITRO GENERATION OF THYMIC ORGANOID FROM HUMAN PLURIPOTENT STEM CELLS National Stage Japan 7372910 2020-516436 Issued Japan <br />National Stage 2020-516436<br />Filed on 2020-03-18<br />Status: Issued 147167353 E-133-2017-0 E-133-2017-0-US-05 IN VITRO GENERATION OF THYMIC ORGANOID FROM HUMAN PLURIPOTENT STEM CELLS National Stage US 11,898,166 16/648,008 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11898166 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11898166">11,898,166</a><br />Filed on 2020-03-17<br />Status: Issued 147172121 Aging 147172122 IMMUNOCOMPROMISED 147172123 Immunotherapy 147172125 Natural Killer T Cells 147172126 NKT 147172128 Organogenesis 147172129 Organoid 147172130 Pluripotent Stem Cells 147172131 T Cells 147172132 THYMUS 147172133 Vizcardo TAB-4276 147157564 Design and Biological Activity of Novel Stealth Polymeric Lipid Nanoparticles for Enhanced Delivery of Hydrophobic Photodynamic Therapy Drugs NCI Collaboration, Infectious Disease, Licensing, Oncology, Therapeutics Collaboration Infectious Disease Licensing Oncology Therapeutics Anu Puri, Mathias Viard <p>Nanoparticles such as lipid-based nanoparticles (LNPs) represent a relatively new era of targeted drug delivery systems wherein these biocompatible particles can carry the drug(s) of interest to a specific tumor site. The new generation of nanoparticles, known as stealth nanoparticles, are engineered to have a coating of polyethylene glycol polymer (PEG) or other glycolipids that enable them to evade the immune system and have a longer circulation lifespan as well as improved bioavailability to diseased tissue and reduced non-specific toxicity.<br /> &nbsp;<br /> Scientists at the National Cancer Institute (NCI) have developed the formulation of novel stealth nanoparticles that have high stability and high payload capacity. These nanoparticles are vesicles made of binary lipid bilayer comprising phospholipid DC8,9PC and a PEGylated lipid such as DSPE-PEG2000. The vesicles can carry high amounts of payload of a hydrophobic photodynamic drug (PDT) such as HPPH (up to 0.5mg of HPPH/mg lipid), a photosensitive drug that has anti-cancer properties when irradiated by near-infrared light. These HPPH- loaded vesicles exhibit &gt;90% serum stability and are stable for at least 42 days at room temperature. These vesicles showed higher doses of the HPPH in the blood samples of intravenously injected mice based on their pharmacokinetic profile (monitored up to 264 hours).&nbsp;</p> <p>When tested in-vivo in animal models, they demonstrate high LNP-associated HPPH uptake in HT29 mice tumors due to improved tumor accumulation and show better tumor regression in Colon-26 bearing BALB/c mouse model with no tumor recurrence up to 100 days compared with animal survival data observed with Tween 80- HPPH , the nanoparticle formulation used in current clinical trials. These HPPH-loaded vesicles represent a novel targeted anti-cancer therapeutic that can also be engineered to carry other cytotoxic, imaging, nucleic acid agents for targeted therapy/diagnostics of other disease types.&nbsp;&nbsp;</p> <p><img alt="" src="https://nih.technologypublisher.com/files/sites/design_and_biological_activity_of_novel_stealth_polymeric_lipid_nanoparticles_for_enhanced_delivery_of_hydrophobic_photodynamic_therapy_drugs5.jpg" /></p> <h2>Competitive Advantages:</h2> <ul> <li>Superior stealth formulation (i.e. evasion from immune recognition) due to high PEGylation ability of the nanoparticle - important for in vivo applications</li> <li>High payload of PDT drug HPPH: up to 0.5mg of HPPH/mg lipid</li> <li>Vesicles remain stable for at least 42 days upon storage at room temperature &ndash; potential translational (See Figure 1) advantage. Improved stability of vesicles compared to the vesicles published previously by the same group&nbsp;</li> <li>Enhanced tumor uptake of LNP-associated HPPH in HT29 mice due to increased PEG density on the surface of the liposomes&nbsp;</li> <li>Superior tumor regression efficiencies in Colon-26 mouse model compared to the nano-formulation of Tween 80-HPPH, which is used in clinical trials</li> <li>Prolonged circulation lifetime of payload</li> </ul> <p><strong>Figure 1.&nbsp;</strong><strong>(A) </strong><em>In vivo</em> tissue distribution of LNP formulated HPPH in liver, tumor and skin of tumor-bearing mice by optical imaging: CT-26 tumor-bearing BALB/c mice were intravenously injected (groups of five) using either Tween 80-HPPH or LNP20-HPPH. LNP20 without HPPH were used to obtain background signals. Images were collected at various time intervals and average radiant efficiency of HPPH in tumor, liver and skin was determined. <strong>(B)</strong> <em>In Vivo</em> PDT response and antitumor activity of LNP20-HPPH in CT-26 bearing BALB/c mice: Tween 80-HPPH or LNP20-HPPH were intravenously injected in tumor-bearing mice at 0.47&mu;mol HPPH/kg body weight. Laser treatments were done post 4 h for LNP20-HPPH-injected animals and post 24 h injections of Tween 80-HPPH. Tumor volumes were measured at indicated days. <strong>(B (i) &amp; (ii))</strong> Tween80-HPPH and LNP20-HPPH respectively (five mice per set). <strong>(B (iii))</strong> LNP20-HPPH injected mice (group of ten animals). <strong>(B (iv))</strong> Animal survival data are presented as Kaplan Meier graph comparing LNP20-HPPH (two independent experiments) and Tween 80-HPPH.</p> <p>&nbsp;</p> <h2>Commercial Applications:</h2> <ul> <li>Nanoparticle platform loaded with PDT and non-PDT drugs for delivery of a therapeutic drug, gene therapy, or imagining agent for the treatment or diagnosis of disease.</li> <li>Drugs otherwise demonstrating inability to reach target sites (which contributes to exceptionally high attrition rates of new chemical entities [NCEs] across all therapeutic areas, with &lt;15% of drugs gaining approval by regulatory authorities).</li> </ul> 2019-11-19 2025-04-22 2019-11-19 2025-04-22 2019-11-19 Lipid-based Nanoparticle, LPN, PDT, Photodynamic Drug, Puri, Stealth Nanoparticle False True Pre-clinical (in vivo) True michael.salgaller@nih.gov, tdiaz@mail.nih.gov True 2019-11-19 52398218 Pre-Clinical (in vivo) 52398218 NCI 37470483 Website Abstract E-482-2013 147162312 Viard M, et al. Design and biological activity of novel stealth polymeric lipid nanoparticles for enhanced delivery of hydrophobic photodynamic therapy drugs. https://www.ncbi.nlm.nih.gov/pubmed/30059754 <a href="https://www.ncbi.nlm.nih.gov/pubmed/30059754">Viard M, et al. Design and biological activity of novel stealth polymeric lipid nanoparticles for enhanced delivery of hydrophobic photodynamic therapy drugs.</a> 147164131 Puri, Anu NIH - NCI NCI Puri, Anu (NCI) 1 147164132 Viard, Mathias NIH - NCI Leidos Viard, Mathias (Leidos) 2 147164131 Puri, Anu NIH - NCI NCI Puri, Anu (NCI) 1 147164132 Viard, Mathias NIH - NCI Leidos Viard, Mathias (Leidos) 2 147158092 Design And Biological Activity Of Novel Stealth Polymeric Lipid Nanoparticles For Enhanced Delivery Of Hydrophobic Photodynamic Therapy Drugs E-154-2018-0 Filing authorized NCI 83732917 Favila, Michelle michelle.favila@nih.gov michael.salgaller@nih.gov, tdiaz@mail.nih.gov
United States of America TTC michelle.favila@nih.gov?subject=Web Inquiry on [TAB-4276] Design and Biological Activity of Novel Stealth Polymeric Lipid Nanoparticles for Enhanced Delivery of Hydrophobic Photodynamic Therapy Drugs&body=Please send me information about technology [TAB-4276] Design and Biological Activity of Novel Stealth Polymeric Lipid Nanoparticles for Enhanced Delivery of Hydrophobic Photodynamic Therapy Drugs.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov Favila, Michelle<br><a href="mailto:michelle.favila@nih.gov?subject=Web Inquiry on [TAB-4276] Design and Biological Activity of Novel Stealth Polymeric Lipid Nanoparticles for Enhanced Delivery of Hydrophobic Photodynamic Therapy Drugs&body=Please send me information about technology [TAB-4276] Design and Biological Activity of Novel Stealth Polymeric Lipid Nanoparticles for Enhanced Delivery of Hydrophobic Photodynamic Therapy Drugs.&cc=michael.salgaller@nih.gov, tdiaz@mail.nih.gov ">michelle.favila@nih.gov</a><br> 147161110 E-154-2018-0 E-154-2018-0-PCT-02 BINARY LIPID BILAYER-CONTAINING VESICLES COMPRISING EMBEDDED CYTOTOXIC AGENTS AND METHODS OF MAKING AND USING THE SAME PCT Patent Cooperation Treaty PCT/US2019/041464 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2019/041464<br />Filed on 2019-07-11<br />Status: Expired 147167823 E-154-2018-0 E-154-2018-0-US-01 BINARY LIPID BILAYER-CONTAINING VESICLES COMPRISING EMBEDDED CYTOTOXIC AGENTS AND METHODS OF MAKING AND USING THE SAME PRV US 62/697,287 Abandoned US <br />Provisional (PRV) 62/697,287<br />Filed on 2018-07-12<br />Status: Abandoned 147167824 E-154-2018-0 E-154-2018-0-CA-03 BINARY LIPID BILAYER-CONTAINING VESICLES COMPRISING EMBEDDED CYTOTOXIC AGENTS AND METHODS OF MAKING AND USING THE SAME National Stage Canada 3106008 Pending Canada <br />National Stage 3106008<br />Filed on 2019-07-11<br />Status: Pending 147167825 E-154-2018-0 E-154-2018-0-EP-04 BINARY LIPID BILAYER-CONTAINING VESICLES COMPRISING EMBEDDED CYTOTOXIC AGENTS AND METHODS OF MAKING AND USING THE SAME National Stage European Patent 19746275.7 Pending European Patent <br />National Stage 19746275.7<br />Filed on 2021-01-08<br />Status: Pending 147167826 E-154-2018-0 E-154-2018-0-JP-05 BINARY LIPID BILAYER-CONTAINING VESICLES COMPRISING EMBEDDED CYTOTOXIC AGENTS AND METHODS OF MAKING AND USING THE SAME National Stage Japan 2021-500734 Abandoned Japan <br />National Stage 2021-500734<br />Filed on 2019-07-11<br />Status: Abandoned 147167827 E-154-2018-0 E-154-2018-0-US-06 BINARY LIPID BILAYER-CONTAINING VESICLES COMPRISING EMBEDDED CYTOTOXIC AGENTS AND METHODS OF MAKING AND USING THE SAME National Stage US 12,178,907 17/259,499 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12178907 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12178907">12,178,907</a><br />Filed on 2021-01-11<br />Status: Issued 147172491 Lipid-based Nanoparticle 147172493 LPN 147172494 PDT 147172496 Photodynamic Drug 147172498 Puri 147172500 Stealth Nanoparticle TAB-3455 114097318 Pre-Biotic Formulation of Topical Chemicals for Use on Human Skin NIAID Collaboration Collaboration Carlo Castillo, Ian Myles Atopic dermatitis (AD) is a common, recurrent, chronic inflammatory skin disease that is a cause of considerable economic and social burden. It is one of the most prevalent skin disorders, affecting ~25% of children in developed and developing countries and is expected to continue to escalate. This increased rate of incidence has changed the focus of research on AD toward epidemiology, prevention, and treatment.<br /><br /> Scientists at NIAID have developed novel topical formulations that promote the growth of health-associated strains of commensal bacteria and inhibit disease-associated bacteria, thereby enhancing skin health.<br /><br /> This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as well as for further development and evaluation under a research collaboration. <ul> <li>Benign safety profile with multiple mechanisms of action</li> <li>Proven enhancement of beneficial microbiota</li> <li>Can be readily incorporated into existing products</li> </ul> <ul> <li>Over-the-counter formulations—this invention could be readily incorporated into popular body lotions or other skincare products to make “enhanced”/“microbiome-friendly” versions that promote the growth of health associated bacterial</li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize this technology. For collaboration opportunities, please contact David Yang at 240-695-6406 or <a href="mailto:yangp3@mail.nih.gov">yangp3@mail.nih.gov</a>. 2022-03-08 2024-10-28 2025-04-21 2021-07-15 CHEMICALS, FORMULATION, Human, Pre-biotic, SKIN, TOPICAL False True True NIHTT 37470483 Website Abstract 114110259 Castillo, Carlo NIAID - VRC Castillo, Carlo 0 114110258 Myles, Ian NIAID - DIR NIAID Myles, Ian (NIAID) 1 114110258 Myles, Ian NIAID - DIR NIAID Myles, Ian (NIAID) 1 114110259 Castillo, Carlo NIAID - VRC Castillo, Carlo 0 114102575 Pre-biotic Formulation Of Topical Chemicals For Use On Human Skin E-100-2021-0 Filing authorized NIAID 83720410 Yang, David (Po-Lung) polung.yang@nih.gov
United States of America Technology Transfer and Intellectual Property Office polung.yang@nih.gov?subject=Web Inquiry on [TAB-3455] Pre-Biotic Formulation of Topical Chemicals for Use on Human Skin&body=Please send me information about technology [TAB-3455] Pre-Biotic Formulation of Topical Chemicals for Use on Human Skin. Yang, David (Po-Lung)<br><a href="mailto:polung.yang@nih.gov?subject=Web Inquiry on [TAB-3455] Pre-Biotic Formulation of Topical Chemicals for Use on Human Skin&body=Please send me information about technology [TAB-3455] Pre-Biotic Formulation of Topical Chemicals for Use on Human Skin.">polung.yang@nih.gov</a><br> 114169145 E-100-2021-0 E-100-2021-0-US-01 PRE-BIOTIC FORMULATION OF TOPICAL CHEMICALS FOR USE ON SKIN PRV US 63/175,368 Abandoned US <br />Provisional (PRV) 63/175,368<br />Filed on 2021-04-15<br />Status: Abandoned 114152277 Pre-biotic 114152278 FORMULATION 114152279 TOPICAL 114152280 CHEMICALS 114152281 Human 114152282 SKIN TAB-3448 114097319 Human Monoclonal and Bispecific Antibodies Targeting SARS-CoV-2 Coronavirus NIAID Collaboration Collaboration Hyeseon Cho, Peter Crompton, Kristina Gonzales-Wartz, Mary Peter, Joshua Tan SARS-CoV-2 is a virus of the Coronavirus family that has emerged as a major public health concern. The first cases of SARS-CoV-2 were reported in China and rapidly spread worldwide leading to a global pandemic. The highest morbidity and mortality have been reported in the elderly and immunocompromised. Antibody therapeutics have great importance for advanced cases of SARS-CoV-2 where a vaccine would not be effective and may be more effective than a vaccine in certain high-risk populations. <br / ><br /> Scientists at NIAID have developed recombinant monoclonal antibodies that are effective in vitro and in vivo at neutralizing SARS-CoV-2. Based on whether they are mono-specific or bi-specific and where they bind to the SARS-CoV-2 virus, these antibodies can be subdivided into four groups that target (A) the receptor-binding-domain (RBD) of the SARS-COV-2 spike protein, (B) the N-terminal domain (NTD) of the SARS-COV-2 spike protein, (C) dual locations on the RBD, or (D) both the RBD and NTD. Crucially, these antibodies effectively neutralize the emerging B.1.1.7 and B.1.351 SARS-CoV-2 variants of concern.<br / ><br /> These recombinant monoclonal antibodies can be used alone, in combination, or with other therapeutics for the treatment of SARS-COV-2. In addition to their potential as therapeutics, these antibodies against SARS-CoV-2 can be used as prophylactics and in assay development. They can contribute to the surveillance, diagnosis, and prevention of SARS-COV-2. Furthermore, the specific antibody sequences and targets will inform vaccine development and establishment of long-term immunity. <li>Potent neutralizing activity against SARS-CoV-2, including against B.1.1.7 and B.1.351 variants.</li> <li>Prophylactic usage against SARS-CoV-2 in normal or high-risk populations.</li> <li>Therapeutic treatment, alone or in combination, in patients with SARS-CoV-2 infection.</li> <li>Assay development for surveillance, diagnostic, and prevention measures.</li> <li>Identification of vaccine candidates which elicit protective antibodies against SARS-CoV-2 infections.</li> </ul> <li>Potent neutralizing activity against SARS-CoV-2, including against B.1.1.7 and B.1.351 variants.</li> <li>Prophylactic usage against SARS-CoV-2 in normal or high-risk populations.</li> <li>Therapeutic treatment, alone or in combination, in patients with SARS-CoV-2 infection.</li> <li>Assay development for surveillance, diagnostic, and prevention measures.</li> <li>Identification of vaccine candidates which elicit protective antibodies against SARS-CoV-2 infections.</li> </ul> For collaboration opportunities, please contact Dawn Taylor-Mulneix at <a href="mailto: dawn.taylor-mulneix@nih.gov."> dawn.taylor-mulneix@nih.gov.</a>or 1-301-767-5189. 2022-03-08 2024-10-28 2025-04-21 2021-07-01 antibodies, Human, monoclonal, SARS-CoV-2, Targeting False True True NIHTT 37470483 Website Abstract 114172609 Cho, Hyeseon, et. al. https://doi.org/10.1101/2021.04.01.437942 <a href="https://doi.org/10.1101/2021.04.01.437942">Cho, Hyeseon, et. al.</a> 114110217 Crompton, Peter NIAID - DMID NIAID Crompton, Peter (NIAID) 0 114110229 Cho, Hyeseon NIAID - DIR NIAID Cho, Hyeseon (NIAID) 0 114110230 Gonzales-Wartz, Kristina NIAID - DIR NIAID Gonzales-Wartz, Kristina (NIAID) 0 114110231 Peter, Mary NIAID - DIR NIAID Peter, Mary (NIAID) 0 114110228 Tan, Joshua NIAID - VRC NIAID Tan, Joshua (NIAID) 1 114110228 Tan, Joshua NIAID - VRC NIAID Tan, Joshua (NIAID) 1 114110217 Crompton, Peter NIAID - DMID NIAID Crompton, Peter (NIAID) 0 114110229 Cho, Hyeseon NIAID - DIR NIAID Cho, Hyeseon (NIAID) 0 114110230 Gonzales-Wartz, Kristina NIAID - DIR NIAID Gonzales-Wartz, Kristina (NIAID) 0 114110231 Peter, Mary NIAID - DIR NIAID Peter, Mary (NIAID) 0 114102569 Human Monoclonal Antibodies Targeting SARS-CoV-2 E-030-2021-0 Filing authorized NIAID 83738793 Taylor-Mulneix, Dawn dawn.taylor-mulneix@nih.gov
United States of America dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-3448] Human Monoclonal and Bispecific Antibodies Targeting SARS-CoV-2 Coronavirus&body=Please send me information about technology [TAB-3448] Human Monoclonal and Bispecific Antibodies Targeting SARS-CoV-2 Coronavirus. Taylor-Mulneix, Dawn<br><a href="mailto:dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-3448] Human Monoclonal and Bispecific Antibodies Targeting SARS-CoV-2 Coronavirus&body=Please send me information about technology [TAB-3448] Human Monoclonal and Bispecific Antibodies Targeting SARS-CoV-2 Coronavirus.">dawn.taylor-mulneix@nih.gov</a><br> 114168844 E-030-2021-0 E-030-2021-0-US-01 Human Monoclonal Antibodies Targeting SARS-CoV-2 PRV US 63/127,077 Abandoned US <br />Provisional (PRV) 63/127,077<br />Filed on 2020-12-17<br />Status: Abandoned 114169177 E-030-2021-0 E-030-2021-0-PCT-02 HUMAN MONOCLONAL ANTIBODIES TARGETING SARS-COV-2 PCT Patent Cooperation Treaty PCT/US2021/063525 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/063525<br />Filed on 2021-12-15<br />Status: Expired 114152183 Human 114152184 monoclonal 114152185 antibodies 114152186 Targeting 114152187 SARS-CoV-2 TAB-2349 114096553 New Cholera Vaccine and Method for Conjugating Bacterial Polysaccharides to Proteins NIDDK Collaboration, Diagnostics, Infectious Disease, Vaccines Collaboration Diagnostics Infectious Disease Vaccines Mohammed Alam, Stephen Calderwood, Richelle Charles, Anuj Kalsy, Pavol Kovac, Dwight Peterson, Firdausi Qadri, Edward Ryan, Willie Vann, Peng Xu A new conjugate vaccine for cholera has been developed. The invention includes a new method to conjugate the O-specific polysaccharide-core part of the bacterial lipopolysaccharide and protein subcomponents. Conventional technology has entailed chemical treatment of both components to introduce linkers, which made them amenable for covalent linking. The new method simplifies production by utilizing squaric acid chemistry for conjugating the free amine-containing species (e.g. polysaccharides) directly to amine-containing species (e.g. proteins) without prior modification of either component. While demonstrated in this new cholera prototype vaccine, the technology is envisioned as generally applicable, thereby streamlining a complex production process. <ul> <li>The method in the present form is simple to perform, gives reproducible results, allows preparation of carbohydrate-protein constructs in a predictable way, and appears to be superior to protocols developed earlier.</li> </ul> <ul> <li>Simplified production of conjugate vaccines</li> <li>New vaccines</li> </ul> The National Institute of Diabetes and Digestive and Kidney Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize conjugate vaccines. For collaboration opportunities, please contact Marguerite J. Miller, M.B.A. at 301-496-9003 or <a href="mailto:millermarg@niddk.nih.gov">millermarg@niddk.nih.gov</a>. 2022-03-08 2024-10-28 2025-04-18 2017-04-17 Amines, CONJUGATING, DA3XXX, DAXXXX, DC4XXX, DCXXXX, DEXXXX, DXXXXX False True Early-stage True NIHTT 37470483 Website Abstract 114171474 Peng Xu, et al. http://www.ncbi.nlm.nih.gov/pubmed/21899371 <a href="http://www.ncbi.nlm.nih.gov/pubmed/21899371">Peng Xu, et al.</a> 114108239 Xu, Peng National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Xu, Peng (NIDDK) 0 114108240 Alam, Mohammed Massachusetts General Hospital Alam, Mohammed 0 114108241 Kalsy, Anuj Massachusetts General Hospital Kalsy, Anuj 0 114108242 Charles, Richelle Massachusetts General Hospital Charles, Richelle 0 114108243 Calderwood, Stephen Massachusetts General Hospital Calderwood, Stephen 0 114108244 Peterson, Dwight FDA - CBER FDA Peterson, Dwight (FDA) 0 114108245 Ryan, Edward Massachusetts General Hospital Ryan, Edward 0 114108246 Qadri, Firdausi International Centre for Diarrhoeal Disease Research Qadri, Firdausi 0 114108247 Vann, Willie FDA - CBER FDA Vann, Willie (FDA) 0 114107388 Kovac, Pavol National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Kovac, Pavol (NIDDK) 1 114107388 Kovac, Pavol National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Kovac, Pavol (NIDDK) 1 114108239 Xu, Peng National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Xu, Peng (NIDDK) 0 114108240 Alam, Mohammed Massachusetts General Hospital Alam, Mohammed 0 114108241 Kalsy, Anuj Massachusetts General Hospital Kalsy, Anuj 0 114108242 Charles, Richelle Massachusetts General Hospital Charles, Richelle 0 114108243 Calderwood, Stephen Massachusetts General Hospital Calderwood, Stephen 0 114108244 Peterson, Dwight FDA - CBER FDA Peterson, Dwight (FDA) 0 114108245 Ryan, Edward Massachusetts General Hospital Ryan, Edward 0 114108246 Qadri, Firdausi International Centre for Diarrhoeal Disease Research Qadri, Firdausi 0 114108247 Vann, Willie FDA - CBER FDA Vann, Willie (FDA) 0 114099906 Conjugating Amines E-234-2011-0 Filing authorized Massachusetts General Hospital, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 114101987 Conjugating Amines E-234-2011-1 Filing authorized Massachusetts General Hospital, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 114101988 Conjugating Amines E-234-2011-2 Filing authorized FDA, International Centre for Diarrhoeal Disease Research, Massachusetts General Hospital, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83728636 Buller, Carolyn carolyn.buller@nih.gov
United States of America Technology Advancement Office carolyn.buller@nih.gov?subject=Web Inquiry on [TAB-2349] New Cholera Vaccine and Method for Conjugating Bacterial Polysaccharides to Proteins&body=Please send me information about technology [TAB-2349] New Cholera Vaccine and Method for Conjugating Bacterial Polysaccharides to Proteins. Buller, Carolyn<br><a href="mailto:carolyn.buller@nih.gov?subject=Web Inquiry on [TAB-2349] New Cholera Vaccine and Method for Conjugating Bacterial Polysaccharides to Proteins&body=Please send me information about technology [TAB-2349] New Cholera Vaccine and Method for Conjugating Bacterial Polysaccharides to Proteins.">carolyn.buller@nih.gov</a><br> 114166594 E-234-2011-0 E-234-2011-0-US-01 Conjugating Amines PRV US 61/507,054 Abandoned US <br />Provisional (PRV) 61/507,054<br />Filed on 2011-07-12<br />Status: Abandoned 114167387 E-234-2011-1 E-234-2011-1-US-01 Conjugating Amines PRV US 61/569,632 Abandoned US <br />Provisional (PRV) 61/569,632<br />Filed on 2011-12-12<br />Status: Abandoned 114167388 E-234-2011-2 E-234-2011-2-PCT-01 Conjugating Amines PCT COMB Patent Cooperation Treaty PCT/US2012/046196 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2012/046196<br />Filed on 2012-07-11<br />Status: Expired 114168151 E-234-2011-2 E-234-2011-2-US-02 Conjugating Amines National Stage US 9,616,139 14/128,958 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9616139 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9616139">9,616,139</a><br />Filed on 2014-09-08<br />Status: Issued 114122434 DXXXXX 114122435 DAXXXX 114122436 DA3XXX 114122437 DCXXXX 114122438 DC4XXX 114122439 DEXXXX 114142280 CONJUGATING 114142281 Amines TAB-2252 114096462 Glucocerebrosidase Activators as a Treatment for Gaucher Disease NCATS Cardiology, Diagnostics, Licensing, Reproductive Health, Research Materials, Therapeutics, Vaccines Cardiology Diagnostics Licensing Reproductive Health Research Materials Therapeutics Vaccines Ehud Goldin, Juan Marugan, Omid Motabar, Samarjit Patnaik, Ellen Sidransky, Noel Southall, Wendy Westbroek, Wei Zheng This technology is a collection of small molecule activators of a genetically defective version of the enzyme called glucocerebrosidase (GCase), which causes Gaucher disease. Gaucher disease is a rare disease affecting 1 in 40,000 babies born. Ashkenazi Jews of eastern European descent (about 1 in 800 live births) are at particular risk of carrying this genetic defect. It is caused by inherited genetic mutations in the gene that encodes GCase, which result in reduced activity of the enzyme. This enzyme is normally made and then transported to an organelle called a lysosome, which is dedicated to the degradation and disposal of molecules the cell no longer needs. GCase is responsible for the breakdown of a fatty material called glucocerebroside (or glucosylceramide). The accumulation of this lipid occurs inside specific cells called macrophages and macrophage-derived cells. The disease has been categorized into three types: neuronopathic (types 2, 3) and non-neuronopathic (type 1) with mild to severe symptoms that can appear at anytime from infancy to adulthood. Clinical manifestations can include an enlarged spleen and liver, anemia, decreased platelets, bone disease and neurodegeneration, with varying severity depending on the type of disease and time of diagnosis. The deficient GCase activity has been attributed to insufficient GCase enzyme in the lysosome. After production in the endoplasmic reticulum (ER), defective GCase does not fold properly and is therefore degraded in the ER and not transported to the lysosome where it would hydrolyze glucocerebroside. The small molecule activators may act by increasing the concentration of GCase that reaches the lysosome by facilitating the proper folding of GCase so that it can be released from the ER and transported to lysosomes. Thus, these small molecules could be acting like “chaperones,” because they facilitate proper folding which results in some active enzyme. Prior failed attempts to use small molecule chaperones to improve GCase folding and transport were made with inhibitors of GCase, which ironically properly folded active GCase that was subsequently transported to the lysosome, but the molecule also inhibited the GCase so that it could not break down glucocerebroside. On the other hand, these proposed small molecules were screened for their ability to activate defective GCase in the presence of a fluorogenic mimic of glucocerebroside, and their ability to facilitate translocation of defective GCase to lysosomes as well. This creates the opportunity to induce proper folding, while avoiding inhibition of enzyme function. Treatment of Gaucher Disease Available for licensing 2022-03-08 2025-04-18 2025-04-18 2011-04-29 ACTIVATORS, Disease, Gaucher, GLUCOCEREBROSIDASE, IA1AXX, IA1XXX, IAXXXX, IB6XXX, IBXXXX, IXXXXX, treatment False True Early development True NIHTT 37470483 Website Abstract 114107157 Southall, Noel National Human Genome Research Institute (NHGRI) NCATS Southall, Noel (NCATS) 0 114107158 Goldin, Ehud National Human Genome Research Institute (NHGRI) NHGRI Goldin, Ehud (NHGRI) 0 114107159 Zheng, Wei National Human Genome Research Institute (NHGRI) NCATS Zheng, Wei (NCATS) 0 114107160 Patnaik, Samarjit National Human Genome Research Institute (NHGRI) NCATS Patnaik, Samarjit (NCATS) 0 114107161 Sidransky, Ellen National Human Genome Research Institute (NHGRI) NHGRI Sidransky, Ellen (NHGRI) 0 114107162 Motabar, Omid National Human Genome Research Institute (NHGRI) Motabar, Omid 0 114107163 Westbroek, Wendy National Human Genome Research Institute (NHGRI) Westbroek, Wendy 0 114107156 Marugan, Juan National Human Genome Research Institute (NHGRI) NCATS Marugan, Juan (NCATS) 1 114107156 Marugan, Juan National Human Genome Research Institute (NHGRI) NCATS Marugan, Juan (NCATS) 1 114107157 Southall, Noel National Human Genome Research Institute (NHGRI) NCATS Southall, Noel (NCATS) 0 114107158 Goldin, Ehud National Human Genome Research Institute (NHGRI) NHGRI Goldin, Ehud (NHGRI) 0 114107159 Zheng, Wei National Human Genome Research Institute (NHGRI) NCATS Zheng, Wei (NCATS) 0 114107160 Patnaik, Samarjit National Human Genome Research Institute (NHGRI) NCATS Patnaik, Samarjit (NCATS) 0 114107161 Sidransky, Ellen National Human Genome Research Institute (NHGRI) NHGRI Sidransky, Ellen (NHGRI) 0 114107162 Motabar, Omid National Human Genome Research Institute (NHGRI) Motabar, Omid 0 114107163 Westbroek, Wendy National Human Genome Research Institute (NHGRI) Westbroek, Wendy 0 114101564 Glucocerebrosidase Activators As A Treatment For Gaucher Disease E-257-2010-0 Filing authorized National Human Genome Research Institute (NHGRI), NCATS - NCGC 93911356 Kalsi, Jasmine jasmine.kalsi@nih.gov
United States of America jasmine.kalsi@nih.gov?subject=Web Inquiry on [TAB-2252] Glucocerebrosidase Activators as a Treatment for Gaucher Disease&body=Please send me information about technology [TAB-2252] Glucocerebrosidase Activators as a Treatment for Gaucher Disease. Kalsi, Jasmine<br><a href="mailto:jasmine.kalsi@nih.gov?subject=Web Inquiry on [TAB-2252] Glucocerebrosidase Activators as a Treatment for Gaucher Disease&body=Please send me information about technology [TAB-2252] Glucocerebrosidase Activators as a Treatment for Gaucher Disease.">jasmine.kalsi@nih.gov</a><br> 114166409 E-257-2010-0 E-257-2010-0-US-01 Substituted Pyrazolopyrimidines As Glucocerebrosidase Activators PRV US 61/420,946 Abandoned US <br />Provisional (PRV) 61/420,946<br />Filed on 2010-12-08<br />Status: Abandoned 114166569 E-257-2010-0 E-257-2010-0-US-16 Substituted Pyrazolopyrimidines as Glucocerebrosidase Activators CON US 9,974,789 15/141,275 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9974789 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9974789">9,974,789</a><br />Filed on 2016-04-28<br />Status: Issued 114166589 E-257-2010-0 E-257-2010-0-PCT-02 Substituted Pyrazolopyrimidines as Glucocerebrosidase Activators PCT Patent Cooperation Treaty PCT/US2011/063928 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2011/063928<br />Filed on 2011-12-08<br />Status: Expired 114167139 E-257-2010-0 E-257-2010-0-US-08 Substituted Pyrazolopyrimidines As Glucocerebrosidase Activators National Stage US 9,353,117 13/991,816 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9353117 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9353117">9,353,117</a><br />Filed on 2013-08-28<br />Status: Issued 114168680 E-257-2010-0 E-257-2010-0-US-19 SUBSTITUTED PYRAZOLOPYRIMIDINES AS GLUCOCEREBROSIDASE ACTIVATORS DIV US 10,925,874 15/983,844 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10925874 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10925874">10,925,874</a><br />Filed on 2018-05-18<br />Status: Issued 114121984 IB6XXX 114121985 IA1AXX 114122344 IXXXXX 114122345 IBXXXX 114122346 IAXXXX 114122347 IA1XXX 114141384 GLUCOCEREBROSIDASE 114141385 ACTIVATORS 114141386 treatment 114141387 Gaucher 114141388 Disease TAB-1991 114096208 Truncated Methanocarba Adenosine Derivatives as A3 Adenosine Receptor Antagonists NIDDK Collaboration, Diagnostics, Immunology, Licensing, Research Materials, Therapeutics Collaboration Diagnostics Immunology Licensing Research Materials Therapeutics Kenneth Jacobson Novel A<sub>3</sub> adenosine antagonists available for licensing. A<sub>3</sub> receptors are particularly highly expressed in inflammatory cells, making it a potentially desirable target for inflammatory diseases. This technology relates to highly specific antagonists and partial agonists of A<sub>3</sub> adenosine receptors, which are negatively coupled to adenylate cyclase and have been broadly implicated in inflammation, cardiovascular disease, endocrine conditions and cancer. Further, A<sub>3</sub> adenosine receptors have been implicated in asthma and glaucoma. <ul> <li>There are four known subtypes of adenosine receptors (A<sub>1</sub>, A<sub>2A</sub>, A<sub>2B</sub>, and A<sub>3</sub>). All are positively or negatively linked to cAMP, but have different distributions and different therapeutic potentials. In particular, the use of A<sub>1</sub> and A<sub>2</sub> selective ligands has been limited by the ubiquity of expression of the receptors throughout the body and the resultant side effects. On the other hand, high levels of A<sub>3</sub> receptor expression are limited to the CNS, testes, and the immune system. Thus, A<sub>3</sub> receptors represent a potentially highly specific target for treating related diseases.</li> </ul> The NIDDK, Laboratory of Bioorganic Chemistry is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize A<sub>3</sub> adenosine receptor antagonists. Please contact Kenneth A. Jacobson, Ph.D. at <a href="mailto:kajacobs@helix.nih.gov">kajacobs@helix.nih.gov</a> or Marguerite Miller at <a href="mailto:Marguerite.Miller@nih.gov">Marguerite.Miller@nih.gov</a> for more information. Available for licensing. 2022-03-08 2025-04-15 2025-04-15 2009-07-29 A3, ADENOSINE, ANTAGONISTS, Derivatives, IB3XXX, IBXXXX, IXXXXX, N-Methanocarba, Patent Category - Chemistry, RECEPTOR, TRUNCATED False True True NIHTT 37470483 Website Abstract E-140-2008-1 114170884 Melman A, et al. Selective A3 adenosine receptor antagonists derived from nucleosides containing a bicyclo[3.1.0]hexane ring system. Bioorg Med Chem. 2008 Sep 15;16(18):8546-56. http://www.ncbi.nlm.nih.gov/pubmed/18752961 <a href="http://www.ncbi.nlm.nih.gov/pubmed/18752961">Melman A, et al. Selective A3 adenosine receptor antagonists derived from nucleosides containing a bicyclo[3.1.0]hexane ring system. Bioorg Med Chem. 2008 Sep 15;16(18):8546-56.</a> 114106701 Jacobson, Kenneth National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Jacobson, Kenneth (NIDDK) 1 114106701 Jacobson, Kenneth National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Jacobson, Kenneth (NIDDK) 1 114101274 Truncated (N)-Methanocarba Adenosine Derivatives As A3 Receptor Antagonists E-285-2008-0 Filing authorized National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83692066 Tong, Betty tongb@niddk.nih.gov
United States of America Senior Technology Advancement Office tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-1991] Truncated Methanocarba Adenosine Derivatives as A3 Adenosine Receptor Antagonists&body=Please send me information about technology [TAB-1991] Truncated Methanocarba Adenosine Derivatives as A3 Adenosine Receptor Antagonists. Tong, Betty<br><a href="mailto:tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-1991] Truncated Methanocarba Adenosine Derivatives as A3 Adenosine Receptor Antagonists&body=Please send me information about technology [TAB-1991] Truncated Methanocarba Adenosine Derivatives as A3 Adenosine Receptor Antagonists.">tongb@niddk.nih.gov</a><br> 114165404 E-285-2008-0 E-285-2008-0-US-01 A3 Adenosine Receptor Antagonists PRV US 61/085,588 Abandoned US <br />Provisional (PRV) 61/085,588<br />Filed on 2008-08-01<br />Status: Abandoned 114165428 E-285-2008-0 E-285-2008-0-PCT-02 Truncated (N)-Methanocarba Adenosine Derivatives As A3 Receptor Antagonists PCT Patent Cooperation Treaty PCT/US2009/52439 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2009/52439<br />Filed on 2009-07-31<br />Status: Expired 114166315 E-285-2008-0 E-285-2008-0-US-07 A3 Adenosine Receptor Antagonists And Partial Agonists National Stage US 8,796,291 13/056,997 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8796291 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8796291">8,796,291</a><br />Filed on 2011-03-18<br />Status: Abandoned 114120474 IXXXXX 114120475 IBXXXX 114120476 IB3XXX 114138357 TRUNCATED 114138358 N-Methanocarba 114138359 ADENOSINE 114138360 Derivatives 114138361 A3 114138362 RECEPTOR 114138363 ANTAGONISTS 114138364 Patent Category - Chemistry TAB-4848 152454370 Sidechain Functionalized S-Acylbenzamides With Anti-HIV Activity NIDDK Daniel Appella, Marco Robello <p>HIV infection remains a major medical problem, with approximately 38 million people worldwide living with HIV. Nipamovir and SAMT-247 are simple and inexpensive small molecules that inactivate HIV virus by interference with final maturation steps of the virus. This mechanism provides a high barrier for HIV to develop resistance. In fact, lab experiments designed to encourage HIV to develop resistance to Nipamovir and SAMT-247 have all failed. In animal tests, Nipamovir and SAMT-247 do not display toxic side effects. SAMT-247 is an effective microbicide that can be used to block HIV infection in animal models. Both Nipamovir and SAMT-247 are rapidly metabolized in blood where the sulfur of molecule is methylated, resulting in loss of antiviral activity. By attaching specific sidechains to the S-acylbenzamide scaffold of Nipamovir and SAMT-247, NIDDK investigators have developed new molecules that have improved anti-HIV activity and also are resistant to metabolism in blood.</p> National Institute of Diabetes and Digestive and Kidney Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize "Sidechain Functionalized S-Acylbenzamides With Anti-HIV Activity". For collaboration opportunities, please contact: Dr. Daniel H. Appella@appellad@niddk.nih.gov 2024-01-29 2024-05-06 2025-04-14 2024-02-01 2024-01-30 False False Preclinical /in vitro True 52406768 Discovery 52406768 37470483 Website Abstract E-127-2019-0 152454793 Appella, Daniel National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Appella, Daniel (NIDDK) 1 152454843 Robello, Marco National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Robello, Marco (NIDDK) 2 152454793 Appella, Daniel National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Appella, Daniel (NIDDK) 1 152454843 Robello, Marco National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Robello, Marco (NIDDK) 2 152454375 Sidechain Functionalized S-acylbenzamides With Anti-HIV Activity E-032-2023-0 Filing authorized National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83692066 Tong, Betty tongb@niddk.nih.gov
United States of America Senior Technology Advancement Office tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-4848] Sidechain Functionalized S-Acylbenzamides With Anti-HIV Activity&body=Please send me information about technology [TAB-4848] Sidechain Functionalized S-Acylbenzamides With Anti-HIV Activity. Tong, Betty<br><a href="mailto:tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-4848] Sidechain Functionalized S-Acylbenzamides With Anti-HIV Activity&body=Please send me information about technology [TAB-4848] Sidechain Functionalized S-Acylbenzamides With Anti-HIV Activity.">tongb@niddk.nih.gov</a><br> 152489955 E-032-2023-0 E-032-2023-0-PC-01 COMPOUNDS AND METHOD FOR TREATING HIV INFECTION PCT COMB Patent Cooperation Treaty PCT/US2023/085968 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2023/085968<br />Filed on 2023-12-27<br />Status: Expired 152489968 E-032-2023-0 E-032-2023-0-US-01 Sidechain Functionalized S-acylbenzamides With Anti-HIV Activity PRV US 63/437,868 Expired US <br />Provisional (PRV) 63/437,868<br />Filed on 2023-01-09<br />Status: Expired 161793080 E-032-2023-0 E-032-2023-0-US-02 COMPOUNDS AND METHOD FOR TREATING HIV INFECTION National Stage US 19/146,060 Pending US <br />National Stage 19/146,060<br />Filed on 2025-07-07<br />Status: Pending 161793110 E-032-2023-0 E-032-2023-0-EP-01 COMPOUNDS AND METHOD FOR TREATING HIV INFECTION National Stage European Patent 23853653.6 Pending European Patent <br />National Stage 23853653.6<br />Filed on 2025-07-28<br />Status: Pending TAB-3474 114097339 A Highly Efficient Differentiation Protocol for Placental Cells Derived from Human Pluripotent Stem Cells NCATS Cardiology, Dental, Endocrinology, Infectious Disease, Oncology, Ophthalmology, Research Equipment, Research Materials Cardiology Dental Endocrinology Infectious Disease Oncology Ophthalmology Research Equipment Research Materials Anton Simeonov, Ilyas Singec, Jaroslav Slamecka This technology includes a robust and highly efficient protocol that differentiates human pluripotent stem cells (hPSCs) into the developmental precursor of placental cells, the trophectoderm (TE), under chemically defined conditions. The in vitro generation of TE cells holds great promise for modeling diseases of the placenta, drug screening, and cell-based therapies. Derivation of definitive placental cells from human pluripotent stem cells in culture remains controversial and, so far, placental cells can only be derived directly from primary placental tissue, which largely limits their access and study in the laboratory. Systematic testing of various cell culture conditions and simultaneous manipulation of specific cell signaling pathways has led to the ability to directly induce TE development within 10 days. These cells expressed typical TE markers such as GA T A3, KR T7, and CDX2. This is the most efficient and most reproducible placental cell differentiation protocol from human pluripotent stem cells. The protocol included in this invention will permit increased in vitro use of placental cells for basic research, drug discovery, disease modeling, and cell therapy. 2022-08-01 2025-04-10 2025-04-10 2022-08-01 2022-02-08 Cells, DERIVED, DIFFERENTIATION, Efficient, Highly, Human, Placental, Pluripotent, PROTOCOL, Stem, VPXXXX, WIXXXX, XHXXXX False True True NIHTT 37470483 Website Abstract E-022-2018-0 E-060-2019-0 E-168-2019-0 114172630 Tristan CA, Ormanoglu P, et al. https://pubmed.ncbi.nlm.nih.gov/34861164/ <a href="https://pubmed.ncbi.nlm.nih.gov/34861164/">Tristan CA, Ormanoglu P, et al.</a> 114110304 Slamecka, Jaroslav NCATS - NCGC NCATS Slamecka, Jaroslav (NCATS) 0 114110305 Simeonov, Anton NCATS - NCGC NCATS Simeonov, Anton (NCATS) 0 114110303 Singec, Ilyas NCATS - NCGC NCATS Singec, Ilyas (NCATS) 1 114110303 Singec, Ilyas NCATS - NCGC NCATS Singec, Ilyas (NCATS) 1 114110304 Slamecka, Jaroslav NCATS - NCGC NCATS Slamecka, Jaroslav (NCATS) 0 114110305 Simeonov, Anton NCATS - NCGC NCATS Simeonov, Anton (NCATS) 0 114102589 A Highly Efficient Differentiation Protocol For Placental Cells Derived From Human Pluripotent Stem Cells E-169-2019-0 Filing authorized NCATS - NCGC 83727060 Gadhia, Ami ami.gadhia@nih.gov
United States of America NCGC ami.gadhia@nih.gov?subject=Web Inquiry on [TAB-3474] A Highly Efficient Differentiation Protocol for Placental Cells Derived from Human Pluripotent Stem Cells&body=Please send me information about technology [TAB-3474] A Highly Efficient Differentiation Protocol for Placental Cells Derived from Human Pluripotent Stem Cells. Gadhia, Ami<br><a href="mailto:ami.gadhia@nih.gov?subject=Web Inquiry on [TAB-3474] A Highly Efficient Differentiation Protocol for Placental Cells Derived from Human Pluripotent Stem Cells&body=Please send me information about technology [TAB-3474] A Highly Efficient Differentiation Protocol for Placental Cells Derived from Human Pluripotent Stem Cells.">ami.gadhia@nih.gov</a><br> 114169211 E-169-2019-0 E-169-2019-0-US-01 DIFFERENTATION OF TROPHECTODERM LINEAGE CELLS FROM PLURIPOTENT STEM CELLS PRV US 63/033,536 Abandoned US <br />Provisional (PRV) 63/033,536<br />Filed on 2020-06-02<br />Status: Abandoned 114169212 E-169-2019-0 E-169-2019-0-PCT-02 DIFFERENTIATION OF TROPHECTODERM LINEAGE CELLS FROM PLURIPOTENT STEM CELLS PCT Patent Cooperation Treaty PCT/US2021/035527 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/035527<br />Filed on 2021-06-02<br />Status: Expired 114128524 VPXXXX 114128525 WIXXXX 114128526 XHXXXX 114152440 Highly 114152441 Efficient 114152442 DIFFERENTIATION 114152443 PROTOCOL 114152444 Placental 114152445 Cells 114152446 DERIVED 114152447 Human 114152448 Pluripotent 114152449 Stem TAB-4849 152456870 Thyclotide Peptide Conjugates With Cell Permeability And Inhibitory Activity NIDDK Harsha Amarasekara, Daniel Appella, Victor Clausse, Hongchao Zheng <p>Thyclotides are oligomeric molecules with chiral tetrahydrofuran (THF) diamine units consisting of either R,R or<br /> S,S stereochemistry. Thyclotide sequences with R,R stereochemistry bind to complementary DNA and RNA<br /> sequences with strong affinity and sequence specificity, while thyclotides with S,S stereochemistry have a helical<br /> handedness that does not allow binding to DNA or RNA. Thyclotides are cell permeable and can be used to<br /> suppress microRNA activity in cells. Peptides are oligomeric molecules consisting of amino acids found in<br /> proteins as well as other non-natural amino acids. Peptides are often developed as inhibitors of enzymes and<br /> protein-protein interactions, yet peptides typically are poor drugs as they do not penetrate cell membranes<br /> therefore have low bioactivity. NIDDK investigators have discovered that thyclotides can be covalently<br /> conjugated to peptides that are enzyme inhibitors to enhance the cell permeability of the peptide. Using<br /> thyclotide to enhance peptide cell penetration is a novel way to help peptides gain entry into cells to improve<br /> their bioavailability. Using thyclotides+peptide conjugates may greatly expand the range of therapeutic<br /> applications of peptide inhibitors.</p> National Institute of Diabetes and Digestive and Kidney Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize "Thyclotide Peptide Conjugates With Cell Permeability And Inhibitory Activity" . For collaboration opportunities, please contact: Dr. Daniel H. Appella @appellad@niddk.nih.gov 2024-01-29 2024-03-12 2025-04-09 2024-02-01 False False Preclinical/ in vitro True 52406768 Discovery 52406768 37470483 Website Abstract E-108-2020-0 152456959 Appella, Daniel National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Appella, Daniel (NIDDK) 1 152456974 Zheng, Hongchao National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Zheng, Hongchao (NIDDK) 2 152456996 Clausse, Victor National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Clausse, Victor (NIDDK) 3 152457193 Amarasekara, Harsha National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Amarasekara, Harsha (NIDDK) 4 152456959 Appella, Daniel National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Appella, Daniel (NIDDK) 1 152456974 Zheng, Hongchao National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Zheng, Hongchao (NIDDK) 2 152456996 Clausse, Victor National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Clausse, Victor (NIDDK) 3 152457193 Amarasekara, Harsha National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Amarasekara, Harsha (NIDDK) 4 152456875 Thyclotide Peptide Conjugates With Cell Permeability And Inhibitory Activity E-033-2023-0 Filing authorized National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83692066 Tong, Betty tongb@niddk.nih.gov
United States of America Senior Technology Advancement Office tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-4849] Thyclotide Peptide Conjugates With Cell Permeability And Inhibitory Activity&body=Please send me information about technology [TAB-4849] Thyclotide Peptide Conjugates With Cell Permeability And Inhibitory Activity. Tong, Betty<br><a href="mailto:tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-4849] Thyclotide Peptide Conjugates With Cell Permeability And Inhibitory Activity&body=Please send me information about technology [TAB-4849] Thyclotide Peptide Conjugates With Cell Permeability And Inhibitory Activity.">tongb@niddk.nih.gov</a><br> 152489805 E-033-2023-0 E-033-2023-0-US-01 Thyclotide Peptide Conjugates With Cell Permeability And Inhibitory Activity PRV US 63/387,131 Expired US <br />Provisional (PRV) 63/387,131<br />Filed on 2022-12-13<br />Status: Expired 152489882 E-033-2023-0 E-033-2023-0-PC-01 Thyclotide Peptide Conjugates With Cell Permeability And Inhibitory Activity PCT Patent Cooperation Treaty PCT/US2023/082871 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2023/082871<br />Filed on 2023-12-07<br />Status: Expired 161724303 E-033-2023-0 E-033-2023-0-US-02 THYCLOTIDE PEPTIDE CONJUGATES WITH CELL PERMEABILITY AND INHIBITORY ACTIVITY National Stage US 19/136,698 Pending US <br />National Stage 19/136,698<br />Filed on 2025-06-06<br />Status: Pending 161724419 E-033-2023-0 E-033-2023-0-EP-01 THYCLOTIDE PEPTIDE CONJUGATES WITH CELL PERMEABILITY AND INHIBITORY ACTIVITY National Stage European Patent 23828316.2 Pending European Patent <br />National Stage 23828316.2<br />Filed on 2025-06-10<br />Status: Pending TAB-2427 114096629 Construct for Tetracycline Inducible Podocyte Specific Gene Expression in Mice NIDDK Diagnostics, Licensing, Research Materials, Therapeutics Diagnostics Licensing Research Materials Therapeutics Jeffrey Kopp The National Institutes of Health announces the generation of a construct by ligating 2.5kb human podocin promoter sequence to gene encoding reverse tetracycline-controlled transcriptional activator which enables tetracycline-inducible podocyte specific gene of interest expression with another construct consisting of tetracycline responsive element, minimal CMV promoter and gene of interest.<br /><br /> Podocytes are post-mitotic epithelial cells that are positioned on the exterior aspect of the glomerular capillary wall and contribute to the selective molecular permeability of glomeruli. Podocyte damage or dysfunction results in loss of the characteristic foot processes that normally interdigitate and form the selective permeability barriers composed of filtration slits bridged by slit diaphragms. Minimal damage causes proteinuria that in the case of minimal change disease can be reversed by steroid treatment. In focal segmental glomerulosclerosis, more severe loss of podocytes ultimately results in glomerulosclerosis. The podocyte-specific inducible transgene system can be used to identify factors that exacerbate or ameliorate podocyte injury, and can be used to express Cre-recombinase. <ul> <li>The podocyte-specific inducible transgene system can be used to identify factors that exacerbate or ameliorate podocyte injury, and can be used to express Cre-recombinase.</li> </ul> <ul> <li>This technology can be used for the study of renal disease.</li> </ul> Research Material — Patent protection has not been pursued for this technology. <br /><br /> [Note: The use of Tetracycline controllable expression systems is covered by a series of patents including US #5,464,758 and 5,814,618 which are proprietary to TET Systems GmbH & Co. KG. Interested parties are also advised to contact TET Systems, info@tetsystems.com or by electronic request at http://www.tetsystems.com/ip-licensing/licensing/for-profit-research/] 2022-03-08 2025-04-08 2025-04-08 2012-04-30 CONSTRUCT, Expression, Gene, IDXXXX, INDUCIBLE, IXXXXX, Mice, Podocyte, Specific, Tetracycline False True Pre-clinical True NIHTT 37470483 Website Abstract 114171572 Shigehara T, et al. http://www.ncbi.nlm.nih.gov/pubmed/12874453 <a href="http://www.ncbi.nlm.nih.gov/pubmed/12874453">Shigehara T, et al.</a> 114107538 Kopp, Jeffrey National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Kopp, Jeffrey (NIDDK) 1 114107538 Kopp, Jeffrey National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Kopp, Jeffrey (NIDDK) 1 114101729 Construct For Tetracycline Inducible Podocyte Specific Gene Expression In Mice E-299-2007-0 Research Material National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83698007 Rooke, Agnes rookeab@mail.nih.gov
United States of America Technology Advancement Office rookeab@mail.nih.gov?subject=Web Inquiry on [TAB-2427] Construct for Tetracycline Inducible Podocyte Specific Gene Expression in Mice&body=Please send me information about technology [TAB-2427] Construct for Tetracycline Inducible Podocyte Specific Gene Expression in Mice. Rooke, Agnes<br><a href="mailto:rookeab@mail.nih.gov?subject=Web Inquiry on [TAB-2427] Construct for Tetracycline Inducible Podocyte Specific Gene Expression in Mice&body=Please send me information about technology [TAB-2427] Construct for Tetracycline Inducible Podocyte Specific Gene Expression in Mice.">rookeab@mail.nih.gov</a><br> 114122755 IDXXXX 114122756 IXXXXX 114142955 CONSTRUCT 114142956 Tetracycline 114142957 INDUCIBLE 114142958 Podocyte 114142959 Specific 114142960 Gene 114142961 Expression 114142962 Mice TAB-2294 114096502 Conditionally Immortalized Human Podocyte Cell Lines NIDDK Diagnostics, Licensing, Research Materials, Therapeutics Diagnostics Licensing Research Materials Therapeutics Jeffrey Kopp, Toru Sakairi Podocytes, cells of the visceral epithelium in the kidneys, are a key component of the glomerular filtration barrier. Podocyte damage and loss contribute to the initiation of glomerular diseases. NIH investigators recently established long-term urinary cell cultures from two patients with focal segmental glomerulosclerosis and two healthy volunteers, via transformation with the thermosensitive SV40 large T antigen (U19tsA58) together with human telomerase (hTERT). Characterization of randomly selected clonal cell lines from each human subject showed mRNA expression for the podocyte markers synaptopodin, nestin, and CD2AP in all clones. Podocin mRNA was absent from all clones. The expression of nephrin, Wilms tumor 1 (WT1), and podocalyxin mRNA varied among the clones, which may be due to transformation and/or cloning. These novel human urine-derived podocyte-like epithelial cell lines (HUPECs) generated from urine of patients and healthy volunteers will be useful to study podocyte cell biology. These podocyte-like cells are unique and novel compared to the currently available podocyte cells because these are obtained from individuals with glomerular disease. <ul> <li>Model system for study of glomerular disorders.</li> <li>Useful tools to study podocyte biology.</li> </ul> Research Tool — Patent protection is not being pursued for this technology. 2022-03-08 2025-04-08 2025-04-08 2011-07-27 Cell, Conditionally, ESTABLISHED, Human, IDXXXX, immortalized, IXXXXX, Lines, Podocyte, RXXXXX, Urine False True <ul> <li>Early-stage</li> <li>Pre-clinical</li> <li>In vitro data available</li> </ul> True NIHTT 37470483 Website Abstract E-049-2007-0 E-287-2010-0 114171382 Sakairi T, et al. http://www.ncbi.nlm.nih.gov/pubmed/19955187 <a href="http://www.ncbi.nlm.nih.gov/pubmed/19955187">Sakairi T, et al.</a> 114107256 Sakairi, Toru National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Sakairi, Toru (NIDDK) 0 114107255 Kopp, Jeffrey National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Kopp, Jeffrey (NIDDK) 1 114107255 Kopp, Jeffrey National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Kopp, Jeffrey (NIDDK) 1 114107256 Sakairi, Toru National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Sakairi, Toru (NIDDK) 0 114101606 Conditionally Immortalized Human Podocyte Cell Lines Established From Urine E-252-2010-0 Research Material National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83698007 Rooke, Agnes rookeab@mail.nih.gov
United States of America Technology Advancement Office rookeab@mail.nih.gov?subject=Web Inquiry on [TAB-2294] Conditionally Immortalized Human Podocyte Cell Lines&body=Please send me information about technology [TAB-2294] Conditionally Immortalized Human Podocyte Cell Lines. Rooke, Agnes<br><a href="mailto:rookeab@mail.nih.gov?subject=Web Inquiry on [TAB-2294] Conditionally Immortalized Human Podocyte Cell Lines&body=Please send me information about technology [TAB-2294] Conditionally Immortalized Human Podocyte Cell Lines.">rookeab@mail.nih.gov</a><br> 114122180 RXXXXX 114122189 IXXXXX 114122190 IDXXXX 114141745 Conditionally 114141746 immortalized 114141747 Human 114141748 Podocyte 114141749 Cell 114141750 Lines 114141751 ESTABLISHED 114141752 Urine TAB-1023 114095353 Monoclonal Antibodies to HIV-1 Vpr NIDDK Diagnostics, Infectious Disease, Licensing, Research Materials, Therapeutics, Vaccines Diagnostics Infectious Disease Licensing Research Materials Therapeutics Vaccines Jeffrey Kopp, Terrence Phillips, Ulrich Schubert, Jonathan (Jon) Yewdell Available for licensing are monoclonal antibodies against HIV-1 viral protein R (Vpr) and the respective hybridoma cell lines expressing the same. The antibodies provide a means for detecting HIV-1 Vpr. Currently, the mechanism of HIV pathogenesis believed to involve viral replication inside immune cells and other cells. At present, there are no clinical assays for detecting HIV-1 Vpr. Vpr circulates at detectable levels in the blood and is likely derived from degraded virions or released from infected cells. Vpr facilitates viral replication and disrupt normal cell function. Thus measurement of Vpr levels in blood, extracellular fluid, and tissue may be of benefit in understanding the pathogenesis of HIV-1 infection and its myriad complications. <br><br> The hybridoma cell lines (9F12 and 10F2) were selected from a group of hybridoma cell lines. These antibodies can be used for detection, including immunoasssays (ELISA) and immunoaffinity-capillary electrophoresis. The amount of detected HIV-1 Vpr is compared to a standardized control sample for determining the progress of disease or the presence of known complications like neuropathy, dementia, metabolic syndrome, or nephropathy. 2022-03-08 2025-04-08 2025-04-08 2008-08-01 (4)r syndrome, Abdominal obesity metabolic syndrome, AC6XXX, ACCESSORY, ACXXXX, Antibody-based, AXXXXX, Biological, C syndrome, Chromosome 4 ring syndrome, Chromosome 6 ring syndrome, Chromosome 7 ring syndrome, DA4AXX, DA4XXX, DAXXXX, DB4AXX, DB4XXX, DBXXXX, DC5AXX, DC5XXX, DCXXXX, DDXXXX, Detection, DXXXXX, G syndrome, HIV-1, Hypertelorism with esophageal abnormality and hypospadias, Metabolic syndrome X, Methodologies, monoclonal, N syndrome, Protein, QUANTIFICATION, R(6) syndrome, R(7) syndrome, SAMPLES, Syndrome X, VPR, W syndrome, W syndrome; Syndrome W False True True NIHTT 37470483 Website Abstract 114106230 Schubert, Ulrich NIAID - DIR NIAID Schubert, Ulrich (NIAID) 0 114106231 Phillips, Terrence Phillips, Terrence 0 114106232 Yewdell, Jonathan (Jon) NIAID - DIR NIAID Yewdell, Jonathan (Jon) (NIAID) 0 114104927 Kopp, Jeffrey National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Kopp, Jeffrey (NIDDK) 1 114104927 Kopp, Jeffrey National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Kopp, Jeffrey (NIDDK) 1 114106230 Schubert, Ulrich NIAID - DIR NIAID Schubert, Ulrich (NIAID) 0 114106231 Phillips, Terrence Phillips, Terrence 0 114106232 Yewdell, Jonathan (Jon) NIAID - DIR NIAID Yewdell, Jonathan (Jon) (NIAID) 0 114100237 Monoclonal Antibody-based Methodologies For The Detection And Quantification Of The HIV-1 Accessory Protein Vpr In Biological Samples E-141-2003-0 Filing authorized National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIAID, NIBIB 83698007 Rooke, Agnes rookeab@mail.nih.gov
United States of America Technology Advancement Office rookeab@mail.nih.gov?subject=Web Inquiry on [TAB-1023] Monoclonal Antibodies to HIV-1 Vpr&body=Please send me information about technology [TAB-1023] Monoclonal Antibodies to HIV-1 Vpr. Rooke, Agnes<br><a href="mailto:rookeab@mail.nih.gov?subject=Web Inquiry on [TAB-1023] Monoclonal Antibodies to HIV-1 Vpr&body=Please send me information about technology [TAB-1023] Monoclonal Antibodies to HIV-1 Vpr.">rookeab@mail.nih.gov</a><br> 114164246 E-141-2003-0 E-141-2003-0-US-03 Monoclonal Antibodies to HIV-1 and Methods of Using Same National Stage US 7,993,647 11/630,880 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7993647 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7993647">7,993,647</a><br />Filed on 2008-01-10<br />Status: Expired 114115735 DDXXXX 114115736 DXXXXX 114119007 AC6XXX 114119008 DA4AXX 114119009 DC5AXX 114119010 DB4AXX 114119011 AXXXXX 114119012 ACXXXX 114119013 DAXXXX 114119014 DA4XXX 114119015 DBXXXX 114119016 DB4XXX 114119017 DCXXXX 114119018 DC5XXX 114132007 monoclonal 114132008 Antibody-based 114132009 Methodologies 114132010 Detection 114132011 QUANTIFICATION 114132012 HIV-1 114132013 ACCESSORY 114132014 Protein 114132015 VPR 114132016 Biological 114132017 SAMPLES 114155829 Syndrome X 114155830 C syndrome 114155831 Chromosome 7 ring syndrome 114155832 W syndrome 114155833 Hypertelorism with esophageal abnormality and hypospadias 114155834 N syndrome 114155835 Abdominal obesity metabolic syndrome 114155836 Chromosome 6 ring syndrome 114155837 Chromosome 4 ring syndrome 114157997 R(7) syndrome 114157998 W syndrome; Syndrome W 114157999 G syndrome 114158000 Metabolic syndrome X 114158001 R(6) syndrome 114158002 (4)r syndrome TAB-3742 114097594 Polyclonal Antibodies to Apolipoprotein L1 for Use in Basic Science Research NIDDK Antibodies, Cardiology, Dental, Endocrinology, Immunology, Infectious Disease, Oncology, Ophthalmology, Research Materials Antibodies Cardiology Dental Endocrinology Immunology Infectious Disease Oncology Ophthalmology Research Materials Patrick Dummer, Jeffrey Kopp, Trairak Pisitkun This technology includes antibodies to apolipoprotein L1 (ApoL 1) to be used in basic science laboratory studies. ApoL 1 is a protein that is present within cells and circulates as component of high-density lipoprotein. Its functions are not well understood. Recently APOL 1 genetic variants have been shown to be highly associated with kidney disease in African Americans. <ul> <li>K5 antibody: peptide in N terminal portion is unique in that there are no commercially available ApoL 1 N terminal antibodies with an epitope that does not overlap the signaling peptide.</li> <li>K9 antibody: peptide in C terminal portion is peptide selected is unique in that it that does not overlap the ApoL 1 kidney-disease risk mutations.</li> </ul> Utilization in basic science laboratory work: Immunostaining of cells or tissue, Western blotting, immunoprecipitation, possibly a capture ELISA. 2022-11-30 2025-04-08 2025-04-08 2022-11-30 2022-07-11 antibodies, APOLIPOPROTEIN, L1, Listed LPM Vepa as of 4/15/2015, polyclonal, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, RXXXXX, VPXXXX, WIXXXX, XAXXXX False True True NIHTT 37470483 Website Abstract 114111451 Dummer, Patrick National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Dummer, Patrick 0 114111452 Pisitkun, Trairak National Heart, Lung, and Blood Institute (NHLBI) NHLBI Pisitkun, Trairak (NHLBI) 0 114111450 Kopp, Jeffrey National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Kopp, Jeffrey (NIDDK) 1 114111450 Kopp, Jeffrey National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Kopp, Jeffrey (NIDDK) 1 114111451 Dummer, Patrick National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Dummer, Patrick 0 114111452 Pisitkun, Trairak National Heart, Lung, and Blood Institute (NHLBI) NHLBI Pisitkun, Trairak (NHLBI) 0 114102846 Polyclonal Antibodies To Apolipoprotein L1 E-099-2012-0 Research Material National Heart, Lung, and Blood Institute (NHLBI), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83698007 Rooke, Agnes rookeab@mail.nih.gov
United States of America Technology Advancement Office rookeab@mail.nih.gov?subject=Web Inquiry on [TAB-3742] Polyclonal Antibodies to Apolipoprotein L1 for Use in Basic Science Research&body=Please send me information about technology [TAB-3742] Polyclonal Antibodies to Apolipoprotein L1 for Use in Basic Science Research. Rooke, Agnes<br><a href="mailto:rookeab@mail.nih.gov?subject=Web Inquiry on [TAB-3742] Polyclonal Antibodies to Apolipoprotein L1 for Use in Basic Science Research&body=Please send me information about technology [TAB-3742] Polyclonal Antibodies to Apolipoprotein L1 for Use in Basic Science Research.">rookeab@mail.nih.gov</a><br> 114129460 RXXXXX 114129461 VPXXXX 114129462 WIXXXX 114129463 XAXXXX 114154968 polyclonal 114154969 antibodies 114154970 APOLIPOPROTEIN 114154971 L1 114154972 Listed LPM Vepa as of 4/15/2015 114154973 Pre LPM working set 20150418 114154974 Post LPM Assignment Set 20150420 TAB-3739 114097591 Podocin Promoter, Reverse Tetracycline Transactivator Mice for Studying Podocyte Injury NIDDK Cardiology, Dental, Endocrinology, Infectious Disease, Oncology, Ophthalmology, Research Materials, Therapeutics Cardiology Dental Endocrinology Infectious Disease Oncology Ophthalmology Research Materials Therapeutics Jeffrey Kopp This technology includes mice which are intended to be bred with mice that have the tetracycline-response element promoter driving a gene of interest, for the study of kidney diseases. When the dual transgenic mice are fed tetracycline or doxycycline, the transgene is activated in glomerular podocytes. This approach provides podocyte-specific transgene expression. To study podocyte injury and repair in vivo. 2022-11-30 2024-10-28 2025-04-08 2022-11-30 2022-07-10 Listed LPM Contreras as of 4/15/2015, Mice, Podocin, Podocyte, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, PROMOTER, Reverse, Tetracycline, TRANSACTIVATOR, VPXXXX, WIXXXX, XEXXXX False True True NIHTT 37470483 Website Abstract 114111445 Kopp, Jeffrey National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Kopp, Jeffrey (NIDDK) 1 114111445 Kopp, Jeffrey National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Kopp, Jeffrey (NIDDK) 1 114102843 Podocin Promoter, Reverse Tetracycline Transactivator Mice E-085-2014-0 Research Material National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83698007 Rooke, Agnes rookeab@mail.nih.gov
United States of America Technology Advancement Office rookeab@mail.nih.gov?subject=Web Inquiry on [TAB-3739] Podocin Promoter, Reverse Tetracycline Transactivator Mice for Studying Podocyte Injury&body=Please send me information about technology [TAB-3739] Podocin Promoter, Reverse Tetracycline Transactivator Mice for Studying Podocyte Injury. Rooke, Agnes<br><a href="mailto:rookeab@mail.nih.gov?subject=Web Inquiry on [TAB-3739] Podocin Promoter, Reverse Tetracycline Transactivator Mice for Studying Podocyte Injury&body=Please send me information about technology [TAB-3739] Podocin Promoter, Reverse Tetracycline Transactivator Mice for Studying Podocyte Injury.">rookeab@mail.nih.gov</a><br> 114129452 VPXXXX 114129453 WIXXXX 114129454 XEXXXX 114154946 Podocin 114154947 PROMOTER 114154948 Reverse 114154949 Tetracycline 114154950 TRANSACTIVATOR 114154951 Mice 114154952 Podocyte 114154953 Listed LPM Contreras as of 4/15/2015 114154954 Pre LPM working set 20150418 114154955 Post LPM Assignment Set 20150420 TAB-2436 114096637 Java Applet for Modeling Human Metabolism and Energy Expenditure for Adaptive Dieting and Exercise Regimens NIDDK Diagnostics, Licensing, Research Materials, Therapeutics Diagnostics Licensing Research Materials Therapeutics Dhruva Chandramohan, Carson Chou, Kevin Hall Known methods for predicting weight loss fail to account for slowing of metabolism as weight is lost and therefore overestimate the degree of weight loss. While this limitation of the 3500 Calorie per pound rule has been known for some time, it was not clear how to dynamically account for the metabolic slowing. The invention provides a Java applet for modeling of human metabolism to improve the weight change predictions. The model has been validated using previously published human data and the model equations have been published. A web-based implementation of the published dynamic model has been created to allow users to perform simulations for planning weight loss interventions in adults and accounts for individual differences in metabolism and body composition. Values to the user include being able to see whether the target weight loss is realistic when the necessary caloric restriction, exercise and timeframe components are highlighted. Unrealistic goals become apparent. More moderate goals may result in greater long term success. The model also defines the caloric intake to be followed once the new weight target has been met to prevent weight being regained.<br /><br /> The Body Weight Planner webpage is available at <a href="http://www.niddk.nih.gov/health-information/weight-management/body-weight-planner" target="_blank" title="Body Weight Planner webpage">http://www.niddk.nih.gov/health-information/weight-management/body-weight-planner</a>. Personalized predictions <ul> <li>Obesity</li> <li>Weight Loss</li> </ul> Research Tool — Patent protection is not being pursued for this technology. 2022-03-08 2025-04-08 2025-04-08 2012-05-15 AC2XXX, ACXXXX, AD1XXX, Adaptions, Adn, Adult, ADXXXX, AXXXXX, Body, CHANGES, Dieting, During, Energy, EXERCISE, Expenditure, Fat, Human, ID2XXX, IDXXXX, IXXXXX, Mathematical, Metabolism, Model, PREDICTS, Simulates, That, Weight False True Prototype True NIHTT 37470483 Website Abstract E-063-2012-0 114171781 Hall KD, et al. http://www.ncbi.nlm.nih.gov/pubmed/21872751 <a href="http://www.ncbi.nlm.nih.gov/pubmed/21872751">Hall KD, et al.</a> 114171782 “NIH research model predicts weight with varying diet, exercise changes” http://www.nih.gov/news/health/aug2011/niddk-25.htm <a href="http://www.nih.gov/news/health/aug2011/niddk-25.htm">“NIH research model predicts weight with varying diet, exercise changes”</a> 114171783 "Biggest Loser" study finds modest diet and exercise can sustain weight loss” http://www.nih.gov/news/health/oct2012/niddk-15.htm <a href="http://www.nih.gov/news/health/oct2012/niddk-15.htm">"Biggest Loser" study finds modest diet and exercise can sustain weight loss”</a> 114107550 Chandramohan, Dhruva Chandramohan, Dhruva 0 114107552 Chou, Carson National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Chou, Carson (NIDDK) 0 114104489 Hall, Kevin National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Hall, Kevin (NIDDK) 1 114104489 Hall, Kevin National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Hall, Kevin (NIDDK) 1 114107550 Chandramohan, Dhruva Chandramohan, Dhruva 0 114107552 Chou, Carson National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Chou, Carson (NIDDK) 0 114101739 Mathematical Model For Adult Human Metabolism That Simulates Energy Expenditure Adaptions During Dieting And Exercise Adn Predicts Body Weight Fat Changes E-160-2012-0 Research Material National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83739611 Yonter, Ediz ediz.yonter@nih.gov
United States of America Technology Advancement Office ediz.yonter@nih.gov?subject=Web Inquiry on [TAB-2436] Java Applet for Modeling Human Metabolism and Energy Expenditure for Adaptive Dieting and Exercise Regimens&body=Please send me information about technology [TAB-2436] Java Applet for Modeling Human Metabolism and Energy Expenditure for Adaptive Dieting and Exercise Regimens. Yonter, Ediz<br><a href="mailto:ediz.yonter@nih.gov?subject=Web Inquiry on [TAB-2436] Java Applet for Modeling Human Metabolism and Energy Expenditure for Adaptive Dieting and Exercise Regimens&body=Please send me information about technology [TAB-2436] Java Applet for Modeling Human Metabolism and Energy Expenditure for Adaptive Dieting and Exercise Regimens.">ediz.yonter@nih.gov</a><br> 114122783 AC2XXX 114122784 AD1XXX 114122785 ID2XXX 114122786 AXXXXX 114122787 ACXXXX 114122788 ADXXXX 114122789 IXXXXX 114122790 IDXXXX 114143040 Mathematical 114143041 Model 114143042 Adult 114143043 Human 114143044 Metabolism 114143045 That 114143046 Simulates 114143047 Energy 114143048 Expenditure 114143049 Adaptions 114143050 During 114143051 Dieting 114143052 EXERCISE 114143053 Adn 114143054 PREDICTS 114143055 Body 114143056 Weight 114143057 Fat 114143058 CHANGES TAB-3566 114097421 Deuterated alpha5 Subunit-selective Negative Allosteric Modulators of Gamma-Aminobutyric Acid Type A Receptors as Fast Acting Treatments for Depression and Mood Disorders NCATS Neurology, Therapeutics Neurology Therapeutics Patrick Morris, Craig Thomas, Scott Thompson, Adam Van Dyke This technology includes GABAa a5 Negative Allosteric modulators (GABAa a5 NAMs) which have been recently discovered to act as fast-acting antidepressants in a variety of mouse models of depression. These NAMs are actively metabolized in vivo. This invention involves the conceptualization and synthesis of GABAa a5 NAM molecules with a deuterium in the active metabolic position. This significantly increased the metabolic stability, while still retaining the antidepressant activity. These molecules have similar activity as GABAa a5 NAMs to the current molecules in clinical trials, while having significantly improved metabolic stability, and likely longer half lives in vivo. Treatment for depression or other neurological disorders. 2022-08-12 2024-10-28 2025-04-04 2022-08-01 2022-05-06 Acid, ACTING, ALLOSTERIC, Alpha5, depression, Deuterated, DISORDERS, fast, Gamma-Aminobutyric, MODULATORS, MOOD, NEGATIVE, RECEPTORS, Subunit-selective, TREATMENTS, TYPE, VEXXXX, WKXXXX False True True NIHTT 37470483 Website Abstract 114110821 Van Dyke, Adam University of Maryland, School of Medicine Van Dyke, Adam 0 114110822 Thomas, Craig NCATS - NCGC NCATS Thomas, Craig (NCATS) 0 114110823 Morris, Patrick NCATS - NCGC NCATS Morris, Patrick (NCATS) 0 114110820 Thompson, Scott University of Maryland, Baltimore Thompson, Scott 1 114110820 Thompson, Scott University of Maryland, Baltimore Thompson, Scott 1 114110821 Van Dyke, Adam University of Maryland, School of Medicine Van Dyke, Adam 0 114110822 Thomas, Craig NCATS - NCGC NCATS Thomas, Craig (NCATS) 0 114110823 Morris, Patrick NCATS - NCGC NCATS Morris, Patrick (NCATS) 0 114102675 Deuterated Alpha5 Subunit-selective Negative Allosteric Modulators Of Gamma-Aminobutyric Acid Type A Receptors As Fast Acting Treatments For Depression And Mood Disorders E-232-2017-0 Filing authorized NCATS - NCGC, University of Maryland 83727060 Gadhia, Ami ami.gadhia@nih.gov
United States of America NCGC ami.gadhia@nih.gov?subject=Web Inquiry on [TAB-3566] Deuterated alpha5 Subunit-selective Negative Allosteric Modulators of Gamma-Aminobutyric Acid Type A Receptors as Fast Acting Treatments for Depression and Mood Disorders&body=Please send me information about technology [TAB-3566] Deuterated alpha5 Subunit-selective Negative Allosteric Modulators of Gamma-Aminobutyric Acid Type A Receptors as Fast Acting Treatments for Depression and Mood Disorders. Gadhia, Ami<br><a href="mailto:ami.gadhia@nih.gov?subject=Web Inquiry on [TAB-3566] Deuterated alpha5 Subunit-selective Negative Allosteric Modulators of Gamma-Aminobutyric Acid Type A Receptors as Fast Acting Treatments for Depression and Mood Disorders&body=Please send me information about technology [TAB-3566] Deuterated alpha5 Subunit-selective Negative Allosteric Modulators of Gamma-Aminobutyric Acid Type A Receptors as Fast Acting Treatments for Depression and Mood Disorders.">ami.gadhia@nih.gov</a><br> 114169399 E-232-2017-0 E-232-2017-0-US-01 Deuterated Alpha5 Subunit-selective Negative Allosteric Modulators Of Gamma-Aminobutyric Acid Type A Receptors As Fast Acting Treatments For Depression And Mood Disorders PRV US 62/550,826 Abandoned US <br />Provisional (PRV) 62/550,826<br />Filed on 2017-08-28<br />Status: Abandoned 114169400 E-232-2017-0 E-232-2017-0-PCT-02 Deuterated Alpha5 Subunit-selective Negative Allosteric Modulators Of Gamma-Aminobutyric Acid Type A Receptors As Fast Acting Treatments For Depression And Mood Disorders PCT Patent Cooperation Treaty PCT/US2018/048339 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2018/048339<br />Filed on 2018-08-28<br />Status: Expired 114169401 E-232-2017-0 E-232-2017-0-US-03 Deuterated Alpha5 Subunit-selective Negative Allosteric Modulators Of Gamma-Aminobutyric Acid Type A Receptors As Fast Acting Treatments For Depression And Mood Disorders National Stage US 11,459,320 16/642,445 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11459320 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11459320">11,459,320</a><br />Filed on 2018-08-28<br />Status: Issued 114169637 E-232-2017-0 E-232-2017-0-US-14 Deuterated Alpha5 Subunit-selective Negative Allosteric Modulators Of Gamma-Aminobutyric Acid Type A Receptors As Fast Acting Treatments For Depression And Mood Disorders DIV US 11,897,875 17/883,734 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11897875 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11897875">11,897,875</a><br />Filed on 2022-08-09<br />Status: Issued 114128768 VEXXXX 114128769 WKXXXX 114153229 Deuterated 114153230 Alpha5 114153231 Subunit-selective 114153232 NEGATIVE 114153233 ALLOSTERIC 114153234 MODULATORS 114153235 Gamma-Aminobutyric 114153236 Acid 114153237 TYPE 114153238 RECEPTORS 114153239 fast 114153240 ACTING 114153241 TREATMENTS 114153242 depression 114153243 MOOD 114153244 DISORDERS TAB-4519 151719095 3D Bioprinting of Cardiac Patch with Anisotropic and Perfusable Architecture for the Repair of Damaged Cardiac Muscle NHLBI Cardiology, Licensing, Medical Devices, Research Equipment, Research Materials Cardiology Licensing Medical Devices Research Equipment Research Materials Haitao Cui, Yimin Huang, Lijie Zhang <p>This technology includes a novel cardiac patch which was 3D printed to repair damaged cardiac tissue. Based on biological and anatomical understanding of myocardial tissue, a novel 3D bioprinting technique was developed to directly fabricate the cellularized and vascularized cardiac patch with anisotropic fiber and perfusable vessel architecture. The design will integrate biomimetic aligned myocardial fibers and perfusable blood vessels to create a thick, functional cardiac patch, suitable for the human heart implantation. Due to the anisotropic contraction properties, it not only provides a physical support to prevent the dilation of heart wall, but also improve the cardiac tissue regeneration.</p> Current therapeutics, including autografts, allografts, xenografts, and artificial prostheses, have several disadvantages including: donor tissue shortage, immune rejection, anticoagulation therapy, and limited durability; 3D bioprinting is one of the most feasible techniques for creating complicated implants with macro/micro features. To provide the fabricating service of 3D bioprinting vascularized cardiac patch scaffold. We are seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. 2023-12-08 2024-08-12 2025-02-18 2024-03-27 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 151719103 Zhang, Lijie George Washington University Medical Center (GWU) Zhang, Lijie 1 151719112 Cui, Haitao George Washington University Medical Center (GWU) Cui, Haitao 2 151719120 Huang, Yimin Capital Medical University Huang, Yimin 3 151719103 Zhang, Lijie George Washington University Medical Center (GWU) Zhang, Lijie 1 151719112 Cui, Haitao George Washington University Medical Center (GWU) Cui, Haitao 2 151719120 Huang, Yimin Capital Medical University Huang, Yimin 3 151719098 3D Bioprinting Of Cardiac Patch With Anisotropic And Perfusable Architecture E-183-2018-0 Filing authorized George Washington University, National Heart, Lung, and Blood Institute (NHLBI) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-4519] 3D Bioprinting of Cardiac Patch with Anisotropic and Perfusable Architecture for the Repair of Damaged Cardiac Muscle&body=Please send me information about technology [TAB-4519] 3D Bioprinting of Cardiac Patch with Anisotropic and Perfusable Architecture for the Repair of Damaged Cardiac Muscle. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-4519] 3D Bioprinting of Cardiac Patch with Anisotropic and Perfusable Architecture for the Repair of Damaged Cardiac Muscle&body=Please send me information about technology [TAB-4519] 3D Bioprinting of Cardiac Patch with Anisotropic and Perfusable Architecture for the Repair of Damaged Cardiac Muscle.">shmilovm@nih.gov</a><br> 157755558 E-183-2018-0 E-183-2018-0-US-01 3D Bioprinting Of Cardiac Patch With Anisotropic And Perfusable Architecture PRV US 62/571,684 Abandoned US <br />Provisional (PRV) 62/571,684<br />Filed on 2017-10-12<br />Status: Abandoned 157755563 E-183-2018-0 E-183-2018-0-PCT-02 3D Bioprinting Of Cardiac Patch With Anisotropic And Perfusable Architecture PCT Patent Cooperation Treaty PCT/US2018/055707 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2018/055707<br />Filed on 2018-10-12<br />Status: Expired 157755568 E-183-2018-0 E-183-2018-0-US-03 3D Bioprinting Of Cardiac Patch With Anisotropic And Perfusable Architecture National Stage US 12,029,832 16/845,329 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12029832 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12029832">12,029,832</a><br />Filed on 2020-04-10<br />Status: Issued TAB-4463 147340165 Apparatus for Cryogenic-Electron Microscopy Sample Preparation NIEHS Collaboration, Licensing, Non-Medical Devices, Research Equipment Collaboration Licensing Non-Medical Devices Research Equipment Mario Borgnia, Venkata Dandey, Tony Huang, Wyatt Peele, Kaichun Yang <p>Cryo-Electron Microscopy (cryo-EM) is used to obtain high-resolution structural images of macromolecular structures. Samples must be purified and loaded onto cryo-EM grids before imaging. The ideal cryo-EM grid consists of particles that are evenly and richly distributed in a broad distribution of orientations throughout the holes of the support film. Current techniques to prepare cryo-EM grids are performed manually and require trial and error, resulting in a bottleneck in cryo-EM workflows.</p> <p>Researchers from NIEHS developed a device and method for time-resolved preparation of liquid samples for cryo-EM experiments. In particular, the mixing and dispensation of liquid samples is achieved by electrical signals that are transduced into specific acoustic frequencies to mix the liquid samples (low frequency) and then dispense the mixture (high frequency) in small, nanoliter volumes onto a cryo-EM grid. This novel apparatus and method provides more precise control over liquid sample mixing and dispensing, and improved dispensation of the mixture onto the EM grid. Also, the improved quality of captured images of homogeneous macromolecular structures is achieved due to a uniformly mixed and dispensed sample on the EM grid. This allows electrons to be transmitted through the very thin liquid film in the holes of the cryo-EM grid to form an image.</p> <ul> <li>Automated workflow eliminates the guesswork out of cryo-EM sample preparation.</li> <li>Increases sample prep success rate and decreases the need to screen repeated trials.</li> <li>Using acoustic-based, multiple-sample mixing enables homogeneous mixing and facilitates the observation of transient molecular interactions with high time resolution.</li> <li>Python code is available for command and control of a robot that manipulates the cryo-EM grid.</li> </ul> <ul> <li>Automation of cryo-EM experiments aimed at structure-based drug design by examining macromolecular structure and its interactions with ligands</li> <li>Kits with hardware and software components to setup robotic automation of cryo-EM sample preparation, dispensation, plunging and storage</li> </ul> The NIEHS is seeking statements of capability or interest from parties interested in collaborative research to improve the prototype for commercialization. For collaboration opportunities, please contact Sharon Soucek, Ph.D. at sharon.soucek@nih.gov. 2023-08-15 2025-01-22 2025-01-22 2023-09-01 False True Prototype True 52406769 Prototype 52406769 37470483 Website Abstract 147340787 Dandey, Venkata NIH - NIEHS Dandey, Venkata 1 147340993 Borgnia, Mario NIEHS NIEHS Borgnia, Mario (NIEHS) 2 147341109 Peele, Wyatt NIH - NIEHS Peele, Wyatt 3 147341148 Huang, Tony Duke University Huang, Tony 4 147345255 Yang, Kaichun Duke University Yang, Kaichun 5 147340787 Dandey, Venkata NIH - NIEHS Dandey, Venkata 1 147340993 Borgnia, Mario NIEHS NIEHS Borgnia, Mario (NIEHS) 2 147341109 Peele, Wyatt NIH - NIEHS Peele, Wyatt 3 147341148 Huang, Tony Duke University Huang, Tony 4 147345255 Yang, Kaichun Duke University Yang, Kaichun 5 147340169 Apparatus and methods for time-resolved preparation of samples for Cryo-EM using acoustics E-184-2023-0 Filing authorized Duke University, NIEHS, NIEHS 83739538 Choudhry, Vidita vidita.choudhry@nih.gov
United States of America Office of Technology Transfer and Development vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-4463] Apparatus for Cryogenic-Electron Microscopy Sample Preparation&body=Please send me information about technology [TAB-4463] Apparatus for Cryogenic-Electron Microscopy Sample Preparation. Choudhry, Vidita<br><a href="mailto:vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-4463] Apparatus for Cryogenic-Electron Microscopy Sample Preparation&body=Please send me information about technology [TAB-4463] Apparatus for Cryogenic-Electron Microscopy Sample Preparation.">vidita.choudhry@nih.gov</a><br> TAB-3798 114097648 KCNN4 Knockout Mice for Mechanistic Research NIDCR Cardiology, Dental, Endocrinology, Infectious Disease, Oncology, Ophthalmology, Research Materials, Therapeutics Cardiology Dental Endocrinology Infectious Disease Oncology Ophthalmology Research Materials Therapeutics James Melvin <p>This technology includes a transgenic allele for a mouse knockout model for the KCNN4 gene. Secretion of fluids from these salivary glands requires the coordination of multiple water and ion channel proteins. Notably, the majority of these channels have been shown to be up-regulated by increased calcium concentrations. The relevant calcium-activated potassium channels are split into the small, intermediate, and large conductance channels (called the SK, IK, and BK channels). The KCNN4 gene plays a part in the IK and BK channels. The mouse knockout model described in this technology is the only model for the KCNN4 gene.&nbsp;The animal is only available from JAX (<a href="https://www.jax.org/strain/018826" target="_blank">https://www.jax.org/strain/018826</a>).</p> This is the only mouse knockout model for the KCNN4 gene. Research to study the role of IK and BK channels in the fluid-secreting acinar cells of the parotid gland. Animal model is available for non-exclusive licensing 2022-11-30 2024-12-31 2024-12-31 2022-11-30 2022-08-03 KCNN4, Knockout, Listed LPM Nguyen-Antczak as of 4/15/2015, Mice, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, RXXXXX, VPXXXX, WIXXXX, XEXXXX False True True NIHTT 37470483 Website Abstract 114172957 Begenisich T, Nakamoto T, et al. https://pubmed.ncbi.nlm.nih.gov/15347667/ <a href="https://pubmed.ncbi.nlm.nih.gov/15347667/">Begenisich T, Nakamoto T, et al.</a> 114111598 Melvin, James NIDCR NIDCR Melvin, James (NIDCR) 1 114111598 Melvin, James NIDCR NIDCR Melvin, James (NIDCR) 1 114102900 KCNN4 Knockout Mice E-179-2012-0 Research Material NIDCR 83656052 Knezevic, Vladimir vlado.knezevic@nih.gov
United States of America Technology Advancement Office vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-3798] KCNN4 Knockout Mice for Mechanistic Research&body=Please send me information about technology [TAB-3798] KCNN4 Knockout Mice for Mechanistic Research. Knezevic, Vladimir<br><a href="mailto:vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-3798] KCNN4 Knockout Mice for Mechanistic Research&body=Please send me information about technology [TAB-3798] KCNN4 Knockout Mice for Mechanistic Research.">vlado.knezevic@nih.gov</a><br> 114129642 RXXXXX 114129643 VPXXXX 114129644 WIXXXX 114129645 XEXXXX 114155519 KCNN4 114155520 Knockout 114155521 Mice 114155522 Listed LPM Nguyen-Antczak as of 4/15/2015 114155523 Pre LPM working set 20150418 114155524 Post LPM Assignment Set 20150420 TAB-3266 114097201 Potential New Drugs for Treating or Preventing Pruritus NIDCR Cardiology, Consumer Products, Dental, Endocrinology, Infectious Disease, Oncology, Ophthalmology, Reproductive Health, Research Equipment, Therapeutics, Vaccines Cardiology Consumer Products Dental Endocrinology Infectious Disease Oncology Ophthalmology Reproductive Health Research Equipment Therapeutics Vaccines Patricia Dranchak, Mark Hoon, James Inglese, Hans Solinski NIH scientists have identified new compositions that could potentially be used to treat or prevent pruritus (itchiness). The newly discovered compounds can block a newly identified itch pathway and might be effective for persistent itch caused by psoriasis, atopic dermatitis, renal failure, liver cirrhosis and chemotherapy. These compounds are different from commonly used antihistamines which induce drowsiness and sedation. These compounds have the potential to be used for human and animals. <ul> <li>A new category of drug for pruritus treatment.</li> <li>Various screening tests used to minimize potential side effects.</li> </ul> <ul> <li>Therapeutics for preventing or treating pruritus/itching.</li> </ul> Technology is available for non-exclusive or exclusive licensing 2022-03-08 2024-12-31 2024-12-31 2018-05-28 BLOCKAGE, IB6XXX, Itch, Listed LPM Vepa as of 4/15/2015, Nppb, Npr1, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, RECEPTOR, Sensation, TRANSMITTER, treatment, VOXXXX, VPXXXX, WKXXXX, XHXXXX, YAXXXX, YBXXXX, YCXXXX False True True 52406768 Discovery 52406768 NIHTT 37470483 Website Abstract 114172480 Mishra SK, Hoon MA. https://www.ncbi.nlm.nih.gov/pubmed/19853036 <a href="https://www.ncbi.nlm.nih.gov/pubmed/19853036">Mishra SK, Hoon MA.</a> 114109690 Solinski, Hans NIDCR NIDCR Solinski, Hans (NIDCR) 0 114109691 Inglese, James NCATS - NCGC NCATS Inglese, James (NCATS) 0 114109692 Dranchak, Patricia NCATS - NCGC NCATS Dranchak, Patricia (NCATS) 0 114109689 Hoon, Mark NIDCR NIDCR Hoon, Mark (NIDCR) 1 114109689 Hoon, Mark NIDCR NIDCR Hoon, Mark (NIDCR) 1 114109690 Solinski, Hans NIDCR NIDCR Solinski, Hans (NIDCR) 0 114109691 Inglese, James NCATS - NCGC NCATS Inglese, James (NCATS) 0 114109692 Dranchak, Patricia NCATS - NCGC NCATS Dranchak, Patricia (NCATS) 0 114102429 Blockage Of NPR1 Receptor For Treatment Of Itch E-485-2013-1 Filing authorized NCATS - NCGC, NIDCR 114102430 Blockage Of NPR1 Receptor For Treatment Of Itch E-485-2013-2 Filing authorized NCATS - NCGC, NIDCR 83739611 Yonter, Ediz ediz.yonter@nih.gov
United States of America Technology Advancement Office ediz.yonter@nih.gov?subject=Web Inquiry on [TAB-3266] Potential New Drugs for Treating or Preventing Pruritus&body=Please send me information about technology [TAB-3266] Potential New Drugs for Treating or Preventing Pruritus. Yonter, Ediz<br><a href="mailto:ediz.yonter@nih.gov?subject=Web Inquiry on [TAB-3266] Potential New Drugs for Treating or Preventing Pruritus&body=Please send me information about technology [TAB-3266] Potential New Drugs for Treating or Preventing Pruritus.">ediz.yonter@nih.gov</a><br> 114169016 E-485-2013-1 E-485-2013-1-US-04 COMPOSITIONS AND METHODS FOR THE INHIBITION OF PRURITUS National Stage US 11,324,725 16/761,047 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11324725 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11324725">11,324,725</a><br />Filed on 2020-05-01<br />Status: Issued 114127861 IB6XXX 114127862 VOXXXX 114127863 VPXXXX 114127864 WKXXXX 114127865 XHXXXX 114127866 YAXXXX 114127867 YBXXXX 114127868 YCXXXX 114150672 Nppb 114150673 TRANSMITTER 114150674 Itch 114150675 Sensation 114150676 Listed LPM Vepa as of 4/15/2015 114150677 Pre LPM working set 20150418 114150678 Post LPM Assignment Set 20150420 114150679 BLOCKAGE 114150680 Npr1 114150681 RECEPTOR 114150682 treatment TAB-2976 114094639 A Novel Rapid Point-of Care Diagnostic Method for Infectious and Autoimmune Diseases NIDCR Antibodies, Diagnostics, Endocrinology, Geriatrics, Immunology, Infectious Disease, Medical Devices, Non-Medical Devices, Research Equipment Antibodies Diagnostics Endocrinology Geriatrics Immunology Infectious Disease Medical Devices Non-Medical Devices Research Equipment Peter Burbelo Rapid point-of-care, antibody-based testing is not available for the diagnosis of autoimmune and most infectious diseases. For detecting autoantibodies associated with most autoimmune conditions, fluid-phase immunoprecipitation assays are required. However, these assays usually involve radioactivity and are not feasible for point-of-care applications. The subject invention describes methods of using neodymium magnet for diagnosis of infectious and autoimmune diseases including lupus, Sjögren's syndrome, type I diabetes, HIV and Lyme disease. The assay takes 3.5 minutes, is highly efficient, and has low background. <ul> <li>Highly efficient, rapid, and easy to perform.</li> <li>Low background signals.</li> </ul> <ul> <li>A rapid assay for point-of-care diagnosis of infectious and autoimmune diseases.</li> <li>Applications to different assay platforms, such as a portable, commercially available hand-held luminometer or an automated, high-throughput device.</li> </ul> Technology is available for non-exclusive or exclusive licensing 2022-03-08 2024-12-31 2024-12-31 2015-09-17 Autoimmune, Diagnosis, DISEASES, INFECTIOUS, Magnet, Methods, Neodymium, RAPID, VAXXXX, VFXXXX, VJXXXX, VKXXXX, VLXXXX, VQXXXX, WBXXXX, XAXXXX, XDXXXX, XHXXXX, YAXXXX, YBXXXX, YFXXXX False True <ul> <li>Early-stage</li> <li>In vitro data available</li> <li>Prototype</li> </ul> True 52406768 Discovery 52406768 NIHTT 37470483 Website Abstract 114172274 Burbelo PD, et al. https://www.ncbi.nlm.nih.gov/pubmed/25241936 <a href="https://www.ncbi.nlm.nih.gov/pubmed/25241936">Burbelo PD, et al.</a> 114172275 Burbelo PD, et al. https://www.ncbi.nlm.nih.gov/pubmed/25203116 <a href="https://www.ncbi.nlm.nih.gov/pubmed/25203116">Burbelo PD, et al.</a> 114172276 Burbelo PD, et al. https://www.ncbi.nlm.nih.gov/pubmed/21679112 <a href="https://www.ncbi.nlm.nih.gov/pubmed/21679112">Burbelo PD, et al.</a> 114172277 Burbelo PD, et al. https://www.ncbi.nlm.nih.gov/pubmed/19812534 <a href="https://www.ncbi.nlm.nih.gov/pubmed/19812534">Burbelo PD, et al.</a> 114103510 Burbelo, Peter NIDCR NIDCR Burbelo, Peter (NIDCR) 1 114103510 Burbelo, Peter NIDCR NIDCR Burbelo, Peter (NIDCR) 1 114099439 Methods Of Using Neodymium Magnet For Rapid Diagnosis Of Infectious And Autoimmune Diseases E-190-2015-0 Filing authorized NIDCR 83739611 Yonter, Ediz ediz.yonter@nih.gov
United States of America Technology Advancement Office ediz.yonter@nih.gov?subject=Web Inquiry on [TAB-2976] A Novel Rapid Point-of Care Diagnostic Method for Infectious and Autoimmune Diseases&body=Please send me information about technology [TAB-2976] A Novel Rapid Point-of Care Diagnostic Method for Infectious and Autoimmune Diseases. Yonter, Ediz<br><a href="mailto:ediz.yonter@nih.gov?subject=Web Inquiry on [TAB-2976] A Novel Rapid Point-of Care Diagnostic Method for Infectious and Autoimmune Diseases&body=Please send me information about technology [TAB-2976] A Novel Rapid Point-of Care Diagnostic Method for Infectious and Autoimmune Diseases.">ediz.yonter@nih.gov</a><br> 114168565 E-190-2015-0 E-190-2015-0-US-04 METHOD AND DEVICE FOR DETECTING ANTIGEN-SPECIFIC ANTIBODIES IN A BIOLOGICAL FLUID SAMPLE BY USING NEODYMIUM MAGNETS National Stage US 10,564,152 15/756,012 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10564152 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10564152">10,564,152</a><br />Filed on 2018-02-27<br />Status: Issued 114112570 XDXXXX 114112571 XHXXXX 114112596 VLXXXX 114112597 VQXXXX 114112598 WBXXXX 114112779 VAXXXX 114112780 VFXXXX 114112781 VJXXXX 114118755 XAXXXX 114120131 VKXXXX 114122034 YAXXXX 114127183 YBXXXX 114127184 YFXXXX 114130269 Methods 114130270 Neodymium 114130271 Magnet 114130272 RAPID 114130273 Diagnosis 114130274 INFECTIOUS 114130275 Autoimmune 114130276 DISEASES TAB-2967 114096748 mNFHcre Transgenic Mice NIDCR Neurology, Research Materials, Therapeutics Neurology Research Materials Therapeutics Ashok Kulkarni Knockout mouse is a valuable model to study biological functions of target genes. When Cre expressing mice are bred with mice containing a loxP-flanked gene, the gene between the loxP sites will be deleted in the offsprings. Scientists at the NIH have generated mNF-H-<em>cre</em> transgenic mouse lines that express Cre recombinase under the control of the promoter of the neurofilament-H gene, which is expressed in the late stage of neuronal maturation. The transgenic mice express <em>cre</em> in neurons (but not astrocytes) with highest expression in the cortex and hippocampus. The mNF-H-<em>cre</em> transgenic mouse line can be used to generate conditional knockout mice with targeted excision of neuron-specific genes during the late stage of mouse development. This mouse model will be useful for the study of neuronal functions of particular genes. <ul> <li>Transgenic mice express Cre recombinase selectively in neurons (but not in astrocytes) in the late stage of brain development.</li> </ul> <ul> <li>Generating conditional knockout mice for neurobiological, neuro-developmental, or aging studies involving neurons of the brain and the spinal cord.</li> </ul> Research Tool – Patent protection is not being pursued for this technology. Animal model is available for non-exclusive licensing 2022-03-08 2024-12-31 2024-12-31 2015-08-10 Listed LPM Tong as of 4/15/2015, Mice, MNFHcre, MNHFcre, Patent Category - Biotechnology, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, RXXXXX, TRANSGENIC, VEXXXX, WIXXXX, XEXXXX, YCXXXX False True In vivo data available (animal) True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114170152 Hirasawa M, et al. http://www.ncbi.nlm.nih.gov/pubmed/11377750 <a href="http://www.ncbi.nlm.nih.gov/pubmed/11377750">Hirasawa M, et al.</a> 114170153 Hirasawa M, et al. http://www.ncbi.nlm.nih.gov/pubmed/15067135 <a href="http://www.ncbi.nlm.nih.gov/pubmed/15067135">Hirasawa M, et al.</a> 114109056 Kulkarni, Ashok NIDCR NIDCR Kulkarni, Ashok (NIDCR) 1 114109056 Kulkarni, Ashok NIDCR NIDCR Kulkarni, Ashok (NIDCR) 1 114102278 MNFHcre Transgenic Mice E-293-2009-0 Research Material NIDCR 83739611 Yonter, Ediz ediz.yonter@nih.gov
United States of America Technology Advancement Office ediz.yonter@nih.gov?subject=Web Inquiry on [TAB-2967] mNFHcre Transgenic Mice&body=Please send me information about technology [TAB-2967] mNFHcre Transgenic Mice. Yonter, Ediz<br><a href="mailto:ediz.yonter@nih.gov?subject=Web Inquiry on [TAB-2967] mNFHcre Transgenic Mice&body=Please send me information about technology [TAB-2967] mNFHcre Transgenic Mice.">ediz.yonter@nih.gov</a><br> 114127098 RXXXXX 114127099 VEXXXX 114127100 WIXXXX 114127101 XEXXXX 114127102 YCXXXX 114148443 MNHFcre 114148444 TRANSGENIC 114148445 Mice 114148446 MNFHcre 114148447 Patent Category - Biotechnology 114148448 Listed LPM Tong as of 4/15/2015 114148449 Pre LPM working set 20150418 114148450 Post LPM Assignment Set 20150420 TAB-2716 114096895 Methods of Treating or Preventing Pruritis (Itch) NIDCR Cardiology, Consumer Products, Dental, Diagnostics, Endocrinology, Infectious Disease, Neurology, Oncology, Ophthalmology, Reproductive Health, Research Equipment, Research Materials, Therapeutics, Vaccines Cardiology Consumer Products Dental Diagnostics Endocrinology Infectious Disease Neurology Oncology Ophthalmology Reproductive Health Research Equipment Research Materials Therapeutics Vaccines Mark Hoon, Santosh Mishra This technology provides a novel method of treating or preventing pruritis (itch) using natriuretic polypeptide b (Nppb) blocking agents. Itch (also known as pruritis) is a sensation that may be perceived as an unpleasant skin irritation and may drive an urge to scratch. Conditions such as, for example, psoriasis, atopic dermatitis, renal failure, liver cirrhosis and some cancers may cause persistent itch. Itch is triggered by somatosensory neurons expressing the ion channel TRPV1 (transient receptor potential cation channel subfamily V member 1). The inventors of this technology show that the Nppb is expressed in a subset of TRPV1 neurons and found that Nppb-/- mice selectively lose all behavioral responses to itch-inducing agents. Nppb triggered potent scratching when injected intrathecally in wild-type and Nppb-/- mice. Itch responses were blocked by toxin-mediated ablation of Nppb-receptor-expressing cells, but a second neuropeptide, gastrin-releasing peptide, still induced strong responses in the toxin-treated animals. <ul> <li>A new mode of treating itch and itch induced conditions using selective Nppb antagonists.</li> </ul> <ul> <li>Therapeutics for preventing or treating pruritis/itching.</li> <li>Screening of novel Nppb blocking agents.</li> </ul> Technology is available for non-exclusive or exclusive licensing 2022-03-08 2024-12-31 2024-12-31 2014-01-16 IB6XXX, IBXXXX, Itch, IXXXXX, Listed LPM Vepa as of 4/15/2015, Nppb, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Sensation, TRANSMITTER, VEXXXX, VMXXXX, VOXXXX, VPXXXX, WJXXXX, WKXXXX, XHXXXX, YAXXXX, YBXXXX, YCXXXX False True <ul> <li>Early-stage</li> <li>In vitro data available</li> </ul> True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114171985 Mishra SK, Hoon MA. https://www.ncbi.nlm.nih.gov/pubmed/23704570 <a href="https://www.ncbi.nlm.nih.gov/pubmed/23704570">Mishra SK, Hoon MA.</a> 114109709 Mishra, Santosh NIDCR Mishra, Santosh 0 114109708 Hoon, Mark NIDCR NIDCR Hoon, Mark (NIDCR) 1 114109708 Hoon, Mark NIDCR NIDCR Hoon, Mark (NIDCR) 1 114109709 Mishra, Santosh NIDCR Mishra, Santosh 0 114102435 Nppb Is A Transmitter Of Itch Sensation E-485-2013-0 Filing authorized NIDCR 83739611 Yonter, Ediz ediz.yonter@nih.gov
United States of America Technology Advancement Office ediz.yonter@nih.gov?subject=Web Inquiry on [TAB-2716] Methods of Treating or Preventing Pruritis (Itch)&body=Please send me information about technology [TAB-2716] Methods of Treating or Preventing Pruritis (Itch). Yonter, Ediz<br><a href="mailto:ediz.yonter@nih.gov?subject=Web Inquiry on [TAB-2716] Methods of Treating or Preventing Pruritis (Itch)&body=Please send me information about technology [TAB-2716] Methods of Treating or Preventing Pruritis (Itch).">ediz.yonter@nih.gov</a><br> 114168632 E-485-2013-0 E-485-2013-0-US-03 Methods of Treating or Preventing Pruritis by Blocking Natriuretic Polypeptide B15/039982 National Stage US 9,987,330 15/039,982 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9987330 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9987330">9,987,330</a><br />Filed on 2016-05-27<br />Status: Issued 114168633 E-485-2013-0 E-485-2013-0-US-04 METHODS OF TREATING OR PREVENTING PRURITIS BY BLOCKING NATRIURETIC POLYPEPTIDE B DIV US 10,583,173 15/971,671 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10583173 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10583173">10,583,173</a><br />Filed on 2018-05-04<br />Status: Issued 114124367 IB6XXX 114124368 IXXXXX 114124369 IBXXXX 114124370 VEXXXX 114124371 VMXXXX 114124372 VPXXXX 114124373 WJXXXX 114124374 WKXXXX 114124375 YAXXXX 114124376 YBXXXX 114127907 VOXXXX 114127908 XHXXXX 114127909 YCXXXX 114145934 Nppb 114145935 TRANSMITTER 114145936 Itch 114145937 Sensation 114150744 Listed LPM Vepa as of 4/15/2015 114150745 Pre LPM working set 20150418 114150746 Post LPM Assignment Set 20150420 TAB-2657 114096842 Development of Immune System Tolerance for the Treatment of Autoimmune Disease NIDCR Diagnostics, Immunology, Research Materials, Therapeutics Diagnostics Immunology Research Materials Therapeutics Wanjun Chen The present invention provides a therapeutic method for the treatment of autoimmune or autoinflammatory diseases by first breaking down the dysregulated immune system and then reprogramming the immune system to restore tolerance to the patient's self-antigens by induction of antigen specific regulatory T cells. The inventors have shown that only with the combination of apoptosis, phagocytes, and antigen can antigen-specific regulatory T cells (T<sub>reg</sub>) cells be optimally generated to develop long-term immune tolerance. This strategy for developing immune tolerance can be applied to the treatment of autoimmune diseases. <ul> <li>This technology represents a novel means of treating autoimmune disease.</li> </ul> <ul> <li>Treatment of autoimmune disease.</li> </ul> Technology is available for non-exclusive or exclusive licensing 2022-03-08 2024-12-31 2024-12-31 2013-09-19 Alloantigen-specific, Apototic, CELL-MEDIATED, Cells, IB3XXX, IBXXXX, INDUCTION, IXXXXX, Patent Category - Biotechnology, Prevention, Regulatory, REJECTION, T, TRANSPLANT False True <ul> <li>Early-stage</li> <li>In vivo data available (animal)</li> </ul> True NIHTT 37470483 Website Abstract 114108172 Chen, Wanjun NIDCR NIDCR Chen, Wanjun (NIDCR) 1 114108172 Chen, Wanjun NIDCR NIDCR Chen, Wanjun (NIDCR) 1 114101966 Apototic Cell-mediated Induction Of Alloantigen-specific Regulatory T Cells For Prevention Of Transplant Rejection E-186-2009-0 Filing authorized NIDCR 83739611 Yonter, Ediz ediz.yonter@nih.gov
United States of America Technology Advancement Office ediz.yonter@nih.gov?subject=Web Inquiry on [TAB-2657] Development of Immune System Tolerance for the Treatment of Autoimmune Disease&body=Please send me information about technology [TAB-2657] Development of Immune System Tolerance for the Treatment of Autoimmune Disease. Yonter, Ediz<br><a href="mailto:ediz.yonter@nih.gov?subject=Web Inquiry on [TAB-2657] Development of Immune System Tolerance for the Treatment of Autoimmune Disease&body=Please send me information about technology [TAB-2657] Development of Immune System Tolerance for the Treatment of Autoimmune Disease.">ediz.yonter@nih.gov</a><br> 114161500 E-186-2009-0 E-186-2009-0-US-03 Apototic Cell-mediated Induction Of Antigen-specific Regulatory T Cells For The Therapy of Automimmune Diseases in Animals and Humans National Stage US 14/904,054 Pending US <br />National Stage 14/904,054<br />Filed on 2016-01-08<br />Status: Pending 114169095 E-186-2009-0 E-186-2009-0-US-09 APOPTOTIC CELL-MEDIATED INDUCTION OF ANTIGEN SPECIFIC REGULATORY T-CELLS FOR THE THERAPY OF AUTOIMMUNE DISEASES IN ANIMALS AND HUMANS CON US 17/167,737 Abandoned US <br />Continuation (CON) 17/167,737<br />Filed on 2021-02-04<br />Status: Abandoned 114123799 IB3XXX 114123800 IXXXXX 114123801 IBXXXX 114145164 Apototic 114145165 CELL-MEDIATED 114145166 INDUCTION 114145167 Alloantigen-specific 114145168 Regulatory 114145169 T 114145170 Cells 114145171 Prevention 114145172 TRANSPLANT 114145173 REJECTION 114145174 Patent Category - Biotechnology TAB-1707 114095936 Recombinant Modified Bacillus anthracis Protective Antigen for Use in Vaccines NIDCR Diagnostics, Infectious Disease, Rare/Neglected Diseases, Research Materials, Therapeutics, Vaccines Diagnostics Infectious Disease Rare/Neglected Diseases Research Materials Therapeutics Vaccines Stephen Leppla, John Robbins, M Rosovitz, Rachel Schneerson This invention relates to improved methods of preparing <i>Bacillus anthracis</i> protective antigen (PA) for use in vaccines. PA is a secreted, non-toxic protein with a molecular weight of 83 KDa. PA is a major component of the currently licensed human vaccine (Anthrax Vaccine Adsorbed, AVA). Although the licensed human vaccine has been shown to be effective against cutaneous anthrax infection in animals and humans and against inhalation anthrax in rhesus monkeys, the licensed vaccine has several limitations: (1) AVA elicits a relatively high degree of local and systemic adverse reactions, probably mediated by variable amounts of undefined bacterial products, making standardization difficult; (2) the immunization schedule requires administration of six doses within an eighteen (18) month period, followed by annual boosters; (3) there is no defined vaccine-induced protective level of antibody to PA by which to evaluate new lots of vaccines; and (4) AVA is comprised of a wild-type PA. It has been suggested that a vaccine comprising a modified purified recombinant PA would be effective, safe, allow precise standardization, and require fewer injections. <br><br> This invention claims methods of producing and recovering PA from a cell or organism, particularly a recombinant cell or microorganism. The invention claims production and purification of modified PA from a non-sporogenic strain of <i>Bacillus anthracis</i>. In contrast to other previously described methods, greater quantities of PA are obtainable from these cells or microorganisms. Specifically, a scalable fermentation and purification process is claimed that is suitable for vaccine development, and that produces almost three times more product than earlier-reported processes. This is accomplished using a biologically inactive protease-resistant PA variant in a protease-deficient non-sporogenic avirulent strain of <i>B. anthracis</i> (BH445). One of the PA variants described in the patent application lacks the furin and chymotrypsin cleavage sites. <br><br> The invention relates to improved methods of producing and recovering sporulation-deficient <i>B. anthracis</i> mutant stains, and for producing and recovering recombinant <i>B. anthracis</i> protective antigen (PA), especially modified PA which is protease resistant, and to methods of using of these PAs or nucleic acids encoding these PAs for eliciting an immunogenic response in humans, including responses which provide protection against, or reduce the severity of, <i>B. anthracis</i> bacterial infections and which are useful to prevent and/or treat illnesses caused by <i>B. anthracis</i>, such as inhalation anthrax, cutaneous anthrax and gastrointestinal anthrax. Improved <i>B. anthracis</i> vaccines. Available for exclusive or nonexclusive licensing. 2022-03-08 2024-12-31 2024-12-31 2008-09-01 Anthrax, ANTIGEN, Chromosome 18 ring, Chymotrypsin-Sensitive, CREATION, Cutaneous anthrax, DAXXXX, DBXXXX, DC4XXX, DC6XXX, DCXXXX, DDXXXX, DELETIONS, DXXXXX, Furin-Cleavage..., Loop, MOLECULE, Protective, R 18, recombinant, rPA, STABLE, UAXXXX False True Phase I clinical studies are being performed. Phase I clinical studies are being performed. True NIHTT 37470483 Website Abstract 114105959 Robbins, John NICHD NICHD Robbins, John (NICHD) 0 114105961 Leppla, Stephen NIDCR NIAID Leppla, Stephen (NIAID) 0 114106157 Schneerson, Rachel NICHD NICHD Schneerson, Rachel (NICHD) 0 114105962 Rosovitz, M NIDCR Rosovitz, M 1 114105962 Rosovitz, M NIDCR Rosovitz, M 1 114105959 Robbins, John NICHD NICHD Robbins, John (NICHD) 0 114105961 Leppla, Stephen NIDCR NIAID Leppla, Stephen (NIAID) 0 114106157 Schneerson, Rachel NICHD NICHD Schneerson, Rachel (NICHD) 0 114100928 Creation of a Stable Recombinant Protective Antigen (rPA) Molecule By Deletions of the Chymotrypsin-Sensitive Loop and the Furin-Cleavage... E-268-2002-0 Filing authorized NICHD, NIDCR 83656052 Knezevic, Vladimir vlado.knezevic@nih.gov
United States of America Technology Advancement Office vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-1707] Recombinant Modified Bacillus anthracis Protective Antigen for Use in Vaccines&body=Please send me information about technology [TAB-1707] Recombinant Modified Bacillus anthracis Protective Antigen for Use in Vaccines. Knezevic, Vladimir<br><a href="mailto:vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-1707] Recombinant Modified Bacillus anthracis Protective Antigen for Use in Vaccines&body=Please send me information about technology [TAB-1707] Recombinant Modified Bacillus anthracis Protective Antigen for Use in Vaccines.">vlado.knezevic@nih.gov</a><br> 114164147 E-268-2002-0 E-268-2002-0-US-03 RECOMBINANT MODIFIED BACILLUS ANTHRACIS PROTECTIVE ANTIGEN FOR USE IN VACCINES DIV US 8,394,387 11/831,860 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8394387 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8394387">8,394,387</a><br />Filed on 2007-07-31<br />Status: Issued 114118442 DC4XXX 114118443 DC6XXX 114118444 DDXXXX 114118445 DAXXXX 114118446 DBXXXX 114118447 DCXXXX 114118448 UAXXXX 114118449 DXXXXX 114130595 CREATION 114130596 STABLE 114130597 recombinant 114130598 Protective 114130599 ANTIGEN 114130600 rPA 114130601 MOLECULE 114130602 DELETIONS 114130603 Chymotrypsin-Sensitive 114130604 Loop 114130605 Furin-Cleavage... 114156425 Cutaneous anthrax 114156426 Anthrax 114156427 Chromosome 18 ring 114158307 R 18 TAB-4550 151737361 DLX3 Knockout Mice for the Study Mouse Models of Tooth, Hair, and Epidermal Defects NIAMS Animal Models, Dermatology, Materials Available, Research Materials Animal Models Dermatology Materials Available Research Materials Oliver Duverger, Maria Morasso <p>This technology includes K14creDLX3 conditional knockout (cKO) mice which will be used to study ectodermal dysplasia disorders such as Amelogenesis Imperfecta, and to study molecular mechanisms of DLX3 regulation in skin and ectodermal appendages. DLX3 is expressed in the epidermis, hair matrix cells in the hair follicle and in the mesenchymal and epithelial compartment of the tooth during embryonic development. To determine the transcriptional network dependent on DLX3-function, we will generate and analyze an epithelial-specific conditional knockout of DLX3.</p> First knockout mouse model of this type. Mouse model to study ectodermal dysplasia disorders and to give further insight into the role of DLX3 gene in skin, hair, and tooth function. Animal model is also available for non-exclusive licensing 2023-12-11 2024-12-31 2024-12-31 2024-03-27 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 151737458 Hwang J, et al. Publicaiton: Kim JC, et al. (https://pubmed.ncbi.nlm.nih.gov/25120002/) https://pubmed.ncbi.nlm.nih.gov/21709238/ <a href="https://pubmed.ncbi.nlm.nih.gov/21709238/">Hwang J, et al. Publicaiton: Kim JC, et al. (https://pubmed.ncbi.nlm.nih.gov/25120002/)</a> 151737368 Morasso, Maria NIAMS - IRP NIAMS Morasso, Maria (NIAMS) 1 151737372 Duverger, Oliver NIDCR NIDCR Duverger, Oliver (NIDCR) 2 151737368 Morasso, Maria NIAMS - IRP NIAMS Morasso, Maria (NIAMS) 1 151737372 Duverger, Oliver NIDCR NIDCR Duverger, Oliver (NIDCR) 2 151737364 K14cre Ablation Of DLX3 Gene To Study Mouse Models Of Tooth, Hair And Epidermal Defects E-013-2015-0 Research Material NIAMS 83656052 Knezevic, Vladimir vlado.knezevic@nih.gov
United States of America Technology Advancement Office vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-4550] DLX3 Knockout Mice for the Study Mouse Models of Tooth, Hair, and Epidermal Defects&body=Please send me information about technology [TAB-4550] DLX3 Knockout Mice for the Study Mouse Models of Tooth, Hair, and Epidermal Defects. Knezevic, Vladimir<br><a href="mailto:vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-4550] DLX3 Knockout Mice for the Study Mouse Models of Tooth, Hair, and Epidermal Defects&body=Please send me information about technology [TAB-4550] DLX3 Knockout Mice for the Study Mouse Models of Tooth, Hair, and Epidermal Defects.">vlado.knezevic@nih.gov</a><br> TAB-3800 114097650 Locally Delivered Alkaline Phosphatase for Treatment of Periodontal Disease NIDCR Cardiology, Collaboration, Dental, Endocrinology, Infectious Disease, Licensing, Medical Devices, Non-Medical Devices, Oncology, Ophthalmology, Research Materials, Therapeutics Cardiology Collaboration Dental Endocrinology Infectious Disease Licensing Medical Devices Non-Medical Devices Oncology Ophthalmology Research Materials Therapeutics Brian Foster, Jose Millan, Atsuhiro Nagasaki, Nadine Samara, Martha Somerman This technology includes a product for local delivery of alkaline phosphatase for the treatment of periodontal disease. Our laboratory has discovered that factors regulating phosphate metabolism and specifically the appropriate balance between phosphate (Pi) and pyrophosphate (PPi) at local sites are needed for formation (development), maintenance and regeneration of the tooth root surface (cementum), periodontal ligament (PDL) and surrounding alveolar bone, i.e., the periodontal apparatus. Furthermore, we have shown in alkaline phosphatase knock out mice that targeting alkaline phosphatase to mineralized tissues promotes formation and regeneration of the periodontal apparatus. <ul><li>Less difficulty in the purification of the protein</li> <li>Suitable for local delivery to the oral cavity</li> <li>Tailored toward regeneration of tissues, not just formation</li></ul> Product for use as a local delivery to treat periodontal disease, to form new bone at local sites in preparation for implants and other dental appliances and to treat peri-implantitis. Available for non-exclusive or exclusive licensing 2022-11-30 2024-12-27 2024-12-27 2022-11-30 2022-08-03 Alkaline, Delivered, Disease, Locally, PERIODONTAL, PHOSPHATASE, treatment, VPXXXX, WIXXXX, WJXXXX, XDXXXX False True True NIHTT 37470483 Website Abstract 114172958 McKee M, Nakano Y, et al. https://pubmed.ncbi.nlm.nih.gov/21212313/ <a href="https://pubmed.ncbi.nlm.nih.gov/21212313/">McKee M, Nakano Y, et al.</a> 114111603 Nagasaki, Atsuhiro NIAMS - IRP NIAMS Nagasaki, Atsuhiro (NIAMS) 0 114111604 Foster, Brian Ohio State University Foster, Brian 0 114111605 Millan, Jose Sanford Burnham Prebys Medical Discovery Institute Millan, Jose 0 114111606 Samara, Nadine NIDCR NIDCR Samara, Nadine (NIDCR) 0 114111602 Somerman, Martha NIAMS - IRP NIDCR Somerman, Martha (NIDCR) 1 114111602 Somerman, Martha NIAMS - IRP NIDCR Somerman, Martha (NIDCR) 1 114111603 Nagasaki, Atsuhiro NIAMS - IRP NIAMS Nagasaki, Atsuhiro (NIAMS) 0 114111604 Foster, Brian Ohio State University Foster, Brian 0 114111605 Millan, Jose Sanford Burnham Prebys Medical Discovery Institute Millan, Jose 0 114111606 Samara, Nadine NIDCR NIDCR Samara, Nadine (NIDCR) 0 114102902 Locally Delivered Alkaline Phosphatase For Treatment Of Periodontal Disease E-186-2019-0 Filing authorized NIAMS, NIDCR, Ohio State University, Sanford Burnham Prebys Medical Discovery Institute 83739611 Yonter, Ediz ediz.yonter@nih.gov
United States of America Technology Advancement Office ediz.yonter@nih.gov?subject=Web Inquiry on [TAB-3800] Locally Delivered Alkaline Phosphatase for Treatment of Periodontal Disease&body=Please send me information about technology [TAB-3800] Locally Delivered Alkaline Phosphatase for Treatment of Periodontal Disease. Yonter, Ediz<br><a href="mailto:ediz.yonter@nih.gov?subject=Web Inquiry on [TAB-3800] Locally Delivered Alkaline Phosphatase for Treatment of Periodontal Disease&body=Please send me information about technology [TAB-3800] Locally Delivered Alkaline Phosphatase for Treatment of Periodontal Disease.">ediz.yonter@nih.gov</a><br> 114169631 E-186-2019-0 E-186-2019-0-US-05 TNAP LOCALLY ADMINISTERED FOR PROMOTING PERIODONTAL HEALTH National Stage US 12,478,662 17/789,742 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12478662 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12478662">12,478,662</a><br />Filed on 2022-06-28<br />Status: Issued 114129650 VPXXXX 114129651 WIXXXX 114129652 WJXXXX 114129653 XDXXXX 114155538 Locally 114155539 Delivered 114155540 Alkaline 114155541 PHOSPHATASE 114155542 treatment 114155543 PERIODONTAL 114155544 Disease TAB-3163 114097110 Chimeric Antibodies Against Hepatitis B e-Antigen NIAMS Antibodies, Immunology, Infectious Disease, Therapeutics Antibodies Immunology Infectious Disease Therapeutics Alasdair Steven, Norman Watts, Paul Wingfield The invention relates to recombinant chimeric rabbit/human monoclonal antibody fragments (Fabs) against hepatitis B Virus e-antigen (HBeAg), notably Fab me6. Viral hepatitis is the seventh leading cause of death worldwide. Hepatitis B core antigen (HBcAg) forms an icosahedral structure containing the viral genome. Both the HBcAg and the HBeAg of interest here are expressed by two different start codons of the viral C gene. Unlike the related HBcAg which activates type 1 T helper (Th1) cells leading to immune attack, the HBeAg activates Th2 cells which promote immune tolerance. The long-term persistence of HBeAg is associated with the development of hepatocellular carcinoma. Conversely, HBeAg seroconversion (from HBeAg carrier to anti-HBeAg carrier) is a marker for successful therapy of chronically infected patients. The presently phage display engineered antibody Fab me6 shows higher sensitivity and selectivity against HBeAg compared to three commercial diagnostics kits tested; additionally, it also inhibits capsid assembly which is essential for viral replication; furthermore, it can also be fully humanized and has potential for anti-hepatitis B virus therapeutic interventions. <ul> <li>Hepatocellular carcinoma prophylaxis</li> <li>Hepatitis B diagnostics and therapy</li> </ul> The National Institute of Arthritis and Musculoskeletal and Skin Diseases seeks statements of capability or interest from parties interested in collaborative research to further develop and evaluate this technology. For further information, please contact Cecilia Pazman, PhD, Technology Development Specialist, Office of Technology Transfer and Development, National Heart, Lung, and Blood Institute, Phone: 301-594-4273; Email: <a href="mailto:pazmance@nhlbi.nih.gov">pazmance@nhlbi.nih.gov</a>. Available for non-exclusive or exclusive licensing 2022-03-08 2024-12-27 2024-12-27 2017-09-11 Against, antibodies, APPLICATIONS, assay, B, CHARACTERIZATION, chimeric, Chimic, DB4XXX, E-antigen, FAB, Hepalitis, Hepatitis, Potential, Rabbit/human, Their, THERAPY, VLXXXX, WJXXXX, XAXXXX False True True NIHTT 37470483 Website Abstract 114109330 Watts, Norman NIAMS - IRP NIAMS Watts, Norman (NIAMS) 0 114109331 Steven, Alasdair NIAMS - IRP NIAMS Steven, Alasdair (NIAMS) 0 114109329 Wingfield, Paul NIAMS - IRP NIAMS Wingfield, Paul (NIAMS) 1 114109329 Wingfield, Paul NIAMS - IRP NIAMS Wingfield, Paul (NIAMS) 1 114109330 Watts, Norman NIAMS - IRP NIAMS Watts, Norman (NIAMS) 0 114109331 Steven, Alasdair NIAMS - IRP NIAMS Steven, Alasdair (NIAMS) 0 114102311 Chimeric Rabbit/Human Fab Antibodies Against Hepatitis B E-antigen And Their Potential Applications In Assay, Characterization, And Therapy E-192-2017-0 Filing authorized NIAMS 83656052 Knezevic, Vladimir vlado.knezevic@nih.gov
United States of America Technology Advancement Office vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-3163] Chimeric Antibodies Against Hepatitis B e-Antigen&body=Please send me information about technology [TAB-3163] Chimeric Antibodies Against Hepatitis B e-Antigen. Knezevic, Vladimir<br><a href="mailto:vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-3163] Chimeric Antibodies Against Hepatitis B e-Antigen&body=Please send me information about technology [TAB-3163] Chimeric Antibodies Against Hepatitis B e-Antigen.">vlado.knezevic@nih.gov</a><br> 114168873 E-192-2017-0 E-192-2017-0-US-06 ANTIBODIES AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF HEPATITIS B VIRUS INFECTION National Stage US 11,827,669 16/631,290 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11827669 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11827669">11,827,669</a><br />Filed on 2020-01-15<br />Status: Issued 114127355 XAXXXX 114127356 DB4XXX 114127357 VLXXXX 114127358 WJXXXX 114149347 Chimic 114149348 Rabbit/human 114149349 FAB 114149350 antibodies 114149351 Against 114149352 Hepalitis 114149353 B 114149354 E-antigen 114149355 Their 114149356 Potential 114149357 APPLICATIONS 114149358 assay 114149359 CHARACTERIZATION 114149360 THERAPY 114149361 Hepatitis 114149362 chimeric TAB-2804 114096983 Engineering Neural Stem Cells Using Homologous Recombination NIAMS Neurology, Research Materials, Therapeutics Neurology Research Materials Therapeutics Raymond Funahashi, Nasir Malik, Mahendra Rao, Jizhong Zou Methods for modifying the genome of a Neural Stem Cell (NSC) are disclosed. Also, methods for differentiating NSCs into neurons and glia are described. NSCs are multipotent, self-renewing cells found in the central nervous system, capable of differentiating into neurons and glia. NSCs can be generated efficiently from pluripotent stem cells (PSCs) and have the capacity to differentiate into any neuronal or glial cell type of the central nervous system. Improvements in genome engineering of NSCs can potentially facilitate cellular replacement therapies for the treatment of neurodegenerative disorders. Recently, NIH investigators have developed a procedure to efficiently engineer NSCs through homologous recombination by introducing TAL effector nucleases (TALENs) and donor vectors. They have designed TALENs that efficiently generate double stranded breaks at two safe harbor loci (AAVS1 and CLYBL). These TALENs facilitate homologous recombination without silencing at these loci. The TALENs were delivered along with a DNA donor vector with a ubiquitous promoter driving expression of a cDNA using a nucleofector to get high transfection efficiencies. NSCs modified in this manner have therapeutic potential in treating neurodegenerative diseases. NSC lines engineered by this methodology as well as constructs and protocols for evaluation are also available. <ul> <li>The novel methods provide highly pure engineered NSC populations which maintain the capacity to self-renew and differentiate to neurons and astrocytes suitable for cell replacement therapies.</li> <li>Safe harbor TALEN-mediated homologous recombination is a high-efficiency method to generate targeted mini-gene transfer or reporter knock-in cell lines in both human iPSCs and NSCs.</li> </ul> <ul> <li>Cellular replacement therapies for neurodegenerative disorders.</li> </ul> Available for non-exclusive or exclusive licensing 2022-03-08 2024-12-27 2024-12-27 2014-04-14 Cells, EFFECTOR, Gene, Listed LPM Vepa as of 4/15/2015, NB1XXX, Nucleases, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, SOMATIC, TAl, Targeting, VEXXXX, WIXXXX, WJXXXX, XEXXXX, YAXXXX, YBXXXX False True <ul> <li>Early-stage</li> <li>In vitro data available</li> </ul> True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114108664 Rao, Mahendra NIAMS - CRM NIAMS Rao, Mahendra (NIAMS) 0 114108665 Zou, Jizhong NIAMS - CRM NHLBI Zou, Jizhong (NHLBI) 0 114108666 Funahashi, Raymond Funahashi, Raymond 0 114108663 Malik, Nasir NIAMS - IRP NINDS Malik, Nasir (NINDS) 1 114108663 Malik, Nasir NIAMS - IRP NINDS Malik, Nasir (NINDS) 1 114108664 Rao, Mahendra NIAMS - CRM NIAMS Rao, Mahendra (NIAMS) 0 114108665 Zou, Jizhong NIAMS - CRM NHLBI Zou, Jizhong (NHLBI) 0 114108666 Funahashi, Raymond Funahashi, Raymond 0 114099402 Gene Targeting Of Somatic Cells With TAl Effector Nucleases E-762-2013-1 Waived NIAMS 114102131 Gene Targeting Of Somatic Cells With TAl Effector Nucleases E-762-2013-0 Waived NIAMS 83656052 Knezevic, Vladimir vlado.knezevic@nih.gov
United States of America Technology Advancement Office vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-2804] Engineering Neural Stem Cells Using Homologous Recombination&body=Please send me information about technology [TAB-2804] Engineering Neural Stem Cells Using Homologous Recombination. Knezevic, Vladimir<br><a href="mailto:vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-2804] Engineering Neural Stem Cells Using Homologous Recombination&body=Please send me information about technology [TAB-2804] Engineering Neural Stem Cells Using Homologous Recombination.">vlado.knezevic@nih.gov</a><br> 114160581 E-762-2013-1 E-762-2013-1-US-02 Engineering Neural Stem Cells using Homologous Recombination National Stage US 9,951,353 15/035,958 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9951353 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9951353">9,951,353</a><br />Filed on 2016-05-11<br />Status: Issued 114125899 NB1XXX 114125900 VEXXXX 114125901 WIXXXX 114125902 WJXXXX 114125903 XEXXXX 114125904 YAXXXX 114125905 YBXXXX 114147111 Gene 114147112 Targeting 114147113 SOMATIC 114147114 Cells 114147115 TAl 114147116 EFFECTOR 114147117 Nucleases 114150633 Listed LPM Vepa as of 4/15/2015 114150634 Pre LPM working set 20150418 114150635 Post LPM Assignment Set 20150420 TAB-2395 114096597 Potential Use of anti-IgE in the Treatment of Lupus Nephritis NIAMS Diagnostics, Immunology, Research Materials, Therapeutics Diagnostics Immunology Research Materials Therapeutics Nicolas Charles, Juan Rivera Systemic lupus erythematosus (SLE) is a multi-organ inflammatory disease characterized by a significant morbidity and mortality related to both disease evolution as well as therapeutic side effects. At least half of SLE patients develop lupus nephritis.</br /><br /> The inventors have used a <i>Lyn</i> -/- mouse model that develops an autoimmune disease exhibiting some features of human SLE. Using this model the inventors identified basophils and self-reactive IgEs as important components in the development of autoantibody-mediated kidney disease. The inventors found that depletion of basophils or the absence of IgE causes a considerable reduction in autoantibody production and preserves kidney function in the <i>Lyn</i> -/- mice. The inventors' work demonstrates that IgE immune complexes can activate basophils and that removal of self-reactive IgEs that form functional circulating immune complexes prevents kidney disease. Further, the inventors have shown that basophils are contributors to the production of the self-reactive antibodies that cause lupus-like nephritis in the <i>Lyn</i> -/- mice. Accordingly, reducing circulating IgE levels or reducing basophil activation may be of therapeutic benefit. Current treatment of lupus has not advanced for many years. This finding is of importance for its potential in advancing treatment of the disease. Further research and development of therapeutic approach to treat lupus nephritis. The National Institute of Arthritis and Musculoskeletal and Skin Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize the technology for the use of anti-IgE in the treatment of Lupus Nephritis. For collaboration opportunities, please contact Cecilia Pazman at <a href="mailto:pazmance@mail.nih.gov">pazmance@mail.nih.gov</a>. Available for non-exclusive or exclusive licensing 2022-03-08 2024-12-27 2024-12-27 2012-03-27 antibodies, Anti-IgE, Are, AUTOREACTIVE, IB3XXX, IBXXXX, IGE, IXXXXX, Lupus, Nephritis, Nephritis:, PATHOLOGICAL, Potential, treatment False True <ul> <li>Early-stage</li> <li>Pre-clinical</li> </ul> True NIHTT 37470483 Website Abstract 114171524 Charles N, et al. http://www.ncbi.nlm.nih.gov/pubmed/20512127 <a href="http://www.ncbi.nlm.nih.gov/pubmed/20512127">Charles N, et al.</a> 114171525 Brightbill HD, et al. http://www.ncbi.nlm.nih.gov/pubmed/20458139 <a href="http://www.ncbi.nlm.nih.gov/pubmed/20458139">Brightbill HD, et al.</a> 114171526 Mack M, et al. http://www.ncbi.nlm.nih.gov/pubmed/19692999 <a href="http://www.ncbi.nlm.nih.gov/pubmed/19692999">Mack M, et al.</a> 114171527 Busse W, et al. http://www.ncbi.nlm.nih.gov/pubmed/11496232 <a href="http://www.ncbi.nlm.nih.gov/pubmed/11496232">Busse W, et al.</a> 114107493 Charles, Nicolas NIAMS - IRP Charles, Nicolas 0 114107492 Rivera, Juan NIAMS - IRP NIAMS Rivera, Juan (NIAMS) 1 114107492 Rivera, Juan NIAMS - IRP NIAMS Rivera, Juan (NIAMS) 1 114107493 Charles, Nicolas NIAMS - IRP Charles, Nicolas 0 114101697 Autoreactive IgE Antibodies Are Pathological In Lupus Nephritis: Potential Use Of Anti-IgE In Treatment Of Lupus Nephritis E-216-2010-0 Filing authorized NIAMS 83656052 Knezevic, Vladimir vlado.knezevic@nih.gov
United States of America Technology Advancement Office vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-2395] Potential Use of anti-IgE in the Treatment of Lupus Nephritis&body=Please send me information about technology [TAB-2395] Potential Use of anti-IgE in the Treatment of Lupus Nephritis. Knezevic, Vladimir<br><a href="mailto:vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-2395] Potential Use of anti-IgE in the Treatment of Lupus Nephritis&body=Please send me information about technology [TAB-2395] Potential Use of anti-IgE in the Treatment of Lupus Nephritis.">vlado.knezevic@nih.gov</a><br> 114167206 E-216-2010-0 E-216-2010-0-US-06 Compositions and Methods for Treating or Preventing Lupus National Stage US 9,657,292 13/989,744 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9657292 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9657292">9,657,292</a><br />Filed on 2014-01-15<br />Status: Issued 114168262 E-216-2010-0 E-216-2010-0-US-07 Compositions and Methods for Treating or Preventing Lupus CON US 10,017,762 15/498,202 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10017762 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10017762">10,017,762</a><br />Filed on 2017-04-26<br />Status: Issued 114168691 E-216-2010-0 E-216-2010-0-US-08 COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING LUPUS DIV US 10,907,151 16/030,185 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10907151 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10907151">10,907,151</a><br />Filed on 2018-07-09<br />Status: Issued 114122633 IB3XXX 114122634 IXXXXX 114122635 IBXXXX 114142723 AUTOREACTIVE 114142724 IGE 114142725 antibodies 114142726 Are 114142727 PATHOLOGICAL 114142728 Lupus 114142729 Nephritis: 114142730 Potential 114142731 Anti-IgE 114142732 treatment 114142733 Nephritis TAB-3844 145383479 Vitamin C renal leak as a clinical diagnostic tool in the detection, monitoring, and management of acute and chronic diseases NIDDK Cardiology, Collaboration, Diagnostics, Endocrinology, Licensing, Metabolic Disease, Neurology, Non-Medical Devices, Research Materials Cardiology Collaboration Diagnostics Endocrinology Licensing Metabolic Disease Neurology Non-Medical Devices Research Materials Ifechukwude Ebenuwa, Mark Levine, Pierre-Christian Violet <p>This technology includes a clinical diagnostic tool for measuring vitamin C elimination by human kidneys that can be used for detecting, monitoring, and managing acute and chronic diseases. Findings revealed significant associations between vitamin C renal leak status and clinical variables affecting renal function and blood glucose. The technology uses vitamin C depletion-repletion kinetics and pharmacokinetic models to establish a physiological vitamin C renal threshold. This allowed us to define &ldquo;vitamin C renal leak&rdquo; as urinary vitamin C levels below the established minimal elimination threshold. The technology was tested and validated in multiple clinical studies involving more than five cohorts of healthy controls or those with chronic disease.</p> Characterization of vitamin C renal leak may be used in the prevention, screening, diagnosis, treatment, or management of many diseases. For various acute or chronic medical conditions, vitamin C renal leak status may be the earliest indicator of underlying pathogenesis when compared to current laboratory measures such as creatinine or proteinuria. Vitamin C renal leak can also potentially be used to monitor disease progression (staging) and for positive responses or adverse reactions to therapeutic interventions (drugs or procedures). Additionally, knowledge of vitamin C renal leak status in individual patients or its prevalence in disease states may provide guidelines and recommendations for daily intake. <ul> <li>Establishment of a commercial service to measure vitamin C renal leak in plasma and urine for diagnostic or management purposes of many conditions (to include but not be limited to diabetes and Fabry disease).</li> <li>Vitamin C renal leak may help detect and monitor renal damage in diabetes and other chronic conditions and potentially guide the timeline for protective medications such as ACE/ARBs.</li> <li>Vitamin C renal leak may identify patients who would benefit from alternative medications for managing conditions. For example, GLP-1 agonists or SGLT-2 inhibitors may more effectively protect cardiovascular disease patients with vitamin C leaks.</li> <li>Vitamin C loss may be a biomarker to indicate the need for earlier treatment of Fabry disease.</li> </ul> We are seeking statements of capability or interest from parties interested in collaborative research to further developer, evaluate, or commercialize this technology. Available for non-exclusive or exclusive licensing 2023-05-17 2024-12-26 2024-12-26 2023-05-17 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract E-112-2021-0 145528929 Monti, D.A., 2023 https://pubmed.ncbi.nlm.nih.gov/36806448/ <a href="https://pubmed.ncbi.nlm.nih.gov/36806448/">Monti, D.A., 2023</a> 145529092 Ebenuwa, I., 2022 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9194231/ <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9194231/">Ebenuwa, I., 2022</a> 146510480 Ebenuwa, I., 2023 https://pubmed.ncbi.nlm.nih.gov/37264998/ <a href="https://pubmed.ncbi.nlm.nih.gov/37264998/">Ebenuwa, I., 2023</a> 150987351 Tu, H., 2015 https://pubmed.ncbi.nlm.nih.gov/26870799/ <a href="https://pubmed.ncbi.nlm.nih.gov/26870799/">Tu, H., 2015</a> 150987354 Ebenuwa, I., 2022 https://pubmed.ncbi.nlm.nih.gov/35537862/ <a href="https://pubmed.ncbi.nlm.nih.gov/35537862/">Ebenuwa, I., 2022</a> 150987357 Ebenuwa, I., 2023 https://pubmed.ncbi.nlm.nih.gov/37229630/ <a href="https://pubmed.ncbi.nlm.nih.gov/37229630/">Ebenuwa, I., 2023</a> 150987360 Monti, D., 2023 https://pubmed.ncbi.nlm.nih.gov/36806448/ <a href="https://pubmed.ncbi.nlm.nih.gov/36806448/">Monti, D., 2023</a> 150987363 Ebenuwa, I., 2023 https://pubmed.ncbi.nlm.nih.gov/37264998/ <a href="https://pubmed.ncbi.nlm.nih.gov/37264998/">Ebenuwa, I., 2023</a> 150987366 Levine, M., 1996 https://pubmed.ncbi.nlm.nih.gov/8623000/ <a href="https://pubmed.ncbi.nlm.nih.gov/8623000/">Levine, M., 1996</a> 145383490 Ebenuwa, Ifechukwude National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Ebenuwa, Ifechukwude 1 145383589 Violet, Pierre-Christian National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Violet, Pierre-Christian 2 145383598 Levine, Mark National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Levine, Mark (NIDDK) 3 145383490 Ebenuwa, Ifechukwude National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Ebenuwa, Ifechukwude 1 145383589 Violet, Pierre-Christian National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Violet, Pierre-Christian 2 145383598 Levine, Mark National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Levine, Mark (NIDDK) 3 145383482 Vitamin C Renal Leak As A Clinical Diagnostic Tool In The Detection, Monitoring And Management Of Acute And Chronic Diseases E-112-2021-0 Filing authorized National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83656052 Knezevic, Vladimir vlado.knezevic@nih.gov
United States of America Technology Advancement Office vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-3844] Vitamin C renal leak as a clinical diagnostic tool in the detection, monitoring, and management of acute and chronic diseases&body=Please send me information about technology [TAB-3844] Vitamin C renal leak as a clinical diagnostic tool in the detection, monitoring, and management of acute and chronic diseases. Knezevic, Vladimir<br><a href="mailto:vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-3844] Vitamin C renal leak as a clinical diagnostic tool in the detection, monitoring, and management of acute and chronic diseases&body=Please send me information about technology [TAB-3844] Vitamin C renal leak as a clinical diagnostic tool in the detection, monitoring, and management of acute and chronic diseases.">vlado.knezevic@nih.gov</a><br> TAB-2072 114096289 Diagnostic Biomarker of Metastasis for Improved Clinical Management of Head and Neck Cancer NIDCR Diagnostics, Licensing, Oncology Diagnostics Licensing Oncology J Silvio Gutkind Squamous Cell Carcinoma of the Head and Neck (HNSCC) is associated with poor prognosis due to the advanced stage of disease (metastasis) typically found at the time of diagnosis. Investigators at the NIH have developed a sensitive method using a protein biomarker for detecting even just a few HNSCC tumor cells in lymph nodes with occult disease. Combination of this staging technique with intraoperative sentinel lymph node mapping would improve the management of HNSCC by identifying patients for which radical lymph node dissection is most appropriate, sparing those for which it is not, and informing decisions for adjuvant cancer therapy during a single surgery.<br /><br /> This technology arose from the discovery that the Desmoglein-3 (DSG3) protein which is highly expressed in tumors of squamous epithelial origin, like HNSCC, is also expressed in invaded lymph nodes but it is not found in normal lymph nodes. Therefore, DSG3 can serve as a biomarker for detecting metastastatic spread of squamous cell carcinoma tumors. This is achieved by performing protein detection immunoassays to samples (biopsy, aspirate, or isolated cells) of suspect lymph nodes. <ul> <li>Rapid diagnosis during surgery increases effectiveness of intervention thereby reducing need for subsequent surgery</li> <li>Improved accuracy of direct measurement of protein levels over RNA assays</li> <li>More robust assay as protein is more stable than RNA</li> </ul> <ul> <li>Use with sentinel lymph node mapping for rapid, intraoperational diagnosis of metastatic HNSCC for guiding proper therapeutic approach</li> </ul> Available for non-exclusive or exclusive licensing 2022-03-08 2024-12-26 2024-12-26 2010-03-01 Biomarker, CA1XXX, Carcinoma, squamous cell of head and neck, CAXXXX, CXXXXX, Detection, DSG3, Identification, lymph, MEN 1, Metastasis, nodes, OCCULT, Patent Category - Biotechnology, Sentinel, Squamous cell carcinoma, Squamous cell carcinoma of the head and neck, Zollinger-Ellison syndrome False True <ul> <li>Early stage</li> <li>Clinical data available</li> </ul> True NIHTT 37470483 Website Abstract 114171019 Patel V, et al. https://www.ncbi.nlm.nih.gov/pubmed/18281532 <a href="https://www.ncbi.nlm.nih.gov/pubmed/18281532">Patel V, et al.</a> 114103605 Gutkind, J Silvio NIDCR NIDCR Gutkind, J Silvio (NIDCR) 1 114103605 Gutkind, J Silvio NIDCR NIDCR Gutkind, J Silvio (NIDCR) 1 114101361 Identification Of DSG3 As A Biomarker For The Detection Of Occult Metastasis In Sentinel Lymph Nodes E-300-2008-0 Filing authorized NCI, NIDCR 83656052 Knezevic, Vladimir vlado.knezevic@nih.gov
United States of America Technology Advancement Office vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-2072] Diagnostic Biomarker of Metastasis for Improved Clinical Management of Head and Neck Cancer&body=Please send me information about technology [TAB-2072] Diagnostic Biomarker of Metastasis for Improved Clinical Management of Head and Neck Cancer. Knezevic, Vladimir<br><a href="mailto:vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-2072] Diagnostic Biomarker of Metastasis for Improved Clinical Management of Head and Neck Cancer&body=Please send me information about technology [TAB-2072] Diagnostic Biomarker of Metastasis for Improved Clinical Management of Head and Neck Cancer.">vlado.knezevic@nih.gov</a><br> 114166581 E-300-2008-0 E-300-2008-0-US-03 Identification Of DSG-3 As A Biomarker For The Detection Of Metastasis In Lymph Nodes National Stage US 9,151,762 13/376,984 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9151762 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9151762">9,151,762</a><br />Filed on 2011-12-08<br />Status: Issued 114120924 CXXXXX 114120925 CAXXXX 114120926 CA1XXX 114139368 Identification 114139369 DSG3 114139370 Biomarker 114139371 Detection 114139372 OCCULT 114139373 Metastasis 114139374 Sentinel 114139375 lymph 114139376 nodes 114139377 Patent Category - Biotechnology 114156997 Zollinger-Ellison syndrome 114156998 Carcinoma, squamous cell of head and neck 114156999 Squamous cell carcinoma 114158597 MEN 1 114158598 Squamous cell carcinoma of the head and neck TAB-2504 114096700 Diagnostic Test and Therapeutic Target for Sjogren's Syndrome NIDCR Diagnostics, Immunology, Research Materials, Therapeutics Diagnostics Immunology Research Materials Therapeutics John (Jay) Chiorini, Melodie Weller, Hongen Yin Sjögren's syndrome is an autoimmune disease that attacks salivary glands resulting in chronic dry mouth and dry eyes. Currently, there is no single diagnostic test to confirm the presence of Sjögren's. Physicians presently reach diagnosis after conducting a series of blood and functional tests for tear and salivary production. Diagnosis is further complicated as Sjögren's symptoms frequently mimic those of other autoimmune diseases (e.g., lupus, rheumatoid arthritis, etc.) and is often overlooked as dryness associated with medications being taken by the patient. <br /><br /> Researchers at NIDCR have identified overexpression of a growth factor, bone morphogenetic protein 6 (BMP6), in patients with Sjögren's. By detecting BMP6 expression and/or activity, this invention potentially presents a singular confirmation to diagnose those suffering and those at risk for developing Sjögren's. BMP6 also presents a potential therapeutic target for Sjögren's, a disease for which there is presently no cure. <br /><br /> Researchers have also discovered unique expression profiles for two other genes (XIST and MECP2) in male Sjögren's patients. Detecting aberrant expression and/or activity of these genes also offer a potential singular test for diagnosing Sjögren's in male subjects. <ul> <li>Currently no single test available to diagnose Sjögren's</li> <li>Currently there is no cure for Sjögren's; present palliative treatments only reduce symptoms (e.g., moisture replacement therapy for eyes and mouth, and systemic anti-inflammatory or immunosuppressive agents for more advanced forms of disease)</li> </ul> <ul> <li>Singular diagnostic test to diagnose Sjögren's</li> <li>Therapeutic target to develop treatment for Sjögren's</li> </ul> Available for non-exclusive or exclusive licensing 2022-03-08 2024-12-26 2024-12-26 2012-11-21 Alteration, BMP6, Detection, Diagnosis, Expression, Gland, IA3XXX, IAXXXX, IXXXXX, LEVELS, Listed LPM Contreras as of 4/15/2015, Locally, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Salivary, Sjogren's, Syndrome, treatment False True <ul> <li>Pre-clinical</li> <li>In vitro data available</li> <li>In vivo data available (animal)</li> <li>In vivo data available (human)</li> </ul> True NIHTT 37470483 Website Abstract 114171724 Dix DJ, et al. http://www.ncbi.nlm.nih.gov/pubmed/8622925 <a href="http://www.ncbi.nlm.nih.gov/pubmed/8622925">Dix DJ, et al.</a> 114109192 Weller, Melodie NIDCR NIDCR Weller, Melodie (NIDCR) 0 114109193 Yin, Hongen NIDCR NIDCR Yin, Hongen (NIDCR) 0 114109191 Chiorini, John (Jay) NIDCR NIDCR Chiorini, John (Jay) (NIDCR) 1 114109191 Chiorini, John (Jay) NIDCR NIDCR Chiorini, John (Jay) (NIDCR) 1 114109192 Weller, Melodie NIDCR NIDCR Weller, Melodie (NIDCR) 0 114109193 Yin, Hongen NIDCR NIDCR Yin, Hongen (NIDCR) 0 114100884 Diagnosis And Treatment Of Sjogren's Syndrome By Detection And Alteration Of BMP6 Levels Of Expression Locally In The Salivary Gland E-232-2011-0 Filing authorized NIDCR 114101469 Diagnosis And Treatment Of Sjogren's Syndrome By Detection And Alteration Of BMP6 Levels Of Expression Locally In The Salivary Gland E-232-2011-1 Filing authorized NIDCR 83656052 Knezevic, Vladimir vlado.knezevic@nih.gov
United States of America Technology Advancement Office vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-2504] Diagnostic Test and Therapeutic Target for Sjogren's Syndrome&body=Please send me information about technology [TAB-2504] Diagnostic Test and Therapeutic Target for Sjogren's Syndrome. Knezevic, Vladimir<br><a href="mailto:vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-2504] Diagnostic Test and Therapeutic Target for Sjogren's Syndrome&body=Please send me information about technology [TAB-2504] Diagnostic Test and Therapeutic Target for Sjogren's Syndrome.">vlado.knezevic@nih.gov</a><br> 114167954 E-232-2011-1 E-232-2011-1-US-05 METHODS FOR THE DIAGNOSIS AND TREATMENT OF SJÖGREN'S SYNDROME DIV US 10,864,285 15/798,969 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10864285 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10864285">10,864,285</a><br />Filed on 2017-10-31<br />Status: Issued 114168246 E-232-2011-1 E-232-2011-1-US-03 METHODS FOR THE DIAGNOSIS AND TREATMENT OF SJOGRENS SYNDROME National Stage US 9,833,519 14/428,929 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9833519 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9833519">9,833,519</a><br />Filed on 2015-03-17<br />Status: Issued 114123026 IXXXXX 114123027 IAXXXX 114123028 IA3XXX 114143723 Diagnosis 114143724 treatment 114143725 Sjogren's 114143726 Syndrome 114143727 Detection 114143728 Alteration 114143729 BMP6 114143730 LEVELS 114143731 Expression 114143732 Locally 114143733 Salivary 114143734 Gland 114148891 Listed LPM Contreras as of 4/15/2015 114148892 Pre LPM working set 20150418 114148893 Post LPM Assignment Set 20150420 TAB-2499 114096695 Adeno-Associated Virus Gene Therapy for Diabetes and Obesity NIDCR Therapeutics Therapeutics John (Jay) Chiorini, Giovanni Di Pasquale, Edward Mannucci This invention is directed to adeno-associated virus (AAV) vector delivery of exendin-4 (Ex-4) to salivary glands as treatment for diabetes and obesity. Ex-4 is a potent and long-acting agonist of the receptor for glucagon-like peptide 1 (GLP-1). Scientists at NIDCR have shown that AAV-mediated delivery of Ex-4 resulted in improved glucose homeostasis and weight profile in two rat models of obesity and type 2 diabetes. Further, AAV-mediated delivery of Ex-4 to rat salivary glands resulted in localized and sustained expression of Ex-4 that was biologically active and well tolerated.<br /><br /> AAV-mediated delivery of Ex-4 is superior to administering GLP-1 analogs in that AAV-Ex-4 expression is more stable and longer acting. Like GLP-1 analogs, Ex-4 expression also potentially provides beneficial effects like reduced hypoglycemia, appetite suppression, and potential weight loss. <ul> <li>Potential for potent glucose homeostasis therapy with longer duration than current drugs.</li> <li>More convenient than daily or weekly injections.</li> </ul> <ul> <li>Therapy for diabetes or obesity.</li> </ul> Available for non-exclusive or exclusive licensing 2022-03-08 2024-12-26 2024-12-26 2012-11-16 DIABETES, EPITHELIA, Expression, Fusion, GBXXXX, Gland, IBXXXX, Listed LPM Contreras as of 4/15/2015, NGF/exendin-4, Novel, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Protein, Salivary, treatment False True <ul> <li>Early-stage</li> <li>In vitro data available</li> <li>In vivo data available (animal)</li> </ul> True NIHTT 37470483 Website Abstract 114171718 Di Pasquale G, et al. https://www.ncbi.nlm.nih.gov/pubmed/22808093 <a href="https://www.ncbi.nlm.nih.gov/pubmed/22808093">Di Pasquale G, et al.</a> 114105720 Di Pasquale, Giovanni NIDCR NIDCR Di Pasquale, Giovanni (NIDCR) 0 114107661 Mannucci, Edward Careggi Teaching Hospital Mannucci, Edward 0 114105719 Chiorini, John (Jay) NIDCR NIDCR Chiorini, John (Jay) (NIDCR) 1 114105719 Chiorini, John (Jay) NIDCR NIDCR Chiorini, John (Jay) (NIDCR) 1 114105720 Di Pasquale, Giovanni NIDCR NIDCR Di Pasquale, Giovanni (NIDCR) 0 114107661 Mannucci, Edward Careggi Teaching Hospital Mannucci, Edward 0 114101649 Treatment Of Diabetes By Expression Of A Novel NGF/exendin-4 Fusion Protein From The Salivary Gland Epithelia E-142-2011-0 Filing authorized Careggi Teaching Hospital, NIDCR 83656052 Knezevic, Vladimir vlado.knezevic@nih.gov
United States of America Technology Advancement Office vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-2499] Adeno-Associated Virus Gene Therapy for Diabetes and Obesity&body=Please send me information about technology [TAB-2499] Adeno-Associated Virus Gene Therapy for Diabetes and Obesity. Knezevic, Vladimir<br><a href="mailto:vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-2499] Adeno-Associated Virus Gene Therapy for Diabetes and Obesity&body=Please send me information about technology [TAB-2499] Adeno-Associated Virus Gene Therapy for Diabetes and Obesity.">vlado.knezevic@nih.gov</a><br> 114162537 E-142-2011-0 E-142-2011-0-US-06 AAV Mediated Exendin-4 Gene Transfer to Salivary Glands to Protect Subjects from Diabetes or Obesity DIV US 10,300,095 15/368,940 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10300095 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10300095">10,300,095</a><br />Filed on 2016-12-05<br />Status: Issued 114165476 E-142-2011-0 E-142-2011-0-US-05 AAV MEDIATED EXENDIN-4 GENE TRANSFER TO SALIVARY GLANDS TO PROTECT SUBJECTS FROM DIABETES OR OBESITY National Stage US 9,511,103 14/112,790 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9511103 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9511103">9,511,103</a><br />Filed on 2014-03-20<br />Status: Issued 114168875 E-142-2011-0 E-142-2011-0-US-10 AAV MEDIATED EXENDIN-4 GENE TRANSFER TO SALIVARY GLANDS TO PROTECT SUBJECTS FROM DIABETES OR OBESITY DIV US 11,207,361 16/396,262 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11207361 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11207361">11,207,361</a><br />Filed on 2019-04-26<br />Status: Issued 114123003 GBXXXX 114123004 IBXXXX 114143416 Listed LPM Contreras as of 4/15/2015 114143464 Pre LPM working set 20150418 114143465 Post LPM Assignment Set 20150420 114143665 Novel 114143666 DIABETES 114143667 Fusion 114143668 treatment 114143669 NGF/exendin-4 114143670 Expression 114143671 Protein 114143672 Salivary 114143673 Gland 114143674 EPITHELIA TAB-2954 114094518 A Novel Adeno-Associated Virus for Gene Therapy NIDCR Endocrinology, Geriatrics, Immunology, Neurology, Oncology, Therapeutics Endocrinology Geriatrics Immunology Neurology Oncology Therapeutics John (Jay) Chiorini, Giovanni Di Pasquale Scientists at the NIH disclosed a novel adeno-associated virus (AAV) termed "44-9." AAV44-9 based vectors have high gene transfer activity in a number of cell types, including salivary gland cells, liver cells, and different types of neurons (e.g., cells of the cortex, olfactory bulb, and brain stem, and Purkinje cells of the cerebellum). These vectors can increase the transduction efficiency and decrease the potential of being neutralized by preexisting antibodies compared to the wild type AAV. Preliminary results from animal studies suggest that AAV44-9 vectors can efficiently deliver genes of interest, and the protein products of the delivered genes can be detected in bloodstream and at the local tissues. Therefore, these vectors are suitable for gene therapy for cells/tissues that are not efficiently targeted by other vectors. <ul> <li>High gene transfer activity in a number of cell types including salivary gland cells, liver cells, and different types of neurons (e.g., cells of the cortex, olfactory bulb, and brain stem, and Purkinje cells of the cerebellum).</li> <li>As a gene transfer vector for cells that are not efficiently targeted by other vector.</li> </ul> <ul> <li>AAV44-9 can be used as a delivery vector in gene therapy.</li> </ul> Available for non-exclusive or exclusive licensing 2022-03-08 2024-12-26 2024-12-26 2021-07-19 AAV, CHARACTERIZATION, Gene, Generation, Listed LPM Hu as of 4/17/2015, Novel, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, THERAPY, USEFUL, VAXXXX, VCXXXX, VEXXXX, VFXXXX, VGXXXX, WJXXXX, XEXXXX, YBXXXX, YCXXXX False True <ul> <li>In vitro data available</li> <li>In vivo data available (animal)</li> </ul> True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114171852 Schmidt M, et al. http://www.ncbi.nlm.nih.gov/pubmed/16641301 <a href="http://www.ncbi.nlm.nih.gov/pubmed/16641301">Schmidt M, et al.</a> 114108022 Di Pasquale, Giovanni NIDCR NIDCR Di Pasquale, Giovanni (NIDCR) 0 114108021 Chiorini, John (Jay) NIDCR NIDCR Chiorini, John (Jay) (NIDCR) 1 114108021 Chiorini, John (Jay) NIDCR NIDCR Chiorini, John (Jay) (NIDCR) 1 114108022 Di Pasquale, Giovanni NIDCR NIDCR Di Pasquale, Giovanni (NIDCR) 0 114099309 Generation And Characterization Of A Novel AAV Useful For Gene Therapy E-175-2015-0 Filing authorized NIDCR 145257839 Generation And Characterization Of A Novel AAV Useful For Gene Therapy E-175-2015-1 Filing authorized NIDCR 83656052 Knezevic, Vladimir vlado.knezevic@nih.gov
United States of America Technology Advancement Office vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-2954] A Novel Adeno-Associated Virus for Gene Therapy&body=Please send me information about technology [TAB-2954] A Novel Adeno-Associated Virus for Gene Therapy. Knezevic, Vladimir<br><a href="mailto:vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-2954] A Novel Adeno-Associated Virus for Gene Therapy&body=Please send me information about technology [TAB-2954] A Novel Adeno-Associated Virus for Gene Therapy.">vlado.knezevic@nih.gov</a><br> 145257847 E-175-2015-1 E-175-2015-1-JP-04 AAV Isolate and Fusion Protein Comprising Nerve Growth Factor Signal Peptide and Parathyroid Hormone National Stage Japan 6805174 2017-558710 Issued Japan <br />National Stage 2017-558710<br />Filed on 2017-11-09<br />Status: Issued 145257848 E-175-2015-1 E-175-2015-1-US-05 AAV ISOLATE AND FUSION PROTEIN COMPRISING NERVE GROWTH FACTOR SIGNAL PEPTIDE AND PARATHYROID HORMONE National Stage US 11,447,797 15/573,214 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11447797 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11447797">11,447,797</a><br />Filed on 2017-11-10<br />Status: Issued 114112424 VCXXXX 114112425 VEXXXX 114112426 VFXXXX 114114321 VGXXXX 114121228 VAXXXX 114121479 WJXXXX 114121480 XEXXXX 114121481 YBXXXX 114121482 YCXXXX 114139043 Pre LPM working set 20150418 114139044 Post LPM Assignment Set 20150420 114142543 USEFUL 114142544 Gene 114142545 THERAPY 114142546 Listed LPM Hu as of 4/17/2015 114144739 Generation 114144740 CHARACTERIZATION 114144741 Novel 114144742 AAV TAB-2953 114094448 Modified AAV5 Vectors for Enhanced Transduction and Reduced Antibody Neutralization NIDCR Endocrinology, Geriatrics, Immunology, Oncology, Therapeutics Endocrinology Geriatrics Immunology Oncology Therapeutics Sandra Afione-Wainer, Mavis Agbandje-Mckenna, John (Jay) Chiorini, Sujata Halder Scientists at the NIH disclosed a mutated adeno-associated virus (AAV) serotype 5 by modifying sialic acid binding regions which mediate viral entry into host cells. Preliminary results from animal studies suggest that this modification can increase transduction by 3-4 folds in salivary glands and muscles, and can significantly decrease the potential of being neutralized by preexisting antibodies compared to the wild type AAV. Thus, the modified AAV5 vectors seem to be optimal for gene therapy. This invention overcomes two major issues in AAV-based gene therapy: the ability to efficiently transduce the target cells and the ability to evade the immune response to vectors. <ul> <li>Enhanced transduction activity.</li> <li>Reduced the potential for being neutralized by preexisting antibodies.</li> </ul> <ul> <li>Genetically engineered AAV5 vectors for gene therapy.</li> </ul> Available for non-exclusive or exclusive licensing 2022-03-08 2024-12-26 2024-12-26 2015-08-03 AAV5, ANTIBODY, ENGINEERED, Enhanced, GENETICALLY, Listed LPM Reichman as of 4/15/2015, Neutralization, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, REDUCED, transduction, VAXXXX, VCXXXX, vectors, VFXXXX, VGXXXX, WJXXXX, XEXXXX, YAXXXX, YCXXXX False True <ul> <li>Early-stage</li> <li>In vivo data available (animal)</li> </ul> True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114169729 Afione S, et al. https://www.ncbi.nlm.nih.gov/pubmed/25410855 <a href="https://www.ncbi.nlm.nih.gov/pubmed/25410855">Afione S, et al.</a> 114169730 Chiorini J, et al. https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6468524 <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6468524">Chiorini J, et al.</a> 114169731 Chiorini J, et al. https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6984517 <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6984517">Chiorini J, et al.</a> 114171850 Chiorini J, et al. https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7479554 <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7479554">Chiorini J, et al.</a> 114171851 Chiorini J, et al. https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6855314 <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6855314">Chiorini J, et al.</a> 114108018 Afione-Wainer, Sandra National Heart, Lung, and Blood Institute (NHLBI) NIDCR Afione-Wainer, Sandra (NIDCR) 0 114108019 Agbandje-Mckenna, Mavis University of Florida Agbandje-Mckenna, Mavis 0 114108020 Halder, Sujata University of Florida Halder, Sujata 0 114108017 Chiorini, John (Jay) NIDCR NIDCR Chiorini, John (Jay) (NIDCR) 1 114108017 Chiorini, John (Jay) NIDCR NIDCR Chiorini, John (Jay) (NIDCR) 1 114108018 Afione-Wainer, Sandra National Heart, Lung, and Blood Institute (NHLBI) NIDCR Afione-Wainer, Sandra (NIDCR) 0 114108019 Agbandje-Mckenna, Mavis University of Florida Agbandje-Mckenna, Mavis 0 114108020 Halder, Sujata University of Florida Halder, Sujata 0 114099234 Genetically Engineered AAV5 Vectors For Enhanced Transduction And Reduced Antibody Neutralization E-097-2015-0 Filing authorized NIDCR, University of Florida 83656052 Knezevic, Vladimir vlado.knezevic@nih.gov
United States of America Technology Advancement Office vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-2953] Modified AAV5 Vectors for Enhanced Transduction and Reduced Antibody Neutralization&body=Please send me information about technology [TAB-2953] Modified AAV5 Vectors for Enhanced Transduction and Reduced Antibody Neutralization. Knezevic, Vladimir<br><a href="mailto:vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-2953] Modified AAV5 Vectors for Enhanced Transduction and Reduced Antibody Neutralization&body=Please send me information about technology [TAB-2953] Modified AAV5 Vectors for Enhanced Transduction and Reduced Antibody Neutralization.">vlado.knezevic@nih.gov</a><br> 114165852 E-097-2015-0 E-097-2015-0-US-02 Adeno-Associated Vectors for Enhanced Transduction and Reduced Immunogenicity ORD US 10,081,659 15/092,482 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10081659 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10081659">10,081,659</a><br />Filed on 2016-04-06<br />Status: Issued 114112621 VGXXXX 114112622 WJXXXX 114112623 XEXXXX 114112624 YAXXXX 114121227 YCXXXX 114123499 VAXXXX 114123500 VCXXXX 114123501 VFXXXX 114135768 GENETICALLY 114135769 ENGINEERED 114135770 AAV5 114135771 vectors 114135772 Enhanced 114135773 transduction 114144733 REDUCED 114144734 ANTIBODY 114144735 Neutralization 114144736 Listed LPM Reichman as of 4/15/2015 114144737 Pre LPM working set 20150418 114144738 Post LPM Assignment Set 20150420 TAB-2543 114096738 mTOR Inhibition for the Prevention of Epithelial Stem Cell Loss and Mucositis NIDCR Licensing, Oncology, Therapeutics Licensing Oncology Therapeutics Ana Cotrim, J Silvio Gutkind, Ramiro Iglesias-Bartolome, James Mitchell, Alfredo Molinolo, Vyomesh Patel The integrity of the epidermis and mucosal epithelia is highly dependent on self-renewing stem cells and, therefore, is vulnerable to physical and chemical damage from common cancer treatments, such as radiation or chemotherapy. Consequently, many cancer patients undergoing these treatments develop mucositis, a debilitating condition involving painful and deep mucosal ulcerations. Since current prevention and treatment options for mucositis are limited, providing only minor relief and no protection to stem cells, novel therapies are needed.<br /><br /> The NIH inventors have recently discovered that the mammalian target of rapamycin (mTOR) mediates stem cells exhaustion in the skin and leads to progressive hair loss. More importantly, they have shown that mTOR inhibition reduces oxidative stress in the epithelial stem cells and mTOR inhibitors can be used to increase the re-populative capacity of tissue resident stem cells to maintain tissue homeostasis after injury or stress. Therefore, this technology could be used to prevent epithelial stem cell loss and provide relief from radiation-induced mucositis. Likewise, it could be used to prevent mucositis and hair loss in patients undergoing chemotherapy and stem cell transplantation. For optimal delivery and effectiveness, rapamycin or other mTOR inhibitor could be administered in the form of a mouthwash or gel product to patients prior to receiving radiation (or other) treatments. <ul> <li>Reduces the oxidative stress in epithelial stem cells and can increase their repopulative capacity.</li> <li>Preserves the integrity of the oral mucosa and protects from radiation-induced stem cell loss and mucositis.</li> </ul> <ul> <li>Prevention and treatment of epithelial stem cell loss and mucositis.</li> </ul> Available for non-exclusive or exclusive licensing 2022-03-08 2024-12-26 2024-12-26 2013-03-12 CBXXXX, Cell, CXXXXX, Epithelial, inhibition, mTOR, Mucositis, PREVENTS, PROTECTS, Radiation-induced, Senescence, Stem False True <ul> <li>Pre-clinical</li> <li>In vitro data available</li> <li>In vivo data available (animal)</li> </ul> True NIHTT 37470483 Website Abstract 114171771 Iglesias-Bartolome R, et al. https://www.ncbi.nlm.nih.gov/pubmed/22958932 <a href="https://www.ncbi.nlm.nih.gov/pubmed/22958932">Iglesias-Bartolome R, et al.</a> 114107831 Iglesias-Bartolome, Ramiro NIDCR NCI Iglesias-Bartolome, Ramiro (NCI) 0 114107832 Patel, Vyomesh NIDCR Patel, Vyomesh 0 114107833 Cotrim, Ana NIDCR Cotrim, Ana 0 114107834 Molinolo, Alfredo NIDCR Molinolo, Alfredo 0 114107835 Mitchell, James NCI - CCR NCI Mitchell, James (NCI) 0 114107830 Gutkind, J Silvio NIDCR NIDCR Gutkind, J Silvio (NIDCR) 1 114107830 Gutkind, J Silvio NIDCR NIDCR Gutkind, J Silvio (NIDCR) 1 114107831 Iglesias-Bartolome, Ramiro NIDCR NCI Iglesias-Bartolome, Ramiro (NCI) 0 114107832 Patel, Vyomesh NIDCR Patel, Vyomesh 0 114107833 Cotrim, Ana NIDCR Cotrim, Ana 0 114107834 Molinolo, Alfredo NIDCR Molinolo, Alfredo 0 114107835 Mitchell, James NCI - CCR NCI Mitchell, James (NCI) 0 114101856 MTOR Inhibition Prevents Epithelial Stem Cell Senescence And Protects From Radiation-induced Mucositis E-257-2012-0 Filing authorized NCI, NIDCR 83656052 Knezevic, Vladimir vlado.knezevic@nih.gov
United States of America Technology Advancement Office vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-2543] mTOR Inhibition for the Prevention of Epithelial Stem Cell Loss and Mucositis&body=Please send me information about technology [TAB-2543] mTOR Inhibition for the Prevention of Epithelial Stem Cell Loss and Mucositis. Knezevic, Vladimir<br><a href="mailto:vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-2543] mTOR Inhibition for the Prevention of Epithelial Stem Cell Loss and Mucositis&body=Please send me information about technology [TAB-2543] mTOR Inhibition for the Prevention of Epithelial Stem Cell Loss and Mucositis.">vlado.knezevic@nih.gov</a><br> 114167024 E-257-2012-0 E-257-2012-0-US-02 Methods Of Preventing The Development Of Mucositis And Related Disorders ORD US 9,278,090 13/798,863 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9278090 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9278090">9,278,090</a><br />Filed on 2013-03-13<br />Status: Issued 114123238 CXXXXX 114123239 CBXXXX 114144168 mTOR 114144169 inhibition 114144170 PREVENTS 114144171 Epithelial 114144172 Stem 114144173 Cell 114144174 Senescence 114144175 PROTECTS 114144176 Radiation-induced 114144177 Mucositis TAB-2238 114096447 Identification of EGFR as A Receptor for AAV6 Transduction NIDCR Licensing, Therapeutics Licensing Therapeutics John (Jay) Chiorini, Michael Schmidt, Melodie Weller AAV vectors offer unique advantages in gene therapy applications. Studies have shown that these replication deficient parvovirus vectors can deliver DNA to specific tissues and confer long-term transgene expression in a variety of systems. Although many studies have looked at the tissue-specific expression elicited by each of the AAV serotypes, a true understanding of how AAV transduces these tissues is still unclear. Of the large AAV family, only a few receptors or co-receptors have been identified. The ability to better target transduction to specific tissues on the basis of the receptors that each serotype uses for entry is essential for selecting a serotype given the receptor expression in specific tissue, or to exploit altered receptor expression under disease conditions.<br /><br /> AAV6 has been reported to effectively transduce muscle, lung, brain, and multiple types of tumors, including gliomas and lung adenocarcinomas. By using a bioinformatics based screen approach, the NIH investigators discovered that the epidermal growth factor receptor (EGFR) is a co-receptor for AAV6 infection in mammalian cells, and is necessary for efficient vector internalization. Improved gene therapy applications Available for non-exclusive or exclusive licensing 2022-03-08 2024-12-26 2024-12-26 2011-03-15 AAV6, EGFR, GB2A2X, GB2AXX, GB2XXX, GBXXXX, GXXXXX, Identification, RECEPTOR, transduction False True Pre-clinical True NIHTT 37470483 Website Abstract 114171278 Weller ML, et al. http://www.ncbi.nlm.nih.gov/pubmed/20473307 <a href="http://www.ncbi.nlm.nih.gov/pubmed/20473307">Weller ML, et al.</a> 114107136 Schmidt, Michael NIDCR NCI Schmidt, Michael (NCI) 0 114107137 Weller, Melodie NIDCR NIDCR Weller, Melodie (NIDCR) 0 114107138 Chiorini, John (Jay) NIDCR NIDCR Chiorini, John (Jay) (NIDCR) 1 114107138 Chiorini, John (Jay) NIDCR NIDCR Chiorini, John (Jay) (NIDCR) 1 114107136 Schmidt, Michael NIDCR NCI Schmidt, Michael (NCI) 0 114107137 Weller, Melodie NIDCR NIDCR Weller, Melodie (NIDCR) 0 114101546 Identification Of EGFR As A Receptor For AAV6 Transduction E-194-2010-0 Filing authorized NIDCR 83656052 Knezevic, Vladimir vlado.knezevic@nih.gov
United States of America Technology Advancement Office vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-2238] Identification of EGFR as A Receptor for AAV6 Transduction&body=Please send me information about technology [TAB-2238] Identification of EGFR as A Receptor for AAV6 Transduction. Knezevic, Vladimir<br><a href="mailto:vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-2238] Identification of EGFR as A Receptor for AAV6 Transduction&body=Please send me information about technology [TAB-2238] Identification of EGFR as A Receptor for AAV6 Transduction.">vlado.knezevic@nih.gov</a><br> 114166360 E-194-2010-0 E-194-2010-0-US-01 Epidermal Growth Factor Receptor (EGFR) And Methods Of Use In Adenoviral-Associated Virus Type 6 (AAV6) Transduction ORD US 8,808,684 12/879,142 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8808684 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8808684">8,808,684</a><br />Filed on 2010-09-10<br />Status: Issued 114167841 E-194-2010-0 E-194-2010-0-US-02 Epidermal Growth Factor Receptor (EGFR) and Methods of Use in Adenoviral-Associated Virus Type 6 (AAV6) Transduction ORD US 9,439,979 14/301,973 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9439979 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9439979">9,439,979</a><br />Filed on 2014-06-11<br />Status: Issued 114121916 GB2A2X 114121917 GXXXXX 114121918 GBXXXX 114121919 GB2XXX 114121920 GB2AXX 114141261 Identification 114141262 EGFR 114141263 RECEPTOR 114141264 AAV6 114141265 transduction TAB-3795 114097645 Application of AAV44.9 Vector in Gene Therapy for the Inner Ear NIDCR Cardiology, Dental, Endocrinology, Infectious Disease, Licensing, Oncology, Ophthalmology, Research Materials, Therapeutics Cardiology Dental Endocrinology Infectious Disease Licensing Oncology Ophthalmology Research Materials Therapeutics John (Jay) Chiorini, Giovanni Di Pasquale, Fabio Mammano, Veronica Zorzi This technology includes a novel AAV isolate (AAV44.9) to be used as gene therapy for the inner ear for the treatment of deafness. The ability of AAV vectors to transduce dividing and non-dividing cells, establish long-term transgene expression, and the lack of pathogenicity has made them attractive for use in gene therapy applications. Vectors based on new AAV isolates may have different host range and different immunological properties, thus allowing for more efficient transduction in certain cell types. We recently identified a novel AAV isolate as a contaminant of a laboratory stock of adenovirus and is referred to as AAV44.9. Surprisingly, this isolate has high gene transfer activity in a number of cell types including salivary gland cell, liver and nerves. Hearing and balance depend on the function of the inner ear sensory epithelium, which consists of hair cells and a number of supporting cells that provide mechanical support for the sensory cells. The development of efficient transgene delivery for the inner ear is an important step toward potential application of gene-based therapies for cochlear disorders. Enhanced spread and transduction of hair cells in the inner ear. Gene transfer for deafness and specifically targeting hair cells. Available for non-exclusive or exclusive licensing 2022-11-30 2024-12-26 2024-12-26 2022-11-30 2022-08-03 AAV44.9, APPLICATION, EAR, Gene, Inner, THERAPY, Vector, VPXXXX, WIXXXX, WJXXXX, XEXXXX False True True NIHTT 37470483 Website Abstract 114111591 Di Pasquale, Giovanni NIDCR NIDCR Di Pasquale, Giovanni (NIDCR) 0 114111592 Zorzi, Veronica CNR - Direzione Centrale Servizi per la Ricerca Zorzi, Veronica 0 114111593 Mammano, Fabio University of Padua Mammano, Fabio 0 114111590 Chiorini, John (Jay) NIDCR NIDCR Chiorini, John (Jay) (NIDCR) 1 114111590 Chiorini, John (Jay) NIDCR NIDCR Chiorini, John (Jay) (NIDCR) 1 114111591 Di Pasquale, Giovanni NIDCR NIDCR Di Pasquale, Giovanni (NIDCR) 0 114111592 Zorzi, Veronica CNR - Direzione Centrale Servizi per la Ricerca Zorzi, Veronica 0 114111593 Mammano, Fabio University of Padua Mammano, Fabio 0 114102897 Application Of AAV44.9 Vector In Gene Therapy For The Inner Ear E-150-2019-0 Filing authorized CNR - Direzione Centrale Servizi per la Ricerca, NIDCR 83656052 Knezevic, Vladimir vlado.knezevic@nih.gov
United States of America Technology Advancement Office vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-3795] Application of AAV44.9 Vector in Gene Therapy for the Inner Ear&body=Please send me information about technology [TAB-3795] Application of AAV44.9 Vector in Gene Therapy for the Inner Ear. Knezevic, Vladimir<br><a href="mailto:vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-3795] Application of AAV44.9 Vector in Gene Therapy for the Inner Ear&body=Please send me information about technology [TAB-3795] Application of AAV44.9 Vector in Gene Therapy for the Inner Ear.">vlado.knezevic@nih.gov</a><br> 114169669 E-150-2019-0 E-150-2019-0-US-03 Application Of AAV44.9 Vector In Gene Therapy For The Inner Ear National Stage US 17/922,300 Pending US <br />National Stage 17/922,300<br />Filed on 2022-10-28<br />Status: Pending 114129628 VPXXXX 114129629 WIXXXX 114129630 WJXXXX 114129631 XEXXXX 114155489 APPLICATION 114155490 AAV44.9 114155491 Vector 114155492 Gene 114155493 THERAPY 114155494 Inner 114155495 EAR TAB-4513 151706643 High Density Lipoprotein Targeting Protease Inhibitor Peptide for the Treatment of Alpha-1-antitrypsin (A1AT) Deficiency NHLBI Licensing, Respiratory, Therapeutics Licensing Respiratory Therapeutics Scott Gordon, Alan Remaley <p>This technology includes a novel concept and design for a lipoprotein targeting protease inhibitor for the treatment of Alpha-1-antitrypsin (A1AT) deficiency. A1AT deficiency occurs in about 1 in 2500 individuals in the United States and Europe, and people with this condition develop severe liver disease and emphysema/chronic obstructive pulmonary disease (COPD). Current treatment involves intravenous infusion of purified human A1AT protein, which is very expensive and only modestly effective. A recent study has demonstrated improvement in A1AT treatment effectiveness in a mouse model of emphysema by pre-incubating A1AT with high density lipoprotein (HDL) particles prior to infusion. This resulted in improvements in lung morphology and inflammatory markers in the lung compared to A1AT treatment alone. The mechanism for this improvement in function of A1AT when bound to HDL is believed to be increased trafficking of A1AT to the lung. Our invention of a lipoprotein targeting protease inhibitor peptide represents several significant advances upon these existing methods.</p> This approach is expected to provide improved efficacy over the current standard of care (A1AT infusion) because this design is a small molecule of about 2.5 kDa, much smaller than the full-length protein (52 kDa). An HDL particle can generally accommodate only one molecule of A1AT, whereas many copies of our VitE-PEG-AAPV peptide can reside on an HDL particle providing a significant increase in potency. Therapy for the treatment of A1AT deficiency. We are seeking statements of capability or interest from parties interested in collaborative research to further developer, evaluate, or commercialize this technology. 2023-12-07 2024-08-12 2024-12-13 2024-03-20 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 151706650 Remaley, Alan National Heart, Lung, and Blood Institute (NHLBI) NHLBI Remaley, Alan (NHLBI) 1 151706654 Gordon, Scott University of Kentucky Gordon, Scott 2 151706650 Remaley, Alan National Heart, Lung, and Blood Institute (NHLBI) NHLBI Remaley, Alan (NHLBI) 1 151706654 Gordon, Scott University of Kentucky Gordon, Scott 2 151706646 High Density Lipoprotein Targeting Protease Inhibitor Peptide E-155-2016-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 153929528 Ghosh, Malabika malabika.ghosh@nih.gov
United States of America malabika.ghosh@nih.gov?subject=Web Inquiry on [TAB-4513] High Density Lipoprotein Targeting Protease Inhibitor Peptide for the Treatment of Alpha-1-antitrypsin (A1AT) Deficiency&body=Please send me information about technology [TAB-4513] High Density Lipoprotein Targeting Protease Inhibitor Peptide for the Treatment of Alpha-1-antitrypsin (A1AT) Deficiency. Ghosh, Malabika<br><a href="mailto:malabika.ghosh@nih.gov?subject=Web Inquiry on [TAB-4513] High Density Lipoprotein Targeting Protease Inhibitor Peptide for the Treatment of Alpha-1-antitrypsin (A1AT) Deficiency&body=Please send me information about technology [TAB-4513] High Density Lipoprotein Targeting Protease Inhibitor Peptide for the Treatment of Alpha-1-antitrypsin (A1AT) Deficiency.">malabika.ghosh@nih.gov</a><br> 157755376 E-155-2016-0 E-155-2016-0-US-01 LIPOPROTEIN TARGETING PROTEASE INHIBITORS AND USES PRV US 62/332,277 Abandoned US <br />Provisional (PRV) 62/332,277<br />Filed on 2016-05-05<br />Status: Abandoned 157755381 E-155-2016-0 E-155-2016-0-US-02 Lipoprotein Targeting Protease Inhibitors and Uses ORD US 15/297,054 Abandoned US <br />Ordinary Patent (ORD) 15/297,054<br />Filed on 2016-10-18<br />Status: Abandoned 157755386 E-155-2016-0 E-155-2016-0-US-03 LIPOPROTEIN TARGETING PROTEASE INHIBITORS AND USES CON US 16/692,849 Abandoned US <br />Continuation (CON) 16/692,849<br />Filed on 2019-11-22<br />Status: Abandoned 157755391 E-155-2016-0 E-155-2016-0-US-04 LIPOPROTEIN TARGETING PROTEASE INHIBITORS AND USES CON US 11,872,261 17/673,361 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11872261 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11872261">11,872,261</a><br />Filed on 2022-02-16<br />Status: Issued 157755396 E-155-2016-0 E-155-2016-0-US-05 LIPOPROTEIN TARGETING PROTEASE INHIBITORS AND USES CON US 17/839,264 Abandoned US <br />Continuation (CON) 17/839,264<br />Filed on 2022-06-13<br />Status: Abandoned TAB-4514 151706774 Derivation of a >25 million-year-old Adeno-associated Virus Coat Protein Sequence for Gene Transfer Studies NHLBI Licensing, Therapeutics Licensing Therapeutics Ian Alexander, Claus Hallwirth, Robert Kotin, Richard Smith <p>This technology includes a novel capsid protein for recombinant adeno-associated virus (AAV)-mediated gene transfer evaluation. We have identified a &quot;fossilized&quot; endogenous AAV sequence element (referred to as mAAV-EVE) within the germline of an ancient lineage of Australian marsupials and have cloned and sequenced mAAV-EVE orthologs from at least fifteen lineage-specific taxa. Using computational analysis of mAAV-EVE sequence alignments, we have inferred the coat protein sequence of a >25-million-year-old adeno-associated virus which circulated among host species sometime during the Eocene-Oligocene transition. This novel AAV coat protein sequence may provide the basis for recombinant AAV vectors with unique biological properties. Moreover, the method of derivation of the ancient marsupial AAV coat protein sequence may be used for any endogenous AAV sequences occurring within related taxa in sufficient number.</p> <ul> <li>Novel AAV coat proteins may confer distinct, advantageous tissue tropisms and/or antigenic properties relative to a specific therapeutic application.</li> <li>As a method, AAV "fossil" mining has the advantage of identifying coat protein variants with a higher probability of biological activity than screening methods relying on random mutagenesis of existing AAV serotypes (such as domain shuffling).</li> </ul> Sequence provides a novel capsid protein for recombinant AAV-mediated gene transfer evaluation. We are seeking statements of capability or interest from parties interested in collaborative research to further developer, evaluate, or commercialize this technology. 2023-12-07 2024-08-12 2024-12-12 2024-03-20 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 151706782 Smith, Richard National Heart, Lung, and Blood Institute (NHLBI) NHLBI Smith, Richard (NHLBI) 1 151706790 Kotin, Robert Carbon Biosciences Kotin, Robert 2 151706794 Hallwirth, Claus Children's Medical Research Institute Hallwirth, Claus 3 151706803 Alexander, Ian Children's Medical Research Institute Alexander, Ian 4 151706782 Smith, Richard National Heart, Lung, and Blood Institute (NHLBI) NHLBI Smith, Richard (NHLBI) 1 151706790 Kotin, Robert Carbon Biosciences Kotin, Robert 2 151706794 Hallwirth, Claus Children's Medical Research Institute Hallwirth, Claus 3 151706803 Alexander, Ian Children's Medical Research Institute Alexander, Ian 4 151706777 Derivation Of A Greater Than 25 Million-year-old Adeno-associated Virus Coat Protein Sequence E-156-2016-0 Filing authorized Children's Medical Research Institute, National Heart, Lung, and Blood Institute (NHLBI) 83714317 Devany, John john.devany@nih.gov
United States of America Office of Technology Transfer and Development john.devany@nih.gov?subject=Web Inquiry on [TAB-4514] Derivation of a >25 million-year-old Adeno-associated Virus Coat Protein Sequence for Gene Transfer Studies&body=Please send me information about technology [TAB-4514] Derivation of a >25 million-year-old Adeno-associated Virus Coat Protein Sequence for Gene Transfer Studies. Devany, John<br><a href="mailto:john.devany@nih.gov?subject=Web Inquiry on [TAB-4514] Derivation of a >25 million-year-old Adeno-associated Virus Coat Protein Sequence for Gene Transfer Studies&body=Please send me information about technology [TAB-4514] Derivation of a >25 million-year-old Adeno-associated Virus Coat Protein Sequence for Gene Transfer Studies.">john.devany@nih.gov</a><br> 157755423 E-156-2016-0 E-156-2016-0-US-01 Derivation Of A Greater Than 25 Million-year-old Adeno-associated Virus Coat Protein Sequence PRV US 62/331,188 Abandoned US <br />Provisional (PRV) 62/331,188<br />Filed on 2016-05-03<br />Status: Abandoned 157755430 E-156-2016-0 E-156-2016-0-PCT-02 ADENO-ASSOCIATED VIRUS POLYNUCLEOTIDES, POLYPEPTIDES AND VIRIONS PCT Patent Cooperation Treaty PCT/US2017/030808 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2017/030808<br />Filed on 2017-05-03<br />Status: Expired 157755435 E-156-2016-0 E-156-2016-0-AU-03 ADENO-ASSOCIATED VIRUS POLYNUCLEOTIDES, POLYPEPTIDES AND VIRIONS National Stage Australia 2017261249 2017261249 Issued Australia <br />National Stage 2017261249<br />Filed on 2018-10-30<br />Status: Issued 157755440 E-156-2016-0 E-156-2016-0-US-04 Derivation Of A Greater Than 25 Million-year-old Adeno-associated Virus Coat Protein Sequence National Stage US 10,882,886 16/098,810 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10882886 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10882886">10,882,886</a><br />Filed on 2018-11-02<br />Status: Issued 157755445 E-156-2016-0 E-156-2016-0-EP-05 ADENO-ASSOCIATED VIRUS POLYNUCLEOTIDES, POLYPEPTIDES AND VIRIONS National Stage European Patent 3452495 17793239.9 Issued European Patent <br />National Stage 17793239.9<br />Filed on 2018-12-03<br />Status: Issued TAB-5039 159568531 Stable Cell Line Technology for Enhanced Production of Varicella-Zoster Virus Vaccines NIAID Jeffrey Cohen, Xueqiao Liu <p><span style="font-size:11pt"><span style="line-height:107%"><span style="font-family:Calibri,sans-serif">This technology includes a stable cell line engineered to have reduced expression of the pro-apoptotic protein Bim when exposed to doxycycline. This reduction in Bim expression allows for significantly higher yields of the Varicella-Zoster Virus (VZV), which is used in the production of live, attenuated VZV vaccines. The enhanced viral production makes this cell line particularly useful for vaccine manufacturing.</span></span></span></p> This cell line technology provides a tenfold increase in VZV production, which can significantly reduce production costs for VZV vaccines. Additionally, it offers a more efficient method for growing high-titer vaccine strains compared to standard cell lines. This technology can be applied in the production of childhood vaccines against VZV, such as those for chickenpox and shingles. It also has potential research applications for studying apoptosis and viral replication mechanisms. 2024-12-10 2024-12-10 2024-12-10 2024-12-10 False False True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 159568543 Cohen, Jeffrey NIAID - DIR NIAID Cohen, Jeffrey (NIAID) 1 159568547 Liu, Xueqiao NIAID - DIR NIAID Liu, Xueqiao (NIAID) 2 159568543 Cohen, Jeffrey NIAID - DIR NIAID Cohen, Jeffrey (NIAID) 1 159568547 Liu, Xueqiao NIAID - DIR NIAID Liu, Xueqiao (NIAID) 2 159568534 Stable Cell Line With Reduced Expression Of Bim That Enhances Yields Of Varicella-Zoster Virus E-491-2013-0 Research Material NIAID 83643855 Soukas, Peter peter.soukas@nih.gov
United States of America Technology Transfer and Intellectual Property Office peter.soukas@nih.gov?subject=Web Inquiry on [TAB-5039] Stable Cell Line Technology for Enhanced Production of Varicella-Zoster Virus Vaccines&body=Please send me information about technology [TAB-5039] Stable Cell Line Technology for Enhanced Production of Varicella-Zoster Virus Vaccines. Soukas, Peter<br><a href="mailto:peter.soukas@nih.gov?subject=Web Inquiry on [TAB-5039] Stable Cell Line Technology for Enhanced Production of Varicella-Zoster Virus Vaccines&body=Please send me information about technology [TAB-5039] Stable Cell Line Technology for Enhanced Production of Varicella-Zoster Virus Vaccines.">peter.soukas@nih.gov</a><br> TAB-4913 153307987 Bispecific Antibody Targeting Anthrax Toxins and Capsule for Enhanced Biodefense NIAID Antibodies, Collaboration, Immunology, Infectious Disease, Licensing, Therapeutics, Vaccines Antibodies Collaboration Immunology Infectious Disease Licensing Therapeutics Vaccines Zhao Chun Chen, Stephen Leppla, Mahtab Moayeri, Robert Purcell <p>The technology focuses on the development of a tetravalent bispecific antibody effective against Bacillus anthracis, the bacterium responsible for anthrax. This antibody combines the specificities of two monoclonal antibodies (mAbs): one targeting anthrax protective antigen (PA) and the other targeting the bacterial capsule. The anti-PA mAb shows potent toxin-neutralizing activity, while the anti-capsule mAb efficiently kills anthrax bacteria. By merging these specificities into a single lgG framework, the resulting bispecific antibody can simultaneously neutralize toxins and kill bacteria, potentially offering comprehensive protection against anthrax infection. The bispecific antibody is produced from transfected mammalian cells, ensuring scalability for large-scale production. This technology represents a significant advancement in anthrax biodefense, providing a simpler, more effective approach for treatment following exposure to aerosolized B. anthracis spores.</p> The tetravalent bispecific antibody targeting anthrax toxins and capsule offers several competitive advantages over existing approaches. Unlike conventional monoclonal antibodies that target only one antigen, this bispecific antibody can simultaneously neutralize toxins and kill bacteria, providing comprehensive protection against anthrax infection. Additionally, the simplicity of using a single molecule instead of a combination of two monoclonal antibodies enhances efficacy and ease of administration. The ability to express and purify the antibody from transfected mammalian cells ensures scalability for large-scale production, further enhancing its potential as a biodefense tool. The tetravalent bispecific antibody targeting anthrax toxins and capsule has significant potential applications in biodefense and anthrax treatment. It could be used as a post-exposure prophylactic following potential exposure to aerosolized B. anthracis spores, offering rapid and targeted protection. Additionally, this antibody may find utility in the treatment of anthrax infections, potentially improving outcomes and reducing the need for complex treatment regimens. Its ability to target multiple virulence factors simultaneously makes it a promising candidate for use in biodefense strategies against anthrax. 2024-02-26 2024-12-10 2024-12-10 2024-12-10 False True True 52406768 Discovery 52406768 37470483 Website Abstract 153307995 Chen, Zhao Chun NIAID Chen, Zhao Chun (NIAID) 1 153308014 Purcell, Robert National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Purcell, Robert (NIAID) 2 153308018 Moayeri, Mahtab NIAID - DIR NIAID Moayeri, Mahtab (NIAID) 3 153308026 Leppla, Stephen NIAID - DIR NIAID Leppla, Stephen (NIAID) 4 153307995 Chen, Zhao Chun NIAID Chen, Zhao Chun (NIAID) 1 153308014 Purcell, Robert National Institute of Allergy and Infectious Diseases (NIAID/NIH) NIAID Purcell, Robert (NIAID) 2 153308018 Moayeri, Mahtab NIAID - DIR NIAID Moayeri, Mahtab (NIAID) 3 153308026 Leppla, Stephen NIAID - DIR NIAID Leppla, Stephen (NIAID) 4 153307990 Development Of A Bispecific Antibody With An Ability To Neutralize Anthrax Toxins And Kill The Bacteria E-100-2013-0 Research Material NIAID 83643855 Soukas, Peter peter.soukas@nih.gov
United States of America Technology Transfer and Intellectual Property Office peter.soukas@nih.gov?subject=Web Inquiry on [TAB-4913] Bispecific Antibody Targeting Anthrax Toxins and Capsule for Enhanced Biodefense&body=Please send me information about technology [TAB-4913] Bispecific Antibody Targeting Anthrax Toxins and Capsule for Enhanced Biodefense. Soukas, Peter<br><a href="mailto:peter.soukas@nih.gov?subject=Web Inquiry on [TAB-4913] Bispecific Antibody Targeting Anthrax Toxins and Capsule for Enhanced Biodefense&body=Please send me information about technology [TAB-4913] Bispecific Antibody Targeting Anthrax Toxins and Capsule for Enhanced Biodefense.">peter.soukas@nih.gov</a><br> TAB-4832 152366146 Replicative-Defective Mutant Human Cytomegalovirus: Potential Applications in Vaccinology and Cancer Immunotherapy NIAID Collaboration, Computational models/software, Diagnostics, Therapeutics, Vaccines Collaboration Computational models/software Diagnostics Therapeutics Vaccines John Bowman, Jeffrey Cohen <p>The potential applications of a replicative-defective mutant form of human cytomegalovirus (HCMV) are significant in the fields of vaccinology and cancer immunotherapy. This innovative approach involves engineering a mutant HCMV that can selectively target specific cells. Firstly, it holds promise as a vaccine candidate for protecting against HCMV infection, given the success of a similar strategy against herpes simplex virus in animal models. Secondly, as an immunotherapeutic agent for cancer treatment, the mutant HCMV could stimulate the immune system to recognize and combat cancer cells, analogous to its success in treating cancer in mice. While these prospects are exciting, extensive research, safety evaluations, and clinical trials will be imperative to determine the viability and safety of these applications in human medicine.</p> The competitive advantages of using a replicative-defective mutant human cytomegalovirus (HCMV) stem from its safety and precision. As a potential HCMV vaccine, it offers a safer option compared to live attenuated vaccines, preserving immune stimulation without disease risk. In cancer immunotherapy, the mutant HCMV's ability to target cancer cells directly holds promise for reducing collateral damage and enhancing treatment efficacy. The successful application of similar strategies against herpes simplex virus and cancer in mice further supports its potential in human medicine, pending rigorous testing and regulatory approval. A replicative-defective mutant human cytomegalovirus (HCMV) holds potential in two key areas. Firstly, as a safer vaccine against HCMV infection, and secondly, as a precision tool in cancer immunotherapy, offering targeted treatment with minimized side effects. These applications align with emerging trends in healthcare, but extensive research and clinical trials are necessary for validation. 2024-01-24 2024-12-10 2024-12-10 2024-12-10 False True True 72159142 Clinical Phase III 72159142 37470483 Website Abstract 152366426 Cohen, Jeffrey National Institute of Allergy and Infectious Diseases (NIAID/NIH) Cohen, Jeffrey 1 152366431 Bowman, John Bowman, John 2 152366426 Cohen, Jeffrey National Institute of Allergy and Infectious Diseases (NIAID/NIH) Cohen, Jeffrey 1 152366431 Bowman, John Bowman, John 2 152366149 Development Of A Replication-defective Human Cytomegalovirus E-006-2012-0 Research Material NIAID 83643855 Soukas, Peter peter.soukas@nih.gov
United States of America Technology Transfer and Intellectual Property Office peter.soukas@nih.gov?subject=Web Inquiry on [TAB-4832] Replicative-Defective Mutant Human Cytomegalovirus: Potential Applications in Vaccinology and Cancer Immunotherapy&body=Please send me information about technology [TAB-4832] Replicative-Defective Mutant Human Cytomegalovirus: Potential Applications in Vaccinology and Cancer Immunotherapy. Soukas, Peter<br><a href="mailto:peter.soukas@nih.gov?subject=Web Inquiry on [TAB-4832] Replicative-Defective Mutant Human Cytomegalovirus: Potential Applications in Vaccinology and Cancer Immunotherapy&body=Please send me information about technology [TAB-4832] Replicative-Defective Mutant Human Cytomegalovirus: Potential Applications in Vaccinology and Cancer Immunotherapy.">peter.soukas@nih.gov</a><br> TAB-3757 114097608 Compounds and Methods for Treating Brain Injury NIDDK Neurology, Research Materials, Therapeutics Neurology Research Materials Therapeutics Kenneth Jacobson, William Korinek, James Lechleiter, Theodore Liston This technology includes MRS4322, which is an A3 agonist that is currently being evaluated for treatment of traumatic brain injury. Although its affinity in the receptor is in the micromolar range, it enters the brain in sufficient concentration to activate a protective CNS receptor, A3 adenosine receptor. Potential applications of such A3 agonists could also include neurodegenerative conditions. This compound produced fully agonizes the human A3 adenosine receptor with µmolar affinity with moderate selectivity vs. other adenosine receptors and displays the appropriate physicochemical properties for effective agonism and bioavailability in vivo. Treatment of traumatic brain injury and neurodegenerative conditions. 2022-11-30 2024-10-28 2024-12-10 2022-11-30 2022-07-11 brain, compounds, INJURY, Methods, TREATING, VEXXXX, WIXXXX, WKXXXX False True True NIHTT 37470483 Website Abstract 114172918 Lubitz D, Lin R, et al. https://pubmed.ncbi.nlm.nih.gov/7821362/ <a href="https://pubmed.ncbi.nlm.nih.gov/7821362/">Lubitz D, Lin R, et al.</a> 114172919 Lubitz D, Carter M, et al. https://pubmed.ncbi.nlm.nih.gov/7774659/ <a href="https://pubmed.ncbi.nlm.nih.gov/7774659/">Lubitz D, Carter M, et al.</a> 114172920 Lubitz D, Carter M, et al. https://pubmed.ncbi.nlm.nih.gov/7486604/ <a href="https://pubmed.ncbi.nlm.nih.gov/7486604/">Lubitz D, Carter M, et al.</a> 114172921 Abbracchio M, Ceruti S, et al. https://pubmed.ncbi.nlm.nih.gov/9369971/ <a href="https://pubmed.ncbi.nlm.nih.gov/9369971/">Abbracchio M, Ceruti S, et al.</a> 114172922 Lubitz D, Lin R, et al. https://pubmed.ncbi.nlm.nih.gov/10078988/ <a href="https://pubmed.ncbi.nlm.nih.gov/10078988/">Lubitz D, Lin R, et al.</a> 114111484 Jacobson, Kenneth National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Jacobson, Kenneth (NIDDK) 0 114111486 Lechleiter, James University of Texas Health Science Center at San Antonio Lechleiter, James 0 114111487 Liston, Theodore Astrocyte Pharmaceuticals, Inc Liston, Theodore 0 114111485 Korinek, William Astrocyte Pharmaceuticals, Inc Korinek, William 1 114111485 Korinek, William Astrocyte Pharmaceuticals, Inc Korinek, William 1 114111484 Jacobson, Kenneth National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Jacobson, Kenneth (NIDDK) 0 114111486 Lechleiter, James University of Texas Health Science Center at San Antonio Lechleiter, James 0 114111487 Liston, Theodore Astrocyte Pharmaceuticals, Inc Liston, Theodore 0 114102860 Compounds And Methods For Treating Brain Injury E-138-2017-0 Filing authorized Astrocyte Pharmaceuticals, Inc, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), University of Texas Health Science Center at San Antonio 83692066 Tong, Betty tongb@niddk.nih.gov
United States of America Senior Technology Advancement Office tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-3757] Compounds and Methods for Treating Brain Injury&body=Please send me information about technology [TAB-3757] Compounds and Methods for Treating Brain Injury. Tong, Betty<br><a href="mailto:tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-3757] Compounds and Methods for Treating Brain Injury&body=Please send me information about technology [TAB-3757] Compounds and Methods for Treating Brain Injury.">tongb@niddk.nih.gov</a><br> 114169593 E-138-2017-0 E-138-2017-0-US-01 Compounds And Methods For Treating Brain Injury PRV US 62/325,860 Abandoned US <br />Provisional (PRV) 62/325,860<br />Filed on 2016-04-21<br />Status: Abandoned 114169594 E-138-2017-0 E-138-2017-0-PCT-02 COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS PCT Patent Cooperation Treaty PCT/US2017/028996 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2017/028996<br />Filed on 2017-04-21<br />Status: Expired 114169595 E-138-2017-0 E-138-2017-0-US-11 Compounds And Methods For Treating Brain Injury National Stage US 12,239,654 16/095,282 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12239654 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12239654">12,239,654</a><br />Filed on 2018-10-19<br />Status: Issued 114129500 VEXXXX 114129501 WIXXXX 114129502 WKXXXX 114155080 compounds 114155081 Methods 114155082 TREATING 114155083 brain 114155084 INJURY TAB-4878 152594696 Transgenic Mouse Models for Studying HLA-B57:01 and HLA-B15:02 Linked Immune Responses and Hypersensitivity Reactions NIAID Animal Models, Collaboration, Immunology, Research Equipment, Research Materials Animal Models Collaboration Immunology Research Equipment Research Materials Lisa Boyd, David Margulies, Kannan Natarajan, Michael Norcross, Mulualem Tilahun <p>Transgenic mouse models expressing human HLA-B57:01 and HLA-B15:02 molecules have emerged as invaluable tools for unraveling the intricacies of immune responses and hypersensitivity reactions. The major histocompatibility complex (MHC) encoded proteins play a pivotal role in the immune system by presenting peptide fragments to T lymphocytes, and HLA-B57:01 has been associated with severe hypersensitivity reactions triggered by abacavir, a widely used anti-retroviral drug. These transgenic mice, with HLA-B57:01 broadly expressed on their nucleated cells, provide a unique platform for investigating the underlying mechanisms of drug hypersensitivity, immune responses controlled by HLA-B57:01, and autoimmune pathology linked to this MHC molecule. Additionally, similar models expressing HLA-B15:02 facilitate the study of hypersensitivity reactions related to carbamazepine. Notably, these models represent a significant breakthrough, as prior to this research, animal models for exploring immune responses based on HLA-B57:01 and HLA-B15:02 had not been reported, and specific HLA-B*57:01 restricted immune responses have been observed, offering new avenues for research in immunology and drug safety.</p> <p>&nbsp;</p> Transgenic mouse models expressing HLA-B57:01 and HLA-B15:02 provide unique advantages in immunological research. Their stable genetic background on the C57BL/6 strain ensures reliable results. These models are crucial for studying drug hypersensitivity, offering insights into adverse drug reactions for safer drug development. Additionally, they facilitate investigations into immune responses controlled by HLA-B*57:01, benefiting autoimmune disease research and immunotherapy development. Overall, these models are a powerful asset for academia and the pharmaceutical industry. These transgenic mouse models have versatile applications. They can enhance drug safety research, shedding light on hypersensitivity reactions related to specific drugs. Additionally, they offer insights into immune responses linked to HLA-B57:01 and HLA-B15:02, potentially guiding autoimmune disease treatments. Their broader impact extends to improving our understanding of the immune system, aiding in vaccine development and immunotherapy research. In summary, these models hold immense potential across various fields, from drug safety to immunology and beyond. 2024-02-05 2024-12-10 2024-12-10 2024-12-10 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 152594709 Margulies, David NIAID - DIR NIAID Margulies, David (NIAID) 1 152594716 Natarajan, Kannan NIAID - DIR NIAID Natarajan, Kannan (NIAID) 2 152594724 Tilahun, Mulualem NIAID - DIR NIAID Tilahun, Mulualem (NIAID) 3 152594732 Norcross, Michael FDA - CDER FDA Norcross, Michael (FDA) 4 152595551 Boyd, Lisa NIAID - DIR NIAID Boyd, Lisa (NIAID) 5 152594709 Margulies, David NIAID - DIR NIAID Margulies, David (NIAID) 1 152594716 Natarajan, Kannan NIAID - DIR NIAID Natarajan, Kannan (NIAID) 2 152594724 Tilahun, Mulualem NIAID - DIR NIAID Tilahun, Mulualem (NIAID) 3 152594732 Norcross, Michael FDA - CDER FDA Norcross, Michael (FDA) 4 152595551 Boyd, Lisa NIAID - DIR NIAID Boyd, Lisa (NIAID) 5 152594702 HLA-B*57:01 And HLA-B*15:02 Transgenic Mouse Strains-Models For Human HLA-linked Immune Responses E-058-2019-0 Research Material FDA, NIAID 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-4878] Transgenic Mouse Models for Studying HLA-B57:01 and HLA-B15:02 Linked Immune Responses and Hypersensitivity Reactions&body=Please send me information about technology [TAB-4878] Transgenic Mouse Models for Studying HLA-B57:01 and HLA-B15:02 Linked Immune Responses and Hypersensitivity Reactions. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-4878] Transgenic Mouse Models for Studying HLA-B57:01 and HLA-B15:02 Linked Immune Responses and Hypersensitivity Reactions&body=Please send me information about technology [TAB-4878] Transgenic Mouse Models for Studying HLA-B57:01 and HLA-B15:02 Linked Immune Responses and Hypersensitivity Reactions.">yogikala.prabhu@nih.gov</a><br> TAB-4955 153932165 SARS-CoV-2 Pseudotyping Plasmids for Cutting-Edge Studies NIAID Infectious Disease, Licensing, Plasmids/Vectors, Research Materials, Therapeutics, Vaccines Infectious Disease Licensing Plasmids/Vectors Research Materials Therapeutics Vaccines Kizzmekia Corbett, Barney Graham, John Mascola, Lingshu Wang <p>NIAID scientists have developed plasmids that allow for production of pseudoviruses expressing SARS-CoV-2 spike protein. As SARS-CoV-2 is a lethal airborne virus, it must be handled in high-containment Biosafety Level 3 (BSL-3) laboratories that require strict airflow, ventilation and decontamination procedures. The pseudotyping plasmids of this invention provide a secure platform for exploring SARS-CoV-2 dynamics without the need for high-risk handling of live virus and ensure a controlled environment for scientists to study SARS-CoV-2 more expeditiously in standard Biosafety Level 2 (BSL -2) laboratories. The plasmids can be used for diverse SARS-CoV-2 research applications, including the study of newly emerging or potential future variants of interest.</p> <ul> <li>Expedite SARS-CoV-2 related experiments by enabling them to be conducted in laboratories with a lower Biosafety Level (BSL-2) than that required for handling SARS-CoV-2 (BSL-3)</li> </ul> <ul> <li>Research material that can be used in the development of neutralization assays</li> </ul> To license this technology, please contact Brian Bailey, PhD; 240-669-5128 or 301-201-9217; <a href="mailto:bbailey@mail.nih.gov"> bbailey@mail.nih.gov</a>, and reference E-223-2020. 2024-03-19 2024-11-21 2024-11-21 2024-06-21 PLASMIDS, Pseudotyping, SARS-CoV-2 False False Research material True 37470483 Website Abstract 153932470 Graham, Barney NIH - NIAID NIAID Graham, Barney (NIAID) 1 153932474 Wang, Lingshu NIH - NIAID NIAID Wang, Lingshu (NIAID) 2 153932478 Mascola, John NIH - NIAID NIAID Mascola, John (NIAID) 3 153932482 Corbett, Kizzmekia NIH - NIAID NIAID Corbett, Kizzmekia (NIAID) 4 153932470 Graham, Barney NIH - NIAID NIAID Graham, Barney (NIAID) 1 153932474 Wang, Lingshu NIH - NIAID NIAID Wang, Lingshu (NIAID) 2 153932478 Mascola, John NIH - NIAID NIAID Mascola, John (NIAID) 3 153932482 Corbett, Kizzmekia NIH - NIAID NIAID Corbett, Kizzmekia (NIAID) 4 153932172 SARS CoV 2 Pseudotyping Plasmid E-223-2020-0 Research Material NIAID 83682222 Bailey, Brian bbailey@mail.nih.gov
United States of America TTIPO bbailey@mail.nih.gov?subject=Web Inquiry on [TAB-4955] SARS-CoV-2 Pseudotyping Plasmids for Cutting-Edge Studies&body=Please send me information about technology [TAB-4955] SARS-CoV-2 Pseudotyping Plasmids for Cutting-Edge Studies. Bailey, Brian<br><a href="mailto:bbailey@mail.nih.gov?subject=Web Inquiry on [TAB-4955] SARS-CoV-2 Pseudotyping Plasmids for Cutting-Edge Studies&body=Please send me information about technology [TAB-4955] SARS-CoV-2 Pseudotyping Plasmids for Cutting-Edge Studies.">bbailey@mail.nih.gov</a><br> 155051361 SARS-CoV-2 155051410 Pseudotyping 155051414 PLASMIDS TAB-3593 114097446 Identification and Use of 12/15-Lipoxygenase (LOX) Inhibitors for Post-Strike Treatment NCATS Neurology, Research Materials, Therapeutics Neurology Research Materials Therapeutics Theodore Holman, Ajit Jadhav, David Maloney, Ganesha Rai Bantukallu, Anton Simeonov, Klaus Van Leyen This technology includes the identification and use of 12/15-lipoxygenase (LOX) inhibitors, including ML351 and related analogs, for post-stroke treatment. The 12/15-LOX directly oxidizes lipid membranes leading to their direct attack. After a stroke, the activity of 12/15-LOX is upregulated and is thought to contribute to increased neuronal loss and blood-brain barrier leakage. A high-throughput screen was undertaken to find inhibitors, which were then subjected to medical chemistry optimization. Identification of LOX inhibitors has been difficult because many of the inhibitors found have been antioxidants with low selectivity and low potency. The identified ML351-based compounds have been used in human and mouse studies and found to be potent and selective LOX inhibitors. Further clinical work on the compounds described in this technology could lead to a potential treatment post-stroke to limit brain injury. These compounds have potential use with other neurodegenerative conditions. 2022-08-01 2024-10-28 2024-11-18 2022-08-01 2022-05-06 12/15-Li, 12/15-Lipoxygenase, Enase, Inhibitors, Ox, VEXXXX, WIXXXX, WKXXXX, XEXXXX False True True NIHTT 37470483 Website Abstract 114172767 Rai G, Joshi N, et al. https://pubmed.ncbi.nlm.nih.gov/24684213/ <a href="https://pubmed.ncbi.nlm.nih.gov/24684213/">Rai G, Joshi N, et al.</a> 114110941 Holman, Theodore University of California, Santa Cruz Holman, Theodore 0 114110942 Maloney, David NCATS - NCGC NCATS Maloney, David (NCATS) 0 114110943 Rai Bantukallu, Ganesha NCATS - NCGC NCATS Rai Bantukallu, Ganesha (NCATS) 0 114110944 Jadhav, Ajit NCATS - NCGC NCATS Jadhav, Ajit (NCATS) 0 114110945 Simeonov, Anton NCATS - NCGC NCATS Simeonov, Anton (NCATS) 0 114110940 Van Leyen, Klaus Harvard Medical School Van Leyen, Klaus 1 114110940 Van Leyen, Klaus Harvard Medical School Van Leyen, Klaus 1 114110941 Holman, Theodore University of California, Santa Cruz Holman, Theodore 0 114110942 Maloney, David NCATS - NCGC NCATS Maloney, David (NCATS) 0 114110943 Rai Bantukallu, Ganesha NCATS - NCGC NCATS Rai Bantukallu, Ganesha (NCATS) 0 114110944 Jadhav, Ajit NCATS - NCGC NCATS Jadhav, Ajit (NCATS) 0 114110945 Simeonov, Anton NCATS - NCGC NCATS Simeonov, Anton (NCATS) 0 114102700 Inhibitors Of 12/15-Lipoxygenase E-088-2016-0 Filing authorized Harvard Medical School, NCATS - NCGC, University of California, Santa Cruz 83682485 Vepa, Suryanarayana sury.vepa@nih.gov
United States of America Office of Strategic Alliances (OSA) sury.vepa@nih.gov?subject=Web Inquiry on [TAB-3593] Identification and Use of 12/15-Lipoxygenase (LOX) Inhibitors for Post-Strike Treatment&body=Please send me information about technology [TAB-3593] Identification and Use of 12/15-Lipoxygenase (LOX) Inhibitors for Post-Strike Treatment. Vepa, Suryanarayana<br><a href="mailto:sury.vepa@nih.gov?subject=Web Inquiry on [TAB-3593] Identification and Use of 12/15-Lipoxygenase (LOX) Inhibitors for Post-Strike Treatment&body=Please send me information about technology [TAB-3593] Identification and Use of 12/15-Lipoxygenase (LOX) Inhibitors for Post-Strike Treatment.">sury.vepa@nih.gov</a><br> 114169434 E-088-2016-0 E-088-2016-0-US-01 Inhibitors Of 12/15-Lipoxygenase PRV US 61/868,611 Abandoned US <br />Provisional (PRV) 61/868,611<br />Filed on 2013-08-22<br />Status: Abandoned 114169435 E-088-2016-0 E-088-2016-0-PCT-02 Inhibitors Of 12/15-Lipoxygenase PCT Patent Cooperation Treaty PCT/US2014/052269 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2014/052269<br />Filed on 2014-08-22<br />Status: Expired 114128861 WIXXXX 114128862 WKXXXX 114128863 VEXXXX 114128864 XEXXXX 114153478 12/15-Lipoxygenase 114153479 Enase 114153480 Ox 114153481 Inhibitors 114153482 12/15-Li TAB-3544 114097402 Small Molecule Inhibitors of Clk and Dyrk Kinases for Potential Therapeutic Intervention of Down Syndrome, Alzheimer's Disease and Cancer NCATS Neurology, Oncology, Therapeutics Neurology Oncology Therapeutics Jeffrey Aube, Douglas Auld, Thomas Coombs, Frank Schoenen, Min Shen, Cordelle Tanega, Craig Thomas This technology includes small molecule inhibitors of the cdc2-like kinase (Clk) and Dyrk kinase which can restore splicing outcomes within many dysregulated splicing events potentially reversing phenotypes associated with diseases associated with abnormal splicing. The Clks regulate the alternative splicing of microtubule-associated protein tau and are implicated in frontotemporal dementia and Parkinson's disease through the phosphorylation of splicing factors (SF). DyrklA is proposed to play a critical role in the development of Down Syndrome (DS) due to the location of the DyrklA gene on Chromosome 21 in the Down Syndrome critical region. Inhibitors of Clk and Dyrk isoforms may alter important dysregulated splicing events and could prove to be useful agents in disease phenotypes characterized by abnormal splicing. There are no existing therapies based upon splicing regulation and therapies for diseases such as Down syndrome, Alzheimer's Disease and other diseases associated with incorrect splicing. Treatment for diseases associated with abnormal splicing such as Down Syndrome, Alzheimer’s Disease and cancer. 2022-08-01 2024-10-28 2024-11-05 2022-08-01 2022-05-04 Alzheimer', ALZHEIMER'S, CANCER, Clk, Disease, Down', Down's, Dyrk, Indications, Inhibitors, INTERVENTION, KINASES, Listed LPM Vepa as of 4/15/2015, MOLECULE, Post LPM Assignment Set 20150420, Potential, Pre LPM working set 20150418, S, Small, Syndrome, therapeutic, VCXXXX, VEXXXX, WKXXXX False True True NIHTT 37470483 Website Abstract 114172709 Mott B, Tanega C, et al. https://pubmed.ncbi.nlm.nih.gov/19837585/ <a href="https://pubmed.ncbi.nlm.nih.gov/19837585/">Mott B, Tanega C, et al.</a> 114172710 Black D https://pubmed.ncbi.nlm.nih.gov/12626338/ <a href="https://pubmed.ncbi.nlm.nih.gov/12626338/">Black D</a> 114172711 Wang Z, Burge C https://pubmed.ncbi.nlm.nih.gov/18369186/ <a href="https://pubmed.ncbi.nlm.nih.gov/18369186/">Wang Z, Burge C</a> 114172712 Faustino N, Cooper T https://pubmed.ncbi.nlm.nih.gov/12600935/ <a href="https://pubmed.ncbi.nlm.nih.gov/12600935/">Faustino N, Cooper T</a> 114172713 He C, Zhou F, et al. https://pubmed.ncbi.nlm.nih.gov/19266097/ <a href="https://pubmed.ncbi.nlm.nih.gov/19266097/">He C, Zhou F, et al.</a> 114172714 Matlin A, Clark F, et al. https://pubmed.ncbi.nlm.nih.gov/15956978/ <a href="https://pubmed.ncbi.nlm.nih.gov/15956978/">Matlin A, Clark F, et al.</a> 114110654 Thomas, Craig National Human Genome Research Institute (NHGRI) NCATS Thomas, Craig (NCATS) 0 114110655 Shen, Min National Human Genome Research Institute (NHGRI) NCATS Shen, Min (NCATS) 0 114110656 Auld, Douglas Novartis Institutes for BioMedical Research, Inc. NHGRI Auld, Douglas (NHGRI) 0 114110658 Schoenen, Frank The University of Kansas Schoenen, Frank 0 114110659 Coombs, Thomas University of Arkansas Coombs, Thomas 0 114110660 Tanega, Cordelle National Human Genome Research Institute (NHGRI) NCATS Tanega, Cordelle (NCATS) 0 114110657 Aube, Jeffrey The University of Kansas Aube, Jeffrey 1 114110657 Aube, Jeffrey The University of Kansas Aube, Jeffrey 1 114110654 Thomas, Craig National Human Genome Research Institute (NHGRI) NCATS Thomas, Craig (NCATS) 0 114110655 Shen, Min National Human Genome Research Institute (NHGRI) NCATS Shen, Min (NCATS) 0 114110656 Auld, Douglas Novartis Institutes for BioMedical Research, Inc. NHGRI Auld, Douglas (NHGRI) 0 114110658 Schoenen, Frank The University of Kansas Schoenen, Frank 0 114110659 Coombs, Thomas University of Arkansas Coombs, Thomas 0 114110660 Tanega, Cordelle National Human Genome Research Institute (NHGRI) NCATS Tanega, Cordelle (NCATS) 0 114102655 Small Molecule Inhibitors Of Clk And Dyrk Kinases For Potential Therapeutic Intervention Within Down's Syndrome, Alzheimer's Disease And Several Cancer Indications E-087-2012-0 Filing authorized NCATS - NCGC, The University of Kansas, University of Arkansas 83682485 Vepa, Suryanarayana sury.vepa@nih.gov
United States of America Office of Strategic Alliances (OSA) sury.vepa@nih.gov?subject=Web Inquiry on [TAB-3544] Small Molecule Inhibitors of Clk and Dyrk Kinases for Potential Therapeutic Intervention of Down Syndrome, Alzheimer's Disease and Cancer&body=Please send me information about technology [TAB-3544] Small Molecule Inhibitors of Clk and Dyrk Kinases for Potential Therapeutic Intervention of Down Syndrome, Alzheimer's Disease and Cancer. Vepa, Suryanarayana<br><a href="mailto:sury.vepa@nih.gov?subject=Web Inquiry on [TAB-3544] Small Molecule Inhibitors of Clk and Dyrk Kinases for Potential Therapeutic Intervention of Down Syndrome, Alzheimer's Disease and Cancer&body=Please send me information about technology [TAB-3544] Small Molecule Inhibitors of Clk and Dyrk Kinases for Potential Therapeutic Intervention of Down Syndrome, Alzheimer's Disease and Cancer.">sury.vepa@nih.gov</a><br> 114169357 E-087-2012-0 E-087-2012-0-US-01 CLK and DYRK Inhibitors and Methods of Use Thereof PRV US 61/584,935 Abandoned US <br />Provisional (PRV) 61/584,935<br />Filed on 2012-01-10<br />Status: Abandoned 114128711 VCXXXX 114128712 VEXXXX 114128713 WKXXXX 114153040 Small 114153041 MOLECULE 114153042 Inhibitors 114153043 Clk 114153044 Dyrk 114153045 KINASES 114153046 Potential 114153047 therapeutic 114153048 INTERVENTION 114153049 Down' 114153050 S 114153051 Syndrome 114153052 Alzheimer' 114153053 Disease 114153054 CANCER 114153055 Indications 114153056 Down's 114153057 ALZHEIMER'S 114153058 Listed LPM Vepa as of 4/15/2015 114153059 Pre LPM working set 20150418 114153060 Post LPM Assignment Set 20150420 TAB-2564 114096761 Pyruvate Kinase M2 Activators for the Treatment of Cancer NCATS Collaboration, Diagnostics, Oncology, Research Materials, Therapeutics Collaboration Diagnostics Oncology Research Materials Therapeutics Douglas Auld, Matthew Boxer, Jiankang Jiang, Min Shen, Craig Thomas This technology describes a series of small-molecule activators of the pyruvate kinase M2 isoform (PK-M2). <br /><br /> Pyruvate kinase (PK) is a critical metabolic enzyme that catalyzes the last step of the glycolytic pathway. It exists in several isoforms with different patterns of tissue expression. One isoform, PK-M2, is expressed in cells with a high rate of nucleic acid synthesis, including most tumors, which makes this enzyme an attractive target for cancer therapy. PK-M2 can occur in either a tetrameric form or a dimeric form in proliferating cells; a high tetramer to dimer ratio leads to energy production, while a low ratio channels metabolites into synthetic processes. In tumor cells, oncoproteins induce dimerization of PK-M2, resulting in the inactive form of the protein and allowing synthesis of building blocks for cell proliferation. Activation of PK-M2 in these cells may prevent the buildup of metabolic intermediates and thereby stall tumor cell proliferation. Further, after embryonic development PK-M2 expression is primarily restricted to tumor cells, so specific activators of PK-M2 would be expected to affect only tumor cells, and would be less likely to be toxic in normal tissues. <br /><br /> Investigators at the National Center for Advancing Translational Sciences have discovered a series of small molecules that specifically activate the PK-M2 isoform and that may be useful for the treatment of cancer. These compounds are based upon a substituted thieno[3,2-b]pyrrole[3,2-d]pyridazinone scaffold. <ul> <li>Compounds are specific to one isoform of pyruvate kinase</li> <li>Compounds target tumor cells and not normal cells, so side effects may be reduced</li> <li>Compounds are small molecules which may be further optimized</li> </ul> <ul> <li>Targeted therapeutic agent for cancer and other cell proliferation disorders.</li> </ul> The National Center for Advancing Translational Sciences (NCATS) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize Pyruvate Kinase M2 Activators for the Treatment of Cancer. For collaboration opportunities, please contact the Office of Strategic Alliances at <a href="mailto:NCATSPartnerships@mail.nih.gov">NCATSPartnerships@mail.nih.gov</a>. Various international patent applications filed 2022-03-08 2024-10-28 2024-11-05 2013-05-10 Activator, ACTIVATORS, CANCER, CBXXXX, CXXXXX, Dimer, IBXXXX, ISOFORM, IXXXXX, M2, METABOLIC, METABOLITE, PK, PKM2, PK-M2, Proliferation, PYRUVATE, pyruvate kinase, small molecule, Tetramer, tumor False True <ul> <li>Early-stage</li> <li>In vitro data available</li> </ul> True NIHTT 37470483 Website Abstract E-326-2008-0 E-120-2010-0 114171797 Anastasiou D, et al. https://www.ncbi.nlm.nih.gov/pubmed/22922757 <a href="https://www.ncbi.nlm.nih.gov/pubmed/22922757">Anastasiou D, et al.</a> 114171798 Anastasiou D, et al. https://www.ncbi.nlm.nih.gov/pubmed/22052977 <a href="https://www.ncbi.nlm.nih.gov/pubmed/22052977">Anastasiou D, et al.</a> 114171799 Jiang J, et al. https://www.ncbi.nlm.nih.gov/pubmed/20451379 <a href="https://www.ncbi.nlm.nih.gov/pubmed/20451379">Jiang J, et al.</a> 114107911 Jiang, Jiankang NCATS - NCGC NCATS Jiang, Jiankang (NCATS) 0 114107912 Boxer, Matthew NCATS - NCGC Boxer, Matthew 0 114107913 Shen, Min NCATS - NCGC NCATS Shen, Min (NCATS) 0 114107914 Auld, Douglas Novartis Institutes for BioMedical Research, Inc. NHGRI Auld, Douglas (NHGRI) 0 114107910 Thomas, Craig National Human Genome Research Institute (NHGRI) NCATS Thomas, Craig (NCATS) 1 114107910 Thomas, Craig National Human Genome Research Institute (NHGRI) NCATS Thomas, Craig (NCATS) 1 114107911 Jiang, Jiankang NCATS - NCGC NCATS Jiang, Jiankang (NCATS) 0 114107912 Boxer, Matthew NCATS - NCGC Boxer, Matthew 0 114107913 Shen, Min NCATS - NCGC NCATS Shen, Min (NCATS) 0 114107914 Auld, Douglas Novartis Institutes for BioMedical Research, Inc. NHGRI Auld, Douglas (NHGRI) 0 114101878 Small Molecule Activators Of The M2 Isoform Of Pyruvate Kinase E-298-2011-1 Filing authorized NCATS - NCGC, Novartis Institutes for BioMedical Research, Inc. 83682485 Vepa, Suryanarayana sury.vepa@nih.gov
United States of America Office of Strategic Alliances (OSA) sury.vepa@nih.gov?subject=Web Inquiry on [TAB-2564] Pyruvate Kinase M2 Activators for the Treatment of Cancer&body=Please send me information about technology [TAB-2564] Pyruvate Kinase M2 Activators for the Treatment of Cancer. Vepa, Suryanarayana<br><a href="mailto:sury.vepa@nih.gov?subject=Web Inquiry on [TAB-2564] Pyruvate Kinase M2 Activators for the Treatment of Cancer&body=Please send me information about technology [TAB-2564] Pyruvate Kinase M2 Activators for the Treatment of Cancer.">sury.vepa@nih.gov</a><br> 114167063 E-298-2011-1 E-298-2011-1-US-01 Activators Of Human Pyruvate Kinase PRV US 61/752,698 Abandoned US <br />Provisional (PRV) 61/752,698<br />Filed on 2013-01-15<br />Status: Abandoned 114123352 CBXXXX 114123353 IBXXXX 114123354 CXXXXX 114123355 IXXXXX 114144374 PYRUVATE 114144375 M2 114144376 ACTIVATORS 114144377 ISOFORM 114144378 PKM2 114144379 pyruvate kinase 114144380 Activator 114144381 small molecule 114144382 tumor 114144383 Tetramer 114144384 Dimer 114144385 CANCER 114144386 PK-M2 114144387 PK 114144388 Proliferation 114144389 METABOLIC 114144390 METABOLITE TAB-996 114095329 Multimeric Protein Toxins to Target Cells Having Multiple Identifying Characteristics NIAID Collaboration, Diagnostics, Immunology, Oncology, Therapeutics Collaboration Diagnostics Immunology Oncology Therapeutics Thomas Bugge, Stephen Leppla, Shihui Liu This technology relates to multimeric bacterial protein toxins which can be used to specifically target cells. Specifically, this is a modified recombinant anthrax toxin protective antigen (PrAg) that has been modified in several ways. First, the PrAg can be activated both by a metalloproteinase (MMP) and by urokinase plasminogen activator (uPA). Second, the native PrAg lethal factor (LF) binding site has been modified so that only a modified PrAg comprising two different monomers can bind anthrax LF. When administered with an effector component, the recombinant anthrax toxins are toxic only to cells expressing both a MMP and uPA on their surface. This technology is therefore useful for selective methods of treating cancers, because many cancer cells express multiple cell-surface proteases. The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize this invention. For collaboration opportunities, please contact Dr. Natalie Greco at <a href="mailto:Natalie.Greco@nih.gov">Natalie.Greco@nih.gov</a> or 301-761-7898. 2022-03-08 2024-10-28 2024-10-28 2017-07-06 Anthrax, CA2AXX, CAXXXX, CB1AXX, CB1BXX, CBXXXX, CXXXXX False True True NIHTT 37470483 Website Abstract 114104892 Leppla, Stephen NIAID Leppla, Stephen (NIAID) 0 114104893 Liu, Shihui NIDCR Liu, Shihui (NIDCR) 0 114104894 Bugge, Thomas NIDCR Bugge, Thomas (NIDCR) 0 114104892 Leppla, Stephen NIAID Leppla, Stephen (NIAID) 0 114104893 Liu, Shihui NIDCR Liu, Shihui (NIDCR) 0 114104894 Bugge, Thomas NIDCR Bugge, Thomas (NIDCR) 0 114100204 Exploiting The Multimeric Nature Of Certain Protein Toxins To Target Cells Having More Than One Identifying Characteristic E-059-2004-0 Filing authorized NIAID, NIDCR 91026778 Green, Wade wade.green@nih.gov
United States of America TTIPO wade.green@nih.gov?subject=Web Inquiry on [TAB-996] Multimeric Protein Toxins to Target Cells Having Multiple Identifying Characteristics&body=Please send me information about technology [TAB-996] Multimeric Protein Toxins to Target Cells Having Multiple Identifying Characteristics. Green, Wade<br><a href="mailto:wade.green@nih.gov?subject=Web Inquiry on [TAB-996] Multimeric Protein Toxins to Target Cells Having Multiple Identifying Characteristics&body=Please send me information about technology [TAB-996] Multimeric Protein Toxins to Target Cells Having Multiple Identifying Characteristics.">wade.green@nih.gov</a><br> 114162492 E-059-2004-0 E-059-2004-0-US-01 Multimeric Protein Toxins To Target Cells Having Multiple Identifying Characteristics PRV US 60/543,417 Abandoned US <br />Provisional (PRV) 60/543,417<br />Filed on 2004-02-09<br />Status: Abandoned 114162493 E-059-2004-0 E-059-2004-0-US-02 Multimeric Protein Toxins to Target Cells Having Multiple Identifying Characteristics ORD US 7,947,289 11/055,557 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7947289 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7947289">7,947,289</a><br />Filed on 2005-02-09<br />Status: Issued 114162494 E-059-2004-0 E-059-2004-0-PCT-03 Multimeric Protein Toxins To Target Cells Having Multiple Identifying Characteristics PCT Patent Cooperation Treaty PCT/US2005/04216 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2005/04216<br />Filed on 2005-02-09<br />Status: Expired 114166395 E-059-2004-0 E-059-2004-0-US-04 Multimeric Protein Toxins To Target Cells Having Multiple Identifying Characteristics DIV US 8,388,933 13/088,011 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8388933 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8388933">8,388,933</a><br />Filed on 2011-04-15<br />Status: Expired 114115608 CA2AXX 114115609 CB1AXX 114115610 CB1BXX 114115611 CAXXXX 114115612 CBXXXX 114115613 CXXXXX 114157873 Anthrax TAB-923 114095256 Novel Method of Fat Suppression in Steady State Free Precession (SSFP) Based Magnetic Resonance Imaging (MRI) NHLBI Licensing Licensing John Derbyshire, Daniel Herzka, Elliot Mcveigh Available for licensing is a technique for improving magnetic resonance imaging (MRI) that employs steady state free precession (SSFP). One such technique, fast imaging with steady-state free precession (FISP), is a well established and is a fast MR imaging method commonly used to evaluate cardiovascular anatomy and function. FISP provides high signal to noise ratio (SNR) images with excellent contrast between blood and the myocardium. However, these images are often contaminated with high signal from fatty tissue resulting in image artifacts. Conventional methods of fat signal suppression in FISP are often inefficient and result in a loss of temporal resolution. The present pulse sequence provides intrinsic chemical selectivity and significant attenuation of fat-based signals (by a factor of four compared to conventional FISP imaging) while maintaining the preferred high SNR for water-based tissues provided by standard FISP. In addition, the pulse sequence design is such that the high temporal resolution of FISP is not compromised. Thus, this technology offers a valuable improvement to standard cardiac MRI methods. 2022-03-08 2024-10-28 2024-10-28 2004-05-01 AA2XXX, AA3XXX, AA5XXX, AAXXXX, AXXXXX False True True NIHTT 37470483 Website Abstract 114104750 Derbyshire, John NIMH Derbyshire, John (NIMH) 0 114104751 Herzka, Daniel Herzka, Daniel 0 114104752 Mcveigh, Elliot Mcveigh, Elliot 0 114104750 Derbyshire, John NIMH Derbyshire, John (NIMH) 0 114104751 Herzka, Daniel Herzka, Daniel 0 114104752 Mcveigh, Elliot Mcveigh, Elliot 0 114100113 Fisptrain: A High Signal Magnetic Resonance Imaging (MRI) Sequence With Steady-state Free Precession And Intrinsic Fat Suppression E-237-2003-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-923] Novel Method of Fat Suppression in Steady State Free Precession (SSFP) Based Magnetic Resonance Imaging (MRI)&body=Please send me information about technology [TAB-923] Novel Method of Fat Suppression in Steady State Free Precession (SSFP) Based Magnetic Resonance Imaging (MRI). Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-923] Novel Method of Fat Suppression in Steady State Free Precession (SSFP) Based Magnetic Resonance Imaging (MRI)&body=Please send me information about technology [TAB-923] Novel Method of Fat Suppression in Steady State Free Precession (SSFP) Based Magnetic Resonance Imaging (MRI).">shmilovm@nih.gov</a><br> 114162297 E-237-2003-0 E-237-2003-0-US-02 Fisptrain: A High Signal Magnetic Resonance Imaging (MRI) Sequence With Steady-state Free Precession And Intrinsic Fat Suppression ORD US 7,253,620 11/075,415 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7253620 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7253620">7,253,620</a><br />Filed on 2005-03-08<br />Status: Expired 114162298 E-237-2003-0 E-237-2003-0-US-03 Fisptrain: A High Signal Magnetic Resonance Imaging (MRI) Sequence With Steady-state Free Precession And Intrinsic Fat Suppression CON US 7,880,466 11/751,479 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7880466 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7880466">7,880,466</a><br />Filed on 2007-05-21<br />Status: Expired 114165441 E-237-2003-0 E-237-2003-0-US-01 A High Signal Magnetic Resonance Imaging (MRI) Sequence With Steady-state Free Precession And Intrinsic Fat Suppression PRV US 60/551,273 Abandoned US <br />Provisional (PRV) 60/551,273<br />Filed on 2004-03-08<br />Status: Abandoned 114115316 AA2XXX 114115317 AA3XXX 114115318 AA5XXX 114115319 AAXXXX 114115320 AXXXXX TAB-917 114095251 Cannula for Pressure Mediated Drug Delivery NHLBI Licensing Licensing Randall Clevenger, John Deleonardis, Robert Hoyt, Robert Lutz, Brian Safer Available for licensing are methods and devices for selectively delivering therapeutic substances to specific histological or microanatomical areas of organs (e.g., introduction of the therapeutic substance into a hollow organ space such as the hepatobiliary duct or the gallbladder lumen) at a controlled pressure, volume and/or rate which allows the substance to reach a predetermined cellular layer. The volume or flow rate of the substance can be controlled so that the intralumenal pressure reaches a predetermined threshold beyond which subsequent subepithehal delivery of the substance occurs. Alternatively, a lower pressure is selected that does not exceed the threshold level, so that delivery occurs substantially to the epithelial layer. Such site-specific delivery of therapeutic agents permits localized delivery in concentrations that may otherwise produce systemic toxicity. Occlusion of venous or lymphatic drainage from the organ can also help prevent systemic administration of therapeutic substances, and increases selective delivery to superficial epithelial cellular layers. Delivery of genetic vectors can also be delivered to target cells. The access device comprises a cannula with a wall piercing tracar within the lumen. Two axially spaced inflatable balloons engage the wall securing the cannula and sealing the puncture site. A catheter equipped with an occlusion balloon is guided through the cannula to the location where the therapeutic substance is to be delivered. 2022-03-08 2024-10-28 2024-10-28 2005-03-01 AB3CXX, AB3FXX, AB3XXX, ABXXXX, AXXXXX, Delivery, Mediated, PCT/US99/11277, PRESSURE, Psoukas, SELECTIVE, SUBSTANCES, therapeutic False True True NIHTT 37470483 Website Abstract 114104741 Clevenger, Randall National Heart, Lung, and Blood Institute (NHLBI) NHLBI Clevenger, Randall (NHLBI) 0 114104742 Deleonardis, John National Heart, Lung, and Blood Institute (NHLBI) NEI Deleonardis, John (NEI) 0 114104743 Hoyt, Robert National Heart, Lung, and Blood Institute (NHLBI) NINDS Hoyt, Robert (NINDS) 0 114106436 Lutz, Robert NIBIB Lutz, Robert (NIBIB) 0 114106439 Safer, Brian National Heart, Lung, and Blood Institute (NHLBI) NHLBI Safer, Brian (NHLBI) 0 114104741 Clevenger, Randall National Heart, Lung, and Blood Institute (NHLBI) NHLBI Clevenger, Randall (NHLBI) 0 114104742 Deleonardis, John National Heart, Lung, and Blood Institute (NHLBI) NEI Deleonardis, John (NEI) 0 114104743 Hoyt, Robert National Heart, Lung, and Blood Institute (NHLBI) NINDS Hoyt, Robert (NINDS) 0 114106436 Lutz, Robert NIBIB Lutz, Robert (NIBIB) 0 114106439 Safer, Brian National Heart, Lung, and Blood Institute (NHLBI) NHLBI Safer, Brian (NHLBI) 0 114100108 Pressure Mediated Selective Delivery of Therapeutic Substances E-196-1998-2 Filing authorized National Heart, Lung, and Blood Institute (NHLBI), NIBIB 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-917] Cannula for Pressure Mediated Drug Delivery&body=Please send me information about technology [TAB-917] Cannula for Pressure Mediated Drug Delivery. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-917] Cannula for Pressure Mediated Drug Delivery&body=Please send me information about technology [TAB-917] Cannula for Pressure Mediated Drug Delivery.">shmilovm@nih.gov</a><br> 114162284 E-196-1998-2 E-196-1998-2-US-15 Method for Pressure Mediated Selective Delivery of Therapeutic Substances And Cannula DIV US 12/009,646 Abandoned US <br />Divisional (DIV) 12/009,646<br />Filed on 2008-01-17<br />Status: Abandoned 114162285 E-196-1998-2 E-196-1998-2-US-07 Method For Pressure Mediated Selective Delivery of Therapeutic Substances and Cannula National Stage US 09/700,999 Abandoned US <br />National Stage 09/700,999<br />Filed on 2000-12-04<br />Status: Abandoned 114163931 E-196-1998-2 E-196-1998-2-PCT-01 METHOD FOR PRESSURE MEDIATED SELECTIVE DELIVERY OF THERAPEUTIC SUBSTANCES AND CANNULA PCT COMB Patent Cooperation Treaty PCT/US1999/011277 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US1999/011277<br />Filed on 1999-05-21<br />Status: Expired 114166411 E-196-1998-2 E-196-1998-2-US-16 Method For Pressure Mediated Selective Delivery of Therapeutic Substances and Cannula CON US 8,409,166 13/094,764 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8409166 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8409166">8,409,166</a><br />Filed on 2011-04-26<br />Status: Abandoned 114115296 AB3FXX 114115297 AB3CXX 114119592 AB3XXX 114119593 ABXXXX 114119594 AXXXXX 114135111 PCT/US99/11277 114135112 Psoukas 114135113 PRESSURE 114135114 Mediated 114135115 SELECTIVE 114135116 Delivery 114135117 therapeutic 114135118 SUBSTANCES TAB-909 114095243 Construction of an Infectious Full-Length cDNA Clone of the Porcine Enteric Calicivirus RNA Genome NIAID Collaboration, Diagnostics, Infectious Disease, Licensing, Materials Available, Research Materials, Therapeutics, Vaccines Collaboration Diagnostics Infectious Disease Licensing Materials Available Research Materials Therapeutics Vaccines Gael Belliot, Kyeong-Ok Chang, Lisbeth Kim Green, Stanislav Sosnovtsev <p>Porcine enteric calicivirus (PEC) is a member of the genus Sapovirus in the family Caliciviridae. This virus causes diarrheal illness in pigs, and is presently the only enteric calicivirus that can be grown in cell culture. In addition to its relevance to veterinary medicine as a diarrheal agent in pigs, PEC serves as an important model for the study of enteric caliciviruses that cause diarrhea and that cannot be grown in cell culture (including the noroviruses represented by Norwalk virus). The development of an infectious cDNA clone is important because it enables the use of &ldquo;reverse genetics&rdquo; to engineer mutations of interest into the genome of PEC and to study their effects. In addition, it allows the introduction of foreign coding sequences into the genome of PEC that could be useful for vaccine development in swine and possibly humans. This discovery has both basic research applications such as mapping mutations involved in tissue culture adaptation, tissue tropism, and virulence as well as practical applications such as providing a genetic backbone for the development of chimeric vaccine viruses.</p> The Laboratory of Infectious Diseases, NIAID, NIH, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize reagents derived from an infectious cDNA copy of the genome of porcine enteric calicivirus. Please contact Kim Y. Green at <a href="mailto:kgreen@niaid.nih.gov">kgreen@niaid.nih.gov</a> for more information. Research Material -- Patent protection is not being pursued for this technology Research Material -- Patent prosecution is not being pursued for these technologies. The materials embodied in this invention are available nonexclusively through a biological materials license. 2022-03-08 2024-10-28 2024-10-28 2008-06-01 CALICIVIRUS, cDNA, CLONE, Construction, DA4BXX, DAXXXX, DB4BXX, DBXXXX, DC5BXX, DCXXXX, DDXXXX, DXXXXX, ENTERIC, FULL-LENGTH, Genome, INFECTIOUS, PORCINE, RNA False True True NIHTT 37470483 Website Abstract E-283-2003-0 E-212-2003-0 E-198-2003-0 114169963 Chang KO, et al. Cell-culture propagation of porcine enteric calicivirus mediated by intestinal contents is dependent on the cyclic AMP signaling pathway. https://www.ncbi.nlm.nih.gov/pubmed/12504571 <a href="https://www.ncbi.nlm.nih.gov/pubmed/12504571">Chang KO, et al. Cell-culture propagation of porcine enteric calicivirus mediated by intestinal contents is dependent on the cyclic AMP signaling pathway.</a> 114104722 Sosnovtsev, Stanislav NIAID - DIR NIAID Sosnovtsev, Stanislav (NIAID) 0 114104723 Green, Lisbeth Kim NIAID - DIR NIAID Green, Lisbeth Kim (NIAID) 0 114104724 Belliot, Gael NIAID Belliot, Gael (NIAID) 0 114104725 Chang, Kyeong-Ok NIAID - DIR Chang, Kyeong-Ok 1 114104725 Chang, Kyeong-Ok NIAID - DIR Chang, Kyeong-Ok 1 114104722 Sosnovtsev, Stanislav NIAID - DIR NIAID Sosnovtsev, Stanislav (NIAID) 0 114104723 Green, Lisbeth Kim NIAID - DIR NIAID Green, Lisbeth Kim (NIAID) 0 114104724 Belliot, Gael NIAID Belliot, Gael (NIAID) 0 114100101 Construction Of An Infectious Full-Length CDNA Clone Of The Porcine Enteric Calicivirus RNA Genome E-214-2003-0 Research Material NIAID, Ohio State University 83643855 Soukas, Peter peter.soukas@nih.gov
United States of America Technology Transfer and Intellectual Property Office peter.soukas@nih.gov?subject=Web Inquiry on [TAB-909] Construction of an Infectious Full-Length cDNA Clone of the Porcine Enteric Calicivirus RNA Genome&body=Please send me information about technology [TAB-909] Construction of an Infectious Full-Length cDNA Clone of the Porcine Enteric Calicivirus RNA Genome. Soukas, Peter<br><a href="mailto:peter.soukas@nih.gov?subject=Web Inquiry on [TAB-909] Construction of an Infectious Full-Length cDNA Clone of the Porcine Enteric Calicivirus RNA Genome&body=Please send me information about technology [TAB-909] Construction of an Infectious Full-Length cDNA Clone of the Porcine Enteric Calicivirus RNA Genome.">peter.soukas@nih.gov</a><br> 114115244 DA4BXX 114115245 DB4BXX 114115246 DC5BXX 114115247 DDXXXX 114115248 DAXXXX 114115249 DBXXXX 114115250 DCXXXX 114115251 DXXXXX 114130401 FULL-LENGTH 114130402 INFECTIOUS 114130403 Construction 114130404 Genome 114130405 RNA 114130406 CALICIVIRUS 114130407 ENTERIC 114130408 PORCINE 114130409 CLONE 114130410 cDNA TAB-908 114095242 Enzymatically-Active RNA-Dependent RNA Polymerase From a Human Norovirus (Calicivirus) NIAID Collaboration, Diagnostics, Infectious Disease, Licensing, Materials Available, Research Materials, Therapeutics, Vaccines Collaboration Diagnostics Infectious Disease Licensing Materials Available Research Materials Therapeutics Vaccines Gael Belliot, Kyeong-Ok Chang, Lisbeth Kim Green, Stanislav Sosnovtsev <p>The noroviruses (formerly known as &ldquo;Norwalk-like viruses&rdquo;) are associated with gastroenteritis outbreaks, affecting large numbers of individuals each year. Emerging data are supporting their increasing recognition as important agents of diarrhea-related morbidity and mortality. The frequency with which noroviruses are associated with gastroenteritis as &ldquo;food and water-borne pathogens&rdquo; has led to the inclusion of caliciviruses as Category B Bioterrorism Agents/Diseases. Because the noroviruses cannot be propagated by any means in the laboratory, an important strategy in their study is to development of molecular biology-based tools and replication systems. This invention reports the isolation of the first recombinant, enzymatically-active proteinase and RNA dependent RNA polymerase (RdRp) complex for a human norovirus. This enzyme should facilitate studies aimed at developing therapeutic drugs for norovirus disease.</p> The Laboratory of Infectious Diseases, NIAID, NIH, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize an active human norovirus proteinase-polymerase enzyme. Please contact Kim Y. Green at <a href="mailto:kgreen@niaid.nih.gov">kgreen@niaid.nih.gov</a> for more information. Research Material -- Patent protection is not being pursued for this technology Research Material -- Patent prosecution is not being pursued for these technologies The materials embodied in this invention are available nonexclusively through a biological materials license. 2022-03-08 2024-10-28 2024-10-28 2008-06-01 CALICIVIRUS, DA4BXX, DAXXXX, DB4BXX, DBXXXX, DC5BXX, DCXXXX, DDXXXX, DXXXXX, Enzymatically-active, Human, Norovirus, polymerase, RNA, RNA-Dependent False True True NIHTT 37470483 Website Abstract E-214-2003-0 E-212-2003-0 E-198-2003-0 114169962 Wei L, et al. Proteinase-polymerase precursor as the active form of feline calicivirus RNA-dependent RNA polymerase. https://www.ncbi.nlm.nih.gov/pubmed/11152494 <a href="https://www.ncbi.nlm.nih.gov/pubmed/11152494">Wei L, et al. Proteinase-polymerase precursor as the active form of feline calicivirus RNA-dependent RNA polymerase.</a> 114104718 Sosnovtsev, Stanislav NIAID - DIR NIAID Sosnovtsev, Stanislav (NIAID) 0 114104719 Green, Lisbeth Kim NIAID - DIR NIAID Green, Lisbeth Kim (NIAID) 0 114104720 Chang, Kyeong-Ok Chang, Kyeong-Ok 0 114104721 Belliot, Gael NIAID - DIR NIAID Belliot, Gael (NIAID) 1 114104721 Belliot, Gael NIAID - DIR NIAID Belliot, Gael (NIAID) 1 114104718 Sosnovtsev, Stanislav NIAID - DIR NIAID Sosnovtsev, Stanislav (NIAID) 0 114104719 Green, Lisbeth Kim NIAID - DIR NIAID Green, Lisbeth Kim (NIAID) 0 114104720 Chang, Kyeong-Ok Chang, Kyeong-Ok 0 114100100 Enzymatically-active RNA-Dependent RNA Polymerase From A Human Norovirus (Calicivirus) E-283-2003-0 Research Material NIAID 83643855 Soukas, Peter peter.soukas@nih.gov
United States of America Technology Transfer and Intellectual Property Office peter.soukas@nih.gov?subject=Web Inquiry on [TAB-908] Enzymatically-Active RNA-Dependent RNA Polymerase From a Human Norovirus (Calicivirus)&body=Please send me information about technology [TAB-908] Enzymatically-Active RNA-Dependent RNA Polymerase From a Human Norovirus (Calicivirus). Soukas, Peter<br><a href="mailto:peter.soukas@nih.gov?subject=Web Inquiry on [TAB-908] Enzymatically-Active RNA-Dependent RNA Polymerase From a Human Norovirus (Calicivirus)&body=Please send me information about technology [TAB-908] Enzymatically-Active RNA-Dependent RNA Polymerase From a Human Norovirus (Calicivirus).">peter.soukas@nih.gov</a><br> 114115236 DA4BXX 114115237 DB4BXX 114115238 DC5BXX 114115239 DDXXXX 114115240 DAXXXX 114115241 DBXXXX 114115242 DCXXXX 114115243 DXXXXX 114130411 Enzymatically-active 114130412 RNA-Dependent 114130413 RNA 114130414 polymerase 114130415 Human 114130416 Norovirus 114130417 CALICIVIRUS TAB-885 114095219 Multipotent Postnatal Stem Cells From Human Periodontal Ligament and Uses Thereof NIDCR Diagnostics, Licensing, Reproductive Health, Research Materials, Therapeutics, Vaccines Diagnostics Licensing Reproductive Health Research Materials Therapeutics Vaccines Songtao Shi It is estimated that over 40 percent of the adult population in the United States has periodontal disease in one form or another. Periodontal Disease is a chronic infection of the periodontal ligament (PDL) and the adjacent bone and cementum. The effects of Periodontal Disease range from simple gum inflammation to, in extreme cases, tooth loss.<br /><br /> The NIH announces a new technology wherein stem cells from the PDL have been isolated from adult human PDL. These cells are capable of forming cementum and PDL in immunocompromised mice. In cell culture, PDL stem cells differentiate into collagen fiber forming cells (fibroblasts), cementoblasts, and adipocytes. It is anticipated that these PDL stem cells will be useful for periodontal tissue regeneration to treat periodontal disease. 2022-03-08 2024-10-28 2024-10-28 2005-07-01 IB6XXX, IBXXXX, IXXXXX False True True NIHTT 37470483 Website Abstract 114104675 Shi, Songtao Shi, Songtao 0 114104675 Shi, Songtao Shi, Songtao 0 114100073 Multipotent Postnatal Stem Cells From Human Periodontal Ligament E-033-2004-0 Filing authorized NIDCR 83656052 Knezevic, Vladimir vlado.knezevic@nih.gov
United States of America Technology Advancement Office vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-885] Multipotent Postnatal Stem Cells From Human Periodontal Ligament and Uses Thereof&body=Please send me information about technology [TAB-885] Multipotent Postnatal Stem Cells From Human Periodontal Ligament and Uses Thereof. Knezevic, Vladimir<br><a href="mailto:vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-885] Multipotent Postnatal Stem Cells From Human Periodontal Ligament and Uses Thereof&body=Please send me information about technology [TAB-885] Multipotent Postnatal Stem Cells From Human Periodontal Ligament and Uses Thereof.">vlado.knezevic@nih.gov</a><br> 114162201 E-033-2004-0 E-033-2004-0-US-01 Multipotent Postnatal Stem Cells From Human Periodontal Ligament and Uses Thereof PRV US 60/523,602 Abandoned US <br />Provisional (PRV) 60/523,602<br />Filed on 2003-11-20<br />Status: Abandoned 114162202 E-033-2004-0 E-033-2004-0-PCT-02 Multipotent Postnatal Stem Cells From Human Periodontal Ligament PCT Patent Cooperation Treaty PCT/US2004/039248 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2004/039248<br />Filed on 2004-11-22<br />Status: Expired 114162203 E-033-2004-0 E-033-2004-0-US-03 Multipotent Postnatal Stem Cells From Human Periodontal Ligament And Uses Thereof National Stage US 9,210,925 11/433,627 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9210925 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9210925">9,210,925</a><br />Filed on 2006-05-12<br />Status: Issued 114165509 E-033-2004-0 E-033-2004-0-US-13 Multipotent Postnatal Stem Cells From Human Periodontal Ligament and Uses Thereof CON US 10,046,012 14/936,529 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10046012 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10046012">10,046,012</a><br />Filed on 2015-11-09<br />Status: Expired 114115104 IB6XXX 114115105 IBXXXX 114115106 IXXXXX TAB-860 114095193 Brother of the Regulator of Imprinted Sites (BORIS) NIAID Diagnostics, Licensing, Oncology Diagnostics Licensing Oncology Victor Lobanenkov The subject application discloses an isolated or purified nucleic acid molecule consisting essentially of a nucleotide sequence encoding a human or a non-human BORIS, or a fragment of either of the foregoing; an isolated or purified nucleic acid molecule consisting essentially of a nucleotide sequence that is complementary to a nucleotide sequence encoding a human or a non-human BORIS, or a fragment of either of the following; a vector comprising such an isolated or purified polypeptide molecule consisting essentially of an amino acid sequence encoding a human or a non-human BORIS, or a fragment or either of the foregoing; a cell line that produces a monoclonal antibody that is specific for an aforementioned isolated or purified polypeptide molecule; and the monoclonal antibody produced by the cell line; methods of diagnosing a cancer or a predisposition to a cancer in a male or female mammal; a method of prognosticating a cancer in a mammal; a method of assessing the effectiveness of treatment of a cancer in a mammal; a method of treating a mammal prophylactically or therapeutically for a cancer; and a composition comprising a carrier and an inhibitor of BORIS. 2022-03-08 2024-10-28 2024-10-28 2004-02-01 CA1AXX, CA1CXX, CAXXXX, CXXXXX False True True NIHTT 37470483 Website Abstract 114104638 Lobanenkov, Victor NIAID Lobanenkov, Victor (NIAID) 0 114104638 Lobanenkov, Victor NIAID Lobanenkov, Victor (NIAID) 0 114100037 Brother of The Regulator of Imprinted Sites (Boris) E-227-2001-0 Filing authorized NIAID 83738793 Taylor-Mulneix, Dawn dawn.taylor-mulneix@nih.gov
United States of America dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-860] Brother of the Regulator of Imprinted Sites (BORIS)&body=Please send me information about technology [TAB-860] Brother of the Regulator of Imprinted Sites (BORIS). Taylor-Mulneix, Dawn<br><a href="mailto:dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-860] Brother of the Regulator of Imprinted Sites (BORIS)&body=Please send me information about technology [TAB-860] Brother of the Regulator of Imprinted Sites (BORIS).">dawn.taylor-mulneix@nih.gov</a><br> 114162124 E-227-2001-0 E-227-2001-0-US-01 Brother of The Regulator of Imprinted Sites (Boris) PRV US 60/358,889 Abandoned US <br />Provisional (PRV) 60/358,889<br />Filed on 2002-02-22<br />Status: Abandoned 114162126 E-227-2001-0 E-227-2001-0-US-03 Brother of The Regulator of Imprinted Sites (Boris) National Stage US 7,375,206 10/505,377 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7375206 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7375206">7,375,206</a><br />Filed on 2004-10-20<br />Status: Expired 114164090 E-227-2001-0 E-227-2001-0-PCT-02 Brother of The Regulator of Imprinted Sites (BORIS) PCT Patent Cooperation Treaty PCT/US2003/05186 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2003/05186<br />Filed on 2003-02-21<br />Status: Expired 114114998 CA1AXX 114114999 CA1CXX 114115000 CAXXXX 114115001 CXXXXX TAB-874 114095208 Cloning and Characterization of an Avian Adeno-Associated Virus and Uses Thereof NIDCR Licensing, Therapeutics Licensing Therapeutics Ioannis Bossis, John (Jay) Chiorini Currently, adeno-associated virus (AAV) represents the gene therapy vehicle of choice because it has many advantages over current strategies for therapeutic gene insertion. AAV is less pathogenic than other virus types; stably integrates into dividing and non-dividing cells; integrates at a consistent site in the host genome; and shows good specificity towards various cell types for targeted gene delivery. <br><br> To date, 11 AAV isolates have been isolated and characterized. New serotypes derived from non-human animal species have added to the specificity and repertoire of current AAV gene therapy techniques by avoiding the immunologic complications associated with human isolates. <br><br> This invention describes vectors derived from an avian AAV. These vectors have innate properties related to their origin that may confer them with a unique cellular specificity in targeted human gene therapy and a unique immunologic profile that would avoid neutralization by pre-existing antibodies. Therefore, vectors derived from this avian AAV are likely to find novel applications for gene therapy in humans. Furthermore because of their species of origin, this vector would also be useful in the engineering of avian cells. The National Institute of Dental and Craniofacial Research, Laboratory of Dr. John Chiorini, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize gene therapy methods using AAV vectors. Please contact David W. Bradley, Ph.D. at <a href="mailto:bradleyda@nidcr.nih.gov">bradleyda@nidcr.nih.gov</a> for more information. Available for non-exclusive or exclusive licensing. 2022-03-08 2024-10-28 2024-10-28 2007-03-01 GB2A2X, GB2AXX, GB2XXX, GB3XXX, GBXXXX, GXXXXX False True True NIHTT 37470483 Website Abstract 114169956 I Bossis, JA Chiorini. Cloning of an avian adeno-associated virus (AAAV) and generation of recombinant AAAV particles. J Virol. 2003 Jun;77(12):6799-6810. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=12768000&query_hl=7&itool=pubmed_DocSum <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=12768000&query_hl=7&itool=pubmed_DocSum">I Bossis, JA Chiorini. Cloning of an avian adeno-associated virus (AAAV) and generation of recombinant AAAV particles. J Virol. 2003 Jun;77(12):6799-6810.</a> 114104659 Chiorini, John (Jay) NIDCR NIDCR Chiorini, John (Jay) (NIDCR) 0 114104658 Bossis, Ioannis NIDCR Bossis, Ioannis 1 114104658 Bossis, Ioannis NIDCR Bossis, Ioannis 1 114104659 Chiorini, John (Jay) NIDCR NIDCR Chiorini, John (Jay) (NIDCR) 0 114100055 Cloning And Characterization Of An Avian Adeno-Associated Virus And Uses Thereof E-105-2003-0 Filing authorized NIDCR 83656052 Knezevic, Vladimir vlado.knezevic@nih.gov
United States of America Technology Advancement Office vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-874] Cloning and Characterization of an Avian Adeno-Associated Virus and Uses Thereof&body=Please send me information about technology [TAB-874] Cloning and Characterization of an Avian Adeno-Associated Virus and Uses Thereof. Knezevic, Vladimir<br><a href="mailto:vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-874] Cloning and Characterization of an Avian Adeno-Associated Virus and Uses Thereof&body=Please send me information about technology [TAB-874] Cloning and Characterization of an Avian Adeno-Associated Virus and Uses Thereof.">vlado.knezevic@nih.gov</a><br> 114162167 E-105-2003-0 E-105-2003-0-US-03 Avian Adeno-Associated Virus (AAAV) and Uses Thereof National Stage US 8,927,269 10/557,662 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8927269 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8927269">8,927,269</a><br />Filed on 2006-12-21<br />Status: Issued 114115051 GB2A2X 114115052 GB2AXX 114115053 GB2XXX 114115054 GB3XXX 114115055 GBXXXX 114115056 GXXXXX TAB-846 114095180 Codon-optimization of HIV-1 Viral Infectivity Factor (VIF) Gene NIAID Diagnostics, Infectious Disease, Licensing, Research Materials Diagnostics Infectious Disease Licensing Research Materials Stephan Bour, Kim-Lien Nguyen, Klaus Strebel Expression of the HIV-1 Vif protein in the absence of other viral factors such a Tat and Rev is extremely inefficient due to the presence of inhibitory sequences on its mRNA. This invention uses codon optimization to remove such inhibitory sequences without altering the amino acid sequence of the protein. The modified vif gene in the resulting pcDNA -hVIF vector is expressed under the control of the CMV promoter. In this, the protein functions as wild type and is more amendable to high-level expression in mammalian cells.<br /><br /> Currently this vector is used in on-going studies of HIV infection and its ability to overcome cellular restriction to replication. As such, the reagent will be valuable to other researchers in discovering mechanisms of replication, next generation therapeutics and potentially prevention of infection as well. <ul> <li>A plasmid pcDNA-hVif capable of expressing VIF independent of other HIV genes through removal of inhibitory sequences on its mRNA.</li> </ul> Research Material - Patent protection is not being pursued for this technology. (IC Reference No. 2004-036) 2022-03-08 2024-10-28 2024-10-28 2004-01-01 AAXXXX, AXXXXX, DA4AXX, DAXXXX, DDXXXX, DXXXXX, PLASMID, RM, VLXXXX, WIXXXX False True True NIHTT 37470483 Website Abstract 114104604 Strebel, Klaus NIAID Strebel, Klaus (NIAID) 0 114104605 Bour, Stephan NIAID Bour, Stephan (NIAID) 0 114104606 Nguyen, Kim-Lien Nguyen, Kim-Lien 0 114104604 Strebel, Klaus NIAID Strebel, Klaus (NIAID) 0 114104605 Bour, Stephan NIAID Bour, Stephan (NIAID) 0 114104606 Nguyen, Kim-Lien Nguyen, Kim-Lien 0 114100019 Condon-optimization Of HIV-1 Vf Gene` E-041-2004-0 Research Material NIAID 83724572 Tung, Peter peter.tung@nih.gov
United States of America DIR peter.tung@nih.gov?subject=Web Inquiry on [TAB-846] Codon-optimization of HIV-1 Viral Infectivity Factor (VIF) Gene&body=Please send me information about technology [TAB-846] Codon-optimization of HIV-1 Viral Infectivity Factor (VIF) Gene. Tung, Peter<br><a href="mailto:peter.tung@nih.gov?subject=Web Inquiry on [TAB-846] Codon-optimization of HIV-1 Viral Infectivity Factor (VIF) Gene&body=Please send me information about technology [TAB-846] Codon-optimization of HIV-1 Viral Infectivity Factor (VIF) Gene.">peter.tung@nih.gov</a><br> 114114918 DA4AXX 114114919 AAXXXX 114114920 DDXXXX 114114921 DAXXXX 114114922 AXXXXX 114114923 DXXXXX 114127361 VLXXXX 114127362 WIXXXX 114149408 RM 114149409 PLASMID TAB-817 114095152 A Tet-Regulated Mouse Model for Cataract NIEHS Animal Models, Diagnostics, Licensing, Research Materials, Therapeutics Animal Models Diagnostics Licensing Research Materials Therapeutics Robert Sobol Cataract is the most common cause of blindness worldwide, with an estimated 25 million blind and 119 million visually impaired individuals worldwide. Over 20 million adults in the US alone are currently diagnosed with cataracts making this disease a major health concern. The incidence of cataract increases with age and a number of etiologic factors have been proposed in the pathogenesis of age-related cataract in humans including genetic factors, environmental factors and metabolic and biochemical changes in the crystalline lens. Ultraviolet radiation exposure and oxidative injury to the lens has been considered by some to be one of the most important factors in cataractogenesis. The present therapy of choice for cataract is laser surgery. <p>Experimental investigation of human age-related cataract is hindered by a lack of available animal models of cataract. Several laboratory mice strains with heritable cataracts have been studied including the Nakona, Frasier and the Philly mouse strains. An animal model with a predictable phenotype of cataract, particularly one with a pathogenesis relating to oxidative injury to the lens (the proposed central factor in human-related cataract) would be of great value to ophthalmic researchers and in the development of pharmacological agents for delaying or preventing cataract.</p> <p>Researchers at the NIEHS have developed a transgenic mouse model in which the DNA repair gene DNA polymerase ß (ß-pol) is highly over-expressed in the lens epithelial cells of the eye (<i>DNA Repair</i> (2003) 609-622). A bicistronic tetracycline-responsive transgenic system was used to over-express ß-pol in mice. Over-expression of ß-pol in the lens epithelium results in the early onset of severe cortical cataract with cataractogenesis beginning within 4 days after birth. <i>In utero</i> and post-natal suppression of transgenic Flag-ß-pol-expression by doxycycline administration completely prevents cataract formation through adulthood, yet cataract is subsequently observed following removal of doxycycline and re-expression of the transgene. This predictable and regulated onset of cataract make this mouse an ideal animal model both for evaluating new therapeutics for delaying or preventing cataract as well as for understanding the mechanisms responsible for cataract formation.</p> 2022-03-08 2024-10-28 2024-10-28 2003-12-01 BAXXXX, IDXXXX, IXXXXX False True True NIHTT 37470483 Website Abstract 114104560 Sobol, Robert Sobol, Robert 0 114104560 Sobol, Robert Sobol, Robert 0 114099988 Mouse Model for Early Onset Cataract E-316-2002-0 Research Material NIEHS, North Carolina State University (NCSU) 83739538 Choudhry, Vidita vidita.choudhry@nih.gov
United States of America Office of Technology Transfer and Development vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-817] A Tet-Regulated Mouse Model for Cataract&body=Please send me information about technology [TAB-817] A Tet-Regulated Mouse Model for Cataract. Choudhry, Vidita<br><a href="mailto:vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-817] A Tet-Regulated Mouse Model for Cataract&body=Please send me information about technology [TAB-817] A Tet-Regulated Mouse Model for Cataract.">vidita.choudhry@nih.gov</a><br> 114114804 IDXXXX 114114805 IXXXXX 114121329 BAXXXX TAB-778 114095114 Peptides for Treatment of Tumor Necrosis Factor alpha Mediated Inflammatory Disease NHLBI Diagnostics, Immunology, Licensing, Research Materials, Therapeutics Diagnostics Immunology Licensing Research Materials Therapeutics Stewart Levine Tumor Necrosis Factor alpha (TNF-alpha) is a multifunctional cytokine that mediates inflammation, immune regulation, and cellular proliferation. This cytokine is converted to its active form by TNF-alpha converting enzyme (TACE). Pathological increases in TNF-alpha activity have been associated with a wide variety of inflammatory diseases, including inflammatory bowel disease, rheumatoid arthritis, and cancer. Inhibiting the conversion of TNF-alpha to its active form by inhibiting TACE represents a potential treatment for these diseases. <br /><br /> The current technology provides peptides, derived from an N-terminal fragment of the TACE protein, that inhibit TACE activity. Also described are methods of using these peptides to lower levels of active TNF-alpha. These peptides could be used as a treatment for TNF-alpha-mediated inflammatory diseases. Inhibition of TACE activity represents a novel mechanism to treat inflammatory disease. Treatment of TNF-alpha mediated inflammatory diseases. 2022-03-08 2024-10-28 2024-10-28 2006-03-01 Crohn disease, Demyelinating diseases, IB3XXX, IBXXXX, Inflammatory bowel disease 1, IXXXXX False True <ul> <li>Early-stage</li> <li>In vitro data available</li> </ul> True NIHTT 37470483 Website Abstract 114171669 Buckley CA, et al. http://www.ncbi.nlm.nih.gov/pubmed/15749738 <a href="http://www.ncbi.nlm.nih.gov/pubmed/15749738">Buckley CA, et al.</a> 114104490 Levine, Stewart NHLBI Levine, Stewart (NHLBI) 0 114104490 Levine, Stewart NHLBI Levine, Stewart (NHLBI) 0 114099945 Identification Of An Endogenous TACE Inhibitory Peptide (eTIP) E-208-2003-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-778] Peptides for Treatment of Tumor Necrosis Factor alpha Mediated Inflammatory Disease&body=Please send me information about technology [TAB-778] Peptides for Treatment of Tumor Necrosis Factor alpha Mediated Inflammatory Disease. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-778] Peptides for Treatment of Tumor Necrosis Factor alpha Mediated Inflammatory Disease&body=Please send me information about technology [TAB-778] Peptides for Treatment of Tumor Necrosis Factor alpha Mediated Inflammatory Disease.">shmilovm@nih.gov</a><br> 114161925 E-208-2003-0 E-208-2003-0-US-01 TNF-alpha Converting Enzyme Inhibitory Agents and Stimulatory Agents PRV US 60/505,394 Abandoned US <br />Provisional (PRV) 60/505,394<br />Filed on 2003-09-24<br />Status: Abandoned 114161927 E-208-2003-0 E-208-2003-0-US-03 TNF-Alpha Converting Enzyme Inhibitory Agents And Stimulatory Agents National Stage US 7,655,752 11/389,675 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7655752 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7655752">7,655,752</a><br />Filed on 2006-03-24<br />Status: Expired 114167594 E-208-2003-0 E-208-2003-0-PCT-02 Identification Of An Endogenous TACE Inhibitory Peptide (eTIP) PCT Patent Cooperation Treaty PCT/US2004/031608 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2004/031608<br />Filed on 2004-09-24<br />Status: Expired 114114630 IB3XXX 114114631 IBXXXX 114114632 IXXXXX 114157694 Inflammatory bowel disease 1 114157695 Demyelinating diseases 114158957 Crohn disease TAB-787 114095124 Vaccines Comprising Sand Fly Salivary Proteins for Control of Leishmania Infection NIAID Collaboration, Diagnostics, Infectious Disease, Research Materials, Therapeutics, Vaccines Collaboration Diagnostics Infectious Disease Research Materials Therapeutics Vaccines Jesus Valenzuela This invention relates to the use of several peptides from the salivary glands of various sand fly species for the control of leishmania infection. Many of these peptides were shown to be effective in eliciting potent immune responses in animal models and are excellent candidates for the development of vaccines against the disease. A vaccine comprising one of the peptides was used to protect mice challenged with parasites and salivary gland homogenates. A DNA vaccine containing the cDNA for this same peptide also provided protection that lasted at least 3 months after immunization and produced both intense humoral and delayed-type hypersensitivity reactions. Other experiments have shown that B cell-deficient mice immunized with the plasmid vaccine also successfully controlled leishmania infection. Current <em>in-vivo</em> studies continue to explore the use of these sand fly salivary peptides for use as animal vaccines.<br /><br /> Leishmania parasites are transmitted to their vertebrate hosts by infected sand fly bites. Sand fly saliva helps to enhance infection but immunity to the saliva protects against the infection, allowing the possibility of vaccine development. A number of major salivary proteins from sand fly species such as <em>Lutzomyia longipalpis</em>, <em>Phlebotomus ariasi</em>, and <em>Phlebotomus perniciosus</em> are claimed in the invention.<br /><br /> Leishmania infection affects as many as 12 million people worldwide, with 1.5-2 million new cases each year. Control of this disease will be a major milestone for public health efforts in endemic areas of the world. The current invention provides a potential means to achieve widespread vaccination that may lead to significantly control of the disease in areas such as South America, South Asia, and the Mediterranean where it is still a significant health problem. An effective veterinary vaccine will be of benefit to veterinary medicine and may pave the way for human vaccines against Leishmaniasis. The vaccination of animals may also have a positive impact on the epidemiology of the disease by reducing the number of animal reservoirs and the possibility of human infection. <ul> <li>Vaccines to control leishmania infection</li> <li>Use of peptides to elicit potent immune responses</li> </ul> The National Institute of Allergy and Infectious Diseases, Technology Transfer and Intellectual Property Office, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize "Vaccines Comprising Sand Fly Salivary Proteins for Control of Leishmania Infection." Please contact Dana Hsu at 240-627-3698 for more information. and related international patents/patent applications 2022-03-08 2024-10-28 2024-10-28 2003-11-01 Adn, America, ARIASI, Cellular, Chagase, DA2XXX, DAXXXX, DB2XXX, DBXXXX, DC2XXX, DCXXXX, DDXXXX, Dogs, DXXXXX, Efficient, ELICIT, Fly, Identification, IFN-gamma, Immunity, Infantum, KILLING, Latin, LEISHMANIA, LEISHMANIASIS, Leishmaniasis (Leishmania sp.), Listed LPM Stansberry as of 4/15/2015, LJL143, LJM17, Longipalpis, Lutzomyiz, Method, P., Patent Category - Biotechnology, PERNICIOSUS, POLYPEPTIDES, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, production, proteins, RESULTING, Salivary, SAND, That, Vector, Visceral, WIPO Re:search False True Early stage True NIHTT 37470483 Website Abstract 114171095 Oliveira F, et al. http://www.ncbi.nlm.nih.gov/pubmed/18768167 <a href="http://www.ncbi.nlm.nih.gov/pubmed/18768167">Oliveira F, et al.</a> 114171096 Valenzuela JG, et al. http://www.ncbi.nlm.nih.gov/pubmed/15371479 <a href="http://www.ncbi.nlm.nih.gov/pubmed/15371479">Valenzuela JG, et al.</a> 114171097 Valenzuela JG, et al. http://www.ncbi.nlm.nih.gov/pubmed/11489952 <a href="http://www.ncbi.nlm.nih.gov/pubmed/11489952">Valenzuela JG, et al.</a> 114171098 Belkaid Y, et al. http://www.ncbi.nlm.nih.gov/pubmed/10841567 <a href="http://www.ncbi.nlm.nih.gov/pubmed/10841567">Belkaid Y, et al.</a> 114104504 Valenzuela, Jesus NIAID Valenzuela, Jesus (NIAID) 0 114104504 Valenzuela, Jesus NIAID Valenzuela, Jesus (NIAID) 0 114099956 Full-length cDNA Sequences COding for Secreted Proteins from the Salivary Glands of Lutzomyia Longipalpis Sand Flies E-285-2002-0 Filing authorized Centro de Pesquisa Goncalo Moniz, LIP, NIAID 114101558 Identification Of LJL143 And LJM17 Salivary Proteins From The Sand Fly Lutzomyiz Longipalpis, The Vector Of Visceral Leishmaniasis In Latin America, That Elicit Cellular Immunity Adn IFN-gamma Production In Dogs Resulting In Efficient Killing Of Leis E-189-2008-2 Filing authorized NIAID 114102287 P. ARIASI POLYPEPTIDES AND P. PERNICIOSUS POLYPEPTIDES METHOD OF USE E-130-2002-0 Filing authorized Merial Limited, Merial Limited and Merial S.A.S., NIAID 83724572 Tung, Peter peter.tung@nih.gov
United States of America DIR peter.tung@nih.gov?subject=Web Inquiry on [TAB-787] Vaccines Comprising Sand Fly Salivary Proteins for Control of Leishmania Infection&body=Please send me information about technology [TAB-787] Vaccines Comprising Sand Fly Salivary Proteins for Control of Leishmania Infection. Tung, Peter<br><a href="mailto:peter.tung@nih.gov?subject=Web Inquiry on [TAB-787] Vaccines Comprising Sand Fly Salivary Proteins for Control of Leishmania Infection&body=Please send me information about technology [TAB-787] Vaccines Comprising Sand Fly Salivary Proteins for Control of Leishmania Infection.">peter.tung@nih.gov</a><br> 114161858 E-285-2002-0 E-285-2002-0-US-21 LUTZOMYIA LONGIPALPIS POLYPEPTIDES AND METHODS OF USE DIV US 9,120,867 14/097,991 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9120867 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9120867">9,120,867</a><br />Filed on 2013-12-05<br />Status: Expired 114161948 E-285-2002-0 E-285-2002-0-PCT-02 Lutzomyia Longipalpis Polypeptides and Methods of Use PCT Patent Cooperation Treaty PCT/US2003/034453 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2003/034453<br />Filed on 2003-10-29<br />Status: Expired 114161949 E-285-2002-0 E-285-2002-0-US-03 Lutzomyia Longipalpis Polypeptides and Methods of Use National Stage US 7,485,306 10/533,811 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7485306 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7485306">7,485,306</a><br />Filed on 2005-04-29<br />Status: Expired 114161950 E-285-2002-0 E-285-2002-0-US-01 Lutzomyia Longipalpis polypeptides and methods of use PRV US 60/422,303 Abandoned US <br />Provisional (PRV) 60/422,303<br />Filed on 2002-10-29<br />Status: Abandoned 114163661 E-285-2002-0 E-285-2002-0-US-13 LUTZOMYIA LONGIPALPIS POLYPEPTIDES AND METHODS OF USE DIV US 8,628,780 12/350,179 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8628780 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8628780">8,628,780</a><br />Filed on 2009-01-07<br />Status: Expired 114165710 E-285-2002-0 E-285-2002-0-US-26 LUTZOMYIA LONGIPALPIS POLYPEPTIDES AND METHODS OF USE DIV US 9,884,100 15/175,329 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9884100 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9884100">9,884,100</a><br />Filed on 2016-06-07<br />Status: Expired 114167163 E-285-2002-0 E-285-2002-0-US-25 LUTZOMYIA LONGIPALPIS POLYPEPTIDES AND METHODS OF USE DIV US 9,382,302 14/802,168 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9382302 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9382302">9,382,302</a><br />Filed on 2015-07-17<br />Status: Expired 114168202 E-189-2008-2 E-189-2008-2-PCT-01 LEISHMANIA VACCINE USING SAND FLY SALIVARY IMMUNOGEN PCT COMB Patent Cooperation Treaty PCT/US2009/042980 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2009/042980<br />Filed on 2009-05-06<br />Status: Expired 114168203 E-189-2008-2 E-189-2008-2-US-03 LEISHMANIA VACCINE USING SAND FLY SALIVARY IMMUNOGEN National Stage US 8,603,808 12/436,398 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8603808 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8603808">8,603,808</a><br />Filed on 2009-05-06<br />Status: Issued 114168204 E-189-2008-2 E-189-2008-2-US-06 LEISHMANIA VACCINE USING SAND FLY SALIVARY IMMUNOGEN CON US 9,228,002 14/069,406 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9228002 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9228002">9,228,002</a><br />Filed on 2013-11-01<br />Status: Issued 114168205 E-130-2002-0 E-130-2002-0-US-01 P. ARIASI POLYPEPTIDES AND P. PERNICIOSUS POLYPEPTIDES METHOD OF USE PRV US 60/412,327 Abandoned US <br />Provisional (PRV) 60/412,327<br />Filed on 2002-09-19<br />Status: Abandoned 114168206 E-130-2002-0 E-130-2002-0-PCT-02 P. ARIASI POLYPEPTIDES, P. PERNICIOSUS POLYPEPTIDES AND METHODS OF USE PCT Patent Cooperation Treaty PCT/US2003/029833 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2003/029833<br />Filed on 2003-09-18<br />Status: Expired 114168207 E-130-2002-0 E-130-2002-0-US-03 P. ARIASI POLYPEPTIDES, P. PERNICIOSUS POLYPEPTIDES AND METHODS OF USE National Stage US 7,741,437 10/527,500 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7741437 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7741437">7,741,437</a><br />Filed on 2005-03-11<br />Status: Expired 114168208 E-130-2002-0 E-130-2002-0-US-13 P. ARIASI POLYPEPTIDES AND P. PERNICIOSUS POLYPEPTIDES METHOD OF USE DIV US 12/759,649 Abandoned US <br />Divisional (DIV) 12/759,649<br />Filed on 2010-04-13<br />Status: Abandoned 114168542 E-285-2002-0 E-285-2002-0-US-28 LUTZOMYIA LONGIPALPIS POLYPEPTIDES AND METHODS OF USE CON US 10,314,900 15/866,050 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10314900 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10314900">10,314,900</a><br />Filed on 2018-01-09<br />Status: Expired 114114674 DA2XXX 114114675 DB2XXX 114114676 DC2XXX 114114677 DDXXXX 114114678 DAXXXX 114114679 DBXXXX 114114680 DCXXXX 114114681 DXXXXX 114139932 Identification 114139933 LJL143 114139934 LJM17 114139935 Salivary 114139936 proteins 114139937 SAND 114139938 Fly 114139939 Lutzomyiz 114139940 Longipalpis 114139941 Vector 114139942 Visceral 114139943 LEISHMANIASIS 114139944 Latin 114139945 America 114139946 That 114139947 ELICIT 114139948 Cellular 114139949 Immunity 114139950 Adn 114139951 IFN-gamma 114139952 production 114139953 Dogs 114139954 RESULTING 114139955 Efficient 114139956 KILLING 114139957 LEISHMANIA 114139958 Infantum 114139959 Chagase 114139960 P. 114139961 ARIASI 114139962 POLYPEPTIDES 114139963 PERNICIOSUS 114139964 Method 114139965 Patent Category - Biotechnology 114141501 WIPO Re:search 114141502 Listed LPM Stansberry as of 4/15/2015 114148526 Pre LPM working set 20150418 114148527 Post LPM Assignment Set 20150420 114157899 Leishmaniasis (Leishmania sp.) TAB-777 114095113 Isolation of Hybridomas Producing Monoclonal Antibodies (MAbs) Inhibitory to Human CYP2J2 NIEHS Collaboration, Diagnostics, Research Materials, Therapeutics Collaboration Diagnostics Research Materials Therapeutics Darryl Zeldin The National Institutes of Health announces three specific monoclonal antibodies that strongly inhibit and/or immunoblot the human cytochrome P450 2J2 (CYP2J2). <br /><br /> Cytochrome P450s catalyze the NADPH-dependent oxidation of arachidonic acid to various eicosanoids found in several species. The eicosanoids are biosynthesized in numerous tissues including pancreas, intestine, kidney, heart and lung where they are involved in many different biological activities. <br /><br /> MAb 6-5-20-8 selectively inhibits CYP2J2-mediated arachidonic acid metabolism by more than 80% and also immunoblots the enzyme. MAb 6-2-16-1 also selectively inhibits arachidonic acid metabolism by more than 80% but does not immunoblot the enzyme. MAb 5-3-2-2 is not inhibitory but selectively immunoblots the enzyme. These antibodies can be used to identify and quantify inter-individual variation in physiological functions and to study pharmacological drug metabolism in various tissues. These antibodies strongly inhibit and/or immunoblot the human cytochrome P450 2J2 (CYP2J2). <ul> <li>These antibodies can be used to identify and quantify inter-individual variation in physiological functions.</li> <li>These antibodies can be used to study pharmacological drug metabolism in various tissues.</li> </ul> The NIEHS is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize this antibody. For collaboration opportunities, please contact Dr. Sharon Soucek at <a href="mailto:sharon.soucek@nih.gov">sharon.soucek@nih.gov</a>. Research Material — Patent protection has not been pursued for this technology. 2022-03-08 2024-10-28 2024-10-28 2003-11-01 IDXXXX, IXXXXX False True In vitro data available True NIHTT 37470483 Website Abstract 114169927 Wu S, et al. http://www.ncbi.nlm.nih.gov/pubmed/8631948 <a href="http://www.ncbi.nlm.nih.gov/pubmed/8631948">Wu S, et al.</a> 114169928 Node K, et al. http://www.ncbi.nlm.nih.gov/pubmed/10455056 <a href="http://www.ncbi.nlm.nih.gov/pubmed/10455056">Node K, et al.</a> 114169929 Node K, et al. http://www.ncbi.nlm.nih.gov/pubmed/11279071 <a href="http://www.ncbi.nlm.nih.gov/pubmed/11279071">Node K, et al.</a> 114169930 Zeldin DC. http://www.ncbi.nlm.nih.gov/pubmed/11451964 <a href="http://www.ncbi.nlm.nih.gov/pubmed/11451964">Zeldin DC.</a> 114169931 Yang B, et al. http://www.ncbi.nlm.nih.gov/pubmed/11455018 <a href="http://www.ncbi.nlm.nih.gov/pubmed/11455018">Yang B, et al.</a> 114169932 King LM, et al. http://www.ncbi.nlm.nih.gov/pubmed/11901223 <a href="http://www.ncbi.nlm.nih.gov/pubmed/11901223">King LM, et al.</a> 114169933 Sun J, et al. http://www.ncbi.nlm.nih.gov/pubmed/12016269 <a href="http://www.ncbi.nlm.nih.gov/pubmed/12016269">Sun J, et al.</a> 114104488 Zeldin, Darryl NIEHS Zeldin, Darryl (NIEHS) 0 114104488 Zeldin, Darryl NIEHS Zeldin, Darryl (NIEHS) 0 114099944 Isolation Of Hybridomas Producing Monoclonal Antibodies E-337-2003-0 Research Material NCI, NIEHS 83739538 Choudhry, Vidita vidita.choudhry@nih.gov
United States of America Office of Technology Transfer and Development vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-777] Isolation of Hybridomas Producing Monoclonal Antibodies (MAbs) Inhibitory to Human CYP2J2&body=Please send me information about technology [TAB-777] Isolation of Hybridomas Producing Monoclonal Antibodies (MAbs) Inhibitory to Human CYP2J2. Choudhry, Vidita<br><a href="mailto:vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-777] Isolation of Hybridomas Producing Monoclonal Antibodies (MAbs) Inhibitory to Human CYP2J2&body=Please send me information about technology [TAB-777] Isolation of Hybridomas Producing Monoclonal Antibodies (MAbs) Inhibitory to Human CYP2J2.">vidita.choudhry@nih.gov</a><br> 114114628 IDXXXX 114114629 IXXXXX TAB-771 114095108 Recombinant Plasmids for Soluble Immunoreceptors NIAID Licensing, Research Materials Licensing Research Materials Peter Sun <p>Immunoreceptors initiate signals leading to the activation of immune system against invasion pathogens. A number of soluble receptors, representing the extracellular ligand binding domains of the immunoreceptors, have been expressed using a recombinant bacteria expression and reconstitution system. This set of 21 plasmids, which can be used as immunological research reagents or to develop diagnostic tools, comprise the following:</p> <div align="left"> <table border="0" cellpadding="2" width="50%"> <tr> <td width="43%"><b><u>Plasmid</u></b></td> <td width="57%"><b><u>Description</u></b></td> </tr> <tr> <td width="43%">CD16-28b</td> <td width="57%">Soluble CD16</td> </tr> <tr> <td width="43%">CD94 (S34) - 30a</td> <td width="57%">Soluble CD94 truncated at S34</td> </tr> <tr> <td width="43%">CD94 (E51) - 30a</td> <td width="57%">Soluble CD94 truncated at E51</td> </tr> <tr> <td width="43%">NKG2A (109R) - 30a</td> <td width="57%">Soluble NKG2A 109R construct</td> </tr> <tr> <td width="43%">NKG2A (117G) - 30a</td> <td width="57%">Soluble NKG2A 117G construct</td> </tr> <tr> <td width="43%">TBRII-30a</td> <td width="57%">Soluble type II TGF-beta receptor</td> </tr> <tr> <td width="43%">C143-30a</td> <td width="57%">Soluble KIR2DL2 receptor</td> </tr> <tr> <td width="43%">NKG2D-22b</td> <td width="57%">Soluble NKG2D receptor</td> </tr> <tr> <td width="43%">ULBP-1-22-b</td> <td width="57%">Soluble ULBP-1</td> </tr> <tr> <td width="43%">ULBP-2-22-b</td> <td width="57%">Soluble ULBP-2</td> </tr> <tr> <td width="43%">ULBP-3-22b</td> <td width="57%">Soluble ULBP-3</td> </tr> <tr> <td width="43%">HLA-E-30a</td> <td width="57%">Soluble HLA-E heavy chain</td> </tr> <tr> <td width="43%">HLA-Cw3</td> <td width="57%">Soluble HLA-Cw3 heavy chain</td> </tr> <tr> <td width="43%">TREM-1-22b</td> <td width="57%">Soluble TREM-1 receptor</td> </tr> <tr> <td width="43%">TREM-2-22b</td> <td width="57%">Soluble TREM-2 receptor</td> </tr> <tr> <td width="43%">NKp30-22b</td> <td width="57%">Soluble NKp30</td> </tr> <tr> <td width="43%">NKp46-22b</td> <td width="57%">Soluble NKp46</td> </tr> <tr> <td width="43%">NKp44-22b</td> <td width="57%">Soluble NKp44</td> </tr> <tr> <td width="43%">Siglec-3-30a</td> <td width="57%">Soluble Siglec-3</td> </tr> <tr> <td width="43%">Siglec-5-30a</td> <td width="57%">Soluble Siglec-5</td> </tr> <tr> <td width="43%">Siglec-7-30a</td> <td width="57%">Soluble Siglec-7</td> </tr> </table> </div> 2022-03-08 2024-10-28 2024-10-28 2003-10-01 AC5XXX, ACXXXX, AXXXXX, Chromosome 22 ring, R 22, RXXXXX False True True NIHTT 37470483 Website Abstract 114104481 Sun, Peter NIAID Sun, Peter (NIAID) 0 114104481 Sun, Peter NIAID Sun, Peter (NIAID) 0 114099934 Recombinant Plasmids For Soluble Immunoreceptors E-305-2003-0 Research Material NIAID 83738793 Taylor-Mulneix, Dawn dawn.taylor-mulneix@nih.gov
United States of America dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-771] Recombinant Plasmids for Soluble Immunoreceptors&body=Please send me information about technology [TAB-771] Recombinant Plasmids for Soluble Immunoreceptors. Taylor-Mulneix, Dawn<br><a href="mailto:dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-771] Recombinant Plasmids for Soluble Immunoreceptors&body=Please send me information about technology [TAB-771] Recombinant Plasmids for Soluble Immunoreceptors.">dawn.taylor-mulneix@nih.gov</a><br> 114114595 AC5XXX 114114596 ACXXXX 114114597 AXXXXX 114114598 RXXXXX 114157692 Chromosome 22 ring 114158956 R 22 TAB-757 114095093 Oral Treatment of Hemophilia NIAID Cardiology, Dental, Diagnostics, Endocrinology, Infectious Disease, Licensing, Oncology, Ophthalmology, Research Materials, Therapeutics Cardiology Dental Diagnostics Endocrinology Infectious Disease Licensing Oncology Ophthalmology Research Materials Therapeutics Oral Alpan, Tirumalai Kamala, Polly Matzinger, William Velander This invention portrays a simple method for treatment of antigen-deficiency diseases by orally administering to a subject a therapeutically effective amount of the deficient antigen, wherein the antigen is not present in a liposome. This method increases hemostasis in a subject having hemophilia A or B, by orally administering to the hemophiliac a therapeutically effective amount of the appropriate clotting factor, sufficient to induce oral tolerance and supply exogenous clotting factor to the subject. <ul> <li>Less invasive than current modes of treatment</li> <li>Reduced inflammatory response</li> <li>Immunotolerization against future bleeding episodes</li> </ul> <ul> <li>Oral-based treatment for hemophilia A or B</li> </ul> 2022-03-08 2024-10-28 2024-10-28 2003-07-01 3-@hydroxyacyl-coa dehydrogenase deficiency, HAD deficiency, Hemophilia A, Hemophilia B, HIS deficiency, Histidinemia, IBXXXX, IXXXXX, VPXXXX, WJXXXX, YBXXXX, YCXXXX False True <ul> <li>In vitro data available</li> <li>In vivo data available (animal)</li> </ul> True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114104455 Alpan, Oral NIAID Alpan, Oral (NIAID) 0 114108291 Matzinger, Polly NIAID - DIR NIAID Matzinger, Polly (NIAID) 0 114108292 Kamala, Tirumalai NIAID - DIR NIAID Kamala, Tirumalai (NIAID) 0 114108293 Velander, William Virginia Tech Intellectual Properties, Inc. Velander, William 0 114104455 Alpan, Oral NIAID Alpan, Oral (NIAID) 0 114108291 Matzinger, Polly NIAID - DIR NIAID Matzinger, Polly (NIAID) 0 114108292 Kamala, Tirumalai NIAID - DIR NIAID Kamala, Tirumalai (NIAID) 0 114108293 Velander, William Virginia Tech Intellectual Properties, Inc. Velander, William 0 114099918 Oral Treatment of Hemophilia E-281-2001-0 Filing authorized NIAID, Virginia Tech Intellectual Properties, Inc. 91025211 Rainwater, Charles crainwater@mail.nih.gov
United States of America crainwater@mail.nih.gov?subject=Web Inquiry on [TAB-757] Oral Treatment of Hemophilia&body=Please send me information about technology [TAB-757] Oral Treatment of Hemophilia. Rainwater, Charles<br><a href="mailto:crainwater@mail.nih.gov?subject=Web Inquiry on [TAB-757] Oral Treatment of Hemophilia&body=Please send me information about technology [TAB-757] Oral Treatment of Hemophilia.">crainwater@mail.nih.gov</a><br> 114161860 E-281-2001-0 E-281-2001-0-US-03 Oral Treatment of Hemophilia National Stage US 7,220,718 10/485,696 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7220718 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7220718">7,220,718</a><br />Filed on 2004-02-02<br />Status: Expired 114165113 E-281-2001-0 E-281-2001-0-US-05 Induction of Tolerance by Oral Administration of Factor VIII and Treatment of Hemophilia DIV US 7,867,974 11/734,489 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7867974 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7867974">7,867,974</a><br />Filed on 2007-04-12<br />Status: Expired 114167588 E-281-2001-0 E-281-2001-0-PCT-02 Oral Treatment of Hemophilia PCT Patent Cooperation Treaty PCT/US2002/024544 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2002/024544<br />Filed on 2002-08-02<br />Status: Expired 114114545 IBXXXX 114114546 IXXXXX 114124012 VPXXXX 114124013 WJXXXX 114124014 YBXXXX 114124015 YCXXXX 114157672 3-@hydroxyacyl-coa dehydrogenase deficiency 114157673 Histidinemia 114157674 Hemophilia B 114157675 Hemophilia A 114158944 HAD deficiency 114158945 HIS deficiency TAB-764 114095100 Diagnostics and Therapeutics for Hydrocephalus NIEHS Diagnostics, Licensing, Research Materials, Therapeutics Diagnostics Licensing Research Materials Therapeutics Perry Blackshear, Joan Graves, Deborah Stumpo, Darryl Zeldin Congenital hydrocephalus is a significant public health problem, affecting approximately one in 500 live births in the United States. Congenital hydrocephalus has an adverse effect on developing brain and may persist as neurological defects in children and adults. Some of these defects may manifest as mental retardation, cerebral palsy, epilepsy and visual disabilities. Improved diagnostics are needed for assessing the risks of developing this debilitating disease. <br><br> The inventors have shown that RFX4_v3, a splice variant of the Regulatory Factor X4 (RFX4) transcription factor, is associated with the development of neurological structures. The reduction or absence of RFX4_v3 promotes the development of congenital hydrocephalus. This invention describes RFX4_v3 polypeptides and nucleic acids, as well as methods for detection of RFX4_v3 polymorphisms associated with congenital hydrocephalus. Also described are treatment methods including the RFX4_v3 polypeptide and RFX4_v3 transgenic animals and antibodies. <ul> <li>Prenatal diagnostic assay for identifying children at risk for congenital hydrocephalus</li> <li>Genotyping assay for congenital hydrocephalus</li> </ul> Available for exclusive or nonexclusive licensing. 2022-03-08 2024-10-28 2024-10-28 2007-01-01 BBXXXX, Hydrocephalus, IAXXXX, IXXXXX False True In vitro data are available. In vitro data are available. True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114169916 Perry J. Blackshear et al. Graded phenotypic response to partial and complete deficiency of a brain-specific transcript variant of the winged helix transcription factor RFX4. Development. 2003 Oct;130(19):4539-4552. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=12925582&query_hl=1&itool=pubmed_docsum <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=12925582&query_hl=1&itool=pubmed_docsum">Perry J. Blackshear et al. Graded phenotypic response to partial and complete deficiency of a brain-specific transcript variant of the winged helix transcription factor RFX4. Development. 2003 Oct;130(19):4539-4552.</a> 114169917 Donghui Zhang et al. Identification of potential target genes for RFX4_v3, a transcription factor critical for brain development. J Neurochem. 2006 Aug;98(3):860-875. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16893423&query_hl=1&itool=pubmed_docsum <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16893423&query_hl=1&itool=pubmed_docsum">Donghui Zhang et al. Identification of potential target genes for RFX4_v3, a transcription factor critical for brain development. J Neurochem. 2006 Aug;98(3):860-875.</a> 114169918 Donghui Zhang et al. Regulatory factor X4 variant 3 (RFX4_v3): a transcription factor involved in brain development and disease. Submitted for publication, Journal of Neuroscience Research. Donghui Zhang et al. Regulatory factor X4 variant 3 (RFX4_v3): a transcription factor involved in brain development and disease. Submitted for publication, Journal of Neuroscience Research. 114104467 Blackshear, Perry NIH - NIEHS NIEHS Blackshear, Perry (NIEHS) 1 114104468 Zeldin, Darryl NIH - NIEHS NIEHS Zeldin, Darryl (NIEHS) 2 114104469 Graves, Joan NIH - NIEHS NIEHS Graves, Joan (NIEHS) 3 114104470 Stumpo, Deborah NIH - NIEHS NIEHS Stumpo, Deborah (NIEHS) 4 114104467 Blackshear, Perry NIH - NIEHS NIEHS Blackshear, Perry (NIEHS) 1 114104468 Zeldin, Darryl NIH - NIEHS NIEHS Zeldin, Darryl (NIEHS) 2 114104469 Graves, Joan NIH - NIEHS NIEHS Graves, Joan (NIEHS) 3 114104470 Stumpo, Deborah NIH - NIEHS NIEHS Stumpo, Deborah (NIEHS) 4 114099927 Compositions And Methods For Diagnostics And Therapeutics For Hydrocephalus E-163-2002-2 Filing authorized NIEHS 83739538 Choudhry, Vidita vidita.choudhry@nih.gov
United States of America Office of Technology Transfer and Development vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-764] Diagnostics and Therapeutics for Hydrocephalus&body=Please send me information about technology [TAB-764] Diagnostics and Therapeutics for Hydrocephalus. Choudhry, Vidita<br><a href="mailto:vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-764] Diagnostics and Therapeutics for Hydrocephalus&body=Please send me information about technology [TAB-764] Diagnostics and Therapeutics for Hydrocephalus.">vidita.choudhry@nih.gov</a><br> 114161881 E-163-2002-2 E-163-2002-2-PCT-01 Compositions And Methods For Diagnostics And Therapeutics For Hydrocephalus PCT COMB Patent Cooperation Treaty PCT/US03/12348 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US03/12348<br />Filed on 2003-04-18<br />Status: Expired 114161882 E-163-2002-2 E-163-2002-2-US-02 Compositions And Methods For Diagnostics And Therapeutics For Hydrocephalus National Stage US 8,008,463 10/511,362 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8008463 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8008463">8,008,463</a><br />Filed on 2004-10-15<br />Status: Expired 114114576 IAXXXX 114114577 IXXXXX 114121166 BBXXXX 114157691 Hydrocephalus TAB-755 114095091 Detection of Mutational Frequency in Human Bone Marrow NHLBI Diagnostics, Licensing, Oncology Diagnostics Licensing Oncology Neal Young To date there have been no adequate methods to determine the frequency of mutations in humans. This invention discloses a method of measuring the mutational frequency of a mitochondrial DNA sequence by sequencing mitochondrial DNA from clonally expanded single cells such as CD34+ human stem cells. Sequencing for mitochondrial DNA polymorphisms and mutations may also be useful as a general method to detect minimal residual disease in leukemia. The mitochondrial genome is particularly susceptible to mutations and these may be used to measure genomic mutagenesis by virtue of comparison. The application of this invention includes the determination of mutational frequency after chemotherapy, radiation, environmental toxic exposure and genetic disease. The invention also provides a screening for an agent that has a mutagenic effect on a cell. 2022-03-08 2024-10-28 2024-10-28 2003-07-01 CAXXXX, CXXXXX False True True NIHTT 37470483 Website Abstract 114104453 Young, Neal NHLBI Young, Neal (NHLBI) 0 114104453 Young, Neal NHLBI Young, Neal (NHLBI) 0 114099914 Detection of Mutational Frequency in Human Bone Marrow By Sequencing of Mitochondrial DNA From Single Cells E-320-2002-0 EM, National Heart, Lung, and Blood Institute (NHLBI) 114099915 DETECTION OF MUTATIONAL FREQUENCY AND RELATED METHODS E-320-2002-1 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 83739538 Choudhry, Vidita vidita.choudhry@nih.gov
United States of America Office of Technology Transfer and Development vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-755] Detection of Mutational Frequency in Human Bone Marrow&body=Please send me information about technology [TAB-755] Detection of Mutational Frequency in Human Bone Marrow. Choudhry, Vidita<br><a href="mailto:vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-755] Detection of Mutational Frequency in Human Bone Marrow&body=Please send me information about technology [TAB-755] Detection of Mutational Frequency in Human Bone Marrow.">vidita.choudhry@nih.gov</a><br> 114161847 E-320-2002-0 E-320-2002-0-US-01 Detection of Mutational Frequency in Human Bone Marrow By Sequencing of Mitochondrial DNA From Single Cells PRV US 60/424,515 Abandoned US <br />Provisional (PRV) 60/424,515<br />Filed on 2002-11-06<br />Status: Abandoned 114161850 E-320-2002-1 E-320-2002-1-US-01 DETECTION OF MUTATIONAL FREQUENCY AND RELATED METHODS CIP US 7,255,993 10/704,283 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7255993 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7255993">7,255,993</a><br />Filed on 2003-11-06<br />Status: Expired 114164522 E-320-2002-1 E-320-2002-1-US-02 DETECTION OF MUTATIONAL FREQUENCY AND RELATED METHODS DIV US 11/770,456 Abandoned US <br />Divisional (DIV) 11/770,456<br />Filed on 2007-06-28<br />Status: Abandoned 114114537 CAXXXX 114114538 CXXXXX TAB-737 114095073 Methanocarba Cycloalkyl Nucleoside Analogues NIDDK Diagnostics, Licensing, Reproductive Health, Research Materials, Therapeutics, Vaccines Diagnostics Licensing Reproductive Health Research Materials Therapeutics Vaccines Kenneth Jacobson Purines such as adenosine and ATP have been shown to play a wide array of roles in biological systems such as inter alia, modulator of vasodilation and hypotension, muscle relaxant, central depressant, inhibitor of platelet aggregation, regulator of energy supply/demand, responder to oxygen availability, neurotransmitter and neuromodulator. All P1 and P2 receptor nucleoside ligands suffer from chemical instability that is caused by the labile glycosidic linkage in the sugar moiety of the nucleoside. However, it has been found that relatively few ribose modifications are tolerated by the presently known agonists and antagonists of P1 and P2 receptors. <br><br> The NIH announces a new technology wherein a new class of nucleoside and nucleotide analogs has been identified that serve as selective agonists or antagonists for P1 and P2 receptors. The technology relates to a chemical modification of purines and pyrimidines, which provide enhanced therapeutic profile and potentially greater in vivo stability, because of the absence of a glycosidic bond. The P2Y receptor agonists and antagonists could potentially be used in immune modulation, inflammation, cardiovascular diseases, neurodegeneration, diabetes, and cancer. In addition, the A3 receptor agonists and antagonists could be useful in cardioprotection, neuroprotection, and asthma. 2022-03-08 2024-10-28 2024-10-28 2003-05-01 IB6XXX, IBXXXX, IXXXXX False True True NIHTT 37470483 Website Abstract 114169910 K.A. Jacobson et al., "Methanocarba analogues of purine nucleosides as potent and selective adenosine receptor agonists," J. Med. Chem., 2000, 43:2196-2203. K.A. Jacobson et al., "Methanocarba analogues of purine nucleosides as potent and selective adenosine receptor agonists," J. Med. Chem., 2000, 43:2196-2203. 114169911 H.S. Kim et al., "Methanocarba modification of uracil and adenine nucleotides: High potency of Northern ring conformation at P2Y1, P2Y2, or P2Y4 and P2Y11, but not P2Y6 receptors," J. Med. Chem., 2002, 45:208-218. H.S. Kim et al., "Methanocarba modification of uracil and adenine nucleotides: High potency of Northern ring conformation at P2Y1, P2Y2, or P2Y4 and P2Y11, but not P2Y6 receptors," J. Med. Chem., 2002, 45:208-218. 114104428 Jacobson, Kenneth NIDDK Jacobson, Kenneth (NIDDK) 0 114104428 Jacobson, Kenneth NIDDK Jacobson, Kenneth (NIDDK) 0 114099894 Methanocarba Analogues of Purine And Pyrimidine Nucleosides And Nucleotides as Ligands For P1 And P2 Receptors. E-176-1999-0 Filing authorized National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NCI 83692066 Tong, Betty tongb@niddk.nih.gov
United States of America Senior Technology Advancement Office tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-737] Methanocarba Cycloalkyl Nucleoside Analogues&body=Please send me information about technology [TAB-737] Methanocarba Cycloalkyl Nucleoside Analogues. Tong, Betty<br><a href="mailto:tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-737] Methanocarba Cycloalkyl Nucleoside Analogues&body=Please send me information about technology [TAB-737] Methanocarba Cycloalkyl Nucleoside Analogues.">tongb@niddk.nih.gov</a><br> 114160931 E-176-1999-0 E-176-1999-0-US-01 Methanocarba Cycloalkyl Nucleoside Analogues PRV US 60/176,373 Abandoned US <br />Provisional (PRV) 60/176,373<br />Filed on 2000-01-14<br />Status: Abandoned 114161795 E-176-1999-0 E-176-1999-0-US-06 Methanocarba Cycloalkyl Nucleoside Analogues National Stage US 7,087,589 10/169,975 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7087589 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7087589">7,087,589</a><br />Filed on 2002-07-12<br />Status: Expired 114161796 E-176-1999-0 E-176-1999-0-US-07 Methanocarba Cycloalkyl Nucleoside Analogues DIV US 7,790,735 11/500,860 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7790735 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7790735">7,790,735</a><br />Filed on 2006-08-08<br />Status: Expired 114165043 E-176-1999-0 E-176-1999-0-PCT-02 Methanylcarba Cycloalkyl Nucleoside Analogues PCT Patent Cooperation Treaty PCT/US01/00981 Expired Patent Cooperation Treaty <br />(PCT) PCT/US01/00981<br />Filed on 2001-01-12<br />Status: Expired 114114481 IB6XXX 114114482 IBXXXX 114114483 IXXXXX TAB-698 114095034 Novel Acylthiol Compositions and Methods of Making and Using Them Against HIV NIAID Infectious Disease, Licensing, Therapeutics Infectious Disease Licensing Therapeutics Ettore Appella, Atul Goel, John Inman, Marco Schito, James Turpin This invention provides a novel family of acylthiols and uses thereof. More specifically, this invention provides effective inhibitors of HIV that selectively target its highly conserved nucleocapsid protein (NCp7) by interacting with metal chelating structures of a zinc finger-containing protein. Because of the mutationally intolerant nature of NCp7, drug resistance is much less likely to occur with compounds attacking this target. In addition, these drugs should inactivate all types and strains of HIV and could also inactivate other retroviruses, since most retroviruses share one or two highly conserved zinc fingers that have the CCHC motif of the HIV Ncp7. Finally, this invention could be very useful for the large-scale practical synthesis of HIV inhibitors, because these compounds can be prepared by using inexpensive starting materials and facile reactions. Thus, it opens the possibility that an effective drug treatment for HIV could be made available to much larger populations. These thioesters may also be used as an active component in topical applications that serve as a barrier to HIV infection. 2022-03-08 2024-10-28 2024-10-28 2006-08-01 DB4XXX, DBXXXX, DXXXXX False True True NIHTT 37470483 Website Abstract 114169883 Schito ML, et al. http://www.ncbi.nlm.nih.gov/pubmed/12639244 <a href="http://www.ncbi.nlm.nih.gov/pubmed/12639244">Schito ML, et al.</a> 114169884 Srivastava P, et al. http://www.ncbi.nlm.nih.gov/pubmed/15556761 <a href="http://www.ncbi.nlm.nih.gov/pubmed/15556761">Srivastava P, et al.</a> 114169885 Jenkins LM, et al. http://www.ncbi.nlm.nih.gov/pubmed/15828823 <a href="http://www.ncbi.nlm.nih.gov/pubmed/15828823">Jenkins LM, et al.</a> 114169886 Basrur V, et al. http://www.ncbi.nlm.nih.gov/pubmed/10809733 <a href="http://www.ncbi.nlm.nih.gov/pubmed/10809733">Basrur V, et al.</a> 114169887 Turpin JA, et al. http://www.ncbi.nlm.nih.gov/pubmed/9888834 <a href="http://www.ncbi.nlm.nih.gov/pubmed/9888834">Turpin JA, et al.</a> 114104359 Inman, John Inman, John 0 114104360 Goel, Atul Goel, Atul 0 114104361 Appella, Ettore NCI Appella, Ettore (NCI) 0 114104362 Turpin, James NIAID Turpin, James (NIAID) 0 114104363 Schito, Marco Schito, Marco 0 114104359 Inman, John Inman, John 0 114104360 Goel, Atul Goel, Atul 0 114104361 Appella, Ettore NCI Appella, Ettore (NCI) 0 114104362 Turpin, James NIAID Turpin, James (NIAID) 0 114104363 Schito, Marco Schito, Marco 0 114099846 Novel Acythiol Compositions And Methods of Making and Using Them E-329-2000-0 Filing authorized NCI, NIAID 83692066 Tong, Betty tongb@niddk.nih.gov
United States of America Senior Technology Advancement Office tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-698] Novel Acylthiol Compositions and Methods of Making and Using Them Against HIV&body=Please send me information about technology [TAB-698] Novel Acylthiol Compositions and Methods of Making and Using Them Against HIV. Tong, Betty<br><a href="mailto:tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-698] Novel Acylthiol Compositions and Methods of Making and Using Them Against HIV&body=Please send me information about technology [TAB-698] Novel Acylthiol Compositions and Methods of Making and Using Them Against HIV.">tongb@niddk.nih.gov</a><br> 114161683 E-329-2000-0 E-329-2000-0-US-06 ACYLTHIOLS AND COMPONENT THIOL COMPOSITIONS AS ANTI-HIV AND ANTI-RETROVIRAL AGENTS National Stage US 7,528,274 10/485,165 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7528274 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7528274">7,528,274</a><br />Filed on 2004-08-26<br />Status: Expired 114161763 E-329-2000-0 E-329-2000-0-PCT-02 ACYLTHIOL AND COMPONENT THIOL COMPOSITIONS AS ANTI-HIV AND ANTI- RETROVIRAL AGENTS PCT Patent Cooperation Treaty PCT/US2002/023924 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2002/023924<br />Filed on 2002-07-25<br />Status: Expired 114165263 E-329-2000-0 E-329-2000-0-US-01 Novel Acythiol Compositions And Methods of Making and Using Them PRV US 60/310,133 Abandoned US <br />Provisional (PRV) 60/310,133<br />Filed on 2001-08-03<br />Status: Abandoned 114165361 E-329-2000-0 E-329-2000-0-US-07 ACYTHIOLS AND COMPONENT THIOL COMPOSITIONS AS ANTI-HIV AND ANTI-RETROVIRAL AGENTS CON US 8,076,372 12/414,321 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8076372 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8076372">8,076,372</a><br />Filed on 2009-03-30<br />Status: Expired 114114347 DB4XXX 114114348 DBXXXX 114114349 DXXXXX TAB-713 114095049 Method for the Diagnosis and Treatment of Vascular Disease NHLBI Diagnostics, Licensing, Research Materials, Therapeutics Diagnostics Licensing Research Materials Therapeutics Toren Finkel, Jonathan Hill, Arshed Quyyumi Cardiovascular disease is a major health risk throughout the industrialized world. Atherosclerosis, the most prevalent of cardiovascular diseases, is the principal cause of heart attack, stroke, and gangrene of the extremities. It is also the principal cause of death in the United States.<br /><br /> This invention portrays a method for diagnosing decreased vascular function, detecting increased cardiovascular risk and diagnosing atherosclerosis. An embodiment includes assaying the number of endothelial progenitor cells and treating a subject with decreased vascular function by administering a therapeutically effective amount of endothelial progenitor cells. 2022-03-08 2024-10-28 2024-10-28 2003-04-01 Cells, Diagnosis, Disease, Endothelial, IAXXXX, IXXXXX, Listed LPM Nguyen-Antczak as of 4/15/2015, Method, Patent Category - Biotechnology, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Progenitor, treatment, vascular False True True NIHTT 37470483 Website Abstract 114169900 Hill JM, et al. https://www.ncbi.nlm.nih.gov/pubmed/12584367 <a href="https://www.ncbi.nlm.nih.gov/pubmed/12584367">Hill JM, et al.</a> 114109665 Quyyumi, Arshed National Heart, Lung, and Blood Institute (NHLBI) Quyyumi, Arshed 0 114109666 Hill, Jonathan National Heart, Lung, and Blood Institute (NHLBI) Hill, Jonathan 0 114109664 Finkel, Toren National Heart, Lung, and Blood Institute (NHLBI) NHLBI Finkel, Toren (NHLBI) 1 114109664 Finkel, Toren National Heart, Lung, and Blood Institute (NHLBI) NHLBI Finkel, Toren (NHLBI) 1 114109665 Quyyumi, Arshed National Heart, Lung, and Blood Institute (NHLBI) Quyyumi, Arshed 0 114109666 Hill, Jonathan National Heart, Lung, and Blood Institute (NHLBI) Hill, Jonathan 0 114102423 Endothelial Progenitor Cells For The Diagnosis And Treatment Of Vascular Disease E-037-2003-0 National Heart, Lung, and Blood Institute (NHLBI) 114102424 METHOD FOR THE DIAGNOSIS AND TREATMENT OF VASCULAR DISEASE E-037-2003-1 National Heart, Lung, and Blood Institute (NHLBI) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-713] Method for the Diagnosis and Treatment of Vascular Disease&body=Please send me information about technology [TAB-713] Method for the Diagnosis and Treatment of Vascular Disease. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-713] Method for the Diagnosis and Treatment of Vascular Disease&body=Please send me information about technology [TAB-713] Method for the Diagnosis and Treatment of Vascular Disease.">shmilovm@nih.gov</a><br> 114161933 E-037-2003-1 E-037-2003-1-PCT-01 METHOD FOR THE DIAGNOSIS AND TREATMENT OF VASCULAR DISEASE PCT COMB Patent Cooperation Treaty PCT/US03/36317 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US03/36317<br />Filed on 2003-11-12<br />Status: Expired 114161935 E-037-2003-0 E-037-2003-0-US-01 Method for the Diagnosis and Treatment of Vascular Disease PRV US 60/426,545 Abandoned US <br />Provisional (PRV) 60/426,545<br />Filed on 2002-11-15<br />Status: Abandoned 114168614 E-037-2003-1 E-037-2003-1-US-02 METHOD FOR THE DIAGNOSIS AND TREATMENT OF VASCULAR DISEASE National Stage US 7,708,977 10/534,626 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7708977 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7708977">7,708,977</a><br />Filed on 2005-05-11<br />Status: Expired 114114394 IAXXXX 114114395 IXXXXX 114150565 Endothelial 114150566 Progenitor 114150567 Cells 114150568 Diagnosis 114150569 treatment 114150570 vascular 114150571 Disease 114150572 Patent Category - Biotechnology 114150573 Listed LPM Nguyen-Antczak as of 4/15/2015 114150574 Pre LPM working set 20150418 114150575 Post LPM Assignment Set 20150420 114150576 Method TAB-662 114094998 Rapid Motion Perception MRI Navigator Method NHLBI Collaboration, Licensing Collaboration Licensing Vinay Pai, Han Wen Available for licensing and commercial development is a non-breathhold flow sensitive navigator technique for reducing respiratory motion artifacts in magnetic resonance (MR) images. The method, called Rapid Motion Perception (RaMP), tracks bulk translational motion of the heart in real-time. The position of the blood volume is a direct representation of the heart position. RaMP tracks fast-moving blood volume during systole as a marker for the heart position, while suppressing stationary or slow moving spins. This approach allows cardiac navigation in two orthogonal directions simultaneously, eliminates the need to obtain empirical correlations between the diaphragm and the heart, and increases tracking reliability among individual patients. The method uses a spoiled-Fast Low Angle Shot (FLASH) navigator and incorporates an alternating pair of bipolar velocity-encoding gradients. Data at 1.5T indicate that RaMP is capable of correcting bulk motion of the heart over multiple cardiac cycles to within +/-1.43 mm in the superior-inferior direction and +/- 0.84 mm in the anterior-posterior direction. <ul> <li>Reduction of MR image artifacts due to respiration motion </li> <li>Real-time tracking of cardiac motion</li> </ul> The National Heart, Lung, and Blood Institute is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. Please contact Alan H. Deutch, Ph.D. at 301-402-5579 or via email at <a href="mailto:deutcha@nhlbi.nih.gov">deutcha@nhlbi.nih.gov</a> for more information. 2022-03-08 2024-10-28 2024-10-28 2007-09-01 AA3AXX, AA3B1X, AA3BXX, AA3XXX, AAXXXX, AXXXXX False True Late-stage technology Late-stage technology True NIHTT 37470483 Website Abstract 114104277 Pai, Vinay NHLBI Pai, Vinay (NHLBI) 0 114104278 Wen, Han NHLBI Wen, Han (NHLBI) 0 114104277 Pai, Vinay NHLBI Pai, Vinay (NHLBI) 0 114104278 Wen, Han NHLBI Wen, Han (NHLBI) 0 114099805 MRI NAVIGATOR METHODS AND SYSTEMS E-164-2002-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-662] Rapid Motion Perception MRI Navigator Method&body=Please send me information about technology [TAB-662] Rapid Motion Perception MRI Navigator Method. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-662] Rapid Motion Perception MRI Navigator Method&body=Please send me information about technology [TAB-662] Rapid Motion Perception MRI Navigator Method.">shmilovm@nih.gov</a><br> 114161587 E-164-2002-0 E-164-2002-0-US-01 MRI NAVIGATOR METHODS AND SYSTEMS ORD US 7,561,909 10/244,903 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7561909 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7561909">7,561,909</a><br />Filed on 2002-09-16<br />Status: Expired 114114218 AA3B1X 114114219 AA3AXX 114114220 AA3BXX 114114221 AA3XXX 114114222 AAXXXX 114114223 AXXXXX TAB-664 114095000 Tryptophan as a Functional Replacement for ADP-ribose-arginine in Recombinant Proteins NHLBI Collaboration, Infectious Disease, Licensing, Therapeutics Collaboration Infectious Disease Licensing Therapeutics Joel Moss Bacterial toxins such as cholera toxin and diphtheria toxin catalyze the ADP-ribosylation of important cellular target proteins in their human hosts, thereby, as in the case of cholera toxin, irreversibly activating adenylyl cyclase. In this reaction, the toxin transfers the ADP-ribose moiety of Nicotinamide Adenine Dinucleotide (NAD) to an acceptor amino acid in a protein or peptide. ADP-ribosylation leads to a peptide/protein with altered biochemical or pharmacological properties. Mammalians proteins catalyze reactions similar to the bacterial toxins. The ADP-ribosylated proteins represent useful pharmacological agents, however, their use is limited by the inherent instability of the ADP-ribose-protein linkage. <br><br> The NIH announces a new technology wherein recombinant proteins are created that substitute tryptophan for an arginine, thereby making the protein more stable, and better suited as agents for therapeutic purposes. The modification creates an effect similar to ADP-ribosylation of the arginine. An example of a protein that can be modified is the defensin molecule, which is a broad-spectrum antimicrobial that acts against infectious agents and plays an important role in the innate immune defense in vertebrates. In addition to licensing, the technology is available for further development through collaborative research opportunities with the inventors. 2022-03-08 2024-10-28 2024-10-28 2005-03-01 cholera, DB3XXX, DBXXXX, DIPHTHERIA, DXXXXX False True True NIHTT 37470483 Website Abstract 114104281 Moss, Joel NHLBI Moss, Joel (NHLBI) 0 114104281 Moss, Joel NHLBI Moss, Joel (NHLBI) 0 114099807 Trypotophan as a Functional Replacement for ADP-ribose-arginine in Recombinant Proteins E-160-2002-0 Filing authorized EM, National Heart, Lung, and Blood Institute (NHLBI) 90072936 Mistry, Pragnesh pragnesh.mistry@nih.gov
HNH6Z08 pragnesh.mistry@nih.gov?subject=Web Inquiry on [TAB-664] Tryptophan as a Functional Replacement for ADP-ribose-arginine in Recombinant Proteins&body=Please send me information about technology [TAB-664] Tryptophan as a Functional Replacement for ADP-ribose-arginine in Recombinant Proteins. Mistry, Pragnesh<br><a href="mailto:pragnesh.mistry@nih.gov?subject=Web Inquiry on [TAB-664] Tryptophan as a Functional Replacement for ADP-ribose-arginine in Recombinant Proteins&body=Please send me information about technology [TAB-664] Tryptophan as a Functional Replacement for ADP-ribose-arginine in Recombinant Proteins.">pragnesh.mistry@nih.gov</a><br> 114161592 E-160-2002-0 E-160-2002-0-US-03 Tryptophan as a Functional Replacement for ADP-ribose-arginine in Recombinant Proteins National Stage US 7,541,139 10/517,565 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7541139 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7541139">7,541,139</a><br />Filed on 2004-12-07<br />Status: Expired 114165080 E-160-2002-0 E-160-2002-0-PCT-02 Trypotophan as a Functional Replacement for ADP-ribose-arginine in Recombinant Proteins PCT Patent Cooperation Treaty PCT/US2003/020498 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2003/020498<br />Filed on 2003-06-27<br />Status: Expired 114165098 E-160-2002-0 E-160-2002-0-US-01 Trypotophan as a Functional Replacement for ADP-ribose-arginine in Recombinant Proteins PRV US 60/393,033 Abandoned US <br />Provisional (PRV) 60/393,033<br />Filed on 2002-06-28<br />Status: Abandoned 114165134 E-160-2002-0 E-160-2002-0-US-08 Trypotophan as a Functional Replacement for ADP-ribose-arginine in Recombinant Proteins CON US 7,923,535 12/430,023 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7923535 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7923535">7,923,535</a><br />Filed on 2009-04-24<br />Status: Expired 114114227 DB3XXX 114114228 DBXXXX 114114229 DXXXXX 114157580 DIPHTHERIA 114157581 cholera TAB-660 114094996 Modified Defensins and Their Use NHLBI Diagnostics, Immunology, Infectious Disease, Licensing, Pulmonology, Research Materials, Therapeutics Diagnostics Immunology Infectious Disease Licensing Pulmonology Research Materials Therapeutics Joel Moss The ubiquitous use of antibiotics has resulted in the selection of bacteria that are relatively resistant to these drugs. Furthermore, few drugs are effective against viral and fungal microorganisms. There is therefore a continuing need to identify novel agents that reduce or inhibit the growth of such microorganisms, or to identify ways of modifying existing agents in order to give them superior antimicrobial activities, or to identify agents that may recruit inflammatory cells. <br><br> Defensins are broad-spectrum antimicrobial molecules that act against infectious agents and play important roles in the innate immune defense in vertebrates. These molecules exhibit a wide range of antimicrobial activities, including cytotoxicity towards bacteria cells, but are also cytotoxic for mammalian cells, which limits their usefulness as antimicrobial agents. The NIH announces the creation of modified defensins through their arginine residues. These compounds can be used to inhibit the toxic effect of defensins, while retaining their T cell chemotactic properties and promoting recruitment of inflammatory cells. In the case of pulmonary disease, these agents can be delivered directly to the site of inflammation by inhalation. 2022-03-08 2024-10-28 2024-10-28 2002-11-01 DB3XXX, DBXXXX, DXXXXX, IB3XXX, IB4XXX, IBXXXX, IXXXXX False True True NIHTT 37470483 Website Abstract 114104274 Moss, Joel NHLBI Moss, Joel (NHLBI) 0 114104274 Moss, Joel NHLBI Moss, Joel (NHLBI) 0 114099802 Modified Defensins And Their Use E-080-2002-0 Filing authorized EM, National Heart, Lung, and Blood Institute (NHLBI) 90072936 Mistry, Pragnesh pragnesh.mistry@nih.gov
HNH6Z08 pragnesh.mistry@nih.gov?subject=Web Inquiry on [TAB-660] Modified Defensins and Their Use&body=Please send me information about technology [TAB-660] Modified Defensins and Their Use. Mistry, Pragnesh<br><a href="mailto:pragnesh.mistry@nih.gov?subject=Web Inquiry on [TAB-660] Modified Defensins and Their Use&body=Please send me information about technology [TAB-660] Modified Defensins and Their Use.">pragnesh.mistry@nih.gov</a><br> 114161579 E-080-2002-0 E-080-2002-0-US-01 Modified Defensins And their Use PRV US 60/358,504 Abandoned US <br />Provisional (PRV) 60/358,504<br />Filed on 2002-02-19<br />Status: Abandoned 114161581 E-080-2002-0 E-080-2002-0-PCT-02 Modified Defensins And Their Use PCT Patent Cooperation Treaty PCT/US03/04649 Expired Patent Cooperation Treaty <br />(PCT) PCT/US03/04649<br />Filed on 2003-02-18<br />Status: Expired 114161582 E-080-2002-0 E-080-2002-0-US-03 Modified Defensins And Their Use National Stage US 7,511,015 10/504,838 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7511015 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7511015">7,511,015</a><br />Filed on 2004-08-13<br />Status: Abandoned 114165011 E-080-2002-0 E-080-2002-0-US-04 Modified Defensins And Their Use DIV US 8,106,006 12/388,427 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8106006 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8106006">8,106,006</a><br />Filed on 2003-02-18<br />Status: Expired 114166600 E-080-2002-0 E-080-2002-0-US-05 Modified Defensins And Their Use DIV US 8,609,607 13/344,509 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8609607 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8609607">8,609,607</a><br />Filed on 2012-01-05<br />Status: Abandoned 114114208 DB3XXX 114114209 IB3XXX 114114210 IB4XXX 114114211 DBXXXX 114114212 IBXXXX 114114213 DXXXXX 114114214 IXXXXX TAB-586 114094925 Endotracheal Tube Using Unique Leak Hole to Lower Dead Space NHLBI Collaboration, Licensing Collaboration Licensing Theodor Kolobow Through injury or diseases, human or animal lungs may become too weak to sustain a sufficient flow of oxygen to the body and to remove adequate amounts of expired carbon dioxide. The present invention is a tracheal tube ventilation apparatus which efficiently rids patients of expired gases and promotes healthier breathing. This is accomplished by creating one or more leak holes in the wall of the endotracheal tube above the larynx, such as in the back of the mouth (i.e., oropharynx), so that expired gases can leak out of the endotracheal tube. The described apparatus is a two stage tube where the first stage has a smaller diameter such that it fits within the confined area of the lower trachea and the second stage has a larger diameter, which fits properly within the larger diameter of the patient's pharynx. The endotracheal tube is preferably wire reinforced and ultra-thin walled so as to reduce airway resistance. The invention substantially reduces endotracheal dead space and is expected to benefit those patients with both early and late stage acute respiratory failure, and reduce or obviate the need for mechanical pulmonary ventilation in many patients. <br><br> <img src="/gifs/E-269-2001_endotube_image.gif" border="0" alt="diagram of endotracheal tube"> <ul> <li>Tracheal tube ventilation</li> <li>Efficiently rid patient of expired gases and thereby promote healthier breathing</li> </ul> The NHLBI/Pulmonary Critical Care Medicine Branch (PCCMB) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize innovative endotracheal tube technology. Please contact Marianne Lynch at 301-594-4094 or <a href="mailto:lynchm@nhlbi.nih.gov">lynchm@nhlbi.nih.gov</a> for more information. Available for non-exclusive or exclusive licensing. 2022-03-08 2024-10-28 2024-10-28 2007-06-01 AA1XXX, AA4XXX, AAXXXX, AXXXXX, Dead, ENDOTRACHEAL, HOLE, LEAK, LOWER, Resistance, SPACE, Tube False True System is well developed and operational. System is well developed and operational. True NIHTT 37470483 Website Abstract 114104145 Kolobow, Theodor National Heart, Lung, and Blood Institute (NHLBI) Kolobow, Theodor 1 114104145 Kolobow, Theodor National Heart, Lung, and Blood Institute (NHLBI) Kolobow, Theodor 1 114099723 Endotracheal Tube Using Leak Hole To Lower Resistance And Dead Space E-269-2001-0 National Heart, Lung, and Blood Institute (NHLBI) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-586] Endotracheal Tube Using Unique Leak Hole to Lower Dead Space&body=Please send me information about technology [TAB-586] Endotracheal Tube Using Unique Leak Hole to Lower Dead Space. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-586] Endotracheal Tube Using Unique Leak Hole to Lower Dead Space&body=Please send me information about technology [TAB-586] Endotracheal Tube Using Unique Leak Hole to Lower Dead Space.">shmilovm@nih.gov</a><br> 114161374 E-269-2001-0 E-269-2001-0-US-01 Endotracheal Tube Using Leak Hole To Lower Resistance And Dead Space ORD US 7,107,991 09/967,903 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7107991 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7107991">7,107,991</a><br />Filed on 2001-09-28<br />Status: Abandoned 114165919 E-269-2001-0 E-269-2001-0-PCT-02 Endotracheal Tube Using Leak Hole To Lower Dead Space PCT Patent Cooperation Treaty PCT/US2002/029319 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2002/029319<br />Filed on 2002-09-16<br />Status: Expired 114113923 AA1XXX 114113924 AA4XXX 114113925 AAXXXX 114113926 AXXXXX 114136197 ENDOTRACHEAL 114136198 Tube 114136199 LEAK 114136200 HOLE 114136201 LOWER 114136202 Resistance 114136203 Dead 114136204 SPACE TAB-579 114094917 Production of Adeno-Associated Viruses in Insect Cells NHLBI Licensing, Oncology, Therapeutics Licensing Oncology Therapeutics Robert Kotin Adeno-associated virus (AAV) is being developed for gene therapy applications. This virus type presents several advantages over alternate vectors for therapeutic gene delivery. AAV is not considered pathogenic and transduces stably dividing and non-dividing cells. AAV also shows good serotype specificity to various cell types for targeted gene delivery.<br /><br /> The present invention describes a highly scalable adeno-associated virus (AAV) vector production method in insect cells. The system for producing recombinant AAV (rAAV) uses the AAV Rep protein and an AAV ITR. This production method produces virus particles much more efficiently than the standard mammalian cell culture system. Yields of rAAV produced in Sf9 cells exceed 10e15 per liter for some constructs. The improvement in production efficiency translates into lower production costs and potential for commercial scale manufacturing. In addition, all serotypes of AAV can be produced, with the respective AAV serotype vectors available for the immediate scale up of AAV production.<br /><br /> This technology will give a company producing large quantities of AAV a significant competitive advantage over traditional AAV production methods. Available for licensing. 2022-03-08 2024-10-28 2024-10-28 2004-08-01 AAV, AAV1, AAV2, AAV5, Adeno-associated, CB2AXX, CB2XXX, CBXXXX, Cells, CXXXXX, Duke DNA Project, GB2A2X, GB2AXX, GB2XXX, GBXXXX, GENE THERAPY, GXXXXX, insect, production, virus False True True NIHTT 37470483 Website Abstract E-308-2001-0 114169831 Ding C, et al. https://www.ncbi.nlm.nih.gov/pubmed/11739698 <a href="https://www.ncbi.nlm.nih.gov/pubmed/11739698">Ding C, et al.</a> 114104136 Kotin, Robert National Heart, Lung, and Blood Institute (NHLBI) Kotin, Robert 1 114104136 Kotin, Robert National Heart, Lung, and Blood Institute (NHLBI) Kotin, Robert 1 114099716 Production of Adeno-Associated Virus in Insect Cells E-325-2001-1 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 114101083 Production Of Adeno-Associated Virus In Insect Cells E-325-2001-2 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 83714317 Devany, John john.devany@nih.gov
United States of America Office of Technology Transfer and Development john.devany@nih.gov?subject=Web Inquiry on [TAB-579] Production of Adeno-Associated Viruses in Insect Cells&body=Please send me information about technology [TAB-579] Production of Adeno-Associated Viruses in Insect Cells. Devany, John<br><a href="mailto:john.devany@nih.gov?subject=Web Inquiry on [TAB-579] Production of Adeno-Associated Viruses in Insect Cells&body=Please send me information about technology [TAB-579] Production of Adeno-Associated Viruses in Insect Cells.">john.devany@nih.gov</a><br> 114161356 E-325-2001-2 E-325-2001-2-US-02 Production of Adeno-Associated Virus In Insect Cells National Stage US 7,271,002 10/415,834 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7271002 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7271002">7,271,002</a><br />Filed on 2003-05-02<br />Status: Expired 114161357 E-325-2001-1 E-325-2001-1-US-01 Production of Adeno-Associated Virus in Insect Cells CIP US 6,723,551 10/216,870 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6723551 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6723551">6,723,551</a><br />Filed on 2002-08-13<br />Status: Expired 114166734 E-325-2001-2 E-325-2001-2-PCT-01 Production of Adeno-Associated Virus in Insect Cells PCT COMB Patent Cooperation Treaty PCT/US2002/035829 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2002/035829<br />Filed on 2002-11-08<br />Status: Expired 114113893 GB2A2X 114113894 CB2AXX 114113895 GB2AXX 114113896 CB2XXX 114113897 GB2XXX 114113898 CBXXXX 114113899 GBXXXX 114113900 CXXXXX 114113901 GXXXXX 114132924 production 114132925 Adeno-associated 114132926 virus 114132927 insect 114132928 AAV 114132929 AAV1 114132930 AAV2 114132931 AAV5 114132932 GENE THERAPY 114132933 Duke DNA Project 114132934 Cells TAB-572 114094910 Development of Reagents to Examine the Expression and Function of CYP2J Subfamily P450s NIEHS Collaboration, Research Materials Collaboration Research Materials Jennifer Bradbury, Darryl Zeldin Cytochrome P450s catalyze the metabolism of a wide range of exogenous compounds, including drugs, industrial chemicals, environmental pollutants, and carcinogens. The 2C family of cytochrome P450 metabolizes an extensive number of drugs which include tolbutamide, S-Warfarin, mephenytoin, diazepam and taxol. The inventors cloned the cDNAs for several different CYP2J subfamily members including human CYP2J2, rat CYP2J3, mouse CYP2J5, mouse CYP2J6, and mouse CYP2J9. The recombinant proteins were expressed in insect cells. Additionally, the inventors also developed specific peptide-based antibodies to these P450 proteins and characterized their specificity and cross-reactivity by immunoblotting.<br /><br /> The following materials are available for licensing for commercial use: <ul> <li>human CYP2J2 cDNA</li> <li>rat CYP2J3 cDNA</li> <li>mouse CYP2J5 cDNA</li> <li>mouse CYP2J9 cDNA</li> <li>anti-CYP2J2rec (cross-reacts with all CYP2Js)</li> <li>anti-CYPeJ2pep2 (human CYP2J2 specific)</li> <li>anti-CYP2J9pep2 (cross-reacts with rat CYP2J3 and mouse CYp2J9)</li> <li>anti-CYP2J5pep (mouse CYP2J5 specific)</li> <li>anti-CYP2J6pep (cross reacts with rat CYP2J4 and mouse CYP2J6)</li> <li>CYP2J2-CRPOR microsomes (baculovirus expressed)</li> </ul> <ul> <li>The cDNAs and antibodies can be used to examine expression of the CYP2J subfamily P450s at the RNA and protein level in various cell systems, tissues and body fluids from a number of species including but not limited to human, rat and mouse.</li> <li>The recombinant CP2J2 proteins can be used by investigators (particularly in pharmaceutical firms) to screen drugs and chemicals for possible metabolism by P450 and/or to identify endogenous substrates for this enzyme.</li> <li>The recombinant proteins may also be used to examine cross-reactivity for other antibodies.</li> </ul> The National Institute of Environmental Health Sciences seeks statements of capability or interest from parties interested in collaborative research to further develop and evaluate this technology. Please contact Sharon Soucek, PhD, Director, Office of Technology Transfer, National Institute of Environmental Health Sciences; Phone: (984) 287-4152; Email: <a href="mailto:sharon.soucek@nih.gov">sharon.soucek@nih.gov</a>. Research Tool - Patent protection is not being pursued for this technology. 2022-03-08 2024-10-28 2024-10-28 2002-02-01 CYP2J, Development, Examine, Expression, FUNCTION, Listed LPM Contreras as of 4/15/2015, P450s, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, R1XXXX, REAGENTS, RXXXXX, SUBFAMILY False True True NIHTT 37470483 Website Abstract 114170314 King LM, et al. http://www.ncbi.nlm.nih.gov/pubmed/11901223 <a href="http://www.ncbi.nlm.nih.gov/pubmed/11901223">King LM, et al.</a> 114170315 MA J, et al. http://www.ncbi.nlm.nih.gov/pubmed/12417258 <a href="http://www.ncbi.nlm.nih.gov/pubmed/12417258">MA J, et al.</a> 114170316 Wang H, et al. http://www.ncbi.nlm.nih.gov/pubmed/15102943 <a href="http://www.ncbi.nlm.nih.gov/pubmed/15102943">Wang H, et al.</a> 114104123 Zeldin, Darryl NIEHS Zeldin, Darryl (NIEHS) 0 114109063 Bradbury, Jennifer NIEHS NIEHS Bradbury, Jennifer (NIEHS) 0 114104123 Zeldin, Darryl NIEHS Zeldin, Darryl (NIEHS) 0 114109063 Bradbury, Jennifer NIEHS NIEHS Bradbury, Jennifer (NIEHS) 0 114102282 Development of reagents To Examine The Expression And Function of CYP2J Subfamily P450s E-033-2002-0 Research Material NIEHS 83739538 Choudhry, Vidita vidita.choudhry@nih.gov
United States of America Office of Technology Transfer and Development vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-572] Development of Reagents to Examine the Expression and Function of CYP2J Subfamily P450s&body=Please send me information about technology [TAB-572] Development of Reagents to Examine the Expression and Function of CYP2J Subfamily P450s. Choudhry, Vidita<br><a href="mailto:vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-572] Development of Reagents to Examine the Expression and Function of CYP2J Subfamily P450s&body=Please send me information about technology [TAB-572] Development of Reagents to Examine the Expression and Function of CYP2J Subfamily P450s.">vidita.choudhry@nih.gov</a><br> 114113874 RXXXXX 114127154 R1XXXX 114148484 Development 114148485 REAGENTS 114148486 Examine 114148487 Expression 114148488 FUNCTION 114148489 CYP2J 114148490 SUBFAMILY 114148491 P450s 114148492 Listed LPM Contreras as of 4/15/2015 114148493 Pre LPM working set 20150418 114148494 Post LPM Assignment Set 20150420 TAB-566 114094904 Anti-Arthropod Vector Vaccines, Methods of Selecting, and Uses Thereof NIAID Infectious Disease, Licensing, Therapeutics, Vaccines Infectious Disease Licensing Therapeutics Vaccines Yasmine Belkaid, Shaden Kamhawi, Jose Ribeiro, David Sacks, Jesus Valenzuela <i>Leishmania</i> parasites are transmitted to their vertebrate hosts by infected phlebotomine sand fly bites. Sand fly saliva is known to enhance <i>Leishmania</i> infection, while immunity to the saliva protects against infection. This invention claims nine major salivary proteins from the sand fly vector of <i>Leishmania major</i>, <i>Phlebotomus papatasi</i>, nucleic acids encoding the proteins, vaccines comprising the proteins and/or nucleic acids, and methods of producing an immune response to prevent <i>Leshmaniasis</i>. The inventors have shown that one of these salivary proteins was able to protect vaccinated mice challenged with parasites plus salivary gland homogenates (SGH). A DNA vaccine containing the cDNA for the same protein provided this same protection. Protection lasted at least 3 months after immunization. The vaccine produced both intense humoral and delayed-type hypersensitivity (DTH) reactions. B cell-deficient mice immunized with the plasmid vaccine successfully controlled <i>Leishmania</i> infection when injected with <i>Leishmania</i> plus SGH. 2022-03-08 2024-10-28 2024-10-28 2002-02-01 DB3XXX, DBXXXX, DC4XXX, DCXXXX, DXXXXX False True True NIHTT 37470483 Website Abstract 114169824 Valenzuela JG et al. http://www.ncbi.nlm.nih.gov/pubmed/11489952 <a href="http://www.ncbi.nlm.nih.gov/pubmed/11489952">Valenzuela JG et al.</a> 114104105 Valenzuela, Jesus NIAID Valenzuela, Jesus (NIAID) 0 114104106 Belkaid, Yasmine NIAID Belkaid, Yasmine (NIAID) 0 114104107 Kamhawi, Shaden NIAID Kamhawi, Shaden (NIAID) 0 114104108 Sacks, David NIAID Sacks, David (NIAID) 0 114104109 Ribeiro, Jose NIAID Ribeiro, Jose (NIAID) 0 114104105 Valenzuela, Jesus NIAID Valenzuela, Jesus (NIAID) 0 114104106 Belkaid, Yasmine NIAID Belkaid, Yasmine (NIAID) 0 114104107 Kamhawi, Shaden NIAID Kamhawi, Shaden (NIAID) 0 114104108 Sacks, David NIAID Sacks, David (NIAID) 0 114104109 Ribeiro, Jose NIAID Ribeiro, Jose (NIAID) 0 114099705 Anti-Arthropod Vector Vaccines,Methods of Selecting and Uses Thereof E-122-2001-0 Filing authorized NIAID 83724572 Tung, Peter peter.tung@nih.gov
United States of America DIR peter.tung@nih.gov?subject=Web Inquiry on [TAB-566] Anti-Arthropod Vector Vaccines, Methods of Selecting, and Uses Thereof&body=Please send me information about technology [TAB-566] Anti-Arthropod Vector Vaccines, Methods of Selecting, and Uses Thereof. Tung, Peter<br><a href="mailto:peter.tung@nih.gov?subject=Web Inquiry on [TAB-566] Anti-Arthropod Vector Vaccines, Methods of Selecting, and Uses Thereof&body=Please send me information about technology [TAB-566] Anti-Arthropod Vector Vaccines, Methods of Selecting, and Uses Thereof.">peter.tung@nih.gov</a><br> 114161331 E-122-2001-0 E-122-2001-0-US-01 Anti-Arthropod Vector Vaccines,Methods of Selecting and Uses Thereof PRV US 60/299,391 Abandoned US <br />Provisional (PRV) 60/299,391<br />Filed on 2001-06-19<br />Status: Abandoned 114161332 E-122-2001-0 E-122-2001-0-PCT-02 Anti-Arthropod Vector Vaccines,Methods of Selecting and Uses Thereof PCT Patent Cooperation Treaty PCT/US02/19663 Expired Patent Cooperation Treaty <br />(PCT) PCT/US02/19663<br />Filed on 2002-06-18<br />Status: Expired 114161334 E-122-2001-0 E-122-2001-0-US-05 Anti-Arthropod Vector Vaccines, Methods of Selecting and Uses Thereof National Stage US 7,388,089 10/481,180 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7388089 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7388089">7,388,089</a><br />Filed on 2003-12-17<br />Status: Expired 114164625 E-122-2001-0 E-122-2001-0-US-08 Anti-Arthropod Vector Vaccines, Methods of Selecting and Uses Thereof DIV US 7,964,576 12/082,369 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7964576 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7964576">7,964,576</a><br />Filed on 2008-04-09<br />Status: Expired 114166421 E-122-2001-0 E-122-2001-0-US-09 Anti-Arthropod Vector Vaccines,Methods of Selecting and Uses Thereof CON US 8,343,499 13/102,936 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8343499 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8343499">8,343,499</a><br />Filed on 2011-05-06<br />Status: Expired 114166920 E-122-2001-0 E-122-2001-0-US-10 Anti-Arthropod Vector Vaccines, Methods of Selecting and Uses Thereof DIV US 8,629,260 13/711,167 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8629260 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8629260">8,629,260</a><br />Filed on 2012-12-11<br />Status: Expired 114113846 DB3XXX 114113847 DC4XXX 114113848 DBXXXX 114113849 DCXXXX 114113850 DXXXXX TAB-519 114094857 Recombinant Proteins of the Swine Hepatitis E Virus and Their Uses as a Vaccine and Diagnostic Reagents for Medical and Veterinary Applications NIAID Diagnostics, Infectious Disease, Licensing, Vaccines Diagnostics Infectious Disease Licensing Vaccines Suzanne Emerson, Xiang-jin Meng, Robert Purcell This invention is based on the discovery of the swine hepatitis E virus (swine HEV), the first animal strain of HEV identified and characterized, and its ability to infect across species. The inventors have found that the swine HEV is widespread in the general pig population in the United States and other countries and that swine HEV can infect non-human primates. The inventors have amplified and sequenced the complete genome of swine HEV. The capsid gene (ORF2) of swine HEV has been cloned and expressed in a baculovirus expression system. <br><br> The possibility that swine HEV may infect humans raises a potential public health concern for zoonosis or xenozoonosis in the United States and perhaps other countries. Therefore, it is likely that a vaccine based on the recombinant capsid protein of swine HEV will protect humans against zoonotic, as well as other, HEV infections and pigs against infection with the swine HEV. Also, diagnostic reagents based on these recombinant proteins of swine HEV will be very useful in screening donor pigs used in xenotransplantation and in detecting swine HEV or similar virus infection in humans. The diagnostic reagents may also be useful for veterinary studies and monitoring pig herds in general. 2022-03-08 2024-10-28 2024-10-28 2020-07-06 DA4BXX, DAXXXX, DC5BXX, DCXXXX, DXXXXX, Hepatitis A, Hepatitis D, Hepatitis E False True True NIHTT 37470483 Website Abstract 114104000 Meng, Xiang-jin Meng, Xiang-jin 0 114104001 Purcell, Robert NIAID Purcell, Robert (NIAID) 0 114104002 Emerson, Suzanne NIAID Emerson, Suzanne (NIAID) 0 114104000 Meng, Xiang-jin Meng, Xiang-jin 0 114104001 Purcell, Robert NIAID Purcell, Robert (NIAID) 0 114104002 Emerson, Suzanne NIAID Emerson, Suzanne (NIAID) 0 114099657 Recombinant proteins of the swine hepatitis E virus and their uses as a vaccine and diagnostic reagents for medical and veterinary applns. E-304-1998-0 Filing authorized NIAID 83643855 Soukas, Peter peter.soukas@nih.gov
United States of America Technology Transfer and Intellectual Property Office peter.soukas@nih.gov?subject=Web Inquiry on [TAB-519] Recombinant Proteins of the Swine Hepatitis E Virus and Their Uses as a Vaccine and Diagnostic Reagents for Medical and Veterinary Applications&body=Please send me information about technology [TAB-519] Recombinant Proteins of the Swine Hepatitis E Virus and Their Uses as a Vaccine and Diagnostic Reagents for Medical and Veterinary Applications. Soukas, Peter<br><a href="mailto:peter.soukas@nih.gov?subject=Web Inquiry on [TAB-519] Recombinant Proteins of the Swine Hepatitis E Virus and Their Uses as a Vaccine and Diagnostic Reagents for Medical and Veterinary Applications&body=Please send me information about technology [TAB-519] Recombinant Proteins of the Swine Hepatitis E Virus and Their Uses as a Vaccine and Diagnostic Reagents for Medical and Veterinary Applications.">peter.soukas@nih.gov</a><br> 114161204 E-304-1998-0 E-304-1998-0-PCT-02 Recombinant ORF2 Proteins of the Swine Hepatitis E Virus and Their Use as A Vaccine and as a Diagnostic Reagent for Medical and Vetinirary Applications PCT Patent Cooperation Treaty PCT/US02/14100 Expired Patent Cooperation Treaty <br />(PCT) PCT/US02/14100<br />Filed on 2002-05-02<br />Status: Expired 114161206 E-304-1998-0 E-304-1998-0-US-03 Recombinant ORF2 Proteins of the Swine Hepatitis E virus and their use as a Vaccine and as a Diagnostic Reagent for Medical and Veterinary Applications National Stage US 10/476,777 Abandoned US <br />National Stage 10/476,777<br />Filed on 2003-11-05<br />Status: Abandoned 114163797 E-304-1998-0 E-304-1998-0-US-01 Recombinant proteins of t he swine hepatitis E virus and their uses as a vaccine and diagnostic reagents for medical and veterinary applns. PRV US 60/289,220 Abandoned US <br />Provisional (PRV) 60/289,220<br />Filed on 2001-05-07<br />Status: Abandoned 114113640 DA4BXX 114113641 DC5BXX 114113642 DAXXXX 114113643 DCXXXX 114113644 DXXXXX 114157456 Hepatitis D 114157457 Hepatitis A 114157458 Hepatitis E TAB-518 114094856 Mapping Internal and Bulk Motion of an Object with Phase Labeling in Magnetic Resonance Imaging NHLBI Licensing Licensing Anthony Aletras, Han Wen Current MRI methods for tracking the motion of an object over a relatively long period of time requires the use of precisely defined grid points that may be inexact because of limited image resolution or the size of the element being tracked. Phase contrast velocity mapping generally provides high spatial resolution and simple data processing. However, it is generally unsuitable for motion tracking and prone to error. This invention is a cutting edge Magnetic Resonance Imaging (MRI) technique that provides a method for mapping the internal and bulk motion of a specimen by labeling the phase of the specimen magnetization with a selected spatial function and measuring changes in the phase of the magnetization. The special function is selectable to provide magnetization phase modulation corresponding to displacements in a selected direction such as Cartesian or radial or azimuthal direction. This method and associated apparatus is capable of producing images based on magnetization phase modulation using data from stimulated echoes and anti-echoes. This invention has important applications in, among other areas, cardiac functional imaging and can be used to compute accurate strain maps of the heart. 2022-03-08 2024-10-28 2024-10-28 2008-04-01 AA3AXX, AA3B1X, AA3BXX, AA3XXX, AAXXXX, AXXXXX False True True NIHTT 37470483 Website Abstract 114103998 Aletras, Anthony NHLBI Aletras, Anthony (NHLBI) 0 114103999 Wen, Han NHLBI Wen, Han (NHLBI) 0 114103998 Aletras, Anthony NHLBI Aletras, Anthony (NHLBI) 0 114103999 Wen, Han NHLBI Wen, Han (NHLBI) 0 114099656 Fast Displacement Encoding With Stimulated Magnetic Resonance Echoes By Sampling Both Components Of A Stimulated Echo E-234-1999-3 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-518] Mapping Internal and Bulk Motion of an Object with Phase Labeling in Magnetic Resonance Imaging&body=Please send me information about technology [TAB-518] Mapping Internal and Bulk Motion of an Object with Phase Labeling in Magnetic Resonance Imaging. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-518] Mapping Internal and Bulk Motion of an Object with Phase Labeling in Magnetic Resonance Imaging&body=Please send me information about technology [TAB-518] Mapping Internal and Bulk Motion of an Object with Phase Labeling in Magnetic Resonance Imaging.">shmilovm@nih.gov</a><br> 114161200 E-234-1999-3 E-234-1999-3-US-06 METHODS AND APPARATUS FOR MAPPING INTERNAL AND BULK MOTION OF AN OBJECT WITH PHASE LAABELING IN MAGNETIC RESONANCE IMAGING National Stage US 7,233,818 10/049,005 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7233818 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7233818">7,233,818</a><br />Filed on 2002-03-01<br />Status: Expired 114161203 E-234-1999-3 E-234-1999-3-US-08 Methods and Apparatus for Mapping Internal and Bulk Motion of an Object with Phase Labeling in Magnetic Resonance Imaging DIV US 7,706,857 11/800,398 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7706857 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7706857">7,706,857</a><br />Filed on 2007-05-03<br />Status: Expired 114164887 E-234-1999-3 E-234-1999-3-PCT-01 Fast Displacement Encoding With Stimulated Magnetic Resonance Echoes By Sampling Both Components Of A Stimulated Echo PCT COMB Patent Cooperation Treaty PCT/US2000/021299 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2000/021299<br />Filed on 2000-08-04<br />Status: Expired 114113634 AA3B1X 114113635 AA3AXX 114113636 AA3BXX 114113637 AA3XXX 114113638 AAXXXX 114113639 AXXXXX TAB-489 114094827 HCV/BVDV Chimeric Genomes and Uses Thereof NIAID Infectious Disease, Licensing, Research Materials, Vaccines Infectious Disease Licensing Research Materials Vaccines Jens Bukh, Suzanne Emerson, Jae-hwan Nam, Robert Purcell The current invention provides nucleic acid sequences comprising chimeric viral genome of hepatitis C Virus (HCV) and bovine viral diarrhea viruses (BVDV). The chimeric viruses are produced by replacing the structural region or a structural gene of an infectious BVDV clone with the corresponding region or gene of an infectious HCV. It covers the use of these sequences and polypeptides encoded by all or part of the sequences in the development of vaccines and diagnostic assays for HCV and the development of screening assays for the identification of antiviral agents for HCV. 2022-03-08 2024-10-28 2024-10-28 2020-07-06 DC5XXX, DCXXXX, DDXXXX, DXXXXX, Hepatitis A, Hepatitis D, Hepatitis E False True True NIHTT 37470483 Website Abstract E-050-1998-0 E-100-1999-0 E-173-1999-0 114103940 Nam, Jae-hwan Nam, Jae-hwan 0 114103941 Bukh, Jens NIAID Bukh, Jens (NIAID) 0 114103942 Purcell, Robert NIAID Purcell, Robert (NIAID) 0 114103943 Emerson, Suzanne NIAID Emerson, Suzanne (NIAID) 0 114103940 Nam, Jae-hwan Nam, Jae-hwan 0 114103941 Bukh, Jens NIAID Bukh, Jens (NIAID) 0 114103942 Purcell, Robert NIAID Purcell, Robert (NIAID) 0 114103943 Emerson, Suzanne NIAID Emerson, Suzanne (NIAID) 0 114099630 HCV/BVDV Chimeric Genomes and Uses Thereof E-102-1999-0 Filing authorized NIAID 83643855 Soukas, Peter peter.soukas@nih.gov
United States of America Technology Transfer and Intellectual Property Office peter.soukas@nih.gov?subject=Web Inquiry on [TAB-489] HCV/BVDV Chimeric Genomes and Uses Thereof&body=Please send me information about technology [TAB-489] HCV/BVDV Chimeric Genomes and Uses Thereof. Soukas, Peter<br><a href="mailto:peter.soukas@nih.gov?subject=Web Inquiry on [TAB-489] HCV/BVDV Chimeric Genomes and Uses Thereof&body=Please send me information about technology [TAB-489] HCV/BVDV Chimeric Genomes and Uses Thereof.">peter.soukas@nih.gov</a><br> 114161140 E-102-1999-0 E-102-1999-0-US-04 HCV/BVDV Chimeric Genomes and Uses Thereof National Stage US 7,009,044 10/009,011 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7009044 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7009044">7,009,044</a><br />Filed on 2002-07-19<br />Status: Abandoned 114163075 E-102-1999-0 E-102-1999-0-PCT-02 HCV/BVDV Chimeric Genomes and Uses Thereof PCT Patent Cooperation Treaty PCT/US00/15527 Expired Patent Cooperation Treaty <br />(PCT) PCT/US00/15527<br />Filed on 2000-06-02<br />Status: Expired 114163076 E-102-1999-0 E-102-1999-0-US-01 HCV/BVDV Chimeric Genomes and Uses Thereof PRV US 60/137,817 Abandoned US <br />Provisional (PRV) 60/137,817<br />Filed on 1999-06-04<br />Status: Abandoned 114113513 DC5XXX 114113514 DDXXXX 114113515 DCXXXX 114113516 DXXXXX 114157424 Hepatitis D 114157425 Hepatitis A 114157426 Hepatitis E TAB-490 114094828 Infectious cDNA Clone of GB Virus B and Uses Thereof NIAID Infectious Disease, Licensing, Research Materials, Vaccines Infectious Disease Licensing Research Materials Vaccines Jens Bukh, Suzanne Emerson, Robert Purcell, Masayuki Yanagi The current invention provides nucleic acid sequences comprising the genomes of infectious GB virus B, the most closely related member of the Flaviviridae to hepatitis C virus (HCV). It also covers chimeric GBVB-HCV sequences and polypeptides for use in the development of vaccines and diagnostic assays for HCV and the development of screening assays for the identification of antiviral agents for HCV. Additional information can be found in Bukh et al. (1999), Virology 262, 470-478. 2022-03-08 2024-10-28 2024-10-28 2020-07-06 DC5XXX, DCXXXX, DDXXXX, DXXXXX, Hepatitis A, Hepatitis D, Hepatitis E False True True NIHTT 37470483 Website Abstract E-050-1998-0 E-100-1999-0 E-102-1999-0 114103944 Bukh, Jens NIAID Bukh, Jens (NIAID) 0 114103945 Yanagi, Masayuki Yanagi, Masayuki 0 114103946 Purcell, Robert NIAID Purcell, Robert (NIAID) 0 114103947 Emerson, Suzanne NIAID Emerson, Suzanne (NIAID) 0 114103944 Bukh, Jens NIAID Bukh, Jens (NIAID) 0 114103945 Yanagi, Masayuki Yanagi, Masayuki 0 114103946 Purcell, Robert NIAID Purcell, Robert (NIAID) 0 114103947 Emerson, Suzanne NIAID Emerson, Suzanne (NIAID) 0 114099631 Infectious cDNA Clone of GB Virus B and Uses Thereof E-173-1999-0 Filing authorized NIAID 83643855 Soukas, Peter peter.soukas@nih.gov
United States of America Technology Transfer and Intellectual Property Office peter.soukas@nih.gov?subject=Web Inquiry on [TAB-490] Infectious cDNA Clone of GB Virus B and Uses Thereof&body=Please send me information about technology [TAB-490] Infectious cDNA Clone of GB Virus B and Uses Thereof. Soukas, Peter<br><a href="mailto:peter.soukas@nih.gov?subject=Web Inquiry on [TAB-490] Infectious cDNA Clone of GB Virus B and Uses Thereof&body=Please send me information about technology [TAB-490] Infectious cDNA Clone of GB Virus B and Uses Thereof.">peter.soukas@nih.gov</a><br> 114161142 E-173-1999-0 E-173-1999-0-US-04 Infectious cDNA Clone of GB Virus B and Uses Thereof National Stage US 7,129,342 10/009,002 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7129342 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7129342">7,129,342</a><br />Filed on 2003-01-14<br />Status: Abandoned 114163073 E-173-1999-0 E-173-1999-0-PCT-02 Infectious cDNA Clone of GB Virus B and Uses Thereof PCT Patent Cooperation Treaty PCT/US00/15293 Expired Patent Cooperation Treaty <br />(PCT) PCT/US00/15293<br />Filed on 2000-06-02<br />Status: Expired 114163074 E-173-1999-0 E-173-1999-0-US-01 Infectious cDNA Clone of GB Virus B and Uses Thereof PRV US 60/137,694 Abandoned US <br />Provisional (PRV) 60/137,694<br />Filed on 1999-06-04<br />Status: Abandoned 114113517 DC5XXX 114113518 DDXXXX 114113519 DCXXXX 114113520 DXXXXX 114157427 Hepatitis D 114157428 Hepatitis A 114157429 Hepatitis E TAB-484 114094822 Real Time Interactive Volumetric Magnetic Resonance Imaging NHLBI Licensing Licensing Michael Guttman, Elliot Mcveigh The invention makes possible "live" volume renderings from a Magnetic Resonance Imaging (MRI) scanner. Previously, volume renderings from MRI data could only be generated off-line, some time after the image data was collected. In one embodiment of the invention, the time between data collection and volume rendering update (the latency) is approximately one third of a second at a frame rate of approximately 10 updates per second. User interaction with the rendering, such as rotation and cut planes, is allowed during imaging. This gives a caregiver real-time three-dimensional feedback while manipulating devices within a patient's body. The invention may be of benefit to several types of image-guided interventional procedures, including cardiac catheterization, tumor removal, ablation or biopsies. 2022-03-08 2024-10-28 2024-10-28 2001-07-01 AA3B1X, AA3BXX, AA3XXX, AAXXXX, AC2XXX, ACXXXX, AXXXXX False True True NIHTT 37470483 Website Abstract 114103929 Guttman, Michael Guttman, Michael 0 114103930 Mcveigh, Elliot Mcveigh, Elliot 0 114103929 Guttman, Michael Guttman, Michael 0 114103930 Mcveigh, Elliot Mcveigh, Elliot 0 114099627 Real-Time, Interactive Volumetric Magnetic Resonance Imaging E-082-2001-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-484] Real Time Interactive Volumetric Magnetic Resonance Imaging&body=Please send me information about technology [TAB-484] Real Time Interactive Volumetric Magnetic Resonance Imaging. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-484] Real Time Interactive Volumetric Magnetic Resonance Imaging&body=Please send me information about technology [TAB-484] Real Time Interactive Volumetric Magnetic Resonance Imaging.">shmilovm@nih.gov</a><br> 114161132 E-082-2001-0 E-082-2001-0-US-01 Real-Time, Interactive Volumetric Magnetic Resonance Imaging PRV US 60/269,363 Abandoned US <br />Provisional (PRV) 60/269,363<br />Filed on 2001-02-16<br />Status: Abandoned 114161133 E-082-2001-0 E-082-2001-0-PCT-03 REAL-TIME, INTERACTIVE VOLUMETRIC MRI PCT Patent Cooperation Treaty PCT/US2002/004537 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2002/004537<br />Filed on 2002-02-14<br />Status: Expired 114161134 E-082-2001-0 E-082-2001-0-US-02 Real Time, Interactive, Volumetric Magnetic Resonance Imaging National Stage US 8,068,893 10/076,882 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8068893 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8068893">8,068,893</a><br />Filed on 2002-02-14<br />Status: Expired 114162178 E-082-2001-0 E-082-2001-0-US-04 Real-Time, Interactive Volumetric Magnetic Resonance Imaging CON US 9,008,751 13/305,496 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9008751 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9008751">9,008,751</a><br />Filed on 2011-11-28<br />Status: Expired 114169250 E-082-2001-0 E-082-2001-0-US-05 Real-Time, Interactive Volumetric Magnetic Resonance Imaging CON US 14/686,631 Abandoned US <br />Continuation (CON) 14/686,631<br />Filed on 2015-04-14<br />Status: Abandoned 114113488 AA3B1X 114113489 AA3BXX 114113490 AA3XXX 114113491 AC2XXX 114113492 AAXXXX 114113493 ACXXXX 114113494 AXXXXX TAB-488 114094826 Cloned Genome of Infectious Hepatitis C Virus of Genotype 2a and Uses Thereof NIAID Infectious Disease, Licensing, Research Materials, Vaccines Infectious Disease Licensing Research Materials Vaccines Jens Bukh, Suzanne Emerson, Robert Purcell, Masayuki Yanagi The current invention provides a nucleic acid sequence comprising the genome of infectious hepatitis C viruses (HCV) of genotype 2a. The encoded polyprotein differs from those of the infectious clones of genotypes 1a and 1b (U.S. Patent 6,153,421) by approximately thirty (30) percent. It covers the use of this sequence and polypeptides encoded by all or part of the sequence, in the development of vaccines and diagnostic assays for HCV and the development of screening assays for the identification of antiviral agents for HCV. Additional information can be found in Yanagi et al. (1999), Virology 262, 250-263. 2022-03-08 2024-10-28 2024-10-28 2020-07-06 DC5XXX, DCXXXX, DDXXXX, DXXXXX, Hepatitis A, Hepatitis D, Hepatitis E False True True NIHTT 37470483 Website Abstract E-050-1998-0 E-102-1999-0 E-173-1999-0 114103936 Bukh, Jens NIAID Bukh, Jens (NIAID) 0 114103937 Yanagi, Masayuki Yanagi, Masayuki 0 114103938 Purcell, Robert NIAID Purcell, Robert (NIAID) 0 114103939 Emerson, Suzanne NIAID Emerson, Suzanne (NIAID) 0 114103936 Bukh, Jens NIAID Bukh, Jens (NIAID) 0 114103937 Yanagi, Masayuki Yanagi, Masayuki 0 114103938 Purcell, Robert NIAID Purcell, Robert (NIAID) 0 114103939 Emerson, Suzanne NIAID Emerson, Suzanne (NIAID) 0 114099629 Cloned Genome of Infectious Hepatitis C Virus of Genotype 2a and Uses Thereof E-100-1999-0 Filing authorized NIAID 83643855 Soukas, Peter peter.soukas@nih.gov
United States of America Technology Transfer and Intellectual Property Office peter.soukas@nih.gov?subject=Web Inquiry on [TAB-488] Cloned Genome of Infectious Hepatitis C Virus of Genotype 2a and Uses Thereof&body=Please send me information about technology [TAB-488] Cloned Genome of Infectious Hepatitis C Virus of Genotype 2a and Uses Thereof. Soukas, Peter<br><a href="mailto:peter.soukas@nih.gov?subject=Web Inquiry on [TAB-488] Cloned Genome of Infectious Hepatitis C Virus of Genotype 2a and Uses Thereof&body=Please send me information about technology [TAB-488] Cloned Genome of Infectious Hepatitis C Virus of Genotype 2a and Uses Thereof.">peter.soukas@nih.gov</a><br> 114161137 E-100-1999-0 E-100-1999-0-US-04 Cloned Genome of Infectious Hepatitis C Virus of Genotype 2A and Uses Thereof National Stage US 7,084,266 09/980,559 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7084266 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7084266">7,084,266</a><br />Filed on 2002-05-14<br />Status: Expired 114161139 E-100-1999-0 E-100-1999-0-US-05 Cloned Genome of Infectious Hepatitis C Virus of Genotype 2a and Uses Thereof CON US 11/451,212 Abandoned US <br />Continuation (CON) 11/451,212<br />Filed on 2006-06-12<br />Status: Abandoned 114163794 E-100-1999-0 E-100-1999-0-PCT-02 Cloned Genome of Infectious Hepatitis C Virus of Genotype 2a and Uses Thereof PCT Patent Cooperation Treaty PCT/US00/15446 Expired Patent Cooperation Treaty <br />(PCT) PCT/US00/15446<br />Filed on 2000-06-02<br />Status: Expired 114163795 E-100-1999-0 E-100-1999-0-US-01 Cloned Genome of Infectious Hepatitis C Virus of Genotype 2a and Uses Thereof PRV US 60/137,693 Abandoned US <br />Provisional (PRV) 60/137,693<br />Filed on 1999-06-04<br />Status: Abandoned 114113509 DC5XXX 114113510 DDXXXX 114113511 DCXXXX 114113512 DXXXXX 114157421 Hepatitis D 114157422 Hepatitis A 114157423 Hepatitis E TAB-460 114094798 Antibodies that Selectively Detect the Human Nestin Protein NINDS Licensing, Research Materials Licensing Research Materials Jean Hou, Eugene Major, Conrad Messam Nestin is an intermediate filament protein first described in early embryonic neuroepithelial stem cells. Although not found in most cells of the mature CNS, nestin is the predominant marker used to detect the small population of undifferentiated cells. The presence of nestin identifies stem, progenitor and some tumor cells in the CNS, and also labels areas of reactive gliosis in the CNS. Available methods to detect nestin use antibodies generated against rat nestin protein. Since rat and human nestin have only about fifty percent sequence homology, these antibodies may not be optimal for detecting nestin in human cells. NIH scientists used a novel human nestin immunogen to generate polyclonal and monoclonal antibodies that bind with high affinity and specificity to human nestin. The immunogen was expressed from a 450 base-pair segment of human nestin mRNA, which has 11 nucleotide differences from previously published human nestin. These antibodies increase the specificity to accurately detect human nestin in all stages of brain development and will increase our understanding of glial differentiation. In addition, this technology may be useful for detecting glioblastomas or other early stage neuroectodermal tumors and for following transplanted stem cells. Research Tool – Patent protection is not being pursued for this technology. 2022-03-08 2024-10-28 2024-10-28 2015-10-06 2008-06-22 Antisera, Cross, Human, Listed LPM Maddox as of 4/15/2015, Nestin, polyclonal, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, R1XXXX, rabbit, Reactive, Rodent, RXXXXX, Specific, X False True True NIHTT 37470483 Website Abstract 114103884 Messam, Conrad Messam, Conrad 0 114109105 Major, Eugene NINDS NINDS Major, Eugene (NINDS) 0 114109106 Hou, Jean NINDS Hou, Jean 0 114103884 Messam, Conrad Messam, Conrad 0 114109105 Major, Eugene NINDS NINDS Major, Eugene (NINDS) 0 114109106 Hou, Jean NINDS Hou, Jean 0 114101414 Rabbit Polyclonal Antisera Specific To Human Nestin And Not Cross Reactive To Rodent E-145-1999-0 Research Material NINDS 83667829 Ano, Susan susan.ano@nih.gov
United States of America susan.ano@nih.gov?subject=Web Inquiry on [TAB-460] Antibodies that Selectively Detect the Human Nestin Protein&body=Please send me information about technology [TAB-460] Antibodies that Selectively Detect the Human Nestin Protein. Ano, Susan<br><a href="mailto:susan.ano@nih.gov?subject=Web Inquiry on [TAB-460] Antibodies that Selectively Detect the Human Nestin Protein&body=Please send me information about technology [TAB-460] Antibodies that Selectively Detect the Human Nestin Protein.">susan.ano@nih.gov</a><br> 114113389 RXXXXX 114127234 R1XXXX 114148618 X 114148619 rabbit 114148620 polyclonal 114148621 Antisera 114148622 Specific 114148623 Human 114148624 Nestin 114148625 Cross 114148626 Reactive 114148627 Rodent 114148628 Listed LPM Maddox as of 4/15/2015 114148629 Pre LPM working set 20150418 114148630 Post LPM Assignment Set 20150420 TAB-470 114094808 Attenuated Host-Range Restricted Dengue Viruses Derived by Site-Directed Mutagenesis of the Conserved 3-Stem and Loop Structure in Genomic RNA for Use as Vaccines FDA Infectious Disease, Licensing, Vaccines Infectious Disease Licensing Vaccines Lewis Markoff, Lingling Zeng Although flaviviruses cause a great deal of human suffering and economic loss, there is a shortage of effective vaccines. The present invention is directed toward vector stage replication-defective flaviviruses that are replication-defective in mosquito vectors that transmit them to humans. The replication-defective flaviviruses of the present invention demonstrate a limited ability to replicate in the vector organisms that transmit flaviviruses from one host to another. More specifically, the present invention is directed toward the construction and propagation of flaviviruses that possess 3'-noncoding regions altered in such a way as to prevent or severely limit viral reproduction in a vector organism. Not only is the dengue 1 mutant replication defective in mosquitoes, but it is also attenuated and immunogenic in monkeys. Moreover, it protects against challenge, thus it has strong potential as a dengue vaccine. 2022-03-08 2024-10-28 2024-10-28 2001-05-01 DC5BXX, DC5XXX, DCXXXX, Dengue (Flaviviridae), DXXXXX False True True NIHTT 37470483 Website Abstract 114103902 Zeng, Lingling FDA Zeng, Lingling (FDA) 0 114103903 Markoff, Lewis FDA Markoff, Lewis (FDA) 0 114103902 Zeng, Lingling FDA Zeng, Lingling (FDA) 0 114103903 Markoff, Lewis FDA Markoff, Lewis (FDA) 0 114099614 Replication-Defective Dengue Viruses That are Replication-Defective in Mosquitoes for use as Vaccines E-067-1998-0 FDA 83682188 Ronnenberg, William wronnenberg@mail.nih.gov
United States of America Headquarters wronnenberg@mail.nih.gov?subject=Web Inquiry on [TAB-470] Attenuated Host-Range Restricted Dengue Viruses Derived by Site-Directed Mutagenesis of the Conserved 3-Stem and Loop Structure in Genomic RNA for Use as Vaccines&body=Please send me information about technology [TAB-470] Attenuated Host-Range Restricted Dengue Viruses Derived by Site-Directed Mutagenesis of the Conserved 3-Stem and Loop Structure in Genomic RNA for Use as Vaccines. Ronnenberg, William<br><a href="mailto:wronnenberg@mail.nih.gov?subject=Web Inquiry on [TAB-470] Attenuated Host-Range Restricted Dengue Viruses Derived by Site-Directed Mutagenesis of the Conserved 3-Stem and Loop Structure in Genomic RNA for Use as Vaccines&body=Please send me information about technology [TAB-470] Attenuated Host-Range Restricted Dengue Viruses Derived by Site-Directed Mutagenesis of the Conserved 3-Stem and Loop Structure in Genomic RNA for Use as Vaccines.">wronnenberg@mail.nih.gov</a><br> 114161101 E-067-1998-0 E-067-1998-0-US-06 Replication-Defective Dengue Viruses that are Replication-Defective in Mosquitoes for use as Vaccines National Stage US 6,685,948 09/798,542 Administratively Closed https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6685948 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6685948">6,685,948</a><br />Filed on 2001-03-02<br />Status: Administratively Closed 114163838 E-067-1998-0 E-067-1998-0-US-01 Replication-Defective Dengue Viruses That are Replication-Defective in Mosquitoes for use as Vaccines ORD US 60/098,981 Administratively Closed US <br />Ordinary Patent (ORD) 60/098,981<br />Filed on 1998-09-02<br />Status: Administratively Closed 114165209 E-067-1998-0 E-067-1998-0-PCT-02 DENGUE VIRUSES THAT ARE REPLICATION DEFECTIVE IN MOSQUITOS FOR USE AS VACCINES PCT Patent Cooperation Treaty PCT/US1999/002598 Administratively Closed Patent Cooperation Treaty <br />(PCT) PCT/US1999/002598<br />Filed on 1999-02-05<br />Status: Administratively Closed 114113424 DC5BXX 114113425 DC5XXX 114113426 DCXXXX 114113427 DXXXXX 114157903 Dengue (Flaviviridae) TAB-393 114094731 Method Of Identifying Inhibitors Of The Jak-STAT Signal Transduction Pathway NHLBI Diagnostics, Licensing, Research Materials, Therapeutics Diagnostics Licensing Research Materials Therapeutics Warren Leonard The invention provides identification methods for agents which inhibit the Jak-STAT signaling transduction pathway. Drugs identified by these methods are candidates for the treatment of proliferative disorders dependent on the Jak-STAT pathway, including those caused by HTLV-1. In addition, such agents may be potent immunosuppressive drugs with potential applications not only for organ transplantation but also for treatment of autoimmune diseases. 2022-03-08 2024-10-28 2024-10-28 1996-04-01 HTLV-1, HTLV-2, HTLV-3, Human T Cell Leukemia Virus 1, Human T-cell leukemia viruses type 2, Human T-lymphotropic virus type 3, IBXXXX, ICXXXX, IXXXXX False True True NIHTT 37470483 Website Abstract 114103717 Leonard, Warren NHLBI Leonard, Warren (NHLBI) 0 114103717 Leonard, Warren NHLBI Leonard, Warren (NHLBI) 0 114099527 METHOD OF IDENTIFYING INHIBITORS OF THE JAK-STAT SIGNAL TRANSDUCTION PATHWAY E-176-1995-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-393] Method Of Identifying Inhibitors Of The Jak-STAT Signal Transduction Pathway&body=Please send me information about technology [TAB-393] Method Of Identifying Inhibitors Of The Jak-STAT Signal Transduction Pathway. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-393] Method Of Identifying Inhibitors Of The Jak-STAT Signal Transduction Pathway&body=Please send me information about technology [TAB-393] Method Of Identifying Inhibitors Of The Jak-STAT Signal Transduction Pathway.">shmilovm@nih.gov</a><br> 114160892 E-176-1995-0 E-176-1995-0-US-03 METHOD OF IDENTIFYING INHIBITORS OF THE JAK-STAT SIGNAL TRANSDUCTION PATHWAY ORD US 6,265,160 09/003,903 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6265160 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6265160">6,265,160</a><br />Filed on 1998-01-07<br />Status: Abandoned 114165240 E-176-1995-0 E-176-1995-0-US-01 METHOD OF IDENTIFYING INHIBITORS OF THE JAK-STAT SIGNAL TRANSDUCTION PATHWAY PRV US 60/000,971 Abandoned US <br />Provisional (PRV) 60/000,971<br />Filed on 1995-07-07<br />Status: Abandoned 114165241 E-176-1995-0 E-176-1995-0-PCT-02 METHOD OF IDENTIFYING INHIBITORS OF THE JAK-STAT SIGNAL TRANSDUCTION PATHWAY PCT Patent Cooperation Treaty PCT/US1996/011206 Abandoned Patent Cooperation Treaty <br />(PCT) PCT/US1996/011206<br />Filed on 1996-07-02<br />Status: Abandoned 114113156 IBXXXX 114113157 ICXXXX 114113158 IXXXXX 114157358 Human T-cell leukemia viruses type 2 114157359 Human T Cell Leukemia Virus 1 114157360 Human T-lymphotropic virus type 3 114158783 HTLV-2 114158784 HTLV-1 114158785 HTLV-3 TAB-3824 114097670 Potentiating Antibody Therapy for the Treatment of Cancer NHLBI Antibodies, Immunology, Oncology, Therapeutics Antibodies Immunology Oncology Therapeutics Sivasubramanian Baskar, Erika Gaglione, Haiyong Peng, Christoph Rader, Adrian Wiestner This technology includes a strategy to target tumor cells that lost antigen following reaction with a therapeutic antibody by targeting the complement component C3d that has been deposited on target cells by the primary antibody. We previously generated a C3d-specific mouse/human chimeric antibody called C8xi and obtained proof of principle for the approach in two preclinical models. Here we summarize the generation of a new set of C3d targeting antibodies. We obtained several rabbit/ chimeric antibodies, some of these antibodies bind both human and mouse C3d; having different sequences and binding epitopes than C8xi. Two mouse C3d reactive antibodies were tested in an aggressive lymphoma model and synergized with anti-CD20 antibodies. This is a novel principle for antibody therapy which expands the array of antibodies that can be advanced towards clinical translation, with the potential for a large commercial market. Anti-C3d antibodies could be used in cancer treatment, being combined with or administered sequentially after a first targeting antibody to enhance overall response; key oncology indications include lymphoma, chronic lymphocytic leukemia, and multiple myeloma. 2022-11-06 2024-10-28 2024-10-28 2024-03-20 2JXXXX, 4GXXXX, 5OXXXX, ANTIBODY, CANCER, CB1XXX, Cells, Complement, Deposited, Potentiating, Targeting, THERAPY, VCXXXX, WJXXXX, XAXXXX False True True 52398218 Pre-Clinical (in vivo) 52398218 NIHTT 37470483 Website Abstract 114111662 Gaglione, Erika National Heart, Lung, and Blood Institute (NHLBI) NHLBI Gaglione, Erika (NHLBI) 0 114111664 Rader, Christoph The Scripps Research Institute, Scripps Florida NCI Rader, Christoph (NCI) 0 114111665 Peng, Haiyong The Scripps Research Institute, Scripps Florida Peng, Haiyong 0 114111666 Baskar, Sivasubramanian National Heart, Lung, and Blood Institute (NHLBI) NHLBI Baskar, Sivasubramanian (NHLBI) 0 114111663 Wiestner, Adrian National Heart, Lung, and Blood Institute (NHLBI) NHLBI Wiestner, Adrian (NHLBI) 1 114111663 Wiestner, Adrian National Heart, Lung, and Blood Institute (NHLBI) NHLBI Wiestner, Adrian (NHLBI) 1 114111662 Gaglione, Erika National Heart, Lung, and Blood Institute (NHLBI) NHLBI Gaglione, Erika (NHLBI) 0 114111664 Rader, Christoph The Scripps Research Institute, Scripps Florida NCI Rader, Christoph (NCI) 0 114111665 Peng, Haiyong The Scripps Research Institute, Scripps Florida Peng, Haiyong 0 114111666 Baskar, Sivasubramanian National Heart, Lung, and Blood Institute (NHLBI) NHLBI Baskar, Sivasubramanian (NHLBI) 0 114102922 Potentiating Antibody Therapy By Targeting Complement Deposited On Cancer Cells E-025-2019-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI), The Scripps Research Institute, Scripps Florida 83739538 Choudhry, Vidita vidita.choudhry@nih.gov
United States of America Office of Technology Transfer and Development vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-3824] Potentiating Antibody Therapy for the Treatment of Cancer&body=Please send me information about technology [TAB-3824] Potentiating Antibody Therapy for the Treatment of Cancer. Choudhry, Vidita<br><a href="mailto:vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-3824] Potentiating Antibody Therapy for the Treatment of Cancer&body=Please send me information about technology [TAB-3824] Potentiating Antibody Therapy for the Treatment of Cancer.">vidita.choudhry@nih.gov</a><br> 114169679 E-025-2019-0 E-025-2019-0-US-01 ANTIBODIES TARGETING CELL SURFACE DEPOSITED COMPLEMENT PROTEIN C3d AND USE THEREOF PRV US 62/945,569 Abandoned US <br />Provisional (PRV) 62/945,569<br />Filed on 2019-12-09<br />Status: Abandoned 114169680 E-025-2019-0 E-025-2019-0-PCT-02 ANTIBODIES TARGETING CELL SURFACE DEPOSITED COMPLEMENT PROTEIN C3D AND USE THEREOF PCT Patent Cooperation Treaty PCT/US2020/063809 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2020/063809<br />Filed on 2020-12-08<br />Status: Expired 114169681 E-025-2019-0 E-025-2019-0-US-03 ANTIBODIES TARGETING CELL SURFACE DEPOSITED COMPLEMENT PROTEIN C3d AND USE THEREOF National Stage US 17/783,345 Pending US <br />National Stage 17/783,345<br />Filed on 2022-06-08<br />Status: Pending 114129740 4GXXXX 114129741 5OXXXX 114129742 2JXXXX 114129743 VCXXXX 114129744 CB1XXX 114129745 WJXXXX 114129746 XAXXXX 114155731 Cells 114155732 CANCER 114155733 Deposited 114155734 Complement 114155735 Targeting 114155736 THERAPY 114155737 ANTIBODY 114155738 Potentiating TAB-3823 114097669 A Machine Learning Strategy to Improve the Fidelity of Imaging Time-Varying Signals to Improve Clinical Imaging NHLBI Computational models/software, Diagnostics, Research Materials, Software / Apps Computational models/software Diagnostics Research Materials Software / Apps Andrew Arai, Mitchel Benovoy, Vy Bui, Li-Yueh Hsu, Matthew Jacobs This technology includes a new technique to improve the fidelity of time-varying signals acquired in the dynamic contrast enhanced (DCE) imaging. This technique enhances the time-varying signals in a given DCE image series through deep convolutional neural networks (CNN) to learn the relationship of signal versus contrast concentration from other series of different contrast doses. The method includes an automatic framework to detect target regions of interest (ROI), match key signal-time frames, and register anatomical structures in different DCE series to train the CNN and produce an image series with improved signal fidelity. Depending on specific ROI in the DCE images, signal fidelity may include the linearity of the signal versus contrast concentration, or measurements of image quality. The method automatically selects key signature frames in two calibrated DCE image series and matches only those frames in the training. Once properly trained, the inference network can be applied to the entire DCE image series to generate a synthetic DCE image series that has improved fidelity. The propose technique not only can improve region specific time-varying signals in a DCE image series, it can also reduce the amount of required matched image data to significantly reduce the CNN training time. Application to clinical DCE imaging application to improve quantitative analysis of time-varying signals and qualitative interpretation of the DCE image, as well as reduce contrast dose required in DCE imaging for clinical diagnosis. 2022-11-06 2024-10-28 2024-10-28 2024-03-20 APPLICATIONS, BREATHING, Contrast, CORRECTED, dynamic, Enhanced, Example, FIDELITY, FREE, IMAGING, LEARNING, MAPPING, MECHANICAL, MOTION, MRI, MYOCARDIAL, PARAMETER, PIXEL-WISE, SIGNALS, STRATEGY, T1, Time-Varying, WBXXXX, WIXXXX, XJXXXX False True True NIHTT 37470483 Website Abstract 114111658 Bui, Vy National Heart, Lung, and Blood Institute (NHLBI) Bui, Vy 0 114111659 Jacobs, Matthew National Heart, Lung, and Blood Institute (NHLBI) NHLBI Jacobs, Matthew (NHLBI) 0 114111660 Benovoy, Mitchel Corstem Inc. Benovoy, Mitchel 0 114111661 Arai, Andrew National Heart, Lung, and Blood Institute (NHLBI) NHLBI Arai, Andrew (NHLBI) 0 114111657 Hsu, Li-Yueh National Heart, Lung, and Blood Institute (NHLBI) NHLBI Hsu, Li-Yueh (NHLBI) 1 114111657 Hsu, Li-Yueh National Heart, Lung, and Blood Institute (NHLBI) NHLBI Hsu, Li-Yueh (NHLBI) 1 114111658 Bui, Vy National Heart, Lung, and Blood Institute (NHLBI) Bui, Vy 0 114111659 Jacobs, Matthew National Heart, Lung, and Blood Institute (NHLBI) NHLBI Jacobs, Matthew (NHLBI) 0 114111660 Benovoy, Mitchel Corstem Inc. Benovoy, Mitchel 0 114111661 Arai, Andrew National Heart, Lung, and Blood Institute (NHLBI) NHLBI Arai, Andrew (NHLBI) 0 114102921 A Machine Learning Strategy To Improve The Fidelity Of Imaging Time-Varying Signals With Example Applications To Dynamic Contrast Enhanced Imaging E-024-2019-0 Closed National Heart, Lung, and Blood Institute (NHLBI), National Heart, Lung, and Blood Institute (NHLBI) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-3823] A Machine Learning Strategy to Improve the Fidelity of Imaging Time-Varying Signals to Improve Clinical Imaging&body=Please send me information about technology [TAB-3823] A Machine Learning Strategy to Improve the Fidelity of Imaging Time-Varying Signals to Improve Clinical Imaging. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-3823] A Machine Learning Strategy to Improve the Fidelity of Imaging Time-Varying Signals to Improve Clinical Imaging&body=Please send me information about technology [TAB-3823] A Machine Learning Strategy to Improve the Fidelity of Imaging Time-Varying Signals to Improve Clinical Imaging.">shmilovm@nih.gov</a><br> 114129737 WBXXXX 114129738 WIXXXX 114129739 XJXXXX 114155709 Enhanced 114155710 Contrast 114155711 dynamic 114155712 APPLICATIONS 114155713 Example 114155714 SIGNALS 114155715 Time-Varying 114155716 IMAGING 114155717 FIDELITY 114155718 STRATEGY 114155719 LEARNING 114155720 FREE 114155721 BREATHING 114155722 MOTION 114155723 CORRECTED 114155724 PIXEL-WISE 114155725 MRI 114155726 MYOCARDIAL 114155727 T1 114155728 PARAMETER 114155729 MAPPING 114155730 MECHANICAL TAB-3820 114097662 Compatible 3-D Intracardiac Echography Catheter and System for Interventional Cardiac Procedures NHLBI Cardiology, Computational models/software, Diagnostics, Medical Devices, Non-Medical Devices, Research Materials, Software / Apps Cardiology Computational models/software Diagnostics Medical Devices Non-Medical Devices Research Materials Software / Apps Fahrettin Degertekin, Ozgur Kocaturk, Robert Lederman, Coskun Tekes This technology includes a versatile intravascular 3D intracardiac echocardiography (ICE) catheter that can operate under conventional X-ray and MRI for use during interventional cardiac procedures. The 3D MRICE and custom, GPU-based, real-time imaging system are also included. Structural heart disease affects more than 2.9% of the US population, and common interventional procedures can be difficult because of limitations in catheter devices and inadequate image guidance. Miniaturization of ultrasound probes to provide uninterrupted real-time full-volume intra-procedural 3D en-face depiction of cardiac pathology and catheter devices would represent a dramatic advance in image-guided intervention. A 3D ICE probe that can operate safely during MRI and conventional X-ray would revolutionize the capabilities of transcatheter therapy by enabling radiation-free, non-surgical catheter navigation. This invention describes such a catheter, the 3D MRICE. This catheter uses CMUT-on-CMOS technology and massive parallel RF data multiplexing to implement an ultraminiature, single chip volumetric ultrasound imaging system. Currently there are no 3-D ICE catheters that provide a field of view wide enough for effective image guidance under either X-ray or MRI; an MRI compatible catheter will eliminate the X-ray exposure, which will be a significant breakthrough for interventional cardiology. Catheter-based structural heart disease interventional procedures including repair of congenital heart defects and transcatheter valve repair and replacement 2022-11-06 2024-10-28 2024-10-28 2024-03-20 3-D, catheter, COMPATIBLE, Echography, Inracardiac, Listed LPM Shmilovich as of 4/15/2015, MRI, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, System, VDXXXX, WBXXXX, WIXXXX, XDXXXX, XJXXXX False True True NIHTT 37470483 Website Abstract 114111647 Degertekin, Fahrettin Georgia Tech Research Corporation Degertekin, Fahrettin 0 114111648 Tekes, Coskun Georgia Tech Research Corporation Tekes, Coskun 0 114111650 Kocaturk, Ozgur National Heart, Lung, and Blood Institute (NHLBI) NHLBI Kocaturk, Ozgur (NHLBI) 0 114111649 Lederman, Robert National Heart, Lung, and Blood Institute (NHLBI) NHLBI Lederman, Robert (NHLBI) 1 114111649 Lederman, Robert National Heart, Lung, and Blood Institute (NHLBI) NHLBI Lederman, Robert (NHLBI) 1 114111647 Degertekin, Fahrettin Georgia Tech Research Corporation Degertekin, Fahrettin 0 114111648 Tekes, Coskun Georgia Tech Research Corporation Tekes, Coskun 0 114111650 Kocaturk, Ozgur National Heart, Lung, and Blood Institute (NHLBI) NHLBI Kocaturk, Ozgur (NHLBI) 0 114102918 MRI Compatible 3-D Inracardiac Echography Catheter And System E-006-2014-0 Filing authorized Georgia Tech Research Corporation, National Heart, Lung, and Blood Institute (NHLBI) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-3820] Compatible 3-D Intracardiac Echography Catheter and System for Interventional Cardiac Procedures&body=Please send me information about technology [TAB-3820] Compatible 3-D Intracardiac Echography Catheter and System for Interventional Cardiac Procedures. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-3820] Compatible 3-D Intracardiac Echography Catheter and System for Interventional Cardiac Procedures&body=Please send me information about technology [TAB-3820] Compatible 3-D Intracardiac Echography Catheter and System for Interventional Cardiac Procedures.">shmilovm@nih.gov</a><br> 114169670 E-006-2014-0 E-006-2014-0-US-01 MRI Compatible 3-D Inracardiac Echography Catheter And System PRV US 61/882,371 Abandoned US <br />Provisional (PRV) 61/882,371<br />Filed on 2013-09-25<br />Status: Abandoned 114169671 E-006-2014-0 E-006-2014-0-PCT-02 MRI Compatible 3-D Inracardiac Echography Catheter And System PCT Patent Cooperation Treaty PCT/US2014/057506 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2014/057506<br />Filed on 2014-09-25<br />Status: Expired 114169672 E-006-2014-0 E-006-2014-0-US-04 MRI Compatible 3-D Inracardiac Echography Catheter And System National Stage US 10,123,768 15/024,995 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10123768 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10123768">10,123,768</a><br />Filed on 2014-09-25<br />Status: Issued 114169673 E-006-2014-0 E-006-2014-0-US-13 MRI Compatible 3-D Inracardiac Echography Catheter And System CON US 11,039,811 16/178,665 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11039811 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11039811">11,039,811</a><br />Filed on 2018-11-02<br />Status: Issued 114129727 VDXXXX 114129728 WBXXXX 114129729 WIXXXX 114129730 XDXXXX 114129731 XJXXXX 114155681 MRI 114155682 COMPATIBLE 114155683 3-D 114155684 Inracardiac 114155685 Echography 114155686 catheter 114155687 System 114155688 Listed LPM Shmilovich as of 4/15/2015 114155689 Pre LPM working set 20150418 114155690 Post LPM Assignment Set 20150420 TAB-3821 114097667 Closed-ended Linear Duplex DNA (CELiD or ceDNA) for Non-viral Gene Transfer NHLBI Research Materials, Therapeutics Research Materials Therapeutics Robert Kotin, Lina Li This technology includes an alternative source of plasmid DNA produced in eukaryotic cells for non-viral gene transfer, which represent a novel eukaryotic alternative to bacterial plasmid DNA. Once introduced into non-dividing cells, ceDNA persists and transgene expression remains stable whereas plasmid (p) DNA is lost. The ceDNA and transfection reagent complex is nonimmunogenic allowing re-administration as needed: recombinant adeno-associated virus (rMV) is immunogenic precluding repeated administration. Conventional non-viral gene transfer uses bacterial plasmid DNA containing antibiotic resistance genes, cis-acting bacterial sequence elements, and prokaryotic methylation patterns that may adversely affect transgene expression and vector stability in vivo. Use in non-viral gene transfer. 2022-11-06 2024-10-28 2024-10-28 2024-03-20 2022-11-06 CeDNA, CELiD, Close-ended, DNA, DUPLEX, Gene, LINEAR, Non-Viral, TRANSFER, WIXXXX, XEXXXX False True True NIHTT 37470483 Website Abstract 114172979 Li Lina, Dimitriadis E, et al. https://pubmed.ncbi.nlm.nih.gov/23936358/ <a href="https://pubmed.ncbi.nlm.nih.gov/23936358/">Li Lina, Dimitriadis E, et al.</a> 114111652 Kotin, Robert National Heart, Lung, and Blood Institute (NHLBI) Kotin, Robert 0 114111651 Li, Lina National Heart, Lung, and Blood Institute (NHLBI) NHGRI Li, Lina (NHGRI) 1 114111651 Li, Lina National Heart, Lung, and Blood Institute (NHLBI) NHGRI Li, Lina (NHGRI) 1 114111652 Kotin, Robert National Heart, Lung, and Blood Institute (NHLBI) Kotin, Robert 0 114102919 Close-ended Linear Duplex DNA (CELiD Or CeDNA) For Non-viral Gene Transfer E-011-2016-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 83714317 Devany, John john.devany@nih.gov
United States of America Office of Technology Transfer and Development john.devany@nih.gov?subject=Web Inquiry on [TAB-3821] Closed-ended Linear Duplex DNA (CELiD or ceDNA) for Non-viral Gene Transfer&body=Please send me information about technology [TAB-3821] Closed-ended Linear Duplex DNA (CELiD or ceDNA) for Non-viral Gene Transfer. Devany, John<br><a href="mailto:john.devany@nih.gov?subject=Web Inquiry on [TAB-3821] Closed-ended Linear Duplex DNA (CELiD or ceDNA) for Non-viral Gene Transfer&body=Please send me information about technology [TAB-3821] Closed-ended Linear Duplex DNA (CELiD or ceDNA) for Non-viral Gene Transfer.">john.devany@nih.gov</a><br> 114169674 E-011-2016-0 E-011-2016-0-PCT-01 Close-Ended, Linear, Duplex Adenoassociated Virus DNA and Uses Thereof PCT Patent Cooperation Treaty PCT/US2017/046059 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2017/046059<br />Filed on 2017-08-09<br />Status: Expired 114169675 E-011-2016-0 E-011-2016-0-US-03 CLOSED-ENDED, LINEAR, DUPLEX ADENOASSOCIATED VIRUS DNA, AND USES THEREOF National Stage US 11,549,125 16/637,152 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11549125 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11549125">11,549,125</a><br />Filed on 2020-02-06<br />Status: Issued 114129732 WIXXXX 114129733 XEXXXX 114155691 Close-ended 114155692 LINEAR 114155693 DUPLEX 114155694 DNA 114155695 CELiD 114155696 CeDNA 114155697 Non-Viral 114155698 Gene 114155699 TRANSFER TAB-3812 114097660 Minibody for Conditioning prior to Hematopoietic Stem Cell and Progenitor Cell Transplantation NHLBI Antibodies, Cardiology, Consumer Products, Dental, Endocrinology, Immunology, Infectious Disease, Oncology, Ophthalmology, Therapeutics Antibodies Cardiology Consumer Products Dental Endocrinology Immunology Infectious Disease Oncology Ophthalmology Therapeutics Daisuke Araki, Andre Larochelle, Diogo Magnani, Zhirui Wang Patient conditioning is a critical initial step in hematopoietic stem and progenitor cell (HSPC) transplantation procedures to enable marrow engraftment of infused cells. Conditioning regimens have traditionally been achieved by delivering cytotoxic doses of chemotherapeutic agents and radiation. However, these regimens are associated with significant morbidity and mortality, and cannot be used safely in elderly or subjects with comorbidities. Scientists at the National Heart, Lung, and Blood Institute (NHLBI), the University of Massachusetts Medical School (UMMS), and the University of Colorado (CU) have developed a recombinant bivalent (bi) single-chain variable fragment (scFV) minibody targeting the cMPL receptor on HSPCs, fused with diphtheria toxin (DT) truncated at residue 390 (DT390-biscFV(cMPL)) that can be used to deplete HSPCs with increased safety in patients undergoing HSPC transplantation. <ul> <li>Increased safety for patients undergoing transplantation</li> <li>Limits off-target effect</li> <li>Short half-life allowing rapid clearance before cell re-infusion</li> <li>Better penetrates into deep tissue, such as bone marrow niche</li> <li>More efficiently dimerizes cMPL receptor than the whole IgG</li> </ul> <ul> <li>Use as a novel conditioning regimen with increased safety for patients undergoing transplantation</li> <li>Investigational tool to study hematopoietic stem and progenitor cell (HSPC) biology and improve gene and cell therapies</li> <li>Treatment of leukemia</li> </ul> The National Heart, Lung, and Blood Institute is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize the DT390-biscFV(cMPL) minibody. For collaboration opportunities, please contact Dr. Vincent Kolesnitchenko at <a href="mailto:vk5q@nih.gov">vk5q@nih.gov</a> or 301-594-4115. at 2022-09-30 2024-10-28 2024-10-28 2022-09-02 1CXXXX, 2IXXXX, 2JXXXX, Anti-cMPL, Cells, DEPLETION, Divalent, DT-390-Conjugated, hematopoietic, Progenitor, ScFv, Stem, VCXXXX, VPXXXX, WJXXXX, WMXXXX, XAXXXX False True True 52398218 Pre-Clinical (in vivo) 52398218 NIHTT 37470483 Website Abstract 114111632 Araki, Daisuke National Heart, Lung, and Blood Institute (NHLBI) Araki, Daisuke 0 114111633 Magnani, Diogo University of Massachusetts Medical School Magnani, Diogo 0 114111634 Wang, Zhirui University of Colorado, Denver Wang, Zhirui 0 114111631 Larochelle, Andre National Heart, Lung, and Blood Institute (NHLBI) NHLBI Larochelle, Andre (NHLBI) 1 114111631 Larochelle, Andre National Heart, Lung, and Blood Institute (NHLBI) NHLBI Larochelle, Andre (NHLBI) 1 114111632 Araki, Daisuke National Heart, Lung, and Blood Institute (NHLBI) Araki, Daisuke 0 114111633 Magnani, Diogo University of Massachusetts Medical School Magnani, Diogo 0 114111634 Wang, Zhirui University of Colorado, Denver Wang, Zhirui 0 114102912 DT-390-Conjugated Anti-cMPL Divalent ScFV For Depletion Of Hematopoietic Stem And Progenitor Cells E-188-2021-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI), University of Colorado, Denver, University of Massachusetts Medical School 89788013 Kolesnitchenko, Vincent vk5q@nih.gov
United States of America Office of Technology Transfer and Development vk5q@nih.gov?subject=Web Inquiry on [TAB-3812] Minibody for Conditioning prior to Hematopoietic Stem Cell and Progenitor Cell Transplantation&body=Please send me information about technology [TAB-3812] Minibody for Conditioning prior to Hematopoietic Stem Cell and Progenitor Cell Transplantation. Kolesnitchenko, Vincent<br><a href="mailto:vk5q@nih.gov?subject=Web Inquiry on [TAB-3812] Minibody for Conditioning prior to Hematopoietic Stem Cell and Progenitor Cell Transplantation&body=Please send me information about technology [TAB-3812] Minibody for Conditioning prior to Hematopoietic Stem Cell and Progenitor Cell Transplantation.">vk5q@nih.gov</a><br> 114169650 E-188-2021-0 E-188-2021-0-US-01 ANTI-CMPL DIVALENT SCFV AND USES THEREOF PRV US 63/251,883 Abandoned US <br />Provisional (PRV) 63/251,883<br />Filed on 2021-10-04<br />Status: Abandoned 114169660 E-188-2021-0 E-188-2021-0-PCT-02 ANTI-CMPL DIVALENT SCFV AND USES THEREOF PCT Patent Cooperation Treaty PCT/US22/77326 Expired Patent Cooperation Treaty <br />(PCT) PCT/US22/77326<br />Filed on 2022-09-30<br />Status: Expired 114129698 1CXXXX 114129699 2IXXXX 114129700 2JXXXX 114129701 VCXXXX 114129702 VPXXXX 114129703 WJXXXX 114129704 WMXXXX 114129705 XAXXXX 114155615 DT-390-Conjugated 114155616 Anti-cMPL 114155617 Divalent 114155618 ScFv 114155619 DEPLETION 114155620 hematopoietic 114155621 Stem 114155622 Progenitor 114155623 Cells TAB-3809 114097658 Methods for Using Modulators of Extracellular Adenosine or an Adenosine Receptor To Enhance Immune Response and Inflammation NIAID Diagnostics, Immunology, Infectious Disease, Oncology, Therapeutics, Vaccines Diagnostics Immunology Infectious Disease Oncology Therapeutics Vaccines Akio Ohta, Michail Sitkovsky Local inflammation processes are crucially important in the host defense against pathogens and for successful immunization because proinflammatory cytokines are necessary for initiation and propagation of an immune response. However, normal inflammatory responses are eventually terminated by physiological termination mechanisms, thereby limiting the strength and duration of immune responses, especially to weak antigens. The inventors have shown that adenosine A2a and A3a receptors play a critical role in down-regulation of inflammation in vivo. They act as the physiological termination mechanism that can limit the immune response. Thus, a method was developed for inhibiting signaling through the adenosine receptor to prolong and intensify the immune response. The method involves administering either an adenosine-degrading drug or an adenosine receptor agonist. These compounds can be also used as vaccine adjuvants and treatments for accomplishing targeted tissue damage such as for tumor destruction. <ul> <li>Use of Adenosine Receptor Agonist or Adenosine-Degrading Drug to Inhibit Signaling Through the Adenosine Receptor to Prolong and Intensify the Immune Response.</li> <li>Use of Adenosine Receptor Agonists or Adenosine-Degrading Drugs as Vaccine Adjuvants for Tumor Destruction.</li> </ul> <ul> <li>Anti-Tumor Therapy</li> <li>Vaccine Adjuvants for Tumors</li> <li>Immunotherapy</li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize this technology. For collaboration opportunities, please contact Yogikala Prabhu, Ph.D., 301-761-7789; <a href="mailto:prabhuyo@niaid.nih.gov">prabhuyo@niaid.nih.gov</a>. 2022-09-27 2024-10-28 2024-10-28 2022-09-27 2IXXXX, 2JXXXX, CB3CXX, CB6XXX, Controlling, DC1XXX, IA3XXX, Inflammation, Listed LPM Thalhammer-Reyero as of 4/15/2015, Method, Patent Category - Chemistry, Post LPM Assignment Set 20150420, Pre LPM working set 20150418 False True True 52398218 Pre-Clinical (in vivo) 52398218 NIHTT 37470483 Website Abstract 114172970 Ohta A. et al. Nature. 2001 Dec 20-27 https://doi.org/10.1038/414916a <a href="https://doi.org/10.1038/414916a">Ohta A. et al. Nature. 2001 Dec 20-27</a> 114111626 Ohta, Akio NIAID - DIR Ohta, Akio 0 114111625 Sitkovsky, Michail NIAID - DIR NIAID Sitkovsky, Michail (NIAID) 1 114111625 Sitkovsky, Michail NIAID - DIR NIAID Sitkovsky, Michail (NIAID) 1 114111626 Ohta, Akio NIAID - DIR Ohta, Akio 0 114102910 Method of Controlling Inflammation E-051-2002-0 NIAID 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-3809] Methods for Using Modulators of Extracellular Adenosine or an Adenosine Receptor To Enhance Immune Response and Inflammation&body=Please send me information about technology [TAB-3809] Methods for Using Modulators of Extracellular Adenosine or an Adenosine Receptor To Enhance Immune Response and Inflammation. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-3809] Methods for Using Modulators of Extracellular Adenosine or an Adenosine Receptor To Enhance Immune Response and Inflammation&body=Please send me information about technology [TAB-3809] Methods for Using Modulators of Extracellular Adenosine or an Adenosine Receptor To Enhance Immune Response and Inflammation.">yogikala.prabhu@nih.gov</a><br> 114169642 E-051-2002-0 E-051-2002-0-PCT-01 Methods for Using Extracellular Adenosine Inhibitors and Adenosine Receptor Inhibitors to Enhance Immune Response and Inflammation PCT COMB Patent Cooperation Treaty PCT/US2002/036829 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2002/036829<br />Filed on 2002-11-14<br />Status: Expired 114169643 E-051-2002-0 E-051-2002-0-US-01 Method of Controlling Inflammation PRV US 60/340,772 Abandoned US <br />Provisional (PRV) 60/340,772<br />Filed on 2001-12-12<br />Status: Abandoned 114169644 E-051-2002-0 E-051-2002-0-US-06 Method for Using Extracellular Adenosine Inhibitors and Adenosine Receptor Inhibitors to Enhance Immune Response and Inflammation National Stage US 8,080,554 10/498,416 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8080554 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8080554">8,080,554</a><br />Filed on 2004-06-10<br />Status: Issued 114169645 E-051-2002-0 E-051-2002-0-US-07 METHODS FOR USING EXTRACELLULAR ADENOSINE INHIBITORS AND ADENOSINE RECEPTOR INHIBITORS TO ENHANCE IMMUNE RESPONSE AND INFLAMMATION DIV US 8,716,301 13/310,264 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8716301 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8716301">8,716,301</a><br />Filed on 2011-12-02<br />Status: Expired 114169646 E-051-2002-0 E-051-2002-0-US-08 METHOD FOR USING EXTRACELLULAR ADENOSINE INHIBITORS AND ADENOSINE RECEPTOR INHIBITORS TO ENHANCE IMMUNE RESPONSE AND INFLAMMATION CON US 9,415,105 14/067,005 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9415105 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9415105">9,415,105</a><br />Filed on 2013-10-30<br />Status: Expired 114169647 E-051-2002-0 E-051-2002-0-US-18 METHODS FOR USING EXTRACELLULAR ADENOSINE INHIBITORS AND ADENOSINE RECEPTOR INHIBITORS TO ENHANCE IMMUNE RESPONSE AND INFLAMMATION CON US 10,314,908 15/237,316 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10314908 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10314908">10,314,908</a><br />Filed on 2016-08-15<br />Status: Expired 114169648 E-051-2002-0 E-051-2002-0-US-19 METHODS FOR USING EXTRACELLULAR ADENOSINE INHIBITORS AND ADENOSINE RECEPTOR INHIBITORS TO ENHANCE IMMUNE RESPONSE AND INFLAMMATION CON US 11,471,528 16/391,423 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11471528 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11471528">11,471,528</a><br />Filed on 2019-04-23<br />Status: Expired 114129683 DC1XXX 114129684 CB3CXX 114129685 CB6XXX 114129686 IA3XXX 114129687 2IXXXX 114129688 2JXXXX 114155604 Method 114155605 Controlling 114155606 Inflammation 114155607 Patent Category - Chemistry 114155608 Listed LPM Thalhammer-Reyero as of 4/15/2015 114155609 Pre LPM working set 20150418 114155610 Post LPM Assignment Set 20150420 TAB-3808 114097657 Beta Globin Mimetic Peptides and Their Use NIAID Cardiology, Collaboration, Therapeutics Cardiology Collaboration Therapeutics Hans Ackerman, Steven Brooks, Phillip (Phil) Cruz Feedback vasodilation by endothelium-derived nitric oxide (NO) is under the regulation of globins. NIH Researchers discovered that not only the alpha globin but also the beta globin subunits of hemoglobin are expressed in the human artery wall, with beta globin interacting directly with endothelial nitric oxide synthase (eNOS). This discovery of tetrameric hemoglobin binding to eNOS has led inventors to develop novel mimetic peptides that disrupt the binding of beta globin to eNOS, diminishing the ability of hemoglobin to restrict NO release and thereby enhancing NO-mediated feedback vasodilation. These agents can be used to increase NO signaling from endothelial cells and thus inhibit, prevent, or reverse vasoconstriction. <ul> <li>New pathway for regulation of vasoconstriction/vasodilation that is separate from the pathways that current products available for treating nitric oxide deficiency target. Combination therapy with current vasoconstriction/vasodilation medications of different mechanisms may be possible.</li> <li>Enhancement of NO release at the junction between the endothelial cell and smooth muscle cell may provide greater potency and fewer off-target effects than other forms of NO delivery.</li> </ul> <ul> <li>Novel peptides to treat vascular diseases characterized by vasoconstriction, excess alpha adrenergic signaling, or insufficient nitric oxide signaling. Applications could range from cerebral vasospasm to pulmonary hypertension to chronic kidney disease to transfusion medicine to erectile dysfunction to exercise physiology.</li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize Beta Globin Mimetic Peptides and Their Use. For collaboration opportunities, please contact Peter Tung, PhD at <a href="mailto:peter.tung@nih.gov"> peter.tung@nih.gov</a>or 1-240-669-5483. 2022-08-17 2024-10-28 2024-10-28 2022-08-17 ARTERIES, COMPLEX, Endothelial, Forms, hemoglobin, Human, NITRIC, OXIDE, REGULATES, Signlaing, SYNTHASE False True True 52398218 Pre-Clinical (in vivo) 52398218 NIHTT 37470483 Website Abstract 114172969 Brooks, SD et al. Hemoglobin Interacts with Endothelial Nitric Oxide Synthase to Regulate Vasodilation in Human Resistance Arteries MedRxiv 2021 April 9 https://doi.org/10.1101/2021.04.06.21255004 <a href="https://doi.org/10.1101/2021.04.06.21255004">Brooks, SD et al. Hemoglobin Interacts with Endothelial Nitric Oxide Synthase to Regulate Vasodilation in Human Resistance Arteries MedRxiv 2021 April 9</a> 114111623 Brooks, Steven NIAID - DIADS NIAID Brooks, Steven (NIAID) 0 114111624 Cruz, Phillip (Phil) NIAID - DIADS NIAID Cruz, Phillip (Phil) (NIAID) 0 114111622 Ackerman, Hans National Heart, Lung, and Blood Institute (NHLBI) NHLBI Ackerman, Hans (NHLBI) 1 114111622 Ackerman, Hans National Heart, Lung, and Blood Institute (NHLBI) NHLBI Ackerman, Hans (NHLBI) 1 114111623 Brooks, Steven NIAID - DIADS NIAID Brooks, Steven (NIAID) 0 114111624 Cruz, Phillip (Phil) NIAID - DIADS NIAID Cruz, Phillip (Phil) (NIAID) 0 114102909 Hemoglobin Forms A Complex With Endothelial Nitric Oxide Synthase And Regulates Nitric Oxide Signlaing In Human Arteries E-060-2022-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI), NIAID 83724572 Tung, Peter peter.tung@nih.gov
United States of America DIR peter.tung@nih.gov?subject=Web Inquiry on [TAB-3808] Beta Globin Mimetic Peptides and Their Use&body=Please send me information about technology [TAB-3808] Beta Globin Mimetic Peptides and Their Use. Tung, Peter<br><a href="mailto:peter.tung@nih.gov?subject=Web Inquiry on [TAB-3808] Beta Globin Mimetic Peptides and Their Use&body=Please send me information about technology [TAB-3808] Beta Globin Mimetic Peptides and Their Use.">peter.tung@nih.gov</a><br> 114169640 E-060-2022-0 E-060-2022-0-US-01 BETA GLOBIN MIMETIC PEPTIDES AND THEIR USE PRV US 63/328,615 Expired US <br />Provisional (PRV) 63/328,615<br />Filed on 2022-04-07<br />Status: Expired 114155593 hemoglobin 114155594 Forms 114155595 COMPLEX 114155596 Endothelial 114155597 NITRIC 114155598 OXIDE 114155599 SYNTHASE 114155600 REGULATES 114155601 Signlaing 114155602 Human 114155603 ARTERIES TAB-3793 114097643 Detection of Nucleocapsid and Spike SARS-CoV2 Antibodies Using Luciferase Immunoprecipitation Systems (LIPS) NIDCR Antibodies, Immunology, Infectious Disease, Therapeutics Antibodies Immunology Infectious Disease Therapeutics Peter Burbelo, Jeffrey Cohen This technology includes an immunoassay to measure SARS-CoV-2 antibodies against the nucleocapsid and spike proteins. Using the luciferase immunoprecipitation technology (LIPS), this highly quantitative test for nucleocapsid antibodies showed 100% sensitivity and 100% specificity with COVID-19 patient samples from fifteen or more days after symptom onset, and antibodies against SARS-CoV-2 spike protein were detected with 91% sensitivity and 100% specificity These assays have a high degree of sensitivity and specificity and should have commercial application related to seroepidemiologic studies and developing biomarkers for COV1D-19 disease. Unlike standard ELISA assays, LIPS assays are more likely to identity antibodies to conformational dependent antibodies, to correlate well with neutralizing antibody responses, and have a dynamic range up to 7 10910 for some antigens. LIPS assays require < 5 uL of sera which can be obtained from a finger stick. Diagnostic test for COVID-19. 2022-11-30 2024-10-28 2024-10-28 2022-11-30 2022-08-03 antibodies, Detection, Lips, Lmmunoprecipitation, LUCIFERASE, Nucleocapsicl, SARS-CoV2, spike, SYSTEMS, VLXXXX, WJXXXX, XAXXXX False True True NIHTT 37470483 Website Abstract 114172953 Burbelo P, Riedo F, et al. https://pubmed.ncbi.nlm.nih.gov/32511445/ <a href="https://pubmed.ncbi.nlm.nih.gov/32511445/">Burbelo P, Riedo F, et al.</a> 114111587 Cohen, Jeffrey NIAID - DIR NIAID Cohen, Jeffrey (NIAID) 0 114111586 Burbelo, Peter NIDCR NIDCR Burbelo, Peter (NIDCR) 1 114111586 Burbelo, Peter NIDCR NIDCR Burbelo, Peter (NIDCR) 1 114111587 Cohen, Jeffrey NIAID - DIR NIAID Cohen, Jeffrey (NIAID) 0 114102895 Detection Of Nucleocapsicl And Spike SARS-CoV2 Antibodies Using Luciferase Lmmunoprecipitation Systems (LIPS) E-139-2020-0 Research Material NIAID, NIDCR 83739611 Yonter, Ediz ediz.yonter@nih.gov
United States of America Technology Advancement Office ediz.yonter@nih.gov?subject=Web Inquiry on [TAB-3793] Detection of Nucleocapsid and Spike SARS-CoV2 Antibodies Using Luciferase Immunoprecipitation Systems (LIPS)&body=Please send me information about technology [TAB-3793] Detection of Nucleocapsid and Spike SARS-CoV2 Antibodies Using Luciferase Immunoprecipitation Systems (LIPS). Yonter, Ediz<br><a href="mailto:ediz.yonter@nih.gov?subject=Web Inquiry on [TAB-3793] Detection of Nucleocapsid and Spike SARS-CoV2 Antibodies Using Luciferase Immunoprecipitation Systems (LIPS)&body=Please send me information about technology [TAB-3793] Detection of Nucleocapsid and Spike SARS-CoV2 Antibodies Using Luciferase Immunoprecipitation Systems (LIPS).">ediz.yonter@nih.gov</a><br> 114129622 VLXXXX 114129623 WJXXXX 114129624 XAXXXX 114155469 Detection 114155470 Nucleocapsicl 114155471 spike 114155472 SARS-CoV2 114155473 antibodies 114155474 LUCIFERASE 114155475 Lmmunoprecipitation 114155476 SYSTEMS 114155477 Lips TAB-3774 114097625 Identification and Characterization of the Wild Mouse Gut Microbiome as the Optimal Standard for Laboratory Mice NIDDK Cardiology, Dental, Endocrinology, Infectious Disease, Oncology, Ophthalmology, Research Materials Cardiology Dental Endocrinology Infectious Disease Oncology Ophthalmology Research Materials Barbara Rehermann, Stephan Rosshart This technology includes identification of the wild mouse microbiome as a method to increase resistance to lethal viral infection. We establish that the gut microbiome of barrier-raised C57BL/6 mice is dysbiotic compared to that of their outbred, wild-living progenitors, Mus musculus domesticus. We find that the multigenerational offspring of pregnant germfree C57BL/6 mice reconstituted with the gut microbiome of wild mice exhibit a less inflammatory response and increased survival following influenza A virus infection. Thus, replacing the gut microbiome of laboratory mice with the wild mouse microbiome via fecal material transfer increases resistance to lethal viral infection. By simply restoring the natural microbial identity of laboratory mice, we crease a more physiologically balanced and biologically relevant model. We propose that the natural “gold-standard” wild mouse microbiome become the standard used in laboratory mice, with obvious applications to other animal models. Here we identify, characterize and propose a natural candidate the “gold-standard” microbiome present in wild mice creased by co-evolution. Development of more physiologically balanced and biologically relevant mouse models. 2022-11-30 2024-10-28 2024-10-28 2022-11-30 2022-07-22 CHARACTERIZATION, Gut, Identification, Laboratory, Mice, Microbiome, Mouse, OPTIMAL, STANDARD, VLXXXX, VPXXXX, Wild, WIXXXX False True True NIHTT 37470483 Website Abstract 114172941 Rosshart S, Vassallo B, et al. https://pubmed.ncbi.nlm.nih.gov/29056339/ <a href="https://pubmed.ncbi.nlm.nih.gov/29056339/">Rosshart S, Vassallo B, et al.</a> 114111531 Rehermann, Barbara National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Rehermann, Barbara (NIDDK) 0 114111530 Rosshart, Stephan National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Rosshart, Stephan 1 114111530 Rosshart, Stephan National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Rosshart, Stephan 1 114111531 Rehermann, Barbara National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Rehermann, Barbara (NIDDK) 0 114102877 Identification And Characterization Of The Wild Mouse Gut Microbiome As The Optimal Standard For Laboratory Mice E-290-2016-0 Research Material National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83656052 Knezevic, Vladimir vlado.knezevic@nih.gov
United States of America Technology Advancement Office vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-3774] Identification and Characterization of the Wild Mouse Gut Microbiome as the Optimal Standard for Laboratory Mice&body=Please send me information about technology [TAB-3774] Identification and Characterization of the Wild Mouse Gut Microbiome as the Optimal Standard for Laboratory Mice. Knezevic, Vladimir<br><a href="mailto:vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-3774] Identification and Characterization of the Wild Mouse Gut Microbiome as the Optimal Standard for Laboratory Mice&body=Please send me information about technology [TAB-3774] Identification and Characterization of the Wild Mouse Gut Microbiome as the Optimal Standard for Laboratory Mice.">vlado.knezevic@nih.gov</a><br> 114129561 VLXXXX 114129562 VPXXXX 114129563 WIXXXX 114155289 Identification 114155290 CHARACTERIZATION 114155291 Wild 114155292 Mouse 114155293 Gut 114155294 Microbiome 114155295 OPTIMAL 114155296 STANDARD 114155297 Laboratory 114155298 Mice TAB-3775 114097626 Transgenic Mice with Conditionally Activated Islet Beta Cell M3 Muscarinic Acetylcholine Receptor for Improving Glucose Tolerance in High-fat Diet Obese Insulin-resistant Mice NIDDK Cardiology, Dental, Endocrinology, Infectious Disease, Oncology, Ophthalmology, Research Materials Cardiology Dental Endocrinology Infectious Disease Oncology Ophthalmology Research Materials Jurgen Wess This technology includes transgenic mice in which designer rat M3 muscarinic receptor mutants were expressed only in islet 13-cells (directed by rat insulin promoter II), were unable to bind acetylcholine (the endogenous ligand) but could be selectively activated by an otherwise pharmacologically inert compound (clozapine-N-oxide (CNO)). The R-q receptor contained a Y148C point mutation, which enabled CNO to selectively activate G proteins of the Gq/11 family. The R-5 receptor contained an A238G mutation, which enabled CNO to selectively activate G proteins of the G5 family. Novel mouse model. CNO-treatment that selectively activated 13-cell Gq111 increased first and second phase insulin release, greatly improved glucose tolerance in high-fat diet obese insulin-resistant mice, and increased 13-cell mass. 2022-11-30 2024-10-28 2024-10-28 2022-11-30 2022-07-22 ACETYLCHOLINE, ACTIVATED, Beta, Cell, Conditionally, ISLET, Listed LPM Greene as of 4/15/2015, M3, Mice, MUSCARINIC, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, RECEPTOR, TRANSGENIC, VFXXXX, VPXXXX, WIXXXX False True True NIHTT 37470483 Website Abstract 114172942 Guettier J-M, Gautam D, et al. https://pubmed.ncbi.nlm.nih.gov/19858481/ <a href="https://pubmed.ncbi.nlm.nih.gov/19858481/">Guettier J-M, Gautam D, et al.</a> 114111532 Wess, Jurgen National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Wess, Jurgen (NIDDK) 1 114111532 Wess, Jurgen National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Wess, Jurgen (NIDDK) 1 114102878 Transgenic Mice With Conditionally Activated Islet Beta Cell M3 Muscarinic Acetylcholine Receptor E-454-2013-0 Research Material National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83739550 Shastri, Mythreyi shastrim@mail.nih.gov
United States of America Technology Advancement Office shastrim@mail.nih.gov?subject=Web Inquiry on [TAB-3775] Transgenic Mice with Conditionally Activated Islet Beta Cell M3 Muscarinic Acetylcholine Receptor for Improving Glucose Tolerance in High-fat Diet Obese Insulin-resistant Mice&body=Please send me information about technology [TAB-3775] Transgenic Mice with Conditionally Activated Islet Beta Cell M3 Muscarinic Acetylcholine Receptor for Improving Glucose Tolerance in High-fat Diet Obese Insulin-resistant Mice. Shastri, Mythreyi<br><a href="mailto:shastrim@mail.nih.gov?subject=Web Inquiry on [TAB-3775] Transgenic Mice with Conditionally Activated Islet Beta Cell M3 Muscarinic Acetylcholine Receptor for Improving Glucose Tolerance in High-fat Diet Obese Insulin-resistant Mice&body=Please send me information about technology [TAB-3775] Transgenic Mice with Conditionally Activated Islet Beta Cell M3 Muscarinic Acetylcholine Receptor for Improving Glucose Tolerance in High-fat Diet Obese Insulin-resistant Mice.">shastrim@mail.nih.gov</a><br> 114129564 VFXXXX 114129565 VPXXXX 114129566 WIXXXX 114155299 TRANSGENIC 114155300 Mice 114155301 Conditionally 114155302 ACTIVATED 114155303 ISLET 114155304 Beta 114155305 Cell 114155306 M3 114155307 MUSCARINIC 114155308 ACETYLCHOLINE 114155309 RECEPTOR 114155310 Listed LPM Greene as of 4/15/2015 114155311 Pre LPM working set 20150418 114155312 Post LPM Assignment Set 20150420 TAB-3771 114097622 Adenosine Receptor Binding Compounds with Subtype and Functional Selectivity for Therapeutic Development NIDDK Therapeutics Therapeutics Ruben Abagyan, Kenneth Jacobson, Vsevolod Katritch, Dilip Tosh This technology includes adenosine receptor binding compounds which could potentially be used for development of more selective and safe treatment of cardiovascular, psychiatric and neurodegenerative disorders. Though adenosine has been extensively studied as a primary chemical scaffold for adenosine receptor agonists, very little structure activity data exist for C5' substitution. This technology presents novel rationally designed small molecule compounds capable of selective binding to adenosine receptor (subtypes A2a, A1, A2b and A3) and inducing effector-biased downstream signaling. High resolution crystal structure of Adenosine A2 receptor (AA2AR) in complex with agonist UK-432097 makes possible rational design of small molecules specifically targeting C5' substitutions of the agonist ribose ring, making possible more high affinity and subtype selective binding and potentially ligand specific modulation of adenosine receptor function. The final set of candidate compounds was selected by their synthetic feasibility and drug-likeness. The selected substitutions are expected to work by engaging new polar contacts with residues in TM helix 5, potentially changing signaling properties of new agonists. High resolution crystal structure makes possible rational design of small molecules specifically targeting C5' substitutions of the agonist ribose ring, making possible more high affinity and subtype selective binding and potentially ligand specific modulation of adenosine receptor function. Therapeutics for cardiovascular, psychiatric and neurodegenerative disorders. 2022-11-30 2024-10-28 2024-10-28 2022-11-30 2022-07-22 ADENOSINE, BINDING, compounds, FUNCTIONAL, Listed LPM Tong as of 4/15/2015, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, RECEPTOR, SELECTIVITY, Subtype, WKXXXX False True True NIHTT 37470483 Website Abstract 114172933 Kiesman W, Elzein E, et al. https://pubmed.ncbi.nlm.nih.gov/19639278/ <a href="https://pubmed.ncbi.nlm.nih.gov/19639278/">Kiesman W, Elzein E, et al.</a> 114172934 Kalla R, Zablocki J, et al. https://pubmed.ncbi.nlm.nih.gov/19639280/ <a href="https://pubmed.ncbi.nlm.nih.gov/19639280/">Kalla R, Zablocki J, et al.</a> 114172935 Jacobson K, Klutz A, et al. https://pubmed.ncbi.nlm.nih.gov/19639281/ <a href="https://pubmed.ncbi.nlm.nih.gov/19639281/">Jacobson K, Klutz A, et al.</a> 114172936 Cristalli G, Muller C, et al. https://pubmed.ncbi.nlm.nih.gov/19639279/ <a href="https://pubmed.ncbi.nlm.nih.gov/19639279/">Cristalli G, Muller C, et al.</a> 114111520 Abagyan, Ruben University of California, San Diego Abagyan, Ruben 0 114111521 Jacobson, Kenneth National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Jacobson, Kenneth (NIDDK) 0 114111522 Tosh, Dilip National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Tosh, Dilip (NIDDK) 0 114111519 Katritch, Vsevolod University of California, San Diego Katritch, Vsevolod 1 114111519 Katritch, Vsevolod University of California, San Diego Katritch, Vsevolod 1 114111520 Abagyan, Ruben University of California, San Diego Abagyan, Ruben 0 114111521 Jacobson, Kenneth National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Jacobson, Kenneth (NIDDK) 0 114111522 Tosh, Dilip National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Tosh, Dilip (NIDDK) 0 114102874 Adenosine Receptor Binding Compounds With Subtype And Functional Selectivity E-232-2012-0 Filing authorized National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), University of California, San Diego 83692066 Tong, Betty tongb@niddk.nih.gov
United States of America Senior Technology Advancement Office tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-3771] Adenosine Receptor Binding Compounds with Subtype and Functional Selectivity for Therapeutic Development&body=Please send me information about technology [TAB-3771] Adenosine Receptor Binding Compounds with Subtype and Functional Selectivity for Therapeutic Development. Tong, Betty<br><a href="mailto:tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-3771] Adenosine Receptor Binding Compounds with Subtype and Functional Selectivity for Therapeutic Development&body=Please send me information about technology [TAB-3771] Adenosine Receptor Binding Compounds with Subtype and Functional Selectivity for Therapeutic Development.">tongb@niddk.nih.gov</a><br> 114129551 WKXXXX 114155247 ADENOSINE 114155248 RECEPTOR 114155249 BINDING 114155250 compounds 114155251 Subtype 114155252 FUNCTIONAL 114155253 SELECTIVITY 114155254 Listed LPM Tong as of 4/15/2015 114155255 Pre LPM working set 20150418 114155256 Post LPM Assignment Set 20150420 TAB-3772 114097623 Vectors for the Treatment of Sickle Cell Disease and Beta Thalassemia NIDDK Cardiology, Dental, Endocrinology, Infectious Disease, Neurology, Oncology, Ophthalmology, Therapeutics Cardiology Dental Endocrinology Infectious Disease Neurology Oncology Ophthalmology Therapeutics Colleen Byrnes, Yuanwei Lee, Jeffery Miller, Jaira Vasconcellos This technology includes lentivirus vectors to be used to treat sickle cell disease and beta thalassemia. (i) Lin28A or Lin28B vectors designed for erythroid-specific expression using EKLF1, SPTA1, or similar erythroid-specific regulatory elements will be used to transduce hematopoietic stem cells isolated from humans with sickle cell disease or beta-thalassemia syndromes. (ii) Lentiviral vectors or other means of delivery for tough decoy inhibitors or other means of reducing the expression of the most critical Let-7 mRNA will be used to transduce hematopoietic stem cells isolated from humans with sickle cell disease or beta-thalassemia syndromes. Cells that have received the genetic modifications can be reinfused into the same patient (autologous transfusion), after which they home to the bone marrow and persist. These vectors will also be combined with other drugs or approaches to modify or increase globin gene or protein expression via alternate mechanisms in order to achieve additive or synergistic effects. Potential life-long therapy for sickle cell disease and beta thalassemia with a single autologous transfusion of corrected erythrocytes expressing therapeutic levels of HbF. Treatment for sickle cell disease and beta thalassemia. 2022-11-30 2024-10-28 2024-10-28 2022-11-30 2022-07-22 Erythroid, Expression, FETAL, fetal hemoglobin, Gene, GLOBIN, Lentivirus, Let-7, Lin28, Listed LPM Contreras as of 4/15/2015, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, PROMOTERS, red blood cells, tough decoy, vectors, VMXXXX, VPXXXX, WJXXXX, XEXXXX, YAXXXX, YBXXXX, YCXXXX False True True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114172937 Vasconcellos J, Fasano R, et al. https://pubmed.ncbi.nlm.nih.gov/25188417/ <a href="https://pubmed.ncbi.nlm.nih.gov/25188417/">Vasconcellos J, Fasano R, et al.</a> 114111524 Lee, Yuanwei National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Lee, Yuanwei (NIDDK) 0 114111525 Vasconcellos, Jaira National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Vasconcellos, Jaira (NIDDK) 0 114111526 Byrnes, Colleen National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Byrnes, Colleen (NIDDK) 0 114111523 Miller, Jeffery National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Miller, Jeffery (NIDDK) 1 114111523 Miller, Jeffery National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Miller, Jeffery (NIDDK) 1 114111524 Lee, Yuanwei National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Lee, Yuanwei (NIDDK) 0 114111525 Vasconcellos, Jaira National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Vasconcellos, Jaira (NIDDK) 0 114111526 Byrnes, Colleen National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Byrnes, Colleen (NIDDK) 0 114102875 LIN28 EXPRESSING LENTIVIRUS VECTORS WITH ERYTHROID PROMOTERS THAT ARE ACTIVE PRIOR TO THE MANIFESTATION OF HIGH-LEVEL GLOBIN GENE EXPRESSION E-249-2014-0 Filing authorized National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83698007 Rooke, Agnes rookeab@mail.nih.gov
United States of America Technology Advancement Office rookeab@mail.nih.gov?subject=Web Inquiry on [TAB-3772] Vectors for the Treatment of Sickle Cell Disease and Beta Thalassemia&body=Please send me information about technology [TAB-3772] Vectors for the Treatment of Sickle Cell Disease and Beta Thalassemia. Rooke, Agnes<br><a href="mailto:rookeab@mail.nih.gov?subject=Web Inquiry on [TAB-3772] Vectors for the Treatment of Sickle Cell Disease and Beta Thalassemia&body=Please send me information about technology [TAB-3772] Vectors for the Treatment of Sickle Cell Disease and Beta Thalassemia.">rookeab@mail.nih.gov</a><br> 114169605 E-249-2014-0 E-249-2014-0-US-01 LIN28 EXPRESSING LENTIVIRUS VECTORS WITH ERYTHROID PROMOTERS AND KNOCKDOWN OF LET-7 MICRO RNAS TO INCREASE FETAL HEMOGLOBIN PRODUCTION PRV US 62/046,247 Abandoned US <br />Provisional (PRV) 62/046,247<br />Filed on 2014-09-05<br />Status: Abandoned 114129552 VMXXXX 114129553 VPXXXX 114129554 WJXXXX 114129555 XEXXXX 114129556 YAXXXX 114129557 YBXXXX 114129558 YCXXXX 114155257 Lin28 114155258 Lentivirus 114155259 vectors 114155260 Erythroid 114155261 PROMOTERS 114155262 GLOBIN 114155263 Gene 114155264 Expression 114155265 fetal hemoglobin 114155266 FETAL 114155267 Let-7 114155268 red blood cells 114155269 tough decoy 114155270 Listed LPM Contreras as of 4/15/2015 114155271 Pre LPM working set 20150418 114155272 Post LPM Assignment Set 20150420 TAB-3769 114097620 Clinical Model for Predicting Kidney Failure NIDDK Diagnostics, Research Materials Diagnostics Research Materials Eric Elster, Roslyn Mannon This technology includes a model for providing a patient-specific diagnosis of disease using clinical data. Specifically, the present invention relates to a fully unsupervised, machine-learned, cross-validated, and dynamic Bayesian Belief Network model that utilizes clinical parameters for determining a patient-specific probability of transplant glomerulopathy. Kidney failure is a growing problem worldwide, in part related to the increase incidence of diabetes and hypertension. Renal replacement therapy includes dialysis or renal transplantation. The average lifespan of a kidney transplant is about 10 years and graft loss may be due to both patient death as well as primary graft failure mediated by an entity known as transplant glomerulopathy ("chronic rejection"). Understanding the determinants of this disease would lead to new treatments and biomarkers of disease. This invention provides a method to predict the diagnosis based on clinical parameters. Thus, more accurate diagnosis and prediction of disease will help in patient management. First model of its kind to predict transplant glomerulopathy. Used in clinical practice to predict transplant glomerulopathy. 2022-11-30 2024-10-28 2024-10-28 2022-11-30 2022-07-22 Clinical, Dataprobability, Diagnosis, Disease, Glomerulopathy, Listed LPM Ano as of 4/15/2015, Model, Patient-specific, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, PROVIDING, TRANSPLANT, WBXXXX, WIXXXX False True True NIHTT 37470483 Website Abstract 114172932 Elster E, Hawksworth J, et al. https://pubmed.ncbi.nlm.nih.gov/20688906/ <a href="https://pubmed.ncbi.nlm.nih.gov/20688906/">Elster E, Hawksworth J, et al.</a> 114111514 Mannon, Roslyn University of Alabama Mannon, Roslyn 0 114111515 Elster, Eric Navy Medical Research Center (NMRC) Elster, Eric 1 114111515 Elster, Eric Navy Medical Research Center (NMRC) Elster, Eric 1 114111514 Mannon, Roslyn University of Alabama Mannon, Roslyn 0 114102872 Model For Providing A Patient-specific Diagnosis Of Disease Using Clinical Dataprobability Of Transplant Glomerulopathy E-219-2011-0 Filing authorized National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Navy Medical Research Center (NMRC) 83692066 Tong, Betty tongb@niddk.nih.gov
United States of America Senior Technology Advancement Office tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-3769] Clinical Model for Predicting Kidney Failure&body=Please send me information about technology [TAB-3769] Clinical Model for Predicting Kidney Failure. Tong, Betty<br><a href="mailto:tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-3769] Clinical Model for Predicting Kidney Failure&body=Please send me information about technology [TAB-3769] Clinical Model for Predicting Kidney Failure.">tongb@niddk.nih.gov</a><br> 114169604 E-219-2011-0 E-219-2011-0-US-01 SURROGATE MARKERS AND BAYESIAN MODELING OF WOUND HEALING PRV US 61/105,786 Abandoned US <br />Provisional (PRV) 61/105,786<br />Filed on 2008-10-15<br />Status: Abandoned 114129547 WBXXXX 114129548 WIXXXX 114155230 Model 114155231 Glomerulopathy 114155232 TRANSPLANT 114155233 Dataprobability 114155234 Clinical 114155235 Disease 114155236 Diagnosis 114155237 Patient-specific 114155238 PROVIDING 114155239 Listed LPM Ano as of 4/15/2015 114155240 Pre LPM working set 20150418 114155241 Post LPM Assignment Set 20150420 TAB-3770 114097621 Methanocarba-7-Deazaadenosine Analogues as Inhibitors of Adenosine Kinase for the Prevention of Seizures NIDDK Neurology, Therapeutics Neurology Therapeutics Detlev Boison, Kenneth Jacobson, Kiran Toti This technology includes new nucleoside inhibitors containing rigid rings that provide high potency for use as antiepileptic drugs. Adenosine kinase (AdK) inhibitors raise the level of endogenous adenosine, particularly in disease states, and are of interest for the potential treatment of seizures and neurodegenerative and inflammatory conditions. This is a new concept in treatment with a focus on suppressing epileptogenesis by inhibiting AdK in the brain. Antiepileptic drugs to prevent seizures. 2022-11-30 2024-10-28 2024-10-28 2022-11-30 2022-07-22 ADENOSINE, ANALOGUES, Inhibitors, Kinase, Methanocarba-7-Deazaadenosine, VEXXXX, WKXXXX False True True NIHTT 37470483 Website Abstract 114111517 Boison, Detlev Robert S. Dow Neurobiology Laboratories Boison, Detlev 0 114111518 Toti, Kiran National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Toti, Kiran (NIDDK) 0 114111516 Jacobson, Kenneth National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Jacobson, Kenneth (NIDDK) 1 114111516 Jacobson, Kenneth National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Jacobson, Kenneth (NIDDK) 1 114111517 Boison, Detlev Robert S. Dow Neurobiology Laboratories Boison, Detlev 0 114111518 Toti, Kiran National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Toti, Kiran (NIDDK) 0 114102873 Methanocarba-7-Deazaadenosine Analogues As Inhibitors Of Adenosine Kinase E-226-2017-0 Filing authorized National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Robert S. Dow Neurobiology Laboratories 83692066 Tong, Betty tongb@niddk.nih.gov
United States of America Senior Technology Advancement Office tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-3770] Methanocarba-7-Deazaadenosine Analogues as Inhibitors of Adenosine Kinase for the Prevention of Seizures&body=Please send me information about technology [TAB-3770] Methanocarba-7-Deazaadenosine Analogues as Inhibitors of Adenosine Kinase for the Prevention of Seizures. Tong, Betty<br><a href="mailto:tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-3770] Methanocarba-7-Deazaadenosine Analogues as Inhibitors of Adenosine Kinase for the Prevention of Seizures&body=Please send me information about technology [TAB-3770] Methanocarba-7-Deazaadenosine Analogues as Inhibitors of Adenosine Kinase for the Prevention of Seizures.">tongb@niddk.nih.gov</a><br> 114129549 VEXXXX 114129550 WKXXXX 114155242 Methanocarba-7-Deazaadenosine 114155243 ANALOGUES 114155244 Inhibitors 114155245 ADENOSINE 114155246 Kinase TAB-3767 114097618 Figla-Cre Transgenic Mice Expressing Myristoylated EGFP in Germ Cells as a Model for Investigating Perinatal Oocyte Dynamics NIDDK Cardiology, Dental, Endocrinology, Infectious Disease, Oncology, Ophthalmology, Research Materials, Therapeutics Cardiology Dental Endocrinology Infectious Disease Oncology Ophthalmology Research Materials Therapeutics Jurrien Dean, Ruei-Shiuan Lin This technology includes a transgenic mouse model which can be used to study perinatal oocyte dynamics. In the first two days after birth, the number of primordial ovarian follicles and their germ cells undergo a major decrease. The mechanism for this decrease was studied. Ablation of FIGLA (Factor in the germline, alpha), a basic helix-loop-transcription factor, results in massive perinatal oocyte loss. A transgenic mouse line was established, Figla-EGFP /Cre, in which EGFP and Cre recombinase are expressed just before birth in germ cells. When Figla-EGFP /Cre mice were crossed with mTomato/mEGFP (where m = myristoylated) mice, red Tomato was excised in germ cells, and EGFP fluorescence was observed in both cytosol and on the plasma membrane. Somatic cells remained red because mTomato continued to be expressed. Results indicate that oocyte loss is due to caspase-dependent apoptosis, rather than autophagy or exit. Novel mouse model Research surrounding perinatal oocyte dynamics 2022-11-30 2024-10-28 2024-10-28 2022-11-30 2022-07-22 BGFP, Cells, DYNAMICS, Expressing, Figla-Cre, GERM, INVESTIGATING, Listed LPM Nguyen-Antczak as of 4/15/2015, Mice, Model, Myristoylated, OOCYTE, Perinataly, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, PROVIDE, TRANSGENIC, VPXXXX, WIXXXX, XEXXXX False True True NIHTT 37470483 Website Abstract 114172930 Lin R-S, Jimenez-Movilla M, et al. https://pubmed.ncbi.nlm.nih.gov/24400092/ <a href="https://pubmed.ncbi.nlm.nih.gov/24400092/">Lin R-S, Jimenez-Movilla M, et al.</a> 114111510 Lin, Ruei-Shiuan MindSpec Lin, Ruei-Shiuan 0 114111509 Dean, Jurrien National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Dean, Jurrien (NIDDK) 1 114111509 Dean, Jurrien National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Dean, Jurrien (NIDDK) 1 114111510 Lin, Ruei-Shiuan MindSpec Lin, Ruei-Shiuan 0 114102870 Figla-Cre Transgenic Mice Expressing Myristoylated BGFP In Germ Cells Provide A Model For Investigating Perinataly Oocyte Dynamics E-217-2014-0 Research Material National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83728636 Buller, Carolyn carolyn.buller@nih.gov
United States of America Technology Advancement Office carolyn.buller@nih.gov?subject=Web Inquiry on [TAB-3767] Figla-Cre Transgenic Mice Expressing Myristoylated EGFP in Germ Cells as a Model for Investigating Perinatal Oocyte Dynamics&body=Please send me information about technology [TAB-3767] Figla-Cre Transgenic Mice Expressing Myristoylated EGFP in Germ Cells as a Model for Investigating Perinatal Oocyte Dynamics. Buller, Carolyn<br><a href="mailto:carolyn.buller@nih.gov?subject=Web Inquiry on [TAB-3767] Figla-Cre Transgenic Mice Expressing Myristoylated EGFP in Germ Cells as a Model for Investigating Perinatal Oocyte Dynamics&body=Please send me information about technology [TAB-3767] Figla-Cre Transgenic Mice Expressing Myristoylated EGFP in Germ Cells as a Model for Investigating Perinatal Oocyte Dynamics.">carolyn.buller@nih.gov</a><br> 114129542 VPXXXX 114129543 WIXXXX 114129544 XEXXXX 114155198 Figla-Cre 114155199 TRANSGENIC 114155200 Mice 114155201 Expressing 114155202 Myristoylated 114155203 BGFP 114155204 GERM 114155205 Cells 114155206 PROVIDE 114155207 Model 114155208 INVESTIGATING 114155209 Perinataly 114155210 OOCYTE 114155211 DYNAMICS 114155212 Listed LPM Nguyen-Antczak as of 4/15/2015 114155213 Pre LPM working set 20150418 114155214 Post LPM Assignment Set 20150420 TAB-3768 114097619 MiR-193b and MiR-365-1 are Not Required for the Development and Function of Brown Fat in the Mouse NIDDK Research Materials, Therapeutics Research Materials Therapeutics Kenneth Jacobson, Daniela Salvemini, Dilip Tosh This technology includes the discovery that two specific microRNAs are not required for the development and function of brown fat in mice. Effects of inactivating microRNAs in cell culture in vitro have not always been reproduced in vivo. The paper tests the effect of inactivating two microRNAs, miR-193b and miR-365-1 on the differentiation, function and development of brown adipose tissue. In contrast to positive results previously observed in vitro, the mouse in vivo studies failed to demonstrate significant effects. First discovery of its kind. N/A 2022-11-30 2024-10-28 2024-10-28 2022-11-30 2022-07-22 2-Arylethynyl, A3, ADENOSINE, AGONISTS, Chronic, Focus, Listed LPM Tong as of 4/15/2015, Neuropathic, Pain:, PHENOTYPIC, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, screening, Subsititution, TREATING, WIXXXX, XEXXXX False True True NIHTT 37470483 Website Abstract 114172931 Feuermann Y, Kang K, et al. https://pubmed.ncbi.nlm.nih.gov/24356587/ <a href="https://pubmed.ncbi.nlm.nih.gov/24356587/">Feuermann Y, Kang K, et al.</a> 114111511 Salvemini, Daniela Saint Louis University School of Medicine Salvemini, Daniela 0 114111512 Tosh, Dilip National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Tosh, Dilip (NIDDK) 0 114111513 Jacobson, Kenneth National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Jacobson, Kenneth (NIDDK) 1 114111513 Jacobson, Kenneth National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Jacobson, Kenneth (NIDDK) 1 114111511 Salvemini, Daniela Saint Louis University School of Medicine Salvemini, Daniela 0 114111512 Tosh, Dilip National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Tosh, Dilip (NIDDK) 0 152358746 MiR-193b And MiR-365-1 Are Not Required For The Development And Function Of Brown Fat In The Mouse E-218-2014-0 Research Material National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83692066 Tong, Betty tongb@niddk.nih.gov
United States of America Senior Technology Advancement Office tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-3768] MiR-193b and MiR-365-1 are Not Required for the Development and Function of Brown Fat in the Mouse&body=Please send me information about technology [TAB-3768] MiR-193b and MiR-365-1 are Not Required for the Development and Function of Brown Fat in the Mouse. Tong, Betty<br><a href="mailto:tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-3768] MiR-193b and MiR-365-1 are Not Required for the Development and Function of Brown Fat in the Mouse&body=Please send me information about technology [TAB-3768] MiR-193b and MiR-365-1 are Not Required for the Development and Function of Brown Fat in the Mouse.">tongb@niddk.nih.gov</a><br> 114169603 E-210-2014-0 E-210-2014-0-US-01 A3 Adenosine Receptor Agonists PRV US 62/033,723 Abandoned US <br />Provisional (PRV) 62/033,723<br />Filed on 2014-08-06<br />Status: Abandoned 114129545 WIXXXX 114129546 XEXXXX 114155215 PHENOTYPIC 114155216 screening 114155217 TREATING 114155218 Chronic 114155219 Neuropathic 114155220 Pain: 114155221 Focus 114155222 2-Arylethynyl 114155223 Subsititution 114155224 A3 114155225 ADENOSINE 114155226 AGONISTS 114155227 Listed LPM Tong as of 4/15/2015 114155228 Pre LPM working set 20150418 114155229 Post LPM Assignment Set 20150420 TAB-3765 114097616 Eukaryotic Transposase Mutants and Transposon End Compositions for Modifying Nucleic Acids and Methods for Production and Use in the Generation of Sequencing Libraries NIDDK Diagnostics, Research Materials, Therapeutics Diagnostics Research Materials Therapeutics Nancy Craig, Frederick Dyda, Sunil Gangadharan, Allison Hickman This technology includes novel hyperactive Hermes Transposase mutants and their encoding genes. These transposases are easily purified in large quantity after expression in bacteria. The modified Hermes Transposases are soluble and stable and exist as smaller active complexes compared to the native enzyme. The consensus target DNA recognition sequence is the same as the native enzyme and shows minimal insertional sequence bias. These properties are especially useful in whole genome sequencing applications that involve sample DNA preparation requiring simultaneous fragmentation and attachment of custom sequences to the ends of the fragments. Methods and compositions using these transposases in fragmentation and 5' end-tagging are also disclosed. <ul><li>The transposases described in this invention have a similar mechanism of action as the wild type, can easily be expressed in the bacterium, E. coli and purified in large quantities.</li> <li>The modified Hermes Transposases have a higher transposition activity in vitro than the wild type transposase.</li> <li>The modified Hermes Transposase has less insertional sequence bias when used for in vitro fragmentation of genomic DNA and 51 end tagging followed by next generation sequencing.</li></ul> Production and use in the generation of sequencing libraries. 2022-11-30 2024-10-28 2024-10-28 2022-11-30 2022-07-13 AC5BXX, AC5XXX, Acids, ACXXXX, Compositions, End, EUKARYOTIC, Generation, IXXXXX, Libraries, Listed LPM Nguyen-Antczak as of 4/15/2015, Methods, Modifying, Mutants, Nucleic, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, production, sequencing, Transposase, Transposon, WIXXXX, XEXXXX False True True NIHTT 37470483 Website Abstract 114172928 Hickman A, Perez Z, et al. https://pubmed.ncbi.nlm.nih.gov/16041385/ <a href="https://pubmed.ncbi.nlm.nih.gov/16041385/">Hickman A, Perez Z, et al.</a> 114172929 Gangadharan S, Mularoni L, et al. https://pubmed.ncbi.nlm.nih.gov/21131571/ <a href="https://pubmed.ncbi.nlm.nih.gov/21131571/">Gangadharan S, Mularoni L, et al.</a> 114111503 Gangadharan, Sunil Johns Hopkins School of Medicine Gangadharan, Sunil 0 114111504 Dyda, Frederick National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Dyda, Frederick (NIDDK) 0 114111505 Hickman, Allison National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Hickman, Allison (NIDDK) 0 114111502 Craig, Nancy Johns Hopkins School of Medicine Craig, Nancy 1 114111502 Craig, Nancy Johns Hopkins School of Medicine Craig, Nancy 1 114111503 Gangadharan, Sunil Johns Hopkins School of Medicine Gangadharan, Sunil 0 114111504 Dyda, Frederick National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Dyda, Frederick (NIDDK) 0 114111505 Hickman, Allison National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Hickman, Allison (NIDDK) 0 114102868 Eukaryotic Transposase Mutants And Transposon End Compositions For Modifying Nucleic Acids And Methods For Production And Use In The Generation Of Sequencing Libraries E-194-2012-0 Filing authorized Johns Hopkins School of Medicine, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83692066 Tong, Betty tongb@niddk.nih.gov
United States of America Senior Technology Advancement Office tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-3765] Eukaryotic Transposase Mutants and Transposon End Compositions for Modifying Nucleic Acids and Methods for Production and Use in the Generation of Sequencing Libraries&body=Please send me information about technology [TAB-3765] Eukaryotic Transposase Mutants and Transposon End Compositions for Modifying Nucleic Acids and Methods for Production and Use in the Generation of Sequencing Libraries. Tong, Betty<br><a href="mailto:tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-3765] Eukaryotic Transposase Mutants and Transposon End Compositions for Modifying Nucleic Acids and Methods for Production and Use in the Generation of Sequencing Libraries&body=Please send me information about technology [TAB-3765] Eukaryotic Transposase Mutants and Transposon End Compositions for Modifying Nucleic Acids and Methods for Production and Use in the Generation of Sequencing Libraries.">tongb@niddk.nih.gov</a><br> 114169597 E-194-2012-0 E-194-2012-0-US-01 Eukaryotic Transposase Mutants And Transposon End Compositions For Modifying Nucleic Acids And Methods For Production And Use In The Generation Of Sequencing Libraries PRV US 61/652,560 Abandoned US <br />Provisional (PRV) 61/652,560<br />Filed on 2012-05-29<br />Status: Abandoned 114169598 E-194-2012-0 E-194-2012-0-PCT-02 EUKARYOTIC TRANSPOSASE MUTANTS AND TRANSPOSON END COMPOSITIONS FOR MODIFYING NUCLEIC ACIDS AND METHODS FOR PRODUCTION AND USE IN THE GENERATION OF SEQUENCING LIBRARIES PCT Patent Cooperation Treaty PCT/US2013/043138 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2013/043138<br />Filed on 2013-05-29<br />Status: Expired 114169599 E-194-2012-0 E-194-2012-0-US-03 Eukaryotic Transposase Mutants And Transposon End Compositions For Modifying Nucleic Acids And Methods For Production And Use In The Generation Of Sequencing Libraries National Stage US 14/403,506 Abandoned US <br />National Stage 14/403,506<br />Filed on 2014-11-24<br />Status: Abandoned 114129534 IXXXXX 114129535 ACXXXX 114129536 AC5XXX 114129537 AC5BXX 114129538 WIXXXX 114129539 XEXXXX 114155166 EUKARYOTIC 114155167 Transposase 114155168 Mutants 114155169 Transposon 114155170 End 114155171 Compositions 114155172 Modifying 114155173 Nucleic 114155174 Acids 114155175 Methods 114155176 production 114155177 Generation 114155178 sequencing 114155179 Libraries 114155180 Listed LPM Nguyen-Antczak as of 4/15/2015 114155181 Pre LPM working set 20150418 114155182 Post LPM Assignment Set 20150420 TAB-3766 114097617 Phenotypic Screening for Treating Chronic Neuropathic Pain: Focus on 2-Arylethynyl Substitution of A3 Adenosine Agonists NIDDK Neurology, Therapeutics Neurology Therapeutics Kenneth Jacobson, Daniela Salvemini, Dilip Tosh This technology includes (N)-methanocarba derivatives that are selective agonists of the A3 receptor to be used for the treatment of chronic neuropathic pain. This class of compounds produced full agonists of the human A3AR of nanomolar affinity that were consistently highly selective (>1000-fold vs. A1AR and A2AAR). The selectivity at mouse A3 receptors is smaller, but the compounds are still effective in vivo in reducing or preventing development of neuropathic pain. We have carried out phenotypic screening – thus we have identified unexpected in vivo activity of specific C2 substituents in a chronic neuropathic pain model. The advantages over similar structures are a smaller molecular weight, and therefore greater oral bioavailability. Treatment of chronic neuropathic pain 2022-11-30 2024-10-28 2024-10-28 2022-11-30 2022-07-13 2-Arylethynyl, A3, ADENOSINE, AGONISTS, Chronic, Focus, Listed LPM Tong as of 4/15/2015, Neuropathic, Pain:, PHENOTYPIC, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, screening, Subsititution, TREATING, VMXXXX, WKXXXX False True True NIHTT 37470483 Website Abstract 114111506 Salvemini, Daniela Saint Louis University School of Medicine Salvemini, Daniela 0 114111507 Tosh, Dilip National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Tosh, Dilip (NIDDK) 0 114111508 Jacobson, Kenneth National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Jacobson, Kenneth (NIDDK) 1 114111508 Jacobson, Kenneth National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Jacobson, Kenneth (NIDDK) 1 114111506 Salvemini, Daniela Saint Louis University School of Medicine Salvemini, Daniela 0 114111507 Tosh, Dilip National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Tosh, Dilip (NIDDK) 0 114102869 Phenotypic Screening For Treating Chronic Neuropathic Pain: Focus On 2-Arylethynyl Subsititution Of A3 Adenosine Agonists E-210-2014-0 Filing authorized National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Saint Louis University School of Medicine 83692066 Tong, Betty tongb@niddk.nih.gov
United States of America Senior Technology Advancement Office tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-3766] Phenotypic Screening for Treating Chronic Neuropathic Pain: Focus on 2-Arylethynyl Substitution of A3 Adenosine Agonists&body=Please send me information about technology [TAB-3766] Phenotypic Screening for Treating Chronic Neuropathic Pain: Focus on 2-Arylethynyl Substitution of A3 Adenosine Agonists. Tong, Betty<br><a href="mailto:tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-3766] Phenotypic Screening for Treating Chronic Neuropathic Pain: Focus on 2-Arylethynyl Substitution of A3 Adenosine Agonists&body=Please send me information about technology [TAB-3766] Phenotypic Screening for Treating Chronic Neuropathic Pain: Focus on 2-Arylethynyl Substitution of A3 Adenosine Agonists.">tongb@niddk.nih.gov</a><br> 114169600 E-210-2014-0 E-210-2014-0-US-01 A3 Adenosine Receptor Agonists PRV US 62/033,723 Abandoned US <br />Provisional (PRV) 62/033,723<br />Filed on 2014-08-06<br />Status: Abandoned 114129540 VMXXXX 114129541 WKXXXX 114155183 PHENOTYPIC 114155184 screening 114155185 TREATING 114155186 Chronic 114155187 Neuropathic 114155188 Pain: 114155189 Focus 114155190 2-Arylethynyl 114155191 Subsititution 114155192 A3 114155193 ADENOSINE 114155194 AGONISTS 114155195 Listed LPM Tong as of 4/15/2015 114155196 Pre LPM working set 20150418 114155197 Post LPM Assignment Set 20150420 TAB-3763 114097614 A Cell Line Secreting an IgG Monoclonal Antibody to Mouse ZP2 for the Study of Anti-Psychotic Therapies NIDDK Antibodies, Immunology, Neurology, Psychiatry/Mental Health, Research Materials Antibodies Immunology Neurology Psychiatry/Mental Health Research Materials Jongrye Jeon, Jurgen Wess This technology includes a cell line to be used for the study of anti-psychotic therapies and potentially Parkinson’s disease. Activation of D1 dopamine receptors plays a critical role in many fundamental CNS processes. M4 mAChRs are coexpressed with D1 dopamine receptors in a specific subset of striatal medium spiny neurons that contain GABA as the major neurotransmitter. The present study used Cre/LoxP technology to generate mutant mice that lack M4-¬-AChRs only in D1 dopamine receptor-¬-expressing cells to investigate the physiological relevance of mAChRs in this neuronal subpopulation. A floxed mouse M4 mAChRs mutant mouse strain was created, and mated with a mouse strain expressing Cre-¬-recombinase exclusively in cells expressing the D1 dopamine receptor (D1-¬-M4-¬-KO mice). D1-¬-M4-¬-KO mice exhibited increased locomotor stimulation induced by dopamine itself or psychostimulants such as amphetamines and cocaine, suggesting that the M4 receptor may play a role as an antipsychotic agent in schizophrenia; reduced cataleptic side effects of many anti-¬psychotic drugs and possibly Parkinson’s disease; increased dopamine efflux in the nucleus accumbens, suggesting that striatal M4 receptor activity inhibits the central dopaminergic reward system that contributes to addiction, and increased behavioral sensitization, suggesting that the M4 receptor might inhibit behavioral sensitization in addiction. The floxed M4 mAChR mouse may be mated with mice expressing the Cre recombinase in other specific cell types to specifically establish the role of the M4 mAChR. Modulation of D1 dopamine receptors by M4-¬-AChR may provide therapeutic options for the increased locomotor activity associated with schizophrenia and other psychotic disorders, behavioral sensitization and modulating the reward system for psychoactive drugs (drug abuse), and overcoming the catalepsy (rigidity) associated with Parkinson’s disease. 2022-11-30 2024-10-28 2024-10-28 2022-11-30 2022-07-13 ACETYLCHOLINE, BEHAVIORS, Dopamine-dependent, Floxed, floxedM4mAChR, Listed LPM Greene as of 4/15/2015, M4, MAChR, Modulates, Mouse, MUSCARINIC, NEURONAL, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, RECEPTORS, Subpopulation, VEXXXX, VNXXXX, WIXXXX, XAXXXX False True True NIHTT 37470483 Website Abstract 114172925 Jeon J, Dencker D, et al. https://pubmed.ncbi.nlm.nih.gov/20147565/ <a href="https://pubmed.ncbi.nlm.nih.gov/20147565/">Jeon J, Dencker D, et al.</a> 114111499 Jeon, Jongrye St. Jude Children's Research Hospital Jeon, Jongrye 0 114111498 Wess, Jurgen National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Wess, Jurgen (NIDDK) 1 114111498 Wess, Jurgen National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Wess, Jurgen (NIDDK) 1 114111499 Jeon, Jongrye St. Jude Children's Research Hospital Jeon, Jongrye 0 114102866 A Subpopulation Of Neuronal M4 Muscarinic Acetylcholine Receptors Modulates Dopamine-dependent Behaviors (floxed M4 MAChR Mouse) E-184-2014-0 Research Material National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83739550 Shastri, Mythreyi shastrim@mail.nih.gov
United States of America Technology Advancement Office shastrim@mail.nih.gov?subject=Web Inquiry on [TAB-3763] A Cell Line Secreting an IgG Monoclonal Antibody to Mouse ZP2 for the Study of Anti-Psychotic Therapies&body=Please send me information about technology [TAB-3763] A Cell Line Secreting an IgG Monoclonal Antibody to Mouse ZP2 for the Study of Anti-Psychotic Therapies. Shastri, Mythreyi<br><a href="mailto:shastrim@mail.nih.gov?subject=Web Inquiry on [TAB-3763] A Cell Line Secreting an IgG Monoclonal Antibody to Mouse ZP2 for the Study of Anti-Psychotic Therapies&body=Please send me information about technology [TAB-3763] A Cell Line Secreting an IgG Monoclonal Antibody to Mouse ZP2 for the Study of Anti-Psychotic Therapies.">shastrim@mail.nih.gov</a><br> 114129527 VEXXXX 114129528 VNXXXX 114129529 WIXXXX 114129530 XAXXXX 114155138 Subpopulation 114155139 NEURONAL 114155140 M4 114155141 MUSCARINIC 114155142 ACETYLCHOLINE 114155143 RECEPTORS 114155144 Modulates 114155145 Dopamine-dependent 114155146 BEHAVIORS 114155147 floxedM4mAChR 114155148 Floxed 114155149 MAChR 114155150 Mouse 114155151 Listed LPM Greene as of 4/15/2015 114155152 Pre LPM working set 20150418 114155153 Post LPM Assignment Set 20150420 TAB-3764 114097615 A Cell Line Secreting an IgG Monoclonal Antibody to Mouse ZP2 NIDDK Antibodies, Immunology, Research Materials Antibodies Immunology Research Materials Jurrien Dean, Iain East This technology includes a cell line secreting an IgG monoclonal antibody to mouse ZP2 which is useful to detect mouse ZP2 on immunoblot, immunohistology and immunoprecipitation, and prevents female fertility if administered IP in mice. Novel cell line. License use of monoclonal antibodies. 2022-11-30 2024-10-28 2024-10-28 2022-11-30 2022-07-13 ANTIBODY, CONTRACEPTIVE, DECOY, egg, Hybridoma, ID1XXX, IgG, monoclonal, Mouse, reproduction, Sperm, WIXXXX, XAXXXX, zona pellucida 2 protein, ZP2 False True True NIHTT 37470483 Website Abstract 114172926 East I, Dean J https://pubmed.ncbi.nlm.nih.gov/6699085/ <a href="https://pubmed.ncbi.nlm.nih.gov/6699085/">East I, Dean J</a> 114172927 East I, Mattison D, et al. https://pubmed.ncbi.nlm.nih.gov/6376213/ <a href="https://pubmed.ncbi.nlm.nih.gov/6376213/">East I, Mattison D, et al.</a> 114111501 East, Iain East, Iain 0 114111500 Dean, Jurrien National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Dean, Jurrien (NIDDK) 1 114111500 Dean, Jurrien National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Dean, Jurrien (NIDDK) 1 114111501 East, Iain East, Iain 0 114102867 A Cell Line Secreting An IgG Monoclonal Antibody To Mouse ZP2 Was Established By Standard Hybridoma Technology E-187-2016-0 Research Material National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83728636 Buller, Carolyn carolyn.buller@nih.gov
United States of America Technology Advancement Office carolyn.buller@nih.gov?subject=Web Inquiry on [TAB-3764] A Cell Line Secreting an IgG Monoclonal Antibody to Mouse ZP2&body=Please send me information about technology [TAB-3764] A Cell Line Secreting an IgG Monoclonal Antibody to Mouse ZP2. Buller, Carolyn<br><a href="mailto:carolyn.buller@nih.gov?subject=Web Inquiry on [TAB-3764] A Cell Line Secreting an IgG Monoclonal Antibody to Mouse ZP2&body=Please send me information about technology [TAB-3764] A Cell Line Secreting an IgG Monoclonal Antibody to Mouse ZP2.">carolyn.buller@nih.gov</a><br> 114129531 ID1XXX 114129532 WIXXXX 114129533 XAXXXX 114155154 IgG 114155155 monoclonal 114155156 ANTIBODY 114155157 Mouse 114155158 ZP2 114155159 Hybridoma 114155160 zona pellucida 2 protein 114155161 Sperm 114155162 egg 114155163 reproduction 114155164 CONTRACEPTIVE 114155165 DECOY TAB-3761 114097612 Truncated (N)-Methanocarba Nucleosides as Al Adenosine Receptor Agonists and Partial Agonists: Receptor Docking and Potent Anticonvulsant Activity for the Treatment of Various Conditions NIDDK Cardiology, Dental, Endocrinology, Infectious Disease, Neurology, Oncology, Ophthalmology, Psychiatry/Mental Health, Therapeutics Cardiology Dental Endocrinology Infectious Disease Neurology Oncology Ophthalmology Psychiatry/Mental Health Therapeutics Kenneth Jacobson, Dilip Tosh This technology includes A1AR-selective agonists which are full or partial agonists of the A1AR and are being considered for treatment of various conditions: seizures, stroke, diabetes, pain, cardio-protection and arrhythmias. A1AR agonists are highly neuroprotective in ischemic and epileptic models. A1AR agonists are also being explored for antidepressant, antianxiety, and other neuropsychiatric effects, due to their presynaptic action to decrease the release of excitatory amino acids in the brain. However, peripheral cardiovascular side effects have prevented the introduction of A1AR agonist for treating disorders of the central nervous system (CNS). This class of compounds produced some full agonists of the human A1AR of moderate affinity and selectivity (>10-fold vs. A2AAR and A3AR). For use in clinical diagnostics or therapeutically for the treatment of various conditions, such as stroke, epilepsy and pain. 2022-11-30 2024-10-28 2024-10-28 2022-11-30 2022-07-13 Activity, ADENOSINE, AGONISTS, Agonists:, Al, Anticonvulsant, Docking, Listed LPM Tong as of 4/15/2015, N-Methanocarba, Nucleosides, PARTIAL, Post LPM Assignment Set 20150420, POTENT, Pre LPM working set 20150418, RECEPTOR, TRUNCATED, VCXXXX, VEXXXX, VFXXXX, VMXXXX, VNXXXX, VPXXXX, WKXXXX False True True NIHTT 37470483 Website Abstract 114172924 Tosh D, Phan K, et al. https://pubmed.ncbi.nlm.nih.gov/21858244/ <a href="https://pubmed.ncbi.nlm.nih.gov/21858244/">Tosh D, Phan K, et al.</a> 114111495 Tosh, Dilip National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Tosh, Dilip (NIDDK) 0 114111494 Jacobson, Kenneth National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Jacobson, Kenneth (NIDDK) 1 114111494 Jacobson, Kenneth National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Jacobson, Kenneth (NIDDK) 1 114111495 Tosh, Dilip National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Tosh, Dilip (NIDDK) 0 114102864 Truncated (N)-Methanocarba Nucleosides As Al Adenosine Receptor Agonists And Partial Agonists: Receptor Docking And Potent Anticonvulsant Activity E-166-2012-0 Filing authorized National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83692066 Tong, Betty tongb@niddk.nih.gov
United States of America Senior Technology Advancement Office tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-3761] Truncated (N)-Methanocarba Nucleosides as Al Adenosine Receptor Agonists and Partial Agonists: Receptor Docking and Potent Anticonvulsant Activity for the Treatment of Various Conditions&body=Please send me information about technology [TAB-3761] Truncated (N)-Methanocarba Nucleosides as Al Adenosine Receptor Agonists and Partial Agonists: Receptor Docking and Potent Anticonvulsant Activity for the Treatment of Various Conditions. Tong, Betty<br><a href="mailto:tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-3761] Truncated (N)-Methanocarba Nucleosides as Al Adenosine Receptor Agonists and Partial Agonists: Receptor Docking and Potent Anticonvulsant Activity for the Treatment of Various Conditions&body=Please send me information about technology [TAB-3761] Truncated (N)-Methanocarba Nucleosides as Al Adenosine Receptor Agonists and Partial Agonists: Receptor Docking and Potent Anticonvulsant Activity for the Treatment of Various Conditions.">tongb@niddk.nih.gov</a><br> 114129513 VCXXXX 114129514 VEXXXX 114129515 VFXXXX 114129516 VMXXXX 114129517 VNXXXX 114129518 VPXXXX 114129519 WKXXXX 114155113 TRUNCATED 114155114 N-Methanocarba 114155115 Nucleosides 114155116 Al 114155117 ADENOSINE 114155118 RECEPTOR 114155119 AGONISTS 114155120 PARTIAL 114155121 Agonists: 114155122 Docking 114155123 POTENT 114155124 Anticonvulsant 114155125 Activity 114155126 Listed LPM Tong as of 4/15/2015 114155127 Pre LPM working set 20150418 114155128 Post LPM Assignment Set 20150420 TAB-3762 114097613 Sphingosine-1-phosphate 1 (S1P1) Receptor Signaling Mouse for Therapeutic Development NIDDK Cardiology, Dental, Endocrinology, Geriatrics, Immunology, Infectious Disease, Oncology, Ophthalmology, Research Materials, Therapeutics Cardiology Dental Endocrinology Geriatrics Immunology Infectious Disease Oncology Ophthalmology Research Materials Therapeutics Mari Kono, Richard Proia This technology includes a mouse model for studying SiP1 receptor signaling for development of therapeutics for a variety of conditions. The S1P1 receptor locus of the mouse has been modified by gene targeting to encode a fusion of the S1P1 receptor and the tetracycline-controlled activator protein (tTA) connected by a Tobacco Etch Virus (TEV) cleavage sequence, internal ribosome initiation sequence (IRES), followed by a beta-arrestin-Tobacco Etch Virus (TEV) protease fusion protein. When activated, the modified S1P1 receptor binds the beta-arrestin-TEV protease fusion, which cleaves the tTA. The released tTA activates a reporter gene under transcriptional control of a tetracyclineresponsive promoter element (TRE) thereby reporting S1P1 receptor activation. Since S1P1 receptor signaling may be important in diseases such as multiple sclerosis, cancer and atherosclerosis, the mouse can be used to identify active compounds that alter S1P1 receptor signaling and that may be therapeutically useful. Potential for wide variety of uses for therapeutic development. The mouse can be used to identify active compounds that alter S1P1 receptor signaling and that may be therapeutically useful. 2022-11-30 2024-10-28 2024-10-28 2022-11-30 2022-07-13 1, Listed LPM Greene as of 4/15/2015, Mouse, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, RECEPTOR, RXXXXX, S1P1, SIGNALING, Sphingosine-1-phosphate, VAXXXX, VCXXXX, VPXXXX, WIXXXX, WKXXXX, XEXXXX False True True NIHTT 37470483 Website Abstract 114111497 Kono, Mari National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Kono, Mari (NIDDK) 0 114111496 Proia, Richard National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Proia, Richard (NIDDK) 1 114111496 Proia, Richard National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Proia, Richard (NIDDK) 1 114111497 Kono, Mari National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Kono, Mari (NIDDK) 0 114102865 Sphingosine-1-phosphate 1 (S1P1) Receptor Signaling Mouse E-183-2011-0 Research Material National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83739550 Shastri, Mythreyi shastrim@mail.nih.gov
United States of America Technology Advancement Office shastrim@mail.nih.gov?subject=Web Inquiry on [TAB-3762] Sphingosine-1-phosphate 1 (S1P1) Receptor Signaling Mouse for Therapeutic Development&body=Please send me information about technology [TAB-3762] Sphingosine-1-phosphate 1 (S1P1) Receptor Signaling Mouse for Therapeutic Development. Shastri, Mythreyi<br><a href="mailto:shastrim@mail.nih.gov?subject=Web Inquiry on [TAB-3762] Sphingosine-1-phosphate 1 (S1P1) Receptor Signaling Mouse for Therapeutic Development&body=Please send me information about technology [TAB-3762] Sphingosine-1-phosphate 1 (S1P1) Receptor Signaling Mouse for Therapeutic Development.">shastrim@mail.nih.gov</a><br> 114129520 RXXXXX 114129521 VAXXXX 114129522 VCXXXX 114129523 VPXXXX 114129524 WIXXXX 114129525 WKXXXX 114129526 XEXXXX 114155129 Sphingosine-1-phosphate 114155130 1 114155131 S1P1 114155132 RECEPTOR 114155133 SIGNALING 114155134 Mouse 114155135 Listed LPM Greene as of 4/15/2015 114155136 Pre LPM working set 20150418 114155137 Post LPM Assignment Set 20150420 TAB-3759 114097610 Treatment and Prevention of Neuropathic Pain with P2Y14 Antagonists NIDDK Neurology, Therapeutics Neurology Therapeutics Kenneth Jacobson, Daniela Salvemini This technology includes the use of selective antagonist for the P2Y14 receptor for the treatment and prevention of neuropathic pain. Neuropathic pain conditions arising from injuries to the nervous system due to trauma, disease or neurotoxins are exceedingly difficult to treat. Clinicians and patients are often left to manage neuropathic pain with opioids, but these approaches are limited by the eventual loss in opioid efficacy with developing tolerance, the occurrence of severe adverse side effects and the strong potential for their abuse. With over 15-20 million people in the US affected by neuropathic pain, a high priority has been placed upon developing novel non-narcotic analgesics. We have discovered that P2Y14 antagonists given systemically reverse neuropathic pain in a well characterized mouse model of neuropathic pain caused by constriction of the sciatic nerve. P2Y14 antagonists may be useful in the pathogenesis of other disorders of the central nervous system such as cognitive deficits (following chemotherapy or traumatic brain injuries) and Alzheimer’s. Neuroinflammatory processes driven by glial activation are key components of neuropathic pain and these other disorders of the central nervous system. Current FDA-approved drugs for the treatment of neuropathic pain are not very effective, however this invention is unique – the first demonstration that selective P2Y14 antagonists are effective for treatment of neuropathic pain. Treatment and prevention of neuropathic pain. 2022-11-30 2024-10-28 2024-10-28 2022-11-30 2022-07-13 ANTAGONISTS, Neuropathic, P2Y14, Pain, Prevention, treatment, VMXXXX, WKXXXX False True True NIHTT 37470483 Website Abstract 114111492 Salvemini, Daniela Saint Louis University School of Medicine Salvemini, Daniela 0 114111491 Jacobson, Kenneth National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Jacobson, Kenneth (NIDDK) 1 114111491 Jacobson, Kenneth National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Jacobson, Kenneth (NIDDK) 1 114111492 Salvemini, Daniela Saint Louis University School of Medicine Salvemini, Daniela 0 114102862 Treatment And Prevention Of Neuropathic Pain With P2Y14 Antagonists E-144-2019-0 Filing authorized National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Saint Louis University School of Medicine 83692066 Tong, Betty tongb@niddk.nih.gov
United States of America Senior Technology Advancement Office tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-3759] Treatment and Prevention of Neuropathic Pain with P2Y14 Antagonists&body=Please send me information about technology [TAB-3759] Treatment and Prevention of Neuropathic Pain with P2Y14 Antagonists. Tong, Betty<br><a href="mailto:tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-3759] Treatment and Prevention of Neuropathic Pain with P2Y14 Antagonists&body=Please send me information about technology [TAB-3759] Treatment and Prevention of Neuropathic Pain with P2Y14 Antagonists.">tongb@niddk.nih.gov</a><br> 114169596 E-144-2019-0 E-144-2019-0-US-01 Treatment And Prevention Of Neuropathic Pain With P2Y14 Antagonists PRV US 62/877,385 Abandoned US <br />Provisional (PRV) 62/877,385<br />Filed on 2019-07-23<br />Status: Abandoned 114129507 VMXXXX 114129508 WKXXXX 114155093 treatment 114155094 Prevention 114155095 Neuropathic 114155096 Pain 114155097 P2Y14 114155098 ANTAGONISTS TAB-3760 114097611 Mouse Model for the Study of Glycosphingolipid Storage Disorders NIDDK Cardiology, Dental, Endocrinology, Infectious Disease, Neurology, Oncology, Ophthalmology, Research Materials, Therapeutics Cardiology Dental Endocrinology Infectious Disease Neurology Oncology Ophthalmology Research Materials Therapeutics Richard Proia This technology includes a conventional knockout mice: beta- 1,4-N-acetylgalactosaminyl transferase 1 (GM2 Synthase) KO; B4galntltm1Rlp for the study of glycosphingolipid storage disorders. The glycosphingolipid (GSL) storage diseases are caused by genetic disruption in the lysosomal degradation pathway of GSLs, and include Tay-Sachs disease, Sandhoff's disease, Gaucher's disease, Fabry's disease, Krabbe's disease, and several others. In most of these diseases, GSLs accumulate to massive levels in cells, particularly in neurons, causing neurodegeneration and a shortened life span. There are currently no effective treatments for the majority of GSL storage disorders. Further work with this mouse model may lead to approved treatments of GSL storage diseases. 2022-11-30 2024-10-28 2024-10-28 2022-11-30 2022-07-13 1, 4-Nacetyl-galactosaminyl, As:, B4gal, beta-1, DEFINED, Gene, Knockout, Listed LPM Greene as of 4/15/2015, Mice, Nt1, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, TRANSFERASE, VEXXXX, VPXXXX, WIXXXX, XEXXXX False True True NIHTT 37470483 Website Abstract 114172923 Liu Y, Wada R, et al. https://pubmed.ncbi.nlm.nih.gov/10021458/ <a href="https://pubmed.ncbi.nlm.nih.gov/10021458/">Liu Y, Wada R, et al.</a> 114111493 Proia, Richard National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Proia, Richard (NIDDK) 1 114111493 Proia, Richard National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Proia, Richard (NIDDK) 1 114102863 The Gene In The Knockout Mice Is Defined As: Beta-1, 4-Nacetyl-galactosaminyl Transferase 1 (B4gal Nt1 ) E-146-2014-0 Research Material National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83739550 Shastri, Mythreyi shastrim@mail.nih.gov
United States of America Technology Advancement Office shastrim@mail.nih.gov?subject=Web Inquiry on [TAB-3760] Mouse Model for the Study of Glycosphingolipid Storage Disorders&body=Please send me information about technology [TAB-3760] Mouse Model for the Study of Glycosphingolipid Storage Disorders. Shastri, Mythreyi<br><a href="mailto:shastrim@mail.nih.gov?subject=Web Inquiry on [TAB-3760] Mouse Model for the Study of Glycosphingolipid Storage Disorders&body=Please send me information about technology [TAB-3760] Mouse Model for the Study of Glycosphingolipid Storage Disorders.">shastrim@mail.nih.gov</a><br> 114129509 VEXXXX 114129510 VPXXXX 114129511 WIXXXX 114129512 XEXXXX 114155099 Gene 114155100 Knockout 114155101 Mice 114155102 DEFINED 114155103 As: 114155104 beta-1 114155105 4-Nacetyl-galactosaminyl 114155106 TRANSFERASE 114155107 1 114155108 B4gal 114155109 Nt1 114155110 Listed LPM Greene as of 4/15/2015 114155111 Pre LPM working set 20150418 114155112 Post LPM Assignment Set 20150420 TAB-3758 114097609 Mouse Models for the Study of Male Fertility NIDDK Cardiology, Dental, Endocrinology, Infectious Disease, Oncology, Ophthalmology, Research Materials, Therapeutics Cardiology Dental Endocrinology Infectious Disease Oncology Ophthalmology Research Materials Therapeutics Yuanzheng He, Geun-Shik Lee, S. Stoney Simons This technology includes two mouse models to be used in studying male sterility. One mouse is deficient in the full-length protein for STAMP/TtH5. The second is a conditional mutant STAMP mouse that can be used to produce tissues/organs that are deficient in full length STAMP. STAMP represents an intriguing new protein in the study of male fertility. More detailed future studies should identify the precise defect(s) leading to male sterility and may identify other behavioral and developmental consequences, such as a role in the immune system that is suggested by the microarray studies. First development of these two mutant mice. More detailed future studies should identify the precise defect(s) leading to male sterility and may identify other behavioral and developmental consequences, such as a role in the immune system that is suggested by the microarray studies. 2022-11-30 2024-10-28 2024-10-28 2022-11-30 2022-07-13 Conditional, Knock, Listed LPM Tong as of 4/15/2015, Mice, MUTANT, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, RXXXXX, STAMP, VPXXXX, WIXXXX, XEXXXX False True True NIHTT 37470483 Website Abstract 114111488 He, Yuanzheng Van Andel Institute He, Yuanzheng 0 114111489 Lee, Geun-Shik Lee, Geun-Shik 0 114111490 Simons, S. Stoney National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Simons, S. Stoney (NIDDK) 1 114111490 Simons, S. Stoney National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Simons, S. Stoney (NIDDK) 1 114111488 He, Yuanzheng Van Andel Institute He, Yuanzheng 0 114111489 Lee, Geun-Shik Lee, Geun-Shik 0 114102861 STAMP Knock Out And Conditional Mutant Mice E-141-2012-0 Research Material National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83692066 Tong, Betty tongb@niddk.nih.gov
United States of America Senior Technology Advancement Office tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-3758] Mouse Models for the Study of Male Fertility&body=Please send me information about technology [TAB-3758] Mouse Models for the Study of Male Fertility. Tong, Betty<br><a href="mailto:tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-3758] Mouse Models for the Study of Male Fertility&body=Please send me information about technology [TAB-3758] Mouse Models for the Study of Male Fertility.">tongb@niddk.nih.gov</a><br> 114129503 RXXXXX 114129504 VPXXXX 114129505 WIXXXX 114129506 XEXXXX 114155085 Knock 114155086 STAMP 114155087 Conditional 114155088 MUTANT 114155089 Mice 114155090 Listed LPM Tong as of 4/15/2015 114155091 Pre LPM working set 20150418 114155092 Post LPM Assignment Set 20150420 TAB-3756 114097607 PPTN as a Selective P2Y14 Receptor Antagonist for the Discovery of Treatments of Inflammatory Disorders NIDDK Cardiology, Dental, Endocrinology, Infectious Disease, Oncology, Ophthalmology, Research Materials, Therapeutics Cardiology Dental Endocrinology Infectious Disease Oncology Ophthalmology Research Materials Therapeutics Kenneth Jacobson This technology includes PPTN which can be used to study treatments of inflammatory diseases. PPTN is currently a useful pharmacological probe that many labs in the field of purinergic signaling are interested in obtaining. The availability of PPTN as a research tool will stimulate basic advances in the field and possibly eventually lead to new treatments. However, PPTN itself is unsuitable for therapeutic applications. Separately, we are working on new and improved antagonists of the P2Y14 receptor. This compound produced fully antagonizes the human P2Y14R with subnanomolar affinity with insignificant antagonism of other P2Y receptors at 10 µM, therefore it is highly selective. Useful for the study of future treatments for inflammatory disorders. 2022-11-30 2024-10-28 2024-10-28 2022-11-30 2022-07-11 ANTAGONIST, P2Y14, PPTN, RECEPTOR, SELECTIVE, VPXXXX, WIXXXX, WKXXXX False True True NIHTT 37470483 Website Abstract 114172913 Gao Z-G, Wei Q, et al. https://pubmed.ncbi.nlm.nih.gov/22825617/ <a href="https://pubmed.ncbi.nlm.nih.gov/22825617/">Gao Z-G, Wei Q, et al.</a> 114172914 Barrett M, Sesma J, et al. https://pubmed.ncbi.nlm.nih.gov/23592514/ <a href="https://pubmed.ncbi.nlm.nih.gov/23592514/">Barrett M, Sesma J, et al.</a> 114172915 Kiselev E, Barrett M, et al. https://pubmed.ncbi.nlm.nih.gov/25299434/ [PMID 25299434] <a href="https://pubmed.ncbi.nlm.nih.gov/25299434/ [PMID 25299434]">Kiselev E, Barrett M, et al.</a> 114172916 Azroyan A, Cortez-Retamozo V, et al. https://pubmed.ncbi.nlm.nih.gov/25799465/ <a href="https://pubmed.ncbi.nlm.nih.gov/25799465/">Azroyan A, Cortez-Retamozo V, et al.</a> 114172917 Sesma J, Weitzer C, et al. https://pubmed.ncbi.nlm.nih.gov/27421735/ <a href="https://pubmed.ncbi.nlm.nih.gov/27421735/">Sesma J, Weitzer C, et al.</a> 114111483 Jacobson, Kenneth National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Jacobson, Kenneth (NIDDK) 1 114111483 Jacobson, Kenneth National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Jacobson, Kenneth (NIDDK) 1 114102859 PPTN As A Selective P2Y14 Receptor Antagonist E-129-2017-0 Research Material National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83692066 Tong, Betty tongb@niddk.nih.gov
United States of America Senior Technology Advancement Office tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-3756] PPTN as a Selective P2Y14 Receptor Antagonist for the Discovery of Treatments of Inflammatory Disorders&body=Please send me information about technology [TAB-3756] PPTN as a Selective P2Y14 Receptor Antagonist for the Discovery of Treatments of Inflammatory Disorders. Tong, Betty<br><a href="mailto:tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-3756] PPTN as a Selective P2Y14 Receptor Antagonist for the Discovery of Treatments of Inflammatory Disorders&body=Please send me information about technology [TAB-3756] PPTN as a Selective P2Y14 Receptor Antagonist for the Discovery of Treatments of Inflammatory Disorders.">tongb@niddk.nih.gov</a><br> 114129497 VPXXXX 114129498 WIXXXX 114129499 WKXXXX 114155075 PPTN 114155076 SELECTIVE 114155077 P2Y14 114155078 RECEPTOR 114155079 ANTAGONIST TAB-3754 114097605 Methanocarba Derivatives of Pesudoribose That Inhibit Adenosine Kinase for the Prevention and Treatment of Epilepsy NIDDK Neurology, Therapeutics Neurology Therapeutics Detlev Boison, Kenneth Jacobson, Danielle Osborne, Kiran Toti This technology includes a novel family of adenosine kinase (AdK) inhibitors, including pharmaceutical compositions containing the adenosine kinase inhibitors, and their use for preventing epilepsy and its progression in patients. Endogenous adenosine (i.e., naturally occurring adenosine) acts on G protein-coupled receptors (adenosine receptors, ARs) in the central nervous system to suppress seizures and pain, and to blunt the effects of ischemia (a restriction in blood supply to tissues). In addition, adenosine has AR-independent epigenetic effects based on interactions with the transmethylation pathway. There is a dynamic equilibrium between extracellular adenosine levels and its intracellular content that is mediated by either equilibrative (ENTs) or concentrative (CNTs) transporters of nucleosides. Within the brain the concentration of adenosine is largely under the control of metabolic clearance through astrocytic AdK, which converts adenosine to 5'-AMP. By inhibiting AdK, the adenosine concentration can be exogenously raised. It may therefore be possible to target the AR-independent effects of adenosine while avoiding excessive AR activation, by administering brain-penetrant human (h) AdK inhibitors. Potential that the novel non-ribose ring system will provide a cleaner pharmacological profile. Preventing epilepsy and its progression. 2022-11-30 2024-10-28 2024-10-28 2022-11-30 2022-07-11 Derivatives, INHIBITADENOSINE, Kinase, Methanocarba, PSEUDORIBOSE, That, VEXXXX, WKXXXX False True True NIHTT 37470483 Website Abstract 114111476 Boison, Detlev Robert S. Dow Neurobiology Laboratories Boison, Detlev 0 114111477 Toti, Kiran National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Toti, Kiran (NIDDK) 0 114111478 Osborne, Danielle National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Osborne, Danielle 0 114111475 Jacobson, Kenneth National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Jacobson, Kenneth (NIDDK) 1 114111475 Jacobson, Kenneth National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Jacobson, Kenneth (NIDDK) 1 114111476 Boison, Detlev Robert S. Dow Neurobiology Laboratories Boison, Detlev 0 114111477 Toti, Kiran National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Toti, Kiran (NIDDK) 0 114111478 Osborne, Danielle National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Osborne, Danielle 0 114102857 METHANOCARBA DERIVATIVES OF PSEUDORIBOSE THAT INHIBIT ADENOSINE KINASE E-121-2019-0 Filing authorized National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Robert S. Dow Neurobiology Laboratories 83692066 Tong, Betty tongb@niddk.nih.gov
United States of America Senior Technology Advancement Office tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-3754] Methanocarba Derivatives of Pesudoribose That Inhibit Adenosine Kinase for the Prevention and Treatment of Epilepsy&body=Please send me information about technology [TAB-3754] Methanocarba Derivatives of Pesudoribose That Inhibit Adenosine Kinase for the Prevention and Treatment of Epilepsy. Tong, Betty<br><a href="mailto:tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-3754] Methanocarba Derivatives of Pesudoribose That Inhibit Adenosine Kinase for the Prevention and Treatment of Epilepsy&body=Please send me information about technology [TAB-3754] Methanocarba Derivatives of Pesudoribose That Inhibit Adenosine Kinase for the Prevention and Treatment of Epilepsy.">tongb@niddk.nih.gov</a><br> 114169588 E-121-2019-0 E-121-2019-0-US-01 METHANOCARBA DERIVATIVES OF PSEUDORIBOSE THAT INHIBIT ADENOSINE KINASE PRV US 62/642,854 Abandoned US <br />Provisional (PRV) 62/642,854<br />Filed on 2016-05-27<br />Status: Abandoned 114169589 E-121-2019-0 E-121-2019-0-US-02 METHANOCARBA DERIVATIVES OF PSEUDORIBOSE THAT INHIBIT ADENOSINE KINASE ORD US 10,016,432 15/607,379 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10016432 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10016432">10,016,432</a><br />Filed on 2017-05-26<br />Status: Issued 114129493 VEXXXX 114129494 WKXXXX 114155060 Methanocarba 114155061 Derivatives 114155062 PSEUDORIBOSE 114155063 That 114155064 INHIBITADENOSINE 114155065 Kinase TAB-3751 114097602 Shingosine Kinase 2 (Sphk2) Knock Out Mouse for Neurobiology and Immunology Research NIDDK Cardiology, Dental, Endocrinology, Infectious Disease, Oncology, Ophthalmology, Research Materials Cardiology Dental Endocrinology Infectious Disease Oncology Ophthalmology Research Materials Richard Proia This technology includes a knockout mouse model for Sphingosine kinase 2 (Sphk2) to be used in neurobiology and immunology research studies. Sphingosine kinase 1 and 2 are enzymes that produce sphingosine-1-phosphate, a potent bioactive compound that activates a family of G-protein coupled receptors known as Edg or S1P receptors. Triggering these receptors on cells may have important effects related to inflammation, immunity, cancer, angiogenesis, cell proliferation, adhesion, cardiovascular function, nervous system function and injury responses. Sphingosine kinase also activates FTY710, an immunosuppressive drug. Mice have been produced with a deleted gene for sphingosine kinase 2 (sphingosine kinase 2 knockout mice), which will be valuable in determining the functions of sphingosine phosphate and the Edg/S1P receptors. These mice also will be useful for the study of FTY720 and related compounds. Establishment of a knockout mouse for Sphingosine kinase 2 (Sphk2). Mouse Model for neurobiology and immunology research. 2022-11-30 2024-10-28 2024-10-28 2022-11-30 2022-07-11 2, Kinase, Knock, Listed LPM Greene as of 4/15/2015, Mouse, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, RXXXXX, Shingosine, Sphk2, VPXXXX, WIXXXX False True True NIHTT 37470483 Website Abstract 114172911 Mizugishi K, Yamashita T, et al. https://pubmed.ncbi.nlm.nih.gov/16314531/ <a href="https://pubmed.ncbi.nlm.nih.gov/16314531/">Mizugishi K, Yamashita T, et al.</a> 114111471 Proia, Richard National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Proia, Richard (NIDDK) 1 114111471 Proia, Richard National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Proia, Richard (NIDDK) 1 114102854 Shingosine Kinase 2 (Sphk2) Knock Out Mouse E-109-2012-0 Research Material National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83739550 Shastri, Mythreyi shastrim@mail.nih.gov
United States of America Technology Advancement Office shastrim@mail.nih.gov?subject=Web Inquiry on [TAB-3751] Shingosine Kinase 2 (Sphk2) Knock Out Mouse for Neurobiology and Immunology Research&body=Please send me information about technology [TAB-3751] Shingosine Kinase 2 (Sphk2) Knock Out Mouse for Neurobiology and Immunology Research. Shastri, Mythreyi<br><a href="mailto:shastrim@mail.nih.gov?subject=Web Inquiry on [TAB-3751] Shingosine Kinase 2 (Sphk2) Knock Out Mouse for Neurobiology and Immunology Research&body=Please send me information about technology [TAB-3751] Shingosine Kinase 2 (Sphk2) Knock Out Mouse for Neurobiology and Immunology Research.">shastrim@mail.nih.gov</a><br> 114129482 RXXXXX 114129483 VPXXXX 114129484 WIXXXX 114155029 Shingosine 114155030 Kinase 114155031 2 114155032 Sphk2 114155033 Knock 114155034 Mouse 114155035 Listed LPM Greene as of 4/15/2015 114155036 Pre LPM working set 20150418 114155037 Post LPM Assignment Set 20150420 TAB-3752 114097603 Methods For Pharmacologic Treatment of Stroke NIDDK Neurology, Research Materials, Therapeutics Neurology Research Materials Therapeutics Kenneth Jacobson This technology includes P2X4R adenosine receptor antagonists, including NP-1815-PX and 5-BDBD, for treating stroke. Stroke is the fifth leading cause of death for Americans and a leading cause of serious long-term disability. Current approaches to treating ischemic stroke are primarily limited to the administration of thrombolytic therapeutics such as tissue plasminogen activator, or to an invasive endovascular procedure involving the use of a clot removing/retrieving device. Thrombolytic therapeutics, however, must be given during the first few hours of a stroke, are associated with a risk of bleeding, and are only useful for ischemic strokes, not for hemorrhagic strokes. The clot removing/retrieving device is applicable in less than 10% of embolic stroke cases. Thus, improved medical therapy for stroke, particularly ischemic stroke, is needed and represents an unmet area of need. Focuses on unmet medical need. Treatment for stroke. 2022-11-30 2024-10-28 2024-10-28 2022-11-30 2022-07-11 Methods, PHARMACOLOGIC, STROKE, treatment, VEXXXX, WIXXXX, WKXXXX False True True NIHTT 37470483 Website Abstract 114111472 Jacobson, Kenneth National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Jacobson, Kenneth (NIDDK) 1 114111472 Jacobson, Kenneth National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Jacobson, Kenneth (NIDDK) 1 114102855 Methods For Pharmacologic Treatment Of Stroke E-112-2018-0 Filing authorized National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83692066 Tong, Betty tongb@niddk.nih.gov
United States of America Senior Technology Advancement Office tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-3752] Methods For Pharmacologic Treatment of Stroke&body=Please send me information about technology [TAB-3752] Methods For Pharmacologic Treatment of Stroke. Tong, Betty<br><a href="mailto:tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-3752] Methods For Pharmacologic Treatment of Stroke&body=Please send me information about technology [TAB-3752] Methods For Pharmacologic Treatment of Stroke.">tongb@niddk.nih.gov</a><br> 114169586 E-112-2018-0 E-112-2018-0-US-01 Methods For Pharmacologic Treatment Of Ischemic Stroke PRV US 62/478,655 Abandoned US <br />Provisional (PRV) 62/478,655<br />Filed on 2017-03-30<br />Status: Abandoned 114169587 E-112-2018-0 E-112-2018-0-US-02 Methods For Pharmacologic Treatment Of Ischemic Stroke ORD US 10,695,355 15/933,536 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10695355 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10695355">10,695,355</a><br />Filed on 2018-03-23<br />Status: Issued 114129485 VEXXXX 114129486 WIXXXX 114129487 WKXXXX 114155038 Methods 114155039 PHARMACOLOGIC 114155040 treatment 114155041 STROKE TAB-3749 114097600 S1pr1 LoxP (S1p1 FM2Rip) Mouse Model for Developmental Biology NIDDK Research Materials, Therapeutics Research Materials Therapeutics Richard Proia This technology includes a mouse model for S1 pr1 to be used in development biology research. Sphingosine-1-phosphate is a potent bioactive compound that activates a family of G-protein coupled receptors known as Edg or S1P receptors. Triggering these receptors on cells may have important effects related to inflammation, immunity, cancer, angio-genesis, cell proliferation, adhesion, cardiovascular function, nervous system function and injury responses. Mice were produced with the gene for Edg1/S1P1 surrounded by loxp sites (Edg1/S1P1 conditional mice) which will be valuable in determining the functions of sphingosine phosphate and the Edg1/S1 P1 receptors. Since deletion of the Edg1 gene causes embryonic lethality, a conditional knockout (after birth) is required. Mice with a floxed S1P1 receptor gene were mated with mice expressing Cre-recombinase only in endothelial cells to disrupt the S1P1 gene exclusively in endothelial cells. The phenotype of the conditional mutant embryos was indistinguishable from the phenotype of S1P1 null embryos which indicate that S1P1 receptors in endothelial cells direct the coverage of embryonic blood vessels by vascular smooth muscle cells. Establishment of a conditional knockout mouse for S1 pr1. Mouse model for developmental biology research, useful for determining the function of sphingosine phosphate and the Edg3/S1 P3 receptor. 2022-11-30 2024-10-28 2024-10-28 2022-11-30 2022-07-11 FM2Rip, Listed LPM Greene as of 4/15/2015, LOXP, Mouse, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, RXXXXX, S1P1, S1pr1, WIXXXX, XEXXXX False True True NIHTT 37470483 Website Abstract 114172910 Allende M, Yamashita T, et al. https://pubmed.ncbi.nlm.nih.gov/12869509/ <a href="https://pubmed.ncbi.nlm.nih.gov/12869509/">Allende M, Yamashita T, et al.</a> 114111466 Proia, Richard National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Proia, Richard (NIDDK) 1 114111466 Proia, Richard National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Proia, Richard (NIDDK) 1 114102852 S1pr1 LoxP (S1p1 FM2Rip) Mouse E-108-2012-0 Research Material National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83739550 Shastri, Mythreyi shastrim@mail.nih.gov
United States of America Technology Advancement Office shastrim@mail.nih.gov?subject=Web Inquiry on [TAB-3749] S1pr1 LoxP (S1p1 FM2Rip) Mouse Model for Developmental Biology&body=Please send me information about technology [TAB-3749] S1pr1 LoxP (S1p1 FM2Rip) Mouse Model for Developmental Biology. Shastri, Mythreyi<br><a href="mailto:shastrim@mail.nih.gov?subject=Web Inquiry on [TAB-3749] S1pr1 LoxP (S1p1 FM2Rip) Mouse Model for Developmental Biology&body=Please send me information about technology [TAB-3749] S1pr1 LoxP (S1p1 FM2Rip) Mouse Model for Developmental Biology.">shastrim@mail.nih.gov</a><br> 114129476 RXXXXX 114129477 WIXXXX 114129478 XEXXXX 114155020 S1pr1 114155021 LOXP 114155022 S1P1 114155023 FM2Rip 114155024 Mouse 114155025 Listed LPM Greene as of 4/15/2015 114155026 Pre LPM working set 20150418 114155027 Post LPM Assignment Set 20150420 TAB-3750 114097601 Thyclotides for the Development of Clinical Diagnostics and Targeted Therapeutics NIDDK Diagnostics, Research Materials, Therapeutics Diagnostics Research Materials Therapeutics Harsha Amarasekara, Daniel Appella, Victor Clausse, Hongchao Zheng This technology includes a new class of oligomeric molecules called thyclotides for diagnostic and therapeutic development. Thyclotides is described where chiral tetrahydrofuran (THF) diamine units are linked together with alternating glycines, and nucleobases are attached to this backbone as sidechains. The thyclotide sequence consists of a series of nucleobases similar to that of a nucleic acid sequence. Thyclotides are easily synthesized and purified with excellent solubility in water. Thyclotide sequences bind to complementary DNA and RNA sequences with very strong affinity. Thyclotides can be used to inhibit PCR amplification, which is useful for application where PCR clamping is needed to suppress amplification of native DNA when trying to detect low levels of mutant DNA. Thyclotides are surprisingly cell-permeable, and can be used to suppress microRNA in cells and therefore effect important biological responses. Thyclotides overcome obstacles of peptide nucleic acids by being water soluble, ability to bind very strongly to complementary DNA and RNA, and being cell permeable. Development of clinical diagnostics or any RNA-targeted or DNA-targeted therapy, or gene editing. 2022-11-30 2024-10-28 2024-10-28 2022-11-30 2022-07-11 Thyclotides, WBXXXX, WIXXXX, WKXXXX False True True NIHTT 37470483 Website Abstract 114111468 Zheng, Hongchao National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Zheng, Hongchao (NIDDK) 0 114111469 Clausse, Victor National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Clausse, Victor (NIDDK) 0 114111470 Amarasekara, Harsha National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Amarasekara, Harsha (NIDDK) 0 114111467 Appella, Daniel National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Appella, Daniel (NIDDK) 1 114111467 Appella, Daniel National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Appella, Daniel (NIDDK) 1 114111468 Zheng, Hongchao National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Zheng, Hongchao (NIDDK) 0 114111469 Clausse, Victor National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Clausse, Victor (NIDDK) 0 114111470 Amarasekara, Harsha National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Amarasekara, Harsha (NIDDK) 0 114102853 Thyclotides E-108-2020-0 Filing authorized National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83692066 Tong, Betty tongb@niddk.nih.gov
United States of America Senior Technology Advancement Office tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-3750] Thyclotides for the Development of Clinical Diagnostics and Targeted Therapeutics&body=Please send me information about technology [TAB-3750] Thyclotides for the Development of Clinical Diagnostics and Targeted Therapeutics. Tong, Betty<br><a href="mailto:tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-3750] Thyclotides for the Development of Clinical Diagnostics and Targeted Therapeutics&body=Please send me information about technology [TAB-3750] Thyclotides for the Development of Clinical Diagnostics and Targeted Therapeutics.">tongb@niddk.nih.gov</a><br> 114169584 E-108-2020-0 E-108-2020-0-US-01 Thyclotides PRV US 63/011,398 Abandoned US <br />Provisional (PRV) 63/011,398<br />Filed on 2020-04-17<br />Status: Abandoned 114169585 E-108-2020-0 E-108-2020-0-PCT-02 Thyclotides PCT Patent Cooperation Treaty PCT/US2021/027397 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/027397<br />Filed on 2021-04-15<br />Status: Expired 114169664 E-108-2020-0 E-108-2020-0-US-04 Thyclotides National Stage US 17/918,725 Pending US <br />National Stage 17/918,725<br />Filed on 2022-10-13<br />Status: Pending 114129479 WBXXXX 114129480 WIXXXX 114129481 WKXXXX 114155028 Thyclotides TAB-3746 114097598 Mouse Models for the Study of Gaucher Disease and Therapeutic Development NIDDK Cardiology, Dental, Endocrinology, Infectious Disease, Oncology, Ophthalmology, Research Materials Cardiology Dental Endocrinology Infectious Disease Oncology Ophthalmology Research Materials Richard Proia This technology includes mouse models for both mild and severe Gaucher disease. Gba-L444P and Gba-L444P A456P mice, respectively, carry common gene mutations for milder or severe Gaucher disease, a lysosomal storage disease. Gaucher Disease is caused by mutations in the lysosomal enzyme, glucocerebrosidase. Deficiency of enzyme activity leads to the accumulation of glucosylceramide in liver, spleen, bone, and in the most severe cases, the central nervous system. A single insertion mutagenesis procedure was used to introduce mutations found in human Gaucher Disease into the mouse glucocerebrosidase gene. Mice homozygous for the double mutation L444P A456P had little enzyme activity and accumulated glucosylceramide in brain and liver. Mice homozygous only for the L444P mutation seen in a milder chronic form of Gaucher disease had higher levels of enzyme activity and did not accumulate glucosylceramide in brain and liver. Mice with either point mutation died within 48 h of birth. Gba-444 knock-in mice carrying the milder L444P Gaucher disease mutation (Gba-L444P mice) and the severe Gaucher disease mutation Gba-L444P A456P mice). The mice can be useful for the study of disease pathogenesis and for devising new therapies, including gene transfer therapy, enzyme replacement therapy, cell replacement therapy and small molecule therapy (synthesis inhibitors, enzyme activators). 2022-11-30 2024-10-28 2024-10-28 2022-11-30 2022-07-11 Gaucher, Gba-L444P, Knock-inGba-fm2RIP, Listed LPM Greene as of 4/15/2015, Mouse, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, RXXXXX, VPXXXX, WIXXXX False True True NIHTT 37470483 Website Abstract 114172905 Liu Y, Suzuki K, et al. https://pubmed.ncbi.nlm.nih.gov/9482915/ <a href="https://pubmed.ncbi.nlm.nih.gov/9482915/">Liu Y, Suzuki K, et al.</a> 114111462 Proia, Richard National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Proia, Richard (NIDDK) 1 114111462 Proia, Richard National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Proia, Richard (NIDDK) 1 114102850 Gaucher Gba-L444p Knock-in(Gba-fm2RIP) Mouse E-107-2012-0 Research Material National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83739550 Shastri, Mythreyi shastrim@mail.nih.gov
United States of America Technology Advancement Office shastrim@mail.nih.gov?subject=Web Inquiry on [TAB-3746] Mouse Models for the Study of Gaucher Disease and Therapeutic Development&body=Please send me information about technology [TAB-3746] Mouse Models for the Study of Gaucher Disease and Therapeutic Development. Shastri, Mythreyi<br><a href="mailto:shastrim@mail.nih.gov?subject=Web Inquiry on [TAB-3746] Mouse Models for the Study of Gaucher Disease and Therapeutic Development&body=Please send me information about technology [TAB-3746] Mouse Models for the Study of Gaucher Disease and Therapeutic Development.">shastrim@mail.nih.gov</a><br> 114129472 RXXXXX 114129473 VPXXXX 114129474 WIXXXX 114155001 Gaucher 114155002 Gba-L444P 114155003 Knock-inGba-fm2RIP 114155004 Mouse 114155005 Listed LPM Greene as of 4/15/2015 114155006 Pre LPM working set 20150418 114155007 Post LPM Assignment Set 20150420 TAB-3748 114097599 A Novel Oxygen-induced Expression Vector for Production of Recombinant Proteins in Escherichia Coli NIDDK Research Materials Research Materials Antonino Baez Rogelio, Nadim Majdalani, Joseph Shiloach This technology includes a new method to induce recombinant protein expression in E. coli through the activating the SoxS promoter by molecular oxygen. We previously discovered that the SoxRS regulon of E. coli is activated in response to elevated dissolved oxygen concentration mainly to protect the bacteria from possible oxygen damage. We hypothesized that the 16-fold increase in the expression of this regulon make it possible candidate for inducing the expression of recombinant proteins. Compared with the existing induction approaches oxygen induction offers several advantages; it does not involve addition or depletion of growth factors or nutrients, addition of chemical inducers or temperature changes that can affect growth and metabolism of the producing bacteria. It also offers another advantage by not affecting the composition of the growth media simplifying the recovery and purification process. Compared with the existing induction approaches the oxygen induction offers several advantages; it does not involve addition or depletion of growth factors or nutrients, addition of chemical inducers or temperature changes that can affect growth and metabolism of the producing bacteria. It also offers another advantage by not affecting the composition of the growth media simplifying the recovery and purification process. The invented method will introduce another way to produce therapeutic or diagnostic proteins from E. coli. 2022-11-30 2024-10-28 2024-10-28 2022-11-30 2022-07-11 COLI, ESCHERICHIA, Expression, Listed LPM Maddox as of 4/15/2015, Novel, Oxygen-induced, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, production, proteins, recombinant, Vector, WIXXXX False True True NIHTT 37470483 Website Abstract 114172906 Gu M, Imlay J, et al. https://pubmed.ncbi.nlm.nih.gov/21226770/ <a href="https://pubmed.ncbi.nlm.nih.gov/21226770/">Gu M, Imlay J, et al.</a> 114172907 Krapp A, Humbert M, et al. https://pubmed.ncbi.nlm.nih.gov/21178165/ <a href="https://pubmed.ncbi.nlm.nih.gov/21178165/">Krapp A, Humbert M, et al.</a> 114172908 Rui B, Shen T, et al. https://pubmed.ncbi.nlm.nih.gov/20809933/ <a href="https://pubmed.ncbi.nlm.nih.gov/20809933/">Rui B, Shen T, et al.</a> 114172909 Pomposiello P, Bennik M, et al. https://pubmed.ncbi.nlm.nih.gov/11395452/ <a href="https://pubmed.ncbi.nlm.nih.gov/11395452/">Pomposiello P, Bennik M, et al.</a> 114111464 Shiloach, Joseph National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Shiloach, Joseph (NIDDK) 0 114111465 Majdalani, Nadim NCI - CCR NCI Majdalani, Nadim (NCI) 0 114111463 Baez Rogelio, Antonino National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Baez Rogelio, Antonino 1 114111463 Baez Rogelio, Antonino National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Baez Rogelio, Antonino 1 114111464 Shiloach, Joseph National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Shiloach, Joseph (NIDDK) 0 114111465 Majdalani, Nadim NCI - CCR NCI Majdalani, Nadim (NCI) 0 114102851 A Novel Oxygen-induced Expression Vector For Production Of Recombinant Proteins In Escherichia Coli E-107-2014-0 Research Material National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NCI 83692066 Tong, Betty tongb@niddk.nih.gov
United States of America Senior Technology Advancement Office tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-3748] A Novel Oxygen-induced Expression Vector for Production of Recombinant Proteins in Escherichia Coli&body=Please send me information about technology [TAB-3748] A Novel Oxygen-induced Expression Vector for Production of Recombinant Proteins in Escherichia Coli. Tong, Betty<br><a href="mailto:tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-3748] A Novel Oxygen-induced Expression Vector for Production of Recombinant Proteins in Escherichia Coli&body=Please send me information about technology [TAB-3748] A Novel Oxygen-induced Expression Vector for Production of Recombinant Proteins in Escherichia Coli.">tongb@niddk.nih.gov</a><br> 114129475 WIXXXX 114155008 COLI 114155009 ESCHERICHIA 114155010 proteins 114155011 recombinant 114155012 production 114155013 Vector 114155014 Expression 114155015 Oxygen-induced 114155016 Novel 114155017 Listed LPM Maddox as of 4/15/2015 114155018 Pre LPM working set 20150418 114155019 Post LPM Assignment Set 20150420 TAB-3744 114097596 (N)-methanocarba Phosphonate Analogues of 5'-AMP as Cardioprotective Agents NIDDK Cardiology, Therapeutics Cardiology Therapeutics Kenneth Jacobson, Bhalchandra Joshi, Bruce Liang, Santhosh Thatikonda This technology includes the use of the (N)-methanocarba phosphonate analogues of 5’-AMP as cardioprotective agents for use in conditions such as cardiomyopathy and heart failure. We previously found a compound, MRS2339 (a phosphate derivative that can be slowly cleaved in vivo and lose potency), which activates the appropriate receptors and is protective in models of heart failure in several species (mouse, dog). MRS2339 is a phosphate derivative that can be slowly cleaved in vivo and lose potency. We now extend this technology to more stable derivatives, i.e. phosphonates that are not subject to hydrolysis because they contain the stable C-P bond. Like MRS2339, they are held in the receptor-preferred conformation by virtue of the (N)-methanocarba ring system in place of the ribose moiety. Note that we previously applied the methanocarba ring system to nucleosides and nucleotides that are selective ligands of the adenosine and P2Y receptors, so some of the synthetic routes to the new compounds are common to both areas of study (i.e., previously GPCRs and now P2X ion channels). Some of the synthetic routes to the new compounds are common to both areas of study (i.e., previously GPCRs and now P2X ion channels). Use as cardioprotective agents. 2022-11-30 2024-10-28 2024-10-28 2022-11-30 2022-07-11 5'-AMP, Agents, ANALOGUES, Cardioprotective, Listed LPM Tong as of 4/15/2015, N-Methanocarba, PHOSPHONATE, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, VDXXXX, WKXXXX False True True NIHTT 37470483 Website Abstract 114111457 Jacobson, Kenneth National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Jacobson, Kenneth (NIDDK) 0 114111458 Thatikonda, Santhosh National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Thatikonda, Santhosh 0 114111460 Joshi, Bhalchandra Nektar Joshi, Bhalchandra 0 114111459 Liang, Bruce University of Connecticut Liang, Bruce 1 114111459 Liang, Bruce University of Connecticut Liang, Bruce 1 114111457 Jacobson, Kenneth National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Jacobson, Kenneth (NIDDK) 0 114111458 Thatikonda, Santhosh National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Thatikonda, Santhosh 0 114111460 Joshi, Bhalchandra Nektar Joshi, Bhalchandra 0 114102848 (N)-Methanocarba Phosphonate Analogues Of 5'-AMP As Cardioprotective Agents E-102-2011-0 Filing authorized National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), University of Connecticut 83692066 Tong, Betty tongb@niddk.nih.gov
United States of America Senior Technology Advancement Office tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-3744] (N)-methanocarba Phosphonate Analogues of 5'-AMP as Cardioprotective Agents&body=Please send me information about technology [TAB-3744] (N)-methanocarba Phosphonate Analogues of 5'-AMP as Cardioprotective Agents. Tong, Betty<br><a href="mailto:tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-3744] (N)-methanocarba Phosphonate Analogues of 5'-AMP as Cardioprotective Agents&body=Please send me information about technology [TAB-3744] (N)-methanocarba Phosphonate Analogues of 5'-AMP as Cardioprotective Agents.">tongb@niddk.nih.gov</a><br> 114169579 E-102-2011-0 E-102-2011-0-US-01 COMPOSITIONS AND METHODS TO TREAT CARDIAC DISEASES PRV US 61/306,687 Abandoned US <br />Provisional (PRV) 61/306,687<br />Filed on 2010-02-22<br />Status: Abandoned 114169580 E-102-2011-0 E-102-2011-0-PCT-02 COMPOSITIONS AND METHODS TO TREAT CARDIAC DISEASES PCT Patent Cooperation Treaty PCT/US2011/025680 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2011/025680<br />Filed on 2011-02-22<br />Status: Expired 114169581 E-102-2011-0 E-102-2011-0-US-03 (N)-Methanocarba Phosphonate Analogues Of 5'-AMP As Cardioprotective Agents ORD US 8,822,434 13/031,805 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8822434 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8822434">8,822,434</a><br />Filed on 2011-02-22<br />Status: Issued 114169582 E-102-2011-0 E-102-2011-0-US-04 (N)-Methanocarba Phosphonate Analogues Of 5'-AMP As Cardioprotective Agents DIV US 9,303,053 14/338,987 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9303053 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9303053">9,303,053</a><br />Filed on 2014-07-23<br />Status: Issued 114169583 E-102-2011-0 E-102-2011-0-US-06 COMPOSITIONS AND METHODS TO TREAT CARDIAC DISEASES DIV US 9,526,739 15/046,630 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9526739 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9526739">9,526,739</a><br />Filed on 2016-02-18<br />Status: Issued 114129467 VDXXXX 114129468 WKXXXX 114154982 N-Methanocarba 114154983 PHOSPHONATE 114154984 ANALOGUES 114154985 5'-AMP 114154986 Cardioprotective 114154987 Agents 114154988 Listed LPM Tong as of 4/15/2015 114154989 Pre LPM working set 20150418 114154990 Post LPM Assignment Set 20150420 TAB-3745 114097597 Sphingosine Kinase 1 (Sphk1) Knockout Mouse for Utilization in Developmental Biology NIDDK Research Materials, Therapeutics Research Materials Therapeutics Richard Proia This technology includes a sphingosine kinase 1 (Sphk1) knockout mouse model for use in developmental biology research. Sphingosine-1-phosphate (S1P) is synthesized from sphingosine and ATP by the action of sphingosine kinase, and activates cell signaling. Two sphingosine kinases, SPHK1 and SPHK2, have been identified. To study the physiological function of SPHK1, Sphki null mice were generated. The mice were viable, fertile, with no obvious abnormalities. Total SPHK activity in most tissues was substantially reduced, suggesting the presence of other sphingosine kinases. Some reduction in S1P levels was observed in tissues, but a more significant decrease was observed in serum. Neither vascular development nor lymphocyte distribution were affected in Sphki-/- mice. Sphingosine kinase also phosphorylates and activates the immunosuppressant drug FTY720. FTY720 was phosphorylated and elicited lymphopenia in the Sphki null mice, suggesting that some key activities that require S1P receptor signaling can occur in the absence of SPHK1. The mice with the gene for sphingosine kinase 1 deleted will be valuable in determining the functions of sphingosine phosphate and S1P1 receptors. First sphingosine kinase 1 (Sphki) knockout mouse. Mouse model for use in development biology research. 2022-11-30 2024-10-28 2024-10-28 2022-11-30 2022-07-11 1, Kinase, Knockout, KO, Listed LPM Greene as of 4/15/2015, Mouse, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, RXXXXX, Sphingosine, Sphk1, WIXXXX, XEXXXX False True True NIHTT 37470483 Website Abstract 114172904 Allende M, Sasaki T, et al. https://pubmed.ncbi.nlm.nih.gov/15459201/ <a href="https://pubmed.ncbi.nlm.nih.gov/15459201/">Allende M, Sasaki T, et al.</a> 114111461 Proia, Richard National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Proia, Richard (NIDDK) 1 114111461 Proia, Richard National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Proia, Richard (NIDDK) 1 114102849 Sphingosine Kinase 1 (Sphk1) Knockout Mouse E-106-2012-0 Research Material National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83739550 Shastri, Mythreyi shastrim@mail.nih.gov
United States of America Technology Advancement Office shastrim@mail.nih.gov?subject=Web Inquiry on [TAB-3745] Sphingosine Kinase 1 (Sphk1) Knockout Mouse for Utilization in Developmental Biology&body=Please send me information about technology [TAB-3745] Sphingosine Kinase 1 (Sphk1) Knockout Mouse for Utilization in Developmental Biology. Shastri, Mythreyi<br><a href="mailto:shastrim@mail.nih.gov?subject=Web Inquiry on [TAB-3745] Sphingosine Kinase 1 (Sphk1) Knockout Mouse for Utilization in Developmental Biology&body=Please send me information about technology [TAB-3745] Sphingosine Kinase 1 (Sphk1) Knockout Mouse for Utilization in Developmental Biology.">shastrim@mail.nih.gov</a><br> 114129469 RXXXXX 114129470 WIXXXX 114129471 XEXXXX 114154991 Sphk1 114154992 KO 114154993 Mouse 114154994 Sphingosine 114154995 Kinase 114154996 1 114154997 Knockout 114154998 Listed LPM Greene as of 4/15/2015 114154999 Pre LPM working set 20150418 114155000 Post LPM Assignment Set 20150420 TAB-3743 114097595 Antibacterial and Antifungal Polyketides from Environmental Amycolatopsis Strains NIDDK Infectious Disease, Therapeutics Infectious Disease Therapeutics Carole Bewley Clore, Hongbing Liu, Shannon Ohlemacher, Gengxiang Zhao This technology includes three new chemical entities discovered for antibacterial and antifungal activities. The compounds are novel tetramic acid containing polyketides obtained from two different Amycolatopsis strains. Their planar structures and relative stereochemistry were elucidated by 1D and 2D NMR methods, including 1H-1H and 13C-13C COSY, TOCSY, HSQC, HMBC and ROESY. Whole genome sequencing of these two strains revealed a 158 kb biosynthetic gene cluster (BGC) containing a 23-module, mixed NRPS-PKS pathway responsible for their biosynthesis. Glycosylation appears to be a self-protection mechanism based on the activities of a glycosyltransferase and secreted glycosyl hydrolase encoded in the BGC. Databases show the closest related compounds are blasticidin A and aflastatin A. However, our compound has a different molecular weight, different hydroxylation patterns, and an unsaturated C-8 starter unit. These changes are significant in terms of chemical space and biological activity. Novel tetramic acid containing polyketides, with the active components inhibiting drug susceptible and drug resistant strains of Staphylococcus aureus, Candida albicans and other Gram-positive bacteria. These molecules have the potential as antibacterial and antifungal drugs or drug-leads. 2022-11-30 2024-10-28 2024-10-28 2022-11-30 2022-07-11 Amycolatopsis, Antibacterial, ANTIFUNGAL, ENVIRONMENTAL, L-149-2017, Polyketides, Spp., VJXXXX, VKXXXX, WKXXXX False True True NIHTT 37470483 Website Abstract 114172902 Sakuda S, Ono M, et al. https://pubmed.ncbi.nlm.nih.gov/11213287/ <a href="https://pubmed.ncbi.nlm.nih.gov/11213287/">Sakuda S, Ono M, et al.</a> 114172903 Konda T, Sakurada M, et al. https://pubmed.ncbi.nlm.nih.gov/11592501/ <a href="https://pubmed.ncbi.nlm.nih.gov/11592501/">Konda T, Sakurada M, et al.</a> 114111454 Liu, Hongbing National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Liu, Hongbing (NIDDK) 0 114111455 Ohlemacher, Shannon National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Ohlemacher, Shannon (NIDDK) 0 114111456 Zhao, Gengxiang National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Zhao, Gengxiang (NIDDK) 0 114111453 Bewley Clore, Carole National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Bewley Clore, Carole (NIDDK) 1 114111453 Bewley Clore, Carole National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Bewley Clore, Carole (NIDDK) 1 114111454 Liu, Hongbing National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Liu, Hongbing (NIDDK) 0 114111455 Ohlemacher, Shannon National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Ohlemacher, Shannon (NIDDK) 0 114111456 Zhao, Gengxiang National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Zhao, Gengxiang (NIDDK) 0 114102847 Antibacterial And Antifungal Polyketides From Environmental Amycolatopsis Spp. E-101-2020-0 Filing authorized National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83728636 Buller, Carolyn carolyn.buller@nih.gov
United States of America Technology Advancement Office carolyn.buller@nih.gov?subject=Web Inquiry on [TAB-3743] Antibacterial and Antifungal Polyketides from Environmental Amycolatopsis Strains&body=Please send me information about technology [TAB-3743] Antibacterial and Antifungal Polyketides from Environmental Amycolatopsis Strains. Buller, Carolyn<br><a href="mailto:carolyn.buller@nih.gov?subject=Web Inquiry on [TAB-3743] Antibacterial and Antifungal Polyketides from Environmental Amycolatopsis Strains&body=Please send me information about technology [TAB-3743] Antibacterial and Antifungal Polyketides from Environmental Amycolatopsis Strains.">carolyn.buller@nih.gov</a><br> 114169577 E-101-2020-0 E-101-2020-0-US-01 ANTIBACTERIAL AND ANTIFUNGAL POLYKETIDES FROM ENVIRONMENTAL AMYCOLATOPSIS SPP PRV US 62/990,557 Expired US <br />Provisional (PRV) 62/990,557<br />Filed on 2020-03-17<br />Status: Expired 114169578 E-101-2020-0 E-101-2020-0-PCT-03 Antibacterial And Antifungal Polyketides From Environmental Amycolatopsis Spp. PCT Patent Cooperation Treaty PCT/US2021/022571 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/022571<br />Filed on 2021-03-16<br />Status: Expired 114169651 E-101-2020-0 E-101-2020-0-US-04 Antibacterial And Antifungal Polyketides From Environmental Amycolatopsis Spp. National Stage US 17/909,051 Pending US <br />National Stage 17/909,051<br />Filed on 2022-09-02<br />Status: Pending 114129464 VJXXXX 114129465 VKXXXX 114129466 WKXXXX 114154975 L-149-2017 114154976 Antibacterial 114154977 ANTIFUNGAL 114154978 Polyketides 114154979 ENVIRONMENTAL 114154980 Amycolatopsis 114154981 Spp. TAB-3741 114097593 Ribose Derivatives as A3 Adenosine Receptor Modulator for Various Therapeutic Uses NIDDK Cardiology, Dental, Endocrinology, Infectious Disease, Neurology, Oncology, Ophthalmology, Therapeutics Cardiology Dental Endocrinology Infectious Disease Neurology Oncology Ophthalmology Therapeutics Kenneth Jacobson, Dilip Tosh This technology includes a class of A3AR-selective agonists to be used therapeutically to treat a variety of conditions, including chronic pain, cancer, and inflammatory diseases. This class of compounds produced full agonists of the human A3AR of nanomolar affinity that were consistently highly selective (>1000-fold vs. A1AR and A2AAR). The selectivity at mouse A3 receptors is smaller, but the compounds are still effective in vivo in reducing or preventing development of neuropathic pain. The advantages over previous, structurally similar compounds are a smaller molecular weight, and therefore greater oral bioavailability. We have carried out phenotypic screening – thus we have identified unexpected in vivo activity of specific C2 substituents in a chronic neuropathic pain model. This class of compounds produced full agonists of the human A3AR of nanomolar affinity that were consistently highly selective (>1000-fold vs. A1AR and A2AAR), and have a small molecular weight, and therefore greater oral bioavailability. The discovery could be primarily utilized therapeutically, with the main focus in the present set of compounds being chronic neuropathic pain. Other A3 agonists (our prototypical A3 agonists) are in advanced clinical trials for treatment of autoimmune inflammatory diseases and cancer, and the present compounds might be superior in animal tests in those diseases. 2022-11-30 2024-10-28 2024-10-28 2022-11-30 2022-07-10 A3, ADENOSINE, Derivatives, MODULATORS, RECEPTOR, Ribose, VMXXXX, VPXXXX, WKXXXX False True True NIHTT 37470483 Website Abstract 114172901 Tosh D, Janowsky A, et al. https://pubmed.ncbi.nlm.nih.gov/28319392/ <a href="https://pubmed.ncbi.nlm.nih.gov/28319392/">Tosh D, Janowsky A, et al.</a> 114111449 Tosh, Dilip National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Tosh, Dilip (NIDDK) 0 114111448 Jacobson, Kenneth National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Jacobson, Kenneth (NIDDK) 1 114111448 Jacobson, Kenneth National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Jacobson, Kenneth (NIDDK) 1 114111449 Tosh, Dilip National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Tosh, Dilip (NIDDK) 0 114102845 Ribose Derivatives As A3 Adenosine Receptor Modulators E-089-2017-0 Filing authorized National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83692066 Tong, Betty tongb@niddk.nih.gov
United States of America Senior Technology Advancement Office tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-3741] Ribose Derivatives as A3 Adenosine Receptor Modulator for Various Therapeutic Uses&body=Please send me information about technology [TAB-3741] Ribose Derivatives as A3 Adenosine Receptor Modulator for Various Therapeutic Uses. Tong, Betty<br><a href="mailto:tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-3741] Ribose Derivatives as A3 Adenosine Receptor Modulator for Various Therapeutic Uses&body=Please send me information about technology [TAB-3741] Ribose Derivatives as A3 Adenosine Receptor Modulator for Various Therapeutic Uses.">tongb@niddk.nih.gov</a><br> 114169576 E-089-2017-0 E-089-2017-0-US-01 Ribose Derivatives As A3 Adenosine Receptor Modulators PRV US 62/466,851 Abandoned US <br />Provisional (PRV) 62/466,851<br />Filed on 2017-03-03<br />Status: Abandoned 114129457 VMXXXX 114129458 VPXXXX 114129459 WKXXXX 114154962 Ribose 114154963 Derivatives 114154964 A3 114154965 ADENOSINE 114154966 RECEPTOR 114154967 MODULATORS TAB-3736 114097588 HEK293 Cell Line Deficient in Functional CASP8AP2 for Improved Production Efficiency NIDDK Research Materials Research Materials Laura Abaandou, Ashish Sharma, Joseph Shiloach This technology includes an engineered HEK293 cell line expressing firefly luciferase by functionally knocking out the caspase 8 associated protein 2 (CASP8AP2) gene using CRIPSR/Cas9 genome editing for improved production efficiency. This engineered cell line possesses superior recombinant protein expression capabilities than the parental cell line from which it was created, while proliferating and metabolizing carbon at a comparable rate. Improved recombinant protein expression is mediated by growth arrest at the G0/G1 phase. This G0/G1 growth arrest is not associated with decreased cell proliferation. This engineered cell line exhibits up to a 5-fold increase in specific recombinant luciferase production, with comparable growth and metabolism to the parental cell line. Improved production efficiency in bioproduction. 2022-11-30 2024-10-28 2024-10-28 2022-11-30 2022-07-10 CASP8AP2, Cell, DEFICIENT, FUNCTIONAL, HEK293, Line, WIXXXX False True True NIHTT 37470483 Website Abstract 114172899 Abaandou L, Sharma A, et al. https://pubmed.ncbi.nlm.nih.gov/32910455/ <a href="https://pubmed.ncbi.nlm.nih.gov/32910455/">Abaandou L, Sharma A, et al.</a> 114111438 Abaandou, Laura National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Abaandou, Laura 0 114111439 Sharma, Ashish National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Sharma, Ashish 0 114111437 Shiloach, Joseph National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Shiloach, Joseph (NIDDK) 1 114111437 Shiloach, Joseph National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Shiloach, Joseph (NIDDK) 1 114111438 Abaandou, Laura National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Abaandou, Laura 0 114111439 Sharma, Ashish National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Sharma, Ashish 0 114102840 HEK293 Cell Line Deficient In Functional CASP8AP2 E-074-2021-0 Research Material National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83739550 Shastri, Mythreyi shastrim@mail.nih.gov
United States of America Technology Advancement Office shastrim@mail.nih.gov?subject=Web Inquiry on [TAB-3736] HEK293 Cell Line Deficient in Functional CASP8AP2 for Improved Production Efficiency&body=Please send me information about technology [TAB-3736] HEK293 Cell Line Deficient in Functional CASP8AP2 for Improved Production Efficiency. Shastri, Mythreyi<br><a href="mailto:shastrim@mail.nih.gov?subject=Web Inquiry on [TAB-3736] HEK293 Cell Line Deficient in Functional CASP8AP2 for Improved Production Efficiency&body=Please send me information about technology [TAB-3736] HEK293 Cell Line Deficient in Functional CASP8AP2 for Improved Production Efficiency.">shastrim@mail.nih.gov</a><br> 114129444 WIXXXX 114154925 HEK293 114154926 Cell 114154927 Line 114154928 DEFICIENT 114154929 FUNCTIONAL 114154930 CASP8AP2 TAB-3737 114097589 Structure-Based Design of A3 Adenosine Receptor-Selective 2-Arylethynyl (N)-methanocarba Nucleosides for Diagnostic and Therapeutic Uses NIDDK Cardiology, Dental, Diagnostics, Endocrinology, Infectious Disease, Oncology, Ophthalmology, Research Materials, Therapeutics Cardiology Dental Diagnostics Endocrinology Infectious Disease Oncology Ophthalmology Research Materials Therapeutics Kenneth Jacobson, Dilip Tosh This technology includes compounds that are selective agonists of the A3 receptor for the treatment of various disorders such as cancer and autoinflammatory diseases. Structurally, these compounds extend the class of (N)-methanocarba derivatives that are selective agonists of the A3 receptor. This class of compounds produced full agonists of the human A3AR of nanomolar affinity that were consistently highly selective >1000-fold vs. A1AR and A2AAR. The discovery could be used in either a therapeutic or diagnostic mode. Other A3 agonists are in advanced clinical trials for treatment of various disorders such as hepatocellular carcinoma, autoimmune inflammatory diseases, and other conditions. 2022-11-30 2024-10-28 2024-10-28 2022-11-30 2022-07-10 2-Arylethynyl, A3, ADENOSINE, Design, Listed LPM Tong as of 4/15/2015, N-Methanocarba, Nucleosides, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Receptor-Selective, Structure-based, VCXXXX, VPXXXX, WBXXXX, WIXXXX, WKXXXX False True True NIHTT 37470483 Website Abstract 114172900 Tosh D, Deflorian F, et al. https://pubmed.ncbi.nlm.nih.gov/22559880/ <a href="https://pubmed.ncbi.nlm.nih.gov/22559880/">Tosh D, Deflorian F, et al.</a> 114111441 Tosh, Dilip National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Tosh, Dilip (NIDDK) 0 114111440 Jacobson, Kenneth National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Jacobson, Kenneth (NIDDK) 1 114111440 Jacobson, Kenneth National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Jacobson, Kenneth (NIDDK) 1 114111441 Tosh, Dilip National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Tosh, Dilip (NIDDK) 0 114102841 Structure-Based Design Of A3 Adenosine Receptor-Selective 2-Arylethynyl (N)-Methanocarba Nucleosides E-075-2012-0 Filing authorized National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83692066 Tong, Betty tongb@niddk.nih.gov
United States of America Senior Technology Advancement Office tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-3737] Structure-Based Design of A3 Adenosine Receptor-Selective 2-Arylethynyl (N)-methanocarba Nucleosides for Diagnostic and Therapeutic Uses&body=Please send me information about technology [TAB-3737] Structure-Based Design of A3 Adenosine Receptor-Selective 2-Arylethynyl (N)-methanocarba Nucleosides for Diagnostic and Therapeutic Uses. Tong, Betty<br><a href="mailto:tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-3737] Structure-Based Design of A3 Adenosine Receptor-Selective 2-Arylethynyl (N)-methanocarba Nucleosides for Diagnostic and Therapeutic Uses&body=Please send me information about technology [TAB-3737] Structure-Based Design of A3 Adenosine Receptor-Selective 2-Arylethynyl (N)-methanocarba Nucleosides for Diagnostic and Therapeutic Uses.">tongb@niddk.nih.gov</a><br> 114129445 VCXXXX 114129446 VPXXXX 114129447 WBXXXX 114129448 WIXXXX 114129449 WKXXXX 114154931 Structure-based 114154932 Design 114154933 A3 114154934 ADENOSINE 114154935 Receptor-Selective 114154936 2-Arylethynyl 114154937 N-Methanocarba 114154938 Nucleosides 114154939 Listed LPM Tong as of 4/15/2015 114154940 Pre LPM working set 20150418 114154941 Post LPM Assignment Set 20150420 TAB-3733 114097585 Synthetic Biotin-streptavidin Replacement for Use in the Development of Clinical Diagnostics NIDDK Diagnostics, Research Materials Diagnostics Research Materials Daniel Appella This technology includes an alternative synthetic biotin-streptavidin replacement system for use in the development of clinical diagnostics. Peptide nucleic acids (PNA) when functionalized onto the surface of microspheres are capable of targeting short RNA targets from solutions. However, when the target nucleic acid becomes longer and complicated in structure, the PNA no longer efficiently binds due to steric hindrance from the microspheres and/or slow hybridization kinetics of larger nucleic acid targets. To circumvent this issue, nucleic acid probes are used with a biotin-streptavidin system to have a two-step hybridization-capture where a biotinylated free probe hybridizes to a target nucleic acid and is then captured on a streptavidin coated bead. Here, we propose an alternative; isolation of target nucleic acids from a complex mixture is enabled by the use of cyclopentane peptide nucleic acids with two different chiralities: right-handed helices that bind nucleic acids and left-handed helices that are biorthogonal to binding nucleic acids but will bind to other left-handed molecules. Ability to target nucleic acid which is longer and more complex in structure. Utilized in the development of clinical diagnostics. 2022-11-30 2024-10-28 2024-10-28 2022-11-30 2022-07-10 Biotin-streptavidin, REPLACEMENT, Synthetic, WBXXXX, WIXXXX False True True NIHTT 37470483 Website Abstract 114111429 Appella, Daniel National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Appella, Daniel (NIDDK) 1 114111429 Appella, Daniel National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Appella, Daniel (NIDDK) 1 114102837 Synthetic Biotin-streptavidin Replacement E-043-2020-0 Filing authorized National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83692066 Tong, Betty tongb@niddk.nih.gov
United States of America Senior Technology Advancement Office tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-3733] Synthetic Biotin-streptavidin Replacement for Use in the Development of Clinical Diagnostics&body=Please send me information about technology [TAB-3733] Synthetic Biotin-streptavidin Replacement for Use in the Development of Clinical Diagnostics. Tong, Betty<br><a href="mailto:tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-3733] Synthetic Biotin-streptavidin Replacement for Use in the Development of Clinical Diagnostics&body=Please send me information about technology [TAB-3733] Synthetic Biotin-streptavidin Replacement for Use in the Development of Clinical Diagnostics.">tongb@niddk.nih.gov</a><br> 114169655 E-043-2020-0 E-043-2020-0-US-01 RNA Target Enrichment or Depletion of Biological Supplies PRV US 62/986,055 Abandoned US <br />Provisional (PRV) 62/986,055<br />Filed on 2020-03-06<br />Status: Abandoned 114169656 E-043-2020-0 E-043-2020-0-US-02 RNA TARGET ENRICHMENT OR DEPLETION OF BIOLOGICAL SAMPLES ORD US 12,071,616 17/193,652 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12071616 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12071616">12,071,616</a><br />Filed on 2021-03-05<br />Status: Issued 114129435 WBXXXX 114129436 WIXXXX 114154913 Synthetic 114154914 Biotin-streptavidin 114154915 REPLACEMENT TAB-3734 114097586 Ionophores as Treatment for Sickle Cell Disease NIDDK Cardiology, Dental, Endocrinology, Infectious Disease, Oncology, Ophthalmology, Research Materials, Therapeutics Cardiology Dental Endocrinology Infectious Disease Oncology Ophthalmology Research Materials Therapeutics William Eaton, Jeffrey Henry, Harry Hofrichter, Jeffrey Smith This technology includes a method using ionophores to reduce sickling in patients with sickle cell disease. Sickle cell disease is caused by polymerization of a hemoglobin mutant, and the only approved treatment acts by replacing sickle hemoglobin with fetal hemoglobin, thereby increasing the delay time prior to polymerization. This drug is only partially successful because it does not induce fetal hemoglobin synthesis in all cells. The discovery of a drug that inhibits sickling in all cells has been hampered by the lack of a sensitive, quantitative and automated cellular assay for screening that is directly related to the pathogenesis. We have developed such a method and used it to discover that decreasing the intracellular-sickle hemoglobin concentration by increasing the volume of the red cell with ionophores is a powerful method to reduce sickling. Because of the enormous dependence of the delay time prior to polymerization on concentration, the resulting increase in sickling time from small a concentration decrease will be therapeutic because it will allow more cells to escape the narrow vessels of the tissues before fibers can form and result in vaso-occlusion. Novel mechanism of action; there are no current drugs that have been discovered to treat sickle cell disease that act by inhibiting polymerization of deoxyhemoglobin, the basic cause of the disease. Treatment of sickle cell disease. 2022-11-30 2024-10-28 2024-10-28 2022-11-30 2022-07-10 Cell, Disease, Ionophores, Lonophores, SICKLE, treatment, VPXXXX, WIXXXX, WKXXXX False True True NIHTT 37470483 Website Abstract 114111431 Hofrichter, Harry National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Hofrichter, Harry (NIDDK) 0 114111432 Henry, Jeffrey National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Henry, Jeffrey (NIDDK) 0 114111433 Smith, Jeffrey McKinsey & Company Smith, Jeffrey 0 114111430 Eaton, William National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Eaton, William (NIDDK) 1 114111430 Eaton, William National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Eaton, William (NIDDK) 1 114111431 Hofrichter, Harry National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Hofrichter, Harry (NIDDK) 0 114111432 Henry, Jeffrey National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Henry, Jeffrey (NIDDK) 0 114111433 Smith, Jeffrey McKinsey & Company Smith, Jeffrey 0 114102838 Ionophores As Treatment Of Sickle Cell Disease E-046-2017-0 Filing authorized National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83692066 Tong, Betty tongb@niddk.nih.gov
United States of America Senior Technology Advancement Office tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-3734] Ionophores as Treatment for Sickle Cell Disease&body=Please send me information about technology [TAB-3734] Ionophores as Treatment for Sickle Cell Disease. Tong, Betty<br><a href="mailto:tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-3734] Ionophores as Treatment for Sickle Cell Disease&body=Please send me information about technology [TAB-3734] Ionophores as Treatment for Sickle Cell Disease.">tongb@niddk.nih.gov</a><br> 114169572 E-046-2017-0 E-046-2017-0-US-01 Ionophores As Treatment Of Sickle Cell Disease PRV US 62/435,534 Abandoned US <br />Provisional (PRV) 62/435,534<br />Filed on 2016-12-16<br />Status: Abandoned 114129437 VPXXXX 114129438 WIXXXX 114129439 WKXXXX 114154916 Ionophores 114154917 Lonophores 114154918 treatment 114154919 SICKLE 114154920 Cell 114154921 Disease TAB-3731 114097583 Nucleoside Agonists of Adenosine Receptors as Cardio- and Cerebroprotective Agents NIDDK Cardiology, Dental, Endocrinology, Infectious Disease, Neurology, Oncology, Ophthalmology, Psychiatry/Mental Health, Research Materials, Therapeutics Cardiology Dental Endocrinology Infectious Disease Neurology Oncology Ophthalmology Psychiatry/Mental Health Research Materials Therapeutics Oksana Gavrilova, Kenneth Jacobson, Marc Reitman, Dilip Tosh This technology includes a compound for use as a selective agonist of the A1 adenosine receptor (AR) for therapeutic hypothermia and other conditions. We have examined various synthesized nucleosides in a model of mouse hypothermia, in conjunction with AR knockout mice, to characterize the biological profiles. In trying to identify novel highly selective A1AR agonists that have superior in vivo activities, we have adapted a means of rigidifying the ribose moiety of adenosine in the form of a bicyclic (N)-methanocarba ring. We identified and modeled the N6-bicyclobutylmethyl group as a new substituent for the design of A1AR agonists, and peripherally administered compound 9 (MRS7469, containing this group) predominantly activates A1AR in the brain to lower body temperature. In the parallel methanocarba series, enhancement of A1AR affinity and selectivity was found with an alternative nucleobase, which opens the field for more broad synthesis of atypical A1AR agonists. Compound is bioavailable and drug-like, with no evident toxicity or potent off-target effects. These compounds could potentially be used for therapeutic hypothermia (i.e., to protect the brain in cases of cardiac arrest or stroke). There is also potential for their use in chronic pain, diabetes, cardiac arrhythmias, myocardial infarction, depression and brain ischemia. 2022-11-30 2024-10-28 2024-10-28 2022-11-30 2022-07-10 ADENOSINE, AGONISTS, NUCLEOSIDE, RECEPTORS, VDXXXX, VFXXXX, VMXXXX, VNXXXX, VPXXXX, WIXXXX, WKXXXX False True True NIHTT 37470483 Website Abstract 114172898 Tosh D, Rao H, et al. https://pubmed.ncbi.nlm.nih.gov/30605331/ <a href="https://pubmed.ncbi.nlm.nih.gov/30605331/">Tosh D, Rao H, et al.</a> 114111422 Tosh, Dilip National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Tosh, Dilip (NIDDK) 0 114111423 Reitman, Marc National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Reitman, Marc (NIDDK) 0 114111424 Gavrilova, Oksana National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Gavrilova, Oksana (NIDDK) 0 114111421 Jacobson, Kenneth National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Jacobson, Kenneth (NIDDK) 1 114111421 Jacobson, Kenneth National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Jacobson, Kenneth (NIDDK) 1 114111422 Tosh, Dilip National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Tosh, Dilip (NIDDK) 0 114111423 Reitman, Marc National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Reitman, Marc (NIDDK) 0 114111424 Gavrilova, Oksana National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Gavrilova, Oksana (NIDDK) 0 114102835 Nucleoside Agonists Of Adenosine Receptors E-022-2019-0 Filing authorized National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83692066 Tong, Betty tongb@niddk.nih.gov
United States of America Senior Technology Advancement Office tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-3731] Nucleoside Agonists of Adenosine Receptors as Cardio- and Cerebroprotective Agents&body=Please send me information about technology [TAB-3731] Nucleoside Agonists of Adenosine Receptors as Cardio- and Cerebroprotective Agents. Tong, Betty<br><a href="mailto:tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-3731] Nucleoside Agonists of Adenosine Receptors as Cardio- and Cerebroprotective Agents&body=Please send me information about technology [TAB-3731] Nucleoside Agonists of Adenosine Receptors as Cardio- and Cerebroprotective Agents.">tongb@niddk.nih.gov</a><br> 114169569 E-022-2019-0 E-022-2019-0-US-01 A1 ADENOSINE RECEPTOR AGONISTS AND METHODS OF USE THEREOF PRV US 62/776,528 Abandoned US <br />Provisional (PRV) 62/776,528<br />Filed on 2018-12-07<br />Status: Abandoned 114169570 E-022-2019-0 E-022-2019-0-PCT-02 A1 ADENOSINE RECEPTOR AGONISTS AND METHODS OF USE THEREOF PCT Patent Cooperation Treaty PCT/US2019/064844 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2019/064844<br />Filed on 2019-12-06<br />Status: Expired 114169571 E-022-2019-0 E-022-2019-0-US-03 A1 ADENOSINE RECEPTOR AGONISTS AND METHODS OF USE THEREOF National Stage US 12,378,248 17/299,890 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12378248 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12378248">12,378,248</a><br />Filed on 2021-06-04<br />Status: Issued 114129423 VDXXXX 114129424 VFXXXX 114129425 VMXXXX 114129426 VNXXXX 114129427 VPXXXX 114129428 WIXXXX 114129429 WKXXXX 114154898 RECEPTORS 114154899 ADENOSINE 114154900 AGONISTS 114154901 NUCLEOSIDE TAB-3732 114097584 MicroRNAs for Cell Line Utilization and Future Therapeutic Application NIDDK Cardiology, Dental, Endocrinology, Infectious Disease, Oncology, Ophthalmology, Research Materials, Therapeutics Cardiology Dental Endocrinology Infectious Disease Oncology Ophthalmology Research Materials Therapeutics Michael Betenbaugh, Chia Chu, Aliaksandr Druz, Joseph Shiloach This technology includes microRNAs for use in cell lines for protein production and potentially future treatments of cancer or diseases related to metabolism. Mmu-miR-466h was identified as a major apoptotic regulator in suspension adapted Chinese Hamster Ovary cells. Mmu-miR-466h was found to have the pro-apoptotic activity by targeting some anti-apoptotic genes for degradation during the exposure of CHO-S cells to the nutrients depleted media. Inhibition of mmu-miR-466h activity resulted in uninhibition of those anti-apoptotic targets and rendered CHO-S more viable with decreased Caspase-3,7 activation during nutrients depleted media incubation. While being pro-apoptotic, mmu-miR466h may also have a tumor suppressor activity in mammalian cells by sensitizing the cancer cells to programmed cell’s death (apoptosis). Mmu-miR-466h is the member of the same microRNA cluster with the pro-apoptotic activity complementary to mmu-miR-466h activity. Generation of more robust and apoptosis resistant cell lines for protein production. The stable inhibition of mmu-miR-466h/mmu-miR-466h activity in biotechnology utilized mammalian cell lines will generate more robust and apoptosis resistant cell lines for protein production. Also, mmu-miR-466h/mmi-miR-466h may be considered in treatment of cancer and other diseases related to deregulation in apoptosis program and/or metabolism. 2022-11-30 2024-10-28 2024-10-28 2022-11-30 2022-07-10 Activity, Cells, HAVE, Listed LPM Maddox as of 4/15/2015, MAMMALIAN, MicroRNAs, Mmu-miR-466g, Mmu-miR-466h, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Pro-Apoptotic, RXXXXX, VCXXXX, VPXXXX, WIXXXX, WKXXXX False True True NIHTT 37470483 Website Abstract 114111426 Druz, Aliaksandr National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIAID Druz, Aliaksandr (NIAID) 0 114111427 Chu, Chia National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Chu, Chia 0 114111428 Betenbaugh, Michael Johns Hopkins University Betenbaugh, Michael 0 114111425 Shiloach, Joseph National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Shiloach, Joseph (NIDDK) 1 114111425 Shiloach, Joseph National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Shiloach, Joseph (NIDDK) 1 114111426 Druz, Aliaksandr National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIAID Druz, Aliaksandr (NIAID) 0 114111427 Chu, Chia National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Chu, Chia 0 114111428 Betenbaugh, Michael Johns Hopkins University Betenbaugh, Michael 0 114102836 MicroRNAs Mmu-miR-466h And Mmu-miR-466g Have A Pro-apoptotic Activity In Mammalian Cells E-031-2011-0 Research Material Johns Hopkins University, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83692066 Tong, Betty tongb@niddk.nih.gov
United States of America Senior Technology Advancement Office tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-3732] MicroRNAs for Cell Line Utilization and Future Therapeutic Application&body=Please send me information about technology [TAB-3732] MicroRNAs for Cell Line Utilization and Future Therapeutic Application. Tong, Betty<br><a href="mailto:tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-3732] MicroRNAs for Cell Line Utilization and Future Therapeutic Application&body=Please send me information about technology [TAB-3732] MicroRNAs for Cell Line Utilization and Future Therapeutic Application.">tongb@niddk.nih.gov</a><br> 114129430 RXXXXX 114129431 VCXXXX 114129432 VPXXXX 114129433 WIXXXX 114129434 WKXXXX 114154902 Mmu-miR-466g 114154903 Mmu-miR-466h 114154904 MicroRNAs 114154905 HAVE 114154906 Pro-Apoptotic 114154907 Activity 114154908 MAMMALIAN 114154909 Cells 114154910 Listed LPM Maddox as of 4/15/2015 114154911 Pre LPM working set 20150418 114154912 Post LPM Assignment Set 20150420 TAB-3730 114097582 Luciferase Immunoprecipitation System (LIPS) for Point-of-care Diagnosis of COVID-19 Antibodies NIDCR Antibodies, Diagnostics, Immunology, Infectious Disease, Research Materials Antibodies Diagnostics Immunology Infectious Disease Research Materials Peter Burbelo, Blake Warner This technology includes a sensitive and specific method to rapidly detect antibodies in biofluids. This assay has been used for the detection of antibodies in blood, urine, and saliva. Until now, no one has used LIPS to detect clinically relevant antibodies to SARS-CoV-2 Nucleocapsid (N) or Spike (S) in saliva. Briefly, LIPS employs recombinantly synthesized target proteins or peptides (e.g., S and N proteins) tagged with light-emitting proteins as targets to be captured by host produced immunoglobulins. These immunoglobulins can be captured by protein A/G beads and immobilized. After immobilization, captured proteins tagged with luciferase can enzymatically react with substrate (luciferin) to emit light if captured, and then detected by a luminometer. The novelty of this method is that it can take less than 5 minutes, be scaled for use in a hand-held reader, and can be diversified to include a multitude of other detectable tagged proteins. Scalable to hand-held devices up to clinical laboratory testing, based on simple technology with an inexpensive per-test cost, providing rapid (<5 minutes), accurate and also quantitative results. Hand-held COVID-19 antibody saliva or urine analyzer, or commercial lab bead-based high-throughput flow assays. 2022-11-30 2024-10-28 2024-10-28 2022-11-30 2022-07-10 antibodies, Biofluids, COVID-19, Diagnosis, IMMUNOPRECIPITATION, Lips, LUCIFERASE, Point-of-care, System, VLXXXX, WBXXXX, WIXXXX, XAXXXX False True True NIHTT 37470483 Website Abstract 114111420 Warner, Blake NIDCR NIDCR Warner, Blake (NIDCR) 0 114111419 Burbelo, Peter NIDCR NIDCR Burbelo, Peter (NIDCR) 1 114111419 Burbelo, Peter NIDCR NIDCR Burbelo, Peter (NIDCR) 1 114111420 Warner, Blake NIDCR NIDCR Warner, Blake (NIDCR) 0 114102834 Luciferase Immunoprecipitation System (LIPS) For Point-of-care Diagnosis Of COVID-19 Antibodies Biofluids E-015-2021-0 Under Review NIDCR 83739611 Yonter, Ediz ediz.yonter@nih.gov
United States of America Technology Advancement Office ediz.yonter@nih.gov?subject=Web Inquiry on [TAB-3730] Luciferase Immunoprecipitation System (LIPS) for Point-of-care Diagnosis of COVID-19 Antibodies&body=Please send me information about technology [TAB-3730] Luciferase Immunoprecipitation System (LIPS) for Point-of-care Diagnosis of COVID-19 Antibodies. Yonter, Ediz<br><a href="mailto:ediz.yonter@nih.gov?subject=Web Inquiry on [TAB-3730] Luciferase Immunoprecipitation System (LIPS) for Point-of-care Diagnosis of COVID-19 Antibodies&body=Please send me information about technology [TAB-3730] Luciferase Immunoprecipitation System (LIPS) for Point-of-care Diagnosis of COVID-19 Antibodies.">ediz.yonter@nih.gov</a><br> 114129419 VLXXXX 114129420 WBXXXX 114129421 WIXXXX 114129422 XAXXXX 114154889 LUCIFERASE 114154890 IMMUNOPRECIPITATION 114154891 System 114154892 Lips 114154893 Point-of-care 114154894 Diagnosis 114154895 COVID-19 114154896 antibodies 114154897 Biofluids TAB-3729 114097581 microRNAs for the Improvement of Functional Protein Expression from HEK Cells NIDDK Research Materials Research Materials Michael Betenbaugh, Yui-Chi Chen, Scott Martin, Joseph Shiloach, Su Xiao This technology includes five microRNA mimics which were identified to improve the functional expression of hard-to-express membrane protein. These miRNAs are: hsa-miR-22-5p; hsa-miR-18a-5p, hsa-miR-22-3p, hsa-miR-429 and hsa-miR-2110. Improving expression level of recombinant mammalian proteins is vital, as the adequate supply of correctly folded proteins is the prerequisite for all structure and function studies. Rational attempts to improve membrane protein expression may not lead to expected results as membrane proteins involve particularly complex folding, assembly, and processing pathways, and there is only limited information for the bottlenecks that may reside in the protein production steps, such as transcription, translation, protein folding, secretion and cell viability. These miRNAs could be used to enhance expression of other membrane, intracellular or even secreted proteins with medical significance. The capacity of miRNAs to globally regulate entire gene networks without introducing additional translational burden, compared with conventional overexpression strategies, makes them advantageous for the development of high producing cell lines. The discovered miRNAs could be used for engineering cell lines with enhanced productivity for membrane proteins for medical research as well as for therapeutic proteins and vaccines. 2022-11-30 2024-10-28 2024-10-28 2022-11-30 2022-07-10 Cells, CHO, Cytosolic, Expression, FUNCTIONAL, glycoengineering, HEK, Hsa-miR-18a-5p, Hsa-miR-2110, Hsa-miR-22-3p, Hsa-miR-22-5p, Hsa-miR-429, Listed LPM Maddox as of 4/15/2015, MEMBRANE, Micro-RNA, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, proteins, WIXXXX False True True NIHTT 37470483 Website Abstract 114172896 Fischer S, Buck T, et al. https://pubmed.ncbi.nlm.nih.gov/25061012/ <a href="https://pubmed.ncbi.nlm.nih.gov/25061012/">Fischer S, Buck T, et al.</a> 114172897 Strotbek M, Florin L, et al. https://pubmed.ncbi.nlm.nih.gov/24144501/ <a href="https://pubmed.ncbi.nlm.nih.gov/24144501/">Strotbek M, Florin L, et al.</a> 114111415 Xiao, Su National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Xiao, Su (NIDDK) 0 114111416 Martin, Scott NCATS - NCGC Martin, Scott 0 114111417 Betenbaugh, Michael Johns Hopkins University Betenbaugh, Michael 0 114111418 Chen, Yui-Chi NCATS - TRND Chen, Yui-Chi 0 114111414 Shiloach, Joseph National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Shiloach, Joseph (NIDDK) 1 114111414 Shiloach, Joseph National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Shiloach, Joseph (NIDDK) 1 114111415 Xiao, Su National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Xiao, Su (NIDDK) 0 114111416 Martin, Scott NCATS - NCGC Martin, Scott 0 114111417 Betenbaugh, Michael Johns Hopkins University Betenbaugh, Michael 0 114111418 Chen, Yui-Chi NCATS - TRND Chen, Yui-Chi 0 114102833 Hsa-miR-22-5p, Hsa-miR-18a-5p, Hsa-miR-22-3p, Hsa-miR-429 And Hsa-miR-2110 Were Identified To Improve Functional Expression Of Membrane And Cytosolic Proteins From HEK Cells E-015-2015-0 Filing authorized Johns Hopkins University, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NCATS - NCGC 83692066 Tong, Betty tongb@niddk.nih.gov
United States of America Senior Technology Advancement Office tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-3729] microRNAs for the Improvement of Functional Protein Expression from HEK Cells&body=Please send me information about technology [TAB-3729] microRNAs for the Improvement of Functional Protein Expression from HEK Cells. Tong, Betty<br><a href="mailto:tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-3729] microRNAs for the Improvement of Functional Protein Expression from HEK Cells&body=Please send me information about technology [TAB-3729] microRNAs for the Improvement of Functional Protein Expression from HEK Cells.">tongb@niddk.nih.gov</a><br> 114169567 E-015-2015-0 E-015-2015-0-US-01 Hsa-miR-22-5p, Hsa-miR-18a-5p, Hsa-miR-22-3p, Hsa-miR-429 And Hsa-miR-2110 Were Identified To Improve Functional Expression Of Membrane And Cytosolic Proteins From HEK Cells PRV US 62/108,976 Abandoned US <br />Provisional (PRV) 62/108,976<br />Filed on 2015-01-28<br />Status: Abandoned 114169568 E-015-2015-0 E-015-2015-0-US-02 Methods of Improved Protein Production Using MIRNAs and SIRNAs ORD US 15/009,481 Administratively Closed US <br />Ordinary Patent (ORD) 15/009,481<br />Filed on 2016-01-28<br />Status: Administratively Closed 114129418 WIXXXX 114154871 Hsa-miR-22-5p 114154872 Hsa-miR-18a-5p 114154873 Hsa-miR-22-3p 114154874 Hsa-miR-429 114154875 Hsa-miR-2110 114154876 FUNCTIONAL 114154877 MEMBRANE 114154878 HEK 114154879 Cells 114154880 Expression 114154881 Cytosolic 114154882 proteins 114154883 Listed LPM Maddox as of 4/15/2015 114154884 Pre LPM working set 20150418 114154885 Post LPM Assignment Set 20150420 114154886 Micro-RNA 114154887 glycoengineering 114154888 CHO TAB-3728 114097580 Cyclopentane-modified FIT-PNAs as Highly Emissive and Selective RNA/DNA Sensors for Use in Clinical Diagnostics NIDDK Diagnostics, Medical Devices, Non-Medical Devices, Research Materials, Software / Apps Diagnostics Medical Devices Non-Medical Devices Research Materials Software / Apps Daniel Appella, Eylon Yavin, Hongchao Zheng This technology includes Cyclopentane-modified Peptide Nucleic Acids (cp-PNAs) which can be combined with (forced-intercalation) FIT-PNAs to create highly sensitive probes that detect the presence of complementary RNA sequences. We have studied the beneficial effects of incorporating cyclopentane groups into the backbone of PNAs, which leads to proper preorganization of the PNA backbone into the conformations needed to bind complementary RNA sequences. The cp-PNAs typically have improved thermodynamic stability for binding to complementary nucleic acids compared to unmodified PNAs. FIT-PNAs have a fluorescent group attached to one position in a PNA sequence so that the fluorescent group replaces one nucleobase in the sequence. When a FIT-PNA binds to complementary RNA, the fluorescence increases due to steric hindrance in the bound PNA. By combining cp-PNA and FIT-PNA strategies, more sensitive RNA detection is achieved. The PNAs that contain both cyclopentane groups and also a FIT group are called cpFIT-PNAs. Potentially applicable to the development of clinical diagnostics. The new cpFIT-PNAs should be useful to detect biologically relevant RNA sequences associated with different disease states, such as cancer or viral infections or bacterial infections, and can be used when analyzing fresh human tissues or human fluid samples in clinical settings. 2022-11-30 2024-10-28 2024-10-28 2022-11-30 2022-07-10 Cyclopentane-modified, Emissive, FIT-PNAs, Highly, RNA/DNA, SELECTIVE, SENSORS, WBXXXX, WIXXXX, XFXXXX False True True NIHTT 37470483 Website Abstract 114111411 Appella, Daniel National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Appella, Daniel (NIDDK) 0 114111412 Zheng, Hongchao National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Zheng, Hongchao (NIDDK) 0 114111413 Yavin, Eylon Yissum Research Development Company Yavin, Eylon 1 114111413 Yavin, Eylon Yissum Research Development Company Yavin, Eylon 1 114111411 Appella, Daniel National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Appella, Daniel (NIDDK) 0 114111412 Zheng, Hongchao National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Zheng, Hongchao (NIDDK) 0 114102832 Cyclopentane-modified FIT-PNAs As Highly Emissive And Selective RNA/DNA Sensors E-011-2021-0 Filing authorized National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Yissum Research Development Company 83692066 Tong, Betty tongb@niddk.nih.gov
United States of America Senior Technology Advancement Office tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-3728] Cyclopentane-modified FIT-PNAs as Highly Emissive and Selective RNA/DNA Sensors for Use in Clinical Diagnostics&body=Please send me information about technology [TAB-3728] Cyclopentane-modified FIT-PNAs as Highly Emissive and Selective RNA/DNA Sensors for Use in Clinical Diagnostics. Tong, Betty<br><a href="mailto:tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-3728] Cyclopentane-modified FIT-PNAs as Highly Emissive and Selective RNA/DNA Sensors for Use in Clinical Diagnostics&body=Please send me information about technology [TAB-3728] Cyclopentane-modified FIT-PNAs as Highly Emissive and Selective RNA/DNA Sensors for Use in Clinical Diagnostics.">tongb@niddk.nih.gov</a><br> 114169565 E-011-2021-0 E-011-2021-0-US-01 CYCLOPENTANE FIT-PNAS: BRIGHT RNA SENSORS PRV US 63/111,370 Abandoned US <br />Provisional (PRV) 63/111,370<br />Filed on 2020-11-09<br />Status: Abandoned 114169566 E-011-2021-0 E-011-2021-0-PCT-02 RNA SENSORS AND USES THEREOF PCT Patent Cooperation Treaty PCT/IL2021/051318 Expired Patent Cooperation Treaty <br />(PCT) PCT/IL2021/051318<br />Filed on 2021-11-08<br />Status: Expired 114129415 WBXXXX 114129416 WIXXXX 114129417 XFXXXX 114154864 SENSORS 114154865 RNA/DNA 114154866 SELECTIVE 114154867 Emissive 114154868 Highly 114154869 FIT-PNAs 114154870 Cyclopentane-modified TAB-3725 114097577 Human Salivary Gland Cell Lines for Propagation of Enteric Viruses NHLBI Research Materials Research Materials Nihal Altan-Bonnet, John (Jay) Chiorini, Sourish Ghosh Enteric viruses like norovirus, rotavirus and astrovirus mainly transmit through fecal-oral route by ingestion of contaminated food and water and productively replicate in the intestines. Recently, researchers at National Heart, Lung, and Blood Institute (NHLBI) and National Institute of Dental and Craniofacial Research (NIDCR) identified a second route of enteric viral transmission by demonstrating that these viruses also productively and persistently infect salivary glands, reaching titers comparable to that in intestines. To effectively propagate the human norovirus, researches also developed cell lines derived from human salivary gland. The two SV40 transformed adherent cell lines were adapted to grow in serum-free conditions and express acinar (NS-SV-TT-AC) and ductal (NS-SV-TT-DC ) characteristics respectively. Unlike conventional methods for propagating human norovirus, these cells don’t require special incubation conditions and have been extensively characterized. Importantly, these cell lines are permissive to human norovirus, and would also be useful in investigating the virus-host cell interactions. <br /><br /> NHLBI is seeking parties to non-exclusively license the NS-SV-TT-AC and NS-SV-TT-DC human salivary gland cell lines. <ul> <li>Well characterized cell lines</li> <li>Adapted to grow in serum-free media</li> </ul> <ul> <li>Research tool for propagation of human enteric viruses</li> <li>Research tool to identify cell surface receptor(s) for viruses</li> <li>Research tool to investigate virus-host cell interaction</li> </ul> Research Material – Patent protection is not being pursued for this technology. 2022-06-30 2024-10-28 2024-10-28 2022-06-30 1BXXXX, 2JXXXX, 4CXXXX, Cells, ENTERIC, Human, Norovirus, PROPAGATE, Salivary, Viruses False True True 52398218 Pre-Clinical (in vivo) 52398218 NIHTT 37470483 Website Abstract 114172895 Ghosh S, et al. https://pubmed.ncbi.nlm.nih.gov/35768512/ <a href="https://pubmed.ncbi.nlm.nih.gov/35768512/">Ghosh S, et al.</a> 114111401 Ghosh, Sourish National Heart, Lung, and Blood Institute (NHLBI) Ghosh, Sourish 0 114111402 Chiorini, John (Jay) NIDCR NIDCR Chiorini, John (Jay) (NIDCR) 0 114111400 Altan-Bonnet, Nihal National Heart, Lung, and Blood Institute (NHLBI) NHLBI Altan-Bonnet, Nihal (NHLBI) 1 114111400 Altan-Bonnet, Nihal National Heart, Lung, and Blood Institute (NHLBI) NHLBI Altan-Bonnet, Nihal (NHLBI) 1 114111401 Ghosh, Sourish National Heart, Lung, and Blood Institute (NHLBI) Ghosh, Sourish 0 114111402 Chiorini, John (Jay) NIDCR NIDCR Chiorini, John (Jay) (NIDCR) 0 114102829 Salivary Cells Propagate Human Norovirus And Other Enteric Viruses E-087-2022-0 Research Material National Heart, Lung, and Blood Institute (NHLBI), NIDCR 83739538 Choudhry, Vidita vidita.choudhry@nih.gov
United States of America Office of Technology Transfer and Development vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-3725] Human Salivary Gland Cell Lines for Propagation of Enteric Viruses&body=Please send me information about technology [TAB-3725] Human Salivary Gland Cell Lines for Propagation of Enteric Viruses. Choudhry, Vidita<br><a href="mailto:vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-3725] Human Salivary Gland Cell Lines for Propagation of Enteric Viruses&body=Please send me information about technology [TAB-3725] Human Salivary Gland Cell Lines for Propagation of Enteric Viruses.">vidita.choudhry@nih.gov</a><br> 114129407 2JXXXX 114129408 4CXXXX 114129409 1BXXXX 114154841 Salivary 114154842 Cells 114154843 PROPAGATE 114154844 Human 114154845 Norovirus 114154846 ENTERIC 114154847 Viruses TAB-3721 114097573 Longer-lived Mouse Models for Studying Gaucher Disease NIMH Cardiology, Consumer Products, Dental, Endocrinology, Infectious Disease, Oncology, Ophthalmology, Research Materials, Therapeutics Cardiology Consumer Products Dental Endocrinology Infectious Disease Oncology Ophthalmology Research Materials Therapeutics Edward Ginns, Mary LaMarca (Estate) The invention is a novel longer-lived mouse model for Gaucher disease. Gaucher disease is a genetic disorder that results from deficiencies in the enzyme glucocerebrosidase (GBA). The use of animal models to study how the disease progresses has been invaluable in research of this disorder. However, existing mouse models have been limited due to early mortality because the GBA enzyme plays an important role in lysosomal storage. <br /><br /> Researchers at the National Institute of Mental Health (NIMH) generated the Gaucher mice were generated by inserting mutations that reduced GBA enzyme activity into normal mouse DNA. As observed in human patients, the reduced GBA enzyme activity in these Gaucher mice results in glucocerebroside lipid storage in tissue macrophages (Gaucher cells). The availability of these longer-lived mutant Gaucher mice provides a means to understand the development of pathology in bone, brain, and other organs, as well as enabling the unmet public health need for the development of novel treatments that could be safer, more efficient, and cost-effective for patients. The mouse models are longer-lived Gaucher mice that carry some of the more common mutations found in Gaucher patients. In vivo and in vitro animal model experiments to develop novel treatments for Gaucher disease. 2022-06-02 2024-10-28 2024-10-28 2022-06-02 ANIMAL, DISORDERS, Gaucher, Gaucher Disease, Human, IDXXXX, Inherited, Models, RXXXXX, TRANSGENIC, VHXXXX, VPXXXX, WIXXXX, WJXXXX, WKXXXX, WMXXXX, XEXXXX False True True NIHTT 37470483 Website Abstract 114111385 LaMarca (Estate), Mary National Institute of Mental Health (NIMH) NIMH LaMarca (Estate), Mary (NIMH) 0 114111384 Ginns, Edward Brudnick Neuropsychiatric Research Institute Ginns, Edward 1 114111384 Ginns, Edward Brudnick Neuropsychiatric Research Institute Ginns, Edward 1 114111385 LaMarca (Estate), Mary National Institute of Mental Health (NIMH) NIMH LaMarca (Estate), Mary (NIMH) 0 114102825 Transgenic Animal Models Of Human Inherited Disorders E-304-2011-0 Research Material National Institute of Mental Health (NIMH) 83739514 Dawson, Anton anton.dawson@nih.gov
United States of America anton.dawson@nih.gov?subject=Web Inquiry on [TAB-3721] Longer-lived Mouse Models for Studying Gaucher Disease&body=Please send me information about technology [TAB-3721] Longer-lived Mouse Models for Studying Gaucher Disease. Dawson, Anton<br><a href="mailto:anton.dawson@nih.gov?subject=Web Inquiry on [TAB-3721] Longer-lived Mouse Models for Studying Gaucher Disease&body=Please send me information about technology [TAB-3721] Longer-lived Mouse Models for Studying Gaucher Disease.">anton.dawson@nih.gov</a><br> 114129385 RXXXXX 114129386 IDXXXX 114129387 VHXXXX 114129388 VPXXXX 114129389 WIXXXX 114129390 WJXXXX 114129391 WKXXXX 114129392 WMXXXX 114129393 XEXXXX 114154795 TRANSGENIC 114154796 ANIMAL 114154797 Models 114154798 Human 114154799 Inherited 114154800 DISORDERS 114154801 Gaucher Disease 114154802 Gaucher TAB-3718 114097570 Design of Switch-Mode Amplifier to Transform Single Transmit Hardware for Multi-Nuclear MRI NINDS Diagnostics, Medical Devices, Non-Medical Devices, Research Materials, Software / Apps Diagnostics Medical Devices Non-Medical Devices Research Materials Software / Apps Natalia Gudino This technology includes the design and implementation for 1H-nuclear magnetic resonance imaging (MRI) that allows single transmit hardware to be "transformed" for another nucleus excitation to perform multi-nuclear MR. A radiofrequency (RF) optically controlled switch-mode amplifier prototype is tuned for excitation of two nuclei. The amplifier received the nuclei carrier signals optically through a single fiber. This signal is amplified first through a broadband low current stage that provides a pair of gate-source voltage signals 180 degrees out of phase to switch ON a pair of field effect transistors (FETs) in push-pull class-D configuration (FET are turned ON only during half a cycle). In this preamplification stage gate circuitry has been dual tuned, through a dual-resonance LC network, for maximizing the gate-source voltage to fully switch ON the FETs at the selected nuclei frequencies. A similar approach is followed to permit the gate control signals to fully switch ON the FETs of the power stage in Current-Mode Class-D topology. A prototype for 1H and 31P excitation at 7T was implemented, tested on the bench and MRI scanner. To simplify the implementation of multi-nuclear multi-channel hardware, I designed, implemented and tested an optically controlled dual-tuned on-coil current-source amplifier for 1H and X-nuclei excitation. On-coil current-source amplification has been proposed for the practical implementation of 1H pTx systems. I expect this new prototype will allow a more flexible multi-nuclear multi-channel transmitter hardware by eliminating the need of multiple cable traps, matching networks and coaxial connections as needed for each resonance frequency in conventional broadband voltage mode amplification available in commercial scanners with multi-nuclear capability. This prototype can be used in the implementation of a versatile parallel transmission system for 1H imaging that allows one or more transmit channels to be "transformed" for another nucleus excitation to perform multi-nuclear MR with a single transmit hardware. 2022-06-07 2024-10-28 2024-10-28 2022-06-07 AMPLIFIER, Controlled, Dual-Tuned, On-Coil, Optically, Switch-Mode, WBXXXX, WIXXXX, XFXXXX False True True NIHTT 37470483 Website Abstract 114111377 Gudino, Natalia NINDS NINDS Gudino, Natalia (NINDS) 1 114111377 Gudino, Natalia NINDS NINDS Gudino, Natalia (NINDS) 1 114102822 Dual-Tuned Optically Controlled On-Coil Switch-Mode Amplifier E-120-2020-0 Filing authorized NINDS 83667829 Ano, Susan susan.ano@nih.gov
United States of America susan.ano@nih.gov?subject=Web Inquiry on [TAB-3718] Design of Switch-Mode Amplifier to Transform Single Transmit Hardware for Multi-Nuclear MRI&body=Please send me information about technology [TAB-3718] Design of Switch-Mode Amplifier to Transform Single Transmit Hardware for Multi-Nuclear MRI. Ano, Susan<br><a href="mailto:susan.ano@nih.gov?subject=Web Inquiry on [TAB-3718] Design of Switch-Mode Amplifier to Transform Single Transmit Hardware for Multi-Nuclear MRI&body=Please send me information about technology [TAB-3718] Design of Switch-Mode Amplifier to Transform Single Transmit Hardware for Multi-Nuclear MRI.">susan.ano@nih.gov</a><br> 114169542 E-120-2020-0 E-120-2020-0-US-01 DUAL-TUNED OPTICALLY CONTROLLED ON-COIL AMPLIFIER FOR HIGH-FIELD MAGNETIC RESONANCE IMAGING SYSTEMS PRV US 63/046,896 Abandoned US <br />Provisional (PRV) 63/046,896<br />Filed on 2020-07-01<br />Status: Abandoned 114129370 WBXXXX 114129371 WIXXXX 114129372 XFXXXX 114154771 Dual-Tuned 114154772 Optically 114154773 Controlled 114154774 On-Coil 114154775 Switch-Mode 114154776 AMPLIFIER TAB-3717 114097546 The Generation and Use of Novel Anti-mitofusin 1 Polyclonal Antibodies NINDS Antibodies, Immunology, Research Materials Antibodies Immunology Research Materials Der-Fen Suen, Richard Youle This technology includes the generation and use of novel rabbit polyclonal antibodies against a GST-tagged portion of the human protein mitofusin 1 (amino acids 667-741). The rabbit polyclonal antibodies in this technology have high specificity to the GST-tagged portion of human mitofusion 1 (amino acids 667-741). This discovery provides a new antibody that recognizes a portion of the human mitofusin 1 protein that is much better than other commercially-available anti-mitofusin 1 antibodies. 2022-06-02 2024-10-28 2024-10-28 2022-06-02 2022-06-01 1, ANTIBODY, Anti-mitofusion, polyclonal, rabbit, WIXXXX, XAXXXX False True True NIHTT 37470483 Website Abstract 114172880 Tanaka A, Cleland MM, et al. https://pubmed.ncbi.nlm.nih.gov/21173115/ <a href="https://pubmed.ncbi.nlm.nih.gov/21173115/">Tanaka A, Cleland MM, et al. </a> 114172881 Lazarou M, Narendra DP, et al. https://pubmed.ncbi.nlm.nih.gov/23319602/ <a href="https://pubmed.ncbi.nlm.nih.gov/23319602/">Lazarou M, Narendra DP, et al.</a> 114172882 Hasson SA, Kane LA, et al. https://pubmed.ncbi.nlm.nih.gov/24270810/ <a href="https://pubmed.ncbi.nlm.nih.gov/24270810/">Hasson SA, Kane LA, et al.</a> 114172883 Yamano K, Youle RJ, et al. https://pubmed.ncbi.nlm.nih.gov/24121706/ <a href="https://pubmed.ncbi.nlm.nih.gov/24121706/ ">Yamano K, Youle RJ, et al.</a> 114172884 Shen Q, Yamano K, et al. https://pubmed.ncbi.nlm.nih.gov/24196833/ <a href="https://pubmed.ncbi.nlm.nih.gov/24196833/ ">Shen Q, Yamano K, et al. </a> 114172885 Yamano K, Fogel AI, et al. https://pubmed.ncbi.nlm.nih.gov/24569479/ <a href="https://pubmed.ncbi.nlm.nih.gov/24569479/ ">Yamano K, Fogel AI, et al. </a> 114172886 Kane LA, Lazarou M, et al. https://pubmed.ncbi.nlm.nih.gov/24751536/ <a href="https://pubmed.ncbi.nlm.nih.gov/24751536/">Kane LA, Lazarou M, et al. </a> 114172887 Nezich CL, Wang C, et al. https://pubmed.ncbi.nlm.nih.gov/26240184/ <a href="https://pubmed.ncbi.nlm.nih.gov/26240184/">Nezich CL, Wang C, et al.</a> 114172888 Lazarou M, Sliter DA, et al. https://pubmed.ncbi.nlm.nih.gov/26266977/ <a href="https://pubmed.ncbi.nlm.nih.gov/26266977/ ">Lazarou M, Sliter DA, et al. </a> 114111375 Suen, Der-Fen Agricultural Biotechnology Research Center, Academia Sinica Suen, Der-Fen 0 114111376 Youle, Richard NINDS NINDS Youle, Richard (NINDS) 1 114111376 Youle, Richard NINDS NINDS Youle, Richard (NINDS) 1 114111375 Suen, Der-Fen Agricultural Biotechnology Research Center, Academia Sinica Suen, Der-Fen 0 114102821 Rabbit Polyclonal Anti-mitofusion 1 Antibody E-147-2016-0 Research Material NINDS 83687767 Olufemi, Olufunmilola (Lola) olufunmilola.olufemi@nih.gov
United States of America olufunmilola.olufemi@nih.gov?subject=Web Inquiry on [TAB-3717] The Generation and Use of Novel Anti-mitofusin 1 Polyclonal Antibodies&body=Please send me information about technology [TAB-3717] The Generation and Use of Novel Anti-mitofusin 1 Polyclonal Antibodies. Olufemi, Olufunmilola (Lola)<br><a href="mailto:olufunmilola.olufemi@nih.gov?subject=Web Inquiry on [TAB-3717] The Generation and Use of Novel Anti-mitofusin 1 Polyclonal Antibodies&body=Please send me information about technology [TAB-3717] The Generation and Use of Novel Anti-mitofusin 1 Polyclonal Antibodies.">olufunmilola.olufemi@nih.gov</a><br> 114129368 WIXXXX 114129369 XAXXXX 114154766 rabbit 114154767 polyclonal 114154768 Anti-mitofusion 114154769 1 114154770 ANTIBODY TAB-3716 114097569 Development of an Antibody, VA-17, that Detects All Forms of Oxytocin in Radioimmunoassay (RIA) NINDS Antibodies, Immunology, Research Materials Antibodies Immunology Research Materials Harold Gainer (Estate) This technology includes the development and use of the VA-17 antibody that detects both amidated and extended forms of Oxytocin in radioimmunoassay. This antibody can be used for in vitro work, including RIA assays, to detect both forms of Oxytocin: amidated and extended. The antibody described in this technology can be used in an RIA assay to measure both amidated and extended forms of Oxytocin. There are no other commercially-available antibodies with this specificity to label both amidated and extended forms of Oxytocin. 2022-06-02 2024-10-28 2024-10-28 2022-06-02 2022-06-01 ANTIBODY, DETECTS, Development, Forms, Listed LPM Contreras as of 4/15/2015, OXYTOCIN, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Radioimmunoassay, RIA., That, VA-17, WIXXXX, XAXXXX False True True NIHTT 37470483 Website Abstract 114172879 Alstein M, Whitnall MH, et al. https://pubmed.ncbi.nlm.nih.gov/3362746/ <a href="https://pubmed.ncbi.nlm.nih.gov/3362746/">Alstein M, Whitnall MH, et al.</a> 114111374 Gainer (Estate), Harold NINDS NINDS Gainer (Estate), Harold (NINDS) 1 114111374 Gainer (Estate), Harold NINDS NINDS Gainer (Estate), Harold (NINDS) 1 114102820 Development Of VA-17, An Antibody That Detects All Forms Of Oxytocin In Radioimmunoassay (RIA). E-489-2013-0 Research Material NINDS 83667829 Ano, Susan susan.ano@nih.gov
United States of America susan.ano@nih.gov?subject=Web Inquiry on [TAB-3716] Development of an Antibody, VA-17, that Detects All Forms of Oxytocin in Radioimmunoassay (RIA)&body=Please send me information about technology [TAB-3716] Development of an Antibody, VA-17, that Detects All Forms of Oxytocin in Radioimmunoassay (RIA). Ano, Susan<br><a href="mailto:susan.ano@nih.gov?subject=Web Inquiry on [TAB-3716] Development of an Antibody, VA-17, that Detects All Forms of Oxytocin in Radioimmunoassay (RIA)&body=Please send me information about technology [TAB-3716] Development of an Antibody, VA-17, that Detects All Forms of Oxytocin in Radioimmunoassay (RIA).">susan.ano@nih.gov</a><br> 114129366 WIXXXX 114129367 XAXXXX 114154754 Development 114154755 VA-17 114154756 ANTIBODY 114154757 That 114154758 DETECTS 114154759 Forms 114154760 OXYTOCIN 114154761 Radioimmunoassay 114154762 RIA. 114154763 Listed LPM Contreras as of 4/15/2015 114154764 Pre LPM working set 20150418 114154765 Post LPM Assignment Set 20150420 TAB-3714 114097567 Automated Identification of Subjects at Risk of Multiple Sclerosis (AIMS) NINDS Cardiology, Computational models/software, Dental, Diagnostics, Endocrinology, Infectious Disease, Neurology, Oncology, Ophthalmology, Research Equipment, Software / Apps Cardiology Computational models/software Dental Diagnostics Endocrinology Infectious Disease Neurology Oncology Ophthalmology Research Equipment Software / Apps Sunil Patil, Daniel Reich, Pascal Sati This technology includes an automated and non-invasive assessment system called Automated Identification of subjects at risks of Multiple Sclerosis (AIMS) to assist clinicians in their diagnostic evaluation. A focus of AIMS is the ‘central vein sign’ (and other radiological findings). The methodology is composed of the following features: <ol> <li>Ultra-fast high-resolution susceptibility imaging of the brain using novel MRI technique called 3D segmented echo-planar-imaging</li> <li>Novel MRI contrasts (e.g., FLAIR*, QSM) using advanced processing</li> <li>Fully automated detection for brain lesions, central vein sign and lesion rims, using novel statistical/machine-learning techniques</li> </ol> AIMS will ultimately generate a report describing all the information obtained from the image analysis and will classify the patients as either a low risk or high risk for MS. AIMS is the first non-invasive automated assessment of the ‘central vein sign’ (small veins inside lesions) in patient brains. There are no commercially-available tools for automatically detecting central veins in cerebral plaques and assisting clinicians in the diagnosis of MS using radiological findings. 2022-06-02 2024-10-28 2024-10-28 2022-06-02 2022-06-01 AIMS, Automated, Identification, MULTIPLE, Risks, SCLEROSIS, SUBJECTS, VEXXXX, VPXXXX, WBXXXX, XBXXXX, XHXXXX, XJXXXX False True True NIHTT 37470483 Website Abstract 114172876 Sati P, Oh J, et al. https://pubmed.ncbi.nlm.nih.gov/27834394/ <a href="https://pubmed.ncbi.nlm.nih.gov/27834394/">Sati P, Oh J, et al.</a> 114172877 Sati P, Patil S, et al. https://cdn0.scrvt.com/39b415fb07de4d9656c7b516d8e2d907/1800000003913222/2abb22287602/magnetom-flash-68_rapid-mr-susceptibility-imaging-of-the-brain_sati_1800000003913222.pdf <a href="https://cdn0.scrvt.com/39b415fb07de4d9656c7b516d8e2d907/1800000003913222/2abb22287602/magnetom-flash-68_rapid-mr-susceptibility-imaging-of-the-brain_sati_1800000003913222.pdf">Sati P, Patil S, et al.</a> 114172878 Sati P, George IC, et al. https://pubmed.ncbi.nlm.nih.gov/23074257/ <a href="https://pubmed.ncbi.nlm.nih.gov/23074257/ ">Sati P, George IC, et al.</a> 114111370 Reich, Daniel NINDS NINDS Reich, Daniel (NINDS) 0 114111371 Patil, Sunil Siemens Medical Solutions USA, Inc. Patil, Sunil 0 114111369 Sati, Pascal NINDS NINDS Sati, Pascal (NINDS) 1 114111369 Sati, Pascal NINDS NINDS Sati, Pascal (NINDS) 1 114111370 Reich, Daniel NINDS NINDS Reich, Daniel (NINDS) 0 114111371 Patil, Sunil Siemens Medical Solutions USA, Inc. Patil, Sunil 0 114102818 Automated Identification Of Subjects At Risks Of Multiple Sclerosis (AIMS) E-009-2019-0 Filing authorized NINDS, Siemens Medical Solutions USA, Inc. 83722849 Sharma, Smita smita.sharma@nih.gov
United States of America smita.sharma@nih.gov?subject=Web Inquiry on [TAB-3714] Automated Identification of Subjects at Risk of Multiple Sclerosis (AIMS)&body=Please send me information about technology [TAB-3714] Automated Identification of Subjects at Risk of Multiple Sclerosis (AIMS). Sharma, Smita<br><a href="mailto:smita.sharma@nih.gov?subject=Web Inquiry on [TAB-3714] Automated Identification of Subjects at Risk of Multiple Sclerosis (AIMS)&body=Please send me information about technology [TAB-3714] Automated Identification of Subjects at Risk of Multiple Sclerosis (AIMS).">smita.sharma@nih.gov</a><br> 114169541 E-009-2019-0 E-009-2019-0-US-01 Automated Identification Of Subjects At Risks Of Multiple Sclerosis (AIMS) ORD US 11,272,843 16/254,710 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11272843 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11272843">11,272,843</a><br />Filed on 2019-01-23<br />Status: Issued 114129356 VEXXXX 114129357 VPXXXX 114129358 WBXXXX 114129359 XBXXXX 114129360 XHXXXX 114129361 XJXXXX 114154740 Automated 114154741 Identification 114154742 SUBJECTS 114154743 Risks 114154744 MULTIPLE 114154745 SCLEROSIS 114154746 AIMS TAB-3715 114097568 Treatment of Immune-mediated Brain Swelling with Combined Anti-LFA1/VLA4 Therapy NINDS Antibodies, Cardiology, Consumer Products, Dental, Endocrinology, Immunology, Infectious Disease, Neurology, Oncology, Ophthalmology Antibodies Cardiology Consumer Products Dental Endocrinology Immunology Infectious Disease Neurology Oncology Ophthalmology Panagiotis (Panos) Mastorakos, Dorian McGavern This technology includes a therapeutic approach to prevent secondary edema after cerebrovascular hemorrhage. Using an animal model, we found that edema is triggered by massive extravasation of myelomonocytic cells from the blood into the brain in response to hemorrhaging vessels. Administration of anti-LFA1 and anti-VLA4 antibodies resulted in an inhibition of extravasation of the myelomonocytic cells. This single dose treatment prevented secondary edema and markedly improved functional outcomes if administered within the first six hours following cerebrovascular hemorrhage. Moreover, these two antibodies had to be administered in combination, as neither antibody alone was effective. This single dose anti-adhesion molecule therapy will have broad-reaching clinical relevance, offering the ability to quickly treat several life-threatening CNS disorders associated with immune-mediated brain swelling. This technology can be developed into a combination anti-LFA1/VLA4 therapy that can be administered intravenously in emergency situations when acute brain swelling develops in response to brain injury, intracranial hemorrhage, stroke, cerebral malaria, etc. Simultaneous intravenous injection of anti-LFA1/VLA4 can rapidly reduce brain swelling by displacing immune cells from CNS vasculature. This therapy is also far more effective than administering anti-LFA1 and anti-VLA4 alone and should have a better safety profile because it will only be given once. 2022-06-02 2024-10-28 2024-10-28 2022-06-02 2022-06-01 Anti-LFA1/VLA4, brain, COMBINED, IMMUNE-MEDIATED, Swelling, THERAPY, treatment, VEXXXX, VPXXXX, WMXXXX, XAXXXX False True True NIHTT 37470483 Website Abstract 114111373 Mastorakos, Panagiotis (Panos) NINDS NINDS Mastorakos, Panagiotis (Panos) (NINDS) 0 114111372 McGavern, Dorian NINDS NINDS McGavern, Dorian (NINDS) 1 114111372 McGavern, Dorian NINDS NINDS McGavern, Dorian (NINDS) 1 114111373 Mastorakos, Panagiotis (Panos) NINDS NINDS Mastorakos, Panagiotis (Panos) (NINDS) 0 114102819 Treatment Of Immune-mediated Brain Swelling With Combined Anti-LFA1/VLA4 Therapy E-026-2021-0 Filing authorized NINDS 83722849 Sharma, Smita smita.sharma@nih.gov
United States of America smita.sharma@nih.gov?subject=Web Inquiry on [TAB-3715] Treatment of Immune-mediated Brain Swelling with Combined Anti-LFA1/VLA4 Therapy&body=Please send me information about technology [TAB-3715] Treatment of Immune-mediated Brain Swelling with Combined Anti-LFA1/VLA4 Therapy. Sharma, Smita<br><a href="mailto:smita.sharma@nih.gov?subject=Web Inquiry on [TAB-3715] Treatment of Immune-mediated Brain Swelling with Combined Anti-LFA1/VLA4 Therapy&body=Please send me information about technology [TAB-3715] Treatment of Immune-mediated Brain Swelling with Combined Anti-LFA1/VLA4 Therapy.">smita.sharma@nih.gov</a><br> 114129362 VEXXXX 114129363 VPXXXX 114129364 WMXXXX 114129365 XAXXXX 114154747 treatment 114154748 IMMUNE-MEDIATED 114154749 brain 114154750 Swelling 114154751 COMBINED 114154752 Anti-LFA1/VLA4 114154753 THERAPY TAB-3713 114097566 Diagnosing and Treating Collagen type VI-related Dystrophies Based on a New COL6A1 Mutation NINDS Cardiology, Dental, Diagnostics, Endocrinology, Infectious Disease, Oncology, Ophthalmology, Research Materials, Therapeutics Cardiology Dental Diagnostics Endocrinology Infectious Disease Oncology Ophthalmology Research Materials Therapeutics Veronique Bolduc, Carsten Bonnemann, Beryl Cumming, Daniel MacArthur, Lek Monkol, Francesco Muntoni, Steve Wilton This invention includes the identification of a new mutation in the collagen type VI (COL6A1) gene, including a method for diagnosing and treating patients with this mutation. Collagen type VI-related dystrophies (COL6-RD) are devastating neuromuscular disorders that manifest with progressive generalized muscle weakness, contractures, and respiratory failure. Currently, no cure exists for COL6-RD. In addition, despite the effectiveness of current targeted genetic testing methods to detect many of the mutations causing COL6-RD, there are still a large number of patients presenting with clinical and biochemical features of COL6-RD, but without any identified mutations. Our novel identification includes a mutation in intron 11 of the COL6A1 gene that alters the splicing of the gene pre-mRNA and produces a mature alpha 1 (VI) chain mRNA that comprises an additional exon. We describe a method for diagnosing this mutation, as well as a method for specifically treating this mutation using exon-skipping technologies. Currently, no cure exists for COL6-RD. In addition, despite the effectiveness of current targeted genetic testing methods to detect most of the mutations causing COL6-RD, there is still a large number of patients presenting with clinical and biochemical features of COL6-RD, but for whom no mutations have been identified indicating that current methods of diagnosing and treating COL6-RD are insufficient. We found this particular mutation to be the single most common individual mutation in our COL6-RD cohort. <ul> <li>Diagnosis services or kits to detect this mutation</li> <li>Oligomers or vectors for therapeutic clinical application</li> </ul> 2022-06-02 2024-10-28 2024-10-28 2022-06-02 2022-06-01 6, COL6-Related, DIAGNOSING, DISORDERS, Methods, SAME, TREATING, VPXXXX, WBXXXX, WIXXXX, WJXXXX, XCXXXX, XEXXXX False True True NIHTT 37470483 Website Abstract 114111363 Bolduc, Veronique NINDS NINDS Bolduc, Veronique (NINDS) 0 114111364 Muntoni, Francesco UCL Business PLC Muntoni, Francesco 0 114111365 Wilton, Steve Murdoch University Wilton, Steve 0 114111366 MacArthur, Daniel The General Hospital Corporation MacArthur, Daniel 0 114111367 Monkol, Lek The General Hospital Corporation Monkol, Lek 0 114111368 Cumming, Beryl President and Fellows of Harvard College Cumming, Beryl 0 114111362 Bonnemann, Carsten NINDS NINDS Bonnemann, Carsten (NINDS) 1 114111362 Bonnemann, Carsten NINDS NINDS Bonnemann, Carsten (NINDS) 1 114111363 Bolduc, Veronique NINDS NINDS Bolduc, Veronique (NINDS) 0 114111364 Muntoni, Francesco UCL Business PLC Muntoni, Francesco 0 114111365 Wilton, Steve Murdoch University Wilton, Steve 0 114111366 MacArthur, Daniel The General Hospital Corporation MacArthur, Daniel 0 114111367 Monkol, Lek The General Hospital Corporation Monkol, Lek 0 114111368 Cumming, Beryl President and Fellows of Harvard College Cumming, Beryl 0 114102817 Diagnosing COL6-Related Disorders And Methods For Treating Same E-252-2016-0 Filing authorized Murdoch University, NINDS, President and Fellows of Harvard College, The General Hospital Corporation, UCL Business PLC 83700966 Dukhanina, Oksana oksana.dukhanina@nih.gov
United States of America oksana.dukhanina@nih.gov?subject=Web Inquiry on [TAB-3713] Diagnosing and Treating Collagen type VI-related Dystrophies Based on a New COL6A1 Mutation&body=Please send me information about technology [TAB-3713] Diagnosing and Treating Collagen type VI-related Dystrophies Based on a New COL6A1 Mutation. Dukhanina, Oksana<br><a href="mailto:oksana.dukhanina@nih.gov?subject=Web Inquiry on [TAB-3713] Diagnosing and Treating Collagen type VI-related Dystrophies Based on a New COL6A1 Mutation&body=Please send me information about technology [TAB-3713] Diagnosing and Treating Collagen type VI-related Dystrophies Based on a New COL6A1 Mutation.">oksana.dukhanina@nih.gov</a><br> 114169540 E-252-2016-0 E-252-2016-0-US-01 Diagnosing COL6-Related Disorders And Methods For Treating Same PRV US 62/358,482 Abandoned US <br />Provisional (PRV) 62/358,482<br />Filed on 2016-07-05<br />Status: Abandoned 114129350 VPXXXX 114129351 WBXXXX 114129352 WIXXXX 114129353 WJXXXX 114129354 XCXXXX 114129355 XEXXXX 114154733 6 114154734 DIAGNOSING 114154735 COL6-Related 114154736 DISORDERS 114154737 Methods 114154738 TREATING 114154739 SAME TAB-3711 114097564 Development of a Rabbit Polyclonal Antibody for the pT707 Phosphorylated Site of Neuroligin-4 (NLHN4) NINDS Antibodies, Diagnostics, Immunology, Neurology, Research Materials Antibodies Diagnostics Immunology Neurology Research Materials John Badger, Michael Bemben, Katherine Roche This technology includes the creation and use of a polyclonal antibody for Neuroligin-4, NLGN4, that was created by injecting a peptide surrounding the pT707 phosphorylation site into rabbits and affinity purifying the resulting serum. Neuroligin-4 is a member of the neuroligin family of cell adhesion proteins. This family has been shown to play a role in the maturation and function of the neuronal synapse and has been implicated in patients with autism and intellectual disability. This is currently the only antibody to detect the phosphorylation site pT707 of Neuroligin-4. It is also the only antibody that is also specific to Neuroligin 4 in humans. The polyclonal antibody against NLGN4 can be potentially used as a biomarker for autism. 2022-06-02 2024-10-28 2024-10-28 2022-06-02 2022-05-31 ANTIBODY, Development, NLGN4, polyclonal, PT707, VEXXXX, WIXXXX, XAXXXX, XCXXXX False True True NIHTT 37470483 Website Abstract 114111358 Bemben, Michael NINDS NINDS Bemben, Michael (NINDS) 0 114111359 Badger, John NINDS NINDS Badger, John (NINDS) 0 114111357 Roche, Katherine NINDS NINDS Roche, Katherine (NINDS) 1 114111357 Roche, Katherine NINDS NINDS Roche, Katherine (NINDS) 1 114111358 Bemben, Michael NINDS NINDS Bemben, Michael (NINDS) 0 114111359 Badger, John NINDS NINDS Badger, John (NINDS) 0 114102815 Development Of A Polyclonal Antibody For NLGN4 PT707 E-232-2016-0 Research Material NINDS 83722849 Sharma, Smita smita.sharma@nih.gov
United States of America smita.sharma@nih.gov?subject=Web Inquiry on [TAB-3711] Development of a Rabbit Polyclonal Antibody for the pT707 Phosphorylated Site of Neuroligin-4 (NLHN4)&body=Please send me information about technology [TAB-3711] Development of a Rabbit Polyclonal Antibody for the pT707 Phosphorylated Site of Neuroligin-4 (NLHN4). Sharma, Smita<br><a href="mailto:smita.sharma@nih.gov?subject=Web Inquiry on [TAB-3711] Development of a Rabbit Polyclonal Antibody for the pT707 Phosphorylated Site of Neuroligin-4 (NLHN4)&body=Please send me information about technology [TAB-3711] Development of a Rabbit Polyclonal Antibody for the pT707 Phosphorylated Site of Neuroligin-4 (NLHN4).">smita.sharma@nih.gov</a><br> 114129342 VEXXXX 114129343 WIXXXX 114129344 XAXXXX 114129345 XCXXXX 114154718 Development 114154719 polyclonal 114154720 ANTIBODY 114154721 NLGN4 114154722 PT707 TAB-3712 114097565 Highly-sensitive and Dynamic Biomarkers for Intrathecal Inflammation for Neuroimmunological Diseases NINDS Diagnostics, Neurology, Research Materials Diagnostics Neurology Research Materials Bibiana ('Bibi') Bielekova, Mika Komori The technology relates to the identification and validation of eight biomarkers for active central nervous system (CNS) intrathecal inflammation. The management of neuroimmunological diseases is severely hindered by an inability to reliably measure intrathecal inflammation. Current laboratory tests, that were developed over 40 years ago, do not capture low to moderate levels of CNS inflammation and provide limited information about its phenotype. The identified biomarkers include five useful soluble biomarkers (sCD27, sCD21, sCD14, IL-12p40, IL-8) and three composite markers 9sCD27/T cells, sCD21/B cells, sCD14/monocytes). The developed and validated biomarkers here greatly outperform currently available laboratory tests. The biomarkers described here have much higher sensitivity/specificity and are dynamic, responding acutely to effective therapies. Broad implementation of these biomarkers to the clinic would revolutionize clinical care for neuroimmunological patients by: <ul> <li>Providing highly-sensitive markers to identify and quantify the level of intrathecal inflammation</li> <li>Judge the phenotype associated with the intrathecal inflammation to aid in diagnosis</li> <li>Serve as a pharmacodynamic marker for the development of immunomodulatory agents</li> </ul> 2022-06-02 2024-10-28 2024-10-28 2022-06-02 2022-06-01 Biomarkers, Cell, Diagnosis, DISEASES, IMMUNE, Listed LPM Vepa as of 4/15/2015, MANAGEMENT, Neuro-immunological, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, VEXXXX, WBXXXX, WIXXXX, XCXXXX False True True NIHTT 37470483 Website Abstract 114172875 Komori M, Blake A, et al. https://pubmed.ncbi.nlm.nih.gov/25808056/ <a href="https://pubmed.ncbi.nlm.nih.gov/25808056/">Komori M, Blake A, et al.</a> 114111361 Komori, Mika NINDS Komori, Mika 0 114111360 Bielekova, Bibiana ('Bibi') NINDS NIAID Bielekova, Bibiana ('Bibi') (NIAID) 1 114111360 Bielekova, Bibiana ('Bibi') NINDS NIAID Bielekova, Bibiana ('Bibi') (NIAID) 1 114111361 Komori, Mika NINDS Komori, Mika 0 114102816 Immune Cell Biomarkers For Diagnosis And Management Of Neuro-immunological Diseases E-235-2014-0 Filing authorized NINDS 83667829 Ano, Susan susan.ano@nih.gov
United States of America susan.ano@nih.gov?subject=Web Inquiry on [TAB-3712] Highly-sensitive and Dynamic Biomarkers for Intrathecal Inflammation for Neuroimmunological Diseases&body=Please send me information about technology [TAB-3712] Highly-sensitive and Dynamic Biomarkers for Intrathecal Inflammation for Neuroimmunological Diseases. Ano, Susan<br><a href="mailto:susan.ano@nih.gov?subject=Web Inquiry on [TAB-3712] Highly-sensitive and Dynamic Biomarkers for Intrathecal Inflammation for Neuroimmunological Diseases&body=Please send me information about technology [TAB-3712] Highly-sensitive and Dynamic Biomarkers for Intrathecal Inflammation for Neuroimmunological Diseases.">susan.ano@nih.gov</a><br> 114169539 E-235-2014-0 E-235-2014-0-US-01 BIOMARKERS FOR DIAGNOSIS AND MANAGEMENT OF NEURO-IMMUNOLOGICAL DISEASES PRV US 62/038,530 Abandoned US <br />Provisional (PRV) 62/038,530<br />Filed on 2014-08-18<br />Status: Abandoned 114129346 VEXXXX 114129347 WBXXXX 114129348 WIXXXX 114129349 XCXXXX 114154723 Diagnosis 114154724 Biomarkers 114154725 Cell 114154726 IMMUNE 114154727 MANAGEMENT 114154728 Neuro-immunological 114154729 DISEASES 114154730 Listed LPM Vepa as of 4/15/2015 114154731 Pre LPM working set 20150418 114154732 Post LPM Assignment Set 20150420 TAB-3709 114097562 Stable SVG Cell Lines for Studying JCV Infection and Progressive Multifocal Leukoencephalopathy NINDS Neurology, Research Materials, Vaccines Neurology Research Materials Vaccines Michael Ferenczy, Peter Jensen, Eugene Major, Leslie Marshall, Shannon Steinberg This invention relates to the derivation of two stable cell lines, SVG5F4 and SVG1OB1, which can be used to study JC-virus infection. SVG cells are a heterogeneous population of immortalized human fetal glial cells, which express SV40 large T antigen. They are capable of supporting JC virus infection; however, the culture is mixed and changes over time. The two SV40-derived cell lines described here are stable over many passages. SVG5F4 cells have a greatly reduced ability to support JCV infection, while SVG10B1 cells support robust infection and can maintain persistent JCV infection over several months (unlike SVG cells, in which susceptible cells are depleted by persistent infection). These cells will provide tools to study JCV and cellular differences in JCV infection. In addition, there is currently no available treatment for the often-fatal disease caused by JCV: Progressive Multifocal Leukoencephalopathy. The SVG4F4 cell line is uniquely capable of maintaining a stable JCV infection over the course of several months. The SVG10B1 cells can provide a platform for anti-JCV drug studies and are potentially useful to grow JCV vaccines. 2022-06-02 2024-10-28 2024-10-28 2022-06-02 2022-05-31 Cell, CLONES, Listed LPM Soukas as of 4/15/2015, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Single, SVG, SVG10B1, SVG5F4, VEXXXX, WIXXXX, WNXXXX, XKXXXX False True True NIHTT 37470483 Website Abstract 114172871 Jiang Z-G, Cojen J, et al. https://pubmed.ncbi.nlm.nih.gov/20823288/ <a href="https://pubmed.ncbi.nlm.nih.gov/20823288/">Jiang Z-G, Cojen J, et al.</a> 114172872 Major EO, Miller AE, et al. https://pubmed.ncbi.nlm.nih.gov/2983332/ <a href="https://pubmed.ncbi.nlm.nih.gov/2983332/">Major EO, Miller AE, et al.</a> 114172873 Frye S, Trebst C, et al. https://pubmed.ncbi.nlm.nih.gov/9015278/ <a href="https://pubmed.ncbi.nlm.nih.gov/9015278/">Frye S, Trebst C, et al.</a> 114172874 Gee GV, Manley K, et al. https://pubmed.ncbi.nlm.nih.gov/14517064/ <a href="https://pubmed.ncbi.nlm.nih.gov/14517064/">Gee GV, Manley K, et al.</a> 114111349 Ferenczy, Michael NINDS Ferenczy, Michael 0 114111350 Marshall, Leslie NINDS NINDS Marshall, Leslie (NINDS) 0 114111351 Jensen, Peter NINDS NINDS Jensen, Peter (NINDS) 0 114111352 Steinberg, Shannon Dartmouth College Steinberg, Shannon 0 114111348 Major, Eugene NINDS NINDS Major, Eugene (NINDS) 1 114111348 Major, Eugene NINDS NINDS Major, Eugene (NINDS) 1 114111349 Ferenczy, Michael NINDS Ferenczy, Michael 0 114111350 Marshall, Leslie NINDS NINDS Marshall, Leslie (NINDS) 0 114111351 Jensen, Peter NINDS NINDS Jensen, Peter (NINDS) 0 114111352 Steinberg, Shannon Dartmouth College Steinberg, Shannon 0 114102813 SVG Single Cell Clones E-151-2012-0 Research Material Dartmouth College, NINDS 83667829 Ano, Susan susan.ano@nih.gov
United States of America susan.ano@nih.gov?subject=Web Inquiry on [TAB-3709] Stable SVG Cell Lines for Studying JCV Infection and Progressive Multifocal Leukoencephalopathy&body=Please send me information about technology [TAB-3709] Stable SVG Cell Lines for Studying JCV Infection and Progressive Multifocal Leukoencephalopathy. Ano, Susan<br><a href="mailto:susan.ano@nih.gov?subject=Web Inquiry on [TAB-3709] Stable SVG Cell Lines for Studying JCV Infection and Progressive Multifocal Leukoencephalopathy&body=Please send me information about technology [TAB-3709] Stable SVG Cell Lines for Studying JCV Infection and Progressive Multifocal Leukoencephalopathy.">susan.ano@nih.gov</a><br> 114129335 VEXXXX 114129336 WIXXXX 114129337 WNXXXX 114129338 XKXXXX 114154707 SVG 114154708 Single 114154709 Cell 114154710 CLONES 114154711 Listed LPM Soukas as of 4/15/2015 114154712 Pre LPM working set 20150418 114154713 Post LPM Assignment Set 20150420 114154714 SVG5F4 114154715 SVG10B1 TAB-3710 114097563 Development of a plasmid (pRT029) to enable CRISPRi gene knowndown in human stem cells (iPSCs) NINDS Diagnostics, Research Materials, Therapeutics Diagnostics Research Materials Therapeutics Martin Kampmann, Connor Ludwig, Ruilin Tian, Michael Ward The invention relates to a plasmid that enables gene knowndown (via CRISPRi) in human induced pluripotent stem cells (iPSCs), including derived cell types such as neurons. The plasmid contains homology arms to direct insertion of a cassette into the CLYBL safe-harbor locus in the human genome. The cassette expresses CRISPRi machinery using a CAG promoter. The CRISPRi machinery consists of double degron-tagged dCas9-BFP-KRAB. Addition of the small molecule trimethoprim to cell culture media stabilizes the degron and thereby increases dCas9-BFPKRAB levels, enabling CRISPRi activity. This plasmid could be used to screen for drug targets in human iPSC derived disease cellular models. No tools currently exist to enable inducible, targeted gene silencing via CRISPR-related technology in iPSC-derived cells. The plasmid described here encodes an enzymatically-dead variant of Cas9, fused to a degradation domain that can be stabilized by the addition of trimethoprim, a small molecule. 2022-06-02 2024-10-28 2024-10-28 2022-06-02 2022-05-31 PLASMID, PRT029, WBXXXX, WIXXXX, XEXXXX False True True NIHTT 37470483 Website Abstract 114111354 Kampmann, Martin University of California, San Francisco (UCSF) Kampmann, Martin 0 114111355 Ludwig, Connor University of California, San Francisco (UCSF) Ludwig, Connor 0 114111356 Tian, Ruilin University of California, San Francisco (UCSF) Tian, Ruilin 0 114111353 Ward, Michael NINDS NINDS Ward, Michael (NINDS) 1 114111353 Ward, Michael NINDS NINDS Ward, Michael (NINDS) 1 114111354 Kampmann, Martin University of California, San Francisco (UCSF) Kampmann, Martin 0 114111355 Ludwig, Connor University of California, San Francisco (UCSF) Ludwig, Connor 0 114111356 Tian, Ruilin University of California, San Francisco (UCSF) Tian, Ruilin 0 114102814 Plasmid PRT029 E-207-2018-0 Research Material NINDS, University of California, San Francisco (UCSF) 83687767 Olufemi, Olufunmilola (Lola) olufunmilola.olufemi@nih.gov
United States of America olufunmilola.olufemi@nih.gov?subject=Web Inquiry on [TAB-3710] Development of a plasmid (pRT029) to enable CRISPRi gene knowndown in human stem cells (iPSCs)&body=Please send me information about technology [TAB-3710] Development of a plasmid (pRT029) to enable CRISPRi gene knowndown in human stem cells (iPSCs). Olufemi, Olufunmilola (Lola)<br><a href="mailto:olufunmilola.olufemi@nih.gov?subject=Web Inquiry on [TAB-3710] Development of a plasmid (pRT029) to enable CRISPRi gene knowndown in human stem cells (iPSCs)&body=Please send me information about technology [TAB-3710] Development of a plasmid (pRT029) to enable CRISPRi gene knowndown in human stem cells (iPSCs).">olufunmilola.olufemi@nih.gov</a><br> 114129339 WBXXXX 114129340 WIXXXX 114129341 XEXXXX 114154716 PLASMID 114154717 PRT029 TAB-3708 114097561 Identification of a novel and selective D3 dopamine receptor-selective agonist NINDS Neurology, Research Materials, Therapeutics Neurology Research Materials Therapeutics Jeffrey Aube, Marc Ferrer-Alegre, Kevin Frankowski, R Benjamin Free, Amy Moritz, David Sibley, Noel Southall, Joseph Steiner, Warren Weiner, Xin Xu This technology relates to the description and therapeutic use of a small molecule that selectively binds to and activates the D3 dopamine receptor. Dopamine receptors (DARs) are members of the G protein-coupled receptor (GPCR) superfamily that play a critical role in cell signaling processes, especially modulating the transfer of information within the nervous system. Members of the DAR subfamilies share high sequence homology, especially the D2 and D3 DARs. Most currently available dopaminergic drugs cross-react with both subtypes to varying degrees. Research indicates that D3 agonism may have important therapeutic potential while D2 agonism may induce negative side effects. Despite numerous attempts to produce D3 selective modulators, current FDA-approved drugs display relatively poor selectivity between the closely related D2 and D3 DARs. Our best representative analog shows a more selective profile to D3 DAR compared to the best previously reported selective D3 DAR agonist in the literature. Current FDA-approved treatments for Parkinson’s Disease are relatively nonselective agonists of the D3/2 DAR subtypes. Through a high-throughput screening campaign and systematic medicinal chemistry efforts, we have identified and developed a series of novel, highly selective small molecule D3 DAR agonists which can be further developed as agents for potential treatment of dopaminergic diseases. The best representative analog in this chemical scaffold shows a more selective profile compared to the best previously reported selective D3 DAR agonist in the literature. Selective D3 DAR agonists could offer improved therapy of disorders currently treated with relatively nonselective D3/D2 DAR agonists, including Parkinson’s Disease and Restless Leg Syndrome. The most significant impact on the patient population is likely to be in the treatment of Parkinson’s Disease, which has an estimated national economic burden of $14.4 billion, with costs projected to increase substantially over the coming decades as the American population ages. 2022-06-02 2024-10-28 2024-10-28 2022-06-02 2022-05-31 AGONIST, D3, Dopamine, Identification, Novel, Receptor-Selective, VEXXXX, WIXXXX, WKXXXX False True True NIHTT 37470483 Website Abstract 114172867 Li C, Biswas S, et al. https://pubmed.ncbi.nlm.nih.gov/20623619/ <a href="https://pubmed.ncbi.nlm.nih.gov/20623619/">Li C, Biswas S, et al.</a> 114172868 J Chen, Collins GT, et al. https://pubmed.ncbi.nlm.nih.gov/22125662/ <a href="https://pubmed.ncbi.nlm.nih.gov/22125662/">J Chen, Collins GT, et al.</a> 114172869 Chen J, Jiang C, et al. https://pubmed.ncbi.nlm.nih.gov/25338762/ <a href="https://pubmed.ncbi.nlm.nih.gov/25338762/">Chen J, Jiang C, et al.</a> 114172870 Shah M, Rajagopalan S, et al. https://pubmed.ncbi.nlm.nih.gov/24848702/ <a href="https://pubmed.ncbi.nlm.nih.gov/24848702/">Shah M, Rajagopalan S, et al.</a> 114111339 Moritz, Amy NINDS NINDS Moritz, Amy (NINDS) 0 114111340 Free, R Benjamin NINDS NINDS Free, R Benjamin (NINDS) 0 114111341 Steiner, Joseph NINDS NINDS Steiner, Joseph (NINDS) 0 114111342 Southall, Noel NCATS - TRND NCATS Southall, Noel (NCATS) 0 114111343 Ferrer-Alegre, Marc NCATS - NCGC NCATS Ferrer-Alegre, Marc (NCATS) 0 114111344 Xu, Xin NCATS - TRND NCATS Xu, Xin (NCATS) 0 114111345 Aube, Jeffrey University of North Carolina, Chapel Hill Aube, Jeffrey 0 114111346 Frankowski, Kevin University of North Carolina, Chapel Hill Frankowski, Kevin 0 114111347 Weiner, Warren Weiner, Warren 0 114111338 Sibley, David NINDS NINDS Sibley, David (NINDS) 1 114111338 Sibley, David NINDS NINDS Sibley, David (NINDS) 1 114111339 Moritz, Amy NINDS NINDS Moritz, Amy (NINDS) 0 114111340 Free, R Benjamin NINDS NINDS Free, R Benjamin (NINDS) 0 114111341 Steiner, Joseph NINDS NINDS Steiner, Joseph (NINDS) 0 114111342 Southall, Noel NCATS - TRND NCATS Southall, Noel (NCATS) 0 114111343 Ferrer-Alegre, Marc NCATS - NCGC NCATS Ferrer-Alegre, Marc (NCATS) 0 114111344 Xu, Xin NCATS - TRND NCATS Xu, Xin (NCATS) 0 114111345 Aube, Jeffrey University of North Carolina, Chapel Hill Aube, Jeffrey 0 114111346 Frankowski, Kevin University of North Carolina, Chapel Hill Frankowski, Kevin 0 114111347 Weiner, Warren Weiner, Warren 0 114102812 Identification Of A Novel D3 Dopamine Receptor-selective Agonist E-146-2016-0 Filing authorized NCATS - NCGC, NINDS, University of Kansas, University of North Carolina, Chapel Hill 83667829 Ano, Susan susan.ano@nih.gov
United States of America susan.ano@nih.gov?subject=Web Inquiry on [TAB-3708] Identification of a novel and selective D3 dopamine receptor-selective agonist&body=Please send me information about technology [TAB-3708] Identification of a novel and selective D3 dopamine receptor-selective agonist. Ano, Susan<br><a href="mailto:susan.ano@nih.gov?subject=Web Inquiry on [TAB-3708] Identification of a novel and selective D3 dopamine receptor-selective agonist&body=Please send me information about technology [TAB-3708] Identification of a novel and selective D3 dopamine receptor-selective agonist.">susan.ano@nih.gov</a><br> 114169538 E-146-2016-0 E-146-2016-0-US-01 Selective D3 Dopamine Receptor Agonists and Methods of Their Use PRV US 62/322,361 Abandoned US <br />Provisional (PRV) 62/322,361<br />Filed on 2016-04-14<br />Status: Abandoned 114129332 VEXXXX 114129333 WIXXXX 114129334 WKXXXX 114154701 Identification 114154702 Novel 114154703 D3 114154704 Dopamine 114154705 Receptor-Selective 114154706 AGONIST TAB-3706 114097559 Combinatorial Knockout Cell Line Series Relevant to Cargo Selective Autophagy NINDS Neurology, Research Materials, Therapeutics Neurology Research Materials Therapeutics Richard Youle This technology includes multiple cells with various combinations of autophagy receptors knocked out. The cell lines include knockouts of the OPTN, NDP52, and TAX1BP1 genes that are involved in cargo selective autophagy. These lines may be used to explore how cell biology debris is catabolized, which may be relevant to neurodegenerative diseases like amyotrophic lateral sclerosis (ALS). We have made a complete combinatorial autophagy receptor knock out line series, including a penta-KO lines that lacks all five receptors. This offers a unique tool set to probe autophagy mechanism and for drug screening. This includes the following cell lines: <ul> <li>OPTN KO</li> <li>NDP52 KO</li> <li>NDP52/0PTN dKO</li> <li>NDP52/OPTN/TAX1BP1 tKO</li> </ul> This is a valuable cell series for identifying drugs that function to augment autophagy via specific receptor pathways. 2022-06-02 2024-10-28 2024-10-28 2022-06-02 2022-05-31 Autophagy, Cell, Knock, Lines, RECEPTOR, VEXXXX, WIXXXX, XEXXXX False True True NIHTT 37470483 Website Abstract 114172865 Lazarou M, Sliter MA, et al. https://pubmed.ncbi.nlm.nih.gov/26266977/ <a href="https://pubmed.ncbi.nlm.nih.gov/26266977/">Lazarou M, Sliter MA, et al.</a> 114111336 Youle, Richard NINDS NINDS Youle, Richard (NINDS) 1 114111336 Youle, Richard NINDS NINDS Youle, Richard (NINDS) 1 114102810 Autophagy Receptor Knock Out Cell Lines E-108-2017-0 Research Material NINDS 83687767 Olufemi, Olufunmilola (Lola) olufunmilola.olufemi@nih.gov
United States of America olufunmilola.olufemi@nih.gov?subject=Web Inquiry on [TAB-3706] Combinatorial Knockout Cell Line Series Relevant to Cargo Selective Autophagy&body=Please send me information about technology [TAB-3706] Combinatorial Knockout Cell Line Series Relevant to Cargo Selective Autophagy. Olufemi, Olufunmilola (Lola)<br><a href="mailto:olufunmilola.olufemi@nih.gov?subject=Web Inquiry on [TAB-3706] Combinatorial Knockout Cell Line Series Relevant to Cargo Selective Autophagy&body=Please send me information about technology [TAB-3706] Combinatorial Knockout Cell Line Series Relevant to Cargo Selective Autophagy.">olufunmilola.olufemi@nih.gov</a><br> 114129325 VEXXXX 114129326 WIXXXX 114129327 XEXXXX 114154691 Autophagy 114154692 RECEPTOR 114154693 Knock 114154694 Cell 114154695 Lines TAB-3707 114097560 A Neuronal Induced Pluripotent Stem Cell (iPSC) Line with CRIPSR Inhibition Gene Knockdown NINDS Neurology, Research Equipment, Research Materials, Therapeutics Neurology Research Equipment Research Materials Therapeutics Michael Ward This technology includes the combination of an induced pluripotent stem cell (iPSC) line that can inducibly be differentiated into neurons (using an inducible Neurogenin 2, Ngn2, cassette) and enable CRISPR inhibition gene knockdown (via stable expression of dCas9-BFP-KRAB). The combination of these elements in a cell line enables multiple lines of research, including small molecule screens for drug development in neuronal disease models, as well as studying stem cell biology in an iPSC neuronal cell model. The NCRM5 iPSC line is an NIH resource and resulting cell lines should be more easily shared with other institutions than from other parental lines (e.g., WTC11). The neuronal stem cell line permits screens by commercial entities for drug development or target identification in iPSC neurons. 2022-06-02 2024-10-28 2024-10-28 2022-06-02 2022-05-31 CRISPR, DERIVED, inhibition, iPSC, Neurons, VEXXXX, WIXXXX, XEXXXX, XHXXXX False True True NIHTT 37470483 Website Abstract 114172866 Tian R, Gachechiladze MA, et al. https://pubmed.ncbi.nlm.nih.gov/31422865/ <a href="https://pubmed.ncbi.nlm.nih.gov/31422865/">Tian R, Gachechiladze MA, et al.</a> 114111337 Ward, Michael NINDS NINDS Ward, Michael (NINDS) 1 114111337 Ward, Michael NINDS NINDS Ward, Michael (NINDS) 1 114102811 CRISPR Inhibition In IPSC Derived Neurons E-124-2020-0 Research Material NINDS 83687767 Olufemi, Olufunmilola (Lola) olufunmilola.olufemi@nih.gov
United States of America olufunmilola.olufemi@nih.gov?subject=Web Inquiry on [TAB-3707] A Neuronal Induced Pluripotent Stem Cell (iPSC) Line with CRIPSR Inhibition Gene Knockdown&body=Please send me information about technology [TAB-3707] A Neuronal Induced Pluripotent Stem Cell (iPSC) Line with CRIPSR Inhibition Gene Knockdown. Olufemi, Olufunmilola (Lola)<br><a href="mailto:olufunmilola.olufemi@nih.gov?subject=Web Inquiry on [TAB-3707] A Neuronal Induced Pluripotent Stem Cell (iPSC) Line with CRIPSR Inhibition Gene Knockdown&body=Please send me information about technology [TAB-3707] A Neuronal Induced Pluripotent Stem Cell (iPSC) Line with CRIPSR Inhibition Gene Knockdown.">olufunmilola.olufemi@nih.gov</a><br> 114129328 VEXXXX 114129329 WIXXXX 114129330 XEXXXX 114129331 XHXXXX 114154696 CRISPR 114154697 inhibition 114154698 iPSC 114154699 DERIVED 114154700 Neurons TAB-3704 114097557 Improved cortical lesion detection by MRI using high resolution CSF-suppressed T2*-weighted imaging NINDS Diagnostics, Medical Devices, Neurology, Non-Medical Devices, Research Materials, Software / Apps Diagnostics Medical Devices Neurology Non-Medical Devices Research Materials Software / Apps Erin Beck, Govind Bhagavatheeshwaran, Neville Gai, Daniel Reich This technology is an improvement on the ability to visualize cortical lesions in neurological diseases that cause focal tissue damage to the cortex, including multiple sclerosis (MS). Two approaches are used. The first approach includes optimization of routinely available diffusion-weighted sequences to maximize resolution and contrast, both of which are required to differentiate small cortical lesions from normal-appearing cortex. A second approach includes suppression of the cerebrospinal fluid (CSF) in an optimal high-resolution 3D-T2*-weighted image using inversion pulse (3D IR-T2*) along with appropriate T2-preparation for desired contrast and reduced scan time. The T2* signal changes that are measured are induced by changing iron concentrations. The combination of these techniques permits the visualization of cortical lesions more clearly than with standard 3T clinical MRI techniques. Other MRI approaches for cortical lesion detection at clinical magnetic field strength are currently being used, including double-inversion, phase-sensitive inversion recovery MRI, and magnetization-transfer imaging. Published studies have shown these to be inaccurate for subpial cortical lesion detection. <ul> <li>Reliable visualization of cortical lesions will be of interest across a wide range of neurological conditions.</li> <li>Manufacturers of MRI scanners may be interested in packaging these techniques for distribution to clinics and research institutions.</li> </ul> 2022-06-02 2024-10-28 2024-10-28 2022-06-02 2022-05-31 CORTICAL, CSF-suppressed, Detection, High, IMAGING, LESIONS, MRI, RESOLUTION, software, T2*-weighted, VEXXXX, WBXXXX, WIXXXX, XFXXXX False True True NIHTT 37470483 Website Abstract 114111331 Beck, Erin NINDS NINDS Beck, Erin (NINDS) 0 114111332 Bhagavatheeshwaran, Govind NINDS NINDS Bhagavatheeshwaran, Govind (NINDS) 0 114111333 Gai, Neville Clinical Center (CC) Gai, Neville 0 114111330 Reich, Daniel NINDS NINDS Reich, Daniel (NINDS) 1 114111330 Reich, Daniel NINDS NINDS Reich, Daniel (NINDS) 1 114111331 Beck, Erin NINDS NINDS Beck, Erin (NINDS) 0 114111332 Bhagavatheeshwaran, Govind NINDS NINDS Bhagavatheeshwaran, Govind (NINDS) 0 114111333 Gai, Neville Clinical Center (CC) Gai, Neville 0 114102808 High Resolution CSF-suppressed T2*-weighted Imaging For The Detection Of Cortical Lesions By MRI E-102-2019-0 Filing authorized Clinical Center (CC), NINDS 83722849 Sharma, Smita smita.sharma@nih.gov
United States of America smita.sharma@nih.gov?subject=Web Inquiry on [TAB-3704] Improved cortical lesion detection by MRI using high resolution CSF-suppressed T2*-weighted imaging&body=Please send me information about technology [TAB-3704] Improved cortical lesion detection by MRI using high resolution CSF-suppressed T2*-weighted imaging. Sharma, Smita<br><a href="mailto:smita.sharma@nih.gov?subject=Web Inquiry on [TAB-3704] Improved cortical lesion detection by MRI using high resolution CSF-suppressed T2*-weighted imaging&body=Please send me information about technology [TAB-3704] Improved cortical lesion detection by MRI using high resolution CSF-suppressed T2*-weighted imaging.">smita.sharma@nih.gov</a><br> 114169537 E-102-2019-0 E-102-2019-0-US-01 HIGH-RESOLUTION CEREBROSPINAL FLUID-SUPPRESSED T2*-WEIGHTED MAGNETIC RESONANCE IMAGING OF CORTICAL LESIONS PRV US 62/838,578 Abandoned US <br />Provisional (PRV) 62/838,578<br />Filed on 2019-04-25<br />Status: Abandoned 114129317 VEXXXX 114129318 WBXXXX 114129319 WIXXXX 114129320 XFXXXX 114154676 High 114154677 RESOLUTION 114154678 CSF-suppressed 114154679 T2*-weighted 114154680 IMAGING 114154681 Detection 114154682 CORTICAL 114154683 LESIONS 114154684 MRI 114154685 software TAB-3705 114097558 TBK1 and NDP52/OPTN Double Knockout Cell Lines for Studying Mitochondrial Degradation Biology NINDS Neurology, Research Materials, Therapeutics Neurology Research Materials Therapeutics Danielle Sliter, Richard Youle This technology includes the generation and use of HeLa cell lines that have the TANK-binding kinase 1 (TBK1) gene knocked out solely or in combination with either the genes NDP52 or OPTN. Both NDP52 and OPTN are receptors involved in the degradation of mitochondria, mitophagy. The TBK1 kinase has a role in enhancing the effect of mitophagy on these receptors. Mutations in TBK1 have been shown to be associated with neurodegenerative diseases such as Parkinson, frontotemporal dementia, and amyotrophic lateral sclerosis (ALS). There are no other double knockout mice to study the role of these mitophagy-related genes. This discovery allows for exploration into the specific function of NDP52 and Optineurin(OPTN)/TBK1 in mitochondrial degradation (mitophagy). 2022-06-02 2024-10-28 2024-10-28 2022-06-02 2022-05-31 Cell, DOUBLE, Knockout, Line, R1XXXX, TBK1/NDP52, VEXXXX, WIXXXX, XEXXXX False True True NIHTT 37470483 Website Abstract 114172864 Lazarou M, Sliter DA, et al. https://pubmed.ncbi.nlm.nih.gov/26266977/ <a href="https://pubmed.ncbi.nlm.nih.gov/26266977/">Lazarou M, Sliter DA, et al.</a> 114111335 Youle, Richard NINDS NINDS Youle, Richard (NINDS) 0 114111334 Sliter, Danielle NINDS NINDS Sliter, Danielle (NINDS) 1 114111334 Sliter, Danielle NINDS NINDS Sliter, Danielle (NINDS) 1 114111335 Youle, Richard NINDS NINDS Youle, Richard (NINDS) 0 114102809 TBK1/NDP52 Double Knockout Cell Line E-103-2016-0 Research Material NINDS 83687767 Olufemi, Olufunmilola (Lola) olufunmilola.olufemi@nih.gov
United States of America olufunmilola.olufemi@nih.gov?subject=Web Inquiry on [TAB-3705] TBK1 and NDP52/OPTN Double Knockout Cell Lines for Studying Mitochondrial Degradation Biology&body=Please send me information about technology [TAB-3705] TBK1 and NDP52/OPTN Double Knockout Cell Lines for Studying Mitochondrial Degradation Biology. Olufemi, Olufunmilola (Lola)<br><a href="mailto:olufunmilola.olufemi@nih.gov?subject=Web Inquiry on [TAB-3705] TBK1 and NDP52/OPTN Double Knockout Cell Lines for Studying Mitochondrial Degradation Biology&body=Please send me information about technology [TAB-3705] TBK1 and NDP52/OPTN Double Knockout Cell Lines for Studying Mitochondrial Degradation Biology.">olufunmilola.olufemi@nih.gov</a><br> 114129321 R1XXXX 114129322 VEXXXX 114129323 WIXXXX 114129324 XEXXXX 114154686 TBK1/NDP52 114154687 DOUBLE 114154688 Knockout 114154689 Cell 114154690 Line TAB-3703 114097556 Synthesis and use of deuterated L-DOPS to treat norepinephrine deficiency NINDS Cardiology, Dental, Endocrinology, Infectious Disease, Neurology, Oncology, Ophthalmology, Therapeutics Cardiology Dental Endocrinology Infectious Disease Neurology Oncology Ophthalmology Therapeutics David Goldstein, Courtney Holmes, Frannk Schneider, Patricia Sullivan This invention relates to the synthesis and methods of using a drug, deuterated L-DOPS, to treat deficiencies in the neurotransmitter norepinephrine. This classic neurotransmitter has roles in both the brain and the periphery. In the brain, norepinephrine is thought to play important roles in attention, memory, sleep, pain, movement, distress, and mood. Outside the brain, norepinephrine mediates regulation of the circulation by the sympathetic nervous system by increasing blood pressure. <br /><br /> Oral norepinephrine is ineffective in treating deficiencies because the gut-blood and blood-brain barriers effectively block this neurotransmitter from crossing. A norepinephrine pro-drug (L-DOPS, droxidopa, Northera) is being developed for treating deficiencies of norepinephrine. While L-DOPS can induce the synthesis of norephinephrine, the produced neurotransmitter is rapidly degraded into toxic byproducts. Substituting deuterium for the hydrogen in L-DOPS, deuterated L-DOPS, decreases the ability of the synthesized norepinephrine from being degraded. Norepinephrine generated from L-DOPS undergoes substantial degradation by the enzyme monoamine oxidase. The immediate product of the oxidative deamination is an aldehyde, dihydroxyphenylglycolaldehyde, which is toxic. Deuterium substitution at the alpha carbon of catecholamines decreases susceptibility to monoamine oxidase. Therefore, deuterated L-DOPS should be more effective and less toxic than non-deuterated L-DOPS in treating norepinephrine deficiency states. Deuterated L-DOPS may prove useful for treating any of a variety of forms of norepinephrine deficiency. A New Drug Application to the US FDA has been filed by Chelsea Therapeutics for L-DOPS (brand-name Northera) to treat symptomatic orthostatic hypotension. 2022-06-02 2024-10-28 2024-10-28 2022-06-02 2022-05-31 3, 4-Dihydroxyphenylserine, Deuterated, L-DOPS, Listed LPM Nguyen-Antczak as of 4/15/2015, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, VDXXXX, VEXXXX, VPXXXX, WKXXXX False True True NIHTT 37470483 Website Abstract 114172863 Malmlöf T, Rylander D, et al. https://pubmed.ncbi.nlm.nih.gov/20659451/ <a href="https://pubmed.ncbi.nlm.nih.gov/20659451/">Malmlöf T, Rylander D, et al.</a> 114111326 Sullivan, Patricia NINDS NINDS Sullivan, Patricia (NINDS) 0 114111327 Holmes, Courtney NINDS NINDS Holmes, Courtney (NINDS) 0 114111329 Schneider, Frannk CDRD Berolina AB Schneider, Frannk 0 114111328 Goldstein, David NINDS NINDS Goldstein, David (NINDS) 1 114111328 Goldstein, David NINDS NINDS Goldstein, David (NINDS) 1 114111326 Sullivan, Patricia NINDS NINDS Sullivan, Patricia (NINDS) 0 114111327 Holmes, Courtney NINDS NINDS Holmes, Courtney (NINDS) 0 114111329 Schneider, Frannk CDRD Berolina AB Schneider, Frannk 0 114102807 Deuterated 3,4-Dihydroxyphenylserine (Deuterated L-DOPS) E-101-2012-0 Filing authorized CDRD Berolina AB, NINDS 83722849 Sharma, Smita smita.sharma@nih.gov
United States of America smita.sharma@nih.gov?subject=Web Inquiry on [TAB-3703] Synthesis and use of deuterated L-DOPS to treat norepinephrine deficiency&body=Please send me information about technology [TAB-3703] Synthesis and use of deuterated L-DOPS to treat norepinephrine deficiency. Sharma, Smita<br><a href="mailto:smita.sharma@nih.gov?subject=Web Inquiry on [TAB-3703] Synthesis and use of deuterated L-DOPS to treat norepinephrine deficiency&body=Please send me information about technology [TAB-3703] Synthesis and use of deuterated L-DOPS to treat norepinephrine deficiency.">smita.sharma@nih.gov</a><br> 114169536 E-101-2012-0 E-101-2012-0-US-01 DEUTERATED DROXIDOPA DERIVATIVES AND MEDICAMENTS COMPRISING SAID COMPOUNDS PRV US 61/669,772 Abandoned US <br />Provisional (PRV) 61/669,772<br />Filed on 2012-07-10<br />Status: Abandoned 114129313 VDXXXX 114129314 VEXXXX 114129315 VPXXXX 114129316 WKXXXX 114154669 L-DOPS 114154670 4-Dihydroxyphenylserine 114154671 3 114154672 Deuterated 114154673 Listed LPM Nguyen-Antczak as of 4/15/2015 114154674 Pre LPM working set 20150418 114154675 Post LPM Assignment Set 20150420 TAB-3700 114097553 Transgenic mice useful for study of gonadotropin-releasing hormone (GnRH) and a GnRH-secreting neuronal cell line (GN cell line) NINDS Endocrinology, Neurology, Research Materials, Therapeutics Endocrinology Neurology Research Materials Therapeutics Sally Radovick, Bruce Weintraub, Fredric Wondisford, Susan Wray This technology involves the generation and use of a mouse model for studying hypogonadism in humans and a cell line to study cellular and molecular properties of gonadotropin-releasing hormone (GnRH) cells. The mouse model expresses the simian virus 40 T antigen driven by the GnRH promoter, resulting in hypogonadism due to an arrest in neuronal migration during development and tumor formation along the migratory pathway. Olfactory bulb tumors in this model animal were dispersed, and GnRH-secreting neuronal cell line (GN/NLT cell line) was established. The mouse and cell line provide a novel method to study the gonadotropin-release hormone pathway. Animal model or cell line could be sold by research reagent companies for research use purposes. Cell lines are models for: 1) identifying genes and cellular mechanisms influencing maturation of neuronal phenotype, 2) delineating mechanisms and genes underlying neuronal migration and 3) factors which influence neuronal movement. 2022-06-02 2024-10-28 2024-10-28 2022-06-02 2022-05-31 1991, 40, ANTIGEN, Cell, DRIVEN, Drivenby, Expressing, Gene, Gn, GnRH, GnRH-secreting, Gonadotropin-releasing, HORMONE, Human, ISOLATED, Line, Mice, NEURONAL, PNAS, PROMOTER, Simian, T, TRANSGENIC, USEFUL, VEXXXX, VGXXXX, virus, WIXXXX, XEXXXX False True True NIHTT 37470483 Website Abstract 114172857 Radovick S, Wray S, et al. https://pubmed.ncbi.nlm.nih.gov/2014260/ <a href="https://pubmed.ncbi.nlm.nih.gov/2014260/">Radovick S, Wray S, et al.</a> 114172858 Zhen S, Dunn IC, et al. https://pubmed.ncbi.nlm.nih.gov/9139717/ <a href="https://pubmed.ncbi.nlm.nih.gov/9139717/">Zhen S, Dunn IC, et al.</a> 114111319 Radovick, Sally Rutgers, The State University of New Jersey Radovick, Sally 0 114111320 Weintraub, Bruce Trophogen, Inc Weintraub, Bruce 0 114111321 Wondisford, Fredric Rutgers, The State University of New Jersey Wondisford, Fredric 0 114111318 Wray, Susan NINDS NINDS Wray, Susan (NINDS) 1 114111318 Wray, Susan NINDS NINDS Wray, Susan (NINDS) 1 114111319 Radovick, Sally Rutgers, The State University of New Jersey Radovick, Sally 0 114111320 Weintraub, Bruce Trophogen, Inc Weintraub, Bruce 0 114111321 Wondisford, Fredric Rutgers, The State University of New Jersey Wondisford, Fredric 0 114102804 Transgenic Mice Useful For Study Of Gonadotropin-releasing Hormone (GnRH) And A GnRH-secreting Neuronal Cell Line (GN Cell Line) Isolated From Transgenic Mice Expressing The Simian Virus 40 T Antigen, Driven By The Promoter Of Human GnRH Gene (PNAS, E-087-2018-0 Research Material Case Western Reserve University, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NINDS 83667829 Ano, Susan susan.ano@nih.gov
United States of America susan.ano@nih.gov?subject=Web Inquiry on [TAB-3700] Transgenic mice useful for study of gonadotropin-releasing hormone (GnRH) and a GnRH-secreting neuronal cell line (GN cell line)&body=Please send me information about technology [TAB-3700] Transgenic mice useful for study of gonadotropin-releasing hormone (GnRH) and a GnRH-secreting neuronal cell line (GN cell line). Ano, Susan<br><a href="mailto:susan.ano@nih.gov?subject=Web Inquiry on [TAB-3700] Transgenic mice useful for study of gonadotropin-releasing hormone (GnRH) and a GnRH-secreting neuronal cell line (GN cell line)&body=Please send me information about technology [TAB-3700] Transgenic mice useful for study of gonadotropin-releasing hormone (GnRH) and a GnRH-secreting neuronal cell line (GN cell line).">susan.ano@nih.gov</a><br> 114129302 VEXXXX 114129303 VGXXXX 114129304 WIXXXX 114129305 XEXXXX 114154620 TRANSGENIC 114154621 Mice 114154622 USEFUL 114154623 Gonadotropin-releasing 114154624 HORMONE 114154625 GnRH 114154626 GnRH-secreting 114154627 NEURONAL 114154628 Cell 114154629 Line 114154630 Gn 114154631 ISOLATED 114154632 Expressing 114154633 Simian 114154634 virus 114154635 40 114154636 T 114154637 ANTIGEN 114154638 Drivenby 114154639 PROMOTER 114154640 Human 114154641 Gene 114154642 PNAS 114154643 1991 114154644 DRIVEN TAB-3701 114097554 HeLa Cells Stably Expressing YFP-Parkin and mt-mKeima to Study Parkinson Disease NINDS Diagnostics, Medical Devices, Neurology, Non-Medical Devices, Research Materials, Software / Apps Diagnostics Medical Devices Neurology Non-Medical Devices Research Materials Software / Apps Chunxin (Black) Wang, Richard Youle This technology includes a cell line that stably expresses YFP-Parkin and mt-mKeima that can be used to study mitochondrial degradation, mitophagy, using flow cytometry (FACS). Compromised mitophagy is implicated in Parkinson disease. The effects of any compounds or genetic alteration on Parkin-mediated mitophagy can be monitored. There is a similar technique to monitor mitophagy with mito-QC (mCherry-GFP-Fis1) but it is not commercialized. Mitophagy can be examined using Western, however, this method is tedious, less sensitive and can be affected by many human errors during the Western blot process. In contrast, the mt-mKeima based mitophagy assay is more robust, consistent, objective, and quantitative. This cell line could be useful for testing potential drugs' effect on Parkin-mediated mitophagy using flow cytometry (FACS). 2022-06-02 2024-10-28 2024-10-28 2022-06-02 2022-05-31 Cells, Expressing, Hela, Mt-mKeima, Stably, VEXXXX, WIXXXX, XFXXXX, YFP-Parkin False True True NIHTT 37470483 Website Abstract 114172859 Lazarou M, Sliter DA, et al. https://pubmed.ncbi.nlm.nih.gov/26266977/ <a href="https://pubmed.ncbi.nlm.nih.gov/26266977/">Lazarou M, Sliter DA, et al.</a> 114172860 Proikas-Cezanne T, Codongo P. et al. https://pubmed.ncbi.nlm.nih.gov/21867908/ <a href="https://pubmed.ncbi.nlm.nih.gov/21867908/">Proikas-Cezanne T, Codongo P. et al.</a> 114111323 Wang, Chunxin (Black) NINDS NINDS Wang, Chunxin (Black) (NINDS) 0 114111322 Youle, Richard NINDS NINDS Youle, Richard (NINDS) 1 114111322 Youle, Richard NINDS NINDS Youle, Richard (NINDS) 1 114111323 Wang, Chunxin (Black) NINDS NINDS Wang, Chunxin (Black) (NINDS) 0 114102805 HeLa Cells Stably Expressing YFP-Parkin And Mt-mKeima E-093-2018-0 Research Material NINDS 83687767 Olufemi, Olufunmilola (Lola) olufunmilola.olufemi@nih.gov
United States of America olufunmilola.olufemi@nih.gov?subject=Web Inquiry on [TAB-3701] HeLa Cells Stably Expressing YFP-Parkin and mt-mKeima to Study Parkinson Disease&body=Please send me information about technology [TAB-3701] HeLa Cells Stably Expressing YFP-Parkin and mt-mKeima to Study Parkinson Disease. Olufemi, Olufunmilola (Lola)<br><a href="mailto:olufunmilola.olufemi@nih.gov?subject=Web Inquiry on [TAB-3701] HeLa Cells Stably Expressing YFP-Parkin and mt-mKeima to Study Parkinson Disease&body=Please send me information about technology [TAB-3701] HeLa Cells Stably Expressing YFP-Parkin and mt-mKeima to Study Parkinson Disease.">olufunmilola.olufemi@nih.gov</a><br> 114129306 VEXXXX 114129307 WIXXXX 114129308 XFXXXX 114154645 Hela 114154646 Cells 114154647 Stably 114154648 Expressing 114154649 YFP-Parkin 114154650 Mt-mKeima TAB-3698 114097551 Automatic brain lesion incidence and detection from multimodal longitudinal magnetic resonance imaging using SuBLIME NINDS Computational models/software, Diagnostics, Neurology, Research Materials, Software / Apps Computational models/software Diagnostics Neurology Research Materials Software / Apps Ciprian Crainiceanu, Arthur Goldsmith, Daniel Reich, Colin Shea, Russell Shinohara, Elizabeth Sweeney This invention relates to methods and algorithms that incorporate information from multiple imaging modalities to identify, estimate the size, and track the time course of brain lesions. Subjects develop brain lesions over the natural course of a disease. Currently, lesions are measured and tracked by a trained neuroradiologist using slice-by-slice inspection, a slow process that is prone to human error and hard to generalize to large observational studies. <br /><br /> Researchers at the National Institute of Neurological Disorders and Stroke (NINDS) and Johns Hopkins University have created a novel method for automatically detecting brain lesion incidence in longitudinal brain magnetic resonance imaging (MRI) studies (data collected at multiple visits). The software embodying the invention, Subtraction Based Logistic Inference for Modeling and Estimation (SuBLIME), was applied on MRI studies with only T2-weighted images, and studies with T2-weighted, T1-weighted, fluid attenuated inversion recovery (FLAIR) and proton density (PD) MRI modalities. Automated detection and characterization of brain lesions. The technology can be extended to additional diseases of the brain (including stroke, small vessel disease, tumors, metabolic disorders, and inflammatory disorders), include additional imaging modalities (such as CT, PET, and PET-CT). In addition, the algorithm could be extended to whole-brain segmentation and to account for shrinking and disappearing lesions. Other body parts where lesions need to be tracked could also be included. 2022-06-02 2024-10-28 2024-10-28 2022-06-02 2022-05-31 Automatic, brain, Detection, IMAGING, Incidence, Lesion, Listed LPM Shmilovich as of 4/15/2015, Longitudinal, Magnetic, MULTIMODALITY, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Resonance, software, SuBLIME:, VEXXXX, WBXXXX, WIXXXX, XBXXXX, XJXXXX False True True NIHTT 37470483 Website Abstract 114172855 Sweeney EM, Shinohara RT, et al. https://pubmed.ncbi.nlm.nih.gov/22766673/ <a href="https://pubmed.ncbi.nlm.nih.gov/22766673/">Sweeney EM, Shinohara RT, et al.</a> 114172856 Moraal B, Wattjes MP, et al. https://pubmed.ncbi.nlm.nih.gov/20308453/ <a href="https://pubmed.ncbi.nlm.nih.gov/20308453/">Moraal B, Wattjes MP, et al.</a> 114111311 Shea, Colin NINDS NINDS Shea, Colin (NINDS) 0 114111312 Crainiceanu, Ciprian Johns Hopkins University Crainiceanu, Ciprian 0 114111313 Sweeney, Elizabeth Johns Hopkins University Sweeney, Elizabeth 0 114111314 Shinohara, Russell Johns Hopkins University Shinohara, Russell 0 114111315 Goldsmith, Arthur Johns Hopkins University Goldsmith, Arthur 0 114111310 Reich, Daniel NINDS NINDS Reich, Daniel (NINDS) 1 114111310 Reich, Daniel NINDS NINDS Reich, Daniel (NINDS) 1 114111311 Shea, Colin NINDS NINDS Shea, Colin (NINDS) 0 114111312 Crainiceanu, Ciprian Johns Hopkins University Crainiceanu, Ciprian 0 114111313 Sweeney, Elizabeth Johns Hopkins University Sweeney, Elizabeth 0 114111314 Shinohara, Russell Johns Hopkins University Shinohara, Russell 0 114111315 Goldsmith, Arthur Johns Hopkins University Goldsmith, Arthur 0 114102802 SuBLIME: Automatic Brain Lesion Incidence And Detection Using Multimodality Longitudinal Magnetic Resonance Imaging E-043-2012-0 Filing authorized Johns Hopkins University, NINDS 83722849 Sharma, Smita smita.sharma@nih.gov
United States of America smita.sharma@nih.gov?subject=Web Inquiry on [TAB-3698] Automatic brain lesion incidence and detection from multimodal longitudinal magnetic resonance imaging using SuBLIME&body=Please send me information about technology [TAB-3698] Automatic brain lesion incidence and detection from multimodal longitudinal magnetic resonance imaging using SuBLIME. Sharma, Smita<br><a href="mailto:smita.sharma@nih.gov?subject=Web Inquiry on [TAB-3698] Automatic brain lesion incidence and detection from multimodal longitudinal magnetic resonance imaging using SuBLIME&body=Please send me information about technology [TAB-3698] Automatic brain lesion incidence and detection from multimodal longitudinal magnetic resonance imaging using SuBLIME.">smita.sharma@nih.gov</a><br> 114169533 E-043-2012-0 E-043-2012-0-US-01 SuBLIME: Automatic Brain Lesion Incidence And Detection Using Multimodality Longitudinal Magnetic Resonance Imaging PRV US 61/630,101 Abandoned US <br />Provisional (PRV) 61/630,101<br />Filed on 2011-12-05<br />Status: Abandoned 114169534 E-043-2012-0 E-043-2012-0-PCT-02 SYSTEM AND METHOD OF AUTOMATICALLY DETECTING TISSUE ABNORMALITIES PCT Patent Cooperation Treaty PCT/US2012/067997 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2012/067997<br />Filed on 2012-12-05<br />Status: Expired 114169535 E-043-2012-0 E-043-2012-0-US-03 SuBLIME: Automatic Brain Lesion Incidence And Detection Using Multimodality Longitudinal Magnetic Resonance Imaging National Stage US 9,607,392 14/362,354 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9607392 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9607392">9,607,392</a><br />Filed on 2014-06-02<br />Status: Issued 114129294 VEXXXX 114129295 WBXXXX 114129296 WIXXXX 114129297 XBXXXX 114129298 XJXXXX 114154601 SuBLIME: 114154602 Automatic 114154603 brain 114154604 Lesion 114154605 Incidence 114154606 Detection 114154607 MULTIMODALITY 114154608 Longitudinal 114154609 Magnetic 114154610 Resonance 114154611 IMAGING 114154612 Listed LPM Shmilovich as of 4/15/2015 114154613 Pre LPM working set 20150418 114154614 Post LPM Assignment Set 20150420 114154615 software TAB-3699 114097552 USP30 Knockout HeLa Cells for Studying Parkinson Disease NINDS Neurology, Research Materials, Therapeutics Neurology Research Materials Therapeutics Polixeni Sideris, Richard Youle The technology includes USP30 knockout HeLa cells that were generated using CRISPR technology. Parkin and Pink1 are key master genes for triggering the degradation of mitochondria (mitophagy). In contrast, USP30 has been found to be localized in the mitochondria and have a role in antagonizing Parkin function, thereby impeding mitophagy. <br /><br /> To create the HeLa cells, one CRISPR gRNAs targeting exon 5 of USP30 genome was used for transfection with Cas9 and a GFP-C1 reporter. Cells were sorted 2 days after transfection and plated out in 96-well plates. 10 days later, single colonies were transferred to 24-well plates and then genomic DNA of each colony was isolated for PCR genotyping. The positive clones were then confirmed by sequencing. USP30 is constantly degraded in normal conditions, and it has been difficult to raise a good and specific USP30 antibody. The USP30 knockout cell line can be the gold standard to verify if an antibody is functional and specific. The knockout cell line permits the study of regulatory steps of mitophagy. The knockout cells can also be used for verifying USP30 antibody. 2022-06-02 2024-10-28 2024-10-28 2022-06-02 2022-05-31 Cells, Hela, Knockout, USP30, VEXXXX, WIXXXX, XEXXXX False True True NIHTT 37470483 Website Abstract 114111317 Sideris, Polixeni NINDS NINDS Sideris, Polixeni (NINDS) 0 114111316 Youle, Richard NINDS NINDS Youle, Richard (NINDS) 1 114111316 Youle, Richard NINDS NINDS Youle, Richard (NINDS) 1 114111317 Sideris, Polixeni NINDS NINDS Sideris, Polixeni (NINDS) 0 114102803 USP30 Knockout HeLa Cells E-074-2016-0 Research Material NINDS 83687767 Olufemi, Olufunmilola (Lola) olufunmilola.olufemi@nih.gov
United States of America olufunmilola.olufemi@nih.gov?subject=Web Inquiry on [TAB-3699] USP30 Knockout HeLa Cells for Studying Parkinson Disease&body=Please send me information about technology [TAB-3699] USP30 Knockout HeLa Cells for Studying Parkinson Disease. Olufemi, Olufunmilola (Lola)<br><a href="mailto:olufunmilola.olufemi@nih.gov?subject=Web Inquiry on [TAB-3699] USP30 Knockout HeLa Cells for Studying Parkinson Disease&body=Please send me information about technology [TAB-3699] USP30 Knockout HeLa Cells for Studying Parkinson Disease.">olufunmilola.olufemi@nih.gov</a><br> 114129299 VEXXXX 114129300 WIXXXX 114129301 XEXXXX 114154616 USP30 114154617 Knockout 114154618 Hela 114154619 Cells TAB-3696 114097549 Therapeutic Approaches to Inhibit Replication of ALS-related Endogenous Retroviruses NINDS Infectious Disease, Neurology, Research Materials, Therapeutics Infectious Disease Neurology Research Materials Therapeutics Lisa Henderson, Myoung Hwa Lee, Wenxue Li, Avindra Nath, Richa Tyagi The technology relates to therapeutic approaches that inhibit and block the replication of the endogenous HERV-K retrovirus. Previous work has shown that patients with Amyotrophic Lateral Sclerosis (ALS) can have HERV-K activation. In animal models, activation of HERV-K can lead to neurodegenerative symptoms similar to those exhibited by ALS patients. Work in these animal models has allowed the identification of the responsible transcription factor (TDP-43) as well as the corresponding positions of the HERV-K promoter binding sites. <br /><br /> This work has shown that existing retroviral drugs used for treating HIV infection can also inhibit HERV-K replication, although this requires a different dose range and combination of drugs. In addition, antisense molecules have been developed that can block the replication of HERV-K specifically. Currently there are no available methods to block the replication of HERV-K. The use of existing retroviral drugs, or modified variants of these, could be useful to treat diseases related to HERV-K replication, including potentially ALS. 2022-06-02 2024-10-28 2024-10-28 2022-06-02 2022-05-31 APPROACHES, ENDOGENOUS, Retroviruses, therapeutic, VEXXXX, VLXXXX, WIXXXX, WKXXXX False True True NIHTT 37470483 Website Abstract 114172852 Wenxue L, Lee M-H, et al. https://pubmed.ncbi.nlm.nih.gov/26424568/ <a href="https://pubmed.ncbi.nlm.nih.gov/26424568/">Wenxue L, Lee M-H, et al.</a> 114172853 Douville R, Liu J, et al. https://pubmed.ncbi.nlm.nih.gov/21280084/ <a href="https://pubmed.ncbi.nlm.nih.gov/21280084/">Douville R, Liu J, et al.</a> 114111296 Li, Wenxue NINDS NINDS Li, Wenxue (NINDS) 0 114111297 Lee, Myoung Hwa NINDS NINDS Lee, Myoung Hwa (NINDS) 0 114111298 Henderson, Lisa NINDS NINDS Henderson, Lisa (NINDS) 0 114111299 Tyagi, Richa NINDS Tyagi, Richa 0 114111300 Nath, Avindra NINDS NINDS Nath, Avindra (NINDS) 1 114111300 Nath, Avindra NINDS NINDS Nath, Avindra (NINDS) 1 114111296 Li, Wenxue NINDS NINDS Li, Wenxue (NINDS) 0 114111297 Lee, Myoung Hwa NINDS NINDS Lee, Myoung Hwa (NINDS) 0 114111298 Henderson, Lisa NINDS NINDS Henderson, Lisa (NINDS) 0 114111299 Tyagi, Richa NINDS Tyagi, Richa 0 114102800 Therapeutic Approaches To Endogenous Retroviruses E-024-2016-0 Filing authorized NINDS 83700966 Dukhanina, Oksana oksana.dukhanina@nih.gov
United States of America oksana.dukhanina@nih.gov?subject=Web Inquiry on [TAB-3696] Therapeutic Approaches to Inhibit Replication of ALS-related Endogenous Retroviruses&body=Please send me information about technology [TAB-3696] Therapeutic Approaches to Inhibit Replication of ALS-related Endogenous Retroviruses. Dukhanina, Oksana<br><a href="mailto:oksana.dukhanina@nih.gov?subject=Web Inquiry on [TAB-3696] Therapeutic Approaches to Inhibit Replication of ALS-related Endogenous Retroviruses&body=Please send me information about technology [TAB-3696] Therapeutic Approaches to Inhibit Replication of ALS-related Endogenous Retroviruses.">oksana.dukhanina@nih.gov</a><br> 114169531 E-024-2016-0 E-024-2016-0-US-01 Methods of Treating and Preventing Amyotrophic Lateral Sclerosis (ALS) PRV US 62/234,419 Abandoned US <br />Provisional (PRV) 62/234,419<br />Filed on 2015-09-29<br />Status: Abandoned 114129286 VEXXXX 114129287 VLXXXX 114129288 WIXXXX 114129289 WKXXXX 114154590 therapeutic 114154591 APPROACHES 114154592 ENDOGENOUS 114154593 Retroviruses TAB-3697 114097550 Synthesis and Use of Positive Allosteric Modulators to Modify D1 Dopamine Receptor Activity NINDS Neurology, Psychiatry/Mental Health, Research Materials, Therapeutics Neurology Psychiatry/Mental Health Research Materials Therapeutics Jeffrey Aube, Jennie Conroy, Marc Ferrer-Alegre, Kevin Frankowski, R Benjamin Free, Prashi Jain, Kathryn Luderman, David Sibley, Noel Southall This technology relates to the creation and use of newly identified ligands to the D1 dopamine receptor (D1R). The D1 dopamine receptor is linked to a variety of neuropsychiatric disorders and represents an attractive drug target for the enhancement of cognition in schizophrenia, Alzheimer disease, and other disorders. These ligands are positive allosteric modulators (PAMs) that bind to the dopamine receptor at a site other than where dopamine binds and causes the receptor to have an increased response. These PAMs potentiate dopamine-stimulated G-protein and 13-arrestin-mediated signaling of the D1R. Several analogs of the D1R PAM compounds have been synthesized and characterized. The PAMs may have several advantages over existing synthetic orthosteric agonists, which bind to the same site as dopamine. PAMs potentiate the receptor activation caused by dopamine, but there is a limit to the potentiation caused by the PAM. This can result in a larger therapeutic window, compared to a synthetic orthosteric agonist, which can overstimulate the receptor resulting in adverse side effects. Also, by their nature, PAMs bind to a site on the receptor that is different from the dopamine binding site that is targeted by orthosteric ligands. PAMs should have an increased selectivity for the D1 dopamine receptor while minimizing off-target side effects. 2022-06-02 2024-10-28 2024-10-28 2022-06-02 2022-05-31 ALLOSTERIC, D1, DI, Dopamine, MODULATORS, POSITIVE, RECEPTOR, VEXXXX, VNXXXX, WIXXXX, WKXXXX False True True NIHTT 37470483 Website Abstract 114172854 Luderman KD, Conroy JL, et al. https://pubmed.ncbi.nlm.nih.gov/30068735/ <a href="https://pubmed.ncbi.nlm.nih.gov/30068735/">Luderman KD, Conroy JL, et al.</a> 114111301 Free, R Benjamin NINDS NINDS Free, R Benjamin (NINDS) 0 114111302 Luderman, Kathryn NINDS NINDS Luderman, Kathryn (NINDS) 0 114111304 Southall, Noel NCATS - TRND NCATS Southall, Noel (NCATS) 0 114111305 Ferrer-Alegre, Marc NCATS - NCGC NCATS Ferrer-Alegre, Marc (NCATS) 0 114111306 Frankowski, Kevin University of North Carolina, Chapel Hill Frankowski, Kevin 0 114111307 Aube, Jeffrey University of North Carolina, Chapel Hill Aube, Jeffrey 0 114111308 Conroy, Jennie NINDS NICHD Conroy, Jennie (NICHD) 0 114111309 Jain, Prashi University of Kansas Jain, Prashi 0 114111303 Sibley, David NINDS NINDS Sibley, David (NINDS) 1 114111303 Sibley, David NINDS NINDS Sibley, David (NINDS) 1 114111301 Free, R Benjamin NINDS NINDS Free, R Benjamin (NINDS) 0 114111302 Luderman, Kathryn NINDS NINDS Luderman, Kathryn (NINDS) 0 114111304 Southall, Noel NCATS - TRND NCATS Southall, Noel (NCATS) 0 114111305 Ferrer-Alegre, Marc NCATS - NCGC NCATS Ferrer-Alegre, Marc (NCATS) 0 114111306 Frankowski, Kevin University of North Carolina, Chapel Hill Frankowski, Kevin 0 114111307 Aube, Jeffrey University of North Carolina, Chapel Hill Aube, Jeffrey 0 114111308 Conroy, Jennie NINDS NICHD Conroy, Jennie (NICHD) 0 114111309 Jain, Prashi University of Kansas Jain, Prashi 0 114102801 Positive Allosteric Modulators For The D1 Dopamine Receptor E-025-2018-0 Filing authorized NCATS - NCGC, NINDS, University of Kansas, University of North Carolina, Chapel Hill 83667829 Ano, Susan susan.ano@nih.gov
United States of America susan.ano@nih.gov?subject=Web Inquiry on [TAB-3697] Synthesis and Use of Positive Allosteric Modulators to Modify D1 Dopamine Receptor Activity&body=Please send me information about technology [TAB-3697] Synthesis and Use of Positive Allosteric Modulators to Modify D1 Dopamine Receptor Activity. Ano, Susan<br><a href="mailto:susan.ano@nih.gov?subject=Web Inquiry on [TAB-3697] Synthesis and Use of Positive Allosteric Modulators to Modify D1 Dopamine Receptor Activity&body=Please send me information about technology [TAB-3697] Synthesis and Use of Positive Allosteric Modulators to Modify D1 Dopamine Receptor Activity.">susan.ano@nih.gov</a><br> 114169532 E-025-2018-0 E-025-2018-0-US-01 POSITIVE ALLOSTERIC MODULATORS OF DOPAMINE 1 RECEPTOR AND METHOD OF USE THEREOF PRV US 62/639,271 Abandoned US <br />Provisional (PRV) 62/639,271<br />Filed on 2018-03-06<br />Status: Abandoned 114129290 VEXXXX 114129291 VNXXXX 114129292 WIXXXX 114129293 WKXXXX 114154594 Dopamine 114154595 DI 114154596 MODULATORS 114154597 ALLOSTERIC 114154598 POSITIVE 114154599 D1 114154600 RECEPTOR TAB-3694 114097547 Development of monoclonal antibodies that detect specific forms of neurophysin bound to either vasopressin or oxytocin NINDS Antibodies, Endocrinology, Immunology, Neurology, Research Materials Antibodies Endocrinology Immunology Neurology Research Materials Harold Gainer (Estate) This invention includes the generation and use of monoclonal antibodies that specifically recognize either arginine vasopressin (AVP) or oxytocin (OT) when bound to neurophysins. The neurophysins (NPs) are a family of proteins that bind to hormones as they are released from the hypothalamus and make their way to the pituitary gland. Monoclonal antibodies were generated that specifically recognize vasopressin bound to a neurophysin (NP-AVP) or oxytocin bound to a neurophysin (NP-OT). Seven monoclonal antibodies were characterized. The PS41 and PS45 antibodies were found to specifically detect NP-AVP and the PS38 antibody specifically detects NP-OT. No other antibody with these specificities exists commercially. The monoclonal antibodies can be used in R1A, immunoblot, and immunohistochemistry assays to detect specific forms of neurophysin bound to either vasopressin or oxytocin. 2022-06-02 2024-10-28 2024-10-28 2022-06-02 2022-05-31 AFTER, antibodies, ATCC, Available, AVP, Detect, Development, Forms, HYBRIDOMAS, LICENSE, Listed LPM Contreras as of 4/15/2015, monoclonal, NEUROHYPOPHYSIAL, Neurophysin, ot, OXYTOCIN, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, RELATED, RXXXXX, Specific, That, VASOPRESSIN, VEXXXX, VGXXXX, WIXXXX, XAXXXX False True True NIHTT 37470483 Website Abstract 114172849 Ben-Barak Y, Russell JT, et al. https://pubmed.ncbi.nlm.nih.gov/3880813/ <a href="https://pubmed.ncbi.nlm.nih.gov/3880813/">Ben-Barak Y, Russell JT, et al.</a> 114172850 Whitnall MH, Key S, et al. https://pubmed.ncbi.nlm.nih.gov/3880814/ <a href="https://pubmed.ncbi.nlm.nih.gov/3880814/">Whitnall MH, Key S, et al.</a> 114111292 Gainer (Estate), Harold NINDS NINDS Gainer (Estate), Harold (NINDS) 1 114111292 Gainer (Estate), Harold NINDS NINDS Gainer (Estate), Harold (NINDS) 1 114102798 AVAILABLE THROUGH ATCC AFTER LICENSE Development Of Monoclonal Antibodies That Detect Specific Forms Of Neurophysin And Related Hybridomas E-004-2014-0 Research Material NINDS 83667829 Ano, Susan susan.ano@nih.gov
United States of America susan.ano@nih.gov?subject=Web Inquiry on [TAB-3694] Development of monoclonal antibodies that detect specific forms of neurophysin bound to either vasopressin or oxytocin&body=Please send me information about technology [TAB-3694] Development of monoclonal antibodies that detect specific forms of neurophysin bound to either vasopressin or oxytocin. Ano, Susan<br><a href="mailto:susan.ano@nih.gov?subject=Web Inquiry on [TAB-3694] Development of monoclonal antibodies that detect specific forms of neurophysin bound to either vasopressin or oxytocin&body=Please send me information about technology [TAB-3694] Development of monoclonal antibodies that detect specific forms of neurophysin bound to either vasopressin or oxytocin.">susan.ano@nih.gov</a><br> 114129277 RXXXXX 114129278 VEXXXX 114129279 VGXXXX 114129280 WIXXXX 114129281 XAXXXX 114154560 Development 114154561 monoclonal 114154562 antibodies 114154563 Detect 114154564 Neurophysin 114154565 VASOPRESSIN 114154566 OXYTOCIN 114154567 NEUROHYPOPHYSIAL 114154568 AVP 114154569 ot 114154570 That 114154571 Specific 114154572 Forms 114154573 RELATED 114154574 HYBRIDOMAS 114154575 Listed LPM Contreras as of 4/15/2015 114154576 Pre LPM working set 20150418 114154577 Post LPM Assignment Set 20150420 114154578 Available 114154579 ATCC 114154580 AFTER 114154581 LICENSE TAB-3695 114097548 Development of a polyclonal antibody that detects phosphorylated glutamate receptor 1 protein (GluA1 pS567) NINDS Antibodies, Immunology, Neurology, Research Materials Antibodies Immunology Neurology Research Materials John Badger, Marc Lussier, Katherine Roche This invention includes the generation and use of polyclonal antibodies that specifically recognize the glutamate receptor 1 protein that has been phosphorylated at Serine 567 (GluA1 pS567). Glutamate receptors are ligand-gated ion channels and are the predominant excitatory neurotransmitter receptor type in humans. A peptide sequence on the gene was selected surrounding the phosphorylation site. This peptide was then generated and injected into rabbits to create an immune response. Serum was then collected from the rabbit and the antibodies were affinity purified. The specificity of the antibody was determined using various biochemical techniques. No other antibody with these specificities exists commercially. It can be used to study the localization of phosphorylated GluA1. 2022-06-02 2024-10-28 2024-10-28 2022-06-02 2022-05-31 ANTIBODY, Development, GluA1, Listed LPM Contreras as of 4/15/2015, polyclonal, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, PS567, RXXXXX, VEXXXX, WIXXXX, XAXXXX False True True NIHTT 37470483 Website Abstract 114172851 Lu W, Isozaki K, et al. https://pubmed.ncbi.nlm.nih.gov/21135237/ <a href="https://pubmed.ncbi.nlm.nih.gov/21135237/">Lu W, Isozaki K, et al.</a> 114111294 Badger, John NINDS NINDS Badger, John (NINDS) 0 114111295 Lussier, Marc Lussier, Marc 0 114111293 Roche, Katherine NINDS NINDS Roche, Katherine (NINDS) 1 114111293 Roche, Katherine NINDS NINDS Roche, Katherine (NINDS) 1 114111294 Badger, John NINDS NINDS Badger, John (NINDS) 0 114111295 Lussier, Marc Lussier, Marc 0 114102799 Development Of A Polyclonal Antibody For GluA1 PS567 E-004-2015-0 Research Material NINDS 83722849 Sharma, Smita smita.sharma@nih.gov
United States of America smita.sharma@nih.gov?subject=Web Inquiry on [TAB-3695] Development of a polyclonal antibody that detects phosphorylated glutamate receptor 1 protein (GluA1 pS567)&body=Please send me information about technology [TAB-3695] Development of a polyclonal antibody that detects phosphorylated glutamate receptor 1 protein (GluA1 pS567). Sharma, Smita<br><a href="mailto:smita.sharma@nih.gov?subject=Web Inquiry on [TAB-3695] Development of a polyclonal antibody that detects phosphorylated glutamate receptor 1 protein (GluA1 pS567)&body=Please send me information about technology [TAB-3695] Development of a polyclonal antibody that detects phosphorylated glutamate receptor 1 protein (GluA1 pS567).">smita.sharma@nih.gov</a><br> 114129282 RXXXXX 114129283 VEXXXX 114129284 WIXXXX 114129285 XAXXXX 114154582 Development 114154583 polyclonal 114154584 ANTIBODY 114154585 GluA1 114154586 PS567 114154587 Listed LPM Contreras as of 4/15/2015 114154588 Pre LPM working set 20150418 114154589 Post LPM Assignment Set 20150420 TAB-3692 114097544 CRISPR-Mediated Gene Inhibition and Neuronal Differentiation in Human Induced Pluripotent Stem Cell (iPSC) Lines NINDS Neurology, Research Materials, Therapeutics Neurology Research Materials Therapeutics Martin Kampmann, Connor Ludwig, Ruilin Tian, Michael Ward This invention includes human induced pluripotent stem cell (iPSC) lines that harbor a single copy dCas9-BFP-KRAB at the CLYBL safe harbor locus (mediating CRISPR inhibition of human gene expression) and/or a single copy of dox-inducible NGN2 at the AAVS1 locus (enabling the differentiation of the iPSCs into neurons). The CRISPR-mediated inhibition of human gene expression is maintained into the differentiated neurons, permitting functional studies of targeted genes in neurons. The stem cell lines included in this technology permit direct genetic and screening approaches on neurons. The stem cell lines can be used for forward genetic and chemogenetic screens for drug tests of neurological diseases. 2022-06-02 2024-10-28 2024-10-28 2022-06-02 2022-05-31 Cell, CRISPRi-, INDUCED, Llines, Pluripotent, Stem, VEXXXX, WIXXXX, WTC11, XEXXXX False True True NIHTT 37470483 Website Abstract 114172846 Ruilin T, Gachechiladze MA, et al. https://pubmed.ncbi.nlm.nih.gov/31422865/ <a href="https://pubmed.ncbi.nlm.nih.gov/31422865/">Ruilin T, Gachechiladze MA, et al.</a> 114111287 Kampmann, Martin University of California, San Francisco (UCSF) Kampmann, Martin 0 114111288 Ludwig, Connor University of California, San Francisco (UCSF) Ludwig, Connor 0 114111289 Tian, Ruilin University of California, San Francisco (UCSF) Tian, Ruilin 0 114111286 Ward, Michael NINDS NINDS Ward, Michael (NINDS) 1 114111286 Ward, Michael NINDS NINDS Ward, Michael (NINDS) 1 114111287 Kampmann, Martin University of California, San Francisco (UCSF) Kampmann, Martin 0 114111288 Ludwig, Connor University of California, San Francisco (UCSF) Ludwig, Connor 0 114111289 Tian, Ruilin University of California, San Francisco (UCSF) Tian, Ruilin 0 114102796 CRISPRi- WTC11 Induced Pluripotent Stem Cell Llines E-002-2020-0 Research Material NINDS, University of California, San Francisco (UCSF) 83687767 Olufemi, Olufunmilola (Lola) olufunmilola.olufemi@nih.gov
United States of America olufunmilola.olufemi@nih.gov?subject=Web Inquiry on [TAB-3692] CRISPR-Mediated Gene Inhibition and Neuronal Differentiation in Human Induced Pluripotent Stem Cell (iPSC) Lines&body=Please send me information about technology [TAB-3692] CRISPR-Mediated Gene Inhibition and Neuronal Differentiation in Human Induced Pluripotent Stem Cell (iPSC) Lines. Olufemi, Olufunmilola (Lola)<br><a href="mailto:olufunmilola.olufemi@nih.gov?subject=Web Inquiry on [TAB-3692] CRISPR-Mediated Gene Inhibition and Neuronal Differentiation in Human Induced Pluripotent Stem Cell (iPSC) Lines&body=Please send me information about technology [TAB-3692] CRISPR-Mediated Gene Inhibition and Neuronal Differentiation in Human Induced Pluripotent Stem Cell (iPSC) Lines.">olufunmilola.olufemi@nih.gov</a><br> 114129271 VEXXXX 114129272 WIXXXX 114129273 XEXXXX 114154544 CRISPRi- 114154545 WTC11 114154546 INDUCED 114154547 Pluripotent 114154548 Stem 114154549 Cell 114154550 Llines TAB-3693 114097545 Development of a Polyclonal Antibody for SAP102 and a Polyclonal Antibody for mGluR7 PS862 NINDS Antibodies, Immunology, Neurology, Research Materials Antibodies Immunology Neurology Research Materials John Badger, Katherine Roche This invention includes the generation and use of a polyclonal antibody for synapse-associated protein 102 (SAP102) and a polyclonal antibody that binds to mGluR7 when phosphorylated at Serine 862. Peptides of the sites were generated and injected into rabbits to create an immune response. Serum was collected from the rabbits that was then affinity purified. The specificity of the resulting polyclonal antibodies was then determined using biochemical techniques. These antibodies are specific to these sites and can be used to detect phosphorylation of the amino acid at this specific site. They will be used in laboratories as a tool for studying SAP102 and phosphorylated GluR7. They will be used in laboratories as a tool for studying SAP102 and phosphorylated GluR7. 2022-06-02 2024-10-28 2024-10-28 2022-06-02 2022-05-31 ANTIBODY, Development, Listed LPM Contreras as of 4/15/2015, MGluR7, polyclonal, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, PS862, SAP102, VEXXXX, WIXXXX, XAXXXX False True True NIHTT 37470483 Website Abstract 114172847 Young HS, Pelkey KA, et al. https://pubmed.ncbi.nlm.nih.gov/18549785/ <a href="https://pubmed.ncbi.nlm.nih.gov/18549785/">Young HS, Pelkey KA, et al.</a> 114172848 Chen B-S, Thomas EV, et al. https://pubmed.ncbi.nlm.nih.gov/21209193/ <a href="https://pubmed.ncbi.nlm.nih.gov/21209193/">Chen B-S, Thomas EV, et al.</a> 114111291 Badger, John NINDS NINDS Badger, John (NINDS) 0 114111290 Roche, Katherine NINDS NINDS Roche, Katherine (NINDS) 1 114111290 Roche, Katherine NINDS NINDS Roche, Katherine (NINDS) 1 114111291 Badger, John NINDS NINDS Badger, John (NINDS) 0 114102797 Development Of A Polyclonal Antibody For SAP102 And A Polyclonal Antibody For MGluR7 PS862 E-003-2015-0 Research Material NINDS 83722849 Sharma, Smita smita.sharma@nih.gov
United States of America smita.sharma@nih.gov?subject=Web Inquiry on [TAB-3693] Development of a Polyclonal Antibody for SAP102 and a Polyclonal Antibody for mGluR7 PS862&body=Please send me information about technology [TAB-3693] Development of a Polyclonal Antibody for SAP102 and a Polyclonal Antibody for mGluR7 PS862. Sharma, Smita<br><a href="mailto:smita.sharma@nih.gov?subject=Web Inquiry on [TAB-3693] Development of a Polyclonal Antibody for SAP102 and a Polyclonal Antibody for mGluR7 PS862&body=Please send me information about technology [TAB-3693] Development of a Polyclonal Antibody for SAP102 and a Polyclonal Antibody for mGluR7 PS862.">smita.sharma@nih.gov</a><br> 114129274 VEXXXX 114129275 WIXXXX 114129276 XAXXXX 114154551 Development 114154552 polyclonal 114154553 ANTIBODY 114154554 SAP102 114154555 MGluR7 114154556 PS862 114154557 Listed LPM Contreras as of 4/15/2015 114154558 Pre LPM working set 20150418 114154559 Post LPM Assignment Set 20150420 TAB-3690 114097542 Anti-Atlastin-1 Mouse Monoclonal Antibody 3194 (lgG1) For Studying Hereditary Spastic Paraplegia (SPG3A) NINDS Antibodies, Immunology, Neurology, Research Materials Antibodies Immunology Neurology Research Materials Craig Blackstone, Peng Peng Zhu This technology includes the creation and use of a mouse anti-Atlastin-1 monoclonal antibody (3194, IgG1). Mutations in Atlastin-1 are commonly found in hereditary spastic paraplegia, SPG3A. In addition, this protein is conserved in all eukaryotes, and it mediates fusion of endoplasmic reticulum tubules in cells, giving it its characteristic polygonal appearance. Thus, this protein is of interest to both those interested in disease pathogenesis and those studying basic cell biology. Companies and other laboratories have generated polyclonal antibodies against this same epitope, based on our original publication, but to our knowledge no one else has developed a monoclonal antibody with this specificity. This anti-Atlastin-1 monoclonal antibody can be used for immunoblotting and immunocytochemistry to detect this protein. 2022-06-02 2024-10-28 2024-10-28 2022-06-02 2022-05-31 2017, 3194, Added, Against, Anti-Atlastin-1, Anti-Atlastin-3, ANTIBODY, Epitope, IgG1, Listed LPM Contreras as of 4/15/2015, monoclonal, Mouse, Peptide, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, PRODUCED, Specific, VEXXXX, WIXXXX, XAXXXX False True True NIHTT 37470483 Website Abstract 114172845 Park SH, Zhu P-P, et al. https://pubmed.ncbi.nlm.nih.gov/20200447/ <a href="https://pubmed.ncbi.nlm.nih.gov/20200447/">Park SH, Zhu P-P, et al.</a> 114111283 Zhu, Peng Peng NINDS NINDS Zhu, Peng Peng (NINDS) 0 114111282 Blackstone, Craig NINDS NINDS Blackstone, Craig (NINDS) 1 114111282 Blackstone, Craig NINDS NINDS Blackstone, Craig (NINDS) 1 114111283 Zhu, Peng Peng NINDS NINDS Zhu, Peng Peng (NINDS) 0 114102794 Anti-Atlastin-1 Specific Mouse Monoclonal Antibody 3194 (IgG1) Produced Against A Specific Peptide Epitope And Anti-Atlastin-3 Specific Mouse Monoclonal Antibody (added 2017) E-129-2015-0 Research Material NINDS 83667829 Ano, Susan susan.ano@nih.gov
United States of America susan.ano@nih.gov?subject=Web Inquiry on [TAB-3690] Anti-Atlastin-1 Mouse Monoclonal Antibody 3194 (lgG1) For Studying Hereditary Spastic Paraplegia (SPG3A)&body=Please send me information about technology [TAB-3690] Anti-Atlastin-1 Mouse Monoclonal Antibody 3194 (lgG1) For Studying Hereditary Spastic Paraplegia (SPG3A). Ano, Susan<br><a href="mailto:susan.ano@nih.gov?subject=Web Inquiry on [TAB-3690] Anti-Atlastin-1 Mouse Monoclonal Antibody 3194 (lgG1) For Studying Hereditary Spastic Paraplegia (SPG3A)&body=Please send me information about technology [TAB-3690] Anti-Atlastin-1 Mouse Monoclonal Antibody 3194 (lgG1) For Studying Hereditary Spastic Paraplegia (SPG3A).">susan.ano@nih.gov</a><br> 114129265 VEXXXX 114129266 WIXXXX 114129267 XAXXXX 114154522 Anti-Atlastin-1 114154523 Specific 114154524 Mouse 114154525 monoclonal 114154526 ANTIBODY 114154527 3194 114154528 IgG1 114154529 PRODUCED 114154530 Against 114154531 Peptide 114154532 Epitope 114154533 Listed LPM Contreras as of 4/15/2015 114154534 Pre LPM working set 20150418 114154535 Post LPM Assignment Set 20150420 114154536 Anti-Atlastin-3 114154537 Added 114154538 2017 TAB-3691 114097543 Neutralizing the neurodegenerative effect of ALS-related HERV-K using antibodies NINDS Neurology, Research Materials, Therapeutics Neurology Research Materials Therapeutics Julie Medina, Herve Perron This technology relates to the therapeutic use of antibodies to decrease the potential neurodegenerative effect of the HERV-K retrovirus. Previous work has shown that patients with Amyotrophic Lateral Sclerosis (ALS) can have HERV-K activation. In animal models, activation of HERV-K can lead to neurodegenerative symptoms similar to those exhibited by ALS patients. This neurodegenerative effect is thought to be caused by the release of HERV-K envelope proteins into the extracellular space. Work with monoclonal antibodies in vitro has neutralized the toxicity of this protein. Currently there is no treatment available that targets HERV-K. Hence use of this antibody could be of therapeutic efficacy. The antibodies could be used therapeutically for treating patients with ALS. 2022-06-02 2024-10-28 2024-10-28 2022-06-02 2022-05-31 ANTIBODY, Anti-HERV-K, Envelope, THEREOF, USES, VEXXXX, WIXXXX, WJXXXX False True True NIHTT 37470483 Website Abstract 114111285 Medina, Julie Geneuro SA Medina, Julie 0 114111284 Perron, Herve Geneuro SA Perron, Herve 1 114111284 Perron, Herve Geneuro SA Perron, Herve 1 114111285 Medina, Julie Geneuro SA Medina, Julie 0 114102795 Anti-HERV-K Envelope Antibody And Uses Thereof E-088-2018-0 Filing authorized Geneuro SA 83700966 Dukhanina, Oksana oksana.dukhanina@nih.gov
United States of America oksana.dukhanina@nih.gov?subject=Web Inquiry on [TAB-3691] Neutralizing the neurodegenerative effect of ALS-related HERV-K using antibodies&body=Please send me information about technology [TAB-3691] Neutralizing the neurodegenerative effect of ALS-related HERV-K using antibodies. Dukhanina, Oksana<br><a href="mailto:oksana.dukhanina@nih.gov?subject=Web Inquiry on [TAB-3691] Neutralizing the neurodegenerative effect of ALS-related HERV-K using antibodies&body=Please send me information about technology [TAB-3691] Neutralizing the neurodegenerative effect of ALS-related HERV-K using antibodies.">oksana.dukhanina@nih.gov</a><br> 157764803 E-088-2018-0 E-088-2018-0-EP-01 Anti-HERV-K Envelope Antibody And Uses Thereof ORD France 17305062.6 Pending France <br />Ordinary Patent (ORD) 17305062.6<br />Filed on 2017-01-20<br />Status: Pending 157764808 E-088-2018-0 E-088-2018-0-AR-02 Anti-HERV-K Envelope Antibody And Uses Thereof ORD Argentina 20180100129 Pending Argentina <br />Ordinary Patent (ORD) 20180100129<br />Filed on 2018-01-19<br />Status: Pending 157764818 E-088-2018-0 E-088-2018-0-TW-04 Anti-HERV-K Envelope Antibody And Uses Thereof ORD Taiwan 201831518 107102219 Issued Taiwan <br />Ordinary Patent (ORD) 107102219<br />Filed on 2018-01-22<br />Status: Issued 114129268 VEXXXX 114129269 WIXXXX 114129270 WJXXXX 114154539 Anti-HERV-K 114154540 Envelope 114154541 ANTIBODY 114154542 USES 114154543 THEREOF TAB-3688 114097540 An Antibody to Detect Neuroligin 4Y (NLGN4Y) to Study Autism Spectrum Disorder and Intellectual Disability NINDS Antibodies, Immunology, Neurology, Research Materials, Therapeutics Antibodies Immunology Neurology Research Materials Therapeutics John Badger, Thien Nguyen, Katherine Roche This technology includes the generation and use of an antibody that can detect endogenous Neuroligin 4Y, NLGN4Y, a cell adhesion molecule on the X-chromosome. NLGN4Y is part of an X-Y pair with NLGN4X, which has been implicated with autism spectrum disorder (ASD) and intellectual disability. ASD has a sex bias etiology that is not well understood, affecting four times as many males as females. Previous work has revealed a potential pathogenic mechanism for male-bias based on mutations in NLGN4X and NLGN4Y. The use of the NLGN4Y antibody could be used to study potential mechanisms. Specific Neuroligin 4Y antibody that can detect endogenous Neuroligin 4Y (NLGN4Y) protein level. Current NLGN4Y antibodies do not work well and cannot detect the protein. The Neuroligin 4Y (NLGN4Y) antibody can be used to further study the role of NLGN4Y function in the brain. The antibody can be used to visualize NLGN4Y localization in the brain. 2022-06-02 2024-10-28 2024-10-28 2022-06-02 2022-05-31 Autism-associated, CLUSTER, FUNCTIONALLY, NLGN4X, NLGN4Y, Resemble, VARIANTS, VEXXXX, WIXXXX, XAXXXX, XEXXXX, X-LINKED False True True NIHTT 37470483 Website Abstract 114172843 Nguyen TA, Wu K, et al. https://pubmed.ncbi.nlm.nih.gov/32243781/ <a href="https://pubmed.ncbi.nlm.nih.gov/32243781/ ">Nguyen TA, Wu K, et al.</a> 114111276 Nguyen, Thien NINDS NINDS Nguyen, Thien (NINDS) 0 114111278 Badger, John NINDS NINDS Badger, John (NINDS) 0 114111277 Roche, Katherine NINDS NINDS Roche, Katherine (NINDS) 1 114111277 Roche, Katherine NINDS NINDS Roche, Katherine (NINDS) 1 114111276 Nguyen, Thien NINDS NINDS Nguyen, Thien (NINDS) 0 114111278 Badger, John NINDS NINDS Badger, John (NINDS) 0 114102792 A Cluster Of Autism-associated Variants On X-linked NLGN4X Functionally Resemble NLGN4Y E-226-2020-0 Research Material NINDS 83722849 Sharma, Smita smita.sharma@nih.gov
United States of America smita.sharma@nih.gov?subject=Web Inquiry on [TAB-3688] An Antibody to Detect Neuroligin 4Y (NLGN4Y) to Study Autism Spectrum Disorder and Intellectual Disability&body=Please send me information about technology [TAB-3688] An Antibody to Detect Neuroligin 4Y (NLGN4Y) to Study Autism Spectrum Disorder and Intellectual Disability. Sharma, Smita<br><a href="mailto:smita.sharma@nih.gov?subject=Web Inquiry on [TAB-3688] An Antibody to Detect Neuroligin 4Y (NLGN4Y) to Study Autism Spectrum Disorder and Intellectual Disability&body=Please send me information about technology [TAB-3688] An Antibody to Detect Neuroligin 4Y (NLGN4Y) to Study Autism Spectrum Disorder and Intellectual Disability.">smita.sharma@nih.gov</a><br> 114129258 VEXXXX 114129259 WIXXXX 114129260 XAXXXX 114129261 XEXXXX 114154503 CLUSTER 114154504 Autism-associated 114154505 VARIANTS 114154506 X-LINKED 114154507 NLGN4X 114154508 FUNCTIONALLY 114154509 Resemble 114154510 NLGN4Y TAB-3689 114097541 An Antibody to Detect Phosphorylation (S1459) of the GRIN2A Gene to Study Epilepsy and Autism Spectrum Disorder NINDS Antibodies, Immunology, Neurology, Research Materials Antibodies Immunology Neurology Research Materials John Badger, Marta Dias da Mota Vieira, Katherine Roche This technology relates to the generation and use of an antibody that recognizes the S1459 phosphorylated site of the GRIN2A gene, which encodes the GluN2A subunit of the NMDA receptor. This gene is widely accepted as an epilepsy-causative gene and has been implicated in autism spectrum disorder (ASD). The S1459 phosphorylation site was selected based on an identified mutation in an epilepsy patient. This antibody can be used to specifically visualize the localization of the phosphorylated version of the GRIN2A protein product in the brain. There are no other antibodies on the market that detect this specific phosphorylation site of the GRIN2A gene, GluN2A-S1459. This GRIN2A antibody could potentially be used to visualize phosphorylation of this site in the brain. 2022-06-02 2024-10-28 2024-10-28 2022-06-02 2022-05-31 CaMKllalpha, Disrupts, Epilepsy-Associated, GLuN2A, GRIN2A, NMDA, PHOSPHORYLATION, RARE, RECEPTOR, Trafficking, VARIANT, VEXXXX, WIXXXX, XAXXXX False True True NIHTT 37470483 Website Abstract 114172844 Vieira MM, Nguyen TA, et al. https://pubmed.ncbi.nlm.nih.gov/32877683/ <a href="https://pubmed.ncbi.nlm.nih.gov/32877683/">Vieira MM, Nguyen TA, et al.</a> 114111279 Dias da Mota Vieira, Marta NINDS NINDS Dias da Mota Vieira, Marta (NINDS) 0 114111281 Badger, John NINDS NINDS Badger, John (NINDS) 0 114111280 Roche, Katherine NINDS NINDS Roche, Katherine (NINDS) 1 114111280 Roche, Katherine NINDS NINDS Roche, Katherine (NINDS) 1 114111279 Dias da Mota Vieira, Marta NINDS NINDS Dias da Mota Vieira, Marta (NINDS) 0 114111281 Badger, John NINDS NINDS Badger, John (NINDS) 0 114102793 An Epilepsy-Associated GRIN2A Rare Variant Disrupts CaMKllalpha Phosphorylation Of GLuN2A And NMDA Receptor Trafficking E-255-2020-0 Research Material NINDS 83722849 Sharma, Smita smita.sharma@nih.gov
United States of America smita.sharma@nih.gov?subject=Web Inquiry on [TAB-3689] An Antibody to Detect Phosphorylation (S1459) of the GRIN2A Gene to Study Epilepsy and Autism Spectrum Disorder&body=Please send me information about technology [TAB-3689] An Antibody to Detect Phosphorylation (S1459) of the GRIN2A Gene to Study Epilepsy and Autism Spectrum Disorder. Sharma, Smita<br><a href="mailto:smita.sharma@nih.gov?subject=Web Inquiry on [TAB-3689] An Antibody to Detect Phosphorylation (S1459) of the GRIN2A Gene to Study Epilepsy and Autism Spectrum Disorder&body=Please send me information about technology [TAB-3689] An Antibody to Detect Phosphorylation (S1459) of the GRIN2A Gene to Study Epilepsy and Autism Spectrum Disorder.">smita.sharma@nih.gov</a><br> 114129262 VEXXXX 114129263 WIXXXX 114129264 XAXXXX 114154511 Epilepsy-Associated 114154512 GRIN2A 114154513 RARE 114154514 VARIANT 114154515 Disrupts 114154516 CaMKllalpha 114154517 PHOSPHORYLATION 114154518 GLuN2A 114154519 NMDA 114154520 RECEPTOR 114154521 Trafficking TAB-3686 114097538 Radioligand for imaging brain PDE4 subtype D receptors with positron emission tomography NIMH Diagnostics, Medical Devices, Neurology, Non-Medical Devices, Psychiatry/Mental Health, Research Materials, Software / Apps Diagnostics Medical Devices Neurology Non-Medical Devices Psychiatry/Mental Health Research Materials Software / Apps Mark Gurney, Robert Innis, Xuesheng Mo, Robert Nugent, Victor Pike, Sanjay Telu The technology relates to the first radioligands that can be used to image and quantify the enzyme phosphodiesterase subtype D (PDE4D). The PDE4D proteins have a role in carrying out signal transduction pathways in several cell types and is thought to be the key target of various antidepressants. Current work with imaging the radioligands in monkey brains using positron emission tomography (PET) has been successful, and further work with humans is needed. An effective radioligand that can visualize PDE4D levels in human using PET can be useful in evaluation of health human subjects and in the development of PDE4D inhibitors. There is no alternative technology for this specific purpose of PET imaging of PDE4D This radioligand can be used in the development of inhibitors of PDE4D for the treatment of depression and cognition enhancement 2022-06-02 2024-10-28 2024-10-28 2022-06-02 2022-05-31 brain, D, Emission, IMAGING, PDE4, Positron, Radioligand, RECEPTORS, Subtype, tomography, VEXXXX, VNXXXX, WBXXXX, WIXXXX, XCXXXX, XFXXXX False True True NIHTT 37470483 Website Abstract 114111269 Telu, Sanjay National Institute of Mental Health (NIMH) NIMH Telu, Sanjay (NIMH) 0 114111270 Innis, Robert National Institute of Mental Health (NIMH) NIMH Innis, Robert (NIMH) 0 114111271 Nugent, Robert Tetra Discovery Partners Inc. Nugent, Robert 0 114111272 Gurney, Mark Tetra Discovery Partners Inc. Gurney, Mark 0 114111273 Mo, Xuesheng Tetra Discovery Partners Inc. Mo, Xuesheng 0 114111268 Pike, Victor National Institute of Mental Health (NIMH) NIMH Pike, Victor (NIMH) 1 114111268 Pike, Victor National Institute of Mental Health (NIMH) NIMH Pike, Victor (NIMH) 1 114111269 Telu, Sanjay National Institute of Mental Health (NIMH) NIMH Telu, Sanjay (NIMH) 0 114111270 Innis, Robert National Institute of Mental Health (NIMH) NIMH Innis, Robert (NIMH) 0 114111271 Nugent, Robert Tetra Discovery Partners Inc. Nugent, Robert 0 114111272 Gurney, Mark Tetra Discovery Partners Inc. Gurney, Mark 0 114111273 Mo, Xuesheng Tetra Discovery Partners Inc. Mo, Xuesheng 0 114102790 Radioligand For Imaging Brain PDE4 Subtype D Receptors With Positron Emission Tomography E-107-2019-0 Filing authorized National Institute of Mental Health (NIMH), Tetra Discovery Partners Inc. 83739514 Dawson, Anton anton.dawson@nih.gov
United States of America anton.dawson@nih.gov?subject=Web Inquiry on [TAB-3686] Radioligand for imaging brain PDE4 subtype D receptors with positron emission tomography&body=Please send me information about technology [TAB-3686] Radioligand for imaging brain PDE4 subtype D receptors with positron emission tomography. Dawson, Anton<br><a href="mailto:anton.dawson@nih.gov?subject=Web Inquiry on [TAB-3686] Radioligand for imaging brain PDE4 subtype D receptors with positron emission tomography&body=Please send me information about technology [TAB-3686] Radioligand for imaging brain PDE4 subtype D receptors with positron emission tomography.">anton.dawson@nih.gov</a><br> 114169529 E-107-2019-0 E-107-2019-0-US-01 PDE4D INHIBITORS PRV US 62/837,352 Abandoned US <br />Provisional (PRV) 62/837,352<br />Filed on 2019-04-23<br />Status: Abandoned 114129247 VEXXXX 114129248 VNXXXX 114129249 WBXXXX 114129250 WIXXXX 114129251 XCXXXX 114129252 XFXXXX 114154489 Radioligand 114154490 IMAGING 114154491 brain 114154492 PDE4 114154493 Subtype 114154494 D 114154495 RECEPTORS 114154496 Positron 114154497 Emission 114154498 tomography TAB-3687 114097539 A Mood-Machine-Interface as an Intervention for Emotional Self-Regulation in Real-Time NIMH Computational models/software, Consumer Products, Medical Devices, Non-Medical Devices, Psychiatry/Mental Health, Research Equipment, Software / Apps Computational models/software Consumer Products Medical Devices Non-Medical Devices Psychiatry/Mental Health Research Equipment Software / Apps Hanna Keren, Argyris Stringaris This technology relates to a closed-loop controller that is being developed as a phone app for emotional self-regulation in real-time. There is a significant association between emotion dysregulation and symptoms of depression, anxiety, eating pathology, and substance abuse, affecting millions worldwide. Consisting of a closed-loop controller that adjusts reward values in real-time according to individual mood response, the Mood Machine Interface technology compensates for adaptation to stimuli over time allowing it to generate substantial mood changes in the user. This provides a quantitative assessment of mood that is independent of the user being aware of the experimental goal. This technology provides a superior alternative to current technologies, which are qualitative, and where participants are aware of the experimental goal. The technology fills a market need for a widely accessible and useful intervention measure for personalized emotional self-regulation in a non-clinical setting for individuals suffering from such symptoms. 2022-06-02 2024-10-28 2024-10-28 2022-06-02 2022-05-31 INTERVENTION, MEASURE, Mood-Machine-Interface, OUTCOME, VNXXXX, WMXXXX, XDXXXX, XHXXXX, XJXXXX False True True NIHTT 37470483 Website Abstract 114172842 Karen H, Zheng C, et al. https://pubmed.ncbi.nlm.nih.gov/34128464/ <a href="https://pubmed.ncbi.nlm.nih.gov/34128464/">Karen H, Zheng C, et al.</a> 114111275 Stringaris, Argyris National Institute of Mental Health (NIMH) NIMH Stringaris, Argyris (NIMH) 0 114111274 Keren, Hanna National Institute of Mental Health (NIMH) NIMH Keren, Hanna (NIMH) 1 114111274 Keren, Hanna National Institute of Mental Health (NIMH) NIMH Keren, Hanna (NIMH) 1 114111275 Stringaris, Argyris National Institute of Mental Health (NIMH) NIMH Stringaris, Argyris (NIMH) 0 114102791 Mood-Machine-Interface As An Intervention Outcome Measure E-142-2020-0 Filing authorized National Institute of Mental Health (NIMH) 83739514 Dawson, Anton anton.dawson@nih.gov
United States of America anton.dawson@nih.gov?subject=Web Inquiry on [TAB-3687] A Mood-Machine-Interface as an Intervention for Emotional Self-Regulation in Real-Time&body=Please send me information about technology [TAB-3687] A Mood-Machine-Interface as an Intervention for Emotional Self-Regulation in Real-Time. Dawson, Anton<br><a href="mailto:anton.dawson@nih.gov?subject=Web Inquiry on [TAB-3687] A Mood-Machine-Interface as an Intervention for Emotional Self-Regulation in Real-Time&body=Please send me information about technology [TAB-3687] A Mood-Machine-Interface as an Intervention for Emotional Self-Regulation in Real-Time.">anton.dawson@nih.gov</a><br> 114169530 E-142-2020-0 E-142-2020-0-US-01 SYSTEMS AND METHODS FOR MEASURING INTERVENTION OUTCOMES USING MOOD MACHINE INTERFACE PRV US 63/025,776 Abandoned US <br />Provisional (PRV) 63/025,776<br />Filed on 2020-05-15<br />Status: Abandoned 114129253 VNXXXX 114129254 WMXXXX 114129255 XDXXXX 114129256 XHXXXX 114129257 XJXXXX 114154499 Mood-Machine-Interface 114154500 INTERVENTION 114154501 OUTCOME 114154502 MEASURE TAB-3684 114097536 NIMH DAO Toolbox: Data acquisition software that enables real-time sample analysis NIMH Cardiology, Computational models/software, Consumer Products, Dental, Endocrinology, Infectious Disease, Occupational Safety and Health, Oncology, Ophthalmology, Research Equipment, Software / Apps Cardiology Computational models/software Consumer Products Dental Endocrinology Infectious Disease Occupational Safety and Health Oncology Ophthalmology Research Equipment Software / Apps Jaewon Hwang This technology relates to a software package called NIMH DAO Toolbox that uses multithreading and a unique buffer structure to shorten gaps in sample readouts. Data acquisition devices running in continuous sampling mode collect data samples at a given sampling rate. The samples are typically stored in a memory buffer and read out at a regular interval. If the sampling rate is short enough, there can be a gap between the time the first sample is acquired and the time that sample is available to the user. This gap is typically on the order of tens of milliseconds. However, the maximum delay tolerable when doing real-time monitoring in behavioral/physiological experiments is typically one millisecond or less. This technology enables real-time data monitoring during continuous sample acquisition. In addition, the NIMH DAO Toolbox also has high performance in analog output, digital 1/0, and supports data acquisition from devices that do not produce voltage output. <ul> <li>The fast performance of NIMH DAO Toolbox lowers the cost of neurophysiology research solving the slow readout issue without the need for redundant data acquisition devices. This cuts the hardware costs by about half.</li> <li>NIMH DAO Toolbox supports experiments that demand fast response latencies, such as closed-loop deep brain stimulation, without the need for more sophisticated and expensive hardware and software.</li> </ul> <ul> <li>NIMH DAQ Toolbox provides the management of memory and multi-threads that supports user applications with high-precision data acquisition requirements, with just a few function calls.</li> <li>NIMH DAQ Toolbox is already being used as a data acquisition component of NIMH MonkeyLoglc, which is a popular software package for behavioral control. NIMH MonkeyLogic presents audio/video/electrical stimuli and records subject's behavioral response for psychophysical/neurophysiological experiments.</li> </ul> 2022-06-02 2024-10-28 2024-10-28 2022-06-02 2022-05-31 3FXXXX, 4FXXXX, Acquisition, analysis, DAO, DATA, NIMH, REAL-TIME, SAMPLE, SIMULTANEOUSLY, software, Toolbox:, VPXXXX, WEXXXX, WMXXXX, XBXXXX, XHXXXX, XJXXXX False True True NIHTT 37470483 Website Abstract 114111265 Hwang, Jaewon National Institute of Mental Health (NIMH) NIMH Hwang, Jaewon (NIMH) 1 114111265 Hwang, Jaewon National Institute of Mental Health (NIMH) NIMH Hwang, Jaewon (NIMH) 1 114102788 NIMH DAO Toolbox: Data Acquisition Software That Enables Continuous Acquisition And Real-time Sample Analysis, Simultaneously E-104-2018-0 Research Material National Institute of Mental Health (NIMH) 83739514 Dawson, Anton anton.dawson@nih.gov
United States of America anton.dawson@nih.gov?subject=Web Inquiry on [TAB-3684] NIMH DAO Toolbox: Data acquisition software that enables real-time sample analysis&body=Please send me information about technology [TAB-3684] NIMH DAO Toolbox: Data acquisition software that enables real-time sample analysis. Dawson, Anton<br><a href="mailto:anton.dawson@nih.gov?subject=Web Inquiry on [TAB-3684] NIMH DAO Toolbox: Data acquisition software that enables real-time sample analysis&body=Please send me information about technology [TAB-3684] NIMH DAO Toolbox: Data acquisition software that enables real-time sample analysis.">anton.dawson@nih.gov</a><br> 114129237 4FXXXX 114129238 3FXXXX 114129239 VPXXXX 114129240 WEXXXX 114129241 WMXXXX 114129242 XBXXXX 114129243 XHXXXX 114129244 XJXXXX 114154471 NIMH 114154472 DAO 114154473 Toolbox: 114154474 DATA 114154475 Acquisition 114154476 software 114154477 REAL-TIME 114154478 SAMPLE 114154479 analysis 114154480 SIMULTANEOUSLY TAB-3685 114097537 Novel NMDA ligands that are specific and selective to the NR2B subunits based on the derivatives of 7-methoxy-3-(4-phenylbutyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepin-1-ol NIMH Psychiatry/Mental Health, Research Materials Psychiatry/Mental Health Research Materials Lisheng Cai, Victor Pike This invention includes the design and synthesis of ligands that bind selectively and specifically to the NR2B subunit of the NMDA receptor. The NMDA receptor is thought to play a role in the pathophysiology of psychiatric disorders, including depression, stroke, drug addiction, and neuropathic pain. Existing ligands to the NMDA receptor are widely used to treat these conditions. <br /><br /> Researchers at the National Institute of Mental Health (NIMH) have synthesized new ligands based on the 7-methoxy-3-(4-phenylbutyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepin-1-ol molecule. Binding affinities were checked, and candidate ligands were radiolabeled with an 11C isotope. The radiolabeled compounds were evaluated by PET (positron emission tomography) imaging in rodents. The PET imaging showed that these radioligands bind selectively and specifically to the NR2B receptor. A number of new and unique chemical compounds have been synthesized that show specific binding with the NR2B receptor of the NMDA complex These novel NMDA ligands may have clinically-relevant psychiatric effects 2022-06-02 2024-10-28 2024-10-28 2022-06-02 2022-05-31 3, 4, 5-tetrahydro-1H-benzo[d]azepin-1-ol, 7-methoxy-3-4-phenylbutyl-2, Based, Derivatives, LIGANDS, NR2B, VNXXXX, WIXXXX False True True NIHTT 37470483 Website Abstract 114172841 Kramer SD, Betzel T, et al. https://pubmed.ncbi.nlm.nih.gov/29191857/ <a href="https://pubmed.ncbi.nlm.nih.gov/29191857/">Kramer SD, Betzel T, et al.</a> 114111267 Pike, Victor National Institute of Mental Health (NIMH) NIMH Pike, Victor (NIMH) 0 114111266 Cai, Lisheng National Institute of Mental Health (NIMH) NIMH Cai, Lisheng (NIMH) 1 114111266 Cai, Lisheng National Institute of Mental Health (NIMH) NIMH Cai, Lisheng (NIMH) 1 114111267 Pike, Victor National Institute of Mental Health (NIMH) NIMH Pike, Victor (NIMH) 0 114102789 NR2B Ligands Based On The Derivatives Of 7-methoxy-3-(4-phenylbutyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepin-1-ol E-126-2018-0 Filing authorized National Institute of Mental Health (NIMH) 83739514 Dawson, Anton anton.dawson@nih.gov
United States of America anton.dawson@nih.gov?subject=Web Inquiry on [TAB-3685] Novel NMDA ligands that are specific and selective to the NR2B subunits based on the derivatives of 7-methoxy-3-(4-phenylbutyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepin-1-ol&body=Please send me information about technology [TAB-3685] Novel NMDA ligands that are specific and selective to the NR2B subunits based on the derivatives of 7-methoxy-3-(4-phenylbutyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepin-1-ol. Dawson, Anton<br><a href="mailto:anton.dawson@nih.gov?subject=Web Inquiry on [TAB-3685] Novel NMDA ligands that are specific and selective to the NR2B subunits based on the derivatives of 7-methoxy-3-(4-phenylbutyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepin-1-ol&body=Please send me information about technology [TAB-3685] Novel NMDA ligands that are specific and selective to the NR2B subunits based on the derivatives of 7-methoxy-3-(4-phenylbutyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepin-1-ol.">anton.dawson@nih.gov</a><br> 114169526 E-126-2018-0 E-126-2018-0-US-01 NR2B LIGANDS; METHOD OF MAKING; AND USE THEREOF PRV US 62/663,085 Abandoned US <br />Provisional (PRV) 62/663,085<br />Filed on 2018-04-26<br />Status: Abandoned 114169527 E-126-2018-0 E-126-2018-0-PCT-02 NR2B LIGANDS; METHOD OF MAKING; AND USE THEREOF PCT Patent Cooperation Treaty PCT/US2019/029285 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2019/029285<br />Filed on 2019-04-26<br />Status: Expired 114169528 E-126-2018-0 E-126-2018-0-US-03 NR2B LIGANDS; METHODS OF MAKING; AND USE THEREOF National Stage US 17/050,209 Abandoned US <br />National Stage 17/050,209<br />Filed on 2020-10-23<br />Status: Abandoned 114129245 VNXXXX 114129246 WIXXXX 114154481 LIGANDS 114154482 NR2B 114154483 Based 114154484 Derivatives 114154485 7-methoxy-3-4-phenylbutyl-2 114154486 3 114154487 4 114154488 5-tetrahydro-1H-benzo[d]azepin-1-ol TAB-3682 114097534 Detecting Levels of Chymotrypsin and Amylase using Rabbit Polyclonal Antibodies Generated from Purified Human Enzymes NIMH Antibodies, Cardiology, Dental, Diagnostics, Endocrinology, Immunology, Infectious Disease, Oncology, Ophthalmology, Research Materials Antibodies Cardiology Dental Diagnostics Endocrinology Immunology Infectious Disease Oncology Ophthalmology Research Materials David Jacobowitz The invention relates to rabbit antisera raised against purified human chymotrypsin and amylase. Both chymotrypsin and amylase are produced by the pancreas and play important roles in digestion. Abnormal levels of chymotrypsin and amylase have been known to occur with multiple pancreas-related disorders, including pancreatitis. Measuring levels of these two enzymes using these polyclonal antibodies can help determine if a pancreas is functioning correctly. Few human antibodies exist for chymotrypsin and amylase Diagnostic test measuring the levels of chymotrypsin or amylase 2022-06-02 2024-10-28 2024-10-28 2022-06-02 2022-05-31 Amylase, antibodies, Chymotrypsin, Human, Listed LPM Maddox as of 4/15/2015, polyclonal, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, rabbit, VPXXXX, WBXXXX, WIXXXX, XAXXXX False True True NIHTT 37470483 Website Abstract 114111258 Jacobowitz, David Uniformed Services University of the Health Sciences Jacobowitz, David 1 114111258 Jacobowitz, David Uniformed Services University of the Health Sciences Jacobowitz, David 1 114102786 Rabbit Polyclonal Antibodies To Human Chymotrypsin And Amylase E-029-2015-0 Research Material National Institute of Mental Health (NIMH) 83686256 Wong, Jennifer jennifer.wong2@nih.gov
United States of America jennifer.wong2@nih.gov?subject=Web Inquiry on [TAB-3682] Detecting Levels of Chymotrypsin and Amylase using Rabbit Polyclonal Antibodies Generated from Purified Human Enzymes&body=Please send me information about technology [TAB-3682] Detecting Levels of Chymotrypsin and Amylase using Rabbit Polyclonal Antibodies Generated from Purified Human Enzymes. Wong, Jennifer<br><a href="mailto:jennifer.wong2@nih.gov?subject=Web Inquiry on [TAB-3682] Detecting Levels of Chymotrypsin and Amylase using Rabbit Polyclonal Antibodies Generated from Purified Human Enzymes&body=Please send me information about technology [TAB-3682] Detecting Levels of Chymotrypsin and Amylase using Rabbit Polyclonal Antibodies Generated from Purified Human Enzymes.">jennifer.wong2@nih.gov</a><br> 114129230 VPXXXX 114129231 WBXXXX 114129232 WIXXXX 114129233 XAXXXX 114154454 rabbit 114154455 polyclonal 114154456 antibodies 114154457 Human 114154458 Chymotrypsin 114154459 Amylase 114154460 Listed LPM Maddox as of 4/15/2015 114154461 Pre LPM working set 20150418 114154462 Post LPM Assignment Set 20150420 TAB-3683 114097535 Stable, High-Yield Production of DT390-EGF Fusion Protein for Treatment of EGF-Receptor-Positive Cancers NIMH Oncology, Therapeutics Oncology Therapeutics Thomas Flaig, Arthur Frankel, Michael Glode, David Neville (Estate), Andrew Thorburn, Jung-hee Woo This invention relates to the stable and high-yield production of a high-potency toxin protein called DT390-EGF. This toxin was developed for the treatment of EGF-receptor-positive cancers, including bladder cancer. Initial methods for synthesizing DT390-EGF relied on the use of E. coli. However, the production in E. coli was difficult to prepare and had limited stability. Repeated efforts to standardize the process in E. coli gave poor yields, purity, and high variation. <br /><br /> To overcome the problems with production using E. coli, this invention employs the Pichia pastoris strain of yeast. To produce DT390-EGF in P. pastoris, the DNA encoding the DT390-EGF protein was modified to (a) introduce an N-terminal alanine, (b) optimize codon usage for efficient translation in P. pastoris, (c) abolish N-linked glycosylation sites, and (d) add a (G4S)3 linker between the DT390 and EGF moieties. With these changes, DT390-EFG can be reproducibly produced in P. pastoris with more stability and potency compared to that produced in E. coli. Production of DT390-EGF using this invention has a higher-yield and more stable product than competing methods. DT390-EGF has shown in vitro and in vivo efficacy in bladder cancer models. 2022-06-02 2024-10-28 2024-10-28 2022-06-02 2022-05-31 cancers, DT390-EGF, EGF, Fusion, POSITIVE, Protein, RECEPTOR, treatment, VCXXXX, WKXXXX, XEXXXX False True True NIHTT 37470483 Website Abstract 114111259 Woo, Jung-hee Baylor Scott and White Research Institute Woo, Jung-hee 0 114111260 Neville (Estate), David Angimmune LLC NIMH Neville (Estate), David (NIMH) 0 114111261 Frankel, Arthur Baylor Scott and White Research Institute Frankel, Arthur 0 114111262 Thorburn, Andrew University of Colorado, Denver Thorburn, Andrew 0 114111263 Glode, Michael University of Colorado, Denver Glode, Michael 0 114111264 Flaig, Thomas University of Colorado, Denver Flaig, Thomas 1 114111264 Flaig, Thomas University of Colorado, Denver Flaig, Thomas 1 114111259 Woo, Jung-hee Baylor Scott and White Research Institute Woo, Jung-hee 0 114111260 Neville (Estate), David Angimmune LLC NIMH Neville (Estate), David (NIMH) 0 114111261 Frankel, Arthur Baylor Scott and White Research Institute Frankel, Arthur 0 114111262 Thorburn, Andrew University of Colorado, Denver Thorburn, Andrew 0 114111263 Glode, Michael University of Colorado, Denver Glode, Michael 0 114102787 DT390-EGF Fusion Protein For Treatment Of EGF Receptor Positive Cancers E-274-2015-0 Filing authorized Angimmune LLC, Baylor Scott and White Research Institute, University of Colorado, Denver 83686256 Wong, Jennifer jennifer.wong2@nih.gov
United States of America jennifer.wong2@nih.gov?subject=Web Inquiry on [TAB-3683] Stable, High-Yield Production of DT390-EGF Fusion Protein for Treatment of EGF-Receptor-Positive Cancers&body=Please send me information about technology [TAB-3683] Stable, High-Yield Production of DT390-EGF Fusion Protein for Treatment of EGF-Receptor-Positive Cancers. Wong, Jennifer<br><a href="mailto:jennifer.wong2@nih.gov?subject=Web Inquiry on [TAB-3683] Stable, High-Yield Production of DT390-EGF Fusion Protein for Treatment of EGF-Receptor-Positive Cancers&body=Please send me information about technology [TAB-3683] Stable, High-Yield Production of DT390-EGF Fusion Protein for Treatment of EGF-Receptor-Positive Cancers.">jennifer.wong2@nih.gov</a><br> 114169523 E-274-2015-0 E-274-2015-0-US-01 DT390-EGF Fusion Protein For Treatment Of EGF Receptor Positive Cancers PRV US 61/251,676 Abandoned US <br />Provisional (PRV) 61/251,676<br />Filed on 2009-10-14<br />Status: Abandoned 114169524 E-274-2015-0 E-274-2015-0-PCT-02 COMPOSITIONS AND METHODS FOR TREATING BLADDER CANCER PCT Patent Cooperation Treaty PCT/US2010/52634 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2010/52634<br />Filed on 2010-10-14<br />Status: Expired 114169525 E-274-2015-0 E-274-2015-0-US-03 Compositions and Methods for Treating Bladder Cancer National Stage US 9,321,820 13/502,132 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9321820 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9321820">9,321,820</a><br />Filed on 2012-05-25<br />Status: Issued 114129234 VCXXXX 114129235 WKXXXX 114129236 XEXXXX 114154463 DT390-EGF 114154464 Fusion 114154465 Protein 114154466 treatment 114154467 EGF 114154468 RECEPTOR 114154469 POSITIVE 114154470 cancers TAB-3680 114097532 Diagnosis and Treatment of Pediatric Acute Neurologic Syndrome with Antineuronal Antibodies NIMH Antibodies, Diagnostics, Immunology, Neurology, Psychiatry/Mental Health, Research Materials Antibodies Diagnostics Immunology Neurology Psychiatry/Mental Health Research Materials Madelein Cunningham, Christine Kirvan, Susan Swedo The invention is a panel of five tests of patient sera for immune responses that may attack the brain and lead to the characteristic symptoms of pediatric acute neurologic syndrome (PANS). PANS is a condition defined by a sudden onset of obsessive-compulsive symptoms, eating restrictions, and other cognitive and/or behavioral symptoms. Currently, the diagnosis of PANS is made when other possible symptoms are ruled out, a diagnosis of exclusion. <br /><br /> The panel of tests in this invention provides a basis for the diagnosis and treatment of PANS in the setting of symptoms such as obsessions and compulsions, tics, autistic-like behaviors, anorexia nervosa, and deterioration in handwriting. The elevation above the normal mean or range of antibody titers in one or more of these assays indicates that the individual may be a candidate for treatment for PANS, including antibiotic therapy in the case of known infection, and also immunotherapy to treat the autoimmune/inflammatory condition of the brain. The panel of tests may allow the diagnosis of PANS directly as oppose to a diagnosis of exclusion Diagnostic test for pediatric acute neurologic syndrome (PANS) 2022-06-02 2024-10-28 2024-10-28 2022-06-02 2022-05-31 ACUTE, antibodies, Antineuronal, Diagnosis, Listed LPM Greene as of 4/15/2015, Neurologic, pediatric, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Syndrome, treatment, VEXXXX, VNXXXX, WBXXXX, WIXXXX, XAXXXX, XCXXXX False True True NIHTT 37470483 Website Abstract 114111253 Swedo, Susan National Institute of Mental Health (NIMH) NIMH Swedo, Susan (NIMH) 0 114111255 Kirvan, Christine California State University,Sacramento Kirvan, Christine 0 114111254 Cunningham, Madelein University of Oklahoma Health Sciences Center Cunningham, Madelein 1 114111254 Cunningham, Madelein University of Oklahoma Health Sciences Center Cunningham, Madelein 1 114111253 Swedo, Susan National Institute of Mental Health (NIMH) NIMH Swedo, Susan (NIMH) 0 114111255 Kirvan, Christine California State University,Sacramento Kirvan, Christine 0 114102784 Antineuronal Antibodies In Pediatric Acute Neurologic Syndrome For Diagnosis And Treatment E-448-2013-0 Filing authorized California State University,Sacramento, National Institute of Mental Health (NIMH), University of Oklahoma Health Sciences Center 83686256 Wong, Jennifer jennifer.wong2@nih.gov
United States of America jennifer.wong2@nih.gov?subject=Web Inquiry on [TAB-3680] Diagnosis and Treatment of Pediatric Acute Neurologic Syndrome with Antineuronal Antibodies&body=Please send me information about technology [TAB-3680] Diagnosis and Treatment of Pediatric Acute Neurologic Syndrome with Antineuronal Antibodies. Wong, Jennifer<br><a href="mailto:jennifer.wong2@nih.gov?subject=Web Inquiry on [TAB-3680] Diagnosis and Treatment of Pediatric Acute Neurologic Syndrome with Antineuronal Antibodies&body=Please send me information about technology [TAB-3680] Diagnosis and Treatment of Pediatric Acute Neurologic Syndrome with Antineuronal Antibodies.">jennifer.wong2@nih.gov</a><br> 114169517 E-448-2013-0 E-448-2013-0-US-01 Method for Pediatric Acute-Onset Neurologic Syndrome (PANS) and Pediatric Autoimmune Neurologic Disorder Assocated with Streptococci (PANDAS) PRV US 61/787,919 Abandoned US <br />Provisional (PRV) 61/787,919<br />Filed on 2013-03-15<br />Status: Abandoned 114169518 E-448-2013-0 E-448-2013-0-US-02 DIAGNOSTIC METHOD FOR PEDIATRIC ACUTE-ONSET NEUROPSYCHIATRIC SYNDROME (PANS) AND PEDIATRIC AUTOIMMUNE NEUROPSYCHIATRIC DISORDER ASSOCIATED WITH STREPTOCOCCI INFECTION (PANDAS) ORD US 14/209,493 Abandoned US <br />Ordinary Patent (ORD) 14/209,493<br />Filed on 2014-03-13<br />Status: Abandoned 114169519 E-448-2013-0 E-448-2013-0-US-03 Antineuronal Antibodies In Pediatric Acute Neurologic Syndrome For Diagnosis And Treatment CON US 14/790,416 Abandoned US <br />Continuation (CON) 14/790,416<br />Filed on 2015-07-02<br />Status: Abandoned 114169520 E-448-2013-0 E-448-2013-0-US-04 DIAGNOSTIC METHOD FOR PEDIATRIC ACUTE-ONSET NEUROPSYCHIATRIC SYNDROME (PANS) AND PEDIATRIC AUTOIMMUNE NEUROPSYCHIATRIC DISORDER ASSOCIATED WITH STREPTOCOCCI INFECTION (PANDAS) CON US 9,804,171 15/045,146 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9804171 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9804171">9,804,171</a><br />Filed on 2016-02-16<br />Status: Issued 114169521 E-448-2013-0 E-448-2013-0-US-05 Antineuronal Antibodies In Pediatric Acute Neurologic Syndrome For Diagnosis And Treatment CON US 10,228,376 15/783,541 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10228376 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10228376">10,228,376</a><br />Filed on 2017-10-13<br />Status: Issued 114169522 E-448-2013-0 E-448-2013-0-US-06 Antineuronal Antibodies In Pediatric Acute Neurologic Syndrome For Diagnosis And Treatment CON US 16/259,062 Abandoned US <br />Continuation (CON) 16/259,062<br />Filed on 2019-01-28<br />Status: Abandoned 114129221 VEXXXX 114129222 VNXXXX 114129223 WBXXXX 114129224 WIXXXX 114129225 XAXXXX 114129226 XCXXXX 114154430 Antineuronal 114154431 antibodies 114154432 pediatric 114154433 ACUTE 114154434 Neurologic 114154435 Syndrome 114154436 Diagnosis 114154437 treatment 114154438 Listed LPM Greene as of 4/15/2015 114154439 Pre LPM working set 20150418 114154440 Post LPM Assignment Set 20150420 TAB-3681 114097533 Stopping Neurogenesis in Transgenic Mice and Rat Models that Express the HSV-thymidine kinase Gene in Neuronal Precursor Cells NIMH Neurology, Research Materials, Therapeutics Neurology Research Materials Therapeutics Heather Cameron, James Pickel This invention relates to novel mouse and rat models that permit the temporal death of neuronal precursor cells at any time point. Other existing methods of decreasing neurogenesis are relatively non-specific (e.g., injecting glucocorticoids) or require expensive equipment (e.g., focal x-irradiation) <br /> These mice and rats are being used to inhibit adult neurogenesis in order to study the normal function of adult neurogenesis and to model disease states thought to feature decreased neurogenesis, such as chronic stress, anxiety, and depression. <br /> The murine models have been engineered to express a herpes simplex virus gene called HSV-TK in neuronal precursor cells (through the use of a GFAP promoter). Cells that express HSV-TK undergo programmed death when exposed to a molecule called ganciclovir. The combination of these elements permits stopping neurogenesis at any time point in development by selectively providing ganciclovir to mice or rats expressing HSV-TK in neuronal precursor cells. Mouse and rat models are specific and require minimal equipment <ul> <li>These transgenic animals could be used as models for diseases thought to feature deficits in adult neurogenesis, including depression, anxiety, chronic stress-related illnesses, schizophrenia, drug addiction.</li> <li>The animals could be used to determine whether drugs alter behavioral phenotypes by altering neurogenesis or whether they act downstream or independently of neurogenesis.</li> </ul> 2022-06-02 2024-10-28 2024-10-28 2022-06-02 2022-05-31 Driving, Expression, GFAP, HSV, Kinase, Listed LPM Maddox as of 4/15/2015, Mice, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, PROMOTER, RATS, Thymidine, TRANSGENIC, VEXXXX, WIXXXX, XEXXXX False True True NIHTT 37470483 Website Abstract 114172839 Snyder JS, Soumier A, et al. https://pubmed.ncbi.nlm.nih.gov/21814201/ <a href="https://pubmed.ncbi.nlm.nih.gov/21814201/">Snyder JS, Soumier A, et al.</a> 114172840 Snyder JS, Grigereit L, et al. https://pubmed.ncbi.nlm.nih.gov/27257630/ <a href="https://pubmed.ncbi.nlm.nih.gov/27257630/">Snyder JS, Grigereit L, et al.</a> 114111257 Pickel, James National Institute of Mental Health (NIMH) NIMH Pickel, James (NIMH) 0 114111256 Cameron, Heather National Institute of Mental Health (NIMH) NIMH Cameron, Heather (NIMH) 1 114111256 Cameron, Heather National Institute of Mental Health (NIMH) NIMH Cameron, Heather (NIMH) 1 114111257 Pickel, James National Institute of Mental Health (NIMH) NIMH Pickel, James (NIMH) 0 114102785 Transgenic Mice And Rats With GFAP Promoter Driving HSV Thymidine Kinase Expression E-100-2014-0 Research Material National Institute of Mental Health (NIMH) 83686256 Wong, Jennifer jennifer.wong2@nih.gov
United States of America jennifer.wong2@nih.gov?subject=Web Inquiry on [TAB-3681] Stopping Neurogenesis in Transgenic Mice and Rat Models that Express the HSV-thymidine kinase Gene in Neuronal Precursor Cells&body=Please send me information about technology [TAB-3681] Stopping Neurogenesis in Transgenic Mice and Rat Models that Express the HSV-thymidine kinase Gene in Neuronal Precursor Cells. Wong, Jennifer<br><a href="mailto:jennifer.wong2@nih.gov?subject=Web Inquiry on [TAB-3681] Stopping Neurogenesis in Transgenic Mice and Rat Models that Express the HSV-thymidine kinase Gene in Neuronal Precursor Cells&body=Please send me information about technology [TAB-3681] Stopping Neurogenesis in Transgenic Mice and Rat Models that Express the HSV-thymidine kinase Gene in Neuronal Precursor Cells.">jennifer.wong2@nih.gov</a><br> 114129227 VEXXXX 114129228 WIXXXX 114129229 XEXXXX 114154441 TRANSGENIC 114154442 Mice 114154443 RATS 114154444 GFAP 114154445 PROMOTER 114154446 Driving 114154447 HSV 114154448 Thymidine 114154449 Kinase 114154450 Expression 114154451 Listed LPM Maddox as of 4/15/2015 114154452 Pre LPM working set 20150418 114154453 Post LPM Assignment Set 20150420 TAB-3678 114097530 Imaging Inflammation using PET Radioligands that Target Translocator Protein 18?kDa with High Affinity Regardless of Genotype NIMH Diagnostics, Medical Devices, Neurology, Non-Medical Devices, Psychiatry/Mental Health, Research Materials, Software / Apps Diagnostics Medical Devices Neurology Non-Medical Devices Psychiatry/Mental Health Research Materials Software / Apps Chad Brouwer, Victor Pike This technology includes a group of radioligands that label inflammatory cells specifically, accurately, and across different genotypes and can be detected using Positron Emission Tomography (PET). The radioligands target the Translocator protein 18 kDa (TSPO) receptor which is present on the outer mitochondrial membrane and is involved in the production of steroids. Current TSPO radioligands either lack specificity or have highly variable inter-subject sensitivities due to TSPO genotypic differences. These new ligands permit a simplified interpretation and quantification of the binding signal. <br /><br /> During inflammation of the central nervous system, TSPO levels are increased. Neuroinflammation is symptomatic of many neuropsychiatric and neurodegenerative disorders, such as multiple sclerosis, stroke, epilepsy, dementia, and traumatic brain injuries. Thus, monitoring and quantifying TSPO with radioligands using PET may have clinical application in understanding, diagnosing, and treating many neuropsychiatric disorders. Radioligands are specific and accurate, regardless of genotype Biomarker or diagnostic for neuroinflammation 2022-06-02 2024-10-28 2024-10-28 2022-06-02 2022-05-31 18kDa, Emission, Genotype, Human, Listed LPM Fenn as of 4/15/2015, Positron, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Quantifying/imaging, Radioligands, Regardless, tomography, TSPO, VEXXXX, VNXXXX, WBXXXX, WIXXXX, XCXXXX, XFXXXX False True True NIHTT 37470483 Website Abstract 114172833 Oh U, Fujita M, et al. https://pubmed.ncbi.nlm.nih.gov/20872081/ <a href="https://pubmed.ncbi.nlm.nih.gov/20872081/">Oh U, Fujita M, et al.</a> 114172834 Kreisl WC, Mbeo G, et al. https://pubmed.ncbi.nlm.nih.gov/19822787/ <a href="https://pubmed.ncbi.nlm.nih.gov/19822787/">Kreisl WC, Mbeo G, et al.</a> 114172835 Hirvonen J, Kreisl WC, et al. https://pubmed.ncbi.nlm.nih.gov/22238156/ <a href="https://pubmed.ncbi.nlm.nih.gov/22238156/">Hirvonen J, Kreisl WC, et al.</a> 114172836 Kreisl WC, Lyoo CH, et al. https://pubmed.ncbi.nlm.nih.gov/23775979/ <a href="https://pubmed.ncbi.nlm.nih.gov/23775979/">Kreisl WC, Lyoo CH, et al.</a> 114111251 Brouwer, Chad National Institute of Mental Health (NIMH) Brouwer, Chad 0 114111250 Pike, Victor National Institute of Mental Health (NIMH) NIMH Pike, Victor (NIMH) 1 114111250 Pike, Victor National Institute of Mental Health (NIMH) NIMH Pike, Victor (NIMH) 1 114111251 Brouwer, Chad National Institute of Mental Health (NIMH) Brouwer, Chad 0 114102782 Radioligands For Quantifying/imaging TSPO 18kDa With Positron Emission Tomography In Human, Regardless Of Genotype E-072-2013-0 Filing authorized National Institute of Mental Health (NIMH) 83686256 Wong, Jennifer jennifer.wong2@nih.gov
United States of America jennifer.wong2@nih.gov?subject=Web Inquiry on [TAB-3678] Imaging Inflammation using PET Radioligands that Target Translocator Protein 18?kDa with High Affinity Regardless of Genotype&body=Please send me information about technology [TAB-3678] Imaging Inflammation using PET Radioligands that Target Translocator Protein 18?kDa with High Affinity Regardless of Genotype. Wong, Jennifer<br><a href="mailto:jennifer.wong2@nih.gov?subject=Web Inquiry on [TAB-3678] Imaging Inflammation using PET Radioligands that Target Translocator Protein 18?kDa with High Affinity Regardless of Genotype&body=Please send me information about technology [TAB-3678] Imaging Inflammation using PET Radioligands that Target Translocator Protein 18?kDa with High Affinity Regardless of Genotype.">jennifer.wong2@nih.gov</a><br> 114129209 VEXXXX 114129210 VNXXXX 114129211 WBXXXX 114129212 WIXXXX 114129213 XCXXXX 114129214 XFXXXX 114154406 Human 114154407 tomography 114154408 Emission 114154409 Positron 114154410 18kDa 114154411 TSPO 114154412 Quantifying/imaging 114154413 Radioligands 114154414 Regardless 114154415 Genotype 114154416 Listed LPM Fenn as of 4/15/2015 114154417 Pre LPM working set 20150418 114154418 Post LPM Assignment Set 20150420 TAB-3679 114097531 Generation of mutant mouse alleles that functionally disrupt production of BDNF from its ndividual promoters NIMH Neurology, Research Materials, Therapeutics Neurology Research Materials Therapeutics Keri Martinowich This technology relates to a mouse model that improves an existing method of disrupting the production of the BDNF protein in specific parts of the brain. A current avenue of research seeks to examine how gene expression may effect long-lasting changes in the nervous system. Previous work has resulted in a mouse line in which the production of BDNF was disrupted. However, these mice had an inadvertent genetic component left in: a neomycin cassette. This unintentional addition led to significant deleterious effects. Researchers at NCI and NIMH have updated these mouse models by removing the neomycin cassette, alleviating the undesired side effects. The mouse models in this invention allow the study of the role of BDNF in the nervous system without the undesired side effects Improved mouse model for disease invetigation 2022-06-02 2024-10-28 2024-10-28 2022-06-02 2022-05-31 ALLELES, AXXXXX, BDNF, DISRUPT, FUNCTIONALLY, Generation, Indiividual, Mouse, MUTANT, NC4XXX, NCXXXX, production, PROMOTERS, That, VEXXXX, WIXXXX, XEXXXX False True True NIHTT 37470483 Website Abstract 114172837 Hill JL, Hardy NF, et al. https://pubmed.ncbi.nlm.nih.gov/27552586/ <a href="https://pubmed.ncbi.nlm.nih.gov/27552586/">Hill JL, Hardy NF, et al.</a> 114172838 Hong EJ, McCord AE, et al. https://pubmed.ncbi.nlm.nih.gov/19038219/ <a href="https://pubmed.ncbi.nlm.nih.gov/19038219/">Hong EJ, McCord AE, et al.</a> 114111252 Martinowich, Keri National Institute of Mental Health (NIMH) NIMH Martinowich, Keri (NIMH) 1 114111252 Martinowich, Keri National Institute of Mental Health (NIMH) NIMH Martinowich, Keri (NIMH) 1 114102783 Generation Of Mutant Mouse Alleles That Functionally Disrupt Production Of BDNF From Indiividual Promoters E-143-2020-0 Research Material National Institute of Mental Health (NIMH) 83739514 Dawson, Anton anton.dawson@nih.gov
United States of America anton.dawson@nih.gov?subject=Web Inquiry on [TAB-3679] Generation of mutant mouse alleles that functionally disrupt production of BDNF from its ndividual promoters&body=Please send me information about technology [TAB-3679] Generation of mutant mouse alleles that functionally disrupt production of BDNF from its ndividual promoters. Dawson, Anton<br><a href="mailto:anton.dawson@nih.gov?subject=Web Inquiry on [TAB-3679] Generation of mutant mouse alleles that functionally disrupt production of BDNF from its ndividual promoters&body=Please send me information about technology [TAB-3679] Generation of mutant mouse alleles that functionally disrupt production of BDNF from its ndividual promoters.">anton.dawson@nih.gov</a><br> 114129215 AXXXXX 114129216 NCXXXX 114129217 NC4XXX 114129218 VEXXXX 114129219 WIXXXX 114129220 XEXXXX 114154419 Generation 114154420 MUTANT 114154421 Mouse 114154422 ALLELES 114154423 That 114154424 FUNCTIONALLY 114154425 DISRUPT 114154426 production 114154427 BDNF 114154428 Indiividual 114154429 PROMOTERS TAB-3676 114097528 Retroviral Vector Packaging Cell Lines and Purification Methods for Gene Therapy NIMH Cardiology, Dental, Endocrinology, Infectious Disease, Oncology, Ophthalmology, Research Materials, Therapeutics Cardiology Dental Endocrinology Infectious Disease Oncology Ophthalmology Research Materials Therapeutics Maribeth Eiden, Wenqin Xu This invention relates to a novel gammaretroviral vector packaging cell line and a method of producing gammaretroviral vectors suitable for gene therapy. The described vectors may contain the gibbon ape leukemia virus (GALV) envelope with a CD11D8 epitope tag enabling their purification on a monoclonal antibody conjugated column. These vectors have several advantages over existing systems, including a broader host range, higher infectivity, and lower potential for replication. Further, purification of retroviral vector particles via an epitope tag may remove cellular components and debris toxic to target cells and tissues, providing a safer method of delivery for patients receiving gene therapy. <ul> <li>Broader host range</li> <li>Higher infectivity</li> <li>Lower potential for replication</li> <li>Decreased toxicity after purification</li> </ul> Retroviral vector particles for gene therapy 2022-06-02 2024-10-28 2024-10-28 2022-06-02 2022-05-31 Cell, Gammaretroviral, GB2A2X, GB2CXX, Genetic, Line, Listed LPM Maddox as of 4/15/2015, Method, Novel, Packaging, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Producing, Suitable, THERAPY, Vector, vectors, VPXXXX, WIXXXX, WJXXXX, XEXXXX False True True NIHTT 37470483 Website Abstract 114111245 Xu, Wenqin National Institute of Mental Health (NIMH) NIMH Xu, Wenqin (NIMH) 0 114111244 Eiden, Maribeth National Institute of Mental Health (NIMH) NINDS Eiden, Maribeth (NINDS) 1 114111244 Eiden, Maribeth National Institute of Mental Health (NIMH) NINDS Eiden, Maribeth (NINDS) 1 114111245 Xu, Wenqin National Institute of Mental Health (NIMH) NIMH Xu, Wenqin (NIMH) 0 114102780 A Novel Gammaretroviral Vector Packaging Cell Line And Method Of Producing Gammaretroviral Vectors Suitable For Genetic Therapy E-036-2013-0 Filing authorized National Institute of Mental Health (NIMH) 83686256 Wong, Jennifer jennifer.wong2@nih.gov
United States of America jennifer.wong2@nih.gov?subject=Web Inquiry on [TAB-3676] Retroviral Vector Packaging Cell Lines and Purification Methods for Gene Therapy&body=Please send me information about technology [TAB-3676] Retroviral Vector Packaging Cell Lines and Purification Methods for Gene Therapy. Wong, Jennifer<br><a href="mailto:jennifer.wong2@nih.gov?subject=Web Inquiry on [TAB-3676] Retroviral Vector Packaging Cell Lines and Purification Methods for Gene Therapy&body=Please send me information about technology [TAB-3676] Retroviral Vector Packaging Cell Lines and Purification Methods for Gene Therapy.">jennifer.wong2@nih.gov</a><br> 114169514 E-036-2013-0 E-036-2013-0-US-01 Retroviral Vector Packaging Cell Lines And Methods of Purifying And Producing Retroviral Particles PRV US 61/759,516 Abandoned US <br />Provisional (PRV) 61/759,516<br />Filed on 2013-02-01<br />Status: Abandoned 114169515 E-036-2013-0 E-036-2013-0-PCT-02 Retroviral Vector Packaging Cell Lines and Methods of Purifying and Producing Retroviral Particles PCT Patent Cooperation Treaty PCT/US2014/014013 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2014/014013<br />Filed on 2014-01-31<br />Status: Expired 114129196 GB2A2X 114129197 GB2CXX 114129198 VPXXXX 114129199 WIXXXX 114129200 WJXXXX 114129201 XEXXXX 114154379 Novel 114154380 Gammaretroviral 114154381 Vector 114154382 Packaging 114154383 Cell 114154384 Line 114154385 Method 114154386 Producing 114154387 vectors 114154388 Suitable 114154389 Genetic 114154390 THERAPY 114154391 Listed LPM Maddox as of 4/15/2015 114154392 Pre LPM working set 20150418 114154393 Post LPM Assignment Set 20150420 TAB-3677 114097529 A Diagnostic Kit for Assessing Exposure or Infection by the Koala Family of Retroviruses NIMH Consumer Products, Diagnostics, Infectious Disease, Oncology, Research Materials Consumer Products Diagnostics Infectious Disease Oncology Research Materials Maribeth Eiden, William Switzer, Wenqin Xu, HaoQiang Zheng This invention relates to a diagnostic kit for assessing exposure to or infection by a koala retrovirus. The kit consists of specific primers and probes for the detection of three distinct subtypes of infectious koala retrovirus and may be useful in various species, including humans, primates, and koalas. <br /><br /> A family of infectious koala retroviruses are correlated with the development of malignant neoplasias, including lymphomas and leukemias. Infectious koala retroviruses have been shown to infect human cells in culture, though the health implications in humans have not yet been fully determined. Detection of newly discovered subtypes of infectious koala retroviruses <ul> <li>A diagnostic kit for assessing exposure or infection by the koala family of retroviruses</li> <li>May be useful in monitoring effectiveness of antiretroviral treatment</li> </ul> 2022-06-02 2024-10-28 2024-10-28 2022-06-02 2022-05-31 ASSESSING, CA1AXX, DA4BXX, diagnostic, Exposure, FAMILY, Gammaretroviruses, Infection, KIT, Koala, Listed LPM Maddox as of 4/15/2015, Ofgammaretroviruses, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, VCXXXX, VLXXXX, VOXXXX, WBXXXX, XCXXXX False True True NIHTT 37470483 Website Abstract 114111247 Xu, Wenqin National Institute of Mental Health (NIMH) NIMH Xu, Wenqin (NIMH) 0 114111248 Switzer, William CDC - DIR CDC Switzer, William (CDC) 0 114111249 Zheng, HaoQiang CDC - DIR CDC Zheng, HaoQiang (CDC) 0 114111246 Eiden, Maribeth National Institute of Mental Health (NIMH) NINDS Eiden, Maribeth (NINDS) 1 114111246 Eiden, Maribeth National Institute of Mental Health (NIMH) NINDS Eiden, Maribeth (NINDS) 1 114111247 Xu, Wenqin National Institute of Mental Health (NIMH) NIMH Xu, Wenqin (NIMH) 0 114111248 Switzer, William CDC - DIR CDC Switzer, William (CDC) 0 114111249 Zheng, HaoQiang CDC - DIR CDC Zheng, HaoQiang (CDC) 0 114102781 A Diagnostic Kit For Assessing Exposure Or Infection By The Koala Family Of Gammaretroviruses E-053-2013-0 Filing authorized Centers for Disease Control and Prevention (CDC), National Institute of Mental Health (NIMH) 83686256 Wong, Jennifer jennifer.wong2@nih.gov
United States of America jennifer.wong2@nih.gov?subject=Web Inquiry on [TAB-3677] A Diagnostic Kit for Assessing Exposure or Infection by the Koala Family of Retroviruses&body=Please send me information about technology [TAB-3677] A Diagnostic Kit for Assessing Exposure or Infection by the Koala Family of Retroviruses. Wong, Jennifer<br><a href="mailto:jennifer.wong2@nih.gov?subject=Web Inquiry on [TAB-3677] A Diagnostic Kit for Assessing Exposure or Infection by the Koala Family of Retroviruses&body=Please send me information about technology [TAB-3677] A Diagnostic Kit for Assessing Exposure or Infection by the Koala Family of Retroviruses.">jennifer.wong2@nih.gov</a><br> 114169516 E-053-2013-0 E-053-2013-0-US-01 A Diagnostic Kit For Assessing Exposure Or Infection By The Koala Family Of Gammaretroviruses PRV US 61/784,763 Abandoned US <br />Provisional (PRV) 61/784,763<br />Filed on 2013-03-14<br />Status: Abandoned 114129202 DA4BXX 114129203 CA1AXX 114129204 VCXXXX 114129205 VLXXXX 114129206 VOXXXX 114129207 WBXXXX 114129208 XCXXXX 114154394 diagnostic 114154395 KIT 114154396 ASSESSING 114154397 Exposure 114154398 Infection 114154399 Koala 114154400 FAMILY 114154401 Ofgammaretroviruses 114154402 Gammaretroviruses 114154403 Listed LPM Maddox as of 4/15/2015 114154404 Pre LPM working set 20150418 114154405 Post LPM Assignment Set 20150420 TAB-3671 114097523 Prematurely-Graying Mouse Line Demonstrates Regulation of Melanocyte Stem Cell Development by SOX10 (Sry-Related HMG-Box) Transcription Factor for Use in Regenerative Medicine NHGRI Cardiology, Dental, Endocrinology, Infectious Disease, Oncology, Ophthalmology, Research Materials, Therapeutics Cardiology Dental Endocrinology Infectious Disease Oncology Ophthalmology Research Materials Therapeutics Melissa Harris, William ("Bill") Pavan This technology includes transgenic mice to be used in the study of melanocyte stem cells (MSCs) for utilization in regenerative medicine. Using the melanocyte system as a model, we investigated establishment of MSCs in the hair bulge - the stem cell compartment of the hair. During embryogenesis, all melanoblasts express SOX10, but this expression is downregulated during hair follicle morphogenesis and MSC differentiation. To further study the role of SOX10, we generated transgenic mice overexpressing SOX10 in melanoblasts. In these mice, named Tg(DctSox10), SOX10 expression was controlled by the minimal promoter of dopachrome tautomerase (DCT), a gene whose protein product functions to regulate pigment synthesis and is used as a melanoblast marker. We found that SOX10 overexpression in the melanoblasts of Tg(DctSox10) heterozygous mice results in aberrant differentiation and ectopic pigmentation of cells residing in the hair bulge. Furthermore, Tg(DctSox10) homozygotes exhibit premature hair graying, attributable to the absence of MSCs and the consequential loss of melanocyte progeny that localize to the hair bulb. Potential to be used in regenerative medicine and in diseases with cells with stem cell-like characteristics. <ul> <li>Understanding the etiology of stem cells during development could aid in their use in regenerative medicine and in diseases where cells exhibit stem cell-like characteristics.</li> <li>Studying the factors regulating melanocyte development could add to the understanding of the complex transition of melanocytes into melanoma cells and the progression of this cancer.</li> </ul> 2022-09-26 2024-10-28 2024-10-28 2022-09-26 2022-05-31 Cell, Demonstrates, Development, factor, HMG-Box, Line, Listed LPM Maddox as of 4/15/2015, Melanocyte, Mouse, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Prematurely-Graying, REGULATION, RXXXXX, SOX10, Sry-Related, Stem, transcription, VPXXXX, WIXXXX, XEXXXX False True True NIHTT 37470483 Website Abstract 114172824 Hakami R, Hou L, et al. https://pubmed.ncbi.nlm.nih.gov/16412618/ <a href="https://pubmed.ncbi.nlm.nih.gov/16412618/">Hakami R, Hou L, et al.</a> 114172825 Harris M, Buac K, et al. https://pubmed.ncbi.nlm.nih.gov/23935512/ <a href="https://pubmed.ncbi.nlm.nih.gov/23935512/">Harris M, Buac K, et al.</a> 114111225 Harris, Melissa National Human Genome Research Institute (NHGRI) Harris, Melissa 0 114111224 Pavan, William ("Bill") National Human Genome Research Institute (NHGRI) NHGRI Pavan, William ("Bill") (NHGRI) 1 114111224 Pavan, William ("Bill") National Human Genome Research Institute (NHGRI) NHGRI Pavan, William ("Bill") (NHGRI) 1 114111225 Harris, Melissa National Human Genome Research Institute (NHGRI) Harris, Melissa 0 114102775 Prematurely-Graying Mouse Line Demonstrates Regulation Of Melanocyte Stem Cell Development By SOX10 (Sry-Related HMG-Box) Transcription Factor E-293-2012-0 Research Material National Human Genome Research Institute (NHGRI) 83716782 Campbell, Eggerton eggerton.campbell@nih.gov
United States of America eggerton.campbell@nih.gov?subject=Web Inquiry on [TAB-3671] Prematurely-Graying Mouse Line Demonstrates Regulation of Melanocyte Stem Cell Development by SOX10 (Sry-Related HMG-Box) Transcription Factor for Use in Regenerative Medicine&body=Please send me information about technology [TAB-3671] Prematurely-Graying Mouse Line Demonstrates Regulation of Melanocyte Stem Cell Development by SOX10 (Sry-Related HMG-Box) Transcription Factor for Use in Regenerative Medicine. Campbell, Eggerton<br><a href="mailto:eggerton.campbell@nih.gov?subject=Web Inquiry on [TAB-3671] Prematurely-Graying Mouse Line Demonstrates Regulation of Melanocyte Stem Cell Development by SOX10 (Sry-Related HMG-Box) Transcription Factor for Use in Regenerative Medicine&body=Please send me information about technology [TAB-3671] Prematurely-Graying Mouse Line Demonstrates Regulation of Melanocyte Stem Cell Development by SOX10 (Sry-Related HMG-Box) Transcription Factor for Use in Regenerative Medicine.">eggerton.campbell@nih.gov</a><br> 114129166 RXXXXX 114129167 VPXXXX 114129168 WIXXXX 114129169 XEXXXX 114154315 Prematurely-Graying 114154316 Mouse 114154317 Line 114154318 Demonstrates 114154319 REGULATION 114154320 Melanocyte 114154321 Stem 114154322 Cell 114154323 Development 114154324 SOX10 114154325 Sry-Related 114154326 HMG-Box 114154327 transcription 114154328 factor 114154329 Listed LPM Maddox as of 4/15/2015 114154330 Pre LPM working set 20150418 114154331 Post LPM Assignment Set 20150420 TAB-3675 114097527 Imaging Inflammation using PET Radioligands that Target Translocator Protein 18?kDa with High Affinity Regardless of Genotype NIMH Diagnostics, Medical Devices, Neurology, Non-Medical Devices, Psychiatry/Mental Health, Research Materials, Software / Apps Diagnostics Medical Devices Neurology Non-Medical Devices Psychiatry/Mental Health Research Materials Software / Apps Sabrina Castellano, Federico Da Settimo, Robert Innis, Claudia Martini, Victor Pike, Giorgio Stefancich, Sabrina Taliani, Yi Zhang This technology includes a group of radioligands that label inflammatory cells specifically, accurately, and across different genotypes and can be detected using Positron Emission Tomography (PET). The radioligands target the Translocator protein 18 kDa (TSPO) receptor which is present on the outer mitochondrial membrane and is involved in the production of steroids. Current TSPO radioligands either lack specificity or have highly variable inter-subject sensitivities due to TSPO genotypic differences. These new ligands permit a simplified interpretation and quantification of the binding signal. <br /><br /> During inflammation of the central nervous system, TSPO levels are increased. Neuroinflammation is symptomatic of many neuropsychiatric and neurodegenerative disorders, such as multiple sclerosis, stroke, epilepsy, dementia, and traumatic brain injuries. Thus, monitoring and quantifying TSPO with radioligands using PET may have clinical application in understanding, diagnosing, and treating many neuropsychiatric disorders. Radioligands are specific and accurate, regardless of genotype Biomarker or diagnostic for neuroinflammation 2022-06-02 2024-10-28 2024-10-28 2022-06-02 2022-05-31 18kDa, Emission, Genotype, Human, Listed LPM Fenn as of 4/15/2015, NA1XXX, Positron, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Quantifying/imaging, Radioligands, Regardless, tomography, TSPO, VEXXXX, VNXXXX, WBXXXX, WIXXXX, XCXXXX, XFXXXX False True True NIHTT 37470483 Website Abstract 114172829 Oh U, Fujita M, et al. https://pubmed.ncbi.nlm.nih.gov/20872081/ <a href="https://pubmed.ncbi.nlm.nih.gov/20872081/">Oh U, Fujita M, et al.</a> 114172830 Kreisl WC, Mbeo G, et al. https://pubmed.ncbi.nlm.nih.gov/19822787/ <a href="https://pubmed.ncbi.nlm.nih.gov/19822787/">Kreisl WC, Mbeo G, et al.</a> 114172831 Hirvonen J, Kreisl WC, et al. https://pubmed.ncbi.nlm.nih.gov/22238156/ <a href="https://pubmed.ncbi.nlm.nih.gov/22238156/">Hirvonen J, Kreisl WC, et al.</a> 114172832 Kreisl WC, Lyoo CH, et al. https://pubmed.ncbi.nlm.nih.gov/23775979/ <a href="https://pubmed.ncbi.nlm.nih.gov/23775979/">Kreisl WC, Lyoo CH, et al.</a> 114111237 Innis, Robert National Institute of Mental Health (NIMH) NIMH Innis, Robert (NIMH) 0 114111238 Da Settimo, Federico University of Pisa Da Settimo, Federico 0 114111239 Stefancich, Giorgio University of Trieste Stefancich, Giorgio 0 114111240 Taliani, Sabrina University of Pisa Taliani, Sabrina 0 114111241 Castellano, Sabrina University of Pisa Castellano, Sabrina 0 114111242 Martini, Claudia University of Pisa Martini, Claudia 0 114111243 Zhang, Yi Clinical Center (CC) Zhang, Yi 0 114111236 Pike, Victor National Institute of Mental Health (NIMH) NIMH Pike, Victor (NIMH) 1 114111236 Pike, Victor National Institute of Mental Health (NIMH) NIMH Pike, Victor (NIMH) 1 114111237 Innis, Robert National Institute of Mental Health (NIMH) NIMH Innis, Robert (NIMH) 0 114111238 Da Settimo, Federico University of Pisa Da Settimo, Federico 0 114111239 Stefancich, Giorgio University of Trieste Stefancich, Giorgio 0 114111240 Taliani, Sabrina University of Pisa Taliani, Sabrina 0 114111241 Castellano, Sabrina University of Pisa Castellano, Sabrina 0 114111242 Martini, Claudia University of Pisa Martini, Claudia 0 114111243 Zhang, Yi Clinical Center (CC) Zhang, Yi 0 114102779 Radioligands For Quantifying/imaging TSPO 18kDa With Positron Emission Tomography In Human, Regardless Of Genotype E-262-2012-0 Filing authorized National Institute of Mental Health (NIMH), University of Pisa, University of Trieste 83686256 Wong, Jennifer jennifer.wong2@nih.gov
United States of America jennifer.wong2@nih.gov?subject=Web Inquiry on [TAB-3675] Imaging Inflammation using PET Radioligands that Target Translocator Protein 18?kDa with High Affinity Regardless of Genotype&body=Please send me information about technology [TAB-3675] Imaging Inflammation using PET Radioligands that Target Translocator Protein 18?kDa with High Affinity Regardless of Genotype. Wong, Jennifer<br><a href="mailto:jennifer.wong2@nih.gov?subject=Web Inquiry on [TAB-3675] Imaging Inflammation using PET Radioligands that Target Translocator Protein 18?kDa with High Affinity Regardless of Genotype&body=Please send me information about technology [TAB-3675] Imaging Inflammation using PET Radioligands that Target Translocator Protein 18?kDa with High Affinity Regardless of Genotype.">jennifer.wong2@nih.gov</a><br> 114169512 E-262-2012-0 E-262-2012-0-US-01 TRANSLOCATOR PROTEIN IMAGING AGENTS; METHODS OF MANUFACTURE, AND METHODS OF USE THEREOF PRV US 61/777,542 Abandoned US <br />Provisional (PRV) 61/777,542<br />Filed on 2013-03-12<br />Status: Abandoned 114169513 E-262-2012-0 E-262-2012-0-PCT-02 TRANSLOCATOR PROTEIN IMAGING AGENTS; METHODS OF MANUFACTURE, AND METHODS OF USE THEREOF PCT Patent Cooperation Treaty PCT/US2014/023195 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2014/023195<br />Filed on 2014-03-11<br />Status: Expired 114129189 NA1XXX 114129190 VEXXXX 114129191 VNXXXX 114129192 WBXXXX 114129193 WIXXXX 114129194 XCXXXX 114129195 XFXXXX 114154366 Radioligands 114154367 Quantifying/imaging 114154368 TSPO 114154369 18kDa 114154370 Positron 114154371 Emission 114154372 tomography 114154373 Human 114154374 Regardless 114154375 Genotype 114154376 Listed LPM Fenn as of 4/15/2015 114154377 Pre LPM working set 20150418 114154378 Post LPM Assignment Set 20150420 TAB-3670 114097522 Murine Model of Niemann-Pick Disease Type C NHGRI Cardiology, Dental, Endocrinology, Infectious Disease, Neurology, Oncology, Ophthalmology, Psychiatry/Mental Health, Research Materials, Therapeutics Cardiology Dental Endocrinology Infectious Disease Neurology Oncology Ophthalmology Psychiatry/Mental Health Research Materials Therapeutics Stacie Loftus, William ("Bill") Pavan This technology includes a transgenic mouse model of Niemann-Pick Disease Type C (NPC), which is a rare neurodegenerative disorder, characterized by intracellular accumulation of cholesterol and gangliosides. The mouse strain, Tg(Npcl), expresses wild-type NPC1 gene under the control of the prion promoter. When combined with the NPC deficient mouse model, BALB/c npcnih/nih, also known as Npcl-/-, the transgene insertion allele rescues life expectancy of Npc1-/- mice. Npc1-/- mouse have reduced life expectancy and die around 8 weeks, making it a difficult model to be utilized. The Tg(Npcl) mouse strain we generated, when mated to the Npc1-/- mouse model rescues a portion of the disease effects related to neurologic degeneration and allows for a normal life span of Npcl-/- mice. The new mouse strain defined by both alleles (Tg (Npcl) ; BALB/ c npcnih/nih rescues NPC1 disease reduced viability and maintains the visceral defects that corresponds to the NPC visceral phenotype associated with cholesterol accumulation. The establishment of Tg(Npcl); BALB/c npcnih/nih creates an animal model that is useful to study both the visceral disease aspects of NPC and also the general biology of cholesterol accumulation and its effect on visceral organ systems. Animals live beyond 8 weeks and can be maintained at a reduced cost. Drug development for NPC and to study general biology related to cholesterol accumulation which has implications for more common human diseases pertaining to hypercholesterolemia and atherosclerosis. 2022-09-26 2024-10-28 2024-10-28 2022-09-26 2022-05-31 C, Disease, Listed LPM Maddox as of 4/15/2015, Model, Murine, NIEMANN-PICK, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, RXXXXX, VEXXXX, VHXXXX, VNXXXX, VPXXXX, WIXXXX, WKXXXX, XEXXXX False True True NIHTT 37470483 Website Abstract 114172823 Loftus S, Erickson R, et al. https://pubmed.ncbi.nlm.nih.gov/12417532/ <a href="https://pubmed.ncbi.nlm.nih.gov/12417532/">Loftus S, Erickson R, et al.</a> 114111223 Loftus, Stacie National Human Genome Research Institute (NHGRI) NHGRI Loftus, Stacie (NHGRI) 0 114111222 Pavan, William ("Bill") National Human Genome Research Institute (NHGRI) NHGRI Pavan, William ("Bill") (NHGRI) 1 114111222 Pavan, William ("Bill") National Human Genome Research Institute (NHGRI) NHGRI Pavan, William ("Bill") (NHGRI) 1 114111223 Loftus, Stacie National Human Genome Research Institute (NHGRI) NHGRI Loftus, Stacie (NHGRI) 0 114102774 Murine Model Of Niemann-Pick C Disease E-004-2011-0 Research Material National Human Genome Research Institute (NHGRI) 83716782 Campbell, Eggerton eggerton.campbell@nih.gov
United States of America eggerton.campbell@nih.gov?subject=Web Inquiry on [TAB-3670] Murine Model of Niemann-Pick Disease Type C&body=Please send me information about technology [TAB-3670] Murine Model of Niemann-Pick Disease Type C. Campbell, Eggerton<br><a href="mailto:eggerton.campbell@nih.gov?subject=Web Inquiry on [TAB-3670] Murine Model of Niemann-Pick Disease Type C&body=Please send me information about technology [TAB-3670] Murine Model of Niemann-Pick Disease Type C.">eggerton.campbell@nih.gov</a><br> 114129158 RXXXXX 114129159 VEXXXX 114129160 VHXXXX 114129161 VNXXXX 114129162 VPXXXX 114129163 WIXXXX 114129164 WKXXXX 114129165 XEXXXX 114154307 Murine 114154308 Model 114154309 NIEMANN-PICK 114154310 C 114154311 Disease 114154312 Listed LPM Maddox as of 4/15/2015 114154313 Pre LPM working set 20150418 114154314 Post LPM Assignment Set 20150420 TAB-3665 114097517 Human Cell Lines with Mannosyl Oligosaccharide Glucosidase (MOGS) Defect for the Study and Prevention of Infection NHGRI Cardiology, Dental, Endocrinology, Infectious Disease, Oncology, Ophthalmology, Research Materials Cardiology Dental Endocrinology Infectious Disease Oncology Ophthalmology Research Materials David Adams, William Gahl, Sergio Rosenzweig, Cynthia Tifft, Lynne Wolfe This technology includes human cell lines from patients who have genetic defects in MOGS, the gene encoding mannosyl-oligosaccharide glucosidase, causing the rare congenital disorder of glycosylation type IIb, also known as MOGS-CDG. This defects appears to impair the ability of viruses to infect a second round of cells, which can be used to study and prevent infections. This is likely related to impaired viral replication and cellular entry. This finding has implications for Ebola and Zika, as well as other viral infections. Novel cell line isolation with potential for widespread use. This finding has implications for Ebola and Zika, as well as other viral infections. 2022-09-26 2024-10-28 2024-10-28 2022-09-26 2022-05-31 Cell, Defect, GLYCOPROTEIN, Glycosidase, Human, Lines, Mannosyl, MOG, MOGS, MYELIN, Oligodendrocyte, Olygosaccharide, VLXXXX, VPXXXX, WIXXXX False True True NIHTT 37470483 Website Abstract 114111202 Tifft, Cynthia National Human Genome Research Institute (NHGRI) NHGRI Tifft, Cynthia (NHGRI) 0 114111203 Rosenzweig, Sergio Clinical Center (CC) CC Rosenzweig, Sergio (CC) 0 114111204 Adams, David National Human Genome Research Institute (NHGRI) NHGRI Adams, David (NHGRI) 0 114111205 Wolfe, Lynne National Human Genome Research Institute (NHGRI) NHGRI Wolfe, Lynne (NHGRI) 0 114111201 Gahl, William National Human Genome Research Institute (NHGRI) NHGRI Gahl, William (NHGRI) 1 114111201 Gahl, William National Human Genome Research Institute (NHGRI) NHGRI Gahl, William (NHGRI) 1 114111202 Tifft, Cynthia National Human Genome Research Institute (NHGRI) NHGRI Tifft, Cynthia (NHGRI) 0 114111203 Rosenzweig, Sergio Clinical Center (CC) CC Rosenzweig, Sergio (CC) 0 114111204 Adams, David National Human Genome Research Institute (NHGRI) NHGRI Adams, David (NHGRI) 0 114111205 Wolfe, Lynne National Human Genome Research Institute (NHGRI) NHGRI Wolfe, Lynne (NHGRI) 0 114102769 Human Cell Lines With Mannosyl Olygosaccharide Glycosidase (MOGS) Defect E-129-2016-0 Research Material Clinical Center (CC), National Human Genome Research Institute (NHGRI) 83716782 Campbell, Eggerton eggerton.campbell@nih.gov
United States of America eggerton.campbell@nih.gov?subject=Web Inquiry on [TAB-3665] Human Cell Lines with Mannosyl Oligosaccharide Glucosidase (MOGS) Defect for the Study and Prevention of Infection&body=Please send me information about technology [TAB-3665] Human Cell Lines with Mannosyl Oligosaccharide Glucosidase (MOGS) Defect for the Study and Prevention of Infection. Campbell, Eggerton<br><a href="mailto:eggerton.campbell@nih.gov?subject=Web Inquiry on [TAB-3665] Human Cell Lines with Mannosyl Oligosaccharide Glucosidase (MOGS) Defect for the Study and Prevention of Infection&body=Please send me information about technology [TAB-3665] Human Cell Lines with Mannosyl Oligosaccharide Glucosidase (MOGS) Defect for the Study and Prevention of Infection.">eggerton.campbell@nih.gov</a><br> 114129140 VLXXXX 114129141 VPXXXX 114129142 WIXXXX 114154249 Cell 114154250 Human 114154251 MOGS 114154252 Glycosidase 114154253 Olygosaccharide 114154254 Mannosyl 114154255 Lines 114154256 MYELIN 114154257 Oligodendrocyte 114154258 GLYCOPROTEIN 114154259 MOG 114154260 Defect TAB-3666 114097518 Human Fibroblast Cell Lines with PMM2 Congenital Disorder of Glycosylation for Therapeutic Development NHGRI Cardiology, Dental, Endocrinology, Infectious Disease, Neurology, Oncology, Ophthalmology, Research Materials, Therapeutics Cardiology Dental Endocrinology Infectious Disease Neurology Oncology Ophthalmology Research Materials Therapeutics Carlos Ferreira Lopez, William Gahl, Lynne Wolfe Congenital disorders of glycosylation (CDGs) are inherited disorders of abnormal protein glycosylation that affect multiple organ systems. More than 100 different CDGs have been described, affecting protein and lipid glycosylation. NHGRI investigators have been able to isolate fibroblasts from patients with PMM2 (phosphomannomutase)-CDG, also known at CDG type Ia, which is an inherited, broad-spectrum disorder with developmental and neurological abnormalities. Evaluation of potential therapies for this disorder, which has limited treatment options. These cells can be used to test potential therapeutics for PMM2-CDG. 2022-09-26 2024-10-28 2024-10-28 2022-09-26 2022-05-31 Cell, Congenital, DISORDER, Fibroblast, Glycosylatlon, Human, Lines, PMM2, VEXXXX, VPXXXX, WIXXXX, WKXXXX False True True NIHTT 37470483 Website Abstract 114172820 Kane M, Davids M, et al. https://pubmed.ncbi.nlm.nih.gov/26805780/ <a href="https://pubmed.ncbi.nlm.nih.gov/26805780/">Kane M, Davids M, et al.</a> 114111207 Wolfe, Lynne National Human Genome Research Institute (NHGRI) NHGRI Wolfe, Lynne (NHGRI) 0 114111208 Ferreira Lopez, Carlos National Human Genome Research Institute (NHGRI) NICHD Ferreira Lopez, Carlos (NICHD) 0 114111206 Gahl, William National Human Genome Research Institute (NHGRI) NHGRI Gahl, William (NHGRI) 1 114111206 Gahl, William National Human Genome Research Institute (NHGRI) NHGRI Gahl, William (NHGRI) 1 114111207 Wolfe, Lynne National Human Genome Research Institute (NHGRI) NHGRI Wolfe, Lynne (NHGRI) 0 114111208 Ferreira Lopez, Carlos National Human Genome Research Institute (NHGRI) NICHD Ferreira Lopez, Carlos (NICHD) 0 114102770 Human Fibroblast Cell Lines With PMM2 Congenital Disorder Of Glycosylatlon E-086-2017-0 Research Material National Human Genome Research Institute (NHGRI) 83703934 Solowiej, Anna anna.solowiej@nih.gov
United States of America anna.solowiej@nih.gov?subject=Web Inquiry on [TAB-3666] Human Fibroblast Cell Lines with PMM2 Congenital Disorder of Glycosylation for Therapeutic Development&body=Please send me information about technology [TAB-3666] Human Fibroblast Cell Lines with PMM2 Congenital Disorder of Glycosylation for Therapeutic Development. Solowiej, Anna<br><a href="mailto:anna.solowiej@nih.gov?subject=Web Inquiry on [TAB-3666] Human Fibroblast Cell Lines with PMM2 Congenital Disorder of Glycosylation for Therapeutic Development&body=Please send me information about technology [TAB-3666] Human Fibroblast Cell Lines with PMM2 Congenital Disorder of Glycosylation for Therapeutic Development.">anna.solowiej@nih.gov</a><br> 114129143 VEXXXX 114129144 VPXXXX 114129145 WIXXXX 114129146 WKXXXX 114154261 Human 114154262 Fibroblast 114154263 Cell 114154264 Lines 114154265 PMM2 114154266 Congenital 114154267 DISORDER 114154268 Glycosylatlon TAB-3658 114097509 First-in-class Small Molecule Agonists of the Insulin-like (INSL3) Peptide Receptor RXFP2 and Uses in Bone Disorders and Fertility NCATS Research Materials, Therapeutics Research Materials Therapeutics Marc Ferrer-Alegre, Mark Henderson, Juan Marugan, Noel Southall Recent studies have identified the G-protein-coupled receptor (GPCR) for insulin-like 3 peptide (INSL3), relaxin family peptide receptor 2 (RXFP2), as an attractive target for the treatment of bone diseases such as osteoporosis and rare bone diseases such as osteogenesis imperfecta. Currently, the most effective available treatment for osteoporosis is an expensive hormone therapy that requires daily injections. A stable, orally deliverable drug is a much more desirable alternative. Our RXFP2 agonists perform as well as the natural ligand INSL3 in cellular assays. <br /><br /> NCATS in collaboration with Florida International University (FIU) has identified low molecular weight, highly potent, and efficient full RXFP2 agonists with low cytotoxicity. The identification and characterization of these compounds may lead to the development of a new class of cost-effective drugs for the treatment of osteoporosis and other diseases associated with bone loss. <br /><br /> NCATS is actively seeking licensing and/or co-development research collaborations for the treatment of osteoporosis and other diseases associated with bone loss as well as bone development disorders such as rickets and osteomalacia. <ul> <li>First and only small molecule agonists of RXFP2</li> <li>Potent and highly selective</li> <li>Scalable synthesis</li> </ul> <ul> <li>Drug development</li> <li>Rare disease therapeutic communities</li> </ul> Researchers at the National Center for Advancing Translational Sciences (NCATS) seek collaborators to co-development these small molecules. 2022-05-26 2024-10-28 2024-10-28 2022-05-26 Bone, bone formation, bone mass, CAMP, cyclic adenosine monophosphate, DISEASES, FERTILITY, FUNCTIONALLY, G protein-coupled receptor, gubernaculum, HEK-293, insl3, insulin-like3, LIGAND, mineralizing surface, NCGC00686641, Novel, osteoblasts with INSL3, osteoclast, peptide receptor, rare bone diseases, rare disease, RECEPTOR, REPRODUCTIVE, RXFP2, SELECTIVE, testicular descent, treatment, Uterus, WIXXXX, WKXXXX False True True NIHTT 37470483 Website Abstract 114111175 Henderson, Mark NCATS - NCGC NCATS Henderson, Mark (NCATS) 0 114111176 Ferrer-Alegre, Marc NCATS - NCGC NCATS Ferrer-Alegre, Marc (NCATS) 0 114111177 Southall, Noel NCATS - TRND NCATS Southall, Noel (NCATS) 0 114111178 Marugan, Juan NCATS - NCGC NCATS Marugan, Juan (NCATS) 1 114111178 Marugan, Juan NCATS - NCGC NCATS Marugan, Juan (NCATS) 1 114111175 Henderson, Mark NCATS - NCGC NCATS Henderson, Mark (NCATS) 0 114111176 Ferrer-Alegre, Marc NCATS - NCGC NCATS Ferrer-Alegre, Marc (NCATS) 0 114111177 Southall, Noel NCATS - TRND NCATS Southall, Noel (NCATS) 0 114102762 NCGC00686641 Is A Novel Functionally Selective RXFP2 Receptor Ligand For The Treatment Of Bone And Reproductive Diseases E-218-2021-0 Filing authorized National Center for Advancing Translational Sciences, NCATS - NCGC, NCATS - NCGC 93911356 Kalsi, Jasmine jasmine.kalsi@nih.gov
United States of America jasmine.kalsi@nih.gov?subject=Web Inquiry on [TAB-3658] First-in-class Small Molecule Agonists of the Insulin-like (INSL3) Peptide Receptor RXFP2 and Uses in Bone Disorders and Fertility&body=Please send me information about technology [TAB-3658] First-in-class Small Molecule Agonists of the Insulin-like (INSL3) Peptide Receptor RXFP2 and Uses in Bone Disorders and Fertility. Kalsi, Jasmine<br><a href="mailto:jasmine.kalsi@nih.gov?subject=Web Inquiry on [TAB-3658] First-in-class Small Molecule Agonists of the Insulin-like (INSL3) Peptide Receptor RXFP2 and Uses in Bone Disorders and Fertility&body=Please send me information about technology [TAB-3658] First-in-class Small Molecule Agonists of the Insulin-like (INSL3) Peptide Receptor RXFP2 and Uses in Bone Disorders and Fertility.">jasmine.kalsi@nih.gov</a><br> 114169499 E-218-2021-0 E-218-2021-0-US-01 SMALL MOLECULE AGONISTS OF THE INSULIN-LIKE 3 (INSL3) PEPTIDE RECEPTOR RXFP2 AND METHODS OF USE THEREOF PRV US 63/308,768 Expired US <br />Provisional (PRV) 63/308,768<br />Filed on 2022-02-10<br />Status: Expired 114129111 WIXXXX 114129112 WKXXXX 114154133 testicular descent 114154134 gubernaculum 114154135 Uterus 114154136 osteoblasts with INSL3 114154137 osteoclast 114154138 bone formation 114154139 mineralizing surface 114154140 bone mass 114154141 HEK-293 114154142 CAMP 114154143 cyclic adenosine monophosphate 114154144 G protein-coupled receptor 114154145 peptide receptor 114154146 insl3 114154147 insulin-like3 114154148 FERTILITY 114154149 rare bone diseases 114154150 rare disease 114154151 DISEASES 114154152 REPRODUCTIVE 114154153 Bone 114154154 treatment 114154155 LIGAND 114154156 RECEPTOR 114154157 RXFP2 114154158 SELECTIVE 114154159 FUNCTIONALLY 114154160 Novel 114154161 NCGC00686641 TAB-3646 114097499 Human Cell Lines with NGLY1 Mutations for the Study of NGLY1 Deficiency and Therapeutic Development NHGRI Neurology, Research Materials Neurology Research Materials William Gahl, May Malicdan, Lynne Wolfe Congenital disorders of glycosylation (CDGs) are a group of inborn errors characterized by abnormalities in the process of glycosylation of biomolecules. Although more than 100 different CDGs have been reported, only one has been thoroughly described, namely NGLY1 deficiency or NGLY1-CDG. NGLY1 encodes N-glycanase 1, an enzyme involved in the cytosolic degradation of misfolded glycoproteins and other glycoproteins bound for degradation. This technology includes fifteen fibroblast cell lines isolated from patients from 2.5 years to 21.3 years to be used to study the defects in NGLY1 gene and protein and to screen small molecules for involvement in NGLY1 deficiency. They could also be used to generate induced pluripotent stem cells (iPSCs) as models of this deficiency. These cell lines can be used to study the defects in NGLY1 gene and protein and to screen small molecules for involvement in NGLY1 deficiency, and can also be used to generate iPSCs as models of this deficiency. Screening tool for small molecule treatments for NGLY1 deficiency. 2022-09-26 2024-10-28 2024-10-28 2022-09-26 2022-05-18 Cell, Human, Lines, Mutations, NGL, VEXXXX, WIXXXX, Y1 False True True NIHTT 37470483 Website Abstract 114111139 Gahl, William National Human Genome Research Institute (NHGRI) NHGRI Gahl, William (NHGRI) 0 114111140 Malicdan, May National Human Genome Research Institute (NHGRI) NHGRI Malicdan, May (NHGRI) 0 114111138 Wolfe, Lynne National Human Genome Research Institute (NHGRI) NHGRI Wolfe, Lynne (NHGRI) 1 114111138 Wolfe, Lynne National Human Genome Research Institute (NHGRI) NHGRI Wolfe, Lynne (NHGRI) 1 114111139 Gahl, William National Human Genome Research Institute (NHGRI) NHGRI Gahl, William (NHGRI) 0 114111140 Malicdan, May National Human Genome Research Institute (NHGRI) NHGRI Malicdan, May (NHGRI) 0 114102751 Human Cell Lines With NGL Y1 Mutations E-251-2017-0 Research Material National Human Genome Research Institute (NHGRI) 83703934 Solowiej, Anna anna.solowiej@nih.gov
United States of America anna.solowiej@nih.gov?subject=Web Inquiry on [TAB-3646] Human Cell Lines with NGLY1 Mutations for the Study of NGLY1 Deficiency and Therapeutic Development&body=Please send me information about technology [TAB-3646] Human Cell Lines with NGLY1 Mutations for the Study of NGLY1 Deficiency and Therapeutic Development. Solowiej, Anna<br><a href="mailto:anna.solowiej@nih.gov?subject=Web Inquiry on [TAB-3646] Human Cell Lines with NGLY1 Mutations for the Study of NGLY1 Deficiency and Therapeutic Development&body=Please send me information about technology [TAB-3646] Human Cell Lines with NGLY1 Mutations for the Study of NGLY1 Deficiency and Therapeutic Development.">anna.solowiej@nih.gov</a><br> 114129060 VEXXXX 114129061 WIXXXX 114154025 Human 114154026 Cell 114154027 Lines 114154028 NGL 114154029 Y1 114154030 Mutations TAB-3655 114097508 Mouse Model of Hutchinson-Gilford Progeria Syndrome (HGPS) and Vascular Abnormalities (G608G) mutated form of human LNMA) for Therapeutic Development NHGRI Cardiology, Dental, Endocrinology, Infectious Disease, Neurology, Oncology, Ophthalmology, Research Materials, Therapeutics Cardiology Dental Endocrinology Infectious Disease Neurology Oncology Ophthalmology Research Materials Therapeutics Francis Collins, Michael Erdos, Maria Eriksson, Renee Varga Children with Hutchinson-Gilford progeria syndrome (HGPS) suffer from acceleration of certain aging symptoms, mainly cardiovascular disease that generally leads to death from myocardial infarction and/or stroke. The cause of HGPS has been discovered to be a de novo point mutation in lamin A (LNMA) gene. NHGRI Scientist have generated a transgenic mouse model of HGPS. This mouse carries a bacterial artificial chromosome (BAC) with a De novo mutation 1824 C to T (G608G) mutated form of human LNMA. The transgenic animals lack external phenotype seen in human progeria but have vascular abnormalities that resemble the human phenotype. Specifically, the mice have progressive vascular smooth muscle cell loss in large arteries and replacement with proteoglycan and collagen, that is, they show progressive vascular calcification. This mouse model can be used to further understand the vascular pathology of progeria and to study potential progeria therapies. Novel mouse model for a condition lacking efficacious treatment options. <ul> <li>This mouse model can be used to further understand the vascular pathology of progeria and to study potential progeria therapies.</li> <li>Used to investigate symptoms of and treatments for other cardiovascular and aging disorders, especially those that involve atherosclerotic lesions and vascular calcification.</li> </ul> 2022-09-26 2024-10-28 2024-10-28 2022-09-26 2022-05-19 Abnormalities, HGPS, Hutchinson-Gilford, Listed LPM Maddox as of 4/15/2015, Model, Mouse, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Progeria, RXXXXX, Syndrome, vascular, VEXXXX, VPXXXX, XEXXXX False True True NIHTT 37470483 Website Abstract 114172808 Varga R, Eriksson M, et al. https://pubmed.ncbi.nlm.nih.gov/16492728/ <a href="https://pubmed.ncbi.nlm.nih.gov/16492728/">Varga R, Eriksson M, et al.</a> 114172809 Sullivan T, Escalante-Alcalde D, et al. https://pubmed.ncbi.nlm.nih.gov/10579712/ <a href="https://pubmed.ncbi.nlm.nih.gov/10579712/">Sullivan T, Escalante-Alcalde D, et al.</a> 114172810 Mounkes L, Kozlov S, et al. https://pubmed.ncbi.nlm.nih.gov/12748643/ <a href="https://pubmed.ncbi.nlm.nih.gov/12748643/">Mounkes L, Kozlov S, et al.</a> 114172811 Yang S, Bergo M, et al. https://pubmed.ncbi.nlm.nih.gov/16014412/ <a href="https://pubmed.ncbi.nlm.nih.gov/16014412/">Yang S, Bergo M, et al.</a> 114111169 Collins, Francis National Human Genome Research Institute (NHGRI) NHGRI Collins, Francis (NHGRI) 0 114111170 Eriksson, Maria Karolinska Institute [Karolinska Institutet] Eriksson, Maria 0 114111171 Varga, Renee GeneDx, Inc. Varga, Renee 0 114111168 Erdos, Michael National Human Genome Research Institute (NHGRI) NHGRI Erdos, Michael (NHGRI) 1 114111168 Erdos, Michael National Human Genome Research Institute (NHGRI) NHGRI Erdos, Michael (NHGRI) 1 114111169 Collins, Francis National Human Genome Research Institute (NHGRI) NHGRI Collins, Francis (NHGRI) 0 114111170 Eriksson, Maria Karolinska Institute [Karolinska Institutet] Eriksson, Maria 0 114111171 Varga, Renee GeneDx, Inc. Varga, Renee 0 114102760 Mouse Model Of Hutchinson-Gilford Progeria Syndrome (HGPS Or Progeria) And Vascular Abnormalities E-243-2011-0 Research Material National Human Genome Research Institute (NHGRI) 83716782 Campbell, Eggerton eggerton.campbell@nih.gov
United States of America eggerton.campbell@nih.gov?subject=Web Inquiry on [TAB-3655] Mouse Model of Hutchinson-Gilford Progeria Syndrome (HGPS) and Vascular Abnormalities (G608G) mutated form of human LNMA) for Therapeutic Development&body=Please send me information about technology [TAB-3655] Mouse Model of Hutchinson-Gilford Progeria Syndrome (HGPS) and Vascular Abnormalities (G608G) mutated form of human LNMA) for Therapeutic Development. Campbell, Eggerton<br><a href="mailto:eggerton.campbell@nih.gov?subject=Web Inquiry on [TAB-3655] Mouse Model of Hutchinson-Gilford Progeria Syndrome (HGPS) and Vascular Abnormalities (G608G) mutated form of human LNMA) for Therapeutic Development&body=Please send me information about technology [TAB-3655] Mouse Model of Hutchinson-Gilford Progeria Syndrome (HGPS) and Vascular Abnormalities (G608G) mutated form of human LNMA) for Therapeutic Development.">eggerton.campbell@nih.gov</a><br> 114129094 RXXXXX 114129095 VEXXXX 114129096 VPXXXX 114129097 XEXXXX 114154118 Mouse 114154119 Model 114154120 Hutchinson-Gilford 114154121 Progeria 114154122 Syndrome 114154123 HGPS 114154124 vascular 114154125 Abnormalities 114154126 Listed LPM Maddox as of 4/15/2015 114154127 Pre LPM working set 20150418 114154128 Post LPM Assignment Set 20150420 TAB-3645 114097498 Lymphoblastoid Cell Lines with a Specific Allele of ABCA7 Gene for the Screening of Small Molecules for Therapeutic Development NHGRI Cardiology, Dental, Endocrinology, Infectious Disease, Oncology, Ophthalmology, Research Materials, Therapeutics Cardiology Dental Endocrinology Infectious Disease Oncology Ophthalmology Research Materials Therapeutics Leslie Biesecker, Jennifer Johnston, James ("Jim") Mullikin This technology includes lymphoblastoid cell lines from individuals genotyped as carrying the minor (G) allele of ABCA7 SNP rs113809142 [ss491752998; SNV-chr19-1007244], to be used for small molecule screening and eventual therapeutic development. The ABCA7 gene is the ATP-binding cassette, sub-family A (ABC1), member 7. It encodes a protein that is a transporter and has been associated with such diseases as neonatal respiratory failure and Asperger's syndrome. It is also known to play a role in phagocytosis of apoptotic cells by macrophages and may mediate cholesterol efflux. First human cell lines available with this specific allele. These cell lines can be used to study the defects in ABCA7 gene and protein and screen small molecules for involvement in the diseases mediated by this gene. 2022-09-26 2024-10-28 2024-10-28 2022-09-26 2022-05-18 ABCA7, ALLELE, Cell, Gene, Lines, Listed LPM Contreras as of 4/15/2015, Lymphoblastoid, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, RXXXXX, Specific, VHXXXX, VPXXXX, WIXXXX, WJXXXX, XEXXXX False True True NIHTT 37470483 Website Abstract 114172799 Biesecker L, Mullikin J, et al. https://pubmed.ncbi.nlm.nih.gov/19602640/ <a href="https://pubmed.ncbi.nlm.nih.gov/19602640/">Biesecker L, Mullikin J, et al.</a> 114111136 Mullikin, James ("Jim") National Human Genome Research Institute (NHGRI) NHGRI Mullikin, James ("Jim") (NHGRI) 0 114111137 Johnston, Jennifer National Human Genome Research Institute (NHGRI) NHGRI Johnston, Jennifer (NHGRI) 0 114111135 Biesecker, Leslie National Human Genome Research Institute (NHGRI) NHGRI Biesecker, Leslie (NHGRI) 1 114111135 Biesecker, Leslie National Human Genome Research Institute (NHGRI) NHGRI Biesecker, Leslie (NHGRI) 1 114111136 Mullikin, James ("Jim") National Human Genome Research Institute (NHGRI) NHGRI Mullikin, James ("Jim") (NHGRI) 0 114111137 Johnston, Jennifer National Human Genome Research Institute (NHGRI) NHGRI Johnston, Jennifer (NHGRI) 0 114102750 Lymphoblastoid Cell Lines With A Specific Allele Of ABCA7 Gene E-147-2014-0 Research Material National Human Genome Research Institute (NHGRI) 83716782 Campbell, Eggerton eggerton.campbell@nih.gov
United States of America eggerton.campbell@nih.gov?subject=Web Inquiry on [TAB-3645] Lymphoblastoid Cell Lines with a Specific Allele of ABCA7 Gene for the Screening of Small Molecules for Therapeutic Development&body=Please send me information about technology [TAB-3645] Lymphoblastoid Cell Lines with a Specific Allele of ABCA7 Gene for the Screening of Small Molecules for Therapeutic Development. Campbell, Eggerton<br><a href="mailto:eggerton.campbell@nih.gov?subject=Web Inquiry on [TAB-3645] Lymphoblastoid Cell Lines with a Specific Allele of ABCA7 Gene for the Screening of Small Molecules for Therapeutic Development&body=Please send me information about technology [TAB-3645] Lymphoblastoid Cell Lines with a Specific Allele of ABCA7 Gene for the Screening of Small Molecules for Therapeutic Development.">eggerton.campbell@nih.gov</a><br> 114129054 RXXXXX 114129055 VHXXXX 114129056 VPXXXX 114129057 WIXXXX 114129058 WJXXXX 114129059 XEXXXX 114154015 Lymphoblastoid 114154016 Cell 114154017 Lines 114154018 Specific 114154019 ALLELE 114154020 ABCA7 114154021 Gene 114154022 Listed LPM Contreras as of 4/15/2015 114154023 Pre LPM working set 20150418 114154024 Post LPM Assignment Set 20150420 TAB-3642 114097495 Three-Dimensional Respiratory Epithelial Tissue Constructs With Perfusable Microvasculature NCATS Cardiology, Infectious Disease, Research Equipment, Research Materials Cardiology Infectious Disease Research Equipment Research Materials Marc Ferrer-Alegre, Olive Jung, Min Jae Song, Yen-Ting Tung The invention provides two vascularized, multi-chip models for the alveoli and the small airway. Both models comprise a perfusable three-dimensional (3D) microvascular network consisting of human primary microvascular endothelial cells, fibroblasts, and pericytes with a differentiated lung epithelial layer exposed at the air-liquid interface (ALI) on top, built on a high-throughput, 64-chip microfluidic plate platform. The platform does not require the support of a permeable membrane and the epithelial cells are directly seeded on the perfused microvascular network. This allows for direct, physical cell-cell interaction and more physiologically-relevant biological phenomena at the epithelium-capillary interface. The invention also provides several methods of making and methods of using the perfused vascularized, ALI exposed lung epithelial, multi-chip models for the study of diseases affecting the alveoli and the small airway, and drug screening (e.g., high-throughput screening). In addition to a simple monolayer respiratory epithelial, this invention also includes a perfusable microvascular network that is amenable for high-throughput therapeutics screening and disease modeling. Tissue modeling, disease modeling, drug screening. For collaboration opportunities, please contact CDC TTO at <a href="mailto:tto@cdc.gov">tto@cdc.gov</a> or 1-404-639-1330. 2022-09-28 2024-10-28 2024-10-28 2022-09-27 3D, AEROSOLS, ALI, analysis, Biofabricated, Bioprinting, Chemical, Chips/Microarrays, DEVELOP, Discovery, DRUG, EPITHELIUM, Human, Laser, LUNG, Manufacturing, Membrane-free, Methods, optical, Perfused, PROCESS, screening, Spectroscopies, That, Tissue, Tissue chip, tissue model, Used, Vascularized, VASCULATURE, VDXXXX, VLXXXX, WIXXXX, XHXXXX False True True NIHTT 37470483 Website Abstract 114172797 Olive J, Tung Y-T, et al. https://pubmed.ncbi.nlm.nih.gov/35166694/ <a href="https://pubmed.ncbi.nlm.nih.gov/35166694/">Olive J, Tung Y-T, et al.</a> 114111128 Jung, Olive NCATS - NCGC NCATS Jung, Olive (NCATS) 0 114111639 Tung, Yen-Ting NCATS - NCGC NCATS Tung, Yen-Ting (NCATS) 0 114111640 Ferrer-Alegre, Marc NCATS - NCGC NCATS Ferrer-Alegre, Marc (NCATS) 0 114111129 Song, Min Jae National Eye Institute (NEI) NCATS Song, Min Jae (NCATS) 1 114111129 Song, Min Jae National Eye Institute (NEI) NCATS Song, Min Jae (NCATS) 1 114111128 Jung, Olive NCATS - NCGC NCATS Jung, Olive (NCATS) 0 114111639 Tung, Yen-Ting NCATS - NCGC NCATS Tung, Yen-Ting (NCATS) 0 114111640 Ferrer-Alegre, Marc NCATS - NCGC NCATS Ferrer-Alegre, Marc (NCATS) 0 114102747 3D Vascularized Human Lung Tissue For Drug Discovery And A Manufacturing Process To Develop A 3D Biofabricated Human Lung Tissue With Perfused Vasculature And Membrane-free ALI Epithelium That Can Be Used For Drug Discovery And Screening E-005-2022-0 Filing authorized NCATS - NCGC 83682485 Vepa, Suryanarayana sury.vepa@nih.gov
United States of America Office of Strategic Alliances (OSA) sury.vepa@nih.gov?subject=Web Inquiry on [TAB-3642] Three-Dimensional Respiratory Epithelial Tissue Constructs With Perfusable Microvasculature&body=Please send me information about technology [TAB-3642] Three-Dimensional Respiratory Epithelial Tissue Constructs With Perfusable Microvasculature. Vepa, Suryanarayana<br><a href="mailto:sury.vepa@nih.gov?subject=Web Inquiry on [TAB-3642] Three-Dimensional Respiratory Epithelial Tissue Constructs With Perfusable Microvasculature&body=Please send me information about technology [TAB-3642] Three-Dimensional Respiratory Epithelial Tissue Constructs With Perfusable Microvasculature.">sury.vepa@nih.gov</a><br> 114169657 E-005-2022-0 E-005-2022-0-US-01 THREE-DIMENSIONAL RESPIRATORY EPITHELIAL TISSUE CONSTRUCTS WITH PERFUSABLE MICROVASCULATURE ON A HIGH-THROUGHPUT MICROFLUIDICS SCREENING PLATFORM PRV US 63/284,504 Expired US <br />Provisional (PRV) 63/284,504<br />Filed on 2021-11-30<br />Status: Expired 114129042 VDXXXX 114129043 WIXXXX 114129044 XHXXXX 114129045 VLXXXX 114153986 Methods 114153987 Chemical 114153988 analysis 114153989 AEROSOLS 114153990 Laser 114153991 optical 114153992 Spectroscopies 114153993 Chips/Microarrays 114153994 Bioprinting 114153995 Tissue chip 114153996 tissue model 114155641 3D 114155642 Vascularized 114155643 Human 114155644 LUNG 114155645 Tissue 114155646 DRUG 114155647 Discovery 114155648 Manufacturing 114155649 PROCESS 114155650 DEVELOP 114155651 Biofabricated 114155652 Perfused 114155653 VASCULATURE 114155654 Membrane-free 114155655 ALI 114155656 EPITHELIUM 114155657 That 114155658 Used 114155659 screening TAB-3638 114097491 Mouse Model Created Using Glucocerebrosidase-Deficient Neuronal Cell Line to Study Gaucher Disease Pathophysiology and Evaluate New Therapies NHGRI Cardiology, Dental, Endocrinology, Infectious Disease, Neurology, Oncology, Ophthalmology, Research Materials, Therapeutics Cardiology Dental Endocrinology Infectious Disease Neurology Oncology Ophthalmology Research Materials Therapeutics Matthew Nguyen, Ellen Sidransky, Nahid Tayebi, Wendy Westbroek This technology includes a high-yield, easy-to-culture mouse neuronal cell model with nearly complete glucocerebrosidase deficiency representative of Gaucher disease (GD) to study pathophysiology and evaluate new therapies. GD is an autosomal recessive lysosomal storage disorder caused by loss-of function mutations in the GBA1 gene, which codes for the lysosomal hydrolase glucocerebrosidase (GCase). Inventors have successfully immortalized cortical neurons from embryonic null allele GBA-/- mice and the control littermate (GBA+/+) by infecting differentiated primary cortical neurons in culture with an EF1aSV40T lentivirus. Immortalized GBA-/- neurons lack glucocerebrosidase protein and enzyme activity and exhibit a dramatic increase in glucosylceramide and glucosylsphingosine accumulation,enlarged lysosomes, and an impaired ATP-dependent calcium-influx response. This new cell line exhibits a dramatic increase in glucosylceramide and glucosylsphingosine accumulation, enlarged lysosomes, and an impaired ATP-dependent calcium-influx response, compared to other cell lines which have limitations such as low yield, difficulty in propagation, and introduction of exogenous mutant GBA 1. The null allele GBA-/- mouse neuronal cell line model provides a much-needed tool to study the pathophysiology of Gaucher disease and to evaluate new therapies. Because mutations in GBA1 are also a genetic risk factor for Parkinson disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA), this cell line may also provide a basis to explore the molecular mechanism of these disorders and other synucleinopathies. 2022-09-26 2024-10-28 2024-10-28 2022-09-26 2022-05-12 Cell, DEFICIENT, Disease, Gaucher, GLUCOCEREBROSIDASE, Line, Model, Mouse, NEURONAL, VEXXXX, VPXXXX, WIXXXX, XEXXXX False True True NIHTT 37470483 Website Abstract 114172795 Tybulewicz V, Tremblay M, et al. https://pubmed.ncbi.nlm.nih.gov/1594045/ <a href="https://pubmed.ncbi.nlm.nih.gov/1594045/">Tybulewicz V, Tremblay M, et al.</a> 114111115 Nguyen, Matthew National Human Genome Research Institute (NHGRI) Nguyen, Matthew 0 114111116 Westbroek, Wendy National Human Genome Research Institute (NHGRI) Westbroek, Wendy 0 114111117 Tayebi, Nahid National Human Genome Research Institute (NHGRI) NHGRI Tayebi, Nahid (NHGRI) 0 114111114 Sidransky, Ellen National Human Genome Research Institute (NHGRI) NHGRI Sidransky, Ellen (NHGRI) 1 114111114 Sidransky, Ellen National Human Genome Research Institute (NHGRI) NHGRI Sidransky, Ellen (NHGRI) 1 114111115 Nguyen, Matthew National Human Genome Research Institute (NHGRI) Nguyen, Matthew 0 114111116 Westbroek, Wendy National Human Genome Research Institute (NHGRI) Westbroek, Wendy 0 114111117 Tayebi, Nahid National Human Genome Research Institute (NHGRI) NHGRI Tayebi, Nahid (NHGRI) 0 114102743 Mouse Glucocerebrosidase Deficient Neuronal Cell Line As A Model Of Gaucher Disease E-239-2016-0 Research Material National Human Genome Research Institute (NHGRI) 83716782 Campbell, Eggerton eggerton.campbell@nih.gov
United States of America eggerton.campbell@nih.gov?subject=Web Inquiry on [TAB-3638] Mouse Model Created Using Glucocerebrosidase-Deficient Neuronal Cell Line to Study Gaucher Disease Pathophysiology and Evaluate New Therapies&body=Please send me information about technology [TAB-3638] Mouse Model Created Using Glucocerebrosidase-Deficient Neuronal Cell Line to Study Gaucher Disease Pathophysiology and Evaluate New Therapies. Campbell, Eggerton<br><a href="mailto:eggerton.campbell@nih.gov?subject=Web Inquiry on [TAB-3638] Mouse Model Created Using Glucocerebrosidase-Deficient Neuronal Cell Line to Study Gaucher Disease Pathophysiology and Evaluate New Therapies&body=Please send me information about technology [TAB-3638] Mouse Model Created Using Glucocerebrosidase-Deficient Neuronal Cell Line to Study Gaucher Disease Pathophysiology and Evaluate New Therapies.">eggerton.campbell@nih.gov</a><br> 114129027 VPXXXX 114129028 VEXXXX 114129029 WIXXXX 114129030 XEXXXX 114153942 Model 114153943 Line 114153944 Cell 114153945 NEURONAL 114153946 DEFICIENT 114153947 GLUCOCEREBROSIDASE 114153948 Mouse 114153949 Gaucher 114153950 Disease TAB-3636 114097489 Fibroblast Cell Lines Homozygous for Glucocerebrosidase (GBA1) Mutation N370S for the Screening of Small Molecules for Gaucher Disease Treatment NHGRI Cardiology, Dental, Endocrinology, Infectious Disease, Oncology, Ophthalmology, Research Equipment, Research Materials, Therapeutics Cardiology Dental Endocrinology Infectious Disease Oncology Ophthalmology Research Equipment Research Materials Therapeutics Ellen Sidransky, Barbara Stubblefield This technology includes two human fibroblast cell lines be used to study the defects in GBA1 gene and protein and to screen small molecules for involvement in Gaucher disease. Glucocerebrosidase (GBA1 or GCase or beta-glucosidase) is a lysosomal enzyme, responsible for breakdown of a fatty material called glucocerebroside (or glucosyl ceramide). Deficiency or malfunction of GBA1 leads to the accumulation of insoluble glucocerebrosides in tissues, which is a major symptom of Gaucher disease. Gaucher disease is a rare and heterogeneous disorder, caused by inherited genetic mutations in GBA1. Inventors have collected fibroblasts from various patients, including those with homozygous mutation N370S. This is the most common mutation found in Gaucher patients and is found in the non-neuronopathic form of the disease. Because this mutation is involved in non-neuronopathic type of Gaucher disease, it can probably serve as a good control line for studying Parkinson's disease and neurodegenerative disorders that involve other GBA1 mutations. These cell lines can be used to study the defects in GBA1 gene and protein and to screen small molecules for involvement in Gaucher disease. 2022-09-26 2024-10-28 2024-10-28 2022-09-26 2022-05-12 Cell, Fibroblast, GBA1, GLUCOCEREBROSIDASE, HOMOZYGOUS, Lines, Listed LPM Vepa as of 4/15/2015, MUTATION, N370S, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, VPXXXX, WIXXXX, WKXXXX, XHXXXX False True True NIHTT 37470483 Website Abstract 114172794 Panicker L, Miller D, et al. https://pubmed.ncbi.nlm.nih.gov/23071332/ <a href="https://pubmed.ncbi.nlm.nih.gov/23071332/">Panicker L, Miller D, et al.</a> 114111110 Stubblefield, Barbara National Human Genome Research Institute (NHGRI) NHGRI Stubblefield, Barbara (NHGRI) 0 114111109 Sidransky, Ellen National Human Genome Research Institute (NHGRI) NHGRI Sidransky, Ellen (NHGRI) 1 114111109 Sidransky, Ellen National Human Genome Research Institute (NHGRI) NHGRI Sidransky, Ellen (NHGRI) 1 114111110 Stubblefield, Barbara National Human Genome Research Institute (NHGRI) NHGRI Stubblefield, Barbara (NHGRI) 0 114102741 Fibroblast Cell Lines Homozygous For Glucocerebrosidase (GBA1) Mutation N370S E-059-2014-0 Research Material National Human Genome Research Institute (NHGRI) 83718085 Surabian, Karen karen.surabian@nih.gov
United States of America Technology Transfer Office (TTO) karen.surabian@nih.gov?subject=Web Inquiry on [TAB-3636] Fibroblast Cell Lines Homozygous for Glucocerebrosidase (GBA1) Mutation N370S for the Screening of Small Molecules for Gaucher Disease Treatment&body=Please send me information about technology [TAB-3636] Fibroblast Cell Lines Homozygous for Glucocerebrosidase (GBA1) Mutation N370S for the Screening of Small Molecules for Gaucher Disease Treatment. Surabian, Karen<br><a href="mailto:karen.surabian@nih.gov?subject=Web Inquiry on [TAB-3636] Fibroblast Cell Lines Homozygous for Glucocerebrosidase (GBA1) Mutation N370S for the Screening of Small Molecules for Gaucher Disease Treatment&body=Please send me information about technology [TAB-3636] Fibroblast Cell Lines Homozygous for Glucocerebrosidase (GBA1) Mutation N370S for the Screening of Small Molecules for Gaucher Disease Treatment.">karen.surabian@nih.gov</a><br> 114129020 VPXXXX 114129021 WIXXXX 114129022 WKXXXX 114129023 XHXXXX 114153922 Fibroblast 114153923 Cell 114153924 Lines 114153925 HOMOZYGOUS 114153926 GLUCOCEREBROSIDASE 114153927 GBA1 114153928 MUTATION 114153929 N370S 114153930 Listed LPM Vepa as of 4/15/2015 114153931 Pre LPM working set 20150418 114153932 Post LPM Assignment Set 20150420 TAB-3637 114097490 Human Fibroblast Cell Lines Heterozygous for Glucocerebrosidase (GBA1) Mutation N370S for the Study of Neurodegenerative Disorders and their Treatments NHGRI Neurology, Research Materials, Therapeutics Neurology Research Materials Therapeutics Grisel Lopez, Ellen Sidransky, Barbara Stubblefield This technology includes six cell lines for the study of Glucocerebrosidase (GBA1) mutations which could be used for the evaluation and eventual treatments for conditions such as Gaucher's disease and Parkinson's disease. GBA1 is a lysosomal enzyme, responsible for breakdown of a fatty material called glucocerebroside (or glucosyl ceramide). Deficiency or malfunction of GBA1 leads to the accumulation of insoluble glucocerebrosides (derived mostly from ingested red and white blood cell membranes) in tissues, which is a major symptom of Gaucher disease. Gaucher disease is a rare and heterogeneous disorder, caused by inherited GBA1 genetic mutations. The disease has been classified into three types, two of which include neurological abnormalities. There also appears to be a link between GBA1 mutations, Gaucher's disease and Parkinson's disease, thus, the insights gained from studying Gaucher's disease could allow for better understanding of other neurodegenerative disorders. The GBA1 N370S mutation is involved in non-neuronopathic type of Gaucher disease, thus the homozygous line can likely serve as a good control line for studying Parkinson’s disease and neurodegenerative disorders that involve other GBA1 mutations. These cell lines can be used to study the defects in GBA1 gene and protein and to screen small molecules for involvement in Gaucher disease and other neurodegenerative diseases involving GBA1. 2022-09-26 2024-10-28 2024-10-28 2022-09-26 2022-05-12 Cell, Fibroblast, GBA1, GLUCOCEREBROSIDASE, HETEROZYGOUS, Human, Lines, MUTATION, N370S, VEXXXX, WIXXXX, XEXXXX False True True NIHTT 37470483 Website Abstract 114111112 Lopez, Grisel National Human Genome Research Institute (NHGRI) NHGRI Lopez, Grisel (NHGRI) 0 114111113 Stubblefield, Barbara National Human Genome Research Institute (NHGRI) NHGRI Stubblefield, Barbara (NHGRI) 0 114111111 Sidransky, Ellen National Human Genome Research Institute (NHGRI) NHGRI Sidransky, Ellen (NHGRI) 1 114111111 Sidransky, Ellen National Human Genome Research Institute (NHGRI) NHGRI Sidransky, Ellen (NHGRI) 1 114111112 Lopez, Grisel National Human Genome Research Institute (NHGRI) NHGRI Lopez, Grisel (NHGRI) 0 114111113 Stubblefield, Barbara National Human Genome Research Institute (NHGRI) NHGRI Stubblefield, Barbara (NHGRI) 0 114102742 Human Fibroblast Cell Lines Heterozygous For Glucocerebrosidase (GBA1) Mutation N370S E-218-2020-0 Research Material National Human Genome Research Institute (NHGRI) 83718085 Surabian, Karen karen.surabian@nih.gov
United States of America Technology Transfer Office (TTO) karen.surabian@nih.gov?subject=Web Inquiry on [TAB-3637] Human Fibroblast Cell Lines Heterozygous for Glucocerebrosidase (GBA1) Mutation N370S for the Study of Neurodegenerative Disorders and their Treatments&body=Please send me information about technology [TAB-3637] Human Fibroblast Cell Lines Heterozygous for Glucocerebrosidase (GBA1) Mutation N370S for the Study of Neurodegenerative Disorders and their Treatments. Surabian, Karen<br><a href="mailto:karen.surabian@nih.gov?subject=Web Inquiry on [TAB-3637] Human Fibroblast Cell Lines Heterozygous for Glucocerebrosidase (GBA1) Mutation N370S for the Study of Neurodegenerative Disorders and their Treatments&body=Please send me information about technology [TAB-3637] Human Fibroblast Cell Lines Heterozygous for Glucocerebrosidase (GBA1) Mutation N370S for the Study of Neurodegenerative Disorders and their Treatments.">karen.surabian@nih.gov</a><br> 114129024 VEXXXX 114129025 WIXXXX 114129026 XEXXXX 114153933 Human 114153934 Fibroblast 114153935 Cell 114153936 Lines 114153937 HETEROZYGOUS 114153938 GLUCOCEREBROSIDASE 114153939 GBA1 114153940 MUTATION 114153941 N370S TAB-3633 114097486 Human Serous Endometrial Cancer Cell Lines CRISPR-edited to knock-in FBXW7 mutations for Use in Cancer related Molecular and Cellular Studies NHGRI Oncology, Research Materials, Therapeutics Oncology Research Materials Therapeutics Daphne Bell, Mary Urick This technology includes endometrial cancer cell lines for use in molecular and cellular studies to determine the effects of cancer-associated FBXW7 (F-box and WD repeat domain-containing 7) mutations, including but not limited to biochemical studies, proteomic studies, and drug sensitivity/resistance studies. Clustered Regularly Interspaced Palindromic Repeats (CRISPR) editing was used to knock-in individual FBXW7 mutations into the ARK1 serous EC cell line, which lacks detectable endogenous FBXW7 mutation(s). For each CRISPR-edited cell line, and parental ARK1 cells, STR (Short Tandem Repeat) profiles were generated. STR profiles of CRISPR-edited cell lines authenticated to the parental ARK1 line. The generation of ARK1 cell lines, CRISPR-edited to knock-in a FBXW7 mutation(s), provides unique reagents to use in molecular and cellular studies to determine the effects of cancer-associated FBXW7 mutations including but not limited to biochemical studies, proteomic studies, and drug sensitivity/resistance studies. Development of therapeutic targeting of dysregulated gene expression, protein expression, signal transduction, metabolomics linked to FBXW7 mutations in human endometrial cancer. 2022-09-26 2024-10-28 2024-10-28 2022-09-26 2022-05-12 CANCER, Cell, CRISPR-edited, endometrial, FBXW7, Human, Knock-in, Lines, Mutations, Serous, VCXXXX, WIXXXX, XEXXXX False True True NIHTT 37470483 Website Abstract 114111097 Urick, Mary National Human Genome Research Institute (NHGRI) NHGRI Urick, Mary (NHGRI) 0 114111096 Bell, Daphne National Human Genome Research Institute (NHGRI) NHGRI Bell, Daphne (NHGRI) 1 114111096 Bell, Daphne National Human Genome Research Institute (NHGRI) NHGRI Bell, Daphne (NHGRI) 1 114111097 Urick, Mary National Human Genome Research Institute (NHGRI) NHGRI Urick, Mary (NHGRI) 0 114102738 Human Serous Endometrial Cancer Cell Lines CRISPR-edited To Knock-in FBXW7 Mutations E-147-2018-0 Research Material National Human Genome Research Institute (NHGRI) 83716782 Campbell, Eggerton eggerton.campbell@nih.gov
United States of America eggerton.campbell@nih.gov?subject=Web Inquiry on [TAB-3633] Human Serous Endometrial Cancer Cell Lines CRISPR-edited to knock-in FBXW7 mutations for Use in Cancer related Molecular and Cellular Studies&body=Please send me information about technology [TAB-3633] Human Serous Endometrial Cancer Cell Lines CRISPR-edited to knock-in FBXW7 mutations for Use in Cancer related Molecular and Cellular Studies. Campbell, Eggerton<br><a href="mailto:eggerton.campbell@nih.gov?subject=Web Inquiry on [TAB-3633] Human Serous Endometrial Cancer Cell Lines CRISPR-edited to knock-in FBXW7 mutations for Use in Cancer related Molecular and Cellular Studies&body=Please send me information about technology [TAB-3633] Human Serous Endometrial Cancer Cell Lines CRISPR-edited to knock-in FBXW7 mutations for Use in Cancer related Molecular and Cellular Studies.">eggerton.campbell@nih.gov</a><br> 114129010 VCXXXX 114129011 WIXXXX 114129012 XEXXXX 114153899 Human 114153900 Serous 114153901 endometrial 114153902 CANCER 114153903 Cell 114153904 Lines 114153905 CRISPR-edited 114153906 Knock-in 114153907 FBXW7 114153908 Mutations TAB-3629 114097482 Human Fibroblast Cell Lines from Patients with Gangliosidosis Diseases for the Screening of Disease Therapeutics NHGRI Cardiology, Consumer Products, Dental, Diagnostics, Endocrinology, Infectious Disease, Neurology, Occupational Safety and Health, Oncology, Ophthalmology, Research Materials Cardiology Consumer Products Dental Diagnostics Endocrinology Infectious Disease Neurology Occupational Safety and Health Oncology Ophthalmology Research Materials Elena-Raluca Nicoli, Cynthia Tifft This technology includes cell lines from patients with gangliosidosis diseases for the screening of potential therapeutics. Gangliosidosis contains different types of lipid storage disorders caused by the accumulation of lipids known as gangliosides. GM1 gangliosidosis is an ultra-rare lysosomal storage disorder caused by mutations in galactosidase beta 1 (GLB1) that result in a deficiency of beta-galactosidase. GM2 gangliosidoses are a group of autosomal recessive lysosomal storage disorders caused by accumulation of GM2 ganglioside due to the absence or near absence of B-hexosamindase. GM2 gangliosidosis is caused by a loss of function mutation in the gene that codes for the alpha subunit of B-hexosamindase (HEXA), the beta subunit of B-hexosamindase (HEXB), or GM2 activator protein (GM2A). Mutations in these three genes cause the three forms of GM2 gangliosidosis - Tay Sachs disease, Sandhoff disease and GM2 activator protein deficiency, respectively. NHGRI investigators isolated fibroblasts from patients with lysosomal storage disorders who have various mutations in GLB1 or HEXA, and those lines are available for licensing. Novel cell lines for the development of novel therapeutics. These lines could be used for screening of possible disease therapeutics. 2022-09-26 2024-10-28 2024-10-28 2022-09-26 2022-05-12 Cell, DISEASES, Fibroblast, Gangllosldosls, Human, Lines, Patients, VEXXXX, VPXXXX, WBXXXX, WFXXXX, XCXXXX False True True NIHTT 37470483 Website Abstract 114111089 Nicoli, Elena-Raluca National Human Genome Research Institute (NHGRI) Nicoli, Elena-Raluca 0 114111088 Tifft, Cynthia National Human Genome Research Institute (NHGRI) NHGRI Tifft, Cynthia (NHGRI) 1 114111088 Tifft, Cynthia National Human Genome Research Institute (NHGRI) NHGRI Tifft, Cynthia (NHGRI) 1 114111089 Nicoli, Elena-Raluca National Human Genome Research Institute (NHGRI) Nicoli, Elena-Raluca 0 114102734 Human Fibroblast Cell Lines From Patients With Gangliosidosls Diseases; note Addendum with one more line and single inventor E-252-2020-0 Research Material National Human Genome Research Institute (NHGRI) 83703934 Solowiej, Anna anna.solowiej@nih.gov
United States of America anna.solowiej@nih.gov?subject=Web Inquiry on [TAB-3629] Human Fibroblast Cell Lines from Patients with Gangliosidosis Diseases for the Screening of Disease Therapeutics&body=Please send me information about technology [TAB-3629] Human Fibroblast Cell Lines from Patients with Gangliosidosis Diseases for the Screening of Disease Therapeutics. Solowiej, Anna<br><a href="mailto:anna.solowiej@nih.gov?subject=Web Inquiry on [TAB-3629] Human Fibroblast Cell Lines from Patients with Gangliosidosis Diseases for the Screening of Disease Therapeutics&body=Please send me information about technology [TAB-3629] Human Fibroblast Cell Lines from Patients with Gangliosidosis Diseases for the Screening of Disease Therapeutics.">anna.solowiej@nih.gov</a><br> 114128998 VEXXXX 114128999 VPXXXX 114129000 WBXXXX 114129001 WFXXXX 114129002 XCXXXX 114153868 Human 114153869 Fibroblast 114153870 Cell 114153871 Lines 114153872 Patients 114153873 Gangllosldosls 114153874 DISEASES TAB-3630 114097483 Murine Models of an Autoinflammatory Disease, Familial Mediterranean Fever (FMF), to Study the Pathophysiology of Inherited Disorders of Inflammation and Evaluate New Therapies NHGRI Cardiology, Dental, Endocrinology, Infectious Disease, Oncology, Ophthalmology, Research Materials, Therapeutics Cardiology Dental Endocrinology Infectious Disease Oncology Ophthalmology Research Materials Therapeutics Jae Chae, Daniel ("Dan") Kastner This technology includes mouse models (heterozygous for the knock-in (KI) and homozygous for the knock-out (KO)) to be used as research reagents and to study molecular mechanisms and potential therapies for Familial Mediterranean fever (FMF). FMF is the prototype of a group of inherited disorders characterized by recurring, spontaneous episodes of fever and localized inflammation. The gene responsible for FMF is composed of 10 exons encoding a 781 amino acid protein known as pyrin. In addition to FMF, some recent findings show that an abnormal activation of the pyrin inflammasome is the inflammation inducing factor for seemingly distinct autoinflammatory disorder, hyperimmunoglobulinemia D syndrome, and a mutation in pyrin is also a genetic risk factor for pyrin-associated autoinflammation and neutrophilic dermatosis. Thus, these murine models may be used to evaluate other autoinflammatory disorders in addition to FMF. Previous pyrin-deficient mice models develop normally and exhibit no overt phenotype; however, these models support a gain-of-function model with a gene-dosage effect, display varying disease severity, and can be used to investigate innate immune responses in autoinflammatory diseases other than FMF. Mice models provide a much-needed tool to study the pathophysiology of inherited disorders of inflammation and to evaluate new therapies. 2022-09-26 2024-10-28 2024-10-28 2022-09-26 2022-05-12 Autoinfla~-~atory, Autoinflamatory, Disease, FAMILIAL, FEVER, FMF, MEDITERRANEAN, Models, Murine, VPXXXX, WIXXXX, XEXXXX False True True NIHTT 37470483 Website Abstract 114172788 Park Y, Wood G, et al. https://pubmed.ncbi.nlm.nih.gov/27270401/ <a href="https://pubmed.ncbi.nlm.nih.gov/27270401/">Park Y, Wood G, et al.</a> 114172789 Chae J, Cho Y-H, et al https://pubmed.ncbi.nlm.nih.gov/21600797/ <a href="https://pubmed.ncbi.nlm.nih.gov/21600797/">Chae J, Cho Y-H, et al</a> 114172790 Chae J, Komarow H, et al. https://pubmed.ncbi.nlm.nih.gov/12667444/ <a href="https://pubmed.ncbi.nlm.nih.gov/12667444/">Chae J, Komarow H, et al.</a> 114111091 Chae, Jae National Human Genome Research Institute (NHGRI) NHGRI Chae, Jae (NHGRI) 0 114111090 Kastner, Daniel ("Dan") National Human Genome Research Institute (NHGRI) NHGRI Kastner, Daniel ("Dan") (NHGRI) 1 114111090 Kastner, Daniel ("Dan") National Human Genome Research Institute (NHGRI) NHGRI Kastner, Daniel ("Dan") (NHGRI) 1 114111091 Chae, Jae National Human Genome Research Institute (NHGRI) NHGRI Chae, Jae (NHGRI) 0 114102735 Murine Models Of An Autoinflamatory Disease Familial Mediterranean Fever (FMF) E-284-2016-0 Research Material National Human Genome Research Institute (NHGRI) 83716782 Campbell, Eggerton eggerton.campbell@nih.gov
United States of America eggerton.campbell@nih.gov?subject=Web Inquiry on [TAB-3630] Murine Models of an Autoinflammatory Disease, Familial Mediterranean Fever (FMF), to Study the Pathophysiology of Inherited Disorders of Inflammation and Evaluate New Therapies&body=Please send me information about technology [TAB-3630] Murine Models of an Autoinflammatory Disease, Familial Mediterranean Fever (FMF), to Study the Pathophysiology of Inherited Disorders of Inflammation and Evaluate New Therapies. Campbell, Eggerton<br><a href="mailto:eggerton.campbell@nih.gov?subject=Web Inquiry on [TAB-3630] Murine Models of an Autoinflammatory Disease, Familial Mediterranean Fever (FMF), to Study the Pathophysiology of Inherited Disorders of Inflammation and Evaluate New Therapies&body=Please send me information about technology [TAB-3630] Murine Models of an Autoinflammatory Disease, Familial Mediterranean Fever (FMF), to Study the Pathophysiology of Inherited Disorders of Inflammation and Evaluate New Therapies.">eggerton.campbell@nih.gov</a><br> 114129003 VPXXXX 114129004 WIXXXX 114129005 XEXXXX 114153875 Murine 114153876 Models 114153877 Autoinfla~-~atory 114153878 Disease 114153879 FAMILIAL 114153880 MEDITERRANEAN 114153881 FEVER 114153882 FMF 114153883 Autoinflamatory TAB-3626 114097479 Synthetic Genes for the Treatment of Propionic Acidemia (PA) Caused by Mutations in Propionyl-coA Carboxylase Beta (PCCB) NHGRI Cardiology, Dental, Endocrinology, Infectious Disease, Oncology, Ophthalmology, Research Materials, Therapeutics Cardiology Dental Endocrinology Infectious Disease Oncology Ophthalmology Research Materials Therapeutics Randy Chandler, Charles Venditti This technology includes a new set of synthetic PCCB genes that can be used to treat propionic acidemia (PA) caused by propionyl-coA carboxylase beta (PCCB) mutations. The amino acid sequence of PCCB was reverse translated, using a variety of algorithms and expert input, to generate novel DNA sequences encoding PCCB (synPCCB1-5) expected to have increased expression. Next, the synPCCB sequences were cloned into a canonical adeno-associated virus (AAV) vector and tested for expression in human cells to demonstrate that the codon optimized alleles showed improved expression compared to the wild type (WT) PCCB gene. Finally, a synPCCBl AAV was pseudoserotyped with a serotype 9 capsid and used to rescue Pech-I- knock-out mice from neonatal lethality and improve their clinical and metabolic phenotypes. As these alleles are synthetic and express at higher levels than the WT PCCB allele, they have multiple advantages such as being useful for genomic medication applications, creation of vectors for genome editing, and specific nucleotide based-assays are possible for improved detection of the DNA and RNA expressed from these genes. These alleles will be useful to develop new therapies for propionic acidemia including AAV, genome editing and mRNA therapies. 2022-09-26 2024-10-28 2024-10-28 2022-09-26 2022-05-12 Acidemia, ALPHA, Beta, Carboxylase, CAUSED, GENES, Mutations, PA, Pccb, Propionic, Propionyl-CoA, Synthetic, treatment, VPXXXX, WIXXXX, XEXXXX False True True NIHTT 37470483 Website Abstract 114111082 Chandler, Randy National Human Genome Research Institute (NHGRI) NHGRI Chandler, Randy (NHGRI) 0 114111083 Venditti, Charles National Human Genome Research Institute (NHGRI) NHGRI Venditti, Charles (NHGRI) 1 114111083 Venditti, Charles National Human Genome Research Institute (NHGRI) NHGRI Venditti, Charles (NHGRI) 1 114111082 Chandler, Randy National Human Genome Research Institute (NHGRI) NHGRI Chandler, Randy (NHGRI) 0 114102731 Synthetic Genes For The Treatment Propionic Acidemia (PA) Caused By Mutations In Propionyl-coA Carboxylase Beta (PCCB) E-175-2019-0 Filing authorized National Human Genome Research Institute (NHGRI) 83716782 Campbell, Eggerton eggerton.campbell@nih.gov
United States of America eggerton.campbell@nih.gov?subject=Web Inquiry on [TAB-3626] Synthetic Genes for the Treatment of Propionic Acidemia (PA) Caused by Mutations in Propionyl-coA Carboxylase Beta (PCCB)&body=Please send me information about technology [TAB-3626] Synthetic Genes for the Treatment of Propionic Acidemia (PA) Caused by Mutations in Propionyl-coA Carboxylase Beta (PCCB). Campbell, Eggerton<br><a href="mailto:eggerton.campbell@nih.gov?subject=Web Inquiry on [TAB-3626] Synthetic Genes for the Treatment of Propionic Acidemia (PA) Caused by Mutations in Propionyl-coA Carboxylase Beta (PCCB)&body=Please send me information about technology [TAB-3626] Synthetic Genes for the Treatment of Propionic Acidemia (PA) Caused by Mutations in Propionyl-coA Carboxylase Beta (PCCB).">eggerton.campbell@nih.gov</a><br> 114169470 E-175-2019-0 E-175-2019-0-US-01 Synthetic Genes For The Treatment Propionic Acidemia (PA) Caused By Mutations In Propionyl-coA Carboxylase Alpha (PCCB) PRV US 62/915,347 Abandoned US <br />Provisional (PRV) 62/915,347<br />Filed on 2019-10-15<br />Status: Abandoned 114169471 E-175-2019-0 E-175-2019-0-PCT-02 SYNTHETIC GENES FOR THE TREATMENT OF PROPIONIC ACIDEMIA CAUSED BY MUTATIONS IN PROPIONYL-COA CARBOXYLASE BETA PCT Patent Cooperation Treaty PCT/US2020/055836 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2020/055836<br />Filed on 2020-10-15<br />Status: Expired 114169472 E-175-2019-0 E-175-2019-0-US-04 SYNTHETIC GENES FOR THE TREATMENT OF PROPIONIC ACIDEMIA CAUSED BY MUTATIONS IN PROPIONYL-COA CARBOXYLASE BETA National Stage US 17/766,067 Abandoned US <br />National Stage 17/766,067<br />Filed on 2022-04-01<br />Status: Abandoned 114128987 VPXXXX 114128988 WIXXXX 114128989 XEXXXX 114153818 Synthetic 114153819 GENES 114153820 treatment 114153821 Propionic 114153822 Acidemia 114153823 PA 114153824 CAUSED 114153825 Mutations 114153826 Propionyl-CoA 114153827 Carboxylase 114153828 ALPHA 114153829 Pccb 114153830 Beta TAB-3623 114097476 Novel mouse models of methylmalonic acidemia (MMA) : C57Bl6/Sv129 Mut-/- (full knock-out) and (C57Bl6/Sv129) FvBN Mut -/- (full knock-out) NHGRI Cardiology, Dental, Endocrinology, Infectious Disease, Oncology, Ophthalmology, Research Materials, Therapeutics Cardiology Dental Endocrinology Infectious Disease Oncology Ophthalmology Research Materials Therapeutics Randy Chandler, Charles Venditti Methylmalonic acidemia (MMA) is an autosomal recessive disorder caused by the deficiency of the mitochondrial enzyme methylmalonyl-CoA mutase (MUT). It is characterized by metabolic instability, multiorgan pathology, and poor prognosis for long-term survival. To study MMA caused by MUT deficiency, a series of murine models have been constructed using gene targeting and analyzed. The model is a full knock out of the mouse Mut gene that produces neonatal lethality on the C57Bl6/Sv129 background. Another embodiment of this allele is used to create a related mouse model of Mut deficiency that can survive the immediate neonatal period and therefore be used to study the effects of MMA on an older animal, which is larger and easier to manipulate. To derive this model, C57Bl6/Sv129 Mut +/- mice are crossed to FvBN mice to create (C57Bl6/Sv129) FvBN Mut +/- carriers, which are intercrossed to generate (C57Bl6/Sv129) FvBN Mut -/- in the G2. A subset of such full knock outs are viable and can be very useful for pathophysiology and to assess MUT therapeutics. This transgenic mouse model is a valuable research tool to further understand the pathological mechanism of MMA and can be used to develop and assess targeted treatments <ul> <li>Cells from these mice can be extracted and used to create in vitro and ex vivo models as well as stem cells</li> <li>This allele can be used to create new animal models, by combined it with germ line or viral transgenes, or small molecules</li> </ul> This transgenic mouse model is a valuable research tool to further understand the pathological mechanism of MMA and can be used to develop and assess targeted treatments. 2022-09-26 2024-10-28 2024-10-28 2022-09-26 2022-05-12 -/-, :, Acidemia, C57Bl6/Sv129, FULL, FvBN, KNOCK-OUT, Methylmalonic, MMA, Models, Mouse, MUT, Mut-/-, Novel, VPXXXX, WIXXXX, XEXXXX False True True NIHTT 37470483 Website Abstract 114172786 Chandler R, Sloan J https://pubmed.ncbi.nlm.nih.gov/17937813/ [PMID 17937813] <a href="https://pubmed.ncbi.nlm.nih.gov/17937813/ [PMID 17937813]">Chandler R, Sloan J</a> 114172787 Chandler R, Zerfas P https://pubmed.ncbi.nlm.nih.gov/19088183/ <a href="https://pubmed.ncbi.nlm.nih.gov/19088183/">Chandler R, Zerfas P</a> 114111077 Chandler, Randy National Human Genome Research Institute (NHGRI) NHGRI Chandler, Randy (NHGRI) 0 114111076 Venditti, Charles National Human Genome Research Institute (NHGRI) NHGRI Venditti, Charles (NHGRI) 1 114111076 Venditti, Charles National Human Genome Research Institute (NHGRI) NHGRI Venditti, Charles (NHGRI) 1 114111077 Chandler, Randy National Human Genome Research Institute (NHGRI) NHGRI Chandler, Randy (NHGRI) 0 114102728 Novel Mouse Models Of Methylmalonic Acidemia (MMA) : C57Bl6/Sv129 Mut-/- (full Knock-out) And (C57Bl6/Sv129) FvBN Mut -/- (full Knock-out) E-139-2016-0 Research Material National Human Genome Research Institute (NHGRI) 83716782 Campbell, Eggerton eggerton.campbell@nih.gov
United States of America eggerton.campbell@nih.gov?subject=Web Inquiry on [TAB-3623] Novel mouse models of methylmalonic acidemia (MMA) : C57Bl6/Sv129 Mut-/- (full knock-out) and (C57Bl6/Sv129) FvBN Mut -/- (full knock-out)&body=Please send me information about technology [TAB-3623] Novel mouse models of methylmalonic acidemia (MMA) : C57Bl6/Sv129 Mut-/- (full knock-out) and (C57Bl6/Sv129) FvBN Mut -/- (full knock-out). Campbell, Eggerton<br><a href="mailto:eggerton.campbell@nih.gov?subject=Web Inquiry on [TAB-3623] Novel mouse models of methylmalonic acidemia (MMA) : C57Bl6/Sv129 Mut-/- (full knock-out) and (C57Bl6/Sv129) FvBN Mut -/- (full knock-out)&body=Please send me information about technology [TAB-3623] Novel mouse models of methylmalonic acidemia (MMA) : C57Bl6/Sv129 Mut-/- (full knock-out) and (C57Bl6/Sv129) FvBN Mut -/- (full knock-out).">eggerton.campbell@nih.gov</a><br> 114128976 VPXXXX 114128977 WIXXXX 114128978 XEXXXX 114153779 Novel 114153780 Mouse 114153781 Models 114153782 Methylmalonic 114153783 Acidemia 114153784 MMA 114153785 : 114153786 C57Bl6/Sv129 114153787 Mut-/- 114153788 FULL 114153789 KNOCK-OUT 114153790 FvBN 114153791 MUT 114153792 -/- TAB-3624 114097477 Serum Protein Biomarkers that Predict the Response to Liver Directed Therapy in Methymalonic Acidemia (MMA) and Propionic Acidemia (PA) NHGRI Cardiology, Dental, Diagnostics, Endocrinology, Infectious Disease, Oncology, Ophthalmology, Research Materials, Therapeutics Cardiology Dental Diagnostics Endocrinology Infectious Disease Oncology Ophthalmology Research Materials Therapeutics Eirini (Irini) Manoli, Charles Venditti Isolated Methylmalonic Acidemia (MMA) comprises a relatively common and heterogeneous group of inborn errors of metabolism. The most common cause of isolated MMA is genetic deficiency of the enzyme methylmalonyl-coA mutase (MUT), which, unfortunately for the affected patients, is also the most clinically severe. NHGRI scientist have discovered biomarkers previously described cytokines that has never been associated with MMA or propionic acidemia (PA) such as FGF-21 (fibroblast like-growth factor - 21). The cytokines have been studied in patients with mitochondrial myopathies and other unrelated metabolic disorders, but never MMA. These cytokines have also been associated with mitochondrial dysfunction but never studied in MMA or PA. These new biomarkers could be used to measure the effects of any intervention on hepatic MUT or PCC activity and the effects of hepatic MUT or propionyl-Co A carboxylase (PCC) deficiency, and the secondary mitochondropathy associated with MUT and PCC deficiency. This is the only non-invasive, blood-based biomarker for monitoring mitochondrial dysfunction in MMA and PA. Monitor the effects of gene, mRNA, cell, small molecule, microbiome, or any other therapy for mitochondrial dysfunction, including MMA, PA, and vitamin B12 deficiency. 2022-09-26 2024-10-28 2024-10-28 2022-09-26 2022-05-12 Acidemia, Biomarkers, Directed, liver, Methymalonic, MMA, PREDICT, Protein, RESPONSE, SERUM, That, THERAPY, VPXXXX, WBXXXX, WIXXXX, XCXXXX, XEXXXX False True True NIHTT 37470483 Website Abstract 114111079 Manoli, Eirini (Irini) National Human Genome Research Institute (NHGRI) NHGRI Manoli, Eirini (Irini) (NHGRI) 0 114111078 Venditti, Charles National Human Genome Research Institute (NHGRI) NHGRI Venditti, Charles (NHGRI) 1 114111078 Venditti, Charles National Human Genome Research Institute (NHGRI) NHGRI Venditti, Charles (NHGRI) 1 114111079 Manoli, Eirini (Irini) National Human Genome Research Institute (NHGRI) NHGRI Manoli, Eirini (Irini) (NHGRI) 0 114102729 Serum Protein Biomarkers That Predict The Response To Liver Directed Therapy In Methymalonic Acidemia (MMA) E-149-2017-0 Filing authorized National Human Genome Research Institute (NHGRI) 83716782 Campbell, Eggerton eggerton.campbell@nih.gov
United States of America eggerton.campbell@nih.gov?subject=Web Inquiry on [TAB-3624] Serum Protein Biomarkers that Predict the Response to Liver Directed Therapy in Methymalonic Acidemia (MMA) and Propionic Acidemia (PA)&body=Please send me information about technology [TAB-3624] Serum Protein Biomarkers that Predict the Response to Liver Directed Therapy in Methymalonic Acidemia (MMA) and Propionic Acidemia (PA). Campbell, Eggerton<br><a href="mailto:eggerton.campbell@nih.gov?subject=Web Inquiry on [TAB-3624] Serum Protein Biomarkers that Predict the Response to Liver Directed Therapy in Methymalonic Acidemia (MMA) and Propionic Acidemia (PA)&body=Please send me information about technology [TAB-3624] Serum Protein Biomarkers that Predict the Response to Liver Directed Therapy in Methymalonic Acidemia (MMA) and Propionic Acidemia (PA).">eggerton.campbell@nih.gov</a><br> 114169464 E-149-2017-0 E-149-2017-0-US-01 Biomarkers of Organic Acidemias PRV US 62/556,071 Abandoned US <br />Provisional (PRV) 62/556,071<br />Filed on 2017-09-08<br />Status: Abandoned 114169465 E-149-2017-0 E-149-2017-0-PCT-02 BIOMARKERS OF ORGANIC ACIDEMIAS PCT Patent Cooperation Treaty PCT/US2018/049757 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2018/049757<br />Filed on 2018-09-06<br />Status: Expired 114169466 E-149-2017-0 E-149-2017-0-US-04 BIOMARKERS OF ORGANIC ACIDEMIAS National Stage US 11,372,004 16/641,994 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11372004 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11372004">11,372,004</a><br />Filed on 2020-02-25<br />Status: Issued 114128979 VPXXXX 114128980 WBXXXX 114128981 WIXXXX 114128982 XCXXXX 114128983 XEXXXX 114153793 SERUM 114153794 Protein 114153795 Biomarkers 114153796 That 114153797 PREDICT 114153798 RESPONSE 114153799 liver 114153800 Directed 114153801 THERAPY 114153802 Methymalonic 114153803 Acidemia 114153804 MMA TAB-3621 114097474 Novel mouse model of methylmalonic acidemia (MMA) Mut-/- Tg INS-Mck-Mut NHGRI Cardiology, Dental, Endocrinology, Infectious Disease, Oncology, Ophthalmology, Research Materials, Therapeutics Cardiology Dental Endocrinology Infectious Disease Oncology Ophthalmology Research Materials Therapeutics Randy Chandler, Eirini (Irini) Manoli, Charles Venditti Methylmalonic acidemia (MMA) is an autosomal recessive disorder, caused by the deficiency of the mitochondrial enzyme methylmalonyl-CoA mutase (MUT). It is characterized by metabolic instability, multiorgan pathology, and poor prognosis for long-term survival. Deletion of Mut in mice results in neonathal lethality, thus, to overcome this limitation, we have generated novel transgenic mice that have the Mut knockout background but express the Mut gene under the control of a muscle-specific creatine kinase promoter (Mut-/- Tg INS-Mck-Mut). These animals are viable but display massive elevations of serum metabolites, severe growth retardation, and precisely replicate the hepatorenal mitochondropathy and renal failure seen in patients. Mut-/-;TgINS-MCK-Mut mice are fragile and require a high carbohydrate, high fat diet as well as heating pads to survive, but despite these measures, only attain 40% of the bodyweight of age, sex and diet matched littermates. This transgenic mouse model is a valuable research tool to further understand the pathological mechanism of MMA, which can help in developing accurate diagnostics and more effective targeted treatments. These mice precisely replicate the most important features of MUT MMA in that they have total hepatic MUT deficiency, growth retardation, kidney disease, high levels of disease related metabolites, and diet sensitivity yet can be rescued with liver directed gene therapy, and thus they represent a unique reagent to test liver directed therapies for MUT MMA. This transgenic mouse model is a valuable research tool to further understand the pathological mechanism of MMA, which can help in developing accurate diagnostics and more effective targeted treatments. 2022-09-26 2024-10-28 2024-10-28 2022-09-26 2022-05-12 Acidemia, INS-Mck-Mut, Methylmalonic, MMA, Model, Mouse, Mut-/-, Novel, Tg, VPXXXX, WIXXXX, XEXXXX False True True NIHTT 37470483 Website Abstract 114111071 Manoli, Eirini (Irini) National Human Genome Research Institute (NHGRI) NHGRI Manoli, Eirini (Irini) (NHGRI) 0 114111072 Chandler, Randy National Human Genome Research Institute (NHGRI) NHGRI Chandler, Randy (NHGRI) 0 114111070 Venditti, Charles National Human Genome Research Institute (NHGRI) NHGRI Venditti, Charles (NHGRI) 1 114111070 Venditti, Charles National Human Genome Research Institute (NHGRI) NHGRI Venditti, Charles (NHGRI) 1 114111071 Manoli, Eirini (Irini) National Human Genome Research Institute (NHGRI) NHGRI Manoli, Eirini (Irini) (NHGRI) 0 114111072 Chandler, Randy National Human Genome Research Institute (NHGRI) NHGRI Chandler, Randy (NHGRI) 0 114102726 Novel Mouse Model Of Methylmalonic Acidemia (MMA) Mut-/- Tg INS-Mck-Mut E-141-2016-0 Research Material National Human Genome Research Institute (NHGRI) 83716782 Campbell, Eggerton eggerton.campbell@nih.gov
United States of America eggerton.campbell@nih.gov?subject=Web Inquiry on [TAB-3621] Novel mouse model of methylmalonic acidemia (MMA) Mut-/- Tg INS-Mck-Mut&body=Please send me information about technology [TAB-3621] Novel mouse model of methylmalonic acidemia (MMA) Mut-/- Tg INS-Mck-Mut. Campbell, Eggerton<br><a href="mailto:eggerton.campbell@nih.gov?subject=Web Inquiry on [TAB-3621] Novel mouse model of methylmalonic acidemia (MMA) Mut-/- Tg INS-Mck-Mut&body=Please send me information about technology [TAB-3621] Novel mouse model of methylmalonic acidemia (MMA) Mut-/- Tg INS-Mck-Mut.">eggerton.campbell@nih.gov</a><br> 114128970 VPXXXX 114128971 WIXXXX 114128972 XEXXXX 114153757 Novel 114153758 Mouse 114153759 Model 114153760 Methylmalonic 114153761 Acidemia 114153762 MMA 114153763 Mut-/- 114153764 Tg 114153765 INS-Mck-Mut TAB-3622 114097475 Novel mouse model of mut- methylmalonic acidemia (MMA) Mut-/- Tg CBAMutG715V : Mut partial-deficiency NHGRI Cardiology, Dental, Endocrinology, Infectious Disease, Oncology, Ophthalmology, Research Materials, Therapeutics Cardiology Dental Endocrinology Infectious Disease Oncology Ophthalmology Research Materials Therapeutics Randy Chandler, Eirini (Irini) Manoli, Charles Venditti Methylmalonic acidemia (MMA) is an autosomal recessive disorder, caused by the deficiency of the mitochondrial enzyme methylmalonyl-CoA mutase (MUT). It is characterized by metabolic instability, multiorgan pathology, and poor prognosis for long-term survival. A well-characterized human mutation, p.G717V, has been introduced into mice. This mutation has been characterized as a "pure" adenosylcobalamin Km mutation. NHGRI scientist have used site-directed mutagenesis to generate the homologous mouse mutation, p.G715V, and verified the kinetic properties of this mutant enzyme in vitro. They have determined that it possesses a similar defect in adenosylcobalamin binding as the human p.G717V enzyme. Partial deficiency animals are ideally suited to the study of disease mechanisms, pharmacogenomics and late onset disease manifestations of MMA. These mice are unique in that they are viable, can be bred in larger quantities than other mouse models, and are much more robust, yet display modest biochemical changes associated with MMA and can be induced to be very sick by a simple manipulation of dietary change. <ul> <li>The Mut-/- Tg CBAMutG715V mice are unique in that they are viable, can be bred in larger quantities than other mouse models, and are much more robust, yet display modest biochemical changes associated with MMA and can be induced to be very sick by a simple manipulation of dietary change.</li> <li>Mice have MMA-related disease processes in all the tissues and cells of the body.</li> </ul> Partial deficiency animals are ideally suited to the study of disease mechanisms, pharmacogenomics and late onset disease manifestations of MMA. 2022-09-26 2024-10-28 2024-10-28 2022-09-26 2022-05-12 :, Acidemia, CBAMutG715V, Methylmalonic, MMA, Model, Mouse, MUT, Mut-, Mut-/-, Novel, Partial-deficiency, Tg, VPXXXX, WIXXXX, XEXXXX False True True NIHTT 37470483 Website Abstract 114111074 Chandler, Randy National Human Genome Research Institute (NHGRI) NHGRI Chandler, Randy (NHGRI) 0 114111075 Manoli, Eirini (Irini) National Human Genome Research Institute (NHGRI) NHGRI Manoli, Eirini (Irini) (NHGRI) 0 114111073 Venditti, Charles National Human Genome Research Institute (NHGRI) NHGRI Venditti, Charles (NHGRI) 1 114111073 Venditti, Charles National Human Genome Research Institute (NHGRI) NHGRI Venditti, Charles (NHGRI) 1 114111074 Chandler, Randy National Human Genome Research Institute (NHGRI) NHGRI Chandler, Randy (NHGRI) 0 114111075 Manoli, Eirini (Irini) National Human Genome Research Institute (NHGRI) NHGRI Manoli, Eirini (Irini) (NHGRI) 0 114102727 Novel Mouse Model Of Mut- Methylmalonic Acidemia (MMA) Mut-/- Tg CBAMutG715V : Mut Partial-deficiency E-140-2016-0 Research Material National Human Genome Research Institute (NHGRI) 83716782 Campbell, Eggerton eggerton.campbell@nih.gov
United States of America eggerton.campbell@nih.gov?subject=Web Inquiry on [TAB-3622] Novel mouse model of mut- methylmalonic acidemia (MMA) Mut-/- Tg CBAMutG715V : Mut partial-deficiency&body=Please send me information about technology [TAB-3622] Novel mouse model of mut- methylmalonic acidemia (MMA) Mut-/- Tg CBAMutG715V : Mut partial-deficiency. Campbell, Eggerton<br><a href="mailto:eggerton.campbell@nih.gov?subject=Web Inquiry on [TAB-3622] Novel mouse model of mut- methylmalonic acidemia (MMA) Mut-/- Tg CBAMutG715V : Mut partial-deficiency&body=Please send me information about technology [TAB-3622] Novel mouse model of mut- methylmalonic acidemia (MMA) Mut-/- Tg CBAMutG715V : Mut partial-deficiency.">eggerton.campbell@nih.gov</a><br> 114128973 VPXXXX 114128974 WIXXXX 114128975 XEXXXX 114153766 Novel 114153767 Mouse 114153768 Model 114153769 Mut- 114153770 Methylmalonic 114153771 Acidemia 114153772 MMA 114153773 Mut-/- 114153774 Tg 114153775 CBAMutG715V 114153776 : 114153777 MUT 114153778 Partial-deficiency TAB-3618 114097471 Non-invasive Isotopic Biomarkers that Predict the Response to Liver Directed Therapy in Methymalonic Acidemia (MMA) and Propionic Acidemia (PA) NHGRI Cardiology, Consumer Products, Dental, Diagnostics, Endocrinology, Infectious Disease, Occupational Safety and Health, Oncology, Ophthalmology, Research Materials Cardiology Consumer Products Dental Diagnostics Endocrinology Infectious Disease Occupational Safety and Health Oncology Ophthalmology Research Materials Eirini (Irini) Manoli, Charles Venditti Isolated Methylmalonic Acidemia (MMA) comprises a relatively common and heterogeneous group of inborn errors of metabolism. The most common cause of isolated MMA is genetic deficiency of the enzyme methylmalonyl-coA mutase (MUT), which, unfortunately for the affected patients, is also the most clinically severe. NHGRI scientist have invented a series of assays to assess hepatic MUT activity using a stable isotopic tracing assays to measure MUT function to assess corrective therapy on hepatic mitochondrial function. The assays involve preparation of the isotope, mixing the isotope, dosing the isotope, collecting breaths from the patient, measuring the enrichment of the isotope in expired CO2, and then calculating the dose recovered/percent oxidized. These assays could be applied to propionate oxidation disorders, including all forms of propionic acidemia, methylmalonic acidemia, cobalamin defects ( cblA-J), vitamin B12 and biotin deficiency; disorders that affect hepatic mitochondrial metabolism; for testing the effects of drugs that affect hepatic metabolism. This is the only non-invasive, VCO2, label dosing, breath collection, measurement of 1-C-13 enrichment and calculations Monitor mitochondrial dysfunction responses to therapeutics before showing clinical symptoms of the late stage kidney failure. 2022-09-26 2024-10-28 2024-10-28 2022-09-26 2022-05-12 Acidemia, Biomarkers, Directed, ISOTOPIC, liver, Methymalonic, MMA, NON-INVASIVE, PREDICT, RESPONSE, That, THERAPY, VPXXXX, WFXXXX, WIXXXX, XCXXXX False True True NIHTT 37470483 Website Abstract 114111065 Manoli, Eirini (Irini) National Human Genome Research Institute (NHGRI) NHGRI Manoli, Eirini (Irini) (NHGRI) 0 114111064 Venditti, Charles National Human Genome Research Institute (NHGRI) NHGRI Venditti, Charles (NHGRI) 1 114111064 Venditti, Charles National Human Genome Research Institute (NHGRI) NHGRI Venditti, Charles (NHGRI) 1 114111065 Manoli, Eirini (Irini) National Human Genome Research Institute (NHGRI) NHGRI Manoli, Eirini (Irini) (NHGRI) 0 114102723 Non-invasive Isotopic Biomarkers That Predict The Response To Liver Directed Therapy In Methymalonic Acidemia (MMA) E-148-2017-0 Filing authorized National Human Genome Research Institute (NHGRI) 83716782 Campbell, Eggerton eggerton.campbell@nih.gov
United States of America eggerton.campbell@nih.gov?subject=Web Inquiry on [TAB-3618] Non-invasive Isotopic Biomarkers that Predict the Response to Liver Directed Therapy in Methymalonic Acidemia (MMA) and Propionic Acidemia (PA)&body=Please send me information about technology [TAB-3618] Non-invasive Isotopic Biomarkers that Predict the Response to Liver Directed Therapy in Methymalonic Acidemia (MMA) and Propionic Acidemia (PA). Campbell, Eggerton<br><a href="mailto:eggerton.campbell@nih.gov?subject=Web Inquiry on [TAB-3618] Non-invasive Isotopic Biomarkers that Predict the Response to Liver Directed Therapy in Methymalonic Acidemia (MMA) and Propionic Acidemia (PA)&body=Please send me information about technology [TAB-3618] Non-invasive Isotopic Biomarkers that Predict the Response to Liver Directed Therapy in Methymalonic Acidemia (MMA) and Propionic Acidemia (PA).">eggerton.campbell@nih.gov</a><br> 114169459 E-148-2017-0 E-148-2017-0-US-01 ISOTOPIC BIOMARKERS OF ORGANIC ACIDEMIAS PRV US 62/579,247 Abandoned US <br />Provisional (PRV) 62/579,247<br />Filed on 2017-10-31<br />Status: Abandoned 114169460 E-148-2017-0 E-148-2017-0-PCT-02 ISOTOPIC BIOMARKERS OF ORGANIC ACIDEMIAS PCT Patent Cooperation Treaty PCT/US2018/058515 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2018/058515<br />Filed on 2018-10-31<br />Status: Expired 114169461 E-148-2017-0 E-148-2017-0-US-04 ISOTOPIC BIOMARKERS OF ORGANIC ACIDEMIAS National Stage US 16/758,009 Pending US <br />National Stage 16/758,009<br />Filed on 2020-04-21<br />Status: Pending 114128958 VPXXXX 114128959 WFXXXX 114128960 XCXXXX 114128961 WIXXXX 114153713 MMA 114153714 Acidemia 114153715 Methymalonic 114153716 THERAPY 114153717 Directed 114153718 liver 114153719 RESPONSE 114153720 PREDICT 114153721 That 114153722 Biomarkers 114153723 ISOTOPIC 114153724 NON-INVASIVE TAB-3619 114097472 Novel Adeno-associated Viral (AAV) Vectors to Treat Hereditary Methylmalonic Acidemia (MMA) Caused by Methylmalonyl-coA Mutase (MMUT) Deficiency NHGRI Cardiology, Dental, Endocrinology, Infectious Disease, Oncology, Ophthalmology, Research Materials, Therapeutics Cardiology Dental Endocrinology Infectious Disease Oncology Ophthalmology Research Materials Therapeutics Randy Chandler, Charles Venditti Deficiency of the enzyme in methylmalonyl-CoA mutase (MMUT) results is a life-threatening disease, methylmalonic acidemia (MMA), that carries high rates of morbidity and mortality. NHGRI scientists have developed novel AAV vectors that combine the proprietary codon-optimized synMMUT alleles with either a liver-specific promoter from the human alpha-1 antitrypsin (hAA T) locus to produce a vector that directs MMUT protein expression in a liver-specific fashion or the human elongation factor 1a (EF1 alpha) promoter to produce a vector that expresses the MMUT protein at moderate levels in a global fashion, including the liver. These AAV vectors have high potency in vivo, and therefore represent a class of new gene therapies that might be given to patients with MMA. The AAV constructs developed and enabled as serotype 8 or 9 vectors could be immediately translated to the clinic. The lead AAV developed and enabled as serotype 8 or 9 vectors could be immediately translated to the clinic. This technology enables systemic gene therapy for MMUT type MMA, the most common form of this devastating inborn error of metabolism. 2022-09-26 2024-10-28 2024-10-28 2022-09-26 2022-05-12 AAV, Acidemia, Adeno-associated, CAUSED, DEFICIENCY, Hereditary, Methylmalonic, Methylmalonyl-CoA, MMA, Mmut, Mutase, Novel, TREAT, vectors, viral, VPXXXX, WIXXXX, WJXXXX, XEXXXX False True True NIHTT 37470483 Website Abstract 114111067 Chandler, Randy National Human Genome Research Institute (NHGRI) NHGRI Chandler, Randy (NHGRI) 0 114111066 Venditti, Charles National Human Genome Research Institute (NHGRI) NHGRI Venditti, Charles (NHGRI) 1 114111066 Venditti, Charles National Human Genome Research Institute (NHGRI) NHGRI Venditti, Charles (NHGRI) 1 114111067 Chandler, Randy National Human Genome Research Institute (NHGRI) NHGRI Chandler, Randy (NHGRI) 0 114102724 Novel Adeno-associated Viral (AAV) Vectors To Treat Hereditary Methylmalonic Acidemia (MMA) Caused By Methylmalonyl-coA Mutase (MMUT) Deficiency E-167-2020-0 Filing authorized National Human Genome Research Institute (NHGRI) 83716782 Campbell, Eggerton eggerton.campbell@nih.gov
United States of America eggerton.campbell@nih.gov?subject=Web Inquiry on [TAB-3619] Novel Adeno-associated Viral (AAV) Vectors to Treat Hereditary Methylmalonic Acidemia (MMA) Caused by Methylmalonyl-coA Mutase (MMUT) Deficiency&body=Please send me information about technology [TAB-3619] Novel Adeno-associated Viral (AAV) Vectors to Treat Hereditary Methylmalonic Acidemia (MMA) Caused by Methylmalonyl-coA Mutase (MMUT) Deficiency. Campbell, Eggerton<br><a href="mailto:eggerton.campbell@nih.gov?subject=Web Inquiry on [TAB-3619] Novel Adeno-associated Viral (AAV) Vectors to Treat Hereditary Methylmalonic Acidemia (MMA) Caused by Methylmalonyl-coA Mutase (MMUT) Deficiency&body=Please send me information about technology [TAB-3619] Novel Adeno-associated Viral (AAV) Vectors to Treat Hereditary Methylmalonic Acidemia (MMA) Caused by Methylmalonyl-coA Mutase (MMUT) Deficiency.">eggerton.campbell@nih.gov</a><br> 114169462 E-167-2020-0 E-167-2020-0-US-01 Novel Adeno-associated Viral (AAV) Vectors To Treat Hereditary Methylmalonic Acidemia (MMA) Caused By Methylmalonyl-coA Mutase (MMUT) Deficiency PRV US 63/080,337 Abandoned US <br />Provisional (PRV) 63/080,337<br />Filed on 2020-09-18<br />Status: Abandoned 114169463 E-167-2020-0 E-167-2020-0-PCT-02 Novel Adeno-associated Viral (AAV) Vectors To Treat Hereditary Methylmalonic Acidemia (MMA) Caused By Methylmalonyl-coA Mutase (MMUT) Deficiency PCT Patent Cooperation Treaty PCT/US2021/050699 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/050699<br />Filed on 2021-09-16<br />Status: Expired 114128962 VPXXXX 114128963 WIXXXX 114128964 WJXXXX 114128965 XEXXXX 114153725 Novel 114153726 Adeno-associated 114153727 viral 114153728 AAV 114153729 vectors 114153730 TREAT 114153731 Hereditary 114153732 Methylmalonic 114153733 Acidemia 114153734 MMA 114153735 CAUSED 114153736 Methylmalonyl-CoA 114153737 Mutase 114153738 Mmut 114153739 DEFICIENCY TAB-3616 114097469 Mmut P.R106C/P.R106C Knock-In Methylmalonyl-CoA Mutase (Mmut) Allele mouse models for the Study of Methylmalonic Acidemia (MMA) NHGRI Cardiology, Dental, Endocrinology, Infectious Disease, Oncology, Ophthalmology, Research Materials, Therapeutics Cardiology Dental Endocrinology Infectious Disease Oncology Ophthalmology Research Materials Therapeutics Randy Chandler, Jessica Schneller, Charles Venditti Isolated Methylmalonic Acidemia (MMA) comprises a relatively common and heterogeneous group of inborn errors of metabolism. In order to create mouse models of MMA to resemble the pathogenic mutations seen in patients, the NHGRI scientist used genome editing to generate new mutants of the Mmut allele - p.R106C. This allele recapitulates a missense mutation seen in multiple patients with the disorder. Of note and emphasis is the fact that there are no transgene cassettes or other alternations to the Mmut locus in these new mouse models. These mice display elevations of MMA biomarkers, such as 2-methylcitrate, are viable, without obvious gross pathology, and fully fertile, they can be easily bred. These new models can be used for physiology studies, biomarker discovery, and to test the effects of gene therapy, cell therapy, mRNA therapy, nucleic acid therapies, small molecules, the microbiome, and especially genome editing using AAV, Cas/CRISPR, and other editing approaches as treatments for MMA and related conditions. The mouse models are especially unique in that they more closely mimic the nature of mutations seen in patients and they can be bred in larger quantities than other mouse models and genotyped using digital droplet PCR. They also have MMA related disease processes in all the tissues and cells of the body. Furthermore, we have demonstrated the utility of these mice to test AAV gene therapy as a therapeutic intervention. These new models can be used for physiology studies, biomarker discovery, and to test the effects of gene therapy, cell therapy, mRNA therapy, nucleic acid therapies, small molecules, the microbiome, and especially genome editing using adeno-associated viruses (AAV), Cas/CRISPR, and other editing approaches as treatments for MMA and related conditions. 2022-09-26 2024-10-28 2024-10-28 2022-09-26 2022-05-12 Acidemia, ALLELE, Knock-in, Methylmalonic, Methylmalonyl-CoA, MMA, Mmut, MutaseMmut, P.R106C, P.R106C/, VPXXXX, WIXXXX, XEXXXX False True True NIHTT 37470483 Website Abstract 114111060 Schneller, Jessica National Human Genome Research Institute (NHGRI) NHGRI Schneller, Jessica (NHGRI) 0 114111061 Chandler, Randy National Human Genome Research Institute (NHGRI) NHGRI Chandler, Randy (NHGRI) 0 114111059 Venditti, Charles National Human Genome Research Institute (NHGRI) NHGRI Venditti, Charles (NHGRI) 1 114111059 Venditti, Charles National Human Genome Research Institute (NHGRI) NHGRI Venditti, Charles (NHGRI) 1 114111060 Schneller, Jessica National Human Genome Research Institute (NHGRI) NHGRI Schneller, Jessica (NHGRI) 0 114111061 Chandler, Randy National Human Genome Research Institute (NHGRI) NHGRI Chandler, Randy (NHGRI) 0 114102721 Mmut P.R106C/ P.R106C Knock-In Methylmalonyl-CoA Mutase (Mmut) Allele For The Study Of Methylmalonic Acidemia (MMA) E-159-2020-0 Research Material National Human Genome Research Institute (NHGRI) 83716782 Campbell, Eggerton eggerton.campbell@nih.gov
United States of America eggerton.campbell@nih.gov?subject=Web Inquiry on [TAB-3616] Mmut P.R106C/P.R106C Knock-In Methylmalonyl-CoA Mutase (Mmut) Allele mouse models for the Study of Methylmalonic Acidemia (MMA)&body=Please send me information about technology [TAB-3616] Mmut P.R106C/P.R106C Knock-In Methylmalonyl-CoA Mutase (Mmut) Allele mouse models for the Study of Methylmalonic Acidemia (MMA). Campbell, Eggerton<br><a href="mailto:eggerton.campbell@nih.gov?subject=Web Inquiry on [TAB-3616] Mmut P.R106C/P.R106C Knock-In Methylmalonyl-CoA Mutase (Mmut) Allele mouse models for the Study of Methylmalonic Acidemia (MMA)&body=Please send me information about technology [TAB-3616] Mmut P.R106C/P.R106C Knock-In Methylmalonyl-CoA Mutase (Mmut) Allele mouse models for the Study of Methylmalonic Acidemia (MMA).">eggerton.campbell@nih.gov</a><br> 114128952 VPXXXX 114128953 WIXXXX 114128954 XEXXXX 114153695 Mmut 114153696 P.R106C/ 114153697 P.R106C 114153698 Knock-in 114153699 Methylmalonyl-CoA 114153700 MutaseMmut 114153701 ALLELE 114153702 Methylmalonic 114153703 Acidemia 114153704 MMA TAB-3617 114097470 Propionyl-CoA Carboxylase Beta (PCCB) Alleles in Propionic Acidemia (PA) mouse models NHGRI Cardiology, Dental, Endocrinology, Infectious Disease, Oncology, Ophthalmology, Research Materials, Therapeutics Cardiology Dental Endocrinology Infectious Disease Oncology Ophthalmology Research Materials Therapeutics Randy Chandler, Charles Venditti Propionic acidemia (PA) is an autosomal recessive metabolic disorder caused by mutations in either Propionyl-CoA carboxylase alpha (PCCA) or Propionyl-CoA carboxylase beta (PCCB). The products of these genes form the alpha and beta subunits of the enzyme propionyl-Co A carboxylase (PCC), a critically important mitochondrial enzyme involved in the catabolism of branched chain amino acids. NHGRI scientist have developed new mouse models that recapitulate the human clinical phenotype of severe propionic acidemia caused by PCCB deficiency, namely neonatal lethality and increased propionyl-CoA derived metabolites. These new PCCB alleles are the first described and can be used to model the spectrum of clinically important features of PA, and support testing of new treatments, including adeno-associated virus (AAV) gene therapy, mRNA therapy, genome editing, base editing, mRNA editing, small molecules, enzyme replacement therapy, and microbiome targeted therapies. These new mouse models recapitulate the severe mutations seen in patients and do not rely upon gene replacement. Carriers of these new PCCB mutations are fully fertile and can be easily bred and genotyped using fluorescent or conventional PCR. These alleles will be useful to study new therapies for PA. 2022-09-26 2024-10-28 2024-10-28 2022-09-26 2022-05-12 Acidemia, ALLELES, Beta, Carboxylase, PA, Pccb, Propionic, Propionyl-CoA, VPXXXX, WIXXXX, XEXXXX False True True NIHTT 37470483 Website Abstract 114111063 Chandler, Randy National Human Genome Research Institute (NHGRI) NHGRI Chandler, Randy (NHGRI) 0 114111062 Venditti, Charles National Human Genome Research Institute (NHGRI) NHGRI Venditti, Charles (NHGRI) 1 114111062 Venditti, Charles National Human Genome Research Institute (NHGRI) NHGRI Venditti, Charles (NHGRI) 1 114111063 Chandler, Randy National Human Genome Research Institute (NHGRI) NHGRI Chandler, Randy (NHGRI) 0 114102722 New Propionyl-CoA Carboxylase Beta (Pccb) Alleles For The Study Of Propionic Acidemia (PA) E-030-2019-0 Research Material National Human Genome Research Institute (NHGRI) 83716782 Campbell, Eggerton eggerton.campbell@nih.gov
United States of America eggerton.campbell@nih.gov?subject=Web Inquiry on [TAB-3617] Propionyl-CoA Carboxylase Beta (PCCB) Alleles in Propionic Acidemia (PA) mouse models&body=Please send me information about technology [TAB-3617] Propionyl-CoA Carboxylase Beta (PCCB) Alleles in Propionic Acidemia (PA) mouse models. Campbell, Eggerton<br><a href="mailto:eggerton.campbell@nih.gov?subject=Web Inquiry on [TAB-3617] Propionyl-CoA Carboxylase Beta (PCCB) Alleles in Propionic Acidemia (PA) mouse models&body=Please send me information about technology [TAB-3617] Propionyl-CoA Carboxylase Beta (PCCB) Alleles in Propionic Acidemia (PA) mouse models.">eggerton.campbell@nih.gov</a><br> 114128955 VPXXXX 114128956 WIXXXX 114128957 XEXXXX 114153705 PA 114153706 Acidemia 114153707 Propionic 114153708 ALLELES 114153709 Pccb 114153710 Beta 114153711 Carboxylase 114153712 Propionyl-CoA TAB-3614 114097467 Mmut p.G715v/p.G71 Knock-ln Methylmalonyl-CoA Mutase (Mmut) Allele Mouse Models for the Study of Methylmalonic Acidemia (MMA) NHGRI Cardiology, Dental, Endocrinology, Infectious Disease, Oncology, Ophthalmology, Research Materials, Therapeutics Cardiology Dental Endocrinology Infectious Disease Oncology Ophthalmology Research Materials Therapeutics Randy Chandler, Jessica Schneller, Charles Venditti Isolated Methylmalonic Acidemia (MMA) comprises a relatively common and heterogeneous group of inborn errors of metabolism. In order to create mouse models of MMA to resemble the pathogenic mutations seen in patients, the NHGRI scientist used genome editing to generate new mutants of Mmut allele -p.G715V. This allele recapitulates a missense mutation seen in multiple patients with the disorder. Of note and emphasis is the fact that there are no transgene cassettes or other alternations to the Mmut locus in these new mouse models. These mice display elevations of MMA biomarkers, such as 2-methylcitrate, are viable, without obvious gross pathology, and fully fertile, they can be easily bred. These new models can be used for physiology studies, biomarker discovery, and to test the effects of gene therapy, cell therapy, mRNA therapy, nucleic acid therapies, small molecules, the microbiome, and especially genome editing using AAV, Cas/CRISPR, and other editing approaches as treatments for MMA and related conditions. The Mmut 6115v/G7isv mice are especially unique in that they are viable, can be bred in larger quantities than other mouse models, display modest biochemical changes associated with MMA and can be induced to be very sick by a simple manipulation of dietary change. They also have MMA related disease processes in all the tissues and cells of the body. Furthermore, we have demonstrated the utility of these mice to test AAV gene therapy as a therapeutic intervention. These new models can be used for physiology studies, biomarker discovery, and to test the effects of gene therapy, cell therapy, mRNA therapy, nucleic acid therapies, small molecules, the microbiome, and especially genome editing using adeno-associated viruses (AAV), Cas/CRISPR, and other editing approaches as treatments for MMA and related conditions. 2022-09-26 2024-10-28 2024-10-28 2022-09-26 2022-05-12 Acidemia, ALLELE, Knock-in, Methylmalonic, Methylmalonyl-CoA, MMA, Mmut, Mutase, P.G715V, P.G715V/, VPXXXX, WIXXXX, XEXXXX False True True NIHTT 37470483 Website Abstract 114111054 Schneller, Jessica National Human Genome Research Institute (NHGRI) NHGRI Schneller, Jessica (NHGRI) 0 114111055 Chandler, Randy National Human Genome Research Institute (NHGRI) NHGRI Chandler, Randy (NHGRI) 0 114111053 Venditti, Charles National Human Genome Research Institute (NHGRI) NHGRI Venditti, Charles (NHGRI) 1 114111053 Venditti, Charles National Human Genome Research Institute (NHGRI) NHGRI Venditti, Charles (NHGRI) 1 114111054 Schneller, Jessica National Human Genome Research Institute (NHGRI) NHGRI Schneller, Jessica (NHGRI) 0 114111055 Chandler, Randy National Human Genome Research Institute (NHGRI) NHGRI Chandler, Randy (NHGRI) 0 114102719 Mmut P.G715V/ P.G715V Knock-In Methylmalonyl-CoA Mutase (Mmut) Allele For The Study Of Methylmalonic Acidemia (MMA) E-160-2020-0 Research Material National Human Genome Research Institute (NHGRI) 83716782 Campbell, Eggerton eggerton.campbell@nih.gov
United States of America eggerton.campbell@nih.gov?subject=Web Inquiry on [TAB-3614] Mmut p.G715v/p.G71 Knock-ln Methylmalonyl-CoA Mutase (Mmut) Allele Mouse Models for the Study of Methylmalonic Acidemia (MMA)&body=Please send me information about technology [TAB-3614] Mmut p.G715v/p.G71 Knock-ln Methylmalonyl-CoA Mutase (Mmut) Allele Mouse Models for the Study of Methylmalonic Acidemia (MMA). Campbell, Eggerton<br><a href="mailto:eggerton.campbell@nih.gov?subject=Web Inquiry on [TAB-3614] Mmut p.G715v/p.G71 Knock-ln Methylmalonyl-CoA Mutase (Mmut) Allele Mouse Models for the Study of Methylmalonic Acidemia (MMA)&body=Please send me information about technology [TAB-3614] Mmut p.G715v/p.G71 Knock-ln Methylmalonyl-CoA Mutase (Mmut) Allele Mouse Models for the Study of Methylmalonic Acidemia (MMA).">eggerton.campbell@nih.gov</a><br> 114128946 VPXXXX 114128947 WIXXXX 114128948 XEXXXX 114153675 Mmut 114153676 P.G715V/ 114153677 P.G715V 114153678 Knock-in 114153679 Methylmalonyl-CoA 114153680 Mutase 114153681 ALLELE 114153682 Methylmalonic 114153683 Acidemia 114153684 MMA TAB-3615 114097468 Mmut P.Pro207_Lysl10del/P.Pro207_Lysl10del Knock-In Methylmalonyl-CoA Mutase (Mmut) Allele Mouse Models for the Study of Methylmalonic Acidemia (MMA) NHGRI Cardiology, Dental, Endocrinology, Infectious Disease, Oncology, Ophthalmology, Research Materials, Therapeutics Cardiology Dental Endocrinology Infectious Disease Oncology Ophthalmology Research Materials Therapeutics Randy Chandler, Jessica Schneller, Charles Venditti Isolated Methylmalonic Acidemia (MMA) comprises a relatively common and heterogeneous group of inborn errors of metabolism. In order to create mouse models of MMA to resemble the pathogenic mutations seen in patients, the NHGRI scientist used genome editing to generate new mutants of the Mmut allele -p.Pro207 _Lys210del. In order to create mouse models of MMA to resemble the pathogenic mutations seen in patients, the NHGRI scientist used genome editing to generate new mutants of Mmut allele -p.Pro207 _Lys210del. This allele recapitulates a 12-nucleotide deletion in exon 3 of Mmut. Of note and emphasis is the fact that there are no transgene cassettes or other alternations to the Mmut locus in these new mouse models. These mice display elevations of MMA biomarkers, such as 2-methylcitrate, are viable, without obvious gross pathology, and fully fertile, they can be easily bred. These new models can be used for physiology studies, biomarker discovery, and to test the effects of gene therapy, cell therapy, mRNA therapy, nucleic acid therapies, small molecules, and the microbiome. The mouse models are especially unique in that they more closely mimic the nature of mutations seen in patients and they can be bred in larger quantities than other mouse models and genotyped using digital droplet PCR. They also have MMA related disease processes in all the tissues and cells of the body. Furthermore, we have demonstrated the utility of these mice to test AAV gene therapy as a therapeutic intervention. These new models can be used for physiology studies, biomarker discovery, and to test the effects of gene therapy, cell therapy, mRNA therapy, nucleic acid therapies, small molecules, the microbiome, and especially genome editing using adeno-associated viruses (AAV), Cas/CRISPR, and other editing approaches as treatments for MMA and related conditions. 2022-09-26 2024-10-28 2024-10-28 2022-09-26 2022-05-12 Acidemia, ALLELE, Knock-in, Methylmalonic, Methylmalonyl-CoA, MMA, Mmut, Mutase, P.Pro207_Lys210del, P.Pro207_Lys210del/, VPXXXX, WIXXXX, XEXXXX False True True NIHTT 37470483 Website Abstract 114111057 Schneller, Jessica National Human Genome Research Institute (NHGRI) NHGRI Schneller, Jessica (NHGRI) 0 114111058 Chandler, Randy National Human Genome Research Institute (NHGRI) NHGRI Chandler, Randy (NHGRI) 0 114111056 Venditti, Charles National Human Genome Research Institute (NHGRI) NHGRI Venditti, Charles (NHGRI) 1 114111056 Venditti, Charles National Human Genome Research Institute (NHGRI) NHGRI Venditti, Charles (NHGRI) 1 114111057 Schneller, Jessica National Human Genome Research Institute (NHGRI) NHGRI Schneller, Jessica (NHGRI) 0 114111058 Chandler, Randy National Human Genome Research Institute (NHGRI) NHGRI Chandler, Randy (NHGRI) 0 114102720 Mmut P.Pro207_Lys210del/ P.Pro207_Lys210del Knock-In Methylmalonyl-CoA Mutase (Mmut) Allele For The Study Of Methylmalonic Acidemia (MMA) E-161-2020-0 Research Material National Human Genome Research Institute (NHGRI) 83716782 Campbell, Eggerton eggerton.campbell@nih.gov
United States of America eggerton.campbell@nih.gov?subject=Web Inquiry on [TAB-3615] Mmut P.Pro207_Lysl10del/P.Pro207_Lysl10del Knock-In Methylmalonyl-CoA Mutase (Mmut) Allele Mouse Models for the Study of Methylmalonic Acidemia (MMA)&body=Please send me information about technology [TAB-3615] Mmut P.Pro207_Lysl10del/P.Pro207_Lysl10del Knock-In Methylmalonyl-CoA Mutase (Mmut) Allele Mouse Models for the Study of Methylmalonic Acidemia (MMA). Campbell, Eggerton<br><a href="mailto:eggerton.campbell@nih.gov?subject=Web Inquiry on [TAB-3615] Mmut P.Pro207_Lysl10del/P.Pro207_Lysl10del Knock-In Methylmalonyl-CoA Mutase (Mmut) Allele Mouse Models for the Study of Methylmalonic Acidemia (MMA)&body=Please send me information about technology [TAB-3615] Mmut P.Pro207_Lysl10del/P.Pro207_Lysl10del Knock-In Methylmalonyl-CoA Mutase (Mmut) Allele Mouse Models for the Study of Methylmalonic Acidemia (MMA).">eggerton.campbell@nih.gov</a><br> 114128949 VPXXXX 114128950 WIXXXX 114128951 XEXXXX 114153685 Mmut 114153686 P.Pro207_Lys210del/ 114153687 P.Pro207_Lys210del 114153688 Knock-in 114153689 Methylmalonyl-CoA 114153690 Mutase 114153691 ALLELE 114153692 Methylmalonic 114153693 Acidemia 114153694 MMA TAB-3612 114097465 High Concentration Methylcobalamin (Me-Cbl) or Combination of Methyl- and Hydroxocobalamin (Me/OH-Cbl) for the Treatment of Cobalamin C Deficiency and Related Disorders NHGRI Cardiology, Dental, Endocrinology, Infectious Disease, Oncology, Ophthalmology, Therapeutics Cardiology Dental Endocrinology Infectious Disease Oncology Ophthalmology Therapeutics Eirini (Irini) Manoli, Jennifer Sloan, Charles Venditti Cobalamin C deficiency (cblC), caused by mutations in MMACHC, is the most common inborn error of intracellular vitamin B12 metabolism. NHGRI scientist have generated a number of Mmachc knockout mouse models. The cblC mice present with early lethality, recapitulate the neurological phenotype seen in patients, and have enabled proof of concept testing with traditional hydroxocobalamin formulations and doses. The scientist have also developed a novel combination of hydroxo- and methylcobalamin, having superior performance to traditional hydroxocobalamin only treatment. The immediate use of the results and models are to enable the formulation and testing of new cobalamin preparations (injectables) for the treatment of a large group of inborn errors of metabolism, neurological, ocular and vascular disorders. This technology enables the use of new doses and formulations of cobalamin (vitamin B12) for diseases with limited treatment options. <ul> <li>Enable the formulation and testing of new cobalamin preparations (injectables) for the treatment of a large group of inborn errors of metabolism, neurological, ocular and vascular disorders. </li> <li>Used to treat primary or secondary vitamin B12 deficiency, nutritional conditions, hyperhomocysteinemia, thrombotic microangiopathies, and possibly behavioral conditions</li> </ul> 2022-09-26 2024-10-28 2024-10-28 2022-09-26 2022-05-12 C, Cobalamin, Combination, Concentration, DEFICIENCY, DISORDERS, High, Hydroxocobalamin, Me/OH-Cbl, Me-Cbl, Methyl-, Methylcobalamin, RELATED, treatment, VPXXXX, WKXXXX False True True NIHTT 37470483 Website Abstract 114111048 Sloan, Jennifer National Human Genome Research Institute (NHGRI) NHGRI Sloan, Jennifer (NHGRI) 0 114111049 Manoli, Eirini (Irini) National Human Genome Research Institute (NHGRI) NHGRI Manoli, Eirini (Irini) (NHGRI) 0 114111047 Venditti, Charles National Human Genome Research Institute (NHGRI) NHGRI Venditti, Charles (NHGRI) 1 114111047 Venditti, Charles National Human Genome Research Institute (NHGRI) NHGRI Venditti, Charles (NHGRI) 1 114111048 Sloan, Jennifer National Human Genome Research Institute (NHGRI) NHGRI Sloan, Jennifer (NHGRI) 0 114111049 Manoli, Eirini (Irini) National Human Genome Research Institute (NHGRI) NHGRI Manoli, Eirini (Irini) (NHGRI) 0 114102717 High Concentration Methylcobalamin (Me-Cbl) Or Combination Of Methyl- And Hydroxocobalamin (Me/OH-Cbl) For The Treatment Of Cobalamin C Deficiency And Related Disorders E-147-2020-0 Filing authorized National Human Genome Research Institute (NHGRI) 83716782 Campbell, Eggerton eggerton.campbell@nih.gov
United States of America eggerton.campbell@nih.gov?subject=Web Inquiry on [TAB-3612] High Concentration Methylcobalamin (Me-Cbl) or Combination of Methyl- and Hydroxocobalamin (Me/OH-Cbl) for the Treatment of Cobalamin C Deficiency and Related Disorders&body=Please send me information about technology [TAB-3612] High Concentration Methylcobalamin (Me-Cbl) or Combination of Methyl- and Hydroxocobalamin (Me/OH-Cbl) for the Treatment of Cobalamin C Deficiency and Related Disorders. Campbell, Eggerton<br><a href="mailto:eggerton.campbell@nih.gov?subject=Web Inquiry on [TAB-3612] High Concentration Methylcobalamin (Me-Cbl) or Combination of Methyl- and Hydroxocobalamin (Me/OH-Cbl) for the Treatment of Cobalamin C Deficiency and Related Disorders&body=Please send me information about technology [TAB-3612] High Concentration Methylcobalamin (Me-Cbl) or Combination of Methyl- and Hydroxocobalamin (Me/OH-Cbl) for the Treatment of Cobalamin C Deficiency and Related Disorders.">eggerton.campbell@nih.gov</a><br> 114169457 E-147-2020-0 E-147-2020-0-US-01 High Concentration Methylcobalamin (Me-Cbl) Or Combination Of Methyl- And Hydroxocobalamin (Me/OH-Cbl) For The Treatment Of Cobalamin C Deficiency And Related Disorders PRV US 63/093,084 Abandoned US <br />Provisional (PRV) 63/093,084<br />Filed on 2020-10-16<br />Status: Abandoned 114169458 E-147-2020-0 E-147-2020-0-PCT-03 HIGH CONCENTRATION METHYLCOBALAMIN OR COMBINATION OF METHYL- AND HYDROXOCOBALAMIN FOR THE TREATMENT OF COBALAMIN C DEFICIENCY AND RELATED DISORDERS PCT Patent Cooperation Treaty PCT/US2021/054619 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/054619<br />Filed on 2021-10-12<br />Status: Expired 114128942 VPXXXX 114128943 WKXXXX 114153652 High 114153653 Concentration 114153654 Methylcobalamin 114153655 Me-Cbl 114153656 Combination 114153657 Methyl- 114153658 Hydroxocobalamin 114153659 Me/OH-Cbl 114153660 treatment 114153661 Cobalamin 114153662 C 114153663 DEFICIENCY 114153664 RELATED 114153665 DISORDERS TAB-3613 114097466 Improved Propionyl-CoA Carboxylase Alpha (PCCA) Alleles in Mouse Models for the Study of Propionic Acidemia (PA) and its Potential Treatments NHGRI Cardiology, Dental, Endocrinology, Infectious Disease, Oncology, Ophthalmology, Research Materials Cardiology Dental Endocrinology Infectious Disease Oncology Ophthalmology Research Materials Randy Chandler, Stephanie Smith, Charles Venditti Propionic acidemia (PA) is an autosomal recessive metabolic disorder caused by mutations in either PCCA or PCCB. The products of these genes form the alpha and beta subunits of the enzyme propionyl-Co A carboxylase (PCC), a critically important mitochondrial enzyme involved in the catabolism of branched chain amino acids. NHGRI scientist have developed new mouse models that more closely mimic the nature of mutations seen in patients, such as missense mutations, small insertion and deletions, splicing defects, and frameshift changes. Also, there are no rescue transgenes and the alleles are at the Pcca locus, making breeding of the mice easier than if a rescue transgene was required. The new PCCA mutations generated should be useful to model the spectrum of clinically important postnatal features of PA, such as dietary sensitivity to precursors, growth failure, metabolic instability, cardiomyopathy, and afford testing of new treatments, including adeno-associated virus (AAV) gene therapy, mRNA therapy, genome editing, base editing, mRNA editing, small molecules and enzyme replacement therapy. These new mouse models more closely mimic the nature of mutations seen in patients, there are no rescue transgenes and the alleles are at the PCCA locus, making breeding of the mice easier, and they can be easily bred and genotyped using digital droplet PCR. These alleles will be useful to study new therapies for PA. 2022-09-26 2024-10-28 2024-10-28 2022-09-26 2022-05-12 Acidemia, ALLELES, ALPHA, Carboxylase, Improved, PA, Pcca, Propionic, Propionyl-CoA, VPXXXX, WIXXXX False True True NIHTT 37470483 Website Abstract 114111051 Smith, Stephanie National Human Genome Research Institute (NHGRI) NHGRI Smith, Stephanie (NHGRI) 0 114111052 Chandler, Randy National Human Genome Research Institute (NHGRI) NHGRI Chandler, Randy (NHGRI) 0 114111050 Venditti, Charles National Human Genome Research Institute (NHGRI) NHGRI Venditti, Charles (NHGRI) 1 114111050 Venditti, Charles National Human Genome Research Institute (NHGRI) NHGRI Venditti, Charles (NHGRI) 1 114111051 Smith, Stephanie National Human Genome Research Institute (NHGRI) NHGRI Smith, Stephanie (NHGRI) 0 114111052 Chandler, Randy National Human Genome Research Institute (NHGRI) NHGRI Chandler, Randy (NHGRI) 0 114102718 Improved Propionyl-CoA Carboxylase Alpha (Pcca) Alleles For The Study Of Propionic Acidemia (PA) E-165-2018-0 Research Material National Human Genome Research Institute (NHGRI) 83716782 Campbell, Eggerton eggerton.campbell@nih.gov
United States of America eggerton.campbell@nih.gov?subject=Web Inquiry on [TAB-3613] Improved Propionyl-CoA Carboxylase Alpha (PCCA) Alleles in Mouse Models for the Study of Propionic Acidemia (PA) and its Potential Treatments&body=Please send me information about technology [TAB-3613] Improved Propionyl-CoA Carboxylase Alpha (PCCA) Alleles in Mouse Models for the Study of Propionic Acidemia (PA) and its Potential Treatments. Campbell, Eggerton<br><a href="mailto:eggerton.campbell@nih.gov?subject=Web Inquiry on [TAB-3613] Improved Propionyl-CoA Carboxylase Alpha (PCCA) Alleles in Mouse Models for the Study of Propionic Acidemia (PA) and its Potential Treatments&body=Please send me information about technology [TAB-3613] Improved Propionyl-CoA Carboxylase Alpha (PCCA) Alleles in Mouse Models for the Study of Propionic Acidemia (PA) and its Potential Treatments.">eggerton.campbell@nih.gov</a><br> 114128944 VPXXXX 114128945 WIXXXX 114153666 ALPHA 114153667 Carboxylase 114153668 Improved 114153669 Propionyl-CoA 114153670 Pcca 114153671 ALLELES 114153672 Propionic 114153673 Acidemia 114153674 PA TAB-3610 114097463 Aberrant Post-translational Modifications (PTMs) in Methyl- and Propionic Acidemia and the Construction of a Novel Sirtuin (SIRT) Gene to Metabolize PTMs NHGRI Cardiology, Dental, Endocrinology, Infectious Disease, Oncology, Ophthalmology, Research Materials, Therapeutics Cardiology Dental Endocrinology Infectious Disease Oncology Ophthalmology Research Materials Therapeutics Pamelasara Head, Charles Venditti Isolated Methylmalonic Acidemia (MMA) and the related disorder Propionic Acidemia (PA) comprise a relatively common and heterogeneous group of inborn errors of metabolism. NHGRI scientist discovered that in isolated MMA, a novel inhibitory PTM, methylmalonyllysine, is generated and inactivates protein targets through the failure of SIRT-mediated deacylation, and identified a series of antibodies for PTM specificity. A novel acylation resistant SIRT5 was created that did not exhibit enzymatic inhibition after hyper-methylmalonylation and appears to be resistant to inhibition by nicotinamide, which may be a universal therapy for all forms of MMA and PA. The scientist also developed a new assay involving sirtuin modulation, for targeted therapies that might be widely applicable to all forms of MMA as well as other the larger group of organic acidemias and fatty acid oxidation disorders where acyl-CoA accretion occurs. The new assays will be useful to develop small molecules that stimulate removal of methylmalonyl- and propionyl- groups for novel therapies. The existing approaches to treat MMA and PA rely upon delivery of the missing gene specific to the form of MMA or PA (there are 17 types) while the SIRT5 approach we describe could be used to treat all forms of MMA and PA. This discovery could be used to find new targets causing symptoms in MMA and PA patients, the assay used to devise a chemical screen for activators and inhibitors of activity, and perhaps most importantly, the novel SIRT5 might be delivered as a therapeutic agent for patients with MMA or PA, and perhaps other organic acidemias. 2022-11-08 2024-10-28 2024-10-28 2022-09-26 2022-05-12 Aberrant, Acidemia, Construction, Discovery, Ene, Metabolize, Methyl-, Modifications, Novel, Post-translational, Propionic, PTMs, Sirt, Sirtuin, VPXXXX, WIXXXX, WKXXXX, XEXXXX False True True NIHTT 37470483 Website Abstract 114111044 Head, Pamelasara National Human Genome Research Institute (NHGRI) NHGRI Head, Pamelasara (NHGRI) 0 114111043 Venditti, Charles National Human Genome Research Institute (NHGRI) NHGRI Venditti, Charles (NHGRI) 1 114111043 Venditti, Charles National Human Genome Research Institute (NHGRI) NHGRI Venditti, Charles (NHGRI) 1 114111044 Head, Pamelasara National Human Genome Research Institute (NHGRI) NHGRI Head, Pamelasara (NHGRI) 0 114102715 Discovery Of Aberrant Post-translational Modifications (PTMs) In Methyl- And Propionic Acidemia And The Construction Of A Novel Sirtuin SIRT Ene To Metabolize PTMs E-054-2020-0 Filing authorized National Human Genome Research Institute (NHGRI) 83716782 Campbell, Eggerton eggerton.campbell@nih.gov
United States of America eggerton.campbell@nih.gov?subject=Web Inquiry on [TAB-3610] Aberrant Post-translational Modifications (PTMs) in Methyl- and Propionic Acidemia and the Construction of a Novel Sirtuin (SIRT) Gene to Metabolize PTMs&body=Please send me information about technology [TAB-3610] Aberrant Post-translational Modifications (PTMs) in Methyl- and Propionic Acidemia and the Construction of a Novel Sirtuin (SIRT) Gene to Metabolize PTMs. Campbell, Eggerton<br><a href="mailto:eggerton.campbell@nih.gov?subject=Web Inquiry on [TAB-3610] Aberrant Post-translational Modifications (PTMs) in Methyl- and Propionic Acidemia and the Construction of a Novel Sirtuin (SIRT) Gene to Metabolize PTMs&body=Please send me information about technology [TAB-3610] Aberrant Post-translational Modifications (PTMs) in Methyl- and Propionic Acidemia and the Construction of a Novel Sirtuin (SIRT) Gene to Metabolize PTMs.">eggerton.campbell@nih.gov</a><br> 114169452 E-054-2020-0 E-054-2020-0-US-01 ABERRANT POST-TRANSLATIONAL MODIFICATIONS (PTMS) IN METHYL- AND PROPIONIC ACIDEMIA AND A MUTANT SIRTUIN (SIRT) TO METABOLIZE PTMS PRV US 63/021,179 Abandoned US <br />Provisional (PRV) 63/021,179<br />Filed on 2020-05-07<br />Status: Abandoned 114169453 E-054-2020-0 E-054-2020-0-PCT-02 ABERRANT POST-TRANSLATIONAL MODIFICATIONS (PTMS) IN METHYL- AND PROPIONIC ACIDEMIA AND A MUTANT SIRTUIN (SIRT) TO METABOLIZE PTMS PCT Patent Cooperation Treaty PCT/US2021/028228 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/028228<br />Filed on 2021-04-20<br />Status: Expired 114169685 E-054-2020-0 E-054-2020-0-US-03 ABERRANT POST-TRANSLATIONAL MODIFICATIONS(PTMS) IN METHYL- AND PROPIONIC ACIDEMIA AND A MUTANT SIRTUIN (SIRT) TO METABOLIZE PTMS National Stage US 17/923,394 Pending US <br />National Stage 17/923,394<br />Filed on 2022-11-04<br />Status: Pending 114128935 VPXXXX 114128936 WIXXXX 114128937 WKXXXX 114128938 XEXXXX 114153632 Modifications 114153633 Post-translational 114153634 Aberrant 114153635 Discovery 114153636 PTMs 114153637 Methyl- 114153638 Propionic 114153639 Acidemia 114153640 Construction 114153641 Novel 114153642 Sirtuin 114153643 Sirt 114153644 Ene 114153645 Metabolize TAB-3611 114097464 Gene Therapy for Cobalamin C Deficiency (cblC) with Viable Mouse Models NHGRI Cardiology, Dental, Endocrinology, Infectious Disease, Neurology, Oncology, Ophthalmology, Research Materials, Therapeutics Cardiology Dental Endocrinology Infectious Disease Neurology Oncology Ophthalmology Research Materials Therapeutics Jennifer Sloan, Charles Venditti Cobalamin C deficiency (cblC) is the most common inborn error of intracellular cobalamin metabolism and is caused by mutations in MMACHC, a gene responsible for processing and trafficking dependent enzymes: intracellular cobalamin, resulting in elevated methylmalonic acid and homocysteine and methionine deficiency. Disease manifestations include growth failure, anemia, cardial defects and progressive blindness. NHGRI scientist have generated the first viable mouse models of cblC using TALEN mediated genome editing and created two specific mutants of MMACHC that manifested the cblC-related biochemical perturbations. AAV vectors, and new genes, such as the synthetic and tagged MMACHC genes have also been developed that may enable gene therapy treatment for vision loss experienced by the cblC patients and possibly engender substantial commercial interest. Results of pre-clinical efficacy studies demonstrate a promising therapy for cblC disorders. The mouse models generated are viable, as compared with others that have been published. The AAV vectors, and new genes, such as the synthetic and tagged MMACHC genes, are also novel. These animal studies demonstrate that gene therapy could be used to treat human subjects with cobalamin C defect. 2022-11-17 2024-10-28 2024-10-28 2022-09-26 2022-05-12 C, cblC, Cobalamin, DEFICIENCY, Gene, THERAPY, VDXXXX, VEXXXX, VPXXXX, WIXXXX, WJXXXX, XEXXXX False True True NIHTT 37470483 Website Abstract E-275-2015-1 114172784 Weisfeld-Adams J, Morrissey M https://pubmed.ncbi.nlm.nih.gov/19836982/ <a href="https://pubmed.ncbi.nlm.nih.gov/19836982/">Weisfeld-Adams J, Morrissey M</a> 114172785 Moreno-Garcia M, Pupavac M https://pubmed.ncbi.nlm.nih.gov/24889031/ <a href="https://pubmed.ncbi.nlm.nih.gov/24889031/">Moreno-Garcia M, Pupavac M</a> 114111045 Sloan, Jennifer National Human Genome Research Institute (NHGRI) NHGRI Sloan, Jennifer (NHGRI) 0 114111046 Venditti, Charles National Human Genome Research Institute (NHGRI) NHGRI Venditti, Charles (NHGRI) 1 114111046 Venditti, Charles National Human Genome Research Institute (NHGRI) NHGRI Venditti, Charles (NHGRI) 1 114111045 Sloan, Jennifer National Human Genome Research Institute (NHGRI) NHGRI Sloan, Jennifer (NHGRI) 0 114102716 Gene Therapy For Cobalamin C Deficiency (cblC) E-275-2015-0 Filing authorized National Human Genome Research Institute (NHGRI) 152358458 Gene Therapy For Cobalamin C Deficiency (cblC) E-275-2015-1 Filing authorized National Human Genome Research Institute (NHGRI) 83716782 Campbell, Eggerton eggerton.campbell@nih.gov
United States of America eggerton.campbell@nih.gov?subject=Web Inquiry on [TAB-3611] Gene Therapy for Cobalamin C Deficiency (cblC) with Viable Mouse Models&body=Please send me information about technology [TAB-3611] Gene Therapy for Cobalamin C Deficiency (cblC) with Viable Mouse Models. Campbell, Eggerton<br><a href="mailto:eggerton.campbell@nih.gov?subject=Web Inquiry on [TAB-3611] Gene Therapy for Cobalamin C Deficiency (cblC) with Viable Mouse Models&body=Please send me information about technology [TAB-3611] Gene Therapy for Cobalamin C Deficiency (cblC) with Viable Mouse Models.">eggerton.campbell@nih.gov</a><br> 114169454 E-275-2015-0 E-275-2015-0-US-01 Gene Therapy For Cobalamin C Deficiency PRV US 62/266,352 Abandoned US <br />Provisional (PRV) 62/266,352<br />Filed on 2015-12-11<br />Status: Abandoned 114169455 E-275-2015-0 E-275-2015-0-PCT-02 GENE THERAPY FOR COMBINED METHYLMALONIC ACIDEMIA/ACIDURIA AND HYPERHOMOCYSTEINEMIA/HOMOCYSTINURIA, COBALAMIN C TYPE, AND DEFICIENCY OF MMACHC PCT Patent Cooperation Treaty PCT/US2016/029512 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2016/029512<br />Filed on 2016-04-27<br />Status: Expired 114169456 E-275-2015-0 E-275-2015-0-US-04 GENE THERAPY FOR COMBINED METHYLMALONIC ACIDEMIA/ACIDURIA AND HYPERHOMOCYSTEINEMIA/HOMOCYSTINURIA, COBALAMIN C TYPE, AND DEFICIENCY OF MMACHC National Stage US 11,510,998 16/061,091 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11510998 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11510998">11,510,998</a><br />Filed on 2018-06-11<br />Status: Issued 114169686 E-275-2015-0 E-275-2015-0-US-05 GENE THERAPY FOR COMBINED METHYLMALONIC ACIDEMIA/ACIDURIA AND HYPERHOMOCYSTEINEMIA/HOMOCYSTINURIA, COBALAMIN C TYPE, AND DEFICIENCY OF MMACHC DIV US 18/056,356 Pending US <br />Divisional (DIV) 18/056,356<br />Filed on 2022-11-17<br />Status: Pending 152358463 E-275-2015-1 E-275-2015-1-US-01 Gene Therapy For Combined Methylmalonic Acidemia/Aciduria and Hyperhomocysteinemia/Homocystinuria, Cobalamin C Type, and Deficiency of MMACHC PRV US 62/279,285 Abandoned US <br />Provisional (PRV) 62/279,285<br />Filed on 2016-01-15<br />Status: Abandoned 114128939 VPXXXX 114128940 WIXXXX 114128941 XEXXXX 114129706 VEXXXX 114129708 VDXXXX 114129711 WJXXXX 114153646 Gene 114153647 THERAPY 114153648 Cobalamin 114153649 C 114153650 DEFICIENCY 114153651 cblC TAB-3607 114097460 Mouse Model of Cobalamin A (cblA) Class Isolated Methylmalonic Acidemia (MMA) to Study New Therapies NHGRI Cardiology, Dental, Diagnostics, Endocrinology, Infectious Disease, Neurology, Oncology, Ophthalmology, Research Materials, Therapeutics Cardiology Dental Diagnostics Endocrinology Infectious Disease Neurology Oncology Ophthalmology Research Materials Therapeutics Eirini (Irini) Manoli, Charles Venditti Isolated Methylmalonic Acidemia (MMA) comprises a relatively common and heterogeneous group of inborn errors of metabolism. Most affected individuals display severe multisystemic disease characterized by metabolic instability, chronic renal disease, and neurological complications. Patients with the cobalamin A (cblA) subtype of MMA can have variable presentations, spanning the full spectrum of MMA associated symptoms and pathology, yet always harbor an element of clinical and biochemical responsiveness to injectable vitamin B12. NHGRI scientist have developed a model that would allow the testing of new therapies for cblA type MMA, and other forms of isolated MMA, they utilized homologous recombination to create a deletion allele of Mmaa, the enzyme that protects the enzyme methylmalonyl-CoA mutase, Mut, from oxidative inactivation. The NGHRI mouse model generated is severely affected but shows an element of vitamin B12 responsiveness which makes it useful for therapeutic studies in that an investigator can compare their intervention/results to that obtained with the vitamin cofactor as a control. This mouse model is the first tractable animal model of cblA deficiency. Useful for the study of new small molecule or mitochondrial based therapies for MMA, or more generally, therapies designed to improve mitochondrial function. 2022-09-26 2024-10-28 2024-10-28 2022-09-26 2022-05-11 Acidemia, cblA, Class, Cobalamin, ISOLATED, Methylmalonic, MMA, Model, Mouse, VEXXXX, VPXXXX, WKXXXX, XCXXXX False True True NIHTT 37470483 Website Abstract 114110561 Manoli, Eirini (Irini) National Human Genome Research Institute (NHGRI) NHGRI Manoli, Eirini (Irini) (NHGRI) 0 114110562 Venditti, Charles National Human Genome Research Institute (NHGRI) NHGRI Venditti, Charles (NHGRI) 1 114110562 Venditti, Charles National Human Genome Research Institute (NHGRI) NHGRI Venditti, Charles (NHGRI) 1 114110561 Manoli, Eirini (Irini) National Human Genome Research Institute (NHGRI) NHGRI Manoli, Eirini (Irini) (NHGRI) 0 114102641 A Mouse Model Of Cobalamin A (cblA) Class Isolated Methylmalonic Acidemia (MMA) E-050-2017-0 Research Material National Human Genome Research Institute (NHGRI) 83716782 Campbell, Eggerton eggerton.campbell@nih.gov
United States of America eggerton.campbell@nih.gov?subject=Web Inquiry on [TAB-3607] Mouse Model of Cobalamin A (cblA) Class Isolated Methylmalonic Acidemia (MMA) to Study New Therapies&body=Please send me information about technology [TAB-3607] Mouse Model of Cobalamin A (cblA) Class Isolated Methylmalonic Acidemia (MMA) to Study New Therapies. Campbell, Eggerton<br><a href="mailto:eggerton.campbell@nih.gov?subject=Web Inquiry on [TAB-3607] Mouse Model of Cobalamin A (cblA) Class Isolated Methylmalonic Acidemia (MMA) to Study New Therapies&body=Please send me information about technology [TAB-3607] Mouse Model of Cobalamin A (cblA) Class Isolated Methylmalonic Acidemia (MMA) to Study New Therapies.">eggerton.campbell@nih.gov</a><br> 114128917 VEXXXX 114128918 VPXXXX 114128919 WKXXXX 114128920 XCXXXX 114153591 Mouse 114153592 Model 114153593 Cobalamin 114153594 cblA 114153595 Class 114153596 ISOLATED 114153597 Methylmalonic 114153598 Acidemia 114153599 MMA TAB-3606 114097459 Creation and Use of 12-LO inhibitors (4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide derivatives) for the Treatment of Diabetes and Large Platelet-Derived Clots NCATS Cardiology, Endocrinology, Therapeutics Cardiology Endocrinology Therapeutics Michael Holinstat, Theodore Holman, Ajit Jadhav, Diane Luci, David Maloney, Jerry Nadler, Anton Simeonov, David Taylor-Fishwick, Adam Yasgar This technology includes the discovery and use of novel selective 12-LO (lipoxygenase) inhibitors, 4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide derivatives, for attenuating large clots and for the treatment of Type 1/2 diabetes. A 12-LO inhibitor could be a potent intracellular approach to block platelets from forming large clots in response to vessel injury or activation of the coagulation pathway, either due to diabetes and/or cardiovascular disease. Blocking clot formation can significantly decrease the occurrence of myocardial infarction and death. The small molecules covered in this patent represent novel 12-LO inhibitors which are soluble, have favorable ADME properties, and good in vivo PK. There are no current commercially available 12-LO inhibitors, so these agents have the possibility of being first in class. With further development, the small molecules covered by this technology have the potential to be a therapeutic, but minimally can serve as a starting point to further validate 12-LO as a therapeutic target. 2022-08-01 2024-10-28 2024-10-28 2022-08-01 2022-05-06 12-Lipoxygenase., 4-2-hydroxy-3-methoxybenzylaminobenzenesulfon, Derivatives, Discovery, Human, Inhibitors, Listed LPM Nguyen-Antczak as of 4/15/2015, Post LPM Assignment Set 20150420, POTENT, Pre LPM working set 20150418, SELECTIVE, VDXXXX, VFXXXX, WKXXXX, XEXXXX False True True NIHTT 37470483 Website Abstract 114172776 Luci D, Jameson JB, et al. https://pubmed.ncbi.nlm.nih.gov/25506969/ <a href="https://pubmed.ncbi.nlm.nih.gov/25506969/">Luci D, Jameson JB, et al.</a> 114172777 Bleich D, Chen S, et al. https://pubmed.ncbi.nlm.nih.gov/10330425/ <a href="https://pubmed.ncbi.nlm.nih.gov/10330425/">Bleich D, Chen S, et al.</a> 114172778 Ma K, Nunemaker CS, et al. https://pubmed.ncbi.nlm.nih.gov/20089617/ <a href="https://pubmed.ncbi.nlm.nih.gov/20089617/">Ma K, Nunemaker CS, et al.</a> 114172779 Kenyon V, Rai G, et al. https://pubmed.ncbi.nlm.nih.gov/21739938/ <a href="https://pubmed.ncbi.nlm.nih.gov/21739938/">Kenyon V, Rai G, et al.</a> 114172780 Yeung J, Apopa PL, et al. https://pubmed.ncbi.nlm.nih.gov/22155783/ <a href="https://pubmed.ncbi.nlm.nih.gov/22155783/">Yeung J, Apopa PL, et al.</a> 114172781 Weaver JR, Holman TR, et al. https://pubmed.ncbi.nlm.nih.gov/22502743/ <a href="https://pubmed.ncbi.nlm.nih.gov/22502743/">Weaver JR, Holman TR, et al.</a> 114111024 Jadhav, Ajit NCATS - NCGC NCATS Jadhav, Ajit (NCATS) 0 114111025 Simeonov, Anton NCATS - NCGC NCATS Simeonov, Anton (NCATS) 0 114111026 Yasgar, Adam NCATS - NCGC NCATS Yasgar, Adam (NCATS) 0 114111027 Luci, Diane NCATS - NCGC NCATS Luci, Diane (NCATS) 0 114111028 Holinstat, Michael Thomas Jefferson University Holinstat, Michael 0 114111029 Holman, Theodore University of California, Santa Cruz Holman, Theodore 0 114111030 Nadler, Jerry Eastern Virginia Medical School Nadler, Jerry 0 114111031 Taylor-Fishwick, David Eastern Virginia Medical School Taylor-Fishwick, David 0 114111023 Maloney, David NCATS - NCGC NCATS Maloney, David (NCATS) 1 114111023 Maloney, David NCATS - NCGC NCATS Maloney, David (NCATS) 1 114111024 Jadhav, Ajit NCATS - NCGC NCATS Jadhav, Ajit (NCATS) 0 114111025 Simeonov, Anton NCATS - NCGC NCATS Simeonov, Anton (NCATS) 0 114111026 Yasgar, Adam NCATS - NCGC NCATS Yasgar, Adam (NCATS) 0 114111027 Luci, Diane NCATS - NCGC NCATS Luci, Diane (NCATS) 0 114111028 Holinstat, Michael Thomas Jefferson University Holinstat, Michael 0 114111029 Holman, Theodore University of California, Santa Cruz Holman, Theodore 0 114111030 Nadler, Jerry Eastern Virginia Medical School Nadler, Jerry 0 114111031 Taylor-Fishwick, David Eastern Virginia Medical School Taylor-Fishwick, David 0 114102713 Discovery Of 4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide Derivatives As Potent And Selective Inhibitors Of Human 12-Lipoxygenase. E-757-2013-0 Filing authorized Eastern Virginia Medical School, NCATS - NCGC, Thomas Jefferson University, University of California, Santa Cruz 83682485 Vepa, Suryanarayana sury.vepa@nih.gov
United States of America Office of Strategic Alliances (OSA) sury.vepa@nih.gov?subject=Web Inquiry on [TAB-3606] Creation and Use of 12-LO inhibitors (4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide derivatives) for the Treatment of Diabetes and Large Platelet-Derived Clots&body=Please send me information about technology [TAB-3606] Creation and Use of 12-LO inhibitors (4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide derivatives) for the Treatment of Diabetes and Large Platelet-Derived Clots. Vepa, Suryanarayana<br><a href="mailto:sury.vepa@nih.gov?subject=Web Inquiry on [TAB-3606] Creation and Use of 12-LO inhibitors (4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide derivatives) for the Treatment of Diabetes and Large Platelet-Derived Clots&body=Please send me information about technology [TAB-3606] Creation and Use of 12-LO inhibitors (4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide derivatives) for the Treatment of Diabetes and Large Platelet-Derived Clots.">sury.vepa@nih.gov</a><br> 114169450 E-757-2013-0 E-757-2013-0-US-01 4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide Derivatives As Potent And Selective Inhibitors Of Human 12-Lipoxygenase. PRV US 61/889,396 Abandoned US <br />Provisional (PRV) 61/889,396<br />Filed on 2013-10-10<br />Status: Abandoned 114128913 VDXXXX 114128914 VFXXXX 114128915 WKXXXX 114128916 XEXXXX 114153580 Discovery 114153581 4-2-hydroxy-3-methoxybenzylaminobenzenesulfon 114153582 Derivatives 114153583 POTENT 114153584 SELECTIVE 114153585 Inhibitors 114153586 Human 114153587 12-Lipoxygenase. 114153588 Listed LPM Nguyen-Antczak as of 4/15/2015 114153589 Pre LPM working set 20150418 114153590 Post LPM Assignment Set 20150420 TAB-3604 114097457 Inhibition of Thioredoxin Reductase 1 (Trxr1) by Pyridine Compounds for Cancer Treatment NCATS Oncology, Research Materials, Therapeutics Oncology Research Materials Therapeutics Nathan Coussens, Thomas Dexheimer, Ajit Jadhav, Diane Luci, David Maloney, Anton Simeonov This technology includes the use of pyridines for anticancer treatment. A common feature of cancer cells is a high level of reactive oxygen species with a concomitant increase of two antioxidative systems to combat the toxicity: the glutathione and thioredoxin systems. Inhibiting either, or both, of these systems is a promising avenue to target cancer cells. Thioredoxin Reductase 1 (Trxr1) is an important selenoprotein in the thioredoxin antioxidative system which has been implicated as a potential anti-cancer target. The inventors have found that pyridinyl sulphone compounds may achieve highly selective inhibition of cytosolic thioredoxin reductase (Trxr1) by strongly-binding (in some cases, effectively irreversibly) without causing significant inhibition of glutathione reductase, an important protein in the gluthathione antioxidative system. In principle, cancer cells may be uniquely sensitive to inhibition of Thioredoxin Reductase 1 (Trxr1) by compounds like pyridines. Targeting Trxr1 has the potential of causing fewer side effects than other anti-cancer treatments such as chemotherapy. Further clinical work may establish the identified compounds as anti-cancer agents (as single agent or in combination with other approaches). 2022-08-01 2024-10-28 2024-10-28 2022-08-01 2022-05-06 CANCER, Novel, PYRIDINES, Their, treatment, VCXXXX, WIXXXX, WKXXXX, XEXXXX False True True NIHTT 37470483 Website Abstract 114111015 Jadhav, Ajit NCATS - NCGC NCATS Jadhav, Ajit (NCATS) 0 114111016 Luci, Diane NCATS - NCGC NCATS Luci, Diane (NCATS) 0 114111017 Dexheimer, Thomas Michigan State University Leidos Dexheimer, Thomas (Leidos) 0 114111018 Simeonov, Anton NCATS - NCGC NCATS Simeonov, Anton (NCATS) 0 114111019 Coussens, Nathan NCATS - NCGC Leidos Coussens, Nathan (Leidos) 0 114111014 Maloney, David NCATS - NCGC NCATS Maloney, David (NCATS) 1 114111014 Maloney, David NCATS - NCGC NCATS Maloney, David (NCATS) 1 114111015 Jadhav, Ajit NCATS - NCGC NCATS Jadhav, Ajit (NCATS) 0 114111016 Luci, Diane NCATS - NCGC NCATS Luci, Diane (NCATS) 0 114111017 Dexheimer, Thomas Michigan State University Leidos Dexheimer, Thomas (Leidos) 0 114111018 Simeonov, Anton NCATS - NCGC NCATS Simeonov, Anton (NCATS) 0 114111019 Coussens, Nathan NCATS - NCGC Leidos Coussens, Nathan (Leidos) 0 114102711 NOVEL PYRIDINES AND THEIR USE IN THE TREATMENT OF CANCER E-281-2015-0 Filing authorized NCATS - NCGC 83682485 Vepa, Suryanarayana sury.vepa@nih.gov
United States of America Office of Strategic Alliances (OSA) sury.vepa@nih.gov?subject=Web Inquiry on [TAB-3604] Inhibition of Thioredoxin Reductase 1 (Trxr1) by Pyridine Compounds for Cancer Treatment&body=Please send me information about technology [TAB-3604] Inhibition of Thioredoxin Reductase 1 (Trxr1) by Pyridine Compounds for Cancer Treatment. Vepa, Suryanarayana<br><a href="mailto:sury.vepa@nih.gov?subject=Web Inquiry on [TAB-3604] Inhibition of Thioredoxin Reductase 1 (Trxr1) by Pyridine Compounds for Cancer Treatment&body=Please send me information about technology [TAB-3604] Inhibition of Thioredoxin Reductase 1 (Trxr1) by Pyridine Compounds for Cancer Treatment.">sury.vepa@nih.gov</a><br> 114169447 E-281-2015-0 E-281-2015-0-PCT-02 NOVEL PYRIDINES AND THEIR USE IN THE TREATMENT OF CANCER PCT Patent Cooperation Treaty PCT/US2016/045731 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2016/045731<br />Filed on 2016-08-05<br />Status: Expired 114169448 E-281-2015-0 E-281-2015-0-US-12 PYRIDINES AND THEIR USE IN THE TREATMENT OF CANCER National Stage US 10,899,710 15/750,805 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10899710 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10899710">10,899,710</a><br />Filed on 2016-08-05<br />Status: Issued 114128906 VCXXXX 114128907 WIXXXX 114128908 WKXXXX 114128909 XEXXXX 114153563 Novel 114153564 PYRIDINES 114153565 Their 114153566 treatment 114153567 CANCER TAB-3605 114097458 Discovery of Proteasome Inhibitors to Target PMP22 Gene Expression for the Treatment of Charcot-Marie-Tooth Disease Type 1A NCATS Neurology, Therapeutics Neurology Therapeutics James Inglese, Sung-Wook Jang, John Svaren This technology includes the use of proteasome inhibitors, such as Bortezomib, for the treatment of the most prevalent form of Charcot-Marie-Tooth disease type 1A (CMT1A). Duplication of the peripheral myelin protein 22 (PMP22) gene, normally involved in myelination of the peripheral nervous system, is the causative agent in most forms of CMT1A. A drug discovery program was initiated and found that proteasome inhibitors can be used to target PMP22. This discovery identified a biological pathway for which drugs have already been developed. The current drugs that target the proteasome are highly toxic and used as anticancer agents. This discovery can be used to treat CMT1A with existing products such as proteasome inhibitors, including Bortezomib. 2022-08-01 2024-10-28 2024-10-28 2022-08-01 2022-05-06 Discovery, DOWN, Expression, Gene, inhibition, Listed LPM Tong as of 4/15/2015, MEANS, Pmp22, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Proteasome, REGULATE, VEXXXX, WKXXXX, XEXXXX False True True NIHTT 37470483 Website Abstract 114172775 Jang S-W, Lopez-Anido C, et al. https://pubmed.ncbi.nlm.nih.gov/22530759/ <a href="https://pubmed.ncbi.nlm.nih.gov/22530759/">Jang S-W, Lopez-Anido C, et al.</a> 114111020 Jang, Sung-Wook NCATS - NCGC Jang, Sung-Wook 0 114111022 Svaren, John Charcot-Marie-Tooth Association Svaren, John 0 114111021 Inglese, James NCATS - NCGC NCATS Inglese, James (NCATS) 1 114111021 Inglese, James NCATS - NCGC NCATS Inglese, James (NCATS) 1 114111020 Jang, Sung-Wook NCATS - NCGC Jang, Sung-Wook 0 114111022 Svaren, John Charcot-Marie-Tooth Association Svaren, John 0 114102712 Discovery Of Proteasome Inhibition As A Means To Down Regulate Pmp22 Gene Expression E-529-2013-0 Filing authorized Charcot-Marie-Tooth Association, NCATS - NCGC 83682485 Vepa, Suryanarayana sury.vepa@nih.gov
United States of America Office of Strategic Alliances (OSA) sury.vepa@nih.gov?subject=Web Inquiry on [TAB-3605] Discovery of Proteasome Inhibitors to Target PMP22 Gene Expression for the Treatment of Charcot-Marie-Tooth Disease Type 1A&body=Please send me information about technology [TAB-3605] Discovery of Proteasome Inhibitors to Target PMP22 Gene Expression for the Treatment of Charcot-Marie-Tooth Disease Type 1A. Vepa, Suryanarayana<br><a href="mailto:sury.vepa@nih.gov?subject=Web Inquiry on [TAB-3605] Discovery of Proteasome Inhibitors to Target PMP22 Gene Expression for the Treatment of Charcot-Marie-Tooth Disease Type 1A&body=Please send me information about technology [TAB-3605] Discovery of Proteasome Inhibitors to Target PMP22 Gene Expression for the Treatment of Charcot-Marie-Tooth Disease Type 1A.">sury.vepa@nih.gov</a><br> 114169449 E-529-2013-0 E-529-2013-0-US-01 The Use of Boronate Proteasome Inhibitors in the Treatment of Neuropathies Associated with Charcot-Marie-Tooth 1A (CMT1A) Disease PRV US 61/702,295 Abandoned US <br />Provisional (PRV) 61/702,295<br />Filed on 2012-09-18<br />Status: Abandoned 114128910 VEXXXX 114128911 WKXXXX 114128912 XEXXXX 114153568 Discovery 114153569 Proteasome 114153570 inhibition 114153571 MEANS 114153572 DOWN 114153573 REGULATE 114153574 Pmp22 114153575 Gene 114153576 Expression 114153577 Listed LPM Tong as of 4/15/2015 114153578 Pre LPM working set 20150418 114153579 Post LPM Assignment Set 20150420 TAB-3602 114097455 Development and Use of O-linked beta-N-acetylglucosamine (O-GlcNAc) Transferase (OGT) Inhibitors for Multiple Conditions, Including Cancer NCATS Neurology, Research Materials, Therapeutics Neurology Research Materials Therapeutics Damien Duveau, Sara Martin Schwanger, Craig Thomas, Suzanne Walker This technology includes the development and use of small molecules that inhibit O-linked beta-N-acetylglucosamine (O-GlcNAc) transferase (OGT) for a variety of pathologies, including Alzheimer's disease, cancer, cancer, diabetes, and neurodegenerative disorders the treatment of cancer and as a potential antiviral. OGT is a ubiquitous enzyme that catalyzes the transfer of N-acetylglucosamine (GlcNAc) to the serine or threonine residues of nuclear and cytoplasmic proteins. The addition of GlcNAc to proteins is a similar post-translational modification as phosphorylation and has been described to occur thousands of proteins. The series of O-linked beta-N-acetylglucosamine transferase (OGT) inhibitors described in this technology exhibit improved binding properties and OGT inhibition. Further work with O-linked beta-N-acetylglucosamine transferase (OGT) inhibitors will permit the further study of the biological role of OGT in cell homeostasis. Further clinical work could establish OGT inhibitors, alone or in combination with other agents, for the treatment of several disorders including cancer and as an antiviral. 2022-08-01 2024-10-28 2024-10-28 2022-08-01 2022-05-06 0-GlcNAc, Development, Developmtent, Inhibitors, OGT, THEREOF, TRANSFERASE, USES, VEXXXX, WIXXXX, WKXXXX False True True NIHTT 37470483 Website Abstract 114111009 Martin Schwanger, Sara Harvard University Martin Schwanger, Sara 0 114111010 Thomas, Craig NCATS - NCGC NCATS Thomas, Craig (NCATS) 0 114111011 Duveau, Damien NCATS - NCGC NCATS Duveau, Damien (NCATS) 0 114111008 Walker, Suzanne Harvard University Walker, Suzanne 1 114111008 Walker, Suzanne Harvard University Walker, Suzanne 1 114111009 Martin Schwanger, Sara Harvard University Martin Schwanger, Sara 0 114111010 Thomas, Craig NCATS - NCGC NCATS Thomas, Craig (NCATS) 0 114111011 Duveau, Damien NCATS - NCGC NCATS Duveau, Damien (NCATS) 0 114102709 Development Of 0-GlcNAc Transferase (OGT) Inhibitors And Uses Thereof E-234-2018-0 Under Review Harvard University, NCATS - NCGC 83727060 Gadhia, Ami ami.gadhia@nih.gov
United States of America NCGC ami.gadhia@nih.gov?subject=Web Inquiry on [TAB-3602] Development and Use of O-linked beta-N-acetylglucosamine (O-GlcNAc) Transferase (OGT) Inhibitors for Multiple Conditions, Including Cancer&body=Please send me information about technology [TAB-3602] Development and Use of O-linked beta-N-acetylglucosamine (O-GlcNAc) Transferase (OGT) Inhibitors for Multiple Conditions, Including Cancer. Gadhia, Ami<br><a href="mailto:ami.gadhia@nih.gov?subject=Web Inquiry on [TAB-3602] Development and Use of O-linked beta-N-acetylglucosamine (O-GlcNAc) Transferase (OGT) Inhibitors for Multiple Conditions, Including Cancer&body=Please send me information about technology [TAB-3602] Development and Use of O-linked beta-N-acetylglucosamine (O-GlcNAc) Transferase (OGT) Inhibitors for Multiple Conditions, Including Cancer.">ami.gadhia@nih.gov</a><br> 114128899 VEXXXX 114128900 WIXXXX 114128901 WKXXXX 114153542 Developmtent 114153543 0-GlcNAc 114153544 TRANSFERASE 114153545 OGT 114153546 Inhibitors 114153547 USES 114153548 THEREOF 114153549 Development TAB-3603 114097456 Use of beclin 1 Inhibitors, including 17-hydroxy Wortmannin, to Treat TRAIL-resistant Cancer NCATS Oncology, Research Materials, Therapeutics Oncology Research Materials Therapeutics Sheng Dai, Wei Zheng This technology includes the use of a beclin 1 inhibitor, 17-hydroxy Wortmannin, for the treatment of TRAIL-resistant colon cancer. TRAIL (TNF-related apoptosis-inducing ligand) binds to death receptors (DR4/DR5) and activates apoptosis in cancer cells. Multiple clinical trials have focused on promoting TRAIL-induced death but have had a lack of efficacy due to TRAIL resistance developing quickly in cancer cells. Recent work has found that this resistance may be mediated by a lack of activation of the apoptosis/autophagy regulator beclin 1. A compound screen was performed to find inhibitors of beclin 1 and identified 17-hydroxy Wortmannin. We found that 17-hydroxy Wortmannin can completely overcome TRAIL's resistance due to increased beclin 1 level in resistant colon cancer cells. Combination therapy of TRAIL and beclin 1 inhibitors presents a new therapeutic approach. Further clinical work investigating TRAIL therapy in combination with beclin 1 inhibitors, such as 17-hydroxy Wortmannin, may support the combination therapy as a new therapeutic approach to treat a subpopulation of TRAIL resistant cancer patients. 2022-08-01 2024-10-28 2024-10-28 2022-08-01 2022-05-06 1, 17-hydroxy, Autophagy, Beclin, CANCER, Cells, COLON, Increased, Inhibitions, Overcomes, Resistance, TRAIL, VCXXXX, WIXXXX, WKXXXX, Wortmannin, XEXXXX False True True NIHTT 37470483 Website Abstract 114172774 Dai S, Yang S, et al. https://pubmed.ncbi.nlm.nih.gov/31092562/ <a href="https://pubmed.ncbi.nlm.nih.gov/31092562/">Dai S, Yang S, et al.</a> 114111013 Dai, Sheng NCATS - NCGC Dai, Sheng 0 114111012 Zheng, Wei NCATS - TRND NCATS Zheng, Wei (NCATS) 1 114111012 Zheng, Wei NCATS - TRND NCATS Zheng, Wei (NCATS) 1 114111013 Dai, Sheng NCATS - NCGC Dai, Sheng 0 114102710 17-hydroxy Wortmannin Overcomes TRAIL Resistance In Colon Cancer Cells By Inhibitions Of Increased Beclin 1 And Autophagy E-252-2017-0 Filing authorized NCATS - NCGC 83682485 Vepa, Suryanarayana sury.vepa@nih.gov
United States of America Office of Strategic Alliances (OSA) sury.vepa@nih.gov?subject=Web Inquiry on [TAB-3603] Use of beclin 1 Inhibitors, including 17-hydroxy Wortmannin, to Treat TRAIL-resistant Cancer&body=Please send me information about technology [TAB-3603] Use of beclin 1 Inhibitors, including 17-hydroxy Wortmannin, to Treat TRAIL-resistant Cancer. Vepa, Suryanarayana<br><a href="mailto:sury.vepa@nih.gov?subject=Web Inquiry on [TAB-3603] Use of beclin 1 Inhibitors, including 17-hydroxy Wortmannin, to Treat TRAIL-resistant Cancer&body=Please send me information about technology [TAB-3603] Use of beclin 1 Inhibitors, including 17-hydroxy Wortmannin, to Treat TRAIL-resistant Cancer.">sury.vepa@nih.gov</a><br> 114169446 E-252-2017-0 E-252-2017-0-US-01 METHOD OF TREATMENT OF CANCER CELLS EXHIBITING TRAIL RESISTANCE PRV US 62/650,147 Abandoned US <br />Provisional (PRV) 62/650,147<br />Filed on 2018-03-29<br />Status: Abandoned 114128902 VCXXXX 114128903 WIXXXX 114128904 WKXXXX 114128905 XEXXXX 114153550 17-hydroxy 114153551 Wortmannin 114153552 Overcomes 114153553 TRAIL 114153554 Resistance 114153555 COLON 114153556 CANCER 114153557 Cells 114153558 Inhibitions 114153559 Increased 114153560 Beclin 114153561 1 114153562 Autophagy TAB-3600 114097453 Novel ALDH1A1 (aldehyde dehydrogenase 1 family member A1) Inhibitors for the Treatment of Cancer NCATS Oncology, Research Materials, Therapeutics Oncology Research Materials Therapeutics John Arcaroli, Ying Chen, Ajit Jadhav, Antonio Jimeno, Madhu Lal, David Maloney, Wells Messersmith, Bettina Miller, Anton Simeonov, David Thompson, Vasilis Vasiliou, Shyh-Ming Yang, Adam Yasgar This technology includes the identification and use of novel inhibitors of ALDH1A1 (aldehyde dehydrogenase 1 family member A1) for the treatment of multiple diseases, including cancer, inflammation, and obesity. ALDH1A1 is an enzyme that has a role in alcohol metabolism, and has been implicated in maintaining cancer stem cells. A high-throughput screen was conducted that identified novel ALDH1A1 inhibitors. Medicinal chemistry optimization led to the identification of two chemical series with high potency, selectivity, and favorable ADME (absorption, distribution, metabolism, and excretion) properties. The compounds of this series represent the most potent, selective, and drug-like inhibitors of ALDH1A 1 described to date. Further clinical work with the novel inhibitors could support the indication of these novel ALDH1A1 inhibitors for a variety of indications including but not limited to cancer, inflammation, and obesity. 2022-08-01 2024-10-28 2024-10-28 2022-08-01 2022-05-06 1A1, Aldehyde, DEHYDROGENASE, Inhibitors, Listed LPM Nguyen-Antczak as of 4/15/2015, MOLECULE, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Small, VCXXXX, WIXXXX, WKXXXX, XEXXXX False True True NIHTT 37470483 Website Abstract 114110993 Simeonov, Anton NCATS - NCGC NCATS Simeonov, Anton (NCATS) 0 114110994 Jadhav, Ajit NCATS - NCGC NCATS Jadhav, Ajit (NCATS) 0 114110995 Yang, Shyh-Ming NCATS Yang, Shyh-Ming (NCATS) 0 114110996 Maloney, David NCATS - NCGC NCATS Maloney, David (NCATS) 0 114110997 Yasgar, Adam NCATS - NCGC NCATS Yasgar, Adam (NCATS) 0 114110998 Lal, Madhu NCATS - NCGC NCATS Lal, Madhu (NCATS) 0 114111000 Chen, Ying University of Colorado, Denver Chen, Ying 0 114111001 Miller, Bettina University of Colorado, Denver Miller, Bettina 0 114111002 Messersmith, Wells University of Colorado, Denver Messersmith, Wells 0 114111003 Arcaroli, John University of Colorado, Denver Arcaroli, John 0 114111004 Jimeno, Antonio The Regents of the University of Colorado, A Body Corporate Jimeno, Antonio 0 114111005 Thompson, David The Regents of the University of Colorado, A Body Corporate Thompson, David 0 114110999 Vasiliou, Vasilis University of Colorado, Denver Vasiliou, Vasilis 1 114110999 Vasiliou, Vasilis University of Colorado, Denver Vasiliou, Vasilis 1 114110993 Simeonov, Anton NCATS - NCGC NCATS Simeonov, Anton (NCATS) 0 114110994 Jadhav, Ajit NCATS - NCGC NCATS Jadhav, Ajit (NCATS) 0 114110995 Yang, Shyh-Ming NCATS Yang, Shyh-Ming (NCATS) 0 114110996 Maloney, David NCATS - NCGC NCATS Maloney, David (NCATS) 0 114110997 Yasgar, Adam NCATS - NCGC NCATS Yasgar, Adam (NCATS) 0 114110998 Lal, Madhu NCATS - NCGC NCATS Lal, Madhu (NCATS) 0 114111000 Chen, Ying University of Colorado, Denver Chen, Ying 0 114111001 Miller, Bettina University of Colorado, Denver Miller, Bettina 0 114111002 Messersmith, Wells University of Colorado, Denver Messersmith, Wells 0 114111003 Arcaroli, John University of Colorado, Denver Arcaroli, John 0 114111004 Jimeno, Antonio The Regents of the University of Colorado, A Body Corporate Jimeno, Antonio 0 114111005 Thompson, David The Regents of the University of Colorado, A Body Corporate Thompson, David 0 114102707 Small Molecule Inhibitors Of Aldehyde Dehydrogenase 1A1 E-214-2014-0 Filing authorized NCATS - NCGC, The Regents of the University of Colorado, A Body Corporate, University of Colorado, Denver 83673536 Erwin-Cohen, Rebecca rebecca.erwin-cohen@nih.gov
NCGC rebecca.erwin-cohen@nih.gov?subject=Web Inquiry on [TAB-3600] Novel ALDH1A1 (aldehyde dehydrogenase 1 family member A1) Inhibitors for the Treatment of Cancer&body=Please send me information about technology [TAB-3600] Novel ALDH1A1 (aldehyde dehydrogenase 1 family member A1) Inhibitors for the Treatment of Cancer. Erwin-Cohen, Rebecca<br><a href="mailto:rebecca.erwin-cohen@nih.gov?subject=Web Inquiry on [TAB-3600] Novel ALDH1A1 (aldehyde dehydrogenase 1 family member A1) Inhibitors for the Treatment of Cancer&body=Please send me information about technology [TAB-3600] Novel ALDH1A1 (aldehyde dehydrogenase 1 family member A1) Inhibitors for the Treatment of Cancer.">rebecca.erwin-cohen@nih.gov</a><br> 114169444 E-214-2014-0 E-214-2014-0-US-01 Small Molecule Aldehyde Dehydrogenase Inhibitors and Methods of Use Thereof PRV US 62/084,830 Abandoned US <br />Provisional (PRV) 62/084,830<br />Filed on 2014-11-26<br />Status: Abandoned 114128892 VCXXXX 114128893 WIXXXX 114128894 WKXXXX 114128895 XEXXXX 114153526 Small 114153527 MOLECULE 114153528 Inhibitors 114153529 Aldehyde 114153530 DEHYDROGENASE 114153531 1A1 114153532 Listed LPM Nguyen-Antczak as of 4/15/2015 114153533 Pre LPM working set 20150418 114153534 Post LPM Assignment Set 20150420 TAB-3601 114097454 Development of a Therapy for the Treatment of Zellweger Spectrum Disorder NCATS Neurology, Research Materials, Therapeutics Neurology Research Materials Therapeutics Patricia Dranchak, James Inglese This technology includes a method for selecting a therapeutic effective amount of one of two compounds (including naltriben and naltrin) for the treatment of Zellweger Spectrum Disorder (ZSD), or any disease associated with peroxisome dysfunction. The compounds were identified using a cell-image based high-content screening (HCS) assay to identify small molecules that enhance peroxisome assembly in immortalized skin fibroblasts obtained from a ZSD patient. Current treatment options are palliative in nature and there is a need to develop targeted therapies that address the peroxisome assembly defects responsible for disease development and progression. Clinical work with the identified compounds may result in the establishment of new therapeutic agents effective for Zellweger Spectrum Disorder. 2022-08-01 2024-10-28 2024-10-28 2022-08-01 2022-05-06 DEVELOP, DISORDER, Spectrum, THERAPY, TOOLS, treatment, VEXXXX, WIXXXX, WKXXXX, Zellweger False True True NIHTT 37470483 Website Abstract 114111007 Dranchak, Patricia NCATS - NCGC NCATS Dranchak, Patricia (NCATS) 0 114111006 Inglese, James NCATS - NCGC NCATS Inglese, James (NCATS) 1 114111006 Inglese, James NCATS - NCGC NCATS Inglese, James (NCATS) 1 114111007 Dranchak, Patricia NCATS - NCGC NCATS Dranchak, Patricia (NCATS) 0 114102708 Tools To Develop A Therapy For The Treatment Of Zellweger Spectrum Disorder E-230-2016-0 Filing authorized NCATS - NCGC 83727060 Gadhia, Ami ami.gadhia@nih.gov
United States of America NCGC ami.gadhia@nih.gov?subject=Web Inquiry on [TAB-3601] Development of a Therapy for the Treatment of Zellweger Spectrum Disorder&body=Please send me information about technology [TAB-3601] Development of a Therapy for the Treatment of Zellweger Spectrum Disorder. Gadhia, Ami<br><a href="mailto:ami.gadhia@nih.gov?subject=Web Inquiry on [TAB-3601] Development of a Therapy for the Treatment of Zellweger Spectrum Disorder&body=Please send me information about technology [TAB-3601] Development of a Therapy for the Treatment of Zellweger Spectrum Disorder.">ami.gadhia@nih.gov</a><br> 114169445 E-230-2016-0 E-230-2016-0-US-01 Tools To Develop A Therapy For The Treatment Of Zellweger Spectrum Disorder PRV US 62/350,139 Abandoned US <br />Provisional (PRV) 62/350,139<br />Filed on 2016-06-14<br />Status: Abandoned 114128896 VEXXXX 114128897 WIXXXX 114128898 WKXXXX 114153535 TOOLS 114153536 DEVELOP 114153537 THERAPY 114153538 treatment 114153539 Zellweger 114153540 Spectrum 114153541 DISORDER TAB-3597 114097450 The Use of Emetine for the Treatment of SARS-CoV-2 Infection NCATS Infectious Disease, Research Materials, Therapeutics Infectious Disease Research Materials Therapeutics Andres Dulcey Garcia, Marc Ferrer-Alegre, Mark Henderson, Xin Hu, Juan Marugan, Noel Southall This technology includes the clinical use of the small compound emetine for the treatment of SARS-CoV-2. Previous work has shown that emetine has antiviral properties against some DNA and RNA viruses. It is thought that the mechanism may involve blocking protein synthesis. Work has shown that emetine has potential antiviral activity in multiple tissues that may make it suitable for the treatment of COVID-19. There are no current approved therapies for SARS-CoV-2 infection. Further clinical work may establish emetine as a therapeutic for SARS-CoV-2. 2022-08-01 2024-10-28 2024-10-28 2022-08-01 2022-05-06 Emetine, Infection, SARS-CoV-2, treatment, VLXXXX, WIXXXX, WKXXXX False True True NIHTT 37470483 Website Abstract 114110966 Ferrer-Alegre, Marc NCATS - NCGC NCATS Ferrer-Alegre, Marc (NCATS) 0 114110968 Henderson, Mark NCATS - NCGC NCATS Henderson, Mark (NCATS) 0 114110969 Marugan, Juan NCATS - NCGC NCATS Marugan, Juan (NCATS) 0 114110970 Dulcey Garcia, Andres NCATS - NCGC NCATS Dulcey Garcia, Andres (NCATS) 0 114110971 Hu, Xin NCATS - NCGC NCATS Hu, Xin (NCATS) 0 114110967 Southall, Noel NCATS - TRND NCATS Southall, Noel (NCATS) 1 114110967 Southall, Noel NCATS - TRND NCATS Southall, Noel (NCATS) 1 114110966 Ferrer-Alegre, Marc NCATS - NCGC NCATS Ferrer-Alegre, Marc (NCATS) 0 114110968 Henderson, Mark NCATS - NCGC NCATS Henderson, Mark (NCATS) 0 114110969 Marugan, Juan NCATS - NCGC NCATS Marugan, Juan (NCATS) 0 114110970 Dulcey Garcia, Andres NCATS - NCGC NCATS Dulcey Garcia, Andres (NCATS) 0 114110971 Hu, Xin NCATS - NCGC NCATS Hu, Xin (NCATS) 0 114102704 Emetine For The Treatment Of SARS-CoV-2 Infection E-157-2020-0 Filing authorized NCATS - NCGC 83727060 Gadhia, Ami ami.gadhia@nih.gov
United States of America NCGC ami.gadhia@nih.gov?subject=Web Inquiry on [TAB-3597] The Use of Emetine for the Treatment of SARS-CoV-2 Infection&body=Please send me information about technology [TAB-3597] The Use of Emetine for the Treatment of SARS-CoV-2 Infection. Gadhia, Ami<br><a href="mailto:ami.gadhia@nih.gov?subject=Web Inquiry on [TAB-3597] The Use of Emetine for the Treatment of SARS-CoV-2 Infection&body=Please send me information about technology [TAB-3597] The Use of Emetine for the Treatment of SARS-CoV-2 Infection.">ami.gadhia@nih.gov</a><br> 114169438 E-157-2020-0 E-157-2020-0-US-01 METHODS OF TREATING CORONAVIRUS INFECTIONS PRV US 63/000,425 Abandoned US <br />Provisional (PRV) 63/000,425<br />Filed on 2020-03-26<br />Status: Abandoned 114128878 VLXXXX 114128879 WIXXXX 114128880 WKXXXX 114153508 Emetine 114153509 treatment 114153510 SARS-CoV-2 114153511 Infection TAB-3596 114097449 The NCGC BioPlanet: A Computational Algorithm to Display Networks in Three Dimensions NCATS Cardiology, Computational models/software, Consumer Products, Dental, Endocrinology, Infectious Disease, Oncology, Ophthalmology, Research Equipment, Research Materials, Software / Apps Cardiology Computational models/software Consumer Products Dental Endocrinology Infectious Disease Oncology Ophthalmology Research Equipment Research Materials Software / Apps Christopher Austin, Ruili Huang, Yuhong Wang This technology includes a novel computational algorithm and software implementation to map and display biological pathways and their relationship on the surface of a globe in a three-dimensional space. Currently, biological pathways and genes are represented as two-dimensional networks, which is not effective for displaying complicated relationships between pathways and genes. Current representations of biological pathways and genes are represented as two-dimensional networks. A three-dimensional representation is potentially a more effective means for displaying these complicated relationships. This pathway globe and the corresponding algorithm could significantly enhance the presentation and effectiveness of existing commercial software and applications. For example, biological software and application vendors such as GeneGo could use this idea and algorithm in their products. 2022-08-01 2024-10-28 2024-10-28 2022-08-01 2022-05-06 Biological, BioPlanet:, Globe, NCGC, NCTT, PATHWAY, VPXXXX, WIXXXX, WMXXXX, XBXXXX, XHXXXX, XJXXXX False True True NIHTT 37470483 Website Abstract 114172769 Huang R, Grishagin I, et al. https://pubmed.ncbi.nlm.nih.gov/31133849/ <a href="https://pubmed.ncbi.nlm.nih.gov/31133849/">Huang R, Grishagin I, et al.</a> 114110963 Wang, Yuhong National Human Genome Research Institute (NHGRI) NCATS Wang, Yuhong (NCATS) 0 114110965 Austin, Christopher National Human Genome Research Institute (NHGRI) NCATS Austin, Christopher (NCATS) 0 114110964 Huang, Ruili National Human Genome Research Institute (NHGRI) NCATS Huang, Ruili (NCATS) 1 114110964 Huang, Ruili National Human Genome Research Institute (NHGRI) NCATS Huang, Ruili (NCATS) 1 114110963 Wang, Yuhong National Human Genome Research Institute (NHGRI) NCATS Wang, Yuhong (NCATS) 0 114110965 Austin, Christopher National Human Genome Research Institute (NHGRI) NCATS Austin, Christopher (NCATS) 0 114102703 The NCGC BioPlanet: Biological Pathway Globe E-143-2011-0 Research Material NCATS - NCGC 83682485 Vepa, Suryanarayana sury.vepa@nih.gov
United States of America Office of Strategic Alliances (OSA) sury.vepa@nih.gov?subject=Web Inquiry on [TAB-3596] The NCGC BioPlanet: A Computational Algorithm to Display Networks in Three Dimensions&body=Please send me information about technology [TAB-3596] The NCGC BioPlanet: A Computational Algorithm to Display Networks in Three Dimensions. Vepa, Suryanarayana<br><a href="mailto:sury.vepa@nih.gov?subject=Web Inquiry on [TAB-3596] The NCGC BioPlanet: A Computational Algorithm to Display Networks in Three Dimensions&body=Please send me information about technology [TAB-3596] The NCGC BioPlanet: A Computational Algorithm to Display Networks in Three Dimensions.">sury.vepa@nih.gov</a><br> 114128872 VPXXXX 114128873 WIXXXX 114128874 WMXXXX 114128875 XBXXXX 114128876 XHXXXX 114128877 XJXXXX 114153502 NCGC 114153503 BioPlanet: 114153504 Biological 114153505 PATHWAY 114153506 Globe 114153507 NCTT TAB-3594 114097447 Creation of a High-density Screening Format and the Identification of Small Molecule Inhibitors of the SIX/EYA Interaction for the Treatment of Cancers NCATS Oncology, Research Materials, Therapeutics Oncology Research Materials Therapeutics Melanie Blevins, Marc Ferrer-Alegre, Heide Ford, Xin Hu, Juan Marugan, Lesley Mathews, Rebecca Mull, Rui Zhao The technology includes the creation of a high-throughput assay and the identification and use of small molecules that inhibit the SIX/EYA interaction as a treatment for cancer. The Eya proteins are phosphatases that form a complex and are activated by the Six family of homeobox transcription factors. The interaction of Eya and Six mediates breast cancer cell transformation, migration, invasion and metastasis. An assay was designed to screen a large collection of compounds to identify inhibitors of the SIX/EYA interaction. The miniaturization of the assay to a high-density screening format (1536-well plates) enables screening large collections of compounds. The identified compounds are the first small compounds that apparently inhibit the SIX/EYA interaction. Further clinical work could establish the SIX/EYA inhibitors for the treatment of cancers. 2022-08-01 2024-10-28 2024-10-28 2022-08-01 2022-05-06 cancers, Identification, Identifying, Inhibitors, INTERACTION, Listed LPM Vathyam as of 4/15/2015, Method, MOLECULE, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, SIX/EYA, Small, treatment, VCXXXX, WIXXXX, WKXXXX, XEXXXX False True True NIHTT 37470483 Website Abstract 114110946 Ferrer-Alegre, Marc NCATS - NCGC NCATS Ferrer-Alegre, Marc (NCATS) 0 114110947 Hu, Xin NCATS - NCGC NCATS Hu, Xin (NCATS) 0 114110948 Marugan, Juan NCATS - NCGC NCATS Marugan, Juan (NCATS) 0 114110949 Mathews, Lesley NCATS - NCGC NCATS Mathews, Lesley (NCATS) 0 114110951 Ford, Heide Regents of the University of Colorado Ford, Heide 0 114110952 Blevins, Melanie University of Colorado Blevins, Melanie 0 114110953 Mull, Rebecca NCATS - NCGC NCATS Mull, Rebecca (NCATS) 0 114110950 Zhao, Rui Regents of the University of Colorado Zhao, Rui 1 114110950 Zhao, Rui Regents of the University of Colorado Zhao, Rui 1 114110946 Ferrer-Alegre, Marc NCATS - NCGC NCATS Ferrer-Alegre, Marc (NCATS) 0 114110947 Hu, Xin NCATS - NCGC NCATS Hu, Xin (NCATS) 0 114110948 Marugan, Juan NCATS - NCGC NCATS Marugan, Juan (NCATS) 0 114110949 Mathews, Lesley NCATS - NCGC NCATS Mathews, Lesley (NCATS) 0 114110951 Ford, Heide Regents of the University of Colorado Ford, Heide 0 114110952 Blevins, Melanie University of Colorado Blevins, Melanie 0 114110953 Mull, Rebecca NCATS - NCGC NCATS Mull, Rebecca (NCATS) 0 114102701 Method For Identifying And Identification Of Small Molecule Inhibitors Of SIX/EYA Interaction For The Treatment Of Cancers E-091-2013-0 Filing authorized NCATS - NCGC, Regents of the University of Colorado, University of Colorado 83682485 Vepa, Suryanarayana sury.vepa@nih.gov
United States of America Office of Strategic Alliances (OSA) sury.vepa@nih.gov?subject=Web Inquiry on [TAB-3594] Creation of a High-density Screening Format and the Identification of Small Molecule Inhibitors of the SIX/EYA Interaction for the Treatment of Cancers&body=Please send me information about technology [TAB-3594] Creation of a High-density Screening Format and the Identification of Small Molecule Inhibitors of the SIX/EYA Interaction for the Treatment of Cancers. Vepa, Suryanarayana<br><a href="mailto:sury.vepa@nih.gov?subject=Web Inquiry on [TAB-3594] Creation of a High-density Screening Format and the Identification of Small Molecule Inhibitors of the SIX/EYA Interaction for the Treatment of Cancers&body=Please send me information about technology [TAB-3594] Creation of a High-density Screening Format and the Identification of Small Molecule Inhibitors of the SIX/EYA Interaction for the Treatment of Cancers.">sury.vepa@nih.gov</a><br> 114169436 E-091-2013-0 E-091-2013-0-US-01 Method For Identifying And Identification Of Small Molecule Inhibitors Of SIX/EYA Interaction For The Treatment Of Cancers PRV US 61/718,659 Abandoned US <br />Provisional (PRV) 61/718,659<br />Filed on 2012-10-25<br />Status: Abandoned 114128865 VCXXXX 114128866 WIXXXX 114128867 WKXXXX 114128868 XEXXXX 114153483 Identification 114153484 Identifying 114153485 Method 114153486 Small 114153487 MOLECULE 114153488 Inhibitors 114153489 SIX/EYA 114153490 INTERACTION 114153491 treatment 114153492 cancers 114153493 Listed LPM Vathyam as of 4/15/2015 114153494 Pre LPM working set 20150418 114153495 Post LPM Assignment Set 20150420 TAB-3588 114097443 Treatment of Acute Myeloid Leukemia (AML) with the Multi-kinase FLT3-IRAK1/4 Inhibitor, NCGC1481, to Avoid Adaptive Resistance NCATS Oncology, Research Materials, Therapeutics Oncology Research Materials Therapeutics Jiankang Jiang, Craig Thomas This technology includes the identification and use of a novel small molecule, NCGC1481, to inhibit both the FLT3 and IRAK1/4 kinase pathways for treating acute myeloid leukemia (AML). An activating mutation of the FMS-like receptor kinase 3 (FMT3) occurs in approximately 25% of AML cases. Consequently, FLT3 inhibitors (FLT3i) have a good initial clinical response, however patients relapse with FLT3i-resistance. This adaptive resistance following FLT3i treatment is partially conferred by activation of the IRAK1/4 kinase complex. Given the challenges of achieving multi-drug combination regimens, a high-throughput screen was performed to identify compounds that could inhibit both FLT3i and IRAK1/4 kinases simultaneously. The multi-kinase FLT3-IRAK1/4 inhibitor NCGC1481eliminated adaptive resistant FLT3-ITD AML cells in vitro and in vivo, and displayed superior efficacy as compared to current targeted FLT3 therapies. Treatment of acute myeloid leukemia (AML) with the multi-kinase FLT3-IRAK1/4 inhibitor, NCGC1481, may overcome adaptive resistance in therapy. Further clinical work with NCGC1481could support the clinical use of the multi-kinase FLT3-IRAK1/4 inhibitor for the treatment of acute myeloid leukemia (AML). 2022-08-01 2024-10-28 2024-10-28 2022-08-01 2022-05-06 FTL3/IRAK, Inhibitors, MOLECULE, Small, VCXXXX, WIXXXX, WKXXXX, XEXXXX False True True NIHTT 37470483 Website Abstract 114172765 Melgar K, Walker MM, et al. https://pubmed.ncbi.nlm.nih.gov/31484791/ <a href="https://pubmed.ncbi.nlm.nih.gov/31484791/">Melgar K, Walker MM, et al.</a> 114110929 Jiang, Jiankang NCATS - NCGC NCATS Jiang, Jiankang (NCATS) 0 114110928 Thomas, Craig NCATS - NCGC NCATS Thomas, Craig (NCATS) 1 114110928 Thomas, Craig NCATS - NCGC NCATS Thomas, Craig (NCATS) 1 114110929 Jiang, Jiankang NCATS - NCGC NCATS Jiang, Jiankang (NCATS) 0 114102697 Small Molecule Inhibitors Of FTL3/IRAK E-055-2020-0 Under Review NCATS - NCGC 83727060 Gadhia, Ami ami.gadhia@nih.gov
United States of America NCGC ami.gadhia@nih.gov?subject=Web Inquiry on [TAB-3588] Treatment of Acute Myeloid Leukemia (AML) with the Multi-kinase FLT3-IRAK1/4 Inhibitor, NCGC1481, to Avoid Adaptive Resistance&body=Please send me information about technology [TAB-3588] Treatment of Acute Myeloid Leukemia (AML) with the Multi-kinase FLT3-IRAK1/4 Inhibitor, NCGC1481, to Avoid Adaptive Resistance. Gadhia, Ami<br><a href="mailto:ami.gadhia@nih.gov?subject=Web Inquiry on [TAB-3588] Treatment of Acute Myeloid Leukemia (AML) with the Multi-kinase FLT3-IRAK1/4 Inhibitor, NCGC1481, to Avoid Adaptive Resistance&body=Please send me information about technology [TAB-3588] Treatment of Acute Myeloid Leukemia (AML) with the Multi-kinase FLT3-IRAK1/4 Inhibitor, NCGC1481, to Avoid Adaptive Resistance.">ami.gadhia@nih.gov</a><br> 114128848 VCXXXX 114128849 WIXXXX 114128850 WKXXXX 114128851 XEXXXX 114153449 Small 114153450 MOLECULE 114153451 Inhibitors 114153452 FTL3/IRAK TAB-3586 114097441 Discovery of imidazo[1,2-b]pyridazines with Anticancer Properties NCATS Oncology, Research Materials, Therapeutics Oncology Research Materials Therapeutics Chris Finocchio, Scott Hoyt, Daniel Starczynowski, Patrick Sutter, Gregory Tawa, Craig Thomas This technology includes a series of imidazo[1,2-b]pyridazines that display potent inhibition of FLT3, as well as potent binding and activity against FLT3 tyrosine kinase domain and gatekeeper mutations. This chemotype exhibits superior anti-leukemic activity against the common clinically-relevant FLT3-mutant acute myeloid leukemia (AML) in vitro and in vivo. Tyrosine kinase domain mutations are a common cause of acquired resistance to FLT3 inhibitors used to treat FLT3-mutant AML. These agents have activity versus mutations in the acquired resistance space and versus non-IRAK inhibitors in the adaptive resistance space. If successful in human clinical trials, these agents could be used to treat a variety of hematological diseases, including but not limited to AML, myelodysplastic syndrome, diffuse large B-cell lymphoma, and other blood cancers. 2022-08-01 2024-10-28 2024-10-28 2022-08-01 2022-05-06 2-b]pyridazines, ANTICANCER, Discovery, Imidazo[1, PROPERTIES, VCXXXX, WIXXXX, WKXXXX False True True NIHTT 37470483 Website Abstract 114172758 Melgar K, Walker M, et al. https://pubmed.ncbi.nlm.nih.gov/31484791/ <a href="https://pubmed.ncbi.nlm.nih.gov/31484791/">Melgar K, Walker M, et al.</a> 114172759 Jones L, Melgar K, et al. https://pubmed.ncbi.nlm.nih.gov/32149729/ <a href="https://pubmed.ncbi.nlm.nih.gov/32149729/">Jones L, Melgar K, et al.</a> 114110917 Hoyt, Scott NCATS - NCGC NCATS Hoyt, Scott (NCATS) 0 114110918 Sutter, Patrick Baylor University Sutter, Patrick 0 114110919 Finocchio, Chris NCATS - NCGC NCATS Finocchio, Chris (NCATS) 0 114110920 Starczynowski, Daniel Cincinnati Children's Hospital Medical Center Starczynowski, Daniel 0 114110921 Tawa, Gregory NCATS - TRND NCATS Tawa, Gregory (NCATS) 0 114110916 Thomas, Craig NCATS - NCGC NCATS Thomas, Craig (NCATS) 1 114110916 Thomas, Craig NCATS - NCGC NCATS Thomas, Craig (NCATS) 1 114110917 Hoyt, Scott NCATS - NCGC NCATS Hoyt, Scott (NCATS) 0 114110918 Sutter, Patrick Baylor University Sutter, Patrick 0 114110919 Finocchio, Chris NCATS - NCGC NCATS Finocchio, Chris (NCATS) 0 114110920 Starczynowski, Daniel Cincinnati Children's Hospital Medical Center Starczynowski, Daniel 0 114110921 Tawa, Gregory NCATS - TRND NCATS Tawa, Gregory (NCATS) 0 152358046 Two Cell Lines That Have Been Genetically Engineered, Selected And Validated For 1536-well QHTS Compatibility To Express Coincidence Reporters Of Firefly Luciferase And Secreted Nano-luciferase To Recapitulate Expression Of The Pmp22 Gene And MPZ Fro E-044-2016-0 Research Material NCATS - NCGC 83727060 Gadhia, Ami ami.gadhia@nih.gov
United States of America NCGC ami.gadhia@nih.gov?subject=Web Inquiry on [TAB-3586] Discovery of imidazo[1,2-b]pyridazines with Anticancer Properties&body=Please send me information about technology [TAB-3586] Discovery of imidazo[1,2-b]pyridazines with Anticancer Properties. Gadhia, Ami<br><a href="mailto:ami.gadhia@nih.gov?subject=Web Inquiry on [TAB-3586] Discovery of imidazo[1,2-b]pyridazines with Anticancer Properties&body=Please send me information about technology [TAB-3586] Discovery of imidazo[1,2-b]pyridazines with Anticancer Properties.">ami.gadhia@nih.gov</a><br> 114128843 VCXXXX 114128844 WIXXXX 114128845 WKXXXX 114153425 Discovery 114153426 Imidazo[1 114153427 2-b]pyridazines 114153428 ANTICANCER 114153429 PROPERTIES TAB-3584 114097439 Formulation of a Modified Stable FGF-1 (TTHX1114) to Accelerate Corneal Endothelium Regeneration NCATS Cardiology, Dental, Endocrinology, Infectious Disease, Oncology, Ophthalmology, Research Materials, Therapeutics Cardiology Dental Endocrinology Infectious Disease Oncology Ophthalmology Research Materials Therapeutics Asaf Alimardanov, Trevor Broadt, Hui Fang Dong, David Eveleth, Gautam ("George") Mitra, Vinay Vyas This technology includes the use of a novel formulation for an engineered version of Fibroblast Growth Factor 1 (FGF1), TTHX1114, that can be used to accelerate regeneration of the corneal endothelium after surgical lesions. FGFs are well-established regulators of migration and proliferation of corneal endothelial cells (CECs). Fibroblast growth factors 1 and 2 are currently used to accelerate healing in ocular surface wounds. These FGFs have three cystine residues that can lead to inactivation of the factor. The formulations in this technology remove these residues and result in the stable preservation of a functionally active recombinant FGF-1 (TTHX1114). The engineered FGF1, TTHX1114, is currently being commercialized. 2022-08-01 2024-10-28 2024-10-28 2022-08-01 2022-05-06 FGF-1, FORMULATION, Modified, PRESERVATION, STABLE, TTHX1114, VPXXXX, WIXXXX, WKXXXX, XEXXXX False True True NIHTT 37470483 Website Abstract 114172756 Eveleth DD, Eveleth JJ, et al. https://pubmed.ncbi.nlm.nih.gov/30267094/ <a href="https://pubmed.ncbi.nlm.nih.gov/30267094/">Eveleth DD, Eveleth JJ, et al.</a> 114110905 Vyas, Vinay NCI - FCRDC (Leidos) Leidos Vyas, Vinay (Leidos) 0 114110906 Dong, Hui Fang NCI - FCRDC (Leidos) Leidos Dong, Hui Fang (Leidos) 0 114110907 Alimardanov, Asaf NCATS - NCGC NCATS Alimardanov, Asaf (NCATS) 0 114110908 Mitra, Gautam ("George") NCI - FCRDC (Leidos) Leidos Mitra, Gautam ("George") (Leidos) 0 114110910 Broadt, Trevor NCI - FCRDC (Leidos) Leidos Broadt, Trevor (Leidos) 0 114110909 Eveleth, David Trefoil Therapeutics, Inc. Eveleth, David 1 114110909 Eveleth, David Trefoil Therapeutics, Inc. Eveleth, David 1 114110905 Vyas, Vinay NCI - FCRDC (Leidos) Leidos Vyas, Vinay (Leidos) 0 114110906 Dong, Hui Fang NCI - FCRDC (Leidos) Leidos Dong, Hui Fang (Leidos) 0 114110907 Alimardanov, Asaf NCATS - NCGC NCATS Alimardanov, Asaf (NCATS) 0 114110908 Mitra, Gautam ("George") NCI - FCRDC (Leidos) Leidos Mitra, Gautam ("George") (Leidos) 0 114110910 Broadt, Trevor NCI - FCRDC (Leidos) Leidos Broadt, Trevor (Leidos) 0 114102693 Formulation For The Stable Preservation Of Modified FGF-1 (TTHX1114) E-038-2021-0 Filing authorized NCATS - NCGC, NCI, Trefoil Therapeutics, Inc. 83682485 Vepa, Suryanarayana sury.vepa@nih.gov
United States of America Office of Strategic Alliances (OSA) sury.vepa@nih.gov?subject=Web Inquiry on [TAB-3584] Formulation of a Modified Stable FGF-1 (TTHX1114) to Accelerate Corneal Endothelium Regeneration&body=Please send me information about technology [TAB-3584] Formulation of a Modified Stable FGF-1 (TTHX1114) to Accelerate Corneal Endothelium Regeneration. Vepa, Suryanarayana<br><a href="mailto:sury.vepa@nih.gov?subject=Web Inquiry on [TAB-3584] Formulation of a Modified Stable FGF-1 (TTHX1114) to Accelerate Corneal Endothelium Regeneration&body=Please send me information about technology [TAB-3584] Formulation of a Modified Stable FGF-1 (TTHX1114) to Accelerate Corneal Endothelium Regeneration.">sury.vepa@nih.gov</a><br> 114169430 E-038-2021-0 E-038-2021-0-US-01 Modified FGF-1 Formulation and Manufacturing PRV US 63/044,985 Abandoned US <br />Provisional (PRV) 63/044,985<br />Filed on 2020-06-26<br />Status: Abandoned 114128835 VPXXXX 114128836 WIXXXX 114128837 WKXXXX 114128838 XEXXXX 114153415 TTHX1114 114153416 FGF-1 114153417 Modified 114153418 PRESERVATION 114153419 STABLE 114153420 FORMULATION TAB-3581 114097436 Patient-derived induced pluripotent stem cell (iPSC) lines for the study of lysosomal storage diseases (LSDs) NCATS Cardiology, Dental, Endocrinology, Infectious Disease, Oncology, Ophthalmology, Research Equipment, Research Materials Cardiology Dental Endocrinology Infectious Disease Oncology Ophthalmology Research Equipment Research Materials Jeanette Beers, Yu-Shan Cheng, Manisha Pradhan, Miao Xu, Wei Zheng, Jizhong Zou This technology includes the generation and use of human induced pluripotent stem cell (iPSC) lines that can be used to study and screen potential therapeutics for lysosomal storage diseases (LSDs). LSDs are a group of 50 genetic disorders caused by mutations in the genes encoding lysosomal enzymes and proteins. Although various therapeutic approaches exist, most cases of LSDs are not effectively treated due to a lack of therapeutics (including stem cells and recombinant proteins). The iPSC lines in this technology were generated from patient fibroblasts that were differentiated into neural stem cells and neurons appropriate for disease modeling and evaluation of drug efficacy. The human-derived induced pluripotent stem cell (iPSC) lines enable a much more direct method for modeling lysosomal storage disease (LSD) and evaluating compound efficacy. Previous work with fibroblast cell lines revealed that drug potency and efficacy were significantly different from human responses. The use of iPSC technology is expected to lead to more relevant potency and efficacy measures. The induced pluripotent stem cell (iPSC) lines can be used for lysosomal storage disease (LSD) modeling and as a cell-based assay for drug discovery and development. 2022-08-01 2024-10-28 2024-10-28 2022-08-01 2022-05-06 Cell, COMPOUND, DERIVED, Disease, iPS, Lines, Lysosomal, Modeling, PATIENT, screening, Storage, VPXXXX, WIXXXX, XHXXXX False True True NIHTT 37470483 Website Abstract 114172745 Long Y, Xu M, et al. https://pubmed.ncbi.nlm.nih.gov/27484861/ <a href="https://pubmed.ncbi.nlm.nih.gov/27484861/">Long Y, Xu M, et al.</a> 114172747 Aguisanda F, Yeh CD, et al. https://pubmed.ncbi.nlm.nih.gov/28659158/ <a href="https://pubmed.ncbi.nlm.nih.gov/28659158/">Aguisanda F, Yeh CD, et al.</a> 114172748 Sima N, Li R, et al. https://pubmed.ncbi.nlm.nih.gov/29631617/ <a href="https://pubmed.ncbi.nlm.nih.gov/29631617/">Sima N, Li R, et al.</a> 114172749 Swaroop M, Brooks MJ, et al. https://pubmed.ncbi.nlm.nih.gov/30052969/ <a href="https://pubmed.ncbi.nlm.nih.gov/30052969/">Swaroop M, Brooks MJ, et al.</a> 114172750 Vu M, Li R, et al. https://pubmed.ncbi.nlm.nih.gov/30220252/ <a href="https://pubmed.ncbi.nlm.nih.gov/30220252/">Vu M, Li R, et al.</a> 114172751 Baskfield A, Li R, et al. https://pubmed.ncbi.nlm.nih.gov/31009819/ <a href="https://pubmed.ncbi.nlm.nih.gov/31009819/">Baskfield A, Li R, et al.</a> 114172752 Cheng Y-S, Li R, et al. https://pubmed.ncbi.nlm.nih.gov/31026687/ <a href="https://pubmed.ncbi.nlm.nih.gov/31026687/">Cheng Y-S, Li R, et al.</a> 114172753 Hong J, Xu M, et al. https://pubmed.ncbi.nlm.nih.gov/31071499/ <a href="https://pubmed.ncbi.nlm.nih.gov/31071499/">Hong J, Xu M, et al.</a> 114172754 Huang W, Xu M, et al. https://pubmed.ncbi.nlm.nih.gov/30933722/ <a href="https://pubmed.ncbi.nlm.nih.gov/30933722/">Huang W, Xu M, et al.</a> 114110888 Xu, Miao NCATS - NCGC NCATS Xu, Miao (NCATS) 0 114110889 Cheng, Yu-Shan NCATS - NCGC NCATS Cheng, Yu-Shan (NCATS) 0 114110890 Pradhan, Manisha NCATS - NCGC NCATS Pradhan, Manisha (NCATS) 0 114110891 Zou, Jizhong National Heart, Lung, and Blood Institute (NHLBI) NHLBI Zou, Jizhong (NHLBI) 0 114110892 Beers, Jeanette National Heart, Lung, and Blood Institute (NHLBI) NHLBI Beers, Jeanette (NHLBI) 0 114110887 Zheng, Wei NCATS - TRND NCATS Zheng, Wei (NCATS) 1 114110887 Zheng, Wei NCATS - TRND NCATS Zheng, Wei (NCATS) 1 114110888 Xu, Miao NCATS - NCGC NCATS Xu, Miao (NCATS) 0 114110889 Cheng, Yu-Shan NCATS - NCGC NCATS Cheng, Yu-Shan (NCATS) 0 114110890 Pradhan, Manisha NCATS - NCGC NCATS Pradhan, Manisha (NCATS) 0 114110891 Zou, Jizhong National Heart, Lung, and Blood Institute (NHLBI) NHLBI Zou, Jizhong (NHLBI) 0 114110892 Beers, Jeanette National Heart, Lung, and Blood Institute (NHLBI) NHLBI Beers, Jeanette (NHLBI) 0 114102690 Lysosomal Storage Disease Modeling And Compound Screening Using The Patient Derived IPS Cell Lines E-032-2021-0 Research Material National Heart, Lung, and Blood Institute (NHLBI), NCATS - NCGC 83682485 Vepa, Suryanarayana sury.vepa@nih.gov
United States of America Office of Strategic Alliances (OSA) sury.vepa@nih.gov?subject=Web Inquiry on [TAB-3581] Patient-derived induced pluripotent stem cell (iPSC) lines for the study of lysosomal storage diseases (LSDs)&body=Please send me information about technology [TAB-3581] Patient-derived induced pluripotent stem cell (iPSC) lines for the study of lysosomal storage diseases (LSDs). Vepa, Suryanarayana<br><a href="mailto:sury.vepa@nih.gov?subject=Web Inquiry on [TAB-3581] Patient-derived induced pluripotent stem cell (iPSC) lines for the study of lysosomal storage diseases (LSDs)&body=Please send me information about technology [TAB-3581] Patient-derived induced pluripotent stem cell (iPSC) lines for the study of lysosomal storage diseases (LSDs).">sury.vepa@nih.gov</a><br> 114128822 VPXXXX 114128823 WIXXXX 114128824 XHXXXX 114153391 Lysosomal 114153392 Storage 114153393 Disease 114153394 Modeling 114153395 COMPOUND 114153396 screening 114153397 PATIENT 114153398 DERIVED 114153399 iPS 114153400 Cell 114153401 Lines TAB-3578 114097433 A Cell Line that Expresses secNluc and GFP to Recapitulate PMP22 Gene Expression for Studying Peripheral Neuropathy NCATS Neurology, Research Materials, Therapeutics Neurology Research Materials Therapeutics James Inglese, Sung-Wook Jang, John Svaren This technology includes a cell line that expresses two reporters (a secreted luciferase, secNLuc, and GFP) in a pattern that recapitulates the endogenous expression of the peripheral myelin protein 22 (Pmp22) gene. Pmp22 is mainly expressed in the Schwann cells of the peripheral nervous system. Many neurological disorders are associated with aberrations in Schwann cells, including the most common inherited peripheral neuropathy known as Charcot-Marie-Tooth (CMT) disease. This cell line will permit the study of the regulatory elements behind the gene. Whereas the previous use of reporter genes has little control over the location of the reporter genes in the genome, this cell line has been genetically modified to simultaneously express the reporters secNluc and GFP to recapitulate expression of the Pmp22 gene from its native genomic locus and therefore enhance the physiological representation of the reporter genes. This cell line serves as an indispensable tool to investigate the regulatory circuitry of the Pmp22 gene whose aberrant expression is clinically linked with the most common inherited peripheral neuropathy known as Charcot-Marie-Tooth (CMT) disease. In particular, the utility of the cell line as a cell-based assay platform could significantly enable a large-scale screening campaign to develop treatments for CMT. 2022-08-01 2024-10-28 2024-10-28 2022-08-01 2022-05-06 Cell, Coincidence, ENDOGENOUS, ENGINEERED, Express, Expression, Gene, GENETICALLY, GFP, Line, Listed LPM Tong as of 4/15/2015, LOCUS, Pmp22, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Recapitulate, Reporters, SecNluc, That, VEXXXX, WIXXXX, XEXXXX False True True NIHTT 37470483 Website Abstract 114172742 Jang SW, Lopez-Anido C, et al. https://pubmed.ncbi.nlm.nih.gov/22530759/ <a href="https://pubmed.ncbi.nlm.nih.gov/22530759/">Jang SW, Lopez-Anido C, et al.</a> 114172743 Cheng KC-C, Inglese J https://pubmed.ncbi.nlm.nih.gov/23018994/ <a href="https://pubmed.ncbi.nlm.nih.gov/23018994/">Cheng KC-C, Inglese J</a> 114172744 Miller JC, Tan S, et al. https://pubmed.ncbi.nlm.nih.gov/21179091/ <a href="https://pubmed.ncbi.nlm.nih.gov/21179091/">Miller JC, Tan S, et al.</a> 114110881 Svaren, John University of Wisconsin - Madison Svaren, John 0 114110883 Jang, Sung-Wook NCATS - NCGC Jang, Sung-Wook 0 114110882 Inglese, James NCATS - NCGC NCATS Inglese, James (NCATS) 1 114110882 Inglese, James NCATS - NCGC NCATS Inglese, James (NCATS) 1 114110881 Svaren, John University of Wisconsin - Madison Svaren, John 0 114110883 Jang, Sung-Wook NCATS - NCGC Jang, Sung-Wook 0 114102687 A Cell Line That Has Been Genetically Engineered To Express Coincidence Reporters Of SecNluc And GFP To Recapitulate Expression Of The Pmp22 Gene From Its Endogenous Locus E-012-2014-0 Research Material NCATS - NCGC 83682485 Vepa, Suryanarayana sury.vepa@nih.gov
United States of America Office of Strategic Alliances (OSA) sury.vepa@nih.gov?subject=Web Inquiry on [TAB-3578] A Cell Line that Expresses secNluc and GFP to Recapitulate PMP22 Gene Expression for Studying Peripheral Neuropathy&body=Please send me information about technology [TAB-3578] A Cell Line that Expresses secNluc and GFP to Recapitulate PMP22 Gene Expression for Studying Peripheral Neuropathy. Vepa, Suryanarayana<br><a href="mailto:sury.vepa@nih.gov?subject=Web Inquiry on [TAB-3578] A Cell Line that Expresses secNluc and GFP to Recapitulate PMP22 Gene Expression for Studying Peripheral Neuropathy&body=Please send me information about technology [TAB-3578] A Cell Line that Expresses secNluc and GFP to Recapitulate PMP22 Gene Expression for Studying Peripheral Neuropathy.">sury.vepa@nih.gov</a><br> 114128816 VEXXXX 114128817 WIXXXX 114128818 XEXXXX 114153363 Cell 114153364 Line 114153365 That 114153366 GENETICALLY 114153367 ENGINEERED 114153368 Express 114153369 Coincidence 114153370 Reporters 114153371 SecNluc 114153372 GFP 114153373 Recapitulate 114153374 Expression 114153375 Pmp22 114153376 Gene 114153377 ENDOGENOUS 114153378 LOCUS 114153379 Listed LPM Tong as of 4/15/2015 114153380 Pre LPM working set 20150418 114153381 Post LPM Assignment Set 20150420 TAB-3576 114097431 Small Molecule Inhibitors of the p53/S100B Interaction for Treating Cancer NCATS Oncology, Therapeutics Oncology Therapeutics Ajit Jadhav, Daniel Jansen, Stephen Kales, Diane Luci, David Maloney, Anton Simeonov, Hongmao Sun This technology includes newly identified best-in-class inhibitors of the p53-S100B interaction that plays a role in malignant melanoma. S100B contributes to cancer cell proliferation (particularly malignant melanoma) by binding to p53 and inhibiting its tumor suppressor function. A high-throughput screen was used to find p53-S100B inhibitors, leading to the identification of a putative inhibitor, which was then subjected to medicinal chemistry optimization. Structure-based design was then used to develop compounds with significantly improved potency. The identified compounds are best-in-class inhibitors of p53/S100B protein-protein interactions. The identified compounds can be developed into anti-cancer agents. 2022-08-01 2024-10-28 2024-10-28 2022-08-01 2022-05-06 Inhibitors, MOLECULE, P53-S100B, Small, VCXXXX, WKXXXX, XEXXXX False True True NIHTT 37470483 Website Abstract 114110867 Simeonov, Anton NCATS - NCGC NCATS Simeonov, Anton (NCATS) 0 114110868 Maloney, David NCATS - NCGC NCATS Maloney, David (NCATS) 0 114110869 Jansen, Daniel NCATS - NCGC Jansen, Daniel 0 114110870 Sun, Hongmao NCATS - NCGC NCATS Sun, Hongmao (NCATS) 0 114110871 Luci, Diane NCATS - NCGC NCATS Luci, Diane (NCATS) 0 114110872 Jadhav, Ajit NCATS - NCGC NCATS Jadhav, Ajit (NCATS) 0 114110866 Kales, Stephen NCATS - NCGC NCATS Kales, Stephen (NCATS) 1 114110866 Kales, Stephen NCATS - NCGC NCATS Kales, Stephen (NCATS) 1 114110867 Simeonov, Anton NCATS - NCGC NCATS Simeonov, Anton (NCATS) 0 114110868 Maloney, David NCATS - NCGC NCATS Maloney, David (NCATS) 0 114110869 Jansen, Daniel NCATS - NCGC Jansen, Daniel 0 114110870 Sun, Hongmao NCATS - NCGC NCATS Sun, Hongmao (NCATS) 0 114110871 Luci, Diane NCATS - NCGC NCATS Luci, Diane (NCATS) 0 114110872 Jadhav, Ajit NCATS - NCGC NCATS Jadhav, Ajit (NCATS) 0 114102685 Small Molecule Inhibitors Of P53-S100B E-009-2017-0 Filing authorized NCATS - NCGC 83727060 Gadhia, Ami ami.gadhia@nih.gov
United States of America NCGC ami.gadhia@nih.gov?subject=Web Inquiry on [TAB-3576] Small Molecule Inhibitors of the p53/S100B Interaction for Treating Cancer&body=Please send me information about technology [TAB-3576] Small Molecule Inhibitors of the p53/S100B Interaction for Treating Cancer. Gadhia, Ami<br><a href="mailto:ami.gadhia@nih.gov?subject=Web Inquiry on [TAB-3576] Small Molecule Inhibitors of the p53/S100B Interaction for Treating Cancer&body=Please send me information about technology [TAB-3576] Small Molecule Inhibitors of the p53/S100B Interaction for Treating Cancer.">ami.gadhia@nih.gov</a><br> 114169416 E-009-2017-0 E-009-2017-0-US-01 Inhibitors Of P53-S100B and Methods of Using the Same PRV US 62/459,830 Abandoned US <br />Provisional (PRV) 62/459,830<br />Filed on 2017-02-16<br />Status: Abandoned 114128807 VCXXXX 114128808 WKXXXX 114128809 XEXXXX 114153347 Small 114153348 MOLECULE 114153349 Inhibitors 114153350 P53-S100B TAB-3572 114097427 AMPK Modulators for Treatment of Niemann Pick Type C Disease NCATS Cardiology, Dental, Endocrinology, Infectious Disease, Oncology, Ophthalmology, Research Materials, Therapeutics Cardiology Dental Endocrinology Infectious Disease Oncology Ophthalmology Research Materials Therapeutics Sheng Dai, Xin Hu, Juan Marugan, Daniel Talley, Wei Zheng This technology includes a group of eight AMPK activating compounds to be further developed for the treatment of Niemann Pick Type C (NPC) disease. Through the recent molecular biology and pharmacological experiments, we have identified the cyclodextrin which directly binds to beta-subunits of AMP-activated protein kinase (AMP), resulting in subsequently activations of AMPK and AMPK linked autophagy, and restoration of autophagy function that is impaired in the NPC cells. Based on this knowledge, we performed computer-modeling research of compounds binding to AMPK beta subunits that led to identification of a group of AMPK activating compounds. We further found that this group of eight compounds (AMPK modulators) also effectively reduced lysosomal cholesterol accumulation in NPC cells. Therefore, this group of AMPK modulators can be further developed for treatment of NPC. The small molecule AMPK modulators can be optimized for better blood-brain-barrier penetration, and the allosteric modulation of AMPK function by these compounds is more tolerable as a treatment. The AMPK modulators can be further developed to improve potency and ability of blood-brain-barrier penetration as a new drug for treatment of Niemann Pick disease Type C. 2022-08-01 2024-10-28 2024-10-28 2022-08-01 2022-05-06 AMPK, C, Disease, MODULATORS, Niemann, Pick, treatment, TYPE, VHXXXX, VPXXXX, WIXXXX, WKXXXX False True True NIHTT 37470483 Website Abstract 114110845 Marugan, Juan NCATS - NCGC NCATS Marugan, Juan (NCATS) 0 114110846 Dai, Sheng NCATS - NCGC Dai, Sheng 0 114110847 Hu, Xin NCATS - NCGC NCATS Hu, Xin (NCATS) 0 114110848 Talley, Daniel NCATS - NCGC NCATS Talley, Daniel (NCATS) 0 114110844 Zheng, Wei NCATS - TRND NCATS Zheng, Wei (NCATS) 1 114110844 Zheng, Wei NCATS - TRND NCATS Zheng, Wei (NCATS) 1 114110845 Marugan, Juan NCATS - NCGC NCATS Marugan, Juan (NCATS) 0 114110846 Dai, Sheng NCATS - NCGC Dai, Sheng 0 114110847 Hu, Xin NCATS - NCGC NCATS Hu, Xin (NCATS) 0 114110848 Talley, Daniel NCATS - NCGC NCATS Talley, Daniel (NCATS) 0 114102681 AMPK Modulators For Treatment Of Niemann Pick Type C Disease E-066-2017-0 Filing authorized NCATS - NCGC 83682485 Vepa, Suryanarayana sury.vepa@nih.gov
United States of America Office of Strategic Alliances (OSA) sury.vepa@nih.gov?subject=Web Inquiry on [TAB-3572] AMPK Modulators for Treatment of Niemann Pick Type C Disease&body=Please send me information about technology [TAB-3572] AMPK Modulators for Treatment of Niemann Pick Type C Disease. Vepa, Suryanarayana<br><a href="mailto:sury.vepa@nih.gov?subject=Web Inquiry on [TAB-3572] AMPK Modulators for Treatment of Niemann Pick Type C Disease&body=Please send me information about technology [TAB-3572] AMPK Modulators for Treatment of Niemann Pick Type C Disease.">sury.vepa@nih.gov</a><br> 114169407 E-066-2017-0 E-066-2017-0-US-01 AMPK Modulators and Methods of Use PRV US 62/445,452 Abandoned US <br />Provisional (PRV) 62/445,452<br />Filed on 2017-01-12<br />Status: Abandoned 114128787 VHXXXX 114128788 VPXXXX 114128789 WIXXXX 114128790 WKXXXX 114153307 AMPK 114153308 MODULATORS 114153309 treatment 114153310 Niemann 114153311 Pick 114153312 TYPE 114153313 C 114153314 Disease TAB-3573 114097428 A Method for the Measurement of Cellular FMRP Levels for High Throughput Screening and Diagnosis of Fragile X Syndrome NCATS Antibodies, Cardiology, Consumer Products, Dental, Diagnostics, Endocrinology, Immunology, Infectious Disease, Neurology, Occupational Safety and Health, Oncology, Ophthalmology, Research Materials, Therapeutics Antibodies Cardiology Consumer Products Dental Diagnostics Endocrinology Immunology Infectious Disease Neurology Occupational Safety and Health Oncology Ophthalmology Research Materials Therapeutics Wenwei Huang, Daman Kumari, John McKew, Noel Southall, Manju Swaroop, Karen Usdin, Wei Zheng This technology includes a precise measurement assay of cellular FMRP levels in patients, which can assist in the diagnosis and assess the severity of Fragile X syndrome (FXS). FXS is an X-linked disorder that produces intellectual disability, cognitive impairment, epilepsy, depression and anxiety. FXS is caused by mutations in the Fragile X Mental Retardation-1 (FMR1) gene that result in the absence or a loss of function of its protein product, FMRP. This TR-FRET based FMRP assay method uses two specific antibodies against two different sites of FRMP that has very high specificity for the measurement. The application of TR-FRET based HTRF detection in this assay (by labeling HTRF detection pair to the two antibodies) enables a homogenous measurement of cellular FMRP levels in 96-, 384- and 1536-well plate formats. This TR-FRET based FMRP assay method uses two specific antibodies against two different sites of FRMP that has very high specificity for the measurement, which is better than the conventional assays used (Western blot and ELISA). <ul> <li>Precise measurement of cellular FMRP levels in patients can assist in the diagnosis and assess the severity of FXS.</li> <li>The quantitative measurement of cellular FMRP levels can be used to screen a compound collection for identification of compounds which may be used for FXS treatment.</li> </ul> 2022-08-01 2024-10-28 2024-10-28 2022-08-01 2022-05-06 Cellular, Diagnosis, FMRP, Fragile, High, IAXXXX, IXXXXX, LEVELS, Listed LPM Nguyen-Antczak as of 4/15/2015, MEASUREMENT, Method, NA2AXX, NA2XXX, NAXXXX, NXXXXX, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, screening, Syndrome, THROUGHPUT, VPXXXX, WFXXXX, WIXXXX, X, XAXXXX False True True NIHTT 37470483 Website Abstract 114172737 Willemsen R, Anar B, et al. https://pubmed.ncbi.nlm.nih.gov/10364521/ <a href="https://pubmed.ncbi.nlm.nih.gov/10364521/">Willemsen R, Anar B, et al.</a> 114172738 Kaufmann W, Abrams M, et al. https://pubmed.ncbi.nlm.nih.gov/10208163/ <a href="https://pubmed.ncbi.nlm.nih.gov/10208163/">Kaufmann W, Abrams M, et al.</a> 114172739 Iwahashi C, Tassone F, et al. https://pubmed.ncbi.nlm.nih.gov/19460937/ <a href="https://pubmed.ncbi.nlm.nih.gov/19460937/">Iwahashi C, Tassone F, et al.</a> 114172740 Lessard M, Chouiali A, et al. https://pubmed.ncbi.nlm.nih.gov/21992468/ <a href="https://pubmed.ncbi.nlm.nih.gov/21992468/">Lessard M, Chouiali A, et al.</a> 114110850 Usdin, Karen National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Usdin, Karen (NIDDK) 0 114110851 Swaroop, Manju NCATS - NCGC NCATS Swaroop, Manju (NCATS) 0 114110852 Kumari, Daman National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Kumari, Daman (NIDDK) 0 114110853 Huang, Wenwei NCATS - TRND NCATS Huang, Wenwei (NCATS) 0 114110854 Southall, Noel NCATS - TRND NCATS Southall, Noel (NCATS) 0 114110855 McKew, John NCATS - TRND McKew, John 0 114110849 Zheng, Wei NCATS - TRND NCATS Zheng, Wei (NCATS) 1 114110849 Zheng, Wei NCATS - TRND NCATS Zheng, Wei (NCATS) 1 114110850 Usdin, Karen National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Usdin, Karen (NIDDK) 0 114110851 Swaroop, Manju NCATS - NCGC NCATS Swaroop, Manju (NCATS) 0 114110852 Kumari, Daman National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Kumari, Daman (NIDDK) 0 114110853 Huang, Wenwei NCATS - TRND NCATS Huang, Wenwei (NCATS) 0 114110854 Southall, Noel NCATS - TRND NCATS Southall, Noel (NCATS) 0 114110855 McKew, John NCATS - TRND McKew, John 0 114102682 A Method For The Measurement Of Cellular FMRP Levels For High Throughput Screening And Diagnosis Of Fragile X Syndrome E-083-2013-0 Filing authorized National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NCATS - NCGC 83682485 Vepa, Suryanarayana sury.vepa@nih.gov
United States of America Office of Strategic Alliances (OSA) sury.vepa@nih.gov?subject=Web Inquiry on [TAB-3573] A Method for the Measurement of Cellular FMRP Levels for High Throughput Screening and Diagnosis of Fragile X Syndrome&body=Please send me information about technology [TAB-3573] A Method for the Measurement of Cellular FMRP Levels for High Throughput Screening and Diagnosis of Fragile X Syndrome. Vepa, Suryanarayana<br><a href="mailto:sury.vepa@nih.gov?subject=Web Inquiry on [TAB-3573] A Method for the Measurement of Cellular FMRP Levels for High Throughput Screening and Diagnosis of Fragile X Syndrome&body=Please send me information about technology [TAB-3573] A Method for the Measurement of Cellular FMRP Levels for High Throughput Screening and Diagnosis of Fragile X Syndrome.">sury.vepa@nih.gov</a><br> 114169408 E-083-2013-0 E-083-2013-0-US-01 Measurement of Cellular FMRP Levels for High Throughput Drug Screening and Diagnosis of Fragile X Syndrome PRV US 61/793,577 Abandoned US <br />Provisional (PRV) 61/793,577<br />Filed on 2013-03-15<br />Status: Abandoned 114169409 E-083-2013-0 E-083-2013-0-PCT-02 Measurement Of Cellular FMRP Levels For High Throughput Screening And Diagnosis Of Fragile X Syndrome PCT Patent Cooperation Treaty PCT/US2014/027517 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2014/027517<br />Filed on 2014-03-14<br />Status: Expired 114128791 IXXXXX 114128792 IAXXXX 114128793 NXXXXX 114128794 NAXXXX 114128795 NA2XXX 114128796 NA2AXX 114128797 VPXXXX 114128798 WFXXXX 114128799 WIXXXX 114128800 XAXXXX 114153315 Method 114153316 MEASUREMENT 114153317 Cellular 114153318 FMRP 114153319 LEVELS 114153320 High 114153321 THROUGHPUT 114153322 screening 114153323 Diagnosis 114153324 Fragile 114153325 X 114153326 Syndrome 114153327 Listed LPM Nguyen-Antczak as of 4/15/2015 114153328 Pre LPM working set 20150418 114153329 Post LPM Assignment Set 20150420 TAB-3570 114097425 Novel Dual 5-lipoxgenase and East CYP51 Inhibitors for the Treatment of Dandruff NCATS Cardiology, Dental, Endocrinology, Infectious Disease, Oncology, Ophthalmology, Research Materials, Therapeutics Cardiology Dental Endocrinology Infectious Disease Oncology Ophthalmology Research Materials Therapeutics Theodore Holman, Ajit Jadhav, Steven Kelly, David Maloney, Ganesha Rai Bantukallu, Anton Simeonov This technology includes a newly designed chemical molecule that is both an antifungal agent, by inhibiting CYP51, and an anti-inflammatory agent, by inhibiting 5-lipoxygenase, for the treatment of dandruff. Both of these properties would be useful for antifungal treatments, and both of these attributes are required to combat dandruff. However, typical therapies involve treating the infection and inflammation separately. Single agent therapy for dandruff with a dual mechanism. Utilized for the treatment of dandruff. 2022-08-01 2024-10-28 2024-10-28 2022-08-01 2022-05-06 5-li, 5-LIPOXYGENASE, Against, Ainst, CYP51, Dandruff, Dual, East, Enase, Inhibitors, Listed LPM Nguyen-Antczak as of 4/15/2015, Novel, Ox, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, VPXXXX, WIXXXX, WKXXXX False True True NIHTT 37470483 Website Abstract 114110835 Maloney, David NCATS - NCGC NCATS Maloney, David (NCATS) 0 114110836 Jadhav, Ajit NCATS - NCGC NCATS Jadhav, Ajit (NCATS) 0 114110837 Rai Bantukallu, Ganesha NCATS - NCGC NCATS Rai Bantukallu, Ganesha (NCATS) 0 114110838 Simeonov, Anton NCATS - NCGC NCATS Simeonov, Anton (NCATS) 0 114110840 Kelly, Steven Swansea University Kelly, Steven 0 114110839 Holman, Theodore University of California, Santa Cruz Holman, Theodore 1 114110839 Holman, Theodore University of California, Santa Cruz Holman, Theodore 1 114110835 Maloney, David NCATS - NCGC NCATS Maloney, David (NCATS) 0 114110836 Jadhav, Ajit NCATS - NCGC NCATS Jadhav, Ajit (NCATS) 0 114110837 Rai Bantukallu, Ganesha NCATS - NCGC NCATS Rai Bantukallu, Ganesha (NCATS) 0 114110838 Simeonov, Anton NCATS - NCGC NCATS Simeonov, Anton (NCATS) 0 114110840 Kelly, Steven Swansea University Kelly, Steven 0 114102679 Novel Dual 5-lipoxygenase And East CYP51 Inhibitors Against Dandruff E-217-2013-0 Filing authorized NCATS - NCGC, Swansea University, University of California, Santa Cruz 83682485 Vepa, Suryanarayana sury.vepa@nih.gov
United States of America Office of Strategic Alliances (OSA) sury.vepa@nih.gov?subject=Web Inquiry on [TAB-3570] Novel Dual 5-lipoxgenase and East CYP51 Inhibitors for the Treatment of Dandruff&body=Please send me information about technology [TAB-3570] Novel Dual 5-lipoxgenase and East CYP51 Inhibitors for the Treatment of Dandruff. Vepa, Suryanarayana<br><a href="mailto:sury.vepa@nih.gov?subject=Web Inquiry on [TAB-3570] Novel Dual 5-lipoxgenase and East CYP51 Inhibitors for the Treatment of Dandruff&body=Please send me information about technology [TAB-3570] Novel Dual 5-lipoxgenase and East CYP51 Inhibitors for the Treatment of Dandruff.">sury.vepa@nih.gov</a><br> 114169405 E-217-2013-0 E-217-2013-0-US-01 A new chemical entity useful for treating various diseases PRV US 61/710,505 Abandoned US <br />Provisional (PRV) 61/710,505<br />Filed on 2012-10-05<br />Status: Abandoned 114169406 E-217-2013-0 E-217-2013-0-PCT-02 A NEW CHEMICAL ENTITY USEFUL FOR TREATING VARIOUS DISEASES PCT Patent Cooperation Treaty PCT/US2013/063616 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2013/063616<br />Filed on 2013-10-07<br />Status: Expired 114128779 VPXXXX 114128780 WKXXXX 114128781 WIXXXX 114153269 Novel 114153270 Dual 114153271 5-li 114153272 Ox 114153273 Enase 114153274 East 114153275 CYP51 114153276 Inhibitors 114153277 Ainst 114153278 Dandruff 114153279 5-LIPOXYGENASE 114153280 Against 114153281 Listed LPM Nguyen-Antczak as of 4/15/2015 114153282 Pre LPM working set 20150418 114153283 Post LPM Assignment Set 20150420 TAB-3571 114097426 Optimized Nucleotide Sequence for RLIP-76 - A Membrane-associated Lipid Peroxidation Transporter for Radiation Poisoning NCATS Cardiology, Dental, Endocrinology, Infectious Disease, Occupational Safety and Health, Oncology, Ophthalmology, Research Materials, Therapeutics Cardiology Dental Endocrinology Infectious Disease Occupational Safety and Health Oncology Ophthalmology Research Materials Therapeutics Trevor Broadt, Dominic Esposito, Vinay Vyas This technology includes a codon optimized expression vector for the high expression and production of RLIP-76 which can be used to provide protection from radiation. RLIP-76 is a multifunctional membrane protein that transports glutathione conjugates of electrophilic compounds outside the cell. The sequence was generated with codon bias alterations, reduction of secondary structure, lowering of GC content, and removal of cryptic elements that could affect expression in E.coli. The final plasmid construct was flanked by Nde1 and Xho1 restriction sites, and contained a triple stop codon to ensure complete translation stop without readthrough. Ability to rapidly produce RLIP-76. High level expression of codon optimized expression vector would help in the rapid production of RLIP-76 in the event of a radiological event. 2022-08-01 2024-10-28 2024-10-28 2022-08-01 2022-05-06 5-HTP, AADC, And/or, assay, Benefit, Combination, COMPRISING, Gene, L-DOPA, Lipid, Membrane-associated, Nucleotide, OPTIMIZED, Peroxidation, POTENCY, Potential, PRODUCT, RAAV·AADC, RLIP-76, sequence, therapeutic, THERAPY, TRANSPORTER, VPXXXX, WGXXXX, WIXXXX, WJXXXX, XEXXXX False True True NIHTT 37470483 Website Abstract 114110841 Esposito, Dominic NCI - FCRDC (Leidos) Leidos Esposito, Dominic (Leidos) 0 114110843 Broadt, Trevor NCI - FCRDC (Leidos) Leidos Broadt, Trevor (Leidos) 0 114110842 Vyas, Vinay NCI - FCRDC (Leidos) Leidos Vyas, Vinay (Leidos) 1 114110842 Vyas, Vinay NCI - FCRDC (Leidos) Leidos Vyas, Vinay (Leidos) 1 114110841 Esposito, Dominic NCI - FCRDC (Leidos) Leidos Esposito, Dominic (Leidos) 0 114110843 Broadt, Trevor NCI - FCRDC (Leidos) Leidos Broadt, Trevor (Leidos) 0 114102680 Optimized Nucleotide Sequence For RLIP-76 - A Membrane-associated Lipid Peroxidation Transporter E-226-2018-0 Filing authorized NCATS - NCGC 83682485 Vepa, Suryanarayana sury.vepa@nih.gov
United States of America Office of Strategic Alliances (OSA) sury.vepa@nih.gov?subject=Web Inquiry on [TAB-3571] Optimized Nucleotide Sequence for RLIP-76 - A Membrane-associated Lipid Peroxidation Transporter for Radiation Poisoning&body=Please send me information about technology [TAB-3571] Optimized Nucleotide Sequence for RLIP-76 - A Membrane-associated Lipid Peroxidation Transporter for Radiation Poisoning. Vepa, Suryanarayana<br><a href="mailto:sury.vepa@nih.gov?subject=Web Inquiry on [TAB-3571] Optimized Nucleotide Sequence for RLIP-76 - A Membrane-associated Lipid Peroxidation Transporter for Radiation Poisoning&body=Please send me information about technology [TAB-3571] Optimized Nucleotide Sequence for RLIP-76 - A Membrane-associated Lipid Peroxidation Transporter for Radiation Poisoning.">sury.vepa@nih.gov</a><br> 114128782 VPXXXX 114128783 WGXXXX 114128784 WIXXXX 114128785 WJXXXX 114128786 XEXXXX 114153284 POTENCY 114153285 assay 114153286 AADC 114153287 Gene 114153288 THERAPY 114153289 PRODUCT 114153290 Potential 114153291 therapeutic 114153292 Benefit 114153293 Combination 114153294 COMPRISING 114153295 RAAV·AADC 114153296 L-DOPA 114153297 And/or 114153298 5-HTP 114153299 OPTIMIZED 114153300 Nucleotide 114153301 sequence 114153302 RLIP-76 114153303 Membrane-associated 114153304 Lipid 114153305 Peroxidation 114153306 TRANSPORTER TAB-3569 114097424 O-GlcNAc Transferase (OGT) Inhibitors for the Treatment of Cancer and Viral Infections NCATS Infectious Disease, Oncology, Research Materials, Therapeutics Infectious Disease Oncology Research Materials Therapeutics Damien Duveau, Rodrigo Ortiz Meoz, Craig Thomas, Suzanne Walker This technology includes small molecule inhibitors of O-linked N-acetyl glucosamine (OGlcNAc) transferase (OGT) as molecular probes to better understand OGT function in cell homeostasis, and to eventually be used as therapeutic agents against cancer and to reduce viral replication. OGT is a ubiquitous enzyme catalyzing the transfer of N-acetylglucosamine to the serine or threonine residues of nuclear and cytoplasmic proteins. This cellular process is tightly regulated and is sensitive to levels of cellular stress and of nutrients levels. In addition, OGT modulation may inform on the metabolic reprograming of cancer cells. The inhibitors developed show on-target OGT engagement, as judged by several readouts but does not appear to alter N- or O-glycan structures substantially. The first series of cell-permeable and selective OGT inhibitors with on-target engagement. Inhibitors of OGT could be used alone, or in combination with other agents for the treatment of cancer and to reduce replication of a number of viruses. 2022-08-01 2024-10-28 2024-10-28 2022-08-01 2022-05-06 Inhibitors, O-GlcNAc, OGT, THEREOF, TRANSFERASE, USES, VCXXXX, VLXXXX, WIXXXX, WKXXXX False True True NIHTT 37470483 Website Abstract 114172734 Ortiz-Meoz R, Jiang J, et al. https://pubmed.ncbi.nlm.nih.gov/25751766/ <a href="https://pubmed.ncbi.nlm.nih.gov/25751766/">Ortiz-Meoz R, Jiang J, et al.</a> 114172735 Itkonen H, Gorad S, et al. https://pubmed.ncbi.nlm.nih.gov/26824323/ <a href="https://pubmed.ncbi.nlm.nih.gov/26824323/">Itkonen H, Gorad S, et al.</a> 114172736 Angelova M, Ortiz-Meoz R, et al. https://pubmed.ncbi.nlm.nih.gov/26041297/ <a href="https://pubmed.ncbi.nlm.nih.gov/26041297/">Angelova M, Ortiz-Meoz R, et al.</a> 114110832 Ortiz Meoz, Rodrigo Harvard University Ortiz Meoz, Rodrigo 0 114110833 Thomas, Craig NCATS - NCGC NCATS Thomas, Craig (NCATS) 0 114110834 Duveau, Damien NCATS - NCGC NCATS Duveau, Damien (NCATS) 0 114110831 Walker, Suzanne Harvard University Walker, Suzanne 1 114110831 Walker, Suzanne Harvard University Walker, Suzanne 1 114110832 Ortiz Meoz, Rodrigo Harvard University Ortiz Meoz, Rodrigo 0 114110833 Thomas, Craig NCATS - NCGC NCATS Thomas, Craig (NCATS) 0 114110834 Duveau, Damien NCATS - NCGC NCATS Duveau, Damien (NCATS) 0 114102678 O-GlcNAc Transferase (OGT) Inhibitors And Uses Thereof E-061-2017-0 Filing authorized Harvard University, NCATS - NCGC 83727060 Gadhia, Ami ami.gadhia@nih.gov
United States of America NCGC ami.gadhia@nih.gov?subject=Web Inquiry on [TAB-3569] O-GlcNAc Transferase (OGT) Inhibitors for the Treatment of Cancer and Viral Infections&body=Please send me information about technology [TAB-3569] O-GlcNAc Transferase (OGT) Inhibitors for the Treatment of Cancer and Viral Infections. Gadhia, Ami<br><a href="mailto:ami.gadhia@nih.gov?subject=Web Inquiry on [TAB-3569] O-GlcNAc Transferase (OGT) Inhibitors for the Treatment of Cancer and Viral Infections&body=Please send me information about technology [TAB-3569] O-GlcNAc Transferase (OGT) Inhibitors for the Treatment of Cancer and Viral Infections.">ami.gadhia@nih.gov</a><br> 114169402 E-061-2017-0 E-061-2017-0-US-01 O-GlcNAc Transferase (OGT) Inhibitors And Uses Thereof PRV US 62/019,528 Abandoned US <br />Provisional (PRV) 62/019,528<br />Filed on 2014-07-01<br />Status: Abandoned 114169403 E-061-2017-0 E-061-2017-0-PCT-02 O-GLCNAC TRANSFERASE (OGT) INHIBITORS AND USES THEREOF PCT Patent Cooperation Treaty PCT/US2015/038792 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2015/038792<br />Filed on 2015-07-01<br />Status: Expired 114169404 E-061-2017-0 E-061-2017-0-US-03 O-GlcNAc Transferase (OGT) Inhibitors And Uses Thereof National Stage US 15/323,206 Abandoned US <br />National Stage 15/323,206<br />Filed on 2016-12-30<br />Status: Abandoned 114128775 VCXXXX 114128776 VLXXXX 114128777 WIXXXX 114128778 WKXXXX 114153263 O-GlcNAc 114153264 TRANSFERASE 114153265 OGT 114153266 Inhibitors 114153267 USES 114153268 THEREOF TAB-3567 114097422 Discovery of Imidazo[1,2-a]pyridines for the Treatment of Blood Cancers NCATS Oncology, Therapeutics Oncology Therapeutics Ajit Jadhav, David Maloney, Jeffrey Strovel, Shyh-Ming Yang, Makoto Yoshioka This technology includes a series of imidazo[1,2-a]pyridines that potently inhibit FLT3, which can be utilized as an anticancer agent. These molecules retain potent binding and activity against FLT3 tyrosine kinase domain and gatekeeper mutations. This chemotype exhibits superior anti-leukemic activity against clinically-relevant FLT3-mutant acute myeloid leukemia (AML) in vitro and in vivo. Tyrosine kinase domain mutations are a common cause of acquired resistance to FLT3 inhibitors used to treat FLT3-mutant AML. These agents have activity versus mutations in the acquired resistance space and versus non-IRAK inhibitors in the adaptive resistance space. Used to treat a variety of hematological diseases, including but not limited to AML, myeloid dysplastic syndrome, Diffuse Large B-cell Lymphoma, and other blood cancers. 2022-08-01 2024-10-28 2024-10-28 2022-08-01 2022-05-06 Bet, FAMILY, Inhibitors, QUINAZOLINE-BASED, THEREOF, USES, VCXXXX, WKXXXX False True True NIHTT 37470483 Website Abstract 114172732 Melgar K, Walker M, et al. https://pubmed.ncbi.nlm.nih.gov/31484791/ <a href="https://pubmed.ncbi.nlm.nih.gov/31484791/">Melgar K, Walker M, et al.</a> 114172733 Jones L, Melgar K, et al. https://pubmed.ncbi.nlm.nih.gov/32149729/ <a href="https://pubmed.ncbi.nlm.nih.gov/32149729/">Jones L, Melgar K, et al.</a> 114110825 Maloney, David Veralox Therapeutics Inc NCATS Maloney, David (NCATS) 0 114110826 Jadhav, Ajit NCATS - NCGC NCATS Jadhav, Ajit (NCATS) 0 114110827 Strovel, Jeffrey ConverGene, LLC Strovel, Jeffrey 0 114110828 Yoshioka, Makoto ConverGene, LLC Yoshioka, Makoto 0 114110824 Yang, Shyh-Ming NCATS - NCGC NCATS Yang, Shyh-Ming (NCATS) 1 114110824 Yang, Shyh-Ming NCATS - NCGC NCATS Yang, Shyh-Ming (NCATS) 1 114110825 Maloney, David Veralox Therapeutics Inc NCATS Maloney, David (NCATS) 0 114110826 Jadhav, Ajit NCATS - NCGC NCATS Jadhav, Ajit (NCATS) 0 114110827 Strovel, Jeffrey ConverGene, LLC Strovel, Jeffrey 0 114110828 Yoshioka, Makoto ConverGene, LLC Yoshioka, Makoto 0 114102676 Quinazoline-based BET Family Inhibitors And Uses Thereof E-233-2020-0 Filing authorized ConverGene, LLC, NCATS - NCGC, Veralox Therapeutics Inc 83682485 Vepa, Suryanarayana sury.vepa@nih.gov
United States of America Office of Strategic Alliances (OSA) sury.vepa@nih.gov?subject=Web Inquiry on [TAB-3567] Discovery of Imidazo[1,2-a]pyridines for the Treatment of Blood Cancers&body=Please send me information about technology [TAB-3567] Discovery of Imidazo[1,2-a]pyridines for the Treatment of Blood Cancers. Vepa, Suryanarayana<br><a href="mailto:sury.vepa@nih.gov?subject=Web Inquiry on [TAB-3567] Discovery of Imidazo[1,2-a]pyridines for the Treatment of Blood Cancers&body=Please send me information about technology [TAB-3567] Discovery of Imidazo[1,2-a]pyridines for the Treatment of Blood Cancers.">sury.vepa@nih.gov</a><br> 114128770 VCXXXX 114128771 WKXXXX 114153245 QUINAZOLINE-BASED 114153246 Bet 114153247 FAMILY 114153248 Inhibitors 114153249 USES 114153250 THEREOF TAB-3565 114097420 Discovery of Imidazo[1,2-a]pyridines for the Treatment of Blood Cancers NCATS Oncology, Research Materials, Therapeutics Oncology Research Materials Therapeutics Chris Finocchio, Scott Hoyt, Daniel Starczynowski, Gregory Tawa, Craig Thomas This technology includes a series of imidazo[1,2-a]pyridines that potently inhibit FLT3, which can be utilized as an anticancer agent. These molecules retain potent binding and activity against FLT3 tyrosine kinase domain and gatekeeper mutations. This chemotype exhibits superior anti-leukemic activity against clinically-relevant FLT3-mutant acute myeloid leukemia (AML) in vitro and in vivo. Tyrosine kinase domain mutations are a common cause of acquired resistance to FLT3 inhibitors used to treat FLT3-mutant AML. These agents have activity versus mutations in the acquired resistance space and versus non-IRAK inhibitors in the adaptive resistance space. Used to treat a variety of hematological diseases, including but not limited to AML, myeloid dysplastic syndrome, Diffuse Large B-cell Lymphoma, and other blood cancers. 2022-08-01 2024-10-28 2024-10-28 2022-08-01 2022-05-06 2-alpha]pyridines, ANTICANCER, Discovery, Imidazo[1, Properties., VCXXXX, WIXXXX, WKXXXX False True True NIHTT 37470483 Website Abstract 114172730 Melgar K, Walker M, et al. https://pubmed.ncbi.nlm.nih.gov/31484791/ <a href="https://pubmed.ncbi.nlm.nih.gov/31484791/">Melgar K, Walker M, et al.</a> 114172731 Jones L, Melgar K, et al. https://pubmed.ncbi.nlm.nih.gov/32149729/ <a href="https://pubmed.ncbi.nlm.nih.gov/32149729/">Jones L, Melgar K, et al.</a> 114110815 Thomas, Craig NCATS - NCGC NCATS Thomas, Craig (NCATS) 0 114110817 Tawa, Gregory NCATS - TRND NCATS Tawa, Gregory (NCATS) 0 114110818 Finocchio, Chris NCATS - NCGC NCATS Finocchio, Chris (NCATS) 0 114110819 Starczynowski, Daniel Cincinnati Children's Hospital Medical Center Starczynowski, Daniel 0 114110816 Hoyt, Scott NCATS - NCGC NCATS Hoyt, Scott (NCATS) 1 114110816 Hoyt, Scott NCATS - NCGC NCATS Hoyt, Scott (NCATS) 1 114110815 Thomas, Craig NCATS - NCGC NCATS Thomas, Craig (NCATS) 0 114110817 Tawa, Gregory NCATS - TRND NCATS Tawa, Gregory (NCATS) 0 114110818 Finocchio, Chris NCATS - NCGC NCATS Finocchio, Chris (NCATS) 0 114110819 Starczynowski, Daniel Cincinnati Children's Hospital Medical Center Starczynowski, Daniel 0 114102674 Discovery Of Imidazo[1,2-alpha]pyridines With Anticancer Properties. E-232-2020-0 Filing authorized Cincinnati Children's Hospital Medical Center, NCATS - NCGC 83727060 Gadhia, Ami ami.gadhia@nih.gov
United States of America NCGC ami.gadhia@nih.gov?subject=Web Inquiry on [TAB-3565] Discovery of Imidazo[1,2-a]pyridines for the Treatment of Blood Cancers&body=Please send me information about technology [TAB-3565] Discovery of Imidazo[1,2-a]pyridines for the Treatment of Blood Cancers. Gadhia, Ami<br><a href="mailto:ami.gadhia@nih.gov?subject=Web Inquiry on [TAB-3565] Discovery of Imidazo[1,2-a]pyridines for the Treatment of Blood Cancers&body=Please send me information about technology [TAB-3565] Discovery of Imidazo[1,2-a]pyridines for the Treatment of Blood Cancers.">ami.gadhia@nih.gov</a><br> 114169397 E-232-2020-0 E-232-2020-0-US-01 MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF PRV US 63/059,815 Abandoned US <br />Provisional (PRV) 63/059,815<br />Filed on 2020-07-31<br />Status: Abandoned 114169398 E-232-2020-0 E-232-2020-0-PCT-02 MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF PCT Patent Cooperation Treaty PCT/US2021/044089 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/044089<br />Filed on 2021-07-31<br />Status: Expired 114128765 VCXXXX 114128766 WIXXXX 114128767 WKXXXX 114153224 Discovery 114153225 Imidazo[1 114153226 2-alpha]pyridines 114153227 ANTICANCER 114153228 Properties. TAB-3562 114097418 Inhibitors of Eya2 Phosphatase as an Anticancer Therapy NCATS Oncology, Therapeutics Oncology Therapeutics Seameen Dehdashti, Erika Englund, Marc Ferrer-Alegre, Heide Ford, Samarjit Patnaik, Noel Southall, Rui Zhao, Wei Zheng This technology includes inhibitors of the Eya phosphatase which can be utilized as anticancer therapy. The Eya proteins are essential co-activators of the Six1 transcription factor, a gene that is abnormally re-expressed in a large percentage of breast cancers. This over-expression plays a causal role in the initiation and metastatic development of breast cancers. The Eya family of proteins was also found to contain a unique haloacid dehalogenase phosphatase domain with protein Tyr phosphatase activity which can potentially play a role in Six1- mediated breast tumorigenesis. Recently, Eya was found to dephosphorylate the histone variant H2AX and direct cells to the DNA repair instead of apoptosis pathway in the event of DNA damage. <ul> <li>One in 8 women will be diagnosed with breast cancer in their lifetime and the Six1 gene is over-expressed in 50% of primary breast tumors and 90% of metastatic lesions; large market share.</li> <li>Half of patients with cancer receive radiation therapy and selectively sensitizing tumor tissue by engaging the apoptotic program of a cell is of great interest to the field of radiation oncology.</li> </ul> <ul> <li>Therapy for Six1-mediated breast cancer.</li> <li>Utilized as agents that increase the efficiency of radiation and certain chemotherapy agents.</li> </ul> 2022-08-01 2024-10-28 2024-10-28 2022-08-01 2022-05-06 EYA2, Inhibitors, Listed LPM Vathyam as of 4/15/2015, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, VCXXXX, WKXXXX False True True NIHTT 37470483 Website Abstract 114172727 Krueger AB, Drasin DJ, et al. https://pubmed.ncbi.nlm.nih.gov/24755226/ <a href="https://pubmed.ncbi.nlm.nih.gov/24755226/">Krueger AB, Drasin DJ, et al.</a> 114110797 Ford, Heide Regents of the University of Colorado Ford, Heide 0 114110798 Southall, Noel National Human Genome Research Institute (NHGRI) NCATS Southall, Noel (NCATS) 0 114110799 Englund, Erika NCATS - NCGC Englund, Erika 0 114110800 Patnaik, Samarjit National Human Genome Research Institute (NHGRI) NCATS Patnaik, Samarjit (NCATS) 0 114110801 Ferrer-Alegre, Marc NCATS - NCGC NCATS Ferrer-Alegre, Marc (NCATS) 0 114110802 Zheng, Wei National Human Genome Research Institute (NHGRI) NCATS Zheng, Wei (NCATS) 0 114110803 Dehdashti, Seameen NCATS - NCGC NCATS Dehdashti, Seameen (NCATS) 0 114110796 Zhao, Rui Regents of the University of Colorado Zhao, Rui 1 114110796 Zhao, Rui Regents of the University of Colorado Zhao, Rui 1 114110797 Ford, Heide Regents of the University of Colorado Ford, Heide 0 114110798 Southall, Noel National Human Genome Research Institute (NHGRI) NCATS Southall, Noel (NCATS) 0 114110799 Englund, Erika NCATS - NCGC Englund, Erika 0 114110800 Patnaik, Samarjit National Human Genome Research Institute (NHGRI) NCATS Patnaik, Samarjit (NCATS) 0 114110801 Ferrer-Alegre, Marc NCATS - NCGC NCATS Ferrer-Alegre, Marc (NCATS) 0 114110802 Zheng, Wei National Human Genome Research Institute (NHGRI) NCATS Zheng, Wei (NCATS) 0 114110803 Dehdashti, Seameen NCATS - NCGC NCATS Dehdashti, Seameen (NCATS) 0 114102672 INHIBITORS OF EYA2 E-083-2012-0 Filing authorized NCATS - NCGC, Regents of the University of Colorado 83682485 Vepa, Suryanarayana sury.vepa@nih.gov
United States of America Office of Strategic Alliances (OSA) sury.vepa@nih.gov?subject=Web Inquiry on [TAB-3562] Inhibitors of Eya2 Phosphatase as an Anticancer Therapy&body=Please send me information about technology [TAB-3562] Inhibitors of Eya2 Phosphatase as an Anticancer Therapy. Vepa, Suryanarayana<br><a href="mailto:sury.vepa@nih.gov?subject=Web Inquiry on [TAB-3562] Inhibitors of Eya2 Phosphatase as an Anticancer Therapy&body=Please send me information about technology [TAB-3562] Inhibitors of Eya2 Phosphatase as an Anticancer Therapy.">sury.vepa@nih.gov</a><br> 114169390 E-083-2012-0 E-083-2012-0-US-01 INHIBITORS OF EYA2 PRV US 61/431,306 Abandoned US <br />Provisional (PRV) 61/431,306<br />Filed on 2011-01-10<br />Status: Abandoned 114169391 E-083-2012-0 E-083-2012-0-PCT-02 INHIBITORS OF EYA2 PCT Patent Cooperation Treaty PCT/US2012/020805 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2012/020805<br />Filed on 2012-01-10<br />Status: Expired 114169392 E-083-2012-0 E-083-2012-0-US-03 INHIBITORS OF EYA2 National Stage US 13/978,820 Abandoned US <br />National Stage 13/978,820<br />Filed on 2013-07-09<br />Status: Abandoned 114128761 VCXXXX 114128762 WKXXXX 114153209 Inhibitors 114153210 EYA2 114153211 Listed LPM Vathyam as of 4/15/2015 114153212 Pre LPM working set 20150418 114153213 Post LPM Assignment Set 20150420 TAB-3560 114097416 Mounted Nitrocellulose Membrane Plates for Aqueous Acoustic Dispensing Nanoliter-Scale Reverse Phase Protein and Biological Arrays for Antibody-Based Protein Detection and Quantification NCATS Antibodies, Immunology, Medical Devices, Non-Medical Devices, Research Materials Antibodies Immunology Medical Devices Non-Medical Devices Research Materials Michael Iannotti, James Inglese, Richard Jones, Ryan Macarthur, Samuel Michael This technology includes the enablement of the nanoliter-scale transfer of biological liquids in array format from a microplate (source plate) containing cultured cells or other protein-containing mixtures onto a nitrocellulose membrane that has been mounted within a custom-designed target plate. Using this method and the prototype nitrocellulose target plate, reverse phase protein arrays can be generated in which protein levels from each well transferred onto the membrane can be detected and quantified. Various designs for the nitrocellulose target plate are in development to offer flexibility into the immunoblotting process for both manual and automation compatibility. Importantly, this process is 384-well and 1536-well compatible to enable its use in high-throughput screening, and is capable of detecting native, endogenous proteins depending on the antibodies used. The discovery connects two seemingly disparate biological concepts, acoustic dispensing and immunoblotting, to enable protein-based high-throughput screening among other applications while minimizing cost, reagents, and biological material. The present discovery enables the generation of reverse phase protein arrays for the detection of native, untagged proteins in biological liquids (cell culture media, cell lysate, and other protein-containing mixtures) in 384-well and 1536-well formats, for which there are currently very few available options. <ul> <li>Utilization in manual and automated protein-based high-throughput screening, especially within reverse phase protein arrays</li> <li>Enzymatic assays (including protein-, DNA-, and RNA-based) on the surface of the nitrocellulose membrane</li> <li>Diagnostics</li> <li>Generation of biological sample libraries</li> </ul> 2022-08-01 2024-10-28 2024-10-28 2022-08-01 2022-05-06 Acoustic, Antibody-based, AQUEOUS, ARRAYS, Biological, Detection, Dispensing, MECHANICAL, MEMBRANE, MOUNTED, Nanoliter-Scale, Nitrocellulose, PHASE, Plates, Protein, QUANTIFICATION, Reverse, WIXXXX, XAXXXX, XDXXXX False True True NIHTT 37470483 Website Abstract 114110784 Macarthur, Ryan NCATS - NCGC NCATS Macarthur, Ryan (NCATS) 0 114110785 Jones, Richard NCATS - NCGC NCATS Jones, Richard (NCATS) 0 114110786 Inglese, James NCATS - NCGC NCATS Inglese, James (NCATS) 0 114110787 Michael, Samuel NCATS - NCGC NCATS Michael, Samuel (NCATS) 0 114110783 Iannotti, Michael NCATS - NCGC NCATS Iannotti, Michael (NCATS) 1 114110783 Iannotti, Michael NCATS - NCGC NCATS Iannotti, Michael (NCATS) 1 114110784 Macarthur, Ryan NCATS - NCGC NCATS Macarthur, Ryan (NCATS) 0 114110785 Jones, Richard NCATS - NCGC NCATS Jones, Richard (NCATS) 0 114110786 Inglese, James NCATS - NCGC NCATS Inglese, James (NCATS) 0 114110787 Michael, Samuel NCATS - NCGC NCATS Michael, Samuel (NCATS) 0 114102670 Mounted Nitrocellulose Membrane Plates For Aqueous Acoustic Dispensing Nanoliter-Scale Reverse Phase Protein And Biological Arrays For Antibody-Based Protein Detection And Quantification E-091-2017-0 Filing authorized NCATS - NCGC 83727060 Gadhia, Ami ami.gadhia@nih.gov
United States of America NCGC ami.gadhia@nih.gov?subject=Web Inquiry on [TAB-3560] Mounted Nitrocellulose Membrane Plates for Aqueous Acoustic Dispensing Nanoliter-Scale Reverse Phase Protein and Biological Arrays for Antibody-Based Protein Detection and Quantification&body=Please send me information about technology [TAB-3560] Mounted Nitrocellulose Membrane Plates for Aqueous Acoustic Dispensing Nanoliter-Scale Reverse Phase Protein and Biological Arrays for Antibody-Based Protein Detection and Quantification. Gadhia, Ami<br><a href="mailto:ami.gadhia@nih.gov?subject=Web Inquiry on [TAB-3560] Mounted Nitrocellulose Membrane Plates for Aqueous Acoustic Dispensing Nanoliter-Scale Reverse Phase Protein and Biological Arrays for Antibody-Based Protein Detection and Quantification&body=Please send me information about technology [TAB-3560] Mounted Nitrocellulose Membrane Plates for Aqueous Acoustic Dispensing Nanoliter-Scale Reverse Phase Protein and Biological Arrays for Antibody-Based Protein Detection and Quantification.">ami.gadhia@nih.gov</a><br> 114169384 E-091-2017-0 E-091-2017-0-US-01 Mounted Nitrocellulose Membrane Plates For Aqueous Acoustic Dispensing Nanoliter-Scale Reverse Phase Protein And Biological Arrays For Antibody-Based Protein Detection And Quantification PRV US 62/825,397 Abandoned US <br />Provisional (PRV) 62/825,397<br />Filed on 2019-03-28<br />Status: Abandoned 114169385 E-091-2017-0 E-091-2017-0-US-01_78650 MEMBRANE PLATES FOR HIGH-THROUGHPUT PROTEIN DETECTION AND QUANTIFICATION PRV US 62/822,326 Abandoned US <br />Provisional (PRV) 62/822,326<br />Filed on 2019-03-22<br />Status: Abandoned 114128755 WIXXXX 114128756 XAXXXX 114128757 XDXXXX 114153181 MOUNTED 114153182 Nitrocellulose 114153183 MEMBRANE 114153184 Plates 114153185 AQUEOUS 114153186 Acoustic 114153187 Dispensing 114153188 Nanoliter-Scale 114153189 Reverse 114153190 PHASE 114153191 Protein 114153192 Biological 114153193 ARRAYS 114153194 Antibody-based 114153195 Detection 114153196 QUANTIFICATION 114153197 MECHANICAL TAB-3558 114097414 Identification and Use of Heterocyclic Alcohol Compounds for the Treatment of SULT1A1-expressing Cancers NCATS Diagnostics, Oncology, Research Materials, Therapeutics Diagnostics Oncology Research Materials Therapeutics Mindy Davis, Matthew Hall, Ke Kong, Olivia Lee, Toble Lee, Juan Marugan, Samarjit Patnaik, Min Shen, Jonathan Shrimp, Wei Zhao This technology includes the identification and use of heterocyclic alcohol compounds, including RITA and N-BIC, for the treatment of SULT1A1-expression cancers. A high-throughput screen (qHTS) was performed using >1,000 caner cell lines identified a compound called YC-1 (also called Lificiguat) that is effective across cancer cell types that express the phase 2 detoxifying enzyme SULT1A1. The identification of structurally related anti-cancer compounds is a novel treatment type for SULT1A1-expressing cancer cells. In addition, the work done to establish these compounds suggests that SULT1A1 expression may serve as a biomarker for patient selection. Further clinical work with the YC-1 derivates could establish these heterocyclic alcohol compounds as therapies for SULT1A1 expressing cancers. 2022-08-01 2024-10-28 2024-10-28 2022-08-01 2022-05-06 Agents, Alcohol, anti-cancer, Class, compounds, HETEROCYCLIC, SULT1A1-dependent, VCXXXX, WKXXXX, XCXXXX, XEXXXX False True True NIHTT 37470483 Website Abstract 114110762 Shen, Min NCATS - NCGC NCATS Shen, Min (NCATS) 0 114110763 Kong, Ke NCATS - NCGC NCATS Kong, Ke (NCATS) 0 114110764 Lee, Toble Lee, Toble 0 114110765 Patnaik, Samarjit NCATS - NCGC NCATS Patnaik, Samarjit (NCATS) 0 114110766 Lee, Olivia NCATS - NCGC NCI Lee, Olivia (NCI) 0 114110767 Shrimp, Jonathan NCATS - NCGC NCATS Shrimp, Jonathan (NCATS) 0 114110768 Davis, Mindy NCATS - NCGC NCATS Davis, Mindy (NCATS) 0 114110769 Marugan, Juan NCATS - NCGC NCATS Marugan, Juan (NCATS) 0 114110770 Zhao, Wei FDA - CVM FDA Zhao, Wei (FDA) 0 114110761 Hall, Matthew NCATS - NCGC NCATS Hall, Matthew (NCATS) 1 114110761 Hall, Matthew NCATS - NCGC NCATS Hall, Matthew (NCATS) 1 114110762 Shen, Min NCATS - NCGC NCATS Shen, Min (NCATS) 0 114110763 Kong, Ke NCATS - NCGC NCATS Kong, Ke (NCATS) 0 114110764 Lee, Toble Lee, Toble 0 114110765 Patnaik, Samarjit NCATS - NCGC NCATS Patnaik, Samarjit (NCATS) 0 114110766 Lee, Olivia NCATS - NCGC NCI Lee, Olivia (NCI) 0 114110767 Shrimp, Jonathan NCATS - NCGC NCATS Shrimp, Jonathan (NCATS) 0 114110768 Davis, Mindy NCATS - NCGC NCATS Davis, Mindy (NCATS) 0 114110769 Marugan, Juan NCATS - NCGC NCATS Marugan, Juan (NCATS) 0 114110770 Zhao, Wei FDA - CVM FDA Zhao, Wei (FDA) 0 114102668 Use Of A Class Of Heterocyclic Alcohol Compounds As SULT1A1-dependent Anti-cancer Agents E-068-2020-0 Filing authorized NCATS - NCGC 83727060 Gadhia, Ami ami.gadhia@nih.gov
United States of America NCGC ami.gadhia@nih.gov?subject=Web Inquiry on [TAB-3558] Identification and Use of Heterocyclic Alcohol Compounds for the Treatment of SULT1A1-expressing Cancers&body=Please send me information about technology [TAB-3558] Identification and Use of Heterocyclic Alcohol Compounds for the Treatment of SULT1A1-expressing Cancers. Gadhia, Ami<br><a href="mailto:ami.gadhia@nih.gov?subject=Web Inquiry on [TAB-3558] Identification and Use of Heterocyclic Alcohol Compounds for the Treatment of SULT1A1-expressing Cancers&body=Please send me information about technology [TAB-3558] Identification and Use of Heterocyclic Alcohol Compounds for the Treatment of SULT1A1-expressing Cancers.">ami.gadhia@nih.gov</a><br> 114128748 VCXXXX 114128749 WKXXXX 114128750 XCXXXX 114128751 XEXXXX 114153170 Class 114153171 HETEROCYCLIC 114153172 Alcohol 114153173 compounds 114153174 SULT1A1-dependent 114153175 anti-cancer 114153176 Agents TAB-3559 114097415 Galactose Kinase (GALK) Inhibitors for the Treatment of Galactosemia and Other Disorders of Galactose Metabolism NCATS Cardiology, Dental, Endocrinology, Infectious Disease, Oncology, Ophthalmology, Therapeutics Cardiology Dental Endocrinology Infectious Disease Oncology Ophthalmology Therapeutics Bijina Balakrishnan, Matthew Boxer, Matthew Hall, Surendra Karavadhi, Kent Lai, Toble Lee, Li Liu, Samarjit Patnaik, Rajan Pragani, Min Shen, Manshu Tang, Ya-Qin Non Zhang This technology includes selective inhibitors of the human enzyme galactokinase (EC 2.7.1.6), which may be useful for the treatment of Galactosemia and other diseases caused by aberrant galactose metabolism, including cancer. These compounds inhibit the first step in galactose metabolism, thereby eliminating the build-up of toxic metabolites during the aberrant metabolism of galactose, as well as inhibitor the entry of galactose into glycolysis and other downstream assays. Classic Galactosemia is a potentially lethal disorder with a high mortality rate when left untreated; our galactokinase inhibitors could provide the first therapeutic treatment for this disorder. Additionally, GALK1 is necessary for the survival of PTEN/AKT mis-regulated cancers, which consist of a large number of cancers studied to date. We have shown that our compounds can selectively kill cancer cells harboring these mutations as well as those with high expression levels of GALK. These inhibitors represent the best-known inhibitors of GALK, and demonstrate improved activity compared with previous inhibitors. Treatment of Galactosemia and other diseases caused by aberrant galactose metabolism, including some cancers. 2022-08-01 2024-10-28 2024-10-28 2022-08-01 2022-05-06 Development, Galactose, Inhibitors, Kinase, VPXXXX, WJXXXX, XEXXXX False True True NIHTT 37470483 Website Abstract 114110771 Tang, Manshu University of Utah Tang, Manshu 0 114110773 Shen, Min NCATS - NCGC NCATS Shen, Min (NCATS) 0 114110774 Boxer, Matthew NCATS - NCGC Boxer, Matthew 0 114110775 Pragani, Rajan NCATS - NCGC FDA Pragani, Rajan (FDA) 0 114110776 Lee, Toble NCATS - NCGC Lee, Toble 0 114110777 Liu, Li NCATS - NCGC NCATS Liu, Li (NCATS) 0 114110778 Karavadhi, Surendra NCATS - NCGC NCATS Karavadhi, Surendra (NCATS) 0 114110779 Zhang, Ya-Qin Non NCATS - NCGC NCATS Zhang, Ya-Qin Non (NCATS) 0 114110780 Balakrishnan, Bijina University of Utah Balakrishnan, Bijina 0 114110781 Lai, Kent University of Utah Lai, Kent 0 114110782 Patnaik, Samarjit NCATS - NCGC NCATS Patnaik, Samarjit (NCATS) 0 114110772 Hall, Matthew NCATS - NCGC NCATS Hall, Matthew (NCATS) 1 114110772 Hall, Matthew NCATS - NCGC NCATS Hall, Matthew (NCATS) 1 114110771 Tang, Manshu University of Utah Tang, Manshu 0 114110773 Shen, Min NCATS - NCGC NCATS Shen, Min (NCATS) 0 114110774 Boxer, Matthew NCATS - NCGC Boxer, Matthew 0 114110775 Pragani, Rajan NCATS - NCGC FDA Pragani, Rajan (FDA) 0 114110776 Lee, Toble NCATS - NCGC Lee, Toble 0 114110777 Liu, Li NCATS - NCGC NCATS Liu, Li (NCATS) 0 114110778 Karavadhi, Surendra NCATS - NCGC NCATS Karavadhi, Surendra (NCATS) 0 114110779 Zhang, Ya-Qin Non NCATS - NCGC NCATS Zhang, Ya-Qin Non (NCATS) 0 114110780 Balakrishnan, Bijina University of Utah Balakrishnan, Bijina 0 114110781 Lai, Kent University of Utah Lai, Kent 0 114110782 Patnaik, Samarjit NCATS - NCGC NCATS Patnaik, Samarjit (NCATS) 0 114102669 Development Of Inhibitors Of Galactose Kinase E-235-2017-0 Filing authorized NCATS - NCGC, University of Utah 83727060 Gadhia, Ami ami.gadhia@nih.gov
United States of America NCGC ami.gadhia@nih.gov?subject=Web Inquiry on [TAB-3559] Galactose Kinase (GALK) Inhibitors for the Treatment of Galactosemia and Other Disorders of Galactose Metabolism&body=Please send me information about technology [TAB-3559] Galactose Kinase (GALK) Inhibitors for the Treatment of Galactosemia and Other Disorders of Galactose Metabolism. Gadhia, Ami<br><a href="mailto:ami.gadhia@nih.gov?subject=Web Inquiry on [TAB-3559] Galactose Kinase (GALK) Inhibitors for the Treatment of Galactosemia and Other Disorders of Galactose Metabolism&body=Please send me information about technology [TAB-3559] Galactose Kinase (GALK) Inhibitors for the Treatment of Galactosemia and Other Disorders of Galactose Metabolism.">ami.gadhia@nih.gov</a><br> 114128752 VPXXXX 114128753 WJXXXX 114128754 XEXXXX 114153177 Development 114153178 Inhibitors 114153179 Galactose 114153180 Kinase TAB-3555 114097411 Mutant IDH1 Inhibitors for Anticancer Therapy NCATS Oncology, Therapeutics Oncology Therapeutics Matthew Boxer, Kyle Brimacombe, Mindy Davis, Yuhong Fang, Matthew Hall, Ajit Jadhav, Surendra Karavadhi, Li Liu, Natalia Martinez, Andrew McIver, Rajan Pragani, Jason Rohde, Min Shen, Anton Simeonov, Xiaodong Wang, Wei Zhao This technology includes mutant isocitrate dehydrogenase (IDH1) inhibitors to be utilized as anticancer therapy. These potent inhibitors are aimed at lowering levels of the oncometabolite–2-hydroxyglutarate. Anticancer agent that targets IDH1 mutations. 2022-08-01 2024-10-28 2024-10-28 2022-08-01 2022-05-06 IDH1, Inhibitors, MUTANT, VCXXXX, WKXXXX False True True NIHTT 37470483 Website Abstract 114110727 Rohde, Jason NCATS - NCGC NCATS Rohde, Jason (NCATS) 0 114110728 Pragani, Rajan NCATS - NCGC FDA Pragani, Rajan (FDA) 0 114110729 Liu, Li NCATS - NCGC NCATS Liu, Li (NCATS) 0 114110730 Davis, Mindy NCATS - NCGC NCATS Davis, Mindy (NCATS) 0 114110731 Brimacombe, Kyle NCATS - NCGC NCATS Brimacombe, Kyle (NCATS) 0 114110732 Shen, Min NCATS - NCGC NCATS Shen, Min (NCATS) 0 114110733 Simeonov, Anton NCATS - NCGC NCATS Simeonov, Anton (NCATS) 0 114110734 Karavadhi, Surendra NCATS - NCGC NCATS Karavadhi, Surendra (NCATS) 0 114110735 Jadhav, Ajit NCATS - NCGC NCATS Jadhav, Ajit (NCATS) 0 114110736 Hall, Matthew NCATS - NCGC NCATS Hall, Matthew (NCATS) 0 114110737 Zhao, Wei NCATS - NCGC FDA Zhao, Wei (FDA) 0 114110738 Fang, Yuhong NCATS - NCGC NCATS Fang, Yuhong (NCATS) 0 114110739 Martinez, Natalia NCATS - NCGC NCATS Martinez, Natalia (NCATS) 0 114110740 Wang, Xiaodong University of North Carolina, Chapel Hill Wang, Xiaodong 0 114110741 McIver, Andrew University of North Carolina, Chapel Hill McIver, Andrew 0 114110726 Boxer, Matthew NCATS - NCGC Boxer, Matthew 1 114110726 Boxer, Matthew NCATS - NCGC Boxer, Matthew 1 114110727 Rohde, Jason NCATS - NCGC NCATS Rohde, Jason (NCATS) 0 114110728 Pragani, Rajan NCATS - NCGC FDA Pragani, Rajan (FDA) 0 114110729 Liu, Li NCATS - NCGC NCATS Liu, Li (NCATS) 0 114110730 Davis, Mindy NCATS - NCGC NCATS Davis, Mindy (NCATS) 0 114110731 Brimacombe, Kyle NCATS - NCGC NCATS Brimacombe, Kyle (NCATS) 0 114110732 Shen, Min NCATS - NCGC NCATS Shen, Min (NCATS) 0 114110733 Simeonov, Anton NCATS - NCGC NCATS Simeonov, Anton (NCATS) 0 114110734 Karavadhi, Surendra NCATS - NCGC NCATS Karavadhi, Surendra (NCATS) 0 114110735 Jadhav, Ajit NCATS - NCGC NCATS Jadhav, Ajit (NCATS) 0 114110736 Hall, Matthew NCATS - NCGC NCATS Hall, Matthew (NCATS) 0 114110737 Zhao, Wei NCATS - NCGC FDA Zhao, Wei (FDA) 0 114110738 Fang, Yuhong NCATS - NCGC NCATS Fang, Yuhong (NCATS) 0 114110739 Martinez, Natalia NCATS - NCGC NCATS Martinez, Natalia (NCATS) 0 114110740 Wang, Xiaodong University of North Carolina, Chapel Hill Wang, Xiaodong 0 114110741 McIver, Andrew University of North Carolina, Chapel Hill McIver, Andrew 0 114102665 Mutant IDH1 Inhibitors E-189-2016-0 Filing authorized NCATS - NCGC, University of North Carolina, Chapel Hill 83682485 Vepa, Suryanarayana sury.vepa@nih.gov
United States of America Office of Strategic Alliances (OSA) sury.vepa@nih.gov?subject=Web Inquiry on [TAB-3555] Mutant IDH1 Inhibitors for Anticancer Therapy&body=Please send me information about technology [TAB-3555] Mutant IDH1 Inhibitors for Anticancer Therapy. Vepa, Suryanarayana<br><a href="mailto:sury.vepa@nih.gov?subject=Web Inquiry on [TAB-3555] Mutant IDH1 Inhibitors for Anticancer Therapy&body=Please send me information about technology [TAB-3555] Mutant IDH1 Inhibitors for Anticancer Therapy.">sury.vepa@nih.gov</a><br> 114169375 E-189-2016-0 E-189-2016-0-US-01 Mutant IDH1 Inhibitors Useful for Treating Cancer PRV US 62/353,298 Abandoned US <br />Provisional (PRV) 62/353,298<br />Filed on 2016-06-22<br />Status: Abandoned 114169376 E-189-2016-0 E-189-2016-0-PCT-02 Mutant IDH1 Inhibitors Useful for Treating Cancer PCT Patent Cooperation Treaty PCT/US2017/038549 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2017/038549<br />Filed on 2017-06-21<br />Status: Expired 114169377 E-189-2016-0 E-189-2016-0-US-03 THIAZOLE DERIVATIVES USEFUL AS MUTANT IDH1 INHIBITORS FOR TREATING CANCER National Stage US 10,836,759 16/312,206 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10836759 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10836759">10,836,759</a><br />Filed on 2018-12-20<br />Status: Issued 114128739 VCXXXX 114128740 WKXXXX 114153148 MUTANT 114153149 IDH1 114153150 Inhibitors TAB-3556 114097412 Mutant IDH1 Inhibitors for Cancer Treatment NCATS Oncology, Therapeutics Oncology Therapeutics Matthew Boxer, Kyle Brimacombe, Mindy Davis, Ajit Jadhav, Surendra Karavadhi, Li Liu, Andrew McIver, Rajan Pragani, Jason Rohde, Min Shen, Anton Simeonov, Daniel Urban, Xiaodong Wang This technology includes a novel chemotype against mutant (R 132H) isocitrate dehydrogenase 1 (IDH1) enzyme to be utilized as an anticancer therapy. We have progressed the structure activity relationship (SAR) and optimized the compound to be low nanomolar inhibitor of the enzyme with low nanomolar inhibition of the target in cells. These compounds lower 2-hydroxyglutarate, which has been termed an 'oncometabolite' and is common in a subset of cancers including glioma, cholangiocarcinoma, chondrosarcoma and acute myeloid leukemia. Wide variety of cancers which harbor IDH1 mutations, with potential for large market share. These IDH1 inhibitors would be used to treat cancers in which mutated IDH1 has been discovered. 2022-08-01 2024-10-28 2024-10-28 2022-08-01 2022-05-06 BIOCHEMISTRY, CANCER, CB5EXX, Glycolysis, IDH1, Inhibitors, Listed LPM McCue as of 4/15/2015, Patent Category - Chemistry, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, VCXXXX, WJXXXX False True True NIHTT 37470483 Website Abstract 114172723 Losman J, Looper R, et al. https://pubmed.ncbi.nlm.nih.gov/23393090/ <a href="https://pubmed.ncbi.nlm.nih.gov/23393090/">Losman J, Looper R, et al.</a> 114172724 Cairns R, Mak T https://pubmed.ncbi.nlm.nih.gov/23796461/ <a href="https://pubmed.ncbi.nlm.nih.gov/23796461/">Cairns R, Mak T</a> 114172725 Rohle D, Popovici-Muller J, et al. https://pubmed.ncbi.nlm.nih.gov/23558169/ <a href="https://pubmed.ncbi.nlm.nih.gov/23558169/">Rohle D, Popovici-Muller J, et al.</a> 114110743 Rohde, Jason NCATS - NCGC NCATS Rohde, Jason (NCATS) 0 114110744 Pragani, Rajan NCATS - NCGC FDA Pragani, Rajan (FDA) 0 114110745 Liu, Li NCATS - NCGC NCATS Liu, Li (NCATS) 0 114110746 Davis, Mindy NCATS - NCGC NCATS Davis, Mindy (NCATS) 0 114110747 Brimacombe, Kyle NCATS - NCGC NCATS Brimacombe, Kyle (NCATS) 0 114110748 Shen, Min NCATS - NCGC NCATS Shen, Min (NCATS) 0 114110749 Simeonov, Anton NCATS - NCGC NCATS Simeonov, Anton (NCATS) 0 114110750 Urban, Daniel NCATS - NCGC FDA Urban, Daniel (FDA) 0 114110751 Jadhav, Ajit NCATS - NCGC NCATS Jadhav, Ajit (NCATS) 0 114110752 Wang, Xiaodong University of North Carolina, Chapel Hill Wang, Xiaodong 0 114110753 McIver, Andrew University of North Carolina, Chapel Hill McIver, Andrew 0 114110754 Karavadhi, Surendra NCATS - NCGC NCATS Karavadhi, Surendra (NCATS) 0 114110742 Boxer, Matthew NCATS - NCGC Boxer, Matthew 1 114110742 Boxer, Matthew NCATS - NCGC Boxer, Matthew 1 114110743 Rohde, Jason NCATS - NCGC NCATS Rohde, Jason (NCATS) 0 114110744 Pragani, Rajan NCATS - NCGC FDA Pragani, Rajan (FDA) 0 114110745 Liu, Li NCATS - NCGC NCATS Liu, Li (NCATS) 0 114110746 Davis, Mindy NCATS - NCGC NCATS Davis, Mindy (NCATS) 0 114110747 Brimacombe, Kyle NCATS - NCGC NCATS Brimacombe, Kyle (NCATS) 0 114110748 Shen, Min NCATS - NCGC NCATS Shen, Min (NCATS) 0 114110749 Simeonov, Anton NCATS - NCGC NCATS Simeonov, Anton (NCATS) 0 114110750 Urban, Daniel NCATS - NCGC FDA Urban, Daniel (FDA) 0 114110751 Jadhav, Ajit NCATS - NCGC NCATS Jadhav, Ajit (NCATS) 0 114110752 Wang, Xiaodong University of North Carolina, Chapel Hill Wang, Xiaodong 0 114110753 McIver, Andrew University of North Carolina, Chapel Hill McIver, Andrew 0 114110754 Karavadhi, Surendra NCATS - NCGC NCATS Karavadhi, Surendra (NCATS) 0 114102666 Mutant IDH1 Inhibitors E-243-2014-0 Filing authorized NCATS - NCGC, University of North Carolina, Chapel Hill 83682485 Vepa, Suryanarayana sury.vepa@nih.gov
United States of America Office of Strategic Alliances (OSA) sury.vepa@nih.gov?subject=Web Inquiry on [TAB-3556] Mutant IDH1 Inhibitors for Cancer Treatment&body=Please send me information about technology [TAB-3556] Mutant IDH1 Inhibitors for Cancer Treatment. Vepa, Suryanarayana<br><a href="mailto:sury.vepa@nih.gov?subject=Web Inquiry on [TAB-3556] Mutant IDH1 Inhibitors for Cancer Treatment&body=Please send me information about technology [TAB-3556] Mutant IDH1 Inhibitors for Cancer Treatment.">sury.vepa@nih.gov</a><br> 114169378 E-243-2014-0 E-243-2014-0-US-01 Mutant IDH1 Inhibitors Useful for Treating Cancer PRV US 62/095,322 Abandoned US <br />Provisional (PRV) 62/095,322<br />Filed on 2014-12-22<br />Status: Abandoned 114169379 E-243-2014-0 E-243-2014-0-PCT-02 Mutant IDH1 Inhibitors Useful for Treating Cancer PCT Patent Cooperation Treaty PCT/US2015/067406 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2015/067406<br />Filed on 2015-12-22<br />Status: Expired 114169380 E-243-2014-0 E-243-2014-0-US-08 MUTANT IDH1 INHIBITORS USEFUL FOR TREATING CANCER National Stage US 10,703,746 15/538,570 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10703746 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10703746">10,703,746</a><br />Filed on 2015-12-22<br />Status: Issued 114128741 CB5EXX 114128742 VCXXXX 114128743 WJXXXX 114153151 IDH1 114153152 Inhibitors 114153153 Glycolysis 114153154 BIOCHEMISTRY 114153155 Patent Category - Chemistry 114153156 CANCER 114153157 Listed LPM McCue as of 4/15/2015 114153158 Pre LPM working set 20150418 114153159 Post LPM Assignment Set 20150420 TAB-3552 114097408 Biofabrication of Skin Tissues with Dermis and Epidermis in Multiwell Plate Format to be Utilized for Chemical and Biologic Testing as well as Transplantation and Regenerative Medicine NCATS Medical Devices, Non-Medical Devices, Research Materials, Therapeutics Medical Devices Non-Medical Devices Research Materials Therapeutics Kristy Derr, Paige Derr, Marc Ferrer-Alegre, Xue (Lucia) Liu, Samuel Michael, Min Jae Song This technology includes methods for the biofabrication of full thickness skin tissues in 12, 24, 48 and 96-well plates, using commercially available hardware to enable the implementation of large-scale toxicity and efficacy testing of chemical and biologics. The invention includes several protocols, including but not limited to: 1) fully 3D bioprinted skin tissue with dermis composed of human fibroblast and a collagen/fibrin/gelatin-based hydrogel; a coating of laminin, and a stratified epidermis composed of human neonatal keratinocytes, all on top of a commercially available transwell insert membrane. 2) A 3D bioprinted skin tissue protocol with a dermis composed on human fibroblasts and a collagen/fibrin/gelatin-based hydrogel which is bioprinted on the bottom side of the transwell well insert membrane; and keratinocytes that are added on top of the insert membrane to develop a stratified epidermis. The protocol enables skin tissues products to be produced in multiwell plate format for chemical and biologics testing; the use of biodegradable scaffolds to make the skin tissue enables their potential use as tissue sheets for transplantation and regenerative medicine. 2022-08-01 2024-10-28 2024-10-28 2022-08-01 2022-05-04 Biofabrication, Dermis, EPIDERMIS, FORMAT, Multiwell, Plate, SKIN, TISSUES, WIXXXX, WKXXXX, XDXXXX False True True NIHTT 37470483 Website Abstract 114172720 Derr K, Zou J, et al. https://pubmed.ncbi.nlm.nih.gov/31007132/ <a href="https://pubmed.ncbi.nlm.nih.gov/31007132/">Derr K, Zou J, et al.</a> 114110703 Song, Min Jae National Eye Institute (NEI) NCATS Song, Min Jae (NCATS) 0 114110704 Derr, Paige NCATS - NCGC NCATS Derr, Paige (NCATS) 0 114110705 Derr, Kristy NCATS - NCGC NCATS Derr, Kristy (NCATS) 0 114110706 Liu, Xue (Lucia) NCATS - NCGC NCATS Liu, Xue (Lucia) (NCATS) 0 114110707 Michael, Samuel NCATS - NCGC NCATS Michael, Samuel (NCATS) 0 114110702 Ferrer-Alegre, Marc NCATS - NCGC NCATS Ferrer-Alegre, Marc (NCATS) 1 114110702 Ferrer-Alegre, Marc NCATS - NCGC NCATS Ferrer-Alegre, Marc (NCATS) 1 114110703 Song, Min Jae National Eye Institute (NEI) NCATS Song, Min Jae (NCATS) 0 114110704 Derr, Paige NCATS - NCGC NCATS Derr, Paige (NCATS) 0 114110705 Derr, Kristy NCATS - NCGC NCATS Derr, Kristy (NCATS) 0 114110706 Liu, Xue (Lucia) NCATS - NCGC NCATS Liu, Xue (Lucia) (NCATS) 0 114110707 Michael, Samuel NCATS - NCGC NCATS Michael, Samuel (NCATS) 0 114102662 Biofabrication Of Skin Tissues With Dermis And Epidermis In Multiwell Plate Format E-129-2019-0 Filing authorized National Eye Institute (NEI), NCATS - NCGC 83682485 Vepa, Suryanarayana sury.vepa@nih.gov
United States of America Office of Strategic Alliances (OSA) sury.vepa@nih.gov?subject=Web Inquiry on [TAB-3552] Biofabrication of Skin Tissues with Dermis and Epidermis in Multiwell Plate Format to be Utilized for Chemical and Biologic Testing as well as Transplantation and Regenerative Medicine&body=Please send me information about technology [TAB-3552] Biofabrication of Skin Tissues with Dermis and Epidermis in Multiwell Plate Format to be Utilized for Chemical and Biologic Testing as well as Transplantation and Regenerative Medicine. Vepa, Suryanarayana<br><a href="mailto:sury.vepa@nih.gov?subject=Web Inquiry on [TAB-3552] Biofabrication of Skin Tissues with Dermis and Epidermis in Multiwell Plate Format to be Utilized for Chemical and Biologic Testing as well as Transplantation and Regenerative Medicine&body=Please send me information about technology [TAB-3552] Biofabrication of Skin Tissues with Dermis and Epidermis in Multiwell Plate Format to be Utilized for Chemical and Biologic Testing as well as Transplantation and Regenerative Medicine.">sury.vepa@nih.gov</a><br> 114169369 E-129-2019-0 E-129-2019-0-US-01 Biofabrication Of Skin Tissues With Dermis And Epidermis In Multiwell Plate Format PRV US 62/936,399 Abandoned US <br />Provisional (PRV) 62/936,399<br />Filed on 2019-11-16<br />Status: Abandoned 114128728 WIXXXX 114128729 WKXXXX 114128730 XDXXXX 114153122 Biofabrication 114153123 SKIN 114153124 TISSUES 114153125 Dermis 114153126 EPIDERMIS 114153127 Multiwell 114153128 Plate 114153129 FORMAT TAB-3554 114097410 Nrf2 Inhibitors for the Enhancement of Cancer Chemotherapy and Radiotherapy NCATS Oncology, Therapeutics Oncology Therapeutics Shyam Biswal, Matthew Boxer, Fraydoon Rastinejad, Jason Rohde, Min Shen, Anju Singh, Ya-Qin Non Zhang This technology includes the identification of small molecule inhibitors of nuclear factor erythroid-2 related factor-2 (Nrf2) as therapeutic anticancer agents. Multiple mechanisms lead to frequent dysregulation of Nrf2 activity in cancer cells, which promotes both tumorigenesis and therapeutic resistance. Dysregulated Nrf2-Keap1 pathway is a novel determinant of chemoresistance/radioresistance and inhibition of Nrf2 signaling will enhance the efficacy of chemotherapeutic and radiotherapy. Based on their potency, specificity and tractability, we have selected 3 compounds for bulk synthesis and screening additional analogues. These compounds belonging to three different structural classes showed direct inhibition of DNA binding activity of Nrf2-MAF complex and were validated as specific inhibitors using a Fluorescence Polarization assay. In combination with platinum-based chemotherapy, these compounds significantly enhanced inhibition compared with single agent in clonogenic assay. These 3 compounds have been resynthesized and their activity as Nrf2 inhibitors has been confirmed using the aforementioned assays. First-in-class; currently, there are no known direct pharmacological inhibitors of Nrf2. Agent to circumvent therapeutic resistance and enhance the efficacy of chemotherapy and radiotherapy in the treatment of cancer. 2022-08-01 2024-10-28 2024-10-28 2022-08-01 2022-05-06 CANCER, CB5XXX, CHEMOTHERAPY, Identification, Inhibitors, Listed LPM McCue as of 4/15/2015, Nrf2, Patent Category - Chemistry, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Radiotherapy, VCXXXX, WKXXXX False True True NIHTT 37470483 Website Abstract 114172721 Nioi P, Nguyen T https://pubmed.ncbi.nlm.nih.gov/17822677/ [PMID 17822677] <a href="https://pubmed.ncbi.nlm.nih.gov/17822677/ [PMID 17822677]">Nioi P, Nguyen T</a> 114172722 Shibata T, Ohta T, et al. https://pubmed.ncbi.nlm.nih.gov/18757741/ <a href="https://pubmed.ncbi.nlm.nih.gov/18757741/">Shibata T, Ohta T, et al.</a> 114110719 Shen, Min NCATS - NCGC NCATS Shen, Min (NCATS) 0 114110721 Zhang, Ya-Qin Non NCATS - NCGC NCATS Zhang, Ya-Qin Non (NCATS) 0 114110722 Rohde, Jason NCATS - NCGC NCATS Rohde, Jason (NCATS) 0 114110723 Singh, Anju Johns Hopkins University Singh, Anju 0 114110724 Biswal, Shyam Johns Hopkins University Biswal, Shyam 0 114110725 Rastinejad, Fraydoon Sanford Burnham Medical Research Institute (SBMRI) Rastinejad, Fraydoon 0 114110720 Boxer, Matthew NCATS - NCGC Boxer, Matthew 1 114110720 Boxer, Matthew NCATS - NCGC Boxer, Matthew 1 114110719 Shen, Min NCATS - NCGC NCATS Shen, Min (NCATS) 0 114110721 Zhang, Ya-Qin Non NCATS - NCGC NCATS Zhang, Ya-Qin Non (NCATS) 0 114110722 Rohde, Jason NCATS - NCGC NCATS Rohde, Jason (NCATS) 0 114110723 Singh, Anju Johns Hopkins University Singh, Anju 0 114110724 Biswal, Shyam Johns Hopkins University Biswal, Shyam 0 114110725 Rastinejad, Fraydoon Sanford Burnham Medical Research Institute (SBMRI) Rastinejad, Fraydoon 0 114102664 Identification Of Nrf2 Inhibitors To Enhance Cancer Chemotherapy And Radiotherapy E-023-2013-0 Filing authorized Johns Hopkins University, NCATS - NCGC, Sanford Burnham Medical Research Institute (SBMRI) 83727060 Gadhia, Ami ami.gadhia@nih.gov
United States of America NCGC ami.gadhia@nih.gov?subject=Web Inquiry on [TAB-3554] Nrf2 Inhibitors for the Enhancement of Cancer Chemotherapy and Radiotherapy&body=Please send me information about technology [TAB-3554] Nrf2 Inhibitors for the Enhancement of Cancer Chemotherapy and Radiotherapy. Gadhia, Ami<br><a href="mailto:ami.gadhia@nih.gov?subject=Web Inquiry on [TAB-3554] Nrf2 Inhibitors for the Enhancement of Cancer Chemotherapy and Radiotherapy&body=Please send me information about technology [TAB-3554] Nrf2 Inhibitors for the Enhancement of Cancer Chemotherapy and Radiotherapy.">ami.gadhia@nih.gov</a><br> 114169372 E-023-2013-0 E-023-2013-0-US-01 NRF2 SMALL MOLECULE INHIBITORS FOR CANCER THERAPY PRV US 61/798,843 Abandoned US <br />Provisional (PRV) 61/798,843<br />Filed on 2013-03-15<br />Status: Abandoned 114169373 E-023-2013-0 E-023-2013-0-PCT-02 NRF2 SMALL MOLECULE INHIBITORS FOR CANCER THERAPY PCT Patent Cooperation Treaty PCT/US2014/030442 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2014/030442<br />Filed on 2014-03-17<br />Status: Expired 114169374 E-023-2013-0 E-023-2013-0-US-03 NRF2 Small Molecule Inhibitors for Cancer Therapy National Stage US 14/774,956 Abandoned US <br />National Stage 14/774,956<br />Filed on 2015-09-11<br />Status: Abandoned 114128736 CB5XXX 114128737 VCXXXX 114128738 WKXXXX 114153138 Identification 114153139 Nrf2 114153140 Inhibitors 114153141 CANCER 114153142 CHEMOTHERAPY 114153143 Radiotherapy 114153144 Patent Category - Chemistry 114153145 Listed LPM McCue as of 4/15/2015 114153146 Pre LPM working set 20150418 114153147 Post LPM Assignment Set 20150420 TAB-3551 114097407 Discovery of DPTIP a Small Molecule Inhibitor of Neutral Sphingomyelinase 2 (nSMase2) for the Treatment of Neurodegenerative and Oncologic Diseases NCATS Neurology, Oncology, Therapeutics Neurology Oncology Therapeutics Marc Ferrer-Alegre, Norman Haughey, Xin Hu, Camilo Rojas, Barbara Slusher, Ajit Thomas This technology includes a newly discovered molecule 2,6-Dimethoxy-4-(5-Phenyl-4-Thiophen-2-yl-1H-Imidazol-2-yl)-Phenol (DPTIP) as potent inhibitor of neutral sphingomyelinase 2 (nSMase2), to be used for the treatment of neurodegenerative and oncologic diseases. This discovery was identified through unbiased screening of the National Center for Advancing Chemical Sciences (NCATS) chemical library using our human neutral sphingomyelinase assay. DPTIP is a non-competitive inhibitor with respect to sphingomyelin, it inhibits exosome release both in vitro and in vivo, it is metabolically stable and it penetrates the brain (AUCbrain/AUCplasma = 0.26). Based upon genetic and pharmacological inhibition studies, DPTIP will have broad therapeutic utility in neurodegenerative and oncologic diseases wherein abnormal exosome secretion is presumed pathogenic. Treatment of neurodegenerative diseases and cancer. Treatment of neurodegenerative diseases and cancer. 2022-08-01 2024-10-28 2024-10-28 2022-08-01 2022-05-04 2, 6-Dimethoxy-4-5-Phenyl-4-Thiophen-2-yl-1H-Imi, Discovery, DISEASES, DPTIP, inhibitor, MOLECULE, NEURODEGENERATIVE, Neutral, nSMase2, Oncologic, Phingomyelinase, Small, treatment, VCXXXX, VEXXXX, WKXXXX False True True NIHTT 37470483 Website Abstract 114110697 Hu, Xin NCATS - NCGC NCATS Hu, Xin (NCATS) 0 114110698 Haughey, Norman Johns Hopkins University Haughey, Norman 0 114110699 Thomas, Ajit Johns Hopkins University Thomas, Ajit 0 114110700 Rojas, Camilo Johns Hopkins University Rojas, Camilo 0 114110701 Slusher, Barbara Johns Hopkins University Slusher, Barbara 0 114110696 Ferrer-Alegre, Marc NCATS - NCGC NCATS Ferrer-Alegre, Marc (NCATS) 1 114110696 Ferrer-Alegre, Marc NCATS - NCGC NCATS Ferrer-Alegre, Marc (NCATS) 1 114110697 Hu, Xin NCATS - NCGC NCATS Hu, Xin (NCATS) 0 114110698 Haughey, Norman Johns Hopkins University Haughey, Norman 0 114110699 Thomas, Ajit Johns Hopkins University Thomas, Ajit 0 114110700 Rojas, Camilo Johns Hopkins University Rojas, Camilo 0 114110701 Slusher, Barbara Johns Hopkins University Slusher, Barbara 0 114102661 Discovery Of 2,6-Dimethoxy-4-(5-Phenyl-4-Thiophen-2-yl-1H-Imidazol-2-yl)-Phenol (DPTIP) A Small Molecule Inhibitor Of Neutral Phingomyelinase 2 (nSMase2) For The Treatment Of Neurodegenerative And Oncologic Diseases E-117-2018-0 Filing authorized Johns Hopkins University, NCATS - NCGC 83727060 Gadhia, Ami ami.gadhia@nih.gov
United States of America NCGC ami.gadhia@nih.gov?subject=Web Inquiry on [TAB-3551] Discovery of DPTIP a Small Molecule Inhibitor of Neutral Sphingomyelinase 2 (nSMase2) for the Treatment of Neurodegenerative and Oncologic Diseases&body=Please send me information about technology [TAB-3551] Discovery of DPTIP a Small Molecule Inhibitor of Neutral Sphingomyelinase 2 (nSMase2) for the Treatment of Neurodegenerative and Oncologic Diseases. Gadhia, Ami<br><a href="mailto:ami.gadhia@nih.gov?subject=Web Inquiry on [TAB-3551] Discovery of DPTIP a Small Molecule Inhibitor of Neutral Sphingomyelinase 2 (nSMase2) for the Treatment of Neurodegenerative and Oncologic Diseases&body=Please send me information about technology [TAB-3551] Discovery of DPTIP a Small Molecule Inhibitor of Neutral Sphingomyelinase 2 (nSMase2) for the Treatment of Neurodegenerative and Oncologic Diseases.">ami.gadhia@nih.gov</a><br> 114169366 E-117-2018-0 E-117-2018-0-US-01 Discovery Of 2,6-Dimethoxy-4-(5-Phenyl-4-Thiophen-2-yl-1H-Imidazol-2-yl)-Phenol (DPTIP) A Small Molecule Inhibitor Of Neutral Phingomyelinase 2 (nSMase2) For The Treatment Of Neurodegenerative And Oncologic Diseases PRV US 62/636,998 Abandoned US <br />Provisional (PRV) 62/636,998<br />Filed on 2018-03-01<br />Status: Abandoned 114169367 E-117-2018-0 E-117-2018-0-PCT-02 DISCOVERY OF 2,6-DIMETHOXY-4-(5-PHENYL-4-THIOPHENE-2-YL-1H-IMIDAZOL-2-YL)-PHENOL (DPTIP) A SMALL MOLECULE INHIBITOR OF NEUTRAL SPHINGOMYELINASE 2 (nSMase-2) FOR THE TREATMENT OF NEURODEGENERATIVE AND ONCOLOGIC DISEASES PCT Patent Cooperation Treaty PCT/US2019/020254 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2019/020254<br />Filed on 2019-03-01<br />Status: Expired 114169368 E-117-2018-0 E-117-2018-0-US-03 2,6-DIMETHOXY-4-(5-PHENYL-4-THIOPHENE-2-YL-1H-IMIDAZOL-2-YL)-PHENOL (DPTIP) A SMALL MOLECULE INHIBITOR OF NEUTRAL SPHINGOMYELINASE 2 (nSMase-2) FOR THE TREATMENT OF NEURODEGENERATIVE AND ONCOLOGIC DISEASES National Stage US 11,766,423 16/977,305 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11766423 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11766423">11,766,423</a><br />Filed on 2020-09-01<br />Status: Issued 114128725 VCXXXX 114128726 VEXXXX 114128727 WKXXXX 114153108 Discovery 114153109 2 114153110 6-Dimethoxy-4-5-Phenyl-4-Thiophen-2-yl-1H-Imi 114153111 DPTIP 114153112 Small 114153113 MOLECULE 114153114 inhibitor 114153115 Neutral 114153116 Phingomyelinase 114153117 nSMase2 114153118 treatment 114153119 NEURODEGENERATIVE 114153120 Oncologic 114153121 DISEASES TAB-3548 114097404 Selective KCNH2-3.1 Inhibitors for the Treatment of Schizophrenia and Other CNS Disorders NCATS Neurology, Therapeutics Neurology Therapeutics James Barrow, Marc Ferrer-Alegre, Juan Marugan, Michael Poslusney, Noel Southall, Steven Titus, Jingbo Xiao, Wei Zheng This technology includes compounds, pharmaceutical compositions and methods of treating or preventing neurological or psychiatric disorders for which inhibiting KCNH2-3.1 containing potassium channels provides a therapeutic effect. Polymorphisms in the KCNH2 gene have been associated with altered cognitive function and schizophrenia. The KCNH2 gene encodes the protein which forms the human ether-a-go-go related (hERG) voltage-gated potassium channel 4, 5. The risk-associated alleles predict impaired cognitive function in both patients and healthy controls as well as overexpression of KCNH2-3.1, a truncated isoform with unique electrophysiological properties. KCNH2-3.1 is a primate-specific isoform, enriched in the brain, which lacks the PAS domain critical for the slow-deactivation properties of hERG channels. ERG channels have been shown to regulate the activity of neurons in multiple brain regions, suggesting a possible cause of the cognitive dysfunction in patients with schizophrenia associated with elevated KCNH2-3.1 may be decreased synchrony among functionally connected neurons. Those with overexpression of KCNH2-3.1 exhibit more inefficient neuronal processing in the hippocampus and frontal cortex during memory tasks as measured with fMRI1. Cognitive dysfunction associated with schizophrenia is a major unmet therapeutic need. Treatment and prevention of schizophrenia and other CNS disorders. 2022-08-01 2024-10-28 2024-10-28 2022-08-01 2022-05-04 CNS, DISORDERS, Inhibitors, KCNH2-3.1, Listed LPM Vepa as of 4/15/2015, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, SCHIZOPHRENIA, SELECTIVE, treatment, VEXXXX, WKXXXX False True True NIHTT 37470483 Website Abstract 114110683 Barrow, James Lieber Institute for Brain Development Barrow, James 0 114110684 Xiao, Jingbo FDA - CBER FDA Xiao, Jingbo (FDA) 0 114110685 Southall, Noel NCATS - TRND NCATS Southall, Noel (NCATS) 0 114110686 Zheng, Wei NCATS - TRND NCATS Zheng, Wei (NCATS) 0 114110687 Titus, Steven NCATS - NCGC NCATS Titus, Steven (NCATS) 0 114110688 Ferrer-Alegre, Marc NCATS - NCGC NCATS Ferrer-Alegre, Marc (NCATS) 0 114110689 Poslusney, Michael Lieber Institute for Brain Development Poslusney, Michael 0 114110682 Marugan, Juan NCATS - NCGC NCATS Marugan, Juan (NCATS) 1 114110682 Marugan, Juan NCATS - NCGC NCATS Marugan, Juan (NCATS) 1 114110683 Barrow, James Lieber Institute for Brain Development Barrow, James 0 114110684 Xiao, Jingbo FDA - CBER FDA Xiao, Jingbo (FDA) 0 114110685 Southall, Noel NCATS - TRND NCATS Southall, Noel (NCATS) 0 114110686 Zheng, Wei NCATS - TRND NCATS Zheng, Wei (NCATS) 0 114110687 Titus, Steven NCATS - NCGC NCATS Titus, Steven (NCATS) 0 114110688 Ferrer-Alegre, Marc NCATS - NCGC NCATS Ferrer-Alegre, Marc (NCATS) 0 114110689 Poslusney, Michael Lieber Institute for Brain Development Poslusney, Michael 0 114102658 Selective KCNH2-3.1 Inhibitors For The Treatment Of Schizophrenia And Other CNS Disorders E-162-2015-0 Filing authorized Lieber Institute for Brain Development, NCATS - NCGC 83682485 Vepa, Suryanarayana sury.vepa@nih.gov
United States of America Office of Strategic Alliances (OSA) sury.vepa@nih.gov?subject=Web Inquiry on [TAB-3548] Selective KCNH2-3.1 Inhibitors for the Treatment of Schizophrenia and Other CNS Disorders&body=Please send me information about technology [TAB-3548] Selective KCNH2-3.1 Inhibitors for the Treatment of Schizophrenia and Other CNS Disorders. Vepa, Suryanarayana<br><a href="mailto:sury.vepa@nih.gov?subject=Web Inquiry on [TAB-3548] Selective KCNH2-3.1 Inhibitors for the Treatment of Schizophrenia and Other CNS Disorders&body=Please send me information about technology [TAB-3548] Selective KCNH2-3.1 Inhibitors for the Treatment of Schizophrenia and Other CNS Disorders.">sury.vepa@nih.gov</a><br> 114169362 E-162-2015-0 E-162-2015-0-US-01 KCNH2-3.1 Inhibiting Methods and Compositions PRV US 62/150,675 Abandoned US <br />Provisional (PRV) 62/150,675<br />Filed on 2015-04-21<br />Status: Abandoned 114128718 VEXXXX 114128719 WKXXXX 114153078 SELECTIVE 114153079 KCNH2-3.1 114153080 Inhibitors 114153081 treatment 114153082 SCHIZOPHRENIA 114153083 CNS 114153084 DISORDERS 114153085 Listed LPM Vepa as of 4/15/2015 114153086 Pre LPM working set 20150418 114153087 Post LPM Assignment Set 20150420 TAB-3549 114097405 Quantum Dot Conjugated Virus Spike Protein for Cell-based Bio-sensing Systems and Drug Screening for the Prevention of Viral Infections NCATS Consumer Products, Infectious Disease, Occupational Safety and Health, Therapeutics Consumer Products Infectious Disease Occupational Safety and Health Therapeutics Kirill Gorshkov, Eunkeu Oh, Kimihiro Susumu, Mason Wolak This technology includes a method to facilitate identification of drug targets that can prevent SARS-related viruses from entering human cells with ACE2 receptors on the plasma membrane. Surface binding to cellular ACE2 of the SARS-CoV-2 virus is the first step of infection for the disease COVID-19. The invention allows for visualization of cell binding and entry of a “quantum dot conjugated virus spike protein” (hereafter referred to as either a ‘QD-Spike conjugate’ or a ‘pseudo-virion’) and can be used to screen libraries of drugs that prevent/inhibit this cell entry. The QD-Spike conjugates can be visualized in real time using high-content microscopy in live assays of human cells treated with both QD-Spike and drug targets. To date, there is no assay that can report on the binding of Spike to ACE2 on the cell surface, nor is there an assay that can report on the endocytosis of ACE2 in living cells without the need for complicated immunostaining procedures in a BSL-2 facility. The QD pseudo-virion mimics the shape and physiological activity of a SARS virus particle without being infectious or hazardous to humans. <ul> <li>QDs can be used as a platform technology for viral Spike or other receptor binding proteins to screen for compounds or biologics that prevent viral infection.</li> <li>The nanoparticles developed can be used to specifically target certain cells or tissue types by conjugated nanoparticles with the particular protein that binds to them and the nanoparticle can encapsulate a drug to be used as a drug delivery device</li> </ul> 2022-08-01 2024-10-28 2024-10-28 2022-08-01 2022-05-04 Bio-sensing, CELL-BASED, CONJUGATED, dot, DRUG, Protein, Quantum, screening, spike, SYSTEMS, virus, VLXXXX, WFXXXX, WKXXXX False True True NIHTT 37470483 Website Abstract 114172718 Gorshkov K, Susumu K, et al. https://pubmed.ncbi.nlm.nih.gov/32845122/ <a href="https://pubmed.ncbi.nlm.nih.gov/32845122/">Gorshkov K, Susumu K, et al.</a> 114110690 Oh, Eunkeu Naval Research Laboratories (NRL) Oh, Eunkeu 0 114110692 Wolak, Mason Wolak, Mason 0 114110693 Susumu, Kimihiro Naval Research Laboratories (NRL) Susumu, Kimihiro 0 114110691 Gorshkov, Kirill NCATS - NCGC NCATS Gorshkov, Kirill (NCATS) 1 114110691 Gorshkov, Kirill NCATS - NCGC NCATS Gorshkov, Kirill (NCATS) 1 114110690 Oh, Eunkeu Naval Research Laboratories (NRL) Oh, Eunkeu 0 114110692 Wolak, Mason Wolak, Mason 0 114110693 Susumu, Kimihiro Naval Research Laboratories (NRL) Susumu, Kimihiro 0 114102659 Quantum Dot Conjugated Virus Spike Protein For Cell-based Bio-sensing Systems And Drug Screening E-027-2021-0 Filing authorized Naval Research Laboratories, Navel Research Laboratory, NCATS - NCGC 83673536 Erwin-Cohen, Rebecca rebecca.erwin-cohen@nih.gov
NCGC rebecca.erwin-cohen@nih.gov?subject=Web Inquiry on [TAB-3549] Quantum Dot Conjugated Virus Spike Protein for Cell-based Bio-sensing Systems and Drug Screening for the Prevention of Viral Infections&body=Please send me information about technology [TAB-3549] Quantum Dot Conjugated Virus Spike Protein for Cell-based Bio-sensing Systems and Drug Screening for the Prevention of Viral Infections. Erwin-Cohen, Rebecca<br><a href="mailto:rebecca.erwin-cohen@nih.gov?subject=Web Inquiry on [TAB-3549] Quantum Dot Conjugated Virus Spike Protein for Cell-based Bio-sensing Systems and Drug Screening for the Prevention of Viral Infections&body=Please send me information about technology [TAB-3549] Quantum Dot Conjugated Virus Spike Protein for Cell-based Bio-sensing Systems and Drug Screening for the Prevention of Viral Infections.">rebecca.erwin-cohen@nih.gov</a><br> 114169363 E-027-2021-0 E-027-2021-0-US-01 Quantum Dot Conjugated Virus Spike Protein For Cell-based Bio-sensing Systems And Drug Screening PRV US 63/060,161 Abandoned US <br />Provisional (PRV) 63/060,161<br />Filed on 2020-08-03<br />Status: Abandoned 114128720 VLXXXX 114128721 WFXXXX 114128722 WKXXXX 114153088 Quantum 114153089 dot 114153090 CONJUGATED 114153091 virus 114153092 spike 114153093 Protein 114153094 CELL-BASED 114153095 Bio-sensing 114153096 SYSTEMS 114153097 DRUG 114153098 screening TAB-3546 114097387 New Antimalarial Chemotypes Discovered Through Chemical Methodology and Library Development NCATS Infectious Disease, Therapeutics Infectious Disease Therapeutics Aaron Beeler, Lauren Brown, Chih-Chien (Ken) Cheng, Rajarshi Guha, James Inglese, Ryan Macarthur, Feng Ni, John Porco, Scott Schaus, Xin-zhuan Su, John Synder, Jing Yuan This technology includes three new compound classes displaying either differential or comprehensive antimalarial activity across geographically diverse lines. These compounds were identified from a quantitative high throughput screen of a novel chemical library with unique chemical complexity and are potential candidates for treating malaria. Compounds display comprehensive antimalarial activity. This new compound class will be utilized to treat malaria. 2022-08-01 2024-10-28 2024-10-28 2022-08-01 2022-05-04 ANTIMALARIAL, Chemical, Chemotypes, Development, Discovery, LIBRARY, methodology, NCTT, VQXXXX, WKXXXX False True True NIHTT 37470483 Website Abstract 114172715 Yuan J, Johnson R, et al. https://pubmed.ncbi.nlm.nih.gov/19734910/ <a href="https://pubmed.ncbi.nlm.nih.gov/19734910/">Yuan J, Johnson R, et al.</a> 114172716 Guiguemde W, Shelat A, et al. https://pubmed.ncbi.nlm.nih.gov/20485428/ <a href="https://pubmed.ncbi.nlm.nih.gov/20485428/">Guiguemde W, Shelat A, et al.</a> 114172717 Gamo F, Sanz L, et al. https://pubmed.ncbi.nlm.nih.gov/20485427/ <a href="https://pubmed.ncbi.nlm.nih.gov/20485427/">Gamo F, Sanz L, et al.</a> 114110661 Inglese, James National Human Genome Research Institute (NHGRI) NCATS Inglese, James (NCATS) 0 114110662 Cheng, Chih-Chien (Ken) NCATS - NCGC NCATS Cheng, Chih-Chien (Ken) (NCATS) 0 114110663 Macarthur, Ryan NCATS - NCGC NCATS Macarthur, Ryan (NCATS) 0 114110664 Guha, Rajarshi NCATS - NCGC NCATS Guha, Rajarshi (NCATS) 0 114110665 Su, Xin-zhuan NIAID - DIR NIAID Su, Xin-zhuan (NIAID) 0 114110666 Yuan, Jing NIAID - DIR NIAID Yuan, Jing (NIAID) 0 114110668 Ni, Feng Boston University Ni, Feng 0 114110669 Beeler, Aaron Boston University Beeler, Aaron 0 114110670 Schaus, Scott Boston University Schaus, Scott 0 114110671 Brown, Lauren Boston University Brown, Lauren 0 114110672 Porco, John Boston University Porco, John 0 114110667 Synder, John Boston University Synder, John 1 114110667 Synder, John Boston University Synder, John 1 114110661 Inglese, James National Human Genome Research Institute (NHGRI) NCATS Inglese, James (NCATS) 0 114110662 Cheng, Chih-Chien (Ken) NCATS - NCGC NCATS Cheng, Chih-Chien (Ken) (NCATS) 0 114110663 Macarthur, Ryan NCATS - NCGC NCATS Macarthur, Ryan (NCATS) 0 114110664 Guha, Rajarshi NCATS - NCGC NCATS Guha, Rajarshi (NCATS) 0 114110665 Su, Xin-zhuan NIAID - DIR NIAID Su, Xin-zhuan (NIAID) 0 114110666 Yuan, Jing NIAID - DIR NIAID Yuan, Jing (NIAID) 0 114110668 Ni, Feng Boston University Ni, Feng 0 114110669 Beeler, Aaron Boston University Beeler, Aaron 0 114110670 Schaus, Scott Boston University Schaus, Scott 0 114110671 Brown, Lauren Boston University Brown, Lauren 0 114110672 Porco, John Boston University Porco, John 0 114102656 Discovery Of New Antimalarial Chemotypes Through Chemical Methodology And Library Development E-221-2011-0 Filing authorized Boston University, NCATS - NCGC, NIAID 83682485 Vepa, Suryanarayana sury.vepa@nih.gov
United States of America Office of Strategic Alliances (OSA) sury.vepa@nih.gov?subject=Web Inquiry on [TAB-3546] New Antimalarial Chemotypes Discovered Through Chemical Methodology and Library Development&body=Please send me information about technology [TAB-3546] New Antimalarial Chemotypes Discovered Through Chemical Methodology and Library Development. Vepa, Suryanarayana<br><a href="mailto:sury.vepa@nih.gov?subject=Web Inquiry on [TAB-3546] New Antimalarial Chemotypes Discovered Through Chemical Methodology and Library Development&body=Please send me information about technology [TAB-3546] New Antimalarial Chemotypes Discovered Through Chemical Methodology and Library Development.">sury.vepa@nih.gov</a><br> 114169358 E-221-2011-0 E-221-2011-0-US-01 Discovery Of New Antimalarial Chemotypes Through Chemical Methodology And Library Development PRV US 61/475,482 Abandoned US <br />Provisional (PRV) 61/475,482<br />Filed on 2011-04-14<br />Status: Abandoned 114128714 VQXXXX 114128715 WKXXXX 114153061 Development 114153062 LIBRARY 114153063 methodology 114153064 Chemical 114153065 Chemotypes 114153066 ANTIMALARIAL 114153067 Discovery 114153068 NCTT TAB-3547 114097403 New Allosteric Inhibitors of C-Abl Tyrosine Kinase for the Treatment of Alzheimer’s and other Neurodegenerative Diseases NCATS Neurology, Therapeutics Neurology Therapeutics Alejandra Alvarez, Christopher Dextras, Andres Dulcey Garcia, Marc Ferrer-Alegre, Xin Hu, Juan Marugan, Noel Southall, Daniel Talley, Silvana Zanlungo This technology includes a variety of structures that can effectively target the c-Abl myristate binding pocket with increased potency and brain permeability. C-Abl is a ubiquitous non-receptor tyrosine kinase involved in signal transduction. In addition to its classic function in leukemia pathogenesis, c-Abl kinase is also thought to play a role in neuronal health, whereby deregulation of c-Abl could be related to early neuronal dysfunction and cytoskeletal alterations. Mounting evidence points to the role of the Abl tyrosine kinase family as an important player in Alzheimer’s Disease, and thus a potential therapeutic target to delay and ameliorate neurodegeneration. Modelling and cell-based structure-activity relationships were used to guide the optimization and diversification of ligands that are capable of crossing the blood brain barrier (BBB), and bind to the myristate pocket on the c-Abl tyrosine kinase. <ul> <li>Molecules display favorable physical properties for BBB penetration, a prerequisite for neurodegenerative diseases</li> <li>Discovery includes the allosteric mode of inhibition of c-Abl, which renders our molecules exquisitely selective against other kinases, a problem commonly encountered in kinase inhibition programs</li> </ul> Treatment for Alzheimer’s Disease and other neurodegenerative diseases. 2022-08-01 2024-10-28 2024-10-28 2022-08-01 2022-05-04 ALLOSTERIC, ALZHEIMER, C-ABL, DISEASES, Inhibitors, Kinase, NEURODEGENERATIVE, treatment, TYROSINE, VEXXXX, WKXXXX False True True NIHTT 37470483 Website Abstract 114110673 Southall, Noel NCATS - TRND NCATS Southall, Noel (NCATS) 0 114110674 Zanlungo, Silvana Pontifical Catholic University of Chile Zanlungo, Silvana 0 114110675 Alvarez, Alejandra Pontifical Catholic University of Chile Alvarez, Alejandra 0 114110677 Ferrer-Alegre, Marc NCATS - NCGC NCATS Ferrer-Alegre, Marc (NCATS) 0 114110678 Dulcey Garcia, Andres NCATS - NCGC NCATS Dulcey Garcia, Andres (NCATS) 0 114110679 Hu, Xin NCATS - NCGC NCATS Hu, Xin (NCATS) 0 114110680 Talley, Daniel NCATS - NCGC NCATS Talley, Daniel (NCATS) 0 114110681 Dextras, Christopher NCATS - NCGC Dextras, Christopher 0 114110676 Marugan, Juan NCATS - NCGC NCATS Marugan, Juan (NCATS) 1 114110676 Marugan, Juan NCATS - NCGC NCATS Marugan, Juan (NCATS) 1 114110673 Southall, Noel NCATS - TRND NCATS Southall, Noel (NCATS) 0 114110674 Zanlungo, Silvana Pontifical Catholic University of Chile Zanlungo, Silvana 0 114110675 Alvarez, Alejandra Pontifical Catholic University of Chile Alvarez, Alejandra 0 114110677 Ferrer-Alegre, Marc NCATS - NCGC NCATS Ferrer-Alegre, Marc (NCATS) 0 114110678 Dulcey Garcia, Andres NCATS - NCGC NCATS Dulcey Garcia, Andres (NCATS) 0 114110679 Hu, Xin NCATS - NCGC NCATS Hu, Xin (NCATS) 0 114110680 Talley, Daniel NCATS - NCGC NCATS Talley, Daniel (NCATS) 0 114110681 Dextras, Christopher NCATS - NCGC Dextras, Christopher 0 114102657 New Allosteric Inhibitors Of C-Abl Tyrosine Kinase For The Treatment Of Alzheimer And Other Neurodegenerative Diseases E-253-2017-0 Filing authorized NCATS - NCGC, Pontificia Universidad Catolica de Chile, Pontificia Universidad Catolica de Chile 93911356 Kalsi, Jasmine jasmine.kalsi@nih.gov
United States of America jasmine.kalsi@nih.gov?subject=Web Inquiry on [TAB-3547] New Allosteric Inhibitors of C-Abl Tyrosine Kinase for the Treatment of Alzheimer’s and other Neurodegenerative Diseases&body=Please send me information about technology [TAB-3547] New Allosteric Inhibitors of C-Abl Tyrosine Kinase for the Treatment of Alzheimer’s and other Neurodegenerative Diseases. Kalsi, Jasmine<br><a href="mailto:jasmine.kalsi@nih.gov?subject=Web Inquiry on [TAB-3547] New Allosteric Inhibitors of C-Abl Tyrosine Kinase for the Treatment of Alzheimer’s and other Neurodegenerative Diseases&body=Please send me information about technology [TAB-3547] New Allosteric Inhibitors of C-Abl Tyrosine Kinase for the Treatment of Alzheimer’s and other Neurodegenerative Diseases.">jasmine.kalsi@nih.gov</a><br> 114169359 E-253-2017-0 E-253-2017-0-US-01 C-ABL TYROSINE KINASE INHIBITORY COMPOUND EMBODIMENTS AND METHODS OF MAKING AND USING THE SAME PRV US 62/641,126 Abandoned US <br />Provisional (PRV) 62/641,126<br />Filed on 2018-03-09<br />Status: Abandoned 114169360 E-253-2017-0 E-253-2017-0-PCT-02 C-ABL TYROSINE KINASE INHIBITORY COMPOUND EMBODIMENTS AND METHODS OF MAKING AND USING THE SAME PCT Patent Cooperation Treaty PCT/US2019/021434 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2019/021434<br />Filed on 2019-03-08<br />Status: Expired 114169361 E-253-2017-0 E-253-2017-0-US-03 C-ABL TYROSINE KINASE INHIBITORY COMPOUND EMBODIMENTS AND METHODS OF MAKING AND USING THE SAME National Stage US 11,649,218 16/976,012 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11649218 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11649218">11,649,218</a><br />Filed on 2020-08-26<br />Status: Issued 114128716 VEXXXX 114128717 WKXXXX 114153069 ALLOSTERIC 114153070 Inhibitors 114153071 C-ABL 114153072 TYROSINE 114153073 Kinase 114153074 treatment 114153075 ALZHEIMER 114153076 NEURODEGENERATIVE 114153077 DISEASES TAB-3543 114097401 Cell-based High-throughput High-content Assays Using Glycolytic Enzymes for Drug Discovery NCATS Cardiology, Dental, Endocrinology, Infectious Disease, Oncology, Ophthalmology, Research Materials Cardiology Dental Endocrinology Infectious Disease Oncology Ophthalmology Research Materials Patricia Dranchak, James Inglese This technology includes an assay capable of monitoring glycosome formation for use in high throughput screening (HTS). The reversible assembly and disassembly of a multi-enzyme complex, known as the glycosome, visualized by GFP-labeled human phosphofructokinase-1 (PFK1), is employed as an intracellular marker in human cells to screen small molecule libraries under high-content imaging in a high-throughput fashion. The glycolytic enzymes have been proposed to form a multi-enzyme complex in the cell. It has recently been shown in several human cancer cells that human liver-type PFK1 forms cytoplasmic clusters by recruiting other rate-limiting enzymes in glycolysis and gluconeogenesis, indicating the formation of a multi-enzyme metabolic assembly, namely the “glucosome”. It appears that the enzymes in glucose metabolism are spatially organized into cytoplasmic clusters in human cells. This assay enables a phenotypic analysis of regulatory aspects of cellular glycolysis that have are highly amenable to HTS. The assay may provide a means to discover agents targeting a novel aspect of cellular physiology important to diseases such as cancer. 2022-08-01 2024-10-28 2024-10-28 2022-08-01 2022-05-04 ASSAYS, CELL-BASED, Discovery, DRUG, ENZYMES, Glycolytic, High-content, High-throughput, VPXXXX, WIXXXX False True True NIHTT 37470483 Website Abstract 114172707 An S, Kumar R, et al. https://pubmed.ncbi.nlm.nih.gov/18388293/ <a href="https://pubmed.ncbi.nlm.nih.gov/18388293/">An S, Kumar R, et al.</a> 114172708 Schmitt D, An S https://pubmed.ncbi.nlm.nih.gov/28580779/ <a href="https://pubmed.ncbi.nlm.nih.gov/28580779/">Schmitt D, An S</a> 114110653 Dranchak, Patricia NCATS - NCGC NCATS Dranchak, Patricia (NCATS) 0 114110652 Inglese, James NCATS - NCGC NCATS Inglese, James (NCATS) 1 114110652 Inglese, James NCATS - NCGC NCATS Inglese, James (NCATS) 1 114110653 Dranchak, Patricia NCATS - NCGC NCATS Dranchak, Patricia (NCATS) 0 114102654 Cell-based High-throughput High-content Assays Using Glycolytic Enzymes For Drug Discovery E-178-2018-0 Filing authorized NCATS - NCGC 83727060 Gadhia, Ami ami.gadhia@nih.gov
United States of America NCGC ami.gadhia@nih.gov?subject=Web Inquiry on [TAB-3543] Cell-based High-throughput High-content Assays Using Glycolytic Enzymes for Drug Discovery&body=Please send me information about technology [TAB-3543] Cell-based High-throughput High-content Assays Using Glycolytic Enzymes for Drug Discovery. Gadhia, Ami<br><a href="mailto:ami.gadhia@nih.gov?subject=Web Inquiry on [TAB-3543] Cell-based High-throughput High-content Assays Using Glycolytic Enzymes for Drug Discovery&body=Please send me information about technology [TAB-3543] Cell-based High-throughput High-content Assays Using Glycolytic Enzymes for Drug Discovery.">ami.gadhia@nih.gov</a><br> 114169355 E-178-2018-0 E-178-2018-0-US-01 Cell-based High-throughput High-content Assays Using Glycolytic Enzymes For Drug Discovery PRV US 62/690,027 Abandoned US <br />Provisional (PRV) 62/690,027<br />Filed on 2018-06-26<br />Status: Abandoned 114169356 E-178-2018-0 E-178-2018-0-US-02 METHOD OF IDENTIFYING A COMPOUND WHICH AFFECTS THE MULTIENZYME METABOLIC ASSEMBLY OF GLUCOSE METABOLISM AND ITS ASSOCIATION WITH CELL CYCLE PROGRESSION IN CANCER CELLS ORD US 11,474,097 16/452,767 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11474097 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11474097">11,474,097</a><br />Filed on 2019-06-26<br />Status: Issued 114128709 VPXXXX 114128710 WIXXXX 114153032 CELL-BASED 114153033 High-throughput 114153034 High-content 114153035 ASSAYS 114153036 Glycolytic 114153037 ENZYMES 114153038 DRUG 114153039 Discovery TAB-3538 114097396 Treatment for Wolfram Syndrome and Other Endoplasmic Reticulum Stress Disorders with Endoplasmic Reticulum Calcium Modulators NCATS Endocrinology, Therapeutics Endocrinology Therapeutics Brandon Harvey, Mark Henderson, Ajit Jadhav, Jana Mahadevan, David Maloney, Fumihiko Urano, Shyh-Ming Yang This technology includes the use of JTV-519 and oxidized form of JTV-519, as a novel treatment for Wolfram syndrome and other diseases associated with endoplasmic reticulum (ER). JTV-519 can prevent the leakage of ER calcium to the cytosol and abnormal activation of a pro-apoptotic enzyme, calpain 2, in cell models of Wolfram syndrome. Further, these compounds can prevent cell death in beta cell models of these diseases. Novel treatment for diseases currently lacking therapeutic options. Wolfram syndrome and other diseases associated with endoplasmic reticulum. 2022-08-01 2024-10-28 2024-10-28 2022-08-01 2022-05-04 CALCIUM, DISORDERS, Endoplasmic, MODULATORS, RETICULUM, STRESS, Syndrome, treatment, VGXXXX, WKXXXX, WOLFRAM False True True NIHTT 37470483 Website Abstract 114110612 Mahadevan, Jana Washington University School of Medicine Mahadevan, Jana 0 114110613 Jadhav, Ajit NCATS - NCGC NCATS Jadhav, Ajit (NCATS) 0 114110614 Yang, Shyh-Ming NCATS - NCGC NCATS Yang, Shyh-Ming (NCATS) 0 114110615 Maloney, David NCATS - NCGC NCATS Maloney, David (NCATS) 0 114110616 Henderson, Mark NIDA - Biomedical Research Center NCATS Henderson, Mark (NCATS) 0 114110617 Harvey, Brandon NIDA - Biomedical Research Center NIDA Harvey, Brandon (NIDA) 0 114110611 Urano, Fumihiko Washington University School of Medicine Urano, Fumihiko 1 114110611 Urano, Fumihiko Washington University School of Medicine Urano, Fumihiko 1 114110612 Mahadevan, Jana Washington University School of Medicine Mahadevan, Jana 0 114110613 Jadhav, Ajit NCATS - NCGC NCATS Jadhav, Ajit (NCATS) 0 114110614 Yang, Shyh-Ming NCATS - NCGC NCATS Yang, Shyh-Ming (NCATS) 0 114110615 Maloney, David NCATS - NCGC NCATS Maloney, David (NCATS) 0 114110616 Henderson, Mark NIDA - Biomedical Research Center NCATS Henderson, Mark (NCATS) 0 114110617 Harvey, Brandon NIDA - Biomedical Research Center NIDA Harvey, Brandon (NIDA) 0 114102649 Treatment For Wolfram Syndrome And Other Endoplasmic Reticulum Stress Disorders With Endoplasmic Reticulum Calcium Modulators E-095-2017-0 Filing authorized National Institute on Drug Abuse (NIDA), NCATS - NCGC, Washington University School of Medicine 83727060 Gadhia, Ami ami.gadhia@nih.gov
United States of America NCGC ami.gadhia@nih.gov?subject=Web Inquiry on [TAB-3538] Treatment for Wolfram Syndrome and Other Endoplasmic Reticulum Stress Disorders with Endoplasmic Reticulum Calcium Modulators&body=Please send me information about technology [TAB-3538] Treatment for Wolfram Syndrome and Other Endoplasmic Reticulum Stress Disorders with Endoplasmic Reticulum Calcium Modulators. Gadhia, Ami<br><a href="mailto:ami.gadhia@nih.gov?subject=Web Inquiry on [TAB-3538] Treatment for Wolfram Syndrome and Other Endoplasmic Reticulum Stress Disorders with Endoplasmic Reticulum Calcium Modulators&body=Please send me information about technology [TAB-3538] Treatment for Wolfram Syndrome and Other Endoplasmic Reticulum Stress Disorders with Endoplasmic Reticulum Calcium Modulators.">ami.gadhia@nih.gov</a><br> 114169342 E-095-2017-0 E-095-2017-0-US-01 TREATMENT FOR WOLFRAM SYNDROME AND OTHER ENDOPLASMIC RETICULUM STRESS DISORDERS PRV US 62/467,632 Abandoned US <br />Provisional (PRV) 62/467,632<br />Filed on 2017-03-06<br />Status: Abandoned 114169343 E-095-2017-0 E-095-2017-0-PCT-02 TREATMENT FOR WOLFRAM SYNDROME AND OTHER ENDOPLASMIC RETICULUM STRESS DISORDERS PCT Patent Cooperation Treaty PCT/US2018/021167 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2018/021167<br />Filed on 2018-03-06<br />Status: Expired 114169344 E-095-2017-0 E-095-2017-0-US-03 TREATMENT FOR WOLFRAM SYNDROME AND OTHER ENDOPLASMIC RETICULUM STRESS DISORDERS National Stage US 11,426,415 16/491,826 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11426415 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11426415">11,426,415</a><br />Filed on 2018-03-06<br />Status: Issued 114128700 VGXXXX 114128701 WKXXXX 114152986 treatment 114152987 WOLFRAM 114152988 Syndrome 114152989 Endoplasmic 114152990 RETICULUM 114152991 STRESS 114152992 DISORDERS 114152993 CALCIUM 114152994 MODULATORS TAB-3539 114097397 RALDH1 Inhibitors for the Immunotherapy of Hepatocellular Carcinoma NCATS Oncology, Therapeutics Oncology Therapeutics Malay Haldar, Natalia Martinez, Ganesha Rai Bantukallu, Anton Simeonov, Shyh-Ming Yang, Adam Yasgar, Alexey Zakharov This technology includes the utility of the novel small molecule inhibitors of ALDH1A1 (RALDH1) in combination with immunotherapy for the treatment of hepatocellular carcinoma (HCC). Recently it was shown that the ALDH1A1 catalyzed production of retinoic acid (RA) in tumor cells promotes their differentiation into immunosuppressive antigen-presenting cells. Therefore, blocking RA production by tumor cells and/or blocking RA signaling in monocytes using our ALDH1A1 inhibitors can alleviate immunosuppression and engender anti-tumor immune responses. First approach to combine ALDH1A1 inhibitors with cancer immunotherapy. Treatment of hepatocellular carcinoma and other solid tumors where the RA-based immune evasion pathway is active. 2022-08-01 2024-10-28 2024-10-28 2022-08-01 2022-05-04 Carcinoma, Hepatocellular, Immunotherapy, Inhibitors, RALDH1, VCXXXX, WKXXXX False True True NIHTT 37470483 Website Abstract 114172702 Devalaraja S, To T, et al. https://pubmed.ncbi.nlm.nih.gov/32169218/ <a href="https://pubmed.ncbi.nlm.nih.gov/32169218/">Devalaraja S, To T, et al.</a> 114172703 Yang S, Martinez N, et al. https://pubmed.ncbi.nlm.nih.gov/29767973/ <a href="https://pubmed.ncbi.nlm.nih.gov/29767973/">Yang S, Martinez N, et al.</a> 114110619 Yang, Shyh-Ming NCATS - NCGC NCATS Yang, Shyh-Ming (NCATS) 0 114110620 Martinez, Natalia NCATS - NCGC NCATS Martinez, Natalia (NCATS) 0 114110621 Simeonov, Anton NCATS - NCGC NCATS Simeonov, Anton (NCATS) 0 114110622 Yasgar, Adam NCATS - NCGC NCATS Yasgar, Adam (NCATS) 0 114110623 Zakharov, Alexey NCATS - NCGC NCATS Zakharov, Alexey (NCATS) 0 114110624 Haldar, Malay University of Pennsylvania Haldar, Malay 0 114110618 Rai Bantukallu, Ganesha NCATS - NCGC NCATS Rai Bantukallu, Ganesha (NCATS) 1 114110618 Rai Bantukallu, Ganesha NCATS - NCGC NCATS Rai Bantukallu, Ganesha (NCATS) 1 114110619 Yang, Shyh-Ming NCATS - NCGC NCATS Yang, Shyh-Ming (NCATS) 0 114110620 Martinez, Natalia NCATS - NCGC NCATS Martinez, Natalia (NCATS) 0 114110621 Simeonov, Anton NCATS - NCGC NCATS Simeonov, Anton (NCATS) 0 114110622 Yasgar, Adam NCATS - NCGC NCATS Yasgar, Adam (NCATS) 0 114110623 Zakharov, Alexey NCATS - NCGC NCATS Zakharov, Alexey (NCATS) 0 114110624 Haldar, Malay University of Pennsylvania Haldar, Malay 0 114102650 RALDH1 Inhibitors For The Immunotherapy Of Hepatocellular Carcinoma E-041-2021-0 Filing authorized NCATS - NCGC, University of Pennsylvania 83673536 Erwin-Cohen, Rebecca rebecca.erwin-cohen@nih.gov
NCGC rebecca.erwin-cohen@nih.gov?subject=Web Inquiry on [TAB-3539] RALDH1 Inhibitors for the Immunotherapy of Hepatocellular Carcinoma&body=Please send me information about technology [TAB-3539] RALDH1 Inhibitors for the Immunotherapy of Hepatocellular Carcinoma. Erwin-Cohen, Rebecca<br><a href="mailto:rebecca.erwin-cohen@nih.gov?subject=Web Inquiry on [TAB-3539] RALDH1 Inhibitors for the Immunotherapy of Hepatocellular Carcinoma&body=Please send me information about technology [TAB-3539] RALDH1 Inhibitors for the Immunotherapy of Hepatocellular Carcinoma.">rebecca.erwin-cohen@nih.gov</a><br> 114169345 E-041-2021-0 E-041-2021-0-US-01 RALDH1 Inhibitors For The Immunotherapy Of Hepatocellular Carcinoma PRV US 63/163,299 Expired US <br />Provisional (PRV) 63/163,299<br />Filed on 2021-03-19<br />Status: Expired 114128702 VCXXXX 114128703 WKXXXX 114152995 RALDH1 114152996 Inhibitors 114152997 Immunotherapy 114152998 Hepatocellular 114152999 Carcinoma TAB-3537 114097395 Use of NCGC00117362, NCGC117328, NCGC00117505, NCGC00117477 and NCGC00117166 for the Treatment of Ovarian Cancer NCATS Oncology, Therapeutics Oncology Therapeutics Marc Ferrer-Alegre, Hilary Kenny, Madhu Lal, Ernst Lengyel, Juan Marugan, Min Shen This technology includes the use of a chemical series (compounds NCGC00117362, NCGC117328, NCGC00117505, NCGC00117477, NCGC00117166 and their analogs) as potential treatment for ovarian cancer. These compounds were identified through a high throughput screen (HTS) of 44,806 compounds implemented at NCATS using a layered 3D organotypic assay model of human ovarian cancer metastatic microenvironment containing primary human mesothelial cells, primary human fibroblasts, and extracellular matrix. This is a novel chemical series of compounds that prevent ovarian cancer metastasis in vitro and in animal models. Compounds to be utilized for the treatment of ovarian cancer. 2022-08-01 2024-10-28 2024-10-28 2022-08-01 2022-05-04 CANCER, NCGC00117166, NCGC00117362, NCGC00117477, NCGC00117505, NCGC117328, treatment, VCXXXX, WKXXXX False True True NIHTT 37470483 Website Abstract 114110606 Kenny, Hilary University of Chicago Kenny, Hilary 0 114110607 Ferrer-Alegre, Marc NCATS - NCGC NCATS Ferrer-Alegre, Marc (NCATS) 0 114110608 Shen, Min NCATS - NCGC NCATS Shen, Min (NCATS) 0 114110609 Marugan, Juan NCATS - NCGC NCATS Marugan, Juan (NCATS) 0 114110610 Lal, Madhu NCATS Lal, Madhu (NCATS) 0 114110605 Lengyel, Ernst University of Chicago Lengyel, Ernst 1 114110605 Lengyel, Ernst University of Chicago Lengyel, Ernst 1 114110606 Kenny, Hilary University of Chicago Kenny, Hilary 0 114110607 Ferrer-Alegre, Marc NCATS - NCGC NCATS Ferrer-Alegre, Marc (NCATS) 0 114110608 Shen, Min NCATS - NCGC NCATS Shen, Min (NCATS) 0 114110609 Marugan, Juan NCATS - NCGC NCATS Marugan, Juan (NCATS) 0 114110610 Lal, Madhu NCATS Lal, Madhu (NCATS) 0 114102648 Use Of NCGC00117362, NCGC117328, NCGC00117505, NCGC00117477 And NCGC00117166 For Treatment Of Cancer E-085-2020-0 Filing authorized NCATS - NCGC, University of Chicago 83727060 Gadhia, Ami ami.gadhia@nih.gov
United States of America NCGC ami.gadhia@nih.gov?subject=Web Inquiry on [TAB-3537] Use of NCGC00117362, NCGC117328, NCGC00117505, NCGC00117477 and NCGC00117166 for the Treatment of Ovarian Cancer&body=Please send me information about technology [TAB-3537] Use of NCGC00117362, NCGC117328, NCGC00117505, NCGC00117477 and NCGC00117166 for the Treatment of Ovarian Cancer. Gadhia, Ami<br><a href="mailto:ami.gadhia@nih.gov?subject=Web Inquiry on [TAB-3537] Use of NCGC00117362, NCGC117328, NCGC00117505, NCGC00117477 and NCGC00117166 for the Treatment of Ovarian Cancer&body=Please send me information about technology [TAB-3537] Use of NCGC00117362, NCGC117328, NCGC00117505, NCGC00117477 and NCGC00117166 for the Treatment of Ovarian Cancer.">ami.gadhia@nih.gov</a><br> 114128698 VCXXXX 114128699 WKXXXX 114152979 NCGC00117362 114152980 NCGC117328 114152981 NCGC00117505 114152982 NCGC00117477 114152983 NCGC00117166 114152984 treatment 114152985 CANCER TAB-3533 114097392 Novel Methods of MHC-I - LILRB Checkpoint Inhibition NIAID Collaboration Collaboration David Margulies, Kannan Natarajan, Abir Panda, Ethan Shevach The technology encompasses antibodies and methods that may overcome the shortcomings of commercial checkpoint inhibitors (CPIs). Scientists at NIAID have identified MHC-I specific antibodies that selectively inhibit interactions with inhibitory leukocyte immunoglobin-like receptors (LILRs) but not T-cell receptors. Administration of the antibodies increased proliferation and activation of both innate and adaptive immune system cells, and lead to anti-tumor and anti-viral activity in an array of relevant mouse models of disease.<br /><br /> Immune CPIs that target PD-1/PD-L1, CTLA-4 and other well-known molecules can provide significant clinical benefit as part of a mono or combination immunotherapy regimen. However, many patients do not respond to treatment, leading to an ongoing search for novel checkpoint targets. One attractive family of targets are the inhibitory Leukocyte Immunoglobin-like receptors (LILRB1-5). LILRB1, LILRB2, and LILRB5 can inhibit immune cell function by binding to many MHC-I subtypes. However, LILRB1/2/5 expression is variable and the three members cannot be targeted by any single blocking anti-LILB antibody, possibly limiting the efficacy of targeting LILRBs. NIAID scientists have circumvented these issues by identifying antibodies that can inhibit LILRB function by binding to MHC-I without interfering with T-cell receptor engagement.<br /><br /> To date, the MHC-I specific antibodies have been shown to induce activation and proliferation of human T cells and NK cells in xenogeneic models using NSG mice.<br /><br /> This technology is available for licensing for commercial development in accordance with 35 U.S.C. § 209 and 37 CFR Part 404, as well as for further development and evaluation under a research collaboration. <ul> <li>Activation of innate (NK) and adaptive (CD8+ and CD4+) immune cell types</li> <li>Causes proliferation and activation of immune effector cells regardless of target expression in tumors</li> </ul> <ul> <li>Anti-tumor checkpoint inhibitor</li> <li>Anti-viral checkpoint inhibitor</li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize this technology. For collaboration opportunities, please contact Yogikala Prabhu, Ph.D., 301-761-7789; <a href="mailto:prabhuyo@niaid.nih.gov">prabhuyo@niaid.nih.gov</a>. 2022-10-21 2024-10-28 2024-10-28 2022-04-28 ADAPTIVE, AUGMENTATION, Immunity, inhibition, INHIBITORY, Innate, INTERACTION, LILR, MHC-1, RECEPTORS False True True NIHTT 37470483 Website Abstract 114172699 Panda A, et. al. https://pubmed.ncbi.nlm.nih.gov/32601097/ <a href="https://pubmed.ncbi.nlm.nih.gov/32601097/">Panda A, et. al.</a> 114110595 Panda, Abir NIAID - DIR NIAID Panda, Abir (NIAID) 0 114110596 Margulies, David NIAID - DIR NIAID Margulies, David (NIAID) 0 114110597 Natarajan, Kannan NIAID - DIR NIAID Natarajan, Kannan (NIAID) 0 114110594 Shevach, Ethan NIAID - DIR NIAID Shevach, Ethan (NIAID) 1 114110594 Shevach, Ethan NIAID - DIR NIAID Shevach, Ethan (NIAID) 1 114110595 Panda, Abir NIAID - DIR NIAID Panda, Abir (NIAID) 0 114110596 Margulies, David NIAID - DIR NIAID Margulies, David (NIAID) 0 114110597 Natarajan, Kannan NIAID - DIR NIAID Natarajan, Kannan (NIAID) 0 114102645 Augmentation Of Innate And Adaptive Immunity By Inhibition Of The Interaction Of LILR Inhibitory Receptors With MHC-1 E-160-2021-0 Filing authorized NIAID 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-3533] Novel Methods of MHC-I - LILRB Checkpoint Inhibition&body=Please send me information about technology [TAB-3533] Novel Methods of MHC-I - LILRB Checkpoint Inhibition. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-3533] Novel Methods of MHC-I - LILRB Checkpoint Inhibition&body=Please send me information about technology [TAB-3533] Novel Methods of MHC-I - LILRB Checkpoint Inhibition.">yogikala.prabhu@nih.gov</a><br> 114169337 E-160-2021-0 E-160-2021-0-US-01 AUGMENTATION OF INNATE AND ADAPTIVE IMMUNITY BY INHIBITION OF INTERACTION OF LILRBS WITH MHC-1 PRV US 63/262,120 Abandoned US <br />Provisional (PRV) 63/262,120<br />Filed on 2021-10-05<br />Status: Abandoned 114169665 E-160-2021-0 E-160-2021-0-PCT-02 AUGMENTATION OF INNATE AND ADAPTIVE IMMUNITY BY INHIBITION OF INTERACTION OF LILRBS WITH MHC-1 PCT Patent Cooperation Treaty PCT/US2022/077634 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2022/077634<br />Filed on 2022-10-05<br />Status: Expired 114152929 AUGMENTATION 114152930 Innate 114152931 ADAPTIVE 114152932 Immunity 114152933 inhibition 114152934 INTERACTION 114152935 LILR 114152936 INHIBITORY 114152937 RECEPTORS 114152938 MHC-1 TAB-3535 114097393 Use of Auranofin for the Treatment of Chronic Lymphocytic Leukemia (CLL) NCATS Oncology, Therapeutics Oncology Therapeutics Douglas Auld, Christopher Austin, Min Shen, Adrian Wiestner This technology includes the use of auranofin for the treatment of Chronic Lymphocytic Leukemia (CLL). Auranofin is currently approved for the treatment of rheumatoid arthritis and has been shown to display anti-cancer activity. CLL is a blood and bone marrow disease that usually progresses over a lengthy period of time and normally occurs in middle-age adults. The current therapeutic options for CLL patients are limited, and there are few therapies under development. Using an in vitro assay against primary lymphocytes from patients with CLL, auranofin was identified as a drug repurposing candidate for the treatment of CLL. The use of auranofin could be the first oral therapy for treatment of CLL. Further clinical work with auranofin could establish this drug for the treatment of chronic lympocytic leukemia (CLL). 2022-08-01 2024-10-28 2024-10-28 2022-08-01 2022-05-04 Auranofin, CB5XXX, Chronic, CLL, cytokine, GOLD, IL-1B, IL-6, JAK1, Leukemia, Listed LPM McCue as of 4/15/2015, Lymphocytic, Method, NCTT, NFkB, ORAL ADMINISTRATION, Patent Category - Chemistry, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, ROS, STAT3, Thioredoxin reductase, TNF alpha, treatment, VCXXXX, WKXXXX False True True NIHTT 37470483 Website Abstract 114172701 Simon T, Kunishima D, et al. https://pubmed.ncbi.nlm.nih.gov/6778607/ <a href="https://pubmed.ncbi.nlm.nih.gov/6778607/">Simon T, Kunishima D, et al.</a> 114110599 Shen, Min National Human Genome Research Institute (NHGRI) NCATS Shen, Min (NCATS) 0 114110600 Austin, Christopher National Human Genome Research Institute (NHGRI) NCATS Austin, Christopher (NCATS) 0 114110601 Wiestner, Adrian National Heart, Lung, and Blood Institute (NHLBI) NHLBI Wiestner, Adrian (NHLBI) 0 114110598 Auld, Douglas National Human Genome Research Institute (NHGRI) NHGRI Auld, Douglas (NHGRI) 1 114110598 Auld, Douglas National Human Genome Research Institute (NHGRI) NHGRI Auld, Douglas (NHGRI) 1 114110599 Shen, Min National Human Genome Research Institute (NHGRI) NCATS Shen, Min (NCATS) 0 114110600 Austin, Christopher National Human Genome Research Institute (NHGRI) NCATS Austin, Christopher (NCATS) 0 114110601 Wiestner, Adrian National Heart, Lung, and Blood Institute (NHLBI) NHLBI Wiestner, Adrian (NHLBI) 0 114102646 Use Of Auranofin For The Treatment Of Chronic Lymphocytic Leukemia (CLL) E-069-2011-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI), NCATS - NCGC 83682485 Vepa, Suryanarayana sury.vepa@nih.gov
United States of America Office of Strategic Alliances (OSA) sury.vepa@nih.gov?subject=Web Inquiry on [TAB-3535] Use of Auranofin for the Treatment of Chronic Lymphocytic Leukemia (CLL)&body=Please send me information about technology [TAB-3535] Use of Auranofin for the Treatment of Chronic Lymphocytic Leukemia (CLL). Vepa, Suryanarayana<br><a href="mailto:sury.vepa@nih.gov?subject=Web Inquiry on [TAB-3535] Use of Auranofin for the Treatment of Chronic Lymphocytic Leukemia (CLL)&body=Please send me information about technology [TAB-3535] Use of Auranofin for the Treatment of Chronic Lymphocytic Leukemia (CLL).">sury.vepa@nih.gov</a><br> 114169339 E-069-2011-0 E-069-2011-0-US-01 Use Of Auranofin For The Treatment Of Chronic Lymphocytic Leukemia (CLL) PRV US 61/439,186 Abandoned US <br />Provisional (PRV) 61/439,186<br />Filed on 2011-02-03<br />Status: Abandoned 114128692 CB5XXX 114128693 VCXXXX 114128694 WKXXXX 114152939 Method 114152940 Auranofin 114152941 treatment 114152942 Chronic 114152943 Lymphocytic 114152944 Leukemia 114152945 CLL 114152946 Patent Category - Chemistry 114152947 ORAL ADMINISTRATION 114152948 NFkB 114152949 GOLD 114152950 cytokine 114152951 JAK1 114152952 STAT3 114152953 IL-6 114152954 IL-1B 114152955 TNF alpha 114152956 Thioredoxin reductase 114152957 ROS 114152958 NCTT 114152959 Listed LPM McCue as of 4/15/2015 114152960 Pre LPM working set 20150418 114152961 Post LPM Assignment Set 20150420 TAB-3532 114097381 Prefusion Coronavirus Spike Proteins and Their Use NIAID Licensing Licensing Olubukola Abiona, Kizzmekia Corbett, Barney Graham, Geoffrey Hutchinson, Jason McLellan, Nianshuang Wang, Daniel Wrapp When a coronavirus was identified as the causative agent of the COVID-19 pandemic, researchers at the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases (NIAID), together with their collaborators at the University of Texas at Austin and Dartmouth College, responded quickly to engineer the SARS-CoV-2 spike (S) protein for use in vaccines against SARS-CoV-2.<br /><br /> Coronavirus S proteins mediate cellular attachment and membrane fusion and are therefore the target of protective antibodies. This technology employs protein engineering to stabilize the SARS-CoV-2 S in its prefusion conformation, preventing structural rearrangement, and exposing antigencally preferable surfaces. This technology is being utilized in approved SARS-CoV-2 vaccines as well as in diagnostic applications.<br /><br /> This technology is available for licensing for commercial development in accordance with 35 U.S.C. § 209 and 37 CFR Part 404.. <ul> <li>Improved immunogenicity compared to other coronavirus S vaccine formulations.</li> <li>Increased protein expression, stability, and manufacturability compared to wild-type SARS-CoV-2 spike..</li> </ul> <ul> <li>The stabilized prefusion SARS-CoV-2 spike protein can be used as a vaccine antigen to elicit robust neutralizing antibody responses. It is also useful in diagnostic applications and to isolate SARS-CoV-2 antibodies.</li> </ul> 2022-08-15 2024-10-28 2024-10-28 2022-04-28 Constructs, CORONAVIRUS, SARS-CoV-2, Stabilized, VACCINATION, Wuhan False True True NIHTT 37470483 Website Abstract E-234-2016-0 E-234-2016-1 114110587 Corbett, Kizzmekia NIAID - DIR NIAID Corbett, Kizzmekia (NIAID) 0 114110588 Hutchinson, Geoffrey NIAID - VRC NIAID Hutchinson, Geoffrey (NIAID) 0 114110590 Abiona, Olubukola NIAID - VRC NIAID Abiona, Olubukola (NIAID) 0 114110591 McLellan, Jason University of Texas NIAID McLellan, Jason (NIAID) 0 114110592 Wang, Nianshuang University of Texas at Austin Wang, Nianshuang 0 114110593 Wrapp, Daniel Dartmouth College Wrapp, Daniel 0 114110589 Graham, Barney NIAID - VRC NIAID Graham, Barney (NIAID) 1 114110589 Graham, Barney NIAID - VRC NIAID Graham, Barney (NIAID) 1 114110587 Corbett, Kizzmekia NIAID - DIR NIAID Corbett, Kizzmekia (NIAID) 0 114110588 Hutchinson, Geoffrey NIAID - VRC NIAID Hutchinson, Geoffrey (NIAID) 0 114110590 Abiona, Olubukola NIAID - VRC NIAID Abiona, Olubukola (NIAID) 0 114110591 McLellan, Jason University of Texas NIAID McLellan, Jason (NIAID) 0 114110592 Wang, Nianshuang University of Texas at Austin Wang, Nianshuang 0 114110593 Wrapp, Daniel Dartmouth College Wrapp, Daniel 0 114102644 Stabilized Wuhan Coronavirus Constructs For Vaccination E-086-2020-0 Filing authorized Dartmouth College, NIAID, University of Texas, University of Texas at Austin 83682222 Bailey, Brian bbailey@mail.nih.gov
United States of America TTIPO bbailey@mail.nih.gov?subject=Web Inquiry on [TAB-3532] Prefusion Coronavirus Spike Proteins and Their Use&body=Please send me information about technology [TAB-3532] Prefusion Coronavirus Spike Proteins and Their Use. Bailey, Brian<br><a href="mailto:bbailey@mail.nih.gov?subject=Web Inquiry on [TAB-3532] Prefusion Coronavirus Spike Proteins and Their Use&body=Please send me information about technology [TAB-3532] Prefusion Coronavirus Spike Proteins and Their Use.">bbailey@mail.nih.gov</a><br> 114169335 E-086-2020-0 E-086-2020-0-US-01 2019-nCoV VACCINE PRV US 62/972,886 Abandoned US <br />Provisional (PRV) 62/972,886<br />Filed on 2020-02-11<br />Status: Abandoned 114169336 E-086-2020-0 E-086-2020-0-PCT-02 SARS-CoV-2 VACCINE PCT Patent Cooperation Treaty PCT/US2021/017709 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/017709<br />Filed on 2021-02-11<br />Status: Expired 114169638 E-086-2020-0 E-086-2020-0-US-03 SARS-COV-2 VACCINE National Stage US 17/798,021 Abandoned US <br />National Stage 17/798,021<br />Filed on 2022-08-05<br />Status: Abandoned 114152923 Constructs 114152924 CORONAVIRUS 114152925 Wuhan 114152926 Stabilized 114152927 VACCINATION 114152928 SARS-CoV-2 TAB-3530 114097390 Improved Synthesis of Dopamine D3 Receptor Selective Antagonists / Partial Agonists NCATS Cardiology, Collaboration, Dental, Endocrinology, Infectious Disease, Licensing, Neurology, Oncology, Ophthalmology, Psychiatry/Mental Health, Therapeutics Cardiology Collaboration Dental Endocrinology Infectious Disease Licensing Neurology Oncology Ophthalmology Psychiatry/Mental Health Therapeutics Asaf Alimardanov, Bangwei Ding, Junfeng Huang In the last decade, prescription opioid abuse and misuse has been a major contributor to mortality in the United States, resulting in a serious national public health crisis. Nearly 12 million Americans used prescription opioids nonmedically in 2018, with >67,000 people dying from an opioid overdose. <br><br> The federal response to the opioid crisis includes research support toward the development of non-addictive analgesics and additional medications to treat opioid use disorders (OUD). Recently, a novel series of (R)-N-(4-(4-(3-chloro-5-ethyl-2-methoxyphenyl) piperazin-1-yl)-3-hydroxybutyl)-1H-indole-2-carboxamide (8)-(R)VK4-116 have been discovered as high affinity and selective D3R (Dopamine D3 receptor) lead molecules for the treatment of opioid use disorders (OUD) by a discovery team at NIDA (NIH). <br><br> Furthering the earlier work by colleagues at NIDA, NCATS scientists have developed new synthetic routes to accelerate synthesis and yields for preclinical and clinical trial studies of (R)-VK4-116. The method describes a novel synthesis method that reduces the number of steps to synthesize selective Dopamine D3 Antagonists, specifically, (R)VK4-116. <ul> <li>Reduces number of steps in synthesis method from 15 to 7</li> <li>Dramatically increases synthesis yield from 1.5% to >48% overall yield</li> <li>Eliminates the use of a controlled substance in the synthesis route</li> <li>New synthesis route successfully tested in 2 kg GMP Scale up</li> <li>Novel synthesis method created novel intermediates useful for other drug synthesis routes</li> </ul> <ul> <li>Dopamine D3 Antagonist synthesis</li> <li>Opioid addiction mitigation</li> <li>Reduce severity of opioid addiction withdrawal</li> <li>Prevent opioid addiction relapse</li> <li>Alternate route for Atorvastatin synthesis</li> </ul> NCATS seeks partners for licensing or research collaborations to co-develop and test the drug candidate (including to conduct in vivo efficacy studies and to progress to clinical trials) for the technology described in NIH Reference # E-042-2022. 2022-04-26 2024-10-28 2024-10-28 2022-04-26 ANALGESIA, ANTAGONIST, D3, DEPENDENCE, Dopamine, opioid, Piperazin-1-yl-3-hydroxybutyl-1H-indole-2-car, Practial, RECEPTOR, R-N-4-4-3-chloro-5-ethyl-2-methoxyphenyl, Synthesis, VMXXXX, VNXXXX, VPXXXX, WITHDRAWAL, WKXXXX False True True NIHTT 37470483 Website Abstract 114172692 You Z-B, et al. https://pubmed.ncbi.nlm.nih.gov/30555159/ <a href="https://pubmed.ncbi.nlm.nih.gov/30555159/">You Z-B, et al. </a> 114172697 Jordan CJ, et al. https://pubmed.ncbi.nlm.nih.gov/31562201/ <a href="https://pubmed.ncbi.nlm.nih.gov/31562201/">Jordan CJ, et al.</a> 114172698 de Guglielmo G, et al. https://pubmed.ncbi.nlm.nih.gov/31992976/ <a href="https://pubmed.ncbi.nlm.nih.gov/31992976/">de Guglielmo G, et al.</a> 114110584 Alimardanov, Asaf NCATS - NCGC NCATS Alimardanov, Asaf (NCATS) 0 114110586 Huang, Junfeng NCATS - TRND NCATS Huang, Junfeng (NCATS) 0 114110585 Ding, Bangwei NCATS - NCGC NCATS Ding, Bangwei (NCATS) 1 114110585 Ding, Bangwei NCATS - NCGC NCATS Ding, Bangwei (NCATS) 1 114110584 Alimardanov, Asaf NCATS - NCGC NCATS Alimardanov, Asaf (NCATS) 0 114110586 Huang, Junfeng NCATS - TRND NCATS Huang, Junfeng (NCATS) 0 114102643 A Practical Synthesis Of Dopamine D3 Receptor Antagonist (R)-N-(4-(4-(3-chloro-5-ethyl-2-methoxyphenyl) Piperazin-1-yl)-3-hydroxybutyl)-1H-indole-2-carboxamide-(R)-VK4-116 E-042-2022-0 Filing authorized NCATS - NCGC 83673536 Erwin-Cohen, Rebecca rebecca.erwin-cohen@nih.gov
NCGC rebecca.erwin-cohen@nih.gov?subject=Web Inquiry on [TAB-3530] Improved Synthesis of Dopamine D3 Receptor Selective Antagonists / Partial Agonists&body=Please send me information about technology [TAB-3530] Improved Synthesis of Dopamine D3 Receptor Selective Antagonists / Partial Agonists. Erwin-Cohen, Rebecca<br><a href="mailto:rebecca.erwin-cohen@nih.gov?subject=Web Inquiry on [TAB-3530] Improved Synthesis of Dopamine D3 Receptor Selective Antagonists / Partial Agonists&body=Please send me information about technology [TAB-3530] Improved Synthesis of Dopamine D3 Receptor Selective Antagonists / Partial Agonists.">rebecca.erwin-cohen@nih.gov</a><br> 114169333 E-042-2022-0 E-042-2022-0-US-01 SYNTHESIS OF DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS PRV US 63/325,313 Expired US <br />Provisional (PRV) 63/325,313<br />Filed on 2022-03-30<br />Status: Expired 114128686 VMXXXX 114128687 VNXXXX 114128688 VPXXXX 114128689 WKXXXX 114152904 Practial 114152905 Synthesis 114152906 Dopamine 114152907 D3 114152908 RECEPTOR 114152909 ANTAGONIST 114152910 R-N-4-4-3-chloro-5-ethyl-2-methoxyphenyl 114152911 Piperazin-1-yl-3-hydroxybutyl-1H-indole-2-car 114152912 opioid 114152913 ANALGESIA 114152914 WITHDRAWAL 114152915 DEPENDENCE TAB-3526 114097385 Peptide Inhibitors of Phosphoglycerate Mutase and Methods of Use NCATS Collaboration, Infectious Disease, Licensing, Therapeutics Collaboration Infectious Disease Licensing Therapeutics Patricia Dranchak, James Inglese, Ryan Macarthur The invention includes compounds and compositions for inhibiting phosphoglycerate mutase (PGM) activity. In some examples, the compounds selectively inhibit cofactor-independent PGM (iPGM). In particular embodiments, the compounds include one or more cyclic peptides. <br><br> The co-factor independent phosphoglycerate mutase (iPGM) is an essential glycolytic enzyme and validated target in several infectious organisms structurally distinct from its human isozyme. iPGM, present in several types of parasitic roundworms, including Brugia malayi and Onchocerca volvulus, infects roughly 150 million people living mostly in tropical regions. The parasites can cause devastating infectious diseases, such as river blindness. The enzyme also is found in bacteria, including Staphylococcus aureus, which can cause the hospital-borne infection MRSA (methicillin-resistant Staphylococcus aureus), and anthrax. However, the enzyme has been considered “undruggable” due to unsuccessful attempts to identify inhibitors suitable for development from small molecule high throughput screening (HTS). As an alternative approach to HTS the exceedingly vast chemical space available from nucleic acid-encoded cyclic peptide libraries was used to isolate a potent and selective iPGM inhibitor class, called Ipglycermides. <br><br> The technique of mRNA-display affinity selection was used to identify, enrich, and decode high-affinity iPGM cyclic peptide ligands we termed Ipglycermides. Using solid phase peptide synthesis, the ipglycermides and analogs were prepared in milligram quantity and evaluated in functional target-based assays on a panel of phosphoglycerate mutase enzymes from target and anti-target (i.e., human dPGM) species. The molecules were found to potently and selectively inhibit the catalytic activity of various microorganism iPGMs versus the human isozyme. The pharmacological evaluation of ipglycermide analogs and the binding site interaction revealed from an iPGM-ipglycermide co-crystal structure provide general molecular insights for the development of a therapeutic towards this highly undruggable target. NCATS, University of Tokyo and New England Biolabs researchers identified cyclic peptide inhibitors of the enzyme 2,3-bisphosphoglycerate-independent phosphoglycerate mutase (ipgm-1) that could treat both parasitic and bacterial infections. <ul> <li>Cyclic peptide inhibitors of the enzyme 2,3-bisphosphoglycerate-independent phosphoglycerate mutase (ipgm-1) for the treatment of both parasitic and bacterial infections.</li> </ul> This invention is available for licensing and/or co-development to achieve expeditious commercialization of results of federal funded research and development. 2022-04-01 2024-10-28 2024-10-28 2022-04-01 Agents, Anti-infective, Cyclic, DB2XXX, DB3XXX, Inhibitors, Mutase, PARASITIC, Peptide, Phosphoglycerate, POTENT, SELECTIVE, VJXXXX, VQXXXX, WKXXXX False True True NIHTT 37470483 Website Abstract 114172680 Crowther GJ, et al. https://pubmed.ncbi.nlm.nih.gov/24416464/ <a href="https://pubmed.ncbi.nlm.nih.gov/24416464/">Crowther GJ, et al.</a> 114172681 Yu H, et al. https://pubmed.ncbi.nlm.nih.gov/28368002/ <a href="https://pubmed.ncbi.nlm.nih.gov/28368002/">Yu H, et al.</a> 114172682 Okuma R, et al. https://pubmed.ncbi.nlm.nih.gov/32633882/ <a href="https://pubmed.ncbi.nlm.nih.gov/32633882/">Okuma R, et al.</a> 114172683 Wiedmann M, et al. https://pubmed.ncbi.nlm.nih.gov/33812994/ <a href="https://pubmed.ncbi.nlm.nih.gov/33812994/">Wiedmann M, et al.</a> 114110558 Dranchak, Patricia NCATS - NCGC NCATS Dranchak, Patricia (NCATS) 0 114110559 Macarthur, Ryan NCATS - NCGC NCATS Macarthur, Ryan (NCATS) 0 114110557 Inglese, James NCATS - NCGC NCATS Inglese, James (NCATS) 1 114110557 Inglese, James NCATS - NCGC NCATS Inglese, James (NCATS) 1 114110558 Dranchak, Patricia NCATS - NCGC NCATS Dranchak, Patricia (NCATS) 0 114110559 Macarthur, Ryan NCATS - NCGC NCATS Macarthur, Ryan (NCATS) 0 114102637 Potent And Selective Cyclic Peptide Inhibitors Of Phosphoglycerate Mutase As Anti-infective Agents E-229-2016-0 Filing authorized NCATS - NCGC 83673536 Erwin-Cohen, Rebecca rebecca.erwin-cohen@nih.gov
NCGC rebecca.erwin-cohen@nih.gov?subject=Web Inquiry on [TAB-3526] Peptide Inhibitors of Phosphoglycerate Mutase and Methods of Use&body=Please send me information about technology [TAB-3526] Peptide Inhibitors of Phosphoglycerate Mutase and Methods of Use. Erwin-Cohen, Rebecca<br><a href="mailto:rebecca.erwin-cohen@nih.gov?subject=Web Inquiry on [TAB-3526] Peptide Inhibitors of Phosphoglycerate Mutase and Methods of Use&body=Please send me information about technology [TAB-3526] Peptide Inhibitors of Phosphoglycerate Mutase and Methods of Use.">rebecca.erwin-cohen@nih.gov</a><br> 114169311 E-229-2016-0 E-229-2016-0-US-01 PEPTIDE INHIBITORS OF PHOSPHOGLYCERATE MUTASE AND METHODS OF USE PRV US 62/373,835 Abandoned US <br />Provisional (PRV) 62/373,835<br />Filed on 2016-08-11<br />Status: Abandoned 114169312 E-229-2016-0 E-229-2016-0-PCT-02 PEPTIDE INHIBITORS OF PHOSPHOGLYCERATE MUTASE AND METHODS OF USE PCT Patent Cooperation Treaty PCT/US2017/046228 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2017/046228<br />Filed on 2017-08-10<br />Status: Expired 114169313 E-229-2016-0 E-229-2016-0-US-04 PEPTIDE INHIBITORS OF PHOSPHOGLYCERATE MUTASE AND METHODS OF USE National Stage US 10,808,010 16/324,424 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10808010 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10808010">10,808,010</a><br />Filed on 2019-02-08<br />Status: Issued 114169314 E-229-2016-0 E-229-2016-0-US-05 PEPTIDE INHIBITORS OF PHOSPHOGLYCERATE MUTASE AND METHODS OF USE DIV US 17/016,168 Abandoned US <br />Divisional (DIV) 17/016,168<br />Filed on 2020-09-09<br />Status: Abandoned 114128671 DB2XXX 114128672 DB3XXX 114128673 VQXXXX 114128674 VJXXXX 114128675 WKXXXX 114152846 POTENT 114152847 SELECTIVE 114152848 Cyclic 114152849 Peptide 114152850 Inhibitors 114152851 Phosphoglycerate 114152852 Mutase 114152853 Anti-infective 114152854 Agents 114152855 PARASITIC TAB-3527 114097386 Substituted Quinoline Analogs as Aldehyde Dehydrogenase 1A1 (ALDH1A1) Inhibitors NCATS Cardiology, Dental, Endocrinology, Infectious Disease, Licensing, Oncology, Ophthalmology, Therapeutics Cardiology Dental Endocrinology Infectious Disease Licensing Oncology Ophthalmology Therapeutics David Maloney, Natalia Martinez, Anton Simeonov, Shyh-Ming Yang, Adam Yasgar Aldehyde dehydrogenase enzymes (ALDHs) have a broad spectrum of biological activities through the oxidation of both endogenous and exogenous aldehydes. Unbalanced expression levels of ALDHs have been associated with a variety of disease states such as alcoholic liver disease, Parkinson’s disease, obesity, and multiple types of cancers. ALDH1A1 also plays a major role in preserving the tumor microenvironment via differentiation, self-protection, and proliferation of cancer stem cells. The cancer cell stemness is associated with cancer relapse and poor prognosis, raising the potential of ALDH1A1 as an attractive therapeutic target. <br><br> We performed a systematic medicinal chemistry optimization and biological characterization of newly designed quinoline series that ultimately led to potent ALDH1A1 inhibitors with excellent enzymatic potency and Aldefluor cellular activity (e.g., MIA PaCa-2, OV-90, HT-29 cancer cell lines), as well as improved pharmacokinetic (PK) properties. This chemotype also demonstrated a high degree of selectivity over other ALDH isozymes (ALDH1A2, ALDH1A3, ALDH1B1, ALDH3A1, and ALDH2) and other dehydrogenases (HPGD and HSD17ß4). <br><br> Further development of the series indicated that NCATS-101 and NCATS-102 exhibit low nanomolar potency in both enzymatic and cellular assays, demonstrate target engagement in a cellular thermal shift assay (CETSA), and can inhibit the formation of 3D spheroid cultures of OV-90 ovarian cancer cells. In addition, lead compounds potentiated the cytotoxicity of Paclitaxel in SKOV-3-TR, a Taxol-resistant ovarian cancer cell line, which suggest the potential feasibility of combined treatment with existing cancer drugs. PK studies demonstrated that NCATS-101 and NCATS-102 have good drug exposure via oral administration and should be suitable for in vivo studies or testing in other disease-relevant models. <ul> <li>In vitro results suggest these ALDH1A1 inhibitors may reduce the toxicity of paclitaxel-eluting stents.</li> </ul> <ul> <li>Compounds and compositions that inhibit aldehyde dehydrogenases, may be used for the treatment of multiple types of cancers, inflammation, and obesity.</li> </ul> This invention is available for licensing and/or co-development to achieve expeditious commercialization. 2022-04-01 2024-10-28 2024-10-28 2022-04-01 1A1, 3D spheroid, ALDEFLUOR assay, Aldehyde, ALDH, ALDH1A1, cancer stem cells, combined treatment, DEHYDROGENASE, high-content imaging, high-throughput screening, Inhibitors, liver, METABOLIC, MOLECULE, OBESITY, OV-90, Parkinson, RESISTANT, SKOV-3, Small, VCXXXX, VGXXXX, VPXXXX, WKXXXX False True True NIHTT 37470483 Website Abstract 114172684 Yang S-M, et al. https://pubmed.ncbi.nlm.nih.gov/26207746/ <a href="https://pubmed.ncbi.nlm.nih.gov/26207746/">Yang S-M, et al.</a> 114172685 Yasgar A, et al. https://pubmed.ncbi.nlm.nih.gov/28129349/ <a href="https://pubmed.ncbi.nlm.nih.gov/28129349/">Yasgar A, et al.</a> 114172686 Yang S-M, et al. https://pubmed.ncbi.nlm.nih.gov/29767973/ <a href="https://pubmed.ncbi.nlm.nih.gov/29767973/">Yang S-M, et al.</a> 114110564 Simeonov, Anton NCATS - NCGC NCATS Simeonov, Anton (NCATS) 0 114110565 Maloney, David NCATS - NCGC NCATS Maloney, David (NCATS) 0 114110566 Martinez, Natalia NCATS - NCGC NCATS Martinez, Natalia (NCATS) 0 114110567 Yasgar, Adam NCATS - NCGC NCATS Yasgar, Adam (NCATS) 0 114110563 Yang, Shyh-Ming NCATS - NCGC NCATS Yang, Shyh-Ming (NCATS) 1 114110563 Yang, Shyh-Ming NCATS - NCGC NCATS Yang, Shyh-Ming (NCATS) 1 114110564 Simeonov, Anton NCATS - NCGC NCATS Simeonov, Anton (NCATS) 0 114110565 Maloney, David NCATS - NCGC NCATS Maloney, David (NCATS) 0 114110566 Martinez, Natalia NCATS - NCGC NCATS Martinez, Natalia (NCATS) 0 114110567 Yasgar, Adam NCATS - NCGC NCATS Yasgar, Adam (NCATS) 0 114102639 Small Molecule Inhibitors Of Aldehyde Dehydrogenase 1A1 (ALDH1A1) E-101-2017-0 Filing authorized NCATS - NCGC, Yale University 83673536 Erwin-Cohen, Rebecca rebecca.erwin-cohen@nih.gov
NCGC rebecca.erwin-cohen@nih.gov?subject=Web Inquiry on [TAB-3527] Substituted Quinoline Analogs as Aldehyde Dehydrogenase 1A1 (ALDH1A1) Inhibitors&body=Please send me information about technology [TAB-3527] Substituted Quinoline Analogs as Aldehyde Dehydrogenase 1A1 (ALDH1A1) Inhibitors. Erwin-Cohen, Rebecca<br><a href="mailto:rebecca.erwin-cohen@nih.gov?subject=Web Inquiry on [TAB-3527] Substituted Quinoline Analogs as Aldehyde Dehydrogenase 1A1 (ALDH1A1) Inhibitors&body=Please send me information about technology [TAB-3527] Substituted Quinoline Analogs as Aldehyde Dehydrogenase 1A1 (ALDH1A1) Inhibitors.">rebecca.erwin-cohen@nih.gov</a><br> 114169317 E-101-2017-0 E-101-2017-0-US-01 SSUBSTITUTED QUINOLINE ANALOGS AS ALDEHYDE DEHYDROGENASE 1A1 (ALDH1A1) INHIBITORS PRV US 62/578,899 Abandoned US <br />Provisional (PRV) 62/578,899<br />Filed on 2017-10-30<br />Status: Abandoned 114169318 E-101-2017-0 E-101-2017-0-PCT-02 SUBSTITUTED QUINOLINE ANALOGS AS ALDEHYDE DEHYDROGENASE 1A1 (ALDH1A1) INHIBITORS PCT Patent Cooperation Treaty PCT/US2018/058257 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2018/058257<br />Filed on 2018-10-30<br />Status: Expired 114169319 E-101-2017-0 E-101-2017-0-US-04 SUBSTITUTED QUINOLINE ANALOGS AS ALDEHYDEDE DEHYDROGENASE 1A1 (ALDH1A1) INHIBITORS National Stage US 11,505,559 16/760,345 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11505559 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11505559">11,505,559</a><br />Filed on 2020-04-29<br />Status: Issued 114169320 E-101-2017-0 E-101-2017-0-US-06 SUBSTITUTED QUINOLINE ANALOGS AS ALDEHYDE DEHYDROGENASE 1A1 (ALDH1A1) INHIBITORS DIV US 11,795,177 17/682,654 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11795177 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11795177">11,795,177</a><br />Filed on 2022-02-28<br />Status: Issued 114128676 VCXXXX 114128677 VPXXXX 114128678 VGXXXX 114128679 WKXXXX 114152862 Small 114152863 MOLECULE 114152864 Inhibitors 114152865 Aldehyde 114152866 DEHYDROGENASE 114152867 1A1 114152868 ALDH1A1 114152869 combined treatment 114152870 3D spheroid 114152871 RESISTANT 114152872 OV-90 114152873 SKOV-3 114152874 ALDH 114152875 high-content imaging 114152876 ALDEFLUOR assay 114152877 high-throughput screening 114152878 liver 114152879 Parkinson 114152880 OBESITY 114152881 METABOLIC 114152882 cancer stem cells TAB-3524 114097383 Methotrexate Analogs with Enhanced Efficacy and Safety Profile NCATS Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics James Inglese, Laurence Lamy, Ganesha Rai Bantukallu, Sandeep Rana Scientists at NCATS have developed an analog of Methotrexate (MTX) that incorporates the proteasome-targeting properties of E3-ubiquitin ligase small molecule ligands (MTX-PROTACs) to directly bind to the MTX target dihydrofolate reductase (DHFR) and mark the protein for proteasomal degradation. This unique property may dramatically lower the therapeutic dose required in a treatment setting. The initial series of molecules that utilized differing E3 ligase ligands and linkers to MTX demonstrated dramatically differential effects on the cellular turnover of DHFR in a lymphoma B-cell (HBL-1) line. These results suggested that it was possible to achieve targeted tissue selectivity with specific analog designs. Further, in comparative cell culture studies with the parent MTX, scientists observed that MTX appeared to lead to an increase in cellular DHFR, a mechanism that may allow some cancer cells to continue to proliferate once MTX administration is discontinued. The disappearance of DHFR from the HBL-1 cells treated with the MTX-PROTACs analog could have a significant positive effect on overcoming chemotherapy resistance that results from drug discontinuance. <br><br> The MTX-PROTACs of this invention result in the degradation of the DHFR in the cell, lowering the levels dramatically, in direct contrast to MTX which by stabilizes DHFR from turnover, while binding tightly to it. When MTX is withdrawn or its plasma levels decrease, DHFR bound MTX may eventually dissociate from DHFR and diffuse from a cancer cell allowing the remaining high levels of DHFR to function again, resulting in proliferation of any remaining cancer cells. By utilizing MTX-PROTAC, it is possible to achieve the efficacy of MTX, without the danger of chemotherapy resistance. Methotrexate (MTX) is a chemotherapy agent and immune system suppressant widely used since 1974 for the treatment of a range of cancers and autoimmune diseases. While thousands of MTX analogs have been created to improve the efficacy and side-effect profile, yet nothing has replaced MTX. MTX-PROTACs may offer competitive advantages over traditional standards of care including reduced dose and toxicity, reduced incidence of chemotherapy resistance, and novel attack pathway for the therapeutic target, DHFR. <br><br> The MTX-PROTAC analogs could offer a competitive therapeutic advantage across a broad scope of cancer and autoimmune markets, all of which have projected growth in the coming years. The value of the drug is further amplified by the variety of large markets to which it could apply. The MTX-PROTAC analogs could be used to treat a broad range of cancers and autoimmune diseases, including osteosarcoma, acute lymphoblastic leukemia, lymphoma, head and neck cancers, and Rheumatoid arthritis, etc. NCATS seeks partners for licensing or research collaborations to co-develop and test the drug candidate with other target ligands (including to conduct in vivo efficacy studies and conduct manufacturing scale-up to progress to clinical trials). 2022-04-01 2024-10-28 2024-10-28 2022-04-01 Analogs, CHEMOTHERAPHY, DHFR, E3, EFFICACY, Enhanced, METHOTREXATE, PROFILE, PROTACs, Proteosome, SAFETY, VCXXXX, WKXXXX False True True NIHTT 37470483 Website Abstract 114110539 Rai Bantukallu, Ganesha NCATS - NCGC NCATS Rai Bantukallu, Ganesha (NCATS) 0 114110543 Rana, Sandeep NCATS - NCGC NCATS Rana, Sandeep (NCATS) 0 114110544 Lamy, Laurence NCATS - NCGC NCATS Lamy, Laurence (NCATS) 0 114110540 Inglese, James NCATS - NCGC NCATS Inglese, James (NCATS) 1 114110540 Inglese, James NCATS - NCGC NCATS Inglese, James (NCATS) 1 114110539 Rai Bantukallu, Ganesha NCATS - NCGC NCATS Rai Bantukallu, Ganesha (NCATS) 0 114110543 Rana, Sandeep NCATS - NCGC NCATS Rana, Sandeep (NCATS) 0 114110544 Lamy, Laurence NCATS - NCGC NCATS Lamy, Laurence (NCATS) 0 114102634 Methotrexate Analogs With Enhanced Efficacy And Safety Profile E-136-2020-0 Filing authorized NCATS - NCGC 83673536 Erwin-Cohen, Rebecca rebecca.erwin-cohen@nih.gov
NCGC rebecca.erwin-cohen@nih.gov?subject=Web Inquiry on [TAB-3524] Methotrexate Analogs with Enhanced Efficacy and Safety Profile&body=Please send me information about technology [TAB-3524] Methotrexate Analogs with Enhanced Efficacy and Safety Profile. Erwin-Cohen, Rebecca<br><a href="mailto:rebecca.erwin-cohen@nih.gov?subject=Web Inquiry on [TAB-3524] Methotrexate Analogs with Enhanced Efficacy and Safety Profile&body=Please send me information about technology [TAB-3524] Methotrexate Analogs with Enhanced Efficacy and Safety Profile.">rebecca.erwin-cohen@nih.gov</a><br> 114169305 E-136-2020-0 E-136-2020-0-US-01 METHOTREXATE ANALOGS AND METHODS OF USE PRV US 63/042,262 Abandoned US <br />Provisional (PRV) 63/042,262<br />Filed on 2020-06-22<br />Status: Abandoned 114169306 E-136-2020-0 E-136-2020-0-PCT-03 METHOTREXATE ANALOGS AND METHODS OF USE PCT Patent Cooperation Treaty PCT/US2021/038441 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/038441<br />Filed on 2021-06-22<br />Status: Expired 114128665 WKXXXX 114128666 VCXXXX 114152813 E3 114152814 DHFR 114152815 Proteosome 114152816 PROTACs 114152817 CHEMOTHERAPHY 114152818 PROFILE 114152819 SAFETY 114152820 EFFICACY 114152821 Enhanced 114152822 Analogs 114152823 METHOTREXATE TAB-3525 114097384 Real-time Cellular Thermal Shift Assay and Analysis (RT-CETSA) for Research and Drug Discovery NCATS Collaboration, Computational models/software, Consumer Products, Research Equipment, Research Materials, Software / Apps Collaboration Computational models/software Consumer Products Research Equipment Research Materials Software / Apps Bolormaa Baljinnyam, Mark Henderson, Samuel Michael, Ashley Owens, Ganesha Rai Bantukallu, Michael Ronzetti, Tino Sanchez, Anton Simeonov, Daniel Talley, Ty Voss, Linus Wallgren Scientists at NCATS have developed a novel Cellular Thermal Shift Assay (CETSA), named “Real-time CETSA” in which temperature-induced aggregation of proteins can be monitored in cells in real time across a range of compound concentrations and simultaneously across a temperature gradient in a high-throughput manner. Real-time CETSA streamlines the thermal shift assay and allows investigators to capture full aggregation profiles for every sample. A traditional CETSA assay can only be run at a single temperature (dose-response compounds) or a single compound concentration (across temperature range). The real-time CETSA approach allows both variables to be captured in a single experiment in high throughput, as protein aggregation is monitored in real-time over a temperature gradient. The real-time method also allows multiple different proteins (e.g., multiple members of a target class) to be examined in parallel, even if they have vastly different aggregation profiles. Importantly, RT-CETSA can be measured in intact living cells as well as cell lysates. <br><br> Additionally, the scientists have developed a novel method of analyzing the RE-CETSA data that uses a nonparametric analysis of goodness of fit tests between linear and log-logistic models across the entire melting curve, in contrast to the current single-parameter analysis. While traditional methods of analysis for CETSA data rely on single parameter measurements, such as Tagg (temperature of aggregation, or the midpoint of the sigmoidal thermal unfolding curve) and AUC (area under the curve of a sigmoidal fit), such analyses do not take into account the entire thermal curve that RT-CETSA generates. Using a nonparametric analysis of goodness of fit tests between linear and log-logistic models across the entire melting curve results in more sensitive and reproducible hit identification and full use of the RT-CETSA data. There is no current analysis method for RT-CETSA, differential scanning fluorimetry (DSF), or other such methods, where there is integration of goodness of fit nonparametric testing with concentration-response data. The invention represents a revolutionary improvement over traditional CETSA assays and protocols. Additionally, the inventors have created unique tools (a thermally stable NanoLuciferase variant (thermNLuc), a working hardware prototype, and software tools for analysis that elevate the traditional assay into one that can be leveraged to screen multiple proteins at a variety of doses and over a broad temperature gradient – all in real time. <br><br> The drug discovery market has long embraced high-throughput screening; this technology and the unique tools developed may further the discovery of novel drugs and discovery of new uses for repurposed drugs. <ul> <li>High-throughput drug discovery in a cellular assay that is broadly applicable to a variety of targets</li> <li>High-throughput screening for target engagement</li> <li>High-throughput screening for drug repurposing</li> </ul> Researchers at NCATS seek research collaborations to co-develop and test the platform with a variety of target proteins to promote drug discovery. 2022-04-26 2024-10-28 2024-10-28 2022-04-01 AGGREGATION, analysis, assay, Cellular, CETSA, COMPARISONS, CURVES, DATA, Discovery, DRUG, Identification, NonParametric, Realtime, REAL-TIME, RT-CETSA, SHIFT, thermal, Unfolding, WIXXXX, WMXXXX, XHXXXX, XJXXXX False True True NIHTT 37470483 Website Abstract E-022-2022-0 114172679 Sanchez TW, et al. https://doi.org/10.1101/2022.01.24.477382 <a href="https://doi.org/10.1101/2022.01.24.477382">Sanchez TW, et al.</a> 114110546 Talley, Daniel NCATS - NCGC NCATS Talley, Daniel (NCATS) 0 114110547 Ronzetti, Michael NCATS - TRND NCATS Ronzetti, Michael (NCATS) 0 114110548 Baljinnyam, Bolormaa NCATS - NCGC NCATS Baljinnyam, Bolormaa (NCATS) 0 114110549 Rai Bantukallu, Ganesha NCATS - NCGC NCATS Rai Bantukallu, Ganesha (NCATS) 0 114110550 Sanchez, Tino NCATS - NCGC NCATS Sanchez, Tino (NCATS) 0 114110551 Michael, Samuel NCATS - NCGC NCATS Michael, Samuel (NCATS) 0 114110552 Voss, Ty NCATS - TRND NCATS Voss, Ty (NCATS) 0 114110553 Owens, Ashley NCATS - NCGC NCATS Owens, Ashley (NCATS) 0 114110554 Simeonov, Anton NCATS - NCGC NCATS Simeonov, Anton (NCATS) 0 114110555 Wallgren, Linus NCATS - NCGC NCATS Wallgren, Linus (NCATS) 0 114110545 Henderson, Mark NCATS - NCGC NCATS Henderson, Mark (NCATS) 1 114110545 Henderson, Mark NCATS - NCGC NCATS Henderson, Mark (NCATS) 1 114110546 Talley, Daniel NCATS - NCGC NCATS Talley, Daniel (NCATS) 0 114110547 Ronzetti, Michael NCATS - TRND NCATS Ronzetti, Michael (NCATS) 0 114110548 Baljinnyam, Bolormaa NCATS - NCGC NCATS Baljinnyam, Bolormaa (NCATS) 0 114110549 Rai Bantukallu, Ganesha NCATS - NCGC NCATS Rai Bantukallu, Ganesha (NCATS) 0 114110550 Sanchez, Tino NCATS - NCGC NCATS Sanchez, Tino (NCATS) 0 114110551 Michael, Samuel NCATS - NCGC NCATS Michael, Samuel (NCATS) 0 114110552 Voss, Ty NCATS - TRND NCATS Voss, Ty (NCATS) 0 114110553 Owens, Ashley NCATS - NCGC NCATS Owens, Ashley (NCATS) 0 114110554 Simeonov, Anton NCATS - NCGC NCATS Simeonov, Anton (NCATS) 0 114110555 Wallgren, Linus NCATS - NCGC NCATS Wallgren, Linus (NCATS) 0 114102635 Realtime Cellular Thermal Shift Assay (RT-CETSA) For Research And Drug Discovery E-200-2020-0 Filing authorized NCATS - NCGC 83673536 Erwin-Cohen, Rebecca rebecca.erwin-cohen@nih.gov
NCGC rebecca.erwin-cohen@nih.gov?subject=Web Inquiry on [TAB-3525] Real-time Cellular Thermal Shift Assay and Analysis (RT-CETSA) for Research and Drug Discovery&body=Please send me information about technology [TAB-3525] Real-time Cellular Thermal Shift Assay and Analysis (RT-CETSA) for Research and Drug Discovery. Erwin-Cohen, Rebecca<br><a href="mailto:rebecca.erwin-cohen@nih.gov?subject=Web Inquiry on [TAB-3525] Real-time Cellular Thermal Shift Assay and Analysis (RT-CETSA) for Research and Drug Discovery&body=Please send me information about technology [TAB-3525] Real-time Cellular Thermal Shift Assay and Analysis (RT-CETSA) for Research and Drug Discovery.">rebecca.erwin-cohen@nih.gov</a><br> 114169308 E-200-2020-0 E-200-2020-0-US-01 REAL-TIME CELLULAR THERMAL SHIFT ASSAY (RT-CETSA) FOR RESEARCH AND DRUG DISCOVERY PRV US 63/063,689 Abandoned US <br />Provisional (PRV) 63/063,689<br />Filed on 2020-08-10<br />Status: Abandoned 114169309 E-200-2020-0 E-200-2020-0-PCT-02 REAL-TIME CELLULAR THERMAL SHIFT ASSAY (RT-CETSA) FOR RESEARCH AND DRUG DISCOVERY PCT Patent Cooperation Treaty PCT/US2021/045184 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/045184<br />Filed on 2021-08-09<br />Status: Expired 114128667 XHXXXX 114128668 WIXXXX 114128669 XJXXXX 114128670 WMXXXX 114152809 SHIFT 114152810 thermal 114152811 Cellular 114152812 Realtime 114152832 assay 114152833 RT-CETSA 114152834 DRUG 114152835 Discovery 114152836 analysis 114152837 REAL-TIME 114152838 CETSA 114152839 DATA 114152840 NonParametric 114152841 COMPARISONS 114152842 Unfolding 114152843 CURVES 114152844 AGGREGATION 114152845 Identification TAB-352 114094690 Murine Monoclonal Antibodies Effective To Treat Respiratory Syncytial Virus NIAID Infectious Disease, Licensing, Materials Available, Therapeutics Infectious Disease Licensing Materials Available Therapeutics Judith (Judy) Beeler, Robert Chanock (Estate), Kathleen Coelingh, Peter Collins, Brian Murphy Available for licensing through a Biological Materials License Agreement are the murine MAbs described in Beeler et al, "Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function," J Virol. 1989 Jul;63(7):2941-2950 (<a href="http://www.ncbi.nlm.nih.gov/pubmed/2470922" target="_blank">PubMed abs</a>). The MAbs that are available for licensing are the following: 1129, 1153, 1142, 1200, 1214, 1237, 1112, 1269, and 1243. One of these MAbs, 1129, is the basis for a humanized murine MAb (see U.S. Patent 5,824,307 to humanized 1129 owned by MedImmune, Inc.), recently approved for marketing in the United States. MAbs in the panel reported by Beeler et al. have been shown to be effective therapeutically when administered into the lungs of cotton rats by small-particle aerosol. Among these MAbs several exhibited a high affinity (approximately 10<sup>9</sup>M<sup>-1</sup>) for the RSV F glycoprotein and are directed at epitopes encompassing amino acid 262, 272, 275, 276 or 389. These epitopes are separate, nonoverlapping and distinct from the epitope recognized by the human Fab of U.S. Patent 5,762,905 owned by The Scripps Research Institute. Research and drug development for treatment of respiratory syncytial virus Research Material -- Patent protection is not being pursued for this technology Available for non-exclusive licensing under a Biological Materials License Agreement. 2022-03-08 2024-10-28 2024-10-28 2008-09-01 #s, 1107;, 1112;, 1121;, 1129;, 1142;, 1153;, 1175-40; 1113-44; 1105-1, 1200;, 1214;, 1269, Cell, DB4BXX, DBXXXX, DXXXXX, Hybridoma, Lines, monoclonal False True True NIHTT 37470483 Website Abstract 114103214 Collins, Peter NIAID - DIR NIAID Collins, Peter (NIAID) 0 114103215 Coelingh, Kathleen NIAID - DIR Coelingh, Kathleen 0 114103630 Chanock (Estate), Robert NIAID Chanock (Estate), Robert (NIAID) 0 114103631 Murphy, Brian NIAID Murphy, Brian (NIAID) 0 114103632 Beeler, Judith (Judy) FDA Beeler, Judith (Judy) (FDA) 0 114103214 Collins, Peter NIAID - DIR NIAID Collins, Peter (NIAID) 0 114103215 Coelingh, Kathleen NIAID - DIR Coelingh, Kathleen 0 114103630 Chanock (Estate), Robert NIAID Chanock (Estate), Robert (NIAID) 0 114103631 Murphy, Brian NIAID Murphy, Brian (NIAID) 0 114103632 Beeler, Judith (Judy) FDA Beeler, Judith (Judy) (FDA) 0 114099370 Monoclonal Hybridoma Cell Lines #s 1107; 1112; 1121; 1129; 1142; 1153; 1200; 1214; 1269, 1237 B-056-1994-1 Research Material NIAID 83643855 Soukas, Peter peter.soukas@nih.gov
United States of America Technology Transfer and Intellectual Property Office peter.soukas@nih.gov?subject=Web Inquiry on [TAB-352] Murine Monoclonal Antibodies Effective To Treat Respiratory Syncytial Virus&body=Please send me information about technology [TAB-352] Murine Monoclonal Antibodies Effective To Treat Respiratory Syncytial Virus. Soukas, Peter<br><a href="mailto:peter.soukas@nih.gov?subject=Web Inquiry on [TAB-352] Murine Monoclonal Antibodies Effective To Treat Respiratory Syncytial Virus&body=Please send me information about technology [TAB-352] Murine Monoclonal Antibodies Effective To Treat Respiratory Syncytial Virus.">peter.soukas@nih.gov</a><br> 114112998 DB4BXX 114112999 DBXXXX 114113000 DXXXXX 114130449 1175-40; 1113-44; 1105-1 114130450 monoclonal 114130451 Hybridoma 114130452 Cell 114130453 Lines 114130454 #s 114130455 1107; 114130456 1112; 114130457 1121; 114130458 1129; 114130459 1142; 114130460 1153; 114130461 1200; 114130462 1214; 114130463 1269 TAB-3519 114097379 Remodelins, a New Class of Compounds to Prevent or Treat Cancer Metastasis or Glaucoma NCATS Cardiology, Dental, Endocrinology, Infectious Disease, Oncology, Ophthalmology, Therapeutics Cardiology Dental Endocrinology Infectious Disease Oncology Ophthalmology Therapeutics Stephen Byrn, Bohao Chen, Suzanne Conzen, Nickolai Dulin, Jeffery Fredberg, Vadim Gurvich, Tong-Chuan He, Ramaswamy Krishnan, Tera Lavoie, Bharathi Laxman, Diane Luci, David Maloney, David McCormick, Miguel Muzzio, ChanYoung Park, Marsha Rosner, Julian Solway, Jiaolong Wang, Stephen White This technology includes a series of small molecule organic compounds, called remodelins, that are synthetic derivative analogs of a parent compound discovered by screening of a Chembridge library. The novel synthetic derivative analogs were generated through multiple iterations of compounds directed by in vitro experiments. The invention also includes use of these or related molecules to treat cancer and/or glaucoma. This invention is a new class of compounds for the treatment of cancer and/or glaucoma. Further clinical work with the remodelins could establish these compounds for the inhibition or treatment of cancer metastasis and/or glaucoma. 2022-08-01 2024-10-28 2024-10-28 2022-08-01 2022-03-30 CANCER, Class, compounds, GLAUCOMA, Metastasis, Prevent, Remodelins, TREAT, VCXXXX, VPXXXX, WKXXXX False True True NIHTT 37470483 Website Abstract 114110517 Solway, Julian University of Chicago Medical Center Solway, Julian 0 114110518 Park, ChanYoung Harvard University School of Public Health Park, ChanYoung 0 114110519 Fredberg, Jeffery Harvard University School of Public Health Fredberg, Jeffery 0 114110520 McCormick, David Illinois Institute of Technology (IIT) McCormick, David 0 114110521 Maloney, David Inspyr Therapeutics, Inc. (ITRI) NCATS Maloney, David (NCATS) 0 114110522 Dulin, Nickolai University of Chicago Dulin, Nickolai 0 114110523 Krishnan, Ramaswamy Beth Israel Deaconess Medical Center Krishnan, Ramaswamy 0 114110524 Chen, Bohao University of Chicago Chen, Bohao 0 114110525 Wang, Jiaolong University of Chicago Wang, Jiaolong 0 114110526 Lavoie, Tera University of Chicago Lavoie, Tera 0 114110527 Gurvich, Vadim University of Minnesota Gurvich, Vadim 0 114110528 Byrn, Stephen Purdue University Byrn, Stephen 0 114110529 Muzzio, Miguel Illinois Institute of Technology (IIT) Muzzio, Miguel 0 114110530 White, Stephen University of Chicago White, Stephen 0 114110531 Laxman, Bharathi University of Chicago Laxman, Bharathi 0 114110532 He, Tong-Chuan University of Chicago He, Tong-Chuan 0 114110533 Conzen, Suzanne University of Chicago Conzen, Suzanne 0 114110534 Rosner, Marsha University of Chicago Rosner, Marsha 0 114110516 Luci, Diane NCATS - NCGC NCATS Luci, Diane (NCATS) 1 114110516 Luci, Diane NCATS - NCGC NCATS Luci, Diane (NCATS) 1 114110517 Solway, Julian University of Chicago Medical Center Solway, Julian 0 114110518 Park, ChanYoung Harvard University School of Public Health Park, ChanYoung 0 114110519 Fredberg, Jeffery Harvard University School of Public Health Fredberg, Jeffery 0 114110520 McCormick, David Illinois Institute of Technology (IIT) McCormick, David 0 114110521 Maloney, David Inspyr Therapeutics, Inc. (ITRI) NCATS Maloney, David (NCATS) 0 114110522 Dulin, Nickolai University of Chicago Dulin, Nickolai 0 114110523 Krishnan, Ramaswamy Beth Israel Deaconess Medical Center Krishnan, Ramaswamy 0 114110524 Chen, Bohao University of Chicago Chen, Bohao 0 114110525 Wang, Jiaolong University of Chicago Wang, Jiaolong 0 114110526 Lavoie, Tera University of Chicago Lavoie, Tera 0 114110527 Gurvich, Vadim University of Minnesota Gurvich, Vadim 0 114110528 Byrn, Stephen Purdue University Byrn, Stephen 0 114110529 Muzzio, Miguel Illinois Institute of Technology (IIT) Muzzio, Miguel 0 114110530 White, Stephen University of Chicago White, Stephen 0 114110531 Laxman, Bharathi University of Chicago Laxman, Bharathi 0 114110532 He, Tong-Chuan University of Chicago He, Tong-Chuan 0 114110533 Conzen, Suzanne University of Chicago Conzen, Suzanne 0 114110534 Rosner, Marsha University of Chicago Rosner, Marsha 0 114102631 Remodelins, A New Class Of Compounds To Prevent Or Treat Cancer Metastasis Or Glaucoma E-179-2018-0 Filing authorized Beth Israel Deaconess Medical Center, Harvard University School of Public Health, Harvard University School of Public Health, IIT Research Institute, NCATS - NCGC, Purdue University, University of Chicago, University of Chicago Medical Center, University of Minnesota 83727060 Gadhia, Ami ami.gadhia@nih.gov
United States of America NCGC ami.gadhia@nih.gov?subject=Web Inquiry on [TAB-3519] Remodelins, a New Class of Compounds to Prevent or Treat Cancer Metastasis or Glaucoma&body=Please send me information about technology [TAB-3519] Remodelins, a New Class of Compounds to Prevent or Treat Cancer Metastasis or Glaucoma. Gadhia, Ami<br><a href="mailto:ami.gadhia@nih.gov?subject=Web Inquiry on [TAB-3519] Remodelins, a New Class of Compounds to Prevent or Treat Cancer Metastasis or Glaucoma&body=Please send me information about technology [TAB-3519] Remodelins, a New Class of Compounds to Prevent or Treat Cancer Metastasis or Glaucoma.">ami.gadhia@nih.gov</a><br> 114169300 E-179-2018-0 E-179-2018-0-US-01 Remodelins, A New Class Of Compounds To Prevent Or Treat Cancer Metastasis Or Glaucoma PRV US 62/828,122 Abandoned US <br />Provisional (PRV) 62/828,122<br />Filed on 2019-04-02<br />Status: Abandoned 114128660 VCXXXX 114128661 VPXXXX 114128662 WKXXXX 114152798 Remodelins 114152799 Class 114152800 compounds 114152801 Prevent 114152802 TREAT 114152803 CANCER 114152804 Metastasis 114152805 GLAUCOMA TAB-3518 114097378 Remodelins, a New Class of Compounds to Prevent Airway Remodeling and to Treat and Prevent Fibrosis in Multiple Organs NCATS Cardiology, Dental, Endocrinology, Infectious Disease, Oncology, Ophthalmology, Therapeutics Cardiology Dental Endocrinology Infectious Disease Oncology Ophthalmology Therapeutics Diane Luci, David Maloney This technology includes a new class of compounds, called remodelins, which can be used to prevent airway remodeling and prevent lung fibrosis. Currently no effective therapies are available for lung fibrosis. This compound could also be employed as a treatment for asthma. There are currently no therapies available for lung fibrosis and no asthma treatments are specifically targeted against airway remodelin. Further clinical work with the remodelins could establish them as a treatment =for lung fibrosis and asthma. 2022-08-01 2024-10-28 2024-10-28 2022-08-01 2022-03-30 AIRWAY, Class, compounds, FIBROSIS, MULTIPLE, ORGANS, Prevent, Remodeling, Remodelins, VPXXXX, WKXXXX False True True NIHTT 37470483 Website Abstract 114110515 Maloney, David NCATS - NCGC NCATS Maloney, David (NCATS) 0 114110514 Luci, Diane NCATS - NCGC NCATS Luci, Diane (NCATS) 1 114110514 Luci, Diane NCATS - NCGC NCATS Luci, Diane (NCATS) 1 114110515 Maloney, David NCATS - NCGC NCATS Maloney, David (NCATS) 0 114102630 Remodelins, A New Class Of Compounds To Prevent Airway Remodeling And To Prevent Fibrosis In Multiple Organs E-120-2018-0 Filing authorized NCATS - NCGC 83727060 Gadhia, Ami ami.gadhia@nih.gov
United States of America NCGC ami.gadhia@nih.gov?subject=Web Inquiry on [TAB-3518] Remodelins, a New Class of Compounds to Prevent Airway Remodeling and to Treat and Prevent Fibrosis in Multiple Organs&body=Please send me information about technology [TAB-3518] Remodelins, a New Class of Compounds to Prevent Airway Remodeling and to Treat and Prevent Fibrosis in Multiple Organs. Gadhia, Ami<br><a href="mailto:ami.gadhia@nih.gov?subject=Web Inquiry on [TAB-3518] Remodelins, a New Class of Compounds to Prevent Airway Remodeling and to Treat and Prevent Fibrosis in Multiple Organs&body=Please send me information about technology [TAB-3518] Remodelins, a New Class of Compounds to Prevent Airway Remodeling and to Treat and Prevent Fibrosis in Multiple Organs.">ami.gadhia@nih.gov</a><br> 114169299 E-120-2018-0 E-120-2018-0-US-01 Remodelins, A New Class Of Compounds To Prevent Airway Remodeling And To Prevent Fibrosis In Multiple Organs PRV US 62/827,980 Abandoned US <br />Provisional (PRV) 62/827,980<br />Filed on 2019-04-02<br />Status: Abandoned 114128658 VPXXXX 114128659 WKXXXX 114152789 Remodelins 114152790 Class 114152791 compounds 114152792 Prevent 114152793 AIRWAY 114152794 Remodeling 114152795 FIBROSIS 114152796 MULTIPLE 114152797 ORGANS TAB-3515 114097375 Use Of p21-Activated Kinases (PAK) Inhibitors for the Treatment of CNS Disorders and Cancer NCATS Neurology, Oncology, Research Materials, Therapeutics Neurology Oncology Research Materials Therapeutics Mark Behnke, David Campbell, Seameen Dehdashti, Sergio Duron, Wenwei Huang, John McKew, Min Shen, Na (Nora) Yang, Wei Zheng This technology includes the compounds, compositions, and methods for treating CNS disorders and cancer with an inhibitor of a p21-activated kinase (PAK). PAK activation is shown to play a key role in spine morphogenesis, and attenuation of PAK can reduce, prevent or reverse defects in spine morphogenesis leading to improvements in synaptic function, cognition, and/or behavior. This could be used to treat a wide variety of CNS disorders such as schizophrenia, Alzheimer’s, Parkinson’s Disease, depression, bipolar, and many others. Additionally, the PAK family of serine/threonine kinases plays a pivotal role in physiological processes including motility, survival, mitosis, transcription, and translation. PAKs are widely expressed in a variety of tissues and activated in multiple cancer types (i.e., breast, skin, lung, colon, brain, prostate, kidney, liver). PAK inhibitors can be administered to inhibit aberrant cellular proliferation as a cancer therapy. PAK inhibitors have a wide range of potential therapeutic uses with a large market size. Further clinical work with these PAK inhibitors could establish them as a treatment of CNS disorders and cancer. 2022-08-01 2024-10-28 2024-10-28 2022-08-01 2022-03-30 1, 3-d]pyrimidines, GROUP, Inhibitors, Listed LPM Nguyen-Antczak as of 4/15/2015, PAK, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, PREPARATION, Pyrido[2, VCXXXX, VEXXXX, WIXXXX, WKXXXX False True True NIHTT 37470483 Website Abstract 114110482 Dehdashti, Seameen NCATS - NCGC NCATS Dehdashti, Seameen (NCATS) 0 114110483 Yang, Na (Nora) NCATS - TRND NCATS Yang, Na (Nora) (NCATS) 0 114110484 Shen, Min NCATS - NCGC NCATS Shen, Min (NCATS) 0 114110485 McKew, John NCATS - TRND McKew, John 0 114110486 Behnke, Mark NCATS - TRND NCATS Behnke, Mark (NCATS) 0 114110487 Zheng, Wei NCATS - TRND NCATS Zheng, Wei (NCATS) 0 114110488 Huang, Wenwei NCATS - TRND NCATS Huang, Wenwei (NCATS) 0 114110489 Duron, Sergio Afraxis, Inc. Duron, Sergio 0 114110490 Campbell, David Afraxis, Inc. Campbell, David 1 114110490 Campbell, David Afraxis, Inc. Campbell, David 1 114110482 Dehdashti, Seameen NCATS - NCGC NCATS Dehdashti, Seameen (NCATS) 0 114110483 Yang, Na (Nora) NCATS - TRND NCATS Yang, Na (Nora) (NCATS) 0 114110484 Shen, Min NCATS - NCGC NCATS Shen, Min (NCATS) 0 114110485 McKew, John NCATS - TRND McKew, John 0 114110486 Behnke, Mark NCATS - TRND NCATS Behnke, Mark (NCATS) 0 114110487 Zheng, Wei NCATS - TRND NCATS Zheng, Wei (NCATS) 0 114110488 Huang, Wenwei NCATS - TRND NCATS Huang, Wenwei (NCATS) 0 114110489 Duron, Sergio Afraxis, Inc. Duron, Sergio 0 114102627 Preparation Of Pyrido[2,3-d]pyrimidines As Group 1 PAK Inhibitors E-234-2012-0 Filing authorized Afraxis, Inc., NCATS - NCGC 83682485 Vepa, Suryanarayana sury.vepa@nih.gov
United States of America Office of Strategic Alliances (OSA) sury.vepa@nih.gov?subject=Web Inquiry on [TAB-3515] Use Of p21-Activated Kinases (PAK) Inhibitors for the Treatment of CNS Disorders and Cancer&body=Please send me information about technology [TAB-3515] Use Of p21-Activated Kinases (PAK) Inhibitors for the Treatment of CNS Disorders and Cancer. Vepa, Suryanarayana<br><a href="mailto:sury.vepa@nih.gov?subject=Web Inquiry on [TAB-3515] Use Of p21-Activated Kinases (PAK) Inhibitors for the Treatment of CNS Disorders and Cancer&body=Please send me information about technology [TAB-3515] Use Of p21-Activated Kinases (PAK) Inhibitors for the Treatment of CNS Disorders and Cancer.">sury.vepa@nih.gov</a><br> 114169290 E-234-2012-0 E-234-2012-0-US-28 Preparation Of Pyrido[2,3-d]pyrimidines As Group 1 PAK Inhibitors National Stage US 14/356,118 Abandoned US <br />National Stage 14/356,118<br />Filed on 2014-05-02<br />Status: Abandoned 114169291 E-234-2012-0 E-234-2012-0-PCT-03 PAK Inhibitors For the Treatment of Fragile X Syndrome PCT Patent Cooperation Treaty PCT/US12/063426 Expired Patent Cooperation Treaty <br />(PCT) PCT/US12/063426<br />Filed on 2012-11-02<br />Status: Expired 114169292 E-234-2012-0 E-234-2012-0-PCT-02 Preparation Of Pyrido[2,3-d]pyrimidines As Group 1 PAK Inhibitors PCT Patent Cooperation Treaty PCT/US12/063413 Administratively Closed Patent Cooperation Treaty <br />(PCT) PCT/US12/063413<br />Filed on 2012-11-02<br />Status: Administratively Closed 114169293 E-234-2012-0 E-234-2012-0-US-01 PAK Inhibitors for the Treatment of CNS Disorders and Cancer PRV US 61/555,902 Abandoned US <br />Provisional (PRV) 61/555,902<br />Filed on 2011-11-04<br />Status: Abandoned 114128649 VCXXXX 114128650 VEXXXX 114128651 WIXXXX 114128652 WKXXXX 114152762 Post LPM Assignment Set 20150420 114152763 Pre LPM working set 20150418 114152764 Listed LPM Nguyen-Antczak as of 4/15/2015 114152765 Inhibitors 114152766 PAK 114152767 1 114152768 GROUP 114152769 3-d]pyrimidines 114152770 Pyrido[2 114152771 PREPARATION TAB-3516 114097376 Small Molecule Inhibitors Against Human apurinic/apyrimidinic endonuclease 1 (APEl) for the Treatment of Cancer NCATS Oncology, Research Materials, Therapeutics Oncology Research Materials Therapeutics Ajit Jadhav, David Maloney, Ganesha Rai Bantukallu, Anton Simeonov This technology includes a novel APEl small molecule inhibitor, which exhibits potent in vitro activity and potentiates the cytotoxicity of DNA damaging agents. APEl is the primary mammalian enzyme responsible for the removal of abasic (AP sites) in DNA and functions as part of the base excision DNA repair pathway (BER). BER is instrumental in the repair of DNA damage caused by DNA alkylating agents (e.g., many cancer chemotherapeutics). Thus, inhibition of this pathway should potentiate the cytotoxicity of such compounds. Preclinical and clinical data confirm that APEl is a valid anticancer drug target, with APEI being overexpressed in cancer cells compared to normal cells. This approach has been further validated by the success in clinical trials of another BER pathway inhibitor (PARP inhibitors), either in combination or single-agent therapy. Given the role of APEl in DNA repair, inhibition of this enzyme should improve the therapeutic efficacy and clinical outcome of anti-cancer paradigms involving DNA-interactive treatments. APEl inhibitors could be used for cancer chemotherapy either alone or in combination with relevant DNA damaging chemotherapeutics. 2022-08-01 2024-10-28 2024-10-28 2022-08-01 2022-03-30 1, Against, APE1, Apurinic/apyrimidinic, CB3CXX, endonuclease, Human, Inhibitors, Listed LPM Reichman as of 4/15/2015, MOLECULE, NCTT, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Small, WIXXXX, WKXXXX False True True NIHTT 37470483 Website Abstract 114110492 Rai Bantukallu, Ganesha National Human Genome Research Institute (NHGRI) NCATS Rai Bantukallu, Ganesha (NCATS) 0 114110493 Simeonov, Anton National Human Genome Research Institute (NHGRI) NCATS Simeonov, Anton (NCATS) 0 114110494 Jadhav, Ajit National Human Genome Research Institute (NHGRI) NCATS Jadhav, Ajit (NCATS) 0 114110491 Maloney, David National Human Genome Research Institute (NHGRI) NCATS Maloney, David (NCATS) 1 114110491 Maloney, David National Human Genome Research Institute (NHGRI) NCATS Maloney, David (NCATS) 1 114110492 Rai Bantukallu, Ganesha National Human Genome Research Institute (NHGRI) NCATS Rai Bantukallu, Ganesha (NCATS) 0 114110493 Simeonov, Anton National Human Genome Research Institute (NHGRI) NCATS Simeonov, Anton (NCATS) 0 114110494 Jadhav, Ajit National Human Genome Research Institute (NHGRI) NCATS Jadhav, Ajit (NCATS) 0 114102628 Small Molecule Inhibitors Against Human Apurinic/apyrimidinic Endonuclease 1 (APE1) E-094-2011-0 Filing authorized NCATS - NCGC 83682485 Vepa, Suryanarayana sury.vepa@nih.gov
United States of America Office of Strategic Alliances (OSA) sury.vepa@nih.gov?subject=Web Inquiry on [TAB-3516] Small Molecule Inhibitors Against Human apurinic/apyrimidinic endonuclease 1 (APEl) for the Treatment of Cancer&body=Please send me information about technology [TAB-3516] Small Molecule Inhibitors Against Human apurinic/apyrimidinic endonuclease 1 (APEl) for the Treatment of Cancer. Vepa, Suryanarayana<br><a href="mailto:sury.vepa@nih.gov?subject=Web Inquiry on [TAB-3516] Small Molecule Inhibitors Against Human apurinic/apyrimidinic endonuclease 1 (APEl) for the Treatment of Cancer&body=Please send me information about technology [TAB-3516] Small Molecule Inhibitors Against Human apurinic/apyrimidinic endonuclease 1 (APEl) for the Treatment of Cancer.">sury.vepa@nih.gov</a><br> 114169294 E-094-2011-0 E-094-2011-0-US-01 Inhibitors Of Human Apurinic/apyrimidinic Endonuclease 1 (APE1) PRV US 61/480,145 Abandoned US <br />Provisional (PRV) 61/480,145<br />Filed on 2011-04-28<br />Status: Abandoned 114169295 E-094-2011-0 E-094-2011-0-PCT-02 Inhibitors Of Human Apurinic/Apyrimidinic Endonuclease 1 PCT Patent Cooperation Treaty PCT/US12/34755 Abandoned Patent Cooperation Treaty <br />(PCT) PCT/US12/34755<br />Filed on 2012-04-24<br />Status: Abandoned 114128653 CB3CXX 114128654 WIXXXX 114128656 WKXXXX 114152772 1 114152773 endonuclease 114152774 Apurinic/apyrimidinic 114152775 Human 114152776 Against 114152777 Inhibitors 114152778 MOLECULE 114152779 Small 114152780 APE1 114152781 NCTT 114152782 Listed LPM Reichman as of 4/15/2015 114152783 Pre LPM working set 20150418 114152784 Post LPM Assignment Set 20150420 TAB-3511 114097372 Potent and selective RORgt inhibitors can be used to developed novel treatments for Th17-related autoimmune diseases NCATS Cardiology, Dental, Endocrinology, Geriatrics, Immunology, Infectious Disease, Oncology, Ophthalmology, Research Materials, Therapeutics Cardiology Dental Endocrinology Geriatrics Immunology Infectious Disease Oncology Ophthalmology Research Materials Therapeutics Erika Englund, Ruili Huang, Wenwei Huang, Jun Huh, Daniel ("Dan") Littman This technology includes a series of diphenylpropanamides as potent and selective RORgt inhibitors for the treatment of Th17-related autoimmune diseases. The retinoic acid-related orphan receptor RORgt plays an important role in the differentiation of thymocytes, lymphoid tissue inducer cells, and inflammatory T helper-expressing interleukin 17a (Th17) cells. Small molecule RORgt inhibitors may provide means to regulate Th17 mediated immune response. This technology includes a series of diphenylpropanamides as potent and selective RORgt inhibitors for the treatment of Th17-related autoimmune diseases. The retinoic acid-related orphan receptor RORgt plays an important role in the differentiation of thymocytes, lymphoid tissue inducer cells, and inflammatory T helper-expressing interleukin 17a (Th17) cells. Small molecule RORgt inhibitors may provide means to regulate Th17 mediated immune response. Potent and selective RORgt inhibitors can be used to developed novel treatments for Th17-related autoimmune diseases. 2022-08-01 2024-10-28 2024-10-28 2022-08-01 2022-03-16 ANTAGONISTS, Listed LPM Maddox as of 4/15/2015, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, PREPARATION, RORt, Substituteddiphenylpropanamides, VAXXXX, VPXXXX, WIXXXX, WKXXXX False True True NIHTT 37470483 Website Abstract 114172673 Solt L, Kumar N, et al. https://pubmed.ncbi.nlm.nih.gov/21499262/ <a href="https://pubmed.ncbi.nlm.nih.gov/21499262/">Solt L, Kumar N, et al.</a> 114172674 Huh J, Leung M, et al. https://pubmed.ncbi.nlm.nih.gov/21441909/ <a href="https://pubmed.ncbi.nlm.nih.gov/21441909/">Huh J, Leung M, et al.</a> 114110466 Huang, Wenwei NCATS - TRND NCATS Huang, Wenwei (NCATS) 0 114110467 Huang, Ruili NCATS - NCGC NCATS Huang, Ruili (NCATS) 0 114110468 Englund, Erika NCATS - NCGC Englund, Erika 0 114110470 Huh, Jun New York University Medical Center Huh, Jun 0 114110469 Littman, Daniel ("Dan") New York University School of Medicine Littman, Daniel ("Dan") 1 114110469 Littman, Daniel ("Dan") New York University School of Medicine Littman, Daniel ("Dan") 1 114110466 Huang, Wenwei NCATS - TRND NCATS Huang, Wenwei (NCATS) 0 114110467 Huang, Ruili NCATS - NCGC NCATS Huang, Ruili (NCATS) 0 114110468 Englund, Erika NCATS - NCGC Englund, Erika 0 114110470 Huh, Jun New York University Medical Center Huh, Jun 0 114102624 Preparation Of Substituteddiphenylpropanamides As RORt Antagonists E-107-2013-0 Filing authorized NCATS - NCGC, New York University Medical Center, New York University School of Medicine 83682485 Vepa, Suryanarayana sury.vepa@nih.gov
United States of America Office of Strategic Alliances (OSA) sury.vepa@nih.gov?subject=Web Inquiry on [TAB-3511] Potent and selective RORgt inhibitors can be used to developed novel treatments for Th17-related autoimmune diseases&body=Please send me information about technology [TAB-3511] Potent and selective RORgt inhibitors can be used to developed novel treatments for Th17-related autoimmune diseases. Vepa, Suryanarayana<br><a href="mailto:sury.vepa@nih.gov?subject=Web Inquiry on [TAB-3511] Potent and selective RORgt inhibitors can be used to developed novel treatments for Th17-related autoimmune diseases&body=Please send me information about technology [TAB-3511] Potent and selective RORgt inhibitors can be used to developed novel treatments for Th17-related autoimmune diseases.">sury.vepa@nih.gov</a><br> 114169278 E-107-2013-0 E-107-2013-0-US-01 AMIDO COMPOUNDS AS RORgt MODULATORS AND USES THEREOF PRV US 61/698,708 Abandoned US <br />Provisional (PRV) 61/698,708<br />Filed on 2012-09-09<br />Status: Abandoned 114128638 VAXXXX 114128639 VPXXXX 114128640 WIXXXX 114128641 WKXXXX 114152738 PREPARATION 114152739 Substituteddiphenylpropanamides 114152740 RORt 114152741 ANTAGONISTS 114152742 Listed LPM Maddox as of 4/15/2015 114152743 Pre LPM working set 20150418 114152744 Post LPM Assignment Set 20150420 TAB-3512 114097373 Amido compounds as RORgt Modulators for the Treatment of Th17-related Autoimmune Diseases NCATS Cardiology, Dental, Endocrinology, Geriatrics, Immunology, Infectious Disease, Oncology, Ophthalmology, Research Materials, Therapeutics Cardiology Dental Endocrinology Geriatrics Immunology Infectious Disease Oncology Ophthalmology Research Materials Therapeutics Erika Englund, Ruili Huang, Wenwei Huang, Jun Huh, Daniel ("Dan") Littman This technology includes a series of diphenylpropanamides as potent and selective RORgt inhibitors for the treatment of Th17-related autoimmune diseases. The retinoic acid-related orphan receptor RORgt plays an important role in the differentiation of thymocytes, lymphoid tissue inducer cells, and inflammatory T helper-expressing interleukin 17a (Th17) cells. Small molecule RORgt inhibitors may provide means to regulate Th17 mediated immune response. This invention may offer novel therapeutics for the treatment of Th17 autoimmune diseases. Potent and selective RORgt inhibitors can be used to developed novel treatments for Th17-related autoimmune diseases. 2022-08-01 2024-10-28 2024-10-28 2022-08-01 2022-03-16 Amido, compounds, Listed LPM Maddox as of 4/15/2015, MODULATORS, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, RORgt, THEREOF, USES, VAXXXX, VPXXXX, WIXXXX, WKXXXX False True True NIHTT 37470483 Website Abstract 114172675 Solt L, Kumar N, et al. https://pubmed.ncbi.nlm.nih.gov/21499262/ <a href="https://pubmed.ncbi.nlm.nih.gov/21499262/">Solt L, Kumar N, et al.</a> 114172676 Huh J, Leung M, et al. https://pubmed.ncbi.nlm.nih.gov/21441909/ <a href="https://pubmed.ncbi.nlm.nih.gov/21441909/">Huh J, Leung M, et al.</a> 114110472 Huang, Wenwei National Human Genome Research Institute (NHGRI) NCATS Huang, Wenwei (NCATS) 0 114110473 Huang, Ruili National Human Genome Research Institute (NHGRI) NCATS Huang, Ruili (NCATS) 0 114110474 Englund, Erika NCATS - NCGC Englund, Erika 0 114110475 Huh, Jun New York University Medical Center Huh, Jun 0 114110471 Littman, Daniel ("Dan") New York University School of Medicine Littman, Daniel ("Dan") 1 114110471 Littman, Daniel ("Dan") New York University School of Medicine Littman, Daniel ("Dan") 1 114110472 Huang, Wenwei National Human Genome Research Institute (NHGRI) NCATS Huang, Wenwei (NCATS) 0 114110473 Huang, Ruili National Human Genome Research Institute (NHGRI) NCATS Huang, Ruili (NCATS) 0 114110474 Englund, Erika NCATS - NCGC Englund, Erika 0 114110475 Huh, Jun New York University Medical Center Huh, Jun 0 114102625 Amido Compounds As RORgt Modulators And Uses Thereof E-287-2011-0 Filing authorized NCATS - NCGC, New York University, New York University Medical Center 83682485 Vepa, Suryanarayana sury.vepa@nih.gov
United States of America Office of Strategic Alliances (OSA) sury.vepa@nih.gov?subject=Web Inquiry on [TAB-3512] Amido compounds as RORgt Modulators for the Treatment of Th17-related Autoimmune Diseases&body=Please send me information about technology [TAB-3512] Amido compounds as RORgt Modulators for the Treatment of Th17-related Autoimmune Diseases. Vepa, Suryanarayana<br><a href="mailto:sury.vepa@nih.gov?subject=Web Inquiry on [TAB-3512] Amido compounds as RORgt Modulators for the Treatment of Th17-related Autoimmune Diseases&body=Please send me information about technology [TAB-3512] Amido compounds as RORgt Modulators for the Treatment of Th17-related Autoimmune Diseases.">sury.vepa@nih.gov</a><br> 114169279 E-287-2011-0 E-287-2011-0-US-01 Amido Compounds As RORgt Modulators And Uses Thereof PRV US 61/573,635 Abandoned US <br />Provisional (PRV) 61/573,635<br />Filed on 2011-09-09<br />Status: Abandoned 114169280 E-287-2011-0 E-287-2011-0-PCT-02 Amido Compounds As RORgt Modulators And Uses Thereof PCT Patent Cooperation Treaty PCT/US2012/054424 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2012/054424<br />Filed on 2012-09-10<br />Status: Expired 114169281 E-287-2011-0 E-287-2011-0-US-18 Amido Compounds As RORgt Modulators And Uses Thereof National Stage US 9,765,063 14/343,410 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9765063 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9765063">9,765,063</a><br />Filed on 2014-03-07<br />Status: Abandoned 114128642 VAXXXX 114128643 VPXXXX 114128644 WIXXXX 114128645 WKXXXX 114152745 Amido 114152746 compounds 114152747 RORgt 114152748 MODULATORS 114152749 USES 114152750 THEREOF 114152751 Listed LPM Maddox as of 4/15/2015 114152752 Pre LPM working set 20150418 114152753 Post LPM Assignment Set 20150420 TAB-3507 114097370 Salt and Crystal Forms of 2R,6R-Hydroxynorketamine for the Treatment of Depression NCATS Neurology, Psychiatry/Mental Health, Research Materials, Therapeutics Neurology Psychiatry/Mental Health Research Materials Therapeutics Patrick Morris, Craig Thomas This technology includes two new salt forms for (2R,6R)-hydroxynorketamine (2R,6R-HNK), which is the lead molecule being developed for treatment-resistant depression. Currently, 2R,6R-HNK is being developed as the HCl salt. The HCl salt is slightly hygroscopic at high RH. This is a potential liability, especially in an oral pill form. Recently the malonate and salicylate salt have been discovered and found to have excellent crystalline behavior while also not having the hygroscopic liability the HCl salt holds. This represents a clear advantage. Two new salt forms have been discovered which have good crystallinity and do not have the hygrocopicity that the HCl salt possesses. This can form the basis of a solid oral formulation for 2R,6R-HNK, as the malonate or salicylate salt. 2022-08-01 2024-10-28 2024-10-28 2022-08-01 2022-03-16 2R, 6R-hydroxynorketamine, Crystal, Forms, SALT, VEXXXX, VNXXXX, WIXXXX, WKXXXX False True True NIHTT 37470483 Website Abstract 114172670 Zanos P, Moaddel R, et al. https://pubmed.ncbi.nlm.nih.gov/27144355/ <a href="https://pubmed.ncbi.nlm.nih.gov/27144355/">Zanos P, Moaddel R, et al.</a> 114110463 Morris, Patrick NCATS - NCGC NCATS Morris, Patrick (NCATS) 0 114110462 Thomas, Craig NCATS - NCGC NCATS Thomas, Craig (NCATS) 1 114110462 Thomas, Craig NCATS - NCGC NCATS Thomas, Craig (NCATS) 1 114110463 Morris, Patrick NCATS - NCGC NCATS Morris, Patrick (NCATS) 0 114102622 Salt And Crystal Forms Of 2R,6R-Hydroxynorketamine E-128-2019-0 Filing authorized ARC Trinova Ltd., National Institute of Mental Health (NIMH), National Institute on Aging (NIH/NIA), NCATS - NCGC, University of Maryland 83682485 Vepa, Suryanarayana sury.vepa@nih.gov
United States of America Office of Strategic Alliances (OSA) sury.vepa@nih.gov?subject=Web Inquiry on [TAB-3507] Salt and Crystal Forms of 2R,6R-Hydroxynorketamine for the Treatment of Depression&body=Please send me information about technology [TAB-3507] Salt and Crystal Forms of 2R,6R-Hydroxynorketamine for the Treatment of Depression. Vepa, Suryanarayana<br><a href="mailto:sury.vepa@nih.gov?subject=Web Inquiry on [TAB-3507] Salt and Crystal Forms of 2R,6R-Hydroxynorketamine for the Treatment of Depression&body=Please send me information about technology [TAB-3507] Salt and Crystal Forms of 2R,6R-Hydroxynorketamine for the Treatment of Depression.">sury.vepa@nih.gov</a><br> 114169275 E-128-2019-0 E-128-2019-0-US-01 SALTS OF (2R, 6R)-HYDROXYNORKETAMINE, THEIR CRYSTAL FORMS, AND METHODS OF MAKING THE SAME PRV US 62/936,823 Abandoned US <br />Provisional (PRV) 62/936,823<br />Filed on 2019-11-18<br />Status: Abandoned 114169276 E-128-2019-0 E-128-2019-0-PCT-02 SALTS OF (2R, 6R)-HYDROXYNORKETAMINE, THEIR CRYSTAL FORMS, AND METHODS OF MAKING THE SAME PCT Patent Cooperation Treaty PCT/US2020/060848 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2020/060848<br />Filed on 2020-11-17<br />Status: Expired 114169500 E-128-2019-0 E-128-2019-0-US-07 SALTS OF (2R, 6R)-HYDROXYNORKETAMINE, THEIR CRYSTAL FORMS, AND METHODS OF MAKING THE SAME National Stage US 12,552,737 17/777,654 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12552737 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12552737">12,552,737</a><br />Filed on 2022-05-18<br />Status: Issued 114128630 VNXXXX 114128631 VEXXXX 114128632 WIXXXX 114128633 WKXXXX 114152714 SALT 114152715 Crystal 114152716 Forms 114152717 2R 114152718 6R-hydroxynorketamine TAB-3506 114097369 Discovery of an imidazo[1,2-a]pyridines with Anticancer Properties NCATS Oncology, Research Materials, Therapeutics Oncology Research Materials Therapeutics Chris Finocchio, Scott Hoyt, Jiankang Jiang, Patrick Sutter, Craig Thomas, Morgan Walker This technology includes a series of imidazo[1,2-a]pyridines with potent inhibition of FLT3, which retains potent binding and activity against FLT3 tyrosine kinase domain and gatekeeper mutations. This chemotype exhibits superior anti-leukemic activity against the common clinically-relevant FLT3-mutant acute myeloid leukemia (AML) in vitro and in vivo. Tyrosine kinase domain mutations are a common cause of acquired resistance to FLT3 inhibitors used to treat FLT3-mutant AML. This invention builds upon an earlier IP position with new analogs. These agents have activity versus mutations in the acquired resistance space and versus non-IRAK inhibitors in the adaptive resistance space, and our lead agents have better activity relative to all existing FLT3 inhibitors in relevant FLT3 models. If successful in human clinical trials, these agents could be used to treat a variety of hematological diseases, including but not limited to AML, myelodysplastic syndrome, diffuse large B-cell lymphoma, and other blood cancers. 2022-08-01 2024-10-28 2024-10-28 2022-08-01 2022-03-16 2-a]pyridines, 2-alpha]pyridines, ANTICANCER, Discovery, Imidazo[1, Properties., VCXXXX, WIXXXX, WKXXXX False True True NIHTT 37470483 Website Abstract 114172668 Melgar K, Walker M, et al. https://pubmed.ncbi.nlm.nih.gov/31484791/ <a href="https://pubmed.ncbi.nlm.nih.gov/31484791/">Melgar K, Walker M, et al.</a> 114172669 Jones L, Melgar K, et al. https://pubmed.ncbi.nlm.nih.gov/32149729/ <a href="https://pubmed.ncbi.nlm.nih.gov/32149729/">Jones L, Melgar K, et al.</a> 114110457 Hoyt, Scott NCATS - NCGC NCATS Hoyt, Scott (NCATS) 0 114110458 Walker, Morgan Yale University Walker, Morgan 0 114110459 Sutter, Patrick Baylor University Sutter, Patrick 0 114110460 Jiang, Jiankang NCATS - NCGC NCATS Jiang, Jiankang (NCATS) 0 114110461 Finocchio, Chris NCATS - NCGC NCATS Finocchio, Chris (NCATS) 0 114110456 Thomas, Craig NCATS - NCGC NCATS Thomas, Craig (NCATS) 1 114110456 Thomas, Craig NCATS - NCGC NCATS Thomas, Craig (NCATS) 1 114110457 Hoyt, Scott NCATS - NCGC NCATS Hoyt, Scott (NCATS) 0 114110458 Walker, Morgan Yale University Walker, Morgan 0 114110459 Sutter, Patrick Baylor University Sutter, Patrick 0 114110460 Jiang, Jiankang NCATS - NCGC NCATS Jiang, Jiankang (NCATS) 0 114110461 Finocchio, Chris NCATS - NCGC NCATS Finocchio, Chris (NCATS) 0 114102621 Discovery Of An Imidazo[1,2-alpha]pyridines With Anticancer Properties. E-221-2020-0 Under Review NCATS - NCGC 83727060 Gadhia, Ami ami.gadhia@nih.gov
United States of America NCGC ami.gadhia@nih.gov?subject=Web Inquiry on [TAB-3506] Discovery of an imidazo[1,2-a]pyridines with Anticancer Properties&body=Please send me information about technology [TAB-3506] Discovery of an imidazo[1,2-a]pyridines with Anticancer Properties. Gadhia, Ami<br><a href="mailto:ami.gadhia@nih.gov?subject=Web Inquiry on [TAB-3506] Discovery of an imidazo[1,2-a]pyridines with Anticancer Properties&body=Please send me information about technology [TAB-3506] Discovery of an imidazo[1,2-a]pyridines with Anticancer Properties.">ami.gadhia@nih.gov</a><br> 114128627 VCXXXX 114128628 WIXXXX 114128629 WKXXXX 114152708 Discovery 114152709 Imidazo[1 114152710 2-a]pyridines 114152711 ANTICANCER 114152712 Properties. 114152713 2-alpha]pyridines TAB-3504 114097367 Discovery of imidazo[1,2-a]pyrazines with Anticancer Properties NCATS Oncology, Research Materials, Therapeutics Oncology Research Materials Therapeutics Scott Hoyt, Daniel Starczynowski, Craig Thomas This technology includes a series of imidazo[1,2-a]pyrazines that display potent inhibition of FLT3, as well as potent binding and activity against FLT3 tyrosine kinase domain and gatekeeper mutations. This chemotype exhibits superior anti-leukemic activity against the common clinically-relevant FLT3-mutant acute myeloid leukemia (AML) in vitro and in vivo. Tyrosine kinase domain mutations are a common cause of acquired resistance to FLT3 inhibitors used to treat FLT3-mutant AML. These agents have activity versus mutations in the acquired resistance space and versus non-IRAK inhibitors in the adaptive resistance space. If successful in human clinical trials, these agents could be used to treat a variety of hematological diseases, including but not limited to AML, myelodysplastic syndrome, diffuse large B-cell lymphoma, and other blood cancers. 2022-08-01 2024-10-28 2024-10-28 2022-08-01 2022-03-16 2-a]pyrazines, ANTICANCER, Discovery, Imidazo[1, PROPERTIES, VCXXXX, WIXXXX, WKXXXX False True True NIHTT 37470483 Website Abstract 114172664 Melgar K, Walker M, et al. https://pubmed.ncbi.nlm.nih.gov/31484791/ <a href="https://pubmed.ncbi.nlm.nih.gov/31484791/">Melgar K, Walker M, et al.</a> 114172665 Jones L, Melgar K, et al. https://pubmed.ncbi.nlm.nih.gov/32149729/ <a href="https://pubmed.ncbi.nlm.nih.gov/32149729/">Jones L, Melgar K, et al.</a> 114110447 Hoyt, Scott NCATS - NCGC NCATS Hoyt, Scott (NCATS) 0 114110448 Starczynowski, Daniel Cincinnati Children's Hospital Medical Center Starczynowski, Daniel 0 114110446 Thomas, Craig NCATS - NCGC NCATS Thomas, Craig (NCATS) 1 114110446 Thomas, Craig NCATS - NCGC NCATS Thomas, Craig (NCATS) 1 114110447 Hoyt, Scott NCATS - NCGC NCATS Hoyt, Scott (NCATS) 0 114110448 Starczynowski, Daniel Cincinnati Children's Hospital Medical Center Starczynowski, Daniel 0 114102619 Discovery Of Imidazo[1,2-a]pyrazines With Anticancer Properties E-047-2021-0 Filing authorized Cincinnati Children's Hospital Medical Center, Kurome, Inc., NCATS - NCGC 83727060 Gadhia, Ami ami.gadhia@nih.gov
United States of America NCGC ami.gadhia@nih.gov?subject=Web Inquiry on [TAB-3504] Discovery of imidazo[1,2-a]pyrazines with Anticancer Properties&body=Please send me information about technology [TAB-3504] Discovery of imidazo[1,2-a]pyrazines with Anticancer Properties. Gadhia, Ami<br><a href="mailto:ami.gadhia@nih.gov?subject=Web Inquiry on [TAB-3504] Discovery of imidazo[1,2-a]pyrazines with Anticancer Properties&body=Please send me information about technology [TAB-3504] Discovery of imidazo[1,2-a]pyrazines with Anticancer Properties.">ami.gadhia@nih.gov</a><br> 114128621 VCXXXX 114128622 WIXXXX 114128623 WKXXXX 114152698 Discovery 114152699 Imidazo[1 114152700 2-a]pyrazines 114152701 ANTICANCER 114152702 PROPERTIES TAB-3505 114097368 Discovery of an imidazo[1,2-a]pyridines with Anticancer Properties NCATS Oncology, Research Materials, Therapeutics Oncology Research Materials Therapeutics Chris Finocchio, Scott Hoyt, Jiankang Jiang, Daniel Starczynowski, Patrick Sutter, Craig Thomas, Morgan Walker This technology includes a series of imidazo[1,2-a]pyridines with potent inhibition of FLT3, which retains potent binding and activity against FLT3 tyrosine kinase domain and gatekeeper mutations. This chemotype exhibits superior anti-leukemic activity against the common clinically-relevant FLT3-mutant acute myeloid leukemia (AML) in vitro and in vivo. Tyrosine kinase domain mutations are a common cause of acquired resistance to FLT3 inhibitors used to treat FLT3-mutant AML. This invention builds upon an earlier IP position with new analogs. These agents have activity versus mutations in the acquired resistance space and versus non-IRAK inhibitors in the adaptive resistance space. If successful in human clinical trials, these agents could be used to treat a variety of hematological diseases, including but not limited to AML, myelodysplastic syndrome, diffuse large B-cell lymphoma, and other blood cancers. 2022-08-01 2024-10-28 2024-10-28 2022-08-01 2022-03-16 2-alpha]pyridines, ANTICANCER, Discovery, Imidazo[1, PROPERTIES, VCXXXX, WIXXXX, WKXXXX False True True NIHTT 37470483 Website Abstract 114172666 Melgar K, Walker M, et al. https://pubmed.ncbi.nlm.nih.gov/31484791/ <a href="https://pubmed.ncbi.nlm.nih.gov/31484791/">Melgar K, Walker M, et al.</a> 114172667 Jones L, Melgar K, et al. https://pubmed.ncbi.nlm.nih.gov/32149729/ <a href="https://pubmed.ncbi.nlm.nih.gov/32149729/">Jones L, Melgar K, et al.</a> 114110450 Hoyt, Scott NCATS - NCGC NCATS Hoyt, Scott (NCATS) 0 114110451 Walker, Morgan Yale University Walker, Morgan 0 114110452 Sutter, Patrick Baylor University Sutter, Patrick 0 114110453 Jiang, Jiankang NCATS - NCGC NCATS Jiang, Jiankang (NCATS) 0 114110454 Finocchio, Chris NCATS - NCGC NCATS Finocchio, Chris (NCATS) 0 114110455 Starczynowski, Daniel Cincinnati Children's Hospital Medical Center Starczynowski, Daniel 0 114110449 Thomas, Craig NCATS - NCGC NCATS Thomas, Craig (NCATS) 1 114110449 Thomas, Craig NCATS - NCGC NCATS Thomas, Craig (NCATS) 1 114110450 Hoyt, Scott NCATS - NCGC NCATS Hoyt, Scott (NCATS) 0 114110451 Walker, Morgan Yale University Walker, Morgan 0 114110452 Sutter, Patrick Baylor University Sutter, Patrick 0 114110453 Jiang, Jiankang NCATS - NCGC NCATS Jiang, Jiankang (NCATS) 0 114110454 Finocchio, Chris NCATS - NCGC NCATS Finocchio, Chris (NCATS) 0 114110455 Starczynowski, Daniel Cincinnati Children's Hospital Medical Center Starczynowski, Daniel 0 114102620 Discovery Of An Imidazo[1,2-alpha]pyridines With Anticancer Properties E-151-2020-0 Filing authorized Baylor University, Cincinnati Children's Hospital Medical Center, NCATS - NCGC 83727060 Gadhia, Ami ami.gadhia@nih.gov
United States of America NCGC ami.gadhia@nih.gov?subject=Web Inquiry on [TAB-3505] Discovery of an imidazo[1,2-a]pyridines with Anticancer Properties&body=Please send me information about technology [TAB-3505] Discovery of an imidazo[1,2-a]pyridines with Anticancer Properties. Gadhia, Ami<br><a href="mailto:ami.gadhia@nih.gov?subject=Web Inquiry on [TAB-3505] Discovery of an imidazo[1,2-a]pyridines with Anticancer Properties&body=Please send me information about technology [TAB-3505] Discovery of an imidazo[1,2-a]pyridines with Anticancer Properties.">ami.gadhia@nih.gov</a><br> 114128624 VCXXXX 114128625 WIXXXX 114128626 WKXXXX 114152703 Imidazo[1 114152704 Discovery 114152705 2-alpha]pyridines 114152706 ANTICANCER 114152707 PROPERTIES TAB-3502 114097365 Discovery of imidazo[1,2-b]pyridazines with Anticancer Properties NCATS Oncology, Research Materials, Therapeutics Oncology Research Materials Therapeutics Chris Finocchio, Scott Hoyt, Daniel Starczynowski, Patrick Sutter, Gregory Tawa, Craig Thomas This technology includes a series of imidazo[1,2-b]pyridazines that display potent inhibition of FLT3, as well as potent binding and activity against FLT3 tyrosine kinase domain and gatekeeper mutations. This chemotype exhibits superior anti-leukemic activity against the common clinically-relevant FLT3-mutant acute myeloid leukemia (AML) in vitro and in vivo. Tyrosine kinase domain mutations are a common cause of acquired resistance to FLT3 inhibitors used to treat FLT3-mutant AML. These agents have activity versus mutations in the acquired resistance space and versus non-IRAK inhibitors in the adaptive resistance space. If successful in human clinical trials, these agents could be used to treat a variety of hematological diseases, including but not limited to AML, myelodysplastic syndrome, diffuse large B-cell lymphoma, and other blood cancers. 2022-08-01 2024-10-28 2024-10-28 2022-08-01 2022-03-16 2-b]pyridazines, ANTICANCER, Discovery, Imidazo[1, PROPERTIES, VCXXXX, WIXXXX, WKXXXX False True True NIHTT 37470483 Website Abstract 114172660 Melgar K, Walker M, et al. https://pubmed.ncbi.nlm.nih.gov/31484791/ <a href="https://pubmed.ncbi.nlm.nih.gov/31484791/">Melgar K, Walker M, et al.</a> 114172661 Jones L, Melgar K, et al. https://pubmed.ncbi.nlm.nih.gov/32149729/ <a href="https://pubmed.ncbi.nlm.nih.gov/32149729/">Jones L, Melgar K, et al.</a> 114110434 Hoyt, Scott NCATS - NCGC NCATS Hoyt, Scott (NCATS) 0 114110436 Sutter, Patrick Baylor University Sutter, Patrick 0 114110437 Finocchio, Chris NCATS - NCGC NCATS Finocchio, Chris (NCATS) 0 114110438 Starczynowski, Daniel Cincinnati Children's Hospital Medical Center Starczynowski, Daniel 0 114110439 Tawa, Gregory NCATS - TRND NCATS Tawa, Gregory (NCATS) 0 114110435 Thomas, Craig NCATS - NCGC NCATS Thomas, Craig (NCATS) 1 114110435 Thomas, Craig NCATS - NCGC NCATS Thomas, Craig (NCATS) 1 114110434 Hoyt, Scott NCATS - NCGC NCATS Hoyt, Scott (NCATS) 0 114110436 Sutter, Patrick Baylor University Sutter, Patrick 0 114110437 Finocchio, Chris NCATS - NCGC NCATS Finocchio, Chris (NCATS) 0 114110438 Starczynowski, Daniel Cincinnati Children's Hospital Medical Center Starczynowski, Daniel 0 114110439 Tawa, Gregory NCATS - TRND NCATS Tawa, Gregory (NCATS) 0 114102617 Discovery Of Imidazo[1,2-b]pyridazines With Anticancer Properties E-043-2021-0 Filing authorized Baylor University, Cincinnati Children's Hospital Medical Center, NCATS - NCGC 83727060 Gadhia, Ami ami.gadhia@nih.gov
United States of America NCGC ami.gadhia@nih.gov?subject=Web Inquiry on [TAB-3502] Discovery of imidazo[1,2-b]pyridazines with Anticancer Properties&body=Please send me information about technology [TAB-3502] Discovery of imidazo[1,2-b]pyridazines with Anticancer Properties. Gadhia, Ami<br><a href="mailto:ami.gadhia@nih.gov?subject=Web Inquiry on [TAB-3502] Discovery of imidazo[1,2-b]pyridazines with Anticancer Properties&body=Please send me information about technology [TAB-3502] Discovery of imidazo[1,2-b]pyridazines with Anticancer Properties.">ami.gadhia@nih.gov</a><br> 114128615 WKXXXX 114128616 WIXXXX 114128617 VCXXXX 114152688 ANTICANCER 114152689 2-b]pyridazines 114152690 Imidazo[1 114152691 Discovery 114152692 PROPERTIES TAB-3503 114097366 Discovery of imidazo[1,2-b]pyridazines with Anticancer Properties NCATS Oncology, Research Materials, Therapeutics Oncology Research Materials Therapeutics Chris Finocchio, Scott Hoyt, Daniel Starczynowski, Patrick Sutter, Gregory Tawa, Craig Thomas This technology includes a series of imidazo[1,2-b]pyridazines that display potent inhibition of FLT3, as well as potent binding and activity against FLT3 tyrosine kinase domain and gatekeeper mutations. This chemotype exhibits superior anti-leukemic activity against the common clinically-relevant FLT3-mutant acute myeloid leukemia (AML) in vitro and in vivo. Tyrosine kinase domain mutations are a common cause of acquired resistance to FLT3 inhibitors used to treat FLT3-mutant AML. These agents have activity versus mutations in the acquired resistance space and versus non-IRAK inhibitors in the adaptive resistance space. If successful in human clinical trials, these agents could be used to treat a variety of hematological diseases, including but not limited to AML, myelodysplastic syndrome, diffuse large B-cell lymphoma, and other blood cancers. 2022-08-01 2024-10-28 2024-10-28 2022-08-01 2022-03-16 2-b]pyridazines, ANTICANCER, Discovery, Imidazo[1, PROPERTIES, VCXXXX, WIXXXX, WKXXXX False True True NIHTT 37470483 Website Abstract 114172662 Melgar K, Walker M, et al. https://pubmed.ncbi.nlm.nih.gov/31484791/ <a href="https://pubmed.ncbi.nlm.nih.gov/31484791/">Melgar K, Walker M, et al.</a> 114172663 Jones L, Melgar K, et al. https://pubmed.ncbi.nlm.nih.gov/32149729/ <a href="https://pubmed.ncbi.nlm.nih.gov/32149729/">Jones L, Melgar K, et al.</a> 114110441 Hoyt, Scott NCATS - NCGC NCATS Hoyt, Scott (NCATS) 0 114110442 Finocchio, Chris NCATS - NCGC NCATS Finocchio, Chris (NCATS) 0 114110443 Starczynowski, Daniel Cincinnati Children's Hospital Medical Center Starczynowski, Daniel 0 114110444 Tawa, Gregory NCATS - TRND NCATS Tawa, Gregory (NCATS) 0 114110445 Sutter, Patrick NCATS - NCGC Sutter, Patrick 0 114110440 Thomas, Craig NCATS - NCGC NCATS Thomas, Craig (NCATS) 1 114110440 Thomas, Craig NCATS - NCGC NCATS Thomas, Craig (NCATS) 1 114110441 Hoyt, Scott NCATS - NCGC NCATS Hoyt, Scott (NCATS) 0 114110442 Finocchio, Chris NCATS - NCGC NCATS Finocchio, Chris (NCATS) 0 114110443 Starczynowski, Daniel Cincinnati Children's Hospital Medical Center Starczynowski, Daniel 0 114110444 Tawa, Gregory NCATS - TRND NCATS Tawa, Gregory (NCATS) 0 114110445 Sutter, Patrick NCATS - NCGC Sutter, Patrick 0 114102618 Discovery Of Imidazo[1,2-b]pyridazines With Anticancer Properties E-046-2021-0 Filing authorized Cincinnati Children's Hospital Medical Center, Kurome, Inc., NCATS - NCGC 83727060 Gadhia, Ami ami.gadhia@nih.gov
United States of America NCGC ami.gadhia@nih.gov?subject=Web Inquiry on [TAB-3503] Discovery of imidazo[1,2-b]pyridazines with Anticancer Properties&body=Please send me information about technology [TAB-3503] Discovery of imidazo[1,2-b]pyridazines with Anticancer Properties. Gadhia, Ami<br><a href="mailto:ami.gadhia@nih.gov?subject=Web Inquiry on [TAB-3503] Discovery of imidazo[1,2-b]pyridazines with Anticancer Properties&body=Please send me information about technology [TAB-3503] Discovery of imidazo[1,2-b]pyridazines with Anticancer Properties.">ami.gadhia@nih.gov</a><br> 114128618 VCXXXX 114128619 WIXXXX 114128620 WKXXXX 114152693 Discovery 114152694 Imidazo[1 114152695 2-b]pyridazines 114152696 ANTICANCER 114152697 PROPERTIES TAB-3499 114097363 A HeLa Cell Line that Activates the Parkinson Disease-Related PINK1/Parkin Pathways in Mitochondria NINDS Licensing, Neurology, Research Materials, Therapeutics Licensing Neurology Research Materials Therapeutics Seok-Min Jin, Richard Youle This invention includes HeLa cells that are engineered to inducibly express a mutant form of ornithine decarboxylase that is targeted to the mitochondrial matrix and forms insoluble protein aggregates. The presence of unfolded proteins in the matrix causes the accumulation of the mitochondrial kinase PINK1 and the E3 ubiquitin ligase PARK2/Parkin. These proteins play a critical role in degrading the mitochondria where they are expressed, a process call mitophagy. Mutations in these two genes are associated with familial Parkinson disease. Prior models of PINK1/Parkin activation relied on mitochondrial depolarizing agents. This model may be more physiological and subtle, allowing a more valid way to assess compounds that increase PINK1 activity. This cell line provides a unique and physiologically-relevant method to assess compounds that increase PINK1 activity. 2022-03-15 2024-10-28 2024-10-28 2022-03-15 Activation, Misfolded, Mitochondria, PATHWAY, PINK1/Parkin, PIONK1/Parkin, proteins, VEXXXX, WIXXXX, XEXXXX False True True NIHTT 37470483 Website Abstract 114172657 Jin SM, Youle RJ https://pubmed.ncbi.nlm.nih.gov/24149988/ <a href="https://pubmed.ncbi.nlm.nih.gov/24149988/">Jin SM, Youle RJ</a> 114172658 Burman JL, Pickles S, et al. https://pubmed.ncbi.nlm.nih.gov/28893839/ <a href="https://pubmed.ncbi.nlm.nih.gov/28893839/">Burman JL, Pickles S, et al.</a> 114110431 Jin, Seok-Min Aprogen, Inc. Jin, Seok-Min 0 114110430 Youle, Richard NINDS NINDS Youle, Richard (NINDS) 1 114110430 Youle, Richard NINDS NINDS Youle, Richard (NINDS) 1 114110431 Jin, Seok-Min Aprogen, Inc. Jin, Seok-Min 0 114102615 Activation Of PINK1/Parkin Pathway By Misfolded Proteins Within Mitochondria E-013-2019-0 Research Material NINDS 83687767 Olufemi, Olufunmilola (Lola) olufunmilola.olufemi@nih.gov
United States of America olufunmilola.olufemi@nih.gov?subject=Web Inquiry on [TAB-3499] A HeLa Cell Line that Activates the Parkinson Disease-Related PINK1/Parkin Pathways in Mitochondria&body=Please send me information about technology [TAB-3499] A HeLa Cell Line that Activates the Parkinson Disease-Related PINK1/Parkin Pathways in Mitochondria. Olufemi, Olufunmilola (Lola)<br><a href="mailto:olufunmilola.olufemi@nih.gov?subject=Web Inquiry on [TAB-3499] A HeLa Cell Line that Activates the Parkinson Disease-Related PINK1/Parkin Pathways in Mitochondria&body=Please send me information about technology [TAB-3499] A HeLa Cell Line that Activates the Parkinson Disease-Related PINK1/Parkin Pathways in Mitochondria.">olufunmilola.olufemi@nih.gov</a><br> 114128609 VEXXXX 114128610 WIXXXX 114128611 XEXXXX 114152677 Activation 114152678 PIONK1/Parkin 114152679 PATHWAY 114152680 Misfolded 114152681 proteins 114152682 Mitochondria 114152683 PINK1/Parkin TAB-3500 114097364 Pink1 Knockout HeLa Cells for Studying Parkinson Disease NINDS Licensing, Neurology, Research Materials, Therapeutics Licensing Neurology Research Materials Therapeutics Chunxin (Black) Wang, Richard Youle The technology includes Pink1 knockout HeLa cells that were generated using CRISPR technology. Pink1 is the key master gene to trigger degradation of mitochondria, mitophagy, and is implicated in familial Parkinson Disease. Knocking out Pink1 allows us to study the roles of Pink1 in many aspects of mitophagy and to display Pink1-dependent or independent activity. To create the HeLa cells, two CRISPR gRNAs targeting exon 1 and exon 7 of the Pink1 genome were used for transfection with Cas9 and GFP-C1 reporter. Cells were sorted 2 days after transfection and plated out in 96-well plates. Ten days later, single colonies were transferred to 24-well plates and then genomic DNA of each colony was isolated for genotyping. The positive clones were then confirmed by Western blot. Pink1 is constantly degraded in normal condition and it has been difficult to raise a good and specific Pink1 antibody. The Pink1 knockout cell line can be the gold standard to verify if the antibody is specific. The knockout cells permit studying different regulation events related to Pink1 (such as phosphorylation or kinase mutants). The knockout cells can also be used for verifying Pink1 antibody. 2022-03-15 2024-10-28 2024-10-28 2022-03-15 Cells, Hela, Knockout, Pink, VEXXXX, WIXXXX, XEXXXX False True True NIHTT 37470483 Website Abstract 114172659 Lesley AK, Lazarou M, et al. https://pubmed.ncbi.nlm.nih.gov/24751536/ <a href="https://pubmed.ncbi.nlm.nih.gov/24751536/ ">Lesley AK, Lazarou M, et al.</a> 114110432 Wang, Chunxin (Black) NINDS NINDS Wang, Chunxin (Black) (NINDS) 0 114110433 Youle, Richard NINDS NINDS Youle, Richard (NINDS) 1 114110433 Youle, Richard NINDS NINDS Youle, Richard (NINDS) 1 114110432 Wang, Chunxin (Black) NINDS NINDS Wang, Chunxin (Black) (NINDS) 0 114102616 Pink Knockout HeLa Cells E-072-2016-0 Research Material NINDS 83687767 Olufemi, Olufunmilola (Lola) olufunmilola.olufemi@nih.gov
United States of America olufunmilola.olufemi@nih.gov?subject=Web Inquiry on [TAB-3500] Pink1 Knockout HeLa Cells for Studying Parkinson Disease&body=Please send me information about technology [TAB-3500] Pink1 Knockout HeLa Cells for Studying Parkinson Disease. Olufemi, Olufunmilola (Lola)<br><a href="mailto:olufunmilola.olufemi@nih.gov?subject=Web Inquiry on [TAB-3500] Pink1 Knockout HeLa Cells for Studying Parkinson Disease&body=Please send me information about technology [TAB-3500] Pink1 Knockout HeLa Cells for Studying Parkinson Disease.">olufunmilola.olufemi@nih.gov</a><br> 114128612 VEXXXX 114128613 WIXXXX 114128614 XEXXXX 114152684 Pink 114152685 Knockout 114152686 Hela 114152687 Cells TAB-3497 114097361 Rapid and Robust Differentiation of Human iPSCs into Motor Neurons NINDS Cardiology, Dental, Endocrinology, Infectious Disease, Licensing, Oncology, Ophthalmology, Research Materials, Therapeutics Cardiology Dental Endocrinology Infectious Disease Licensing Oncology Ophthalmology Research Materials Therapeutics Christopher Grunseich, Michael Ward This technology includes a system that allows for robust differentiation of human-induced pluripotent stem cells (iPSC) into motor neurons within a time frame of 7 to 10 days. To differentiate the iPSC, a stable transgene is inserted into the CLYBL safe harbor locus in the human genome using TALENs. The transgene allows for doxycycline-inducible expression of the transcription factors (NGN2, ISL1, and LHX3) that are needed for the cells to differentiate to motor neurons. The technology is described in detail in the protocol paper published by Fernandopulle et al, cited below. We knocked in a doxycycline-inducible transgene cassette into the CLYBI safe harbor locus of iPSCs using TALENs. The cassette drives expression of human NGN2, Isl1, and LXZH3, separated by 2A linker peptides. The targeting vector was a heavily-modified version of a CLYBL targeting vector from Mahendra Rao’s lab at the NIH (essentially, only the homology arms of the original vector were used). The plasmids introduced into the WTC11 and then clones that harbored the transcription factor cassette were selected. The system allows for robust differentiation of human induced pluripotent stem cells (iPSC) into motor neuron cells with an efficient time frame of 7 to 10 days. The system also allows for large scale preparation of motor neurons with few media changes. To differentiate the iPSC, a stable transgene is inserted into the CLYBL safe harbor locus in the human genome. The transgene allows for doxycycline inducible expression of the transcription factors (NGN2, ISL1, and LHX3) that are needed for the cells to differentiate to motor neuron. This technology permits for robust differentiation in a short time frame (7-10 days) requiring fewer media changes and expensive small molecules. Differentiation can be scaled according to the needs to the user to achieve large numbers of differentiated cells. Differentiation is also from a well-defined clone of cells containing the transgene, which allows more reproducible differentiation between different experiments. The system also allows for large scale preparation of motor neurons in a short time frame with few media changes. 2022-03-15 2024-10-28 2024-10-28 2022-03-15 DIFFERENTIATION, Factor-Medeated, Human, iPSC, MOTOR, Neurons, transcription, VPXXXX, WIXXXX, XEXXXX False True True NIHTT 37470483 Website Abstract 114172655 Fernandopulle MS, Prestil R, et al. https://pubmed.ncbi.nlm.nih.gov/29924488/ <a href="https://pubmed.ncbi.nlm.nih.gov/29924488/">Fernandopulle MS, Prestil R, et al.</a> 114110425 Ward, Michael NINDS NINDS Ward, Michael (NINDS) 0 114110424 Grunseich, Christopher NINDS NINDS Grunseich, Christopher (NINDS) 1 114110424 Grunseich, Christopher NINDS NINDS Grunseich, Christopher (NINDS) 1 114110425 Ward, Michael NINDS NINDS Ward, Michael (NINDS) 0 114102613 Transcription Factor-Mediated Differentiation Of Human IPSC Into Motor Neurons E-001-2020-0 Research Material NINDS 83687767 Olufemi, Olufunmilola (Lola) olufunmilola.olufemi@nih.gov
United States of America olufunmilola.olufemi@nih.gov?subject=Web Inquiry on [TAB-3497] Rapid and Robust Differentiation of Human iPSCs into Motor Neurons&body=Please send me information about technology [TAB-3497] Rapid and Robust Differentiation of Human iPSCs into Motor Neurons. Olufemi, Olufunmilola (Lola)<br><a href="mailto:olufunmilola.olufemi@nih.gov?subject=Web Inquiry on [TAB-3497] Rapid and Robust Differentiation of Human iPSCs into Motor Neurons&body=Please send me information about technology [TAB-3497] Rapid and Robust Differentiation of Human iPSCs into Motor Neurons.">olufunmilola.olufemi@nih.gov</a><br> 114128603 VPXXXX 114128604 WIXXXX 114128605 XEXXXX 114152663 transcription 114152664 Factor-Medeated 114152665 DIFFERENTIATION 114152666 Human 114152667 iPSC 114152668 MOTOR 114152669 Neurons TAB-3498 114097362 CRISPR-Mediated Gene Inhibition and Neuronal Differentiation in Human Induced Pluripotent Stem Cell (iPSC) Lines NINDS Licensing, Neurology, Research Materials, Therapeutics Licensing Neurology Research Materials Therapeutics Martin Kampmann, Connor Ludwig, Ruilin Tian, Michael Ward This invention includes human induced pluripotent stem cell (iPSC) lines that harbor a single copy dCas9-BFP-KRAB at the CLYBL safe harbor locus (mediating CRISPR inhibition of human gene expression) and/or a single copy of dox-inducible NGN2 at the AAVS1 locus (enabling the differentiation of the iPSCs into neurons). The CRISPR-mediated inhibition of human gene expression is maintained into the differentiated neurons, permitting functional studies of targeted genes in neurons. The stem cell lines included in this technology permit direct genetic and screening approaches on neurons. The stem cell lines can be used for forward genetic and chemogenetic screens for drug tests of neurological diseases. 2022-03-15 2024-10-28 2024-10-28 2022-03-15 Cell, CRISPRi-, INDUCED, Llines, Pluripotent, Stem, VEXXXX, WIXXXX, WTC11, XEXXXX False True True NIHTT 37470483 Website Abstract 114172656 Ruilin T, Gachechiladze MA, et al. https://pubmed.ncbi.nlm.nih.gov/31422865/ <a href="https://pubmed.ncbi.nlm.nih.gov/31422865/">Ruilin T, Gachechiladze MA, et al.</a> 114110427 Kampmann, Martin University of California, San Francisco (UCSF) Kampmann, Martin 0 114110428 Ludwig, Connor University of California, San Francisco (UCSF) Ludwig, Connor 0 114110429 Tian, Ruilin University of California, San Francisco (UCSF) Tian, Ruilin 0 114110426 Ward, Michael NINDS NINDS Ward, Michael (NINDS) 1 114110426 Ward, Michael NINDS NINDS Ward, Michael (NINDS) 1 114110427 Kampmann, Martin University of California, San Francisco (UCSF) Kampmann, Martin 0 114110428 Ludwig, Connor University of California, San Francisco (UCSF) Ludwig, Connor 0 114110429 Tian, Ruilin University of California, San Francisco (UCSF) Tian, Ruilin 0 114102614 CRISPRi- WTC11 Induced Pluripotent Stem Cell Llines E-002-2020-0 Research Material NINDS, University of California, San Francisco (UCSF) 83687767 Olufemi, Olufunmilola (Lola) olufunmilola.olufemi@nih.gov
United States of America olufunmilola.olufemi@nih.gov?subject=Web Inquiry on [TAB-3498] CRISPR-Mediated Gene Inhibition and Neuronal Differentiation in Human Induced Pluripotent Stem Cell (iPSC) Lines&body=Please send me information about technology [TAB-3498] CRISPR-Mediated Gene Inhibition and Neuronal Differentiation in Human Induced Pluripotent Stem Cell (iPSC) Lines. Olufemi, Olufunmilola (Lola)<br><a href="mailto:olufunmilola.olufemi@nih.gov?subject=Web Inquiry on [TAB-3498] CRISPR-Mediated Gene Inhibition and Neuronal Differentiation in Human Induced Pluripotent Stem Cell (iPSC) Lines&body=Please send me information about technology [TAB-3498] CRISPR-Mediated Gene Inhibition and Neuronal Differentiation in Human Induced Pluripotent Stem Cell (iPSC) Lines.">olufunmilola.olufemi@nih.gov</a><br> 114128606 VEXXXX 114128607 WIXXXX 114128608 XEXXXX 114152670 CRISPRi- 114152671 WTC11 114152672 INDUCED 114152673 Pluripotent 114152674 Stem 114152675 Cell 114152676 Llines TAB-3495 114097359 Stable Pharmaceutical Formulation of Propofol Hemisuccinate for Inhalation Delivery Stable Pharmaceutical Formulation of Propofol Hemisuccinate for Inhalation Delivery NCATS Neurology, Therapeutics Neurology Therapeutics Vadim Gurvich, Swayam Prabha, Tanmoy Sadhukha, Raj Suryanarayanan, Seema Thakral This technology includes a stable pharmaceutical formulation of propofol hemisuccinate for inhalation delivery to treat intractable epilepsy and migraine. The formulation can be used to treat a patient experiencing a seizure aura to prevent a motor seizure. Alternatively, the formulation can be used to treat an epileptic patient who is experiencing seizure clusters in an out-of-hospital or in-hospital setting. For migraines, the formulation can be used to treat a patient experiencing a migraine aura or early migraine to forestall the development of the full symptoms of a migraine headache. The current formulation is the first available treatment optimized for inhalation delivery for the treatment of both epilepsy and migraine. Further clinical work could establish the formulation described in this technology for inhalation delivery to treat intractable epilepsy and migraine. 2022-08-01 2024-10-28 2024-10-28 2022-08-01 2022-03-04 Delivery, FORMULATION, Hemisuccinate, Inhalation, PHARMACEUTICAL, Propofol, STABLE, VEXXXX, WKXXXX False True True NIHTT 37470483 Website Abstract 114110411 Suryanarayanan, Raj University of Minnesota Suryanarayanan, Raj 0 114110412 Gurvich, Vadim University of Minnesota Gurvich, Vadim 0 114110413 Sadhukha, Tanmoy University of Minnesota Sadhukha, Tanmoy 0 114110414 Thakral, Seema University of Minnesota Thakral, Seema 0 114110410 Prabha, Swayam University of Minnesota Prabha, Swayam 1 114110410 Prabha, Swayam University of Minnesota Prabha, Swayam 1 114110411 Suryanarayanan, Raj University of Minnesota Suryanarayanan, Raj 0 114110412 Gurvich, Vadim University of Minnesota Gurvich, Vadim 0 114110413 Sadhukha, Tanmoy University of Minnesota Sadhukha, Tanmoy 0 114110414 Thakral, Seema University of Minnesota Thakral, Seema 0 114102609 Stable Pharmaceutical Formulation Of Propofol Hemisuccinate For Inhalation Delivery E-245-2015-0 Filing authorized NIH - NCATS, University of Minnesota 83682485 Vepa, Suryanarayana sury.vepa@nih.gov
United States of America Office of Strategic Alliances (OSA) sury.vepa@nih.gov?subject=Web Inquiry on [TAB-3495] Stable Pharmaceutical Formulation of Propofol Hemisuccinate for Inhalation Delivery Stable Pharmaceutical Formulation of Propofol Hemisuccinate for Inhalation Delivery&body=Please send me information about technology [TAB-3495] Stable Pharmaceutical Formulation of Propofol Hemisuccinate for Inhalation Delivery Stable Pharmaceutical Formulation of Propofol Hemisuccinate for Inhalation Delivery. Vepa, Suryanarayana<br><a href="mailto:sury.vepa@nih.gov?subject=Web Inquiry on [TAB-3495] Stable Pharmaceutical Formulation of Propofol Hemisuccinate for Inhalation Delivery Stable Pharmaceutical Formulation of Propofol Hemisuccinate for Inhalation Delivery&body=Please send me information about technology [TAB-3495] Stable Pharmaceutical Formulation of Propofol Hemisuccinate for Inhalation Delivery Stable Pharmaceutical Formulation of Propofol Hemisuccinate for Inhalation Delivery.">sury.vepa@nih.gov</a><br> 114128596 VEXXXX 114128597 WKXXXX 114152638 STABLE 114152639 PHARMACEUTICAL 114152640 FORMULATION 114152641 Propofol 114152642 Hemisuccinate 114152643 Inhalation 114152644 Delivery TAB-3496 114097360 Potentiating Antibody Therapy by Targeting Complement Deposited on Cancer Cells NHLBI Immunology, Licensing, Oncology, Therapeutics Immunology Licensing Oncology Therapeutics Sivasubramanian Baskar, Erika Gaglione, Margaret Lindorfer, Haiyong Peng, Christoph Rader, Martin Skarzynski, Ronald Taylor, Berengere Vire, Adrian Wiestner Monoclonal antibodies (mAbs) have become a mainstay of therapy for many cancers. However, antibody therapy is not completely effective in some applications due to loss of the target surface antigen on cancer cells. Such mAb-induced “escape variants” are no longer sensitive to the therapeutic mAb therapy. It was observed that the escape variants carried covalently bound complement activation fragments, especially C3d. NIH inventors have generated several C3d-specific mouse and rabbit monoclonal antibodies to re-target cells that have escaped from mAb therapy. Proof of principle for this “one-two punch” approach in preclinical models indicates that these C3d specific antibodies can potentiate the anti-tumor activity of therapeutic mAbs and eliminate antigen loss variants that survive after antibody therapy. This approach can enhance mAb-dependent cancer cells killing in an additive or even synergistic way, and will play a prominent role in filling an unmet cancer immunotherapeutic need specially for patients with refractory and relapsed diseases. Foreign filings in Canada, Europe, Switzerland, Germany, France, Great Britain 2022-06-09 2024-10-28 2024-10-28 2022-03-10 2JXXXX, 4GXXXX, 5OXXXX, ANTIBODY, C3, C3d, CANCER, CB1XXX, Cell, Cells, Complement, Deposited, Listed LPM Vathyam as of 4/15/2015, Patent Category - Biotechnology, Post LPM Assignment Set 20150420, Potentiating, Pre LPM working set 20150418, Protein, Surface, Targeting, THERAPY, THEROF, VCXXXX False True True 52398218 Pre-Clinical (in vivo) 52398218 NIHTT 37470483 Website Abstract 114110416 Skarzynski, Martin National Heart, Lung, and Blood Institute (NHLBI) NHLBI Skarzynski, Martin (NHLBI) 0 114110417 Lindorfer, Margaret University of Virginia School of Medicine Lindorfer, Margaret 0 114110418 Taylor, Ronald University of Virginia School of Medicine Taylor, Ronald 0 114110419 Rader, Christoph The Scripps Research Institute, Scripps Florida NCI Rader, Christoph (NCI) 0 114110420 Vire, Berengere EraMiondi R&D Vire, Berengere 0 114110421 Gaglione, Erika National Heart, Lung, and Blood Institute (NHLBI) NHLBI Gaglione, Erika (NHLBI) 0 114110422 Peng, Haiyong The Scripps Research Institute, Scripps Florida Peng, Haiyong 0 114110423 Baskar, Sivasubramanian National Heart, Lung, and Blood Institute (NHLBI) NHLBI Baskar, Sivasubramanian (NHLBI) 0 114110415 Wiestner, Adrian National Heart, Lung, and Blood Institute (NHLBI) NHLBI Wiestner, Adrian (NHLBI) 1 114110415 Wiestner, Adrian National Heart, Lung, and Blood Institute (NHLBI) NHLBI Wiestner, Adrian (NHLBI) 1 114110416 Skarzynski, Martin National Heart, Lung, and Blood Institute (NHLBI) NHLBI Skarzynski, Martin (NHLBI) 0 114110417 Lindorfer, Margaret University of Virginia School of Medicine Lindorfer, Margaret 0 114110418 Taylor, Ronald University of Virginia School of Medicine Taylor, Ronald 0 114110419 Rader, Christoph The Scripps Research Institute, Scripps Florida NCI Rader, Christoph (NCI) 0 114110420 Vire, Berengere EraMiondi R&D Vire, Berengere 0 114110421 Gaglione, Erika National Heart, Lung, and Blood Institute (NHLBI) NHLBI Gaglione, Erika (NHLBI) 0 114110422 Peng, Haiyong The Scripps Research Institute, Scripps Florida Peng, Haiyong 0 114110423 Baskar, Sivasubramanian National Heart, Lung, and Blood Institute (NHLBI) NHLBI Baskar, Sivasubramanian (NHLBI) 0 114102610 Antibody Targeting Of Cell Surface Deposited Complement Protein C3 E-758-2013-0 Filing authorized EraMiondi R&D, National Heart, Lung, and Blood Institute (NHLBI), NCI, University of Virginia School of Medicine 114102611 Antibody Targeting Of Cell Surface Deposited Complement Protein C3d And Use Therof E-758-2013-1 Filing authorized EraMiondi R&D, National Heart, Lung, and Blood Institute (NHLBI), NCI, University of Virginia School of Medicine 114102612 Potentiating Antibody Therapy By Targeting Complement Deposited On Cancer Cells E-025-2019-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI), The Scripps Research Institute, Scripps Florida 83739538 Choudhry, Vidita vidita.choudhry@nih.gov
United States of America Office of Technology Transfer and Development vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-3496] Potentiating Antibody Therapy by Targeting Complement Deposited on Cancer Cells&body=Please send me information about technology [TAB-3496] Potentiating Antibody Therapy by Targeting Complement Deposited on Cancer Cells. Choudhry, Vidita<br><a href="mailto:vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-3496] Potentiating Antibody Therapy by Targeting Complement Deposited on Cancer Cells&body=Please send me information about technology [TAB-3496] Potentiating Antibody Therapy by Targeting Complement Deposited on Cancer Cells.">vidita.choudhry@nih.gov</a><br> 114169258 E-758-2013-0 E-758-2013-0-US-01 Antibody Targeting Cell Surface Deposited Complement Protein C3d and Use Thereof PRV US 61/924,967 Abandoned US <br />Provisional (PRV) 61/924,967<br />Filed on 2014-01-08<br />Status: Abandoned 114169259 E-758-2013-1 E-758-2013-1-PCT-01 Antibody Targeting Cell Surface Deposited Complement Protein C3d And Use Thereof PCT COMB Patent Cooperation Treaty PCT/US2015/010620 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2015/010620<br />Filed on 2015-01-08<br />Status: Expired 114169260 E-758-2013-1 E-758-2013-1-US-02 Antibody Targeting Cell Surface Deposited Complement Protein C3d And Use Therof National Stage US 10,035,848 15/110,577 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10035848 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10035848">10,035,848</a><br />Filed on 2016-07-08<br />Status: Issued 114169261 E-758-2013-1 E-758-2013-1-US-05 ANTIBODY TARGETING CELL SURFACE DEPOSITED COMPLEMENT PROTEIN C3d AND USE THEREOF CON US 11,384,139 16/047,929 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11384139 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11384139">11,384,139</a><br />Filed on 2018-07-27<br />Status: Issued 114169262 E-025-2019-0 E-025-2019-0-US-01 ANTIBODIES TARGETING CELL SURFACE DEPOSITED COMPLEMENT PROTEIN C3d AND USE THEREOF PRV US 62/945,569 Abandoned US <br />Provisional (PRV) 62/945,569<br />Filed on 2019-12-09<br />Status: Abandoned 114169263 E-025-2019-0 E-025-2019-0-PCT-02 ANTIBODIES TARGETING CELL SURFACE DEPOSITED COMPLEMENT PROTEIN C3D AND USE THEREOF PCT Patent Cooperation Treaty PCT/US2020/063809 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2020/063809<br />Filed on 2020-12-08<br />Status: Expired 114169554 E-025-2019-0 E-025-2019-0-US-03 ANTIBODIES TARGETING CELL SURFACE DEPOSITED COMPLEMENT PROTEIN C3d AND USE THEREOF National Stage US 17/783,345 Pending US <br />National Stage 17/783,345<br />Filed on 2022-06-08<br />Status: Pending 114128598 2JXXXX 114128599 4GXXXX 114128600 5OXXXX 114128601 CB1XXX 114128602 VCXXXX 114152645 ANTIBODY 114152646 Targeting 114152647 Cell 114152648 Surface 114152649 Complement 114152650 Protein 114152651 C3 114152652 Patent Category - Biotechnology 114152653 Listed LPM Vathyam as of 4/15/2015 114152654 Pre LPM working set 20150418 114152655 Post LPM Assignment Set 20150420 114152656 Deposited 114152657 C3d 114152658 THEROF 114152659 Cells 114152660 CANCER 114152661 THERAPY 114152662 Potentiating TAB-3493 114097357 Methods and Compositions for the Inhibition of PIN1 for the Treatment of Immune, Proliferative and Neurodegenerative Disorders NCATS Neurology, Oncology, Research Materials, Therapeutics Neurology Oncology Research Materials Therapeutics Matthew Boxer, Mindy Davis, Kun Ping Lu, Rajan Pragani, Min Shen, Anton Simeonov, Shuo Wei, Xiao Zhen Zhou This technology includes the compositions and methods for inhibiting PIN1 for the treatment of disorders characterized by elevated PIN1 levels (e.g., immune disorders, proliferative disorders, and neurodegenerative disorders) with small molecules. Pin1 dysregulation has been associated with a number of pathological conditions. In particular, PIN1 has been shown to promote oncogenesis by modulating several oncogenic signaling pathways and its overexpression has been shown to correlate with poor clinical outcome. There are no current drug-like small molecule inhibitors of PIN1 that could be used therapeutically. There are currently no drug-like small molecule inhibitors of PIN1. Inhibitors of PIN1 could be used to treat diseases such as: immune disorders, proliferative disorders, and neurodegenerative disorders. 2022-08-01 2024-10-28 2024-10-28 2022-08-01 2022-03-04 Compositions, inhibition, Listed LPM Vepa as of 4/15/2015, Methods, PIN1, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, VCXXXX, VEXXXX, WIXXXX, WKXXXX, XEXXXX False True True NIHTT 37470483 Website Abstract 114110399 Boxer, Matthew NCATS - NCGC Boxer, Matthew 0 114110400 Simeonov, Anton NCATS - NCGC NCATS Simeonov, Anton (NCATS) 0 114110401 Davis, Mindy NCATS - NCGC NCATS Davis, Mindy (NCATS) 0 114110402 Pragani, Rajan NCATS - NCGC FDA Pragani, Rajan (FDA) 0 114110403 Shen, Min NCATS - NCGC NCATS Shen, Min (NCATS) 0 114110405 Wei, Shuo Beth Israel Deaconess Medical Center Wei, Shuo 0 114110406 Zhou, Xiao Zhen Beth Israel Deaconess Medical Center Zhou, Xiao Zhen 0 114110404 Lu, Kun Ping Beth Israel Deaconess Medical Center Lu, Kun Ping 1 114110404 Lu, Kun Ping Beth Israel Deaconess Medical Center Lu, Kun Ping 1 114110399 Boxer, Matthew NCATS - NCGC Boxer, Matthew 0 114110400 Simeonov, Anton NCATS - NCGC NCATS Simeonov, Anton (NCATS) 0 114110401 Davis, Mindy NCATS - NCGC NCATS Davis, Mindy (NCATS) 0 114110402 Pragani, Rajan NCATS - NCGC FDA Pragani, Rajan (FDA) 0 114110403 Shen, Min NCATS - NCGC NCATS Shen, Min (NCATS) 0 114110405 Wei, Shuo Beth Israel Deaconess Medical Center Wei, Shuo 0 114110406 Zhou, Xiao Zhen Beth Israel Deaconess Medical Center Zhou, Xiao Zhen 0 114102607 METHODS AND COMPOSITIONS FOR THE INHIBITION OF PIN1 E-203-2012-0 Filing authorized Beth Israel Deaconess Medical Center, NCATS - NCGC 83682485 Vepa, Suryanarayana sury.vepa@nih.gov
United States of America Office of Strategic Alliances (OSA) sury.vepa@nih.gov?subject=Web Inquiry on [TAB-3493] Methods and Compositions for the Inhibition of PIN1 for the Treatment of Immune, Proliferative and Neurodegenerative Disorders&body=Please send me information about technology [TAB-3493] Methods and Compositions for the Inhibition of PIN1 for the Treatment of Immune, Proliferative and Neurodegenerative Disorders. Vepa, Suryanarayana<br><a href="mailto:sury.vepa@nih.gov?subject=Web Inquiry on [TAB-3493] Methods and Compositions for the Inhibition of PIN1 for the Treatment of Immune, Proliferative and Neurodegenerative Disorders&body=Please send me information about technology [TAB-3493] Methods and Compositions for the Inhibition of PIN1 for the Treatment of Immune, Proliferative and Neurodegenerative Disorders.">sury.vepa@nih.gov</a><br> 114169251 E-203-2012-0 E-203-2012-0-US-01 METHODS AND COMPOSITIONS FOR THE INHIBITION OF PIN1 PRV US 61/656,806 Abandoned US <br />Provisional (PRV) 61/656,806<br />Filed on 2012-06-07<br />Status: Abandoned 114169252 E-203-2012-0 E-203-2012-0-PCT-02 METHODS AND COMPOSITIONS FOR THE INHIBITION OF PIN1 PCT Patent Cooperation Treaty PCT/US2013/044747 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2013/044747<br />Filed on 2013-06-07<br />Status: Expired 114169253 E-203-2012-0 E-203-2012-0-US-07 METHODS AND COMPOSITIONS FOR THE INHIBITION OF PIN1 National Stage US 9,730,941 14/406,401 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9730941 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9730941">9,730,941</a><br />Filed on 2014-12-08<br />Status: Issued 114169254 E-203-2012-0 E-203-2012-0-US-08 METHODS AND COMPOSITIONS FOR THE INHIBITION OF PIN1 CON US 10,413,548 15/645,683 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10413548 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10413548">10,413,548</a><br />Filed on 2017-07-10<br />Status: Issued 114169255 E-203-2012-0 E-203-2012-0-US-12 METHODS AND COMPOSITIONS FOR THE INHIBITION OF PIN1 CON US 11,129,835 16/570,470 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11129835 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11129835">11,129,835</a><br />Filed on 2019-09-13<br />Status: Issued 114128587 VCXXXX 114128588 VEXXXX 114128589 WKXXXX 114128590 WIXXXX 114128591 XEXXXX 114152619 Methods 114152620 Compositions 114152621 inhibition 114152622 PIN1 114152623 Listed LPM Vepa as of 4/15/2015 114152624 Pre LPM working set 20150418 114152625 Post LPM Assignment Set 20150420 TAB-3494 114097358 Use of Repurposed Drugs and Combinations of Proteasome Inhibitors and Topoisomerase Inhibitors for the Treatment of Chordoma NCATS Oncology, Research Materials, Therapeutics Oncology Research Materials Therapeutics Christopher Austin, Ruili Huang, Menghang Xia This technology includes a group of 20 drugs that can be further developed as a treatment for chordoma. Chordoma is a rare, slow-growing malignant tumor arising from remnants of the fetal notochord, with a high recurrence rate and no effective chemotherapy agents. These 20 drugs inhibited chordoma cell growth, with potencies ranging from 10 to 370 nM in the chordoma cell line UCH1 cells. These agents also had significant inhibitory effects on chordoma patient cells, C24, C25, and C32. Furthermore, a combination treatment of proteasome inhibitors, such as bortezomib and MG-132, with topoisomerase inhibitors, such as topotecan, rubitecan, camptothecin, doxorubicin, and daunomycin, significantly increased the therapeutic potency in the human chordoma cell line, UCH2, and primary chordoma patient cells, C24, C25, and C32. Currently, there are no effective chemotherapy agents available for treating chordoma and since many of these agents have been previously tested or approved for use in humans or animals, they are good candidates as chemotherapeutic agents for chordoma. The individual drugs and drug combinations in this technology may be further developed for chordoma treatment. 2022-08-01 2024-10-28 2024-10-28 2022-08-01 2022-03-04 CB5EXX, Chordoma, Combinations, DRUGS, Inhibitors, Listed LPM Chatterjee as of 4/15/2015, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Proteasome, Repurposed, TOPOISOMERASE, treatment, USES, VCXXXX, WIXXXX, WKXXXX False True True NIHTT 37470483 Website Abstract 114110408 Huang, Ruili NCATS - NCGC NCATS Huang, Ruili (NCATS) 0 114110409 Austin, Christopher NCATS - NCGC NCATS Austin, Christopher (NCATS) 0 114110407 Xia, Menghang NCATS - NCGC NCATS Xia, Menghang (NCATS) 1 114110407 Xia, Menghang NCATS - NCGC NCATS Xia, Menghang (NCATS) 1 114110408 Huang, Ruili NCATS - NCGC NCATS Huang, Ruili (NCATS) 0 114110409 Austin, Christopher NCATS - NCGC NCATS Austin, Christopher (NCATS) 0 114102608 Uses Of Repurposed Drugs And Combinations Of Proteasome Inhibitors And Topoisomerase Inhibitors For The Treatment Of Chordoma E-156-2012-0 Filing authorized NCATS - NCGC 83682485 Vepa, Suryanarayana sury.vepa@nih.gov
United States of America Office of Strategic Alliances (OSA) sury.vepa@nih.gov?subject=Web Inquiry on [TAB-3494] Use of Repurposed Drugs and Combinations of Proteasome Inhibitors and Topoisomerase Inhibitors for the Treatment of Chordoma&body=Please send me information about technology [TAB-3494] Use of Repurposed Drugs and Combinations of Proteasome Inhibitors and Topoisomerase Inhibitors for the Treatment of Chordoma. Vepa, Suryanarayana<br><a href="mailto:sury.vepa@nih.gov?subject=Web Inquiry on [TAB-3494] Use of Repurposed Drugs and Combinations of Proteasome Inhibitors and Topoisomerase Inhibitors for the Treatment of Chordoma&body=Please send me information about technology [TAB-3494] Use of Repurposed Drugs and Combinations of Proteasome Inhibitors and Topoisomerase Inhibitors for the Treatment of Chordoma.">sury.vepa@nih.gov</a><br> 114169256 E-156-2012-0 E-156-2012-0-US-01 Cancer Treatment by Combined Inhibition of Proteasome and Topoisomerase Activities PRV US 61/692,560 Abandoned US <br />Provisional (PRV) 61/692,560<br />Filed on 2012-08-23<br />Status: Abandoned 114128592 CB5EXX 114128593 VCXXXX 114128594 WIXXXX 114128595 WKXXXX 114152626 USES 114152627 Repurposed 114152628 DRUGS 114152629 Combinations 114152630 Proteasome 114152631 Inhibitors 114152632 TOPOISOMERASE 114152633 treatment 114152634 Chordoma 114152635 Listed LPM Chatterjee as of 4/15/2015 114152636 Pre LPM working set 20150418 114152637 Post LPM Assignment Set 20150420 TAB-3492 114097356 APLS Method to Screen Libraries by Multiplex Gene Expression NCATS Medical Devices, Non-Medical Devices, Research Equipment, Research Materials, Therapeutics Medical Devices Non-Medical Devices Research Equipment Research Materials Therapeutics John Braisted, Pei-Hsuan Chu, David Gerhold, Hyun Hee Kim, David Kuo This technology includes the use of the Anneal-Pool-Ligate-Sequence method (APLS) to quantify the cellular expression of dozens of genes for high throughput chemical library screening. This method is performed by culturing eucaryotic cells in 384-well format microplates, treating the cells with a library of chemicals, and producing cell lysates. Oligodeoxynucleotide (oligo) pairs representing (21) selected genes, and carrying index sequences for each well (384) and microplate (26), are annealed to mRNAs in cell lysates. Pools of ligated oligo-pairs are amplified by PCR and subjected to “Next-Generation Sequencing” en-masse. Gene sequences are mapped to individual treated cell samples using index sequences for each sample and counted to determine which genes were up- or down-regulated by each treatment. This method demonstrates quantitation of expression using 21 genes in 9984 samples (26 microplates x 384-wells) in a single day using only 26 PCR reactions. This technology could be used to identify leads and optimize drug candidates for target selectivity and in vitro safety assessment. 2022-08-01 2024-10-28 2024-10-28 2022-08-01 2022-03-02 APLS, Expression, Gene, Libraries, Method, Multiplex, SCREEN, WIXXXX, WKXXXX, XDXXXX, XHXXXX False True True NIHTT 37470483 Website Abstract 114172652 Landegren U, Kaiser R, et al. https://pubmed.ncbi.nlm.nih.gov/3413476/ <a href="https://pubmed.ncbi.nlm.nih.gov/3413476/">Landegren U, Kaiser R, et al.</a> 114172653 Li H, Qiu J, et al. https://pubmed.ncbi.nlm.nih.gov/22470064/ <a href="https://pubmed.ncbi.nlm.nih.gov/22470064/">Li H, Qiu J, et al.</a> 114172654 Simon J, Paranjape S, et al. https://pubmed.ncbi.nlm.nih.gov/30872602/ <a href="https://pubmed.ncbi.nlm.nih.gov/30872602/">Simon J, Paranjape S, et al.</a> 114110395 Kim, Hyun Hee NCATS - NCGC NCATS Kim, Hyun Hee (NCATS) 0 114110396 Chu, Pei-Hsuan NCATS - NCGC NCATS Chu, Pei-Hsuan (NCATS) 0 114110397 Braisted, John NCATS - NCGC NCATS Braisted, John (NCATS) 0 114110398 Kuo, David NCATS - NCGC NCATS Kuo, David (NCATS) 0 114110394 Gerhold, David NCATS - NCGC NCATS Gerhold, David (NCATS) 1 114110394 Gerhold, David NCATS - NCGC NCATS Gerhold, David (NCATS) 1 114110395 Kim, Hyun Hee NCATS - NCGC NCATS Kim, Hyun Hee (NCATS) 0 114110396 Chu, Pei-Hsuan NCATS - NCGC NCATS Chu, Pei-Hsuan (NCATS) 0 114110397 Braisted, John NCATS - NCGC NCATS Braisted, John (NCATS) 0 114110398 Kuo, David NCATS - NCGC NCATS Kuo, David (NCATS) 0 114102606 APLS Method To Screen Libraries By Multiplex Gene Expression E-040-2021-0 Filing authorized NCATS - NCGC 83673536 Erwin-Cohen, Rebecca rebecca.erwin-cohen@nih.gov
NCGC rebecca.erwin-cohen@nih.gov?subject=Web Inquiry on [TAB-3492] APLS Method to Screen Libraries by Multiplex Gene Expression&body=Please send me information about technology [TAB-3492] APLS Method to Screen Libraries by Multiplex Gene Expression. Erwin-Cohen, Rebecca<br><a href="mailto:rebecca.erwin-cohen@nih.gov?subject=Web Inquiry on [TAB-3492] APLS Method to Screen Libraries by Multiplex Gene Expression&body=Please send me information about technology [TAB-3492] APLS Method to Screen Libraries by Multiplex Gene Expression.">rebecca.erwin-cohen@nih.gov</a><br> 114169248 E-040-2021-0 E-040-2021-0-US-01 Method To Screen Libraries By Multiplex Gene Expression PRV US 63/196,438 Abandoned US <br />Provisional (PRV) 63/196,438<br />Filed on 2021-06-03<br />Status: Abandoned 114128583 WIXXXX 114128584 WKXXXX 114128585 XDXXXX 114128586 XHXXXX 114152612 APLS 114152613 Method 114152614 SCREEN 114152615 Libraries 114152616 Multiplex 114152617 Gene 114152618 Expression TAB-3489 114097353 Process for Synthesis of VBP15 as a Treatment for Duchenne Muscular Dystrophy NCATS Cardiology, Dental, Endocrinology, Infectious Disease, Oncology, Ophthalmology, Therapeutics Cardiology Dental Endocrinology Infectious Disease Oncology Ophthalmology Therapeutics Asaf Alimardanov, Mark Behnke, Marco Burello, John McCall, Charla Ramsey This technology includes processes for the synthesis of VBP15 (17a,21-dihydroxy-16a-methyl-pregna-1,4,9(11)-triene-3,20-dione) of high purity and large quantities as a treatment for Duchenne muscular dystrophy. The synthesis of VBP15 has several deficiencies which has hindered larger-scale preparation for clinical evaluation and potential manufacturing. The deficiencies included formation of significant levels of undesired epoxide impurity, formation of undesired ketone impurity, and resultant need for costly chromatographic purification. This new method relies on oxidizing agent (peracetic acid) that is typically not used for similar substrates (MCPBA is usually utilized), allows oxidation under milder conditions, and generates lower levels of epoxide impurity. The method also uses treatment with hydrogen bromide in a biphasic aqueous-organic solvent system to selectively decompose epoxide impurity to easily removable by-products. <ul> <li>Avoids use of costly extensive chromatographic purification</li> <li>Allows preparation of VBP15 with purity level acceptable for clinical use, including epoxide content below limit of detection of typical HPLC analytical method.</li> </ul> The method allows manufacture of clinical and commercial quantities of VBP15, which is being investigated as a potential treatment for Duchenne muscular dystrophy. 2022-08-01 2024-10-28 2024-10-28 2022-08-01 2022-03-01 17alpha21-dihydroxy-16?-methyl-pregna-1, 17alpha21-dihydroxy-16alpha-methyl-pregna-1, 20-dione., 4, 911-triene-3, Listed LPM Nguyen-Antczak as of 4/15/2015, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, PROCESS, Synthesis, VPXXXX, WKXXXX False True True NIHTT 37470483 Website Abstract 114110364 Behnke, Mark NCATS - TRND NCATS Behnke, Mark (NCATS) 0 114110366 McCall, John ReveraGen BioPharma Inc. McCall, John 0 114110367 Ramsey, Charla Ricerca Biosciences, LLC Ramsey, Charla 0 114110368 Burello, Marco Ricerca Biosciences, LLC Burello, Marco 0 114110365 Alimardanov, Asaf NCATS - NCGC NCATS Alimardanov, Asaf (NCATS) 1 114110365 Alimardanov, Asaf NCATS - NCGC NCATS Alimardanov, Asaf (NCATS) 1 114110364 Behnke, Mark NCATS - TRND NCATS Behnke, Mark (NCATS) 0 114110366 McCall, John ReveraGen BioPharma Inc. McCall, John 0 114110367 Ramsey, Charla Ricerca Biosciences, LLC Ramsey, Charla 0 114110368 Burello, Marco Ricerca Biosciences, LLC Burello, Marco 0 114102603 Process For Synthesis Of 17alpha21-dihydroxy-16alpha-methyl-pregna-1,4,9(11)-triene-3,20-dione. E-152-2014-0 Filing authorized NCATS - NCGC, ReveraGen BioPharma Inc., Ricerca Biosciences, LLC, Ricerca Biosciences, LLC 83682485 Vepa, Suryanarayana sury.vepa@nih.gov
United States of America Office of Strategic Alliances (OSA) sury.vepa@nih.gov?subject=Web Inquiry on [TAB-3489] Process for Synthesis of VBP15 as a Treatment for Duchenne Muscular Dystrophy&body=Please send me information about technology [TAB-3489] Process for Synthesis of VBP15 as a Treatment for Duchenne Muscular Dystrophy. Vepa, Suryanarayana<br><a href="mailto:sury.vepa@nih.gov?subject=Web Inquiry on [TAB-3489] Process for Synthesis of VBP15 as a Treatment for Duchenne Muscular Dystrophy&body=Please send me information about technology [TAB-3489] Process for Synthesis of VBP15 as a Treatment for Duchenne Muscular Dystrophy.">sury.vepa@nih.gov</a><br> 114128574 VPXXXX 114128575 WKXXXX 114152577 PROCESS 114152578 Synthesis 114152579 17alpha21-dihydroxy-16?-methyl-pregna-1 114152580 4 114152581 911-triene-3 114152582 20-dione. 114152583 17alpha21-dihydroxy-16alpha-methyl-pregna-1 114152584 Listed LPM Nguyen-Antczak as of 4/15/2015 114152585 Pre LPM working set 20150418 114152586 Post LPM Assignment Set 20150420 TAB-3488 114097352 A Scalable Synthesis of Dual-Target Inhibitor of Cannabinoid-1 Receptor and Inducible Nitric Oxide Synthase NCATS Endocrinology, Licensing, Therapeutics Endocrinology Licensing Therapeutics Asaf Alimardanov, Junfeng Huang The present invention is directed to a synthesis of a dual-target inhibitor of cannabinoid-1 (CB1R) receptor and inducible nitric oxide synthase, and more specifically, to an improved process for synthesis of (S,1E,NE)-N-(1-aminoethylidene)-3-(4-chlorophenyl)-4-phenyl-N'-((4-(trifluoromethyl)phenyl)sulfonyl)-4,5-dihydro-1H-pyrazole-1-carboximidamide. This process to produce S-MRI1867 is more time efficient and cost effective. It gives a new version to synthesis the compounds with the core structure similar to S-MRI1867. This new route and process to synthesis S-MRI1867 without chromatography can be easily adapted to GMP manufacture to produce S-MRI1867 for clinical studies and further commercial production. 2022-04-06 2024-10-28 2024-10-28 2022-04-06 2022-03-01 1867, 5-dihydro-1, both, Bothcannabinoid-1, Cannabinoid-1, CB1, CB1R, Dual, H-pyrazole-1-carboximidamide, INDUCIBLE, inhibitor, iNOS., Intermediates, NITRIC, OXIDE, PREPARATION, PROCESS, r, RECEPTOR, S-MRI, S-N--1-aminoethylidene-3-4-chlorophenyl-4-phe, SYNTHASE, Synthesis, VFXXXX, WKXXXX False True True NIHTT 37470483 Website Abstract 114172678 Cinar R, et al. https://pubmed.ncbi.nlm.nih.gov/34323400/ <a href="https://pubmed.ncbi.nlm.nih.gov/34323400/">Cinar R, et al.</a> 114110363 Huang, Junfeng NCATS - TRND NCATS Huang, Junfeng (NCATS) 0 114110362 Alimardanov, Asaf NCATS - NCGC NCATS Alimardanov, Asaf (NCATS) 1 114110362 Alimardanov, Asaf NCATS - NCGC NCATS Alimardanov, Asaf (NCATS) 1 114110363 Huang, Junfeng NCATS - TRND NCATS Huang, Junfeng (NCATS) 0 114102602 Process And Intermediates For Preparation Of (S)-N--1-aminoethylidene)-3-(4-chlorophenyl)-4-phenyl-N'-((-(trifluoromethyl)phenyl)sulfonyl)-4,5-dihydro-1 H-pyrazole-1-carboximidamide (S-MRI 1867) As A Dual Inhibitor Of Both Cannabinoid-1 Receptor (CB1 E-098-2019-0 Filing authorized NCATS - NCGC 83727060 Gadhia, Ami ami.gadhia@nih.gov
United States of America NCGC ami.gadhia@nih.gov?subject=Web Inquiry on [TAB-3488] A Scalable Synthesis of Dual-Target Inhibitor of Cannabinoid-1 Receptor and Inducible Nitric Oxide Synthase&body=Please send me information about technology [TAB-3488] A Scalable Synthesis of Dual-Target Inhibitor of Cannabinoid-1 Receptor and Inducible Nitric Oxide Synthase. Gadhia, Ami<br><a href="mailto:ami.gadhia@nih.gov?subject=Web Inquiry on [TAB-3488] A Scalable Synthesis of Dual-Target Inhibitor of Cannabinoid-1 Receptor and Inducible Nitric Oxide Synthase&body=Please send me information about technology [TAB-3488] A Scalable Synthesis of Dual-Target Inhibitor of Cannabinoid-1 Receptor and Inducible Nitric Oxide Synthase.">ami.gadhia@nih.gov</a><br> 114169235 E-098-2019-0 E-098-2019-0-US-01 A SCALABLE SYNTHESIS OF DUAL-TARGET INHIBITOR OF CANNABINOID-1 RECEPTOR AND INDUCIBLE NITRIC OXIDE SYNTHASE PRV US 62/849,193 Abandoned US <br />Provisional (PRV) 62/849,193<br />Filed on 2019-05-17<br />Status: Abandoned 114169236 E-098-2019-0 E-098-2019-0-PCT-02 SCALABLE SYNTHESIS OF DUAL-TARGET INHIBITOR OF CANNABINOID-1 RECEPTOR AND INDUCIBLE NITRIC OXIDE SYNTHASE PCT Patent Cooperation Treaty PCT/US2020/030624 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2020/030624<br />Filed on 2020-04-30<br />Status: Expired 114169237 E-098-2019-0 E-098-2019-0-US-03 A SCALABLE SYNTHESIS OF DUAL-TARGET INHIBITOR OF CANNABINOID-1 RECEPTOR AND INDUCIBLE NITRIC OXIDE SYNTHASE National Stage US 12,286,405 17/610,537 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12286405 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12286405">12,286,405</a><br />Filed on 2021-11-11<br />Status: Issued 114128572 VFXXXX 114128573 WKXXXX 114152556 PROCESS 114152557 Intermediates 114152558 PREPARATION 114152559 S-N--1-aminoethylidene-3-4-chlorophenyl-4-phe 114152560 5-dihydro-1 114152561 H-pyrazole-1-carboximidamide 114152562 S-MRI 114152563 1867 114152564 Dual 114152565 inhibitor 114152566 Bothcannabinoid-1 114152567 RECEPTOR 114152568 CB1 114152569 r 114152570 INDUCIBLE 114152571 NITRIC 114152572 OXIDE 114152573 SYNTHASE 114152574 iNOS. 114152575 both 114152576 Cannabinoid-1 114152888 Synthesis 114152892 CB1R TAB-3483 114097348 Compositions and Methods for Treating Cancers NCATS Oncology, Research Materials, Therapeutics Oncology Research Materials Therapeutics Catherine Chen, John McKew, Aaron Schimmer, Noel Southall, Wei Zheng This technology includes the combination therapy of tyrosine kinase inhibitors (TKIs) and tigecycline as a potential new treatment for acute myeloid leukemia (AML). The existing treatments available for AML are not adequate; for patients older than 60, the prognosis is poor, with a two-year survival probability of less than 10%. Tigecycline is a glycylcycline antibiotic that induces cell death via inhibition of mitochondrial protein synthesis. Research in cell lines shows that the following group of TKIs exhibited the synergistic effect with tigecycline for killing AML cells: Erlotinib (EGFR inhibitor), Bosutinib (BCR-Abl, MOR inhibitor), Dasatinib (BCR-Abl, Src inhibitor), Sunitinib (Multiple RTK inhibitor) and Vandetinib (EGFR, VEGFR inhibitor). Current treatment approaches to AML are severely lacking and novel therapeutic strategies are essential. The combination therapy of TKI and tigecycline is a potential new treatment for AML. 2022-08-01 2024-10-28 2024-10-28 2022-08-01 2022-02-22 cancers, Compositions, Listed LPM Campbell as of 4/15/2015, Methods, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, TREATING, VCXXXX, WIXXXX, WKXXXX False True True NIHTT 37470483 Website Abstract 114110341 Zheng, Wei NCATS - TRND NCATS Zheng, Wei (NCATS) 0 114110343 McKew, John NCATS - TRND McKew, John 0 114110344 Chen, Catherine NCATS - TRND Chen, Catherine 0 114110345 Southall, Noel NCATS - TRND NCATS Southall, Noel (NCATS) 0 114110342 Schimmer, Aaron University of Toronto Schimmer, Aaron 1 114110342 Schimmer, Aaron University of Toronto Schimmer, Aaron 1 114110341 Zheng, Wei NCATS - TRND NCATS Zheng, Wei (NCATS) 0 114110343 McKew, John NCATS - TRND McKew, John 0 114110344 Chen, Catherine NCATS - TRND Chen, Catherine 0 114110345 Southall, Noel NCATS - TRND NCATS Southall, Noel (NCATS) 0 114102598 Compositions And Methods For Treating Cancers E-277-2012-0 Filing authorized NCATS - NCGC, University of Toronto 83682485 Vepa, Suryanarayana sury.vepa@nih.gov
United States of America Office of Strategic Alliances (OSA) sury.vepa@nih.gov?subject=Web Inquiry on [TAB-3483] Compositions and Methods for Treating Cancers&body=Please send me information about technology [TAB-3483] Compositions and Methods for Treating Cancers. Vepa, Suryanarayana<br><a href="mailto:sury.vepa@nih.gov?subject=Web Inquiry on [TAB-3483] Compositions and Methods for Treating Cancers&body=Please send me information about technology [TAB-3483] Compositions and Methods for Treating Cancers.">sury.vepa@nih.gov</a><br> 114169225 E-277-2012-0 E-277-2012-0-US-01 Compositions And Methods For Treating Cancers PRV US 61/692,843 Abandoned US <br />Provisional (PRV) 61/692,843<br />Filed on 2012-08-24<br />Status: Abandoned 114169226 E-277-2012-0 E-277-2012-0-PCT-02 COMPOSITIONS COMPRISING A GLYCYLCYCLINE AND A TYROSINE KINASE INHIBITOR FOR TREATING CANCER PCT Patent Cooperation Treaty PCT/CA2013/000742 Expired Patent Cooperation Treaty <br />(PCT) PCT/CA2013/000742<br />Filed on 2013-08-23<br />Status: Expired 114128559 VCXXXX 114128560 WKXXXX 114128561 WIXXXX 114152523 cancers 114152524 TREATING 114152525 Methods 114152526 Compositions 114152527 Listed LPM Campbell as of 4/15/2015 114152528 Pre LPM working set 20150418 114152529 Post LPM Assignment Set 20150420 TAB-3484 114097349 Benchtop Solid Phase Extractor NCATS Medical Devices, Non-Medical Devices, Research Materials Medical Devices Non-Medical Devices Research Materials Pranav Bende, Alexander Godfrey, Vishakha Goyal, Samuel Michael, Meghav Verma This technology includes a device to allow chemists to process crude reaction mixtures with the objective of isolating the desired product from reaction by-products and other solvents and impurities to provide material of adequate quality and purity to be submitted for further chromatographic purification or used directly in subsequent reactions. The instrument serves in facilitating the integration of a close-to-universal set of isolation techniques collectively referred to as “solid-phase extraction” (SPE) methods. Alternatively, depending on the overall chemistry objective sought by the user, the media may also selectively absorb impurities or byproducts while desired material is eluted through the media. <ul> <li>Level sensing using state of the art vision system. Used to provide closed loop control of the liquid transfer process.</li> <li>Ability to stage different size of SPE’s using cartridge adapters developed in-house.</li> <li>Ability to stage multiple SPE’s and quickly swap from one to next.</li> </ul> Such an instrument could become an important productivity-enhancing instrument that chemists could use at the bench much like they use personal chromatography equipment today, and could also be integrated into a component to an automated chemical synthesis apparatus. 2022-08-01 2024-10-28 2024-10-28 2022-08-01 2022-02-22 Benchtop, Extractor, PHASE, SOLID, WIXXXX, XDXXXX False True True NIHTT 37470483 Website Abstract 114110347 Verma, Meghav NCATS - NCGC NCATS Verma, Meghav (NCATS) 0 114110348 Goyal, Vishakha NCATS - NCGC NCATS Goyal, Vishakha (NCATS) 0 114110349 Bende, Pranav NCATS - TRND NCATS Bende, Pranav (NCATS) 0 114110350 Michael, Samuel NCATS - NCGC NCATS Michael, Samuel (NCATS) 0 114110346 Godfrey, Alexander NCATS - TRND NCATS Godfrey, Alexander (NCATS) 1 114110346 Godfrey, Alexander NCATS - TRND NCATS Godfrey, Alexander (NCATS) 1 114110347 Verma, Meghav NCATS - NCGC NCATS Verma, Meghav (NCATS) 0 114110348 Goyal, Vishakha NCATS - NCGC NCATS Goyal, Vishakha (NCATS) 0 114110349 Bende, Pranav NCATS - TRND NCATS Bende, Pranav (NCATS) 0 114110350 Michael, Samuel NCATS - NCGC NCATS Michael, Samuel (NCATS) 0 114102599 Benchtop Solid Phase Extractor E-039-2021-0 Filing authorized NCATS - NCGC 83673536 Erwin-Cohen, Rebecca rebecca.erwin-cohen@nih.gov
NCGC rebecca.erwin-cohen@nih.gov?subject=Web Inquiry on [TAB-3484] Benchtop Solid Phase Extractor&body=Please send me information about technology [TAB-3484] Benchtop Solid Phase Extractor. Erwin-Cohen, Rebecca<br><a href="mailto:rebecca.erwin-cohen@nih.gov?subject=Web Inquiry on [TAB-3484] Benchtop Solid Phase Extractor&body=Please send me information about technology [TAB-3484] Benchtop Solid Phase Extractor.">rebecca.erwin-cohen@nih.gov</a><br> 114169227 E-039-2021-0 E-039-2021-0-US-01 METHODS AND SYSTEMS FOR SOLID PHASE EXTRACTION PRV US 63/161,851 Abandoned US <br />Provisional (PRV) 63/161,851<br />Filed on 2021-03-16<br />Status: Abandoned 114169284 E-039-2021-0 E-039-2021-0-PCT-02 METHODS AND SYSTEMS FOR SOLID PHASE EXTRACTION PCT Patent Cooperation Treaty PCT/US2022/020596 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2022/020596<br />Filed on 2022-03-16<br />Status: Expired 114128562 WIXXXX 114128563 XDXXXX 114152530 Benchtop 114152531 SOLID 114152532 PHASE 114152533 Extractor TAB-3481 114097343 OASIS: Automated brain lesion detection using cross-sectional multimodal magnetic resonance imaging NINDS Diagnostics, Licensing, Medical Devices, Neurology, Non-Medical Devices, Research Materials, Software / Apps Diagnostics Licensing Medical Devices Neurology Non-Medical Devices Research Materials Software / Apps Ciprian Crainiceanu, Arthur Goldsmith, Dzung Pham, Daniel Reich, Navid Shiee, Russell Shinohara, Elizabeth Sweeney This invention is a novel statistical method for automatically detecting lesions in cross-sectional brain magnetic resonance imaging (MRI) studies. OASIS uses multimodal MRI from one image acquisition session and produces voxel-level probability maps of the brain that quantifies the likelihood that each voxel is part of a lesion. Binary lesion segmentations are created from these probability maps using a validated population-level threshold. In this application, fluid attenuated inversion recovery (FLAIR), proton density (PD), T2-weighted, and Tl-weighted volumes were used. The OASIS lesion segmentations are robust to changes in imaging centers and scanning parameters. <ul> <li>Use of a robust intensity normalization procedure that allows it to be employed in large population samples from different imaging centers</li> <li>The built-in spatial normalization procedure permits the method to be more successful in segmenting certain areas of the brain</li> <li>Training data from one imaging center was used and validated on data from a separate center to illustrate the robustness of the procedure to different imaging centers and MRI scanning parameters</li> <li>Actual lesion detection is relatively fast</li> </ul> Traditionally trained observers do lesion identification and quantification manually on each MRI image. But this manual quantification is slow and prone to human error. There are many available methods for automated lesion segmentation. These methods are often tuned to one dataset and do not generalize to new datasets with different scanning parameters. The OASIS statistical method provides a fully automated, sensitive, and specific method for lesion segmentation that easily generalizes to new datasets. 2022-03-08 2024-10-28 2024-10-28 2022-02-08 Automated, brain, CNRM CRADA, Cross, Detection, IMAGING, Lesion, Listed LPM Shmilovich as of 4/15/2015, Magnetic, MULTIMODALITY, OASIS:, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Resonance, SECTIONAL, software, VEXXXX, WBXXXX, WIXXXX, XFXXXX False True True NIHTT 37470483 Website Abstract 114172638 Sweeney EM, Shinohara RT, et al. https://pubmed.ncbi.nlm.nih.gov/24179794/ <a href="https://pubmed.ncbi.nlm.nih.gov/24179794/">Sweeney EM, Shinohara RT, et al.</a> 114110330 Crainiceanu, Ciprian Johns Hopkins University Crainiceanu, Ciprian 0 114110331 Sweeney, Elizabeth Johns Hopkins University Sweeney, Elizabeth 0 114110332 Shinohara, Russell Johns Hopkins University Shinohara, Russell 0 114110333 Goldsmith, Arthur Columbia University Goldsmith, Arthur 0 114110334 Shiee, Navid Henry M. Jackson Foundation (HJF) Shiee, Navid 0 114110335 Pham, Dzung Henry M. Jackson Foundation (HJF) Pham, Dzung 0 114110329 Reich, Daniel NINDS NINDS Reich, Daniel (NINDS) 1 114110329 Reich, Daniel NINDS NINDS Reich, Daniel (NINDS) 1 114110330 Crainiceanu, Ciprian Johns Hopkins University Crainiceanu, Ciprian 0 114110331 Sweeney, Elizabeth Johns Hopkins University Sweeney, Elizabeth 0 114110332 Shinohara, Russell Johns Hopkins University Shinohara, Russell 0 114110333 Goldsmith, Arthur Columbia University Goldsmith, Arthur 0 114110334 Shiee, Navid Henry M. Jackson Foundation (HJF) Shiee, Navid 0 114110335 Pham, Dzung Henry M. Jackson Foundation (HJF) Pham, Dzung 0 114102596 OASIS: Automated Brain Lesion Detection Using Cross Sectional Multimodality Magnetic Resonance Imaging E-025-2013-0 Filing authorized Columbia University, Henry M. Jackson Foundation (HJF), Johns Hopkins University, NINDS 83722849 Sharma, Smita smita.sharma@nih.gov
United States of America smita.sharma@nih.gov?subject=Web Inquiry on [TAB-3481] OASIS: Automated brain lesion detection using cross-sectional multimodal magnetic resonance imaging&body=Please send me information about technology [TAB-3481] OASIS: Automated brain lesion detection using cross-sectional multimodal magnetic resonance imaging. Sharma, Smita<br><a href="mailto:smita.sharma@nih.gov?subject=Web Inquiry on [TAB-3481] OASIS: Automated brain lesion detection using cross-sectional multimodal magnetic resonance imaging&body=Please send me information about technology [TAB-3481] OASIS: Automated brain lesion detection using cross-sectional multimodal magnetic resonance imaging.">smita.sharma@nih.gov</a><br> 114169220 E-025-2013-0 E-025-2013-0-US-01 OASIS: Automated Brain Lesion Detection Using Cross Sectional Multimodality Magnetic Resonance Imaging PRV US 61/613,569 Abandoned US <br />Provisional (PRV) 61/613,569<br />Filed on 2012-03-21<br />Status: Abandoned 114169221 E-025-2013-0 E-025-2013-0-PCT-02 A METHOD OF ANALYZING MULTI-SEQUENCE MRI DATA FOR ANALYSING BRAIN ABNORMALITIES IN A SUBJECT PCT Patent Cooperation Treaty PCT/US2013/033334 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2013/033334<br />Filed on 2013-03-21<br />Status: Expired 114169222 E-025-2013-0 E-025-2013-0-US-03 METHOD OF ANALYZING MULTI-SEQUENCE MRI DATA FOR ANALYSING BRAIN ABNORMALITIES IN A SUBJECT National Stage US 9,888,876 14/385,509 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9888876 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9888876">9,888,876</a><br />Filed on 2014-09-16<br />Status: Issued 114128555 VEXXXX 114128556 WBXXXX 114128557 WIXXXX 114128558 XFXXXX 114152501 OASIS: 114152502 Automated 114152503 brain 114152504 Lesion 114152505 Detection 114152506 Cross 114152507 SECTIONAL 114152508 MULTIMODALITY 114152509 Magnetic 114152510 Resonance 114152511 IMAGING 114152512 CNRM CRADA 114152513 Listed LPM Shmilovich as of 4/15/2015 114152514 Pre LPM working set 20150418 114152515 Post LPM Assignment Set 20150420 114152516 software TAB-3480 114097346 Development of a Polyclonal Antibody for Neuroligin 4 pThr707 and a Polyclonal Antibody for Neuroligin 1 pTHR739 NINDS Antibodies, Diagnostics, Immunology, Neurology, Research Materials Antibodies Diagnostics Immunology Neurology Research Materials John Badger, Michael Bemben, Katherine Roche This invention includes the generation and use of two polyclonal antibodies that specifically recognizes the phosphorylation site pThr707 of Neuroligin 4 and pThr739 of Neuroligin 1. A peptide of the site around the phosphorylation site was generated and injected into rabbits to create an immune response. Serum was collected from the rabbits that was then affinity purified. The specificity of the resulting polyclonal antibodies was then determined using biochemical techniques. These antibodies are specific to the sites and can be used to detect phosphorylation of the amino acid at this specific site. The polyclonal antibodies can be used for studying phosphorylated Neuroligin 1 and Neuroligin 4. 2022-06-02 2024-10-28 2024-10-28 2022-06-02 2022-05-04 1, 4, ANTIBODY, Development, Listed LPM Contreras as of 4/15/2015, Neuroligin, polyclonal, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, PThr707, THR739, VEXXXX, WBXXXX, WIXXXX, XAXXXX False True True NIHTT 37470483 Website Abstract 114172636 Bemben MA, Nguyen Q-A, et al. https://pubmed.ncbi.nlm.nih.gov/25675530/ <a href="https://pubmed.ncbi.nlm.nih.gov/25675530/">Bemben MA, Nguyen Q-A, et al.</a> 114172637 Bemben MA, Shipman SL, et al. https://pubmed.ncbi.nlm.nih.gov/24336150/ <a href="https://pubmed.ncbi.nlm.nih.gov/24336150/">Bemben MA, Shipman SL, et al.</a> 114110327 Bemben, Michael NINDS NINDS Bemben, Michael (NINDS) 0 114110328 Badger, John NINDS NINDS Badger, John (NINDS) 0 114110326 Roche, Katherine NINDS NINDS Roche, Katherine (NINDS) 1 114110326 Roche, Katherine NINDS NINDS Roche, Katherine (NINDS) 1 114110327 Bemben, Michael NINDS NINDS Bemben, Michael (NINDS) 0 114110328 Badger, John NINDS NINDS Badger, John (NINDS) 0 114102595 Development Of A Polyclonal Antibody For Neuroligin 4 PThr707 And A Polyclonal Antibody For Neuroligin 1 THR739 E-002-2015-0 Research Material NINDS 83722849 Sharma, Smita smita.sharma@nih.gov
United States of America smita.sharma@nih.gov?subject=Web Inquiry on [TAB-3480] Development of a Polyclonal Antibody for Neuroligin 4 pThr707 and a Polyclonal Antibody for Neuroligin 1 pTHR739&body=Please send me information about technology [TAB-3480] Development of a Polyclonal Antibody for Neuroligin 4 pThr707 and a Polyclonal Antibody for Neuroligin 1 pTHR739. Sharma, Smita<br><a href="mailto:smita.sharma@nih.gov?subject=Web Inquiry on [TAB-3480] Development of a Polyclonal Antibody for Neuroligin 4 pThr707 and a Polyclonal Antibody for Neuroligin 1 pTHR739&body=Please send me information about technology [TAB-3480] Development of a Polyclonal Antibody for Neuroligin 4 pThr707 and a Polyclonal Antibody for Neuroligin 1 pTHR739.">smita.sharma@nih.gov</a><br> 114128551 VEXXXX 114128552 WBXXXX 114128553 WIXXXX 114128554 XAXXXX 114152490 Development 114152491 polyclonal 114152492 ANTIBODY 114152493 Neuroligin 114152494 4 114152495 PThr707 114152496 1 114152497 THR739 114152498 Listed LPM Contreras as of 4/15/2015 114152499 Pre LPM working set 20150418 114152500 Post LPM Assignment Set 20150420 TAB-3477 114097342 Small Molecule Inhibitors of the Ferroptosis Programmed Cell Death Pathway NCATS Cardiology, Dental, Endocrinology, Infectious Disease, Neurology, Oncology, Ophthalmology, Research Materials, Therapeutics Cardiology Dental Endocrinology Infectious Disease Neurology Oncology Ophthalmology Research Materials Therapeutics Diane Luci, Juan Marugan, Ganesha Rai Bantukallu, Anton Simeonov, Adam Yasgar, Alexey Zakharov This technology includes the identification and use of small molecules to rescue cells undergoing ferroptosis, a type of programmed cell death. These small molecules can be used as treatments in situations where epithelial cells are being damaged, including respiratory disorders, brain injury (including traumatic brain injury), renal injury, radiation-induced injury, and neurodegenerative disorders. Ferroptosis is a type of programmed cell death that is triggered by an increased presence of oxidants. The small molecules included in this invention target a complex between 15-Lipoxygenase-2 (15-LOX-2) and phosphatidylethanolamine binding protein 1 (PEBP1) that plays a crucial role in ferroptosis. There is currently a need for an impactful therapy in situations where ferroptosis causes poor clinical outcomes. The therapeutic use of antioxidants is used in some cases, such as traumatic brain injury. Clinical trials with non-specific antioxidants have failed. The small molecules included in this technology are the first targeted modulators of the ferroptosis cell death pathway. Further clinical work could establish the small molecules of this invention as treatments in situations where modulating the programmed cell death ferroptosis may improve clinical outcomes, including respiratory disorders, brain injury (including traumatic brain injury), renal injury, radiation-induced injury, and neurodegenerative disorders. 2022-08-01 2024-10-28 2024-10-28 2022-08-01 2022-02-08 Lipid, Protein, Targets, therapeutic, VEXXXX, VPXXXX, WIXXXX, WKXXXX, XEXXXX False True True NIHTT 37470483 Website Abstract 114110314 Luci, Diane NCATS - NCGC NCATS Luci, Diane (NCATS) 0 114110315 Marugan, Juan NCATS - NCGC NCATS Marugan, Juan (NCATS) 0 114110316 Simeonov, Anton NCATS - NCGC NCATS Simeonov, Anton (NCATS) 0 114110317 Zakharov, Alexey NCATS - NCGC NCATS Zakharov, Alexey (NCATS) 0 114110318 Yasgar, Adam NCATS - NCGC NCATS Yasgar, Adam (NCATS) 0 114110313 Rai Bantukallu, Ganesha NCATS - NCGC NCATS Rai Bantukallu, Ganesha (NCATS) 1 114110313 Rai Bantukallu, Ganesha NCATS - NCGC NCATS Rai Bantukallu, Ganesha (NCATS) 1 114110314 Luci, Diane NCATS - NCGC NCATS Luci, Diane (NCATS) 0 114110315 Marugan, Juan NCATS - NCGC NCATS Marugan, Juan (NCATS) 0 114110316 Simeonov, Anton NCATS - NCGC NCATS Simeonov, Anton (NCATS) 0 114110317 Zakharov, Alexey NCATS - NCGC NCATS Zakharov, Alexey (NCATS) 0 114110318 Yasgar, Adam NCATS - NCGC NCATS Yasgar, Adam (NCATS) 0 114102592 Protein And Lipid Therapeutic Targets E-010-2022-0 Filing authorized NCATS - NCGC 83682485 Vepa, Suryanarayana sury.vepa@nih.gov
United States of America Office of Strategic Alliances (OSA) sury.vepa@nih.gov?subject=Web Inquiry on [TAB-3477] Small Molecule Inhibitors of the Ferroptosis Programmed Cell Death Pathway&body=Please send me information about technology [TAB-3477] Small Molecule Inhibitors of the Ferroptosis Programmed Cell Death Pathway. Vepa, Suryanarayana<br><a href="mailto:sury.vepa@nih.gov?subject=Web Inquiry on [TAB-3477] Small Molecule Inhibitors of the Ferroptosis Programmed Cell Death Pathway&body=Please send me information about technology [TAB-3477] Small Molecule Inhibitors of the Ferroptosis Programmed Cell Death Pathway.">sury.vepa@nih.gov</a><br> 114169215 E-010-2022-0 E-010-2022-0-US-01 Protein And Lipid Therapeutic Targets PRV US 63/114,760 Abandoned US <br />Provisional (PRV) 63/114,760<br />Filed on 2020-11-17<br />Status: Abandoned 114169216 E-010-2022-0 E-010-2022-0-PCT-02 Protein And Lipid Therapeutic Targets PCT Patent Cooperation Treaty PCT/US2021/059641 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/059641<br />Filed on 2021-11-17<br />Status: Expired 114128537 VEXXXX 114128538 VPXXXX 114128539 WIXXXX 114128540 WKXXXX 114128541 XEXXXX 114152479 Protein 114152480 Lipid 114152481 therapeutic 114152482 Targets TAB-3478 114097344 Methods and Systems for Evaporation of Solvents and Solid Phase Extraction NCATS Consumer Products, Licensing, Medical Devices, Non-Medical Devices, Research Materials Consumer Products Licensing Medical Devices Non-Medical Devices Research Materials Pranav Bende, Alexander Godfrey, Linus Wallgren There is an acute deficit in chemical synthesis with respect to benchtop tools that are specifically designed to address the capability and efficiency of certain key aspects of chemical synthesis, namely reaction preparation, product isolation, and solvent removal. Chemical research currently relies upon a variety of devices that function in a manner that is disconnected, as well as difficult to integrate and automate; collectively, these device challenges hinder the efficient isolation and purification of desired chemical synthesis products. This invention addresses a critical need for chemists looking to improve the efficiency of their chemical syntheses. <br><br> Scientists at NCATS have developed a suite of technologies to facilitate the integration of a close-to-universal set of isolation techniques collectively referred to as “solid phase extraction” methods (SPE). The devices allow a crude reaction mixture to be passed through a variety of media with highly selective adsorptive properties allowing for selective separation of the product of interest in very rapid and efficient manner. In addition, the inventions include: the design of a device that attaches to the top of any laboratory vessel and facilitates evaporation by forcing a gas stream through a helical guide while applying vacuum to an exhaust port to accelerate the evaporation of solvents in the vessel; as well as a device for sweeping the headspace of a reaction vial with an inert gas to protect air-sensitive reactions whilst allowing liquid or solid reagents to be readily added. These devices can be manufactured from chemically compatible 3D printed parts significantly improving their accessibility and appeal by laboratory scientists. A variety of SPE media and cartridges exist, but what is missing is equipment that automates associated methods relevant to chemical synthesis versus the more common use in analyte preparation. This invention fills such a gap and will help chemists achieve greater efficiencies and automation in their synthetic work. <br><br> NCATS is actively seeking licensing and/or co-development research collaborations for the suite of Solid Phase Extraction and Purification technologies. <ul> <li>Suite of inventions forms a “close-to-universal” set of methods and equipment for solid phase extraction</li> <li>Currently available methods and equipment are considered “bespoke” but have failed to operate as commercially viable options</li> <li>Expanded extraction selectivity and productivity options</li> <li>Reduced overall footprint makes the system attractive for benchtop use</li> </ul> <ul> <li>Drug development industry</li> <li>Agricultural chemical synthesis and purification</li> <li>New materials industry</li> </ul> 2022-06-28 2024-10-28 2024-10-28 2022-04-01 2022-02-08 AUTOMATION, Benchtop, Chemical, DRUG, Evaporator, Extractor, PHASE, SOLID, VESSEL, WIXXXX, WMXXXX, XDXXXX False True True NIHTT 37470483 Website Abstract E-039-2021-0 114110320 Bende, Pranav NCATS - TRND NCATS Bende, Pranav (NCATS) 0 114110321 Wallgren, Linus NCATS - NCGC NCATS Wallgren, Linus (NCATS) 0 114110319 Godfrey, Alexander NCATS - TRND NCATS Godfrey, Alexander (NCATS) 1 114110319 Godfrey, Alexander NCATS - TRND NCATS Godfrey, Alexander (NCATS) 1 114110320 Bende, Pranav NCATS - TRND NCATS Bende, Pranav (NCATS) 0 114110321 Wallgren, Linus NCATS - NCGC NCATS Wallgren, Linus (NCATS) 0 114102593 Benchtop Vessel Evaporator E-133-2020-0 Filing authorized NCATS - NCGC 83673536 Erwin-Cohen, Rebecca rebecca.erwin-cohen@nih.gov
NCGC rebecca.erwin-cohen@nih.gov?subject=Web Inquiry on [TAB-3478] Methods and Systems for Evaporation of Solvents and Solid Phase Extraction &body=Please send me information about technology [TAB-3478] Methods and Systems for Evaporation of Solvents and Solid Phase Extraction . Erwin-Cohen, Rebecca<br><a href="mailto:rebecca.erwin-cohen@nih.gov?subject=Web Inquiry on [TAB-3478] Methods and Systems for Evaporation of Solvents and Solid Phase Extraction &body=Please send me information about technology [TAB-3478] Methods and Systems for Evaporation of Solvents and Solid Phase Extraction .">rebecca.erwin-cohen@nih.gov</a><br> 114169217 E-133-2020-0 E-133-2020-0-US-01 METHODS AND SYSTEMS FOR EVAPORATION OF SOLVENTS PRV US 63/081,723 Abandoned US <br />Provisional (PRV) 63/081,723<br />Filed on 2020-09-22<br />Status: Abandoned 114128542 WIXXXX 114128543 WMXXXX 114128544 XDXXXX 114152483 Benchtop 114152484 VESSEL 114152485 Evaporator 114152856 SOLID 114152857 PHASE 114152858 Extractor 114152859 Chemical 114152860 DRUG 114152861 AUTOMATION TAB-3475 114097340 Counteracting BECN2-mediated Drug Tolerance to Cannabinoids Through the Use of Autophagy Activation NCATS Neurology, Research Materials, Therapeutics Neurology Research Materials Therapeutics He Congcong, Huang Sui, Chen Wang This technology includes the use of autophagy upregulators such as ML246/metarrestin to counteract the tolerance that can build up through the therapeutic use of cannabinoids. Long-term administration of cannabinoids rapidly introduces tolerance and physical dependence, limiting its medical use and may lead to addiction and withdrawal symptoms. Cannabinoids mediate their effect by binding to and activating the cannabinoid receptor 1 (CNR1/CB1). Chronic exposure leads to CNR1 being targeted for degradation through a process of autophagy. A recently found gene, beclin 2 (Becn2), may be involved in targeting CNR1 for degradation, thereby mediating the observed tolerance of cannabinoids. There are no known approaches to mediate cannabinoid tolerance. Further clinical work of autophagy upregulators, such as ML246/metarrestin, may be developed into compounds to counteract cannabinoid tolerance. 2022-08-01 2024-10-28 2024-10-28 2022-08-01 2022-02-08 Activation, Autophagy, BECN2-mediated, CANNABINOIDS, DISORDERS, DRUG, Inducers, INDUCTION, Methods, NEURODEGENERATIVE, Novel, PREVENTING, PREVENTS, TOLERANCE, TREATING, VEXXXX, Via, VMXXXX, WIXXXX, WKXXXX, XEXXXX False True True NIHTT 37470483 Website Abstract 114172634 Kuramoto K, Wang N, et al. https://pubmed.ncbi.nlm.nih.gov/27305347/ <a href="https://pubmed.ncbi.nlm.nih.gov/27305347/">Kuramoto K, Wang N, et al.</a> 114110307 Sui, Huang Northwestern University Sui, Huang 0 114110308 Wang, Chen Northwestern University Wang, Chen 0 114110306 Congcong, He Northwestern University Congcong, He 1 114110306 Congcong, He Northwestern University Congcong, He 1 114110307 Sui, Huang Northwestern University Sui, Huang 0 114110308 Wang, Chen Northwestern University Wang, Chen 0 114102594 Autophagy Activation By Novel Inducers Prevents BECN2-mediated Drug Tolerance To Cannabinoids E-046-2018-0 Filing authorized NIH - NCATS, Northwestern University 83682485 Vepa, Suryanarayana sury.vepa@nih.gov
United States of America Office of Strategic Alliances (OSA) sury.vepa@nih.gov?subject=Web Inquiry on [TAB-3475] Counteracting BECN2-mediated Drug Tolerance to Cannabinoids Through the Use of Autophagy Activation&body=Please send me information about technology [TAB-3475] Counteracting BECN2-mediated Drug Tolerance to Cannabinoids Through the Use of Autophagy Activation. Vepa, Suryanarayana<br><a href="mailto:sury.vepa@nih.gov?subject=Web Inquiry on [TAB-3475] Counteracting BECN2-mediated Drug Tolerance to Cannabinoids Through the Use of Autophagy Activation&body=Please send me information about technology [TAB-3475] Counteracting BECN2-mediated Drug Tolerance to Cannabinoids Through the Use of Autophagy Activation.">sury.vepa@nih.gov</a><br> 114169218 E-046-2018-0 E-046-2018-0-US-01 Autophagy Activation By Novel Inducers Prevents BECN2-mediated Drug Tolerance To Cannabinoids PRV US 62/450,336 Abandoned US <br />Provisional (PRV) 62/450,336<br />Filed on 2017-01-25<br />Status: Abandoned 114128527 VEXXXX 114128528 VMXXXX 114128529 WIXXXX 114128530 WKXXXX 114128531 XEXXXX 114152450 Autophagy 114152451 Activation 114152452 Novel 114152453 Inducers 114152454 PREVENTS 114152455 BECN2-mediated 114152456 DRUG 114152457 TOLERANCE 114152458 CANNABINOIDS 114152459 Methods 114152460 TREATING 114152461 PREVENTING 114152462 NEURODEGENERATIVE 114152463 DISORDERS 114152464 Via 114152465 INDUCTION TAB-3476 114097341 A High-throughput Protocol for Creation of Brain Region-specific Neural Spheroids for Disease Modeling and Drug Testing NCATS Neurology, Psychiatry/Mental Health, Research Equipment, Research Materials, Therapeutics Neurology Psychiatry/Mental Health Research Equipment Research Materials Therapeutics Molly Boutin, Marc Ferrer-Alegre, Emily Lee, Caroline Strong This technology includes a method for creating functional, brain region-specific neural spheroids that can be used for disease modeling and therapeutic testing of compounds for neurological diseases. The developed protocol uses somatic cells, including iPSC-derived neurons, as well as astrocytes using means such as 96- or 384-well ultra-low attachment round-bottom plates. Spheroids have been generated using this method that model brain regions such as the ventral tegmental area and prefrontal cortex, which are implicated in Parkinson’s and Alzheimer’s disease. Three-dimensional spheroids provide a more physiologically relevant context for disease modeling and compound testing for neurological disorders compared to two-dimensional in vitro culture models. The included technology expands the scope of spheroids that can readily be created, allowing for high-throughput modeling and drug testing of additional brain regions and diseases. Several companies currently provide ready-to-use plates with spheroids. This invention can be used to expand the portfolio of spheroids that could be sold. 2022-08-01 2024-10-28 2024-10-28 2022-08-01 2022-02-08 ASSEMBLY, brain, Cells, FUNCTIONAL, High, neural, Producted, PROTOCOL, RAPID, Region-specific, SOMATIC, Spheroids, THROUGHPUT, VEXXXX, VNXXXX, WIXXXX, WKXXXX, XHXXXX False True True NIHTT 37470483 Website Abstract 114110310 Strong, Caroline NCATS - TRND NCATS Strong, Caroline (NCATS) 0 114110311 Boutin, Molly NCATS - TRND NCATS Boutin, Molly (NCATS) 0 114110312 Ferrer-Alegre, Marc NCATS - NCGC NCATS Ferrer-Alegre, Marc (NCATS) 0 114110309 Lee, Emily NCATS - TRND Lee, Emily 1 114110309 Lee, Emily NCATS - TRND Lee, Emily 1 114110310 Strong, Caroline NCATS - TRND NCATS Strong, Caroline (NCATS) 0 114110311 Boutin, Molly NCATS - TRND NCATS Boutin, Molly (NCATS) 0 114110312 Ferrer-Alegre, Marc NCATS - NCGC NCATS Ferrer-Alegre, Marc (NCATS) 0 114102591 A High Throughput Protocol For The Rapid Assembly Of Functional Brain Region-specific, Neural Spheroids Producted With Somatic Cells E-072-2021-0 Filing authorized NCATS - NCGC 83682485 Vepa, Suryanarayana sury.vepa@nih.gov
United States of America Office of Strategic Alliances (OSA) sury.vepa@nih.gov?subject=Web Inquiry on [TAB-3476] A High-throughput Protocol for Creation of Brain Region-specific Neural Spheroids for Disease Modeling and Drug Testing&body=Please send me information about technology [TAB-3476] A High-throughput Protocol for Creation of Brain Region-specific Neural Spheroids for Disease Modeling and Drug Testing. Vepa, Suryanarayana<br><a href="mailto:sury.vepa@nih.gov?subject=Web Inquiry on [TAB-3476] A High-throughput Protocol for Creation of Brain Region-specific Neural Spheroids for Disease Modeling and Drug Testing&body=Please send me information about technology [TAB-3476] A High-throughput Protocol for Creation of Brain Region-specific Neural Spheroids for Disease Modeling and Drug Testing.">sury.vepa@nih.gov</a><br> 114169214 E-072-2021-0 E-072-2021-0-US-01 FUNCTIONAL BRAIN REGION-SPECIFIC NEURAL SPHEROIDS AND METHODS OF USE PRV US 63/151,698 Abandoned US <br />Provisional (PRV) 63/151,698<br />Filed on 2021-02-20<br />Status: Abandoned 114169231 E-072-2021-0 E-072-2021-0-PCT-02 FUNCTIONAL BRAIN REGION-SPECIFIC NEURAL SPHEROIDS AND METHODS OF USE PCT Patent Cooperation Treaty PCT/US2022/017248 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2022/017248<br />Filed on 2022-02-22<br />Status: Expired 114128532 VEXXXX 114128533 VNXXXX 114128534 WIXXXX 114128535 WKXXXX 114128536 XHXXXX 114152466 neural 114152467 Region-specific 114152468 brain 114152469 FUNCTIONAL 114152470 ASSEMBLY 114152471 RAPID 114152472 PROTOCOL 114152473 THROUGHPUT 114152474 High 114152475 Spheroids 114152476 Producted 114152477 SOMATIC 114152478 Cells TAB-3470 114097335 The Use of Metarrestin for the Treatment of Pancreatic Cancer NCATS Oncology, Research Materials, Therapeutics Oncology Research Materials Therapeutics Marc Ferrer-Alegre, Sui Huang, Juan Marugan, Samarjit Patnaik, Udo Rudloff, Noel Southall This technology includes the use of the small molecule metarrestin (ML246) for the treatment of several types of pancreatic cancer. A subcellular structure called the perinucleolar compartment (PNC) is frequently found in metastatic tumors and cancer stem cells. Reduction of PNC prevalence followed by medicinal chemistry was used to identify metarrestin as a compound that reduces PNC prevalence without significantly impacting cell viability. In vitro and in vivo animal work have demonstrated desirable pharmacokinetic properties as well as a reduction in metastatic burden and extended survival. Metarrestin is an orally active first-in-class and specific perinucleolar compartment inhibitor. Clinical trials using metarrestin in other cancers have shown favorable patient outcomes. Further clinical work could establish the use of metarrestin as an oral adjuvant treatment for pancreatic cancer alone or in combination with existing chemotherapeutic agents such as gemcitabine. 2022-08-01 2024-10-28 2024-10-28 2022-08-01 2022-02-07 CANCER, Metarrestin, Pancreatic, treatment, VCXXXX, WIXXXX, WKXXXX False True True NIHTT 37470483 Website Abstract 114110289 Huang, Sui Northwestern University Huang, Sui 0 114110290 Marugan, Juan NCATS - NCGC NCATS Marugan, Juan (NCATS) 0 114110291 Patnaik, Samarjit NCATS - NCGC NCATS Patnaik, Samarjit (NCATS) 0 114110292 Southall, Noel NCATS - TRND NCATS Southall, Noel (NCATS) 0 114110293 Ferrer-Alegre, Marc NCATS - NCGC NCATS Ferrer-Alegre, Marc (NCATS) 0 114110288 Rudloff, Udo NCI - CCR NCI Rudloff, Udo (NCI) 1 114110288 Rudloff, Udo NCI - CCR NCI Rudloff, Udo (NCI) 1 114110289 Huang, Sui Northwestern University Huang, Sui 0 114110290 Marugan, Juan NCATS - NCGC NCATS Marugan, Juan (NCATS) 0 114110291 Patnaik, Samarjit NCATS - NCGC NCATS Patnaik, Samarjit (NCATS) 0 114110292 Southall, Noel NCATS - TRND NCATS Southall, Noel (NCATS) 0 114110293 Ferrer-Alegre, Marc NCATS - NCGC NCATS Ferrer-Alegre, Marc (NCATS) 0 114102585 Metarrestin For The Treatment Of Pancreatic Cancer E-114-2018-0 Filing authorized NCATS - NCGC, NCI, Northwestern University, The University of Kansas 83682485 Vepa, Suryanarayana sury.vepa@nih.gov
United States of America Office of Strategic Alliances (OSA) sury.vepa@nih.gov?subject=Web Inquiry on [TAB-3470] The Use of Metarrestin for the Treatment of Pancreatic Cancer&body=Please send me information about technology [TAB-3470] The Use of Metarrestin for the Treatment of Pancreatic Cancer. Vepa, Suryanarayana<br><a href="mailto:sury.vepa@nih.gov?subject=Web Inquiry on [TAB-3470] The Use of Metarrestin for the Treatment of Pancreatic Cancer&body=Please send me information about technology [TAB-3470] The Use of Metarrestin for the Treatment of Pancreatic Cancer.">sury.vepa@nih.gov</a><br> 114169201 E-114-2018-0 E-114-2018-0-US-01 FORMULATIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF TUMOR METASTASIS AND TUMORIGENESIS PRV US 62/671,964 Abandoned US <br />Provisional (PRV) 62/671,964<br />Filed on 2018-05-15<br />Status: Abandoned 114169202 E-114-2018-0 E-114-2018-0-PCT-02 FORMULATIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF TUMOR METASTASIS AND TUMORIGENESIS PCT Patent Cooperation Treaty PCT/US2019/32461 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2019/32461<br />Filed on 2019-05-15<br />Status: Expired 114169203 E-114-2018-0 E-114-2018-0-US-07 FORMULATIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF TUMOR METASTASIS AND TUMORIGENESIS National Stage US 17/055,256 Abandoned US <br />National Stage 17/055,256<br />Filed on 2020-11-13<br />Status: Abandoned 114128512 VCXXXX 114128513 WIXXXX 114128514 WKXXXX 114152405 Metarrestin 114152406 treatment 114152407 Pancreatic 114152408 CANCER TAB-347 114094685 Cloned Genomes Of Infectious Hepatitis C Virus And Uses Thereof NIAID Infectious Disease, Licensing, Therapeutics Infectious Disease Licensing Therapeutics Jens Bukh, Suzanne Emerson, Robert Purcell, Masayuki Yanagi The current invention provides nucleic acid sequences comprising the genomes of infectious hepatitis C viruses (HCV) of genotype 1a and 1b. It covers the use of these sequences, and polypeptides encoded by all or part of the sequences, in the development of vaccines and diagnostic assays for HCV and the development of screening assays for the identification of antiviral agents for HCV. <br><br> Additional information can be found in: Yanagi et al., "Transcripts from a single full-length cDNA clone of hepatitis C virus are infectious when directly transfected into the liver of a chimpanzee," Proc. Natl. Acad. Sci. USA (1997 August) 94(16):8738-8743; and Yanagi et al., "Transcripts of a chimeric cDNA clone of hepatitis C virus genotype 1b are infectious in vivo," Virology (25 April 1998) 244(1):161-172. 2022-03-08 2024-10-28 2024-10-28 2020-07-06 BCXXXX, DBXXXX, DXXXXX, Hepatitis A, Hepatitis D, Hepatitis E False True True 52398218 Pre-Clinical (in vivo) 52398218 NIHTT 37470483 Website Abstract E-100-1999-0 E-102-1999-0 E-173-1999-0 114103618 Yanagi, Masayuki Yanagi, Masayuki 0 114103619 Bukh, Jens NIAID Bukh, Jens (NIAID) 0 114103620 Emerson, Suzanne NIAID Emerson, Suzanne (NIAID) 0 114103621 Purcell, Robert NIAID Purcell, Robert (NIAID) 0 114103618 Yanagi, Masayuki Yanagi, Masayuki 0 114103619 Bukh, Jens NIAID Bukh, Jens (NIAID) 0 114103620 Emerson, Suzanne NIAID Emerson, Suzanne (NIAID) 0 114103621 Purcell, Robert NIAID Purcell, Robert (NIAID) 0 114099485 Cloned Genomes of Infectious Hepatitis C Viruses and Uses Thereof E-050-1998-0 Filing authorized NIAID 83643855 Soukas, Peter peter.soukas@nih.gov
United States of America Technology Transfer and Intellectual Property Office peter.soukas@nih.gov?subject=Web Inquiry on [TAB-347] Cloned Genomes Of Infectious Hepatitis C Virus And Uses Thereof&body=Please send me information about technology [TAB-347] Cloned Genomes Of Infectious Hepatitis C Virus And Uses Thereof. Soukas, Peter<br><a href="mailto:peter.soukas@nih.gov?subject=Web Inquiry on [TAB-347] Cloned Genomes Of Infectious Hepatitis C Virus And Uses Thereof&body=Please send me information about technology [TAB-347] Cloned Genomes Of Infectious Hepatitis C Virus And Uses Thereof.">peter.soukas@nih.gov</a><br> 114160783 E-050-1998-0 E-050-1998-0-US-01 Cloned Genomes of Infectious Hepatitis C Viruses and Uses Thereof ORD US 6,153,421 09/014,416 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6153421 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6153421">6,153,421</a><br />Filed on 1998-01-27<br />Status: Expired 114160784 E-050-1998-0 E-050-1998-0-US-03 Cloned Genomes of Infectious Hepatitis C Viruses and Uses Thereof DIV US 7,201,911 09/662,454 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7201911 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7201911">7,201,911</a><br />Filed on 2000-09-14<br />Status: Abandoned 114160786 E-050-1998-0 E-050-1998-0-US-04 Cloned Genomes of Infectious Hepatitis C Viruses and Uses Thereof DIV US 7,846,454 11/784,809 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7846454 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7846454">7,846,454</a><br />Filed on 2007-04-09<br />Status: Expired 114112978 DBXXXX 114112979 DXXXXX 114121232 BCXXXX 114157315 Hepatitis D 114157316 Hepatitis A 114157317 Hepatitis E TAB-3467 114097332 Synthesis and Use of HDAC/PI3K Dual Inhibitors for the Treatment of Rare Cancers (DIRC) NCATS Oncology, Therapeutics Oncology Therapeutics Marc Ferrer-Alegre, Gurmit Grewal, Anton Simeonov, Gregory Tawa, Ashish Thakur This technology includes the synthesis and use of novel PI3K and HDAC dual inhibitors for the treatment of several cancers. Phosphatidylinositol 3-kinase (PI3K) is activated in many human cancers, and inhibition of these kinases is an established cancer treatment. Histone deacetylases (HDACs) are key regulators of the cell cycle that function through regulating expression of tumor suppressors (p21 and p27), c-Myc and cyclin D1. HDAC inhibition is an emerging therapeutic approach for the treatment of several cancers. Recent work has reported that the combination of an HDAC inhibitor and a kinase inhibitor overcomes kinase inhibitor resistance and induces apoptosis in human solid cancers in a synergistic manner. PI3K and HDAC inhibitors are important cancer therapeutics. Several of them have been approved. But both classes of inhibitors suffer from two major limitations, insufficient efficacy and developed resistance. There is strong evidence in the literature that, simultaneous inhibition of both PI3K and HDAC would address both these limitations. The PI3K/HDAC dual inhibitor compounds of this invention potentially could be developed into useful cancer therapeutics, giving better efficacy, and a better therapeutic window than single inhibitors, while avoiding developed resistance. The HDAC/PI3K dual inhibitors of this invention are expected to have synergistic anti-tumor activity. In addition, they also could address issues like resistance and insufficient efficacy associated with PI3K and HDAC inhibitors. These compounds potentially could be developed into useful therapies for certain cancers, e.g. leukemia, lung cancer, pancreatic cancer and melanoma. 2022-08-01 2024-10-28 2024-10-28 2022-08-01 2022-02-04 cancers, DIRC, Dual, HDAC/PI3K, Inhibitors, RARE, treatment, VCXXXX, WKXXXX, XEXXXX False True True NIHTT 37470483 Website Abstract 114110275 Thakur, Ashish NCATS - NCGC NCATS Thakur, Ashish (NCATS) 0 114110276 Tawa, Gregory NCATS - TRND NCATS Tawa, Gregory (NCATS) 0 114110277 Simeonov, Anton NCATS - NCGC NCATS Simeonov, Anton (NCATS) 0 114110278 Ferrer-Alegre, Marc NCATS - NCGC NCATS Ferrer-Alegre, Marc (NCATS) 0 114110268 Grewal, Gurmit NCATS - NCGC NCATS Grewal, Gurmit (NCATS) 1 114110268 Grewal, Gurmit NCATS - NCGC NCATS Grewal, Gurmit (NCATS) 1 114110275 Thakur, Ashish NCATS - NCGC NCATS Thakur, Ashish (NCATS) 0 114110276 Tawa, Gregory NCATS - TRND NCATS Tawa, Gregory (NCATS) 0 114110277 Simeonov, Anton NCATS - NCGC NCATS Simeonov, Anton (NCATS) 0 114110278 Ferrer-Alegre, Marc NCATS - NCGC NCATS Ferrer-Alegre, Marc (NCATS) 0 114102582 HDAC/PI3K Dual Inhibitors For Treatment Of Rare Cancers (DIRC) E-104-2017-0 Filing authorized NCATS - NCGC 83682485 Vepa, Suryanarayana sury.vepa@nih.gov
United States of America Office of Strategic Alliances (OSA) sury.vepa@nih.gov?subject=Web Inquiry on [TAB-3467] Synthesis and Use of HDAC/PI3K Dual Inhibitors for the Treatment of Rare Cancers (DIRC) &body=Please send me information about technology [TAB-3467] Synthesis and Use of HDAC/PI3K Dual Inhibitors for the Treatment of Rare Cancers (DIRC) . Vepa, Suryanarayana<br><a href="mailto:sury.vepa@nih.gov?subject=Web Inquiry on [TAB-3467] Synthesis and Use of HDAC/PI3K Dual Inhibitors for the Treatment of Rare Cancers (DIRC) &body=Please send me information about technology [TAB-3467] Synthesis and Use of HDAC/PI3K Dual Inhibitors for the Treatment of Rare Cancers (DIRC) .">sury.vepa@nih.gov</a><br> 114169194 E-104-2017-0 E-104-2017-0-US-01 Dual Inhibitors of Phosphoinositide 3-Kinase and Histone Deacetylase For Treatment Of Cancer PRV US 62/523,390 Abandoned US <br />Provisional (PRV) 62/523,390<br />Filed on 2017-06-22<br />Status: Abandoned 114169195 E-104-2017-0 E-104-2017-0-PCT-02 INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE AND HISTONE DEACETYLASE FOR TREATMENT OF CANCER PCT Patent Cooperation Treaty PCT/US2018/038507 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2018/038507<br />Filed on 2018-06-20<br />Status: Expired 114169196 E-104-2017-0 E-104-2017-0-US-03 INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE AND HISTONE DEACETYLASE FOR TREATMENT OF CANCER National Stage US 16/621,290 Abandoned US <br />National Stage 16/621,290<br />Filed on 2018-06-20<br />Status: Abandoned 114128498 XEXXXX 114128499 WKXXXX 114128500 VCXXXX 114152369 DIRC 114152370 cancers 114152371 RARE 114152372 treatment 114152373 Inhibitors 114152374 Dual 114152375 HDAC/PI3K TAB-3462 114097330 Novel Activators of Pyruvate Kinase for the Treatment of Hemolytic Anemias NCATS Cardiology, Dental, Endocrinology, Infectious Disease, Oncology, Ophthalmology, Research Materials, Therapeutics Cardiology Dental Endocrinology Infectious Disease Oncology Ophthalmology Research Materials Therapeutics Matthew Boxer, Min Shen, Craig Thomas This technology includes the development and use of small molecule activators of pyruvate kinase (PK) for the treatment of inherited nonspherocytic hemolytic anemia, including PK deficiency. PK deficiency is caused by an inherited deficiency in an enzyme that reduces the lifespan of red blood cells. More than 150 unique mutations have been identified in the PK gene that lead to decreased activity in this essential enzyme in the glycolytic pathway. The prematurely lysed red blood cells can lead to jaundice, splenomegaly, and a hemolytic anemia. Patients with severe cases require blood transfusions. Current therapy for pyruvate kinase deficiency is done using transfusions. The current technology of pyruvate kinase (PK) activators may lead to an additional treatment option. Further clinical work could establish the small PK molecule activators as a treatment for inherited nonspherocytic hemolytic anemia, including pyruvate kinase deficiency. Licensing desired. 2022-08-01 2024-10-28 2024-10-28 2022-08-01 2022-01-27 ACTIVATORS, Anemias, CAUSED, DEFICIENCY, Formation, Hemolytic, ISOFORM, Kinase, Listed LPM Vepa as of 4/15/2015, M2, MOLECULE, PART, PKR, Post LPM Assignment Set 20150420, Potential, Potentialtreatment, Pre LPM working set 20150418, Promote, PYRUVATE, r, Small, SUPPRESS, Tetramer, treatment, tumorigenesis, VDXXXX, VPXXXX, WIXXXX, WKXXXX, XEXXXX, YAXXXX, YBXXXX False True True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114172619 Muir WA, Beutler E, et al. https://pubmed.ncbi.nlm.nih.gov/6731438/ <a href="https://pubmed.ncbi.nlm.nih.gov/6731438/">Muir WA, Beutler E, et al.</a> 114172620 Zanella A, Fermo E, et al. https://pubmed.ncbi.nlm.nih.gov/15982340/ <a href="https://pubmed.ncbi.nlm.nih.gov/15982340/">Zanella A, Fermo E, et al.</a> 114172621 Zanella A, Bianchi P, et al. https://pubmed.ncbi.nlm.nih.gov/17550841/ <a href="https://pubmed.ncbi.nlm.nih.gov/17550841/">Zanella A, Bianchi P, et al.</a> 114172622 Bowman HS, Procopio F. https://pubmed.ncbi.nlm.nih.gov/14014643/ <a href="https://pubmed.ncbi.nlm.nih.gov/14014643/">Bowman HS, Procopio F.</a> 114172623 Bowman HS, McKusick VA, et al. https://pubmed.ncbi.nlm.nih.gov/14255553/ <a href="https://pubmed.ncbi.nlm.nih.gov/14255553/">Bowman HS, McKusick VA, et al.</a> 114172624 Hanno K, Ballas SK, et al. https://pubmed.ncbi.nlm.nih.gov/8161798/ <a href="https://pubmed.ncbi.nlm.nih.gov/8161798/">Hanno K, Ballas SK, et al.</a> 114172625 Rider NL, Strauss KA, et al. https://pubmed.ncbi.nlm.nih.gov/21815188/ <a href="https://pubmed.ncbi.nlm.nih.gov/21815188/">Rider NL, Strauss KA, et al.</a> 114172626 Jiang J-K, Boxer MB, et al. https://pubmed.ncbi.nlm.nih.gov/20451379/ <a href="https://pubmed.ncbi.nlm.nih.gov/20451379/">Jiang J-K, Boxer MB, et al.</a> 114110240 Shen, Min National Human Genome Research Institute (NHGRI) NCATS Shen, Min (NCATS) 0 114110241 Boxer, Matthew National Human Genome Research Institute (NHGRI) Boxer, Matthew 0 114110242 Thomas, Craig National Human Genome Research Institute (NHGRI) NCATS Thomas, Craig (NCATS) 1 114110242 Thomas, Craig National Human Genome Research Institute (NHGRI) NCATS Thomas, Craig (NCATS) 1 114110240 Shen, Min National Human Genome Research Institute (NHGRI) NCATS Shen, Min (NCATS) 0 114110241 Boxer, Matthew National Human Genome Research Institute (NHGRI) Boxer, Matthew 0 114102580 Small Molecule Activators Of The R Isoform Of Pyruvate Kinase For Potential Treatment Of Hemolytic Anemias Caused By PKR Deficiency E-014-2012-0 Filing authorized NCATS - NCGC 83682485 Vepa, Suryanarayana sury.vepa@nih.gov
United States of America Office of Strategic Alliances (OSA) sury.vepa@nih.gov?subject=Web Inquiry on [TAB-3462] Novel Activators of Pyruvate Kinase for the Treatment of Hemolytic Anemias&body=Please send me information about technology [TAB-3462] Novel Activators of Pyruvate Kinase for the Treatment of Hemolytic Anemias. Vepa, Suryanarayana<br><a href="mailto:sury.vepa@nih.gov?subject=Web Inquiry on [TAB-3462] Novel Activators of Pyruvate Kinase for the Treatment of Hemolytic Anemias&body=Please send me information about technology [TAB-3462] Novel Activators of Pyruvate Kinase for the Treatment of Hemolytic Anemias.">sury.vepa@nih.gov</a><br> 114128490 VDXXXX 114128491 YBXXXX 114128492 YAXXXX 114128494 VPXXXX 114128495 WIXXXX 114128496 WKXXXX 114128497 XEXXXX 114152343 Formation 114152344 Tetramer 114152345 Promote 114152346 ACTIVATORS 114152347 M2 114152348 Kinase 114152349 PYRUVATE 114152350 MOLECULE 114152351 Small 114152352 SUPPRESS 114152353 tumorigenesis 114152354 PART 114152355 r 114152356 ISOFORM 114152357 Potentialtreatment 114152358 Hemolytic 114152359 Anemias 114152360 CAUSED 114152361 PKR 114152362 DEFICIENCY 114152363 Potential 114152364 treatment 114152365 Listed LPM Vepa as of 4/15/2015 114152366 Pre LPM working set 20150418 114152367 Post LPM Assignment Set 20150420 TAB-3456 114097325 Tumor Associated Calcium Signal Transducer 2 (TACSTD2)-Overexpressing Huh7.5 Cells That Are More Permissive to HCV Cell Entry and Replication Compared to the Model Huh7.5 Cell Line NIAID Licensing Licensing Patrizia Farci, Vandana Sekhar Worldwide, 130-150 million individuals are chronically infected with hepatitis C virus (HCV), a major cause of liver-associated morbidity and mortality worldwide. Despite recent advances in antiviral drugs that can cure some individuals, a rapid decline of the global disease burden is hampered by remarkably high treatment costs and a high number of undiagnosed infections. Moreover, a significant number of patients develop resistance and additional treatment modalities may be needed to dramatically reduce the worldwide incidence of HCV infection. The subject cell line may be a useful tool for studying the mechanism of HCV cellular entry and replication and could be incorporated into an in vitro assay to measure the effectiveness of novel HCV targeted therapies or as a system for improved propagation of HCV in culture.<br /><br /> By overexpressing TACSTD2 in Huh7.5 cells, scientists at the National Institute of Allergy and Infectious Diseases (NIAID) discovered that they could restore the cellular localization of two host cell HCV-entry factors that become dysregulated in hepatocellular carcinoma (HCC) cells. Overexpression of TACSTD2 makes Huh7.5 cells more broadly permissive to infection and replication by multiple HCV genotypes in comparison to the canonical Huh7.5 cell model. HCV does not replicate in malignant HCC cells, possibly caused in part by downregulation of TACSTD2 expression.<br /><br /> This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR part 404. <ul> <li>Cell line to study hepatitis C virus infection and replication or propagate HCV in culture.</li> <li>Cell line to study cancer.</li> </ul> Elizabeth Pitts, Ph.D., 240-669-5299; <a href="mailto:elizabeth.pitts@nih.gov">elizabeth.pitts@nih.gov</a>. Licensing information may be obtained by communicating with the indicated licensing contact at the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852; tel. 301-496-2644. A signed Confidential Disclosure Agreement will be required to receive copies of unpublished information related to the invention. Research Material - Patent protection is not being pursued for this technology. 2022-03-08 2024-10-28 2024-10-28 2021-08-18 2, Associated, CALCIUM, Cells, Huh7.5, Signal, TACSTD2-overexpressing, TRANSDUCER, tumor False True True NIHTT 37470483 Website Abstract 114110261 Sekhar, Vandana NIAID - DIR Sekhar, Vandana 0 114110260 Farci, Patrizia NIAID - DIR NIAID Farci, Patrizia (NIAID) 1 114110260 Farci, Patrizia NIAID - DIR NIAID Farci, Patrizia (NIAID) 1 114110261 Sekhar, Vandana NIAID - DIR Sekhar, Vandana 0 114102576 Tumor Associated Calcium Signal Transducer 2 (TACSTD2)-overexpressing Huh7.5 Cells E-040-2020-0 Research Material NIAID 91021353 Pitts, Elizabeth elizabeth.pitts@nih.gov
United States of America elizabeth.pitts@nih.gov?subject=Web Inquiry on [TAB-3456] Tumor Associated Calcium Signal Transducer 2 (TACSTD2)-Overexpressing Huh7.5 Cells That Are More Permissive to HCV Cell Entry and Replication Compared to the Model Huh7.5 Cell Line&body=Please send me information about technology [TAB-3456] Tumor Associated Calcium Signal Transducer 2 (TACSTD2)-Overexpressing Huh7.5 Cells That Are More Permissive to HCV Cell Entry and Replication Compared to the Model Huh7.5 Cell Line. Pitts, Elizabeth<br><a href="mailto:elizabeth.pitts@nih.gov?subject=Web Inquiry on [TAB-3456] Tumor Associated Calcium Signal Transducer 2 (TACSTD2)-Overexpressing Huh7.5 Cells That Are More Permissive to HCV Cell Entry and Replication Compared to the Model Huh7.5 Cell Line&body=Please send me information about technology [TAB-3456] Tumor Associated Calcium Signal Transducer 2 (TACSTD2)-Overexpressing Huh7.5 Cells That Are More Permissive to HCV Cell Entry and Replication Compared to the Model Huh7.5 Cell Line.">elizabeth.pitts@nih.gov</a><br> 114152283 tumor 114152284 Associated 114152285 CALCIUM 114152286 Signal 114152287 TRANSDUCER 114152288 2 114152289 TACSTD2-overexpressing 114152290 Huh7.5 114152291 Cells TAB-3442 114097315 Diagnostic Assay to Detect Group C Rotavirus in Humans and Animals—Monoclonal Antibody-based ELISA (Enzyme-linked Immunosorbent Assay) CDC Antibodies, Collaboration, Consumer Products, Diagnostics, Immunology, Infectious Disease, Licensing, Research Materials Antibodies Collaboration Consumer Products Diagnostics Immunology Infectious Disease Licensing Research Materials Baoming Jiang, Sung-SIl Moon Rotaviruses cause severe gastroenteritis in humans and animals globally. Currently, there are eight known serogroups (A-H) of rotaviruses. Group C rotavirus (GpC RV) causes sporadic cases and outbreaks of acute diarrhea in children and adults worldwide. GpC RV is also associated with diarrhea in swine. Currently, no simple and reliable diagnostic test exists for GpC RV, so disease prevalence remains unknown. <br /><br /> CDC has developed a monoclonal antibody (mAb) against the GpC RV VP6 protein. Scientists used the mAb to develop an immunoassay with sensitivity and specificity to human and animal GpC rotavirus, but not with GpA rotavirus, adenovirus, astrovirus, and other enteric viruses. We evaluated and validated this ELISA by testing fecal samples from children who were admitted to hospitals for treatment of diarrhea with nested PCR using primers specific to GpC rotavirus VP7 protein. <br /><br /> With the implementation of widespread vaccine campaigns against group A rotavirus—a once highly prevalent serogroup—and the reduction of GpA RV infection among children worldwide, other gastrointestinal virus agents like this GpC RV may emerge. This technology offers a simple and reliable diagnostic test for determining GpC RV disease incidence in the post-introduction era of GpA RV vaccines. CDC’s new assay may allow us to determine the burden of GpC RV disease in humans and animals. <ul> <li>Currently, no reliable diagnostic test for group C rotavirus exists. CDC’s new assay offers a simple and reliable diagnostic test to determine the burden of GpC RV disease in post-introduction era of GpA RV vaccines</li> <li>Demonstrated sensitivity and specificity for detecting GpC RVs in humans and animals</li> <li> High-throughput tool to screen fecal specimens and determine if GpC RV is an emerging pathogen in children worldwide</li> </ul> <ul> <li>mAb-based ELISA for the detection of Group C rotavirus in humans and animals</li> <li>Public health monitoring and surveillance</li> <li>Research tool</li> </ul> For collaboration opportunities, please contact CDC TTO at <a href="mailto:tto@cdc.gov">tto@cdc.gov</a> or 1-404-639-1330. 2022-06-22 2024-10-28 2024-10-28 2021-05-13 Animals, Antibody-based, C, Detection, Development, ELISA, EVALUATION, GROUP, Humans, monoclonal, rotavirus, VLXXXX, VOXXXX, WBXXXX, WIXXXX, WMXXXX, XAXXXX False True True NIHTT 37470483 Website Abstract E-150-2013-0 E-153-2013-0 E-191-2013-0 E-285-2015-0 114172604 Jiang B, et al. https://www.ncbi.nlm.nih.gov/pubmed/7797945 <a href="https://www.ncbi.nlm.nih.gov/pubmed/7797945">Jiang B, et al. </a> 114172605 Clark, K., et al. https://www.ncbi.nlm.nih.gov/pubmed/19285329 <a href="https://www.ncbi.nlm.nih.gov/pubmed/19285329">Clark, K., et al. </a> 114172606 Moon, S-S, A Montamayeru, F-T Wu, B Jiang. Development of a monoclonal antibody-based ELISA and its evaluation for the detection of rotavirus C in fecal specimens of children Viral Immunol. 2017 http://dx.doi:10.1089/vim.2016.0154 <a href="http://dx.doi:10.1089/vim.2016.0154">Moon, S-S, A Montamayeru, F-T Wu, B Jiang. Development of a monoclonal antibody-based ELISA and its evaluation for the detection of rotavirus C in fecal specimens of children Viral Immunol. 2017 </a> 114109228 Moon, Sung-SIl CDC - DIR CDC Moon, Sung-SIl (CDC) 0 114109229 Jiang, Baoming CDC - DIR CDC Jiang, Baoming (CDC) 1 114109229 Jiang, Baoming CDC - DIR CDC Jiang, Baoming (CDC) 1 114109228 Moon, Sung-SIl CDC - DIR CDC Moon, Sung-SIl (CDC) 0 114102565 Development And Evaluation Of A Monoclonal Antibody-based ELISA For The Detection Of Group C Rotavirus In Humans And Animals E-194-2020-0 Research Material Centers for Disease Control and Prevention (CDC) 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-3442] Diagnostic Assay to Detect Group C Rotavirus in Humans and Animals—Monoclonal Antibody-based ELISA (Enzyme-linked Immunosorbent Assay)&body=Please send me information about technology [TAB-3442] Diagnostic Assay to Detect Group C Rotavirus in Humans and Animals—Monoclonal Antibody-based ELISA (Enzyme-linked Immunosorbent Assay). Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-3442] Diagnostic Assay to Detect Group C Rotavirus in Humans and Animals—Monoclonal Antibody-based ELISA (Enzyme-linked Immunosorbent Assay)&body=Please send me information about technology [TAB-3442] Diagnostic Assay to Detect Group C Rotavirus in Humans and Animals—Monoclonal Antibody-based ELISA (Enzyme-linked Immunosorbent Assay).">jonathan.motley@nih.gov</a><br> 114128457 VLXXXX 114128458 VOXXXX 114128459 WBXXXX 114128460 WIXXXX 114128461 WMXXXX 114128462 XAXXXX 114152148 Development 114152149 EVALUATION 114152150 monoclonal 114152151 Antibody-based 114152152 ELISA 114152153 Detection 114152154 GROUP 114152155 C 114152156 rotavirus 114152157 Humans 114152158 Animals TAB-3443 114097316 Hybridomas to Human Immunoglobulins for SARS-CoV-2 Diagnostics and Additional Indications CDC Antibodies, Collaboration, Consumer Products, Diagnostics, Immunology, Infectious Disease, Licensing, Occupational Safety and Health, Research Materials, Therapeutics, Vaccines Antibodies Collaboration Consumer Products Diagnostics Immunology Infectious Disease Licensing Occupational Safety and Health Research Materials Therapeutics Vaccines Carol Aloisio, Charlotte Black, Gale Galland, Deborah Moore, Donald Phillips, Charles Reimer, Thomas Wells Immunoglobulins play a key role in the immune system. CDC has developed and tested hybridoma cell lines (monoclonal antibody (mAb) clones) for human IgG and other immunoglobulins. The mAbs generated from those hybridomas could be used as a reagent (second Ab) of anti-human immunoglobins in a diagnostic assay for SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), the virus that causes COVID-19 (coronavirus disease 2019) and other assays that detect antigen specific antibodies from human sera.<br/><br/> Collaborating international scientists evaluated the mAbs which showed reactivity and specificity for human IgG (11), the IgG subclasses (59), or Gm allotypes (4) by employing different assay techniques or protocols. These mAbs that can be satisfactorily applied in several diagnostic testing methodologies such as enzyme-linked immunosorbent assay (ELISA), immunofluorescence microscopy, direct hemagglutination and hemagglutination inhibition assays, and more. The hybridomas that produce those mAbs have potential as reference reagents and research tools for investigating infection processes. <ul> <li>Potentially speed up product development with CDC-developed materials that have already been tested and validated</li> <li>Can apply to multiple diagnostic types such as ELISA, immunofluorescent assays, hemagglutination inhibition assays, and more</li> -<li>Easily adapted to a high-throughput assay for mass screening purposes</li> </ul> <ul> <li>Development or refinement of diagnostic assays for coronavirus and other indications</li> <li>Controls or a reference reagent source for diagnostic assay validation</li> <li>Quality control/quality assurance testing for coronavirus vaccine or therapeutic development</li> <li> Monitoring and public health surveillance</li> <li> Research tools</li> </ul> For collaboration opportunities, please contact CDC TTO at <a href="mailto:tto@cdc.gov">tto@cdc.gov</a> or 1-404-639-1330. 2022-07-19 2024-10-28 2024-10-28 2021-05-17 &, 6069, 6103-6147, 6152, 6156, 6160, 6162, 6179, CLONES, GP1, GP2, HP6000-6061, HP6081-6086, Listed LPM Surabian as of 4/15/2015, NCID-DIOHD, NCIRD-DBD, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, VJXXXX, VKXXXX, VLXXXX, VQXXXX, WBXXXX, WFXXXX, WHXXXX, WIXXXX, WJXXXX, WKXXXX, WNXXXX, XAXXXX False True True NIHTT 37470483 Website Abstract 114172607 Jefferis R, et al. https://pubmed.ncbi.nlm.nih.gov/3899923 <a href="https://pubmed.ncbi.nlm.nih.gov/3899923 ">Jefferis R, et al. </a> 114110207 Aloisio, Carol CDC - DIR CDC Aloisio, Carol (CDC) 0 114110208 Black, Charlotte CDC - DIR CDC Black, Charlotte (CDC) 0 114110209 Galland, Gale CDC - DIR CDC Galland, Gale (CDC) 0 114110210 Moore, Deborah CDC - DIR CDC Moore, Deborah (CDC) 0 114110211 Phillips, Donald CDC - DIR CDC Phillips, Donald (CDC) 0 114110213 Wells, Thomas CDC - DIR CDC Wells, Thomas (CDC) 0 114110212 Reimer, Charles CDC - DIR CDC Reimer, Charles (CDC) 1 114110212 Reimer, Charles CDC - DIR CDC Reimer, Charles (CDC) 1 114110207 Aloisio, Carol CDC - DIR CDC Aloisio, Carol (CDC) 0 114110208 Black, Charlotte CDC - DIR CDC Black, Charlotte (CDC) 0 114110209 Galland, Gale CDC - DIR CDC Galland, Gale (CDC) 0 114110210 Moore, Deborah CDC - DIR CDC Moore, Deborah (CDC) 0 114110211 Phillips, Donald CDC - DIR CDC Phillips, Donald (CDC) 0 114110213 Wells, Thomas CDC - DIR CDC Wells, Thomas (CDC) 0 114102566 GP1 Clones HP6000-6061, 6069, 6152, 6160, & 6162 E-138-2014-0 Research Material Centers for Disease Control and Prevention (CDC) 114102567 GP2 Clones HP6081-6086, 6103-6147, 6156, 6179 E-139-2014-0 Research Material Centers for Disease Control and Prevention (CDC) 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-3443] Hybridomas to Human Immunoglobulins for SARS-CoV-2 Diagnostics and Additional Indications&body=Please send me information about technology [TAB-3443] Hybridomas to Human Immunoglobulins for SARS-CoV-2 Diagnostics and Additional Indications. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-3443] Hybridomas to Human Immunoglobulins for SARS-CoV-2 Diagnostics and Additional Indications&body=Please send me information about technology [TAB-3443] Hybridomas to Human Immunoglobulins for SARS-CoV-2 Diagnostics and Additional Indications.">jonathan.motley@nih.gov</a><br> 114128463 VJXXXX 114128464 VKXXXX 114128465 VQXXXX 114128466 VLXXXX 114128467 WBXXXX 114128468 WFXXXX 114128469 WHXXXX 114128470 WIXXXX 114128471 WJXXXX 114128472 WKXXXX 114128473 WNXXXX 114128474 XAXXXX 114152159 GP1 114152160 CLONES 114152161 HP6000-6061 114152162 6152 114152163 6160 114152164 & 114152165 6162 114152166 NCID-DIOHD 114152167 NCIRD-DBD 114152168 Listed LPM Surabian as of 4/15/2015 114152169 Pre LPM working set 20150418 114152170 Post LPM Assignment Set 20150420 114152171 6069 114152172 GP2 114152173 HP6081-6086 114152174 6103-6147 114152175 6156 114152176 6179 TAB-3439 114097313 Newcastle Disease Virus-Like Particle Displaying Prefusion Stabilized SARS-CoV-2 Spike and Its Use NIAID Licensing Licensing Olubukola Abiona, Kizzmekia Corbett, Barney Graham, Peter Kwong, John Mascola, Wei Shi, Yongping Yang SARS-CoV-2 has resulted in a global pandemic, sparking urgent vaccine development efforts. The trimeric SARS-CoV-2 spike stabilized in its prefusion conformation by the addition of 2 proline mutations (“SARS-CoV-2 S2P”) is the antigenic basis of SARS-CoV-2 vaccines that are currently authorized for use in the United States.<br /><br /> Researchers at the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID) sought to optimize the presentation of SARS-CoV-2 S2P to the immune system with the goal of eliciting a strong and durable immune response. The researchers designed fusion proteins made of SARS-CoV-2 S2P and Newcastle Disease fusion transmembrane domain and cytosolic tail which form virus like particles (VLPs) displaying the SARS-CoV-2 S2P on the particle surface.<br /><br /> SARS-CoV-2 S2P displaying Newcastle Disease virus-like particles (“S2P-NDVLP”) elicited a robust immune response two weeks after a single immunization. The S2P-NDVLP also elicited an improved immunogenicity despite delivering a lower number of SARS-CoV-2 S2P antigens than the soluble SARS-CoV-2 S2P to which they were compared. This improved immunogenicity is likely due to several characteristics of S2P-NDVLPs such as the mass and large size of the VLP particle that can result in a strong immune response and increase uptake of the S2P by dendritic cells Displaying multiple SARS-CoV-2 S2P on a single particle could allow multiple B-cell receptors on individual B cells to bind that single particle, thereby cross-linking the B-cell receptors and activating those B cells. Lastly, the lipid membrane of the S2P-NDVLP could allow the immunogen to more closely mimic the real virus and boost immune response.<br /><br /> This technology is available for licensing for commercial development in accordance with 35 U.S.C. § 209 and 37 CFR Part 404. . .. <ul> <li>S2P-NDVLP with potential to elicit higher levels of neutralizing antibodies than current vaccines with a single dose</li> </ul> <ul> <li>A single dose SARS-CoV-2 vaccine</li> </ul> </li> </ul> 2022-03-08 2024-10-28 2024-10-28 2021-04-23 COVID-19, Disease, DISPLAYING, DOSE, Newcastle, PARTICLES, Prefusion-Stabilized, SARS-CoV-2, Single, Spikes, Vaccine, VIRUS-LIKE False True True NIHTT 37470483 Website Abstract 114172601 Yang Y, et al. https://pubmed.ncbi.nlm.nih.gov/33494381/ <a href="https://pubmed.ncbi.nlm.nih.gov/33494381/">Yang Y, et al.</a> 114110194 Mascola, John NIAID - VRC NIAID Mascola, John (NIAID) 0 114110195 Yang, Yongping NIAID - VRC NIAID Yang, Yongping (NIAID) 0 114110196 Shi, Wei NIAID - VRC NIAID Shi, Wei (NIAID) 0 114110197 Abiona, Olubukola NIAID - VRC NIAID Abiona, Olubukola (NIAID) 0 114110198 Corbett, Kizzmekia NIAID - DIR NIAID Corbett, Kizzmekia (NIAID) 0 114110199 Graham, Barney NIAID - VRC NIAID Graham, Barney (NIAID) 0 114110193 Kwong, Peter NIAID - VRC NIAID Kwong, Peter (NIAID) 1 114110193 Kwong, Peter NIAID - VRC NIAID Kwong, Peter (NIAID) 1 114110194 Mascola, John NIAID - VRC NIAID Mascola, John (NIAID) 0 114110195 Yang, Yongping NIAID - VRC NIAID Yang, Yongping (NIAID) 0 114110196 Shi, Wei NIAID - VRC NIAID Shi, Wei (NIAID) 0 114110197 Abiona, Olubukola NIAID - VRC NIAID Abiona, Olubukola (NIAID) 0 114110198 Corbett, Kizzmekia NIAID - DIR NIAID Corbett, Kizzmekia (NIAID) 0 114110199 Graham, Barney NIAID - VRC NIAID Graham, Barney (NIAID) 0 114102564 Newcastle Disease Virus-Like Particles Displaying Prefusion-Stabilized SARS-CoV-2 Spikes As A Single Dose COVID-19 Vaccine E-068-2021-0 Filing authorized NIAID 83682222 Bailey, Brian bbailey@mail.nih.gov
United States of America TTIPO bbailey@mail.nih.gov?subject=Web Inquiry on [TAB-3439] Newcastle Disease Virus-Like Particle Displaying Prefusion Stabilized SARS-CoV-2 Spike and Its Use&body=Please send me information about technology [TAB-3439] Newcastle Disease Virus-Like Particle Displaying Prefusion Stabilized SARS-CoV-2 Spike and Its Use. Bailey, Brian<br><a href="mailto:bbailey@mail.nih.gov?subject=Web Inquiry on [TAB-3439] Newcastle Disease Virus-Like Particle Displaying Prefusion Stabilized SARS-CoV-2 Spike and Its Use&body=Please send me information about technology [TAB-3439] Newcastle Disease Virus-Like Particle Displaying Prefusion Stabilized SARS-CoV-2 Spike and Its Use.">bbailey@mail.nih.gov</a><br> 114169118 E-068-2021-0 E-068-2021-0-US-01 NEWCASTLE DISEASE VIRUS-LIKE PARTICLE DISPLAYING PREFUSION-STABILIZED SARS-COV-2 SPIKE AND ITS USE PRV US 63/140,250 Abandoned US <br />Provisional (PRV) 63/140,250<br />Filed on 2021-01-21<br />Status: Abandoned 114152117 Newcastle 114152118 Disease 114152119 VIRUS-LIKE 114152120 PARTICLES 114152121 DISPLAYING 114152122 Prefusion-Stabilized 114152123 SARS-CoV-2 114152124 Spikes 114152125 Single 114152126 DOSE 114152127 COVID-19 114152128 Vaccine TAB-3436 114097309 Reducing Bloodstream Neutrophils as a Treatment for Lung Infection and Inflammation NIEHS Antibodies, Cardiology, Collaboration, Dental, Diagnostics, Endocrinology, Immunology, Infectious Disease, Oncology, Ophthalmology, Therapeutics Antibodies Cardiology Collaboration Dental Diagnostics Endocrinology Immunology Infectious Disease Oncology Ophthalmology Therapeutics Michael Fessler, Wan-Chi Lin, Carmen Williams During lung infection, bloodstream neutrophils (PMNs) responding to infection travel to the airspace lumen. Although successful arrival of microbicidal PMNs to the airspace is essential for host defense against inhaled pathogens, excessive accumulation of PMNs in the lung contributes to the pathogenesis of several prevalent lung disorders, including acute lung injury, bronchiectasis, and COPD. Unfortunately, there is no treatment for controlling PMN accumulation in the lung.<br /><br /> NIEHS researchers identified epithelial membrane protein 2 (EMP2) as a lung epithelial protein that regulates PMN entry into the inflamed airspace. EMP2 knockout mice have reduced PMN accumulation and exhibit increased survival during bacterial infection. <ul> <li>EMP2 can selectively target PMN accumulation in the lung, rather than broadly affecting PMN trafficking through all tissues</li> </ul> An EMP2 inhibitor can be developed for the treatment or prophylaxis for a wide variety of neutrophil-dependent lung disorders, such as:.<br /><br /> <ul> <li>acute lung injury</li> <li>pneumonia (bacterial, viral, fungal)</li> <li>bronchiectasis</li> <li>COPD and asthma</li> <li>radiation- or chemotherapeutic-induced pneumonitis</li> <li>idiopathic or induced interstitial lung disease</li> <li>bronchopulmonary dysplasia</li> <li>lung transplant rejection </li> </ul> The NIEHS is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize EMP2 inhibitors as a therapeutic or prophylactic. For collaboration opportunities, please contact: Sharon Soucek, Ph.D. at <a href=“mailto:sharon.soucek@nih.gov ”>sharon.soucek@nih.gov</a> Pending patent applications in US, Europe, Israel, and China. 2022-03-08 2024-10-28 2024-10-28 2022-03-03 2022-02-08 2, BARRIER, DA1XXX, DA3XXX, DA4XXX, DAXXXX, DBXXXX, During, DXXXXX, Epithelial, Infection, Inflammation, INTEGRITY, LUNG, MEMBRANE, PROTECT, Protein, respiratory, Targeting, VJXXXX, VKXXXX, VLXXXX, VPXXXX, WBXXXX, WJXXXX, WKXXXX, XAXXXX, YAXXXX, YBXXXX, YCXXXX False True True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114172598 Lin WC, Gowdy KM, Madenspacher JH, et al. https://pubmed.ncbi.nlm.nih.gov/31550239/ <a href="https://pubmed.ncbi.nlm.nih.gov/31550239/">Lin WC, Gowdy KM, Madenspacher JH, et al.</a> 114110177 Williams, Carmen NIEHS NIEHS Williams, Carmen (NIEHS) 0 114110178 Lin, Wan-Chi NIEHS NIEHS Lin, Wan-Chi (NIEHS) 0 114110176 Fessler, Michael NIEHS NIEHS Fessler, Michael (NIEHS) 1 114110176 Fessler, Michael NIEHS NIEHS Fessler, Michael (NIEHS) 1 114110177 Williams, Carmen NIEHS NIEHS Williams, Carmen (NIEHS) 0 114110178 Lin, Wan-Chi NIEHS NIEHS Lin, Wan-Chi (NIEHS) 0 114102558 Targeting Epithelial Membrane Protein 2 To Protect Respiratory Epithelial Barrier Integrity During Lung Infection And Inflammation E-125-2018-0 Filing authorized NIEHS 114102559 Targeting Epithelial Membrane Protein 2 To Protect Respiratory Epithelial Barrier Integrity During Lung Infection And Inflammation E-125-2018-1 Filing authorized NIEHS 114102560 Targeting Epithelial Membrane Protein 2 To Protect Respiratory Epithelial Barrier Integrity During Lung Infection And Inflammation E-125-2018-2 Filing authorized NIEHS 83739538 Choudhry, Vidita vidita.choudhry@nih.gov
United States of America Office of Technology Transfer and Development vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-3436] Reducing Bloodstream Neutrophils as a Treatment for Lung Infection and Inflammation&body=Please send me information about technology [TAB-3436] Reducing Bloodstream Neutrophils as a Treatment for Lung Infection and Inflammation. Choudhry, Vidita<br><a href="mailto:vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-3436] Reducing Bloodstream Neutrophils as a Treatment for Lung Infection and Inflammation&body=Please send me information about technology [TAB-3436] Reducing Bloodstream Neutrophils as a Treatment for Lung Infection and Inflammation.">vidita.choudhry@nih.gov</a><br> 114169103 E-125-2018-0 E-125-2018-0-US-01 Targeting Epithelial Membrane Protein 2 To Protect Respiratory Epithelial Barrier Integrity During Lung Infection And Inflammation PRV US 62/664,805 Abandoned US <br />Provisional (PRV) 62/664,805<br />Filed on 2018-04-30<br />Status: Abandoned 114169104 E-125-2018-1 E-125-2018-1-US-01 Use of Epithelial Membrane Protein 2 (EMP2) Targeting Agents in Treating Lung Disorders PRV US 62/771,326 Abandoned US <br />Provisional (PRV) 62/771,326<br />Filed on 2018-11-26<br />Status: Abandoned 114169105 E-125-2018-2 E-125-2018-2-PCT-01 USE OF EPITHELIAL MEMBRANE PROTEIN 2 (EMP2) TARGETING AGENTS IN TREATING LUNG DISORDERS PCT COMB Patent Cooperation Treaty PCT/US2019/29801 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2019/29801<br />Filed on 2019-04-30<br />Status: Expired 114169114 E-125-2018-2 E-125-2018-2-US-02 USE OF EPITHELIAL MEMBRANE PROTEIN 2 [EMP2] TARGETING AGENTS IN TREATING LUNG DISORDERS National Stage US 11,890,340 17/051,678 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11890340 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11890340">11,890,340</a><br />Filed on 2020-10-29<br />Status: Issued 114128410 DXXXXX 114128411 DAXXXX 114128412 DBXXXX 114128413 XAXXXX 114128414 DA1XXX 114128415 DA3XXX 114128416 DA4XXX 114128417 WJXXXX 114128418 WKXXXX 114128419 WBXXXX 114128420 VJXXXX 114128421 VKXXXX 114128422 VLXXXX 114128423 VPXXXX 114128424 YAXXXX 114128425 YBXXXX 114128426 YCXXXX 114152070 Targeting 114152071 Epithelial 114152072 MEMBRANE 114152073 Protein 114152074 2 114152075 PROTECT 114152076 respiratory 114152077 BARRIER 114152078 INTEGRITY 114152079 During 114152080 LUNG 114152081 Infection 114152082 Inflammation TAB-3428 114097302 COMBINATION THERAPIES FOR COVID-19 (SARS-COV-2) NIDDK Collaboration, Infectious Disease, Therapeutics Collaboration Infectious Disease Therapeutics Catherine Chen, Yihong Ye, Qi Zhang, Wei Zheng The coronavirus disease 2019 (COVID-19) is caused by a novel RNA enveloped coronavirus, SARS-CoV-2 when the virus enters human airway cells via an ACE2-mediated entry process. This entry pathway is facilitated by the cell surface heparan sulfate proteoglycan (HSPG), which enhances viral attachment to the cell surface. Researchers at NIDDK and NCATS have discovered a collection of FDA-approved drugs that can interfere with the entry of SARS-CoV-2. These drugs can be grouped into three classes based on the distinct steps in the viral entry pathway that they target. Specifically, Mitoxantrone, Raloxifene, and Piceatannol bind to heparan sulfate; Sunitinib and BNTX target the actin cytoskeleton and Tilorone inhibits lysosomes. Strikingly, drugs targeting distinct entry steps can be combined in vitro to achieve a synergized anti-SARS-CoV-2 activity either against Spike-bearing pseudoviral particles or authentic SARS-CoV-2. Given that the safety of these drugs have been well documented in previous clinical studies, it is well positioned to advance these drugs to clinical studies to test their efficacy as a COVID-19 therapy. <ul> <li>COVID-19 therapy</li> </ul> <ul> <li>The technology would provide a low cost alternative therapy for COVID-19 patients. Given that the drugs are small molecules, they can easily reach the site of infection to inhibit viral entry and replication. The combination of Tilorone and Raloxifene can be conveniently given orally.</li> </ul> The National Institute of Diabetes and Digestive and Kidney Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize COMBINATION THERAPIES FOR COVID-19. For collaboration opportunities, please contact: Dr. Yihong Ye at <a href="mailto: yihongy@mail.nih.gov">yihongy@mail.nih.gov</a> 2022-03-08 2024-10-28 2024-10-28 2021-01-25 COVID-19, DB4BXX, ENTRY, HEPARAN, option, Sulfate-dependent, Targeting, therapeutic, viral False True True NIHTT 37470483 Website Abstract 114172593 Zhang, Q. et al.Heparan sulfate assists SARS-CoV-2 in cell entry and can be targeted by approved drugs in vitro. Cell Discov 6, 80 (2020) https://doi.org/10.1038/s41421-020-00222-5 <a href="https://doi.org/10.1038/s41421-020-00222-5">Zhang, Q. et al.Heparan sulfate assists SARS-CoV-2 in cell entry and can be targeted by approved drugs in vitro. Cell Discov 6, 80 (2020)</a> 114110144 Zhang, Qi National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Zhang, Qi (NIDDK) 0 114110153 Zheng, Wei NCATS - TRND NCATS Zheng, Wei (NCATS) 0 114110154 Chen, Catherine NCATS - TRND Chen, Catherine 0 114110145 Ye, Yihong National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Ye, Yihong (NIDDK) 1 114110145 Ye, Yihong National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Ye, Yihong (NIDDK) 1 114110144 Zhang, Qi National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Zhang, Qi (NIDDK) 0 114110153 Zheng, Wei NCATS - TRND NCATS Zheng, Wei (NCATS) 0 114110154 Chen, Catherine NCATS - TRND Chen, Catherine 0 114102551 Targeting Heparan Sulfate-dependent Viral Entry As A Therapeutic Option For COVID-19 E-006-2021-0 Filing authorized National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NCATS - NCGC 83692066 Tong, Betty tongb@niddk.nih.gov
United States of America Senior Technology Advancement Office tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-3428] COMBINATION THERAPIES FOR COVID-19 (SARS-COV-2)&body=Please send me information about technology [TAB-3428] COMBINATION THERAPIES FOR COVID-19 (SARS-COV-2). Tong, Betty<br><a href="mailto:tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-3428] COMBINATION THERAPIES FOR COVID-19 (SARS-COV-2)&body=Please send me information about technology [TAB-3428] COMBINATION THERAPIES FOR COVID-19 (SARS-COV-2).">tongb@niddk.nih.gov</a><br> 114169090 E-006-2021-0 E-006-2021-0-US-01 COMBINATION THERAPIES FOR COVID-19 (SARS-COV-2) PRV US 63/121,796 Abandoned US <br />Provisional (PRV) 63/121,796<br />Filed on 2020-12-04<br />Status: Abandoned 114128370 DB4BXX 114152003 Targeting 114152004 HEPARAN 114152005 Sulfate-dependent 114152006 viral 114152007 ENTRY 114152008 therapeutic 114152009 option 114152010 COVID-19 TAB-3426 114097300 P2Y14 Receptor Antagonists Containing A Biaryl Core NIDDK Collaboration, Endocrinology, Immunology, Pulmonology, Research Equipment, Research Materials, Therapeutics Collaboration Endocrinology Immunology Pulmonology Research Equipment Research Materials Therapeutics Antonella Ciancetta, Kenneth Jacobson, Young-Hwan Jung, Zhiwei Wen, Jinha Yu The technology discloses composition of compounds that fully antagonize the human P2Y14 receptor, with moderate affinity with insignificant antagonism of other P2Y receptors. Therefore, they are highly selective P2Y14 receptor antagonists. Even though there is no P2Y14 receptor modulators in clinical use currently, selective P2Y14 receptor antagonists are sought as potential therapeutic treatments for asthma, cystic fibrosis, inflammation and possibly diabetes and neurodegeneration. <ul> <li>Development of P2Y14 receptor antagonist for treatment of disorders, such as:</li> <li>Inflammation</li> <li>diabetes</li> <li>cystic fibrosis</li> <li>asthma</li> <li>neurodegeneration</li> </ul> </li> <li>metabolic syndromer</li> </ul> The NIDDK is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize P2Y14 Receptor Antagonists Containing A Biaryl Core. For collaboration opportunities, please contact Kenneth A. Jacobson, Ph.D. at ,a href="mailto:kennethj@niddk.nih.gov">kennethj@niddk.nih.gov<la> 2022-03-08 2024-10-28 2024-10-28 2020-11-20 Alkyne, ANTAGONISTS, Biaryl, Containing, Core, IB3XXX, IB4XXX, ID1XXX, P2Y14, Patent Category - Chemistry, RECEPTOR, Structure-based, Triazole, VFXXXX, WIXXXX, WKXXXX, XHXXXX, YBXXXX False True True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114172591 Yu J, et al, Structure-guided modification of heterocyclic antagonists of the P2Y14 receptor. J. Med. Chem., 2018, 61: 4860-4882, (doi: 10.1021/acs.jmedchem.8b00168 ) Yu J, et al, Structure-guided modification of heterocyclic antagonists of the P2Y14 receptor. J. Med. Chem., 2018, 61: 4860-4882, (doi: 10.1021/acs.jmedchem.8b00168 ) 114172592 Jung, Y.H., et al, Exploration of alternative scaffolds for P2Y14 receptor antagonists containing a biaryl core. J. Med. Chem., 2020, 63:9563–9589 (doi: 10.1021/acs.jmedchem.0c00745) Jung, Y.H., et al, Exploration of alternative scaffolds for P2Y14 receptor antagonists containing a biaryl core. J. Med. Chem., 2020, 63:9563–9589 (doi: 10.1021/acs.jmedchem.0c00745) 114110149 Yu, Jinha National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Yu, Jinha 0 114110150 Ciancetta, Antonella National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Ciancetta, Antonella 0 114110151 Wen, Zhiwei National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Wen, Zhiwei (NIDDK) 0 114110152 Jung, Young-Hwan National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Jung, Young-Hwan (NIDDK) 0 114110148 Jacobson, Kenneth National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Jacobson, Kenneth (NIDDK) 1 114110148 Jacobson, Kenneth National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Jacobson, Kenneth (NIDDK) 1 114110149 Yu, Jinha National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Yu, Jinha 0 114110150 Ciancetta, Antonella National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Ciancetta, Antonella 0 114110151 Wen, Zhiwei National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Wen, Zhiwei (NIDDK) 0 114110152 Jung, Young-Hwan National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Jung, Young-Hwan (NIDDK) 0 114102549 P2Y14 Receptor Antagonists Containing A Biaryl Core E-028-2018-0 Filing authorized National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 114102550 P2Y14 Receptor Antagonists Containing A Biaryl Core E-028-2018-1 Filing authorized National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83692066 Tong, Betty tongb@niddk.nih.gov
United States of America Senior Technology Advancement Office tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-3426] P2Y14 Receptor Antagonists Containing A Biaryl Core&body=Please send me information about technology [TAB-3426] P2Y14 Receptor Antagonists Containing A Biaryl Core. Tong, Betty<br><a href="mailto:tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-3426] P2Y14 Receptor Antagonists Containing A Biaryl Core&body=Please send me information about technology [TAB-3426] P2Y14 Receptor Antagonists Containing A Biaryl Core.">tongb@niddk.nih.gov</a><br> 114169077 E-028-2018-0 E-028-2018-0-US-01 HETEROCYCLIC P2Y14 RECEPTOR ANTAGONISTS PRV US 62/628,699 Abandoned US <br />Provisional (PRV) 62/628,699<br />Filed on 2018-02-09<br />Status: Abandoned 114169078 E-028-2018-1 E-028-2018-1-PCT-01 HETEROCYCLIC P2Y14 RECEPTOR ANTAGONISTS PCT COMB Patent Cooperation Treaty PCT/US2019/017422 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2019/017422<br />Filed on 2019-02-11<br />Status: Expired 114169079 E-028-2018-1 E-028-2018-1-US-07 HETEROCYCLIC P2Y14 RECEPTOR ANTAGONISTS National Stage US 11,584,736 16/967,177 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11584736 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11584736">11,584,736</a><br />Filed on 2020-08-04<br />Status: Issued 114128355 XHXXXX 114128356 WKXXXX 114128357 WIXXXX 114128358 ID1XXX 114128359 IB4XXX 114128360 VFXXXX 114128361 IB3XXX 114128362 YBXXXX 114151980 Structure-based 114151981 Alkyne 114151982 Triazole 114151983 P2Y14 114151984 RECEPTOR 114151985 ANTAGONISTS 114151986 Patent Category - Chemistry 114151987 Containing 114151988 Biaryl 114151989 Core TAB-3427 114097301 High-Throughput COVID-19 Diagnostic Test that Detects Both Viral and Host Nucleic Acid NIEHS Collaboration, Diagnostics, Infectious Disease, Research Equipment Collaboration Diagnostics Infectious Disease Research Equipment Oswaldo Lozoya, Brian Papa The rapid worldwide spread and impact of COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has created a need for accurate, reliable, and readily accessible testing on a massive scale. <br /><br /> NIEHS researchers developed a massively paralleled multiplexed screening method using next generation sequencing (NGS). This method uses sample-specific barcoded indexes that detect both SARS-COV-2 virus and the host’s transcriptional response to infection simultaneously. By matching existing laboratory protocols for PCR-based sample processing, this assay is easily incorporated into existing CLIA-certified facilities. This testing approach provides the capability for testing tens of thousands of patient samples in a large bolus, allowing accurate and fast-turnaround SARS-CoV-2 testing capacity at population scale, and permits monitoring of at-risk individuals. <ul> <li>Reduction in reagents needed to perform a test, reducing test cost and bottleneck of critical reagents used during nucleic acid amplification</li> <li>Simultaneously detect the pathogen and a host’s transcriptional response to infection by the pathogen</li> <li>Gene expression information from the donor can be used to predict disease severity</li> </ul> <ul> <li>Diagnostic test for detecting infectious organisms, including SARS-CoV-2</li> </ul> The National Institute of Environmental Health Sciences (NIEHS) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize COVID-19 diagnostics. For collaboration opportunities, please contact Sharon Soucek at <a href="mailto:sharon.soucek@nih.gov">sharon.soucek@nih.gov</a>. 2022-03-08 2024-10-28 2024-10-28 2021-01-11 Acid, assay, DA4BXX, Diagnosis, HOST, Infection, Massively, Multi-patient, Nucleic, Paralleled, PATHOGENIC, PHYSIOLOGY, sequencing, Surveillance, VLXXXX, WBXXXX, XHXXXX, YAXXXX, YBXXXX, YFXXXX False True True 52406769 Prototype 52406769 NIHTT 37470483 Website Abstract 114172590 COVID-19 Testing Technologies Boosted by New Funding. https://factor.niehs.nih.gov/2020/8/feature/2-feature-virus-test/index.htm?utm_source=efactor-newsletter&utm_medium=email&utm_campaign=efactor-newsletter-2020-August <a href="https://factor.niehs.nih.gov/2020/8/feature/2-feature-virus-test/index.htm?utm_source=efactor-newsletter&utm_medium=email&utm_campaign=efactor-newsletter-2020-August">COVID-19 Testing Technologies Boosted by New Funding.</a> 114110146 Papa, Brian NIEHS NIEHS Papa, Brian (NIEHS) 0 114110147 Lozoya, Oswaldo NIEHS NIEHS Lozoya, Oswaldo (NIEHS) 1 114110147 Lozoya, Oswaldo NIEHS NIEHS Lozoya, Oswaldo (NIEHS) 1 114110146 Papa, Brian NIEHS NIEHS Papa, Brian (NIEHS) 0 114102548 Massively Paralleled Multi-patient Assay For Pathogenic Infection Diagnosis And Host Physiology Surveillance Using Nucleic Acid Sequencing E-241-2020-0 Filing authorized NIEHS 83739538 Choudhry, Vidita vidita.choudhry@nih.gov
United States of America Office of Technology Transfer and Development vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-3427] High-Throughput COVID-19 Diagnostic Test that Detects Both Viral and Host Nucleic Acid&body=Please send me information about technology [TAB-3427] High-Throughput COVID-19 Diagnostic Test that Detects Both Viral and Host Nucleic Acid. Choudhry, Vidita<br><a href="mailto:vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-3427] High-Throughput COVID-19 Diagnostic Test that Detects Both Viral and Host Nucleic Acid&body=Please send me information about technology [TAB-3427] High-Throughput COVID-19 Diagnostic Test that Detects Both Viral and Host Nucleic Acid.">vidita.choudhry@nih.gov</a><br> 114169087 E-241-2020-0 E-241-2020-0-US-01 Massively Paralleled Multi-patient Assay For Pathogenic Infection Diagnosis And Host Physiology Surveillance Using Nucleic Acid Sequencing PRV US 63/116,031 Abandoned US <br />Provisional (PRV) 63/116,031<br />Filed on 2020-11-19<br />Status: Abandoned 114169135 E-241-2020-0 E-241-2020-0-PCT-02 Massively Paralleled Multi-patient Assay For Pathogenic Infection Diagnosis And Host Physiology Surveillance Using Nucleic Acid Sequencing PCT Patent Cooperation Treaty PCT/US21/59996 Expired Patent Cooperation Treaty <br />(PCT) PCT/US21/59996<br />Filed on 2021-11-19<br />Status: Expired 114128363 VLXXXX 114128364 WBXXXX 114128365 XHXXXX 114128366 YAXXXX 114128367 YBXXXX 114128368 YFXXXX 114128369 DA4BXX 114151990 Massively 114151991 Paralleled 114151992 Multi-patient 114151993 assay 114151994 PATHOGENIC 114151995 Infection 114151996 Diagnosis 114151997 HOST 114151998 PHYSIOLOGY 114151999 Surveillance 114152000 Nucleic 114152001 Acid 114152002 sequencing TAB-3425 114097299 TRIAZOLE DERIVATIVES AS P2Y14 RECEPTOR ANTAGONISTS NIDDK Collaboration, Endocrinology, Immunology, Pulmonology, Research Equipment, Research Materials, Therapeutics Collaboration Endocrinology Immunology Pulmonology Research Equipment Research Materials Therapeutics Kenneth Jacobson, Anna Junker, Evgeny Kiselev, Elisa Uliassi The technology describes the composition of small molecule compounds that are antagonists of the P2Y14 receptor. Also provided are methods of using the compounds, including a method of treating a disorder, such as inflammation, diabetes, insulin resistance, hyperglycemia, a lipid disorder, obesity, a condition associated with metabolic syndrome, and asthma, and a method of antagonizing P2Y14 receptor activity in a cell. <ul> <li>Development of P2Y14 receptor antagonist for treatment of disorders, such as:</li> <li>Inflammation</li> <li>diabetes</li> <li>obesity</li> <li>asthma</li> <li>lipid disorder</li> <li>metabolic syndromer</li> </ul> The NIDDK is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize TRIAZOLE DERIVATIVES AS P2Y14 RECEPTOR ANTAGONISTS. For collaboration opportunities, please contact Kenneth A. Jacobson, Ph.D. at ,a href="mailto:kennethj@niddk.nih.gov">kennethj@niddk.nih.gov<la> 2022-03-08 2024-10-28 2024-10-28 2020-11-20 Alkyne, ANTAGONISTS, IB3XXX, IB4XXX, ID1XXX, P2Y14, Patent Category - Chemistry, RECEPTOR, Structure-based, Triazole, VFXXXX, WIXXXX, WKXXXX, XHXXXX, YBXXXX False True True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114172589 Junker A, et al, Structure-based design of 3-(4-aryl-1H-1,2,3-triazol-1-yl)-biphenyl derivatives as P2Y14 receptor antagonists. J. Med. Chem., 2016, 59:6149-6168. http://dx.doi.org/10.1021/acs.jmedchem.6b00044 <a href="http://dx.doi.org/10.1021/acs.jmedchem.6b00044">Junker A, et al, Structure-based design of 3-(4-aryl-1H-1,2,3-triazol-1-yl)-biphenyl derivatives as P2Y14 receptor antagonists. J. Med. Chem., 2016, 59:6149-6168.</a> 114110141 Kiselev, Evgeny NIGMS NCI Kiselev, Evgeny (NCI) 0 114110142 Uliassi, Elisa National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Uliassi, Elisa 0 114110143 Junker, Anna National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Junker, Anna 0 114110140 Jacobson, Kenneth National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Jacobson, Kenneth (NIDDK) 1 114110140 Jacobson, Kenneth National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Jacobson, Kenneth (NIDDK) 1 114110141 Kiselev, Evgeny NIGMS NCI Kiselev, Evgeny (NCI) 0 114110142 Uliassi, Elisa National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Uliassi, Elisa 0 114110143 Junker, Anna National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Junker, Anna 0 114102547 Structure-Based Design Of Alkyne And Triazole Derivatives As P2Y14 Receptor Antagonists E-213-2015-0 Filing authorized National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83692066 Tong, Betty tongb@niddk.nih.gov
United States of America Senior Technology Advancement Office tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-3425] TRIAZOLE DERIVATIVES AS P2Y14 RECEPTOR ANTAGONISTS&body=Please send me information about technology [TAB-3425] TRIAZOLE DERIVATIVES AS P2Y14 RECEPTOR ANTAGONISTS. Tong, Betty<br><a href="mailto:tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-3425] TRIAZOLE DERIVATIVES AS P2Y14 RECEPTOR ANTAGONISTS&body=Please send me information about technology [TAB-3425] TRIAZOLE DERIVATIVES AS P2Y14 RECEPTOR ANTAGONISTS.">tongb@niddk.nih.gov</a><br> 114169071 E-213-2015-0 E-213-2015-0-US-01 Triazole Derivatives As P2Y14 Receptor Antagonists PRV US 62/233,162 Abandoned US <br />Provisional (PRV) 62/233,162<br />Filed on 2015-09-25<br />Status: Abandoned 114169072 E-213-2015-0 E-213-2015-0-PCT-02 TRIAZOLE DERIVATIVES AS P2Y14 RECEPTOR ANTAGONISTS PCT Patent Cooperation Treaty PCT/US2016/053397 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2016/053397<br />Filed on 2016-09-23<br />Status: Expired 114169073 E-213-2015-0 E-213-2015-0-US-05 TRIAZOLE DERIVATIVES AS P2Y14 RECEPTOR ANTAGONISTS National Stage US 10,683,277 15/762,852 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10683277 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10683277">10,683,277</a><br />Filed on 2018-03-23<br />Status: Issued 114128336 XHXXXX 114128337 WKXXXX 114128338 WIXXXX 114128339 ID1XXX 114128340 IB4XXX 114128341 VFXXXX 114128342 IB3XXX 114128354 YBXXXX 114151973 Structure-based 114151974 Alkyne 114151975 Triazole 114151976 P2Y14 114151977 RECEPTOR 114151978 ANTAGONISTS 114151979 Patent Category - Chemistry TAB-3417 114097294 A method to label heparan sulfate proteoglycan in the plasma membrane of mammalian cells NIDDK Collaboration, Diagnostics, Research Materials Collaboration Diagnostics Research Materials Yihong Ye, Qi Zhang Heparan sulfate proteoglycan (HSPG) is a group of lipid-anchored proteoglycans, engaged in a variety of key biological functions on cell surface. HSPG-mediated endocytosis of neurotoxic protein aggregates has been linked to aging related neurodegenerative diseases. Labeling HSPG is a promising technique to trace cell profile in cell research, monitor its trafficking in live cells and in tissues. Researchers at the NIDDK have discovered a method in which a positively charged fluorescent protein binds specifically to HSPG on cell surface. This is a promising cost-effective technique that will help scientists to monitor the fate of HSPG in real time on live cell surface as well as to rapidly label the cell boundary-frequently required in cell biology research. <ul> <li>This technology allows a rapid way to detect HSPG on cell surface in live cells</li> <li>This is a faster and more cost effective technology which can also be used in live cell imaging to track HSPG-dependent endocytosis of cargo proteins compared to the current practices which use HSPG antibodies to label HSPG</li> <li>This technology offers a quick method to label the cell boundary-often required in cell biology research</li> </ul> <ul> <li>This technology will be useful to the researchers working on HSPG function in mammalian cells</li> <li>This technology will benefit cell biologists in general to quickly label the cell boundary while doing cell imaging</li> <li>This technology will be useful to researchers working in the field of aging related neurodegenerative studies</li> </ul> The NIDDK is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize Method to Label HSPG in Mammalian Cells. For collaboration opportunities, please contact: Dr. Yihong Ye at <a href="mailto: yihongy@mail.nih.gov">yihongy@mail.nih.gov</a> 2022-03-08 2024-10-28 2024-10-28 2020-08-13 Cells, HEPARAN, Label, MAMMALIAN, MEMBRANE, Method, PLASMA, PROTEOGLYCAN, R1XXXX, SULFATE, XCXXXX False True True NIHTT 37470483 Website Abstract 114172584 Zhang Q, et al A myosin-7B–dependent endocytosis pathway mediates cellular entry of a-synuclein fibrils and polycation-bearing cargos. PNAS May 19, 2020 117 (20) 10865-10875 https://doi.org/10.1073/pnas.1918617117 <a href="https://doi.org/10.1073/pnas.1918617117">Zhang Q, et al A myosin-7B–dependent endocytosis pathway mediates cellular entry of a-synuclein fibrils and polycation-bearing cargos. PNAS May 19, 2020 117 (20) 10865-10875</a> 114110120 Zhang, Qi National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Zhang, Qi (NIDDK) 0 114110121 Ye, Yihong National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Ye, Yihong (NIDDK) 1 114110121 Ye, Yihong National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Ye, Yihong (NIDDK) 1 114110120 Zhang, Qi National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Zhang, Qi (NIDDK) 0 114102542 A Method To Label Heparan Sulfate Proteoglycan In The Plasma Membrane Of Mammalian Cells E-143-2019-0 Research Material National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83692066 Tong, Betty tongb@niddk.nih.gov
United States of America Senior Technology Advancement Office tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-3417] A method to label heparan sulfate proteoglycan in the plasma membrane of mammalian cells&body=Please send me information about technology [TAB-3417] A method to label heparan sulfate proteoglycan in the plasma membrane of mammalian cells. Tong, Betty<br><a href="mailto:tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-3417] A method to label heparan sulfate proteoglycan in the plasma membrane of mammalian cells&body=Please send me information about technology [TAB-3417] A method to label heparan sulfate proteoglycan in the plasma membrane of mammalian cells.">tongb@niddk.nih.gov</a><br> 114128333 R1XXXX 114128334 XCXXXX 114151933 Cells 114151934 MAMMALIAN 114151935 MEMBRANE 114151936 PLASMA 114151937 PROTEOGLYCAN 114151938 SULFATE 114151939 HEPARAN 114151940 Label 114151941 Method TAB-3414 114097291 Codon-Optimized Gene Therapy for Niemann-Pick Disease Type C NHGRI Licensing Licensing Randy Chandler, William ("Bill") Pavan, Charles Venditti Niemann Pick Disease Type C (NPC) is a rare and fatal, autosomal recessive, neurodegenerative disease that can present in infants, children, or adults. Most patients with NPC have mutations in NPC1, a gene implicated in intracellular cholesterol trafficking, which results in intracellular accumulation of unesterified cholesterol in late edosomal/lysosomal structures and of glycosphingolipids, especially in neuronal tissue. No curative therapy exists at present. <br /><br /> Adding to their previous work and patent portfolio of NPC gene constructs, NHGRI investigators have generated improved and codon-optimized gene vectors. These new adeno-associated viral (AAV) vectors have been shown to clear or significantly remove accumulated cellular cholesterol in human mutant NPC1 cell models. In addition to codon-optimization, the vectors can include various tags (e.g., a protein transduction domain peptide, which allows for trans-cellular correction of cells that have not been infected with therapy vector), specialized promoter to increase expression, strong translation initiation site, and/or multiple stop signals. Codon-optimization of the sequence and specialized tags. These improved vector constructs may be utilized for gene therapy of NPC and serve as a model vector for other cholesterol storage disease or disorders. Also entered national phases in Europe and Canada For E-185-2014 also entered national phases in Europe (allowed) and Canada 2022-03-08 2024-10-28 2024-10-28 2020-05-29 AAV, C1, Codon-optimized, Conditions, DEFICIENCY, GENES, Human, NIEMANN-PICK, Novel, NPC1, RELATED, TAGGED, treatment, TYPE, vectors False True True NIHTT 37470483 Website Abstract E-185-2014-0 E-060-2013-0 114110114 Pavan, William ("Bill") National Human Genome Research Institute (NHGRI) NHGRI Pavan, William ("Bill") (NHGRI) 0 114110115 Chandler, Randy National Human Genome Research Institute (NHGRI) NHGRI Chandler, Randy (NHGRI) 0 114110113 Venditti, Charles National Human Genome Research Institute (NHGRI) NHGRI Venditti, Charles (NHGRI) 1 114110113 Venditti, Charles National Human Genome Research Institute (NHGRI) NHGRI Venditti, Charles (NHGRI) 1 114110114 Pavan, William ("Bill") National Human Genome Research Institute (NHGRI) NHGRI Pavan, William ("Bill") (NHGRI) 0 114110115 Chandler, Randy National Human Genome Research Institute (NHGRI) NHGRI Chandler, Randy (NHGRI) 0 114102540 Novel Codon-optimized And Tagged Human NPC1 Genes And AAV Vectors For The Treatment Of Niemann-Pick Type C1 Deficiency And Related Conditions E-100-2017-0 Filing authorized National Human Genome Research Institute (NHGRI) 83703934 Solowiej, Anna anna.solowiej@nih.gov
United States of America anna.solowiej@nih.gov?subject=Web Inquiry on [TAB-3414] Codon-Optimized Gene Therapy for Niemann-Pick Disease Type C&body=Please send me information about technology [TAB-3414] Codon-Optimized Gene Therapy for Niemann-Pick Disease Type C. Solowiej, Anna<br><a href="mailto:anna.solowiej@nih.gov?subject=Web Inquiry on [TAB-3414] Codon-Optimized Gene Therapy for Niemann-Pick Disease Type C&body=Please send me information about technology [TAB-3414] Codon-Optimized Gene Therapy for Niemann-Pick Disease Type C.">anna.solowiej@nih.gov</a><br> 114169025 E-100-2017-0 E-100-2017-0-US-01 Novel Codon-optimized And Tagged Human NPC1 Genes And AAV Vectors For The Treatment Of Niemann-Pick Type C1 Deficiency And Related Conditions PRV US 62/522,677 Abandoned US <br />Provisional (PRV) 62/522,677<br />Filed on 2017-06-20<br />Status: Abandoned 114169026 E-100-2017-0 E-100-2017-0-PCT-02 CODON-OPTIMIZED HUMAN NPC1 GENES FOR THE TREATMENT OF NIEMANN-PICK TYPE C1 DEFICIENCY AND RELATED CONDITIONS PCT Patent Cooperation Treaty PCT/US2018/038584 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2018/038584<br />Filed on 2018-06-20<br />Status: Expired 114169027 E-100-2017-0 E-100-2017-0-US-05 CODON-OPTIMIZED HUMAN NPC1 GENES FOR THE TREATMENT OF NIEMANN-PICK TYPE C1 DEFICIENCY AND RELATED CONDITIONS National Stage US 12,116,577 16/623,863 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12116577 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12116577">12,116,577</a><br />Filed on 2019-12-18<br />Status: Issued 114151906 Novel 114151907 Codon-optimized 114151908 TAGGED 114151909 Human 114151910 NPC1 114151911 GENES 114151912 AAV 114151913 vectors 114151914 treatment 114151915 NIEMANN-PICK 114151916 TYPE 114151917 C1 114151918 DEFICIENCY 114151919 RELATED 114151920 Conditions TAB-3415 114097292 Assay for Predicting the Time of Onset of Niemann-Pick Disease Type C (NPC) NHGRI Diagnostics, Licensing, Neurology, Therapeutics Diagnostics Licensing Neurology Therapeutics Denise Larson, William ("Bill") Pavan, Forbes Porter, Jorge Rodriguez-Gil Niemann-Pick Disease, type C (NPC) is a rare, autosomal recessive, neurodegenerative disease. Approximately 95% of patients with NPC have mutations in NPC1, a gene implicated in intracellular cholesterol trafficking. Mutation of NPC1 causes intracellular accumulation of unesterified cholesterol in late endosomal/lysosomal structures and marked accumulation of glycosphingolipids, especially in neuronal tissue. Thus, NPC patients generally present with hepatosplenomegaly (enlargement of liver and spleen) and neurological degeneration. <br /><br /> NPC is highly heterogeneous in both mutations and time of onset. Most mutations in individuals with NPC are unique to the pedigree, are not localized to specific domains and have not been correlated to time of onset or disease severity. Time of onset of the disease varies from neonatal periods to adulthood. We have shown that lysosomal staining in patient derived fibroblasts quantified by FACS analysis is directly correlated to the time of onset of disease symptoms. For the first time we are able to provide a prognostic assay for NPC, allowing for better treatment and quality of life for sufferers. Prognostic and predictive tool. This assay provides a prognostic tool for predicting time of onset for individuals carrying putative genetic alterations identified in per-and perinatal genetic testing. This approach may be applicable to additional lysosomal storage disorders. 2022-03-08 2024-10-28 2024-10-28 2020-05-29 assay, C, Disease, GAXXXX, Listed LPM Tong as of 4/15/2015, NA2BXX, NIEMANN-PICK, NPC, Onset, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, PREDICTING, TIME, TYPE False True True NIHTT 37470483 Website Abstract E-185-2014-0 E-100-2017-0 114172583 Rodriguez-Gil et al. A Somatic Cell Defect Is Associated With the Onset of Neurological Symptoms in a Lysosomal Storage Disease Mol Genet Metab Sep-Oct 2013;110(1-2):188-90 https://pubmed.ncbi.nlm.nih.gov/23850077/?from_single_result=rodriguez-gil+2013+188&expanded_search_query=rodriguez-gil+2013+188 <a href="https://pubmed.ncbi.nlm.nih.gov/23850077/?from_single_result=rodriguez-gil+2013+188&expanded_search_query=rodriguez-gil+2013+188">Rodriguez-Gil et al. A Somatic Cell Defect Is Associated With the Onset of Neurological Symptoms in a Lysosomal Storage Disease Mol Genet Metab Sep-Oct 2013;110(1-2):188-90</a> 114110117 Rodriguez-Gil, Jorge National Human Genome Research Institute (NHGRI) NHGRI Rodriguez-Gil, Jorge (NHGRI) 0 114110118 Larson, Denise National Human Genome Research Institute (NHGRI) NHGRI Larson, Denise (NHGRI) 0 114110119 Porter, Forbes NICHD NICHD Porter, Forbes (NICHD) 0 114110116 Pavan, William ("Bill") National Human Genome Research Institute (NHGRI) NHGRI Pavan, William ("Bill") (NHGRI) 1 114110116 Pavan, William ("Bill") National Human Genome Research Institute (NHGRI) NHGRI Pavan, William ("Bill") (NHGRI) 1 114110117 Rodriguez-Gil, Jorge National Human Genome Research Institute (NHGRI) NHGRI Rodriguez-Gil, Jorge (NHGRI) 0 114110118 Larson, Denise National Human Genome Research Institute (NHGRI) NHGRI Larson, Denise (NHGRI) 0 114110119 Porter, Forbes NICHD NICHD Porter, Forbes (NICHD) 0 114102541 An Assay For Predicting The Time Of Onset Of Niemann-Pick Disease Type C (NPC) E-060-2013-0 Filing authorized National Human Genome Research Institute (NHGRI), NICHD 83703934 Solowiej, Anna anna.solowiej@nih.gov
United States of America anna.solowiej@nih.gov?subject=Web Inquiry on [TAB-3415] Assay for Predicting the Time of Onset of Niemann-Pick Disease Type C (NPC)&body=Please send me information about technology [TAB-3415] Assay for Predicting the Time of Onset of Niemann-Pick Disease Type C (NPC). Solowiej, Anna<br><a href="mailto:anna.solowiej@nih.gov?subject=Web Inquiry on [TAB-3415] Assay for Predicting the Time of Onset of Niemann-Pick Disease Type C (NPC)&body=Please send me information about technology [TAB-3415] Assay for Predicting the Time of Onset of Niemann-Pick Disease Type C (NPC).">anna.solowiej@nih.gov</a><br> 114169028 E-060-2013-0 E-060-2013-0-US-01 Compositions and Methods for Predicting Age of Onset of A Lysosomal Storage Disease or a Disease Associated with a Lysosomal Defect PRV US 61/781,807 Abandoned US <br />Provisional (PRV) 61/781,807<br />Filed on 2013-03-14<br />Status: Abandoned 114169029 E-060-2013-0 E-060-2013-0-PCT-02 COMPOSITIONS AND METHODS FOR PREDICTING AGE OF ONSET OF A LYSOSOMAL STORAGE DISEASE OR A DISEASE ASSOCIATED WITH A LYSOSOMAL DEFECT PCT Patent Cooperation Treaty PCT/US2014/028986 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2014/028986<br />Filed on 2014-03-14<br />Status: Expired 114169030 E-060-2013-0 E-060-2013-0-US-03 Compositions and Methods for Predicting Age of Onset of a Lysosomal Storage Disease or a Disease Associated with a Lysosomal Defect National Stage US 9,983,200 14/776,440 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9983200 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9983200">9,983,200</a><br />Filed on 2015-09-14<br />Status: Issued 114128331 GAXXXX 114128332 NA2BXX 114151921 assay 114151922 PREDICTING 114151923 TIME 114151924 Onset 114151925 NIEMANN-PICK 114151926 Disease 114151927 TYPE 114151928 C 114151929 NPC 114151930 Listed LPM Tong as of 4/15/2015 114151931 Pre LPM working set 20150418 114151932 Post LPM Assignment Set 20150420 TAB-3408 114097288 Use of the Intracellular Signaling Domain of Receptor CD28H as a Component of Chimeric Antigen Receptors to Overcome Inhibition of Cytotoxic Lymphocytes by Checkpoint Receptors NIAID Collaboration Collaboration Eric Long, Xiaoxuan Zhuang Engineered chimeric antigen receptors (CARs) that are expressed in cytotoxic T cells and natural killer (NK) cells have been used to specifically target tumor cells. However, CAR-T and CAR-NK cells are still subject to down regulation by their inhibitory receptors after injection into patients. <br /><br /> Scientists at NIAID have developed CAR constructs that overcome inhibition of NK cells by receptors for human major histocompatibility complex molecules HLA-E and HLA-C, based on in vitro studies. The CAR contains an antigen binding domain of receptor CD28 homolog (CD28H), a CD28H transmembrane domain (TM), a CD28H signaling domain, and other intracellular signaling domains, such as 2B4 (CD244) and CD3 zeta chain (CD3zeta). A variant of this CAR, in which the antigen binding domain of CD28H is replaced by a single-chain antibody variable region (scFv) that binds to CD19, rendered NK cells resistant to inhibition by HLA-E and HLA-C on CD19+ tumor cells. <ul> <li>Resistant to inhibition of NK cells or T cells by HLA-E and HLA-C</li> <li>Manufacturing efficiency</li> <li>CAR-NK can be developed without the need to genetic silencing of TCR</li> </li> <ul> <li>Method of adoptive therapy where CAR-NK cell or CAR-T cell is the effector cell</li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize this technology. For collaboration opportunities, please contact Christopher Kornak at <a href="mailto:chris.kornak@nih.gov">chris.kornak@nih.gov</a>or 1-240-627-3705. 2022-09-28 2024-10-28 2024-10-28 2020-04-20 ANTIGEN, CANCER, CAR, CD28H, CHECKPOINT, chimeric, COMPONENT, cytotoxic, Domain, Immunotherapy, inhibition, Intracellular, lymphocytes, Overcome, RECEPTOR, RECEPTORS, SIGNALING, YXXXXX False True True NIHTT 37470483 Website Abstract 114172580 Zhuang X, Long EO, “CD28 homolog is a strong activator of natural killer cells for lysis of B7H7-positive tumor cells.” Cancer Immunol Res 7(6):939-951. April 24, 2019 https://cancerimmunolres.aacrjournals.org/content/7/6/939.long <a href="https://cancerimmunolres.aacrjournals.org/content/7/6/939.long">Zhuang X, Long EO, “CD28 homolog is a strong activator of natural killer cells for lysis of B7H7-positive tumor cells.” Cancer Immunol Res 7(6):939-951. April 24, 2019</a> 114172581 Zhuang X , Long EO, Trends Immunol: "Inhibition-resistant CARs for NK cell cancer immunotherapy" Trends Immunol 40:1078-1081, December 2019. https://doi.org/10.1016/j.it.2019.10.004 <a href="https://doi.org/10.1016/j.it.2019.10.004">Zhuang X , Long EO, Trends Immunol: "Inhibition-resistant CARs for NK cell cancer immunotherapy" Trends Immunol 40:1078-1081, December 2019. </a> 114110107 Zhuang, Xiaoxuan NIAID - DIR NCI Zhuang, Xiaoxuan (NCI) 0 114110106 Long, Eric NIAID - DIR NIAID Long, Eric (NIAID) 1 114110106 Long, Eric NIAID - DIR NIAID Long, Eric (NIAID) 1 114110107 Zhuang, Xiaoxuan NIAID - DIR NCI Zhuang, Xiaoxuan (NCI) 0 114102425 Use Of Receptor CD28H As A Component Of Chimeric Antigen Receptors In Lymphocytes For Cancer Immunotherapy E-097-2020-0 Filing authorized NIAID 83738793 Taylor-Mulneix, Dawn dawn.taylor-mulneix@nih.gov
United States of America dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-3408] Use of the Intracellular Signaling Domain of Receptor CD28H as a Component of Chimeric Antigen Receptors to Overcome Inhibition of Cytotoxic Lymphocytes by Checkpoint Receptors &body=Please send me information about technology [TAB-3408] Use of the Intracellular Signaling Domain of Receptor CD28H as a Component of Chimeric Antigen Receptors to Overcome Inhibition of Cytotoxic Lymphocytes by Checkpoint Receptors . Taylor-Mulneix, Dawn<br><a href="mailto:dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-3408] Use of the Intracellular Signaling Domain of Receptor CD28H as a Component of Chimeric Antigen Receptors to Overcome Inhibition of Cytotoxic Lymphocytes by Checkpoint Receptors &body=Please send me information about technology [TAB-3408] Use of the Intracellular Signaling Domain of Receptor CD28H as a Component of Chimeric Antigen Receptors to Overcome Inhibition of Cytotoxic Lymphocytes by Checkpoint Receptors .">dawn.taylor-mulneix@nih.gov</a><br> 114160579 E-097-2020-0 E-097-2020-0-PCT-01 CD28H DOMAIN-CONTAINING CHIMERIC ANTIGEN RECEPTORS AND METHODS OF USE PCT Patent Cooperation Treaty PCT/US2020/024985 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2020/024985<br />Filed on 2020-03-26<br />Status: Expired 114169659 E-097-2020-0 E-097-2020-0-US-02 CD28H DOMAIN-CONTAINING CHIMERIC ANTIGEN RECEPTORS AND METHODS OF USE National Stage US 17/914,027 Pending US <br />National Stage 17/914,027<br />Filed on 2022-09-23<br />Status: Pending 114128326 YXXXXX 114151869 Intracellular 114151870 SIGNALING 114151871 Domain 114151872 RECEPTOR 114151873 CD28H 114151874 COMPONENT 114151875 chimeric 114151876 ANTIGEN 114151877 RECEPTORS 114151878 Overcome 114151879 inhibition 114151880 cytotoxic 114151881 lymphocytes 114151882 CHECKPOINT 114151883 CANCER 114151884 Immunotherapy 114151885 CAR TAB-34 114094374 Local Magnetization Spoiling Using a Gradient Insert for Reducing the Field of View in Magnetic Resonance Imaging NHLBI Licensing Licensing Robert Balaban, Han Wen, David Wiesler, Steven Wolff The present invention provides a method and device for eliminating alias artifacts encountered in MRI when the field of view is made smaller than the subject being imaged. Significant advantages accrue from reducing the field of view to a smaller region of interest. These include reduced imaging time, increased spatial and temporal resolution, and less susceptibility to motion artifacts. The device operates by dephasing the magnetic resonance signal in regions away from the region of interest by means of a gradient insert. 2022-03-08 2024-10-28 2024-10-28 1998-06-01 AA3B1X, AA3BXX, AA3XXX, AAXXXX, ALL DISEASES, AXXXXX, CSalata, diagnostic, Field, GENERAL MEDICINE, GRADIENT, IMAGING, INSERT, LOCAL, Magnetic, Magnetization, MRI, REDUCING, Resonance, SPOILING, VIEW False True True NIHTT 37470483 Website Abstract 114102971 Wolff, Steven National Heart, Lung, and Blood Institute (NHLBI) Wolff, Steven 0 114102972 Balaban, Robert National Heart, Lung, and Blood Institute (NHLBI) NHLBI Balaban, Robert (NHLBI) 0 114102973 Wen, Han National Heart, Lung, and Blood Institute (NHLBI) NHLBI Wen, Han (NHLBI) 0 114102974 Wiesler, David National Heart, Lung, and Blood Institute (NHLBI) Wiesler, David 1 114102974 Wiesler, David National Heart, Lung, and Blood Institute (NHLBI) Wiesler, David 1 114102971 Wolff, Steven National Heart, Lung, and Blood Institute (NHLBI) Wolff, Steven 0 114102972 Balaban, Robert National Heart, Lung, and Blood Institute (NHLBI) NHLBI Balaban, Robert (NHLBI) 0 114102973 Wen, Han National Heart, Lung, and Blood Institute (NHLBI) NHLBI Wen, Han (NHLBI) 0 114099161 LOCAL MAGNETIZATION SPOILING USING A GRADIENT INSERT FOR REDUCING THE FIELD OF VIEW IN MAGNETIC RESONANCE IMAGING E-123-1997-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-34] Local Magnetization Spoiling Using a Gradient Insert for Reducing the Field of View in Magnetic Resonance Imaging&body=Please send me information about technology [TAB-34] Local Magnetization Spoiling Using a Gradient Insert for Reducing the Field of View in Magnetic Resonance Imaging. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-34] Local Magnetization Spoiling Using a Gradient Insert for Reducing the Field of View in Magnetic Resonance Imaging&body=Please send me information about technology [TAB-34] Local Magnetization Spoiling Using a Gradient Insert for Reducing the Field of View in Magnetic Resonance Imaging.">shmilovm@nih.gov</a><br> 114159977 E-123-1997-0 E-123-1997-0-US-03 LOCAL MAGNETIZATION SPOILING USING A GRADIENT INSERT FOR REDUCING THE FIELD OF VIEW IN MAGNETIC RESONANCE IMAGING National Stage US 6,384,601 09/403,530 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6384601 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6384601">6,384,601</a><br />Filed on 2000-06-19<br />Status: Expired 114164773 E-123-1997-0 E-123-1997-0-US-01 LOCAL MAGNETIZATION SPOILING USING A GRADIENT INSERT FOR REDUCING THE FIELD OF VIEW IN MAGNETIC RESONANCE IMAGING PRV US 60/043,292 Abandoned US <br />Provisional (PRV) 60/043,292<br />Filed on 1997-04-11<br />Status: Abandoned 114164774 E-123-1997-0 E-123-1997-0-PCT-02 LOCAL MAGNETIZATION SPOILING USING A GRADIENT INSERT FOR REDUCING THE FIELD OF VIEW IN MAGNETIC RESONANCE IMAGING PCT Patent Cooperation Treaty PCT/US1998/006787 Expired Patent Cooperation Treaty <br />(PCT) PCT/US1998/006787<br />Filed on 1998-04-06<br />Status: Expired 114111761 AA3B1X 114111762 AA3BXX 114111763 AA3XXX 114111764 AAXXXX 114111765 AXXXXX 114129901 diagnostic 114129902 MRI 114129903 GENERAL MEDICINE 114129904 ALL DISEASES 114129905 CSalata 114129906 LOCAL 114129907 Magnetization 114129958 SPOILING 114129959 GRADIENT 114129960 INSERT 114129961 REDUCING 114129962 Field 114129963 VIEW 114129964 Magnetic 114129965 Resonance 114129966 IMAGING TAB-3388 114097277 Broadly Protective Influenza Vaccine Comprising a Cocktail of Inactivated Avian Influenza Viruses NIAID Collaboration, Materials Available Collaboration Materials Available Louis Schwartzman, Jeffery Taubenberger There is a great need for broadly protective, “universal” influenza virus vaccines given the antigenic drift and shift of influenza viruses and the variable protective efficacy of the current influenza vaccines. This technology relates to a broadly protective, “universal” influenza vaccine candidate composed of a cocktail of different low pathogenicity avian influenza virus subtypes inactivated by betapropiolactone (BPL). Vaccinating animals with BPL-inactivated whole virus vaccine comprising influenza virus strains belonging to four or more different low pathogenicity avian influenza hemagglutinin subtypes, intranasally or intramuscularly, provided extremely broad protection and heterosubtypic protection to lethal challenge with influenza viruses in both mice and ferrets. This influenza vaccine technology has a great potential to offer broad protection against both seasonal and pandemic-potential influenza viruses.<br /><br /> This technology is available for licensing for commercial development in accordance with 35 U.S.C. § 209 and 37 CFR Part 404. <ul> <li>Broad protection to both seasonal and pandemic-potential influenza viruses</li> <li>Easy and cost-effective inactivation method</li> <li>Effective immune response due to the use of authentic viral antigens</li> <li>Animal data available</li> </ul> <ul> <li>Vaccine against viruses</li> <li>Vaccines against influenza virus</li> <li>Universal influenza virus vaccine</li> </ul> The National Institute of Allergy and Infectious Diseases is also seeking statements of capability or interest from parties interested in collaborative research. NIAID would like a prospective collaborator to have the capacity to generate clinical grade materials and perform clinical studies. NIAID will consider executing a Confidentiality Agreement with a prospective collaborator to facilitate receipt of a Capability Statement if requested. For collaboration opportunities, please contact Dr. Elizabeth Pitts at <a href="mailto: elizabeth.pitts@nih.gov">elizabeth.pitts@nih.gov</a> or 240-669-5299. . . 2022-03-08 2024-10-28 2024-10-28 2020-07-06 1, Avian, Broadly, Cocktail, CONSISTING, Development, INACTIVATED, INFLUENZA, Protective, Vaccine, Viruses False True True NIHTT 37470483 Website Abstract 114110050 Schwartzman, Louis NIAID - DIR NIAID Schwartzman, Louis (NIAID) 0 114110049 Taubenberger, Jeffery NIAID - DIR NIAID Taubenberger, Jeffery (NIAID) 1 114110049 Taubenberger, Jeffery NIAID - DIR NIAID Taubenberger, Jeffery (NIAID) 1 114110050 Schwartzman, Louis NIAID - DIR NIAID Schwartzman, Louis (NIAID) 0 114102521 Development Of A Broadly Protective Influenza Vaccine Consisting Of A Cocktail Of Inactivated Avian Influenza Viruses 1 E-033-2018-0 Filing authorized NIAID 91021353 Pitts, Elizabeth elizabeth.pitts@nih.gov
United States of America elizabeth.pitts@nih.gov?subject=Web Inquiry on [TAB-3388] Broadly Protective Influenza Vaccine Comprising a Cocktail of Inactivated Avian Influenza Viruses&body=Please send me information about technology [TAB-3388] Broadly Protective Influenza Vaccine Comprising a Cocktail of Inactivated Avian Influenza Viruses. Pitts, Elizabeth<br><a href="mailto:elizabeth.pitts@nih.gov?subject=Web Inquiry on [TAB-3388] Broadly Protective Influenza Vaccine Comprising a Cocktail of Inactivated Avian Influenza Viruses&body=Please send me information about technology [TAB-3388] Broadly Protective Influenza Vaccine Comprising a Cocktail of Inactivated Avian Influenza Viruses.">elizabeth.pitts@nih.gov</a><br> 114168942 E-033-2018-0 E-033-2018-0-US-01 BROADLY PROTECTIVE INACTIVATED INFLUENZA VIRUS VACCINE PRV US 62/620,051 Abandoned US <br />Provisional (PRV) 62/620,051<br />Filed on 2018-01-22<br />Status: Abandoned 114168943 E-033-2018-0 E-033-2018-0-PCT-02 Development Of A Broadly Protective Influenza Vaccine Consisting Of A Cocktail Of Inactivated Avian Influenza Viruses 1 PCT Patent Cooperation Treaty PCT/US2019/014220 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2019/014220<br />Filed on 2019-01-18<br />Status: Expired 114169042 E-033-2018-0 E-033-2018-0-US-06 BROADLY PROTECTIVE INACTIVATED INFLUENZA VIRUS VACCINE National Stage US 11,369,675 16/963,718 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11369675 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11369675">11,369,675</a><br />Filed on 2020-07-21<br />Status: Issued 114151703 Development 114151704 Broadly 114151705 Protective 114151706 INFLUENZA 114151707 Vaccine 114151708 CONSISTING 114151709 Cocktail 114151710 INACTIVATED 114151711 Avian 114151712 Viruses 114151713 1 TAB-3390 114097278 Therapeutic and Diagnostic Targets for Severe RSV Infection NIEHS Diagnostics, Infectious Disease, Licensing, Therapeutics, Vaccines Diagnostics Infectious Disease Licensing Therapeutics Vaccines Steven Kleeberger, Daniel Menendez Rendon, Michael Resnick Respiratory Syncytial Virus (RSV) infects nearly all children by their second birthday. RSV usually causes mild respiratory illness, however, a subset of patients experience severe infection that require hospitalization. Successful host defense against viral pathogens requires rapid recognition of the virus and activation of both innate and adaptive immunity. Toll-Like Receptors (TLRs) are responsible for mounting an innate immune response and genetic variations within TLRs modulate severity of infection. Researchers at NIEHS have identified a single nucleotide polymorphism (SNP) in TLR8 that is associated with RSV disease severity. The SNP is p53-responsive allele, indicating that p53, a master cell cycle regulator, can strongly influence TLR8 mediated immune responses. Identification of this SNP can inform diagnosis and prognosis of RSV disease and serve as a therapeutic target for severe RSV infection. <ul> <li>Enhance the innate immune response to respiratory infection</li> <li>Improve clinical trial outcome in patients with TLR8 mediated RSV infection</li> </ul> <ul> <li>Development of therapeutics against severe RSV infection</li> <li>Diagnostic biomarker</li> </ul> 2022-03-08 2024-10-28 2024-10-28 2020-02-06 DAXXXX, DBXXXX, DCXXXX, Human, Identifies, Infection, p53, PROMOTER, RESPONSIVE, Risk, RSV, Serious, SNP, TLR8 False True True NIHTT 37470483 Website Abstract 114110052 Menendez Rendon, Daniel NIEHS NIEHS Menendez Rendon, Daniel (NIEHS) 0 114110053 Kleeberger, Steven NIEHS NIEHS Kleeberger, Steven (NIEHS) 0 114110051 Resnick, Michael NIEHS NIEHS Resnick, Michael (NIEHS) 1 114110051 Resnick, Michael NIEHS NIEHS Resnick, Michael (NIEHS) 1 114110052 Menendez Rendon, Daniel NIEHS NIEHS Menendez Rendon, Daniel (NIEHS) 0 114110053 Kleeberger, Steven NIEHS NIEHS Kleeberger, Steven (NIEHS) 0 114102522 A P53 Responsive SNP In The Human TLR8 Promoter Identifies Risk Of Serious RSV Infection E-072-2019-0 Filing authorized NIEHS 83739538 Choudhry, Vidita vidita.choudhry@nih.gov
United States of America Office of Technology Transfer and Development vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-3390] Therapeutic and Diagnostic Targets for Severe RSV Infection&body=Please send me information about technology [TAB-3390] Therapeutic and Diagnostic Targets for Severe RSV Infection. Choudhry, Vidita<br><a href="mailto:vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-3390] Therapeutic and Diagnostic Targets for Severe RSV Infection&body=Please send me information about technology [TAB-3390] Therapeutic and Diagnostic Targets for Severe RSV Infection.">vidita.choudhry@nih.gov</a><br> 114168958 E-072-2019-0 E-072-2019-0-US-01 USE OF A TLR8-ASSOCIATED SNP IN PROGNOSING AND TREATING INDIVIDUALS PRV US 62/881,656 Abandoned US <br />Provisional (PRV) 62/881,656<br />Filed on 2019-08-01<br />Status: Abandoned 114128285 DAXXXX 114128286 DBXXXX 114128287 DCXXXX 114151714 p53 114151715 RESPONSIVE 114151716 SNP 114151717 Human 114151718 TLR8 114151719 PROMOTER 114151720 Identifies 114151721 Risk 114151722 Serious 114151723 RSV 114151724 Infection TAB-3381 114097271 Potent Nucleotide Inhibitors of Ecto-5'-Nucleotidase (CD73) NIDDK Collaboration, Oncology, Therapeutics Collaboration Oncology Therapeutics Kenneth Jacobson, Anna Junker, Christa Mueller These small molecules are novel nucleotide derivatives, containing either a purine or pyrimidine nucleobase, that competitively block the enzyme CD73, also known as ecto-5'-nucleotidase. This enzyme converts extracellular AMP (not a potent activator of adenosine receptors) to adenosine (the native activator of 4 subtypes of adenosine receptors. CD73 inhibitors are being used, in clinical trials and preclinical research, in conjunction with cancer immunotherapy. CD73 is upregulated around tumors to produce excessive adenosine, and blocking this enzyme greatly reduces immunosuppressive adenosine in the tumor microenvironment. Therefore, combined therapy is expected to be more effective than cancer immunotherapy alone. Pharma companies are working on blockers, either small molecules or monocolonal antibodies, to block CD73 for application to cancer therapy, and some have already entered clinical trials. <ul> <li>Previously, adenine nucleotides have been used as CD73 inhibitors in research, but these can lead to off-target activity at purinergic receptors. Thus, the ability to potently inhibit the enzyme using a different nucleobase derivative can provide greater specificity for the target in comparison to earlier inhibitors.</li> </ul> <ul> <li>Coadministration of an inhibitor of CD73 offers synergistic anti-tumor activity</li> <li> In addition to cancer immunotherapy, CD73 inhibitors might have utility in preeclampsia, pulmonary edema, infectious disease, and other conditions</li> </ul> The NIDDK is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize Potent Nucleotide Inhibitors of Ecto-5'-Nucleotidase (CD73). For collaboration opportunities, please contact Betty B. Tong, Ph.D. at <a href="mailto:tongb@mail.nih.gov">tongb@mial.nih.gov<la> or 301-451-7836. 2022-03-08 2024-10-28 2024-10-28 2019-08-09 CB5EXX, CD73, Ecto-5-nucleotidase, Inhibitors, Nucleotide, POTENT False True True NIHTT 37470483 Website Abstract 114172552 Junker, A., et al Structure-Activity relationship of purine and pyrimidine nucleotides as ecto-5'-nucleotidase (CD73) inhibitors., J. Med. Chem., 2019, 62:3677-369 Junker, A., et al Structure-Activity relationship of purine and pyrimidine nucleotides as ecto-5'-nucleotidase (CD73) inhibitors., J. Med. Chem., 2019, 62:3677-369 114110032 Mueller, Christa University of Bonn [Rheinische Friedrich-Wilhelms-Universitat] Mueller, Christa 0 114110033 Junker, Anna University of Munster Junker, Anna 0 114110031 Jacobson, Kenneth National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Jacobson, Kenneth (NIDDK) 1 114110031 Jacobson, Kenneth National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Jacobson, Kenneth (NIDDK) 1 114110032 Mueller, Christa University of Bonn [Rheinische Friedrich-Wilhelms-Universitat] Mueller, Christa 0 114110033 Junker, Anna University of Munster Junker, Anna 0 114102516 Potent Nucleotide Inhibitors Of Ecto-5’-nucleotidase (CD73) E-132-2018-0 Filing authorized European Institute for Molecular Imaging, European Institute for Molecular Imaging (EIMI), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), University of Bonn [Rheinische Friedrich-Wilhelms-Universitat], University of Munster 83692066 Tong, Betty tongb@niddk.nih.gov
United States of America Senior Technology Advancement Office tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-3381] Potent Nucleotide Inhibitors of Ecto-5'-Nucleotidase (CD73)&body=Please send me information about technology [TAB-3381] Potent Nucleotide Inhibitors of Ecto-5'-Nucleotidase (CD73). Tong, Betty<br><a href="mailto:tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-3381] Potent Nucleotide Inhibitors of Ecto-5'-Nucleotidase (CD73)&body=Please send me information about technology [TAB-3381] Potent Nucleotide Inhibitors of Ecto-5'-Nucleotidase (CD73).">tongb@niddk.nih.gov</a><br> 114168902 E-132-2018-0 E-132-2018-0-US-01 PURINE AND PYRIMIDINE NUCLEOTIDES AS ECTO-5'-NUCLEOTIDASE INHIBITORS PRV US 62/719,492 Abandoned US <br />Provisional (PRV) 62/719,492<br />Filed on 2018-08-17<br />Status: Abandoned 114168904 E-132-2018-1 E-132-2018-1-PCT-01 PURINE AND PYRIMIDINE NUCLEOTIDES AS ECTO-5’-NUCLEOTIDASE INHIBITORS PCT Patent Cooperation Treaty PCT/US2019/046931 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2019/046931<br />Filed on 2019-08-16<br />Status: Expired 114128279 CB5EXX 114151630 POTENT 114151631 Nucleotide 114151632 Inhibitors 114151633 Ecto-5-nucleotidase 114151634 CD73 TAB-3371 114097270 One-Step Random Amplification Method to Detect Extremely Low Input Nucleic Acids for Virome, Microbiome, and Metagenomics in Clinical and Biological Specimens CDC Collaboration, Consumer Products, Diagnostics, Infectious Disease, Licensing, Occupational Safety and Health, Research Materials, Therapeutics Collaboration Consumer Products Diagnostics Infectious Disease Licensing Occupational Safety and Health Research Materials Therapeutics Fei Fan (Terry) Ng Clinical and biological specimens often contain microbial nucleic acid in extremely low quantities, presenting a significant challenge for the detection of viral and bacterial pathogens. This also prevents direct sequencing of non-culturable samples using next-generation sequencing (NGS). Currently, NGS library preparation on most platforms requires 0.1 ng to 10 µg of DNA or cDNA, while microbial or viral nucleic acids in clinically relevant specimens, such as blood, serum, respiratory secretions, cerebral spinal fluid, and stool, often contain less than 0.1 ng.<br/><br/> CDC developed a rapid random amplification method capable of amplifying DNA and/or RNA inputs of less than 0.001 ng from biological samples. CDC’s method produces amplicons in amounts sufficient for NGS platforms. It allows non-biased universal amplification of all nucleic acids in a sample. Compared to traditional specific PCR (polymerase chain reaction), this technology amplifies unknown microorganisms without prior sequence knowledge and eliminates the need for microorganism-specific primer design. The method is rapid and requires minimal hands-on effort, while offering high sensitivity, time-savings, and high-throughput processing for random nucleic acid amplification. <br/><br/> Pilot experiments showed that low-yield clinical specimen viral RNA not amplified by other commercial random-amplification kits was amplified by this method and successfully sequenced. Thus far, CDC has achieved whole genome sequencing of a variety of viruses directly from clinical specimens, including but not limited to enterovirus (EV-D68, CV-A24, and EV-A71), cosavirus, parechovirus, and norovirus. Additional virus studies are underway. <ul> <li>Rapid one-step or two-step protocol with few hands-on procedures with high sensitivity</li> <li> Can amplify either DNA or RNA from biological samples</li> <li>Offers nonbiased amplification of all nucleic acids in a sample </li> <li>Allows high-throughput processing of samples, including both culturable and non-culturable samples, and low to high yield nucleic acids </li> <li>Provides a broadly applicable method when using universal primers and eliminates the need for microorganism-specific primer design</li> </ul> <ul> <li>Virome, microbiome, and metagenomics research using direct, non-culturable samples from humans, animals, and the environment</li> <li>Amplification to detect viruses and microbes in clinical specimens – especially when input nucleic acid is low or when rapid, random amplification is needed</li> <li>Agnostic amplification, or testing sample without prior sequence knowledge</li> <li>One-step whole genome or whole transcriptome amplification kits</li> <li>Amplification of clinical samples in the field, such as remote areas or during an outbreak</li> <li>Monitoring and public health surveillance research</li> </ul> The CDC Technology Transfer Office (TTO) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize: One-step random amplification method to detect extremely low input nucleic acids for virome, microbiome, and metagenomics in clinical and biological specimens. For collaboration opportunities, please contact CDC TTO at <a href="mailto:tto@cdc.gov">tto@cdc.gov</a> or 1-404-639-1330. 2022-05-29 2024-10-28 2024-10-28 2022-03-10 Acids, amplification, EXTREMELY, Input, LOW, Method, Nucleic, ONE-STEP, RANDOM, VJXXXX, VLXXXX, VOXXXX, WBXXXX, WCXXXX, WFXXXX, WHXXXX, WIXXXX, WMXXXX, XEXXXX, YBXXXX False False True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114110030 Ng, Fei Fan (Terry) CDC - DIR CDC Ng, Fei Fan (Terry) (CDC) 1 114110030 Ng, Fei Fan (Terry) CDC - DIR CDC Ng, Fei Fan (Terry) (CDC) 1 114102515 One-step Random Amplification Method For Extremely Low Input Nucleic Acids E-161-2017-0 Filing authorized Centers for Disease Control and Prevention (CDC) 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-3371] One-Step Random Amplification Method to Detect Extremely Low Input Nucleic Acids for Virome, Microbiome, and Metagenomics in Clinical and Biological Specimens&body=Please send me information about technology [TAB-3371] One-Step Random Amplification Method to Detect Extremely Low Input Nucleic Acids for Virome, Microbiome, and Metagenomics in Clinical and Biological Specimens. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-3371] One-Step Random Amplification Method to Detect Extremely Low Input Nucleic Acids for Virome, Microbiome, and Metagenomics in Clinical and Biological Specimens&body=Please send me information about technology [TAB-3371] One-Step Random Amplification Method to Detect Extremely Low Input Nucleic Acids for Virome, Microbiome, and Metagenomics in Clinical and Biological Specimens.">jonathan.motley@nih.gov</a><br> 114168882 E-161-2017-0 E-161-2017-0-US-01 One-step Random Amplification Method For Extremely Low Input Nucleic Acids PRV US 62/625,675 Abandoned US <br />Provisional (PRV) 62/625,675<br />Filed on 2018-02-02<br />Status: Abandoned 114168883 E-161-2017-0 E-161-2017-0-PCT-02 RANDOM AMPLIFICATION METHODS FOR EXTREMELY LOW INPUT NUCLEIC ACIDS PCT Patent Cooperation Treaty PCT/US2019/016383 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2019/016383<br />Filed on 2019-02-01<br />Status: Expired 114169043 E-161-2017-0 E-161-2017-0-US-04 RANDOM AMPLIFICATION METHODS FOR EXTREMELY LOW INPUT NUCLEIC ACIDS National Stage US 11,814,674 16/965,856 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11814674 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11814674">11,814,674</a><br />Filed on 2020-07-29<br />Status: Issued 114128268 YBXXXX 114128269 VJXXXX 114128270 VLXXXX 114128271 VOXXXX 114128272 WBXXXX 114128273 WCXXXX 114128274 WFXXXX 114128275 WHXXXX 114128276 WIXXXX 114128277 WMXXXX 114128278 XEXXXX 114151621 ONE-STEP 114151622 RANDOM 114151623 amplification 114151624 Method 114151625 EXTREMELY 114151626 LOW 114151627 Input 114151628 Nucleic 114151629 Acids TAB-3358 114097264 Potential Treatment for sickle-cell disease and thalassemia NHLBI Collaboration, Therapeutics Collaboration Therapeutics Bjorg Gudmundsdottir, John Tisdale, Laxminath Tumburu The technology addresses treatment options for diseases such as sickle-cell and thalassemia. Traditionally, such beta-globinopathies are treated through bone marrow transplantation. However, this method is limited due to high treatment costs and finding a matched-donor. This relies on increasing fetal hemoglobin to potentially cure the disease. NIH inventors have identified a protein called Rio-Kinase 3 (RIOK3), that inhibits the production of fetal hemoglobin. Their work shows that inhibiting RIOK3 increases the production of fetal hemoglobin. Thus, RIOK3 is a promising novel therapeutic target to increase fetal hemoglobin expression. <ul> <li>A novel and cost-effective treatment strategy in beta-globinopathies</li> </ul> <ul> <li>Designing lentiviral vectors to genetically target RIOK3</li> <li>Gene editing using endonucleases such as CRISPR/Cas9</li> <li>Developing orally administered RIOK3 specific kinase inhibitor drugs</li> </ul> The NHLBI is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize use of RIOK3 as therapeutic target in the treatment of beta-globinopathies. For collaboration opportunities, please contact Mr. Michael Shmilovich at <a href="mailto:michael.shmilovich@nih.gov">michael.shmilovich@nih.gov</a> 2022-03-08 2024-10-28 2024-10-28 2019-01-17 Activity, Beta-globinopathies, inhibition, RIOK3, treatment, WKXXXX, XEXXXX, YBXXXX, YCXXXX False True True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114172549 Gudmundsdottir B., et al. https://www.ncbi.nlm.nih.gov/pubmed/29898395 <a href="https://www.ncbi.nlm.nih.gov/pubmed/29898395">Gudmundsdottir B., et al. </a> 114110007 Gudmundsdottir, Bjorg National Heart, Lung, and Blood Institute (NHLBI) NHLBI Gudmundsdottir, Bjorg (NHLBI) 0 114110008 Tumburu, Laxminath National Heart, Lung, and Blood Institute (NHLBI) NHLBI Tumburu, Laxminath (NHLBI) 0 114110006 Tisdale, John National Heart, Lung, and Blood Institute (NHLBI) NHLBI Tisdale, John (NHLBI) 1 114110006 Tisdale, John National Heart, Lung, and Blood Institute (NHLBI) NHLBI Tisdale, John (NHLBI) 1 114110007 Gudmundsdottir, Bjorg National Heart, Lung, and Blood Institute (NHLBI) NHLBI Gudmundsdottir, Bjorg (NHLBI) 0 114110008 Tumburu, Laxminath National Heart, Lung, and Blood Institute (NHLBI) NHLBI Tumburu, Laxminath (NHLBI) 0 114102509 Treatment Of The Beta-globinopathies Through Inhibition Of RIOK3 Activity E-200-2018-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 89788013 Kolesnitchenko, Vincent vk5q@nih.gov
United States of America Office of Technology Transfer and Development vk5q@nih.gov?subject=Web Inquiry on [TAB-3358] Potential Treatment for sickle-cell disease and thalassemia &body=Please send me information about technology [TAB-3358] Potential Treatment for sickle-cell disease and thalassemia . Kolesnitchenko, Vincent<br><a href="mailto:vk5q@nih.gov?subject=Web Inquiry on [TAB-3358] Potential Treatment for sickle-cell disease and thalassemia &body=Please send me information about technology [TAB-3358] Potential Treatment for sickle-cell disease and thalassemia .">vk5q@nih.gov</a><br> 114168829 E-200-2018-0 E-200-2018-0-US-01 NEW COMPOSITIONS AND METHODS FOR TREATING BETA-GLOBINOPATHIES PRV US 62/756,497 Abandoned US <br />Provisional (PRV) 62/756,497<br />Filed on 2018-11-06<br />Status: Abandoned 114168934 E-200-2018-0 E-200-2018-0-US-03 COMPOSITIONS AND METHODS FOR TREATING BETA-GLOBINOPATHIES ORD US 11,325,978 16/676,369 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11325978 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11325978">11,325,978</a><br />Filed on 2019-11-06<br />Status: Issued 114168938 E-200-2018-0 E-200-2018-0-PCT-02 NEW COMPOSITIONS AND METHODS FOR TREATING BETA-GLOBINOPATHIES PCT Patent Cooperation Treaty PCT/US2019/060151 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2019/060151<br />Filed on 2019-11-06<br />Status: Expired 114128228 XEXXXX 114128229 WKXXXX 114128230 YBXXXX 114128231 YCXXXX 114151567 treatment 114151568 Beta-globinopathies 114151569 inhibition 114151570 RIOK3 114151571 Activity TAB-3326 114097245 A New Class of Immunomodulatory Drugs for Multiple Sclerosis NIAID Collaboration, Neurology, Therapeutics Collaboration Neurology Therapeutics Jae Won Lee, Michael Lenardo, Jian Li, Wei Lu, Lixin Zheng Multiple sclerosis (MS) is an autoimmune disease caused by activated autoimmune T lymphocytes in patients resulting in inflammatory demyelination in the central nervous system. Current treatments are focused on functional control of these activated autoimmune T cells, but these treatments are non-specific T cell inhibitors and have serious, sometimes fatal side effects. A specific therapy aimed at eliminating these autoimmune T cells through restimulation-induced cell death (RICD) could cure the disease and overcome the fatal side effects of current therapies. NIAID inventors have identified a multi-valent tolerogen (MMPt), which can specifically elicit RICD of the activated, disease causing autoimmune T cells without compromising the general T cell-dependent immunity in the host. Animal studies have demonstrated that MMPt exerts robust therapeutic effects on both monophasic as well as relapsing-remitting type of the disease, indicating its medical applicability for treating MS patients with active disease. NIAID is seeking partners to develop this multi-valent peptide to improve its efficacy for use in clinical trials.<br /><br /> This technology is available for licensing for commercial development in accordance with 35 U.S.C. § 209 and 37 CFR Part 404, as well as for further development and evaluation under a research collaboration. <ul> <li>Tolerogen induced elimination of activated autoimmune T cells will overcome the fatal side effects of current therapies</li> <li>Treatment of all types of MS patients</li> </ul> <ul> <li>Therapeutics</li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize the MMPt peptide to improve its efficacy for use in clinical trials. For collaboration opportunities, please contact Yogikala Prabhu, Ph.D.,at <a href="mailto:prabhuyo@niaid.nih.gov">prabhuyo@niaid.nih.gov</a> or 301-761-7789. Various international patent applications may also be available 2022-03-08 2024-10-28 2024-10-28 2018-10-02 Disease, Listed LPM Maddox as of 4/15/2015, MMPt, MPMt, MULTIPLE, MULTIVALENT, NB1XXX, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, SCLEROSIS, therapeutic, Toleragen, Treatina False True True NIHTT 37470483 Website Abstract 114109848 Li, Jian NIAID - DIR NIAID Li, Jian (NIAID) 0 114109849 Zheng, Lixin NIAID - DIR NIAID Zheng, Lixin (NIAID) 0 114109850 Lee, Jae Won NIAID - DIR NIAID Lee, Jae Won (NIAID) 0 114109851 Lu, Wei NIAID - DIR NIAID Lu, Wei (NIAID) 0 114109847 Lenardo, Michael NIAID - DIR NIAID Lenardo, Michael (NIAID) 1 114109847 Lenardo, Michael NIAID - DIR NIAID Lenardo, Michael (NIAID) 1 114109848 Li, Jian NIAID - DIR NIAID Li, Jian (NIAID) 0 114109849 Zheng, Lixin NIAID - DIR NIAID Zheng, Lixin (NIAID) 0 114109850 Lee, Jae Won NIAID - DIR NIAID Lee, Jae Won (NIAID) 0 114109851 Lu, Wei NIAID - DIR NIAID Lu, Wei (NIAID) 0 114102480 Therapeutic Multivalent Toleragen MPMt (MMPt) For Treating Multiple Sclerosis Disease E-064-2015-0 Filing authorized NIAID 114102481 Therapeutic Multivalent Toleragen MPMt (MMPt) For Treatina Multiple Sclerosis Disease E-064-2015-1 Filing authorized NIAID 114102482 Therapeutic Multivalent Toleragen MPMt (MMPt) For Treatina Multiple Sclerosis Disease E-064-2015-2 Filing authorized NIAID 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-3326] A New Class of Immunomodulatory Drugs for Multiple Sclerosis&body=Please send me information about technology [TAB-3326] A New Class of Immunomodulatory Drugs for Multiple Sclerosis. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-3326] A New Class of Immunomodulatory Drugs for Multiple Sclerosis&body=Please send me information about technology [TAB-3326] A New Class of Immunomodulatory Drugs for Multiple Sclerosis.">yogikala.prabhu@nih.gov</a><br> 114168748 E-064-2015-0 E-064-2015-0-US-01 MYELIN OLIGODENDROCYTE GLYCOPROTEIN, MYELIN BASIC PROTEIN, AND PROTEOLIPID PROTEIN COMPOSITIONS AND METHODS OF USE PRV US 62/130,285 Abandoned US <br />Provisional (PRV) 62/130,285<br />Filed on 2015-03-09<br />Status: Abandoned 114168749 E-064-2015-1 E-064-2015-1-US-01 Myelin Oligodendrocyte Glycoprotein, Myelin Basic Protein, and Proteolipid Protein Compositions and Methods of Use PRV US 62/219,851 Abandoned US <br />Provisional (PRV) 62/219,851<br />Filed on 2015-09-17<br />Status: Abandoned 114168750 E-064-2015-2 E-064-2015-2-PCT-01 Myelin Oligodendrocyte Glycoprotein, Myelin Basic Protein, and Proteolipid Protein Compositions and Methods of Use PCT Patent Cooperation Treaty PCT/US2016/021571 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2016/021571<br />Filed on 2016-03-09<br />Status: Expired 114168751 E-064-2015-2 E-064-2015-2-US-05 MYELIN OLIGODENDROCYTE GLYCOPROTEIN, MYELIN BASIC PROTEIN, AND PROTEOLIPID PROTEIN COMPOSITIONS AND METHODS OF USE National Stage US 10,759,838 15/556,738 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10759838 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10759838">10,759,838</a><br />Filed on 2017-09-08<br />Status: Issued 114128151 NB1XXX 114151338 therapeutic 114151339 MULTIVALENT 114151340 Toleragen 114151341 MPMt 114151342 MMPt 114151343 Treatina 114151344 MULTIPLE 114151345 SCLEROSIS 114151346 Disease 114151347 Listed LPM Maddox as of 4/15/2015 114151348 Pre LPM working set 20150418 114151349 Post LPM Assignment Set 20150420 TAB-3311 114097234 Licensing Availability: Methods of Diagnosing and Treating CHAPLE, A Newly Identified Orphan Disease NIAID Antibodies, Collaboration, Immunology, Infectious Disease, Neurology, Research Materials, Therapeutics Antibodies Collaboration Immunology Infectious Disease Neurology Research Materials Therapeutics Rico Ardy, Kaan Boztug, William Comrie, Michael Lenardo, Ahmet Ozen, Helen Su This technology is directed towards a potential treatment for a new disease, CHAPLE (Complement Hyperactivation, Angiopathic thrombosis, and Protein-Losing Enteropathy), identified by NIAID researchers. CHAPLE is associated with GI symptoms and vascular thrombosis and is caused by loss-of-function variants in the gene encoding the complement regulatory protein CD55. The disease is caused by enhanced activation of the complement pathway and complement-mediated induction of intestinal lymphangiectasia and protein-losing enteropathy. There is no current therapy for the newly described heritable genetic disorder and the symptoms are poorly controlled. CHAPLE is similar to other complement activating diseases that can be fatal, particularly for patients who develop severe thrombosis. Recent off-label use of a complement inhibiting drug, eculizumab (CD55 inhibitor) was shown to provide a dramatic benefit in patients with CHAPLE disease with an immediate correction of gastrointestinal protein loss. Thus, identification of CD55 deficiency in CHAPLE patients, and the possibility to use complement inhibitory drugs provide opportunities for treatment.<br /><br /> This technology is available for licensing for commercial development in accordance with 35 U.S.C. § 209 and 37 CFR Part 404, as well as for further development and evaluation under a research collaboration. <ul> <li>There is no therapy currently approved for CHAPLE disease, and patients face a debilitating and often time fatal course of the disease.</li> <li>Anti-complement drugs (including eculizumab) has the potential to treat CHAPLE disease.</li> </ul> <ul> <li>Diagnostic</li> <li>Therapeutic</li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize the use of Eculizumab or other complement inhibitory drugs for the treatment of CHAPLE. For collaboration opportunities, please contact Yogikala Prabhu, Ph.D., at <a href="mailto:Yogikala.Prabhu@nih.gov">Yogikala.Prabhu@nih.gov</a> or 301-761-7789. 2022-03-08 2024-10-28 2024-10-28 2018-09-07 Angiopathic, CD55, CHAPLE, Complement, DBXXXX, DDXXXX, DEFICIENCY, DEXXXX, Disease, DXXXXX, Eculizumab, Enteropathy, Human, Hyperactivation, IB3XXX, Identified, Losing, NBXXXX, NEWLY, Orphan, Protein, thrombosis, TREAT, WJXXXX, XAXXXX, YCXXXX False True True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114109816 Comrie, William NIAID - DIR NIGMS Comrie, William (NIGMS) 0 114109817 Ozen, Ahmet NIAID - DIR NIAID Ozen, Ahmet (NIAID) 0 114109819 Su, Helen NIAID - DIR NIAID Su, Helen (NIAID) 0 114109820 Ardy, Rico Ludwig Boltzmann Institute for Rare and Undiagnosed Diseases Ardy, Rico 0 114109821 Boztug, Kaan Ludwig Boltzmann Institute for Rare and Undiagnosed Diseases Boztug, Kaan 0 114109818 Lenardo, Michael NIAID - DIR NIAID Lenardo, Michael (NIAID) 1 114109818 Lenardo, Michael NIAID - DIR NIAID Lenardo, Michael (NIAID) 1 114109816 Comrie, William NIAID - DIR NIGMS Comrie, William (NIGMS) 0 114109817 Ozen, Ahmet NIAID - DIR NIAID Ozen, Ahmet (NIAID) 0 114109819 Su, Helen NIAID - DIR NIAID Su, Helen (NIAID) 0 114109820 Ardy, Rico Ludwig Boltzmann Institute for Rare and Undiagnosed Diseases Ardy, Rico 0 114109821 Boztug, Kaan Ludwig Boltzmann Institute for Rare and Undiagnosed Diseases Boztug, Kaan 0 114102470 New Use Of Eculizumab To Treat Human CD55 Deficiency, Hyperactivation Of Complement, Angiopathic Thrombosis And Protein Losing Enteropathy (CHAPLE), A Newly Identified Orphan Disease E-251-2016-0 Filing authorized Ludwig Boltzmann Institute for Rare and Undiagnosed Diseases, NIAID 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-3311] Licensing Availability: Methods of Diagnosing and Treating CHAPLE, A Newly Identified Orphan Disease&body=Please send me information about technology [TAB-3311] Licensing Availability: Methods of Diagnosing and Treating CHAPLE, A Newly Identified Orphan Disease. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-3311] Licensing Availability: Methods of Diagnosing and Treating CHAPLE, A Newly Identified Orphan Disease&body=Please send me information about technology [TAB-3311] Licensing Availability: Methods of Diagnosing and Treating CHAPLE, A Newly Identified Orphan Disease.">yogikala.prabhu@nih.gov</a><br> 114168714 E-251-2016-0 E-251-2016-0-PCT-02 METHODS OF DIAGNOSING AND TREATING CD55 DEFICIENCY, HYPERACTIVATION OF COMPLEMENT, ANGIOPATHIC THROMBOSIS AND PROTEIN LOSING ENTEROPATHY (CHAPLE), A NEWLY IDENTIFIED ORPHAN DISEASE PCT Patent Cooperation Treaty PCT/US2017/051413 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2017/051413<br />Filed on 2017-09-13<br />Status: Expired 114168715 E-251-2016-0 E-251-2016-0-US-01 METHODS OF DIAGNOSING AND TREATING CD55 DEFICIENCY HYPERACTIVATION OF COMPLEMENT, ANGIOPATHIC THROMBOSIS AND PROTEIN LOSING ENTEROPATHY (CHAPLE), A NEWLY IDENTIFIED ORPHAN DISEASE PRV US 62/394,630 Abandoned US <br />Provisional (PRV) 62/394,630<br />Filed on 2016-09-14<br />Status: Abandoned 114168863 E-251-2016-0 E-251-2016-0-US-04 METHODS OF DIAGNOSING AND TREATING CD55 DEFICIENCY, HYPERACTIVATION OF COMPLEMENT, ANGIOPATHIC THROMBOSIS AND PROTEIN LOSING ENTEROPATHY (CHAPLE), A NEWLY IDENTIFIED ORPHAN DISEASE National Stage US 16/333,561 Abandoned US <br />National Stage 16/333,561<br />Filed on 2019-03-14<br />Status: Abandoned 114128069 DXXXXX 114128070 DBXXXX 114128071 IB3XXX 114128072 DDXXXX 114128073 DEXXXX 114128074 NBXXXX 114128075 XAXXXX 114128076 YCXXXX 114128077 WJXXXX 114151210 Eculizumab 114151211 TREAT 114151212 Human 114151213 CD55 114151214 DEFICIENCY 114151215 Hyperactivation 114151216 Complement 114151217 Angiopathic 114151218 thrombosis 114151219 Protein 114151220 Losing 114151221 Enteropathy 114151222 CHAPLE 114151223 NEWLY 114151224 Identified 114151225 Orphan 114151226 Disease TAB-3306 114097229 Real-time PCR Detection of <em>Streptococcus pneumoniae</em> with High Sensitivity and Specificity CDC Collaboration, Consumer Products, Diagnostics, Infectious Disease, Licensing, Occupational Safety and Health, Research Materials, Therapeutics Collaboration Consumer Products Diagnostics Infectious Disease Licensing Occupational Safety and Health Research Materials Therapeutics Maria Da Gloria Carvalho, Lesley McGee, Maria-Lucia Tondella <em>Streptococcus pneumoniae</em> is the leading cause of community-acquired pneumonia and is also a frequent cause of bloodstream, brain and spinal cord, ear, and sinus infections. According to 2015 CDC data, an estimated 900,000 Americans get pneumococcal pneumonia each year and approximately 5-7% die from it annually. Accurate diagnosis and early treatment are important for improving patient outcomes.<br /><br /> Pneumonia is typically diagnosed by clinical examination, chest X-rays, and culture of patient blood and secretions. X-rays cannot identify the pathogen; blood cultures take several days to grow with limited reliability; and sputum and throat culture specimens collected may not contain isolates of the organism. CDC researchers developed a Taqman-based assay that uses real-time PCR to detect three specific gene regions of <em>S. pneumoniae</em>with a very low limit of detection of 10 copies, and has shown high sensitivity and specificity against a panel of 67 CDC <em>S. pneumoniae</em> isolates. Targeting multiple genes, this technology would perform well in a multiplex diagnostic testing application. <ul> <li>High throughput</li> <li>High sensitivity and specificity</li> <li>Low limit of detection</li> <li>Rapid, accurate, and cost-effective</li> <li>Easily adapted for use in kits</li> </ul> </li> < << </li> <ul> <li>Diagnosis of respiratory disease from sterile clinical samples (e.g., serum, blood, CSF, pleural fluid)</li> <li>Surveillance of pneumococcal carriage from non-sterile samples (e.g., nasopharyngeal swab) </li> <li>Validation studies and proficiency testing</li> </ul> < < The CDC Technology Transfer Office (TTO) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize: Real-time PCR Detection of Streptococcus pneumonia with High Sensitivity and Specificity. For collaboration opportunities, please contact CDC TTO at <a href="mailto:tto@cdc.gov">tto@cdc.gov</a> or 1-404-639-1330. 2022-07-02 2024-10-28 2024-10-28 2018-07-10 CDC Docket Import, CDC Docket Import CDC Prosecuting, DA3XXX, DAXXXX, Detection, DXXXXX, Listed LPM Surabian as of 4/15/2015, OID-NCIRD-DBD, PNEUMONIAE, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, PRIMERS, Probes, Streptococcus, VJXXXX, WBXXXX, WFXXXX, WHXXXX, WIXXXX, XEXXXX, YCXXXX, YDXXXX False True True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114172513 Carvalho M., et al. https://www.ncbi.nlm.nih.gov/pubmed/17537936 <a href="https://www.ncbi.nlm.nih.gov/pubmed/17537936 ">Carvalho M., et al. </a> 114172514 Carvalho M., et al. https://www.ncbi.nlm.nih.gov/pubmed/23825797 <a href="https://www.ncbi.nlm.nih.gov/pubmed/23825797 ">Carvalho M., et al. </a> 114172515 Diaz M., et al. https://www.ncbi.nlm.nih.gov/pubmed/23805203 <a href="https://www.ncbi.nlm.nih.gov/pubmed/23805203">Diaz M., et al.</a> 114172516 Pimenta F., et al. https://www.ncbi.nlm.nih.gov/pubmed/23224094 <a href="https://www.ncbi.nlm.nih.gov/pubmed/23224094 ">Pimenta F., et al. </a> 114172517 Wu H., et al. https://www.ncbi.nlm.nih.gov/pubmed/23339355 <a href="https://www.ncbi.nlm.nih.gov/pubmed/23339355">Wu H., et al. </a> 114172518 Kodani M., et al. https://www.ncbi.nlm.nih.gov/pubmed/21471348 <a href="https://www.ncbi.nlm.nih.gov/pubmed/21471348">Kodani M., et al.</a> 114109788 McGee, Lesley CDC - DIR CDC McGee, Lesley (CDC) 0 114109789 Tondella, Maria-Lucia CDC - DIR CDC Tondella, Maria-Lucia (CDC) 0 114109790 Carvalho, Maria Da Gloria CDC - DIR CDC Carvalho, Maria Da Gloria (CDC) 1 114109790 Carvalho, Maria Da Gloria CDC - DIR CDC Carvalho, Maria Da Gloria (CDC) 1 114109788 McGee, Lesley CDC - DIR CDC McGee, Lesley (CDC) 0 114109789 Tondella, Maria-Lucia CDC - DIR CDC Tondella, Maria-Lucia (CDC) 0 114102465 PRIMERS AND PROBES FOR THE DETECTION OF STREPTOCOCCUS PNEUMONIAE E-288-2013-0 Closed Centers for Disease Control and Prevention (CDC) 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-3306] Real-time PCR Detection of <em>Streptococcus pneumoniae</em> with High Sensitivity and Specificity&body=Please send me information about technology [TAB-3306] Real-time PCR Detection of <em>Streptococcus pneumoniae</em> with High Sensitivity and Specificity. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-3306] Real-time PCR Detection of <em>Streptococcus pneumoniae</em> with High Sensitivity and Specificity&body=Please send me information about technology [TAB-3306] Real-time PCR Detection of <em>Streptococcus pneumoniae</em> with High Sensitivity and Specificity.">jonathan.motley@nih.gov</a><br> 114168681 E-288-2013-0 E-288-2013-0-US-01 PRIMERS AND PROBES FOR THE DETECTION OF STREPTOCOCCUS PNEUMONIAE PRV US 60/938,799 Abandoned US <br />Provisional (PRV) 60/938,799<br />Filed on 2007-05-18<br />Status: Abandoned 114168682 E-288-2013-0 E-288-2013-0-PCT-02 PRIMERS AND PROBES FOR THE DETECTION OF STREPTOCOCCUS PNEUMONIAE PCT Patent Cooperation Treaty PCT/US2008/063954 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2008/063954<br />Filed on 2008-05-16<br />Status: Expired 114168683 E-288-2013-0 E-288-2013-0-US-07 PRIMERS AND PROBES FOR THE DETECTION OF STREPTOCOCCUS PNEUMONIAE National Stage US 8,357,488 12/600,568 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8357488 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8357488">8,357,488</a><br />Filed on 2010-04-01<br />Status: Abandoned 114128024 DXXXXX 114128025 DAXXXX 114128026 DA3XXX 114128027 YCXXXX 114128028 YDXXXX 114128029 VJXXXX 114128030 WBXXXX 114128031 WFXXXX 114128032 WHXXXX 114128033 WIXXXX 114128034 XEXXXX 114151142 PRIMERS 114151143 Probes 114151144 Detection 114151145 Streptococcus 114151146 PNEUMONIAE 114151147 CDC Docket Import 114151148 CDC Docket Import CDC Prosecuting 114151149 OID-NCIRD-DBD 114151150 Listed LPM Surabian as of 4/15/2015 114151151 Pre LPM working set 20150418 114151152 Post LPM Assignment Set 20150420 TAB-3303 114097219 A Novel Reagent for Labeling PET Tracers at Trifluoromethyl Groups NIMH Cardiology, Collaboration, Diagnostics, Geriatrics, Immunology, Medical Devices, Neurology, Non-Medical Devices, Oncology, Psychiatry/Mental Health, Research Materials, Software / Apps Cardiology Collaboration Diagnostics Geriatrics Immunology Medical Devices Neurology Non-Medical Devices Oncology Psychiatry/Mental Health Research Materials Software / Apps Mohammad Haskali, Victor Pike The molecular imaging technique of positron emission tomography (PET) is an increasingly important tool in biomedical research and in drug discovery and development. Many small molecule drugs and potential PET radiotracers carry trifluoromethyl (CF<sub>3</sub>) groups. Because CF<sub>3</sub> groups are generally considered to be metabolically stable, there is a strong interest in developing drugs with these groups. This invention describes a novel method and apparatus for producing no-carrier added [<sup>11</sup>C]fluoroalkanes, which can be used as labeling agents for PET radiotracers at CF<sub>3</sub> groups. Prior to this technology, no method for [<sup>11</sup>C]fluoroalkyaltion has existed. The reported method, which involves passing [<sup>11</sup>C]methane over a heated column of a metal fluoride, has high yield and high specificity, is simple, fast, and capable of being fully automated. Of special interest is the efficient production of [<sup>11</sup>C]fluoroform, which can be readily applied to labeling a variety of chemotypes with a [<sup>11</sup>C]trifluoromethyl group. <ul> <li>High yield</li> <li>High molar activity</li> <li>Increased simplicity</li> <li>Capable of automation</li> <li>Rapid method to produce PET radiotracers (~15 min)</li> </ul> <ul> <li>Apparatus for producing no-carrier added [<sup>11</sup>C]fluoroalkanes</li> <li>CF3-based PET labeling agents</li> </ul> The National Institute of Mental Health is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize method and labeling agents for PET tracers. For collaboration opportunities, please contact Victor W. Pike, Ph.D. at <a href="mailto:pikev@mail.nih.gov">pikev@mail.nih.gov</a>. 2022-03-08 2024-10-28 2024-10-28 2018-06-28 :, [11C]Fluoroalkanes, Added, AGENT, LABELING, Method, No-Carrier, PET, Producing, Radiotracers, VAXXXX, VCXXXX, VDXXXX, VEXXXX, VNXXXX, WBXXXX, WIXXXX, XDXXXX, XFXXXX, YAXXXX, YBXXXX, YFXXXX False True True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114172508 Haskali MB, Pike VW. https://www.ncbi.nlm.nih.gov/pubmed/28514059 <a href="https://www.ncbi.nlm.nih.gov/pubmed/28514059">Haskali MB, Pike VW.</a> 114109783 Haskali, Mohammad National Institute of Mental Health (NIMH) Haskali, Mohammad 0 114109782 Pike, Victor National Institute of Mental Health (NIMH) NIMH Pike, Victor (NIMH) 1 114109782 Pike, Victor National Institute of Mental Health (NIMH) NIMH Pike, Victor (NIMH) 1 114109783 Haskali, Mohammad National Institute of Mental Health (NIMH) Haskali, Mohammad 0 114102463 A Method For Producing No-Carrier Added [11C]Fluoroalkanes : New Labeling Agent For PET Radiotracers E-259-2016-0 Filing authorized National Institute of Mental Health (NIMH) 83739514 Dawson, Anton anton.dawson@nih.gov
United States of America anton.dawson@nih.gov?subject=Web Inquiry on [TAB-3303] A Novel Reagent for Labeling PET Tracers at Trifluoromethyl Groups&body=Please send me information about technology [TAB-3303] A Novel Reagent for Labeling PET Tracers at Trifluoromethyl Groups. Dawson, Anton<br><a href="mailto:anton.dawson@nih.gov?subject=Web Inquiry on [TAB-3303] A Novel Reagent for Labeling PET Tracers at Trifluoromethyl Groups&body=Please send me information about technology [TAB-3303] A Novel Reagent for Labeling PET Tracers at Trifluoromethyl Groups.">anton.dawson@nih.gov</a><br> 114168675 E-259-2016-0 E-259-2016-0-US-01 Radiolabeling Agents, Methods of Making, and Methods of Use Thereof PRV US 62/420,840 Abandoned US <br />Provisional (PRV) 62/420,840<br />Filed on 2016-11-11<br />Status: Abandoned 114168676 E-259-2016-0 E-259-2016-0-PCT-02 RADIOLABELING AGENTS, METHODS OF MAKING, AND METHODS OF USE THEROF PCT Patent Cooperation Treaty PCT/US2017/060838 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2017/060838<br />Filed on 2017-11-09<br />Status: Expired 114168880 E-259-2016-0 E-259-2016-0-US-04 Radiolabeling Agents, Methods of Making, and Methods of Use Thereof National Stage US 16/349,124 Abandoned US <br />National Stage 16/349,124<br />Filed on 2019-05-10<br />Status: Abandoned 114169066 E-259-2016-0 E-259-2016-0-US-05 RADIOLABELING AGENTS, METHODS OF MAKING, AND METHODS OF USE THEREOF DIV US 17/074,832 Abandoned US <br />Divisional (DIV) 17/074,832<br />Filed on 2020-10-20<br />Status: Abandoned 114128007 VAXXXX 114128008 VCXXXX 114128009 VDXXXX 114128010 VEXXXX 114128011 VNXXXX 114128012 WBXXXX 114128013 WIXXXX 114128014 XDXXXX 114128015 XFXXXX 114128016 YAXXXX 114128017 YBXXXX 114128018 YFXXXX 114151115 Method 114151116 Producing 114151117 No-Carrier 114151118 Added 114151119 [11C]Fluoroalkanes 114151120 : 114151121 LABELING 114151122 AGENT 114151123 PET 114151124 Radiotracers TAB-3295 114097222 New Anti-Influenza Virus Neuraminidase 9 (N9) Monoclonal Antibody – for Prevention or Treatment of H7N9 Influenza (Flu) A with Less Likelihood of Drug Resistance CDC Antibodies, Collaboration, Immunology, Infectious Disease, Licensing, Therapeutics, Vaccines Antibodies Collaboration Immunology Infectious Disease Licensing Therapeutics Vaccines Zhu Guo, James Stevens, Jason Wilson, Ian York H7N9 influenza viruses are predominately avian (bird) pathogens, however, since 2013, they have infected more than 1500 humans with a mortality rate of nearly 40% in confirmed cases. H7N9 viruses continue to be a threat to public health. Treatment for people infected with H7N9-subtype influenza A (H7N9) commonly includes the use of drugs that inhibit neuraminidase, a protein found on the virus’ surface. However, like other influenza viruses, H7N9 can become resistant to these drugs.<br /><br /> CDC researchers have developed a monoclonal antibody (mAb) that binds to the neuraminidase protein of H7N9 influenza viruses, and has been shown in animal studies to provide protection from H7N9 infection. Because this antibody targets a different region of the neuraminidase protein than other antibodies, it is unlikely that H7N9 strains have developed resistance to it, making it an ideal starting point for antibody-based therapy or prevention of H7N9 infection. This technology could be used alone, or in combination with other neuraminidase inhibitor drugs. The antibody can also be useful as a research material. It will need to be humanized in further research. <ul> <li>Unlikely for virus to develop resistance due to unique binding site of antibody</li> <li>Can be used for prevention or treatment</li> <li>Currently available mAbs are not reactive with the N9 influenza subtype</li> <li>Can be used alone or in combination with other drugs</li> </ul></li> <ul> <li>Prevention of H7N9 influenza (flu) infection</li> <li> Treatment of H7N9 influenza (flu) infection</li> <li>Research tool and diagnostic reagent</li> </ul> The CDC Technology Transfer Office (TTO) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize: New Anti-Influenza Virus Neuraminidase 9 (N9) Monoclonal Antibody – for Prevention or Treatment of H7N9 Influenza (Flu) A with Less Likelihood of Drug Resistance. For collaboration opportunities, please contact CDC TTO at <a href="mailto:tto@cdc.gov">tto@cdc.gov</a>or 1-404-639-1330. Patent protection is not being pursued for this technology. 2022-10-26 2024-10-28 2024-10-28 2022-10-26 9, Activity, antibodies, ANTIBODY, Anti-Influenza, INFLUENZA, monoclonal, N9, NCIRD-ID, Neuraminidase, Prophylactic, RECOGNIZE, That, therapeutic, virus, Vivo, VLXXXX, WJXXXX, WNXXXX, XAXXXX, YBXXXX, YCXXXX False True True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114172502 Wilson JR., et al. https://www.ncbi.nlm.nih.gov/pubmed/28888111 <a href="https://www.ncbi.nlm.nih.gov/pubmed/28888111 ">Wilson JR., et al.</a> 114172503 Wilson JR., et al. https://www.ncbi.nlm.nih.gov/pubmed/27713074 <a href="https://www.ncbi.nlm.nih.gov/pubmed/27713074 ">Wilson JR., et al.</a> 114109758 York, Ian CDC - DIR CDC York, Ian (CDC) 0 114109759 Stevens, James CDC - DIR CDC Stevens, James (CDC) 0 114109760 Guo, Zhu CDC - DIR CDC Guo, Zhu (CDC) 0 114109757 Wilson, Jason CDC - DIR CDC Wilson, Jason (CDC) 1 114109757 Wilson, Jason CDC - DIR CDC Wilson, Jason (CDC) 1 114109758 York, Ian CDC - DIR CDC York, Ian (CDC) 0 114109759 Stevens, James CDC - DIR CDC Stevens, James (CDC) 0 114109760 Guo, Zhu CDC - DIR CDC Guo, Zhu (CDC) 0 114102456 Anti-Influenza Virus Neuraminidase 9 (N9) Monoclonal Antibody With Prophylactic And Therapeutic Activity In Vivo E-200-2016-0 Research Material Centers for Disease Control and Prevention (CDC) 114102917 Monoclonal Antibodies That Recognize Influenza A Neuraminidase N9 E-163-2018-0 Research Material Centers for Disease Control and Prevention (CDC) 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-3295] New Anti-Influenza Virus Neuraminidase 9 (N9) Monoclonal Antibody – for Prevention or Treatment of H7N9 Influenza (Flu) A with Less Likelihood of Drug Resistance&body=Please send me information about technology [TAB-3295] New Anti-Influenza Virus Neuraminidase 9 (N9) Monoclonal Antibody – for Prevention or Treatment of H7N9 Influenza (Flu) A with Less Likelihood of Drug Resistance. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-3295] New Anti-Influenza Virus Neuraminidase 9 (N9) Monoclonal Antibody – for Prevention or Treatment of H7N9 Influenza (Flu) A with Less Likelihood of Drug Resistance&body=Please send me information about technology [TAB-3295] New Anti-Influenza Virus Neuraminidase 9 (N9) Monoclonal Antibody – for Prevention or Treatment of H7N9 Influenza (Flu) A with Less Likelihood of Drug Resistance.">jonathan.motley@nih.gov</a><br> 114168662 E-200-2016-0 E-200-2016-0-US-01 ANTI-INFLUENZA VIRUS NEURAMINIDASE 9 (N9) MONOCLONAL ANTIBODY AND METHODS OF USE PRV US 62/365,264 Abandoned US <br />Provisional (PRV) 62/365,264<br />Filed on 2016-07-21<br />Status: Abandoned 114127978 YBXXXX 114127979 YCXXXX 114127980 VLXXXX 114127981 WJXXXX 114127982 WNXXXX 114127983 XAXXXX 114151022 Anti-Influenza 114151023 virus 114151024 Neuraminidase 114151025 9 114151026 N9 114151027 monoclonal 114151028 ANTIBODY 114151029 Prophylactic 114151030 therapeutic 114151031 Activity 114151032 Vivo 114151033 NCIRD-ID 114155677 antibodies 114155678 That 114155679 RECOGNIZE 114155680 INFLUENZA TAB-3296 114097223 The CDC 2009 Influenza A H1N1 (Flu) Pandemic Real-time RT-PCR Panel including Pandemic Influenza A and Pandemic H1 Assays CDC Collaboration, Consumer Products, Diagnostics, Infectious Disease, Licensing, Occupational Safety and Health, Research Equipment, Research Materials, Therapeutics Collaboration Consumer Products Diagnostics Infectious Disease Licensing Occupational Safety and Health Research Equipment Research Materials Therapeutics LaShondra Berman, Shannon Emery, Stephen Lindstrom, Bo Shu, Christine Warnes, Kai-Hui Wu CDC researchers have developed probes and primers for detecting the 2009 pandemic influenza A H1N1 virus in patient samples using real-time reverse transcription-polymerase chain reaction (rRT-PCR) methods. These primers and probes were originally developed in 2009 and were cleared by the FDA as part of a domestic human diagnostic testing panel in June 2010. These were also updated to increase specificity and/or sensitivity of the detection methods. The compositions and methods can be used to quickly identify 2009 pandemic influenza A (pdm InfA) and pandemic H1 (pdm H1), other influenza A virus sub-types (e.g., H3, H5, H7, and H9) and influenza B virus sub-types present in a sample. The CDC-developed probes and primers permit the rapid detection and/or discrimination of influenza virus subtype nucleic acids in initial clinical sample testing. <ul> <li>Assay allows for rapid universal detection and characterization of the 2009 A H1N1 pandemic influenza virus</li> <li>High sensitivity and specificity</li> <li>High-throughput sample screening and easily formatted as a kit or array</li> <li>Faster than culturing and serological identification methods</li> <li>Less laborious and more objective (quantitative) than immunoassays</li> </ul> <ul> <li>Influenza A & pandemic influenza diagnostics using clinical specimens</li> <li>Government and regional influenza surveillance programs</li> <li>Quality control/quality assurance testing for influenza vaccine candidates</li> </ul> The CDC Technology Transfer Office (TTO) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize:The CDC 2009 Influenza A H1N1 (Flu) Pandemic Real-time RT-PCR Panel including Pandemic Influenza A and Pandemic H1 Assays. For collaboration opportunities, please contact CDC TTO at <a href="mailto:tto@cdc.gov">tto@cdc.gov</a>or 1-404-639-1330. 2022-11-17 2024-10-28 2024-10-28 2018-06-20 2009, ASSAYS, CDC, CDC Docket Import, CDC Docket Import CDC Prosecuting, H1, H1N1, Including, INFLUENZA, Listed LPM Surabian as of 4/15/2015, NCIRD-ID, Pandemic, PANEL, pdmH1, pdminfA, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, REAL-TIME, RT-PCR, VLXXXX, VOXXXX, WBXXXX, WFXXXX, WHXXXX, WIXXXX, XEXXXX, XHXXXX False True True NIHTT 37470483 Website Abstract E-562-2013-0 E-274-2013-0 E-331-2013-0 E-560-2013-0 114172504 Shu B., et al. https://www.ncbi.nlm.nih.gov/pubmed/21593260 <a href="https://www.ncbi.nlm.nih.gov/pubmed/21593260">Shu B., et al.</a> 114172505 Shcherbik S., et al. https://www.ncbi.nlm.nih.gov/pubmed/24056261 <a href="https://www.ncbi.nlm.nih.gov/pubmed/24056261">Shcherbik S., et al.</a> 114109762 Lindstrom, Stephen CDC - DIR CDC Lindstrom, Stephen (CDC) 0 114109763 Wu, Kai-Hui CDC - DIR CDC Wu, Kai-Hui (CDC) 0 114109764 Berman, LaShondra CDC - DIR CDC Berman, LaShondra (CDC) 0 114109765 Emery, Shannon CDC - DIR CDC Emery, Shannon (CDC) 0 114109766 Warnes, Christine CDC - DIR CDC Warnes, Christine (CDC) 0 114109761 Shu, Bo CDC - DIR CDC Shu, Bo (CDC) 1 114109761 Shu, Bo CDC - DIR CDC Shu, Bo (CDC) 1 114109762 Lindstrom, Stephen CDC - DIR CDC Lindstrom, Stephen (CDC) 0 114109763 Wu, Kai-Hui CDC - DIR CDC Wu, Kai-Hui (CDC) 0 114109764 Berman, LaShondra CDC - DIR CDC Berman, LaShondra (CDC) 0 114109765 Emery, Shannon CDC - DIR CDC Emery, Shannon (CDC) 0 114109766 Warnes, Christine CDC - DIR CDC Warnes, Christine (CDC) 0 114102457 The CDC Influenza 2009 A (H1N1) Pandemic Real-Time RT-PCR Panel, Including Pandemic Influenza A (pdminfA) And Pandemic H1 (pdmH1) Assays E-563-2013-0 Filing authorized Centers for Disease Control and Prevention (CDC) 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-3296] The CDC 2009 Influenza A H1N1 (Flu) Pandemic Real-time RT-PCR Panel including Pandemic Influenza A and Pandemic H1 Assays&body=Please send me information about technology [TAB-3296] The CDC 2009 Influenza A H1N1 (Flu) Pandemic Real-time RT-PCR Panel including Pandemic Influenza A and Pandemic H1 Assays. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-3296] The CDC 2009 Influenza A H1N1 (Flu) Pandemic Real-time RT-PCR Panel including Pandemic Influenza A and Pandemic H1 Assays&body=Please send me information about technology [TAB-3296] The CDC 2009 Influenza A H1N1 (Flu) Pandemic Real-time RT-PCR Panel including Pandemic Influenza A and Pandemic H1 Assays.">jonathan.motley@nih.gov</a><br> 114168663 E-563-2013-0 E-563-2013-0-US-01 Compositions and Methods for Detection and Discrimination of Emerging Influenza Virus Subtypes PRV US 62/432,340 Abandoned US <br />Provisional (PRV) 62/432,340<br />Filed on 2016-12-09<br />Status: Abandoned 114168664 E-563-2013-0 E-563-2013-0-US-02 COMPOSITIONS AND METHODS FOR DETECTION AND DISCRIMINATION OF EMERGING INFLUENZA VIRUS SUBTYPES ORD US 10,329,630 15/834,555 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10329630 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10329630">10,329,630</a><br />Filed on 2017-12-07<br />Status: Issued 114127984 VLXXXX 114127985 VOXXXX 114127986 WBXXXX 114127987 WFXXXX 114127988 WHXXXX 114127989 WIXXXX 114127990 XEXXXX 114127991 XHXXXX 114151034 CDC 114151035 INFLUENZA 114151036 2009 114151037 H1N1 114151038 Pandemic 114151039 REAL-TIME 114151040 RT-PCR 114151041 PANEL 114151042 Including 114151043 pdminfA 114151044 H1 114151045 pdmH1 114151046 ASSAYS 114151047 CDC Docket Import 114151048 CDC Docket Import CDC Prosecuting 114151049 NCIRD-ID 114151050 Listed LPM Surabian as of 4/15/2015 114151051 Pre LPM working set 20150418 114151052 Post LPM Assignment Set 20150420 TAB-3292 114097220 Novel Peptide of <em>Streptococcus pneumoniae</em> Surface Adhesion A (PsaA) Protein Associated with Adherence and Uses Thereof – for Vaccine Candidate, Therapeutic and Diagnostic Development CDC Antibodies, Collaboration, Consumer Products, Diagnostics, Immunology, Infectious Disease, Licensing, Occupational Safety and Health, Research Materials, Therapeutics, Vaccines Antibodies Collaboration Consumer Products Diagnostics Immunology Infectious Disease Licensing Occupational Safety and Health Research Materials Therapeutics Vaccines Edwin Ades, Joseph Caba, George Carlone, GowriSankar Rajam, Jacquelyn Sampson, Sandra Steiner <em>Streptococcus pneumoniae</em> (<em>S. pneumonia</em>), bacteria commonly referred to as pneumococcus, are a significant cause of disease resulting in 1.5 million deaths every year worldwide according to the World Health Organization. The major types of pneumococcal disease are pneumonia (lung infection), bacteremia (bloodstream infection), and meningitis (infection of the tissue covering of the brain and spinal cord). Less severe pneumococcal illnesses include ear and sinus infections.<br /><br /> CDC scientists have developed a specific amino acid sequence, the P4 peptide, of the Pneumococcal surface adhesin A (PsaA) protein which is an immunogenic epitope and a binding site for adhesion of <em>Streptococcus pneumoniae</em> to human cells. This novel peptide and related sequences, monoclonal antibodies, and uses thereof can be used for vaccine development. Successful polysaccharide vaccines are available in the US, however, countries with limited resources cannot afford these vaccines. PsaA is a streptococcal common protein and a vaccine candidate which could be affordable for all countries. Additionally, there are 90 known serotypes of <em>Streptococcus pneumonia</em> and a need for a vaccine that protects against all known serotypes. The current commercially available vaccines (23-valent polysaccharide (adults); and 7-valent polysaccharide (children)) only protect against more prevalent serotypes. CDC’s peptide technology can also be used for drug receptor modelling, as a highly specific and sensitive diagnostic target, and as an immunogenic mimic of the PsaA protein. Initial rabbit and mouse model research has shown vaccine protection and a therapeutic benefit. <ul> <li>Presently there are no commercially available vaccines that protect against all known serotypes of <em>Streptococcus pneumonia</em></li> <li>PsaA is a streptococcal common protein and could be an affordable vaccine candidate for all countries</li> -<li>Initial rabbit and mice studies have shown vaccine protection and therapeutic benefit</li> <li>Highly sensitive and specific as a diagnostic</li> -<li>The P4 peptide is adaptable for diagnostic kits</li> </ul> <ul> <li><em>Streptococcus pneumoniae</em> vaccine candidate and therapeutic development</li> <li>Diagnostics for pneumococcal disease – particularly suited for immunoassays and ELISAs</li> <li>Sepsis research for vaccine, therapeutic and diagnostic development</li> <li> Public health monitoring and surveillance</li> <li> Research tools for vaccine improvement programs</li> </ul> The CDC Technology Transfer Office (TTO) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize: Novel Peptide of <em>Streptococcus pneumoniae</em>Surface Adhesion A (PsaA) Protein Associated with Adherence and Uses Thereof – for Vaccine Candidate, Therapeutic and Diagnostic Development. For collaboration opportunities, please contact CDC TTO at <a href="mailto:tto@cdc.gov">tto@cdc.gov</a>or 1-404-639-1330. International patents issued for Canada, Europe, the United Kingdom, Hong Kong and Australia. 2022-11-17 2024-10-28 2024-10-28 2018-06-13 ANTIGEN, CDC Docket Import, CDC Docket Import CDC Prosecuting, DC4XXX, Epitopes, FUNCTIONAL, Listed LPM Surabian as of 4/15/2015, OID-NCIRD-DBD, PNEUMONIAE, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, PsaA, Streptococcus, THEREOF, USES, WBXXXX, WFXXXX, WIXXXX, WKXXXX, WNXXXX, XAXXXX, XKXXXX, YBXXXX, YCXXXX False True True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract E-329-2013-0 114172494 Romero-Steiner S., et al. https://www.ncbi.nlm.nih.gov/pubmed/16487631 <a href="https://www.ncbi.nlm.nih.gov/pubmed/16487631">Romero-Steiner S., et al. </a> 114109747 Ades, Edwin CDC - DIR CDC Ades, Edwin (CDC) 0 114109748 Sampson, Jacquelyn CDC - DIR CDC Sampson, Jacquelyn (CDC) 0 114109750 Carlone, George CDC - DIR CDC Carlone, George (CDC) 0 114109751 Caba, Joseph CDC - DIR CDC Caba, Joseph (CDC) 0 114109752 Rajam, GowriSankar CDC - DIR CDC Rajam, GowriSankar (CDC) 0 114109749 Steiner, Sandra CDC - DIR CDC Steiner, Sandra (CDC) 1 114109749 Steiner, Sandra CDC - DIR CDC Steiner, Sandra (CDC) 1 114109747 Ades, Edwin CDC - DIR CDC Ades, Edwin (CDC) 0 114109748 Sampson, Jacquelyn CDC - DIR CDC Sampson, Jacquelyn (CDC) 0 114109750 Carlone, George CDC - DIR CDC Carlone, George (CDC) 0 114109751 Caba, Joseph CDC - DIR CDC Caba, Joseph (CDC) 0 114109752 Rajam, GowriSankar CDC - DIR CDC Rajam, GowriSankar (CDC) 0 114102454 FUNCTIONAL EPITOPES OF STREPTOCOCCUS PNEUMONIAE PSAA ANTIGEN AND USES THEREOF E-338-2013-0 Filing authorized Centers for Disease Control and Prevention (CDC) 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-3292] Novel Peptide of <em>Streptococcus pneumoniae</em> Surface Adhesion A (PsaA) Protein Associated with Adherence and Uses Thereof – for Vaccine Candidate, Therapeutic and Diagnostic Development&body=Please send me information about technology [TAB-3292] Novel Peptide of <em>Streptococcus pneumoniae</em> Surface Adhesion A (PsaA) Protein Associated with Adherence and Uses Thereof – for Vaccine Candidate, Therapeutic and Diagnostic Development. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-3292] Novel Peptide of <em>Streptococcus pneumoniae</em> Surface Adhesion A (PsaA) Protein Associated with Adherence and Uses Thereof – for Vaccine Candidate, Therapeutic and Diagnostic Development&body=Please send me information about technology [TAB-3292] Novel Peptide of <em>Streptococcus pneumoniae</em> Surface Adhesion A (PsaA) Protein Associated with Adherence and Uses Thereof – for Vaccine Candidate, Therapeutic and Diagnostic Development.">jonathan.motley@nih.gov</a><br> 114168652 E-338-2013-0 E-338-2013-0-US-01 FUNCTIONAL EPITOPES OF STREPTOCOCCUS PNEUMONIAE PSAA ANTIGEN AND USES THEREOF PRV US 60/682,495 Abandoned US <br />Provisional (PRV) 60/682,495<br />Filed on 2005-05-19<br />Status: Abandoned 114168653 E-338-2013-0 E-338-2013-0-PCT-02 FUNCTIONAL EPITOPES OF STREPTOCOCCUS PNEUMONIAE PSAA ANTIGEN AND USES THEREOF PCT Patent Cooperation Treaty PCT/US2005/027290 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2005/027290<br />Filed on 2005-07-29<br />Status: Expired 114168654 E-338-2013-0 E-338-2013-0-US-06 FUNCTIONAL EPITOPES OF STREPTOCOCCUS PNEUMONIAE PSAA ANTIGEN AND USES THEREOF National Stage US 7,919,104 11/992,719 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7919104 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7919104">7,919,104</a><br />Filed on 2008-07-18<br />Status: Expired 114127964 DC4XXX 114127965 WBXXXX 114127966 WFXXXX 114127967 WIXXXX 114127968 WKXXXX 114127969 WNXXXX 114127970 XAXXXX 114127971 XKXXXX 114127972 YBXXXX 114127973 YCXXXX 114150994 FUNCTIONAL 114150995 Epitopes 114150996 Streptococcus 114150997 PNEUMONIAE 114150998 PsaA 114150999 ANTIGEN 114151000 USES 114151001 THEREOF 114151002 CDC Docket Import 114151003 CDC Docket Import CDC Prosecuting 114151004 OID-NCIRD-DBD 114151005 Listed LPM Surabian as of 4/15/2015 114151006 Pre LPM working set 20150418 114151007 Post LPM Assignment Set 20150420 TAB-3290 114097217 Edema Factor Adenylate Cyclase Variants Having Potencies That Are Highly Dependent On the N-end Rule NIAID Infectious Disease, Licensing, Research Materials Infectious Disease Licensing Research Materials Stephen Leppla, Clinton Leysath <em>B. anthracis</em> strains BH480; plasmids encoding anthrax edema factor (EF) variants pSJ136EFOS, pSJ 136EFA and pSJ 136EFR. <ul> <li>Speed up product development with NIH developed material that has already been tested and validated.</li> </ul> <ul> <li>A research material that can be used in the development of assays, validation of products or in quality control.</li> </ul> Research Material – Patent protection is not being pursued for this technology. (IC Reference No. 2013-039) 2022-03-08 2024-10-28 2024-10-28 2018-06-07 ADENYLATE, Are, CYCLASE, DD1XXX, Dependent, Edema, factor, Having, Highly, Highlydependent, Listed LPM Soukas as of 4/15/2015, N-END, Post LPM Assignment Set 20150420, Potencies, Pre LPM working set 20150418, RM, RULE, That, VARIANTS, WIXXXX False True True NIHTT 37470483 Website Abstract 114172493 Leysath CR, et al. https://www.ncbi.nlm.nih.gov/pubmed/24015319 <a href="https://www.ncbi.nlm.nih.gov/pubmed/24015319">Leysath CR, et al.</a> 114109743 Leysath, Clinton The Texas A&M University System Leysath, Clinton 0 114109742 Leppla, Stephen NIAID - DIR NIAID Leppla, Stephen (NIAID) 1 114109742 Leppla, Stephen NIAID - DIR NIAID Leppla, Stephen (NIAID) 1 114109743 Leysath, Clinton The Texas A&M University System Leysath, Clinton 0 114102451 Edema Factor Adenylate Cyclase Variants Having Potencies That Are Highly Dependent On The N-end Rule E-737-2013-0 Research Material NIAID 91026778 Green, Wade wade.green@nih.gov
United States of America TTIPO wade.green@nih.gov?subject=Web Inquiry on [TAB-3290] Edema Factor Adenylate Cyclase Variants Having Potencies That Are Highly Dependent On the N-end Rule&body=Please send me information about technology [TAB-3290] Edema Factor Adenylate Cyclase Variants Having Potencies That Are Highly Dependent On the N-end Rule. Green, Wade<br><a href="mailto:wade.green@nih.gov?subject=Web Inquiry on [TAB-3290] Edema Factor Adenylate Cyclase Variants Having Potencies That Are Highly Dependent On the N-end Rule&body=Please send me information about technology [TAB-3290] Edema Factor Adenylate Cyclase Variants Having Potencies That Are Highly Dependent On the N-end Rule.">wade.green@nih.gov</a><br> 114127950 DD1XXX 114127951 WIXXXX 114150947 Edema 114150948 factor 114150949 ADENYLATE 114150950 CYCLASE 114150951 VARIANTS 114150952 Having 114150953 Potencies 114150954 That 114150955 Are 114150956 Highlydependent 114150957 N-END 114150958 RULE 114150959 Highly 114150960 Dependent 114150961 Listed LPM Soukas as of 4/15/2015 114150962 Pre LPM working set 20150418 114150963 Post LPM Assignment Set 20150420 114150970 RM TAB-3280 114097208 CCR9 Knockout Mice NIAID Licensing, Research Materials Licensing Research Materials Joshua Farber, Paul Love, Shoji Uehara <em>Ccr9<sup>-/-</sup></em> mice may be useful for studying the role of CCR9 in T lymphocyte development and migration.<br /><br /> Mice will be distributed by The Jackson Laboratory; details about this mouse strain (Stock No. 027041) may be found at <a href="https://www.jax.org/strain/027041" target="_blank" title="JAX database entry">https://www.jax.org/strain/027041</a>. <ul> <li>Speed up product development with NIH developed material that has already been tested and validated.</li> </ul> <ul> <li>A research material that can be used in the development of assays, validation of products or in quality control.</li> </ul> Research Material – Patent protection is not being pursued for this technology. (IC Reference No. 2015-021) 2022-03-08 2024-10-28 2024-10-28 2018-06-07 CCR9, Distribution, Jackson, Knockout, Laboratories, Mice, RM, WIXXXX False True True NIHTT 37470483 Website Abstract 114172491 Uehara S, et al. https://www.ncbi.nlm.nih.gov/pubmed/11884450 <a href="https://www.ncbi.nlm.nih.gov/pubmed/11884450">Uehara S, et al.</a> 114109723 Love, Paul NICHD NICHD Love, Paul (NICHD) 0 114109724 Uehara, Shoji Uehara, Shoji 0 114109722 Farber, Joshua NIAID - DIR NIAID Farber, Joshua (NIAID) 1 114109722 Farber, Joshua NIAID - DIR NIAID Farber, Joshua (NIAID) 1 114109723 Love, Paul NICHD NICHD Love, Paul (NICHD) 0 114109724 Uehara, Shoji Uehara, Shoji 0 114102442 CCR9 Knockout Mice For Distribution By Jackson Laboratories E-200-2015-0 Research Material NIAID, NICHD 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-3280] CCR9 Knockout Mice&body=Please send me information about technology [TAB-3280] CCR9 Knockout Mice. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-3280] CCR9 Knockout Mice&body=Please send me information about technology [TAB-3280] CCR9 Knockout Mice.">jonathan.motley@nih.gov</a><br> 114127925 WIXXXX 114150830 Laboratories 114150831 Jackson 114150832 Distribution 114150833 Mice 114150834 Knockout 114150835 CCR9 114150836 RM TAB-3281 114097209 Expression, Purification, and Validation of Anthrax Toxin Proteins NIAID Licensing, Research Materials Licensing Research Materials Rasem Fattah, Stephen Leppla Expression, purification, and validation of anthrax toxin proteins. <ul> <li>Speed up product development with NIH developed material that has already been tested and validated.</li> </ul> <ul> <li>A research material that can be used in the development of assays, validation of products or in quality control.</li> </ul> Research Material – Patent protection is not being pursued for this technology. (IC Reference No. 2015-019) 2022-03-08 2024-10-28 2024-10-28 2018-06-07 Anthrax, Expression, proteins, purification, RM, toxin, Validation, WIXXXX False True True NIHTT 37470483 Website Abstract 114109725 Fattah, Rasem NIAID - DIR NIAID Fattah, Rasem (NIAID) 0 114109726 Leppla, Stephen NIAID - DIR NIAID Leppla, Stephen (NIAID) 1 114109726 Leppla, Stephen NIAID - DIR NIAID Leppla, Stephen (NIAID) 1 114109725 Fattah, Rasem NIAID - DIR NIAID Fattah, Rasem (NIAID) 0 114102443 Expression, Purification, And Validation Of Anthrax Toxin Proteins E-201-2015-0 Research Material NIAID 91026778 Green, Wade wade.green@nih.gov
United States of America TTIPO wade.green@nih.gov?subject=Web Inquiry on [TAB-3281] Expression, Purification, and Validation of Anthrax Toxin Proteins&body=Please send me information about technology [TAB-3281] Expression, Purification, and Validation of Anthrax Toxin Proteins. Green, Wade<br><a href="mailto:wade.green@nih.gov?subject=Web Inquiry on [TAB-3281] Expression, Purification, and Validation of Anthrax Toxin Proteins&body=Please send me information about technology [TAB-3281] Expression, Purification, and Validation of Anthrax Toxin Proteins.">wade.green@nih.gov</a><br> 114127926 WIXXXX 114150837 Validation 114150838 purification 114150839 Expression 114150840 Anthrax 114150841 toxin 114150842 proteins 114150843 RM TAB-3278 114097206 RL-5 – Rabbit T Cell Line Derived From a Herpesvirus Ateles-induced Rabbit Tumor From the Inbred Rabbit Line B/J NIAID Infectious Disease, Licensing, Materials Available, Research Materials Infectious Disease Licensing Materials Available Research Materials Bishop Hague Details for this material are provided in the NIH AIDS Reagent Program Catalog (Catalog# 341):<a href="https://www.aidsreagent.org/reagentdetail.cfm?t=cell_lines&id=152" target="_blank" title="Catalog entry"> https://www.aidsreagent.org/reagentdetail.cfm?t=cell_lines&id=152</a>. <ul> <li>Speed up product development with NIH developed material that has already been tested and validated.</li> </ul> <ul> <li>A research material that can be used in the development of assays, validation of products or in quality control.</li> </ul> Research Material – Patent protection is not being pursued for this technology. (IC Reference No. 2015-003) 2022-07-27 2024-10-28 2024-10-28 2018-06-07 Ateles-induced, B/J., Cell, DERIVED, HERPESVIRUS, Inbred, Line, Listed LPM Ano as of 4/15/2015, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, rabbit, RL-5-, RM, T, tumor, VLXXXX, WIXXXX False True True NIHTT 37470483 Website Abstract 114109720 Hague, Bishop NIAID - DIR NIAID Hague, Bishop (NIAID) 1 114109720 Hague, Bishop NIAID - DIR NIAID Hague, Bishop (NIAID) 1 114102440 RL-5- Rabbit T Cell Line Derived From A Herpesvirus Ateles-induced Rabbit Tumor From The Inbred Rabbit Line B/J. E-104-2015-0 Research Material NIAID 91026778 Green, Wade wade.green@nih.gov
United States of America TTIPO wade.green@nih.gov?subject=Web Inquiry on [TAB-3278] RL-5 – Rabbit T Cell Line Derived From a Herpesvirus Ateles-induced Rabbit Tumor From the Inbred Rabbit Line B/J&body=Please send me information about technology [TAB-3278] RL-5 – Rabbit T Cell Line Derived From a Herpesvirus Ateles-induced Rabbit Tumor From the Inbred Rabbit Line B/J. Green, Wade<br><a href="mailto:wade.green@nih.gov?subject=Web Inquiry on [TAB-3278] RL-5 – Rabbit T Cell Line Derived From a Herpesvirus Ateles-induced Rabbit Tumor From the Inbred Rabbit Line B/J&body=Please send me information about technology [TAB-3278] RL-5 – Rabbit T Cell Line Derived From a Herpesvirus Ateles-induced Rabbit Tumor From the Inbred Rabbit Line B/J.">wade.green@nih.gov</a><br> 114127921 VLXXXX 114127922 WIXXXX 114150801 T 114150802 rabbit 114150803 RL-5- 114150804 Cell 114150805 Line 114150806 DERIVED 114150807 HERPESVIRUS 114150808 Ateles-induced 114150809 tumor 114150810 Inbred 114150811 B/J. 114150812 Listed LPM Ano as of 4/15/2015 114150813 Pre LPM working set 20150418 114150814 Post LPM Assignment Set 20150420 114150815 RM TAB-3279 114097207 Amino Acid Substitutions Mutants of Anthrax Protective Antigen, Lethal Factor, and Edema Factor NIAID Infectious Disease, Licensing, Research Materials Infectious Disease Licensing Research Materials Stephen Leppla Anthrax toxin proteins available for licensing. <em>Bacillus anthracis</em> hosts containing plasmids expressing the following proteins are available. (Host strains are generally BH480, or sometimes BH460. Modest amounts of purified proteins (10-50 mg) could also be provided): <ol> <li>PA. Protective antigen, wild type</li> <li>PA-3M (PA D683A, L685E, Y688K)</li> <li>PA-3M Cys</li> <li>PA-U7</li> <li>PA F427A</li> <li>PA K563C</li> <li>PA L687A</li> <li>PA-U7 K562C</li> <li>PA D512K</li> <li>PA GN</li> <li>PA-3M SoSi-H6</li> <li>FP59-AGG</li> <li>EF-A K313R</li> <li>LFn-linker-Cys</li> <li>LF E687A</li> <li>LFnBLA</li> <li>LFnFLA</li> </ol> <ul> <li>Speed up product development with NIH developed material that has already been tested and validated.</li> </ul> <ul> <li>A research material that can be used in the development of assays, validation of products or in quality control.</li> </ul> Research Material – Patent protection is not being pursued for this technology. (IC Reference No. 2014-019) 2022-03-08 2024-10-28 2024-10-28 2018-06-07 Acid, AMINO, Anthrax, ANTIGEN, Edema, factor, Lethal, Listed LPM Ano as of 4/15/2015, Mutants, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Protective, RM, SUBSTITUTIONS, VJXXXX, WIXXXX False True True NIHTT 37470483 Website Abstract 114109721 Leppla, Stephen NIAID - DIR NIAID Leppla, Stephen (NIAID) 1 114109721 Leppla, Stephen NIAID - DIR NIAID Leppla, Stephen (NIAID) 1 114102441 Amino Acid Substitutions Mutants Of Anthrax Protective Antigen, Lethal Factor, And Edema Factor E-196-2014-0 Research Material NIAID 91026778 Green, Wade wade.green@nih.gov
United States of America TTIPO wade.green@nih.gov?subject=Web Inquiry on [TAB-3279] Amino Acid Substitutions Mutants of Anthrax Protective Antigen, Lethal Factor, and Edema Factor&body=Please send me information about technology [TAB-3279] Amino Acid Substitutions Mutants of Anthrax Protective Antigen, Lethal Factor, and Edema Factor. Green, Wade<br><a href="mailto:wade.green@nih.gov?subject=Web Inquiry on [TAB-3279] Amino Acid Substitutions Mutants of Anthrax Protective Antigen, Lethal Factor, and Edema Factor&body=Please send me information about technology [TAB-3279] Amino Acid Substitutions Mutants of Anthrax Protective Antigen, Lethal Factor, and Edema Factor.">wade.green@nih.gov</a><br> 114127923 VJXXXX 114127924 WIXXXX 114150816 AMINO 114150817 Acid 114150818 SUBSTITUTIONS 114150819 Mutants 114150820 Anthrax 114150821 Protective 114150822 ANTIGEN 114150823 Lethal 114150824 factor 114150825 Edema 114150826 Listed LPM Ano as of 4/15/2015 114150827 Pre LPM working set 20150418 114150828 Post LPM Assignment Set 20150420 114150829 RM TAB-3265 114097200 Novel Magnetic Resonance Spectroscopy (MRS) Technique to Quantify Brain Metabolites NIMH Collaboration, Diagnostics, Medical Devices, Neurology, Non-Medical Devices, Oncology, Psychiatry/Mental Health, Research Materials, Software / Apps Collaboration Diagnostics Medical Devices Neurology Non-Medical Devices Oncology Psychiatry/Mental Health Research Materials Software / Apps Linqing Li, Jun Shen With respect to quantification of metabolites in the brain, conventional methods of magnetic resonance spectroscopy (MRS) yield results that are highly variable and highly dependent on the sequence type being applied. This invention describes a novel MRS technique that involves preparing longitudinal steady states at different flip angles using trains of RF pulses interspersed with field gradients to quantify metabolites. The method allows quantification of metabolites and their relaxation rates under specified parameters, which may create new ways of analyzing and interpreting tissue properties or identifying and characterizing diseases of the human brain, including epilepsy, multiple sclerosis, stroke, cancer, and psychiatric diseases. In addition, due to the linear feature (equation), the quantification of metabolites and their relaxation rates in the brain can be achieved several times faster than conventional techniques, especially for quantification of glutamate (neuronexcitatory) and lactate (important cancer and stroke biomarker). <ul> <li>Ability to measure metabolite relaxation under specific parameters</li> <li>Allows fast quantification of glutamate (neuroexcitatory) and lactate (cancer and stroke biomarkers)</li> <li>Can be optimized to eliminate baseline interference from overlapping metabolite signals</li> <li>Minimizes diffusion effect associated with physiological movement</li> </ul> <ul> <li>Non-invasive MRS diagnostic imaging</li> </ul> The National Institute of Mental Health is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize Magnetic Resonance Spectroscopy (MRS) methods. For collaboration opportunities, please contact Linqing Li, Ph.D. at <a href="mailto:linqing.li@nih.gov">linqing.li@nih.gov</a>. 2022-03-08 2024-10-28 2024-10-28 2018-05-23 AAXXXX, DRIVEN, IMAGING, ImagingMRI, LINEAR, METABOLITE, MRI, NCXXXX, Probing, QUANTIFICATION, Relaxation, RF, States, Steady, VCXXXX, VEXXXX, Vivo, VNXXXX, WBXXXX, XFXXXX, YAXXXX, YDXXXX False True True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114172479 Li L, et al. https://www.ncbi.nlm.nih.gov/pubmed/28940581 <a href="https://www.ncbi.nlm.nih.gov/pubmed/28940581">Li L, et al.</a> 114109688 Shen, Jun National Institute of Mental Health (NIMH) NIMH Shen, Jun (NIMH) 0 114109687 Li, Linqing National Institute of Mental Health (NIMH) NIMH Li, Linqing (NIMH) 1 114109687 Li, Linqing National Institute of Mental Health (NIMH) NIMH Li, Linqing (NIMH) 1 114109688 Shen, Jun National Institute of Mental Health (NIMH) NIMH Shen, Jun (NIMH) 0 114102428 Probing In Vivo Metabolite Relaxation By Linear Quantification Of RF Driven Steady States E-206-2017-0 Filing authorized National Institute of Mental Health (NIMH) 83739514 Dawson, Anton anton.dawson@nih.gov
United States of America anton.dawson@nih.gov?subject=Web Inquiry on [TAB-3265] Novel Magnetic Resonance Spectroscopy (MRS) Technique to Quantify Brain Metabolites&body=Please send me information about technology [TAB-3265] Novel Magnetic Resonance Spectroscopy (MRS) Technique to Quantify Brain Metabolites. Dawson, Anton<br><a href="mailto:anton.dawson@nih.gov?subject=Web Inquiry on [TAB-3265] Novel Magnetic Resonance Spectroscopy (MRS) Technique to Quantify Brain Metabolites&body=Please send me information about technology [TAB-3265] Novel Magnetic Resonance Spectroscopy (MRS) Technique to Quantify Brain Metabolites.">anton.dawson@nih.gov</a><br> 114161730 E-206-2017-0 E-206-2017-0-US-01 Systems and Methods for Probing In Vivo Metabolite Relaxation by Linear Quantification of Spatially Modulated Magnetization PRV US 62/567,991 Abandoned US <br />Provisional (PRV) 62/567,991<br />Filed on 2017-10-04<br />Status: Abandoned 114168755 E-206-2017-0 E-206-2017-0-PCT-02 SYSTEMS AND METHODS FOR PROBING IN-VIVO METABOLITE RELAXATION BY LINEAR QUANTIFICATION OF SPATIALLY MODULATED MAGNETIZATION PCT Patent Cooperation Treaty PCT/US2018/054340 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2018/054340<br />Filed on 2018-10-04<br />Status: Expired 114127852 AAXXXX 114127853 NCXXXX 114127854 VCXXXX 114127855 VEXXXX 114127856 VNXXXX 114127857 WBXXXX 114127858 XFXXXX 114127859 YAXXXX 114127860 YDXXXX 114150659 Probing 114150660 Vivo 114150661 METABOLITE 114150662 Relaxation 114150663 LINEAR 114150664 QUANTIFICATION 114150665 RF 114150666 DRIVEN 114150667 Steady 114150668 States 114150669 IMAGING 114150670 ImagingMRI 114150671 MRI TAB-3261 114097196 Prefusion Coronavirus Spike Proteins and Their Use NIAID Collaboration, Infectious Disease, Vaccines Collaboration Infectious Disease Vaccines Kizzmekia Corbett, Christopher Cottrell, Barney Graham, Michael Joyce, Masaru Kanekiyo, Robert Kirchdoerfer, Jason McLellan, Jesper Pallesen, Hannah Turner, Nianshuang Wang, Andrew Ward, Hadi Yassine Coronaviruses (CoVs) can cause severe respiratory disease with high fatality rates in humans. The 2002-2003 SARS-CoV epidemic resulted in 8098 cases and 744 deaths, and MERS-CoV, which emerged in 2012, has resulted in 2144 cases and over 750 deaths as of March 2018. Currently, there are no effective prophylactic or therapeutic measures, and because other CoVs are poised to emerge as new human pathogens, there is a need to define a general CoV vaccine solution. Past efforts to develop CoV vaccines have used whole-inactivated virus, live-attenuated virus, recombinant protein subunit, or genetic approaches.<br /><br /> CoV spike (S) proteins mediate cellular attachment and membrane fusion and are therefore the target of protective antibodies. Inventors at the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases have developed a novel CoV S protein vaccine antigen. This technology employs protein engineering to stabilize S in its prefusion conformation, preventing structural rearrangement, and exposing antigenically preferable surfaces. The technology has been applied to several CoV spikes, including those from human-relevant viruses, such as HKU1-CoV, SARS-CoV, and MERS-CoV. Particularly for MERS-COV, stabilized S proteins have been shown to elicit superior neutralizing antibody responses up to 10-fold higher in animal models and protect mice against lethal MERS-CoV infection. This technology is applicable for delivery via other platforms, such as mRNA.<br /><br /> This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as well as for further development and evaluation under a research collaboration. <ul> <li>Improved immunogenicity compared to other coronavirus S vaccine formulations.</li> <li>Increased protein expression, stability, and manufacturability compared to wild-type CoV S.</li> </ul> <ul> <li>The stabilized prefusion coronavirus spike protein can be used as a vaccine antigen to elicit robust neutralizing antibody responses.</li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize coronavirus diagnostics or vaccines. For collaboration opportunities, please contact Amy Petrik, Ph.D., 240-627-3721; <a href="mailto:amy.petrik@nih.gov">amy.petrik@nih.gov</a>. 2022-08-15 2024-10-28 2024-10-28 2020-04-08 CORONAVIRUS, DC5BXX, proteins, Stabilized, VACCINATION False True True NIHTT 37470483 Website Abstract E-086-2020-0 114110095 Kanekiyo, Masaru NIAID - VRC NIAID Kanekiyo, Masaru (NIAID) 0 114110096 Joyce, Michael NIAID - VRC NIAID Joyce, Michael (NIAID) 0 114110097 Corbett, Kizzmekia NIAID - DIR NIAID Corbett, Kizzmekia (NIAID) 0 114110098 Yassine, Hadi NIAID - VRC NIAID Yassine, Hadi (NIAID) 0 114110099 McLellan, Jason Geisel School of Medicine at Dartmouth College NIAID McLellan, Jason (NIAID) 0 114110100 Cottrell, Christopher The Scripps Research Institute Cottrell, Christopher 0 114110101 Wang, Nianshuang Geisel School of Medicine at Dartmouth College Wang, Nianshuang 0 114110102 Pallesen, Jesper The Scripps Research Institute Pallesen, Jesper 0 114110103 Turner, Hannah The Scripps Research Institute Turner, Hannah 0 114110104 Kirchdoerfer, Robert The Scripps Research Institute Kirchdoerfer, Robert 0 114110105 Ward, Andrew Scripps Research Institute Immunology Lab Ward, Andrew 0 114103450 Graham, Barney NIAID - VRC NIAID Graham, Barney (NIAID) 1 114103450 Graham, Barney NIAID - VRC NIAID Graham, Barney (NIAID) 1 114110095 Kanekiyo, Masaru NIAID - VRC NIAID Kanekiyo, Masaru (NIAID) 0 114110096 Joyce, Michael NIAID - VRC NIAID Joyce, Michael (NIAID) 0 114110097 Corbett, Kizzmekia NIAID - DIR NIAID Corbett, Kizzmekia (NIAID) 0 114110098 Yassine, Hadi NIAID - VRC NIAID Yassine, Hadi (NIAID) 0 114110099 McLellan, Jason Geisel School of Medicine at Dartmouth College NIAID McLellan, Jason (NIAID) 0 114110100 Cottrell, Christopher The Scripps Research Institute Cottrell, Christopher 0 114110101 Wang, Nianshuang Geisel School of Medicine at Dartmouth College Wang, Nianshuang 0 114110102 Pallesen, Jesper The Scripps Research Institute Pallesen, Jesper 0 114110103 Turner, Hannah The Scripps Research Institute Turner, Hannah 0 114110104 Kirchdoerfer, Robert The Scripps Research Institute Kirchdoerfer, Robert 0 114110105 Ward, Andrew Scripps Research Institute Immunology Lab Ward, Andrew 0 114099863 Stabilized Coronavirus Proteins For Vaccination E-234-2016-0 Filing authorized Geisel School of Medicine at Dartmouth College, Geisel School of Medicine Dartmouth, NIAID, Scripps Research Institute Immunology Lab, The Scripps Research Institute 114102537 Stabilized Coronavirus Proteins For Vaccination E-234-2016-1 Filing authorized Geisel School of Medicine at Dartmouth College, NIAID, Scripps Research Institute Immunology Lab, The Scripps Research Institute 83682222 Bailey, Brian bbailey@mail.nih.gov
United States of America TTIPO bbailey@mail.nih.gov?subject=Web Inquiry on [TAB-3261] Prefusion Coronavirus Spike Proteins and Their Use&body=Please send me information about technology [TAB-3261] Prefusion Coronavirus Spike Proteins and Their Use. Bailey, Brian<br><a href="mailto:bbailey@mail.nih.gov?subject=Web Inquiry on [TAB-3261] Prefusion Coronavirus Spike Proteins and Their Use&body=Please send me information about technology [TAB-3261] Prefusion Coronavirus Spike Proteins and Their Use.">bbailey@mail.nih.gov</a><br> 114160580 E-234-2016-0 E-234-2016-0-US-01 Prefusion Coronavirus Spike Proteins And Their Use PRV US 62/412,703 Abandoned US <br />Provisional (PRV) 62/412,703<br />Filed on 2016-10-25<br />Status: Abandoned 114169011 E-234-2016-1 E-234-2016-1-PCT-01 PREFUSION CORONAVIRUS SPIKE PROTEINS AND THEIR USE PCT COMB Patent Cooperation Treaty PCT/US2017/058370 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2017/058370<br />Filed on 2017-10-25<br />Status: Expired 114169012 E-234-2016-1 E-234-2016-1-US-03 PREFUSION CORONAVIRUS SPIKE PROTEINS AND THEIR USE National Stage US 10,960,070 16/344,774 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10960070 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10960070">10,960,070</a><br />Filed on 2019-04-24<br />Status: Issued 114169112 E-234-2016-1 E-234-2016-1-US-04 PREFUSION CORONAVIRUS SPIKE PROTEINS AND THEIR USE DIV US 11,964,010 17/194,834 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11964010 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11964010">11,964,010</a><br />Filed on 2021-03-08<br />Status: Issued 114169338 E-234-2016-1 E-234-2016-1-EP-02 PREFUSION CORONAVIRUS SPIKE PROTEINS AND THEIR USE National Stage European Patent 17800655.7 Pending European Patent <br />National Stage 17800655.7<br />Filed on 2017-10-25<br />Status: Pending 114113409 DC5BXX 114150636 Stabilized 114150637 CORONAVIRUS 114150638 proteins 114150639 VACCINATION TAB-3253 114097186 Novel Human Rotavirus Vaccine CDC-6 Strain for Impacted Subgroup, the Lewis Negative Population CDC Collaboration, Consumer Products, Diagnostics, Infectious Disease, Licensing, Occupational Safety and Health, Research Materials, Vaccines Collaboration Consumer Products Diagnostics Infectious Disease Licensing Occupational Safety and Health Research Materials Vaccines Baoming Jiang, Yuhuan Wang Rotaviral infection is the most common gastrointestinal illness of children in the world, affecting both developed and developing economies. There is no specific drug treatment for rotavirus infection. Vaccination and good hygiene are key to prevention.<br/><br/> Approximately 5-10% of the world's population are Lewis histoblood group antigen negative, that percentage is as high as 30% in some African countries. Despite vaccination, the Lewis negative population show a disproportionate prevalence and recurrence of rotavirus infection. However, initial studies have shown that infection with a rotavirus G9P[6] strain may provide improved protection within this group. Inventors have isolated a human rotavirus G9P[6] strain, designated CDC-6, that grows to a high titer with a stable outer structure, making it an ideal vaccine candidate strain. The CDC-6 strain possesses favorable virological and molecular features and may serve as a promising candidate for a new live oral or an inactivated rotavirus vaccine. CDC seeks partners to jointly develop this technology in pre-clinical and clinical testing. <ul> <li>Broader population coverage (both the Lewis-positive and negative population)</li> <li> Isolated strains are representative of those involved in community-acquired infection</li> <li> Suitable for the development of improved, broadly effective rotavirus vaccines; no current vaccine has the P[6] antigen strain</li> <li> Potential for a new inactivated injection and/or live oral vaccine format</li> <li>May be administered alone or in combination with other vaccines</li> <li>First human G9P[6] genotype that can grow to high titer in Vero cells</li> <li>Shown to maintain the integrity of triple layered particles during upstream and downstream process</li> </ul> <ul> <li>Novel rotavirus vaccines</li> <li>Neonatal/childhood vaccination initiatives</li> <li> Large scale antigen production</li> <li> Use in diagnostics of rotavirus disease</li> <li>Rotavirus surveillance programs, important for both developing and developed nations</li> <li>New vaccine candidate option for animals</li> <li>Research tool</li> </ul> The CDC Technology Transfer Office (TTO) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize: Novel Human Rotavirus Vaccine CDC-6 Strain for Impacted Subgroup, the Lewis Negative Population. For collaboration opportunities, please contact CDC TTO at <a href="mailto:tto@cdc.gov">tto@cdc.gov</a>. 2022-06-22 2024-10-28 2024-10-28 2018-03-07 Candidate, CHARACTERIZATION, G9P[6], Human, Isolation, NCIRD, NCIRD-DVD, rotavirus, Strain, Vaccine, VLXXXX, WBXXXX, WFXXXX, WGXXXX, WHXXXX, WIXXXX, WNXXXX, XKXXXX, YAXXXX, YBXXXX False True True 52406768 Discovery 52406768 NIHTT 37470483 Website Abstract E-150-2013-0 E-153-2013-0 E-191-2013-0 114109637 Wang, Yuhuan CDC - DIR CDC Wang, Yuhuan (CDC) 0 114109636 Jiang, Baoming CDC - DIR CDC Jiang, Baoming (CDC) 1 114109636 Jiang, Baoming CDC - DIR CDC Jiang, Baoming (CDC) 1 114109637 Wang, Yuhuan CDC - DIR CDC Wang, Yuhuan (CDC) 0 114102412 Isolation And Characterization Of A Human Rotavirus G9P[6] Strain As A Vaccine Candidate E-285-2015-0 Filing authorized Centers for Disease Control and Prevention (CDC) 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-3253] Novel Human Rotavirus Vaccine CDC-6 Strain for Impacted Subgroup, the Lewis Negative Population&body=Please send me information about technology [TAB-3253] Novel Human Rotavirus Vaccine CDC-6 Strain for Impacted Subgroup, the Lewis Negative Population. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-3253] Novel Human Rotavirus Vaccine CDC-6 Strain for Impacted Subgroup, the Lewis Negative Population&body=Please send me information about technology [TAB-3253] Novel Human Rotavirus Vaccine CDC-6 Strain for Impacted Subgroup, the Lewis Negative Population.">jonathan.motley@nih.gov</a><br> 114168567 E-285-2015-0 E-285-2015-0-US-01 Isolation and Characterization Of A Human Rotavirus G9P[6] Strain As A Vaccine Candidate PRV US 62/237,452 Abandoned US <br />Provisional (PRV) 62/237,452<br />Filed on 2015-10-05<br />Status: Abandoned 114168568 E-285-2015-0 E-285-2015-0-PCT-02 HUMAN ROTAVIRUS G9P[6] STRAIN AND USE AS A VACCINE PCT Patent Cooperation Treaty PCT/US2016/054211 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2016/054211<br />Filed on 2016-09-28<br />Status: Expired 114168600 E-285-2015-0 E-285-2015-0-US-06 HUMAN ROTAVIRUS G9P[6] STRAIN AND USE AS A VACCINE National Stage US 10,548,970 15/765,716 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10548970 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10548970">10,548,970</a><br />Filed on 2018-04-03<br />Status: Issued 114168949 E-285-2015-0 E-285-2015-0-US-07 HUMAN ROTAVIRUS G9P[6] STRAIN AND USE AS A VACCINE DIV US 11,185,581 16/717,946 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11185581 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11185581">11,185,581</a><br />Filed on 2019-12-17<br />Status: Issued 114169168 E-285-2015-0 E-285-2015-0-US-09 HUMAN ROTAVIRUS G9P[6] STRAIN AND USE AS A VACCINE CON US 11,759,513 17/515,074 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11759513 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11759513">11,759,513</a><br />Filed on 2021-10-29<br />Status: Issued 114127803 YAXXXX 114127804 YBXXXX 114127805 VLXXXX 114127806 WBXXXX 114127807 WFXXXX 114127808 WGXXXX 114127809 WHXXXX 114127810 WIXXXX 114127811 WNXXXX 114127812 XKXXXX 114150464 Isolation 114150465 CHARACTERIZATION 114150466 Human 114150467 rotavirus 114150468 G9P[6] 114150469 Strain 114150470 Vaccine 114150471 Candidate 114150472 NCIRD 114150473 NCIRD-DVD TAB-3254 114097187 Protein Nanoparticles for Antigen Display in Vaccines NIAID Collaboration, Infectious Disease, Materials Available, Vaccines Collaboration Infectious Disease Materials Available Vaccines Audray Harris, Dustin McCraw The technology relates to a protein-based nanoparticle platform that allows presentation of immunogenic molecules such as influenza virus antigens. This protein platform is made up of hepatitis B capsid/core proteins. The core proteins contain immunogenic loop c/e1, where other antigens can be inserted and the chimeric protein retains the ability to form capsid-like particles. The technology describes the insertion of one or more copies of influenza epitopes derived from the globular head or the stem region of hemagglutinin protein into or around the c/e1 loop of the core protein. The nanoparticles formed by the use of Hepatitis B virus core proteins can be disassembled and re-assembled, allowing mixing of antigens. Furthermore, the nanoparticles can be expressed in prokaryotic and eukaryotic expression systems. Thus, the platform provides a means for an optimal display of influenza epitopes for the induction of immune response including broadly neutralizing antibodies against the virus and therefore has the potential to be developed into an efficient universal vaccine against influenza virus infection.<br /><br /> This technology is available for licensing for commercial development in accordance with 35 U.S.C. § 209 and 37 CFR Part 404, as well as for further development and evaluation under a research collaboration. <ul> <li>The nanoparticles may be disassembled and re-assembled allowing mixing of antigens</li> <li>Expression in prokaryotic and eukaryotic systems</li> <li>Avoids production and usage of live viruses for vaccine generation</li> <li>Effective immune response due to the use of authentic viral antigens</li> <li>Stability of particle and immunogenicity after high temperature exposure</li> <li>Incorporation of epitopes from group 1 and group 2 influenza viruses</li> <li>Broadly neutralizing antibodies against influenza virus</li> </ul> <ul> <li>Vaccine against viruses; vaccines against influenza virus; universal influenza virus vaccine</li> </ul> The National Institute of Allergy and Infectious Diseases is also seeking statements of capability or interest from parties interested in collaborative research. NIAID would like a prospective collaborator to have one or more of the following capabilities: (1) capacity to produce recombinant protein for animal vaccine studies; (2) perform and evaluate immunogenicity (antibody response) of influenza vaccine antigens in animal (e.g. mouse models); (3) perform and evaluate challenge and protection studies of vaccines and influenza viruses. (e.g. mouse models); and (4) if results are promising from animal studies, capacity to generate clinical grade materials and perform clinical studies. NIAID will consider executing a Confidentiality Agreement with a prospective collaborator to facilitate receipt of a Capability Statement if requested. For collaboration opportunities, please contact Dr. Elizabeth Pitts at <a href="mailto: elizabeth.pitts@nih.gov">elizabeth.pitts@nih.gov</a> or 240-669-5299. 2022-03-08 2024-10-28 2024-10-28 2020-07-06 ANTIGEN, DC5BXX, DISPLAY, INFLUENZA, Nanoparticles, Protein, Vaccine, virus False True True NIHTT 37470483 Website Abstract 114172458 Dustin M. McCraw, et al. https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1011514 <a href="https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1011514">Dustin M. McCraw, et al.</a> 114109639 McCraw, Dustin NIAID - DIR NIAID McCraw, Dustin (NIAID) 0 114109638 Harris, Audray NIAID - DIR NIAID Harris, Audray (NIAID) 1 114109638 Harris, Audray NIAID - DIR NIAID Harris, Audray (NIAID) 1 114109639 McCraw, Dustin NIAID - DIR NIAID McCraw, Dustin (NIAID) 0 114102413 Protein Nanoparticles For Antigen Display E-005-2017-0 Filing authorized NIAID 91021353 Pitts, Elizabeth elizabeth.pitts@nih.gov
United States of America elizabeth.pitts@nih.gov?subject=Web Inquiry on [TAB-3254] Protein Nanoparticles for Antigen Display in Vaccines&body=Please send me information about technology [TAB-3254] Protein Nanoparticles for Antigen Display in Vaccines. Pitts, Elizabeth<br><a href="mailto:elizabeth.pitts@nih.gov?subject=Web Inquiry on [TAB-3254] Protein Nanoparticles for Antigen Display in Vaccines&body=Please send me information about technology [TAB-3254] Protein Nanoparticles for Antigen Display in Vaccines.">elizabeth.pitts@nih.gov</a><br> 114167575 E-005-2017-0 E-005-2017-0-US-01 Hepatitis B Nanoparticle-Based Vaccine For Influenza Virus PRV US 62/540,474 Abandoned US <br />Provisional (PRV) 62/540,474<br />Filed on 2017-08-02<br />Status: Abandoned 114168703 E-005-2017-0 E-005-2017-0-PCT-02 HEPATITIS B NANOPARTICLE-BASED VACCINE FOR INFLUENZA VIRUS PCT Patent Cooperation Treaty PCT/US2018/045032 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2018/045032<br />Filed on 2018-08-02<br />Status: Expired 114168959 E-005-2017-0 E-005-2017-0-US-06 HEPATITIS B NANOPARTICLE-BASED VACCINE FOR INFLUENZA VIRUS National Stage US 11,535,651 16/635,240 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11535651 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11535651">11,535,651</a><br />Filed on 2020-01-30<br />Status: Issued 114127813 DC5BXX 114150474 ANTIGEN 114150475 Nanoparticles 114150476 Protein 114150477 DISPLAY 114150482 virus 114150483 INFLUENZA 114150484 Vaccine TAB-3239 114097173 A Novel Thermal Method to Inactivate Rotavirus for Use in Vaccines CDC Collaboration, Infectious Disease, Licensing, Therapeutics, Vaccines Collaboration Infectious Disease Licensing Therapeutics Vaccines Roger Glass, Baoming Jiang, Jean-Francois Saluzzo Rotavirus is a highly contagious, diarrhea-inducing pathogen that annually causes approximately 250,000 deaths worldwide and millions of hospitalizations, especially afflicting infants and young children. One strategy to combat this virus is through vaccination. Continuing safety and efficacy concerns with the currently existing live, oral vaccines against rotavirus have led researchers to search for alternative treatment approaches, such as vaccines containing inactivated rotavirus.<br /><br /> This technology describes a method for inactivating rotavirus. Traditional inactivation strategies use chemicals that reduce antigenicity (by altering rotavirus proteins), leading to less protection against the virus. Conversely, this method preserves and/or maintains the integrity of viral particles, leading to greater protection against rotavirus. This strategy has been validated in mice, piglets and cattle and further clinical studies are underway. <ul> <li>Animal studies thus far show greater protection against rotavirus than currently available vaccines</li> <li>No formalin or beta-propiolactone required for inactivation of rotavirus </li> <li>Greater antigenicity of treated particles compared to chemically treated particles</li> <li>Technique preserves and maintains integrity of virus particles</li> </ul> <ul> <li>An inactivated rotavirus virus vaccine</li> <li> Can inactivate potential adventitious agents that might contaminate vaccines</li> </ul> The CDC Technology Transfer Office (TTO) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize: A Novel Thermal Method to Inactivate Rotavirus for Use in Vaccines. For collaboration opportunities, please contact CDC TTO at <a href="mailto: tto@cdc.gov">tto@cdc.gov</a> or 1-404-639-1330 2022-06-22 2024-10-28 2024-10-28 2018-01-16 CDC Docket Import, CDC Docket Import CDC Prosecuting, DB4BXX, DB4XXX, DBXXXX, DC1XXX, DC5BXX, DC5XXX, DCXXXX, DXXXXX, Inactivation, Listed LPM Surabian as of 4/15/2015, NCIRD, OID-NCIRD-DVD, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, rotavirus, thermal False True True NIHTT 37470483 Website Abstract E-150-2013-0 114172439 Jiang B., et al. https://www.ncbi.nlm.nih.gov/pubmed/18382129 <a href="https://www.ncbi.nlm.nih.gov/pubmed/18382129">Jiang B., et al.</a> 114172440 Westerman L., et al. https://www.ncbi.nlm.nih.gov/pubmed/1129131 <a href="https://www.ncbi.nlm.nih.gov/pubmed/1129131">Westerman L., et al.</a> 114172441 Saluzzo JF, et al. https://www.ncbi.nlm.nih.gov/pubmed/3146583 <a href="https://www.ncbi.nlm.nih.gov/pubmed/3146583">Saluzzo JF, et al.</a> 114109604 Glass, Roger CDC - DIR CDC Glass, Roger (CDC) 0 114109605 Saluzzo, Jean-Francois CDC - DIR CDC Saluzzo, Jean-Francois (CDC) 0 114109603 Jiang, Baoming CDC - DIR CDC Jiang, Baoming (CDC) 1 114109603 Jiang, Baoming CDC - DIR CDC Jiang, Baoming (CDC) 1 114109604 Glass, Roger CDC - DIR CDC Glass, Roger (CDC) 0 114109605 Saluzzo, Jean-Francois CDC - DIR CDC Saluzzo, Jean-Francois (CDC) 0 114102399 THERMAL INACTIVATION OF ROTAVIRUS E-153-2013-0 Filing authorized Centers for Disease Control and Prevention (CDC) 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-3239] A Novel Thermal Method to Inactivate Rotavirus for Use in Vaccines&body=Please send me information about technology [TAB-3239] A Novel Thermal Method to Inactivate Rotavirus for Use in Vaccines. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-3239] A Novel Thermal Method to Inactivate Rotavirus for Use in Vaccines&body=Please send me information about technology [TAB-3239] A Novel Thermal Method to Inactivate Rotavirus for Use in Vaccines.">jonathan.motley@nih.gov</a><br> 114168527 E-153-2013-0 E-153-2013-0-US-01 THERMAL INACTIVATION OF ROTAVIRUS PRV US 60/969,826 Abandoned US <br />Provisional (PRV) 60/969,826<br />Filed on 2007-09-04<br />Status: Abandoned 114168528 E-153-2013-0 E-153-2013-0-PCT-02 THERMAL INACTIVATION OF ROTAVIRUS PCT Patent Cooperation Treaty PCT/US2008/075239 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2008/075239<br />Filed on 2008-09-04<br />Status: Expired 114168529 E-153-2013-0 E-153-2013-0-US-08 THERMAL INACTIVATION OF ROTAVIRUS National Stage US 8,357,525 12/676,490 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8357525 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8357525">8,357,525</a><br />Filed on 2010-03-04<br />Status: Issued 114168530 E-153-2013-0 E-153-2013-0-US-09 THERMAL INACTIVATION OF ROTAVIRUS CON US 13/718,648 Abandoned US <br />Continuation (CON) 13/718,648<br />Filed on 2012-12-18<br />Status: Abandoned 114168531 E-153-2013-0 E-153-2013-0-US-19 THERMAL INACTIVATION OF ROTAVIRUS CON US 10,556,001 15/725,221 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10556001 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10556001">10,556,001</a><br />Filed on 2017-10-04<br />Status: Issued 114168951 E-153-2013-0 E-153-2013-0-US-20 THERMAL INACTIVATION OF ROTAVIRUS DIV US 11,103,572 16/722,393 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11103572 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11103572">11,103,572</a><br />Filed on 2019-12-20<br />Status: Issued 114169149 E-153-2013-0 E-153-2013-0-US-21 THERMAL INACTIVATION OF ROTAVIRUS CON US 17/385,416 Abandoned US <br />Continuation (CON) 17/385,416<br />Filed on 2021-07-26<br />Status: Abandoned 114127727 DXXXXX 114127728 DBXXXX 114127729 DB4XXX 114127730 DB4BXX 114127731 DCXXXX 114127732 DC5XXX 114127733 DC5BXX 114127734 DC1XXX 114150321 thermal 114150322 Inactivation 114150323 rotavirus 114150324 CDC Docket Import 114150325 CDC Docket Import CDC Prosecuting 114150326 OID-NCIRD-DVD 114150327 Listed LPM Surabian as of 4/15/2015 114150328 Pre LPM working set 20150418 114150329 Post LPM Assignment Set 20150420 114150330 NCIRD TAB-3231 114097167 Monoclonal Antibody Specific for DNA/RNA Hybrid Molecules NIAID Collaboration, Infectious Disease, Licensing, Research Materials Collaboration Infectious Disease Licensing Research Materials David Garboczi, Larry Lantz, Stephen Leppla, Clinton Leysath, Damilola Phillips NIAID has a hybridoma available for non-exclusive licensing that produces a monoclonal antibody specific for DNA/RNA hybrids. This antibody, which has been extensively characterized by NIH researchers, is already a widely-used research tool. It is currently the only monoclonal antibody available that is specific for DNA/RNA hybrids, making it a unique reagent. It is used in immuno-fluorescence (IF) microscopy, where it can be used to detect sites of transcriptional activity and potentially sites of viral replication. It has also been used in DNA/RNA immunoprecipitation (DRIP) experiments by a variety of researchers.<br /><br /> Aside from its use as a research tool, this antibody has potential to be used in diagnostic kits for viral/bacterial infections, cancers, and a variety of other human diseases. DNA/RNA hybrids arise during normal cellular function, but they are typically present in cells at low levels. When DNA/RNA hybrids are found at high levels in a cell, it indicates that the cell is "abnormal". For example, the cell may be cancerous or infected with a virus. NIH researchers have also incorporated the antibody into a micro-array platform, expanding its potential for use in diagnostic devices.<br /><br /> This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR Part 404, as well as for further development and evaluation under a research collaboration. <ul> <li>Only available monoclonal antibody specific for DNA/RNA hybrids</li> <li>Binding properties extensively characterized by NIH researchers</li> <li>Widely-accepted as a key research reagent</li> <li>Antibody based micro-arrays are inexpensive, efficient, and increase detection of small or structured transcripts, as well as transcripts present at low levels</li> </ul> Research tool: <ul> <li>Detection and visualization of DNA/RNA hybrids, "R-loops", or sites of viral replication in cells</li> <li>DNA/RNA immunoprecipitation (DRIP) studies</li> <li>Antibody based micro-arrays</li> </ul> For use in diagnostic kits that detect: <ul> <li>Viral/bacterial infections</li> <li>miRNA biomarkers of disease (i.e. certain cancers)</li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize antibodies produced by the S9.6 hybridoma. For collaboration opportunities, please contact Dr. Natalie Greco, 301-761-7898; <a href="mailto:Natalie.Greco@nih.gov">Natalie.Greco@nih.gov</a>. Research Tool – Patent protection is not being pursued for this technology. 2022-03-08 2024-10-28 2024-10-28 2017-12-15 89.6, Antibod, DDXXXX, DNA/RNA, HYBRIDS, Listed LPM Ano as of 4/15/2015, MANNER, monoclonal, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Recognizes, S9.6, Sequence-independent False True True NIHTT 37470483 Website Abstract 114170935 Hu Z, et al. https://www.ncbi.nlm.nih.gov/pubmed/16614443 <a href="https://www.ncbi.nlm.nih.gov/pubmed/16614443">Hu Z, et al.</a> 114170936 Phillips DD, et al. https://www.ncbi.nlm.nih.gov/pubmed/23784994 <a href="https://www.ncbi.nlm.nih.gov/pubmed/23784994">Phillips DD, et al.</a> 114109589 Lantz, Larry NIAID - DIR NIAID Lantz, Larry (NIAID) 0 114109590 Garboczi, David NIAID - DIR NIAID Garboczi, David (NIAID) 0 114109591 Phillips, Damilola Cleveland Clinic Lerner College of Medicine Phillips, Damilola 0 114109592 Leysath, Clinton The Texas A&M University System Leysath, Clinton 0 114109593 Leppla, Stephen NIAID - DIR NIAID Leppla, Stephen (NIAID) 1 114109593 Leppla, Stephen NIAID - DIR NIAID Leppla, Stephen (NIAID) 1 114109589 Lantz, Larry NIAID - DIR NIAID Lantz, Larry (NIAID) 0 114109590 Garboczi, David NIAID - DIR NIAID Garboczi, David (NIAID) 0 114109591 Phillips, Damilola Cleveland Clinic Lerner College of Medicine Phillips, Damilola 0 114109592 Leysath, Clinton The Texas A&M University System Leysath, Clinton 0 114100421 Monoclonal Antibody S9.6 Recognizes DNA/RNA Hybrids In A Sequence-independent Manner E-738-2013-0 Research Material NIAID 91026778 Green, Wade wade.green@nih.gov
United States of America TTIPO wade.green@nih.gov?subject=Web Inquiry on [TAB-3231] Monoclonal Antibody Specific for DNA/RNA Hybrid Molecules&body=Please send me information about technology [TAB-3231] Monoclonal Antibody Specific for DNA/RNA Hybrid Molecules. Green, Wade<br><a href="mailto:wade.green@nih.gov?subject=Web Inquiry on [TAB-3231] Monoclonal Antibody Specific for DNA/RNA Hybrid Molecules&body=Please send me information about technology [TAB-3231] Monoclonal Antibody Specific for DNA/RNA Hybrid Molecules.">wade.green@nih.gov</a><br> 114127669 DDXXXX 114150221 monoclonal 114150222 Antibod 114150223 89.6 114150224 Recognizes 114150225 DNA/RNA 114150226 HYBRIDS 114150227 Sequence-independent 114150228 MANNER 114150229 S9.6 114150230 Listed LPM Ano as of 4/15/2015 114150231 Pre LPM working set 20150418 114150232 Post LPM Assignment Set 20150420 TAB-3194 114097134 Hybridoma Cell Line H9.2B8 Producing Monoclonal Anti-mouse CD51 (Vitronectin receptor, alpha chain) Antibody NIAID Licensing, Research Materials Licensing Research Materials Ethan Shevach A hybridoma cell line producing a monoclonal hamster antibody specific to mouse CD51 (vitronectin receptor, alpha chain) (clone H9.2B8) as described in J Exp Med. 1989 Jun 1;169(6):2173-90 and developed by the laboratory of Dr. Ethan Shevach at the National Institute of Allergy and Infectious Diseases. <ul> <li>Speed up product development with NIH developed material that has already been tested and validated.</li> </ul> <ul> <li>A research material that can be used in the development of assays, validation of products or in quality control.</li> </ul> Research Material – Patent protection is not being pursued for this technology. (IC Reference No. 1948-254) 2022-03-08 2024-10-28 2024-10-28 2017-12-04 AC5XXX, Against, ALPHA, antibodies, ANTIGENS, Cell, Chain, Clone:, H9.2B8, Hamster, Hybridoma, Listed LPM Nguyen-Antczak as of 4/15/2015, Mab, Mouse, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, RECEPTOR, RM, Surface, Vitronectin, WIXXXX False True True NIHTT 37470483 Website Abstract 114172379 Maxfield SR, et al. https://www.ncbi.nlm.nih.gov/pubmed/2471776 <a href="https://www.ncbi.nlm.nih.gov/pubmed/2471776">Maxfield SR, et al.</a> 114109453 Shevach, Ethan NIAID - DIR NIAID Shevach, Ethan (NIAID) 1 114109453 Shevach, Ethan NIAID - DIR NIAID Shevach, Ethan (NIAID) 1 114102356 Hamster antibodies against Mouse Cell Surface Antigens Vitronectin receptor (alpha chain) Clone: H9.2B8 B-004-1991-5 Research Material NIAID 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-3194] Hybridoma Cell Line H9.2B8 Producing Monoclonal Anti-mouse CD51 (Vitronectin receptor, alpha chain) Antibody&body=Please send me information about technology [TAB-3194] Hybridoma Cell Line H9.2B8 Producing Monoclonal Anti-mouse CD51 (Vitronectin receptor, alpha chain) Antibody. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-3194] Hybridoma Cell Line H9.2B8 Producing Monoclonal Anti-mouse CD51 (Vitronectin receptor, alpha chain) Antibody&body=Please send me information about technology [TAB-3194] Hybridoma Cell Line H9.2B8 Producing Monoclonal Anti-mouse CD51 (Vitronectin receptor, alpha chain) Antibody.">yogikala.prabhu@nih.gov</a><br> 114127528 AC5XXX 114127529 WIXXXX 114149797 Hamster 114149798 antibodies 114149799 Against 114149800 Mouse 114149801 Cell 114149802 Surface 114149803 ANTIGENS 114149804 Vitronectin 114149805 RECEPTOR 114149806 ALPHA 114149807 Chain 114149808 Clone: 114149809 H9.2B8 114149810 Listed LPM Nguyen-Antczak as of 4/15/2015 114149811 Pre LPM working set 20150418 114149812 Post LPM Assignment Set 20150420 114149813 Hybridoma 114149814 Mab 114149815 RM TAB-3193 114094372 Hybridoma Cell Line G7 Producing Monoclonal Anti-mouse CD90 (Thy-1) Antibody NIAID Licensing, Research Materials Licensing Research Materials Ethan Shevach A hybridoma cell line producing a monoclonal rat antibody specific to mouse CD90 (Thy-1) (clone G7) as described in J Exp Med. 1984 Mar 1;159(3):716-30 and developed by the laboratory of Dr. Ethan Shevach at the National Institute of Allergy and Infectious Diseases. <ul> <li>Speed up product development with NIH developed material that has already been tested and validated.</li> </ul> <ul> <li>A research material that can be used in the development of assays, validation of products or in quality control.</li> </ul> Research Material – Patent protection is not being pursued for this technology. (IC Reference No. 1948-254) 2022-03-08 2024-10-28 2024-10-28 2017-12-04 159:716, 1984, AC5XXX, Cell, Exp., G7, Hybridoma, J., Line, Listed LPM Nguyen-Antczak as of 4/15/2015, Mab, Med., Post LPM Assignment Set 20150420, Pre LPM working set 20150418, RM, WIXXXX False True True NIHTT 37470483 Website Abstract 114170911 Gunter KC, et al. https://www.ncbi.nlm.nih.gov/pubmed/6142077 <a href="https://www.ncbi.nlm.nih.gov/pubmed/6142077">Gunter KC, et al.</a> 114109452 Shevach, Ethan NIAID - DIR NIAID Shevach, Ethan (NIAID) 1 114109452 Shevach, Ethan NIAID - DIR NIAID Shevach, Ethan (NIAID) 1 114102355 Cell line G7 (J. Exp. Med., 159:716, 1984) B-004-1991-4 Research Material NIAID 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-3193] Hybridoma Cell Line G7 Producing Monoclonal Anti-mouse CD90 (Thy-1) Antibody&body=Please send me information about technology [TAB-3193] Hybridoma Cell Line G7 Producing Monoclonal Anti-mouse CD90 (Thy-1) Antibody. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-3193] Hybridoma Cell Line G7 Producing Monoclonal Anti-mouse CD90 (Thy-1) Antibody&body=Please send me information about technology [TAB-3193] Hybridoma Cell Line G7 Producing Monoclonal Anti-mouse CD90 (Thy-1) Antibody.">yogikala.prabhu@nih.gov</a><br> 114127526 AC5XXX 114127527 WIXXXX 114149783 Cell 114149784 Line 114149785 G7 114149786 J. 114149787 Exp. 114149788 Med. 114149789 159:716 114149790 1984 114149791 Listed LPM Nguyen-Antczak as of 4/15/2015 114149792 Pre LPM working set 20150418 114149793 Post LPM Assignment Set 20150420 114149794 Hybridoma 114149795 Mab 114149796 RM TAB-3191 114097132 Hybridoma Cell Line D7 Producing Monoclonal Anti-mouse Ly-6A/E (Sca-1) Antibody NIAID Licensing, Research Materials Licensing Research Materials Ethan Shevach A hybridoma cell line producing a monoclonal rat antibody specific to mouse Ly-6A/E (Sca-1) (clone D7) as described in J Immunol. 1986 Nov 15;137(10):3240-6 and developed by the laboratory of Dr. Ethan Shevach at the National Institute of Allergy and Infectious Diseases. <ul> <li>Speed up product development with NIH developed material that has already been tested and validated.</li> </ul> <ul> <li>A research material that can be used in the development of assays, validation of products or in quality control.</li> </ul> Research Material – Patent protection is not being pursued for this technology. (IC Reference No. 1948-254) 2022-03-08 2024-10-28 2024-10-28 2017-12-04 137:3240-3246, 1986, AC5XXX, Cell, D7, Hybridoma, Immunology, J., Line, Listed LPM Nguyen-Antczak as of 4/15/2015, Mab, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, RM, WIXXXX False True True NIHTT 37470483 Website Abstract 114172163 Ortega G, et al. https://www.ncbi.nlm.nih.gov/pubmed/2430016 <a href="https://www.ncbi.nlm.nih.gov/pubmed/2430016">Ortega G, et al.</a> 114109450 Shevach, Ethan NIAID - DIR NIAID Shevach, Ethan (NIAID) 1 114109450 Shevach, Ethan NIAID - DIR NIAID Shevach, Ethan (NIAID) 1 114102353 Cell line D7 (J. Immunology, 137:3240-3246, 1986) B-004-1991-2 Research Material NIAID 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-3191] Hybridoma Cell Line D7 Producing Monoclonal Anti-mouse Ly-6A/E (Sca-1) Antibody&body=Please send me information about technology [TAB-3191] Hybridoma Cell Line D7 Producing Monoclonal Anti-mouse Ly-6A/E (Sca-1) Antibody. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-3191] Hybridoma Cell Line D7 Producing Monoclonal Anti-mouse Ly-6A/E (Sca-1) Antibody&body=Please send me information about technology [TAB-3191] Hybridoma Cell Line D7 Producing Monoclonal Anti-mouse Ly-6A/E (Sca-1) Antibody.">yogikala.prabhu@nih.gov</a><br> 114127522 AC5XXX 114127523 WIXXXX 114149757 Cell 114149758 Line 114149759 D7 114149760 J. 114149761 Immunology 114149762 137:3240-3246 114149763 1986 114149764 Listed LPM Nguyen-Antczak as of 4/15/2015 114149765 Pre LPM working set 20150418 114149766 Post LPM Assignment Set 20150420 114149767 Hybridoma 114149768 Mab 114149769 RM TAB-3192 114097133 Hybridoma Cell Line H1.2F3 Producing Monoclonal Anti-mouse CD69 (Early activation marker) Antibody NIAID Licensing, Research Materials Licensing Research Materials Ethan Shevach A hybridoma cell line producing a monoclonal hamster antibody specific to mouse CD69 (early activation marker) (clone H1.2F3) as described in J Immunol. 1988 Jul 15;141(2):369-76 and developed by the laboratory of Dr. Ethan Shevach at the National Institute of Allergy and Infectious Diseases. <ul> <li>Speed up product development with NIH developed material that has already been tested and validated.</li> </ul> <ul> <li>A research material that can be used in the development of assays, validation of products or in quality control.</li> </ul> Research Material – Patent protection is not being pursued for this technology. (IC Reference No. 1948-254) 2022-03-08 2024-10-28 2024-10-28 2017-12-04 141:369-376, 1988, AC5XXX, Cell, H12F3, Hybridoma, Immunology, J., Line, Listed LPM Nguyen-Antczak as of 4/15/2015, Mab, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, RM, WIXXXX False True True NIHTT 37470483 Website Abstract 114172162 Yokoyama WM, et al. https://www.ncbi.nlm.nih.gov/pubmed/2838547 <a href="https://www.ncbi.nlm.nih.gov/pubmed/2838547">Yokoyama WM, et al.</a> 114109451 Shevach, Ethan NIAID - DIR NIAID Shevach, Ethan (NIAID) 1 114109451 Shevach, Ethan NIAID - DIR NIAID Shevach, Ethan (NIAID) 1 114102354 Cell line H12F3 (J. Immunology, 141:369-376, 1988) B-004-1991-3 Research Material NIAID 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-3192] Hybridoma Cell Line H1.2F3 Producing Monoclonal Anti-mouse CD69 (Early activation marker) Antibody&body=Please send me information about technology [TAB-3192] Hybridoma Cell Line H1.2F3 Producing Monoclonal Anti-mouse CD69 (Early activation marker) Antibody. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-3192] Hybridoma Cell Line H1.2F3 Producing Monoclonal Anti-mouse CD69 (Early activation marker) Antibody&body=Please send me information about technology [TAB-3192] Hybridoma Cell Line H1.2F3 Producing Monoclonal Anti-mouse CD69 (Early activation marker) Antibody.">yogikala.prabhu@nih.gov</a><br> 114127524 AC5XXX 114127525 WIXXXX 114149770 Cell 114149771 Line 114149772 H12F3 114149773 J. 114149774 Immunology 114149775 141:369-376 114149776 1988 114149777 Listed LPM Nguyen-Antczak as of 4/15/2015 114149778 Pre LPM working set 20150418 114149779 Post LPM Assignment Set 20150420 114149780 Hybridoma 114149781 Mab 114149782 RM TAB-3189 114097130 Hybridoma Cell Line 7D4 Producing Monoclonal Anti-mouse CD25 (IL-2 receptor) Antibody NIAID Licensing, Research Materials Licensing Research Materials Ethan Shevach A hybridoma cell line producing a monoclonal rat antibody specific to mouse CD25 (IL-2 receptor) (clone 7D4) as described in Proc Natl Acad Sci U S A. 1983 Sep;80(18):5694-8 and developed by the laboratory of Dr. Ethan Shevach at the National Institute of Allergy and Infectious Diseases. <ul> <li>Speed up product development with NIH developed material that has already been tested and validated.</li> </ul> <ul> <li>A research material that can be used in the development of assays, validation of products or in quality control.</li> </ul> Research Material – Patent protection is not being pursued for this technology. (IC Reference No. 1948-254) 2022-03-08 2024-10-28 2024-10-28 2017-12-04 1983, 7D4, 80:5694-5698, AC5XXX, Cell, Hybridoma, Line, Listed LPM Nguyen-Antczak as of 4/15/2015, Mab, PNAS, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, RM, WIXXXX False True True NIHTT 37470483 Website Abstract 114172165 Malek TR, et al. https://www.ncbi.nlm.nih.gov/pubmed/6412230 <a href="https://www.ncbi.nlm.nih.gov/pubmed/6412230">Malek TR, et al.</a> 114109448 Shevach, Ethan NIAID - DIR NIAID Shevach, Ethan (NIAID) 1 114109448 Shevach, Ethan NIAID - DIR NIAID Shevach, Ethan (NIAID) 1 114102351 Cell line 7D4 (PNAS, 80:5694-5698, 1983) B-004-1991-0 Research Material NIAID 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-3189] Hybridoma Cell Line 7D4 Producing Monoclonal Anti-mouse CD25 (IL-2 receptor) Antibody&body=Please send me information about technology [TAB-3189] Hybridoma Cell Line 7D4 Producing Monoclonal Anti-mouse CD25 (IL-2 receptor) Antibody. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-3189] Hybridoma Cell Line 7D4 Producing Monoclonal Anti-mouse CD25 (IL-2 receptor) Antibody&body=Please send me information about technology [TAB-3189] Hybridoma Cell Line 7D4 Producing Monoclonal Anti-mouse CD25 (IL-2 receptor) Antibody.">yogikala.prabhu@nih.gov</a><br> 114127518 AC5XXX 114127519 WIXXXX 114149732 Cell 114149733 Line 114149734 7D4 114149735 PNAS 114149736 80:5694-5698 114149737 1983 114149738 Listed LPM Nguyen-Antczak as of 4/15/2015 114149739 Pre LPM working set 20150418 114149740 Post LPM Assignment Set 20150420 114149741 Mab 114149742 Hybridoma 114149743 RM TAB-3190 114097131 Hybridoma Cell Line 3C7 Producing Monoclonal Anti-mouse CD25 (IL-2 receptor, alpha chain) Antibody NIAID Licensing, Research Materials Licensing Research Materials Ethan Shevach A hybridoma cell line producing a monoclonal rat antibody specific to mouse CD25 (IL-2 receptor, alpha chain) (clone 3C7) as described in J Immunol. 1984 Oct;133(4):1970-5 and developed by the laboratory of Dr. Ethan Shevach at the National Institute of Allergy and Infectious Diseases. <ul> <li>Speed up product development with NIH developed material that has already been tested and validated.</li> </ul> <ul> <li>A research material that can be used in the development of assays, validation of products or in quality control.</li> </ul> Research Material – Patent protection is not being pursued for this technology. (IC Reference No. 1948-254) 2022-03-08 2024-10-28 2024-10-28 2017-12-04 133:1970, 1983, 3C7, AC5XXX, Cell, Hybridoma, Immunology, J., Line, Listed LPM Nguyen-Antczak as of 4/15/2015, Mab, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, RM, WIXXXX False True True NIHTT 37470483 Website Abstract 114172164 Ortega G, et al. https://www.ncbi.nlm.nih.gov/pubmed/6206144 <a href="https://www.ncbi.nlm.nih.gov/pubmed/6206144">Ortega G, et al.</a> 114109449 Shevach, Ethan NIAID - DIR NIAID Shevach, Ethan (NIAID) 1 114109449 Shevach, Ethan NIAID - DIR NIAID Shevach, Ethan (NIAID) 1 114102352 Cell line 3C7 (J. Immunology, 133:1970, 1983) B-004-1991-1 Research Material NIAID 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-3190] Hybridoma Cell Line 3C7 Producing Monoclonal Anti-mouse CD25 (IL-2 receptor, alpha chain) Antibody&body=Please send me information about technology [TAB-3190] Hybridoma Cell Line 3C7 Producing Monoclonal Anti-mouse CD25 (IL-2 receptor, alpha chain) Antibody. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-3190] Hybridoma Cell Line 3C7 Producing Monoclonal Anti-mouse CD25 (IL-2 receptor, alpha chain) Antibody&body=Please send me information about technology [TAB-3190] Hybridoma Cell Line 3C7 Producing Monoclonal Anti-mouse CD25 (IL-2 receptor, alpha chain) Antibody.">yogikala.prabhu@nih.gov</a><br> 114127520 AC5XXX 114127521 WIXXXX 114149744 Cell 114149745 Line 114149746 3C7 114149747 J. 114149748 Immunology 114149749 133:1970 114149750 1983 114149751 Listed LPM Nguyen-Antczak as of 4/15/2015 114149752 Pre LPM working set 20150418 114149753 Post LPM Assignment Set 20150420 114149754 Mab 114149755 Hybridoma 114149756 RM TAB-3186 114097127 Plasmids Encoding and Producing Anthrax Toxin Proteins NIAID Licensing, Research Materials Licensing Research Materials Yiu Cheung, Pradeep Gupta, Haijing Hu, Stephen Leppla, Mahtab Moayeri Plasmid pSJ136-EF-A — A plasmid encoding mutant anthrax toxin proteins such as lethal factor (LF) or edema factor (EF). Anthrax toxin and anthrax toxin fusion proteins may be used as therapeutic agents for cancer.<br /><br /> Plasmid PSJ115-LFOS — A plasmid expressing anthrax toxin proteins such as lethal factor (LF) or edema factor (EF) which has the original n-terminal amino acid sequence. <ul> <li>Speed up product development with NIH developed material that has already been tested and validated.</li> </ul> <ul> <li>A research material that can be used in the development of assays, validation of products or in quality control.</li> </ul> Research Material – Patent protection is not being pursued for this technology. (IC Reference No. 2007-096) 2022-03-08 2024-10-28 2024-10-28 2017-12-04 Anthrax, Improved, Listed LPM Soukas as of 4/15/2015, Methods, PLASMID, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, production, proteins, RM, TOXINS, WIXXXX False True True NIHTT 37470483 Website Abstract 114109437 Gupta, Pradeep NIAID - DIR NIAID Gupta, Pradeep (NIAID) 0 114109438 Cheung, Yiu NIAID - DIR NIAID Cheung, Yiu (NIAID) 0 114109439 Hu, Haijing NIAID - DIR NIAID Hu, Haijing (NIAID) 0 114109440 Moayeri, Mahtab NIAID - DIR NIAID Moayeri, Mahtab (NIAID) 0 114109436 Leppla, Stephen NIAID - DIR NIAID Leppla, Stephen (NIAID) 1 114109436 Leppla, Stephen NIAID - DIR NIAID Leppla, Stephen (NIAID) 1 114109437 Gupta, Pradeep NIAID - DIR NIAID Gupta, Pradeep (NIAID) 0 114109438 Cheung, Yiu NIAID - DIR NIAID Cheung, Yiu (NIAID) 0 114109439 Hu, Haijing NIAID - DIR NIAID Hu, Haijing (NIAID) 0 114109440 Moayeri, Mahtab NIAID - DIR NIAID Moayeri, Mahtab (NIAID) 0 114102348 Improved Methods For The Production Of Anthrax Toxins Proteins E-059-2008-0 Research Material NIAID 91026778 Green, Wade wade.green@nih.gov
United States of America TTIPO wade.green@nih.gov?subject=Web Inquiry on [TAB-3186] Plasmids Encoding and Producing Anthrax Toxin Proteins&body=Please send me information about technology [TAB-3186] Plasmids Encoding and Producing Anthrax Toxin Proteins. Green, Wade<br><a href="mailto:wade.green@nih.gov?subject=Web Inquiry on [TAB-3186] Plasmids Encoding and Producing Anthrax Toxin Proteins&body=Please send me information about technology [TAB-3186] Plasmids Encoding and Producing Anthrax Toxin Proteins.">wade.green@nih.gov</a><br> 114127513 WIXXXX 114149689 Improved 114149690 Methods 114149691 production 114149692 Anthrax 114149693 TOXINS 114149694 proteins 114149695 Listed LPM Soukas as of 4/15/2015 114149696 Pre LPM working set 20150418 114149697 Post LPM Assignment Set 20150420 114149698 PLASMID 114149699 RM TAB-3181 114094363 Plasmid pNL4-3, HIV Clone For Easy Mutational Changes NIAID Infectious Disease, Licensing, Research Materials Infectious Disease Licensing Research Materials Akio Adachi, Thomas Folks, John Leonard, Malcolm Martin, Arnold Rabson, Rosamond Rutledge-Burns, Theodore Theodore, Ronald Willey Plasmid DNA (clone pNL4-3) that produces infectious HIV-1 virus particles in a wide variety of cells as described in the J Virol. 1986 Aug;59(2):284-91 and developed in the laboratory of Dr. Malcolm Martin at the National Institute of Allergy and Infectious Diseases. <ul> <li>Speed up product development with NIH developed material that has already been tested and validated.</li> </ul> <ul> <li>A research material that can be used in the development of assays, validation of products or in quality control.</li> </ul> Research Material – Patent protection is not being pursued for this technology. (IC Reference No. 1948-008) 2022-03-08 2024-10-28 2024-10-28 2017-12-04 114, AIDS Research & Reference Reagent Program, CHANGES, CLONES, DDXXXX, DNA, EASY, HIV, INFECTIOUS, Listed LPM Ano as of 4/15/2015, MUTATIONAL, Novel, PLASMID, pNL4-3, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, RM, VLXXXX, WIXXXX False True True NIHTT 37470483 Website Abstract 114171739 Adachi A, et al. https://www.ncbi.nlm.nih.gov/pubmed/3016298 <a href="https://www.ncbi.nlm.nih.gov/pubmed/3016298">Adachi A, et al.</a> 114109414 Leonard, John NIAID - DIR Leonard, John 0 114109415 Martin, Malcolm NIAID - DIR NIAID Martin, Malcolm (NIAID) 0 114109416 Rutledge-Burns, Rosamond NIAID - DIR Rutledge-Burns, Rosamond 0 114109417 Theodore, Theodore NIAID - DIR Theodore, Theodore 0 114109418 Willey, Ronald NIAID - DIR NIAID Willey, Ronald (NIAID) 0 114109419 Folks, Thomas NIAID - DIR Folks, Thomas 0 114109420 Adachi, Akio NIAID - DIR Adachi, Akio 0 114109413 Rabson, Arnold NIAID - DIR Rabson, Arnold 1 114109413 Rabson, Arnold NIAID - DIR Rabson, Arnold 1 114109414 Leonard, John NIAID - DIR Leonard, John 0 114109415 Martin, Malcolm NIAID - DIR NIAID Martin, Malcolm (NIAID) 0 114109416 Rutledge-Burns, Rosamond NIAID - DIR Rutledge-Burns, Rosamond 0 114109417 Theodore, Theodore NIAID - DIR Theodore, Theodore 0 114109418 Willey, Ronald NIAID - DIR NIAID Willey, Ronald (NIAID) 0 114109419 Folks, Thomas NIAID - DIR Folks, Thomas 0 114109420 Adachi, Akio NIAID - DIR Adachi, Akio 0 114102343 Novel Infectious Clones of HIV DNA For Easy Mutational Changes B-005-1999-0 Research Material NIAID 83724572 Tung, Peter peter.tung@nih.gov
United States of America DIR peter.tung@nih.gov?subject=Web Inquiry on [TAB-3181] Plasmid pNL4-3, HIV Clone For Easy Mutational Changes&body=Please send me information about technology [TAB-3181] Plasmid pNL4-3, HIV Clone For Easy Mutational Changes. Tung, Peter<br><a href="mailto:peter.tung@nih.gov?subject=Web Inquiry on [TAB-3181] Plasmid pNL4-3, HIV Clone For Easy Mutational Changes&body=Please send me information about technology [TAB-3181] Plasmid pNL4-3, HIV Clone For Easy Mutational Changes.">peter.tung@nih.gov</a><br> 114127503 DDXXXX 114127504 WIXXXX 114127505 VLXXXX 114149618 pNL4-3 114149619 Novel 114149620 INFECTIOUS 114149621 CLONES 114149622 HIV 114149623 DNA 114149624 EASY 114149625 MUTATIONAL 114149626 CHANGES 114149627 114 114149628 AIDS Research & Reference Reagent Program 114149629 Listed LPM Ano as of 4/15/2015 114149630 Pre LPM working set 20150418 114149631 Post LPM Assignment Set 20150420 114149632 PLASMID 114149633 RM TAB-3166 114097115 Human and Veterinary Cancer Therapeutic Agent Utilizing Anthrax Toxin-Based Technology NIAID Collaboration Collaboration Thomas Bugge, Kuang-Hua Chen, Stephen Leppla, Jie Liu, Shihui Liu, Diane Peters, Alexander Wein Due to the disorganized nature of blood vessels that run through tumors, chemotherapeutic agents often fail to penetrate tumors and kill cancer cells at the tumor’s center. This can lead to ineffective chemotherapeutic treatments, because tumors can quickly grow back if the entire tumor is not destroyed. NIH researchers have developed a therapeutic agent that solves this problem facing current chemotherapy treatments. By elegantly exploiting cell surface proteases present at high levels in tumors, they have developed a tumor-targeted anthrax based toxin that inactivates the blood vessels within tumors. While in some cases cancer cells are also killed by the tumor-targeted toxin, the primary mechanism of action is thought to be a decrease in blood flow to the center of tumors, causing cancer cell death and tumor necrosis. Preliminary and on-going studies have demonstrated that the targeted toxins have antitumor effects on melanomas, lung cancers and colon cancer in mouse models, and on feline and canine oral tumors. Interestingly, this therapy does not target a specific type of cancer cell, rather it targets the vasculature in and around tumors. Therefore, it has great potential to treat a wide range of solid tumors. Additionally, because few non-surgical treatments are available to treat many human and veterinary solid tumors, this technology would fill an unmet need in cancer therapy. <ul> <li>Proven effective in a variety of models, including models of important veterinary cancers</li> <li>Agent is only active in tumor micro-environments, resulting in low toxicity to healthy tissue</li> <li>Cancer cells are not directly targeted, so this agent can be used to treat a broad spectrum of solid tumors and resistance is unlikely to arise</li> <li>Fills an unmet need in cancer therapy, because few non-surgical treatments exist </li> </ul> Therapeutic agent for a wide range of human and veterinary solid tumors, including: <ul> <li>Melanomas</li> <li>Lung and colon cancers</li> <li>Oral squamous carcinomas</li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize anthrax toxin-based cancer therapeutics. For collaboration opportunities, please contact Dr. Natalie Greco at <a href="mailto:Natalie.Greco@nih.gov">Natalie.Greco@nih.gov</a> or 301-761-7898. 2022-03-08 2024-10-28 2024-10-28 2017-10-02 Against, Anthrax, CMG2, EFFICACY, FELINE, FELINE Leukemia, Having, IC2-PA, Improved, Leppla, MARKER, SOLID, Specificity, Strong, Targeting, toxin, tumor, Types, VARIANTS, VASCULATURE, VETERINARY False True True NIHTT 37470483 Website Abstract 114172357 Chen KH, et al. http://www.ncbi.nlm.nih.gov/pubmed/17251181 <a href="http://www.ncbi.nlm.nih.gov/pubmed/17251181">Chen KH, et al.</a> 114172360 Liu S, et al. http://www.ncbi.nlm.nih.gov/pubmed/27357689 <a href="http://www.ncbi.nlm.nih.gov/pubmed/27357689">Liu S, et al.</a> 114172361 Wein AN, et al. http://www.ncbi.nlm.nih.gov/pubmed/26584669 <a href="http://www.ncbi.nlm.nih.gov/pubmed/26584669">Wein AN, et al.</a> 114172362 Peters DE, et al. http://www.ncbi.nlm.nih.gov/pubmed/24971906 <a href="http://www.ncbi.nlm.nih.gov/pubmed/24971906">Peters DE, et al.</a> 114172363 Bachran C, et al. http://www.ncbi.nlm.nih.gov/pubmed/24434511 <a href="http://www.ncbi.nlm.nih.gov/pubmed/24434511">Bachran C, et al.</a> 114172364 Wein AN, et al. http://www.ncbi.nlm.nih.gov/pubmed/22843210 <a href="http://www.ncbi.nlm.nih.gov/pubmed/22843210">Wein AN, et al.</a> 114172365 Phillips DD, et al. http://www.ncbi.nlm.nih.gov/pubmed/23393143 <a href="http://www.ncbi.nlm.nih.gov/pubmed/23393143">Phillips DD, et al.</a> 114172366 Liu S, et al. http://www.ncbi.nlm.nih.gov/pubmed/15895075 <a href="http://www.ncbi.nlm.nih.gov/pubmed/15895075">Liu S, et al.</a> 114109342 Leppla, Stephen NIAID - DIR NIAID Leppla, Stephen (NIAID) 0 114109343 Bugge, Thomas NIDCR NIDCR Bugge, Thomas (NIDCR) 0 114109344 Peters, Diane Cummings Veterinary Medical Center at Tufts University Peters, Diane 0 114109345 Liu, Jie National Heart, Lung, and Blood Institute (NHLBI) Liu, Jie 0 114109346 Wein, Alexander Emory University Wein, Alexander 0 114109347 Chen, Kuang-Hua NIAID - DIR NIAID Chen, Kuang-Hua (NIAID) 0 114105564 Liu, Shihui NIAID - DIR NIDCR Liu, Shihui (NIDCR) 1 114105564 Liu, Shihui NIAID - DIR NIDCR Liu, Shihui (NIDCR) 1 114109342 Leppla, Stephen NIAID - DIR NIAID Leppla, Stephen (NIAID) 0 114109343 Bugge, Thomas NIDCR NIDCR Bugge, Thomas (NIDCR) 0 114109344 Peters, Diane Cummings Veterinary Medical Center at Tufts University Peters, Diane 0 114109345 Liu, Jie National Heart, Lung, and Blood Institute (NHLBI) Liu, Jie 0 114109346 Wein, Alexander Emory University Wein, Alexander 0 114109347 Chen, Kuang-Hua NIAID - DIR NIAID Chen, Kuang-Hua (NIAID) 0 114100629 An Improved Anthrax Toxin (IC2-PA) Has Strong Efficacy Against All Solid Tumor Types E-256-2015-0 Filing authorized Cummings Veterinary Medical Center at Tufts University, Emory University, National Heart, Lung, and Blood Institute (NHLBI), NIAID, NIDCR 114102316 Tumor Targeting Toxin Variants Having Specificity For The Tumor Vasculature Marker CMG2 E-256-2015-1 Filing authorized NIAID, NIDCR, NIH - NHLBI, NIH - NIDCR 114102317 Tumor Targeting Toxin Variants Having Specificity For The Tumor Vasculature Marker CMG2 E-256-2015-2 Filing authorized NIAID, NIDCR, NIH - NHLBI, NIH - NIDCR 91026778 Green, Wade wade.green@nih.gov
United States of America TTIPO wade.green@nih.gov?subject=Web Inquiry on [TAB-3166] Human and Veterinary Cancer Therapeutic Agent Utilizing Anthrax Toxin-Based Technology&body=Please send me information about technology [TAB-3166] Human and Veterinary Cancer Therapeutic Agent Utilizing Anthrax Toxin-Based Technology. Green, Wade<br><a href="mailto:wade.green@nih.gov?subject=Web Inquiry on [TAB-3166] Human and Veterinary Cancer Therapeutic Agent Utilizing Anthrax Toxin-Based Technology&body=Please send me information about technology [TAB-3166] Human and Veterinary Cancer Therapeutic Agent Utilizing Anthrax Toxin-Based Technology.">wade.green@nih.gov</a><br> 114160508 E-256-2015-0 E-256-2015-0-US-01 MODIFIED ANTHRAX TOXIN PROTECTIVE ANTIGEN PRV US 62/210,771 Abandoned US <br />Provisional (PRV) 62/210,771<br />Filed on 2015-08-27<br />Status: Abandoned 114168374 E-256-2015-1 E-256-2015-1-US-01 Modified Anthrax Toxin Protective Antigen PRV US 62/323,218 Abandoned US <br />Provisional (PRV) 62/323,218<br />Filed on 2016-04-15<br />Status: Abandoned 114168375 E-256-2015-2 E-256-2015-2-PCT-01 Modified Anthrax Toxin Protective Antigen PCT COMB Patent Cooperation Treaty PCT/US2016/048706 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2016/048706<br />Filed on 2016-08-25<br />Status: Expired 114168561 E-256-2015-2 E-256-2015-2-US-09 MODIFIED ANTHRAX TOXIN PROTECTIVE ANTIGEN National Stage US 10,835,593 15/755,341 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10835593 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10835593">10,835,593</a><br />Filed on 2018-02-26<br />Status: Issued 114149426 Improved 114149427 Anthrax 114149428 toxin 114149429 IC2-PA 114149430 Strong 114149431 EFFICACY 114149432 Against 114149433 SOLID 114149434 tumor 114149435 Types 114149436 VETERINARY 114149437 FELINE 114149438 FELINE Leukemia 114149439 Targeting 114149440 VARIANTS 114149441 Having 114149442 Specificity 114149443 VASCULATURE 114149444 MARKER 114149445 CMG2 114149446 Leppla TAB-3155 114097104 Development of a Transferrable Norwalk Virus Epitope and Detector Monoclonal Antibody NIAID Antibodies, Collaboration, Diagnostics, Immunology, Infectious Disease, Research Materials Antibodies Collaboration Diagnostics Immunology Infectious Disease Research Materials Eugenio Abente, Karin Bok, Lisbeth Kim Green, Gabriel Parra Gonzalez, Carlos Sandoval-Jaime, Stanislav Sosnovtsev Noroviruses are now recognized as the major cause of non-bacterial gastroenteritis in all age groups, and efforts are underway to develop an effective vaccine. The lack of a robust cell culture system for human noroviruses has complicated vaccine development. Hence, norovirus virus like particles (VLPs) have played an important role in the understanding of virus structure, immune response, antigenic diversity, and vaccine design. The development of monoclonal antibodies (MAbs) against norovirus VLPs has allowed the identification and characterization of key antigenic sites of the virus capsid and facilitated the development of diagnostic assays. During characterization of a panel of MAbs raised against Norwalk virus (NV), a prototype norovirus strain, the inventors identified a monoclonal antibody (MAbNV10) that proved useful in the identification of NV in tissue and in the characterization of an insertion site in the feline calicivirus (FCV) genome. The inventors mapped the precise binding site of the MAb by peptide screening and discovered that the epitope could be expressed when fused to other proteins. The sequence of this peptide (epitope) along with the detector antibody could be used as a new way to tag proteins for functional studies. The small size of the linear epitope, along with the strong avidity of the detector monoclonal antibody makes this system especially useful for many techniques, including immunofluorescence, Western blot, immunoprecipitation (including “pulldown” assays), and immunohistochemistry. The inventors’ epitope system may be comparable to that of the HA tag of influenza virus that is widely used in molecular biology.<br /><br /> This technology is further described in Parra et al., “Mapping and modeling of a strain-specific epitope in the Norwalk virus capsid inner shell,” Virology. 2016 May;492:232-41. doi: 10.1016/j.virol.2016.02.019. Epub 2016 Mar 21.<br /><br /> Materials available for licensing comprise: (1) Hybridoma cell line NV10, (2) Plasmid expressing NV10 epitope as positive control, and (3) Plasmid expressing the NV10 scFV. <br /><br /> This technology is available for licensing for commercial development in accordance with 35 U.S.C. § 209 and 37 CFR Part 404, as well as for further development and evaluation under a research collaboration. <ul> <li>Cross-reactive norovirus antibody</li> <li>Ease of manufacture</li> <li>Efficient norovirus detection</li> </ul> <ul> <li>Diagnostics</li> <li>Vaccines</li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize norovirus diagnostics or vaccines. For collaboration opportunities, please contact Peter Soukas, J.D., at 301-594-8730 or <a href="mailto:Peter.Soukas@nih.gov">Peter.Soukas@nih.gov</a>. Research Tool - Patent protection is not being pursued for this technology. 2022-03-08 2024-10-28 2024-10-28 2017-08-24 ANTIBODY, DA4BXX, DA4XXX, DAXXXX, DDXXXX, DETECTOR, DetectorMonoclonal, Development, DEXXXX, DXXXXX, Epitope, Listed LPM Fenn as of 4/15/2015, monoclonal, NORWALK, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Transferrable, virus, VLXXXX, WBXXXX, WIXXXX, XAXXXX, YCXXXX False True True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114172344 Parra Gl, et al. https://www.ncbi.nlm.nih.gov/pubmed/26971245 <a href="https://www.ncbi.nlm.nih.gov/pubmed/26971245">Parra Gl, et al.</a> 114109311 Parra Gonzalez, Gabriel NIAID - DIR NIAID Parra Gonzalez, Gabriel (NIAID) 0 114109313 Sosnovtsev, Stanislav NIAID - DIR NIAID Sosnovtsev, Stanislav (NIAID) 0 114109314 Bok, Karin NIAID - DIR NIAID Bok, Karin (NIAID) 0 114109315 Sandoval-Jaime, Carlos NIAID - DIR NIAID Sandoval-Jaime, Carlos (NIAID) 0 114109316 Abente, Eugenio Armed Forces Research Institute of Medical Sciences (AFRIMS) NIAID Abente, Eugenio (NIAID) 0 114109312 Green, Lisbeth Kim NIAID - DIR NIAID Green, Lisbeth Kim (NIAID) 1 114109312 Green, Lisbeth Kim NIAID - DIR NIAID Green, Lisbeth Kim (NIAID) 1 114109311 Parra Gonzalez, Gabriel NIAID - DIR NIAID Parra Gonzalez, Gabriel (NIAID) 0 114109313 Sosnovtsev, Stanislav NIAID - DIR NIAID Sosnovtsev, Stanislav (NIAID) 0 114109314 Bok, Karin NIAID - DIR NIAID Bok, Karin (NIAID) 0 114109315 Sandoval-Jaime, Carlos NIAID - DIR NIAID Sandoval-Jaime, Carlos (NIAID) 0 114109316 Abente, Eugenio Armed Forces Research Institute of Medical Sciences (AFRIMS) NIAID Abente, Eugenio (NIAID) 0 114102305 Development Of A Transferrable Norwalk Virus Epitope And Detector Monoclonal Antibody E-101-2013-0 Closed Armed Forces Research Institute of Medical Sciences (AFRIMS), NIAID 83643855 Soukas, Peter peter.soukas@nih.gov
United States of America Technology Transfer and Intellectual Property Office peter.soukas@nih.gov?subject=Web Inquiry on [TAB-3155] Development of a Transferrable Norwalk Virus Epitope and Detector Monoclonal Antibody&body=Please send me information about technology [TAB-3155] Development of a Transferrable Norwalk Virus Epitope and Detector Monoclonal Antibody. Soukas, Peter<br><a href="mailto:peter.soukas@nih.gov?subject=Web Inquiry on [TAB-3155] Development of a Transferrable Norwalk Virus Epitope and Detector Monoclonal Antibody&body=Please send me information about technology [TAB-3155] Development of a Transferrable Norwalk Virus Epitope and Detector Monoclonal Antibody.">peter.soukas@nih.gov</a><br> 114127333 DXXXXX 114127334 DDXXXX 114127335 DAXXXX 114127336 DA4XXX 114127337 DA4BXX 114127338 DEXXXX 114127350 VLXXXX 114127351 WBXXXX 114127352 WIXXXX 114127353 XAXXXX 114127354 YCXXXX 114149292 Development 114149293 Transferrable 114149294 NORWALK 114149295 virus 114149296 Epitope 114149297 DetectorMonoclonal 114149298 ANTIBODY 114149299 DETECTOR 114149300 monoclonal 114149301 Listed LPM Fenn as of 4/15/2015 114149302 Pre LPM working set 20150418 114149303 Post LPM Assignment Set 20150420 TAB-3156 114097105 Pyrophosphate Analog HIV-1 Reverse Transcriptase Inhibitors NIEHS Collaboration, Infectious Disease, Therapeutics Collaboration Infectious Disease Therapeutics William (Bill) Beard, David Shock, Samuel Wilson The invention relates to compounds that inhibit HIV-1 DNA synthesis mediated by reverse transcriptase (RT). HIV-1 DNA synthesis by RT utilizes deoxynucleoside 5’-triphosphate (dNTP) as substrate and like many other enzymes, the reaction is reversible. Pyrophosphate analogs like imidodiphosphate strongly promote reverse reaction dNTP products containing the imidodiphosphate group instead of the naturally occurring pyrophosphate group. This imidodiphosphate-containing dNTP was found to be a potent inhibitor of the forward RT reaction. Whereas pyrophosphorolysis is limited by a nonchemical step, replacing the bridging oxygen of pyrophosphate with an imido group resulted in a change in the rate-limiting step, so that the imidodiphosphate-dependent reverse reaction was limited by chemistry. There exists, then, the potential to use pyrophosphate analogs therapeutically. <ul> <li>Anti-microbial</li> <li>HIV therapeutic</li> </ul> The National Institute of Environmental Health Sciences seeks statements of capability or interest from parties interested in collaborative research to further develop and evaluate this technology. Please contact Sally E. Tilotta, PhD, Director, Office of Technology Transfer, National Institute of Environmental Health Sciences; Phone: (919) 316-4526; Email: <a href="mailto:sally.tilotta@nih.gov">sally.tilotta@nih.gov</a>. 2022-03-08 2024-10-28 2024-10-28 2017-08-23 DB4AXX, HIV-1, INHIBITING, PYROPHOSPHATE, TRANSCRIPTASE, VLXXXX, YBXXXX False True True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114109318 Beard, William (Bill) NIEHS NIEHS Beard, William (Bill) (NIEHS) 0 114109319 Shock, David NIEHS NIEHS Shock, David (NIEHS) 0 114109317 Wilson, Samuel NIEHS NIEHS Wilson, Samuel (NIEHS) 1 114109317 Wilson, Samuel NIEHS NIEHS Wilson, Samuel (NIEHS) 1 114109318 Beard, William (Bill) NIEHS NIEHS Beard, William (Bill) (NIEHS) 0 114109319 Shock, David NIEHS NIEHS Shock, David (NIEHS) 0 114102306 Novel Strategy For Inhibiting HIV-1 Reverse Transcriptase E-210-2017-0 Filing authorized NIEHS 83739538 Choudhry, Vidita vidita.choudhry@nih.gov
United States of America Office of Technology Transfer and Development vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-3156] Pyrophosphate Analog HIV-1 Reverse Transcriptase Inhibitors&body=Please send me information about technology [TAB-3156] Pyrophosphate Analog HIV-1 Reverse Transcriptase Inhibitors. Choudhry, Vidita<br><a href="mailto:vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-3156] Pyrophosphate Analog HIV-1 Reverse Transcriptase Inhibitors&body=Please send me information about technology [TAB-3156] Pyrophosphate Analog HIV-1 Reverse Transcriptase Inhibitors.">vidita.choudhry@nih.gov</a><br> 114168347 E-210-2017-0 E-210-2017-0-US-01 Comositions and Methods for Inhibiting HIV-1 Reverse Transcriptase PRV US 62/542,600 Abandoned US <br />Provisional (PRV) 62/542,600<br />Filed on 2017-08-08<br />Status: Abandoned 114168794 E-210-2017-0 E-210-2017-0-PCT-02 COMPOSITIONS AND METHODS FOR INHIBITING HIV-1 REVERSE TRANSCRIPTASE PCT Patent Cooperation Treaty PCT/US2018/045874 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2018/045874<br />Filed on 2018-08-08<br />Status: Expired 114169038 E-210-2017-0 E-210-2017-0-US-06 COMPOSITIONS AND METHODS FOR INHIBITING HIV-1 REVERSE TRANSCRIPTASE National Stage US 16/637,092 Abandoned US <br />National Stage 16/637,092<br />Filed on 2020-02-06<br />Status: Abandoned 114127339 VLXXXX 114127340 DB4AXX 114127341 YBXXXX 114149304 INHIBITING 114149305 HIV-1 114149306 TRANSCRIPTASE 114149307 PYROPHOSPHATE TAB-3143 114096757 Human and Veterinary Cancer Therapeutic Agent Utilizing Anthrax Toxin-Based Technology NIAID Collaboration, Diagnostics, Immunology, Oncology, Rare/Neglected Diseases, Therapeutics Collaboration Diagnostics Immunology Oncology Rare/Neglected Diseases Therapeutics Sarah Arnett, Christopher Bachran, Thomas Bugge, Kuang-Hua Chen, Henning Hansen, Stephen Leppla, Clinton Leysath, Jie Liu, Shihui Liu, Diane Peters, Damilola Phillips, Alexander Wein Due to the disorganized nature of blood vessels that run through tumors, chemotherapeutic agents often fail to penetrate tumors and kill cancer cells at the tumor’s center. This can lead to ineffective chemotherapeutic treatments, because tumors can quickly grow back if the entire tumor is not destroyed. NIH researchers have developed a therapeutic agent that solves this problem facing current chemotherapy treatments. By elegantly exploiting cell surface proteases present at high levels in tumors, they have developed a tumor-targeted anthrax based toxin that inactivates the blood vessels within tumors. While in some cases cancer cells are also killed by the tumor-targeted toxin, the primary mechanism of action is thought to be a decrease in blood flow to the center of tumors, causing cancer cell death and tumor necrosis. Preliminary and on-going studies have demonstrated that the targeted toxins have antitumor effects on melanomas, lung cancers and colon cancer in mouse models, and on feline and canine oral tumors. Interestingly, this therapy does not target a specific type of cancer cell, rather it targets the vasculature in and around tumors. Therefore, it has great potential to treat a wide range of solid tumors. Additionally, because few non-surgical treatments are available to treat many human and veterinary solid tumors, this technology would fill an unmet need in cancer therapy. <ul> <li>Proven effective in a variety of models, including models of important veterinary cancers</li> <li>Agent is only active in tumor micro-environments, resulting in low toxicity to healthy tissue</li> <li>Cancer cells are not directly targeted, so this agent can be used to treat a broad spectrum of solid tumors and resistance is unlikely to arise</li> <li>Fills an unmet need in cancer therapy, because few non-surgical treatments exist</li> </ul> Therapeutic agent for a wide range of human and veterinary solid tumors, including: <ul> <li>Melanomas</li> <li>Lung and colon cancers</li> <li>Oral squamous carcinomas</li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize anthrax toxin-based cancer therapeutics. For collaboration opportunities, please contact Dr. Natalie Greco at <a href="mailto:Natalie.Greco@nih.gov">Natalie.Greco@nih.gov</a> or 301-761-7898. Various international patent applications may also be available. 2022-03-08 2024-10-28 2024-10-28 2017-07-06 Against, AMOUNTS, Anthrax, AnthraxToxins, ANTIGEN, B, CA1BXX, CB1AXX, CB1BXX, CB1XXX, CB3CXX, CBXXXX, Cells, Cell-Surface, CMG2, COMPLEMENTARY, CONTAIN, Containing, CXXXXX, Cytolethal, Distending, EFFICACY, Efficient, ENGINEERED, exclusively, Exploiting, FELINE, FELINE Leukemia, FORM, Fusion, fusion proteins, Having, High, IC2-PA, Identifying, Improved, Leppla, Listed LPM McCue as of 4/15/2015, MARKER, Metallo..., MULTIMERIC, Mutated, Nature, Octamers, Patent Category - Biotechnology, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Protective, Protein, proteins, SOLID, SPECIFICALLY, Specificity, Strong, TARGET, Targeting, That, THERAPY, toxin, TOXINS, tumor, Types, UAXXXX, VARIANTS, VASCULATURE, VETERINARY False True True NIHTT 37470483 Website Abstract 114171504 Chen KH, et al. http://www.ncbi.nlm.nih.gov/pubmed/17251181 <a href="http://www.ncbi.nlm.nih.gov/pubmed/17251181">Chen KH, et al.</a> 114172333 Liu S, et al. http://www.ncbi.nlm.nih.gov/pubmed/27357689 <a href="http://www.ncbi.nlm.nih.gov/pubmed/27357689">Liu S, et al.</a> 114172334 Wein AN, et al. http://www.ncbi.nlm.nih.gov/pubmed/26584669 <a href="http://www.ncbi.nlm.nih.gov/pubmed/26584669">Wein AN, et al.</a> 114172335 Peters DE, et al. http://www.ncbi.nlm.nih.gov/pubmed/24971906 <a href="http://www.ncbi.nlm.nih.gov/pubmed/24971906">Peters DE, et al.</a> 114172336 Bachran C, et al. http://www.ncbi.nlm.nih.gov/pubmed/24434511 <a href="http://www.ncbi.nlm.nih.gov/pubmed/24434511">Bachran C, et al.</a> 114172337 Wein AN, et al. http://www.ncbi.nlm.nih.gov/pubmed/22843210 <a href="http://www.ncbi.nlm.nih.gov/pubmed/22843210">Wein AN, et al.</a> 114172338 Phillips DD, et al. http://www.ncbi.nlm.nih.gov/pubmed/23393143 <a href="http://www.ncbi.nlm.nih.gov/pubmed/23393143">Phillips DD, et al.</a> 114172339 Liu S, et al. http://www.ncbi.nlm.nih.gov/pubmed/15895075 <a href="http://www.ncbi.nlm.nih.gov/pubmed/15895075">Liu S, et al.</a> 114107451 Leppla, Stephen NIAID - DIR NIAID Leppla, Stephen (NIAID) 0 114107453 Liu, Shihui NIAID - DIR NIDCR Liu, Shihui (NIDCR) 0 114109284 Bugge, Thomas NIDCR NIDCR Bugge, Thomas (NIDCR) 0 114109285 Peters, Diane Cummings Veterinary Medical Center at Tufts University Peters, Diane 0 114109286 Liu, Jie National Heart, Lung, and Blood Institute (NHLBI) Liu, Jie 0 114109287 Wein, Alexander Emory University Wein, Alexander 0 114109288 Chen, Kuang-Hua NIAID - DIR NIAID Chen, Kuang-Hua (NIAID) 0 114109289 Bachran, Christopher NIAID - DIR NIAID Bachran, Christopher (NIAID) 0 114109291 Phillips, Damilola NIAID - DIR Phillips, Damilola 0 114109292 Hansen, Henning NIDCR Hansen, Henning 0 114109293 Arnett, Sarah NIDCR NIDCR Arnett, Sarah (NIDCR) 0 114109290 Leysath, Clinton NIAID - DIR Leysath, Clinton 1 114109290 Leysath, Clinton NIAID - DIR Leysath, Clinton 1 114107451 Leppla, Stephen NIAID - DIR NIAID Leppla, Stephen (NIAID) 0 114107453 Liu, Shihui NIAID - DIR NIDCR Liu, Shihui (NIDCR) 0 114109284 Bugge, Thomas NIDCR NIDCR Bugge, Thomas (NIDCR) 0 114109285 Peters, Diane Cummings Veterinary Medical Center at Tufts University Peters, Diane 0 114109286 Liu, Jie National Heart, Lung, and Blood Institute (NHLBI) Liu, Jie 0 114109287 Wein, Alexander Emory University Wein, Alexander 0 114109288 Chen, Kuang-Hua NIAID - DIR NIAID Chen, Kuang-Hua (NIAID) 0 114109289 Bachran, Christopher NIAID - DIR NIAID Bachran, Christopher (NIAID) 0 114109291 Phillips, Damilola NIAID - DIR Phillips, Damilola 0 114109292 Hansen, Henning NIDCR Hansen, Henning 0 114109293 Arnett, Sarah NIDCR NIDCR Arnett, Sarah (NIDCR) 0 114102294 An Improved Anthrax Toxin (IC2-PA) Has Strong Efficacy Against All Solid Tumor Types E-256-2015-0 Filing authorized Cummings Veterinary Medical Center at Tufts University, Emory University, National Heart, Lung, and Blood Institute (NHLBI), NIAID, NIDCR 114102295 Tumor Targeting Toxin Variants Having Specificity For The Tumor Vasculature Marker CMG2 E-256-2015-1 Filing authorized NIAID, NIDCR, NIH - NHLBI, NIH - NIDCR 114102296 Tumor Targeting Toxin Variants Having Specificity For The Tumor Vasculature Marker CMG2 E-256-2015-2 Filing authorized NIAID, NIDCR, NIH - NHLBI, NIH - NIDCR 114102297 Efficient Tumor Therapy By Anthrax Toxin Fusion Proteins That Contain Cytolethal Distending Toxin B E-120-2013-0 Filing authorized NIAID 114102298 Engineered Complementary Anthrax Toxin Protective Antigen Variants That Exclusively Form Octamers E-246-2012-0 Filing authorized NIAID 114102299 Exploiting The Multimeric Nature Of Certain Protein Toxins To Target Cells Having More Than One Identifying Characteristic E-059-2004-0 Filing authorized NIAID, NIDCR 114102300 Mutated Anthrax Toxin Protective Antigen Proteins That Specifically Target Cells Containing High Amounts of Cell-Surface Metallo... E-293-1999-0 NIDCR 91026778 Green, Wade wade.green@nih.gov
United States of America TTIPO wade.green@nih.gov?subject=Web Inquiry on [TAB-3143] Human and Veterinary Cancer Therapeutic Agent Utilizing Anthrax Toxin-Based Technology&body=Please send me information about technology [TAB-3143] Human and Veterinary Cancer Therapeutic Agent Utilizing Anthrax Toxin-Based Technology. Green, Wade<br><a href="mailto:wade.green@nih.gov?subject=Web Inquiry on [TAB-3143] Human and Veterinary Cancer Therapeutic Agent Utilizing Anthrax Toxin-Based Technology&body=Please send me information about technology [TAB-3143] Human and Veterinary Cancer Therapeutic Agent Utilizing Anthrax Toxin-Based Technology.">wade.green@nih.gov</a><br> 114160543 E-256-2015-0 E-256-2015-0-US-01 MODIFIED ANTHRAX TOXIN PROTECTIVE ANTIGEN PRV US 62/210,771 Abandoned US <br />Provisional (PRV) 62/210,771<br />Filed on 2015-08-27<br />Status: Abandoned 114168311 E-256-2015-1 E-256-2015-1-US-01 Modified Anthrax Toxin Protective Antigen PRV US 62/323,218 Abandoned US <br />Provisional (PRV) 62/323,218<br />Filed on 2016-04-15<br />Status: Abandoned 114168312 E-256-2015-2 E-256-2015-2-PCT-01 Modified Anthrax Toxin Protective Antigen PCT COMB Patent Cooperation Treaty PCT/US2016/048706 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2016/048706<br />Filed on 2016-08-25<br />Status: Expired 114168313 E-120-2013-0 E-120-2013-0-US-01 Cytolethal Distending Toxin Subunit B Conjugated or Fused to Bacillus Anthracis Toxin Lethal Factor PRV US 61/837,428 Abandoned US <br />Provisional (PRV) 61/837,428<br />Filed on 2013-06-20<br />Status: Abandoned 114168314 E-120-2013-0 E-120-2013-0-PCT-02 Cytolethal Distending Toxin Subunit B Conjugated or Fused to Bacillus Anthracis Toxin Lethal Factor PCT Patent Cooperation Treaty PCT/US2014/043131 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2014/043131<br />Filed on 2014-06-19<br />Status: Expired 114168315 E-120-2013-0 E-120-2013-0-US-03 Cytolethal Distending Toxin Subunit B Conjugated or Fused to Bacillus Anthracis Toxin Lethal Factor National Stage US 9,890,369 14/898,248 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9890369 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9890369">9,890,369</a><br />Filed on 2015-12-14<br />Status: Issued 114168316 E-246-2012-0 E-246-2012-0-US-01 Engineered Anthrax Lethal Toxin For Targeted Delivery PRV US 61/692,143 Abandoned US <br />Provisional (PRV) 61/692,143<br />Filed on 2012-08-22<br />Status: Abandoned 114168317 E-246-2012-0 E-246-2012-0-PCT-02 Engineered Anthrax Lethal Toxin For Targeted Delivery PCT Patent Cooperation Treaty PCT/US2013/056205 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2013/056205<br />Filed on 2013-08-22<br />Status: Expired 114168318 E-246-2012-0 E-246-2012-0-US-05 Engineered Anthrax Lethal Toxin for Targeted Delivery National Stage US 9,730,993 14/423,408 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9730993 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9730993">9,730,993</a><br />Filed on 2015-02-23<br />Status: Issued 114168319 E-059-2004-0 E-059-2004-0-US-01 Multimeric Protein Toxins To Target Cells Having Multiple Identifying Characteristics PRV US 60/543,417 Abandoned US <br />Provisional (PRV) 60/543,417<br />Filed on 2004-02-09<br />Status: Abandoned 114168320 E-059-2004-0 E-059-2004-0-US-02 Multimeric Protein Toxins to Target Cells Having Multiple Identifying Characteristics ORD US 7,947,289 11/055,557 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7947289 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7947289">7,947,289</a><br />Filed on 2005-02-09<br />Status: Issued 114168321 E-059-2004-0 E-059-2004-0-PCT-03 Multimeric Protein Toxins To Target Cells Having Multiple Identifying Characteristics PCT Patent Cooperation Treaty PCT/US2005/04216 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2005/04216<br />Filed on 2005-02-09<br />Status: Expired 114168322 E-059-2004-0 E-059-2004-0-US-04 Multimeric Protein Toxins To Target Cells Having Multiple Identifying Characteristics DIV US 8,388,933 13/088,011 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8388933 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8388933">8,388,933</a><br />Filed on 2011-04-15<br />Status: Expired 114168323 E-293-1999-0 E-293-1999-0-US-01 Mutated Anthrax Toxin Protective Antigen Proteins That Specifically Target Cells Containing High Amounts of Cell-Surface Metallo... PRV US 60/155,961 Abandoned US <br />Provisional (PRV) 60/155,961<br />Filed on 1999-09-24<br />Status: Abandoned 114168324 E-293-1999-0 E-293-1999-0-PCT-02 Mutated Anthrax Toxin Protective Antigen Proteins That Specifically Target Cells Containing High Amounts of Cell-Surface Metallo... PCT Patent Cooperation Treaty PCT/US00/26192 Expired Patent Cooperation Treaty <br />(PCT) PCT/US00/26192<br />Filed on 2000-09-22<br />Status: Expired 114168325 E-293-1999-0 E-293-1999-0-US-06 Mutated Anthrax Toxin Protective Antigen Proteins That Specifically Target Cells Containing High Amounts of Cell-Surface Metalloproteinases or Plasminogen Activator Receptors National Stage US 7,468,352 10/088,952 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7468352 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7468352">7,468,352</a><br />Filed on 2002-03-22<br />Status: Abandoned 114168326 E-293-1999-0 E-293-1999-0-US-30 Mutated Anthrax Toxin Protective Antigen Proteins That Specifically Target Cells Containing High Amounts of Cell-Surface Metalloproteinases or Plasminogen Activator Receptors DIV US 8,791,074 12/288,482 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8791074 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8791074">8,791,074</a><br />Filed on 2008-10-20<br />Status: Abandoned 114168327 E-293-1999-0 E-293-1999-0-US-32 Mutated Anthrax Toxin Protective Antigen Proteins That Specifically Target Cells Containing High Amounts of Cell-Surface Metalloproteinases or Plasminogen Activator Receptors DIV US 9,403,872 14/313,575 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9403872 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9403872">9,403,872</a><br />Filed on 2014-06-24<br />Status: Abandoned 114168560 E-256-2015-2 E-256-2015-2-US-09 MODIFIED ANTHRAX TOXIN PROTECTIVE ANTIGEN National Stage US 10,835,593 15/755,341 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10835593 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10835593">10,835,593</a><br />Filed on 2018-02-26<br />Status: Issued 114127304 CB1BXX 114127305 CB3CXX 114127306 CXXXXX 114127307 CBXXXX 114127308 CB1XXX 114127309 CB1AXX 114127310 CA1BXX 114127311 UAXXXX 114149185 Improved 114149186 Anthrax 114149187 toxin 114149188 IC2-PA 114149189 Strong 114149190 EFFICACY 114149191 Against 114149192 SOLID 114149193 tumor 114149194 Types 114149195 VETERINARY 114149196 FELINE 114149197 FELINE Leukemia 114149198 Targeting 114149199 VARIANTS 114149200 Having 114149201 Specificity 114149202 VASCULATURE 114149203 MARKER 114149204 CMG2 114149205 Leppla 114149206 THERAPY 114149207 Patent Category - Biotechnology 114149208 AnthraxToxins 114149209 fusion proteins 114149210 Efficient 114149211 Fusion 114149212 proteins 114149213 That 114149214 CONTAIN 114149215 Cytolethal 114149216 Distending 114149217 B 114149218 Listed LPM McCue as of 4/15/2015 114149219 Pre LPM working set 20150418 114149220 Post LPM Assignment Set 20150420 114149221 COMPLEMENTARY 114149222 ENGINEERED 114149223 Protective 114149224 ANTIGEN 114149225 exclusively 114149226 FORM 114149227 Octamers 114149228 Exploiting 114149229 MULTIMERIC 114149230 Nature 114149231 Protein 114149232 TOXINS 114149233 TARGET 114149234 Cells 114149235 Identifying 114149236 Mutated 114149237 SPECIFICALLY 114149238 Containing 114149239 High 114149240 AMOUNTS 114149241 Cell-Surface 114149242 Metallo... TAB-3127 114095898 Efficient mRNA-Based Genetic Engineering of Human NK Cells with High-Affinity CD16 and CCR7 NHLBI Licensing, Oncology, Therapeutics Licensing Oncology Therapeutics Mattias Carlsten, Richard Childs A highly efficient method to genetically modify natural killer (NK) cells to induce expression of high affinity CD16 (HA-CD16) through mRNA electroporation, to potentiate NK cell-mediated antibody-dependent cellular cytotoxicity (ADCC). ADCC is mediated by CD16+ NK cells following adoptive NK cell transfer, but most humans express CD16 which has a relatively low affinity for IgG1 antibodies. However, a single nucleotide polymorphism (SNP rs396991) in the CD16 gene, resulting in an amino acid substitution at position 158 (F158V), is associated with substantially higher affinity and superior NK cell-mediated ADCC than those with the 158F genotype. This HA-CD16-158V polymorphism has also been linked to enhanced ADCC capacity in vivo. The nearly 100% efficiency of our method resulted in: a) sustained surface expression of transgenes at high levels for up to 4 days without compromising NK cell cytotoxicity and viability; and b) augmented ADCC against Daratumumab coated multiple myeloma cells by ex vivo expanded NK cells electroporated with mRNA coding for HA-CD16. This system is GMP compliant and has been used previously in FDA approved clinical trials. <ul> <li>High efficiency</li> <li>GMP compliant</li> </ul> <ul> <li>Infusion of a large number of highly cytotoxic autologous ex vivo expanded NK cells expressing high-affinity CD16 into patients, to induce a more profound anti-malignancy response to specific monoclonal antibodies, including: multiple myeloma (Daratumumab); lymphoma (Rituximab); breast cancer (Trastuzumab); and colon cancer (Cetuximab).</li> </ul> 2022-03-08 2024-10-28 2024-10-28 2017-05-17 ADCC, antibodies, ANTIBODY, CBXXXX, CD16, ex vivo, Listed LPM Vathyam as of 4/15/2015, monoclonal, NK, NK Cells, Patent Category - Biotechnology, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, TRANSFECTION, TUMORS, VCXXXX, WJXXXX, XEXXXX, YAXXXX, YBXXXX False True True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract E-121-2016-0 114172317 Carlsten M, et al. https://www.ncbi.nlm.nih.gov/pubmed/27047492 <a href="https://www.ncbi.nlm.nih.gov/pubmed/27047492">Carlsten M, et al.</a> 114172318 Carlsten M, Childs RW. https://www.ncbi.nlm.nih.gov/pubmed/26113846 <a href="https://www.ncbi.nlm.nih.gov/pubmed/26113846">Carlsten M, Childs RW.</a> 114109221 Carlsten, Mattias National Heart, Lung, and Blood Institute (NHLBI) Carlsten, Mattias 0 114109220 Childs, Richard National Heart, Lung, and Blood Institute (NHLBI) NHLBI Childs, Richard (NHLBI) 1 114109220 Childs, Richard National Heart, Lung, and Blood Institute (NHLBI) NHLBI Childs, Richard (NHLBI) 1 114109221 Carlsten, Mattias National Heart, Lung, and Blood Institute (NHLBI) Carlsten, Mattias 0 114101303 Transfection Of High-affinity CD16 Into Ex Vivo Expanded NK Cells To Augment Their Ability To Mediate Antibody Dependent Cellular Toxicity (ADCC) Against Tumors Treated With Monoclonal Antibodies E-036-2015-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 114101304 Transfection Of High-affinity CD16 Into Ex Vivo Expanded NK Cells To Augment Their Ability To Mediate Antibody Dependent Cellular Toxicity (ADCC) Against Tumors Treated With Monoclonal Antibodies E-036-2015-1 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-3127] Efficient mRNA-Based Genetic Engineering of Human NK Cells with High-Affinity CD16 and CCR7&body=Please send me information about technology [TAB-3127] Efficient mRNA-Based Genetic Engineering of Human NK Cells with High-Affinity CD16 and CCR7. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-3127] Efficient mRNA-Based Genetic Engineering of Human NK Cells with High-Affinity CD16 and CCR7&body=Please send me information about technology [TAB-3127] Efficient mRNA-Based Genetic Engineering of Human NK Cells with High-Affinity CD16 and CCR7.">shmilovm@nih.gov</a><br> 114168269 E-036-2015-0 E-036-2015-0-US-01 NK Cells with an Increased Antibody-Dependent Cellular Toxicity (ADCC) Against Tumors PRV US 62/079,975 Abandoned US <br />Provisional (PRV) 62/079,975<br />Filed on 2014-11-14<br />Status: Abandoned 114168270 E-036-2015-1 E-036-2015-1-PCT-01 NK Cells with an Increased Antibody-Dependent Cellular Toxicity (ADCC) Against Tumors PCT COMB Patent Cooperation Treaty PCT/US2015/060646 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2015/060646<br />Filed on 2015-11-13<br />Status: Expired 114168276 E-036-2015-1 E-036-2015-1-US-02 NK CELLS WITH AN INCREASED ANTIBODY-DEPENDENT CELLULAR TOXICITY (ADCC) AGAINST TUMORS National Stage US 10,813,952 15/525,921 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10813952 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10813952">10,813,952</a><br />Filed on 2017-05-10<br />Status: Issued 114169045 E-036-2015-1 E-036-2015-1-US-03 NK CELLS WITH AN INCREASED ANTIBODY-DEPENDENT CELLULAR TOXICITY (ADCC) AGAINST TUMORS DIV US 12,188,005 16/985,797 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12188005 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12188005">12,188,005</a><br />Filed on 2020-08-05<br />Status: Issued 114127246 VCXXXX 114127247 WJXXXX 114127248 XEXXXX 114127249 YAXXXX 114127250 YBXXXX 114127251 CBXXXX 114148988 NK 114148989 CD16 114148990 TRANSFECTION 114148991 ANTIBODY 114148992 ADCC 114148993 TUMORS 114148994 monoclonal 114148995 antibodies 114148996 Patent Category - Biotechnology 114148997 NK Cells 114148998 ex vivo 114148999 Listed LPM Vathyam as of 4/15/2015 114149000 Pre LPM working set 20150418 114149001 Post LPM Assignment Set 20150420 TAB-3085 114094687 Immortalized Stria Vascularis Cell Line SV-k1 NIDCD Cardiology, Dental, Endocrinology, Infectious Disease, Licensing, Oncology, Ophthalmology, Research Materials Cardiology Dental Endocrinology Infectious Disease Licensing Oncology Ophthalmology Research Materials Gilda Canseco De Kalinec, Federico Kalinec <p>Available for nonexclusive licensing for research uses is the cell line, SV-k1, derived from the Organ of Corti. The line was developed from the stria vascularis, an organ localized on the lateral wall of the cochlea, adjacent to the Organ of Corti, containing cell populations specialized in the production of an endolymph very rich in K+ characteristic of the mammalian inner ear. SV-k1 cells express a set of biomarkers completely different of those expressed by <a href="https://www.techtransfer.nih.gov/tech/tab-3083" target="_blank" target-="">OC-k3 cells</a>, and are not sensitive to ototoxic drugs.</p> <ul> <li>Research</li> <li>Hearing research</li> </ul> Research Material – Patent protection is not being pursued for this technology. 2022-03-08 2024-10-28 2024-10-28 2016-11-10 ID1XXX, IDXXXX, immortalized, RESEARCH MATERIAL, research reagent, RESEARCH TOOL, Stria, SV-k1, Vascularis, VPXXXX, WIXXXX False True True NIHTT 37470483 Website Abstract 114171448 Gratton MA, et al. https://www.ncbi.nlm.nih.gov/pubmed/11788196 <a href="https://www.ncbi.nlm.nih.gov/pubmed/11788196">Gratton MA, et al.</a> 114171449 Park C, et al. https://www.ncbi.nlm.nih.gov/pubmed/26854618 <a href="https://www.ncbi.nlm.nih.gov/pubmed/26854618">Park C, et al.</a> 114171622 Espreafico EM, et al. https://www.ncbi.nlm.nih.gov/pubmed/9671730 <a href="https://www.ncbi.nlm.nih.gov/pubmed/9671730">Espreafico EM, et al.</a> 114107679 Kalinec, Federico University of California, Los Angeles (UCLA) Kalinec, Federico 0 114107678 Canseco De Kalinec, Gilda Canseco De Kalinec, Gilda 1 114107678 Canseco De Kalinec, Gilda Canseco De Kalinec, Gilda 1 114107679 Kalinec, Federico University of California, Los Angeles (UCLA) Kalinec, Federico 0 114101777 Conditionally Immortalized Stria Vascularis Cell Line SV-k1 E-013-2017-0 Research Material National Institute on Deafness and Other Communication Disorders (NIDCD) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-3085] Immortalized Stria Vascularis Cell Line SV-k1&body=Please send me information about technology [TAB-3085] Immortalized Stria Vascularis Cell Line SV-k1. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-3085] Immortalized Stria Vascularis Cell Line SV-k1&body=Please send me information about technology [TAB-3085] Immortalized Stria Vascularis Cell Line SV-k1.">shmilovm@nih.gov</a><br> 114117628 IDXXXX 114117629 ID1XXX 114117630 VPXXXX 114117631 WIXXXX 114143269 Stria 114143270 Vascularis 114143271 SV-k1 114143272 research reagent 114143273 RESEARCH MATERIAL 114143274 RESEARCH TOOL 114143589 immortalized TAB-3081 114096627 Polyvalent Influenza Virus-Like Particles (VLPs) and Use as Vaccines NIAID Collaboration, Consumer Products, Diagnostics, Infectious Disease, Therapeutics, Vaccines Collaboration Consumer Products Diagnostics Infectious Disease Therapeutics Vaccines Jeffery Taubenberger Influenza virus is a major public health concern, causing up to 500,000 deaths annually. The current strategy of reformulating vaccines annually against dominant circulating strains leads to variable protective efficacy and is unlikely to protect against novel influenza viruses with pandemic potential. Thus, there is a great need for a vaccine that provides “universal” protection against influenza viruses.<br /><br /> This technology relates to a broadly protective, universal influenza vaccine candidate composed of a mixture of virus-like particles (VLPs) expressing the hemagglutinin protein or the neuraminidase protein from influenza virus strains belonging to different virus subtypes. Vaccinating animals with a mixture of VLPs expressing four or more hemagglutinin subtypes provides broad and heterosubtypic protection against lethal challenge with influenza virus strains in both mice and ferrets. This vaccine technology has great potential to provide protection against both annual epidemic and pandemic-potential influenza viruses. This virus-like particle (VLP) vaccine technology for influenza viruses, based on a mixture of VLPs expressing the hemagglutinin protein or the neuraminidase protein from influenza virus strains belonging to different virus subtypes, has demonstrated broad protection against lethal challenge in mice with various influenza virus strains and virus subtypes. Results from ferret and mouse studies demonstrate broad heterosubtypic protection against various influenza virus subtypes further supporting and strengthening the proposed application of this technology as a universal influenza virus vaccine. <ul> <li>Broad/universal protection against influenza viruses</li> <li>Does not require reformulating vaccine each year as is currently necessary with vaccines available on the market</li> <li>Can potentially provide protection against novel influenza viruses that may arise in the future, including potentially pandemic influenza viruses</li> </ul> <ul> <li>Vaccines</li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize this invention, especially for GMP manufacture and clinical evaluation. For collaboration opportunities, please contact Dr. Elizabeth Pitts at <a href="mailto: elizabeth.pitts@nih.gov">elizabeth.pitts@nih.gov</a> or 240-669-5299. 2022-03-08 2024-10-28 2024-10-28 2021-06-23 Against, Broad, DC5BXX, Development, different, INFLUENZA, Listed LPM Chang as of 4/15/2015, PARTICLE, Polyvalent, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Protection, PROVIDE, SUBTYPES, Vaccine, viral, Viruses, VLXXXX, VOXXXX, WAXXXX, WNXXXX, XKXXXX, YAXXXX, YBXXXX, YCXXXX False True True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114171493 Schwartzman LM, et al. https://www.ncbi.nlm.nih.gov/pubmed/26199334 <a href="https://www.ncbi.nlm.nih.gov/pubmed/26199334">Schwartzman LM, et al.</a> 114107579 Taubenberger, Jeffery NIAID - DIR NIAID Taubenberger, Jeffery (NIAID) 1 114107579 Taubenberger, Jeffery NIAID - DIR NIAID Taubenberger, Jeffery (NIAID) 1 114101751 Development Of A Polyvalent Viral Like Particle Vaccine To Provide Broad Protection Against Influenza A Viruses Of Different Subtypes E-195-2014-0 Filing authorized NIAID 91021353 Pitts, Elizabeth elizabeth.pitts@nih.gov
United States of America elizabeth.pitts@nih.gov?subject=Web Inquiry on [TAB-3081] Polyvalent Influenza Virus-Like Particles (VLPs) and Use as Vaccines&body=Please send me information about technology [TAB-3081] Polyvalent Influenza Virus-Like Particles (VLPs) and Use as Vaccines. Pitts, Elizabeth<br><a href="mailto:elizabeth.pitts@nih.gov?subject=Web Inquiry on [TAB-3081] Polyvalent Influenza Virus-Like Particles (VLPs) and Use as Vaccines&body=Please send me information about technology [TAB-3081] Polyvalent Influenza Virus-Like Particles (VLPs) and Use as Vaccines.">elizabeth.pitts@nih.gov</a><br> 114164298 E-195-2014-0 E-195-2014-0-US-06 Polyvalent Influenza Virus-Like Particles (VLPS) And Use As Vaccines National Stage US 10,130,700 15/317,593 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10130700 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10130700">10,130,700</a><br />Filed on 2016-12-09<br />Status: Issued 114165477 E-195-2014-0 E-195-2014-0-PCT-02 Polyvalent Influenza Virus-Like Particles (VLPS) And Use as Vaccines PCT Patent Cooperation Treaty PCT/US2015/029843 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2015/029843<br />Filed on 2015-05-08<br />Status: Expired 114166775 E-195-2014-0 E-195-2014-0-US-01 Polyvalent Influenza Virus-Like Particles (VLPs) And Use as Vaccines PRV US 62/014,821 Abandoned US <br />Provisional (PRV) 62/014,821<br />Filed on 2014-06-20<br />Status: Abandoned 114114412 YAXXXX 114114413 YBXXXX 114122639 WNXXXX 114122640 XKXXXX 114122641 DC5BXX 114122642 VLXXXX 114122643 VOXXXX 114122644 WAXXXX 114122745 YCXXXX 114143469 Development 114143470 Polyvalent 114143471 viral 114143472 PARTICLE 114143473 Vaccine 114143474 PROVIDE 114143475 Broad 114143476 Protection 114143477 Against 114143478 INFLUENZA 114143479 Viruses 114143480 different 114143481 SUBTYPES 114143482 Listed LPM Chang as of 4/15/2015 114143483 Pre LPM working set 20150418 114143576 Post LPM Assignment Set 20150420 TAB-3042 114096497 Transgenic Mice Expressing CNO-sensitive Gq- or Gs-coupled Designer Receptors Selectively in Pancreatic Beta Cells NIDDK Collaboration, Endocrinology, Research Materials Collaboration Endocrinology Research Materials Jean-Marc Guettier, Jurgen Wess Impaired functioning of pancreatic beta cells is a key hallmark of type 2 diabetes. Beta cell function is modulated by the actions of different classes of heterotrimeric G proteins. The functional consequences of activating specific beta cell G protein signaling pathways in vivo are not well understood at present, primarily due to the fact that beta cell G protein-coupled receptors (GPCRs) are also expressed by many other tissues. To circumvent these difficulties, we developed a strategy that allows for the conditional and selective activation of specific beta cell G proteins in intact animals. Specifically, we created two lines of transgenic mice each of which expressed a specific designer GPCR (DREADD = Designer Receptor Exclusively Activated by a Designer Drug) in beta cells only (beta-RASSL-1 = RIPII-Rq Tg = beta Gq DREADD transgenic mice; beta-RASSL-2 = RIPII-Rs = beta Gs DREADD transgenic mice). Importantly, the two designer receptors differ in their G protein-coupling properties (Gq versus Gs). They are unable to bind endogenous ligand(s), but can be efficiently activated by an otherwise pharmacologically inert compound (clozapine-N-oxide = CNO), leading to the conditional activation of either beta cell Gq or Gs G proteins. These newly developed transgenic mice represent powerful new tools to study G protein regulation of beta cell function in vivo. <ul> <li>Simplified study of pathways in single cell type, beta cells, in vivo.</li> </ul> <ul> <li>Probing beta cell signalling pathways.</li> <li>Drug design and development.</li> </ul> The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) is seeking statements of interest from parties interested in collaborative research to further evaluate signalling pathways in beta cells. For collaboration opportunities, please contact: Marguerite J. Miller at <a href="mailto:Marguerite.Miller@nih.gov">Marguerite.Miller@nih.gov</a> or 301-496-9003. Research Tool – Patent protection is not being pursued for this technology. 2022-03-08 2024-10-28 2024-10-28 2017-04-17 =, Beta-RASSL-1, Beta-RASSL-2, ID1XXX, Mice, RIPII-RQ, RIPII-Rs, TRANSGENIC, VFXXXX, YCXXXX False True True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114171371 Guettier JM et al. A chemical-genetic approach to study G protein regulation of Beta-cell function in vivo. Proc Natl Acad Sci U S A. 2009 Nov 10;106(45):19197-202. http://www.ncbi.nlm.nih.gov/pubmed/19858481 <a href="http://www.ncbi.nlm.nih.gov/pubmed/19858481">Guettier JM et al. A chemical-genetic approach to study G protein regulation of Beta-cell function in vivo. Proc Natl Acad Sci U S A. 2009 Nov 10;106(45):19197-202.</a> 114103345 Guettier, Jean-Marc FDA - CDER FDA Guettier, Jean-Marc (FDA) 0 114107303 Wess, Jurgen National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Wess, Jurgen (NIDDK) 1 114107303 Wess, Jurgen National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Wess, Jurgen (NIDDK) 1 114103345 Guettier, Jean-Marc FDA - CDER FDA Guettier, Jean-Marc (FDA) 0 114101601 Beta-RASSL-1 = RIPII-Rq And Beta-RASSL-2 = RIPII-Rs Transgenic Mice E-197-2016-0 Research Material National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83739550 Shastri, Mythreyi shastrim@mail.nih.gov
United States of America Technology Advancement Office shastrim@mail.nih.gov?subject=Web Inquiry on [TAB-3042] Transgenic Mice Expressing CNO-sensitive Gq- or Gs-coupled Designer Receptors Selectively in Pancreatic Beta Cells&body=Please send me information about technology [TAB-3042] Transgenic Mice Expressing CNO-sensitive Gq- or Gs-coupled Designer Receptors Selectively in Pancreatic Beta Cells. Shastri, Mythreyi<br><a href="mailto:shastrim@mail.nih.gov?subject=Web Inquiry on [TAB-3042] Transgenic Mice Expressing CNO-sensitive Gq- or Gs-coupled Designer Receptors Selectively in Pancreatic Beta Cells&body=Please send me information about technology [TAB-3042] Transgenic Mice Expressing CNO-sensitive Gq- or Gs-coupled Designer Receptors Selectively in Pancreatic Beta Cells.">shastrim@mail.nih.gov</a><br> 114122476 VFXXXX 114122477 YCXXXX 114123969 ID1XXX 114141706 Beta-RASSL-1 114141709 = 114141710 RIPII-RQ 114141711 Beta-RASSL-2 114141712 RIPII-Rs 114142186 TRANSGENIC 114142187 Mice TAB-3071 114096565 Capsid-Free AAV Vectors for Gene Delivery and Their Use for Gene Therapy NHLBI Cardiology, Dental, Endocrinology, Infectious Disease, Licensing, Oncology, Ophthalmology, Therapeutics Cardiology Dental Endocrinology Infectious Disease Licensing Oncology Ophthalmology Therapeutics Cyriaque Beley, Luis Garcia, Robert Kotin, Lina Li, Thomas Voit The invention concerns novel capsid-free AAV vectors that can be used for gene delivery and gene therapy applications. The invention provides for a linear nucleic acid molecule comprising in this order: a first adeno-associated virus (AAV) inverted terminal repeat (ITR), a nucleotide sequence of interest, and a second AAV ITR, wherein said nucleic acid molecule is devoid of AAV capsid protein coding sequences. The said nucleic acid molecule can be applied to a host at repetition without eliciting an immune response. Methods of producing and purifying this nucleic acid molecule, as well as its use for gene transfer and gene therapy are also described. <ul> <li>The AAV vectors described in the invention devoid the AAV capsid proteins and thus are not exposed to the adverse effects caused by immunogenicity.</li> <li>In contrast to the use of plasmid DNA for gene delivery, the AAV DNA of the invention seems to confer greater stability in cell nuclei, allowing prolonged expression compared to plasmid DNA.</li> <li>The vector DNA of the invention is not limited in size to the packageable size genome.</li> <li>The production of the AAV DNA vector is economical, simple and provides high yields.</li> </ul> <ul> <li>The commercial applications of the technology relate to the field of gene therapy. It may offer significant advantages compared to existing methods of gene delivery and gene therapy.</li> </ul> and various international counterparts 2022-03-08 2024-10-28 2024-10-28 2016-10-12 AAV, Cell, Clonal, Containing, DNA, GB2AXX, Lines, Listed LPM Reichman as of 4/15/2015, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Rescueable, Sf9, STABLE, Vector, VPXXXX, WJXXXX, XEXXXX, YAXXXX, YBXXXX False True True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114171405 Li L, et al. https://www.ncbi.nlm.nih.gov/pubmed/23936358 <a href="https://www.ncbi.nlm.nih.gov/pubmed/23936358">Li L, et al.</a> 114102934 Li, Lina National Heart, Lung, and Blood Institute (NHLBI) NHGRI Li, Lina (NHGRI) 0 114102977 Garcia, Luis Garcia, Luis 0 114102978 Beley, Cyriaque INSERM Beley, Cyriaque 0 114106103 Voit, Thomas INSERM Voit, Thomas 0 114107491 Kotin, Robert National Heart, Lung, and Blood Institute (NHLBI) Kotin, Robert 1 114107491 Kotin, Robert National Heart, Lung, and Blood Institute (NHLBI) Kotin, Robert 1 114102934 Li, Lina National Heart, Lung, and Blood Institute (NHLBI) NHGRI Li, Lina (NHGRI) 0 114102977 Garcia, Luis Garcia, Luis 0 114102978 Beley, Cyriaque INSERM Beley, Cyriaque 0 114106103 Voit, Thomas INSERM Voit, Thomas 0 114099163 Clonal Stable Sf9 Cell Lines Containing Rescueable AAV Vector DNA E-241-2010-0 Filing authorized INSERM, National Heart, Lung, and Blood Institute (NHLBI) 83714317 Devany, John john.devany@nih.gov
United States of America Office of Technology Transfer and Development john.devany@nih.gov?subject=Web Inquiry on [TAB-3071] Capsid-Free AAV Vectors for Gene Delivery and Their Use for Gene Therapy&body=Please send me information about technology [TAB-3071] Capsid-Free AAV Vectors for Gene Delivery and Their Use for Gene Therapy. Devany, John<br><a href="mailto:john.devany@nih.gov?subject=Web Inquiry on [TAB-3071] Capsid-Free AAV Vectors for Gene Delivery and Their Use for Gene Therapy&body=Please send me information about technology [TAB-3071] Capsid-Free AAV Vectors for Gene Delivery and Their Use for Gene Therapy.">john.devany@nih.gov</a><br> 114162533 E-241-2010-0 E-241-2010-0-US-04 CAPSID-FREE AAV VECTORS, COMPOSITIONS, AND METHODS FOR VECTOR PRODUCTION AND GENE DELIVERY National Stage US 9,598,703 14/004,379 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9598703 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9598703">9,598,703</a><br />Filed on 2013-12-20<br />Status: Issued 114162534 E-241-2010-0 E-241-2010-0-PCT-03 Capsid-free AAV vectors, compositions, and methods for vector production and gene delivery PCT Patent Cooperation Treaty PCT/EP2012/054303 Expired Patent Cooperation Treaty <br />(PCT) PCT/EP2012/054303<br />Filed on 2012-03-12<br />Status: Expired 114166752 E-241-2010-0 E-241-2010-0-US-01 Capsid-Free AAV Vectors, Compositions, And Methods For Vector Production and Gene Delivery PRV US 61/452,071 Abandoned US <br />Provisional (PRV) 61/452,071<br />Filed on 2011-03-11<br />Status: Abandoned 114122534 VPXXXX 114122535 WJXXXX 114122536 XEXXXX 114122537 YAXXXX 114122558 YBXXXX 114122560 GB2AXX 114142748 STABLE 114142749 Sf9 114142750 Cell 114142751 Lines 114142752 Containing 114142753 Rescueable 114142754 AAV 114142755 Vector 114142756 DNA 114142762 Clonal 114142934 Listed LPM Reichman as of 4/15/2015 114142935 Pre LPM working set 20150418 114142936 Post LPM Assignment Set 20150420 TAB-3040 114096496 Triazole Derivatives of 4,7-disubstituted 2 naphthoic acid (PPTN) as P2Y14 Receptor Antagonists NIDDK Collaboration, Endocrinology, Immunology, Pulmonology, Research Equipment, Research Materials, Therapeutics Collaboration Endocrinology Immunology Pulmonology Research Equipment Research Materials Therapeutics Kenneth Jacobson, Anna Junker, Evgeny Kiselev, Elisa Uliassi The Molecular Recognition Section of NIDDK announces the availability of a novel triazole-based probes, structures which act as antagonists at human P2Y<sub>14</sub> receptors. Although the physiologic functions of this receptor remain undefined, recently it has been strongly implicated in immune and inflammatory responses. Prior work with a 4,7-disubstituted 2 naphthoic acid derivative (PPTN) established the ability to inhibit chemotaxis of human neutrophils in the lung and kidney.<br /><br /> In this series, the triazole moiety is used as a bioisosteric replacement for the naphthoic acid core of PPTN. This substitution imparts more stability. This triazole ring has increased polarity and additional H-bond accepting groups when compared to a naphthalene core. The new triazole scaffold can form additional interactions that stabilize the ligand within the receptor binding pocket. It has also been identified that substitution at the para-position of the phenyl ring is favored. <ul> <li>Favorable cLogP for lead compound when compared to PPTN.</li> <li>Wide range of functional groups can be used as terminal aryl substituents in the triazole group.</li> <li>P2Y<sub>14</sub> affinity in the nM range.</li> </ul> <ul> <li>Probe to examine P2Y<sub>14</sub> function.</li> <li>Scaffold for SAR studies and drug design.</li> <li>Potential route to target inflammation, potentially including diabetes and asthma.</li> </ul> The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) is seeking statements of capability or interest from parties interested in collaborative research to further develop and evaluate small molecules that target the P2Y14 receptor. For collaboration opportunities, please contact Marguerite J. Miller at <a href="mailto:Marguerite.Miller@nih.gov">Marguerite.Miller@nih.gov</a> or 301-496-9003. Patent protection is being sought for this invention. 2022-03-08 2024-10-28 2024-10-28 2016-08-16 Alkyne, ANTAGONISTS, IB3XXX, IB4XXX, ID1XXX, P2Y14, Patent Category - Chemistry, Probe, RECEPTOR, small molecule, Structure-based, Triazole, VFXXXX, WIXXXX, WKXXXX, XHXXXX, YBXXXX False True True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114170860 Junker A, et al. Structure-Based Design of 3-(4-Aryl-1H-1,2,3-triazol-1-yl)-Biphenyl Derivatives as P2Y14 Receptor Antagonists. J Med Chem. 2016 Jul 14;59(13):6149-68. http://www.ncbi.nlm.nih.gov/pubmed/27331270 <a href="http://www.ncbi.nlm.nih.gov/pubmed/27331270">Junker A, et al. Structure-Based Design of 3-(4-Aryl-1H-1,2,3-triazol-1-yl)-Biphenyl Derivatives as P2Y14 Receptor Antagonists. J Med Chem. 2016 Jul 14;59(13):6149-68.</a> 114170861 Azroyan A et al. Renal intercalated cells sense and mediate sterile inflammation via the P2Y14 receptor. PLoS One. 2015 Mar 23;10(3):e0121419. http://www.ncbi.nlm.nih.gov/pubmed/25799465 <a href="http://www.ncbi.nlm.nih.gov/pubmed/25799465">Azroyan A et al. Renal intercalated cells sense and mediate sterile inflammation via the P2Y14 receptor. PLoS One. 2015 Mar 23;10(3):e0121419.</a> 114170862 Barrett MO, et al. A selective high-affinity antagonist of the P2Y14 receptor inhibits UDP-glucose-stimulated chemotaxis of human neutrophils. Mol Pharmacol. 2013 Jul;84(1):41-9. http://www.ncbi.nlm.nih.gov/pubmed/23592514 <a href="http://www.ncbi.nlm.nih.gov/pubmed/23592514">Barrett MO, et al. A selective high-affinity antagonist of the P2Y14 receptor inhibits UDP-glucose-stimulated chemotaxis of human neutrophils. Mol Pharmacol. 2013 Jul;84(1):41-9.</a> 114170906 Sesma JI, et al. UDP-glucose promotes neutrophil recruitment in the lung. Purinergic Signal. 2016 Jul 15 (Epub ahead of print). http://www.ncbi.nlm.nih.gov/pubmed/27421735 <a href="http://www.ncbi.nlm.nih.gov/pubmed/27421735">Sesma JI, et al. UDP-glucose promotes neutrophil recruitment in the lung. Purinergic Signal. 2016 Jul 15 (Epub ahead of print).</a> 114106918 Kiselev, Evgeny NIGMS NCI Kiselev, Evgeny (NCI) 0 114106919 Uliassi, Elisa National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Uliassi, Elisa 0 114106920 Junker, Anna National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Junker, Anna 0 114107188 Jacobson, Kenneth National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Jacobson, Kenneth (NIDDK) 1 114107188 Jacobson, Kenneth National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Jacobson, Kenneth (NIDDK) 1 114106918 Kiselev, Evgeny NIGMS NCI Kiselev, Evgeny (NCI) 0 114106919 Uliassi, Elisa National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Uliassi, Elisa 0 114106920 Junker, Anna National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Junker, Anna 0 114101600 Structure-Based Design Of Alkyne And Triazole Derivatives As P2Y14 Receptor Antagonists E-213-2015-0 Filing authorized National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83692066 Tong, Betty tongb@niddk.nih.gov
United States of America Senior Technology Advancement Office tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-3040] Triazole Derivatives of 4,7-disubstituted 2 naphthoic acid (PPTN) as P2Y14 Receptor Antagonists&body=Please send me information about technology [TAB-3040] Triazole Derivatives of 4,7-disubstituted 2 naphthoic acid (PPTN) as P2Y14 Receptor Antagonists. Tong, Betty<br><a href="mailto:tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-3040] Triazole Derivatives of 4,7-disubstituted 2 naphthoic acid (PPTN) as P2Y14 Receptor Antagonists&body=Please send me information about technology [TAB-3040] Triazole Derivatives of 4,7-disubstituted 2 naphthoic acid (PPTN) as P2Y14 Receptor Antagonists.">tongb@niddk.nih.gov</a><br> 114160247 E-213-2015-0 E-213-2015-0-US-01 Triazole Derivatives As P2Y14 Receptor Antagonists PRV US 62/233,162 Abandoned US <br />Provisional (PRV) 62/233,162<br />Filed on 2015-09-25<br />Status: Abandoned 114166166 E-213-2015-0 E-213-2015-0-PCT-02 TRIAZOLE DERIVATIVES AS P2Y14 RECEPTOR ANTAGONISTS PCT Patent Cooperation Treaty PCT/US2016/053397 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2016/053397<br />Filed on 2016-09-23<br />Status: Expired 114168584 E-213-2015-0 E-213-2015-0-US-05 TRIAZOLE DERIVATIVES AS P2Y14 RECEPTOR ANTAGONISTS National Stage US 10,683,277 15/762,852 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10683277 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10683277">10,683,277</a><br />Filed on 2018-03-23<br />Status: Issued 114122286 IB3XXX 114122287 VFXXXX 114122288 IB4XXX 114122289 ID1XXX 114122480 WIXXXX 114122481 WKXXXX 114122499 XHXXXX 114122500 YBXXXX 114141694 RECEPTOR 114141695 ANTAGONISTS 114141696 Patent Category - Chemistry 114141697 Probe 114141698 small molecule 114142003 Structure-based 114142004 Alkyne 114142005 Triazole 114142006 P2Y14 TAB-3041 114096526 Bag6 Polyclonal Antibodies That Recognize Human Bag6 Protein NIDDK Infectious Disease, Licensing, Oncology, Research Materials Infectious Disease Licensing Oncology Research Materials Yihong Ye Bag6 (BCL2 associated athanogene 6) is a multifunctional chaperone involved in tail anchored protein biogenesis, endoplasmic reticulum-associated protein degradation, and degradation of mislocalized membrane proteins. It is the central component of a stable three chaperone complex that also contains two cofactors-Ubl4A and Trc35. This complex acts in conjunction with the co-chaperone SGTA to channel proteins bearing an exposed hydrophobic segment in the cytosol to avoid protein aggregation. The complex also associates with several ubiquitin ligases including gp78 and RNF126, which link it to protein quality control of misfolded or mislocalized polypeptides. This is one of the antibodies used to confirm the that all three proteins were associated with gp78. <ul> <li>A novel, robust mechanism to model mammalian cell protein integrity</li> </ul> <ul> <li>This is a research tool that may be used to study protein quality control in mammalian cells</li> <li>May be of use in creating novel anti-retroviral treatments</li> </ul> Research Material - Patent protection is not being pursued for this technology. 2022-03-08 2024-10-28 2024-10-28 2016-08-16 antibodies, Bag6, CC1AXX, DD1XXX, Human, Polyconal, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Protein, RECOGNIZE, That, WIXXXX, YGXXXX False True True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114171327 Wang Q, et al. A ubiquitin ligase-associated chaperone holdase maintains polypeptides in soluble states for proteasome degradation. Mol Cell. 2011 Jun 24;42(6):758-70. http://www.ncbi.nlm.nih.gov/pubmed/21636303 <a href="http://www.ncbi.nlm.nih.gov/pubmed/21636303">Wang Q, et al. A ubiquitin ligase-associated chaperone holdase maintains polypeptides in soluble states for proteasome degradation. Mol Cell. 2011 Jun 24;42(6):758-70.</a> 114107302 Ye, Yihong National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Ye, Yihong (NIDDK) 1 114107302 Ye, Yihong National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Ye, Yihong (NIDDK) 1 114101630 Bag6 Polyconal Antibodies That Recognize Human Bag6 Protein E-077-2015-0 Research Material National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83692066 Tong, Betty tongb@niddk.nih.gov
United States of America Senior Technology Advancement Office tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-3041] Bag6 Polyclonal Antibodies That Recognize Human Bag6 Protein&body=Please send me information about technology [TAB-3041] Bag6 Polyclonal Antibodies That Recognize Human Bag6 Protein. Tong, Betty<br><a href="mailto:tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-3041] Bag6 Polyclonal Antibodies That Recognize Human Bag6 Protein&body=Please send me information about technology [TAB-3041] Bag6 Polyclonal Antibodies That Recognize Human Bag6 Protein.">tongb@niddk.nih.gov</a><br> 114122443 CC1AXX 114122478 WIXXXX 114122479 YGXXXX 114123968 DD1XXX 114141699 Bag6 114141700 Polyconal 114141701 antibodies 114141702 That 114141703 RECOGNIZE 114141704 Human 114141705 Protein 114141707 Pre LPM working set 20150418 114141708 Post LPM Assignment Set 20150420 TAB-3033 114096521 Remotely Monitored Mouse Feeding Experimentation Device NIDDK Cardiology, Collaboration, Consumer Products, Dental, Endocrinology, Infectious Disease, Medical Devices, Non-Medical Devices, Oncology, Ophthalmology, Research Materials Cardiology Collaboration Consumer Products Dental Endocrinology Infectious Disease Medical Devices Non-Medical Devices Oncology Ophthalmology Research Materials Alexxai Kravitz, Katrina Nguyen How much does a mouse eat per day? If a researcher is conducting dietary studies, the answer is very important. For instance, obesity studies require accurate measures of feeding. Existing automated methods for taking feeding measurements are expensive and use specialized caging that is not compatible with typical vivarium colony racks. As a result, many researchers simply weigh food each day or two to determine how much food the mice ate. This is time-consuming, can be error prone, and provides a low temporal resolution view of feeding.<br /><br /> To address this need, a compact, 3D printed, electronic, feeding experimentation device has been developed. When the mouse takes a pellet, the device sends a timestamp via WiFi to a computer and dispenses another pellet. Multiple mice in a single cage can be identified with an RFID chip and individually monitored. In this way, a record of every pellet eaten by each mouse can be retrieved at the end of an experiment. This permits high-resolution views (# of meals, size of each meal) of feeding over long durations, without any specialized caging but with a reduction in researcher's hands-on time. <ul> <li>Small size, suitable for standard vivarium housing.</li> <li>Electronic monitoring reduces need for personnel to monitor feeding behavior.</li> <li>Can track multiple mice in a single cage.</li> <li>Less-costly solution.</li> <li>The same device can be used as for operant conditioning experiments.</li> </ul> <ul> <li>Mouse diet experiments</li> <li>Behavior - food reward training</li> <li>Mouse health monitoring in other experiments</li> <li>May be adapted for other small rodents</li> </ul> The NIH is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize Remotely Monitored Mouse Feeding Experimentation Device. For collaboration opportunities, please contact Marguerite J. Miller at <a href="mailto:Marguerite.Miller@nih.gov">Marguerite.Miller@nih.gov or 301-496-9003</a>. This technology is not patented. Instructions for 3D printing, parts list, and assembly of components are available from contact below. 2022-03-08 2024-10-28 2024-10-28 2016-07-26 AFXXXX, Caging, DEVICE, Feeding, MEASUREMENT, Mouse, Patent Category - Mech/Elect/Soft, VPXXXX, WIXXXX, WMXXXX, XDXXXX, YFXXXX False True True 52406769 Prototype 52406769 NIHTT 37470483 Website Abstract 114170905 Devarakonda K, et al. http://www.ncbi.nlm.nih.gov/pubmed/26019006 <a href="http://www.ncbi.nlm.nih.gov/pubmed/26019006">Devarakonda K, et al.</a> 114107187 Nguyen, Katrina National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Nguyen, Katrina 0 114107186 Kravitz, Alexxai National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Kravitz, Alexxai (NIDDK) 1 114107186 Kravitz, Alexxai National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Kravitz, Alexxai (NIDDK) 1 114107187 Nguyen, Katrina National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Nguyen, Katrina 0 114100942 A Mouse Feeding Measurement Device That Is Compatible With Typical Vivarium Caging E-209-2015-0 Filing authorized National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83692066 Tong, Betty tongb@niddk.nih.gov
United States of America Senior Technology Advancement Office tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-3033] Remotely Monitored Mouse Feeding Experimentation Device&body=Please send me information about technology [TAB-3033] Remotely Monitored Mouse Feeding Experimentation Device. Tong, Betty<br><a href="mailto:tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-3033] Remotely Monitored Mouse Feeding Experimentation Device&body=Please send me information about technology [TAB-3033] Remotely Monitored Mouse Feeding Experimentation Device.">tongb@niddk.nih.gov</a><br> 114121377 AFXXXX 114121378 VPXXXX 114121379 WIXXXX 114121380 WMXXXX 114121381 XDXXXX 114122285 YFXXXX 114141691 Feeding 114141692 MEASUREMENT 114141693 DEVICE 114141946 Mouse 114142001 Caging 114142002 Patent Category - Mech/Elect/Soft TAB-3015 114096222 Murine Cell Models for Metastatic Squamous Cell Carcinoma NIDCD Licensing, Oncology, Research Materials Licensing Oncology Research Materials Zhong Chen, Carter Van Waes Two cell lines isolated from Pam 212 cells (SCC): Pam LY (lymph node metastasis) and Pam LU (lung metastasis) from metastated <em>in vivo</em> growth in mouse. These stably established cell lines exhibited higher potential to metastasize to lymph nodes and lungs, respectively, in mouse models than their parental Pam 212 cells. <ul> <li>Drug discovery for squamous cell carcinoma</li> <li>Drug discovery for squamous cell carcinoma metastated to lung and lymph nodes</li> </ul> Research Material 2022-03-08 2024-10-28 2024-10-28 2016-06-22 AMD, BUT, CCXXXX, Establish, Including, Limit, Lines, LU, LU1, LY, LY-1, LY-2, LY-8, Pam, VCXXXX, WIXXXX False True True NIHTT 37470483 Website Abstract 114103302 Van Waes, Carter National Institute on Deafness and Other Communication Disorders (NIDCD) NIDCD Van Waes, Carter (NIDCD) 0 114103303 Chen, Zhong National Institute on Deafness and Other Communication Disorders (NIDCD) NIDCD Chen, Zhong (NIDCD) 1 114103303 Chen, Zhong National Institute on Deafness and Other Communication Disorders (NIDCD) NIDCD Chen, Zhong (NIDCD) 1 114103302 Van Waes, Carter National Institute on Deafness and Other Communication Disorders (NIDCD) NIDCD Van Waes, Carter (NIDCD) 0 114101551 Establish Pam LY Amd Pam LU Lines, Including, But Not Limit To Pam LY-1, Pam LY-2, Pam LY-8, And Pam LU1 Lines E-213-2016-0 Research Material National Institute on Deafness and Other Communication Disorders (NIDCD) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-3015] Murine Cell Models for Metastatic Squamous Cell Carcinoma&body=Please send me information about technology [TAB-3015] Murine Cell Models for Metastatic Squamous Cell Carcinoma. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-3015] Murine Cell Models for Metastatic Squamous Cell Carcinoma&body=Please send me information about technology [TAB-3015] Murine Cell Models for Metastatic Squamous Cell Carcinoma.">shmilovm@nih.gov</a><br> 114121911 WIXXXX 114123579 VCXXXX 114123583 CCXXXX 114131321 Establish 114131322 Pam 114131323 LY 114131324 AMD 114131325 LU 114131326 Lines 114131327 Including 114131328 BUT 114131329 Limit 114131330 LY-1 114131331 LY-2 114131332 LY-8 114131333 LU1 TAB-3013 114096446 Alloreactive T Cell Depletion Method For Preventing Graft-Versus-Host Disease NHLBI Licensing Licensing John Barrett, Dhanalakshmi (Donna) Chinnasamy, Gregory Whitehill The invention relates to the use of adenosine to deplete alloreactive T cells from donor grafts to prevent graft-versus-host disease (GVHD). The method includes culturing donor cells that include T cells with recipient antigen presenting cells (APCs) to form a mixture of cells. The recipient’s APCs activate donor T cells. The activated T cells are treated with high doses of adenosine or an adenosine-like molecule to decrease or inhibit viability of the activated donor T-cells. The adenosine or adenosine-like molecule is filtered away from the mixture resulting in cells that can be transplanted into the recipient. <ul> <li>T cell selective</li> <li>Non invasive</li> </ul> <ul> <li>Transplantation rejection prevention</li> <li>Graft-versus-Host disease</li> </ul> 2022-03-08 2024-10-28 2024-10-28 2016-06-22 Alloreactive, Cell, DEPLETION, Disease, DONOR, GRAFTS, GRAFT-VERSUS-HOST, GVHD, Listed LPM Maddox as of 4/15/2015, LYMPHOCYTE, lymphocytes, Method, Novel, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Prevent, SELECTIVE, Stem, T, YAXXXX False True Early-stage True 52406768 Discovery 52406768 NIHTT 37470483 Website Abstract 114106585 Whitehill, Gregory National Heart, Lung, and Blood Institute (NHLBI) NHLBI Whitehill, Gregory (NHLBI) 0 114109085 Barrett, John National Heart, Lung, and Blood Institute (NHLBI) NHLBI Barrett, John (NHLBI) 0 114108592 Chinnasamy, Dhanalakshmi (Donna) National Heart, Lung, and Blood Institute (NHLBI) NHLBI Chinnasamy, Dhanalakshmi (Donna) (NHLBI) 1 114108592 Chinnasamy, Dhanalakshmi (Donna) National Heart, Lung, and Blood Institute (NHLBI) NHLBI Chinnasamy, Dhanalakshmi (Donna) (NHLBI) 1 114106585 Whitehill, Gregory National Heart, Lung, and Blood Institute (NHLBI) NHLBI Whitehill, Gregory (NHLBI) 0 114109085 Barrett, John National Heart, Lung, and Blood Institute (NHLBI) NHLBI Barrett, John (NHLBI) 0 114101545 A Novel Method For The Selective Depletion Of Alloreactive T Lymphocytes From Donor Stem Cell Or Lymphocyte Grafts To Prevent Graft-versus-host Disease (GVHD) E-125-2015-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-3013] Alloreactive T Cell Depletion Method For Preventing Graft-Versus-Host Disease&body=Please send me information about technology [TAB-3013] Alloreactive T Cell Depletion Method For Preventing Graft-Versus-Host Disease. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-3013] Alloreactive T Cell Depletion Method For Preventing Graft-Versus-Host Disease&body=Please send me information about technology [TAB-3013] Alloreactive T Cell Depletion Method For Preventing Graft-Versus-Host Disease.">shmilovm@nih.gov</a><br> 114166440 E-125-2015-0 E-125-2015-0-US-01 METHOD FOR THE SELECTIVE DEPLETION OF ALLOREACTIVE T LYMPHOCYTES FROM DONOR STEM CELL OR LYMPHOCYTE GRAFTS TO PREVENT GRAFT-VERSUS-HOST DISEASE PRV US 62/153,174 Abandoned US <br />Provisional (PRV) 62/153,174<br />Filed on 2015-04-27<br />Status: Abandoned 114166441 E-125-2015-0 E-125-2015-0-PCT-02 Method for the Selective Depletion of Alloreactive T Lymphocytes From Donor Stem Cell or Lymphocyte Grafts to Prevent Graft-Versus-Host Disease PCT Patent Cooperation Treaty PCT/US2016/029333 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2016/029333<br />Filed on 2016-04-26<br />Status: Expired 114123585 YAXXXX 114141238 Novel 114141239 Method 114141240 SELECTIVE 114141241 DEPLETION 114141242 Alloreactive 114141243 T 114141244 lymphocytes 114141245 DONOR 114141246 Stem 114141247 Cell 114141248 LYMPHOCYTE 114141249 GRAFTS 114141250 Prevent 114141251 GRAFT-VERSUS-HOST 114141252 Disease 114141253 GVHD 114141254 Listed LPM Maddox as of 4/15/2015 114141255 Pre LPM working set 20150418 114141256 Post LPM Assignment Set 20150420 TAB-3003 114094656 Software for Fully Automating Myocardial Perfusion Quantification NHLBI Cardiology, Computational models/software, Licensing, Research Materials, Software / Apps Cardiology Computational models/software Licensing Research Materials Software / Apps Andrew Arai, Mitchel Benovoy, Li-Yueh Hsu, Matthew Jacobs Software is has been developed and available for licensing that fully automates image processing for the quantification of myocardial blood flow (MBF) pixel maps from firstpass contrast-enhanced cardiac magnetic resonance (CMR) perfusion images. The system removes the need for laborious manual quantitative CMR perfusion pixel map processing and can process prospective and retrospective studies acquired from various imaging protocols. In full automation, arterial input function (AIF) images are processed for motion correction and myocardial perfusion images are corrected for intensity bias. The corrected AIF images are processed for left ventricle signal detection and the corrected myocardial perfusion images and processed for myocardial signal detection. Both data sets are then corrected for nonlinear signaling, synchronized, and pixel-wise deconvolution processed. The resulting pixel map shows accurate myocardial blood flow. <ul> <li>MRI Imaging of the myocardium</li> <li>Blood Perfusion Imaging</li> </ul> Software Materials 2022-03-08 2024-10-28 2024-10-28 2016-03-03 Automated, Cardiac, First-pass, FULLY, IMAGING, Magnetic, MYOCARDIAL, Perfusion, QUANTIFICATION, Resonance, System, VDXXXX, WIXXXX, XJXXXX False True <ul> <li>In vivo data</li> <li>Software system</li> <li>Source code</li> </ul> True NIHTT 37470483 Website Abstract 114108379 Arai, Andrew National Heart, Lung, and Blood Institute (NHLBI) NHLBI Arai, Andrew (NHLBI) 0 114108918 Jacobs, Matthew National Heart, Lung, and Blood Institute (NHLBI) NHLBI Jacobs, Matthew (NHLBI) 0 114108919 Benovoy, Mitchel National Heart, Lung, and Blood Institute (NHLBI) Benovoy, Mitchel 0 114108378 Hsu, Li-Yueh National Heart, Lung, and Blood Institute (NHLBI) NHLBI Hsu, Li-Yueh (NHLBI) 1 114108378 Hsu, Li-Yueh National Heart, Lung, and Blood Institute (NHLBI) NHLBI Hsu, Li-Yueh (NHLBI) 1 114108379 Arai, Andrew National Heart, Lung, and Blood Institute (NHLBI) NHLBI Arai, Andrew (NHLBI) 0 114108918 Jacobs, Matthew National Heart, Lung, and Blood Institute (NHLBI) NHLBI Jacobs, Matthew (NHLBI) 0 114108919 Benovoy, Mitchel National Heart, Lung, and Blood Institute (NHLBI) Benovoy, Mitchel 0 114100790 A Fully Automated System For Myocardial Perfusion Quantification With First-pass Cardiac Magnetic Resonance Imaging E-097-2016-0 Research Material Centre Hospitalier Universitaire Sainte-Justine, National Heart, Lung, and Blood Institute (NHLBI), Polytechnique Montreal [Ecole Polytechnique de Montreal] 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-3003] Software for Fully Automating Myocardial Perfusion Quantification&body=Please send me information about technology [TAB-3003] Software for Fully Automating Myocardial Perfusion Quantification. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-3003] Software for Fully Automating Myocardial Perfusion Quantification&body=Please send me information about technology [TAB-3003] Software for Fully Automating Myocardial Perfusion Quantification.">shmilovm@nih.gov</a><br> 114112854 XJXXXX 114125937 VDXXXX 114125938 WIXXXX 114134332 Resonance 114134333 IMAGING 114148545 FULLY 114148546 Automated 114148547 System 114148548 MYOCARDIAL 114148549 Perfusion 114148550 QUANTIFICATION 114148551 First-pass 114148552 Cardiac 114148553 Magnetic TAB-2990 114096459 TRPC Knockout (KO) Mice and Mice with a Floxed Allele of TRPC Ion Channel Genes NIEHS Diagnostics, Licensing, Research Materials, Therapeutics Diagnostics Licensing Research Materials Therapeutics Joel Abramowitz, Lutz Birnbaumer TRPCs (Canonical Transient Receptor Potential Channels) are a group of non-selective cation channels that allow sodium and calcium into cells. There are seven different genes in mice that code TRPCs. The in vivo roles played by TRPCs as a whole are poorly understood and very little is known about the in vivo roles played by individual TRPCs nor the role of these channels in specific tissues or cells.<br /><br /> In this invention, mice with a floxed allele of TRPC3, TRPC5, or TRPC7 were generated. Knockout mice of TRPC3, TRPC5, or TRPC7 can be used to study the function of the respective genes. The knockout mice can then be used to identify TRPC3/TRPC5/TRPC7-dependent processes. When mice with a floxed allele of one of the TRPCs are crossed with mice expressing Cre recombinase, mice can be generated in which TRPC3 has been deleted. This can be done in a tissue specific manner. <ul> <li>The in vivo roles played by TRPCs as a whole are poorly understood and very little is known about the in vivo roles played by individual TRPCs. Using these TRPC knockout mice or the mice with a floxed allele of TRPC3/TRPC5/TRPC7 would circumvent these problems for TRPCs.</li> </ul> <ul> <li>This mouse model could be used to identify unknown biomedical functions of TRPCs. Thus the mice could be used in developing therapeutics, diagnosis of disease, drug screening, assay development and as a research tool.</li> </ul> Research Tools - Patent protection is not being pursued for these technologies. 2022-03-08 2024-10-28 2024-10-28 2015-12-08 ALLELE, CHANNEL, Floxed, Gene, ION, Knockout, Listed LPM Tong as of 4/15/2015, Mice, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, TRPC3, TRPC5, TRPC7, WBXXXX, WIXXXX, WJXXXX, WKXXXX, XEXXXX, YAXXXX False True Early-stage True 52406768 Discovery 52406768 NIHTT 37470483 Website Abstract 114170743 Hartmann J, et al. https://www.ncbi.nlm.nih.gov/pubmed/18701065 <a href="https://www.ncbi.nlm.nih.gov/pubmed/18701065">Hartmann J, et al.</a> 114171171 Phelan KD, et al. https://www.ncbi.nlm.nih.gov/pubmed/23188715 <a href="https://www.ncbi.nlm.nih.gov/pubmed/23188715">Phelan KD, et al.</a> 114171356 Perez-Leighton CE, et al. https://www.ncbi.nlm.nih.gov/pubmed/21261756 <a href="https://www.ncbi.nlm.nih.gov/pubmed/21261756">Perez-Leighton CE, et al.</a> 114107837 Abramowitz, Joel NIEHS NIEHS Abramowitz, Joel (NIEHS) 0 114107836 Birnbaumer, Lutz NIEHS NIEHS Birnbaumer, Lutz (NIEHS) 1 114107836 Birnbaumer, Lutz NIEHS NIEHS Birnbaumer, Lutz (NIEHS) 1 114107837 Abramowitz, Joel NIEHS NIEHS Abramowitz, Joel (NIEHS) 0 114099768 Knockout Mice For The TRPC7 Ion Channel Gene E-071-2014-6 Research Material NIEHS 114100997 Mice With A Floxed Allele Of The TRPC7 Ion Channel Gene E-071-2014-7 Research Material NIEHS 114101568 Knockout Mice For The TRPC3 Ion Channel Gene E-071-2014-2 Research Material NIEHS 114101573 Knockout Mice For The TRPC5 Ion Channel Gene E-071-2014-4 Research Material NIEHS 114101637 Mice With A Floxed Allele Of The TRPC5 Ion Channel Gene E-071-2014-5 Research Material NIEHS 114101857 Mice With A Floxed Allele Of The TRPC3 Ion Channel Gene E-071-2014-3 Research Material NIEHS 83739538 Choudhry, Vidita vidita.choudhry@nih.gov
United States of America Office of Technology Transfer and Development vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-2990] TRPC Knockout (KO) Mice and Mice with a Floxed Allele of TRPC Ion Channel Genes&body=Please send me information about technology [TAB-2990] TRPC Knockout (KO) Mice and Mice with a Floxed Allele of TRPC Ion Channel Genes. Choudhry, Vidita<br><a href="mailto:vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-2990] TRPC Knockout (KO) Mice and Mice with a Floxed Allele of TRPC Ion Channel Genes&body=Please send me information about technology [TAB-2990] TRPC Knockout (KO) Mice and Mice with a Floxed Allele of TRPC Ion Channel Genes.">vidita.choudhry@nih.gov</a><br> 114117369 WBXXXX 114117370 WIXXXX 114119361 WJXXXX 114120598 WKXXXX 114120599 XEXXXX 114120600 YAXXXX 114130711 Knockout 114130712 Mice 114130713 TRPC3 114130714 ION 114130715 CHANNEL 114130716 Gene 114133710 Listed LPM Tong as of 4/15/2015 114133711 Pre LPM working set 20150418 114133712 Post LPM Assignment Set 20150420 114133713 ALLELE 114133714 Floxed 114133715 TRPC5 114133716 TRPC7 TAB-2989 114096485 Mice with a Floxed Allele of the alpha Subunit of the Heterotrimeric G Protein Go or Gi2 NIEHS Diagnostics, Licensing, Research Materials, Therapeutics Diagnostics Licensing Research Materials Therapeutics Joel Abramowitz, Lutz Birnbaumer Heterotrimeric G proteins couple signals between GPCRs (G protein coupled receptors) and effectors such as adenylyl cyclase, phospholipase C and ion channels. Among the G proteins are Go and Gi2. Go is highly expressed in the brain and some endocrine tissues while Gi2 is widely expressed throughout the body. The ß?-subunits of Go interact with ion channels, and the a subunit has been shown to inhibit adenylyl cyclase. However a physiological role of the Gi2a has not been determined in a tissue specific manner.<br /><br /> In this invention, mice with a floxed allele of the Go-a subunit and mice with a floxed allele of the Gi2a subunit were generated. These transgenic mice can be used to study the function of Go-a and the function of Gi2a in a tissue specific manner. <ul> <li>Mice in which Go-a has been globally deleted do not grow well and many die early after birth making it difficult to identify specific functions for Go-a. Using this mouse with floxed allele of Go-a would circumvent these problems.</li> <li>Mice in which Gi2a has been globally deleted are immune compromised and do not reproduce complicating the identification of tissue or cell specific Gi2a-dependent processes. Using this mouse with a floxed allele of Gi2a would circumvent these problems.</li> </ul> <ul> <li>The Go-a flox mice can be used to identify unknown biomedical functions of Go-a. Thus the mice could be used in developing therapeutics, diagnosis of disease, drug screening, assay development and as a research tool.</li> <li>The Gi2a mice can be used to identify unknown biomedical functions of Gi2a. Thus the mice could be used in developing therapeutics, diagnosis of disease, drug screening, assay development and as a research tool.</li> </ul> Research Tools - Patent protection is not being pursued for these technologies. 2022-03-08 2024-10-28 2024-10-28 2015-12-08 ?, ALLELE, ALPHA, Floxed, G, Gi2, Go, Heterotrimeric, Listed LPM Tong as of 4/15/2015, Mice, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Protein, SUBUNIT, WBXXXX, WIXXXX, WJXXXX, WKXXXX, XEXXXX, YAXXXX False True Early-stage True 52406768 Discovery 52406768 NIHTT 37470483 Website Abstract 114170395 Ustyugova IV, et al. https://www.ncbi.nlm.nih.gov/pubmed/22550081 <a href="https://www.ncbi.nlm.nih.gov/pubmed/22550081">Ustyugova IV, et al.</a> 114170740 Plummer NW, et al. https://www.ncbi.nlm.nih.gov/pubmed/23236180 <a href="https://www.ncbi.nlm.nih.gov/pubmed/23236180">Plummer NW, et al.</a> 114170741 Zhao A, et al. https://www.ncbi.nlm.nih.gov/pubmed/20622165 <a href="https://www.ncbi.nlm.nih.gov/pubmed/20622165">Zhao A, et al.</a> 114170742 Chamero P, et al. https://www.ncbi.nlm.nih.gov/pubmed/21768373 <a href="https://www.ncbi.nlm.nih.gov/pubmed/21768373">Chamero P, et al.</a> 114107173 Abramowitz, Joel NIEHS NIEHS Abramowitz, Joel (NIEHS) 0 114107172 Birnbaumer, Lutz NIEHS NIEHS Birnbaumer, Lutz (NIEHS) 1 114107172 Birnbaumer, Lutz NIEHS NIEHS Birnbaumer, Lutz (NIEHS) 1 114107173 Abramowitz, Joel NIEHS NIEHS Abramowitz, Joel (NIEHS) 0 114101468 Mice With A Floxed Allele Of The Alpha Subunit Of The Heterotrimeric G Protein Gi2 E-071-2014-0 Research Material NIEHS 114101588 Mice With A Floxed Allele Of The Alpha Subunit Of The Heterotrimeric G Protein Go E-071-2014-1 Research Material NIEHS 83739538 Choudhry, Vidita vidita.choudhry@nih.gov
United States of America Office of Technology Transfer and Development vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-2989] Mice with a Floxed Allele of the alpha Subunit of the Heterotrimeric G Protein Go or Gi2&body=Please send me information about technology [TAB-2989] Mice with a Floxed Allele of the alpha Subunit of the Heterotrimeric G Protein Go or Gi2. Choudhry, Vidita<br><a href="mailto:vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-2989] Mice with a Floxed Allele of the alpha Subunit of the Heterotrimeric G Protein Go or Gi2&body=Please send me information about technology [TAB-2989] Mice with a Floxed Allele of the alpha Subunit of the Heterotrimeric G Protein Go or Gi2.">vidita.choudhry@nih.gov</a><br> 114114121 WBXXXX 114117368 YAXXXX 114118804 WIXXXX 114118806 WJXXXX 114118807 WKXXXX 114118808 XEXXXX 114130702 Heterotrimeric 114130703 G 114130704 Protein 114130705 Gi2 114130706 ALPHA 114130707 Listed LPM Tong as of 4/15/2015 114130708 Pre LPM working set 20150418 114130709 Post LPM Assignment Set 20150420 114130710 Go 114131312 Mice 114131313 Floxed 114131314 ALLELE 114144187 ? 114144188 SUBUNIT TAB-2984 114095864 Mouse Model for Study of Diabetic Nephropathy and Role of Soluble Epoxide Hydrolase NIEHS Cardiology, Dental, Endocrinology, Infectious Disease, Licensing, Oncology, Ophthalmology, Research Materials, Therapeutics Cardiology Dental Endocrinology Infectious Disease Licensing Oncology Ophthalmology Research Materials Therapeutics Darryl Zeldin Diabetic nephropathy (DN) is the leading cause of renal failure and is characterized by proteinuria that progresses to renal inflammation and decline in the glornerular filtration barrier (GFB). Podocytes are specialized epithelia cells in the glomerular capsule that have a role in filtration of blood and maintaining the integrity of the GFB; dysfunction of these cells plays a significant role in the pathogenesis of DN. Soluble epoxide hydrolase (sEH) is a cytosolic enzyme whose inhibition has beneficial effects in inflammatory diseases.<br /><br /> In the present invention, mice with a podocyte-specific deletion of sEH (pod-sEHKO) were generated to determine the effects of podocyte sEH on renal function. These mice showed moderate improvement in kidney function and systemic glucose homeostasis in normoglycemia and a significant improvement in hyperglycemia. Histology of the kidneys of these animals and in vitro assays with mouse podocytes treated with an sEH inhibitor, confirmed that sEH in podocytes is a key contributor to kidney function and systemic glucose homeostasis. These findings demonstrate that pharmacological and gene-based sEH inhibitors can be used to improve kidney function and blood pressure and protect podocytes from hyperglycemia-induced injury, thus inhibiting or preventing DN.<br /><br /> This invention was co-developed with the University of California at Davis. <ul> <li>Novel approach to controlling systemic glucose in diabetes. sEH inhibitors could be used to decrease blood glucose levels in diabetes by increasing glucose clearance in the urine.</li> <li>Improve kidney function and blood pressure by protecting podocytes from hyperglycemia-induced injury.</li> <li>Beneficial cardiovascular effects, due to their ability to increase serum HDL levels in hyperglycemic conditions.</li> </ul> <ul> <li>Potential for one or more sEH inhibitors to be use in the treatment of diabetes and DN.</li> <li>Basic and clinical research into glucose homestasis and kidney function.</li> </ul> 2022-03-08 2024-10-28 2024-10-28 2015-11-24 COMPOSITION, Methods, Nephropathy, TREATING, VFXXXX, VPXXXX, WIXXXX, WJXXXX, WKXXXX, XEXXXX, YBXXXX, YCXXXX False True <ul> <li>In vitro data available</li> <li>In vivo data available (animal)</li> </ul> True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114105675 Zeldin, Darryl NIEHS NIEHS Zeldin, Darryl (NIEHS) 1 114105675 Zeldin, Darryl NIEHS NIEHS Zeldin, Darryl (NIEHS) 1 114100842 Methods And Composition For Treating Nephropathy E-292-2015-0 Filing authorized NIEHS, University of California, Davis (UCD) 83739538 Choudhry, Vidita vidita.choudhry@nih.gov
United States of America Office of Technology Transfer and Development vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-2984] Mouse Model for Study of Diabetic Nephropathy and Role of Soluble Epoxide Hydrolase&body=Please send me information about technology [TAB-2984] Mouse Model for Study of Diabetic Nephropathy and Role of Soluble Epoxide Hydrolase. Choudhry, Vidita<br><a href="mailto:vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-2984] Mouse Model for Study of Diabetic Nephropathy and Role of Soluble Epoxide Hydrolase&body=Please send me information about technology [TAB-2984] Mouse Model for Study of Diabetic Nephropathy and Role of Soluble Epoxide Hydrolase.">vidita.choudhry@nih.gov</a><br> 114163976 E-292-2015-0 E-292-2015-0-US-01 Methods And Composition For Treating Nephropathy PRV US 62/188,544 Abandoned US <br />Provisional (PRV) 62/188,544<br />Filed on 2015-07-03<br />Status: Abandoned 114166642 E-292-2015-0 E-292-2015-0-PCT-02 METHODS AND COMPOSITIONS FOR TREATING NEPHROPATHY PCT Patent Cooperation Treaty PCT/US2016/035548 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2016/035548<br />Filed on 2016-06-02<br />Status: Expired 114168774 E-292-2015-0 E-292-2015-0-US-03 Methods And Composition For Treating Nephropathy National Stage US 15/739,718 Abandoned US <br />National Stage 15/739,718<br />Filed on 2017-12-23<br />Status: Abandoned 114118074 VFXXXX 114118075 VPXXXX 114118076 WIXXXX 114119971 WJXXXX 114119972 WKXXXX 114119973 XEXXXX 114119974 YBXXXX 114119975 YCXXXX 114135540 Methods 114135541 COMPOSITION 114135542 TREATING 114135543 Nephropathy TAB-2985 114096123 SIRT1 KO Human Cell Lines Generated by CRISPR/Cas9-mediated DNA Editing NIEHS Cardiology, Dental, Endocrinology, Infectious Disease, Licensing, Oncology, Ophthalmology, Research Materials, Therapeutics Cardiology Dental Endocrinology Infectious Disease Licensing Oncology Ophthalmology Research Materials Therapeutics Yi Fang, Xiaoling Li SIRT1, a NAD+-dependent protein deacetylase, is the most conserved member of the sirtuins family. Through deacetylation of a number of protein substrates that are important transcription factors or co-factors, SIRT1 regulates many vital biological processes such as metabolism, cellular stress response, stem cell pluripotency, and development.<br /><br /> The present invention describes SIRT1 KO human cell lines in three different cell types generated by using the CRISPR/Cas9-hSIRT1 DNA editing constructs designed and provided by Horizon Discovery, a UK based biotechnology company. The cells lines can be used to elucidate the role of SIRT1 in human and to screen for SIRT1 activators or inhibitors that have potential therapeutic applications in a number of human diseases, such as diabetes, inflammatory bowel diseases, and cancer. <ul> <li>Provides a unique opportunity to study the role of this important gene in human biology. </li> <li>Screen for SIRT1 activators or inhibitors that have potential therapeutic applications in a number of human diseases, such as diabetes, inflammatory bowel diseases, and cancer.</li> </ul> <ul> <li>SIRT1 KO human cell lines can be used to investigate the role of this protein in a wide variety of biological processes.</li> <li>Research community and biotech companies can use this for further studies.</li> </ul> Research Tool - Patent prosecution is not being pursued for this technology. 2022-03-08 2024-10-28 2024-10-28 2015-11-24 Cell, CRISPER/Cas9-mediated, DNA, Editing, GENERATED, Human, KO, Lines, SIRT1, VCXXXX, VFXXXX, VPXXXX, WIXXXX, XEXXXX, YAXXXX False True Early-stage True 52406768 Discovery 52406768 NIHTT 37470483 Website Abstract 114106987 Fang, Yi NIEHS NIEHS Fang, Yi (NIEHS) 0 114106986 Li, Xiaoling NIEHS NIEHS Li, Xiaoling (NIEHS) 1 114106986 Li, Xiaoling NIEHS NIEHS Li, Xiaoling (NIEHS) 1 114106987 Fang, Yi NIEHS NIEHS Fang, Yi (NIEHS) 0 114100843 SIRT1 KO Human Cell Lines Generated By CRISPR/Cas9-mediated DNA Editing E-184-2015-0 Research Material NIEHS 83739538 Choudhry, Vidita vidita.choudhry@nih.gov
United States of America Office of Technology Transfer and Development vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-2985] SIRT1 KO Human Cell Lines Generated by CRISPR/Cas9-mediated DNA Editing&body=Please send me information about technology [TAB-2985] SIRT1 KO Human Cell Lines Generated by CRISPR/Cas9-mediated DNA Editing. Choudhry, Vidita<br><a href="mailto:vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-2985] SIRT1 KO Human Cell Lines Generated by CRISPR/Cas9-mediated DNA Editing&body=Please send me information about technology [TAB-2985] SIRT1 KO Human Cell Lines Generated by CRISPR/Cas9-mediated DNA Editing.">vidita.choudhry@nih.gov</a><br> 114121111 VCXXXX 114121112 VFXXXX 114121113 VPXXXX 114121114 WIXXXX 114121590 XEXXXX 114121591 YAXXXX 114137084 SIRT1 114137085 KO 114137086 Human 114137087 Cell 114137088 Lines 114137089 GENERATED 114137090 CRISPER/Cas9-mediated 114137091 DNA 114137092 Editing TAB-2975 114097100 Tristetraprolin (TTP) Plasmid Vectors for Human and Mouse TTP NIEHS Licensing Licensing Perry Blackshear, Wi Lai Tristetraprolin (TTP) is involved in the physiological regulation of the secretion of at least two important cytokines, tumor necrosis factor alpha (TNF) and granulocyte-macrophage colony-stimulating factor (GM-CSF). TTP exerts its effects by directly binding to the mRNAs encoding these proteins and destabilizing them, resulting in less secretion. Conversely, TTP deficiency results in an excess of both cytokines, leading to a systemic inflammatory syndrome. This invention include three categories of reagents related to TTP:1) Plasmid DNAs and mammalian expression vectors for human and mouse TTP; 2) Antibodies (rabbit antisera) to human and mouse TTP; 3) Immortalized macrophage cell lines derived from TTP-deficient mice and their wild-type littermates. <ul> <li>Reagents and cell lines relating to TTP are useful in the study of inflammation from various perspectives, particularly in the study of the new pathway delineated by these studies for the regulation of these cytokines and their secretion.</li> </ul> Research Tool – Patent protection is not being pursued for this technology. 2022-03-08 2024-10-28 2024-10-28 2015-08-31 Human, Listed LPM Wong as of 4/15/2015, Mouse, PLASMID, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Tristetraprolin, TTP, vectors False True True NIHTT 37470483 Website Abstract 114109078 Lai, Wi NIEHS NIEHS Lai, Wi (NIEHS) 0 114109077 Blackshear, Perry NIEHS NIEHS Blackshear, Perry (NIEHS) 1 114109077 Blackshear, Perry NIEHS NIEHS Blackshear, Perry (NIEHS) 1 114109078 Lai, Wi NIEHS NIEHS Lai, Wi (NIEHS) 0 114102286 Tristetraprolin (TTP) Plasmid Vectors For Human And Mouse TTP E-349-2001-0 Research Material NIEHS 83739538 Choudhry, Vidita vidita.choudhry@nih.gov
United States of America Office of Technology Transfer and Development vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-2975] Tristetraprolin (TTP) Plasmid Vectors for Human and Mouse TTP&body=Please send me information about technology [TAB-2975] Tristetraprolin (TTP) Plasmid Vectors for Human and Mouse TTP. Choudhry, Vidita<br><a href="mailto:vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-2975] Tristetraprolin (TTP) Plasmid Vectors for Human and Mouse TTP&body=Please send me information about technology [TAB-2975] Tristetraprolin (TTP) Plasmid Vectors for Human and Mouse TTP.">vidita.choudhry@nih.gov</a><br> 114148517 Tristetraprolin 114148518 TTP 114148519 PLASMID 114148520 vectors 114148521 Human 114148522 Mouse 114148523 Listed LPM Wong as of 4/15/2015 114148524 Pre LPM working set 20150418 114148525 Post LPM Assignment Set 20150420 TAB-2974 114097099 A Genetic System in Yeast for Functional Identification of Human p53 Mutations NIEHS Diagnostics, Licensing, Oncology, Therapeutics Diagnostics Licensing Oncology Therapeutics Alberto Inga, Michael Resnick Mutations in the p53 gene are associated with 50% of all cancers and nearly 80% of the p53 mutations are missense changes. We have developed genetic assays based in yeast that can functionally categorize expressed p53 mutant proteins. The combined assays are referred to as the FIP53 system. Because human p53 cDNA can be conveniently cloned in yeast, the FIP53 system provides a rapid and sophisticated system for the functional analysis of p53 mutants. Four categories of mutations have already been identified. The FIP53 system provides the first in vivo battery for tests that can subdivide many p53 mutations that can occur in humans. In particular, the FIP53 system may allow the identification of rare or new alleles that may function better than the wild type. <ul> <li>The FIP53 system provides a convenient genetic system for categorizing human mutations. It can also be used to assay potential drug impacts on p53 and for design of such drugs. It can also be used to identify p53 alleles with increased transcriptional capability for various p53 target genes or mutations with different DNA sequence selectivity. Such p53 alleles may be good candidates for p53 based cancer gene therapy.</li> </ul> 2022-03-08 2024-10-28 2024-10-28 2015-08-31 CA1XXX, CAXXXX, FUNCTIONAL, GAXXXX, Genetic, Human, Identification, Listed LPM Wong as of 4/15/2015, Mutations, p53, Patent Category - Biotechnology, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, SACGHS DNA Patent Initial Set, System, X, Yeast False True True NIHTT 37470483 Website Abstract 114172272 Inga A, Resnick MA. http://www.ncbi.nlm.nih.gov/pubmed/11423991 <a href="http://www.ncbi.nlm.nih.gov/pubmed/11423991">Inga A, Resnick MA.</a> 114172273 Resnick MA, Inga A. https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7256260 <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7256260">Resnick MA, Inga A.</a> 114109076 Inga, Alberto NIEHS Inga, Alberto 0 114109075 Resnick, Michael NIEHS NIEHS Resnick, Michael (NIEHS) 1 114109075 Resnick, Michael NIEHS NIEHS Resnick, Michael (NIEHS) 1 114109076 Inga, Alberto NIEHS Inga, Alberto 0 114102285 A Genetic System in Yeast for Functional Identification of Human p53 Mutations E-183-1999-0 Filing authorized NIEHS 83739538 Choudhry, Vidita vidita.choudhry@nih.gov
United States of America Office of Technology Transfer and Development vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-2974] A Genetic System in Yeast for Functional Identification of Human p53 Mutations&body=Please send me information about technology [TAB-2974] A Genetic System in Yeast for Functional Identification of Human p53 Mutations. Choudhry, Vidita<br><a href="mailto:vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-2974] A Genetic System in Yeast for Functional Identification of Human p53 Mutations&body=Please send me information about technology [TAB-2974] A Genetic System in Yeast for Functional Identification of Human p53 Mutations.">vidita.choudhry@nih.gov</a><br> 114168189 E-183-1999-0 E-183-1999-0-US-01 A Genetic System in Yeast for Functional Identification of Human p53 Mutations PRV US 60/146,634 Abandoned US <br />Provisional (PRV) 60/146,634<br />Filed on 1999-07-30<br />Status: Abandoned 114168190 E-183-1999-0 E-183-1999-0-PCT-02 Human P53 Mutations And a Genetic system in Yeast For Functional Identification of Human P53 Mutations PCT Patent Cooperation Treaty PCT/US00/20538 Expired Patent Cooperation Treaty <br />(PCT) PCT/US00/20538<br />Filed on 2000-07-28<br />Status: Expired 114168191 E-183-1999-0 E-183-1999-0-US-07 HUMAN P53 MUTATION AND A GENETIC SYSTEM IN YEAST FOR FUNCTIONAL IDENTI FICATION OF HUMAN P53 MUTATIONS National Stage US 7,256,260 10/048,502 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7256260 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7256260">7,256,260</a><br />Filed on 2002-06-12<br />Status: Abandoned 114168192 E-183-1999-0 E-183-1999-0-US-09 Human p53 Mutations and a Genetic System in Yeast for Functional Identification of Human p53 Mutations DIV US 11/893,037 Abandoned US <br />Divisional (DIV) 11/893,037<br />Filed on 2007-08-14<br />Status: Abandoned 114127180 CAXXXX 114127181 CA1XXX 114127182 GAXXXX 114131578 X 114148504 Genetic 114148505 System 114148506 Yeast 114148507 FUNCTIONAL 114148508 Identification 114148509 Human 114148510 p53 114148511 Mutations 114148512 SACGHS DNA Patent Initial Set 114148513 Patent Category - Biotechnology 114148514 Listed LPM Wong as of 4/15/2015 114148515 Pre LPM working set 20150418 114148516 Post LPM Assignment Set 20150420 TAB-2971 114097097 Immunological Detection of Free Radicals In Animals and In Vitro NIEHS Licensing, Research Materials Licensing Research Materials Charles Detweiler, Ronald Mason Electron Spin Resonance (ESR) is an universal, specific tool for the detection of free radicals in biological systems. Its application to the investigation of free radicals from whole animals, organs, and cells has been made possible by the spin-trapping technique. In a Spin-trapping experiment, a spin trap such as DMPO (5,5-dimetryl-1-pyrroline N-oxide) reacts specifically with one or more types of free radical to form radical-derived nitrone adducts that are much more stable than the original free radicals. In decades of investigation, very few artifacts have been discovered with the use of nitrone spin traps like DPMO. Unfortunately, due to technical limitations inherent in ESR detection, neither the tissue nor cellular distribution of free radicals has ever been determined with ESR. This invention takes advantage of the highly antigenic nature of the nitrone adducts of proteins and aim at developing specific antibodies to nitrone adducts that can be used in western blotting and enzyme immunoassays (EIA). This would allow the visualization of the distribution of free radical damage to tissues and cells. This methodology is both broad and free radical specific, and should open free radical investigations to biomedical investigations in ways never before possible. <ul> <li>The cost of using this method to detect free radicals is substantially cheaper than current ESR methodologies. For example, a western blot assay can be done for a few hundred dollars, whereas an ESR spectrometer can easily cost upwards of $250,000. In addition, detection of nitrone adducts using immunohistological techniques would broaden the scope of free radical detection by providing images of the distribution of free radical damage within tissue and cells.</li> </ul> <ul> <li>The antibodies for spin traps, nitrons adducts, and corresponding hydroxylamines of the radical adducts can be used for detecting free radicals and their distributions in tissues and cells, allowing possibility for clinical applications.</li> </ul> Research Tool - Patent protection is not being pursued for this technology. 2022-03-08 2024-10-28 2024-10-28 2015-08-24 Animals, Detection, FREE, IMMUNOLOGICAL, Listed LPM Vepa as of 4/15/2015, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Radicals, RXXXXX, Vitro False True True NIHTT 37470483 Website Abstract 114170317 Romero N, et al. http://www.ncbi.nlm.nih.gov/pubmed/12920120 <a href="http://www.ncbi.nlm.nih.gov/pubmed/12920120">Romero N, et al.</a> 114171688 He YY, et al. http://www.ncbi.nlm.nih.gov/pubmed/12870842 <a href="http://www.ncbi.nlm.nih.gov/pubmed/12870842">He YY, et al.</a> 114171689 Detweiler CD, et al. http://www.ncbi.nlm.nih.gov/pubmed/12126758 <a href="http://www.ncbi.nlm.nih.gov/pubmed/12126758">Detweiler CD, et al.</a> 114109065 Detweiler, Charles NIEHS Detweiler, Charles 0 114109064 Mason, Ronald NIEHS NIEHS Mason, Ronald (NIEHS) 1 114109064 Mason, Ronald NIEHS NIEHS Mason, Ronald (NIEHS) 1 114109065 Detweiler, Charles NIEHS Detweiler, Charles 0 114102283 Immunological Detection Of Free Radicals In Animals And In VItro E-186-2003-0 Research Material NIEHS 83739538 Choudhry, Vidita vidita.choudhry@nih.gov
United States of America Office of Technology Transfer and Development vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-2971] Immunological Detection of Free Radicals In Animals and In Vitro&body=Please send me information about technology [TAB-2971] Immunological Detection of Free Radicals In Animals and In Vitro. Choudhry, Vidita<br><a href="mailto:vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-2971] Immunological Detection of Free Radicals In Animals and In Vitro&body=Please send me information about technology [TAB-2971] Immunological Detection of Free Radicals In Animals and In Vitro.">vidita.choudhry@nih.gov</a><br> 114127156 RXXXXX 114148495 IMMUNOLOGICAL 114148496 Detection 114148497 FREE 114148498 Radicals 114148499 Animals 114148500 Vitro 114148501 Listed LPM Vepa as of 4/15/2015 114148502 Pre LPM working set 20150418 114148503 Post LPM Assignment Set 20150420 TAB-2962 114094599 Novel Genetic Tristetraprolin (TTP) Knock-in Mouse NIEHS Licensing, Research Materials Licensing Research Materials Perry Blackshear Tristetraprolin (TTP) is the prototype member of a small family of RNA binding proteins that bind to specific types of AU-rich elements in the 3'UTRs of target mRNAs and promote their rapid turnover. One of the targets destabilized by TTP is Tumor necrosis factor alpha (TNF). TNF has long been a target of anti-inflammatory drug development, in which recombinant protein molecules based on TNF antibodies or TNF receptors have been used to bind directly to TNF and inactivate it. These therapies are very expensive because of their recombinant origin, require frequent injections because they are proteins, run the risk of producing antibodies to themselves, and have other problems. This invention describes using the newly discovered endogenous anti-inflammatory protein, TTP, for possible therapeutic development. The inventors generated a novel genetic knock-in mouse line called the TTP?ARE mice, where the entire AU rich region (ARE) in the 3'UTR of TTP mRNA was deleted from the mouse genome. These mice were almost completely protected from the development of collagen antibody-induced arthritis, a standard model of immune-mediated arthritis that involves many of the cytokine systems. This finding supports the concept that general increases in “whole body” TTP might have beneficial consequences in certain inflammatory diseases if they could be achieved therapeutically. <ul> <li>This discovery can eventually lead to the development of small molecule drugs suitable for oral use, which would elevate TTP in cells and tissues of the body and achieve anti-inflammatory effects. Compare to the currently available biologics that have the same effect, the small molecule drug would be much less expensive and without disqualifying side effects. Furthermore, a potential TTP elevating agent would be expected to have beneficial effects by acting to reduce TNF production, as well as production of other cytokines shown to be important in the pathogenesis of inflammatory diseases, such as Il23 and Il17, whose mRNAs are both targets of TTP.</li> </ul> <ul> <li>The invention can primarily be used for developing screens for compounds that stimulate the accumulation of TTP in cells and tissues of the body, without disqualifying side effects.</li> </ul> Research Tool – Patent protection is not being pursued for this technology. 2022-03-08 2024-10-28 2024-10-28 2015-08-05 Cells, DISEASES, Increasing, INFLAMMATORY, Listed LPM Reichman as of 4/15/2015, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, THERAPY, TISSUES, Tristetraprolin, TTP, WIXXXX False True True NIHTT 37470483 Website Abstract 114109054 Blackshear, Perry NIEHS NIEHS Blackshear, Perry (NIEHS) 1 114109054 Blackshear, Perry NIEHS NIEHS Blackshear, Perry (NIEHS) 1 114101449 Increasing Tristetraprolin (TTP) In Cells And Tissues As Therapy For Inflammatory Diseases E-287-2014-0 Closed NIEHS 83739538 Choudhry, Vidita vidita.choudhry@nih.gov
United States of America Office of Technology Transfer and Development vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-2962] Novel Genetic Tristetraprolin (TTP) Knock-in Mouse&body=Please send me information about technology [TAB-2962] Novel Genetic Tristetraprolin (TTP) Knock-in Mouse. Choudhry, Vidita<br><a href="mailto:vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-2962] Novel Genetic Tristetraprolin (TTP) Knock-in Mouse&body=Please send me information about technology [TAB-2962] Novel Genetic Tristetraprolin (TTP) Knock-in Mouse.">vidita.choudhry@nih.gov</a><br> 114127087 WIXXXX 114144354 Increasing 114144355 Tristetraprolin 114144356 TTP 114144357 Cells 114144358 TISSUES 114144359 THERAPY 114144360 INFLAMMATORY 114144361 DISEASES 114144362 Listed LPM Reichman as of 4/15/2015 114144363 Pre LPM working set 20150418 114144364 Post LPM Assignment Set 20150420 TAB-2961 114095029 Mouse Strain CAR-KO C3H/HeNCrl, Deletion of Nuclear Xenobiotic Receptor CAR NIEHS Licensing, Research Materials Licensing Research Materials Masahiko Negishi CAR (nuclear constitutive active receptor) is a member of the nuclear receptor superfamily, and is a key regulator of xenobiotic and endobiotic metabolism. It is primarily responsible for sensing foreign toxic substances and in response up regulating the expression of proteins involved in the detoxification and clearance of these substances from the body. CAR is constitutively active in the absence of a ligand but is regulated by both agonists and inverse agonists. The ligand binding results in the translocation of this protein to the nucleus, where it activates or represses target gene transcription. These ligands include bilirubin, a variety of foreign compounds, steroid hormones, and prescription drugs. Although the nuclear orphan constitutive active receptor (CAR) has been identified as a key transcription factor that regulates the induction of CYP2B, the full scope of CAR-regulated genes still remains a major question. To understand the molecular and cellular mechanisms of these complex processes and enable prediction/prevention nuclear receptor-mediated diseases after environmental exposures, the NIEHS inventors generated a mouse strain that has lost the constitutive CAR function. The CAR KO mouse can be used to investigate CAR-regulated genes and cellular mechanisms. <ul> <li>The CAR KO mouse can be used to investigate CAR-regulated genes and cellular mechanisms. Once CAR-mediated pathways of tumor promotion are defined at the molecular level, the receptor can be useful as a drug target for hepatocellular carcinoma prevention.</li> </ul> Research Tool – Patent protection is not being pursued for this technology. 2022-03-08 2024-10-28 2024-10-28 2015-08-05 ACXXXX, C3H/HeNCrl, CAR, CAR-KO, Deletion, Listed LPM Contreras as of 4/15/2015, Mouse, nuclear, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, RECEPTOR, Strain, WIXXXX, Xenobiotic False True True NIHTT 37470483 Website Abstract 114170514 Yamamoto Y, et al. http://www.ncbi.nlm.nih.gov/pubmed/15492232 <a href="http://www.ncbi.nlm.nih.gov/pubmed/15492232">Yamamoto Y, et al.</a> 114109053 Negishi, Masahiko NIEHS NIEHS Negishi, Masahiko (NIEHS) 1 114109053 Negishi, Masahiko NIEHS NIEHS Negishi, Masahiko (NIEHS) 1 114099330 Mouse Strain CAR-KO C3H/HeNCrl, Deletion Of Nuclear Xenobiotic Receptor CAR E-191-2014-0 Research Material NIEHS 83714317 Devany, John john.devany@nih.gov
United States of America Office of Technology Transfer and Development john.devany@nih.gov?subject=Web Inquiry on [TAB-2961] Mouse Strain CAR-KO C3H/HeNCrl, Deletion of Nuclear Xenobiotic Receptor CAR&body=Please send me information about technology [TAB-2961] Mouse Strain CAR-KO C3H/HeNCrl, Deletion of Nuclear Xenobiotic Receptor CAR. Devany, John<br><a href="mailto:john.devany@nih.gov?subject=Web Inquiry on [TAB-2961] Mouse Strain CAR-KO C3H/HeNCrl, Deletion of Nuclear Xenobiotic Receptor CAR&body=Please send me information about technology [TAB-2961] Mouse Strain CAR-KO C3H/HeNCrl, Deletion of Nuclear Xenobiotic Receptor CAR.">john.devany@nih.gov</a><br> 114127085 ACXXXX 114127086 WIXXXX 114140329 Mouse 114140330 Strain 114140331 CAR-KO 114140332 C3H/HeNCrl 114140333 Deletion 114140334 nuclear 114140335 Xenobiotic 114140336 RECEPTOR 114140337 CAR 114140338 Listed LPM Contreras as of 4/15/2015 114140339 Pre LPM working set 20150418 114144353 Post LPM Assignment Set 20150420 TAB-2960 114094915 Leucine Rich Repeats and Calponin Homology Containing Protein 4 (Lrch4)-deficient Mouse NIEHS Licensing, Research Materials Licensing Research Materials Jim Aloor, Michael Fessler Leucine rich repeats and calponin homology containing protein 4 (Lrch4) is a gene that encodes a protein predicted to have a C-terminal transmembrane domain, a calponin homology domain, and 5-8 leucine rich repeats (LRRs). We silenced Lrch4 in RAW 264.7 macrophages as well as CD14-MD2-TLR4-HEK293 cells and found that Lrch4 knockdown attenuates responsiveness of cells to LPS and other pathogen-associated molecules. These findings suggest that Lrch4 is a regulator of the innate immune response. In order to facilitate more physiologic in vivo investigations of the function and disease-relevant roles of Lrch4, we produced a Lrch4 ene-deleted mouse. The Lrch4-null mouse will be tested in a wide array of pro-inflammatory and host defense model exposures. In addition, given that our mouse has a floxed Lrch4 allele and that Lrch4 expression is fairly ubiquitous, future tissue-specific Lrch4-deficient murine strains can be generated (e.g., myeloid-specific [LysM-Cre], intestinal epithelial-specific [Villin-Cre], liverspecific [Alb-Crej,etc.). In addition, we have a Lrch4 mouse line with a B-galactosidase construct in the Lrch4 locus Lrch4 Tn1/+, which can be used for expression profiling of Lrch4. <ul> <li>To our knowledge, there are no existing Lrch4-deficient organisms available for experimental study. Thus, our mouse (as well as primary cells that can be harvested from it [macrophages, etc.]) will greatly facilitate mechanistic and translational studies of Lrch4 in the inflammatory response and other pathophysiologic pathways and disease models.</li> </ul> <ul> <li>If Lrch4-null mice have an altered phenotype in response to inflammatory challenges, this could create novel opportunities for: 1) development of Lrch4-targeting biologics; 2) development of Lrch4-targeting small molecules; 3) investigation of the relationship of LRCH4 polymorphisms to human disease; and 4) development of potential Lrch4-related biomarkers (eg, leukocyte expression levels of Lrch4). The Lrch4-null mouse line also itself represents a novel research tool that will foreseeably be of wide interest for testing in additional disease models.</li> </ul> Research Tool – Patent protection is not being pursued for this technology. 2022-03-08 2024-10-28 2024-10-28 2015-08-05 Generation, Listed LPM Contreras as of 4/15/2015, Lrch4-deficient, Murine, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, RXXXXX, Strain, WIXXXX False True True NIHTT 37470483 Website Abstract 114109052 Aloor, Jim NIEHS NIEHS Aloor, Jim (NIEHS) 0 114109051 Fessler, Michael NIEHS NIEHS Fessler, Michael (NIEHS) 1 114109051 Fessler, Michael NIEHS NIEHS Fessler, Michael (NIEHS) 1 114109052 Aloor, Jim NIEHS NIEHS Aloor, Jim (NIEHS) 0 114099392 Generation Of A Lrch4-deficient Murine Strain E-179-2014-0 Research Material NIEHS 83739538 Choudhry, Vidita vidita.choudhry@nih.gov
United States of America Office of Technology Transfer and Development vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-2960] Leucine Rich Repeats and Calponin Homology Containing Protein 4 (Lrch4)-deficient Mouse&body=Please send me information about technology [TAB-2960] Leucine Rich Repeats and Calponin Homology Containing Protein 4 (Lrch4)-deficient Mouse. Choudhry, Vidita<br><a href="mailto:vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-2960] Leucine Rich Repeats and Calponin Homology Containing Protein 4 (Lrch4)-deficient Mouse&body=Please send me information about technology [TAB-2960] Leucine Rich Repeats and Calponin Homology Containing Protein 4 (Lrch4)-deficient Mouse.">vidita.choudhry@nih.gov</a><br> 114127083 RXXXXX 114127084 WIXXXX 114131571 Generation 114131572 Lrch4-deficient 114131573 Murine 114131574 Strain 114131575 Listed LPM Contreras as of 4/15/2015 114131576 Pre LPM working set 20150418 114140328 Post LPM Assignment Set 20150420 TAB-2959 114095804 Estrogen-related Receptor (ERR) and Proliferator-activated Receptor Gamma Coactivator (PGC)/ERR Reporter Stable Cell Lines NIEHS Licensing, Research Materials Licensing Research Materials Negin Martin, Christina Teng The estrogen-related receptor alpha (ERRalpha) and proliferator-activated-receptor-gamma coactivator-1alpha (PGC-1alpha) play major roles in transcriptional control of cellular energy metabolism. In particular ERRs are required for the response to various environmental challenges that require high energy levels by the organism. As central regulators of energy homeostasis, ERRs may also implicate in the etiology of metabolic disorders, such as type 2 diabetes and metabolic syndrome. This invention, using a lentivirus delivery system, generated HEK293T cells lines stably expressing a Luciferase reporter controlled by a sensitive estrogen response element (pGreenFire-AAB) alone or in combination with human PGC-1alpha (pCDH-510-hPGC) at the level that may reflect the physiologically acceptable state of the cell. The ERR reporter cell line detects its endogenous ERR activity using the coactivator expressing in the 293T cells, while PGC/ERR reporter cell line measures the ERR activity in the presence of its specific coregulator, PGC. The stable clonal cell lines established responded to the known antagonist, XCT790, at 10 µM level. XCT790 inhibits ERRalpha activity by disrupt its interaction with coactivator and its stability. <ul> <li>PGC/ERR pathway plays an important role in the transcriptional control of cellular energy metabolism. It is required in response to various environmental challenges that require high energy levels by the organism. This pathway implicated in the etiology of metabolic disorders, such as type 2 diabetes and metabolic syndrome.</li> </ul> <ul> <li>Screening and identifying commercial, industrial or natural products for their effects on energy balance pathways.</li> <li>Research on endocrine function or identify endocrine disruptor chemical (e.g. the Tox21 HTS platform).</li> </ul> Research Tool – Patent protection is not being pursued for this technology. 2022-03-08 2024-10-28 2024-10-28 2015-08-03 \Related, Cell, COACTIVATOR, ERR, estrogen, Gamma, Lines, PGC/ERR, Proliferator-activated, RECEPTOR, RELATED, -related, REPORTER, STABLE, WIXXXX False True In vitro/in vivo data available True NIHTT 37470483 Website Abstract 114109050 Martin, Negin NIEHS NIEHS Martin, Negin (NIEHS) 0 114109049 Teng, Christina NIEHS NIEHS Teng, Christina (NIEHS) 1 114109049 Teng, Christina NIEHS NIEHS Teng, Christina (NIEHS) 1 114109050 Martin, Negin NIEHS NIEHS Martin, Negin (NIEHS) 0 114099841 Estrogen -related Receptor (ERR) And Proliferator-activated Receptor Gamma Coactivator (PGC)/ERR Reporter Stable Cell Lines E-224-2015-0 Research Material NIEHS 83739538 Choudhry, Vidita vidita.choudhry@nih.gov
United States of America Office of Technology Transfer and Development vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-2959] Estrogen-related Receptor (ERR) and Proliferator-activated Receptor Gamma Coactivator (PGC)/ERR Reporter Stable Cell Lines&body=Please send me information about technology [TAB-2959] Estrogen-related Receptor (ERR) and Proliferator-activated Receptor Gamma Coactivator (PGC)/ERR Reporter Stable Cell Lines. Choudhry, Vidita<br><a href="mailto:vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-2959] Estrogen-related Receptor (ERR) and Proliferator-activated Receptor Gamma Coactivator (PGC)/ERR Reporter Stable Cell Lines&body=Please send me information about technology [TAB-2959] Estrogen-related Receptor (ERR) and Proliferator-activated Receptor Gamma Coactivator (PGC)/ERR Reporter Stable Cell Lines.">vidita.choudhry@nih.gov</a><br> 114126639 WIXXXX 114131557 -related 114131558 \Related 114131559 estrogen 114131560 RELATED 114131561 RECEPTOR 114131562 ERR 114131563 Proliferator-activated 114131564 Gamma 114131565 COACTIVATOR 114131566 PGC/ERR 114131567 REPORTER 114131568 STABLE 114131569 Cell 114131570 Lines TAB-2958 114095672 Rabbit Polyclonal Antiserum to the Nitrone Spin Trap 5,5-dimethyl-1-pyrroline N-oxide (DMPO) NIEHS Licensing, Research Materials Licensing Research Materials Marilyn (Estate of) Ehrenshaft, Ronald Mason Biological radicals resulted from oxidative stress has been implicated in human diseases, such as cancer and aging. There is, however, a paucity of reliable methods for <em>in vivo</em> or <em>ex vivo</em> detection of either radical formation, the end-products of radical formation or susceptibility for radical formation. The Rabbit polyclonal anti-DMPO can be used to detect the stable nitrone end-product of protein and DNA radicals in ELISA assays, blot analyses and confocal microscopy. This rabbit polyclonal anti-DMPO antiserum will replace a previously licensed one which is no longer available (E-186-2003). The availability of anti-DMPO from three different sources will greatly expand the ability of researchers to use anti-DMPO in conjunction with other antibodies. <ul> <li>DMPO is one of the most frequently used spin traps to detect free radicals and has been cited in over 1000 articles (PubMed). The availability of anti-DMPO of different origins (rabbit, mouse) will increase the ability of the researcher to use anti-DMPO in conjunction with other antibodies of interest.</li> </ul> <ul> <li>The Rabbit polyclonal anti-DMPO can be used to detect the stable nitrone end-product of protein and DNA radicals in ELISA assays, blot analyses and confocal microscopy.</li> </ul> Research Tool – Patent protection is not being pursued for this technology. 2022-03-08 2024-10-28 2024-10-28 2015-08-03 5, 5-dimethyl-1-pyrroline, Antiserum, DMPO, Listed LPM Vepa as of 4/15/2015, Nitrone, N-oxide, polyclonal, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, rabbit, SPIN, TRAP, WIXXXX False True True NIHTT 37470483 Website Abstract 114107906 Ehrenshaft, Marilyn (Estate of) NIEHS NIEHS Ehrenshaft, Marilyn (Estate of) (NIEHS) 0 114107905 Mason, Ronald NIEHS NIEHS Mason, Ronald (NIEHS) 1 114107905 Mason, Ronald NIEHS NIEHS Mason, Ronald (NIEHS) 1 114107906 Ehrenshaft, Marilyn (Estate of) NIEHS NIEHS Ehrenshaft, Marilyn (Estate of) (NIEHS) 0 114099713 Rabbit Polyclonal Antiserum To The Nitrone Spin Trap 5,5-dimethyl-1-pyrroline N-oxide (DMPO) E-109-2013-0 Research Material NIEHS 83739538 Choudhry, Vidita vidita.choudhry@nih.gov
United States of America Office of Technology Transfer and Development vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-2958] Rabbit Polyclonal Antiserum to the Nitrone Spin Trap 5,5-dimethyl-1-pyrroline N-oxide (DMPO)&body=Please send me information about technology [TAB-2958] Rabbit Polyclonal Antiserum to the Nitrone Spin Trap 5,5-dimethyl-1-pyrroline N-oxide (DMPO). Choudhry, Vidita<br><a href="mailto:vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-2958] Rabbit Polyclonal Antiserum to the Nitrone Spin Trap 5,5-dimethyl-1-pyrroline N-oxide (DMPO)&body=Please send me information about technology [TAB-2958] Rabbit Polyclonal Antiserum to the Nitrone Spin Trap 5,5-dimethyl-1-pyrroline N-oxide (DMPO).">vidita.choudhry@nih.gov</a><br> 114126641 WIXXXX 114131546 Antiserum 114131547 Nitrone 114131548 SPIN 114131549 TRAP 114131550 5 114131551 5-dimethyl-1-pyrroline 114131552 N-oxide 114131553 DMPO 114131554 Listed LPM Vepa as of 4/15/2015 114131555 Pre LPM working set 20150418 114131556 Post LPM Assignment Set 20150420 114131592 rabbit 114131593 polyclonal TAB-2957 114095989 Chicken Polyclonal Antiserum to the Nitrone Spin Trap 5,5-dimethyl-1-pyrroline N-oxide (DMPO) NIEHS Licensing, Research Materials Licensing Research Materials Marilyn (Estate of) Ehrenshaft, Ronald Mason Biological radicals resulted from oxidative stress has been implicated in human diseases, such as cancer and aging. There is, however, a paucity of reliable methods for <em>in vivo</em> or <em>ex vivo</em> detection of either radical formation, the end-products of radical formation or susceptibility for radical formation. The chicken polyclonal anti-DMPO can be used to detect the stable nitrone end-product of protein and DNA radicals in ELISA assays, blot analyses and confocal microscopy. This chicken polyclonal anti-DMPO antiserum will supplement both the mouse monoclonal anti-DMPO and the rabbit polyclonal anti-DMPO. The availability of anti-DMPO from three different sources will greatly expand the ability of researchers to use anti-DMPO in conjunction with other antibodies. <ul> <li>DMPO is one of the most frequently used spin traps to detect free radicals and has been cited in over 1000 articles (PubMed). The availability of anti-DMPO of different origins (rabbit, mouse, chicken) will increase the ability of the researcher to use anti-DMPO in conjuction with other antibodies of interest.</li> </ul> <ul> <li>The chicken polyclonal anti-DMPO can be used to detect the stable nitrone end-product of protein and DNA radicals in ELISA assays, blot analyses and confocal microscopy.</li> </ul> Research Tool – Patent protection is not being pursued for this technology. 2022-03-08 2024-10-28 2024-10-28 2015-08-03 5, 5-dimethyl-1-pyrroline, Antiserum, chicken, DMPO, Listed LPM Vepa as of 4/15/2015, Nitrone, N-oxide, polyclonal, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, SPIN, TRAP, WIXXXX False True True NIHTT 37470483 Website Abstract 114103331 Ehrenshaft, Marilyn (Estate of) NIEHS NIEHS Ehrenshaft, Marilyn (Estate of) (NIEHS) 0 114103330 Mason, Ronald NIEHS NIEHS Mason, Ronald (NIEHS) 1 114103330 Mason, Ronald NIEHS NIEHS Mason, Ronald (NIEHS) 1 114103331 Ehrenshaft, Marilyn (Estate of) NIEHS NIEHS Ehrenshaft, Marilyn (Estate of) (NIEHS) 0 114100737 Chicken Polyclonal Antiserum To The Nitrone Spin Trap 5,5-dimethyl-1-pyrroline N-oxide (DMPO) E-108-2013-0 Research Material NIEHS 83739538 Choudhry, Vidita vidita.choudhry@nih.gov
United States of America Office of Technology Transfer and Development vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-2957] Chicken Polyclonal Antiserum to the Nitrone Spin Trap 5,5-dimethyl-1-pyrroline N-oxide (DMPO)&body=Please send me information about technology [TAB-2957] Chicken Polyclonal Antiserum to the Nitrone Spin Trap 5,5-dimethyl-1-pyrroline N-oxide (DMPO). Choudhry, Vidita<br><a href="mailto:vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-2957] Chicken Polyclonal Antiserum to the Nitrone Spin Trap 5,5-dimethyl-1-pyrroline N-oxide (DMPO)&body=Please send me information about technology [TAB-2957] Chicken Polyclonal Antiserum to the Nitrone Spin Trap 5,5-dimethyl-1-pyrroline N-oxide (DMPO).">vidita.choudhry@nih.gov</a><br> 114123348 WIXXXX 114131579 chicken 114131580 polyclonal 114131581 Antiserum 114131582 Nitrone 114131583 SPIN 114131584 TRAP 114131585 5 114131586 5-dimethyl-1-pyrroline 114131587 N-oxide 114131588 DMPO 114131589 Listed LPM Vepa as of 4/15/2015 114131590 Pre LPM working set 20150418 114131591 Post LPM Assignment Set 20150420 TAB-2937 114097088 Real-time RT-PCR assay for Detection of Live Attenuated Influenza Vaccine for A and B Viruses CDC Diagnostics, Infectious Disease, Licensing, Research Equipment, Research Materials, Therapeutics Diagnostics Infectious Disease Licensing Research Equipment Research Materials Therapeutics LaShondra Berman, Stephen Lindstrom, Bo Shu, Christine Warnes, Kai-Hui Wu Upon intranasal vaccination, live attenuated influenza vaccine (LAIV) viruses may replicate within the nose for several days. Current clinical diagnostic tests cannot distinguish between LAIV viruses and multiple influenza viruses in recently inoculated patients that present with respiratory symptoms. This poses a problem for the diagnosis and treatment of patients with respiratory symptoms, as these symptoms may not be caused by influenza. CDC researchers have developed a real-time RT-PCR assay to detect the presence of LAIV viruses. This test is rapid, accurate, and provides diagnostic data about whether patient respiratory symptoms are due to wild-type influenza or LAIV viruses. Detection of LAIV viruses with this assay will allow practitioners to investigate other pathogens as causative agents for a patient's respiratory symptoms. <ul> <li>Ablility to distinguish between LAIV viruses A/B and influenza in patients with respiratory symptoms, thereby allowing for the pursuit of other potential pathogens (if symptoms are caused by LAIV instead of influenza).</li> <li>Can detect LAIV A and B viruses.</li> </ul> <ul> <li>Diagnostic assay for the discrimination of LAIV A and B viruses from the influenza virus.</li> </ul> 2022-10-19 2024-10-28 2024-10-28 2015-05-19 assay, Assays., Attenuated, CDC Docket Import, CDC Docket Import CDC Prosecuting, CDCRM, DA4XXX, Detection, Human, Including, INFLUENZA, LAIV, LAIV-A, LAIV-B, Listed LPM Surabian as of 4/15/2015, Live, NCIRD-ID, PCR, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, REAL-TIME, respiratory, RT-PCR, SPECIMENS, States., United, Vaccine, Viruses, VLXXXX, WBXXXX, WIXXXX, XEXXXX, XHXXXX, YDXXXX False True In vivo data available (human) True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114172257 Shcherbik S, et al. http://www.ncbi.nlm.nih.gov/pubmed/24056261 <a href="http://www.ncbi.nlm.nih.gov/pubmed/24056261">Shcherbik S, et al.</a> 114109034 Lindstrom, Stephen CDC - DIR CDC Lindstrom, Stephen (CDC) 0 114109035 Wu, Kai-Hui CDC - DIR CDC Wu, Kai-Hui (CDC) 0 114109036 Berman, LaShondra CDC - DIR CDC Berman, LaShondra (CDC) 0 114109037 Warnes, Christine CDC - DIR CDC Warnes, Christine (CDC) 0 114109033 Shu, Bo CDC - DIR CDC Shu, Bo (CDC) 1 114109033 Shu, Bo CDC - DIR CDC Shu, Bo (CDC) 1 114109034 Lindstrom, Stephen CDC - DIR CDC Lindstrom, Stephen (CDC) 0 114109035 Wu, Kai-Hui CDC - DIR CDC Wu, Kai-Hui (CDC) 0 114109036 Berman, LaShondra CDC - DIR CDC Berman, LaShondra (CDC) 0 114109037 Warnes, Christine CDC - DIR CDC Warnes, Christine (CDC) 0 114102272 The Real-time RT-PCR Assay For Detection Of Live Attenuated Influenza Vaccine (LAIV) Viruses In Human Respiratory Specimens In The United States. Including LAIV-A And LAIV-B Assays. E-560-2013-0 Closed Centers for Disease Control and Prevention (CDC) 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2937] Real-time RT-PCR assay for Detection of Live Attenuated Influenza Vaccine for A and B Viruses&body=Please send me information about technology [TAB-2937] Real-time RT-PCR assay for Detection of Live Attenuated Influenza Vaccine for A and B Viruses. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2937] Real-time RT-PCR assay for Detection of Live Attenuated Influenza Vaccine for A and B Viruses&body=Please send me information about technology [TAB-2937] Real-time RT-PCR assay for Detection of Live Attenuated Influenza Vaccine for A and B Viruses.">jonathan.motley@nih.gov</a><br> 114162540 E-560-2013-0 E-560-2013-0-PCT-02 DETECTION OF LIVE ATTENUATED INFLUENZA VACCINE VIRUSES PCT Patent Cooperation Treaty PCT/US2016/066370 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2016/066370<br />Filed on 2016-12-13<br />Status: Expired 114165485 E-560-2013-0 E-560-2013-0-US-01 Detection Of Live Attenuated Influenza Vaccine Viruses PRV US 62/267,085 Abandoned US <br />Provisional (PRV) 62/267,085<br />Filed on 2015-12-14<br />Status: Abandoned 114168668 E-560-2013-0 E-560-2013-0-US-03 Detection of Live Attenuated influenza vaccine viruses National Stage US 16/062,483 Abandoned US <br />National Stage 16/062,483<br />Filed on 2018-06-14<br />Status: Abandoned 114127023 VLXXXX 114127024 DA4XXX 114127025 WBXXXX 114127026 WIXXXX 114127027 XEXXXX 114127028 XHXXXX 114127029 YDXXXX 114148325 REAL-TIME 114148326 RT-PCR 114148327 assay 114148328 Detection 114148329 Live 114148330 Attenuated 114148331 INFLUENZA 114148332 Vaccine 114148333 LAIV 114148334 Viruses 114148335 Human 114148336 respiratory 114148337 SPECIMENS 114148338 United 114148339 States. 114148340 Including 114148341 LAIV-A 114148342 LAIV-B 114148343 Assays. 114148344 CDC Docket Import 114148345 CDC Docket Import CDC Prosecuting 114148346 PCR 114148347 CDCRM 114148348 NCIRD-ID 114148349 Listed LPM Surabian as of 4/15/2015 114148350 Pre LPM working set 20150418 114148351 Post LPM Assignment Set 20150420 TAB-2935 114097086 A Novel Therapeutic Vector for Hemoglobin Disorders NHLBI Cardiology, Collaboration, Dental, Endocrinology, Infectious Disease, Oncology, Ophthalmology, Therapeutics Cardiology Collaboration Dental Endocrinology Infectious Disease Oncology Ophthalmology Therapeutics John Tisdale, Naoya Uchida Investigators at the National Heart, Lung, and Blood Institute have designed a novel lentiviral vector as a potential gene therapy for sickle cell anemia and beta-thalassemia. The novel lentiviral vector encodes the beta-globin gene in a forward orientation and can produce 5-10 fold higher viral titer and 4-10 fold higher gene transfer efficiency to hematopoietic stem cells than reverse-oriented lentiviral vectors. In vivo studies conducted in rhesus macaques show beta-globin production after transplantation with this novel lentiviral vector. This technology could provide an alternative therapy for patients suffering from blood disorders associated with beta-globin gene mutations. <ul> <li>Increased viral titers</li> <li>Increased transduction efficiency</li> <li>Large scale vector production</li> </ul> <ul> <li>Gene therapy</li> </ul> The National Heart, Lung and Blood Institute is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize this technology. For collaboration opportunities, please contact Denise Crooks at <a href="mailto:crooksd@mail.nih.gov">crooksd@mail.nih.gov</a>. 2022-03-08 2024-10-28 2024-10-28 2015-05-15 Development, DISORDERS, Forward-oriented, Generation, hemoglobin, Listed LPM Maddox as of 4/15/2015, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, therapeutic, Therpeutic, Vector, VPXXXX, WJXXXX, XEXXXX, YAXXXX, YBXXXX, YCXXXX False True <ul> <li>Early-stage</li> <li>In vitro data available</li> <li>In vivo data available (animal)</li> </ul> True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114109031 Tisdale, John National Heart, Lung, and Blood Institute (NHLBI) NHLBI Tisdale, John (NHLBI) 0 114109030 Uchida, Naoya National Heart, Lung, and Blood Institute (NHLBI) NHLBI Uchida, Naoya (NHLBI) 1 114109030 Uchida, Naoya National Heart, Lung, and Blood Institute (NHLBI) NHLBI Uchida, Naoya (NHLBI) 1 114109031 Tisdale, John National Heart, Lung, and Blood Institute (NHLBI) NHLBI Tisdale, John (NHLBI) 0 114101875 Development Of A New Generation, Forward-oriented Therapeutic Vector For Hemoglobin Disorders E-165-2014-1 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 114102269 Development Of A New Generation, Forward-oriented Therapeutic Vector For Hemoglobin Disorders E-165-2014-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 89788013 Kolesnitchenko, Vincent vk5q@nih.gov
United States of America Office of Technology Transfer and Development vk5q@nih.gov?subject=Web Inquiry on [TAB-2935] A Novel Therapeutic Vector for Hemoglobin Disorders&body=Please send me information about technology [TAB-2935] A Novel Therapeutic Vector for Hemoglobin Disorders. Kolesnitchenko, Vincent<br><a href="mailto:vk5q@nih.gov?subject=Web Inquiry on [TAB-2935] A Novel Therapeutic Vector for Hemoglobin Disorders&body=Please send me information about technology [TAB-2935] A Novel Therapeutic Vector for Hemoglobin Disorders.">vk5q@nih.gov</a><br> 114159933 E-165-2014-1 E-165-2014-1-PCT-01 Lentiviral Vector for Treating Hemoglobin Disorders PCT COMB Patent Cooperation Treaty PCT/US2015/045358 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2015/045358<br />Filed on 2015-08-14<br />Status: Expired 114167041 E-165-2014-1 E-165-2014-1-US-02 LELENTIVIRAL VECTOR FOR TREATING HEMOGLOBIN DISORDERSNTIVIRAL VECTOR FOR TREATING HEMOGLOBIN DISORDERS National Stage US 10,543,257 15/510,014 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10543257 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10543257">10,543,257</a><br />Filed on 2017-03-09<br />Status: Issued 114168148 E-165-2014-0 E-165-2014-0-US-01 Lentiviral Vector for Treating Hemoglobin Disorders PRV US 62/048,881 Abandoned US <br />Provisional (PRV) 62/048,881<br />Filed on 2014-09-11<br />Status: Abandoned 114168948 E-165-2014-1 E-165-2014-1-US-10 LENTIVIRAL VECTOR FOR TREATING HEMOGLOBIN DISORDERS DIV US 11,813,316 16/717,420 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11813316 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11813316">11,813,316</a><br />Filed on 2019-12-17<br />Status: Issued 114127001 VPXXXX 114127002 WJXXXX 114127003 XEXXXX 114127004 YAXXXX 114127005 YBXXXX 114127006 YCXXXX 114148302 Development 114148303 Generation 114148304 Forward-oriented 114148305 Therpeutic 114148306 Vector 114148307 hemoglobin 114148308 DISORDERS 114148309 therapeutic 114148310 Listed LPM Maddox as of 4/15/2015 114148311 Pre LPM working set 20150418 114148312 Post LPM Assignment Set 20150420 TAB-2907 114097068 T Cell-Based Adoptive Transfer Immunotherapy for Polyomavirus-Associated Pathologies NHLBI Antibodies, Collaboration, Immunology, Infectious Disease, Licensing, Oncology, Therapeutics Antibodies Collaboration Immunology Infectious Disease Licensing Oncology Therapeutics John Barrett, Christopher Buck, Dhanalakshmi (Donna) Chinnasamy, Pawel Muranski Available for licensing are methods to generate T cells responsive to multiple polyomaviruses. The resulting T cell populations could be useful in treating immunosuppressed individuals with polyomavirus infections or polyomavirus-associated pathologies such as Merkel cell carcinoma (MCC), polyomavirus-associated nephropathy (PVAN), hemorrhagic cystitis, progressive multifocal leukoencephalopathy (PML), and trichodysplasia spinulosa (TS). The methods could also be used to restore polyomavirus-specific immunity in immunocompromised individuals. <ul> <li>Methods allow development of polyomavirus antigen-specific T cells.</li> </ul> <ul> <li>Immunotherapy for immunosuppressed individuals with polyomavirus-associated pathologies.</li> </ul> The National Heart, Lung, and Blood Institute is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize methods to generate T cells responsive to multiple polyomaviruses. For collaboration opportunities, please contact Dr. Vincent Kolesnitchenko at <a href="mailto:kolesniv@nhlbi.nih.gov">kolesniv@nhlbi.nih.gov</a>. 2022-08-30 2024-10-28 2024-10-28 2015-02-20 adoptive transfer, BKV, CB2AXX, CB6XXX, Immunotherapy, Merkel, MKV, Patent Category - Biotechnology, Polyoma, polyomavirus, viral, virus, VLXXXX, WJXXXX, XAXXXX, XEXXXX, YAXXXX, YBXXXX False True <ul> <li>Early-stage</li> <li>In vitro data available</li> </ul> True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract E-168-2011-0 E-549-2013-0 114108968 Chinnasamy, Dhanalakshmi (Donna) National Heart, Lung, and Blood Institute (NHLBI) NHLBI Chinnasamy, Dhanalakshmi (Donna) (NHLBI) 0 114108969 Muranski, Pawel National Heart, Lung, and Blood Institute (NHLBI) Muranski, Pawel 0 114108970 Buck, Christopher NCI - CCR NCI Buck, Christopher (NCI) 0 114108967 Barrett, John National Heart, Lung, and Blood Institute (NHLBI) NHLBI Barrett, John (NHLBI) 1 114108967 Barrett, John National Heart, Lung, and Blood Institute (NHLBI) NHLBI Barrett, John (NHLBI) 1 114108968 Chinnasamy, Dhanalakshmi (Donna) National Heart, Lung, and Blood Institute (NHLBI) NHLBI Chinnasamy, Dhanalakshmi (Donna) (NHLBI) 0 114108969 Muranski, Pawel National Heart, Lung, and Blood Institute (NHLBI) Muranski, Pawel 0 114108970 Buck, Christopher NCI - CCR NCI Buck, Christopher (NCI) 0 114102249 Generation Of T Cells Specific For A Broad Range Of Polyoma Virus Types For Adoptive Therapy E-166-2014-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI), NCI 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-2907] T Cell-Based Adoptive Transfer Immunotherapy for Polyomavirus-Associated Pathologies&body=Please send me information about technology [TAB-2907] T Cell-Based Adoptive Transfer Immunotherapy for Polyomavirus-Associated Pathologies. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-2907] T Cell-Based Adoptive Transfer Immunotherapy for Polyomavirus-Associated Pathologies&body=Please send me information about technology [TAB-2907] T Cell-Based Adoptive Transfer Immunotherapy for Polyomavirus-Associated Pathologies.">shmilovm@nih.gov</a><br> 114163132 E-166-2014-0 E-166-2014-0-PCT-02 T Cells and Dendritic Cells for Polyomavirus Therapy PCT Patent Cooperation Treaty PCT/US2015/059021 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2015/059021<br />Filed on 2015-11-04<br />Status: Expired 114168080 E-166-2014-0 E-166-2014-0-US-01 T CELLS AND DENDRITIC CELLS FOR POLYOMAVIRUS THERAPY PRV US 62/075,726 Abandoned US <br />Provisional (PRV) 62/075,726<br />Filed on 2014-11-05<br />Status: Abandoned 114126826 CB2AXX 114126827 CB6XXX 114126828 VLXXXX 114126829 WJXXXX 114126830 XAXXXX 114126831 XEXXXX 114126832 YAXXXX 114126833 YBXXXX 114148087 Immunotherapy 114148088 BKV 114148089 Merkel 114148090 viral 114148091 Polyoma 114148092 virus 114148093 Patent Category - Biotechnology 114148094 polyomavirus 114148095 adoptive transfer 114148096 MKV TAB-2899 114097060 Highly Sensitive Tethered-Bead Immune Sandwich Assay NHLBI Antibodies, Cardiology, Consumer Products, Diagnostics, Immunology, Infectious Disease, Licensing, Oncology, Research Equipment, Research Materials, Therapeutics Antibodies Cardiology Consumer Products Diagnostics Immunology Infectious Disease Licensing Oncology Research Equipment Research Materials Therapeutics Zhenyu Li, Keir Neuman, Jonathan Silver This technology is a highly sensitive tethered-bead immune sandwich assay. Analyte molecules are captured between two antibodies, a capture antibody and a detection antibody. The capture antibody on a micron-size bead binds analyte from a sample fluid. The bead-captured analyte is then exposed to a “detection” antibody that binds to the bead-captured analyte, forming a “sandwich”. The sandwiched analyte-bead complex then connects to a flexible polymer (such as DNA) anchored on a solid surface to form tethered particles. Binding the analyte-bead complex to a flexible polymer forms tethered particles and may be done, for example, by streptavidin biotin. Motion of the tethered beads easily identifies bound analyte. The tethered beads are quantified using low-magnification light microscopy. Prior enhanced sensitivity tethered bead technologies require expensive and cumbersome detection equipment. This assay is inherently single molecule, low background, and works with simple inexpensive imaging formats, but is automatable and potentially adaptable to portable technologies. A prototype design using prostate specific antigen (PSA) shows detection sensitivity of ~.03ng/ml, compared with normal PSA sensitivity of ~< 4ng/ml. Design refinements further improve sensitivities. <ul> <li>Highly sensitive single molecule adaptable format, specific, low background, inexpensive, simple to use, automatable for image analysis.</li> </ul> <ul> <li>Diagnostics and research.</li> </ul> 2022-03-08 2024-10-28 2024-10-28 2015-01-13 AA3AXX, assay, IMMUNE, Sandwich, TETHERED-BEAD, VCXXXX, VDXXXX, VJXXXX, VKXXXX, VLXXXX, VOXXXX, WBXXXX, XAXXXX, XGXXXX, XHXXXX, YAXXXX, YFXXXX False True <ul> <li>Early-stage</li> <li>Prototype</li> </ul> True 52406768 Discovery 52406768 NIHTT 37470483 Website Abstract 114172223 Silver J, et al. http://www.ncbi.nlm.nih.gov/pubmed/25064819 <a href="http://www.ncbi.nlm.nih.gov/pubmed/25064819">Silver J, et al.</a> 114108938 Neuman, Keir National Heart, Lung, and Blood Institute (NHLBI) NHLBI Neuman, Keir (NHLBI) 0 114108939 Li, Zhenyu George Washington University Li, Zhenyu 0 114108937 Silver, Jonathan National Heart, Lung, and Blood Institute (NHLBI) NHLBI Silver, Jonathan (NHLBI) 1 114108937 Silver, Jonathan National Heart, Lung, and Blood Institute (NHLBI) NHLBI Silver, Jonathan (NHLBI) 1 114108938 Neuman, Keir National Heart, Lung, and Blood Institute (NHLBI) NHLBI Neuman, Keir (NHLBI) 0 114108939 Li, Zhenyu George Washington University Li, Zhenyu 0 114102233 TETHERED-BEAD, IMMUNE SANDWICH ASSAY E-188-2014-0 Filing authorized George Washington University, National Heart, Lung, and Blood Institute (NHLBI) 83682222 Bailey, Brian bbailey@mail.nih.gov
United States of America TTIPO bbailey@mail.nih.gov?subject=Web Inquiry on [TAB-2899] Highly Sensitive Tethered-Bead Immune Sandwich Assay&body=Please send me information about technology [TAB-2899] Highly Sensitive Tethered-Bead Immune Sandwich Assay. Bailey, Brian<br><a href="mailto:bbailey@mail.nih.gov?subject=Web Inquiry on [TAB-2899] Highly Sensitive Tethered-Bead Immune Sandwich Assay&body=Please send me information about technology [TAB-2899] Highly Sensitive Tethered-Bead Immune Sandwich Assay.">bbailey@mail.nih.gov</a><br> 114167608 E-188-2014-0 E-188-2014-0-PCT-02 METHODS FOR DETECTION OF AN ANALYTE BY MOVEMENT OF TETHERED MICROPARTICLES PCT Patent Cooperation Treaty PCT/US2015/034815 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2015/034815<br />Filed on 2015-06-09<br />Status: Expired 114168045 E-188-2014-0 E-188-2014-0-US-01 Methods For Detection Of An Analyte By Movement Of Tethered Microparticles PRV US 62/015,122 Abandoned US <br />Provisional (PRV) 62/015,122<br />Filed on 2014-06-20<br />Status: Abandoned 114126760 AA3AXX 114126761 VCXXXX 114126762 VDXXXX 114126763 VJXXXX 114126764 VKXXXX 114126765 VLXXXX 114126766 VOXXXX 114126767 WBXXXX 114126768 XAXXXX 114126769 XGXXXX 114126770 XHXXXX 114126771 YAXXXX 114126772 YFXXXX 114148005 TETHERED-BEAD 114148006 IMMUNE 114148007 Sandwich 114148008 assay TAB-2897 114097058 Cannabinoid Receptor Meditating Compounds for Metabolic Disease NIAAA Endocrinology, Licensing, Reproductive Health, Therapeutics, Vaccines Endocrinology Licensing Reproductive Health Therapeutics Vaccines Resat Cinar, Malliga Iyer, George Kunos, Kenner Rice There is evidence that the metabolic effects of endocannabinoids are mediated by CB1 receptors in peripheral tissues. While prior attempts at generating CB1 receptor blockers have had serious neuropsychiatric side effects, inventors at NIH have discovered compounds that block CB1 receptors with reduced brain penetrance. In addition, some of these compounds also have a direct inhibitory effect on inducible nitric oxide synthase (iNOS), whereas another group of the compounds directly activates AMP kinas. These dual-target compounds may be useful for treating metabolic disease and related conditions such as obesity and diabetes and their complications, including liver or kidney fibrosis, without the dangerous the side effects. <ul> <li>Cannabinoid receptor blockers with reduced brain penetrance relative to older drugs of this class, also having secondary target for improved therapeutic efficacy.</li> </ul> <ul> <li>Treatment of metabolic disease and related conditions such as diabetes, obesity and fibrotic disease.</li> </ul> 2022-11-01 2024-10-28 2024-10-28 2014-12-11 4, 5-Dihydro-1H-Pyrazole, Derivatives, IB6XXX, IBXXXX, Peripherally, Restricted, VFXXXX, VHXXXX, WKXXXX, YAXXXX False True Early-stage True 52406768 Discovery 52406768 NIHTT 37470483 Website Abstract E-282-2012-0 E-211-2006-0 E-103-2013-0 114108931 Iyer, Malliga National Institute on Alcohol Abuse and Alcoholism (NIAAA) NIAAA Iyer, Malliga (NIAAA) 0 114108932 Cinar, Resat National Institute on Alcohol Abuse and Alcoholism (NIAAA) NIAAA Cinar, Resat (NIAAA) 0 114108933 Rice, Kenner NIDA - Biomedical Research Center NIDA Rice, Kenner (NIDA) 0 114108930 Kunos, George National Institute on Alcohol Abuse and Alcoholism (NIAAA) NIAAA Kunos, George (NIAAA) 1 114108930 Kunos, George National Institute on Alcohol Abuse and Alcoholism (NIAAA) NIAAA Kunos, George (NIAAA) 1 114108931 Iyer, Malliga National Institute on Alcohol Abuse and Alcoholism (NIAAA) NIAAA Iyer, Malliga (NIAAA) 0 114108932 Cinar, Resat National Institute on Alcohol Abuse and Alcoholism (NIAAA) NIAAA Cinar, Resat (NIAAA) 0 114108933 Rice, Kenner NIDA - Biomedical Research Center NIDA Rice, Kenner (NIDA) 0 114102231 Peripherally Restricted 4,5-Dihydro-1H-Pyrazole Derivatives E-140-2014-0 Filing authorized National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute on Drug Abuse (NIDA) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-2897] Cannabinoid Receptor Meditating Compounds for Metabolic Disease&body=Please send me information about technology [TAB-2897] Cannabinoid Receptor Meditating Compounds for Metabolic Disease. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-2897] Cannabinoid Receptor Meditating Compounds for Metabolic Disease&body=Please send me information about technology [TAB-2897] Cannabinoid Receptor Meditating Compounds for Metabolic Disease.">shmilovm@nih.gov</a><br> 114165497 E-140-2014-0 E-140-2014-0-US-09 Pyrazole Derivatives And Their Use As Cannabinoid Receptor Mediators National Stage US 10,329,259 15/309,728 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10329259 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10329259">10,329,259</a><br />Filed on 2015-05-08<br />Status: Issued 114168021 E-140-2014-0 E-140-2014-0-US-01 Cannabinoid Receptor Mediating Compounds PRV US 61/991,333 Abandoned US <br />Provisional (PRV) 61/991,333<br />Filed on 2014-05-09<br />Status: Abandoned 114168146 E-140-2014-0 E-140-2014-0-PCT-02 Cannabinoid Receptor Mediating Compounds PCT Patent Cooperation Treaty PCT/US2015/029946 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2015/029946<br />Filed on 2015-05-08<br />Status: Expired 114126746 IBXXXX 114126747 IB6XXX 114126748 VFXXXX 114126749 VHXXXX 114126750 WKXXXX 114126751 YAXXXX 114147989 4 114147990 Restricted 114147991 Peripherally 114147992 5-Dihydro-1H-Pyrazole 114147993 Derivatives TAB-2887 114097048 Heterocyclic Compounds for the Treatment of Hepatitis C Virus NIDDK Infectious Disease, Licensing, Therapeutics Infectious Disease Licensing Therapeutics Marc Ferrer-Alegre, Kevin Frankowski, Shanshan (Melissa) He, Xin Hu, Zongyi Hu, Kelin Li, Tsanyang (Jake) Liang, Juan Marugan, Frank Schoenen, Noel Southall, Jingbo Xiao, Wei Zheng The vast majority of people infected with Hepatitis C Virus (HCV) will have chronic infection. Over decades, this can lead to liver disease and liver cancer. In fact, HCV infection is the leading cause of liver transplants in the U.S. Several new drugs have recently come into the market that have changed the HCV treatment paradigm. However, the effectiveness of these new drugs can vary depending on the HCV genotype. Furthermore, all oral, interferon free therapeutic regimens for HCV infection will need combinations of drugs that target different aspects of the HCV life cycle. Thus, there is still the need for additional new therapeutics against HCV.<br /><br /> The subject technologies are aryloxazole based small molecules that are potent inhibitors of HCV infection and replication. The compounds exhibit synergy with currently available therapeutics for HCV and represent a new class of anti-HCV compounds. The compounds affect the entry step of HCV infection, a step not targeted by currently available therapeutics against HCV. <ul> <li>Potent inhibitors of HCV infection and replication.</li> <li>Show synergistic effect with currently available HCV therapeutics.</li> <li>Represent new class of HCV inhibitors that target the entry step of HCV infection.</li> </ul> <ul> <li>Prevention and treatment of HCV infection.</li> </ul> 2022-03-08 2024-10-28 2024-10-28 2018-08-24 C, Class, compounds, DB4BXX, Development, Hepatitis, Novel, treatment, VLXXXX, WKXXXX, YAXXXX, YBXXXX False True <ul> <li>Early-stage</li> <li>In vitro data available</li> </ul> True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114108896 Hu, Zongyi National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Hu, Zongyi (NIDDK) 0 114108897 Marugan, Juan NCATS - NCGC NCATS Marugan, Juan (NCATS) 0 114108898 Southall, Noel NCATS - TRND NCATS Southall, Noel (NCATS) 0 114108899 Hu, Xin NCATS - NCGC NCATS Hu, Xin (NCATS) 0 114108900 Xiao, Jingbo NCATS - NCGC FDA Xiao, Jingbo (FDA) 0 114108901 He, Shanshan (Melissa) National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) He, Shanshan (Melissa) 0 114108902 Ferrer-Alegre, Marc NCATS - NCGC NCATS Ferrer-Alegre, Marc (NCATS) 0 114108903 Zheng, Wei NCATS - TRND NCATS Zheng, Wei (NCATS) 0 114108904 Frankowski, Kevin University of Kansas Frankowski, Kevin 0 114108905 Schoenen, Frank University of Kansas Schoenen, Frank 0 114108906 Li, Kelin University of Kansas Li, Kelin 0 114108895 Liang, Tsanyang (Jake) National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Liang, Tsanyang (Jake) (NIDDK) 1 114108895 Liang, Tsanyang (Jake) National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Liang, Tsanyang (Jake) (NIDDK) 1 114108896 Hu, Zongyi National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Hu, Zongyi (NIDDK) 0 114108897 Marugan, Juan NCATS - NCGC NCATS Marugan, Juan (NCATS) 0 114108898 Southall, Noel NCATS - TRND NCATS Southall, Noel (NCATS) 0 114108899 Hu, Xin NCATS - NCGC NCATS Hu, Xin (NCATS) 0 114108900 Xiao, Jingbo NCATS - NCGC FDA Xiao, Jingbo (FDA) 0 114108901 He, Shanshan (Melissa) National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) He, Shanshan (Melissa) 0 114108902 Ferrer-Alegre, Marc NCATS - NCGC NCATS Ferrer-Alegre, Marc (NCATS) 0 114108903 Zheng, Wei NCATS - TRND NCATS Zheng, Wei (NCATS) 0 114108904 Frankowski, Kevin University of Kansas Frankowski, Kevin 0 114108905 Schoenen, Frank University of Kansas Schoenen, Frank 0 114108906 Li, Kelin University of Kansas Li, Kelin 0 114102218 Development Of A Novel Class Of Compounds In Treatment Of Hepatitis C E-161-2014-0 Filing authorized National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NCATS - NCGC, University of Kansas 83728636 Buller, Carolyn carolyn.buller@nih.gov
United States of America Technology Advancement Office carolyn.buller@nih.gov?subject=Web Inquiry on [TAB-2887] Heterocyclic Compounds for the Treatment of Hepatitis C Virus&body=Please send me information about technology [TAB-2887] Heterocyclic Compounds for the Treatment of Hepatitis C Virus. Buller, Carolyn<br><a href="mailto:carolyn.buller@nih.gov?subject=Web Inquiry on [TAB-2887] Heterocyclic Compounds for the Treatment of Hepatitis C Virus&body=Please send me information about technology [TAB-2887] Heterocyclic Compounds for the Treatment of Hepatitis C Virus.">carolyn.buller@nih.gov</a><br> 114161780 E-161-2014-0 E-161-2014-0-US-07 HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF National Stage US 10,202,367 15/317,864 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10202367 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10202367">10,202,367</a><br />Filed on 2015-06-12<br />Status: Issued 114168711 E-161-2014-0 E-161-2014-0-EP-06 HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF National Stage European Patent 3154966 15730666.3 Issued European Patent <br />National Stage 15730666.3<br />Filed on 2015-06-12<br />Status: Issued 114126657 DB4BXX 114126658 VLXXXX 114126659 WKXXXX 114126660 YAXXXX 114126661 YBXXXX 114147900 Development 114147901 Novel 114147902 Class 114147903 compounds 114147904 treatment 114147905 Hepatitis 114147906 C TAB-2884 114097047 Novel Codon-Optimized Gene Therapeutic for Methylmalonic Acidemia NHGRI Collaboration, Therapeutics Collaboration Therapeutics Randy Chandler, Charles Venditti Methylmalonic Acidemia (MMA) is a metabolic disorder characterized by increased acidity in the blood and tissues due to toxic accumulation of protein and fat by-products resulting in seizures, strokes, and chronic kidney failure. A significant portion of MMA cases stem from a deficiency in a key mitochondrial enzyme, methylmalonyl-CoA mutase (<em>MUT</em>), required to break down amino acids and lipids. Currently, there are no treatments for MMA and the disease is managed primarily with dietary restriction of amino acid precursors and liver-kidney transplantation in severe cases.<br /><br /> The present invention describes a synthetic codon-optimized MUT gene (co-MUT) that improves expression of human methylmalonyl-CoA mutase. A series of novel gene therapy vectors containing co-MUT rescued MMA mice from lethality and lowered levels of methylmalonic acid in the blood. Results of pre-clinical efficacy studies demonstrate a promising therapy for MMA and other renal-associated disorders. <ul> <li>co-MUT transgene could be used through non-viral and viral gene delivery.</li> </ul> <ul> <li>The co-MUT transgene could be used to treat MMA patients.</li> <li>In addition, it could be used to produce MUT in vitro for MMA enzyme replacement therapy.</li> </ul> The Organic Acid Research Section at the National Human Genome Research Institute is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize codon-optimized MUT constructs. For collaboration opportunities, please contact Claire T. Driscoll at <a href="mailto:cdriscoll@mail.nih.gov">cdriscoll@mail.nih.gov</a>. 2022-03-08 2024-10-28 2024-10-28 2014-10-27 Acidemia, Class, GB2AXX, GBXXXX, GXXXXX, Methylmalonic, Methylmalonyl-CoA, MMA, MUT, Mutase, Synthetic, TRANSGENE, treatment False True <ul> <li>In vitro data available</li> <li>In vivo data available (animal)</li> </ul> True NIHTT 37470483 Website Abstract 114108894 Chandler, Randy National Human Genome Research Institute (NHGRI) NHGRI Chandler, Randy (NHGRI) 0 114108893 Venditti, Charles National Human Genome Research Institute (NHGRI) NHGRI Venditti, Charles (NHGRI) 1 114108893 Venditti, Charles National Human Genome Research Institute (NHGRI) NHGRI Venditti, Charles (NHGRI) 1 114108894 Chandler, Randy National Human Genome Research Institute (NHGRI) NHGRI Chandler, Randy (NHGRI) 0 114102217 A Synthetic Methylmalonyl-CoA Mutase Transgene For The Treatment Of Mut Class Methylmalonic Acidemia (MMA) E-243-2012-0 Filing authorized National Human Genome Research Institute (NHGRI) 83716782 Campbell, Eggerton eggerton.campbell@nih.gov
United States of America eggerton.campbell@nih.gov?subject=Web Inquiry on [TAB-2884] Novel Codon-Optimized Gene Therapeutic for Methylmalonic Acidemia&body=Please send me information about technology [TAB-2884] Novel Codon-Optimized Gene Therapeutic for Methylmalonic Acidemia. Campbell, Eggerton<br><a href="mailto:eggerton.campbell@nih.gov?subject=Web Inquiry on [TAB-2884] Novel Codon-Optimized Gene Therapeutic for Methylmalonic Acidemia&body=Please send me information about technology [TAB-2884] Novel Codon-Optimized Gene Therapeutic for Methylmalonic Acidemia.">eggerton.campbell@nih.gov</a><br> 114160733 E-243-2012-0 E-243-2012-0-US-04 Synthetic Methylmalonyl-CoA Mutase Transgene For The Treatment Of Mut Class Methylmalonic Acidemia (MMA) National Stage US 9,719,080 14/773,885 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9719080 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9719080">9,719,080</a><br />Filed on 2015-09-09<br />Status: Issued 114167979 E-243-2012-0 E-243-2012-0-US-01 Synthetic Methylmalonyl-CoA Mutase Transgene For The Treatment Of Mut Class Methylmalonic Acidemia (MMA) PRV US 61/792,081 Abandoned US <br />Provisional (PRV) 61/792,081<br />Filed on 2013-03-15<br />Status: Abandoned 114167980 E-243-2012-0 E-243-2012-0-PCT-02 Synthetic Methylmalonyl-CoA Mutase Transgene For The Treatment Of Mut Class Methylmalonic Acidemia (MMA) PCT Patent Cooperation Treaty PCT/2014/028045 Expired Patent Cooperation Treaty <br />(PCT) PCT/2014/028045<br />Filed on 2014-03-14<br />Status: Expired 114168304 E-243-2012-0 E-243-2012-0-US-05 Synthetic Methylmalonyl-CoA Mutase Transgene For The Treatment Of Mut Class Methylmalonic Acidemia (MMA) CON US 10,307,469 15/633,964 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10307469 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10307469">10,307,469</a><br />Filed on 2017-06-27<br />Status: Issued 114168872 E-243-2012-0 E-243-2012-0-US-18 SYNTHETIC METHYLMALONYL-COA MUTASE TRANSGENE FOR THE TREATMENT OF MUT CLASS METHYLMALONIC ACIDEMIA (MMA) CON US 10,894,077 16/390,917 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10894077 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10894077">10,894,077</a><br />Filed on 2019-04-22<br />Status: Issued 114126654 GXXXXX 114126655 GBXXXX 114126656 GB2AXX 114147890 Synthetic 114147891 Methylmalonyl-CoA 114147892 Mutase 114147893 TRANSGENE 114147894 treatment 114147895 MUT 114147896 Class 114147897 Methylmalonic 114147898 Acidemia 114147899 MMA TAB-288 114094626 Mutants Having a Deficit of Functional Steroid Hormone Receptors NIEHS Animal Models, Diagnostics, Licensing, Research Materials, Therapeutics Animal Models Diagnostics Licensing Research Materials Therapeutics Kenneth Korach This invention concerns "knockout" animals, including mice, which have a deficit of functional steroid hormone receptors, DNA constructs containing the mutations, and methods for producing the animals. The mutation is introduced into the animal or its ancestors at an embryonic stage. These knockout animals provide a model system for studying the biological role of hormones, including steroid hormones and sex steroids, in growth, development, morphological differentiation, and sexual and reproductive behavior and cycles, etc. More specifically, the animals may serve as models for testing sex hormones and synthetics that mimic or antagonize sex hormones for use in birth control methods or as hormone replacement therapies. In addition, they provide a system for the characterization of materials suspected of precipitating or conferring protection against osteoporosis, cardiovascular disease, breast cancer, endometrial cancer, and other cancers. 2022-03-08 2024-10-28 2024-10-28 1996-02-01 BAXXXX, Endometrial cancer, ICXXXX, IXXXXX False True True NIHTT 37470483 Website Abstract 114103491 Korach, Kenneth NIEHS Korach, Kenneth (NIEHS) 0 114103491 Korach, Kenneth NIEHS Korach, Kenneth (NIEHS) 0 114099423 MUTANTS HAVING A DEFICIT OF FUNCTIONAL STEROID HORMONE RECEPTORS RECOMBINATION E-210-1992-0 EM, NIEHS 83739538 Choudhry, Vidita vidita.choudhry@nih.gov
United States of America Office of Technology Transfer and Development vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-288] Mutants Having a Deficit of Functional Steroid Hormone Receptors&body=Please send me information about technology [TAB-288] Mutants Having a Deficit of Functional Steroid Hormone Receptors. Choudhry, Vidita<br><a href="mailto:vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-288] Mutants Having a Deficit of Functional Steroid Hormone Receptors&body=Please send me information about technology [TAB-288] Mutants Having a Deficit of Functional Steroid Hormone Receptors.">vidita.choudhry@nih.gov</a><br> 114160632 E-210-1992-0 E-210-1992-0-US-03 MUTANT MICE HAVING A DEFICIT OF FUNCTIONAL ESTROGEN RECEPTORS FWC US 5,650,550 08/480,854 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/5650550 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/5650550">5,650,550</a><br />Filed on 1995-06-07<br />Status: Expired 114164873 E-210-1992-0 E-210-1992-0-US-01 MUTANTS HAVING A DEFICIT OF FUNCTIONAL STEROID HORMONE RECEPTORS RECOMBINATION ORD US 08/134,132 Abandoned US <br />Ordinary Patent (ORD) 08/134,132<br />Filed on 1993-10-01<br />Status: Abandoned 114112723 ICXXXX 114112724 IXXXXX 114121323 BAXXXX 114157249 Endometrial cancer TAB-2875 114097038 A Current Amplifier for Local Coil Pre-amplification of NMR/MRI Signals NINDS Collaboration, Diagnostics, Medical Devices, Non-Medical Devices, Occupational Safety and Health, Oncology, Research Materials, Software / Apps Collaboration Diagnostics Medical Devices Non-Medical Devices Occupational Safety and Health Oncology Research Materials Software / Apps Stephen Dodd, Alan Koretsky, Joseph Murphy-Boesch, Chunqi Qian The magnetic resonance imaging (MRI) systems are used for a variety of imaging application. The present invention discloses an improving MRI device and method by amplifying signals received by resonant NMR coils of MRI systems. It utilizes positive feedback from low-noise Field-Effect Transistor to amplify the signal current that can be coupled out to receiving loops positioned externally without loss in sensitivity. Therefore, the NMR coil can be flexibly positioned near internal tissues and used to develop high-resolution images in highly invasive situations. The disclosed device can be developed in kit form as integrated modules that are designed to be added to tuned NMR receiver coils and tailored to deliver specific gains at NMR frequencies. <ul> <li>Sensitivity</li> <li>Easy to be integrated into the existed device</li> </ul> <ul> <li>Medical and scientific research</li> <li>Device for diagnostic</li> </ul> The National Institute of Neurological Disorders and Stroke, Laboratory for Functional and Molecular Imaging, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize a surgically implantable NMR detector, battery powered, for imaging of the pituitary. For collaboration opportunities, please contact Joseph Murphy-Boesch at <a href="mailto:murphyboeschj@mail.nih.gov">murphyboeschj@mail.nih.gov</a>. 2022-03-08 2024-10-28 2024-10-28 2014-09-26 AA3AXX, AA3B1X, AC1XXX, AMPLIFIER, Coil, Current, LOCAL, NMR/MRI, OfNMRIMRI, Pre-amplification, SIGNALS, VCXXXX, WBXXXX, WCXXXX, WIXXXX, XDXXXX, XFXXXX, YBXXXX, YCXXXX False True <ul> <li>In vitro data available</li> <li>In vivo data available (animal)</li> </ul> True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114172204 Qian C, et al. http://www.ncbi.nlm.nih.gov/pubmed/23392428 <a href="http://www.ncbi.nlm.nih.gov/pubmed/23392428">Qian C, et al.</a> 114172205 Qian C, et al. http://www.ncbi.nlm.nih.gov/pubmed/22246567 <a href="http://www.ncbi.nlm.nih.gov/pubmed/22246567">Qian C, et al.</a> 114172206 Mueller OM, et al. https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/5545999 <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/5545999">Mueller OM, et al.</a> 114172207 Ratzel D. https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7123090 <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7123090">Ratzel D.</a> 114108862 Dodd, Stephen NINDS NINDS Dodd, Stephen (NINDS) 0 114108863 Koretsky, Alan NINDS NINDS Koretsky, Alan (NINDS) 0 114108864 Qian, Chunqi NINDS Qian, Chunqi 0 114108861 Murphy-Boesch, Joseph NINDS NINDS Murphy-Boesch, Joseph (NINDS) 1 114108861 Murphy-Boesch, Joseph NINDS NINDS Murphy-Boesch, Joseph (NINDS) 1 114108862 Dodd, Stephen NINDS NINDS Dodd, Stephen (NINDS) 0 114108863 Koretsky, Alan NINDS NINDS Koretsky, Alan (NINDS) 0 114108864 Qian, Chunqi NINDS Qian, Chunqi 0 114102208 A Current Amplifier For Local Coil Pre-amplification Of NMR/MRI Signals E-122-2014-0 Filing authorized NINDS 83667829 Ano, Susan susan.ano@nih.gov
United States of America susan.ano@nih.gov?subject=Web Inquiry on [TAB-2875] A Current Amplifier for Local Coil Pre-amplification of NMR/MRI Signals&body=Please send me information about technology [TAB-2875] A Current Amplifier for Local Coil Pre-amplification of NMR/MRI Signals. Ano, Susan<br><a href="mailto:susan.ano@nih.gov?subject=Web Inquiry on [TAB-2875] A Current Amplifier for Local Coil Pre-amplification of NMR/MRI Signals&body=Please send me information about technology [TAB-2875] A Current Amplifier for Local Coil Pre-amplification of NMR/MRI Signals.">susan.ano@nih.gov</a><br> 114165488 E-122-2014-0 E-122-2014-0-US-03 Negative Resistance Preamplifier for Inductively Coupled Local MRI Coils National Stage US 10,393,831 15/309,336 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10393831 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10393831">10,393,831</a><br />Filed on 2016-11-07<br />Status: Issued 114167947 E-122-2014-0 E-122-2014-0-US-01 Systems and Methods for a Current Amplifier For Local Coil Pre-amplification Of NMR/MRI Signals PRV US 61/989,795 Abandoned US <br />Provisional (PRV) 61/989,795<br />Filed on 2014-05-07<br />Status: Abandoned 114168147 E-122-2014-0 E-122-2014-0-PCT-02 Systems and Methods for a Current Amplifier for Local Coil Pre-Amplification of NMR/MRI Signals PCT Patent Cooperation Treaty PCT/US2015/029674 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2015/029674<br />Filed on 2015-05-07<br />Status: Expired 114126562 AA3AXX 114126563 AA3B1X 114126564 VCXXXX 114126565 WBXXXX 114126566 WCXXXX 114126567 WIXXXX 114126568 XDXXXX 114126569 YBXXXX 114126570 YCXXXX 114126571 XFXXXX 114126572 AC1XXX 114147819 Current 114147820 AMPLIFIER 114147821 LOCAL 114147822 Coil 114147823 Pre-amplification 114147824 OfNMRIMRI 114147825 SIGNALS 114147826 NMR/MRI TAB-2863 114097033 A Novel X-ray Grating to Enhance Phase Contrast Imaging NHLBI Cardiology, Collaboration, Diagnostics, Medical Devices, Non-Medical Devices, Oncology, Research Materials, Software / Apps Cardiology Collaboration Diagnostics Medical Devices Non-Medical Devices Oncology Research Materials Software / Apps Han Wen The present invention relates to improving x-ray phase contrast imaging. The invention discloses a novel grating interferometer for phase contrast imaging with hard x-rays that overcomes limitations in the level of sensitivity by utilizing the advantages of far-field interferometers. The novel design and fabrication process can easily acquire absolute and differential phase images of lightly absorbing samples. <ul> <li>More sensitivity</li> <li>Easier to fabricate images</li> </ul> <ul> <li>Clinical diagnostics</li> <li>Research tools</li> </ul> The National Heart, Lung, and Blood Institute is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize the technology. For collaboration opportunities, please contact Dr. Denise Crooks at <a href="mailto:crooksd@mail.nih.gov">crooksd@mail.nih.gov</a>. 2022-03-08 2024-10-28 2024-10-28 2014-09-10 AA3XXX, Balanced, GRATING, INTERFEROMETER, Two-arm, VCXXXX, VDXXXX, WBXXXX, WIXXXX, XDXXXX, XFXXXX, X-RAY, YBXXXX, YCXXXX False True <ul> <li>In vitro data available</li> <li>In vivo data available (animal)</li> </ul> True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114172198 Wen H. Boosting phase contrast with two-arm interferometers using sub-micron period gratings. Presentation - Session 2, The Royal Society, London scientific discussion meeting: Taking x-ray phase contrast imaging into mainstream applications, February 11, 2013, London, UK. https://royalsociety.org/science-events-and-lectures/2013/x-ray-phase-contrast/ <a href="https://royalsociety.org/science-events-and-lectures/2013/x-ray-phase-contrast/">Wen H. Boosting phase contrast with two-arm interferometers using sub-micron period gratings. Presentation - Session 2, The Royal Society, London scientific discussion meeting: Taking x-ray phase contrast imaging into mainstream applications, February 11, 2013, London, UK.</a> 114172199 Momose A, Fukuda J. https://www.ncbi.nlm.nih.gov/pubmed/7609717 <a href="https://www.ncbi.nlm.nih.gov/pubmed/7609717">Momose A, Fukuda J.</a> 114172200 Clauser JF. https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/5812629 <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/5812629">Clauser JF.</a> 114108845 Wen, Han National Heart, Lung, and Blood Institute (NHLBI) NHLBI Wen, Han (NHLBI) 1 114108845 Wen, Han National Heart, Lung, and Blood Institute (NHLBI) NHLBI Wen, Han (NHLBI) 1 114102202 Balanced Two-arm X-ray Grating Interferometer E-114-2013-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-2863] A Novel X-ray Grating to Enhance Phase Contrast Imaging&body=Please send me information about technology [TAB-2863] A Novel X-ray Grating to Enhance Phase Contrast Imaging. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-2863] A Novel X-ray Grating to Enhance Phase Contrast Imaging&body=Please send me information about technology [TAB-2863] A Novel X-ray Grating to Enhance Phase Contrast Imaging.">shmilovm@nih.gov</a><br> 114167934 E-114-2013-0 E-114-2013-0-US-01 Balanced Two-Arm X-ray Grating Interferometer PRV US 61/877,228 Abandoned US <br />Provisional (PRV) 61/877,228<br />Filed on 2013-09-12<br />Status: Abandoned 114167958 E-114-2013-0 E-114-2013-0-PCT-02 Balanced Two-arm X-Ray Grating Interferometer PCT Patent Cooperation Treaty PCT/US2014/055225 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2014/055225<br />Filed on 2014-09-11<br />Status: Expired 114126523 AA3XXX 114126524 VCXXXX 114126525 VDXXXX 114126526 WBXXXX 114126527 WIXXXX 114126528 XDXXXX 114126529 XFXXXX 114126530 YBXXXX 114126531 YCXXXX 114147787 Balanced 114147788 Two-arm 114147789 X-RAY 114147790 GRATING 114147791 INTERFEROMETER TAB-2862 114097032 A Novel Demodulation System in X-ray Imaging NHLBI Cardiology, Collaboration, Dental, Diagnostics, Endocrinology, Infectious Disease, Medical Devices, Neurology, Non-Medical Devices, Oncology, Ophthalmology, Research Materials, Software / Apps Cardiology Collaboration Dental Diagnostics Endocrinology Infectious Disease Medical Devices Neurology Non-Medical Devices Oncology Ophthalmology Research Materials Software / Apps Houxun Miao, Han Wen In various x-ray imaging methods, including scattering correction and phase contrast imaging, intensity modulation in space is introduced into the projection images by the use of masks, gratings, or apertures. The present invention relates to a process to demodulate the modulation. The current demodulation processes are either to remove the modulation pattern through digital processing or to move the modulation pattern on the detector in a series of images that requires mechanical movements of a component and tends to lose some information of the imaged object. The demodulation of the present invention can be realized with a relative movement between the projected image of the sample and the modulation pattern without having to move the modulation pattern. The demodulated images are free of the modulation pattern and have better clarity. <ul> <li>Better clarity for images</li> <li>Simplify the demodulation method</li> </ul> <ul> <li>Clinical diagnostic</li> <li>Research tools</li> <li>Security inspections</li> </ul> The National Heart, Lung, and Blood Institute is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize the technology. For collaboration opportunities, please contact Dr. Denise Crooks at <a href="mailto:crooksd@mail.nih.gov">crooksd@mail.nih.gov</a>. 2022-03-08 2024-10-28 2024-10-28 2014-09-10 AA3XXX, Demodulation, IMAGING, INTENSITY, Modulation, VCXXXX, VDXXXX, VEXXXX, VPXXXX, WBXXXX, WIXXXX, XDXXXX, XFXXXX, X-RAY, YBXXXX, YCXXXX False True <ul> <li>In vitro data available</li> <li>In vivo data available (animal)</li> </ul> True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114172196 David C, et al. https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7889838 <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7889838">David C, et al.</a> 114172197 Schusser S, Vogtmeier G. http://patentscope.wipo.int/search/en/WO2011070489 <a href="http://patentscope.wipo.int/search/en/WO2011070489">Schusser S, Vogtmeier G.</a> 114108844 Miao, Houxun National Heart, Lung, and Blood Institute (NHLBI) Miao, Houxun 0 114108843 Wen, Han National Heart, Lung, and Blood Institute (NHLBI) NHLBI Wen, Han (NHLBI) 1 114108843 Wen, Han National Heart, Lung, and Blood Institute (NHLBI) NHLBI Wen, Han (NHLBI) 1 114108844 Miao, Houxun National Heart, Lung, and Blood Institute (NHLBI) Miao, Houxun 0 114102201 Demodulation Of Intensity Modulation In X-ray Imaging E-113-2013-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-2862] A Novel Demodulation System in X-ray Imaging&body=Please send me information about technology [TAB-2862] A Novel Demodulation System in X-ray Imaging. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-2862] A Novel Demodulation System in X-ray Imaging&body=Please send me information about technology [TAB-2862] A Novel Demodulation System in X-ray Imaging.">shmilovm@nih.gov</a><br> 114161509 E-113-2013-0 E-113-2013-0-US-03 Demodulation Of Intensity Modulation In X-ray Imaging National Stage US 9,939,392 15/021,675 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9939392 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9939392">9,939,392</a><br />Filed on 2016-03-11<br />Status: Issued 114167933 E-113-2013-0 E-113-2013-0-US-01 Demodulation Of Intensity Modulation In X-Ray Imaging PRV US 61/877,219 Abandoned US <br />Provisional (PRV) 61/877,219<br />Filed on 2013-09-12<br />Status: Abandoned 114167957 E-113-2013-0 E-113-2013-0-PCT-02 Demodulation Of Intensity Modulation In X-Ray Imaging PCT Patent Cooperation Treaty PCT/US2014/055224 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2014/055224<br />Filed on 2014-09-11<br />Status: Expired 114126512 AA3XXX 114126513 VCXXXX 114126514 VDXXXX 114126515 VEXXXX 114126516 VPXXXX 114126517 WBXXXX 114126518 WIXXXX 114126519 XDXXXX 114126520 XFXXXX 114126521 YBXXXX 114126522 YCXXXX 114147782 Demodulation 114147783 INTENSITY 114147784 Modulation 114147785 X-RAY 114147786 IMAGING TAB-2836 114097015 Small Molecule Imaging of Fungi by Positron Emission Tomography Scanning NIAID Collaboration, Diagnostics, Infectious Disease, Medical Devices, Non-Medical Devices, Software / Apps Collaboration Diagnostics Infectious Disease Medical Devices Non-Medical Devices Software / Apps Dale Kiesewetter, John Panepinto, Jin Qiu, Peter Williamson This technology relates to the field of radioactive, isotopically-labeled calcofluor derivatives and uses of such compounds to detect a broad spectrum of filamentous fungi including pathogenic species such as <em>Aspergillus</em> and <em>Mucorales</em>, by diagnostic imaging methods such as positron emission tomography (PET) scanning.<br /><br /> Aspergillosis and other filamentous fungal infections are increasingly common fungal lung infection with high mortality rates (over 50%) in immune compromised patients, such as those receiving chemotherapy, stem cell/organ transplantation, or HIV patients. One-year survival of the infected patients ranges from 59% (organ transplant recipients) to as low as 25% (stem cell transplant recipients). Delayed diagnosis and therapy are likely to lead to poor outcomes and death. This disease is often first detected as nodules on CT scans. A diagnosis is typically made following invasive lung bronchoscopy or biopsy. However, as these patients are immunocompromised, these invasive procedures may themselves lead to significant complications and infections. Therefore, to enable timely treatment and minimize complications, there is a critical need for non-invasive means to detect and diagnose fungal infections.<br /><br /> The calcofluor derivatives disclosed in the patent application may be utilized as imaging agents specific for fungal infections and could potentially become a standard, non-invasive procedure in the work-up of immunocompromised patients with lung infections. <ul> <li>Non-invasive</li> <li>Low toxicity</li> <li>Specific for <em>Aspergillus</em></li> </ul> <ul> <li>Diagnostics of <em>Aspergillus</em> and other filamentous fungal infections</li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize for development of this invention. For collaboration opportunities, please contact Dr. David Yang at 240-627-3413 or <a href="mailto:polung.yang@nih.gov">polung.yang@nih.gov</a>. and various international patent applications 2022-03-08 2024-10-28 2024-10-28 2014-07-09 DA1XXX, FUNGI, IMAGING, Listed LPM Fenn as of 4/15/2015, MOLECULE, PET, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, SCANNING, Small, VKXXXX, WBXXXX, XFXXXX, YCXXXX False True In vivo data available (animal) True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114172175 Palmer GE, et al. http://www.ncbi.nlm.nih.gov/pubmed/18927489 <a href="http://www.ncbi.nlm.nih.gov/pubmed/18927489">Palmer GE, et al.</a> 114172176 Panepinto JC, et al. http://www.ncbi.nlm.nih.gov/pubmed/12704156 <a href="http://www.ncbi.nlm.nih.gov/pubmed/12704156">Panepinto JC, et al.</a> 114172177 Desoubeaux D, et al. http://www.ncbi.nlm.nih.gov/pubmed/24548415 <a href="http://www.ncbi.nlm.nih.gov/pubmed/24548415">Desoubeaux D, et al.</a> 114102955 Kiesewetter, Dale NIBIB NIBIB Kiesewetter, Dale (NIBIB) 0 114102956 Panepinto, John University of Buffalo Panepinto, John 0 114105244 Qiu, Jin NIAID - DIR NIAID Qiu, Jin (NIAID) 0 114106362 Williamson, Peter NIAID - DIR NIAID Williamson, Peter (NIAID) 1 114106362 Williamson, Peter NIAID - DIR NIAID Williamson, Peter (NIAID) 1 114102955 Kiesewetter, Dale NIBIB NIBIB Kiesewetter, Dale (NIBIB) 0 114102956 Panepinto, John University of Buffalo Panepinto, John 0 114105244 Qiu, Jin NIAID - DIR NIAID Qiu, Jin (NIAID) 0 114101858 Small Molecule Imaging Of Fungi By PET Scanning E-449-2013-0 Filing authorized NIAID, NIBIB, University of Buffalo 114101860 Small Molecule Imaging Of Fungi By PET Scanning E-449-2013-1 Filing authorized NIAID, NIBIB, University of Buffalo 83720410 Yang, David (Po-Lung) polung.yang@nih.gov
United States of America Technology Transfer and Intellectual Property Office polung.yang@nih.gov?subject=Web Inquiry on [TAB-2836] Small Molecule Imaging of Fungi by Positron Emission Tomography Scanning&body=Please send me information about technology [TAB-2836] Small Molecule Imaging of Fungi by Positron Emission Tomography Scanning. Yang, David (Po-Lung)<br><a href="mailto:polung.yang@nih.gov?subject=Web Inquiry on [TAB-2836] Small Molecule Imaging of Fungi by Positron Emission Tomography Scanning&body=Please send me information about technology [TAB-2836] Small Molecule Imaging of Fungi by Positron Emission Tomography Scanning.">polung.yang@nih.gov</a><br> 114162837 E-449-2013-1 E-449-2013-1-PCT-01 SMALL MOLECULE IMAGING OF FUNGI BY POSITRON EMISSION TOMOGRAPHY SCANNING PCT COMB Patent Cooperation Treaty PCT/US2014/061917 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2014/061917<br />Filed on 2014-10-23<br />Status: Expired 114162978 E-449-2013-0 E-449-2013-0-US-01 Small Molecule Imaging Of Fungi By Positron Emission Tomography Scanning PRV US 61/894,754 Abandoned US <br />Provisional (PRV) 61/894,754<br />Filed on 2013-10-23<br />Status: Abandoned 114163230 E-449-2013-1 E-449-2013-1-US-05 SMALL MOLECULE IMAGING OF FUNGI BY POSITRON EMISSION TOMOGRAPHY SCANNING National Stage US 9,968,693 15/030,554 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9968693 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9968693">9,968,693</a><br />Filed on 2016-04-19<br />Status: Issued 114168604 E-449-2013-1 E-449-2013-1-US-06 SMALL MOLECULE IMAGING OF FUNGI BY POSITRON EMISSION TOMOGRAPHY SCANNING CON US 10,383,960 15/961,554 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10383960 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10383960">10,383,960</a><br />Filed on 2018-04-24<br />Status: Abandoned 114126332 DA1XXX 114126333 VKXXXX 114126334 WBXXXX 114126335 XFXXXX 114126336 YCXXXX 114133967 Listed LPM Fenn as of 4/15/2015 114133968 Pre LPM working set 20150418 114133969 Post LPM Assignment Set 20150420 114147593 Small 114147594 MOLECULE 114147595 IMAGING 114147596 FUNGI 114147597 PET 114147598 SCANNING TAB-2830 114097008 Treatment of Chronic Kidney Disease with Synthetic Amphipathic Peptides NIDDK Cardiology, Collaboration, Dental, Endocrinology, Infectious Disease, Oncology, Ophthalmology, Research Equipment, Research Materials, Therapeutics Cardiology Collaboration Dental Endocrinology Infectious Disease Oncology Ophthalmology Research Equipment Research Materials Therapeutics Alexander Bocharov, Thomas Eggerman, Alan Remaley, Ana Souza, Robert Star, Peter Yuen The invention is directed to treatment of chronic kidney disease by administering a synthetic, amphipathic helical peptide known as 5A-37pA, and novel derivatives thereof. Scientists at NIDDK have demonstrated that invention peptides antagonize activity of a particular scavenger receptor known as CD36. Using an in vivo model, NIDDK scientists have shown that invention peptides slowed progression of chronic kidney disease and can potentially be utilized as a therapeutic treatment.<br /><br /> Additionally, certain invention peptides bind selectively to CD36 with high specificity over other homologous scavenger receptors. Thus, invention peptides can be utilized as a research tool to further evaluate the complex etiology of chronic kidney disease.<br /><br /> 5A-37pA, and derivatives thereof, are peptide mimetic of apolipoprotein A-1. These peptides have been described in NIH owned patents and/or patent applications (see, for example, U.S. Patent Nos. 7,572,771 and 8,071,746 and 8,148,323). Use of these peptides, as well as the novel peptides of this invention, for the treatment of kidney diseases is currently available for licensing. <ul> <li>Selective antagonist of CD36 activity</li> <li>Specific binding to CD36 over other scavenger receptors</li> </ul> <ul> <li>Therapeutic</li> <li><Research Tool</li> </ul> The National Institute of Diabetes and Digestive and Kidney Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize Treatment of Chronic Kidney Disease with 5A-37pA and Derivatives Thereof. For collaboration opportunities, please contact Marguerite Miller at <a href="mailto:marguerite.miller@nih.gov">marguerite.miller@nih.gov</a> or 301-496-9003. 2022-03-08 2024-10-28 2024-10-28 2014-06-02 5A-37pA, AMPHIPATHIC, Chronic, Disease, HELICAL, KIDNEY, Peptide, treatment, VDXXXX, VFXXXX, VGXXXX, VHXXXX, VIXXXX, VPXXXX, WIXXXX, WJXXXX, XHXXXX, YAXXXX, YBXXXX, YCXXXX False True <ul> <li>Early-stage</li> <li>In vitro data available</li> <li>In vivo data available (animal)</li> </ul> True 52406768 Discovery 52406768 NIHTT 37470483 Website Abstract E-114-2004-0 114108753 Yuen, Peter National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Yuen, Peter (NIDDK) 0 114108754 Star, Robert National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Star, Robert (NIDDK) 0 114108755 Bocharov, Alexander Clinical Center (CC) CC Bocharov, Alexander (CC) 0 114108756 Remaley, Alan Clinical Center (CC) NHLBI Remaley, Alan (NHLBI) 0 114108757 Eggerman, Thomas National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Eggerman, Thomas (NIDDK) 0 114108752 Souza, Ana National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Souza, Ana (NIDDK) 1 114108752 Souza, Ana National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Souza, Ana (NIDDK) 1 114108753 Yuen, Peter National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Yuen, Peter (NIDDK) 0 114108754 Star, Robert National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Star, Robert (NIDDK) 0 114108755 Bocharov, Alexander Clinical Center (CC) CC Bocharov, Alexander (CC) 0 114108756 Remaley, Alan Clinical Center (CC) NHLBI Remaley, Alan (NHLBI) 0 114108757 Eggerman, Thomas National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Eggerman, Thomas (NIDDK) 0 114102167 Treatment Of Chronic Kidney Disease With Amphipathic Helical Peptide 5A-37pA E-743-2013-0 Filing authorized Clinical Center (CC), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83692066 Tong, Betty tongb@niddk.nih.gov
United States of America Senior Technology Advancement Office tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-2830] Treatment of Chronic Kidney Disease with Synthetic Amphipathic Peptides&body=Please send me information about technology [TAB-2830] Treatment of Chronic Kidney Disease with Synthetic Amphipathic Peptides. Tong, Betty<br><a href="mailto:tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-2830] Treatment of Chronic Kidney Disease with Synthetic Amphipathic Peptides&body=Please send me information about technology [TAB-2830] Treatment of Chronic Kidney Disease with Synthetic Amphipathic Peptides.">tongb@niddk.nih.gov</a><br> 114167824 E-743-2013-0 E-743-2013-0-US-01 THERAPEUTIC POLYPEPTIDES AND THEIR USE PRV US 61/890,585 Abandoned US <br />Provisional (PRV) 61/890,585<br />Filed on 2013-10-14<br />Status: Abandoned 114167965 E-743-2013-0 E-743-2013-0-PCT-02 TREATMENT OF CHRONIC KIDNEY DISEASE WITH SAHPS PCT Patent Cooperation Treaty PCT/US2014/060304 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2014/060304<br />Filed on 2014-10-13<br />Status: Expired 114126282 VDXXXX 114126283 VFXXXX 114126284 VGXXXX 114126285 VHXXXX 114126286 VIXXXX 114126287 VPXXXX 114126288 WIXXXX 114126289 WJXXXX 114126290 XHXXXX 114126291 YAXXXX 114126292 YBXXXX 114126293 YCXXXX 114147515 treatment 114147516 Chronic 114147517 KIDNEY 114147518 Disease 114147519 AMPHIPATHIC 114147520 HELICAL 114147521 Peptide 114147522 5A-37pA TAB-2832 114097010 AMA1-RON2 Complex-Based Vaccine Against Malaria NIAID Collaboration, Infectious Disease, Vaccines Collaboration Infectious Disease Vaccines Louis Miller, Prakash Srinivasan This technology relates to a malaria vaccine composed of a protein complex of Apical Membrane Antigen (AMA1) and rhoptry neck protein 2 (RON2) with an adjuvant. AMA1 is a crucial component of the <em>Plasmodium</em> invasion machinery and is a leading candidate for antimalarial vaccine development. AMA1-based vaccines have shown ability to block red cell invasion in <em>in vitro</em> assays, but protection has so far not translated to <em>in vivo</em> human infections. NIAID investigators have demonstrated that interaction between AMA1 and RON2 (or peptide thereof) is essential for malaria parasites to successfully enter human red blood cells (RBCs). Vaccination with un-complexed AMA1 and RON2 did not protect against lethal malaria. However, vaccination with a pre-formed AMA1-RON2 complex, highlighted in this technology, produced antibodies that protected against lethal malaria in an <em>in vivo</em> mouse model (<em>P. yoelli</em>) and blocked the entry of human malaria parasites into RBCs <em>in vitro</em>. Additionally, the inhibitory antibody response induced by the AMA1-RON2 complex was greater than AMA1 alone or when AMA1 and RON2 proteins were administered in a un-complexed form.<br /><br /> Immunization using the AMA1-RON2 complex of this technology represents a candidate for an effective malaria vaccine against multiple <em>Plasmodium</em> species. <ul> <li>Lower-cost malarial prevention for developing/developed countries</li> </ul> <ul> <li>Malaria vaccine</li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize MA1-RON2 vaccine by providing well established human adjuvants and clinical trial funding. For collaboration opportunities, please contact Peter Tung, Ph.D. at 240-669-5483 or <a href="mailto:peter.tung@nih.gov">peter.tung@nih.gov</a>. Various international patent applications may also be available. 2022-03-08 2024-10-28 2024-10-28 2017-03-09 Against, AMAI-RON2, CHALLENGE, COMPLEX, DC2XXX, Lethal, PLASMODIUM, Protection, PROVIDES, VACCINATION False True <ul> <li>Early-stage</li> <li>In vitro data available</li> <li>In vivo data available (animal)</li> </ul> True NIHTT 37470483 Website Abstract 114172158 Srinivasan P, et al. http://www.ncbi.nlm.nih.gov/pubmed/21788485 <a href="http://www.ncbi.nlm.nih.gov/pubmed/21788485">Srinivasan P, et al.</a> 114172159 Srinivasan P, et al. http://www.ncbi.nlm.nih.gov/pubmed/23907321 <a href="http://www.ncbi.nlm.nih.gov/pubmed/23907321">Srinivasan P, et al.</a> 114108763 Miller, Louis NIAID - DIR NIAID Miller, Louis (NIAID) 0 114108762 Srinivasan, Prakash NIAID - DIR NIAID Srinivasan, Prakash (NIAID) 1 114108762 Srinivasan, Prakash NIAID - DIR NIAID Srinivasan, Prakash (NIAID) 1 114108763 Miller, Louis NIAID - DIR NIAID Miller, Louis (NIAID) 0 114102170 Vaccination With AMAI-RON2 Complex Provides Protection Against Lethal Plasmodium Challenge E-066-2013-0 Filing authorized NIAID 83724572 Tung, Peter peter.tung@nih.gov
United States of America DIR peter.tung@nih.gov?subject=Web Inquiry on [TAB-2832] AMA1-RON2 Complex-Based Vaccine Against Malaria&body=Please send me information about technology [TAB-2832] AMA1-RON2 Complex-Based Vaccine Against Malaria. Tung, Peter<br><a href="mailto:peter.tung@nih.gov?subject=Web Inquiry on [TAB-2832] AMA1-RON2 Complex-Based Vaccine Against Malaria&body=Please send me information about technology [TAB-2832] AMA1-RON2 Complex-Based Vaccine Against Malaria.">peter.tung@nih.gov</a><br> 114167037 E-066-2013-0 E-066-2013-0-US-06 Vaccine Comprising AMA1 and RON2 National Stage US 9,795,662 14/902,117 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9795662 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9795662">9,795,662</a><br />Filed on 2015-12-30<br />Status: Issued 114167843 E-066-2013-0 E-066-2013-0-US-01 Vaccine Comprising AMA1-RON2 PRV US 61/841,479 Abandoned US <br />Provisional (PRV) 61/841,479<br />Filed on 2013-07-01<br />Status: Abandoned 114167884 E-066-2013-0 E-066-2013-0-PCT-02 Vaccination Comprising AMA1 And RON2 PCT Patent Cooperation Treaty PCT/US2014/045065 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2014/045065<br />Filed on 2014-07-01<br />Status: Expired 114126302 DC2XXX 114147541 Protection 114147542 PROVIDES 114147543 COMPLEX 114147544 AMAI-RON2 114147545 Against 114147546 Lethal 114147547 PLASMODIUM 114147548 CHALLENGE 114147549 VACCINATION TAB-2821 114097000 MDCK-based Reporter System for Detection of Influenza Viruses, Antiviral Drug Screening, and Analysis of Neutralizing Antibodies CDC Antibodies, Consumer Products, Diagnostics, Immunology, Infectious Disease, Licensing, Occupational Safety and Health, Research Equipment, Research Materials, Therapeutics, Vaccines Antibodies Consumer Products Diagnostics Immunology Infectious Disease Licensing Occupational Safety and Health Research Equipment Research Materials Therapeutics Vaccines Ruben Donis, Zhu Guo, Sandra Perez DeBretschneider CDC researchers have developed a Madin-Darby Canine Kidney (MDCK) reporter cell line that is exceptionally permissive for influenza virus replication and provides a highly specific, sensitive approach for the simultaneous detection and isolation of influenza viruses. Simplified antibody neutralization assays and high-throughput antiviral drug screening can also be easily and efficiently implemented using this reporter system.<br /><br /> Laboratories generally rely on embryonated chicken eggs or mammalian cell cultures for isolation and propagation of influenza viruses. This approach is hampered by the relatively long times required to obtain test results (5 to 7 days) and substantial requirements for specialized materials, equipment and specially trained technician labor.<br /><br /> This CDC-generated reporter system for influenza A virus uses highly permissive MDCK cells expressing a luciferase-encoding amplicon controlled by canine RNA polymerase I (POL-I) promoter elements. This cell-based system exploits the specificity of viral transcription factors for their target promoters, and the extreme sensitivity of the luciferase enzyme greatly reduces turnaround times for readouts. In addition, the simplicity of these new reporter assays relative to ELISA and real-time PCR reduces technician labor, reagent/consumables usage, and physical lab space requirements when detecting and diagnosing influenza infection. This system will also be useful for efficient, high-throughput screening of antiviral drug libraries and neutralizing antibody assays. <ul> <li>Provides a very specific and sensitive approach for simultaneous detection and isolation of influenza A viruses; CDC research demonstrates a 1,000-fold gain in sensitivity relative to prior reporter systems</li> <li>High-throughput evaluations of antibodies and antiviral compound screening</li> <li>Rapid approach (results as early as 24 hours) for influenza detection provides greater efficiency than culture methods (5 to 7 days)</li> <li>Replacement of conventional MDCK cells by this technology eliminates the laborious ELISA procedure currently used for virus detection</li> </ul> <ul> <li>Influenza growth and antibody neutralization assays</li> <li>Development and screening of antiviral drug compounds</li> <li>Detection and diagnosis of influenza infection</li> <li>Numerous “increased efficiency” uses for commercial production programs involving influenza viruses</li> </ul> Research Tool – Patent protection is not being pursued for this technology. 2022-07-22 2024-10-28 2024-10-28 2014-05-15 CDC Docket Import, CDC Docket Import CDC Prosecuting, CELL-BASED, Detection, INFLUENZA, MDCK, REPORTER, System, VBXXXX, Viruses, VLXXXX, VOXXXX, WAXXXX, WBXXXX, WFXXXX, WHXXXX, WIXXXX, WJXXXX, WKXXXX, WMXXXX, XAXXXX, XCXXXX, XEXXXX, XHXXXX, YBXXXX False True <ul> <li>In vitro data available</li> </ul> True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114172144 Hossain MJ, et al. http://www.ncbi.nlm.nih.gov/pubmed/20504984 <a href="http://www.ncbi.nlm.nih.gov/pubmed/20504984">Hossain MJ, et al.</a> 114108727 Guo, Zhu CDC - DIR CDC Guo, Zhu (CDC) 0 114108728 Perez DeBretschneider, Sandra CDC - DIR CDC Perez DeBretschneider, Sandra (CDC) 0 114108726 Donis, Ruben CDC - DIR CDC Donis, Ruben (CDC) 1 114108726 Donis, Ruben CDC - DIR CDC Donis, Ruben (CDC) 1 114108727 Guo, Zhu CDC - DIR CDC Guo, Zhu (CDC) 0 114108728 Perez DeBretschneider, Sandra CDC - DIR CDC Perez DeBretschneider, Sandra (CDC) 0 114102154 MDCK Cell-Based Reporter System For The Detection Of Influenza A Viruses E-185-2013-0 Research Material Centers for Disease Control and Prevention (CDC) 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2821] MDCK-based Reporter System for Detection of Influenza Viruses, Antiviral Drug Screening, and Analysis of Neutralizing Antibodies&body=Please send me information about technology [TAB-2821] MDCK-based Reporter System for Detection of Influenza Viruses, Antiviral Drug Screening, and Analysis of Neutralizing Antibodies. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2821] MDCK-based Reporter System for Detection of Influenza Viruses, Antiviral Drug Screening, and Analysis of Neutralizing Antibodies&body=Please send me information about technology [TAB-2821] MDCK-based Reporter System for Detection of Influenza Viruses, Antiviral Drug Screening, and Analysis of Neutralizing Antibodies.">jonathan.motley@nih.gov</a><br> 114126073 VBXXXX 114126074 VLXXXX 114126075 VOXXXX 114126076 WAXXXX 114126077 WBXXXX 114126078 WFXXXX 114126079 WHXXXX 114126080 WIXXXX 114126081 WJXXXX 114126082 WKXXXX 114126083 WMXXXX 114126084 XAXXXX 114126085 XCXXXX 114126086 XEXXXX 114126087 XHXXXX 114126088 YBXXXX 114147327 MDCK 114147328 CELL-BASED 114147329 REPORTER 114147330 System 114147331 Detection 114147332 INFLUENZA 114147333 Viruses 114147334 CDC Docket Import 114147335 CDC Docket Import CDC Prosecuting TAB-2799 114096978 Novel Small Molecule Antimalarials for Elimination of Malaria Transmission NCATS Consumer Products, Infectious Disease, Licensing, Research Equipment, Therapeutics Consumer Products Infectious Disease Licensing Research Equipment Therapeutics Seameen Dehdashti, Wenwei Huang, John McKew, Noel Southall, Wei Sun, Takeshi Tanaka, Wei Zheng The transmission of malaria begins with injection of sporozoites into a human from the bite of a female anopheles mosquito, which initiates the malarial life cycle in humans. When a mosquito bites an infected human, the ingested male and female malaria gametocytes fuse to form a zygote that eventually becomes an oocyst. Each oocyst produces thousands of sporozoites which migrate to the mosquito salivary glands, ready to infect a new human host.<br /><br /> Currently, the available therapeutics for malaria can effectively eliminate the asexual stages of malarial parasites that cause clinical symptoms in patients. However, their abilities to eliminate the gametocyte (sexual stage of the parasites) as well as the liver stage parasites are limited. The subject technology involves novel compounds, which include Torin 2, that are potently gametocytocidal in <em>in vitro</em> assays and in a mouse model of malaria, completely blocked the host-to-mosquito transmission by suppressing oocytes formation in mosquitoes. <ul> <li>These novel compounds are effective against gametocytes, the sexual stage of malarial parasites, whereas currently available antimalarials have limited effectiveness against this form of the parasite.</li> <li>The compounds provide an alternative treatment against malaria for patients with glucose-6-phosphate dehydrogenase deficiency.</li> <li>These compounds are active against drug resistant strains of malaria.</li> </ul> <ul> <li>Novel therapeutics for elimination of malaria transmission and treatment of drug resistant malaria patients.</li> </ul> 2022-03-08 2024-10-28 2024-10-28 2014-04-03 compounds, DB2XXX, Gametocytocidal, Identification, Malaria, Novel, VOXXXX, WKXXXX, XHXXXX, YAXXXX, YBXXXX, YCXXXX False True <ul> <li>Early-stage</li> <li>In vitro data available</li> <li>In vivo data available (animal)</li> </ul> True 52406768 Discovery 52406768 NIHTT 37470483 Website Abstract 114172120 Sun W, et al. http://www.ncbi.nlm.nih.gov/pubmed/24434750 <a href="http://www.ncbi.nlm.nih.gov/pubmed/24434750">Sun W, et al.</a> 114108645 Zheng, Wei NCATS - TRND NCATS Zheng, Wei (NCATS) 0 114108646 Dehdashti, Seameen NCATS - NCGC NCATS Dehdashti, Seameen (NCATS) 0 114108647 Southall, Noel NCATS - TRND NCATS Southall, Noel (NCATS) 0 114108648 Huang, Wenwei NCATS - TRND NCATS Huang, Wenwei (NCATS) 0 114108649 Sun, Wei NCATS - TRND NCATS Sun, Wei (NCATS) 0 114108650 Tanaka, Takeshi NIAID - DIR Tanaka, Takeshi 0 114108644 McKew, John NCATS - TRND McKew, John 1 114108644 McKew, John NCATS - TRND McKew, John 1 114108645 Zheng, Wei NCATS - TRND NCATS Zheng, Wei (NCATS) 0 114108646 Dehdashti, Seameen NCATS - NCGC NCATS Dehdashti, Seameen (NCATS) 0 114108647 Southall, Noel NCATS - TRND NCATS Southall, Noel (NCATS) 0 114108648 Huang, Wenwei NCATS - TRND NCATS Huang, Wenwei (NCATS) 0 114108649 Sun, Wei NCATS - TRND NCATS Sun, Wei (NCATS) 0 114108650 Tanaka, Takeshi NIAID - DIR Tanaka, Takeshi 0 114102124 Identification Of Novel Gametocytocidal Compounds E-751-2013-0 Filing authorized Loyola University Chicago, NCATS - NCGC, NIAID 83682485 Vepa, Suryanarayana sury.vepa@nih.gov
United States of America Office of Strategic Alliances (OSA) sury.vepa@nih.gov?subject=Web Inquiry on [TAB-2799] Novel Small Molecule Antimalarials for Elimination of Malaria Transmission&body=Please send me information about technology [TAB-2799] Novel Small Molecule Antimalarials for Elimination of Malaria Transmission. Vepa, Suryanarayana<br><a href="mailto:sury.vepa@nih.gov?subject=Web Inquiry on [TAB-2799] Novel Small Molecule Antimalarials for Elimination of Malaria Transmission&body=Please send me information about technology [TAB-2799] Novel Small Molecule Antimalarials for Elimination of Malaria Transmission.">sury.vepa@nih.gov</a><br> 114166924 E-751-2013-0 E-751-2013-0-US-03 Method of Blocking Transmission of Malarial Parasite National Stage US 15/036,355 Abandoned US <br />National Stage 15/036,355<br />Filed on 2016-05-12<br />Status: Abandoned 114167730 E-751-2013-0 E-751-2013-0-US-01 Method of Blocking Transmission of Malarial Parasite PRV US 61/904,884 Abandoned US <br />Provisional (PRV) 61/904,884<br />Filed on 2013-11-15<br />Status: Abandoned 114168000 E-751-2013-0 E-751-2013-0-PCT-02 Method of Blocking Transmission of Malarial Parasite PCT Patent Cooperation Treaty PCT/US2014/065671 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2014/065671<br />Filed on 2014-11-14<br />Status: Expired 114125853 DB2XXX 114125854 VOXXXX 114125855 WKXXXX 114125856 XHXXXX 114125857 YAXXXX 114125858 YBXXXX 114125859 YCXXXX 114147027 compounds 114147028 Gametocytocidal 114147029 Novel 114147030 Identification 114147031 Malaria TAB-2766 114096945 Improved Culture Medium for Stem Cell Maintenance and Differentiation NHLBI Collaboration, Research Materials Collaboration Research Materials Guokai Chen, Yongshun Lin A novel low protein culture medium with defined chemical components that allows pluripotent stem cell maintenance and differentiation is disclosed. The present technology also provides for production of high quality cardiac cells from human embryonic and induced pluripotent stem cells in chemically defined medium conditions. Human pluripotent stem cells, including human embryonic stem cells and human induced pluripotent stem cells, can be propagated indefinitely while still retaining the capacity to differentiate into all somatic cell types, and are a potentially inexhaustible supply of human cells. The capacity to sustain survival at high density is critical for maintaining consistent stem cell cultures and avoiding the development of abnormal stem cells, and for proper stem cell differentiation. Also, it is essential to have high quality stem cells for all personalized cellular therapies. NIH investigators developed a low protein medium that supports the proliferation and differentiation of stem cells comprising one or more of a volume expander, a lipid mix and a growth factor modulator. Also, the investigators have used the new medium to produce high quality cardiac cells from human embryonic and induced pluripotent stem cells. <ul> <li>This new medium could significantly improve progenitor cell derivation from embryonic stem cells and induced pluripotent stem cells and could have great usage in future translational applications.</li> </ul> <ul> <li>Improved defined medium to grow, maintain and differentiate stem cells.</li> <li>This medium can be used to develop culture systems that could be used to generate specific cell types for potential clinical applications.</li> </ul> The National Heart, Lung, and Blood Institute is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize Stem Cell Culture Medium. For collaboration opportunities, please contact Peg Koelble at <a href="mailto:koelblep@nhlbi.nih.gov">koelblep@nhlbi.nih.gov</a>. 2022-03-08 2024-10-28 2024-10-28 2014-02-06 AC5XXX, ACXXXX, ADDITIVES, AXXXXX, Cell, Chemically, CM-dextran, CULTURE, DEFINED, DIFFERENTIATION, GLYCOGEN, HEPARIN, Human, IMPROVING, Lipid, Maintenance, Medium, Pluripotent, RXXXXX, Stem, Trehalose False True <ul> <li>Early-stage</li> <li>In vitro data available</li> <li>In vivo data available (animal)</li> </ul> True NIHTT 37470483 Website Abstract 114108524 Lin, Yongshun National Heart, Lung, and Blood Institute (NHLBI) NHLBI Lin, Yongshun (NHLBI) 0 114108523 Chen, Guokai National Heart, Lung, and Blood Institute (NHLBI) Chen, Guokai 1 114108523 Chen, Guokai National Heart, Lung, and Blood Institute (NHLBI) Chen, Guokai 1 114108524 Lin, Yongshun National Heart, Lung, and Blood Institute (NHLBI) NHLBI Lin, Yongshun (NHLBI) 0 114102086 Improving Human Pluripotent Stem Cell Maintenance And Differentiation In Chemically Defined Culture Medium With Additives, Glycogen, Trehalose, CM-dextran, Heparin And Lipid E-089-2013-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-2766] Improved Culture Medium for Stem Cell Maintenance and Differentiation&body=Please send me information about technology [TAB-2766] Improved Culture Medium for Stem Cell Maintenance and Differentiation. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-2766] Improved Culture Medium for Stem Cell Maintenance and Differentiation&body=Please send me information about technology [TAB-2766] Improved Culture Medium for Stem Cell Maintenance and Differentiation.">shmilovm@nih.gov</a><br> 114162289 E-089-2013-0 E-089-2013-0-US-04 Chemically Defined Culture Medium For Stem Cell Maintenance and Differentiation National Stage US 15/023,221 Abandoned US <br />National Stage 15/023,221<br />Filed on 2016-03-18<br />Status: Abandoned 114167628 E-089-2013-0 E-089-2013-0-US-01 CHEMICALLY DEFINED CULTURE MEDIUM FOR STEM CELL MAINTENANCE AND DIFFERENTIATION PRV US 61/879,840 Abandoned US <br />Provisional (PRV) 61/879,840<br />Filed on 2013-09-19<br />Status: Abandoned 114167966 E-089-2013-0 E-089-2013-0-PCT-02 Chemically Defined Culture Medium for Stem Cell Maintenance and Differentiation PCT Patent Cooperation Treaty PCT/US2014/056485 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2014/056485<br />Filed on 2014-09-19<br />Status: Expired 114125300 RXXXXX 114125301 AC5XXX 114125302 AXXXXX 114125303 ACXXXX 114146506 IMPROVING 114146507 Human 114146508 Pluripotent 114146509 Stem 114146510 Cell 114146511 Maintenance 114146512 DIFFERENTIATION 114146513 Chemically 114146514 DEFINED 114146515 CULTURE 114146516 Medium 114146517 ADDITIVES 114146518 GLYCOGEN 114146519 Trehalose 114146520 CM-dextran 114146521 HEPARIN 114146522 Lipid TAB-2746 114096925 Vaccine Attenuation via Deoptimization of Synonymous Codons CDC Consumer Products, Diagnostics, Infectious Disease, Licensing, Research Equipment, Research Materials, Therapeutics, Vaccines Consumer Products Diagnostics Infectious Disease Licensing Research Equipment Research Materials Therapeutics Vaccines Cara Burns, Olen Kew, Jacueline Quay, Jing Shaw Research scientists at CDC have developed compositions and methods that can be used to develop attenuated vaccines having well-defined levels of replicative fitness and enhanced genetic stabilities. Infections by intracellular pathogens, such as viruses, bacteria, and parasites, are cleared in most cases after activation of specific T-cell immune responses that recognize foreign antigens and eliminate infected cells. Vaccines against those infectious organisms traditionally have been developed by administration of whole live attenuated or inactivated microorganisms. Although research has been performed using subunit vaccines, the levels of cellular immunity induced are usually low and not capable of eliciting complete protection against diseases caused by intracellular microbes. CDC inventors discovered that replacement of one or more natural (or native) codons in a pathogen with synonymous unpreferred codons can decrease the replicative fitness of the pathogen, thereby attenuating the pathogen. The unpreferred synonymous codon(s) encode the same amino acid as the native codon(s), but have nonetheless been found to reduce a pathogen's replicative fitness. <ul> <li>Retains the protective and immunogenic advantages of native-codon live attenuated vaccine strains</li> <li>Alleviates some critical safety issues associated with using live attenuated vaccines</li> <li>Likely to possess greater long-term genetic stability than single-point mutations (fewer reversions)</li> </ul> <ul> <li>Vaccine design and development</li> <li>Functional improvements for current vaccines</li> <li>Increasing the phenotypic stability of live attenuated vaccines</li> <li>Attenuation optimization endeavors</li> </ul> Various international patent applications pending or issued 2022-10-25 2024-10-28 2024-10-28 2014-01-28 CDC Docket Import, CDC Docket Import CDC Prosecuting, CODONS, DC2XXX, DC4XXX, DC5XXX, DCXXXX, Deoptimization, DXXXXX, Fitness, Modulation, OID-NCIRD-DVD, Replicative, Synonymous, VBXXXX, VJXXXX, VKXXXX, VLXXXX, VOXXXX, WAXXXX, WHXXXX, WIXXXX, WJXXXX, WMXXXX, XEXXXX, XHXXXX, YBXXXX False True In vitro data available True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114172027 Burns CC, et al. http://www.ncbi.nlm.nih.gov/pubmed/16537593 <a href="http://www.ncbi.nlm.nih.gov/pubmed/16537593">Burns CC, et al.</a> 114108469 Burns, Cara CDC - DIR CDC Burns, Cara (CDC) 0 114108470 Quay, Jacueline CDC - DIR CDC Quay, Jacueline (CDC) 0 114108471 Shaw, Jing CDC - DIR CDC Shaw, Jing (CDC) 0 114108468 Kew, Olen CDC - DIR CDC Kew, Olen (CDC) 1 114108468 Kew, Olen CDC - DIR CDC Kew, Olen (CDC) 1 114108469 Burns, Cara CDC - DIR CDC Burns, Cara (CDC) 0 114108470 Quay, Jacueline CDC - DIR CDC Quay, Jacueline (CDC) 0 114108471 Shaw, Jing CDC - DIR CDC Shaw, Jing (CDC) 0 114102064 Modulation Of Replicative Fitness By Deoptimization Of Synonymous Codons E-328-2013-0 Filing authorized Centers for Disease Control and Prevention (CDC) 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2746] Vaccine Attenuation via Deoptimization of Synonymous Codons&body=Please send me information about technology [TAB-2746] Vaccine Attenuation via Deoptimization of Synonymous Codons. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2746] Vaccine Attenuation via Deoptimization of Synonymous Codons&body=Please send me information about technology [TAB-2746] Vaccine Attenuation via Deoptimization of Synonymous Codons.">jonathan.motley@nih.gov</a><br> 114167556 E-328-2013-0 E-328-2013-0-US-01 Modulation of Replicative Fitness by Using Less Frequently Used Synonymous Codons PRV US 60/617,545 Abandoned US <br />Provisional (PRV) 60/617,545<br />Filed on 2004-10-08<br />Status: Abandoned 114167557 E-328-2013-0 E-328-2013-0-PCT-02 Modulation of Replicative Fitness by Using Less Frequently Used Synonymous Codons PCT Patent Cooperation Treaty PCT/US2005/036241 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2005/036241<br />Filed on 2005-10-07<br />Status: Expired 114167558 E-328-2013-0 E-328-2013-0-US-08 Modulation Of Replicative Fitness By Deoptimization Of Synonymous Codons National Stage US 8,846,051 11/576,941 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8846051 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8846051">8,846,051</a><br />Filed on 2007-11-19<br />Status: Issued 114167915 E-328-2013-0 E-328-2013-0-US-17 Modulation Of Replicative Fitness By Deoptimization Of Synonymous Codons DIV US 14/464,619 Abandoned US <br />Divisional (DIV) 14/464,619<br />Filed on 2014-08-20<br />Status: Abandoned 114168351 E-328-2013-0 E-328-2013-0-US-18 Modulation Of Replicative Fitness By Deoptimization Of Synonymous Codons DIV US 15/684,355 Abandoned US <br />Divisional (DIV) 15/684,355<br />Filed on 2017-08-23<br />Status: Abandoned 114168667 E-328-2013-0 E-328-2013-0-US-27 MODULATION OF REPLICATIVE FITNESS BY DEOPTIMIZATION OF SYNONYMOUS CODONS DIV US 10,695,414 15/994,074 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10695414 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10695414">10,695,414</a><br />Filed on 2018-05-31<br />Status: Expired 114169020 E-328-2013-0 E-328-2013-0-US-42 Modulation Of Replicative Fitness By Deoptimization Of Synonymous Codons DIV US 11,497,803 15/931,336 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11497803 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11497803">11,497,803</a><br />Filed on 2020-05-13<br />Status: Expired 114169667 E-328-2013-0 E-328-2013-0-US-43 MODULATION OF REPLICATIVE FITNESS BY DEOPTIMIZATION OF SYNONYMOUS CODONS DIV US 12,090,197 18/047,395 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12090197 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12090197">12,090,197</a><br />Filed on 2022-10-18<br />Status: Expired 114124911 DXXXXX 114124941 DCXXXX 114124942 DC5XXX 114124943 DC4XXX 114124944 DC2XXX 114124945 VBXXXX 114124946 VJXXXX 114124947 VKXXXX 114124948 VLXXXX 114124949 VOXXXX 114124950 WAXXXX 114124951 WHXXXX 114124952 WIXXXX 114124953 WJXXXX 114124954 WMXXXX 114124955 XEXXXX 114124956 XHXXXX 114124957 YBXXXX 114146267 Modulation 114146268 Replicative 114146269 Fitness 114146270 Deoptimization 114146271 Synonymous 114146272 CODONS 114146273 CDC Docket Import 114146274 CDC Docket Import CDC Prosecuting 114146275 OID-NCIRD-DVD TAB-2720 114096899 Controlled Expression and Assembly of Human Group-C Rotavirus-like Particles for Creation of Rotavirus Diagnostic Assays and Improved Vaccine Formulations CDC Antibodies, Cardiology, Consumer Products, Dental, Diagnostics, Endocrinology, Immunology, Infectious Disease, Licensing, Occupational Safety and Health, Oncology, Ophthalmology, Research Materials, Therapeutics, Vaccines Antibodies Cardiology Consumer Products Dental Diagnostics Endocrinology Immunology Infectious Disease Licensing Occupational Safety and Health Oncology Ophthalmology Research Materials Therapeutics Vaccines Baoming Jiang CDC researchers have developed methods of producing unlimited quantities of Group-C (GpC) rotavirus antigens. GpC rotaviruses are a major, worldwide cause of acute gastroenteritis in children and adults that is distinct from Group-A rotavirus. However, GpC rotaviruses cannot be grown in culture, resulting in a lack of tools for detection and treatment of GpC rotavirus disease. Consequently, the true clinical burden of GpC rotavirus disease has not been clearly established. <p>This technology allows for the expression of the three major capsid proteins (VP2, VP6 and VP7) of GpC rotavirus by recombinant baculovirus and assembly of virus-like particles (2-6-7 and/or 6-7) within insect cells. Further, this CDC generated technology allows for the large-scale access to GpC rotavirus antigens, previously infeasible, and will permit use of these novel virus-like particles for the development of rotavirus diagnostic assays and improved vaccine formulations.</p> <ul> <li>Permits large-scale production of Group-C rotavirus antigens, previously impractical</li> <li>Produced virus-like particles/antigens can be used for rotavirus vaccines, other immunogenic uses and/or sero-diagnostic assay development</li> <li>Diagnostic tools for Group-C rotavirus are currently unavailable; this technology fulfills an unmet need for accurate assessment of the Group-C rotaviral global health burden</li> </ul> <ul> <li>Development or improvement of rotavirus vaccines</li> <li>Rotavirus vaccine composition research</li> <li>Childhood illness vaccination programs and rotavirus monitoring endeavors</li> <li>Development of novel rotavirus diagnostic tools</li> </ul> Various international filings pending and/or deferred 2022-06-22 2024-10-28 2024-10-28 2014-01-16 C, CDC Docket Import, CDC Docket Import CDC Prosecuting, CHILDHOOD, Children, DA4BXX, DA4XXX, DAXXXX, DB4BXX, DB4XXX, DBXXXX, DC1XXX, DC5BXX, DC5XXX, DCXXXX, DXXXXX, GROUP, Human, NEONATAL, Neonates, OID-NCIRD-DVD, PARTICLES, rotavirus, Their, THEREOF, viral, Viral-Like, virus, VLXXXX, VOXXXX, VPXXXX, WBXXXX, WFXXXX, WIXXXX, WMXXXX, XAXXXX, XCXXXX, YBXXXX False True In vitro data available True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract E-122-2013-0 E-150-2013-0 E-153-2013-0 E-521-2013-0 114171991 Clark KB, et al. http://www.ncbi.nlm.nih.gov/pubmed/19285329 <a href="http://www.ncbi.nlm.nih.gov/pubmed/19285329">Clark KB, et al.</a> 114108391 Jiang, Baoming CDC - DIR CDC Jiang, Baoming (CDC) 1 114108391 Jiang, Baoming CDC - DIR CDC Jiang, Baoming (CDC) 1 114102033 Human Group C Rotavirus Viral-Like Particles And Their Use Thereof E-191-2013-2 Closed Centers for Disease Control and Prevention (CDC) 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2720] Controlled Expression and Assembly of Human Group-C Rotavirus-like Particles for Creation of Rotavirus Diagnostic Assays and Improved Vaccine Formulations&body=Please send me information about technology [TAB-2720] Controlled Expression and Assembly of Human Group-C Rotavirus-like Particles for Creation of Rotavirus Diagnostic Assays and Improved Vaccine Formulations. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2720] Controlled Expression and Assembly of Human Group-C Rotavirus-like Particles for Creation of Rotavirus Diagnostic Assays and Improved Vaccine Formulations&body=Please send me information about technology [TAB-2720] Controlled Expression and Assembly of Human Group-C Rotavirus-like Particles for Creation of Rotavirus Diagnostic Assays and Improved Vaccine Formulations.">jonathan.motley@nih.gov</a><br> 114167473 E-191-2013-2 E-191-2013-2-PCT-01 Human Group C Rotavirus Viral-Like Particles And Their Use Thereof PCT COMB Patent Cooperation Treaty PCT/US2009/045688 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2009/045688<br />Filed on 2009-05-29<br />Status: Expired 114167474 E-191-2013-2 E-191-2013-2-US-07 Human Group C Rotavirus Viral-Like Particles And Their Uses Thereof National Stage US 9,169,296 12/995,024 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9169296 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9169296">9,169,296</a><br />Filed on 2011-01-26<br />Status: Abandoned 114124410 DAXXXX 114124421 DXXXXX 114124422 DA4XXX 114124423 DA4BXX 114124424 DCXXXX 114124425 DC5XXX 114124426 DC5BXX 114124427 DC1XXX 114124428 DB4XXX 114124429 DB4BXX 114124430 DBXXXX 114124431 VLXXXX 114124432 VOXXXX 114124433 VPXXXX 114124434 WBXXXX 114124435 WFXXXX 114124436 WIXXXX 114124437 WMXXXX 114124438 XAXXXX 114124439 XCXXXX 114124440 YBXXXX 114145978 Human 114145979 GROUP 114145980 C 114145981 rotavirus 114145982 Viral-Like 114145983 PARTICLES 114145984 Their 114145985 THEREOF 114145986 CDC Docket Import 114145987 CDC Docket Import CDC Prosecuting 114145988 OID-NCIRD-DVD 114145989 virus 114145990 viral 114145991 CHILDHOOD 114145992 Children 114145993 NEONATAL 114145994 Neonates TAB-2695 114096876 Human Rotavirus Strains and Vaccines for Neonatal Childhood Protection CDC Consumer Products, Infectious Disease, Licensing, Research Equipment, Research Materials, Therapeutics, Vaccines Consumer Products Infectious Disease Licensing Research Equipment Research Materials Therapeutics Vaccines Jon Gentsch, Roger Glass, Baoming Jiang, Yuhuan Wang This invention relates to rotavirus vaccine compositions and methods of vaccination. Rotaviral infection is the most commonly occurring gastrointestinal illness of children world, affecting both developed and developing economies. Additionally, rotavirus infections can affect livestock (especially calves and piglets), and resulting mortality/morbidity cause major economic losses for farmers and nations each year.<br /><br /> The vaccine strains include <em>Rotavirus A</em> CDC-9 (P[4]Gl) and CDC-66 (P[4]G2 serotype). These strains represent common rotavirus serotypes and may serve as improvements or alternatives to current live, oral rotavirus vaccine strains. Further, this technology has demonstrated efficacy in a large animal (piglets) modeling. <ul> <li>Isolated strains are representative of those involved in community-acquired infection</li> <li>Suitable for the development of improved, broadly effective rotavirus vaccines</li> <li>Can be developed for injection and/or oral vaccine administration</li> <li>Derived vaccines may be administered alone or in combination with other vaccines</li> </ul> <ul> <li>Novel rotavirus vaccines</li> <li>Neonatal/childhood vaccination initiatives</li> <li>Rotavirus surveillance programs, important for both developing and developed nations</li> </ul> Various international filings pending or deferred 2022-06-22 2024-10-28 2024-10-28 2013-12-23 CDC Docket Import, CDC Docket Import CDC Prosecuting, CHILDHOOD, Children, DB4BXX, DB4XXX, DBXXXX, DC5BXX, DC5XXX, DCXXXX, DEVELOPED, DEVELOPING, DIARRHEA, DXXXXX, Dysentery, GASTRIC, gastrointestinal, Human, Livestock, NEONATAL, Neonates, OID-NCIRD-DVD, rotavirus, Strain, STRAINS, Vaccine, VETERINARY, VETERINARY vaccine, viral, virus, VLXXXX, VOXXXX, WIXXXX, WJXXXX, WMXXXX, XEXXXX, XHXXXX, YBXXXX, YCXXXX, Zoo, Zoonotic False True <ul> <li>In vitro data available</li> <li>In vivo data available (animal)</li> </ul> True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract E-122-2013-0 E-153-2013-0 E-191-2013-2 E-521-2013-0 114171960 Esona MD, et al. http://www.ncbi.nlm.nih.gov/pubmed/20009519 <a href="http://www.ncbi.nlm.nih.gov/pubmed/20009519">Esona MD, et al.</a> 114171961 Wang Y, et al. http://www.ncbi.nlm.nih.gov/pubmed/20558244 <a href="http://www.ncbi.nlm.nih.gov/pubmed/20558244">Wang Y, et al.</a> 114172080 Jiang B, et al. http://www.ncbi.nlm.nih.gov/pubmed/23744507 <a href="http://www.ncbi.nlm.nih.gov/pubmed/23744507">Jiang B, et al.</a> 114108313 Glass, Roger CDC - DIR CDC Glass, Roger (CDC) 0 114108314 Wang, Yuhuan CDC - DIR CDC Wang, Yuhuan (CDC) 0 114108315 Gentsch, Jon CDC - DIR Gentsch, Jon 0 114108312 Jiang, Baoming CDC - DIR CDC Jiang, Baoming (CDC) 1 114108312 Jiang, Baoming CDC - DIR CDC Jiang, Baoming (CDC) 1 114108313 Glass, Roger CDC - DIR CDC Glass, Roger (CDC) 0 114108314 Wang, Yuhuan CDC - DIR CDC Wang, Yuhuan (CDC) 0 114108315 Gentsch, Jon CDC - DIR Gentsch, Jon 0 114102005 HUMAN ROTAVIRUS VACCINE STRAINS E-150-2013-0 Filing authorized Centers for Disease Control and Prevention (CDC) 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2695] Human Rotavirus Strains and Vaccines for Neonatal Childhood Protection&body=Please send me information about technology [TAB-2695] Human Rotavirus Strains and Vaccines for Neonatal Childhood Protection. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2695] Human Rotavirus Strains and Vaccines for Neonatal Childhood Protection&body=Please send me information about technology [TAB-2695] Human Rotavirus Strains and Vaccines for Neonatal Childhood Protection.">jonathan.motley@nih.gov</a><br> 114167413 E-150-2013-0 E-150-2013-0-US-01 HUMAN ROTAVIRUS VACCINE STRAINS PRV US 61/177,393 Abandoned US <br />Provisional (PRV) 61/177,393<br />Filed on 2009-05-12<br />Status: Abandoned 114167414 E-150-2013-0 E-150-2013-0-PCT-02 HUMAN ROTAVIRUS VACCINE STRAINS AND VACCINES PCT Patent Cooperation Treaty PCT/US2010/034537 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2010/034537<br />Filed on 2010-05-12<br />Status: Expired 114167415 E-150-2013-0 E-150-2013-0-US-10 HUMAN ROTAVIRUS VACCINE STRAINS AND DIAGNOSTICS National Stage US 8,822,192 13/320,095 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8822192 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8822192">8,822,192</a><br />Filed on 2011-11-11<br />Status: Issued 114167758 E-150-2013-0 E-150-2013-0-US-12 HUMAN ROTAVIRUS VACCINE STRAINS AND DIAGNOSTICS CON US 9,974,851 15/200,837 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9974851 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9974851">9,974,851</a><br />Filed on 2016-07-01<br />Status: Issued 114167937 E-150-2013-0 E-150-2013-0-US-11 HUMAN ROTAVIRUS VACCINE STRAINS CON US 9,498,526 14/461,663 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9498526 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9498526">9,498,526</a><br />Filed on 2014-08-18<br />Status: Issued 114168606 E-150-2013-0 E-150-2013-0-US-16 HUMAN ROTAVIRUS VACCINE STRAINS AND DIAGNOSTICS CON US 10,500,269 15/956,662 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10500269 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10500269">10,500,269</a><br />Filed on 2018-04-18<br />Status: Issued 114168932 E-150-2013-0 E-150-2013-0-US-22 HUMAN ROTAVIRUS STRAINS AND VACCINES DIV US 11,065,327 16/672,168 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11065327 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11065327">11,065,327</a><br />Filed on 2019-11-01<br />Status: Issued 114169136 E-150-2013-0 E-150-2013-0-US-24 HUMAN ROTAVIRUS STRAINS AND VACCINES DIV US 11,786,589 17/349,639 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11786589 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11786589">11,786,589</a><br />Filed on 2021-06-16<br />Status: Issued 114124103 DXXXXX 114124104 DC5XXX 114124105 DCXXXX 114124106 DC5BXX 114124107 DBXXXX 114124108 DB4XXX 114124109 DB4BXX 114124110 VLXXXX 114124111 WJXXXX 114124112 XHXXXX 114124113 YBXXXX 114125490 VOXXXX 114125496 WIXXXX 114125497 WMXXXX 114125498 XEXXXX 114125499 YCXXXX 114145642 Human 114145643 rotavirus 114145644 Vaccine 114145645 STRAINS 114145646 CDC Docket Import 114145647 CDC Docket Import CDC Prosecuting 114145648 OID-NCIRD-DVD 114145649 GASTRIC 114145650 gastrointestinal 114145651 Dysentery 114145652 DIARRHEA 114145653 NEONATAL 114145654 Neonates 114145655 CHILDHOOD 114145656 Children 114145657 Zoo 114145658 Zoonotic 114145659 VETERINARY 114145660 VETERINARY vaccine 114145661 virus 114145662 viral 114145663 DEVELOPED 114145664 DEVELOPING 114145665 Livestock 114145666 Strain TAB-2683 114096866 Mouse Model for Methylmalonic Acidemia, an Inherited Metabolic Disorder NHGRI Collaboration, Research Materials Collaboration Research Materials Eirini (Irini) Manoli, Charles Venditti Methylmalonic Acidemia (MMA) is a metabolic disorder affecting 1 in 25,000 to 48,000 individuals globally. MMA is characterized by increased acidity in the blood and tissues due to toxic accumulation of protein and fat by-products resulting in seizures, strokes, and chronic kidney failure. About 60% of MMA cases stem from mutations in the methylmalonyl CoA mutase (MUT) gene encoding a key enzyme required to break down amino acids and lipids. Previous efforts to develop mice with null mutations in MUT have been unsuccessful, as such mutations result in neonatal death. <br /><br /> The inventors have developed the first transgenic mouse model available for the long-term study of Mut deficiency, in which low level liver-specific expression of the MUT enzyme confers rescue from neonatal lethality and replicates induction of the severe renal symptoms consistent with human MMA. This model could serve as a valuable research tool for designing treatments for MMA renal disease or a platform for pre-clinical toxicology screening of compounds with potential renal side effects. <ul> <li>The model system provides a relatively non-invasive means of assessing the efficacy of renal-targeted therapies of all classes and biological types (gene therapy, small molecules, nutritional supplements, repurposed drugs).</li> </ul> <ul> <li>Model for examining renoprotective antioxidants or treatments for kidney failure resulting from drug toxicity, mitochondrial dysfunction, environmental exposure, or aging.</li> <li>Used in investigating renoprotective effects of nutritional supplements from drugs known to cause kidney damage.</li> <li>Used in discovery of MMA biomarkers.</li> </ul> The National Human Genome Research Institute, Organic Acid Research Section, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize renotherapeutic or renoprotective small molecules, gene and/or cell therapies to treat MMA. For collaboration opportunities, please contact Charles P. Venditti, M.D., Ph.D. at <a href="mailto:venditti@mail.nih.gov">venditti@mail.nih.gov</a> or 301-496-6213. Research Material – Patent protection is not being pursued for this technology. 2022-03-08 2024-10-28 2024-10-28 2013-12-03 Dysfunction, metabolic disorder, Methylmalonic acidemia, Methylmalonyl-CoA, methylmalonyl-CoA mutase, MITOCHONDRIAL, MMA, Model, Mouse, MUT, RENAL, RXXXXX, TRANSGENIC, transgenic mouse, YAXXXX, YBXXXX, YCXXXX False True <ul> <li>Early-stage</li> <li>Pre-clinical</li> <li>In vitro data available</li> <li>In vivo data available (animal)</li> </ul> True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114171944 Manoli I, et al. http://www.ncbi.nlm.nih.gov/pubmed/23898205 <a href="http://www.ncbi.nlm.nih.gov/pubmed/23898205">Manoli I, et al.</a> 114108276 Manoli, Eirini (Irini) National Human Genome Research Institute (NHGRI) NHGRI Manoli, Eirini (Irini) (NHGRI) 0 114108275 Venditti, Charles National Human Genome Research Institute (NHGRI) NHGRI Venditti, Charles (NHGRI) 1 114108275 Venditti, Charles National Human Genome Research Institute (NHGRI) NHGRI Venditti, Charles (NHGRI) 1 114108276 Manoli, Eirini (Irini) National Human Genome Research Institute (NHGRI) NHGRI Manoli, Eirini (Irini) (NHGRI) 0 114101996 Mouse Model Of Renal And Mitochondrial Dysfunction E-285-2011-1 Research Material National Human Genome Research Institute (NHGRI) 83716782 Campbell, Eggerton eggerton.campbell@nih.gov
United States of America eggerton.campbell@nih.gov?subject=Web Inquiry on [TAB-2683] Mouse Model for Methylmalonic Acidemia, an Inherited Metabolic Disorder&body=Please send me information about technology [TAB-2683] Mouse Model for Methylmalonic Acidemia, an Inherited Metabolic Disorder. Campbell, Eggerton<br><a href="mailto:eggerton.campbell@nih.gov?subject=Web Inquiry on [TAB-2683] Mouse Model for Methylmalonic Acidemia, an Inherited Metabolic Disorder&body=Please send me information about technology [TAB-2683] Mouse Model for Methylmalonic Acidemia, an Inherited Metabolic Disorder.">eggerton.campbell@nih.gov</a><br> 114123991 RXXXXX 114123992 YAXXXX 114123993 YBXXXX 114123994 YCXXXX 114145502 Mouse 114145503 Model 114145504 RENAL 114145505 MITOCHONDRIAL 114145506 Dysfunction 114145507 MMA 114145508 Methylmalonic acidemia 114145509 metabolic disorder 114145510 transgenic mouse 114145511 TRANSGENIC 114145512 MUT 114145513 Methylmalonyl-CoA 114145514 methylmalonyl-CoA mutase TAB-2674 114096857 Device for Vascular Dilation NHLBI Collaboration Collaboration Adam Greenbaum, Ozgur Kocaturk, Robert Lederman The invention is an enhanced vascular dilator that eliminates the vascular injury caused by the size mismatch between vascular introducer sheaths and vascular dilators, as the two are advanced into a blood vessel. The invention provides a “shoulder” to match the diameter of the introducer sheath so that there is a smooth transition, without size mismatch, between the dilator and the introducer sheath. The invention allows the dilator to be withdrawn in segments from the introducer sheath. This is especially valuable to reduce vascular injury when using large-bore introducer sheaths for interventional procedures including transcatheter valves and endografts. <ul> <li>Non-perforating</li> </ul> <ul> <li>Caval access</li> <li>Vascular access</li> </ul> The National Heart, Lung, and Blood Institute is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize interventional catheter-based procedures to reduce vascular injury. For collaboration opportunities, please contact Peg Koelble at <a href="mailto:koelblep@nhlbi.nih.gov">koelblep@nhlbi.nih.gov</a>. 2022-03-08 2024-10-28 2024-10-28 2013-12-03 AA2XXX, AA4CXX, AAXXXX, AXXXXX, Dilator, Segmented, vascular, YFXXXX False True Prototype True 52406769 Prototype 52406769 NIHTT 37470483 Website Abstract 114108249 Kocaturk, Ozgur National Heart, Lung, and Blood Institute (NHLBI) NHLBI Kocaturk, Ozgur (NHLBI) 0 114108250 Greenbaum, Adam Henry Ford Hospital Greenbaum, Adam 0 114108248 Lederman, Robert National Heart, Lung, and Blood Institute (NHLBI) NHLBI Lederman, Robert (NHLBI) 1 114108248 Lederman, Robert National Heart, Lung, and Blood Institute (NHLBI) NHLBI Lederman, Robert (NHLBI) 1 114108249 Kocaturk, Ozgur National Heart, Lung, and Blood Institute (NHLBI) NHLBI Kocaturk, Ozgur (NHLBI) 0 114108250 Greenbaum, Adam Henry Ford Hospital Greenbaum, Adam 0 114101989 Segmented Vascular Dilator E-759-2013-0 Filing authorized Henry Ford Hospital, National Heart, Lung, and Blood Institute (NHLBI) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-2674] Device for Vascular Dilation&body=Please send me information about technology [TAB-2674] Device for Vascular Dilation. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-2674] Device for Vascular Dilation&body=Please send me information about technology [TAB-2674] Device for Vascular Dilation.">shmilovm@nih.gov</a><br> 114161510 E-759-2013-0 E-759-2013-0-US-04 Vascular Dilators National Stage US 10,537,718 15/025,336 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10537718 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10537718">10,537,718</a><br />Filed on 2016-03-28<br />Status: Issued 114167389 E-759-2013-0 E-759-2013-0-US-01 Vascular Dilators PRV US 61/890,961 Abandoned US <br />Provisional (PRV) 61/890,961<br />Filed on 2013-10-15<br />Status: Abandoned 114167969 E-759-2013-0 E-759-2013-0-PCT-02 Vascular Dilators PCT Patent Cooperation Treaty PCT/US2014/060270 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2014/060270<br />Filed on 2014-10-13<br />Status: Expired 114123936 AA2XXX 114123937 AA4CXX 114123938 AXXXXX 114123939 AAXXXX 114123940 YFXXXX 114145451 Segmented 114145452 vascular 114145453 Dilator TAB-2681 114096863 Use of Antisense Oligodeoxynucleotides for Inhibiting JC Virus NINDS Collaboration, Diagnostics, Infectious Disease, Research Materials, Therapeutics Collaboration Diagnostics Infectious Disease Research Materials Therapeutics Michael Ferenczy, Laura Jaeger, Eugene Major, Maria Monaco-Kushner, Avindra Nath Progressive multifocal leukoencephalopathy (PML) is a rare, fatal demyelinating disease of the brain caused by the polyomavirus JC (JCV) under immunosuppressive conditions. It is pathologically characterized by progressive damage of white matter of the brain by destroying oligodendrocytes at multiple locations. Clinically, PML symptoms include weakness or paralysis, vision loss, impaired speech, and cognitive deterioration. The prognosis of PML is generally poor. No effective therapy for PML has been established. The current strategies to develop a PML therapy focus on blocking viral infection or inhibiting JCV replication. Antisense oligodeoxynucleotides (ODNs) that can block JCV replication and multiplication have been identified and optimized. Use of the ODNs provide a method of inhibiting JCV replication and thereby provide a treatment for PML. <ul> <li>Low cost PML therapeutics</li> <li>Lower cost JCV diagnostics</li> <li>Ease of synthesis</li> </ul> <ul> <li>JCV/PML Therapeutics</li> <li>JCV Diagnostics</li> <li>JCV Kits</li> </ul> The National Institute of Neurological Disorders and Stroke is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize anti-JCV antisense cocktails. For collaboration opportunities, please contact Susan Ano, Ph.D. at <a href="mailto:susan.ano@nih.gov">susan.ano@nih.gov</a> or 301-435-5515. 2022-03-08 2024-10-28 2024-10-28 2013-12-03 Anti-JC, Antisense, Cocktail, DAXXXX, DB4BXX, DB4XXX, DB5XXX, DBXXXX, DD1XXX, DDXXXX, DXXXXX, virus, YBXXXX, YCXXXX False True <ul> <li>Pre-clinical</li> <li>In vitro data available</li> <li>In vivo data available (animal)</li> </ul> True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114108269 Nath, Avindra NINDS NINDS Nath, Avindra (NINDS) 0 114108270 Major, Eugene NINDS NINDS Major, Eugene (NINDS) 0 114108377 Monaco-Kushner, Maria NINDS NINDS Monaco-Kushner, Maria (NINDS) 0 114108629 Ferenczy, Michael NINDS Ferenczy, Michael 0 114108268 Jaeger, Laura NINDS FDA Jaeger, Laura (FDA) 1 114108268 Jaeger, Laura NINDS FDA Jaeger, Laura (FDA) 1 114108269 Nath, Avindra NINDS NINDS Nath, Avindra (NINDS) 0 114108270 Major, Eugene NINDS NINDS Major, Eugene (NINDS) 0 114108377 Monaco-Kushner, Maria NINDS NINDS Monaco-Kushner, Maria (NINDS) 0 114108629 Ferenczy, Michael NINDS Ferenczy, Michael 0 114101994 Anti-JC Virus Antisense Cocktail E-547-2013-0 Filing authorized NINDS 83687767 Olufemi, Olufunmilola (Lola) olufunmilola.olufemi@nih.gov
United States of America olufunmilola.olufemi@nih.gov?subject=Web Inquiry on [TAB-2681] Use of Antisense Oligodeoxynucleotides for Inhibiting JC Virus&body=Please send me information about technology [TAB-2681] Use of Antisense Oligodeoxynucleotides for Inhibiting JC Virus. Olufemi, Olufunmilola (Lola)<br><a href="mailto:olufunmilola.olufemi@nih.gov?subject=Web Inquiry on [TAB-2681] Use of Antisense Oligodeoxynucleotides for Inhibiting JC Virus&body=Please send me information about technology [TAB-2681] Use of Antisense Oligodeoxynucleotides for Inhibiting JC Virus.">olufunmilola.olufemi@nih.gov</a><br> 114167079 E-547-2013-0 E-547-2013-0-US-05 Compositions And Methods For Inhibiting JC Virus (JCV) National Stage US 10,036,020 15/023,352 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10036020 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10036020">10,036,020</a><br />Filed on 2016-03-18<br />Status: Issued 114167394 E-547-2013-0 E-547-2013-0-US-01 COMPOSITIONS AND METHODS FOR INHIBITING JC VIRUS (JCV) PRV US 61/879,833 Abandoned US <br />Provisional (PRV) 61/879,833<br />Filed on 2013-09-19<br />Status: Abandoned 114168032 E-547-2013-0 E-547-2013-0-PCT-02 Compositions and Methods for Inhibiting JC Virus (JCV) PCT Patent Cooperation Treaty PCT/US2014/056655 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2014/056655<br />Filed on 2014-09-19<br />Status: Expired 114123974 DXXXXX 114123975 DAXXXX 114123976 DDXXXX 114123977 DD1XXX 114123978 DBXXXX 114123979 DB4XXX 114123980 DB4BXX 114123981 DB5XXX 114123982 YBXXXX 114123983 YCXXXX 114145489 Anti-JC 114145490 virus 114145491 Antisense 114145492 Cocktail TAB-2672 114096856 Human Influenza Virus Real-time RT-PCR Detection and Characterization Panel CDC Consumer Products, Diagnostics, Infectious Disease, Licensing, Occupational Safety and Health, Research Materials, Therapeutics Consumer Products Diagnostics Infectious Disease Licensing Occupational Safety and Health Research Materials Therapeutics Nancy Cox, Alexander Klimov, Stephen Lindstrom, Lamorris Loftin This invention relates to methods of rapidly detecting influenza, including differentiating between type and subtype. Unlike culture and serological tests requiring 5 to 14 days for completion, CDC researchers developed a rapid, accurate assay, which is easily adapted to kit form. This assay also requires less labor input than immunoassays. These methods can be used to quickly identify a broad variety of influenza types and subtypes, including viruses that may be involved in pandemics (such as H5N1, for example). <ul> <li>Already FDA approved</li> <li>Especially useful for H5N1 screening</li> <li>Sensitive detection</li> <li>Specific discrimination of influenza subtypes</li> <li>Easily formatted as kit or array</li> <li>Faster than culturing and serological identification methods</li> <li>Less laborious and more objective than immunoassays</li> </ul> <ul> <li>Influenza diagnostic using clinical specimens</li> <li>High-throughput screenings</li> <li>Influenza surveillance programs</li> </ul> Various international filings pending 2022-07-02 2024-10-28 2024-10-28 2013-11-19 Avian, Avian flu, Avian influenza, CDC, CDC Docket Import, CDC Docket Import CDC Prosecuting, DA4BXX, DA4XXX, DAXXXX, DDXXXX, Detection, DEVELOPED, DEVELOPING, Discriminate, discrimination, DXXXXX, INFLUENZA, PCR, PRIMERS, Probes, Pulmonary, respiratory, Respiratory Diseases, respiratory INFECTION, RT-PCR, Serotypes, SUBTYPES, Swine, tropical, Types, VETERINARY, viral, virus, Viruses, VLXXXX, VOXXXX, WBXXXX, WFXXXX, WMXXXX, XCXXXX, XEXXXX, YBXXXX, Zoo, Zoonotic False True In vitro data available True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114171936 Jernigan DB, et al. http://www.ncbi.nlm.nih.gov/pubmed/21342897 <a href="http://www.ncbi.nlm.nih.gov/pubmed/21342897">Jernigan DB, et al.</a> 114108229 Klimov, Alexander CDC - DIR CDC Klimov, Alexander (CDC) 0 114108230 Cox, Nancy CDC - DIR CDC Cox, Nancy (CDC) 0 114108231 Loftin, Lamorris CDC - DIR CDC Loftin, Lamorris (CDC) 0 114108228 Lindstrom, Stephen CDC - DIR CDC Lindstrom, Stephen (CDC) 1 114108228 Lindstrom, Stephen CDC - DIR CDC Lindstrom, Stephen (CDC) 1 114108229 Klimov, Alexander CDC - DIR CDC Klimov, Alexander (CDC) 0 114108230 Cox, Nancy CDC - DIR CDC Cox, Nancy (CDC) 0 114108231 Loftin, Lamorris CDC - DIR CDC Loftin, Lamorris (CDC) 0 114101983 PRIMERS AND PROBES FOR DETECTION AND DISCRIMINATION OF TYPES AND SUBTYPES OF INFLUENZA VIRUSES E-331-2013-0 Filing authorized Centers for Disease Control and Prevention (CDC) 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2672] Human Influenza Virus Real-time RT-PCR Detection and Characterization Panel&body=Please send me information about technology [TAB-2672] Human Influenza Virus Real-time RT-PCR Detection and Characterization Panel. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2672] Human Influenza Virus Real-time RT-PCR Detection and Characterization Panel&body=Please send me information about technology [TAB-2672] Human Influenza Virus Real-time RT-PCR Detection and Characterization Panel.">jonathan.motley@nih.gov</a><br> 114167366 E-331-2013-0 E-331-2013-0-US-01 PRIMERS AND PROBES FOR DETECTION AND DISCRIMINATION OF TYPES AND SUBTYPES OF INFLUENZA VIRUSES PRV US 60/772,806 Abandoned US <br />Provisional (PRV) 60/772,806<br />Filed on 2006-02-13<br />Status: Abandoned 114167367 E-331-2013-0 E-331-2013-0-PCT-02 PRIMERS AND PROBES FOR DETECTION AND DISCRIMINATION OF TYPES AND SUBTYPES OF INFLUENZA VIRUSES PCT Patent Cooperation Treaty PCT/US2007/003646 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2007/003646<br />Filed on 2007-02-12<br />Status: Expired 114167368 E-331-2013-0 E-331-2013-0-US-09 PRIMERS AND PROBES FOR DETECTION AND DISCRIMINATION OF TYPES AND SUBTYPES OF INFLUENZA VIRUSES National Stage US 8,241,853 12/191,186 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8241853 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8241853">8,241,853</a><br />Filed on 2008-08-13<br />Status: Abandoned 114167369 E-331-2013-0 E-331-2013-0-US-10 PROBE AND METHOD FOR DETECTION AND DISCRIMINATION OF TYPES AND SUBTYPES OF INFLUENZA VIRUSES DIV US 8,568,981 13/554,782 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8568981 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8568981">8,568,981</a><br />Filed on 2012-07-20<br />Status: Abandoned 114167370 E-331-2013-0 E-331-2013-0-US-20 PRIMERS AND PROBES FOR DETECTION AND DISCRIMINATION OF TYPES AND SUBTYPES OF INFLUENZA VIRUSES DIV US 9,382,592 14/056,810 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9382592 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9382592">9,382,592</a><br />Filed on 2013-10-17<br />Status: Abandoned 114167836 E-331-2013-0 E-331-2013-0-US-22 PRIMERS AND PROBES FOR DETECTION AND DISCRIMINATION OF TYPES AND SUBTYPES OF INFLUENZA VIRUSES DIV US 10,036,076 15/182,852 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10036076 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10036076">10,036,076</a><br />Filed on 2016-06-15<br />Status: Issued 114168696 E-331-2013-0 E-331-2013-0-US-23 PRIMERS AND PROBES FOR DETECTION AND DISCRIMINATION OF TYPES AND SUBTYPES OF INFLUENZA VIRUSES DIV US 10,196,699 16/042,061 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10196699 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10196699">10,196,699</a><br />Filed on 2018-07-23<br />Status: Issued 114123911 DXXXXX 114123912 DAXXXX 114123913 DA4XXX 114123914 DA4BXX 114123915 DDXXXX 114124034 VLXXXX 114124035 VOXXXX 114124036 WBXXXX 114124037 WFXXXX 114124038 WMXXXX 114124039 XCXXXX 114124040 XEXXXX 114124041 YBXXXX 114145378 PRIMERS 114145379 Probes 114145380 Detection 114145381 discrimination 114145382 Types 114145383 SUBTYPES 114145384 INFLUENZA 114145385 Viruses 114145386 CDC Docket Import 114145387 CDC Docket Import CDC Prosecuting 114145388 Serotypes 114145389 Discriminate 114145390 PCR 114145391 RT-PCR 114145392 respiratory 114145393 Respiratory Diseases 114145394 respiratory INFECTION 114145395 Pulmonary 114145396 virus 114145397 viral 114145398 tropical 114145399 DEVELOPING 114145400 DEVELOPED 114145401 VETERINARY 114145402 Zoo 114145403 Zoonotic 114145404 Swine 114145405 Avian 114145406 Avian flu 114145407 Avian influenza 114145408 CDC TAB-2658 114096840 Real-Time PCR Assay for Specific Detection of Haemophilus influenzae Serotypes A and B CDC Diagnostics, Infectious Disease, Licensing Diagnostics Infectious Disease Licensing Raydel Anderson, Cynthia Hatcher, Leonard Mayer, Mary Theodore, Jennifer Thomas, Xin Wang <em>Haemophilus influenzae</em> is responsible for life-threatening respiratory infections including meningitis. This assay allows for the qualitative detection of the bacterial meningitis pathogen <em>H. influenzae</em> serotype A (Hia) and serotype B (Hib) in fluid samples, without detecting any of the other serotypes of <em>H. influenzae</em>. This invention is capable of detecting even the very small numbers of Hia or Hib within clinical specimens. <ul> <li>Easily adapted to a real-time PCR assay (monoplex or multiplex) kit</li> <li>Rapid, accurate and specific, especially when compared to sero-diagnostic approaches</li> <li>No further testing need, presently ready for commercialization</li> </ul> <ul> <li>Meningitis nucleic acid-based diagnostics for testing clinical samples</li> <li>Useful for public health monitoring programs</li> <li>Surveillance of circulating H. influenzae serotypes</li> </ul> 2022-10-19 2024-10-28 2024-10-28 2013-10-18 CDC Docket Import, CDC Docket Import CDC Prosecuting, DA3XXX, DAXXXX, Detection, DXXXXX, HAEMOPHILUS, INFLUENZAE, OID-NCIRD-DBD, SELECTIVE False True <ul> <li>Early-stage</li> <li>Pre-clinical</li> <li>In vitro data available</li> </ul> True NIHTT 37470483 Website Abstract 114108181 Wang, Xin CDC - DIR CDC Wang, Xin (CDC) 0 114108182 Hatcher, Cynthia CDC - DIR CDC Hatcher, Cynthia (CDC) 0 114108183 Anderson, Raydel CDC - DIR CDC Anderson, Raydel (CDC) 0 114108184 Theodore, Mary CDC - DIR CDC Theodore, Mary (CDC) 0 114108185 Mayer, Leonard CDC - DIR CDC Mayer, Leonard (CDC) 0 114108180 Thomas, Jennifer CDC - DIR CDC Thomas, Jennifer (CDC) 1 114108180 Thomas, Jennifer CDC - DIR CDC Thomas, Jennifer (CDC) 1 114108181 Wang, Xin CDC - DIR CDC Wang, Xin (CDC) 0 114108182 Hatcher, Cynthia CDC - DIR CDC Hatcher, Cynthia (CDC) 0 114108183 Anderson, Raydel CDC - DIR CDC Anderson, Raydel (CDC) 0 114108184 Theodore, Mary CDC - DIR CDC Theodore, Mary (CDC) 0 114108185 Mayer, Leonard CDC - DIR CDC Mayer, Leonard (CDC) 0 114101968 Selective Detection Of Haemophilus Influenzae E-164-2013-0 Filing authorized Centers for Disease Control and Prevention (CDC) 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2658] Real-Time PCR Assay for Specific Detection of Haemophilus influenzae Serotypes A and B&body=Please send me information about technology [TAB-2658] Real-Time PCR Assay for Specific Detection of Haemophilus influenzae Serotypes A and B. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2658] Real-Time PCR Assay for Specific Detection of Haemophilus influenzae Serotypes A and B&body=Please send me information about technology [TAB-2658] Real-Time PCR Assay for Specific Detection of Haemophilus influenzae Serotypes A and B.">jonathan.motley@nih.gov</a><br> 114161378 E-164-2013-0 E-164-2013-0-US-08 Selective Detection Of Haemophilus Influenzae CON US 10,683,558 15/420,836 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10683558 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10683558">10,683,558</a><br />Filed on 2017-01-31<br />Status: Issued 114167174 E-164-2013-0 E-164-2013-0-US-07 Selective Detection Of Haemophilus Influenzae DIV US 10,669,591 15/420,819 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10669591 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10669591">10,669,591</a><br />Filed on 2017-01-31<br />Status: Issued 114167318 E-164-2013-0 E-164-2013-0-US-01 Selective Detection Of Haemophilus Influenzae PRV US 61/436,535 Abandoned US <br />Provisional (PRV) 61/436,535<br />Filed on 2011-01-26<br />Status: Abandoned 114167319 E-164-2013-0 E-164-2013-0-PCT-02 Selective Detection Of Haemophilus Influenzae PCT Patent Cooperation Treaty PCT/US2012/022753 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2012/022753<br />Filed on 2012-01-26<br />Status: Expired 114167320 E-164-2013-0 E-164-2013-0-US-06 Selective Detection Of Haemophilus Influenzae National Stage US 9,593,385 13/996,913 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9593385 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9593385">9,593,385</a><br />Filed on 2013-06-21<br />Status: Issued 114123802 DXXXXX 114123803 DAXXXX 114123804 DA3XXX 114145179 SELECTIVE 114145180 Detection 114145181 HAEMOPHILUS 114145182 INFLUENZAE 114145183 CDC Docket Import 114145184 CDC Docket Import CDC Prosecuting 114145185 OID-NCIRD-DBD TAB-2655 114096839 Small Interfering RNA Inhibition of Cannabanoid-1 Receptor (CB1R) for Treating Type 2 Diabetes NIAAA Diagnostics, Licensing, Research Materials, Therapeutics Diagnostics Licensing Research Materials Therapeutics Myriam Aouadi, Michael Czech, Tony Jourdan, George Kunos The invention pertains to the use of glucan encapsulated non-immunostimulatory small interfering RNAs (siRNAs) to treat type-2 diabetes. Endocannabinoids (EC) are lipid signaling molecules that act on the same cannabinoid receptors that recognize and mediate the effects of endo- and phytocannabanoids. EC receptor CB1R activation is implicated in the development of obesity and its metabolic consequences, including insulin resistance and type 2 diabetes. Beta-cell loss has been demonstrated in a Zucker diabetic fatty (ZDF) rat model of type-2 diabetes through CB1R-mediated activation of a macrophage-mediated inflammatory response. Conversely, rats treated with a peripheral CB1R antagonist restores normoglycemia and preserves beta-cell function. Similar results are seen following selective in vivo knockdown of macrophage CB1R by daily treatment of ZDF rats with the instant D-glucan-encapsulated CB1R Small interfering RNA (siRNA). Knock-down of CB1R with using glucan encapsulated siRNA may represent a new commecializable method of treating type-2 diabetes or preventing the progression of insulin resistance to overt diabetes. <ul> </li>A new means of inhibiting the endocannabinoid receptor CB1R.</li> </ul> <ul> </li>Treatment of obesity, insulin resistance, and diabetes.</li> </ul> European Patent Application pending 2022-03-08 2024-10-28 2024-10-28 2013-09-19 CB1, DIABETES, GB1AXX, GB1XXX, GBXXXX, GXXXXX, IBXXXX, IXXXXX, Knockdown, MACROPHAGES, RECEPTORS, SELECTIVE, SiRNA-mediated, treatment False True In vivo data available (animal) True NIHTT 37470483 Website Abstract 114108163 Jourdan, Tony National Institute on Alcohol Abuse and Alcoholism (NIAAA) Jourdan, Tony 0 114108164 Czech, Michael University of Massachusetts Medical School Czech, Michael 0 114108165 Aouadi, Myriam University of Massachusetts Medical School Aouadi, Myriam 0 114108162 Kunos, George National Institute on Alcohol Abuse and Alcoholism (NIAAA) NIAAA Kunos, George (NIAAA) 1 114108162 Kunos, George National Institute on Alcohol Abuse and Alcoholism (NIAAA) NIAAA Kunos, George (NIAAA) 1 114108163 Jourdan, Tony National Institute on Alcohol Abuse and Alcoholism (NIAAA) Jourdan, Tony 0 114108164 Czech, Michael University of Massachusetts Medical School Czech, Michael 0 114108165 Aouadi, Myriam University of Massachusetts Medical School Aouadi, Myriam 0 114101964 Selective, SiRNA-mediated Knockdown Of CB1 Receptors In Macrophages For The Treatment Of Diabetes E-103-2013-0 Filing authorized National Institute on Alcohol Abuse and Alcoholism (NIAAA), University of Massachusetts Medical School 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-2655] Small Interfering RNA Inhibition of Cannabanoid-1 Receptor (CB1R) for Treating Type 2 Diabetes&body=Please send me information about technology [TAB-2655] Small Interfering RNA Inhibition of Cannabanoid-1 Receptor (CB1R) for Treating Type 2 Diabetes. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-2655] Small Interfering RNA Inhibition of Cannabanoid-1 Receptor (CB1R) for Treating Type 2 Diabetes&body=Please send me information about technology [TAB-2655] Small Interfering RNA Inhibition of Cannabanoid-1 Receptor (CB1R) for Treating Type 2 Diabetes.">shmilovm@nih.gov</a><br> 114160351 E-103-2013-0 E-103-2013-0-US-04 Glucan-Encapsulated Sirna for Treating Type 2 Diabetes Mellitus National Stage US 10,077,446 14/900,951 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10077446 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10077446">10,077,446</a><br />Filed on 2015-12-22<br />Status: Issued 114167295 E-103-2013-0 E-103-2013-0-US-01 GLUCAN-ENCAPSULATED SIRNA FOR TREATING TYPE 2 DIABETES MELLITUS PRV US 61/839,239 Abandoned US <br />Provisional (PRV) 61/839,239<br />Filed on 2013-06-25<br />Status: Abandoned 114167871 E-103-2013-0 E-103-2013-0-PCT-02 GLUCAN-ENCAPSULATED SIRNA FOR TREATING TYPE 2 DIABETES MELLITUS PCT Patent Cooperation Treaty PCT/US2014/043924 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2014/043924<br />Filed on 2014-06-24<br />Status: Expired 114123789 IBXXXX 114123790 GBXXXX 114123791 GB1AXX 114123792 IXXXXX 114123793 GXXXXX 114123794 GB1XXX 114145148 SELECTIVE 114145149 SiRNA-mediated 114145150 Knockdown 114145151 CB1 114145152 RECEPTORS 114145153 MACROPHAGES 114145154 treatment 114145155 DIABETES TAB-2648 114096836 Real-time PCR Multiplex Assay for Detection of Bacterial Respiratory Pathogens in Clinical Specimens CDC Diagnostics, Infectious Disease, Licensing Diagnostics Infectious Disease Licensing Kathleen Thurman, Agnes Warner, Jonas Winchell CDC researchers have developed a single-tube, real-time PCR assay for the simultaneous detection of three bacterial respiratory pathogens (<em>Mycoplasma pneumoniae</em>, <em>Chlamydiophila pneumoniae</em> and <em>Legionella</em> spp.). The assay has an internal control testing for presence of human DNA. This four-plex real-time PCR assay could potentially become a routine screening test for patients with respiratory illness. Ninety four clinical specimens (in a 96-well format) can be tested at once. This assay is non-invasive, rapid and cost-effective. It has the potential for point-of-care applications in population-based pneumonia surveillance. <ul> <li>Sensitive and specific</li> <li>High-throughput friendly</li> <li>Rapid and cost-effective compared to screening for individual respiratory pathogens</li> <li>Easily developed for use in diagnostic kits</li> </ul> <ul> <li>Population-based pneumonia surveillance</li> <li>Development of broadly-capable respiratory clinical diagnostics</li> </ul> 2022-10-19 2024-10-28 2024-10-28 2013-09-19 AA5XXX, AAXXXX, assay, AXXXXX, Bacterial, CDC Docket Import, CDC Docket Import CDC Prosecuting, DA3XXX, DAXXXX, Detection, DXXXXX, Multiplex, OID-NCIRD-DBD, PATHOGENS, PCR, REAL, respiratory, TIME False True <ul> <li>Pre-clinical</li> <li>In vitro data available</li> </ul> True NIHTT 37470483 Website Abstract 114171913 Thurman KA, et al. http://www.ncbi.nlm.nih.gov/pubmed/21397428 <a href="http://www.ncbi.nlm.nih.gov/pubmed/21397428">Thurman KA, et al.</a> 114108148 Warner, Agnes CDC - DIR CDC Warner, Agnes (CDC) 0 114108152 Thurman, Kathleen CDC - DIR CDC Thurman, Kathleen (CDC) 0 114108149 Winchell, Jonas CDC - DIR CDC Winchell, Jonas (CDC) 1 114108149 Winchell, Jonas CDC - DIR CDC Winchell, Jonas (CDC) 1 114108148 Warner, Agnes CDC - DIR CDC Warner, Agnes (CDC) 0 114108152 Thurman, Kathleen CDC - DIR CDC Thurman, Kathleen (CDC) 0 114101960 REAL TIME MULTIPLEX PCR ASSAY FOR DETECTION OF BACTERIAL RESPIRATORY PATHOGENS E-300-2013-0 Filing authorized Centers for Disease Control and Prevention (CDC) 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2648] Real-time PCR Multiplex Assay for Detection of Bacterial Respiratory Pathogens in Clinical Specimens&body=Please send me information about technology [TAB-2648] Real-time PCR Multiplex Assay for Detection of Bacterial Respiratory Pathogens in Clinical Specimens. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2648] Real-time PCR Multiplex Assay for Detection of Bacterial Respiratory Pathogens in Clinical Specimens&body=Please send me information about technology [TAB-2648] Real-time PCR Multiplex Assay for Detection of Bacterial Respiratory Pathogens in Clinical Specimens.">jonathan.motley@nih.gov</a><br> 114167284 E-300-2013-0 E-300-2013-0-PCT-02 REAL TIME MULTIPLEX PCR ASSAY FOR DETECTION OF BACTERIAL RESPIRATORY PATHOGENS PCT Patent Cooperation Treaty PCT/US2011/032749 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2011/032749<br />Filed on 2011-04-15<br />Status: Expired 114167285 E-300-2013-0 E-300-2013-0-US-01 REAL TIME MULTIPLEX PCR ASSAY FOR DETECTION OF BACTERIAL RESPIRATORY PATHOGENS PRV US 61/324,986 Abandoned US <br />Provisional (PRV) 61/324,986<br />Filed on 2010-04-16<br />Status: Abandoned 114167286 E-300-2013-0 E-300-2013-0-US-07 REAL TIME MULTIPLEX PCR ASSAY FOR DETECTION OF BACTERIAL RESPIRATORY PATHOGENS National Stage US 9,260,762 13/641,444 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9260762 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9260762">9,260,762</a><br />Filed on 2012-11-28<br />Status: Abandoned 114123770 AA5XXX 114123773 DXXXXX 114123774 DAXXXX 114123775 DA3XXX 114123776 AAXXXX 114123777 AXXXXX 114145116 REAL 114145117 TIME 114145118 Multiplex 114145119 PCR 114145120 assay 114145121 Detection 114145122 Bacterial 114145123 respiratory 114145124 PATHOGENS 114145125 CDC Docket Import 114145126 CDC Docket Import CDC Prosecuting 114145127 OID-NCIRD-DBD TAB-2645 114096833 Multiplex Real-time PCR Assay for Detection of Numerous Bacterial Pathogens CDC Diagnostics, Infectious Disease, Licensing Diagnostics Infectious Disease Licensing Maureen Diaz, Jonas Winchell, Bernard Wolff In order to address a global need for rapid, cost-effective, sensitive, and specific assays for many pathogens, CDC scientists have developed a broad-use, multiplexed RT-PCR assay. This comprehensive assay covers numerous pathogens that are common causes of infection in neonates and also important to food-safety. Specifically, this assay (and respective probes, primers, and kits) is capable of detecting one or more of <em>Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, Toxoplasma gondii, Moraxella catarrhalis, Escherichia coli, Shigella, Staphylococcus aureus, Pneumocystis jirovecii, Chlamydia trachomatis, Ureaplasma urealyticum, Ureaplasma parvum, Ureaplasma spp., Bartonella spp., Streptococcus agalactiae,</em> and <em>Neisseria meningitidis</em> in a biological sample. <ul> <li>Cost-effective</li> <li>Simple to implement</li> <li>Rapid, accurate and objectively conclusive</li> <li>Easily implemented into kit format</li> <li>Ideal for high-throughput scenarios</li> </ul> <ul> <li>Clinical diagnostic for several pathogens</li> <li>Drug-resistance surveillance</li> <li>Public health monitoring</li> <li>En masse food-safety screening</li> </ul> 2022-10-19 2024-10-28 2024-10-28 2013-09-18 CDC Docket Import, CDC Docket Import CDC Prosecuting, DA3XXX, DAXXXX, Detection, DXXXXX, PATHOGENS, PCR, REAL-TIME False True <ul> <li>Pre-clinical</li> <li>In vitro data available</li> </ul> True NIHTT 37470483 Website Abstract 114171911 Diaz MH, et al. http://www.ncbi.nlm.nih.gov/pubmed/23805203 <a href="http://www.ncbi.nlm.nih.gov/pubmed/23805203">Diaz MH, et al.</a> 114108144 Wolff, Bernard CDC - DIR CDC Wolff, Bernard (CDC) 0 114108145 Diaz, Maureen CDC - DIR CDC Diaz, Maureen (CDC) 0 114108143 Winchell, Jonas CDC - DIR CDC Winchell, Jonas (CDC) 1 114108143 Winchell, Jonas CDC - DIR CDC Winchell, Jonas (CDC) 1 114108144 Wolff, Bernard CDC - DIR CDC Wolff, Bernard (CDC) 0 114108145 Diaz, Maureen CDC - DIR CDC Diaz, Maureen (CDC) 0 114101958 REAL-TIME PCR FOR THE DETECTION OF PATHOGENS E-276-2013-0 Filing authorized Centers for Disease Control and Prevention (CDC) 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2645] Multiplex Real-time PCR Assay for Detection of Numerous Bacterial Pathogens&body=Please send me information about technology [TAB-2645] Multiplex Real-time PCR Assay for Detection of Numerous Bacterial Pathogens. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2645] Multiplex Real-time PCR Assay for Detection of Numerous Bacterial Pathogens&body=Please send me information about technology [TAB-2645] Multiplex Real-time PCR Assay for Detection of Numerous Bacterial Pathogens.">jonathan.motley@nih.gov</a><br> 114167275 E-276-2013-0 E-276-2013-0-US-01 REAL-TIME PCR FOR THE DETECTION OF PATHOGENS PRV US 61/642,091 Abandoned US <br />Provisional (PRV) 61/642,091<br />Filed on 2012-05-03<br />Status: Abandoned 114167276 E-276-2013-0 E-276-2013-0-PCT-02 REAL-TIME PCR FOR THE DETECTION OF PATHOGENS PCT Patent Cooperation Treaty PCT/US2013/028034 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2013/028034<br />Filed on 2013-02-27<br />Status: Expired 114167990 E-276-2013-0 E-276-2013-0-US-03 REAL-TIME PCR FOR THE DETECTION OF PATHOGENS National Stage US 10,072,305 14/398,390 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10072305 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10072305">10,072,305</a><br />Filed on 2014-10-31<br />Status: Issued 114168704 E-276-2013-0 E-276-2013-0-US-04 REAL-TIME PCR FOR THE DETECTION OF PATHOGENS DIV US 11,162,144 16/056,147 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11162144 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11162144">11,162,144</a><br />Filed on 2018-08-06<br />Status: Issued 114169165 E-276-2013-0 E-276-2013-0-US-05 REAL-TIME PCR FOR THE DETECTION OF PATHOGENS DIV US 12,264,369 17/485,953 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12264369 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12264369">12,264,369</a><br />Filed on 2021-09-27<br />Status: Issued 114123755 DXXXXX 114123756 DAXXXX 114123757 DA3XXX 114145090 REAL-TIME 114145091 PCR 114145092 Detection 114145093 PATHOGENS 114145094 CDC Docket Import 114145095 CDC Docket Import CDC Prosecuting TAB-2646 114096834 Diagnostic Assays Utilizing Real-Time Taqman or Seminested RT-PCR for Parechovirus Detection and Discrimination CDC Collaboration, Diagnostics, Infectious Disease, Licensing Collaboration Diagnostics Infectious Disease Licensing William Nix, Mark Oberste The CDC developed a real-time reverse transcription polymerase chain reaction (RT-PCR) Taqman assay and an RT-semi nested PCR (RT-snPCR) assay for the detection of parechoviruses. Similar to enteroviruses, parechoviruses are responsible for gastrointestinal, respiratory and central nervous system infections. All tests target conserved regions in the 5'-nontranslated region (5-'NTR) of the parechovirus genome and share forward and reverse primers. The Taqman probe and RTsnPCR nested primer target the same conserved site but vary in length. Both assays detect all known human parechoviruses (PPeV) and Ljungan viruses (LV), unlike other published parechovirus 5'-NTR assays, which only detect a limited number of PPeV types. Both assays are more sensitive than current methods (culture and multiple, single-serotype nucleic acid amplification assays) and may be used to test isolates or original clinical specimens. <ul> <li>Detects all Parechovirus genus members with a single assay</li> <li>Rapid, accurate, sensitive and specific</li> <li>Cost-effective in terms or resource-input, labor and turnaround time</li> <li>Does not require culturing</li> <li>Easily adaptable to kit form</li> </ul> <ul> <li>Diagnostic detection of all known species of Parechovirus from clinical samples, including Human parechovirus and Ljungan virus</li> <li>Discrimination of specific species and serotypes</li> <li>Public health surveillance programs</li> <li>Research tool for all lab strains and clinical isolates of parechovirus</li> </ul> The Centers for Disease Control and Prevention (CDC) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize Diagnostic Assays Utilizing Real-Time Taqman or Seminested RT-PCR for Parechovirus Detection and Discrimination. For collaboration opportunities, please contact Suzanne Shope at <a href="mailto:sshope@cdc.gov">sshope@cdc.gov</a> or 770-488-8613. 2022-11-17 2024-10-28 2024-10-28 2013-09-19 Agents, CDC Docket Import, CDC Docket Import CDC Prosecuting, DA4BXX, DA4XXX, DAXXXX, DETECTING, DXXXXX, Methods, OID-NCIRD-DVD, PARECHOVIRUS False True <ul> <li>Early-stage</li> <li>In vitro data available</li> </ul> True NIHTT 37470483 Website Abstract 114108147 Oberste, Mark CDC - DIR CDC Oberste, Mark (CDC) 0 114108146 Nix, William CDC - DIR CDC Nix, William (CDC) 1 114108146 Nix, William CDC - DIR CDC Nix, William (CDC) 1 114108147 Oberste, Mark CDC - DIR CDC Oberste, Mark (CDC) 0 114101959 METHODS AND AGENTS FOR DETECTING PARECHOVIRUS E-295-2013-0 Filing authorized Centers for Disease Control and Prevention (CDC) 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2646] Diagnostic Assays Utilizing Real-Time Taqman or Seminested RT-PCR for Parechovirus Detection and Discrimination&body=Please send me information about technology [TAB-2646] Diagnostic Assays Utilizing Real-Time Taqman or Seminested RT-PCR for Parechovirus Detection and Discrimination. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2646] Diagnostic Assays Utilizing Real-Time Taqman or Seminested RT-PCR for Parechovirus Detection and Discrimination&body=Please send me information about technology [TAB-2646] Diagnostic Assays Utilizing Real-Time Taqman or Seminested RT-PCR for Parechovirus Detection and Discrimination.">jonathan.motley@nih.gov</a><br> 114167278 E-295-2013-0 E-295-2013-0-PCT-01 METHODS AND AGENTS FOR DETECTING PARECHOVIRUS PCT Patent Cooperation Treaty PCT/US2006/016624 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2006/016624<br />Filed on 2006-05-01<br />Status: Expired 114167279 E-295-2013-0 E-295-2013-0-US-04 METHODS AND AGENTS FOR DETECTING PARECHOVIRUS National Stage US 8,048,630 12/299,097 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8048630 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8048630">8,048,630</a><br />Filed on 2008-10-30<br />Status: Expired 114123758 DXXXXX 114123759 DAXXXX 114123760 DA4XXX 114123761 DA4BXX 114145096 Methods 114145097 Agents 114145098 DETECTING 114145099 PARECHOVIRUS 114145100 CDC Docket Import 114145101 CDC Docket Import CDC Prosecuting 114145102 OID-NCIRD-DVD TAB-2644 114096832 Methods of Detecting and Identifying Both Known and Novel Influenza Viruses CDC Collaboration, Diagnostics, Infectious Disease, Licensing, Materials Available Collaboration Diagnostics Infectious Disease Licensing Materials Available Shannon Rogers, Suxiang (Sue) Tong This invention describes materials and methods of detecting novel influenza virus in a sample. As highlighted by the recent H1N1 pandemic strain, influenza viruses are constantly evolving and novel reassortments can quickly spread around the world. <br /><br /> The reagents and methods of this particular technology are capable of detecting any type of influenza virus (such as influenza A virus, influenza B virus, and influenza C virus) in a sample, including novel or previously unknown influenza viruses. Such methods and compositions are useful for diagnosing influenza virus infection in humans and animals. <ul> <li>A full-spectrum, sensitive and specific assay for identification of influenza viruses, known and novel</li> <li>Easily adaptable for commercial production</li> </ul> <ul> <li>Method of rapid, accurate subtype-screening of influenza viruses using "pan-influenza" RT-PCR</li> <li>Diagnostic tool for clinicians, veterinarians, public health programs, food-safety officials, researchers and forensic scientists</li> </ul> The Centers for Disease Control and Prevention (CDC) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize Methods of Detecting and Identifying Both Known and Novel Influenza Viruses. For collaboration opportunities, please contact Suzanne Shope at <a href="mailto:sshope@cdc.gov">sshope@cdc.gov</a> or 770-488-8613. 2022-10-19 2024-10-28 2024-10-28 2013-09-18 AA5XXX, AAXXXX, AXXXXX, CDC Docket Import, CDC Docket Import CDC Prosecuting, DA4BXX, DA4XXX, DAXXXX, DETECTING, DXXXXX, INFLUENZA, Methods, virus False True <ul> <li>Pre-clinical</li> <li>In vitro data available</li> </ul> True NIHTT 37470483 Website Abstract 114171908 Fouchier RA, et al. http://www.ncbi.nlm.nih.gov/pubmed/15709000 <a href="http://www.ncbi.nlm.nih.gov/pubmed/15709000">Fouchier RA, et al.</a> 114171909 Fouchier RA, et al. http://www.ncbi.nlm.nih.gov/pubmed/11060074 <a href="http://www.ncbi.nlm.nih.gov/pubmed/11060074">Fouchier RA, et al.</a> 114171910 Tong S, et al. http://www.ncbi.nlm.nih.gov/pubmed/18579717 <a href="http://www.ncbi.nlm.nih.gov/pubmed/18579717">Tong S, et al.</a> 114108142 Rogers, Shannon CDC - DIR CDC Rogers, Shannon (CDC) 0 114108141 Tong, Suxiang (Sue) CDC - DIR CDC Tong, Suxiang (Sue) (CDC) 1 114108141 Tong, Suxiang (Sue) CDC - DIR CDC Tong, Suxiang (Sue) (CDC) 1 114108142 Rogers, Shannon CDC - DIR CDC Rogers, Shannon (CDC) 0 114101957 METHODS OF DETECTING INFLUENZA VIRUS E-274-2013-0 Filing authorized Centers for Disease Control and Prevention (CDC) 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2644] Methods of Detecting and Identifying Both Known and Novel Influenza Viruses&body=Please send me information about technology [TAB-2644] Methods of Detecting and Identifying Both Known and Novel Influenza Viruses. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2644] Methods of Detecting and Identifying Both Known and Novel Influenza Viruses&body=Please send me information about technology [TAB-2644] Methods of Detecting and Identifying Both Known and Novel Influenza Viruses.">jonathan.motley@nih.gov</a><br> 114167273 E-274-2013-0 E-274-2013-0-US-01 METHODS OF DETECTING INFLUENZA VIRUS PRV US 61/642,098 Abandoned US <br />Provisional (PRV) 61/642,098<br />Filed on 2012-05-03<br />Status: Abandoned 114167274 E-274-2013-0 E-274-2013-0-PCT-02 METHODS OF DETECTING INFLUENZA VIRUS PCT Patent Cooperation Treaty PCT/US2013/029600 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2013/029600<br />Filed on 2013-03-07<br />Status: Expired 114167991 E-274-2013-0 E-274-2013-0-US-03 METHODS OF DETECTING INFLUENZA VIRUS National Stage US 9,803,251 14/398,383 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9803251 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9803251">9,803,251</a><br />Filed on 2014-10-31<br />Status: Issued 114123748 DXXXXX 114123749 DAXXXX 114123750 DA4XXX 114123751 DA4BXX 114123752 AA5XXX 114123753 AXXXXX 114123754 AAXXXX 114145084 Methods 114145085 DETECTING 114145086 INFLUENZA 114145087 virus 114145088 CDC Docket Import 114145089 CDC Docket Import CDC Prosecuting TAB-2641 114096829 Real-time PCR Assay for Detection of Pneumococcal DNA and Diagnosis of Pneumococcal Disease CDC Collaboration, Diagnostics, Infectious Disease, Licensing Collaboration Diagnostics Infectious Disease Licensing Edwin Ades, George Carlone, Maria Da Gloria Carvalho, Karen McCaustland, Jacquelyn Sampson CDC scientists have developed a real-time PCR assay for diagnosing pneumococcal disease using amplification of the bacterial gene encoding pneumococcal surface adhesin A (PsaA). Pneumococcal isolation and identification is often complicated by 1) antimicrobial suppression of growth in culture and 2) contamination by normal flora alpha-streptococci. Further, pneumococcal detection by culture and serological methods can be time-consuming, relatively expensive, laborious and, ultimately, indeterminate. Sensitive and specific assays that can be completed quickly in the clinical laboratory are essential for early diagnosis and effective therapy. This RT-PCR assay provides a tool for quick and accurate diagnosis by physicians and health care technicians and may be useful in evaluating the efficacy of novel pneumococcal vaccines and therapeutics. <ul> <li>Cost-effective</li> <li>Simple to implement</li> <li>Rapid, accurate and objectively conclusive</li> <li>Easily implemented as a kit</li> </ul> <ul> <li>Pneumococcal disease diagnostics and surveillance programs</li> <li>Streptococcus pneumoniae vaccine development and improvementt</li> <li>Evaluation of efficacy of anti-pneumococcal therapeutics</li> </ul> The Centers for Disease Control and Prevention (CDC) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize Real-time PCR Assay for Detection of Pneumococcal DNA and Diagnosis of Pneumococcal Disease. For collaboration opportunities, please contact Suzanne Shope at <a href="mailto:sshope@cdc.gov">sshope@cdc.gov</a> or 770-488-8613. 2022-10-19 2024-10-28 2024-10-28 2013-09-17 assay, CDC Docket Import, CDC Docket Import CDC Prosecuting, DA3XXX, DAXXXX, Detection, Development, Diagnosis, Disease, DNA, DXXXXX, PCR, PNEUMOCOCCAL, REAL-TIME False True <ul> <li>Pre-clinical</li> <li>In vitro data available</li> </ul> True NIHTT 37470483 Website Abstract 114171905 Carvalho MG, et al. http://www.ncbi.nlm.nih.gov/pubmed/17537936 <a href="http://www.ncbi.nlm.nih.gov/pubmed/17537936">Carvalho MG, et al.</a> 114108131 Ades, Edwin CDC - DIR CDC Ades, Edwin (CDC) 0 114108132 Carlone, George CDC - DIR CDC Carlone, George (CDC) 0 114108133 McCaustland, Karen CDC - DIR CDC McCaustland, Karen (CDC) 0 114108134 Carvalho, Maria Da Gloria CDC - DIR CDC Carvalho, Maria Da Gloria (CDC) 0 114108130 Sampson, Jacquelyn CDC - DIR CDC Sampson, Jacquelyn (CDC) 1 114108130 Sampson, Jacquelyn CDC - DIR CDC Sampson, Jacquelyn (CDC) 1 114108131 Ades, Edwin CDC - DIR CDC Ades, Edwin (CDC) 0 114108132 Carlone, George CDC - DIR CDC Carlone, George (CDC) 0 114108133 McCaustland, Karen CDC - DIR CDC McCaustland, Karen (CDC) 0 114108134 Carvalho, Maria Da Gloria CDC - DIR CDC Carvalho, Maria Da Gloria (CDC) 0 114101954 DEVELOPMENT OF A REAL-TIME PCR ASSAY FOR DETECTION OF PNEUMOCOCCAL DNA AND DIAGNOSIS OF PNEUMOCOCCAL DISEASE E-250-2013-0 Closed Centers for Disease Control and Prevention (CDC) 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2641] Real-time PCR Assay for Detection of Pneumococcal DNA and Diagnosis of Pneumococcal Disease&body=Please send me information about technology [TAB-2641] Real-time PCR Assay for Detection of Pneumococcal DNA and Diagnosis of Pneumococcal Disease. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2641] Real-time PCR Assay for Detection of Pneumococcal DNA and Diagnosis of Pneumococcal Disease&body=Please send me information about technology [TAB-2641] Real-time PCR Assay for Detection of Pneumococcal DNA and Diagnosis of Pneumococcal Disease.">jonathan.motley@nih.gov</a><br> 114167262 E-250-2013-0 E-250-2013-0-US-01 DEVELOPMENT OF A REAL-TIME PCR ASSAY FOR DETECTION OF PNEUMOCOCCAL DNA AND DIAGNOSIS OF PNEUMOCOCCAL DISEASE ORD US 7,476,733 11/089,938 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7476733 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7476733">7,476,733</a><br />Filed on 2005-03-25<br />Status: Abandoned 114167263 E-250-2013-0 E-250-2013-0-PCT-02 DEVELOPMENT OF A REAL-TIME PCR ASSAY FOR DETECTION OF PNEUMOCOCCAL DNA AND DIAGNOSIS OF PNEUMOCOCCAL DISEASE PCT Patent Cooperation Treaty PCT/US2005/010449 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2005/010449<br />Filed on 2005-03-28<br />Status: Expired 114123734 DXXXXX 114123735 DAXXXX 114123736 DA3XXX 114145058 Development 114145059 REAL-TIME 114145060 PCR 114145061 assay 114145062 Detection 114145063 PNEUMOCOCCAL 114145064 DNA 114145065 Diagnosis 114145066 Disease 114145067 CDC Docket Import 114145068 CDC Docket Import CDC Prosecuting TAB-2640 114096828 Real-time PCR Assays for Selective Detection and Differentiation of B. pertussis, B. parapertussis and B. homesii CDC Diagnostics, Infectious Disease, Licensing Diagnostics Infectious Disease Licensing Kansas Sparks, Kathleen Tatti, Maria-Lucia Tondella CDC researchers developed a real-time PCR assay targeting insertion sequence (IS481) and pertussis toxin subunit 1 (ptxS1) of <em>Bordetella pertussis</em>. This real-time nucleic acid assay offers rapid, sensitive, and quantitative results. The employed primers have been validated through extensive diagnostic testing of 41 <em>Bordetella</em> and 64 non-<em>Bordetella</em> clinical isolates. This technology can be used to diagnose and distinguish <em>B. pertussis</em>, <em>B. parapertussis</em> and <em>B. homesii</em>, the three most common <em>Bordetella</em> human upper respiratory pathogens. A standalone assay or multi-faceted kit may be used. <ul> <li>Validated for the three major pathogens responsible for <em>Bordetella</em>-related upper respiratory infections</li> <li>Rapid, sensitive and quantitative</li> <li>Easily adapted to kit form</li> <li>Useful as an added, internal control for present <em>Bordetella pertussis</em> diagnostics</li> </ul> <ul> <li>Diagnostics for <em>Bordetella</em> pathogens</li> <li>Investigation of acute upper respiratory illness and outbreaks</li> </ul> 2022-10-19 2024-10-28 2024-10-28 2013-09-17 BORDETELLA, CDC Docket Import, CDC Docket Import CDC Prosecuting, DA3XXX, DAXXXX, Detection, DXXXXX, SELECTIVE, Species False True <ul> <li>Early-stage</li> <li>In vitro data available</li> </ul> True NIHTT 37470483 Website Abstract 114171904 Tatti KM, et al. http://www.ncbi.nlm.nih.gov/pubmed/18440175 <a href="http://www.ncbi.nlm.nih.gov/pubmed/18440175">Tatti KM, et al.</a> 114108128 Sparks, Kansas CDC - DIR CDC Sparks, Kansas (CDC) 0 114108129 Tondella, Maria-Lucia CDC - DIR CDC Tondella, Maria-Lucia (CDC) 0 114108127 Tatti, Kathleen CDC - DIR CDC Tatti, Kathleen (CDC) 1 114108127 Tatti, Kathleen CDC - DIR CDC Tatti, Kathleen (CDC) 1 114108128 Sparks, Kansas CDC - DIR CDC Sparks, Kansas (CDC) 0 114108129 Tondella, Maria-Lucia CDC - DIR CDC Tondella, Maria-Lucia (CDC) 0 114101953 Selective Detection Of Bordetella Species E-193-2013-0 Filing authorized Centers for Disease Control and Prevention (CDC) 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2640] Real-time PCR Assays for Selective Detection and Differentiation of B. pertussis, B. parapertussis and B. homesii&body=Please send me information about technology [TAB-2640] Real-time PCR Assays for Selective Detection and Differentiation of B. pertussis, B. parapertussis and B. homesii. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2640] Real-time PCR Assays for Selective Detection and Differentiation of B. pertussis, B. parapertussis and B. homesii&body=Please send me information about technology [TAB-2640] Real-time PCR Assays for Selective Detection and Differentiation of B. pertussis, B. parapertussis and B. homesii.">jonathan.motley@nih.gov</a><br> 114167259 E-193-2013-0 E-193-2013-0-US-01 Selective Detection Of Bordetella Species PRV US 61/172,382 Abandoned US <br />Provisional (PRV) 61/172,382<br />Filed on 2009-04-24<br />Status: Abandoned 114167260 E-193-2013-0 E-193-2013-0-PCT-02 Selective Detection Of Bordetella Species PCT Patent Cooperation Treaty PCT/US2010/032408 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2010/032408<br />Filed on 2010-04-26<br />Status: Expired 114167261 E-193-2013-0 E-193-2013-0-US-06 Selective Detection Of Bordetella Species National Stage US 9,096,908 13/266,099 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9096908 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9096908">9,096,908</a><br />Filed on 2009-04-24<br />Status: Issued 114123731 DXXXXX 114123732 DAXXXX 114123733 DA3XXX 114145052 SELECTIVE 114145053 Detection 114145054 BORDETELLA 114145055 Species 114145056 CDC Docket Import 114145057 CDC Docket Import CDC Prosecuting TAB-2637 114096825 sodC-Based Real-Time PCR Assay for Detection of Neisseria meningitidis Infection CDC Diagnostics, Infectious Disease, Licensing Diagnostics Infectious Disease Licensing Cynthia Hatcher, Raydel Mair, Mary Theodore, Jennifer Thomas CDC researchers have developed a real-time PCR assay for the detection of <em>Neisseria meningitidis</em> sodC within clinical specimens. The ability to detect all strains of <em>N. meningitidis</em>, regardless of individual serogroup, is the central innovation of this technology. Further, the assay is sensitive enough to detect even the very limited sample sizes of <em>N. meningitidis</em> that would typically be found in clinical specimens. This technology avoids potentially catastrophic false-negative results associated with current <em>N. meningitidis</em> carriage study testing methods. At least 16% of carried <em>N. meningitidis</em> lacks the ctrA gene, which is the current target of serogroup-based real-time PCR. <em>N. meningitidis</em> is the etiologic agent of epidemic bacterial meningitis and sepsis throughout the world and rapid detection of <em>N. meningitidis</em> infection is essential for patient well-being. <ul> <li>Rapid, sensitive and specific</li> <li>Present culture detection methods are limited by low sensitivity and long incubation periods; this assay demonstrates improved detection of meningococci, regardless of encapsulation status or bacteria viability</li> <li>Circumvents ctrA-based testing-related false negative results in carriage studies</li> <li>No further technical development needed for commercialization</li> </ul> <ul> <li>Routine </em>N. meningitis</em> surveillance, especially useful in carriage studies</li> <li>Rapid, specific identification of <em>N. meningitis</em> infection</li> </ul> 2022-10-19 2024-10-28 2024-10-28 2013-09-17 CDC Docket Import, CDC Docket Import CDC Prosecuting, DA3XXX, DAXXXX, Detection, DXXXXX, Meningitidis, Neisseria, SELECTIVE False True <ul> <li>Early-stage</li> <li>In vitro data available</li> </ul> True NIHTT 37470483 Website Abstract 114171900 Dolan TJ, et al. http://www.ncbi.nlm.nih.gov/pubmed/21573213 <a href="http://www.ncbi.nlm.nih.gov/pubmed/21573213">Dolan TJ, et al.</a> 114108119 Hatcher, Cynthia CDC - DIR CDC Hatcher, Cynthia (CDC) 0 114108120 Mair, Raydel CDC - DIR CDC Mair, Raydel (CDC) 0 114108121 Theodore, Mary CDC - DIR CDC Theodore, Mary (CDC) 0 114108122 Thomas, Jennifer CDC - DIR CDC Thomas, Jennifer (CDC) 1 114108122 Thomas, Jennifer CDC - DIR CDC Thomas, Jennifer (CDC) 1 114108119 Hatcher, Cynthia CDC - DIR CDC Hatcher, Cynthia (CDC) 0 114108120 Mair, Raydel CDC - DIR CDC Mair, Raydel (CDC) 0 114108121 Theodore, Mary CDC - DIR CDC Theodore, Mary (CDC) 0 114101950 Selective Detection Of Neisseria Meningitidis E-165-2013-0 Closed Centers for Disease Control and Prevention (CDC) 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2637] sodC-Based Real-Time PCR Assay for Detection of Neisseria meningitidis Infection&body=Please send me information about technology [TAB-2637] sodC-Based Real-Time PCR Assay for Detection of Neisseria meningitidis Infection. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2637] sodC-Based Real-Time PCR Assay for Detection of Neisseria meningitidis Infection&body=Please send me information about technology [TAB-2637] sodC-Based Real-Time PCR Assay for Detection of Neisseria meningitidis Infection.">jonathan.motley@nih.gov</a><br> 114167225 E-165-2013-0 E-165-2013-0-US-11 Selective Detection Of Neisseria Meningitidis DIV US 15/251,507 Abandoned US <br />Divisional (DIV) 15/251,507<br />Filed on 2016-08-30<br />Status: Abandoned 114167250 E-165-2013-0 E-165-2013-0-PCT-02 Selective Detection Of Neisseria Meningitidis PCT Patent Cooperation Treaty PCT/US2011/055784 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2011/055784<br />Filed on 2011-10-11<br />Status: Expired 114167251 E-165-2013-0 E-165-2013-0-US-01 Selective Detection Of Neisseria Meningitidis PRV US 61/391,493 Abandoned US <br />Provisional (PRV) 61/391,493<br />Filed on 2010-10-11<br />Status: Abandoned 114167252 E-165-2013-0 E-165-2013-0-US-06 Selective Detection Of Neisseria Meningitidis National Stage US 9,487,832 13/816,903 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9487832 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9487832">9,487,832</a><br />Filed on 2013-06-13<br />Status: Abandoned 114123705 DXXXXX 114123706 DAXXXX 114123707 DA3XXX 114145031 SELECTIVE 114145032 Detection 114145033 Neisseria 114145034 Meningitidis 114145035 CDC Docket Import 114145036 CDC Docket Import CDC Prosecuting TAB-2631 114096819 Aortic Access from Vena Cava for Large Caliber Transcatheter Cardiovascular Interventions NHLBI Collaboration Collaboration Ozgur Kocaturk, Robert Lederman The invention pertains to a device and method for transcatheter correction of cardiovascular abnormalities, such as the delivery of prosthetic valves to the heart. Featured is a device implant for closing a caval-aortic iatrogenic fistula created by the introduction of a transcatheter device from the inferior vena cava into the abdominal aorta. The occlusion device includes an expandable transvascular implant with an elastomeric surface capable of extending between a vein and artery which conforms to the boundaries of an arteriovenous fistula tract between the artery and vein. A guidewire channel is disposed within the occlusion device where the channel also has elastomeric wall surfaces that conform or can be expanded to the area so that it occludes the channel when the guidewire is not present. The implant is resiliently deformable into a radially compressed configuration for delivery through the catheter. When not deformed into the radially compressed configuration, the distal end of the device is radially enlarged, relative to the intermediate neck, whereby the distal end forms an enlarged distal skirt, such as a disk or button shaped member. A polymer coating on the radially enlarged distal end conforms to the endoluminal aortic wall for deployment against an internal wall of the artery. <ul> <li>Closure of the caval-aortic iatrogenic fistula</li> <li>Vascular access</li> </ul> <ul> <li>Cardiovascular surgery</li> <li>Heart valve implantation</li> <li>Valve-repair</li> </ul> The National Heart Lung & Blood Institute is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize Transcatheter Cardiovascular Interventions. For collaboration opportunities, please contact Ms. Peg Koelble at <a href="mailto:koelblep@mail.nih.gov">koelblep@mail.nih.gov</a> or 301-402-5579. 2022-03-08 2024-10-28 2024-10-28 2013-09-10 AB3AXX, AB3CXX, AB3EXX, AB3FXX, AB3XXX, ABXXXX, Aortic, AXXXXX, Cardiovascular, Caval, mitral valve, PROSTHETIC, prosthetic device coating, Transcatheter False True <ul> <li>Prototype</li> <li>In vivo data available (animal)</li> <li>In vivo data available (human)</li> </ul> True NIHTT 37470483 Website Abstract E-115-2013-0 E-027-2013-0 114171890 Kodali SK, et al. http://www.ncbi.nlm.nih.gov/pubmed/22443479 <a href="http://www.ncbi.nlm.nih.gov/pubmed/22443479">Kodali SK, et al.</a> 114171891 Makkar RR, et al. http://www.ncbi.nlm.nih.gov/pubmed/22443478 <a href="http://www.ncbi.nlm.nih.gov/pubmed/22443478">Makkar RR, et al.</a> 114171892 Smith CR, et al. http://www.ncbi.nlm.nih.gov/pubmed/21639811 <a href="http://www.ncbi.nlm.nih.gov/pubmed/21639811">Smith CR, et al.</a> 114108101 Kocaturk, Ozgur National Heart, Lung, and Blood Institute (NHLBI) NHLBI Kocaturk, Ozgur (NHLBI) 0 114108100 Lederman, Robert National Heart, Lung, and Blood Institute (NHLBI) NHLBI Lederman, Robert (NHLBI) 1 114108100 Lederman, Robert National Heart, Lung, and Blood Institute (NHLBI) NHLBI Lederman, Robert (NHLBI) 1 114108101 Kocaturk, Ozgur National Heart, Lung, and Blood Institute (NHLBI) NHLBI Kocaturk, Ozgur (NHLBI) 0 114101943 Caval Aortic Catheter Port Closure Device E-553-2013-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-2631] Aortic Access from Vena Cava for Large Caliber Transcatheter Cardiovascular Interventions&body=Please send me information about technology [TAB-2631] Aortic Access from Vena Cava for Large Caliber Transcatheter Cardiovascular Interventions. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-2631] Aortic Access from Vena Cava for Large Caliber Transcatheter Cardiovascular Interventions&body=Please send me information about technology [TAB-2631] Aortic Access from Vena Cava for Large Caliber Transcatheter Cardiovascular Interventions.">shmilovm@nih.gov</a><br> 114161859 E-553-2013-0 E-553-2013-0-PCT-02 TRANSVASCULAR AND TRANSCAMERAL DEVICE ACCESS AND CLOSURE PCT Patent Cooperation Treaty PCT/US2013/072344 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2013/072344<br />Filed on 2013-11-27<br />Status: Expired 114163665 E-553-2013-0 E-553-2013-0-US-04 Transvascular and Transcameral Device Access and Closure National Stage US 10,376,253 14/901,980 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10376253 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10376253">10,376,253</a><br />Filed on 2015-12-29<br />Status: Issued 114167240 E-553-2013-0 E-553-2013-0-US-01 Aortic Access From Vena Cava for Large Caliber Transcatheter Cardiovascular Interventions PRV US 61/863,071 Abandoned US <br />Provisional (PRV) 61/863,071<br />Filed on 2013-08-07<br />Status: Abandoned 114123675 AB3CXX 114123676 AB3EXX 114123677 AB3FXX 114123678 AB3AXX 114123679 AXXXXX 114123680 ABXXXX 114123681 AB3XXX 114144960 Caval 114144961 Aortic 114144962 Transcatheter 114144963 PROSTHETIC 114144964 prosthetic device coating 114144965 Cardiovascular 114144966 mitral valve TAB-2633 114096821 Signatures of Genetic Control in Digestive and Liver Disorders NINR Diagnostics, Immunology, Licensing, Oncology, Research Materials, Therapeutics Diagnostics Immunology Licensing Oncology Research Materials Therapeutics Sarah Abey, Nicolaas Fourie, Wendy Henderson, Ralph Peace Our technology describes unique genetic signatures in patients with digestive diseases and liver disorders. Using comprehensive analysis of 735 microRNAs and 19,000 mRNAs, we have identified a unique set of microRNAs and/or mRNAs which predict disease phenotypes in patients with digestive and liver disorders. The identification of such point-of- care genetic signatures is significant for both personalized biomarkers and novel targeted biotherapeutics. These microRNAs and mRNAs function either together or separately thus modulating protein expressions in one or more signaling pathways. A particular noteworthy signature of genetic control includes miR-150, which is known to modulate target proteins within the Akt signaling pathways implicated in inflammatory processes as well as processes affecting cancer cell proliferation and/or survival. <ul> <li>Point-of-care signatures from minimally invasive samples.</li> <li>Protocol streamlined for high-throughput analysis.</li> <li>Quantitative molecular diagnostics.</li> <li>Unique microRNAs and/or mRNAs reveal biological targets within synergistic cellular pathways.</li> </ul> <ul> <li>Personalized biomarkers</li> <li>Novel targeted biotherapeutic</li> </ul> 2022-03-08 2024-10-28 2024-10-28 2013-09-10 Acid, Altered, CAXXXX, CXXXXX, Digestive, DISORDERS, Expressions, IA3XXX, IAXXXX, IB3XXX, IBXXXX, Identification, IXXXXX, Listed LPM Vepa as of 4/15/2015, liver, MESSENGER, MICRO, miRNA, PHENOTYPE, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Ribonucleic, RNA, Species, THERAPY False True <ul> <li>Pilot</li> <li>Early-stage</li> <li>Pre-clinical</li> <li>In vitro data available</li> </ul> True NIHTT 37470483 Website Abstract 114108107 Peace, Ralph NINR Peace, Ralph 0 114108108 Fourie, Nicolaas NINR Fourie, Nicolaas 0 114108109 Abey, Sarah NINR NIMH Abey, Sarah (NIMH) 0 114108106 Henderson, Wendy NINR NINR Henderson, Wendy (NINR) 1 114108106 Henderson, Wendy NINR NINR Henderson, Wendy (NINR) 1 114108107 Peace, Ralph NINR Peace, Ralph 0 114108108 Fourie, Nicolaas NINR Fourie, Nicolaas 0 114108109 Abey, Sarah NINR NIMH Abey, Sarah (NIMH) 0 114101945 Altered Expressions Of Micro Ribonucleic Acid (miRNA) And Messenger RNA Species For Phenotype Identification And Therapy In Digestive And Liver Disorders E-349-2013-0 Filing authorized NINR 114101946 Altered Expressions Of Micro Ribonucleic Acid (miRNA) And Messenger RNA Species For Phenotype Identification And Therapy In Digestive And Liver Disorders E-349-2013-1 Filing authorized NINR 114102281 Altered Expressions Of Micro Ribonucleic Acid (miRNA) And Messenger RNA Species For Phenotype Identification And Therapy In Digestive And Liver Disorders E-349-2013-2 Filing authorized NINR 89788013 Kolesnitchenko, Vincent vk5q@nih.gov
United States of America Office of Technology Transfer and Development vk5q@nih.gov?subject=Web Inquiry on [TAB-2633] Signatures of Genetic Control in Digestive and Liver Disorders&body=Please send me information about technology [TAB-2633] Signatures of Genetic Control in Digestive and Liver Disorders. Kolesnitchenko, Vincent<br><a href="mailto:vk5q@nih.gov?subject=Web Inquiry on [TAB-2633] Signatures of Genetic Control in Digestive and Liver Disorders&body=Please send me information about technology [TAB-2633] Signatures of Genetic Control in Digestive and Liver Disorders.">vk5q@nih.gov</a><br> 114166813 E-349-2013-2 E-349-2013-2-US-02 Detection and Treatment of Irritable Bowel Syndrome National Stage US 9,683,263 14/892,999 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9683263 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9683263">9,683,263</a><br />Filed on 2015-11-20<br />Status: Issued 114167242 E-349-2013-0 E-349-2013-0-US-01 Altered Expression Of Mirna And Mrna For Identification And Therapy In Digestive And Liver Disorders PRV US 61/825,154 Abandoned US <br />Provisional (PRV) 61/825,154<br />Filed on 2013-05-20<br />Status: Abandoned 114167243 E-349-2013-1 E-349-2013-1-US-01 ALTERED EXPRESSION OF MIRNA AND MRNA FOR IDENTIFICATION AND THERAPY IN DIGESTIVE AND LIVER DISORDERS PRV US 61/825,489 Abandoned US <br />Provisional (PRV) 61/825,489<br />Filed on 2013-05-20<br />Status: Abandoned 114168178 E-349-2013-2 E-349-2013-2-PCT-01 Detection And Treatment Of Irritable Bowel Syndrome PCT COMB Patent Cooperation Treaty PCT/US2014/038638 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2014/038638<br />Filed on 2014-05-19<br />Status: Expired 114123687 IA3XXX 114123688 CAXXXX 114123689 IB3XXX 114123690 IXXXXX 114123691 IAXXXX 114123692 CXXXXX 114123693 IBXXXX 114144985 Altered 114144986 Expressions 114144987 MICRO 114144988 Ribonucleic 114144989 Acid 114144990 miRNA 114144991 MESSENGER 114144992 RNA 114144993 Species 114144994 PHENOTYPE 114144995 Identification 114144996 THERAPY 114144997 Digestive 114144998 liver 114144999 DISORDERS 114148471 Listed LPM Vepa as of 4/15/2015 114148472 Pre LPM working set 20150418 114148473 Post LPM Assignment Set 20150420 TAB-2617 114096811 Human and Veterinary Cancer Therapeutic Agent Utilizing Anthrax Toxin-Based Technology NIAID Collaboration, Immunology, Oncology, Therapeutics Collaboration Immunology Oncology Therapeutics Christopher Bachran, Stephen Leppla Due to the disorganized nature of blood vessels that run through tumors, chemotherapeutic agents often fail to penetrate tumors and kill cancer cells at the tumor’s center. This can lead to ineffective chemotherapeutic treatments, because tumors can quickly grow back if the entire tumor is not destroyed. NIH researchers have developed a therapeutic agent that solves this problem facing current chemotherapy treatments. By elegantly exploiting cell surface proteases present at high levels in tumors, they have developed a tumor-targeted anthrax based toxin that inactivates the blood vessels within tumors. While in some cases cancer cells are also killed by the tumor-targeted toxin, the primary mechanism of action is thought to be a decrease in blood flow to the center of tumors, causing cancer cell death and tumor necrosis. Preliminary and on-going studies have demonstrated that the targeted toxins have antitumor effects on melanomas, lung cancers and colon cancer in mouse models, and on feline and canine oral tumors. Interestingly, this therapy does not target a specific type of cancer cell, rather it targets the vasculature in and around tumors. Therefore, it has great potential to treat a wide range of solid tumors. Additionally, because few non-surgical treatments are available to treat many human and veterinary solid tumors, this technology would fill an unmet need in cancer therapy. <ul> <li>Proven effective in a variety of models, including models of important veterinary cancers</li> <li>Agent is only active in tumor micro-environments, resulting in low toxicity to healthy tissue</li> <li>Cancer cells are not directly targeted, so this agent can be used to treat a broad spectrum of solid tumors and resistance is unlikely to arise</li> <li>Fills an unmet need in cancer therapy, because few non-surgical treatments exist</li> </ul> Therapeutic agent for a wide range of human and veterinary solid tumors, including: <ul> <li>Melanomas</li> <li>Lung and colon cancers</li> <li>Oral squamous carcinomas</li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize this invention. For collaboration opportunities, please contact Dr. Natalie Greco at <a href="mailto:Natalie.Greco@nih.gov">Natalie.Greco@nih.gov</a> or 301-761-7898. 2022-03-08 2024-10-28 2024-10-28 2017-10-02 Anthrax, AnthraxToxins, CB1BXX, CB1XXX, CB3CXX, CB3XXX, CBXXXX, CXXXXX, fusion proteins, Patent Category - Biotechnology, THERAPY, toxin, tumor False True <ul> <li>Early-stage</li> <li>In vitro data available</li> <li>In vivo data available (animal)</li> </ul> True NIHTT 37470483 Website Abstract 114172353 Chen, KH et al. http://www.ncbi.nlm.nih.gov/pubmed/17251181 <a href="http://www.ncbi.nlm.nih.gov/pubmed/17251181">Chen, KH et al.</a> 114172354 Liu S, et al. http://www.ncbi.nlm.nih.gov/pubmed/27357689 <a href="http://www.ncbi.nlm.nih.gov/pubmed/27357689">Liu S, et al.</a> 114172355 Wein AN, et al. http://www.ncbi.nlm.nih.gov/pubmed/26584669 <a href="http://www.ncbi.nlm.nih.gov/pubmed/26584669">Wein AN, et al.</a> 114172356 Peters DE, et al. http://www.ncbi.nlm.nih.gov/pubmed/24971906 <a href="http://www.ncbi.nlm.nih.gov/pubmed/24971906">Peters DE, et al.</a> 114172358 Wein AN, et al. http://www.ncbi.nlm.nih.gov/pubmed/22843210 <a href="http://www.ncbi.nlm.nih.gov/pubmed/22843210">Wein AN, et al.</a> 114172359 Phillips DD, et al. http://www.ncbi.nlm.nih.gov/pubmed/23393143 <a href="http://www.ncbi.nlm.nih.gov/pubmed/23393143">Phillips DD, et al.</a> 114108072 Bachran, Christopher NIAID - DIR NIAID Bachran, Christopher (NIAID) 0 114108071 Leppla, Stephen NIAID - DIR NIAID Leppla, Stephen (NIAID) 1 114108071 Leppla, Stephen NIAID - DIR NIAID Leppla, Stephen (NIAID) 1 114108072 Bachran, Christopher NIAID - DIR NIAID Bachran, Christopher (NIAID) 0 114101935 Efficient Tumor Therapy By Anthrax Toxin Fusion Proteins That Contain Cytolethal Distending Toxin B E-120-2013-0 Filing authorized NIAID 91026778 Green, Wade wade.green@nih.gov
United States of America TTIPO wade.green@nih.gov?subject=Web Inquiry on [TAB-2617] Human and Veterinary Cancer Therapeutic Agent Utilizing Anthrax Toxin-Based Technology&body=Please send me information about technology [TAB-2617] Human and Veterinary Cancer Therapeutic Agent Utilizing Anthrax Toxin-Based Technology. Green, Wade<br><a href="mailto:wade.green@nih.gov?subject=Web Inquiry on [TAB-2617] Human and Veterinary Cancer Therapeutic Agent Utilizing Anthrax Toxin-Based Technology&body=Please send me information about technology [TAB-2617] Human and Veterinary Cancer Therapeutic Agent Utilizing Anthrax Toxin-Based Technology.">wade.green@nih.gov</a><br> 114165482 E-120-2013-0 E-120-2013-0-US-03 Cytolethal Distending Toxin Subunit B Conjugated or Fused to Bacillus Anthracis Toxin Lethal Factor National Stage US 9,890,369 14/898,248 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9890369 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9890369">9,890,369</a><br />Filed on 2015-12-14<br />Status: Issued 114167208 E-120-2013-0 E-120-2013-0-US-01 Cytolethal Distending Toxin Subunit B Conjugated or Fused to Bacillus Anthracis Toxin Lethal Factor PRV US 61/837,428 Abandoned US <br />Provisional (PRV) 61/837,428<br />Filed on 2013-06-20<br />Status: Abandoned 114167852 E-120-2013-0 E-120-2013-0-PCT-02 Cytolethal Distending Toxin Subunit B Conjugated or Fused to Bacillus Anthracis Toxin Lethal Factor PCT Patent Cooperation Treaty PCT/US2014/043131 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2014/043131<br />Filed on 2014-06-19<br />Status: Expired 114123605 CB1BXX 114123606 CB3CXX 114123607 CXXXXX 114123608 CBXXXX 114123609 CB1XXX 114123610 CB3XXX 114144877 tumor 114144878 Anthrax 114144879 toxin 114144880 THERAPY 114144881 Patent Category - Biotechnology 114144882 AnthraxToxins 114144883 fusion proteins TAB-2612 114096806 Real-time TaqMan RT-PCR Assays for Selective Detection of Human Rhinovirus CDC Diagnostics, Infectious Disease, Licensing Diagnostics Infectious Disease Licensing Dean Erdman, Xiaoyan Lu This invention relates to selective detection of human rhinovirus (HRV) in biological media. Specifically, this invention discloses a real-time TaqMan RT-PCR assay targeting the 5'-noncoding region of the HRV genome. This is a one-step, real-time nucleic acid assay that offers rapid, sensitive, and quantitative results. The assay is validated against all 100 recognized HRV prototype strains. <br /><br /> HRV is the most frequent cause of the common cold. From a clinical standpoint, diagnosis of HRV infection is quite difficult as the related symptoms can be caused by other agents as well. Additionally, laboratory detection of HRV is challenging as HRV exhibits extreme antigenic variability and certain strains cannot be maintained by cell culture. <ul> <li>Validated against all 100 human rhinovirus prototype strains</li> <li>Rapid, sensitive and quantitative</li> <li>One-step assay</li> <li>Easily adapted to kit form</li> </ul> <ul> <li>Development of human rhinovirus (HRV) diagnostics</li> <li>Acute lower respiratory illness diagnostics and investigation</li> </ul> 2022-10-19 2024-10-28 2024-10-28 2013-08-13 DA4BXX, DA4XXX, DAXXXX, Detection, Human, Rhinovirus, SELECTIVE False True </ul> <li>Early-stage</li> <li>In vitro data available</li> </ul> True NIHTT 37470483 Website Abstract 114171877 Lu X, et al. http://www.ncbi.nlm.nih.gov/pubmed/18057136 <a href="http://www.ncbi.nlm.nih.gov/pubmed/18057136">Lu X, et al.</a> 114108058 Erdman, Dean CDC - DIR CDC Erdman, Dean (CDC) 0 114108057 Lu, Xiaoyan CDC - DIR CDC Lu, Xiaoyan (CDC) 1 114108057 Lu, Xiaoyan CDC - DIR CDC Lu, Xiaoyan (CDC) 1 114108058 Erdman, Dean CDC - DIR CDC Erdman, Dean (CDC) 0 114101930 Selective Detection Of Human Rhinovirus E-177-2013-0 Filing authorized Centers for Disease Control and Prevention (CDC) 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2612] Real-time TaqMan RT-PCR Assays for Selective Detection of Human Rhinovirus&body=Please send me information about technology [TAB-2612] Real-time TaqMan RT-PCR Assays for Selective Detection of Human Rhinovirus. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2612] Real-time TaqMan RT-PCR Assays for Selective Detection of Human Rhinovirus&body=Please send me information about technology [TAB-2612] Real-time TaqMan RT-PCR Assays for Selective Detection of Human Rhinovirus.">jonathan.motley@nih.gov</a><br> 114167195 E-177-2013-0 E-177-2013-0-US-01 Selective Detection of Human Rhinovirus ORD US 8,986,933 12/315,758 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8986933 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8986933">8,986,933</a><br />Filed on 2008-12-05<br />Status: Issued 114168029 E-177-2013-0 E-177-2013-0-US-03 Selective Detection Of Human Rhinovirus DIV US 9,650,685 14/570,569 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9650685 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9650685">9,650,685</a><br />Filed on 2014-12-15<br />Status: Issued 114123573 DAXXXX 114123574 DA4XXX 114123575 DA4BXX 114144844 SELECTIVE 114144845 Detection 114144846 Human 114144847 Rhinovirus TAB-2613 114096807 Real-Time PCR for Detecting Legionella Species and Discriminating Legionella pneumophila CDC Diagnostics, Infectious Disease, Licensing Diagnostics Infectious Disease Licensing Robert Benson, Brian Holloway, Karen McCaustland, Patrick Yang <em>Legionella pneumophila</em> is the causative species in most cases of Legionnaires' disease (LD). CDC scientists have developed a real-time PCR assay capable of detecting all <em>Legionella</em> species and discriminating <em>L. pneumophila</em> from other <em>Legionella</em> species. LD is typically difficult to diagnose from a clinical standpoint as it confers no unique clinical features or symptoms. This assay provides a rapid and accurate alternative to laborious PCR assays, prone to aberrant results. It provides a sensitive alternative for diagnosis of Legionnaires' disease and detection of <em>L. pneumophila</em>. <ul> <li>Faster than immunoassays</li> <li>Less laborious than current LD diagnostics</li> <li>Rapid, sensitive, and specific</li> <li>Curtails misdiagnoses associated with serological evaluations</li> <li>Easily adaptable to kit form</li> </ul> <ul> <li>Diagnostic for Legionnaires’ disease</li> <li>Detection of all Legionella species and specific discrimination of <em>L. pneumophila</em></li> </ul> 2022-10-19 2024-10-28 2024-10-28 2013-08-13 DA3XXX, DAXXXX, Detection, DXXXXX, L., LEGIONELLA, Multiplexed, PCR, Pneumophilia, REAL-TIME, Spp False True <ul> <li>Early-stage</li> <li>In vitro data available</li> </ul> True NIHTT 37470483 Website Abstract 114171878 Yang G, et al. http://www.ncbi.nlm.nih.gov/pubmed/19438641 <a href="http://www.ncbi.nlm.nih.gov/pubmed/19438641">Yang G, et al.</a> 114108060 Holloway, Brian CDC - DIR CDC Holloway, Brian (CDC) 0 114108061 McCaustland, Karen CDC - DIR CDC McCaustland, Karen (CDC) 0 114108062 Yang, Patrick CDC - DIR CDC Yang, Patrick (CDC) 0 114108059 Benson, Robert CDC - DIR CDC Benson, Robert (CDC) 1 114108059 Benson, Robert CDC - DIR CDC Benson, Robert (CDC) 1 114108060 Holloway, Brian CDC - DIR CDC Holloway, Brian (CDC) 0 114108061 McCaustland, Karen CDC - DIR CDC McCaustland, Karen (CDC) 0 114108062 Yang, Patrick CDC - DIR CDC Yang, Patrick (CDC) 0 114101931 Real-Time PCR For The Detection Of Legionella Pneumophilia And L. SPP Multiplexed E-194-2013-0 Closed Centers for Disease Control and Prevention (CDC) 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2613] Real-Time PCR for Detecting Legionella Species and Discriminating Legionella pneumophila&body=Please send me information about technology [TAB-2613] Real-Time PCR for Detecting Legionella Species and Discriminating Legionella pneumophila. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2613] Real-Time PCR for Detecting Legionella Species and Discriminating Legionella pneumophila&body=Please send me information about technology [TAB-2613] Real-Time PCR for Detecting Legionella Species and Discriminating Legionella pneumophila.">jonathan.motley@nih.gov</a><br> 114167196 E-194-2013-0 E-194-2013-0-US-01 Real-Time PCR For The Detection Of Legionella Pneumophilia And L. SPP Multiplexed PRV US 61/138,727 Abandoned US <br />Provisional (PRV) 61/138,727<br />Filed on 2008-12-18<br />Status: Abandoned 114167197 E-194-2013-0 E-194-2013-0-PCT-02 Real-Time PCR For The Detection Of Legionella Pneumophilia And L. SPP Multiplexed PCT Patent Cooperation Treaty PCT/US2009/068461 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2009/068461<br />Filed on 2009-12-17<br />Status: Expired 114167198 E-194-2013-0 E-194-2013-0-US-05 REAL TIME POLYMERASE CHAIN REACTION DETECTION OF LEGIONELLA PNEUMOPHILA AND DIFFERENTIATION FROM OTHER LEGIONELLA SPECIES National Stage US 13/140,922 Abandoned US <br />National Stage 13/140,922<br />Filed on 2011-09-12<br />Status: Abandoned 114123576 DAXXXX 114123577 DA3XXX 114123578 DXXXXX 114144848 REAL-TIME 114144849 PCR 114144850 Detection 114144851 LEGIONELLA 114144852 Pneumophilia 114144853 L. 114144854 Spp 114144855 Multiplexed TAB-2610 114096804 Diffusion Through Skull as Route of Delivery for Treatment of Brain Injury and Disease NINDS Collaboration, Neurology, Therapeutics Collaboration Neurology Therapeutics Dorian McGavern, Theodore Roth Traumatic Brain injury (TBI) often results from head impact and is a major cause of death and disability. Brain injuries vary in severity and can be associated with hemorrhaging, swelling, inflammation, and death of brain tissue. Inventors at NINDS developed a novel approach to treating brain injuries that involves transcranial application of small molecules. They discovered, using two photon laser scanning microscopy, that compounds as large as 40,000 molecular weight (MW) can pass directly through the intact skull into the underlying cerebral spinal fluid (CSF) that circulates through the brain and spinal cord. Small molecular weight compounds (e.g. 600 MW) pass through the skull more quickly than large ones and appear to do so by simple diffusion. Researchers have shown that application of a variety of agents, including glutathione, TNP-ATP hydrase (P2X4 inhibitor), oxidated ATP (P2X7 inhibitor), MRS2578 (P2Y6 inhibitor), MeSAMP (P2Y12 inhibitor) and Carbenoxelone (Connexin Hemichannel Inhibitor) directly to the head results in delivery of the agents to the brain. Transcranial drug application can be used to pharmacologically target several tiers of brain injury responses, from the toxic mediators that cause cell death to the molecular signals that drive inflammation. Application can be by direct application to the skull through the scalp (e.g. rubbing it in), transdermal patch, or subcutaneous injection under the scalp. <ul> <li>Quickly achieves a high local drug concentration at the site of brain injury.</li> <li>Bypasses the blood brain barrier and allows rapid administration of therapeutic agents directly into injured or inflamed brain.</li> <li>Current therapies to treat Traumatic Brain Injury with neuroprotective agents are often limited by ability to achieve therapeutic concentrations of therapeutic agent in the brain.</li> </ul> <ul> <li>Treating Traumatic Brain Injury</li> <li>Treating stroke</li> <li>Treating other acute CNS conditions, including encephalitis and meningitis</li> <li>Treating chronic CNS disorders such as brain tumors, Alzheimer’s, Parkinson’s, and multiple sclerosis</li> </ul> The National Institute of Neurological Disorders and Stroke (NINDS) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize treatment of brain injury or disease through transcranial drug delivery. For collaboration opportunities, please contact Melissa Maderia, Ph.D., M.B.A. at <a href="mailto:maderiam@mail.nih.gov">maderiam@mail.nih.gov</a> or 240-276-5533. 2022-03-08 2024-10-28 2024-10-28 2013-08-06 AB3DXX, AB3XXX, ABXXXX, AXXXXX, brain, Delivery, diffusion, Disease, INJURY, NB1JXX, NB1XXX, NBXXXX, NXXXXX, Route, Skull, TREATMENTS False True <ul> <li>In vitro data available</li> <li>In vivo data available (animal)</li> </ul> True NIHTT 37470483 Website Abstract 114171875 Manuscript in preparation. Manuscript in preparation. 114108052 Roth, Theodore Stanford University (aka Leland Stanford Junior University) Roth, Theodore 0 114108051 McGavern, Dorian NINDS NINDS McGavern, Dorian (NINDS) 1 114108051 McGavern, Dorian NINDS NINDS McGavern, Dorian (NINDS) 1 114108052 Roth, Theodore Stanford University (aka Leland Stanford Junior University) Roth, Theodore 0 114101928 Diffusion Through Skull As Route Of Delivery For Treatments Of Brain Injury And Disease E-025-2012-0 Filing authorized NINDS 83722849 Sharma, Smita smita.sharma@nih.gov
United States of America smita.sharma@nih.gov?subject=Web Inquiry on [TAB-2610] Diffusion Through Skull as Route of Delivery for Treatment of Brain Injury and Disease&body=Please send me information about technology [TAB-2610] Diffusion Through Skull as Route of Delivery for Treatment of Brain Injury and Disease. Sharma, Smita<br><a href="mailto:smita.sharma@nih.gov?subject=Web Inquiry on [TAB-2610] Diffusion Through Skull as Route of Delivery for Treatment of Brain Injury and Disease&body=Please send me information about technology [TAB-2610] Diffusion Through Skull as Route of Delivery for Treatment of Brain Injury and Disease.">smita.sharma@nih.gov</a><br> 114166574 E-025-2012-0 E-025-2012-0-US-07 Methods of Treating and Preventing Diseases and Disorders of the Central Nervous System CON US 9,974,801 15/095,957 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9974801 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9974801">9,974,801</a><br />Filed on 2016-04-11<br />Status: Issued 114166911 E-025-2012-0 E-025-2012-0-US-01 Methods of Treating And Preventing Diseses and Disorders of the Central Nervous System PRV US 61/599,107 Abandoned US <br />Provisional (PRV) 61/599,107<br />Filed on 2012-02-15<br />Status: Abandoned 114167185 E-025-2012-0 E-025-2012-0-PCT-02 Methods Of Treating And Preventing Diseases And Disorders Of The Central Nervous System PCT Patent Cooperation Treaty PCT/US13/24741 Expired Patent Cooperation Treaty <br />(PCT) PCT/US13/24741<br />Filed on 2013-02-05<br />Status: Expired 114167906 E-025-2012-0 E-025-2012-0-US-06 Methods of Treating and Preventing Diseases and Disorders of the Central Nervous System National Stage US 9,308,163 14/377,348 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9308163 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9308163">9,308,163</a><br />Filed on 2014-08-07<br />Status: Issued 114123561 NB1JXX 114123563 AB3DXX 114123564 NXXXXX 114123565 NBXXXX 114123566 NB1XXX 114123567 AXXXXX 114123568 ABXXXX 114123569 AB3XXX 114144825 diffusion 114144826 Skull 114144827 Route 114144828 Delivery 114144829 TREATMENTS 114144830 brain 114144831 INJURY 114144832 Disease TAB-2607 114096801 MRI Scanner Bore Covering NHLBI Collaboration Collaboration Robert Balaban, Anthony Faranesh, Michael Hansen, Robert Lederman, Kanishka Ratnayaka This invention pertains to a bore covering for creating controlled environments and specifically for maintaining temperature within the bore of an MRI scanner. The bore covering includes a covering sheet with fastening means (e.g., weak-tack adhesive, pressure-sensitive adhesive or low-tack adhesive) around its inner surfaces that permits reversible attachment to the scanner. The adhesive ends can be peeled away to expose an edge of the bore opening or the entire sheet may be constructed with peel away gaps so that warm air can be pumped into the bore. On the inner surface the bore covering may include a gap that is connected to a climate control device or an exhaust vent to expel air out of the MRI scanner bore. <ul> <li>Temperature control</li> <li>Comfort</li> </ul> <ul> <li>MR imaging of infants and neonates</li> </ul> The National Heart, Lung, and Blood Institute (NHLBI) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize MRI Scanner Bore Covering. For collaboration opportunities, please contact Dr. Denise Crooks at <a href="mailto:crooksd@mail.nih.gov">crooksd@mail.nih.gov</a>. 2022-03-08 2024-10-28 2024-10-28 2013-08-06 AA2XXX, AA3B1X, AA3BXX, AA3XXX, AA4BXX, AA4XXX, AA6XXX, AAXXXX, AE1CXX, AE1XXX, AEXXXX, AXXXXX, BORE, Climate Control, INCUBATOR, MRI, temperature, Temperature-controlled False True Prototype True NIHTT 37470483 Website Abstract 114107760 Hansen, Michael National Heart, Lung, and Blood Institute (NHLBI) NHLBI Hansen, Michael (NHLBI) 0 114107761 Lederman, Robert National Heart, Lung, and Blood Institute (NHLBI) NHLBI Lederman, Robert (NHLBI) 0 114108044 Faranesh, Anthony National Heart, Lung, and Blood Institute (NHLBI) Faranesh, Anthony 0 114108045 Ratnayaka, Kanishka National Heart, Lung, and Blood Institute (NHLBI) Ratnayaka, Kanishka 0 114107762 Balaban, Robert National Heart, Lung, and Blood Institute (NHLBI) NHLBI Balaban, Robert (NHLBI) 1 114107762 Balaban, Robert National Heart, Lung, and Blood Institute (NHLBI) NHLBI Balaban, Robert (NHLBI) 1 114107760 Hansen, Michael National Heart, Lung, and Blood Institute (NHLBI) NHLBI Hansen, Michael (NHLBI) 0 114107761 Lederman, Robert National Heart, Lung, and Blood Institute (NHLBI) NHLBI Lederman, Robert (NHLBI) 0 114108044 Faranesh, Anthony National Heart, Lung, and Blood Institute (NHLBI) Faranesh, Anthony 0 114108045 Ratnayaka, Kanishka National Heart, Lung, and Blood Institute (NHLBI) Ratnayaka, Kanishka 0 114101925 MRI Scanner To Infant Incubator Kit E-026-2013-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-2607] MRI Scanner Bore Covering&body=Please send me information about technology [TAB-2607] MRI Scanner Bore Covering. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-2607] MRI Scanner Bore Covering&body=Please send me information about technology [TAB-2607] MRI Scanner Bore Covering.">shmilovm@nih.gov</a><br> 114165487 E-026-2013-0 E-026-2013-0-US-03 MRI Scanner Bore Coverings National Stage US 14/899,480 Abandoned US <br />National Stage 14/899,480<br />Filed on 2014-06-19<br />Status: Abandoned 114167182 E-026-2013-0 E-026-2013-0-US-01 MRI Scanner Bore Coverings PRV US 61/836,817 Abandoned US <br />Provisional (PRV) 61/836,817<br />Filed on 2013-06-19<br />Status: Abandoned 114167849 E-026-2013-0 E-026-2013-0-PCT-02 MRI Scanner Bore Coverings PCT Patent Cooperation Treaty PCT/US2014/043268 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2014/043268<br />Filed on 2014-06-19<br />Status: Expired 114123544 AE1CXX 114123545 AA2XXX 114123546 AA4BXX 114123547 AA3B1X 114123548 AA6XXX 114123549 AXXXXX 114123550 AAXXXX 114123551 AA4XXX 114123552 AEXXXX 114123553 AE1XXX 114123554 AA3XXX 114123555 AA3BXX 114144801 INCUBATOR 114144802 MRI 114144803 BORE 114144804 Climate Control 114144805 temperature 114144806 Temperature-controlled TAB-2608 114096802 Cotranslational Protein Expression System for High-throughput Screening NCATS Collaboration Collaboration Chih-Chien (Ken) Cheng, Samuel Hasson, James Inglese Reporter gene-based assays are used extensively in high-throughput screening (HTS) to identify chemical modulators of cellular pathways for drug discovery and development. However, such screening frequently results in a large number of false “hits” due to interactions of screened compounds with reporter proteins, producing confounding results. Thus, validation of results using these assays often involves significant time and expense.<br /><br /> The inventors have developed an assay system that significantly improves detection of target-relevant active compounds by discriminating between signals arising from the target activity and those caused by reporter bias. This system utilizes simultaneous detection (also known as “coincidence detection”) of non-homologous reporter proteins with dissimilar properties, such as differing catalysis, light emission, or fluorescence characteristics; simultaneous observation of signals from these reporters indicates a high probability that it is a true target response. The reporters are cotranslationally expressed from a single RNA transcript, which ensures stable stoichiometry of the expressed proteins. <ul> <li>This method will significantly enhance the ability to identify and prioritize active compounds from reporter gene-based assays.</li> </ul> <ul> <li>High-throughput screening of chemical libraries in a single assay platform for commercial or research use.</li> </ul> The National Center for Advancing Translational Sciences (NCATS) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize Cotranslational Protein Expression System for High-throughput Screening. For collaboration opportunities, please contact NCATS Technology Development Coordinator at <a href="mailto:NCATSPartnerships@mail.nih.gov">NCATSPartnerships@mail.nih.gov</a>. 2022-03-08 2024-10-28 2024-10-28 2013-08-06 AC4XXX, ACXXXX, AXXXXX, Coincidence, drug discovery, Drug Screening, High-throughput, High-throughput screen, HTS, REPORTER, reporter gene False True Early-stage True NIHTT 37470483 Website Abstract 114171873 Chan K, Inglese J. http://www.ncbi.nlm.nih.gov/pubmed/23018994 <a href="http://www.ncbi.nlm.nih.gov/pubmed/23018994">Chan K, Inglese J.</a> 114108047 Cheng, Chih-Chien (Ken) NCATS - NCGC NCATS Cheng, Chih-Chien (Ken) (NCATS) 0 114108048 Hasson, Samuel NCATS - NCGC Hasson, Samuel 0 114108046 Inglese, James NCATS - NCGC NCATS Inglese, James (NCATS) 1 114108046 Inglese, James NCATS - NCGC NCATS Inglese, James (NCATS) 1 114108047 Cheng, Chih-Chien (Ken) NCATS - NCGC NCATS Cheng, Chih-Chien (Ken) (NCATS) 0 114108048 Hasson, Samuel NCATS - NCGC Hasson, Samuel 0 114101926 A Coincidence Reporter Gene-system For High Throughput Screening E-300-2012-0 Filing authorized NCATS - NCGC 83727060 Gadhia, Ami ami.gadhia@nih.gov
United States of America NCGC ami.gadhia@nih.gov?subject=Web Inquiry on [TAB-2608] Cotranslational Protein Expression System for High-throughput Screening&body=Please send me information about technology [TAB-2608] Cotranslational Protein Expression System for High-throughput Screening. Gadhia, Ami<br><a href="mailto:ami.gadhia@nih.gov?subject=Web Inquiry on [TAB-2608] Cotranslational Protein Expression System for High-throughput Screening&body=Please send me information about technology [TAB-2608] Cotranslational Protein Expression System for High-throughput Screening.">ami.gadhia@nih.gov</a><br> 114166514 E-300-2012-0 E-300-2012-0-US-02 Coincidence Reporter Gene System National Stage US 14/775,293 Abandoned US <br />National Stage 14/775,293<br />Filed on 2015-09-11<br />Status: Abandoned 114167183 E-300-2012-0 E-300-2012-0-PCT-01 Coincidence Reporter Gene System PCT Patent Cooperation Treaty PCT/US2013/032184 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2013/032184<br />Filed on 2013-03-15<br />Status: Expired 114168570 E-300-2012-0 E-300-2012-0-US-04 COINCIDENCE REPORTER GENE SYSTEM DIV US 15/916,762 Abandoned US <br />Divisional (DIV) 15/916,762<br />Filed on 2018-03-09<br />Status: Abandoned 114123556 AC4XXX 114123558 ACXXXX 114123559 AXXXXX 114144807 Coincidence 114144808 REPORTER 114144809 High-throughput screen 114144810 High-throughput 114144811 HTS 114144812 drug discovery 114144813 Drug Screening 114144814 reporter gene TAB-2604 114096798 Rabbit Antibody to Mouse Sphingosine-1-phosphate (S1P) lyase NIDDK Diagnostics, Licensing, Research Materials, Therapeutics Diagnostics Licensing Research Materials Therapeutics Richard Proia The cleavage of sphingoid base phosphates by sphingosine-1-phosphate (S1P) lyase to produce phosphoethanolamine and a fatty aldehyde is the final degradative step in the sphingolipid metabolic pathway. Researchers at NIH injected rabbits with the C-terminal peptide of the mouse S1P lyase — 551-TTDPVTQGNQMNGSPKPR-568 — to develop an antibody that can be used in western blotting to study this pathway. The antibody works very well for western blotting. The antibody can be used to detect and measure S1P lyase. Research Tool – Patent protection is not being pursued for this technology. 2022-03-08 2024-10-28 2024-10-28 2013-08-06 ANTIBODY, IDXXXX, IXXXXX, Lyase, Mouse, rabbit, S1P False True In vitro data available True NIHTT 37470483 Website Abstract 114171871 Bektas M, et al. http://www.ncbi.nlm.nih.gov/pubmed/20097939 <a href="http://www.ncbi.nlm.nih.gov/pubmed/20097939">Bektas M, et al.</a> 114107768 Proia, Richard National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Proia, Richard (NIDDK) 1 114107768 Proia, Richard National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Proia, Richard (NIDDK) 1 114101922 Rabbit Antibody To Mouse S1P Lyase E-465-2013-0 Research Material National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83739550 Shastri, Mythreyi shastrim@mail.nih.gov
United States of America Technology Advancement Office shastrim@mail.nih.gov?subject=Web Inquiry on [TAB-2604] Rabbit Antibody to Mouse Sphingosine-1-phosphate (S1P) lyase&body=Please send me information about technology [TAB-2604] Rabbit Antibody to Mouse Sphingosine-1-phosphate (S1P) lyase. Shastri, Mythreyi<br><a href="mailto:shastrim@mail.nih.gov?subject=Web Inquiry on [TAB-2604] Rabbit Antibody to Mouse Sphingosine-1-phosphate (S1P) lyase&body=Please send me information about technology [TAB-2604] Rabbit Antibody to Mouse Sphingosine-1-phosphate (S1P) lyase.">shastrim@mail.nih.gov</a><br> 114123532 IDXXXX 114123533 IXXXXX 114144777 rabbit 114144778 ANTIBODY 114144779 Mouse 114144780 S1P 114144781 Lyase TAB-2605 114096799 Rabbit Antibody to Mouse Sphingosine kinase 2 (SphK2) NIDDK Diagnostics, Licensing, Research Materials, Therapeutics Diagnostics Licensing Research Materials Therapeutics Richard Proia Two isoforms of sphingosine kinase, sphingosine kinase 1 (SphK1) and sphingosine kinase 2 (SphK2), convert sphingosine to sphingosine 1-phosphate (S1P) in mammalian cells. While the importance of SphK1 has been known for some time, information about SphK2 is still being revealed. Therefore, researchers at NIH have developed an antibody against mouse SphK2, which can be used to further understand the role of this enzyme. The antibody works very well for western blotting. The antibody can be used to detect and measure SphK2. Research Tool – Patent protection is not being pursued for this technology. 2022-03-08 2024-10-28 2024-10-28 2013-08-06 2, ANTIBODY, IDXXXX, IXXXXX, Kinase, Mouse, rabbit, Sphingosine False True In vitro data available True NIHTT 37470483 Website Abstract 114171872 Olivera A, et al. http://www.ncbi.nlm.nih.gov/pubmed/16316995 <a href="http://www.ncbi.nlm.nih.gov/pubmed/16316995">Olivera A, et al.</a> 114107767 Proia, Richard National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Proia, Richard (NIDDK) 1 114107767 Proia, Richard National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Proia, Richard (NIDDK) 1 114101923 Rabbit Antibody To Mouse Sphingosine Kinase 2 E-466-2013-0 Research Material National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83739550 Shastri, Mythreyi shastrim@mail.nih.gov
United States of America Technology Advancement Office shastrim@mail.nih.gov?subject=Web Inquiry on [TAB-2605] Rabbit Antibody to Mouse Sphingosine kinase 2 (SphK2)&body=Please send me information about technology [TAB-2605] Rabbit Antibody to Mouse Sphingosine kinase 2 (SphK2). Shastri, Mythreyi<br><a href="mailto:shastrim@mail.nih.gov?subject=Web Inquiry on [TAB-2605] Rabbit Antibody to Mouse Sphingosine kinase 2 (SphK2)&body=Please send me information about technology [TAB-2605] Rabbit Antibody to Mouse Sphingosine kinase 2 (SphK2).">shastrim@mail.nih.gov</a><br> 114123534 IDXXXX 114123535 IXXXXX 114144782 rabbit 114144783 ANTIBODY 114144784 Mouse 114144785 Sphingosine 114144786 Kinase 114144787 2 TAB-2599 114096793 Simultaneous Detection of Non-pneumophila Legionella Strains Using Real-time PCR CDC Diagnostics, Infectious Disease, Licensing Diagnostics Infectious Disease Licensing Alvaro Benitez, Jonas Winchell Legionnaires' disease is caused by a type of bacteria called <em>Legionella</em>. CDC scientists have developed a real-time multiplex PCR assay for diagnosis and identification of <em>Legionella</em> strains. The assay consists of five sets of primers (targeting <em>L. bozemanii</em>, <em>L. dumoffii</em>, <em>L. feeleii</em>, <em>L. longbeachae</em>, or <em>L. micdadei</em>) and corresponding probes. Each probe is labeled with a different fluorophore which allows the detection of a particular strain in a single tube reaction. Using this assay format, the presence of any one of the five pathogenic non-pneumophila strains of <em>Legionella</em> can be detected rapidly from clinical or environmental samples. Rapid and sensitive identification enables initiation of appropriate antibiotic therapy and identification of the source of bacteria so that proper public health responses may occur. <ul> <li>Currently available tests are time consuming and labor intensive.</li> <li>This assay enables rapid identification and differentiation on clinically relevant non-pneumophila <em>Legionella</em> strains.</li> <li>This assay can be used as a standalone confirmatory assay for the detection of common non-pneumophila <em>Legionella</em> species or as one of the valuable assays in conjunction with other standard assays.</li> </ul> <ul> <li>Rapid and real-time assay to detect the presence of clinically relevant non-pneumophila <em>Legionella</em> strains.</li> </ul> 2022-11-17 2024-10-28 2024-10-28 2013-08-02 Compositions, DA3XXX, DAXXXX, Detection, DXXXXX, LEGIONELLA, Methods False True <ul> <li>Pre-clinical</li> <li>In vitro data available</li> </ul> True NIHTT 37470483 Website Abstract 114171854 Benitez AJ, Winchell JM. http://www.ncbi.nlm.nih.gov/pubmed/23135949 <a href="http://www.ncbi.nlm.nih.gov/pubmed/23135949">Benitez AJ, Winchell JM.</a> 114108027 Benitez, Alvaro CDC - DIR CDC Benitez, Alvaro (CDC) 0 114108026 Winchell, Jonas CDC - DIR CDC Winchell, Jonas (CDC) 1 114108026 Winchell, Jonas CDC - DIR CDC Winchell, Jonas (CDC) 1 114108027 Benitez, Alvaro CDC - DIR CDC Benitez, Alvaro (CDC) 0 114101916 METHODS AND COMPOSITIONS FOR DETECTION OF LEGIONELLA E-277-2013-0 Filing authorized Centers for Disease Control and Prevention (CDC) 114101917 METHODS AND COMPOSITIONS FOR DETECTION OF LEGIONELLA E-277-2013-1 Filing authorized Centers for Disease Control and Prevention (CDC) 91821264 Motley, Jonathan jonathan.motley@nih.gov
United States of America jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2599] Simultaneous Detection of Non-pneumophila Legionella Strains Using Real-time PCR&body=Please send me information about technology [TAB-2599] Simultaneous Detection of Non-pneumophila Legionella Strains Using Real-time PCR. Motley, Jonathan<br><a href="mailto:jonathan.motley@nih.gov?subject=Web Inquiry on [TAB-2599] Simultaneous Detection of Non-pneumophila Legionella Strains Using Real-time PCR&body=Please send me information about technology [TAB-2599] Simultaneous Detection of Non-pneumophila Legionella Strains Using Real-time PCR.">jonathan.motley@nih.gov</a><br> 114166683 E-277-2013-1 E-277-2013-1-US-03 METHODS FOR DETECTING OF LEGIONELLA NUCLEIC ACIDS IN A SAMPLE DIV US 10,202,654 15/186,979 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10202654 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10202654">10,202,654</a><br />Filed on 2016-06-20<br />Status: Issued 114167167 E-277-2013-1 E-277-2013-1-US-01 Methods For Detecting Legionella Nucleic Acids in a Sample CIP US 9,394,574 13/895,898 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9394574 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9394574">9,394,574</a><br />Filed on 2013-05-16<br />Status: Issued 114167168 E-277-2013-0 E-277-2013-0-PCT-02 METHODS AND COMPOSITIONS FOR DETECTION OF LEGIONELLA PCT Patent Cooperation Treaty PCT/US2013/030217 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2013/030217<br />Filed on 2013-03-11<br />Status: Expired 114167169 E-277-2013-0 E-277-2013-0-US-01 METHODS AND COMPOSITIONS FOR DETECTION OF LEGIONELLA PRV US 61/658,627 Abandoned US <br />Provisional (PRV) 61/658,627<br />Filed on 2012-06-12<br />Status: Abandoned 114167805 E-277-2013-1 E-277-2013-1-PCT-02 METHODS AND COMPOSITIONS FOR DETECTION OF LEGIONELLA PCT Patent Cooperation Treaty PCT/US2014/038441 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2014/038441<br />Filed on 2014-05-16<br />Status: Expired 114168026 E-277-2013-0 E-277-2013-0-US-05 METHODS AND COMPOSITIONS FOR DETECTION OF LEGIONELLA National Stage US 14/407,347 Abandoned US <br />National Stage 14/407,347<br />Filed on 2014-12-11<br />Status: Abandoned 114123510 DA3XXX 114123511 DXXXXX 114123512 DAXXXX 114144751 Methods 114144752 Compositions 114144753 Detection 114144754 LEGIONELLA TAB-2586 114096783 Transgenic Mice Overexpressing Islet Beta Cell M3 Muscarinic Acetylcholine Receptors NIDDK Diagnostics, Licensing, Research Materials, Therapeutics Diagnostics Licensing Research Materials Therapeutics Jurgen Wess Researchers at NIH have generated transgenic mice in which the M3 muscarinic receptor is overexpressed in pancreatic beta cells. This was done by placing the receptor gene under the control of the 650 bp rat insulin promoter II (RIP II). The resulting mice show a pronounced increase in glucose tolerance and enhanced plasma insulin levels. Strikingly, these mutant mice were resistant to diet-induced glucose intolerance and hyperglycemia. These transgenic mice overexpress the M3 muscarinic acetylcholine receptor only in pancreatic beta cells but notably are resistant to diet-induced glucose intolerance and hyperglycemia Diabetes research, especially type II Diabetes. Research Tool — Patent protection is not being pursued for this technology. 2022-03-08 2024-10-28 2024-10-28 2017-04-18 ACETYLCHOLINE, Beta, Cell, IDXXXX, ISLET, IXXXXX, M3, Mice, MUSCARINIC, Overexpressing, RECEPTORS, TRANSGENIC False True In vivo data available (animal) True NIHTT 37470483 Website Abstract 114171833 Gautam D, et al. http://www.ncbi.nlm.nih.gov/pubmed/16753580 <a href="http://www.ncbi.nlm.nih.gov/pubmed/16753580">Gautam D, et al.</a> 114107976 Wess, Jurgen National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Wess, Jurgen (NIDDK) 1 114107976 Wess, Jurgen National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Wess, Jurgen (NIDDK) 1 114101903 Transgenic Mice Overexpressing Islet Beta Cell M3 Muscarinic Acetylcholine Receptors E-455-2013-0 Research Material National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83739550 Shastri, Mythreyi shastrim@mail.nih.gov
United States of America Technology Advancement Office shastrim@mail.nih.gov?subject=Web Inquiry on [TAB-2586] Transgenic Mice Overexpressing Islet Beta Cell M3 Muscarinic Acetylcholine Receptors&body=Please send me information about technology [TAB-2586] Transgenic Mice Overexpressing Islet Beta Cell M3 Muscarinic Acetylcholine Receptors. Shastri, Mythreyi<br><a href="mailto:shastrim@mail.nih.gov?subject=Web Inquiry on [TAB-2586] Transgenic Mice Overexpressing Islet Beta Cell M3 Muscarinic Acetylcholine Receptors&body=Please send me information about technology [TAB-2586] Transgenic Mice Overexpressing Islet Beta Cell M3 Muscarinic Acetylcholine Receptors.">shastrim@mail.nih.gov</a><br> 114123456 IDXXXX 114123457 IXXXXX 114144635 TRANSGENIC 114144636 Mice 114144637 Overexpressing 114144638 ISLET 114144639 Beta 114144640 Cell 114144641 M3 114144642 MUSCARINIC 114144643 ACETYLCHOLINE 114144644 RECEPTORS TAB-2584 114096779 Islet Beta Cell Only M3 Muscarinic Acetylcholine Receptor Knockout Mouse NIDDK Diagnostics, Licensing, Research Materials, Therapeutics Diagnostics Licensing Research Materials Therapeutics Jurgen Wess Researchers at NIH have developed islet beta cell M3 muscarinic acetylcholine receptor knockout mouse. The mice were generated by crossing floxed mouse M3 muscarinic acetylcholine receptor mice with mice in which Cre recombinase was controlled by the beta-cell specific rat insulin promoter (RIP-Cre mice). Allows for study of the role of the M3 receptors in the pancreas without whole body effects confounding the results. Study of the physiological role of beta-cell M3 muscarinic receptors in the regulation of glucose homeostasis and insulin release in vivo. Research Tool — Patent protection is not being pursued for this technology. 2022-03-08 2024-10-28 2024-10-28 2017-04-18 ACETYLCHOLINE, Beta, Cell, IDXXXX, ISLET, IXXXXX, Knockout, M3, MUSCARINIC, RECEPTOR False True In vivo data available (animal) True NIHTT 37470483 Website Abstract 114171831 Gautam D, et al. http://www.ncbi.nlm.nih.gov/pubmed/16753580 <a href="http://www.ncbi.nlm.nih.gov/pubmed/16753580">Gautam D, et al.</a> 114107974 Wess, Jurgen National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Wess, Jurgen (NIDDK) 1 114107974 Wess, Jurgen National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Wess, Jurgen (NIDDK) 1 114101901 Islet Beta Cell M3 Muscarinic Acetylcholine Receptor Knockout E-452-2013-0 Research Material National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83739550 Shastri, Mythreyi shastrim@mail.nih.gov
United States of America Technology Advancement Office shastrim@mail.nih.gov?subject=Web Inquiry on [TAB-2584] Islet Beta Cell Only M3 Muscarinic Acetylcholine Receptor Knockout Mouse&body=Please send me information about technology [TAB-2584] Islet Beta Cell Only M3 Muscarinic Acetylcholine Receptor Knockout Mouse. Shastri, Mythreyi<br><a href="mailto:shastrim@mail.nih.gov?subject=Web Inquiry on [TAB-2584] Islet Beta Cell Only M3 Muscarinic Acetylcholine Receptor Knockout Mouse&body=Please send me information about technology [TAB-2584] Islet Beta Cell Only M3 Muscarinic Acetylcholine Receptor Knockout Mouse.">shastrim@mail.nih.gov</a><br> 114123452 IDXXXX 114123453 IXXXXX 114144617 ISLET 114144618 Beta 114144619 Cell 114144620 M3 114144621 MUSCARINIC 114144622 ACETYLCHOLINE 114144623 RECEPTOR 114144624 Knockout TAB-2585 114096780 Transgenic Mice with Constitutively Active M3 Muscarinic Receptor in Islet Beta Cells NIDDK Diagnostics, Licensing, Research Materials, Therapeutics Diagnostics Licensing Research Materials Therapeutics Jurgen Wess Q490L point mutation was introduced into the rat M3 muscarinic receptor cDNA to confer persistent, constitutive (ligand-independent) activity. Expression of the M3 receptor mutant was placed under the control of a 650 bp fragment of the rat insulin promoter II (RIP II) to limit expression to the islet beta cell. Beneficial metabolic effects of this mouse model include high basal insulin secretion, improved glucose tolerance, increased serum insulin, and resistance to high-fat diet-induced glucose intolerance and hyperglycemia. Diabetes research, especially type II Diabetes. Research Tool — Patent protection is not being pursued for this technology. 2022-03-08 2024-10-28 2024-10-28 2013-07-11 Active, Beta, Cells, CONSTITUTIVELY, IDXXXX, ISLET, IXXXXX, M3, Mice, MUSCARINIC, RECEPTOR, TRANSGENIC False True In vivo data available (animal) True NIHTT 37470483 Website Abstract 114171832 Gautam D, et al. http://www.ncbi.nlm.nih.gov/pubmed/20843999 <a href="http://www.ncbi.nlm.nih.gov/pubmed/20843999">Gautam D, et al.</a> 114107975 Wess, Jurgen National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Wess, Jurgen (NIDDK) 1 114107975 Wess, Jurgen National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Wess, Jurgen (NIDDK) 1 114101902 Transgenic Mice With Constitutively Active M3 Muscarinic Receptor In Islet Beta Cells E-453-2013-0 Research Material National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83739550 Shastri, Mythreyi shastrim@mail.nih.gov
United States of America Technology Advancement Office shastrim@mail.nih.gov?subject=Web Inquiry on [TAB-2585] Transgenic Mice with Constitutively Active M3 Muscarinic Receptor in Islet Beta Cells&body=Please send me information about technology [TAB-2585] Transgenic Mice with Constitutively Active M3 Muscarinic Receptor in Islet Beta Cells. Shastri, Mythreyi<br><a href="mailto:shastrim@mail.nih.gov?subject=Web Inquiry on [TAB-2585] Transgenic Mice with Constitutively Active M3 Muscarinic Receptor in Islet Beta Cells&body=Please send me information about technology [TAB-2585] Transgenic Mice with Constitutively Active M3 Muscarinic Receptor in Islet Beta Cells.">shastrim@mail.nih.gov</a><br> 114123454 IDXXXX 114123455 IXXXXX 114144625 TRANSGENIC 114144626 Mice 114144627 CONSTITUTIVELY 114144628 Active 114144629 M3 114144630 MUSCARINIC 114144631 RECEPTOR 114144632 ISLET 114144633 Beta 114144634 Cells TAB-2579 114096776 Rat Model for Alzheimer's Disease NIMH Licensing, Research Materials Licensing Research Materials Robert Cohen, Daniel (missing inve Ye The present invention is directed to a transgenic rat model of Alzheimer's Disease (AD) termed TgF344-19+/-. The invention rat overexpresses two human genes (APPswe and PS1deltaE9 genes), each of which are believed to be independent dominant causes of early-onset AD. The hemizygote exhibits major features of AD pathology (i.e., dense and diffuse amyloid plaques, neurofibrillary tangles, cerebral amyloid angiopathy, hyperphosphorylated tau, paired-helical filaments, Hirano bodies, granulovacuolar degeneration, cognitive impairment, and cortical neuronal loss).<br /><br /> The rat included in this technology is superior to AD mice models because the rat has a larger sized brain to accommodate <em>in vivo</em> imaging studies and complex behavioral testing. Further, the invention rat has a longer life span so that studies of longer duration or studies involving serial sampling can be conducted. The invention rat can be used to evaluate potential treatments for AD and to further investigate AD physiology. <ul> <li>Rat model in contrast to available mice models</li> <li>Rat model based on over-expression of genes responsible for early onset AD</li> </ul> <ul> <li>In vivo validation of AD therapeutics</li> <li>Development and validation of imaging methods to diagnose AD</li> <li>Detailed investigation of AD pathology and physiology</li> </ul> Research Tool – Patent protection is not being pursued for this technology. 2022-03-08 2024-10-28 2024-10-28 2013-06-21 ALZHEIMER'S, Disease, Model, rat, RXXXXX, TgF344+/- False True <ul> <li>Prototype</li> <li>In vivo data available (animal)</li> </ul> True NIHTT 37470483 Website Abstract 114171824 Borchelt DR, et al. https://www.ncbi.nlm.nih.gov/pubmed/8938131 <a href="https://www.ncbi.nlm.nih.gov/pubmed/8938131">Borchelt DR, et al.</a> 114172446 Cohen RM, et al. https://www.ncbi.nlm.nih.gov/pubmed/23575824 <a href="https://www.ncbi.nlm.nih.gov/pubmed/23575824">Cohen RM, et al.</a> 114107958 Ye, Daniel (missing inventor) Office of Research Services (ORS) Ye, Daniel (missing inventor) 0 114107957 Cohen, Robert Cedars-Sinai Medical Center NIMH Cohen, Robert (NIMH) 1 114107957 Cohen, Robert Cedars-Sinai Medical Center NIMH Cohen, Robert (NIMH) 1 114107958 Ye, Daniel (missing inventor) Office of Research Services (ORS) Ye, Daniel (missing inventor) 0 114101894 TgF344+/- Rat Model Of Alzheimer's Disease E-211-2012-0 Research Material National Institute of Mental Health (NIMH) 83739514 Dawson, Anton anton.dawson@nih.gov
United States of America anton.dawson@nih.gov?subject=Web Inquiry on [TAB-2579] Rat Model for Alzheimer's Disease&body=Please send me information about technology [TAB-2579] Rat Model for Alzheimer's Disease. Dawson, Anton<br><a href="mailto:anton.dawson@nih.gov?subject=Web Inquiry on [TAB-2579] Rat Model for Alzheimer's Disease&body=Please send me information about technology [TAB-2579] Rat Model for Alzheimer's Disease.">anton.dawson@nih.gov</a><br> 114123427 RXXXXX 114144558 TgF344+/- 114144559 rat 114144560 Model 114144561 ALZHEIMER'S 114144562 Disease TAB-2576 114096774 Engineered Anthrax Toxin Variants that Target Cancer NIAID Collaboration, Immunology, Oncology, Therapeutics Collaboration Immunology Oncology Therapeutics Stephen Leppla, Clinton Leysath, Damilola Phillips This technology describes the use of novel mutated anthrax protective antigen (PA) protein variants to target tumor cells and tumor vasculature. NIH scientists have engineered two PA variants that selectively complement one another and combine to form active octamers that target tumor cells. This controlled oligomeric activation of the PA proteins makes the likelihood of toxicity to non-tumor cells very low since non-tumor tissue does not express certain cell-surface proteases required to activate the PA variants. Using proteases that are highly expressed in tumor cells, e.g., matrix metalloproteases (MMP) and urokinase plasminogen activator (uPA), the scientists have shown significant tumor growth suppression with the oligomer in a mouse model. Furthermore, other tumor-specific proteases could also be used to control formation of the targeted octameric anthrax toxin structures. Moreover, the structures can be expanded to include several PA variants. In summary, this technology provides a unique, expandable platform that reduces toxicity to normal tissues compared to other systems and can be used to treat cancers more effectively. <ul> <li>Specificity in targeting tumors while eliminating side effects associated with non-specific targeting of normal cells</li> <li>Method can be expanded to include different proteases and up to eight PA variants.</li> </ul> Therapeutic treatment for solid tumors, cancers, and infectious diseases. The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize this invention. For collaboration opportunities, please contact Dr. Natalie Greco at <a href="mailto:Natalie.Greco@nih.gov">Natalie.Greco@nih.gov</a> or 301-761-7898. 2022-03-08 2024-10-28 2024-10-28 2017-07-06 Anthrax, ANTIGEN, CB1BXX, CB1XXX, CBXXXX, COMPLEMENTARY, CXXXXX, ENGINEERED, exclusively, FORM, Octamers, Protective, That, toxin, VARIANTS False True <ul> <li>Pre-clinical</li> <li>In vitro data available</li> <li>In vivo data available (animal)</li> </ul> True NIHTT 37470483 Website Abstract E-293-1999-0 E-059-2004-0 114171822 Phillips DD, et al. http://www.ncbi.nlm.nih.gov/pubmed/23393143 <a href="http://www.ncbi.nlm.nih.gov/pubmed/23393143">Phillips DD, et al.</a> 114107944 Leppla, Stephen NIAID - DIR NIAID Leppla, Stephen (NIAID) 0 114107946 Phillips, Damilola NIAID - DIR Phillips, Damilola 0 114107945 Leysath, Clinton NIAID - DIR Leysath, Clinton 1 114107945 Leysath, Clinton NIAID - DIR Leysath, Clinton 1 114107944 Leppla, Stephen NIAID - DIR NIAID Leppla, Stephen (NIAID) 0 114107946 Phillips, Damilola NIAID - DIR Phillips, Damilola 0 114101891 Engineered Complementary Anthrax Toxin Protective Antigen Variants That Exclusively Form Octamers E-246-2012-0 Filing authorized NIAID 91026778 Green, Wade wade.green@nih.gov
United States of America TTIPO wade.green@nih.gov?subject=Web Inquiry on [TAB-2576] Engineered Anthrax Toxin Variants that Target Cancer&body=Please send me information about technology [TAB-2576] Engineered Anthrax Toxin Variants that Target Cancer. Green, Wade<br><a href="mailto:wade.green@nih.gov?subject=Web Inquiry on [TAB-2576] Engineered Anthrax Toxin Variants that Target Cancer&body=Please send me information about technology [TAB-2576] Engineered Anthrax Toxin Variants that Target Cancer.">wade.green@nih.gov</a><br> 114167105 E-246-2012-0 E-246-2012-0-US-01 Engineered Anthrax Lethal Toxin For Targeted Delivery PRV US 61/692,143 Abandoned US <br />Provisional (PRV) 61/692,143<br />Filed on 2012-08-22<br />Status: Abandoned 114167227 E-246-2012-0 E-246-2012-0-PCT-02 Engineered Anthrax Lethal Toxin For Targeted Delivery PCT Patent Cooperation Treaty PCT/US2013/056205 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2013/056205<br />Filed on 2013-08-22<br />Status: Expired 114168086 E-246-2012-0 E-246-2012-0-US-05 Engineered Anthrax Lethal Toxin for Targeted Delivery National Stage US 9,730,993 14/423,408 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9730993 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9730993">9,730,993</a><br />Filed on 2015-02-23<br />Status: Issued 114123408 CBXXXX 114123409 CXXXXX 114123413 CB1XXX 114123414 CB1BXX 114144531 toxin 114144532 Anthrax 114144533 COMPLEMENTARY 114144534 ENGINEERED 114144535 Protective 114144536 ANTIGEN 114144537 VARIANTS 114144538 That 114144539 exclusively 114144540 FORM 114144541 Octamers TAB-2577 114096775 Intra-bone Drug Delivery Device and Method NHLBI Collaboration Collaboration Omer Aras, Richard Childs, Randall Clevenger, Robert Hoyt, Timothy Hunt, Jeremy Pantin The invention pertains to devices for directly infusing cellular therapeutics into patient bone. The device monitors intra-bone pressure using pressure sensors disposed at its proximal end and adjusts infusion pressures during infusion such that intra-bone pressure does not exceed levels of systemic blood pressure. Such devices, apparatus and methods are particularly suitable for use in performing bone marrow transplants, particularly transplants that utilize cord blood as a stem cell source. <ul> <li>Therapeutic uptake efficiency</li> <li>Drug delivery efficiency</li> <li>Target specificity</li> </ul> <ul> <li>Drug delivery to bones</li> </ul> The National Heart, Lung, and Blood Institute is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize Intra-bone Drug Delivery Device and Method. For collaboration opportunities, please contact Denise Crooks at <a href="mailto:crooksd@nhlbi.nih.gov">crooksd@nhlbi.nih.gov</a>. 2022-05-07 2024-10-28 2024-10-28 2013-06-18 AB2XXX, AB3FXX, AB3GXX, AB3XXX, ABXXXX, AXXXXX, DEVICE, Devices, Drug Delivery, Intrabone, PRESSURE, PRESSURE SENSOR, Pressure-mediated False True <ul> <li>In vitro data available</li> <li>Prototype</li> </ul> True NIHTT 37470483 Website Abstract E-196-1998-2 114171823 Pantin JM, et al. "Optimization of an Intra-Bone Hematopoietic Stem Cell Delivery Technique in a Swine Model." Poster abstract presented at the 54th ASH Annual Meeting and Exposition, Atlanta, Georgia, December 8-11, 2012. https://ash.confex.com/ash/2012/webprogram/Paper53150.html <a href="https://ash.confex.com/ash/2012/webprogram/Paper53150.html">Pantin JM, et al. "Optimization of an Intra-Bone Hematopoietic Stem Cell Delivery Technique in a Swine Model." Poster abstract presented at the 54th ASH Annual Meeting and Exposition, Atlanta, Georgia, December 8-11, 2012.</a> 114172230 Pantin JM, et al. http://www.ncbi.nlm.nih.gov/pubmed/25656824 <a href="http://www.ncbi.nlm.nih.gov/pubmed/25656824">Pantin JM, et al.</a> 114107948 Hoyt, Robert National Heart, Lung, and Blood Institute (NHLBI) NINDS Hoyt, Robert (NINDS) 0 114107949 Hunt, Timothy National Heart, Lung, and Blood Institute (NHLBI) NHLBI Hunt, Timothy (NHLBI) 0 114107950 Clevenger, Randall National Heart, Lung, and Blood Institute (NHLBI) NHLBI Clevenger, Randall (NHLBI) 0 114107951 Aras, Omer Clinical Center (CC) Aras, Omer 0 114107952 Childs, Richard National Heart, Lung, and Blood Institute (NHLBI) NHLBI Childs, Richard (NHLBI) 0 114107947 Pantin, Jeremy National Heart, Lung, and Blood Institute (NHLBI) Pantin, Jeremy 1 114107947 Pantin, Jeremy National Heart, Lung, and Blood Institute (NHLBI) Pantin, Jeremy 1 114107948 Hoyt, Robert National Heart, Lung, and Blood Institute (NHLBI) NINDS Hoyt, Robert (NINDS) 0 114107949 Hunt, Timothy National Heart, Lung, and Blood Institute (NHLBI) NHLBI Hunt, Timothy (NHLBI) 0 114107950 Clevenger, Randall National Heart, Lung, and Blood Institute (NHLBI) NHLBI Clevenger, Randall (NHLBI) 0 114107951 Aras, Omer Clinical Center (CC) Aras, Omer 0 114107952 Childs, Richard National Heart, Lung, and Blood Institute (NHLBI) NHLBI Childs, Richard (NHLBI) 0 114101892 Direct Pressure-mediated Intrabone Delivery System For Cellular Therapeutics E-165-2012-0 Filing authorized Clinical Center (CC), National Heart, Lung, and Blood Institute (NHLBI) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-2577] Intra-bone Drug Delivery Device and Method&body=Please send me information about technology [TAB-2577] Intra-bone Drug Delivery Device and Method. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-2577] Intra-bone Drug Delivery Device and Method&body=Please send me information about technology [TAB-2577] Intra-bone Drug Delivery Device and Method.">shmilovm@nih.gov</a><br> 114161202 E-165-2012-0 E-165-2012-0-US-04 Direct Pressure-mediated Intrabone Delivery System For Cellular Therapeutics National Stage US 14/772,044 Abandoned US <br />National Stage 14/772,044<br />Filed on 2015-09-01<br />Status: Abandoned 114161980 E-165-2012-0 E-165-2012-0-PCT-02 Direct Pressure-mediated Intrabone Delivery System For Cellular Therapeutics PCT Patent Cooperation Treaty PCT/US2014/019401 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2014/019401<br />Filed on 2014-02-28<br />Status: Expired 114167106 E-165-2012-0 E-165-2012-0-US-01 Direct Pressure-mediated Intrabone Delivery System For Cellular Therapeutics PRV US 61/771,463 Abandoned US <br />Provisional (PRV) 61/771,463<br />Filed on 2013-03-01<br />Status: Abandoned 114123415 AB2XXX 114123416 AB3XXX 114123417 AB3FXX 114123418 AB3GXX 114123419 AXXXXX 114123420 ABXXXX 114144542 Pressure-mediated 114144543 Intrabone 114144544 Drug Delivery 114144545 DEVICE 114144546 Devices 114144547 PRESSURE 114144548 PRESSURE SENSOR TAB-2574 114096772 Super-Resolution Fluorescence Enhanced Imaging using Bleaching/Blinking Assisted Localization Microscopy (BALM) NIDCD Licensing Licensing Bechara Kachar The invention relates to systems and methods for localization microscopy for superresolution imaging of fluorescent molecules. The method utilizes intrinsic bleaching/blinking properties of fluorophores in which superresolution is achieved by capturing successive images and subtracting from each either the subsequent image. The location of a single fluorescent molecule can be identified when the molecules either photobleach, blink off, or blink between successive images using a higher magnification lens to achieve a smaller pixel size. Higher magnification at lower pixel size <ul> <li>Tissue imaging</li> <li>Cell structure imaging</li> </ul> 2022-03-08 2024-10-28 2024-10-28 2013-06-06 AC4XXX, ACXXXX, AXXXXX, BALM, Bleaching/blinking, fluorescent, IMAGING, MICROSCOPY, Superresolution False True <ul> <li>Prototype</li> <li>In vitro data available</li> </ul> True NIHTT 37470483 Website Abstract 114107940 Kachar, Bechara National Institute on Deafness and Other Communication Disorders (NIDCD) NIDCD Kachar, Bechara (NIDCD) 1 114107940 Kachar, Bechara National Institute on Deafness and Other Communication Disorders (NIDCD) NIDCD Kachar, Bechara (NIDCD) 1 114101889 Bleaching/blinking Assisted Localization Microscopy (BALM) For Superresolution Imaging Using Standard Fluorescent Molecules E-247-2011-0 Filing authorized National Institute on Deafness and Other Communication Disorders (NIDCD) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-2574] Super-Resolution Fluorescence Enhanced Imaging using Bleaching/Blinking Assisted Localization Microscopy (BALM)&body=Please send me information about technology [TAB-2574] Super-Resolution Fluorescence Enhanced Imaging using Bleaching/Blinking Assisted Localization Microscopy (BALM). Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-2574] Super-Resolution Fluorescence Enhanced Imaging using Bleaching/Blinking Assisted Localization Microscopy (BALM)&body=Please send me information about technology [TAB-2574] Super-Resolution Fluorescence Enhanced Imaging using Bleaching/Blinking Assisted Localization Microscopy (BALM).">shmilovm@nih.gov</a><br> 114167096 E-247-2011-0 E-247-2011-0-US-01 SYSTEMS AND METHODS FOR BLEACHING/BLINKING ASSISTED LOCALIZATION MICROSCOPY FOR SUPERRESOLUTION IMAGING USING STANDARD FLUORESCENT MOLECULES PRV US 61/784,266 Abandoned US <br />Provisional (PRV) 61/784,266<br />Filed on 2013-03-14<br />Status: Abandoned 114123405 AXXXXX 114123406 AC4XXX 114123407 ACXXXX 114144517 Bleaching/blinking 114144518 MICROSCOPY 114144519 BALM 114144520 Superresolution 114144521 IMAGING 114144522 fluorescent TAB-2558 114096754 Induced Pluripotent Stem Cells Generated Using Lentivirus-based Reprogramming NHLBI Collaboration, Diagnostics, Research Materials, Therapeutics Collaboration Diagnostics Research Materials Therapeutics Manfred Boehm, Guibin Chen Five human induced pluripotent stem cells (iPSC) lines are generated using lentivirus-based reprogramming technology. These lines are pluripotent, meaning they have the potential to differentiate into all cells in the body, and theoretically can proliferate/self-renew indefinitely. The iPSC lines are: NC1 (derived from female's fibroblasts), NC2 (derived from female's fibroblasts ), NC3 (derived from male's HUVECS), NC4 (derived from male's fibroblasts) and NC5 (derived from female's fibroblasts). Further details of these cells are available upon request. NC1 uses a retrovirus delivery system incorporating the following vectors: pMIG-hKLF4, pMIG-hOCT4, pMIG-hSOX2, and MSCV h c-MYC IRES GFP. NC2-NC5 use the hSTEMCCA-loxP lentivirus delivery system (a gift from Dr. Gustavo Mostoslavsky). These cell lines will be useful for studies related to stem cell biology, understanding diseases, potential cell therapies, and small molecule screening. <ul> <li>These cells can serve as control cells and, thus, significantly reduce the cost of initiating many research projects.</li> <li>These cells can be a good source of control cells.</li> </ul> The iPSCs of this technology are useful: <ul> <li>to study the biology of stem cell development</li> <li>as controls in studies to screen for small molecules to change cell fate and/or to alleviate the phenotypes of various diseases</li> <li>to test different characterization and differentiation assays</li> </ul> The National Heart, Lung, and Blood Institute is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize Induced Pluripotent Stem Cells. For collaboration opportunities, please contact Denise Crooks at 301-435-0103. Research Tools – Patent protection is not being pursued for this technology. 2022-03-08 2024-10-28 2024-10-28 2013-05-07 Cell, FIVE, GCXXXX, Generation, GXXXXX, Human, IDXXXX, INDUCED, iPSC, IXXXXX, Lines, Pluripotent, RXXXXX, Stem False True <ul> <li>Prototype</li> <li>Pilot</li> <li>Early-stage</li> <li>In vitro data available</li> </ul> True NIHTT 37470483 Website Abstract 114107891 Chen, Guibin National Heart, Lung, and Blood Institute (NHLBI) NHLBI Chen, Guibin (NHLBI) 0 114107890 Boehm, Manfred National Heart, Lung, and Blood Institute (NHLBI) NHLBI Boehm, Manfred (NHLBI) 1 114107890 Boehm, Manfred National Heart, Lung, and Blood Institute (NHLBI) NHLBI Boehm, Manfred (NHLBI) 1 114107891 Chen, Guibin National Heart, Lung, and Blood Institute (NHLBI) NHLBI Chen, Guibin (NHLBI) 0 114101869 Generation Of Five Human Induced Pluripotent Stem Cell (iPSC) Lines E-274-2012-0 Research Material National Heart, Lung, and Blood Institute (NHLBI) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-2558] Induced Pluripotent Stem Cells Generated Using Lentivirus-based Reprogramming&body=Please send me information about technology [TAB-2558] Induced Pluripotent Stem Cells Generated Using Lentivirus-based Reprogramming. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-2558] Induced Pluripotent Stem Cells Generated Using Lentivirus-based Reprogramming&body=Please send me information about technology [TAB-2558] Induced Pluripotent Stem Cells Generated Using Lentivirus-based Reprogramming.">shmilovm@nih.gov</a><br> 114123314 RXXXXX 114123317 IXXXXX 114123318 IDXXXX 114123319 GXXXXX 114123320 GCXXXX 114144306 Generation 114144307 FIVE 114144308 Human 114144309 INDUCED 114144310 Pluripotent 114144311 Stem 114144312 Cell 114144313 iPSC 114144314 Lines TAB-2560 114096756 Parvovirus B19 Vaccine NHLBI Collaboration, Diagnostics, Infectious Disease, Rare/Neglected Diseases, Vaccines Collaboration Diagnostics Infectious Disease Rare/Neglected Diseases Vaccines Sachiko Kajigaya, Takashi Shimada, Neal Young, Ning Zhi Parvovirus B19 (B19V) infection causes fifth disease, a disease characterized by rashes to the face and other parts of the body that primarily affects children. However, adults can also develop fifth disease and it can lead to more severe conditions. Patients that are immunocompromised, such as those who are HIV infected, organ transplant recipients, and cancer patients, can be particularly susceptible to more severe outcomes from B19V infection. Infection can also cause anemia and in pregnant women, it can lead to hydrops fetalis.<br /><br /> The subject technologies are expression vectors for the production of B19V VP1 and VP2 capsid proteins. Co-expression of the two proteins produce empty virus-like particles (VLPs) that can be used to develop a vaccine against parvovirus B19 and a packaging system for infectious B19V virus. Different expression vectors have been developed and optimized for expression in insects cells and more recently in mammalian cell lines such as 293, Cos7, Hela cells and 293T cells. There is currently no B19V vaccine on the market. Vaccine against parvovirus B19V. The National Heart, Lung, and Blood Institute is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize the technology for producing Parvovirus B19 vaccine. For collaboration opportunities, please contact Cecilia Pazman, Ph.D. at <a href="mailto:pazmance@mail.nih.gov">pazmance@mail.nih.gov</a>. 2022-09-28 2024-10-28 2024-10-28 2013-05-07 Admin Lic Spec Review Mar-09 Active Determina, AgainstB19V, B19, B19V, BBXXXX, CAPSID, Capsids, CODON, CRADA, DA4BXX, DA4XXX, DAXXXX, DC5BXX, DC5XXX, DCXXXX, diagnostic, DNA-based, DXXXXX, GENES, Infection, Non-pennissive, PARTICLE, PARVOVIRUS, Patent Category - Biotechnology, SACGHS DNA Patent Initial Set, UA1XXX, VACCCINE, vaccines, VIRUS-LIKE, VLP-and False True <ul> <li>Early-stage</li> <li>Pre-clinical</li> <li>Clinical</li> <li>In vitro data available</li> <li>In vivo data available (animal)</li> <li>In vivo data available (human)</li> </ul> True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114171794 Bernstein DI, et al. http://www.ncbi.nlm.nih.gov/pubmed/21807052 <a href="http://www.ncbi.nlm.nih.gov/pubmed/21807052">Bernstein DI, et al.</a> 114171795 Zhi N, et al. http://www.ncbi.nlm.nih.gov/pubmed/20943969 <a href="http://www.ncbi.nlm.nih.gov/pubmed/20943969">Zhi N, et al.</a> 114107897 Young, Neal National Heart, Lung, and Blood Institute (NHLBI) NHLBI Young, Neal (NHLBI) 0 114107898 Kajigaya, Sachiko NHLBI Kajigaya, Sachiko (NHLBI) 0 114107899 Shimada, Takashi Shimada, Takashi 0 114107900 Zhi, Ning National Heart, Lung, and Blood Institute (NHLBI) Zhi, Ning 1 114107900 Zhi, Ning National Heart, Lung, and Blood Institute (NHLBI) Zhi, Ning 1 114107897 Young, Neal National Heart, Lung, and Blood Institute (NHLBI) NHLBI Young, Neal (NHLBI) 0 114107898 Kajigaya, Sachiko NHLBI Kajigaya, Sachiko (NHLBI) 0 114107899 Shimada, Takashi Shimada, Takashi 0 114101871 PARVOVIRUS CAPSIDS E-286-1988-2 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 114101872 B19 PARVOVIRUS CAPSIDS E-286-1988-1 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 114101873 Parvovirus Capsids E-266-2000-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 114101874 The Optimized Codon Usage Of B19V Capsid Genes In Non-pennissive Cells And Its Application In Developing Virus-like Particle (VLP)-and DNA-based Vaccines Against B19V Infection E-011-2010-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 83739538 Choudhry, Vidita vidita.choudhry@nih.gov
United States of America Office of Technology Transfer and Development vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-2560] Parvovirus B19 Vaccine&body=Please send me information about technology [TAB-2560] Parvovirus B19 Vaccine. Choudhry, Vidita<br><a href="mailto:vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-2560] Parvovirus B19 Vaccine&body=Please send me information about technology [TAB-2560] Parvovirus B19 Vaccine.">vidita.choudhry@nih.gov</a><br> 114167044 E-286-1988-1 E-286-1988-1-US-02 PARVOVIRUS CAPSIDS DIV US 6,132,732 08/407,939 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6132732 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6132732">6,132,732</a><br />Filed on 1995-03-21<br />Status: Expired 114167045 E-286-1988-2 E-286-1988-2-US-02 Parvovirus Protein Presenting Capsids DIV US 5,916,563 08/253,539 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/5916563 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/5916563">5,916,563</a><br />Filed on 1994-06-03<br />Status: Expired 114167046 E-011-2010-0 E-011-2010-0-PCT-02 Compositions And Methods For Preventing or Treating A Human Parvovirus Infection PCT Patent Cooperation Treaty PCT/US2011/024199 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2011/024199<br />Filed on 2011-02-09<br />Status: Expired 114167047 E-286-1988-1 E-286-1988-1-US-03 PARVOVIRUS CAPSIDS DIV US 6,001,371 08/462,464 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6001371 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6001371">6,001,371</a><br />Filed on 1995-06-05<br />Status: Expired 114167048 E-011-2010-0 E-011-2010-0-US-01 The Optimized Codon Usage Of B19V Capsid Genes In Non-pennissive Cells And Its Application In Developing Virus-like Particle (VLP)-and DNA-based Vaccines Against B19V Infection PRV US 61/337,983 Abandoned US <br />Provisional (PRV) 61/337,983<br />Filed on 2010-02-12<br />Status: Abandoned 114167049 E-266-2000-0 E-266-2000-0-US-01 Parvovirus Capsids CON US 6,558,676 09/611,066 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6558676 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6558676">6,558,676</a><br />Filed on 2000-07-06<br />Status: Expired 114167050 E-011-2010-0 E-011-2010-0-US-04 Compositions And Methods For Preventing Or Treating A Human Parvovirus Infection National Stage US 13/578,577 Abandoned US <br />National Stage 13/578,577<br />Filed on 2012-11-13<br />Status: Abandoned 114167052 E-286-1988-2 E-286-1988-2-US-01 PARVOVIRUS CAPSIDS CIP US 07/843,067 Abandoned US <br />Continuation in Part (CIP) 07/843,067<br />Filed on 1992-03-02<br />Status: Abandoned 114167053 E-286-1988-2 E-286-1988-2-PCT-03 No_Patent_Title PCT Patent Cooperation Treaty * Administratively Closed Patent Cooperation Treaty <br />(PCT) *<br />Filed on 1989-11-14<br />Status: Administratively Closed 114167054 E-286-1988-1 E-286-1988-1-PCT-05 No_Patent_Title PCT Patent Cooperation Treaty PCT/US91/08310 Expired Patent Cooperation Treaty <br />(PCT) PCT/US91/08310<br />Filed on 1989-11-14<br />Status: Expired 114167055 E-286-1988-1 E-286-1988-1-US-04 PARVOVIRUS CAPSIDS DIV US 5,827,647 08/463,332 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/5827647 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/5827647">5,827,647</a><br />Filed on 1995-06-05<br />Status: Expired 114167056 E-286-1988-1 E-286-1988-1-US-01 B19 PARVOVIRUS CAPSIDS CIP US 5,508,186 07/612,672 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/5508186 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/5508186">5,508,186</a><br />Filed on 1990-11-14<br />Status: Expired 114167057 E-266-2000-0 E-266-2000-0-US-02 Parvovirus Capsids CON US 10/366,810 Abandoned US <br />Continuation (CON) 10/366,810<br />Filed on 2003-02-13<br />Status: Abandoned 114123326 DA4BXX 114123327 DC5BXX 114123328 UA1XXX 114123329 BBXXXX 114123330 DXXXXX 114123331 DAXXXX 114123332 DA4XXX 114123333 DCXXXX 114123334 DC5XXX 114144323 VACCCINE 114144324 PARVOVIRUS 114144325 diagnostic 114144326 CRADA 114144327 Capsids 114144328 Patent Category - Biotechnology 114144329 B19 114144330 SACGHS DNA Patent Initial Set 114144331 Admin Lic Spec Review Mar-09 Active Determina 114144332 CODON 114144333 B19V 114144334 CAPSID 114144335 GENES 114144336 Non-pennissive 114144337 VIRUS-LIKE 114144338 PARTICLE 114144339 VLP-and 114144340 DNA-based 114144341 vaccines 114144342 AgainstB19V 114144343 Infection TAB-2545 114096740 Highly Potent and Selective Deubiquitinating Enzyme Inhibitor NCATS Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Thomas Dexheimer, Ajit Jadhav, Qin Liang, David Maloney, Andrew Rosenthal, Anton Simeonov, Zhihao Zhuang Available for licensing are inhibitors that target the USP1/ UAF1 deubiquitinating enzyme (DUB) complex. The FDA approval and commercial success of Velcade®, a small molecule proteasome inhibitor, has established the ubiquitin-proteasome system (UPS) as a valid target for anticancer treatment. However, proteasome inhibitors in general suffer from a narrow therapeutic index and acquired resistance. A promising alternative to proteasome inhibition has been to target the enzymes upstream of proteasome-mediated protein degradation, i.e. the ubiquitin conjugation and deconjugation, to generate more specific, less toxic therapeutic agents. The investigators have developed small molecules that target the USP1/ UAF1 DUB complex that acts upstream of UPS and has been implicated in the DNA damage response. These compounds are the most potent and selective DUB inhibitors reported to date. Moreover, the inhibitors act synergistically with cisplatin, a DNA damaging anti-cancer drug, to overcome chemoresistance and enhance cytotoxicity. These results suggest the inhibitors may also improve the efficacy and potency of other commonly prescribed chemotherapeutic agents that are known to induce DNA damage. <ul> <li>Represents the most potent and selective DUB inhibitor reported to date.</li> <li>Promising alternative to proteasome inhibition offering the potential of more selective and less toxic therapeutic agents.</li> <li>Acts synergistically with DNA damaging agents to overcome chemoresistance.</li> </ul> <ul> <li>Method to treat cancer</li> <li>Method to overcome chemoresistance to cisplatin</li> <li>Pharmaceutical compositions</li> </ul> The National Center for Advancing Translational Sciences is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize this invention. For collaboration opportunities, please contact Lili Portilla at <a href="mailto:lili.portilla@nih.gov">lili.portilla@nih.gov</a> or 301-217-2589, or Dr. Krishna Balakrishnan at <a href="mailto:balakrik@mail.nih.gov">balakrik@mail.nih.gov</a> or 301-217-2336. A notice was published in the Federal Register on Tuesday, June 24, 2014 detailing this opportunity: <a href="https://federalregister.gov/a/2014-14719" target="_blank" title="Click here to view the published notice">https://federalregister.gov/a/2014-14719</a>. 2022-03-08 2024-10-28 2024-10-28 2013-04-04 CANCER, CANCER THERAPEUTICS, CB5XXX, CB7XXX, CBXXXX, Combination Therapy, CXXXXX, Deubiquitinase, Inhibitors, POTENT, protease inhibitors, SELECTIVE, small molecule, USP1/UAF1 False True <ul> <li>Early-stage</li> <li>In vitro data available</li> </ul> True NIHTT 37470483 Website Abstract E-208-2007-0 E-156-2012-0 E-231-2002-0 E-070-2005-0 114172166 Liang Q, et al. http://www.ncbi.nlm.nih.gov/pubmed/24531842 <a href="http://www.ncbi.nlm.nih.gov/pubmed/24531842">Liang Q, et al.</a> 114172167 Singhal S, et al. http://www.ncbi.nlm.nih.gov/pubmed/19007433 <a href="http://www.ncbi.nlm.nih.gov/pubmed/19007433">Singhal S, et al.</a> 114172168 Reyes-Turcu FE, et al. http://www.ncbi.nlm.nih.gov/pubmed/19489724 <a href="http://www.ncbi.nlm.nih.gov/pubmed/19489724">Reyes-Turcu FE, et al.</a> 114172169 Hussain S, et al. http://www.ncbi.nlm.nih.gov/pubmed/19448430 <a href="http://www.ncbi.nlm.nih.gov/pubmed/19448430">Hussain S, et al.</a> 114172170 Oestergaard VH, et al. http://www.ncbi.nlm.nih.gov/pubmed/18082605 <a href="http://www.ncbi.nlm.nih.gov/pubmed/18082605">Oestergaard VH, et al.</a> 114172171 Kim JM, et al. http://www.ncbi.nlm.nih.gov/pubmed/19217432 <a href="http://www.ncbi.nlm.nih.gov/pubmed/19217432">Kim JM, et al.</a> 114172172 Chen J, et al. http://www.ncbi.nlm.nih.gov/pubmed/22118673 <a href="http://www.ncbi.nlm.nih.gov/pubmed/22118673">Chen J, et al.</a> 114172232 Dexheimer TS, et al. http://www.ncbi.nlm.nih.gov/pubmed/25506968 <a href="http://www.ncbi.nlm.nih.gov/pubmed/25506968">Dexheimer TS, et al.</a> 114107841 Rosenthal, Andrew NCATS - NCGC Rosenthal, Andrew 0 114107842 Jadhav, Ajit NCATS - NCGC NCATS Jadhav, Ajit (NCATS) 0 114107843 Dexheimer, Thomas NCATS - NCGC Leidos Dexheimer, Thomas (Leidos) 0 114107844 Simeonov, Anton NCATS - NCGC NCATS Simeonov, Anton (NCATS) 0 114107845 Liang, Qin University of Delaware Liang, Qin 0 114107846 Zhuang, Zhihao University of Delaware Zhuang, Zhihao 0 114106009 Maloney, David NCATS - NCGC NCATS Maloney, David (NCATS) 1 114106009 Maloney, David NCATS - NCGC NCATS Maloney, David (NCATS) 1 114107841 Rosenthal, Andrew NCATS - NCGC Rosenthal, Andrew 0 114107842 Jadhav, Ajit NCATS - NCGC NCATS Jadhav, Ajit (NCATS) 0 114107843 Dexheimer, Thomas NCATS - NCGC Leidos Dexheimer, Thomas (Leidos) 0 114107844 Simeonov, Anton NCATS - NCGC NCATS Simeonov, Anton (NCATS) 0 114107845 Liang, Qin University of Delaware Liang, Qin 0 114107846 Zhuang, Zhihao University of Delaware Zhuang, Zhihao 0 114100959 Discovery Of Potent And Selective Inhibitors Of The USP1/UAF1 Deubiquitinase Complex E-043-2013-0 Filing authorized NCATS - NCGC, University of Delaware 83727060 Gadhia, Ami ami.gadhia@nih.gov
United States of America NCGC ami.gadhia@nih.gov?subject=Web Inquiry on [TAB-2545] Highly Potent and Selective Deubiquitinating Enzyme Inhibitor&body=Please send me information about technology [TAB-2545] Highly Potent and Selective Deubiquitinating Enzyme Inhibitor. Gadhia, Ami<br><a href="mailto:ami.gadhia@nih.gov?subject=Web Inquiry on [TAB-2545] Highly Potent and Selective Deubiquitinating Enzyme Inhibitor&body=Please send me information about technology [TAB-2545] Highly Potent and Selective Deubiquitinating Enzyme Inhibitor.">ami.gadhia@nih.gov</a><br> 114159991 E-043-2013-0 E-043-2013-0-US-07 Inhibitors Of The USP1/UAF1 Deubiquitinase Complex and Uses Thereof National Stage US 9,802,904 14/655,538 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9802904 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9802904">9,802,904</a><br />Filed on 2015-06-25<br />Status: Issued 114167036 E-043-2013-0 E-043-2013-0-US-01 Inhibitors Of The USP1/UAF1 Deubiquitinase Complex And Uses Thereof PRV US 61/747,052 Abandoned US <br />Provisional (PRV) 61/747,052<br />Filed on 2012-12-28<br />Status: Abandoned 114167441 E-043-2013-0 E-043-2013-0-PCT-02 Inhibitors of the USP1/UAF1 Deubiquitinase Complex and Uses Thereof PCT Patent Cooperation Treaty PCT/US2013/077804 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2013/077804<br />Filed on 2013-12-26<br />Status: Expired 114123244 CBXXXX 114123245 CB5XXX 114123246 CB7XXX 114123247 CXXXXX 114144189 POTENT 114144190 SELECTIVE 114144191 Inhibitors 114144192 USP1/UAF1 114144193 Deubiquitinase 114144194 Combination Therapy 114144195 protease inhibitors 114144196 CANCER 114144197 CANCER THERAPEUTICS 114144198 small molecule TAB-2532 114096727 Background-Free Fluorescent Nanodiamond Imaging NHLBI Collaboration, Licensing Collaboration Licensing Ambika Bumb, Keir Neuman Available for licensing and commercial development are intellectual property rights covering a method of imaging a biological specimen (e.g., human tissue) using fluorescent nanodiamonds implanted into the subject of interest, applying a magnetic field to said subject and producing a resultant image by a net juxtaposition of a second acquired image. This process suppresses the background and permits selective imaging of the nanodiamonds in the presence of background fluorescence that exceeds the signal from the nanodiamonds. Another aspect of the invention provides an imaging method in which the resulting image is acquired by applying time-varying magnetic fields using one or more secondary image averaged against the first. The technique relies on imposing a small (~100 Gauss) magnetic field on the sample of interest during optical imaging combined with post-processing of the acquired images to remove the background. This technology can readily be added onto any commercial optical imaging platform to achieve background-free images of the nanodiamonds in a biological specimen. <ul> <li>Improved resolution through composite imagery</li> <li>Background elimination</li> <li>Indefinite tracking due to the exceptional stability of the fluorescent nanodiamonds</li> <li>Wide excitation band (~500-600 nm)</li> <li>Broad-band Near IR emission (600-700 nm)</li> <li>Nanodiamonds are stable in aqueous solution</li> <li>In related technologies we have developed a method to specifically coat and functionalize nanodiamonds for targeting and labeling applications</li> </ul> <ul> <li>In vitro and in vivo optical imaging and diagnostics</li> <li>MRI imaging</li> </ul> The NHLBI Laboratory of Single Molecule Biophysics is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize background-free imaging of fluorescent nanodiamonds for in vivo and in vitro applications. For collaboration opportunities, please contact Keir C. Neuman, Ph.D. at <a href="mailto:neumankc@mail.nih.gov">neumankc@mail.nih.gov</a> or 301-496-3376. 2022-03-08 2024-10-28 2024-10-28 2013-02-21 AA3AXX, AA3XXX, AAXXXX, AXXXXX, Background-free, IMAGING, MRI, Nanodiamond False True <ul> <li>Prototype</li> <li>In vitro data available</li> <li>In vivo data available (animal)</li> </ul> True NIHTT 37470483 Website Abstract E-175-2012-0 114107801 Bumb, Ambika National Heart, Lung, and Blood Institute (NHLBI) NCI Bumb, Ambika (NCI) 0 114107802 Neuman, Keir National Heart, Lung, and Blood Institute (NHLBI) NHLBI Neuman, Keir (NHLBI) 0 114107801 Bumb, Ambika National Heart, Lung, and Blood Institute (NHLBI) NCI Bumb, Ambika (NCI) 0 114107802 Neuman, Keir National Heart, Lung, and Blood Institute (NHLBI) NHLBI Neuman, Keir (NHLBI) 0 114101845 Background-free Imaging By Selective Modulation Of Nanodiamond Fluorescence Using A Magnetic Field. E-261-2012-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-2532] Background-Free Fluorescent Nanodiamond Imaging&body=Please send me information about technology [TAB-2532] Background-Free Fluorescent Nanodiamond Imaging. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-2532] Background-Free Fluorescent Nanodiamond Imaging&body=Please send me information about technology [TAB-2532] Background-Free Fluorescent Nanodiamond Imaging.">shmilovm@nih.gov</a><br> 114166803 E-261-2012-0 E-261-2012-0-US-03 IMAGING METHODS AND COMPUTER-READABLE MEDIA DIV US 11,024,018 15/243,765 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11024018 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11024018">11,024,018</a><br />Filed on 2016-08-22<br />Status: Abandoned 114167002 E-261-2012-0 E-261-2012-0-US-01 Imaging Methods and Computer-Readable Media PRV US 61/711,702 Abandoned US <br />Provisional (PRV) 61/711,702<br />Filed on 2012-10-09<br />Status: Abandoned 114167358 E-261-2012-0 E-261-2012-0-US-02 Imaging Methods and Computer-Readable Media ORD US 9,449,377 14/049,096 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9449377 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9449377">9,449,377</a><br />Filed on 2013-10-08<br />Status: Abandoned 114123192 AA3AXX 114123193 AXXXXX 114123194 AAXXXX 114123195 AA3XXX 114144068 Background-free 114144069 MRI 114144070 Nanodiamond 114144071 IMAGING TAB-2535 114096730 Modified Peptide Nucleic Acids (PNAs) for Detection of DNA or RNA and Identification of a Disease or Pathogen NIDDK Collaboration, Diagnostics, Infectious Disease Collaboration Diagnostics Infectious Disease Daniel Appella, Christopher Micklitsch, Bereket Yemane (formerly Oquare), Chao Zhao The NIH announces a novel method for fast, simple, and accurate detection of nucleic acids outside the modern laboratory. Nucleic acid testing is highly specific and often provides definitive identification of a disease or pathogen. Methods to detect nucleic acid sequences and identify a disease or pathogen are dominated by PCR, but applying PCR-based techniques in remote settings is challenging. Researchers at the NIH have developed a universal, colorimetric, nucleic acid-responsive diagnostic system that uses two short peptide nucleic acid (PNA) probes and does not rely on PCR. The design of a cyclopentane-modified surface probe and a biotin-containing reporter probe allows excellent DNA and RNA detection. NIH researchers have specifically demonstrated this technology's suitability for early detection of HIV RNA or anthrax DNA. <ul> <li>Eliminates requirement for PCR</li> <li>Fast, simple method that can be used outside the laboratory</li> <li>Modified PNAs provide resistance to degradation by enzymes and a high degree of stability to any diagnostic device</li> </ul> <ul> <li>Ultra-high sensitive detection of nucleic acids</li> <li>Convenient, universal, colorimetric diagnostic tool</li> <li>Can be used to detect any kind of infectious disease by simply changing the PNA sequences of the specific probe</li> <li>Suitable for early detection of HIV, anthrax, tuberculosis, human papilloma virus (HPV), avian flu, <em>E. coli</em>, and more</li> </ul> The NIDDK is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize Modified Peptide Nucleic Acids (PNAs) for Detection of DNA or RNA. For collaboration opportunities, please contact Marguerite Miller at <a href="mailto:Marguerite.Miller@nih.gov">Marguerite.Miller@nih.gov</a> or 301-496-9003. 2022-03-08 2024-10-28 2024-10-28 2013-02-21 Acids, Cyclopentane-Peptide, DAXXXX, Detection, DXXXXX, Nucleic, Qualitative, QUANTITATIVE, YXXXXX False True <ul> <li>Prototype</li> <li>In vitro data available</li> </ul> True NIHTT 37470483 Website Abstract 114171762 Micklitsch CM, et al. http://www.ncbi.nlm.nih.gov/pubmed/23214925 <a href="http://www.ncbi.nlm.nih.gov/pubmed/23214925">Micklitsch CM, et al.</a> 114107810 Micklitsch, Christopher Micklitsch, Christopher 0 114107811 Yemane (formerly Oquare), Bereket ImClone Systems, Inc. Yemane (formerly Oquare), Bereket 0 114107812 Zhao, Chao National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Zhao, Chao 0 114107809 Appella, Daniel National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Appella, Daniel (NIDDK) 1 114107809 Appella, Daniel National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Appella, Daniel (NIDDK) 1 114107810 Micklitsch, Christopher Micklitsch, Christopher 0 114107811 Yemane (formerly Oquare), Bereket ImClone Systems, Inc. Yemane (formerly Oquare), Bereket 0 114107812 Zhao, Chao National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Zhao, Chao 0 114101848 Cyclopentane-Peptide Nucleic Acids For Qualitative And Quantitative Detection Of Nucleic Acids E-260-2012-0 Filing authorized National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83692066 Tong, Betty tongb@niddk.nih.gov
United States of America Senior Technology Advancement Office tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-2535] Modified Peptide Nucleic Acids (PNAs) for Detection of DNA or RNA and Identification of a Disease or Pathogen&body=Please send me information about technology [TAB-2535] Modified Peptide Nucleic Acids (PNAs) for Detection of DNA or RNA and Identification of a Disease or Pathogen. Tong, Betty<br><a href="mailto:tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-2535] Modified Peptide Nucleic Acids (PNAs) for Detection of DNA or RNA and Identification of a Disease or Pathogen&body=Please send me information about technology [TAB-2535] Modified Peptide Nucleic Acids (PNAs) for Detection of DNA or RNA and Identification of a Disease or Pathogen.">tongb@niddk.nih.gov</a><br> 114167005 E-260-2012-0 E-260-2012-0-US-01 Cyclopentane-Peptide Nucleic Acids For Qualitative And Quantitative Detection Of Nucleic Acids PRV US 61/684,354 Abandoned US <br />Provisional (PRV) 61/684,354<br />Filed on 2012-08-17<br />Status: Abandoned 114167237 E-260-2012-0 E-260-2012-0-PCT-02 Cyclopentane-Peptide Nucleic Acids For Qualitative And Quantitative Detection Of Nucleic Acids PCT Patent Cooperation Treaty PCT/US2013/055252 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2013/055252<br />Filed on 2013-08-16<br />Status: Expired 114168082 E-260-2012-0 E-260-2012-0-US-05 Cyclopentane-Peptide Nucleic Acids For Qualitative And Quantitative Detection Of Nucleic Acids National Stage US 10,457,978 14/421,732 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10457978 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10457978">10,457,978</a><br />Filed on 2015-02-13<br />Status: Issued 114123208 YXXXXX 114123209 DXXXXX 114123210 DAXXXX 114144086 Cyclopentane-Peptide 114144087 Nucleic 114144088 Acids 114144089 Qualitative 114144090 QUANTITATIVE 114144091 Detection TAB-2507 114096704 Methods and Composition for Identification of Variants of JC Virus DNA; An Etiologic Agent for Progressive Multifocal Leukoencephalopathy (PML) NINDS Collaboration, Diagnostics, Infectious Disease, Research Materials Collaboration Diagnostics Infectious Disease Research Materials Eugene Major, Caroline Ryschkewitsch JC Virus causes a fatal disease in the brain called progressive multifocal leukoencephalopathy (PML) that occurs in many patients with immunocompromised conditions. The finding of JCV DNA in the patients with neurological symptoms of PML is a diagnostic criterion and is needed to confirm the diagnosis of PML to rule out other neurological conditions. Certain JC virus variants are known to have a greater association with PML. For example, "Prototype" JC virus is far more pathogenic than "Archetype" JC virus. <br /><br /> This invention claims novel assays for identifying Archetype and/or Prototype JC virus by detecting the presence or absence of the unique Archetype nucleic acid sequence in the non-coding regulatory region of JC virus. While the sequences of Archetype and Prototype JC virus are known, these are the first assays that allow discrimination between Prototype and Archetype JC virus in a simple assay without the need for DNA sequencing. The identification of a JC virus as a prototype can lead to early treatment of infected individuals. <ul> <li>DNA sequencing not required.</li> <li>Single assay format using same template to identify prototype and archetype with 10c/ml sensitivity.</li> </ul> <ul> <li>JCV diagnostic kits.</li> <li>JCV diagnostics.</li> </ul> The National Institute of Neurological Disorders and Stroke is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize assays for the detection of JC Virus. For collaboration opportunities, please contact Melissa Maderia at <a href="mailto:maderiam@mail.nih.gov">maderiam@mail.nih.gov</a> or 301-451-3943. Research Material — Patent protection is not being pursued for this technology. 2022-03-08 2024-10-28 2024-10-28 2013-01-11 Chain, DA4BXX, DA4XXX, DAXXXX, DD1XXX, DDXXXX, DETECTS, DEXXXX, Distinguishes, DNA, DXXXXX, GENOTYPES, Multiplex, NON-PATHOGENIC, PATHOGENIC, polymerase, PRESENCE, REACTION, That, viral False True <ul> <li>Clinical</li> <li>In vitro data available</li> <li>In vivo data available (human)</li> </ul> True NIHTT 37470483 Website Abstract E-152-2009-0 114170671 Perkins MR, et al. http://www.ncbi.nlm.nih.gov/pubmed/23144619 <a href="http://www.ncbi.nlm.nih.gov/pubmed/23144619">Perkins MR, et al.</a> 114107727 Ryschkewitsch, Caroline NINDS NINDS Ryschkewitsch, Caroline (NINDS) 0 114107726 Major, Eugene NINDS NINDS Major, Eugene (NINDS) 1 114107726 Major, Eugene NINDS NINDS Major, Eugene (NINDS) 1 114107727 Ryschkewitsch, Caroline NINDS NINDS Ryschkewitsch, Caroline (NINDS) 0 114101818 Multiplex Polymerase Chain Reaction That Detects Presence Of Viral DNA And Distinguishes Pathogenic From Non-pathogenic Genotypes E-088-2012-0 Filing authorized NINDS 83687767 Olufemi, Olufunmilola (Lola) olufunmilola.olufemi@nih.gov
United States of America olufunmilola.olufemi@nih.gov?subject=Web Inquiry on [TAB-2507] Methods and Composition for Identification of Variants of JC Virus DNA; An Etiologic Agent for Progressive Multifocal Leukoencephalopathy (PML)&body=Please send me information about technology [TAB-2507] Methods and Composition for Identification of Variants of JC Virus DNA; An Etiologic Agent for Progressive Multifocal Leukoencephalopathy (PML). Olufemi, Olufunmilola (Lola)<br><a href="mailto:olufunmilola.olufemi@nih.gov?subject=Web Inquiry on [TAB-2507] Methods and Composition for Identification of Variants of JC Virus DNA; An Etiologic Agent for Progressive Multifocal Leukoencephalopathy (PML)&body=Please send me information about technology [TAB-2507] Methods and Composition for Identification of Variants of JC Virus DNA; An Etiologic Agent for Progressive Multifocal Leukoencephalopathy (PML).">olufunmilola.olufemi@nih.gov</a><br> 114166938 E-088-2012-0 E-088-2012-0-US-01 Methods And Compositions For Identifying JC Virus PRV US 61/661,289 Abandoned US <br />Provisional (PRV) 61/661,289<br />Filed on 2012-06-18<br />Status: Abandoned 114167109 E-088-2012-0 E-088-2012-0-PCT-02 METHODS AND COMPOSITIONS FOR IDENTIFYING JC VIRUS PCT Patent Cooperation Treaty PCT/US2013/046158 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2013/046158<br />Filed on 2013-06-17<br />Status: Expired 114168033 E-088-2012-0 E-088-2012-0-US-03 METHODS AND COMPOSITIONS FOR IDENTIFYING JC VIRUS National Stage US 9,631,243 14/408,919 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9631243 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9631243">9,631,243</a><br />Filed on 2014-12-17<br />Status: Issued 114123047 DXXXXX 114123048 DAXXXX 114123049 DA4XXX 114123050 DA4BXX 114123051 DDXXXX 114123052 DD1XXX 114123053 DEXXXX 114143754 Multiplex 114143755 polymerase 114143756 Chain 114143757 REACTION 114143758 That 114143759 DETECTS 114143760 PRESENCE 114143761 viral 114143762 DNA 114143763 Distinguishes 114143764 PATHOGENIC 114143765 NON-PATHOGENIC 114143766 GENOTYPES TAB-2517 114096713 Derivatives of Docosahexaenoylethanolamide (DEA) for Neurogenesis NIAAA Diagnostics, Licensing, Neurology, Reproductive Health, Research Materials, Therapeutics, Vaccines Diagnostics Licensing Neurology Reproductive Health Research Materials Therapeutics Vaccines Erika Englund, Hee-Yong Kim, Juan Marugan, Samarjit Patnaik The invention pertains to derivatives of docosahexaenoylethanolamide (synaptamide or DEA) and their use in inducing neurogenesis, neurite growth, and/or synaptogenesis. As such, these DEA derivatives can be used as therapeutics for neurodegenerative diseases such as traumatic brain injury, spinal cord injury, peripheral nerve injury, stroke, multiple sclerosis, autism, Alzheimer's disease, Huntington's disease, Parkinson's disease, amyotrophic lateral sclerosis. The DEA derivatives of the invention have increased potency and hydrolysis resistance as compared to native DEA. Docosahexaenoic acid (DHA), an n-3 polyunsaturated fatty acid accumulates in the brain during development, and has been implicated in learning and memory development. DEA, a metabolite derived from DHA, also has been shown to accelerate neuronal growth and development. In vitro studies in which neural progenitor cells were treated with DEA derivatives showed an increase in the number of somatic neurons produced after differentiation. <ul> <li>These derivatives of DEA provide increased potency and hydrolysis resistance compared to DEA.</li> </ul> <ul> <li>Neurogenesis</li> <li>Neurite growth</li> <li>Synaptogenesis</li> <li>Therapeutics for traumatic brain injury, spinal cord injury, peripheral nerve injury, stroke, multiple sclerosis, autism, Alzheimer’s disease, Huntington’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis.</li> </ul> Patents issued in Germany, France, United Kingdom 2022-03-08 2024-10-28 2024-10-28 2013-01-24 Derivatives, Development, Discovery, Docosahexaenoylamide, Growth, IB6XXX, IBXXXX, IXXXXX, Listed LPM Vepa as of 4/15/2015, NB1FXX, NB1HXX, NB1XXX, NBXXXX, Neurons, NXXXXX, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Promote, That, VEXXXX, YAXXXX, YBXXXX, YFXXXX False True <ul> <li>Early-stage</li> <li>In vitro data available</li> <li>Prototype</li> </ul> True 52406768 Discovery 52406768 NIHTT 37470483 Website Abstract 114109407 Englund, Erika NCATS - NCGC Englund, Erika 0 114109408 Marugan, Juan National Human Genome Research Institute (NHGRI) NCATS Marugan, Juan (NCATS) 0 114109409 Patnaik, Samarjit National Human Genome Research Institute (NHGRI) NCATS Patnaik, Samarjit (NCATS) 0 114109410 Kim, Hee-Yong National Institute on Alcohol Abuse and Alcoholism (NIAAA) NIAAA Kim, Hee-Yong (NIAAA) 1 114109410 Kim, Hee-Yong National Institute on Alcohol Abuse and Alcoholism (NIAAA) NIAAA Kim, Hee-Yong (NIAAA) 1 114109407 Englund, Erika NCATS - NCGC Englund, Erika 0 114109408 Marugan, Juan National Human Genome Research Institute (NHGRI) NCATS Marugan, Juan (NCATS) 0 114109409 Patnaik, Samarjit National Human Genome Research Institute (NHGRI) NCATS Patnaik, Samarjit (NCATS) 0 114102338 Discovery Of Docosahexaenoylamide Derivatives That Promote The Growth And Development Of Neurons E-070-2012-0 Filing authorized National Institute on Alcohol Abuse and Alcoholism (NIAAA), NCATS - NCGC 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-2517] Derivatives of Docosahexaenoylethanolamide (DEA) for Neurogenesis&body=Please send me information about technology [TAB-2517] Derivatives of Docosahexaenoylethanolamide (DEA) for Neurogenesis. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-2517] Derivatives of Docosahexaenoylethanolamide (DEA) for Neurogenesis&body=Please send me information about technology [TAB-2517] Derivatives of Docosahexaenoylethanolamide (DEA) for Neurogenesis.">shmilovm@nih.gov</a><br> 114168416 E-070-2012-0 E-070-2012-0-US-01 Derivatives Of Docosahexaenoylamide and Uses Thereof PRV US 61/624,741 Abandoned US <br />Provisional (PRV) 61/624,741<br />Filed on 2012-04-16<br />Status: Abandoned 114168417 E-070-2012-0 E-070-2012-0-PCT-02 Derivatives of Docosahexaenoylethanolamide and Uses Thereof PCT Patent Cooperation Treaty PCT/US2013/032333 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2013/032333<br />Filed on 2013-03-15<br />Status: Expired 114168418 E-070-2012-0 E-070-2012-0-US-04 Derivatives of Docosahexaenoylamide and Uses Thereof National Stage US 9,422,308 14/387,410 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9422308 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9422308">9,422,308</a><br />Filed on 2014-09-23<br />Status: Issued 114123112 IB6XXX 114123114 NB1FXX 114123115 NB1HXX 114123116 IXXXXX 114123117 IBXXXX 114123118 NXXXXX 114123119 NBXXXX 114123120 NB1XXX 114125537 VEXXXX 114125538 YAXXXX 114125539 YBXXXX 114125540 YFXXXX 114143893 Discovery 114143894 Docosahexaenoylamide 114143895 Derivatives 114143896 That 114143897 Promote 114143898 Growth 114143899 Development 114143900 Neurons 114149567 Listed LPM Vepa as of 4/15/2015 114149568 Pre LPM working set 20150418 114149569 Post LPM Assignment Set 20150420 TAB-2506 114096703 Transmission-Blocking Malaria Vaccine NIAID Collaboration, Diagnostics, Infectious Disease, Research Materials, Therapeutics, Vaccines Collaboration Diagnostics Infectious Disease Research Materials Therapeutics Vaccines Carolina Barillas-Mury, Alvaro Molina-Cruz There is no vaccine for malaria, and there is growing resistance to existing anti-malarial drugs. Sexual stage-specific antigens are of interest as vaccine candidates because disruption of these antigens would reduce the fertility and, thus, the infectivity of the parasite.<br /><br /> This invention claims methods and compositions for delivering a <em>Plasmodium</em> P47 vaccine or antibody to P47 to prevent <em>Plasmodium falciparum</em> or <em>Plasmodium vivax</em> malaria. P47 and other antigens have been mentioned as potential transmission-blocking vaccines due to their surface location on gametes. The gene for P47 antigens is also well characterized. Recent discoveries have noted that P47 allows the parasite to suppress or evade the immune system, thereby ensuring the mosquitoes' survival. Recent discoveries have also shown the mechanism by which P47 enables survival of the parasite by manipulation of the mosquito immune system. Based on the critical role of P47 antigens in transmission, the disruption of the function of P47 by various means can be an innovative and forceful means to control and/or reduce the prevalence of malaria. <ul> <li>Single protein malaria transmission-blocking vaccine.</li> <li>Cost-effective, simple manufacturing process for vaccine.</li> <li>Potentially lower-cost malarial vaccine for developing/developed countries.</li> </ul> <ul> <li>Malaria vaccine, diagnostic and therapeutic.</li> </ul> The National Institute of Allergy and Infectious Diseases (NIAID) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize malaria vaccines, diagnostics and therapeutics. For collaboration opportunities, please contact Tristan J. Mahyera at <a href="mailto:tristan.mahyera@nih.gov">tristan.mahyera@nih.gov</a> or 301-827-0251. 2022-03-08 2024-10-28 2024-10-28 2013-01-11 Anopheles, Critical, DA2XXX, DA5XXX, DAXXXX, DB2XXX, DB5XXX, DBXXXX, DC2XXX, DCXXXX, DD1XXX, DDXXXX, DEXXXX, DXXXXX, FALCIPARUM, Gambiae, Gene, Human, Malaria, Mosquitoes, Pfs47, PLASMODIUM, TRANSMISSION False True <ul> <li>Pre-clinical</li> <li>In vitro data available</li> <li>In vivo data available (animal)</li> </ul> True NIHTT 37470483 Website Abstract 114170672 Molina-Cruz A, et al. https://www.ncbi.nlm.nih.gov/pubmed/22623529 <a href="https://www.ncbi.nlm.nih.gov/pubmed/22623529">Molina-Cruz A, et al.</a> 114107725 Molina-Cruz, Alvaro NIAID - DIR NIAID Molina-Cruz, Alvaro (NIAID) 0 114107724 Barillas-Mury, Carolina NIAID - DIR NIAID Barillas-Mury, Carolina (NIAID) 1 114107724 Barillas-Mury, Carolina NIAID - DIR NIAID Barillas-Mury, Carolina (NIAID) 1 114107725 Molina-Cruz, Alvaro NIAID - DIR NIAID Molina-Cruz, Alvaro (NIAID) 0 114101817 The Plasmodium Falciparum Gene Pfs47 Is Critical For Human Malaria Transmission By Anopheles Gambiae Mosquitoes E-222-2012-0 Filing authorized NIAID 83724572 Tung, Peter peter.tung@nih.gov
United States of America DIR peter.tung@nih.gov?subject=Web Inquiry on [TAB-2506] Transmission-Blocking Malaria Vaccine&body=Please send me information about technology [TAB-2506] Transmission-Blocking Malaria Vaccine. Tung, Peter<br><a href="mailto:peter.tung@nih.gov?subject=Web Inquiry on [TAB-2506] Transmission-Blocking Malaria Vaccine&body=Please send me information about technology [TAB-2506] Transmission-Blocking Malaria Vaccine.">peter.tung@nih.gov</a><br> 114166937 E-222-2012-0 E-222-2012-0-US-01 USE OF P47 FROM PLASMODIUM FALCIPARUM (PFS47) OR PLASMODIUM VIVAX (PVS47) AS A VACCINE OR DRUG SCREENING TARGETS FOR THE INHIBITION OF HUMAN MALARIA TRANSMISSION PRV US 61/684,333 Abandoned US <br />Provisional (PRV) 61/684,333<br />Filed on 2012-08-17<br />Status: Abandoned 114167229 E-222-2012-0 E-222-2012-0-PCT-02 Use Of P47 From Plasmodium Falciparum (Pfs47) Or A Plasmodium Vivax (PVS47) As A Vaccine Or Drug Screening Targets For The Inhibition of Human Malaria Transmission PCT Patent Cooperation Treaty PCT/US2013/055372 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2013/055372<br />Filed on 2013-08-16<br />Status: Expired 114168084 E-222-2012-0 E-222-2012-0-US-07 Use Of P47 From Plasmodium Falciparum (PFS47) Or Plasmodium Vivax (PVS47) As A Vaccine Or Drug Screening Targets For The Inhibition of Human Malaria Transmission National Stage US 14/421,964 Abandoned US <br />National Stage 14/421,964<br />Filed on 2015-02-16<br />Status: Abandoned 114116285 DCXXXX 114116288 DXXXXX 114123037 DC2XXX 114123038 DEXXXX 114123039 DDXXXX 114123040 DD1XXX 114123041 DBXXXX 114123042 DB2XXX 114123043 DB5XXX 114123044 DAXXXX 114123045 DA2XXX 114123046 DA5XXX 114143743 PLASMODIUM 114143744 FALCIPARUM 114143745 Gene 114143746 Pfs47 114143747 Critical 114143748 Human 114143749 Malaria 114143750 TRANSMISSION 114143751 Anopheles 114143752 Gambiae 114143753 Mosquitoes TAB-2501 114096697 Glucocorticoid-induced TNFR Family-Related Receptor Ligand (GITRL) Antibodies for Diagnosis and Treatment of Immune System Disorders NIAID Diagnostics, Immunology, Licensing, Research Materials, Therapeutics Diagnostics Immunology Licensing Research Materials Therapeutics Ethan Shevach This technology provides novel antibodies and methods for diagnostics and treatment of disorders arising from dysregulation of the immune system using antibodies directed against glucocorticoid-induced tumor necrosis factor receptor family-related receptor ligand (GITRL). Also available are hybridomas producing anti-mouse GITRL monoclonal antibodies (clone 5F1). <br /><br /> Glucocorticoid-induced TNFR family-related receptor (GITR, also known as TNFRSF18) is expressed on the surface of responder T cells (CD4+CD25- or CD8+CD25- T cells). Upon activation of the immune response, GITR is up-regulated and binds to its ligand, GITRL (also known as TNFSF18), which enhances the immune response. The inventors have developed anti-GITRL monoclonal antibodies that block the interaction between GITR and GITRL, and have demonstrated in in vitro experiments that administration of these blocking antibodies can suppress the immune response. These antibodies may be useful for treatment of immune system disorders such as multiple sclerosis, rheumatoid arthritis, and other inflammatory diseases. The GITR/GITRL pathway is a novel target for the treatment of autoimmune diseases. <ul> <li>Development of therapeutic agents for autoimmune diseases, including autoimmune and inflammatory diseases, allergy and transplant rejection.</li> <li>Tool for investigating the role of GITRL in enhancement of the T-cell mediated immune response.</li> </ul> 2022-03-08 2024-10-28 2024-10-28 2012-11-16 antibodies, AUTOIMMUNE DISEASE, CD25, CD4, GITR, GITRL, IB3XXX, IBXXXX, IDXXXX, immune response, immune suppressor, IXXXXX, Multiple sclerosis, Patent Category - Biotechnology, RHEUMATOID ARTHRITIS, T cell, Treg False True <ul> <li>In vitro data available</li> <li>In vivo data available (animal)</li> </ul> True NIHTT 37470483 Website Abstract 114171720 Stephens GL, et al. http://www.ncbi.nlm.nih.gov/pubmed/15470044 <a href="http://www.ncbi.nlm.nih.gov/pubmed/15470044">Stephens GL, et al.</a> 114107721 Shevach, Ethan NIAID - DIR NIAID Shevach, Ethan (NIAID) 1 114107721 Shevach, Ethan NIAID - DIR NIAID Shevach, Ethan (NIAID) 1 114101811 GITR Ligand And Antibodies And Uses Thereof E-229-2003-2 Filing authorized NIAID, Wyeth 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2501] Glucocorticoid-induced TNFR Family-Related Receptor Ligand (GITRL) Antibodies for Diagnosis and Treatment of Immune System Disorders&body=Please send me information about technology [TAB-2501] Glucocorticoid-induced TNFR Family-Related Receptor Ligand (GITRL) Antibodies for Diagnosis and Treatment of Immune System Disorders. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2501] Glucocorticoid-induced TNFR Family-Related Receptor Ligand (GITRL) Antibodies for Diagnosis and Treatment of Immune System Disorders&body=Please send me information about technology [TAB-2501] Glucocorticoid-induced TNFR Family-Related Receptor Ligand (GITRL) Antibodies for Diagnosis and Treatment of Immune System Disorders.">yogikala.prabhu@nih.gov</a><br> 114166905 E-229-2003-2 E-229-2003-2-US-02 A Method of Treating or Ameliorating an Immune Cell Associated Pathology Using GITR Ligand Antibodies ORD US 7,618,632 10/853,032 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7618632 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7618632">7,618,632</a><br />Filed on 2004-05-24<br />Status: Expired 114166906 E-229-2003-2 E-229-2003-2-PCT-01 GITR Ligand and GITR Ligand-Related Molecules and Antibodies and Uses Thereof PCT COMB Patent Cooperation Treaty PCT/US2004/016381 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2004/016381<br />Filed on 2004-05-24<br />Status: Expired 114166907 E-229-2003-2 E-229-2003-2-US-23 GITR Ligand And GITR Ligand-Related Molecules and Antibodies And Uses Thereof DIV US 12/550,244 Abandoned US <br />Divisional (DIV) 12/550,244<br />Filed on 2009-07-31<br />Status: Abandoned 114123014 IB3XXX 114123015 IDXXXX 114123016 IXXXXX 114123017 IBXXXX 114143692 GITR 114143693 antibodies 114143694 Patent Category - Biotechnology 114143695 GITRL 114143696 T cell 114143697 Treg 114143698 CD25 114143699 CD4 114143700 AUTOIMMUNE DISEASE 114143701 Multiple sclerosis 114143702 RHEUMATOID ARTHRITIS 114143703 immune response 114143704 immune suppressor TAB-2502 114096698 Axon Regeneration After Brain or Spinal Cord Injury NHLBI Collaboration, Neurology, Therapeutics Collaboration Neurology Therapeutics Herbert Geller, Yasuhiro Katagiri The invention is directed to modification of a particular sugar by the enzyme arylsulfatase B (ARSB), which results in axon regeneration. <br /><br /> Following traumatic brain or spinal cord injury, glial scars prevent regeneration of axons. Chondroitin sulfate proteoglycans (CSPGs) are major components of glial scars. CSPGs are made of a protein core containing glycosaminoglycan (GAG) sugar side chains, which, when sulfated, are responsible for the inhibitory activity of glial scars. Specifically, NIH researchers have shown that the 4-sulfate unit on a certain sugar on GAG is responsible for inhibiting axon regrowth and, when the 4-sulfate unit is reduced, axon regrowth is observed. Moreover, removal of this 4-sulfate unit by the ARSB enzyme promotes axon regrowth. <br /><br /> As a potential therapy for spinal cord injuries, researchers developed a vector expressing ARSB and demonstrated that this vector promotes axon regeneration when injected into the spinal cord of a mouse. <ul> <li>There are no existing products for treatment of traumatic spinal cord injury</li> <li>ARSB is already approved for treatment of Mucopolysaccharoidosis VI, a lysosomal storage disease</li> </ul> <ul> <li>Treatment of brain and spinal cord injury</li> <li>Treatment of other CNS injuries, including stroke</li> <li>Treatment of heart attack</li> </ul> The NHLBI is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize the use of ARSB in axonal regeneration after brain or spinal cord injury using animal models. For collaboration opportunities, please contact Denise Crooks, Ph.D. at 301-435-0103 or <a href+"mailto:crooksd@mail.nih.gov">crooksd@mail.nih.gov</a>. 2022-03-08 2024-10-28 2024-10-28 2012-11-21 AFTER, Arylsulfatase, AXONAL, B, Brain/spinal, CORD, INJURY, NB1JXX, NB1XXX, NBXXXX, NXXXXX, PROMOTES, Regeneration False True <ul> <li>Early-stage</li> <li>In vitro data available</li> <li>In vivo data available (animal)</li> </ul> True NIHTT 37470483 Website Abstract 114171723 Wang H, et al. http://www.ncbi.nlm.nih.gov/pubmed/18768934 <a href="http://www.ncbi.nlm.nih.gov/pubmed/18768934">Wang H, et al.</a> 114107716 Katagiri, Yasuhiro National Heart, Lung, and Blood Institute (NHLBI) NHLBI Katagiri, Yasuhiro (NHLBI) 0 114107715 Geller, Herbert National Heart, Lung, and Blood Institute (NHLBI) NHLBI Geller, Herbert (NHLBI) 1 114107715 Geller, Herbert National Heart, Lung, and Blood Institute (NHLBI) NHLBI Geller, Herbert (NHLBI) 1 114107716 Katagiri, Yasuhiro National Heart, Lung, and Blood Institute (NHLBI) NHLBI Katagiri, Yasuhiro (NHLBI) 0 114101812 Arylsulfatase B Promotes Axonal Regeneration After Brain/spinal Cord Injury E-214-2012-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 83685986 Crooks, Denise crooksd@mail.nih.gov
United States of America Office of Technology Transfer and Development crooksd@mail.nih.gov?subject=Web Inquiry on [TAB-2502] Axon Regeneration After Brain or Spinal Cord Injury&body=Please send me information about technology [TAB-2502] Axon Regeneration After Brain or Spinal Cord Injury. Crooks, Denise<br><a href="mailto:crooksd@mail.nih.gov?subject=Web Inquiry on [TAB-2502] Axon Regeneration After Brain or Spinal Cord Injury&body=Please send me information about technology [TAB-2502] Axon Regeneration After Brain or Spinal Cord Injury.">crooksd@mail.nih.gov</a><br> 114162583 E-214-2012-0 E-214-2012-0-US-04 Treatment of Central Nervous System (CNS) Injury National Stage US 14/430,850 Abandoned US <br />National Stage 14/430,850<br />Filed on 2015-03-24<br />Status: Abandoned 114166910 E-214-2012-0 E-214-2012-0-US-01 COMPOSITIONS AND METHODS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM (CNS) INJURY PRV US 61/705,555 Abandoned US <br />Provisional (PRV) 61/705,555<br />Filed on 2012-09-25<br />Status: Abandoned 114167316 E-214-2012-0 E-214-2012-0-PCT-02 TREATMENT OF CENTRAL NERVOUS SYSTEM (CNS) INJURY PCT Patent Cooperation Treaty PCT/US2013/061693 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2013/061693<br />Filed on 2013-09-25<br />Status: Expired 114123018 NXXXXX 114123019 NBXXXX 114123020 NB1XXX 114123021 NB1JXX 114143705 Arylsulfatase 114143706 B 114143707 PROMOTES 114143708 AXONAL 114143709 Regeneration 114143710 AFTER 114143711 Brain/spinal 114143712 CORD 114143713 INJURY TAB-2500 114096696 Small Molecule MRS5474 with Anticonvulsant Activity for Treatment of Epilepsy NIDDK Cardiology, Collaboration, Diagnostics, Neurology, Research Materials, Therapeutics Cardiology Collaboration Diagnostics Neurology Research Materials Therapeutics Kenneth Jacobson, Dilip Tosh Adenosine modulates many physiological processes by activating specific adenosine receptors. These adenosine receptors play a critical role in the regulation of cellular signaling and are broadly distributed throughout the body. Thus, the ability to modulate adenosine receptor-mediated signaling is an attractive therapeutic strategy for a broad range of diseases. This technology relates to a group of compounds that display high affinity and specificity for the A1 adenosine receptor subtype.<br /><br /> One of the compounds, MRS5474, displays anticonvulsant activity in the 6 Hz animal model of clonic seizures. In the minimal behavioral toxicity test using the rotarod, no toxicity (zero out of eight mice) was observed at all doses tested up to 30 mg/kg, the highest dose tested, which was nearly completely protective (seven out of eight animals) in the 6 Hz model. MRS 5474 also tested well in the corneal kindled mouse model to examine its effect on focal seizures. <ul> <li>These small molecules display increased specificity for the A1 type of adenosine receptors, which may reduce unwanted side effects previously seen in A1AR agonist therapies.</li> <li>The physical properties of these molecules are drug-like, which makes them attractive for pre-clinical development.</li> </ul> <ul> <li>Oral anticonvulsant drug.</li> <li>Provides a means to mimic A1AR mediated signaling in vitro and in vivo.</li> </ul> The NIDDK is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize MRS5474, A1 adenosine receptor agonist for treatment of seizures. For collaboration opportunities, please contact Marguerite Miller at <a href="mailto:Marguerite.Miller@nih.gov">Marguerite.Miller@nih.gov</a>. 2022-03-08 2024-10-28 2024-10-28 2012-11-16 A3, Activity, ADENOSINE, AGONISTS, Agonists:, Al, ANTAGONISTS, Anticonvulsant, Derivatives, Docking, IB1FXX, IB1XXX, IBXXXX, IXXXXX, NB1EXX, NB1HXX, NB1XXX, NBXXXX, N-Methanocarba, Nucleosides, NXXXXX, PARTIAL, Patent Category - Chemistry, POTENT, RECEPTOR, TRUNCATED False True <ul> <li>Early-stage</li> <li>In vitro data available</li> <li>In vivo data available (animal)</li> </ul> True NIHTT 37470483 Website Abstract E-285-2008-0 114171719 Tosh DK, et al. http://www.ncbi.nlm.nih.gov/pubmed/22921089 <a href="http://www.ncbi.nlm.nih.gov/pubmed/22921089">Tosh DK, et al.</a> 114107714 Tosh, Dilip National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Tosh, Dilip (NIDDK) 0 114107713 Jacobson, Kenneth National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Jacobson, Kenneth (NIDDK) 1 114107713 Jacobson, Kenneth National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Jacobson, Kenneth (NIDDK) 1 114107714 Tosh, Dilip National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Tosh, Dilip (NIDDK) 0 114101810 Truncated (N)-Methanocarba Nucleosides As Al Adenosine Receptor Agonists And Partial Agonists: Receptor Docking And Potent Anticonvulsant Activity E-285-2008-1 Filing authorized National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83692066 Tong, Betty tongb@niddk.nih.gov
United States of America Senior Technology Advancement Office tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-2500] Small Molecule MRS5474 with Anticonvulsant Activity for Treatment of Epilepsy&body=Please send me information about technology [TAB-2500] Small Molecule MRS5474 with Anticonvulsant Activity for Treatment of Epilepsy. Tong, Betty<br><a href="mailto:tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-2500] Small Molecule MRS5474 with Anticonvulsant Activity for Treatment of Epilepsy&body=Please send me information about technology [TAB-2500] Small Molecule MRS5474 with Anticonvulsant Activity for Treatment of Epilepsy.">tongb@niddk.nih.gov</a><br> 114166904 E-285-2008-1 E-285-2008-1-US-01 Adenosine Receptor Agonists, Partial Agonists, and Antagonists CIP US 9,181,253 13/479,973 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9181253 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9181253">9,181,253</a><br />Filed on 2012-05-24<br />Status: Issued 114123005 IB1FXX 114123006 NB1EXX 114123007 NB1HXX 114123008 IXXXXX 114123009 IBXXXX 114123010 IB1XXX 114123011 NXXXXX 114123012 NBXXXX 114123013 NB1XXX 114143675 ADENOSINE 114143676 N-Methanocarba 114143677 TRUNCATED 114143678 Derivatives 114143679 A3 114143680 RECEPTOR 114143681 ANTAGONISTS 114143682 Patent Category - Chemistry 114143683 Nucleosides 114143684 Al 114143685 AGONISTS 114143686 PARTIAL 114143687 Agonists: 114143688 Docking 114143689 POTENT 114143690 Anticonvulsant 114143691 Activity TAB-2488 114096685 Antimalarial Inhibitors that Target the Plasmodial Surface Anion Channel (PSAC) Protein and Development of the PSAC Protein as Vaccine Targets NIAID Collaboration, Infectious Disease, Vaccines Collaboration Infectious Disease Vaccines Sanjay Desai There are two related technologies, the first being small molecule inhibitors of the malarial plasmodial surface anion channel (PSAC) and the second being the PSAC protein itself as a vaccine candidate. The PSAC protein is produced by the malaria parasite within host erythrocytes and is crucial for mediating nutrient uptake. In vitro data show that the PSAC inhibitors are able to inhibit growth of malaria parasites, have high specificity, and low toxicity. Portions of the PSAC protein are found on the outer surface of infected host erythrocytes and the protein was recently shown to be encoded by the clag3 gene. This discovery opens the possibility of developing the PSAC protein as a potential vaccine candidate against malaria. <ul> <li>Novel target against malaria</li> <li>Small molecule inhibitors of PSAC inhibit malarial parasite growth, have low toxicity, and high specificity</li> <li>PSAC protein is exposed on the surface of the infected host erythrocytes, making it an attractive vaccine candidate</li> </ul> <ul> <li>Antimalarial drugs</li> <li>Malaria vaccine</li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize Antimalarial Inhibitors that Target the Plasmodial Surface Anion Channel (PSAC) Protein. For collaboration opportunities, please contact Dana Hsu at <a href="mailto:dhsu@niaid.nih.gov">dhsu@niaid.nih.gov</a> or 301-451-3521. 2022-03-08 2024-10-28 2024-10-28 2012-10-22 Anion, ANTIMALARIAL, CHANNEL, DC2XXX, DCXXXX, DXXXXX, Plasmodial, Surface, TARGET, THERAPY False True <ul> <li>Early-stage</li> <li>Pre-clinical</li> <li>In vitro data available</li> </ul> True NIHTT 37470483 Website Abstract E-202-2008-0 114171684 Pillai AD, et al. http://www.ncbi.nlm.nih.gov/pubmed/22949525 <a href="http://www.ncbi.nlm.nih.gov/pubmed/22949525">Pillai AD, et al.</a> 114171685 Desai SA. http://www.ncbi.nlm.nih.gov/pubmed/22432505 <a href="http://www.ncbi.nlm.nih.gov/pubmed/22432505">Desai SA.</a> 114171686 Nguitragool W, et al. http://www.ncbi.nlm.nih.gov/pubmed/21620134 <a href="http://www.ncbi.nlm.nih.gov/pubmed/21620134">Nguitragool W, et al.</a> 114171687 Pillai AD, et al. http://www.ncbi.nlm.nih.gov/pubmed/20101003 <a href="http://www.ncbi.nlm.nih.gov/pubmed/20101003">Pillai AD, et al.</a> 114107673 Desai, Sanjay NIAID - DIR NIAID Desai, Sanjay (NIAID) 1 114107673 Desai, Sanjay NIAID - DIR NIAID Desai, Sanjay (NIAID) 1 114101795 The Plasmodial Surface Anion Channel As A Target For Antimalarial Therapy E-145-2011-0 Filing authorized NIAID 83724572 Tung, Peter peter.tung@nih.gov
United States of America DIR peter.tung@nih.gov?subject=Web Inquiry on [TAB-2488] Antimalarial Inhibitors that Target the Plasmodial Surface Anion Channel (PSAC) Protein and Development of the PSAC Protein as Vaccine Targets&body=Please send me information about technology [TAB-2488] Antimalarial Inhibitors that Target the Plasmodial Surface Anion Channel (PSAC) Protein and Development of the PSAC Protein as Vaccine Targets. Tung, Peter<br><a href="mailto:peter.tung@nih.gov?subject=Web Inquiry on [TAB-2488] Antimalarial Inhibitors that Target the Plasmodial Surface Anion Channel (PSAC) Protein and Development of the PSAC Protein as Vaccine Targets&body=Please send me information about technology [TAB-2488] Antimalarial Inhibitors that Target the Plasmodial Surface Anion Channel (PSAC) Protein and Development of the PSAC Protein as Vaccine Targets.">peter.tung@nih.gov</a><br> 114160857 E-145-2011-0 E-145-2011-0-US-09 Plasmodial Surface Anion Channel Inhibitors For The Treatment Or Prevention Of Malaria DIV US 9,808,458 15/072,902 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9808458 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9808458">9,808,458</a><br />Filed on 2016-03-17<br />Status: Issued 114164807 E-145-2011-0 E-145-2011-0-US-01 Plasmodial Surface Anion Channel Inhibitors For The Treatment of Malaria PRV US 61/474,583 Abandoned US <br />Provisional (PRV) 61/474,583<br />Filed on 2011-04-12<br />Status: Abandoned 114166883 E-145-2011-0 E-145-2011-0-PCT-02 Plasmodial Surface Anion Channel Inhibitors For The Treatment Of Prevention Of Malaria PCT Patent Cooperation Treaty PCT/US2012/033072 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2012/033072<br />Filed on 2012-04-11<br />Status: Expired 114167315 E-145-2011-0 E-145-2011-0-US-08 Plasmodial Surface Anion Channel Inhibitors for the Treatment or Prevention of Malaria National Stage US 9,320,786 14/111,256 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9320786 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9320786">9,320,786</a><br />Filed on 2013-11-07<br />Status: Issued 114168378 E-145-2011-0 E-145-2011-0-US-12 PLASMODIAL SURFACE ANION CHANNEL INHIBITORS FOR THE TREATMENT OR PREVENTION OF MALARIA DIV US 10,265,313 15/723,677 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10265313 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10265313">10,265,313</a><br />Filed on 2017-10-03<br />Status: Issued 114168852 E-145-2011-0 E-145-2011-0-US-14 PLASMODIAL SURFACE ANION CHANNEL INHIBITORS FOR THE TREATMENT OR PREVENTION OF MALARIA DIV US 10,869,865 16/292,722 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10869865 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10869865">10,869,865</a><br />Filed on 2019-03-05<br />Status: Issued 114169074 E-145-2011-0 E-145-2011-0-US-17 PLASMODIAL SURFACE ANION CHANNEL INHIBITORS FOR THE TREATMENT OR PREVENTION OF MALARIA DIV US 12,059,418 17/115,317 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12059418 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12059418">12,059,418</a><br />Filed on 2020-12-08<br />Status: Issued 114122962 DC2XXX 114122963 DXXXXX 114122964 DCXXXX 114143550 THERAPY 114143551 ANTIMALARIAL 114143552 TARGET 114143553 CHANNEL 114143554 Anion 114143555 Surface 114143556 Plasmodial TAB-2493 114096689 Glucocerebrosidase Non-inhibitory Chaperones for the Treatment of Gaucher Disease, Parkinson's Disease, and Other Proteinopathies NCATS Collaboration, Licensing, Neurology, Rare/Neglected Diseases, Therapeutics Collaboration Licensing Neurology Rare/Neglected Diseases Therapeutics Ehud Goldin, Juan Marugan, Samarjit Patnaik, Steven Rogers, Frank Schoenen, Ellen Sidransky, Noel Southall, Wendy Westbroek, Wei Zheng Gaucher disease is a rare lysosomal storage disease that is characterized by a loss of function of the glucocerebrosidase (GCase) enzyme, which results in a decreased ability to degrade its lipid substrate, glucocerebroside. The intracellular build up of this lipid causes a broad range of clinical manifestations, ranging from enlarged spleen/liver and anemia to neurodegeneration. In Gaucher disease, the loss of GCase function has been attributed to low levels of the protein in the lysosomal compartment, resulting from improper GCase folding and transport. Also, mutations in the GCase gene have been linked to some forms of Parkinson's disease, and may also be involved in other proteinopathies.<br /><br /> This technology describes a collection of salicylic acid-derived small molecules that act as chaperones to activate proper GCase folding and subsequent transport from the endoplasmic reticulum into the lysosome. Unlike many other small molecule chaperones, these salicylic acid derivatives do not inhibit the activity of the GCase enzyme. These small molecules have been tested for the ability to activate GCase <em>in vitro</em> and show chaperone activity in a patient-derived fibroblast translocation assay. <ul> <li>The compounds are novel small molecules that enhance proper GCase folding and transport without inhibiting enzyme activity in the lysosome.</li> </ul> <ul> <li>Treatment of Gaucher disease</li> <li>Treatment of Parkinson’s disease</li> <li>Treatment of other lysosomal storage diseases</li> </ul> The National Center for Advancing Translational Sciences is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize this technology. For collaboration opportunities, please contact Dr. Juan Marugan at <a href="mailto:maruganj@mail.nih.gov">maruganj@mail.nih.gov</a>. A Collaborative Research/Licensing Opportunity Notice related to this technology was published in the Federal Register on Wednesday, February 6, 2013 (78 FR 8546); this notice may be viewed at <a href="https://www.gpo.gov/fdsys/pkg/FR-2013-02-06/pdf/2013-02609.pdf" target="_blank" title="Link to published notice">https://www.gpo.gov/fdsys/pkg/FR-2013-02-06/pdf/2013-02609.pdf</a>. 2022-03-08 2024-10-28 2024-10-28 2012-11-06 CHAPERONES, Gaucher Disease, GLUCOCEREBROSIDASE, IBXXXX, NB1BXX, NBXXXX, NON-INHIBITORY, Parkinson's Disease, proteinopathy, UAXXXX, VEXXXX, WKXXXX, YAXXXX, YBXXXX False True <ul> <li>Early-stage</li> <li>In vitro data available</li> </ul> True 52406768 Discovery 52406768 NIHTT 37470483 Website Abstract 114107684 Zheng, Wei NCATS - TRND NCATS Zheng, Wei (NCATS) 0 114107685 Patnaik, Samarjit NCATS - NCGC NCATS Patnaik, Samarjit (NCATS) 0 114107686 Southall, Noel NCATS - TRND NCATS Southall, Noel (NCATS) 0 114107687 Sidransky, Ellen National Human Genome Research Institute (NHGRI) NHGRI Sidransky, Ellen (NHGRI) 0 114107688 Goldin, Ehud National Human Genome Research Institute (NHGRI) NHGRI Goldin, Ehud (NHGRI) 0 114107689 Westbroek, Wendy National Human Genome Research Institute (NHGRI) Westbroek, Wendy 0 114107888 Rogers, Steven University of Kansas Rogers, Steven 0 114107889 Schoenen, Frank University of Kansas Schoenen, Frank 0 114107683 Marugan, Juan NCATS - NCGC NCATS Marugan, Juan (NCATS) 1 114107683 Marugan, Juan NCATS - NCGC NCATS Marugan, Juan (NCATS) 1 114107684 Zheng, Wei NCATS - TRND NCATS Zheng, Wei (NCATS) 0 114107685 Patnaik, Samarjit NCATS - NCGC NCATS Patnaik, Samarjit (NCATS) 0 114107686 Southall, Noel NCATS - TRND NCATS Southall, Noel (NCATS) 0 114107687 Sidransky, Ellen National Human Genome Research Institute (NHGRI) NHGRI Sidransky, Ellen (NHGRI) 0 114107688 Goldin, Ehud National Human Genome Research Institute (NHGRI) NHGRI Goldin, Ehud (NHGRI) 0 114107689 Westbroek, Wendy National Human Genome Research Institute (NHGRI) Westbroek, Wendy 0 114107888 Rogers, Steven University of Kansas Rogers, Steven 0 114107889 Schoenen, Frank University of Kansas Schoenen, Frank 0 114101801 Non-inhibitory Chaperones Of Glucocerebrosidase E-144-2012-0 Filing authorized National Human Genome Research Institute (NHGRI), NCATS - NCGC, University of Kansas 114101802 Non-inhibitory Chaperones Of Glucocerebrosidase E-144-2012-1 Filing authorized National Human Genome Research Institute (NHGRI), NCATS - NCGC, University of Kansas 114102129 Non-inhibitory Chaperones Of Glucocerebrosidase E-144-2012-2 Filing authorized National Human Genome Research Institute (NHGRI), NCATS - NCGC, University of Kansas 83682485 Vepa, Suryanarayana sury.vepa@nih.gov
United States of America Office of Strategic Alliances (OSA) sury.vepa@nih.gov?subject=Web Inquiry on [TAB-2493] Glucocerebrosidase Non-inhibitory Chaperones for the Treatment of Gaucher Disease, Parkinson's Disease, and Other Proteinopathies&body=Please send me information about technology [TAB-2493] Glucocerebrosidase Non-inhibitory Chaperones for the Treatment of Gaucher Disease, Parkinson's Disease, and Other Proteinopathies. Vepa, Suryanarayana<br><a href="mailto:sury.vepa@nih.gov?subject=Web Inquiry on [TAB-2493] Glucocerebrosidase Non-inhibitory Chaperones for the Treatment of Gaucher Disease, Parkinson's Disease, and Other Proteinopathies&body=Please send me information about technology [TAB-2493] Glucocerebrosidase Non-inhibitory Chaperones for the Treatment of Gaucher Disease, Parkinson's Disease, and Other Proteinopathies.">sury.vepa@nih.gov</a><br> 114166891 E-144-2012-0 E-144-2012-0-US-01 Salicylic Acid Derivatives Useful As Glucocerebrosidase Activators PRV US 61/616,758 Abandoned US <br />Provisional (PRV) 61/616,758<br />Filed on 2012-03-28<br />Status: Abandoned 114166892 E-144-2012-1 E-144-2012-1-US-01 Salicylic Acid Derivatives And Additional Compounds Useful As Glucocerebrosidase Activators PRV US 61/616,773 Abandoned US <br />Provisional (PRV) 61/616,773<br />Filed on 2012-03-28<br />Status: Abandoned 114167739 E-144-2012-2 E-144-2012-2-PCT-01 SALICYLIC ACID DERIVATIVES USEFUL AS GLUCOCEREBROSIDASE ACTIVATORS PCT COMB Patent Cooperation Treaty PCT/US13/32253 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US13/32253<br />Filed on 2013-03-15<br />Status: Expired 114167971 E-144-2012-2 E-144-2012-2-US-06 SALICYLIC ACID DERIVATIVES USEFUL AS GLUCOCEREBROSIDASE ACTIVATORS National Stage US 9,464,035 14/388,494 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9464035 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9464035">9,464,035</a><br />Filed on 2014-09-26<br />Status: Issued 114122975 NBXXXX 114122976 IBXXXX 114122977 NB1BXX 114122978 UAXXXX 114123283 VEXXXX 114125884 WKXXXX 114125885 YAXXXX 114125886 YBXXXX 114143614 NON-INHIBITORY 114143615 CHAPERONES 114143616 GLUCOCEREBROSIDASE 114143617 Gaucher Disease 114143618 Parkinson's Disease 114143619 proteinopathy TAB-2485 114096681 Zuma Mutant Mice as a Tool for Investigating Mammalian Developmental Defects NHGRI Collaboration, Research Materials Collaboration Research Materials William ("Bill") Pavan, Dawn Watkins-Chow <p>In vertebrates, mutations in different ribosomal protein subunits result in a variety of phenotypes, suggesting unique and perhaps extra-ribosomal functions for these proteins. Diamond-Blackfan Anemia (DBA) is a ribosomal protein disease, in which the bone marrow fails to produce red blood cells.</p> <p>NHGRI investigators recently generated a mouse line with a mutation in small ribosomal protein7 (Rps7), known to be involved in DBA. This line named Zuma (made with the use of the mutagen N-ethyl-N-nitrosourea (ENU)) carries a point mutation in exon 7 of Rps7, which is predicted to cause a substitution of a conserved amino acid (pY177S). The mutation results in the disruption of ribosomal biogenesis, as well as in abnormal skeletal, melanocyte, and central nervous system development. Thus, the Zuma line can be used as a model of DBA, as well as a tool for investigating other defects of mammalian development.</p> Not available elsewhere <ul> <li>Animal model of Diamond-Blackfan Anemia (DBA)</li> <li>Research tool to study other mammalian developmental defects</li> </ul> The Mouse Embryology Section of the National Human Genome Research Institute is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize Diamond-Blackfan Anemia therapies. For collaboration opportunities, please contact Claire T. Driscoll, Director, NHGRI Technology Transfer Office, at <a href="mailto:cdriscoll@mail.nih.gov">cdriscoll@mail.nih.gov</a> or 301-594-2235. Research Tool — Patent protection is not being pursued for this technology. 2022-03-08 2024-10-28 2024-10-28 2012-10-22 57, anemia, CAUSING, DEFECTS, Development, Diamond-Biackfan, INVESTIGATING, MAMMALIAN, Mouse, MUTANT, Protein, Ribosomal, RPS7, RXXXXX, Small, Such, THOSE, Tool False True <ul> <li>Prototype</li> <li>Pre-clinical</li> <li>In vitro data available</li> </ul> True NIHTT 37470483 Website Abstract 114171674 Manuscript submitted Manuscript submitted 114107668 Watkins-Chow, Dawn National Human Genome Research Institute (NHGRI) NICHD Watkins-Chow, Dawn (NICHD) 0 114107667 Pavan, William ("Bill") National Human Genome Research Institute (NHGRI) NHGRI Pavan, William ("Bill") (NHGRI) 1 114107667 Pavan, William ("Bill") National Human Genome Research Institute (NHGRI) NHGRI Pavan, William ("Bill") (NHGRI) 1 114107668 Watkins-Chow, Dawn National Human Genome Research Institute (NHGRI) NICHD Watkins-Chow, Dawn (NICHD) 0 114101792 Small Ribosomal Protein 57 (RPS7) Mouse Mutant As A Tool For Investigating Defects Of Mammalian Development, Such As Those Causing Diamond-Biackfan Anemia E-294-2012-0 Research Material National Human Genome Research Institute (NHGRI) 83716782 Campbell, Eggerton eggerton.campbell@nih.gov
United States of America eggerton.campbell@nih.gov?subject=Web Inquiry on [TAB-2485] Zuma Mutant Mice as a Tool for Investigating Mammalian Developmental Defects&body=Please send me information about technology [TAB-2485] Zuma Mutant Mice as a Tool for Investigating Mammalian Developmental Defects. Campbell, Eggerton<br><a href="mailto:eggerton.campbell@nih.gov?subject=Web Inquiry on [TAB-2485] Zuma Mutant Mice as a Tool for Investigating Mammalian Developmental Defects&body=Please send me information about technology [TAB-2485] Zuma Mutant Mice as a Tool for Investigating Mammalian Developmental Defects.">eggerton.campbell@nih.gov</a><br> 114122953 RXXXXX 114143513 Small 114143514 Ribosomal 114143515 Protein 114143516 57 114143517 RPS7 114143518 Mouse 114143519 MUTANT 114143520 Tool 114143521 INVESTIGATING 114143522 DEFECTS 114143523 MAMMALIAN 114143524 Development 114143525 Such 114143526 THOSE 114143527 CAUSING 114143528 Diamond-Biackfan 114143529 anemia TAB-2481 114096680 A Method to Expand a Population of Regulatory T Cells Optimal for the Treatment of Autoimmune Diseases NIAID Diagnostics, Licensing, Research Materials, Therapeutics Diagnostics Licensing Research Materials Therapeutics Yong Chan Kim, Ethan Shevach The transfusion of regulatory T cells (Tregs) has been used in the clinic to successfully prevent graft vs. host disease and is currently being evaluated in the treatment of other autoimmune diseases, such as organ graft rejection, type 1 diabetes and multiple sclerosis. Prior to transfusion, adoptive regulatory T cell transfer requires the expansion of regulatory T cells in culture; this results in a mixed population of regulatory T cells that limits the effectiveness of the transferred cells.<br /><br /> Scientists at the NIH have developed a method that promotes the expansion of regulatory T cells that are longer lived, more stable, and more suppressive of the autoimmune response. By supplementing T cell cultures with DNA oligonucleotides, the inventors were able to enrich the regulatory T cell population that enhanced the suppression of the autoimmune response. This method has the potential to more effectively generate regulatory T cells for the treatment of autoimmune diseases. <ul> <li>More effective therapy when compared to traditional T cell expansion methods.</li> <li>Expansion method is inexpensive and similar to current methods.</li> </ul> <ul> <li>Treatment of autoimmune diseases, such as Graft vs. Host Disease, Organ Graft Rejection Type 1 Diabetes, Multiple Sclerosis.</li> </ul> 2022-03-08 2024-10-28 2024-10-28 2012-09-28 Cells, FOXP3+, Helios-expressing, Human, IBXXXX, IDXXXX, IXXXXX, oligonucleotides, Random-sequenced, Regulatory, Stabilization, T, Usingrandom-sequenced False True In vitro data available True NIHTT 37470483 Website Abstract 114171668 Kim Y, et al. http://www.ncbi.nlm.nih.gov/pubmed/22294730 <a href="http://www.ncbi.nlm.nih.gov/pubmed/22294730">Kim Y, et al.</a> 114107664 Shevach, Ethan NIAID - DIR NIAID Shevach, Ethan (NIAID) 0 114107663 Kim, Yong Chan NIAID - DIR NINDS Kim, Yong Chan (NINDS) 1 114107663 Kim, Yong Chan NIAID - DIR NINDS Kim, Yong Chan (NINDS) 1 114107664 Shevach, Ethan NIAID - DIR NIAID Shevach, Ethan (NIAID) 0 114101788 Stabilization Of Helios-expressing Foxp3+ Human Regulatory T Cells Using Random-sequenced Oligonucleotides E-279-2011-0 Filing authorized NIAID 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2481] A Method to Expand a Population of Regulatory T Cells Optimal for the Treatment of Autoimmune Diseases&body=Please send me information about technology [TAB-2481] A Method to Expand a Population of Regulatory T Cells Optimal for the Treatment of Autoimmune Diseases. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2481] A Method to Expand a Population of Regulatory T Cells Optimal for the Treatment of Autoimmune Diseases&body=Please send me information about technology [TAB-2481] A Method to Expand a Population of Regulatory T Cells Optimal for the Treatment of Autoimmune Diseases.">yogikala.prabhu@nih.gov</a><br> 114166754 E-279-2011-0 E-279-2011-0-US-03 METHODS OF PRODUCING T CELL POPULATIONS ENRICHED FOR STABLE REGULATORY T-CELLS DIV US 11,060,059 15/284,840 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11060059 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11060059">11,060,059</a><br />Filed on 2016-10-04<br />Status: Issued 114166864 E-279-2011-0 E-279-2011-0-US-01 Methods of Producing T Cell Populations Enriched for Stable Regulatory T Cells PRV US 61/576,837 Abandoned US <br />Provisional (PRV) 61/576,837<br />Filed on 2011-12-16<br />Status: Abandoned 114166929 E-279-2011-0 E-279-2011-0-US-02 Methods of Producing T Cell Populations Enriched for Stable Regulatory T-Cells ORD US 9,481,866 13/716,900 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9481866 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9481866">9,481,866</a><br />Filed on 2012-12-17<br />Status: Issued 114169141 E-279-2011-0 E-279-2011-0-US-04 METHODS OF PRODUCING T CELL POPULATIONS ENRICHED FOR STABLE REGULATORY T-CELLS DIV US 12,195,724 17/371,589 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12195724 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12195724">12,195,724</a><br />Filed on 2021-07-09<br />Status: Issued 114116962 IXXXXX 114116966 IDXXXX 114117268 IBXXXX 114143484 Stabilization 114143485 Helios-expressing 114143486 FOXP3+ 114143487 Human 114143488 Regulatory 114143489 T 114143490 Cells 114143491 Usingrandom-sequenced 114143492 oligonucleotides 114143493 Random-sequenced TAB-2467 114096667 Polyclonal Antibodies for the Specialized Signaling G protein, Gbeta5 NIDDK Licensing Licensing William Simonds, Jianhua Zhang Researchers at NIDDK have developed polyclonal antibodies against the G protein, Gbeta5. Gbeta5 is a unique and highly specialized G protein that exhibits much less homology than other Gbeta isoforms (~50%) and is preferentially expressed in brain and neuroendocrine tissue. It is expressed prominently in the neuronal cell membrane, as well as in the cytosol and nucleus. Although this distribution pattern suggests that Gbeta5 may shuttle information between classical G protein-signaling elements at the plasma membrane and the cell interior, its function in the brain is largely unknown. <br /><br /> The antibodies were separately generated in rabbits to KLH-conjugates of peptides from the N-terminus of Gbeta5 (antibody ATDG) and the C-terminus of Gbeta5 (antibody SGS). The antibodies can be used for immunoblotting (ATDG, SGS), and immunoprecipitation (ATDG). They can be used to facilitate our understanding of the unique biology and function of Gbeta5 in brain and neurons. Very specific antibodies to study Gbeta5 and G protein signaling. These antibodies can be used for research purposes (immunoblotting, immunoprecipitation) by those studying the biology and function of Gbeta5. Research Tool — Patent protection is not being pursued for this technology. 2022-03-08 2024-10-28 2024-10-28 2012-07-27 AC5XXX, ACXXXX, antibodies, AXXXXX, Gbeta5, Neuron-Specific, Protein, Specified False True In vitro data available True NIHTT 37470483 Website Abstract 114171634 Zhang JH and Simonds WF. http://www.ncbi.nlm.nih.gov/pubmed/10648734 <a href="http://www.ncbi.nlm.nih.gov/pubmed/10648734">Zhang JH and Simonds WF.</a> 114171635 Zhang JH, et al. http://www.ncbi.nlm.nih.gov/pubmed/11152459 <a href="http://www.ncbi.nlm.nih.gov/pubmed/11152459">Zhang JH, et al.</a> 114171636 Zhang S, et al. http://www.ncbi.nlm.nih.gov/pubmed/8969224 <a href="http://www.ncbi.nlm.nih.gov/pubmed/8969224">Zhang S, et al.</a> 114171637 Zachariou V, et al. http://www.ncbi.nlm.nih.gov/pubmed/16415864 <a href="http://www.ncbi.nlm.nih.gov/pubmed/16415864">Zachariou V, et al.</a> 114107630 Zhang, Jianhua National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Zhang, Jianhua (NIDDK) 0 114107631 Simonds, William National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Simonds, William (NIDDK) 1 114107631 Simonds, William National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Simonds, William (NIDDK) 1 114107630 Zhang, Jianhua National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Zhang, Jianhua (NIDDK) 0 114101772 Antibodies To The Specified Neuron-specific G Protein, Gbeta5 E-192-2006-0 Research Material National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83692066 Tong, Betty tongb@niddk.nih.gov
United States of America Senior Technology Advancement Office tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-2467] Polyclonal Antibodies for the Specialized Signaling G protein, Gbeta5&body=Please send me information about technology [TAB-2467] Polyclonal Antibodies for the Specialized Signaling G protein, Gbeta5. Tong, Betty<br><a href="mailto:tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-2467] Polyclonal Antibodies for the Specialized Signaling G protein, Gbeta5&body=Please send me information about technology [TAB-2467] Polyclonal Antibodies for the Specialized Signaling G protein, Gbeta5.">tongb@niddk.nih.gov</a><br> 114122931 ACXXXX 114122932 AXXXXX 114122933 AC5XXX 114143375 antibodies 114143376 Specified 114143377 Neuron-Specific 114143378 Protein 114143379 Gbeta5 TAB-2459 114096660 Antagonists of Hyaluronan Signaling for Treatment of Airway Diseases NIEHS Cardiology, Collaboration, Dental, Diagnostics, Endocrinology, Infectious Disease, Oncology, Ophthalmology, Pulmonology, Research Materials, Therapeutics Cardiology Collaboration Dental Diagnostics Endocrinology Infectious Disease Oncology Ophthalmology Pulmonology Research Materials Therapeutics Stavros Garantziotis, John Hollingsworth, Jian Liu, Bryan Toole Airway diseases, such as Asthma and Chronic Obstructive Pulmonary Disease (COPD), constitute a major health burden worldwide. It is estimated, for example, that nearly 15.0% of the adult population in the US are affected with such diseases, and the economic cost burden is over $23 billion annually. Unfortunately, the current options for treatment of such diseases are quite limited, consisting only of bronchodilators and inhaled steroids. The need for a novel and more effective class of therapeutics agents is imperative. The subject invention provides for a potentially more specific and effective treatment of airway diseases as compared with existing treatments. It is based on the inhibition of Hyaluronan (HA), a structural polysaccharide that plays a role in the signaling pathway that leads to the onset of airway diseases. Such inhibition blocks the development of airway inflammation and airway hyperresponsiveness (AHR), two of the components associated with airway diseases, and thus may be useful in the treatment of such diseases. The invention discloses two antagonists of HA, i.e. heparosan, and Hyaluronan oligosaccharides (oHAs). Their administration to a human subject in need can be accomplished via the use of an inhaler or nebulizer. <ul> <li>Potentially cost-effective treatment for airway diseases, with higher specificity and reduced side effect as compared to existing treatments</li> </ul> <ul> <li>Effective treatment of airway diseases</li> </ul> The NIEHS is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize the use of hyaluronan antagonists to treat chronic respiratory diseases. For collaboration opportunities, please contact Sharon Soucek, Ph.D. at <a href="mailto:sharon.soucek@nih.gov">sharon.soucek@nih.gov</a>. European Patent No. 2827877 issued 05/08/2019 and validated in Germany, France, and the United Kingdom<br /><br /> Canadian Patent Application No. 2872569 filed 03/08/2013 2022-03-08 2024-10-28 2024-10-28 2012-07-03 AIRWAY, ANTAGONISTS, hyaluronan, Hyperresponsiveness, IB4XXX, IBXXXX, Inflammation, IXXXXX, SIGNALING, treatment, VPXXXX, WKXXXX, YBXXXX, YCXXXX False True In vitro data available True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114107609 Hollingsworth, John Duke University Medical Center Hollingsworth, John 0 114107610 Toole, Bryan Medical University of South Carolina Toole, Bryan 0 114107611 Liu, Jian University of North Carolina, Chapel Hill Liu, Jian 0 114107608 Garantziotis, Stavros NIEHS NIEHS Garantziotis, Stavros (NIEHS) 1 114107608 Garantziotis, Stavros NIEHS NIEHS Garantziotis, Stavros (NIEHS) 1 114107609 Hollingsworth, John Duke University Medical Center Hollingsworth, John 0 114107610 Toole, Bryan Medical University of South Carolina Toole, Bryan 0 114107611 Liu, Jian University of North Carolina, Chapel Hill Liu, Jian 0 114101763 Use Of Antagonists Of Hyaluronan Signaling For Treatment Of Airway Inflammation And Hyperresponsiveness E-080-2012-0 Filing authorized Duke University Medical Center, Medical University of South Carolina, NIEHS, University of North Carolina, Chapel Hill 83739538 Choudhry, Vidita vidita.choudhry@nih.gov
United States of America Office of Technology Transfer and Development vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-2459] Antagonists of Hyaluronan Signaling for Treatment of Airway Diseases&body=Please send me information about technology [TAB-2459] Antagonists of Hyaluronan Signaling for Treatment of Airway Diseases. Choudhry, Vidita<br><a href="mailto:vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-2459] Antagonists of Hyaluronan Signaling for Treatment of Airway Diseases&body=Please send me information about technology [TAB-2459] Antagonists of Hyaluronan Signaling for Treatment of Airway Diseases.">vidita.choudhry@nih.gov</a><br> 114166806 E-080-2012-0 E-080-2012-0-US-01 Use Of Antagonists Of Hyaluronan Signaling For Treatment Of Airway Inflammation And Hyperresponsiveness PRV US 61/647,101 Abandoned US <br />Provisional (PRV) 61/647,101<br />Filed on 2012-05-15<br />Status: Abandoned 114167021 E-080-2012-0 E-080-2012-0-PCT-02 USES OF ANTAGONISTS OF HYALURONAN SIGNALING PCT Patent Cooperation Treaty PCT/US2013/029776 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2013/029776<br />Filed on 2013-03-08<br />Status: Expired 114167989 E-080-2012-0 E-080-2012-0-US-05 USES OF ANTAGONISTS OF HYALURONAN SIGNALING National Stage US 9,717,752 14/398,837 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9717752 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9717752">9,717,752</a><br />Filed on 2014-11-04<br />Status: Issued 114122900 IXXXXX 114122901 IB4XXX 114122902 IBXXXX 114127371 VPXXXX 114127372 WKXXXX 114127373 YBXXXX 114127374 YCXXXX 114143298 Hyperresponsiveness 114143299 Inflammation 114143300 AIRWAY 114143301 treatment 114143302 SIGNALING 114143303 hyaluronan 114143304 ANTAGONISTS TAB-2452 114096652 Mouse Model of STAT5 for the Drug Screen and the Research of Cancer and Autoimmunity NHLBI Infectious Disease, Licensing, Research Materials Infectious Disease Licensing Research Materials Warren Leonard, Jian-xin Lin The invention is a STAT5 mutant mouse that can be used in research related to cancer, autoimmunity and infectious diseases as well as drug screening. The mouse model itself has multiple immunological defects resulting in formation of STAT5 dimers but not tetramers. <br /><br /> It reports that only a minority of IL-2-modulated genes is regulated by STAT5 tetramers. Therefore, selectively targeting tetramer formation might be a relatively specific therapeutic tool wherein one could modulate only part of the actions of a cytokine or growth factor, which allows a new therapeutic approach to modulating immune responses, controlling inflammation, and inhibiting tumor growth. <br /><br /> The STAT5 tetramer deficient mouse is an ideal tool to screen for tetramerization inhibitors that can be used for the treatment of cancer, autoimmunity and inflammation in addition to the basic research applications. <ul> <li>The tetramer-deficient mice of this invention are viable while mice completely lacking expression of Stat5a and Stat5b exhibit perinatal lethality.</li> <li>A model for basic research, to study the cancer, autoimmunity, and infectious diseases associated with STAT5 signaling.</li> </ul> <ul> <li>To design and screen tetramerization inhibitors that are potential new drugs for cancer, autoimmunity and transplantation.</li> <li>To identify and study a key subset of STAT5A and/or STAT5B-dependent genes without affecting viability is extremely </li> <li>To seek a new therapeutic approach to modulating immune responses, controlling inflammation, and inhibiting tumor growth.</li> </ul> Research Tool — Patent protection is not being pursued for this technology. 2022-03-08 2024-10-28 2024-10-28 2012-06-13 BINDING, CONSENSUS, Critical, DDXXXX, DXXXXX, FUNCTION, Identification, IMMUNE, motifs, Roles, STAT5, Tetramer, Tetramerization False True True NIHTT 37470483 Website Abstract 114171614 Lin JX, et al. http://www.ncbi.nlm.nih.gov/pubmed/22520852 <a href="http://www.ncbi.nlm.nih.gov/pubmed/22520852">Lin JX, et al.</a> 114107590 Lin, Jian-xin National Heart, Lung, and Blood Institute (NHLBI) NHLBI Lin, Jian-xin (NHLBI) 0 114107589 Leonard, Warren National Heart, Lung, and Blood Institute (NHLBI) NHLBI Leonard, Warren (NHLBI) 1 114107589 Leonard, Warren National Heart, Lung, and Blood Institute (NHLBI) NHLBI Leonard, Warren (NHLBI) 1 114107590 Lin, Jian-xin National Heart, Lung, and Blood Institute (NHLBI) NHLBI Lin, Jian-xin (NHLBI) 0 114101756 Identification Of Critical Roles Of STAT5 Tetramerization In Immune Function And Identification Of STAT5 Tetramer Binding Consensus Motifs E-080-2011-0 Research Material National Heart, Lung, and Blood Institute (NHLBI) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-2452] Mouse Model of STAT5 for the Drug Screen and the Research of Cancer and Autoimmunity&body=Please send me information about technology [TAB-2452] Mouse Model of STAT5 for the Drug Screen and the Research of Cancer and Autoimmunity. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-2452] Mouse Model of STAT5 for the Drug Screen and the Research of Cancer and Autoimmunity&body=Please send me information about technology [TAB-2452] Mouse Model of STAT5 for the Drug Screen and the Research of Cancer and Autoimmunity.">shmilovm@nih.gov</a><br> 114122868 DXXXXX 114122869 DDXXXX 114143226 Identification 114143227 Critical 114143228 Roles 114143229 STAT5 114143230 Tetramerization 114143231 IMMUNE 114143232 FUNCTION 114143233 Tetramer 114143234 BINDING 114143235 CONSENSUS 114143236 motifs TAB-2442 114096643 Rabbit Polyclonal Antibody to Detect a Pro-peptide Fragment of NSAID-activated Gene (NAG-1)/GDF15, a Protein Associated with Cancer NIEHS Collaboration, Oncology, Research Materials Collaboration Oncology Research Materials Thomas Eling Chronic inflammation is clearly associated with an increase in the risk of cancer. Non-steroidal anti-inflammatory drugs (NSAIDs) are well documented as agents that inhibit tumor growth and with long-term use can prevent tumor development. NSAID-activated gene (NAG-1), a unique member of the TGF-beta superfamily, is highly induced by NSAIDs and numerous drugs and chemicals with anti-tumorigenic activities.<br /><br /> The protein product of NAG-1 is first formed into an immature peptide dimer that must be cut at a specific site before it can be secreted as a mature protein. Currently available antibodies can only detect either the immature form of NAG-1 or the secreted mature protein, but do not recognize the peptide fragment that remains when the immature dimer is cut to form the mature protein. Now available for the first time, the present new antibody recognizes this NAG-1 pro-peptide fragment. <ul> </li>No other antibody is currently available to detect the NAG-1/GDF15 pro-peptide fragment.</li> </ul> <ul> </li>As a research tool to detect expression of the NAG-1/GDF15 cleavage fragment in cells and media from cultured cells.</li> </ul> The NIEHS is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize this antibody. For collaboration opportunities, please contact Sally E. Tilotta, Ph.D. at <a href="mailto:sally.tilotta@nih.gov">sally.tilotta@nih.gov</a>. Research Tool — Patent protection is not being pursued for this technology. Research Tool — Transgenic mice expressing human GDF15/Nag-1/Mic-1 2022-03-08 2024-10-28 2024-10-28 2012-05-24 ANTIBODY, CC3AXX, CC3XXX, CCXXXX, CXXXXX, Detection, NAG-1/Gdf15, polyclonal, Pro-peptide, rabbit False True In vitro data available True NIHTT 37470483 Website Abstract E-093-2011-0 114107564 Eling, Thomas NIEHS NIEHS Eling, Thomas (NIEHS) 1 114107564 Eling, Thomas NIEHS NIEHS Eling, Thomas (NIEHS) 1 114101746 Rabbit Polyclonal Antibody For Detection Of NAG-1/Gdf15 Pro-peptide E-177-2012-0 Research Material NIEHS 83739538 Choudhry, Vidita vidita.choudhry@nih.gov
United States of America Office of Technology Transfer and Development vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-2442] Rabbit Polyclonal Antibody to Detect a Pro-peptide Fragment of NSAID-activated Gene (NAG-1)/GDF15, a Protein Associated with Cancer&body=Please send me information about technology [TAB-2442] Rabbit Polyclonal Antibody to Detect a Pro-peptide Fragment of NSAID-activated Gene (NAG-1)/GDF15, a Protein Associated with Cancer. Choudhry, Vidita<br><a href="mailto:vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-2442] Rabbit Polyclonal Antibody to Detect a Pro-peptide Fragment of NSAID-activated Gene (NAG-1)/GDF15, a Protein Associated with Cancer&body=Please send me information about technology [TAB-2442] Rabbit Polyclonal Antibody to Detect a Pro-peptide Fragment of NSAID-activated Gene (NAG-1)/GDF15, a Protein Associated with Cancer.">vidita.choudhry@nih.gov</a><br> 114122823 CC3AXX 114122824 CXXXXX 114122825 CCXXXX 114122826 CC3XXX 114143132 Pro-peptide 114143133 NAG-1/Gdf15 114143134 Detection 114143135 ANTIBODY 114143136 polyclonal 114143137 rabbit TAB-2450 114096650 Endothelial Cell Line to Study Prevention of Atherosclerosis NHLBI Collaboration, Diagnostics, Research Materials, Therapeutics Collaboration Diagnostics Research Materials Therapeutics Alan Remaley Atherosclerosis underlies most cases of cardiovascular disease (CVD), which is now the major cause of morbidity and mortality in developed countries. An inflammatory reaction is an essential component in the appearance and development of an atherosclerotic lesion. The inflammatory process is associated with the expression of adhesion molecules such as vascular cell adhesion molecule (VCAM) at the surface of endothelial cells. Antiatherogenic lipoprotein, high density lipoprotein (HDL), is known to down regulate the expression of VCAM. Increasing levels of HDL is a promising way to reduce the risk of CVD. <br /><br /> This technology is directed to the generation of a stable endothelial cell line expressing a luciferase reporter construct driven by the VCAM promoter. This reporter system enables an easier measurement of VCAM expression and determination of the effect of HDL on endothelial cell inflammation. This technology can be used to screen for the effect of drugs that modulate HDL metabolism and it is more convenient than doing Western blots. <ul> <li>Easy monitoring of down regulation of VCAM with luciferase</li> <li>More convenient than doing Western blots</li> </ul> <ul> <li>Study of prevention of atherosclerosis</li> <li>Screen serum for the effect of HDL on endothelial cell inflammation</li> <li>Screen for the effect of drugs that modulate HDL metabolism</li> </ul> The Cardiovascular & Pulmonary Branch, NHLBI/NIH, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize endothelial cells to study prevention of atherosclerosis. For collaboration opportunities, please contact Dr. Alan Remaley at <a href="mailto:aremaley1@cc.nih.gov">aremaley1@cc.nih.gov</a>. Research Tool — Patent protection is not being pursued for this technology. 2022-03-08 2024-10-28 2024-10-28 2012-06-13 Cell, Development, Endothelial, IDXXXX, IXXXXX, REPORTER, System False True In vitro data available True NIHTT 37470483 Website Abstract 114171607 D'Souza W, et al. http://www.ncbi.nlm.nih.gov/pubmed/20508181 <a href="http://www.ncbi.nlm.nih.gov/pubmed/20508181">D'Souza W, et al.</a> 114107585 Remaley, Alan Clinical Center (CC) NHLBI Remaley, Alan (NHLBI) 1 114107585 Remaley, Alan Clinical Center (CC) NHLBI Remaley, Alan (NHLBI) 1 114101754 Development Of An Endothelial Cell Reporter System E-149-2012-0 Closed National Heart, Lung, and Blood Institute (NHLBI) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-2450] Endothelial Cell Line to Study Prevention of Atherosclerosis&body=Please send me information about technology [TAB-2450] Endothelial Cell Line to Study Prevention of Atherosclerosis. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-2450] Endothelial Cell Line to Study Prevention of Atherosclerosis&body=Please send me information about technology [TAB-2450] Endothelial Cell Line to Study Prevention of Atherosclerosis.">shmilovm@nih.gov</a><br> 114122854 IDXXXX 114122856 IXXXXX 114143203 Development 114143204 Endothelial 114143205 Cell 114143206 REPORTER 114143207 System TAB-2440 114096641 M3 Muscarinic Receptor Knockout Mice (Chrm3 tm1Jwe) for the Study of Obesity and Other Metabolic Disorders NIDDK Diagnostics, Licensing, Research Materials, Therapeutics Diagnostics Licensing Research Materials Therapeutics Jurgen Wess The five Muscarinic Acetylcholine (ACh) receptors are G-protein coupled receptors (M1R-M5R). M3 muscarinic ACh receptors are present in the central nervous system and the periphery. <br /><br /> M3R knockout mice are viable and fertile, and have no major morphological abnormalities. They have a lean phenotype due to a combination of reduced caloric intake and increased energy expenditure. Because of their lean phenotype, M3R knockout mice have improved glucose tolerance and increased insulin sensitivity. Pharmacological blockade of central M3Rs may be a novel strategy for the treatment of obesity and associated metabolic disorders. <br /><br /> In the airway, vagally-mediated bronchoconstriction responses were abolished in M3R knockout mice in vivo, suggesting that M3R antagonists may be useful in the treatment of chronic obstructive pulmonary disease (COPD) and asthma. Studies with M3R knockout mice also have shown that the M3R is the major muscarinic receptor mediating ACh-induced glandular secretion from exocrine and endocrine glands, including the secretion of insulin from pancreatic beta cells. M3R knockout mice are viable and fertile, and have no major morphological abnormalities. Animal model to study COPD and metabolism. Research Tool — Patent protection is not being pursued for this technology. HHS Reference No. E-346-2004/0 — M1 Muscarinic receptor KO (Chrm1tm1Jwe) Mice <br /> HHS Reference No. E-346-2004/1 — M2 Muscarinic receptor KO (Chrm2 tm1Jwe) Mice 2022-03-08 2024-10-28 2024-10-28 2017-04-17 ACXXXX, AXXXXX, Discovery, DOUBLE, DRUG, Generation, ID1XXX, IDXXXX, IXXXXX, KnockoutKO, M1/M3, M1/M4, M2/M3, M2/M4, Mice:, MUSCARINIC, Novel, RECEPTOR, TOOLS False True Pre-clinical True NIHTT 37470483 Website Abstract E-346-2004-0 E-346-2004-1 114171587 Yamada M, et al. http://www.ncbi.nlm.nih.gov/pubmed/11242080 <a href="http://www.ncbi.nlm.nih.gov/pubmed/11242080">Yamada M, et al.</a> 114107558 Wess, Jurgen National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Wess, Jurgen (NIDDK) 1 114107558 Wess, Jurgen National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Wess, Jurgen (NIDDK) 1 114101743 Generation M1/M3, M2/M3, M2/M4, And M1/M4 Muscarinic Receptor Double Knockout(KO) Mice: Novel Tools For Drug Discovery E-346-2004-2 Research Material National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83739550 Shastri, Mythreyi shastrim@mail.nih.gov
United States of America Technology Advancement Office shastrim@mail.nih.gov?subject=Web Inquiry on [TAB-2440] M3 Muscarinic Receptor Knockout Mice (Chrm3 tm1Jwe) for the Study of Obesity and Other Metabolic Disorders&body=Please send me information about technology [TAB-2440] M3 Muscarinic Receptor Knockout Mice (Chrm3 tm1Jwe) for the Study of Obesity and Other Metabolic Disorders. Shastri, Mythreyi<br><a href="mailto:shastrim@mail.nih.gov?subject=Web Inquiry on [TAB-2440] M3 Muscarinic Receptor Knockout Mice (Chrm3 tm1Jwe) for the Study of Obesity and Other Metabolic Disorders&body=Please send me information about technology [TAB-2440] M3 Muscarinic Receptor Knockout Mice (Chrm3 tm1Jwe) for the Study of Obesity and Other Metabolic Disorders.">shastrim@mail.nih.gov</a><br> 114122808 ACXXXX 114122809 ID1XXX 114122810 AXXXXX 114122811 IXXXXX 114122812 IDXXXX 114143089 Generation 114143090 M1/M3 114143091 M2/M3 114143092 M2/M4 114143093 M1/M4 114143094 MUSCARINIC 114143095 RECEPTOR 114143096 DOUBLE 114143097 KnockoutKO 114143098 Mice: 114143099 Novel 114143100 TOOLS 114143101 DRUG 114143102 Discovery TAB-2437 114096638 Antagonist of A3 Adenosine Receptor Fluorescent Probes for the Study of Diseases that Involve A3 Signaling NIDDK Dermatology, Diagnostics, Immunology, Licensing, Oncology, Research Materials, Therapeutics Dermatology Diagnostics Immunology Licensing Oncology Research Materials Therapeutics Kenneth Jacobson This molecular probe may serve as a companion tool to identify and stratify patient populations based on the prevalence of the target A<sub>3</sub> adenosine receptors.<br /><br /> Small molecule drugs, A<sub>3</sub>AR-selective agonists, are currently in advanced clinical trials for the treatment of hepatocellular carcinoma, autoimmune inflammatory diseases, such as rheumatoid arthritis, psoriasis, and dry eye disease, and other conditions. <ul> <li>Avoids the use of radioisotopes in this part of the R&D process.</li> </ul> <ul> <li>Tools to study prevalence of this receptor on neutrophils, a predictor of response to agonist drugs.</li> </ul> (Note: a separate license may be required for the fluorescent portion of the molecule.) 2022-03-08 2024-10-28 2024-10-28 2012-05-15 A3, ADENOSINE, ANTAGONISTS, BINDING, CA1CXX, CA1XXX, CAXXXX, CXXXXX, fluorescent, IA2XXX, IA3XXX, IAXXXX, IXXXXX, Molecular, Novel, Probes, RECEPTOR False True <ul> <li>Early-stage</li> <li>In vitro data available</li> </ul> True NIHTT 37470483 Website Abstract 114171584 Kozma E, et al. http://www.ncbi.nlm.nih.gov/pubmed/22402302 <a href="http://www.ncbi.nlm.nih.gov/pubmed/22402302">Kozma E, et al.</a> 114107553 Jacobson, Kenneth National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Jacobson, Kenneth (NIDDK) 1 114107553 Jacobson, Kenneth National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Jacobson, Kenneth (NIDDK) 1 114101740 Novel Fluorescent Antagonists As Molecular Probes In A3 Adenosine Receptor Binding E-073-2012-0 Filing authorized National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83692066 Tong, Betty tongb@niddk.nih.gov
United States of America Senior Technology Advancement Office tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-2437] Antagonist of A3 Adenosine Receptor Fluorescent Probes for the Study of Diseases that Involve A3 Signaling&body=Please send me information about technology [TAB-2437] Antagonist of A3 Adenosine Receptor Fluorescent Probes for the Study of Diseases that Involve A3 Signaling. Tong, Betty<br><a href="mailto:tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-2437] Antagonist of A3 Adenosine Receptor Fluorescent Probes for the Study of Diseases that Involve A3 Signaling&body=Please send me information about technology [TAB-2437] Antagonist of A3 Adenosine Receptor Fluorescent Probes for the Study of Diseases that Involve A3 Signaling.">tongb@niddk.nih.gov</a><br> 114166758 E-073-2012-0 E-073-2012-0-US-01 Fluorescent Antagonists Of The A3 Adenosine Receptor PRV US 61/590,596 Abandoned US <br />Provisional (PRV) 61/590,596<br />Filed on 2012-01-25<br />Status: Abandoned 114166985 E-073-2012-0 E-073-2012-0-US-02 Fluorescent Antagonists Of The A3 Adenosine Receptor ORD US 9,227,979 13/748,826 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9227979 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9227979">9,227,979</a><br />Filed on 2013-01-24<br />Status: Abandoned 114122791 CA1CXX 114122792 IA2XXX 114122793 IA3XXX 114122794 CXXXXX 114122795 CAXXXX 114122796 CA1XXX 114122797 IXXXXX 114122798 IAXXXX 114143059 Novel 114143060 fluorescent 114143061 ANTAGONISTS 114143062 Molecular 114143063 Probes 114143064 A3 114143065 ADENOSINE 114143066 RECEPTOR 114143067 BINDING TAB-2439 114096640 GLI-Similar 3(GLIS3) Knock Out (KO) Mice as Models to Screen Therapeutics for Diabetes, Polycystic Kidney Disease, and Hypothyroidism NIEHS Collaboration, Research Materials, Therapeutics Collaboration Research Materials Therapeutics Anton Jetten, Hong Soon Kang, Kristin Lichti-Kaiser GLI-similar (Glis) 1-3 proteins constitute a subfamily of the Krüppel-like zinc finger transcription factors that are closely related to the Gli family. Mutations in human GLIS3 have been implicated in a syndrome characterized by neonatal diabetes and congenital hypothyroidism (NDH) and in some patients accompanied by polycystic kidney disease, glaucoma, and liver fibrosis. To further identify and study the physiological functions of GLIS3, NIEHS investigators generated mice in which GLIS3 is ubiquitously knocked out (GLIS3-KO) or conditionally knocked out in a cell type-specific manner. GLIS3-KO mice develop polycystic kidney disease, hypothyroidism, and neonatal diabetes, as indicated by the development of hyperglycemia and hypoinsulinemia. The pancreatic endocrine cells, particularly insulin-producing pancreatic beta cells, are greatly diminished in these mice. The pancreas-selective knockout mice GLIS3(Pdx1-Cre) develop severe diabetes within 2-3 months, much later than the GLIS3-KO mice. The kidney-selective knockout of GLIS3 (GLIS3(Ksp-Cre) mice lack expression of GLIS3 in the collecting ducts and develop severe polycystic kidney disease within a period of 2-4 months. These mice can be used as models to screen therapeutics for diabetes, polycystic kidney disease, and hypothyroidism. <ul> <li>Provides opportunity to discover upstream signals that regulate GLIS3 activity</li> <li>Can be used in stem cell therapy in diabetes treatment</li> <li>Excellent model to study the role of GLIS3 in neonatal diabetes</li> </ul> <ul> <li>Therapeutic target in the management of diabetes, polycystic kidney disease, and hypothyroidism</li> <li>Models to test therapeutic drugs for diabetes, polycystic kidney disease, and hypothyroidism</li> </ul> The NIEHS is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize GLIS3 Knock Out Mice. For collaboration opportunities, please contact Sharon Soucek, Ph.D. at <a href="mailto:sharon.soucek@nih.gov">sharon.soucek@nih.gov</a>. Research Tool — Patent protection is not being pursued for this technology. HHS Reference No. E-253-2010/0 — An In-Vitro Cell System Useful for Identification of RORgamma Antagonists <br /> HHS Reference No. E-222-2009/0 — RORgamma (RORC) Deficient Mice Which Are Useful for the Study of Lymph Node Organogenesis and Immune Responses 2022-03-08 2024-10-28 2024-10-28 2012-05-15 ACXXXX, AXXXXX, GCXXXX, GLIS3, GXXXXX, Knock, KO, Mice, Mice:, RXXXXX, SELECTIVE, TISSUES, Which False True <ul> <li>Early-stage</li> <li>Pre-clinical</li> <li>In vivo data available (animal)</li> </ul> True NIHTT 37470483 Website Abstract E-253-2010-0 E-222-2009-0 114171585 Kang HS, et al. http://www.ncbi.nlm.nih.gov/pubmed/19805515 <a href="http://www.ncbi.nlm.nih.gov/pubmed/19805515">Kang HS, et al.</a> 114171586 Kang HS, et al. http://www.ncbi.nlm.nih.gov/pubmed/19273592 <a href="http://www.ncbi.nlm.nih.gov/pubmed/19273592">Kang HS, et al.</a> 114107554 Lichti-Kaiser, Kristin NIEHS Lichti-Kaiser, Kristin 0 114107556 Kang, Hong Soon NIEHS NIEHS Kang, Hong Soon (NIEHS) 0 114107557 Jetten, Anton NIEHS NIEHS Jetten, Anton (NIEHS) 1 114107557 Jetten, Anton NIEHS NIEHS Jetten, Anton (NIEHS) 1 114107554 Lichti-Kaiser, Kristin NIEHS Lichti-Kaiser, Kristin 0 114107556 Kang, Hong Soon NIEHS NIEHS Kang, Hong Soon (NIEHS) 0 114101742 GLIS3 Knock Out (KO) Mice: GLIS3 KO Mice And Mice In Which GLIS3 Is KO In Selective Tissues E-303-2011-0 Research Material NIEHS 83739538 Choudhry, Vidita vidita.choudhry@nih.gov
United States of America Office of Technology Transfer and Development vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-2439] GLI-Similar 3(GLIS3) Knock Out (KO) Mice as Models to Screen Therapeutics for Diabetes, Polycystic Kidney Disease, and Hypothyroidism&body=Please send me information about technology [TAB-2439] GLI-Similar 3(GLIS3) Knock Out (KO) Mice as Models to Screen Therapeutics for Diabetes, Polycystic Kidney Disease, and Hypothyroidism. Choudhry, Vidita<br><a href="mailto:vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-2439] GLI-Similar 3(GLIS3) Knock Out (KO) Mice as Models to Screen Therapeutics for Diabetes, Polycystic Kidney Disease, and Hypothyroidism&body=Please send me information about technology [TAB-2439] GLI-Similar 3(GLIS3) Knock Out (KO) Mice as Models to Screen Therapeutics for Diabetes, Polycystic Kidney Disease, and Hypothyroidism.">vidita.choudhry@nih.gov</a><br> 114122803 RXXXXX 114122804 ACXXXX 114122805 GCXXXX 114122806 AXXXXX 114122807 GXXXXX 114143081 Mice 114143082 Mice: 114143083 KO 114143084 Knock 114143085 GLIS3 114143086 Which 114143087 SELECTIVE 114143088 TISSUES TAB-2432 114096633 Transgenic Hspa2-Cre Mice for Studying Spermatogenesis and Male Infertility NIEHS Collaboration, Diagnostics, Research Materials, Therapeutics Collaboration Diagnostics Research Materials Therapeutics Edward Eddy HSPA2 is a member of the HSP70 family of heat-shock proteins that serve as molecular chaperones. Hspa2-cre expression mimics the spermatogenic cell-specific expression of endogenous HSPA2 within the testis, being first observed in leptotene/zygotene spermatocytes. Expression of the transgene is also detected at restricted sites in the brain, as occurs for endogenous HSPA2. <br /><br /> Researchers at NIEHS developed the first transgenic mouse line that expresses Cre-recombinase under the control of the promoter of the heat shock protein A2 (Hspa2) gene. Expression of the Hspa2-Cre transgene during meiosis in male germ cells makes these mice a useful tool for defining the roles of genes expressed at different times during spermatogenesis or expressed in spermatogenic cells. <ul> <li>Researchers generated an Hspa2-cre line that expresses cre in spermatocytes to overcome the limitations of other transgenic lines.</li> </ul> <ul> <li>New mouse model to study spermatogenesis and male infertility</li> <li>New mouse model to study meiosis or the roles of heat-shock proteins in general</li> </ul> The NIEHS is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize this mouse strain. For collaboration opportunities, please contact Sharon Soucek, Ph.D. at <a href="mailto:sharon.soucek@nih.gov">sharon.soucek@nih.gov</a>. Research Tool — Patent protection is not being pursued for this technology. Research Tool — Patent protection is not being pursued for this technology. 2022-03-08 2024-10-28 2024-10-28 2012-05-04 Cells, Cre, EXPRESSED, Gene, Generation, Hspa2, IDXXXX, IXXXXX, Line, Mouse, PROMOTER, Recombinase, REGULATION, Spermatogenesis, Spermatogenic, TRANSGENIC False True <ul> <li>In vitro data available</li> <li>In vivo data available (animal)</li> </ul> True NIHTT 37470483 Website Abstract E-052-2011-0 114171581 Inselman AL, et al. http://www.ncbi.nlm.nih.gov/pubmed/20027617 <a href="http://www.ncbi.nlm.nih.gov/pubmed/20027617">Inselman AL, et al.</a> 114107547 Eddy, Edward NIEHS NIEHS Eddy, Edward (NIEHS) 1 114107547 Eddy, Edward NIEHS NIEHS Eddy, Edward (NIEHS) 1 114101733 Generation Of A Transgenic Mouse Line With Cre Recombinase Expressed In Spermatogenic Cells Under The Regulation Of The Hspa2 Gene Promoter E-290-2011-0 Research Material NIEHS 83739538 Choudhry, Vidita vidita.choudhry@nih.gov
United States of America Office of Technology Transfer and Development vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-2432] Transgenic Hspa2-Cre Mice for Studying Spermatogenesis and Male Infertility&body=Please send me information about technology [TAB-2432] Transgenic Hspa2-Cre Mice for Studying Spermatogenesis and Male Infertility. Choudhry, Vidita<br><a href="mailto:vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-2432] Transgenic Hspa2-Cre Mice for Studying Spermatogenesis and Male Infertility&body=Please send me information about technology [TAB-2432] Transgenic Hspa2-Cre Mice for Studying Spermatogenesis and Male Infertility.">vidita.choudhry@nih.gov</a><br> 114122771 IXXXXX 114122772 IDXXXX 114142991 Spermatogenesis 114142992 Generation 114142993 TRANSGENIC 114142994 Mouse 114142995 Line 114142996 Cre 114142997 Recombinase 114142998 EXPRESSED 114142999 Spermatogenic 114143000 Cells 114143001 REGULATION 114143002 Hspa2 114143003 Gene 114143004 PROMOTER TAB-2434 114096635 Human DNA Polymerase Gamma for Testing the Effect of Drugs on Mitochondrial Function NIEHS Collaboration, Infectious Disease, Research Materials, Therapeutics Collaboration Infectious Disease Research Materials Therapeutics William Copeland, Rajesh Kasiviswanathan, Susan Lim One of the primary means for treating HIV infection is the use of antiviral nucleotide or nucleoside analogs. These analogs work by inhibiting the activity of reverse transcriptase, the enzyme responsible for preparing the HIV genome for integration into the DNA of the host cell. Although these analogs do not have an effect on the polymerases responsible for replicating the human genome, the polymerase responsible for replicating the mitochondrial genome is sensitive to these analogs. When patients are exposed to nucleotide or nucleoside analogs through long-term treatment regimens, the replication of the mitochondrial genome can be adversely affected. Since mitochondrial functionality is necessary for cell activity, the nucleotide and nucleoside analogs can cause serious and unwanted side-effects.<br /><br /> This invention concerns the cloning and purification of DNA polymerase gamma, the polymerase responsible for replicating the mitochondrial genome. The enzymes that have been purified include the wild-type version, a version which lacks exonuclease (proofreading) activity, and several versions with modified activity due to the mutation of the enzyme. These purified enzymes can be used to directly test the effects of new drugs that affect the activity of polymerases, such as nucleotide and nucleoside analogs. <ul> <li>Purified polymerase allows for direct analysis of the effect of nucleotide analogs on DNA polymerase gamma</li> <li>Different formats of the enzyme such as the exonuclease-deficient version, allows comprehensive testing of drug candidates</li> </ul> <ul> <li>Research reagent to screen the effects of antiviral drugs (nucleotide and nucleoside analogs) on mitochondrial function</li> <li>Research reagent to test the mitochondrial toxicity of other drugs that can affect polymerase activity</li> </ul> The NIEHS is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize DNA polymerase G and method of purifying. For collaboration opportunities, please contact Sally E. Tilotta, Ph.D. at <a href="mailto:sally.tilotta@nih.gov">sally.tilotta@nih.gov</a>. HHS Reference Nos. E-191-2011/0, B-035-1998/0, B-035-1998/1 - Research Materials. Patent protection is not being pursued for these technologies. 2022-03-08 2024-10-28 2024-10-28 2012-05-09 CLONE, DDXXXX, DEFICIENT, Directed, DNA, DXXXXX, Enzyme, EXONUCLEASE, Expression, Gamma, Human, Improved, Includes, Listed LPM Campbell as of 4/15/2015, Method, Modifications, polymerase, Polymerase., Post LPM Assignment Set 20150420, Pre LPM working set 20150418, purification, recombinant, RXXXXX, SITE, TYPE, VLXXXX, Which, Wild, WIXXXX, XEXXXX, YBXXXX False True In vitro data available True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114171583 Longley MJ, et al. https://www.ncbi.nlm.nih.gov/pubmed/9671525 <a href="https://www.ncbi.nlm.nih.gov/pubmed/9671525">Longley MJ, et al.</a> 114109132 Kasiviswanathan, Rajesh NIEHS Kasiviswanathan, Rajesh 0 114109133 Lim, Susan NIEHS NIAMS Lim, Susan (NIAMS) 0 114104914 Copeland, William NIEHS NIEHS Copeland, William (NIEHS) 1 114104914 Copeland, William NIEHS NIEHS Copeland, William (NIEHS) 1 114109132 Kasiviswanathan, Rajesh NIEHS Kasiviswanathan, Rajesh 0 114109133 Lim, Susan NIEHS NIAMS Lim, Susan (NIAMS) 0 114100223 Improved Method For The Purification Of The Recombinant Human DNA Polymerase Gamma Enzyme, Which Includes The Wild Type DNA Polymerase, The Exonuclease Deficient DNA Polymerase, And Other Site Directed Modifications Of This Polymerase. E-191-2011-0 Research Material NIEHS 114100470 Human DNA Polymerase Gamma B-035-1998-0 Research Material NIEHS 114101299 Human DNA Polymerase Gamma Expression Clone B-035-1998-1 Research Material NIEHS 83739538 Choudhry, Vidita vidita.choudhry@nih.gov
United States of America Office of Technology Transfer and Development vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-2434] Human DNA Polymerase Gamma for Testing the Effect of Drugs on Mitochondrial Function&body=Please send me information about technology [TAB-2434] Human DNA Polymerase Gamma for Testing the Effect of Drugs on Mitochondrial Function. Choudhry, Vidita<br><a href="mailto:vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-2434] Human DNA Polymerase Gamma for Testing the Effect of Drugs on Mitochondrial Function&body=Please send me information about technology [TAB-2434] Human DNA Polymerase Gamma for Testing the Effect of Drugs on Mitochondrial Function.">vidita.choudhry@nih.gov</a><br> 114116225 XEXXXX 114116226 YBXXXX 114116311 VLXXXX 114116312 WIXXXX 114122776 RXXXXX 114122777 DDXXXX 114122778 DXXXXX 114138694 Listed LPM Campbell as of 4/15/2015 114138695 Pre LPM working set 20150418 114138696 Post LPM Assignment Set 20150420 114143013 Improved 114143014 Method 114143015 purification 114143016 recombinant 114143017 Human 114143018 DNA 114143019 polymerase 114143020 Gamma 114143021 Enzyme 114143022 Which 114143023 Includes 114143024 Wild 114143025 TYPE 114143026 EXONUCLEASE 114143027 DEFICIENT 114143028 SITE 114143029 Directed 114143030 Modifications 114143031 Polymerase. 114143032 Expression 114143033 CLONE TAB-2431 114096630 Hspa2 Knockout Mice for Study of Spermatogenesis and Male Infertility NIEHS Collaboration, Diagnostics, Research Materials, Therapeutics Collaboration Diagnostics Research Materials Therapeutics Edward Eddy HSPA2 is a member of the HSP70 family of heat-shock proteins that serve as molecular chaperones. Researchers discovered that HSPA2 protein is expressed in spermatogenesis during the meiotic phase. Spermatogenic cells lacking the HSPA2 protein arrest in mid-meiosis and undergo apoptosis. HSPA2 is present in the synaptonemal complex of wild-type mice and the chromosomes fail to separate in HSPA2-deficient mice (previously known as Hsp70-2-/- mice), suggesting that HSPA2 is required for the chromosomal events of meiosis such as synapsis, crossing over, or recombination.<br /><br /> Researchers at NIEHS developed a knockout strain of mice in which the heat shock protein gene (Hspa2) is disrupted. This mouse model is useful in studying the process of spermatogenesis and the influence of various environmental toxins or drugs on sperm production and male infertility. <ul> <li>Mouse model to study spermatogenesis and male infertility</li> <li>Mouse model to study meiosis or the roles of heat-shock proteins in general</li> <li>Mouse model to evaluate effects of meiosis-disrupting agents on meiotic recombination and generation of mutations transmitted to offspring</li> </ul> The NIEHS is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize this mouse strain. For collaboration opportunities, please contact Sharon Soucek, Ph.D. at <a href="mailto:sharon.soucek@nih.gov">sharon.soucek@nih.gov</a>. Research Tool — Patent protection is not being pursued for this technology. Research Tool — Patent protection is not being pursued for this technology. 2022-03-08 2024-10-28 2024-10-28 2012-05-04 Deletion, Gene, Generation, Hsp70-2, Hspa2, IDXXXX, IXXXXX, KNOWN, Mouse, previously, Spermatogenesis, Strain, Targeted False True <ul> <li>In vitro data available</li> <li>In vivo data available (animal)</li> </ul> True NIHTT 37470483 Website Abstract E-290-2011-0 114171580 Dix DJ, et al. http://www.ncbi.nlm.nih.gov/pubmed/8622925 <a href="http://www.ncbi.nlm.nih.gov/pubmed/8622925">Dix DJ, et al.</a> 114107546 Eddy, Edward NIEHS NIEHS Eddy, Edward (NIEHS) 1 114107546 Eddy, Edward NIEHS NIEHS Eddy, Edward (NIEHS) 1 114101732 Generation Of A Mouse Strain With A Targeted Deletion Of The Hspa2 Gene (previously Known As The Hsp70-2 Gene) E-052-2011-0 Research Material NIEHS 83739538 Choudhry, Vidita vidita.choudhry@nih.gov
United States of America Office of Technology Transfer and Development vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-2431] Hspa2 Knockout Mice for Study of Spermatogenesis and Male Infertility&body=Please send me information about technology [TAB-2431] Hspa2 Knockout Mice for Study of Spermatogenesis and Male Infertility. Choudhry, Vidita<br><a href="mailto:vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-2431] Hspa2 Knockout Mice for Study of Spermatogenesis and Male Infertility&body=Please send me information about technology [TAB-2431] Hspa2 Knockout Mice for Study of Spermatogenesis and Male Infertility.">vidita.choudhry@nih.gov</a><br> 114122769 IXXXXX 114122770 IDXXXX 114142980 Generation 114142981 Mouse 114142982 Strain 114142983 Targeted 114142984 Deletion 114142985 Hspa2 114142986 Gene 114142987 previously 114142988 KNOWN 114142989 Hsp70-2 114142990 Spermatogenesis TAB-2418 114096620 Fgfr3 Knockout Mouse Model for Developmental Biology Studies NIDDK Diagnostics, Licensing, Research Materials, Therapeutics Diagnostics Licensing Research Materials Therapeutics Chuxia Deng FGFR3 knockout. Complete knockout of the FGFR3 gene, the gene in which missense mutants cause short statue achondroplasia, fails to restrain cartilage growth at the bone growth plate, allowing bones to elongate excessively but fail to ossify.<br /><br /> Endochondral ossification is a major mode of bone formation. Cartilage proliferates, undergoes hypertrophy, begins to calcify, undergoes a program of cell death, and is replaced by osteoblasts. Fibroblast Growth Factor Receptor 3 (FGFR3) is expressed in cartilage rudiments of a wide variety of bones, and dominant missense mutations in the human FGFR3 gene cause achondroplasia, a common form of human dwarfism characterized by minimal proliferation of the growth plate cartilage in long bones. To determine the effect of complete absence of FGFR3 on bone development in mice, targeted disruption of the FGFR3 gene was accomplished by homologous recombination in embryonic stem cells. Remarkably, the vertebral column and long bones of FGFR3 null mice were extremely long, suggesting that in normal development, FGFR3 restrains cartilage promotion and limits bone elongation so that the endochondral ossification program can proceed. Restraint of cartilage growth by FGFR3 provides a plausible explanation for the role of FGFR3 missense mutations in human achondroplastic dwarfs. <ul> <li>Mouse model to study developmental biology.</li> </ul> Research Tool — Patent protection is not being pursued for this technology. 2022-03-08 2024-10-28 2024-10-28 2012-04-19 FGFR3, IDXXXX, IXXXXX, Knock, Mouse False True Pre-clinical True NIHTT 37470483 Website Abstract 114171563 Deng C, et al. https://www.ncbi.nlm.nih.gov/pubmed/8601314 <a href="https://www.ncbi.nlm.nih.gov/pubmed/8601314">Deng C, et al.</a> 114107521 Deng, Chuxia National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Deng, Chuxia (NIDDK) 1 114107521 Deng, Chuxia National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Deng, Chuxia (NIDDK) 1 114101720 Fgfr3 Knock Out Mouse E-123-2012-0 Research Material National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83692066 Tong, Betty tongb@niddk.nih.gov
United States of America Senior Technology Advancement Office tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-2418] Fgfr3 Knockout Mouse Model for Developmental Biology Studies&body=Please send me information about technology [TAB-2418] Fgfr3 Knockout Mouse Model for Developmental Biology Studies. Tong, Betty<br><a href="mailto:tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-2418] Fgfr3 Knockout Mouse Model for Developmental Biology Studies&body=Please send me information about technology [TAB-2418] Fgfr3 Knockout Mouse Model for Developmental Biology Studies.">tongb@niddk.nih.gov</a><br> 114122717 IXXXXX 114122718 IDXXXX 114142896 FGFR3 114142897 Knock 114142898 Mouse TAB-2419 114096621 Fgfr2 Knockout (Fgfr2tm1Cxd) Mouse Model for Developmental Biology Studies NIDDK Diagnostics, Licensing, Research Materials, Therapeutics Diagnostics Licensing Research Materials Therapeutics Chuxia Deng FGFR2 knockout is an embryonic lethal mutation and blocks limb bud initiation.<br /><br /> Fibroblast Growth Factor Receptor 2 (FGFR2) is a high affinity receptor for several members of the FGF family. The FGFR2 gene was inactivated by deleting the entire immunoglobulin-like domain of the receptor which is critical for FGF binding and FGFR2 activity. Embryos that lack this domain die at E10-11.5 owing to a failure in chorioallantoic fusion or placental formation. The deletion also blocks limb bud initiation, establishing FGFR2 as the major receptor that mediates FGF signals during limb induction. <ul> <li>Mouse model to study developmental biology.</li> </ul> Research Tool — Patent protection is not being pursued for this technology. 2022-03-08 2024-10-28 2024-10-28 2012-04-19 FGFR2, IDXXXX, IXXXXX, Knock, Mouse, Tm1Cxd False True Pre-clinical True NIHTT 37470483 Website Abstract 114171564 Xu X, et al. https://www.ncbi.nlm.nih.gov/pubmed/9435295 <a href="https://www.ncbi.nlm.nih.gov/pubmed/9435295">Xu X, et al.</a> 114107522 Deng, Chuxia National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Deng, Chuxia (NIDDK) 1 114107522 Deng, Chuxia National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Deng, Chuxia (NIDDK) 1 114101721 Fgfr2 Knock Out (Fgfr2 Tm1Cxd) Mouse E-124-2012-0 Research Material National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83692066 Tong, Betty tongb@niddk.nih.gov
United States of America Senior Technology Advancement Office tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-2419] Fgfr2 Knockout (Fgfr2tm1Cxd) Mouse Model for Developmental Biology Studies&body=Please send me information about technology [TAB-2419] Fgfr2 Knockout (Fgfr2tm1Cxd) Mouse Model for Developmental Biology Studies. Tong, Betty<br><a href="mailto:tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-2419] Fgfr2 Knockout (Fgfr2tm1Cxd) Mouse Model for Developmental Biology Studies&body=Please send me information about technology [TAB-2419] Fgfr2 Knockout (Fgfr2tm1Cxd) Mouse Model for Developmental Biology Studies.">tongb@niddk.nih.gov</a><br> 114122719 IXXXXX 114122720 IDXXXX 114142899 FGFR2 114142900 Knock 114142901 Tm1Cxd 114142902 Mouse TAB-2417 114096619 Sirt1 LoxP (Sirt1tm1Cxd) Mouse Model for Metabolism and Hepatology Studies NIDDK Diagnostics, Licensing, Research Materials, Therapeutics Diagnostics Licensing Research Materials Therapeutics Chuxia Deng Generation of floxed Sirtuin 1 Exon5-Exon6 for the construction of conditional knockout mice.<br /><br /> Sirtuin 1 (Sirt1), a homolog of yeast Sir 2, is an NAD-dependent histone and protein deacetylase. It has a wide range of biological functions, ranging from DNA damage repair to effects on glucose metabolism. Sirt1 null mice die before birth due to chromosomal aberrations and impaired DNA damage repair. Sirt1 is thought to affect energy metabolism, but the mechanism remains poorly understood. In order to study tissue-specific metabolic effects of Sirt1, floxed Sirt1 was constructed so that exons 5 and 6 would be deleted using the Cre-Lox strategy. In contrast to a previously reported deletion of Sirt1 exon4, no truncated (and potentially active) Sirt1 forms were detected when exons 5 and 6 were deleted.<br /><br /> Hepatic exon 5-6 null Sirt1 mice were generated when Floxed Sirt1 exon 5 and 6 mice were mated with mice that expressed the Cre-recombinase in liver. The hepatic exon 5-6 null Sirt1 mice developed fatty liver under normal feeding conditions. This was accompanied by increased expression of the carbohydrate responsive element binding protein, which is a major regulator of lipid synthesis. Sirt1-deficient liver also has an impaired insulin response, primarily due to reduced phosphorylation of the serine-threonine kinase Akt in the presence of insulin. <ul> <li>Mouse model to study metabolism and hepatology.</li> </ul> Research Tool — Patent protection is not being pursued for this technology. 2022-03-08 2024-10-28 2024-10-28 2012-04-19 1, IDXXXX, IXXXXX, LOXP, Mouse, Sirt, SIRT1, Tm1Cxd False True Pre-clinical True NIHTT 37470483 Website Abstract 114171561 Wang RH, et al. https://www.ncbi.nlm.nih.gov/pubmed/21103071 <a href="https://www.ncbi.nlm.nih.gov/pubmed/21103071">Wang RH, et al.</a> 114171562 Wang RH, et al. https://www.ncbi.nlm.nih.gov/pubmed/21965330 <a href="https://www.ncbi.nlm.nih.gov/pubmed/21965330">Wang RH, et al.</a> 114107520 Deng, Chuxia National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Deng, Chuxia (NIDDK) 1 114107520 Deng, Chuxia National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Deng, Chuxia (NIDDK) 1 114101719 Sirt 1 LoxP (Sirt1 Tm1Cxd) Mouse E-122-2012-0 Research Material National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83692066 Tong, Betty tongb@niddk.nih.gov
United States of America Senior Technology Advancement Office tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-2417] Sirt1 LoxP (Sirt1tm1Cxd) Mouse Model for Metabolism and Hepatology Studies&body=Please send me information about technology [TAB-2417] Sirt1 LoxP (Sirt1tm1Cxd) Mouse Model for Metabolism and Hepatology Studies. Tong, Betty<br><a href="mailto:tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-2417] Sirt1 LoxP (Sirt1tm1Cxd) Mouse Model for Metabolism and Hepatology Studies&body=Please send me information about technology [TAB-2417] Sirt1 LoxP (Sirt1tm1Cxd) Mouse Model for Metabolism and Hepatology Studies.">tongb@niddk.nih.gov</a><br> 114122715 IXXXXX 114122716 IDXXXX 114142890 Sirt 114142891 1 114142892 LOXP 114142893 SIRT1 114142894 Tm1Cxd 114142895 Mouse TAB-2415 114096617 Sirt1 Knockout (Sirt1tm1.1Cxd) Mouse Model for Oncology and Metabolism Studies NIDDK Diagnostics, Licensing, Oncology, Research Materials, Therapeutics Diagnostics Licensing Oncology Research Materials Therapeutics Chuxia Deng Sirt1 knockout: Sirt1, a protein deacetylase, is a tumor suppressor that promotes genome stability and regulates proteins involved in energy metabolism.<br /><br /> Yeast Sir2, a nicotinamide adenine dinucleotide (NAD)-dependent protein deacetylase, has been implicated in chromatin silencing, longevity and genome stability. Mammals contain a family of related deacetylases, the sirtuins, of which 7 have been identified. Sirt1 is the closest mammalian orthologue of yeast Sir 2. The Sirt1 gene in mice was disrupted by homologous recombination in embryonic stem cells. The majority of Sirt1 (-/-) embryos die between E9.5 and E14.5, displaying altered histone modification, increased chromosomal aberrations, and impaired DNA damage repair. Tumor formation was increased in mutant tissues in Sirt1(+/-): p53(+/-) double heterozygotes, indicating that full levels of Sirt1 are necessary for tumor suppression. Tumorigenesis is reduced by treatment with the polyphenol, resveratrol, which activates Sirt1. Sirt1 may act as a tumor suppressor by promoting DNA damage repair and maintaining genome integrity. Sirt1also is involved in the regulation of proteins involved in energy metabolism, and components of the circadian clock. <ul> <li>Oncology</li> <li>Metabolism</li> </ul> Research Tool — Patent protection is not being pursued for this technology. 2022-03-08 2024-10-28 2024-10-28 2012-04-19 CCXXXX, cre-lox, Cre-loxP, CXXXXX, GCXXXX, GXXXXX, IDXXXX, IXXXXX, knockout mice, Mouse, Mouse animal model, SIRT1, Tm1.1Cxd False True Pre-clinical True NIHTT 37470483 Website Abstract 114171559 Wang RH, et al. https://www.ncbi.nlm.nih.gov/pubmed/18835033 <a href="https://www.ncbi.nlm.nih.gov/pubmed/18835033">Wang RH, et al.</a> 114107518 Deng, Chuxia National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Deng, Chuxia (NIDDK) 1 114107518 Deng, Chuxia National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Deng, Chuxia (NIDDK) 1 114101717 Sirt1 Knock Out (Sirt1 Tm1.1Cxd) Mouse E-120-2012-0 Research Material National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83692066 Tong, Betty tongb@niddk.nih.gov
United States of America Senior Technology Advancement Office tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-2415] Sirt1 Knockout (Sirt1tm1.1Cxd) Mouse Model for Oncology and Metabolism Studies&body=Please send me information about technology [TAB-2415] Sirt1 Knockout (Sirt1tm1.1Cxd) Mouse Model for Oncology and Metabolism Studies. Tong, Betty<br><a href="mailto:tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-2415] Sirt1 Knockout (Sirt1tm1.1Cxd) Mouse Model for Oncology and Metabolism Studies&body=Please send me information about technology [TAB-2415] Sirt1 Knockout (Sirt1tm1.1Cxd) Mouse Model for Oncology and Metabolism Studies.">tongb@niddk.nih.gov</a><br> 114122707 CXXXXX 114122708 CCXXXX 114122709 GXXXXX 114122710 GCXXXX 114122711 IXXXXX 114122712 IDXXXX 114142878 knockout mice 114142879 Mouse animal model 114142880 SIRT1 114142881 Tm1.1Cxd 114142882 Mouse 114142883 Cre-loxP 114142884 cre-lox TAB-2416 114096618 Sirt6 LoxP (Sirt6tm1.1Cxd) Mouse Model for Liver Studies NIDDK Diagnostics, Licensing, Research Materials, Therapeutics Diagnostics Licensing Research Materials Therapeutics Chuxia Deng Generation of floxed Sirtuin 6 for the construction of conditional knockout mice.<br /><br /> The Sirtuins (Sirt1-7), a family of seven proteins related to yeast Sir2, are histone deacetylases that regulate many critical biological processes including genomic stability, adaptation to calorie restriction and aging. Mice with a targeted disruption of Sirt6 had very low levels of blood glucose (and paradoxically, low insulin levels) and died shortly after weaning. Hypoglycemia, attributed to increased sensitivity to insulin, was the major cause for lethality.<br /><br /> Because of the post-weaning mortality of Sirt6 null mice, liver-specific Sirt6 conditional knockout mice were constructed using Cre-Lox technology to study the effects on glucose and lipid metabolism. Hepatic-specific Sirt6 deficient mice exhibited increased glycolysis and triglyceride synthesis, resulting in the development of fatty liver. Sirt6 is a potential therapeutic target for treating fatty liver disease, the most common cause of liver dysfunction. <ul> <li>Mouse model to study the liver.</li> </ul> Research Tool — Patent protection is not being pursued for this technology. 2022-03-08 2024-10-28 2024-10-28 2012-04-19 IDXXXX, IXXXXX, LOXP, Mouse, Sirt6, Sirt6tm1.1Cxd, Tm1.1Cxd False True Pre-clinical True NIHTT 37470483 Website Abstract 114171560 Kim HS, et al. https://www.ncbi.nlm.nih.gov/pubmed/20816089 <a href="https://www.ncbi.nlm.nih.gov/pubmed/20816089">Kim HS, et al.</a> 114107519 Deng, Chuxia National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Deng, Chuxia (NIDDK) 1 114107519 Deng, Chuxia National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Deng, Chuxia (NIDDK) 1 114101718 Sirt6 LoxP (Sirt6 Tm1.1Cxd) Mouse E-121-2012-0 Research Material National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83692066 Tong, Betty tongb@niddk.nih.gov
United States of America Senior Technology Advancement Office tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-2416] Sirt6 LoxP (Sirt6tm1.1Cxd) Mouse Model for Liver Studies&body=Please send me information about technology [TAB-2416] Sirt6 LoxP (Sirt6tm1.1Cxd) Mouse Model for Liver Studies. Tong, Betty<br><a href="mailto:tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-2416] Sirt6 LoxP (Sirt6tm1.1Cxd) Mouse Model for Liver Studies&body=Please send me information about technology [TAB-2416] Sirt6 LoxP (Sirt6tm1.1Cxd) Mouse Model for Liver Studies.">tongb@niddk.nih.gov</a><br> 114122713 IDXXXX 114122714 IXXXXX 114142885 Sirt6 114142886 LOXP 114142887 Sirt6tm1.1Cxd 114142888 Mouse 114142889 Tm1.1Cxd TAB-2414 114096616 Sirt3 Knockout (Sirt3tm1.1Cxd) Mouse Model for Cardiology and Metabolism Studies NIDDK Diagnostics, Licensing, Research Materials, Therapeutics Diagnostics Licensing Research Materials Therapeutics Chuxia Deng Sirt3 knockout: Sirt3 is a mitochondrial-localized tumor suppressor that maintains mitochondrial integrity and metabolism during stress. <br /><br /> Sirt3 is a mitochondrial protein that is a member of the Sirtuin family of NAD-dependent protein deacetylases. Sirt3(-/-) mice are phenotypically normal, but exhibit many proteins whose acetylation is increased. They generate more reactive oxygen species and are more susceptible to mammary tumors than normal mice. Sirt3 is inactivated in a large percentage of human breast and ovarian cancers, suggesting that Sirt3 may be a mitochondria-localized tumor suppressor by maintaining mitochondrial integrity and efficient oxidative metabolism. <ul> <li>Cardiology</li> <li>Metabolism</li> </ul> Research Tool — Patent protection is not being pursued for this technology. 2022-03-08 2024-10-28 2024-10-28 2012-04-19 cre-lox, Cre-loxP, IDXXXX, IXXXXX, Knock, Mouse, Sirt3, Tm1.1Cxd, Tm1Cxd False True Pre-clinical True NIHTT 37470483 Website Abstract 114171558 Kim HS, et al. https://www.ncbi.nlm.nih.gov/pubmed/20129246 <a href="https://www.ncbi.nlm.nih.gov/pubmed/20129246">Kim HS, et al.</a> 114107517 Deng, Chuxia National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Deng, Chuxia (NIDDK) 1 114107517 Deng, Chuxia National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Deng, Chuxia (NIDDK) 1 114101716 Sirt3 Knock Out (Sirt3 Tm1.1Cxd) Mouse E-119-2012-0 Research Material National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83692066 Tong, Betty tongb@niddk.nih.gov
United States of America Senior Technology Advancement Office tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-2414] Sirt3 Knockout (Sirt3tm1.1Cxd) Mouse Model for Cardiology and Metabolism Studies&body=Please send me information about technology [TAB-2414] Sirt3 Knockout (Sirt3tm1.1Cxd) Mouse Model for Cardiology and Metabolism Studies. Tong, Betty<br><a href="mailto:tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-2414] Sirt3 Knockout (Sirt3tm1.1Cxd) Mouse Model for Cardiology and Metabolism Studies&body=Please send me information about technology [TAB-2414] Sirt3 Knockout (Sirt3tm1.1Cxd) Mouse Model for Cardiology and Metabolism Studies.">tongb@niddk.nih.gov</a><br> 114122705 IXXXXX 114122706 IDXXXX 114142871 Sirt3 114142872 Knock 114142873 Tm1Cxd 114142874 Mouse 114142875 Tm1.1Cxd 114142876 cre-lox 114142877 Cre-loxP TAB-2411 114096613 Stat5a Knockout (Stat5atm1Mam) Mouse Model for Mammopoietic and Lactogenic Signaling Studies NIDDK Diagnostics, Licensing, Research Materials, Therapeutics Diagnostics Licensing Research Materials Therapeutics Lothar Hennighausen Stat 5a Knockout: Stat5a deficiency results in the loss of prolactin-dependent mammary gland development and lactogenesis. <br /><br /> Prolactin induces mammary gland development and lactogenesis. Binding of Prolactin to its receptor leads to the phosphorylation and activation of STAT (signal transducers and activators of transcription) proteins. Two Stat proteins, Stat 5a and Stat5b, are expressed in mammary tissues during pregnancy. Stat5a null mice developed normally, and were indistinguishable from hemizygous and wild-type littermates in size, weight and fertility. Mammary lobulo-alveolar outgrowth during pregnancy was reduced and females failed to lactate after parturition. Stat5b, despite 96% similarity to Stat5a, could not compensate for the loss of Stat5a. Stat5a is the principal and obligate mediator of mammopoietic and lactogenic signaling. Mouse model to study mammopoietic and lactogenic signaling. Research Tool — Patent protection is not being pursued for this technology. 2022-03-08 2024-10-28 2024-10-28 2012-04-19 GC1XXX, GCXXXX, GXXXXX, ID1XXX, IDXXXX, IXXXXX, Knock, Mouse, RXXXXX, STAT5A, Tm1Mam False True Pre-clinical True NIHTT 37470483 Website Abstract 114171555 Liu X, et al. http://www.ncbi.nlm.nih.gov/pubmed/9009201 <a href="http://www.ncbi.nlm.nih.gov/pubmed/9009201">Liu X, et al.</a> 114107514 Hennighausen, Lothar National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Hennighausen, Lothar (NIDDK) 1 114107514 Hennighausen, Lothar National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Hennighausen, Lothar (NIDDK) 1 114101713 Stat5a Knock Out (Stat5a Tm1Mam) Mouse E-116-2012-0 Research Material National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83692066 Tong, Betty tongb@niddk.nih.gov
United States of America Senior Technology Advancement Office tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-2411] Stat5a Knockout (Stat5atm1Mam) Mouse Model for Mammopoietic and Lactogenic Signaling Studies&body=Please send me information about technology [TAB-2411] Stat5a Knockout (Stat5atm1Mam) Mouse Model for Mammopoietic and Lactogenic Signaling Studies. Tong, Betty<br><a href="mailto:tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-2411] Stat5a Knockout (Stat5atm1Mam) Mouse Model for Mammopoietic and Lactogenic Signaling Studies&body=Please send me information about technology [TAB-2411] Stat5a Knockout (Stat5atm1Mam) Mouse Model for Mammopoietic and Lactogenic Signaling Studies.">tongb@niddk.nih.gov</a><br> 114122692 RXXXXX 114122693 ID1XXX 114122694 GC1XXX 114122695 IXXXXX 114122696 IDXXXX 114122697 GXXXXX 114122698 GCXXXX 114142858 STAT5A 114142859 Knock 114142860 Tm1Mam 114142861 Mouse TAB-2412 114096614 Gs Alpha LoxP (Gnastm1Lsw) Mouse Model for Metabolism Studies NIDDK Licensing, Research Materials, Therapeutics Licensing Research Materials Therapeutics Lee Weinstein Generation of a floxed <i>Gnsa</i> gene for the G-protein Gs alpha (G<sub>s</sub>alpha) for the construction of conditional knockout mice. The heterotrimeric G protein G<sub>s</sub>alpha couples many receptors to adenylyl cyclase and is essential for hormone-stimulated cAMP generation. Previous mouse models with germ-line mutations in <i>Gnas</i>, the gene that encodes G<sub>s</sub>alpha had limited usefulness in trying to decipher the role of G<sub>s</sub>alpha pathways in specific tissues since only heterozygotes were viable and could be analyzed. Analysis was further complicated by the fact that G<sub>s</sub>alpha is imprinted expressed in many metabolically active tissues. G<sub>s</sub>alpha-floxed mice were generated so that the metabolic effects of G<sub>s</sub>alpha deficiency could be examined in specific tissues. Exon1, which is specific for G<sub>s</sub>alpha, was surrounded with loxP recombination sites. Liver-specific knockouts of G<sub>s</sub>alpha were obtained by mating the G<sub>s</sub>alpha-floxed mice with albumin promoter-Cre-transgenic mice. G<sub>s</sub>alpha exon1 was efficiently deleted. These mice have been used successfully to generate other tissue-specfic G<sub>s</sub>alpha knockout mice. Mouse model to study metabolism. Research Tool — Patent protection is not being pursued for this technology. 2022-03-08 2024-10-28 2024-10-28 2012-04-19 ALPHA, AXXXXX, GCXXXX, Ghas, GS, GXXXXX, LOXP, Mouse, RXXXXX, Tm1LSW False True Pre-clinical True NIHTT 37470483 Website Abstract 114171556 Chen M, et al. http://www.ncbi.nlm.nih.gov/pubmed/16239968 <a href="http://www.ncbi.nlm.nih.gov/pubmed/16239968">Chen M, et al.</a> 114107515 Weinstein, Lee National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Weinstein, Lee (NIDDK) 1 114107515 Weinstein, Lee National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Weinstein, Lee (NIDDK) 1 114101714 Gs Alpha LoxP (Ghas Tm1LSW) Mouse E-117-2012-0 Research Material National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83739550 Shastri, Mythreyi shastrim@mail.nih.gov
United States of America Technology Advancement Office shastrim@mail.nih.gov?subject=Web Inquiry on [TAB-2412] Gs Alpha LoxP (Gnastm1Lsw) Mouse Model for Metabolism Studies&body=Please send me information about technology [TAB-2412] Gs Alpha LoxP (Gnastm1Lsw) Mouse Model for Metabolism Studies. Shastri, Mythreyi<br><a href="mailto:shastrim@mail.nih.gov?subject=Web Inquiry on [TAB-2412] Gs Alpha LoxP (Gnastm1Lsw) Mouse Model for Metabolism Studies&body=Please send me information about technology [TAB-2412] Gs Alpha LoxP (Gnastm1Lsw) Mouse Model for Metabolism Studies.">shastrim@mail.nih.gov</a><br> 114122699 GCXXXX 114122700 RXXXXX 114122701 AXXXXX 114122702 GXXXXX 114142862 GS 114142863 ALPHA 114142864 LOXP 114142865 Ghas 114142866 Tm1LSW 114142867 Mouse TAB-2409 114096611 Stat5a LoxP/Stat5b LoxP (Stat5a/Stat5btm2Mam) Mouse Model for Mammopoietic and Lactogenic Signaling Studies NIDDK Diagnostics, Licensing, Research Materials, Therapeutics Diagnostics Licensing Research Materials Therapeutics Lothar Hennighausen Conditional knockout of Stat5a and Stat5b: Combined deletion of conserved Stat5a and Stat5b in mammary epithelium at different times during pregnancy reveal multiple distinct functions. <br /><br /> The signal transducer and activator of transcription (STAT) family of transcription factors conveys signals from membrane receptors to the nucleus, where they activate diverse genetic programs. Stat5a and Stat5b are highly conserved proteins that are activated by many cytokines, erythropoietin, prolactin and growth hormone. Despite their similarities, they have many unique functions. Stat5a deficiency results in the loss of prolactin-dependent mammary gland development, but does not affect body growth. Inactivation of Stat5b does not adversely affect mammary development and function, but leads to severe growth retardation. To study the effects of combined deficiency of Stat 5a and 5b before and during pregnancy, loxP was added to the ends of a DNA fragment that contains the two genes which are located within a stretch of 110 kb on chromosome 11 in a head to head orientation with no other genes between them. The loxP-flanked fragment was introduced into the genome using homologous recombination, and deleted using two transgenic lines expressing Cre in mammary epithelium at different times. Deletion of Stat 5 before pregnancy prevents epithelial proliferation. Ductal characteristics are retained but differentiation into secretory alveoli does not occur. When deletion of Stat5 occurs late in pregnancy after differentiation has started, differentiation is halted and premature death occurs. Mouse model to study mammopoietic and lactogenic signaling. Research Tool — Patent protection is not being pursued for this technology. 2022-03-08 2024-10-28 2024-10-28 2012-04-19 ACXXXX, AXXXXX, ID1XXX, IDXXXX, IXXXXX, LOXP, LoxP/Stat5b, Mouse, R1XXXX, RXXXXX, STAT5A, Stat5a/Stat5b, Tm2Mam False True Pre-clinical True NIHTT 37470483 Website Abstract 114171553 Cui Y, et al. http://www.ncbi.nlm.nih.gov/pubmed/15340066 <a href="http://www.ncbi.nlm.nih.gov/pubmed/15340066">Cui Y, et al.</a> 114107512 Hennighausen, Lothar National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Hennighausen, Lothar (NIDDK) 1 114107512 Hennighausen, Lothar National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Hennighausen, Lothar (NIDDK) 1 114101711 Stat5a LoxP/Stat5b LoxP (Stat5a/Stat5b Tm2Mam) Mouse E-114-2012-0 Research Material National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83692066 Tong, Betty tongb@niddk.nih.gov
United States of America Senior Technology Advancement Office tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-2409] Stat5a LoxP/Stat5b LoxP (Stat5a/Stat5btm2Mam) Mouse Model for Mammopoietic and Lactogenic Signaling Studies&body=Please send me information about technology [TAB-2409] Stat5a LoxP/Stat5b LoxP (Stat5a/Stat5btm2Mam) Mouse Model for Mammopoietic and Lactogenic Signaling Studies. Tong, Betty<br><a href="mailto:tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-2409] Stat5a LoxP/Stat5b LoxP (Stat5a/Stat5btm2Mam) Mouse Model for Mammopoietic and Lactogenic Signaling Studies&body=Please send me information about technology [TAB-2409] Stat5a LoxP/Stat5b LoxP (Stat5a/Stat5btm2Mam) Mouse Model for Mammopoietic and Lactogenic Signaling Studies.">tongb@niddk.nih.gov</a><br> 114122681 ID1XXX 114122682 ACXXXX 114122683 R1XXXX 114122684 IXXXXX 114122685 IDXXXX 114122686 AXXXXX 114122687 RXXXXX 114142847 STAT5A 114142848 LoxP/Stat5b 114142849 LOXP 114142850 Stat5a/Stat5b 114142851 Tm2Mam 114142852 Mouse TAB-2405 114096607 M5 Muscarinic Receptor Knockout (Chrm5tm1Jwe) Mouse Model for Neurological Studies NIDDK Licensing, Neurology, Research Materials Licensing Neurology Research Materials Jurgen Wess M5 muscarinic receptor knockout: Deficiency of M5Rs reduces drug-seeking behavior.<br /><br /> The five Muscarinic Acetylcholine (ACh) receptors are G-protein coupled receptors (M1R-M5R). M1R, M3R and M5R selectively couple to Gq/G11; M2R and M4R selectively couple to Gi/Go. M5R knockout mice are viable and fertile, and have no major morphological abnormalities.<br /><br /> M5 muscarinic ACh receptors are located in the central nervous system and may contribute to the cognitive-enhancing effects of ACh. M5R knockout mice show deficits in two hippocampus-dependent cognitive tasks, and exhibit reduced cerebral blood flow in the cerebral cortex and hippocampus, consistent with the observation that M5Rs mediate ACh-mediated dilation of cerebral blood vessels. M5R agonists or agonists for mixed M1/M5 receptors may be effective in the treatment of Alzheimer’s disease and related memory disorders. The M5R knockout mutation also appears to exert a stabilizing effect on sensorimotor gating in intact mice, which is decreased in schizophrenia. Analysis of M5R knockout mice also has shown that the lack of M5Rs reduces drug-seeking behavior. <ul> <li>Mouse model for use in neurological studies.</li> </ul> Research Tool – Patent protection is not being pursued for this technology. 2022-03-08 2024-10-28 2024-10-28 2017-04-17 Chrm5, Knock, M5, Mouse, MUSCARINIC, NCXXXX, NXXXXX, RECEPTOR, TmJwe False True Pre-clinical True NIHTT 37470483 Website Abstract 114171549 Yamada M, et al. http://www.ncbi.nlm.nih.gov/pubmed/11707605 <a href="http://www.ncbi.nlm.nih.gov/pubmed/11707605">Yamada M, et al.</a> 114107511 Wess, Jurgen National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Wess, Jurgen (NIDDK) 1 114107511 Wess, Jurgen National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Wess, Jurgen (NIDDK) 1 114101707 M5 Muscarinic Receptor Knock Out (Chrm5 TmJwe) Mouse E-110-2012-0 Research Material National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83739550 Shastri, Mythreyi shastrim@mail.nih.gov
United States of America Technology Advancement Office shastrim@mail.nih.gov?subject=Web Inquiry on [TAB-2405] M5 Muscarinic Receptor Knockout (Chrm5tm1Jwe) Mouse Model for Neurological Studies&body=Please send me information about technology [TAB-2405] M5 Muscarinic Receptor Knockout (Chrm5tm1Jwe) Mouse Model for Neurological Studies. Shastri, Mythreyi<br><a href="mailto:shastrim@mail.nih.gov?subject=Web Inquiry on [TAB-2405] M5 Muscarinic Receptor Knockout (Chrm5tm1Jwe) Mouse Model for Neurological Studies&body=Please send me information about technology [TAB-2405] M5 Muscarinic Receptor Knockout (Chrm5tm1Jwe) Mouse Model for Neurological Studies.">shastrim@mail.nih.gov</a><br> 114122669 NXXXXX 114122670 NCXXXX 114142832 M5 114142833 MUSCARINIC 114142834 RECEPTOR 114142835 Knock 114142836 Chrm5 114142837 TmJwe 114142838 Mouse TAB-2401 114096603 Monoclonal Antibodies Targeting Human DNA Polymerase beta, a DNA Repair Enzyme NIEHS Collaboration, Licensing, Oncology, Research Materials Collaboration Licensing Oncology Research Materials Rajendra Prasad, Samuel Wilson Available for licensing are monoclonal antibodies targeting human DNA polymerase beta (Pol B). Pol B is a constitutively expressed "housekeeping" enzyme that plays a role in base excision repair (BER), a cellular defense mechanism that repairs DNA base damage and loss. Aberrant Pol B expression is associated with genomic instability indicating that Pol B is required for DNA maintenance, replication and recombination.<br /><br /> These antibodies can be utilized to elucidate BER's mechanism of action and Pol B's structure and function. Moreover, the antibodies can be used to detect Pol B in samples with a variety of techniques including immunoblotting, ELISA, immunoprecipitation, and immunohistochemistry. <ul> <li>Can be utilized in a variety of applications to study Pol B</li> </ul> <ul> <li>Research tool to elucidate the mechanism of base excision repair</li> <li>Research reagents</li> </ul> The NIEHS is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize these monoclonal antibodies. For collaboration opportunities, please contact Sally E. Tilotta, Ph.D. at <a href="mailto:sally.tilotta@nih.gov">sally.tilotta@nih.gov</a>. Research Tool — Patent protection is not being pursued for this technology. 2022-03-08 2024-10-28 2024-10-28 2022-01-31 AC5XXX, ACXXXX, ANTIBODY, AXXXXX, CC2XXX, CCXXXX, CDXXXX, CXXXXX, DNA, DNA polymerase, DNA polymerase beta, monoclonal, Monoclonal Antibody, monoclonal antibody based assays, polymerase False True <ul> <li>Early-stage</li> <li>In vitro data available</li> </ul> True NIHTT 37470483 Website Abstract 114171540 Srivastava DK, et al. http://www.ncbi.nlm.nih.gov/pubmed/7608211 <a href="http://www.ncbi.nlm.nih.gov/pubmed/7608211">Srivastava DK, et al.</a> 114171541 Singhal R, et al. http://www.ncbi.nlm.nih.gov/pubmed/7822335 <a href="http://www.ncbi.nlm.nih.gov/pubmed/7822335">Singhal R, et al.</a> 114171542 Prasad R, et al. http://www.ncbi.nlm.nih.gov/pubmed/8663274 <a href="http://www.ncbi.nlm.nih.gov/pubmed/8663274">Prasad R, et al.</a> 114171543 Piersen C, et al. http://www.ncbi.nlm.nih.gov/pubmed/8663612 <a href="http://www.ncbi.nlm.nih.gov/pubmed/8663612">Piersen C, et al.</a> 114171544 Sobol R, et al. http://www.ncbi.nlm.nih.gov/pubmed/12713817 <a href="http://www.ncbi.nlm.nih.gov/pubmed/12713817">Sobol R, et al.</a> 114171545 Poltoratsky V, et al. http://www.ncbi.nlm.nih.gov/pubmed/17127106 <a href="http://www.ncbi.nlm.nih.gov/pubmed/17127106">Poltoratsky V, et al.</a> 114104456 Prasad, Rajendra NIEHS NIEHS Prasad, Rajendra (NIEHS) 0 114107502 Wilson, Samuel NIEHS NIEHS Wilson, Samuel (NIEHS) 1 114107502 Wilson, Samuel NIEHS NIEHS Wilson, Samuel (NIEHS) 1 114104456 Prasad, Rajendra NIEHS NIEHS Prasad, Rajendra (NIEHS) 0 114099919 Development Of Specific Monoclonal Antibody To Human DNA Poymerase Beta E-036-2008-0 Closed NIEHS 83691647 Chang, Kevin changke@mail.nih.gov
United States of America TTB changke@mail.nih.gov?subject=Web Inquiry on [TAB-2401] Monoclonal Antibodies Targeting Human DNA Polymerase beta, a DNA Repair Enzyme&body=Please send me information about technology [TAB-2401] Monoclonal Antibodies Targeting Human DNA Polymerase beta, a DNA Repair Enzyme. Chang, Kevin<br><a href="mailto:changke@mail.nih.gov?subject=Web Inquiry on [TAB-2401] Monoclonal Antibodies Targeting Human DNA Polymerase beta, a DNA Repair Enzyme&body=Please send me information about technology [TAB-2401] Monoclonal Antibodies Targeting Human DNA Polymerase beta, a DNA Repair Enzyme.">changke@mail.nih.gov</a><br> 114122653 AC5XXX 114122654 CC2XXX 114122655 CDXXXX 114122656 AXXXXX 114122657 ACXXXX 114122658 CXXXXX 114122659 CCXXXX 114142805 DNA 114142806 ANTIBODY 114142807 monoclonal 114142808 polymerase 114142809 Monoclonal Antibody 114142810 monoclonal antibody based assays 114142811 DNA polymerase beta 114142812 DNA polymerase TAB-2404 114096606 mEpoR Knockout/Tg(hEpoR) Mouse Model for Anemia and Renal Function Studies NIDDK Diagnostics, Licensing, Research Materials, Therapeutics Diagnostics Licensing Research Materials Therapeutics Constance Noguchi mEpoR-/- hEpoR+: The mouse Erythropoietin Receptor knockout that contains a human Erythropoietin Receptor transgene can be used to define the potency of recombinant erythropoietin preparations used to treat anemia associated with chronic kidney disease. <br /><br /> Erythropoietin, acting by binding to Erythropoietin receptors (EpoR) on erythroid progenitor cells, is required for erythropoiesis. Absence of erythropoietin or the EpoR in mice interrupts erythropoiesis in the fetal liver and result in death at embryonic day 13.5. An 80-kb human EpoR transgene bred onto a mouse EpoR null background (provided by F. Constantini of Columbia University) restored effective erythropoiesis in the EpoR null mouse. Erythropoietin preparations made utilizing recombinant DNA technology are used in the treatment of anemia in chronic kidney disease and other critical illnesses. The mouse EpoR null mouse containing the human EpoR transgene can be used to define the potency of erythropoietin preparation in humans. Model for study of anemia and renal function and possible drug screening. Research Tool - Patent protection is not being pursued for this technology. 2022-03-08 2024-10-28 2024-10-28 2012-04-19 ACXXXX, AXXXXX, EPO, EpoR, Erythropoietin, ICXXXX, IDXXXX, IXXXXX, Mice, RECEPTOR False True Pre-clinical True NIHTT 37470483 Website Abstract 114171548 Yu X, et al. http://www.ncbi.nlm.nih.gov/pubmed/11435319 <a href="http://www.ncbi.nlm.nih.gov/pubmed/11435319">Yu X, et al.</a> 114107507 Noguchi, Constance National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Noguchi, Constance (NIDDK) 1 114107507 Noguchi, Constance National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Noguchi, Constance (NIDDK) 1 114101706 Mice Expressing Exclusively The Human Erythropoietin Receptor E-127-2001-0 Research Material EM, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NCI 83692066 Tong, Betty tongb@niddk.nih.gov
United States of America Senior Technology Advancement Office tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-2404] mEpoR Knockout/Tg(hEpoR) Mouse Model for Anemia and Renal Function Studies&body=Please send me information about technology [TAB-2404] mEpoR Knockout/Tg(hEpoR) Mouse Model for Anemia and Renal Function Studies. Tong, Betty<br><a href="mailto:tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-2404] mEpoR Knockout/Tg(hEpoR) Mouse Model for Anemia and Renal Function Studies&body=Please send me information about technology [TAB-2404] mEpoR Knockout/Tg(hEpoR) Mouse Model for Anemia and Renal Function Studies.">tongb@niddk.nih.gov</a><br> 114122664 ACXXXX 114122665 IDXXXX 114122666 ICXXXX 114122667 AXXXXX 114122668 IXXXXX 114142827 Mice 114142828 EpoR 114142829 EPO 114142830 Erythropoietin 114142831 RECEPTOR TAB-2400 114096602 Cytochromes P450 CYP2J and CYP2C Polyclonal Antibodies and Recombinant Proteins NIEHS Collaboration, Diagnostics, Research Materials, Therapeutics Collaboration Diagnostics Research Materials Therapeutics Darryl Zeldin The National Institutes of Health announces polyclonal antibodies against mouse cytochrome P450s CYP2J and CYP2C. Cytochrome P450s catalyze the metabolism of a wide range of exogenous compounds, including drugs, industrial chemicals, environmental pollutants, and carcinogens. The 2C family of cytochrome P450 metabolizes an extensive number of drugs which include tolbutamide, S-Warfarin, mephenytoin, diazepam and taxol. Many of the P450 enzymes are also active in the NADPH-dependent oxidation of arachidonic acid to various eicosanoids found in several species. The 2J family is expressed at high levels in the heart and has been shown to metabolize both arachidonic acid and linoleic acid. The CYP2J and CYP2C subfamily members have a wide tissue distribution and may be useful as model systems for studies of cardiovascular disease, drug metabolism and toxicity.<br /><br /> Recombinant proteins of mouse cytochrome P450s CYP2C and CYP2J have also been expressed and can be used as controls in immunoblotting, as well as for metabolism studies. <ul> <li>The CYP2J and CYP2C subfamily members have a wide tissue distribution and may be useful as model systems for studies of cardiovascular disease, drug metabolism and toxicity.</li> </ul> <ul> <li>These antibodies can be used to study the expression of the P450s in various tissues by immunohistochemistry and immunoblotting.</li> <li>The recombinant proteins can be used as controls in immunoblotting as well as for metabolism studies.</li> </ul> The NIEHS is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize antibodies against mouse cytochrome P450s CYP2J and CYP2C. For collaboration opportunities, please contact Sharon Soucek, Ph.D. at <a href="mailto:sharon.soucek@nih.gov">sharon.soucek@nih.gov</a>. Research Material — Patent protection has not been pursued for this technology. 2022-03-08 2024-10-28 2024-10-28 2012-04-18 antibodies, CYP2C, CYP2J, CYTOCHROMES, IDXXXX, IXXXXX, P450, polyclonal, proteins, recombinant False True In vitro data available True NIHTT 37470483 Website Abstract 114107504 Zeldin, Darryl NIEHS NIEHS Zeldin, Darryl (NIEHS) 1 114107504 Zeldin, Darryl NIEHS NIEHS Zeldin, Darryl (NIEHS) 1 114101702 Cytochromes P450 CYP2J Polyclonal Antibodies And Recombinant Proteins E-153-2011-0 Research Material NIEHS 83739538 Choudhry, Vidita vidita.choudhry@nih.gov
United States of America Office of Technology Transfer and Development vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-2400] Cytochromes P450 CYP2J and CYP2C Polyclonal Antibodies and Recombinant Proteins&body=Please send me information about technology [TAB-2400] Cytochromes P450 CYP2J and CYP2C Polyclonal Antibodies and Recombinant Proteins. Choudhry, Vidita<br><a href="mailto:vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-2400] Cytochromes P450 CYP2J and CYP2C Polyclonal Antibodies and Recombinant Proteins&body=Please send me information about technology [TAB-2400] Cytochromes P450 CYP2J and CYP2C Polyclonal Antibodies and Recombinant Proteins.">vidita.choudhry@nih.gov</a><br> 114122649 IDXXXX 114122650 IXXXXX 114142773 CYTOCHROMES 114142774 P450 114142775 CYP2J 114142776 CYP2C 114142777 polyclonal 114142778 antibodies 114142779 recombinant 114142780 proteins TAB-2383 114096585 Small-Molecule Inhibitors of Human Galactokinase for the Treatment of Galactosemia and Cancers NCATS Collaboration, Diagnostics, Oncology, Rare/Neglected Diseases, Research Materials, Therapeutics Collaboration Diagnostics Oncology Rare/Neglected Diseases Research Materials Therapeutics Matthew Boxer Lactose, found in dairy products and other foods, is comprised of two simple sugars, glucose and galactose. In galactosemia, where galactose is not properly metabolized, build-up of toxic compounds, such as galactose-1-phosphate, can lead to liver disease, renal failure, cataracts, brain damage, and even death if this disorder is left untreated. Currently, the only treatment for galactosemia is elimination of lactose and galactose from the diet, but in some cases this is not sufficient to avoid long-term complications from the disorder.<br /><br /> This technology describes selective small-molecule inhibitors of human galactokinase, which inhibit the first step in galactose metabolism. These compounds could be used to treat galactosemia by eliminating the build-up of toxic metabolites in brain, liver and other tissues, and could form the basis for the first effective treatment for this disorder.<br /><br /> These inhibitors are also promising candidates for the treatment of certain cancers, such as PTEN/AKT misregulated cancers. The inventors have already shown that the inhibitors are cytotoxic for several cancer cell lines. <ul> <li>There is currently no effective treatment for classic galactosemia, where dietary restriction cannot prevent long-term complications in some cases.</li> <li>Cancer therapeutics based on these inhibitors are predicted to have minimal side-effects.</li> </ul> <ul> <li>Treatment of galactosemia</li> <li>Treatment of certain cancers, such as PTEN/AKT misregulated cancers</li> </ul> The National Center for Advancing Translational Sciences is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize Small-Molecule Inhibitors of Human Galactokinase for the Treatment of Galactosemia and Cancers. For collaboration opportunities, please contact the NCATS Office of Strategic Alliances at <a href="mailto:NCATSPartnerships@mail.nih.gov">NCATSPartnerships@mail.nih.gov</a>. 2022-03-08 2024-10-28 2024-10-28 2012-03-02 AKT, CANCER, CB7XXX, CBXXXX, CXXXXX, Galactokinase, Galactose, Galactosemia, IBXXXX, Inhibitors, IXXXXX, lactose, Metabolism, PTEN, rare disease, small molecule, UAXXXX False True <ul> <li>Early-stage</li> <li>In vitro data available</li> </ul> True NIHTT 37470483 Website Abstract 114107464 Boxer, Matthew National Human Genome Research Institute (NHGRI) Boxer, Matthew 1 114107464 Boxer, Matthew National Human Genome Research Institute (NHGRI) Boxer, Matthew 1 114101684 Human Galactokinase Inhibitors For The Treatment Of Galactosemia And Cancers E-240-2011-0 Filing authorized NCATS - NCGC, University of Utah 83727060 Gadhia, Ami ami.gadhia@nih.gov
United States of America NCGC ami.gadhia@nih.gov?subject=Web Inquiry on [TAB-2383] Small-Molecule Inhibitors of Human Galactokinase for the Treatment of Galactosemia and Cancers&body=Please send me information about technology [TAB-2383] Small-Molecule Inhibitors of Human Galactokinase for the Treatment of Galactosemia and Cancers. Gadhia, Ami<br><a href="mailto:ami.gadhia@nih.gov?subject=Web Inquiry on [TAB-2383] Small-Molecule Inhibitors of Human Galactokinase for the Treatment of Galactosemia and Cancers&body=Please send me information about technology [TAB-2383] Small-Molecule Inhibitors of Human Galactokinase for the Treatment of Galactosemia and Cancers.">ami.gadhia@nih.gov</a><br> 114163308 E-240-2011-0 E-240-2011-0-PCT-01 Galactokinase Inhibitors For The Treatment And Prevention Of Associated Diseases And Disorders PCT Patent Cooperation Treaty PCT/US2011/053021 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2011/053021<br />Filed on 2011-09-23<br />Status: Expired 114166061 E-240-2011-0 E-240-2011-0-US-03 GALACTOKINASE INHIBITORS FOR THE TREATMENT AND PREVENTION OF ASSOCIATED DISEASES AND DISORDERS CON US 15/234,934 Abandoned US <br />Continuation (CON) 15/234,934<br />Filed on 2016-08-11<br />Status: Abandoned 114167724 E-240-2011-0 E-240-2011-0-US-02 Galactokinase Inhibitors For The Treatment and Prevention of Associated Diseases and Disorders National Stage US 9,447,087 14/346,400 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9447087 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9447087">9,447,087</a><br />Filed on 2014-03-21<br />Status: Issued 114168843 E-240-2011-0 E-240-2011-0-US-04 Human Galactokinase Inhibitors For The Treatment Of Galactosemia And Cancers CON US 10,471,061 16/152,735 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10471061 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10471061">10,471,061</a><br />Filed on 2018-10-05<br />Status: Issued 114122588 IBXXXX 114122589 CB7XXX 114122590 UAXXXX 114122591 IXXXXX 114122592 CXXXXX 114122593 CBXXXX 114142608 CANCER 114142609 Galactokinase 114142610 Inhibitors 114142611 Galactosemia 114142612 PTEN 114142613 AKT 114142614 rare disease 114142615 small molecule 114142616 Galactose 114142617 lactose 114142618 Metabolism TAB-2386 114096589 Personalized Body Weight Management System Using Monitoring Devices and Mathematical Models of Metabolism NIDDK Collaboration, Diagnostics, Licensing, Research Materials, Therapeutics Collaboration Diagnostics Licensing Research Materials Therapeutics Kevin Hall Attempts to manage body weight are often unsuccessful or only temporary. This is, in part, due to antiquated dieting methods that attempt to address calorie consumption while ignoring metabolic and physical changes. Personalized and more comprehensive methods to track and manage body weight may be more effective. To that end, scientists at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) developed and launched the Body Weight Planner (<a href="http://www.niddk.nih.gov/health-information/weight-management/body-weight-planner" target="_blank" title="Body Weight Planner webpage">http://www.niddk.nih.gov/health-information/weight-management/body-weight-planner</a>) that uses validated mathematical models of human metabolism to set weight management goals and predict individual body weight outcomes in the context of changing metabolic needs and calorie consumption. <br /><br /> More recently, developers at NIDDK have created a prototype personalized body weight management system that builds on the science behind Body Weight Planner with the addition of patented tracking and feedback technology. This new system is targeted for use by professionals and is designed to be integrated into a comprehensive healthcare or wellness program. Improvements enable users to more accurately plan, track, and update personalized weight management interventions by accounting for changes in human appetite, metabolism, and calorie expenditure over time. There are opportunities for the prototype to be combined with other devices to provide data input through wearables and at-home measurements. This system provides meaningful feedback through enhanced functionality and features to meet weight management goals. The NIDDK Laboratory of Biological Modeling is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize this technology. For collaboration opportunities or licensing inquaries, please contact Ediz Yonter at <a href="mailto:ediz.yonter@niddk.nih.gov">ediz.yonter@niddk.nih.gov</a>. 2022-03-08 2024-10-28 2024-10-28 2021-07-02 2021-07-01 ADXXXX, AXXXXX, Body, CONTROL, FEEDBACK, IA6XXX, IAXXXX, IXXXXX, Model-based, Personalized, System, Weight False True True NIHTT 37470483 Website Abstract E-160-2012-0 114171512 Hall KD, et al. http://www.ncbi.nlm.nih.gov/pubmed/21872751 <a href="http://www.ncbi.nlm.nih.gov/pubmed/21872751">Hall KD, et al.</a> 114171513 Hall KD and Chow CC. http://www.ncbi.nlm.nih.gov/pubmed/21562087 <a href="http://www.ncbi.nlm.nih.gov/pubmed/21562087">Hall KD and Chow CC.</a> 114171514 Hall KD. http://www.ncbi.nlm.nih.gov/pubmed/19934407 <a href="http://www.ncbi.nlm.nih.gov/pubmed/19934407">Hall KD.</a> 114105771 Hall, Kevin National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Hall, Kevin (NIDDK) 1 114105771 Hall, Kevin National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Hall, Kevin (NIDDK) 1 114101387 System For Personalized, Model-based, Feedback Control Of Body Weight E-063-2012-0 Filing authorized National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83739611 Yonter, Ediz ediz.yonter@nih.gov
United States of America Technology Advancement Office ediz.yonter@nih.gov?subject=Web Inquiry on [TAB-2386] Personalized Body Weight Management System Using Monitoring Devices and Mathematical Models of Metabolism&body=Please send me information about technology [TAB-2386] Personalized Body Weight Management System Using Monitoring Devices and Mathematical Models of Metabolism. Yonter, Ediz<br><a href="mailto:ediz.yonter@nih.gov?subject=Web Inquiry on [TAB-2386] Personalized Body Weight Management System Using Monitoring Devices and Mathematical Models of Metabolism&body=Please send me information about technology [TAB-2386] Personalized Body Weight Management System Using Monitoring Devices and Mathematical Models of Metabolism.">ediz.yonter@nih.gov</a><br> 114165992 E-063-2012-0 E-063-2012-0-US-01 Personalized Dynamic Feedback Control of Body Weight PRV US 61/592,325 Abandoned US <br />Provisional (PRV) 61/592,325<br />Filed on 2012-01-30<br />Status: Abandoned 114166989 E-063-2012-0 E-063-2012-0-US-02 Personalized Dynamic Feedback Control Of Body Weight ORD US 9,569,483 13/754,058 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9569483 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9569483">9,569,483</a><br />Filed on 2013-01-30<br />Status: Abandoned 114122599 ADXXXX 114122600 IA6XXX 114122601 AXXXXX 114122602 IXXXXX 114122603 IAXXXX 114142648 System 114142649 Personalized 114142650 Model-based 114142651 FEEDBACK 114142652 CONTROL 114142653 Body 114142654 Weight TAB-2373 114096576 Non-toxic Compounds that Inhibit the Formation and Spreading of Tumors NCATS Collaboration, Licensing, Oncology, Therapeutics Collaboration Licensing Oncology Therapeutics Samarjit Patnaik Available for licensing are novel pyrrolopyrimidine compounds that disrupt the assembly of the perinucleolar compartment (PNC), a sub-nuclear structure highly prevalent in metastatic tumors. These notable compounds act without overt cytotoxicity.<br /><br /> The presence of the PNC positively correlates with metastatic capacity, making it a potential marker for cancer development and prognosis. These compounds could also serve as useful tools to elucidate the biology driving the formation and maintenance of the PNC, and unravel its association with metastasis. <ul> <li>No existing FDA-approved treatment for the clinical management of metastasis</li> <li>Target is specific to metastatic tumors</li> <li>Compounds are not toxic</li> <li>Broadly acting across all metastatic cancers</li> </ul> <ul> <li>Use in the therapeutic intervention of metastasis in cancer</li> <li>Use as tools to elucidate the biology of the PNC</li> </ul> The National Center for Advancing Translational Sciences is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize this technology. For collaboration opportunities, please contact the NCATS Office of Strategic Alliances at <a href="mailto:NCATSPartnerships@mail.nih.gov">NCATSPartnerships@mail.nih.gov</a>. 2022-03-08 2024-10-28 2024-10-28 2012-02-22 CB5EXX, CB5XXX, CBXXXX, CXXXXX, Metastasis, MODULATORS, Patent Category - Chemistry, PNC, small molecule, Tumorgenesis False True <ul> <li>Early-stage</li> <li>In vitro data available</li> </ul> True NIHTT 37470483 Website Abstract 114107438 Patnaik, Samarjit National Human Genome Research Institute (NHGRI) NCATS Patnaik, Samarjit (NCATS) 1 114107438 Patnaik, Samarjit National Human Genome Research Institute (NHGRI) NCATS Patnaik, Samarjit (NCATS) 1 114101675 PNC Modulators For The Treatment Of Metastasis And Tumorgenesis E-276-2011-0 Filing authorized NCATS - NCGC, Northwestern University, University of Kansas 83682485 Vepa, Suryanarayana sury.vepa@nih.gov
United States of America Office of Strategic Alliances (OSA) sury.vepa@nih.gov?subject=Web Inquiry on [TAB-2373] Non-toxic Compounds that Inhibit the Formation and Spreading of Tumors&body=Please send me information about technology [TAB-2373] Non-toxic Compounds that Inhibit the Formation and Spreading of Tumors. Vepa, Suryanarayana<br><a href="mailto:sury.vepa@nih.gov?subject=Web Inquiry on [TAB-2373] Non-toxic Compounds that Inhibit the Formation and Spreading of Tumors&body=Please send me information about technology [TAB-2373] Non-toxic Compounds that Inhibit the Formation and Spreading of Tumors.">sury.vepa@nih.gov</a><br> 114166636 E-276-2011-0 E-276-2011-0-US-01 Compounds And Methods For The Prevention And Treatment of Tumor Metastasis And Tumorigenesis PRV US 61/576,780 Abandoned US <br />Provisional (PRV) 61/576,780<br />Filed on 2011-12-16<br />Status: Abandoned 114167209 E-276-2011-0 E-276-2011-0-PCT-02 Compounds And Methods For The Prevention And Treatment Of Metastasis And Tumorgenesis PCT Patent Cooperation Treaty PCT/US2012/070155 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2012/070155<br />Filed on 2012-12-17<br />Status: Expired 114167851 E-276-2011-0 E-276-2011-0-US-07 Compounds and Methods for the Prevention and Treatment of Tumor Metastasis and Tumorigenesis National Stage US 9,663,521 14/364,759 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9663521 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9663521">9,663,521</a><br />Filed on 2014-06-12<br />Status: Issued 114168283 E-276-2011-0 E-276-2011-0-US-08 COMPOUNDS AND METHODS FOR THE PREVENTION AND TREATMENT OF TUMOR METASTASIS AND TUMORIGENESIS CON US 10,301,314 15/606,740 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10301314 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10301314">10,301,314</a><br />Filed on 2017-05-26<br />Status: Issued 114122551 CB5EXX 114122552 CXXXXX 114122553 CBXXXX 114122554 CB5XXX 114142516 PNC 114142517 MODULATORS 114142518 Metastasis 114142519 Tumorgenesis 114142520 Patent Category - Chemistry 114142521 small molecule TAB-2357 114096561 Transgenic Human Interleukin-21 Mouse Model NHLBI Diagnostics, Licensing, Oncology, Research Materials, Therapeutics Diagnostics Licensing Oncology Research Materials Therapeutics Warren Leonard, Katsutoshi Ozaki Available for licensing is a mouse model that constitutively expresses human interleukin-21 (IL-21). Traditionally, human IL-21 transgenic mouse models are difficult to produce as those with high IL-21 levels exhibit growth retardation and die before sexual maturity. The investigators generated transgenic mice that express human IL-21, which can stimulate murine cells <i>in vitro</i> thereby providing an accurate model to elucidate IL-21's role in immunity, immune disorders, and cancer.<br /><br /> IL-21 is a type I cytokine whose receptor is expressed on T, B, and natural killer cells. IL-21 has pleiotropic actions ranging from augmenting the proliferation of T cells to driving the differentiation of B cells into memory cells and terminally differentiated plasma cells. Moreover, IL-21 has anti-tumor activity by augmenting natural killer cell activity. This mouse model allows studying human IL-21 <i>in vivo</i> and its role in a variety of diseases such as autoimmunity, immunodeficiency, allergy, and cancer. Mouse model that constitutively expresses human IL-21, without the negative side effects of growth retardation and high toxicity present in other human IL-21 transgenic mice. <ul> <li>Model to study human IL-21 <i>in vivo</i></li> <li>Research tool to elucidate IL-21's role in T, B, and natural killer cell function and regulating antibody production</li> <li>Model to study IL-21's pathology in autoimmunity, immunodeficiency, allergy, and cancer</li> </ul> Research Tool — Patent protection is not being pursued for this technology. 2022-03-08 2024-10-28 2024-10-28 2012-01-18 AC5XXX, ACXXXX, AXXXXX, CCXXXX, CXXXXX, IDXXXX, IL-21, INTERLEUKIN, interleukin 21, IXXXXX, Mice, Mouse, Mouse animal model, mouse model, TRANSGENIC False True <ul> <li>Pre-clinical</li> <li>In vivo data available (animal)</li> </ul> True NIHTT 37470483 Website Abstract E-211-2002-1 E-120-2003-1 E-120-2003-2 114171483 Ozaki K, et al. http://www.ncbi.nlm.nih.gov/pubmed/15494482 <a href="http://www.ncbi.nlm.nih.gov/pubmed/15494482">Ozaki K, et al.</a> 114107404 Ozaki, Katsutoshi Ozaki, Katsutoshi 0 114107405 Leonard, Warren National Heart, Lung, and Blood Institute (NHLBI) NHLBI Leonard, Warren (NHLBI) 1 114107405 Leonard, Warren National Heart, Lung, and Blood Institute (NHLBI) NHLBI Leonard, Warren (NHLBI) 1 114107404 Ozaki, Katsutoshi Ozaki, Katsutoshi 0 114101659 Development Of IL-21 Transgenic Mice E-231-2010-0 Research Material National Heart, Lung, and Blood Institute (NHLBI) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-2357] Transgenic Human Interleukin-21 Mouse Model&body=Please send me information about technology [TAB-2357] Transgenic Human Interleukin-21 Mouse Model. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-2357] Transgenic Human Interleukin-21 Mouse Model&body=Please send me information about technology [TAB-2357] Transgenic Human Interleukin-21 Mouse Model.">shmilovm@nih.gov</a><br> 114122469 AXXXXX 114122470 IDXXXX 114122471 AC5XXX 114122472 CCXXXX 114122473 IXXXXX 114122474 CXXXXX 114122475 ACXXXX 114142364 IL-21 114142365 TRANSGENIC 114142366 Mice 114142367 interleukin 21 114142368 INTERLEUKIN 114142369 Mouse 114142370 mouse model 114142371 Mouse animal model TAB-2372 114096575 Model Cell Lines With and Without AKT1 Mutations Derived from Proteus Syndrome Patients NHGRI Licensing, Oncology, Research Materials Licensing Oncology Research Materials Leslie Biesecker, Marjorie Lindhurst The Proteus syndrome is a congenital disorder characterized by patchy overgrowth and hyperplasia (cell proliferation) of multiple tissues and organs, along with susceptibility to developing tumors. It is a rare disorder, with incidence of less than one case per million, caused by a somatic mutation. It is also a mosaic disorder, that is one in which cells of the same person have different genetic content from one another. The NHGRI inventors have generated cell lines from patients with Proteus syndrome and discovered that a somatic activating mutation in the serine-threonine kinase AKT1 is associated with Proteus syndrome. AKT1 is an oncogene and an enzyme known to mediate cell proliferation and apoptosis (programmed cell death process) and has been a target for anti-cancer therapies. A number of single-cell lines with the AKT1 mutation showing increased AKT1 phosphorylation and their matched controls without the mutation have been generated. The cell lines can be used to screen therapeutic targets for AKT1, for study design, as models of Proteus syndrome and early stages of cancerous conditions. <ul> <li>Screening of potential therapeutics that target AKT1</li> <li>Cell lines have well-matched controls for rigorous study design</li> <li>Serves as model cell lines of Proteus syndrome and early stages of cancerous conditions</li> </ul> <ul> <li>Cell lines generated from patients with Proteus syndrome</li> <li>Obtained a number of single-cell lines with the AKT1 mutation and their matched controls without the mutation</li> <li>Cell lines with the mutation showed increased AKT1 phosphorylation for activating mutation</li> </ul> Research Tool — Patent protection is not being pursued for this technology. 2022-03-08 2024-10-28 2024-10-28 2012-02-22 CC3AXX, CCXXXX, CXXXXX, DERIVED, Lines, Patients, Proteus, Single-cell, Syndrome False True <ul> <li>Prototype</li> <li>Clinical</li> <li>In vivo data available (human)</li> </ul> True NIHTT 37470483 Website Abstract 114171500 Lindhurst MJ, et al. http://www.ncbi.nlm.nih.gov/pubmed/21793738 <a href="http://www.ncbi.nlm.nih.gov/pubmed/21793738">Lindhurst MJ, et al.</a> 114107439 Lindhurst, Marjorie National Human Genome Research Institute (NHGRI) NHGRI Lindhurst, Marjorie (NHGRI) 0 114107440 Biesecker, Leslie National Human Genome Research Institute (NHGRI) NHGRI Biesecker, Leslie (NHGRI) 1 114107440 Biesecker, Leslie National Human Genome Research Institute (NHGRI) NHGRI Biesecker, Leslie (NHGRI) 1 114107439 Lindhurst, Marjorie National Human Genome Research Institute (NHGRI) NHGRI Lindhurst, Marjorie (NHGRI) 0 114101674 Single-cell Lines Derived From Proteus Syndrome Patients E-033-2012-0 Research Material National Human Genome Research Institute (NHGRI) 83716782 Campbell, Eggerton eggerton.campbell@nih.gov
United States of America eggerton.campbell@nih.gov?subject=Web Inquiry on [TAB-2372] Model Cell Lines With and Without AKT1 Mutations Derived from Proteus Syndrome Patients&body=Please send me information about technology [TAB-2372] Model Cell Lines With and Without AKT1 Mutations Derived from Proteus Syndrome Patients. Campbell, Eggerton<br><a href="mailto:eggerton.campbell@nih.gov?subject=Web Inquiry on [TAB-2372] Model Cell Lines With and Without AKT1 Mutations Derived from Proteus Syndrome Patients&body=Please send me information about technology [TAB-2372] Model Cell Lines With and Without AKT1 Mutations Derived from Proteus Syndrome Patients.">eggerton.campbell@nih.gov</a><br> 114122548 CXXXXX 114122549 CCXXXX 114122550 CC3AXX 114142510 Single-cell 114142511 Lines 114142512 DERIVED 114142513 Proteus 114142514 Syndrome 114142515 Patients TAB-2342 114096544 Biomarkers for Cancer-Related Fatigue and Their Use in the Management of Such Fatigue (CRF) NINR Diagnostics, Licensing, Oncology Diagnostics Licensing Oncology Leorey Saligan The invention relates to the diagnosis and management of cancer-related fatigue (CRF). More specifically the invention relates to identification and measurement of a single Biomarker or a group of biomarkers (e.g. genes) that are associated with cancer related fatigue. The identification and measurement of such biomarkers can be utilized in the diagnosis and management of fatigue and may facilitate the development of therapy for such fatigue. In particular, the invention provides for a method of diagnosing a subject with CRF by detecting expression of at least one gene associated with CRF in a sample obtained from the subject; and comparing expression of the gene to a control. The invention also describes a method of treating a patient with CRF by administering to the subject an agent that alters expression or activity of a gene associated with CRF. Further provided in the invention is array that includes a plurality of genes associated with CRF, such as TNFRSF25, SLC6A8, OGT, SNCA, APBA2, CASK, OR2W3, MYL4, IL7R, ARHGEF10 and ITGA6. Some of these genes are over expressed in a CRF patient (e.g., SNCA and SLC6A8) while others (e.g., IL7R, ARHGEF10) are under expressed. The array can provide detailed and comprehensive information that can result in improved diagnostics and in increased options for therapeutic treatment. <ul> <li>The technology provides for an array of multiple biomarkers, all associated with CRF. Thus it may offer a more detailed and accurate diagnosis of CRF as well as larger number of therapeutic options.</li> <ul> <li>Diagnostics and therapeutic of cancer-related fatigue.</li> </ul> 2022-03-08 2024-10-28 2024-10-28 2011-12-02 CA1AXX, CA1XXX, CAXXXX, Chain, CHIP, CXXXXX, Fatigue, polymerase, REACTION False True <ul> <li>In vitro data available (animal)</li> <li>In vivo data available (human)</li> </ul> True NIHTT 37470483 Website Abstract 114107373 Saligan, Leorey NINR NIMH Saligan, Leorey (NIMH) 1 114107373 Saligan, Leorey NINR NIMH Saligan, Leorey (NIMH) 1 114099511 Fatigue Polymerase Chain Reaction Chip E-280-2010-0 Filing authorized NINR 89788013 Kolesnitchenko, Vincent vk5q@nih.gov
United States of America Office of Technology Transfer and Development vk5q@nih.gov?subject=Web Inquiry on [TAB-2342] Biomarkers for Cancer-Related Fatigue and Their Use in the Management of Such Fatigue (CRF)&body=Please send me information about technology [TAB-2342] Biomarkers for Cancer-Related Fatigue and Their Use in the Management of Such Fatigue (CRF). Kolesnitchenko, Vincent<br><a href="mailto:vk5q@nih.gov?subject=Web Inquiry on [TAB-2342] Biomarkers for Cancer-Related Fatigue and Their Use in the Management of Such Fatigue (CRF)&body=Please send me information about technology [TAB-2342] Biomarkers for Cancer-Related Fatigue and Their Use in the Management of Such Fatigue (CRF).">vk5q@nih.gov</a><br> 114161000 E-280-2010-0 E-280-2010-0-US-01 Biomarkers For Cancer-Related Fatigue And Use Thereof PRV US 61/442,605 Abandoned US <br />Provisional (PRV) 61/442,605<br />Filed on 2011-02-14<br />Status: Abandoned 114166653 E-280-2010-0 E-280-2010-0-US-02 Biomarkers For Cancer-Related Fatigue And Use Thereof ORD US 8,597,883 13/396,465 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8597883 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8597883">8,597,883</a><br />Filed on 2012-02-14<br />Status: Issued 114122399 CA1AXX 114122401 CXXXXX 114122402 CAXXXX 114122403 CA1XXX 114142214 Fatigue 114142215 polymerase 114142216 Chain 114142217 REACTION 114142218 CHIP TAB-2341 114096546 Fibroblast Growth Factor Receptor 1 (Fgfr1) Conditional Knock Out Mouse NIDDK Licensing Licensing Chuxia Deng Scientists at NIDDK have developed a fibroblast growth factor receptor 1 (Fgfr1) conditional knock out mouse. Fgfr1 is a member of the Fgfr family of transmembrane protein receptors with intrinsic tyrosine kinase activity. Fgfr1 is important in multiple biological processes, including mesoderm induction and patterning, cell growth and migration, organ formation and bone growth. Fgfr1 is highly expressed in central nervous system tissues and plays a critical role in proliferation, migration, and survival of neurons and glial cells. Additionally, overexpression of Fgfr1 has been associated with mammary gland transformation and may be crucial for the development of some cancers. The Fgfr1 conditional knockout mouse can be used to study development and biological processes in a variety of tissues and can provide information on signaling pathways that interact with Fgfr1 to induce genes important for critical cellular events, such as proliferation, differentiation, adhesion, movement, survival, and transformation. <ul> <li>Unlike Fgfr1 null mice that are embryonic lethal, Fgfr1 conditional knockout mice are viable and can be used to study the role of Fgfr1 in tissue and organ development.</li> <li>Mice carrying the Fgfr1 conditional knockout mutation can be cross-bred using, for example, Cre-expressing mice to generate tissue specific knockouts of Fgfr1 and used for more detailed tissue studies of Fgfr1 signaling.</li> </ul> <ul> <li>Basic research tool to investigate intracellular pathways dependent on Fgfr1.</li> <li>Tool to study skeletal and neural development.</li> <li>Model of stress-related environments such as bone fractures or tumorigenic induction.</li> </ul> Research Tool — Patent protection is not being pursued for this technology. 2022-03-08 2024-10-28 2024-10-28 2011-12-02 1, AC5XXX, ACXXXX, AXXXXX, Conditional, factor, FGFR1, Fibroblast, Growth, Knockout, Mice, RECEPTOR False True In vivo data available (animal) True NIHTT 37470483 Website Abstract 114171447 Xu X, et al. https://www.ncbi.nlm.nih.gov/pubmed/11857785 <a href="https://www.ncbi.nlm.nih.gov/pubmed/11857785">Xu X, et al.</a> 114107374 Deng, Chuxia National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Deng, Chuxia (NIDDK) 1 114107374 Deng, Chuxia National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Deng, Chuxia (NIDDK) 1 114099512 Fibroblast Growth Factor Receptor 1 (FGFR1) Conditional Knockout Mice E-071-2011-0 Research Material National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83692066 Tong, Betty tongb@niddk.nih.gov
United States of America Senior Technology Advancement Office tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-2341] Fibroblast Growth Factor Receptor 1 (Fgfr1) Conditional Knock Out Mouse&body=Please send me information about technology [TAB-2341] Fibroblast Growth Factor Receptor 1 (Fgfr1) Conditional Knock Out Mouse. Tong, Betty<br><a href="mailto:tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-2341] Fibroblast Growth Factor Receptor 1 (Fgfr1) Conditional Knock Out Mouse&body=Please send me information about technology [TAB-2341] Fibroblast Growth Factor Receptor 1 (Fgfr1) Conditional Knock Out Mouse.">tongb@niddk.nih.gov</a><br> 114122397 ACXXXX 114122398 AXXXXX 114122400 AC5XXX 114142205 Fibroblast 114142206 Growth 114142207 factor 114142208 RECEPTOR 114142209 1 114142210 FGFR1 114142211 Conditional 114142212 Knockout 114142213 Mice TAB-2330 114096534 Protease Deficient Bacillus anthracis with Improved Recombinant Protein Yield Capabilities NIAID Collaboration, Infectious Disease, Research Materials, Therapeutics, Vaccines Collaboration Infectious Disease Research Materials Therapeutics Vaccines Stephen Leppla, Andrei Pomerantsev Species of <em>Bacillus</em>, such as <em>Bacillus anthracis</em>, <em>Bacillus cereus</em>, and <em>Bacillus subtilis</em>, are attractive microorganisms for recombinant protein production in view of their fast growth rate, high yield, and ability to secrete produced products directly into the medium. <em>Bacillus anthracis</em> is also attractive in view of its ability to produce anthrax toxin and ability to fold proteins correctly. This application claims a <em>B. anthracis</em> strain in which more than one secreted protease is inactivated by genetic modification. Such a protease-deficient <em>B. anthracis</em> has an improved ability to produce recombinant secreted proteins compared to other bacteria, particularly other <em>Bacillus</em>. Improvements include production of intact (i.e., mature full-length) proteins, often at high yield. <ul> <li>Highly efficient production of recombinant proteins</li> <li>Low cost production of recombinant proteins</li> </ul> <ul> <li>Vaccine production</li> <li>Recombinant protein production</li> <li><em>B. anthracis</em> vaccine production</li> </ul> The NIAID is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize <em>B. anthracis</em> vaccines, <i>B. anthracis</i> protein production. For collaboration opportunities, please contact Charles Rainwater at 301-435-8617. 2022-03-08 2024-10-28 2024-10-28 2011-10-21 Anthracis, Anthrax, ATCC, Bacillus, Bacterial, BH460, DB3XXX, DBXXXX, DC4XXX, DC6XXX, DCXXXX, DDXXXX, DEXXXX, DXXXXX, HOST, Improved, production, proteins, toxin, vaccines False True <ul> <li>Early-stage</li> <li>In vitro data available</li> </ul> True NIHTT 37470483 Website Abstract 114171438 Pomerantsev A, et al. http://www.ncbi.nlm.nih.gov/pubmed/21827967 <a href="http://www.ncbi.nlm.nih.gov/pubmed/21827967">Pomerantsev A, et al.</a> 114107336 Leppla, Stephen NIAID - DIR NIAID Leppla, Stephen (NIAID) 0 114107335 Pomerantsev, Andrei NIAID - DIR NIAID Pomerantsev, Andrei (NIAID) 1 114107335 Pomerantsev, Andrei NIAID - DIR NIAID Pomerantsev, Andrei (NIAID) 1 114107336 Leppla, Stephen NIAID - DIR NIAID Leppla, Stephen (NIAID) 0 114101425 Improved Bacterial Host For Production Of Anthrax Toxin Proteins And Vaccines - Bacillus Anthracis, BH460 E-202-2011-0 Filing authorized NIAID 114101638 Improved Bacterial Host For Production Of Anthrax Toxin Proteins And Vaccines - Bacillus Anthracis, BH460 E-202-2011-1 Filing authorized NIAID 91026778 Green, Wade wade.green@nih.gov
United States of America TTIPO wade.green@nih.gov?subject=Web Inquiry on [TAB-2330] Protease Deficient Bacillus anthracis with Improved Recombinant Protein Yield Capabilities&body=Please send me information about technology [TAB-2330] Protease Deficient Bacillus anthracis with Improved Recombinant Protein Yield Capabilities. Green, Wade<br><a href="mailto:wade.green@nih.gov?subject=Web Inquiry on [TAB-2330] Protease Deficient Bacillus anthracis with Improved Recombinant Protein Yield Capabilities&body=Please send me information about technology [TAB-2330] Protease Deficient Bacillus anthracis with Improved Recombinant Protein Yield Capabilities.">wade.green@nih.gov</a><br> 114162602 E-202-2011-1 E-202-2011-1-PCT-02 PROTEASE-DEFICIENT BACILLUS ANTHRACIS PCT Patent Cooperation Treaty PCT/US2012/049321 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2012/049321<br />Filed on 2012-08-02<br />Status: Expired 114165506 E-202-2011-1 E-202-2011-1-US-07 Protease-Deficient Bacillus Anthracis DIV US 10,273,548 15/379,002 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10273548 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10273548">10,273,548</a><br />Filed on 2016-12-14<br />Status: Issued 114166543 E-202-2011-0 E-202-2011-0-US-01 Protease-Deficient Bacillus Anthracis PRV US 61/514,384 Abandoned US <br />Provisional (PRV) 61/514,384<br />Filed on 2011-08-02<br />Status: Abandoned 114166544 E-202-2011-1 E-202-2011-1-US-01 PROTEASE-DEFICIENT BACILLUS ANTHRACIS PRV US 61/521,617 Abandoned US <br />Provisional (PRV) 61/521,617<br />Filed on 2011-08-09<br />Status: Abandoned 114167684 E-202-2011-1 E-202-2011-1-US-06 Protease-Deficient Bacillus Anthracis National Stage US 9,555,064 14/236,430 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9555064 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9555064">9,555,064</a><br />Filed on 2014-01-31<br />Status: Issued 114122348 DXXXXX 114122349 DCXXXX 114122350 DC6XXX 114122351 DC4XXX 114122352 DDXXXX 114122354 DB3XXX 114122355 DEXXXX 114122356 DBXXXX 114142083 Anthrax 114142084 production 114142085 HOST 114142086 Bacterial 114142087 Improved 114142088 Bacillus 114142089 vaccines 114142090 proteins 114142091 toxin 114142092 Anthracis 114142093 BH460 114142094 ATCC TAB-2325 114096529 mGluR5 Tumor Mouse Model NINDS Licensing, Oncology, Research Materials Licensing Oncology Research Materials Kyu Yeong Choi, Katherine Roche Glutamate receptor mGluR5 has been reported to function in the brain. There were no prior reports of it being involved in melanoma. The NIH investigators have discovered that when over expressed in transgenic animals, mGluR5 induces melanoma. The establishment of an mGluR5 tumor mouse model will provide a unique opportunity to help elucidate the mechanisms underlying tumor formation, and allow the study of aggressive melanoma in animals and a screen of potential therapeutics. Such an mGluR5 tumor mouse model is established at the National Institutes of Health and is available for licensing. Tumor mouse model only available from the NIH lab. <ul> <li>Drug screening for melanoma therapeutics</li> <li>Research Tool</li> </ul> Research Tool — Patent protection is not being pursued for this technology 2022-03-08 2024-10-28 2024-10-28 2011-09-29 CCXXXX, CXXXXX, MGluR5, Model, Mouse, RXXXXX, tumor False True <ul> <li>Prototype</li> <li>Pre-clinical</li> <li>In vivo data available (animal)</li> </ul> True NIHTT 37470483 Website Abstract 114171426 Choi KY, et al. http://www.ncbi.nlm.nih.gov/pubmed/21896768 <a href="http://www.ncbi.nlm.nih.gov/pubmed/21896768">Choi KY, et al.</a> 114107323 Choi, Kyu Yeong NINDS Choi, Kyu Yeong 0 114107322 Roche, Katherine NINDS NINDS Roche, Katherine (NINDS) 1 114107322 Roche, Katherine NINDS NINDS Roche, Katherine (NINDS) 1 114107323 Choi, Kyu Yeong NINDS Choi, Kyu Yeong 0 114101633 MGluR5 Tumor Mouse Model E-123-2010-0 Research Material NINDS 83722849 Sharma, Smita smita.sharma@nih.gov
United States of America smita.sharma@nih.gov?subject=Web Inquiry on [TAB-2325] mGluR5 Tumor Mouse Model&body=Please send me information about technology [TAB-2325] mGluR5 Tumor Mouse Model. Sharma, Smita<br><a href="mailto:smita.sharma@nih.gov?subject=Web Inquiry on [TAB-2325] mGluR5 Tumor Mouse Model&body=Please send me information about technology [TAB-2325] mGluR5 Tumor Mouse Model.">smita.sharma@nih.gov</a><br> 114122313 CCXXXX 114122314 RXXXXX 114122315 CXXXXX 114142026 MGluR5 114142027 tumor 114142028 Mouse 114142029 Model TAB-2328 114096532 Human Phospho-Serine134 Glucocorticoid Receptor Polyclonal Antibody: Useful for the Characterization of Glucocorticoid Signaling Processes, e.g., in Cancer and Inflammation NIEHS Collaboration Collaboration Amy Beckley, John Cidlowski The glucocorticoid receptor (GR) functions as a hormone-dependent transcription factor that is involved in the maintenance of basal and stress-related homeostasis. Serine 134 is a newly discovered phosphorylation target on the human glucocorticoid receptor that becomes phosphorylated during stress-activating conditions such as ultraviolet irradiation, nutrient starvation, and oxidative stress. The inventors have developed a rabbit polyclonal antibody that specifically recognizes the Ser 134 phosphorylated form of the human glucocorticoid receptor. This antibody may be particularly useful for a variety of basic research applications, such as the characterization and study of glucocorticoid signaling in cancer, inflammation, and other diseases.<br /><br /> The antibody is available as crude antisera and has been epitope purified; it has cross reactivity with human, rat, and mouse tissues. <ul> <li>Western analysis, immunoprecipitation, and immunofluorescence studies</li> </ul> The NIEHS, Molecular Endocrine Group, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize Human Phospho-Serine134 Glucocorticoid Receptor Polyclonal Antibody. Please contact Sharon Soucek, Ph.D. at <a href-"mailto:sharon.soucek@nih.gov">sharon.soucek@nih.gov</a> for more information. Research Tool – Patent protection is not being pursued for this technology 2022-03-08 2024-10-28 2024-10-28 2011-10-06 AC5XXX, ACXXXX, ANTIBODY, CANCER, Glucocorticoid, Glucocorticoid Receptor, Human, Phospho-Serine134, STRESS, Stress-mediated False True True NIHTT 37470483 Website Abstract 114171436 Galliher-Beckley AJ, et al. http://www.ncbi.nlm.nih.gov/pubmed/21930780 <a href="http://www.ncbi.nlm.nih.gov/pubmed/21930780">Galliher-Beckley AJ, et al.</a> 114107328 Cidlowski, John NIEHS NIEHS Cidlowski, John (NIEHS) 0 114107324 Beckley, Amy NIEHS Beckley, Amy 1 114107324 Beckley, Amy NIEHS Beckley, Amy 1 114107328 Cidlowski, John NIEHS NIEHS Cidlowski, John (NIEHS) 0 114101636 Human Phospho-Serine134 Glucocorticoid Receptor Antibody And Human Phospho-Serine404 Glucocorticoid Receptor Antibody E-182-2011-0 Research Material NIEHS 83739538 Choudhry, Vidita vidita.choudhry@nih.gov
United States of America Office of Technology Transfer and Development vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-2328] Human Phospho-Serine134 Glucocorticoid Receptor Polyclonal Antibody: Useful for the Characterization of Glucocorticoid Signaling Processes, e.g., in Cancer and Inflammation&body=Please send me information about technology [TAB-2328] Human Phospho-Serine134 Glucocorticoid Receptor Polyclonal Antibody: Useful for the Characterization of Glucocorticoid Signaling Processes, e.g., in Cancer and Inflammation. Choudhry, Vidita<br><a href="mailto:vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-2328] Human Phospho-Serine134 Glucocorticoid Receptor Polyclonal Antibody: Useful for the Characterization of Glucocorticoid Signaling Processes, e.g., in Cancer and Inflammation&body=Please send me information about technology [TAB-2328] Human Phospho-Serine134 Glucocorticoid Receptor Polyclonal Antibody: Useful for the Characterization of Glucocorticoid Signaling Processes, e.g., in Cancer and Inflammation.">vidita.choudhry@nih.gov</a><br> 114122335 ACXXXX 114122336 AC5XXX 114142055 Human 114142056 Phospho-Serine134 114142057 Glucocorticoid 114142058 ANTIBODY 114142059 Glucocorticoid Receptor 114142060 CANCER 114142061 STRESS 114142062 Stress-mediated TAB-2319 114096524 Humanized Monoclonal Antibodies Efficient for Neutralization of Tick-Borne Encephalitis Virus (TBEV) NIAID Collaboration, Diagnostics, Infectious Disease, Research Materials, Therapeutics Collaboration Diagnostics Infectious Disease Research Materials Therapeutics Ching-juh Lai, Alexander Pletnev, Robert Purcell TBEV causes serious illnesses from meningitis to meningo-encephalitis, totaling 3,000 cases of hospitalization in Europe and between 5,000-10,000 cases in Russia reported every year. The Far Eastern hemorrhagic TBEV strains are associated with a mortality rate (between 1-2%), higher than other strains isolated in the Siberia or Western Europe. There is a high proportion (up to 46%) of TBEV patients with temporary or permanent neurological sequelae. The number of TBEV infections has increased steadily and TBEV cases have been reported in new areas, probably reflecting an increased spread of vector tick species. Prevention of TBEV infections has been carried out in a few countries in Europe by immunization using an inactivated TBEV vaccine. The vaccine carries a high manufacturing cost and requires a regimen of multiple doses, and for this reason, vaccination is not generally carried out. The materials disclosed are humanized monoclonal antibodies derived from TBEV-neutralizing Fab antibodies isolated from infected chimpanzees by repertoire cloning. One antibody in particular, MAb 2E6, has been demonstrated to bind to and neutralize a TBEV/dengue type 4 virus chimera (via interaction with the TBEV antigenic determinants) as well as the related Langat virus. Protection against TBEV/DEN-4 infection and Langat infection has been demonstrated using animal models of infection. The antibodies disclosed, in particular MAb 2E6, have the potential for use as prophylactic and therapeutic agents against TBEV and Langat virus. Additionally, these antibodies may be suitable as diagnostic reagents for the detection of TBEV and/or Langat virus. <ul> <li>Cost effective alternative to existing vaccine</li> <li>Fully humanized antibody</li> <li>Strongly neutralizing antibody</li> <li>Efficient production methods</li> </ul> <ul> <li>TBEV Prophylaxis</li> <li>TBEV Therapy</li> <li>TBEV Diagnostics </ul> The NIAID is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize TBEV monoclonal antibodies. For collaboration opportunities, please contact Wade Williams at 301-827-0258. Research Tool — Patent protection is not being pursued for this technology 2022-03-08 2024-10-28 2024-10-28 2011-09-29 antibodies, ANTIBODY, Binding/Neutralization, Chimpanzee, DA4BXX, DA4XXX, DAXXXX, DB4BXX, DB4XXX, DBXXXX, DDXXXX, DERIVED, DXXXXX, Efficient, ENCEPHALITIS, FAB, Fragments, HUMANIZED, monoclonal, TBEV, TICK-BORNE, virus False True <ul> <li>Pre-clinical</li> <li>In vitro data available</li> <li>In vivo data available (animal)</li> </ul> True NIHTT 37470483 Website Abstract 114107305 Pletnev, Alexander NIAID - DIR NIAID Pletnev, Alexander (NIAID) 0 114107306 Lai, Ching-juh NIAID - DIR NIAID Lai, Ching-juh (NIAID) 0 114107297 Purcell, Robert NIAID - DIR NIAID Purcell, Robert (NIAID) 1 114107297 Purcell, Robert NIAID - DIR NIAID Purcell, Robert (NIAID) 1 114107305 Pletnev, Alexander NIAID - DIR NIAID Pletnev, Alexander (NIAID) 0 114107306 Lai, Ching-juh NIAID - DIR NIAID Lai, Ching-juh (NIAID) 0 114101627 Humanized Monoclonal Antibodies Derived From Chimpanzee Fab Antibody Fragments Efficient For Binding/Neutralization Of Tick-Borne Encephalitis Virus (TBEV) E-231-2011-0 Research Material NIAID 83643855 Soukas, Peter peter.soukas@nih.gov
United States of America Technology Transfer and Intellectual Property Office peter.soukas@nih.gov?subject=Web Inquiry on [TAB-2319] Humanized Monoclonal Antibodies Efficient for Neutralization of Tick-Borne Encephalitis Virus (TBEV)&body=Please send me information about technology [TAB-2319] Humanized Monoclonal Antibodies Efficient for Neutralization of Tick-Borne Encephalitis Virus (TBEV). Soukas, Peter<br><a href="mailto:peter.soukas@nih.gov?subject=Web Inquiry on [TAB-2319] Humanized Monoclonal Antibodies Efficient for Neutralization of Tick-Borne Encephalitis Virus (TBEV)&body=Please send me information about technology [TAB-2319] Humanized Monoclonal Antibodies Efficient for Neutralization of Tick-Borne Encephalitis Virus (TBEV).">peter.soukas@nih.gov</a><br> 114122290 DXXXXX 114122291 DAXXXX 114122292 DBXXXX 114122293 DDXXXX 114122295 DB4XXX 114122296 DB4BXX 114122297 DA4XXX 114122298 DA4BXX 114141966 HUMANIZED 114141967 monoclonal 114141968 antibodies 114141969 DERIVED 114141970 Chimpanzee 114141971 FAB 114141972 ANTIBODY 114141973 Fragments 114141974 Efficient 114141975 Binding/Neutralization 114141976 TICK-BORNE 114141977 ENCEPHALITIS 114141978 virus 114141979 TBEV TAB-2310 114096514 Transgenic Mice Expressing Human Arginase II Gene in Endothelium: Useful for Studying Atherosclerosis and Other Vasculopathies NHLBI Infectious Disease, Licensing, Research Materials Infectious Disease Licensing Research Materials Alan Remaley, Boris Vaisman Cardiovascular disorders associated with endothelial dysfunction, like atherosclerosis, have decreased endothelial nitric oxide (NO) bioavailability. L-arginine, the primary substrate for endothelial nitric oxide synthase (eNOS), is important in the regulation of NO production. Arginase competes with eNOS for L-arginine and has been implicated in the endothelial dysfunction. NIH investigators have generated transgenic mice with human ArgII (hArgII) gene under control of endothelial-specific Tie2 promoter. In these mice, hArgII was expressed at very high levels in all tissues except liver. Analysis has shown that expression of hArgII was endothelium-specific. Overexpression of hArgII neither led to significant changes in plasma level of arginine, citrulline, NOHA, ADMA, SDMA and ornithine, nor to changes in plasma lipid levels. Level of arginase activity in peritoneal macrophages isolated from the transgenic mice also was also unchanged. However, ArgII overexpression induced signs of endothelial dysfunction. In apoE-knockout mice hArgII led to 2-fold increasing in aortic area with atherosclerotic lesions. The Tie2hArgII transgenic mouse can be useful as a new model for investigating the role of ArgII in endothelial function and development of atherosclerosis. Better model system to study functional significance of arginase II. <ul> <li>Useful to study the role of arginase II gene in endothelium.</li> <li>Useful for testing the drugs for treatment of the endothelial dysfunction related to eNOS insufficiency, including hypertension.</li> <li>Useful to study mechanisms of atherosclerosis.</li> </ul> Research Tool — Patent protection is not being pursued for this technology. 2022-03-08 2024-10-28 2024-10-28 2011-08-30 2, AC5XXX, ACXXXX, Arginase, AXXXXX, DDXXXX, DXXXXX, Endothelial, FUNCTION, Gene, Model, Mouse, Novel, Role, RXXXXX, STUDIES, That False True <ul> <li>Early-stage</li> <li>Pre-clinical</li> <li>In vivo data available (animal)</li> </ul> True NIHTT 37470483 Website Abstract 114171399 Vaisman BL, et al. Abstract 3636: The Effects of Arginase II Overexpression on Endothelial Function in Transgenic Mouse Model. Circulation. 2008 Oct 28;118:S_455. Vaisman BL, et al. Abstract 3636: The Effects of Arginase II Overexpression on Endothelial Function in Transgenic Mouse Model. Circulation. 2008 Oct 28;118:S_455. 114107286 Remaley, Alan NHLBI Remaley, Alan (NHLBI) 0 114107285 Vaisman, Boris National Heart, Lung, and Blood Institute (NHLBI) NHLBI Vaisman, Boris (NHLBI) 1 114107285 Vaisman, Boris National Heart, Lung, and Blood Institute (NHLBI) NHLBI Vaisman, Boris (NHLBI) 1 114107286 Remaley, Alan NHLBI Remaley, Alan (NHLBI) 0 114101619 Novel Mouse Model That Studies The Role Of Arginase 2 Gene In Endothelial Function E-255-2010-0 Research Material National Heart, Lung, and Blood Institute (NHLBI) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-2310] Transgenic Mice Expressing Human Arginase II Gene in Endothelium: Useful for Studying Atherosclerosis and Other Vasculopathies&body=Please send me information about technology [TAB-2310] Transgenic Mice Expressing Human Arginase II Gene in Endothelium: Useful for Studying Atherosclerosis and Other Vasculopathies. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-2310] Transgenic Mice Expressing Human Arginase II Gene in Endothelium: Useful for Studying Atherosclerosis and Other Vasculopathies&body=Please send me information about technology [TAB-2310] Transgenic Mice Expressing Human Arginase II Gene in Endothelium: Useful for Studying Atherosclerosis and Other Vasculopathies.">shmilovm@nih.gov</a><br> 114122246 AXXXXX 114122247 ACXXXX 114122248 AC5XXX 114122249 DXXXXX 114122250 DDXXXX 114122251 RXXXXX 114141873 Novel 114141874 Mouse 114141875 Model 114141876 That 114141877 STUDIES 114141878 Role 114141879 Arginase 114141880 2 114141881 Gene 114141882 Endothelial 114141883 FUNCTION TAB-2295 114096503 An In-Vitro Cell System Useful For Identification of RORgamma Antagonists NIEHS Collaboration, Diagnostics, Research Materials, Therapeutics Collaboration Diagnostics Research Materials Therapeutics Anton Jetten, Yukimasa Takeda The retinoid-related orphan receptors alpha, beta and gamma (RORalpha, beta and gamma , also referred to as NR1F1, 2 and 3, respectively) comprise a distinct subfamily of nuclear receptors. Study of ROR-deficient mice has implicated RORs in the regulation of a number of biological processes and revealed potential roles for these proteins in several pathologies. NIH investigators have developed an in-vitro system using CHO cells stably expressing a TET-On expression vector regulating RORgamma and a RORE-Luciferase reporter. This system allows inducible expression of RORgamma upon addition of doxycycline. Upon its induction RORgamma binds to the RORE in the luciferase reporter plasmid and induces luciferase. This system can be used to identify RORgamma antagonists. This system has been tested successfully in 1536-well plate high throughput analysis. <ul> <li>Novel and unique system to screen and identify chemical and drugs for their RORgamma antagonistic activity.</li> </ul> <ul> <li>Identification of therapeutic compounds to treat asthma, inflammation, and various autoimmune diseases such as osteoarthritis, multiple sclerosis.</li> </ul> The NIEHS, Laboratory of Respiratory Biology, Cell Biology Group, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize retinoid-related orphan receptors (RORs) function in chronic diseases. For collaboration opportunities, please contact Sharon Soucek, Ph.D. at <a href="mailto:sharon.soucek@nih.gov">sharon.soucek@niehs.nih.gov</a>. Research Tool — Patent protection is not being pursued for this technology. Research Tool — RORgamma (RORC) Deficient Mice Which Are Useful for the Study of Lymph Node Organogenesis and Immune Responses (Dr. Anton M. Jetten, NIEHS) 2022-03-08 2024-10-28 2024-10-28 2011-07-27 AC5XXX, ACXXXX, AXXXXX, Cell, Cells, CHO, Co-expressing, DEVELOPED, Expression, IDXXXX, IXXXXX, Reporter., RORC, RORE5-Luciferase, RORgamma, RXXXXX, System, TET-ON, Vector, Vitro False True <ul> <li>Early-stage</li> <li>Pre-clinical</li> <li>In vitro data available</li> </ul> True NIHTT 37470483 Website Abstract E-222-2009-0 114171383 Jetten AM. http://www.ncbi.nlm.nih.gov/pubmed/19381306 <a href="http://www.ncbi.nlm.nih.gov/pubmed/19381306">Jetten AM.</a> 114171384 Yang XO, et al. http://www.ncbi.nlm.nih.gov/pubmed/18164222 <a href="http://www.ncbi.nlm.nih.gov/pubmed/18164222">Yang XO, et al.</a> 114171385 Kurebayashi S, et al. http://www.ncbi.nlm.nih.gov/pubmed/10963675 <a href="http://www.ncbi.nlm.nih.gov/pubmed/10963675">Kurebayashi S, et al.</a> 114107258 Takeda, Yukimasa NIEHS Takeda, Yukimasa 0 114107257 Jetten, Anton NIEHS NIEHS Jetten, Anton (NIEHS) 1 114107257 Jetten, Anton NIEHS NIEHS Jetten, Anton (NIEHS) 1 114107258 Takeda, Yukimasa NIEHS Takeda, Yukimasa 0 114101607 An In Vitro Cell System Was Developed Using CHO Cells Co-expressing A Tet-on RORC (RORgamma) Expression Vector And An (RORE)5-Luciferase Reporter. E-253-2010-0 Research Material NIEHS 83739538 Choudhry, Vidita vidita.choudhry@nih.gov
United States of America Office of Technology Transfer and Development vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-2295] An In-Vitro Cell System Useful For Identification of RORgamma Antagonists&body=Please send me information about technology [TAB-2295] An In-Vitro Cell System Useful For Identification of RORgamma Antagonists. Choudhry, Vidita<br><a href="mailto:vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-2295] An In-Vitro Cell System Useful For Identification of RORgamma Antagonists&body=Please send me information about technology [TAB-2295] An In-Vitro Cell System Useful For Identification of RORgamma Antagonists.">vidita.choudhry@nih.gov</a><br> 114122192 RXXXXX 114122193 IXXXXX 114122194 IDXXXX 114122195 AXXXXX 114122196 ACXXXX 114122197 AC5XXX 114141753 Vitro 114141754 Cell 114141755 System 114141756 DEVELOPED 114141757 CHO 114141758 Cells 114141759 Co-expressing 114141760 TET-ON 114141761 RORC 114141762 RORgamma 114141763 Expression 114141764 Vector 114141765 RORE5-Luciferase 114141766 Reporter. TAB-2287 114096495 Multivalent Vaccines for Rabies Virus and Filoviruses NIAID Diagnostics, Infectious Disease, Licensing, Rare/Neglected Diseases, Research Materials, Vaccines Diagnostics Infectious Disease Licensing Rare/Neglected Diseases Research Materials Vaccines Joseph Blaney, Peter Jahrling, Reed Johnson, Jason Paragas No vaccine candidates against Ebola virus (EBOV) or Marburg virus (MARV) are nearing licensure and the need to develop a safe and efficacious vaccine against filoviruses continues. Whereas several preclinical vaccine candidates against EBOV or MARV exist, their further development is a major challenge based on safety concerns, pre-existing vector immunity, and issues such as manufacturing, dosage, and marketability. The inventors have developed a new platform based on live or chemically inactivated (killed) rabies virus (RABV) virions containing EBOV glycoprotein (GP) in their envelope. In preclinical trials, immunization with such recombinant RABV virions provided excellent protection in mice against lethal challenge with the mouse adapted EBOV and RABV. More specifically, the inventors have developed a trivalent filovirus vaccine based on killed rabies virus virions for use in humans to confer protection from all medically relevant filoviruses and RABV. Two additional vectors containing EBOV Sudan GP or MARV GP are planned to be constructed in addition to the previously developed EBOV Zaire GP containing vaccine. The efficiency of these vaccines against challenge with EBOV, MARV and RABV will be studied in multiple preclinical studies. Live attenuated vaccines are being developed for use in at risk nonhuman primate populations in Africa and inactivated vaccines are being developed for use in humans. <ul> <li>Vaccines are replication deficient and/or inactivated</li> <li>Protection against rabies and Ebola</li> <li>Reliable and cost-effective manufacture</li> <li>No preexisting immunity to vectors</li> <li>No potential vaccine reactogenicity</li> </ul> <ul> <li>Biodefense vaccine</li> <li>Developing country vaccine</li> <li>Multivalent prophylactic Ebola/Marburg/rabies vaccine</li> </ul> 2022-03-08 2024-10-28 2024-10-28 2011-07-26 Against, Bivalent, Confer, DA4BXX, DA4XXX, DAXXXX, DC5BXX, DC5XXX, DC6XXX, DCXXXX, DDXXXX, Dual, DXXXXX, Ebola, Ebola virus disease, INACTIVATED, Live-Attenuated, Marburg hemorrhagic fever, Protection, rabies, That, UAXXXX, vaccines, Viruses False True <ul> <li>Pre-clinical</li> <li><i>In vitro</i> data available</li> <li><i>In vivo data</i> available (animal)</li> </ul> True NIHTT 37470483 Website Abstract 114107239 Paragas, Jason NIAID - DCR NIAID Paragas, Jason (NIAID) 0 114107240 Johnson, Reed NIAID - DIR NIAID Johnson, Reed (NIAID) 0 114107241 Jahrling, Peter US Army Medical Research Institute of Infectious Disease NIAID Jahrling, Peter (NIAID) 0 114107237 Blaney, Joseph NIAID - DIR NIAID Blaney, Joseph (NIAID) 1 114107237 Blaney, Joseph NIAID - DIR NIAID Blaney, Joseph (NIAID) 1 114107239 Paragas, Jason NIAID - DCR NIAID Paragas, Jason (NIAID) 0 114107240 Johnson, Reed NIAID - DIR NIAID Johnson, Reed (NIAID) 0 114107241 Jahrling, Peter US Army Medical Research Institute of Infectious Disease NIAID Jahrling, Peter (NIAID) 0 114101599 Live-Attenuated Or Inactivated Bivalent Vaccines That Confer Dual Protection Against Rabies And Ebola Viruses E-032-2011-0 Filing authorized NIAID, Thomas Jefferson University 91026778 Green, Wade wade.green@nih.gov
United States of America TTIPO wade.green@nih.gov?subject=Web Inquiry on [TAB-2287] Multivalent Vaccines for Rabies Virus and Filoviruses&body=Please send me information about technology [TAB-2287] Multivalent Vaccines for Rabies Virus and Filoviruses. Green, Wade<br><a href="mailto:wade.green@nih.gov?subject=Web Inquiry on [TAB-2287] Multivalent Vaccines for Rabies Virus and Filoviruses&body=Please send me information about technology [TAB-2287] Multivalent Vaccines for Rabies Virus and Filoviruses.">wade.green@nih.gov</a><br> 114166472 E-032-2011-0 E-032-2011-0-US-01 Multivalent Vaccines For Rabies Virus And FiloViruses PRV US 61/439,046 Abandoned US <br />Provisional (PRV) 61/439,046<br />Filed on 2011-02-03<br />Status: Abandoned 114166649 E-032-2011-0 E-032-2011-0-PCT-02 Multivalent Vaccines for Rabies Virus and Filoviruses PCT Patent Cooperation Treaty PCT/US2012/023575 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2012/023575<br />Filed on 2012-02-02<br />Status: Expired 114167383 E-032-2011-0 E-032-2011-0-US-05 Multivalent Vaccines for Rabies Virus and Filoviruses National Stage US 10,849,975 13/983,545 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10849975 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10849975">10,849,975</a><br />Filed on 2014-03-25<br />Status: Issued 114122141 DXXXXX 114122142 DCXXXX 114122143 DC5XXX 114122144 DC5BXX 114122145 DC6XXX 114122146 DDXXXX 114122147 DAXXXX 114122148 DA4XXX 114122149 DA4BXX 114122150 UAXXXX 114141679 Live-Attenuated 114141680 INACTIVATED 114141681 Bivalent 114141682 vaccines 114141683 That 114141684 Confer 114141685 Dual 114141686 Protection 114141687 Against 114141688 rabies 114141689 Ebola 114141690 Viruses 114156794 Ebola virus disease 114157963 Marburg hemorrhagic fever TAB-2276 114096484 Mouse Model and Derived Cells That Hypersecrete Leukemia Inhibitory Factor (LIF) NIEHS Animal Models, Collaboration, Oncology, Research Materials Animal Models Collaboration Oncology Research Materials Perry Blackshear Embryonic stem cells (ESCs) are pluripotent cells that can be cultured indefinitely, and maintain their capability to differentiate into all cell lineages. To maintain these cells as well as various types of related induced stem cells and progenitor cells in culture, Mouse Embryonic Fibroblasts (MEFs) are routinely used as feeder cells, largely to serve as a source of Leukemia Inhibitory Factor (LIF). ESCs can also be cultured without feeders if the medium is supplemented with recombinant LIF and other factors. However, these methods of culturing ESCs suffer from certain drawbacks, such as limited proliferation capacity and variability of primary MEFs. Therefore, finding improved conditions that maintain ESC pluripotency is an area of great interest.<br /><br /> Scientists at NIEHS have now developed a knock-in (KI) mouse model in which LIF is overproduced from its endogenous locus because of increased stability of its mRNA. MEFs and presumably other cells derived from the homozygous mice hypersecrete LIF protein; lesser degrees of overexpression would be expected from heterozygous mice. These mice can be used to study LIF function, including how LIF contributes to various physiological and pathological states. Cells derived from these mice can be used to culture ESCs, as well as other progenitor cells. Cells or genetic material derived from these mice can also be used as sources of LIF for isolation and purification. <ul> <li>Maintenance of ESCs and progenitor cells</li> <li><i>In vivo</i>, cellular and cell-free sources of LIF</li> <li>Sources of LIF for isolation and purification</li> <li>Studies of LIF function in mice, such as contribution of LIF to tumor growth</li> </ul> The NIEHS Laboratory of Signal Transduction is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize these mice or other strains derived from them, or cells or other reagents derived from them. Please contact Sally E. Tilotta, Ph.D. in the NIEHS Office of Technology Transfer at <a href="mailto:sally.tilotta@nih.gov">sally.tilotta@nih.gov</a>) , or the Inventor Dr. Perry Blackshear (<a href="mailto:black009@niehs.nih.gov">black009@niehs.nih.gov</a>) for more information. Research Tool — Patent protection is not being pursued for this technology. 2022-03-08 2024-10-28 2024-10-28 2011-07-01 BAXXXX, CC3XXX, CCXXXX, Cells, CXXXXX, DERIVED, factor, HypersecreteLeukemia, INHIBITORY, Knock-in, LIF., Mice, RXXXXX, That False True True NIHTT 37470483 Website Abstract 114107219 Blackshear, Perry NIEHS NIEHS Blackshear, Perry (NIEHS) 0 114107219 Blackshear, Perry NIEHS NIEHS Blackshear, Perry (NIEHS) 0 114101587 Knock-in Mice And Derived Cells Derived From Them That Hypersecrete Leukemia Inhibitory Factor (LIF) E-175-2011-0 Research Material NIEHS 83739538 Choudhry, Vidita vidita.choudhry@nih.gov
United States of America Office of Technology Transfer and Development vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-2276] Mouse Model and Derived Cells That Hypersecrete Leukemia Inhibitory Factor (LIF)&body=Please send me information about technology [TAB-2276] Mouse Model and Derived Cells That Hypersecrete Leukemia Inhibitory Factor (LIF). Choudhry, Vidita<br><a href="mailto:vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-2276] Mouse Model and Derived Cells That Hypersecrete Leukemia Inhibitory Factor (LIF)&body=Please send me information about technology [TAB-2276] Mouse Model and Derived Cells That Hypersecrete Leukemia Inhibitory Factor (LIF).">vidita.choudhry@nih.gov</a><br> 114122080 BAXXXX 114122081 RXXXXX 114122082 CXXXXX 114122083 CCXXXX 114122084 CC3XXX 114141575 Knock-in 114141576 Mice 114141577 DERIVED 114141578 Cells 114141579 That 114141580 HypersecreteLeukemia 114141581 INHIBITORY 114141582 factor 114141583 LIF. TAB-2281 114096489 Wirelessly Powered MRI Signal Amplification System and Method NINDS Licensing Licensing Chunqi Qian The invention is in the field of MRI, and more specifically relates to device and method that may provide great improvements in the area of interventional MRI. The technology describes an MRI detection coil that has been integrated with a parametric amplifier to provide local signal detection fully integrated with amplification. This amplification is done in a way that is inherently wireless, thus enabling efficient signal transmission. The integrated MRI detector/amplifier can be used in a number of applications. First, it can replace conventional MRI amplification typically done with transistor, thus eliminating the need for wires. Second, it can replace what is traditionally used as part of implanted or catheter coils for interventional procedures with MRI. The advantage is that the signal can be amplified, and wireless transmission is part of the amplification scheme. Therefore signal can be transmitted from the subject in a way that provides detection at higher sensitivity than conventional coils without internal amplification. <ul> <li>The detector/amplifier integrated system eliminates the need for transistors and is wireless, therefore heat is reduced and sensitivity of detection is increased.</li> <li>The system is compatible with interventional MRI devices.</li> </ul> MRI diagnostics and in particular in interventional MRI applications: <ul> <li>The device can be used as part of a catheter MRI coil for MRI guided surgery.</li> <li>It can also be used as implantable NMR coils for localized spectroscopy with better sensitivity.</li> <li>The device can potentially be used as a free floating MRI detector/amplifier and swallowed for internal MRI detection as has been done quite successful with optical imaging devices for imaging the human intestine. </li> <li>There may be use in MRI coil arrays where interaction between wires in large element arrays is a problem.</li> </ul> 2022-03-08 2024-10-28 2024-10-28 2011-07-21 AA3BXX, AA3XXX, AAXXXX, amplification, AMPLIFIER, AXXXXX, Detection, Integrated, MRI, Parametric, SIGNALS, TRANSMISSION, Wireless False True <ul> <li>Proof of principle has been demonstrated on a prototype device.</li> <li>Testing a second generation device right now with smaller dimension that could be implanted into transplanted organs and used in mm sized catheters for interventional devices or the digestive tract.</li> <li>Plans to develop methods to decouple elements for use in MRI detector arrays.</li> </ul> True NIHTT 37470483 Website Abstract 114171367 Qian C, Murphy-Borsch J, Dodd S, Koretsky A. Local detection and parametric amplification of MRI signals. Abstract/Presentation, 52nd Experimental Nuclear Magnetic Resonance Conference, April 10-15, 2011, Pacific Grove, CA. Qian C, Murphy-Borsch J, Dodd S, Koretsky A. Local detection and parametric amplification of MRI signals. Abstract/Presentation, 52nd Experimental Nuclear Magnetic Resonance Conference, April 10-15, 2011, Pacific Grove, CA. 114171368 Qian C, Murphy-Borsch J, Dodd S, Koretsky A. Integrated detection and wireless transmission of MRI signal using parametric amplifier. Abstract/Presentation, 19th Annual Meeting & Exhibition of the International Society of Magnetic Resonance in Medicine, May 7-13, 2011, Montreal, Quebec, Canada. Qian C, Murphy-Borsch J, Dodd S, Koretsky A. Integrated detection and wireless transmission of MRI signal using parametric amplifier. Abstract/Presentation, 19th Annual Meeting & Exhibition of the International Society of Magnetic Resonance in Medicine, May 7-13, 2011, Montreal, Quebec, Canada. 114171369 Qian C, et al. http://www.ncbi.nlm.nih.gov/pubmed/22246567 <a href="http://www.ncbi.nlm.nih.gov/pubmed/22246567">Qian C, et al.</a> 114107225 Qian, Chunqi NINDS Qian, Chunqi 1 114107225 Qian, Chunqi NINDS Qian, Chunqi 1 114101593 Integrated Detection, Amplification And Wireless Transmission Of MRI Signals Using A Parametric Amplifier E-113-2011-0 Filing authorized NINDS 83667829 Ano, Susan susan.ano@nih.gov
United States of America susan.ano@nih.gov?subject=Web Inquiry on [TAB-2281] Wirelessly Powered MRI Signal Amplification System and Method&body=Please send me information about technology [TAB-2281] Wirelessly Powered MRI Signal Amplification System and Method. Ano, Susan<br><a href="mailto:susan.ano@nih.gov?subject=Web Inquiry on [TAB-2281] Wirelessly Powered MRI Signal Amplification System and Method&body=Please send me information about technology [TAB-2281] Wirelessly Powered MRI Signal Amplification System and Method.">susan.ano@nih.gov</a><br> 114161745 E-113-2011-0 E-113-2011-0-PCT-02 WIRELESSLY POWERED MRI SIGNAL AMPLIFICATION SYSTEM AND METHOD PCT Patent Cooperation Treaty PCT/US2012/031083 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2012/031083<br />Filed on 2012-03-29<br />Status: Expired 114166466 E-113-2011-0 E-113-2011-0-US-01 Wirelessly Powered MRI Signals Amplification System and Method PRV US 61/468,911 Abandoned US <br />Provisional (PRV) 61/468,911<br />Filed on 2011-03-29<br />Status: Abandoned 114167190 E-113-2011-0 E-113-2011-0-US-07 Wirelessly Powered Magnetic Resonance Imaging Signal Amplification System DIV US 10,203,382 15/825,316 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10203382 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10203382">10,203,382</a><br />Filed on 2017-11-29<br />Status: Issued 114167314 E-113-2011-0 E-113-2011-0-US-06 Wirelessly Powered MRI Signal Amplification System and Method National Stage US 9,864,026 14/008,133 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9864026 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9864026">9,864,026</a><br />Filed on 2013-09-27<br />Status: Issued 114122108 AA3BXX 114122109 AXXXXX 114122110 AAXXXX 114122111 AA3XXX 114141631 Integrated 114141632 Detection 114141633 amplification 114141634 Wireless 114141635 TRANSMISSION 114141636 MRI 114141637 SIGNALS 114141638 Parametric 114141639 AMPLIFIER TAB-2266 114096475 Polyclonal Antibodies for the Gbeta5-associated Regulator of G Protein Signaling Protein, RGS7 NIDDK Licensing, Research Materials Licensing Research Materials William Simonds, Jianhua Zhang Researchers at NIDDK have developed polyclonal antibodies against the Regulator of G Protein Signalling (RGS) protein, RGS7. RGS7 binds tightly to Gbeta5, a unique and highly specialized G protein that exhibits much less homology than other Gbeta isoforms (~50%). RGS7 is preferentially expressed in brain and neuroendocrine tissue. Like Gbeta5, RGS7 is expressed prominently in the cell membrane, as well as in the cytosol. Although this distribution pattern suggests that complexes containing Gbeta5 and RGS7 may shuttle information between classical G protein-signaling elements at the plasma membrane and the cell interior, the function of the complex in the brain is largely unknown. <br /><br /> The antibodies were generated in rabbits to a glutathione S-transferase (GST) fusion protein with residues 312-469 of bovine RGS7 (antibody 7RC-1) and react with human and rodent RGS7. The antibodies (7RC-1) can be used for immunoblotting and immunoprecipitation. They can be used to facilitate our understanding of the function of Gbeta5/ RGS7 complexes in brain and neurons. High-titer, multi-epitope antibodies to study RGS7 and RGS7/Gbeta5 complexes and G protein signaling. These antibodies can be used for research purposes (immunoblotting, immunoprecipitation) by those studying the biology and function of RGS7. Research Tool — Patent protection is not being pursued for this technology. 2022-03-08 2024-10-28 2024-10-28 2011-06-15 antibodies, BOVINE, box, Fusion, GST, Includes, Protein, Region, RGS, RGS7, RXXXXX, That False True In vitro data available True NIHTT 37470483 Website Abstract 114171343 Rojkova AM, et al. http://www.ncbi.nlm.nih.gov/pubmed/12551930 <a href="http://www.ncbi.nlm.nih.gov/pubmed/12551930">Rojkova AM, et al.</a> 114171344 Cao Y, et al. http://www.ncbi.nlm.nih.gov/pubmed/19625520 <a href="http://www.ncbi.nlm.nih.gov/pubmed/19625520">Cao Y, et al.</a> 114171345 Anderson GR, et al. http://www.ncbi.nlm.nih.gov/pubmed/19332565 <a href="http://www.ncbi.nlm.nih.gov/pubmed/19332565">Anderson GR, et al.</a> 114171633 Panicker LM, et al. http://www.ncbi.nlm.nih.gov/pubmed/20100282 <a href="http://www.ncbi.nlm.nih.gov/pubmed/20100282">Panicker LM, et al.</a> 114107200 Zhang, Jianhua National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Zhang, Jianhua (NIDDK) 0 114107199 Simonds, William National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Simonds, William (NIDDK) 1 114107199 Simonds, William National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Simonds, William (NIDDK) 1 114107200 Zhang, Jianhua National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Zhang, Jianhua (NIDDK) 0 114101579 Antibodies To A GST Fusion Protein That Includes The RGS Box Region Of Bovine RGS7 E-077-2011-0 Research Material National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83692066 Tong, Betty tongb@niddk.nih.gov
United States of America Senior Technology Advancement Office tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-2266] Polyclonal Antibodies for the Gbeta5-associated Regulator of G Protein Signaling Protein, RGS7&body=Please send me information about technology [TAB-2266] Polyclonal Antibodies for the Gbeta5-associated Regulator of G Protein Signaling Protein, RGS7. Tong, Betty<br><a href="mailto:tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-2266] Polyclonal Antibodies for the Gbeta5-associated Regulator of G Protein Signaling Protein, RGS7&body=Please send me information about technology [TAB-2266] Polyclonal Antibodies for the Gbeta5-associated Regulator of G Protein Signaling Protein, RGS7.">tongb@niddk.nih.gov</a><br> 114122035 RXXXXX 114141503 GST 114141504 Fusion 114141505 Protein 114141506 That 114141507 Includes 114141508 RGS 114141509 box 114141510 Region 114141511 BOVINE 114141512 RGS7 114141513 antibodies TAB-2263 114096472 Novel Small Molecule Inhibitors for the Treatment of Huntington’s Disease NCATS Collaboration, Diagnostics, Licensing, Reproductive Health, Research Materials, Therapeutics, Vaccines Collaboration Diagnostics Licensing Reproductive Health Research Materials Therapeutics Vaccines Wenwei Huang, Juan Marugan, Joshua McCoy, Samarjit Patnaik, Noel Southall, Steven Titus, Wei Zheng This technology is a collection of small molecules screened for their ability to prevent or reduce the cytotoxic effects of the protein, Huntingtin. Huntington's disease is a neurodegenerative disorder due to a dominantly acting expansion of a CAG trinucleotide repeat in exon 1 of the Huntington (<i>HTT</i>) gene resulting in production of the altered (mutant) protein Huntingtin, which has a long chain of polyglutamine (poly Q) attached to the exon 1 encoded protein sequence. Clinical and statistical analyses have shown that an increased number of poly Q repetition correlates with the probability of developing the disease, with 36 to 40 being the accepted cut off number for developing the disorder with high probability. It is known that poly Q repetitions impact the physical properties of Huntingtin and cause it to produce aggregates that precipitate and form inclusion bodies, which are toxic to the neuronal cells. The compounds of this invention have been screened multiply in a neuronal cell model of Huntington’s disease containing an <i>HTT</i> with an expanded repeat in exon 1 of 103 Qs for their ability to inhibit cytotoxicity and protein aggregation. Treatment of Huntington’s disease. The National Center for Translational Therapeutics is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology further. Please contact Ms. Lili Portilla at <a href="mailto:Lilip@nih.gov">Lilip@nih.gov</a> for more information. Available for licensing. 2022-03-08 2024-10-28 2024-10-28 2011-06-03 ANALOGUES, Disease, HUNTINGTON'S, IB6XXX, IBXXXX, IXXXXX, NCTT, Novel, Thio-ether, treatment False True Early development. True NIHTT 37470483 Website Abstract 114171339 None None 114107190 McCoy, Joshua National Human Genome Research Institute (NHGRI) McCoy, Joshua 0 114107191 Patnaik, Samarjit National Human Genome Research Institute (NHGRI) NCATS Patnaik, Samarjit (NCATS) 0 114107192 Titus, Steven National Human Genome Research Institute (NHGRI) NCATS Titus, Steven (NCATS) 0 114107193 Zheng, Wei National Human Genome Research Institute (NHGRI) NCATS Zheng, Wei (NCATS) 0 114107194 Southall, Noel National Human Genome Research Institute (NHGRI) NCATS Southall, Noel (NCATS) 0 114107195 Huang, Wenwei National Human Genome Research Institute (NHGRI) NCATS Huang, Wenwei (NCATS) 0 114107189 Marugan, Juan National Human Genome Research Institute (NHGRI) NCATS Marugan, Juan (NCATS) 1 114107189 Marugan, Juan National Human Genome Research Institute (NHGRI) NCATS Marugan, Juan (NCATS) 1 114107190 McCoy, Joshua National Human Genome Research Institute (NHGRI) McCoy, Joshua 0 114107191 Patnaik, Samarjit National Human Genome Research Institute (NHGRI) NCATS Patnaik, Samarjit (NCATS) 0 114107192 Titus, Steven National Human Genome Research Institute (NHGRI) NCATS Titus, Steven (NCATS) 0 114107193 Zheng, Wei National Human Genome Research Institute (NHGRI) NCATS Zheng, Wei (NCATS) 0 114107194 Southall, Noel National Human Genome Research Institute (NHGRI) NCATS Southall, Noel (NCATS) 0 114107195 Huang, Wenwei National Human Genome Research Institute (NHGRI) NCATS Huang, Wenwei (NCATS) 0 114101576 Novel Thio-ether Analogues As A Treatment For Huntington's Disease E-258-2010-0 Filing authorized NCATS - NCGC 83682485 Vepa, Suryanarayana sury.vepa@nih.gov
United States of America Office of Strategic Alliances (OSA) sury.vepa@nih.gov?subject=Web Inquiry on [TAB-2263] Novel Small Molecule Inhibitors for the Treatment of Huntington’s Disease&body=Please send me information about technology [TAB-2263] Novel Small Molecule Inhibitors for the Treatment of Huntington’s Disease. Vepa, Suryanarayana<br><a href="mailto:sury.vepa@nih.gov?subject=Web Inquiry on [TAB-2263] Novel Small Molecule Inhibitors for the Treatment of Huntington’s Disease&body=Please send me information about technology [TAB-2263] Novel Small Molecule Inhibitors for the Treatment of Huntington’s Disease.">sury.vepa@nih.gov</a><br> 114159941 E-258-2010-0 E-258-2010-0-US-01 Compounds, Pharmaceutical Compositions, And Methods of Treating Or Preventing Neurodegenerative Diseases Or Disorders PRV US 61/388,482 Abandoned US <br />Provisional (PRV) 61/388,482<br />Filed on 2010-09-30<br />Status: Abandoned 114162364 E-258-2010-0 E-258-2010-0-PCT-02 COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF TREATING OR PREVENTING NEURODEGENERATIVE DISEASES OR DISORDERS PCT Patent Cooperation Treaty PCT/US2011/54325 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2011/54325<br />Filed on 2011-09-30<br />Status: Expired 114122018 IB6XXX 114122026 IXXXXX 114122027 IBXXXX 114141479 Novel 114141480 Thio-ether 114141481 ANALOGUES 114141482 treatment 114141483 HUNTINGTON'S 114141484 Disease 114141485 NCTT TAB-2264 114096473 Mouse Model for Cerebral Cavernous Malformation, an Inherited Brain Disorder NIAID Diagnostics, Licensing, Materials Available, Research Materials, Therapeutics Diagnostics Licensing Materials Available Research Materials Therapeutics YoSuke Mukoyama, Ulrich Siebenlist (Estate) Cerebral Cavernous Malformation (CCM) is a brain disease affecting up to 0.5% of the worldwide population. CCM is characterized by grossly dilated vessels prone to leaking and hemorrhage which result in severe headaches, seizures, and strokes. Inherited forms of the disease are due to mutations in one of three loci, CCM1, CCM2, and CCM3. Prior efforts to develop mice with targeted null mutations in <i>Ccm1</i>, <i>Ccm2</i>, or <i>Ccm3</i> have been unsuccessful, as such mutations result in embryonic death.<br /><br /> The inventors have developed the first mouse model available for the study of CCM, in which mouse <i>Ccm2</i> can be conditionally deleted in blood-accessible and endothelial cells, resulting in neurological defects, ataxia, and brain hemorrhages consistent with the human disease. The model was generated through a cross of C57BL/6 <i>Ccm2</i>-floxed mice with C57BL/6 <i>MX-1-Cre</i> mice, which permits inducible ablation by polyinosinic:polycytidylic acid (pIpC). Research Material — Patent protection is not being pursued for this technology. Available for licensing under a Biological Materials License Agreement. 2022-03-08 2024-10-28 2024-10-28 2011-06-15 brain, Cavernous Cerebral Malformation, CCM, CEREBRAL, Conditional, Cre, cre-lox, Floxed, Human, IDXXXX, Inherited, IXXXXX, Mouse, mouse model, RXXXXX False True True NIHTT 37470483 Website Abstract 114107196 Mukoyama, YoSuke National Heart, Lung, and Blood Institute (NHLBI) NHLBI Mukoyama, YoSuke (NHLBI) 0 114107197 Siebenlist (Estate), Ulrich NIAID - DIR NIAID Siebenlist (Estate), Ulrich (NIAID) 1 114107197 Siebenlist (Estate), Ulrich NIAID - DIR NIAID Siebenlist (Estate), Ulrich (NIAID) 1 114107196 Mukoyama, YoSuke National Heart, Lung, and Blood Institute (NHLBI) NHLBI Mukoyama, YoSuke (NHLBI) 0 114101577 Mouse Model For Human Disease, Cerebral Cavernous Malformation(CCM) E-158-2011-0 Research Material National Heart, Lung, and Blood Institute (NHLBI), NIAID 91025211 Rainwater, Charles crainwater@mail.nih.gov
United States of America crainwater@mail.nih.gov?subject=Web Inquiry on [TAB-2264] Mouse Model for Cerebral Cavernous Malformation, an Inherited Brain Disorder&body=Please send me information about technology [TAB-2264] Mouse Model for Cerebral Cavernous Malformation, an Inherited Brain Disorder. Rainwater, Charles<br><a href="mailto:crainwater@mail.nih.gov?subject=Web Inquiry on [TAB-2264] Mouse Model for Cerebral Cavernous Malformation, an Inherited Brain Disorder&body=Please send me information about technology [TAB-2264] Mouse Model for Cerebral Cavernous Malformation, an Inherited Brain Disorder.">crainwater@mail.nih.gov</a><br> 114122028 IDXXXX 114122029 RXXXXX 114122030 IXXXXX 114141486 Mouse 114141487 Human 114141488 CEREBRAL 114141489 CCM 114141490 mouse model 114141491 brain 114141492 Inherited 114141493 Cavernous Cerebral Malformation 114141494 Floxed 114141495 Cre 114141496 cre-lox 114141497 Conditional TAB-2257 114096466 Mouse IL-12p40 Expressing Cell Line NIAID Licensing Licensing Nevil Singh The subject invention is a recombinant human 293T cell line that expresses mouse IL-12p40 protein to high levels. IL-12p40 is a subunit of both Interleukin-12 (IL-12) and IL-23; however, it can also be expressed as a monomer (IL-12p40) and as a homodimer (IL-12p80). IL-12p40 is produced mainly by antigen presenting cells such as macrophages, neutrophils, microglia, and dendritic cells in response to pathogens or inflammatory agents. It is an immunostimulatory messenger molecule that can disseminate in the body and signal the presence of a pathogen. The role of IL-12p40 is still being elucidated. This cell line produces and secretes mouse IL-12p40 proteins that have post-translational modifications similar to native IL-12p40 protein, overcoming an issue that is seen with IL-12p40 protein expressed in bacterial, insect, or hamster cells. IL-12p40 protein is expressed in human cell line, so post-translational modifications are similar to native protein. Production of mouse IL-12p40 for research applications. Research Tool — Patent protection is not being pursued for this technology. Available for licensing. 2022-07-27 2024-10-28 2024-10-28 2011-05-20 ACXXXX, AXXXXX, Cell, CULTURE, Generation, High, IL-12p40, LEVELS, Line, Mouse, Secreting, Supernatants False True <i>In vitro</i> data can be provided upon request. True NIHTT 37470483 Website Abstract 114107174 Singh, Nevil NIAID - DIR NIAID Singh, Nevil (NIAID) 1 114107174 Singh, Nevil NIAID - DIR NIAID Singh, Nevil (NIAID) 1 114101569 Generation Of A Cell Line Secreting High Levels Of Mouse IL-12p40 In Cell Culture Supernatants E-247-2010-0 Research Material NIAID 91026778 Green, Wade wade.green@nih.gov
United States of America TTIPO wade.green@nih.gov?subject=Web Inquiry on [TAB-2257] Mouse IL-12p40 Expressing Cell Line&body=Please send me information about technology [TAB-2257] Mouse IL-12p40 Expressing Cell Line. Green, Wade<br><a href="mailto:wade.green@nih.gov?subject=Web Inquiry on [TAB-2257] Mouse IL-12p40 Expressing Cell Line&body=Please send me information about technology [TAB-2257] Mouse IL-12p40 Expressing Cell Line.">wade.green@nih.gov</a><br> 114122005 ACXXXX 114122006 AXXXXX 114141424 Generation 114141425 Cell 114141426 Line 114141427 Secreting 114141428 High 114141429 LEVELS 114141430 Mouse 114141431 IL-12p40 114141432 CULTURE 114141433 Supernatants TAB-2247 114096456 NAG-1 Transgenic Mouse Model NIEHS Collaboration, Oncology, Research Materials Collaboration Oncology Research Materials Thomas Eling The nonsteroidal anti-inflammatory drug-activated gene-1 (NAG-1) encodes a protein that has anti-inflammatory, proapoptotic, and antitumor properties. It plays a pivotal role in antitumorigenesis induced by chemopreventive compounds. Transgenic mice expressing human NAG-1 have been developed by the NIH investigator and collaborator.<br /><br /> The NAG-1 transgenic mice are shown to develop few tumors in response to carcinogenic stimuli than wild type mice. They are also leaner with less fat than their wild type counterparts. As such, these mice can be used to investigate the development of cancers, and they could be of value in studying obesity and the relationship to cancer risk, and inflammation. The NIEHS is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. Please contact Elizabeth M. Denholm, NIEHS Office of Technology Transfer, <a href="mailto:denholme@niehs.nih.gov">denholme@niehs.nih.gov</a>, 919-541-0981, for more information. Research Tool — Patent protection is not being pursued for this technology. 2022-03-08 2024-10-28 2024-10-28 2011-04-14 CC3XXX, CCXXXX, CXXXXX, Expressing, Gdf15/Nag-1/Mic-1, Human, Mice, RXXXXX, TRANSGENIC, Ubiquitously False True True NIHTT 37470483 Website Abstract 114171303 Baek SJ, et al. http://www.ncbi.nlm.nih.gov/pubmed/17101328 <a href="http://www.ncbi.nlm.nih.gov/pubmed/17101328">Baek SJ, et al.</a> 114171304 Cekanova M, et al. http://www.ncbi.nlm.nih.gov/pubmed/19401523 <a href="http://www.ncbi.nlm.nih.gov/pubmed/19401523">Cekanova M, et al.</a> 114107146 Eling, Thomas NIEHS NIEHS Eling, Thomas (NIEHS) 1 114107146 Eling, Thomas NIEHS NIEHS Eling, Thomas (NIEHS) 1 114101559 Transgenic Mice Ubiquitously Expressing Human Gdf15/Nag-1/Mic-1 E-093-2011-0 Research Material NIEHS 83739538 Choudhry, Vidita vidita.choudhry@nih.gov
United States of America Office of Technology Transfer and Development vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-2247] NAG-1 Transgenic Mouse Model&body=Please send me information about technology [TAB-2247] NAG-1 Transgenic Mouse Model. Choudhry, Vidita<br><a href="mailto:vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-2247] NAG-1 Transgenic Mouse Model&body=Please send me information about technology [TAB-2247] NAG-1 Transgenic Mouse Model.">vidita.choudhry@nih.gov</a><br> 114121964 RXXXXX 114121966 CXXXXX 114121967 CCXXXX 114121968 CC3XXX 114141347 Mice 114141348 TRANSGENIC 114141349 Ubiquitously 114141350 Expressing 114141351 Human 114141352 Gdf15/Nag-1/Mic-1 TAB-2243 114096453 Modulation of Leucine-rich Repeats and Calponin Homology Domain-containing Protein 4 (Lrch4) Activity for Therapeutic Applications NIEHS Collaboration, Diagnostics, Immunology, Oncology, Research Materials, Therapeutics Collaboration Diagnostics Immunology Oncology Research Materials Therapeutics Michael Fessler NIH Inventors have recently discovered a novel Leucine-rich repeat and calponin homology domain-containing protein 4 (Lrch4) in a proteomic screen of the plasma membrane of lipopolysaccharide (LPS)-exposed macrophages. Expression data by RT-PCR revealed that all Lrch family members (1-4) are expressed in macrophages, but only Lrch4 was recruited into lipid rafts (signaling microdomains of the plasma membrane) by LPS. Lrch4 is the most highly expressed Lrch family member in mouse tissues. It is a predicted single-spanning transmembrane protein that is encoded by the Lrch4 gene in humans. The Lrch4 ectodomain is predicted to have a series of leucine-rich repeats, the motifs by which Toll like Receptors (TLR) are thought to bind microbial ligands. The human form of Lrch4 is 83% identical to murine Lrch4 and is predicted to have 680 amino acids and a molecular weight of 73 kDa.<br /><br /> NIH inventors have shown that Lrch4 is expressed on the plasma membrane of macrophages. They have determined that Lrch4 regulates pro-inflammatory signals (NF-kappaB activation, cytokine induction) emanating from all TLRs tested, and also regulates ligand-independent signals from MyD88. Further, LPS-induced p38, JNK, and NFkappaB activation are attenuated following Lrch4 knockdown, indicating that Lrch4 regulates upstream LPS signaling events. LPS-induced expression of the NF-kappaB-dependent cytokine TNFalpha was attenuated following Lrch4 knockdown at the level of both transcript and protein. Based on these and other findings, the inventors of this technology propose that Lrch4 may be a novel component of TLR receptor complexes and that modulation of Lrch4 activity might open up new opportunities for developing novel therapeutics for inflammatory diseases. Identification and development of modulators of Lrch4 activity to treat inflammatory disorders, cancer, and sepsis. The National Institute of Environmental Health Sciences (NIEHS) Laboratory of Respiratory Biology is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize Lrch4. Please contact Dr. Sharon Soucek at <a href="mailto:sharon.soucek@nih.gov">sharon.soucek@niehs.nih.gov</a> for more information. 2022-03-08 2024-10-28 2024-10-28 2011-03-29 CB6XXX, CBXXXX, CXXXXX, DISEASES, GB1XXX, GBXXXX, GXXXXX, IB3XXX, IBXXXX, INFLAMMATORY, IXXXXX, Lrch4, Sepsis, TARGET, therapeutic False True Early-stage. True NIHTT 37470483 Website Abstract 114171285 Dhungana S, et al. http://www.ncbi.nlm.nih.gov/pubmed/18815123 <a href="http://www.ncbi.nlm.nih.gov/pubmed/18815123">Dhungana S, et al.</a> 114107140 Fessler, Michael NIEHS NIEHS Fessler, Michael (NIEHS) 1 114107140 Fessler, Michael NIEHS NIEHS Fessler, Michael (NIEHS) 1 114101553 Lrch4 As A Therapeutic Target For Sepsis And Inflammatory Diseases E-012-2011-0 Filing authorized NIEHS 83739538 Choudhry, Vidita vidita.choudhry@nih.gov
United States of America Office of Technology Transfer and Development vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-2243] Modulation of Leucine-rich Repeats and Calponin Homology Domain-containing Protein 4 (Lrch4) Activity for Therapeutic Applications&body=Please send me information about technology [TAB-2243] Modulation of Leucine-rich Repeats and Calponin Homology Domain-containing Protein 4 (Lrch4) Activity for Therapeutic Applications. Choudhry, Vidita<br><a href="mailto:vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-2243] Modulation of Leucine-rich Repeats and Calponin Homology Domain-containing Protein 4 (Lrch4) Activity for Therapeutic Applications&body=Please send me information about technology [TAB-2243] Modulation of Leucine-rich Repeats and Calponin Homology Domain-containing Protein 4 (Lrch4) Activity for Therapeutic Applications.">vidita.choudhry@nih.gov</a><br> 114166377 E-012-2011-0 E-012-2011-0-US-01 Modulation Of Lrch4 Activity And Therapeutic Application Thereof PRV US 61/433,491 Abandoned US <br />Provisional (PRV) 61/433,491<br />Filed on 2011-01-17<br />Status: Abandoned 114166651 E-012-2011-0 E-012-2011-0-PCT-02 MODULATION OF LRCH4 ACTIVITY AND THERAPEUTIC APPLICATION THEREOF PCT Patent Cooperation Treaty PCT/US2012/021538 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2012/021538<br />Filed on 2012-01-17<br />Status: Expired 114167257 E-012-2011-0 E-012-2011-0-US-03 Modulation of LRCH4 Activity and Therapeutic Application Thereof National Stage US 9,211,302 13/980,097 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9211302 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9211302">9,211,302</a><br />Filed on 2013-07-17<br />Status: Issued 114121940 CB6XXX 114121941 IB3XXX 114121942 GB1XXX 114121943 CXXXXX 114121944 CBXXXX 114121945 IXXXXX 114121946 IBXXXX 114121947 GXXXXX 114121948 GBXXXX 114141295 Lrch4 114141296 therapeutic 114141297 TARGET 114141298 Sepsis 114141299 INFLAMMATORY 114141300 DISEASES TAB-2239 114096448 Therapeutic Approach to Neurodegenerative Disorders Using a TFP5-Peptide NINDS Collaboration, Neurology, Therapeutics Collaboration Neurology Therapeutics Harish (Estate of) Pant This invention discloses methods for treating neurodegenerative diseases by administering cyclin dependent kinase 5 (Cdk5) inhibitory peptides derived from P35, the activator of Cdk5. Abnormally hyperactive Cdk5 has been shown to be associated with a variety of neurodegenerative disorders. Disclosed in this invention are isolated peptide fragments, pharmaceutical compositions and methods for use of such for treating subjects with a neurodegenerative disease, such as Alzheimer’s disease (AD), Amyotrophic Lateral Sclerosis (ALS) and Parkinson’s disease (PD). An inhibitory fragment, TFP5, disclosed in this invention, has been shown to ameliorate symptoms of AD in disease animal models without any evidence of toxicity. In particular, TFP5 treatment of rat cortical neurons reduced hyperactivation of Cdk5 upon neuronal stress and insults. Following intraperitoneal (ip) injection, TFP5 was capable of crossing the BBB and localizing within the brain where it was found to rescue memory deficits and pathology in a double transgenic mouse (APP/PS1) AD model. <ul> <li>The products are small peptides that pass the blood brain barrier.</li> </ul> <ul> <li>Therapeutic developments (AD, PD, ALS)</li> </ul> The National Institute of Neurological Disorders and Stroke, Neuronal Cytoskeletal Protein Regulation Section, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize topic of invention or related laboratory interests. Please contact Susan Ano, Ph.D. at 301-435-5515 or <a href="mailto:susan.ano@nih.gov">susan.ano@nih.gov</a> for more information. 2022-03-08 2024-10-28 2024-10-28 2011-03-15 Approach, DISORDERS, NB1BXX, NB1FXX, NB1XXX, NBXXXX, NEURODEGENERATIVE, NXXXXX, TFP5-peptide, therapeutic False True Pre-clinical; some animal data True NIHTT 37470483 Website Abstract 114107135 Pant, Harish (Estate of) NINDS NINDS Pant, Harish (Estate of) (NINDS) 1 114107135 Pant, Harish (Estate of) NINDS NINDS Pant, Harish (Estate of) (NINDS) 1 114101547 Therapeutic Approach To Neurodegenerative Disorders Using A TFP5-peptide E-144-2010-0 Filing authorized NINDS 83722849 Sharma, Smita smita.sharma@nih.gov
United States of America smita.sharma@nih.gov?subject=Web Inquiry on [TAB-2239] Therapeutic Approach to Neurodegenerative Disorders Using a TFP5-Peptide&body=Please send me information about technology [TAB-2239] Therapeutic Approach to Neurodegenerative Disorders Using a TFP5-Peptide. Sharma, Smita<br><a href="mailto:smita.sharma@nih.gov?subject=Web Inquiry on [TAB-2239] Therapeutic Approach to Neurodegenerative Disorders Using a TFP5-Peptide&body=Please send me information about technology [TAB-2239] Therapeutic Approach to Neurodegenerative Disorders Using a TFP5-Peptide.">smita.sharma@nih.gov</a><br> 114166361 E-144-2010-0 E-144-2010-0-US-01 Therapeutic Approach To Neurodegenerative Disorders Using A TFP5-peptide PRV US 61/387,839 Abandoned US <br />Provisional (PRV) 61/387,839<br />Filed on 2010-09-29<br />Status: Abandoned 114166542 E-144-2010-0 E-144-2010-0-US-02 Therapeutic Approach To Neurodegenerative Disorders Using A TFP5-peptide ORD US 8,597,660 13/249,003 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8597660 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8597660">8,597,660</a><br />Filed on 2011-09-29<br />Status: Issued 114121921 NB1FXX 114121922 NB1BXX 114121923 NXXXXX 114121924 NBXXXX 114121925 NB1XXX 114141266 therapeutic 114141267 Approach 114141268 NEURODEGENERATIVE 114141269 DISORDERS 114141270 TFP5-peptide TAB-2233 114096442 Single Channel MRI Guidewire NHLBI Collaboration, Licensing Collaboration Licensing Ozgur Kocaturk, Christina Saikus, Merdim Sonmez The invention offered for licensing and commercial development is in the field of Interventional Magnetic Resonance Imaging (“iMRI”). More specifically the invention discloses a guidewire for magnetic resonance imaging with a single channel design to reduce complexity and to provide conspicuous tip visibility under MRI. In the design of the present device, the guidewire body includes an antenna formed from a rod and a helical coil coupled together. The helical coil can have multiple windings without a gap between the windings. The rod passes through the windings of the helical coil and is coupled to the helical coil using a conductive joint positioned at an end of the rod and at an end of the helical coil. Insulation can be positioned between the rod and the windings of the helical coil. The configuration allows visibility of the antenna along the length of a rod, except where it enters the windings of the coil. Thus, the tip visibility is enhanced as being separated from the rod. <ul> <li>The unique design of the device and its dipole antenna, provide a lower profile guidewire (such as coronary 0.014: guidewire) and it is therefore safer and more convenient to use compared with existing guidewires.</li> <li>The modified dipole antenna of the device can combine the distinct tip signal profile typical of loop antennae with the whole-shaft visibility of dipole antennae, all operating on a single receiver channel. This overcomes challenges both of conspicuity and of undesirable coupling of comparable two-channel devices that causes heating.</li> </ul> <ul> <li>Interventional cardiology</li> <li>MRI guided surgery</li> </ul> The National Heart, Lung, and Blood Institute is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize technology involving single channel MRI guidewires. Please contact Peg Koelble at <a href="mailto:koelblep@nhlbi.nih.gov">koelblep@nhlbi.nih.gov</a> for more information. Available for licensing. 2022-03-08 2024-10-28 2024-10-28 2011-03-04 AA3BXX, AA3XXX, AAXXXX, Active, AXXXXX, CHANNEL, Conspicuous, Design, Guidewire, MRI, SHAFT, Single, Tip, Visibility False True In development. Prototype is being built. True NIHTT 37470483 Website Abstract E-209-2007-0 114171272 Kocaturk O, Kim AH, Saikus CE, Guttman MA, Faranesh AZ, Ozturk C, Lederman RJ. Active two-channel 0.035" guidewire for interventional cardiovascular MRI. J Magn Reson Imaging. 2009 Aug;30(2):461-465. http://www.ncbi.nlm.nih.gov/pubmed/19629968 <a href="http://www.ncbi.nlm.nih.gov/pubmed/19629968">Kocaturk O, Kim AH, Saikus CE, Guttman MA, Faranesh AZ, Ozturk C, Lederman RJ. Active two-channel 0.035" guidewire for interventional cardiovascular MRI. J Magn Reson Imaging. 2009 Aug;30(2):461-465.</a> 114171273 Qian D, El-Sharkawy AM, Atalar E, Bottomley PA. Interventional MRI: tapering improves the distal sensitivity of the loopless antenna. Magn Reson Med. 2010 Mar;63(3):797-802. http://www.ncbi.nlm.nih.gov/pubmed/20187186 <a href="http://www.ncbi.nlm.nih.gov/pubmed/20187186">Qian D, El-Sharkawy AM, Atalar E, Bottomley PA. Interventional MRI: tapering improves the distal sensitivity of the loopless antenna. Magn Reson Med. 2010 Mar;63(3):797-802.</a> 114107120 Kocaturk, Ozgur National Heart, Lung, and Blood Institute (NHLBI) NHLBI Kocaturk, Ozgur (NHLBI) 0 114107124 Saikus, Christina National Heart, Lung, and Blood Institute (NHLBI) NHLBI Saikus, Christina (NHLBI) 0 114107121 Sonmez, Merdim National Heart, Lung, and Blood Institute (NHLBI) NHLBI Sonmez, Merdim (NHLBI) 1 114107121 Sonmez, Merdim National Heart, Lung, and Blood Institute (NHLBI) NHLBI Sonmez, Merdim (NHLBI) 1 114107120 Kocaturk, Ozgur National Heart, Lung, and Blood Institute (NHLBI) NHLBI Kocaturk, Ozgur (NHLBI) 0 114107124 Saikus, Christina National Heart, Lung, and Blood Institute (NHLBI) NHLBI Saikus, Christina (NHLBI) 0 114101541 Single Channel Guidewire Design With Conspicuous Active Tip And Shaft Visibility Under MRI E-274-2010-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-2233] Single Channel MRI Guidewire&body=Please send me information about technology [TAB-2233] Single Channel MRI Guidewire. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-2233] Single Channel MRI Guidewire&body=Please send me information about technology [TAB-2233] Single Channel MRI Guidewire.">shmilovm@nih.gov</a><br> 114166339 E-274-2010-0 E-274-2010-0-US-01 Single Channel MRI Guidewire PRV US 61/429,833 Abandoned US <br />Provisional (PRV) 61/429,833<br />Filed on 2011-01-05<br />Status: Abandoned 114166612 E-274-2010-0 E-274-2010-0-PCT-02 Single Channel MRI Guidewire PCT Patent Cooperation Treaty PCT/US2012/020139 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2012/020139<br />Filed on 2012-01-04<br />Status: Expired 114167121 E-274-2010-0 E-274-2010-0-US-04 Single Channel MRI Guideware National Stage US 13/977,557 Abandoned US <br />National Stage 13/977,557<br />Filed on 2013-06-28<br />Status: Abandoned 114121892 AA3BXX 114121893 AXXXXX 114121894 AAXXXX 114121895 AA3XXX 114141214 Single 114141215 CHANNEL 114141216 Guidewire 114141217 Design 114141218 Conspicuous 114141219 Active 114141220 Tip 114141221 SHAFT 114141222 Visibility 114141223 MRI TAB-2234 114096443 Active Adaptive Detuning Systems to Improve Safety of Interventional Devices NHLBI Collaboration, Licensing Collaboration Licensing Ozgur Kocaturk The invention offered for licensing and commercial development is in the field of Interventional Magnetic Resonance Imaging (“iMRI”). More specifically the invention discloses interventional devices in which the heat generated at the device during the imaging process can be controlled to not exceed acceptable levels.<br /><br /> Active MRI compatible intravascular devices contain RF antenna to so that they are visible under MRI. However, these metallic structures may heat up significantly during interventional MRI procedures due to eddy current formation over the conductive transmission lines. The electrical field coupling between interventional devices and RF transmission coils strongly depend on the device position and orientation within the bore and insertion length of the device. Currently, conventional detuning circuit is used to decouple the conductive intravascular device during RF transmission phase of the MRI by activating the circuit with a PIN diode. However, conventional passive techniques do not adapt for each possible orientation or insertion length of the device. The current invention provides for a new active detuning system that adapts its circuit component to limit heating for every possible orientation and insertion length. The system reads out the received current signal value during RF transmission phase and changes the decoupling capacitor value by using varactor and integrated circuit components to reach new resonant condition (very high impedance). The device may fundamentally enable any "active" MRI catheter device (independent of the orientation and insertion length of the device) to be safe during real-time MRI guided interventional procedures. <ul> <li>Interventional cardiology</li> <li>MRI guided surgery</li> </ul> The National Heart, Lung, and Blood Institute is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. Please contact Peg Koelble at <a href="mailto:koelblep@nhlbi.nih.gov">koelblep@nhlbi.nih.gov</a> for more information. Available for licensing. 2022-03-08 2024-10-28 2024-10-28 2011-03-04 AA2XXX, AAXXXX, Active, ADAPTIVE, AXXXXX, Detuning, Devices, Interventional, MRI, Patent Category - Mech/Elect/Soft, System False True In development. Prototype is being built. True NIHTT 37470483 Website Abstract 114171274 Overall WR, Pauly JM, Stang PP, Scott GC. Ensuring safety of implanted devices under MRI using reversed RF polarization. Magn Reson Med. 2010 Sep;64(3):823-833. http://www.ncbi.nlm.nih.gov/pubmed/20593374 <a href="http://www.ncbi.nlm.nih.gov/pubmed/20593374">Overall WR, Pauly JM, Stang PP, Scott GC. Ensuring safety of implanted devices under MRI using reversed RF polarization. Magn Reson Med. 2010 Sep;64(3):823-833.</a> 114107125 Kocaturk, Ozgur National Heart, Lung, and Blood Institute (NHLBI) NHLBI Kocaturk, Ozgur (NHLBI) 1 114107125 Kocaturk, Ozgur National Heart, Lung, and Blood Institute (NHLBI) NHLBI Kocaturk, Ozgur (NHLBI) 1 114101542 Active Adaptive Detuning System For Interventional MRI Devices E-114-2010-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-2234] Active Adaptive Detuning Systems to Improve Safety of Interventional Devices&body=Please send me information about technology [TAB-2234] Active Adaptive Detuning Systems to Improve Safety of Interventional Devices. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-2234] Active Adaptive Detuning Systems to Improve Safety of Interventional Devices&body=Please send me information about technology [TAB-2234] Active Adaptive Detuning Systems to Improve Safety of Interventional Devices.">shmilovm@nih.gov</a><br> 114164176 E-114-2010-0 E-114-2010-0-PCT-02 Active Adaptive Detuning Systems And Methods For Interventional MRI Devices PCT Patent Cooperation Treaty PCT/US2011/042746 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2011/042746<br />Filed on 2011-07-01<br />Status: Expired 114166340 E-114-2010-0 E-114-2010-0-US-01 Active Adaptive Detuning System For Interventional MRI Devices PRV US 61/360,998 Abandoned US <br />Provisional (PRV) 61/360,998<br />Filed on 2010-07-02<br />Status: Abandoned 114166926 E-114-2010-0 E-114-2010-0-US-03 Active Adaptive Detuning Systems and Methods for Interventional Devices National Stage US 9,486,158 13/805,454 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9486158 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9486158">9,486,158</a><br />Filed on 2013-03-21<br />Status: Issued 114121896 AA2XXX 114121897 AXXXXX 114121898 AAXXXX 114141224 Active 114141225 ADAPTIVE 114141226 Detuning 114141227 System 114141228 Interventional 114141229 MRI 114141230 Devices 114141231 Patent Category - Mech/Elect/Soft TAB-2224 114096433 Selective 12-Human Lipoxygenase Inhibitors for the Treatment of Diabetes and Clotting NCATS Cardiology, Diagnostics, Licensing, Research Materials, Therapeutics Cardiology Diagnostics Licensing Research Materials Therapeutics Michael Holinstat, Theodore Holman, Ajit Jadhav, David Maloney, Jerry Nadler, Anton Simeonov This invention discloses small molecule inhibitors of human 12-lipoxygenase (12-hLO). 12-lipoxygenase expression, activation, and lipid metabolites have been implicated in type 1 and type 2 diabetes, cardiovascular disease, hypertension, Alzheimer’s, and Parkinson’s disease. The development of 12-hLO inhibitors may be a potent intracellular approach to decreasing the ability of platelets to form large clots in response to vessel injury or activation of the coagulation pathway. Thus, 12-hLO inhibition has the potential to attenuate platelet-mediated clot formation caused by diabetes and/or cardiovascular disease and significantly decrease the occurrence of myocardial infarction and death. Moreover, Type 1 and Type 2 diabetes are serious disorders that can lead to major complications and reduced lifespan. An unmet medical need is to identify new ways to protect beta cells in these metabolic disorders. A selective 12-hLO inhibitor could provide a new therapeutic approach to prevent or treat either form of diabetes. <ul> <li>Small molecule (series of analogs can be derived in search of improved performances and/or different functions)</li> <li>Selective inhibitor of human 12-lipoxygenase</li> </ul> <ul> <li>Therapeutic developments (blood clots; Type 1 and Type 2 diabetes, cardiovascular disease, and neurodegenerative diseases)</li> <li>Inflammatory responses</li> </ul> 2022-03-08 2024-10-28 2024-10-28 2011-02-17 12-human, Cardiovascular, CAUSED, Clot, DIABETES, Discovery, Disease, Formation, IA1AXX, IA1XXX, IAXXXX, Inhibitors, IXXXXX, LIPOXYGENASE, Platelet-mediated, Prevention, SELECTIVE, treatment False True Pre-clinical True NIHTT 37470483 Website Abstract 114169816 Bleich D, et al. http://www.ncbi.nlm.nih.gov/pubmed/10330425 <a href="http://www.ncbi.nlm.nih.gov/pubmed/10330425">Bleich D, et al.</a> 114169863 Yeung J, Holinstat M. http://www.ncbi.nlm.nih.gov/pubmed/21838667 <a href="http://www.ncbi.nlm.nih.gov/pubmed/21838667">Yeung J, Holinstat M.</a> 114169864 Ma K, et al. http://www.ncbi.nlm.nih.gov/pubmed/20089617 <a href="http://www.ncbi.nlm.nih.gov/pubmed/20089617">Ma K, et al.</a> 114170914 Yeung J, et al. http://www.ncbi.nlm.nih.gov/pubmed/22155783 <a href="http://www.ncbi.nlm.nih.gov/pubmed/22155783">Yeung J, et al.</a> 114170915 Kenyon V, et al. http://www.ncbi.nlm.nih.gov/pubmed/21739938 <a href="http://www.ncbi.nlm.nih.gov/pubmed/21739938">Kenyon V, et al.</a> 114171301 Nunemaker CS, et al. http://www.ncbi.nlm.nih.gov/pubmed/18780776 <a href="http://www.ncbi.nlm.nih.gov/pubmed/18780776">Nunemaker CS, et al.</a> 114171302 Chakrabarti SK, et al. http://www.ncbi.nlm.nih.gov/pubmed/19521344 <a href="http://www.ncbi.nlm.nih.gov/pubmed/19521344">Chakrabarti SK, et al.</a> 114107105 Holman, Theodore University of California, San Diego Holman, Theodore 0 114107107 Nadler, Jerry Nadler, Jerry 0 114107108 Holinstat, Michael Thomas Jefferson University Holinstat, Michael 0 114107110 Simeonov, Anton National Human Genome Research Institute (NHGRI) NCATS Simeonov, Anton (NCATS) 0 114107111 Jadhav, Ajit National Human Genome Research Institute (NHGRI) NCATS Jadhav, Ajit (NCATS) 0 114107106 Maloney, David National Human Genome Research Institute (NHGRI) NCATS Maloney, David (NCATS) 1 114107106 Maloney, David National Human Genome Research Institute (NHGRI) NCATS Maloney, David (NCATS) 1 114107105 Holman, Theodore University of California, San Diego Holman, Theodore 0 114107107 Nadler, Jerry Nadler, Jerry 0 114107108 Holinstat, Michael Thomas Jefferson University Holinstat, Michael 0 114107110 Simeonov, Anton National Human Genome Research Institute (NHGRI) NCATS Simeonov, Anton (NCATS) 0 114107111 Jadhav, Ajit National Human Genome Research Institute (NHGRI) NCATS Jadhav, Ajit (NCATS) 0 114101532 Discovery Of Selective 12-human Lipoxygenase Inhibitors For The Treatment Of Diabetes And Prevention Of Platelet-mediated Clot Formation Caused By Cardiovascular Disease E-134-2010-0 Filing authorized Eastern Virginia Medical School, NCATS - NCGC, Thomas Jefferson University, University of California, Santa Cruz 83682485 Vepa, Suryanarayana sury.vepa@nih.gov
United States of America Office of Strategic Alliances (OSA) sury.vepa@nih.gov?subject=Web Inquiry on [TAB-2224] Selective 12-Human Lipoxygenase Inhibitors for the Treatment of Diabetes and Clotting&body=Please send me information about technology [TAB-2224] Selective 12-Human Lipoxygenase Inhibitors for the Treatment of Diabetes and Clotting. Vepa, Suryanarayana<br><a href="mailto:sury.vepa@nih.gov?subject=Web Inquiry on [TAB-2224] Selective 12-Human Lipoxygenase Inhibitors for the Treatment of Diabetes and Clotting&body=Please send me information about technology [TAB-2224] Selective 12-Human Lipoxygenase Inhibitors for the Treatment of Diabetes and Clotting.">sury.vepa@nih.gov</a><br> 114166321 E-134-2010-0 E-134-2010-0-US-01 Inhibitors of Human 12-Lipoxygenase PRV US 61/345,708 Abandoned US <br />Provisional (PRV) 61/345,708<br />Filed on 2010-05-18<br />Status: Abandoned 114166432 E-134-2010-0 E-134-2010-0-PCT-02 Inhibitors of human 12-Lipoxygenase PCT Patent Cooperation Treaty PCT/US11/37000 Expired Patent Cooperation Treaty <br />(PCT) PCT/US11/37000<br />Filed on 2011-05-18<br />Status: Expired 114166916 E-134-2010-0 E-134-2010-0-US-07 Inhibitors of Human 12-Lipoxygenase National Stage US 13/698,340 Abandoned US <br />National Stage 13/698,340<br />Filed on 2012-11-16<br />Status: Abandoned 114121852 IA1AXX 114121857 IXXXXX 114121858 IAXXXX 114121859 IA1XXX 114141100 Discovery 114141101 SELECTIVE 114141102 12-human 114141103 LIPOXYGENASE 114141104 Inhibitors 114141105 treatment 114141106 DIABETES 114141107 Prevention 114141108 Platelet-mediated 114141109 Clot 114141110 Formation 114141111 CAUSED 114141112 Cardiovascular 114141113 Disease TAB-2196 114096411 Novel Therapeutic Compounds for Treatment of Cancer and Immune Disorders NHLBI Immunology, Infectious Disease, Licensing, Oncology, Therapeutics Immunology Infectious Disease Licensing Oncology Therapeutics William Trenkle, Adrian Wiestner, Yihong Ye The global market for cancer therapeutics is over $40 billion and is anticipated to continue to rise in the future. There remains a significant unmet need for therapeutics for cancers that affect blood, bone marrow, and lymph nodes and the immune system, such as leukemia, multiple myeloma, and lymphoma. The proteasome inhibitor bortezomib, which may prevent degradation of pro-apoptotic factors permitting activation of programmed cell death in neoplastic cells dependent upon suppression of pro-apoptotic pathways, has been a successful mode of treatment for such cancers. However, some patient’s cancers have been found to be resistant to the drug.<br /><br /> Researchers at the National Institutes of Health have developed novel hydrazone and diacyl hydrazine compounds that are inhibitors of the endoplasmic reticulum-associated protein degradation (ERAD) pathway. These compounds preferentially target the proteasome assistant ATPase p97/VCP at a site independent of nucleotide binding. The researchers have shown that these ERAD inhibitors can induce cancer cell death and can also synergize with bortezomib in cytotoxic activity. In addition to treating diseases or disorders in which inhibition of the ERAD pathway is an effective therapy, these novel compounds may also be useful in the study of protein degradation. <ul> <li>Potent anti-tumor activity</li> <li>Simpler chemical structure makes synthesis easier and more cost-effective than previous ERAD inhibitors</li> <li>Retain activity against bortezomib-resistant cells and can synergize with bortezomib</li> <li>Fluorescent</li> <li>High affinity for the ER</li> </ul> <ul> <li>Development of therapies against tumors that are resistant to bortezomib</li> <li>Use in therapies in combination with proteasome inhibitors</li> <li>Development of immunosuppressive therapies that target the ubiquitin proteasome system</li> <li>Studies of the mechanism of protein degradation and other biological processes that involve the p97 ATPase</li> <li>Bioprobes to detect endoplasmic reticulum (ER) structures in live cells</li> </ul> Available for licensing 2022-03-08 2024-10-28 2024-10-28 2010-11-26 anti-cancer, Bortezomib, CANCER, CB5AXX, CB5EXX, CB5XXX, CB6XXX, CBXXXX, CXXXXX, DB4AXX, DB4XXX, DBXXXX, Diacyl, DXXXXX, ERAD, Hematologic, HYDRAZINE, Hydrazone, immunosuppressant, inhibitor, Patent Category - Chemistry, Proteasome, Proteasome inhibitor, retroviral, tumor False True Pre-clinical True NIHTT 37470483 Website Abstract 114171220 Qiuyan Wang et al. ERAD inhibitors integrate ER stress with an epigenetic mechanism to activate BH3-only protein NOXA in cancer cells. Proc Natl Acad Sci USA 2009 Feb 17;106(7):2200-2205. http://www.ncbi.nlm.nih.gov/pubmed/19164757 <a href="http://www.ncbi.nlm.nih.gov/pubmed/19164757">Qiuyan Wang et al. ERAD inhibitors integrate ER stress with an epigenetic mechanism to activate BH3-only protein NOXA in cancer cells. Proc Natl Acad Sci USA 2009 Feb 17;106(7):2200-2205.</a> 114171221 Qiuyan Wang et al. The ERAD inhibitor Eeyarestatin I is a bifunctional compound with a membrane-binding domain and a p97/VCP inhibitory group. PloS ONE 2010, in press. Qiuyan Wang et al. The ERAD inhibitor Eeyarestatin I is a bifunctional compound with a membrane-binding domain and a p97/VCP inhibitory group. PloS ONE 2010, in press. 114107062 Ye, Yihong National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Ye, Yihong (NIDDK) 0 114107063 Trenkle, William National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Trenkle, William 0 114107061 Wiestner, Adrian National Heart, Lung, and Blood Institute (NHLBI) NHLBI Wiestner, Adrian (NHLBI) 1 114107061 Wiestner, Adrian National Heart, Lung, and Blood Institute (NHLBI) NHLBI Wiestner, Adrian (NHLBI) 1 114107062 Ye, Yihong National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Ye, Yihong (NIDDK) 0 114107063 Trenkle, William National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Trenkle, William 0 114101508 A Class Hydrazone And Diacyl Hydrazine ERAD Inhibitors Are Highly Active Against Hematologic Tumor Cells Including Cells Resistant To The Proteasome Inhibitor Bortezomib E-291-2009-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83739538 Choudhry, Vidita vidita.choudhry@nih.gov
United States of America Office of Technology Transfer and Development vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-2196] Novel Therapeutic Compounds for Treatment of Cancer and Immune Disorders&body=Please send me information about technology [TAB-2196] Novel Therapeutic Compounds for Treatment of Cancer and Immune Disorders. Choudhry, Vidita<br><a href="mailto:vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-2196] Novel Therapeutic Compounds for Treatment of Cancer and Immune Disorders&body=Please send me information about technology [TAB-2196] Novel Therapeutic Compounds for Treatment of Cancer and Immune Disorders.">vidita.choudhry@nih.gov</a><br> 114166254 E-291-2009-0 E-291-2009-0-US-01 HYDRAZONE AND DIACYL HYDRAZINE COMPOUNDS AND METHODS OF USE PRV US 61/266,760 Abandoned US <br />Provisional (PRV) 61/266,760<br />Filed on 2009-12-04<br />Status: Abandoned 114166276 E-291-2009-0 E-291-2009-0-PCT-02 Hydrazone And Diacyl Hydrazine Compunds And Methods Of Use PCT Patent Cooperation Treaty PCT/US2010/058849 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2010/058849<br />Filed on 2010-12-03<br />Status: Expired 114166798 E-291-2009-0 E-291-2009-0-US-03 Hydrazone And Diacyl Hydrazine Compounds And Methods Of Use National Stage US 8,518,968 13/513,819 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8518968 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8518968">8,518,968</a><br />Filed on 2012-06-04<br />Status: Issued 114121741 DB4AXX 114121742 CB5EXX 114121743 CB5AXX 114121744 CB6XXX 114121745 DXXXXX 114121746 DBXXXX 114121747 DB4XXX 114121748 CXXXXX 114121749 CBXXXX 114121750 CB5XXX 114140877 Hydrazone 114140878 Diacyl 114140879 HYDRAZINE 114140880 ERAD 114140881 Hematologic 114140882 tumor 114140883 Patent Category - Chemistry 114140884 Proteasome 114140885 inhibitor 114140886 Bortezomib 114140887 Proteasome inhibitor 114140888 CANCER 114140889 anti-cancer 114140890 retroviral 114140891 immunosuppressant TAB-2201 114096416 Compounds That Treat Malaria and Prevent Malaria Transmission NIAID Collaboration, Infectious Disease, Licensing, Rare/Neglected Diseases, Therapeutics Collaboration Infectious Disease Licensing Rare/Neglected Diseases Therapeutics Ruili Huang, Ronald Johnson, Sittiporn Pattaradilokrat, Dipak Raj, Xin-zhuan Su, Jing Yuan Malaria is the single leading cause of death, especially among children, in the developing world. Malaria is caused by infection with parasites of the genus <em>Plasmodium</em>, transmitted by mosquitos. In addition to transmission, vital steps in the parasite lifecycle occur in the mosquito host. The invention offered for licensing relates to therapeutic compounds and related pharmaceutical compositions that can be used in the prevention and treatment of malaria infection. More specifically, the invention is drawn to compounds that may kill sexual and mosquito stage malaria parasites to block transmission. Specifically claimed is the antihistamine Ketotifen, which has demonstrated activity blocking parasite development in mosquitoes. Also claimed are treatments encompassing Ketotifen with other existing antimalarial drugs in a combination treatment aimed at multiple stages in the malaria life cycle. <ul> <li>Drugs that kill sexual and mosquito stages of the parasite are important for preventing and/or slowing the spread of malaria infection and ultimately for malaria eradication.</li> <li>Primaquine, the only currently available drug shown to block transmission, is known to cause serious adverse side effects.</li> </ul> <ul> <li>Prevention and treatment of malaria infections.</li> </ul> The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize this technology. For collaboration opportunities, please contact Peter Tung at <a href="mailto:Peter.Tung@nih.gov">Peter.Tung@nih.gov</a> or 240-669-5483. Various international patent applications may also be available. Available for licensing. 2022-03-08 2024-10-28 2024-10-28 2017-07-18 ANTIMALARIAL, DB2XXX, DBXXXX, Discovery, DRUGS, DXXXXX, Malaria (Plasmodium sp.), Potential, UBXXXX, UXXXXX False True True NIHTT 37470483 Website Abstract 114172340 Eastman RT, et al. http://www.ncbi.nlm.nih.gov/pubmed/23129054 <a href="http://www.ncbi.nlm.nih.gov/pubmed/23129054">Eastman RT, et al.</a> 114107071 Yuan, Jing NIAID - DIR NIAID Yuan, Jing (NIAID) 0 114109294 Pattaradilokrat, Sittiporn NIAID - DIR Pattaradilokrat, Sittiporn 0 114109295 Huang, Ruili NCATS - NCGC NCATS Huang, Ruili (NCATS) 0 114109296 Johnson, Ronald NCI - CCR NCI Johnson, Ronald (NCI) 0 114109297 Raj, Dipak NIAID - DIR Raj, Dipak 0 114107070 Su, Xin-zhuan NIAID - DIR NIAID Su, Xin-zhuan (NIAID) 1 114107070 Su, Xin-zhuan NIAID - DIR NIAID Su, Xin-zhuan (NIAID) 1 114107071 Yuan, Jing NIAID - DIR NIAID Yuan, Jing (NIAID) 0 114109294 Pattaradilokrat, Sittiporn NIAID - DIR Pattaradilokrat, Sittiporn 0 114109295 Huang, Ruili NCATS - NCGC NCATS Huang, Ruili (NCATS) 0 114109296 Johnson, Ronald NCI - CCR NCI Johnson, Ronald (NCI) 0 114109297 Raj, Dipak NIAID - DIR Raj, Dipak 0 114101513 Discovery Of Potential Antimalarial Drugs E-283-2009-1 Filing authorized NCATS - NCGC, NIAID 114102301 Discovery Of Potential Antimalarial Drugs E-283-2009-0 Filing authorized NCATS - NCGC, NIAID 83724572 Tung, Peter peter.tung@nih.gov
United States of America DIR peter.tung@nih.gov?subject=Web Inquiry on [TAB-2201] Compounds That Treat Malaria and Prevent Malaria Transmission&body=Please send me information about technology [TAB-2201] Compounds That Treat Malaria and Prevent Malaria Transmission. Tung, Peter<br><a href="mailto:peter.tung@nih.gov?subject=Web Inquiry on [TAB-2201] Compounds That Treat Malaria and Prevent Malaria Transmission&body=Please send me information about technology [TAB-2201] Compounds That Treat Malaria and Prevent Malaria Transmission.">peter.tung@nih.gov</a><br> 114166260 E-283-2009-1 E-283-2009-1-PCT-01 Compounds That Treat Malaria And Prevent Malaria Transmission PCT COMB Patent Cooperation Treaty PCT/US2010/047019 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2010/047019<br />Filed on 2010-08-27<br />Status: Expired 114166619 E-283-2009-1 E-283-2009-1-US-07 Compounds That Treat Malaria and Prevent Malaria Transmission DIV US 15/192,779 Abandoned US <br />Divisional (DIV) 15/192,779<br />Filed on 2016-06-24<br />Status: Abandoned 114166677 E-283-2009-1 E-283-2009-1-US-06 Compounds That Treat Malaria And Prevent Malaria Transmission National Stage US 9,375,424 13/392,668 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9375424 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9375424">9,375,424</a><br />Filed on 2012-04-19<br />Status: Issued 114168329 E-283-2009-0 E-283-2009-0-US-01 Discovery Of Potential Antimalarial Drugs PRV US 61/237,417 Abandoned US <br />Provisional (PRV) 61/237,417<br />Filed on 2009-08-27<br />Status: Abandoned 114121767 DB2XXX 114121768 DXXXXX 114121769 DBXXXX 114121770 UXXXXX 114121771 UBXXXX 114140934 Discovery 114140935 Potential 114140936 ANTIMALARIAL 114140937 DRUGS 114157957 Malaria (Plasmodium sp.) TAB-2171 114096386 Full-Length Infectious cDNA Clones of Tick Borne Flavivirus NIAID Infectious Disease, Licensing, Rare/Neglected Diseases, Vaccines Infectious Disease Licensing Rare/Neglected Diseases Vaccines Robert Chanock (Estate), Alexander Pletnev The tick-borne encephalitis virus complex of flavivirus family includes tick-borne encephalitis (TBEV), Kyasanur forest disease, Langat, Louping ill, Negishi, Omsk hemorrhagic fever and Povassan viruses. These viruses are endemic throughout most of the Northern Hemisphere and except for Langat, cause human disease of varying severity that can have mortality as high as 20 to 30%. Tick-borne encephalitis remains a pressing public health problem in Eastern Europe and Russia, where 9,000 to 12,000 patients are diagnosed annually and there is a need for a vaccine which can prevent this disease.<br /><br /> This invention relates to an infectious full length Langat virus cDNA which has been successfully constructed and can be used to further attenuate this naturally attenuated tick-borne flavivirus. This full length Langat virus can be used as a live attenuated virus vaccine for the prevention of severe, often fatal disease caused by its more virulent tick-borne flavivirus relatives such as tick-borne encephalitis virus. Available for licensing. 2022-03-08 2024-10-28 2024-10-28 2010-09-28 Borne, cDNA, CLONES, DC5BXX, DC5XXX, DCXXXX, DXXXXX, Flavivirus, FULL-LENGTH, Hemorrhagic fever, INFECTIOUS, Omsk hemorrhagic fever, Patent Category - Biotechnology, Q fever, SACGHS DNA Patent Initial Set, TICK, Tick-borne encephalitis, UAXXXX False True True NIHTT 37470483 Website Abstract 114107005 Chanock (Estate), Robert NIAID - DIR NIAID Chanock (Estate), Robert (NIAID) 0 114107004 Pletnev, Alexander NIAID - DIR NIAID Pletnev, Alexander (NIAID) 1 114107004 Pletnev, Alexander NIAID - DIR NIAID Pletnev, Alexander (NIAID) 1 114107005 Chanock (Estate), Robert NIAID - DIR NIAID Chanock (Estate), Robert (NIAID) 0 114101472 Full-Length Infectious cDNA Clones Of Tick Borne Flavivirus E-281-1998-0 NIAID 83643855 Soukas, Peter peter.soukas@nih.gov
United States of America Technology Transfer and Intellectual Property Office peter.soukas@nih.gov?subject=Web Inquiry on [TAB-2171] Full-Length Infectious cDNA Clones of Tick Borne Flavivirus&body=Please send me information about technology [TAB-2171] Full-Length Infectious cDNA Clones of Tick Borne Flavivirus. Soukas, Peter<br><a href="mailto:peter.soukas@nih.gov?subject=Web Inquiry on [TAB-2171] Full-Length Infectious cDNA Clones of Tick Borne Flavivirus&body=Please send me information about technology [TAB-2171] Full-Length Infectious cDNA Clones of Tick Borne Flavivirus.">peter.soukas@nih.gov</a><br> 114166175 E-281-1998-0 E-281-1998-0-US-02 Full-Length Infectious cDNA Clones Of Tick Borne Flavivirus National Stage US 6,794,174 10/207,745 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6794174 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6794174">6,794,174</a><br />Filed on 2002-07-26<br />Status: Abandoned 114166728 E-281-1998-0 E-281-1998-0-PCT-03 Full-Length Infectious cDNA Clones Of Tick Borne Flavivirus PCT Patent Cooperation Treaty PCT/US01/04460 Expired Patent Cooperation Treaty <br />(PCT) PCT/US01/04460<br />Filed on 2001-02-09<br />Status: Expired 114168292 E-281-1998-0 E-281-1998-0-US-01 Full-Length Infectious cDNA Clones Of Tick Borne Flavivirus PRV US 60/181,490 Abandoned US <br />Provisional (PRV) 60/181,490<br />Filed on 2000-02-10<br />Status: Abandoned 114121609 DCXXXX 114121610 DC5BXX 114121611 UAXXXX 114121612 DXXXXX 114121613 DC5XXX 114140557 FULL-LENGTH 114140558 INFECTIOUS 114140559 cDNA 114140560 CLONES 114140561 TICK 114140562 Borne 114140563 Flavivirus 114140564 SACGHS DNA Patent Initial Set 114140565 Patent Category - Biotechnology 114157160 Q fever 114157161 Omsk hemorrhagic fever 114157162 Hemorrhagic fever 114157163 Tick-borne encephalitis TAB-2157 114096372 Superresolution Microscopy via Azicon Beam Polarization Devices NHLBI Collaboration, Licensing Collaboration Licensing Jay Knutson The technology offered for licensing pertains to novel polarizers that produce tangentially and radially polarized beams. The polarizers and polarizing beam splitter of the technology include one or more pairs of axicons (also known as conical lenses) that are configured to separate an input beam into a radially polarized component and a tangentially (or azimuthally) polarized component. A second axicon pair can be positioned to recombine the tangentially polarized component so as to provide a more uniform beam intensity. The radial polarized component can be reflected or otherwise directed so that one or both the radial and tangential components are available for use. The technology provides higher optical resolution for certain applications as compared with currently used methodologies. The disclosed methods and apparatus of the technology can be used to provide radially or tangentially polarized beams (or both) to many applications. In particular the technology can be effectively utilized in applications such as: <ul> <li>Multi-photon microscopy</li> <li>Microlithography</li> <li>Ultrafine imaging in conjunction with the use of fluorophores</li> </ul> The NHLBI Laboratory of Molecular Biophysics is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. Please contact Brian Bailey at 301-594-4094 for more information. Available for licensing. 2022-03-08 2024-10-28 2024-10-28 2010-08-31 AA2XXX, AAXXXX, AXXXXX, Azicon:, BEAM, DEVICE, Microscopyimprovements, Patent Category - Mech/Elect/Soft, POLARIZATION, Superresolution False True The invention is fully developed. True NIHTT 37470483 Website Abstract 114106971 Knutson, Jay National Heart, Lung, and Blood Institute (NHLBI) NHLBI Knutson, Jay (NHLBI) 1 114106971 Knutson, Jay National Heart, Lung, and Blood Institute (NHLBI) NHLBI Knutson, Jay (NHLBI) 1 114101456 "Azicon": Beam Polarization Device For Superresolution Microscopy Improvements E-251-2009-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-2157] Superresolution Microscopy via Azicon Beam Polarization Devices&body=Please send me information about technology [TAB-2157] Superresolution Microscopy via Azicon Beam Polarization Devices. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-2157] Superresolution Microscopy via Azicon Beam Polarization Devices&body=Please send me information about technology [TAB-2157] Superresolution Microscopy via Azicon Beam Polarization Devices.">shmilovm@nih.gov</a><br> 114166142 E-251-2009-0 E-251-2009-0-US-01 "Azicon": Beam Polarization Device For Superresolution Microscopy improvements PRV US 61/308,202 Abandoned US <br />Provisional (PRV) 61/308,202<br />Filed on 2010-02-25<br />Status: Abandoned 114166336 E-251-2009-0 E-251-2009-0-PCT-02 Azicon Beam Polarization Devices PCT Patent Cooperation Treaty PCT/US2011/025755 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2011/025755<br />Filed on 2011-02-22<br />Status: Expired 114166834 E-251-2009-0 E-251-2009-0-US-04 Azicon Beam Polarization Devices National Stage US 9,086,509 13/581,107 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9086509 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9086509">9,086,509</a><br />Filed on 2012-08-24<br />Status: Issued 114121526 AA2XXX 114121527 AXXXXX 114121528 AAXXXX 114140396 BEAM 114140397 Azicon: 114140398 POLARIZATION 114140399 DEVICE 114140400 Superresolution 114140401 Microscopyimprovements 114140402 Patent Category - Mech/Elect/Soft TAB-2162 114096377 Phantasmidine, a Nicotinic Receptor Agonist for the Treatment of Addiction and Neurological Disorders NIDDK Diagnostics, Licensing, Neurology, Research Materials, Therapeutics Diagnostics Licensing Neurology Research Materials Therapeutics Richard Fitch The inventors have isolated and characterized an alkaloid, phantasmidine, from the skin of the Ecuadoran poison frog <i>E. anthonyi</i>. Phantasmidine is selective for beta4-containing receptor subtypes, unlike many nicotinic receptor agonists currently in development, which target beta2-containing receptor subtypes. This selectivity makes phantasmidine a unique pharmacological probe, as well as a promising lead compound for the development of selective therapeutics targeting beta4-containing receptor subtypes, which appear to play any important role in nicotine addiction and other substance dependencies.<br /><br /> Nicotinic acetylcholine receptors (nAChRs) are broadly distributed in both the peripheral and central nervous systems; activation of brain nAChRs results in enhanced release of various key neurotransmitters. Dysfunction of these receptors is associated with a variety of neurological diseases, including nicotine addiction. Nicotinic agonists, which enhance action at nicotinic acetylcholine receptors, have been shown to possess potential clinical utility in many of these diseases, although development is hindered by the existence of a large number of nAChR subtypes with highly variable properties.<br /><br /> Alkaloids, such as epibatidine found in skin from the frog species <i>E. tricolor</i>, have been shown to activate nicotinic acetylcholine receptors. However, while epibatidine has been shown to be a powerful analgesic, it is also extremely toxic, so research has focused on the identification and development of less toxic analogs. <ul> <li>Development of therapies for the treatment of addiction, including nicotine and alcohol addictions.</li> <li>Development of therapies for neurological diseases such as Alzheimer’s disease, attention deficit hyperactivity disorder (ADHD), and schizophrenia.</li> <li>Development of selective pharmacological probes for bioimaging, binding assays, and functional assays of nicotinic receptors.</li> </ul> Available for licensing. 2022-03-08 2024-10-28 2024-10-28 2010-09-20 ADDICTION, AGONIST, Alkaloid, Alzheimer disease 1, Alzheimer disease 3, Alzheimer disease 4, Alzheimer disease type 1, Alzheimer disease type 4, Alzheimer disease, familial, type 3, EPIBATIDINE, IBXXXX, IXXXXX, nAChR, NBXXXX, NC2XXX, NCXXXX, Neurological, neurological disease, nicotine, NICOTINIC, NXXXXX, Patent Category - Chemistry, Phantasmidine False True True NIHTT 37470483 Website Abstract 114171162 R Fitch et al. Phantasmidine: An epibatidine congener from the Ecuadorian poison frog <i>Epipedobates anthonyi</i>. J Nat Prod. 2010 Mar 26;73(3):331-337. http://www.ncbi.nlm.nih.gov/pubmed/20337496 <a href="http://www.ncbi.nlm.nih.gov/pubmed/20337496">R Fitch et al. Phantasmidine: An epibatidine congener from the Ecuadorian poison frog <i>Epipedobates anthonyi</i>. J Nat Prod. 2010 Mar 26;73(3):331-337.</a> 114106976 Fitch, Richard National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Fitch, Richard 1 114106976 Fitch, Richard National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Fitch, Richard 1 114101463 Phantasmidine As A Nicotinic Receptor Agonist With Altered Selectivity Relative To Epibatidine E-125-2010-0 Filing authorized National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83692066 Tong, Betty tongb@niddk.nih.gov
United States of America Senior Technology Advancement Office tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-2162] Phantasmidine, a Nicotinic Receptor Agonist for the Treatment of Addiction and Neurological Disorders&body=Please send me information about technology [TAB-2162] Phantasmidine, a Nicotinic Receptor Agonist for the Treatment of Addiction and Neurological Disorders. Tong, Betty<br><a href="mailto:tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-2162] Phantasmidine, a Nicotinic Receptor Agonist for the Treatment of Addiction and Neurological Disorders&body=Please send me information about technology [TAB-2162] Phantasmidine, a Nicotinic Receptor Agonist for the Treatment of Addiction and Neurological Disorders.">tongb@niddk.nih.gov</a><br> 114166158 E-125-2010-0 E-125-2010-0-US-01 Nicotinic Acetylcholine Receptor Agonists PRV US 61/315,674 Abandoned US <br />Provisional (PRV) 61/315,674<br />Filed on 2010-03-19<br />Status: Abandoned 114166383 E-125-2010-0 E-125-2010-0-PCT-02 Nicotinic Acetylcholine Receptor Agonists PCT Patent Cooperation Treaty PCT/US2011/028989 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2011/028989<br />Filed on 2011-03-18<br />Status: Expired 114166849 E-125-2010-0 E-125-2010-0-US-03 Nicotinic Acetylcholine Receptor Agonists National Stage US 9,018,227 13/583,420 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9018227 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9018227">9,018,227</a><br />Filed on 2013-04-16<br />Status: Issued 114168137 E-125-2010-0 E-125-2010-0-US-04 Phantasmidine As A Nicotinic Receptor Agonist With Altered Selectivity Relative To Epibatidine DIV US 9,902,734 14/695,460 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9902734 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9902734">9,902,734</a><br />Filed on 2015-04-24<br />Status: Issued 114168564 E-125-2010-0 E-125-2010-0-US-05 Phantasmidine As A Nicotinic Receptor Agonist With Altered Selectivity Relative To Epibatidine DIV US 15/905,485 Abandoned US <br />Divisional (DIV) 15/905,485<br />Filed on 2018-02-26<br />Status: Abandoned 114121553 IBXXXX 114121554 NBXXXX 114121555 NCXXXX 114121556 NC2XXX 114121557 IXXXXX 114121558 NXXXXX 114140457 Phantasmidine 114140458 NICOTINIC 114140459 nicotine 114140460 AGONIST 114140461 Patent Category - Chemistry 114140462 EPIBATIDINE 114140463 nAChR 114140464 ADDICTION 114140465 Neurological 114140466 neurological disease 114140467 Alkaloid 114157133 Alzheimer disease type 1 114157134 Alzheimer disease type 4 114157135 Alzheimer disease, familial, type 3 114158663 Alzheimer disease 1 114158664 Alzheimer disease 4 114158665 Alzheimer disease 3 TAB-2142 114096360 A Novel Scaffold for Multivalent Display of Ligands NIDDK Collaboration Collaboration Daniel Appella Multivalent interactions are important in cell attachment, wound healing and immune responses. Such interactions are associated with cancer metastasis, blood clotting and the generation of antibodies from a vaccination. Mimicking multivalent interactions on a synthetic scaffold is challenging especially when large numbers of ligands (such as 5 or more) need to be displayed. There are numerous synthetic scaffolds that have been developed, but there are significant limitations that remain.<br /><br /> Scientists at the NIH have designed a novel multivalent scaffold that can display anywhere from 1 to 200 ligands. This system allows different types of ligands to be displayed in a controlled, spatially-addressable manner. This system uses peptide nucleic acids (PNAs) containing gamma-substituted side chains. PNAs are synthetic molecules that possess the bases derived from DNA. This invention could revolutionize the way in which multivalent display is used in research as well as help make vaccinations or prevent disease. <ul> <li>Controlled interactions ensure only a single stoichiometry is attained.</li> <li>Simple access to a wide range of multivalent platforms.</li> </ul> The NIDDK Laboratory of Bioorganic Chemistry is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this novel scaffold or to collaborate on related laboratory interests. Please contact Marguerite J. Miller at 301-496-9003 or <a href="mailto:Marguerite.Miller@nih.gov">Marguerite.Miller@nih.gov</a> for more information. 2022-03-08 2024-10-28 2024-10-28 2017-04-17 AAXXXX, AXXXXX, Based, Chain-Modified, DISPLAY, LIGANDS, MULTIVALENT, Nanostructures, PNA, PNAfor, PROGRAMMABLE, Self-assembled, SIDE, Sidechain-Modified, YXXXXX False True Early-stage True NIHTT 37470483 Website Abstract 114106944 Appella, Daniel National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Appella, Daniel (NIDDK) 1 114106944 Appella, Daniel National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Appella, Daniel (NIDDK) 1 114099695 Programmable Self-Assembled Nanostructures Based On Side Chain-Modified PNA For The Multivalent Display Of Ligands E-129-2010-0 Filing authorized National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83692066 Tong, Betty tongb@niddk.nih.gov
United States of America Senior Technology Advancement Office tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-2142] A Novel Scaffold for Multivalent Display of Ligands&body=Please send me information about technology [TAB-2142] A Novel Scaffold for Multivalent Display of Ligands. Tong, Betty<br><a href="mailto:tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-2142] A Novel Scaffold for Multivalent Display of Ligands&body=Please send me information about technology [TAB-2142] A Novel Scaffold for Multivalent Display of Ligands.">tongb@niddk.nih.gov</a><br> 114166120 E-129-2010-0 E-129-2010-0-US-01 Programmable Self-Assembled Nanostructures Based On Sidechain-Modified PNAfor The Multivalent Display Of Ligands` PRV US 61/333,442 Abandoned US <br />Provisional (PRV) 61/333,442<br />Filed on 2010-05-11<br />Status: Abandoned 114166434 E-129-2010-0 E-129-2010-0-PCT-02 Programmable Self-Assembled Nanostructures Based On Side Chain-Modified PNA For The Multivalent Display Of Ligands PCT Patent Cooperation Treaty PCT/US2011/036090 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2011/036090<br />Filed on 2011-05-11<br />Status: Expired 114166917 E-129-2010-0 E-129-2010-0-US-04 Programmable Self-Assembled Nanostructures Based On Sidechain-Modified PNA For The Multivalent Display Of Ligands National Stage US 13/697,123 Abandoned US <br />National Stage 13/697,123<br />Filed on 2012-12-06<br />Status: Abandoned 114121451 YXXXXX 114121934 AXXXXX 114121935 AAXXXX 114140246 PROGRAMMABLE 114140247 Self-assembled 114140248 Nanostructures 114140249 Based 114140250 Sidechain-Modified 114140251 PNAfor 114140252 MULTIVALENT 114140253 DISPLAY 114140254 LIGANDS 114140255 SIDE 114140256 Chain-Modified 114140257 PNA TAB-2143 114096361 N-Methanocarba Adenosine Derivatives and Their Dendrimer Conjugates as A3 Receptor Agonists NIDDK Collaboration, Diagnostics, Ophthalmology, Research Materials, Therapeutics Collaboration Diagnostics Ophthalmology Research Materials Therapeutics Kenneth Jacobson, Dilip Tosh This technology relates to specific (N)-methanocarba adenine nucleosides that have been developed and dendrimers that connect these compounds to create molecules with multiple targets. Dendrimers are essentially repeated molecular branches presenting the core receptor-binding molecules. The compounds synthesized function as agonists and antagonists of a receptor of the G-protein coupled receptor (GPCR) superfamily. In particular, the receptors of interest for this invention include A<sub>3</sub> adenosine receptors and agonists and antagonists of P2Y receptors, such as P2Y<sub>1</sub> and P2Y<sub>14</sub>.<br /><br /> Dendrimer conjugates may have one or more advantages, such as increased solubility, reduced toxicity, and improved pharmacokinetic properties. They can also be used to connect other types of molecules without affecting the agonist or antagonists properties. For instance, molecules such as those used for imaging or tracing can be added. Dendrimers can also be used to link more than one type of agonist or antagonist to confer multiple functionalities. This technology provides a novel mechanism to treat a number of disorders related to dysregulation of A<sub>3</sub> adenosine receptors. <ul> <li>cardiac arrhythmias or ischemia</li> <li>inflammation</li> <li>stroke</li> <li>diabetes</li> <li>asthma</li> <li>cancer</li> <li>imaging</li> </ul> The National Institute of Diabetes and Digestive and Kidney Diseases, Laboratory of Bioorganic Chemistry, Molecular Recognition Section, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. Please contact Dr. Kenneth Jacobson at <a href="mailto:kajacobs@helix.nih.gov">kajacobs@helix.nih.gov</a> for more information. 2022-03-08 2024-10-28 2024-10-28 2010-08-11 A3, ADENOSINE, AGONISTS, CONJUGATES, DENDRIMER, Derivatives, IAXXXX, IBXXXX, IXXXXX, N-Methanocarba, OBXXXX, OXXXXX, Patent Category - Chemistry, RECEPTOR, Their False True Research quantities of compounds have been synthesized and tested for receptor selectivity. True NIHTT 37470483 Website Abstract 114107407 Tosh, Dilip National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Tosh, Dilip (NIDDK) 0 114107406 Jacobson, Kenneth National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Jacobson, Kenneth (NIDDK) 1 114107406 Jacobson, Kenneth National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Jacobson, Kenneth (NIDDK) 1 114107407 Tosh, Dilip National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Tosh, Dilip (NIDDK) 0 114101661 (N)-Methanocarba Adenosine Derivatives And Their Dendrimer Conjugates As A3 Receptor Agonists E-049-2010-2 Filing authorized National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83692066 Tong, Betty tongb@niddk.nih.gov
United States of America Senior Technology Advancement Office tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-2143] N-Methanocarba Adenosine Derivatives and Their Dendrimer Conjugates as A3 Receptor Agonists&body=Please send me information about technology [TAB-2143] N-Methanocarba Adenosine Derivatives and Their Dendrimer Conjugates as A3 Receptor Agonists. Tong, Betty<br><a href="mailto:tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-2143] N-Methanocarba Adenosine Derivatives and Their Dendrimer Conjugates as A3 Receptor Agonists&body=Please send me information about technology [TAB-2143] N-Methanocarba Adenosine Derivatives and Their Dendrimer Conjugates as A3 Receptor Agonists.">tongb@niddk.nih.gov</a><br> 114166618 E-049-2010-2 E-049-2010-2-PCT-01 Methanocarba Adenosine Derivatives And Their Dendrimer Conjugates Thereof PCT COMB Patent Cooperation Treaty PCT/US2010/058746 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2010/058746<br />Filed on 2010-12-02<br />Status: Expired 114166796 E-049-2010-2 E-049-2010-2-US-03 Methanocarba Adenosine Derivatives, Pharmaceutical Compositions, and Method of Reducing Intraocular Pressure National Stage US 8,518,957 13/512,681 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8518957 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8518957">8,518,957</a><br />Filed on 2012-06-21<br />Status: Abandoned 114121452 IXXXXX 114121453 IAXXXX 114121454 IBXXXX 114121455 OXXXXX 114121456 OBXXXX 114140258 N-Methanocarba 114140259 ADENOSINE 114140260 Derivatives 114140261 Their 114140262 DENDRIMER 114140263 CONJUGATES 114140264 A3 114140265 RECEPTOR 114140266 AGONISTS 114140267 Patent Category - Chemistry TAB-2114 114096332 Software System for Processing and Analysis of Multi-dimensional NMR Data NIDDK Collaboration, Licensing Collaboration Licensing Frank Delaglio Available for licensing is a software system useful in applications involving nuclear magnetic resonance (NMR). The software system, called NMRPipe, is written in the C programming language, and makes use of the TCL/TK scripting environment. The system includes over 500 modules for processing and analyzing experimental data of one to four dimensions collected on NMR spectrometers. The system exploits the UNIX computer operating system facilities of pipelines and scripts to link modules in a highly flexible, user-definable manner. NMR is a widely used analytical method, applied to both solution and solid state samples. The information obtained from such data pertains to the structure, motion, and interactions of molecular systems, including proteins, nucleic acids, and organic molecules. <ul> <li>Biomedical research for studying protein and nucleic acid structures and their interactions</li> <li>Chemical applications involving synthesis, identification, or production of organic molecules</li> </ul> The National Institute of Diabetes and Digestive and Kidney Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize the NMRPipe software system. Please contact Marguerite Miller at 301-496-9003 or Frank Delaglio at <a href="mailto:frankde@niddk.nih.gov">frankde@niddk.nih.gov</a> for more information. Software - Patent protection is not being pursued for this technology. 2022-03-08 2024-10-28 2024-10-28 2010-05-21 ADXXXX, analysis, AXXXXX, DATA, Multi-dimensional, NMR, NMRPipe, Processing, software, System False True <ul> <li>The software is mature.</li> <li>Binary executables of the software have been widely distributed, both to academic institutions as well as commercial organizations.</li> <li>The software is under active development.</li> <li>The software will be readily available upon request.</li> </ul> True NIHTT 37470483 Website Abstract 114171079 Kontaxis G, et al. http://www.ncbi.nlm.nih.gov/pubmed/15808217 <a href="http://www.ncbi.nlm.nih.gov/pubmed/15808217">Kontaxis G, et al.</a> 114171080 Delaglio F, et al. http://www.ncbi.nlm.nih.gov/pubmed/11318630 <a href="http://www.ncbi.nlm.nih.gov/pubmed/11318630">Delaglio F, et al.</a> 114171081 Cornilescu G, et al. http://www.ncbi.nlm.nih.gov/pubmed/10212987 <a href="http://www.ncbi.nlm.nih.gov/pubmed/10212987">Cornilescu G, et al.</a> 114171082 Delaglio F, et al. http://www.ncbi.nlm.nih.gov/pubmed/8520220 <a href="http://www.ncbi.nlm.nih.gov/pubmed/8520220">Delaglio F, et al.</a> 114106900 Delaglio, Frank National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Delaglio, Frank (NIDDK) 1 114106900 Delaglio, Frank National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Delaglio, Frank (NIDDK) 1 114101410 Software System For Processing And Analysis Of Multi-dimensional NMR Data E-076-2009-0 Research Material National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83692066 Tong, Betty tongb@niddk.nih.gov
United States of America Senior Technology Advancement Office tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-2114] Software System for Processing and Analysis of Multi-dimensional NMR Data&body=Please send me information about technology [TAB-2114] Software System for Processing and Analysis of Multi-dimensional NMR Data. Tong, Betty<br><a href="mailto:tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-2114] Software System for Processing and Analysis of Multi-dimensional NMR Data&body=Please send me information about technology [TAB-2114] Software System for Processing and Analysis of Multi-dimensional NMR Data.">tongb@niddk.nih.gov</a><br> 114121097 ADXXXX 114121098 AXXXXX 114139894 software 114139895 System 114139896 Processing 114139897 analysis 114139898 Multi-dimensional 114139899 NMR 114139900 DATA 114139901 NMRPipe TAB-2119 114096337 Sound Attenuation Canopy for Reducing Noise Transmitted Through Suspended Ceilings NIAID Licensing Licensing Robert Alexander, John Jenkins, Franklin Koh, Daniel O'Brien, Judit Quasney Available for licensing and commercial implementation in commercial facilities design and construction are intellectual property rights covering a sound attenuation canopy for reducing noise transmitted through suspended ceiling systems commonly used in most office buildings. The canopy is designed to absorb sound energy and effectively reduce the direct path of sound travelling within open plenum suspended ceilings like those used in most office building environments. The canopy can also act as an umbrella to shield loose debris and dust which may be located in the plenum and potentially fall when ceiling suspended return-air grilles are moved or accessed. The canopy has an added benefit of reducing heating or cooling loss which may naturally ventilate through the return air plenum grille from a conditioned office space below. Also, the canopy controls leakage of heating and cooling, reducing loads on the central building systems thereby lessening energy costs and extending the life-cycle of the building's physical plant.<br><br> The canopy does not impede natural air flow for ventilating the plenum cavity but deters the spread of smoke or fire between the plenum and the office space below. The canopy can also act as a secondary air balancer or K Factor balancer to equate supply and return air to control room temperature. The canopy is pliable and therefore allows for ease of adjustment within varying plenum conditions as well as readily installed in ceiling plenums. <ul> <li>Building design and construction</li> <li>Sound attenuation</li> <li>Energy load reduction</li> </ul> 2022-07-27 2024-10-28 2024-10-28 2010-06-01 AE1CXX, AE1XXX, AE2BXX, AE2CXX, AE2XXX, AEXXXX, AFXXXX, AXXXXX, Buildings, Canopy, Ceiling, NOISE, Patent Category - Mech/Elect/Soft, Sound, Sound Reduction False True True NIHTT 37470483 Website Abstract 114104505 O'Brien, Daniel NIAID - Technology Transfer and Intellectual Property Office NIAID O'Brien, Daniel (NIAID) 0 114106901 Alexander, Robert NIAID - Technology Transfer and Intellectual Property Office NIAID Alexander, Robert (NIAID) 0 114106902 Jenkins, John NIAID - Technology Transfer and Intellectual Property Office Jenkins, John 0 114106903 Koh, Franklin NIAID - Technology Transfer and Intellectual Property Office Koh, Franklin 0 114106904 Quasney, Judit NIAID - Technology Transfer and Intellectual Property Office NIAID Quasney, Judit (NIAID) 1 114106904 Quasney, Judit NIAID - Technology Transfer and Intellectual Property Office NIAID Quasney, Judit (NIAID) 1 114104505 O'Brien, Daniel NIAID - Technology Transfer and Intellectual Property Office NIAID O'Brien, Daniel (NIAID) 0 114106901 Alexander, Robert NIAID - Technology Transfer and Intellectual Property Office NIAID Alexander, Robert (NIAID) 0 114106902 Jenkins, John NIAID - Technology Transfer and Intellectual Property Office Jenkins, John 0 114106903 Koh, Franklin NIAID - Technology Transfer and Intellectual Property Office Koh, Franklin 0 114101417 Sound Attenuation Canopy (SAC); Reduces Noise Transmitted Through The Suspended Ceiling System Present In Most Office Buildings E-102-2010-0 Filing authorized NIAID 91026778 Green, Wade wade.green@nih.gov
United States of America TTIPO wade.green@nih.gov?subject=Web Inquiry on [TAB-2119] Sound Attenuation Canopy for Reducing Noise Transmitted Through Suspended Ceilings&body=Please send me information about technology [TAB-2119] Sound Attenuation Canopy for Reducing Noise Transmitted Through Suspended Ceilings. Green, Wade<br><a href="mailto:wade.green@nih.gov?subject=Web Inquiry on [TAB-2119] Sound Attenuation Canopy for Reducing Noise Transmitted Through Suspended Ceilings&body=Please send me information about technology [TAB-2119] Sound Attenuation Canopy for Reducing Noise Transmitted Through Suspended Ceilings.">wade.green@nih.gov</a><br> 114160855 E-102-2010-0 E-102-2010-0-US-03 Sound Attenuation Canopy CON US 8,316,986 13/303,063 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8316986 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8316986">8,316,986</a><br />Filed on 2010-04-21<br />Status: Issued 114163767 E-102-2010-0 E-102-2010-0-US-01 Sound Attenuation Canopy ORD US 8,069,947 12/764,872 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8069947 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8069947">8,069,947</a><br />Filed on 2010-04-21<br />Status: Issued 114166403 E-102-2010-0 E-102-2010-0-PCT-02 Sound Attenuation Canopy PCT Patent Cooperation Treaty PCT/US2011/033246 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2011/033246<br />Filed on 2011-04-20<br />Status: Expired 114121119 AE1CXX 114121120 AFXXXX 114121121 AE2BXX 114121122 AE2CXX 114121123 AXXXXX 114121124 AEXXXX 114121125 AE1XXX 114121126 AE2XXX 114139987 Sound 114139988 Canopy 114139989 NOISE 114139990 Ceiling 114139991 Sound Reduction 114139992 Buildings 114139993 Patent Category - Mech/Elect/Soft TAB-2110 114096328 Parvovirus B19 Codon Optimized Structural Proteins for Vaccine and Diagnostic Applications NHLBI Collaboration, Diagnostics, Infectious Disease, Vaccines Collaboration Diagnostics Infectious Disease Vaccines Sachiko Kajigaya, Neal Young, Ning Zhi Parvovirus B19 (B19V) is the only known pathogenic human parvovirus. Infection by this viral pathogen can cause transient aplastic crisis in individuals with high red cell turnover, pure red cell aplasia in immunosuppressed patients, and hydrops fetalis during pregnancy. In children, B19V most commonly causes erythema infectiosum, or fifth's disease. Infection can also cause arthropathy and arthralgia. The virus is very erythrotropic, targeting human erythroid (red blood) progenitors found in the blood, bone marrow, and fetal liver. Currently, there are no approved vaccines or antiviral drugs for the treatment or prevention of B19V infection.<br /><br /> The subject technology is a series of plasmid constructs with codon optimized B19 viral capsid genes (VP1 and VP2) that can be expressed in mammalian cells. Transfection of vectors encoding these optimized VP1 and VP2 genes into different mammalian cell lines, including 293, Cos7, and Hela cells produce virus-like particles (VLPs). The vectors include bicistronic plasmids expressing the VP1 and VP2 proteins at different ratios to produce B19V VLPs with optimal antigenicity for vaccine applications. This technology can also be used for diagnostic applications and development of a viral packaging system for producing infectious B19V virus. <ul> <li>Codon optimized VP1 and VP2 genes for better expression in mammalian cell lines</li> <li>Expression of B19V VLPs from "nonpermissive" cell lines</li> </ul> <ul> <li>VLPs based vaccines for the prevention and/or treatment of B19V infection</li> <li>DNA based vaccines for the prevention and/or treatment of B19V infection</li> <li>B19V diagnostics</li> <li>Viral packaging system</li> </ul> The National Heart Lung and Blood Institute, Hematology Branch, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize the subject technology. Please contact Cecilia Pazman, Ph.D., at <a href="mailto:pazmance@mail.nih.gov">pazmance@mail.nih.gov</a> for more information. 2022-03-08 2024-10-28 2024-10-28 2010-05-06 Against, AgainstB19V, APPLICATION, B19V, BBXXXX, CAPSID, Cells, CODON, DA4BXX, DA4XXX, DAXXXX, DC5BXX, DC5XXX, DCXXXX, DEVELOPING, DNA-based, DXXXXX, Erythema infectiosum, Fifth Disease, GENES, Human parvovirus B19 infection, Hydrops fetalis, Infection, Non-pennissive, OPTIMIZED, PARTICLE, Parvovirus antenatal infection, Patent Category - Biotechnology, Pure red cell aplasia, USAGE, vaccines, VIRUS-LIKE, VLP-and False True In vitro data available. True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114106892 Young, Neal National Heart, Lung, and Blood Institute (NHLBI) NHLBI Young, Neal (NHLBI) 0 114106893 Kajigaya, Sachiko National Heart, Lung, and Blood Institute (NHLBI) NHLBI Kajigaya, Sachiko (NHLBI) 0 114106891 Zhi, Ning National Heart, Lung, and Blood Institute (NHLBI) Zhi, Ning 1 114106891 Zhi, Ning National Heart, Lung, and Blood Institute (NHLBI) Zhi, Ning 1 114106892 Young, Neal National Heart, Lung, and Blood Institute (NHLBI) NHLBI Young, Neal (NHLBI) 0 114106893 Kajigaya, Sachiko National Heart, Lung, and Blood Institute (NHLBI) NHLBI Kajigaya, Sachiko (NHLBI) 0 114101406 The Optimized Codon Usage Of B19V Capsid Genes In Non-pennissive Cells And Its Application In Developing Virus-like Particle (VLP)-and DNA-based Vaccines Against B19V Infection E-011-2010-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 83739538 Choudhry, Vidita vidita.choudhry@nih.gov
United States of America Office of Technology Transfer and Development vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-2110] Parvovirus B19 Codon Optimized Structural Proteins for Vaccine and Diagnostic Applications&body=Please send me information about technology [TAB-2110] Parvovirus B19 Codon Optimized Structural Proteins for Vaccine and Diagnostic Applications. Choudhry, Vidita<br><a href="mailto:vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-2110] Parvovirus B19 Codon Optimized Structural Proteins for Vaccine and Diagnostic Applications&body=Please send me information about technology [TAB-2110] Parvovirus B19 Codon Optimized Structural Proteins for Vaccine and Diagnostic Applications.">vidita.choudhry@nih.gov</a><br> 114162292 E-011-2010-0 E-011-2010-0-US-01 The Optimized Codon Usage Of B19V Capsid Genes In Non-pennissive Cells And Its Application In Developing Virus-like Particle (VLP)-and DNA-based Vaccines Against B19V Infection PRV US 61/337,983 Abandoned US <br />Provisional (PRV) 61/337,983<br />Filed on 2010-02-12<br />Status: Abandoned 114166348 E-011-2010-0 E-011-2010-0-PCT-02 Compositions And Methods For Preventing or Treating A Human Parvovirus Infection PCT Patent Cooperation Treaty PCT/US2011/024199 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2011/024199<br />Filed on 2011-02-09<br />Status: Expired 114166744 E-011-2010-0 E-011-2010-0-US-04 Compositions And Methods For Preventing Or Treating A Human Parvovirus Infection National Stage US 13/578,577 Abandoned US <br />National Stage 13/578,577<br />Filed on 2012-11-13<br />Status: Abandoned 114120877 BBXXXX 114121078 DC5BXX 114121079 DA4BXX 114121080 DXXXXX 114121081 DAXXXX 114121082 DCXXXX 114121083 DA4XXX 114121084 DC5XXX 114139849 OPTIMIZED 114139850 CODON 114139851 USAGE 114139852 B19V 114139853 CAPSID 114139854 GENES 114139855 Non-pennissive 114139856 Cells 114139857 APPLICATION 114139858 DEVELOPING 114139859 VIRUS-LIKE 114139860 PARTICLE 114139861 VLP-and 114139862 DNA-based 114139863 vaccines 114139864 AgainstB19V 114139865 Infection 114139866 Against 114139867 Patent Category - Biotechnology 114157034 Hydrops fetalis 114157035 Pure red cell aplasia 114157036 Human parvovirus B19 infection 114157037 Parvovirus antenatal infection 114158610 Erythema infectiosum 114158611 Fifth Disease TAB-2109 114096326 Erythroid Progenitor Cell Line for Hematological Disease Applications NHLBI Collaboration, Infectious Disease, Licensing, Materials Available, Research Materials Collaboration Infectious Disease Licensing Materials Available Research Materials Susan Wong, Neal Young, Ning Zhi <i>Plasmodium vivax</i> (malaria) is a significant health concern in many parts of Asia, Latin America, North Africa, and the Middle East. There is a lack of continuous culture systems for this pathogen. The subject technology is an erythroid progenitor continuous cell line (termed CD36E) identified by erythroid markers CD36, CD33, CD44, CD71, CD235, and globoside. These CD36E cells are heterozygous for Fya and Fyb (Duffy antigen). Due to recent evidence that <i>Plasmodium vivax</i> (<i>P. vivax</i>) can infect erythroid progenitor cells (reference: YX Ru et al. and T Panichakul et al.), these cells can be potentially used for culturing <i>P. vivax</i> and other species of malaria. This in turn could aid development of malaria related treatments and/or products. In addition, the cell line can also be used for other hematological disease applications that involve red blood cells or red blood cell precursors. The CD36E cells also produce alpha, beta, and chi hemoglobin and therefore may be used for research involving hemoglobin. Immortalized erythroid progenitor cell line <ul> <li>Culture system for <i>Plasmodium</i> species (malaria)</li> <li>Hematological diseases</li> </ul> The National Heart Lung and Blood Institute, Hematology Branch, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize the CD36E cell line. Please contact Cecilia Pazman, Ph.D., at <a href="mailto:pazmance@mail.nih.gov">pazmance@mail.nih.gov</a> for more information. Research Tool -- patent protection is not being pursued for this technology Available for biological materials licensing. 2022-03-08 2024-10-28 2024-10-28 2010-05-05 &, Blod, Blood, CD36E, Cell, Cells, continuous, DDXXXX, DISEASES, DXXXXX, Erythroid, Involving, Line, Malaria, Malaria (Plasmodium sp.), Patent Category - Biotechnology, PLASMODIUM, Potential, PRECURSORS, Progenitor, RED, Spp., STUDIES, termed, USES False True <i>In vitro</i> data can be provided upon request. True NIHTT 37470483 Website Abstract 114171074 YX Ru et al. Invasion of erythroblasts by Pasmodium vivax: A new mechanism contributing to malarial anemia. Ultrastruct Pathol. 2009 Oct;33(5):236-242. http://preview.ncbi.nlm.nih.gov/pubmed/19895296 <a href="http://preview.ncbi.nlm.nih.gov/pubmed/19895296">YX Ru et al. Invasion of erythroblasts by Pasmodium vivax: A new mechanism contributing to malarial anemia. Ultrastruct Pathol. 2009 Oct;33(5):236-242.</a> 114171075 T Panichakul et al. Production of erythropoietic cells in vitro for continuous culture of Plasmodium vivax. Int J Parasitol. 2007 Dec;37(14):1551-1557. http://preview.ncbi.nlm.nih.gov/pubmed/17610880 <a href="http://preview.ncbi.nlm.nih.gov/pubmed/17610880">T Panichakul et al. Production of erythropoietic cells in vitro for continuous culture of Plasmodium vivax. Int J Parasitol. 2007 Dec;37(14):1551-1557.</a> 114106889 Zhi, Ning National Heart, Lung, and Blood Institute (NHLBI) Zhi, Ning 0 114106890 Young, Neal National Heart, Lung, and Blood Institute (NHLBI) NHLBI Young, Neal (NHLBI) 0 114106238 Wong, Susan National Heart, Lung, and Blood Institute (NHLBI) NHLBI Wong, Susan (NHLBI) 1 114106238 Wong, Susan National Heart, Lung, and Blood Institute (NHLBI) NHLBI Wong, Susan (NHLBI) 1 114106889 Zhi, Ning National Heart, Lung, and Blood Institute (NHLBI) Zhi, Ning 0 114106890 Young, Neal National Heart, Lung, and Blood Institute (NHLBI) NHLBI Young, Neal (NHLBI) 0 114101405 Erythroid Progenitor Continuous Cell Line (termed CD36E) & Its Potential Uses For Malaria (Plasmodium Spp.) Studies And Diseases Involving Red Blod Cells Or Red Blood Cell Precursors E-151-2010-0 Research Material National Heart, Lung, and Blood Institute (NHLBI) 83739538 Choudhry, Vidita vidita.choudhry@nih.gov
United States of America Office of Technology Transfer and Development vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-2109] Erythroid Progenitor Cell Line for Hematological Disease Applications&body=Please send me information about technology [TAB-2109] Erythroid Progenitor Cell Line for Hematological Disease Applications. Choudhry, Vidita<br><a href="mailto:vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-2109] Erythroid Progenitor Cell Line for Hematological Disease Applications&body=Please send me information about technology [TAB-2109] Erythroid Progenitor Cell Line for Hematological Disease Applications.">vidita.choudhry@nih.gov</a><br> 114121076 DXXXXX 114121077 DDXXXX 114139827 Erythroid 114139828 Progenitor 114139829 continuous 114139830 Cell 114139831 Line 114139832 termed 114139833 CD36E 114139834 & 114139835 Potential 114139836 USES 114139837 Malaria 114139838 PLASMODIUM 114139839 Spp. 114139840 STUDIES 114139841 DISEASES 114139842 Involving 114139843 RED 114139844 Blod 114139845 Cells 114139846 Blood 114139847 PRECURSORS 114139848 Patent Category - Biotechnology 114157956 Malaria (Plasmodium sp.) TAB-2097 114096314 Composite Probes and Use Thereof in Super Resolution Microscopy NHLBI Collaboration Collaboration Gary Griffiths, Jay Knutson The technology is in the field of fluorescence microscopy. More specifically, the invention describes and claims the composite probes for super resolution optical techniques using super resolution via transiently activated quenchers (STAQ). The composite probes include a donor moiety and an acceptor moiety joined by a linker. The acceptor moiety, when excited by incident radiation, is excited to a state which, for example, absorbs in the donor emission region, such that the acceptor moiety in its excited state quenches at least a portion of the donor moiety emission. Other transiently activated quenching mechanisms and moieties could accomplish the same task by reducing donor population. Also disclosed are methods for irradiating a selected region of a target material including the composite probe, wherein the composite probe enables improved resolution by point spread function modification. Improved ultrafine imaging – <ul> <li>Imaging objects as small as 10 nm</li> <li>Narrow the point spread function</li> <li>STAQ uses less power, making live cell study practical at theoretically high resolution</li> </ul> <ul> <li>Ultrafine imaging for biomolecules, vesicles and organelles, particularly of living biological samples, in biomedical research</li> <li>Potential applications in clinical diagnostics</li> <li>Nanoscopic Lithography - STAQ composites could, in principle, control polymerization of photoresist masks to make feature sizes below 20nm</li> </ul> The National Heart, Lung and Blood Institute, Laboratory of Molecular Biophysics, is also seeking statements of capability or interest from parties interested in collaborative partnerships to further develop, evaluate, or commercialize this technology. Please contact Brian Bailey, Ph.D. at <a href="mailto:bbailey@mail.nih.gov">bbailey@mail.nih.gov</a> for more information. 2022-03-08 2024-10-28 2024-10-28 2010-04-20 AC3XXX, ACTIVATED, ACXXXX, AXXXXX, Concept, LABELS, MICROSCOPY, Patent Category - Chemistry, Quenchers, STAQ, Superresolution, Transiently, Via False True <ul> <li>The invention is fully developed</li> <li>Need to build multicolor palette that can be integrated into a commercial microscope</li> <li>May need to make certain protein chimeras and photoinitiators for validation</li> </ul> True NIHTT 37470483 Website Abstract 114171054 Doose S, et al. http://www.ncbi.nlm.nih.gov/pubmed/17956989 <a href="http://www.ncbi.nlm.nih.gov/pubmed/17956989">Doose S, et al.</a> 114171055 Schuler B, et al. http://www.ncbi.nlm.nih.gov/pubmed/15699337 <a href="http://www.ncbi.nlm.nih.gov/pubmed/15699337">Schuler B, et al.</a> 114171056 Best RB, et al. http://www.ncbi.nlm.nih.gov/pubmed/18029448 <a href="http://www.ncbi.nlm.nih.gov/pubmed/18029448">Best RB, et al.</a> 114171057 Sahoo H, et al. http://www.ncbi.nlm.nih.gov/pubmed/17629273 <a href="http://www.ncbi.nlm.nih.gov/pubmed/17629273">Sahoo H, et al.</a> 114171058 Li L, et al. http://www.ncbi.nlm.nih.gov/pubmed/19359543 <a href="http://www.ncbi.nlm.nih.gov/pubmed/19359543">Li L, et al.</a> 114171059 Hell SW. http://www.ncbi.nlm.nih.gov/pubmed/17525330 <a href="http://www.ncbi.nlm.nih.gov/pubmed/17525330">Hell SW.</a> 114171060 Masia F, et al. http://www.ncbi.nlm.nih.gov/pubmed/19529713 <a href="http://www.ncbi.nlm.nih.gov/pubmed/19529713">Masia F, et al.</a> 114171061 Schmidt R, et al. http://www.ncbi.nlm.nih.gov/pubmed/19459703 <a href="http://www.ncbi.nlm.nih.gov/pubmed/19459703">Schmidt R, et al.</a> 114106869 Griffiths, Gary National Heart, Lung, and Blood Institute (NHLBI) Griffiths, Gary 0 114106868 Knutson, Jay National Heart, Lung, and Blood Institute (NHLBI) NHLBI Knutson, Jay (NHLBI) 1 114106868 Knutson, Jay National Heart, Lung, and Blood Institute (NHLBI) NHLBI Knutson, Jay (NHLBI) 1 114106869 Griffiths, Gary National Heart, Lung, and Blood Institute (NHLBI) Griffiths, Gary 0 114101391 Labels For Superresolution Microscopy Using The STAQ Concept (Superresolution Via Transiently Activated Quenchers) E-253-2009-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-2097] Composite Probes and Use Thereof in Super Resolution Microscopy&body=Please send me information about technology [TAB-2097] Composite Probes and Use Thereof in Super Resolution Microscopy. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-2097] Composite Probes and Use Thereof in Super Resolution Microscopy&body=Please send me information about technology [TAB-2097] Composite Probes and Use Thereof in Super Resolution Microscopy.">shmilovm@nih.gov</a><br> 114166011 E-253-2009-0 E-253-2009-0-PCT-02 Composite Probes And Use Thereof In Super resolution Methods PCT Patent Cooperation Treaty PCT/US2010/062214 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2010/062214<br />Filed on 2010-12-28<br />Status: Expired 114166303 E-253-2009-0 E-253-2009-0-US-01 Compisite Probes and Use Thereof in Super Resolution Methods PRV US 61/290,282 Abandoned US <br />Provisional (PRV) 61/290,282<br />Filed on 2009-12-28<br />Status: Abandoned 114166814 E-253-2009-0 E-253-2009-0-US-04 COMPOSITE PROBES AND USE THEREOF IN SUPER RESOLUTION METHODS National Stage US 8,547,533 13/519,737 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8547533 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8547533">8,547,533</a><br />Filed on 2012-06-28<br />Status: Issued 114167205 E-253-2009-0 E-253-2009-0-US-05 Composite Probes And Use Thereof in Super Resolution Methods DIV US 9,273,089 13/967,851 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9273089 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9273089">9,273,089</a><br />Filed on 2013-08-15<br />Status: Issued 114121022 AC3XXX 114121023 AXXXXX 114121024 ACXXXX 114139684 LABELS 114139685 Superresolution 114139686 MICROSCOPY 114139687 STAQ 114139688 Concept 114139689 Via 114139690 Transiently 114139691 ACTIVATED 114139692 Quenchers 114139693 Patent Category - Chemistry TAB-2099 114096316 New Mouse Strain with Conditional Deletion of SMAD7: Analysis of Disease Processes Involving Immunological, Fibrotic or Cardiovascular Indications NIEHS Animal Models, Collaboration, Licensing, Materials Available, Research Materials Animal Models Collaboration Licensing Materials Available Research Materials Marilyn Diaz SMAD7 conditional knockout mice are available for licensing. SMAD7 can be knocked out by breeding with CRE-recombinase transgenic mice with a variety of promoters to yield tissue or cell type-specific deletions of SMAD7. SMAD7 has been shown to play a role in bone morphogenesis, cardiovascular tissue generation, immune regulation and fibrosis. Therefore, these mice provide a unique model to examine the role of the SMAD7 gene in disease processes that involve immunological, fibrotic, or cardiovascular components. Specifically, these mice may represent a novel model of Scleroderma, a disease with both an immunological and fibrotic component. <ul> <li>Mouse model of Scleroderma</li> <li>Means of studying bone morphogenesis and cardiovascular tissue generation</li> <li>Means of studying the role of SMAD7 in immune regulation</li> </ul> The NIEHS is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. Please contact Sharon Soucek, Ph.D. at <a href="mailto:sharon.soucek@nih.gov">sharon.soucek@nih.gov</a> for more information. Research Material -- patent protection is not being pursued for this technology This technology is available as a research tool under a Biological Materials License. 2022-03-08 2024-10-28 2024-10-28 2010-04-20 BAXXXX, Chromosome 7, monosomy, Conditional, Deletion, Deletion 7, Gene., Mouse, RXXXXX, Scleroderma, Scleroderma, systemic, SMAD7, Strain False True True NIHTT 37470483 Website Abstract 114171064 Dong C, et al. http://www.ncbi.nlm.nih.gov/pubmed/11904440 <a href="http://www.ncbi.nlm.nih.gov/pubmed/11904440">Dong C, et al.</a> 114106875 Diaz, Marilyn NIEHS Diaz, Marilyn 1 114106875 Diaz, Marilyn NIEHS Diaz, Marilyn 1 114101393 New Mouse Strain With Conditional Deletion Of The SMAD7 Gene. E-040-2010-0 Research Material NIEHS 83739538 Choudhry, Vidita vidita.choudhry@nih.gov
United States of America Office of Technology Transfer and Development vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-2099] New Mouse Strain with Conditional Deletion of SMAD7: Analysis of Disease Processes Involving Immunological, Fibrotic or Cardiovascular Indications&body=Please send me information about technology [TAB-2099] New Mouse Strain with Conditional Deletion of SMAD7: Analysis of Disease Processes Involving Immunological, Fibrotic or Cardiovascular Indications. Choudhry, Vidita<br><a href="mailto:vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-2099] New Mouse Strain with Conditional Deletion of SMAD7: Analysis of Disease Processes Involving Immunological, Fibrotic or Cardiovascular Indications&body=Please send me information about technology [TAB-2099] New Mouse Strain with Conditional Deletion of SMAD7: Analysis of Disease Processes Involving Immunological, Fibrotic or Cardiovascular Indications.">vidita.choudhry@nih.gov</a><br> 114114591 RXXXXX 114121355 BAXXXX 114139700 SMAD7 114139701 Deletion 114139702 Conditional 114139703 Strain 114139704 Mouse 114139705 Gene. 114157027 Chromosome 7, monosomy 114157028 Scleroderma, systemic 114158607 Deletion 7 114158608 Scleroderma TAB-2080 114096298 Defensin-Based Therapeutics for the Treatment of Pulmonary Disease NHLBI Collaboration, Diagnostics, Infectious Disease, Licensing, Pulmonology, Research Materials, Therapeutics Collaboration Diagnostics Infectious Disease Licensing Pulmonology Research Materials Therapeutics Joel Moss Investigators at the National Heart, Lung and Blood Institute have developed modified defensins that are resistant to degradation, have improved characteristics compared to unmodified defensins, and are promising candidates for pulmonary disease therapeutics.<br><br> Defensins are small cationic peptides that defend the lung against pathogenic microorganisms and play an important role in innate immunity. However, during lung inflammation, defensin concentrations can reach levels that are cytotoxic for airway epithelial cells. Therefore, the development of methods to produce modified defensins that exhibit reduced cytotoxicity, while retaining the ability to stimulate the innate immune response, would be of potential therapeutic benefit for pulmonary diseases.<br><br> The inventors have previously shown that a defensin, human neutrophil peptide 1 (HNP-1), is elevated in samples from the lungs of patients with inflammatory lung disease, and that the HNP-1 in these samples is ADP-ribosylated at one or both of two arginine residues within the protein. <i>In vitro</i> studies by the inventors show that ADP-ribosyl-HNP-1 has reduced cytotoxic activity compared to HNP-1, while retaining its T cell chemotactic properties and ability to promote neutrophil recruitment, and thus ADP-ribosyl-HNP-1 may play an important role as a regulator of the inflammatory response. These properties would also be useful for treatment of pulmonary inflammation and lung diseases. However, ADP-ribosylated HNP-1 and other defensins are degraded rapidly <i>in vivo</i> due to the susceptibility of the ADP-ribose moiety to attack by hydrolases and pyrophosphatases, which limits their therapeutic potential.<br><br> The inventors have recently discovered that the ADP-ribosylated arginine residues in HNP-1 can be converted to ornithine through a non-enzymatic process that results in a peptide with an altered pharmacological profile. The investigators have also successfully generated ornithine-substituted ADP-ribosyl HNP-1 and ornithine-HNP-1 <i>in vitro</i>, which are currently being characterized. Thus, ornithine-substituted ADP-ribosyl HNP-1 and ornithine-HNP-1 may be promising candidates for the development of therapeutics to treat pulmonary disease, and the strategy of replacing ADP-ribosylated residues with ornithine to enhance stability and therapeutic efficacy may also be extended to other defensins.<br><br> Through an earlier, related invention, the inventors have also demonstrated that recombinant proteins wherein tryptophan or phenylalanine residues substitute for ADP-ribosylarginine have a similar stabilizing impact on polypeptides, making them more suitable as therapeutic agents.<br><br> The inventors also hypothesize that it would be possible to develop a treatment that increases levels of an ADP-ribosylated therapeutic protein, such as HNP-1, in the lung via inhalation administration of the therapeutic protein in conjunction with nicotinamide adenine dinucleotide (NAD), which is required for ADP-ribosylation. This could represent a unique therapeutic strategy for treating pulmonary disease. <ul> <li>Modified defensins are less cytotoxic, while retaining ability to stimulate innate immunity.</li> <li>Ornithine-substituted defensins are resistant to enzymatic degradation, making them more promising as drug candidates.</li> </ul> Development of defensin-based therapeutics that enhance the immune response in pulmonary disease patients, without damaging the epithelial cells lining the airway. The National Heart, Lung and Blood Institute Translational Medicine Branch is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize defensin-based therapeutic agents to treat pulmonary diseases. Please contact Brian W. Bailey, Ph.D. at 301-494-4094 or <a href="mailto:bbailey@mail.nih.gov">bbailey@mail.nih.gov</a> for more information. Available for licensing. 2022-03-08 2024-10-28 2024-10-28 2010-03-11 ADP-ribose, ADP-ribose-arginine, ADP-RIBOSYLARGININE, ADP-ribosylation, AIRWAY, Arginines, ASTHMA, BBXXXX, cytotoxic, CYTOTOXICITY, DBXXXX, defensin, Defensins, DXXXXX, HNP-1, human neutrophil peptide 1, IB4XXX, IBXXXX, Inflammation, IXXXXX, neutrophil, Patent Category - Biotechnology, Pulmonary, PULMONARY FIBROSIS False True <i>In vitro</i> studies, as well as analysis of patient samples, have been performed. True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract E-080-2002-0 E-160-2002-0 114171027 Stevens LA, Levine RL, Gochuico BR, Moss J. ADP-ribosylation of human defensin HNP-1 results in the replacement of the modified arginine with the noncoded amino acid ornithine. Proc Natl Acad Sci U S A. 2009 Nov 24;106(47):19796-19800. http://preview.ncbi.nlm.nih.gov/pubmed/19897717 <a href="http://preview.ncbi.nlm.nih.gov/pubmed/19897717">Stevens LA, Levine RL, Gochuico BR, Moss J. ADP-ribosylation of human defensin HNP-1 results in the replacement of the modified arginine with the noncoded amino acid ornithine. Proc Natl Acad Sci U S A. 2009 Nov 24;106(47):19796-19800.</a> 114106837 Moss, Joel National Heart, Lung, and Blood Institute (NHLBI) NHLBI Moss, Joel (NHLBI) 1 114106837 Moss, Joel National Heart, Lung, and Blood Institute (NHLBI) NHLBI Moss, Joel (NHLBI) 1 114101370 ADP-ribosylation Of Specific Arginines In Human Neutrophil Peptide-l (HNP-l) E-243-2009-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-2080] Defensin-Based Therapeutics for the Treatment of Pulmonary Disease&body=Please send me information about technology [TAB-2080] Defensin-Based Therapeutics for the Treatment of Pulmonary Disease. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-2080] Defensin-Based Therapeutics for the Treatment of Pulmonary Disease&body=Please send me information about technology [TAB-2080] Defensin-Based Therapeutics for the Treatment of Pulmonary Disease.">shmilovm@nih.gov</a><br> 114165963 E-243-2009-0 E-243-2009-0-US-01 METHOD FOR THE TREATMENT OF PULMONARY DISEASE AND METHOD OF PRODUCING PROTEINS OF USE THEREIN PRV US 61/241,311 Abandoned US <br />Provisional (PRV) 61/241,311<br />Filed on 2009-09-10<br />Status: Abandoned 114166157 E-243-2009-0 E-243-2009-0-PCT-02 METHOD FOR THE TREATMENT OF PULMONARY DISEASE AND METHOD OF PRODUCING PROTEINS OF USE THEREIN PCT Patent Cooperation Treaty PCT/US2010/048068 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2010/048068<br />Filed on 2010-09-08<br />Status: Expired 114166669 E-243-2009-0 E-243-2009-0-US-03 Method for the Treatment of Pulmonary Disease and Method of Producing Proteins of Use Therein: National Stage US 8,828,380 13/394,393 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8828380 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8828380">8,828,380</a><br />Filed on 2012-03-06<br />Status: Issued 114167905 E-243-2009-0 E-243-2009-0-US-04 Method For The Treatment Of Pulmonary Disease And Method of Producing Proteins Of Use Therein DIV US 14/450,512 Abandoned US <br />Divisional (DIV) 14/450,512<br />Filed on 2014-08-04<br />Status: Abandoned 114120949 DBXXXX 114120950 IB4XXX 114120951 DXXXXX 114120952 IXXXXX 114120953 IBXXXX 114121195 BBXXXX 114139462 ADP-ribosylation 114139463 Inflammation 114139464 Arginines 114139465 Pulmonary 114139466 neutrophil 114139467 Defensins 114139468 HNP-1 114139469 Patent Category - Biotechnology 114139470 CYTOTOXICITY 114139471 cytotoxic 114139472 human neutrophil peptide 1 114139473 defensin 114139474 AIRWAY 114139475 ASTHMA 114139476 PULMONARY FIBROSIS 114139477 ADP-ribose 114139478 ADP-ribose-arginine 114139479 ADP-RIBOSYLARGININE TAB-2093 114096310 Use of Modified Peptide Nucleic Acids for Visualizing DNA NIDDK Collaboration Collaboration Daniel Appella The compounds described in this technology may be useful in the development of nucleic acid detection kits for various pathogens.<br /><br /> Technologies for genomic detection most commonly use DNA probes to hybridize to target sequences, and require the use of Polymerase Chain Reaction (PCR) to amplify target sequences. Replacing the DNA probe with peptide nucleic acid (PNA) can greatly eliminate the need for PCR because the binding strength of PNAs to complementary DNA is stronger than DNA binding to complementary DNA. In addition, PNAs are nuclease and protease resistant, and form very stable and highly sequence-specific complexes with DNA.<br /><br /> This technology describes a method of making pure enantiomers of <i>trans-tert</i>-butyl-2-aminocyclopentylcarbamate (tcycp) and methods of modifying PNAs by incorporating tcycp compounds into the PNA. This technology may also be practical for detecting infectious agents such as anthrax, avian flu, tuberculosis (TB), severe acute respiratory syndrome (SARS), human papilloma virus (HPV) and human immunodeficiency virus (HIV). <ul> <li>Very stable diagnostic method to detect nucleic acids without using Polymerase Chain Reaction (PCR)</li> <li>Binding to complementary DNA can be seen by eye</li> <li>Visual detection of anthrax has been shown</li> <li>Useful for outside of a laboratory environment</li> </ul> The National Institute of Diabetes and Digestive and Kidney Diseases, Laboratory of Bioorganic Chemistry, Drug-Receptor Interactions Section, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. Please contact Dr. Daniel Appella at <a href="mailto:appellad@niddk.nih.gov ">appellad@niddk.nih.gov</a> for more information. 2022-03-08 2024-10-28 2024-10-28 2017-04-17 2, Acid, Acids, Anthrax, APPLICATIONS, Cross-Coupled, Cyclopentan, Detection, Diamine-modified, Gamma-lysine, Modified, Nucleic, Patent Category - Chemistry, PATHOGENS, Peptide, Probes, SARS, Severe acute respiratory syndrome, Synthesis, Trans-1, YXXXXX False True Early-stage True NIHTT 37470483 Website Abstract 114106855 Appella, Daniel National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Appella, Daniel (NIDDK) 1 114106855 Appella, Daniel National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Appella, Daniel (NIDDK) 1 114101688 Cross-Coupled Peptide Nucleic Acids For Detection Of Nucleic Acids Of Pathogens E-308-2006-3 Filing authorized National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83692066 Tong, Betty tongb@niddk.nih.gov
United States of America Senior Technology Advancement Office tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-2093] Use of Modified Peptide Nucleic Acids for Visualizing DNA&body=Please send me information about technology [TAB-2093] Use of Modified Peptide Nucleic Acids for Visualizing DNA. Tong, Betty<br><a href="mailto:tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-2093] Use of Modified Peptide Nucleic Acids for Visualizing DNA&body=Please send me information about technology [TAB-2093] Use of Modified Peptide Nucleic Acids for Visualizing DNA.">tongb@niddk.nih.gov</a><br> 114162606 E-308-2006-3 E-308-2006-3-US-02 Cross-Coupled Peptide Nucleic Acids For Detection Of Nucleic Acids Of Pathogens CON US 9,156,778 13/592,490 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9156778 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9156778">9,156,778</a><br />Filed on 2012-08-23<br />Status: Issued 114166670 E-308-2006-3 E-308-2006-3-US-01 Cross-Coupled Peptide Nucleic Acids For Detection Of Nucleic Acids Of Pathogens CIP US 12/409,159 Abandoned US <br />Continuation in Part (CIP) 12/409,159<br />Filed on 2009-03-23<br />Status: Abandoned 114121015 YXXXXX 114139642 Trans-1 114139643 2 114139644 Cyclopentan 114139645 Diamine-modified 114139646 Gamma-lysine 114139647 Modified 114139648 Peptide 114139649 Nucleic 114139650 Acids 114139651 Probes 114139652 Acid 114139653 Detection 114139654 Synthesis 114139655 APPLICATIONS 114139656 Patent Category - Chemistry 114142646 Cross-Coupled 114142647 PATHOGENS 114157021 SARS 114157022 Anthrax 114158605 Severe acute respiratory syndrome TAB-2059 114096278 T-Cell-Specific Gfi-1 Knockout Mouse NIAID Animal Models, Licensing, Materials Available, Research Materials Animal Models Licensing Materials Available Research Materials William Paul (Estate Of), Jinfang (Jeff) Zhu This is a mouse model available to study T-cell differentiation. Growth factor independent 1 (GFi-1) is a transcriptional repressor that is transiently induced during T-cell activation. This knockout mouse line is a GFi-1[flox/flox] introduced into a mouse Cre controlled by a CD4 promoter, which allows selective removal of GFi-1 exclusively in T-cells. It has thus-far been used to demonstrate that GFi-1 plays a critical role in enhancing Th2 cell expansion and repressing induction of Th17 and CD103+ iTreg cells. <ul> <li>Tool for studying T-cell proliferation and differentiation.</li> </ul> Research Tool -- patent protection is not being pursued for this technology This technology is available as a research tool under a Biological Materials License. 2022-03-08 2024-10-28 2024-10-28 2010-01-25 BAXXXX, Cells, FUNCTION, Gfi-1, Gfi1[fl/fl]-CD4Cre, IMPORTANT, KO, Mouse, Regulatory, REVEALS, RXXXXX, Specific, Strain, T, T-cell False True True NIHTT 37470483 Website Abstract 114171000 Zhu J, et al. https://www.ncbi.nlm.nih.gov/pubmed/19188499 <a href="https://www.ncbi.nlm.nih.gov/pubmed/19188499">Zhu J, et al.</a> 114106074 Paul (Estate Of), William NIAID - DIR Paul (Estate Of), William 0 114106075 Zhu, Jinfang (Jeff) NIAID - DIR NIAID Zhu, Jinfang (Jeff) (NIAID) 1 114106075 Zhu, Jinfang (Jeff) NIAID - DIR NIAID Zhu, Jinfang (Jeff) (NIAID) 1 114106074 Paul (Estate Of), William NIAID - DIR Paul (Estate Of), William 0 114101349 The Gfi1[fl/fl]-CD4Cre (T-cell Specific Gfi-1 KO) Mouse Strain Reveals An Important Function Of Gfi-1 In Regulatory T Cells E-242-2009-0 Research Material NIAID 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2059] T-Cell-Specific Gfi-1 Knockout Mouse&body=Please send me information about technology [TAB-2059] T-Cell-Specific Gfi-1 Knockout Mouse. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-2059] T-Cell-Specific Gfi-1 Knockout Mouse&body=Please send me information about technology [TAB-2059] T-Cell-Specific Gfi-1 Knockout Mouse.">yogikala.prabhu@nih.gov</a><br> 114120818 RXXXXX 114121354 BAXXXX 114139237 Gfi1[fl/fl]-CD4Cre 114139238 T-cell 114139239 Specific 114139240 Gfi-1 114139241 KO 114139242 Mouse 114139243 Strain 114139244 REVEALS 114139245 IMPORTANT 114139246 FUNCTION 114139247 Regulatory 114139248 T 114139249 Cells TAB-2049 114096268 Device for Selective Partitioning of Frozen Cellular Products NHLBI Cardiology, Collaboration, Consumer Products, Dental, Diagnostics, Endocrinology, Infectious Disease, Materials Available, Medical Devices, Neurology, Non-Medical Devices, Oncology, Ophthalmology, Research Materials, Therapeutics Cardiology Collaboration Consumer Products Dental Diagnostics Endocrinology Infectious Disease Materials Available Medical Devices Neurology Non-Medical Devices Oncology Ophthalmology Research Materials Therapeutics Richard Childs, Sumithira Vasu Cryopreservation using liquid nitrogen frozen polyvinyl bags allows for storing cellular materials for extended periods while maintaining their activity and viability. Such bags are commonly used in the clinic to store blood products including blood cells, plasma, hematopoietic stem cells, umbilical cord blood for future uses including transplantation. These materials, typically obtained in limited quantities, may be of great therapeutic value, as is the case of stem cells or cord blood derived cells which can be used to potentially treat a number of diseases. Currently, even if only a small portion of the cryopreserved sample is needed the whole bag must be thawed, wasting much of the sample or rendering the remaining sample susceptible to contamination since it cannot be effectively refrozen or sterilized. The present device meets an unmet need for retrieving a portion of a frozen sample stored in polyvinyl cryopreserved bags, resealing the remainder of the sample and preserving the cryopreserved state and integrity of the rest of the cellular product without compromising viability and sterility. <ul> <li>Cryopreservation</li> <li>Cellular Products</li> <li>Hematopoietic stem cells</li> <li>Umbilical cord blood</li> <li>iPSCs</li> <li>Transplantation</li> <li>Chronic spinal cord injury</li> <li>Neurological disorders</li> <li>Cancer immunotherapy</li> <li>Cell banking</li> <li>Cell replacement therapy</li> </ul> <ul> <li>Partitioning cryopreserved cell products</li> <li>Maintenance of sterility of partitioned product</li> <li>Maintenance of viability of partitioned product</li> <li>Resealing of cryopreservation bag</li> <li>Multiple use of patient derived cellular products</li> </ul> The National Heart, Lung, and Blood Institute is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize Device for Partitioning Cryopreserved Cellular Products. For collaboration opportunities, please contact Cecilia Pazman, Ph.D. at 301.594.4273 or <a href="mailto:pazmance@nhlbi.nih.gov">pazmance@nhlbi.nih.gov</a>. Related international patents/patent applications 2022-05-07 2024-10-28 2024-10-28 2015-05-29 AC3XXX, ACXXXX, AE1BXX, AE1XXX, AEXXXX, AXXXXX, BAG, Cryopreserved, DEVICE, Method, Patent Category - Mech/Elect/Soft, SAMPLE, STERILE, Umbilical Cord Blood, VCXXXX, VEXXXX, VPXXXX, WBXXXX, WHXXXX, WIXXXX, WJXXXX, WMXXXX, XDXXXX, YFXXXX False True Prototype True 52406769 Prototype 52406769 NIHTT 37470483 Website Abstract 114106803 Vasu, Sumithira Clinical Center (CC) Vasu, Sumithira 0 114106804 Childs, Richard National Heart, Lung, and Blood Institute (NHLBI) NHLBI Childs, Richard (NHLBI) 1 114106804 Childs, Richard National Heart, Lung, and Blood Institute (NHLBI) NHLBI Childs, Richard (NHLBI) 1 114106803 Vasu, Sumithira Clinical Center (CC) Vasu, Sumithira 0 114101340 Device & Method For Sterile Sample Removal From Cryopreserved Bag E-173-2009-0 Filing authorized Clinical Center (CC), National Heart, Lung, and Blood Institute (NHLBI), The American Fluoroseal Corporation 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-2049] Device for Selective Partitioning of Frozen Cellular Products&body=Please send me information about technology [TAB-2049] Device for Selective Partitioning of Frozen Cellular Products. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-2049] Device for Selective Partitioning of Frozen Cellular Products&body=Please send me information about technology [TAB-2049] Device for Selective Partitioning of Frozen Cellular Products.">shmilovm@nih.gov</a><br> 114163156 E-173-2009-0 E-173-2009-0-US-06 Selective Access To Cryopreserved Samples National Stage US 8,790,597 13/318,122 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8790597 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8790597">8,790,597</a><br />Filed on 2011-10-28<br />Status: Issued 114165692 E-173-2009-0 E-173-2009-0-US-01 Device And Method For Sterile Removal Of Sample From Cryopreserved Bag PRV US 61/175,131 Abandoned US <br />Provisional (PRV) 61/175,131<br />Filed on 2009-05-04<br />Status: Abandoned 114166046 E-173-2009-0 E-173-2009-0-PCT-02 Selective Access To Cryopreserved Samples PCT Patent Cooperation Treaty PCT/US2010/033575 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2010/033575<br />Filed on 2010-05-04<br />Status: Expired 114167839 E-173-2009-0 E-173-2009-0-US-07 Selective Access to Cryopreserved Samples DIV US 9,296,500 14/305,578 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9296500 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9296500">9,296,500</a><br />Filed on 2014-06-16<br />Status: Issued 114120776 AE1BXX 114120777 AC3XXX 114120778 AXXXXX 114120779 ACXXXX 114120780 AEXXXX 114120781 AE1XXX 114127061 VCXXXX 114127062 VEXXXX 114127063 VPXXXX 114127064 WBXXXX 114127065 WHXXXX 114127066 WIXXXX 114127067 WJXXXX 114127068 WMXXXX 114127069 XDXXXX 114127070 YFXXXX 114139111 DEVICE 114139112 Method 114139113 STERILE 114139114 Umbilical Cord Blood 114139115 SAMPLE 114139116 Cryopreserved 114139117 BAG 114139118 Patent Category - Mech/Elect/Soft TAB-2046 114096265 Device and Method for Direct Measurement of Isotopes of Expired Gases: Application in Research of Metabolism and Metabolic Disorders, and in Medical Screening and Diagnostics NHGRI Collaboration, Licensing Collaboration Licensing Randy Chandler, Charles Venditti The technology offered for licensing and for further development concerns a novel device for intervallic collection of expired gas from subjects and subsequent measurement of the isotopic content of such expired gases. The device is specifically designed for medical research and clinical applications, and in particular in the area of metabolic disorders. The device may facilitate the development and testing of new therapies for such disorders and may be used for medical screening and diagnostics of metabolic diseases. The unique design of the device includes a constant volume respiratory chamber equipped with a series of valves and stopcocks to allow precise and repetitive removal of expired gases, and addition of air or other gas to maintain the chamber at a constant volume. Also included is a vacuum tube adapter linked to a port on a three-way stopcock to allow facile transfer of the chamber gases to vacuum tubes for subsequent chemical analyses. The device also includes gas sensors operably linked to detectors and inserted to the chamber through airtight ports; this allows the operator to independently and directly measure the carbon dioxide production rate and oxygen consumption of the test subject while the expired gases are removed for study. <br /><br /> The experimental subject (e.g. mammal) is first contacted with a substrate (e.g. amino acid, fatty acid, organic acid) containing an isotope (e.g. <sup>13</sup>C) and placed in the chamber. The unique design allows easy gas removal and addition while maintaining a constant chamber volume. Precisely measured air samples are collected from the chamber by the syringe and subsequently transferred to a self-sealing vacuum tube which is then removed for analysis. Subsequent sampling is accomplished in the exact same manner, after an equivalent volume of ambient air, or other gas such as pure oxygen, is reinjected in the chamber to maintain pressure and volume. Air samples from the chamber are collected periodically and the content of the isotope (<sup>13</sup>C) accumulated in the chamber gas due to metabolism and the formation of <sup>13</sup>CO<sub>2</sub> is measured (e.g. via Isotope Ratio Mass Spectroscopy (IRMS)) from the collected samples. The rate of the metabolite's development (i.e. <sup>13</sup>CO<sub>2</sub>) can thus be determined and can thus provide information on the metabolic status of the subject, such as the rate and extent of oxidation of the administered isotope. Furthermore, results of such analysis can provide fundamental information on the ability of the subject to metabolize a compound, quantitate the effectiveness of an experimental therapy (i.e. enzyme replacement, gene therapy, hormone administration, etc.) and thus facilitate progress in the development of interventional therapies. <ul> <li>The device of this invention is uniquely designed for precise periodic collection of expired gas samples from a test subject and their transfer for analytical processing while the carbon dioxide production rate and oxygen consumption rate are independently and simultaneously measured.</li> <li>The unique configuration of the device and the manner in which the valves and stopcocks are attached to the main chamber facilitates the performance of repetitive measurements in a seamless, precise and reliable fashion.</li> <li>The technique and device uses stable isotopes, so treated animals can be returned to the cage after study with no concerns of radioactive contamination. This also allows animals that are difficult and expensive to create, such as genetically engineered rodents, to be repeatedly studied, pre- and post-intervention(s) and with various compounds at different times.</li> <li>The device can be readily fabricated in a relatively inexpensive manner and operated with simple instructions.</li> </ul> <ul> <li>Research in the area of metabolic disorders</li> <li>Development of therapies (including enzyme replacement and gene therapy) for metabolic disorders</li> <li>Potential applications in screening and diagnostics of metabolic disorders</li> <li>Assessment of non-invasive breath tests to study metabolism</li> </ul> The Organic Acid Research Section, Genetics and Molecular Biology Branch, National Human Genome Research Institute (NHGRI), is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology or related laboratory interests. Please contact Claire T. Driscoll at <a href="mailto:cdriscol@mail.nih.gov">cdriscol@mail.nih.gov</a> for more information. 2022-03-08 2024-10-28 2024-10-28 2009-12-23 (4)r syndrome, 3-@hydroxyacyl-coa dehydrogenase deficiency, AC3XXX, Acid, Acidemia, isovaleric, ACXXXX, AMINO, AXXXXX, C syndrome, C13CO2, Chamber, Chromosome 4 ring syndrome, Chromosome 6 ring syndrome, Chromosome 7 ring syndrome, CO2, Detection, Direct, FATTY, G syndrome, HAD deficiency, HIS deficiency, Histidinemia, Hypertelorism with esophageal abnormality and hypospadias, Isotope, Isovaleric acidemia, Maple syrup urine disease, Mass, MEASURE, Measureirent, MEASUREMENT, metabolic disorder, Method, Methylmalonic acidemia, Mice, N syndrome, Non-alcoholic steatohepatitis (NASH), ORGANIC, OXIDATION, Patent Category - Mech/Elect/Soft, Phenylketonuria, production, QUANTITATION, R(6) syndrome, R(7) syndrome, RATES, RATIO, respiratory, SPECTROMETRY, SUBSTRATES, Syndrome X, Vivo, W syndrome, W syndrome; Syndrome W False True Prototype True NIHTT 37470483 Website Abstract 114170973 Venditti CP, Manoli E, Chandler RJ. A Method To Determine The In Vivo Oxidative Capacity For 13C Isotopomers In Mice : Use To Study Intermediary Metabolism And To Monitor Transgene Activity. Presented at the American Society of Gene Therapy 12th Annual Meeting, May 2009. Venditti CP, Manoli E, Chandler RJ. A Method To Determine The In Vivo Oxidative Capacity For 13C Isotopomers In Mice : Use To Study Intermediary Metabolism And To Monitor Transgene Activity. Presented at the American Society of Gene Therapy 12th Annual Meeting, May 2009. 114170974 Chandler RJ, Venditti CP. http://www.ncbi.nlm.nih.gov/pubmed/19861951 <a href="http://www.ncbi.nlm.nih.gov/pubmed/19861951">Chandler RJ, Venditti CP.</a> 114106800 Chandler, Randy National Human Genome Research Institute (NHGRI) NHGRI Chandler, Randy (NHGRI) 0 114106801 Venditti, Charles National Human Genome Research Institute (NHGRI) NHGRI Venditti, Charles (NHGRI) 1 114106801 Venditti, Charles National Human Genome Research Institute (NHGRI) NHGRI Venditti, Charles (NHGRI) 1 114106800 Chandler, Randy National Human Genome Research Institute (NHGRI) NHGRI Chandler, Randy (NHGRI) 0 114101337 A Respiratory Chamber And Method Using Direct CO2 Measurement And Isotope Ratio Mass Spectrometry To Measure In Vivo Oxidation Rates Of Amino, Organic And Fatty Acid Substrates In Mice By The Detection And Quantitation Of C13CO2 Production E-099-2009-0 Filing authorized National Human Genome Research Institute (NHGRI) 83716782 Campbell, Eggerton eggerton.campbell@nih.gov
United States of America eggerton.campbell@nih.gov?subject=Web Inquiry on [TAB-2046] Device and Method for Direct Measurement of Isotopes of Expired Gases: Application in Research of Metabolism and Metabolic Disorders, and in Medical Screening and Diagnostics&body=Please send me information about technology [TAB-2046] Device and Method for Direct Measurement of Isotopes of Expired Gases: Application in Research of Metabolism and Metabolic Disorders, and in Medical Screening and Diagnostics. Campbell, Eggerton<br><a href="mailto:eggerton.campbell@nih.gov?subject=Web Inquiry on [TAB-2046] Device and Method for Direct Measurement of Isotopes of Expired Gases: Application in Research of Metabolism and Metabolic Disorders, and in Medical Screening and Diagnostics&body=Please send me information about technology [TAB-2046] Device and Method for Direct Measurement of Isotopes of Expired Gases: Application in Research of Metabolism and Metabolic Disorders, and in Medical Screening and Diagnostics.">eggerton.campbell@nih.gov</a><br> 114161682 E-099-2009-0 E-099-2009-0-US-01 Device And Method For Direct Measurement Of Isotopes Of Expired Gases ORD US 8,293,187 12/418,795 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8293187 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8293187">8,293,187</a><br />Filed on 2009-04-06<br />Status: Abandoned 114166878 E-099-2009-0 E-099-2009-0-US-02 Device and Method for Direct Measurement of Isotopes of Expired Gases DIV US 8,721,988 13/620,490 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8721988 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8721988">8,721,988</a><br />Filed on 2012-09-14<br />Status: Abandoned 114120763 AC3XXX 114120764 AXXXXX 114120765 ACXXXX 114139071 respiratory 114139072 Chamber 114139073 Method 114139074 Direct 114139075 CO2 114139076 Measureirent 114139077 Isotope 114139078 RATIO 114139079 Mass 114139080 SPECTROMETRY 114139081 MEASURE 114139082 Vivo 114139083 OXIDATION 114139084 RATES 114139085 AMINO 114139086 ORGANIC 114139087 FATTY 114139088 Acid 114139089 SUBSTRATES 114139090 Mice 114139091 Detection 114139092 QUANTITATION 114139093 C13CO2 114139094 production 114139095 MEASUREMENT 114139096 Patent Category - Mech/Elect/Soft 114156945 Acidemia, isovaleric 114156946 Syndrome X 114156947 C syndrome 114156948 Phenylketonuria 114156949 Methylmalonic acidemia 114156950 Chromosome 7 ring syndrome 114156951 W syndrome 114156952 Hypertelorism with esophageal abnormality and hypospadias 114156953 3-@hydroxyacyl-coa dehydrogenase deficiency 114156954 N syndrome 114156955 Chromosome 6 ring syndrome 114156956 Non-alcoholic steatohepatitis (NASH) 114156957 Histidinemia 114156958 metabolic disorder 114156959 Chromosome 4 ring syndrome 114156960 Maple syrup urine disease 114158570 Isovaleric acidemia 114158571 R(7) syndrome 114158572 W syndrome; Syndrome W 114158573 G syndrome 114158574 HAD deficiency 114158575 R(6) syndrome 114158576 HIS deficiency 114158577 (4)r syndrome TAB-2047 114096266 Vaccines Against Malarial Diseases NIAID Collaboration, Infectious Disease, Licensing, Vaccines Collaboration Infectious Disease Licensing Vaccines David Narum The invention offered for licensing is in the field of use of vaccines for malaria. The invention provides gene sequences encoding an erythrocyte binding protein of a malaria pathogen for the expression of the erythrocyte binding protein. The codon composition of the synthetic gene sequences approximates the mammalian codon composition. The synthetic gene sequences are useful for incorporation into DNA vaccine vectors, for the incorporation into various expression vectors for production of malaria proteins, or both. The synthetic genes may be modified to avoid post-translational modification of the encoded protein in other hosts. Administration of the synthetic gene sequences, or the encoded protein, as an immunization agent is useful for induction of immunity against malaria, treatment of malaria, or both. The approach presented in this invention, i.e. vaccine that may block the binding of the malaria parasite and subsequent erythrocyte invasion, may work independently or in combination with other vaccines which are based on different mechanisms. Due to the complex nature of the malaria parasite, multiple approaches have been attempted to develop malaria vaccines. In particular, due to the diversity attributed to the different life cycle stages of the parasite, there are several sites that can be used as vaccine targets. The approach offered in the present invention, i.e. blockage of the binding to blood erythrocyte, may work independently or in combination with other vaccines based on different mechanisms to create an effective vaccine against malaria. Vaccine compositions against malaria in the form of DNA vaccines or as protein immunogens. The NIAID Office of Technology Development is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize the erythrocyte binding protein as a malaria vaccine. Please contact Dana Hsu at 301-496-2644 for more information. Available for licensing. 2022-03-08 2024-10-28 2024-10-28 2009-12-23 DC2XXX, DCXXXX, DXXXXX, GENES, Malaria, Malaria (Plasmodium sp.), MALARIAL, Methods, proteins, SACGHS DNA Patent Initial Set, Synthetic False True Proof of concept demonstrated. True NIHTT 37470483 Website Abstract 114170975 H Liang and BK Sim. Conservation of structure and function of the erythrocyte-binding domain of Plasmodium falciparum EBA-175. Mol Biochem Parasitol. 1997 Feb;84(2):241-245. H Liang and BK Sim. Conservation of structure and function of the erythrocyte-binding domain of Plasmodium falciparum EBA-175. Mol Biochem Parasitol. 1997 Feb;84(2):241-245. 114170976 DL Narum et al. Codon optimization of gene fragments encoding Plasmodium falciparum merzoite proteins enhances DNA vaccine protein expression and immunogenicity in mice. Infect Immun. 2001 Dec;69(12):7250-7253. http://www.ncbi.nlm.nih.gov/pubmed/11705894?dopt <a href="http://www.ncbi.nlm.nih.gov/pubmed/11705894?dopt">DL Narum et al. Codon optimization of gene fragments encoding Plasmodium falciparum merzoite proteins enhances DNA vaccine protein expression and immunogenicity in mice. Infect Immun. 2001 Dec;69(12):7250-7253.</a> 114170977 DL Narum et al. A novel Plasmodium falciparum erythrocyte binding protein-2 (EBP2/BAEBL) involved in erythrocyte receptor binding. Mol Biochem Parasitol. 2002 Feb;119(2):159-168. http://www.ncbi.nlm.nih.gov/pubmed/11814568?dopt <a href="http://www.ncbi.nlm.nih.gov/pubmed/11814568?dopt">DL Narum et al. A novel Plasmodium falciparum erythrocyte binding protein-2 (EBP2/BAEBL) involved in erythrocyte receptor binding. Mol Biochem Parasitol. 2002 Feb;119(2):159-168.</a> 114106802 Narum, David NIAID Narum, David (NIAID) 1 114106802 Narum, David NIAID Narum, David (NIAID) 1 114101338 Synthetic Genes For Malarial Proteins And Methods Of Use E-052-2004-0 Filing authorized EntreMed, Inc. 83720410 Yang, David (Po-Lung) polung.yang@nih.gov
United States of America Technology Transfer and Intellectual Property Office polung.yang@nih.gov?subject=Web Inquiry on [TAB-2047] Vaccines Against Malarial Diseases&body=Please send me information about technology [TAB-2047] Vaccines Against Malarial Diseases. Yang, David (Po-Lung)<br><a href="mailto:polung.yang@nih.gov?subject=Web Inquiry on [TAB-2047] Vaccines Against Malarial Diseases&body=Please send me information about technology [TAB-2047] Vaccines Against Malarial Diseases.">polung.yang@nih.gov</a><br> 114165688 E-052-2004-0 E-052-2004-0-US-02 Synthetic Genes For Malarial Proteins and Methods of Use ORD US 7,078,507 10/293,913 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7078507 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7078507">7,078,507</a><br />Filed on 2002-11-12<br />Status: Expired 114165689 E-052-2004-0 E-052-2004-0-US-01 Synthetic Genes For Malarial Proteins And Methods Of Use PRV US 60/345,051 Abandoned US <br />Provisional (PRV) 60/345,051<br />Filed on 2001-11-09<br />Status: Abandoned 114165690 E-052-2004-0 E-052-2004-0-PCT-03 Synthetic Genes For Malarial Proteins and Methods Of Use PCT Patent Cooperation Treaty PCT/US02/036368 Expired Patent Cooperation Treaty <br />(PCT) PCT/US02/036368<br />Filed on 2002-11-12<br />Status: Expired 114120766 DC2XXX 114120767 DXXXXX 114120768 DCXXXX 114139097 Synthetic 114139098 GENES 114139099 MALARIAL 114139100 proteins 114139101 Methods 114139102 SACGHS DNA Patent Initial Set 114156961 Malaria 114157954 Malaria (Plasmodium sp.) TAB-2041 114096260 RORgamma (RORC) Deficient Mice Which Are Useful for the Study of Lymph Node Organogenesis and Immune Responses NIEHS Collaboration, Diagnostics, Licensing, Materials Available, Research Materials, Therapeutics Collaboration Diagnostics Licensing Materials Available Research Materials Therapeutics Anton Jetten The retinoid-related orphan receptor gamma (RORgamma) is a member of the nuclear receptor superfamily. NIH investigators used homologous recombination in embryonic stem cells to generate mice in which the RORgamma gene was disrupted. RORgamma deficient mice lack peripheral and mesenteric lymph nodes and Peyer's patches indicating that ROR expression is indispensable for lymph node organogenesis. In addition, RORgamma is required for the generation of Th17 cells which play a critical role in autoimmune disease.<br><br> The RORgamma deficient mice are useful to identify the physiological functions of the RORgamma. RORgamma deficient mice also provide an excellent tool to study the role of RORgamma in immune responses and autoimmune disease, the study of the role of Th17 and interleukin 17 in these processes, and the analysis. The NIEHS is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize the ROR gamma mice or related laboratory research interests. Please contact Dr. Sharon Soucek at <a href="mailto:sharon.soucek@nih.gov">sharon.soucek@nih.gov</a> or 984-287-4152 for more information. Research Tool -- patent protection is not being pursued for this technology Available for licensing under a Biological Materials License Agreement. 2022-03-08 2024-10-28 2024-10-28 2009-11-23 Autoimmune, DEFICIENT, Disease, IDXXXX, IMMUNE, IXXXXX, Mice, Responses, RORC, RORgamma, RXXXXX, TOOLS False True True NIHTT 37470483 Website Abstract 114170968 S Kurebayashi, E Ueda, M Sakaue, DD Patel, A Medvedev, F Zhang, AM Jetten. Retinoid-related orphan receptor ? (ROR?) is essential for lymphoid organogenesis and controls apoptosis during thymopoiesis. Proc Natl Acad Sci USA. 2000 Aug 29;97(18):10132-10137. http://www.ncbi.nlm.nih.gov/pubmed/10963675?dopt <a href="http://www.ncbi.nlm.nih.gov/pubmed/10963675?dopt">S Kurebayashi, E Ueda, M Sakaue, DD Patel, A Medvedev, F Zhang, AM Jetten. Retinoid-related orphan receptor ? (ROR?) is essential for lymphoid organogenesis and controls apoptosis during thymopoiesis. Proc Natl Acad Sci USA. 2000 Aug 29;97(18):10132-10137.</a> 114106795 Jetten, Anton NIEHS NIEHS Jetten, Anton (NIEHS) 1 114106795 Jetten, Anton NIEHS NIEHS Jetten, Anton (NIEHS) 1 114101331 RORgamma (RORC) Deficient Mice As Tools In The Study Of Immune Responses And Autoimmune Disease E-222-2009-0 Research Material NIEHS 83739538 Choudhry, Vidita vidita.choudhry@nih.gov
United States of America Office of Technology Transfer and Development vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-2041] RORgamma (RORC) Deficient Mice Which Are Useful for the Study of Lymph Node Organogenesis and Immune Responses&body=Please send me information about technology [TAB-2041] RORgamma (RORC) Deficient Mice Which Are Useful for the Study of Lymph Node Organogenesis and Immune Responses. Choudhry, Vidita<br><a href="mailto:vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-2041] RORgamma (RORC) Deficient Mice Which Are Useful for the Study of Lymph Node Organogenesis and Immune Responses&body=Please send me information about technology [TAB-2041] RORgamma (RORC) Deficient Mice Which Are Useful for the Study of Lymph Node Organogenesis and Immune Responses.">vidita.choudhry@nih.gov</a><br> 114120741 RXXXXX 114120742 IXXXXX 114120743 IDXXXX 114139020 RORgamma 114139021 RORC 114139022 DEFICIENT 114139023 Mice 114139024 TOOLS 114139025 IMMUNE 114139026 Responses 114139027 Autoimmune 114139028 Disease TAB-1999 114096219 Multilayered RF Coil System for Improving Transmit B1 Field Homogeneity in High-Field MRI NINDS Collaboration, Licensing Collaboration Licensing Jozef (Jeff) Duyn, Alan Koretsky, Hellmut Merkle, Shumin Wang Available for licensing and commercial development is a multilayered radio-frequency (RF) coil system for improving the transmit B1 field homogeneity for magnetic resonance imaging (MRI) at high field strengths. The current invention aims at manipulating the inhomogeneous profile of the transmit B1 field, which causes MR images to become less uniform as the magnetic field strength is increased, by utilizing an inner array of RF elements (e.g. surface coils) within and coupled to an outer transmit unit (e.g. a birdcage coil or other volume coil). Improvement in B1 field homogeneity is achieved by tuning the surface coils of the inner layer to an appropriate resonant frequency and then passively coupling them to the outer-layer volume coil. Furthermore, the amount of coupling is determined by the intrinsic properties of the transmit unit and can be adjusted accordingly. The current design provides an effective approach for reducing B1 field homogeneity at high fields and can be implemented without the need for independent RF channels, thereby reducing MRI system complexity. Furthermore it can be readily implemented on existing MRI coil systems by detuning surface coils rather than decoupling them during the transmit phase. <ul> <li>High-Field MRI</li> <li>Improvement of MR Image Uniformity</li> </ul> The Laboratory of Functional and Molecular Imaging (LFMI) at the National Institute of Neurological Disorders and Stroke (NINDS) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize MRI applications that aim to provide novel functional and molecular imaging techniques to study brain structure and function. Please contact Laurie Arrants at <a href="mailto:arrantsl@ninds.nih.gov">arrantsl@ninds.nih.gov</a> or 301-435-3112 for more information. 2022-03-08 2024-10-28 2024-10-28 2009-08-11 AA3AXX, AA3B1X, AA3BXX, AA3XXX, AAXXXX, AXXXXX, Circuitry, IMAGING, Magnetic Resonance, MRI, PASSIVE, Patent Category - Mech/Elect/Soft, RF coil False True The technology is ready to be used and requires only testing in humans for development. True NIHTT 37470483 Website Abstract 114170895 S Wang and JH Duyn, "Three-Dimensional Automatic Mesh Generation for Hybrid Electromagnetic Simulations", IEEE Antennas and Propagation Magazine, Vol. 51, pp. 71-85, April 2009. S Wang and JH Duyn, "Three-Dimensional Automatic Mesh Generation for Hybrid Electromagnetic Simulations", IEEE Antennas and Propagation Magazine, Vol. 51, pp. 71-85, April 2009. 114170896 H Merkle, J Murphy-Boesch, S Wang, P van Gelderen, AP Koretsky, and JH. Duyn, "Graded Transmit B1 Field Correction at 7T using Tunable Inner Elements", ISMRM High-field Workshop, Rome, Italy, October 2008. H Merkle, J Murphy-Boesch, S Wang, P van Gelderen, AP Koretsky, and JH. Duyn, "Graded Transmit B1 Field Correction at 7T using Tunable Inner Elements", ISMRM High-field Workshop, Rome, Italy, October 2008. 114170897 H Merkle, S Wang, P van Gelderen, TQ. Li, J Murphy-Boesch, AP Koretsky, and JH Duyn, "B1 Transmit Field Correction at 7T using Coupled Inner Elements", ISMRM 2008, Toronto, Canada, May 2008. H Merkle, S Wang, P van Gelderen, TQ. Li, J Murphy-Boesch, AP Koretsky, and JH Duyn, "B1 Transmit Field Correction at 7T using Coupled Inner Elements", ISMRM 2008, Toronto, Canada, May 2008. 114170898 S Wang, H Merkle, AP Koretsky, and JH Duyn, "Improving High-Field Transmit B1 Field Homogeneity Using Coupled Inner Elements", 15th Scientific Meeting and Exhibition, International Society for Magnetic Resonance in Medicine, Berlin, Germany, May 2007. S Wang, H Merkle, AP Koretsky, and JH Duyn, "Improving High-Field Transmit B1 Field Homogeneity Using Coupled Inner Elements", 15th Scientific Meeting and Exhibition, International Society for Magnetic Resonance in Medicine, Berlin, Germany, May 2007. 114103951 Wang, Shumin NINDS NINDS Wang, Shumin (NINDS) 0 114103952 Duyn, Jozef (Jeff) NINDS NINDS Duyn, Jozef (Jeff) (NINDS) 0 114106712 Merkle, Hellmut NINDS NINDS Merkle, Hellmut (NINDS) 0 114106710 Koretsky, Alan NINDS NINDS Koretsky, Alan (NINDS) 1 114106710 Koretsky, Alan NINDS NINDS Koretsky, Alan (NINDS) 1 114103951 Wang, Shumin NINDS NINDS Wang, Shumin (NINDS) 0 114103952 Duyn, Jozef (Jeff) NINDS NINDS Duyn, Jozef (Jeff) (NINDS) 0 114106712 Merkle, Hellmut NINDS NINDS Merkle, Hellmut (NINDS) 0 114101282 Passive Circuitry Control Of Transmit Profile In Magnetic Resonance Imaging E-020-2007-0 Filing authorized NINDS 83667829 Ano, Susan susan.ano@nih.gov
United States of America susan.ano@nih.gov?subject=Web Inquiry on [TAB-1999] Multilayered RF Coil System for Improving Transmit B1 Field Homogeneity in High-Field MRI&body=Please send me information about technology [TAB-1999] Multilayered RF Coil System for Improving Transmit B1 Field Homogeneity in High-Field MRI. Ano, Susan<br><a href="mailto:susan.ano@nih.gov?subject=Web Inquiry on [TAB-1999] Multilayered RF Coil System for Improving Transmit B1 Field Homogeneity in High-Field MRI&body=Please send me information about technology [TAB-1999] Multilayered RF Coil System for Improving Transmit B1 Field Homogeneity in High-Field MRI.">susan.ano@nih.gov</a><br> 114165433 E-020-2007-0 E-020-2007-0-US-01 Transmit Profile Control in MRI PRV US 60/900,972 Abandoned US <br />Provisional (PRV) 60/900,972<br />Filed on 2007-02-13<br />Status: Abandoned 114165434 E-020-2007-0 E-020-2007-0-PCT-02 Transmit Profile Control in MRI PCT Patent Cooperation Treaty PCT/US2008/001911 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2008/001911<br />Filed on 2008-02-13<br />Status: Expired 114165452 E-020-2007-0 E-020-2007-0-US-03 Transmit Profile Control In MRI National Stage US 8,125,225 12/449,514 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8125225 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8125225">8,125,225</a><br />Filed on 2009-08-12<br />Status: Issued 114120525 AA3B1X 114120526 AA3AXX 114120527 AXXXXX 114120528 AAXXXX 114120529 AA3XXX 114120530 AA3BXX 114138451 PASSIVE 114138452 Circuitry 114138453 RF coil 114138454 Magnetic Resonance 114138455 MRI 114138456 IMAGING 114138457 Patent Category - Mech/Elect/Soft TAB-1995 114096215 Therapeutic Peptide Treatment for Dyslipidemic and Vascular Disorders NHLBI Cardiology, Collaboration, Diagnostics, Endocrinology, Research Materials, Therapeutics Cardiology Collaboration Diagnostics Endocrinology Research Materials Therapeutics Marcelo Amar, Alan Remaley This invention is directed to use of certain peptide analogs comprising multiple amphipathic helical domains that are able to promote cellular lipid efflux and stimulate lipoprotein lipase activity. As a result, administration of invention peptides lead to reduced incidences of hypertriglyceridemia without inducing toxicity. Existing peptides that stimulate efflux of lipids from cells exhibit unacceptably high toxicity. Invention peptides are superior to existing peptides and can also be used to treat or prevent a vast range of vascular diseases, and their dyslipidemic precursors. Exemplary vascular diseases and conditions that could benefit from treatment with the invention peptides include: dyslipidemia, hyperlipidemia, hypercholesterolemia, HDL deficiency, coronary heart disease, atherosclerosis, and thrombic stroke. <ul> <li>Specific control of lipid efflux and transport</li> <li>Transient hypertriglyceridemia with no reported toxicity</li> </ul> <ul> <li>Treatment of dyslipidemic and vascular disorders</li> <li>Method of identifying therapeutic non-cytotoxic peptides</li> </ul> The National Heart, Lung, and Blood Institute is seeking parties interested in collaborative research to further co-develop novel ApoC-II mimetic peptides for the treatment of hypertriglyceridemia. For collaboration opportunities, please contact Denise Crooks at <a href="mailto:crooksd@nhlbi.nih.gov">crooksd@nhlbi.nih.gov</a>. 2022-03-08 2024-10-28 2024-10-28 2009-07-29 3-@hydroxyacyl-coa dehydrogenase deficiency, ApoA-I, HAD deficiency, HIS deficiency, Histidinemia, Hypertriglyceridemia, IB1XXX, IBXXXX, IXXXXX, Mimetic, Patent Category - Biotechnology, Peptides, VDXXXX, VHXXXX, WBXXXX, WJXXXX, YAXXXX, YBXXXX, YCXXXX False True <ul> <li>Early-stage</li> <li>Pre-clinical</li> <li>In vitro data available</li> <li>In vivo data available (animal)</li> </ul> True 52406768 Discovery 52406768 NIHTT 37470483 Website Abstract 114170891 Remaley AT, et al. http://www.ncbi.nlm.nih.gov/pubmed/12562845 <a href="http://www.ncbi.nlm.nih.gov/pubmed/12562845">Remaley AT, et al.</a> 114171734 Sviridov DO, et al. http://www.ncbi.nlm.nih.gov/pubmed/21672528 <a href="http://www.ncbi.nlm.nih.gov/pubmed/21672528">Sviridov DO, et al.</a> 114171735 Osei-Hwedieh DO, et al. http://www.ncbi.nlm.nih.gov/pubmed/21172387 <a href="http://www.ncbi.nlm.nih.gov/pubmed/21172387">Osei-Hwedieh DO, et al.</a> 114106708 Amar, Marcelo National Heart, Lung, and Blood Institute (NHLBI) NHLBI Amar, Marcelo (NHLBI) 0 114106707 Remaley, Alan NHLBI Remaley, Alan (NHLBI) 1 114106707 Remaley, Alan NHLBI Remaley, Alan (NHLBI) 1 114106708 Amar, Marcelo National Heart, Lung, and Blood Institute (NHLBI) NHLBI Amar, Marcelo (NHLBI) 0 114101278 Hypertriglyceridemia From ApoA-I And ApoA-I Mimetic Peptides E-138-2008-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-1995] Therapeutic Peptide Treatment for Dyslipidemic and Vascular Disorders&body=Please send me information about technology [TAB-1995] Therapeutic Peptide Treatment for Dyslipidemic and Vascular Disorders. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-1995] Therapeutic Peptide Treatment for Dyslipidemic and Vascular Disorders&body=Please send me information about technology [TAB-1995] Therapeutic Peptide Treatment for Dyslipidemic and Vascular Disorders.">shmilovm@nih.gov</a><br> 114165409 E-138-2008-0 E-138-2008-0-US-01 Peptides And Methods of Their Use PRV US 61/045,213 Abandoned US <br />Provisional (PRV) 61/045,213<br />Filed on 2008-04-15<br />Status: Abandoned 114166208 E-138-2008-0 E-138-2008-0-US-03 Peptides Promoting Lipid Efflux National Stage US 8,936,787 12/937,974 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8936787 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8936787">8,936,787</a><br />Filed on 2010-10-14<br />Status: Issued 114167601 E-138-2008-0 E-138-2008-0-PCT-02 Hypertriglyceridemia From ApoA-I And ApoA-I Mimetic Peptides PCT Patent Cooperation Treaty PCT/US2009/040560 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2009/040560<br />Filed on 2009-04-14<br />Status: Expired 114120505 IB1XXX 114120506 IXXXXX 114120507 IBXXXX 114122157 WBXXXX 114122158 WJXXXX 114122159 YAXXXX 114122160 YBXXXX 114122305 VDXXXX 114122306 VHXXXX 114122370 YCXXXX 114138409 Hypertriglyceridemia 114138410 ApoA-I 114138411 Mimetic 114138412 Peptides 114138413 Patent Category - Biotechnology 114156857 3-@hydroxyacyl-coa dehydrogenase deficiency 114156858 Histidinemia 114158515 HAD deficiency 114158516 HIS deficiency TAB-1965 114096185 Self-Expanding Stent for Valve Replacement NHLBI Collaboration, Licensing Collaboration Licensing Keith Horvath, Ming Li, Dumitru Mazilu Aortic stenosis and aortic regurgitation are the most common types of aortic valvular diseases. Such diseased aortic valves in the body are traditionally replaced with valve prosthesis by an open surgical implantation. Available for licensing and commercial development is intellectual property covering stents for use with valve prostheses. As illustrated below, one possible embodiment of the invention includes a self-expandable stent with an elastic tubular latticework having radial and longitudinal direction. The stent geometry and mechanical parameters provide more anatomically-correct placement and the flexible scaffolding of the valve (using an interconnected four-sided polygons and longitudinal rods comprising a self-expanding stent with a plurality of struts connecting a plurality of rods) allow for secure implantation with adaptable apposition of the prosthesis in the aorta.<br><br> <img src="/sites/default/files/documents/images/gifs/E-337-2008_stent.gif"> <br><br> <ul> <li>Cardiac Surgery</li> <li>Cardiology</li> <li>Surgery</li> <li>Stent implantation</li> </ul> The National Heart, Lung, and Blood Institute, Cardiothoracic Surgery Research Program, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. Please contact Peg Koelbe at 301-594-4095 or <a href="mailto:koelblep@nhlbi.nih.gov">koelblep@nhlbi.nih.gov</a> for more information. Available for licensing. 2022-03-08 2024-10-28 2024-10-28 2009-06-01 AB3AXX, AB3CXX, AB3XXX, ABXXXX, Aortic Retinosis, AXXXXX, Patent Category - Mech/Elect/Soft, Self-expanding, STENT, Valve False True True NIHTT 37470483 Website Abstract 114170844 Li M, et al. Robotic system for transapical aortic valve replacement with MRI guidance. https://www.ncbi.nlm.nih.gov/pubmed/18982639 <a href="https://www.ncbi.nlm.nih.gov/pubmed/18982639">Li M, et al. Robotic system for transapical aortic valve replacement with MRI guidance.</a> 114170845 Horvath KA, et al. Real-time magnetic resonance imaging guidance for cardiovascular procedures. https://www.ncbi.nlm.nih.gov/pubmed/18395633 <a href="https://www.ncbi.nlm.nih.gov/pubmed/18395633">Horvath KA, et al. Real-time magnetic resonance imaging guidance for cardiovascular procedures.</a> 114106637 Mazilu, Dumitru National Heart, Lung, and Blood Institute (NHLBI) NHLBI Mazilu, Dumitru (NHLBI) 0 114106638 Li, Ming National Heart, Lung, and Blood Institute (NHLBI) NHLBI Li, Ming (NHLBI) 0 114106636 Horvath, Keith National Heart, Lung, and Blood Institute (NHLBI) NHLBI Horvath, Keith (NHLBI) 1 114106636 Horvath, Keith National Heart, Lung, and Blood Institute (NHLBI) NHLBI Horvath, Keith (NHLBI) 1 114106637 Mazilu, Dumitru National Heart, Lung, and Blood Institute (NHLBI) NHLBI Mazilu, Dumitru (NHLBI) 0 114106638 Li, Ming National Heart, Lung, and Blood Institute (NHLBI) NHLBI Li, Ming (NHLBI) 0 114101236 Self-expanding Stent For Aortic Valve Replacement E-337-2008-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-1965] Self-Expanding Stent for Valve Replacement&body=Please send me information about technology [TAB-1965] Self-Expanding Stent for Valve Replacement. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-1965] Self-Expanding Stent for Valve Replacement&body=Please send me information about technology [TAB-1965] Self-Expanding Stent for Valve Replacement.">shmilovm@nih.gov</a><br> 114165237 E-337-2008-0 E-337-2008-0-US-01 Self-expanding Stent For Aortic Valve Replacement PRV US 61/172,568 Abandoned US <br />Provisional (PRV) 61/172,568<br />Filed on 2009-04-24<br />Status: Abandoned 114166045 E-337-2008-0 E-337-2008-0-PCT-02 STENT FOR VALVE REPLACEMENT PCT Patent Cooperation Treaty PCT/US2010/032257 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2010/032257<br />Filed on 2010-04-23<br />Status: Expired 114166558 E-337-2008-0 E-337-2008-0-US-03 Stent For Valve Replacement National Stage US 13/265,315 Abandoned US <br />National Stage 13/265,315<br />Filed on 2011-10-19<br />Status: Abandoned 114120309 AB3AXX 114120310 AB3CXX 114120311 AXXXXX 114120312 ABXXXX 114120313 AB3XXX 114137929 Self-expanding 114137930 STENT 114137931 Valve 114137932 Aortic Retinosis 114137933 Patent Category - Mech/Elect/Soft TAB-1963 114096183 Interactive Venn Diagram Software Designed for Microarray Analysis NIAID Licensing Licensing Daniel Sturdevant Multiple conditions from any source, but designed for experiments involving microarrays, will produce (significant gene lists for arrays) lists from each condition, thus multiple lists. This Java® based software provides investigators with a method of displaying multiple conditions in a single graphic along with producing a text output of genes that are the product of these conditional intersections along with each conditions unique list. A standard Venn diagram is limited to only display three (3) comparisons; this software can display any number of comparisons and will automatically create lists from all intersections even if not able to be displayed along with each conditions unique list. <ul> <li>Microarray analysis</li> <li>Genomics</li> <li>Bioinformatics</li> <li>Any environment creating multiple lists (Business, Accounting, Inventory Control, etc.)</li> </ul> Research Tool -- patent protection is not being pursued for this technology Available for licensing. 2022-07-27 2024-10-28 2024-10-28 2009-06-01 AD1XXX, AD3XXX, ADXXXX, AXXXXX, Bioinformatic, Bioinformatics, Genomic, Genomics, Java, Java-based, microarray, MICROARRAYS, software, Venn, Venn Diagram False True True NIHTT 37470483 Website Abstract 114106631 Sturdevant, Daniel NIAID - DIR NIAID Sturdevant, Daniel (NIAID) 1 114106631 Sturdevant, Daniel NIAID - DIR NIAID Sturdevant, Daniel (NIAID) 1 114101234 An Unlimited And Interactive Venn (iVenn) Diagram Created In Java To Automatically Display Intersecting Numbers And Unique Numbers From Any Type Of Lists Submitted E-189-2009-0 Research Material NIAID 91026778 Green, Wade wade.green@nih.gov
United States of America TTIPO wade.green@nih.gov?subject=Web Inquiry on [TAB-1963] Interactive Venn Diagram Software Designed for Microarray Analysis&body=Please send me information about technology [TAB-1963] Interactive Venn Diagram Software Designed for Microarray Analysis. Green, Wade<br><a href="mailto:wade.green@nih.gov?subject=Web Inquiry on [TAB-1963] Interactive Venn Diagram Software Designed for Microarray Analysis&body=Please send me information about technology [TAB-1963] Interactive Venn Diagram Software Designed for Microarray Analysis.">wade.green@nih.gov</a><br> 114120295 AD1XXX 114120296 AD3XXX 114120297 AXXXXX 114120298 ADXXXX 114137909 Java 114137910 Java-based 114137911 Genomics 114137912 Genomic 114137913 Bioinformatics 114137914 Bioinformatic 114137915 Venn Diagram 114137916 Venn 114137917 microarray 114137918 MICROARRAYS 114137919 software TAB-1934 114096155 Polyclonal Antibodies to the Kidney Protein Urea Transporter 1 (UTA1) NHLBI Licensing, Materials Available, Research Materials Licensing Materials Available Research Materials Mark Knepper Antibodies to UTA1, useful for immunoblotting and immunocytochemistry, are available to resell for research purposes. Urea Transporter 1 (UTA1) is activated by vasopressin and is responsible for urea transport across the apical membrane into the intracellular space within the renal inner medullary collecting duct. The inventor has developed rabbit polyclonal antibodies directed against a peptide sequence in human UTA1. Antibody also recognizes UTA3, another product of the same gene. Western blotting and immunocytochemistry Research Tool -- patent protection is not being pursued for this technology This technology is available as a research tool under a Biological Materials License. 2022-03-08 2024-10-28 2024-10-28 2009-05-05 ANTIBODY, Polycionai, rabbit, RXXXXX, UT-A1-LL194 False True True NIHTT 37470483 Website Abstract 114170812 S Nielsen, J Terris, CP Smith, MA Hediger, CA Ecelbarger, MA Knepper. Cellular and subcellular localization of the vasopressin-regulated urea transporter in rat kidney. Proc Natl Acad Sci USA. 1996 May 28;93(11):5495-5500. http://www.ncbi.nlm.nih.gov/pubmed/8643603?dopt <a href="http://www.ncbi.nlm.nih.gov/pubmed/8643603?dopt">S Nielsen, J Terris, CP Smith, MA Hediger, CA Ecelbarger, MA Knepper. Cellular and subcellular localization of the vasopressin-regulated urea transporter in rat kidney. Proc Natl Acad Sci USA. 1996 May 28;93(11):5495-5500.</a> 114106590 Knepper, Mark National Heart, Lung, and Blood Institute (NHLBI) NHLBI Knepper, Mark (NHLBI) 1 114106590 Knepper, Mark National Heart, Lung, and Blood Institute (NHLBI) NHLBI Knepper, Mark (NHLBI) 1 114101207 UT-A1-LL194 Rabbit Polycionai Antibody E-268-2008-0 Research Material National Heart, Lung, and Blood Institute (NHLBI) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-1934] Polyclonal Antibodies to the Kidney Protein Urea Transporter 1 (UTA1)&body=Please send me information about technology [TAB-1934] Polyclonal Antibodies to the Kidney Protein Urea Transporter 1 (UTA1). Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-1934] Polyclonal Antibodies to the Kidney Protein Urea Transporter 1 (UTA1)&body=Please send me information about technology [TAB-1934] Polyclonal Antibodies to the Kidney Protein Urea Transporter 1 (UTA1).">shmilovm@nih.gov</a><br> 114120147 RXXXXX 114137608 UT-A1-LL194 114137609 rabbit 114137610 Polycionai 114137611 ANTIBODY TAB-1933 114096154 Polyclonal Antibodies to NKCC2, a Kidney-Specific Member of the Cation Chloride Co-transporter Family, SLC12A1 NHLBI Licensing, Materials Available, Research Materials Licensing Materials Available Research Materials Mark Knepper Antibodies to NKCC2, useful for immunoblotting and immunocytochemistry, are available to resell for research purposes. NKCC2 is found on the apical surface of the thick ascending limb of the loop of Henle, where it facilitates transport of sodium, potassium, and chloride ions from the lumen of the renal thick ascending limb into the cell. Transport of sodium dilutes the luminal fluid, decreasing its osmolality creating an osmotic driving force for water reabsorption in the connecting tubule and cortical collecting duct under the influence of the hormone vasopressin. NKCC2 is blocked by loop diuretics such as furosemide. The inventor has developed rabbit polyclonal antibodies directed against a peptide sequence in the N-terminal tail of NKCC2. Western blotting and immunocytochemistry Research Tool -- patent protection is not being pursued for this technology This technology is available as a research tool under a Biological Materials License. 2022-03-08 2024-10-28 2024-10-28 2009-05-05 ANTIBODY, Anti-NKCC2, RXXXXX False True True NIHTT 37470483 Website Abstract 114170810 GH Kim, CA Ecelbarger, C Mitchell, RK Packer, JB Wade, MA Knepper. Vasopressin increases Na-K-2CI cotransporter expression in thick ascending limb of Henle's loop. Am J Physiol. 1999 Jan;276(1 Pt 2):F96-F103. http://www.ncbi.nlm.nih.gov/pubmed/9887085?dopt <a href="http://www.ncbi.nlm.nih.gov/pubmed/9887085?dopt">GH Kim, CA Ecelbarger, C Mitchell, RK Packer, JB Wade, MA Knepper. Vasopressin increases Na-K-2CI cotransporter expression in thick ascending limb of Henle's loop. Am J Physiol. 1999 Jan;276(1 Pt 2):F96-F103.</a> 114170811 HL Brooks, AJ Allred, KT Beutler, TM Cofiman, MA Knepper. Targeted proteomic profiling of renal Na+ transporter and channel abundances in angiotensin II type 1a receptor knockout mice. Hypertension. 2002 Feb;39(2 Pt 2):470-473. http://www.ncbi.nlm.nih.gov/pubmed/11882592?dopt <a href="http://www.ncbi.nlm.nih.gov/pubmed/11882592?dopt">HL Brooks, AJ Allred, KT Beutler, TM Cofiman, MA Knepper. Targeted proteomic profiling of renal Na+ transporter and channel abundances in angiotensin II type 1a receptor knockout mice. Hypertension. 2002 Feb;39(2 Pt 2):470-473.</a> 114106589 Knepper, Mark National Heart, Lung, and Blood Institute (NHLBI) NHLBI Knepper, Mark (NHLBI) 1 114106589 Knepper, Mark National Heart, Lung, and Blood Institute (NHLBI) NHLBI Knepper, Mark (NHLBI) 1 114101206 Anti-NKCC2 Antibody E-255-2008-0 Research Material National Heart, Lung, and Blood Institute (NHLBI) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-1933] Polyclonal Antibodies to NKCC2, a Kidney-Specific Member of the Cation Chloride Co-transporter Family, SLC12A1&body=Please send me information about technology [TAB-1933] Polyclonal Antibodies to NKCC2, a Kidney-Specific Member of the Cation Chloride Co-transporter Family, SLC12A1. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-1933] Polyclonal Antibodies to NKCC2, a Kidney-Specific Member of the Cation Chloride Co-transporter Family, SLC12A1&body=Please send me information about technology [TAB-1933] Polyclonal Antibodies to NKCC2, a Kidney-Specific Member of the Cation Chloride Co-transporter Family, SLC12A1.">shmilovm@nih.gov</a><br> 114120146 RXXXXX 114137606 Anti-NKCC2 114137607 ANTIBODY TAB-1932 114096153 Polyclonal Antibodies to Thiazide-Sensitive Sodium-Chloride Cotransporter (NCC) NHLBI Licensing, Materials Available, Research Materials Licensing Materials Available Research Materials Mark Knepper Antibodies to thiazide-sensitive sodium-chloride cotransporter (NCC), useful for immunoblotting and immunocytochemistry, are available to resell for research purposes. NCC is found on the apical membrane of the distal convoluted tubule, where it is the principal mediator of Na+ and CI- reabsorption in this segment of the nephron. NCC is the target of thiazide diuretics used in the treatment of hypertension. The inventors have developed rabbit polyclonal antibodies directed against a peptide sequence in the C-terminal region of NCC. Western blotting and immunohistochemistry Research Tool -- patent protection is not being pursued for this technology This technology is available as a research tool under a Biological Materials License. 2022-03-08 2024-10-28 2024-10-28 2009-05-05 ANTIBODY, Anti-NCC, RXXXXX False True True NIHTT 37470483 Website Abstract 114170809 HL Biner, MP Arpin-Bott, J Loffing, X Wang, M Knepper, SC Hebert, B Kaissling. Human cortical distal nephron: distribution of electrolyte and water transport pathways. J Am Soc Nephrol. 2002 Apr;13(4):836-847. http://www.ncbi.nlm.nih.gov/pubmed/11912242?dopt <a href="http://www.ncbi.nlm.nih.gov/pubmed/11912242?dopt">HL Biner, MP Arpin-Bott, J Loffing, X Wang, M Knepper, SC Hebert, B Kaissling. Human cortical distal nephron: distribution of electrolyte and water transport pathways. J Am Soc Nephrol. 2002 Apr;13(4):836-847.</a> 114106576 Knepper, Mark National Heart, Lung, and Blood Institute (NHLBI) NHLBI Knepper, Mark (NHLBI) 1 114106576 Knepper, Mark National Heart, Lung, and Blood Institute (NHLBI) NHLBI Knepper, Mark (NHLBI) 1 114101205 Anti-NCC Antibody E-254-2008-0 Research Material National Heart, Lung, and Blood Institute (NHLBI) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-1932] Polyclonal Antibodies to Thiazide-Sensitive Sodium-Chloride Cotransporter (NCC)&body=Please send me information about technology [TAB-1932] Polyclonal Antibodies to Thiazide-Sensitive Sodium-Chloride Cotransporter (NCC). Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-1932] Polyclonal Antibodies to Thiazide-Sensitive Sodium-Chloride Cotransporter (NCC)&body=Please send me information about technology [TAB-1932] Polyclonal Antibodies to Thiazide-Sensitive Sodium-Chloride Cotransporter (NCC).">shmilovm@nih.gov</a><br> 114120145 RXXXXX 114137604 Anti-NCC 114137605 ANTIBODY TAB-1931 114096152 Polyclonal Antibodies to the Kidney Protein Sodium-Hydrogen Exchanger 3 (NHE3) NHLBI Licensing, Materials Available, Research Materials Licensing Materials Available Research Materials Mark Knepper Antibodies to NHE3, useful for immunoblotting and immunocytochemistry, are available to resell for research purposes. NHE3 is a membrane Na+/H+ exchanger involved in maintenance of fluid volume homeostasis in the kidney. It is expressed on the apical membrane of the renal proximal tubule and plays a major role in NaCl and HCO3 absorption. The inventor has developed rabbit polyclonal antibodies directed against a peptide sequence common to human, rat and mouse NHE3. Western blotting and immunocytochemistry Research Tool -- patent protection is not being pursued for this technology This technology is available as a research tool under a Biological Materials License. 2022-03-08 2024-10-28 2024-10-28 2009-05-05 ANTIBODY, Anti-NHE3, RXXXXX False True True NIHTT 37470483 Website Abstract 114170808 Unpublished Unpublished 114106577 Knepper, Mark National Heart, Lung, and Blood Institute (NHLBI) NHLBI Knepper, Mark (NHLBI) 1 114106577 Knepper, Mark National Heart, Lung, and Blood Institute (NHLBI) NHLBI Knepper, Mark (NHLBI) 1 114101204 Anti-NHE3 Antibody E-253-2008-0 Research Material National Heart, Lung, and Blood Institute (NHLBI) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-1931] Polyclonal Antibodies to the Kidney Protein Sodium-Hydrogen Exchanger 3 (NHE3)&body=Please send me information about technology [TAB-1931] Polyclonal Antibodies to the Kidney Protein Sodium-Hydrogen Exchanger 3 (NHE3). Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-1931] Polyclonal Antibodies to the Kidney Protein Sodium-Hydrogen Exchanger 3 (NHE3)&body=Please send me information about technology [TAB-1931] Polyclonal Antibodies to the Kidney Protein Sodium-Hydrogen Exchanger 3 (NHE3).">shmilovm@nih.gov</a><br> 114120144 RXXXXX 114137602 Anti-NHE3 114137603 ANTIBODY TAB-1913 114096134 Mouse Monoclonal Antibodies to Human Tristetraprolin (TTP) NIEHS Collaboration, Diagnostics, Research Materials, Therapeutics Collaboration Diagnostics Research Materials Therapeutics Perry Blackshear, Elizabeth Kennington TTP has been implicated in autoimmune and inflammatory diseases through its role as a regulator of the transcripts encoding several pro-inflammatory cytokines, including tumor necrosis factor alpha. However, it has been difficult to study endogenous TTP in man and other animals because it is expressed at very low levels in most cells and tissues, and because of the lack of mouse monoclonal antibodies directed at the human protein. <br /><br /> Scientists at the NIH have developed three mouse monoclonal antibodies (TTP-16, TTP-214 and TTP-409) that react to different regions of the human TTP to allow for the identification and localization of the TTP protein by standard protocols. Although validation has only been conducted at the level of western blotting to date, they do not appear to cross-react with other human members of the TTP protein family. <ul> <li>Mouse monoclonal antibodies to human TTP will be useful in both clinical and basic research on a variety of inflammatory diseases and studies of mRNA destabilization. They can be used to identify or isolate TTP in cells or tissues by Western blotting, immunoprecipitation, immunohistochemistry, immunofluorescence, flow cytometry, and RNA super-shift assays, and can also be used in cross-linking and immunoprecipitation protocols.</li> </ul> The NIEHS, Polypeptide Hormone Action Group, of the Laboratory of Signal Transduction, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize antibodies to human TTP. Please contact Sally E. Tilotta, Ph.D. at <a href="mailto:sally.tilotta@nih.gov">sally.tilotta@nih.gov</a> in the NIEHS Office of Technology Transfer, or the inventor Dr. Perry Blackshear at <a href="mailto:black009@niehs.nih.gov">black009@niehs.nih.gov</a> for more information. Research Material -- patent protection is not being pursued for this technology 2022-03-08 2024-10-28 2024-10-28 2009-03-25 antibodies, Human, IDXXXX, IXXXXX, monoclonal, Mouse, Tristetraprolin, TTP False True True NIHTT 37470483 Website Abstract 114106568 Blackshear, Perry NIEHS NIEHS Blackshear, Perry (NIEHS) 0 114106567 Kennington, Elizabeth NIEHS Kennington, Elizabeth 1 114106567 Kennington, Elizabeth NIEHS Kennington, Elizabeth 1 114106568 Blackshear, Perry NIEHS NIEHS Blackshear, Perry (NIEHS) 0 114101180 Mouse Monoclonal Antibodies To Human Tristetraprolin (TTP) E-123-2009-0 Research Material NIEHS 83739538 Choudhry, Vidita vidita.choudhry@nih.gov
United States of America Office of Technology Transfer and Development vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-1913] Mouse Monoclonal Antibodies to Human Tristetraprolin (TTP)&body=Please send me information about technology [TAB-1913] Mouse Monoclonal Antibodies to Human Tristetraprolin (TTP). Choudhry, Vidita<br><a href="mailto:vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-1913] Mouse Monoclonal Antibodies to Human Tristetraprolin (TTP)&body=Please send me information about technology [TAB-1913] Mouse Monoclonal Antibodies to Human Tristetraprolin (TTP).">vidita.choudhry@nih.gov</a><br> 114120047 IDXXXX 114120048 IXXXXX 114137324 Mouse 114137325 monoclonal 114137326 antibodies 114137327 Human 114137328 Tristetraprolin 114137329 TTP TAB-1910 114096131 Cell Based Immunotherapy NIAID Collaboration, Diagnostics, Immunology, Licensing, Research Materials, Therapeutics Collaboration Diagnostics Immunology Licensing Research Materials Therapeutics Ethan Shevach, Dat Tran The invention hereby offered for licensing is in the field of Immunotherapy and more specifically in therapy of autoimmune diseases such as Type I diabetes, multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosis and immune mediated allergies such as asthma as well as in transplantation-related disorders, such as graft acceptance and graft-versus-host-disease (GVHD).<br /><br /> While the role of FOXP3<sup>+</sup> regulatory T cells (Tregs) in the maintenance of self-tolerance and immune homeostasis has been established and thus their use in adoptive immunotherapy has been contemplated, there is still no good way to purify and expand these cells in an efficient and reproducible manner <em>ex vivo</em> for use in human therapy. The subject invention provides a method that allows such purification for use in expansion cultures to generate sufficient numbers of cells and purity for cell-base immunotherapy. The method is based on the finding that Tregs selectively express Latency Associated Peptide (LAP) and CD121b (IL-1 Receptor Type 2) and on the ability to selectively separate these cells from other immune cells that are potentially hazardous, through the use of magnetic particles which specifically bind to either one of these two surface molecules and selectively separate those cells from the non-Tregs. <ul> <li>The method of purification of FOXP3<sup>+</sup> Tregs for human treatment may be superior in efficiency and practicality than currently existing techniques. After the magnetic separation, the final product contains more than 90% fully functional FOXP3<sup>+</sup> Tregs. This novel protocol should facilitate the purification of Tregs for both cell-based therapy as well as for detailed studies of human Treg function in health and disease. It is important to note that most of the treatments for specific autoimmune diseases (i.e. hormone replacement therapy, enzyme replacement therapy, corticosteroids, NSAIDs, plasmapherisis, immunosuppressants and intravenous immunoglobulins) do not constitute cure for the specific diseases. Immunotherapy with Tregs has a potential to provide cure or prolonged remission for many of these diseases.</li> </ul> <ul> <li>Immunotherapy, primarily for autoimmune diseases such as Type I diabetes, hematologic disorders such as aplastic anemia, transplantation-related disorders, such as graft acceptance and graft-versus-host-disease (GVHD) and allergic diseases such as asthma.</li> <li>Facilitating detailed studies and analysis of human Treg function in health and disease.</li> <li>Assay to differentiate thymic-derived versus peripheral-derived FOXP3<sup>+</sup> Tregs.</li> <li>Potential assay to monitor disease status, progression and prognosis such as early detection or response to therapy of GVHD after transplantation, solid organ graft rejection post-transplantation or a flare-up of systemic lupus erythematosus.</li> </ul> The NIAID/NIH Laboratory of Immunology is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize the use of CD121b or LAP to produce a Treg product for cell-based immunotherapy. Please contact Richard Williams at 301-496-2644 for more information. 2022-03-08 2024-10-28 2024-10-28 2009-03-25 2, ACTIVATED, ALLOWS, Aplastic anemia, Aplastic anemia, idiopathic; Aplastic anemia, Associated, CD121b, CELL-BASED, Cells, CULTURES, EXPANSION, Expression, FOXP3+, Generate, Graft versus host disease, Human, IB3XXX, IBXXXX, Idiopathic thrombocytopenic purpura, IL-l, Immunotherapy, IXXXXX, LAP, Latency, NUMBERS, Patent Category - Biotechnology, Peptide, purification, RECEPTOR, Regulatory, SELECTIVE, Sufficient, Systemic lupus erythematosus, T, Their, Thrombocytopenic purpura, autoimmune, TYPE False True The purification protocol has been proven simple and efficient in a laboratory setting. True NIHTT 37470483 Website Abstract 114170755 Andersson J, et al. http://www.ncbi.nlm.nih.gov/pubmed/18710931 <a href="http://www.ncbi.nlm.nih.gov/pubmed/18710931">Andersson J, et al.</a> 114170756 Shevach EM, et al. http://www.ncbi.nlm.nih.gov/pubmed/18395859 <a href="http://www.ncbi.nlm.nih.gov/pubmed/18395859">Shevach EM, et al.</a> 114170757 Tran DQ, et al. http://www.ncbi.nlm.nih.gov/pubmed/17644734 <a href="http://www.ncbi.nlm.nih.gov/pubmed/17644734">Tran DQ, et al.</a> 114106561 Shevach, Ethan NIAID - DIR NIAID Shevach, Ethan (NIAID) 0 114106560 Tran, Dat NIAID - DIR NIAID Tran, Dat (NIAID) 1 114106560 Tran, Dat NIAID - DIR NIAID Tran, Dat (NIAID) 1 114106561 Shevach, Ethan NIAID - DIR NIAID Shevach, Ethan (NIAID) 0 114101177 Selective Expression Of Latency Associated Peptide (LAP) And CD121b (IL-l Receptor Type 2) On Activated Human FOXP3+ Regulatory T Cells Allows For Their Purification For Use In Expansion Cultures To Generate Sufficient Numbers Of Cells For Cell-Based E-312-2008-0 Filing authorized NIAID 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-1910] Cell Based Immunotherapy&body=Please send me information about technology [TAB-1910] Cell Based Immunotherapy. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-1910] Cell Based Immunotherapy&body=Please send me information about technology [TAB-1910] Cell Based Immunotherapy.">yogikala.prabhu@nih.gov</a><br> 114162019 E-312-2008-0 E-312-2008-0-US-01 Cell-Based Immunotherapy PRV US 61/090,788 Abandoned US <br />Provisional (PRV) 61/090,788<br />Filed on 2008-08-21<br />Status: Abandoned 114165621 E-312-2008-0 E-312-2008-0-PCT-02 Methods of Enriching and Using T-Regulatory Cells PCT Patent Cooperation Treaty PCT/US2009/054631 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2009/054631<br />Filed on 2009-08-21<br />Status: Expired 114166349 E-312-2008-0 E-312-2008-0-US-03 METHOD OF MAKING AN ISOLATED POPULATION OF FOXP3+ REGULATORY T CELLS National Stage US 8,951,793 13/060,043 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8951793 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8951793">8,951,793</a><br />Filed on 2011-05-10<br />Status: Issued 114120036 IB3XXX 114120037 IXXXXX 114120038 IBXXXX 114137272 SELECTIVE 114137273 Expression 114137274 Latency 114137275 Associated 114137276 Peptide 114137277 LAP 114137278 CD121b 114137279 IL-l 114137280 RECEPTOR 114137281 TYPE 114137282 2 114137283 ACTIVATED 114137284 Human 114137285 FOXP3+ 114137286 Regulatory 114137287 T 114137288 Cells 114137289 ALLOWS 114137290 Their 114137291 purification 114137292 EXPANSION 114137293 CULTURES 114137294 Generate 114137295 Sufficient 114137296 NUMBERS 114137297 CELL-BASED 114137298 Immunotherapy 114137299 Patent Category - Biotechnology 114156743 Thrombocytopenic purpura, autoimmune 114156744 Systemic lupus erythematosus 114156745 Aplastic anemia 114156746 Graft versus host disease 114158467 Idiopathic thrombocytopenic purpura 114158468 Aplastic anemia, idiopathic; Aplastic anemia TAB-1909 114096130 Radiotracers for Imaging P-glycoprotein Transporter Function NIMH Collaboration Collaboration Robert Innis, Neva Lazarous, Victor Pike, Sami Zoghbi This invention offers technology to help treat certain brain diseases, such as Alzheimer's disease and Parkinson's, and may lead to more effective and personalized treatments. P-glycoprotein transporter (P-gp) acts as a pump at the blood-brain barrier to exclude a wide range of xenobiotics (e.g., toxins, drugs, etc.) from the brain and is also expressed in a tumor in response to exposure to established/prospective chemotherapeutics (a phenomenon known as multidrug resistance; MDR). The instant invention relates to compounds that are avid substrates for P-gp, and their preparation and use as radiotracers for imaging P-gp function <em>in vitro</em> and <em>in vivo</em>. <ul> <li>This class of radiotracer, typified by the described [<sup>11</sup>C]dLop, is designed to restrict the formation of radiometabolites that would obstruct the measurement of P-gp function at the blood-brain barrier or at tumors. In this sense these radiotracers are vastly superior to progenitors (e.g. [<sup>11</sup>C]verapamil, [<sup>11</sup>C]loperamide), which can only give qualitative not quantitative information.</li> </ul> <ul> <li>These radiotracers have potential application for investigating the function of P-gp at the blood-brain barrier for human subjects and patients in relation to neuropsychiatric disorders and in cancer. Their application may lead to a better general understanding of the role of P-gp in the unfolding of certain brain diseases (e.g. Alzheimer's disease, Parkinson's disease), and ultimately to more effective and personalized treatment. Likewise, these radiotracers may be applied in oncology to help understand MDR and its clinical manifestation, and to help seek out cancer therapies that avoid MDR.</li> </ul> The National Institute of Mental Health <a href="http://www.nimh.nih.gov/labs-at-nimh/research-areas/clinics-and-labs/mib/molecular-imaging-branch-mib.shtml" target="blank" title="Link: Molecular Imaging Branch website">Molecular Imaging Branch</a> is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize radiotracers for imaging P-gp function. Please contact Victor Pike at <a href="mailto:pikev@mail.nih.gov">pikev@mail.nih.gov</a> for more information. 2022-03-08 2024-10-28 2024-10-28 2009-03-24 AA3XXX, AAXXXX, ABXXXX, Alzheimer disease 1, Alzheimer disease 3, Alzheimer disease 4, Alzheimer disease type 1, Alzheimer disease type 4, Alzheimer disease, familial, type 3, AXXXXX, BBXXXX, BCXXXX, FUNCTION, IMAGING, Parkinson disease 2, Parkinson disease 3, Parkinson disease 9, Parkinson disease, juvenile, autosomal recessive, Patent Category - Chemistry, P-GP, Radiotracers, Vivo False True Radiotracer studies in human subjects are in progress. Longer-lived versions of the radiotracers are in development. True 52398218 Pre-Clinical (in vivo) 52398218 NIHTT 37470483 Website Abstract 114170752 Zoghbi SS, et al. http://www.ncbi.nlm.nih.gov/pubmed/18344435 <a href="http://www.ncbi.nlm.nih.gov/pubmed/18344435">Zoghbi SS, et al.</a> 114170753 Lazarova N, et al. http://www.ncbi.nlm.nih.gov/pubmed/18783208 <a href="http://www.ncbi.nlm.nih.gov/pubmed/18783208">Lazarova N, et al.</a> 114170754 Liow JS, et al. http://www.ncbi.nlm.nih.gov/pubmed/19091890 <a href="http://www.ncbi.nlm.nih.gov/pubmed/19091890">Liow JS, et al.</a> 114106557 Zoghbi, Sami National Institute of Mental Health (NIMH) NIMH Zoghbi, Sami (NIMH) 0 114106558 Lazarous, Neva National Institute of Mental Health (NIMH) Lazarous, Neva 0 114106559 Innis, Robert National Institute of Mental Health (NIMH) NIMH Innis, Robert (NIMH) 0 114106556 Pike, Victor National Institute of Mental Health (NIMH) NIMH Pike, Victor (NIMH) 1 114106556 Pike, Victor National Institute of Mental Health (NIMH) NIMH Pike, Victor (NIMH) 1 114106557 Zoghbi, Sami National Institute of Mental Health (NIMH) NIMH Zoghbi, Sami (NIMH) 0 114106558 Lazarous, Neva National Institute of Mental Health (NIMH) Lazarous, Neva 0 114106559 Innis, Robert National Institute of Mental Health (NIMH) NIMH Innis, Robert (NIMH) 0 114101176 Radiotracers For Imaging P-gp Function In Vivo E-318-2007-0 Filing authorized National Institute of Mental Health (NIMH) 83686256 Wong, Jennifer jennifer.wong2@nih.gov
United States of America jennifer.wong2@nih.gov?subject=Web Inquiry on [TAB-1909] Radiotracers for Imaging P-glycoprotein Transporter Function&body=Please send me information about technology [TAB-1909] Radiotracers for Imaging P-glycoprotein Transporter Function. Wong, Jennifer<br><a href="mailto:jennifer.wong2@nih.gov?subject=Web Inquiry on [TAB-1909] Radiotracers for Imaging P-glycoprotein Transporter Function&body=Please send me information about technology [TAB-1909] Radiotracers for Imaging P-glycoprotein Transporter Function.">jennifer.wong2@nih.gov</a><br> 114160846 E-318-2007-0 E-318-2007-0-US-01 Radiotracers For Imaging P-Glycoproteing Function ORD US 7,989,630 12/112,994 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7989630 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7989630">7,989,630</a><br />Filed on 2008-04-30<br />Status: Abandoned 114120032 AA3XXX 114120033 ABXXXX 114120034 AXXXXX 114120035 AAXXXX 114121215 BBXXXX 114121299 BCXXXX 114137266 Radiotracers 114137267 IMAGING 114137268 P-GP 114137269 FUNCTION 114137270 Vivo 114137271 Patent Category - Chemistry 114156737 Parkinson disease, juvenile, autosomal recessive 114156738 Parkinson disease 9 114156739 Alzheimer disease type 1 114156740 Parkinson disease 3 114156741 Alzheimer disease type 4 114156742 Alzheimer disease, familial, type 3 114158463 Parkinson disease 2 114158464 Alzheimer disease 1 114158465 Alzheimer disease 4 114158466 Alzheimer disease 3 TAB-1893 114096115 MDCK Cells with Enhanced Characteristics for Vaccine and Virus Production NIDDK Collaboration, Infectious Disease, Licensing, Research Materials, Therapeutics, Vaccines Collaboration Infectious Disease Licensing Research Materials Therapeutics Vaccines Chia Chu, Joseph Shiloach This technology relates to compositions and methods for improving the growth characteristics of cells engineered to produce live viruses such as the Influenza virus. Featured is a method that uses the gene candidate, siat7e, or its expressed or inhibited products in Madin Darby Canine Kidney (MDCK) cells. The gene expression modulates anchorage-dependence of the cell line thereby allowing scale-up on bioreactor platforms without the use of microcarrier beads and reducing production costs. More specifically, this technology claims use of the methods embodied in the patent application for production of the Influenza viruses (human, avian and canine). These MDCK cells offer the ability to improve yields and reduce the cost associated with the production of the Influenza virus through the genetic modification that provides: <ul> <li>Altered growth characteristics.</li> <li>Altered adhesion characteristics.</li> <li>Altered rate of proliferation.</li> <li>Improvement in cell density growth in suspension.</li> <li>Improvement in hemagglutinin production.</li> </ul> <ul> <li>This technology may be used to improve the production of prophylactic compounds against the seasonal flu. Influenza viruses are traditionally isolated and propagated in chicken embryonated eggs. Egg-derived viruses are the source of Influenza vaccine preparation. Issues associated with this current Influenza virus production strategy are prolonged planning of egg supplies and cultivation periods, variants in antigenic properties of egg-derived viruses, sterility and hypersensitivity to egg compounds in a fractional population of potential vaccine recipients. Defined cell substrates are currently being investigated. MDCK cells have been shown to produce sufficient viral titers. However, these cells are anchorage-dependent and thus limited in scale-up even with the use of microcarrier beads. This technology provides a method for converting the MDCK cells into suspension culture and thus a promising alternative for Influenza virus production.</li> </ul> The Biotechnology Core laboratory will consider collaborative research to further develop, evaluate, or commercialize the above invention. Please contact Dr. Joseph Shiloach at <a href="mailto:joseph.shiloach@nih.gov">joseph.shiloach@nih.gov</a> or 301-496-9719 for more information. Available for licensing. 2022-03-08 2024-10-28 2024-10-28 2017-04-12 Anchorage-independent, CAPABILITY, Cells, DB4XXX, DBXXXX, DC5BXX, DC5XXX, DC6XXX, DCXXXX, DDXXXX, DEXXXX, DXXXXX, EXHIBIT, Gene, Growth, Human, Inserts, MDCK, Patent Category - Biotechnology, Siat7e False True Late Stage -- Ready for Production True NIHTT 37470483 Website Abstract 114106520 Chu, Chia National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Chu, Chia 0 114106519 Shiloach, Joseph National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Shiloach, Joseph (NIDDK) 1 114106519 Shiloach, Joseph National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Shiloach, Joseph (NIDDK) 1 114106520 Chu, Chia National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Chu, Chia 0 114101159 MDCK Cells With Human Siat7e Gene Inserts Exhibit Capability Of Anchorage-independent Growth E-173-2008-0 Filing authorized Johns Hopkins University, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83692066 Tong, Betty tongb@niddk.nih.gov
United States of America Senior Technology Advancement Office tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-1893] MDCK Cells with Enhanced Characteristics for Vaccine and Virus Production&body=Please send me information about technology [TAB-1893] MDCK Cells with Enhanced Characteristics for Vaccine and Virus Production. Tong, Betty<br><a href="mailto:tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-1893] MDCK Cells with Enhanced Characteristics for Vaccine and Virus Production&body=Please send me information about technology [TAB-1893] MDCK Cells with Enhanced Characteristics for Vaccine and Virus Production.">tongb@niddk.nih.gov</a><br> 114165000 E-173-2008-0 E-173-2008-0-US-01 MDCK Cells With Human Siat7e Gene Inserts Exhibit Capability Of Anchorage-independent Growth PRV US 61/124,077 Abandoned US <br />Provisional (PRV) 61/124,077<br />Filed on 2008-04-11<br />Status: Abandoned 114165303 E-173-2008-0 E-173-2008-0-PCT-02 MDCK Cells With Human Siat7e Gene Inserts Exhibit Capability Of Anchorage-independent Growth PCT Patent Cooperation Treaty PCT/US2009/002252 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2009/002252<br />Filed on 2009-04-10<br />Status: Expired 114166374 E-173-2008-0 E-173-2008-0-US-03 MDCK Cells With Human Siat7e Gene Inserts Exhibit Capability Of Anchorage-independent Growth National Stage US 12/937,185 Abandoned US <br />National Stage 12/937,185<br />Filed on 2010-10-08<br />Status: Abandoned 114119912 DXXXXX 114119913 DDXXXX 114119914 DEXXXX 114119915 DCXXXX 114119916 DC5XXX 114119917 DC5BXX 114119918 DC6XXX 114119919 DB4XXX 114119920 DBXXXX 114136799 MDCK 114136800 Cells 114136801 Human 114136802 Siat7e 114136803 Gene 114136804 Inserts 114136805 EXHIBIT 114136806 CAPABILITY 114136807 Anchorage-independent 114136808 Growth 114136809 Patent Category - Biotechnology TAB-188 114094527 Therapeutic Methods Based on In Vivo Modulation of the Production of Interferon gamma NIAID Infectious Disease, Licensing, Therapeutics, Vaccines Infectious Disease Licensing Therapeutics Vaccines Eric Long, Sumati (Sumi) Rajagopalan The technology offered for licensing is in the field of Therapeutics. More specifically, the technology relates to biological ligands and their use as modulators of the production of Interferon gamma as a means to treat a broad spectrum of diseases. The invention describes and claims antibodies and other ligands that can stimulate Natural Killer (NK) immune cells to produce Interferon gamma which contributes to the combat against foreign pathogens. Conversely, the invention also describes and claims methods that can inhibit such Interferon gamma production for treatment of diseases where excess of Interferon is not desirable. The invention also describes methods and assays to identify both inducing and inhibiting ligands <br /><br /> The license agreement may include biological materials, such as monoclonal antibodies that were made and identified by the inventors as Interferon gamma stimulators. <br /><br /> Interferon-gamma is a potent antiviral and antimicrobial substance produced by natural killer (NK) white blood cells. NK cells are activated during infections by viruses and by other intracellular pathogens, such as parasites and bacteria. Soluble substances, such as interleukins, produced by infected cells activate NK cells to secrete interferon-gamma. Injection of interleukins into patients to stimulate NK cells to secrete interferon-gamma has not been a successful therapeutic approach because of the toxicity involved. The invention is based on the discovery by the inventors that activation of the KIR2DL4 receptor expressed by all NK cells stimulates them to produce interferon-gamma. The invention claims monoclonal antibodies and derivatives thereof, as well as natural and synthetic ligands of KIR2DL4 that can be utilized to stimulate interferon-gamma production by NK cells without any other stimulus. The possibility of inducing interferon-gamma production by NK cells without the toxic side effects of interleukins could be an effective therapy for various types of infections and of cancers. Also claimed in the invention are methods of treating various cancers and viral infections, methods of treating autoimmune disease, and methods of administration of the antibody or derivatives thereof. Certain diseases benefit from reduction in the amount of Interferon gamma. The instant invention claims such ligands that are capable of inhibiting KIR2DL4 from producing interferon gamma. It also describes methods of identifying such ligands. <ul> <li>Absence of toxicity as compared with current methods such as IL-2 treatment.</li> </ul> <ul> <li>Therapeutics of infectious diseases, cancer and autoimmune diseases</li> <li>The mAbs can be used as research reagents</li> </ul> 2022-03-08 2024-10-28 2024-10-28 2009-05-04 Against, antibodies, DB3XXX, DB4XXX, DBXXXX, DC1XXX, DCXXXX, Directed, DXXXXX, Gamma, INTERFERON, KIR2DL4, LIGANDS, Patent Category - Biotechnology, production, RECEPTOR False True Early-stage True NIHTT 37470483 Website Abstract 114170774 Rajagopalan S, et al. http://www.ncbi.nlm.nih.gov/pubmed/11489965 <a href="http://www.ncbi.nlm.nih.gov/pubmed/11489965">Rajagopalan S, et al.</a> 114170775 Kikuchi-Maki A, et al. http://www.ncbi.nlm.nih.gov/pubmed/15778339 <a href="http://www.ncbi.nlm.nih.gov/pubmed/15778339">Kikuchi-Maki A, et al.</a> 114170776 Rajagopalan S, et al. http://www.ncbi.nlm.nih.gov/pubmed/16366734 <a href="http://www.ncbi.nlm.nih.gov/pubmed/16366734">Rajagopalan S, et al.</a> 114103304 Rajagopalan, Sumati (Sumi) NIAID - DIR NIAID Rajagopalan, Sumati (Sumi) (NIAID) 0 114103305 Long, Eric NIAID - DIR NIAID Long, Eric (NIAID) 1 114103305 Long, Eric NIAID - DIR NIAID Long, Eric (NIAID) 1 114103304 Rajagopalan, Sumati (Sumi) NIAID - DIR NIAID Rajagopalan, Sumati (Sumi) (NIAID) 0 114099317 Antibodies and Other Ligands Directed Against KIR2DL4 Receptor For Production of Interferon Gamma E-255-2000-0 NIAID 83738793 Taylor-Mulneix, Dawn dawn.taylor-mulneix@nih.gov
United States of America dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-188] Therapeutic Methods Based on In Vivo Modulation of the Production of Interferon gamma&body=Please send me information about technology [TAB-188] Therapeutic Methods Based on In Vivo Modulation of the Production of Interferon gamma. Taylor-Mulneix, Dawn<br><a href="mailto:dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-188] Therapeutic Methods Based on In Vivo Modulation of the Production of Interferon gamma&body=Please send me information about technology [TAB-188] Therapeutic Methods Based on In Vivo Modulation of the Production of Interferon gamma.">dawn.taylor-mulneix@nih.gov</a><br> 114162767 E-255-2000-0 E-255-2000-0-US-01 Antibodies and Other Ligands Directed Against KIR2DL4 Receptor For Production of Interferon Gamma PRV US 60/242,419 Abandoned US <br />Provisional (PRV) 60/242,419<br />Filed on 2000-10-23<br />Status: Abandoned 114164351 E-255-2000-0 E-255-2000-0-US-04 Antibodies and Other Ligands Directed Against KIR2DL4 Receptor For Production of Interferon Gamma CON US 12/249,703 Abandoned US <br />Continuation (CON) 12/249,703<br />Filed on 2008-10-10<br />Status: Abandoned 114164513 E-255-2000-0 E-255-2000-0-US-03 Antibodies and Other Ligands Directed Against KIR2DL4 Receptor For Production of Interferon Gamma National Stage US 7,435,801 10/420,067 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7435801 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7435801">7,435,801</a><br />Filed on 2003-04-18<br />Status: Expired 114165192 E-255-2000-0 E-255-2000-0-PCT-02 Antibodies and Other Ligands Directed Against KIR2DL4 Receptor For Production of Interferon Gamma PCT Patent Cooperation Treaty PCT/US2001/046098 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2001/046098<br />Filed on 2001-10-23<br />Status: Expired 114112366 DB3XXX 114112367 DB4XXX 114112368 DC1XXX 114112369 DBXXXX 114112370 DCXXXX 114112371 DXXXXX 114136730 antibodies 114136731 LIGANDS 114136732 Directed 114136733 Against 114136734 KIR2DL4 114136735 RECEPTOR 114136736 production 114136737 INTERFERON 114136738 Gamma 114136739 Patent Category - Biotechnology TAB-1864 114096086 Mice with a Conditional LoxP-Flanked Glucosylceramide Synthase Allele Controlling Glycosphingolipid Synthesis NIDDK Collaboration, Licensing, Materials Available, Research Materials Collaboration Licensing Materials Available Research Materials Richard Proia Glycosphingolipids are organizational building blocks of plasma membranes that participate in key cellular functions, such as signaling and cell-to-cell interactions. Glucosylceramide synthase - encoded by the <i>Ugcg</i> gene - controls the first committed step in the major pathway of glycosphingolipid synthesis. Global disruption of the <i>Ugcg</i> gene in mice is lethal during gastrulation. The inventors have established a <i>Ugcg</i> allele flanked by loxP sites (floxed). When cre recombinase was expressed in the nervous system under control of the <i>nestin</i> promoter, the floxed gene underwent recombination, resulting in a substantial reduction of <i>Ugcg</i> expression and of glycosphingolipid ganglio-series levels. The mice deficient in <i>Ugcg</i> expression in the nervous system show a striking loss of Purkinje cells and abnormal neurologic sphingo-lipid behavior. <br><br> The Research Tools available are mice with a floxed <i>Ugcg</i> allele that can be deleted in a conditional manner. These mice carrying floxed <i>Ugcg</i> alleles will be useful for delineating the functional roles of glycosphingolipid synthesis in the nervous system and in other physiologic systems. <br><br> <ul> <li>Study of the functional roles of glycosphingolipid synthesis in the nervous system and other physiologic systems.</li> <li>The floxed <i>Ugcg</i> allele will facilitate analysis of the function of glycosphingolipids in development, physiology, and in diseases such as diabetes and cancer.</li> </ul> The NIDDK Genetics of Development and Disease Branch is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize the sphingolipid metabolism in physiology and disease. Please contact Dr. Proia at <a href="mailto:proia@nih.gov">proia@nih.gov</a> for more information. Research Material -- patent protection is not being pursued for this technology Available for licensing under a Biological Materials license agreement. 2022-03-08 2024-10-28 2024-10-28 2009-01-01 ACXXXX, AXXXXX, Carrying, ESTABLISHMENT, Floxed, Gene, glucosylceramide, Mice, RXXXXX, SYNTHASE, Ugcg False True Ready to Use True NIHTT 37470483 Website Abstract 114169779 T Yamashita, ML Allende, DN Kalkofen, N Werth, K Sandhoff, RL Proia. Conditional LoxP-flanked glucosylceramide synthase allele controlling glycosphingolipid synthesis. Genesis 2005 Dec;43(4):175-180. http://www.ncbi.nlm.nih.gov/pubmed/16283624?dopt <a href="http://www.ncbi.nlm.nih.gov/pubmed/16283624?dopt">T Yamashita, ML Allende, DN Kalkofen, N Werth, K Sandhoff, RL Proia. Conditional LoxP-flanked glucosylceramide synthase allele controlling glycosphingolipid synthesis. Genesis 2005 Dec;43(4):175-180.</a> 114106473 Proia, Richard National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Proia, Richard (NIDDK) 1 114106473 Proia, Richard National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Proia, Richard (NIDDK) 1 114101130 Establishment Of Mice Carrying A Floxed Ugcg Gene (glucosylceramide Synthase) E-320-2007-0 Research Material National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83739550 Shastri, Mythreyi shastrim@mail.nih.gov
United States of America Technology Advancement Office shastrim@mail.nih.gov?subject=Web Inquiry on [TAB-1864] Mice with a Conditional LoxP-Flanked Glucosylceramide Synthase Allele Controlling Glycosphingolipid Synthesis&body=Please send me information about technology [TAB-1864] Mice with a Conditional LoxP-Flanked Glucosylceramide Synthase Allele Controlling Glycosphingolipid Synthesis. Shastri, Mythreyi<br><a href="mailto:shastrim@mail.nih.gov?subject=Web Inquiry on [TAB-1864] Mice with a Conditional LoxP-Flanked Glucosylceramide Synthase Allele Controlling Glycosphingolipid Synthesis&body=Please send me information about technology [TAB-1864] Mice with a Conditional LoxP-Flanked Glucosylceramide Synthase Allele Controlling Glycosphingolipid Synthesis.">shastrim@mail.nih.gov</a><br> 114119722 RXXXXX 114119723 ACXXXX 114119724 AXXXXX 114136065 ESTABLISHMENT 114136066 Mice 114136067 Carrying 114136068 Floxed 114136069 Ugcg 114136070 Gene 114136071 glucosylceramide 114136072 SYNTHASE TAB-1858 114096080 Mouse Monoclonal Antibody to the Nitrone Spin Trap 5,5-dimethyl-1-pyrroline N-oxide (DMPO) NIEHS Licensing, Materials Available, Research Materials Licensing Materials Available Research Materials Marilyn (Estate of) Ehrenshaft, Ronald Mason Oxidative stress resulting in the formation of biological radicals has been implicated in a number of human diseases, such as cancer as well as aging. There is, however, a paucity of reliable methods for <i>in vivo</i> or <i>ex vivo</i> detection of radical formation. Until now the only general technique that allowed for the detection of these highly reactive species was electron spin resonance (ESR) using spin traps. One of the most popular of these spin traps is 5,5-dimethyl-1-pyrroline <i>N</i>-oxide (DMPO). In the ESR method, radicals are trapped by DMPO, and the DMPO spin adduct signal is measured quantitatively by an ESR spectrometer. <br><br> The Research Tool available is a mouse monoclonal antibody that specifically reacts with DMPO-protein and DMPO-DNA adducts. The inventors have used DMPO-octanoic acid conjugated to ovalbumin as the antigen to develop this monoclonal antibody. This product was assayed by ELISA and found to be reactive against DMPO-protein adducts at a dilution of 1 &#956;g/ml of affinity purified mouse IgG when used in combination with alkaline phosphatase conjugated, affinity purified anti-mouse IgG (Goat). <ul> <li>ELISA and Immunoblotting of protein-DMPO adducts.</li> <li>Immuno-spin trapping analyses of DNA radicals.</li> <li>Immunoprecipitation of protein-DMPO adducts.</li> </ul> Research Material -- patent protection is not being pursued for this technology Hybridoma producing the monoclonal antibody and the monoclonal antibody are available for Biological Material Licensing. 2022-03-08 2024-10-28 2024-10-28 2008-11-24 5, 5-dimethyl-1-pyrroline, AC5XXX, ACXXXX, ANTIBODY, AXXXXX, Detection, DMPO, ELISA, End-products, I cell disease, MBb, ML 2, ML 3 A, ML 4, monoclonal, Mouse, Mucolipidosis type 3 A, Mucolipidosis type 4, Nitrone, N-oxide, Protein, Radicals, RXXXXX, Sandwich, Specific, SPIN, STABLE, TRAP False True True NIHTT 37470483 Website Abstract 114106449 Ehrenshaft, Marilyn (Estate of) NIEHS NIEHS Ehrenshaft, Marilyn (Estate of) (NIEHS) 0 114106448 Mason, Ronald NIEHS NIEHS Mason, Ronald (NIEHS) 1 114106448 Mason, Ronald NIEHS NIEHS Mason, Ronald (NIEHS) 1 114106449 Ehrenshaft, Marilyn (Estate of) NIEHS NIEHS Ehrenshaft, Marilyn (Estate of) (NIEHS) 0 114101119 Mouse Monoclonal Antibody (MBb) To The Nitrone Spin Trap 5,5-dimethyl-1-pyrroline N-oxide (DMPO) For Use In Detection Of Stable Nitrone End-products Of Specific Protein Radicals In Sandwich ELISA E-175-2006-0 Research Material NIEHS 83739538 Choudhry, Vidita vidita.choudhry@nih.gov
United States of America Office of Technology Transfer and Development vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-1858] Mouse Monoclonal Antibody to the Nitrone Spin Trap 5,5-dimethyl-1-pyrroline N-oxide (DMPO)&body=Please send me information about technology [TAB-1858] Mouse Monoclonal Antibody to the Nitrone Spin Trap 5,5-dimethyl-1-pyrroline N-oxide (DMPO). Choudhry, Vidita<br><a href="mailto:vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-1858] Mouse Monoclonal Antibody to the Nitrone Spin Trap 5,5-dimethyl-1-pyrroline N-oxide (DMPO)&body=Please send me information about technology [TAB-1858] Mouse Monoclonal Antibody to the Nitrone Spin Trap 5,5-dimethyl-1-pyrroline N-oxide (DMPO).">vidita.choudhry@nih.gov</a><br> 114119623 AC5XXX 114119624 RXXXXX 114119625 AXXXXX 114119626 ACXXXX 114135226 Mouse 114135227 monoclonal 114135228 ANTIBODY 114135229 MBb 114135230 Nitrone 114135231 SPIN 114135232 TRAP 114135233 5 114135234 5-dimethyl-1-pyrroline 114135235 N-oxide 114135236 DMPO 114135237 Detection 114135238 STABLE 114135239 End-products 114135240 Specific 114135241 Protein 114135242 Radicals 114135243 Sandwich 114135244 ELISA 114156679 Mucolipidosis type 3 A 114156680 I cell disease 114156681 Mucolipidosis type 4 114158431 ML 3 A 114158432 ML 2 114158433 ML 4 TAB-1831 114096042 Transgenic Mice with Conditionally-Enhanced Bone Morphogen Protein (BMP) Signaling: A Model for Human Bone Diseases NIEHS Animal Models, Diagnostics, Licensing, Research Materials, Therapeutics Animal Models Diagnostics Licensing Research Materials Therapeutics Yuji Mishina, Manas Ray, Gregory Scott This technology relates to novel animal models of several human bone diseases that have been linked to enhanced BMP signaling. More specifically, this mouse model expresses a mutant receptor for BMP, known as Alk2 that is always actively signaling. This receptor is under the control of the Cre-loxP system, which allows control of expression of the mutant Alk2 in both a developmental and tissue-specific manner. As a result, the enhanced signaling conditions exhibited in multiple human bone-related diseases can be studied with the same animals. The mouse model can be applied to the study of BMP signaling-related human diseases such as fibrodysplasia ossificans progressiva, which involves the postnatal transformation of connective tissue into bone. Another example of BMP signaling-related disease is Craniosynostosis, which involves the premature closing of the sutures in childhood so that normal brain and skull growth are inhibited. This mouse model can potentially be used in other human diseases where BMP signaling might play a pivotal role, for example cleft lip and cleft palate, breast cancer, osteoarthritis, lung fibrosis, multiple myeloma, juvenile polyposis, cephalic neural tube closure detects, diabetes and other types of blood glucose control problems, and pulmonary hypertension. Research Material -- patent protection is not being pursued for this technology Available for non-exclusive licensing. 2022-03-08 2024-10-28 2024-10-28 2008-09-01 BAXXXX, BMP:, Bone, Craniosynostosis, Disease, Enhanced, Expressing, Fibrodysplasia ossificans progressiva, Human, IDXXXX, IXXXXX, Model, MORPHOGENETIC, Mouse, MULTIPLE MYELOMA, Protein, SIGNALING False True Early-stage development. True NIHTT 37470483 Website Abstract 114170638 T Fukada et al. Generation of a mouse with conditionally activated signaling through the BMP receptor, ALK2. Genesis. 2006;44:159-167. T Fukada et al. Generation of a mouse with conditionally activated signaling through the BMP receptor, ALK2. Genesis. 2006;44:159-167. 114170639 L Kan et al. Transgenic mice overexpressing BMP4 develop a fibrodysplasia ossificans progressiva (FOP)-like phenotype. Am J Path. 2004 Oct;165(4):1107-1115. http://www.ncbi.nlm.nih.gov/pubmed/15466378?dopt <a href="http://www.ncbi.nlm.nih.gov/pubmed/15466378?dopt">L Kan et al. Transgenic mice overexpressing BMP4 develop a fibrodysplasia ossificans progressiva (FOP)-like phenotype. Am J Path. 2004 Oct;165(4):1107-1115.</a> 114170640 EM Shore et al. A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressive. Nat Genet. 2006 May;38(5):525-527. http://www.ncbi.nlm.nih.gov/pubmed/16642017?dopt <a href="http://www.ncbi.nlm.nih.gov/pubmed/16642017?dopt">EM Shore et al. A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressive. Nat Genet. 2006 May;38(5):525-527.</a> 114105960 Ray, Manas NIEHS NIEHS Ray, Manas (NIEHS) 0 114106295 Scott, Gregory NIEHS NIEHS Scott, Gregory (NIEHS) 0 114106155 Mishina, Yuji Mishina, Yuji 1 114106155 Mishina, Yuji Mishina, Yuji 1 114105960 Ray, Manas NIEHS NIEHS Ray, Manas (NIEHS) 0 114106295 Scott, Gregory NIEHS NIEHS Scott, Gregory (NIEHS) 0 114100963 Mouse Expressing Enhanced Signaling For Bone Morphogenetic Protein (BMP): A Model For Human Disease E-328-2008-0 Research Material NIEHS 83739538 Choudhry, Vidita vidita.choudhry@nih.gov
United States of America Office of Technology Transfer and Development vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-1831] Transgenic Mice with Conditionally-Enhanced Bone Morphogen Protein (BMP) Signaling: A Model for Human Bone Diseases&body=Please send me information about technology [TAB-1831] Transgenic Mice with Conditionally-Enhanced Bone Morphogen Protein (BMP) Signaling: A Model for Human Bone Diseases. Choudhry, Vidita<br><a href="mailto:vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-1831] Transgenic Mice with Conditionally-Enhanced Bone Morphogen Protein (BMP) Signaling: A Model for Human Bone Diseases&body=Please send me information about technology [TAB-1831] Transgenic Mice with Conditionally-Enhanced Bone Morphogen Protein (BMP) Signaling: A Model for Human Bone Diseases.">vidita.choudhry@nih.gov</a><br> 114119253 IDXXXX 114119255 IXXXXX 114121350 BAXXXX 114132775 Mouse 114132776 Expressing 114132777 Enhanced 114132778 SIGNALING 114132779 Bone 114132780 MORPHOGENETIC 114132781 Protein 114132782 BMP: 114132783 Model 114132784 Human 114132785 Disease 114156650 Fibrodysplasia ossificans progressiva 114156651 MULTIPLE MYELOMA 114156652 Craniosynostosis TAB-1827 114096050 A Novel Treatment for Malarial Infections NIAID Collaboration, Infectious Disease, Therapeutics Collaboration Infectious Disease Therapeutics Sanjay Desai The inventions described herein are antimalarial small molecule inhibitors of the plasmodial surface anion channel (PSAC), an essential nutrient acquisition ion channel expressed on human erythrocytes infected with malaria parasites. These inhibitors were discovered by high-throughput screening of chemical libraries and analysis of their ability to kill malaria parasites in culture. Two separate classes of inhibitors were found to work synergistically in combination against PSAC and killed malaria cultures at markedly lower concentrations than separately. These inhibitors have high affinity and specificity for PSAC and have acceptable cytotoxicity profiles. Preliminary <i>in vivo</i> testing of these compounds in a mouse malaria model is currently ongoing. <ul> <li>Novel drug treatment for malarial infections</li> <li>Synergistic effect of these compounds on PSAC</li> </ul> <ul> <li>Treatment of malarial infections</li> </ul> The NIAID Office of Technology Development is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize antimalarial drugs that target PSAC or other parasite-specific transporters. Please contact Dana Hsu at 301-496-2644 for more information. 2022-03-08 2024-10-28 2024-10-28 2008-09-01 Anion, ANTAGONISTS, ANTIMALARIAL, BBXXXX, BCXXXX, CHANNEL, DB2XXX, DBXXXX, Development, DRUG, DXXXXX, LEAD, Malaria, Malaria (Plasmodium sp.), MOLECULES, Plasmodial, Surface False True <ul> <li>In vitro data available</li> <li>In vivo data available (animal)</li> </ul> True 52398218 Pre-Clinical (in vivo) 52398218 NIHTT 37470483 Website Abstract 114170629 Kang M, et al. http://www.ncbi.nlm.nih.gov/pubmed/15843600 <a href="http://www.ncbi.nlm.nih.gov/pubmed/15843600">Kang M, et al.</a> 114170630 Desai SA, et al. http://www.ncbi.nlm.nih.gov/pubmed/10984055 <a href="http://www.ncbi.nlm.nih.gov/pubmed/10984055">Desai SA, et al.</a> 114106301 Desai, Sanjay NIAID - DIR NIAID Desai, Sanjay (NIAID) 1 114106301 Desai, Sanjay NIAID - DIR NIAID Desai, Sanjay (NIAID) 1 114101074 Plasmodial Surface Anion Channel Antagonists As Lead Molecules For Antimalarial Drug Development E-202-2008-0 Filing authorized NIAID 83724572 Tung, Peter peter.tung@nih.gov
United States of America DIR peter.tung@nih.gov?subject=Web Inquiry on [TAB-1827] A Novel Treatment for Malarial Infections&body=Please send me information about technology [TAB-1827] A Novel Treatment for Malarial Infections. Tung, Peter<br><a href="mailto:peter.tung@nih.gov?subject=Web Inquiry on [TAB-1827] A Novel Treatment for Malarial Infections&body=Please send me information about technology [TAB-1827] A Novel Treatment for Malarial Infections.">peter.tung@nih.gov</a><br> 114161857 E-202-2008-0 E-202-2008-0-US-12 Inhibitors of the Plasmodial Surface Anion Channel as Antimalarials CON US 9,394,316 14/094,842 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9394316 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9394316">9,394,316</a><br />Filed on 2013-12-03<br />Status: Issued 114162863 E-202-2008-0 E-202-2008-0-US-18 INHIBITORS OF THE PLASMODIAL SURFACE ANION CHANNEL AS ANTIMALARIALS DIV US 10,881,669 15/984,956 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10881669 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10881669">10,881,669</a><br />Filed on 2018-05-21<br />Status: Issued 114164072 E-202-2008-0 E-202-2008-0-PCT-02 Plasmodial Surface Anion Channel Antagonists As Lead Molecules For Antimalarial Drug Development PCT Patent Cooperation Treaty PCT/US09/50637 Expired Patent Cooperation Treaty <br />(PCT) PCT/US09/50637<br />Filed on 2009-07-15<br />Status: Expired 114166122 E-202-2008-0 E-202-2008-0-US-01 INHIBITORS OF THE PLASMODIAL SURFACE ANION CHANNEL AS ANTIMALARIALS PRV US 61/083,000 Abandoned US <br />Provisional (PRV) 61/083,000<br />Filed on 2008-07-23<br />Status: Abandoned 114166301 E-202-2008-0 E-202-2008-0-US-10 Inhibitors of The Plasmodial Surface Anion Channel As Antimalarials National Stage US 8,618,090 13/055,104 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8618090 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8618090">8,618,090</a><br />Filed on 2011-01-20<br />Status: Issued 114166681 E-202-2008-0 E-202-2008-0-US-13 Inhibitors of the Plasmodial Surface Anion Channel as Antimalarials CON US 9,974,796 15/213,181 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9974796 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9974796">9,974,796</a><br />Filed on 2016-07-18<br />Status: Issued 114169085 E-202-2008-0 E-202-2008-0-US-19 INHIBITORS OF THE PLASMODIAL SURFACE ANION CHANNEL AS ANTIMALARIALS DIV US 17/140,704 Abandoned US <br />Divisional (DIV) 17/140,704<br />Filed on 2021-01-04<br />Status: Abandoned 114119221 DXXXXX 114119222 DBXXXX 114119223 DB2XXX 114121183 BBXXXX 114121291 BCXXXX 114132707 ANTIMALARIAL 114132708 Surface 114132709 Anion 114132710 CHANNEL 114132711 ANTAGONISTS 114132712 LEAD 114132713 MOLECULES 114132714 Plasmodial 114132715 DRUG 114132716 Development 114156641 Malaria 114157952 Malaria (Plasmodium sp.) TAB-1824 114096047 Active Guidewire Visualization Device and System for MRI Guided Interventions NHLBI Collaboration, Licensing Collaboration Licensing Ozgur Kocaturk Available for licensing and commercial development is a guidewire device and system for MRI guidance of vascular interventions. The guidewire design, and its coupled system, enables interventionalists to visualize the location of the tip and distal shaft of an MRI compatible guidewire relative to the vascular system and surrounding anatomy. Visualization of both the shaft and tip enables interventionalists to advance the guidewire through tortuous vessels reducing the risk of puncturing vessel walls and also steering it through labyrinthine vasculature. The guidewire provided by the present invention includes distal and proximal ends with a space therein, a dipole antenna disposed in the space reserved within the guidewire body, the dipole antenna being adapted to be electrically connected to a signal processing system through a first signal channel through the proximal end of the guidewire body, and a loop antenna disposed in the space reserved within the guidewire body toward the distal end of the guidewire body, the loop antenna being adapted to be electrically connected to the signal processing system through a second signal channel through the proximal end of the guidewire body. The dipole antenna and the loop antenna are each constructed to receive magnetic resonance imaging signals independently of each other and to transmit received signals through the first and second signal channels, respectively, to be received by the signal processing system. More specifically, both loop and dipole antenna are tuned to resonate at the same Larmour frequency as produced by the magnet. <ul> <li>Interventional cardiology</li> <li>MRI guided surgery</li> </ul> The National Institutes of Health / Cardiac Catheter Core Lab is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize Active two channel 0.035" guidewire. Please contact Ozgur Kocaturk at 301-402-9430 or <a href="mailto:kocaturko@nhlbi.nih.gov">kocaturko@nhlbi.nih.gov</a>. Available for licensing. 2022-03-08 2024-10-28 2024-10-28 2008-09-01 AA2XXX, AAXXXX, AB3FXX, AB3GXX, AB3XXX, ABXXXX, AXXXXX, Cardiology, Guidewire, Interventional, Magnetic Resonance, MRI False True True NIHTT 37470483 Website Abstract 114170622 GC McKinnon et al. Towards active guidewire visualization in interventional magnetic resonance imaging. MAGMA. 1996 Mar;4(1):13-18. http://www.ncbi.nlm.nih.gov/pubmed/8773997?dopt <a href="http://www.ncbi.nlm.nih.gov/pubmed/8773997?dopt">GC McKinnon et al. Towards active guidewire visualization in interventional magnetic resonance imaging. MAGMA. 1996 Mar;4(1):13-18.</a> 114170623 ME Ladd et al. Active MR visualization of a vascular guidewire in vivo. J Magn Reson Imaging. 1998 Jan-Feb;8(1):220-225. http://www.ncbi.nlm.nih.gov/pubmed/9500284?dopt <a href="http://www.ncbi.nlm.nih.gov/pubmed/9500284?dopt">ME Ladd et al. Active MR visualization of a vascular guidewire in vivo. J Magn Reson Imaging. 1998 Jan-Feb;8(1):220-225.</a> 114106277 Kocaturk, Ozgur National Heart, Lung, and Blood Institute (NHLBI) NHLBI Kocaturk, Ozgur (NHLBI) 1 114106277 Kocaturk, Ozgur National Heart, Lung, and Blood Institute (NHLBI) NHLBI Kocaturk, Ozgur (NHLBI) 1 114101069 Active 0.035" Guidewire With Two Separate Channels E-209-2007-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-1824] Active Guidewire Visualization Device and System for MRI Guided Interventions&body=Please send me information about technology [TAB-1824] Active Guidewire Visualization Device and System for MRI Guided Interventions. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-1824] Active Guidewire Visualization Device and System for MRI Guided Interventions&body=Please send me information about technology [TAB-1824] Active Guidewire Visualization Device and System for MRI Guided Interventions.">shmilovm@nih.gov</a><br> 114163678 E-209-2007-0 E-209-2007-0-PCT-02 Active 0.035" Guidewire With Two Separate Channels PCT Patent Cooperation Treaty PCT/US2008/088655 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2008/088655<br />Filed on 2008-12-31<br />Status: Expired 114163845 E-209-2007-0 E-209-2007-0-US-01 MRI GUIDEWIRE PRV US 61/006,265 Abandoned US <br />Provisional (PRV) 61/006,265<br />Filed on 2008-01-03<br />Status: Abandoned 114166100 E-209-2007-0 E-209-2007-0-US-03 MRI Guidewire National Stage US 8,478,381 12/810,481 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8478381 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8478381">8,478,381</a><br />Filed on 2010-06-24<br />Status: Issued 114167101 E-209-2007-0 E-209-2007-0-US-04 MRI GUIDEWIRE DIV US 9,259,556 13/907,743 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9259556 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9259556">9,259,556</a><br />Filed on 2013-05-31<br />Status: Issued 114119194 AB3XXX 114119195 AB3FXX 114119196 AB3GXX 114119197 AA2XXX 114119198 AXXXXX 114119199 AAXXXX 114119200 ABXXXX 114132410 Guidewire 114132411 Cardiology 114132412 Interventional 114132413 MRI 114132414 Magnetic Resonance TAB-181 114094520 NAG-1: A Non-Steroidal Anti-Inflammatory Drug Related Gene Which Has Anti-Tumorigenic Properties NIEHS Diagnostics, Licensing, Oncology, Therapeutics Diagnostics Licensing Oncology Therapeutics Richard Diaugustine, Thomas Eling, Baek Seung Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used in the treatment of inflammatory disease, and their anti-inflammatory effects are believed to result from their ability to inhibit the formation of prostaglandins by prostaglandin H synthase (COX). Two forms of prostaglandin H have been identified, COX-1 and COX-2. The former seems to be constitutively expressed in a variety of tissues while the high expression of the latter has been reported in colorectal tumors. NSAIDs have been shown to be effective in reducing human colorectal cancers and possibly breast and lung cancers. While the exact mechanism(s) by which NSAIDs function has not been elucidated, they could potentially play a critical role in detecting, diagnosing and treating inflammatory diseases as well as cancer. The present invention relates to screening methods for the identification of agonistic and/or antagonistic agents for the activation of the promoter region of NAG-1. Additional claims are directed to 1) the DNA sequence of NAG-1, 2) compositions containing the NAG-1 sequence and 3) methods for treating cancer patients using NAG-1. 2022-03-08 2024-10-28 2024-10-28 2000-12-01 ANTI-INFLAMMATORY, Anti-Tumorigenic, CAXXXX, CBXXXX, CXXXXX, Diagnostics, DRUG, Duke DNA Project, GAXXXX, GBXXXX, Gene, GXXXXX, NAG-1, Non-Steroidal, Patent Category - Biotechnology, PROPERTIES, Protein, RELATED, screening, SECRETED, That, therapeutics False True True NIHTT 37470483 Website Abstract 114106529 Diaugustine, Richard NIEHS Diaugustine, Richard 0 114106530 Seung, Baek NIEHS NIEHS Seung, Baek (NIEHS) 0 114103284 Eling, Thomas NIEHS NIEHS Eling, Thomas (NIEHS) 1 114103284 Eling, Thomas NIEHS NIEHS Eling, Thomas (NIEHS) 1 114106529 Diaugustine, Richard NIEHS Diaugustine, Richard 0 114106530 Seung, Baek NIEHS NIEHS Seung, Baek (NIEHS) 0 114099311 A Non-Steroidal Anti-Inflammatory Drug Related Gene (NAG-1) And Secreted Protein That Has Anti-Tumorigenic Properties E-170-2000-0 NIEHS 83739538 Choudhry, Vidita vidita.choudhry@nih.gov
United States of America Office of Technology Transfer and Development vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-181] NAG-1: A Non-Steroidal Anti-Inflammatory Drug Related Gene Which Has Anti-Tumorigenic Properties&body=Please send me information about technology [TAB-181] NAG-1: A Non-Steroidal Anti-Inflammatory Drug Related Gene Which Has Anti-Tumorigenic Properties. Choudhry, Vidita<br><a href="mailto:vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-181] NAG-1: A Non-Steroidal Anti-Inflammatory Drug Related Gene Which Has Anti-Tumorigenic Properties&body=Please send me information about technology [TAB-181] NAG-1: A Non-Steroidal Anti-Inflammatory Drug Related Gene Which Has Anti-Tumorigenic Properties.">vidita.choudhry@nih.gov</a><br> 114160343 E-170-2000-0 E-170-2000-0-US-01 A Non-Steroidal Anti-Inflammatory Drug Activated Gene With Anti-Tumorigenic Properties PRV US 60/231,246 Abandoned US <br />Provisional (PRV) 60/231,246<br />Filed on 2000-09-08<br />Status: Abandoned 114160344 E-170-2000-0 E-170-2000-0-US-04 A Non-Steroidal Anti-Inflammatory Drug Related Gene (NAG-1) And Secreted Protein That Has Anti-Tumorigenic Properties DIV US 11/563,586 Abandoned US <br />Divisional (DIV) 11/563,586<br />Filed on 2006-11-27<br />Status: Abandoned 114164507 E-170-2000-0 E-170-2000-0-US-03 Non-Steroidal Anti-Inflammatory Drug Related Gene With Anti-Tumorigenic Properties National Stage US 7,141,661 10/363,514 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7141661 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7141661">7,141,661</a><br />Filed on 2003-08-15<br />Status: Expired 114165066 E-170-2000-0 E-170-2000-0-PCT-02 A Non-Steroidal Anti-Inflammatory Drug Activated Gene With Anti-Tumorigenic Properties PCT Patent Cooperation Treaty PCT/US2001/027544 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2001/027544<br />Filed on 2001-09-06<br />Status: Expired 114165198 E-170-2000-0 E-170-2000-0-US-05 A Non-Steroidal Anti-Inflammatory Drug Related Gene (NAG-1) And Secreted Protein That Has Anti-Tumorigenic Properties DIV US 12/463,666 Abandoned US <br />Divisional (DIV) 12/463,666<br />Filed on 2009-05-11<br />Status: Abandoned 114112334 CAXXXX 114112335 CBXXXX 114112336 GAXXXX 114112337 GBXXXX 114112338 CXXXXX 114112339 GXXXXX 114136899 therapeutics 114136900 Diagnostics 114136901 screening 114136902 ANTI-INFLAMMATORY 114136903 Non-Steroidal 114136904 DRUG 114136905 RELATED 114136906 Gene 114136907 NAG-1 114136908 SECRETED 114136909 Protein 114136910 That 114136911 Anti-Tumorigenic 114136912 PROPERTIES 114136913 Duke DNA Project 114136914 Patent Category - Biotechnology TAB-1796 114096019 Species-Independent A3 Adenosine Receptor Agonists Which May Be Useful for Treating Ischemia, Controlling Inflammation, and Regulating Cell Proliferation NIDDK Cardiology, Collaboration, Diagnostics, Immunology, Ophthalmology, Research Materials, Therapeutics Cardiology Collaboration Diagnostics Immunology Ophthalmology Research Materials Therapeutics Kenneth Jacobson, Artem Melman This invention claims species-independent agonists of A<sub>3</sub>AR, specifically (N)-methanocarba adenine nucleosides and pharmaceutical compositions comprising such nucleosides. The A<sub>3</sub> adenosine receptor (A<sub>3</sub>AR) subtype has been linked with helping protect the heart from ischemia, controlling inflammation, and regulating cell proliferation. Agonists of the human A<sub>3</sub>AR subtype have been developed that are also selective for the mouse A<sub>3</sub>AR while retaining selectivity for the human receptor. This solves a problem for clinical development because animal model testing is important for pre-clinical validation of drug function. Novel agonists have been made that exhibit as much as 6000x selectivity for A<sub>3</sub> versus A<sub>1</sub> in humans while retaining at least 400x selectivity for A<sub>3</sub> versus A<sub>1</sub> in mice. In addition, the molecules of the invention exhibit very low nanomolar affinity. This innovation will not only facilitate moving A<sub>3</sub> agonists into the clinical phase of drug development by being more amenable to animal studies, but also provide much greater selectivity in humans, and thereby potentially fewer side effects than drugs currently undergoing clinical trials. <ul> <li>cardiac arrhythmias or ischemia</li> <li>inflammation</li> <li>stroke</li> <li>diabetes</li> <li>asthma</li> <li>cancer</li> </ul> The NIDDK Laboratory of Bioorganic Chemistry is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize A<sub>3</sub> Adenosine Receptor Agonists. Please contact Marguerite J. Miller at 301-496-9003 or <a href="mailto:millermarg@niddk.nih.gov">millermarg@niddk.nih.gov</a> for more information. 2022-03-08 2024-10-28 2024-10-28 2008-08-01 5'Uronamides, A3, ADENOSINE, AGONISTS, Design, IA3XXX, IAXXXX, IB1XXX, IBXXXX, IXXXXX, N-Methanocarba, OB1XXX, OBXXXX, OXXXXX, Receptor-Selective, Species-Independent False True Research quantities of compounds have been synthesized and tested for receptor selectivity. True NIHTT 37470483 Website Abstract E-140-2008-1 114170553 Melman A, et al. http://www.ncbi.nlm.nih.gov/pubmed/18424135 <a href="http://www.ncbi.nlm.nih.gov/pubmed/18424135">Melman A, et al.</a> 114106216 Melman, Artem National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Melman, Artem 0 114106219 Jacobson, Kenneth National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Jacobson, Kenneth (NIDDK) 1 114106219 Jacobson, Kenneth National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Jacobson, Kenneth (NIDDK) 1 114106216 Melman, Artem National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Melman, Artem 0 114101032 Design Of (N)-Methanocarba Adenosine 5'Uronamides As Species-Independent A3 Receptor-Selective Agonists E-140-2008-0 Filing authorized National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83692066 Tong, Betty tongb@niddk.nih.gov
United States of America Senior Technology Advancement Office tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-1796] Species-Independent A3 Adenosine Receptor Agonists Which May Be Useful for Treating Ischemia, Controlling Inflammation, and Regulating Cell Proliferation&body=Please send me information about technology [TAB-1796] Species-Independent A3 Adenosine Receptor Agonists Which May Be Useful for Treating Ischemia, Controlling Inflammation, and Regulating Cell Proliferation. Tong, Betty<br><a href="mailto:tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-1796] Species-Independent A3 Adenosine Receptor Agonists Which May Be Useful for Treating Ischemia, Controlling Inflammation, and Regulating Cell Proliferation&body=Please send me information about technology [TAB-1796] Species-Independent A3 Adenosine Receptor Agonists Which May Be Useful for Treating Ischemia, Controlling Inflammation, and Regulating Cell Proliferation.">tongb@niddk.nih.gov</a><br> 114160456 E-140-2008-0 E-140-2008-0-PCT-02 Design Of (N)-Methanocarba Adenosine 5'Uronamides As Species-Independent A3 Receptor-Selective Agonists PCT Patent Cooperation Treaty PCT/US2009/038026 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2009/038026<br />Filed on 2009-03-24<br />Status: Expired 114166124 E-140-2008-0 E-140-2008-0-US-01 Adenosine Receptor Agonists PRV US 61/040,985 Abandoned US <br />Provisional (PRV) 61/040,985<br />Filed on 2008-03-31<br />Status: Abandoned 114166179 E-140-2008-0 E-140-2008-0-US-06 Purine Derivatives As A3 Adenosine Receptor-Selective Agonists National Stage US 8,735,407 12/935,461 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8735407 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8735407">8,735,407</a><br />Filed on 2010-11-01<br />Status: Issued 114118978 IB1XXX 114118979 IA3XXX 114118980 OB1XXX 114118981 IXXXXX 114118982 IAXXXX 114118983 IBXXXX 114118984 OXXXXX 114118985 OBXXXX 114131875 Design 114131876 N-Methanocarba 114131877 ADENOSINE 114131878 5'Uronamides 114131879 Species-Independent 114131880 A3 114131881 Receptor-Selective 114131882 AGONISTS TAB-1736 114095964 Generation of Wild-Type Dengue Viruses for Use in Rhesus Monkey Infection Studies NIAID Diagnostics, Infectious Disease, Licensing, Research Materials, Therapeutics, Vaccines Diagnostics Infectious Disease Licensing Research Materials Therapeutics Vaccines Joseph Blaney, Stephen Whitehead Dengue virus is a positive-sense RNA virus belonging to the <i>Flavivirus</i> genus of the family Flaviviridae. Dengue virus is widely distributed throughout the tropical and semitropical regions of the world and is transmitted to humans by mosquito vectors. Dengue virus is a leading cause of hospitalization and death in children in at least eight tropical Asian countries. There are four serotypes of dengue virus (DEN-1, DEN-2, DEN-3, and DEN-4) that annually cause an estimated 50-100 million cases of dengue fever and 500,000 cases of the more severe form of dengue virus infection known as dengue hemorrhagic fever/dengue shock syndrome (DHFIDSS). This latter disease is seen predominately in children and adults experiencing a second dengue virus infection with a serotype different than that of their first dengue virus infection and in primary infection of infants who still have circulating dengue-specific maternal antibody. A vaccine is needed to lessen the disease burden caused by dengue virus, but none is licensed. <br /><br /> Because of the association of more severe disease with secondary dengue virus infection, a successful vaccine must induce immunity to all four serotypes. Immunity is primarily mediated by neutralizing antibody directed against the envelope (E) glycoprotein, a virion structural protein. Infection with one serotype induces long-lived homotypic immunity and a short-lived heterotypic immunity. Therefore, the goal of immunization is to induce a long-lived neutralizing antibody response against DEN-1, DEN-2, DEN-3, and DEN-4, which can best be achieved economically using live attenuated virus vaccines. This is a reasonable goal since a live attenuated vaccine has already been developed for the related yellow fever virus, another mosquito-borne flavivirus present in tropical and semitropical regions of the world. <br /><br /> The evaluation of live attenuated dengue vaccine candidates in rhesus monkeys requires wild type control viruses for each of the four dengue serotypes. These control viruses are used for comparison to the attenuated strains and post-vaccination challenge to assess vaccine efficacy. As such, these viruses need to be well characterized and sufficiently pure to ensure that they will replicate to consistent levels in rhesus monkeys. Characterization generally includes sequence analysis, titration, and evaluation in monkeys. The following viruses have been characterized: (1) DEN1 WP (2) DEN1 Puerto Rico/94 (3) DEN2 NGC prototype (4) DEN2 Tonga/74 (5) DEN3 Sleman/78 and (6) DEN4 Dominica/81. <ul> <li>Dengue/flavivirus vaccine studies</li> <li>Dengue/flavivirus diagnostics</li> <li>Dengue/flavivirus research tools</li> </ul> Research Tool — Patent protection is not being pursued for this technology. 2022-03-08 2024-10-28 2024-10-28 2008-10-01 (4)r syndrome, C syndrome, Chromosome 4 ring syndrome, Chromosome 6 ring syndrome, Chromosome 7 ring syndrome, DA4BXX, DA4XXX, DAXXXX, DB4XXX, DBXXXX, DCXXXX, DDXXXX, DENGUE, Dengue (Flaviviridae), DENGUE FEVER, DXXXXX, G syndrome, Generation, Hemorrhagic fever, Hypertelorism with esophageal abnormality and hypospadias, Infection, MONKEY, N syndrome, Q fever, R(6) syndrome, R(7) syndrome, RHESUS, STUDIES, Syndrome X, Viruses, W syndrome, W syndrome; Syndrome W, WILD-TYPE, Yellow fever False True Materials are available for transfer. Materials are available for transfer. True NIHTT 37470483 Website Abstract 114170482 Durbin AP, et al. http://www.ncbi.nlm.nih.gov/pubmed/11716091 <a href="http://www.ncbi.nlm.nih.gov/pubmed/11716091">Durbin AP, et al.</a> 114170483 Whitehead SS, et al. http://www.ncbi.nlm.nih.gov/pubmed/12502885 <a href="http://www.ncbi.nlm.nih.gov/pubmed/12502885">Whitehead SS, et al.</a> 114170484 Whitehead SS, et al. http://www.ncbi.nlm.nih.gov/pubmed/14505913 <a href="http://www.ncbi.nlm.nih.gov/pubmed/14505913">Whitehead SS, et al.</a> 114170485 Blaney JE Jr, et al. http://www.ncbi.nlm.nih.gov/pubmed/15461822 <a href="http://www.ncbi.nlm.nih.gov/pubmed/15461822">Blaney JE Jr, et al.</a> 114170486 Blaney JE Jr, et al. http://www.ncbi.nlm.nih.gov/pubmed/15642976 <a href="http://www.ncbi.nlm.nih.gov/pubmed/15642976">Blaney JE Jr, et al.</a> 114170487 Blaney JE Jr, et al. http://www.ncbi.nlm.nih.gov/pubmed/15827166 <a href="http://www.ncbi.nlm.nih.gov/pubmed/15827166">Blaney JE Jr, et al.</a> 114170488 Blaney JE Jr, et al. http://www.ncbi.nlm.nih.gov/pubmed/17328799 <a href="http://www.ncbi.nlm.nih.gov/pubmed/17328799">Blaney JE Jr, et al.</a> 114106014 Blaney, Joseph NIAID - DIR NIAID Blaney, Joseph (NIAID) 0 114106015 Whitehead, Stephen NIAID - DIR NIAID Whitehead, Stephen (NIAID) 1 114106015 Whitehead, Stephen NIAID - DIR NIAID Whitehead, Stephen (NIAID) 1 114106014 Blaney, Joseph NIAID - DIR NIAID Blaney, Joseph (NIAID) 0 114100962 Generation Of Wild-Type Dengue Viruses For Use In Rhesus Monkey Infection Studies E-042-2008-0 Research Material NIAID 83643855 Soukas, Peter peter.soukas@nih.gov
United States of America Technology Transfer and Intellectual Property Office peter.soukas@nih.gov?subject=Web Inquiry on [TAB-1736] Generation of Wild-Type Dengue Viruses for Use in Rhesus Monkey Infection Studies&body=Please send me information about technology [TAB-1736] Generation of Wild-Type Dengue Viruses for Use in Rhesus Monkey Infection Studies. Soukas, Peter<br><a href="mailto:peter.soukas@nih.gov?subject=Web Inquiry on [TAB-1736] Generation of Wild-Type Dengue Viruses for Use in Rhesus Monkey Infection Studies&body=Please send me information about technology [TAB-1736] Generation of Wild-Type Dengue Viruses for Use in Rhesus Monkey Infection Studies.">peter.soukas@nih.gov</a><br> 114118559 DA4BXX 114118560 DDXXXX 114118561 DAXXXX 114118562 DBXXXX 114118563 DCXXXX 114118564 DXXXXX 114118907 DA4XXX 114118908 DB4XXX 114131155 WILD-TYPE 114131156 Generation 114131157 STUDIES 114131158 Infection 114131159 MONKEY 114131160 RHESUS 114131161 Viruses 114131162 DENGUE 114156460 Q fever 114156461 Syndrome X 114156462 C syndrome 114156463 Yellow fever 114156464 DENGUE FEVER 114156465 Chromosome 7 ring syndrome 114156466 W syndrome 114156467 Hypertelorism with esophageal abnormality and hypospadias 114156468 N syndrome 114156469 Chromosome 6 ring syndrome 114156470 Hemorrhagic fever 114156471 Chromosome 4 ring syndrome 114157914 Dengue (Flaviviridae) 114158322 R(7) syndrome 114158323 W syndrome; Syndrome W 114158324 G syndrome 114158325 R(6) syndrome 114158326 (4)r syndrome TAB-173 114094512 Ixodes scapularis Tissue Factor Pathway Inhibitor NIAID Infectious Disease, Licensing, Therapeutics, Vaccines Infectious Disease Licensing Therapeutics Vaccines Ivo Francischetti, Jose Ribeiro, Jesus Valenzuela <em>Ixodes scapularis</em> is a blood-sucking tick and the principal vector of Lyme disease, a spirochetal illness caused by <em>Borrelia burgdorferi</em> and now the most common vector-borne infection in the United States; more than 50,000 cases have been reported during the last ten years. The salivary gland of <em>I. scapularis</em> has a number of pharmacologically active molecules that help the tick to successfully feed on blood, such as inhibitors of complement system, in addition to coagulation and platelet aggregation inhibitors. This invention describes Ixolaris, a protein that inhibits the initiation of blood coagulation by inhibition of components of the extrinsic pathway. Accordingly, Ixolaris blocks Factor X activation by Factor VIIa/TissueFactor, it attenuates Factor Xa production by the prothrombinase, and inhibits fibrin formation in a diluted prothrombin time. Ixolaris is highly specific since it does not inhibit other serine proteases. Because Ixolaris has anticoagulant properties, it could be used to ameliorate a number of clinical conditions such as disseminated intravascular coagulation, and hypercoagulation states. In addition, Ixolaris may be useful as a vaccine candidate for Lyme disease because inactivation of Ixolaris by antibodies may make transmission of <em>Borrelia burgdorferi</em> more difficult. In addition to the composition of Ixolaris, the invention claims vaccines utilizing Ixolaris, methods of stimulating an immune response, and methods of treatment of restenosis, arterial thrombosis, and stroke. 2022-03-08 2024-10-28 2024-10-28 2000-12-01 Borreliosis, DB3XXX, DBXXXX, DC4XXX, DCXXXX, DXXXXX, Lyme Disease False True True NIHTT 37470483 Website Abstract 114103266 Francischetti, Ivo NCI Francischetti, Ivo (NCI) 0 114103267 Valenzuela, Jesus NIAID Valenzuela, Jesus (NIAID) 0 114103268 Ribeiro, Jose NIAID Ribeiro, Jose (NIAID) 0 114103266 Francischetti, Ivo NCI Francischetti, Ivo (NCI) 0 114103267 Valenzuela, Jesus NIAID Valenzuela, Jesus (NIAID) 0 114103268 Ribeiro, Jose NIAID Ribeiro, Jose (NIAID) 0 114099303 Ixodes Scapularis Tissue Factor pathway Inhibitor E-208-2000-0 Filing authorized NIAID 83724572 Tung, Peter peter.tung@nih.gov
United States of America DIR peter.tung@nih.gov?subject=Web Inquiry on [TAB-173] Ixodes scapularis Tissue Factor Pathway Inhibitor&body=Please send me information about technology [TAB-173] Ixodes scapularis Tissue Factor Pathway Inhibitor. Tung, Peter<br><a href="mailto:peter.tung@nih.gov?subject=Web Inquiry on [TAB-173] Ixodes scapularis Tissue Factor Pathway Inhibitor&body=Please send me information about technology [TAB-173] Ixodes scapularis Tissue Factor Pathway Inhibitor.">peter.tung@nih.gov</a><br> 114160315 E-208-2000-0 E-208-2000-0-US-04 Ixodes Scapularis Tissue Factor Pathway Inhibitor National Stage US 7,078,508 10/408,166 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7078508 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7078508">7,078,508</a><br />Filed on 2003-04-04<br />Status: Expired 114164347 E-208-2000-0 E-208-2000-0-US-01 Ixodes Scapularis Tissue Factor Pathway Inhibitor PRV US 60/240,575 Abandoned US <br />Provisional (PRV) 60/240,575<br />Filed on 2000-10-05<br />Status: Abandoned 114165244 E-208-2000-0 E-208-2000-0-PCT-02 Ixodes Scapularis Tissue Factor Pathway Inhibitor PCT Patent Cooperation Treaty PCT/US01/42472 Expired Patent Cooperation Treaty <br />(PCT) PCT/US01/42472<br />Filed on 2001-10-05<br />Status: Expired 114112303 DB3XXX 114112304 DC4XXX 114112305 DBXXXX 114112306 DCXXXX 114112307 DXXXXX 114156452 Borreliosis 114158318 Lyme Disease TAB-1734 114095962 Nitrite and Nitrite-Methemoglobin Therapy to Detoxify Stroma-Free Hemoglobin Based Blood Substitutes NHLBI Diagnostics, Licensing, Research Materials, Therapeutics Diagnostics Licensing Research Materials Therapeutics Mark Gladwin Cell-free hemoglobin based oxygen carriers (HBOCs) are blood substitutes and resuscitative agents that can be used to replace whole blood donations, alleviate blood shortages and reduce the risks of infections such as HIV and hepatitis. Stroma-free HBOCs offer the advantages of increased stability, consistency of supply, and reduced immunogenicity over the use of the alternative cell based sources. However, the side effects associated with their use, including vascular toxicity, pulmonary and systemic hypertension, myocardial infarction, inflammation, and platelet aggregation severely limit their scope of clinical applications. These adverse effects are due in part to the ability of free deoxygenated hemoglobin (deoxyHb) to scavenge for nitric oxide (NO) thus rendering it unavailable for vasodilating blood vessels.<br /><br /> This technology is a method of using nitrites to reduce the deleterious effects associated with HBOC use as blood substitutes. Free nitrites or nitrite-methemoglobin when added to stroma-free HBOCs are converted to NO and N<sub>2</sub>O<sub>3</sub> which escapes the scavenging activity of deoxyHb and thus is free to vasodilate blood vessels. This maintains oxygen release and NO delivery enabling improved clinical outcomes. Recent studies, using this technology as a blood substitute, have led to a reversal of vasoconstriction, hypertension and hemorrhagic shock in animal models. This new approach also reduces the toxicity associated with the use of HBOCs as a blood substitute and may allow the wide spread use of HBOCs as an alternative to cell based sources. In combination with this technology, HBOC blood substitutes may now be used to efficiently deliver therapeutic agents and maintain organ perfusion during trauma and surgery. <ul> <li>Reduced toxicity of cell free hemoglobin blood substitutes</li> <li>Increased blood perfusion in patients</li> <li>Decreased dependence on blood donations</li> </ul> 2022-03-08 2024-10-28 2024-10-28 2008-04-01 Based, Blood, Detoxify, hemoglobin, Hepatitis A, Hepatitis D, Hepatitis E, ICXXXX, IXXXXX, Nitrite, Nitrite-methemoglobin, Stroma-free, Substitutes, THERAPY False True Pre-clinical Pre-clinical True NIHTT 37470483 Website Abstract 114170481 Basu S, et al. http://www.ncbi.nlm.nih.gov/pubmed/17982448 <a href="http://www.ncbi.nlm.nih.gov/pubmed/17982448">Basu S, et al.</a> 114106010 Gladwin, Mark National Heart, Lung, and Blood Institute (NHLBI) Gladwin, Mark 1 114106010 Gladwin, Mark National Heart, Lung, and Blood Institute (NHLBI) Gladwin, Mark 1 114100960 Nitrite And Nitrite-methemoglobin Therapy To Detoxify Stroma-free Hemoglobin Based Blood Substitutes" E-259-2007-0 Filing authorized Clinical Center (CC), National Heart, Lung, and Blood Institute (NHLBI), University of Alabama at Birmingham, Wake Forest University 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-1734] Nitrite and Nitrite-Methemoglobin Therapy to Detoxify Stroma-Free Hemoglobin Based Blood Substitutes&body=Please send me information about technology [TAB-1734] Nitrite and Nitrite-Methemoglobin Therapy to Detoxify Stroma-Free Hemoglobin Based Blood Substitutes. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-1734] Nitrite and Nitrite-Methemoglobin Therapy to Detoxify Stroma-Free Hemoglobin Based Blood Substitutes&body=Please send me information about technology [TAB-1734] Nitrite and Nitrite-Methemoglobin Therapy to Detoxify Stroma-Free Hemoglobin Based Blood Substitutes.">shmilovm@nih.gov</a><br> 114163046 E-259-2007-0 E-259-2007-0-US-05 Nitrite And Nitrite-methemoglobin Therapy To Detoxify Stroma-free Hemoglobin Based Blood Substitutes CON US 15/146,190 Abandoned US <br />Continuation (CON) 15/146,190<br />Filed on 2016-05-04<br />Status: Abandoned 114164212 E-259-2007-0 E-259-2007-0-US-01 Nitrite-methemoglobin Therapy To Detoxify Stroma-free Hemoglobin Based Blood Substitutes PRV US 60/969,530 Abandoned US <br />Provisional (PRV) 60/969,530<br />Filed on 2007-08-31<br />Status: Abandoned 114164673 E-259-2007-0 E-259-2007-0-PCT-02 Nitrite And Nitrite-methemoglobin Therapy To Detoxify Stroma-free Hemoglobin Based Blood Substitutes" PCT Patent Cooperation Treaty PCT/US2008/074856 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2008/074856<br />Filed on 2008-08-29<br />Status: Expired 114165981 E-259-2007-0 E-259-2007-0-US-03 Nitrite And Nitrite-methemoglobin Therapy To Detoxify Stroma-free Hemoglobin Based Blood Substitutes" National Stage US 8,551,536 12/675,347 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8551536 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8551536">8,551,536</a><br />Filed on 2010-02-25<br />Status: Issued 114167328 E-259-2007-0 E-259-2007-0-US-04 Nitrite And Nitrite-methemoglobin Therapy To Detoxify Stroma-free Hemoglobin Based Blood Substitutes ORD US 14/028,850 Abandoned US <br />Ordinary Patent (ORD) 14/028,850<br />Filed on 2013-09-17<br />Status: Abandoned 114118550 ICXXXX 114118551 IXXXXX 114131294 Nitrite 114131295 Nitrite-methemoglobin 114131296 THERAPY 114131297 Detoxify 114131298 Stroma-free 114131299 hemoglobin 114131300 Based 114131301 Blood 114131302 Substitutes 114156455 Hepatitis D 114156456 Hepatitis A 114156457 Hepatitis E TAB-1711 114095940 A Fold-Back Diabody Format for Diphtheria Toxin-Based Immunotoxins That Can Increase Binding and Potency NIMH Collaboration, Immunology, Oncology, Therapeutics Collaboration Immunology Oncology Therapeutics David Neville (Estate) NIH inventors, in collaboration with Scott and White Memorial Hospital inventors, have developed new immunotoxins comprising a mutant diphtheria toxin linked to an anti-prostate specific membrane antigen (PSMA) fold-back diabody. The fold-back diabody construct has a shortened linker region between the heavy and light chains of the antibody variable domain. This construct allows interactions between the longer-linked variable domains while preventing interactions between the shorter-linked variable domains. This results in increased efficiency of epitope recognition and delivery to the appropriate target cells. These immunotoxins can be used for the treatment of cancers that overexpress PMSA, with specific application against prostate cancer. <ul> <li>Increased potency of 10-40-fold resulting from the use of the fold-back diabody construct.</li> <li>First treatment with applications to metastatic prostate cancer.</li> <li><i>Pichia pastoris</i> production process of the fold-back immunotoxin can be used to scale up for GMP production.</li> </ul> <ul> <li>Treatment of primary prostate tumors.</li> <li>Treatment of metastatic prostate tumors, for which no currently effective treatment exists.</li> <li>Application against other tumors expressing the PSMA epitope on the tumor neovasculature such as breast cancer.</li> </ul> 2022-03-08 2024-10-28 2024-10-28 2008-02-01 A-dmDT390scfbDb591, Anti-prostratic, APPLICATION, Based, BINDING, CANCER, CB1AXX, CB1BXX, CB1CXX, CB1XXX, CBXXXX, CXXXXX, Diabody, DIPHTHERIA, Diptheria, Fold-back, FORMAT, Immunotoxin, IMMUNOTOXINS, INCREASE, particular, Potentcy, That, toxin False True True NIHTT 37470483 Website Abstract 114106217 Neville (Estate), David National Institute of Mental Health (NIMH) NIMH Neville (Estate), David (NIMH) 1 114106217 Neville (Estate), David National Institute of Mental Health (NIMH) NIMH Neville (Estate), David (NIMH) 1 114100935 A Fold-back Diabody Format For Diptheria Toxin Based Immunotoxins That Can Increase Binding And Potentcy With Particular Application To An Anti-prostratic Cancer Immunotoxin A-dmDT390scfbDb(591) E-268-2007-0 Filing authorized Baylor Scott and White Research Institute, National Institute of Mental Health (NIMH) 83686256 Wong, Jennifer jennifer.wong2@nih.gov
United States of America jennifer.wong2@nih.gov?subject=Web Inquiry on [TAB-1711] A Fold-Back Diabody Format for Diphtheria Toxin-Based Immunotoxins That Can Increase Binding and Potency&body=Please send me information about technology [TAB-1711] A Fold-Back Diabody Format for Diphtheria Toxin-Based Immunotoxins That Can Increase Binding and Potency. Wong, Jennifer<br><a href="mailto:jennifer.wong2@nih.gov?subject=Web Inquiry on [TAB-1711] A Fold-Back Diabody Format for Diphtheria Toxin-Based Immunotoxins That Can Increase Binding and Potency&body=Please send me information about technology [TAB-1711] A Fold-Back Diabody Format for Diphtheria Toxin-Based Immunotoxins That Can Increase Binding and Potency.">jennifer.wong2@nih.gov</a><br> 114163898 E-268-2007-0 E-268-2007-0-PCT-02 A FOLD-BACK DIABODY DIPHTHERIA TOXIN IMMUNOTOXIN AND METHODS OF USE PCT Patent Cooperation Treaty PCT/US2008/009321 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2008/009321<br />Filed on 2008-08-01<br />Status: Expired 114163899 E-268-2007-0 E-268-2007-0-US-01 A Fold-back Diabody Format For Diptheria Toxin Based Immunotoxins That Can Increase Binding And Potentcy With Particular Application To An Anti-prostratic Cancer Immunotoxin A-dmDT390scfbDb(591) PRV US 60/953,416 Abandoned US <br />Provisional (PRV) 60/953,416<br />Filed on 2007-08-01<br />Status: Abandoned 114165750 E-268-2007-0 E-268-2007-0-US-06 FOLD-BACK DIABODY DIPHTHERIA TOXIN IMMUNOTOXIN AND METHODS OF USE National Stage US 9,364,557 12/671,629 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9364557 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9364557">9,364,557</a><br />Filed on 2010-02-01<br />Status: Issued 114118464 CB1AXX 114118465 CB1BXX 114118466 CB1CXX 114118467 CBXXXX 114118468 CXXXXX 114118930 CB1XXX 114131529 Diabody 114131530 Fold-back 114131531 FORMAT 114131532 Diptheria 114131533 toxin 114131534 Based 114131535 IMMUNOTOXINS 114131536 That 114131537 INCREASE 114131538 BINDING 114131539 Potentcy 114131540 particular 114131541 APPLICATION 114131542 Anti-prostratic 114131543 CANCER 114131544 Immunotoxin 114131545 A-dmDT390scfbDb591 114156429 DIPHTHERIA TAB-1716 114095945 Eeyarestatins: Novel Deubiquitination Inhibitors for the Treatment of Drug-Resistant Cancers NHLBI Collaboration, Infectious Disease, Licensing, Oncology, Therapeutics Collaboration Infectious Disease Licensing Oncology Therapeutics Helena Mora-Jensen, Qiuyan Wang, Adrian Wiestner, Yihong Ye The ubiquitin-proteasome system has recently been recognized to play a central role in tumor biology. Bortezomib, an inhibitor of the chymotrypsin-like activity of the proteasome, has clinical activity in a variety of hematologic malignancies and is FDA approved for use in Multiple Myeloma and Mantle Cell Lymphoma. <br><br> The present invention for the first time describes that Eeyarestatins, a new class of small molecules, are potential anti-cancer agents. The compounds inhibit the deubiquitination of proteins by targeting the deubiquitination enzymes in the protein degradation pathway. More specifically, the inventors have demonstrated that the Eeyarestatins successfully kill different leukemia and lymphoma cell lines as well as leukemia cells isolated from patients with chronic lymphocytic leukemia by inducing the expression of Noxa, a pro-apoptotic member of the Bcl-2 protein family. Additionally, Eeyarestatins are active against cells that are resistant to Bortezomib and thus can be effective against drug-resistant tumors. <ul> <li>Eeyarestatins are active against cells that are resistant to Bortezomib.</li> <li><i>In vitro</i> data shows activity of Eeyarestatins against primary cells from patients with chronic lymphocytic leukemia. Clinical trials show that Bortezomib is inactive against patients suffering from chronic lymphocytic leukemia.</li> </ul <ul> <li>Eeyarestatins can be developed for the treatment of deubiquitination related disorders such as cancers and proliferative disorders.</li> <li>Eeyarestatins can potentially have broader use against HIV and immune related disorders considering the role of deubiquitination in budding of retroviruses and immune regulation.</li> </ul> The National Institutes of Health laboratories of Dr. Adrian Wiestner (NHLBI) and Dr. Yihong Ye (NIDDK) are seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize Eeyarestatins. Please contact Dr. Wiestner (301-594-6855, <a href="mailto:wiestnera@mail.nih.gov">wiestnera@mail.nih.gov</a>) or Dr. Ye (301-594-0845, <a href="mailto:yihongy@mail.nih.gov">yihongy@mail.nih.gov</a>) for more information. Available for licensing. 2022-03-08 2024-10-28 2024-10-28 2008-02-01 Active, Against, BBXXXX, Bortezomib, CANCER, CB5EXX, CB5XXX, CBXXXX, Cells, Chronic lymphocytic leukemia, COMPOSITION, CXXXXX, DB4AXX, DB4XXX, DBXXXX, Deubiquination, DXXXXX, Eeyarestatin, Hematologic, Highly, HIV AIDS - Therapeutics, Including, inhibitor, lymphoma, Mantle cell lymphoma, MULTIPLE MYELOMA, Proteasome, RESISTANT, That, tumor False True <i>In vitro</i> studies are completed and in vivo animal model studies are planned. <i>In vitro</i> studies are completed and in vivo animal model studies are planned. True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114170460 Q Wang, L Li, Y Ye. Inhibition of p97-dependent protein degradation by Eeyarestatin I. J Biol Chem. 2008 Jan 16; Epub ahead of print, doi 10.1074/jbc.M708347200. http://www.ncbi.nlm.nih.gov/pubmed/18199748?dopt <a href="http://www.ncbi.nlm.nih.gov/pubmed/18199748?dopt">Q Wang, L Li, Y Ye. Inhibition of p97-dependent protein degradation by Eeyarestatin I. J Biol Chem. 2008 Jan 16; Epub ahead of print, doi 10.1074/jbc.M708347200.</a> 114105974 Mora-Jensen, Helena National Heart, Lung, and Blood Institute (NHLBI) Mora-Jensen, Helena 0 114105975 Wang, Qiuyan National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Wang, Qiuyan 0 114105976 Ye, Yihong National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Ye, Yihong (NIDDK) 0 114105977 Wiestner, Adrian National Heart, Lung, and Blood Institute (NHLBI) NHLBI Wiestner, Adrian (NHLBI) 1 114105977 Wiestner, Adrian National Heart, Lung, and Blood Institute (NHLBI) NHLBI Wiestner, Adrian (NHLBI) 1 114105974 Mora-Jensen, Helena National Heart, Lung, and Blood Institute (NHLBI) Mora-Jensen, Helena 0 114105975 Wang, Qiuyan National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Wang, Qiuyan 0 114105976 Ye, Yihong National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Ye, Yihong (NIDDK) 0 114100940 Eeyarestatin Is A Deubiquination Inhibitor That Is Highly Active Against Hematologic Tumor Cells Including Cells Resistant To The Proteasome Inhibitor Bortezomib E-208-2007-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-1716] Eeyarestatins: Novel Deubiquitination Inhibitors for the Treatment of Drug-Resistant Cancers&body=Please send me information about technology [TAB-1716] Eeyarestatins: Novel Deubiquitination Inhibitors for the Treatment of Drug-Resistant Cancers. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-1716] Eeyarestatins: Novel Deubiquitination Inhibitors for the Treatment of Drug-Resistant Cancers&body=Please send me information about technology [TAB-1716] Eeyarestatins: Novel Deubiquitination Inhibitors for the Treatment of Drug-Resistant Cancers.">shmilovm@nih.gov</a><br> 114164172 E-208-2007-0 E-208-2007-0-US-01 IMIDAZOLIDINONE COMPOUNDS, METHODS TO INHIBIT DEUBIQUITINATION AND METHODS OF TREATMENT PRV US 60/961,202 Abandoned US <br />Provisional (PRV) 60/961,202<br />Filed on 2007-07-18<br />Status: Abandoned 114164652 E-208-2007-0 E-208-2007-0-PCT-02 IMIDAZOLIDINONE COMPOUNDS, METHODS TO INHIBIT DEUBIQUITINATION AND METHODS OF TREATMENT PCT Patent Cooperation Treaty PCT/US2008/08797 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2008/08797<br />Filed on 2008-07-18<br />Status: Expired 114165996 E-208-2007-0 E-208-2007-0-US-03 Imidazolidinone Compounds, Methods to Inhibit Deubiquination And Methods of Treatment National Stage US 8,637,560 12/669,361 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8637560 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8637560">8,637,560</a><br />Filed on 2010-01-15<br />Status: Issued 114118483 CB5EXX 114118484 DB4AXX 114118485 CBXXXX 114118486 DBXXXX 114118487 CXXXXX 114118488 DXXXXX 114118927 DB4XXX 114118928 CB5XXX 114121184 BBXXXX 114131462 Eeyarestatin 114131463 Deubiquination 114131464 inhibitor 114131465 HIV AIDS - Therapeutics 114131466 CANCER 114131467 Active 114131468 Hematologic 114131469 tumor 114131470 Cells 114131471 COMPOSITION 114131472 RESISTANT 114131473 Proteasome 114131474 Bortezomib 114131475 That 114131476 Highly 114131477 Against 114131478 Including 114156432 lymphoma 114156433 Mantle cell lymphoma 114156434 Chronic lymphocytic leukemia 114156435 MULTIPLE MYELOMA TAB-1669 114095897 Novel Roles of a DNA Repair Protein, DNA-PKcs, in Obesity, Neurological Function, and Aging NHLBI Cardiology, Collaboration, Diagnostics, Immunology, Licensing, Reproductive Health, Research Materials, Therapeutics, Vaccines Cardiology Collaboration Diagnostics Immunology Licensing Reproductive Health Research Materials Therapeutics Vaccines Jay Chung The catalytic subunit of the DNA-dependent protein kinase complex (DNA-PKcs) has been shown to be important in DNA repair and VDJ recombination in lymphocytes. The inventors have discovered that DNA-PKcs also plays novel, important roles in energy regulation and neurological function. The inventors observed that mature DNA-PKcs-deficient mice (also known as SCID mice) have a lower proportion of fat, resist obesity, and have significantly greater physical endurance than wild-type control mice, particularly with increasing age. The inventors also observed that DNA-PKcs-deficient mice have better memory and less anxiety. One potential explanation for this is that they express higher levels of brain-derived neurotrophic factor (BDNF), which is associated with neurogenesis, memory formation and suppression of anxiety and depression. Moreover, DNA-PKcs-deficient cells produce less oxidative stress. Thus, inhibition of DNA-PKcs may have unexpected utility in the treatment of a wide range of diseases and conditions.<br><br> The invention discloses methods of inhibiting DNA-PKcs activity to decrease adiposity, improve physical endurance and increase insulin sensitivity and the number of mitochondria. Also claimed are methods directed to improved neurological function, such as methods for protection from neurodegenerative disease, improving memory and learning ability, and for reducing depression and anxiety. Additionally, the invention discloses methods for reducing inflammation and for treating heart disease. <ul> <li>Development of therapeutics targeting obesity, insulin-resistant diabetes, and age-related loss of physical endurance.</li> <li>Development of therapeutics to treat neurological disorders such as depression and memory loss.</li> </ul> The National Heart Lung and Blood Institute, Laboratory of Biochemical Genetics, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize DNA-PKcs inhibitors for treatment or prevention of metabolic and degenerative diseases. Please contact Jay Chung (<a href="mailto:chungj@nhlbi.nih.gov">chungj@nhlbi.nih.gov</a>) for more information. Available for licensing. 2022-03-08 2024-10-28 2024-10-28 2007-10-01 Aging, ANXIETY, Cardiovascular, depression, DIABETES, DNA-Dependent, DNA-PKcs, Endurance, Energy, HEART, IB1XXX, IB3XXX, IB6XXX, IBXXXX, Inflammation, insulin, INSULIN-DEPENDENT, IXXXXX, LEARNING, MEMORY, METABOLIC, Metabolism, Mitochondria, Neurological, OBESITY, REGULATION, TYPE-2, Weight False True Early stage Early stage True NIHTT 37470483 Website Abstract 114170433 In preparation In preparation 114105896 Chung, Jay National Heart, Lung, and Blood Institute (NHLBI) NHLBI Chung, Jay (NHLBI) 1 114105896 Chung, Jay National Heart, Lung, and Blood Institute (NHLBI) NHLBI Chung, Jay (NHLBI) 1 114100883 The Role Of DNA-PKcs In Energy Regulation E-068-2007-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 90072936 Mistry, Pragnesh pragnesh.mistry@nih.gov
HNH6Z08 pragnesh.mistry@nih.gov?subject=Web Inquiry on [TAB-1669] Novel Roles of a DNA Repair Protein, DNA-PKcs, in Obesity, Neurological Function, and Aging&body=Please send me information about technology [TAB-1669] Novel Roles of a DNA Repair Protein, DNA-PKcs, in Obesity, Neurological Function, and Aging. Mistry, Pragnesh<br><a href="mailto:pragnesh.mistry@nih.gov?subject=Web Inquiry on [TAB-1669] Novel Roles of a DNA Repair Protein, DNA-PKcs, in Obesity, Neurological Function, and Aging&body=Please send me information about technology [TAB-1669] Novel Roles of a DNA Repair Protein, DNA-PKcs, in Obesity, Neurological Function, and Aging.">pragnesh.mistry@nih.gov</a><br> 114164059 E-068-2007-0 E-068-2007-0-PCT-02 DNA-PKCS MODULATES ENERGY REGULATION AND BRAIN FUNCTION PCT Patent Cooperation Treaty PCT/US2008/008234 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2008/008234<br />Filed on 2008-07-03<br />Status: Expired 114164060 E-068-2007-0 E-068-2007-0-US-01 DNA-PKcs Modulates Energy Regulation and Brain Function PRV US 60/958,714 Abandoned US <br />Provisional (PRV) 60/958,714<br />Filed on 2007-07-06<br />Status: Abandoned 114165715 E-068-2007-0 E-068-2007-0-US-04 DNA-PKcs Modulates Energy Regulation and Brain Function National Stage US 12/667,840 Abandoned US <br />National Stage 12/667,840<br />Filed on 2010-02-01<br />Status: Abandoned 114118255 IB1XXX 114118256 IB3XXX 114118257 IB6XXX 114118258 IBXXXX 114118259 IXXXXX 114132671 OBESITY 114132672 DNA-PKcs 114132673 Energy 114132674 REGULATION 114132675 Aging 114132676 Neurological 114132677 DIABETES 114132678 INSULIN-DEPENDENT 114132679 insulin 114132680 Endurance 114132681 Mitochondria 114132682 Weight 114132683 depression 114132684 ANXIETY 114132685 MEMORY 114132686 LEARNING 114132687 Inflammation 114132688 HEART 114132689 Cardiovascular 114132690 Metabolism 114132691 METABOLIC 114132692 TYPE-2 114132693 DNA-Dependent TAB-1611 114095879 Collagen-Induced Platelet Aggregation Inhibitor from Mosquito Salivary Glands NIAID Cardiology, Collaboration, Diagnostics, Immunology, Research Materials, Therapeutics Cardiology Collaboration Diagnostics Immunology Research Materials Therapeutics Eric Calvo Exposed collagen in injured blood vessels provides a substrate for platelets to adhere and aggregate initiating the first step in thrombosis, the formation of blood clots inside a blood vessel. Despite the essential role of platelets in vascular injury, excessive platelet aggregation may also result in thrombotic diseases such as stroke and heart attack.<br /><br /> Available for licensing is a collagen binding protein, named aegyptin, which selectively inhibits collagen-platelet aggregation, but not platelet aggregation induced by other agonists. Collagen initiates recruitment of circulating platelets and triggers platelet activation. Collagen also plays a critical role in angiogenesis. Aegyptin blocks the interaction of collagen with its major ligands, von Willebrand factor, glycoprotein VI (GPVI), and integrin alpha2beta1. These three ligands are of particular importance because von Willebrand factor plays a critical role in tethering platelets to collagen, GPVI is the major signaling platelet receptor, and integrin alpha2beta1 mediates platelet adhesion and contributes to activation. Since these ligands play a critical role in the early stages of thrombus formation, aegyptin represents a potentially highly effective therapeutic that can prevent and treat patients with thrombotic disease. Alternatively, aegyptin is potentially useful in conditions where collagen plays a critical role in angiogenesis or in conditions where excessive deposition of collagen plays a pathological role (e.g., pancreatic carcinoma). <ul> <li>Highly effective therapeutics can negatively modulate thrombosis in its early stages by preventing collagen interaction with three major ligands involved in thrombus/clot formation.</li> <li>Aegyptin’s potential use as a prototype for drug delivery as an oral therapeutic, which can reduce the need for invasive surgeries that dilate blood vessels such as stents or catheters.</li> </ul> <ul> <li>Adjuvant to “Clot busting” therapeutics.</li> <li>Method to prevent and/or treat cardiovascular/thrombotic disease.</li> <li>Method to treat patients undergoing invasive cardiovascular procedures (e.g., angioplasty).</li> <li>Model to study collagen-dependent platelet aggregation or collagen-mediated angiogenesis.</li> </ul> The National Institute of Allergy and Infectious Diseases, Laboratory of Malaria and Vector Research, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize the platelet aggregation inhibitor Aegyptin. Please contact Dr. Jose Ribeiro, Head, Vector Biology Section, at 301-496-9389 or <a href="mailto:jribeiro@niaid.nih.gov">jribeiro@niaid.nih.gov</a> for more information. 2022-03-08 2024-10-28 2024-10-28 2008-02-01 AGGREGATION, Collagen-platelet, GLANDS, IB1EXX, IB1XXX, IB3XXX, IBXXXX, inhibitor, IXXXXX, Malaria, Mosquito, Salivary False True The technology is currently in the pre-clinical stage of development. Pre-clinical True NIHTT 37470483 Website Abstract 114170410 Calvo E, et al. http://www.ncbi.nlm.nih.gov/pubmed/17650501 <a href="http://www.ncbi.nlm.nih.gov/pubmed/17650501">Calvo E, et al.</a> 114170411 Calvo E. Collagen-platelet aggregation inhibitor from mosquito salivary glands. Biacore T100 seminar series, November 2006, St. Louis, Missouri. Calvo E. Collagen-platelet aggregation inhibitor from mosquito salivary glands. Biacore T100 seminar series, November 2006, St. Louis, Missouri. 114170412 Yoshida S, Watanabe H. http://www.ncbi.nlm.nih.gov/pubmed/16907827 <a href="http://www.ncbi.nlm.nih.gov/pubmed/16907827">Yoshida S, Watanabe H.</a> 114170413 Sun D, et al. http://www.ncbi.nlm.nih.gov/pubmed/16702045 <a href="http://www.ncbi.nlm.nih.gov/pubmed/16702045">Sun D, et al.</a> 114105866 Calvo, Eric NIAID - DIR FDA Calvo, Eric (FDA) 1 114105866 Calvo, Eric NIAID - DIR FDA Calvo, Eric (FDA) 1 114100863 Collagen-platelet Aggregation Inhibitor From Mosquito Salivary Glands E-172-2007-1 Filing authorized NIAID, University of California, Irvine 114100864 Collagen-platelet Aggregation Inhibitor From Mosquito Salivary Glands E-172-2007-0 Filing authorized NIAID, University of California, Irvine 114101126 Collagen-platelet Aggregation Inhibitor From Mosquito Salivary Glands E-172-2007-2 Filing authorized NIAID, University of California, Irvine 83724572 Tung, Peter peter.tung@nih.gov
United States of America DIR peter.tung@nih.gov?subject=Web Inquiry on [TAB-1611] Collagen-Induced Platelet Aggregation Inhibitor from Mosquito Salivary Glands&body=Please send me information about technology [TAB-1611] Collagen-Induced Platelet Aggregation Inhibitor from Mosquito Salivary Glands. Tung, Peter<br><a href="mailto:peter.tung@nih.gov?subject=Web Inquiry on [TAB-1611] Collagen-Induced Platelet Aggregation Inhibitor from Mosquito Salivary Glands&body=Please send me information about technology [TAB-1611] Collagen-Induced Platelet Aggregation Inhibitor from Mosquito Salivary Glands.">peter.tung@nih.gov</a><br> 114164021 E-172-2007-2 E-172-2007-2-PCT-01 AEGYPTIN AND USES THEREOF PCT COMB Patent Cooperation Treaty PCT/US2008/069349 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2008/069349<br />Filed on 2008-07-07<br />Status: Expired 114164022 E-172-2007-1 E-172-2007-1-US-01 AEGYPTIN AND USES THEREOF PRV US 60/982,241 Abandoned US <br />Provisional (PRV) 60/982,241<br />Filed on 2007-10-24<br />Status: Abandoned 114164023 E-172-2007-0 E-172-2007-0-US-01 Collagen-platelet Aggregation Inhibitor From Mosquito Salivary Glands PRV US 60/198,629 Abandoned US <br />Provisional (PRV) 60/198,629<br />Filed on 2007-07-09<br />Status: Abandoned 114165738 E-172-2007-2 E-172-2007-2-US-02 Aegyptin and Uses Thereof National Stage US 8,383,589 12/668,177 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8383589 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8383589">8,383,589</a><br />Filed on 2010-01-07<br />Status: Issued 114166959 E-172-2007-2 E-172-2007-2-US-03 Aegyptin And Uses Thereof CON US 8,980,859 13/746,631 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8980859 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8980859">8,980,859</a><br />Filed on 2013-01-22<br />Status: Issued 114167945 E-172-2007-2 E-172-2007-2-US-04 Aegyptin And Uses Thereof DIV US 9,441,022 14/488,983 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9441022 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9441022">9,441,022</a><br />Filed on 2014-09-17<br />Status: Issued 114118155 IB1EXX 114118156 IBXXXX 114118157 IXXXXX 114119669 IB1XXX 114119670 IB3XXX 114135417 Collagen-platelet 114135418 AGGREGATION 114135419 inhibitor 114135420 Mosquito 114135421 Salivary 114135422 GLANDS 114156375 Malaria TAB-1646 114095893 Hepatitis C Virus Cell Culture System NIAID Infectious Disease, Licensing, Research Materials Infectious Disease Licensing Research Materials Suzanne Emerson, Robert Purcell, Rodney Russell Hepatitis C virus (HCV) infection causes chronic liver disease and is a major global health problem with an estimated 170 million people affected worldwide and 3-4 million new cases every year. Therapeutic advances will be greatly aided by the ability of researchers to successfully replicate and characterize the virus in vitro. The study of HCV replication has, however, been hindered by the lack of an efficient virus culture system. One approach, using cell culture adaptive mutations in the viral RNA has been found to significantly enhance HCV virus production, but it has been difficult to define which stage of the viral lifecycle is affected by a given adaptive mutation. <br><br> NIH researchers have now developed a single-cycle virus production system that allows the stage of the viral lifecycle affected by a specific adaptive mutation to be determined. They have isolated a unique subclone of Huh 7 Hepatoma cells, S29, that permits HCV replication and infectious virion release, but is resistant to infection by HCV. This permits the use of single cycle growth studies, and removes the confounding effects of virus re-infection allowing progress to be made on structure/function studies, or on studies of the effects of drugs on replication and virus assembly. <ul> <li>HCV drug discovery</li> <li>HCV single-cycle virus studies</li> <li>HCV structure/function studies</li> </ul> Research Tool -- Patent protection is not being pursued for this technology Available for licensing. 2022-03-08 2024-10-28 2024-10-28 2007-10-01 Cells, CULTURE, DDXXXX, DXXXXX, Hepatitis A, HEPATITIS C, Hepatitis D, Hepatitis E, Hepatocellular carcinoma, adult, HEPATOMA, Huh-7, Huh-7.5, Subclone False True True NIHTT 37470483 Website Abstract 114105888 Russell, Rodney NIAID - DIR NIAID Russell, Rodney (NIAID) 0 114105889 Purcell, Robert NIAID - DIR NIAID Purcell, Robert (NIAID) 0 114105890 Emerson, Suzanne NIAID - DIR NIAID Emerson, Suzanne (NIAID) 1 114105890 Emerson, Suzanne NIAID - DIR NIAID Emerson, Suzanne (NIAID) 1 114105888 Russell, Rodney NIAID - DIR NIAID Russell, Rodney (NIAID) 0 114105889 Purcell, Robert NIAID - DIR NIAID Purcell, Robert (NIAID) 0 114100879 A Subclone Of Huh-7 Hepatoma Cells (Huh-7.5) E-324-2007-0 Research Material NIAID 83643855 Soukas, Peter peter.soukas@nih.gov
United States of America Technology Transfer and Intellectual Property Office peter.soukas@nih.gov?subject=Web Inquiry on [TAB-1646] Hepatitis C Virus Cell Culture System&body=Please send me information about technology [TAB-1646] Hepatitis C Virus Cell Culture System. Soukas, Peter<br><a href="mailto:peter.soukas@nih.gov?subject=Web Inquiry on [TAB-1646] Hepatitis C Virus Cell Culture System&body=Please send me information about technology [TAB-1646] Hepatitis C Virus Cell Culture System.">peter.soukas@nih.gov</a><br> 114118241 DDXXXX 114118242 DXXXXX 114133767 Subclone 114133768 Huh-7 114133769 HEPATOMA 114133770 Cells 114133771 Huh-7.5 114133772 HEPATITIS C 114133773 CULTURE 114156390 Hepatitis D 114156391 Hepatitis A 114156392 Hepatocellular carcinoma, adult 114156393 Hepatitis E TAB-1602 114095870 Neutralizing Monoclonal Antibodies to Respiratory Syncytial Virus NIAID Infectious Disease, Licensing, Therapeutics Infectious Disease Licensing Therapeutics Robert Chanock (Estate), James Crowe, Brian Murphy Respiratory syncytial virus (RSV) is the most common cause of bronchiolitis and pneumonia among infants and children under 1 year of age. Illness begins most frequently with fever, runny nose, cough, and sometimes wheezing. During their first RSV infection, between 25% and 40% of infants and young children have signs or symptoms of bronchiolitis or pneumonia, and 0.5% to 2% require hospitalization. Most children recover from illness in 8 to 15 days. The majority of children hospitalized for RSV infection are under 6 months of age. RSV also causes repeated infections throughout life, usually associated with moderate-to-severe cold-like symptoms; however, severe lower respiratory tract disease may occur at any age, especially among the elderly or among those with compromised cardiac, pulmonary, or immune systems. <br><br> This invention is a human monoclonal antibody fragment (Fab) discovered utilizing phage display technology. The neutralizing monoclonal antibody was isolated and its binding site was identified. Fab F2-5 is a broadly reactive fusion (F) protein-specific recombinant Fab generated by antigen selection from a random combinatorial library displayed on the surface of filamentous phage. In an in vitro plaque-reduction test, the Fab RSVF2-5 neutralized the infectivity of a variety of field isolates representing viruses of both RSV subgroups A and B. The Fab recognized an antigenic determinant that differed from the only other human anti-F monoclonal antibody (RSV Fab 19) described thus far. A single dose of 4.0 mg of Fab RSVF2-5/kg of body weight administered by inhalation was sufficient to achieve a 2000-fold reduction in pulmonary virus titer in RSV-infected mice. The antigen-binding domain of Fab RSVF2-5 offers promise as part of a prophylactic regimen for RSV infection in humans. Respiratory Syncytial Virus prophylaxis/therapeutic. Foreign rights are also available. Available for licensing. 2022-03-08 2024-10-28 2024-10-28 2008-09-01 antibodies, DB4BXX, DB4XXX, DBXXXX, DXXXXX, monoclonal, Neutralizing, Q fever, respiratory, Syncytial, virus False True The antibodies have been synthesized and preclinical studies have been performed. The antibodies have been synthesized and preclinical studies have been performed. True NIHTT 37470483 Website Abstract 114170399 JE Crowe et al. Isolation of a second recombinant human respiratory syncytial virus monoclonal antibody fragment (Fab RSVF2-5) that exhibits therapeutic efficacy in vivo. J Infect Dis. 1998 Apr;177(4):1073-1076. http://www.ncbi.nlm.nih.gov/pubmed/9534985?dopt <a href="http://www.ncbi.nlm.nih.gov/pubmed/9534985?dopt">JE Crowe et al. Isolation of a second recombinant human respiratory syncytial virus monoclonal antibody fragment (Fab RSVF2-5) that exhibits therapeutic efficacy in vivo. J Infect Dis. 1998 Apr;177(4):1073-1076.</a> 114105840 Chanock (Estate), Robert NIAID - DIR NIAID Chanock (Estate), Robert (NIAID) 0 114105841 Murphy, Brian NIAID - DIR NIAID Murphy, Brian (NIAID) 0 114105842 Crowe, James NIAID - DIR NIAID Crowe, James (NIAID) 1 114105842 Crowe, James NIAID - DIR NIAID Crowe, James (NIAID) 1 114105840 Chanock (Estate), Robert NIAID - DIR NIAID Chanock (Estate), Robert (NIAID) 0 114105841 Murphy, Brian NIAID - DIR NIAID Murphy, Brian (NIAID) 0 114100850 NEUTRALIZING MONOCLONAL ANTIBODIES TO RESPIRATORY SYNCYTIAL VIRUS E-001-1996-0 Filing authorized EM, NIAID 83643855 Soukas, Peter peter.soukas@nih.gov
United States of America Technology Transfer and Intellectual Property Office peter.soukas@nih.gov?subject=Web Inquiry on [TAB-1602] Neutralizing Monoclonal Antibodies to Respiratory Syncytial Virus&body=Please send me information about technology [TAB-1602] Neutralizing Monoclonal Antibodies to Respiratory Syncytial Virus. Soukas, Peter<br><a href="mailto:peter.soukas@nih.gov?subject=Web Inquiry on [TAB-1602] Neutralizing Monoclonal Antibodies to Respiratory Syncytial Virus&body=Please send me information about technology [TAB-1602] Neutralizing Monoclonal Antibodies to Respiratory Syncytial Virus.">peter.soukas@nih.gov</a><br> 114162265 E-001-1996-0 E-001-1996-0-US-05 NEUTRALIZING MONOCLONAL ANTIBODIES TO RESPIRATORY SYNCYTIAL VIRUS National Stage US 09/043,530 Abandoned US <br />National Stage 09/043,530<br />Filed on 1998-03-18<br />Status: Abandoned 114162266 E-001-1996-0 E-001-1996-0-US-06 NEUTRALIZING MONOCLONAL ANTIBODIES TO RESPIRATORY SYNCYTIAL VIRUS CON US 7,488,477 10/425,855 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7488477 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7488477">7,488,477</a><br />Filed on 2003-04-30<br />Status: Expired 114164109 E-001-1996-0 E-001-1996-0-PCT-02 NEUTRALIZING MONOCLONAL ANTIBODIES TO RESPIRATORY SYNCYTIAL VIRUS PCT Patent Cooperation Treaty PCT/US1996/014937 Expired Patent Cooperation Treaty <br />(PCT) PCT/US1996/014937<br />Filed on 1996-09-18<br />Status: Expired 114164110 E-001-1996-0 E-001-1996-0-US-01 NEUTRALIZING MONOCLONAL ANTIBODIES TO RESPIRATORY SYNCYTIAL VIRUS PRV US 60/003,931 Abandoned US <br />Provisional (PRV) 60/003,931<br />Filed on 1995-09-18<br />Status: Abandoned 114166168 E-001-1996-0 E-001-1996-0-US-07 NEUTRALIZING MONOCLONAL ANTIBODIES TO RESPIRATORY SYNCYTIAL VIRUS DIV US 12/082,000 Abandoned US <br />Divisional (DIV) 12/082,000<br />Filed on 2008-04-24<br />Status: Abandoned 114166550 E-001-1996-0 E-001-1996-0-US-08 NEUTRALIZING MONOCLONAL ANTIBODIES TO RESPIRATORY SYNCYTIAL VIRUS DIV US 8,221,759 13/250,357 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8221759 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8221759">8,221,759</a><br />Filed on 2011-09-30<br />Status: Expired 114118107 DB4BXX 114118108 DBXXXX 114118109 DXXXXX 114118767 DB4XXX 114130443 Neutralizing 114130444 monoclonal 114130445 antibodies 114130446 respiratory 114130447 Syncytial 114130448 virus 114156355 Q fever TAB-1604 114095872 Recombinant Baculoviruses Containing Inserts of the Major Structural Genes (vp1) of the Human Polyomaviruses JCV and BKV NINDS Collaboration, Diagnostics, Infectious Disease, Licensing, Research Materials Collaboration Diagnostics Infectious Disease Licensing Research Materials Peter Jensen, Eugene Major The development of sensitive and specific tests for JC virus and BK virus activity may provide tools essential in the steps required to find a treatment for these fatal infections. This invention describes a Recombinant Vpl protein (rVp1) that can be used 1) as an antigen source for ELISA assays 2) for studies of viral proteins in cells and 3) for the self assembly of icosahedral particles encapsidating DNA [gene expression of choice in range of up to 5.1kb size gene]. <br><br> rVp1 can be utilized in ELISA assays to detect both JCV and BKV antibodies. The JCV and BKV rVp1 proteins may serve as antigens for the production of useful anti-sera and monoclonal-antibodies for polyomavirus research, as well as for the detection of existing and/or changing levels of antibodies in human sera by way of ELISA assays. Such ELISA studies allow for tracking of the spread and/or reactivation of polyomavirus infections in the human population, of special importance for individuals at high risk of polyomavirus associated pathologies. The rVp1s eliminate the need to produce infectious, native polyomavirus virions as antigens for such work. <br><br> The rVp1 proteins may also be utilized as vector delivery systems. The rVp1 proteins self-assemble into Virus-Like Particles (VLPs) which can be dissociated, reconstituted in the presence of exogenous DNA (that is non-specifically encapsidated), and then internalized through cell membranes that native virions normally cross. <ul> <li>JCV or BKV antigens useful for polyomavirus research</li> <li>ELISA studies for individuals at high risk of polyomavirus associated pathologies</li> <li>Vector Delivery systems</li> </ul> The National Institute of Neurological Disorders and Stroke is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize treatment and prevention of polyomavirus infections in immunocompromised patients. Please contact Melissa Maderia, Ph.D., at <a href="mailto:maderiam@mail.nih.gov">maderiam@mail.nih.gov</a> for more information. Research Material -- patent protection is not being pursued for this technology Available for non-exclusive licensing. 2022-03-08 2024-10-28 2024-10-28 2007-08-01 Baculovirus, BKV, Containing, DA4BXX, DA4XXX, DAXXXX, DDXXXX, DXXXXX, GENES, Human, Inserts, JCV, MAJOR, Polyomavirus Infections, Polyomaviruses, recombinant, STRUCTURAL, VP1 False True ELISA is fully developed and materials are available for licensing. ELISA is fully developed and materials are available for licensing. True NIHTT 37470483 Website Abstract 114170401 C Goldmann et al. Molecular cloning and expression of major structural protein VP1 of the human polyomavirus JC virus: formation of virus-like particles useful for immunological and therapeutic studies. J Virol 1999 May;73(5):4465-4469. http://www.ncbi.nlm.nih.gov/pubmed/10196348?dopt <a href="http://www.ncbi.nlm.nih.gov/pubmed/10196348?dopt">C Goldmann et al. Molecular cloning and expression of major structural protein VP1 of the human polyomavirus JC virus: formation of virus-like particles useful for immunological and therapeutic studies. J Virol 1999 May;73(5):4465-4469.</a> 114170402 RS Hamilton et al. Comparison of antibody titers determined by hemagglutination inhibition and enzyme immunoassay for JC virus and BK virus. J Clin Microbiol. 2000 Jan;38(1):105-109. http://www.ncbi.nlm.nih.gov/pubmed/10618072?dopt <a href="http://www.ncbi.nlm.nih.gov/pubmed/10618072?dopt">RS Hamilton et al. Comparison of antibody titers determined by hemagglutination inhibition and enzyme immunoassay for JC virus and BK virus. J Clin Microbiol. 2000 Jan;38(1):105-109.</a> 114170403 P Lenz et al. Papillomavirus-like particles induce acute activation of dendritic cells. J Immunol. 2001 May 1;166(9):5346-5355. http://www.ncbi.nlm.nih.gov/pubmed/11313370?dopt <a href="http://www.ncbi.nlm.nih.gov/pubmed/11313370?dopt">P Lenz et al. Papillomavirus-like particles induce acute activation of dendritic cells. J Immunol. 2001 May 1;166(9):5346-5355.</a> 114170404 DL Bohl et al. Donor origin of BK virus in renal transplantation and role of HLA C7 in susceptibility to sustained BK viremia. Am J Transplant. 2005 Sep;5(9):2213-2221. http://www.ncbi.nlm.nih.gov/pubmed/16095500?dopt <a href="http://www.ncbi.nlm.nih.gov/pubmed/16095500?dopt">DL Bohl et al. Donor origin of BK virus in renal transplantation and role of HLA C7 in susceptibility to sustained BK viremia. Am J Transplant. 2005 Sep;5(9):2213-2221.</a> 114170405 EO Major and P Matsumura. Human embryonic kidney cells: stable transformation with an origin-defective simian virus 40 DNA and use as hosts for human papovavirus replication. Mol Cell Biol. 1984 Feb;4(2):379-382. http://www.ncbi.nlm.nih.gov/pubmed/6321962?dopt <a href="http://www.ncbi.nlm.nih.gov/pubmed/6321962?dopt">EO Major and P Matsumura. Human embryonic kidney cells: stable transformation with an origin-defective simian virus 40 DNA and use as hosts for human papovavirus replication. Mol Cell Biol. 1984 Feb;4(2):379-382.</a> 114170406 EO Major et al. Establishment of a line of human fetal glial cells that supports JC virus multiplication. Proc Natl Acad Sci USA. 1985 Feb;82(4):1257-1261. http://www.ncbi.nlm.nih.gov/pubmed/2983332?dopt <a href="http://www.ncbi.nlm.nih.gov/pubmed/2983332?dopt">EO Major et al. Establishment of a line of human fetal glial cells that supports JC virus multiplication. Proc Natl Acad Sci USA. 1985 Feb;82(4):1257-1261.</a> 114105847 Jensen, Peter NINDS NINDS Jensen, Peter (NINDS) 0 114105848 Major, Eugene NINDS NINDS Major, Eugene (NINDS) 1 114105848 Major, Eugene NINDS NINDS Major, Eugene (NINDS) 1 114105847 Jensen, Peter NINDS NINDS Jensen, Peter (NINDS) 0 114100852 Recombinant Baculovirus Containing Inserts Of The Major Structural Genes (vp1) Of The Human Polyomaviruses JCV And BKV E-216-2006-0 Research Material NINDS 83667829 Ano, Susan susan.ano@nih.gov
United States of America susan.ano@nih.gov?subject=Web Inquiry on [TAB-1604] Recombinant Baculoviruses Containing Inserts of the Major Structural Genes (vp1) of the Human Polyomaviruses JCV and BKV&body=Please send me information about technology [TAB-1604] Recombinant Baculoviruses Containing Inserts of the Major Structural Genes (vp1) of the Human Polyomaviruses JCV and BKV. Ano, Susan<br><a href="mailto:susan.ano@nih.gov?subject=Web Inquiry on [TAB-1604] Recombinant Baculoviruses Containing Inserts of the Major Structural Genes (vp1) of the Human Polyomaviruses JCV and BKV&body=Please send me information about technology [TAB-1604] Recombinant Baculoviruses Containing Inserts of the Major Structural Genes (vp1) of the Human Polyomaviruses JCV and BKV.">susan.ano@nih.gov</a><br> 114118112 DA4BXX 114118113 DDXXXX 114118114 DAXXXX 114118115 DXXXXX 114119681 DA4XXX 114135528 recombinant 114135529 Baculovirus 114135530 Containing 114135531 Inserts 114135532 MAJOR 114135533 STRUCTURAL 114135534 GENES 114135535 VP1 114135536 Human 114135537 Polyomaviruses 114135538 JCV 114135539 BKV 114156356 Polyomavirus Infections TAB-1572 114095837 Methods for Expression and Purification of Immunotoxins NIMH Diagnostics, Immunology, Licensing, Oncology, Research Materials, Therapeutics Diagnostics Immunology Licensing Oncology Research Materials Therapeutics David Neville (Estate) The invention concerns immunotoxins and methods of making the immunotoxins. Targeting of the immunotoxins occurs via an antibody that is specific to T cells. This allows the specific ablation of malignant T cells and resting T cells. The transient ablation of resting T cells can "reset" the immune system by accentuating tolerizing responses. As a result, the immunotoxin can be used to treat autoimmune disease, malignant T cell-related cancers, and graft-versus-host disease. The toxin portion of the immunotoxin is engineered to maintain bioactivity when produced in yeast, specifically <em>Pichia pastoris</em>. This system allows the production of dimeric antibody fragments with increased binding affinity and potency. <ul> <li>Method produces GMP quality immunotoxin and can be scaled up to industry scales.</li> <li>Modified toxin moiety has reduced glycosylation in this system, resulting in a more effective and efficient immunotoxin.</li> <li>Immunotoxin doesn't produce the deleterious side-effects seen with other methods of treating autoimmune disease, malignant T cell leukemia/lymphoma and graft-versus-host disease. </li> </ul> <ul> <li>Immunotoxins produced by this method can be used for the treatment of autoimmune diseases such as multiple sclerosis, lupus, type I diabetes, aplastic anemia.</li> <li>Immunotoxins produced by this method can be used for treatment of T-cell leukemias and lymphomas such as cutaneous T cell leukemia/lymphoma (CTCL).</li> <li>Immunotoxins produced by this method can be used for increasing immune tolerance in patients requiring transplants/grafts.</li> </ul> Foreign rights are also available. Foreign rights are also available. 2022-03-08 2024-10-28 2024-10-28 2007-07-01 Aplastic anemia, Are, Bivalent, CB6XXX, CBXXXX, COMPLEX, CXXXXX, ESSENTIAL, Graft versus host disease, IB3XXX, IBXXXX, Immunotoxin, IXXXXX, LOW, lymphoma, Media, PASTORIS, PICHIA, production, temperature False True True NIHTT 37470483 Website Abstract E-044-1997-1 E-044-1997-0 114106315 Neville (Estate), David National Institute of Mental Health (NIMH) NIMH Neville (Estate), David (NIMH) 1 114106315 Neville (Estate), David National Institute of Mental Health (NIMH) NIMH Neville (Estate), David (NIMH) 1 114100810 Complex Media And Low Temperature Are Essential For Production Of Bivalent Immunotoxin In Pichia Pastoris E-043-1997-2 Filing authorized National Institute of Mental Health (NIMH) 83686256 Wong, Jennifer jennifer.wong2@nih.gov
United States of America jennifer.wong2@nih.gov?subject=Web Inquiry on [TAB-1572] Methods for Expression and Purification of Immunotoxins&body=Please send me information about technology [TAB-1572] Methods for Expression and Purification of Immunotoxins. Wong, Jennifer<br><a href="mailto:jennifer.wong2@nih.gov?subject=Web Inquiry on [TAB-1572] Methods for Expression and Purification of Immunotoxins&body=Please send me information about technology [TAB-1572] Methods for Expression and Purification of Immunotoxins.">jennifer.wong2@nih.gov</a><br> 114163901 E-043-1997-2 E-043-1997-2-US-01 METHODS FOR EXPRESSION AND PURIFICATION OF IMMUNOTOXINS PRV US 60/491,923 Abandoned US <br />Provisional (PRV) 60/491,923<br />Filed on 2003-08-01<br />Status: Abandoned 114164399 E-043-1997-2 E-043-1997-2-US-03 Methods for Expression and Purification of Immunotoxins National Stage US 7,892,786 10/566,886 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7892786 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7892786">7,892,786</a><br />Filed on 2006-02-01<br />Status: Expired 114166283 E-043-1997-2 E-043-1997-2-US-11 Methods For Expression and Purification Of Immunotoxins DIV US 8,921,097 12/957,165 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8921097 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8921097">8,921,097</a><br />Filed on 2010-11-30<br />Status: Issued 114117948 CB6XXX 114117949 IB3XXX 114117950 CBXXXX 114117951 IBXXXX 114117952 CXXXXX 114117953 IXXXXX 114133205 COMPLEX 114133206 Media 114133207 LOW 114133208 temperature 114133209 Are 114133210 ESSENTIAL 114133211 production 114133212 Bivalent 114133213 Immunotoxin 114133214 PICHIA 114133215 PASTORIS 114156319 lymphoma 114156320 Aplastic anemia 114156321 Graft versus host disease TAB-1566 114095834 Total Emission Detection System for Multi-Photon Microscopy NHLBI Collaboration, Licensing Collaboration Licensing Robert Balaban, Christian Combs, Jay Knutson Available for licensing and commercial development is a novel two-photon microscope system, which would allow improved fluorescent light collection, the use of less excitation power and deeper penetration of tissue and isolated cells. Multi-photon fluorescence microscopy (MPFM) is an imaging technique that can investigate biological processes to sub-cellular resolution at depths of hundreds of microns below the surface of biological tissues. MPFM provides higher resolution imaging of tissues than confocal imaging, but is currently limited by the use of inefficient light collection systems, which lead to detection of only a fraction of the light that is emitted from the sample. The new system consists of an array of mirrors, lenses, and reflecting surfaces designed to collectively maximize the probability of collecting all emitted fluorescent light to a detector, thereby providing enhanced brightness of light detected from the sample and an increase in signal-to-noise ratio (SNR). This increase is SNR can be used to improve time resolution, reduce laser power requirements and reduce photodynamic damage. <ul> <li>Three-dimensional imaging of biological tissues and cells</li> <li>Three-dimensional imaging of semiconductor integrated circuits</li> </ul> The NHLBI Light Microscopy Core Facility is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize a total emission detection system for multi-photon imaging. Please contact Alan Deutch, Ph.D., Director of the NHLBI Office of Technology Transfer and Development, at 301-402-5579 or via Email at <a href="mailto:deutcha@nhlbi.nih.gov">deutcha@nhlbi.nih.gov</a> for more information. Available for licensing. 2022-03-08 2024-10-28 2024-10-28 2007-06-01 AC3XXX, ACXXXX, AXXXXX, Detection, Fluorescence, MICROSCOPY, System, Two-photon, Wide-area False True Late-stage technology Late-stage technology True NIHTT 37470483 Website Abstract 114105764 Knutson, Jay National Heart, Lung, and Blood Institute (NHLBI) NHLBI Knutson, Jay (NHLBI) 0 114105765 Balaban, Robert National Heart, Lung, and Blood Institute (NHLBI) NHLBI Balaban, Robert (NHLBI) 0 114105766 Combs, Christian National Heart, Lung, and Blood Institute (NHLBI) NHLBI Combs, Christian (NHLBI) 1 114105766 Combs, Christian National Heart, Lung, and Blood Institute (NHLBI) NHLBI Combs, Christian (NHLBI) 1 114105764 Knutson, Jay National Heart, Lung, and Blood Institute (NHLBI) NHLBI Knutson, Jay (NHLBI) 0 114105765 Balaban, Robert National Heart, Lung, and Blood Institute (NHLBI) NHLBI Balaban, Robert (NHLBI) 0 114100797 Wide-area Fluorescence Detection System For Two-photon Microscopy E-257-2005-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 83734242 Varonin, Jillian jillian.varonin@nih.gov
United States of America Office of Technology Transfer and Development jillian.varonin@nih.gov?subject=Web Inquiry on [TAB-1566] Total Emission Detection System for Multi-Photon Microscopy&body=Please send me information about technology [TAB-1566] Total Emission Detection System for Multi-Photon Microscopy. Varonin, Jillian<br><a href="mailto:jillian.varonin@nih.gov?subject=Web Inquiry on [TAB-1566] Total Emission Detection System for Multi-Photon Microscopy&body=Please send me information about technology [TAB-1566] Total Emission Detection System for Multi-Photon Microscopy.">jillian.varonin@nih.gov</a><br> 114163881 E-257-2005-0 E-257-2005-0-US-04 Wide-Area Fluorescence Detection System For Multi-Photon Microscopy CON US 7,667,210 11/979,600 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7667210 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7667210">7,667,210</a><br />Filed on 2007-11-06<br />Status: Abandoned 114164495 E-257-2005-0 E-257-2005-0-PCT-02 Wide-area Fluorescence Detection System For Two-photon Microscopy PCT Patent Cooperation Treaty PCT/US2007/17478 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2007/17478<br />Filed on 2007-08-06<br />Status: Expired 114164658 E-257-2005-0 E-257-2005-0-US-01 Wide-area Fluorescence Detection System For Two-photon Microscopy PRV US 60/835,462 Abandoned US <br />Provisional (PRV) 60/835,462<br />Filed on 2006-08-04<br />Status: Abandoned 114117920 AC3XXX 114117921 ACXXXX 114117922 AXXXXX 114133761 Wide-area 114133762 Fluorescence 114133763 Detection 114133764 System 114133765 Two-photon 114133766 MICROSCOPY TAB-1571 114095840 Methods of Inducing Immune Tolerance Using Immunotoxins NIMH Diagnostics, Immunology, Licensing, Oncology, Research Materials, Therapeutics Diagnostics Immunology Licensing Oncology Research Materials Therapeutics David Neville (Estate) The invention concerns immunotoxins and methods of using the immunotoxins for the treatment of rejection response in a patient, including graft-versus-host disease and transplantation of organs, tissues and cells into a host. In a specific embodiment of the invention, the transplant involves pancreatic islet cells. The immunotoxins are targeted via an antibody that is specific to T cells. This allows the specific ablation of resting T cells, resulting in an accentuation of immune tolerizing responses and an increased tolerance to transplants and grafts. The toxin portion of the immunotoxin is genetically engineered to maintain bioactivity when recombinantly produced in <em>Pichia pastoris</em>. Data are available in transgenic animals expressing human CD3epsilon which supports the effects of the immunotoxin against T cells. <ul> <li>Specificity of the immunotoxin avoids the killing of other cells, reducing side-effects associated with other mechanisms of treatment (X-ray and cyclophosphamide) such as infection and induced malignancy.</li> <li>A GMP production process for the immunotoxin has already been successfully implemented.</li> </ul> <ul> <li>Use of immunotoxins decreases T cell population, allowing greater host immune tolerance of transplants and grafts.</li> <li>Specific method for increasing immune tolerance to pancreatic islet transplants.</li> </ul> Foreign rights may also available. 2022-03-08 2024-10-28 2024-10-28 2007-06-01 Activity, Agents, CB1XXX, CBXXXX, Cell, COMBINED, CXXXXX, Dendritic, Graft versus host disease, IB3XXX, IBXXXX, IMMUNE, Immunotoxin, IMMUNOTOXINS, Induce, INDUCING, INHIBIT, IN-VIVO, ISLET, IXXXXX, Maturation, Methds, Method, Methods, Novel, Pancreatic, RELATED, SUPPRESSANT, T, That, TOLERANCE, TRANSPLANTATION False True True NIHTT 37470483 Website Abstract 114106319 Neville (Estate), David National Institute of Mental Health (NIMH) NIMH Neville (Estate), David (NIMH) 1 114106319 Neville (Estate), David National Institute of Mental Health (NIMH) NIMH Neville (Estate), David (NIMH) 1 114100803 NOVEL IMMUNOTOXINS AND METHODS OF INDUCING IMMUNE TOLERANCE E-044-1997-1 Filing authorized National Institute of Mental Health (NIMH), University of Alabama at Birmingham, University of Wisconsin 114100804 NOVEL IMMUNOTOXINS AND METHODS OF INDUCING IMMUNE TOLERANCE E-044-1997-0 Filing authorized National Institute of Mental Health (NIMH), University of Alabama at Birmingham, University of Wisconsin 114100806 Use of Immunotoxins to Induce Immune Tolerance to Pancreatic Islet Transplantation E-059-1998-0 Filing authorized National Institute of Mental Health (NIMH), University of Alabama at Birmingham 114100807 Methds Of Inducing Immune Tolerance Using Immunotoxins E-012-1991-7 Filing authorized National Institute of Mental Health (NIMH), University of Alabama at Birmingham, University of Wisconsin 114100808 IMMUNOTOXIN WITH IN-VIVO T CELL SUPPRESSANT ACTIVITY E-012-1991-0 Filing authorized National Institute of Mental Health (NIMH) 114100809 IMMUNOTOXIN WITH IN-VIVO T CELL SUPPRESSANT ACTIVITY AND METHOD OF USE E-012-1991-4 Filing authorized National Institute of Mental Health (NIMH), University of Wisconsin 83686256 Wong, Jennifer jennifer.wong2@nih.gov
United States of America jennifer.wong2@nih.gov?subject=Web Inquiry on [TAB-1571] Methods of Inducing Immune Tolerance Using Immunotoxins&body=Please send me information about technology [TAB-1571] Methods of Inducing Immune Tolerance Using Immunotoxins. Wong, Jennifer<br><a href="mailto:jennifer.wong2@nih.gov?subject=Web Inquiry on [TAB-1571] Methods of Inducing Immune Tolerance Using Immunotoxins&body=Please send me information about technology [TAB-1571] Methods of Inducing Immune Tolerance Using Immunotoxins.">jennifer.wong2@nih.gov</a><br> 114163792 E-012-1991-4 E-012-1991-4-US-01 THYMIC TOLERANCE IN PRIMATES CIP US 08/422,100 Abandoned US <br />Continuation in Part (CIP) 08/422,100<br />Filed on 1995-04-14<br />Status: Abandoned 114163900 E-044-1997-1 E-044-1997-1-US-06 IMMUNOTOXIN FUSION PROTEINS AND MEANS FOR EXPRESSION THEREOF National Stage US 7,696,338 10/296,085 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7696338 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7696338">7,696,338</a><br />Filed on 2002-11-18<br />Status: Expired 114163902 E-044-1997-0 E-044-1997-0-US-07 IMMUNOTOXINS AND METHODS OF INDUCING IMMUNE TOLERANCE National Stage US 6,632,928 09/380,484 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6632928 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6632928">6,632,928</a><br />Filed on 1999-12-06<br />Status: Expired 114163904 E-059-1998-0 E-059-1998-0-US-02 Use of Immunotoxins to Induce Immune Tolerance to Pancreatic Islet Transplantation CON US 7,288,254 09/810,999 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7288254 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7288254">7,288,254</a><br />Filed on 2001-03-16<br />Status: Expired 114163905 E-012-1991-7 E-012-1991-7-US-02 Methds Of Inducing Immune Tolerance Using Immunotoxins DIV US 7,125,553 09/383,695 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7125553 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7125553">7,125,553</a><br />Filed on 1999-08-26<br />Status: Expired 114163906 E-012-1991-7 E-012-1991-7-US-01 METHOD OF INDUCING IMMUNE TOLERANCE USING IMMUNOTOXINS CIP US 6,103,235 08/843,409 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6103235 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6103235">6,103,235</a><br />Filed on 1997-04-15<br />Status: Expired 114163907 E-012-1991-0 E-012-1991-0-US-01 Immunotoxin with in-vivo T-Cell suppressant activity and Methods of Use ORD US 5,167,956 07/653,164 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/5167956 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/5167956">5,167,956</a><br />Filed on 1991-02-11<br />Status: Expired 114164465 E-012-1991-4 E-012-1991-4-US-02 IMMUNOTOXIN WITH IN-VIVO T CELL SUPPRESSANT ACTIVITY AND METHOD OF USE CON US 5,762,927 08/827,772 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/5762927 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/5762927">5,762,927</a><br />Filed on 1997-04-11<br />Status: Expired 114165975 E-044-1997-1 E-044-1997-1-US-12 IMMUNOTOXINS FUSION PROTEINS AND MEANS FOR EXPRESSION THEREOF DIV US 8,217,158 12/718,673 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8217158 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8217158">8,217,158</a><br />Filed on 2010-03-05<br />Status: Expired 114166069 E-044-1997-1 E-044-1997-1-US-01 Immunotoxin Fusion Proteins and Means For Expression Thereof CIP US 09/573,797 Abandoned US <br />Continuation in Part (CIP) 09/573,797<br />Filed on 2000-05-18<br />Status: Abandoned 114166762 E-044-1997-1 E-044-1997-1-US-13 IMMUNOTOXINS FUSION PROTEINS AND MEANS FOR EXPRESSION THEREOF DIV US 8,987,426 13/443,779 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8987426 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8987426">8,987,426</a><br />Filed on 2012-04-10<br />Status: Expired 114167124 E-012-1991-0 E-012-1991-0-US-02 Immunotoxin with in-vivo T-Cell suppressant activity and Methods of Use CON US 07/907,409 Abandoned US <br />Continuation (CON) 07/907,409<br />Filed on 1992-07-01<br />Status: Abandoned 114167126 E-012-1991-0 E-012-1991-0-PCT-03 An Immunotoxin with in vivo T Cell suppressant activity PCT Patent Cooperation Treaty PCT/US1992/000813 Expired Patent Cooperation Treaty <br />(PCT) PCT/US1992/000813<br />Filed on 1992-02-11<br />Status: Expired 114167128 E-044-1997-0 E-044-1997-0-US-01 NOVEL IMMUNOTOXINS AND METHODS OF INDUCING IMMUNE TOLERANCE PRV US 60/039,987 Abandoned US <br />Provisional (PRV) 60/039,987<br />Filed on 1997-03-05<br />Status: Abandoned 114167130 E-044-1997-0 E-044-1997-0-PCT-02 IMMUNOTOXINS AND METHODS OF INDUCING IMMUNE TOLERANCE PCT Patent Cooperation Treaty PCT/US1998/004303 Expired Patent Cooperation Treaty <br />(PCT) PCT/US1998/004303<br />Filed on 1998-03-05<br />Status: Expired 114167132 E-044-1997-0 E-044-1997-0-US-08 NOVEL IMMUNOTOXINS AND METHODS OF INDUCING IMMUNE TOLERANCE DIV US 10/435,567 Abandoned US <br />Divisional (DIV) 10/435,567<br />Filed on 2003-05-09<br />Status: Abandoned 114167133 E-059-1998-0 E-059-1998-0-US-01 Use of Immunotoxins to Induce Immune Tolerance to Pancreatic Islet Transplantation ORD US 09/064,413 Abandoned US <br />Ordinary Patent (ORD) 09/064,413<br />Filed on 1998-04-22<br />Status: Abandoned 114167134 E-059-1998-0 E-059-1998-0-PCT-03 Use of Immunotoxins to Induce Immune Tolerance to Pancreatic Islet Transplantation PCT Patent Cooperation Treaty PCT/US1999/008606 Expired Patent Cooperation Treaty <br />(PCT) PCT/US1999/008606<br />Filed on 1999-04-20<br />Status: Expired 114167158 E-012-1991-7 E-012-1991-7-US-03 Methds Of Inducing Immune Tolerance Using Immunotoxins DIV US 09/636,251 Abandoned US <br />Divisional (DIV) 09/636,251<br />Filed on 2000-08-10<br />Status: Abandoned 114117942 CB1XXX 114117943 IB3XXX 114117944 CBXXXX 114117945 IBXXXX 114117946 CXXXXX 114117947 IXXXXX 114133216 Immunotoxin 114133217 IN-VIVO 114133218 T 114133219 Cell 114133220 SUPPRESSANT 114133221 Activity 114133222 Method 114133223 Methds 114133224 INDUCING 114133225 IMMUNE 114133226 TOLERANCE 114133227 IMMUNOTOXINS 114133228 Induce 114133229 Pancreatic 114133230 ISLET 114133231 TRANSPLANTATION 114133232 Methods 114133233 RELATED 114133234 COMBINED 114133235 Agents 114133236 That 114133237 INHIBIT 114133238 Dendritic 114133239 Maturation 114133240 Novel 114156318 Graft versus host disease TAB-1556 114095824 Diagnostic and Therapeutic Use of Brother of the Regulator of Imprinted Sites (BORIS) Alternative Splice Forms NIAID Collaboration, Diagnostics, Immunology, Licensing, Oncology, Therapeutics Collaboration Diagnostics Immunology Licensing Oncology Therapeutics Victor Lobanenkov This technology identifies twenty five (25) new alternatively spliced transcripts of the BORIS gene. The transcripts lead to the expression of seventeen different protein isoforms with variable N- and C-termini encoded by BORIS gene locus. Differential expression levels of BORIS isoforms were observed in different cancers. While some BORIS alternative splice variants were expressed at different levels in all types of cancers, other expressed forms are specific to particular cancer(s). <ul> <li>Simple, rapid, RT-PCR based diagnostic test to detect BORIS isoforms in cancer patients.</li> <li>Profiling of BORIS splice variants can be useful as a diagnostic tool for the detection of cancers.</li> <li>BORIS can be a therapeutic target antigen for immunotherapeutic and/or siRNA based treatments for cancer.</li> <li>BORIS can be used in combination with other established immunogens for immunotherapeutic treatment of several cancers.</li> </ul> The NIAID Laboratory of Immunopathology is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize methods of cancer diagnostics and treatment based on detection of BORIS isoforms. Please contact Cecilia Pazman at <a href="mailto:pazmance@niaid.nih.gov">pazmance@niaid.nih.gov</a> or (301) 451-3526 for more information. Available for exclusive and non-exclusive licensing. 2022-03-08 2024-10-28 2024-10-28 2007-06-01 Alternate, Boris, CA1AXX, CA1XXX, CANCER, CAXXXX, CB6XXX, CBXXXX, CXXXXX, Diagnostics, Forms, MULTIPLE, SPLICE, Tool, treatment False True The technology is currently in the pre-clinical stage of development. The technology is currently in the pre-clinical stage of development. True NIHTT 37470483 Website Abstract 114105753 Lobanenkov, Victor NIAID - DIR NIAID Lobanenkov, Victor (NIAID) 1 114105753 Lobanenkov, Victor NIAID - DIR NIAID Lobanenkov, Victor (NIAID) 1 114100784 Multiple BORIS Alternate Splice Forms As A Tool For Cancer Diagnostics And Treatment E-117-2006-0 Filing authorized NIAID 83738793 Taylor-Mulneix, Dawn dawn.taylor-mulneix@nih.gov
United States of America dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-1556] Diagnostic and Therapeutic Use of Brother of the Regulator of Imprinted Sites (BORIS) Alternative Splice Forms&body=Please send me information about technology [TAB-1556] Diagnostic and Therapeutic Use of Brother of the Regulator of Imprinted Sites (BORIS) Alternative Splice Forms. Taylor-Mulneix, Dawn<br><a href="mailto:dawn.taylor-mulneix@nih.gov?subject=Web Inquiry on [TAB-1556] Diagnostic and Therapeutic Use of Brother of the Regulator of Imprinted Sites (BORIS) Alternative Splice Forms&body=Please send me information about technology [TAB-1556] Diagnostic and Therapeutic Use of Brother of the Regulator of Imprinted Sites (BORIS) Alternative Splice Forms.">dawn.taylor-mulneix@nih.gov</a><br> 114163852 E-117-2006-0 E-117-2006-0-PCT-02 BORIS ISOFORMS AND METHODS OF DETECTING AND TREATING DISEASE PCT Patent Cooperation Treaty PCT/US2007/77281 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2007/77281<br />Filed on 2007-08-30<br />Status: Expired 114163853 E-117-2006-0 E-117-2006-0-US-01 Multiple BORIS Alternate Splice Forms As A Tool For Cancer Diagnostics And Treatment PRV US 60/841,342 Abandoned US <br />Provisional (PRV) 60/841,342<br />Filed on 2006-08-31<br />Status: Abandoned 114165022 E-117-2006-0 E-117-2006-0-US-07 Boris Isoforms And Methods Of Detecting And Treating Disease National Stage US 8,206,933 12/439,063 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8206933 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8206933">8,206,933</a><br />Filed on 2009-02-26<br />Status: Issued 114166780 E-117-2006-0 E-117-2006-0-US-08 BORIS Isoforms And Methods of Detecting And Treating Disease DIV US 8,440,415 13/478,779 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8440415 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8440415">8,440,415</a><br />Filed on 2012-05-23<br />Status: Issued 114117865 CA1AXX 114117866 CAXXXX 114117867 CBXXXX 114117868 CXXXXX 114119699 CB6XXX 114119700 CA1XXX 114135774 MULTIPLE 114135775 Boris 114135776 Alternate 114135777 SPLICE 114135778 Forms 114135779 Tool 114135780 CANCER 114135781 Diagnostics 114135782 treatment TAB-1563 114095831 Immunotoxin with in-vivo T cell Suppressant Activity NIMH Diagnostics, Immunology, Licensing, Oncology, Rare/Neglected Diseases, Research Materials, Therapeutics Diagnostics Immunology Licensing Oncology Rare/Neglected Diseases Research Materials Therapeutics David Neville (Estate) The invention concerns immunotoxins and methods of using the immunotoxins for the treatment of autoimmune diseases and T cell malignancies. The immunotoxins are targeted via an antibody that is specific to T cells. This allows the specific ablation of malignant T cells and resting T cells. The transient ablation of resting T cells can "reset" the immune system by accentuating tolerizing responses. The toxin portion of the immunotoxin is genetically engineered to maintain bioactivity when recombinantly produced in <em>Pichia pastoris</em>. Data are available in transgenic animals expressing human CD3epsilon which supports the effects of the immunotoxin against T cells. <ul> <li>Specificity of the immunotoxin avoids the killing of non-T cells, reducing side-effects associated with other mechanisms of treatment (e.g., radiation and cyclophosphamide) such as infection and induced malignancy.</li> <li>A GMP production process has already been successfully implemented, and patient doses are available.</li> <li>All testing required for an FDA issued IND has been completed, allowing faster evaluation of the efficacy of the invention.</li> </ul> <ul> <li>Treatment of autoimmune diseases such as multiple sclerosis, lupus, type I diabetes, aplastic anemia</li> <li>Treatment of T cell leukemias and lymphomas such as cutaneous T cell leukemia/lymphoma (CTCL)</li> </ul> Foreign rights are also available. 2022-03-08 2024-10-28 2024-10-28 2007-06-01 Activity, Aplastic anemia, CB1XXX, CBXXXX, Cell, CXXXXX, IB3XXX, IBXXXX, IMMUNE, Immunotoxin, IMMUNOTOXINS, INDUCING, IN-VIVO, IXXXXX, lymphoma, Methods, Novel, SUPPRESSANT, T, TOLERANCE, UAXXXX, Vivo False True True NIHTT 37470483 Website Abstract 114106324 Neville (Estate), David National Institute of Mental Health (NIMH) NIMH Neville (Estate), David (NIMH) 1 114106324 Neville (Estate), David National Institute of Mental Health (NIMH) NIMH Neville (Estate), David (NIMH) 1 114100791 NOVEL IMMUNOTOXINS AND METHODS OF INDUCING IMMUNE TOLERANCE E-044-1997-1 Filing authorized National Institute of Mental Health (NIMH), University of Alabama at Birmingham, University of Wisconsin 114100792 NOVEL IMMUNOTOXINS AND METHODS OF INDUCING IMMUNE TOLERANCE E-044-1997-0 Filing authorized National Institute of Mental Health (NIMH), University of Alabama at Birmingham, University of Wisconsin 114100793 IMMUNOTOXIN WITH IN VIVO T CELL SUPPRESSANT ACTIVITY AND METHODS OF E-012-1991-2 Filing authorized National Institute of Mental Health (NIMH) 114100794 IMMUNOTOXIN WITH IN-VIVO T CELL SUPPRESSANT ACTIVITY E-012-1991-0 Filing authorized National Institute of Mental Health (NIMH) 83686256 Wong, Jennifer jennifer.wong2@nih.gov
United States of America jennifer.wong2@nih.gov?subject=Web Inquiry on [TAB-1563] Immunotoxin with in-vivo T cell Suppressant Activity&body=Please send me information about technology [TAB-1563] Immunotoxin with in-vivo T cell Suppressant Activity. Wong, Jennifer<br><a href="mailto:jennifer.wong2@nih.gov?subject=Web Inquiry on [TAB-1563] Immunotoxin with in-vivo T cell Suppressant Activity&body=Please send me information about technology [TAB-1563] Immunotoxin with in-vivo T cell Suppressant Activity.">jennifer.wong2@nih.gov</a><br> 114161371 E-044-1997-0 E-044-1997-0-US-07 IMMUNOTOXINS AND METHODS OF INDUCING IMMUNE TOLERANCE National Stage US 6,632,928 09/380,484 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6632928 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6632928">6,632,928</a><br />Filed on 1999-12-06<br />Status: Expired 114163871 E-044-1997-1 E-044-1997-1-US-06 IMMUNOTOXIN FUSION PROTEINS AND MEANS FOR EXPRESSION THEREOF National Stage US 7,696,338 10/296,085 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7696338 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7696338">7,696,338</a><br />Filed on 2002-11-18<br />Status: Expired 114163873 E-012-1991-2 E-012-1991-2-US-01 Immunotoxin with in-vivo T-Cell suppressant activity and Methods of Use CIP US 5,725,857 08/308,730 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/5725857 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/5725857">5,725,857</a><br />Filed on 1994-09-19<br />Status: Expired 114163874 E-012-1991-0 E-012-1991-0-US-01 Immunotoxin with in-vivo T-Cell suppressant activity and Methods of Use ORD US 5,167,956 07/653,164 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/5167956 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/5167956">5,167,956</a><br />Filed on 1991-02-11<br />Status: Expired 114165677 E-044-1997-1 E-044-1997-1-US-01 Immunotoxin Fusion Proteins and Means For Expression Thereof CIP US 09/573,797 Abandoned US <br />Continuation in Part (CIP) 09/573,797<br />Filed on 2000-05-18<br />Status: Abandoned 114165974 E-044-1997-1 E-044-1997-1-US-12 IMMUNOTOXINS FUSION PROTEINS AND MEANS FOR EXPRESSION THEREOF DIV US 8,217,158 12/718,673 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8217158 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8217158">8,217,158</a><br />Filed on 2010-03-05<br />Status: Expired 114166761 E-044-1997-1 E-044-1997-1-US-13 IMMUNOTOXINS FUSION PROTEINS AND MEANS FOR EXPRESSION THEREOF DIV US 8,987,426 13/443,779 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8987426 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8987426">8,987,426</a><br />Filed on 2012-04-10<br />Status: Expired 114167123 E-012-1991-0 E-012-1991-0-US-02 Immunotoxin with in-vivo T-Cell suppressant activity and Methods of Use CON US 07/907,409 Abandoned US <br />Continuation (CON) 07/907,409<br />Filed on 1992-07-01<br />Status: Abandoned 114167125 E-012-1991-0 E-012-1991-0-PCT-03 An Immunotoxin with in vivo T Cell suppressant activity PCT Patent Cooperation Treaty PCT/US1992/000813 Expired Patent Cooperation Treaty <br />(PCT) PCT/US1992/000813<br />Filed on 1992-02-11<br />Status: Expired 114167127 E-044-1997-0 E-044-1997-0-US-01 NOVEL IMMUNOTOXINS AND METHODS OF INDUCING IMMUNE TOLERANCE PRV US 60/039,987 Abandoned US <br />Provisional (PRV) 60/039,987<br />Filed on 1997-03-05<br />Status: Abandoned 114167129 E-044-1997-0 E-044-1997-0-PCT-02 IMMUNOTOXINS AND METHODS OF INDUCING IMMUNE TOLERANCE PCT Patent Cooperation Treaty PCT/US1998/004303 Expired Patent Cooperation Treaty <br />(PCT) PCT/US1998/004303<br />Filed on 1998-03-05<br />Status: Expired 114167131 E-044-1997-0 E-044-1997-0-US-08 NOVEL IMMUNOTOXINS AND METHODS OF INDUCING IMMUNE TOLERANCE DIV US 10/435,567 Abandoned US <br />Divisional (DIV) 10/435,567<br />Filed on 2003-05-09<br />Status: Abandoned 114117905 CB1XXX 114117906 IB3XXX 114117907 CBXXXX 114117908 IBXXXX 114117909 CXXXXX 114117910 IXXXXX 114117911 UAXXXX 114133241 Immunotoxin 114133242 IN-VIVO 114133243 T 114133244 Cell 114133245 SUPPRESSANT 114133246 Activity 114133247 Vivo 114133248 Methods 114133249 Novel 114133250 IMMUNOTOXINS 114133251 INDUCING 114133252 IMMUNE 114133253 TOLERANCE 114156314 lymphoma 114156315 Aplastic anemia TAB-1549 114095817 Retrovirus Packaging Cell Lines Based on Gibbon Ape Leukemia Virus NIMH Collaboration, Diagnostics, Research Materials, Therapeutics Collaboration Diagnostics Research Materials Therapeutics Maribeth Eiden Gene therapy and gene transfer have recently been recognized as effective therapeutic tools to combat diseases. Accordingly, market demands for vectors and carriers to facilitate such interventions have surged in recent years. Retroviral vectors provide an efficient and safe means of gene transfer to eukaryotic cells. The present invention relates to genetic engineering involving retrovirus packaging cells that produce retroviral vectors. Specifically, the invention involves the expression plasmids encoding the envelop glycoproteins of a family of primate type C retrovirus, namely, the Gibbon Ape leukemia virus (GALV). Recombinant vectors derived from murine leukemia virus (MLV) have been widely used to introduce genes in human gene therapy clinical trials. A key determinant for their use in clinical gene therapy is the availability of packaging cell lines capable of producing large amounts of virus with identical titers. The present invention describes the packaging cell lines that produce MLV-based gene transfer vectors with the envelope from gibbon ape leukemia virus. Retroviral vectors produced are of high titer and have an expanded host range providing a means for gene transfer to a wide range of animal species. The gene transfer vectors produced are non-infectious and there was no evidence of production of helper virus, making these vectors safe. These cell lines are critical for producing large amounts of standardized vector necessary for efficient for in vivo and ex vivo gene transfer. Therefore, this invention has a significant commercial application as a tool in the development of diagnostic and therapeutic interventions related to gene transfer and gene therapy. The National Institute of Mental Health, Laboratory of Cellular and Molecular Regulation, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize the Gibbon Ape leukemia virus (GALV) packaging cell line. Please contact Jennifer Wong at <a href="mailto:jennifer.wong2@nih.gov">jennifer.wong2@nih.gov</a> for more information. Research Materials -- patent prosecution is no longer being pursued for this technology. 2022-03-08 2024-10-28 2024-10-28 2015-11-18 APE, Based, Cell, Duke DNA Project, GCXXXX, GIBBON, GXXXXX, IDXXXX, IXXXXX, Leukemia, Lines, LT CASE, Packaging, Retrovirus, virus, WIXXXX False True True NIHTT 37470483 Website Abstract 114105742 Eiden, Maribeth National Institute of Mental Health (NIMH) NINDS Eiden, Maribeth (NINDS) 1 114105742 Eiden, Maribeth National Institute of Mental Health (NIMH) NINDS Eiden, Maribeth (NINDS) 1 114100760 RETROVIRUS PACKAGING CELL LINES BASED ON GIBBON APE LEUKEMIA VIRUS E-201-1991-0 Filing authorized EM, National Institute of Mental Health (NIMH) 83686256 Wong, Jennifer jennifer.wong2@nih.gov
United States of America jennifer.wong2@nih.gov?subject=Web Inquiry on [TAB-1549] Retrovirus Packaging Cell Lines Based on Gibbon Ape Leukemia Virus&body=Please send me information about technology [TAB-1549] Retrovirus Packaging Cell Lines Based on Gibbon Ape Leukemia Virus. Wong, Jennifer<br><a href="mailto:jennifer.wong2@nih.gov?subject=Web Inquiry on [TAB-1549] Retrovirus Packaging Cell Lines Based on Gibbon Ape Leukemia Virus&body=Please send me information about technology [TAB-1549] Retrovirus Packaging Cell Lines Based on Gibbon Ape Leukemia Virus.">jennifer.wong2@nih.gov</a><br> 114163782 E-201-1991-0 E-201-1991-0-US-02 RETROVIRUS PACKAGING CELL LINES BASED ON GIBBON APE LEUKEMIA VIRUS FWC US 5,470,726 08/105,471 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/5470726 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/5470726">5,470,726</a><br />Filed on 1993-08-11<br />Status: Expired 114165945 E-201-1991-0 E-201-1991-0-US-01 RETROVIRUS PACKAGING CELL LINES BASED ON GIBBON APE LEUKEMIA VIRUS ORD US 07/660,616 Abandoned US <br />Ordinary Patent (ORD) 07/660,616<br />Filed on 1991-02-22<br />Status: Abandoned 114117822 GCXXXX 114117823 IDXXXX 114117824 GXXXXX 114117825 IXXXXX 114118260 WIXXXX 114135847 LT CASE 114135848 Retrovirus 114135849 Packaging 114135850 Cell 114135851 Lines 114135852 Based 114135853 GIBBON 114135854 APE 114135855 Leukemia 114135856 virus 114135857 Duke DNA Project TAB-1517 114095785 High Level Expression and Purification of Untagged and Histidine-tagged Human Immunodeficiency Virus Type-1 Reverse Transcriptase NIEHS Infectious Disease, Licensing, Research Materials Infectious Disease Licensing Research Materials Ester Hou, Rajendra Prasad, Samuel Wilson Human immunodeficiency virus type-1 reverse transcriptase (HIV-1 RT) gene encodes 560 amino acids. In the virus, however, HIV-1 RT occurs as a dimer of two related polypeptides, p66 and p51 subunits at a molar ratio of 1:1. The p51 subunit is derived from a C-terminal proteolytic cleavage of the p66 subunit. This invention describes a simplified protocol to purify large quantities of histidine-tagged and untagged heterodimeric forms of human immunodeficiency virus type-1 reverse transcriptase (HIV-1 RT) from <em>Escherichia coli</em>. The coding sequences of p66 and p51 subunits of RT were placed in expression plasmids under a strong T7-lac promoter that is induced by isopropyl B-D-thiogalactopyranoside. Purification of heterodimeric forms of RT was facilitated by high-level expression of these subunits that represented approximately 30-40% of total cellular proteins. For purification of the histidine-tagged heterodimer RT, cell pellet from cells expression the untagged p66 subunit was mixed in excess with a cell pellet expression tagged p51. For untagged heterodimer RT, the pellet from cells expressing p51 was mixed in excess with pellet expressing p66. Subunit dimerization occurred during cell lysis. During the subsequent chromatography steps, stable p66/p51 heterodimer was purified to homogeneity. The heterodimeric nature of the final preparations of RT was confirmed by analytical gel filtration, mass spectrometry, and denaturing gel electrophoresis. <ul> </li>This invention makes available a new and simplified protocols to purify large quantities of homogeneous heterodimeric forms of HIV-1 reverse transcriptase. The preparations were fully characterized for the activity and inhibitor sensitivity, and can be used for structural and kinetic studies. Furthermore, the protocols of expression and purification can be applied to preparing subunit-specific amino acid alterations necessary for structure-function investigations.</li> </ul> Research Tool -- Patent protection is not being pursued for this technology. 2022-03-08 2024-10-28 2024-10-28 2007-04-01 BBXXXX, DDXXXX, DEXXXX, DXXXXX, Expression, High, Histidine-tagged, Human, Hyper IgM syndrome, Immunodeficiency, Immunodeficiency 2, Immunodeficiency 4, Immunodeficiency-3, Level, purification, Reverse, Severe combined immunodeficiency, x-linked, TRANSCRIPTASE, TYPE-1, Untagged, virus, Wiskott Aldrich syndrome False True <i>In vitro</i> data available True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114170298 Hou EW, et al. http://www.ncbi.nlm.nih.gov/pubmed/14766302 <a href="http://www.ncbi.nlm.nih.gov/pubmed/14766302">Hou EW, et al.</a> 114105696 Prasad, Rajendra NIEHS NIEHS Prasad, Rajendra (NIEHS) 0 114106325 Hou, Ester NIEHS Hou, Ester 0 114105697 Wilson, Samuel NIEHS NIEHS Wilson, Samuel (NIEHS) 1 114105697 Wilson, Samuel NIEHS NIEHS Wilson, Samuel (NIEHS) 1 114105696 Prasad, Rajendra NIEHS NIEHS Prasad, Rajendra (NIEHS) 0 114106325 Hou, Ester NIEHS Hou, Ester 0 114100710 High Level Expression And Purification Of Untagged And Histidine-tagged Human Immunodeficiency Virus Type-1 Reverse Transcriptase E-141-2007-0 Research Material NIEHS 83739538 Choudhry, Vidita vidita.choudhry@nih.gov
United States of America Office of Technology Transfer and Development vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-1517] High Level Expression and Purification of Untagged and Histidine-tagged Human Immunodeficiency Virus Type-1 Reverse Transcriptase&body=Please send me information about technology [TAB-1517] High Level Expression and Purification of Untagged and Histidine-tagged Human Immunodeficiency Virus Type-1 Reverse Transcriptase. Choudhry, Vidita<br><a href="mailto:vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-1517] High Level Expression and Purification of Untagged and Histidine-tagged Human Immunodeficiency Virus Type-1 Reverse Transcriptase&body=Please send me information about technology [TAB-1517] High Level Expression and Purification of Untagged and Histidine-tagged Human Immunodeficiency Virus Type-1 Reverse Transcriptase.">vidita.choudhry@nih.gov</a><br> 114117662 DDXXXX 114117663 DEXXXX 114117664 DXXXXX 114121152 BBXXXX 114133298 High 114133299 Level 114133300 Expression 114133301 purification 114133302 Untagged 114133303 Histidine-tagged 114133304 Human 114133305 Immunodeficiency 114133306 virus 114133307 TYPE-1 114133308 Reverse 114133309 TRANSCRIPTASE 114156272 Severe combined immunodeficiency, x-linked 114156273 Hyper IgM syndrome 114156274 Wiskott Aldrich syndrome 114158243 Immunodeficiency 4 114158244 Immunodeficiency-3 114158245 Immunodeficiency 2 TAB-1515 114095779 Fluorescent Intracellular Calcium Indicators NIEHS Collaboration, Diagnostics, Licensing, Research Materials, Therapeutics Collaboration Diagnostics Licensing Research Materials Therapeutics Louis Levy, Robert London Calcium is a key element in the regulation of many cellular processes, including muscle contraction, hormone excretion from gland cells, neurotransmitter release from nerve synapses, and the regulation of cellular metabolism. Elevated calcium levels are found in a number of diseases. <br><br> The present invention relates to chromophoric or fluorescent dye calcium indicators that are superior for measurement of high concentrations of calcium ions due to their high dissociation constants. As a result of the high calcium ion dissociation constants, the perturbation resulting from introducing the indicator into the cell is greatly reduced. These calcium ion indicators can be measured by various techniques including 19F NMR spectroscopy, flow cytometry, and quantitative fluorescence techniques, and are useful for measuring calcium levels within the cytosol or within cellular organelles. Research tool for quantifying intracellular calcium concentrations. The NIEHS Laboratory of Structural Biology is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. Please contact Dr. Robert London at 919/541-4879 or <a href="mailto:london@niehs.nih.gov">london@niehs.nih.gov</a> for more information. Available for nonexclusive licensing. 2022-03-08 2024-10-28 2024-10-28 2007-03-01 CALCUIM, fluorescent, IA4AXX, IA4XXX, IAXXXX, INDICATORS, Intracellular, IXXXXX False True True NIHTT 37470483 Website Abstract 114105690 Levy, Louis NIEHS Levy, Louis 0 114105691 London, Robert NIEHS NIEHS London, Robert (NIEHS) 1 114105691 London, Robert NIEHS NIEHS London, Robert (NIEHS) 1 114105690 Levy, Louis NIEHS Levy, Louis 0 114100707 FLUORESCENT INTRACELLULAR CALCUIM INDICATORS E-015-1993-0 NIEHS 83739538 Choudhry, Vidita vidita.choudhry@nih.gov
United States of America Office of Technology Transfer and Development vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-1515] Fluorescent Intracellular Calcium Indicators&body=Please send me information about technology [TAB-1515] Fluorescent Intracellular Calcium Indicators. Choudhry, Vidita<br><a href="mailto:vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-1515] Fluorescent Intracellular Calcium Indicators&body=Please send me information about technology [TAB-1515] Fluorescent Intracellular Calcium Indicators.">vidita.choudhry@nih.gov</a><br> 114163666 E-015-1993-0 E-015-1993-0-US-01 FLUORESCENT INTRACELLULAR CALCIUM INDICATORS ORD US 5,516,911 08/175,590 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/5516911 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/5516911">5,516,911</a><br />Filed on 1993-12-30<br />Status: Expired 114117656 IA4AXX 114117657 IAXXXX 114117658 IXXXXX 114117720 IA4XXX 114136575 fluorescent 114136576 Intracellular 114136577 CALCUIM 114136578 INDICATORS TAB-1514 114095783 Serotonin-Deficient Knock-out Mouse NIMH Consumer Products, Diagnostics, Licensing, Neurology, Research Materials, Therapeutics Consumer Products Diagnostics Licensing Neurology Research Materials Therapeutics Dennis Murphy Serotonin is an important modulator of many developmental, behavioral, and physiological processes, and it has been implicated in depression, anxiety, schizophrenia, obsessive compulsive disorders, and substance abuse. Serotonin’s pharmacology is extremely complex and it is mediated by seven of serotonin receptor subtypes and it is present in several tissues. Although it has been a subject of a number of studies, its role has been difficult to ascertain. To investigate the role of serotonin in these disorders, the murine gene was disrupted by homologous recombination. Results indicate that serotonin binding sites were absent in different brain regions (brain stem, frontal cortex, hippocampus, and striatum), and its concentrations were reduced by 60-80%. These mice represent a powerful tool for the investigation of behavioral and neuropsychiatric disorders, and development of drug treatments for these disorders. <ul> <li>A model to study serotonin’s role in behavioral and neuropsychiatric disorders.</li> </ul> Research Tool -- Patent protection is not being pursued for this technology. 2022-03-08 2024-10-28 2024-10-28 2007-03-01 AC6XXX, ACXXXX, AXXXXX, KNOCK-OUT, Mouse, MXXXXX, NC4XXX, NCXXXX, NXXXXX, Serotonin-Deficient, VEXXXX, WIXXXX False True True NIHTT 37470483 Website Abstract 114170289 Ren-Patterson RF, et al. https://www.ncbi.nlm.nih.gov/pubmed/15672416 <a href="https://www.ncbi.nlm.nih.gov/pubmed/15672416">Ren-Patterson RF, et al.</a> 114170290 Murphy DL, et al. https://www.ncbi.nlm.nih.gov/pubmed/15087484 <a href="https://www.ncbi.nlm.nih.gov/pubmed/15087484">Murphy DL, et al.</a> 114170291 Ren-Patterson RF, et al. https://www.ncbi.nlm.nih.gov/pubmed/15972295 <a href="https://www.ncbi.nlm.nih.gov/pubmed/15972295">Ren-Patterson RF, et al.</a> 114170292 Li Q, et al. https://www.ncbi.nlm.nih.gov/pubmed/15574737 <a href="https://www.ncbi.nlm.nih.gov/pubmed/15574737">Li Q, et al.</a> 114170293 Kilic F, et al. https://www.ncbi.nlm.nih.gov/pubmed/12869649 <a href="https://www.ncbi.nlm.nih.gov/pubmed/12869649">Kilic F, et al.</a> 114170294 Murphy DL, et al. https://www.ncbi.nlm.nih.gov/pubmed/14653307 <a href="https://www.ncbi.nlm.nih.gov/pubmed/14653307">Murphy DL, et al.</a> 114170295 Ozaki N, et al. https://www.ncbi.nlm.nih.gov/pubmed/14593431 <a href="https://www.ncbi.nlm.nih.gov/pubmed/14593431">Ozaki N, et al.</a> 114105689 Murphy, Dennis Murphy, Dennis 0 114105689 Murphy, Dennis Murphy, Dennis 0 114101143 Serotonin-Deficient Knock-out Mouse B-019-1999-0 Research Material National Institute of Mental Health (NIMH) 83686256 Wong, Jennifer jennifer.wong2@nih.gov
United States of America jennifer.wong2@nih.gov?subject=Web Inquiry on [TAB-1514] Serotonin-Deficient Knock-out Mouse&body=Please send me information about technology [TAB-1514] Serotonin-Deficient Knock-out Mouse. Wong, Jennifer<br><a href="mailto:jennifer.wong2@nih.gov?subject=Web Inquiry on [TAB-1514] Serotonin-Deficient Knock-out Mouse&body=Please send me information about technology [TAB-1514] Serotonin-Deficient Knock-out Mouse.">jennifer.wong2@nih.gov</a><br> 114112558 WIXXXX 114117648 NC4XXX 114117649 AC6XXX 114117650 NCXXXX 114117651 ACXXXX 114117652 MXXXXX 114117653 NXXXXX 114117654 AXXXXX 114118261 VEXXXX 114136328 Serotonin-Deficient 114136329 KNOCK-OUT 114136330 Mouse TAB-1493 114095761 Epithelial Cell Line Expressing a Cystic Fibrosis Phenotype NIEHS Diagnostics, Licensing, Pulmonology, Research Materials, Therapeutics Diagnostics Licensing Pulmonology Research Materials Therapeutics Anton Jetten Cystic fibrosis (CF) is a common genetic disease that affects the entire body, producing thick, sticky mucus that clogs the lungs, pancreas, and other organs. It is the most common fatal genetic disease in the United States, and is caused by a mutation in the cystic fibrosis transmembrane conductance regulator (CFTR). <br><br> Researchers at NIEHS have developed a cell line, CF/T43, which was produced by infection of airway epithelial cells isolated from CF patients with an SV40T retrovirus. CF/T43 cells maintain the abnormal ion transport characteristics of CF while having proliferation capability beyond that of a primary epithelial cell culture. Key features of the CF/T43 cell line include the formation of functional tight junctions, reduced apical membrane chloride conductance, and activation of apical chloride channels by calcium ionophores but not by cAMP-dependent agonists. This cell line may be used for elucidation of the mechanisms of CF, testing candidate complementary genes for correction of the observed CF abnormalities, and for developing and testing therapeutic CF drugs. <ul> <li>Research tool for developing new therapies to treat cystic fibrosis</li> <li>Research tool for studying the mechanisms of cystic fibrosis</li> </ul> Available for exclusive or nonexclusive licensing. 2022-03-08 2024-10-28 2024-10-28 2007-01-01 Cystic fibrosis, IB4XXX, IBXXXX, IXXXXX False True True NIHTT 37470483 Website Abstract 114170266 AM Jetten, JR Yankaskas, MJ Stutts, NJ Willumsen, and RC Boucher. Persistence of abnormal chloride conductance regulation in SV40 T transformed cystic fibrosis airway epithelia. Science 1989 Jun 23;244(4911):1472-1475. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=2472008&query_hl=4&itool=pubmed_docsum <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=2472008&query_hl=4&itool=pubmed_docsum">AM Jetten, JR Yankaskas, MJ Stutts, NJ Willumsen, and RC Boucher. Persistence of abnormal chloride conductance regulation in SV40 T transformed cystic fibrosis airway epithelia. Science 1989 Jun 23;244(4911):1472-1475.</a> 114105650 Jetten, Anton NIEHS Jetten, Anton (NIEHS) 0 114105650 Jetten, Anton NIEHS Jetten, Anton (NIEHS) 0 114100684 EPITHELIAL CELL LINE EXPRESSING A CYSTIC FIBROSIS PHENOTYPE E-201-1989-0 NIEHS 83739538 Choudhry, Vidita vidita.choudhry@nih.gov
United States of America Office of Technology Transfer and Development vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-1493] Epithelial Cell Line Expressing a Cystic Fibrosis Phenotype&body=Please send me information about technology [TAB-1493] Epithelial Cell Line Expressing a Cystic Fibrosis Phenotype. Choudhry, Vidita<br><a href="mailto:vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-1493] Epithelial Cell Line Expressing a Cystic Fibrosis Phenotype&body=Please send me information about technology [TAB-1493] Epithelial Cell Line Expressing a Cystic Fibrosis Phenotype.">vidita.choudhry@nih.gov</a><br> 114163615 E-201-1989-0 E-201-1989-0-US-01 EPITHELIAL CELL LINE EXPRESSING A CYSTIC FIBROSIS PHENOTYPE ORD US 5,420,033 07/368,725 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/5420033 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/5420033">5,420,033</a><br />Filed on 1989-06-21<br />Status: Expired 114165580 E-201-1989-0 E-201-1989-0-PCT-02 Epithelial cell line expressing a cystic fibrosis phenotype PCT Patent Cooperation Treaty PCT/US1990/003225 Expired Patent Cooperation Treaty <br />(PCT) PCT/US1990/003225<br />Filed on 1990-06-13<br />Status: Expired 114117562 IB4XXX 114117563 IBXXXX 114117564 IXXXXX 114156243 Cystic fibrosis TAB-1492 114095762 Enriched Natural Killer Cells for Adoptive Infusion Cancer Therapy NHLBI Collaboration, Immunology, Licensing, Oncology, Therapeutics Collaboration Immunology Licensing Oncology Therapeutics Richard Childs Immuno-therapy has taken a lead among the new cancer therapeutic approaches. It is one of the most promising new therapeutic approaches that exploit the innate immune mechanism of an individual to fight against a certain disease.<br /><br /> Natural killer (NK) cells are a form of cytotoxic lymphocytes which constitute a major portion of the innate immune system. NK cells have tumor cytotoxic properties independent of tumor specific antigens and have been shown in murine models to control and prevent tumor growth and dissemination. Inactivation of NK cells potentially allows cancer cells to evade host NK-cell-mediated immunity. Ligation of killer immunoglobulin like receptors (KIRs) by MHC class I on both normal and malignant tissues suppresses the function of NK cells.<br /><br /> The present invention relates to treating cancer and other hyperproliferative disorders by administering an enriched composition of allogeneic or autologous (KIR/KIR ligand incompatible) NK cell population. This enriched composition can potentially override the inactivation of NK cells by self HLA molecules or MHC class I expressing tumors. Claims cover compositions of enriched NK cell populations and method of treating malignancies or prevent recurrence of malignancies and treating any hyperproliferative disorders with these enriched compositions. Claims also cover a method to sensitize malignancies to NK cell TRAIL-mediated killing by pretreatment with bortezomib. <ul> <li>New adoptive infusion immunotherapeutic method for treating solid tumors</li> <li>New cancer treatment method exploiting the function of NK cells</li> <li>Enriched composition of allogeneic and autologous NK cell population</li> <li>Enriched NK cell composition has potential to override the natural NK cell inactivation process by HLA or MHC class I expressing tumors</li> <li>Sensitizing cancers to adoptively infused NK cells by treatment with bortezomib as a method to sensitize to NK cell TRAIL cytotoxicity</li> </ul> The Hematology Branch of the National Heart, Lung, and Blood Institute is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize the use of in vitro expanded adoptively infused NK cells to treat advanced and incurable cancers. Please contact Dr. Richard W. Childs at 301/496-5093 or 301/451-7128 (email: <a href="mailto:childsr@nih.gov">childsr@nih.gov</a>) for more information. Available for licensing. 2022-03-08 2024-10-28 2024-10-28 2007-01-01 47 XYY syndrome, BBXXXX, CB6XXX, CBXXXX, CXXXXX, Double Y False True The technology is currently in the pre-clinical stage of development. The technology is currently in the pre-clinical stage of development. True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114170263 T Igarashi et al. Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells. Blood. 2004 Jul 1;104(1):170-177. http://www.ncbi.nlm.nih.gov/pubmed/15016654 <a href="http://www.ncbi.nlm.nih.gov/pubmed/15016654">T Igarashi et al. Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells. Blood. 2004 Jul 1;104(1):170-177.</a> 114170264 A Lundqvist et al. Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity. Cancer Res. 2006 Jul 15;66(14):7317-7325. http://www.ncbi.nlm.nih.gov/pubmed/16849582 <a href="http://www.ncbi.nlm.nih.gov/pubmed/16849582">A Lundqvist et al. Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity. Cancer Res. 2006 Jul 15;66(14):7317-7325.</a> 114170265 A Lundqvist et al. Reduction of GVHD and enhanced anti-tumor effects after adoptive infusion of alloreactive Ly49-mismatched NK-cells from MHC-matched donors. Blood. Prepublished online 2006 Dec 19, doi 10.1182/blood-2006-05-024315. http://www.ncbi.nlm.nih.gov/pubmed/17179231 <a href="http://www.ncbi.nlm.nih.gov/pubmed/17179231">A Lundqvist et al. Reduction of GVHD and enhanced anti-tumor effects after adoptive infusion of alloreactive Ly49-mismatched NK-cells from MHC-matched donors. Blood. Prepublished online 2006 Dec 19, doi 10.1182/blood-2006-05-024315.</a> 114105649 Childs, Richard NHLBI Childs, Richard (NHLBI) 0 114105649 Childs, Richard NHLBI Childs, Richard (NHLBI) 0 114100683 A Method To Enhance The Susceptibility Of Tumor Cells To NK Cell Mediated Cytotoxicity E-183-2004-1 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-1492] Enriched Natural Killer Cells for Adoptive Infusion Cancer Therapy&body=Please send me information about technology [TAB-1492] Enriched Natural Killer Cells for Adoptive Infusion Cancer Therapy. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-1492] Enriched Natural Killer Cells for Adoptive Infusion Cancer Therapy&body=Please send me information about technology [TAB-1492] Enriched Natural Killer Cells for Adoptive Infusion Cancer Therapy.">shmilovm@nih.gov</a><br> 114163612 E-183-2004-1 E-183-2004-1-PCT-01 COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISORDERS PCT COMB Patent Cooperation Treaty PCT/US2005/039282 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2005/039282<br />Filed on 2005-10-31<br />Status: Expired 114163614 E-183-2004-1 E-183-2004-1-US-06 COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISORDERS National Stage US 11/718,387 Abandoned US <br />National Stage 11/718,387<br />Filed on 2008-05-07<br />Status: Abandoned 114167349 E-183-2004-1 E-183-2004-1-US-08 Compositions and Methods for Treating Hyperproliferative Disorders CON US 14/058,000 Abandoned US <br />Continuation (CON) 14/058,000<br />Filed on 2013-10-18<br />Status: Abandoned 114117559 CB6XXX 114117560 CBXXXX 114117561 CXXXXX 114121171 BBXXXX 114156242 47 XYY syndrome 114158222 Double Y TAB-1462 114095732 A Novel Magnetic Resonance Radio-Frequency Coil Array that Eliminates Inductive Coupling NINDS Licensing Licensing George Nascimento, Alfonso Silva Parallel magnetic resonance imaging (MRI) techniques employ RF coil arrays for faster data acquisition, and have been shown to reduce the overall length of MRI procedures, improve signal-to–noise ratio (SNR) and image quality, thus making MRI more attractive and less costly. Elimination of inductive coupling is an essential step in designing RF coil arrays for parallel MRI. If mutual inductance remains among coils in the RF coil array, the MR signal obtained from one coil may disturb the flux in another coil, making it difficult to match the impedance of each individual element to the input impedance its preamplifier. This non-optimal matching can lead to degradation of MR signal thereby yielding images with low quality. The most common strategy for inductive decoupling involves the use of preamplifiers with very low input impedance and decoupling networks with lumped elements. However, the construction of preamplifiers with low input impedance is not easy to accomplish, and these preamplifiers impose technical restrictions on coil design, requiring the use of overlapping loops to further minimize the amount of mutual inductance between the coils. <br><br> The present invention describes a novel RF coil circuitry scheme to remove inductive coupling and to overcome the limitations of having to use overlapping geometries and low-impedance preamplifiers. The coil array employs a transformer to match the input impedance of the preamplifier. The signal that reaches the preamplifier is coupled in an inductive fashion to the RF coil decoupling network through the transformer’s primary coil. Because primary and secondary coils in the transformer are isolated, the preamplifier circuit (and the MRI scanner electronics) is electrically isolated from the MR pickup coil. This arrangement provides a perfect electrical balance and isolation between the array channels, thus making it unnecessary to use traps and balluns in the circuit. At 7T, a 4-channel small animal coil array implementing the novel circuitry provided images with excellent SNR and demonstrated isolation of all individual RF coils and immunity to standing waves and other parasitic signals. <ul> <li>Allows for increased flexibility of coil design including geometries that require array with overlapping receiver coil loops</li> <li>Can provide high level of mutual inductance decoupling within coils in the array</li> <li>Isolates the grounds from coil to coil, and cancels all ground loops related to the coil array</li> <li>Greatly increases the signal to noise ratio in MR imaging</li> </ul> <ul> <li>MR imaging of humans, including imaging of brain</li> <li>MR imaging of animals, including non-human primates and rodents</li> <li>Functional imaging of humans and animals</li> </ul> Available for non-exclusive or exclusive licensing. 2022-03-08 2024-10-28 2024-10-28 2006-10-01 AA2XXX, AA3B1X, AA3BXX, AA3XXX, AAXXXX, AXXXXX, Decoupling, Inductive, MULTIPLE, PASSIVE, RF coil, Transformers False True Early stage; Working model made and tested, improved model for animals under testing Early stage; Working model made and tested, improved model for animals under testing True NIHTT 37470483 Website Abstract 114106330 Silva, Alfonso NINDS NINDS Silva, Alfonso (NINDS) 0 114105600 Nascimento, George NINDS Nascimento, George 1 114105600 Nascimento, George NINDS Nascimento, George 1 114106330 Silva, Alfonso NINDS NINDS Silva, Alfonso (NINDS) 0 114100650 Inductive Decoupling Of Multiple RF Coils Using Passive Transformers E-099-2006-0 Filing authorized NINDS 83667829 Ano, Susan susan.ano@nih.gov
United States of America susan.ano@nih.gov?subject=Web Inquiry on [TAB-1462] A Novel Magnetic Resonance Radio-Frequency Coil Array that Eliminates Inductive Coupling&body=Please send me information about technology [TAB-1462] A Novel Magnetic Resonance Radio-Frequency Coil Array that Eliminates Inductive Coupling. Ano, Susan<br><a href="mailto:susan.ano@nih.gov?subject=Web Inquiry on [TAB-1462] A Novel Magnetic Resonance Radio-Frequency Coil Array that Eliminates Inductive Coupling&body=Please send me information about technology [TAB-1462] A Novel Magnetic Resonance Radio-Frequency Coil Array that Eliminates Inductive Coupling.">susan.ano@nih.gov</a><br> 114163545 E-099-2006-0 E-099-2006-0-PCT-02 Inductive Decoupling Of Multiple RF Coils Using Passive Transformers PCT Patent Cooperation Treaty PCT/US2007/008586 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2007/008586<br />Filed on 2007-04-06<br />Status: Expired 114163546 E-099-2006-0 E-099-2006-0-US-01 Inductive Decoupling Of Multiple RF Coils Using Passive Transformers PRV US 60/789,934 Abandoned US <br />Provisional (PRV) 60/789,934<br />Filed on 2006-04-07<br />Status: Abandoned 114165005 E-099-2006-0 E-099-2006-0-US-04 Inductive Decoupling Of A RF Coil Array National Stage US 7,932,721 12/296,417 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7932721 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7932721">7,932,721</a><br />Filed on 2007-04-06<br />Status: Issued 114117429 AXXXXX 114117430 AAXXXX 114117431 AA2XXX 114117432 AA3XXX 114117433 AA3BXX 114117434 AA3B1X 114133367 Inductive 114133368 Decoupling 114133369 MULTIPLE 114133370 RF coil 114133371 PASSIVE 114133372 Transformers TAB-1421 114095712 Neutralizing Monoclonal Antibodies to Botulinum Neurotoxin Type A NIAID Antibodies, Diagnostics, Immunology, Infectious Disease, Licensing, Rare/Neglected Diseases, Research Materials, Therapeutics, Vaccines Antibodies Diagnostics Immunology Infectious Disease Licensing Rare/Neglected Diseases Research Materials Therapeutics Vaccines Zhaochun Chen, Suzanne Emerson, Robert Purcell Two chimpanzee mAbs specifically reacted with light chain of the botulinum neurotoxin A and neutralize the toxin in the mouse model. They can be used for emergency prophylaxis and treatment of either naturally acquired or terrorist associated botulism. Since the sequence of chimpanzee immune globulin is virtually identical to that of humans, the MAbs are not expected to have problems in repeated administration as equine antibodies. They can also be used for rapid diagnosis of botulinum neurotoxin A. <ul> <li>Speed up product development with NIH developed material that has already been tested and validated.</li> </ul> <ul> <li>A research material that can be used in the development of assays, validation of products or in quality control.</li> </ul> Research Material – Patent protection is not being pursued for this technology. (IC Reference No. 2006-059) Available for non-exclusive licensing. 2022-03-08 2024-10-28 2024-10-28 2020-07-06 Botulinum, DB3XXX, DBXXXX, DXXXXX, Hybridoma, Listed LPM Chang as of 4/15/2015, mabs, Neurotoxin, Neutralizing, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, RM, UA1XXX, VJXXXX, WAXXXX, WIXXXX, XAXXXX False True True NIHTT 37470483 Website Abstract 114106163 Purcell, Robert NIAID - DIR NIAID Purcell, Robert (NIAID) 0 114109341 Emerson, Suzanne NIAID - DIR NIAID Emerson, Suzanne (NIAID) 0 114109340 Chen, Zhaochun NIAID - DIR NIAID Chen, Zhaochun (NIAID) 1 114109340 Chen, Zhaochun NIAID - DIR NIAID Chen, Zhaochun (NIAID) 1 114106163 Purcell, Robert NIAID - DIR NIAID Purcell, Robert (NIAID) 0 114109341 Emerson, Suzanne NIAID - DIR NIAID Emerson, Suzanne (NIAID) 0 114100991 Neutralizing Mabs To Botulinum Neurotoxin A E-180-2006-0 Research Material NIAID 83643855 Soukas, Peter peter.soukas@nih.gov
United States of America Technology Transfer and Intellectual Property Office peter.soukas@nih.gov?subject=Web Inquiry on [TAB-1421] Neutralizing Monoclonal Antibodies to Botulinum Neurotoxin Type A&body=Please send me information about technology [TAB-1421] Neutralizing Monoclonal Antibodies to Botulinum Neurotoxin Type A. Soukas, Peter<br><a href="mailto:peter.soukas@nih.gov?subject=Web Inquiry on [TAB-1421] Neutralizing Monoclonal Antibodies to Botulinum Neurotoxin Type A&body=Please send me information about technology [TAB-1421] Neutralizing Monoclonal Antibodies to Botulinum Neurotoxin Type A.">peter.soukas@nih.gov</a><br> 114117346 DB3XXX 114117347 DBXXXX 114117348 DXXXXX 114127363 UA1XXX 114127364 VJXXXX 114127365 WAXXXX 114127366 WIXXXX 114127367 XAXXXX 114149410 Neutralizing 114149411 mabs 114149412 Botulinum 114149413 Neurotoxin 114149414 Listed LPM Chang as of 4/15/2015 114149415 Pre LPM working set 20150418 114149416 Post LPM Assignment Set 20150420 114149417 Hybridoma 114149418 RM TAB-1455 114095728 Swine Hepatitis E Virus Available For Use in Diagnosis, Prevention and Treatment of Hepatitis E NIAID Collaboration, Infectious Disease, Licensing, Rare/Neglected Diseases, Vaccines Collaboration Infectious Disease Licensing Rare/Neglected Diseases Vaccines Suzanne Emerson, Xiang-jin Meng, Robert Purcell Hepatitis E virus (HEV) is the cause of Hepatitis E, a liver disease that occurs primarily in developing countries due to fecal contaminated drinking water. Outbreaks of HEV infection have caused epidemics in Africa, Central and Southeast Asia and Mexico and cases of the disease have also been reported sporadically in more developed countries. Hepatitis E is most often overcome by a host’s natural defenses; however the disease is more severe in pregnant women, who exhibit a 20% mortality rate due to HEV infection. Presently, no vaccines or therapeutic agents, which prevent or treat HEV infection, are commercially provided. <br><br> An isolated strain of swine HEV is currently available for licensing and commercial development. The nucleotide and amino acid sequences of the available virus are significantly homologous to human HEV and antibodies induced by the agent were shown to cross react with a human HEV antigen. The present technology provides a mechanism for augmenting the immune response against HEV in infected individuals and is thus useful for the development of novel vaccines and therapeutics for prevention and treatment of HEV infection in humans. In addition, the available viral strain may be used to develop diagnostic tools for efficient detection of HEV contamination of food and water in developing countries, especially in regions of Africa, Asia and Mexico, where HEV is endemic. <ul> <li>Development of diagnostic tools for identification and detection of HEV infection</li> <li>HEV vaccination in developing countries, where individuals are at higher risk for infection </li> <li>Research and development of anti-HEV therapeutics agents</li> </ul> The NIAID Laboratory of Infectious Diseases, Hepatitis Viruses Section, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize swine HEV or its products. Please contact Robert H. Purcell at <a href="mailto:rpurcell@niaid.nih.gov" target="blank">rpurcell@niaid.nih.gov</a> for more information. Available for non-exclusive or exclusive licensing. 2022-03-08 2024-10-28 2024-10-28 2020-07-06 DC5BXX, DC5XXX, DCXXXX, Duke DNA Project, DXXXXX, e, Hepatitis, Hepatitis A, Hepatitis D, Hepatitis E, HEV, PCT/US98/14665, Swine, THEREOF, UAXXXX, USES, virus False True Preclinical data are available at this time. Preclinical data are available at this time. True NIHTT 37470483 Website Abstract 114105590 Emerson, Suzanne NIAID - DIR NIAID Emerson, Suzanne (NIAID) 0 114105591 Purcell, Robert NIAID - DIR NIAID Purcell, Robert (NIAID) 0 114105592 Meng, Xiang-jin NIAID - DIR Meng, Xiang-jin 1 114105592 Meng, Xiang-jin NIAID - DIR Meng, Xiang-jin 1 114105590 Emerson, Suzanne NIAID - DIR NIAID Emerson, Suzanne (NIAID) 0 114105591 Purcell, Robert NIAID - DIR NIAID Purcell, Robert (NIAID) 0 114100645 A SWINE HEPATITIS E VIRUS AND USES THEREOF E-203-1997-0 Filing authorized NIAID 83643855 Soukas, Peter peter.soukas@nih.gov
United States of America Technology Transfer and Intellectual Property Office peter.soukas@nih.gov?subject=Web Inquiry on [TAB-1455] Swine Hepatitis E Virus Available For Use in Diagnosis, Prevention and Treatment of Hepatitis E&body=Please send me information about technology [TAB-1455] Swine Hepatitis E Virus Available For Use in Diagnosis, Prevention and Treatment of Hepatitis E. Soukas, Peter<br><a href="mailto:peter.soukas@nih.gov?subject=Web Inquiry on [TAB-1455] Swine Hepatitis E Virus Available For Use in Diagnosis, Prevention and Treatment of Hepatitis E&body=Please send me information about technology [TAB-1455] Swine Hepatitis E Virus Available For Use in Diagnosis, Prevention and Treatment of Hepatitis E.">peter.soukas@nih.gov</a><br> 114163560 E-203-1997-0 E-203-1997-0-PCT-02 A SWINE HEPATITIS E VIRUS AND USES THEREOF PCT Patent Cooperation Treaty PCT/US1998/014665 Expired Patent Cooperation Treaty <br />(PCT) PCT/US1998/014665<br />Filed on 1998-07-17<br />Status: Expired 114163880 E-203-1997-0 E-203-1997-0-US-01 A SWINE HEPATITIS E VIRUS AND USES THEREOF PRV US 60/053,069 Abandoned US <br />Provisional (PRV) 60/053,069<br />Filed on 1997-07-18<br />Status: Abandoned 114164293 E-203-1997-0 E-203-1997-0-US-04 A SWINE HEPATITIS E VIRUS AND USES THEREOF National Stage US 6,432,408 09/462,606 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6432408 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6432408">6,432,408</a><br />Filed on 2000-06-12<br />Status: Expired 114117412 DC5BXX 114117413 DCXXXX 114117414 DXXXXX 114119368 DC5XXX 114119369 UAXXXX 114133752 PCT/US98/14665 114133753 Hepatitis 114133754 HEV 114133755 Swine 114133756 e 114133757 virus 114133758 USES 114133759 THEREOF 114133760 Duke DNA Project 114156199 Hepatitis D 114156200 Hepatitis A 114156201 Hepatitis E TAB-1389 114095696 A Newly Discovered Bacterium in the Family Acetobacteraceae NIAID Collaboration, Licensing, Rare/Neglected Diseases, Research Materials Collaboration Licensing Rare/Neglected Diseases Research Materials David Greenberg, Steven Holland, Patrick Murray, Adrian Zelazny Available for licensing and commercial development is a newly discovered bacterium in the Acetobacteraceae family. This bacterium was isolated, characterized and grown from lymph nodes of a patient with chronic granulomatous disease (CGD), a rare genetic disorder that impairs the immune system.<br /><br /> This Gram-negative bacterium is an aerobic, facultative methylotroph that produces yellow pigmented colonies. The closest nucleic acid sequence match was to Gluconacetobacter sacchari (95.7% similarity) of the acetic acid bacteria. The newly described bacterium belongs to a new genus and species in the Acetobacteraceae family and was named Granulibacter bethesdensis. Acetobacteraceae are characterized by their ability to convert alcohol (ethanol) to acetic acid in the presence of air. Members of this family are used industrially in the production of vinegar, and are encountered during fermentation of wine.<br /><br /> G. bethesdensis can breakdown methanol, formaldehyde, ethanol and their intermediate breakdown products into non-toxic end-products. Examples of non-toxic end-products include carbon dioxide, water, and acetic acid.<br /><br /> The invention provides the complete genome sequence from the bacterium. Also included are permission to purify and utilize unique enzymes that the bacterium uses to degrade organic materials, for example methanol dehydrogenase, formaldehyde-activating enzyme, and methylenetetrahydrofolate dehydrogenase (NADP+). <ul> <li>Biodegradation of organic waste</li> <li>Microbial fuel cell</li> <li>Production of purified polypeptide enzymes for industrial use</li> </ul> The NIAID Laboratory of Host Defenses is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. Please contact Vincent Feliccia, Ph.D., J.D. at vfeliccia@niaid.nih.gov for more information. 2022-03-08 2024-10-28 2024-10-28 2006-07-01 Acetobacteraceae, alternative energy source, BACTERIUM, Chronic granulomatous disease, fuel cell, new bacterium, RXXXXX, UA1XXX False True True NIHTT 37470483 Website Abstract 114170177 Greenberg DE, et al. http://www.ncbi.nlm.nih.gov/pubmed/16617373 <a href="http://www.ncbi.nlm.nih.gov/pubmed/16617373">Greenberg DE, et al.</a> 114105518 Greenberg, David NIAID - DIR NIAID Greenberg, David (NIAID) 0 114105519 Zelazny, Adrian Clinical Center (CC) CC Zelazny, Adrian (CC) 0 114105520 Murray, Patrick Clinical Center (CC) CC Murray, Patrick (CC) 0 114105521 Holland, Steven NIAID - DIR NIAID Holland, Steven (NIAID) 1 114105521 Holland, Steven NIAID - DIR NIAID Holland, Steven (NIAID) 1 114105518 Greenberg, David NIAID - DIR NIAID Greenberg, David (NIAID) 0 114105519 Zelazny, Adrian Clinical Center (CC) CC Zelazny, Adrian (CC) 0 114105520 Murray, Patrick Clinical Center (CC) CC Murray, Patrick (CC) 0 114100611 A Newly Discovered Bacterium In The Family Acetobacteraceae E-083-2006-0 Filing authorized Clinical Center (CC), NIAID 83720410 Yang, David (Po-Lung) polung.yang@nih.gov
United States of America Technology Transfer and Intellectual Property Office polung.yang@nih.gov?subject=Web Inquiry on [TAB-1389] A Newly Discovered Bacterium in the Family Acetobacteraceae&body=Please send me information about technology [TAB-1389] A Newly Discovered Bacterium in the Family Acetobacteraceae. Yang, David (Po-Lung)<br><a href="mailto:polung.yang@nih.gov?subject=Web Inquiry on [TAB-1389] A Newly Discovered Bacterium in the Family Acetobacteraceae&body=Please send me information about technology [TAB-1389] A Newly Discovered Bacterium in the Family Acetobacteraceae.">polung.yang@nih.gov</a><br> 114160532 E-083-2006-0 E-083-2006-0-US-03 Newly Discovered Bacterium In The Family Acetobacteraceae ORD US 9,051,573 12/225,615 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9051573 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9051573">9,051,573</a><br />Filed on 2009-09-16<br />Status: Issued 114162504 E-083-2006-0 E-083-2006-0-PCT-02 A Newly Discovered Bacterium In The Family Acetobacteraceae PCT Patent Cooperation Treaty PCT/US2007/007795 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2007/007795<br />Filed on 2007-03-28<br />Status: Expired 114164058 E-083-2006-0 E-083-2006-0-US-01 A Newly Discovered Bacterium In The Family Acetobacteraceae PRV US 60/788,521 Abandoned US <br />Provisional (PRV) 60/788,521<br />Filed on 2006-03-31<br />Status: Abandoned 114168169 E-083-2006-0 E-083-2006-0-US-04 Newly Discovered Bacterium In The Family Acetobacteraceae DIV US 14/717,911 Abandoned US <br />Divisional (DIV) 14/717,911<br />Filed on 2015-05-20<br />Status: Abandoned 114117245 RXXXXX 114119353 UA1XXX 114133635 alternative energy source 114133636 fuel cell 114133637 BACTERIUM 114133638 new bacterium 114133639 Acetobacteraceae 114156182 Chronic granulomatous disease TAB-1360 114095687 Agonist Epitopes for Renal Cell Carcinoma NHLBI Collaboration, Diagnostics, Licensing, Oncology, Therapeutics, Vaccines Collaboration Diagnostics Licensing Oncology Therapeutics Vaccines Richard Childs Approximately 30,000 patients are diagnosed with renal cell carcinoma (RCC) each year in the United States, and an estimated 12,000 patients die of this disease. Most patients are diagnosed with advanced local disease or metastatic disease. Metastatic RCC carries a poor prognosis with median survivals in the range of 10-12 months. Drugs that inhibit VEGF receptor tyrosine kinases such as Sorafenib and Sunitinib have recently been approved by the FDA to treat metastatic RCC. Although a significant percentage of patients will achieve a partial response or disease stabilization with these agents, complete responses are rare and disease progression eventually ensues. RCC is unusual among solid tumors as it appears to be susceptible to immunotherapy. Cytokines such as IL-2 and IFN-alpha nonspecifically stimulate the immune system resulting in disease regression. Unfortunately, these drugs achieve success in only a minority (15-20%) of the metastatic RCC patient population. Therefore, new methods are needed to improve on immune-based therapies and expand the curative potential of therapies for patients with RCC. <br><br> The present invention discloses peptides and antigen epitopes specific for RCC for use in the diagnosis, vaccination, or adoptive infusion of antigen specific T cells to treat patients with metastatic RCC. The immunogenic peptide, which binds to the HLA-A11 epitope, was identified in a patient with metastatic RCC that under went an investigational allogeneic hematopoietic stem cell transplant. Cancer regression occurred post-transplant consistent with a graft-vs-tumor effect. A T-cell line, expanded from the patient’s blood cells at the time of tumor regression, was isolated and subsequently shown to kill the patients RCC cells in vitro. Expression and sequencing studies revealed that the patient’s T-cells recognize an antigen epitope derived from a human endogenous retrovirus (HERV). Further, pre-clinical studies using quantitative real-time PCR found that this HERV was expressed in eight of 14 RCC tumor cell lines with no HERV expression in patient fibroblasts, hematopoietic cells or in c-DNAs analyzed from 48 different normal tissues. Plans are underway to investigate the immunogenic potential of this peptide to induce expansion of T-cells that are cytotoxic to RCC cells in vitro and in pre-clinical animal models. The Hematology Branch of the NHLBI is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize therapeutic treatment approaches targeting this novel RCC antigen. Please contact Dr. Richard Childs at 301/594-8008 or <a href="mailto:childsr@nhlbi.nih.gov">childsr@nhlbi.nih.gov</a> for more information. Available for licensing. 2022-03-08 2024-10-28 2024-10-28 2006-06-01 BBXXXX, CA1AXX, CA1XXX, CA2CXX, CA2XXX, Carcinoma, CAXXXX, CB2BXX, CB2XXX, CB4XXX, CBXXXX, Cell, Cells, CXXXXX, Discovery, Expression, Gene, Kidney cancer, adult, Patent Category - Biotechnology, previously, RDD, RENAL, Renal cell carcinoma 1, Renal cell carcinoma 4, Restricted, Uncharacterized, WHOSE False True True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114170158 I Espinoza-Delgado and RW Childs. Nonmyeloablative transplantation for solid tumors: a new frontier for allogeneic immunotherapy. Expert Rev Anticancer Ther. 2004 Oct;4(5):865-875. http://www.ncbi.nlm.nih.gov/pubmed/15485320?dopt <a href="http://www.ncbi.nlm.nih.gov/pubmed/15485320?dopt">I Espinoza-Delgado and RW Childs. Nonmyeloablative transplantation for solid tumors: a new frontier for allogeneic immunotherapy. Expert Rev Anticancer Ther. 2004 Oct;4(5):865-875.</a> 114170159 Y Takahashi and RW Childs. Nonmyeloablative transplantation: an allogeneic-based immunotherapy for renal cell carcinoma. Clin Cancer Res. 2004 Sep 15;10(18 Pt 2):6353S-6359S. http://www.ncbi.nlm.nih.gov/pubmed/15448030?dopt <a href="http://www.ncbi.nlm.nih.gov/pubmed/15448030?dopt">Y Takahashi and RW Childs. Nonmyeloablative transplantation: an allogeneic-based immunotherapy for renal cell carcinoma. Clin Cancer Res. 2004 Sep 15;10(18 Pt 2):6353S-6359S.</a> 114170160 R Childs et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med. 2000 Sep 14;343(11):750-758. http://www.ncbi.nlm.nih.gov/pubmed/10984562?dopt <a href="http://www.ncbi.nlm.nih.gov/pubmed/10984562?dopt">R Childs et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med. 2000 Sep 14;343(11):750-758.</a> 114170161 Marco Bregni, Naoto T. Ueno, and Richard Childs. Meeting Report: The Second International Meeting on Allogeneic Transplantation in Solid Tumors (ATST). Bone Marrow Transplantation (Submitted 2006). Marco Bregni, Naoto T. Ueno, and Richard Childs. Meeting Report: The Second International Meeting on Allogeneic Transplantation in Solid Tumors (ATST). Bone Marrow Transplantation (Submitted 2006). 114105496 Childs, Richard National Heart, Lung, and Blood Institute (NHLBI) NHLBI Childs, Richard (NHLBI) 1 114105496 Childs, Richard National Heart, Lung, and Blood Institute (NHLBI) NHLBI Childs, Richard (NHLBI) 1 114100602 The Discovery Of A Previously Uncharacterized Gene Whose Expression Is Restricted To Renal Cell Carcinoma (RCC) Cells E-122-2006-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 83685986 Crooks, Denise crooksd@mail.nih.gov
United States of America Office of Technology Transfer and Development crooksd@mail.nih.gov?subject=Web Inquiry on [TAB-1360] Agonist Epitopes for Renal Cell Carcinoma&body=Please send me information about technology [TAB-1360] Agonist Epitopes for Renal Cell Carcinoma. Crooks, Denise<br><a href="mailto:crooksd@mail.nih.gov?subject=Web Inquiry on [TAB-1360] Agonist Epitopes for Renal Cell Carcinoma&body=Please send me information about technology [TAB-1360] Agonist Epitopes for Renal Cell Carcinoma.">crooksd@mail.nih.gov</a><br> 114160552 E-122-2006-0 E-122-2006-0-US-04 COMPOSITIONS AND METHODS FOR PREVENTION OR TREATMENT OF NEOPLASTIC DISEASE IN A MAMMALIAN SUBJECT CON US 9,856,453 14/549,296 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9856453 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9856453">9,856,453</a><br />Filed on 2014-11-20<br />Status: Issued 114163351 E-122-2006-0 E-122-2006-0-US-01 AGONIST EPITOPES FOR RENAL CELL CARCINOMA PRV US 60/783,350 Abandoned US <br />Provisional (PRV) 60/783,350<br />Filed on 2006-03-17<br />Status: Abandoned 114163443 E-122-2006-0 E-122-2006-0-PCT-02 Compositions and Methods for Prevention or Treatment of Neoplastic Disease in a Mammalian Subject PCT Patent Cooperation Treaty PCT/US2007/64237 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2007/64237<br />Filed on 2007-03-16<br />Status: Expired 114165002 E-122-2006-0 E-122-2006-0-US-03 Methods of Diagnosing Renal Cell Carcinoma National Stage US 8,921,050 12/293,180 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8921050 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8921050">8,921,050</a><br />Filed on 2007-03-16<br />Status: Issued 114167709 E-122-2006-0 E-122-2006-0-US-05 COMPOSITIONS AND METHODS FOR PREVENTION OR TREATMENT OF NEOPLASTIC DISEASE IN A MAMMALIAN SUBJECT DIV US 10,214,726 15/821,523 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10214726 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10214726">10,214,726</a><br />Filed on 2017-11-22<br />Status: Issued 114168825 E-122-2006-0 E-122-2006-0-US-06 The Discovery Of A Previously Uncharacterized Gene Whose Expression Is Restricted To Renal Cell Carcinoma (RCC) Cells CON US 10,557,118 16/241,017 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10557118 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10557118">10,557,118</a><br />Filed on 2019-01-07<br />Status: Issued 114117216 CA1AXX 114117217 CA2CXX 114117218 CB2BXX 114117219 CAXXXX 114117220 CB4XXX 114117221 CBXXXX 114117222 CXXXXX 114120009 CA1XXX 114120010 CA2XXX 114120011 CB2XXX 114120866 BBXXXX 114137174 Discovery 114137175 previously 114137176 Uncharacterized 114137177 Gene 114137178 WHOSE 114137179 Expression 114137180 Restricted 114137181 RENAL 114137182 Cell 114137183 Carcinoma 114137184 RDD 114137185 Cells 114137186 Patent Category - Biotechnology 114156171 Renal cell carcinoma 4 114156172 Kidney cancer, adult 114158177 Renal cell carcinoma 1 TAB-1356 114095682 Method for Improved Phase Contrast MRI Resolution NHLBI Licensing Licensing Elliot Mcveigh, Reza Nezafat, Richard Thompson This invention is a method to significantly improve the temporal or spatial resolution in a phase contrast MRI (PC-MRI) study. In general, conventional PC-MRI involves encoding the motion information of spins in the phase of the image. The velocity of the spin motion can be extracted by calculating the phase difference between two consecutive images acquired with two different bipolar encoding gradients. Two scans are required in order to reconstruct flow velocity data, resulting in an increase in image acquisition and reconstruction time by a factor of two compared to that of a standard anatomical image. As a means of reducing the PC-MRI scan time, the inventors propose a method of acquiring only a fraction of k-space data. The k-space is sampled using an under-sampled spiral or single projection, radial scheme. Subsequently, the two data sets in the PC-MRI are subtracted to extract the motion information from undersampled data without any aliasing artifacts. This method of partial-field of view acquisition and reconstruction of PC-MRI results in an increased temporal resolution, while maintaining high spatial resolution. The increase in image acquisition efficiency could be used to increase the spatial resolution while maintaining the temporal resolution. 2022-03-08 2024-10-28 2024-10-28 2006-06-01 AA3XXX, AAXXXX, AXXXXX, Contrast, Field, IMAGING, Method, MRI, PARTIAL, PHASE, Reconstruction, VIEW False True True NIHTT 37470483 Website Abstract 114109086 Mcveigh, Elliot National Heart, Lung, and Blood Institute (NHLBI) Mcveigh, Elliot 0 114109087 Thompson, Richard University of Alberta Thompson, Richard 0 114105488 Nezafat, Reza National Heart, Lung, and Blood Institute (NHLBI) Nezafat, Reza 1 114105488 Nezafat, Reza National Heart, Lung, and Blood Institute (NHLBI) Nezafat, Reza 1 114109086 Mcveigh, Elliot National Heart, Lung, and Blood Institute (NHLBI) Mcveigh, Elliot 0 114109087 Thompson, Richard University of Alberta Thompson, Richard 0 114100598 Method For Imaging And Reconstruction Of Partial Field Of View Phase Contrast MRI E-134-2005-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-1356] Method for Improved Phase Contrast MRI Resolution&body=Please send me information about technology [TAB-1356] Method for Improved Phase Contrast MRI Resolution. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-1356] Method for Improved Phase Contrast MRI Resolution&body=Please send me information about technology [TAB-1356] Method for Improved Phase Contrast MRI Resolution.">shmilovm@nih.gov</a><br> 114163433 E-134-2005-0 E-134-2005-0-US-01 Imaging And Reconstruction Of Partial Field Of View In Phase Contrast MRI ORD US 7,285,954 11/227,406 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7285954 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7285954">7,285,954</a><br />Filed on 2005-09-14<br />Status: Expired 114117201 AA3XXX 114117202 AAXXXX 114117203 AXXXXX 114133666 Method 114133667 IMAGING 114133668 Reconstruction 114133669 PARTIAL 114133670 Field 114133671 VIEW 114133672 PHASE 114133673 Contrast 114133674 MRI TAB-1347 114095673 Novel Methods for Using Biomarkers to Monitor Glucose Levels and Screen for Diabetes Risk NIEHS Diagnostics, Licensing, Research Materials, Therapeutics Diagnostics Licensing Research Materials Therapeutics Perry Blackshear A primary goal of diabetes therapy is to improve control of blood glucose levels (known as glycemic control) in patients. Prospective studies of both Type 1 and Type 2 diabetes indicate that careful glycemic control significantly reduces the risk of microvascular, neurological, and cardiovascular complications of diabetes. The current method of monitoring glycemic control involves measuring levels of the intracellular hemoglobin (HbA1C). However, levels of HbA1C reflect glycemic control over a timeframe of several months and are susceptible to a variety of perturbing factors such as hematologic disorders, kidney disease, aspirin or penicillin use, or alcohol intake. <br /><br /> This technology describes a family of novel glycated peptide and protein biomarkers for glycemic control, as well as a method to monitor glycemic control in diabetic patients. In contrast to intracellular HbA1C, this technology detects glycated plasma proteins, which may reflect changes in glycemic control more rapidly and with more sensitivity. A diagnostic test developed using this technology could be envisioned to supplement or replace current HbA1C-based glycemic monitoring and screen individuals for risk of diabetes. <ul> <li>Detects plasma proteins rather than intracellular markers</li> <li>May provide more rapid and sensitive detection than currently used methods</li> </ul> <ul> <li>Diagnostic test to measure glycemic control in diabetic patients</li> <li>Diagnostic test to screen patients for risk of developing diabetes</li> </ul> 2022-03-08 2024-10-28 2024-10-28 2022-03-03 IA6XXX, IAXXXX, IXXXXX False True Early stage <ul> <li>Early-stage</li> <li>In vitro data available</li> </ul> True NIHTT 37470483 Website Abstract 114105460 Blackshear, Perry NIEHS Blackshear, Perry (NIEHS) 0 114105460 Blackshear, Perry NIEHS Blackshear, Perry (NIEHS) 0 114100587 Novel Glycated Peptides And Proteins To Serve As Biomarkers For Diabetes Control E-057-2005-0 Filing authorized NIEHS 83739538 Choudhry, Vidita vidita.choudhry@nih.gov
United States of America Office of Technology Transfer and Development vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-1347] Novel Methods for Using Biomarkers to Monitor Glucose Levels and Screen for Diabetes Risk&body=Please send me information about technology [TAB-1347] Novel Methods for Using Biomarkers to Monitor Glucose Levels and Screen for Diabetes Risk. Choudhry, Vidita<br><a href="mailto:vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-1347] Novel Methods for Using Biomarkers to Monitor Glucose Levels and Screen for Diabetes Risk&body=Please send me information about technology [TAB-1347] Novel Methods for Using Biomarkers to Monitor Glucose Levels and Screen for Diabetes Risk.">vidita.choudhry@nih.gov</a><br> 114163407 E-057-2005-0 E-057-2005-0-US-01 Novel Glycated Peptides And Proteins To Serve As Biomarkers For Diabetes Control PRV US 60/779,710 Abandoned US <br />Provisional (PRV) 60/779,710<br />Filed on 2006-03-06<br />Status: Abandoned 114164709 E-057-2005-0 E-057-2005-0-US-03 Glycated Peptides And Methods Of Use National Stage US 8,309,313 12/281,909 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8309313 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8309313">8,309,313</a><br />Filed on 2008-09-05<br />Status: Issued 114166842 E-057-2005-0 E-057-2005-0-PCT-02 Glycated Peptides And Methods Of Use PCT Patent Cooperation Treaty PCT/US2007/63385 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2007/63385<br />Filed on 2007-03-06<br />Status: Expired 114117155 IA6XXX 114117156 IAXXXX 114117157 IXXXXX TAB-1316 114095642 Transformation-Associated Recombination (TAR) Cloning NIEHS Diagnostics, Licensing, Research Materials, Therapeutics Diagnostics Licensing Research Materials Therapeutics Natalay Kouprina, Vladimir Larionov, Michael Resnick Transformation-Associated Recombination (TAR) cloning in yeast is a unique method for selective isolation of large chromosomal fragments or entire genes from complex genomes without the time-consuming step of library construction.<sup>1</sup> The technique involves homologous recombination during yeast spheroplast transformation between genomic DNA and a TAR vector that has short (approximately 60bp) 5’ and 3’ gene targeting sequences (hooks). Further, because up to 15% sequence divergence does not prevent recombination in yeast, TAR cloning is highly efficient for isolation of gene homologs and synthenic regions. Using this technology, chromosomal regions up to 250kb can be rescued in yeast as circular YACs within 3-5 working days.<sup2,3</sup>.<br /><br /> NIH researchers Drs. Larionov, Kouprina and Resnick have championed the use of this technology and TAR cloning has been used to efficiently isolate haplotypes, gene families<sup>4</sup> as well as genomic regions which are not present in existing BAC libraries. Known mutations and new modifications, including point mutations, deletions and insertions, can easily be introduced into DNA fragments hundreds of kilobases in size without introducing any unwanted alterations. The modified DNAs can then be tested functionally in mammalian cells and transgenic mice. TAR has also been used for structural biology studies, long-range haplotyping, evolutionary studies, centromere analysis and analysis of other regions which cannot be cloned by a routine technique based on in vitro ligation.<sup>5</sup> In particular, construction of human artificial chromosome vectors and the combining of a HAC vector with a gene of interest can be effectively performed using the TAR methodology. Human genes isolated by TAR for expression in HACs include HPRT (60kb), BRCA1 (84kb), BRCA2 (90kb), PTEN (120kb), hTERT (60kb), KA11 (200kb), ASPM (70kb), SPANX-C (83kb) among others. TAR is a flexible and efficient means for employing in vivo recombination in yeast in order to clone entire genomic loci which can then be used for structural and functional analysis and for expression in HAC vectors for a variety of uses including for potential use in gene therapy.<br /><br /> The TAR cloning portfolio, including methods of use and vectors, is available for licensing and will be of direct use to those using a functional genomics approach in their work. 2022-03-08 2024-10-28 2024-10-28 2006-03-01 ACXXXX, AXXXXX, GDXXXX, GXXXXX, ICXXXX, IXXXXX False True True NIHTT 37470483 Website Abstract E-128-2005-0 114171127 Larionov V, et al. http://www.ncbi.nlm.nih.gov/pubmed/8552668 <a href="http://www.ncbi.nlm.nih.gov/pubmed/8552668">Larionov V, et al.</a> 114171638 Leem SH, et al. http://www.ncbi.nlm.nih.gov/pubmed/12626728 <a href="http://www.ncbi.nlm.nih.gov/pubmed/12626728">Leem SH, et al.</a> 114171639 Kouprina N, Larionov V. http://www.ncbi.nlm.nih.gov/pubmed/18428393 <a href="http://www.ncbi.nlm.nih.gov/pubmed/18428393">Kouprina N, Larionov V.</a> 114171640 Kouprina N, et al. http://www.ncbi.nlm.nih.gov/pubmed/16251457 <a href="http://www.ncbi.nlm.nih.gov/pubmed/16251457">Kouprina N, et al.</a> 114171641 Kouprina N, Larionov V. http://www.ncbi.nlm.nih.gov/pubmed/16983376 <a href="http://www.ncbi.nlm.nih.gov/pubmed/16983376">Kouprina N, Larionov V.</a> 114105400 Larionov, Vladimir NCI Larionov, Vladimir (NCI) 0 114105401 Kouprina, Natalay NCI Kouprina, Natalay (NCI) 0 114105402 Resnick, Michael NIEHS Resnick, Michael (NIEHS) 0 114105400 Larionov, Vladimir NCI Larionov, Vladimir (NCI) 0 114105401 Kouprina, Natalay NCI Kouprina, Natalay (NCI) 0 114105402 Resnick, Michael NIEHS Resnick, Michael (NIEHS) 0 114100548 Transformation-Associated Recombination (TAR) System in Yeast for Specific Cloning of DNAs as Yeast Artificial Chromosomes (YACs) E-121-1996-0 Filing authorized NIEHS 83739538 Choudhry, Vidita vidita.choudhry@nih.gov
United States of America Office of Technology Transfer and Development vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-1316] Transformation-Associated Recombination (TAR) Cloning&body=Please send me information about technology [TAB-1316] Transformation-Associated Recombination (TAR) Cloning. Choudhry, Vidita<br><a href="mailto:vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-1316] Transformation-Associated Recombination (TAR) Cloning&body=Please send me information about technology [TAB-1316] Transformation-Associated Recombination (TAR) Cloning.">vidita.choudhry@nih.gov</a><br> 114163309 E-121-1996-0 E-121-1996-0-US-06 Transformation-Associated Recombination (TAR) System in Yeast for Specific Cloning of DNAs as Yeast Artificial Chromosomes (YACs) National Stage US 6,391,642 09/060,023 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6391642 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6391642">6,391,642</a><br />Filed on 1998-04-14<br />Status: Expired 114116959 ACXXXX 114116960 GDXXXX 114116961 ICXXXX 114116963 AXXXXX 114116964 GXXXXX 114116965 IXXXXX TAB-1324 114095651 A Novel MRI Adiabatic T<sub>2</sub> Preparation Sequence with Reduced B1 Sensitivity NHLBI Licensing Licensing Reza Nezafat This invention relates to a novel magnetic resonance angiography (MRA) method that accomplishes uniform contrast enhancement between coronary arteries and the surrounding tissue across the entire imaging volume. The disclosed technique utilizes an adiabatic refocusing transverse relaxation time (T<sub>2</sub>)-preparation pulse sequence, in which the magnetization is tipped into the transverse plane with a hard radio-frequency (RF) pulse and refocused using a pair of adiabatic fast-passage RF pulses. The isochromats are subsequently returned to the longitudinal axis using a hard RF pulse. Simulations and in vivo images acquired with the T<sub>2</sub>-Prep sequence illustrate excellent suppression of artifacts originating from B<sub>1</sub> inhomogeneity while achieving contrast-to-noise (CNR) enhancement between coronary arteries and surrounding tissues. Furthermore, images acquired with the T<sub>2</sub>-Prep sequence show suppression of the banding artifacts and improvement of the visual sharpness of distal segments of the coronaries as compared to images acquired without the T<sub>2</sub>-Prep sequence. 2022-03-08 2024-10-28 2024-10-28 2006-04-01 AA3AXX, AAXXXX, AXXXXX False True True NIHTT 37470483 Website Abstract 114105418 Nezafat, Reza Nezafat, Reza 0 114105418 Nezafat, Reza Nezafat, Reza 0 114100557 Beta1-insensitive T2 Magnetization Preparation Of MR Imaging At High Field E-073-2005-0 Filing authorized Johns Hopkins University, National Heart, Lung, and Blood Institute (NHLBI) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-1324] A Novel MRI Adiabatic T<sub>2</sub> Preparation Sequence with Reduced B1 Sensitivity&body=Please send me information about technology [TAB-1324] A Novel MRI Adiabatic T<sub>2</sub> Preparation Sequence with Reduced B1 Sensitivity. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-1324] A Novel MRI Adiabatic T<sub>2</sub> Preparation Sequence with Reduced B1 Sensitivity&body=Please send me information about technology [TAB-1324] A Novel MRI Adiabatic T<sub>2</sub> Preparation Sequence with Reduced B1 Sensitivity.">shmilovm@nih.gov</a><br> 114163332 E-073-2005-0 E-073-2005-0-US-02 Adiabatic T2 Preparation Sequence for Magnetic Resonance Imaging with Reduced B1 Sensitivity ORD US 7,787,930 11/147,151 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7787930 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7787930">7,787,930</a><br />Filed on 2005-06-06<br />Status: Issued 114165424 E-073-2005-0 E-073-2005-0-US-01 Adiabatic T2 Preparation Sequence for Magnetic Resonance Imaging with Reduced B1 Sensitivity PRV US 60/679,949 Abandoned US <br />Provisional (PRV) 60/679,949<br />Filed on 2005-04-25<br />Status: Abandoned 114117025 AA3AXX 114117026 AAXXXX 114117027 AXXXXX TAB-1294 114095620 Rapid Anti-Depressant Response Produced by Low Dose Treatment with Anti-Muscarinic Drugs NIMH Licensing, Neurology, Therapeutics Licensing Neurology Therapeutics Wayne Drevets Available for licensing are new methods of rapidly treating depression. The drugs currently used to treat depression work by increasing the activity at serotonin, norepinephrine and perhaps dopamine receptors in the CNS. However these drugs are effective in only 60-70% of patients, require 3-4 weeks of treatment before clinical improvement and have many side effects. These inventors have shown that in human patients, the administration of anti-muscarinic agents produces a rapid, prolonged alleviation of depressive symptoms. Beginning the day following administration of the anti-muscarinic agent, a majority of patients show significant improvements in mood, anxiety, sleep and other depressive symptoms that last days or weeks. The very slow dissociation of some muscarinic agents from their receptors may account for the prolonged therapeutic effects. 2022-03-08 2024-10-28 2024-10-28 2006-02-01 NB2AXX, NB2DXX, NBXXXX, NXXXXX False True True NIHTT 37470483 Website Abstract 114105367 Drevets, Wayne Drevets, Wayne 1 114105367 Drevets, Wayne Drevets, Wayne 1 114100525 Scopolamine For The Treatment Of Depression And Anxiety E-175-2004-0 Filing authorized National Institute of Mental Health (NIMH) 83686256 Wong, Jennifer jennifer.wong2@nih.gov
United States of America jennifer.wong2@nih.gov?subject=Web Inquiry on [TAB-1294] Rapid Anti-Depressant Response Produced by Low Dose Treatment with Anti-Muscarinic Drugs&body=Please send me information about technology [TAB-1294] Rapid Anti-Depressant Response Produced by Low Dose Treatment with Anti-Muscarinic Drugs. Wong, Jennifer<br><a href="mailto:jennifer.wong2@nih.gov?subject=Web Inquiry on [TAB-1294] Rapid Anti-Depressant Response Produced by Low Dose Treatment with Anti-Muscarinic Drugs&body=Please send me information about technology [TAB-1294] Rapid Anti-Depressant Response Produced by Low Dose Treatment with Anti-Muscarinic Drugs.">jennifer.wong2@nih.gov</a><br> 114163243 E-175-2004-0 E-175-2004-0-US-01 Scopolamine For The Treatment Of Depression And Anxiety ORD US 8,859,585 11/137,114 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8859585 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8859585">8,859,585</a><br />Filed on 2005-05-25<br />Status: Issued 114163244 E-175-2004-0 E-175-2004-0-PCT-02 Scopolamine For The Treatment Of Depression And Anxiety PCT Patent Cooperation Treaty PCT/US2006/019335 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2006/019335<br />Filed on 2006-05-18<br />Status: Expired 114167943 E-175-2004-0 E-175-2004-0-US-10 Scopolamine For The Treatment Of Depression And Anxiety DIV US 9,707,220 14/478,442 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9707220 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9707220">9,707,220</a><br />Filed on 2014-09-05<br />Status: Expired 114116863 NB2AXX 114116864 NB2DXX 114116865 NBXXXX 114116866 NXXXXX TAB-129 114094469 Methods for Diagnoses and Treatment of XSCID NHLBI Diagnostics, Immunology, Licensing, Research Materials, Therapeutics Diagnostics Immunology Licensing Research Materials Therapeutics Warren Leonard, Wesley Mcbride, Masayuki Noguchi The invention provides a method of diagnosing X-linked severe combined immunodeficiency (XSCID) in males or determining whether females are carriers. This method is based upon the presence of either a mutated or truncated IL-2Rgamma gene. The invention also discloses a method of treating XSCID as well as a method for monitoring the therapy. Lastly, the invention provides a promoter which regulates the expression of IL-2Rgamma, a vector comprising a DNA molecule operably linked to the promoter, a cell host that has been transformed with the vector, and a transgenic mouse comprising the promoter or a mutant IL-2Rgamma. <ul> <li>Diagnostic test is only way of definitively diagnosing XSCID</li> <li>Process for diagnosis is completely developed</li> </ul> <ul> <li>Diagnosing XSCID</li> <li>Identifying a carrier</li> <li>Treating XSCID</li> <li>Monitoring effectiveness of therapy for XSCID</li> <li>Research reagent</li> </ul> 2022-03-08 2024-10-28 2024-10-28 1993-11-01 Hyper IgM syndrome, IA3XXX, IAXXXX, IB3XXX, IBXXXX, ICXXXX, Immunodeficiency 2, Immunodeficiency 4, Immunodeficiency-3, IXXXXX, Severe combined immunodeficiency, Severe combined immunodeficiency, x-linked, Wiskott Aldrich syndrome False True True NIHTT 37470483 Website Abstract 114169718 Leonard WJ. http://www.ncbi.nlm.nih.gov/pubmed/8795294 <a href="http://www.ncbi.nlm.nih.gov/pubmed/8795294">Leonard WJ.</a> 114169719 Leonard WJ. http://www.ncbi.nlm.nih.gov/pubmed/8712778 <a href="http://www.ncbi.nlm.nih.gov/pubmed/8712778">Leonard WJ.</a> 114169720 Qazilbash MH, et al. http://www.ncbi.nlm.nih.gov/pubmed/7633846 <a href="http://www.ncbi.nlm.nih.gov/pubmed/7633846">Qazilbash MH, et al.</a> 114169721 Leonard WJ, et al. http://www.ncbi.nlm.nih.gov/pubmed/8070818 <a href="http://www.ncbi.nlm.nih.gov/pubmed/8070818">Leonard WJ, et al.</a> 114169722 Noguchi M, et al. http://www.ncbi.nlm.nih.gov/pubmed/8462096 <a href="http://www.ncbi.nlm.nih.gov/pubmed/8462096">Noguchi M, et al.</a> 114103179 Leonard, Warren NHLBI Leonard, Warren (NHLBI) 0 114103180 Noguchi, Masayuki Noguchi, Masayuki 0 114103181 Mcbride, Wesley NCI Mcbride, Wesley (NCI) 0 114103179 Leonard, Warren NHLBI Leonard, Warren (NHLBI) 0 114103180 Noguchi, Masayuki Noguchi, Masayuki 0 114103181 Mcbride, Wesley NCI Mcbride, Wesley (NCI) 0 114099255 METHODS FOR DIAGNOSIS AND TREATMENT OF XSCID AND KITS THEREOF E-079-1993-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI), NCI 114099256 MURINE IL-2RY CDNA AND USES THEREOF E-079-1993-1 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-129] Methods for Diagnoses and Treatment of XSCID&body=Please send me information about technology [TAB-129] Methods for Diagnoses and Treatment of XSCID. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-129] Methods for Diagnoses and Treatment of XSCID&body=Please send me information about technology [TAB-129] Methods for Diagnoses and Treatment of XSCID.">shmilovm@nih.gov</a><br> 114160196 E-079-1993-0 E-079-1993-0-US-01 METHODS FOR DIAGNOSIS AND TREATMENT OF XSCID AND KITS THEREOF ORD US 5,518,880 08/031,143 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/5518880 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/5518880">5,518,880</a><br />Filed on 1993-03-12<br />Status: Expired 114160197 E-079-1993-1 E-079-1993-1-US-02 A TRANSGENIC MURINE MODEL FOR XSCID FWC US 5,912,173 08/424,224 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/5912173 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/5912173">5,912,173</a><br />Filed on 1995-04-19<br />Status: Expired 114168894 E-079-1993-1 E-079-1993-1-US-01 MURINE IL-2RY CDNA AND USES THEREOF CIP US 08/121,435 Abandoned US <br />Continuation in Part (CIP) 08/121,435<br />Filed on 1993-09-14<br />Status: Abandoned 114112133 IA3XXX 114112134 IB3XXX 114112135 IAXXXX 114112136 IBXXXX 114112137 ICXXXX 114112138 IXXXXX 114156091 Severe combined immunodeficiency 114156092 Severe combined immunodeficiency, x-linked 114156093 Hyper IgM syndrome 114156094 Wiskott Aldrich syndrome 114158126 Immunodeficiency 4 114158127 Immunodeficiency-3 114158128 Immunodeficiency 2 TAB-1270 114095596 The Use of an Inducible Plasmid Vector Encoding for Active TGF-beta for the Treatment of Autoimmune Diseases NIAID Diagnostics, Immunology, Licensing, Oncology, Research Materials, Therapeutics Diagnostics Immunology Licensing Oncology Research Materials Therapeutics Warren Strober This application describes a composition and method for treating inflammatory bowel disease or other autoimmune diseases. The composition utilizes a vector which contains a first promoter which controls the expression of a regulatory transcription factor and a second inducible promoter which controls the expression of the gene of interest. The preferred gene of interest encodes an isoform of TGF-beta such as TGF-beta<sub>1</sub> or TGF-beta<sub>3</sub>. The isoform of TGF-beta does not have to be hTGF-beta and can be a latent or active isoform of TGF-beta. The preferred inducible promoter is TRE-CMV which can be induced using doxycycline. The usefulness of the composition for treating autoimmune diseases is demonstrated in the application in a murine model of inflammatory bowel disease in which intestinal inflammation was abrogated by the administration of a plasmid vector encoding active TGF-beta. The composition may be administered by a variety of delivery systems and intranasal delivery is exemplified. 2022-03-08 2024-10-28 2024-10-28 2008-05-01 CB3AXX, CB3BXX, CB3XXX, CBXXXX, CXXXXX, GB2A1X, GB2A3X, GB2AXX, GB2BXX, GB2CXX, GB2XXX, GBXXXX, GXXXXX, IB3XXX, IBXXXX, Inflammatory bowel disease 1, IXXXXX False True True NIHTT 37470483 Website Abstract 114105336 Strober, Warren NIAID Strober, Warren (NIAID) 0 114105336 Strober, Warren NIAID Strober, Warren (NIAID) 0 114100506 INDUCIBLE PLASMID VECTOR ENCODING TGF-beta AND USES THEREOF E-096-2000-0 Filing authorized NIAID 83720410 Yang, David (Po-Lung) polung.yang@nih.gov
United States of America Technology Transfer and Intellectual Property Office polung.yang@nih.gov?subject=Web Inquiry on [TAB-1270] The Use of an Inducible Plasmid Vector Encoding for Active TGF-beta for the Treatment of Autoimmune Diseases&body=Please send me information about technology [TAB-1270] The Use of an Inducible Plasmid Vector Encoding for Active TGF-beta for the Treatment of Autoimmune Diseases. Yang, David (Po-Lung)<br><a href="mailto:polung.yang@nih.gov?subject=Web Inquiry on [TAB-1270] The Use of an Inducible Plasmid Vector Encoding for Active TGF-beta for the Treatment of Autoimmune Diseases&body=Please send me information about technology [TAB-1270] The Use of an Inducible Plasmid Vector Encoding for Active TGF-beta for the Treatment of Autoimmune Diseases.">polung.yang@nih.gov</a><br> 114163193 E-096-2000-0 E-096-2000-0-US-01 INDUCIBLE PLASMID VECTOR ENCODING TGF-beta AND USES THEREOF PRV US 60/199,014 Abandoned US <br />Provisional (PRV) 60/199,014<br />Filed on 2000-04-20<br />Status: Abandoned 114163194 E-096-2000-0 E-096-2000-0-PCT-02 INDUCIBLE PLASMID VECTOR ENCODING TGF-beta AND USES THEREOF PCT Patent Cooperation Treaty PCT/US01/12980 Abandoned Patent Cooperation Treaty <br />(PCT) PCT/US01/12980<br />Filed on 2001-04-20<br />Status: Abandoned 114163196 E-096-2000-0 E-096-2000-0-US-03 INDUCIBLE PLASMID VECTOR ENCODING TGF-beta AND USES THEREOF National Stage US 7,531,352 10/258,109 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7531352 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7531352">7,531,352</a><br />Filed on 2003-06-30<br />Status: Expired 114116733 GB2A1X 114116734 GB2A3X 114116735 CB3AXX 114116736 CB3BXX 114116737 GB2AXX 114116738 GB2BXX 114116739 GB2CXX 114116740 CB3XXX 114116741 GB2XXX 114116742 IB3XXX 114116743 CBXXXX 114116744 GBXXXX 114116745 IBXXXX 114116746 CXXXXX 114116747 GXXXXX 114116748 IXXXXX 114156060 Inflammatory bowel disease 1 TAB-1268 114095594 Monoclonal Antibodies That Bind or Neutralize Hepatitis B Virus NIAID Infectious Disease, Licensing, Research Materials, Therapeutics Infectious Disease Licensing Research Materials Therapeutics Suzanne Emerson, Robert Purcell Hepatitis B virus (HBV) chronically infects over 300 million people worldwide. Many of them will die of chronic hepatitis or hepatocellular carcinoma. The present technology relates to the isolation and characterization of a novel neutralizing chimpanzee monoclonal antibody to HBV. The antibody was identified through a combinatorial antibody library constructed from bone marrow cells of a chimpanzee experimentally infected with HBV. The selected monoclonal antibody has been shown to react equally well with wild-type HBV and the most common neutralization escape mutant variants. Therefore, this monoclonal antibody with high affinity and broad reactivity may have distinct advantages over other approaches to immunoprophylaxis and immunotherapy of chronic HBV infection, as most of the monoclonal antibodies currently in use are not sufficiently and broadly reactive to prevent the emergence of neutralization escape mutants of HBV. This technology describes such antibodies, fragments of such antibodies retaining hepatitis B virus-binding ability, fully human or humanized antibodies retaining hepatitis B virus-binding ability, and pharmaceutical compositions including such antibodies. This invention further describes isolated nucleic acids encoding the antibodies and host cells transformed with nucleic acids. In addition, this invention provides methods of employing these antibodies and nucleic acids in the in vitro and in vivo diagnosis, prevention and therapy of HBV diseases. 2022-03-08 2024-10-28 2024-10-28 2020-07-06 ANTIBODY, B, Chimpanzee, DB4BXX, DB4XXX, DBXXXX, DDXXXX, DXXXXX, Hepatitis, Hepatitis A, Hepatitis D, Hepatitis E, monoclonal, Neutralizes, That, virus False True True NIHTT 37470483 Website Abstract 114105333 Purcell, Robert NIAID - DIR NIAID Purcell, Robert (NIAID) 0 114105334 Emerson, Suzanne NIAID - DIR NIAID Emerson, Suzanne (NIAID) 0 114105333 Purcell, Robert NIAID - DIR NIAID Purcell, Robert (NIAID) 0 114105334 Emerson, Suzanne NIAID - DIR NIAID Emerson, Suzanne (NIAID) 0 114100505 A Chimpanzee Monoclonal Antibody That Neutralizes Hepatitis B Virus E-144-2004-0 Filing authorized NIAID, The Wellcome Trust Sanger Institute 83643855 Soukas, Peter peter.soukas@nih.gov
United States of America Technology Transfer and Intellectual Property Office peter.soukas@nih.gov?subject=Web Inquiry on [TAB-1268] Monoclonal Antibodies That Bind or Neutralize Hepatitis B Virus&body=Please send me information about technology [TAB-1268] Monoclonal Antibodies That Bind or Neutralize Hepatitis B Virus. Soukas, Peter<br><a href="mailto:peter.soukas@nih.gov?subject=Web Inquiry on [TAB-1268] Monoclonal Antibodies That Bind or Neutralize Hepatitis B Virus&body=Please send me information about technology [TAB-1268] Monoclonal Antibodies That Bind or Neutralize Hepatitis B Virus.">peter.soukas@nih.gov</a><br> 114163191 E-144-2004-0 E-144-2004-0-US-05 Monoclonal Antibodies That Bind or Neutralize Hepatitis B Virus National Stage US 11/795,255 Abandoned US <br />National Stage 11/795,255<br />Filed on 2007-07-13<br />Status: Abandoned 114163192 E-144-2004-0 E-144-2004-0-PCT-02 Monoclonal Antibodies that Bind or Neutralize Hepatitis B Virus PCT Patent Cooperation Treaty PCT/US2006/001336 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2006/001336<br />Filed on 2006-01-13<br />Status: Expired 114164668 E-144-2004-0 E-144-2004-0-US-01 Monoclonal Antibody That Neutralizes Hepatitis B Virus PRV US 60/644,309 Abandoned US <br />Provisional (PRV) 60/644,309<br />Filed on 2005-01-14<br />Status: Abandoned 114116727 DB4BXX 114116728 DDXXXX 114116729 DBXXXX 114116730 DXXXXX 114119356 DB4XXX 114133650 Chimpanzee 114133651 monoclonal 114133652 ANTIBODY 114133653 That 114133654 Neutralizes 114133655 Hepatitis 114133656 B 114133657 virus 114156057 Hepatitis D 114156058 Hepatitis A 114156059 Hepatitis E TAB-1233 114095559 AAV5 Vector and Uses Thereof NHLBI Collaboration, Licensing, Therapeutics Collaboration Licensing Therapeutics John (Jay) Chiorini, Robert Kotin The invention described and claimed in this patent application provides for novel vectors and viral particles which comprise adeno-associated virus serotype 5 (AAV5). AAV5 is a single-stranded DNA virus of either plus or minus polarity which, like other AAV serotypes (e.g., AAV4, AAV2) requires a helper virus for replication. AAV type 2 has the interesting and potentially useful ability to integrate into human chromosome 19 q 13.3-q ter. This activity is dependent on the non-structural, Rep, proteins of AAV2. The Rep proteins of AAV types 2 and 5 are dissimilar and are not able to substitute in DNA replication of the heterologous serotype. AAV5 offers several advantages which make it attractive for use in gene therapy: 1. increased production (10-50 fold greater than AAV2); 2. distinct integration locus when compared to AAV2; 3. Rep protein and ITR regions do not complement other AAV serotypes; and 4. appears to utilize different cell surface attachment molecules than those of AAV type 2. In addition to licensing, the technology may be available for further development through collaborative research opportunities with the inventors. 2022-03-08 2024-10-28 2024-10-28 2005-10-01 AAV, AAV5, control seq, Duke DNA Project, GB2A1X, GB2A2X, GB2AXX, GB2XXX, GBXXXX, GENE THERAPY, GXXXXX, Listed LPM Reichman as of 4/15/2015, Patent Category - Biotechnology, PCT/US99/11958; WO 99/61601 (12/02/99), Post LPM Assignment Set 20150420, Pre LPM working set 20150418, SACGHS DNA Patent Initial Set, viral vector False True True NIHTT 37470483 Website Abstract E-072-2000-0 114172471 Chiorini JA, et al. https://www.ncbi.nlm.nih.gov/pubmed/10196327 <a href="https://www.ncbi.nlm.nih.gov/pubmed/10196327">Chiorini JA, et al.</a> 114172472 Chiorini JA, et al. https://www.ncbi.nlm.nih.gov/pubmed/9882336 <a href="https://www.ncbi.nlm.nih.gov/pubmed/9882336">Chiorini JA, et al.</a> 114105179 Kotin, Robert National Heart, Lung, and Blood Institute (NHLBI) Kotin, Robert 0 114105180 Chiorini, John (Jay) National Heart, Lung, and Blood Institute (NHLBI) NIDCR Chiorini, John (Jay) (NIDCR) 1 114105180 Chiorini, John (Jay) National Heart, Lung, and Blood Institute (NHLBI) NIDCR Chiorini, John (Jay) (NIDCR) 1 114105179 Kotin, Robert National Heart, Lung, and Blood Institute (NHLBI) Kotin, Robert 0 114100397 AAV5 AND USES THEREOF E-127-1998-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 83714317 Devany, John john.devany@nih.gov
United States of America Office of Technology Transfer and Development john.devany@nih.gov?subject=Web Inquiry on [TAB-1233] AAV5 Vector and Uses Thereof&body=Please send me information about technology [TAB-1233] AAV5 Vector and Uses Thereof. Devany, John<br><a href="mailto:john.devany@nih.gov?subject=Web Inquiry on [TAB-1233] AAV5 Vector and Uses Thereof&body=Please send me information about technology [TAB-1233] AAV5 Vector and Uses Thereof.">john.devany@nih.gov</a><br> 114161732 E-127-1998-0 E-127-1998-0-US-08 AAV5 NUCLEIC ACIDS DIV US 7,479,554 11/184,380 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7479554 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7479554">7,479,554</a><br />Filed on 2005-07-19<br />Status: Expired 114162927 E-127-1998-0 E-127-1998-0-US-07 AAV5 and Uses Thereof National Stage US 6,984,517 09/717,789 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6984517 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6984517">6,984,517</a><br />Filed on 2000-11-21<br />Status: Expired 114162928 E-127-1998-0 E-127-1998-0-PCT-02 AAV5 VECTOR AND USES THEREOF PCT Patent Cooperation Treaty PCT/US1999/011958 Expired Patent Cooperation Treaty <br />(PCT) PCT/US1999/011958<br />Filed on 1999-05-28<br />Status: Expired 114165539 E-127-1998-0 E-127-1998-0-US-01 AAV5 AND USES THEREOF PRV US 60/087,029 Abandoned US <br />Provisional (PRV) 60/087,029<br />Filed on 1998-05-28<br />Status: Abandoned 114116592 GB2A1X 114116593 GB2A2X 114116594 GB2AXX 114116595 GB2XXX 114116596 GBXXXX 114116597 GXXXXX 114131977 PCT/US99/11958; WO 99/61601 (12/02/99) 114131978 GENE THERAPY 114131979 viral vector 114131980 control seq 114131981 AAV5 114131982 AAV 114131983 Duke DNA Project 114150601 SACGHS DNA Patent Initial Set 114150602 Patent Category - Biotechnology 114150603 Listed LPM Reichman as of 4/15/2015 114150604 Pre LPM working set 20150418 114150605 Post LPM Assignment Set 20150420 TAB-1232 114095558 Methods and Materials for Identifying Polymorphic Variants, Diagnosing Susceptibilities, and Treating Disease NHGRI Collaboration, Diagnostics, Licensing, Materials Available, Research Materials, Therapeutics Collaboration Diagnostics Licensing Materials Available Research Materials Therapeutics Lawrence Brody This invention relates to materials and methods associated with polymorphic variants in two enzymes involved in folate-dependent and one-carbon metabolic pathways important in pregnancy-related complications and neural tube birth defects: MTHFD1 (5,10-methylenetrahydrofolate dehydrogenase, 5,10-methenyltetrahydrofolate cyclohydrolase, 10-formyltetrahydrofolate synthase) and methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1-like (MTHFD1L). These enzymes are extremely important in the promotion of DNA synthesis, a process that is critical for normal placental and fetal development. <br><br> Recently, the inventors have discovered that a MTHFD1 polymorphism is also a maternal genetic risk factor for placental abruption, premature separation of a normally implanted placenta. This polymorphism may also be a risk factor for first and second trimester miscarriages. Diagnostic and therapeutic methods are provided in this invention involving the correlation of polymorphic variants in MTHFD1 and MTHFD1L and other genes with relative susceptibility for various pregnancy-related and other complications such as cancer, cardiovascular disease, developmental anomalies and psychiatric illnesses. Both nutrient status and genetic background are independent yet interacting risk factors for impaired folate metabolism. However, the mechanisms that lead to pathology or the mechanisms whereby folate prevents these disorders are unknown. Therefore, a diagnostic and therapeutic invention of this kind would significantly improve the detection and treatment of disorders associated with folate metabolism. The National Human Genome Research Institute is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. Please contact Claire Driscoll at 301-402-2537 or <a href="mailto:cdriscol@mail.nih.gov">cdriscol@mail.nih.gov</a> for more information. Available for licensing. 2022-03-08 2024-10-28 2024-10-28 2007-07-01 IAXXXX, IBXXXX, IXXXXX False True True NIHTT 37470483 Website Abstract 114170095 A Parle-McDermott et al. MTHFD1 R653Q polymorphism is a maternal genetic risk factor for severe abruptio placentae. Am J Med Genet A. 2005 Feb 1;132(4):365-368. http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=15633187&ordinalpos=9&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum <a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=15633187&ordinalpos=9&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum">A Parle-McDermott et al. MTHFD1 R653Q polymorphism is a maternal genetic risk factor for severe abruptio placentae. Am J Med Genet A. 2005 Feb 1;132(4):365-368.</a> 114170096 A Parle-McDermott et al. A polymorphism in the MTHFD1 gene increases a mother’s risk of having an unexplained second trimester pregnancy loss. Mol Hum Reprod. 2005 Jul;11(7):477-480. http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=16123074&ordinalpos=6&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum <a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=16123074&ordinalpos=6&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum">A Parle-McDermott et al. A polymorphism in the MTHFD1 gene increases a mother’s risk of having an unexplained second trimester pregnancy loss. Mol Hum Reprod. 2005 Jul;11(7):477-480.</a> 114170097 A Parle-McDermott et al. Confirmation of the R653Q polymorphism of the trifunctional C1-synthase enzyme as a maternal risk for neural tube defects in the Irish population. Eur J Hum Genet. 2006 Jun;14(6):768-772. http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=16552426&ordinalpos=3&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum <a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=16552426&ordinalpos=3&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum">A Parle-McDermott et al. Confirmation of the R653Q polymorphism of the trifunctional C1-synthase enzyme as a maternal risk for neural tube defects in the Irish population. Eur J Hum Genet. 2006 Jun;14(6):768-772.</a> 114170098 B Kempisty et al. MTHFD 1958G>A and MTR 2756A>G polymorphisms are associated with bipolar disorder and schizophrenia. Psychiatr Genet. 2007 Jun;17(3):177-181. http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=17417062&ordinalpos=2&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum <a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=17417062&ordinalpos=2&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum">B Kempisty et al. MTHFD 1958G>A and MTR 2756A>G polymorphisms are associated with bipolar disorder and schizophrenia. Psychiatr Genet. 2007 Jun;17(3):177-181.</a> 114105265 Brody, Lawrence NHGRI Brody, Lawrence (NHGRI) 0 114105265 Brody, Lawrence NHGRI Brody, Lawrence (NHGRI) 0 114100467 Use Of Genetic Polymorphisms To Assess Risk Of Pregnancy Complications, Miscarriage And Of Bearing Children With Birth Defects E-149-2005-0 Filing authorized Health Research Board, National Human Genome Research Institute (NHGRI), NICHD, Trinity College Dublin 83716782 Campbell, Eggerton eggerton.campbell@nih.gov
United States of America eggerton.campbell@nih.gov?subject=Web Inquiry on [TAB-1232] Methods and Materials for Identifying Polymorphic Variants, Diagnosing Susceptibilities, and Treating Disease&body=Please send me information about technology [TAB-1232] Methods and Materials for Identifying Polymorphic Variants, Diagnosing Susceptibilities, and Treating Disease. Campbell, Eggerton<br><a href="mailto:eggerton.campbell@nih.gov?subject=Web Inquiry on [TAB-1232] Methods and Materials for Identifying Polymorphic Variants, Diagnosing Susceptibilities, and Treating Disease&body=Please send me information about technology [TAB-1232] Methods and Materials for Identifying Polymorphic Variants, Diagnosing Susceptibilities, and Treating Disease.">eggerton.campbell@nih.gov</a><br> 114163096 E-149-2005-0 E-149-2005-0-PCT-01 Methods and Materials for Identifying Polymorphic Variants, Diagnosing Susceptibilities, and Treating Disease PCT Patent Cooperation Treaty PCT/US2005/021288 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2005/021288<br />Filed on 2005-06-16<br />Status: Expired 114164052 E-149-2005-0 E-149-2005-0-US-02 Methods And Materials For Identifying Polymorphic Variants, Diagnosing Susceptibilities, And Treating Disease National Stage US 7,879,551 11/958,126 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7879551 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7879551">7,879,551</a><br />Filed on 2007-12-17<br />Status: Abandoned 114166294 E-149-2005-0 E-149-2005-0-US-03 Methods And Materials For Identifying Polymorphic Variants, Diagnosing Susceptibilities, And Treating Disease DIV US 13/008,528 Abandoned US <br />Divisional (DIV) 13/008,528<br />Filed on 2011-01-18<br />Status: Abandoned 114116589 IAXXXX 114116590 IBXXXX 114116591 IXXXXX TAB-1204 114095530 Amelioration of Inflammatory Arthritis Targeting the Pre-ligand Assembly Domain (PLAD) of Tumor Necrosis Factor Receptors NIAID Licensing, Oncology, Research Materials, Therapeutics Licensing Oncology Research Materials Therapeutics Francis Chan, Michael Lenardo, Richard Siegel The invention relates to compositions of matter and methods for treating arthritis by modulating Tumor Necrosis Factor Alpha (TNF-alpha) signaling. TNF-alpha plays a key role in the pathogenesis of numerous diseases including rheumatoid and septic arthritis, and other autoimmune and inflammatory diseases. TNF-alpha mediates its effects through receptors that contain a Pre-ligand Assembly Domain (PLAD). The inventors have discovered compounds that interfere with PLAD can block the effects of TNF-alpha in vitro. Treatment of mice with these compounds in vivo ameliorated disease in several models of arthritis. Therefore, the compositions and methods of the current invention may lead to novel arthritis treatments. 2022-03-08 2024-10-28 2024-10-28 2005-09-01 ASSEMBLY, BCXXXX, CB3AXX, CBXXXX, CC1XXX, CCXXXX, CXXXXX, Domain, factor, FAMILY, FUNCTION., Identification, Listed LPM Hastings as of 4/15/2015, Mediates, NECROSIS, Novel, Patent Category - Biotechnology, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, PRE-LIGAND, RECEPTOR, SACGHS DNA Patent Initial Set, That, tumor False True True 52398218 Pre-Clinical (in vivo) 52398218 NIHTT 37470483 Website Abstract 114105224 Lenardo, Michael NIAID Lenardo, Michael (NIAID) 0 114109116 Chan, Francis NIAID - DIR NIAID Chan, Francis (NIAID) 0 114109117 Siegel, Richard NIAID - DIR NIAMS Siegel, Richard (NIAMS) 0 114105224 Lenardo, Michael NIAID Lenardo, Michael (NIAID) 0 114109116 Chan, Francis NIAID - DIR NIAID Chan, Francis (NIAID) 0 114109117 Siegel, Richard NIAID - DIR NIAMS Siegel, Richard (NIAMS) 0 114100170 IDENTIFICATION OF A NOVEL DOMAIN IN THE TUMOR NECROSIS FACTOR RECEPTOR FAMILY THAT MEDIATES PRE-LIGAND RECEPTOR ASSEMBLY AND FUNCTION. E-095-2000-0 NIAID 91017752 Prabhu, Yogikala yogikala.prabhu@nih.gov
United States of America yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-1204] Amelioration of Inflammatory Arthritis Targeting the Pre-ligand Assembly Domain (PLAD) of Tumor Necrosis Factor Receptors&body=Please send me information about technology [TAB-1204] Amelioration of Inflammatory Arthritis Targeting the Pre-ligand Assembly Domain (PLAD) of Tumor Necrosis Factor Receptors. Prabhu, Yogikala<br><a href="mailto:yogikala.prabhu@nih.gov?subject=Web Inquiry on [TAB-1204] Amelioration of Inflammatory Arthritis Targeting the Pre-ligand Assembly Domain (PLAD) of Tumor Necrosis Factor Receptors&body=Please send me information about technology [TAB-1204] Amelioration of Inflammatory Arthritis Targeting the Pre-ligand Assembly Domain (PLAD) of Tumor Necrosis Factor Receptors.">yogikala.prabhu@nih.gov</a><br> 114161408 E-095-2000-0 E-095-2000-0-US-08 INHIBITORS OF PRE-LIGAND ASSEMBLY DOMAIN AND FUNCTION OF THE TUMOR NECROSIS FACTOR RECEPTOR FAMILY DIV US 9,051,392 11/637,272 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9051392 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9051392">9,051,392</a><br />Filed on 2006-12-12<br />Status: Expired 114161409 E-095-2000-0 E-095-2000-0-US-03 IDENTIFICATION OF A NOVEL DOMAIN IN THE TUMOR NECROSIS FACTOR RECEPTOR FAMILY THAT MEDIATES PRE-LIGAND RECEPTOR ASSEMBLY AND FUNCTION. National Stage US 7,148,061 10/203,495 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7148061 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7148061">7,148,061</a><br />Filed on 2002-08-09<br />Status: Expired 114163534 E-095-2000-0 E-095-2000-0-PCT-02 IDENTIFICATION OF A NOVEL DOMAIN IN THE TUMOR NECROSIS FACTOR RECEPTOR FAMILY THAT MEDIATES PRE-LIGAND RECEPTOR ASSEMBLY AND FUNCTION. PCT Patent Cooperation Treaty PCT/US01/04125 Expired Patent Cooperation Treaty <br />(PCT) PCT/US01/04125<br />Filed on 2001-02-09<br />Status: Expired 114165959 E-095-2000-0 E-095-2000-0-US-01 IDENTIFICATION OF A NOVEL DOMAIN IN THE TUMOR NECROSIS FACTOR RECEPTOR FAMILY THAT MEDIATES PRE-LIGAND RECEPTOR ASSEMBLY AND FUNCTION. PRV US 60/181,909 Abandoned US <br />Provisional (PRV) 60/181,909<br />Filed on 2000-02-11<br />Status: Abandoned 114112363 CC1XXX 114116474 CB3AXX 114116475 CBXXXX 114116476 CCXXXX 114116477 CXXXXX 114120858 BCXXXX 114138653 Identification 114138654 Novel 114138655 Domain 114138656 tumor 114138657 NECROSIS 114138658 factor 114138659 RECEPTOR 114138660 FAMILY 114138661 That 114138662 Mediates 114138663 PRE-LIGAND 114138664 ASSEMBLY 114138665 FUNCTION. 114138666 SACGHS DNA Patent Initial Set 114138667 Patent Category - Biotechnology 114138668 Listed LPM Hastings as of 4/15/2015 114138669 Pre LPM working set 20150418 114138670 Post LPM Assignment Set 20150420 TAB-1181 114095507 Anti-Plasmodium Compositions and Methods of Use NIAID Diagnostics, Infectious Disease, Licensing, Therapeutics, Vaccines Diagnostics Infectious Disease Licensing Therapeutics Vaccines David Narum This invention describes methods and compositions of peptides that inhibit the binding of <i>Plasmodium falciparum</i> (<i>P. falciparum</i>) to erythrocytes. Malarial parasites enter the red blood cell through several erythrocyte receptors, each being specific for a given species of <i>Plasmodia</i>. For <i>P. falciparum</i>, the erythrocyte binding antigen (EBA-175) is the ligand of the plasmodia merozoites that interacts with the receptor glycophorin A on the surface of red blood cells. Inhibiting this ligand/receptor interaction is one method of preventing further malarial attacks and is an active area of vaccine research. <p>This invention describes another specific peptide and antibodies that inhibit this ligand/receptor binding, thus is a potential source for vaccine development. The peptide described herein is a paralogue of EBA-175, identified as EBP2. Further, the invention includes antibodies and peptides that are specific for the claimed paralogue. Claims include the development of vaccines to the EBA-175 and EBP2. In addition, these antibodies and peptides can be developed as diagnostic and analytical reagents as well. Methods include the use of the peptides and the antibodies for the diagnosis, prevention and potential treatment of malaria. Further claims include their use in detection of <i>P. falciparum</i> in biological samples and culture methods.</p> 2022-03-08 2024-10-28 2024-10-28 2004-10-01 DA2XXX, DAXXXX, DB2XXX, DBXXXX, DC2XXX, DCXXXX, DXXXXX, Malaria, Malaria (Plasmodium sp.) False True True NIHTT 37470483 Website Abstract 114105191 Narum, David NIAID Narum, David (NIAID) 0 114105191 Narum, David NIAID Narum, David (NIAID) 0 114100404 Anti-Plasmodium Compostions And Methods Of Use E-049-2004-0 Filing authorized EntreMed, Inc. 83720410 Yang, David (Po-Lung) polung.yang@nih.gov
United States of America Technology Transfer and Intellectual Property Office polung.yang@nih.gov?subject=Web Inquiry on [TAB-1181] Anti-Plasmodium Compositions and Methods of Use&body=Please send me information about technology [TAB-1181] Anti-Plasmodium Compositions and Methods of Use. Yang, David (Po-Lung)<br><a href="mailto:polung.yang@nih.gov?subject=Web Inquiry on [TAB-1181] Anti-Plasmodium Compositions and Methods of Use&body=Please send me information about technology [TAB-1181] Anti-Plasmodium Compositions and Methods of Use.">polung.yang@nih.gov</a><br> 114161914 E-049-2004-0 E-049-2004-0-PCT-03 Anti-Plasmodium Compostions And Methods Of Use PCT Patent Cooperation Treaty PCT/US2001/024725 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2001/024725<br />Filed on 2001-08-07<br />Status: Expired 114162945 E-049-2004-0 E-049-2004-0-US-02 Anti-Plasmodium Compostions And Methods Of Use ORD US 09/924,154 Abandoned US <br />Ordinary Patent (ORD) 09/924,154<br />Filed on 2001-08-07<br />Status: Abandoned 114162946 E-049-2004-0 E-049-2004-0-US-04 Anti-Plasmodium Compostions and Methods Of Use CON US 7,303,751 10/630,629 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7303751 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7303751">7,303,751</a><br />Filed on 2003-07-29<br />Status: Expired 114164403 E-049-2004-0 E-049-2004-0-US-01 Anti-Plasmodium Compostions And Methods Of Use PRV US 60/223,525 Abandoned US <br />Provisional (PRV) 60/223,525<br />Filed on 2000-08-07<br />Status: Abandoned 114116396 DA2XXX 114116397 DB2XXX 114116398 DC2XXX 114116399 DAXXXX 114116400 DBXXXX 114116401 DCXXXX 114116402 DXXXXX 114155942 Malaria 114157940 Malaria (Plasmodium sp.) TAB-1175 114095501 AAV5 Vector for Transducing Brain Cells and Lung Cells NHLBI Diagnostics, Licensing, Neurology, Oncology, Pulmonology, Research Materials, Therapeutics Diagnostics Licensing Neurology Oncology Pulmonology Research Materials Therapeutics John (Jay) Chiorini, Beverly Davidson, Robert Kotin, Joseph Zabner The invention described and claimed in this patent application is related to the delivery of heterologous nucleic acids or genes to particular target cells. In particular, the application relates to methods of delivering a heterologous nucleic acid or gene of interest to particular target cells using an Adeno-Associated Virus of serotype 5 (AAV5). The particular target cells identified include the alveolar cells of the lung and cerebellar and ependymal cells of the brain. The methods described herein may be useful in carrying out gene therapy related to diseases of the brain or central nervous system and the respiratory tract. 2022-03-08 2024-10-28 2024-10-28 2004-12-01 AAV, AAV5, brain, CB2AXX, CBXXXX, CXXXXX, GB2A2X, GB2XXX, GENE THERAPY, IB4XXX, IBXXXX, IXXXXX, Listed LPM Reichman as of 4/15/2015, LUNG, NB1XXX, NBXXXX, NXXXXX, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, SACGHS DNA Patent Initial Set, USES, Vector, viral vector False True True NIHTT 37470483 Website Abstract E-127-1998-0 114172469 Davidson BL, et al. https://www.ncbi.nlm.nih.gov/pubmed/10688913 <a href="https://www.ncbi.nlm.nih.gov/pubmed/10688913">Davidson BL, et al.</a> 114172470 Zabner J, et al. https://www.ncbi.nlm.nih.gov/pubmed/10729159 <a href="https://www.ncbi.nlm.nih.gov/pubmed/10729159">Zabner J, et al.</a> 114105176 Davidson, Beverly Davidson, Beverly 0 114109669 Kotin, Robert National Heart, Lung, and Blood Institute (NHLBI) Kotin, Robert 0 114109670 Zabner, Joseph University of Iowa College of Medicine Zabner, Joseph 0 114105177 Chiorini, John (Jay) NIDCR NIDCR Chiorini, John (Jay) (NIDCR) 1 114105177 Chiorini, John (Jay) NIDCR NIDCR Chiorini, John (Jay) (NIDCR) 1 114105176 Davidson, Beverly Davidson, Beverly 0 114109669 Kotin, Robert National Heart, Lung, and Blood Institute (NHLBI) Kotin, Robert 0 114109670 Zabner, Joseph University of Iowa College of Medicine Zabner, Joseph 0 114100396 AAV5 Vector For Transducing Brain Cells and Lung Cells E-072-2000-0 Filing authorized EM, National Heart, Lung, and Blood Institute (NHLBI), NIDCR 83714317 Devany, John john.devany@nih.gov
United States of America Office of Technology Transfer and Development john.devany@nih.gov?subject=Web Inquiry on [TAB-1175] AAV5 Vector for Transducing Brain Cells and Lung Cells&body=Please send me information about technology [TAB-1175] AAV5 Vector for Transducing Brain Cells and Lung Cells. Devany, John<br><a href="mailto:john.devany@nih.gov?subject=Web Inquiry on [TAB-1175] AAV5 Vector for Transducing Brain Cells and Lung Cells&body=Please send me information about technology [TAB-1175] AAV5 Vector for Transducing Brain Cells and Lung Cells.">john.devany@nih.gov</a><br> 114162925 E-072-2000-0 E-072-2000-0-PCT-02 AAV5 Vector For Transducing Brain Cells and Lung Cells PCT Patent Cooperation Treaty PCT/US2001/009123 Abandoned Patent Cooperation Treaty <br />(PCT) PCT/US2001/009123<br />Filed on 2001-03-22<br />Status: Abandoned 114162926 E-072-2000-0 E-072-2000-0-US-01 AAV5 Vector for Transducing Brain Cells and Lung Cells ORD US 6,855,314 09/533,427 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6855314 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6855314">6,855,314</a><br />Filed on 2000-03-22<br />Status: Expired 114116371 CB2AXX 114116372 CBXXXX 114116373 NBXXXX 114116374 IBXXXX 114116375 CXXXXX 114116376 NXXXXX 114116377 IXXXXX 114127844 GB2A2X 114127845 GB2XXX 114127846 NB1XXX 114127847 IB4XXX 114150589 AAV5 114150590 Vector 114150591 viral vector 114150592 brain 114150593 AAV 114150594 LUNG 114150595 GENE THERAPY 114150596 USES 114150597 SACGHS DNA Patent Initial Set 114150598 Listed LPM Reichman as of 4/15/2015 114150599 Pre LPM working set 20150418 114150600 Post LPM Assignment Set 20150420 TAB-1176 114095502 TTP as a Regulator of GM-CSF mRNA Deadenylation and Stability NIEHS Diagnostics, Licensing, Materials Available, Rare/Neglected Diseases, Reproductive Health, Research Materials, Therapeutics, Vaccines Diagnostics Licensing Materials Available Rare/Neglected Diseases Reproductive Health Research Materials Therapeutics Vaccines Perry Blackshear, Ester Carballo, Wi Lai The disclosed invention provides materials and methods to treat granulocytopenia (low white cell count in the blood) which is characterized by a reduced number of granulocytes (relative) or an absence of granulocytes (absolute). This condition is commonly associated with cancer chemotherapy, but is seen less frequently in a number of conditions including the use of propylthiouracil, radiotherapy for marrow ablation for bone marrow transplantation, aplastic anemia, systemic lupus erythematosus, AIDS and a variety of other situations. The invention proposes a method to increase GM-CSF levels in a treated subject, and this increase is achieved by inhibiting the degradation of GM-CSF messenger RNA (mRNA). Tristetraprolin (TTP) is one member of a family of cys-cys-cys-his (CCCH) zinc finger proteins, and it is a factor that binds to and causes the instability of GM-CSF mRNA. Methods are provided for the development of screening assays for molecules that inhibit the binding of TTP and its related proteins to GM-CSF mRNA, or otherwise inhibit the effect of TTP to promote breakdown of the mRNA, leading in turn to increased mRNA stability and enhanced production of GM-CSF. Compounds identified by such screens, and their derivatives, could be useful in treating granulocytopenia from whatever cause. 2022-03-08 2024-10-28 2024-10-28 2004-12-01 Aplastic anemia, Deadenylation, Duke DNA Project, GM-CSF, Granulocytopenia, IB6XXX, IBXXXX, IXXXXX, REGULATOR, STABILITY, Systemic lupus erythematosus, TTP, UA1XXX False True True NIHTT 37470483 Website Abstract 114170077 Carballo E, Lai WS, Blackshear PJ. Evidence that tristetraprolin (TTP) is a physiological regulator of granulocyte-macrophage colony-stimulating factor (GM-CSF) mRNA deadenylation and stability. Blood 2000 Mar 15;95(6):1891-1899. http://www.ncbi.nlm.nih.gov/pubmed/10706852?dopt <a href="http://www.ncbi.nlm.nih.gov/pubmed/10706852?dopt">Carballo E, Lai WS, Blackshear PJ. Evidence that tristetraprolin (TTP) is a physiological regulator of granulocyte-macrophage colony-stimulating factor (GM-CSF) mRNA deadenylation and stability. Blood 2000 Mar 15;95(6):1891-1899.</a> 114170078 Lai WS, Carballo E, Thorn JM, Kennington EA, Blackshear PJ. Interactions of CCCH zinc finger proteins with mRNA. Binding of tristetraprolin-related zinc finger proteins to Au-rich elements and destabilization of mRNA. J Biol Chem. 2000 Jun 9;275(23):17827-17837. http://www.ncbi.nlm.nih.gov/pubmed/10751406?dopt <a href="http://www.ncbi.nlm.nih.gov/pubmed/10751406?dopt">Lai WS, Carballo E, Thorn JM, Kennington EA, Blackshear PJ. Interactions of CCCH zinc finger proteins with mRNA. Binding of tristetraprolin-related zinc finger proteins to Au-rich elements and destabilization of mRNA. J Biol Chem. 2000 Jun 9;275(23):17827-17837.</a> 114105181 Lai, Wi NIEHS NIEHS Lai, Wi (NIEHS) 0 114106259 Blackshear, Perry NIEHS NIEHS Blackshear, Perry (NIEHS) 0 114105182 Carballo, Ester NIEHS Carballo, Ester 1 114105182 Carballo, Ester NIEHS Carballo, Ester 1 114105181 Lai, Wi NIEHS NIEHS Lai, Wi (NIEHS) 0 114106259 Blackshear, Perry NIEHS NIEHS Blackshear, Perry (NIEHS) 0 114100398 TTP as a Regulator of GM-CSF Deadenylation and Stability E-204-1999-0 Filing authorized NIEHS 83739538 Choudhry, Vidita vidita.choudhry@nih.gov
United States of America Office of Technology Transfer and Development vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-1176] TTP as a Regulator of GM-CSF mRNA Deadenylation and Stability&body=Please send me information about technology [TAB-1176] TTP as a Regulator of GM-CSF mRNA Deadenylation and Stability. Choudhry, Vidita<br><a href="mailto:vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-1176] TTP as a Regulator of GM-CSF mRNA Deadenylation and Stability&body=Please send me information about technology [TAB-1176] TTP as a Regulator of GM-CSF mRNA Deadenylation and Stability.">vidita.choudhry@nih.gov</a><br> 114161841 E-204-1999-0 E-204-1999-0-PCT-02 TTP -Related Zinc Finger Domains And Methods Of Use PCT Patent Cooperation Treaty PCT/US00/22199 Expired Patent Cooperation Treaty <br />(PCT) PCT/US00/22199<br />Filed on 2000-08-14<br />Status: Expired 114162932 E-204-1999-0 E-204-1999-0-US-03 Ttp-Related Zinc Finger Domains and Methods of Use National Stage US 7,238,473 10/049,586 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7238473 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7238473">7,238,473</a><br />Filed on 2002-02-12<br />Status: Expired 114164674 E-204-1999-0 E-204-1999-0-US-01 TTP as a Regulator of GM-CSF Deadenylation and Stability PRV US 60/148,810 Abandoned US <br />Provisional (PRV) 60/148,810<br />Filed on 1999-08-13<br />Status: Abandoned 114116378 IB6XXX 114116379 IBXXXX 114116380 IXXXXX 114119133 UA1XXX 114132286 TTP 114132287 REGULATOR 114132288 GM-CSF 114132289 Deadenylation 114132290 STABILITY 114132291 Duke DNA Project 114155938 Systemic lupus erythematosus 114155939 Aplastic anemia 114155940 Granulocytopenia TAB-1174 114095500 AAV4 Vector and Uses Thereof NHLBI Licensing, Neurology, Oncology, Therapeutics Licensing Neurology Oncology Therapeutics John (Jay) Chiorini, Beverly Davidson, Robert Kotin, Brian Safer The invention described and claimed in this patent application relates to the delivery of heterologous nucleic acids or genes to particular target cells. In particular, the application relates to methods of delivering a heterologous nucleic acid or gene of interest to particular target cells using Adeno-Associated Virus of serotype 4 (AAV4). The particular target cells identified are the ependymal cells of the brain. The methods described herein may be useful in carrying out gene therapy for diseases of the brain or central nervous system. 2022-03-08 2024-10-28 2024-10-28 2004-12-01 AAV, AAV4, brain, CB2AXX, CBXXXX, CXXXXX, ependymal cells, GB2A2X, GB2XXX, GENE THERAPY, Listed LPM Reichman as of 4/15/2015, NB1XXX, NBXXXX, NXXXXX, Patent Category - Biotechnology, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, SACGHS DNA Patent Initial Set, USES, viral vector False True True NIHTT 37470483 Website Abstract E-066-1996-0 114171968 Davidson BL, et al. https://www.ncbi.nlm.nih.gov/pubmed/10688913 <a href="https://www.ncbi.nlm.nih.gov/pubmed/10688913">Davidson BL, et al.</a> 114104384 Kotin, Robert National Heart, Lung, and Blood Institute (NHLBI) Kotin, Robert 0 114105178 Safer, Brian NHLBI Safer, Brian (NHLBI) 0 114109667 Davidson, Beverly Davidson, Beverly 0 114109668 Chiorini, John (Jay) NIDCR NIDCR Chiorini, John (Jay) (NIDCR) 1 114109668 Chiorini, John (Jay) NIDCR NIDCR Chiorini, John (Jay) (NIDCR) 1 114104384 Kotin, Robert National Heart, Lung, and Blood Institute (NHLBI) Kotin, Robert 0 114105178 Safer, Brian NHLBI Safer, Brian (NHLBI) 0 114109667 Davidson, Beverly Davidson, Beverly 0 114099865 AAV4 VECTOR AND USES THEREOF E-071-2000-0 Filing authorized EM, National Heart, Lung, and Blood Institute (NHLBI), NIDCR 83714317 Devany, John john.devany@nih.gov
United States of America Office of Technology Transfer and Development john.devany@nih.gov?subject=Web Inquiry on [TAB-1174] AAV4 Vector and Uses Thereof&body=Please send me information about technology [TAB-1174] AAV4 Vector and Uses Thereof. Devany, John<br><a href="mailto:john.devany@nih.gov?subject=Web Inquiry on [TAB-1174] AAV4 Vector and Uses Thereof&body=Please send me information about technology [TAB-1174] AAV4 Vector and Uses Thereof.">john.devany@nih.gov</a><br> 114161733 E-071-2000-0 E-071-2000-0-US-01 AAV4 VECTOR AND USES THEREOF ORD US 6,468,524 09/532,594 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6468524 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6468524">6,468,524</a><br />Filed on 2000-03-22<br />Status: Expired 114116366 CB2AXX 114116367 CBXXXX 114116368 NBXXXX 114116369 CXXXXX 114116370 NXXXXX 114127841 NB1XXX 114127842 GB2XXX 114127843 GB2A2X 114150577 Post LPM Assignment Set 20150420 114150578 Pre LPM working set 20150418 114150579 Listed LPM Reichman as of 4/15/2015 114150580 Patent Category - Biotechnology 114150581 SACGHS DNA Patent Initial Set 114150582 GENE THERAPY 114150583 AAV 114150584 USES 114150585 viral vector 114150586 AAV4 114150587 ependymal cells 114150588 brain TAB-1157 114095483 Isolation, Cloning and Characterization of New Adeno-Associated Virus (AAV) Serotypes NIDCR Therapeutics Therapeutics John (Jay) Chiorini, Michael Schmidt Adeno-associated viruses (AAV) are used in gene delivery, but with limited success due to toxicity. The novel AAVs described in this technology may be more effective and useful in gene therapy applications. <br><br> This invention relates to new adeno-associated viruses (AAV), vectors and particles derived therefrom and also provides methods for delivering specific nucleic acids to cells using the AAV vectors and particles. The inventors cloned and sequenced the genomes of AAVs found in twelve (12) simian adenovirus isolates and determined that the AAVs were novel. Ten (10) of these isolates had high similarity to AAV1 and AAV6 (>98%). Despite the high homology to AAV6, these novel AAVs demonstrated distinct cell tropisms and reactivity towards a panel of lectins, suggesting that they may use a distinct entry pathway. <ul> <li>Vectors based on these new AAV serotypes may have a different host range and different immunological properties, thus allowing for more efficient transduction in certain cell types than previously used AAV.</li> <li>Gene therapy has tremendous potential in treating several life threatening diseases, and this technology has the potential to benefit millions of patients that could benefit from the proper use of gene therapy treatments. Additionally, the gene therapy market is now a multi-million dollar industry can substantially benefit from the use of this technology.</li> </ul> <ul> <li>AAVs can be used as delivery systems in gene therapy</li> <li>AAV’s also have gene transfer applications</li> </ul> A range of licensing opportunities exist, including material licenses, commercial licenses, nonexclusive and exclusive licenses, as well as fields of use directed towards clinical applications. 2022-03-08 2024-10-28 2024-10-28 2007-08-01 Adeno-associated, CHARACTERIZATION, Cloning, GB2A2X, GB2AXX, GB2XXX, GBXXXX, GXXXXX, Isolation, Novel, Serotypes, virus False True True NIHTT 37470483 Website Abstract 114105153 Chiorini, John (Jay) NIDCR NIDCR Chiorini, John (Jay) (NIDCR) 0 114105154 Schmidt, Michael NIDCR NCI Schmidt, Michael (NCI) 1 114105154 Schmidt, Michael NIDCR NCI Schmidt, Michael (NCI) 1 114105153 Chiorini, John (Jay) NIDCR NIDCR Chiorini, John (Jay) (NIDCR) 0 114100379 Isolation, Cloning, And Characterization Of Novel Adeno-associated Virus Serotypes E-179-2005-0 Filing authorized American Type Culture Collection, NIDCR 83656052 Knezevic, Vladimir vlado.knezevic@nih.gov
United States of America Technology Advancement Office vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-1157] Isolation, Cloning and Characterization of New Adeno-Associated Virus (AAV) Serotypes&body=Please send me information about technology [TAB-1157] Isolation, Cloning and Characterization of New Adeno-Associated Virus (AAV) Serotypes. Knezevic, Vladimir<br><a href="mailto:vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-1157] Isolation, Cloning and Characterization of New Adeno-Associated Virus (AAV) Serotypes&body=Please send me information about technology [TAB-1157] Isolation, Cloning and Characterization of New Adeno-Associated Virus (AAV) Serotypes.">vlado.knezevic@nih.gov</a><br> 114162881 E-179-2005-0 E-179-2005-0-US-03 Isolation, Cloning, And Characterization Of New Adeno-Associated Virus (AAV) Serotypes National Stage US 8,283,151 11/912,803 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8283151 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8283151">8,283,151</a><br />Filed on 2006-05-01<br />Status: Issued 114116293 GB2A2X 114116294 GB2AXX 114116295 GB2XXX 114116296 GBXXXX 114116297 GXXXXX 114132948 Isolation 114132949 Cloning 114132950 CHARACTERIZATION 114132951 Novel 114132952 Adeno-associated 114132953 virus 114132954 Serotypes TAB-1160 114095486 Monoclonal Antibody to the Protein NCOA6 (also called ASC-2, AIB-3) NHGRI Collaboration, Licensing, Oncology, Research Materials Collaboration Licensing Oncology Research Materials Paul Meltzer The invention relates to monoclonal antibodies that bind to the transcription factor NCOA6 (ASC-2, AIB-3, TRB, TRAP250, NRC). The antibodies have proven successful reagents for Western blotting and for purifying complexes containing NCOA6. The Western blot experiments revealed that NCOA6 is over-expressed in several breast cancer cell lines, and the purification experiments identified a protein complex containing NCOA6 (the ASCOM complex). The monoclonal antibodies may be useful reagents for studying the role of NCOA6 in transcription and for studying the ASCOM complex. In addition to licensing, the technology is available for further development through collaborative research opportunities with the inventors. 2022-03-08 2024-10-28 2024-10-28 2005-08-01 CC2XXX, CCXXXX, CXXXXX False True True NIHTT 37470483 Website Abstract 114170064 Young-Hwa Goo et al., "Activating Signal Cointegrator 2 Belongs to a Novel Steady-State Complex That Contains a Subset of Trithorax Group Proteins," Mol. Cell. Biol. (Jan 2003) 23(1):140-149; DOI:10.1128/MCB.23.1.140-149.2003. https://www.tandfonline.com/doi/10.1128/mcb.23.1.140-149.2003 <a href="https://www.tandfonline.com/doi/10.1128/mcb.23.1.140-149.2003">Young-Hwa Goo et al., "Activating Signal Cointegrator 2 Belongs to a Novel Steady-State Complex That Contains a Subset of Trithorax Group Proteins," Mol. Cell. Biol. (Jan 2003) 23(1):140-149; DOI:10.1128/MCB.23.1.140-149.2003.</a> 114170065 Soo-Kyung Lee et al., "A Nuclear Factor, ASC-2, as a Cancer-amplified Transcriptional Coactivator Essential for Ligand-dependent Transactivation by Nuclear Receptors in Vivo," J. Biol. Chem. (26 Nov 1999) 274(48):34283-34893. https://www.sciencedirect.com/science/article/pii/S0021925819535311 <a href="https://www.sciencedirect.com/science/article/pii/S0021925819535311">Soo-Kyung Lee et al., "A Nuclear Factor, ASC-2, as a Cancer-amplified Transcriptional Coactivator Essential for Ligand-dependent Transactivation by Nuclear Receptors in Vivo," J. Biol. Chem. (26 Nov 1999) 274(48):34283-34893.</a> 114105158 Meltzer, Paul NCI Meltzer, Paul (NCI) 0 114105158 Meltzer, Paul NCI Meltzer, Paul (NCI) 0 114100382 Monoclonal Antibody To The Protein NCOA6 (also Called ASC-2, AIB-3) E-168-2005-0 Research Material National Human Genome Research Institute (NHGRI) 83716782 Campbell, Eggerton eggerton.campbell@nih.gov
United States of America eggerton.campbell@nih.gov?subject=Web Inquiry on [TAB-1160] Monoclonal Antibody to the Protein NCOA6 (also called ASC-2, AIB-3)&body=Please send me information about technology [TAB-1160] Monoclonal Antibody to the Protein NCOA6 (also called ASC-2, AIB-3). Campbell, Eggerton<br><a href="mailto:eggerton.campbell@nih.gov?subject=Web Inquiry on [TAB-1160] Monoclonal Antibody to the Protein NCOA6 (also called ASC-2, AIB-3)&body=Please send me information about technology [TAB-1160] Monoclonal Antibody to the Protein NCOA6 (also called ASC-2, AIB-3).">eggerton.campbell@nih.gov</a><br> 114116304 CC2XXX 114116305 CCXXXX 114116306 CXXXXX TAB-1120 114095449 Tristetraprolin (TTP) Knockout Mice NIEHS Animal Models, Diagnostics, Licensing, Materials Available, Oncology, Research Materials, Therapeutics Animal Models Diagnostics Licensing Materials Available Oncology Research Materials Therapeutics Perry Blackshear National Institutes of Health researchers have developed knockout mice that do not express Tristetraprolin (TTP). TTP is an AU-rich element (ARE) binding protein and the prototype of a family of CCCH zinc finger proteins. AREs were identified as conserved sequences found in the 3’ untranslated region (3’ UTR) of a variety of transiently expressed genes including early response genes, proto-oncogenes, and other growth regulatory genes. AREs function as instability sequences that target ARE-containing transcripts for rapid mRNA decay. TTP functions by binding directly to the ARE sequence contained in the TNF-alpha mRNA, which destabilizes and mediates rapid decay of the TNF-alpha mRNA. More recent studies demonstrate TTP’s ability to downregulate IL-2 gene expression. <br><br> TTP knockout mice appear normal at birth but soon develop inflammatory arthritis, dermatitis, cachexia, autoimmunity, and myeloid hyperplasia. Almost all aspects of these phenotypes can be prevented with repeated injections of antibodies to TNF. Moreover, macrophages isolated from these mice exhibit increased production of TNF-alpha and increased amounts of TNF-alpha mRNA. <br><br> This transgenic mouse model will be valuable in advancing our understanding of the mechanisms controlling mRNA turnover in immune homeostasis as well as autoimmune diseases. This model will also permit the development of screening assays to elucidate the functions and binding partners for other members of the CCCH zinc finger family as well as compounds capable of inhibiting aberrant TNF-alpha and IL-2 biosynthesis. Lastly, this model will advance understanding of the pathogenetic role for IL-2 and/or TNF in various autoimmune and inflammatory diseases. Research Material -- patent protection is not being pursued for this technology. The mice will be made available on a non-exclusive basis under a Biological Materials License Agreement. 2022-03-08 2024-10-28 2024-10-28 2022-03-03 AC5XXX, ACXXXX, AXXXXX, BAXXXX, CCXXXX, CXXXXX, IDXXXX, IXXXXX, KNOCK-OUT, Mouse, TTP False True True NIHTT 37470483 Website Abstract 114170056 RL Olgivie et al. Tristetraprolin down-regulates IL-2 gene expression through AU-rich element-mediated mRNA decay. J Immunol. 2005 Jan 15;174(2):953-961. http://www.ncbi.nlm.nih.gov/pubmed/15634918?dopt <a href="http://www.ncbi.nlm.nih.gov/pubmed/15634918?dopt">RL Olgivie et al. Tristetraprolin down-regulates IL-2 gene expression through AU-rich element-mediated mRNA decay. J Immunol. 2005 Jan 15;174(2):953-961.</a> 114170057 DM Carrick et al. The tandem CCCH zinc finger protein tristetraprolin and its relevance to cytokine mRNA turnover and arthritis. Arthritis Res Ther. 2004;6(6):248-264. http://www.ncbi.nlm.nih.gov/pubmed/15535838?dopt <a href="http://www.ncbi.nlm.nih.gov/pubmed/15535838?dopt">DM Carrick et al. The tandem CCCH zinc finger protein tristetraprolin and its relevance to cytokine mRNA turnover and arthritis. Arthritis Res Ther. 2004;6(6):248-264.</a> 114170058 E Carballo et al. Feedback inhibition of macrophage tumor necrosis factor-alpha production by tristetraprolin. Science 1998 Aug 14;281(5379):1001-1005. http://www.ncbi.nlm.nih.gov/pubmed/9703499?dopt <a href="http://www.ncbi.nlm.nih.gov/pubmed/9703499?dopt">E Carballo et al. Feedback inhibition of macrophage tumor necrosis factor-alpha production by tristetraprolin. Science 1998 Aug 14;281(5379):1001-1005.</a> 114105096 Blackshear, Perry NIEHS Blackshear, Perry (NIEHS) 0 114105096 Blackshear, Perry NIEHS Blackshear, Perry (NIEHS) 0 114101137 TTP KNOCK-OUT MOUSE B-015-1999-0 Research Material EM, NIEHS 83739538 Choudhry, Vidita vidita.choudhry@nih.gov
United States of America Office of Technology Transfer and Development vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-1120] Tristetraprolin (TTP) Knockout Mice&body=Please send me information about technology [TAB-1120] Tristetraprolin (TTP) Knockout Mice. Choudhry, Vidita<br><a href="mailto:vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-1120] Tristetraprolin (TTP) Knockout Mice&body=Please send me information about technology [TAB-1120] Tristetraprolin (TTP) Knockout Mice.">vidita.choudhry@nih.gov</a><br> 114116158 AC5XXX 114116159 CCXXXX 114116160 ACXXXX 114116161 IDXXXX 114116162 CXXXXX 114116163 AXXXXX 114116164 IXXXXX 114121335 BAXXXX 114136280 TTP 114136281 KNOCK-OUT 114136282 Mouse TAB-1121 114095450 Farnesyltransferase Inhibitors for Treatment of Laminopathies, Cellular Aging and Atherosclerosis NHGRI Cardiology, Diagnostics, Licensing, Research Materials, Therapeutics Cardiology Diagnostics Licensing Research Materials Therapeutics Francis Collins Hutchinson-Gilford Progeria Syndrome (HGPS) is a very rare progressive childhood disorder characterized by premature aging (progeria). Recently, the gene responsible for HGPS was identified (Eriksson M, et al. Nature 2003), and HGPS joined a group of syndromes — the laminopathies — all of which are caused by various mutations in the lamin A/C gene (<i>LMNA</i>). Lamin A is one of the family of proteins that is modified post-translationally by the addition of a farnesyl group. In progeria, the abnormal protein (progerin) can still be farnesylated, however, a subsequent cleavage is blocked.<br /><br /> The present invention describes a possible treatment of laminopathies, cellular aging and aging-related conditions such as HGPS through the use of farnesyltransferase inhibitors (FTIs) and other related compounds. This treatment should lead to a decrease in the accumulation of abnormal proteins such as progerin in case of HGPS patients and therefore reduce or eliminate many of the devastating clinical symptoms of the underlying biological defect of nuclear membrane instability (Goldman R, et al. PNAS 2004). 2022-03-08 2024-10-28 2024-10-28 2005-06-01 (4)r syndrome, AA5XXX, AAXXXX, AXXXXX, C syndrome, Chromosome 4 ring syndrome, Chromosome 6 ring syndrome, Chromosome 7 ring syndrome, G syndrome, Hutchinson Gilford Syndrome, Hypertelorism with esophageal abnormality and hypospadias, IA1XXX, IAXXXX, IXXXXX, N syndrome, Premature aging, Progeria, Progeria; Hutchinson-Gilford progeria syndrome, R(6) syndrome, R(7) syndrome, Syndrome X, W syndrome, W syndrome; Syndrome W False True True NIHTT 37470483 Website Abstract 114171460 Eriksson M, et al. http://www.ncbi.nlm.nih.gov/pubmed/12714972 <a href="http://www.ncbi.nlm.nih.gov/pubmed/12714972">Eriksson M, et al.</a> 114171461 Goldman RD, et al. http://www.ncbi.nlm.nih.gov/pubmed/15184648 <a href="http://www.ncbi.nlm.nih.gov/pubmed/15184648">Goldman RD, et al.</a> 114105097 Collins, Francis NHGRI Collins, Francis (NHGRI) 0 114105097 Collins, Francis NHGRI Collins, Francis (NHGRI) 0 114100347 Methods And Use Of Farnesyl Transferase Inhibitors (FTIs) For Laminopathies, Cellular Aging, And Artherosclerosis E-055-2005-2 Filing authorized National Human Genome Research Institute (NHGRI), Progeria Research Foundation, University of Michigan, University of North Carolina, Chapel Hill 83716782 Campbell, Eggerton eggerton.campbell@nih.gov
United States of America eggerton.campbell@nih.gov?subject=Web Inquiry on [TAB-1121] Farnesyltransferase Inhibitors for Treatment of Laminopathies, Cellular Aging and Atherosclerosis&body=Please send me information about technology [TAB-1121] Farnesyltransferase Inhibitors for Treatment of Laminopathies, Cellular Aging and Atherosclerosis. Campbell, Eggerton<br><a href="mailto:eggerton.campbell@nih.gov?subject=Web Inquiry on [TAB-1121] Farnesyltransferase Inhibitors for Treatment of Laminopathies, Cellular Aging and Atherosclerosis&body=Please send me information about technology [TAB-1121] Farnesyltransferase Inhibitors for Treatment of Laminopathies, Cellular Aging and Atherosclerosis.">eggerton.campbell@nih.gov</a><br> 114160000 E-055-2005-2 E-055-2005-2-US-02 Farnesyl Transferase Inhibitors For Treatment of Laminopathies, Cellular Aging, And Artherosclerosis ORD US 7,838,531 11/828,117 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7838531 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7838531">7,838,531</a><br />Filed on 2007-07-25<br />Status: Expired 114162812 E-055-2005-2 E-055-2005-2-PCT-01 Methods And Use Of Farnesyl Transferase Inhibitors (FTIs) For Laminopathies, Cellular Aging, And Artherosclerosis PCT COMB Patent Cooperation Treaty PCT/US2006/002977 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2006/002977<br />Filed on 2006-01-27<br />Status: Expired 114163798 E-055-2005-2 E-055-2005-2-US-06 Farnesyltransferase Inhibitors for Treatment of Laminopathies, Cellular Aging and Atherosclerosis CON US 8,828,356 13/857,052 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8828356 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8828356">8,828,356</a><br />Filed on 2013-04-04<br />Status: Abandoned 114164661 E-055-2005-2 E-055-2005-2-US-05 Methods And Use Of Farnesyl Transferase Inhibitors (FTIs) For Laminopathies, Cellular Aging, And Artherosclerosis DIV US 8,691,501 13/567,432 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8691501 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8691501">8,691,501</a><br />Filed on 2012-08-06<br />Status: Abandoned 114166240 E-055-2005-2 E-055-2005-2-US-04 Farnesyl Transferase Inhibitors (FTIs) For Treatment Of Laminopathies, Cellular Aging, And Artherosclerosis DIV US 8,257,915 12/905,838 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8257915 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8257915">8,257,915</a><br />Filed on 2010-10-15<br />Status: Abandoned 114167895 E-055-2005-2 E-055-2005-2-US-07 Farnesyl Transferase Inhibitors (FTIs) For Treatment of Laminopathies, Cellular Aging, And Artherosclerosis CON US 14/336,457 Abandoned US <br />Continuation (CON) 14/336,457<br />Filed on 2014-07-21<br />Status: Abandoned 114116165 AA5XXX 114116166 IA1XXX 114116167 AAXXXX 114116168 IAXXXX 114116169 AXXXXX 114116170 IXXXXX 114155890 Syndrome X 114155891 C syndrome 114155892 Chromosome 7 ring syndrome 114155893 W syndrome 114155894 Premature aging 114155895 Hypertelorism with esophageal abnormality and hypospadias 114155896 N syndrome 114155897 Chromosome 6 ring syndrome 114155898 Hutchinson Gilford Syndrome 114155899 Progeria 114155900 Chromosome 4 ring syndrome 114158030 R(7) syndrome 114158031 W syndrome; Syndrome W 114158032 G syndrome 114158033 R(6) syndrome 114158034 Progeria; Hutchinson-Gilford progeria syndrome 114158035 (4)r syndrome TAB-1100 114095429 Methods for Diagnosis of Atherosclerosis NHLBI Cardiology, Diagnostics, Licensing, Research Materials, Therapeutics Cardiology Diagnostics Licensing Research Materials Therapeutics Paul Hwang The identification of more sensitive and specific markers of atherosclerosis that are non-invasive and cost-effective may have profound impacts on public health. One such strategy involves the detection of marker genes or their products in blood or serum. Such markers may help identify high-risk patients with subclinical atherosclerosis who may benefit from intensive primary prevention or they may help determine the activity of established disease for monitoring response to treatment, resulting in more targeted secondary prevention. <br /><br /> The present invention relates to methods for detecting atherosclerosis using highly reactive biomarkers (FOS and/or DUSP1) expressed in blood cells or released into serum. Because these markers are also involved in pathogenesis, they may serve as potential targets for drug discovery and for intervention to modify disease progression. 2022-03-08 2024-10-28 2024-10-28 2004-12-01 ATHEROSCLEROSIS, FOS, IA1XXX, IAXXXX, IXXXXX, MARKER, Novel, Patent Category - Biotechnology False True True NIHTT 37470483 Website Abstract 114107617 Hwang, Paul National Heart, Lung, and Blood Institute (NHLBI) NHLBI Hwang, Paul (NHLBI) 1 114107617 Hwang, Paul National Heart, Lung, and Blood Institute (NHLBI) NHLBI Hwang, Paul (NHLBI) 1 114101765 FOS As A Novel Marker Of Atherosclerosis E-276-2004-2 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 90072936 Mistry, Pragnesh pragnesh.mistry@nih.gov
HNH6Z08 pragnesh.mistry@nih.gov?subject=Web Inquiry on [TAB-1100] Methods for Diagnosis of Atherosclerosis&body=Please send me information about technology [TAB-1100] Methods for Diagnosis of Atherosclerosis. Mistry, Pragnesh<br><a href="mailto:pragnesh.mistry@nih.gov?subject=Web Inquiry on [TAB-1100] Methods for Diagnosis of Atherosclerosis&body=Please send me information about technology [TAB-1100] Methods for Diagnosis of Atherosclerosis.">pragnesh.mistry@nih.gov</a><br> 114162759 E-276-2004-2 E-276-2004-2-PCT-01 Methods for Assessing Atherosclerosis PCT COMB Patent Cooperation Treaty PCT/US2005/031469 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2005/031469<br />Filed on 2005-09-02<br />Status: Expired 114166812 E-276-2004-2 E-276-2004-2-US-06 Methods for Assessing Atherosclerosis by Measuring Expression of FOS or DUSP1 In Monocytes National Stage US 7,998,682 11/661,714 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7998682 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7998682">7,998,682</a><br />Filed on 2007-02-27<br />Status: Issued 114116082 IA1XXX 114116083 IAXXXX 114116084 IXXXXX 114143322 FOS 114143323 Novel 114143324 MARKER 114143325 ATHEROSCLEROSIS 114143326 Patent Category - Biotechnology TAB-1115 114095444 Method of Diagnosing Multidrug Resistant Tuberculosis NIAID Diagnostics, Infectious Disease, Licensing, Rare/Neglected Diseases, Therapeutics Diagnostics Infectious Disease Licensing Rare/Neglected Diseases Therapeutics Clifton Barry, Andrea Debarber, Khisimuzi Mdluli The invention can be used to develop tests that are much more rapid than conventional tests for determining drug resistance. It relates to the discovery that a putative gene of Mycobacterium tuberculosis (MTb) with no previously identified function is responsible for the ability of the bacteria to activate a class of second line thioamide drugs used for MTb infections. The gene, termed "etaA", codes for the synthesis of a monooxygenase, the enzyme responsible for the oxidative activation of the drugs. Mutation in the etaA gene leads to the expression of mutated, inactivated enzyme, thus resulting in thioamide drug-resistant bacteria. The significance of this discovery is that now, resistance to the class of thioamide drugs in clinical isolates can be identified in a relatively short time, eliminating the need to perform lengthy culturing procedures. <br><br> The invention claims test methods for determining resistance to thioamide drugs by detecting gene mutation. These include (a) amplifying the etaA gene or a portion of it containing the mutation, with a set of primers which provide amplified product, and sequencing the amplified product to compare the sequence with a known sequence of the wild-type etaA; a difference in sequence patterns indicates mutation; (b) subjecting the amplified gene product to digestion by restriction enzymes and comparing the cleaved DNA gel pattern to the one obtained from digestion of the wild type etaA gene; a difference indicates mutation in etaA; and (c) detecting the mutations by probe hybridization techniques, where the amplified product hybridizes to a nucleic acid of known sequence under stringent conditions, and the hybridized product is detected. In addition to the above, the invention proposes other detection methods such as commonly used for SNPs. Other methods claimed in the invention are immunoassay (i.e., ELISA) for the etaA gene product or mutated versions of it, or immunoassay and chemical analysis of the drug metabolites, whereby the absence of the metabolites indicates gene mutation and impaired activating ability. <ul> <li>Novel methods for diagnosing multidrug resistant tuberculosis that are much more rapid than conventional tests.</li> </ul> <ul> <li>Infectious diseases, diagnostics (bacterial)</li> <li>Infectious diseases, therapeutics (anti-bacterial)</li> </ul> Available for licensing. 2022-03-08 2024-10-28 2024-10-28 2000-09-01 DA3XXX, DAXXXX, DB3XXX, DBXXXX, DIAGNOSING, Duke DNA Project, DXXXXX, Methods, Multidrug, RESISTANT, TUBERCULOSIS, Tuberculosis (Mycobacterium tuberculosis), UA1XXX False True True NIHTT 37470483 Website Abstract 114170846 DeBarber AE, et al. https://www.ncbi.nlm.nih.gov/pubmed/10944230 <a href="https://www.ncbi.nlm.nih.gov/pubmed/10944230">DeBarber AE, et al.</a> 114105085 Debarber, Andrea Debarber, Andrea 0 114106371 Mdluli, Khisimuzi NIAID - DIR Mdluli, Khisimuzi 0 114105086 Barry, Clifton NIAID - DIR NIAID Barry, Clifton (NIAID) 1 114105086 Barry, Clifton NIAID - DIR NIAID Barry, Clifton (NIAID) 1 114105085 Debarber, Andrea Debarber, Andrea 0 114106371 Mdluli, Khisimuzi NIAID - DIR Mdluli, Khisimuzi 0 114100339 Methods of Diagnosing Multidrug Resistant Tuberculosis E-093-2000-0 EM, NIAID 83720410 Yang, David (Po-Lung) polung.yang@nih.gov
United States of America Technology Transfer and Intellectual Property Office polung.yang@nih.gov?subject=Web Inquiry on [TAB-1115] Method of Diagnosing Multidrug Resistant Tuberculosis&body=Please send me information about technology [TAB-1115] Method of Diagnosing Multidrug Resistant Tuberculosis. Yang, David (Po-Lung)<br><a href="mailto:polung.yang@nih.gov?subject=Web Inquiry on [TAB-1115] Method of Diagnosing Multidrug Resistant Tuberculosis&body=Please send me information about technology [TAB-1115] Method of Diagnosing Multidrug Resistant Tuberculosis.">polung.yang@nih.gov</a><br> 114162796 E-093-2000-0 E-093-2000-0-US-03 Methods of Diagnosing Multidrug Resistant Tuberculosis DIV US 7,547,519 11/058,484 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7547519 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7547519">7,547,519</a><br />Filed on 2005-02-14<br />Status: Expired 114162797 E-093-2000-0 E-093-2000-0-US-02 Methods of Diagnosing Multidrug Resistant Tuberculosis ORD US 6,905,822 09/888,320 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6905822 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6905822">6,905,822</a><br />Filed on 2001-06-22<br />Status: Expired 114165238 E-093-2000-0 E-093-2000-0-US-01 Methods of Diagnosing Multidrug Resistant Tuberculosis PRV US 60/214,187 Abandoned US <br />Provisional (PRV) 60/214,187<br />Filed on 2000-06-26<br />Status: Abandoned 114116137 DA3XXX 114116138 DB3XXX 114116139 DAXXXX 114116140 DBXXXX 114116141 DXXXXX 114119416 UA1XXX 114134217 Methods 114134218 DIAGNOSING 114134219 Multidrug 114134220 RESISTANT 114134221 TUBERCULOSIS 114134222 Duke DNA Project 114157877 Tuberculosis (Mycobacterium tuberculosis) TAB-1052 114095382 Chromatin Insulator Protecting Expressed Genes of Interest for Human Gene Therapy or Other Mammalian Transgenic Systems NIDDK Licensing, Oncology, Therapeutics Licensing Oncology Therapeutics Jay Chung, Gary Felsenfeld The technology provides the isolation of a functional DNA sequence comprising a chromatin insulating element from a vertebrate system and provides the first employment of the pure insulator element as a functional insulator in mammalian cells. The technology further relates to a method for insulating the expression of a gene from the activity of cis-acting regulatory sequences in eukaryotic chromatin. <br><br> This technology could be of major importance in providing a mechanism and a tool to restrict the action of cis-acting regulatory elements on genes whose activities or encoded products are needed or desired to be expressed in mammalian transgenic systems. This technology provides the first pure insulator element to function solely as an insulator element in human cells. Accordingly, this technology could have tremendous practical implications for transgenic technology and human gene therapies, either in vitro or in vivo. <br><br> The technology further provides a method and constructs for insulating the expression of a gene or genes in transgenic animals such that the transfected genes will be protected and stably expressed in the tissues of the transgenic animal or its offspring. For example, even if the DNA of the construct integrates into areas of silent chromatin in the genomic DNA of the host animal, the gene will continue to be expressed. The invention could provide a means of improving the stable integration and expression of any transgenic construct of interest, with efficiencies higher than are achieved presently. Use of this invention may represent a large potential savings for licensee's constructing transgenic cell lines or animals. 2022-03-08 2024-10-28 2024-10-28 2005-03-01 CB2XXX, CBXXXX, CXXXXX False True True NIHTT 37470483 Website Abstract 114104985 Chung, Jay NHLBI Chung, Jay (NHLBI) 0 114104986 Felsenfeld, Gary NIDDK Felsenfeld, Gary (NIDDK) 0 114104985 Chung, Jay NHLBI Chung, Jay (NHLBI) 0 114104986 Felsenfeld, Gary NIDDK Felsenfeld, Gary (NIDDK) 0 114100272 DNA Sequence Which Acts As A Chromatin Insulator Element To Protect Expressed Genes From Cis-acting Regulatory Sequences In Mammalian Cells E-206-1992-1 Filing authorized National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83692066 Tong, Betty tongb@niddk.nih.gov
United States of America Senior Technology Advancement Office tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-1052] Chromatin Insulator Protecting Expressed Genes of Interest for Human Gene Therapy or Other Mammalian Transgenic Systems&body=Please send me information about technology [TAB-1052] Chromatin Insulator Protecting Expressed Genes of Interest for Human Gene Therapy or Other Mammalian Transgenic Systems. Tong, Betty<br><a href="mailto:tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-1052] Chromatin Insulator Protecting Expressed Genes of Interest for Human Gene Therapy or Other Mammalian Transgenic Systems&body=Please send me information about technology [TAB-1052] Chromatin Insulator Protecting Expressed Genes of Interest for Human Gene Therapy or Other Mammalian Transgenic Systems.">tongb@niddk.nih.gov</a><br> 114162650 E-206-1992-1 E-206-1992-1-US-01 DNA sequence which acts as a chromatin insulator element to protect expressed genes from cis-acting regulatory sequences in mammalian cells CIP US 5,610,053 08/283,125 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/5610053 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/5610053">5,610,053</a><br />Filed on 1994-07-29<br />Status: Expired 114163894 E-206-1992-1 E-206-1992-1-PCT-02 DNA SEQUENCE WHICH ACTS AS A CHROMATIN INSULATOR ELEMENT TO PROTECT EXPRESSED GENES FROM CIS-ACTING REGULATORY SEQUENCES IN MAMMALIAN CELLS PCT Patent Cooperation Treaty PCT/US1995/009473 Expired Patent Cooperation Treaty <br />(PCT) PCT/US1995/009473<br />Filed on 1995-07-28<br />Status: Expired 114115857 CB2XXX 114115858 CBXXXX 114115859 CXXXXX TAB-1077 114095408 Wild-Type and DNA Polymerase beta Null Mouse Embryotic Fibroblast Cell Lines Harboring a lambda-LIZ Transgene NIEHS Licensing Licensing Robert Sobol Of great utility in toxicology and DNA repair research are knockout mice with cell lines enabling one to evaluate generations of gene mutations as a direct function of base excision repair. Of particular importance are lambda-LIZ transgenes. Likewise, wild-type and beta-pol null cell lines are equally important. While there exist cell lines carrying the lambda-LIZ transgene, only wild-type cells are currently available. And while wild-type and beta-pol null cell lines exist, none carry the lambda-LIZ transgene. <br><br> The present cell line incorporates both of these beneficial properties. These cell lines were created by crossing a transgenic mouse with multiple copies of the lambda-LIZ transgene with a mouse with but a single copy of the DNA polymerase beta. Rebreeding offspring produced cells of both wild type and beta-pol null genotype. The utility of these cells stem from the deficiency in base excision repair as a result of the null mutation in the DNA polymerase beta gene. <br><br> Also available for licensing are cell lines created using: <ul> <li>Ung KO mice + lambda-LIZ transgene </li> <li>Aag KO mice + lambda-LIZ transgene </li> <li>PMS-2 KO mice + lambda-LIZ transgene </li> <li>Pol-beta/Aag double KO mice + lambda-LIZ transgene </li> <li>Pol-beta/PMS-2 double KO mice + lambda-LIZ transgene </li> <li>Aag/PMS-2 double KO mice + lambda-LIZ transgene</li> </ul> Research Tool -- patent prosecution is not being pursued for this technology 2022-03-08 2024-10-28 2024-10-28 2005-04-01 3-@hydroxyacyl-coa dehydrogenase deficiency, 47 XYY syndrome, AC5XXX, ACXXXX, AXXXXX, B, Cell, DNA, Double Y, Embryonic, Fibroblast, HAD deficiency, harboring, HIS deficiency, Histidinemia, KO, Lines, Mouse, NULL, polymerase, SV40T-Ag, TRANSFORMED, TRANSGENE, WILD-TYPE, Y-LIZ False True True NIHTT 37470483 Website Abstract 114105032 Sobol, Robert Sobol, Robert 0 114105032 Sobol, Robert Sobol, Robert 0 114100859 Wild-type and DNA polymerase B null (KO) mouse embryonic fibroblast cell lines, transformed with SV40T-Ag and harboring a Y-LIZ transgene E-049-2000-0 Research Material NIEHS 83739538 Choudhry, Vidita vidita.choudhry@nih.gov
United States of America Office of Technology Transfer and Development vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-1077] Wild-Type and DNA Polymerase beta Null Mouse Embryotic Fibroblast Cell Lines Harboring a lambda-LIZ Transgene&body=Please send me information about technology [TAB-1077] Wild-Type and DNA Polymerase beta Null Mouse Embryotic Fibroblast Cell Lines Harboring a lambda-LIZ Transgene. Choudhry, Vidita<br><a href="mailto:vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-1077] Wild-Type and DNA Polymerase beta Null Mouse Embryotic Fibroblast Cell Lines Harboring a lambda-LIZ Transgene&body=Please send me information about technology [TAB-1077] Wild-Type and DNA Polymerase beta Null Mouse Embryotic Fibroblast Cell Lines Harboring a lambda-LIZ Transgene.">vidita.choudhry@nih.gov</a><br> 114115981 AC5XXX 114115982 ACXXXX 114115983 AXXXXX 114134258 WILD-TYPE 114134259 DNA 114134260 polymerase 114134261 B 114134262 NULL 114134263 KO 114134264 Mouse 114134265 Embryonic 114134266 Fibroblast 114134267 Cell 114134268 Lines 114134269 TRANSFORMED 114134270 SV40T-Ag 114134271 harboring 114134272 Y-LIZ 114134273 TRANSGENE 114155858 47 XYY syndrome 114155859 3-@hydroxyacyl-coa dehydrogenase deficiency 114155860 Histidinemia 114158010 Double Y 114158011 HAD deficiency 114158012 HIS deficiency TAB-1041 114095371 Mouse Lactoferrin Antibody NIEHS Collaboration, Licensing Collaboration Licensing Christina Teng Lactoferrin, an iron-binding glycoprotein, kills bacteria and modulates inflammatory and immune responses. It is expressed in mucosa membrane and is present in saliva, tears, vaginal secretion and neutrophils. It modulates immune and inflammatory response by down-regulating several cytokines. Therefore, lactoferrin is an important protein in first line of defense and protecting health. Changes in lactoferrin expression could also be used as a marker of gene activation, especially estrogen-induced gene activity in the uterus.<br><br> The inventors have uniquely purified a novel 70 kDa estrogen-stimulated glycoprotein, lactoferrin, from mouse uterine luminal fluid. CM-Affi-Gel Blue column chromatography provided a simple one step separation of lactoferrin from the other luminal and serum proteins. Furthermore, a polyclonal antibody was created in rabbit, which has been utilized for immunostaining, Western blot, and elisa assays on human, mouse, rat, and hamster tissues. The cDNA to both human and mouse were cloned. Probes designed to detect the methylation status or polymorphisms of the human lactoferrin gene are available and can be used as diagnostic tool in cancer study.<br><br> The inventor has available polyclonal antibodies for both human and mouse, as well as purified mouse lactoferrin protein. Research Material – Patent prosecution is not being pursued for this technology. In addition to licensing, the technology is available for further development through collaborative research opportunities with the inventors. 2022-03-08 2024-10-28 2024-10-28 2005-02-01 AC5XXX, ACXXXX, AXXXXX False True True NIHTT 37470483 Website Abstract 114170024 Teng CT, et al. https://www.ncbi.nlm.nih.gov/pubmed/3814091 <a href="https://www.ncbi.nlm.nih.gov/pubmed/3814091">Teng CT, et al.</a> 114170025 Teng CT, et al. https://www.ncbi.nlm.nih.gov/pubmed/12390874 <a href="https://www.ncbi.nlm.nih.gov/pubmed/12390874">Teng CT, et al.</a> 114104960 Teng, Christina NIEHS Teng, Christina (NIEHS) 0 114104960 Teng, Christina NIEHS Teng, Christina (NIEHS) 0 114100259 Mouse Lactoferrin Antibody E-158-2004-0 Research Material NIEHS 83739538 Choudhry, Vidita vidita.choudhry@nih.gov
United States of America Office of Technology Transfer and Development vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-1041] Mouse Lactoferrin Antibody&body=Please send me information about technology [TAB-1041] Mouse Lactoferrin Antibody. Choudhry, Vidita<br><a href="mailto:vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-1041] Mouse Lactoferrin Antibody&body=Please send me information about technology [TAB-1041] Mouse Lactoferrin Antibody.">vidita.choudhry@nih.gov</a><br> 114115811 AC5XXX 114115812 ACXXXX 114115813 AXXXXX TAB-1042 114095372 Antibody to Estrogen Related Receptor alpha NIEHS Collaboration, Licensing Collaboration Licensing Christina Teng Estrogen related receptor alpha (ERRalpha) is a family member of the steroid/thyroid nuclear receptor superfamily. Estrogen related receptors are thought to regulate similar target genes in the absence of known ligands. For example, the inventors previously cloned the human estrogen receptor-related orphan receptor alpha1 cDNA and demonstrated that it enhances estrogen responsiveness of the lactoferrin gene promoter in transfected human endometrial carcinoma cells.<br><br> The inventors have produced a peptide and fusion protein rabbit polyclonal antibody against ERRalpha1-C terminal (anti-ERRalpha-CT), which has been utilized for immunostaining, Chromatin immunoprecipitation (ChIP), immunoprecipitation/immunoblottin (IP/IB) and Western blot. This antibody targets the C-terminus of the protein, which is a conserved region in human and mouse. The antibody will be a valuable tool to study the expression and function of the protein in rodent models, whereas the human antibody is already commercially available. The inventors also have available mouse cDNA for ERRalpha1, which can be used to detect mRNA. Research Materiall – Patent protection is not being pursued for this technology In addition to licensing, the technology is available for further development through collaborative research opportunities with the inventors. 2022-03-08 2024-10-28 2024-10-28 2005-02-01 AC5XXX, ACXXXX, AXXXXX False True True NIHTT 37470483 Website Abstract 114170026 Shigeta H, et al. https://www.ncbi.nlm.nih.gov/pubmed/9460651 <a href="https://www.ncbi.nlm.nih.gov/pubmed/9460651">Shigeta H, et al.</a> 114104961 Teng, Christina NIEHS Teng, Christina (NIEHS) 0 114104961 Teng, Christina NIEHS Teng, Christina (NIEHS) 0 114100260 Peptide Antibody To Estrogen Related Receptor (eRR) Alpha E-157-2004-0 Research Material NIEHS 83739538 Choudhry, Vidita vidita.choudhry@nih.gov
United States of America Office of Technology Transfer and Development vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-1042] Antibody to Estrogen Related Receptor alpha&body=Please send me information about technology [TAB-1042] Antibody to Estrogen Related Receptor alpha. Choudhry, Vidita<br><a href="mailto:vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-1042] Antibody to Estrogen Related Receptor alpha&body=Please send me information about technology [TAB-1042] Antibody to Estrogen Related Receptor alpha.">vidita.choudhry@nih.gov</a><br> 114115814 AC5XXX 114115815 ACXXXX 114115816 AXXXXX TAB-1011 114095344 ApoA-1 Mimetic Peptides Promoting Lipid Efflux from Cells for Treatment of Vascular Disorders NHLBI Cardiology, Collaboration, Diagnostics, Endocrinology, Licensing, Rare/Neglected Diseases, Research Materials, Therapeutics Cardiology Collaboration Diagnostics Endocrinology Licensing Rare/Neglected Diseases Research Materials Therapeutics Marcelo Amar, H. Bryan Brewer, Stephen Demosky, Edward Neufeld, Alan Remaley, John Stonik, Fairwell Thomas This invention involves ApoA-1 mimetic peptides with multiple amphipathic alpha-helical domains that promote lipid efflux from cells and are useful in the treatment and prevention of dyslipidemic, inflammatory and vascular disorders. IND-enabling studies for one of the peptides, named Fx-5A, are completed in preparation for an IND filing at the FDA, to be followed by a Phase I clinical trial planned for 2017. Disorders amenable to treatment with the peptides include hyperlipidemia, hyperlipoproteinemia, hypercholesterolemia, HDL deficiency, hypertriglyceridemia, apoA-I deficiency, acute coronary syndrome, angina pectoris, aortic valve stenosis, atherosclerosis, carotid atherosclerosis, congestive heart failure, cerebral stroke, coronary artery disease, inflammation of the cardiovascular system, intermittent claudication, myocardial infarction, peripheral vascular disease, post-ischemic reperfusion, renal artery stenosis, reperfusion myocardial injury, restenosis, and thrombotic stroke. <ul> <li>Treatment and prevention of many hereditary, chronic and acute dyslipidemic and vascular disorders, where other treatments are not effective or too invasive, such as statins, partial ileal bypass surgery, portacaval shunt, liver transplantation, and removal of atherogenic lipoproteins by one of several apheresis procedures.</li> <li>Also applicable to the treatment of inflammation, asthma, colitis, inflammatory bowel disease (IBD), chronic kidney disease (CKD).</li> </ul> The National Heart, Lung, and Blood Institute is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize ApoA-1 mimetic peptides. For collaboration opportunities, please contact Denise Crooks, Ph.D. at 301-435-0103 or <a href="mailto:crooksd@nhlbi.nih.gov">crooksd@nhlbi.nih.gov</a>. Various international patents issued In addition to licensing, the technology is available for further development through a collaborative research opportunity with the inventors. Details were provided in a CRADA/Licensing Opportunity notice published in the Federal Register on February 14, 2008 (<a href="http://a257.g.akamaitech.net/7/257/2422/01jan20081800/edocket.access.gpo.gov/2008/pdf/E8-2750.pdf" target="blank">73 FR 8702</a>). 2022-03-08 2024-10-28 2024-10-28 2008-02-01 (4)r syndrome, 3-@hydroxyacyl-coa dehydrogenase deficiency, AMPHIPATHIC, assay, Atherosclerosis., C syndrome, Chromosome 4 ring syndrome, Chromosome 6 ring syndrome, Chromosome 7 ring syndrome, COMPOSITION, G syndrome, HAD deficiency, HELICAL, HIS deficiency, Histidinemia, Hyperlipoproteinemia, Hypertelorism with esophageal abnormality and hypospadias, IA1XXX, IAXXXX, IXXXXX, Listed LPM Nguyen-Antczak as of 4/15/2015, Multi-domain, N syndrome, Patent Category - Biotechnology, Peptides, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, R(6) syndrome, R(7) syndrome, Syndrome X, System, treatment, UA1XXX, VDXXXX, VHXXXX, W syndrome, W syndrome; Syndrome W, WJXXXX, YAXXXX, YBXXXX, YCXXXX False True True 52406768 Discovery 52406768 NIHTT 37470483 Website Abstract 114170283 Sethi AA, et al. https://www.ncbi.nlm.nih.gov/pubmed/18805791 <a href="https://www.ncbi.nlm.nih.gov/pubmed/18805791">Sethi AA, et al.</a> 114170375 D'Souza W, et al. https://www.ncbi.nlm.nih.gov/pubmed/20508181 <a href="https://www.ncbi.nlm.nih.gov/pubmed/20508181">D'Souza W, et al.</a> 114171453 Jin X, et al. https://www.ncbi.nlm.nih.gov/pubmed/27758769 <a href="https://www.ncbi.nlm.nih.gov/pubmed/27758769">Jin X, et al.</a> 114171454 Nowacki TM, et al. https://www.ncbi.nlm.nih.gov/pubmed/27425846 <a href="https://www.ncbi.nlm.nih.gov/pubmed/27425846">Nowacki TM, et al.</a> 114171495 Yao X, et al. https://www.ncbi.nlm.nih.gov/pubmed/21115733 <a href="https://www.ncbi.nlm.nih.gov/pubmed/21115733">Yao X, et al.</a> 114171503 Osei-Hwedieh DO, et al. https://www.ncbi.nlm.nih.gov/pubmed/21172387 <a href="https://www.ncbi.nlm.nih.gov/pubmed/21172387">Osei-Hwedieh DO, et al.</a> 114171667 Yao X, et al. https://www.ncbi.nlm.nih.gov/pubmed/27327118 <a href="https://www.ncbi.nlm.nih.gov/pubmed/27327118">Yao X, et al.</a> 114171725 Souza AC, et al. https://www.ncbi.nlm.nih.gov/pubmed/26994575 <a href="https://www.ncbi.nlm.nih.gov/pubmed/26994575">Souza AC, et al.</a> 114171772 Schwendeman A, et al. https://www.ncbi.nlm.nih.gov/pubmed/26117661 <a href="https://www.ncbi.nlm.nih.gov/pubmed/26117661">Schwendeman A, et al.</a> 114171778 Sviridov DO, et al. https://www.ncbi.nlm.nih.gov/pubmed/23042953 <a href="https://www.ncbi.nlm.nih.gov/pubmed/23042953">Sviridov DO, et al.</a> 114171834 Dai C, et al. https://www.ncbi.nlm.nih.gov/pubmed/22427535 <a href="https://www.ncbi.nlm.nih.gov/pubmed/22427535">Dai C, et al.</a> 114171988 Tabet F, et al. https://www.ncbi.nlm.nih.gov/pubmed/19965776 <a href="https://www.ncbi.nlm.nih.gov/pubmed/19965776">Tabet F, et al.</a> 114172115 Amar MJ, et al. https://www.ncbi.nlm.nih.gov/pubmed/20484557 <a href="https://www.ncbi.nlm.nih.gov/pubmed/20484557">Amar MJ, et al.</a> 114107420 Neufeld, Edward National Heart, Lung, and Blood Institute (NHLBI) NHLBI Neufeld, Edward (NHLBI) 0 114107424 Thomas, Fairwell National Heart, Lung, and Blood Institute (NHLBI) Thomas, Fairwell 0 114107425 Brewer, H. Bryan National Heart, Lung, and Blood Institute (NHLBI) NHLBI Brewer, H. Bryan (NHLBI) 0 114108002 Demosky, Stephen National Heart, Lung, and Blood Institute (NHLBI) Demosky, Stephen 0 114108003 Stonik, John National Heart, Lung, and Blood Institute (NHLBI) NHLBI Stonik, John (NHLBI) 0 114108004 Amar, Marcelo National Heart, Lung, and Blood Institute (NHLBI) NHLBI Amar, Marcelo (NHLBI) 0 114107979 Remaley, Alan NHLBI Remaley, Alan (NHLBI) 1 114107979 Remaley, Alan NHLBI Remaley, Alan (NHLBI) 1 114107420 Neufeld, Edward National Heart, Lung, and Blood Institute (NHLBI) NHLBI Neufeld, Edward (NHLBI) 0 114107424 Thomas, Fairwell National Heart, Lung, and Blood Institute (NHLBI) Thomas, Fairwell 0 114107425 Brewer, H. Bryan National Heart, Lung, and Blood Institute (NHLBI) NHLBI Brewer, H. Bryan (NHLBI) 0 114108002 Demosky, Stephen National Heart, Lung, and Blood Institute (NHLBI) Demosky, Stephen 0 114108003 Stonik, John National Heart, Lung, and Blood Institute (NHLBI) NHLBI Stonik, John (NHLBI) 0 114108004 Amar, Marcelo National Heart, Lung, and Blood Institute (NHLBI) NHLBI Amar, Marcelo (NHLBI) 0 114099938 Assay System And Composition Of Multi-domain Amphipathic Helical Peptides For The Treatment Of Atherosclerosis. E-114-2004-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-1011] ApoA-1 Mimetic Peptides Promoting Lipid Efflux from Cells for Treatment of Vascular Disorders&body=Please send me information about technology [TAB-1011] ApoA-1 Mimetic Peptides Promoting Lipid Efflux from Cells for Treatment of Vascular Disorders. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-1011] ApoA-1 Mimetic Peptides Promoting Lipid Efflux from Cells for Treatment of Vascular Disorders&body=Please send me information about technology [TAB-1011] ApoA-1 Mimetic Peptides Promoting Lipid Efflux from Cells for Treatment of Vascular Disorders.">shmilovm@nih.gov</a><br> 114165500 E-114-2004-0 E-114-2004-0-US-01 Assay System And Composition Of Multi-domain Amphipathic Helical Peptides For The Treatment Of Atherosclerosis. PRV US 60/619,392 Abandoned US <br />Provisional (PRV) 60/619,392<br />Filed on 2004-10-15<br />Status: Abandoned 114165501 E-114-2004-0 E-114-2004-0-PCT-02 Multi-domain Amphipathic Helical Peptides and Methods of Their Use PCT Patent Cooperation Treaty PCT/US2005/036933 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2005/036933<br />Filed on 2005-10-14<br />Status: Expired 114165502 E-114-2004-0 E-114-2004-0-US-07 MULTI-DOMAIN AMPHIPATHIC HELICAL PEPTIDES AND METHODS OF THEIR USE National Stage US 7,572,771 11/577,259 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7572771 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7572771">7,572,771</a><br />Filed on 2007-04-13<br />Status: Expired 114165503 E-114-2004-0 E-114-2004-0-US-08 Multi-Domain Amphipathic Helical Peptides And Methods Of Their Use DIV US 8,071,746 12/497,443 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8071746 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8071746">8,071,746</a><br />Filed on 2009-07-02<br />Status: Expired 114165504 E-114-2004-0 E-114-2004-0-US-09 A Method of Treating Or Inhibiting Inflammation by Multi-Domain Amphipathic Helical Peptides CON US 8,148,323 12/766,761 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8148323 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8148323">8,148,323</a><br />Filed on 2010-04-23<br />Status: Expired 114165505 E-114-2004-0 E-114-2004-0-US-17 Multi-Domain Amphipathic Helical Peptides And Methods Of Their Use DIV US 8,835,378 13/407,132 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8835378 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8835378">8,835,378</a><br />Filed on 2012-02-28<br />Status: Abandoned 114115697 IA1XXX 114115698 IAXXXX 114115699 IXXXXX 114121204 YBXXXX 114121301 YCXXXX 114121867 VDXXXX 114121868 VHXXXX 114121869 WJXXXX 114121870 YAXXXX 114122410 UA1XXX 114144661 assay 114144662 System 114144663 COMPOSITION 114144701 Multi-domain 114144702 AMPHIPATHIC 114144703 HELICAL 114144704 Peptides 114144705 treatment 114144706 Atherosclerosis. 114144707 Patent Category - Biotechnology 114144708 Listed LPM Nguyen-Antczak as of 4/15/2015 114144709 Pre LPM working set 20150418 114144710 Post LPM Assignment Set 20150420 114155806 Syndrome X 114155807 C syndrome 114155808 Chromosome 7 ring syndrome 114155809 W syndrome 114155810 Hypertelorism with esophageal abnormality and hypospadias 114155811 3-@hydroxyacyl-coa dehydrogenase deficiency 114155812 Hyperlipoproteinemia 114155813 N syndrome 114155814 Chromosome 6 ring syndrome 114155815 Histidinemia 114155816 Chromosome 4 ring syndrome 114157985 R(7) syndrome 114157986 W syndrome; Syndrome W 114157987 G syndrome 114157988 HAD deficiency 114157989 R(6) syndrome 114157990 HIS deficiency 114157991 (4)r syndrome TAB-1010 114095342 Novel Methods for Reducing Inflammation and Treating Diseases such as Parkinson's and Alzheimer's Disease NIEHS Collaboration, Diagnostics, Immunology, Neurology, Research Materials, Therapeutics Collaboration Diagnostics Immunology Neurology Research Materials Therapeutics MIchelle Block, Po-See Chen, Jau-Shyong Hong, Guorong Li, Giia-Shuen Peng, Liya Qin, Wei Zhang Microglia activation leads to inflammation mediated dopaminergic degeneration in the brain of patients with Parkinson and Alzheimer's Disease. Thus Identification of drugs that reduce microglia activation could prevent or reverse neuronal degeneration in these diseases and other degenerative CNS disorders.<br /><br /> This invention describes small-peptide and non-peptide molecules that inhibit microglia activation and prevent neuronal degeneration with a bi-modal dose response curve. The non-peptide compounds have also been shown to prevent dopamine neuronal degeneration in animal models. This invention provides compositions and methods for inhibiting inflammatory mechanisms and treating inflammation-related condition by administering ultra-low (femto-molar) doses of at least one compound of the invention. These compounds include morphinans, opioid peptides, and the tripeptide GGF. <ul> <li>These compounds are active at ultra-low concentrations.</li> </ul> <ul> <li>Therapeutic treatment of Parkinson, Alzheimers and other degenerative CNS disorders.</li> </ul> The NIEHS is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize this technology. For collaboration opportunities, please contact Sharon Soucek, Ph.D. at<a href="mailto:sharon.soucek@nih.gov"> sharon.soucek@nih.gov</a> 2022-03-08 2024-10-28 2024-10-28 2022-03-03 Alzheimer disease 1, Alzheimer disease 3, Alzheimer disease 4, Alzheimer disease type 1, Alzheimer disease type 4, Alzheimer disease, familial, type 3, BBXXXX, Discovery, DOSE, femto-molar, IB3XXX, IBXXXX, Inflammation-associated, IXXXXX, Listed LPM Greene as of 4/15/2015, NB1BXX, NBXXXX, NEURODEGENERATIVE, NXXXXX, Parkinson disease 2, Parkinson disease 3, Parkinson disease 9, Parkinson disease, juvenile, autosomal recessive, Parkinson's, Patent Category - Biotechnology, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Prevention, therapeutic, therapeutics, Ultra-low, VEXXXX, WJXXXX, WKXXXX, YAXXXX, YBXXXX, YCXXXX False True <ul> <li>Early-stage</li> <li>Pre-clinical</li> <li>In vitro data available</li> <li>In vivo data available (animal)</li> </ul> True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114170165 Liu B, et al. https://www.ncbi.nlm.nih.gov/pubmed/10991969 <a href="https://www.ncbi.nlm.nih.gov/pubmed/10991969">Liu B, et al.</a> 114109126 Qin, Liya NIEHS Qin, Liya 0 114109127 Li, Guorong NIEHS Li, Guorong 0 114109128 Block, MIchelle NIEHS NIEHS Block, MIchelle (NIEHS) 0 114109129 Zhang, Wei Zhang, Wei 0 114109130 Chen, Po-See Chen, Po-See 0 114109131 Peng, Giia-Shuen Peng, Giia-Shuen 0 114109125 Hong, Jau-Shyong NIEHS NIEHS Hong, Jau-Shyong (NIEHS) 1 114109125 Hong, Jau-Shyong NIEHS NIEHS Hong, Jau-Shyong (NIEHS) 1 114109126 Qin, Liya NIEHS Qin, Liya 0 114109127 Li, Guorong NIEHS Li, Guorong 0 114109128 Block, MIchelle NIEHS NIEHS Block, MIchelle (NIEHS) 0 114109129 Zhang, Wei Zhang, Wei 0 114109130 Chen, Po-See Chen, Po-See 0 114109131 Peng, Giia-Shuen Peng, Giia-Shuen 0 114100169 The Discovery And Identification For New Therapeutics Indications, Novel Compounds With Ultra-low Dose (femto-molar) For The Treatment And Prevention Of Neurodegenerative Or Inflammation-associated Diseases. E-130-2004-0 Filing authorized NIEHS 83739538 Choudhry, Vidita vidita.choudhry@nih.gov
United States of America Office of Technology Transfer and Development vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-1010] Novel Methods for Reducing Inflammation and Treating Diseases such as Parkinson's and Alzheimer's Disease&body=Please send me information about technology [TAB-1010] Novel Methods for Reducing Inflammation and Treating Diseases such as Parkinson's and Alzheimer's Disease. Choudhry, Vidita<br><a href="mailto:vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-1010] Novel Methods for Reducing Inflammation and Treating Diseases such as Parkinson's and Alzheimer's Disease&body=Please send me information about technology [TAB-1010] Novel Methods for Reducing Inflammation and Treating Diseases such as Parkinson's and Alzheimer's Disease.">vidita.choudhry@nih.gov</a><br> 114160596 E-130-2004-0 E-130-2004-0-PCT-02 Methods For The Treatment Of Neurodegenerative And Inflammatory Conditions. PCT Patent Cooperation Treaty PCT/US2005/16691 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2005/16691<br />Filed on 2005-05-12<br />Status: Expired 114160945 E-130-2004-0 E-130-2004-0-US-09 Methods Related to the Treatment of Neurodegenerative and Inflammatory Conditions CON US 9,498,511 14/323,557 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9498511 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9498511">9,498,511</a><br />Filed on 2014-07-03<br />Status: Expired 114160946 E-130-2004-0 E-130-2004-0-US-07 METHODS RELATED TO THE TREATMENT OF NEURODEGENERATIVE AND INFLAMMATORY CONDITIONS CON US 8,796,302 13/324,876 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8796302 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8796302">8,796,302</a><br />Filed on 2011-12-13<br />Status: Expired 114161719 E-130-2004-0 E-130-2004-0-US-01 Methods Related to the Treatment of Inflammatory Conditions PRV US 60/570,566 Abandoned US <br />Provisional (PRV) 60/570,566<br />Filed on 2004-05-12<br />Status: Abandoned 114161921 E-130-2004-0 E-130-2004-0-US-06 Methods Related to the Treatment of Neurodegenerative and Inflammatory Conditions National Stage US 8,088,787 11/596,296 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8088787 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8088787">8,088,787</a><br />Filed on 2006-11-13<br />Status: Issued 114114954 WKXXXX 114114955 YAXXXX 114114956 YBXXXX 114115692 NB1BXX 114115693 NBXXXX 114115694 IBXXXX 114115695 NXXXXX 114115696 IXXXXX 114116310 YCXXXX 114116638 IB3XXX 114116639 VEXXXX 114116640 WJXXXX 114120854 BBXXXX 114138680 Discovery 114138681 therapeutics 114138682 Ultra-low 114138683 DOSE 114138684 femto-molar 114138685 therapeutic 114138686 Prevention 114138687 NEURODEGENERATIVE 114138688 Inflammation-associated 114138689 Parkinson's 114138690 Patent Category - Biotechnology 114138691 Listed LPM Greene as of 4/15/2015 114138692 Pre LPM working set 20150418 114138693 Post LPM Assignment Set 20150420 114155800 Parkinson disease, juvenile, autosomal recessive 114155801 Parkinson disease 9 114155802 Alzheimer disease type 1 114155803 Parkinson disease 3 114155804 Alzheimer disease type 4 114155805 Alzheimer disease, familial, type 3 114157981 Parkinson disease 2 114157982 Alzheimer disease 1 114157983 Alzheimer disease 4 114157984 Alzheimer disease 3 TAB-1001 114095333 Infectious Clone of Human Parvovirus B19 and Methods of Use NHLBI Infectious Disease, Licensing, Therapeutics, Vaccines Infectious Disease Licensing Therapeutics Vaccines Ning Zhi This technology described in this patent application relates the first reported infectious human parvovirus B19 clone, methods of cloning the parvovirus B19 genome as well as other viral genomes that have secondary DNA structures that are unstable in bacterial cells. The infectious clone and methods of producing the same would be useful in producing infectious virus, which can in turn be used, among other things, to identify and develop therapeutic agents for treatment and/or prevention of human parvovirus B19 infections. The infectious parvovirus B19 clone is also available for licensing. Additional information about this invention can be found in Virology 2004, 318(1), 142-152. 2022-03-08 2024-10-28 2024-10-28 2004-11-01 DC5BXX, DCXXXX, DXXXXX, GB2AXX, GBXXXX, GXXXXX False True True NIHTT 37470483 Website Abstract 114104903 Zhi, Ning Zhi, Ning 0 114104903 Zhi, Ning Zhi, Ning 0 114100211 Construction Of An Infectious Clone Of Human Parvovirus B19 And Its Application To Gene Therapy Targeting Of Human Hemapoietic Cells E-178-2004-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI), Universite du Quebec 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-1001] Infectious Clone of Human Parvovirus B19 and Methods of Use&body=Please send me information about technology [TAB-1001] Infectious Clone of Human Parvovirus B19 and Methods of Use. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-1001] Infectious Clone of Human Parvovirus B19 and Methods of Use&body=Please send me information about technology [TAB-1001] Infectious Clone of Human Parvovirus B19 and Methods of Use.">shmilovm@nih.gov</a><br> 114162510 E-178-2004-0 E-178-2004-0-US-01 Infectious Clone Of Human Parvovirus B19 And Methods ORD US 7,598,071 10/887,770 Expired https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7598071 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7598071">7,598,071</a><br />Filed on 2004-07-09<br />Status: Expired 114165636 E-178-2004-0 E-178-2004-0-US-03 Infectious Clone Of Human Parvovirus B19 And Methods DIV US 8,603,784 12/569,848 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8603784 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8603784">8,603,784</a><br />Filed on 2009-09-29<br />Status: Abandoned 114115649 GB2AXX 114115650 DC5BXX 114115651 GBXXXX 114115652 DCXXXX 114115653 GXXXXX 114115654 DXXXXX TAB-4558 151738602 Mouse Models of Cryopyrin-Associated Periodic Syndrome (CAPS) for Drug Discovery NIAMS Animal Models, Immunology, Materials Available, Research Materials Animal Models Immunology Materials Available Research Materials Susannah Brydges, Harold Hoffman, Daniel ("Dan") Kastner, James Mueller <p>This technology includes mouse models that express versions of mouse cryopyrin protein containing mutations associated with human CAPS disease. We engineered mutations associated with three specific CAPS phenotypes (familial cold autoinflammatory syndrome (FCAS); Muckle-Wells syndrome (MWS); and neonatal onset multisystem inflammatory disease (NOMID)) into the mouse cryopyrin gene (called Nlrp3) to examine the roles of IL-1 &beta; and related cytokines, and better characterize inflammasome functions.</p> First available mouse model of CAPS and only available model of uncontrolled IL-1β signaling (the IL-1 receptor antagonist knock-out) did not address IL-1 β independent functions of the inflammasome. Mice could be used for testing additional IL-1, IL-18, and/or inflammasome or innate immune targeting drug moieties before entering the clinic. We are seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. 2023-12-11 2024-08-12 2024-10-03 2024-03-27 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 151738612 Brydges, Susannah Regeneron Pharmaceuticals, Inc. Brydges, Susannah 1 151738616 Hoffman, Harold University of California, San Diego Hoffman, Harold 2 151738624 Kastner, Daniel ("Dan") NHGRI Kastner, Daniel ("Dan") (NHGRI) 3 151738628 Mueller, James University of California, San Francisco (UCSF) Mueller, James 4 151738612 Brydges, Susannah Regeneron Pharmaceuticals, Inc. Brydges, Susannah 1 151738616 Hoffman, Harold University of California, San Diego Hoffman, Harold 2 151738624 Kastner, Daniel ("Dan") NHGRI Kastner, Daniel ("Dan") (NHGRI) 3 151738628 Mueller, James University of California, San Francisco (UCSF) Mueller, James 4 151738605 Mouse Models Of Cryopyrin-Associated Periodic Syndrome (CAPS) E-175-2018-0 Research Material NIAMS, University of California, San Diego 83656052 Knezevic, Vladimir vlado.knezevic@nih.gov
United States of America Technology Advancement Office vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-4558] Mouse Models of Cryopyrin-Associated Periodic Syndrome (CAPS) for Drug Discovery&body=Please send me information about technology [TAB-4558] Mouse Models of Cryopyrin-Associated Periodic Syndrome (CAPS) for Drug Discovery. Knezevic, Vladimir<br><a href="mailto:vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-4558] Mouse Models of Cryopyrin-Associated Periodic Syndrome (CAPS) for Drug Discovery&body=Please send me information about technology [TAB-4558] Mouse Models of Cryopyrin-Associated Periodic Syndrome (CAPS) for Drug Discovery.">vlado.knezevic@nih.gov</a><br> TAB-4507 151705837 Novel ApoC-11 Mimetic Peptides That Activate LPL for the Treatment of ApoC-11 Deficiency and Hypertriglyceridemia NHLBI Cardiology, Licensing, Research Materials, Therapeutics Cardiology Licensing Research Materials Therapeutics Soumitra Ghosh, Chih-Hung (Larry) Lo, Alan Remaley, Denis Sviridov, Anna Wolska <p>This technology includes a new class of synthetic peptides that activate Lipoprotein Lipase (LPL), a key plasma enzyme that lowers triglycerides. Mutations in apoC-II is a genetic cause of severe hypertriglyceridemia, which can lead to cardiovascular disease and pancreatitis. The last helical domain (3rd helix) of apoC-ll activates LPL, and we discovered by making a series of amino acids substitutions in the second helix to increase its ability to bind to lipoproteins that we were able to produce novel apoC-II mimetic peptides that potently activate LPL and are less likely to be immunogenic.</p> There is currently no known therapy for apoC-11 deficiency. Treatment of apoC-11 deficiency and hypertriglyceridemia. We are seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. 2023-12-07 2024-08-12 2024-09-11 2024-03-27 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 151706058 Ghosh, Soumitra Corvidia Therapeutics, Inc. Ghosh, Soumitra 1 151706062 Lo, Chih-Hung (Larry) Corvidia Therapeutics, Inc. Lo, Chih-Hung (Larry) 2 151706066 Remaley, Alan National Heart, Lung, and Blood Institute (NHLBI) NHLBI Remaley, Alan (NHLBI) 3 151706070 Sviridov, Denis National Heart, Lung, and Blood Institute (NHLBI) NHLBI Sviridov, Denis (NHLBI) 4 151706074 Wolska, Anna National Heart, Lung, and Blood Institute (NHLBI) NHLBI Wolska, Anna (NHLBI) 5 151706058 Ghosh, Soumitra Corvidia Therapeutics, Inc. Ghosh, Soumitra 1 151706062 Lo, Chih-Hung (Larry) Corvidia Therapeutics, Inc. Lo, Chih-Hung (Larry) 2 151706066 Remaley, Alan National Heart, Lung, and Blood Institute (NHLBI) NHLBI Remaley, Alan (NHLBI) 3 151706070 Sviridov, Denis National Heart, Lung, and Blood Institute (NHLBI) NHLBI Sviridov, Denis (NHLBI) 4 151706074 Wolska, Anna National Heart, Lung, and Blood Institute (NHLBI) NHLBI Wolska, Anna (NHLBI) 5 151705840 ApoC-II Mimetic Peptides That Activate LPLI E-139-2017-0 Filing authorized Corvidia Therapeutics, Inc., National Heart, Lung, and Blood Institute (NHLBI) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-4507] Novel ApoC-11 Mimetic Peptides That Activate LPL for the Treatment of ApoC-11 Deficiency and Hypertriglyceridemia&body=Please send me information about technology [TAB-4507] Novel ApoC-11 Mimetic Peptides That Activate LPL for the Treatment of ApoC-11 Deficiency and Hypertriglyceridemia. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-4507] Novel ApoC-11 Mimetic Peptides That Activate LPL for the Treatment of ApoC-11 Deficiency and Hypertriglyceridemia&body=Please send me information about technology [TAB-4507] Novel ApoC-11 Mimetic Peptides That Activate LPL for the Treatment of ApoC-11 Deficiency and Hypertriglyceridemia.">shmilovm@nih.gov</a><br> 157755207 E-139-2017-0 E-139-2017-0-US-01 ApoC-II Mimetic Peptides PRV US 62/476,531 Abandoned US <br />Provisional (PRV) 62/476,531<br />Filed on 2017-03-24<br />Status: Abandoned TAB-4506 151705743 Anti-sense Therapy Against ApoC-III as a Treatment for High Cholesterol NHLBI Cardiology, Licensing, Therapeutics Cardiology Licensing Therapeutics Madhav (Matt) Devalaraja, Soumitra Ghosh, Chih-Hung (Larry) Lo, Alan Remaley, Denis Sviridov, Anna Wolska <p>This technology includes a new class of synthetic peptides that activate Lipoprotein Lipase (LPL), a key plasma enzyme that lowers triglycerides, by displacing apoC-111, a potent inhibitor of LPL. ApoC-11 is a known activator of LPL, whereas ApoC-111 inhibits LPL and raises triglycerides either directly by blocking lipolysis and or by preventing hepatic uptake of lipoproteins. Both apoC-II and apoC-III have to bind to the surface of a lipoprotein particle to mediate their effects. We discovered that we can displace apoC-III from lipoproteins and improve lipolysis by adding short synthetic peptide mimetics of apoC-II. These peptides are described in another EIR. Anti-sense therapy against apoC-111 has been shown in late-stage clinical trials to be useful for a wide variety of causes of hypertriglyceridemia, including LPL deficiency, thus our new peptides that antagonize apoC-III can be an alternative approach.</p> A novel therapeutic peptide with large potential patient population and less hematologic and injection site toxicity. Treatment of hypertriglyceridemia. We are seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. 2023-12-07 2024-08-12 2024-09-11 2024-03-20 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 151705750 Ghosh, Soumitra Ghosh, Soumitra 1 151705755 Lo, Chih-Hung (Larry) Corvidia Therapeutics, Inc. Lo, Chih-Hung (Larry) 2 151705759 Remaley, Alan National Heart, Lung, and Blood Institute (NHLBI) NHLBI Remaley, Alan (NHLBI) 3 151705763 Devalaraja, Madhav (Matt) Corvidia Therapeutics, Inc. Devalaraja, Madhav (Matt) 4 151705767 Sviridov, Denis National Heart, Lung, and Blood Institute (NHLBI) NHLBI Sviridov, Denis (NHLBI) 5 151705771 Wolska, Anna National Heart, Lung, and Blood Institute (NHLBI) NHLBI Wolska, Anna (NHLBI) 6 151705750 Ghosh, Soumitra Ghosh, Soumitra 1 151705755 Lo, Chih-Hung (Larry) Corvidia Therapeutics, Inc. Lo, Chih-Hung (Larry) 2 151705759 Remaley, Alan National Heart, Lung, and Blood Institute (NHLBI) NHLBI Remaley, Alan (NHLBI) 3 151705763 Devalaraja, Madhav (Matt) Corvidia Therapeutics, Inc. Devalaraja, Madhav (Matt) 4 151705767 Sviridov, Denis National Heart, Lung, and Blood Institute (NHLBI) NHLBI Sviridov, Denis (NHLBI) 5 151705771 Wolska, Anna National Heart, Lung, and Blood Institute (NHLBI) NHLBI Wolska, Anna (NHLBI) 6 151705746 ApoC-llA Mimetic Peptides That Antagonize ApoC-111 E-134-2017-0 Filing authorized Corvidia Therapeutics, Inc., National Heart, Lung, and Blood Institute (NHLBI) 153929528 Ghosh, Malabika malabika.ghosh@nih.gov
United States of America malabika.ghosh@nih.gov?subject=Web Inquiry on [TAB-4506] Anti-sense Therapy Against ApoC-III as a Treatment for High Cholesterol&body=Please send me information about technology [TAB-4506] Anti-sense Therapy Against ApoC-III as a Treatment for High Cholesterol. Ghosh, Malabika<br><a href="mailto:malabika.ghosh@nih.gov?subject=Web Inquiry on [TAB-4506] Anti-sense Therapy Against ApoC-III as a Treatment for High Cholesterol&body=Please send me information about technology [TAB-4506] Anti-sense Therapy Against ApoC-III as a Treatment for High Cholesterol.">malabika.ghosh@nih.gov</a><br> 157755178 E-134-2017-0 E-134-2017-0-US-01 ApoC-llA Mimetic Peptides That Antagonize ApoC-III PRV US 62/448,358 Abandoned US <br />Provisional (PRV) 62/448,358<br />Filed on 2017-01-19<br />Status: Abandoned TAB-4482 151644645 ApoE-ApoCII Chimeric Peptides for Treating Hypertriglyceridemia NHLBI Cardiology, Licensing, Materials Available, Research Materials, Therapeutics Cardiology Licensing Materials Available Research Materials Therapeutics Madhav (Matt) Devalaraja, Soumitra Ghosh, Chih-Hung (Larry) Lo, Alan Remaley, Denis Sviridov, Anna Wolska <p>This technology includes apoE-apoCII chimeric peptides that possess the ability to lower the triglyceride level both in vitro and in vivo. These peptides can be used for treating hypertriglyceridemia and alleviating other diseases and conditions associated with increased triglycerides.</p> The peptide sequence is novel and is the first example of an apoC-11 mimetic peptide that contains an additional motif based on ApoE that enhances removal of triglyceride-rich lipoproteins. Treatment for hypertriglyceridemia. We are seeking statements of capability or interest from parties interested in collaborative research to further developer, evaluate, or commercialize this technology. 2023-12-06 2024-08-12 2024-09-11 2024-03-27 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 151644652 Ghosh, Soumitra Corvidia Therapeutics, Inc. Ghosh, Soumitra 1 151644657 Lo, Chih-Hung (Larry) Corvidia Therapeutics, Inc. Lo, Chih-Hung (Larry) 2 151644854 Remaley, Alan National Heart, Lung, and Blood Institute (NHLBI) NHLBI Remaley, Alan (NHLBI) 3 151644858 Sviridov, Denis National Heart, Lung, and Blood Institute (NHLBI) NHLBI Sviridov, Denis (NHLBI) 4 151644862 Wolska, Anna National Heart, Lung, and Blood Institute (NHLBI) NHLBI Wolska, Anna (NHLBI) 5 151644866 Devalaraja, Madhav (Matt) Corvidia Therapeutics, Inc. Devalaraja, Madhav (Matt) 6 151644652 Ghosh, Soumitra Corvidia Therapeutics, Inc. Ghosh, Soumitra 1 151644657 Lo, Chih-Hung (Larry) Corvidia Therapeutics, Inc. Lo, Chih-Hung (Larry) 2 151644854 Remaley, Alan National Heart, Lung, and Blood Institute (NHLBI) NHLBI Remaley, Alan (NHLBI) 3 151644858 Sviridov, Denis National Heart, Lung, and Blood Institute (NHLBI) NHLBI Sviridov, Denis (NHLBI) 4 151644862 Wolska, Anna National Heart, Lung, and Blood Institute (NHLBI) NHLBI Wolska, Anna (NHLBI) 5 151644866 Devalaraja, Madhav (Matt) Corvidia Therapeutics, Inc. Devalaraja, Madhav (Matt) 6 151644648 ApoE-ApoCII Chimeric Peptides E-055-2019-0 Filing authorized Corvidia Therapeutics, Inc., National Heart, Lung, and Blood Institute (NHLBI) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-4482] ApoE-ApoCII Chimeric Peptides for Treating Hypertriglyceridemia&body=Please send me information about technology [TAB-4482] ApoE-ApoCII Chimeric Peptides for Treating Hypertriglyceridemia. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-4482] ApoE-ApoCII Chimeric Peptides for Treating Hypertriglyceridemia&body=Please send me information about technology [TAB-4482] ApoE-ApoCII Chimeric Peptides for Treating Hypertriglyceridemia.">shmilovm@nih.gov</a><br> 157754177 E-055-2019-0 E-055-2019-0-US-01 ApoE-ApoCII Chimeric Peptides PRV US 62/700,751 Abandoned US <br />Provisional (PRV) 62/700,751<br />Filed on 2018-07-19<br />Status: Abandoned TAB-4571 151739798 Generation of AAVS1 and C13 “Safe Harbor” Transcription Activator-life Effector Nucleases (TALENs) for Drug Screening or Gene Therapy Development NIAMS Diagnostics, Licensing, Plasmids/Vectors, Research Materials, Therapeutics Diagnostics Licensing Plasmids/Vectors Research Materials Therapeutics Mahendra Rao, Jizhong Zou <p>This technology includes AAVS1 and C13 &ldquo;safe harbor&rdquo; transcription activator-life effector nucleases (TALENs) for drug screening or gene therapy applications. TALENs are engineered sequence-specific DNA endonucleases that can significantly enhance genome-editing efficiency by &gt;100-1000 folds. &ldquo;Safe harbor&rdquo; such as AAVS1 safe harbor and C13 safe harbor is genome locus that allows robust and persistent transgene expression with no or minimal interference of endogenous gene expression and cell properties. Construction of TALEN-expression vectors that specifically target safe harbor locus will create high-efficiency and widely-applicable system to achieve precise genome engineering in human cells. Plasmids are available from Addgene:</p> <ul> <li><a href="https://www.addgene.org/62196/" target="_blank">https://www.addgene.org/62196/</a></li> <li><a href="https://www.addgene.org/62196/" target="_blank">https://www.addgene.org/62197/</a></li> <li><a href="https://www.addgene.org/52637/" target="_blank">https://www.addgene.org/52637/</a></li> <li><a href="https://www.addgene.org/52638/" target="_blank">https://www.addgene.org/52638/</a></li> </ul> <p>&nbsp;</p> When used with safe harbor locus-specific gene targeting donor vector, AAVS1- or C13-TALEN will allow efficient insertion of cell-type specific reporter cassette or functional minigene into these safe harbors, and the transgene expression won’t diminish over the extended culture or differentiation. Safe harbor, TALENs have broad applications on engineering any human primary cells and cell lines; safe harbor targeted human cell line, from either pluripotent stem cells or somatic cells, can be used for drug screening by reporter gene expression, or gene therapy by restoration of normal gene function. We are seeking statements of capability or interest from parties interested in collaborative research to further developer, evaluate, or commercialize this technology. 2023-12-11 2024-07-24 2024-09-10 2024-03-27 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 157295776 Cerbini T, et al. https://pubmed.ncbi.nlm.nih.gov/25587899/ <a href="https://pubmed.ncbi.nlm.nih.gov/25587899/">Cerbini T, et al.</a> 157295779 Luo Y, et al. https://pubmed.ncbi.nlm.nih.gov/24833591/ <a href="https://pubmed.ncbi.nlm.nih.gov/24833591/">Luo Y, et al.</a> 151739805 Zou, Jizhong National Heart, Lung, and Blood Institute (NHLBI) NHLBI Zou, Jizhong (NHLBI) 1 151739809 Rao, Mahendra New York Stem Cell Foundation Rao, Mahendra 2 151739805 Zou, Jizhong National Heart, Lung, and Blood Institute (NHLBI) NHLBI Zou, Jizhong (NHLBI) 1 151739809 Rao, Mahendra New York Stem Cell Foundation Rao, Mahendra 2 151739801 Generation Of AAVS1 And C13 "safe Harbor" Transcription Activator-like Nucleases (TALENs) E-616-2013-0 Research Material NIAMS 83656052 Knezevic, Vladimir vlado.knezevic@nih.gov
United States of America Technology Advancement Office vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-4571] Generation of AAVS1 and C13 “Safe Harbor” Transcription Activator-life Effector Nucleases (TALENs) for Drug Screening or Gene Therapy Development&body=Please send me information about technology [TAB-4571] Generation of AAVS1 and C13 “Safe Harbor” Transcription Activator-life Effector Nucleases (TALENs) for Drug Screening or Gene Therapy Development. Knezevic, Vladimir<br><a href="mailto:vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-4571] Generation of AAVS1 and C13 “Safe Harbor” Transcription Activator-life Effector Nucleases (TALENs) for Drug Screening or Gene Therapy Development&body=Please send me information about technology [TAB-4571] Generation of AAVS1 and C13 “Safe Harbor” Transcription Activator-life Effector Nucleases (TALENs) for Drug Screening or Gene Therapy Development.">vlado.knezevic@nih.gov</a><br> TAB-4538 151735625 Identification of a Novel Parvovirus for Vaccine Development and Use as a Diagnostic Tool NHLBI Diagnostics, Infectious Disease, Licensing Diagnostics Infectious Disease Licensing Gangqing Hu, Baoyan Xu, Neal Young, Keji Zhao, Ning Zhi <p>This technology includes a procedure for novel virus identification in a variety of human specimens by solexa high-throughput sequencing, which allows for the screening a large number of clinical specimens for novel virus discovery in a highly efficient and relatively economical method. By using this technique, we have successfully identified a novel parvovirus from samples of seronegative hepatitis patients. In a total of 70 samples tested, nineteen of them (27%) were positive by solexa sequencing and 23 (33%) were positive by PCR, which was developed based on the viral sequences obtained from the solexa data. Based on phylogenetic and genome structure analysis, this newly identified virus represents a new genus of parvoviridae family. This discovery potentially lays a foundation for the development of diagnostic reagents, vaccine and treatment against the viral hepatitis.</p> The method would be more efficient and cheaper than regular methods, especially in the cases of multiple pathogen co infection, unknown etiology infection, and fast detection of bioterrorism attack. <ul> <li>Since the virus identified is novel, our discovery could be used in development of vaccine against the viral hepatitis diagnostic testing kit and treatment reagents.</li> <li>The procedure and reagents invented for novel virus discovery could be used in clinical diagnosis of bacterial and/or viral infection.</li> </ul> We are seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. 2023-12-11 2024-08-12 2024-09-05 2024-03-20 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 151735796 Zhi, Ning National Heart, Lung, and Blood Institute (NHLBI) Zhi, Ning 1 151735810 Young, Neal National Heart, Lung, and Blood Institute (NHLBI) NHLBI Young, Neal (NHLBI) 2 151735815 Xu, Baoyan Xu, Baoyan 3 151735820 Zhao, Keji National Heart, Lung, and Blood Institute (NHLBI) NHLBI Zhao, Keji (NHLBI) 4 151735824 Hu, Gangqing National Heart, Lung, and Blood Institute (NHLBI) NHLBI Hu, Gangqing (NHLBI) 5 151735796 Zhi, Ning National Heart, Lung, and Blood Institute (NHLBI) Zhi, Ning 1 151735810 Young, Neal National Heart, Lung, and Blood Institute (NHLBI) NHLBI Young, Neal (NHLBI) 2 151735815 Xu, Baoyan Xu, Baoyan 3 151735820 Zhao, Keji National Heart, Lung, and Blood Institute (NHLBI) NHLBI Zhao, Keji (NHLBI) 4 151735824 Hu, Gangqing National Heart, Lung, and Blood Institute (NHLBI) NHLBI Hu, Gangqing (NHLBI) 5 151735628 A Novel Parvovirus Is Identified In Seronegative Hepatitis Patients By Solexa High Throughput Sequencing E-248-2011-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 83739538 Choudhry, Vidita vidita.choudhry@nih.gov
United States of America Office of Technology Transfer and Development vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-4538] Identification of a Novel Parvovirus for Vaccine Development and Use as a Diagnostic Tool&body=Please send me information about technology [TAB-4538] Identification of a Novel Parvovirus for Vaccine Development and Use as a Diagnostic Tool. Choudhry, Vidita<br><a href="mailto:vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-4538] Identification of a Novel Parvovirus for Vaccine Development and Use as a Diagnostic Tool&body=Please send me information about technology [TAB-4538] Identification of a Novel Parvovirus for Vaccine Development and Use as a Diagnostic Tool.">vidita.choudhry@nih.gov</a><br> 157756169 E-248-2011-0 E-248-2011-0-US-01 METHODS FOR DETECTING INFECTIOUS AGENTS AND A NOVEL PARVOVIRUS DETECTED THEREBY PRV US 61/558,363 Abandoned US <br />Provisional (PRV) 61/558,363<br />Filed on 2011-11-10<br />Status: Abandoned 157756174 E-248-2011-0 E-248-2011-0-PCT-02 Methods for Detecting Infectious Agents and A Novel Virus Detected Thereby PCT Patent Cooperation Treaty PCT/US2012/064668 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2012/064668<br />Filed on 2012-11-12<br />Status: Expired TAB-4549 151737307 DLX3-floxed mice (DLX3f/f) for Use in Drug Development and In Vivo Research Studies for Ectodermal Dysplasia Disorders NIAMS Animal Models, Dermatology, Licensing, Materials Available, Research Materials Animal Models Dermatology Licensing Materials Available Research Materials Maria Morasso <p>This technology includes the creation of DLX3-floxed mice, specifically designed for conditional deletion of the DLX3 gene via Cre-mediated recombination. This innovative approach aims to develop mouse models for studying ectodermal dysplasia disorders. Ectodermal dysplasias are a diverse group of genetic conditions affecting the development of ectodermal structures, including hair, teeth, and bones. The DLX3f/f mice are particularly valuable for modeling specific disorders such as Tricho-dento-osseous syndrome (TDO), Amelogenesis Imperfecta (AI), and Dentinogenesis Imperfecta (DI). By selectively ablating the DLX3 gene, the genetic and phenotypic aspects of these disorders can be closely mimicked, enhancing our understanding and potentially leading to new therapeutic strategies.</p> Floxed DLX3 allele allows conditional knockout of this gene in different tissues at specific time during development. A potential use of DLX3f/f mice is for the generation of mouse models for ectodermal dysplasia disorders, perform targeted drug development, and to study molecular mechanisms of DLX3 regulation in skin and ectodermal appendages. 2023-12-11 2024-09-05 2024-09-05 2024-03-27 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 151737314 Morasso, Maria NIAMS - IRP NIAMS Morasso, Maria (NIAMS) 1 151737314 Morasso, Maria NIAMS - IRP NIAMS Morasso, Maria (NIAMS) 1 151737310 DLX3-floxed Mice (DLX3f/f) Developed For Conditional Ere-mediated Ablation Of DLX3 Gene E-012-2015-0 Research Material NIAMS 83656052 Knezevic, Vladimir vlado.knezevic@nih.gov
United States of America Technology Advancement Office vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-4549] DLX3-floxed mice (DLX3f/f) for Use in Drug Development and In Vivo Research Studies for Ectodermal Dysplasia Disorders&body=Please send me information about technology [TAB-4549] DLX3-floxed mice (DLX3f/f) for Use in Drug Development and In Vivo Research Studies for Ectodermal Dysplasia Disorders. Knezevic, Vladimir<br><a href="mailto:vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-4549] DLX3-floxed mice (DLX3f/f) for Use in Drug Development and In Vivo Research Studies for Ectodermal Dysplasia Disorders&body=Please send me information about technology [TAB-4549] DLX3-floxed mice (DLX3f/f) for Use in Drug Development and In Vivo Research Studies for Ectodermal Dysplasia Disorders.">vlado.knezevic@nih.gov</a><br> TAB-2353 114096557 Modulating Autophagy as a Treatment for Lysosomal Storage Diseases NIAMS Collaboration, Diagnostics, Rare/Neglected Diseases, Research Materials, Therapeutics Collaboration Diagnostics Rare/Neglected Diseases Research Materials Therapeutics Rebecca Baum, Paul (Estate of) Plotz, Nina Raben, Cynthia Schreiner, Shoichi Takikita, Tao Xie Researchers at NIAMS have developed a technology for treatment of lysosomal storage diseases by inhibition of autophagy. Pompe disease is an example of a genetic lysosomal storage disease caused by a reduction or absence of acid alpha-glucosidase (GAA). Patients with Pompe disease have a lysosomal buildup of glycogen in cardiac and skeletal muscle cells and severe cardiomyopathy and skeletal muscle myopathy. Treatment of Pompe disease by GAA enzyme replacement therapy is quite ineffective for the skeletal muscle myopathy. Skeletal muscle resistance to therapy is associated with increased cellular buildup of autophagic debris. Inactivation of autophagy results in effective GAA replacement therapy and a reduction in glycogen back to normal levels. This technology provides a novel approach for the treatment of Pompe disease as well as other diseases where autophagy is a critical contributor to disease development. <ul> <li>This technology is the first use of autophagy disablement to reverse an intracellular pathology</li> <li>More effective than enzyme replacement therapy alone for the treatment of the lysosomal storage disease, Pompe disease</li> </ul> <ul> <li>Development of tools for autophagy suppression and treatment of a variety of diseases</li> <li>Development of chemical inhibitors of autophagy</li> <li>Development of animal models to study lysosomal storage diseases</li> </ul> 2022-03-08 2024-08-15 2024-08-15 2012-01-17 Acid, A-glucosidase, Autophagy, B, Clearance, Complete, DEFICIENCY, Disabling, Disease, Enzyme, ERT, GB1XXX, GBXXXX, Genetic, GLYCOGEN, GXXXXX, IBXXXX, Inactivation, IXXXXX, Lysosomal, Model, Mouse, MUSCLE, Near, Patent Category - Biotechnology, Permits, Pompe, REPLACEMENT, SKELETAL, Storage, STORED, THERAPY, UA1XXX False True In vivo data available (animal) True NIHTT 37470483 Website Abstract 114171480 Raben N, et al. http://www.ncbi.nlm.nih.gov/pubmed/20861693 <a href="http://www.ncbi.nlm.nih.gov/pubmed/20861693">Raben N, et al.</a> 114171481 Raben N, et al. http://www.ncbi.nlm.nih.gov/pubmed/18782848 <a href="http://www.ncbi.nlm.nih.gov/pubmed/18782848">Raben N, et al.</a> 114107391 Schreiner, Cynthia NIAMS - IRP NIAMS Schreiner, Cynthia (NIAMS) 0 114107392 Plotz, Paul (Estate of) NIAMS - IRP NIAMS Plotz, Paul (Estate of) (NIAMS) 0 114107393 Takikita, Shoichi NIAMS - IRP Takikita, Shoichi 0 114107394 Xie, Tao NIAMS - IRP NIAMS Xie, Tao (NIAMS) 0 114107395 Baum, Rebecca NIAMS - IRP Baum, Rebecca 0 114107390 Raben, Nina NIAMS - IRP NHLBI Raben, Nina (NHLBI) 1 114107390 Raben, Nina NIAMS - IRP NHLBI Raben, Nina (NHLBI) 1 114107391 Schreiner, Cynthia NIAMS - IRP NIAMS Schreiner, Cynthia (NIAMS) 0 114107392 Plotz, Paul (Estate of) NIAMS - IRP NIAMS Plotz, Paul (Estate of) (NIAMS) 0 114107393 Takikita, Shoichi NIAMS - IRP Takikita, Shoichi 0 114107394 Xie, Tao NIAMS - IRP NIAMS Xie, Tao (NIAMS) 0 114107395 Baum, Rebecca NIAMS - IRP Baum, Rebecca 0 114101655 Disabling Autophagy By Genetic Inactivation In Skeletal Muscle Permits Near Complete Clearance B Enzyme Replacement Therapy (ERT) Of Stored Glycogen From Skeletal Muscle In A Mouse Model Of The Lysosomal Storage Disease, Acid A-glucosidase Deficiency E-210-2009-0 Filing authorized NIAMS 83656052 Knezevic, Vladimir vlado.knezevic@nih.gov
United States of America Technology Advancement Office vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-2353] Modulating Autophagy as a Treatment for Lysosomal Storage Diseases&body=Please send me information about technology [TAB-2353] Modulating Autophagy as a Treatment for Lysosomal Storage Diseases. Knezevic, Vladimir<br><a href="mailto:vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-2353] Modulating Autophagy as a Treatment for Lysosomal Storage Diseases&body=Please send me information about technology [TAB-2353] Modulating Autophagy as a Treatment for Lysosomal Storage Diseases.">vlado.knezevic@nih.gov</a><br> 114166667 E-210-2009-0 E-210-2009-0-US-03 Disabling Autophagy As a Treatment For Lysosomal Storage Diseases National Stage US 8,536,148 13/391,265 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8536148 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8536148">8,536,148</a><br />Filed on 2012-02-17<br />Status: Issued 114122448 UA1XXX 114122449 IBXXXX 114122450 GB1XXX 114122451 IXXXXX 114122452 GXXXXX 114122453 GBXXXX 114142316 Disabling 114142317 Autophagy 114142318 Genetic 114142319 Inactivation 114142320 SKELETAL 114142321 MUSCLE 114142322 Permits 114142323 Near 114142324 Complete 114142325 Clearance 114142326 B 114142327 Enzyme 114142328 REPLACEMENT 114142329 THERAPY 114142330 ERT 114142331 STORED 114142332 GLYCOGEN 114142333 Mouse 114142334 Model 114142335 Lysosomal 114142336 Storage 114142337 Disease 114142338 Acid 114142339 A-glucosidase 114142340 DEFICIENCY 114142341 Pompe 114142342 Patent Category - Biotechnology TAB-3727 114097579 A Novel Therapy/Companion Diagnostic (BAM15 And mtDNA) for Sepsis and Sepsis-induced Acute Kidney Injury NIDDK Cardiology, Dental, Diagnostics, Endocrinology, Infectious Disease, Oncology, Ophthalmology, Research Materials Cardiology Dental Diagnostics Endocrinology Infectious Disease Oncology Ophthalmology Research Materials Robert Star, Naoko Tsuji, Takayuki Tsuji, Peter Yuen This technology includes a therapy and companion diagnostic which can be used for the early diagnosis and treatment of sepsis and sepsis-induced acute kidney injury (AKI). Mitochondrial damage plays a key role in sepsis-induced acute kidney injury BAM15 [2-ftuorophenyl){6-[(2- fluorophenyl)am ino]{1 ,2,5-oxadiazolo[3,4-e]pyrazin-5-yl)}amine] is a mitochondrial uncoupler that protects mitochondria with more specificity and less cytotoxicity than other uncouplers. Mitochondrial DNA (mtDNA) is a damage associated molecular pattern that is increased in human sepsis. Using a mouse model of sepsis, we showed that BAM15 improved survival and reduced kidney injury, and also reduced circulating and urinary mtDNA. Scientifically, this suggests that BAM15 reduces mitochondrial injury and/or improves recovery from damage. More critically, BAM15 and mtDNA form a drug-companion biomarker pair for sepsis/sepsis AKI that would allow selection of patients for therapy, enhance drug dose finding, and create a novel surrogate biomarker for drug effect. There is no current sepsis or sepsis/SKI therapy available that has been shown to improve outcomes. Diagnosis and treatment of sepsis and sepsis-induced acute kidney injury. 2022-11-30 2024-08-12 2024-08-12 2022-11-30 2022-07-10 ACUTE, BAM15, diagnostic, Injury., KIDNEY, mtDNA, Novel, Sepsis, Sepsis-Induced, Therapy/companion, VPXXXX, WBXXXX, XCXXXX False True True 52398218 Pre-Clinical (in vivo) 52398218 NIHTT 37470483 Website Abstract 146781161 Tsuji N, et al., 2023 https://pubmed.ncbi.nlm.nih.gov/36757801/ <a href="https://pubmed.ncbi.nlm.nih.gov/36757801/">Tsuji N, et al., 2023</a> 114111408 Tsuji, Naoko National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Tsuji, Naoko (NIDDK) 0 114111409 Yuen, Peter National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Yuen, Peter (NIDDK) 0 114111410 Tsuji, Takayuki National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Tsuji, Takayuki (NIDDK) 0 114111407 Star, Robert National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Star, Robert (NIDDK) 1 114111407 Star, Robert National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Star, Robert (NIDDK) 1 114111408 Tsuji, Naoko National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Tsuji, Naoko (NIDDK) 0 114111409 Yuen, Peter National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Yuen, Peter (NIDDK) 0 114111410 Tsuji, Takayuki National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Tsuji, Takayuki (NIDDK) 0 114102831 A Novel Therapy/companion Diagnostic (BAM15 And MtDNA) For Sepsis And Sepsis-induced Acute Kidney Injury. E-011-2020-0 Filing authorized National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83656052 Knezevic, Vladimir vlado.knezevic@nih.gov
United States of America Technology Advancement Office vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-3727] A Novel Therapy/Companion Diagnostic (BAM15 And mtDNA) for Sepsis and Sepsis-induced Acute Kidney Injury&body=Please send me information about technology [TAB-3727] A Novel Therapy/Companion Diagnostic (BAM15 And mtDNA) for Sepsis and Sepsis-induced Acute Kidney Injury. Knezevic, Vladimir<br><a href="mailto:vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-3727] A Novel Therapy/Companion Diagnostic (BAM15 And mtDNA) for Sepsis and Sepsis-induced Acute Kidney Injury&body=Please send me information about technology [TAB-3727] A Novel Therapy/Companion Diagnostic (BAM15 And mtDNA) for Sepsis and Sepsis-induced Acute Kidney Injury.">vlado.knezevic@nih.gov</a><br> 114129412 VPXXXX 114129413 WBXXXX 114129414 XCXXXX 114154854 Novel 114154855 Therapy/companion 114154856 diagnostic 114154857 BAM15 114154858 mtDNA 114154859 Sepsis 114154860 Sepsis-Induced 114154861 ACUTE 114154862 KIDNEY 114154863 Injury. TAB-4606 151784081 Synthesis and Characterization of d8-JD5037 for Drug Discovery Studies NIAAA Computational models/software, Human Cell Lines, Licensing, Research Materials, Therapeutics Computational models/software Human Cell Lines Licensing Research Materials Therapeutics Resat Cinar, Nathan Coffey, Malliga Iyer <p>This technology includes synthesis of S-2-((S)-3-(4-chlorophenyl)-N&#39;-((4-chlorophenyl) sulfonyl)-4-phenyl-4,5-dihydro-1 H-pyrazole-1-carboximidamido)- 3-(methyld3) butanamide-d5, octadeuterated JD5037 for possible use in clinical Absorption, Distribution, Metabolism, and Excretion (ADME) studies for drug discovery studies.</p> Novel; first synthesis of d8-JD5037. Use in ADME studies for drug discovery. We are seeking statements of capability or interest from parties interested in collaborative research to further developer, evaluate, or commercialize this technology. 2023-12-13 2024-08-12 2024-08-12 2024-03-20 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 151784217 Iyer M, Cinar R, et al. https://pubmed.ncbi.nlm.nih.gov/28545167/ [PMID 28545167] https://pubmed.ncbi.nlm.nih.gov/28545167/ <a href="https://pubmed.ncbi.nlm.nih.gov/28545167/">Iyer M, Cinar R, et al. https://pubmed.ncbi.nlm.nih.gov/28545167/ [PMID 28545167]</a> 151784095 Iyer, Malliga National Institute on Alcohol Abuse and Alcoholism (NIAAA) NIAAA Iyer, Malliga (NIAAA) 1 151784107 Cinar, Resat National Institute on Alcohol Abuse and Alcoholism (NIAAA) NIAAA Cinar, Resat (NIAAA) 2 151784168 Coffey, Nathan National Institute on Alcohol Abuse and Alcoholism (NIAAA) NIAAA Coffey, Nathan (NIAAA) 3 151784095 Iyer, Malliga National Institute on Alcohol Abuse and Alcoholism (NIAAA) NIAAA Iyer, Malliga (NIAAA) 1 151784107 Cinar, Resat National Institute on Alcohol Abuse and Alcoholism (NIAAA) NIAAA Cinar, Resat (NIAAA) 2 151784168 Coffey, Nathan National Institute on Alcohol Abuse and Alcoholism (NIAAA) NIAAA Coffey, Nathan (NIAAA) 3 151784084 Synthesis And Characterization Of D8-JD5037 E-012-2019-0 Research Material National Institute on Alcohol Abuse and Alcoholism (NIAAA) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-4606] Synthesis and Characterization of d8-JD5037 for Drug Discovery Studies&body=Please send me information about technology [TAB-4606] Synthesis and Characterization of d8-JD5037 for Drug Discovery Studies. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-4606] Synthesis and Characterization of d8-JD5037 for Drug Discovery Studies&body=Please send me information about technology [TAB-4606] Synthesis and Characterization of d8-JD5037 for Drug Discovery Studies.">shmilovm@nih.gov</a><br> TAB-4525 151719676 Single cell profiling of chromatin Occupancy and RNAs Sequencing (scPCOR-seq) NHLBI Diagnostics, Licensing, Oncology, Research Materials Diagnostics Licensing Oncology Research Materials Keji Zhao <p>Cell-to-cell heterogeneity in gene expression is a widespread phenomenon, and may play important roles in cellular differentiation, function and disease development. Human Cell Atlas aims to profile gene expression in every single human cells. Recent studies have implicated a potential role of chromatin in the heterogeneity in gene expression. Understanding the mechanisms of cellular heterogeneity requires simultaneous measurement of RNA and occupancy of histone modifications and transcription factors on chromatin due to their critical roles in transcriptional regulation. However, methods for simultaneous profiling of chromatin occupancy and RNA in the same single cell are not available currently. Scientists at the National Heart, Lung, and Blood Institute have developed a technique, called scPCORseq (single-cell Profiling of Chromatin Occupancy and RNAs Sequencing), for simultaneously profiling genome-wide chromatin protein binding or histone modification marks and RNA expression in the same cell.</p> <ul> <li>Measures both protein binding or histone modifications and RNA levels (transcriptome) at a single-cell resolution.</li> </ul> <ul> <li>Tools to study clinical samples for diagnostic purpose.</li> <li>Research tool for understanding basic biological mechanisms.</li> </ul> We are seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. 2023-12-08 2024-08-12 2024-08-12 2024-01-04 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract U.S. Provisional Application No. 63/1 11 951 filed on November 10 2020; International Publication No. WO/2022/103857; NIH Ref. No. E-197-2020-0-US-01 151874794 Pan, L., et al. https://pubmed.ncbi.nlm.nih.gov/35804086/ <a href="https://pubmed.ncbi.nlm.nih.gov/35804086/">Pan, L., et al.</a> 151719683 Zhao, Keji National Heart, Lung, and Blood Institute (NHLBI) NHLBI Zhao, Keji (NHLBI) 1 151719683 Zhao, Keji National Heart, Lung, and Blood Institute (NHLBI) NHLBI Zhao, Keji (NHLBI) 1 151719679 Single Cell Profiling Of Chromatin Occupancy And RNAs (scPCOR-seq) E-197-2020-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 89788013 Kolesnitchenko, Vincent vk5q@nih.gov
United States of America Office of Technology Transfer and Development vk5q@nih.gov?subject=Web Inquiry on [TAB-4525] Single cell profiling of chromatin Occupancy and RNAs Sequencing (scPCOR-seq)&body=Please send me information about technology [TAB-4525] Single cell profiling of chromatin Occupancy and RNAs Sequencing (scPCOR-seq). Kolesnitchenko, Vincent<br><a href="mailto:vk5q@nih.gov?subject=Web Inquiry on [TAB-4525] Single cell profiling of chromatin Occupancy and RNAs Sequencing (scPCOR-seq)&body=Please send me information about technology [TAB-4525] Single cell profiling of chromatin Occupancy and RNAs Sequencing (scPCOR-seq).">vk5q@nih.gov</a><br> 157755808 E-197-2020-0 E-197-2020-0-US-01 Single Cell Profiling Of Chromatin Occupancy And RNAs (scPCOR-seq) PRV US 63/111,951 Abandoned US <br />Provisional (PRV) 63/111,951<br />Filed on 2020-11-10<br />Status: Abandoned 157755826 E-197-2020-0 E-197-2020-0-PCT-02 SINGLE-CELL PROFILING OF CHROMATIN OCCUPANCY AND RNA SEQUENCING PCT Patent Cooperation Treaty PCT/US2021/058809 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/058809<br />Filed on 2021-11-10<br />Status: Expired 157755831 E-197-2020-0 E-197-2020-0-IL-01 SINGLE-CELL PROFILING OF CHROMATIN OCCUPANCY AND RNA SEQUENCING National Stage Israel 302823 Pending Israel <br />National Stage 302823<br />Filed on 2023-05-10<br />Status: Pending 157755836 E-197-2020-0 E-197-2020-0-CN-01 SINGLE-CELL PROFILING OF CHROMATIN OCCUPANCY AND RNA SEQUENCING National Stage China 202180089986.2 Abandoned China <br />National Stage 202180089986.2<br />Filed on 2023-07-10<br />Status: Abandoned 157755841 E-197-2020-0 E-197-2020-0-US-02 SINGLE-CELL PROFILING OF CHROMATIN OCCUPANCY AND RNA SEQUENCING National Stage US 18/036,392 Pending US <br />National Stage 18/036,392<br />Filed on 2023-05-10<br />Status: Pending 157755846 E-197-2020-0 E-197-2020-0-EP-01 SINGLE-CELL PROFILING OF CHROMATIN OCCUPANCY AND RNA SEQUENCING National Stage European Patent 21892742.4 Pending European Patent <br />National Stage 21892742.4<br />Filed on 2023-06-08<br />Status: Pending TAB-4512 151706429 Fluorogen-binding RNA Aptamers for Imaging and Analysis of RNA NHLBI Licensing, Research Materials Licensing Research Materials Amir Abdolahzadeh, Alexis Autour, Sunny Chiu Yuk Jeng, Razvan Cojocaru, Elena Dolgosheina, Adrian Ferre-D'Amare, Shanker Panchapakesan, Michael Ryckelynck, Robert Trachman, Peter Unrau <p>This technology includes a number of RNAs that can induce strong fluorescence of otherwise non-fluorescent small molecules to be used for imaging and analysis of RNA. These RNAs have many potential applications as tags for live-cell imaging of cellular RNAs, as well as reporters for in vitro diagnostics. The &quot;Mango&quot; family of fluorescent RNA-fluorophore complexes has been previously reported. Work in this laboratory led to the determination of the 30, atomic structure of four different versions of Mango RNAs (Mango-I, Mango-II, Mango-Ill, Mango IV), and these structures were used by the laboratory to generate versions with greatly improved fluorescent and biochemical properties.</p> Fluorescent RNA-small molecule tags with improved properties will allow their routine use in vivo and expand their potential for in vitro applications. Imaging of RNA and RNA-containing particles in live cells and organisms, localization of medically important RNA (including viral RNAs) in live cells and organisms, imaging-based detection and analysis of RNA, RNA-protein and RNA-small molecule complexes in vitro and in vivo. We are seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. 2023-12-07 2024-08-12 2024-08-12 2024-03-27 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 151706436 Unrau, Peter Simon Fraser University Unrau, Peter 1 151706442 Ryckelynck, Michael Universite de Strasbourg Ryckelynck, Michael 2 151706448 Ferre-D'Amare, Adrian National Heart, Lung, and Blood Institute (NHLBI) NHLBI Ferre-D'Amare, Adrian (NHLBI) 3 151706456 Trachman, Robert National Heart, Lung, and Blood Institute (NHLBI) NHLBI Trachman, Robert (NHLBI) 4 151706464 Dolgosheina, Elena Simon Fraser University Dolgosheina, Elena 5 151706470 Chiu Yuk Jeng, Sunny Simon Fraser University Chiu Yuk Jeng, Sunny 6 151706476 Panchapakesan, Shanker Simon Fraser University Panchapakesan, Shanker 7 151706482 Abdolahzadeh, Amir Simon Fraser University Abdolahzadeh, Amir 8 151706613 Cojocaru, Razvan Simon Fraser University Cojocaru, Razvan 9 151706622 Autour, Alexis Universite de Strasbourg Autour, Alexis 10 151706436 Unrau, Peter Simon Fraser University Unrau, Peter 1 151706442 Ryckelynck, Michael Universite de Strasbourg Ryckelynck, Michael 2 151706448 Ferre-D'Amare, Adrian National Heart, Lung, and Blood Institute (NHLBI) NHLBI Ferre-D'Amare, Adrian (NHLBI) 3 151706456 Trachman, Robert National Heart, Lung, and Blood Institute (NHLBI) NHLBI Trachman, Robert (NHLBI) 4 151706464 Dolgosheina, Elena Simon Fraser University Dolgosheina, Elena 5 151706470 Chiu Yuk Jeng, Sunny Simon Fraser University Chiu Yuk Jeng, Sunny 6 151706476 Panchapakesan, Shanker Simon Fraser University Panchapakesan, Shanker 7 151706482 Abdolahzadeh, Amir Simon Fraser University Abdolahzadeh, Amir 8 151706613 Cojocaru, Razvan Simon Fraser University Cojocaru, Razvan 9 151706622 Autour, Alexis Universite de Strasbourg Autour, Alexis 10 151706432 Fluorogen-binding RNA Aptamers E-152-2018-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI), Simon Fraser University, Universite de Strasbourg 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-4512] Fluorogen-binding RNA Aptamers for Imaging and Analysis of RNA&body=Please send me information about technology [TAB-4512] Fluorogen-binding RNA Aptamers for Imaging and Analysis of RNA. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-4512] Fluorogen-binding RNA Aptamers for Imaging and Analysis of RNA&body=Please send me information about technology [TAB-4512] Fluorogen-binding RNA Aptamers for Imaging and Analysis of RNA.">shmilovm@nih.gov</a><br> 157755334 E-152-2018-0 E-152-2018-0-US-01 Fluorogen-binding RNA Aptamers PRV US 62/489,346 Abandoned US <br />Provisional (PRV) 62/489,346<br />Filed on 2017-04-24<br />Status: Abandoned 157755343 E-152-2018-0 E-152-2018-0-PCT-02 Fluorogen-binding RNA Aptamers PCT Patent Cooperation Treaty PCT/IB2018/052808 Expired Patent Cooperation Treaty <br />(PCT) PCT/IB2018/052808<br />Filed on 2018-04-23<br />Status: Expired 157755348 E-152-2018-0 E-152-2018-0-CA-03 Fluorogen-binding RNA Aptamers National Stage Canada 3060379 Pending Canada <br />National Stage 3060379<br />Filed on 2018-04-23<br />Status: Pending 157755353 E-152-2018-0 E-152-2018-0-EP-04 Fluorogen-binding RNA Aptamers National Stage European Patent 18725646.6 Pending European Patent <br />National Stage 18725646.6<br />Filed on 2018-04-23<br />Status: Pending TAB-4504 151705421 Blocking CD38 using Daratumumab F(ab)2 to Protect Natural Killer Cells from Daratumumab-induced Apoptosis and Cell Death for the Treatment of Multiple Myeloma NHLBI Human Cell Lines, Licensing, Materials Available, Oncology, Research Materials Human Cell Lines Licensing Materials Available Oncology Research Materials Maria Berg, Richard Childs, Jorge Luis Espinoza-Calderon <p>This technology includes the method of blocking CD38 in expanded natural killer (NK) cell therapy in combination with daratumumab in patients with multiple myeloma. Our in vitro studies have already confirmed the addition of NK cells to myeloma cells that have been exposed to daratumumab enhances myeloma killing compared to single agent treatment. Studies exploring adoptive NK cell transfer after daratumumab treatment to bolster daratumumab-mediated killing of myeloma via ADCC could be limited by the fact that these transferred NK cells might be killed by the antibody before they could reach their antibody-bound tumor targets. To overcome this obstacle, we have explored blocking CD38 on the surface of NK cells with a daratumumab F(ab)2 fragment as a method to prevent daratumumab- induced apoptosis of NK cells. We have generated daratumumab F(ab)2 fragments using enzymatic cleavage of daratumumab and have confirmed these fragments bind to CD38 expressed on NK cells.</p> We have generated F(ab)2 fragments from daratumumab which protect NK cells from daratumumab-mediated killing. At present, there exists no method to protect NK cells from Daratumumab-mediated killing. Therapeutic advancement to improve treatment for multiple myeloma patients. We are seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. 2023-12-07 2024-08-12 2024-08-12 2024-03-27 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 151705428 Childs, Richard National Heart, Lung, and Blood Institute (NHLBI) NHLBI Childs, Richard (NHLBI) 1 151705432 Espinoza-Calderon, Jorge Luis Espinoza-Calderon, Jorge Luis 2 151705437 Berg, Maria National Heart, Lung, and Blood Institute (NHLBI) NHLBI Berg, Maria (NHLBI) 3 151705428 Childs, Richard National Heart, Lung, and Blood Institute (NHLBI) NHLBI Childs, Richard (NHLBI) 1 151705432 Espinoza-Calderon, Jorge Luis Espinoza-Calderon, Jorge Luis 2 151705437 Berg, Maria National Heart, Lung, and Blood Institute (NHLBI) NHLBI Berg, Maria (NHLBI) 3 151705424 Daratumumab F(ab)2 To Protect NK Cells From Apotosis E-133-2014-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-4504] Blocking CD38 using Daratumumab F(ab)2 to Protect Natural Killer Cells from Daratumumab-induced Apoptosis and Cell Death for the Treatment of Multiple Myeloma&body=Please send me information about technology [TAB-4504] Blocking CD38 using Daratumumab F(ab)2 to Protect Natural Killer Cells from Daratumumab-induced Apoptosis and Cell Death for the Treatment of Multiple Myeloma. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-4504] Blocking CD38 using Daratumumab F(ab)2 to Protect Natural Killer Cells from Daratumumab-induced Apoptosis and Cell Death for the Treatment of Multiple Myeloma&body=Please send me information about technology [TAB-4504] Blocking CD38 using Daratumumab F(ab)2 to Protect Natural Killer Cells from Daratumumab-induced Apoptosis and Cell Death for the Treatment of Multiple Myeloma.">shmilovm@nih.gov</a><br> 157755101 E-133-2014-0 E-133-2014-0-US-01 Blocking CD38 Using Anti-CD38 F(ab)2 To Protect NK Cells PRV US 62/012,864 Abandoned US <br />Provisional (PRV) 62/012,864<br />Filed on 2014-06-16<br />Status: Abandoned 157755106 E-133-2014-0 E-133-2014-0-PCT-02 Blocking CD38 Using Anti-CD38 Fab2 To Protect NK Cells PCT Patent Cooperation Treaty PCT/US2015/035832 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2015/035832<br />Filed on 2015-06-15<br />Status: Expired 157755111 E-133-2014-0 E-133-2014-0-US-03 BLOCKING CD38 USING ANTI-CD38 F(AB')2 TO PROTECT NK CELLS National Stage US 10,106,620 15/319,344 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10106620 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10106620">10,106,620</a><br />Filed on 2016-12-15<br />Status: Issued 157755116 E-133-2014-0 E-133-2014-0-EP-04 Blocking CD38 Using Anti-CD38 Fab2 To Protect NK Cells National Stage European Patent 3154581 15747597.1 Issued European Patent <br />National Stage 15747597.1<br />Filed on 2015-06-15<br />Status: Issued 157755121 E-133-2014-0 E-133-2014-0-CH-05 Blocking CD38 Using Anti-CD38 Fab2 To Protect NK Cells EP Switzerland 3154581 15747597.1 Issued Switzerland <br />European patent (EP) 15747597.1<br />Filed on 2015-06-15<br />Status: Issued 157755126 E-133-2014-0 E-133-2014-0-DE-06 Blocking CD38 Using Anti-CD38 Fab2 To Protect NK Cells EP Germany 3154581 15747597.1 Issued Germany <br />European patent (EP) 15747597.1<br />Filed on 2015-06-15<br />Status: Issued 157755137 E-133-2014-0 E-133-2014-0-FR-07 Blocking CD38 Using Anti-CD38 Fab2 To Protect NK Cells EP France 3154581 15747597.1 Issued France <br />European patent (EP) 15747597.1<br />Filed on 2015-06-15<br />Status: Issued 157755143 E-133-2014-0 E-133-2014-0-GB-08 Blocking CD38 Using Anti-CD38 Fab2 To Protect NK Cells EP United Kingdom 3154581 15747597.1 Issued United Kingdom <br />European patent (EP) 15747597.1<br />Filed on 2015-06-15<br />Status: Issued 157755148 E-133-2014-0 E-133-2014-0-IE-09 Blocking CD38 Using Anti-CD38 Fab2 To Protect NK Cells EP Ireland 3154581 15747597.1 Issued Ireland <br />European patent (EP) 15747597.1<br />Filed on 2015-06-15<br />Status: Issued TAB-4493 151704210 Genetic Manipulation of Natural Killer Cells to Express c-MPL Growth Factor Receptor as a Therapy for Cancer NHLBI Licensing, Oncology, Research Equipment, Research Materials, Therapeutics Licensing Oncology Research Equipment Research Materials Therapeutics David Allan, Richard Childs <p>This technology includes genetic manipulation of natural killer (NK) cells to express thrombopoietin receptor (c-MPL) growth factor receptor as strategy to augment NK cell proliferation and anti-tumor immunity. Many investigational adoptive immunotherapy regimens utilizing NK cells require the administration of IL-2 or IL-15 cytokines to support the survival and function of the cells in patients, however administration of these cytokines causes a number of serious dose-dependent toxicities. In the presence of thrombopoietin (TPO) ligand, lentiviral transduction of primary human NK cells to express c-MPL enhanced in vitro cellular proliferation and increased degranulation and cytokine production towards target cells. Data from our study could be translated to a clinical trial setting, where the infusion of genetically modified c-MPL-expressing NK cells is followed by the off-label administration of an FDA-approved TPO-mimetic (e.g., eltrombopag, romiplostim).</p> Treatment of patients with c-MPL-modified NK cells may reduce or eliminate the necessity for IL-2 administration, which can cause severe toxicity, and allow for the specific pharmacological stimulation of infused modified cells but not endogenous immune cells, while simultaneously boosting their anti-tumor function. <ul> <li>NK immunotherapy using cells trans-genetically modified to express c-MPL for a large number of hematological malignancies </li> <li>CAR-T immunotherapy cells modified to express c-MPL</li> <li>TCR-transgenic T cells modified to express c-MPL</li> <li>CD34+ hematogenic stem and progenitor cells modified to express mutated c-MPL (iii of section 7) to facilitate selective eltrombopag-mediated expansion after transplant relative to unmodified endogenous stem cells</li> </ul> We are seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. 2023-12-07 2024-08-12 2024-08-12 2024-03-27 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 151704217 Allan, David YM BioSciences Inc. Allan, David 1 151704221 Childs, Richard National Heart, Lung, and Blood Institute (NHLBI) NHLBI Childs, Richard (NHLBI) 2 151704217 Allan, David YM BioSciences Inc. Allan, David 1 151704221 Childs, Richard National Heart, Lung, and Blood Institute (NHLBI) NHLBI Childs, Richard (NHLBI) 2 151704213 Transgenic Expression Of C-MPL Receptor In Human NK Cells Increases Their Proliferation, Anti-tumor Function, And In Vivo Persistence, Upon Ligand Stimulation E-090-2020-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-4493] Genetic Manipulation of Natural Killer Cells to Express c-MPL Growth Factor Receptor as a Therapy for Cancer&body=Please send me information about technology [TAB-4493] Genetic Manipulation of Natural Killer Cells to Express c-MPL Growth Factor Receptor as a Therapy for Cancer. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-4493] Genetic Manipulation of Natural Killer Cells to Express c-MPL Growth Factor Receptor as a Therapy for Cancer&body=Please send me information about technology [TAB-4493] Genetic Manipulation of Natural Killer Cells to Express c-MPL Growth Factor Receptor as a Therapy for Cancer.">shmilovm@nih.gov</a><br> 157754679 E-090-2020-0 E-090-2020-0-US-01 NK CELLS OR T CELLS EXPRESSING HEMATOPOIETIC GROWTH FACTOR RECEPTORS AND METHODS OF USE PRV US 62/980,854 Abandoned US <br />Provisional (PRV) 62/980,854<br />Filed on 2020-02-24<br />Status: Abandoned 157754696 E-090-2020-0 E-090-2020-0-PCT-02 NK CELLS OR T CELLS EXPRESSING HEMATOPOIETIC GROWTH FACTOR RECEPTORS AND METHODS OF USE PCT Patent Cooperation Treaty PCT/US2021/019288 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/019288<br />Filed on 2021-02-23<br />Status: Expired 157754701 E-090-2020-0 E-090-2020-0-US-03 NK CELLS OR T CELLS EXPRESSING HEMATOPOIETIC GROWTH FACTOR RECEPTORS AND METHODS OF USE CON US 17/821,703 Abandoned US <br />Continuation (CON) 17/821,703<br />Filed on 2022-08-23<br />Status: Abandoned 157754706 E-090-2020-0 E-090-2020-0-CN-04 NK CELLS OR T CELLS EXPRESSING HEMATOPOIETIC GROWTH FACTOR RECEPTORS AND METHODS OF USE National Stage China 202180030182.5 Pending China <br />National Stage 202180030182.5<br />Filed on 2021-02-23<br />Status: Pending 157754810 E-090-2020-0 E-090-2020-0-EP-05 NK CELLS OR T CELLS EXPRESSING HEMATOPOIETIC GROWTH FACTOR RECEPTORS AND METHODS OF USE National Stage European Patent 21711990.8 Pending European Patent <br />National Stage 21711990.8<br />Filed on 2021-02-23<br />Status: Pending 157754819 E-090-2020-0 E-090-2020-0-IL-06 NK CELLS OR T CELLS EXPRESSING HEMATOPOIETIC GROWTH FACTOR RECEPTORS AND USE FOR TREATING CANCER National Stage Israel 295888 Pending Israel <br />National Stage 295888<br />Filed on 2022-08-24<br />Status: Pending 157754824 E-090-2020-0 E-090-2020-0-HK-01 NK CELLS OR T CELLS EXPRESSING HEMATOPOIETIC GROWTH FACTOR RECEPTORS AND METHODS OF USE EP Hong Kong 62023067864.6 Pending Hong Kong <br />European patent (EP) 62023067864.6<br />Filed on 2021-02-23<br />Status: Pending 157754829 E-090-2020-0 E-090-2020-0-US-02 NK CELLS OR T CELLS EXPRESSING HEMATOPOIETIC GROWTH FACTOR RECEPTORS AND METHODS OF USE DIV US 18/425,487 Pending US <br />Divisional (DIV) 18/425,487<br />Filed on 2024-01-29<br />Status: Pending TAB-4486 151701655 Real-time Monitoring of In Vivo Free Radical Scavengers Through Hyperpolarized [1-13C] N-acetyl Cysteine as a Diagnostic and Disease Monitoring Tool NHLBI Diagnostics, Licensing, Neurology, Oncology, Research Materials Diagnostics Licensing Neurology Oncology Research Materials Murali Cherukuri, Ana Opina, Rolf Swenson, Kazutoshi Yamamoto <p>This technology includes synthesized demonstrated [1-13C] NAC as a promising novel probe for hyperpolarized 13C MRI methodologies which could provide diagnostic, and evaluation of response to treatment in various cancers and neurological diseases. N-acetyl cysteine (NAC) is a widely used therapeutic and involved to stimulate glutathione synthesis. Glutathione elevates detoxification and works directly as a free radical scavenger. In vivo hyperpolarized NAC was broadly distributed throughout the body. The chemical conversions into products were observed in pancreatic tumor xenografts, Hs766t, and SU.86.86, with various conversion efficiencies depending on metabolic characteristics and status. Hyperpolarized NAC can provide insights into redox status, metabolic profile, and enzymatic activities.</p> The ability to cross the blood brain barrier is a substantial benefit of this agent. Monitoring the antioxidation and enzymatic status could provide diagnostic, and evaluation of response to treatment in various cancers and neurological diseases. We are seeking statements of capability or interest from parties interested in collaborative research to further developer, evaluate, or commercialize this technology. 2023-12-07 2024-08-12 2024-08-12 2024-03-27 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 151701704 Cherukuri, Murali National Cancer Institute (NCI) NCI Cherukuri, Murali (NCI) 1 151701801 Swenson, Rolf National Heart, Lung, and Blood Institute (NHLBI) NHLBI Swenson, Rolf (NHLBI) 2 151701866 Yamamoto, Kazutoshi National Cancer Institute (NCI) NCI Yamamoto, Kazutoshi (NCI) 3 151701882 Opina, Ana National Heart, Lung, and Blood Institute (NHLBI) NHLBI Opina, Ana (NHLBI) 4 151701704 Cherukuri, Murali National Cancer Institute (NCI) NCI Cherukuri, Murali (NCI) 1 151701801 Swenson, Rolf National Heart, Lung, and Blood Institute (NHLBI) NHLBI Swenson, Rolf (NHLBI) 2 151701866 Yamamoto, Kazutoshi National Cancer Institute (NCI) NCI Yamamoto, Kazutoshi (NCI) 3 151701882 Opina, Ana National Heart, Lung, and Blood Institute (NHLBI) NHLBI Opina, Ana (NHLBI) 4 151701658 Real-time Monitoring Of In Vivo Free Radical Scavengers Through Hyperpolarized [1-13C] N-acetyl Cysteine E-069-2020-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI), NCI 153929528 Ghosh, Malabika malabika.ghosh@nih.gov
United States of America malabika.ghosh@nih.gov?subject=Web Inquiry on [TAB-4486] Real-time Monitoring of In Vivo Free Radical Scavengers Through Hyperpolarized [1-13C] N-acetyl Cysteine as a Diagnostic and Disease Monitoring Tool&body=Please send me information about technology [TAB-4486] Real-time Monitoring of In Vivo Free Radical Scavengers Through Hyperpolarized [1-13C] N-acetyl Cysteine as a Diagnostic and Disease Monitoring Tool. Ghosh, Malabika<br><a href="mailto:malabika.ghosh@nih.gov?subject=Web Inquiry on [TAB-4486] Real-time Monitoring of In Vivo Free Radical Scavengers Through Hyperpolarized [1-13C] N-acetyl Cysteine as a Diagnostic and Disease Monitoring Tool&body=Please send me information about technology [TAB-4486] Real-time Monitoring of In Vivo Free Radical Scavengers Through Hyperpolarized [1-13C] N-acetyl Cysteine as a Diagnostic and Disease Monitoring Tool.">malabika.ghosh@nih.gov</a><br> 157754331 E-069-2020-0 E-069-2020-0-US-01 REAL-TIME MONITORING OF IN VIVO FREE RADICAL SCAVENGERS THROUGH HYPERPOLARIZED N-ACETYL CYSTEINE ISOTOPES PRV US 62/961,855 Abandoned US <br />Provisional (PRV) 62/961,855<br />Filed on 2020-01-16<br />Status: Abandoned 157754336 E-069-2020-0 E-069-2020-0-PCT-02 REAL-TIME MONITORING OF IN VIVO FREE RADICAL SCAVENGERS THROUGH HYPERPOLARIZED N-ACETYL CYSTEINE ISOTOPES PCT Patent Cooperation Treaty PCT/US2021/013634 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2021/013634<br />Filed on 2021-01-15<br />Status: Expired 157754341 E-069-2020-0 E-069-2020-0-EP-03 REAL-TIME MONITORING OF IN VIVO FREE RADICAL SCAVENGERS THROUGH HYPERPOLARIZED N-ACETYL CYSTEINE ISOTOPES National Stage European Patent 21741034.9 Pending European Patent <br />National Stage 21741034.9<br />Filed on 2021-01-15<br />Status: Pending 157754346 E-069-2020-0 E-069-2020-0-IL-04 REAL-TIME MONITORING OF IN VIVO FREE RADICAL SCAVENGERS THROUGH HYPERPOLARIZED N-ACETYL CYSTEINE ISOTOPES National Stage Israel 294365 Pending Israel <br />National Stage 294365<br />Filed on 2022-06-28<br />Status: Pending 157754351 E-069-2020-0 E-069-2020-0-US-05 REAL-TIME MONITORING OF INVIVO FREE RADICAL SCAVENGERS THROUGH HYPERPOLARIZED N-ACETYL CYSTEINE ISOTOPES National Stage US 17/793,083 Pending US <br />National Stage 17/793,083<br />Filed on 2022-07-15<br />Status: Pending TAB-4603 151782991 Paper Strip Tool with Gold Nanoparticle Conjugated Probes for Rapid Detection of Pathogens in Stool NINR Diagnostics, Research Equipment, Research Materials Diagnostics Research Equipment Research Materials Sarah Abey, Eric Ferguson, Nicolaas Fourie, Wendy Henderson, Chang Hee Kim <p>This technology includes a paper strip tool that may be used at the point-of care to detect the presence of a multiplex of pathogen nucleic acid sequences in stool without the need for molecular amplification, laboratory or instrumentation. This invention can be used to rapidly and inexpensively detect gastrointestinal and diarrheal disease in order to guide treatment.</p> The invention is rapid, inexpensive, does not require enzymes or refrigeration, does not require PCR or a laboratory, does not require a scanner, and can detect a multiplex of pathogens in stool. Diagnostic for pathogens that cause diarrheal disease which kills over 1 million children worldwide annually; likewise, may be useful for hospital-based screening of pathogens. 2023-12-13 2024-08-12 2024-08-12 2024-03-27 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 151783087 Henderson, Wendy NINR Henderson, Wendy (NINR) 1 151783407 Kim, Chang Hee GoDx, Inc. Kim, Chang Hee 2 151783425 Fourie, Nicolaas Fourie, Nicolaas 3 151783436 Ferguson, Eric Ferguson, Eric 4 151783451 Abey, Sarah NINR NIMH Abey, Sarah (NIMH) 5 151783087 Henderson, Wendy NINR Henderson, Wendy (NINR) 1 151783407 Kim, Chang Hee GoDx, Inc. Kim, Chang Hee 2 151783425 Fourie, Nicolaas Fourie, Nicolaas 3 151783436 Ferguson, Eric Ferguson, Eric 4 151783451 Abey, Sarah NINR NIMH Abey, Sarah (NIMH) 5 151782994 Paper Strip Tool With Gold Nanoparticle Conjugated Probes For Rapid Detection Of Pathogens In Stool E-134-2015-0 Filing authorized GoDx, Inc., NINR 89788013 Kolesnitchenko, Vincent vk5q@nih.gov
United States of America Office of Technology Transfer and Development vk5q@nih.gov?subject=Web Inquiry on [TAB-4603] Paper Strip Tool with Gold Nanoparticle Conjugated Probes for Rapid Detection of Pathogens in Stool&body=Please send me information about technology [TAB-4603] Paper Strip Tool with Gold Nanoparticle Conjugated Probes for Rapid Detection of Pathogens in Stool. Kolesnitchenko, Vincent<br><a href="mailto:vk5q@nih.gov?subject=Web Inquiry on [TAB-4603] Paper Strip Tool with Gold Nanoparticle Conjugated Probes for Rapid Detection of Pathogens in Stool&body=Please send me information about technology [TAB-4603] Paper Strip Tool with Gold Nanoparticle Conjugated Probes for Rapid Detection of Pathogens in Stool.">vk5q@nih.gov</a><br> 157763016 E-134-2015-0 E-134-2015-0-US-01 Multiplex Detection of Nucleic Acids from Multiple Species on Paper PRV US 62/162,668 Abandoned US <br />Provisional (PRV) 62/162,668<br />Filed on 2015-05-16<br />Status: Abandoned 157763021 E-134-2015-0 E-134-2015-0-PCT-02 POINT OF NEED TESTING DEVICE AND METHODS OF USE THEREOF PCT Patent Cooperation Treaty PCT/US2016/032788 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2016/032788<br />Filed on 2016-05-16<br />Status: Expired 157763026 E-134-2015-0 E-134-2015-0-US-03 Paper Strip Tool With Gold Nanoparticle Conjugated Probes For Rapid Detection Of Pathogens In Stool National Stage US 15/574,750 Abandoned US <br />National Stage 15/574,750<br />Filed on 2017-11-16<br />Status: Abandoned 157763031 E-134-2015-0 E-134-2015-0-US-02 POINT OF NEED TESTING DEVICE AND METHODS OF USE THEREOF DIV US 12,247,250 16/941,333 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12247250 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12247250">12,247,250</a><br />Filed on 2020-07-28<br />Status: Issued TAB-4602 151764421 New Fluorescent Indicator Alleles in Mice that Expand the Power of Recombinase-based Labeling to Uncover Cellular Diversity NIEHS Animal Models, Research Materials Animal Models Research Materials Patricia Jensen, Nicholas Plummer <p>This technology includes a series of recombinase responsive indicator alleles in genetically modified laboratory mice which uniquely permit non-invasive labeling of cells defined by the overlap of up to three distinct gene expression domains. In response to any combination of Cre, Flp and Dre recombinases, these alleles express high levels of eGFP and/or tdTomato that allow the visualization of cells in live and fixed tissue, including samples processed using modern tissue clearing techniques. Together, these features provide experimental access to cell populations at unprecedented resolution and facilitate analysis of their anatomical, molecular, and physiological properties.</p> The unique advantages of these six recombinase-responsive fluorescent indicator alleles are: <ul> <li>Together, these six alleles permit fluorescent labeling driven by any combination of Cre, Flp, or Dre recombinase expression.</li> <li>RC::RFLTG is the only fluorescent indicator allele that is capable of labeling cell populations defined by the overlap of three distinct gene expression domains.</li> <li>RC::RFLTG (Dre/Flp/Cre responsive), RC::RLTG (Dre/Cre responsive), and RC::FLTG (Flp/Cre responsive) each encode two fluorescent proteins that both fill cellular processes, allowing the complete architecture of two cell populations to be visualized in the same animal. In the nervous system, these alleles permit simultaneous tracing of axons from two distinct neuronal subpopulations.</li> </ul> These fluorescent indicator alleles allow permanent fluorescent labeling of genetically defined cell populations in laboratory mice, and likely will primarily be used in basic research. However, they may be useful to companies performing testing of new chemical compounds or pharmaceuticals, because they permit rapid visual inspection of the labeled cells in embryos and adult mice. Thus, it would be easy to test whether a chemical had any effect on survival, proliferation, or migration of a labeled cell population. The labeled cells can be isolated by a variety of procedures (e.g. fluorescence assisted cell sorting, manual dissection) and cultured for further study. 2023-12-12 2024-08-12 2024-08-12 2024-03-20 False True True 37470483 Website Abstract 151764437 Plummer N, et al. https://pubmed.ncbi.nlm.nih.gov/26586220/ <a href="https://pubmed.ncbi.nlm.nih.gov/26586220/">Plummer N, et al.</a> 151764429 Jensen, Patricia NIEHS NIEHS Jensen, Patricia (NIEHS) 1 151764433 Plummer, Nicholas NIEHS NIEHS Plummer, Nicholas (NIEHS) 2 151764429 Jensen, Patricia NIEHS NIEHS Jensen, Patricia (NIEHS) 1 151764433 Plummer, Nicholas NIEHS NIEHS Plummer, Nicholas (NIEHS) 2 151764424 New Fluorescent Indicator Alleles In Mice That Expand The Power Of Recombinase-based Labeling To Uncover Cellular Diversity E-225-2015-0 Research Material NIEHS 83739538 Choudhry, Vidita vidita.choudhry@nih.gov
United States of America Office of Technology Transfer and Development vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-4602] New Fluorescent Indicator Alleles in Mice that Expand the Power of Recombinase-based Labeling to Uncover Cellular Diversity&body=Please send me information about technology [TAB-4602] New Fluorescent Indicator Alleles in Mice that Expand the Power of Recombinase-based Labeling to Uncover Cellular Diversity. Choudhry, Vidita<br><a href="mailto:vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-4602] New Fluorescent Indicator Alleles in Mice that Expand the Power of Recombinase-based Labeling to Uncover Cellular Diversity&body=Please send me information about technology [TAB-4602] New Fluorescent Indicator Alleles in Mice that Expand the Power of Recombinase-based Labeling to Uncover Cellular Diversity.">vidita.choudhry@nih.gov</a><br> TAB-4601 151764275 Cytochrome P450 CYP2J Polyclonal Antibodies and Recombinant Proteins for Immunoblotting and Metabolism Studies NIEHS Antibodies, Metabolic Disease, Plasmids/Vectors, Research Materials Antibodies Metabolic Disease Plasmids/Vectors Research Materials Joyce Blaisdell, Jennifer Bradbury, Joyce Goldstein (Estate), Joan Graves, Darryl Zeldin <p>This technology includes identified members of the mouse cytochromes P450 CYP2J subfamily and antibodies to them for P450 expression studies and metabolism research. Recombinant proteins of the CYP2J subfamily members have also been expressed. The CYP2J subfamily members have a wide tissue distribution and may be useful as model systems for studies of cardiovascular disease, drug metabolism, and toxicity.</p> Wide potential for utilization. The various antibodies for CYP2Js will enable studies on the expression of these P450s in various tissues by immunohistochemistry and immunoblotting. The recombinant proteins can be used as controls in immunoblotting as well as for metabolism studies. 2023-12-12 2024-08-12 2024-08-12 2024-03-20 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 151764283 Graves, Joan NIEHS NIEHS Graves, Joan (NIEHS) 1 151764369 Zeldin, Darryl NIEHS NIEHS Zeldin, Darryl (NIEHS) 2 151764373 Goldstein (Estate), Joyce NIEHS NIEHS Goldstein (Estate), Joyce (NIEHS) 3 151764381 Bradbury, Jennifer NIEHS NIEHS Bradbury, Jennifer (NIEHS) 4 151764389 Blaisdell, Joyce NIEHS NIEHS Blaisdell, Joyce (NIEHS) 5 151764283 Graves, Joan NIEHS NIEHS Graves, Joan (NIEHS) 1 151764369 Zeldin, Darryl NIEHS NIEHS Zeldin, Darryl (NIEHS) 2 151764373 Goldstein (Estate), Joyce NIEHS NIEHS Goldstein (Estate), Joyce (NIEHS) 3 151764381 Bradbury, Jennifer NIEHS NIEHS Bradbury, Jennifer (NIEHS) 4 151764389 Blaisdell, Joyce NIEHS NIEHS Blaisdell, Joyce (NIEHS) 5 151764278 Cytochromes P450 CYP2C Polyclonal Antibodies And Recombinant Proteins E-153-2011-1 Research Material NIEHS 83739538 Choudhry, Vidita vidita.choudhry@nih.gov
United States of America Office of Technology Transfer and Development vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-4601] Cytochrome P450 CYP2J Polyclonal Antibodies and Recombinant Proteins for Immunoblotting and Metabolism Studies&body=Please send me information about technology [TAB-4601] Cytochrome P450 CYP2J Polyclonal Antibodies and Recombinant Proteins for Immunoblotting and Metabolism Studies. Choudhry, Vidita<br><a href="mailto:vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-4601] Cytochrome P450 CYP2J Polyclonal Antibodies and Recombinant Proteins for Immunoblotting and Metabolism Studies&body=Please send me information about technology [TAB-4601] Cytochrome P450 CYP2J Polyclonal Antibodies and Recombinant Proteins for Immunoblotting and Metabolism Studies.">vidita.choudhry@nih.gov</a><br> TAB-4600 151764231 Inhibition of Epoxide Hydrolase 1 in the Treatment of Cardiovascular Diseases NIEHS Animal Models, Cardiology, Research Materials, Therapeutics Animal Models Cardiology Research Materials Therapeutics Matthew Edin, Darryl Zeldin <p>This technology includes EPHX1/EPHX2 null mice and showed that disruption of both EPHX1 and EPHX2 almost completely abolished hydrolysis of several EETs which can be used in the treatment of cardiovascular diseases. EPHX 1 is significantly involved in EET hydrolysis, and we believe the combined use of EPHX1 and EPHX2 inhibitors would provide a better alternative to currently available therapeutic options or the EPHX2-based therapies currently in trials for the treatment of cardiovascular diseases.</p> Dual inhibition of EPHX1 and EPHX2 should potentiate the effects of endogenous EETs more than EPHX2 inhibition alone. <ul> <li>The products that could be made are selective inhibitors of EPHX1 or inhibitors of both EPHX1 and EPHX2 as therapies for the treatment of many cardiovascular diseases. </li> <li>EPHX1 or EPHX1/2 inhibitors could be used as pharmaceutical drugs in humans and animals or used for research purposes.</li> </ul> 2023-12-12 2024-08-12 2024-08-12 2024-03-20 False True True 37470483 Website Abstract 151764239 Edin, Matthew NIEHS NIEHS Edin, Matthew (NIEHS) 1 151764247 Zeldin, Darryl NIEHS NIEHS Zeldin, Darryl (NIEHS) 2 151764239 Edin, Matthew NIEHS NIEHS Edin, Matthew (NIEHS) 1 151764247 Zeldin, Darryl NIEHS NIEHS Zeldin, Darryl (NIEHS) 2 151764234 Inhibition Of Epoxide Hydrolase 1 In The Treatment Of Cardiovascular Diseases E-144-2016-0 Research Material NIEHS 83739538 Choudhry, Vidita vidita.choudhry@nih.gov
United States of America Office of Technology Transfer and Development vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-4600] Inhibition of Epoxide Hydrolase 1 in the Treatment of Cardiovascular Diseases&body=Please send me information about technology [TAB-4600] Inhibition of Epoxide Hydrolase 1 in the Treatment of Cardiovascular Diseases. Choudhry, Vidita<br><a href="mailto:vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-4600] Inhibition of Epoxide Hydrolase 1 in the Treatment of Cardiovascular Diseases&body=Please send me information about technology [TAB-4600] Inhibition of Epoxide Hydrolase 1 in the Treatment of Cardiovascular Diseases.">vidita.choudhry@nih.gov</a><br> TAB-4599 151764035 p300 KO HEK293T Cell Line for Multiple Research Applications NIEHS Human Cell Lines, Neurology, Research Materials Human Cell Lines Neurology Research Materials Ming Ji, Xiaoling Li <p>This technology includes p300 KO HEK293T cells using crispr/cas9 mediated gene editing technology to be used for various research applications. We showed that p300 deficient cells have impaired glycolysis and are hypersensitive to glucose depletion-induced cell death. p300 is one of major transcriptional co-activators that regulates gene transcription as a histone acetyltransferase. Recent studies reveal that it functions as &quot;writer&quot; for a variety of lysine acylations, including acetylation, crotonylation, butryrylation, 2- hydroxyisobutyrylation, and succinylation. Consequently, p300 has important functions in cell migration and invasion, maintenance of the differentiated state, tau-mediated neurodegeneration, and learning and memory.</p> The p300 KO HEK293T cell line could be utilized as an in vitro model to investigate p300 functions in a wide range of research topics. These p300 KO HEK293T cells are ready to be used for a wide range of research applications. 2023-12-12 2024-08-12 2024-08-12 2024-03-20 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 151764211 Huang H, et al. https://pubmed.ncbi.nlm.nih.gov/29775581/ <a href="https://pubmed.ncbi.nlm.nih.gov/29775581/">Huang H, et al.</a> 151764199 Ji, Ming NIEHS NIEHS Ji, Ming (NIEHS) 1 151764207 Li, Xiaoling NIEHS NIEHS Li, Xiaoling (NIEHS) 2 151764199 Ji, Ming NIEHS NIEHS Ji, Ming (NIEHS) 1 151764207 Li, Xiaoling NIEHS NIEHS Li, Xiaoling (NIEHS) 2 151764038 P300-mediated Lysine 2-hydroxyisobutrylation Regulates Glycolysis E-063-2021-0 Research Material NIEHS 83739538 Choudhry, Vidita vidita.choudhry@nih.gov
United States of America Office of Technology Transfer and Development vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-4599] p300 KO HEK293T Cell Line for Multiple Research Applications&body=Please send me information about technology [TAB-4599] p300 KO HEK293T Cell Line for Multiple Research Applications. Choudhry, Vidita<br><a href="mailto:vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-4599] p300 KO HEK293T Cell Line for Multiple Research Applications&body=Please send me information about technology [TAB-4599] p300 KO HEK293T Cell Line for Multiple Research Applications.">vidita.choudhry@nih.gov</a><br> TAB-4598 151764006 Developing a Stable Cell as a Screening Tool for Environmental Chemicals NIEHS Human Cell Lines, Research Materials, Therapeutics Human Cell Lines Research Materials Therapeutics Christina Teng <p>This technology includes a stable cell line (293T2-PGC) which has an intact PGC-1 alpha/ERR-alpha pathway to screen for environmental chemicals. The estrogen-related receptor alpha (ERR-alpha) and proliferator-activated receptor gamma coactivator - 1alpha (PGC-1 alpha) play critical roles in the control of several physiological functions, including the regulation of genes involved in energy homeostasis. However, little is known about the environmental chemicals that could disrupt or modulate this pathway leading to adverse health effects. Currently, hundreds of in vitro cell-based assays have been developed and tested, but none for the pathway that plays an important role in metabolic homeostasis. The goal is to develop a cell-based assay system with an intact PGC-1-alpha/ERR-alpha axis that can be used to screen the effects of environmental chemicals or drugs.</p> This cell line is at the metabolically active state, any compound which disrupts this pathway can be detected as decrease of metabolic activity. It was also discovered that some compounds were able to further enhance the metabolic activity that is not reported in any of the existing products. Can be used to test various gene promoters that play an important role in energy balance including mitochondrial function, TCA cycle, glycolysis, oxidative phosphorylation etc. Work is continuing to introduce a stable reporter into this cell line, which will allow it to be used in Tox 21 HTS platform. 2023-12-12 2024-08-12 2024-08-12 2024-03-20 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 151764028 Teng, Christina NIEHS NIEHS Teng, Christina (NIEHS) 1 151764028 Teng, Christina NIEHS NIEHS Teng, Christina (NIEHS) 1 151764009 Developing A Stable Cell Line Consists Of Intact PGC-dependent Pathway As Screening Tool For Environmental Chemicals E-048-2014-0 Research Material NIEHS 83739538 Choudhry, Vidita vidita.choudhry@nih.gov
United States of America Office of Technology Transfer and Development vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-4598] Developing a Stable Cell as a Screening Tool for Environmental Chemicals&body=Please send me information about technology [TAB-4598] Developing a Stable Cell as a Screening Tool for Environmental Chemicals. Choudhry, Vidita<br><a href="mailto:vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-4598] Developing a Stable Cell as a Screening Tool for Environmental Chemicals&body=Please send me information about technology [TAB-4598] Developing a Stable Cell as a Screening Tool for Environmental Chemicals.">vidita.choudhry@nih.gov</a><br> TAB-4597 151763969 A BL21 (ED3) Codon Plus Competent Cell-derived Bacterial Strain for Research Use NIEHS Antibodies, Research Materials, Therapeutics Antibodies Research Materials Therapeutics Archana Dhasarathy, Paul Wade <p>This technology includes a bacterial strain derived from BL21 (ED3) CodonPlus Competent Cells containing an expression vector for human POLR2C gene for research purposes. The bacterial strain can be used to produce the full-length human RNA polymerase II subunit, RPB3 protein, which can be in turn isolated and purified.</p> Produced human RPB3 protein is particularly valuable to generate an anti-RPB3 antibody that can be used as a research tool. Currently available antibody against the protein was produced using the Drosophila homologue; therefore, it is not optimal for detecting human protein. Purified RPB3 protein can be used to characterize its biochemical property, and can also be used as an antigen to generate an antibody that can specifically recognize the protein in vivo and or in vitro for research purposes. 2023-12-12 2024-08-12 2024-08-12 2024-03-20 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 151763977 Wade, Paul NIEHS NIEHS Wade, Paul (NIEHS) 1 151763981 Dhasarathy, Archana University of North Dakota Dhasarathy, Archana 2 151763977 Wade, Paul NIEHS NIEHS Wade, Paul (NIEHS) 1 151763981 Dhasarathy, Archana University of North Dakota Dhasarathy, Archana 2 151763972 A Bacterial Strain Derived From BL21 (ED3) CodonPlus Competent Cells Containing An Expressionvector For Human POLR2C Gene E-008-2013-0 Research Material NIEHS 83739538 Choudhry, Vidita vidita.choudhry@nih.gov
United States of America Office of Technology Transfer and Development vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-4597] A BL21 (ED3) Codon Plus Competent Cell-derived Bacterial Strain for Research Use&body=Please send me information about technology [TAB-4597] A BL21 (ED3) Codon Plus Competent Cell-derived Bacterial Strain for Research Use. Choudhry, Vidita<br><a href="mailto:vidita.choudhry@nih.gov?subject=Web Inquiry on [TAB-4597] A BL21 (ED3) Codon Plus Competent Cell-derived Bacterial Strain for Research Use&body=Please send me information about technology [TAB-4597] A BL21 (ED3) Codon Plus Competent Cell-derived Bacterial Strain for Research Use.">vidita.choudhry@nih.gov</a><br> TAB-4596 151763762 Affinity Purified Polyclonal Antibody Against Vangl2 (Van Gogh-like) as a Research Tool Product NIDCD Antibodies, Research Materials Antibodies Research Materials Mireille Montcouquiol <p>This technology includes an antibody that enables the identification and isolation of the protein and protein partners of Vangl2 for application by western blotting, immunoprecipitation and immunocytochemistry. Because planar cell polarity signaling disruption leads to direct or indirect pathologies including malformation of the neural tube, mental retardation, disruption of sensory functions (hearing, balance, vision), cancers (polykystic kidneys disease), or cardiac</p> <p>malformations and disruption of chirality (situs inversus), we can envision that the antibody could be used as a diagnostic tool.</p> Enables access to a valuable reagent tool. Vialed and sold as a diagnostic research product, furthering the work of researchers focused on Planar Cell Polarity, including Vangl2, by enabling access to a valuable reagent tool. 2023-12-12 2024-08-12 2024-08-12 2024-03-27 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 151763905 Montcouquiol, Mireille INSERM Montcouquiol, Mireille 1 151763905 Montcouquiol, Mireille INSERM Montcouquiol, Mireille 1 151763765 Affinity Purified Polyclonal Antibody Against Vangl2 (Van Gogh-like) E-548-2013-0 Research Material National Institute on Deafness and Other Communication Disorders (NIDCD) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-4596] Affinity Purified Polyclonal Antibody Against Vangl2 (Van Gogh-like) as a Research Tool Product&body=Please send me information about technology [TAB-4596] Affinity Purified Polyclonal Antibody Against Vangl2 (Van Gogh-like) as a Research Tool Product. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-4596] Affinity Purified Polyclonal Antibody Against Vangl2 (Van Gogh-like) as a Research Tool Product&body=Please send me information about technology [TAB-4596] Affinity Purified Polyclonal Antibody Against Vangl2 (Van Gogh-like) as a Research Tool Product.">shmilovm@nih.gov</a><br> TAB-4594 151763672 Development of High-Throughput ELISA Based Binding Assays to Detect p53/p63/p73 Family Protein-DNA Interaction in the 96-well Microplate Format for Drug Screening and Other Clinical and Diagnostic Uses NIDCD Diagnostics, Oncology, Research Equipment, Research Materials Diagnostics Oncology Research Equipment Research Materials Zhong Chen, Minyoung Jang <p>This technology includes ELISA based binding assays of p53, p63 or p73 provide possibilities to validate genome sequencing results, and allow the performance of more in-depth investigation to address scientific mechanisms, as well as to develop applications for high-throughput clinical and diagnosis usages. While quantitative p53 binding assays have been commercially developed, there is a lack of high-throughput method to detect binding activity of all three p53/p63/p73 family members, which are an important step for these transcription factors to perform their function. Targeting these transcription factors is an important strategy for drug development or clinical diagnostics. These binding assays will accelerate such process. Recent technology development of high-throughput sequencing has revealed genome-wide abnormality of p63/p73 binding in cancers. However, there is a lack of a high-throughput technology to validate the results generated from such technology, such as ChIP-seq (Chromatin Immunoprecipitation-parallel sequencing). This technology bridges the gap and provides the necessary validation.</p> <ul> <li>Currently, study of transcription binding activities is dependent on conventional methods such as EMSA (electrophoretic mobility shift assay), or ChIP (Chromatin Immunoprecipitation), which are very time consuming, and not suitable for high throughput application.</li> <li>The EMSA method needs to use radioisotopes for high sensitivity and reliability, which is not environmentally friendly.</li> <li>There is a lack of high-throughput method to validate lots of results from high throughput ChIP-seq or drug screening. However, these kits can be used for the high-throughput experiments, either in the academics or commercially.</li> </ul> <ul> <li>The binding assays for p53, p63 and p73 transcription factors could be used for drug screening of small molecule inhibitors.</li> <li>This invention can be developed as a commercially available kit for detecting the binding activities of NF-kB transcription factors. p53, p63 p73 binding assays can be commercialized and developed into similar kits to meet the needs for the research community.</li> </ul> 2023-12-12 2024-08-12 2024-08-12 2024-03-27 False True True 37470483 Website Abstract 151763679 Chen, Zhong National Institute on Deafness and Other Communication Disorders (NIDCD) NIDCD Chen, Zhong (NIDCD) 1 151763683 Jang, Minyoung Rutgers Robert Wood Johnson Medical School (RWJMS) Jang, Minyoung 2 151763679 Chen, Zhong National Institute on Deafness and Other Communication Disorders (NIDCD) NIDCD Chen, Zhong (NIDCD) 1 151763683 Jang, Minyoung Rutgers Robert Wood Johnson Medical School (RWJMS) Jang, Minyoung 2 151763675 Development Of High-Throughput ELISA Based Binding Assays To Detect P53/p63/p73 Family Protein-DNA Interaction In The 96-well Microplate Format E-137-2012-0 Research Material National Institute on Deafness and Other Communication Disorders (NIDCD) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-4594] Development of High-Throughput ELISA Based Binding Assays to Detect p53/p63/p73 Family Protein-DNA Interaction in the 96-well Microplate Format for Drug Screening and Other Clinical and Diagnostic Uses&body=Please send me information about technology [TAB-4594] Development of High-Throughput ELISA Based Binding Assays to Detect p53/p63/p73 Family Protein-DNA Interaction in the 96-well Microplate Format for Drug Screening and Other Clinical and Diagnostic Uses. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-4594] Development of High-Throughput ELISA Based Binding Assays to Detect p53/p63/p73 Family Protein-DNA Interaction in the 96-well Microplate Format for Drug Screening and Other Clinical and Diagnostic Uses&body=Please send me information about technology [TAB-4594] Development of High-Throughput ELISA Based Binding Assays to Detect p53/p63/p73 Family Protein-DNA Interaction in the 96-well Microplate Format for Drug Screening and Other Clinical and Diagnostic Uses.">shmilovm@nih.gov</a><br> TAB-4593 151763527 Transgenic Mouse Expressing Cre for the Development for Delivery of Gene Therapy NIDCD Animal Models, Research Materials, Therapeutics Animal Models Research Materials Therapeutics Robert Morell <p>This technology includes a mouse model containing a hypothetical, previously undescribed, gene that we have proven is expressed in hair cells of the inner ear and few other tissues in the body. The hair-cell limited expression of Cre is a genetic tool for creating conditional mutations affecting hair cells almost exclusively. Hair cells are the sensory receptors of both the auditory system and the vestibular system in the ears of all vertebrates.</p> The ability to limit conditional mutations to just the hair cells allows for the study of hair cell development and function, without the confounding effects of pathologies in other cells in the inner ear, or other tissues in the body. Moreover, the targeted insertion does not itself cause any discernable auditory pathology in the heterozygous or homozygous state. Potentially useful for gene therapy delivery of genes to restore or protect hair cell function in the inner ear specifically. 2023-12-12 2024-08-12 2024-08-12 2024-03-27 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 151763534 Morell, Robert National Institute on Deafness and Other Communication Disorders (NIDCD) NIDCD Morell, Robert (NIDCD) 1 151763534 Morell, Robert National Institute on Deafness and Other Communication Disorders (NIDCD) NIDCD Morell, Robert (NIDCD) 1 151763530 GM1714^TmIRESCre, Transgenic Mouse Expressing Cre In Hair Cells Of The Inner Ear E-135-2020-0 Research Material National Institute on Deafness and Other Communication Disorders (NIDCD) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-4593] Transgenic Mouse Expressing Cre for the Development for Delivery of Gene Therapy&body=Please send me information about technology [TAB-4593] Transgenic Mouse Expressing Cre for the Development for Delivery of Gene Therapy. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-4593] Transgenic Mouse Expressing Cre for the Development for Delivery of Gene Therapy&body=Please send me information about technology [TAB-4593] Transgenic Mouse Expressing Cre for the Development for Delivery of Gene Therapy.">shmilovm@nih.gov</a><br> TAB-4556 151738423 Cell Lines of Dopaminergic Neurons Derived from Human Induced Pluripotent Stem Cell (iPSC) lines for Multiple Neurological Therapeutic and Diagnostic Uses NIAMS Human iPSC Lines, Licensing, Neurology, Research Materials Human iPSC Lines Licensing Neurology Research Materials Mahendra Rao <p>This technology includes three cell lines of dopaminergic neurons derived from human induced pluripotent stem cell (iPSC) line BC1, human iPSG line X1 and human embryonic stem cell (hESC) line H14 to be utilized in neurology research. These cell lines will be used for to study the biology of brain development and may also be used to test different characterization and differentiation assays. The dopaminergic neurons and/or their derivatives may also be used as controls in studies to screen for small molecules to change cell fate and/or to alleviate the phenotypes of various diseases.</p> The starting materials (iPSC-BC1, iPSC-X1, and hESC-H14) are all available commercially and do not restrict the usage of their derivatives, and these cells will significantly reduce the financial burden of initiating many research projects. These cell lines will be used in many studies that could facilitate the development of cellular therapies, more effective drug treatments through their use as screening assays, and improved understanding of basic cell biology. We are seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. 2023-12-11 2024-08-12 2024-08-12 2024-03-27 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 151738433 Rao, Mahendra National Institute of Arthritis and Musculoskeletal and Skin Diseases NIAMS Rao, Mahendra (NIAMS) 1 151738433 Rao, Mahendra National Institute of Arthritis and Musculoskeletal and Skin Diseases NIAMS Rao, Mahendra (NIAMS) 1 151738426 Generation Of Three Lines Of Dopaminergic Neurons Derived From Human Induced Pluripotent Stem Cell (iPSC) Line BC1, Human IPSC Line X1 And Human Embryonic Stem Cell (hESC) Line H14 E-092-2012-0 Research Material National Institute on Aging (NIH/NIA) 83656052 Knezevic, Vladimir vlado.knezevic@nih.gov
United States of America Technology Advancement Office vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-4556] Cell Lines of Dopaminergic Neurons Derived from Human Induced Pluripotent Stem Cell (iPSC) lines for Multiple Neurological Therapeutic and Diagnostic Uses&body=Please send me information about technology [TAB-4556] Cell Lines of Dopaminergic Neurons Derived from Human Induced Pluripotent Stem Cell (iPSC) lines for Multiple Neurological Therapeutic and Diagnostic Uses. Knezevic, Vladimir<br><a href="mailto:vlado.knezevic@nih.gov?subject=Web Inquiry on [TAB-4556] Cell Lines of Dopaminergic Neurons Derived from Human Induced Pluripotent Stem Cell (iPSC) lines for Multiple Neurological Therapeutic and Diagnostic Uses&body=Please send me information about technology [TAB-4556] Cell Lines of Dopaminergic Neurons Derived from Human Induced Pluripotent Stem Cell (iPSC) lines for Multiple Neurological Therapeutic and Diagnostic Uses.">vlado.knezevic@nih.gov</a><br> TAB-4547 151736996 Mass Spectrometry Derived Protein Biomarkers of Atherosclerotic Cardiovascular Disease Risk NHLBI Cardiology, Computational models/software, Licensing, Software / Apps Cardiology Computational models/software Licensing Software / Apps Aram Adourian, Martin Larson, Daniel Levy, Pieter Muntendam <p>This technology includes a combination of protein biomarkers and clinical risk factors to be used as an In Vitro Diagnostic Multivariate Index Assay (IVDMIA) that can improve the identification of individuals at high risk for atherosclerotic cardiovascular disease (ASCVD) and myocardial infarction (MI). Incorporation of novel protein biomarkers of ASCVD risk into risk assessment algorithms may improve their ability to identify individuals at high risk for ASCVD. We conducted mass spectrometry (iTRAQ) profiling of 861 circulating plasma proteins in 135 MI cases from the Framingham Heart Study (FHS), and identified panels of protein biomarkers that independently predicted the occurrence of new onset MI/ASCVD above and beyond established risk factors. The IVDMIA invention described combines the values of multiple variables using an interpretation function to yield a single, patient-specific result, that is intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment or prevention of disease.</p> In improving upon current clinical risk factor based ASCVD risk prediction models, the protein biomarker-based strategy that culminates in an IVDMIA will overcome a major limitation of current ASCVD risk assessment methods: <ul> <li>Ability to identify many high-risk individuals early in the course of subclinical disease progression</li> <li>These protein biomarkers can be measured reliably and reproducibly, non-invasively through blood</li> </ul> This risk assessment algorithm can be used to better identify individuals at high risk for MI/ASCVD in whom proven preventive strategies can be applied to delay or prevent the onset of clinical ASCVD We are seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. 2023-12-11 2024-08-12 2024-08-12 2024-03-27 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 151737121 Levy, Daniel University of Chicago Levy, Daniel 1 151737125 Larson, Martin Boston University Larson, Martin 2 151737129 Adourian, Aram BG Medicine, Inc. Adourian, Aram 3 151737134 Muntendam, Pieter BGMedicine Muntendam, Pieter 4 151737121 Levy, Daniel University of Chicago Levy, Daniel 1 151737125 Larson, Martin Boston University Larson, Martin 2 151737129 Adourian, Aram BG Medicine, Inc. Adourian, Aram 3 151737134 Muntendam, Pieter BGMedicine Muntendam, Pieter 4 151736999 Mass Spectrometry Derived Protein Biomarkers Of Atherosclerotic Cardiovascular Disease Risk E-516-2013-0 Filing authorized BG Medicine, Boston University, National Heart, Lung, and Blood Institute (NHLBI), scPharmaceuticals 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-4547] Mass Spectrometry Derived Protein Biomarkers of Atherosclerotic Cardiovascular Disease Risk&body=Please send me information about technology [TAB-4547] Mass Spectrometry Derived Protein Biomarkers of Atherosclerotic Cardiovascular Disease Risk. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-4547] Mass Spectrometry Derived Protein Biomarkers of Atherosclerotic Cardiovascular Disease Risk&body=Please send me information about technology [TAB-4547] Mass Spectrometry Derived Protein Biomarkers of Atherosclerotic Cardiovascular Disease Risk.">shmilovm@nih.gov</a><br> 157756578 E-516-2013-0 E-516-2013-0-US-01 DETECTION OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASE RISK AND MYOCARDIAL INFARCTION RISK PRV US 61/904,408 Abandoned US <br />Provisional (PRV) 61/904,408<br />Filed on 2013-11-14<br />Status: Abandoned 157756586 E-516-2013-0 E-516-2013-0-PCT-02 DETECTION OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASE RISK AND MYOCARDIAL INFARCTION RISK PCT Patent Cooperation Treaty PCT/US2014/065527 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2014/065527<br />Filed on 2014-11-13<br />Status: Expired 157756592 E-516-2013-0 E-516-2013-0-US-03 Detection of Atherosclerotic Cardiovascular Disease Risk National Stage US 15/036,751 Abandoned US <br />National Stage 15/036,751<br />Filed on 2016-05-13<br />Status: Abandoned TAB-4546 151736948 Immunoassay-derived Protein Biomarkers of Atherosclerotic Cardiovascular Disease Risk NHLBI Cardiology, Diagnostics, Licensing, Research Materials Cardiology Diagnostics Licensing Research Materials Ralph D'Agostino, Martin Larson, Daniel Levy <p>This technology includes a combination of 6 protein biomarkers and clinical risk factors to be used as an In Vitro Diagnostic Multivariate Index Assay (IVDMIA) that can improve the identification of individuals at high risk for atherosclerotic cardiovascular disease (ASCVD). Incorporation of novel protein biomarkers of ASCVD risk into risk assessment algorithms may improve their ability to identify individuals at high risk for ASCVD. We conducted an immunoassay profiling of 47 circulating plasma proteins in over 5,000 participants from the Framingham Heart Study (FHS) free of overt cardiovascular disease who were 40 years of age or older, and identified a panel of 6 immunoassay derived protein biomarkers that independently predicted the occurrence of new onset ASCVD above and beyond established risk factors. The IVDMIA invention described combines the values of multiple variables using an interpretation function to yield a single, patient-specific result, that is intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment or prevention of disease.</p> In improving upon current clinical risk factor based ASCVD risk prediction models, the protein biomarker-based strategy that culminates in an IVDMIA will overcome a major limitation of current ASCVD risk assessment methods: <ul> <li>Ability to identify many high-risk individuals early in the course of subclinical disease progression</li> <li>These protein biomarkers can be measured reliably and reproducibly, non-invasively through blood</li> </ul> This risk assessment algorithm can be used to better identify individuals at high risk for ASCVD in whom proven preventive strategies can be applied to delay or prevent the onset of clinical ASCVD. We are seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. 2023-12-11 2024-08-12 2024-08-12 2024-03-27 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 151736955 Levy, Daniel University of Chicago Levy, Daniel 1 151736959 Larson, Martin Boston University Larson, Martin 2 151736967 D'Agostino, Ralph Boston University D'Agostino, Ralph 3 151736955 Levy, Daniel University of Chicago Levy, Daniel 1 151736959 Larson, Martin Boston University Larson, Martin 2 151736967 D'Agostino, Ralph Boston University D'Agostino, Ralph 3 151736951 Immunoassay Derived Protein Biomarkers Of Atherosclerotic Cardiovascular Disease Risk E-515-2013-0 Filing authorized Boston University, National Heart, Lung, and Blood Institute (NHLBI) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-4546] Immunoassay-derived Protein Biomarkers of Atherosclerotic Cardiovascular Disease Risk&body=Please send me information about technology [TAB-4546] Immunoassay-derived Protein Biomarkers of Atherosclerotic Cardiovascular Disease Risk. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-4546] Immunoassay-derived Protein Biomarkers of Atherosclerotic Cardiovascular Disease Risk&body=Please send me information about technology [TAB-4546] Immunoassay-derived Protein Biomarkers of Atherosclerotic Cardiovascular Disease Risk.">shmilovm@nih.gov</a><br> 157756553 E-515-2013-0 E-515-2013-0-US-01 DETECTION OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASE RISK AND HEART FAILURE RISKd PRV US 61/904,410 Abandoned US <br />Provisional (PRV) 61/904,410<br />Filed on 2013-11-14<br />Status: Abandoned 157756558 E-515-2013-0 E-515-2013-0-PCT-02 DETECTION OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASE RISK AND HEART FAILURE RISK PCT Patent Cooperation Treaty PCT/US2014/065524 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2014/065524<br />Filed on 2014-11-13<br />Status: Expired TAB-4542 151736487 Bivalent Tn5 Complex and its Application to Map Enhancer-Promoter Interactions for Use in Diagnostics NHLBI Diagnostics, Licensing, Research Equipment Diagnostics Licensing Research Equipment Qingsong Tang, Keji Zhao <p>This technology includes a new reagent, termed bivalent Tn5 complex, and applied it to mapping genome-wide enhancer-promoter interactions to be utilized for disease diagnostics. Chromatin structure is critical for regulating transcription in normal development and disease states. In particular, the interaction between enhancers and promotes are essential for the temporospatial control of gene expression.</p> The reagent and method can be applied to mapping genome-wide enhancer-promoter interactions, which are predictive of gene expression and could provide diagnostic information for diseases. Reagents for performing this assay could be developed and commercialized We are seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. 2023-12-11 2024-08-12 2024-08-12 2024-03-27 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 151736496 Zhao, Keji National Heart, Lung, and Blood Institute (NHLBI) NHLBI Zhao, Keji (NHLBI) 1 151736500 Tang, Qingsong National Heart, Lung, and Blood Institute (NHLBI) NHLBI Tang, Qingsong (NHLBI) 2 151736496 Zhao, Keji National Heart, Lung, and Blood Institute (NHLBI) NHLBI Zhao, Keji (NHLBI) 1 151736500 Tang, Qingsong National Heart, Lung, and Blood Institute (NHLBI) NHLBI Tang, Qingsong (NHLBI) 2 151736490 Bivalent Tn5 Complex And Its Application To Map Enhancer-Promoter Interactions E-266-2016-0 Research Material National Heart, Lung, and Blood Institute (NHLBI) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-4542] Bivalent Tn5 Complex and its Application to Map Enhancer-Promoter Interactions for Use in Diagnostics&body=Please send me information about technology [TAB-4542] Bivalent Tn5 Complex and its Application to Map Enhancer-Promoter Interactions for Use in Diagnostics. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-4542] Bivalent Tn5 Complex and its Application to Map Enhancer-Promoter Interactions for Use in Diagnostics&body=Please send me information about technology [TAB-4542] Bivalent Tn5 Complex and its Application to Map Enhancer-Promoter Interactions for Use in Diagnostics.">shmilovm@nih.gov</a><br> TAB-4532 151720590 Immunogens, Compositions, and Methods for the Treatment of Dyslipidemia NHLBI Antibodies, Licensing, Metabolic Disease, Research Materials, Therapeutics, Vaccines Antibodies Licensing Metabolic Disease Research Materials Therapeutics Vaccines Alan Remaley <p>This technology includes a novel vaccine for forming autoantibodies against apoC-III, a plasma enzyme that inhibits lipolysis. The vaccine can possibly be used to treat patients with high triglycerides and are at risk for pancreatitis and cardiovascular disease. This disclosure describes an ApoC3 immunogen that includes an antigenicApoC3 peptide linked to a bacteriophage virus-like-particle (VLP) immunogenic carrier.</p> This technology for inducing autoantibodies against endogenous ApoC3 using peptides conjugated to virus-like-particles (VLPs) is completely novel and if successful would be a much lower cost than using antisense oligonucleotides and likely could be more widely used. This vaccine has significant potential for further development as a potential therapeutic for hypertriglyceridemia. We are seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. 2023-12-08 2024-08-12 2024-08-12 2024-03-27 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 151720598 Remaley, Alan National Heart, Lung, and Blood Institute (NHLBI) NHLBI Remaley, Alan (NHLBI) 1 151720598 Remaley, Alan National Heart, Lung, and Blood Institute (NHLBI) NHLBI Remaley, Alan (NHLBI) 1 151720593 Immunogens, Compositions, And Methods For Treating Dyslipidemia E-218-2016-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-4532] Immunogens, Compositions, and Methods for the Treatment of Dyslipidemia&body=Please send me information about technology [TAB-4532] Immunogens, Compositions, and Methods for the Treatment of Dyslipidemia. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-4532] Immunogens, Compositions, and Methods for the Treatment of Dyslipidemia&body=Please send me information about technology [TAB-4532] Immunogens, Compositions, and Methods for the Treatment of Dyslipidemia.">shmilovm@nih.gov</a><br> 157756137 E-218-2016-0 E-218-2016-0-US-01 Immunogens, Compositions, And Methods For Treating Dyslipidemia PRV US 62/340,706 Abandoned US <br />Provisional (PRV) 62/340,706<br />Filed on 2016-05-24<br />Status: Abandoned 157756142 E-218-2016-0 E-218-2016-0-PCT-02 Immunogens, Compositions, And Methods For Treating Dyslipidemia PCT Patent Cooperation Treaty PCT/US2017/034149 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2017/034149<br />Filed on 2017-05-24<br />Status: Expired 157756147 E-218-2016-0 E-218-2016-0-US-03 Immunogens, Compositions, And Methods For Treating Dyslipidemia National Stage US 16/304,020 Abandoned US <br />National Stage 16/304,020<br />Filed on 2018-11-21<br />Status: Abandoned TAB-4531 151720402 Electronic Fringe Scanning for the Improvement of Medical Imaging Technology NHLBI Licensing, Medical Devices, Research Equipment Licensing Medical Devices Research Equipment Han Wen <p>This technology includes an electronic method for fringe scanning in grating-based phase-contrast imaging, which enhances x-ray phase-contrast imaging. Traditional methods use high-density gratings and require fine grating fringes, finer than the detector&#39;s resolution, necessitating fringe scanning to obtain phase-contrast information. This process typically involves complex and precise movements of a grating for each image, challenging in applications like medical computed tomography that demand rapid gantry rotation and acquisition of numerous projection images in less than a second. The innovation of this technology lies in its ability to perform electronic fringe scanning without any moving parts, offering a more efficient, cost-effective, and less complex solution to capturing high-quality phase-contrast images.</p> When compared to the current mechanical scanning of the grating(s), focal spot scanning has the advantages of: <ul> <li>Almost infinite scanning speed,</li> <li>Electronically controlled scanning trajectory of high precision and accuracy,</li> <li>Much lower cost and ease of implementation and maintenance,</li> <li>Much greater stability.</li> </ul> The method will be used to perform fringe scanning electronically in grating-based phase-contrast imaging. The products are modified x-ray tubes with the ability to move the focal spot of the x-ray beam, e.g., by cathode ray electronics, or suitable shaping of the anode target in rotation anode x-ray tubes. We are seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. 2023-12-08 2024-08-12 2024-08-12 2024-03-27 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 151720542 Wen, Han National Heart, Lung, and Blood Institute (NHLBI) NHLBI Wen, Han (NHLBI) 1 151720542 Wen, Han National Heart, Lung, and Blood Institute (NHLBI) NHLBI Wen, Han (NHLBI) 1 151720405 Scanning The Focal Spot Of The X-ray Source For Fringe Scanning In Grating-based X-ray Phase-contrast Imaging E-213-2012-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-4531] Electronic Fringe Scanning for the Improvement of Medical Imaging Technology&body=Please send me information about technology [TAB-4531] Electronic Fringe Scanning for the Improvement of Medical Imaging Technology. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-4531] Electronic Fringe Scanning for the Improvement of Medical Imaging Technology&body=Please send me information about technology [TAB-4531] Electronic Fringe Scanning for the Improvement of Medical Imaging Technology.">shmilovm@nih.gov</a><br> TAB-4529 151720165 Prazoles as Potential Broad Spectrum Anti-viral Agents NHLBI Infectious Disease, Licensing, Therapeutics Infectious Disease Licensing Therapeutics Carol Carter, Lorna Ehrlich <p>The technology described involves the use of a compound called prazole as an anti-viral agent specifically targeting HIV-1. It was found that prazole binds to a protein called Tsg101, which is crucial for the virus&#39;s life cycle. This binding disrupts the normal interaction of Tsg101 with another protein, ubiquitin, thereby inhibiting the release of HIV-1 particles from infected cells. Additionally, the interference caused by prazole leads to the degradation of the viral protein Gag within host cells. Remarkably, any viral particles that do manage to get released in the presence of the drug are rendered non-infectious, further highlighting the potential of prazole as an effective anti-HIV agent.</p> The competitive advantage of this technology lies in its unique ability to both inhibit HIV-1 particle release and render any released particles non-infectious, offering a novel and potentially more effective approach to HIV treatment. This technology has potential applications in developing new antiretroviral therapies for HIV, offering a promising avenue for both treatment and reduction of viral transmission. We are seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. 2023-12-08 2024-08-12 2024-08-12 2024-03-27 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 151720184 Strickland M, et al. https://pubmed.ncbi.nlm.nih.gov/29123089/ <a href="https://pubmed.ncbi.nlm.nih.gov/29123089/">Strickland M, et al.</a> 151720172 Carter, Carol Stony Brook University Carter, Carol 1 151720176 Ehrlich, Lorna Stony Brook University Ehrlich, Lorna 2 151720172 Carter, Carol Stony Brook University Carter, Carol 1 151720176 Ehrlich, Lorna Stony Brook University Ehrlich, Lorna 2 151720168 Methods Of Inhibiting Viruses Using Compositions Targeting TSG101-Ubiquitin Interaction E-211-2018-0 Filing authorized Stony Brook University 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-4529] Prazoles as Potential Broad Spectrum Anti-viral Agents&body=Please send me information about technology [TAB-4529] Prazoles as Potential Broad Spectrum Anti-viral Agents. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-4529] Prazoles as Potential Broad Spectrum Anti-viral Agents&body=Please send me information about technology [TAB-4529] Prazoles as Potential Broad Spectrum Anti-viral Agents.">shmilovm@nih.gov</a><br> 157756095 E-211-2018-0 E-211-2018-0-US-01 Methods Of Inhibiting Viruses Using Compositions Targeting TSG101-Ubiquitin Interaction PRV US 62/416,241 Abandoned US <br />Provisional (PRV) 62/416,241<br />Filed on 2016-11-02<br />Status: Abandoned TAB-4526 151719717 Clonal Spodoptera Frugiperda Cell lines for Enhanced Expression NHLBI Licensing, Plasmids/Vectors, Research Materials, Therapeutics Licensing Plasmids/Vectors Research Materials Therapeutics Robert Kotin, Lina Li <p>This technology includes Spodoptera frugiperda (Sf9) cells which were developed to produce recombinant adeno-associated virus. The cells maintain a copy of the vector genome and for production, require infection with a single baculovirus that expresses either structural and nonstructural proteins to produce rAAV, or the non-structural (Rep) proteins to produce ceDNA.</p> The simplified process has manufacturing advantages compared to the co-infection systems (using either 2 or 3 baculoviruses), with higher production and improved yields. Spodoptera frugiperda (Sf9) cells were developed to produce recombinant adeno-associated virus. This technology can be used for the large-scale production of recombinant adeno-associated virus (rAAV), a critical component in gene therapy, by employing Spodoptera frugiperda (Sf9) cells for efficient and controlled replication and packaging of the virus. We are seeking statements of capability or interest from parties interested in collaborative research to further developer, evaluate, or commercialize this technology. 2023-12-08 2024-08-12 2024-08-12 2024-03-20 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 151719822 Li L, et al. https://pubmed.ncbi.nlm.nih.gov/23936358/ <a href="https://pubmed.ncbi.nlm.nih.gov/23936358/">Li L, et al.</a> 151719729 Li, Lina NHGRI Li, Lina (NHGRI) 1 151719812 Kotin, Robert Carbon Biosciences Kotin, Robert 2 151719729 Li, Lina NHGRI Li, Lina (NHGRI) 1 151719812 Kotin, Robert Carbon Biosciences Kotin, Robert 2 151719720 Clonal Spodoptera Frugiperda Cell Lines For Enhanced Expression E-199-2018-0 Research Material National Heart, Lung, and Blood Institute (NHLBI) 83714317 Devany, John john.devany@nih.gov
United States of America Office of Technology Transfer and Development john.devany@nih.gov?subject=Web Inquiry on [TAB-4526] Clonal Spodoptera Frugiperda Cell lines for Enhanced Expression&body=Please send me information about technology [TAB-4526] Clonal Spodoptera Frugiperda Cell lines for Enhanced Expression. Devany, John<br><a href="mailto:john.devany@nih.gov?subject=Web Inquiry on [TAB-4526] Clonal Spodoptera Frugiperda Cell lines for Enhanced Expression&body=Please send me information about technology [TAB-4526] Clonal Spodoptera Frugiperda Cell lines for Enhanced Expression.">john.devany@nih.gov</a><br> TAB-1281 114095603 A Mouse Model of Multiple Endocrine Neoplasia, Type I NHGRI Licensing, Oncology, Research Materials, Therapeutics Licensing Oncology Research Materials Therapeutics Francis Collins, Judy Crabtree The current invention embodies a mouse model which is heterozygous for a null allele at the Men1 locus of murine chromosome 19. Men1 has similar exon-intron organization and amino acid identity compared with its human analog MEN1, which has been implicated in the pathogenesis of multiple endocrine neoplasia, type I (MENI). This mouse model has been shown to develop features remarkably similar to those of MEN1, which include tumors of the endocrine pancreas, pituitary, and parathyroids. The model embodied in this invention appears to represent a valuable research tool for use in elucidating the role of the wild-type Men1 allele in tumor formation, and ultimately should aid in the testing of possible therapeutic approaches to human MEN1. Research Tool -- Patent protection is not being pursued for this technology. 2022-03-08 2024-08-12 2024-08-12 2001-08-01 CC1XXX, CC3XXX, CCXXXX, CXXXXX, endocrine, GB1A3X, GB1AXX, GB1XXX, GB2BXX, GB2XXX, GBXXXX, GCXXXX, GXXXXX, Men1 locus, Model, Mouse, mouse model, MULTIPLE, Multiple endocrine neoplasia, Multiple endocrine neoplasia type 1, Multiple endocrine neoplasia, type 2, murine chromosome 19, NEOPLASIA, tumor formation, TYPE, Zollinger-Ellison syndrome False True True NIHTT 37470483 Website Abstract 114105350 Crabtree, Judy Crabtree, Judy 0 114105351 Collins, Francis NHGRI Collins, Francis (NHGRI) 0 114105350 Crabtree, Judy Crabtree, Judy 0 114105351 Collins, Francis NHGRI Collins, Francis (NHGRI) 0 114101101 Mouse Model of Multiple Endocrine Neoplasia, Type I E-243-2001-0 Research Material National Human Genome Research Institute (NHGRI) 83725487 Raghavan, Sangeetha sangeetha.raghavan@nih.gov
United States of America Technology Transfer Office sangeetha.raghavan@nih.gov?subject=Web Inquiry on [TAB-1281] A Mouse Model of Multiple Endocrine Neoplasia, Type I&body=Please send me information about technology [TAB-1281] A Mouse Model of Multiple Endocrine Neoplasia, Type I. Raghavan, Sangeetha<br><a href="mailto:sangeetha.raghavan@nih.gov?subject=Web Inquiry on [TAB-1281] A Mouse Model of Multiple Endocrine Neoplasia, Type I&body=Please send me information about technology [TAB-1281] A Mouse Model of Multiple Endocrine Neoplasia, Type I.">sangeetha.raghavan@nih.gov</a><br> 114116803 GB1A3X 114116804 GB1AXX 114116805 GB2BXX 114116806 CC1XXX 114116807 CC3XXX 114116808 GB1XXX 114116809 GB2XXX 114116810 CCXXXX 114116811 GBXXXX 114116812 GCXXXX 114116813 CXXXXX 114116814 GXXXXX 114134850 mouse model 114134851 Men1 locus 114134852 murine chromosome 19 114134853 tumor formation 114134854 Mouse 114134855 Model 114134856 MULTIPLE 114134857 endocrine 114134858 NEOPLASIA 114134859 TYPE 114156077 Multiple endocrine neoplasia type 1 114156078 Zollinger-Ellison syndrome 114156079 Multiple endocrine neoplasia, type 2 114158118 Multiple endocrine neoplasia TAB-4522 151719395 Background-free Imaging by Selective Modulation of Nanodiamond Fluorescence Using a Magnetic Field NHLBI Computational models/software, Diagnostics, Licensing, Medical Devices, Research Equipment, Software / Apps Computational models/software Diagnostics Licensing Medical Devices Research Equipment Software / Apps Ambika Bumb, Keir Neuman, Susanta Sarkar <p>This technology includes the use of nanodiamonds to achieve background-free imaging. We present several techniques to reduce or eliminate background florescence by exploiting properties of the fluorescent nanodiamonds. In particular, magnetic field modulation of the fluorescence intensity offers a simple, robust, and easily adaptable method to obtain background free imaging in a variety of imaging modalities, i.e., fluorescence microscopy and wide field fluorescence animal imaging. The product would consist of a means of modulating a magnetic field in an imaging system combined with the fluorescent nanodiamonds that are the source of the fluorescence. In principle this technique could be adapted for use in wide field and confocal imaging systems. Importantly, this technique makes use of conventional continuous wave illumination.</p> This method is unique, simple and easy to incorporate with existing microscope or animal imaging systems without coming in contact with the sample. The discovery allows background free imaging of fluorescent nanodiamonds in tissue samples and in vivo, where conventional imaging is difficult due to background fluorescence. We are seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. 2023-12-08 2024-08-12 2024-08-12 2024-03-27 False True True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract 151719402 Bumb, Ambika Bikanta Corporation NCI Bumb, Ambika (NCI) 1 151719410 Sarkar, Susanta unknown Sarkar, Susanta 2 151719418 Neuman, Keir National Heart, Lung, and Blood Institute (NHLBI) NHLBI Neuman, Keir (NHLBI) 3 151719402 Bumb, Ambika Bikanta Corporation NCI Bumb, Ambika (NCI) 1 151719410 Sarkar, Susanta unknown Sarkar, Susanta 2 151719418 Neuman, Keir National Heart, Lung, and Blood Institute (NHLBI) NHLBI Neuman, Keir (NHLBI) 3 151719398 Imaging Systems And Methods Using Floursecent Nanodiamonds E-194-2015-0 Filing authorized Bikanta Corporation, National Heart, Lung, and Blood Institute (NHLBI) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-4522] Background-free Imaging by Selective Modulation of Nanodiamond Fluorescence Using a Magnetic Field&body=Please send me information about technology [TAB-4522] Background-free Imaging by Selective Modulation of Nanodiamond Fluorescence Using a Magnetic Field. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-4522] Background-free Imaging by Selective Modulation of Nanodiamond Fluorescence Using a Magnetic Field&body=Please send me information about technology [TAB-4522] Background-free Imaging by Selective Modulation of Nanodiamond Fluorescence Using a Magnetic Field.">shmilovm@nih.gov</a><br> 157755663 E-194-2015-0 E-194-2015-0-US-01 Imaging Systems And Methods Using Floursecent Nanodiamonds PRV US 62/145,466 Abandoned US <br />Provisional (PRV) 62/145,466<br />Filed on 2015-04-09<br />Status: Abandoned 157755668 E-194-2015-0 E-194-2015-0-PCT-02 IMAGING SYSTEMS AND METHODS USING FLUORESCENT NANODIAMONDS PCT Patent Cooperation Treaty PCT/US2016/026791 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2016/026791<br />Filed on 2016-04-08<br />Status: Expired 157755673 E-194-2015-0 E-194-2015-0-CN-03 Imaging Systems And Methods Using Floursecent Nanodiamonds National Stage China ZL201690000878.8 201690000878.8 Abandoned China <br />National Stage 201690000878.8<br />Filed on 2016-04-08<br />Status: Abandoned 157755678 E-194-2015-0 E-194-2015-0-US-04 Imaging Systems And Methods Using Floursecent Nanodiamonds National Stage US 10,627,340 15/565,123 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10627340 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10627340">10,627,340</a><br />Filed on 2017-10-06<br />Status: Issued 157755683 E-194-2015-0 E-194-2015-0-AU-05 Imaging Systems And Methods Using Floursecent Nanodiamonds National Stage Australia 2016246057 Abandoned Australia <br />National Stage 2016246057<br />Filed on 2016-04-08<br />Status: Abandoned TAB-4518 151718810 A Highly Efficient Differentiation Protocol for Placental Cells Derived from Human Pluripotent Stem Cells for Diagnostic and Therapeutic Applications NHLBI Diagnostics, Human Cell Lines, Human iPSC Lines, Licensing, Research Materials, Therapeutics Diagnostics Human Cell Lines Human iPSC Lines Licensing Research Materials Therapeutics Rita Hadley, William Havel, Jeremy Newkirk, Yun Zhou <p>This technology includes in vitro-generated trophectoderm (TE) cells, which are ideal for modeling diseases of the placenta, drug screening, and cell-based therapies. The TE lineage which gives rise to placental cells during early human development. Derivation of definitive placental cells from human pluripotent stem cells in culture remains controversial and so far, placental cells can only be derived directly from primary placental tissue, which largely limits their access and study in the laboratory. This invention describes highly efficient TE differentiation, including cytotrophoblast and syncytiotrophoblast cells, by manipulating specific cell signaling pathways in chemically defined conditions.</p> This is the most efficient and most reproducible astrocyte differentiation protocol from human pluripotent stem cells. This invention will significantly improve the use of human astrocytes for basic research, drug discovery, disease modeling, and cell therapy. We are seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. 2023-12-08 2024-08-12 2024-08-12 2024-03-27 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 151718837 Havel, William Cook Medical Technologies LLC Havel, William 1 151718841 Newkirk, Jeremy Cook Medical Technologies LLC Newkirk, Jeremy 2 151718859 Hadley, Rita Cook Medical Technologies LLC Hadley, Rita 3 151719057 Zhou, Yun Cook Medical Technologies LLC Zhou, Yun 4 151718837 Havel, William Cook Medical Technologies LLC Havel, William 1 151718841 Newkirk, Jeremy Cook Medical Technologies LLC Newkirk, Jeremy 2 151718859 Hadley, Rita Cook Medical Technologies LLC Hadley, Rita 3 151719057 Zhou, Yun Cook Medical Technologies LLC Zhou, Yun 4 151718823 Devices For Placement And Fixation Of Annuloplasty Belt E-180-2019-0 Filing authorized Cook Medical Technologies LLC 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-4518] A Highly Efficient Differentiation Protocol for Placental Cells Derived from Human Pluripotent Stem Cells for Diagnostic and Therapeutic Applications&body=Please send me information about technology [TAB-4518] A Highly Efficient Differentiation Protocol for Placental Cells Derived from Human Pluripotent Stem Cells for Diagnostic and Therapeutic Applications. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-4518] A Highly Efficient Differentiation Protocol for Placental Cells Derived from Human Pluripotent Stem Cells for Diagnostic and Therapeutic Applications&body=Please send me information about technology [TAB-4518] A Highly Efficient Differentiation Protocol for Placental Cells Derived from Human Pluripotent Stem Cells for Diagnostic and Therapeutic Applications.">shmilovm@nih.gov</a><br> TAB-4508 151706099 Phase Sensitive Motion Correction and T1 Mapping for Cardiovascular Magnetic Resonance Imaging NHLBI Cardiology, Computational models/software, Licensing, Medical Devices, Software / Apps Cardiology Computational models/software Licensing Medical Devices Software / Apps Peter Kellman, Hui Xue <p>This technology includes a method of correcting the motion during T1 mapping using cardiovascular magnetic resonance imaging (MRI). Ischemic heart disease is the leading cause of death in the United States. The lack of blood supply among myocardial tissue, especially for scar regions, changes the T1 relaxation value of heart muscles. The non-invasive quantification of T1 value of myocardium (T1 mapping) is therefore of great importance for the diagnosis and treatment of cardiovascular disease. However, the accurate T1 measurement of myocardium is hard to achieve, mainly due to the inevitable respiratory and heart motion. This invention applies the dedicated motion correction and Tl estimation methods and leads to largely improved robustness and accuracy of myocardial T1 mapping.</p> Use of PSIR image reconstruction rather than simpler magnitude image reconstruction. The improved T1 quantification can be used in other MRI applications (not just cardiac imaging). We are seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. 2023-12-07 2024-08-12 2024-08-12 2024-03-27 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 151706114 Xue H, et al. https://pubmed.ncbi.nlm.nih.gov/22736380/ <a href="https://pubmed.ncbi.nlm.nih.gov/22736380/">Xue H, et al.</a> 151706106 Kellman, Peter National Heart, Lung, and Blood Institute (NHLBI) NHLBI Kellman, Peter (NHLBI) 1 151706110 Xue, Hui National Heart, Lung, and Blood Institute (NHLBI) NHLBI Xue, Hui (NHLBI) 2 151706106 Kellman, Peter National Heart, Lung, and Blood Institute (NHLBI) NHLBI Kellman, Peter (NHLBI) 1 151706110 Xue, Hui National Heart, Lung, and Blood Institute (NHLBI) NHLBI Xue, Hui (NHLBI) 2 151706102 Phase Sensitive Motion Correction And Tl Mapping For Cardiovascular Magnetic Resonance Imaging E-143-2012-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI), Siemens Corporation 89788013 Kolesnitchenko, Vincent vk5q@nih.gov
United States of America Office of Technology Transfer and Development vk5q@nih.gov?subject=Web Inquiry on [TAB-4508] Phase Sensitive Motion Correction and T1 Mapping for Cardiovascular Magnetic Resonance Imaging&body=Please send me information about technology [TAB-4508] Phase Sensitive Motion Correction and T1 Mapping for Cardiovascular Magnetic Resonance Imaging. Kolesnitchenko, Vincent<br><a href="mailto:vk5q@nih.gov?subject=Web Inquiry on [TAB-4508] Phase Sensitive Motion Correction and T1 Mapping for Cardiovascular Magnetic Resonance Imaging&body=Please send me information about technology [TAB-4508] Phase Sensitive Motion Correction and T1 Mapping for Cardiovascular Magnetic Resonance Imaging.">vk5q@nih.gov</a><br> 157755230 E-143-2012-0 E-143-2012-0-US-01 Phase Sensitive Motion Correction And Tl Mapping For Cardiovascular Magnetic Resonance Imaging PRV US 61/625,254 Abandoned US <br />Provisional (PRV) 61/625,254<br />Filed on 2012-04-17<br />Status: Abandoned 157755235 E-143-2012-0 E-143-2012-0-US-02 Phase Sensitive Motion Correction And Tl Mapping For Cardiovascular Magnetic Resonance Imaging ORD US 9,129,424 13/864,716 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9129424 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9129424">9,129,424</a><br />Filed on 2013-04-17<br />Status: Issued TAB-4500 151705076 Highly Efficient Gene Transfer into Primary and Expanded Human Natural Killer Cells by Lentiviral Transduction for Cancer Therapy NHLBI Human Cell Lines, Licensing, Oncology, Therapeutics Human Cell Lines Licensing Oncology Therapeutics Richard Childs, Dhanalakshmi (Donna) Chinnasamy <p>This technology includes an efficient lentiviral vector-based method for gene transfer into NK cells and demonstrates a stable and long-term robust expression of transgenes for the treatment of cancer. High gene transfer rates into primary cells being transduced and the ability to produce high titers of virus particles for large-scale transduction of patient cells are prerequisites for clinical trials. Lentiviral vectors can be produced in high titer and concentrated without compromising their transduction efficiency. Additionally, the described method is cheaper and simpler to apply clinically as it does not require the need for several cumbersome and expensive. The present invention of a highly efficient lentiviral vector-based gene transfer protocol can be used to complement a number of already optimized ex vivo NK cell expansion protocols to generate large numbers of genetically reprogrammed NK cells potentially revolutionizing NK cell based immunotherapeutic approaches by enhancing their antitumor efficacy in patient with cancer.</p> This invention has enhanced efficacy over other methodologies for lentiviral vector-mediated genetic manipulation of human primary NK cells. To be used as a method to introduce immunotherapy into cancer patients. We are seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. 2023-12-07 2024-08-12 2024-08-12 2024-03-27 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 151705083 Childs, Richard National Heart, Lung, and Blood Institute (NHLBI) NHLBI Childs, Richard (NHLBI) 1 151705087 Chinnasamy, Dhanalakshmi (Donna) National Heart, Lung, and Blood Institute (NHLBI) NHLBI Chinnasamy, Dhanalakshmi (Donna) (NHLBI) 2 151705083 Childs, Richard National Heart, Lung, and Blood Institute (NHLBI) NHLBI Childs, Richard (NHLBI) 1 151705087 Chinnasamy, Dhanalakshmi (Donna) National Heart, Lung, and Blood Institute (NHLBI) NHLBI Chinnasamy, Dhanalakshmi (Donna) (NHLBI) 2 151705079 Highly Efficient Gene Transfer Into Primary And Expanded Human Natural Killer Cells By Lentiviral Transduction E-121-2016-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-4500] Highly Efficient Gene Transfer into Primary and Expanded Human Natural Killer Cells by Lentiviral Transduction for Cancer Therapy&body=Please send me information about technology [TAB-4500] Highly Efficient Gene Transfer into Primary and Expanded Human Natural Killer Cells by Lentiviral Transduction for Cancer Therapy. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-4500] Highly Efficient Gene Transfer into Primary and Expanded Human Natural Killer Cells by Lentiviral Transduction for Cancer Therapy&body=Please send me information about technology [TAB-4500] Highly Efficient Gene Transfer into Primary and Expanded Human Natural Killer Cells by Lentiviral Transduction for Cancer Therapy.">shmilovm@nih.gov</a><br> 157754962 E-121-2016-0 E-121-2016-0-US-01 METHODS OF PRODUCING MODIFIED NATURAL KILLER CELLS AND METHOD OF USE PRV US 62/366,493 Abandoned US <br />Provisional (PRV) 62/366,493<br />Filed on 2016-07-25<br />Status: Abandoned TAB-4499 151704905 A Pre-emphasis Technique Based on the Temperature-dependent Gradient System Behavior for Trajectory Correction in MR Imaging NHLBI Computational models/software, Licensing, Medical Devices, Software / Apps Computational models/software Licensing Medical Devices Software / Apps Adrienne Campbell-Washburn <p>This technology includes the determination of temperature dependent temporal deviations of the real from the intended gradient waveforms and k-space trajectories during MRI image acquisition, and the use of appropriate temperature dependent pre-compensations to avoid or reduce the image distortion caused by these temporal deviations on the gradient waveforms and k-space trajectories, which will improve imaging quality. The determination of the temperature dependence includes a) direct measurements of the trajectory at the temperature the system operates during the scan, and b) measurements of the trajectory at different temperatures and modelling or interpolating the trajectory at the temperature the system operates during the scan.</p> There are over 30 million MRIs conducted in the US per year, this novel method can improve MR imaging quality. MRI is dependent on accuracy of the magnetic field gradient waveforms; this invention has the potential to improve image quality for a broad range of MR image acquisitions. We are seeking statements of capability or interest from parties interested in collaborative research to further developer, evaluate, or commercialize this technology. 2023-12-07 2024-08-12 2024-08-12 2024-03-27 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 151704912 Campbell-Washburn, Adrienne National Heart, Lung, and Blood Institute (NHLBI) NHLBI Campbell-Washburn, Adrienne (NHLBI) 1 151704912 Campbell-Washburn, Adrienne National Heart, Lung, and Blood Institute (NHLBI) NHLBI Campbell-Washburn, Adrienne (NHLBI) 1 151704908 A Pre-emphasis Technique Based On The Temperature-dependent Gradient System Behavior For Trajectory Correction In MR Imaging E-114-2019-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-4499] A Pre-emphasis Technique Based on the Temperature-dependent Gradient System Behavior for Trajectory Correction in MR Imaging&body=Please send me information about technology [TAB-4499] A Pre-emphasis Technique Based on the Temperature-dependent Gradient System Behavior for Trajectory Correction in MR Imaging. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-4499] A Pre-emphasis Technique Based on the Temperature-dependent Gradient System Behavior for Trajectory Correction in MR Imaging&body=Please send me information about technology [TAB-4499] A Pre-emphasis Technique Based on the Temperature-dependent Gradient System Behavior for Trajectory Correction in MR Imaging.">shmilovm@nih.gov</a><br> 157754946 E-114-2019-0 E-114-2019-0-US-01 A Pre-emphasis Technique Based On The Temperature-dependent Gradient System Behavior For Trajectory Correction In MR Imaging PRV US 62/835,882 Abandoned US <br />Provisional (PRV) 62/835,882<br />Filed on 2019-04-18<br />Status: Abandoned 157754951 E-114-2019-0 E-114-2019-0-US-02 A Pre-emphasis Technique Based On The Temperature-dependent Gradient System Behavior For Trajectory Correction In MR Imaging ORD US 11,112,472 16/699,415 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11112472 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11112472">11,112,472</a><br />Filed on 2019-11-29<br />Status: Issued TAB-4484 151645096 Prior Enhanced Compressed Sensing (PRINCE-CS) Reconstruction for Dynamic 2D-radial Cardiac MRI NHLBI Computational models/software, Diagnostics, Licensing, Software / Apps Computational models/software Diagnostics Licensing Software / Apps Kai Block, Ti-chiun Chang, Jens Guhring, Mariappan Nadar, Peter Speier, Michael Zenge <p>This technology includes a method to reduce scanning time while retaining high image quality during MRI scans. A reconstructed image is rendered from a set of MRI data by first estimating an image with an area which does not contain artifacts or has an artifact with a relatively small magnitude. Corresponding data elements in the estimated image and a trial image are processed, for instance by multiplication, to generate an intermediate data set. The intermediate data set is transformed and minimized iteratively to generate a reconstructed image that is free or substantially free of artifacts. A sparsifying transformation may be applied to generate the reconstructed image.</p> Current techniques require extended computational time and high memory usage. To be used to reduce scanning time during MRI imaging. We are seeking statements of capability or interest from parties interested in collaborative research to further developer, evaluate, or commercialize this technology. 2023-12-06 2024-08-12 2024-08-12 2024-03-27 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 151645103 Chang, Ti-chiun Siemens Corporation Chang, Ti-chiun 1 151645108 Nadar, Mariappan Siemens Corporation Nadar, Mariappan 2 151645152 Guhring, Jens Siemens Corporation Guhring, Jens 3 151645157 Zenge, Michael Siemens Aktiengesellschaft Zenge, Michael 4 151645163 Block, Kai Siemens Aktiengesellschaft Block, Kai 5 151645169 Speier, Peter Siemens Aktiengesellschaft Speier, Peter 6 151645103 Chang, Ti-chiun Siemens Corporation Chang, Ti-chiun 1 151645108 Nadar, Mariappan Siemens Corporation Nadar, Mariappan 2 151645152 Guhring, Jens Siemens Corporation Guhring, Jens 3 151645157 Zenge, Michael Siemens Aktiengesellschaft Zenge, Michael 4 151645163 Block, Kai Siemens Aktiengesellschaft Block, Kai 5 151645169 Speier, Peter Siemens Aktiengesellschaft Speier, Peter 6 151645099 Prior Enhanced Compressed Sensing (PRINCE-CS) Reconstruction For Dynamic 2D-Radial Cardiac MRI E-064-2014-0 Filing authorized Siemens Aktiengesellschaft, Siemens Corporation 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-4484] Prior Enhanced Compressed Sensing (PRINCE-CS) Reconstruction for Dynamic 2D-radial Cardiac MRI&body=Please send me information about technology [TAB-4484] Prior Enhanced Compressed Sensing (PRINCE-CS) Reconstruction for Dynamic 2D-radial Cardiac MRI. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-4484] Prior Enhanced Compressed Sensing (PRINCE-CS) Reconstruction for Dynamic 2D-radial Cardiac MRI&body=Please send me information about technology [TAB-4484] Prior Enhanced Compressed Sensing (PRINCE-CS) Reconstruction for Dynamic 2D-radial Cardiac MRI.">shmilovm@nih.gov</a><br> 157754270 E-064-2014-0 E-064-2014-0-US-01 Prior Enhanced Compressed Sensing (PRINCE-CS) Reconstruction For Dynamic 2D-Radial Cardiac MRI PRV US 61/410,448 Abandoned US <br />Provisional (PRV) 61/410,448<br />Filed on 2010-11-05<br />Status: Abandoned TAB-4479 151644274 Methods and Systems for Automatically Determining Magnetic Field Inversion Time of a Tissue Species NHLBI Cardiology, Computational models/software, Diagnostics, Licensing, Software / Apps Cardiology Computational models/software Diagnostics Licensing Software / Apps Xiaoming Bi, Christopher Glielmi, Andreas Greiser, Peter Kellman, Xlaoguang Lu, Bruce Spottiswoode, Hui Xue <p>This technology includes a computer-implemented method for determining magnetic field inversion time of a tissue species using a T1-mapping image, information about the region of interest, and a tissue classification algorithm. This method includes T1-mapping image comprising a plurality of T1 values within an expected range of T1 values for the tissue of interest. An image mask is created based on predetermined identification information about the tissue of interest. Next, an updated image mask is created based on a largest connected region in the image mask. The updated image mask is applied to the T1-mapping image to yield a masked image. Then, a mean relaxation time value is determined for the largest connected region. The mean relaxation time value is then used to determine a time point for nulling longitudinal magnetization.</p> Current methods and systems are difficult to automate, however this method has been automated which increases efficiency. Ability to identify areas of healthy tissue in cardiac applications. We are seeking statements of capability or interest from parties interested in collaborative research to further developer, evaluate, or commercialize this technology. 2023-12-06 2024-08-12 2024-08-12 2024-03-27 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 151644281 Spottiswoode, Bruce Siemens Medical Solutions USA, Inc. Spottiswoode, Bruce 1 151644285 Lu, Xlaoguang Siemens Corporation Corporate Research Lu, Xlaoguang 2 151644290 Bi, Xiaoming Siemens Medical USA Bi, Xiaoming 3 151644295 Glielmi, Christopher Siemens Medical Solutions USA, Inc. Glielmi, Christopher 4 151644300 Greiser, Andreas Siemans AG Greiser, Andreas 5 151644306 Xue, Hui National Heart, Lung, and Blood Institute (NHLBI) NHLBI Xue, Hui (NHLBI) 6 151644310 Kellman, Peter National Heart, Lung, and Blood Institute (NHLBI) NHLBI Kellman, Peter (NHLBI) 7 151644281 Spottiswoode, Bruce Siemens Medical Solutions USA, Inc. Spottiswoode, Bruce 1 151644285 Lu, Xlaoguang Siemens Corporation Corporate Research Lu, Xlaoguang 2 151644290 Bi, Xiaoming Siemens Medical USA Bi, Xiaoming 3 151644295 Glielmi, Christopher Siemens Medical Solutions USA, Inc. Glielmi, Christopher 4 151644300 Greiser, Andreas Siemans AG Greiser, Andreas 5 151644306 Xue, Hui National Heart, Lung, and Blood Institute (NHLBI) NHLBI Xue, Hui (NHLBI) 6 151644310 Kellman, Peter National Heart, Lung, and Blood Institute (NHLBI) NHLBI Kellman, Peter (NHLBI) 7 151644277 Improved Image Contrast In Inversion MfR Imaging, Improved Workflow And Inter-scan Reliabilibity In MRI Myocardial Viability Imaging E-051-2019-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI), Siemans AG, Siemens Corporation Corporate Research, Siemens Medical Solutions USA, Inc., Siemens Medical USA 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-4479] Methods and Systems for Automatically Determining Magnetic Field Inversion Time of a Tissue Species&body=Please send me information about technology [TAB-4479] Methods and Systems for Automatically Determining Magnetic Field Inversion Time of a Tissue Species. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-4479] Methods and Systems for Automatically Determining Magnetic Field Inversion Time of a Tissue Species&body=Please send me information about technology [TAB-4479] Methods and Systems for Automatically Determining Magnetic Field Inversion Time of a Tissue Species.">shmilovm@nih.gov</a><br> 157754096 E-051-2019-0 E-051-2019-0-US-01 Improved Image Contrast In Inversion MfR Imaging, Improved Workflow And Inter-scan Reliabilibity In MRI Myocardial Viability Imaging PRV US 61/812,746 Abandoned US <br />Provisional (PRV) 61/812,746<br />Filed on 2013-04-17<br />Status: Abandoned 157754101 E-051-2019-0 E-051-2019-0-US-02 Improved Image Contrast In Inversion MfR Imaging, Improved Workflow And Inter-scan Reliabilibity In MRI Myocardial Viability Imaging ORD US 9,734,573 14/245,011 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9734573 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/9734573">9,734,573</a><br />Filed on 2014-04-04<br />Status: Issued 157754106 E-051-2019-0 E-051-2019-0-KR-03 METHODS AND SYSTEMS FOR AUTOMATICALLY DETERMINING MAGNETIC FIELD INVERSION TIME OF A TISSUE SPECIES ORD South Korea 10-2014-0124733 Abandoned South Korea <br />Ordinary Patent (ORD) 10-2014-0124733<br />Filed on 2014-04-17<br />Status: Abandoned 157754111 E-051-2019-0 E-051-2019-0-CN-04 Methods and systems for automatically determining magnetic field inversion time of a tissue species ORD China ZL201410154479.4 201410154479.4 Abandoned China <br />Ordinary Patent (ORD) 201410154479.4<br />Filed on 2014-04-17<br />Status: Abandoned TAB-4476 151643352 Free Breathing Motion Corrected Pixel-wise MRI Myocardial T1 Parameter Mapping for Clinical Cardiac Imaging NHLBI Application, Cardiology, Computational models/software, Medical Devices, Research Equipment, Software / Apps Application Cardiology Computational models/software Medical Devices Research Equipment Software / Apps Peter Kellman, Bruce Spottiswoode <p>This technology includes a method for performing cardiac imaging without the need for the patient to hold their breath. Free breathing pixel-wise myocardial T1 parameter mapping includes performing a free-breathing scan of a cardiac region at a plurality of varying saturation recovery times to acquire a k-space dataset; generating an image dataset based on the k-space dataset; and performing a respiratory motion correction process on the image dataset. The respiratory motion correction process comprises selecting a target image, co-registering each image in the dataset to the target image to determine a spatial alignment measurement for each image, and identifying a subset of the image dataset comprising images with the spatial alignment measurement above a predetermined value. Following the respiratory motion correction process, a pixel-wise fitting is performed on the image dataset to estimate T1 relaxation time values for the cardiac region. Then, a pixel-map of the cardiac region is produced depicting the T1 relaxation time values.</p> Novel method to increase efficiency and patient comfortability during cardiac imaging. Eliminate need for patients to hold their breath during imaging and to scan patients that are unable to hold their breath. 2023-12-06 2024-08-12 2024-08-12 2024-03-27 False True True 52398218 Pre-Clinical (in vivo) 52398218 37470483 Website Abstract 151643364 Spottiswoode, Bruce Siemens Medical Solutions USA, Inc. Spottiswoode, Bruce 1 151643369 Kellman, Peter National Heart, Lung, and Blood Institute (NHLBI) NHLBI Kellman, Peter (NHLBI) 2 151643364 Spottiswoode, Bruce Siemens Medical Solutions USA, Inc. Spottiswoode, Bruce 1 151643369 Kellman, Peter National Heart, Lung, and Blood Institute (NHLBI) NHLBI Kellman, Peter (NHLBI) 2 151643355 Free Breathing Motion Corrected Pixel-wise Mri Myocardial T1 Parameter Mapping E-045-2019-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI), Siemens Medical Solutions USA, Inc. 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-4476] Free Breathing Motion Corrected Pixel-wise MRI Myocardial T1 Parameter Mapping for Clinical Cardiac Imaging&body=Please send me information about technology [TAB-4476] Free Breathing Motion Corrected Pixel-wise MRI Myocardial T1 Parameter Mapping for Clinical Cardiac Imaging. Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-4476] Free Breathing Motion Corrected Pixel-wise MRI Myocardial T1 Parameter Mapping for Clinical Cardiac Imaging&body=Please send me information about technology [TAB-4476] Free Breathing Motion Corrected Pixel-wise MRI Myocardial T1 Parameter Mapping for Clinical Cardiac Imaging.">shmilovm@nih.gov</a><br> 157753880 E-045-2019-0 E-045-2019-0-US-01 Free Breathing Motion Corrected Pixel-wise Mri Myocardial T1 Parameter Mapping ORD US 10,264,994 15/155,205 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10264994 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10264994">10,264,994</a><br />Filed on 2016-05-16<br />Status: Issued TAB-3834 144258380 TSLP Induces Neutrophil-mediated Killing of Methicillin-resistant Staphylococcus Aureus (MRSA) NHLBI Infectious Disease, Research Materials, Therapeutics Infectious Disease Research Materials Therapeutics <p>This technology includes the use of thymic stromal lymphopoetin (TSLP) for the treatment of MRSA. Our studies show that mouse neutrophils express the TSLP receptor, TSLPR, and that TSLP protein is increased during cutaneous MRSA infection. Using in vitro MRSA whole blood killing assays, we show that TSLP acts on mouse neutrophils to enhance MRSA killing. In an in vivo MRSA intradermal ear infection, TSLPR-deficient mice exhibit increased MRSA burden compared to wild-type mice. Moreover, TSLP treatment increases cutaneous MRSA killing in wild-type mice, as intradermal TSLP treatment of wild-type mice results in significantly enhanced MRSA killing in the ear. In addition, using TSLPR-deficient mice, we show that the effect of TSLP on MRSA killing is TSLPR dependent. Furthermore, TSLP increases MRSA killing in human whole blood and also acts directly on purified human neutrophils to increase control of MRSA. These data indicate that TSLP acts on both mouse and human neutrophils to increase MRSA killing and may have implications for the treatment of cutaneous MRSA infections.</p> Likely to overcome antibiotic-resistant MRSA. Treatment of cutaneous MRSA infections. 2023-03-08 2024-08-12 2024-08-12 2024-03-20 False True True 52406768 Discovery 52406768 37470483 Website Abstract 144258383 TSLP Induces Neutrophil Mediated Killing Of Methicillin-resistant Staphylococcus Aureus E-034-2016-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 83669350 Shmilovich, Michael shmilovm@nih.gov
United States of America Office of Technology Transfer and Development shmilovm@nih.gov?subject=Web Inquiry on [TAB-3834] TSLP Induces Neutrophil-mediated Killing of Methicillin-resistant Staphylococcus Aureus (MRSA)&body=Please send me information about technology [TAB-3834] TSLP Induces Neutrophil-mediated Killing of Methicillin-resistant Staphylococcus Aureus (MRSA). Shmilovich, Michael<br><a href="mailto:shmilovm@nih.gov?subject=Web Inquiry on [TAB-3834] TSLP Induces Neutrophil-mediated Killing of Methicillin-resistant Staphylococcus Aureus (MRSA)&body=Please send me information about technology [TAB-3834] TSLP Induces Neutrophil-mediated Killing of Methicillin-resistant Staphylococcus Aureus (MRSA).">shmilovm@nih.gov</a><br> 157753712 E-034-2016-0 E-034-2016-0-US-01 TSLP Induces Neutrophil Mediated Killing Of Methicillin-resistant Staphylococcus Aureus PRV US 62/251,558 Abandoned US <br />Provisional (PRV) 62/251,558<br />Filed on 2015-11-05<br />Status: Abandoned TAB-4736 151915850 Treatment of the beta-globinopathies through inhibition of RIOK3 activity NHLBI Immunology, Licensing, Plasmids/Vectors, Therapeutics Immunology Licensing Plasmids/Vectors Therapeutics Bjorg Gudmundsdottir, John Tisdale, Laxminath Tumburu <p>Disorders of adult beta-globin synthesis, which include sickle cell disease (SCD) and beta-thalassemia, are the most common monogenic disorders in the world. While the curative potential of bone marrow transplantation has been demonstrated, this approach is limited to a small fraction of affected patients due to the requirement for an HLA-matched donor, the highly specialized approach that requires critical infrastructure, and the high cost.</p> <p>Scientists at the National Heart, Lung, and Blood Institute (NHLBI), have developed lentiviral vectors encoding shRNA to Rio-Kinase 3 (RIOK3) that decrease expression of RIOK3, leading to more robust fetal hemoglobin expression.</p> <ul> <li>Increase fetal hemoglobin expression.</li> <li>Novel and more cost-effective treatment.<li> </ul> <ul> <li>Treatment of beta-globinopathies such as Sickle Cell Disease.</li> </ul> 2023-12-22 2024-04-04 2024-04-04 2023-12-22 False True Pre-Clinical (in vivo - animal) True 52396375 Pre-Clinical (in vitro) 52396375 37470483 Website Abstract E-127-2021-0; E-127-2021-1 151915970 Tisdale, John National Heart, Lung, and Blood Institute (NHLBI) NHLBI Tisdale, John (NHLBI) 1 151916040 Gudmundsdottir, Bjorg National Heart, Lung, and Blood Institute (NHLBI) NHLBI Gudmundsdottir, Bjorg (NHLBI) 2 151916048 Tumburu, Laxminath National Heart, Lung, and Blood Institute (NHLBI) NHLBI Tumburu, Laxminath (NHLBI) 3 151915970 Tisdale, John National Heart, Lung, and Blood Institute (NHLBI) NHLBI Tisdale, John (NHLBI) 1 151916040 Gudmundsdottir, Bjorg National Heart, Lung, and Blood Institute (NHLBI) NHLBI Gudmundsdottir, Bjorg (NHLBI) 2 151916048 Tumburu, Laxminath National Heart, Lung, and Blood Institute (NHLBI) NHLBI Tumburu, Laxminath (NHLBI) 3 151915853 Treatment Of The Beta-globinopathies Through Inhibition Of RIOK3 Activity E-127-2021-2 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 89788013 Kolesnitchenko, Vincent vk5q@nih.gov
United States of America Office of Technology Transfer and Development vk5q@nih.gov?subject=Web Inquiry on [TAB-4736] Treatment of the beta-globinopathies through inhibition of RIOK3 activity&body=Please send me information about technology [TAB-4736] Treatment of the beta-globinopathies through inhibition of RIOK3 activity. Kolesnitchenko, Vincent<br><a href="mailto:vk5q@nih.gov?subject=Web Inquiry on [TAB-4736] Treatment of the beta-globinopathies through inhibition of RIOK3 activity&body=Please send me information about technology [TAB-4736] Treatment of the beta-globinopathies through inhibition of RIOK3 activity.">vk5q@nih.gov</a><br> TAB-3735 114097587 Heterocyclic P2Y14 Antagonists for the Treatment of Various Conditions NIDDK Cardiology, Dental, Endocrinology, Infectious Disease, Oncology, Ophthalmology, Research Materials, Therapeutics Cardiology Dental Endocrinology Infectious Disease Oncology Ophthalmology Research Materials Therapeutics Kenneth Jacobson, Young-Hwan Jung, Zhiwei Wen <p>The technology discloses composition of compounds that are highly selective P2Y14 receptor antagonists,<br /> with moderate affinity with insignificant antagonism of other P2Y receptors. These compounds might provide a<br /> treatment for patients for various disease conditions, including lung inflammation, kidney inflammation,<br /> asthma, diabetes, obesity, and neuropathic pain of diverse states. In vivo data using mouse lines with the<br /> receptor knocked out in specific tissues showed that P2Y14 receptor antagonists act on adipocytes to improve<br /> conditions of metabolic disorders. Though there are no P2Y14 receptor modulators in clinical use currently,<br /> selective P2Y14 receptor antagonists are sought as potential therapeutic treatments for asthma, chronic pain,<br /> inflammation and possibly diabetes and neurodegeneration.</p> The first demonstration that selective P2Y14 antagonists are effective for treatment of neuropathic pain. Treatment for patients for various disease conditions, including lung inflammation, kidney inflammation, asthma, diabetes, obesity, metabolic disorders, and neuropathic pain of diverse states. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize Heterocyclic P2Y14 Antagonists. For collaboration opportunities, please contact: Kenneth A. Jacobson, Ph.D. E-mail and/or lkennethj@niddk.nih.gov 2022-11-30 2024-03-12 2024-03-12 2023-09-22 2022-07-10 ANTAGONISTS, HETEROCYCLIC, P2Y14, VFXXXX, VPXXXX, WIXXXX, WKXXXX True True True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract E-028-2018/0/1; E-213-2015/0 150046787 Wen, Z., Pramanik, A., Lewicki, S.A., Jung, Y.H., Gao, Z.G., Randle, J.C.R., Cronin, C., Chen, Z., Giancotti, L.A., Whitehead, G.S., Liang, B.T., Breton, S., Salvemini, D., Cook, D.N., Jacobson, K.A. Alicyclic ring size variation of 4-phenyl-2-naphthoic acid derivatives as P2Y14 receptor antagonists. J. Med. Chem., 2023, 66(13):9076–9094 https://doi.org/10.1021/acs.jmedchem.3c00664 <a href="https://doi.org/10.1021/acs.jmedchem.3c00664">Wen, Z., Pramanik, A., Lewicki, S.A., Jung, Y.H., Gao, Z.G., Randle, J.C.R., Cronin, C., Chen, Z., Giancotti, L.A., Whitehead, G.S., Liang, B.T., Breton, S., Salvemini, D., Cook, D.N., Jacobson, K.A. Alicyclic ring size variation of 4-phenyl-2-naphthoic acid derivatives as P2Y14 receptor antagonists. J. Med. Chem., 2023, 66(13):9076–9094</a> 150115506 Jain, S., Pydi, S.P., Jung, Y.H., Scortichini, M., Kesner, E.L., Karcz, T.P., Cook, D.N., Gavrilova, O., Wess, J., Jacobson, K.A. Adipocyte P2Y14 receptors play a key role in whole-body glucose and lipid homeostasis. JCI Insight 2021, 6(10):e146577 ; https://doi.org/10.1172/jci.insight.146577 <a href="https://doi.org/10.1172/jci.insight.146577">Jain, S., Pydi, S.P., Jung, Y.H., Scortichini, M., Kesner, E.L., Karcz, T.P., Cook, D.N., Gavrilova, O., Wess, J., Jacobson, K.A. Adipocyte P2Y14 receptors play a key role in whole-body glucose and lipid homeostasis. JCI Insight 2021, 6(10):e146577 ;</a> 150115510 Karcz, T.P., Whitehead, G.S., Nakano, K., Nakano, H., Grimm, S.A., Williams, J.G., Deterding, L.J., Jacobson, K.A., Cook, D.N. UDP-glucose and P2Y14 receptor amplify allergen-induced airway eosinophilia. J. Clin. Invest., 2021, 131(7):e140709 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8011887/ <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8011887/">Karcz, T.P., Whitehead, G.S., Nakano, K., Nakano, H., Grimm, S.A., Williams, J.G., Deterding, L.J., Jacobson, K.A., Cook, D.N. UDP-glucose and P2Y14 receptor amplify allergen-induced airway eosinophilia. J. Clin. Invest., 2021, 131(7):e140709</a> 114111435 Jung, Young-Hwan National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Jung, Young-Hwan (NIDDK) 0 114111436 Wen, Zhiwei National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Wen, Zhiwei (NIDDK) 0 114111434 Jacobson, Kenneth National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Jacobson, Kenneth (NIDDK) 1 114111434 Jacobson, Kenneth National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Jacobson, Kenneth (NIDDK) 1 114111435 Jung, Young-Hwan National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Jung, Young-Hwan (NIDDK) 0 114111436 Wen, Zhiwei National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Wen, Zhiwei (NIDDK) 0 114102839 Heterocyclic P2Y14 Antagonists E-051-2021-0 Filing authorized National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83692066 Tong, Betty tongb@niddk.nih.gov
United States of America Senior Technology Advancement Office tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-3735] Heterocyclic P2Y14 Antagonists for the Treatment of Various Conditions&body=Please send me information about technology [TAB-3735] Heterocyclic P2Y14 Antagonists for the Treatment of Various Conditions. Tong, Betty<br><a href="mailto:tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-3735] Heterocyclic P2Y14 Antagonists for the Treatment of Various Conditions&body=Please send me information about technology [TAB-3735] Heterocyclic P2Y14 Antagonists for the Treatment of Various Conditions.">tongb@niddk.nih.gov</a><br> 114169573 E-051-2021-0 E-051-2021-0-US-01 Heterocyclic P2Y14 Antagonists PRV US 63/138,581 Abandoned US <br />Provisional (PRV) 63/138,581<br />Filed on 2021-01-18<br />Status: Abandoned 114169574 E-051-2021-0 E-051-2021-0-PCT-01 HETEROCYCLIC P2Y14 RECEPTOR ANTAGONISTS PCT COMB Patent Cooperation Treaty PCT/US2022/011226 Expired Patent Cooperation Treaty <br />Patent Cooperation Treaty Combined (PCT COMB) PCT/US2022/011226<br />Filed on 2022-01-05<br />Status: Expired 150045510 E-051-2021-0 E-051-2021-0-CA-01 HETEROCYCLIC P2Y14 RECEPTOR ANTAGONISTS National Stage Canada 3208662 Abandoned Canada <br />National Stage 3208662<br />Filed on 2023-07-18<br />Status: Abandoned 150045515 E-051-2021-0 E-051-2021-0-AU-01 HETEROCYCLIC P2Y14 RECEPTOR ANTAGONISTS National Stage Australia 2022207045 Abandoned Australia <br />National Stage 2022207045<br />Filed on 2023-07-21<br />Status: Abandoned 150045520 E-051-2021-0 E-051-2021-0-CN-01 HETEROCYCLIC P2Y14 RECEPTOR ANTAGONISTS National Stage China 202280020636.5 Abandoned China <br />National Stage 202280020636.5<br />Filed on 2023-09-11<br />Status: Abandoned 150045525 E-051-2021-0 E-051-2021-0-US-02 HETEROCYCLIC P2Y14 RECEPTOR ANTAGONISTS National Stage US 18/272,435 Pending US <br />National Stage 18/272,435<br />Filed on 2023-07-14<br />Status: Pending 150045530 E-051-2021-0 E-051-2021-0-EP-01 HETEROCYCLIC P2Y14 RECEPTOR ANTAGONISTS National Stage European Patent 22701105.3 Abandoned European Patent <br />National Stage 22701105.3<br />Filed on 2023-08-07<br />Status: Abandoned 114129440 VFXXXX 114129441 VPXXXX 114129442 WIXXXX 114129443 WKXXXX 114154922 HETEROCYCLIC 114154923 P2Y14 114154924 ANTAGONISTS TAB-3755 114097606 Nipamovir: An Affordable, Oral Treatment for HIV Infection with a High Barrier to Resistance NIDDK Infectious Disease, Therapeutics Infectious Disease Therapeutics Daniel Appella, Herman Nikolayevskiy, Marco Robello, Michael Scerba This technology includes an oral treatment for HIV infection. Nipamovir is a low molecular weight mercaptobenzamide derivative that is simple to produce on kilogram scale and which can be used to lower or eliminate the infectivity of HIV. Extended treatment of Simian immunodeficiency virus (SIV)-infected macaques with Nipamovir lowers the viral load by 1 log unit, and eliminates the ability of remaining virus to infect other cells. Nipamovir shows similar antiviral activity in HIV-infected human cells. There are no toxic side-effects observed in animal studies with Nipamovir. Nipamovir is a simple small molecule that is not expensive or difficult to synthesize. It inactivates HIV by a complicated mechanism of action that involves interference with final maturation steps of the virus, which provides a very high barrier for HIV to develop resistance. Laboratory experiments designed to encourage HIV to develop resistance to Nipamovir have all failed. Nipamovir has a low toxicity profile, a high barrier to viral resistance, and is inexpensive to produce. Treatment for HIV. 2022-11-30 2024-01-23 2024-01-23 2023-09-22 2022-07-11 Affordable, BARRIER, High, HIV, Infection, Nipamovir:, ORAL, Resistance, treatment, VLXXXX, WKXXXX False True True 52396375 Pre-Clinical (in vitro) 52396375 NIHTT 37470483 Website Abstract 114111480 Nikolayevskiy, Herman National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Nikolayevskiy, Herman 0 114111481 Robello, Marco National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Robello, Marco (NIDDK) 0 114111482 Scerba, Michael National Institute on Aging (NIH/NIA) NIA Scerba, Michael (NIA) 0 114111479 Appella, Daniel National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Appella, Daniel (NIDDK) 1 114111479 Appella, Daniel National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Appella, Daniel (NIDDK) 1 114111480 Nikolayevskiy, Herman National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Nikolayevskiy, Herman 0 114111481 Robello, Marco National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Robello, Marco (NIDDK) 0 114111482 Scerba, Michael National Institute on Aging (NIH/NIA) NIA Scerba, Michael (NIA) 0 114102858 Nipamovir: An Affordable, Oral Treatment For HIV Infection With A High Barrier To Resistance E-127-2019-0 Filing authorized National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83692066 Tong, Betty tongb@niddk.nih.gov
United States of America Senior Technology Advancement Office tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-3755] Nipamovir: An Affordable, Oral Treatment for HIV Infection with a High Barrier to Resistance&body=Please send me information about technology [TAB-3755] Nipamovir: An Affordable, Oral Treatment for HIV Infection with a High Barrier to Resistance. Tong, Betty<br><a href="mailto:tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-3755] Nipamovir: An Affordable, Oral Treatment for HIV Infection with a High Barrier to Resistance&body=Please send me information about technology [TAB-3755] Nipamovir: An Affordable, Oral Treatment for HIV Infection with a High Barrier to Resistance.">tongb@niddk.nih.gov</a><br> 114169590 E-127-2019-0 E-127-2019-0-US-01 COMPOUND AND METHOD FOR TREATING HIV INFECTION PRV US 62/948,939 Abandoned US <br />Provisional (PRV) 62/948,939<br />Filed on 2019-12-17<br />Status: Abandoned 114169591 E-127-2019-0 E-127-2019-0-PCT-02 COMPOUND AND METHOD FOR TREATING HIV INFECTION PCT Patent Cooperation Treaty PCT/US2020/065537 Expired Patent Cooperation Treaty <br />(PCT) PCT/US2020/065537<br />Filed on 2020-12-17<br />Status: Expired 114169592 E-127-2019-0 E-127-2019-0-US-04 N-(3-AMINO-3-OXOPROPYL)-2-[(1-METHYL-4-NITRO-1H-IMIDAZOL-5-YL)THIO]BENZAMIDE AND ITS USE FOR TREATING HIV INFECTION National Stage US 12,551,464 17/785,155 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12551464 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12551464">12,551,464</a><br />Filed on 2022-06-14<br />Status: Issued 114129495 VLXXXX 114129496 WKXXXX 114155066 Nipamovir: 114155067 Affordable 114155068 ORAL 114155069 treatment 114155070 HIV 114155071 Infection 114155072 High 114155073 BARRIER 114155074 Resistance TAB-925 114095258 Contrast Agent Enhancement of Chemical Exchange Dependent Saturation Transfer (CEDST) MRI NHLBI Licensing Licensing Anthony Aletras, Robert Balaban, Kathleen Ward Available for licensing is an MRI image improving system wherein at least one contrast agent is administered to a subject in amounts effective to perform chemical exchange dependent saturation transfer (CEDST) MRI analysis. <br><br> Examples of contrast agents suitable for administration as exogenous contrast agents include at least one functional group bearing a proton capable of chemical exchange. Examples of these functional groups include, without limitation, amides, amines, and carboxyl, hydroxyl, and sulfhydryl groups. <br><br> The contrast agent can be administered as a solid, as a dispersion or solution, such as an aqueous composition, as a mixture of two or more agents, etc. The contrast agent may also be in the form of a polymer. <br><br> One feature of the present invention involved identifying contrast agents, which contain the functional groups having the appropriate proton exchange and chemical shift properties at physiological pH and temperature to function effectively for performing CEDST MRI analyses in vivo. A number of different contrast agents can be used to practice the present method for performing CEDST MRI analyses in vivo can be selected from the group consisting of: sugars, including oligosaccharides and polysaccharides, such as dextran; amino acids, such as 5-hydroxy-tryptophan (which also includes an indole -NH) and including oligomers of amino acids and proteins; nitrogen-containing heterocycles generally; indoles, purines and pyrimidines; nucleosides; imidazole and derivatives thereof, such as 2-imidazolidone and 2-imidazoldinethione; imino acids, including azetidines, such as azetidine-2-carboxylic acid, pyrolidines, such as 4-trans-hydroxy-proline, and piperidines, such as pipecolinic acid; barbituric acid and analogs thereof, such as 2-thio-barbituric acid and 5,5-diethylbarbituric acid; miscellaneous materials, such as guanidine, hydantoin, parabanic acid, and biologically active salts thereof; and mixtures of these contrast agents. <br><br> Working embodiments of the invention used all of the above materials at a variety of concentration levels for in-vitro experiments and, using a 500 mM solution of barbituric acid, in an in-vivo rabbit model. <br><br> The method of the present invention is useful for enhancing the contrast of MRI images, including images produced in vivo, using CEDST. <br><br> A second feature of the present invention involved identifying contrast agents which contained the functional groups which could be used, either alone or in combination, to function effectively at performing pH measurement using CEDST in vivo. <br><br> Working embodiments of this feature of the invention used either dihydrouracil or a combination solution of 5-Hydroxytryptophan and 2-Imidazolidinethione as the contrast agent, which was provided as an aqueous composition having about 62.5 mM of each chemical in the solution. Other chemicals with more than one chemical exchange site or mixtures of other contrast agents may also be used to practice the second feature of the present invention. A standard pH curve is prepared by performing in vitro CEDST MRI analyses of the contrast agent, which is then used to evaluate the in vivo pH measurement results. <br><br> A third feature of the present invention involved identifying contrast agents which contained the functional groups which could be used to function effectively at performing temperature measurement using CEDST in vivo. <br><br> Working embodiments of this feature of the invention used barbituric acid as the contrast agent, which was provided as an aqueous composition having about 62.5 mM of chemical in the solution. Other chemicals may be used to practice the third feature of the present invention. A standardized temperature curve is prepared performing in vitro CEDST MRI analyses of the contrast agent, which is then used to evaluate the in vivo temperature results. <br><br> A fourth feature of the present invention involved identifying contrast agents which contained the function groups which could be used to function effectively at measuring a metabolite of interest using CEDST in vivo. <br><br> Working embodiments of this feature of the invention used dihydrouracil as the contrast agent, which was provided as an aqueous composition having about 62.5 mM with phosphate as the metabolite of interest. Other chemicals may be used to practice the third feature of the present invention. A standardized metabolite curve is prepared performing in vitro CEDST MRI analyses of the contrast agent, which is then used to evaluate the in vivo metabolite results. 2022-03-08 2023-07-18 2023-07-18 2004-05-01 AA3AXX, AA3B1X, AA3BXX, AA3XXX, AAXXXX, AXXXXX, Contrast, CSalata, ENHANCING, IMAGES, IMAGING, Magnetic, Method, Patent Category - Mech/Elect/Soft, PRODUCED, Resonance False True True NIHTT 37470483 Website Abstract 114104760 Aletras, Anthony NHLBI Aletras, Anthony (NHLBI) 0 114104761 Ward, Kathleen Ward, Kathleen 0 114104762 Balaban, Robert National Heart, Lung, and Blood Institute (NHLBI) NHLBI Balaban, Robert (NHLBI) 1 114104762 Balaban, Robert National Heart, Lung, and Blood Institute (NHLBI) NHLBI Balaban, Robert (NHLBI) 1 114104760 Aletras, Anthony NHLBI Aletras, Anthony (NHLBI) 0 114104761 Ward, Kathleen Ward, Kathleen 0 114100115 Method for Enhancing Contrast in Images Produced by Magnetic Resonance Imaging E-240-1998-0 Filing authorized National Heart, Lung, and Blood Institute (NHLBI) 83657698 Specialist (ALS), Admin. Licensing nihott@mail.nih.gov
nihott@mail.nih.gov?subject=Web Inquiry on [TAB-925] Contrast Agent Enhancement of Chemical Exchange Dependent Saturation Transfer (CEDST) MRI&body=Please send me information about technology [TAB-925] Contrast Agent Enhancement of Chemical Exchange Dependent Saturation Transfer (CEDST) MRI. Specialist (ALS), Admin. Licensing<br><a href="mailto:nihott@mail.nih.gov?subject=Web Inquiry on [TAB-925] Contrast Agent Enhancement of Chemical Exchange Dependent Saturation Transfer (CEDST) MRI&body=Please send me information about technology [TAB-925] Contrast Agent Enhancement of Chemical Exchange Dependent Saturation Transfer (CEDST) MRI.">nihott@mail.nih.gov</a><br> 114162305 E-240-1998-0 E-240-1998-0-US-06 Method for Enhancing Contrast in Images Produced by Magnetic Resonance Imaging DIV US 12/002,553 Abandoned US <br />Divisional (DIV) 12/002,553<br />Filed on 2007-12-17<br />Status: Abandoned 114162570 E-240-1998-0 E-240-1998-0-US-05 METHOD FOR DETERMINING IN VIVO CONCENTRATION OF A METABOLITE DIV US 7,330,748 10/948,942 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7330748 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7330748">7,330,748</a><br />Filed on 2004-09-24<br />Status: Abandoned 114164129 E-240-1998-0 E-240-1998-0-US-04 Method for Enhancing Contrast in Images Produced by Magnetic Resonance Imaging National Stage US 6,963,769 09/959,138 Abandoned https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6963769 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6963769">6,963,769</a><br />Filed on 2001-10-17<br />Status: Abandoned 114165417 E-240-1998-0 E-240-1998-0-US-01 Method for Enhancing Contrast in Images Produced by Magnetic Resonance Imaging` PRV US 60/130,532 Abandoned US <br />Provisional (PRV) 60/130,532<br />Filed on 1999-04-21<br />Status: Abandoned 114165418 E-240-1998-0 E-240-1998-0-PCT-02 Method for Enhancing Contrast in Images Produced by Magnetic Resonance Imaging PCT Patent Cooperation Treaty PCT/US00/10878 Expired Patent Cooperation Treaty <br />(PCT) PCT/US00/10878<br />Filed on 2000-04-20<br />Status: Expired 114115327 AA3B1X 114115328 AA3AXX 114115329 AA3BXX 114115330 AA3XXX 114115331 AAXXXX 114115332 AXXXXX 114136720 CSalata 114136721 Method 114136722 ENHANCING 114136723 Contrast 114136724 IMAGES 114136725 PRODUCED 114136726 Magnetic 114136727 Resonance 114136728 IMAGING 114136729 Patent Category - Mech/Elect/Soft TAB-2455 114096655 A3 Adenosine Receptor Agonists to Treat Chemotherapy-induced Peripheral Neuropathy NIDDK Collaboration, Oncology, Therapeutics Collaboration Oncology Therapeutics Kenneth Jacobson, Dilip Tosh This invention claims species-independent agonists of A<sub>3</sub>AR, specifically (N)-methanocarba adenine nucleosides and related pharmaceutical compositions. The A<sub>3</sub> adenosine receptor (A<sub>3</sub>AR) subtype has been linked with helping protect the heart from ischemia, controlling inflammation, and regulating cell proliferation. Agonists of the human A<sub>3</sub>AR subtype have been developed that are also selective for the mouse A<sub>3</sub>AR while retaining selectivity for the human receptor. This solves a problem for clinical development because animal model testing is important for pre-clinical validation of drug function. Novel agonists have been made that exhibit as much as 6000x selectivity for A<sub>3</sub> versus A<sub>1</sub> in humans while retaining at least 400x selectivity for A<sub>3</sub> versus A<sub>1</sub> in mice. In addition, the molecules of the invention exhibit very low nanomolar affinity. This innovation will not only facilitate moving A<sub>3</sub> agonists into the clinical phase of drug development by being more amenable to animal studies, but also provide much greater selectivity in humans, and thereby potentially fewer side effects than drugs currently undergoing clinical trials. Oral dosing as these A<sub>3</sub>AR agonists are selective and not associated with cardiac or hemodynamic effects that may result from stimulation of A<sub>1</sub> or A<sub>2</sub>A receptors. <ul> <li>cardiac arrhythmias or ischemia</li> <li>inflammation</li> <li>stroke</li> <li>diabetes</li> <li>asthma</li> <li>cancer</li> <li>pain</li> </ul> The National Institute of Diabetes and Digestive and Kidney Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize this technology. For collaboration opportunities, please contact Marguerite J. Miller at 301-496-9003 or <a href="mailto:millermarg@niddk.nih.gov">millermarg@niddk.nih.gov</a>. 2022-03-08 2023-04-28 2023-04-28 2012-06-13 2-Arylethynyl, A3, ADENOSINE, CB3CXX, CB3XXX, CBXXXX, CXXXXX, Design, N-Methanocarba, Nucleosides, Receptor-Selective, Structure-based False True <ul> <li>Early-stage</li> <li>In vivo data available (animal)</li> </ul> True NIHTT 37470483 Website Abstract E-140-2008-0 E-285-2008-0 E-075-2012-0 114171618 Tosh DK, et al. http://www.ncbi.nlm.nih.gov/pubmed/22559880 <a href="http://www.ncbi.nlm.nih.gov/pubmed/22559880">Tosh DK, et al.</a> 114171619 Chen Z, et al. http://www.ncbi.nlm.nih.gov/pubmed/22345405 <a href="http://www.ncbi.nlm.nih.gov/pubmed/22345405">Chen Z, et al.</a> 114107596 Tosh, Dilip National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Tosh, Dilip (NIDDK) 0 114107595 Jacobson, Kenneth National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Jacobson, Kenneth (NIDDK) 1 114107595 Jacobson, Kenneth National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Jacobson, Kenneth (NIDDK) 1 114107596 Tosh, Dilip National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIDDK Tosh, Dilip (NIDDK) 0 114101759 Structure-Based Design Of A3 Adenosine Receptor-Selective 2-Arylethynyl (N)-Methanocarba Nucleosides E-140-2008-1 Filing authorized National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 83692066 Tong, Betty tongb@niddk.nih.gov
United States of America Senior Technology Advancement Office tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-2455] A3 Adenosine Receptor Agonists to Treat Chemotherapy-induced Peripheral Neuropathy&body=Please send me information about technology [TAB-2455] A3 Adenosine Receptor Agonists to Treat Chemotherapy-induced Peripheral Neuropathy. Tong, Betty<br><a href="mailto:tongb@niddk.nih.gov?subject=Web Inquiry on [TAB-2455] A3 Adenosine Receptor Agonists to Treat Chemotherapy-induced Peripheral Neuropathy&body=Please send me information about technology [TAB-2455] A3 Adenosine Receptor Agonists to Treat Chemotherapy-induced Peripheral Neuropathy.">tongb@niddk.nih.gov</a><br> 114166793 E-140-2008-1 E-140-2008-1-US-01 A3 Adenosine Receptor Agonists And Antagonists CIP US 8,916,570 13/371,081 Issued https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8916570 US Patent <a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8916570">8,916,570</a><br />Filed on 2012-02-10<br />Status: Issued 114122880 CB3CXX 114122881 CXXXXX 114122882 CBXXXX 114122883 CB3XXX 114143261 Structure-based 114143262 Design 114143263 A3 114143264 ADENOSINE 114143265 Receptor-Selective 114143266 2-Arylethynyl 114143267 N-Methanocarba 114143268 Nucleosides